diff --git a/config/satusehatintegration.php b/config/satusehatintegration.php index 4e8d756..4232674 100644 --- a/config/satusehatintegration.php +++ b/config/satusehatintegration.php @@ -8,8 +8,13 @@ */ 'log_table_name' => 'satusehat_log', 'token_table_name' => 'satusehat_token', + 'icd10_table_name' => 'satusehat_icd10', 'icd9cm_table_name' => 'satusehat_icd9cm', + + 'loinc_table_name' => 'satusehat_loinc', + 'loinc_answer_table_name' => 'satusehat_loinc_answer', + 'kode_wilayah_indonesia_table_name' => 'kode_wilayah_indonesia', /* diff --git a/database/migrations/create_satusehat_loinc_answer_table.php.stub b/database/migrations/create_satusehat_loinc_answer_table.php.stub new file mode 100644 index 0000000..34b6114 --- /dev/null +++ b/database/migrations/create_satusehat_loinc_answer_table.php.stub @@ -0,0 +1,41 @@ +create(config('satusehatintegration.loinc_answer_table_name'), function (Blueprint $table) { + $table->bigIncrements('id'); + $table->string('LoincNumber')->nullable(); + $table->string('AnswerListId')->nullable(); + $table->string('AnswerListName')->nullable(); + $table->string('AnswerStringId')->nullable(); + $table->integer('SequenceNumber')->nullable(); + $table->string('DisplayText')->nullable(); + $table->string('ExtCodeId')->nullable(); + $table->string('ExtCodeDisplayName')->nullable(); + $table->string('ExtCodeSystem')->nullable(); + $table->timestamps(); + $table->softDeletes(); + }); + } + + /** + * Reverse the migrations. + * + * @return void + */ + public function down() + { + Schema::connection(config('satusehatintegration.database_connection_master'))->dropIfExists(config('satusehatintegration.loinc_answer_table_name')); + } +} diff --git a/database/migrations/create_satusehat_loinc_table.php.stub b/database/migrations/create_satusehat_loinc_table.php.stub new file mode 100644 index 0000000..2f9894c --- /dev/null +++ b/database/migrations/create_satusehat_loinc_table.php.stub @@ -0,0 +1,47 @@ +create(config('satusehatintegration.loinc_table_name'), function (Blueprint $table) { + $table->bigIncrements('id'); + $table->string('LOINC_NUM')->unique(); + $table->string('COMPONENT')->nullable(); + $table->string('PROPERTY')->nullable(); + $table->string('TIME_ASPCT')->nullable(); + $table->string('SYSTEM')->nullable(); + $table->string('SCALE_TYP')->nullable(); + $table->string('METHOD_TYP')->nullable(); + $table->string('CLASS')->nullable(); + $table->string('CLASSTYPE')->nullable(); + $table->string('LONG_COMMON_NAME')->nullable(); + $table->string('SHORTNAME')->nullable(); + $table->longText('EXTERNAL_COPYRIGHT_NOTICE')->nullable(); + $table->string('STATUS')->nullable(); + $table->string('VersionFirstReleased')->nullable(); + $table->string('VersionLastChanged')->nullable(); + $table->timestamps(); + $table->softDeletes(); + }); + } + + /** + * Reverse the migrations. + * + * @return void + */ + public function down() + { + Schema::connection(config('satusehatintegration.database_connection_master'))->dropIfExists(config('satusehatintegration.loinc_table_name')); + } +} diff --git a/database/seeders/LoincAnswerSeeder.php.stub b/database/seeders/LoincAnswerSeeder.php.stub new file mode 100644 index 0000000..9de6fd7 --- /dev/null +++ b/database/seeders/LoincAnswerSeeder.php.stub @@ -0,0 +1,27 @@ +file = base_path().'/database/seeders/csv/loinc_answer.csv'; + $this->tablename = config('satusehatintegration.loinc_answer_table_name'); + $this->delimiter = ';'; + } + + public function run() + { + // Recommended when importing larger CSVs + DB::disableQueryLog(); + + parent::run(); + } +} diff --git a/database/seeders/LoincSeeder.php.stub b/database/seeders/LoincSeeder.php.stub new file mode 100644 index 0000000..020586b --- /dev/null +++ b/database/seeders/LoincSeeder.php.stub @@ -0,0 +1,27 @@ +file = base_path().'/database/seeders/csv/loinc.csv'; + $this->tablename = config('satusehatintegration.loinc_table_name'); + $this->delimiter = ';'; + } + + public function run() + { + // Recommended when importing larger CSVs + DB::disableQueryLog(); + + parent::run(); + } +} diff --git a/database/seeders/csv/loinc.csv.stub b/database/seeders/csv/loinc.csv.stub new file mode 100644 index 0000000..700ebf1 --- /dev/null +++ b/database/seeders/csv/loinc.csv.stub @@ -0,0 +1,99688 @@ +LOINC_NUM;COMPONENT;PROPERTY;TIME_ASPCT;SYSTEM;SCALE_TYP;METHOD_TYP;CLASS;CLASSTYPE;LONG_COMMON_NAME;SHORTNAME;EXTERNAL_COPYRIGHT_NOTICE;STATUS;VersionFirstReleased;VersionLastChanged +100000-9;Health informatics pioneer and the father of LOINC;Hx;Pt;^Patient;Nar;;H&P.HX;2;Health informatics pioneer and the father of LOINC;Health Info Pioneer+Father of LOINC;;ACTIVE;2.74;2.74 +100001-7;Health informatics pioneer and cofounder of LOINC;Hx;Pt;^Patient;Nar;;H&P.HX;2;Health informatics pioneer and cofounder of LOINC;Health Info Pioneer+Cofound LOINC;;ACTIVE;2.74;2.74 +100002-5;Specimen care is maintained;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Specimen care is maintained;;;ACTIVE;2.72;2.72 +100003-3;Team communication is maintained throughout care;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Team communication is maintained throughout care;;;ACTIVE;2.72;2.72 +100004-1;Demonstrates knowledge of the expected psychosocial responses to the procedure;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Demonstrates knowledge of the expected psychosocial responses to the procedure;;;ACTIVE;2.72;2.72 +100005-8;Demonstrates knowledge of nutritional management related to the procedure;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Demonstrates knowledge of nutritional management related to the procedure;;;ACTIVE;2.72;2.72 +100006-6;Demonstrates knowledge of medication management;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Demonstrates knowledge of medication management;;;ACTIVE;2.72;2.72 +100007-4;Demonstrates knowledge of pain management;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Demonstrates knowledge of pain management;;;ACTIVE;2.72;2.72 +10000-8;R wave duration.lead AVR;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead AVR;R wave dur L-AVR;;ACTIVE;1.0i;2.48 +100008-2;Demonstrates knowledge of wound management;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Demonstrates knowledge of wound management;;;ACTIVE;2.72;2.72 +100009-0;Demonstrates knowledge of the procedure and expected results;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Demonstrates knowledge of the procedure and expected results;;;ACTIVE;2.72;2.72 +100010-8;No injury related to procedure equipment, medical supplies, or instrumentation;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to procedure equipment, medical supplies, or instrumentation;;;ACTIVE;2.72;2.72 +100011-6;No injury related to an electrical source;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to an electrical source;;;ACTIVE;2.72;2.72 +100012-4;Participates in decisions affecting the patient's plan of care;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Participates in decisions affecting the patient's plan of care;;;ACTIVE;2.72;2.72 +100013-2;Participates in the discharge process;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Participates in the discharge process;;;ACTIVE;2.72;2.72 +100014-0;Psychosocial health is maintained at or improved from baseline;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Psychosocial health is maintained at or improved from baseline;;;ACTIVE;2.72;2.72 +100015-7;No injury related to positioning due to care or procedure;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to positioning due to care or procedure;;;ACTIVE;2.72;2.72 +10001-6;R wave duration.lead I;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead I;R wave dur L-I;;ACTIVE;1.0i;2.48 +100016-5;No injury related to a laser source;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to a laser source;;;ACTIVE;2.72;2.72 +100017-3;Perioperative nursing data set outcomes panel;-;Pt;^Patient;-;PNDS;PANEL.SURVEY.PNDS;4;Perioperative nursing data set outcomes panel [PNDS];;©AORN Syntegrity, Inc. Used with permission.Commercial or facility use requires a license from AORN Syntegrity or an authorized reseller.;ACTIVE;2.72;2.72 +100018-1;Note;Find;Pt;{Setting};Doc;Hospice care;DOC.ONTOLOGY;2;Hospice care Note;Hospice care Note;;ACTIVE;2.72;2.72 +100019-9;ALK gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ALK gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ALK gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100020-7;GNA11 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GNA11 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GNA11 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100021-5;GNAQ gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GNAQ gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GNAQ gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100022-3;IDH1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;IDH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;IDH1 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100023-1;IDH2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;IDH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;IDH2 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +10002-4;R wave duration.lead II;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead II;R wave dur L-II;;ACTIVE;1.0i;2.48 +100024-9;SETBP1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SETBP1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SETBP1 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100025-6;SRSF2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SRSF2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SRSF2 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100026-4;MET gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MET gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MET gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100027-2;SMAD4 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SMAD4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SMAD4 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100028-0;FBXW7 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FBXW7 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FBXW7 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +100029-8;Cancer related multigene analysis;Find;Pt;Plas.cfDNA;Doc;Molgen;MOLPATH;1;Cancer related multigene analysis in Plasma cell-free DNA by Molecular genetics method;Cancer multigene analysis Plas.cfDNA;;ACTIVE;2.72;2.72 +100030-6;Axis I: Temporal aspects score;Score;Pt;^Patient;Qn;Mainz Pain Staging System;SURVEY.PAIN;4;Axis I: Temporal aspects score [Mainz Pain Staging System];;© 1999 H.U. Gerbershagen, J. Korb, B. Nagel, P. Nilges. Used with permission.;ACTIVE;2.72;2.72 +100031-4;Axis II: Spatial aspects score;Score;Pt;^Patient;Qn;Mainz Pain Staging System;SURVEY.PAIN;4;Axis II: Spatial aspects score [Mainz Pain Staging System];;© 1999 H.U. Gerbershagen, J. Korb, B. Nagel, P. Nilges. Used with permission.;ACTIVE;2.72;2.72 +10003-2;R wave duration.lead III;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead III;R wave dur L-III;;ACTIVE;1.0i;2.48 +100032-2;Axis III: Drug taking behavior score;Score;Pt;^Patient;Qn;Mainz Pain Staging System;SURVEY.PAIN;4;Axis III: Drug taking behavior score [Mainz Pain Staging System];;© 1999 H.U. Gerbershagen, J. Korb, B. Nagel, P. Nilges. Used with permission.;ACTIVE;2.72;2.72 +100033-0;Axis IV: Utilization of the health care system score;Score;Pt;^Patient;Qn;Mainz Pain Staging System;SURVEY.PAIN;4;Axis IV: Utilization of the health care system score [Mainz Pain Staging System];;© 1999 H.U. Gerbershagen, J. Korb, B. Nagel, P. Nilges. Used with permission.;ACTIVE;2.72;2.72 +100034-8;Provider of automated external defibrillator use;Type;Pt;^Patient;Nom;;TRAUMA;2;Provider of automated external defibrillator use;Provider of AED;;ACTIVE;2.72;2.72 +100035-5;Exam finding location;Find;Pt;Chest;Nom;;H&P.PX;2;Exam finding location of Chest;Exam finding location Chest;;ACTIVE;2.72;2.72 +100036-3;Exam finding location;Find;Pt;Lung;Nom;;H&P.PX;2;Exam finding location of Lung;Exam finding location Lung;;ACTIVE;2.72;2.72 +100037-1;Patient contact disposition;Type;Pt;EMS unit;Nom;;TRAUMA;2;Patient contact disposition EMS unit;Patient contact disposition EMS unit;;ACTIVE;2.72;2.72 +100038-9;Patient evaluation disposition;Type;Pt;EMS unit;Nom;;TRAUMA;2;Patient evaluation disposition EMS unit;Patient eval disposition EMS unit;;ACTIVE;2.72;2.72 +100039-7;Crew disposition for patient care;Type;Pt;EMS unit;Nom;;TRAUMA;2;Crew disposition for patient care EMS unit;Crew disposition EMS unit;;ACTIVE;2.72;2.72 +10004-0;R wave duration.lead V1;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead V1;R wave dur L-V1;;ACTIVE;1.0i;2.48 +100040-5;Patient transport disposition;Type;Pt;EMS unit;Nom;;TRAUMA;2;Patient transport disposition EMS unit;Pt transport disposition EMS unit;;ACTIVE;2.72;2.72 +100041-3;Aminoglycoside;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Aminoglycoside [Susceptibility];Aminoglycoside Susc Islt;;ACTIVE;2.72;2.72 +100042-1;Atovaquone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Atovaquone [Susceptibility];Atovaquone Susc Islt;;ACTIVE;2.72;2.72 +100043-9;Azithromycin+Ethambutol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Azithromycin+Ethambutol [Susceptibility];Azithro+Ethambut Susc Islt;;ACTIVE;2.72;2.72 +100044-7;Cefcapene;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefcapene [Susceptibility];Cefcapene Susc Islt;;ACTIVE;2.72;2.72 +100045-4;Cefozopran;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefozopran [Susceptibility];Cefozopran Susc Islt;;ACTIVE;2.72;2.72 +100046-2;Cefquinome;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefquinome [Susceptibility];CEQ Susc Islt;;ACTIVE;2.72;2.72 +100047-0;Cefteram;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefteram [Susceptibility];Cefteram Susc Islt;;ACTIVE;2.72;2.72 +100048-8;Clarithromycin+Ethambutol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clarithromycin+Ethambutol [Susceptibility];Clarithro+Ethamb Susc Islt;;ACTIVE;2.72;2.72 +100049-6;Eravacycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Eravacycline [Susceptibility];Eravacycline Susc Islt;;ACTIVE;2.72;2.72 +100050-4;Erythromycin+Ethambutol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Erythromycin+Ethambutol [Susceptibility];Erythro+Ethamb Susc Islt;;ACTIVE;2.72;2.72 +100051-2;Ethambutol+rifAMPin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ethambutol+rifAMPin [Susceptibility];Ethambutol+rifAMPin Susc Islt;;ACTIVE;2.72;2.72 +100052-0;Flomoxef;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Flomoxef [Susceptibility];Flomoxef Susc Islt;;ACTIVE;2.72;2.72 +100053-8;Fluoroquinolone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Fluoroquinolone [Susceptibility];FLQ Susc Islt;;ACTIVE;2.72;2.72 +100054-6;Gamithromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Gamithromycin [Susceptibility];Gamithromycin Susc Islt;;ACTIVE;2.72;2.72 +100055-3;Optochin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Optochin [Susceptibility];Optochin Susc Islt;;ACTIVE;2.72;2.72 +100056-1;Panipenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Panipenem [Susceptibility];Panipenem Susc Islt;;ACTIVE;2.72;2.72 +10005-7;R wave duration.lead V2;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead V2;R wave dur L-V2;;ACTIVE;1.0i;2.48 +100057-9;Prothionamide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Prothionamide [Susceptibility];Prothionamide Susc Islt;;ACTIVE;2.72;2.72 +100058-7;Prulifloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Prulifloxacin [Susceptibility];Prulifloxacin Susc Islt;;ACTIVE;2.72;2.72 +100059-5;Rifapentine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Rifapentine [Susceptibility];Rifapentine Susc Islt;;ACTIVE;2.72;2.72 +100060-3;Tildipirosin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tildipirosin [Susceptibility];Tildipirosin Susc Islt;;ACTIVE;2.72;2.72 +100061-1;Tosufloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tosufloxacin [Susceptibility];Tosufloxacin Susc Islt;;ACTIVE;2.72;2.72 +100062-9;Standard Dermatology Outcome Measures panel;-;Pt;^Patient;-;SDOM;PANEL.CLIN;2;Standard Dermatology Outcome Measures panel;SDOM panel;Copyright © 2016 The Regents of the University of California and Emory University. Used with permission.;ACTIVE;2.72;2.72 +100063-7;Primary skin concern;Find;Pt;^Patient;Nom;;CLIN;2;Primary skin concern;Primary skin concern;;ACTIVE;2.72;2.72 +100064-5;Itch severity;Find;RptPeriod;^Patient;Ord;Reported;CLIN;2;Itch severity Reporting Period - Reported;Itch severity RptPeriod Reported;;ACTIVE;2.72;2.72 +10006-5;R wave duration.lead V3;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead V3;R wave dur L-V3;;ACTIVE;1.0i;2.48 +100065-2;Satisfied with treatment;Find;Pt;^Patient;Ord;;CLIN;2;Satisfied with treatment;Satisfied with treatment;;ACTIVE;2.72;2.72 +100066-0;Specular microscopy panel;-;Pt;Eye;-;Specular microscopy;PANEL.EYE;2;Specular microscopy panel;Specular microscopy panel;;TRIAL;2.72;2.72 +100067-8;Image magnification;Len;Pt;Eye;Qn;;EYE.SPECULAR MICROSCOPY;2;Eye Image magnification;Eye Image magnification;;TRIAL;2.72;2.72 +100068-6;Fixation point;Angle;Pt;Eye.right;Nom;;EYE.SPECULAR MICROSCOPY;2;Right eye Fixation point [Angle];R eye Fixation point [Angle];;TRIAL;2.72;2.72 +100069-4;Fixation point;Angle;Pt;Eye.left;Nom;;EYE.SPECULAR MICROSCOPY;2;Left eye Fixation point [Angle];L eye Fixation point [Angle];;TRIAL;2.72;2.72 +100070-2;Cell density;Naric;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Cell density;R cornea Cell density;;TRIAL;2.72;2.72 +100071-0;Cell density;Naric;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Cell density;L cornea Cell density;;TRIAL;2.72;2.72 +100072-8;Coefficient of variation;ArLen;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Coefficient of variation;R cornea Coefficient of variation;;TRIAL;2.72;2.72 +10007-3;R wave duration.lead V4;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead V4;R wave dur L-V4;;ACTIVE;1.0i;2.48 +100073-6;Coefficient of variation;ArLen;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Coefficient of variation;L cornea Coefficient of variation;;TRIAL;2.72;2.72 +100074-4;Hexagonality;RelRto;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Hexagonality;R cornea Hexagonality;;TRIAL;2.72;2.72 +100075-1;Hexagonality;RelRto;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Hexagonality;L cornea Hexagonality;;TRIAL;2.72;2.72 +100076-9;Endothelial cells counted;Num;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Endothelial cells counted;R cornea Endothelial cells counted;;TRIAL;2.72;2.72 +100077-7;Endothelial cells counted;Num;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Endothelial cells counted;L cornea Endothelial cells counted;;TRIAL;2.72;2.72 +100078-5;Endothelial cell area.min;Area;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Endothelial cell area.min;R cornea Endothelial cell area.min;;TRIAL;2.72;2.72 +100079-3;Endothelial cell area.min;Area;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Endothelial cell area.min;L cornea Endothelial cell area.min;;TRIAL;2.72;2.72 +100080-1;Endothelial cell area.max;Area;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Endothelial cell area.max;R cornea Endothelial cell area.max;;TRIAL;2.72;2.72 +10008-1;R wave duration.lead V5;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead V5;R wave dur L-V5;;ACTIVE;1.0i;2.48 +100081-9;Endothelial cell area.max;Area;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Endothelial cell area.max;L cornea Endothelial cell area.max;;TRIAL;2.72;2.72 +100082-7;Endothelial cell area.mean;Area;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Endothelial cell area.mean;R cornea Endothelial cell area.mean;;TRIAL;2.72;2.72 +100083-5;Endothelial cell area.mean;Area;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Endothelial cell area.mean;L cornea Endothelial cell area.mean;;TRIAL;2.72;2.72 +100084-3;Cell area.standard deviation;Area;Pt;Cornea.right;Qn;;EYE.SPECULAR MICROSCOPY;2;Right cornea Cell area.standard deviation;R cornea Cell area.sd;;TRIAL;2.72;2.72 +100085-0;Cell area.standard deviation;Area;Pt;Cornea.left;Qn;;EYE.SPECULAR MICROSCOPY;2;Left cornea Cell area.standard deviation;L cornea Cell area.sd;;TRIAL;2.72;2.72 +100086-8;Analysis method;Type;Pt;Cornea.right;Nom;Specular microscopy;EYE.SPECULAR MICROSCOPY;2;Right cornea Type of Analysis method by Specular microscopy;R cornea Analysis method;;TRIAL;2.72;2.72 +100087-6;Toxocara canis 24-35kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Toxocara canis 24-35kD IgG Ab [Presence] in Serum by Immunoblot;T canis 24-35kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100088-4;Taenia solium larva Ab bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Taenia solium larva Ab bands panel - Serum by Immunoblot;T solium Ab bands Pnl Ser IB;;ACTIVE;2.72;2.72 +100089-2;Taenia solium larva 6-8kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 6-8kD Ab [Presence] in Serum by Immunoblot;T solium 6-8kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +1000-9;DBG Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;DBG Ab [Presence] in Serum or Plasma from Blood product unit;DBG Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +100090-0;Taenia solium larva 45kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 45kD Ab [Presence] in Serum by Immunoblot;T solium 45kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100091-8;Trypanosoma cruzi Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trypanosoma cruzi Ab [Units/volume] in Serum by Immunoassay;T cruzi Ab Ser IA-aCnc;;ACTIVE;2.72;2.72 +100092-6;Trypanosoma cruzi Ab bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Trypanosoma cruzi Ab bands panel - Serum by Immunoblot;T cruzi Ab bands Pnl Ser IB;;ACTIVE;2.72;2.72 +100093-4;Trypanosoma cruzi 15-16kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Trypanosoma cruzi 15-16kD IgG Ab [Presence] in Serum by Immunoblot;T cruzi 15-16kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100094-2;Trypanosoma cruzi 21-22kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Trypanosoma cruzi 21-22kD IgG Ab [Presence] in Serum by Immunoblot;T cruzi 21-22kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100095-9;Trypanosoma cruzi 27-28kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Trypanosoma cruzi 27-28kD IgG Ab [Presence] in Serum by Immunoblot;T cruzi 27-28kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100096-7;Trypanosoma cruzi 42kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Trypanosoma cruzi 42kD IgG Ab [Presence] in Serum by Immunoblot;T cruzi 42kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100097-5;Trypanosoma cruzi 45-47kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Trypanosoma cruzi 45-47kD IgG Ab [Presence] in Serum by Immunoblot;T cruzi 45-47kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100098-3;Trypanosoma cruzi 120-200kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Trypanosoma cruzi 120-200kD IgG Ab [Presence] in Serum by Immunoblot;T cruzi 120-200kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +10009-9;R wave duration.lead V6;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead V6;R wave dur L-V6;;ACTIVE;1.0i;2.48 +100099-1;Trypanosoma cruzi 160kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Trypanosoma cruzi 160kD IgG Ab [Presence] in Serum by Immunoblot;T cruzi 160kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100100-7;Fasciola sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Fasciola sp IgG Ab [Presence] in Serum by Immunoassay;Fasciola IgG Ser Ql IA;;ACTIVE;2.72;2.72 +100101-5;Fasciola sp 8-9kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Fasciola sp 8-9kD IgG Ab [Presence] in Serum by Immunoblot;Fasciola sp 8-9kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100102-3;Fasciola sp 27-28kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Fasciola sp 27-28kD IgG Ab [Presence] in Serum by Immunoblot;Fasciola sp 27-28kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100103-1;Fasciola sp 60kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Fasciola sp 60kD IgG Ab [Presence] in Serum by Immunoblot;Fasciola sp 60kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100104-9;Fasciola sp 42kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Fasciola sp 42kD IgG Ab [Presence] in Serum by Immunoblot;Fasciola sp 42kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100105-6;Filaria Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Filaria IgG and IgM panel - Serum;Filaria Ab.IgG + IgM Pnl Ser;;ACTIVE;2.72;2.72 +100106-4;Filaria Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Filaria IgG Ab [Presence] in Serum by Immunoassay;Filaria IgG Ser Ql IA;;ACTIVE;2.72;2.72 +10010-7;R' wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead AVF;R' wave Amp L-AVF;;ACTIVE;1.0i;2.48 +100107-2;Leishmania sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leishmania sp IgG Ab [Presence] in Serum by Immunoassay;Leishmania IgG Ser Ql IA;;ACTIVE;2.72;2.72 +100108-0;Leishmania sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Leishmania sp IgG Ab [Units/volume] in Serum by Immunoassay;Leishmania IgG Ser IA-aCnc;;ACTIVE;2.72;2.72 +100109-8;Leishmania sp Ab bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Leishmania sp Ab bands panel - Serum by Immunoblot;Leishmania sp Ab IB Pnl Ser IB;;ACTIVE;2.72;2.72 +100110-6;Leishmania sp 14kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Leishmania sp 14kD IgG Ab [Presence] in Serum by Immunoblot;Leishmania sp 14kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100111-4;Leishmania sp 16kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Leishmania sp 16kD IgG Ab [Presence] in Serum by Immunoblot;Leishmania sp 16kD IgG Ser Ql IB;;ACTIVE;2.72;2.72 +100112-2;Fasciola sp Ab bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Fasciola sp Ab bands panel - Serum by Immunoblot;Fasciola sp Ab IB Pnl Ser IB;;ACTIVE;2.72;2.72 +100113-0;Helicobacter pylori Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Helicobacter pylori Ab panel - Serum;H pylori Ab Pnl Ser;;ACTIVE;2.72;2.72 +100114-8;Toxoplasma gondii 30kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Toxoplasma gondii 30kD Ab [Presence] in Serum by Immunoblot;T gondii 30kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +10011-5;R' wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead AVL;R' wave Amp L-AVL;;ACTIVE;1.0i;2.48 +100115-5;Toxoplasma gondii 31kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Toxoplasma gondii 31kD Ab [Presence] in Serum by Immunoblot;T gondii 31kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100116-3;Toxoplasma gondii 33kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Toxoplasma gondii 33kD Ab [Presence] in Serum by Immunoblot;T gondii 33kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100117-1;Toxoplasma gondii 40kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Toxoplasma gondii 40kD Ab [Presence] in Serum by Immunoblot;T gondii 40kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100118-9;Toxoplasma gondii 41kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Toxoplasma gondii 41kD Ab [Presence] in Serum by Immunoblot;T gondii 41kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100119-7;Toxoplasma gondii 45kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Toxoplasma gondii 45kD Ab [Presence] in Serum by Immunoblot;T gondii 45kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100120-5;Chlamydia trachomatis Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Chlamydia trachomatis Ab panel - Serum;C trachomatis Ab Pnl Ser;;ACTIVE;2.72;2.72 +100121-3;Chlamydia trachomatis Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydia trachomatis IgA Ab [Presence] in Serum by Immunoassay;C trach IgA Ser Ql IA;;ACTIVE;2.72;2.72 +100122-1;Chlamydophila pneumoniae Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Chlamydophila pneumoniae Ab panel - Serum;C pneum Ab Pnl Ser;;ACTIVE;2.72;2.72 +10012-3;R' wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead AVR;R' wave Amp L-AVR;;ACTIVE;1.0i;2.48 +100123-9;Chlamydophila pneumoniae Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydophila pneumoniae IgA Ab [Presence] in Serum by Immunoassay;C pneum IgA Ser Ql IA;;ACTIVE;2.72;2.72 +100124-7;Chlamydophila pneumoniae Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum by Immunoassay;C pneum IgA Ser IA-aCnc;;ACTIVE;2.72;2.72 +100125-4;Chlamydophila psittaci Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Chlamydophila psittaci Ab panel - Serum;C psittaci Ab Pnl Ser;;ACTIVE;2.72;2.72 +100126-2;Bordetella pertussis Ab.IgG panel;-;Pt;Ser;-;;PANEL.MICRO;1;Bordetella pertussis Ab.IgG panel - Serum;B pert IgG Pnl Ser;;ACTIVE;2.72;2.72 +100127-0;Campylobacter sp Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Campylobacter sp Ab panel - Serum;Camplybactr sp Ab Pnl Ser;;ACTIVE;2.72;2.72 +100128-8;Cryptococcus sp Ag panel;-;Pt;Ser;-;;PANEL.MICRO;1;Cryptococcus sp Ag panel - Serum;Cryptoc Ag Pnl Ser;;ACTIVE;2.72;2.72 +100129-6;Schistosoma sp Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Schistosoma sp Ab [Titer] in Serum by Hemagglutination;Schistosoma Ab Titr Ser HA;;ACTIVE;2.72;2.72 +100130-4;Schistosoma mansoni Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma mansoni Ab [Presence] in Serum by Immunoblot;S mansoni Ab Ser Ql IB;;ACTIVE;2.72;2.72 +10013-1;R' wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead I;R' wave Amp L-I;;ACTIVE;1.0i;2.48 +100131-2;Schistosoma sp 8kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 8kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 8kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100132-0;Schistosoma sp 9kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 9kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 9kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100133-8;Schistosoma sp 10kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 10kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 10kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100134-6;Schistosoma sp 11kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 11kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 11kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100135-3;Schistosoma sp 12-13kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 12-13kD Ab [Presence] in Serum by Immunoblot;Schist sp 12-13kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100136-1;Schistosoma sp 14-15kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 14-15kD Ab [Presence] in Serum by Immunoblot;Schist sp 14-15kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100137-9;Schistosoma sp 15-16kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 15-16kD Ab [Presence] in Serum by Immunoblot;Schist sp 15-16kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100138-7;Schistosoma sp 18-19kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 18-19kD Ab [Presence] in Serum by Immunoblot;Schist sp 18-19kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100139-5;Schistosoma sp 22-24kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 22-24kD Ab [Presence] in Serum by Immunoblot;Schist sp 22-24kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100140-3;Schistosoma sp 30-34kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 30-34kD Ab [Presence] in Serum by Immunoblot;Schist sp 30-34kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100141-1;Schistosoma sp 65kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 65kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 65kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100142-9;Schistosoma sp 70kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 70kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 70kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100143-7;Schistosoma sp 80kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 80kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 80kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100144-5;Schistosoma sp 95kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 95kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 95kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100145-2;Schistosoma sp 110kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 110kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 110kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100146-0;Schistosoma sp 120kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma sp 120kD Ab [Presence] in Serum by Immunoblot;Schistosoma sp 120kD Ab Ser Ql IB;;ACTIVE;2.72;2.72 +100147-8;Toxoplasma gondii Ab bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Toxoplasma gondii Ab bands panel - Serum by Immunoblot;T gondii Ab bands Pnl Ser IB;;ACTIVE;2.72;2.72 +100148-6;Schistosoma sp Ab bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Schistosoma sp Ab bands panel - Serum by Immunoblot;Schistosoma sp Ab IB Pnl Ser IB;;ACTIVE;2.72;2.72 +10014-9;R' wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead II;R' wave Amp L-II;;ACTIVE;1.0i;2.48 +100149-4;6-oxo-piperidine-2-carboxylate & 6(R+S)-oxo-propylpiperidine-2-carboxylate panel;-;Pt;Urine+Ser/Plas;-;;PANEL.CHEM;1;6-oxo-piperidine-2-carboxylate and 6(R+S)-oxo-propylpiperidine-2-carboxylate panel - Urine and Serum or Plasma;6-oxo-PIP + 6(R+S)-OPP Ur+SerPl;;ACTIVE;2.72;2.72 +100150-2;6(R+S)-oxo-propylpiperidine-2-carboxylate;SCnc;Pt;Plas;Qn;;CHEM;1;6(R+S)-oxo-propylpiperidine-2-carboxylate [Moles/volume] in Plasma;6(R+S)-OPP Plas-sCnc;;ACTIVE;2.72;2.72 +100151-0;6-oxo-piperidine-2-carboxylate;SCnc;Pt;Plas;Qn;;CHEM;1;6-oxo-piperidine-2-carboxylate [Moles/volume] in Plasma;6-oxo-PIP Plas-sCnc;;ACTIVE;2.72;2.72 +100152-8;6-oxo-piperidine-2-carboxylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;6-oxo-piperidine-2-carboxylate/Creatinine [Molar ratio] in Urine;6-oxo-PIP/Creat Ur-sRto;;ACTIVE;2.72;2.72 +100153-6;6(R+S)-oxo-propylpiperidine-2-carboxylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;6(R+S)-oxo-propylpiperidine-2-carboxylate/Creatinine [Molar ratio] in Urine;6(R+S)-OPP/Creat Ur-sRto;;ACTIVE;2.72;2.72 +100154-4;Collection supervision level;Find;Pt;Specimen;Nom;;SPEC;1;Specimen collection supervision level;Spec collect supervision level;;ACTIVE;2.72;2.72 +100155-1;Analysis method;Type;Pt;Cornea.left;Nom;Specular microscopy;EYE.SPECULAR MICROSCOPY;2;Left cornea Type of Analysis method by Specular microscopy;L cornea Analysis method;;TRIAL;2.72;2.72 +10015-6;R' wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead III;R' wave Amp L-III;;ACTIVE;1.0i;2.48 +100156-9;SARS coronavirus 2 variant;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) variant [Type] in Specimen by NAA with probe detection;SARS-CoV-2 variant Spec NAA+probe;;ACTIVE;2.72;2.72 +100157-7;SARS coronavirus 2 lineage;Type;Pt;XXX;Nom;Sequencing;MICRO;1;SARS-CoV-2 (COVID-19) lineage [Type] in Specimen by Sequencing;SARS-CoV-2 lineage Spec Seq;;ACTIVE;2.72;2.72 +100158-5;Albumin;MCnc;XXX;Urine;Qn;Detection limit <= 20 mg/L;UA;1;Microalbumin [Mass/volume] in Urine collected for unspecified duration;Microalbumin ?Tm Ur-mCnc;;ACTIVE;2.73;2.73 +100159-3;Knee Society Score pre-op panel;-;Pt;^Patient;-;Knee Society Score;PANEL.SURVEY.ORTHOPEDICS;4;Knee Society Score pre-op panel [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100160-1;Knee replacement;Type;Pt;^Patient;Ord;;CLIN;2;Knee replacement;Knee replacement;;ACTIVE;2.73;2.73 +100161-9;Charnley Functional Classification;Find;Pt;^Patient;Ord;;CLIN;2;Charnley Functional Classification;Charnley Functional Classification;;ACTIVE;2.73;2.73 +100162-7;Alignment^W standing;Find;Pt;Knee;Ord;XR.measured;CLIN;2;Knee alignment W standing X-ray measured;Alignment W Stand Knee XR;;ACTIVE;2.73;2.73 +100163-5;Medial &or lateral instability^W full extension;Find;Pt;Knee;Ord;Measured;CLIN;2;Knee medial AndOr lateral instability W full extension;Knee med AndOr lat instab W full ext;;ACTIVE;2.73;2.73 +10016-4;R' wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead V1;R' wave Amp L-V1;;ACTIVE;1.0i;2.48 +100164-3;Anterior-posterior instability^W 90 degree flexion;Find;Pt;Knee;Ord;Measured;CLIN;2;Knee AP instability W 90 degree flexion;Knee AP instability W 90 deg flex;;ACTIVE;2.73;2.73 +100165-0;Range of motion;Angle;Pt;Knee;Qn;;H&P.PX;2;Knee range of motion;Knee Qn;;ACTIVE;2.73;2.73 +100166-8;Flexion contracture range;Find;Pt;Knee;Ord;;H&P.PX;2;Flexion contracture range of Knee;Flexion contracture range Knee;;ACTIVE;2.73;2.73 +100167-6;Extensor lag range;Find;Pt;Knee;Ord;;H&P.PX;2;Extensor lag range of Knee;Extensor lag range Knee;;ACTIVE;2.73;2.73 +100168-4;Knee pain severity with level walking;Find;Pt;^Patient;Ord;;SURVEY.PAIN;4;Knee pain severity with level walking;;;ACTIVE;2.73;2.73 +100169-2;Knee pain severity with stairs or inclines;Find;Pt;^Patient;Ord;;SURVEY.PAIN;4;Knee pain severity with stairs or inclines;;;ACTIVE;2.73;2.73 +1001-7;DBG Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;DBG Ab [Presence] in Serum or Plasma from Donor;DBG Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +100170-0;Knee feels normal;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Knee feels normal;;;ACTIVE;2.73;2.73 +100171-8;Satisfaction with level of knee pain while sitting;Find;Pt;^Patient;Ord;;SURVEY.PAIN;4;Satisfaction with level of knee pain while sitting;;;ACTIVE;2.73;2.73 +10017-2;R' wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead V2;R' wave Amp L-V2;;ACTIVE;1.0i;2.48 +100172-6;Satisfaction with level of knee pain while lying in bed;Find;Pt;^Patient;Ord;;SURVEY.PAIN;4;Satisfaction with level of knee pain while lying in bed;;;ACTIVE;2.73;2.73 +100173-4;Satisfaction with knee function while getting out of bed;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Satisfaction with knee function while getting out of bed;;;ACTIVE;2.73;2.73 +100174-2;Satisfaction with knee function while performing light household duties;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Satisfaction with knee function while performing light household duties;;;ACTIVE;2.73;2.73 +100175-9;Satisfaction with knee function while performing recreational activities;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Satisfaction with knee function while performing recreational activities;;;ACTIVE;2.73;2.73 +100176-7;Expect surgery to relieve pain;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Expect surgery to relieve pain;;;ACTIVE;2.73;2.73 +100177-5;Expect surgery will improve ability to perform activities of daily living;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Expect surgery will improve ability to perform activities of daily living;;;ACTIVE;2.73;2.73 +100178-3;Expect surgery will improve ability to perform leisure, recreational, or sports activities;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Expect surgery will improve ability to perform leisure, recreational, or sports activities;;;ACTIVE;2.73;2.73 +100179-1;Walk without assistive mobility devices;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Walk without assistive mobility devices;;;ACTIVE;2.73;2.73 +10018-0;R' wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead V3;R' wave Amp L-V3;;ACTIVE;1.0i;2.48 +100180-9;Assistive mobility devices used;Find;Pt;^Patient;Nom;;SURVEY.ORTHOPEDICS;4;Assistive mobility devices used;;;ACTIVE;2.73;2.73 +100181-7;Assistive mobility devices used due to health condition;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Assistive mobility devices used due to health condition;;;ACTIVE;2.73;2.73 +100182-5;Duration of standing before sitting due to knee discomfort;Time;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Duration of standing before sitting due to knee discomfort;;;ACTIVE;2.73;2.73 +100183-3;Duration of walking before stopping due to knee discomfort;Time;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Duration of walking before stopping due to knee discomfort;;;ACTIVE;2.73;2.73 +100184-1;How bothersome is knee when walking on an uneven surface;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when walking on an uneven surface;;;ACTIVE;2.73;2.73 +100185-8;How bothersome is knee when turning or pivoting leg;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when turning or pivoting leg;;;ACTIVE;2.73;2.73 +100186-6;How bothersome is knee when climbing up or down a flight of stairs;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when climbing up or down a flight of stairs;;;ACTIVE;2.73;2.73 +100187-4;How bothersome is knee when getting up from a low seat without armrests;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when getting up from a low seat without armrests;;;ACTIVE;2.73;2.73 +100188-2;How bothersome is knee when getting into or out of a car;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when getting into or out of a car;;;ACTIVE;2.73;2.73 +100189-0;How bothersome is knee when moving laterally;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when moving laterally;;;ACTIVE;2.73;2.73 +100190-8;How bothersome is knee when climbing a ladder or step stool;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when climbing a ladder or step stool;;;ACTIVE;2.73;2.73 +100191-6;How bothersome is knee when carrying a bag for one block;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when carrying a bag for one block;;;ACTIVE;2.73;2.73 +100192-4;How bothersome is knee when squatting;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when squatting;;;ACTIVE;2.73;2.73 +100193-2;How bothersome is knee when kneeling;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when kneeling;;;ACTIVE;2.73;2.73 +100194-0;How bothersome is knee when running;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;How bothersome is knee when running;;;ACTIVE;2.73;2.73 +100195-7;Pain severity^during activity;Find;Pt;^Patient;Ord;;SURVEY.PAIN;4;Pain severity--during activity;;;ACTIVE;2.73;2.73 +100196-5;Pre-op total score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Pre-op total score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100197-3;Exercise activity & pain severity panel;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Exercise activity and pain severity panel;;;ACTIVE;2.73;2.73 +10019-8;R' wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead V4;R' wave Amp L-V4;;ACTIVE;1.0i;2.48 +100198-1;Pre-op objective knee indicators score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Pre-op objective knee indicators score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100199-9;Pre-op symptoms score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Pre-op symptoms score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100200-5;Pre-op patient expectations score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Pre-op patient expectations score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100201-3;Pre-op functional activities score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Pre-op functional activities score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100202-1;Pre-op discretionary knee activities score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Pre-op discretionary knee activities score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100203-9;Knee Society Score post-op panel;-;Pt;^Patient;-;Knee Society Score;PANEL.SURVEY.ORTHOPEDICS;4;Knee Society Score post-op panel [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100204-7;Accuracy of pre-surgery expectations of pain relief;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Accuracy of pre-surgery expectations of pain relief;;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100205-4;Accuracy of pre-surgery expectations to perform activities of daily living;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Accuracy of pre-surgery expectations to perform activities of daily living;;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +10020-6;R' wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead V5;R' wave Amp L-V5;;ACTIVE;1.0i;2.48 +100206-2;Accuracy of pre-surgery expectations to perform leisure, recreational, or sports activities;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Accuracy of pre-surgery expectations to perform leisure, recreational, or sports activities;;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100207-0;Post-op total score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Post-op total score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100208-8;Post-op objective knee indicators score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Post-op objective knee indicators score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100209-6;Post-op symptoms score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Post-op symptoms score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100210-4;Post-op patient expectations score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Post-op patient expectations score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100211-2;Post-op functional activities score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Post-op functional activities score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100212-0;Post-op discretionary knee activities score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Post-op discretionary knee activities score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100213-8;Prostate cancer multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Prostate cancer multigene analysis in Blood or Tissue by Molecular genetics method;Prostate cancer multigene analysis Bld/T;;ACTIVE;2.73;2.73 +10021-4;R' wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave amplitude in lead V6;R' wave Amp L-V6;;ACTIVE;1.0i;2.48 +100214-6;Dental model prior authorization;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Dental model prior authorization Document;Dental model prior auth Doc;;ACTIVE;2.73;2.73 +100215-3;Episode of care medical records;Find;Pt;^Patient;Doc;Transplant surgery;DOC.MISC;2;Episode of care medical records Document Transplant surgery;Episode of care med rec Doc Transpl surg;;ACTIVE;2.73;2.73 +100216-1;Synoptic report;Find;Pt;^Patient;Doc;Surgery;SURG;2;Surgical synoptic report;Surgical Synoptic Rep;;TRIAL;2.73;2.73 +100217-9;Synoptic report;Find;Pt;^Patient;Doc;Surgical oncology;SURG;2;Surgical oncology synoptic report;Surg Onc Synoptic Rep;;TRIAL;2.73;2.73 +100218-7;Synoptic report;Find;Pt;Colon;Doc;Surgical oncology;SURG;2;Surgical oncology of colon synoptic report;Surg Onc Colon Synoptic Rep;;TRIAL;2.73;2.73 +100219-5;Synoptic report;Find;Pt;Skin melanoma;Doc;Surgical oncology;SURG;2;Surgical oncology of melanoma synoptic report;Surg Onc Melanoma Synoptic Rep;;TRIAL;2.73;2.73 +100220-3;Synoptic report;Find;Pt;Breast;Doc;Surgical oncology;SURG;2;Surgical oncology of breast synoptic report;Surg Onc Breast Synoptic Rep;;TRIAL;2.73;2.73 +100221-1;Synoptic report;Find;Pt;Thyroid;Doc;Surgical oncology;SURG;2;Surgical oncology of thyroid synoptic report;Surg Onc Thyroid Synoptic Rep;;TRIAL;2.73;2.73 +10022-2;R' wave duration.lead AVF;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead AVF;R' wave dur L-AVF;;ACTIVE;1.0i;2.48 +100222-9;Synoptic report;Find;Pt;Pancreas;Doc;Surgical oncology;SURG;2;Surgical oncology of pancreas synoptic report;Surg Onc Pancreas Synoptic Rep;;TRIAL;2.73;2.73 +100223-7;Physical findings;Find;Pt;Retina;Nar;;EYE.PX;2;Physical findings of Retina Narrative;Retina Phys find;;ACTIVE;2.73;2.73 +100224-5;Segmental wall motion panel;-;Pt;Heart.ventricle.left;-;US;PANEL.CARDIAC;2;Cardiac left ventricular segmental wall motion by echo panel;Cardiac LV SWM Pnl LV US;;ACTIVE;2.73;2.73 +100225-2;Bone density quantitative ultrasound study;Find;Pt;^Patient;Doc;;RAD;2;Bone density quantitative ultrasound study;Bone density QUS;;ACTIVE;2.73;2.73 +100226-0;Small bowel capsule endoscopy study;Find;Pt;^Patient;Doc;;ENDO.GI;2;Small bowel capsule endoscopy study Document;Sm bowel capsule endo study Doc;;ACTIVE;2.73;2.73 +100227-8;Colon capsule endoscopy study;Find;Pt;^Patient;Doc;;ENDO.GI;2;Colon capsule endoscopy study Document;Colon capsule endo study Doc;;ACTIVE;2.73;2.73 +100228-6;Upper gastrointestinal capsule endoscopy study;Find;Pt;^Patient;Doc;;ENDO.GI;2;Upper gastrointestinal capsule endoscopy study Document;UGI capsule endo study Doc;;ACTIVE;2.73;2.73 +100229-4;Endoscopic ultrasound study;Find;Pt;^Patient;Doc;;ENDO.GI;2;Endoscopic ultrasound study Document;Endo US study Doc;;ACTIVE;2.73;2.73 +10023-0;R' wave duration.lead AVL;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead AVL;R' wave dur L-AVL;;ACTIVE;1.0i;2.48 +100230-2;Routine prenatal assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Routine prenatal assessment panel;Routine prenatal pnl;;ACTIVE;2.73;2.73 +100231-0;Bronchial endoscopic ultrasound study;Find;Pt;^Patient;Doc;;ENDO.PULM;2;Endobronchial ultrasound study;EBUS study;;ACTIVE;2.73;2.73 +100232-8;Impacts of Events Scale-Revised panel;-;7D;^Patient;-;IES-R;SURVEY.MTLHLTH;4;Impacts of Events Scale-Revised panel;;;ACTIVE;2.73;2.73 +100233-6;Reminders brought back feelings about adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Reminders brought back feelings about adverse event;;;ACTIVE;2.73;2.73 +100234-4;Trouble staying asleep;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Trouble staying asleep;;;ACTIVE;2.73;2.73 +100235-1;Other things triggered persistent thoughts about adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Other things triggered persistent thoughts about adverse event;;;ACTIVE;2.73;2.73 +100236-9;Felt irritable &or angry;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Felt irritable AndOr angry;;;ACTIVE;2.73;2.73 +100237-7;Avoided getting upset when unintentionally thought about adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Avoided getting upset when unintentionally thought about adverse event;;;ACTIVE;2.73;2.73 +100238-5;Thought about adverse event unintentionally;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Thought about adverse event unintentionally;;;ACTIVE;2.73;2.73 +100239-3;Felt as if adverse event did not happen;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Felt as if adverse event did not happen;;;ACTIVE;2.73;2.73 +100240-1;Avoided reminders of adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Avoided reminders of adverse event;;;ACTIVE;2.73;2.73 +100241-9;Experienced mental images of adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Experienced mental images of adverse event;;;ACTIVE;2.73;2.73 +100242-7;Easily startled;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Easily startled;;;ACTIVE;2.73;2.73 +100243-5;Tried to not think of adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Tried to not think of adverse event;;;ACTIVE;2.73;2.73 +100244-3;Aware of feelings about adverse event, but did not address them;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Aware of feelings about adverse event, but did not address them;;;ACTIVE;2.73;2.73 +100245-0;Feelings about adverse event were numb;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feelings about adverse event were numb;;;ACTIVE;2.73;2.73 +100246-8;Acted or felt the same as during adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Acted or felt the same as during adverse event;;;ACTIVE;2.73;2.73 +100247-6;Trouble falling asleep;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Trouble falling asleep;;;ACTIVE;2.73;2.73 +10024-8;R' wave duration.lead AVR;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead AVR;R' wave dur L-AVR;;ACTIVE;1.0i;2.48 +100248-4;Waves of strong feelings about adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Waves of strong feelings about adverse event;;;ACTIVE;2.73;2.73 +100249-2;Tried to remove adverse event from memory;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Tried to remove adverse event from memory;;;ACTIVE;2.73;2.73 +1002-5;DBG Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;DBG Ab [Presence] in Serum or Plasma;DBG Ab SerPl Ql;;ACTIVE;1.0;2.56 +100250-0;Trouble concentrating;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Trouble concentrating;;;ACTIVE;2.73;2.73 +100251-8;Reminders of adverse event caused physical reactions;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Reminders of adverse event caused physical reactions;;;ACTIVE;2.73;2.73 +100252-6;Had dreams about adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Had dreams about adverse event;;;ACTIVE;2.73;2.73 +100253-4;Felt watchful and on-guard;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Felt watchful and on-guard;;;ACTIVE;2.73;2.73 +100254-2;Tried not to talk about adverse event;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Tried not to talk about adverse event;;;ACTIVE;2.73;2.73 +10025-5;R' wave duration.lead I;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead I;R' wave dur L-I;;ACTIVE;1.0i;2.48 +100255-9;Total Score;Score;RptPeriod;^Patient;Qn;IES-R;SURVEY.MTLHLTH;4;Total score [Impact of Event Scale-Revised];;;ACTIVE;2.73;2.73 +100256-7;Fallen in last 6Mo;Find;6Mo;^Patient;Ord;;H&P.HX;2;Fallen in last 6 months;Fallen in last 6Mo;;ACTIVE;2.73;2.73 +100257-5;Feel unsteady when standing or walking;Find;Pt;^Patient;Ord;;H&P.HX;2;Feel unsteady when standing or walking;Feel unsteady when standing or walking;;ACTIVE;2.73;2.73 +100258-3;History of fall related injury;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of fall related injury;History of fall related injury;;ACTIVE;2.73;2.73 +100259-1;Aware of tactile sensations;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Aware of tactile sensations;;;ACTIVE;2.73;2.73 +100260-9;Easy to describe thoughts &or feelings;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Easy to describe thoughts AndOr feelings;;;ACTIVE;2.73;2.73 +100261-7;Critical of own thoughts &or feelings;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Critical of own thoughts AndOr feelings;;;ACTIVE;2.73;2.73 +100262-5;Able to notice distressing thoughts &or feelings without having to react;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Able to notice distressing thoughts AndOr feelings without having to react;;;ACTIVE;2.73;2.73 +10026-3;R' wave duration.lead II;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead II;R' wave dur L-II;;ACTIVE;1.0i;2.48 +100263-3;Easily distracted;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Easily distracted;;;ACTIVE;2.73;2.73 +100264-1;Able to notice thoughts &or feelings without being overwhelmed;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Able to notice thoughts AndOr feelings without being overwhelmed;;;ACTIVE;2.73;2.73 +100265-8;Aware of dietary intake impact on self;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Aware of dietary intake impact on self;;;ACTIVE;2.73;2.73 +100266-6;Difficult to describe thoughts &or feelings;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Difficult to describe thoughts AndOr feelings;;;ACTIVE;2.73;2.73 +100267-4;Aware of auditory stimuli;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Aware of auditory stimuli;;;ACTIVE;2.73;2.73 +100268-2;Able to avoid immediate reaction in difficult situations;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Able to avoid immediate reaction in difficult situations;;;ACTIVE;2.73;2.73 +100269-0;Do things without paying attention;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Do things without paying attention;;;ACTIVE;2.73;2.73 +100270-8;Recover quickly from distressing thoughts &or images;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Recover quickly from distressing thoughts AndOr images;;;ACTIVE;2.73;2.73 +10027-1;R' wave duration.lead III;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead III;R' wave dur L-III;;ACTIVE;1.0i;2.48 +100271-6;Aware of olfactory stimuli;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Aware of olfactory stimuli;;;ACTIVE;2.73;2.73 +100272-4;Aware of visual stimuli;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Aware of visual stimuli;;;ACTIVE;2.73;2.73 +100273-2;Aware of emotions affect on thoughts &or behavior;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Aware of emotions affect on thoughts AndOr behavior;;;ACTIVE;2.73;2.73 +100274-0;Observing score;Score;Pt;^Patient;Qn;FFMQ;SURVEY.MTLHLTH;4;Observing score [FFMQ];;;ACTIVE;2.73;2.73 +100275-7;Describing score;Score;Pt;^Patient;Qn;FFMQ;SURVEY.MTLHLTH;4;Describing score [FFMQ];;;ACTIVE;2.73;2.73 +100276-5;Acting with awareness score;Score;Pt;^Patient;Qn;FFMQ;SURVEY.MTLHLTH;4;Acting with awareness score [FFMQ];;;ACTIVE;2.73;2.73 +100277-3;Nonjudging score;Score;Pt;^Patient;Qn;FFMQ;SURVEY.MTLHLTH;4;Nonjudging score [FFMQ];;;ACTIVE;2.73;2.73 +100278-1;Nonreactivity score;Score;Pt;^Patient;Qn;FFMQ;SURVEY.MTLHLTH;4;Nonreactivity score [FFMQ];;;ACTIVE;2.73;2.73 +100279-9;Total score;Score;Pt;^Patient;Qn;FFMQ;SURVEY.MTLHLTH;4;Total score [FFMQ];;;ACTIVE;2.73;2.73 +100280-7;Five Facet Mindfulness Questionnaire panel;-;Pt;^Patient;-;FFMQ;PANEL.SURVEY.MTLHLTH;4;Five Facet Mindfulness Questionnaire panel [FFMQ];;;ACTIVE;2.73;2.73 +100281-5;D Ab;ACnc;Pt;Ser/Plas;Qn;;BLDBK;1;D Ab [Units/volume] in Serum or Plasma;D Ab SerPl-aCnc;;ACTIVE;2.73;2.73 +100282-3;Vaccine exemption certificate;Find;Pt;{Setting};Doc;{Role};DOC.ADMIN;2;Vaccine exemption certificate;Vaccine exemption cert;;ACTIVE;2.73;2.73 +100283-1;Harris Hip Score panel;-;Pt;^Patient;-;Harris Hip Score;PANEL.SURVEY.ORTHOPEDICS;4;Harris Hip Score panel [Harris Hip Score];;Copyright © Wolters Kluwer Health Used with permission.;ACTIVE;2.73;2.73 +100284-9;Walking - functional ability;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Walking - functional ability;;;ACTIVE;2.73;2.73 +100285-6;Comfortable seated position;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Comfortable seated position;;;ACTIVE;2.73;2.73 +100286-4;Able to board public transportation;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Able to board public transportation;;;ACTIVE;2.73;2.73 +100287-2;Put on shoes and socks;Find;Pt;^Patient;Ord;;SURVEY.ORTHOPEDICS;4;Put on shoes and socks;;;ACTIVE;2.73;2.73 +100288-0;Absence of deformity score;Score;Pt;^Patient;Qn;Harris Hip Score;SURVEY.ORTHOPEDICS;4;Absence of deformity score [Harris Hip Score];;Copyright © Wolters Kluwer Health Used with permission.;ACTIVE;2.73;2.73 +10028-9;R' wave duration.lead V1;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead V1;R' wave dur L-V1;;ACTIVE;1.0i;2.48 +100289-8;Absence of hip deformity measurements;Find;Pt;^Patient;Nom;;SURVEY.ORTHOPEDICS;4;Absence of hip deformity measurements;;;ACTIVE;2.73;2.73 +100290-6;Range of motion score;Score;Pt;^Patient;Qn;Harris Hip Score;SURVEY.ORTHOPEDICS;4;Range of motion score [Harris Hip Score];;Copyright © Wolters Kluwer Health Used with permission.;ACTIVE;2.73;2.73 +100291-4;Total Score;Score;Pt;^Patient;Qn;Harris Hip Score;SURVEY.ORTHOPEDICS;4;Total score [Harris Hip Score];;Copyright © Wolters Kluwer Health Used with permission.;ACTIVE;2.73;2.73 +100292-2;Pre-op patient satisfaction score;Score;-;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Pre-op patient satisfaction score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100293-0;Flexion range of motion;Find;Pt;Hip;Ord;;SURVEY.ORTHOPEDICS;4;Hip Flexion range of motion;;;ACTIVE;2.73;2.73 +100294-8;Abduction range of motion;Find;Pt;Hip;Ord;;SURVEY.ORTHOPEDICS;4;Hip Abduction range of motion;;;ACTIVE;2.73;2.73 +100295-5;Adduction range of motion;Find;Pt;Hip;Ord;;SURVEY.ORTHOPEDICS;4;Hip Adduction range of motion;;;ACTIVE;2.73;2.73 +100296-3;External rotation range of motion;Find;Pt;Hip;Ord;;SURVEY.ORTHOPEDICS;4;Hip External rotation range of motion;;;ACTIVE;2.73;2.73 +10029-7;R' wave duration.lead V2;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead V2;R' wave dur L-V2;;ACTIVE;1.0i;2.48 +100297-1;Internal rotation range of motion;Find;Pt;Hip;Ord;;SURVEY.ORTHOPEDICS;4;Hip Internal rotation range of motion;;;ACTIVE;2.73;2.73 +100298-9;Repetition count;Num;Pt;^Patient;Qn;;H&P.HX;2;Repetition count;Rep count;;ACTIVE;2.73;2.73 +100299-7;Post-op patient satisfaction score;Score;Pt;^Patient;Qn;Knee Society Score;SURVEY.ORTHOPEDICS;4;Post-op patient satisfaction score [Knee Society Score];;© by The Knee Society. All rights reserved. Reproduced with permission.;ACTIVE;2.73;2.73 +100300-3;End time;ClockTime;Pt;XXX;Qn;;CLIN;2;End time Unspecified body region;End time Clock time Spec;;ACTIVE;2.73;2.73 +100301-1;Start time;ClockTime;Pt;XXX;Qn;;CLIN;2;Start time Unspecified body region;Start time Clock time Spec;;ACTIVE;2.73;2.73 +100302-9;Time period start & end panel;-;Pt;XXX;-;;PANEL.CLIN;2;Time period start and end panel Unspecified body region;Time start/end panel Spec;;ACTIVE;2.73;2.73 +100303-7;Condition certainty of presence;Imp;Pt;^Patient;Ord;;H&P.HX;2;Condition certainty of presence;Condition certainty of presence;;ACTIVE;2.73;2.73 +100304-5;Flights climbed;Num;RptPeriod;^Patient;Qn;;H&P.HX;2;Flights climbed [#] Reporting Period;Flights climbed RptPeriod;;ACTIVE;2.73;2.73 +10030-5;R' wave duration.lead V3;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead V3;R' wave dur L-V3;;ACTIVE;1.0i;2.48 +100305-2;IDH1 gene exon 4 targeted mutation analysis;PrThr;Pt;Bld/Bone mar;Ord;Molgen;MOLPATH.MUT;1;IDH1 gene exon 4 targeted mutation analysis [Presence] in Blood or Marrow by Molecular genetics method;IDH1 exon 4 Mut Anl Bld/Mar Ql;;ACTIVE;2.73;2.73 +100306-0;IDH2 gene exon 4 targeted mutation analysis;PrThr;Pt;Bld/Bone mar;Ord;Molgen;MOLPATH.MUT;1;IDH2 gene exon 4 targeted mutation analysis [Presence] in Blood or Marrow by Molecular genetics method;IDH2 exon 4 Mut Anl Bld/Mar Ql;;ACTIVE;2.73;2.73 +100307-8;Behavioral screening elder mistreatment;-;Pt;^Patient;-;;PANEL.SURVEY.MTLHLTH;4;Behavioral screening elder mistreatment;;;ACTIVE;2.73;2.73 +100308-6;Need help getting to essential places;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Need help getting to essential places;;;ACTIVE;2.73;2.73 +100309-4;Activity support person;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Activity support person;;;ACTIVE;2.73;2.73 +100310-2;Reliability of support person;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Reliability of support person;;;ACTIVE;2.73;2.73 +100311-0;Need help to make sure there is enough food, medicines or any other things needed in house;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Need help to make sure there is enough food, medicines or any other things needed in house;;;ACTIVE;2.73;2.73 +100312-8;Person or persons that makes sure there is enough food, medicines or any other things needed in house;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Person or persons that makes sure there is enough food, medicines or any other things needed in house;;;ACTIVE;2.73;2.73 +10031-3;R' wave duration.lead V4;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead V4;R' wave dur L-V4;;ACTIVE;1.0i;2.48 +100313-6;Need help with household things such as cook meals, help feed, or provide correct medicines each day;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Need help with household things such as cook meals, help feed, or provide correct medicines each day;;;ACTIVE;2.73;2.73 +100314-4;Need help with house cleaning or yard work;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Need help with house cleaning or yard work;;;ACTIVE;2.73;2.73 +100315-1;Need help getting out of bed, showered, or dressed;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Need help getting out of bed, showered, or dressed;;;ACTIVE;2.73;2.73 +100316-9;Need help to make sure bills get paid;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Need help to make sure bills get paid;;;ACTIVE;2.73;2.73 +100317-7;Relationship of usual support person for daily activities;Find;Pt;^Patient;Nom;;SURVEY.MTLHLTH;4;Relationship of usual support person for daily activities;;;ACTIVE;2.73;2.73 +100318-5;Have help with finances &or financial decisions;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Have help with finances AndOr financial decisions;;;ACTIVE;2.73;2.73 +100319-3;Relationship of financial support person;Find;Pt;^Patient;Nom;;SURVEY.MTLHLTH;4;Relationship of financial support person;;;ACTIVE;2.73;2.73 +100320-1;Financial support person usually asks for permission before making decisions;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Financial support person usually asks for permission before making decisions;;;ACTIVE;2.73;2.73 +10032-1;R' wave duration.lead V5;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead V5;R' wave dur L-V5;;ACTIVE;1.0i;2.48 +100321-9;Financial support person usually makes good decisions about finances;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Financial support person usually makes good decisions about finances;;;ACTIVE;2.73;2.73 +100322-7;Have access to paperwork for financial decisions made;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Have access to paperwork for financial decisions made;;;ACTIVE;2.73;2.73 +100323-5;Financial support person forged signature;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Financial support person forged signature;;;ACTIVE;2.73;2.73 +100324-3;Coercion of financial support person for signing a document in order to get money or possessions;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Coercion of financial support person for signing a document in order to get money or possessions;;;ACTIVE;2.73;2.73 +100325-0;Experienced theft by support person;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Experienced theft by support person;;;ACTIVE;2.73;2.73 +100326-8;Money spent or property sold without permission;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Money spent or property sold without permission;;;ACTIVE;2.73;2.73 +100327-6;Stranger forged signature for financial gain;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Stranger forged signature for financial gain;;;ACTIVE;2.73;2.73 +100328-4;Stranger forced document signature for financial gain;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Stranger forced document signature for financial gain;;;ACTIVE;2.73;2.73 +100329-2;Feared for safety due to verbal attack;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Feared for safety due to verbal attack;;;ACTIVE;2.73;2.73 +1003-3;Indirect antiglobulin test.complement specific reagent;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Indirect antiglobulin test.complement specific reagent [Presence] in Serum or Plasma;IAT Comp-Sp Reag SerPl Ql;;ACTIVE;1.0;2.73 +100330-0;Felt humiliated due to ridicule;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Felt humiliated due to ridicule;;;ACTIVE;2.73;2.73 +100331-8;Coerced to do something;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Coerced to do something;;;ACTIVE;2.73;2.73 +100332-6;Ignored by close friend or relative for extended period;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Ignored by close friend or relative for extended period;;;ACTIVE;2.73;2.73 +100333-4;Physically hit or threatened;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Physically hit or threatened;;;ACTIVE;2.73;2.73 +100334-2;Been physically hurt with some degree of injury;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Been physically hurt with some degree of injury;;;ACTIVE;2.73;2.73 +100335-9;Coerced sexual activity;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Coerced sexual activity;;;ACTIVE;2.73;2.73 +100336-7;Coerced touching of private body parts of self or others;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Coerced touching of private body parts of self or others;;;ACTIVE;2.73;2.73 +100337-5;Coerced to undress or expose private body area;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Coerced to undress or expose private body area;;;ACTIVE;2.73;2.73 +100338-3;Photographed in any degree of nudity without consent;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Photographed in any degree of nudity without consent;;;ACTIVE;2.73;2.73 +10033-9;R' wave duration.lead V6;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R' wave duration in lead V6;R' wave dur L-V6;;ACTIVE;1.0i;2.48 +100339-1;Experienced attempted physical restraint;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Experienced attempted physical restraint;;;ACTIVE;2.73;2.73 +100340-9;Range of motion panel;-;Pt;Hip;-;;PANEL.SURVEY.ORTHOPEDICS;4;Range of motion panel Hip;;;ACTIVE;2.73;2.73 +100341-7;Rubella virus Ab.IgG index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Rubella virus IgG Ab index [Units/volume] in Serum and CSF;RUBV IgG Index Ser+CSF-aCnc;;ACTIVE;2.73;2.73 +100342-5;Volatile Organic Compounds associated with SARS-CoV-2 infection;PrThr;Pt;Exhl gas;Ord;GC-MS;MICRO;1;Volatile Organic Compounds associated with SARS-CoV-2 infection [Presence] in Exhaled gas by Gas chromatography-mass spectrometry;VOCs (volatiles) SARS-CoV-2 ExG Ql GC-MS;;ACTIVE;2.73;2.73 +100343-3;Influenza virus B RNA;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Saliva (oral fluid) by NAA with probe detection;FLUBV RNA Sal Ql NAA+probe;;ACTIVE;2.73;2.73 +100344-1;Influenza virus A RNA;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Saliva (oral fluid) by NAA with probe detection;FLUAV RNA Sal Ql NAA+probe;;ACTIVE;2.73;2.73 +100345-8;Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection;FLUABV+SARS-CoV-2 RNA Pnl Spec NAA+probe;;ACTIVE;2.73;2.73 +100346-6;Clotting time.extrinsic coagulation system activated.platelets inhibited;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clotting time.extrinsic coagulation system activated.platelets inhibited of Blood by Rotational TEG;CT.extr plt inhib Bld ROTEM;;ACTIVE;2.73;2.73 +10034-7;S wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead AVF;S wave Amp L-AVF;;ACTIVE;1.0i;2.48 +100347-4;Clot formation.extrinsic coagulation system activated.platelets inhibited;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clot formation.extrinsic coagulation system activated.platelets inhibited [Time] in Blood by Rotational TEG;CT.extr plt inhib Bld ROTEM;;ACTIVE;2.73;2.73 +100348-2;Model for end-stage liver disease sodium score;Score;Pt;^Patient;Qn;;TRNSPLNT.ORGAN;2;Model for end-stage liver disease sodium score;MELDNa score;;ACTIVE;2.73;2.73 +100349-0;Multisection^W vasodilator IV;Find;Pt;Pelvis>Penis vessels;Doc;US.doppler;RAD;2;US.doppler Penis vessels W vasodilator IV;DOP Penis ves W vasodilator IV;;ACTIVE;2.73;2.73 +100350-8;Sesamum indicum 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sesamum indicum 1 IgE Ab [Units/volume] in Serum;Ses i 1 IgE Qn;;ACTIVE;2.73;2.73 +100351-6;Pioglitazone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Pioglitazone [Presence] in Serum or Plasma;Pioglitazone SerPl Ql;;ACTIVE;2.73;2.73 +100352-4;Rosiglitazone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Rosiglitazone [Presence] in Serum or Plasma;Rosiglitazone SerPl Ql;;ACTIVE;2.73;2.73 +100353-2;Norwalk Community Health Center Screening Tool;-;Pt;^Patient;-;NCHC;PANEL.SURVEY.SDOH;4;Norwalk Community Health Center Screening Tool [NCHC];;;ACTIVE;2.73;2.73 +10035-4;S wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead AVL;S wave Amp L-AVL;;ACTIVE;1.0i;2.48 +100354-0;Frequency of participating in multi-modal communication without assistance;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of participating in multi-modal communication without assistance;;;ACTIVE;2.73;2.73 +100355-7;Frequency of participating in spoken language expression communication without assistance;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of participating in spoken language expression communication without assistance;;;ACTIVE;2.73;2.73 +100356-5;Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA [Identifier] in Specimen by NAA with probe detection;CT + NG + TV DNA Spec NAA+probe;;ACTIVE;2.73;2.73 +100357-3;Naloxone;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Naloxone [Presence] in Cord tissue by Screen method;Naloxone TissCo Ql Scn;;ACTIVE;2.73;2.73 +100358-1;Phentermine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Phentermine [Presence] in Cord tissue by Screen method;Phentermine TissCo Ql Scn;;ACTIVE;2.73;2.73 +100359-9;Gliadin 33 mer peptide;MCnc;Pt;Stool;Qn;IA;CHEM;1;Gliadin 33 mer peptide [Mass/volume] in Stool by Immunoassay;Gliadin 33 mer Stl IA-mCnc;;ACTIVE;2.73;2.73 +100360-7;Brief Resilience Scale panel;-;Pt;^Patient;-;BRS;PANEL.SURVEY.MTLHLTH;4;Brief Resilience Scale panel [BRS];;;ACTIVE;2.73;2.73 +100361-5;Quickly recover from bad events;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Quickly recover from bad events;;;ACTIVE;2.73;2.73 +10036-2;S wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead AVR;S wave Amp L-AVR;;ACTIVE;1.0i;2.48 +100362-3;Difficulty making it through stressful events;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Difficulty making it through stressful events;;;ACTIVE;2.73;2.73 +100363-1;Easily recover from a stressful event;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Easily recover from a stressful event;;;ACTIVE;2.73;2.73 +100364-9;Difficulty recovering from bad events;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Difficulty recovering from bad events;;;ACTIVE;2.73;2.73 +100365-6;Easily recover from difficulties;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Easily recover from difficulties;;;ACTIVE;2.73;2.73 +100366-4;Lengthy recovery from setbacks;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Lengthy recovery from setbacks;;;ACTIVE;2.73;2.73 +100367-2;Total Score;Score;Pt;^Patient;Qn;BRS;SURVEY.MTLHLTH;4;Total Score BRS;;;ACTIVE;2.73;2.73 +100368-0;Amino Acids Urea Cycle Panel;-;Pt;Ser/Plas;-;LC/MS/MS;PANEL.CHEM;1;Amino Acids Urea Cycle Panel - Serum or Plasma by LC/MS/MS;AAUCD SerPl LC/MS/MS;;ACTIVE;2.73;2.73 +100369-8;Views^W Tl-201 IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views W Tl-201 IV;NM Thyroid Views W Tl-201 IV;;ACTIVE;2.73;2.73 +10037-0;S wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead I;S wave Amp L-I;;ACTIVE;1.0i;2.48 +100370-6;Orthopoxvirus DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Orthopoxvirus DNA [Identifier] in Specimen by NAA with probe detection;Orthopoxvirus DNA Spec NAA+probe;;ACTIVE;2.73;2.73 +100371-4;Titin Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Titin Ab [Units/volume] in Serum by Immunoassay;Titin Ab Ser IA-aCnc;;ACTIVE;2.73;2.73 +100372-2;Abiraterone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Abiraterone [Mass/volume] in Serum or Plasma;Abiraterone SerPl-mCnc;;ACTIVE;2.73;2.73 +100373-0;Eucheuma Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Eucheuma IgG Ab [Units/volume] in Serum;Agar- agar IgG Qn;;ACTIVE;2.73;2.73 +100374-8;Aloe vera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aloe vera IgG Ab [Units/volume] in Serum;Aloe vera IgG Qn;;ACTIVE;2.73;2.73 +100375-5;Pimpinella anisum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Anise IgG Ab [Units/volume] in Serum;Anise IgG Qn;;ACTIVE;2.73;2.73 +100376-3;Bambusa vulgaris Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bambusa vulgaris IgG Ab [Units/volume] in Serum;Bambusa vulgaris IgG Qn;;ACTIVE;2.73;2.73 +100377-1;Goat cheese Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goat cheese IgG Ab [Units/volume] in Serum;Goat cheese IgG Qn;;ACTIVE;2.73;2.73 +100378-9;Sheep cheese Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep cheese IgG Ab [Units/volume] in Serum;Sheep cheese IgG Qn;;ACTIVE;2.73;2.73 +100379-7;Allium ampeloprasum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Leeks IgG Ab [Units/volume] in Serum;Leeks IgG Qn;;ACTIVE;2.73;2.73 +100380-5;Brassica rubra Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red cabbage IgG Ab [Units/volume] in Serum;Red cabbage IgG Qn;;ACTIVE;2.73;2.73 +100381-3;Mentha balsamea Wild Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mentha balsamea Wild IgG Ab [Units/volume] in Serum;Mentha balsamea Wild IgG Qn;;ACTIVE;2.73;2.73 +100382-1;REMS addressed risk;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS addressed risk;FDA insert REMS addressed risk;;ACTIVE;2.73;2.73 +100383-9;Monkeypox virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Monkeypox virus DNA [Presence] in Specimen by NAA with probe detection;MVPX DNA Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100384-7;Brassica rapa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rapeseed IgG Ab [Units/volume] in Serum;Rapeseed IgG Qn;;ACTIVE;2.73;2.73 +100385-4;Valerianella locusta Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Corn salad IgG Ab [Units/volume] in Serum;Corn salad IgG Qn;;ACTIVE;2.73;2.73 +100386-2;Rosmarinus officinalis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rosemary IgG Ab [Units/volume] in Serum;Rosemary IgG Qn;;ACTIVE;2.73;2.73 +100387-0;Papaver somniferum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Poppy Seed IgG Ab [Units/volume] in Serum;Poppy Seed IgG Qn;;ACTIVE;2.73;2.73 +10038-8;S wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead II;S wave Amp L-II;;ACTIVE;1.0i;2.48 +100388-8;Theobroma cacao Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cocoa IgG Ab [Units/volume] in Serum;Cocoa IgG Qn;;ACTIVE;2.73;2.73 +100389-6;Pistacia vera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pistachio IgG Ab [Units/volume] in Serum;Pistachio IgG Qn;;ACTIVE;2.73;2.73 +100390-4;Helianthus annuus seed Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sunflower Seed IgG Ab [Units/volume] in Serum;Sunflower Seed IgG Qn;;ACTIVE;2.73;2.73 +100391-2;Phoenix dactylifera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dates IgG Ab [Units/volume] in Serum;Dates IgG Qn;;ACTIVE;2.73;2.73 +100392-0;Duck meat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Duck meat IgG Ab [Units/volume] in Serum;Duck Meat IgG Qn;;ACTIVE;2.73;2.73 +100393-8;Allergen Mushroom mix 2 (Xerocomus, Boletus) Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Allergen Mushroom mix 2 (Xerocomus, Boletus) IgG Ab [Units/volume] in Serum;AllergenMushroom mix 2 IgG Qn;;ACTIVE;2.73;2.73 +100394-6;Astacoidea Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Astacoidea IgG Ab [Units/volume] in Serum;Decapod crustaceans IgG Qn;;ACTIVE;2.73;2.73 +100395-3;Ceratonia siliqua Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Carob IgG Ab [Units/volume] in Serum;Carob IgG Qn;;ACTIVE;2.73;2.73 +10039-6;S wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead III;S wave Amp L-III;;ACTIVE;1.0i;2.48 +100396-1;Brassica napus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brassica napus IgG Ab [Units/volume] in Serum;Brassica napus IgG Qn;;ACTIVE;2.73;2.73 +100397-9;Capra aegagrus hircus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goat Meat IgG Ab [Units/volume] in Serum;Goat Meat IgG Qn;;ACTIVE;2.73;2.73 +100398-7;Goose meat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goose meat IgG Ab [Units/volume] in Serum;Goose Meat IgG Qn;;ACTIVE;2.73;2.73 +100399-5;Ostrich meat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ostrich meat IgG Ab [Units/volume] in Serum;Ostrich meat IgG Qn;;ACTIVE;2.73;2.73 +100400-1;Quail meat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Quail meat IgG Ab [Units/volume] in Serum;Quail meat IgG Qn;;ACTIVE;2.73;2.73 +100401-9;Rabbit meat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit meat IgG Ab [Units/volume] in Serum;Rabbit Meat IgG Qn;;ACTIVE;2.73;2.73 +100402-7;Venison meat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Venison meat IgG Ab [Units/volume] in Serum;Venison meat IgG Qn;;ACTIVE;2.73;2.73 +100403-5;Guineafowl Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Guineafowl IgG Ab [Units/volume] in Serum;Guineafowl IgG Qn;;ACTIVE;2.73;2.73 +10040-4;S wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead V1;S wave Amp L-V1;;ACTIVE;1.0i;2.48 +100404-3;Horse meat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse meat IgG Ab [Units/volume] in Serum;Horse Meat IgG Qn;;ACTIVE;2.73;2.73 +100405-0;Kefir Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kefir IgG Ab [Units/volume] in Serum;Kefir IgG Qn;;ACTIVE;2.73;2.73 +100406-8;Butter Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Butter IgG Ab [Units/volume] in Serum;Butter IgG Qn;;ACTIVE;2.73;2.73 +100407-6;Camembert cheese Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Camembert cheese IgG Ab [Units/volume] in Serum;Camembert cheese IgG Qn;;ACTIVE;2.73;2.73 +100408-4;Emmental cheese Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Emmental cheese IgG Ab [Units/volume] in Serum;Emmental cheese IgG Qn;;ACTIVE;2.73;2.73 +100409-2;Processed cheese Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Processed cheese IgG Ab [Units/volume] in Serum;Processed cheese IgG Qn;;ACTIVE;2.73;2.73 +1004-1;Direct antiglobulin test.complement specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.complement specific reagent [Presence] on Red Blood Cells;DAT Comp-Sp Reag RBC Ql;;ACTIVE;1.0;2.73 +100410-0;Curd cheese Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Curd cheese IgG Ab [Units/volume] in Serum;Curd cheese IgG Qn;;ACTIVE;2.73;2.73 +100411-8;Beta vulgaris Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Beet IgG Ab [Units/volume] in Serum;Sugar Beet IgG Qn;;ACTIVE;2.73;2.73 +10041-2;S wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead V2;S wave Amp L-V2;;ACTIVE;1.0i;2.48 +100412-6;Chinese cabbage Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chinese cabbage IgG Ab [Units/volume] in Serum;Chinese cabbage IgG Qn;;ACTIVE;2.73;2.73 +100413-4;Foeniculum vulgare fresh Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fennel Fresh IgG Ab [Units/volume] in Serum;Fennel Fresh IgG Qn;;ACTIVE;2.73;2.73 +100414-2;Cucurbitaceae genera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gourd IgG Ab [Units/volume] in Serum;Gourd IgG Qn;;ACTIVE;2.73;2.73 +100415-9;Brassica oleracea var borecole Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kale IgG Ab [Units/volume] in Serum;Kale IgG Qn;;ACTIVE;2.73;2.73 +100416-7;Brassica oleracea var. Sabauda Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Savoy cabbage IgG Ab [Units/volume] in Serum;Savoy cabbage IgG Qn;;ACTIVE;2.73;2.73 +100417-5;Vitis sp leaf Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Vitis sp leaf IgG Ab [Units/volume] in Serum;Vitis sp leaf IgG Qn;;ACTIVE;2.73;2.73 +100418-3;Glycyrrhiza glabra Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Liquorice IgG Ab [Units/volume] in Serum;Liquorice IgG Qn;;ACTIVE;2.73;2.73 +100419-1;Pisum sativum var. saccharatum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Snow pea IgG Ab [Units/volume] in Serum;Snow pea IgG Qn;;ACTIVE;2.73;2.73 +10042-0;S wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead V3;S wave Amp L-V3;;ACTIVE;1.0i;2.48 +100420-9;Vicia faba Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fava bean IgG Ab [Units/volume] in Serum;Fava bean IgG Qn;;ACTIVE;2.73;2.73 +100421-7;Cicer arietinus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chick Pea IgG Ab [Units/volume] in Serum;Chick Pea IgG Qn;;ACTIVE;2.73;2.73 +100422-5;Cichorium intybus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicory IgG Ab [Units/volume] in Serum;Chicory IgG Qn;;ACTIVE;2.73;2.73 +100423-3;(Agaricus bisporus+Pleurotus ostreatus+Lentinula edodes+Cantharellus) Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Allergy Mushroom Mix 1 (Button + oyster + Shiitaki + chanterelle mushroom) IgG Ab [Units/volume] in Serum;Allerg Mushroom Mix 1 IgG Qn;;ACTIVE;2.73;2.73 +100424-1;8(9)-Cholestenol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;8(9)-Cholestenol [Mass/volume] in Serum or Plasma;8(9)-Cholestenol SerPl-mCnc;;ACTIVE;2.73;2.73 +100425-8;DiHydro T-Mas;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;DiHydro T-Mas [Mass/volume] in Serum or Plasma;SerPl-mCnc;;ACTIVE;2.73;2.73 +100426-6;Squalene;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Squalene [Mass/volume] in Serum or Plasma;Squalene SerPl-mCnc;;ACTIVE;2.73;2.73 +100427-4;Stigmasterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Stigmasterol [Mass/volume] in Serum or Plasma;Stigmasterol SerPl-mCnc;;ACTIVE;2.73;2.73 +100428-2;Carnitine Free & Total & Acylcarnitine Panel;-;Pt;Urine;-;;CHEM;1;Carnitine free and total and acylcarnitine panel - Urine;Carnitine + acylcarnitine Pnl Ur;;ACTIVE;2.73;2.73 +100429-0;Lipopolysaccharide-responsive beige-like anchor protein deficiency panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;LRBA deficiency panel - Blood;LRBA deficiency panel Bld;;ACTIVE;2.73;2.73 +100430-8;Cells.LRBA+/100 Cells.CD3+CD14-CD45+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.LRBA+/100 Cells.CD3+CD14-CD45+ in Blood by Flow cytometry (FC);Cells.LRBA+/T Cells NFr Bld FC;;ACTIVE;2.73;2.73 +100431-6;Cells.CD3+CD14-CD45+.LRBA mean fluorescence intensity;Arb;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD3+CD14-CD45+.LRBA mean fluorescence intensity in Blood by Flow cytometry (FC);T-cells LRBA MFI Bld FC;;ACTIVE;2.73;2.73 +100432-4;Cells.LRBA+/100 Cells.CD3-CD14-CD19+CD45+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.LRBA+/100 Cells.CD3-CD14-CD19+CD45+ in Blood by Flow cytometry (FC);Cells.LRBA+/B Cells NFr Bld FC;;ACTIVE;2.73;2.73 +100433-2;Cells.CD3-CD14-CD19+CD45+.LRBA mean fluorescence intensity;Arb;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD3-CD14-CD19+CD45+.LRBA mean fluorescence intensity in Blood by Flow cytometry (FC);B-cells LRBA MFI Bld FC;;ACTIVE;2.73;2.73 +100434-0;Orthopoxvirus.non-variola DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Orthopoxvirus.non-variola DNA [Presence] in Specimen by NAA with probe detection;Nonvar Orthpx DNA Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100435-7;Glial fibrillary acidic protein;MCnc;Pt;Ser;Qn;IA;SERO;1;Glial fibrillary acidic protein [Mass/volume] in Serum by Immunoassay;GFAP Ser IA-mCnc;;ACTIVE;2.73;2.73 +100436-5;Ubiquitin carboxyl-terminal hydrolase-L1;MCnc;Pt;Ser;Qn;IA;SERO;1;Ubiquitin carboxyl-terminal hydrolase-L1 [Mass/volume] in Serum by Immunoassay;UCH-L1 Ser IA-mCnc;;ACTIVE;2.73;2.73 +100437-3;Norsufentanil;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norsufentanil [Mass/volume] in Urine by Confirmatory method;Norsufentanil Ur Cfm-mCnc;;ACTIVE;2.73;2.73 +10043-8;S wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead V4;S wave Amp L-V4;;ACTIVE;1.0i;2.48 +100438-1;Progress note;Find;Pt;Outpatient;Doc;Adolescent medicine;DOC.ONTOLOGY;2;Adolescent medicine Outpatient Progress note;Adolescent med OP Prog note;;ACTIVE;2.73;2.73 +100439-9;Progress note;Find;Pt;Outpatient;Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Outpatient Progress note;Allergy+Immunology OP Prog note;;ACTIVE;2.73;2.73 +100440-7;Progress note;Find;Pt;Outpatient;Doc;Allergy;DOC.ONTOLOGY;2;Allergy Outpatient Progress note;Allergy OP Prog note;;ACTIVE;2.73;2.73 +100441-5;Progress note;Find;Pt;Outpatient;Doc;Attending;DOC.ONTOLOGY;2;Attending Outpatient Progress note;Attend OP Prog note;;ACTIVE;2.73;2.73 +100442-3;Progress note;Find;Pt;Outpatient;Doc;Audiology;DOC.ONTOLOGY;2;Audiology Outpatient Progress note;Audiology OP Prog note;;ACTIVE;2.73;2.73 +100443-1;Progress note;Find;Pt;Outpatient;Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Outpatient Progress note;Bariatric surg OP Prog note;;ACTIVE;2.73;2.73 +100444-9;Progress note;Find;Pt;Outpatient;Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Outpatient Progress note;Bld Bnk+Trans Med OP Prog note;;ACTIVE;2.73;2.73 +100445-6;Progress note;Find;Pt;Outpatient;Doc;Bone marrow transplant;DOC.ONTOLOGY;2;Bone Marrow Transplant Outpatient Progress note;BM Transplant OP Prog note;;ACTIVE;2.73;2.73 +10044-6;S wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead V5;S wave Amp L-V5;;ACTIVE;1.0i;2.48 +100446-4;Progress note;Find;Pt;Outpatient;Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Outpatient Progress note;Breastfeeding OP Prog note;;ACTIVE;2.73;2.73 +100447-2;Progress note;Find;Pt;Outpatient;Doc;Burn management;DOC.ONTOLOGY;2;Burn management Outpatient Progress note;Burn OP Prog note;;ACTIVE;2.73;2.73 +100448-0;Progress note;Find;Pt;Outpatient;Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Outpatient Progress note;Cardiac surgery OP Prog note;;ACTIVE;2.73;2.73 +100449-8;Progress note;Find;Pt;Outpatient;Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Outpatient Progress note;Cardio+Pulm disease OP Prog note;;ACTIVE;2.73;2.73 +100450-6;Progress note;Find;Pt;Outpatient;Doc;Child and adolescent psychiatry;DOC.ONTOLOGY;2;Child and adolescent psychiatry Outpatient Progress note;Child+teen psych OP Prog note;;ACTIVE;2.73;2.73 +100451-4;Progress note;Find;Pt;Outpatient;Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine Outpatient Progress note;Chiropractic med OP Prog note;;ACTIVE;2.73;2.73 +100452-2;Progress note;Find;Pt;Outpatient;Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology Outpatient Progress note;Electrophysiology OP Prog note;;ACTIVE;2.73;2.73 +10045-3;S wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave amplitude in lead V6;S wave Amp L-V6;;ACTIVE;1.0i;2.48 +100453-0;Progress note;Find;Pt;Outpatient;Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Outpatient Progress note;Clinical genetics OP Prog note;;ACTIVE;2.73;2.73 +100454-8;Progress note;Find;Pt;Outpatient;Doc;Clinical neurophysiology;DOC.ONTOLOGY;2;Clinical neurophysiology Outpatient Progress note;Clinical Neurophys OP Prog note;;ACTIVE;2.73;2.73 +100455-5;Progress note;Find;Pt;Outpatient;Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Outpatient Progress note;Clin Path OP Prog note;;ACTIVE;2.73;2.73 +100456-3;Progress note;Find;Pt;Outpatient;Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Outpatient Progress note;Col+rec surg OP Prog note;;ACTIVE;2.73;2.73 +100457-1;Progress note;Find;Pt;Outpatient;Doc;Consultant;DOC.ONTOLOGY;2;Consultant Outpatient Progress note;Consultant OP Prog note;;ACTIVE;2.73;2.73 +100458-9;COVID-19+Intubation+Progress note;Find;Pt;Outpatient;Doc;;DOC.ONTOLOGY;2;Outpatient COVID-19 Intubation Progress note;OP COVID-19 Intub+Progress;;ACTIVE;2.73;2.73 +100459-7;COVID-19+Progress note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient COVID-19 Progress note;OP COVID-19 Progress note;;ACTIVE;2.73;2.73 +100460-5;Progress note;Find;Pt;Outpatient;Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Outpatient Progress note;Dermatology OP Prog note;;ACTIVE;2.73;2.73 +10046-1;S wave duration.lead AVF;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead AVF;S wave dur L-AVF;;ACTIVE;1.0i;2.48 +100461-3;Progress note;Find;Pt;Outpatient;Doc;Developmental-behavioral pediatrics;DOC.ONTOLOGY;2;Developmental-behavioral pediatrics Outpatient Progress note;Develop-behav peds OP Prog note;;ACTIVE;2.73;2.73 +100462-1;Progress note;Find;Pt;Outpatient;Doc;Dialysis+Therapeutic apheresis;DOC.ONTOLOGY;2;Dialysis and Therapeutic apheresis Outpatient Progress note;Dialy+Ther Apher OP Prog note;;ACTIVE;2.73;2.73 +100463-9;Progress note;Find;Pt;Outpatient;Doc;Eating disorders;DOC.ONTOLOGY;2;Eating disorders Outpatient Progress note;Eating disorders OP Prog note;;ACTIVE;2.73;2.73 +100464-7;Progress note;Find;Pt;Outpatient;Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Outpatient Progress note;Endocrinology OP Prog note;;ACTIVE;2.73;2.73 +100465-4;Progress note;Find;Pt;Outpatient;Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Outpatient Progress note;Fam Med OP Prog note;;ACTIVE;2.73;2.73 +100466-2;Progress note;Find;Pt;Outpatient;Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Outpatient Progress note;Gastroenterology OP Prog note;;ACTIVE;2.73;2.73 +100467-0;Progress note;Find;Pt;Outpatient;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Outpatient Progress note;Geri med OP Prog note;;ACTIVE;2.73;2.73 +100468-8;Progress note;Find;Pt;Outpatient;Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Outpatient Progress note;Gyn Onc OP Prog note;;ACTIVE;2.73;2.73 +100469-6;Progress note;Find;Pt;Outpatient;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Outpatient Progress note;Gynecology OP Prog note;;ACTIVE;2.73;2.73 +100470-4;Progress note;Find;Pt;Outpatient;Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Outpatient Progress note;Navigator OP Prog note;;ACTIVE;2.73;2.73 +100471-2;Progress note;Find;Pt;Outpatient;Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Outpatient Progress note;Heart failure OP Prog note;;ACTIVE;2.73;2.73 +100472-0;Progress note;Find;Pt;Outpatient;Doc;Heart failure+Transplant cardiology;DOC.ONTOLOGY;2;Heart failure+Transplant cardiology Outpatient Progress note;HF+TC OP Prog note;;ACTIVE;2.73;2.73 +100473-8;Progress note;Find;Pt;Outpatient;Doc;Hematology;DOC.ONTOLOGY;2;Hematology Outpatient Progress note;Hematology OP Prog note;;ACTIVE;2.73;2.73 +100474-6;Progress note;Find;Pt;Outpatient;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Outpatient Progress note;HemOnc OP Prog note;;ACTIVE;2.73;2.73 +100475-3;Progress note;Find;Pt;Outpatient;Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Outpatient Progress note;Hepatology OP Prog note;;ACTIVE;2.73;2.73 +100476-1;Progress note;Find;Pt;Outpatient;Doc;Immunology;DOC.ONTOLOGY;2;Immunology Outpatient Progress note;Immunology OP Prog note;;ACTIVE;2.73;2.73 +100477-9;Progress note;Find;Pt;Outpatient;Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Outpatient Progress note;Infectious disease OP Prog note;;ACTIVE;2.73;2.73 +100478-7;Progress note;Find;Pt;Outpatient;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Outpatient Progress note;Internal Med OP Prog note;;ACTIVE;2.73;2.73 +10047-9;S wave duration.lead AVL;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead AVL;S wave dur L-AVL;;ACTIVE;1.0i;2.48 +100479-5;Progress note;Find;Pt;Outpatient;Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Outpatient Progress note;IC OP Prog note;;ACTIVE;2.73;2.73 +100480-3;Progress note;Find;Pt;Outpatient;Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Outpatient Progress note;IR OP Prog note;;ACTIVE;2.73;2.73 +100481-1;Mechanical circulatory support+progress note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Mechanical circulatory support Progress note;OP MCS+progress note;;ACTIVE;2.73;2.73 +100482-9;Progress note;Find;Pt;Outpatient;Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying Outpatient Progress note;MAiD OP Prog note;;ACTIVE;2.73;2.73 +100483-7;Progress note;Find;Pt;Outpatient;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Outpatient Progress note;Mental health OP Prog note;;ACTIVE;2.73;2.73 +100484-5;Progress note;Find;Pt;Outpatient;Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Outpatient Progress note;Multi-spec prog OP Prog note;;ACTIVE;2.73;2.73 +100485-2;Progress note;Find;Pt;Outpatient;Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Outpatient Progress note;Neo peri med OP Prog note;;ACTIVE;2.73;2.73 +100486-0;Progress note;Find;Pt;Outpatient;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Outpatient Progress note;Nephrology OP Prog note;;ACTIVE;2.73;2.73 +10048-7;S wave duration.lead AVR;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead AVR;S wave dur L-AVR;;ACTIVE;1.0i;2.48 +100487-8;Progress note;Find;Pt;Outpatient;Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Outpatient Progress note;Neuro surgery OP Prog note;;ACTIVE;2.73;2.73 +100488-6;Progress note;Find;Pt;Outpatient;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Outpatient Progress note;Neurology OP Prog note;;ACTIVE;2.73;2.73 +100489-4;Progress note;Find;Pt;Outpatient;Doc;Neurology w special qualifications in child neuro;DOC.ONTOLOGY;2;Neurology with special qualifications in child neurology Outpatient Progress note;Child neuro OP Prog note;;ACTIVE;2.73;2.73 +100490-2;Progress note;Find;Pt;Outpatient;Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Outpatient Progress note;Nurse pract OP Prog note;;ACTIVE;2.73;2.73 +100491-0;Progress note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Progress note;Nurse OP Prog note;;ACTIVE;2.73;2.73 +100492-8;Progress note;Find;Pt;Outpatient;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Outpatient Progress note;Nutr+diet OP Prog note;;ACTIVE;2.73;2.73 +100493-6;Progress note;Find;Pt;Outpatient;Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Outpatient Progress note;OBGYN OP Prog note;;ACTIVE;2.73;2.73 +100494-4;Progress note;Find;Pt;Outpatient;Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Outpatient Progress note;OB OP Prog note;;ACTIVE;2.73;2.73 +10049-5;S wave duration.lead I;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead I;S wave dur L-I;;ACTIVE;1.0i;2.48 +100495-1;Progress note;Find;Pt;Outpatient;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Outpatient Progress note;OT OP Prog note;;ACTIVE;2.73;2.73 +100496-9;Progress note;Find;Pt;Outpatient;Doc;Oncology;DOC.ONTOLOGY;2;Oncology Outpatient Progress note;Oncology OP Prog note;;ACTIVE;2.73;2.73 +100497-7;Progress note;Find;Pt;Outpatient;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Outpatient Progress note;Ophthalmol OP Prog note;;ACTIVE;2.73;2.73 +100498-5;Progress note;Find;Pt;Outpatient;Doc;Optometry;DOC.ONTOLOGY;2;Optometry Outpatient Progress note;Optometry OP Prog note;;ACTIVE;2.73;2.73 +100499-3;Progress note;Find;Pt;Outpatient;Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Outpatient Progress note;OMS OP Prog note;;ACTIVE;2.73;2.73 +100500-8;Progress note;Find;Pt;Outpatient;Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Outpatient Progress note;Orthopaedic surgery OP Prog note;;ACTIVE;2.73;2.73 +100501-6;Progress note;Find;Pt;Outpatient;Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Outpatient Progress note;Orthotics prosthetics OP Prog note;;ACTIVE;2.73;2.73 +100502-4;Progress note;Find;Pt;Outpatient;Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Outpatient Progress note;Otolaryngology OP Prog note;;ACTIVE;2.73;2.73 +10050-3;S wave duration.lead II;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead II;S wave dur L-II;;ACTIVE;1.0i;2.48 +100503-2;Progress note;Find;Pt;Outpatient;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Outpatient Progress note;Pain medicine OP Prog note;;ACTIVE;2.73;2.73 +100504-0;Progress note;Find;Pt;Outpatient;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Outpatient Progress note;Palliative care OP Prog note;;ACTIVE;2.73;2.73 +100505-7;Progress note;Find;Pt;Outpatient;Doc;Pediatric cardiology;DOC.ONTOLOGY;2;Pediatric cardiology Outpatient Progress note;Peds cardiology OP Prog note;;ACTIVE;2.73;2.73 +100506-5;Progress note;Find;Pt;Outpatient;Doc;Pediatric dermatology;DOC.ONTOLOGY;2;Pediatric dermatology Outpatient Progress note;Peds dermatology OP Prog note;;ACTIVE;2.73;2.73 +100507-3;Progress note;Find;Pt;Outpatient;Doc;Pediatric endocrinology;DOC.ONTOLOGY;2;Pediatric endocrinology Outpatient Progress note;Peds endocrinology OP Prog note;;ACTIVE;2.73;2.73 +100508-1;Progress note;Find;Pt;Outpatient;Doc;Pediatric gastroenterology;DOC.ONTOLOGY;2;Pediatric gastroenterology Outpatient Progress note;Peds gastroenterology OP Prog note;;ACTIVE;2.73;2.73 +100509-9;Progress note;Find;Pt;Outpatient;Doc;Pediatric hematology-oncology;DOC.ONTOLOGY;2;Pediatric hematology-oncology Outpatient Progress note;Peds hem-onc OP Prog note;;ACTIVE;2.73;2.73 +100510-7;Progress note;Find;Pt;Outpatient;Doc;Pediatric infectious diseases;DOC.ONTOLOGY;2;Pediatric infectious diseases Outpatient Progress note;Peds infect disease OP Prog note;;ACTIVE;2.73;2.73 +10051-1;S wave duration.lead III;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead III;S wave dur L-III;;ACTIVE;1.0i;2.48 +100511-5;Progress note;Find;Pt;Outpatient;Doc;Pediatric otolaryngology;DOC.ONTOLOGY;2;Pediatric otolaryngology Outpatient Progress note;Peds otolaryngology OP Prog note;;ACTIVE;2.73;2.73 +100512-3;Progress note;Find;Pt;Outpatient;Doc;Pediatric pulmonology;DOC.ONTOLOGY;2;Pediatric pulmonology Outpatient Progress note;Peds pulmonology OP Prog note;;ACTIVE;2.73;2.73 +100513-1;Progress note;Find;Pt;Outpatient;Doc;Pediatric rheumatology;DOC.ONTOLOGY;2;Pediatric rheumatology Outpatient Progress note;Peds rheumatology OP Prog note;;ACTIVE;2.73;2.73 +100514-9;Progress note;Find;Pt;Outpatient;Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Outpatient Progress note;Peds surgery OP Prog note;;ACTIVE;2.73;2.73 +100515-6;Progress note;Find;Pt;Outpatient;Doc;Pediatric transplant hepatology;DOC.ONTOLOGY;2;Pediatric transplant hepatology Outpatient Progress note;Peds transpl hepato OP Prog note;;ACTIVE;2.73;2.73 +100516-4;Progress note;Find;Pt;Outpatient;Doc;Pediatric urology;DOC.ONTOLOGY;2;Pediatric urology Outpatient Progress note;Peds urology OP Prog note;;ACTIVE;2.73;2.73 +100517-2;Progress note;Find;Pt;Outpatient;Doc;Pharmacogenomics;DOC.ONTOLOGY;2;Pharmacogenomics Outpatient Progress note;Pharmacogenomics OP Prog note;;ACTIVE;2.73;2.73 +100518-0;Progress note;Find;Pt;Outpatient;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Outpatient Progress note;PM+R OP Prog note;;ACTIVE;2.73;2.73 +100519-8;Progress note;Find;Pt;Outpatient;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Outpatient Progress note;PT OP Prog note;;ACTIVE;2.73;2.73 +100520-6;Progress note;Find;Pt;Outpatient;Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Outpatient Progress note;Plastic surgery OP Prog note;;ACTIVE;2.73;2.73 +100521-4;Progress note;Find;Pt;Outpatient;Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Outpatient Progress note;Podiatry OP Prog note;;ACTIVE;2.73;2.73 +100522-2;Progress note;Find;Pt;Hospital;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Hospital Progress note;Psychiatric Hosp Prog note;;ACTIVE;2.73;2.73 +100523-0;Progress note;Find;Pt;Outpatient;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Outpatient Progress note;Psych OP Prog note;;ACTIVE;2.73;2.73 +100524-8;Progress note;Find;Pt;Outpatient;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Outpatient Progress note;Pulmonary disease OP Prog note;;ACTIVE;2.73;2.73 +100525-5;Progress note;Find;Pt;Outpatient;Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Outpatient Progress note;Radiation Onc OP Prog note;;ACTIVE;2.73;2.73 +100526-3;Progress note;Find;Pt;Outpatient;Doc;Radiology;DOC.ONTOLOGY;2;Radiology Outpatient Progress note;Radiology OP Prog note;;ACTIVE;2.73;2.73 +100527-1;Progress note;Find;Pt;Outpatient;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Outpatient Progress note;Rec therapy OP Prog note;;ACTIVE;2.73;2.73 +100528-9;Progress note;Find;Pt;Outpatient;Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Outpatient Progress note;REI OP Prog note;;ACTIVE;2.73;2.73 +10052-9;S wave duration.lead V1;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead V1;S wave dur L-V1;;ACTIVE;1.0i;2.48 +100529-7;Progress note;Find;Pt;Outpatient;Doc;Research;DOC.ONTOLOGY;2;Research Outpatient Progress note;Research OP Prog note;;ACTIVE;2.73;2.73 +100530-5;Progress note;Find;Pt;Outpatient;Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Outpatient Progress note;Rheumatology OP Prog note;;ACTIVE;2.73;2.73 +100531-3;Progress note;Find;Pt;Outpatient;Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Outpatient Progress note;Sleep med OP Prog note;;ACTIVE;2.73;2.73 +100532-1;Progress note;Find;Pt;Outpatient;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Outpatient Progress note;SW OP Prog note;;ACTIVE;2.73;2.73 +100533-9;Progress note;Find;Pt;Outpatient;Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant Outpatient Progress note;Solid Org Transplant OP Prog note;;ACTIVE;2.73;2.73 +100534-7;Progress note;Find;Pt;Outpatient;Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Outpatient Progress note;Speech-lang path OP Prog note;;ACTIVE;2.73;2.73 +100535-4;Progress note;Find;Pt;Outpatient;Doc;Spinal surgery;DOC.ONTOLOGY;2;Spinal surgery Outpatient Progress note;Spinal surgery OP Prog note;;ACTIVE;2.73;2.73 +100536-2;Progress note;Find;Pt;Outpatient;Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Outpatient Progress note;Sports medicine OP Prog note;;ACTIVE;2.73;2.73 +10053-7;S wave duration.lead V2;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead V2;S wave dur L-V2;;ACTIVE;1.0i;2.48 +100537-0;Progress note;Find;Pt;Outpatient;Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Outpatient Progress note;Hand Surgery OP Prog note;;ACTIVE;2.73;2.73 +100538-8;Progress note;Find;Pt;Telehealth+Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Telehealth+Outpatient Progress note;Telehealth+Outpatient Prog note;;ACTIVE;2.73;2.73 +100539-6;Progress note;Find;Pt;Outpatient;Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism Outpatient Progress note;Thromboemb OP Prog note;;ACTIVE;2.73;2.73 +100540-4;Progress note;Find;Pt;Outpatient;Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Outpatient Progress note;Transpl surg OP Prog note;;ACTIVE;2.73;2.73 +100541-2;Progress note;Find;Pt;Outpatient;Doc;Trauma;DOC.ONTOLOGY;2;Trauma Outpatient Progress note;Trauma OP Prog note;;ACTIVE;2.73;2.73 +100542-0;Progress note;Find;Pt;Outpatient;Doc;Urology;DOC.ONTOLOGY;2;Urology Outpatient Progress note;Urology OP Prog note;;ACTIVE;2.73;2.73 +100543-8;Progress note;Find;Pt;Outpatient;Doc;Vascular neurology;DOC.ONTOLOGY;2;Vascular neurology Outpatient Progress note;Vasc Neuro OP Prog note;;ACTIVE;2.73;2.73 +100544-6;Progress note;Find;Pt;Outpatient;Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Outpatient Progress note;Vascular surgery OP Prog note;;ACTIVE;2.73;2.73 +10054-5;S wave duration.lead V3;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead V3;S wave dur L-V3;;ACTIVE;1.0i;2.48 +100545-3;Progress note;Find;Pt;Outpatient;Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Outpatient Progress note;Wound care management OP Prog note;;ACTIVE;2.73;2.73 +100546-1;Progress note;Find;Pt;Outpatient;Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Outpatient Progress note;WOC OP Prog note;;ACTIVE;2.73;2.73 +100547-9;Progress note;Find;Pt;Hospital;Doc;Adolescent medicine;DOC.ONTOLOGY;2;Adolescent medicine Hospital Progress note;Adolescent med Hosp Prog note;;ACTIVE;2.73;2.73 +100548-7;Progress note;Find;Pt;Hospital;Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Hospital Progress note;Allergy+Immunology Hosp Prog note;;ACTIVE;2.73;2.73 +100549-5;Progress note;Find;Pt;Hospital;Doc;Allergy;DOC.ONTOLOGY;2;Allergy Hospital Progress note;Allergy Hosp Prog note;;ACTIVE;2.73;2.73 +100550-3;Progress note;Find;Pt;Hospital;Doc;Attending;DOC.ONTOLOGY;2;Attending Hospital Progress note;Attend Hosp Prog note;;ACTIVE;2.73;2.73 +100551-1;Progress note;Find;Pt;Hospital;Doc;Audiology;DOC.ONTOLOGY;2;Audiology Hospital Progress note;Audiology Hosp Prog note;;ACTIVE;2.73;2.73 +10055-2;S wave duration.lead V4;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead V4;S wave dur L-V4;;ACTIVE;1.0i;2.48 +100552-9;Progress note;Find;Pt;Hospital;Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Hospital Progress note;Bariatric surg Hosp Prog note;;ACTIVE;2.73;2.73 +100553-7;Progress note;Find;Pt;Hospital;Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Hospital Progress note;Bld Bnk+Trans Med Hosp Prog note;;ACTIVE;2.73;2.73 +100554-5;Progress note;Find;Pt;Hospital;Doc;Bone marrow transplant;DOC.ONTOLOGY;2;Bone Marrow Transplant Hospital Progress note;BM Transplant Hosp Prog note;;ACTIVE;2.73;2.73 +100555-2;Progress note;Find;Pt;Hospital;Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Hospital Progress note;Breastfeeding Hosp Prog note;;ACTIVE;2.73;2.73 +100556-0;Progress note;Find;Pt;Hospital;Doc;Burn management;DOC.ONTOLOGY;2;Burn management Hospital Progress note;Burn Hosp Prog note;;ACTIVE;2.73;2.73 +100557-8;Progress note;Find;Pt;Hospital;Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Hospital Progress note;Cardiac surgery Hosp Prog note;;ACTIVE;2.73;2.73 +100558-6;Progress note;Find;Pt;Hospital;Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Hospital Progress note;Cardio+Pulm disease Hosp Prog note;;ACTIVE;2.73;2.73 +100559-4;Progress note;Find;Pt;Hospital;Doc;Child and adolescent psychiatry;DOC.ONTOLOGY;2;Child and adolescent psychiatry Hospital Progress note;Child+teen psych Hosp Prog note;;ACTIVE;2.73;2.73 +10056-0;S wave duration.lead V5;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead V5;S wave dur L-V5;;ACTIVE;1.0i;2.48 +100560-2;Progress note;Find;Pt;Hospital;Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology Hospital Progress note;Electrophysiology Hosp Prog note;;ACTIVE;2.73;2.73 +100561-0;Progress note;Find;Pt;Hospital;Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Hospital Progress note;Clinical genetics Hosp Prog note;;ACTIVE;2.73;2.73 +100562-8;Progress note;Find;Pt;Hospital;Doc;Clinical neurophysiology;DOC.ONTOLOGY;2;Clinical neurophysiology Hospital Progress note;Clinical Neurophys Hosp Prog note;;ACTIVE;2.73;2.73 +100563-6;Progress note;Find;Pt;Hospital;Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Hospital Progress note;Clin Path Hosp Prog note;;ACTIVE;2.73;2.73 +100564-4;Progress note;Find;Pt;Hospital;Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Hospital Progress note;Col+rec surg Hosp Prog note;;ACTIVE;2.73;2.73 +100565-1;Progress note;Find;Pt;Hospital;Doc;Consultant;DOC.ONTOLOGY;2;Consultant Hospital Progress note;Consultant Hosp Prog note;;ACTIVE;2.73;2.73 +100566-9;Progress note;Find;Pt;Hospital;Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Hospital Progress note;Dentistry Hosp Prog note;;ACTIVE;2.73;2.73 +100567-7;Progress note;Find;Pt;Hospital;Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Hospital Progress note;Dermatology Hosp Prog note;;ACTIVE;2.73;2.73 +100568-5;Progress note;Find;Pt;Hospital;Doc;Developmental-behavioral pediatrics;DOC.ONTOLOGY;2;Developmental-behavioral pediatrics Hospital Progress note;Develop-behav peds Hosp Prog note;;ACTIVE;2.73;2.73 +100569-3;Progress note;Find;Pt;Hospital;Doc;Dialysis+Therapeutic apheresis;DOC.ONTOLOGY;2;Dialysis and Therapeutic apheresis Hospital Progress note;Dialy+Ther Apher Hosp Prog note;;ACTIVE;2.73;2.73 +100570-1;Progress note;Find;Pt;Hospital;Doc;Eating disorders;DOC.ONTOLOGY;2;Eating disorders Hospital Progress note;Eating disorders Hosp Prog note;;ACTIVE;2.73;2.73 +100571-9;Progress note;Find;Pt;Hospital;Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Hospital Progress note;Endocrinology Hosp Prog note;;ACTIVE;2.73;2.73 +100572-7;Progress note;Find;Pt;Hospital;Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Hospital Progress note;Fam Med Hosp Prog note;;ACTIVE;2.73;2.73 +100573-5;Progress note;Find;Pt;Hospital;Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Hospital Progress note;Gastroenterology Hosp Prog note;;ACTIVE;2.73;2.73 +100574-3;Progress note;Find;Pt;Hospital;Doc;General medicine;DOC.ONTOLOGY;2;General medicine Hospital Progress note;General medicine Hosp Prog note;;ACTIVE;2.73;2.73 +100575-0;Progress note;Find;Pt;Hospital;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Hospital Progress note;Geri med Hosp Prog note;;ACTIVE;2.73;2.73 +100576-8;Progress note;Find;Pt;Hospital;Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Hospital Progress note;Gyn Onc Hosp Prog note;;ACTIVE;2.73;2.73 +100577-6;Progress note;Find;Pt;Hospital;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Hospital Progress note;Gynecology Hosp Prog note;;ACTIVE;2.73;2.73 +10057-8;S wave duration.lead V6;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S wave duration in lead V6;S wave dur L-V6;;ACTIVE;1.0i;2.48 +100578-4;Progress note;Find;Pt;Hospital;Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Hospital Progress note;Navigator Hosp Prog note;;ACTIVE;2.73;2.73 +100579-2;Progress note;Find;Pt;Hospital;Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Hospital Progress note;Heart failure Hosp Prog note;;ACTIVE;2.73;2.73 +1005-8;Indirect antiglobulin test.IgG specific reagent;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Indirect antiglobulin test.IgG specific reagent [Presence] in Serum or Plasma;IAT IgG-Sp Reag SerPl Ql;;ACTIVE;1.0;2.73 +100580-0;Progress note;Find;Pt;Hospital;Doc;Heart failure+Transplant cardiology;DOC.ONTOLOGY;2;Heart failure+Transplant cardiology Hospital Progress note;HF+TC Hosp Prog note;;ACTIVE;2.73;2.73 +100581-8;Progress note;Find;Pt;Hospital;Doc;Hematology;DOC.ONTOLOGY;2;Hematology Hospital Progress note;Hematology Hosp Prog note;;ACTIVE;2.73;2.73 +100582-6;Progress note;Find;Pt;Hospital;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Hospital Progress note;HemOnc Hosp Prog note;;ACTIVE;2.73;2.73 +100583-4;Progress note;Find;Pt;Hospital;Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Hospital Progress note;Hepatology Hosp Prog note;;ACTIVE;2.73;2.73 +100584-2;Progress note;Find;Pt;Hospital;Doc;Immunology;DOC.ONTOLOGY;2;Immunology Hospital Progress note;Immunology Hosp Prog note;;ACTIVE;2.73;2.73 +100585-9;Progress note;Find;Pt;Hospital;Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Hospital Progress note;Infectious disease Hosp Prog note;;ACTIVE;2.73;2.73 +10058-6;S' wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead AVF;S' wave Amp L-AVF;;ACTIVE;1.0i;2.48 +100586-7;Progress note;Find;Pt;Hospital;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Hospital Progress note;Internal Med Hosp Prog note;;ACTIVE;2.73;2.73 +100587-5;Progress note;Find;Pt;Hospital;Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Hospital Progress note;IC Hosp Prog note;;ACTIVE;2.73;2.73 +100588-3;Progress note;Find;Pt;Hospital;Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Hospital Progress note;IR Hosp Prog note;;ACTIVE;2.73;2.73 +100589-1;Mechanical circulatory support+progress note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Mechanical circulatory support Progress note;Hosp MCS+progress note;;ACTIVE;2.73;2.73 +100590-9;Progress note;Find;Pt;Hospital;Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying Hospital Progress note;MAiD Hosp Prog note;;ACTIVE;2.73;2.73 +100591-7;Progress note;Find;Pt;Hospital;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Hospital Progress note;Mental health Hosp Prog note;;ACTIVE;2.73;2.73 +100592-5;Progress note;Find;Pt;Hospital;Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Hospital Progress note;Multi-spec prog Hosp Prog note;;ACTIVE;2.73;2.73 +100593-3;Progress note;Find;Pt;Hospital;Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Hospital Progress note;Neo peri med Hosp Prog note;;ACTIVE;2.73;2.73 +10059-4;S' wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead AVL;S' wave Amp L-AVL;;ACTIVE;1.0i;2.48 +100594-1;Progress note;Find;Pt;Hospital;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Hospital Progress note;Nephrology Hosp Prog note;;ACTIVE;2.73;2.73 +100595-8;Progress note;Find;Pt;Hospital;Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Hospital Progress note;Neuro surgery Hosp Prog note;;ACTIVE;2.73;2.73 +100596-6;Progress note;Find;Pt;Hospital;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Hospital Progress note;Neurology Hosp Prog note;;ACTIVE;2.73;2.73 +100597-4;Progress note;Find;Pt;Hospital;Doc;Neurology w special qualifications in child neuro;DOC.ONTOLOGY;2;Neurology with special qualifications in child neurology Hospital Progress note;Child neuro Hosp Prog note;;ACTIVE;2.73;2.73 +100598-2;Progress note;Find;Pt;Hospital;Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Hospital Progress note;Nurse pract Hosp Prog note;;ACTIVE;2.73;2.73 +100599-0;Progress note;Find;Pt;Hospital;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Hospital Progress note;Nurse Hosp Prog note;;ACTIVE;2.73;2.73 +100600-6;Progress note;Find;Pt;Hospital;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Hospital Progress note;Nutr+diet Hosp Prog note;;ACTIVE;2.73;2.73 +100601-4;Progress note;Find;Pt;Hospital;Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Hospital Progress note;OBGYN Hosp Prog note;;ACTIVE;2.73;2.73 +10060-2;S' wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead AVR;S' wave Amp L-AVR;;ACTIVE;1.0i;2.48 +100602-2;Progress note;Find;Pt;Hospital;Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Hospital Progress note;OB Hosp Prog note;;ACTIVE;2.73;2.73 +100603-0;Progress note;Find;Pt;Hospital;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Hospital Progress note;OT Hosp Prog note;;ACTIVE;2.73;2.73 +100604-8;Progress note;Find;Pt;Hospital;Doc;Oncology;DOC.ONTOLOGY;2;Oncology Hospital Progress note;Oncology Hosp Prog note;;ACTIVE;2.73;2.73 +100605-5;Progress note;Find;Pt;Hospital;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Hospital Progress note;Ophthalmol Hosp Prog note;;ACTIVE;2.73;2.73 +100606-3;Progress note;Find;Pt;Hospital;Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Hospital Progress note;OMS Hosp Prog note;;ACTIVE;2.73;2.73 +100607-1;Progress note;Find;Pt;Hospital;Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Hospital Progress note;Orthopaedic surgery Hosp Prog note;;ACTIVE;2.73;2.73 +100608-9;Progress note;Find;Pt;Hospital;Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Hospital Progress note;Orthotics prosthetics Hosp Prog note;;ACTIVE;2.73;2.73 +100609-7;Progress note;Find;Pt;Hospital;Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Hospital Progress note;Otolaryngology Hosp Prog note;;ACTIVE;2.73;2.73 +10061-0;S' wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead I;S' wave Amp L-I;;ACTIVE;1.0i;2.48 +100610-5;Progress note;Find;Pt;Hospital;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Hospital Progress note;Pain medicine Hosp Prog note;;ACTIVE;2.73;2.73 +100611-3;Progress note;Find;Pt;Hospital;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Hospital Progress note;Palliative care Hosp Prog note;;ACTIVE;2.73;2.73 +100612-1;Progress note;Find;Pt;Hospital;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Hospital Progress note;Pastoral Care Hosp Prog note;;ACTIVE;2.73;2.73 +100613-9;Progress note;Find;Pt;Hospital;Doc;Pediatric cardiology;DOC.ONTOLOGY;2;Pediatric cardiology Hospital Progress note;Peds cardiology Hosp Prog note;;ACTIVE;2.73;2.73 +100614-7;Progress note;Find;Pt;Hospital;Doc;Pediatric dermatology;DOC.ONTOLOGY;2;Pediatric dermatology Hospital Progress note;Peds dermatology Hosp Prog note;;ACTIVE;2.73;2.73 +100615-4;Progress note;Find;Pt;Hospital;Doc;Pediatric endocrinology;DOC.ONTOLOGY;2;Pediatric endocrinology Hospital Progress note;Peds endocrinology Hosp Prog note;;ACTIVE;2.73;2.73 +100616-2;Progress note;Find;Pt;Hospital;Doc;Pediatric gastroenterology;DOC.ONTOLOGY;2;Pediatric gastroenterology Hospital Progress note;Peds gastroenterology Hosp Prog note;;ACTIVE;2.73;2.73 +100617-0;Progress note;Find;Pt;Hospital;Doc;Pediatric hematology-oncology;DOC.ONTOLOGY;2;Pediatric hematology-oncology Hospital Progress note;Peds hem-onc Hosp Prog note;;ACTIVE;2.73;2.73 +100618-8;Progress note;Find;Pt;Hospital;Doc;Pediatric infectious diseases;DOC.ONTOLOGY;2;Pediatric infectious diseases Hospital Progress note;Peds infect disease Hosp Prog note;;ACTIVE;2.73;2.73 +100619-6;Progress note;Find;Pt;Hospital;Doc;Pediatric otolaryngology;DOC.ONTOLOGY;2;Pediatric otolaryngology Hospital Progress note;Peds otolaryngology Hosp Prog note;;ACTIVE;2.73;2.73 +100620-4;Progress note;Find;Pt;Hospital;Doc;Pediatric pulmonology;DOC.ONTOLOGY;2;Pediatric pulmonology Hospital Progress note;Peds pulmonology Hosp Prog note;;ACTIVE;2.73;2.73 +100621-2;Progress note;Find;Pt;Hospital;Doc;Pediatric rheumatology;DOC.ONTOLOGY;2;Pediatric rheumatology Hospital Progress note;Peds rheumatology Hosp Prog note;;ACTIVE;2.73;2.73 +100622-0;Progress note;Find;Pt;Hospital;Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Hospital Progress note;Peds surgery Hosp Prog note;;ACTIVE;2.73;2.73 +100623-8;Progress note;Find;Pt;Hospital;Doc;Pediatric transplant hepatology;DOC.ONTOLOGY;2;Pediatric transplant hepatology Hospital Progress note;Peds transpl hepato Hosp Prog note;;ACTIVE;2.73;2.73 +100624-6;Progress note;Find;Pt;Hospital;Doc;Pharmacogenomics;DOC.ONTOLOGY;2;Pharmacogenomics Hospital Progress note;Pharmacogenomics Hosp Prog note;;ACTIVE;2.73;2.73 +100625-3;Progress note;Find;Pt;Hospital;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Hospital Progress note;Pharmacology Hosp Prog note;;ACTIVE;2.73;2.73 +100626-1;Progress note;Find;Pt;Hospital;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Hospital Progress note;PM+R Hosp Prog note;;ACTIVE;2.73;2.73 +100627-9;Progress note;Find;Pt;Hospital;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Hospital Progress note;PT Hosp Prog note;;ACTIVE;2.73;2.73 +10062-8;S' wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead II;S' wave Amp L-II;;ACTIVE;1.0i;2.48 +100628-7;Progress note;Find;Pt;Hospital;Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Hospital Progress note;Plastic surgery Hosp Prog note;;ACTIVE;2.73;2.73 +100629-5;Progress note;Find;Pt;Hospital;Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Hospital Progress note;Podiatry Hosp Prog note;;ACTIVE;2.73;2.73 +100630-3;Progress note;Find;Pt;Hospital;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Hospital Progress note;Psych Hosp Prog note;;ACTIVE;2.73;2.73 +100631-1;Progress note;Find;Pt;Hospital;Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Hospital Progress note;Radiation Onc Hosp Prog note;;ACTIVE;2.73;2.73 +100632-9;Progress note;Find;Pt;Hospital;Doc;Radiology;DOC.ONTOLOGY;2;Radiology Hospital Progress note;Radiology Hosp Prog note;;ACTIVE;2.73;2.73 +100633-7;Progress note;Find;Pt;Hospital;Doc;Rapid response team;DOC.ONTOLOGY;2;Rapid response team Hospital Progress note;Rapid response team Hosp Prog note;;ACTIVE;2.73;2.73 +100634-5;Progress note;Find;Pt;Hospital;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Hospital Progress note;Rec therapy Hosp Prog note;;ACTIVE;2.73;2.73 +100635-2;Progress note;Find;Pt;Hospital;Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Hospital Progress note;REI Hosp Prog note;;ACTIVE;2.73;2.73 +10063-6;S' wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead III;S' wave Amp L-III;;ACTIVE;1.0i;2.48 +100636-0;Progress note;Find;Pt;Hospital;Doc;Research;DOC.ONTOLOGY;2;Research Hospital Progress note;Research Hosp Prog note;;ACTIVE;2.73;2.73 +100637-8;Progress note;Find;Pt;Hospital;Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Hospital Progress note;Rheumatology Hosp Prog note;;ACTIVE;2.73;2.73 +100638-6;Progress note;Find;Pt;Hospital;Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Hospital Progress note;Sleep med Hosp Prog note;;ACTIVE;2.73;2.73 +100639-4;Progress note;Find;Pt;Hospital;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Hospital Progress note;SW Hosp Prog note;;ACTIVE;2.73;2.73 +100640-2;Progress note;Find;Pt;Hospital;Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant Hospital Progress note;Solid Org Transplant Hosp Prog note;;ACTIVE;2.73;2.73 +100641-0;Progress note;Find;Pt;Hospital;Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Hospital Progress note;Speech-lang path Hosp Prog note;;ACTIVE;2.73;2.73 +100642-8;Progress note;Find;Pt;Hospital;Doc;Spinal surgery;DOC.ONTOLOGY;2;Spinal surgery Hospital Progress note;Spinal surgery Hosp Prog note;;ACTIVE;2.73;2.73 +100643-6;Progress note;Find;Pt;Hospital;Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Hospital Progress note;Hand Surgery Hosp Prog note;;ACTIVE;2.73;2.73 +10064-4;S' wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead V1;S' wave Amp L-V1;;ACTIVE;1.0i;2.48 +100644-4;Progress note;Find;Pt;Hospital;Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism Hospital Progress note;Thromboemb Hosp Prog note;;ACTIVE;2.73;2.73 +100645-1;Progress note;Find;Pt;Hospital;Doc;Trauma;DOC.ONTOLOGY;2;Trauma Hospital Progress note;Trauma Hosp Prog note;;ACTIVE;2.73;2.73 +100646-9;Progress note;Find;Pt;Hospital;Doc;Urology;DOC.ONTOLOGY;2;Urology Hospital Progress note;Urology Hosp Prog note;;ACTIVE;2.73;2.73 +100647-7;Progress note;Find;Pt;Hospital;Doc;Vascular neurology;DOC.ONTOLOGY;2;Vascular neurology Hospital Progress note;Vasc Neuro Hosp Prog note;;ACTIVE;2.73;2.73 +100648-5;Progress note;Find;Pt;Hospital;Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Hospital Progress note;Vascular surgery Hosp Prog note;;ACTIVE;2.73;2.73 +100649-3;Progress note;Find;Pt;Hospital;Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Hospital Progress note;Wound care management Hosp Prog note;;ACTIVE;2.73;2.73 +100650-1;Progress note;Find;Pt;Hospital;Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Hospital Progress note;WOC Hosp Prog note;;ACTIVE;2.73;2.73 +10065-1;S' wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead V2;S' wave Amp L-V2;;ACTIVE;1.0i;2.48 +100651-9;COVID-19+Intubation+Progress note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital COVID-19 Intubation Progress note;Hosp COVID-19 Intub+Progress;;ACTIVE;2.73;2.73 +100652-7;Pure tone bone conduction threshold audiometry panel;-;Pt;Ear;-;;PANEL.CLIN;2;Pure tone bone conduction threshold audiometry panel;Pure tone bone thresh Pnl;;ACTIVE;2.73;2.73 +100653-5;Pure tone air conduction threshold audiometry panel;-;Pt;Ear;-;;PANEL.CLIN;2;Pure tone air conduction threshold audiometry panel;Pure tone air thresh Pnl;;ACTIVE;2.73;2.73 +100654-3;Pyruvate kinase M2;PrThr;Pt;Stool;Ord;;CHEM;1;Pyruvate kinase M2 [Presence] in Stool;M2-PK Stl Ql;;ACTIVE;2.73;2.73 +100655-0;View lateral;Find;Pt;Head>Sella turcica;Doc;XR;RAD;2;XR Sella turcica Lateral;XR ST Lat;;ACTIVE;2.73;2.73 +100656-8;Progress note;Find;Pt;Outpatient;Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Outpatient Progress note;Mat fetal med OP Prog note;;ACTIVE;2.73;2.73 +100657-6;Progress note;Find;Pt;Telephone encounter+Hospital;Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Telephone encounter+Hospital Progress note;Mat fetal med Phone+Hosp Prog note;;ACTIVE;2.73;2.73 +100658-4;COVID-19+Progress note;Find;Pt;Hospital;Doc;;DOC.ONTOLOGY;2;Hospital COVID-19 Progress note;Hosp COVID-19 Progress note;;ACTIVE;2.73;2.73 +100659-2;Progress note;Find;Pt;Hospital;Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Hospital Progress note;Mat fetal med Hosp Prog note;;ACTIVE;2.73;2.73 +1006-6;Direct antiglobulin test.IgG specific reagent;Imp;Pt;RBC;Nom;;BLDBK;1;Direct antiglobulin test.IgG specific reagent [Interpretation] on Red Blood Cells;DAT IgG-Sp Reag RBC-Imp;;ACTIVE;1.0;2.73 +100660-0;Progress note;Find;Pt;Telephone encounter+Outpatient;Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Telephone encounter+Outpatient Progress note;Mat fetal med Phone+OP Prog note;;ACTIVE;2.73;2.73 +100661-8;Progress note;Find;Pt;Outpatient;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Outpatient Progress note;Psychiatric OP Prog note;;ACTIVE;2.73;2.73 +100662-6;Cortisol free & total panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Cortisol free and total panel - Serum or Plasma;CORTO SerPl;;ACTIVE;2.73;2.73 +100663-4;TPMT gene c.460G>A&c.719A>G;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.PHARMG;1;TPMT gene c.460G>A and c.719A>G [Presence] in Blood by Molecular genetics method;TPMT gene c.460G>A&c.719A>G Bld Ql;;ACTIVE;2.73;2.73 +100664-2;NUDT15 gene c.50_55dup&c.415C>T;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;NUDT15 gene c.50_55dup and c.415C>T [Presence] in Blood by Molecular genetics method;NUDT15 gene c.50_55dup&c.415C>T Bld Ql;;ACTIVE;2.73;2.73 +100665-9;NUDT15 gene c.415C>T;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;NUDT15 gene c.415C>T [Presence] in Blood by Molecular genetics method;NUDT15 gene c.415C>T Bld Ql;;ACTIVE;2.73;2.73 +100666-7;NUDT15 gene c.416G>A;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;NUDT15 gene c.416G>A [Presence] in Blood by Molecular genetics method;NUDT15 gene c.416G>A Bld Ql;;ACTIVE;2.73;2.73 +100667-5;NUDT15 gene c.52G>A;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;NUDT15 gene c.52G>A [Presence] in Blood by Molecular genetics method;NUDT15 gene c.52G>A Bld Ql;;ACTIVE;2.73;2.73 +100668-3;NUDT15 gene c.50_55dup;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;NUDT15 gene c.50_55dup [Presence] in Blood by Molecular genetics method;NUDT15 gene c.50_55dup Bld Ql;;ACTIVE;2.73;2.73 +10066-9;S' wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead V3;S' wave Amp L-V3;;ACTIVE;1.0i;2.48 +100669-1;NUDT15 gene c.50_55del;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;NUDT15 gene c.50_55del [Presence] in Blood by Molecular genetics method;NUDT15 gene c.50_55del Bld Ql;;ACTIVE;2.73;2.73 +100670-9;RHD gene allele^fetus;Prid;Pt;Plas.cfDNA;Nom;;MOLPATH;1;RHD gene allele [Identifier] in Plasma cell-free DNA Nominal--fetus;RHD allele fetus Plas.cfDNA;;ACTIVE;2.73;2.73 +100671-7;Aspergillus sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Aspergillus sp DNA [Presence] in Blood by NAA with probe detection;Aspergillus DNA Bld Ql NAA+probe;;ACTIVE;2.73;2.73 +100672-5;Aspergillus fumigatus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Aspergillus fumigatus DNA [Presence] in Blood by NAA with probe detection;A fumigatus DNA Bld Ql NAA+probe;;ACTIVE;2.73;2.73 +100673-3;Aspergillus terreus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Aspergillus terreus DNA [Presence] in Blood by NAA with probe detection;A terreus DNA Bld Ql NAA+probe;;ACTIVE;2.73;2.73 +100674-1;BK virus DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;BKV DNA Bld NAA+probe-Log#;;ACTIVE;2.73;2.73 +100675-8;Cytomegalovirus DNA;ACnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Units/volume] (viral load) in Blood by NAA with probe detection;CMV DNA Bld NAA+probe-aCnc;;ACTIVE;2.73;2.73 +100676-6;Cytomegalovirus DNA;LaCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [log units/volume] (viral load) in Blood by NAA with probe detection;CMV DNA Bld NAA+probe-Log IU;;ACTIVE;2.73;2.73 +10067-7;S' wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead V4;S' wave Amp L-V4;;ACTIVE;1.0i;2.48 +100677-4;Epstein Barr virus DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;EBV DNA SerPl NAA+probe-Log#;;ACTIVE;2.73;2.73 +100678-2;Epstein Barr virus DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;EBV DNA Bld NAA+probe-Log#;;ACTIVE;2.73;2.73 +100679-0;Herpes virus 6 DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV6 DNA SerPl NAA+probe-Log#;;ACTIVE;2.73;2.73 +100680-8;Herpes virus 6 DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;HHV6 DNA Bld NAA+probe-Log#;;ACTIVE;2.73;2.73 +100681-6;Herpes virus 7 DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV7 DNA SerPl NAA+probe-Log#;;ACTIVE;2.73;2.73 +100682-4;Herpes virus 7 DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;HHV7 DNA Bld NAA+probe-Log#;;ACTIVE;2.73;2.73 +100683-2;Herpes virus 8 DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV8 DNA SerPl NAA+probe-Log#;;ACTIVE;2.73;2.73 +100684-0;Herpes virus 8 DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;HHV8 DNA Bld NAA+probe-Log#;;ACTIVE;2.73;2.73 +10068-5;S' wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead V5;S' wave Amp L-V5;;ACTIVE;1.0i;2.48 +100685-7;JC virus DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;JCPyV DNA SerPl NAA+probe-Log#;;ACTIVE;2.73;2.73 +100686-5;JC virus DNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;JCPyV DNA CSF NAA+probe-Log#;;ACTIVE;2.73;2.73 +100687-3;JC virus DNA;LnCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [Log #/volume] (viral load) in Urine by NAA with probe detection;JCPyV DNA Ur NAA+probe-Log#;;ACTIVE;2.73;2.73 +100688-1;Parvovirus B19 DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;B19V DNA Bld NAA+probe-Log#;;ACTIVE;2.73;2.73 +100689-9;Toxoplasma gondii DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Log #/volume] in Serum or Plasma by NAA with probe detection;T gondii DNA SerPl NAA+probe-Log#;;ACTIVE;2.73;2.73 +100690-7;Toxoplasma gondii DNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Log #/volume] in Cerebral spinal fluid by NAA with probe detection;T gondii DNA CSF NAA+probe-Log#;;ACTIVE;2.73;2.73 +100691-5;Varicella zoster virus DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;VZV DNA Bld NAA+probe-Log#;;ACTIVE;2.73;2.73 +100692-3;Varicella zoster virus DNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;VZV DNA CSF NAA+probe-Log#;;ACTIVE;2.73;2.73 +10069-3;S' wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave amplitude in lead V6;S' wave Amp L-V6;;ACTIVE;1.0i;2.48 +100693-1;Pneumocystis jiroveci DNA;LnCnc;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [Log #/volume] in Respiratory specimen by NAA with probe detection;P jiroveci DNA Resp NAA+probe-Log#;;ACTIVE;2.73;2.73 +100694-9;SMN1 gene silent carrier analysis;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;SMN1 gene silent carrier analysis [Presence] in Blood or Tissue by Molecular genetics method;SMN1 carrier analysis Bld/T Ql;;ACTIVE;2.73;2.73 +100695-6;Genetic disease analysis overall carrier interpretation;Imp;Pt;Bld/Tiss;Nar;Molgen;MOLPATH;1;Genetic disease analysis overall carrier interpretation in Blood or Tissue by Molecular genetics method Narrative;Gene dis anl carrier interp Bld/T-Imp;;ACTIVE;2.73;2.73 +100696-4;CTNS related multigene analysis;Prid;Pt;Body fld+Ser/Plas;Nom;Molgen;MOLPATH.MUT;1;CTNS related multigene analysis [Identifier] in Bodyfluid and Serum or Plasma by Molecular genetics method Nominal;CTNS multigene anal Fld+SerPl;;ACTIVE;2.73;2.73 +100697-2;Note;Find;Pt;Outpatient;Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Outpatient Note;IR OP Note;;ACTIVE;2.73;2.73 +100698-0;Social Determinants of Health screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Social Determinants of Health screening report Document;SDOH screen report Doc;;ACTIVE;2.73;2.73 +100699-8;Rifabutin+Ethambutol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Rifabutin+Ethambutol [Susceptibility];Rifabutin+Ethambutol Susc Islt;;ACTIVE;2.73;2.73 +100700-4;Trichomonas vaginalis DNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis DNA [Presence] in Urethra by NAA with probe detection;T vaginalis DNA Urth Ql NAA+probe;;ACTIVE;2.73;2.73 +10070-1;S' wave duration.lead AVF;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead AVF;S' wave dur L-AVF;;ACTIVE;1.0i;2.48 +100701-2;Trichomonas vaginalis rRNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis rRNA [Presence] in Urethra by NAA with probe detection;T vaginalis rRNA Urth Ql NAA+probe;;ACTIVE;2.73;2.73 +100702-0;Mycoplasma genitalium rRNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium rRNA [Presence] in Urethra by NAA with probe detection;M genitalium rRNA Urth Ql NAA+probe;;ACTIVE;2.73;2.73 +100703-8;Mycoplasma genitalium rRNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium rRNA [Presence] in Urine by NAA with probe detection;M genitalium rRNA Ur Ql NAA+probe;;ACTIVE;2.73;2.73 +100704-6;Mycoplasma genitalium rRNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium rRNA [Presence] in Cervix by NAA with probe detection;M genitalium rRNA Cvx Ql NAA+probe;;ACTIVE;2.73;2.73 +100705-3;Mycoplasma genitalium rRNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium rRNA [Presence] in Anorectal by NAA with probe detection;M genitalium rRNA Anorectl Ql NAA+probe;;ACTIVE;2.73;2.73 +100706-1;Mycoplasma genitalium rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium rRNA [Presence] in Specimen by NAA with probe detection;M genitalium rRNA Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100707-9;Polymorphonuclear cells;NCnc;Pt;Dial fld prt;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells [#/volume] in Peritoneal dialysis fluid by Automated count;Polys # DiafP Auto;;ACTIVE;2.73;2.73 +100708-7;Plasma cells/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Plasma cells/100 leukocytes in Synovial fluid;Plasma Cells/leuk NFr Snv;;ACTIVE;2.73;2.73 +100709-5;Hepatocellular carcinoma risk;Score;Pt;^Patient;Qn;GAAD;CHEM;1;Hepatocellular carcinoma risk [Score] by GAAD;Hep Ca Risk Score Patient GAAD;;ACTIVE;2.73;2.73 +100710-3;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;Thrt;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Throat by NAA with probe detection;C trach+GC pnl Throat NAA+probe;;ACTIVE;2.73;2.73 +100711-1;Borrelia burgdorferi.VlsE1+pepC10 Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi.VlsE1+pepC10 Ab [Units/volume] in Serum by Immunoassay;B burgdor.VlsE1+pepC10 Ab Ser IA-aCnc;;ACTIVE;2.73;2.74 +100712-9;Brexpiprazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Brexpiprazole [Mass/volume] in Serum or Plasma;Brexpiprazole SerPl-mCnc;;ACTIVE;2.73;2.73 +100713-7;Cariprazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cariprazine [Mass/volume] in Serum or Plasma;Cariprazine SerPl-mCnc;;ACTIVE;2.73;2.73 +100714-5;Guanfacine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Guanfacine [Mass/volume] in Serum or Plasma;Guanfacine SerPl-mCnc;;ACTIVE;2.73;2.73 +100715-2;Prothipendyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prothipendyl [Mass/volume] in Serum or Plasma;Prothipendyl SerPl-mCnc;;ACTIVE;2.73;2.73 +100716-0;Prostate Specific Ag;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in DBS;PSA DBS-mCnc;;ACTIVE;2.73;2.73 +100717-8;FCGR3A gene.p.Phe176Val;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;FCGR3A gene.p.Phe176Val [Presence] in Blood or Tissue by Molecular genetics method;FCGR3A gene.p.Phe176Val Bld/T Ql;;ACTIVE;2.73;2.73 +100718-6;Discharge summary note;Find;Pt;{Setting};Doc;Undersea and hyperbaric medicine;DOC.ONTOLOGY;2;Undersea and hyperbaric medicine Discharge summary;Undersea+hyperbar D/C sum;;ACTIVE;2.73;2.73 +10071-9;S' wave duration.lead AVL;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead AVL;S' wave dur L-AVL;;ACTIVE;1.0i;2.48 +100719-4;Discharge summary note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Discharge summary;Surg Onc D/C sum;;ACTIVE;2.73;2.73 +100720-2;Discharge summary note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Discharge summary;REI D/C sum;;ACTIVE;2.73;2.73 +100721-0;Discharge summary note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Discharge summary;Comm hlth care D/C sum;;ACTIVE;2.73;2.73 +100722-8;Discharge summary note;Find;Pt;{Setting};Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine Discharge summary;Integrative medicine D/C sum;;ACTIVE;2.73;2.73 +100723-6;Discharge summary note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Discharge summary;Sports medicine D/C sum;;ACTIVE;2.73;2.73 +100724-4;Discharge summary note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Discharge summary;Diabetology D/C sum;;ACTIVE;2.73;2.73 +100725-1;Discharge summary note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Discharge summary;Optometry D/C sum;;ACTIVE;2.73;2.73 +100726-9;Discharge summary note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Discharge summary;Podiatry D/C sum;;ACTIVE;2.73;2.73 +10072-7;S' wave duration.lead AVR;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead AVR;S' wave dur L-AVR;;ACTIVE;1.0i;2.48 +100727-7;Discharge summary note;Find;Pt;{Setting};Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine Discharge summary;Chiropractic med D/C sum;;ACTIVE;2.73;2.73 +100728-5;Discharge summary note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Discharge summary;Cardiac surgery D/C sum;;ACTIVE;2.73;2.73 +100729-3;Discharge summary note;Find;Pt;{Setting};Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Discharge summary;Breastfeeding D/C sum;;ACTIVE;2.73;2.73 +100730-1;Discharge summary note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Discharge summary;Transpl surg D/C sum;;ACTIVE;2.73;2.73 +100731-9;Discharge summary note;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center Discharge summary;Urgent care D/C sum;;ACTIVE;2.73;2.73 +100732-7;Cholesterol.in lipoprotein (little a) & Cholesterol.in LDL panel;-;Pt;Ser;-;;PANEL.CHEM;1;Cholesterol.in lipoprotein (little a) and Cholesterol.in LDL panel - Serum;LPALD Ser;;ACTIVE;2.73;2.73 +100733-5;Cholesterol.in LDL^corrected for Cholesterol.in lipoprotein (little a);MCnc;Pt;Ser;Qn;Calculated;CHEM;1;Cholesterol in LDL [Mass/volume] in Serum by calculation --corrected for Cholesterol.in lipoprotein (little a);LDLc cor Lpa Cholest;;ACTIVE;2.73;2.73 +100734-3;traMADol & metabolites panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;traMADol and Metabolites Panel - Urine by Confirmatory method;Ur Cfm;;ACTIVE;2.73;2.73 +10073-5;S' wave duration.lead I;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead I;S' wave dur L-I;;ACTIVE;1.0i;2.48 +100735-0;Mannose-6-phosphate isomerase & phosphomannomutase 1 panel;-;Pt;WBC;-;;PANEL.CHEM;1;Mannose-6-phosphate isomerase and phosphomannomutase 1 panel - Leukocytes;M6PI & PMM1 panel WBC;;ACTIVE;2.73;2.73 +100736-8;Acylcarnitine Analysis Post Mortem;Find;Pt;XXX;Doc;;CHEM;1;Acylcarnitine Analysis Post Mortem in Specimen Document;Spec Doc;;ACTIVE;2.73;2.73 +100737-6;Alkaline phosphatase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.macromolecular [Presence] in Serum or Plasma;AP Macro SerPl Ql;;ACTIVE;2.73;2.73 +100738-4;Alanine aminotransferase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alanine aminotransferase.macromolecular [Presence] in Serum or Plasma;ALT Macro SerPl Ql;;ACTIVE;2.73;2.73 +100739-2;Aspartate aminotransferase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Aspartate aminotransferase.macromolecular [Presence] in Serum or Plasma;AST Macro SerPl Ql;;ACTIVE;2.73;2.73 +1007-4;Direct antiglobulin test.polyspecific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.polyspecific reagent [Presence] on Red Blood Cells;DAT Poly-Sp Reag RBC Ql;;ACTIVE;1.0;2.73 +100740-0;Amylase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Amylase.macromolecular [Presence] in Serum or Plasma;Amylase Macro SerPl Ql;;ACTIVE;2.73;2.73 +100741-8;Gamma glutamyl transferase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Gamma glutamyl transferase.macromolecular [Presence] in Serum or Plasma;GGT Macro SerPl Ql;;ACTIVE;2.73;2.73 +100742-6;Lactate dehydrogenase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lactate dehydrogenase.macromolecular [Presence] in Serum or Plasma;LDH Macro SerPl Ql;;ACTIVE;2.73;2.73 +10074-3;S' wave duration.lead II;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead II;S' wave dur L-II;;ACTIVE;1.0i;2.48 +100743-4;Lipase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lipase.macromolecular [Presence] in Serum or Plasma;Lipase Macro SerPl Ql;;ACTIVE;2.73;2.73 +100744-2;Alpha-1-Acid glycoprotein;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha-1-acid glycoprotein [Mass/volume] in Serum or Plasma by Electrophoresis;A1acid Glycoprotein SerPl Elph-mCnc;;ACTIVE;2.73;2.73 +100745-9;Chloride;SCnc;Pt;BldMV;Qn;;CHEM;1;Chloride [Moles/volume] in Mixed venous blood;Chloride BldMV-sCnc;;ACTIVE;2.73;2.73 +100746-7;Glucose;SCnc;Pt;BldMV;Qn;;CHEM;1;Glucose [Moles/volume] in Mixed venous blood;Glucose BldMV-sCnc;;ACTIVE;2.73;2.73 +100747-5;Legionella serogroup panel;-;Pt;XXX;-;;PANEL.MICRO;1;Legionella serogroup panel - Specimen;Lp-SG panel Spec;;ACTIVE;2.73;2.73 +100748-3;Legionella spp;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Legionella spp [Presence] in Specimen by NAA with probe detection;Legionella spp Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100749-1;Legionella pneumophila serogroup 1;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Legionella pneumophila serogroup 1 [Presence] in Specimen by NAA with probe detection;Lp-SG1 Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +10075-0;S' wave duration.lead III;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead III;S' wave dur L-III;;ACTIVE;1.0i;2.48 +100750-9;Legionella pneumophila non serogroup 1;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Legionella pneumophila non-serogroup 1 [Presence] in Specimen by NAA with probe detection;Lp-nonSG1 Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100751-7;Galactose-alpha-1,3-galactose panel;-;Pt;Ser/Plas;-;;PANEL.ALLERGY;1;Galactose-alpha-1,3-galactose (Alpha-Gal) panel - Serum or Plasma;Alpha-Gal panel SerPl;;ACTIVE;2.73;2.73 +100752-5;Exacerbating factors;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Exacerbating factors - Reported;Exacerbating factors Reported;;ACTIVE;2.73;2.73 +100753-3;Alleviating factors;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Alleviating factors - Reported;Alleviating factors Reported;;ACTIVE;2.73;2.73 +100754-1;Platelet disorders multigene analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;Platelet disorders multigene analysis in Blood or Tissue by Sequencing;Plt disorder gene anal Bld/T Seq;;ACTIVE;2.73;2.73 +100755-8;Protein fractions.oligoclonal bands;Num;Pt;Ser/Plas;Qn;Isoelectric focusing;CHEM;1;Oligoclonal bands [#] in Serum or Plasma by Isoelectric focusing;Oligoclonal Bands SerPl IEF;;ACTIVE;2.73;2.73 +100756-6;Protein fractions.oligoclonal bands;Imp;Pt;CSF;Nom;Isoelectric focusing;CHEM;1;Oligoclonal bands [Interpretation] in Cerebral spinal fluid by Isoelectric focusing;Oligoclonal Bands CSF IEF-Imp;;ACTIVE;2.73;2.73 +100757-4;Protein fractions.oligoclonal bands panel;-;Pt;Ser+CSF;-;Isoelectric focusing;PANEL.CHEM;1;Protein fractions.oligoclonal bands panel - Serum and CSF by Isoelectric focusing;Oligoclonal Bands panel Ser+CSF IEF;;ACTIVE;2.73;2.73 +100758-2;Estimated lung age;Time;Pt;^Patient;Qn;Based on clinical data;PULM;2;Estimated lung age by based on clinical data;Estimated lung age from clin data;;ACTIVE;2.73;2.73 +100759-0;Inspiratory reserve;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Inspiratory reserve [Volume] Respiratory system by Spirometry;Inspiratory reserve vol spirometry;;ACTIVE;2.73;2.73 +100760-8;View;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left Single view;XR Radius+Ulna-L 1V;;ACTIVE;2.73;2.73 +100761-6;PALB2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;PALB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PALB2 Mut Anl Bld/T;;ACTIVE;2.73;2.73 +100762-4;HBA2 gene.c.377T>C;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBA2 gene.c.377T>C [Presence] in Blood by Molecular genetics method;HBA2 gene.c.377T>C Bld Ql;;ACTIVE;2.73;2.73 +100763-2;Mycobacterium sp comparative reaction interpretation;Imp;Pt;Skin;Nar;;CHALSKIN;1;Mycobacterium sp comparative reaction interpretation Narrative;Mycobacterium sp comp react interp;;ACTIVE;2.73;2.73 +100764-0;Mycobacterium bovis reaction wheal^3D post dose mammalian tuberculin ID;Diam;Pt;Skin;Ord;;CHALSKIN;1;Mycobacterium bovis reaction wheal [Diameter] Qualitative --3 days post dose mammalian tuberculin intradermal;M bovis reactn wheal 3D p Mam Tuberc Ql;;ACTIVE;2.73;2.73 +100765-7;Homocysteine & Methylmalonate & 2-Methylcitrate panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Homocysteine and methylmalonate and methylcitrate panel - DBS;Hcys+Me-Malonate+2Me-citrate Pnl DBS;;ACTIVE;2.73;2.73 +100766-5;Center for Epidemiologic Studies Depression Scale panel;-;RptPeriod;^Patient;-;CES-D;PANEL.SURVEY.MTLHLTH;4;Center for Epidemiologic Studies Depression Scale panel [CES-D];;;ACTIVE;2.73;2.73 +100767-3;Bothered by things that are not usually bothersome;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Bothered by things that are not usually bothersome;;;ACTIVE;2.73;2.73 +10076-8;S' wave duration.lead V1;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead V1;S' wave dur L-V1;;ACTIVE;1.0i;2.48 +100768-1;Poor appetite;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Poor appetite;;;ACTIVE;2.73;2.73 +100769-9;Unhappy even with help from my family or friends;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Unhappy even with help from my family or friends;;;ACTIVE;2.73;2.73 +100770-7;Feeling just as good as others;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling just as good as others;;;ACTIVE;2.73;2.73 +100771-5;Trouble focusing;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Trouble focusing;;;ACTIVE;2.73;2.73 +100772-3;Feeling depressed;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling depressed;;;ACTIVE;2.73;2.73 +100773-1;Feeling everything is too much of an effort;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling everything is too much of an effort;;;ACTIVE;2.73;2.73 +100774-9;Feeling hopeful about the future;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling hopeful about the future;;;ACTIVE;2.73;2.73 +100775-6;Feeling life had been a failure;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling life had been a failure;;;ACTIVE;2.73;2.73 +10077-6;S' wave duration.lead V2;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead V2;S' wave dur L-V2;;ACTIVE;1.0i;2.48 +100776-4;Feeling fearful;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling fearful;;;ACTIVE;2.73;2.73 +100777-2;Restless sleep;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Restless sleep;;;ACTIVE;2.73;2.73 +100778-0;Feeling happy;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling happy;;;ACTIVE;2.73;2.73 +100779-8;Quieter than usual;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Quieter than usual;;;ACTIVE;2.73;2.73 +100780-6;Feeling lonely;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling lonely;;;ACTIVE;2.73;2.73 +100781-4;People were unfriendly;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;People were unfriendly;;;ACTIVE;2.73;2.73 +100782-2;Enjoying life;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Enjoying life;;;ACTIVE;2.73;2.73 +100783-0;Crying spells;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Crying spells;;;ACTIVE;2.73;2.73 +10078-4;S' wave duration.lead V3;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead V3;S' wave dur L-V3;;ACTIVE;1.0i;2.48 +100784-8;Feeling sad;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling sad;;;ACTIVE;2.73;2.73 +100785-5;Feeling people dislike me;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Feeling people dislike me;;;ACTIVE;2.73;2.73 +100786-3;Lack of energy;Find;RptPeriod;^Patient;Ord;;SURVEY.MTLHLTH;4;Lack of energy;;;ACTIVE;2.73;2.73 +100787-1;Total Score;Score;RptPeriod;^Patient;Qn;CES-D;SURVEY.MTLHLTH;4;Total Score CES-D;;;ACTIVE;2.73;2.73 +100788-9;Stemphylium botryosum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Stemphylium botryosum IgG4 Ab [Mass/volume] in Serum;S botryosum IgG4-mCnc;;ACTIVE;2.73;2.73 +100789-7;Rhizopus nigricans Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rhizopus nigricans IgG4 Ab [Mass/volume] in Serum;R nigricans IgG4-mCnc;;ACTIVE;2.73;2.73 +100790-5;Lepidoglyphus destructor Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lepidoglyphus destructor IgG Ab [Mass/volume] in Serum;L destructor IgG-mCnc;;ACTIVE;2.73;2.73 +100791-3;Hamster epithelium Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hamster epithelium IgG Ab [Mass/volume] in Serum;Hmtr Epith IgG-mCnc;;ACTIVE;2.73;2.73 +10079-2;S' wave duration.lead V4;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead V4;S' wave dur L-V4;;ACTIVE;1.0i;2.48 +100792-1;Forsythia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Forsythia IgE Ab [Units/volume] in Serum;Forsythia IgE Qn;;ACTIVE;2.73;2.73 +100793-9;Testosterone;MCnc;Pt;Body fld;Qn;;CHAL;1;Testosterone [Mass/volume] in Body fluid;Testost Fld-mCnc;;ACTIVE;2.73;2.73 +100794-7;Follitropin;ACnc;Pt;Body fld;Qn;;CHEM;1;Follitropin [Units/volume] in Body fluid;FSH Fld-aCnc;;ACTIVE;2.73;2.74 +100795-4;S100 calcium binding protein B;MCnc;Pt;Body fld;Qn;;CHEM;1;S100 calcium binding protein B [Mass/volume] in Body fluid;S100 Ca binding protein B Fld-mCnc;;ACTIVE;2.73;2.73 +100796-2;Thyroglobulin;MCnc;Pt;Body fld;Qn;;SERO;1;Thyroglobulin [Mass/volume] in Body fluid;Thyroglob Fld-mCnc;;ACTIVE;2.73;2.73 +100797-0;Testosterone.free^1st specimen post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;Testosterone Free [Mass/volume] in Serum --1st specimen post XXX challenge;Testost Free sp1 p chal Ser-mCnc;;ACTIVE;2.73;2.73 +100798-8;Testosterone.free^2nd specimen post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;Testosterone Free [Mass/volume] in Serum --2nd specimen post XXX challenge;Testost Free sp2 p chal Ser-mCnc;;ACTIVE;2.73;2.73 +100799-6;21-Deoxycortisol^1st specimen post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;21-Deoxycortisol [Mass/volume] in Serum --1st specimen post XXX challenge;21DC sp1 p chal Ser-mCnc;;ACTIVE;2.73;2.73 +100-8;Cefoperazone;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC);Cefoperazone Islt MIC;;ACTIVE;1.0;2.73 +10080-0;S' wave duration.lead V5;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead V5;S' wave dur L-V5;;ACTIVE;1.0i;2.48 +100800-2;21-Deoxycortisol^2nd specimen post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;21-Deoxycortisol [Mass/volume] in Serum --2nd specimen post XXX challenge;21DC sp2 p chal Ser-mCnc;;ACTIVE;2.73;2.73 +100801-0;21-Deoxycortisol^3rd specimen post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;21-Deoxycortisol [Mass/volume] in Serum --3rd specimen post XXX challenge;21DC sp3 p chal Ser-mCnc;;ACTIVE;2.73;2.73 +100802-8;21-Deoxycortisol^4th specimen post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;21-Deoxycortisol [Mass/volume] in Serum --4th specimen post XXX challenge;21DC sp4 p chal Ser-mCnc;;ACTIVE;2.73;2.73 +100803-6;21-Deoxycortisol^5th specimen post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;21-Deoxycortisol [Mass/volume] in Serum --5th specimen post XXX challenge;21DC sp5 p chal Ser-mCnc;;ACTIVE;2.73;2.73 +100804-4;Vasopressin^1st specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --1st specimen post XXX challenge;Vasopressin sp1 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100805-1;Vasopressin^2nd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --2nd specimen post XXX challenge;Vasopressin sp2 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100806-9;Vasopressin^3rd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --3rd specimen post XXX challenge;Vasopressin sp3 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100807-7;Vasopressin^4th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --4th specimen post XXX challenge;Vasopressin sp4 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100808-5;Vasopressin^5th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --5th specimen post XXX challenge;Vasopressin sp5 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100809-3;Vasopressin^6th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --6th specimen post XXX challenge;Vasopressin sp6 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100810-1;Vasopressin^7th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --7th specimen post XXX challenge;Vasopressin sp7 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100811-9;Vasopressin^8th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --8th specimen post XXX challenge;Vasopressin sp8 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100812-7;Vasopressin^9th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --9th specimen post XXX challenge;Vasopressin sp9 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100813-5;Vasopressin^10th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --10th specimen post XXX challenge;Vasopressin sp10 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100814-3;Vasopressin^11th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --11th specimen post XXX challenge;Vasopressin sp11 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100815-0;Vasopressin^12th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --12th specimen post XXX challenge;Vasopressin sp12 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100816-8;Glucagon^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Glucagon sp6 p chal SerPl-mCnc;;ACTIVE;2.73;2.73 +100817-6;Glucagon^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Glucagon sp7 p chal SerPl-mCnc;;ACTIVE;2.73;2.73 +10081-8;S' wave duration.lead V6;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;S' wave duration in lead V6;S' wave dur L-V6;;ACTIVE;1.0i;2.48 +100818-4;Renin^1st specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --1st specimen post XXX challenge;Renin sp1 p chal Plas-mCnc;;ACTIVE;2.73;2.73 +100819-2;Renin^2nd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --2nd specimen post XXX challenge;Renin sp2 p chal Plas-mCnc;;ACTIVE;2.73;2.73 +1008-2;Indirect antiglobulin test.polyspecific reagent;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Indirect antiglobulin test.polyspecific reagent [Presence] in Serum or Plasma;IAT Poly-Sp Reag SerPl Ql;;ACTIVE;1.0;2.73 +100820-0;Renin^3rd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --3rd specimen post XXX challenge;Renin sp3 p chal Plas-mCnc;;ACTIVE;2.73;2.73 +100821-8;POLST panel;-;Pt;^Patient;-;POLST;PANEL.CLIN;2;National POLST form: portable medical order panel;POLST panel;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.74 +100822-6;Cardiopulmonary resuscitation orders;Find;Pt;^Patient;Ord;POLST;CLIN;2;Cardiopulmonary resuscitation orders;CPR orders;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.73 +100823-4;Initial portable medical treatment orders;Find;Pt;^Patient;Nom;POLST;CLIN;2;Initial portable medical treatment orders;Initial POLST orders;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.73 +100824-2;Additional portable medical orders or instructions;Find;Pt;^Patient;Nar;POLST;CLIN;2;Additional portable medical orders or instructions;Add portable medical orders instructions;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.73 +100825-9;Medically assisted nutrition orders;Find;Pt;^Patient;Nom;POLST;CLIN;2;Medically assisted nutrition orders;Med assisted nutrition orders;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.73 +10082-6;ST initial amplitude 6 ms.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead AVF;ST I-Amp 6ms L-AVF;;ACTIVE;1.0i;2.48 +100826-7;Portable medical order &or advance directive review;Find;Pt;^Patient;Nom;POLST;CLIN;2;Portable medical order AndOr advance directive review;Portable medical order&or adv dir review;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.73 +100827-5;Portable medical order discussion participants;Find;Pt;^Patient;Nom;POLST;CLIN;2;Portable medical order discussion participants;Portable med order discus participants;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.73 +100828-3;Portable medical order administrative information;Find;Pt;^Patient;Nar;POLST;CLIN;2;Portable medical order administrative information;Portable medical order admin info;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.73;2.73 +100829-1;Renin^4th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --4th specimen post XXX challenge;Renin sp4 p chal Plas-mCnc;;ACTIVE;2.73;2.73 +100830-9;Alpha subunit.free^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Alpha subunit free [Units/volume] in Serum or Plasma --1st specimen post XXX challenge;Alpha subunit free sp1 p chal SerPl-aCnc;;ACTIVE;2.73;2.73 +100831-7;Alpha subunit.free^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Alpha subunit free [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge;Alpha subunit free sp2 p chal SerPl-aCnc;;ACTIVE;2.73;2.73 +100832-5;Alpha subunit.free^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Alpha subunit free [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge;Alpha subunit free sp3 p chal SerPl-aCnc;;ACTIVE;2.73;2.73 +100833-3;Alpha subunit.free^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Alpha subunit free [Units/volume] in Serum or Plasma --4th specimen post XXX challenge;Alpha subunit free sp4 p chal SerPl-aCnc;;ACTIVE;2.73;2.73 +10083-4;ST initial amplitude 6 ms.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead AVL;ST I-Amp 6ms L-AVL;;ACTIVE;1.0i;2.48 +100834-1;Alpha subunit.free^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Alpha subunit free [Units/volume] in Serum or Plasma --5th specimen post XXX challenge;Alpha subunit free sp5 p chal SerPl-aCnc;;ACTIVE;2.73;2.73 +100835-8;Alpha subunit.free^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Alpha subunit free [Units/volume] in Serum or Plasma --6th specimen post XXX challenge;Alpha subunit free sp6 p chal SerPl-aCnc;;ACTIVE;2.73;2.73 +100836-6;Alpha subunit.free^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Alpha subunit free [Units/volume] in Serum or Plasma --7th specimen post XXX challenge;Alpha subunit free sp7 p chal SerPl-aCnc;;ACTIVE;2.73;2.73 +100837-4;Insulin-like growth factor-I^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;IGF-I sp9 p chal SerPl-mCnc;;ACTIVE;2.73;2.73 +100838-2;Testosterone^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Testost sp9 p chal SerPl-mCnc;;ACTIVE;2.73;2.73 +100839-0;Vitamin A/Retinol binding protein;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Vitamin A/Retinol binding protein [Ratio] in Serum or Plasma;Vitamin A/Retinol Bind Prot SerPl-Rto;;ACTIVE;2.73;2.73 +100840-8;IgE;ACnc;Pt;Body fld;Qn;;CHEM;1;IgE [Units/volume] in Body fluid;IgE Fld-aCnc;;ACTIVE;2.73;2.73 +100841-6;Zinc finger protein of the cerebellum 4 Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Zinc finger protein of the cerebellum 4 Ab [Presence] in Cerebral spinal fluid by Line blot;Zic4 Ab CSF Ql Line blot;;ACTIVE;2.73;2.73 +10084-2;ST initial amplitude 6 ms.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead AVR;ST I-Amp 6ms L-AVR;;ACTIVE;1.0i;2.48 +100842-4;Nonalcoholic steatohepatitis score;Score;Pt;Ser/Plas;Qn;Calculated.FAST;CHEM;1;Nonalcoholic steatohepatitis score in Serum or Plasma Calculated by FAST;NASH score SerPl Calculated.FAST;;ACTIVE;2.73;2.73 +100843-2;Liver fibrosis score;Score;Pt;Ser/Plas;Qn;Calculated.Agile3+;CHEM;1;Liver fibrosis score in Serum or Plasma by Calculated.Agile3+;Liver fibr score SerPl Agile3+;;ACTIVE;2.73;2.73 +100844-0;Liver fibrosis score;Score;Pt;Ser/Plas;Qn;Calculated.Agile4;CHEM;1;Liver fibrosis score in Serum or Plasma by Calculated.Agile4;Liver fibr score SerPl Calculated.Agile4;;ACTIVE;2.73;2.73 +100845-7;Neurofascin155 Ab.IgG4;PrThr;Pt;Ser;Ord;Flow cytometry;SERO;1;Neurofascin155 IgG4 Ab [Presence] in Serum by Flow cytometry (FC);Neurofascin155 IgG4 Ser Ql FC;;ACTIVE;2.73;2.73 +100846-5;Dengue virus 1+2+3+4 non-structural protein 1 (nsP1) Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Dengue virus 1+2+3+4 nsP1 IgG Ab [Presence] in Serum or Plasma by Immunoassay;DNV 1+2+3+4 nsP1 IgG SerPl Ql IA;;ACTIVE;2.73;2.73 +100847-3;Gas & ammonia panel;-;Pt;BldA;-;;PANEL.CHEM;1;Gas and ammonia panel - Arterial blood;BldA;;ACTIVE;2.73;2.73 +100848-1;Cell count & Differential panel;-;Pt;Amnio fld;-;Manual count;PANEL.HEM/BC;1;Cell count and Differential panel - Amniotic fluid by Manual count;Cell Cnt + Diff Pnl Amn Manual;;ACTIVE;2.73;2.73 +100849-9;Leukocytes;NCnc;Pt;Amnio fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Amniotic fluid by Manual count;WBC # Amn Manual;;ACTIVE;2.73;2.73 +100850-7;Neutrophils;NCnc;Pt;Amnio fld;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Amniotic fluid by Manual count;Neutrophils # Amn Manual;;ACTIVE;2.73;2.73 +100851-5;Other cells;NCnc;Pt;Amnio fld;Qn;Manual count;HEM/BC;1;Other cells [#/volume] in Amniotic fluid by Manual count;Other cells # Amn Manual;;ACTIVE;2.73;2.73 +100852-3;Views for metastasis^W Sr-89 IV;Find;Pt;XXX>Bones;Doc;NM;RAD;2;NM Bones Views for metastasis W Sr-89 IV;NM Bones Views for mets W Sr-89 IV;;ACTIVE;2.73;2.73 +100853-1;Pericardial effusion;Find;Pt;Pericardial space;Doc;NM;RAD;2;NM Pericardial space Pericardial effusion;NM Pericardial effusion;;ACTIVE;2.73;2.73 +100854-9;Lymphocytes/100 Cells;NFr;Pt;Bld MC;Qn;IA;MICRO;1;Lymphocytes/100 cells in Blood mononuclear cells by Immunoassay;Lymphocytes Bld MC IA-NFr;;TRIAL;2.73;2.73 +100855-6;Cells.CD3/100 cells;NFr;Pt;Bld MC;Qn;;MICRO;1;CD3 cells/100 cells in Blood mononuclear cells;CD3 Cells Bld MC-NFr;;TRIAL;2.73;2.73 +100856-4;Cells.CD3+CD4+/100 cells;NFr;Pt;Bld MC;Qn;;MICRO;1;CD3+CD4+ (T4 helper) cells/100 cells in Blood mononuclear cells;CD3+CD4+ Cells Bld MC-NFr;;TRIAL;2.73;2.73 +100857-2;Cells.CD3+CD8+/100 cells;NFr;Pt;Bld MC;Qn;;MICRO;1;CD3+CD8+ (T8 suppressor) cells/100 cells in Blood mononuclear cells;CD3+CD8+ Cells Bld MC-NFr;;TRIAL;2.73;2.73 +100858-0;Cells.CD4+CD154+/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide;NFr;Pt;Bld;Qn;;MICRO;1;Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide;CD4+154/CD4 stim COVID Spike;;TRIAL;2.73;2.73 +10085-9;ST initial amplitude 6 ms.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead I;ST I-Amp 6ms L-I;;ACTIVE;1.0i;2.48 +100859-8;Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide;NFr;Pt;Bld;Qn;;MICRO;1;Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide;CD4 IFNg/CD4 p Stim COVID Sp;;TRIAL;2.73;2.73 +100860-6;Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide;NFr;Pt;Bld;Qn;;MICRO;1;Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide;CD4 TNFa/CD4 p Stim COVID Sp;;TRIAL;2.73;2.73 +100861-4;Cells.CD4+CD154+/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide;NFr;Pt;Bld;Qn;;MICRO;1;Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide;CD4+154/CD4 p COVID NuclCap;;TRIAL;2.73;2.73 +100862-2;Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide;NFr;Pt;Bld;Qn;;MICRO;1;Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide;CD4 IFNg/CD4 p COVID NuclCap;;TRIAL;2.73;2.73 +100863-0;Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide;NFr;Pt;Bld;Qn;;MICRO;1;Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide;CD4 TNFa/CD4 p COVID NuclCap;;TRIAL;2.73;2.73 +100864-8;Giardia lamblia bg gene;Geno;Pt;XXX;Nom;Molgen;MICRO;1;Giardia lamblia bg gene [Genotype] in Specimen by Molecular genetics method;G. lamblia bg gene Spec-Geno;;ACTIVE;2.73;2.73 +100865-5;Avian schistosomes DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Avian schistosomes DNA [Presence] in Specimen by NAA with probe detection;Avian schistosomes DNA Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100866-3;Febrile antibody profile;-;Pt;Ser;-;;PANEL.MICRO;1;Febrile antibody profile in Serum;Febrile antibody profile Ser;;ACTIVE;2.73;2.73 +10086-7;ST initial amplitude 6 ms.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead II;ST I-Amp 6ms L-II;;ACTIVE;1.0i;2.48 +100867-1;Campylobacter jejuni+coli+lari+upsaliensis Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Campylobacter jejuni+coli+lari+upsaliensis Ag [Presence] in Stool by Rapid immunoassay;C jej+coli+lari+upsa Ag Stl Ql IA.rapid;;ACTIVE;2.73;2.73 +100868-9;Cryptosporidium sp 18S-LC2 rRNA;Geno;Pt;XXX;Nom;Molgen;MICRO;1;Cryptosporidium sp 18S-LC2 rRNA [Genotype] in Specimen by Molecular genetics method;Cryptosp 18S -LC2 rRNA Spec-Geno;;ACTIVE;2.73;2.73 +100869-7;Cryptosporidium gp60 gene;Type;Pt;XXX;Nom;Molgen;MICRO;1;Cryptosporidium gp60 gene [Type] in Specimen by Molecular genetics method;Crypto gp60 Spec;;ACTIVE;2.73;2.73 +100870-5;Cryptosporidium 18S rRNA;Geno;Pt;XXX;Nom;Molgen;MICRO;1;Cryptosporidium 18S rRNA [Genotype] in Specimen by Molecular genetics method;Cryptosp 18S rRNA Spec-Geno;;ACTIVE;2.73;2.73 +100871-3;Giardia lamblia gdh gene;Geno;Pt;XXX;Nom;Molgen;MICRO;1;Giardia lamblia gdh gene [Genotype] in Specimen by Molecular genetics method;G. lamblia gdh gene Spec-Geno;;ACTIVE;2.73;2.73 +100872-1;Bacteria producing polysaccharide from sucrose;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing polysaccharide from sucrose [Presence] in Isolate;Bact polysach from sucrose Islt Ql;;ACTIVE;2.73;2.73 +100873-9;Giardia lamblia tpi gene;Geno;Pt;XXX;Nom;Molgen;MICRO;1;Giardia lamblia tpi gene [Genotype] in Specimen by Molecular genetics method;G. lamblia tpi gene Spec-Geno;;ACTIVE;2.73;2.73 +100874-7;Basidiobolus sp;PrThr;Pt;XXX;Ord;;MICRO;1;Basidiobolus sp [Presence] in Specimen;Basidiobolus sp Spec Ql;;ACTIVE;2.73;2.73 +10087-5;ST initial amplitude 6 ms.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead III;ST I-Amp 6ms L-III;;ACTIVE;1.0i;2.48 +100875-4;Multisection limited;Find;Pt;Heart^Fetus;Doc;US;OB.US;2;Fetal Heart Document limited US;Fet Hrt Doc Ltd US;;ACTIVE;2.73;2.73 +100876-2;Multisection;Find;Pt;Heart^Fetus;Doc;US;OB.US;2;Fetal Heart Document US;Fet Hrt Doc US;;ACTIVE;2.73;2.73 +100877-0;Multisection transesophageal^during surgery;Find;Pt;Chest>Heart;Doc;US;CARD.US;2;US Heart Transesophageal during surgery;US Heart Transesophageal in surgery;;ACTIVE;2.73;2.73 +100878-8;Endoscopic ultrasound study;Find;Pt;Upper GI tract;Doc;US;ENDO.GI;2;Endoscopic ultrasound study Upper GI tract Document;Endo US study Upr GI Tract Doc;;ACTIVE;2.73;2.73 +100879-6;Guidance for cryoablation;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for cryoablation of Breast - right;US Guided Brst-R Cryoablation;;ACTIVE;2.73;2.73 +100880-4;Guidance for cryoablation;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for cryoablation of Breast - left;US Guided Brst-L Cryoablation;;ACTIVE;2.73;2.73 +100881-2;Guidance for cryoablation;Find;Pt;XXX>Bone;Doc;MR;RAD;2;MR Guidance for cryoablation of Bone;MR Guided Bone Cryoablation;;ACTIVE;2.73;2.73 +100882-0;Multisection^W contrast percutaneous intraperitoneal;Find;Pt;Abdomen>Peritoneum;Doc;MR;RAD;2;MR Peritoneum W contrast percutaneous intraperitoneal;MR Peritoneum W contr percu;;ACTIVE;2.73;2.73 +10088-3;ST initial amplitude 6 ms.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead V1;ST I-Amp 6ms L-V1;;ACTIVE;1.0i;2.48 +100883-8;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.left;Doc;MR;RAD;2;MR Guidance for biopsy of Kidney - left;MR Guided Kidney-L Bx;;ACTIVE;2.73;2.73 +100884-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.right;Doc;MR;RAD;2;MR Guidance for biopsy of Kidney - right;MR Guided Kidney-R Bx;;ACTIVE;2.73;2.73 +100885-3;Parapoxvirus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parapoxvirus DNA [Presence] in Specimen by NAA with probe detection;Parapoxvirus DNA Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100886-1;Orf virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Orf virus DNA [Presence] in Specimen by NAA with probe detection;Orf virus DNA Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100887-9;Pseudocowpox virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Pseudocowpox virus DNA [Presence] in Specimen by NAA with probe detection;Pseudocowpox virus DNA Spec Ql NAA+probe;;ACTIVE;2.73;2.73 +100888-7;Monkeypox virus clade II DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Monkeypox virus clade II DNA [Presence] in Specimen by NAA with probe detection;MVPX Clade II DNA;;ACTIVE;2.73;2.74 +100889-5;Monkeypox virus clade I DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Monkeypox virus clade I DNA [Presence] in Specimen by NAA with probe detection;MVPX Clade I DNA Spec Ql NAA+probe;;ACTIVE;2.73;2.74 +100890-3;Poxvirus DNA panel;-;Pt;^Patient;-;;PANEL.MICRO;1;Poxvirus DNA panel;Poxvirus DNA panel Patient;;ACTIVE;2.73;2.73 +10089-1;ST initial amplitude 6 ms.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead V2;ST I-Amp 6ms L-V2;;ACTIVE;1.0i;2.48 +100891-1;Orthopoxvirus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Orthopoxvirus IgG Ab [Presence] in Serum or Plasma by Immunoassay;Orthopoxvirus IgG SerPl Ql IA;;ACTIVE;2.73;2.73 +100892-9;Orthopoxvirus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Orthopoxvirus IgM Ab [Presence] in Serum or Plasma by Immunoassay;Orthopoxvirus IgM SerPl Ql IA;;ACTIVE;2.73;2.73 +100893-7;Orthopoxvirus IgG & IgM Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Orthopoxvirus IgG and IgM Ab panel - Serum or Plasma;Orthopoxvirus IgG + IgM Ab panel SerPl;;ACTIVE;2.73;2.73 +100894-5;Recommended screening frequency;Find;Pt;^Patient;Nar;;DOC.MISC;2;Recommended screening frequency Narrative;Recommended screen freq;;ACTIVE;2.73;2.73 +100895-2;Rickettsia conorii Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Rickettsia conorii IgG and IgM [Interpretation] in Serum;R conorii IgG+IgM Ser-Imp;;ACTIVE;2.73;2.73 +100896-0;Vasopressin^13th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Moles/volume] in Plasma --13th specimen post XXX challenge;Vasopressin sp13 p chal Plas-sCnc;;ACTIVE;2.73;2.73 +100897-8;Staphylococcus aureus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Staphylococcus aureus [Presence] in Specimen by Organism specific culture;S aureus Spec Ql Cult;;ACTIVE;2.73;2.73 +100898-6;Lipid panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Lipid panel - Serum or Plasma;Lipid panel SerPl;;ACTIVE;2.73;2.73 +100899-4;Enterobacteriaceae.extended spectrum beta lactamase resistance phenotype;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Enterobacteriaceae.extended spectrum beta lactamase resistance phenotype [Identifier] in Specimen by Organism specific culture;Enterobac.ESBL pheno Spec Cult;;ACTIVE;2.73;2.73 +1009-0;Direct antiglobulin test.poly specific reagent;ACnc;Pt;RBC;Ord;;BLDBK;1;Deprecated Direct antiglobulin test.poly specific reagent [Presence] on Red Blood Cells;Deprecated DAT Poly-Sp Reag RBC Ql;;DEPRECATED;1.0;2.73 +100900-0;Enterobacteriaceae.carbapenem resistance panel;-;Pt;Anal;-;Organism specific culture;PANEL.MICRO;1;Enterobacteriaceae.carbapenem resistance panel - Anal by Organism specific culture;Enterobac Carb Resis Pnl Anal Cult;;ACTIVE;2.73;2.73 +100901-8;Enterobacteriaceae.carbapenemase resistance phenotype;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Enterobacteriaceae.carbapenemase resistance phenotype [Identifier] in Anal by Organism specific culture;Enterobac.carb res Anal Cult;;ACTIVE;2.73;2.73 +100902-6;Enterobacteriaceae.carbapenemase resistance phenotype.OXA-48;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Enterobacteriaceae.carbapenemase resistance phenotype.OXA-48 [Identifier] in Anal by Organism specific culture;Enterobac.carb res OXA-48 Anal Cult;;ACTIVE;2.73;2.73 +100903-4;Yeast & Candida sp identification panel;-;Pt;XXX;-;Organism specific culture;PANEL.MICRO;1;Yeast and Candida sp identification panel - Specimen by Organism specific culture;Yst+Candida sp ID Pnl Spec Cult;;ACTIVE;2.73;2.73 +100904-2;Urinary tract pathogens panel;-;Pt;Urine;-;Culture;PANEL.MICRO;1;Urinary tract pathogens panel - Urine by Culture;UTI pathogens Pnl Ur Cult;;ACTIVE;2.73;2.73 +100905-9;Gram positive bacteria identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Gram positive bacteria identified in Isolate by Organism specific culture;GP bact Islt Cult;;ACTIVE;2.73;2.73 +100906-7;Bacteria;NCnc;Pt;Urine;Qn;Culture;MICRO;1;Bacteria [#/volume] in Urine by Culture;Bacteria # Ur Cult;;ACTIVE;2.73;2.73 +100907-5;Enterococcus species.vancomycin resistant;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Vancomycin resistant enterococcus [Identifier] in Specimen by Organism specific culture;VRE Spec Cult;;ACTIVE;2.73;2.73 +100908-3;Pseudomonas aeruginosa;PrThr;Pt;Respiratory.lower;Ord;Organism specific culture;MICRO;1;Pseudomonas aeruginosa [Presence] in Lower respiratory specimen by Organism specific culture;P aeruginosa Lower resp Ql Cult;;ACTIVE;2.73;2.73 +10090-9;ST initial amplitude 6 ms.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead V3;ST I-Amp 6ms L-V3;;ACTIVE;1.0i;2.48 +100909-1;Cronobacter sakazakii;PrThr;Pt;Envir;Ord;Organism specific culture;MICRO;1;Cronobacter sakazakii [Presence] by Organism specific culture;C sakazakii Ql Cult;;ACTIVE;2.73;2.73 +100910-9;Gram negative bacteria.colistin resistant identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Gram negative bacteria.colistin resistant identified in Stool by Organism specific culture;Gram neg colistin resist Stl Cult;;ACTIVE;2.73;2.73 +100911-7;Campylobacter sp;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Campylobacter sp [Presence] in Stool by Organism specific culture;Campylobacter Stl Ql Cult;;ACTIVE;2.73;2.73 +100912-5;Enterobacteriaceae.extended spectrum beta lactamase resistance phenotype & Enterococcus species.vancomycin resistant panel;-;Pt;XXX;-;Organism specific culture;PANEL.MICRO;1;Enterobacteriaceae.extended spectrum beta lactamase resistance phenotype and Enterococcus species.vancomycin resistant panel;Enterob ESBL & VRE panel;;ACTIVE;2.73;2.73 +100913-3;Staph aureus and MRSA screening panel;-;Pt;XXX;-;Organism specific culture;PANEL.MICRO;1;Staph aureus and MRSA screening panel - Specimen by Organism specific culture;S. aureus+MRSA screen Pnl Spec Cult;;ACTIVE;2.73;2.73 +100914-1;Protein.abnormal band;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.abnormal band [Mass/volume] in Serum or Plasma by Electrophoresis;Abn Prot SerPl Elph-mCnc;;ACTIVE;2.73;2.73 +100915-8;Burr cells;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Burr cells [Presence] in Body fluid by Light microscopy;Burr Cells Fld Ql Micro;;ACTIVE;2.73;2.73 +100916-6;User satisfaction score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;User satisfaction score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +10091-7;ST initial amplitude 6 ms.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead V4;ST I-Amp 6ms L-V4;;ACTIVE;1.0i;2.48 +100917-4;Product of interest effectiveness;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Product of interest effectiveness;;;ACTIVE;2.73;2.73 +100918-2;Product of interest usability;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Product of interest usability;;;ACTIVE;2.73;2.73 +100919-0;Access to help with product of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Access to help with product of interest;;;ACTIVE;2.73;2.73 +100920-8;Satisfied with product of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfied with product of interest;;;ACTIVE;2.73;2.73 +100921-6;User satisfaction panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;User satisfaction panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100922-4;Privacy panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Privacy panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100923-2;Privacy score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Privacy score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100924-0;Safe and secure healthcare data;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safe and secure healthcare data;;;ACTIVE;2.73;2.73 +10092-5;ST initial amplitude 6 ms.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead V5;ST I-Amp 6ms L-V5;;ACTIVE;1.0i;2.48 +100925-7;Healthcare data exchanged as needed;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Healthcare data exchanged as needed;;;ACTIVE;2.73;2.73 +100926-5;Access to review healthcare data;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Access to review healthcare data;;;ACTIVE;2.73;2.73 +100927-3;Satisfied with healthcare data use;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfied with healthcare data use;;;ACTIVE;2.73;2.73 +100928-1;Digital confidence panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Digital confidence panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100929-9;Digital confidence score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Digital confidence score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100930-7;Digital device use;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Digital device use;;;ACTIVE;2.73;2.73 +100931-5;Friends use digital devices;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Friends use digital devices;;;ACTIVE;2.73;2.73 +100932-3;Access to help with digital devices;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Access to help with digital devices;;;ACTIVE;2.73;2.73 +10093-3;ST initial amplitude 6 ms.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST initial amplitude 6 ms in lead V6;ST I-Amp 6ms L-V6;;ACTIVE;1.0i;2.48 +100933-1;Confident using digital devices;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Confident using digital devices;;;ACTIVE;2.73;2.73 +100934-9;Personal safety panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Personal safety panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100935-6;Personal safety score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Personal safety score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100936-4;Feel safe at home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Feel safe at home;;;ACTIVE;2.73;2.73 +100937-2;Feel respected at home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Feel respected at home;;;ACTIVE;2.73;2.73 +100938-0;Feel safe outside home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Feel safe outside home;;;ACTIVE;2.73;2.73 +100939-8;Feel respected outside home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Feel respected outside home;;;ACTIVE;2.73;2.73 +100940-6;Neighbor relationships panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Neighbor relationships panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +10094-1;ST slope.lead AVF;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead AVF;ST Slope L-AVF;;ACTIVE;1.0i;2.48 +100941-4;Neighbor relationships score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Neighbor relationships score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100942-2;Neighbors and I know each other;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Neighbors and I know each other;;;ACTIVE;2.73;2.73 +100943-0;Neighbors and I trust each other;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Neighbors and I trust each other;;;ACTIVE;2.73;2.73 +100944-8;Neighbors and I share information;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Neighbors and I share information;;;ACTIVE;2.73;2.73 +100945-5;Neighbors and I help each other;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Neighbors and I help each other;;;ACTIVE;2.73;2.73 +100946-3;Loneliness Office of National Statistics score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Loneliness (ONS) score;;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100947-1;Frequency of having no one to talk to;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Frequency of having no one to talk to;;;ACTIVE;2.73;2.73 +100948-9;Frequency of feeling left out;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Frequency of feeling left out;;;ACTIVE;2.73;2.73 +100949-7;Frequency of feeling alone;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Frequency of feeling alone;;;ACTIVE;2.73;2.73 +100950-5;Frequency of feeling lonely;Find;Pt;^Patient;Ord;;SURVEY.MTLHLTH;4;Frequency of feeling lonely;;;ACTIVE;2.73;2.73 +100951-3;Loneliness Office of National Statistics panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Loneliness Office of National Statistics panel;;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100952-1;Product confidence panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Product confidence panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100953-9;Product confidence score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Product confidence score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100954-7;Product of interest use;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Product of interest use;;;ACTIVE;2.73;2.73 +100955-4;Confident using product of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Confident using product of interest;;;ACTIVE;2.73;2.73 +100956-2;Understand potential benefits of product of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Understand potential benefits of product of interest;;;ACTIVE;2.73;2.73 +100957-0;Understand potential problems of product of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Understand potential problems of product of interest;;;ACTIVE;2.73;2.73 +10095-8;ST slope.lead AVL;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead AVL;ST Slope L-AVL;;ACTIVE;1.0i;2.48 +100958-8;Digital readiness panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Digital readiness panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100959-6;Digital readiness score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Digital readiness score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.73;2.73 +100960-4;New ideas are needed in field of work;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;New ideas are needed in field of work;;;ACTIVE;2.73;2.73 +100961-2;Follow new ideas in field of work;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Follow new ideas in field of work;;;ACTIVE;2.73;2.73 +100962-0;Dengue virus Ab.IgG Panel;-;Pt;Ser/Plas/Bld;-;;PANEL.MICRO;1;Dengue virus Ab.IgG Panel - Serum, Plasma or Blood;DENV Ab.IgG Panel SerPlBld;;ACTIVE;2.73;2.73 +100963-8;Dengue virus 1+2+3+4 non-structural protein 1 (nsP1) Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Dengue virus 1+2+3+4 nsP1 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;DNV 1+2+3+4 nsP1 IgG SerPl IA-aCnc;;ACTIVE;2.73;2.73 +100964-6;Dengue virus Ab.IgG;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Dengue virus IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;DENV IgG SerPlBld Ql IA.rapid;;ACTIVE;2.73;2.73 +100965-3;Dengue virus Ab.IgG;Imp;Pt;Ser/Plas/Bld;Nom;;MICRO;1;Dengue virus IgG Ab [Interpretation] in Serum, Plasma or Blood;DENV IgG SerPlBld-Imp;;ACTIVE;2.73;2.73 +10096-6;ST slope.lead AVR;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead AVR;ST Slope L-AVR;;ACTIVE;1.0i;2.48 +100966-1;Oncofertility consultation note;Find;Pt;^Patient;Doc;;DOC.MISC;2;Oncofertility consultation note;Oncofertility consult note;;ACTIVE;2.73;2.73 +100967-9;Fetal Heart Tracing;Find;Pt;^Fetus;Doc;;DOC.MISC;2;Fetal Document Fetal Heart Tracing;Fet Doc Fetal Heart Tracing;;ACTIVE;2.73;2.73 +100968-7;Bovine Tuberculosis Comparative Cervical Test panel;-;Pt;Skin;-;;PANEL.CHAL;1;Bovine tuberculosis comparative cervical test panel - Skin;Bovine Tub comp cervical tst panel Skin;;ACTIVE;2.73;2.73 +100969-5;Pathology report.additional specified observation;Find;Pt;Specimen;Nar;;PATH;1;Pathology report additional specified observation in Specimen Narrative;Path report.add spec obs Spec;;ACTIVE;2.74;2.74 +100970-3;Portable medical order completion information;-;-;^Patient;-;POLST;CLIN;2;Portable medical order completion information;Portable med order completion info;© 2019 National POLST. The National POLST Form may only be used for non-commercial, personal purposes. Commercial or facility use requires a license from National POLST or an authorized reseller. For use options or to discuss permissions, please visit: https://polst.org/terms/.;ACTIVE;2.74;2.74 +100971-1;Clinical record panel;-;Pt;^Patient;-;;PANEL.DOC;2;Clinical record panel;Clin rec panel;;ACTIVE;2.74;2.74 +100972-9;Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel;-;Pt;Nose;-;Non-probe.amp.tar;PANEL.MICRO;1;Influenza virus A and Influenza virus B and SARS coronavirus 2 RNA panel - Nose by NAA with non-probe detection;FLUABV+SARS-CoV2 RNA Pnl Nose NAA+nonprb;;ACTIVE;2.74;2.74 +100973-7;Influenza virus A RNA;PrThr;Pt;Nose;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Nose by NAA with non-probe detection;FLUAV RNA Nose Ql NAA+non-probe;;ACTIVE;2.74;2.74 +10097-4;ST slope.lead I;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead I;ST Slope L-I;;ACTIVE;1.0i;2.48 +100974-5;Influenza virus B RNA;PrThr;Pt;Nose;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Nose by NAA with non-probe detection;FLUBV RNA Nose Ql NAA+non-probe;;ACTIVE;2.74;2.74 +100975-2;Induced abortion method;Type;Pt;^Patient;Nom;*;H&P.HX;2;Induced abortion method;Induced abortion method;;ACTIVE;2.74;2.74 +100976-0;Eosinophil derived neurotoxin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Eosinophil derived neurotoxin [Mass/volume] in Serum or Plasma;EDN SerPl-mCnc;;ACTIVE;2.74;2.74 +100977-8;JC virus Ab Index;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;JC virus Ab Index in Serum or Plasma by Immunoassay;JC virus Ab Index SerPl IA-aCnc;;ACTIVE;2.74;2.74 +100978-6;Thyroxine.free.gestational;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroxine.free.gestational [Moles/volume] in Serum or Plasma by Immunoassay;Thyroxine.free.gestational SerPl IA-sCnc;;ACTIVE;2.74;2.74 +100979-4;Atopobium vaginae DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Atopobium vaginae DNA [Presence] in Urine by NAA with probe detection;A vaginae DNA Ur Ql NAA+probe;;ACTIVE;2.74;2.74 +100980-2;BK Virus DNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;BKV DNA CSF NAA+probe-Log#;;ACTIVE;2.74;2.74 +100981-0;Parvovirus B19 DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;B19V DNA Spec NAA+probe-Log#;;ACTIVE;2.74;2.74 +10098-2;ST slope.lead II;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead II;ST Slope L-II;;ACTIVE;1.0i;2.48 +100982-8;Varicella Zoster Virus DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;VZV DNA Spec NAA+probe-Log#;;ACTIVE;2.74;2.74 +100983-6;HIV reverse transcriptase failed codons;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;HIV reverse transcriptase failed codons [Identifier] by Genotype method;HIV RT failed codons Islt Genotyp;;ACTIVE;2.74;2.74 +100984-4;HIV 1 group M RNA genotype;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;HIV 1 group M RNA genotype [Identifier] by Genotype method;HIV 1 group M RNA Gentyp Islt Genotyp;;ACTIVE;2.74;2.74 +100985-1;HIV protease failed codons;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;HIV protease failed codons [Identifier] by Genotype method;HIV protease failed codons Islt Genotyp;;ACTIVE;2.74;2.74 +100986-9;HIV integrase failed codons;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;HIV integrase failed codons [Identifier] by Genotype method;HIV integrase failed codons Islt Genotyp;;ACTIVE;2.74;2.74 +100987-7;Lymphocyte T-cell & B-cell & Natural killer subsets panel;-;Pt;CSF;-;;PANEL.CELLMARK;1;Lymphocyte T-cell and B-cell and Natural killer subsets panel - Cerebral spinal fluid;Lymph Tcell+Bcell+NK subsets Pnl CSF;;ACTIVE;2.74;2.74 +100988-5;Phosphoglucomutase;CCnc;Pt;Fibroblasts;Qn;;CHEM;1;Phosphoglucomutase [Enzymatic activity/volume] in Fibroblast;Phosphoglucomutase Fib-cCnc;;ACTIVE;2.74;2.74 +100989-3;Phosphoglucomutase;CCnc;Pt;WBC;Qn;;CHEM;1;Phosphoglucomutase [Enzymatic activity/volume] in Leukocytes;Phosphoglucomutase WBC-cCnc;;ACTIVE;2.74;2.74 +10099-0;ST slope.lead III;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead III;ST Slope L-III;;ACTIVE;1.0i;2.48 +100990-1;Blood group antigens panel;-;Pt;RBC^Father;-;;PANEL.BLDBK;1;Fathers Blood group antigens panel;Bld Grp Ag Pnl RBC Father;;ACTIVE;2.74;2.74 +100991-9;CD52 cell expression evaluation;Find;Pt;XXX;Doc;Flow cytometry;CELLMARK;1;CD52 cell expression evaluation in Specimen Document by Flow cytometry (FC);CD52 cell express eval Spec Doc FC;;ACTIVE;2.74;2.74 +100992-7;CD20 cell expression evaluation;Find;Pt;XXX;Doc;Flow cytometry;CELLMARK;1;CD20 cell expression evaluation in Specimen Document by Flow cytometry (FC);Spec Doc FC;;ACTIVE;2.74;2.74 +100993-5;CD49d cell expression evaluation;Find;Pt;XXX;Doc;Flow cytometry;CELLMARK;1;CD49d cell expression evaluation in Specimen Document by Flow cytometry (FC);Spec Doc FC;;ACTIVE;2.74;2.74 +100994-3;B-cell CD19 & CD20 subsets panel;-;Pt;Bld;-;Flow cytometry;PANEL.CELLMARK;1;B-cell CD19 and CD20 subsets panel - Blood by Flow cytometry (FC);Bld FC;;ACTIVE;2.74;2.74 +100995-0;Laceyella sacchari Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Laceyella sacchari IgG Ab [Presence] in Serum;Laceyella sacchari IgG Ser Ql;;ACTIVE;2.74;2.74 +100996-8;Neurofilament light chain;MCnc;Pt;CSF;Qn;;CHEM;1;Neurofilament light chain [Mass/volume] in Cerebral spinal fluid;Nfl chain CSF-mCnc;;ACTIVE;2.74;2.74 +100997-6;Respiratory Allergen Panel, Area 5;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory Allergen Panel, Area 5 - Serum;Respiratory Allergen Panel, Area 5 Ser;;ACTIVE;2.74;2.74 +100998-4;Cortisol post dose insulin IV panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Cortisol post dose insulin IV panel - Serum or Plasma;Cortisol post dose insulin IV pnl SerPl;;ACTIVE;2.74;2.74 +100999-2;Somatotropin post dose insulin IV panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Somatotropin post dose insulin IV panel - Serum or Plasma;GH post dose insulin IV pnl SerPl;;ACTIVE;2.74;2.74 +101000-8;Health informatics leader and champion of semantic interoperability;Hx;Pt;^Patient;Nar;;H&P.HX;2;Health informatics leader and champion of semantic interoperability;Health Info Leader+Champion of Interop;;ACTIVE;2.74;2.74 +101001-6;Chief technical architect and steadfast leader of LOINC;Hx;Pt;^Patient;Nar;;H&P.HX;2;Chief technical architect and steadfast leader of LOINC;Chief Architect+Leader of LOINC;;ACTIVE;2.74;2.74 +101002-4;Monkeypox virus sequencing panel;-;Pt;XXX;-;Sequencing;PANEL.MICRO;1;Monkeypox virus sequencing panel - Specimen by Sequencing;MVPX sequencing panel Spec Seq;;ACTIVE;2.74;2.74 +101003-2;Monkeypox virus clade;Type;Pt;XXX;Nom;Sequencing;MICRO;1;Monkeypox virus clade [Type] in Specimen by Sequencing;MVPX clade Spec Seq;;ACTIVE;2.74;2.74 +101004-0;Monkeypox virus lineage;Type;Pt;XXX;Nom;Sequencing;MICRO;1;Monkeypox virus lineage [Type] in Specimen by Sequencing;MVPX lineage Spec Seq;;ACTIVE;2.74;2.74 +101005-7;Discharge summary note;Find;Pt;{Setting};Doc;Hospitalist;DOC.ONTOLOGY;2;Hospitalist Discharge summary;Hospitalist Discharge sum;;ACTIVE;2.74;2.74 +10100-6;ST slope.lead V1;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead V1;ST Slope L-V1;;ACTIVE;1.0i;2.48 +101006-5;Discharge summary note;Find;Pt;{Setting};Doc;Osteopathic medicine;DOC.ONTOLOGY;2;Osteopathic medicine Discharge summary;Osteopathic med D/C sum;;ACTIVE;2.74;2.74 +101007-3;Discharge summary note;Find;Pt;{Setting};Doc;Chiropody;DOC.ONTOLOGY;2;Chiropody Discharge summary;Chiropody Discharge sum;;ACTIVE;2.74;2.74 +101008-1;History and physical note;Find;Pt;{Setting};Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying History and physical note;MAiD H&P note;;ACTIVE;2.74;2.74 +101009-9;History and physical note;Find;Pt;{Setting};Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine History and physical note;Integrative medicine H&P note;;ACTIVE;2.74;2.74 +101010-7;History and physical note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery History and physical note;Bariatric surg H&P note;;ACTIVE;2.74;2.74 +101011-5;History and physical note;Find;Pt;{Setting};Doc;Chiropody;DOC.ONTOLOGY;2;Chiropody History and physical note;Chiropody H&P note;;ACTIVE;2.74;2.74 +101012-3;History and physical note;Find;Pt;{Setting};Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine History and physical note;Chiropractic med H&P note;;ACTIVE;2.74;2.74 +101013-1;History and physical note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care History and physical note;Comm hlth care H&P note;;ACTIVE;2.74;2.74 +10101-4;ST slope.lead V2;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead V2;ST Slope L-V2;;ACTIVE;1.0i;2.48 +101014-9;History and physical note;Find;Pt;{Setting};Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology History and physical note;Electrophysiology H&P note;;ACTIVE;2.74;2.74 +101015-6;History and physical note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology History and physical note;Surg Onc H&P note;;ACTIVE;2.74;2.74 +101016-4;History and physical note;Find;Pt;{Setting};Doc;Undersea and hyperbaric medicine;DOC.ONTOLOGY;2;Undersea and hyperbaric medicine History and physical note;Undersea+hyperbar H&P note;;ACTIVE;2.74;2.74 +101017-2;History and physical note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy History and physical note;Kinesiotherapy H&P note;;ACTIVE;2.74;2.74 +101018-0;History and physical note;Find;Pt;{Setting};Doc;Hospitalist;DOC.ONTOLOGY;2;Hospitalist History and physical note;Hospitalist H&P note;;ACTIVE;2.74;2.74 +101019-8;History and physical note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine History and physical note;Nuc Medicine H&P note;;ACTIVE;2.74;2.74 +101020-6;History and physical note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology History and physical note;Diabetology H&P note;;ACTIVE;2.74;2.74 +101021-4;History and physical note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry History and physical note;Optometry H&P note;;ACTIVE;2.74;2.74 +10102-2;ST slope.lead V3;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead V3;ST Slope L-V3;;ACTIVE;1.0i;2.48 +101022-2;History and physical note;Find;Pt;{Setting};Doc;Osteopathic medicine;DOC.ONTOLOGY;2;Osteopathic medicine History and physical note;Osteopathic med H&P note;;ACTIVE;2.74;2.74 +101023-0;History and physical note;Find;Pt;{Setting};Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics History and physical note;Orthotics prosthetics H&P note;;ACTIVE;2.74;2.74 +101024-8;History and physical note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility History and physical note;REI H&P note;;ACTIVE;2.74;2.74 +101025-5;History and physical note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine History and physical note;Sports medicine H&P note;;ACTIVE;2.74;2.74 +101026-3;History and physical note;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center History and physical note;Urgent care H&P note;;ACTIVE;2.74;2.74 +101027-1;History and physical note;Find;Pt;{Setting};Doc;Child and adolescent psychology;DOC.ONTOLOGY;2;Child and adolescent psychology History and physical note;Child Adolsnt Psych H&P note;;ACTIVE;2.74;2.74 +101028-9;History and physical note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery History and physical note;Cardiac surgery H&P note;;ACTIVE;2.74;2.74 +101029-7;History and physical note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology History and physical note;HemOnc H&P note;;ACTIVE;2.74;2.74 +10103-0;ST slope.lead V4;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead V4;ST Slope L-V4;;ACTIVE;1.0i;2.48 +101030-5;History and physical note;Find;Pt;{Setting};Doc;Neuropsychology;DOC.ONTOLOGY;2;Neuropsychology History and physical note;Neuropsych H&P note;;ACTIVE;2.74;2.74 +101031-3;Consultation note;Find;Pt;{Setting};Doc;Chiropody;DOC.ONTOLOGY;2;Chiropody Consult note;Chiropody Consult note;;ACTIVE;2.74;2.74 +101032-1;Consultation note;Find;Pt;{Setting};Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Consult note;PA Consult note;;ACTIVE;2.74;2.74 +101033-9;Procedure note;Find;Pt;{Setting};Doc;Chiropody;DOC.ONTOLOGY;2;Chiropody procedure note;Chiropody Procedure note;;ACTIVE;2.74;2.74 +101034-7;Procedure note;Find;Pt;{Setting};Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine procedure note;Chiropractic med Procedure note;;ACTIVE;2.74;2.74 +101035-4;Procedure note;Find;Pt;{Setting};Doc;Osteopathic medicine;DOC.ONTOLOGY;2;Osteopathic medicine Procedure note;Osteopathic med Procedure note;;ACTIVE;2.74;2.74 +101036-2;Progress note;Find;Pt;{Setting};Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine Progress note;Integrative medicine Prog note;;ACTIVE;2.74;2.74 +101037-0;Progress note;Find;Pt;{Setting};Doc;Chiropody;DOC.ONTOLOGY;2;Chiropody Progress note;Chiropody Prog note;;ACTIVE;2.74;2.74 +101038-8;Consultation note;Find;Pt;{Setting};Doc;Aerospace medicine;DOC.ONTOLOGY;2;Aerospace medicine Consult note;Aerospace med Consult note;;ACTIVE;2.74;2.74 +101039-6;Progress note;Find;Pt;{Setting};Doc;Aerospace medicine;DOC.ONTOLOGY;2;Aerospace medicine Progress note;Aerospace med Prog note;;ACTIVE;2.74;2.74 +101040-4;Procedure note;Find;Pt;{Setting};Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine procedure note;Integrative medicine Procedure note;;ACTIVE;2.74;2.74 +101041-2;Procedure note;Find;Pt;{Setting};Doc;Aerospace medicine;DOC.ONTOLOGY;2;Aerospace medicine procedure note;Aerospace med Procedure note;;ACTIVE;2.74;2.74 +101042-0;Progress note;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center Progress note;Urgent care Prog note;;ACTIVE;2.74;2.74 +101043-8;Consultation note;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center Consult note;Urgent care Consult note;;ACTIVE;2.74;2.74 +101044-6;Procedure note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery procedure note;Bariatric surg Procedure note;;ACTIVE;2.74;2.74 +101045-3;Procedure note;Find;Pt;{Setting};Doc;Hospitalist;DOC.ONTOLOGY;2;Hospitalist procedure note;Hospitalist Procedure note;;ACTIVE;2.74;2.74 +101046-1;Progress note;Find;Pt;{Setting};Doc;Hospitalist;DOC.ONTOLOGY;2;Hospitalist Progress note;Hospitalist Prog note;;ACTIVE;2.74;2.74 +101047-9;Consultation note;Find;Pt;{Setting};Doc;Undersea and hyperbaric medicine;DOC.ONTOLOGY;2;Undersea and hyperbaric medicine Consult note;Undersea+hyperbar Consult note;;ACTIVE;2.74;2.74 +10104-8;ST slope.lead V5;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead V5;ST Slope L-V5;;ACTIVE;1.0i;2.48 +101048-7;Consultation note;Find;Pt;{Setting};Doc;Hospitalist;DOC.ONTOLOGY;2;Hospitalist Consult note;Hospitalist Consult note;;ACTIVE;2.74;2.74 +101049-5;Surgical operation note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Surgical operation note;Anesthesiology Operative note;;ACTIVE;2.74;2.74 +101050-3;Surgical operation note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Surgical operation note;Bariatric surg Operative note;;ACTIVE;2.74;2.74 +101051-1;Surgical operation note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Surgical operation note;REI Operative note;;ACTIVE;2.74;2.74 +101052-9;Consultation note;Find;Pt;{Setting};Doc;Osteopathic medicine;DOC.ONTOLOGY;2;Osteopathic medicine Consult note;Osteopathic med Consult note;;ACTIVE;2.74;2.74 +101053-7;Evaluation note;Find;Pt;{Setting};Doc;Obstetrics.midwife;DOC.ONTOLOGY;2;Obstetrics Midwife Evaluation note;OB Midwife Eval note;;ACTIVE;2.74;2.74 +101054-5;Note;Find;Pt;Outpatient;Doc;Chiropody;DOC.ONTOLOGY;2;Chiropody Outpatient Note;Chiropody OP Note;;ACTIVE;2.74;2.74 +10105-5;ST slope.lead V6;ElpotRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST slope in lead V6;ST Slope L-V6;;ACTIVE;1.0i;2.48 +101055-2;Conference note;Find;Pt;{Setting};Doc;Critical care medicine.team;DOC.ONTOLOGY;2;Critical care medicine.team Conference note;Crit care med.team Conf eval note;;ACTIVE;2.74;2.74 +101056-0;Conference note;Find;Pt;{Setting};Doc;Rapid response team;DOC.ONTOLOGY;2;Rapid response team Conference note;Rapid response team Conf eval note;;ACTIVE;2.74;2.74 +101057-8;Admission evaluation note;Find;Pt;Telehealth;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Telehealth Admission evaluation note;Psychiatric Telehealth Admit eval note;;ACTIVE;2.74;2.74 +101058-6;Conference note;Find;Pt;{Setting};Doc;Geriatric medicine.team;DOC.ONTOLOGY;2;Geriatric medicine Team Conference note;Geri med Team Conf eval note;;ACTIVE;2.74;2.74 +101059-4;Letter;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Letter;Geri med Letter;;ACTIVE;2.74;2.74 +101060-2;A little n super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;An^a Ab [Presence] in Serum or Plasma;An^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101061-0;B little e super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Be^a Ab [Presence] in Serum or Plasma;Be^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101062-8;BARC Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;BARC Ab [Presence] in Serum or Plasma;BARC Ab SerPl Ql;;ACTIVE;2.74;2.74 +10106-3;ST wave displacement.end.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead AVF;ST wave ED L-AVF;;ACTIVE;1.0i;2.48 +101063-6;C little o3 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Co3 Ag Ab [Presence] in Serum or Plasma;C little o3 Ab SerPl Ql;;ACTIVE;2.74;2.74 +101064-4;C little o3 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Co3 Ag Ag [Presence] on Red Blood Cells;C little o3 Ag RBC Ql;;ACTIVE;2.74;2.74 +101065-1;C little o4 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Co4 Ab [Presence] in Serum or Plasma;Co4 Ab SerPl Ql;;ACTIVE;2.74;2.74 +101066-9;C little r super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Cr^a Ab [Presence] in Serum or Plasma;Cr^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101067-7;C little s super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Cs^ab Ab [Presence] in Serum or Plasma;Cs^ab Ab SerPl Ql;;ACTIVE;2.74;2.74 +101068-5;C little s super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Cs^ab Ag [Presence] on Red Blood Cells;Cs^ab Ag RBC Ql;;ACTIVE;2.74;2.74 +101069-3;CE Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;CE Ab [Presence] in Serum or Plasma;CE Ab SerPl Ql;;ACTIVE;2.74;2.74 +101070-1;CEAG Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;CEAG Ab [Presence] in Serum or Plasma;CEAG Ab SerPl Ql;;ACTIVE;2.74;2.74 +10107-1;ST wave displacement.end.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead AVL;ST wave ED L-AVL;;ACTIVE;1.0i;2.48 +101071-9;CELO Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;CELO Ab [Presence] in Serum or Plasma;CELO Ab SerPl Ql;;ACTIVE;2.74;2.74 +101072-7;CENR Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;CENR Ab [Presence] in Serum or Plasma;CENR Ab SerPl Ql;;ACTIVE;2.74;2.74 +101073-5;CEST Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;CEST Ab [Presence] in Serum or Plasma;CEST Ab SerPl Ql;;ACTIVE;2.74;2.74 +101074-3;CEVF Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;CEVF Ab [Presence] in Serum or Plasma;CEVF Ab SerPl Ql;;ACTIVE;2.74;2.74 +101075-0;Crawford Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Crawford Ab [Presence] in Serum or Plasma;Crawford Ab SerPl Ql;;ACTIVE;2.74;2.74 +101076-8;D little h super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Dh^a Ab [Presence] in Serum or Plasma;Dh^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101077-6;D little r super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Dr^a Ab [Presence] in Serum or Plasma;Dr^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101078-4;D little w Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Dw Ab [Presence] in Serum or Plasma;Dw Ab SerPl Ql;;ACTIVE;2.74;2.74 +101079-2;DAK Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;DAK Ab [Presence] in Serum or Plasma;DAK Ab SerPl Ql;;ACTIVE;2.74;2.74 +1010-8;E super little w Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;E sup(w) Ab [Presence] in Serum or Plasma from Blood product unit;E sup(w) Ab SerPl BPU Ql;;ACTIVE;1.0;2.63 +101080-0;E little n super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;En^a Ab [Presence] in Serum or Plasma;En^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101081-8;E little s super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Es^a Ab [Presence] in Serum or Plasma;Es^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101082-6;Evans Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Evans Ab [Presence] in Serum or Plasma;Evans Ab SerPl Ql;;ACTIVE;2.74;2.74 +101083-4;F little y5 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Fy5 Ab [Presence] in Serum or Plasma;Fy5 Ab SerPl Ql;;ACTIVE;2.74;2.74 +101084-2;FPTT Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;FPTT Ab [Presence] in Serum or Plasma;FPTT Ab SerPl Ql;;ACTIVE;2.74;2.74 +101085-9;G little e1 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ge1 Ab [Presence] in Serum or Plasma;Ge1 Ab SerPl Ql;;ACTIVE;2.74;2.74 +101086-7;G little e2 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ge2 Ab [Presence] in Serum or Plasma;Ge2 Ab SerPl Ql;;ACTIVE;2.74;2.74 +101087-5;G little e2 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Ge2 Ag [Presence] on Red Blood Cells;Ge2 Ag RBC Ql;;ACTIVE;2.74;2.74 +101088-3;G little e3 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ge3 Ab [Presence] in Serum or Plasma;Ge3 Ab SerPl Ql;;ACTIVE;2.74;2.74 +10108-9;ST wave displacement.end.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead AVR;ST wave ED L-AVR;;ACTIVE;1.0i;2.48 +101089-1;G little e3 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Ge3 Ag [Presence] on Red Blood Cells;Ge3 Ag RBC Ql;;ACTIVE;2.74;2.74 +101090-9;G little e4 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ge4 Ab [Presence] in Serum or Plasma;Ge4 Ab SerPl Ql;;ACTIVE;2.74;2.74 +101091-7;H little r super little s Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Hr^s Ab [Presence] in Serum or Plasma;Hr^s Ab SerPl Ql;;ACTIVE;2.74;2.74 +101092-5;H little r super B Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Hr^B Ab Ab [Presence] in Serum or Plasma;Hr^B Ab SerPl Ql;;ACTIVE;2.74;2.74 +101093-3;H little u little t Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Hut Ab [Presence] in Serum or Plasma;Hut Ab SerPl Ql;;ACTIVE;2.74;2.74 +101094-1;I little n super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;In^a Ab [Presence] in Serum or Plasma;In^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +101095-8;IFC Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;IFC Ab [Presence] in Serum or Plasma;IFC Ab SerPl Ql;;ACTIVE;2.74;2.74 +101096-6;J little o super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Jo sup(a) Ab [Presence] in Serum or Plasma;Jo sup(a) Ab SerPl Ql;;ACTIVE;2.74;2.74 +10109-7;ST wave displacement.end.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead I;ST wave ED L-I;;ACTIVE;1.0i;2.48 +101097-4;JAHK Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;JAHK Ab [Presence] in Serum or Plasma;JAHK Ab SerPl Ql;;ACTIVE;2.74;2.74 +101098-2;JMH Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;JMH Ag [Presence] on Red Blood Cells;JMH Ag RBC Ql;;ACTIVE;2.74;2.74 +101099-0;K little m Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Km Ab [Presence] in Serum or Plasma;Km Ab SerPl Ql;;ACTIVE;2.74;2.74 +101100-6;K little u Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Ku Ag [Presence] on Red Blood Cells;Ku Ag RBC Ql;;ACTIVE;2.74;2.74 +101101-4;K little x Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Kx Ab [Presence] in Serum or Plasma;Kx Ab SerPl Ql;;ACTIVE;2.74;2.74 +101102-2;K little x Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Kx Ag [Presence] on Red Blood Cells;Kx Ag RBC Ql;;ACTIVE;2.74;2.74 +101103-0;C super G Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;C^G Ab [Presence] in Serum or Plasma;C^G Ab SerPl Ql;;ACTIVE;2.74;2.74 +101104-8;Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.18.11;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.18.11 [CMS Assessment];;;ACTIVE;2.74;2.74 +10110-5;ST wave displacement.end.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead II;ST wave ED L-II;;ACTIVE;1.0i;2.48 +101105-5;MDS v3.0 - RAI v1.18.11 - Nursing home comprehensive (NC) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Nursing home comprehensive (NC) item set [CMS Assessment];;;ACTIVE;2.74;2.74 +10111-3;ST wave displacement.end.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead III;ST wave ED L-III;;ACTIVE;1.0i;2.48 +101114-7;National Council of State Boards of Nursing ID;ID;Pt;Provider;Nom;;ADMIN.ID;2;NCSBN ID;NCSBN ID;;ACTIVE;2.74;2.74 +101115-4;Leukotriene E4/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Leukotriene E4/Creatinine [Mass Ratio] in 24 hour Urine;LTE4/Creat 24h Ur;;ACTIVE;2.74;2.74 +101116-2;Thrombospondin type I domain-containing 7A Ag;PrThr;Pt;Tiss;Ord;IF;PATH;1;THSD7A Ag [Presence] in Tissue by Immunofluorescence;THSD7A Ag Tiss Ql IF;;ACTIVE;2.74;2.74 +101117-0;Sezary syndrome monitoring;Find;Pt;Bld;Doc;Flow cytometry;CELLMARK;1;Sezary syndrome monitoring in Blood Document by Flow cytometry (FC);Sezary syndrome monitoring Bld Doc FC;;ACTIVE;2.74;2.74 +101118-8;Sezary syndrome diagnosis;Find;Pt;Bld;Doc;Flow cytometry;CELLMARK;1;Sezary syndrome diagnosis in Blood Document by Flow cytometry (FC);Bld Doc FC;;ACTIVE;2.74;2.74 +101119-6;Leukemia and lymphoma immunophenotyping;Find;Pt;XXX;Doc;Flow cytometry;CELLMARK;1;Leukemia and lymphoma immunophenotyping in Specimen Document by Flow cytometry (FC);Leuk and lymphma immnphntypng Spec;;ACTIVE;2.74;2.74 +101120-4;Candida glabrata+krusei DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Candida glabrata+krusei DNA [Presence] in Blood by NAA with probe detection;Candida glabrata+krusei DNA Bld Ql NAA probe det;;ACTIVE;2.74;2.74 +10112-1;ST wave displacement.end.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead V1;ST wave ED L-V1;;ACTIVE;1.0i;2.48 +101121-2;Candida albicans+tropicalis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Candida albicans and tropicalis DNA [Presence] in Blood by NAA with probe detection;C albicans+tropicalis DNA Bld Ql NAA probe;;ACTIVE;2.74;2.74 +101122-0;Mephobarbital;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Mephobarbital [Mass/volume] in Blood by Confirmatory method;Mephobarbital Bld Cfm-mCnc;;ACTIVE;2.74;2.74 +101123-8;Bacterial carbapenem resistance blaIMI gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Bacterial carbapenem resistance blaIMI gene [Presence] by Molecular method;blaIMI Islt/Spm Ql;;ACTIVE;2.74;2.74 +101124-6;Bacterial carbapenem resistance blaIMI+blaNMC genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Bacterial carbapenem resistance blaIMI+blaNMC genes [Presence] by Molecular method;blaIMI+blaNMC genes Islt/Spm Ql;;ACTIVE;2.74;2.74 +101125-3;Bacterial carbapenem resistance blaOXA-235-like gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Bacterial carbapenem resistance blaOXA-235-like gene [Presence] by Molecular method;blaOXA-235-like gene Islt/Spm Ql;;ACTIVE;2.74;2.74 +101126-1;Bacterial carbapenem resistance blaOXA-24+blaOXA-40 genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Bacterial carbapenem resistance blaOXA-24+blaOXA-40 genes [Presence] by Molecular method;blaOXA-24+blaOXA-40 Islt/Spm Ql;;ACTIVE;2.74;2.74 +101127-9;Bacterial carbapenem resistance blaSIM gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Bacterial carbapenem resistance blaSIM gene [Presence] by Molecular method;blaSIM Islt/Spm Ql;;ACTIVE;2.74;2.74 +101128-7;Theoretical limit of detection;Num;Pt;XXX;Qn;Calculated;MISC;1;Theoretical limit of detection [#] in Specimen by calculation;Theoretical limit of detection Spec Calc;;ACTIVE;2.74;2.74 +101129-5;Assay Sensitivity;Num;Pt;Laboratory device;Qn;;DEVICES;2;Laboratory device Assay Sensitivity;Lab Device;;ACTIVE;2.74;2.74 +101130-3;Mast cells/100 cells;NFr;Pt;Bone mar;Qn;Flow cytometry;HEM/BC;1;Mast cells/100 cells in Bone marrow by Flow cytometry (FC);Masts NFr Mar FC;;ACTIVE;2.74;2.74 +101131-1;B-cell precursors;NFr;Pt;Bone marrow;Qn;Flow cytometry;HEM/BC;1;B-cell precursors in Bone marrow by Flow cytometry (FC);B-cell precursors NFr BM FC;;ACTIVE;2.74;2.74 +101132-9;Glucose post XXX challenge panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Glucose post XXX challenge panel - Serum or Plasma;Glucose post XXX challenge pnl SerPl;;ACTIVE;2.74;2.74 +101133-7;Organ &or tissue donation consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Organ AndOr tissue donation consent Document;Organ AndOr tissue donation consent;;TRIAL;2.74;2.74 +101134-5;Appointment reminder;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Appointment reminder;Appointment reminder;;TRIAL;2.74;2.74 +101135-2;Discharge Summary Note;Find;Pt;Ambulance;Doc;{Role};DOC.ONTOLOGY;2;Ambulance Discharge summary;Ambulance D/C sum;;TRIAL;2.74;2.74 +101136-0;End of treatment letter;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology End of treatment letter;Radiation Onc End of treatment letter;;TRIAL;2.74;2.74 +101137-8;MNS29;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;MNS29 [Presence] in Serum or Plasma;MNS29 SerPl Ql;;ACTIVE;2.74;2.74 +101138-6;ER super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;ER^a Ab [Presence] in Serum or Plasma;ER^a Ab SerPl Ql;;ACTIVE;2.74;2.74 +10113-9;ST wave displacement.end.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead V2;ST wave ED L-V2;;ACTIVE;1.0i;2.48 +101139-4;H little ro Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Hro Ab [Presence] in Serum or Plasma;Hro Ab SerPl Ql;;ACTIVE;2.74;2.74 +101140-2;Salmonella sp Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Salmonella sp Ag [Presence] in Stool by Rapid immunoassay;Salmonella Ag Stl Ql IA.rapid;;ACTIVE;2.74;2.74 +101141-0;NAT2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;NAT2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NAT2 Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101142-8;NAT2 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;NAT2 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;NAT2 gene allele Geno Bld/T;;ACTIVE;2.74;2.74 +101143-6;NAT2 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;NAT2 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;NAT2 gene prod met activ imp Bld/T-Imp;;ACTIVE;2.74;2.74 +101144-4;Ustekinumab & Ustekinumab Ab panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Ustekinumab and Ustekinumab Ab panel - Serum or Plasma;USTEK panel SerPl;;ACTIVE;2.74;2.74 +101145-1;Ustekinumab^trough;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Ustekinumab [Mass/volume] in Serum or Plasma by Immunoassay --trough;Ustekinumab Trough SerPl IA-mCnc;;ACTIVE;2.74;2.74 +101146-9;Monocyte subsets panel;-;Pt;Bld;-;Flow cytometry;PANEL.CELLMARK;1;Monocyte subsets panel - Blood by Flow cytometry (FC);Monocyte subsets panel Bld FC;;ACTIVE;2.74;2.74 +10114-7;ST wave displacement.end.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead V3;ST wave ED L-V3;;ACTIVE;1.0i;2.48 +101147-7;Monocytes/100 leukocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Monocytes/100 leukocytes in Blood by Flow cytometry (FC);Monocytes/leuk NFr Bld FC;;ACTIVE;2.74;2.74 +101148-5;Monocytes.CD14+CD16-/100 Monocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;CD14+CD16- (Classical) Monocytes/100 Monocytes in Blood;MO1/100 Mono NFr Bld;;ACTIVE;2.74;2.74 +101149-3;Borrelia burgdorferi Ab.IgM index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Borrelia burgdorferi IgM Ab index [Units/volume] in Serum and CSF;B burgdor IgM Index Ser+CSF-aCnc;;ACTIVE;2.74;2.74 +101150-1;Cardiac output;VRat;Pt;Heart.ventricle.right;Qn;Fick;HEMODYN.MOLEC;2;Right ventricular Cardiac output by Fick method;RV Output Fick;;ACTIVE;2.74;2.74 +101151-9;Cardiac output;VRat;Pt;Heart.ventricle.right;Qn;Indicator dilution;HEMODYN.MOLEC;2;Right ventricular Cardiac output by Indicator dilution;RV Output Indicator dilution;;ACTIVE;2.74;2.74 +101152-7;Mitochondria whole genome analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Mitochondria whole genome analysis in Blood or Tissue by Molecular genetics method;Mitochondria whole genome analysis Bld/T;;ACTIVE;2.74;2.74 +101153-5;Chemokine (C-C motif) ligand 14;MCnc;Pt;Urine;Qn;IA;CHEM;1;Chemokine (C-C motif) ligand 14 [Mass/volume] in Urine by Immunoassay;CCL14 Ur IA-mCnc;;ACTIVE;2.74;2.74 +10115-4;ST wave displacement.end.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead V4;ST wave ED L-V4;;ACTIVE;1.0i;2.48 +101154-3;Calprotectin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calprotectin [Mass/volume] in Serum or Plasma;Calprotectin SerPl-mCnc;;ACTIVE;2.74;2.74 +101155-0;Alpha hydroxyetizolam/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyetizolam/Creatinine [Mass Ratio] in Urine by Confirmatory method;A-OH-etizolam/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101156-8;Alpha hydroxyetizolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Alpha hydroxyetizolam [Presence] in Urine by Confirmatory method;A-OH-etizolam Ur Ql Cfm;;ACTIVE;2.74;2.74 +101157-6;Flualprazolam/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flualprazolam/Creatinine [Mass Ratio] in Urine by Confirmatory method;Flualprazolam/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101158-4;Flualprazolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Flualprazolam [Presence] in Urine by Confirmatory method;Flualprazolam Ur Ql Cfm;;ACTIVE;2.74;2.74 +101159-2;Flubromazolam/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flubromazolam/Creatinine [Mass Ratio] in Urine by Confirmatory method;Flubromazolam/Creat Ur Cfm;;ACTIVE;2.74;2.74 +1011-6;E super little w Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;E sup(w) Ab [Presence] in Serum or Plasma from Donor;E sup(w) Ab SerPl Donr Ql;;ACTIVE;1.0;2.63 +101160-0;Flubromazolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Flubromazolam [Presence] in Urine by Confirmatory method;Flubromazolam Ur Ql Cfm;;ACTIVE;2.74;2.74 +101161-8;4-Fluorofentanyl/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;p-Fluorofentanyl/Creatinine [Mass Ratio] in Urine by Confirmatory method;4-Fluorofentanyl/Creat Ur Cfm;;ACTIVE;2.74;2.74 +10116-2;ST wave displacement.end.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead V5;ST wave ED L-V5;;ACTIVE;1.0i;2.48 +101162-6;4-Fluorofentanyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;p-Fluorofentanyl [Presence] in Urine by Confirmatory method;4-Fluorofentanyl Ur Ql Cfm;;ACTIVE;2.74;2.74 +101163-4;Brorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Brorphine [Mass/volume] in Urine by Confirmatory method;Brorphine Ur Cfm-mCnc;;ACTIVE;2.74;2.74 +101164-2;Brorphine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Brorphine/Creatinine [Mass Ratio] in Urine by Confirmatory method;Brorphine/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101165-9;Brorphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Brorphine [Presence] in Urine by Confirmatory method;Brorphine Ur Ql Cfm;;ACTIVE;2.74;2.74 +101166-7;Metonitazene;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Metonitazene [Mass/volume] in Urine by Confirmatory method;Metonitazene Ur Cfm-mCnc;;ACTIVE;2.74;2.74 +101167-5;Metonitazene/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Metonitazene/Creatinine [Mass Ratio] in Urine by Confirmatory method;Metonitazene/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101168-3;Metonitazene;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Metonitazene [Presence] in Urine by Confirmatory method;Metonitazene Ur Ql Cfm;;ACTIVE;2.74;2.74 +101169-1;2-Methyl AP-237;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;2-methyl AP-237 [Mass/volume] in Urine by Confirmatory method;2-methyl AP-237 Ur Cfm-mCnc;;ACTIVE;2.74;2.74 +10117-0;ST wave displacement.end.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave end displacement in lead V6;ST wave ED L-V6;;ACTIVE;1.0i;2.48 +101170-9;Soluble urokinase plasminogen activator receptor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Soluble urokinase plasminogen activator receptor [Mass/volume] in Serum or Plasma;suPAR SerPl-mCnc;;ACTIVE;2.74;2.74 +101171-7;2-Methyl AP-237/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;2-methyl AP-237/Creatinine [Mass Ratio] in Urine by Confirmatory method;2-methyl AP-237/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101172-5;Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis rRNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis rRNA panel - Specimen by NAA with probe detection;CT + NG + TV rRNA Pnl Spec NAA+probe;;ACTIVE;2.74;2.74 +101173-3;Melatonin;SCnc;Pt;Saliva;Qn;;CHEM;1;Melatonin [Moles/volume] in Saliva (oral fluid);Melatonin Sal-sCnc;;ACTIVE;2.74;2.74 +101174-1;17-Hydroxyprogesterone;MCnc;Pt;Saliva;Qn;;CHEM;1;17-Hydroxyprogesterone [Mass/volume] in Saliva (oral fluid);17OHP Sal-mCnc;;ACTIVE;2.74;2.74 +101175-8;3-Methoxytyramine.free/Creatinine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;3-Methoxytyramine.free/Creatinine [Molar ratio] in Serum or Plasma;Free 3-MT/Creat SerPl-sRto;;ACTIVE;2.74;2.74 +101176-6;Normetanephrine.free/Creatinine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Normetanephrine Free/Creatinine [Molar ratio] in Serum or Plasma;Normetaneph Free/Creat SerPl-sRto;;ACTIVE;2.74;2.74 +101177-4;Metanephrine.free/Creatinine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Metanephrine Free/Creatinine [Molar ratio] in Serum or Plasma;Metaneph Free/Creat SerPl-sRto;;ACTIVE;2.74;2.74 +101178-2;Pneumocystis jiroveci DNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;P jiroveci DNA Ct Resp Qn NAA+probe;;ACTIVE;2.74;2.74 +101179-0;Immunoglobulin light chains.free/Protein.total;MFr;24H;Urine;Qn;;CHEM;1;Immunoglobulin light chains.free/Protein.total in 24 hour Urine;BJ Protein Free 24h MFr Ur;;ACTIVE;2.74;2.74 +101180-8;2-methyl AP-237;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;2-methyl AP-237 [Presence] in Urine by Confirmatory method;2-methyl AP-237 Ur Ql Cfm;;ACTIVE;2.74;2.74 +101181-6;MDMB-4en-PINACA;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;MDMB-4en-PINACA [Mass/volume] in Urine by Confirmatory method;MDMB-4en-PINACA Ur Cfm-mCnc;;ACTIVE;2.74;2.74 +101182-4;MDMB-4en-PINACA/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;MDMB-4en-PINACA/Creatinine [Mass Ratio] in Urine by Confirmatory method;MDMB-4en-PINACA/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101183-2;MDMB-4en-PINACA;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;MDMB-4en-PINACA [Presence] in Urine by Confirmatory method;MDMB-4en-PINACA Ur Ql Cfm;;ACTIVE;2.74;2.74 +101184-0;4F-MDMB-BINACA;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;4F-MDMB-BINACA [Mass/volume] in Urine by Confirmatory method;4F-MDMB-BINACA Ur Cfm-mCnc;;ACTIVE;2.74;2.74 +101185-7;4F-MDMB-BINACA/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;4F-MDMB-BINACA/Creatinine [Mass Ratio] in Urine by Confirmatory method;4F-MDMB-BINACA/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101186-5;4F-MDMB-BINACA;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;4F-MDMB-BINACA [Presence] in Urine by Confirmatory method;4F-MDMB-BINACA Ur Ql Cfm;;ACTIVE;2.74;2.74 +101187-3;ADB-BUTINACA;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ADB-BUTINACA [Mass/volume] in Urine by Confirmatory method;ADB-BUTINACA Ur Cfm-mCnc;;ACTIVE;2.74;2.74 +10118-8;ST wave displacement.mid.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead AVF;ST wave MD L-AVF;;ACTIVE;1.0i;2.48 +101188-1;ADB-BUTINACA/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ADB-BUTINACA/Creatinine [Mass Ratio] in Urine by Confirmatory method;ADB-BUTINACA/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101189-9;ADB-BUTINACA;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;ADB-BUTINACA [Presence] in Urine by Confirmatory method;ADB-BUTINACA Ur Ql Cfm;;ACTIVE;2.74;2.74 +101190-7;5F-MDMB-PICA;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;5F-MDMB-PICA [Mass/volume] in Urine by Confirmatory method;5F-MDMB-PICA Ur Cfm-mCnc;;ACTIVE;2.74;2.74 +101191-5;5F-MDMB-PICA/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;5F-MDMB-PICA/Creatinine [Mass Ratio] in Urine by Confirmatory method;5F-MDMB-PICA/Creat Ur Cfm;;ACTIVE;2.74;2.74 +101192-3;5F-MDMB-PICA;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;5F-MDMB-PICA [Presence] in Urine by Confirmatory method;5F-MDMB-PICA Ur Ql Cfm;;ACTIVE;2.74;2.74 +101193-1;Sphincter excision plane;Anat;Pt;Colorectal cancer specimen;Nom;;PATH;1;Sphincter excision plane [Anatomy] in Colorectal cancer specimen;Sphincter excision plane CRC spec;;ACTIVE;2.74;2.74 +101194-9;Mesocolic excision plane;Anat;Pt;Colorectal cancer specimen;Nom;;PATH;1;Mesocolic excision plane [Anatomy] in Colorectal cancer specimen;Mesocolic excision plane CRC spec;;ACTIVE;2.74;2.74 +101195-6;Depth of invasion beyond muscularis propria;Len;Pt;Colorectal cancer specimen;Qn;;PATH;1;Depth of invasion beyond muscularis propria [Length] in Colorectal cancer specimen;Dpt invasion muscularis propria CRC spec;;ACTIVE;2.74;2.74 +10119-6;ST wave displacement.mid.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead AVL;ST wave MD L-AVL;;ACTIVE;1.0i;2.48 +101196-4;Inflammatory cell infiltrate;Find;Pt;Colorectal cancer specimen;Nom;;PATH;1;Inflammatory cell infiltrate in Colorectal cancer specimen;Inflammatory cell infiltrate CRC spec;;ACTIVE;2.74;2.74 +101197-2;Lymph nodes with metastasis/Lymph nodes examined;NFr;Pt;Colorectal cancer specimen;Qn;;PATH;1;Lymph nodes with metastasis/Lymph nodes examined in Colorectal cancer specimen;LN met/LN exam NFr CRC spec;;ACTIVE;2.74;2.74 +101198-0;Albumin;MCnc;Pt;Ser/Plas;Qn;Nephelometry;CHEM;1;Albumin [Mass/volume] in Serum or Plasma by Nephelometry;Albumin SerPl Neph-mCnc;;ACTIVE;2.74;2.74 +101199-8;Protein.monoclonal band 5/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 5/Protein.total in Serum or Plasma by Electrophoresis;M Protein 5 MFr SerPl Elph;;ACTIVE;2.74;2.74 +101200-4;Protein.monoclonal band 6/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 6/Protein.total in Serum or Plasma by Electrophoresis;M Protein 6 MFr SerPl Elph;;ACTIVE;2.74;2.74 +101201-2;Measles virus Ab.IgG index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Measles virus IgG Ab index [Units/volume] in Serum and CSF;MeV IgG Index Ser+CSF-aCnc;;ACTIVE;2.74;2.74 +101202-0;Mumps virus Ab.IgG index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Mumps virus IgG Ab index [Units/volume] in Serum and CSF;MuV IgG Index Ser+CSF-aCnc;;ACTIVE;2.74;2.74 +101203-8;Herpes simplex virus 1+2 Ab.IgG index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Herpes simplex virus 1+2 IgG Ab index [Units/volume] in Serum and CSF;HSV1+2 IgG Index Ser+CSF-aCnc;;ACTIVE;2.74;2.74 +10120-4;ST wave displacement.mid.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead AVR;ST wave MD L-AVR;;ACTIVE;1.0i;2.48 +101204-6;Varicella zoster virus Ab.IgA;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Varicella zoster virus IgA Ab [Units/volume] in Serum or Plasma by Immunoassay;VZV IgA SerPl IA-aCnc;;ACTIVE;2.74;2.74 +101205-3;Plasmodium sp Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Plasmodium sp IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Plasmodium IgG SerPl IA-aCnc;;ACTIVE;2.74;2.74 +101206-1;Dengue virus NS1 Ag;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Dengue virus NS1 Ag [Units/volume] in Serum or Plasma by Immunoassay;DENV NS1 Ag SerPl IA-aCnc;;ACTIVE;2.74;2.74 +101207-9;Hepatitis E virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hepatitis E virus IgG Ab [Presence] in Serum or Plasma by Line blot;HEV IgG SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101208-7;Hepatitis E virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hepatitis E virus IgM Ab [Presence] in Serum or Plasma by Line blot;HEV IgM SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101209-5;Hantavirus Ab.IgG panel;-;Pt;Ser/Plas;-;Line blot;PANEL.MICRO;1;Hantavirus IgG panel - Serum or Plasma by Line blot;Hantavirus IgG panel SerPl Line blot;;ACTIVE;2.74;2.74 +101210-3;Hantavirus puumala Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus puumala IgG Ab [Presence] in Serum or Plasma by Line blot;PUUV IgG SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101211-1;Hantavirus sin nombre Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus sin nombre IgG Ab [Presence] in Serum or Plasma by Line blot;SNV IgG SerPl Ql Line blot;;ACTIVE;2.74;2.74 +10121-2;ST wave displacement.mid.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead I;ST wave MD L-I;;ACTIVE;1.0i;2.48 +101212-9;Hantavirus hantaan Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus hantaan IgG Ab [Presence] in Serum or Plasma by Line blot;HTNV IgG SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101213-7;Hantavirus dobrava;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus dobrava [Presence] in Serum or Plasma by Line blot;H dobrava SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101214-5;Hantavirus Ab.IgM panel;-;Pt;Ser/Plas;-;Line blot;PANEL.MICRO;1;Hantavirus IgM panel - Serum or Plasma by Line blot;Hantavirus IgM panel SerPl Line blot;;ACTIVE;2.74;2.74 +101215-2;Hantavirus puumala Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Line blot;PUUV IgM SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101216-0;Hantavirus sin nombre Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus sin nombre IgM Ab [Presence] in Serum or Plasma by Line blot;SNV IgM SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101217-8;Hantavirus hantaan Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus hantaan IgM Ab [Presence] in Serum or Plasma by Line blot;HTNV IgM SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101218-6;Hantavirus dobrava Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus dobrava IgM Ab [Presence] in Serum or Plasma by Line blot;H dobrava IgM SerPl Ql Line blot;;ACTIVE;2.74;2.74 +101219-4;Legionella sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Legionella sp DNA [Presence] in Specimen by NAA with probe detection;Legionella DNA Spec Ql NAA+probe;;ACTIVE;2.74;2.74 +10122-0;ST wave displacement.mid.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead II;ST wave MD L-II;;ACTIVE;1.0i;2.48 +101220-2;SUMO-activating enzyme subunit 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;SUMO-activating enzyme subunit 1 IgG Ab [Units/volume] in Serum by Immunoassay;SAE1 IgG Ser IA-aCnc;;ACTIVE;2.74;2.74 +101221-0;PM-SCL-100 extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;PM-SCL-100 extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA PM-SCL-100 Ab Ser IA-aCnc;;ACTIVE;2.74;2.74 +101222-8;Meropenem+Vaborbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Meropenem+Vaborbactam [Susceptibility] by Disk diffusion (KB);Mero+Vab Islt KB;;ACTIVE;2.74;2.74 +101223-6;Normorphine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Normorphine/Creatinine [Mass Ratio] in Urine;Normorphine/Creat Ur;;ACTIVE;2.74;2.74 +101224-4;PKD1 gene & PKD2 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DELDUP;1;PKD1 and PKD2 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;PKD1 + PKD2 Del+Dup Bld/T MLPA;;ACTIVE;2.74;2.74 +101225-1;Hemosiderin;PrThr;Pt;Bld/Bone mar;Ord;Prussian blue stain;HEM/BC;1;Hemosiderin [Presence] in Blood or Marrow by Prussian blue stain;Hemosiderin Bld/Mar Ql Prus Bl St;;ACTIVE;2.74;2.74 +101226-9;Recoverin Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Recoverin Ab [Presence] in Serum by Immunoblot;Recoverin Ab Ser Ql IB;;ACTIVE;2.74;2.74 +101227-7;Recoverin Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Recoverin Ab [Presence] in Cerebral spinal fluid by Immunoblot;Recoverin Ab CSF Ql IB;;ACTIVE;2.74;2.74 +101228-5;Purkinje cell cytoplasmic type Tr Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;PCA-Tr Ab [Presence] in Cerebral spinal fluid by Immunoblot;PCA-Tr Ab CSF Ql IB;;ACTIVE;2.74;2.74 +101229-3;Zinc finger protein of the cerebellum 4 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Zinc finger protein of the cerebellum 4 Ab [Presence] in Serum by Immunoblot;Zic4 Ab Ser Ql IB;;ACTIVE;2.74;2.74 +101230-1;Zinc finger protein of the cerebellum 4 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Zinc finger protein of the cerebellum 4 Ab [Presence] in Cerebral spinal fluid by Immunoblot;Zic4 Ab CSF Ql IB;;ACTIVE;2.74;2.74 +101231-9;Neuronal nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Neuronal nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Hu Ab CSF Ql IB;;ACTIVE;2.74;2.74 +101232-7;Glutamate decarboxylase 65 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Glutamate decarboxylase 65 Ab [Presence] in Cerebral spinal fluid by Immunoblot;GAD65 Ab CSF Ql IB;;ACTIVE;2.74;2.74 +101233-5;Glutamate decarboxylase 65 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Glutamate decarboxylase 65 Ab [Presence] in Serum by Immunoblot;GAD65 Ab Ser Ql IB;;ACTIVE;2.74;2.74 +101234-3;Glial nuclear type 1 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Glial nuclear type 1 Ab [Presence] in Cerebral spinal fluid by Immunoblot;Glial nuc type 1 Ab CSF Ql IB;;ACTIVE;2.74;2.74 +101235-0;Glial nuclear type 1 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Glial nuclear type 1 Ab [Presence] in Serum by Immunoblot;Glial nuc type 1 Ab Ser Ql IB;;ACTIVE;2.74;2.74 +101236-8;Titin Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Titin Ab [Presence] in Cerebral spinal fluid by Immunoblot;Titin Ab CSF Ql IB;;ACTIVE;2.74;2.74 +101237-6;Titin Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Titin Ab [Presence] in Serum by Immunoblot;Titin Ab Ser Ql IB;;ACTIVE;2.74;2.74 +10123-8;ST wave displacement.mid.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead III;ST wave MD L-III;;ACTIVE;1.0i;2.48 +101238-4;Spermatozoa.immotile/100 spermatozoa^post vasectomy;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Immotile/100 spermatozoa in Semen --post vasectomy;Sperm Immotile p vas NFr Smn;;ACTIVE;2.74;2.74 +101239-2;Mean chromosome banding resolution;Num;Pt;Bld/Tiss;Qn;Banding;MOLPATH.MISC;1;Mean chromosome banding resolution [#] in Blood or Tissue by Banding;Mean chr band resolution Bld/T Banding;;ACTIVE;2.74;2.74 +1012-4;E super little w Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;E sup(w) Ab [Presence] in Serum or Plasma;E sup(w) Ab SerPl Ql;;ACTIVE;1.0;2.63 +101240-0;Contactin-associated protein 2 Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Contactin-associated protein 2 Ab [Presence] in Serum or Plasma by Immunofluorescence;CASPR2 Ab SerPl Ql IF;;ACTIVE;2.74;2.74 +101241-8;Contactin-associated protein 2 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Contactin-associated protein 2 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;CASPR2 Ab CSF Ql IF;;ACTIVE;2.74;2.74 +101242-6;Dipeptidyl aminopeptidase-like protein 6 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Dipeptidyl aminopeptidase-like protein 6 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;DPPX Ab CSF Ql IF;;ACTIVE;2.74;2.74 +101243-4;Dipeptidyl aminopeptidase-like protein 6 Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Dipeptidyl aminopeptidase-like protein 6 Ab [Presence] in Serum or Plasma by Immunofluorescence;DPPX Ab SerPl Ql IF;;ACTIVE;2.74;2.74 +101244-2;Leucine-rich glioma-inactivated protein 1 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Leucine-rich glioma-inactivated protein 1 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;LGI1 Ab CSF Ql IF;;ACTIVE;2.74;2.74 +101245-9;Leucine-rich glioma-inactivated protein 1 Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Leucine-rich glioma-inactivated protein 1 Ab [Presence] in Serum or Plasma by Immunofluorescence;LGI1 Ab SerPl Ql IF;;ACTIVE;2.74;2.74 +10124-6;ST wave displacement.mid.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead V1;ST wave MD L-V1;;ACTIVE;1.0i;2.48 +101246-7;N-methyl-D-aspartate receptor Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;NMDAR Ab [Presence] in Serum or Plasma by Immunofluorescence;NMDAR Ab SerPl Ql IF;;ACTIVE;2.74;2.74 +101247-5;N-methyl-D-aspartate receptor Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;NMDAR Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;NMDAR Ab CSF Ql IF;;ACTIVE;2.74;2.74 +101248-3;Pathologic casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Pathologic casts [Presence] in Urine sediment by Light microscopy;Path casts UrnS Ql Micro;;ACTIVE;2.74;2.74 +101249-1;Delta-8-tetrahydrocannabinol;MCnc;Pt;Urine;Qn;LC/MS/MS;DRUG/TOX;1;Delta-8-tetrahydrocannabinol [Mass/volume] in Urine by LC/MS/MS;Delta-8-THC Ur LC/MS/MS-mCnc;;ACTIVE;2.74;2.74 +101250-9;Aspergillus fumigatus;PrThr;Pt;Isolate;Ord;;MICRO;1;Aspergillus fumigatus [Presence] in Isolate;A fumigatus Islt Ql;;ACTIVE;2.74;2.74 +101251-7;Dense fine speckled 70 protein Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Dense fine speckled 70 protein Ab [Presence] in Serum or Plasma;DFS70 Ab SerPl Ql;;ACTIVE;2.74;2.74 +101252-5;Urea;MCnc;Pt;Dial fld;Qn;;CHEM;1;Urea [Mass/volume] in Dialysis fluid;Urea Dial fld-mCnc;;ACTIVE;2.74;2.74 +10125-3;ST wave displacement.mid.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead V2;ST wave MD L-V2;;ACTIVE;1.0i;2.48 +101253-3;Thrombin generation test;Imp;Pt;PPP;Nar;;COAG;1;Thrombin generation test [Interpretation] in Platelet poor plasma Narrative;TGT PPP-Imp;;ACTIVE;2.74;2.74 +101254-1;Herpes virus 6 DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV6 DNA SerPl NAA+probe-aCnc;;ACTIVE;2.74;2.74 +101255-8;Herpes virus 6 DNA;ACnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Units/volume] (viral load) in Blood by NAA with probe detection;HHV6 DNA Bld NAA+probe-aCnc;;ACTIVE;2.74;2.74 +101256-6;Silica clotting time;RelTime;Pt;PPP;Qn;;COAG;1;Silica clotting time of Platelet poor plasma;SCT PPP;;ACTIVE;2.74;2.74 +101257-4;Silica clotting time.excess phospholipid actual/Normal;RelTime;Pt;PPP;Qn;;COAG;1;Silica clotting time W excess phospholipid actual/normal of Platelet poor plasma;Confirm SCT Act/Nor PPP;;ACTIVE;2.74;2.74 +101258-2;MDS v3.0 - RAI v1.18.11 - Identification Information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Identification Information [CMS Assessment];;;ACTIVE;2.74;2.74 +101259-0;MDS v3.0 - RAI v1.18.11 - Hearing, Speech, and Vision;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Hearing, Speech, and Vision [CMS Assessment];;;ACTIVE;2.74;2.74 +101260-8;MDS v3.0 - RAI v1.18.11 - Cognitive Patterns;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Cognitive Patterns [CMS Assessment];;;ACTIVE;2.74;2.74 +10126-1;ST wave displacement.mid.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead V3;ST wave MD L-V3;;ACTIVE;1.0i;2.48 +101261-6;MDS v3.0 - RAI v1.18.11 - Mood;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CAM;4;MDS v3.0 - RAI v1.18.11 - Mood [CMS Assessment];;;ACTIVE;2.74;2.74 +101262-4;MDS v3.0 - RAI v1.18.11 - Behavior;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Behavior [CMS Assessment];;;ACTIVE;2.74;2.74 +101263-2;MDS v3.0 - RAI v1.18.11 - Preferences for Customary Routine and Activities;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.ACT;4;MDS v3.0 - RAI v1.18.11 - Preferences for Customary Routine and Activities [CMS Assessment];;;ACTIVE;2.74;2.74 +101264-0;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals [CMS Assessment];;;ACTIVE;2.74;2.74 +101265-7;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals - Admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.ACT;4;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals - Admission [CMS Assessment];;;ACTIVE;2.74;2.74 +101266-5;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals - Discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals - Discharge [CMS Assessment];;;ACTIVE;2.74;2.74 +101267-3;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals - OBRA &or Interim;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Functional Abilities and Goals - OBRA/Interim [CMS Assessment];;;ACTIVE;2.74;2.74 +101268-1;MDS v3.0 - RAI v1.18.11 - Bladder and Bowel;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Bladder and Bowel [CMS Assessment];;;ACTIVE;2.74;2.74 +101269-9;MDS v3.0 - RAI v1.18.11 - Active Diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Active Diagnoses [CMS Assessment];;;ACTIVE;2.74;2.74 +101270-7;MDS v3.0 - RAI v1.18.11 - Health Conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Health Conditions [CMS Assessment];;;ACTIVE;2.74;2.74 +101271-5;MDS v3.0 - RAI v1.18.11 - Swallowing &or Nutritional Status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Swallowing/Nutritional Status [CMS Assessment];;;ACTIVE;2.74;2.74 +101272-3;MDS v3.0 - RAI v1.18.11 - Oral &or Dental Status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Oral/Dental Status [CMS Assessment];;;ACTIVE;2.74;2.74 +101273-1;MDS v3.0 - RAI v1.18.11 - Skin Conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.ACT;4;MDS v3.0 - RAI v1.18.11 - Skin Conditions [CMS Assessment];;;ACTIVE;2.74;2.74 +101274-9;MDS v3.0 - RAI v1.18.11 - Medications;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Medications [CMS Assessment];;;ACTIVE;2.74;2.74 +101275-6;MDS v3.0 - RAI v1.18.11 - Header - Special Treatments, Procedures, and Programs;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Header - Special Treatments, Procedures, and Programs [CMS Assessment];;;ACTIVE;2.74;2.74 +101276-4;MDS v3.0 - RAI v1.18.11 - Restraints and Alarms;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Restraints and Alarms [CMS Assessment];;;ACTIVE;2.74;2.74 +101277-2;MDS v3.0 - RAI v1.18.11 - Participation in Assessment and Goal Setting;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Header - Participation in Assessment and Goal Setting [CMS Assessment];;;ACTIVE;2.74;2.74 +101278-0;MDS v3.0 - RAI v1.18.11 - Care Area Assessment (CAA) Summary;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.ACT;4;MDS v3.0 - RAI v1.18.11 - Care Area Assessment (CAA) Summary [CMS Assessment];;;ACTIVE;2.74;2.74 +10127-9;ST wave displacement.mid.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead V4;ST wave MD L-V4;;ACTIVE;1.0i;2.48 +101279-8;MDS v3.0 - RAI v1.18.11 - Correction Request;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Correction Request [CMS Assessment];;;ACTIVE;2.74;2.74 +101280-6;MDS v3.0 - RAI v1.18.11 - Assessment Administration;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Assessment Administration [CMS Assessment];;;ACTIVE;2.74;2.74 +101281-4;Neurofilament light chain;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Neurofilament light chain [Mass/volume] in Serum or Plasma by Immunoassay;Nfl chain SerPl IA-mCnc;;ACTIVE;2.74;2.74 +101282-2;Mitragynine;PrThr;Pt;TissCo;Ord;;DRUG/TOX;1;Mitragynine [Presence] in Cord tissue;Mitragynine TissCo Ql;;ACTIVE;2.74;2.74 +101283-0;Speciociliatine;PrThr;Pt;TissCo;Ord;;DRUG/TOX;1;Speciociliatine [Presence] in Cord tissue;Speciociliatine TissCo Ql;;ACTIVE;2.74;2.74 +101284-8;Bordetella pertussis DNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Bordetella pertussis DNA [Presence] in Nasopharynx by NAA with non-probe detection;B pert DNA Nph Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101285-5;Pharyngeal pathogens DNA & RNA panel;-;Pt;Thrt;-;Non-probe.amp.tar;PANEL.MICRO;1;Pharyngeal pathogens DNA and RNA panel - Throat by NAA with non-probe detection;Pharyngeal path Pnl Non-probe;;ACTIVE;2.74;2.74 +101286-3;Adenovirus DNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Throat by NAA with non-probe detection;HAdV DNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +10128-7;ST wave displacement.mid.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead V5;ST wave MD L-V5;;ACTIVE;1.0i;2.48 +101287-1;Chlamydophila pneumoniae DNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Throat by NAA with non-probe detection;C pneum DNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101288-9;Human coronavirus 229E+HKU1+NL63+OC43 RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus 229E+HKU1+NL63+OC43 RNA [Presence] in Throat by NAA with non-probe detection;HCoV 229E+HKU1+NL63+OC43 Thrt Ql Non-pr;;ACTIVE;2.74;2.74 +101289-7;SARS coronavirus 2 RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Throat by NAA with non-probe detection;SARS-CoV-2 RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101290-5;Human metapneumovirus RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Throat by NAA with non-probe detection;hMPV RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101291-3;Rhinovirus+Enterovirus RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus RNA [Presence] in Throat by NAA with non-probe detection;RV+EV RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101292-1;Influenza virus A RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Throat by NAA with non-probe detection;FLUAV RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101293-9;Influenza virus A H1 2009 pandemic RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic RNA [Presence] in Throat by NAA with non-probe detection;FLUAV H1 2009 pand RNA Thrt Ql Non-pr;;ACTIVE;2.74;2.74 +101294-7;Influenza virus A H3 RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Throat by NAA with non-probe detection;FLUAV H3 RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +10129-5;ST wave displacement.mid.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST wave mid displacement in lead V6;ST wave MD L-V6;;ACTIVE;1.0i;2.48 +101295-4;Influenza virus B RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Throat by NAA with non-probe detection;FLUBV RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101296-2;Mycoplasma pneumoniae DNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Throat by NAA with non-probe detection;M pneumo DNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101297-0;Parainfluenza virus 1+2+3+4 RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 1+2+3+4 RNA [Presence] in Throat by NAA with non-probe detection;HPIV 1+2+3+4 RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101298-8;Respiratory syncytial virus RNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Throat by NAA with non-probe detection;RSV RNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101299-6;Streptococcus dysgalactiae subspecies equisimilis DNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus dysgalactiae subspecies equisimilis DNA [Presence] in Throat by NAA with non-probe detection;S dysgal eqsmls DNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101300-2;Streptococcus pyogenes DNA;PrThr;Pt;Thrt;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Presence] in Throat by NAA with non-probe detection;S pyo DNA Throat Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101301-0;Views 2 && Views AP + lateral;Find;Pt;Chest>Spine.thoracic && Abdomen;Doc;XR;RAD;2;XR Thoracic spine Views 2 and Abdomen AP and Lateral;XR T Spine 2V + Abd Views AP+Lat;;ACTIVE;2.74;2.74 +101302-8;Leptospira sp DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Leptospira sp DNA [Presence] in Blood by NAA with non-probe detection;Leptospira DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +10130-3;T' wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead AVF;T' wave Amp L-AVF;;ACTIVE;1.0i;2.48 +101303-6;Chikungunya virus RNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Chikungunya virus RNA [Presence] in Blood by NAA with non-probe detection;CHIKV RNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101304-4;Dengue virus 1+2+3+4 RNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 RNA [Presence] in Blood by NAA with non-probe detection;DENV1+2+3+4 RNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101305-1;Plasmodium sp DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Plasmodium sp DNA [Presence] in Blood by NAA with non-probe detection;Plasmodium DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101306-9;Plasmodium falciparum DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Plasmodium falciparum DNA [Presence] in Blood by NAA with non-probe detection;P falciparum DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101307-7;Plasmodium vivax+ovale DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Plasmodium vivax+ovale DNA [Presence] in Blood by NAA with non-probe detection;P vivax+ovale DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101308-5;Glucose post arginine stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Glucose post arginine stimulation panel - Serum or Plasma;Glucose p arginine stim panel SerPl;;ACTIVE;2.74;2.74 +101309-3;Glucose^2H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post dose arginine;Glucose 2h p Arg SerPl-mCnc;;ACTIVE;2.74;2.74 +101310-1;Somatotropin post insulin stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Somatotropin post insulin stimulation panel - Serum or Plasma;Somatotropin p insulin stim panel SerPl;;ACTIVE;2.74;2.74 +10131-1;T' wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead AVL;T' wave Amp L-AVL;;ACTIVE;1.0i;2.48 +101311-9;17-Hydroxyprogesterone^30M post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --30 minutes post dose corticotropin;17OHP 30M p ACTH SerPl-mCnc;;ACTIVE;2.74;2.74 +101312-7;17-Hydroxyprogesterone^1H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin;17OHP 1h p ACTH SerPl-mCnc;;ACTIVE;2.74;2.74 +101313-5;17-Hydroxyprogesterone post corticotropin stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;17-Hydroxyprogesterone post corticotropin stimulation panel - Serum or Plasma;17OH-Preg p corticotropin stim pnl SerPl;;ACTIVE;2.74;2.74 +101314-3;17-Hydroxypregnenolone & 17-Hydroxyprogesterone post corticotropin stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;17-Hydroxypregnenolone and 17-Hydroxyprogesterone p corticotropin stim panel - Serum or Plasma;17OH-Preg + 17OHP p corticotrop pl SerPl;;ACTIVE;2.74;2.74 +101315-0;Cortisol & Cortisone panel;-;Pt;Urine;-;;PANEL.CHEM;1;Cortisol and Cortisone panel - Urine;Cortisol + Cortisone panel Ur;;ACTIVE;2.74;2.74 +101316-8;Cortisol & 17-Hydroxyprogesterone post corticotropin stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Cortisol and 17-Hydroxyprogesterone post corticotropin stimulation panel - Serum or Plasma;F+17-OHP p corticotropin stim pl SerPl;;ACTIVE;2.74;2.74 +101317-6;17-Hydroxypregnenolone^30M post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --30 minutes post dose corticotropin;17OH-Preg 30M p ACTH SerPl-mCnc;;ACTIVE;2.74;2.74 +101318-4;17-Hydroxypregnenolone^1H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin;17OH-Preg 1h p ACTH SerPl-mCnc;;ACTIVE;2.74;2.74 +101319-2;Cortisol & Cortisone panel;-;24H;Urine;-;;PANEL.CHEM;1;Cortisol and Cortisone panel - 24 hour Urine;Cortisol + Cortisone panel 24h Ur;;ACTIVE;2.74;2.74 +1013-2;E super little w Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;E sup(w) Ag [Presence] on Red Blood Cells from Blood product unit;E sup(w) Ag RBC BPU Ql;;ACTIVE;1.0;2.63 +101321-8;MDS v3.0 - RAI v1.18.11 - Self-Care - Admission Performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Self-Care - Admission Performance;;;ACTIVE;2.74;2.74 +101322-6;MDS v3.0 - RAI v1.18.11 - Self-Care - Discharge Goal;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Self-Care - Discharge Goal;;;ACTIVE;2.74;2.74 +101323-4;MDS v3.0 - RAI v1.18.11 - Mobility - Admission Performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Mobility - Admission Performance during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +101324-2;MDS v3.0 - RAI v1.18.11 - Mobility - Discharge Goal;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Mobility - Discharge Goal during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +101325-9;Tub &or shower transfer - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Tub/shower transfer - functional goal [CMS Assessment];;;ACTIVE;2.74;2.74 +101326-7;MDS v3.0 - RAI v1.18.11 - Pain assessment interview;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Pain assessment interview during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +101327-5;Nutritional approaches - on admission;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Nutritional approaches - on admission during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +101328-3;Nutritional approaches - at discharge;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Nutritional approaches - at discharge during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +10132-9;T' wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead AVR;T' wave Amp L-AVR;;ACTIVE;1.0i;2.48 +101329-1;Participation in assessment and goal setting;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.ACT;4;MDS v3.0 - RAI v1.18.11 - Participation in assessment and goal setting [CMS Assessment];;;ACTIVE;2.74;2.74 +101330-9;Number of venous and arterial ulcers;Num;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Number of venous and arterial ulcers during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +101331-7;Ulcers, wounds and skin problems;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Ulcers, wounds and skin problems during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +101332-5;Reason referral to local contact agency not made;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.AAOS;4;MDS v3.0 - RAI v1.18.11 - Reason referral to local contact agency not made [CMS Assessment];;;ACTIVE;2.74;2.74 +101333-3;Determination of pressure injury risk;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Determination of pressure injury risk [CMS Assessment];;;ACTIVE;2.74;2.74 +101334-1;Etizolam;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Etizolam [Mass Ratio] in Urine by Confirmatory method;Etizolam Ur Cfm;;ACTIVE;2.74;2.74 +101335-8;Etizolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Etizolam [Presence] in Urine by Confirmatory method;Etizolam Ur Ql Cfm;;ACTIVE;2.74;2.74 +101336-6;W little r super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Wr sup(b) Ag [Presence] on Red Blood Cells;Wr sup(b) Ag RBC Ql;;ACTIVE;2.74;2.74 +10133-7;T' wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead I;T' wave Amp L-I;;ACTIVE;1.0i;2.48 +101337-4;Treatment preferences under certain health conditions;Find;Pt;^Patient;Nar;Reported;SURVEY.GNHLTH;4;Treatment preferences under certain health conditions [Reported];;;ACTIVE;2.74;2.74 +101338-2;Coagulation factor X inhibitor;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Chromogenic method;Fact X Inhib PPP Chro-aCnc;;ACTIVE;2.74;2.74 +101339-0;Cholesterol;PrThr;Pt;Fibroblasts;Ord;Filipin stain;PATH;1;Cholesterol [Presence] in Fibroblast by Filipin stain;Cholest Fib Ql Filipin stain;;ACTIVE;2.74;2.74 +101340-8;Aeromonas sp DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Aeromonas sp DNA [Presence] in Stool by NAA with probe detection;Aeromonas DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101341-6;BK virus DNA;ACnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Units/volume] (viral load) in Blood by NAA with probe detection;BKV DNA Bld NAA+probe-aCnc;;ACTIVE;2.74;2.74 +101342-4;JC virus DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;JCPyV DNA SerPl NAA+probe-aCnc;;ACTIVE;2.74;2.74 +101343-2;Erythrocytes.parasite sp infected/100 cells;NFr;Pt;Bld;Qn;;MICRO;1;Erythrocytes.parasite sp infected/100 cells in Blood;Parasite infected RBC Bld-NFr;;ACTIVE;2.74;2.74 +101344-0;Acute febrile illness global pathogens panel;-;Pt;Bld;-;Non-probe.amp.tar;PANEL.MICRO;1;Acute febrile illness global pathogens panel - Blood by NAA with non-probe detection;Acute feb illness glob path pnl Bld NAA+non-probe;;ACTIVE;2.74;2.74 +10134-5;T' wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead II;T' wave Amp L-II;;ACTIVE;1.0i;2.48 +101345-7;Candida krusei DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Candida krusei DNA [Presence] in Specimen by NAA with probe detection;C krusei DNA Spec Ql NAA+probe;;ACTIVE;2.74;2.74 +101346-5;MDS v3.0 - RAI v1.18.11 - Special Treatments, Procedures, and Programs;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Special Treatments, Procedures, and Programs [CMS Assessment];;;ACTIVE;2.74;2.74 +101347-3;Return to Community;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Return to community [CMS Assessment];;;ACTIVE;2.74;2.74 +101348-1;Palmitoyl protein thioesterase & Tripeptidyl peptidase I panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Palmitoyl protein thioesterase and Tripeptidyl peptidase I panel - DBS;NCLBS DBS;;ACTIVE;2.74;2.74 +101349-9;Jurisdiction where advance directive is accepted;Loc;Pt;^Patient;Nom;;HL7.CCDA;2;Jurisdiction where advance directive is accepted [Location];Jurisdiction where adv direct accepted;;ACTIVE;2.74;2.74 +101350-7;Consultation note;Find;Pt;{Setting};Doc;Orthopaedic+Trauma Surgery;DOC.ONTOLOGY;2;Orthopaedic and Trauma Surgery Consult note;Consult note;;ACTIVE;2.74;2.74 +101351-5;Has lack of transportation kept you from medical appointments, meetings, work, or from getting things needed for daily living;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Has lack of transportation kept you from medical appointments, meetings, work, or from getting things needed for daily living [CMS Assessment];;;ACTIVE;2.74;2.74 +10135-2;T' wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead III;T' wave Amp L-III;;ACTIVE;1.0i;2.48 +101352-3;Borrelia burgdorferi Ab.IgG & IgM with reflex to immunoassay panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Borrelia burgdorferi Ab.IgG and IgM with reflex to immunoassay panel - Serum or Plasma;B burgdor IgG+IgM W reflex to IA pnl SerPl;;ACTIVE;2.74;2.74 +101353-1;Borrelia burgdorferi Ab;Imp;Pt;Ser;Ord;IA.MTTT;MICRO;1;Borrelia burgdorferi Ab [Interpretation] in Serum Qualitative by IA.MTTT;B burgdor Ab Ser IA.MTTT-Imp;;ACTIVE;2.74;2.74 +101354-9;Borrelia afzelii+burgdorferi+garinii Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG+IgM Ab [Presence] in Serum by Immunoassay;B afz+burg+gari IgG+IgM Ser Ql IA;;ACTIVE;2.74;2.74 +101355-6;Borrelia afzelii+burgdorferi+garinii Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgM Ab [Presence] in Serum by Immunoassay;B afz+burg+gari IgM Ser Ql IA;;ACTIVE;2.74;2.74 +101356-4;Borrelia afzelii+burgdorferi+garinii Ab;Imp;Pt;Ser;Nom;IA.MTTT;MICRO;1;Borrelia afzelii+burgdorferi+garinii Ab [Interpretation] in Serum by IA.MTTT;B afz+burg+gari Ab Ser IA.MTTT-Imp;;ACTIVE;2.74;2.74 +101357-2;Borrelia burgdorferi.VlsE+OspC Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia burgdorferi.VlsE+OspC IgG+IgM Ab [Presence] in Serum by Immunoassay;B.burgdor.VlsE+OspC IgG+IgM Ser Ql IA;;ACTIVE;2.74;2.74 +101358-0;Borrelia burgdorferi Ab;Imp;Pt;Ser;Nom;IA.MTTT;MICRO;1;Borrelia burgdorferi Ab [Interpretation] in Serum by IA.MTTT;B burgdor Ab Ser IA.MTTT-Imp;;ACTIVE;2.74;2.74 +101359-8;Bioterrorism agent panel;-;Pt;XXX;-;Non-probe.amp.tar;PANEL.MICRO;1;Bioterrorism agent panel - Specimen by NAA with non-probe detection;Bioterrorism agnt pnl Spec NAA+non-probe;;ACTIVE;2.74;2.74 +10136-0;T' wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead V1;T' wave Amp L-V1;;ACTIVE;1.0i;2.48 +101360-6;Bacillus anthracis plasmid pXO1 DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Bacillus anthracis plasmid pXO1 DNA [Presence] in Blood by NAA with non-probe detection;B anthracis plsmd pXO1 DNA Bld Ql NAA+;;ACTIVE;2.74;2.74 +101361-4;Bacillus anthracis plasmid pXO2 DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Bacillus anthracis plasmid pXO2 DNA [Presence] in Blood by NAA with non-probe detection;B anthracis plsmd pXO2 DNA Bld Ql NAA+;;ACTIVE;2.74;2.74 +101362-2;Bacillus anthracis DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Bacillus anthracis DNA [Presence] in Blood by NAA with non-probe detection;B anthracis DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101363-0;Yersinia pestis DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Yersinia pestis DNA [Presence] in Blood by NAA with non-probe detection;Y pestis DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101364-8;Francisella tularensis DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Francisella tularensis DNA [Presence] in Blood by NAA with non-probe detection;F tular DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101365-5;Coxiella burnetii DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Coxiella burnetii DNA [Presence] in Blood by NAA with non-probe detection;C burnet DNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101366-3;Ebola virus RNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Ebola virus RNA [Presence] in Blood by NAA with non-probe detection;EBOV RNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101367-1;Marburg virus RNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Marburg virus RNA [Presence] in Blood by NAA with non-probe detection;MARV RNA Bld Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101368-9;Bacillus anthracis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Bacillus anthracis DNA [Presence] by NAA with non-probe detection in Positive blood culture;B anthracis DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101369-7;Bacillus anthracis plasmid pXO1 DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Bacillus anthracis plasmid pXO1 DNA [Presence] by NAA with non-probe detection in Positive blood culture;B anthracis plsmd pXO1 DNA Bld Pos Ql;;ACTIVE;2.74;2.74 +101370-5;Bacillus anthracis plasmid pXO2 DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Bacillus anthracis plasmid pXO2 DNA [Presence] by NAA with non-probe detection in Positive blood culture;B anthracis plsmd pXO2 DNA Bld Pos Ql;;ACTIVE;2.74;2.74 +101371-3;Yersinia pestis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Yersinia pestis DNA [Presence] by NAA with non-probe detection in Positive blood culture;Y pestis DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101372-1;Yersinia pestis DNA;PrThr;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Yersinia pestis DNA [Presence] in Sputum by NAA with non-probe detection;Y pestis DNA Spt Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101373-9;Francisella tularensis DNA;PrThr;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Francisella tularensis DNA [Presence] in Sputum by NAA with non-probe detection;F tular DNA Spt Ql NAA+non-probe;;ACTIVE;2.74;2.74 +101374-7;Referral has been made to the local contact agency;Find;-;Patient education material;Ord;CMS Assessment;SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Referral has been made to the local contact agency Patient education material [CMS Assessment];;;ACTIVE;2.74;2.74 +101375-4;Troponin I.cardiac^2H post baseline measurement;MCncDiff;Pt;Ser/Plas;Qn;Calculation;CHEM;1;Troponin I.cardiac [Mass concentration difference] in Serum or Plasma by Calculation --2H post baseline measurement;Troponin I 2H bs meas SerPl Calcn-MCDiff;;ACTIVE;2.74;2.74 +101376-2;Megakaryocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Megakaryocytes [Presence] in Blood by Light microscopy;Megakaryocytes Bld Ql Smear;;ACTIVE;2.74;2.74 +101377-0;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript";Find;Pt;Bld/Bone mar;Doc;Molgen;MOLPATH;1;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript in Blood or Marrow by Molecular genetics method";"inv(16)(p13;q22) Bld/Mar";;ACTIVE;2.74;2.74 +10137-8;T' wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead V2;T' wave Amp L-V2;;ACTIVE;1.0i;2.48 +101378-8;Lung cancer targeted gene fusion transcript analysis;Find;Pt;Tiss;Doc;Sequencing;MOLPATH;1;Lung cancer targeted gene fusion transcript analysis in Tissue by Sequencing;Lung Ca gene fusion analysis Tiss Seq;;ACTIVE;2.74;2.74 +101379-6;DDIT3 gene rearrangement;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.REARRANGE;1;DDIT3 gene rearrangement in Blood or Tissue by FISH;DDIT3 gene rearrangement Bld/T FISH;;ACTIVE;2.74;2.74 +101380-4;ETV6 gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH.REARRANGE;1;ETV6 gene rearrangements in Tissue by FISH;ETV6 rearrange Tiss FISH;;ACTIVE;2.74;2.74 +101381-2;BAP1 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;BAP1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;BAP1 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101382-0;FH gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;FH gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;FH gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101383-8;FUS gene rearrangements;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.REARRANGE;1;FUS gene rearrangements in Blood or Tissue by FISH;FUS gene rearrangements Bld/T FISH;;ACTIVE;2.74;2.74 +101384-6;MYC gene amplification;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;MYC gene amplification in Tissue by FISH;MYC amplification Tiss FISH;;ACTIVE;2.74;2.74 +101385-3;NF1 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;NF1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;NF1 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +10138-6;T' wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead V3;T' wave Amp L-V3;;ACTIVE;1.0i;2.48 +101386-1;RET gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;RET gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;RET gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101387-9;HBA1 & HBA2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;HBA1 and HBA2 gene full mutation analysis in Blood or Tissue by Molecular genetics method;HBA1 + HBA2 Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101388-7;GP1BB gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;GP1BB full mutation analysis in Blood or Tissue by Molecular genetics method;GP1BB Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101389-5;GP1BA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;GP1BA gene full mutation analysis in Blood or Tissue by Molecular genetics method;GP1BA gene Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101390-3;GP9 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;GP9 gene full mutation analysis in Blood or Tissue by Molecular genetics method;GP9 gene Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101391-1;PAH gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;PAH gene full mutation analysis in Blood or Tissue by Molecular genetics method;PAH gene Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101392-9;ADA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;ADA gene full mutation analysis in Blood or Tissue by Molecular genetics method;ADA gene Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +101393-7;CLCN7 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;CLCN7 gene full mutation analysis in Blood or Tissue by Molecular genetics method;CLCN7 gene Full Mut Anl Bld/T;;ACTIVE;2.74;2.74 +10139-4;T' wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead V4;T' wave Amp L-V4;;ACTIVE;1.0i;2.27 +101394-5;Sex;Type;Pt;^Embryo;Nom;Molgen;MOLPATH;1;Sex [Type] in Embryo by Molecular genetics method;Sex Embryo;;ACTIVE;2.74;2.74 +101395-2;Translocation analysis;Find;Pt;^Embryo;Doc;Molgen;MOLPATH.TRNLOC;1;Translocation analysis in Embryo by Molecular genetics method;Translocation analysis Embryo;;ACTIVE;2.74;2.74 +101396-0;Preimplantation multigene analysis;Find;Pt;^Embryo;Doc;Molgen;MOLPATH;1;Preimplantation multigene analysis in Embryo by Molecular genetics method;Preimplant multigene analysis Embryo;;ACTIVE;2.74;2.74 +101397-8;Copy number variation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;Copy number variation analysis in Blood or Tissue by Sequencing;CNV analysis Bld/T Seq;;ACTIVE;2.74;2.74 +101398-6;Monkeypox virus & Orthopoxvirus.non-variola DNA panel;-;Pt;XXX;-;;PANEL.MICRO;1;Monkeypox virus and Orthopoxvirus.non-variola DNA panel - Specimen;MVPX & Nonvar Orthpx DNA panel Spec;;ACTIVE;2.74;2.74 +101399-4;Monkeypox virus & Orthopoxvirus.non-variola DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Monkeypox virus and Orthopoxvirus.non-variola DNA [Identifier] in Specimen by NAA with probe detection;MVPX & Nonvar Orthpx DNA Spec NAA+probe;;ACTIVE;2.74;2.74 +1014-0;E super little w Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;E sup(w) Ag [Presence] on Red Blood Cells from Donor;E sup(w) Ag RBC Donr Ql;;ACTIVE;1.0;2.63 +101400-0;Metanephrine, Normetanephrine, 3-Methoxytyramine panel;-;24H;Urine;-;;PANEL.DRUG/TOX;1;Metanephrine, Normetanephrine, 3-Methoxytyramine panel - 24 hour Urine;Mtnphs+3MT pnl 24h Ur;;ACTIVE;2.74;2.74 +101401-8;Tapentadol & Nortapentadol panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Tapentadol and Nortapentadol panel - Urine;Tapentadol & Nortapentadol pl Ur;;ACTIVE;2.74;2.74 +10140-2;T' wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead V5;T' wave Amp L-V5;;ACTIVE;1.0i;2.27 +101402-6;Phenylalanine & Tyrosine panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Phenylalanine and Tyrosine panel - Serum or Plasma;Phe + Tyr Pnl SerPl;;ACTIVE;2.74;2.74 +101403-4;Borrelia burgdorferi.VlsE1+pepC10 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia burgdorferi.VlsE1+pepC10 IgG+IgM Ab [Presence] in Serum by Immunoassay;B burgdor.VlsE1+pepC10 IgG+IgM Ser Ql IA;;ACTIVE;2.74;2.74 +101404-2;Borrelia afzelii+burgdorferi+garinii Ab.IgG & IgM panel;-;Pt;Ser/Plas;-;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii Ab.IgG and IgM panel - Serum or Plasma by Immunoassay;B afz+burg+gari Ab.IgG & IgM panel SerPl IA;;ACTIVE;2.74;2.74 +101405-9;Amyloid protein;Find;Pt;Tiss;Doc;Congo red stain+LC/MS/MS;CHEM;1;Amyloid protein in Tissue Document;AMPIP/AMPIF Tiss Doc;;ACTIVE;2.74;2.74 +101406-7;Sudan virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Sudan virus RNA [Presence] in Blood by NAA with probe detection;Sudan virus RNA Bld Ql NAA+probe;;ACTIVE;2.74;2.74 +101407-5;Laceyella sacchari Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Laceyella sacchari IgG Ab [Units/volume] in Serum;Laceyella sacchari IgG Ser-aCnc;;ACTIVE;2.74;2.74 +101408-3;Sesamum indicum 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sesamum indicum 1 IgE Ab RAST class [Presence] in Serum;Ses i 1 IgE RAST Ql;;ACTIVE;2.74;2.74 +101409-1;Anaplasma phagocytophilum & Babesia microti & Ehrlichia chaffeensis Ab.IgG panel;-;Pt;Ser;-;;PANEL.MICRO;1;Anaplasma phagocytophilum, Babesia microti and Ehrlichia chaffeensis IgG panel - Serum;Tick IgG Ab Pnl Ser;;ACTIVE;2.74;2.74 +10141-0;T' wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T' wave amplitude in lead V6;T' wave Amp L-V6;;ACTIVE;1.0i;2.48 +101410-9;C peptide post XXX challenge panel;-;Pt;Ser;-;;PANEL.CHAL;1;C peptide post XXX challenge panel - Serum;C peptide p challenge panel Ser;;ACTIVE;2.74;2.74 +101411-7;Dupilumab^trough;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Dupilumab [Mass/volume] in Serum or Plasma by LC/MS/MS --trough;Dupilumab Trough SerPl LC/MS/MS-mCnc;;ACTIVE;2.74;2.74 +101412-5;Dolutegravir^trough;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Dolutegravir [Mass/volume] in Serum or Plasma by LC/MS/MS --trough;Dolutegravir Trough SerPl LC/MS/MS-mCnc;;ACTIVE;2.74;2.74 +101413-3;Bictegravir^trough;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Bictegravir [Mass/volume] in Serum or Plasma by LC/MS/MS --trough;Bictegravir Trough SerPl LC/MS/MS-mCnc;;ACTIVE;2.74;2.74 +101414-1;Lymphocyte TCR alpha beta double negative subsets panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;Lymphocyte TCR alpha beta double negative subsets panel - Blood;Lymphocyte TCR A B dbl neg sub pnl Bld;;ACTIVE;2.74;2.74 +101415-8;Blastomyces sp & Blastomyces dermatitidis Ag panel;-;Pt;Urine;-;;PANEL.MICRO;1;Blastomyces sp and Blastomyces dermatitidis Ag panel;Blastomyces sp + dermatitidis pnl Ur;;ACTIVE;2.74;2.74 +101416-6;Pediatric autoimmune central nervous system disorders evaluation panel;-;Pt;CSF;-;;PANEL.CHEM;1;Pediatric autoimmune central nervous system disorders evaluation panel - Cerebral spinal fluid;Peds autoimmn CNS disordrs eval pnl CSF;;ACTIVE;2.74;2.74 +101417-4;Pediatric autoimmune central nervous system disorders evaluation panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Pediatric autoimmune central nervous system disorders evaluation panel - Serum or Plasma;Peds autoimm CNS disordrs eval pnl SerP;;ACTIVE;2.74;2.74 +101418-2;Microorganism level of similarity to reference sample;Score;Pt;Isolate/Specimen;Qn;MS.MALDI-TOF;MICRO;1;Microorganism level similarity to reference sample [Score] in Isolate or Specimen by MS.MALDI-TOF;Microorg lvl sim ref smpl Islt/Spm M;;ACTIVE;2.74;2.74 +101419-0;Human coronavirus 229E RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Respiratory specimen by NAA with probe detection;HCoV 229E RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101420-8;Human coronavirus HKU1 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Respiratory specimen by NAA with probe detection;HCoV HKU1 RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101421-6;Human coronavirus NL63 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Respiratory specimen by NAA with probe detection;HCoV NL63 RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101422-4;Human coronavirus OC43 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Respiratory specimen by NAA with probe detection;HCoV OC43 RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101423-2;Influenza virus A H1 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Presence] in Respiratory specimen by NAA with probe detection;FLUAV H1 RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101424-0;Influenza virus A H3 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Respiratory specimen by NAA with probe detection;FLUAV H3 RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101425-7;Respiratory syncytial virus A RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus A RNA [Presence] in Respiratory specimen by NAA with probe detection;RSV A RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101426-5;Respiratory syncytial virus B RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus B RNA [Presence] in Respiratory specimen by NAA with probe detection;RSV B RNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101427-3;Shigella sp DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Shigella sp DNA [Presence] in Stool by NAA with probe detection;Shigella DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +10142-8;T wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead AVF;T wave Amp L-AVF;;ACTIVE;1.0i;2.48 +101428-1;Varicella zoster virus DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Respiratory specimen by NAA with probe detection;VZV DNA Resp Ql NAA+probe;;ACTIVE;2.74;2.74 +101429-9;Self-Care - Discharge Performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Self-care - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.74;2.74 +101430-7;Self-Care - OBRA/Interim Performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Self-Care - OBRA/Interim Performance;;;ACTIVE;2.74;2.74 +101431-5;Mobility - Discharge Performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Mobility - discharge performance [CMS Assessment];;;ACTIVE;2.74;2.74 +101432-3;Mobility - OBRA/Interim Performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Mobility - OBRA/Interim Performance;;;ACTIVE;2.74;2.74 +101433-1;Bacterial vaginosis score;Score;Pt;Vag;Ord;Nugent;MICRO;1;Bacterial vaginosis score in Vaginal fluid Qualitative by Nugent;BV score Vag Ql Nugent;;ACTIVE;2.74;2.74 +101434-9;2-Ketobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Ketobutyrate [Moles/volume] in Serum or Plasma;2-Ketobutyrate SerPl-sCnc;;ACTIVE;2.74;2.74 +101435-6;Referral;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Referral [CMS Assessment];;;ACTIVE;2.74;2.74 +10143-6;T wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead AVL;T wave Amp L-AVL;;ACTIVE;1.0i;2.48 +101436-4;Discharge Plan;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.18.11 - Discharge plan [CMS Assessment];;;ACTIVE;2.74;2.74 +101437-2;Intentional animal genomic alteration label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Intentional animal genomic alteration label;FDA label Int animal genomic alter label;;ACTIVE;2.74;2.74 +101438-0;CHAMPS pediatric fall risk assessment;-;Pt;^Patient;-;CHAMPS;PANEL.CLIN.RISK;2;CHAMPS pediatric fall risk assessment;CHAMPS ped fall risk;Copyright © 2006 Razmus & Wilson. Used with permission.;ACTIVE;2.74;2.74 +101439-8;Change in mental status;Find;Pt;^Patient;Ord;;CLIN.RISK;2;Change in mental status;Change in mental status;;ACTIVE;2.74;2.74 +101440-6;Falls;Hx;Pt;^Patient;Ord;;CLIN.RISK;2;History of Falls;Hx of Falls;;ACTIVE;2.74;2.74 +101441-4;CHAMPS pediatric fall risk assessment;Imp;Pt;^Patient;Ord;CHAMPS;CLIN.RISK;2;CHAMPS pediatric fall risk assessment [Interpretation];CHAMPS ped fall risk Imp;Copyright © 2006 Razmus & Wilson. Used with permission.;ACTIVE;2.74;2.74 +101442-2;Total Score;Score;Pt;^Patient;Qn;CHAMPS;CLIN.RISK;2;Total score CHAMPS pediatric fall risk assessment;Total Score CHAMPS;Copyright © 2006 Razmus & Wilson. Used with permission.;ACTIVE;2.74;2.74 +101443-0;Soluble urokinase plasminogen activator receptor;MCnc;Pt;Plas;Qn;;CHEM;1;Soluble urokinase plasminogen activator receptor [Mass/volume] in Plasma;suPAR Plas-mCnc;;ACTIVE;2.74;2.74 +10144-4;T wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead AVR;T wave Amp L-AVR;;ACTIVE;1.0i;2.48 +101444-8;Solitary lung nodule risk of malignancy;Scale;Pt;^Patient;Ord;Calculated.Nodify XL2;SERO;1;Solitary lung nod malignancy risk [Scale] Qualitative by Calculated.Nodify XL2;LC nod risk Patient Ql Calc Nodify XL2;;ACTIVE;2.74;2.74 +101445-5;Solitary lung nodule risk of malignancy;Scale;Pt;^Patient;Ord;Calculated.Nodify CDT;SERO;1;Solitary lung nod malignancy risk [Scale] Qualitative by Calculated.Nodify CDT;LC nod risk Patient Ql Calc Nodify CDT;;ACTIVE;2.74;2.74 +101446-3;Creatine Kinase.MB;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Creatine kinase.MB [Moles/volume] in Serum or Plasma by Immunoassay;CK MB SerPl IA-sCnc;;ACTIVE;2.74;2.74 +101447-1;Contactin-associated protein 1 Ab.IgG & Neurofascin155 Ab.IgG4 panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Contactin-associated protein 1 Ab.IgG and Neurofascin155 Ab.IgG4 panel - Serum or Plasma;CASPR1 IgG + NF155 IgG4 pnl SerPl;;ACTIVE;2.74;2.74 +101448-9;Contactin-associated protein 1 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;CBA IFA;SERO;1;Contactin-associated protein 1 IgG Ab [Presence] in Serum or Plasma by Cell binding immunofluorescent assay;CASPR1 IgG SerPl Ql CBA IFA;;ACTIVE;2.74;2.74 +101449-7;Neurochondrin Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Neurochondrin Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;Neurochondrin Ab CSF Ql CBA IFA;;ACTIVE;2.74;2.74 +101450-5;Neurochondrin Ab;PrThr;Pt;Ser/Plas;Ord;CBA IFA;SERO;1;Neurochondrin Ab [Presence] in Serum or Plasma by Cell binding immunofluorescent assay;Neurochondrin Ab SerPl Ql CBA IFA;;ACTIVE;2.74;2.74 +10145-1;T wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead I;T wave Amp L-I;;ACTIVE;1.0i;2.48 +101451-3;Neurochondrin Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Neurochondrin Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Neurochondrin Ab CSF Ql IF;;ACTIVE;2.74;2.74 +101452-1;Neurochondrin Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Neurochondrin Ab [Presence] in Serum or Plasma by Immunofluorescence;Neurochondrin Ab SerPl Ql IF;;ACTIVE;2.74;2.74 +101453-9;Neurochondrin Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Neurochondrin Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Neurochondrin Ab Titr CSF IF;;ACTIVE;2.74;2.74 +101454-7;Neurochondrin Ab;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Neurochondrin Ab [Titer] in Serum or Plasma by Immunofluorescence;Neurochondrin Ab Titr SerPl IF;;ACTIVE;2.74;2.74 +101455-4;Mitochondrial metabolites panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Mitochondrial metabolites panel - Serum or Plasma;Mitochondrial metabolites panel SerPl;;ACTIVE;2.74;2.74 +101456-2;Septin-7 Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Septin-7 IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;Septin-7 IgG Titr SerPl IF;;ACTIVE;2.74;2.74 +101457-0;Septin-7 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Septin-7 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Septin-7 IgG Titr CSF IF;;ACTIVE;2.74;2.74 +101458-8;Septin-5 Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Septin-5 IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;Septin-5 IgG Titr SerPl IF;;ACTIVE;2.74;2.74 +101459-6;Septin-5 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Septin-5 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Septin-5 IgG Titr CSF IF;;ACTIVE;2.74;2.74 +101460-4;Septin-5 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Septin-5 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;Septin-5 IgG SerPl Ql IF;;ACTIVE;2.74;2.74 +101461-2;Septin-5 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Septin-5 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Septin-5 IgG CSF Ql IF;;ACTIVE;2.74;2.74 +101462-0;Septin-5 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Septin-5 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;Septin-5 IgG CSF Ql CBA IFA;;ACTIVE;2.74;2.74 +101463-8;Septin-5 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;CBA IFA;SERO;1;Septin-5 IgG Ab [Presence] in Serum or Plasma by Cell binding immunofluorescent assay;Septin-5 IgG SerPl Ql CBA IFA;;ACTIVE;2.74;2.74 +101464-6;Septin-7 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Septin-7 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Septin-7 IgG CSF Ql IF;;ACTIVE;2.74;2.74 +101465-3;Septin-7 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Septin-7 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;Septin-7 IgG SerPl Ql IF;;ACTIVE;2.74;2.74 +101466-1;Septin-7 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Septin-7 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;Septin-7 IgG CSF Ql CBA IFA;;ACTIVE;2.74;2.74 +101467-9;Septin-7 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;CBA IFA;SERO;1;Septin-7 IgG Ab [Presence] in Serum or Plasma by Cell binding immunofluorescent assay;Septin-7 IgG SerPl Ql CBA IFA;;ACTIVE;2.74;2.74 +101468-7;Risk adjustment coding gap report;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Risk adjustment coding gap report Document;Risk adjustment coding gap report Doc;;ACTIVE;2.74;2.74 +10146-9;T wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead II;T wave Amp L-II;;ACTIVE;1.0i;2.48 +101469-5;HBA1+2 gene FIL deletion;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.DEL;1;HBA1+2 gene FIL deletion [Presence] in Blood by Molecular genetics method;HBA1+2 FIL Del Bld Ql;;ACTIVE;2.74;2.74 +101470-3;HBA1+2 gene THAI deletion;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.DEL;1;HBA1+2 gene THAI deletion [Presence] in Blood by Molecular genetics method;HBA1+2 THAI Del Bld Ql;;ACTIVE;2.74;2.74 +101471-1;Alpha globin gene deletion panel;-;Pt;Bld;-;;PANEL.MOLPATH;1;Alpha globin gene deletion panel - Blood;Alpha globin gene deletion panel Bld;;ACTIVE;2.74;2.74 +101472-9;Catalase;PrThr;Pt;Urine;Ord;;MICRO;1;Catalase [Presence] in Urine;Catalase Ur Ql;;ACTIVE;2.74;2.74 +101473-7;Gas & electrolytes panel;-;Pt;BldV;Qn;;PANEL.CHEM;1;Gas and electrolytes panel - Venous blood;Gas + Electrolytes Pnl BldV;;ACTIVE;2.74;2.74 +101474-5;Adenovirus DNA & Human Metapneumovirus & Rhinovirus RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;Adenovirus DNA and Human Metapneumovirus and Rhinovirus RNA panel - Respiratory specimen by NAA with probe detection;HAdV DNA + hMPV + Rhinovirus RNA pl Resp NAA+probe;;ACTIVE;2.74;2.74 +101475-2;Creatinine;SCnc;Pt;BldV;Qn;;CHEM;1;Creatinine [Moles/volume] in Venous blood;Creat BldV-sCnc;;ACTIVE;2.74;2.74 +101476-0;Glucose^post CFst;SCnc;Pt;BldV;Qn;;CHAL;1;Fasting glucose [Moles/volume] in Venous blood;Glucose p fast BldV-sCnc;;ACTIVE;2.74;2.74 +10147-7;T wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead III;T wave Amp L-III;;ACTIVE;1.0i;2.48 +101477-8;Ampicillin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Ampicillin [Susceptibility] by MIC.VOC detection in Positive blood culture;Ampicillin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101478-6;Ampicillin+Sulbactam;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility] by MIC.VOC detection in Positive blood culture;Ampicillin+Sulbac Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101479-4;Cefotaxime;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Cefotaxime [Susceptibility] by MIC.VOC detection in Positive blood culture;Cefotaxime Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101480-2;Cefotaxime+Clavulanate;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Cefotaxime+Clavulanate [Susceptibility] by MIC.VOC detection in Positive blood culture;Cefotaxime+Clav Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101481-0;Ceftazidime;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;cefTAZidime [Susceptibility] by MIC.VOC detection in Positive blood culture;cefTAZidime Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101482-8;Ceftazidime+Clavulanate;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;cefTAZidime+Clavulanate [Susceptibility] by MIC.VOC detection in Positive blood culture;cefTAZidime+Clav Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101483-6;cefTAZidime+Avibactam;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;cefTAZidime+Avibactam [Susceptibility] by MIC.VOC detection in Positive blood culture;cefTAZidime+Avibactam Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101484-4;Ceftolozane+Tazobactam;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Ceftolozane+Tazobactam [Susceptibility] by MIC.VOC detection in Positive blood culture;Ceftolozane+Tazobactam BldPos MICVOC det;;ACTIVE;2.74;2.74 +10148-5;T wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead V1;T wave Amp L-V1;;ACTIVE;1.0i;2.48 +101485-1;Ceftriaxone;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;cefTRIAXone [Susceptibility] by MIC.VOC detection in Positive blood culture;cefTRIAXone Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101486-9;Ertapenem;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Ertapenem [Susceptibility] by MIC.VOC detection in Positive blood culture;Ertapenem Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101487-7;Imipenem;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Imipenem [Susceptibility] by MIC.VOC detection in Positive blood culture;Imipenem Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101488-5;Meropenem;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Meropenem [Susceptibility] by MIC.VOC detection in Positive blood culture;Meropenem Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101489-3;Meropenem+Vaborbactam;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Meropenem+Vaborbactam [Susceptibility] by MIC.VOC detection in Positive blood culture;Mero+Vab Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101490-1;Piperacillin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Piperacillin [Susceptibility] by MIC.VOC detection in Positive blood culture;Piperacillin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101491-9;Piperacillin+Tazobactam;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Piperacillin+Tazobactam [Susceptibility] by MIC.VOC detection in Positive blood culture;Pip+Tazo Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101492-7;Cefoxitin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;cefOXitin [Susceptibility] by MIC.VOC detection in Positive blood culture;cefOXitin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +10149-3;T wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead V2;T wave Amp L-V2;;ACTIVE;1.0i;2.48 +101493-5;Amikacin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Amikacin [Susceptibility] by MIC.VOC detection in Positive blood culture;Amikacin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101494-3;Gentamicin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Gentamicin [Susceptibility] by MIC.VOC detection in Positive blood culture;Gentamicin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101495-0;Trimethoprim+Sulfamethoxazole;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility] by MIC.VOC detection in Positive blood culture;TMP SMX Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101496-8;Tobramycin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Tobramycin [Susceptibility] by MIC.VOC detection in Positive blood culture;Tobramycin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101497-6;Aztreonam;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Aztreonam [Susceptibility] by MIC.VOC detection in Positive blood culture;Aztreonam Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101498-4;Amoxicillin+Clavulanate;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility] by MIC.VOC detection in Positive blood culture;Amoxicillin+Clav Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101499-2;Tigecycline;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Tigecycline [Susceptibility] by MIC.VOC detection in Positive blood culture;Tigecycline Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101500-7;Ciprofloxacin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Ciprofloxacin [Susceptibility] by MIC.VOC detection in Positive blood culture;Ciprofloxacin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +10150-1;T wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead V3;T wave Amp L-V3;;ACTIVE;1.0i;2.48 +101501-5;Levofloxacin;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;levoFLOXacin [Susceptibility] by MIC.VOC detection in Positive blood culture;levoFLOXacin Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101502-3;Cefepime;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Cefepime [Susceptibility] by MIC.VOC detection in Positive blood culture;Cefepime Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101503-1;Cefuroxime;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Cefuroxime [Susceptibility] by MIC.VOC detection in Positive blood culture;Cefuroxime Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101504-9;Tetracycline;Susc;Pt;Bld.pos growth;OrdQn;MIC.VOC detection;ABXBACT;1;Tetracycline [Susceptibility] by MIC.VOC detection in Positive blood culture;Tetracycline Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101505-6;Bacterial susceptibility panel;-;Pt;Bld.pos growth;-;MIC.VOC detection;PANEL.ABXBACT;1;Bacterial susceptibility panel by Minimum inhibitory concentration VOC detection;Bacterial Susc Pnl Bld Pos MIC.VOC det;;ACTIVE;2.74;2.74 +101506-4;Phosphatidylethanol panel;-;Pt;Bld;-;;PANEL.DRUG/TOX;1;Phosphatidylethanol panel - Blood;PEth panel Bld;;ACTIVE;2.74;2.74 +101507-2;Suicide screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Suicide screening report;Suicide screening report;;ACTIVE;2.74;2.74 +101508-0;Salmonella serogroup D1;PrThr;Pt;XXX;Ord;IA;MICRO;1;Salmonella serogroup D1 [Presence] in Specimen by Immunoassay;Salmonella serogroup D1 Spec Ql IA;;ACTIVE;2.74;2.74 +101509-8;Colony count;NCnc;Pt;XXX;Qn;Culture.standard plate count;MICRO;1;Colony count [#/volume] in Specimen by Culture Standard Plate Count;CC # Spec Cult Std Plate Cnt;;ACTIVE;2.74;2.74 +101510-6;Porcine DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Porcine DNA Ct Spec Qn NAA+probe;;ACTIVE;2.74;2.74 +101511-4;Salmonella enterica serotype 1,4,[5],12:i:-;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Salmonella enterica serotype 1,4,[5],12:i:- [Cycle Threshold #] in Specimen by NAA with probe detection;S 1,4,[5],12:i:- DNA Ct Spec Qn NAA+prob;;ACTIVE;2.74;2.74 +101512-2;Salmonella typhimurium DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Salmonella typhimurium DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S Typhimur DNA Ct Spec Qn NAA+probe;;ACTIVE;2.74;2.74 +101513-0;Mycoplasma flocculare DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma flocculare DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M flocculare DNA Ct Spec Qn NAA+probe;;ACTIVE;2.74;2.74 +101514-8;Equine herpesvirus 1 non-neuropathogenic A2254 variant DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Equine herpesvirus 1 non-neuropathogenic A2254 variant DNA [Cycle Threshold #] in Specimen by NAA with probe detection;EHV1 A2254 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.74;2.74 +101515-5;Equine herpesvirus 1 neuropathogenic G2254 variant DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Equine herpesvirus 1 neuropathogenic G2254 variant DNA [Cycle Threshold #] in Specimen by NAA with probe detection;EHV1 G2254 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.74;2.74 +101516-3;Salmonella dublin Ab;AFr;Pt;XXX;Qn;IA;MICRO;1;Salmonella dublin Ab in Specimen by Immunoassay;Salmonella dublin Ab Spec IA-%;;ACTIVE;2.74;2.74 +101517-1;Canine parvovirus DNA VP2 gene;PrThr;Pt;Isolate;Ord;Sequencing;MICRO;1;Canine parvovirus DNA VP2 gene [Presence] in Isolate by Sequencing;CPV DNA VP2 gene Islt Ql Seq;;ACTIVE;2.74;2.74 +101518-9;Canine Parvovirus 2 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Canine Parvovirus 2 DNA [Presence] in Specimen by NAA with probe detection;CPV 2 DNA Spec Ql NAA+probe;;ACTIVE;2.74;2.74 +10151-9;T wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead V4;T wave Amp L-V4;;ACTIVE;1.0i;2.27 +101519-7;Hemorrhagic enteritis virus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Hemorrhagic enteritis virus Ab [Titer] in Serum by Immunoassay;HEV Ab Titr Ser IA;;ACTIVE;2.74;2.74 +101520-5;Avian reovirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Avian reovirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;AVREOV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.74;2.74 +101521-3;Hemorrhagic enteritis virus Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Hemorrhagic enteritis virus Ab/Positive control in Serum by Immunoassay;HEV Ab/Pos cntrl Ser IA;;ACTIVE;2.74;2.74 +101522-1;Porcine deltacoronavirus S gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine deltacoronavirus S gene [Nucleotide sequence] in Isolate by Sequencing;PDCoV S gene Islt-Seq;;ACTIVE;2.74;2.74 +101523-9;Bovine parainfluenza virus 3 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bovine parainfluenza virus 3 neutralizing antibody [Titer] in Serum by Neutralization test;BPIV3 NAb Titr Ser Nt;;ACTIVE;2.74;2.74 +101524-7;Mycoplasma hyopneumoniae;Titr;Pt;XXX;Qn;;MICRO;1;Mycoplasma hyopneumoniae [Titer] in Specimen;M hyopneumo Titr Spec;;ACTIVE;2.74;2.74 +101525-4;Valnemulin;Susc;Pt;Isolate;Qn;MIC;ABXBACT;1;Valnemulin [Susceptibility] by Minimum inhibitory concentration (MIC);Valnemulin Islt MIC;;ACTIVE;2.74;2.74 +101526-2;Tylvalosin;Susc;Pt;Isolate;Qn;MIC;ABXBACT;1;Tylvalosin [Susceptibility] by Minimum inhibitory concentration (MIC);Tylvalosin Islt MIC;;ACTIVE;2.74;2.74 +10152-7;T wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead V5;T wave Amp L-V5;;ACTIVE;1.0i;2.27 +101527-0;Porcine epidemic diarrhea virus S1 gene;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine epidemic diarrhea virus S1 gene [Identifier] in Isolate by Sequencing;PEDV S1 gene Islt Seq;;ACTIVE;2.74;2.74 +101528-8;Mycoplasma sp DNA;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Mycoplasma sp DNA [Identifier] in Isolate by Sequencing;Mycoplasma DNA Islt Seq;;ACTIVE;2.74;2.74 +101529-6;Mycoplasma sp DNA;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Mycoplasma sp DNA [Nucleotide sequence] in Isolate by Sequencing;Mycoplasma DNA Islt-Seq;;ACTIVE;2.74;2.74 +101530-4;Porcine epidemic diarrhea virus Ab.IgG;ACnc;Pt;XXX;Qn;IA;MICRO;1;Porcine epidemic diarrhea virus IgG Ab [Units/volume] in Specimen by Immunoassay;PEDv IgG Spec IA-aCnc;;ACTIVE;2.74;2.74 +101531-2;Porcine epidemic diarrhea virus S1 gene Ab.IgA;ACnc;Pt;Saliva;Qn;IA;MICRO;1;Porcine epidemic diarrhea virus S1 gene IgA Ab [Units/volume] in Saliva (oral fluid) by Immunoassay;PEDV S1 gene IgA Sal IA-aCnc;;ACTIVE;2.74;2.74 +101533-8;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to RespPRRS;NFr;Pt;Isolate;Qn;Sequencing;MICRO;1;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to RespPRRS in Isolate by Sequencing;PRRSV RespPRRS Hmlgy Islt Seq-NFr;;ACTIVE;2.74;2.74 +101534-6;Fungal 18S rRNA gene;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Fungal 18s rRNA gene [Identifier] in Specimen by Sequencing;Fungal 18s rRNA gene Spec Seq;;ACTIVE;2.74;2.74 +10153-5;T wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave amplitude in lead V6;T wave Amp L-V6;;ACTIVE;1.0i;2.48 +101535-3;Fungal 18S rRNA gene;Seq;Pt;XXX;Nom;Sequencing;MICRO;1;Fungal 18s rRNA gene [Nucleotide sequence] in Specimen by Sequencing;Fungal 18s rRNA gene Spec-Seq;;ACTIVE;2.74;2.74 +101536-1;Salmonella sp whole genome;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Salmonella sp whole genome [Nucleotide sequence] in Isolate by Sequencing;Salmonella sp whole genome Islt-Seq;;ACTIVE;2.74;2.74 +101537-9;AGA gene;Imp;Pt;Ser;Nom;;MOLPATH;1;AGA gene [Interpretation] in Serum;AGA Ser-Imp;;ACTIVE;2.74;2.74 +101538-7;SMA residual risk;Imp;Pt;Bld;Nar;Molgen;MOLPATH.MUT;1;SMA residual risk [Interpretation] in Blood by Molecular genetics method Narrative;SMA residual risk Bld-Imp;;ACTIVE;2.74;2.74 +101539-5;Tyrosine;Imp;Pt;Plas;Nom;;CHEM;1;Tyrosine [Interpretation] in Plasma;Tyrosine Plas-Imp;;ACTIVE;2.74;2.74 +101540-3;AGA gene;Likelihood;Pt;Ser;Qn;Calculation;MOLPATH;1;AGA gene [Likelihood] in Serum by Calculation;AGA Ser Calcn;;ACTIVE;2.74;2.74 +101541-1;Comprehensive plan of care note;Find;Pt;{Setting};Doc;Multidisciplinary;DOC.ONTOLOGY;2;Multidisciplinary Comprehensive plan of care note;Multidisciplinary Comp plan of care note;;ACTIVE;2.74;2.74 +101542-9;Bacterial versus viral etiology indicator panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Bacterial versus viral etiology indicator panel - Serum or Plasma;Bact vs viral etiol ind pnl SerPl;;ACTIVE;2.74;2.74 +10154-3;Chief complaint;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Chief complaint Narrative - Reported;Chief complaint Reported;;ACTIVE;1.0i;2.63 +101543-7;Tumor necrosis factor ligand superfamily member 10;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tumor necrosis factor ligand superfamily member 10 [Mass/volume] in Serum or Plasma;TNFSF10 SerPl-mCnc;;ACTIVE;2.74;2.74 +101544-5;Bacterial versus viral infection likelihood;Score;Pt;^Patient;Qn;Calculated;CHEM;1;Bacterial versus viral infection likelihood [Score] by calculation;Bact vs virl infct likelihd Scre Pt Calc;;ACTIVE;2.74;2.74 +101545-2;FCGR3A gene.p.Phe158;Prid;Pt;Bld;Nom;Molgen;MOLPATH;1;FCGR3A gene.p.Phe158 [Identifier] in Blood by Molecular genetics method Nominal;FCGR3A gene.p.158 Bld;;ACTIVE;2.74;2.74 +101546-0;FCGR3A gene.p.Val158;Prid;Pt;Bld;Nom;Molgen;MOLPATH;1;FCGR3A gene.p.Val158 [Identifier] in Blood by Molecular genetics method Nominal;FCGR3A gene.p.158 Bld;;ACTIVE;2.74;2.74 +101547-8;Hepatocyte Ag by paraffin 1;Find;Pt;Bld/Tiss;Ord;Immune stain;PATH;1;Hepatocyte Ag by paraffin 1 in Blood or Tissue Qualitative by Immune stain;Hepatocyte by paraffin 1 Bld/T Ql ImStn;;ACTIVE;2.74;2.74 +101548-6;P63 protein;Imp;Pt;Bld/Tiss;Ord;;PATH;1;P63 protein [Interpretation] in Blood or Tissue Qualitative;p63 Bld/T-Imp;;ACTIVE;2.74;2.74 +101549-4;Schmid fall risk assessment;-;Pt;^Patient;-;Schmid;PANEL.CLIN.RISK;2;Schmid fall risk assessment;Schmid fall risk;Copyright © 1990 Used with permission.;ACTIVE;2.74;2.74 +10155-0;Allergies;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of allergies, reported;Hx of Allergies;;ACTIVE;1.0i;2.63 +101550-2;Total Score;Score;Pt;^Patient;Qn;Schmid;CLIN.RISK;2;Total score Schmid fall risk assessment;Total score Schmid;;ACTIVE;2.74;2.74 +101551-0;Schmid fall risk assessment;Imp;Pt;^Patient;Ord;Schmid;CLIN.RISK;2;Schmid fall risk assessment [Interpretation];Schmid fall risk assessment Imp;Copyright © 1990 Used with permission.;ACTIVE;2.74;2.74 +101552-8;Campylobacter coli DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter coli DNA [Presence] in Stool by NAA with probe detection;C coli DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101553-6;Aeromonas hydrophila DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Aeromonas hydrophila DNA [Presence] in Stool by NAA with probe detection;A hydrophila DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101554-4;Campylobacter jejuni DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter jejuni DNA [Presence] in Stool by NAA with probe detection;C jejuni DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101555-1;Campylobacter upsaliensis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter upsaliensis DNA [Presence] in Stool by NAA with probe detection;C upsaliensis DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101556-9;Candida krusei DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Candida krusei DNA [Presence] in Urine by NAA with probe detection;C krusei DNA Ur Ql NAA+probe;;ACTIVE;2.74;2.74 +101557-7;Clostridioides difficile DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Clostridioides difficile DNA [Presence] in Stool by NAA with probe detection;C diff DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101558-5;Escherichia coli enteroinvasive DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enteroinvasive DNA [Presence] in Stool by NAA with probe detection;E coli EIEC DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101559-3;Listeria monocytogenes DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Listeria monocytogenes DNA [Presence] in Stool by NAA with probe detection;L monocytog DNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101560-1;Rotavirus B RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Rotavirus B RNA [Presence] in Stool by NAA with probe detection;RVB RNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101561-9;Rotavirus C RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Rotavirus C RNA [Presence] in Stool by NAA with probe detection;RVC RNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101562-7;Sapovirus genogroups I+II+IV RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Sapovirus genogroups I+II+IV RNA [Presence] in Stool by NAA with probe detection;Sapov I+II+IV RNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101563-5;Sapovirus genogroup V RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Sapovirus genogroup V RNA [Presence] in Stool by NAA with probe detection;Sapo V RNA Stl Ql NAA+probe;;ACTIVE;2.74;2.74 +101564-3;Gliadin peptide Ab.IgA+IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Gliadin peptide IgA+IgG Ab [Units/volume] in Serum by Immunoassay;Gliadin peptide IgA+IgG Ser IA-aCnc;;ACTIVE;2.74;2.74 +101565-0;Electrolytes panel;-;Pt;BldV;-;;PANEL.CHEM;1;Electrolytes panel - Venous blood;Lytes Pnl BldV;;ACTIVE;2.74;2.74 +101566-8;Human Coronavirus RNA;Find;Pt;XXX;Doc;;MICRO;1;Human coronavirus RNA in Specimen Document;HCoV RNA Spec Doc;;ACTIVE;2.74;2.74 +101567-6;Parainfluenza virus RNA;Find;Pt;XXX;Doc;;MICRO;1;Parainfluenza virus RNA in Specimen Document;HPIV RNA Spec Doc;;ACTIVE;2.74;2.74 +10156-8;Childhood diseases;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Childhood diseases Narrative;Hx of Childhood diseases;;ACTIVE;1.0i;2.56 +101568-4;Thyroglobulin & Thyroglobulin Ab panel;-;Pt;Tiss.FNA;-;;PANEL.CHEM;1;Thyroglobulin and Thyroglobulin Ab panel - Tissue fine needle aspirate;Thyroglob + Thyroglob Ab pnl Tiss FNA;;ACTIVE;2.74;2.74 +101569-2;Semen & urine analysis fertility panel;-;Pt;XXX;-;;PANEL.FERT;1;Semen and urine analysis fertility panel - Specimen;Spec;;ACTIVE;2.74;2.74 +1015-7;E super little w Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;E sup(w) Ag [Presence] on Red Blood Cells;E sup(w) Ag RBC Ql;;ACTIVE;1.0;2.63 +101570-0;Spermatozoa.normal chromatin/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Normal chromatin/100 spermatozoa in Semen;Sperm norm chrom NFr Smn;;ACTIVE;2.74;2.74 +101571-8;Candida glabrata+krusei DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida glabrata+krusei DNA [Presence] in Vaginal fluid by NAA with probe detection;C glabrata+krusei DNA Vag Ql NAA+probe;;ACTIVE;2.74;2.74 +101572-6;Prenatal visits for this pregnancy;Find;Pt;^Patient;Ord;;OBGYN;2;Prenatal visits for this pregnancy;Prenatal visits this preg;;ACTIVE;2.74;2.74 +101573-4;Diet at discharge;Find;Pt;^Patient;Ord;;OBGYN;2;Diet at discharge;Diet at d/c;;ACTIVE;2.74;2.74 +101574-2;Body temperature^at admission;Temp;1H;^Patient;Qn;;OBGYN;2;Body temperature 1 hour --at admission;Bdy temp 1h;;ACTIVE;2.74;2.74 +101575-9;Delayed cord clamping;Find;Pt;^Newborn;Ord;;OBGYN;2;Delayed cord clamping Newborn;Delayed cord clamping NB;;ACTIVE;2.74;2.74 +10157-6;History of family member diseases;Hx;Pt;^Family member;Nar;;H&P.HX;2;History of family member diseases Narrative;Family member diseases Hx;;ACTIVE;1.0i;2.73 +101576-7;Bacterial gyrB gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial gyrB gene drug resistance mutation [Identifier] by Molecular method;Bacterial gyrB drug res mut Islt/Spm;;ACTIVE;2.74;2.74 +101577-5;Cardioversion report;Find;Pt;Heart;Doc;;CARD.PROC;2;Cardioversion report Heart Document;Cardioversion report Hrt Doc;;ACTIVE;2.74;2.74 +101578-3;Cardiac device monitoring report;Find;Pt;Heart;Doc;;CARD.PROC;2;Cardiac device monitoring report;Cardiac device monitoring report;;ACTIVE;2.74;2.74 +101579-1;Multisection transthoracic limited;Find;Pt;Chest>Heart;Doc;US;CARD.US;2;Heart Multisection transthoracic limited by US;Hrt Multisection transthoracic limited;;ACTIVE;2.74;2.74 +101580-9;Multisection transthoracic limited for congenital disease;Find;Pt;Chest>Heart;Doc;US;CARD.US;2;US Heart Transthoracic limited for congenital disease;US Hrt Transth Ltd congenital disease;;ACTIVE;2.74;2.74 +101581-7;Multisection transthoracic for congenital disease;Find;Pt;Chest>Heart;Doc;US;CARD.US;2;US Heart Transthoracic for congenital disease;US Hrt Transth congenital disease;;ACTIVE;2.74;2.74 +101582-5;Views for protein-losing enteropathy^W Tc-99m HSA IV;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;NM;RAD;2;NM Gastrointestinal tract Views for protein-losing enteropathy W Tc-99m HSA IV;NM GI tract Vs PLE W Tc-99m HSA IV;;ACTIVE;2.74;2.74 +10158-4;Functional status;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Functional status Narrative;Hx of Functional status;;ACTIVE;1.0i;2.56 +10159-2;Industrial exposure;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Industrial exposure Narrative;Hx of Industrial exposure;;ACTIVE;1.0i;2.56 +101-6;Cefoperazone;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefoperazone [Susceptibility] by Disk diffusion (KB);Cefoperazone Islt KB;;ACTIVE;1.0;2.73 +10160-0;Medication use;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Medication use Narrative;Hx of Medication use;;ACTIVE;1.0i;2.63 +10161-8;Occupational exposure;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Occupational exposure Narrative;Hx of Occupational exposure;;ACTIVE;1.0i;2.56 +10162-6;History of pregnancies;Hx;Pt;Reproductive system;Nar;;H&P.HX;2;History of pregnancies Narrative;Pregnancies Hx;;ACTIVE;1.0i;2.63 +10163-4;History of pregnancies;Hx;Pt;Reproductive system;Nom;;H&P.HX;2;History of pregnancies;Pregnancies Hx;;ACTIVE;1.0i;2.56 +10164-2;Present illness;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Present illness Narrative;Hx of Pres illness;;ACTIVE;1.0i;2.63 +1016-5;E Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;E Ab [Presence] in Serum or Plasma from Blood product unit;E Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10165-9;History of psychiatric symptoms & diseases;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Deprecated History of psychiatric symptoms and diseases Narrative;Deprecated Psych symptoms & diseases Hx;;DEPRECATED;1.0i;2.40 +10166-7;Social function;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Social function Narrative;Hx of Social function;;ACTIVE;1.0i;2.56 +10167-5;Surgical procedures;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Surgical procedures Narrative;Hx of Surg proc;;ACTIVE;1.0i;2.73 +10168-3;Symptoms & diseases;Hx;Pt;Cardiovascular system;Nar;;H&P.HX;2;History of Cardiovascular system disorders Narrative;Hx of CVS disorders;;ACTIVE;1.0i;2.56 +10169-1;Symptoms & diseases;Hx;Pt;Ear;Nar;;H&P.HX;2;History of Ear disorders Narrative;Hx of Ear disorders;;ACTIVE;1.0i;2.56 +10170-9;Symptoms & diseases;Hx;Pt;Endocrine system;Nar;;H&P.HX;2;History of Endocrine system disorders Narrative;Hx of Endocrine disorders;;ACTIVE;1.0i;2.56 +10171-7;Symptoms & diseases;Hx;Pt;Eyes;Nar;;H&P.HX;2;History of Eyes disorders Narrative;Hx of Eyes disorders;;ACTIVE;1.0i;2.56 +10172-5;Symptoms & diseases;Hx;Pt;Hematologic system;Nar;;H&P.HX;2;History of Hematologic system disorders Narrative;Hx of Hematologic disorders;;ACTIVE;1.0i;2.56 +1017-3;E Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;E Ab [Presence] in Serum or Plasma from Donor;E Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10173-3;Symptoms & diseases;Hx;Pt;Musculoskeletal system;Nar;;H&P.HX;2;History of Musculoskeletal system disorders Narrative;Hx of Musculoskeletal disorders;;ACTIVE;1.0i;2.56 +10174-1;Symptoms & diseases;Hx;Pt;Nose;Nar;;H&P.HX;2;History of Nose disorders Narrative;Hx of Nose disorders;;ACTIVE;1.0i;2.56 +10175-8;Symptoms & diseases;Hx;Pt;Oral cavity;Nar;;H&P.HX;2;History of Oral cavity disorders Narrative;Hx of Oral cavity disorders;;ACTIVE;1.0i;2.56 +10176-6;Symptoms & diseases;Hx;Pt;Reproductive system;Nar;;H&P.HX;2;History of Reproductive system disorders Narrative;Hx of Reproductive disorders;;ACTIVE;1.0i;2.56 +10177-4;Symptoms & diseases;Hx;Pt;Respiratory system;Nar;;H&P.HX;2;History of Respiratory system disorders Narrative;Hx of Respiratory disorders;;ACTIVE;1.0i;2.56 +10178-2;Symptoms & diseases;Hx;Pt;Skin;Nar;;H&P.HX;2;History of Skin disorders Narrative;Hx of Skin disorders;;ACTIVE;1.0i;2.56 +10179-0;Symptoms & diseases;Hx;Pt;Throat+Neck;Nar;;H&P.HX;2;History of Throat and Neck disorders Narrative;Hx of Throat+Neck disorders;;ACTIVE;1.0i;2.56 +10180-8;Symptoms & diseases;Hx;Pt;Throat+Neck;Nom;;H&P.HX;2;History of Throat and Neck disorders;Hx of Throat+Neck disorders;;ACTIVE;1.0i;2.56 +1018-1;E Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;E Ab [Presence] in Serum or Plasma;E Ab SerPl Ql;;ACTIVE;1.0;2.73 +10181-6;Symptoms & diseases;Hx;Pt;Urinary tract;Nar;;H&P.HX;2;History of Urinary tract disorders Narrative;Hx of Urinary disorders;;ACTIVE;1.0i;2.56 +10182-4;Travel;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Travel Narrative;Hx of Travel;;ACTIVE;1.0i;2.56 +10183-2;Hospital discharge medications;Find;Pt;^Patient;Nar;;H&P.HX;2;Hospital discharge medications Narrative;Hospital discharge medications;;ACTIVE;1.0i;2.63 +10184-0;Hospital discharge physical findings;Find;Pt;^Patient;Nar;;H&P.HX;2;Hospital discharge physical findings Narrative;Hospital discharge physical findings;;ACTIVE;1.0i;2.63 +10185-7;Hospital discharge procedures;Find;Pt;^Patient;Nar;;H&P.HX;2;Hospital discharge procedures Narrative;Hospital discharge procedures;;ACTIVE;1.0i;2.40 +10186-5;Identifying information;Find;Pt;^Patient;Nar;Observed;H&P.HX;2;Identifying information Narrative Observed;Identifying information Observ;;ACTIVE;1.0i;2.40 +10187-3;Review of systems;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Review of systems Narrative - Reported;Review of systems;;ACTIVE;1.0i;2.63 +10188-1;Review of systems overview;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Review of systems overview Narrative - Reported;Review of systems overview;;ACTIVE;1.0i;2.48 +10189-9;Review of systems overview;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Review of systems overview - Reported;Review of systems overview;;ACTIVE;1.0i;2.48 +10190-7;Mental status;Find;Pt;^Patient;Nar;Observed;H&P.PX;2;Mental status Narrative;Mental status;;ACTIVE;1.0i;2.58 +10191-5;Physical findings;Find;Pt;Abdomen;Nar;Observed;H&P.PX;2;Physical findings of Abdomen Narrative;Phys find Abd;;ACTIVE;1.0i;2.40 +10192-3;Physical findings;Find;Pt;Back;Nar;Observed;H&P.PX;2;Physical findings of Back Narrative;Phys find Back;;ACTIVE;1.0i;2.40 +10193-1;Physical findings;Find;Pt;Breasts;Nar;Observed;H&P.PX;2;Physical findings of Breasts Narrative;Phys find Brsts;;ACTIVE;1.0i;2.40 +10194-9;Physical findings;Find;Pt;Neurologic deep tendon reflexes;Nar;Observed;H&P.PX;2;Physical findings of Neurologic deep tendon reflexes Narrative;Phys find Deep tendon reflexes;;ACTIVE;1.0i;2.40 +10195-6;Physical findings;Find;Pt;Ear;Nar;Observed;H&P.PX;2;Physical findings of Ear Narrative;Phys find Ear;;ACTIVE;1.0i;2.40 +10196-4;Physical findings;Find;Pt;Extremities;Nar;Observed;H&P.PX;2;Physical findings of Extremities Narrative;Phys find Extremities;;ACTIVE;1.0i;2.40 +10197-2;Physical findings;Find;Pt;Eye;Nar;Observed;H&P.PX;2;Physical findings of Eye Narrative;Phys find Eye;;ACTIVE;1.0i;2.40 +10198-0;Physical findings;Find;Pt;Genitourinary tract;Nar;Observed;H&P.PX;2;Physical findings of Genitourinary tract Narrative;Phys find GU Tract;;ACTIVE;1.0i;2.40 +1019-9;E Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;E Ag [Presence] on Red Blood Cells from Blood product unit;E Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10199-8;Physical findings;Find;Pt;Head;Nar;Observed;H&P.PX;2;Physical findings of Head Narrative;Phys find Head;;ACTIVE;1.0i;2.40 +10200-4;Physical findings;Find;Pt;Heart;Nar;Observed;H&P.PX;2;Physical findings of Heart Narrative;Phys find Hrt;;ACTIVE;1.0i;2.40 +10201-2;Physical findings;Find;Pt;Mouth & Throat & Teeth;Nar;Observed;H&P.PX;2;Physical findings of Mouth and Throat and Teeth Narrative;Phys find Mouth+Throat+Teeth;;ACTIVE;1.0i;2.40 +10202-0;Physical findings;Find;Pt;Neurologic system;Nar;Observed;H&P.PX;2;Physical findings of Nervous system Narrative;Phys find Neurologic;;ACTIVE;1.0i;2.40 +10203-8;Physical findings;Find;Pt;Nose;Nar;Observed;H&P.PX;2;Physical findings of Nose Narrative;Phys find Nose;;ACTIVE;1.0i;2.40 +10204-6;Physical findings;Find;Pt;Pelvis;Nar;Observed;H&P.PX;2;Physical findings of Pelvis Narrative;Phys find Pelvis;;ACTIVE;1.0i;2.40 +10205-3;Physical findings;Find;Pt;Rectum;Nar;Observed;H&P.PX;2;Physical findings of Rectum Narrative;Phys find Rectum;;ACTIVE;1.0i;2.73 +10206-1;Physical findings;Find;Pt;Skin;Nar;Observed;H&P.PX;2;Physical findings of Skin Narrative;Phys find Skin;;ACTIVE;1.0i;2.40 +1020-7;E Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;E Ag [Presence] on Red Blood Cells from Donor;E Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10207-9;Physical findings;Find;Pt;Thorax+Lungs;Nar;Observed;H&P.PX;2;Physical findings of Thorax and Lungs Narrative;Phys find Thorax+Lungs;;ACTIVE;1.0i;2.40 +10208-7;Physical findings;Find;Pt;Vessels;Nar;Observed;H&P.PX;2;Physical findings of Vessels Narrative;Phys find Vesl;;ACTIVE;1.0i;2.40 +10209-5;Physical findings;Find;Pt;Neurologic balance+Coordination;Nar;Observed;H&P.PX;2;Physical findings of Neurologic balance and Coordination Narrative;Phys find Balance+Coordination;;ACTIVE;1.0i;2.40 +10210-3;Physical findings;Find;Pt;General status;Nar;Observed;H&P.PX;2;Physical findings of General status Narrative;Phys find General status;;ACTIVE;1.0i;2.63 +10211-1;Physical findings;Find;Pt;Sense of touch;Nar;Observed;H&P.PX;2;Physical findings of Sense of touch Narrative;Phys find Sense of touch;;ACTIVE;1.0i;2.40 +10212-9;Physical findings;Find;Pt;Strength;Nar;Observed;H&P.PX;2;Physical findings of Strength Narrative;Phys find Strength;;ACTIVE;1.0i;2.40 +10213-7;Surgical operation note anesthesia;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note anesthesia Narrative;Operative note anesthesia;;ACTIVE;1.0i;2.63 +10214-5;Surgical operation note anesthesia duration;Time;Procedure dur;Surgical procedure;Qn;;H&P.SURG PROC;2;Surgical operation note anesthesia duration;Operative note anesthesia duration;;ACTIVE;1.0i;2.27 +1021-5;E Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;E Ag [Presence] on Red Blood Cells;E Ag RBC Ql;;ACTIVE;1.0;2.73 +10215-2;Surgical operation note findings;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note findings Narrative;Operative note findings;;ACTIVE;1.0i;2.63 +10216-0;Surgical operation note fluids;Type;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note fluids Narrative;Operative note fluids;;ACTIVE;1.0i;2.63 +10217-8;Surgical operation note indications;Imp;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note indications [Interpretation] Narrative;Operative note indications Imp;;ACTIVE;1.0i;2.63 +10218-6;Surgical operation note postoperative Dx;Imp;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note postoperative diagnosis Narrative;Operative note post-op Dx;;ACTIVE;1.0i;2.63 +10219-4;Surgical operation note preoperative Dx;Imp;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note preoperative diagnosis Narrative;Operative note pre-op Dx;;ACTIVE;1.0i;2.63 +10220-2;Surgical operation note prep time duration;Time;Procedure dur;Surgical procedure;Qn;;H&P.SURG PROC;2;Surgical operation note prep time duration;Operative note prep time duration;;ACTIVE;1.0i;2.27 +10221-0;Surgical operation note specimens taken;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note specimens taken Narrative;Operative note specimens taken;;ACTIVE;1.0i;2.63 +10222-8;Surgical operation note surgical complications;Imp;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note surgical complications [Interpretation] Narrative;Operative note complications Imp;;ACTIVE;1.0i;2.50 +1022-3;F little y super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Fy sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Fy sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10223-6;Surgical operation note surgical procedure;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note surgical procedure Narrative;Operative note procedure;;ACTIVE;1.0i;2.63 +10224-4;Hemodynamic method special circumstances;Type;Pt;^Patient;Nom;;HEMODYN.ATOM;2;Hemodynamic method special circumstances;Hemodynamic method special circumstances;;ACTIVE;1.0i;2.27 +10225-1;Institution inventory number;ID;Pt;Cardiac measurement device;Nom;;HEMODYN.ATOM;2;Cardiac measurement device Institution inventory number;Cardiac Measurement Device Inventory #;;ACTIVE;1.0i;2.29 +10226-9;Oxygen content;SCnc;Pt;Intravascular space.XXX;Qn;;CHEM;1;Oxygen content in Intravascular space;O2 Ct IV space-sCnc;;ACTIVE;1.0i;2.34 +10227-7;Vendor model number;Prid;Pt;Cardiac measurement device;Nom;;HEMODYN.ATOM;2;Cardiac measurement device Vendor model number;Cardiac Measurement Device Model #;;ACTIVE;1.0i;2.29 +10228-5;Vendor serial number;ID;Pt;Cardiac measurement device;Nom;;HEMODYN.ATOM;2;Cardiac measurement device Vendor serial number;Cardiac Measurement Device Serial #;;ACTIVE;1.0i;2.29 +10229-3;Class;Type;Pt;Hemodynamic method;Nom;;HEMODYN.MOLEC;2;Hemodynamic method Type of;Hemodynamic Method Class;;ACTIVE;1.0i;2.29 +10230-1;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventricular Ejection fraction;LV EF;;ACTIVE;1.0i;2.73 +1023-1;F little y super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Fy sup(a) Ab [Presence] in Serum or Plasma from Donor;Fy sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10231-9;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;;HEMODYN.MOLEC;2;Right ventricular Ejection fraction;RV EF;;ACTIVE;1.0i;2.52 +10232-7;Oxygen content;SCnc;Pt;Aorta.root;Qn;;CHEM;1;Oxygen content in Aorta root;O2 Ct AO root-sCnc;;ACTIVE;1.0i;2.54 +10233-5;Oxygen content;SCnc;Pt;Heart.atrium.left;Qn;;CHEM;1;Oxygen content in Left atrium;O2 Ct LA-sCnc;;ACTIVE;1.0i;2.34 +10234-3;Oxygen content;SCnc;Pt;Heart.atrium.right;Qn;;CHEM;1;Oxygen content in Right atrium;O2 Ct RA-sCnc;;ACTIVE;1.0i;2.34 +10235-0;Oxygen content;SCnc;Pt;Heart.atrium.right.high;Qn;;CHEM;1;Oxygen content in High right atrium;O2 Ct RA.high-sCnc;;ACTIVE;1.0i;2.34 +10236-8;Oxygen content;SCnc;Pt;Heart.atrium.right.low;Qn;;CHEM;1;Oxygen content in Low right atrium;O2 Ct RA.low-sCnc;;ACTIVE;1.0i;2.34 +10237-6;Oxygen content;SCnc;Pt;Heart.atrium.right.mid;Qn;;CHEM;1;Oxygen content in Mid right atrium;O2 Ct RA.mid-sCnc;;ACTIVE;1.0i;2.34 +10238-4;Oxygen content;SCnc;Pt;Heart.ventricle.left;Qn;;CHEM;1;Oxygen content in Left ventricle;O2 Ct LV-sCnc;;ACTIVE;1.0i;2.34 +10239-2;Oxygen content;SCnc;Pt;Heart.ventricle.right.outflow tract;Qn;;CHEM;1;Oxygen content in Right ventricular outflow tract;O2 Ct RVOT-sCnc;;ACTIVE;1.0i;2.34 +102-4;Cefoperazone;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefoperazone [Susceptibility] by Serum bactericidal titer;Cefoperazone Titr SBT;;ACTIVE;1.0;2.32 +10240-0;Oxygen content;SCnc;Pt;Heart.ventricle.right;Qn;;CHEM;1;Oxygen content in Right ventricle;O2 Ct RV-sCnc;;ACTIVE;1.0i;2.34 +10241-8;Oxygen content;SCnc;Pt;Coronary sinus;Qn;;CHEM;1;Oxygen content in Coronary sinus;O2 Ct CS-sCnc;;ACTIVE;1.0i;2.34 +10242-6;Oxygen content;SCnc;Pt;Ductus arteriosus;Qn;;CHEM;1;Oxygen content in Ductus arteriosus;O2 Ct DA-sCnc;;ACTIVE;1.0i;2.34 +10243-4;Oxygen content;SCnc;Pt;Vena cava.inferior;Qn;;CHEM;1;Oxygen content in Inferior vena cava;O2 Ct IVC-sCnc;;ACTIVE;1.0i;2.34 +10244-2;Oxygen content;SCnc;Pt;Pulmonary artery.left;Qn;;CHEM;1;Oxygen content in Left pulmonary artery;O2 Ct PA-L-sCnc;;ACTIVE;1.0i;2.54 +10245-9;Oxygen content;SCnc;Pt;Pulmonary artery.main;Qn;;CHEM;1;Oxygen content in Main pulmonary artery;O2 Ct MPA-sCnc;;ACTIVE;1.0i;2.34 +10246-7;Oxygen content;SCnc;Pt;Pulmonary artery.right;Qn;;CHEM;1;Oxygen content in Right pulmonary artery;O2 Ct PA-R-sCnc;;ACTIVE;1.0i;2.54 +10247-5;Oxygen content;SCnc;Pt;Pulmonary wedge;Qn;;CHEM;1;Oxygen content in Pulmonary wedge;O2 Ct PW-sCnc;;ACTIVE;1.0i;2.34 +10248-3;Oxygen content;SCnc;Pt;Vena cava.superior;Qn;;CHEM;1;Oxygen content in Superior vena cava;O2 Ct SVC-sCnc;;ACTIVE;1.0i;2.34 +1024-9;F little y super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Fy sup(a) Ab [Presence] in Serum or Plasma;Fy sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +10249-1;Institution inventory number;ID;Pt;Heart rate device;Nom;;HRTRATE.ATOM;2;Heart rate device Institution inventory number;Hrt Rate Device Inventory #;;ACTIVE;1.0i;2.29 +10250-9;Vendor model number;Prid;Pt;Heart rate device;Nom;;HRTRATE.ATOM;2;Heart rate device Vendor model number;Model # Hrt Rate Device;;ACTIVE;1.0i;2.29 +10251-7;Vendor serial number;ID;Pt;Heart rate device;Nom;;HRTRATE.ATOM;2;Heart rate device Vendor serial number;Serial # Hrt Rate Device;;ACTIVE;1.0i;2.29 +10252-5;Biliary drain site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Biliary drain site;Biliary drain site;;ACTIVE;1.0i;2.27 +10253-3;Class;Type;Pt;Biliary drain;Nom;;IO.TUBE;2;Type of Biliary drain;Biliary drain Class;;ACTIVE;1.0i;2.27 +10254-1;Class;Type;Pt;Peritoneal drain;Nom;;IO.TUBE;2;Type of Peritoneal drain;Peritoneal drain Class;;ACTIVE;1.0i;2.27 +10255-8;Class;Type;Pt;Subarachnoid drain;Nom;;IO.TUBE;2;Type of Subarachnoid drain;Subarachnoid Drain Class;;ACTIVE;1.0i;2.42 +1025-6;F little y super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Fy sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Fy sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10256-6;Institution inventory number;ID;Pt;Biliary drain;Nom;;IO.TUBE;2;Biliary drain Institution inventory number;Biliary drain Inventory #;;ACTIVE;1.0i;2.29 +10257-4;Institution inventory number;ID;Pt;Chest tube;Nom;;IO.TUBE;2;Chest tube Institution inventory number;Chest tube Inventory #;;ACTIVE;1.0i;2.29 +10258-2;Institution inventory number;ID;Pt;Enteral tube;Nom;;IO.TUBE;2;Enteral tube Institution inventory number;Enteral tube Inventory #;;ACTIVE;1.0i;2.29 +10259-0;Institution inventory number;ID;Pt;Gastrostomy tube;Nom;;IO.TUBE;2;Gastrostomy tube Institution inventory number;G-tube Inventory #;;ACTIVE;1.0i;2.29 +10260-8;Institution inventory number;ID;Pt;GI tube;Nom;;IO.TUBE;2;GI tube Institution inventory number;GI tube Inventory #;;ACTIVE;1.0i;2.29 +10261-6;Institution inventory number;ID;Pt;Intravascular tube;Nom;;IO.TUBE;2;Intravascular tube Institution inventory number;IV tube Inventory #;;ACTIVE;1.0i;2.29 +10262-4;Institution inventory number;ID;Pt;IO tube;Nom;;IO.TUBE;2;IO tube Institution inventory number;IO tube Inventory #;;ACTIVE;1.0i;2.29 +10263-2;Institution inventory number;ID;Pt;Nasogastric tube;Nom;;IO.TUBE;2;Nasogastric tube Institution inventory number;NG-tube Inventory #;;ACTIVE;1.0i;2.29 +1026-4;F little y super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Fy sup(a) Ag [Presence] on Red Blood Cells from Donor;Fy sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10264-0;Institution inventory number;ID;Pt;Oral tube;Nom;;IO.TUBE;2;Oral tube Institution inventory number;Oral tube Inventory #;;ACTIVE;1.0i;2.29 +10265-7;Institution inventory number;ID;Pt;Peritoneal drain;Nom;;IO.TUBE;2;Peritoneal drain Institution inventory number;Peritoneal drain Inventory #;;ACTIVE;1.0i;2.29 +10266-5;Institution inventory number;ID;Pt;Peritoneal tube;Nom;;IO.TUBE;2;Peritoneal tube Institution inventory number;Peritoneal tube Inventory #;;ACTIVE;1.0i;2.29 +10267-3;Institution inventory number;ID;Pt;Rate control device;Nom;;IO.TUBE;2;Rate control device Institution inventory number;Rate Control Device Inventory #;;ACTIVE;1.0i;2.29 +10268-1;Institution inventory number;ID;Pt;Stool collection device;Nom;;IO.TUBE;2;Stool collection device Institution inventory number;Stl Collect Device Inventory #;;ACTIVE;1.0i;2.29 +10269-9;Institution inventory number;ID;Pt;Subarachnoid drain;Nom;;IO.TUBE;2;Subarachnoid drain Institution inventory number;Subarachnoid Drain Inventory #;;ACTIVE;1.0i;2.42 +10270-7;Institution inventory number;ID;Pt;Synovial drain;Nom;;IO.TUBE;2;Synovial drain Institution inventory number;Synovial Drain Inventory #;;ACTIVE;1.0i;2.29 +10271-5;Institution inventory number;ID;Pt;Tube/Drain;Nom;;IO.TUBE;2;Tube or drain Institution inventory number;Tube/Drain Inventory #;;ACTIVE;1.0i;2.29 +1027-2;F little y super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Fy sup(a) Ag [Presence] on Red Blood Cells;Fy sup(a) Ag RBC Ql;;ACTIVE;1.0;2.73 +10272-3;Institution inventory number;ID;Pt;Upper GI tube;Nom;;IO.TUBE;2;Upper GI tube Institution inventory number;Upper GI tube Inventory #;;ACTIVE;1.0i;2.29 +10273-1;Institution inventory number;ID;Pt;Urinary bladder irrigation tube;Nom;;IO.TUBE;2;Bladder irrigation tube Institution inventory number;Bladder irrigation tube Inventory #;;ACTIVE;1.0i;2.29 +10274-9;Institution inventory number;ID;Pt;Urine tube;Nom;;IO.TUBE;2;Urine tube Institution inventory number;Urine tube Inventory #;;ACTIVE;1.0i;2.29 +10275-6;Institution inventory number;ID;Pt;Wound drain device;Nom;;IO.TUBE;2;Wound drain device Institution inventory number;Wound drain device Inventory #;;ACTIVE;1.0i;2.29 +10276-4;Peritoneal drain site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Peritoneal drain site;Peritoneal drain site;;ACTIVE;1.0i;2.27 +10277-2;Stool collection site;Type;Pt;*^Patient;Nom;;IO.TUBE;2;Stool collection site;Stool collection site;;ACTIVE;1.0i;2.29 +10278-0;Subarachnoid drain site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Subarachnoid drain site;Subarachnoid drain site;;ACTIVE;1.0i;2.27 +10279-8;Vendor model number;Prid;Pt;Biliary drain;Nom;;IO.TUBE;2;Biliary drain Vendor model number;Model # Biliary drain;;ACTIVE;1.0i;2.29 +1028-0;F little y super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Fy sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Fy sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10280-6;Vendor model number;Prid;Pt;Chest tube;Nom;;IO.TUBE;2;Chest tube Vendor model number;Model # Chest tube;;ACTIVE;1.0i;2.29 +10281-4;Vendor model number;Prid;Pt;Enteral tube;Nom;;IO.TUBE;2;Enteral tube Vendor model number;Model # Enteral tube;;ACTIVE;1.0i;2.29 +10282-2;Vendor model number;Prid;Pt;Gastrostomy tube;Nom;;IO.TUBE;2;Gastrostomy tube Vendor model number;Model # G-tube;;ACTIVE;1.0i;2.29 +10283-0;Vendor model number;Prid;Pt;GI tube;Nom;;IO.TUBE;2;GI tube Vendor model number;Model # GI tube;;ACTIVE;1.0i;2.29 +10284-8;Vendor model number;Prid;Pt;Intravascular tube;Nom;;IO.TUBE;2;Intravascular tube Vendor model number;Model # IV tube;;ACTIVE;1.0i;2.29 +10285-5;Vendor model number;Prid;Pt;IO tube;Nom;;IO.TUBE;2;IO tube Vendor model number;Model # IO tube;;ACTIVE;1.0i;2.29 +10286-3;Vendor model number;Prid;Pt;Nasogastric tube;Nom;;IO.TUBE;2;Nasogastric tube Vendor model number;Model # NG-tube;;ACTIVE;1.0i;2.29 +10287-1;Vendor model number;Prid;Pt;Oral tube;Nom;;IO.TUBE;2;Oral tube Vendor model number;Model # Oral tube;;ACTIVE;1.0i;2.29 +10288-9;Vendor model number;Prid;Pt;Peritoneal drain;Nom;;IO.TUBE;2;Peritoneal drain Vendor model number;Model # Peritoneal drain;;ACTIVE;1.0i;2.29 +10289-7;Vendor model number;Prid;Pt;Peritoneal tube;Nom;;IO.TUBE;2;Peritoneal tube Vendor model number;Model # Peritoneal tube;;ACTIVE;1.0i;2.29 +10290-5;Vendor model number;Prid;Pt;Rate control device;Nom;;IO.TUBE;2;Rate control device Vendor model number;Model # Rate Control Device;;ACTIVE;1.0i;2.29 +10291-3;Vendor model number;Prid;Pt;Stool collection device;Nom;;IO.TUBE;2;Stool collection device Vendor model number;Model # Stl Collect Device;;ACTIVE;1.0i;2.29 +10292-1;Vendor model number;Prid;Pt;Subarachnoid drain;Nom;;IO.TUBE;2;Subarachnoid drain Vendor model number;Model # Subarachnoid Drain;;ACTIVE;1.0i;2.42 +10293-9;Vendor model number;Prid;Pt;Synovial drain;Nom;;IO.TUBE;2;Synovial drain Vendor model number;Model # Synovial Drain;;ACTIVE;1.0i;2.29 +10294-7;Vendor model number;Prid;Pt;Tube/Drain;Nom;;IO.TUBE;2;Tube or drain Vendor model number;Model # Tube/Drain;;ACTIVE;1.0i;2.29 +10295-4;Vendor model number;Prid;Pt;Upper GI tube;Nom;;IO.TUBE;2;Upper GI tube Vendor model number;Model # Upper GI tube;;ACTIVE;1.0i;2.29 +10296-2;Vendor model number;Prid;Pt;Urinary bladder irrigation tube;Nom;;IO.TUBE;2;Bladder irrigation tube Vendor model number;Model # Bladder irrigation tube;;ACTIVE;1.0i;2.29 +10297-0;Vendor model number;Prid;Pt;Urine tube;Nom;;IO.TUBE;2;Urine tube Vendor model number;Model # Urine tube;;ACTIVE;1.0i;2.29 +1029-8;F little y super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Fy sup(b) Ab [Presence] in Serum or Plasma from Donor;Fy sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10298-8;Vendor model number;Prid;Pt;Wound drain device;Nom;;IO.TUBE;2;Wound drain device Vendor model number;Model # Wound drain device;;ACTIVE;1.0i;2.29 +10299-6;Vendor serial number;ID;Pt;Biliary drain;Nom;;IO.TUBE;2;Biliary drain Vendor serial number;Serial # Biliary drain;;ACTIVE;1.0i;2.29 +10300-2;Vendor serial number;ID;Pt;Chest tube;Nom;;IO.TUBE;2;Chest tube Vendor serial number;Serial # Chest tube;;ACTIVE;1.0i;2.29 +10301-0;Vendor serial number;ID;Pt;Enteral tube;Nom;;IO.TUBE;2;Enteral tube Vendor serial number;Serial # Enteral tube;;ACTIVE;1.0i;2.29 +10302-8;Vendor serial number;ID;Pt;Gastrostomy tube;Nom;;IO.TUBE;2;Gastrostomy tube Vendor serial number;Serial # G-tube;;ACTIVE;1.0i;2.29 +10303-6;Vendor serial number;ID;Pt;GI tube;Nom;;IO.TUBE;2;GI tube Vendor serial number;Serial # GI tube;;ACTIVE;1.0i;2.29 +10304-4;Vendor serial number;ID;Pt;Intravascular tube;Nom;;IO.TUBE;2;Intravascular tube Vendor serial number;Serial # IV tube;;ACTIVE;1.0i;2.29 +10305-1;Vendor serial number;ID;Pt;IO tube;Nom;;IO.TUBE;2;IO tube Vendor serial number;Serial # IO tube;;ACTIVE;1.0i;2.29 +1030-6;F little y super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Fy sup(b) Ab [Presence] in Serum or Plasma;Fy sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.56 +10306-9;Vendor serial number;ID;Pt;Nasogastric tube;Nom;;IO.TUBE;2;Nasogastric tube Vendor serial number;Serial # NG-tube;;ACTIVE;1.0i;2.29 +10307-7;Vendor serial number;ID;Pt;Oral tube;Nom;;IO.TUBE;2;Oral tube Vendor serial number;Serial # Oral tube;;ACTIVE;1.0i;2.29 +10308-5;Vendor serial number;ID;Pt;Peritoneal drain;Nom;;IO.TUBE;2;Peritoneal drain Vendor serial number;Serial # Peritoneal drain;;ACTIVE;1.0i;2.29 +10309-3;Vendor serial number;ID;Pt;Peritoneal tube;Nom;;IO.TUBE;2;Peritoneal tube Vendor serial number;Serial # Peritoneal tube;;ACTIVE;1.0i;2.29 +10310-1;Vendor serial number;ID;Pt;Rate control device;Nom;;IO.TUBE;2;Rate control device Vendor serial number;Serial # Rate Control Device;;ACTIVE;1.0i;2.29 +10311-9;Vendor serial number;ID;Pt;Stool collection device;Nom;;IO.TUBE;2;Stool collection device Vendor serial number;Serial # Stl Collect Device;;ACTIVE;1.0i;2.29 +10312-7;Vendor serial number;ID;Pt;Subarachnoid drain;Nom;;IO.TUBE;2;Subarachnoid drain Vendor serial number;Serial # Subarachnoid Drain;;ACTIVE;1.0i;2.42 +10313-5;Vendor serial number;ID;Pt;Synovial drain;Nom;;IO.TUBE;2;Synovial drain Vendor serial number;Serial # Synovial Drain;;ACTIVE;1.0i;2.29 +1031-4;F little y super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Fy sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Fy sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10314-3;Vendor serial number;ID;Pt;Tube/Drain;Nom;;IO.TUBE;2;Tube or drain Vendor serial number;Serial # Tube/Drain;;ACTIVE;1.0i;2.29 +10315-0;Vendor serial number;ID;Pt;Upper GI tube;Nom;;IO.TUBE;2;Upper GI tube Vendor serial number;Serial # Upper GI tube;;ACTIVE;1.0i;2.29 +10316-8;Vendor serial number;ID;Pt;Urinary bladder irrigation tube;Nom;;IO.TUBE;2;Bladder irrigation tube Vendor serial number;Serial # Bladder irrigation tube;;ACTIVE;1.0i;2.29 +10317-6;Vendor serial number;ID;Pt;Urine tube;Nom;;IO.TUBE;2;Urine tube Vendor serial number;Serial # Urine tube;;ACTIVE;1.0i;2.29 +10318-4;Vendor serial number;ID;Pt;Wound drain device;Nom;;IO.TUBE;2;Wound drain device Vendor serial number;Serial # Wound drain device;;ACTIVE;1.0i;2.29 +10319-2;Institution inventory number;ID;Pt;Enema device;Nom;;IO_IN.MOLEC;2;Enema device Institution inventory number;Enema Device Inventory #;;ACTIVE;1.0i;2.29 +103-2;Ceforanide;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ceforanide [Susceptibility] by Minimum lethal concentration (MLC);Ceforanide Islt MLC;;ACTIVE;1.0;2.19 +10320-0;Vendor model number;Prid;Pt;Enema device;Nom;;IO_IN.MOLEC;2;Enema device Vendor model number;Model # Enema Device;;ACTIVE;1.0i;2.29 +10321-8;Vendor serial number;ID;Pt;Enema device;Nom;;IO_IN.MOLEC;2;Enema device Vendor serial number;Serial # Enema Device;;ACTIVE;1.0i;2.29 +1032-2;F little y super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Fy sup(b) Ag [Presence] on Red Blood Cells from Donor;Fy sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10322-6;Potassium intake;SRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Potassium intake 24 hour;Potassium intake 24h;;ACTIVE;1.0i;2.48 +10323-4;Wound drain fluid;Aper;Pt;Lower GI tract;Nom;;IO_OUT.MOLEC;2;Wound drain fluid [Appearance] Lower GI tract;Wound drain fluid Lower GI tract;;ACTIVE;1.0i;2.27 +10324-2;Institution inventory number;ID;Pt;Breath rate device;Nom;;RESP.ATOM;2;Breath rate device Institution inventory number;Breath Rate Device Inventory #;;ACTIVE;1.0i;2.29 +10325-9;Vendor model number;Prid;Pt;Breath rate device;Nom;;RESP.ATOM;2;Breath rate device Vendor model number;Model # Breath Rate Device;;ACTIVE;1.0i;2.29 +10326-7;Vendor serial number;ID;Pt;Breath rate device;Nom;;RESP.ATOM;2;Breath rate device Vendor serial number;Serial # Breath Rate Device;;ACTIVE;1.0i;2.29 +10327-5;Eosinophils/100 leukocytes;NFr;Pt;Sputum;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Sputum by Manual count;Eosinophil/leuk NFr Spt Manual;;ACTIVE;1.0i;2.73 +10328-3;Lymphocytes/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Cerebral spinal fluid by Manual count;Lymphocytes/leuk NFr CSF Manual;;ACTIVE;1.0i;2.73 +10329-1;Monocytes/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Cerebral spinal fluid by Manual count;Monocytes/leuk NFr CSF Manual;;ACTIVE;1.0i;2.73 +1033-0;F little y super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Fy sup(b) Ag [Presence] on Red Blood Cells;Fy sup(b) Ag RBC Ql;;ACTIVE;1.0;2.73 +10330-9;Monocytes/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Body fluid by Manual count;Monocytes/leuk NFr Fld Manual;;ACTIVE;1.0i;2.73 +10331-7;Rh;Type;Pt;Bld;Nom;;BLDBK;1;Rh [Type] in Blood;Rh Bld;;ACTIVE;1.0i;2.73 +10332-5;Cortisol^pre 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM;Cortis pre 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0i;2.73 +10333-3;Appearance;Aper;Pt;CSF;Nom;;SPEC;1;Appearance of Cerebral spinal fluid;Appearance CSF;;ACTIVE;1.0i;2.73 +10334-1;Cancer Ag 125;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag 125 [Units/volume] in Serum or Plasma;Cancer Ag125 SerPl-aCnc;;ACTIVE;1.0i;2.73 +10335-8;Color;Type;Pt;CSF;Nom;;SPEC;1;Color of Cerebral spinal fluid;Color CSF;;ACTIVE;1.0i;2.73 +10336-6;Gonadotropin peptide;MCnc;Pt;Urine;Qn;;CHEM;1;Gonadotropin peptide [Mass/volume] in Urine;GP Ur-mCnc;;ACTIVE;1.0i;2.34 +10337-4;Procollagen type I;MCnc;Pt;Ser;Qn;;CHEM;1;Procollagen type I [Mass/volume] in Serum;Procollagen I Ser-mCnc;;ACTIVE;1.0i;2.73 +10338-2;Barbiturates;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Barbiturates [Mass/volume] in Serum or Plasma;Barbiturates SerPl-mCnc;;ACTIVE;1.0i;2.73 +10339-0;Fluoxetine+Norfluoxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;FLUoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma;FLUoxetine+Nor SerPl-mCnc;;ACTIVE;1.0i;2.73 +10340-8;Molindone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Molindone [Mass/volume] in Serum or Plasma;Molindone SerPl-mCnc;;ACTIVE;1.0i;2.73 +10341-6;Norpropoxyphene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/volume] in Serum or Plasma;Norpropoxyph SerPl-mCnc;;ACTIVE;1.0i;2.73 +10342-4;Sulfamethoxazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfamethoxazole [Mass/volume] in Serum or Plasma;Sulfamethoxazole SerPl-mCnc;;ACTIVE;1.0i;2.73 +10343-2;Temazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Serum or Plasma;Temazepam SerPl-mCnc;;ACTIVE;1.0i;2.73 +10344-0;Tranylcypromine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tranylcypromine [Mass/volume] in Serum or Plasma;Tranylcypromine SerPl-mCnc;;ACTIVE;1.0i;2.73 +10345-7;Trihexyphenidyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trihexyphenidyl [Mass/volume] in Urine;Trihexyphenidyl Ur-mCnc;;ACTIVE;1.0i;2.73 +10346-5;Hemoglobin A;ACnc;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A [Units/volume] in Blood by Electrophoresis;Hgb A Bld Elph-aCnc;;ACTIVE;1.0i;2.73 +10347-3;Babesia microti identified;Prid;Pt;Bld;Nom;Microscopy.light;MICRO;1;Babesia microti identified in Blood by Light microscopy;B microti Bld Smear;;ACTIVE;1.0i;2.73 +1034-8;Fetal cell screen;Imp;Pt;Bld;Nom;;BLDBK;1;Fetal cell screen [Interpretation] in Blood;Fetal Cell Scn Bld-Imp;;ACTIVE;1.0;2.73 +10348-1;Bordetella parapertussis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella parapertussis Ab [Presence] in Serum;B parapert Ab Ser Ql;;ACTIVE;1.0i;2.56 +10349-9;Brucella sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella sp Ab [Units/volume] in Serum;Brucella Ab Ser-aCnc;;ACTIVE;1.0i;2.73 +10350-7;Herpes simplex virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus IgM Ab [Titer] in Serum by Immunoassay;HSV IgM Titr Ser IA;;ACTIVE;1.0i;2.73 +10351-5;HIV 1 RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp;MICRO;1;HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification;HIV1 RNA SerPl Probe amp-aCnc;;ACTIVE;1.0i;2.73 +10352-3;Bacteria identified;Prid;Pt;Genital;Nom;Aerobic culture;MICRO;1;Bacteria identified in Genital specimen by Aerobe culture;Bacteria Genital Aerobe Cult;;ACTIVE;1.0i;2.73 +10353-1;Bacteria identified;Prid;Pt;Nose;Nom;Aerobic culture;MICRO;1;Bacteria identified in Nose by Aerobe culture;Bacteria Nose Aerobe Cult;;ACTIVE;1.0i;2.73 +10354-9;Bacteria identified;Prid;Pt;Urethra;Nom;Culture;MICRO;1;Bacteria identified in Urethra by Culture;Bacteria Urth Cult;;ACTIVE;1.0i;2.73 +1035-5;Fresh frozen plasma given;Vol;Pt;Dose;Qn;;BLDBK;1;Fresh frozen plasma given [Volume];FFP Gvn Vol Dose;;ACTIVE;1.0;2.73 +10355-6;Microscopic observation;Prid;Pt;Bone mar;Nom;Wright Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Bone marrow by Wright Giemsa stain;Wright Gie Stn Mar;;ACTIVE;1.0i;2.73 +10356-4;Microscopic observation;Prid;Pt;Stool;Nom;Trichrome stain;MICRO;1;Deprecated Microscopic observation [Identifier] in Stool by Trichrome stain;Deprecated Tri Stn Stl;;DEPRECATED;1.0i;2.36 +10357-2;Microscopic observation;Prid;Pt;Wound;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Wound by Gram stain;Gram Stn Wnd;;ACTIVE;1.0i;2.73 +10358-0;Teichoate Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Teichoate Ab [Titer] in Serum by Immune diffusion (ID);Teichoate Ab Titr Ser ID;;ACTIVE;1.0i;2.73 +10359-8;Asialoganglioside GM1 Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Asialoganglioside GM1 IgM Ab [Titer] in Serum;GM1 Asialo IgM Titr Ser;;ACTIVE;1.0i;2.73 +10360-6;DNA single strand Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;DNA single strand IgG Ab [Units/volume] in Serum;ssDNA IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +10361-4;DNA single strand Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;DNA single strand IgM Ab [Units/volume] in Serum;ssDNA IgM Ser-aCnc;;ACTIVE;1.0i;2.68 +10362-2;Endomysium Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Endomysium IgA Ab [Presence] in Serum;Endomysium IgA Ser Ql;;ACTIVE;1.0i;2.73 +1036-3;G Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;G Ab [Presence] in Serum or Plasma from Blood product unit;G Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10363-0;Barbiturates;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Specimen;Barbiturates Spec Ql;;ACTIVE;1.0i;2.73 +10364-8;Cotinine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cotinine [Mass/mass] in Hair;Cotinine Hair-mCnt;;ACTIVE;1.0i;2.42 +10365-5;Cotinine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cotinine [Mass/volume] in Serum or Plasma;Cotinine SerPl-mCnc;;ACTIVE;1.0i;2.73 +10366-3;Cotinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cotinine [Mass/volume] in Urine;Cotinine Ur-mCnc;;ACTIVE;1.0i;2.73 +10367-1;Ethanol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Gastric fluid;Ethanol Gast-mCnc;;ACTIVE;1.0i;2.34 +10368-9;Lead;MCnc;Pt;BldC;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Capillary blood;Lead BldC-mCnc;;ACTIVE;1.0i;2.73 +10369-7;Opiates;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Opiates [Mass/mass] in Hair;Opiates Hair-mCnt;;ACTIVE;1.0i;2.73 +10370-5;Phencyclidine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Phencyclidine [Mass/mass] in Hair;PCP Hair-mCnt;;ACTIVE;1.0i;2.73 +1037-1;G Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;G Ab [Presence] in Serum or Plasma from Donor;G Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10371-3;Bite cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Bite cells [Presence] in Blood by Light microscopy;Bite cells Bld Ql Smear;;ACTIVE;1.0i;2.73 +10372-1;Blister cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Blister cells [Presence] in Blood by Light microscopy;Blister Cells Bld Ql Smear;;ACTIVE;1.0i;2.73 +10373-9;Fragments;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Fragments [Presence] in Blood by Light microscopy;Fragments Bld Ql Smear;;ACTIVE;1.0i;2.73 +10374-7;Helmet cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Helmet cells [Presence] in Blood by Light microscopy;Helmet Cells Bld Ql Smear;;ACTIVE;1.0i;2.73 +10375-4;Irregularly contracted cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Irregularly contracted cells [Presence] in Blood by Light microscopy;Irreg Cont Cells Bld Ql Smear;;ACTIVE;1.0i;2.56 +10376-2;Macrocytes.oval;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Oval macrocytes [Presence] in Blood by Light microscopy;Macrocytes Oval Bld Ql Smear;;ACTIVE;1.0i;2.73 +10377-0;Pencil cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Pencil cells [Presence] in Blood by Light microscopy;Pencil Cells Bld Ql Smear;;ACTIVE;1.0i;2.56 +10378-8;Polychromasia;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Polychromasia [Presence] in Blood by Light microscopy;Polychromasia Bld Ql Smear;;ACTIVE;1.0i;2.73 +10379-6;Erythrocytes.dual population;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Erythrocytes.dual population [Presence] in Blood by Light microscopy;RBC Dual Pop Bld Ql Smear;;ACTIVE;1.0i;2.73 +10380-4;Stomatocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Stomatocytes [Presence] in Blood by Light microscopy;Stomatocytes Bld Ql Smear;;ACTIVE;1.0i;2.73 +10381-2;Target cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Target cells [Presence] in Blood by Light microscopy;Targets Bld Ql Smear;;ACTIVE;1.0i;2.73 +10382-0;A,B variant NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated A,B variant NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated A,B Var NOS Ag RBC BPU Ql;;DEPRECATED;1.0i;2.65 +10383-8;A,B variant NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated A,B variant NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated A,B Var NOS Ag RBC Donr Ql;;DEPRECATED;1.0i;2.65 +10384-6;A,B variant NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated A,B variant NOS Ag [Presence] on Red Blood Cells;Deprecated A,B Var NOS Ag RBC Ql;;DEPRECATED;1.0i;2.65 +10385-3;Albumin concentration given;Type;Pt;^Patient;Qn;;BLDBK;1;Albumin concentration given;Albumin Conc Gvn;;ACTIVE;1.0i;2.73 +10386-1;Albumin given;Vol;Pt;^Patient;Qn;;BLDBK;1;Albumin given [Volume];Albumin Gvn Vol;;ACTIVE;1.0i;2.73 +10387-9;Autologous erythrocytes given;Vol;Pt;^Patient;Qn;;BLDBK;1;Autologous erythrocytes given [Volume];Autol RBC Gvn Vol;;ACTIVE;1.0i;2.26 +10388-7;Autologous whole blood given;Vol;Pt;^Patient;Qn;;BLDBK;1;Autologous whole blood given [Volume];Autol Bld Gvn Vol;;ACTIVE;1.0i;2.42 +1038-9;G Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;G Ab [Presence] in Serum or Plasma;G Ab SerPl Ql;;ACTIVE;1.0;2.56 +10389-5;Blood product.other;Type;Pt;^BPU;Nom;;BLDBK;1;Blood product.other [Type];Other Bld Prod BPU;;ACTIVE;1.0i;2.73 +10390-3;Blood product special preparation;Type;Pt;^BPU;Nom;;BLDBK;1;Blood product special preparation [Type];Bld Prod Special Prep BPU;;ACTIVE;1.0i;2.73 +10391-1;Cytomegalovirus immune globulin given;Vol;Pt;^Patient;Qn;;BLDBK;1;Cytomegalovirus immune globulin given [Volume];CMV Ig Gvn Vol;;ACTIVE;1.0i;2.42 +10392-9;Cryoprecipitate given;Vol;Pt;^Patient;Qn;;BLDBK;1;Cryoprecipitate given [Volume];Cryoppt Gvn Vol;;ACTIVE;1.0i;2.42 +10393-7;Factor IX given;Type;Pt;^Patient;Nom;;BLDBK;1;Factor IX given [Type];Fact IX Gvn;;ACTIVE;1.0i;2.26 +10394-5;Factor IX given;Vol;Pt;^Patient;Qn;;BLDBK;1;Factor IX given [Volume];Fact IX Gvn Vol;;ACTIVE;1.0i;2.26 +10395-2;Factor VIII given;Type;Pt;^Patient;Nom;;BLDBK;1;Factor VIII given [Type];Fact VIII Gvn;;ACTIVE;1.0i;2.26 +10396-0;Factor VIII given;Vol;Pt;^Patient;Qn;;BLDBK;1;Factor VIII given [Volume];Fact VIII Gvn Vol;;ACTIVE;1.0i;2.26 +1039-7;G Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;G Ag [Presence] on Red Blood Cells from Blood product unit;G Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10397-8;Hepatitis B virus immune globulin given;Vol;Pt;^Patient;Qn;;BLDBK;1;Hepatitis B immune globulin given [Volume];HBV Ig Gvn Vol;;ACTIVE;1.0i;2.42 +10398-6;I Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;I Ag [Presence] on Red Blood Cells from Blood product unit;I Ag RBC BPU Ql;;ACTIVE;1.0i;2.56 +10399-4;I Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;I Ag [Presence] on Red Blood Cells from Donor;I Ag RBC Donr Ql;;ACTIVE;1.0i;2.56 +104-0;Ceforanide;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceforanide [Susceptibility] by Minimum inhibitory concentration (MIC);Ceforanide Islt MIC;;ACTIVE;1.0;2.19 +10400-0;I Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;I Ag [Presence] on Red Blood Cells;I Ag RBC Ql;;ACTIVE;1.0i;2.56 +10401-8;Immune serum globulin given;Type;Pt;^Patient;Nom;;BLDBK;1;Immune serum globulin given [Type];ISG Gvn;;ACTIVE;1.0i;2.27 +10402-6;Immune serum globulin given;Vol;Pt;^Patient;Qn;;BLDBK;1;Immune serum globulin given [Volume];ISG Gvn Vol;;ACTIVE;1.0i;2.42 +10403-4;Inject immune serum globulin;Vol;Pt;^Patient;Qn;;BLDBK;1;Inject immune serum globulin [Volume];Inject Serum Ig Vol Patient;;ACTIVE;1.0i;2.42 +10404-2;Inject Rh immune globulin;Vol;Pt;^Patient;Qn;;BLDBK;1;Inject Rh immune globulin [Volume];Inject Rh Ig Vol Patient;;ACTIVE;1.0i;2.73 +1040-5;G Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;G Ag [Presence] on Red Blood Cells from Donor;G Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10405-9;Inject varicella zoster virus immune globulin;Vol;Pt;^Patient;Qn;;BLDBK;1;Inject varicella zoster virus immune globulin [Volume];Inject VZIg Vol Patient;;ACTIVE;1.0i;2.42 +10406-7;little i Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little i Ag [Presence] on Red Blood Cells from Blood product unit;little i Ag RBC BPU Ql;;ACTIVE;1.0i;2.56 +10407-5;little i Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little i Ag [Presence] on Red Blood Cells from Donor;little i Ag RBC Donr Ql;;ACTIVE;1.0i;2.56 +10408-3;little i Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;little i Ag [Presence] on Red Blood Cells;little i Ag RBC Ql;;ACTIVE;1.0i;2.56 +10409-1;Pentaspan given;Vol;Pt;^Patient;Qn;;BLDBK;1;Pentaspan given [Volume];Pentaspan Gvn Vol;;ACTIVE;1.0i;2.42 +10410-9;Plasma given;Type;Pt;^Patient;Nom;;BLDBK;1;Plasma given [Type];Plasma Gvn;;ACTIVE;1.0i;2.26 +10411-7;Plasma given;Vol;Pt;^Patient;Qn;;BLDBK;1;Plasma given [Volume];Plasma Gvn Vol;;ACTIVE;1.0i;2.42 +10412-5;Platelets given;Type;Pt;^Patient;Nom;;BLDBK;1;Platelets given [Type];Platelet Gvn;;ACTIVE;1.0i;2.73 +1041-3;G Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;G Ag [Presence] on Red Blood Cells;G Ag RBC Ql;;ACTIVE;1.0;2.56 +10413-3;Rh immune globulin given;Vol;Pt;^Patient;Qn;;BLDBK;1;Rh immune globulin given [Volume];Rh Ig Gvn Vol;;ACTIVE;1.0i;2.73 +10414-1;Transfuse albumin;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse albumin [Volume];Trans Albumin Vol Patient;;ACTIVE;1.0i;2.42 +10415-8;Transfuse blood exchange transfusion;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse blood exchange transfusion [Volume];Transf Bld Xchange Vol Patient;;ACTIVE;1.0i;2.42 +10416-6;Transfuse blood product.other;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse blood product other [Volume];Trans Other Prod Vol Patient;;ACTIVE;1.0i;2.42 +10417-4;Transfuse cryoprecipitate;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse cryoprecipitate [Volume];Trans Cryoppt Vol Patient;;ACTIVE;1.0i;2.42 +10418-2;Transfuse factor IX;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse factor IX [Volume];Trans Fact IX Vol Patient;;ACTIVE;1.0i;2.42 +10419-0;Transfuse factor VIII;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse factor VIII [Volume];Trans Fact VIII Vol Patient;;ACTIVE;1.0i;2.42 +10420-8;Transfuse immune serum globulin;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse immune serum globulin [Volume];Trans Serum Ig Vol Patient;;ACTIVE;1.0i;2.42 +1042-1;H Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;H Ab [Presence] in Serum or Plasma from Blood product unit;H Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10421-6;Transfuse Pentaspan;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse Pentaspan [Volume];Trans Pentaspan Vol Patient;;ACTIVE;1.0i;2.42 +10422-4;Transfuse plasma;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse plasma [Volume];Trans Plasma Vol Patient;;ACTIVE;1.0i;2.42 +10423-2;Transfuse platelets;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse platelets [Volume];Trans Platelets Vol Patient;;ACTIVE;1.0i;2.73 +10424-0;Transfuse erythrocytes;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse erythrocytes [Volume];Trans Erythrocytes Vol Patient;;ACTIVE;1.0i;2.42 +10425-7;Transfuse Rh immune globulin;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse Rh immune globulin [Volume];Trans Rhogam Vol Patient;;ACTIVE;1.0i;2.73 +10426-5;Transfuse whole blood;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse whole blood [Volume];Trans Whole Bld Vol Patient;;ACTIVE;1.0i;2.42 +10427-3;Transfuse whole blood autologous;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse whole blood autologous [Volume];Trans Bld Autol Vol Patient;;ACTIVE;1.0i;2.21 +10428-1;Varicella zoster virus immune globulin given;Vol;Pt;^Patient;Qn;;BLDBK;1;Varicella zoster virus immune globulin given [Volume];VZIg Gvn Vol;;ACTIVE;1.0i;2.42 +10429-9;AE 1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;AE 1 Ag [Presence] in Tissue by Immune stain;AE1 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10430-7;AE 3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;AE 3 Ag [Presence] in Tissue by Immune stain;AE3 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10431-5;B-cell Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;B-cell Ag [Presence] in Tissue by Immune stain;B Cell Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10432-3;CD30 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD30 Ag [Presence] in Tissue by Immune stain;CD30 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10433-1;BR-2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;BR-2 Ag [Presence] in Tissue by Immune stain;BR2 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10434-9;Complement C3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;Complement C3 Ag [Presence] in Tissue by Immune stain;C3 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10435-6;C5B-9 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;C5B-9 Ag [Presence] in Tissue by Immune stain;C5B9 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10436-4;CD15 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD15 Ag [Presence] in Tissue by Immune stain;CD15 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10437-2;CD16 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD16 Ag [Presence] in Tissue by Immune stain;CD16 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10438-0;CD20 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD20 Ag [Presence] in Tissue by Immune stain;CD20 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1043-9;H Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;H Ab [Presence] in Serum or Plasma from Donor;H Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10439-8;CD3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD3 Ag [Presence] in Tissue by Immune stain;CD3 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10440-6;CD30 Ag;ACnc;Pt;Tiss;Ord;Immune stain;CELLMARK;1;Deprecated CD30 Ag [Presence] in Tissue by Immune stain;Deprecated CD30 Ag Tiss Ql ImStn;;DEPRECATED;1.0i;2.36 +10441-4;CD34 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD34 Ag [Presence] in Tissue by Immune stain;CD34 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10442-2;CD56 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD56 Ag [Presence] in Tissue by Immune stain;CD56 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10443-0;CD43.T-Cell monocyte+Myeloid cell Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD43 T-cell monocyte+myeloid cell Ag [Presence] in Tissue by Immune stain;CD43 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10444-8;CD57 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD57 Ag [Presence] in Tissue by Immune stain;CD57 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10445-5;CD11c Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD11c Ag [Presence] in Tissue by Immune stain;CD11c Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10446-3;Leukocyte common Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;Leukocyte common Ag [Presence] in Tissue by Immune stain;LCA Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1044-7;H Ab;PrThr;Pt;Ser;Ord;;BLDBK;1;H Ab [Presence] in Serum;H Ab Ser Ql;;ACTIVE;1.0;2.56 +10447-1;M-5 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;M-5 Ag [Presence] in Tissue by Immune stain;M5 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10448-9;T-cell Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;T-cell Ag [Presence] in Tissue by Immune stain;T cell Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10449-7;Glucose^1H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post meal;Glucose 1h p meal SerPl-mCnc;;ACTIVE;1.0i;2.73 +10450-5;Glucose^post 10H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 hours fasting;Glucose p 10h fast SerPl-mCnc;;ACTIVE;1.0i;2.73 +10451-3;Proinsulin^post 12H CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --12 hours fasting;Proinsulin p 12h fast SerPl-sCnc;;ACTIVE;1.0i;2.73 +10452-1;Xylose^1H post 25 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --1 hour post 25 g xylose PO;Xylose 1h p 25 g Xyl PO SerPl-mCnc;;ACTIVE;1.0i;2.73 +10453-9;Xylose^1H post dose xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --1 hour post dose xylose PO;Xylose 1h p Xyl PO SerPl-mCnc;;ACTIVE;1.0i;2.40 +1045-4;H NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated H NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated H NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +10454-7;Xylose^2H post 25 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --2 hours post 25 g xylose PO;Xylose 2h p 25 g Xyl PO SerPl-mCnc;;ACTIVE;1.0i;2.73 +10455-4;Xylose^30M post 25 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --30 minutes post 25 g xylose PO;Xylose 30M p 25 g Xyl PO SerPl-mCnc;;ACTIVE;1.0i;2.40 +10456-2;Xylose^post 6H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --6 hours fasting;Xylose p 6h fast SerPl-mCnc;;ACTIVE;1.0i;2.40 +10457-0;Actin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Actin Ag [Presence] in Tissue by Immune stain;Actin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10458-8;Alkaline phosphatase.placental Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alkaline phosphatase.placental Ag [Presence] in Tissue by Immune stain;ALP Plac Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10459-6;Alpha-1-Fetoprotein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alpha-1-Fetoprotein Ag [Presence] in Tissue by Immune stain;AFP Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10460-4;Lactalbumin alpha Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Lactalbumin alpha Ag [Presence] in Tissue by Immune stain;A-Lactalb Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10461-2;Alpha-1-Antichymotrypsin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alpha-1-Antichymotrypsin Ag [Presence] in Tissue by Immune stain;A1ACT Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1046-2;H NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated H NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated H NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +10462-0;Alpha 1 antitrypsin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alpha 1 antitrypsin Ag [Presence] in Tissue by Immune stain;A1AT Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10463-8;Amyloid A component Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Amyloid A component Ag [Presence] in Tissue by Immune stain;ALA Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10464-6;Amyloid P component Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Amyloid P component Ag [Presence] in Tissue by Immune stain;ALP Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10465-3;Amyloid.prealbumin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Amyloid.prealbumin Ag [Presence] in Tissue by Immune stain;AL Prealb Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10466-1;Anion gap 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Anion gap 3 in Serum or Plasma;Anion Gap3 SerPl-sCnc;;ACTIVE;1.0i;2.73 +10467-9;Beta-2-Microglobulin amyloid Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Beta-2-Microglobulin amyloid Ag [Presence] in Tissue by Immune stain;B2MG AL Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10468-7;Calcitonin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Calcitonin Ag [Presence] in Tissue by Immune stain;Calcit Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10469-5;Carcinoembryonic Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Carcinoembryonic Ag [Presence] in Tissue by Immune stain;CEA Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1047-0;H NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated H NOS Ab [Presence] in Serum or Plasma;Deprecated H NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +10470-3;Choriogonadotropin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Choriogonadotropin Ag [Presence] in Tissue by Immune stain;HCG Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10471-1;Chromogranin A Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Chromogranin A Ag [Presence] in Tissue by Immune stain;CgA Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10472-9;Chromogranin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Chromogranin Ag [Presence] in Tissue by Immune stain;Cg Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10473-7;Chymotrypsin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Chymotrypsin Ag [Presence] in Tissue by Immune stain;Chymotryp Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10474-5;Collagen type 4 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Collagen type 4 Ag [Presence] in Tissue by Immune stain;Collagen4 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10475-2;Corticotropin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Corticotropin Ag [Presence] in Tissue by Immune stain;ACTH Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10476-0;Desmin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Desmin Ag [Presence] in Tissue by Immune stain;Desmin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10477-8;Enolase.neuron specific Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Enolase.neuron specific Ag [Presence] in Tissue by Immune stain;NSE Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10478-6;Eosinophil major basic protein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Eosinophil major basic protein Ag [Presence] in Tissue by Immune stain;EMBP Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10479-4;CD227 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD227 Ag [Presence] in Tissue by Immune stain;CD227 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10480-2;Estrogen+Progesterone receptor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Estrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain;ERA+PGRA Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10481-0;Follitropin.alpha subunit Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Follitropin.alpha subunit Ag [Presence] in Tissue by Immune stain;A-FSH Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10482-8;Follitropin.beta subunit Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Follitropin.beta subunit Ag [Presence] in Tissue by Immune stain;B-FSH Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10483-6;Gastrin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Gastrin Ag [Presence] in Tissue by Immune stain;Gastrin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10484-4;Glial fibrillary acidic protein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Glial fibrillary acidic protein Ag [Presence] in Tissue by Immune stain;GFAP Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10485-1;Glucagon Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Glucagon Ag [Presence] in Tissue by Immune stain;Glucagon Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10486-9;Hemoglobin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Hemoglobin Ag [Presence] in Tissue by Immune stain;Hgb Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10487-7;HMB-45 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;HMB-45 Ag [Presence] in Tissue by Immune stain;HMB45 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1048-8;H NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated H NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated H NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +10488-5;IgA Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgA Ag [Presence] in Tissue by Immune stain;IgA Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10489-3;IgA.heavy chain Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgA.heavy chain Ag [Presence] in Tissue by Immune stain;IgA HC Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10490-1;IgE Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgE Ag [Presence] in Tissue by Immune stain;IgE Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10491-9;IgG Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgG Ag [Presence] in Tissue by Immune stain;IgG Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10492-7;IgG.heavy chain Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgG.heavy chain Ag [Presence] in Tissue by Immune stain;IgG HC Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10493-5;IgM Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgM Ag [Presence] in Tissue by Immune stain;IgM Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10494-3;IgM.heavy chain Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgM.heavy chain Ag [Presence] in Tissue by Immune stain;IgM HC Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10495-0;Insulin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Insulin Ag [Presence] in Tissue by Immune stain;Insulin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1049-6;H NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated H NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated H NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +10496-8;Immunoglobulin light chains.kappa Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Kappa light chains Ag [Presence] in Tissue by Immune stain;Kappa LC Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10497-6;Immunoglobulin light chains.kappa amyloid Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Immunoglobulin light chains.kappa amyloid Ag [Presence] in Tissue by Immune stain;Kappa AL Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10498-4;Keratin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Keratin Ag [Presence] in Tissue by Immune stain;Keratin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10499-2;Immunoglobulin light chains.lambda Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Lambda light chains Ag [Presence] in Tissue by Immune stain;Lambda LC Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10500-7;Immunoglobulin light chains.lambda amyloid Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Immunoglobulin light chains.lambda amyloid Ag [Presence] in Tissue by Immune stain;Lambda AL Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10501-5;Lutropin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin [Units/volume] in Serum or Plasma;LH SerPl-aCnc;;ACTIVE;1.0i;2.73 +10502-3;Lutropin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Lutropin Ag [Presence] in Tissue by Immune stain;LH Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10503-1;Lysozyme Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Lysozyme Ag [Presence] in Tissue by Immune stain;Lysozyme Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1050-4;H NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated H NOS Ag [Presence] on Red Blood Cells;Deprecated H NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +10504-9;Myelin basic protein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Myelin basic protein Ag [Presence] in Tissue by Immune stain;MBP Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10505-6;Myoglobin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Myoglobin Ag [Presence] in Tissue by Immune stain;Myoglobin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10506-4;Peanut agglutinin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Peanut agglutinin Ag [Presence] in Tissue by Immune stain;PNA Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10507-2;Prolactin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Prolactin Ag [Presence] in Tissue by Immune stain;Prolactin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10508-0;Prostate specific Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Prostate specific Ag [Presence] in Tissue by Immune stain;PSA Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10509-8;Acid phosphatase.prostatic Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Prostatic acid phosphatase Ag [Presence] in Tissue by Immune stain;PACP Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10510-6;S-100 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;S-100 Ag [Presence] in Tissue by Immune stain;S100 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10511-4;Serotonin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Serotonin Ag [Presence] in Tissue by Immune stain;Serotonin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +1051-2;Hemolytic disease of newborn screen;Imp;Pt;Bld;Nom;;BLDBK;1;Hemolytic disease of newborn screen [Interpretation] in Blood;HDNB Scn Bld-Imp;;ACTIVE;1.0;2.73 +10512-2;Somatostatin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Somatostatin Ag [Presence] in Tissue by Immune stain;Somatostat Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10513-0;Somatotropin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Somatotropin Ag [Presence] in Tissue by Immune stain;GH Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10514-8;Synaptophysin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Synaptophysin Ag [Presence] in Tissue by Immune stain;Synaptophys Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10515-5;Thyroglobulin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Thyroglobulin Ag [Presence] in Tissue by Immune stain;Thyroglob Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10516-3;Thyrotropin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Thyrotropin Ag [Presence] in Tissue by Immune stain;TSH Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10517-1;Trypsin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Trypsin Ag [Presence] in Tissue by Immune stain;Trypsin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10518-9;Ulex europaeus I lectin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Ulex europaeus I lectin Ag [Presence] in Tissue by Immune stain;UEA1 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10519-7;Vimentin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Vimentin Ag [Presence] in Tissue by Immune stain;Vimentin Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1052-0;I (int) subtype;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated I (intermediate) subtype [Presence] in Serum or Plasma from Blood product unit;Deprecated I (Int) Subtyp SerPl BPU Ql;;DEPRECATED;1.0;2.40 +10520-5;Coagulation factor VI Ag;PrThr;Pt;Tiss;Ord;Immune stain;COAG;1;Coagulation factor VI Ag [Presence] in Tissue by Immune stain;Fact VI Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10521-3;Coagulation factor VIII Ag;PrThr;Pt;Tiss;Ord;Immune stain;COAG;1;Coagulation factor VIII Ag [Presence] in Tissue by Immune stain;Fact VIII Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10522-1;Coagulation factor XIII Ag;PrThr;Pt;Tiss;Ord;Immune stain;COAG;1;Coagulation factor XIII Ag [Presence] in Tissue by Immune stain;Fact XIII Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10523-9;Fibrinogen Ag;PrThr;Pt;Tiss;Ord;Immune stain;COAG;1;Fibrinogen Ag [Presence] in Tissue by Immune stain;Fibrinogen Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10524-7;Microscopic observation;Prid;Pt;Cvx;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Cervix by Cyto stain;Cyto Cvx;;ACTIVE;1.0i;2.73 +10525-4;Microscopic observation;Prid;Pt;XXX;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Specimen by Cyto stain;Cyto Spec;;ACTIVE;1.0i;2.73 +10526-2;Microscopic observation;Prid;Pt;Sputum;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Sputum by Cyto stain;Cyto Spt;;ACTIVE;1.0i;2.73 +10527-0;Microscopic observation;Prid;Pt;Tiss;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Tissue by Cyto stain;Cyto Tiss;;ACTIVE;1.0i;2.73 +10528-8;Acetophenazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetophenazine [Mass/volume] in Serum or Plasma;Acetophenazine SerPl-mCnc;;ACTIVE;1.0i;2.73 +10529-6;Amoxapine metabolite;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amoxapine metabolite [Mass/volume] in Serum or Plasma;Amoxapine Metab SerPl-mCnc;;ACTIVE;1.0i;2.42 +10530-4;Aprobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aprobarbital [Mass/volume] in Serum or Plasma;Aprobarbital SerPl-mCnc;;ACTIVE;1.0i;2.42 +10531-2;Bretylium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bretylium [Mass/volume] in Serum or Plasma;Bretylium SerPl-mCnc;;ACTIVE;1.0i;2.73 +10532-0;Noramiodarone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Desethylamiodarone [Mass/volume] in Serum or Plasma;Deprecated Noramiodarone SerPl-mCnc;;DEPRECATED;1.0i;2.36 +10533-8;Propoxyphene+Acetaminophen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propoxyphene+Acetaminophen [Mass/volume] in Serum or Plasma;Propoxyph+APAP SerPl-mCnc;;ACTIVE;1.0i;2.44 +10534-6;Diazoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diazoxide [Mass/volume] in Serum or Plasma;Diazoxide SerPl-mCnc;;ACTIVE;1.0i;2.42 +10535-3;Digoxin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digoxin [Mass/volume] in Serum or Plasma;Digoxin SerPl-mCnc;;ACTIVE;1.0i;2.73 +10536-1;Dipyridamole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dipyridamole [Mass/volume] in Serum or Plasma;Dipyridamole SerPl-mCnc;;ACTIVE;1.0i;2.73 +10537-9;Doxepin+Nordoxepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Doxepin+Nordoxepin [Mass/volume] in Serum or Plasma;Deprecated Doxepin+Nor SerPl-mCnc;;DEPRECATED;1.0i;2.36 +1053-8;I (int) subtype;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated I (intermediate) subtype [Presence] in serum or plasma from donor;Deprecated I (Int) Subtyp SerPl Donr Ql;;DEPRECATED;1.0;2.40 +10538-7;Fluoxetine+Norfluoxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Fluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma;Deprecated FLUoxetine+Nor SerPl-mCnc;;DEPRECATED;1.0i;2.36 +10539-5;glipiZIDE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;glipiZIDE [Mass/volume] in Serum or Plasma;glipiZIDE SerPl-mCnc;;ACTIVE;1.0i;2.73 +10540-3;glyBURIDE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;glyBURIDE [Mass/volume] in Serum or Plasma;glyBURIDE SerPl-mCnc;;ACTIVE;1.0i;2.73 +10541-1;Mepivacaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mepivacaine [Mass/volume] in Serum or Plasma;Mepivacaine SerPl-mCnc;;ACTIVE;1.0i;2.42 +10542-9;Metharbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metharbital [Mass/volume] in Serum or Plasma;Metharbital SerPl-mCnc;;ACTIVE;1.0i;2.73 +10543-7;Methsuximide+Normethsuximide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methsuximide+Normethsuximide [Mass/volume] in Serum or Plasma;Methsuximide+Nor SerPl-mCnc;;ACTIVE;1.0i;2.73 +10544-5;Normeperidine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Normeperidine [Presence] in Serum or Plasma;Normeperidine SerPl Ql;;ACTIVE;1.0i;2.73 +10545-2;Normephenytoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normephenytoin [Mass/volume] in Serum or Plasma;Normephenytoin SerPl-mCnc;;ACTIVE;1.0i;2.73 +1054-6;I (int) subtype;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated I (intermediate) subtype [Presence] in srum;Deprecated I (Int) Subtyp Ser Ql;;DEPRECATED;1.0;2.40 +10546-0;Normethsuximide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normethsuximide [Mass/volume] in Serum or Plasma;Normethsuximide SerPl-mCnc;;ACTIVE;1.0i;2.73 +10547-8;Primidone+PHENobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Primidone+PHENobarbital [Mass/volume] in Serum or Plasma;Primidone+Phenobarb SerPl-mCnc;;ACTIVE;1.0i;2.73 +10548-6;Phenytoin.free/Phenytoin.total;MFr;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin Free/Phenytoin.total in Serum or Plasma;Phenytoin Free MFr SerPl;;ACTIVE;1.0i;2.73 +10549-4;Pirmenol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pirmenol [Mass/volume] in Serum or Plasma;Pirmenol SerPl-mCnc;;ACTIVE;1.0i;2.42 +10550-2;Temazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Temazepam [Mass/volume] in Serum or Plasma;Deprecated Temazepam SerPl-mCnc;;DEPRECATED;1.0i;2.36 +10551-0;Triamterene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triamterene [Mass/volume] in Serum or Plasma;Triamterene SerPl-mCnc;;ACTIVE;1.0i;2.40 +10552-8;Tricyclic antidepressants;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tricyclic antidepressants [Mass/volume] in Serum or Plasma;Tricyclics SerPl-mCnc;;ACTIVE;1.0i;2.73 +1055-3;I (int) subtype;ACnc;Pt;RBC^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated I (intermediate) subtype [Presence] on Red Blood Cells from Blood product unit;Deprecated I (Int) Subtyp RBC BPU Ql;;DEPRECATED;1.0;2.36 +10553-6;Acid phosphatase.prostatic;CCnc;Pt;Genital fld;Qn;;CHEM;1;Prostatic acid phosphatase [Enzymatic activity/volume] in Genital fluid;PACP Genital fl-cCnc;;ACTIVE;1.0i;2.70 +10554-4;Acid phosphatase.prostatic;CCnc;Pt;Smpls;Qn;;FERT;1;Deprecated Prostatic acid phosphatase [Enzymatic activity/volume] in Seminal plasma;Deprecated PACP-cCnc;;DEPRECATED;1.0i;2.70 +10555-1;Acrosin;EntCat;Pt;Spermatozoa;Qn;;FERT;1;Acrosin [Entitic Catalytic Activity] in Spermatozoa;Acrosin Sprm Qn;;ACTIVE;1.0i;2.70 +10556-9;Adenosine triphosphatase;CCnc;Pt;Smpls;Qn;;FERT;1;Deprecated Adenosine triphosphatase [Enzymatic activity/volume] in Seminal plasma;Deprecated ATPase-cCnc;;DEPRECATED;1.0i;2.70 +10557-7;Adenosine triphosphate;SCnc;Pt;Semen;Qn;;CHEM;1;Adenosine triphosphate [Moles/volume] in Semen;ATP Smn-sCnc;;ACTIVE;1.0i;2.70 +10558-5;Albumin;SCnc;Pt;Semen;Qn;;CHEM;1;Albumin [Moles/volume] in Semen;Albumin Smn-sCnc;;ACTIVE;1.0i;2.70 +10559-3;Calcium;SCnc;Pt;Smpls;Qn;;FERT;1;Deprecated Calcium [Molecules/volume] in Semen;Deprecated Calcium-sCnc;;DEPRECATED;1.0i;2.70 +10560-1;Carcinoembryonic Ag;ACnc;Pt;Semen;Qn;;CHEM;1;Carcinoembryonic Ag [Units/volume] in Semen;CEA Smn-aCnc;;ACTIVE;1.0i;2.70 +1056-1;I (int) subtype;ACnc;Pt;RBC^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated I (intermediate) subtype [Presence] on Red Blood Cells from donor;Deprecated I (Int) Subtyp RBC Donr Ql;;DEPRECATED;1.0;2.36 +10561-9;Carnitine;SCnc;Pt;Semen;Qn;;CHEM;1;Carnitine [Moles/volume] in Semen;Carnitine Smn-sCnc;;ACTIVE;1.0i;2.70 +10562-7;Cells;NCnc;Pt;Cvm;Qn;;FERT;1;Cells [#/volume] in Cervical mucus;Cells # Cerv mucus;;ACTIVE;1.0i;2.42 +10563-5;Cells other than spermatozoa;NCnc;Pt;Semen;Qn;;FERT;1;Cells other than spermatozoa [#/volume] in Semen;Cells Other # Smn;;ACTIVE;1.0i;2.42 +10564-3;Cervical mucus;Vol;Pt;^Patient;Qn;;FERT;1;Cervical mucus [Volume];Cvx Mucus Vol Patient;;ACTIVE;1.0i;2.70 +10565-0;Choriogonadotropin;ACnc;Pt;Semen;Qn;;CHEM;1;Choriogonadotropin [Units/volume] in Semen;HCG Smn-aCnc;;ACTIVE;1.0i;2.73 +10566-8;Choriogonadotropin;SCnc;Pt;Smpls;Qn;;FERT;1;Deprecated Choriogonadotropin [Molecules/volume] in Semen;Deprecated HCG-sCnc;;DEPRECATED;1.0i;2.70 +10567-6;Citrate;SCnc;Pt;Semen;Qn;;CHEM;1;Citrate [Moles/volume] in Semen;Citrate Smn-sCnc;;ACTIVE;1.0i;2.70 +10568-4;Clarity;Type;Pt;Semen;Nom;;SPEC;1;Clarity of Semen;Clarity Smn;;ACTIVE;1.0i;2.73 +10569-2;Color;Type;Pt;Semen;Nom;;SPEC;1;Color of Semen;Color Smn;;ACTIVE;1.0i;2.73 +105-7;Ceforanide;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceforanide [Susceptibility] by Disk diffusion (KB);Ceforanide Islt KB;;ACTIVE;1.0;2.19 +10570-0;Consistency;PrThr;Pt;Cvm;Ord;;SPEC;1;Consistency of Cervical mucus;Consistency Cerv mucus Ql;;ACTIVE;1.0i;2.56 +10571-8;Consistency;ACnc;Pt;Semen;Ord;;SPEC;1;Deprecated Consistency of Semen;Deprecated Consistency Smn Ql;;DEPRECATED;1.0i;2.54 +10572-6;Duration^post ejaculation;Time;Pt;^Patient;Qn;;FERT;1;Deprecated Duration^post ejaculation;Deprecated Duration p ejac Patient Qn;;DEPRECATED;1.0i;2.70 +10573-4;Ferning;Type;Pt;Cvm;Nom;;FERT;1;Ferning [Type] in Cervical mucus;Ferning Cerv mucus;;ACTIVE;1.0i;2.73 +10574-2;Fructose;SCnc;Pt;Semen;Qn;;CHEM;1;Fructose [Moles/volume] in Semen;Fructose Smn-sCnc;;ACTIVE;1.0i;2.70 +10575-9;Gamma glutamyl transferase;CCnc;Pt;Smpls;Qn;;FERT;1;Deprecated Gamma glutamyl transferase [Enzymatic activity/volume] in Semen;Deprecated GGT-cCnc;;DEPRECATED;1.0i;2.70 +10576-7;Germ cells.immature;NCnc;Pt;Semen;Qn;;FERT;1;Germ cells.immature [#/volume] in Semen;Imm Germ Cells # Smn;;ACTIVE;1.0i;2.73 +10577-5;Glucosidase;CCnc;Pt;Semin plas;Qn;;CHEM;1;Glucosidase [Enzymatic activity/volume] in Seminal plasma;Glucosidase Semin plas-cCnc;;ACTIVE;1.0i;2.70 +10578-3;Glycerophosphocholine;SCnc;Pt;Semin plas;Qn;;CHEM;1;Glycerophosphocholine [Moles/volume] in Seminal plasma;GPC Semin plas-sCnc;;ACTIVE;1.0i;2.70 +1057-9;I (int) subtype;ACnc;Pt;RBC^Patient;Ord;Aggl RBC;BLDBK;1;Deprecated I (intermediate) subtype [Presence] on Red Blood Cells;Deprecated I (Int) Subtyp RBC Patient Ql;;DEPRECATED;1.0;2.36 +10579-1;Leukocytes;NCnc;Pt;Semen;Qn;;FERT;1;Leukocytes [#/volume] in Semen;WBC # Smn;;ACTIVE;1.0i;2.73 +10580-9;Liquefaction;Time;Pt;Semen;Qn;;FERT;1;Liquefaction [Time] in Semen;Liquefaction Time Smn;;ACTIVE;1.0i;2.73 +10581-7;Number of entities;Num;Pt;Spermatozoa;Qn;;FERT;1;Deprecated Number of entities [#] in Spermatozoa;Deprecated # Entities Sprm;;DEPRECATED;1.0i;2.70 +10582-5;pH;LsCnc;Pt;Cvm;Qn;;FERT;1;pH of Cervical mucus;pH Cerv mucus;;ACTIVE;1.0i;2.73 +10583-3;Prostaglandin F1 alpha;SCnc;Pt;Semen;Qn;;CHEM;1;Prostaglandin F1 alpha [Moles/volume] in Semen;Prostaglandin F1A Smn-sCnc;;ACTIVE;1.0i;2.70 +10584-1;Protein;MCnc;Pt;Smpls;Qn;;FERT;1;Deprecated Protein [Mass/volume] in Semen;Deprecated Prot-mCnc;;DEPRECATED;1.0i;2.70 +10585-8;Round cells;NCnc;Pt;Semen;Qn;;FERT;1;Round cells [#/volume] in Semen;Rnd Cells # Smn;;ACTIVE;1.0i;2.73 +10586-6;Semen;Vol;Pt;^Patient;Qn;;FERT;1;Deprecated Volume of Semen;Deprecated Semen Vol Patient;;DEPRECATED;1.0i;2.70 +1058-7;I Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;I Ab [Presence] in Serum or Plasma from Blood product unit;I Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10587-4;Sexual abstinence duration;Time;Pt;^Patient;Qn;;FERT;1;Sexual abstinence duration;Sex Abstin duration Time Patient;;ACTIVE;1.0i;2.73 +10588-2;Spermatogonia;NCnc;Pt;Semen;Qn;;FERT;1;Spermatogonia [#/volume] in Semen;Spermatogonia # Smn;;ACTIVE;1.0i;2.70 +10589-0;Spermatids;NCnc;Pt;Semen;Qn;SAB;FERT;1;Spermatids [#/volume] in Semen by Streptoavidin-biotin method (SAB);Spermatids # Smn SAB;;ACTIVE;1.0i;2.73 +10590-8;Spermatids;NCnc;Pt;Semen;Qn;SCB;FERT;1;Spermatids [#/volume] in Semen by Sertoli cell barrier method (SCB);Spermatids # Smn SCB;;ACTIVE;1.0i;2.70 +10591-6;Spermatocytes.primary;NCnc;Pt;Semen;Qn;;FERT;1;Primary Spermatocytes [#/volume] in Semen;Primary Spermatocytes # Smn;;ACTIVE;1.0i;2.73 +10592-4;Spermatocytes.secondary;NCnc;Pt;Semen;Qn;;FERT;1;Secondary Spermatocytes [#/volume] in Semen;Secondary Spermatocytes # Smn;;ACTIVE;1.0i;2.73 +10593-2;Spermatozoa.pyriform head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Pyriform Head/100 spermatozoa in Semen;Sperm Pyriform Head NFr Smn;;ACTIVE;1.0i;2.70 +10594-0;Spermatozoa.tapering head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Tapering Head/100 spermatozoa in Semen;Sperm Tapering Head NFr Smn;;ACTIVE;1.0i;2.70 +1059-5;I Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;I Ab [Presence] in Serum or Plasma from Donor;I Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10595-7;Spermatozoa;NCnc;Pt;Semen;Qn;;FERT;1;Deprecated Spermatozoa [#/volume] in Semen;Deprecated Sperm # Smn;;DEPRECATED;1.0i;2.70 +10596-5;Spermatozoa Ab;ACnc;Pt;Cvm;OrdQn;;FERT;1;Deprecated Spermatozoa Ab in cervical mucosa;Deprecated Sperm Ab Cerv mucus;;DEPRECATED;1.0i;2.40 +10597-3;Spermatozoa Ab;ACnc;Pt;Semen;OrdQn;;FERT;1;Deprecated Spermatozoa Ab in semen;Deprecated Sperm Ab Smn;;DEPRECATED;1.0i;2.40 +10598-1;Spermatozoa Ab;ACnc;Pt;Ser;OrdQn;;FERT;1;Deprecated Spermatozoa Ab in serum;Deprecated Sperm Ab Ser;;DEPRECATED;1.0i;2.40 +10599-9;Spermatozoa penetration;PrThr;Pt;Semen+Cvm;Ord;Kremer;FERT;1;Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa by Kremer test;Sperm Pen Smn+Cvm Ql Kremer;;ACTIVE;1.0i;2.56 +10600-5;Spermatozoa penetration;PrThr;Pt;Semen+Cvm;Ord;;FERT;1;Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa;Sperm Pen Smn+Cvm Ql;;ACTIVE;1.0i;2.56 +10601-3;Spermatozoa penetration^post coitus;PrThr;Pt;Semen+Cvm;Ord;;FERT;1;Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa --post coitus;Sperm Pen PCT Smn+Cvm Ql;;ACTIVE;1.0i;2.56 +10602-1;Spermatozoa.abnormal head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Abnormal Head/100 spermatozoa in Semen;Sperm Abnorm Head NFr Smn;;ACTIVE;1.0i;2.73 +1060-3;I Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;I Ab [Presence] in Serum or Plasma;I Ab SerPl Ql;;ACTIVE;1.0;2.56 +10603-9;Spermatozoa.abnormal midpiece/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Abnormal Midpiece/100 spermatozoa in Semen;Sperm Abnorm Midpiece NFr Smn;;ACTIVE;1.0i;2.73 +10604-7;Spermatozoa.abnormal tail/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Abnormal Tail/100 spermatozoa in Semen;Sperm Abnorm Tail NFr Smn;;ACTIVE;1.0i;2.73 +10605-4;Spermatozoa.agglutinated/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Agglutinated/100 spermatozoa in Semen;Sperm Agglutinated NFr Smn;;ACTIVE;1.0i;2.73 +10606-2;Spermatozoa.amorphous head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Amorphous Head/100 spermatozoa in Semen;Sperm Amorphous Head NFr Smn;;ACTIVE;1.0i;2.70 +10607-0;Spermatozoa.coiled tail/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Coiled Tail/100 spermatozoa in Semen;Sperm Coiled Tail NFr Smn;;ACTIVE;1.0i;2.70 +10608-8;Spermatozoa.cytoplasmic droplet/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Cytoplasmic Droplet/100 spermatozoa in Semen;Sperm Cytoplasmic Drop NFr Smn;;ACTIVE;1.0i;2.73 +10609-6;Spermatozoa.duplicate head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Duplicate Head/100 spermatozoa in Semen;Sperm Duplicate Head NFr Smn;;ACTIVE;1.0i;2.73 +10610-4;Spermatozoa.duplicate tail/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Duplicate Tail/100 spermatozoa in Semen;Sperm Duplicate Tail NFr Smn;;ACTIVE;1.0i;2.73 +1061-1;I NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated I NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated I NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +10611-2;Spermatozoa.immotile/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Immotile/100 spermatozoa in Semen;Sperm Immotile NFr Smn;;ACTIVE;1.0i;2.73 +10612-0;Spermatozoa.large oval head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Large Oval Head/100 spermatozoa in Semen;Sperm Lg Oval Head NFr Smn;;ACTIVE;1.0i;2.73 +10613-8;Spermatozoa.viable/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Viable/100 spermatozoa in Semen;Sperm Viable NFr Smn;;ACTIVE;1.0i;2.73 +10614-6;Spermatozoa.motile with IgA/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa Motile w IgA/100 spermatozoa in Semen by Immunobead;Sperm Motile w IgA NFr Smn IBT;;ACTIVE;1.0i;2.73 +10615-3;Spermatozoa.motile with IgA/100 spermatozoa;NFr;Pt;Semen;Qn;Mixed antiglobulin reaction;FERT;1;Spermatozoa Motile w IgA/100 spermatozoa in Semen by Mixed antiglobulin reaction;Sperm Motile w IgA NFr Smn MAR;;ACTIVE;1.0i;2.70 +10616-1;Spermatozoa.motile with IgG/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa Motile w IgG/100 spermatozoa in Semen by Immunobead;Sperm Motile w IgG NFr Smn IBT;;ACTIVE;1.0i;2.73 +10617-9;Spermatozoa.motile with IgG/100 spermatozoa;NFr;Pt;Semen;Qn;Mixed antiglobulin reaction;FERT;1;Spermatozoa Motile w IgG/100 spermatozoa in Semen by Mixed antiglobulin reaction;Sperm Motile w IgG NFr Smn MAR;;ACTIVE;1.0i;2.70 +10618-7;Spermatozoa.motile with IgM/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa Motile w IgM/100 spermatozoa in Semen by Immunobead;Sperm Motile w IgM NFr Smn IBT;;ACTIVE;1.0i;2.73 +10619-5;Spermatozoa.motile with IgM/100 spermatozoa;NFr;Pt;Semen;Qn;Mixed antiglobulin reaction;FERT;1;Spermatozoa Motile w IgM/100 spermatozoa in Semen by Mixed antiglobulin reaction;Sperm Motile w IgM NFr Smn MAR;;ACTIVE;1.0i;2.70 +10620-3;Spermatozoa.nonprogressive/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Nonprogressive/100 spermatozoa in Semen;Sperm Nonprog NFr Smn;;ACTIVE;1.0i;2.73 +10621-1;Spermatozoa.normal head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Normal Head/100 spermatozoa in Semen;Sperm Norm Head NFr Smn;;ACTIVE;1.0i;2.70 +10622-9;Spermatozoa.normal/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Normal/100 spermatozoa in Semen;Sperm Norm NFr Smn;;ACTIVE;1.0i;2.73 +10623-7;Spermatozoa.pin head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Pin Head/100 spermatozoa in Semen;Sperm Pin Head NFr Smn;;ACTIVE;1.0i;2.70 +10624-5;Spermatozoa.rapid/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Rapid/100 spermatozoa in Semen;Sperm Rapid NFr Smn;;ACTIVE;1.0i;2.73 +10625-2;Spermatozoa.round head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Round Head/100 spermatozoa in Semen;Sperm Round Head NFr Smn;;ACTIVE;1.0i;2.73 +10626-0;Spermatozoa.slow/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Slow/100 spermatozoa in Semen;Sperm Slow NFr Smn;;ACTIVE;1.0i;2.73 +10627-8;Spermatozoa.small oval head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Small Oval Head/100 spermatozoa in Semen;Sperm Small Oval Head NFr Smn;;ACTIVE;1.0i;2.73 +10628-6;Spermatozoa.tail swelling/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Tail Swelling/100 spermatozoa in Semen;Sperm Tail Swelling NFr Smn;;ACTIVE;1.0i;2.70 +1062-9;I NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated I NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated I NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +10629-4;Spermatozoa.vacuolated head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Vacuolated Head/100 spermatozoa in Semen;Sperm Vacuolated Head NFr Smn;;ACTIVE;1.0i;2.70 +10630-2;Spinnbarkeit;Len;Pt;Cvm;Qn;;FERT;1;Spinnbarkeit [Length] in Cervical mucus;Spinnbarkeit Cerv mucus;;ACTIVE;1.0i;2.70 +10631-0;Testosterone;SCnc;Pt;Semen;Qn;;CHEM;1;Testosterone [Moles/volume] in Semen;Testost Smn-sCnc;;ACTIVE;1.0i;2.70 +10632-8;Time until next menstrual period;Time;Pt;^Patient;Qn;;FERT;1;Time until next menstrual period;Tme til Nxt Menst Patient;;ACTIVE;1.0i;2.70 +10633-6;Zinc;SCnc;Pt;Semen;Qn;;DRUG/TOX;1;Zinc [Moles/volume] in Semen;Zinc Smn-sCnc;;ACTIVE;1.0i;2.70 +10634-4;Complement C1 esterase inhibitor.functional/Complement C1 esterase inhibitor.total;MFr;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor.functional/Complement C1 esterase inhibitor.total in Serum or Plasma;C1INH Functional/C1INH Total MFr SerPl;;ACTIVE;1.0i;2.73 +10635-1;Acanthamoeba sp identified;Prid;Pt;Eye;Nom;Organism specific culture;MICRO;1;Acanthamoeba sp identified in Eye by Organism specific culture;Acanthamoeba Eye Cult;;ACTIVE;1.0i;2.73 +10636-9;Acanthamoeba sp identified;Prid;Pt;Eye;Nom;Wet preparation;MICRO;1;Acanthamoeba sp identified in Eye by Wet preparation;Acanthamoeba Eye Wet Prep;;ACTIVE;1.0i;2.73 +1063-7;I NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated I NOS Ab [Presence] in Serum or Plasma;Deprecated I NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +10637-7;Microscopic observation;Prid;Pt;Tiss;Nom;Night blue stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Night blue stain;Night blue stain Tiss;;ACTIVE;1.0i;2.73 +10638-5;Actinomycetes.thermophilic colony count;NCnc;Pt;XXX;Qn;Organism specific culture;MICRO;1;Thermophilic Actinomycetes colony count [#/volume] in Specimen by Organism specific culture;Therm Actino CC # Spec Cult;;ACTIVE;1.0i;2.69 +10639-3;Actinomycetes.thermophilic identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Thermophilic Actinomycetes identified in Specimen by Organism specific culture;Therm Actino Spec Cult;;ACTIVE;1.0i;2.73 +10640-1;Adenovirus 40+41;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Deprecated Adenovirus 40+41 [Identifier] in Stool by Electron microscopy;Deprecated HAdV40+41 Stl EM;;DEPRECATED;1.0i;2.42 +10641-9;Amoeba identified;Prid;Pt;Asp;Nom;Immune stain;MICRO;1;Amoeba identified in Aspirate by Immune stain;Amoeba Aspirate ImStn;;ACTIVE;1.0i;2.17 +10642-7;Amoeba identified;Prid;Pt;Asp;Nom;Wet preparation;MICRO;1;Amoeba identified in Aspirate by Wet preparation;Amoeba Aspirate Wet Prep;;ACTIVE;1.0i;2.73 +10643-5;Amoeba identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Amoeba identified in Stool by Organism specific culture;Amoeba Stl Cult;;ACTIVE;1.0i;2.19 +10644-3;Arthropod identified;Prid;Pt;XXX;Nom;;MICRO;1;Arthropod identified in Specimen;Insect Spec;;ACTIVE;1.0i;2.73 +1064-5;I NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated I NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated I NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +10645-0;Aspergillus fumigatus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Aspergillus fumigatus Ag [Presence] in Tissue by Immunofluorescence;A fumigatus Ag Tiss Ql IF;;ACTIVE;1.0i;2.56 +10646-8;Astrovirus;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Astrovirus [Identifier] in Stool by Electron microscopy;HAstV Stl EM;;ACTIVE;1.0i;2.19 +10647-6;Babesia sp identified;Prid;Pt;Bld;Nom;Thick film;MICRO;1;Babesia sp identified in Blood by Thick film;Babesia Bld Thick Film;;ACTIVE;1.0i;1.0ma +10648-4;Babesia sp identified;Prid;Pt;Bld;Nom;Thin film;MICRO;1;Babesia sp identified in Blood by Thin film;Babesia Bld Thin Film;;ACTIVE;1.0i;2.73 +10649-2;Calicivirus;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Calicivirus [Identifier] in Stool by Electron microscopy;Calicivirus Stl EM;;ACTIVE;1.0i;2.19 +106-5;Ceforanide;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ceforanide [Susceptibility] by Serum bactericidal titer;Ceforanide Titr SBT;;ACTIVE;1.0;2.32 +10650-0;Candida sp DNA;PrThr;Pt;Bld;Ord;Probe.amp;MICRO;1;Candida sp DNA [Presence] in Blood by Probe with amplification;Candida DNA Bld Ql Probe amp;;ACTIVE;1.0i;2.73 +10651-8;Chlamydophila pneumoniae Ag;PrThr;Pt;Sputum/Bronchial;Ord;;MICRO;1;Chlamydophila pneumoniae Ag [Presence] in Sputum or Bronchial;C pneum Ag Spt/Bro Ql;;ACTIVE;1.0i;2.56 +1065-2;I NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated I NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated I NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +10652-6;Chlamydophila pneumoniae DNA;PrThr;Pt;Sputum/Bronchial;Ord;Probe.amp;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Sputum or Bronchial by Probe with amplification;C pneum DNA Spt/Bro Ql Probe amp;;ACTIVE;1.0i;2.63 +10653-4;Clotrimazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clotrimazole [Susceptibility] by Minimum inhibitory concentration (MIC);Clotrimazole Islt MIC;;ACTIVE;1.0i;2.73 +10654-2;Clotrimazole;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Clotrimazole [Susceptibility] by Minimum lethal concentration (MLC);Clotrimazole Islt MLC;;ACTIVE;1.0i;2.19 +10655-9;Coccidia identified;Prid;Pt;Duod fld;Nom;Acid fast stain;MICRO;1;Coccidia identified in Duodenal fluid by Acid fast stain;Coccidia Duod fl Acid fast Stn;;ACTIVE;1.0i;2.21 +10656-7;Coccidia identified;Prid;Pt;Stool;Nom;Acid fast stain;MICRO;1;Coccidia identified in Stool by Acid fast stain;Coccidia Stl Acid fast Stn;;ACTIVE;1.0i;2.73 +10657-5;Cryptococcus neoformans Ag;ACnc;Pt;Tiss;Ord;IF;MICRO;1;Deprecated Cryptococcus neoformans Ag [Presence] in Tissue by Immunofluorescence;Deprecated C neoform Ag Tiss Ql IF;;DEPRECATED;1.0i;2.56 +10658-3;Cyanobacterium identified;Prid;Pt;Water;Nom;Microscopy.light;MICRO;1;Cyanobacterium identified in Water by Light microscopy;Cyanobacterium Wat Micro;;ACTIVE;1.0i;2.19 +10659-1;Cyclospora sp identified;Prid;Pt;Stool;Nom;Acid fast stain;MICRO;1;Cyclospora sp identified in Stool by Acid fast stain;Cyclospora Stl Acid fast Stn;;ACTIVE;1.0i;2.73 +1066-0;I NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated I NOS Ag [Presence] on Red Blood Cells;Deprecated I NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +10660-9;Cytomegalovirus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Cytomegalovirus Ag [Presence] in Tissue by Immune stain;CMV Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10661-7;Dinoflagellate identified;Prid;Pt;Water;Nom;Microscopy.light;MICRO;1;Dinoflagellate identified in Water by Light microscopy;Dinoflagellate Wat Micro;;ACTIVE;1.0i;2.42 +10662-5;Filaria identified;Prid;Pt;Bld;Nom;Concentration;MICRO;1;Filaria identified in Blood by Concentration;Filaria Bld Conc;;ACTIVE;1.0i;2.21 +10663-3;Filaria identified;Prid;Pt;Bld;Nom;Thick film;MICRO;1;Filaria identified in Blood by Thick film;Filaria Bld Thick Film;;ACTIVE;1.0i;2.21 +10664-1;Filaria identified;Prid;Pt;Bld;Nom;Thin film;MICRO;1;Filaria identified in Blood by Thin film;Filaria Bld Thin Film;;ACTIVE;1.0i;2.21 +10665-8;Fungus colony count;NCnc;Pt;XXX;Qn;Environmental culture;MICRO;1;Fungus colony count [#/volume] in Specimen by Environmental culture;Fungus CC # Spec Envir Cult;;ACTIVE;1.0i;2.69 +10666-6;Fungus identified;Prid;Pt;Tiss;Nom;Fontana-Masson stain;MICRO;1;Fungus identified in Tissue by Fontana-Masson stain;Fungus Tiss FM Stn;;ACTIVE;1.0i;2.22 +10667-4;Fungus identified;Prid;Pt;XXX;Nom;Animal inoculation;MICRO;1;Fungus identified in Specimen by Animal inoculation;Fungus Spec Anim Inoc;;ACTIVE;1.0i;2.69 +10668-2;Fungus identified;Prid;Pt;XXX;Nom;Environmental culture;MICRO;1;Fungus identified in Specimen by Environmental culture;Fungus Spec Envir Cult;;ACTIVE;1.0i;2.73 +10669-0;Fungus identified;Prid;Pt;XXX;Nom;Sticky tape for environmental fungus;MICRO;1;Fungus identified in Specimen by Sticky tape for environmental fungus;Fungus Spec Envir Fungus Tape;;ACTIVE;1.0i;2.69 +10670-8;Giardia lamblia;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Giardia lamblia [Presence] in Stool by Organism specific culture;G lamblia Stl Ql Cult;;ACTIVE;1.0i;2.73 +10671-6;Helminth identified;Prid;Pt;XXX;Nom;;MICRO;1;Helminth identified in Specimen;Worm Spec;;ACTIVE;1.0i;2.69 +10672-4;Helminth+Arthropod identified;Prid;Pt;XXX;Nom;;MICRO;1;Helminth+Arthropod identified in Specimen;Worm+Insect Spec;;ACTIVE;1.0i;2.73 +10673-2;Hepatitis B virus core Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Hepatitis B virus core Ag [Presence] in Tissue by Immune stain;HBV core Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10674-0;Hepatitis B virus surface Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Hepatitis B virus surface Ag [Presence] in Tissue by Immune stain;HBV surface Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10675-7;Hepatitis B virus surface Ag;PrThr;Pt;Tiss;Ord;Orcein stain;MICRO;1;Hepatitis B virus surface Ag [Presence] in Tissue by Orcein stain;HBV surface Ag Tiss Ql Orcein Stn;;ACTIVE;1.0i;2.56 +10676-5;Hepatitis C virus RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification;HCV RNA SerPl Probe amp-aCnc;;ACTIVE;1.0i;2.73 +10677-3;Herpes simplex virus 1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Tissue by Immune stain;HSV1 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +1067-8;J little k super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Jk sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Jk sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10678-1;Herpes simplex virus 1+2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Herpes simplex virus 1+2 Ag [Presence] in Tissue by Immune stain;HSV1+2 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10679-9;Herpes simplex virus 2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Tissue by Immune stain;HSV2 Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.73 +10680-7;Herpes simplex virus identified;Prid;Pt;CSF;Nom;Microscopy.electron;MICRO;1;Herpes simplex virus identified in Cerebral spinal fluid by Electron microscopy;HSV CSF EM;;ACTIVE;1.0i;1.0ma +10681-5;Herpes simplex virus identified;Prid;Pt;Tiss;Nom;Microscopy.electron;MICRO;1;Herpes simplex virus identified in Tissue by Electron microscopy;HSV Tiss EM;;ACTIVE;1.0i;2.22 +10682-3;HIV 1 RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp;MICRO;1;Deprecated HIV 1 RNA [Units/volume] in Serum or Plasma by Probe with amplification;Deprecated HIV1 RNA SerPl Amp Prb-aCnc;;DEPRECATED;1.0i;2.69 +10683-1;Hydatid cyst identified;Prid;Pt;Asp;Nom;Immune stain;MICRO;1;Hydatid cyst identified in Aspirate by Immune stain;Hydatid Cyst Aspirate ImStn;;ACTIVE;1.0i;2.17 +10684-9;Hydatid cyst identified;Prid;Pt;Liver;Nom;Wet preparation;MICRO;1;Hydatid cyst identified in Liver by Wet preparation;Hydatid Cyst Liver Wet Prep;;ACTIVE;1.0i;1.0ma +10685-6;Hydatid cyst identified;Prid;Pt;Lung tiss;Nom;Wet preparation;MICRO;1;Hydatid cyst identified in Lung tissue by Wet preparation;Hydatid Cyst Lung tiss Wet Prep;;ACTIVE;1.0i;2.21 +1068-6;J little k super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Jk sup(a) Ab [Presence] in Serum or Plasma from Donor;Jk sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10686-4;Leishmania sp identified;Prid;Pt;Tiss;Nom;Giemsa stain;MICRO;1;Leishmania sp identified in Tissue by Giemsa stain;Leishmania Tiss Gie Stn;;ACTIVE;1.0i;2.22 +10687-2;Leishmania sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Leishmania sp identified in Tissue by Organism specific culture;Leishmania Tiss Cult;;ACTIVE;1.0i;2.22 +10688-0;Microscopic observation;Prid;Pt;Hair;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Hair by KOH preparation;KOH Prep Hair;;ACTIVE;1.0i;2.58 +10689-8;Microscopic observation;Prid;Pt;Nail;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Nail by KOH preparation;KOH Prep Nail;;ACTIVE;1.0i;2.73 +10690-6;Microsporidia identified;Prid;Pt;Duod fld;Nom;Trichrome modified;MICRO;1;Microsporidia identified in Duodenal fluid by Trichrome stain modified;Microsporid Duod fl Mod Tri Stain;;ACTIVE;1.0i;2.21 +10691-4;Mushroom.toxic identified;Prid;Pt;^Mushroom specimen;Nom;Inspection;MICRO;1;Mushroom.toxic identified by Inspection;Toxic mushroom identified;;ACTIVE;1.0i;2.26 +10692-2;Mushroom.toxic identified;Prid;Pt;Food;Nom;Microscopy.light;MICRO;1;Mushroom.toxic identified in Food by Light microscopy;Toxic Mushroom Food Micro;;ACTIVE;1.0i;1.0ma +10693-0;Mushroom.toxic identified;Prid;Pt;Vomitus;Nom;Microscopy.light;MICRO;1;Mushroom.toxic identified in Vomitus by Light microscopy;Toxic Mushroom Vom Micro;;ACTIVE;1.0i;2.19 +1069-4;J little k super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Jk sup(a) Ab [Presence] in Serum or Plasma;Jk sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.73 +10694-8;Naegleria sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Naegleria sp identified in Tissue by Organism specific culture;Naegleria Tiss Cult;;ACTIVE;1.0i;2.22 +10695-5;Naegleria sp identified;Prid;Pt;Tiss;Nom;Wet preparation;MICRO;1;Naegleria sp identified in Tissue by Wet preparation;Naegleria Tiss Wet Prep;;ACTIVE;1.0i;2.22 +10696-3;Norovirus;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Norovirus [Identifier] in Stool by Electron microscopy;Norovirus Stl EM;;ACTIVE;1.0i;2.48 +10697-1;Nystatin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Nystatin [Susceptibility] by Minimum inhibitory concentration (MIC);Nystatin Islt MIC;;ACTIVE;1.0i;2.19 +10698-9;Nystatin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Nystatin [Susceptibility] by Minimum lethal concentration (MLC);Nystatin Islt MLC;;ACTIVE;1.0i;2.73 +10699-7;Onchocerca sp identified;Prid;Pt;Tiss;Nom;Wet preparation;MICRO;1;Onchocerca sp identified in Tissue by Wet preparation;Onchocerca Tiss Wet Prep;;ACTIVE;1.0i;2.22 +10700-3;Orthopoxvirus;Prid;Pt;Skin;Nom;Microscopy.electron;MICRO;1;Orthopoxvirus [Identifier] in Skin by Electron microscopy;Orthopoxvirus Skin EM;;ACTIVE;1.0i;2.21 +10701-1;Ova & parasites identified;Prid;Pt;Stool;Nom;Concentration;MICRO;1;Ova and parasites identified in Stool by Concentration;O+P Stl Conc;;ACTIVE;1.0i;2.73 +1070-2;J little k super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Jk sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Jk sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10702-9;Ova & parasites identified;Prid;Pt;Stool;Nom;Immune stain;MICRO;1;Ova and parasites identified in Stool by Immune stain;O+P Stl ImStn;;ACTIVE;1.0i;2.38 +10703-7;Ova & parasites identified;Prid;Pt;Stool;Nom;Kinyoun iron hematoxylin stain;MICRO;1;Ova and parasites identified in Stool by Kinyoun iron hematoxylin stain;O+P Stl Kinyoun IH Stn;;ACTIVE;1.0i;2.38 +10704-5;Ova & parasites identified;Prid;Pt;Stool;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Stool by Light microscopy;O+P Stl Micro;;ACTIVE;1.0i;2.73 +10705-2;Human papilloma virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Human papilloma virus Ag [Presence] in Tissue by Immune stain;HPV Ag Tiss Ql ImStn;;ACTIVE;1.0i;2.56 +10706-0;Picornavirus;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Picornavirus [Identifier] in Stool by Electron microscopy;Picornavirus Stl EM;;ACTIVE;1.0i;2.19 +10707-8;Plant.toxic identified;Prid;Pt;^Plant specimen;Nom;Inspection;MICRO;1;Toxic Plant identified in Plant specimen by Inspection;Toxic plant. Identified;;ACTIVE;1.0i;2.26 +10708-6;Plant.toxic identified;Prid;Pt;Vomitus;Nom;Microscopy.light;MICRO;1;Toxic Plant identified in Vomitus by Light microscopy;Toxic Plant Vom Micro;;ACTIVE;1.0i;2.19 +10709-4;Plasmodium falciparum Ag;ACnc;Pt;Bld;Qn;IF;MICRO;1;Plasmodium falciparum Ag [Units/volume] in Blood by Immunofluorescence;P falciparum Ag Bld IF-aCnc;;ACTIVE;1.0i;2.69 +1071-0;J little k super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Jk sup(a) Ag [Presence] on Red Blood Cells from Donor;Jk sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10710-2;Plasmodium sp identified;Prid;Pt;Bld;Nom;Thin film;MICRO;1;Plasmodium sp identified in Blood by Thin film;Plasmodium Bld Thin Film;;ACTIVE;1.0i;2.73 +10711-0;Plasmodium vivax Ag;ACnc;Pt;Bld;Qn;IF;MICRO;1;Plasmodium vivax Ag [Units/volume] in Blood by Immunofluorescence;P vivax Ag Bld IF-aCnc;;ACTIVE;1.0i;2.69 +10712-8;Pneumocystis sp identified;Prid;Pt;Lung tiss;Nom;;MICRO;1;Pneumocystis sp identified in Lung tissue;Pneumocystis Lung tiss;;ACTIVE;1.0i;2.21 +10713-6;Prototheca identified;Prid;Pt;XXX;Nom;Culture;MICRO;1;Prototheca identified in Specimen by Culture;Prototheca Spec Cult;;ACTIVE;1.0i;2.69 +10714-4;Rotavirus;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Deprecated Rotavirus [Identifier] in Stool by Electron microscopy;Deprecated RV Stl EM;;DEPRECATED;1.0i;2.40 +10715-1;Schistosoma sp identified;Prid;Pt;Urine sed;Nom;Microscopy.light;MICRO;1;Schistosoma sp identified in Urine sediment by Light microscopy;Schistosoma UrnS Micro;;ACTIVE;1.0i;2.73 +10716-9;Schistosoma sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Schistosoma sp identified in Specimen by Organism specific culture;Schistosoma Spec Cult;;ACTIVE;1.0i;2.69 +10717-7;Streptococcus pneumoniae Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Streptococcus pneumoniae Ab [Units/volume] in Serum by Latex agglutination;S pneum Ab Ser LA-aCnc;;ACTIVE;1.0i;2.73 +10718-5;Strongyloides sp Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Strongyloides sp Ab [Units/volume] in Serum by Immunoassay;Strongyloides Ab Ser IA-aCnc;;ACTIVE;1.0i;2.69 +10719-3;Taenia solium adult Ab;ACnc;Pt;Ser;Qn;IB;MICRO;1;Taenia solium adult Ab [Units/volume] in Serum by Immunoblot;T sol adult Ab Ser IB-aCnc;;ACTIVE;1.0i;2.69 +10720-1;Terbinafine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Terbinafine [Susceptibility] by Minimum inhibitory concentration (MIC);Terbinafine Islt MIC;;ACTIVE;1.0i;2.73 +10721-9;Terbinafine;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Terbinafine [Susceptibility] by Minimum lethal concentration (MLC);Terbinafine Islt MLC;;ACTIVE;1.0i;2.19 +10722-7;Torovirus;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Torovirus [Identifier] in Stool by Electron microscopy;Torovirus Stl EM;;ACTIVE;1.0i;2.19 +10723-5;Toxoplasma gondii Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxoplasma gondii IgA Ab [Units/volume] in Serum by Immunoassay;T gondii IgA Ser IA-aCnc;;ACTIVE;1.0i;2.73 +10724-3;Toxoplasma gondii Ab.IgE;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxoplasma gondii IgE Ab [Units/volume] in Serum by Immunoassay;T gondii IgE Ser IA-aCnc;;ACTIVE;1.0i;2.73 +10725-0;Toxoplasma gondii DNA;ACnc;Pt;Body fld;Qn;Probe.amp;MICRO;1;Toxoplasma gondii DNA [Units/volume] in Body fluid by Probe with amplification;T gondii DNA Fld Probe amp-aCnc;;ACTIVE;1.0i;2.69 +10726-8;Toxoplasma gondii;PrThr;Pt;Tiss;Ord;Giemsa stain;MICRO;1;Toxoplasma gondii [Presence] in Tissue by Giemsa stain;T gondii Tiss Ql Gie Stn;;ACTIVE;1.0i;2.56 +10727-6;Toxoplasma gondii identified;Prid;Pt;Tiss;Nom;;MICRO;1;Toxoplasma gondii identified in Tissue;T gondii Tiss;;ACTIVE;1.0i;2.22 +1072-8;J little k super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Jk sup(a) Ag [Presence] on Red Blood Cells;Jk sup(a) Ag RBC Ql;;ACTIVE;1.0;2.73 +10728-4;Trichomonas sp identified;Prid;Pt;Genital;Nom;Organism specific culture;MICRO;1;Trichomonas sp identified in Genital specimen by Organism specific culture;Trichomonas Genital Cult;;ACTIVE;1.0i;2.73 +10729-2;Trypanosoma sp identified;Prid;Pt;Bld;Nom;Microscopy.light;MICRO;1;Trypanosoma sp identified in Blood by Light microscopy;Trypanos Bld Smear;;ACTIVE;1.0i;2.73 +107-3;Cefotaxime;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefotaxime [Susceptibility] by Minimum lethal concentration (MLC);Cefotaxime Islt MLC;;ACTIVE;1.0;2.19 +10730-0;Trypanosoma sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Trypanosoma sp identified in Blood by Organism specific culture;Trypanos Bld Cult;;ACTIVE;1.0i;1.0ma +10731-8;Trypanosoma sp identified;Prid;Pt;Bld;Nom;Thick film;MICRO;1;Trypanosoma sp identified in Blood by Thick film;Trypanos Bld Thick Film;;ACTIVE;1.0i;1.0ma +10732-6;Trypanosoma sp identified;Prid;Pt;Bld;Nom;Thin film;MICRO;1;Trypanosoma sp identified in Blood by Thin film;Trypanos Bld Thin Film;;ACTIVE;1.0i;1.0ma +10733-4;Trypanosoma sp identified;Prid;Pt;Bld;Nom;Wet preparation;MICRO;1;Trypanosoma sp identified in Blood by Wet preparation;Trypanos Bld Wet Prep;;ACTIVE;1.0i;1.0ma +10734-2;Varicella zoster virus identified;Prid;Pt;Skin;Nom;Microscopy.electron;MICRO;1;Varicella zoster virus identified in Skin by Electron microscopy;VZV Skin EM;;ACTIVE;1.0i;2.21 +10735-9;Viral sequencing;Prid;Pt;Ser;Nom;Sequencing;MICRO;1;Viral sequencing [Identifier] in Serum by Sequencing;Viral Seq Ser Seq;;DISCOURAGED;1.0i;2.44 +1073-6;J little k super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Jk sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Jk sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10736-7;Virus identified;Prid;Pt;CSF;Nom;Microscopy.electron;MICRO;1;Virus identified in Cerebral spinal fluid by Electron microscopy;Virus CSF EM;;ACTIVE;1.0i;1.0ma +10737-5;Virus identified;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Virus identified in Stool by Electron microscopy;Virus Stl EM;;ACTIVE;1.0i;2.73 +10738-3;Virus identified;Prid;Pt;Tiss;Nom;Microscopy.electron;MICRO;1;Virus identified in Tissue by Electron microscopy;Virus Tiss EM;;ACTIVE;1.0i;2.22 +10739-1;Virus identified;Prid;Pt;XXX;Nom;Microscopy.electron;MICRO;1;Virus identified in Specimen by Electron microscopy;Virus Spec EM;;ACTIVE;1.0i;2.73 +10740-9;Aluminum.microscopic observation;Prid;Pt;Bone;Nom;Histomorphometry stain;PATH;1;Aluminum.microscopic observation [Identifier] in Bone by Histomorphometry stain;Aluminum Bone Histomorph Stn;;ACTIVE;1.0i;2.15 +10741-7;Amyloid.microscopic observation;Prid;Pt;Brain;Nom;Thioflavine-S stain;PATH;1;Amyloid.microscopic observation [Identifier] in Brain by Thioflavine-S stain;AL Brain TFS Stn;;ACTIVE;1.0i;2.15 +10742-5;Amyloid.microscopic observation;Prid;Pt;Tiss;Nom;Bennhold stain.Putchler modified;PATH;1;Amyloid.microscopic observation [Identifier] in Tissue by Bennhold stain.Putchler modified;AL Tiss Puchtler Mod Benn Stn;;ACTIVE;1.0i;2.22 +10743-3;Amyloid.microscopic observation;Prid;Pt;Tiss;Nom;Highman stain;PATH;1;Amyloid.microscopic observation [Identifier] in Tissue by Highman stain;AL Tiss Highman Stn;;ACTIVE;1.0i;2.22 +1074-4;J little k super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Jk sup(b) Ab [Presence] in Serum or Plasma from Donor;Jk sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10744-1;Amyloid.microscopic observation;Prid;Pt;Tiss;Nom;Vassar-culling stain;PATH;1;Amyloid.microscopic observation [Identifier] in Tissue by Vassar-culling stain;AL Tiss Vassar-Culling Stn;;ACTIVE;1.0i;2.22 +10745-8;Bile.microscopic observation;Prid;Pt;Tiss;Nom;Fouchet stain;PATH;1;Bile.microscopic observation [Identifier] in Tissue by Fouchet stain;Bile Tiss Fouchet Stn;;ACTIVE;1.0i;2.22 +10746-6;Calcium.microscopic observation;Prid;Pt;Tiss;Nom;Von Kossa stain;PATH;1;Calcium.microscopic observation [Identifier] in Tissue by Von Kossa stain;Calcium Tiss von Kossa Stn;;ACTIVE;1.0i;2.22 +10747-4;Collagen fibers+Elastic fibers.microscopic observation;Prid;Pt;Tiss;Nom;Lawson-Van Gieson stain;PATH;1;Collagen fibers+Elastic fibers.microscopic observation [Identifier] in Tissue by Lawson-Van Gieson stain;Collagen+Elastic Tiss LVG Stn;;ACTIVE;1.0i;2.22 +10748-2;Collagen fibers+Elastic fibers.microscopic observation;Prid;Pt;Tiss;Nom;Verhoeff-Van Gieson stain;PATH;1;Collagen fibers+Elastic fibers.microscopic observation [Identifier] in Tissue by Verhoeff-Van Gieson stain;Collagen+Elastic Tiss VVG Stn;;ACTIVE;1.0i;2.22 +10749-0;Collagen fibers.microscopic observation;Prid;Pt;Tiss;Nom;Van Gieson stain;PATH;1;Collagen fibers.microscopic observation [Identifier] in Tissue by Van Gieson stain;Collagen Tiss VG Stn;;ACTIVE;1.0i;2.22 +10750-8;Connective tissue.microscopic observation;Prid;Pt;Tiss;Nom;Trichrome stain.Masson;PATH;1;Connective tissue.microscopic observation [Identifier] in Tissue by Trichrome stain.Masson;Conn Tiss Masson Tri Stn;;ACTIVE;1.0i;2.22 +1075-1;J little k super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Jk sup(b) Ab [Presence] in Serum or Plasma;Jk sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.73 +10751-6;Copper.microscopic observation;Prid;Pt;Tiss;Nom;Rhodamine stain;PATH;1;Copper.microscopic observation [Identifier] in Tissue by Rhodamine stain;Copper Tiss Rhodamine Stn;;ACTIVE;1.0i;2.22 +10752-4;Fat.microscopic observation;Prid;Pt;Milk;Nom;Sudan IV stain;PATH;1;Fat.microscopic observation [Identifier] in Milk by Sudan IV stain;Fat Mlk Sudan IV Stn;;ACTIVE;1.0i;2.19 +10753-2;Fat.microscopic observation;Prid;Pt;Stool;Nom;Sudan IV stain;CHEM;1;Fat.microscopic observation [Identifier] in Stool by Sudan IV stain;Fat Stl Sudan IV Stn;;ACTIVE;1.0i;2.73 +10754-0;Fat.microscopic observation;Prid;Pt;Tiss;Nom;Sudan IV stain;PATH;1;Fat.microscopic observation [Identifier] in Tissue by Sudan IV stain;Fat Tiss Sudan IV Stn;;ACTIVE;1.0i;2.22 +10755-7;Fungus.microscopic observation;Prid;Pt;Tiss;Nom;Methenamine silver stain.Grocott;PATH;1;Fungus.microscopic observation [Identifier] in Tissue by Methenamine silver stain.Grocott;Fungus Tiss Grocott MS Stn;;ACTIVE;1.0i;2.73 +10756-5;Glial fibers.microscopic observation;Prid;Pt;Tiss;Nom;Holzer stain;PATH;1;Glial fibers.microscopic observation [Identifier] in Tissue by Holzer stain;Glial Fibers Tiss Holzer Stn;;ACTIVE;1.0i;2.22 +10757-3;Hematologic+Nuclear elements.microscopic observation;Prid;Pt;Tiss;Nom;Giemsa stain.May-Grunwald;PATH;1;Hematologic+Nuclear elements.microscopic observation [Identifier] in Tissue by Giemsa stain.May-Grunwald;Hem+Nuc Elem Tiss MGG Stn;;ACTIVE;1.0i;2.73 +10758-1;Iron.microscopic observation;Prid;Pt;Bone;Nom;Histomorphometry stain;PATH;1;Iron.microscopic observation [Identifier] in Bone by Histomorphometry stain;Iron Bone Histomorph Stn;;ACTIVE;1.0i;2.07 +10759-9;Iron.microscopic observation;Prid;Pt;Sputum;Nom;Gomori stain;PATH;1;Iron.microscopic observation [Identifier] in Sputum by Gomori stain;Iron Spt Gomori Stn;;ACTIVE;1.0i;2.19 +10760-7;Iron.microscopic observation;Prid;Pt;Tiss;Nom;Gomori stain;PATH;1;Iron.microscopic observation [Identifier] in Tissue by Gomori stain;Iron Tiss Gomori Stn;;ACTIVE;1.0i;2.73 +10761-5;Iron.microscopic observation;Prid;Pt;Tiss;Nom;XXX stain;PATH;1;Iron.microscopic observation [Identifier] in Tissue by Other stain;Iron Tiss Other Stn;;ACTIVE;1.0i;2.22 +10762-3;Microscopic observation;Prid;Pt;Bld;Nom;Hemosiderin stain;PATH;1;Microscopic observation [Identifier] in Blood by Hemosiderin stain;Hemosiderin Stn Bld;;ACTIVE;1.0i;2.15 +10763-1;Microscopic observation;Prid;Pt;Body fld;Nom;Sudan black stain;PATH;1;Microscopic observation [Identifier] in Body fluid by Sudan black stain;Sudan Black Stn Fld;;ACTIVE;1.0i;2.19 +10764-9;Microscopic observation;Prid;Pt;Sputum;Nom;Silver stain;PATH;1;Microscopic observation [Identifier] in Sputum by Silver stain;Silv Stn Spt;;ACTIVE;1.0i;2.19 +10765-6;Microscopic observation;Prid;Pt;Tiss;Nom;Acetate esterase stain;PATH;1;Microscopic observation [Identifier] in Tissue by Acetate esterase stain;AE Stn Tiss;;ACTIVE;1.0i;2.22 +10766-4;Microscopic observation;Prid;Pt;Tiss;Nom;Alcian blue stain;PATH;1;Microscopic observation [Identifier] in Tissue by Alcian blue stain;AB Stn Tiss;;ACTIVE;1.0i;2.22 +10767-2;Microscopic observation;Prid;Pt;Tiss;Nom;Alcian blue stain.sulfated;PATH;1;Microscopic observation [Identifier] in Tissue by Alcian blue stain.sulfated;Sulf-AB Stn Tiss;;ACTIVE;1.0i;2.22 +10768-0;Microscopic observation;Prid;Pt;Tiss;Nom;Alcian blue stain.with periodic acid-Schiff;PATH;1;Microscopic observation [Identifier] in Tissue by Alcian blue stain.with periodic acid-Schiff;AB-PAS Stn Tiss;;ACTIVE;1.0i;2.22 +1076-9;J little k super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Jk sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Jk sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10769-8;Microscopic observation;Prid;Pt;Tiss;Nom;Alizarin red S stain;PATH;1;Microscopic observation [Identifier] in Tissue by Alizarin red S stain;AR-S Stn Tiss;;ACTIVE;1.0i;2.22 +10770-6;Microscopic observation;Prid;Pt;Tiss;Nom;Argentaffin stain;PATH;1;Microscopic observation [Identifier] in Tissue by Argentaffin stain;Argentaffin Stn Tiss;;ACTIVE;1.0i;2.22 +10771-4;Microscopic observation;Prid;Pt;Tiss;Nom;Rhodamine-auramine fluorochrome stain;PATH;1;Deprecated Microscopic observation [Identifier] in Tissue by Rhodamine-auramine fluorochrome stain;Deprecated Rhodamine-auramine Stn Tiss;;DEPRECATED;1.0i;2.36 +10772-2;Microscopic observation;Prid;Pt;Tiss;Nom;Azure-eosin stain;PATH;1;Microscopic observation [Identifier] in Tissue by Azure-eosin stain;Azure-Eosin Stn Tiss;;ACTIVE;1.0i;2.22 +10773-0;Microscopic observation;Prid;Pt;Tiss;Nom;Basic fuchsin stain;PATH;1;Microscopic observation [Identifier] in Tissue by Basic fuchsin stain;BF Stn Tiss;;ACTIVE;1.0i;2.22 +10774-8;Microscopic observation;Prid;Pt;Tiss;Nom;Bielschowsky stain;PATH;1;Microscopic observation [Identifier] in Tissue by Bielschowsky stain;Bielschowsky Stn Tiss;;ACTIVE;1.0i;2.22 +10775-5;Microscopic observation;Prid;Pt;Tiss;Nom;Bleach stain;PATH;1;Microscopic observation [Identifier] in Tissue by Bleach stain;Bleach Stn Tiss;;ACTIVE;1.0i;2.22 +10776-3;Microscopic observation;Prid;Pt;Tiss;Nom;Bodian stain;PATH;1;Microscopic observation [Identifier] in Tissue by Bodian stain;Bodian Stn Tiss;;ACTIVE;1.0i;2.22 +1077-7;J little k super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Jk sup(b) Ag [Presence] on Red Blood Cells from Donor;Jk sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10777-1;Microscopic observation;Prid;Pt;Tiss;Nom;Brown and Brenn stain;PATH;1;Microscopic observation [Identifier] in Tissue by Brown and Brenn stain;Brown + Brenn Stn Tiss;;ACTIVE;1.0i;2.22 +10778-9;Microscopic observation;Prid;Pt;Tiss;Nom;Butyrate esterase stain;PATH;1;Microscopic observation [Identifier] in Tissue by Butyrate esterase stain;BE Stn Tiss;;ACTIVE;1.0i;2.73 +10779-7;Microscopic observation;Prid;Pt;Tiss;Nom;Carmine stain.Best;PATH;1;Microscopic observation [Identifier] in Tissue by Carmine stain.Best;Carmine Best Stn Tiss;;ACTIVE;1.0i;2.22 +10780-5;Microscopic observation;Prid;Pt;Tiss;Nom;Chloracetate esterase stain;PATH;1;Microscopic observation [Identifier] in Tissue by Chloracetate esterase stain;CAE Stn Tiss;;ACTIVE;1.0i;2.22 +10781-3;Microscopic observation;Prid;Pt;Tiss;Nom;Churukian-Schenk stain;PATH;1;Microscopic observation [Identifier] in Tissue by Churukian-Schenk stain;Churukian-Schenk Stn Tiss;;ACTIVE;1.0i;2.22 +10782-1;Microscopic observation;Prid;Pt;Tiss;Nom;Congo red stain;PATH;1;Microscopic observation [Identifier] in Tissue by Congo red stain;CR Stn Tiss;;ACTIVE;1.0i;2.74 +10783-9;Microscopic observation;Prid;Pt;Tiss;Nom;Crystal violet stain;PATH;1;Microscopic observation [Identifier] in Tissue by Crystal violet stain;CV Stn Tiss;;ACTIVE;1.0i;2.22 +10784-7;Microscopic observation;Prid;Pt;Tiss;Nom;Esterase stain.non-specific;PATH;1;Microscopic observation [Identifier] in Tissue by Esterase stain.non-specific;NSE Stn Tiss;;ACTIVE;1.0i;2.22 +1078-5;J little k super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Jk sup(b) Ag [Presence] on Red Blood Cells;Jk sup(b) Ag RBC Ql;;ACTIVE;1.0;2.73 +10785-4;Microscopic observation;Prid;Pt;Tiss;Nom;Fite-Faraco stain;PATH;1;Microscopic observation [Identifier] in Tissue by Fite-Faraco stain;Fite-Faraco Stn Tiss;;ACTIVE;1.0i;2.22 +10786-2;Microscopic observation;Prid;Pt;Tiss;Nom;Giemsa stain.3 micron;PATH;1;Deprecated Microscopic observation [Identifier] in Tissue by Giemsa stain.3 micron;Deprecated Gie Stn 3 micron Tiss;;DEPRECATED;1.0i;2.64 +10787-0;Microscopic observation;Prid;Pt;Tiss;Nom;Gridley stain;PATH;1;Microscopic observation [Identifier] in Tissue by Gridley stain;Gridley Stn Tiss;;ACTIVE;1.0i;2.22 +10788-8;Microscopic observation;Prid;Pt;Tiss;Nom;Hansel stain;PATH;1;Microscopic observation [Identifier] in Tissue by Hansel stain;Hansel Stn Tiss;;ACTIVE;1.0i;2.22 +10789-6;Microscopic observation;Prid;Pt;Tiss;Nom;Hematoxylin-eosin-Harris regressive stain;PATH;1;Microscopic observation [Identifier] in Tissue by Hematoxylin-eosin-Harris regressive stain;H+E Stn Harris Regr Tiss;;ACTIVE;1.0i;2.73 +10790-4;Microscopic observation;Prid;Pt;Tiss;Nom;Hematoxylin-eosin-Mayers progressive stain;PATH;1;Microscopic observation [Identifier] in Tissue by Hematoxylin-eosin-Mayers progressive stain;H+E Stn Mayers Progr Tiss;;ACTIVE;1.0i;2.22 +10791-2;Microscopic observation;Prid;Pt;Tiss;Nom;Mallory-Heidenhain stain;PATH;1;Microscopic observation [Identifier] in Tissue by Mallory-Heidenhain stain;Mallory-Heidenhain Stn Tiss;;ACTIVE;1.0i;2.22 +10792-0;Microscopic observation;Prid;Pt;Tiss;Nom;Methenamine silver stain.Jones;PATH;1;Microscopic observation [Identifier] in Tissue by Methenamine silver stain.Jones;Jones MS Stn Tiss;;ACTIVE;1.0i;2.22 +1079-3;J little s super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Js sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Js sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10793-8;Microscopic observation;Prid;Pt;Tiss;Nom;Methyl green stain;PATH;1;Microscopic observation [Identifier] in Tissue by Methyl green stain;MG Stn Tiss;;ACTIVE;1.0i;2.22 +10794-6;Microscopic observation;Prid;Pt;Tiss;Nom;Methyl green-pyronine Y stain;PATH;1;Microscopic observation [Identifier] in Tissue by Methyl green-pyronine Y stain;MG-Pyronine Y Stn Tiss;;ACTIVE;1.0i;2.22 +10795-3;Microscopic observation;Prid;Pt;Tiss;Nom;Methyl violet stain;PATH;1;Microscopic observation [Identifier] in Tissue by Methyl violet stain;MV Stn Tiss;;ACTIVE;1.0i;2.22 +10796-1;Microscopic observation;Prid;Pt;Tiss;Nom;Mucicarmine stain;PATH;1;Microscopic observation [Identifier] in Tissue by Mucicarmine stain;Mucicarm Stn Tiss;;ACTIVE;1.0i;2.22 +10797-9;Microscopic observation;Prid;Pt;Tiss;Nom;Neutral red stain;PATH;1;Microscopic observation [Identifier] in Tissue by Neutral red stain;NR Stn Tiss;;ACTIVE;1.0i;2.22 +10798-7;Microscopic observation;Prid;Pt;Tiss;Nom;Oil red O stain;PATH;1;Microscopic observation [Identifier] in Tissue by Oil red O stain;ORO Stn Tiss;;ACTIVE;1.0i;2.22 +10799-5;Microscopic observation;Prid;Pt;Tiss;Nom;Pentachrome stain.Movat;PATH;1;Microscopic observation [Identifier] in Tissue by Pentachrome stain.Movat;Movat Pentachrome Stn Tiss;;ACTIVE;1.0i;2.22 +10800-1;Microscopic observation;Prid;Pt;Tiss;Nom;Periodic acid-Schiff stain with diatase digestion;PATH;1;Microscopic observation [Identifier] in Tissue by Periodic acid-Schiff stain with diatase digestion;PAS Stn w Diastase Digest Tiss;;ACTIVE;1.0i;2.22 +1080-1;J little s super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Js sup(a) Ab [Presence] in Serum or Plasma from Donor;Js sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10801-9;Microscopic observation;Prid;Pt;Tiss;Nom;Phosphotungstic acid hematoxyl;PATH;1;Microscopic observation [Identifier] in Tissue by Phosphotungstic acid Hematoxylin (PTAH) Stain;PTAH Tiss;;ACTIVE;1.0i;2.52 +10802-7;Microscopic observation;Prid;Pt;Tiss;Nom;Prussian blue stain;PATH;1;Microscopic observation [Identifier] in Tissue by Prussian blue stain;Prus Bl St Tiss;;ACTIVE;1.0i;2.72 +10803-5;Microscopic observation;Prid;Pt;Tiss;Nom;Quinacrine fluorescent stain;PATH;1;Microscopic observation [Identifier] in Tissue by Quinacrine fluorescent stain;Quinacrine Fluor Stn Tiss;;ACTIVE;1.0i;2.22 +10804-3;Microscopic observation;Prid;Pt;Tiss;Nom;Reticulin stain;PATH;1;Microscopic observation [Identifier] in Tissue by Reticulin stain;Ret Stn Tiss;;ACTIVE;1.0i;2.22 +10805-0;Microscopic observation;Prid;Pt;Tiss;Nom;Safranin stain;PATH;1;Microscopic observation [Identifier] in Tissue by Safranin stain;Safranin Stn Tiss;;ACTIVE;1.0i;2.22 +10806-8;Microscopic observation;Prid;Pt;Tiss;Nom;Schmorl stain;PATH;1;Microscopic observation [Identifier] in Tissue by Schmorl stain;Sch Stn Tiss;;ACTIVE;1.0j-a;2.22 +10807-6;Microscopic observation;Prid;Pt;Tiss;Nom;Sevier-Munger stain;PATH;1;Microscopic observation [Identifier] in Tissue by Sevier-Munger stain;Sevier-Munger Stn Tiss;;ACTIVE;1.0j-a;2.22 +10808-4;Microscopic observation;Prid;Pt;Tiss;Nom;Silver impregnation stain.Dieterle;PATH;1;Microscopic observation [Identifier] in Tissue by Silver impregnation stain.Dieterle;Silv Impreg Stn Dieterle Tiss;;ACTIVE;1.0j-a;2.22 +10809-2;Microscopic observation;Prid;Pt;Tiss;Nom;Silver nitrate stain;PATH;1;Microscopic observation [Identifier] in Tissue by Silver nitrate stain;Silv Nitrate Stn Tiss;;ACTIVE;1.0j-a;2.22 +108-1;Cefotaxime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefotaxime [Susceptibility] by Minimum inhibitory concentration (MIC);Cefotaxime Islt MIC;;ACTIVE;1.0;2.73 +10810-0;Microscopic observation;Prid;Pt;Tiss;Nom;Silver stain.Fontana-Masson;PATH;1;Microscopic observation [Identifier] in Tissue by Silver stain.Fontana-Masson;FM Silv Stn Tiss;;ACTIVE;1.0j-a;2.22 +10811-8;Microscopic observation;Prid;Pt;Tiss;Nom;Silver stain.Grimelius;PATH;1;Microscopic observation [Identifier] in Tissue by Silver stain.Grimelius;Grimelius Silv Stn Tiss;;ACTIVE;1.0j-a;2.22 +10812-6;Microscopic observation;Prid;Pt;Tiss;Nom;Steiner stain;PATH;1;Microscopic observation [Identifier] in Tissue by Steiner stain;Steiner Stn Tiss;;ACTIVE;1.0j-a;2.22 +10813-4;Microscopic observation;Prid;Pt;Tiss;Nom;Sudan black stain;PATH;1;Microscopic observation [Identifier] in Tissue by Sudan black stain;Sudan Black Stn Tiss;;ACTIVE;1.0j-a;2.22 +10814-2;Microscopic observation;Prid;Pt;Tiss;Nom;Supravital stain;PATH;1;Microscopic observation [Identifier] in Tissue by Supravital stain;SV Stn Tiss;;ACTIVE;1.0j-a;2.22 +10815-9;Microscopic observation;Prid;Pt;Tiss;Nom;Tetrachrome stain;PATH;1;Microscopic observation [Identifier] in Tissue by Tetrachrome stain;Tetrachrome Stn Tiss;;ACTIVE;1.0j-a;2.22 +10816-7;Microscopic observation;Prid;Pt;Tiss;Nom;Toluidine blue O stain;PATH;1;Deprecated Microscopic observation [Identifier] in Tissue by Toluidine blue O stain;Deprecated TBO Stn Tiss;;DEPRECATED;1.0j-a;2.36 +10817-5;Microscopic observation;Prid;Pt;Tiss;Nom;Trichrome stain.Gomori-Wheatley;PATH;1;Microscopic observation [Identifier] in Tissue by Trichrome stain.Gomori-Wheatley;Gomori-Wheatley Tri Stn Tiss;;ACTIVE;1.0j-a;2.73 +10818-3;Microscopic observation;Prid;Pt;Tiss;Nom;Trichrome stain.Masson modified;PATH;1;Microscopic observation [Identifier] in Tissue by Trichrome stain.Masson modified;Mod Masson Tri Stn Tiss;;ACTIVE;1.0j-a;2.22 +1081-9;J little s super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Js sup(a) Ab [Presence] in Serum or Plasma;Js sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +10819-1;Microscopic observation;Prid;Pt;Tiss;Nom;Wade stain;PATH;1;Microscopic observation [Identifier] in Tissue by Wade stain;Wade Stn Tiss;;ACTIVE;1.0j-a;2.22 +10820-9;Microscopic observation;Prid;Pt;Tiss;Nom;Warthin-Starry stain;PATH;1;Deprecated Microscopic observation [Identifier] in Tissue by Warthin-Starry stain;Deprecated WS Stn Tiss;;DEPRECATED;1.0j-a;2.36 +10821-7;Microscopic observation;Prid;Pt;Tiss;Nom;Wright Giemsa stain;PATH;1;Deprecated Microscopic observation [Identifier] in Tissue by Wright Giemsa stain;Deprecated Wright Gie Stn Tiss;;DEPRECATED;1.0j-a;2.36 +10822-5;Mucin.microscopic observation;Prid;Pt;Tiss;Nom;Mucicarmine stain.Mayer;PATH;1;Mucin.microscopic observation [Identifier] in Tissue by Mucicarmine stain.Mayer;Mucin Tiss Mayer Mucicarm Stn;;ACTIVE;1.0j-a;2.22 +10823-3;Mucopolysaccharides.microscopic observation;Prid;Pt;Tiss;Nom;Colloidal ferric oxide stain.Hale;PATH;1;Mucopolysaccharides.microscopic observation [Identifier] in Tissue by Colloidal ferric oxide stain.Hale;MPS Tiss Hale Colloid Fe Stn;;ACTIVE;1.0j-a;2.22 +10824-1;Myelin+Myelin breakdown products.microscopic observation;Prid;Pt;Tiss;Nom;Luxol fast blue/Periodic acid-Schiff stain;PATH;1;Myelin+Myelin breakdown products.microscopic observation [Identifier] in Tissue by Luxol fast blue/Periodic acid-Schiff stain;Myelin+BDP Tiss LFB/PAS Stn;;ACTIVE;1.0j-a;2.22 +10825-8;Myelin+Nerve cells.microscopic observation;Prid;Pt;Tiss;Nom;Luxol fast blue/Cresyl violet stain;PATH;1;Myelin+Nerve cells.microscopic observation [Identifier] in Tissue by Luxol fast blue/Cresyl violet stain;Myelin+Nerves Tiss LFB/CV Stn;;ACTIVE;1.0j-a;2.22 +10826-6;Nissel.microscopic observation;Prid;Pt;Tiss;Nom;Cresyl echt violet stain;PATH;1;Nissel.microscopic observation [Identifier] in Tissue by Cresyl echt violet stain;Nissel Tiss CEV Stn;;ACTIVE;1.0j-a;2.22 +1082-7;J little s super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Js sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Js sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10827-4;Reticulum.microscopic observation;Prid;Pt;Tiss;Nom;Gomori stain;PATH;1;Reticulum.microscopic observation [Identifier] in Tissue by Gomori stain;Reticulum Tiss Gomori Stn;;ACTIVE;1.0j-a;2.73 +10828-2;Urate crystals.microscopic observation;Prid;Pt;Tiss;Nom;De Galantha stain;PATH;1;Urate crystals.microscopic observation [type] in Tissue by De Galantha stain;Urate Cry Tiss de Galantha Stn;;ACTIVE;1.0j-a;2.22 +10829-0;Silicon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Silicon [Mass/volume] in Serum or Plasma;Silicon SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10830-8;Surgical operation note complications;Imp;Pt;^Patient;Nar;;H&P.SURG PROC;2;Deprecated Surgical operation note complications;DeprecatedSurgical operation note compli;;DEPRECATED;1.0j-a;2.63 +10831-6;Surgical operation note complications;Imp;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note complications [Interpretation];Operative note complications Imp;;ACTIVE;1.0j-a;2.50 +10832-4;Glucose^15M post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 minutes post 50 g lactose PO;Glucose 15M p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10833-2;Insulin^7H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --7 hours post 75 g glucose PO;Insulin 7h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +10834-0;Globulin;MCnc;Pt;Ser;Qn;Calculated;CHEM;1;Globulin [Mass/volume] in Serum by calculation;Globulin Ser Calc-mCnc;;ACTIVE;1.0j-a;2.73 +1083-5;J little s super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Js sup(a) Ag [Presence] on Red Blood Cells from Donor;Js sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.73 +10835-7;Lipoprotein (little a);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein a [Mass/volume] in Serum or Plasma;LPa SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10836-5;Niacin;MCnc;Pt;Bld;Qn;;CHEM;1;Niacin [Mass/volume] in Blood;Niacin Bld-mCnc;;ACTIVE;1.0j-a;2.73 +10837-3;Organic acids;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Organic acids [Presence] in Serum or Plasma;Organic Acids SerPl Ql;;ACTIVE;1.0j-a;2.73 +10838-1;Phosphoserine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphoserine [Mass/volume] in Serum or Plasma;Phosphoserine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10839-9;Troponin I.cardiac;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Troponin I.cardiac [Mass/volume] in Serum or Plasma;Troponin I SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10840-7;Atropine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Atropine [Mass/volume] in Urine;Atropine Ur-mCnc;;ACTIVE;1.0j-a;2.42 +10841-5;methazolAMIDE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;methazolAMIDE [Mass/volume] in Serum or Plasma;methazolAMIDE SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +10842-3;HLA-DQ1;ACnc;Pt;Bld/Tiss;Ord;;HLA;1;Deprecated HLA-DQ1 [Presence];Deprecated HLA-DQ1 Ql;;DEPRECATED;1.0j-a;2.54 +1084-3;J little s super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Js sup(a) Ag [Presence] on Red Blood Cells;Js sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +10843-1;HLA-DQ2;ACnc;Pt;Bld/Tiss;Ord;;HLA;1;Deprecated HLA-DQ2 [Presence];Deprecated HLA-DQ2 Ql;;DEPRECATED;1.0j-a;2.54 +10844-9;HLA-DQ3;ACnc;Pt;Bld/Tiss;Ord;;HLA;1;Deprecated HLA-DQ3 [Presence];Deprecated HLA-DQ3 Ql;;DEPRECATED;1.0j-a;2.54 +10845-6;HLA-DQ4;ACnc;Pt;Bld/Tiss;Ord;;HLA;1;Deprecated HLA-DQ4 [Presence];Deprecated HLA-DQ4 Ql;;DEPRECATED;1.0j-a;2.54 +10846-4;Borrelia burgdorferi DNA;PrThr;Pt;Bld;Ord;Probe.amp;MICRO;1;Borrelia burgdorferi DNA [Presence] in Blood by Probe with amplification;B burgdor DNA Bld Ql Probe amp;;ACTIVE;1.0j-a;2.73 +10847-2;Borrelia burgdorferi DNA;PrThr;Pt;Body fld;Ord;Probe.amp;MICRO;1;Borrelia burgdorferi DNA [Presence] in Body fluid by Probe with amplification;B burgdor DNA Fld Ql Probe amp;;ACTIVE;1.0j-a;2.73 +10848-0;Chlamydia sp Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia sp IgG Ab [Titer] in Serum by Immunofluorescence;Chlamydia IgG Titr Ser IF;;ACTIVE;1.0j-a;2.73 +10849-8;Chlamydia sp Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia sp IgM Ab [Titer] in Serum by Immunofluorescence;Chlamydia IgM Titr Ser IF;;ACTIVE;1.0j-a;2.73 +1085-0;J little s super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Js sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Js sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10850-6;Cyclospora cayetanensis;PrThr;Pt;XXX;Ord;;MICRO;1;Cyclospora cayetanensis [Presence] in Specimen;C cayetanensis Spec Ql;;ACTIVE;1.0j-a;2.73 +10851-4;Escherichia coli O157:H7;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Escherichia coli O157:H7 [Presence] in Stool by Organism specific culture;E coli O157H7 Stl Ql Cult;;ACTIVE;1.0j-a;2.73 +10852-2;Fungus identified;Prid;Pt;Bld;Nom;Routine fungal culture;MICRO;1;Deprecated Fungus identified in Blood by Culture;Deprecated Fungus Bld;;DEPRECATED;1.0j-a;2.36 +10853-0;Isospora belli;PrThr;Pt;XXX;Ord;Acid fast stain.Kinyoun modified;MICRO;1;Isospora belli [Presence] in Specimen by Acid fast stain.Kinyoun modified;I belli Spec Ql Acid fast Mod Kiny Stn;;ACTIVE;1.0j-a;2.73 +10854-8;Microfilaria sp identified;Prid;Pt;Bld;Nom;Concentration;MICRO;1;Deprecated Midrofilaria identified in Blood by Concentration;Deprecated Microfilaria Bld Conc;;DEPRECATED;1.0j-a;2.36 +10855-5;Ova & parasites identified;Prid;Pt;Duod fld/Gast fld;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Duodenal fluid or Gastric fluid by Light microscopy;O+P Duod or Gastric fl Micro;;ACTIVE;1.0j-a;2.73 +10856-3;Microscopic observation;Prid;Pt;Genital muc;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Genital mucus by Gram stain;Gram Stn Genital mucus;;ACTIVE;1.0j-a;2.21 +10857-1;Microsporidia identified;Prid;Pt;XXX;Nom;Microscopy.light;MICRO;1;Microsporidia identified in Specimen by Light microscopy;Microsporid Spec Micro;;ACTIVE;1.0j-a;2.73 +10858-9;Teichoate Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Teichoate Ab [Presence] in Serum;Teichoate Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +10859-7;Trypanosoma sp;Prid;Pt;Bld;Nom;Acridine orange and Giemsa stain;MICRO;1;Trypanosoma sp [Identifier] in Blood by Acridine Orange + Giemsa Stain;Trypanos Bld AO+Gie Stn;;ACTIVE;1.0j-a;1.0ma +10860-5;Varicella zoster virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Varicella zoster virus [Presence] in Specimen by Organism specific culture;VZV Spec Ql Cult;;ACTIVE;1.0j-a;2.73 +10861-3;Progesterone receptor;MCnt;Pt;Tiss;Qn;;PATH;1;Progesterone receptor [Mass/mass] in Tissue;PR Tiss-mCnt;;ACTIVE;1.0j-a;2.61 +10862-1;Basement membrane Ab;Titr;Pt;Ser;Qn;;SERO;1;Basement membrane Ab [Titer] in Serum;BM Ab Titr Ser;;ACTIVE;1.0j-a;2.73 +10863-9;Endomysium Ab.IgA;Titr;Pt;Ser;Qn;;SERO;1;Endomysium IgA Ab [Titer] in Serum;Endomysium IgA Titr Ser;;ACTIVE;1.0j-a;2.73 +10864-7;Immune complex;ACnc;Pt;Ser/Plas;Qn;Raji cell assay;SERO;1;Immune complex [Units/volume] in Serum or Plasma by Raji cell assay;IC SerPl Raji Cell-aCnc;;ACTIVE;1.0j-a;2.73 +10865-4;Intercellular substance Ab;PrThr;Pt;Ser;Ord;;SERO;1;Intercellular substance Ab [Presence] in Serum;ICS Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +10866-2;Sulfatide Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Sulfatide IgG Ab [Titer] in Serum;Sulfatide IgG Titr Ser;;ACTIVE;1.0j-a;2.73 +10867-0;Sulfatide Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Sulfatide IgM Ab [Titer] in Serum;Sulfatide IgM Titr Ser;;ACTIVE;1.0j-a;2.73 +1086-8;J little s super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Js sup(b) Ab [Presence] in Serum or Plasma from Donor;Js sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10868-8;Bacitracin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Bacitracin [Susceptibility] by Disk diffusion (KB);Bacitracin Islt KB;;ACTIVE;1.0j-a;2.73 +10869-6;Xylose^3H post 25 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --3 hours post 25 g xylose PO;Xylose 3h p 25 g Xyl PO Bld-mCnc;;ACTIVE;1.0j-a;2.73 +10870-4;Xylose^4H post 25 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --4 hours post 25 g xylose PO;Xylose 4h p 25 g Xyl PO Bld-mCnc;;ACTIVE;1.0j-a;2.40 +10871-2;Xylose^5H post 25 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --5 hours post 25 g xylose PO;Xylose 5h p 25 g Xyl PO Bld-mCnc;;ACTIVE;1.0j-a;2.40 +10872-0;Xylose^baseline;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --baseline;Xylose BS Bld-mCnc;;ACTIVE;1.0j-a;2.73 +10873-8;Beta-2-Microglobulin;MRat;24H;Urine;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/time] in 24 hour Urine;B2 Microglob 24h Ur-mRate;;ACTIVE;1.0j-a;2.73 +10874-6;Bombesin;MCnc;Pt;Plas;Qn;;CHEM;1;Bombesin [Mass/volume] in Plasma;Bombesin Plas-mCnc;;ACTIVE;1.0j-a;2.70 +10875-3;Carnitine esters;MCnc;Pt;Urine;Qn;;CHEM;1;Carnitine esters [Mass/volume] in Urine;Carn esters Ur-mCnc;;DISCOURAGED;1.0j-a;2.42 +1087-6;J little s super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Js sup(b) Ab [Presence] in Serum or Plasma;Js sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.56 +10876-1;Carnitine esters;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine esters [Mass/volume] in Serum or Plasma;Carn esters SerPl-mCnc;;DISCOURAGED;1.0j-a;2.73 +10877-9;Carnitine.free (C0);MCnc;Pt;Urine;Qn;;CHEM;1;Carnitine free (C0) [Mass/volume] in Urine;Carnitine Free Ur-mCnc;;DISCOURAGED;1.0j-a;2.73 +10878-7;Iodine.protein bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iodine.protein bound [Mass/volume] in Serum or Plasma;PB Iodine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10879-5;Isovalerylglycine;MCnc;Pt;Urine;Qn;;CHEM;1;Isovalerylglycine [Mass/volume] in Urine;Isovalerylgly Ur-mCnc;;DISCOURAGED;1.0j-a;2.44 +10880-3;Magnesium;MCnt;Pt;Stool;Qn;;CHEM;1;Magnesium [Mass/mass] in Stool;Magnesium Stl-mCnt;;ACTIVE;1.0j-a;2.73 +10881-1;Pentacarboxylporphyrins;MCnc;Pt;RBC;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/volume] in Red Blood Cells;Penta-CP RBC-mCnc;;ACTIVE;1.0j-a;2.73 +10882-9;Pentacarboxylporphyrins;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/volume] in Serum or Plasma;Penta-CP SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10883-7;Phenolphthalein;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Phenolphthalein [Mass/mass] in Stool;Phenolphthalein Stl-mCnt;;ACTIVE;1.0j-a;2.73 +1088-4;J little s super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Js sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Js sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10884-5;Phosphate;MCnt;Pt;Stool;Qn;;CHEM;1;Phosphate [Mass/mass] in Stool;Phosphate Stl-mCnt;;ACTIVE;1.0j-a;2.73 +10885-2;Porphyrins;MRat;24H;Urine;Qn;;CHEM;1;Porphyrins [Mass/time] in 24 hour Urine;Porphyrins 24h Ur-mRate;;ACTIVE;1.0j-a;2.73 +10886-0;Prostate specific Ag.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostate Specific Ag Free [Mass/volume] in Serum or Plasma;PSA Free SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10887-8;Pyridinoline;MRat;24H;Urine;Qn;;CHEM;1;Pyridinoline [Mass/time] in 24 hour Urine;PYD 24h Ur-mRate;;DISCOURAGED;1.0j-a;2.73 +10888-6;Triacylglycerol lipase;CCnc;Pt;Urine;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Urine;Lipase Ur-cCnc;;ACTIVE;1.0j-a;2.73 +10889-4;Bisacodyl;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Bisacodyl [Mass/mass] in Stool;Bisacodyl Stl-mCnt;;ACTIVE;1.0j-a;2.73 +10890-2;Normethsuximide;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Normethsuximide [Mass/volume] in Serum or Plasma;Deprecated Normethsuximide Ser-mCnc;;DEPRECATED;1.0j-a;2.70 +10891-0;Oxyphenisatin;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Oxyphenisatin [Mass/mass] in Stool;Oxyphenisatin Stl-mCnt;;ACTIVE;1.0j-a;2.73 +1089-2;J little s super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Js sup(b) Ag [Presence] on Red Blood Cells from Donor;Js sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10892-8;Pentoxifylline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pentoxifylline [Mass/volume] in Serum or Plasma;Pentoxifylline SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10893-6;Trenbolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trenbolone [Mass/volume] in Urine;Trenbolone Ur-mCnc;;ACTIVE;1.0j-a;2.70 +10894-4;Aspergillus niger Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus niger Ab [Presence] in Serum by Immune diffusion (ID);A niger Ab Ser Ql ID;;ACTIVE;1.0j-a;2.73 +10895-1;Clostridioides difficile toxin B;PrThr;Pt;Stool;Ord;;MICRO;1;Clostridioides difficile toxin B [Presence] in Stool;C diff Tox B Stl Ql;;ACTIVE;1.0j-a;2.73 +10896-9;Eastern equine encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Eastern equine encephalitis virus IgG Ab [Titer] in Serum by Immunofluorescence;EEEV IgG Titr Ser IF;;ACTIVE;1.0j-a;2.73 +10897-7;Eastern equine encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Eastern equine encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;EEEV IgG Titr CSF IF;;ACTIVE;1.0j-a;2.73 +10898-5;Eastern equine encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Eastern equine encephalitis virus IgM Ab [Titer] in Serum by Immunofluorescence;EEEV IgM Titr Ser IF;;ACTIVE;1.0j-a;2.73 +10899-3;Eastern equine encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Eastern equine encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;EEEV IgM Titr CSF IF;;ACTIVE;1.0j-a;2.73 +10-9;Amdinocillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Amdinocillin [Susceptibility] by Serum bactericidal titer;Amdinocillin Titr SBT;;ACTIVE;1.0;2.32 +1090-0;J little s super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Js sup(b) Ag [Presence] on Red Blood Cells;Js sup(b) Ag RBC Ql;;ACTIVE;1.0;2.56 +10900-9;Hepatitis B virus surface Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis B virus surface Ab [Presence] in Serum by Immunoassay;HBV surface Ab Ser Ql IA;;ACTIVE;1.0j-a;2.73 +10901-7;HIV 2 gp125 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp125 Ab [Presence] in Serum by Immunoblot;HIV2 gp125 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +10902-5;HIV 2 gp36 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp36 Ab [Presence] in Serum by Immunoblot;HIV2 gp36 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +10903-3;Hyaluronidase Ab;Titr;Pt;Ser;Qn;;MICRO;1;Hyaluronidase Ab [Titer] in Serum;Hyaluronidase Ab Titr Ser;;ACTIVE;1.0j-a;2.70 +10904-1;La Crosse virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;La Crosse virus IgG Ab [Titer] in Serum by Immunofluorescence;LACV IgG Titr Ser IF;;ACTIVE;1.0j-a;2.73 +10905-8;La Crosse virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;La Crosse virus IgM Ab [Titer] in Serum by Immunofluorescence;LACV IgM Titr Ser IF;;ACTIVE;1.0j-a;2.73 +10906-6;Saint Louis encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Saint Louis encephalitis virus IgG Ab [Titer] in Serum by Immunofluorescence;SLEV IgG Titr Ser IF;;ACTIVE;1.0j-a;2.73 +10907-4;Saint Louis encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Saint Louis encephalitis virus IgM Ab [Titer] in Serum by Immunofluorescence;SLEV IgM Titr Ser IF;;ACTIVE;1.0j-a;2.73 +10908-2;Streptococcus pneumoniae 7 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 7 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum7 IgG Ser IA-aCnc;;DEPRECATED;1.0j-a;2.69 +10909-0;Benzidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzidine [Mass/volume] in Urine;Benzidine Ur-mCnc;;ACTIVE;1.0j-a;2.70 +10910-8;Borate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Borate [Mass/volume] in Urine;Borate Ur-mCnc;;ACTIVE;1.0j-a;2.70 +10911-6;Dichlorobenzidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dichlorobenzidine [Mass/volume] in Urine;Dichlorobenzidine Ur-mCnc;;ACTIVE;1.0j-a;2.70 +10912-4;Lead;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Serum or Plasma;Lead SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10913-2;4,4'-Methylene bis(2-Chloroaniline);MCnc;Pt;Urine;Qn;;DRUG/TOX;1;4,4'-Methylene bis(2-Chloroaniline) [Mass/volume] in Urine;4,4'-MBOCA Ur-mCnc;;ACTIVE;1.0j-a;2.70 +10914-0;Methylenediamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylenediamine [Mass/volume] in Urine;Me-enediam Ur-mCnc;;ACTIVE;1.0j-a;2.73 +10915-7;Phencyclidine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Specimen;PCP Spec-mCnc;;ACTIVE;1.0j-a;2.73 +10916-5;Platinum;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Platinum [Mass/volume] in Blood;Platinum Bld-mCnc;;ACTIVE;1.0j-a;2.73 +10917-3;Zinc;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Zinc [Mass/mass] in Stool;Zinc Stl-mCnt;;ACTIVE;1.0j-a;2.70 +1091-8;K Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;K Ab [Presence] in Serum or Plasma from Blood product unit;K Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10918-1;Zinc;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Specimen;Zinc Spec-mCnc;;ACTIVE;1.0j-a;2.73 +10919-9;Anisakis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Anisakis IgE Ab [Units/volume] in Serum;Anisakis IgE Qn;;ACTIVE;1.0j-a;2.73 +10920-7;Phyllostachys pubescens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bamboo shoot IgE Ab [Units/volume] in Serum;Bamboo shoot IgE Qn;;ACTIVE;1.0j-a;2.73 +10921-5;Blomia tropicalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blomia tropicalis IgE Ab [Units/volume] in Serum;B tropicalis IgE Qn;;ACTIVE;1.0j-a;2.73 +10922-3;Bovine serum albumin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bovine serum albumin (BSA) IgE Ab [Units/volume] in Serum;BSA IgE Qn;;ACTIVE;1.0j-a;2.42 +10923-1;Bromelin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bromelin IgE Ab [Units/volume] in Serum;Bromelin IgE Qn;;ACTIVE;1.0j-a;2.73 +10924-9;Averrhoa carambola Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Starfruit IgE Ab [Units/volume] in Serum;Starfruit IgE Qn;;ACTIVE;1.0j-a;2.42 +10925-6;Scomber japonicus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chub Mackerel IgE Ab [Units/volume] in Serum;Chub Mackerel IgE Qn;;ACTIVE;1.0j-a;2.73 +1092-6;K Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;K Ab [Presence] in Serum or Plasma from Donor;K Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10926-4;Deer epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deer epithelium IgE Ab [Units/volume] in Serum;Deer Epith IgE Qn;;ACTIVE;1.0j-a;2.42 +10927-2;Elk meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Elk or Moose Meat IgE Ab [Units/volume] in Serum;Elk Meat IgE Qn;;ACTIVE;1.0j-a;2.42 +10928-0;Foeniculum vulgare fresh Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fennel Fresh IgE Ab [Units/volume] in Serum;Fennel Fresh IgE Qn;;ACTIVE;1.0j-a;2.73 +10929-8;Foeniculum vulgare seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fennel Seed IgE Ab [Units/volume] in Serum;Fennel Seed IgE Qn;;ACTIVE;1.0j-a;2.73 +10930-6;Artemia salina Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fish Feed IgE Ab [Units/volume] in Serum;Fish Feed IgE Qn;;ACTIVE;1.0j-a;2.42 +10931-4;Daphnia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Daphnia (fish feed) IgE Ab [Units/volume] in Serum;Daphnia IgE Qn;;ACTIVE;1.0j-a;2.73 +10932-2;Tetramin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tetramin IgE Ab [Units/volume] in Serum;Tetramin IgE Qn;;ACTIVE;1.0j-a;2.42 +10933-0;Cyamopsis tetragonoloba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Guar gum IgE Ab [Units/volume] in Serum;Guar gum IgE Qn;;ACTIVE;1.0j-a;2.73 +1093-4;K Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;K Ab [Presence] in Serum or Plasma;K Ab SerPl Ql;;ACTIVE;1.0;2.56 +10934-8;Psidium guajava Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Guava IgE Ab [Units/volume] in Serum;Guava IgE Qn;;ACTIVE;1.0j-a;2.73 +10935-5;Horse serum proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse serum proteins IgE Ab [Units/volume] in Serum;Horse Serum Prot IgE Qn;;ACTIVE;1.0j-a;2.42 +10936-3;Mare milk Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mare milk IgE Ab [Units/volume] in Serum;Mare Milk IgE Qn;;ACTIVE;1.0j-a;2.73 +10937-1;Origanum majorana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Marjoram IgE Ab [Units/volume] in Serum;Marjoram IgE Qn;;ACTIVE;1.0j-a;2.73 +10938-9;Ephestia kuehniella Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mediterranean flour moth IgE Ab [Units/volume] in Serum;Med flour moth IgE Qn;;ACTIVE;1.0j-a;2.42 +10939-7;Lepidorhombus whiffiagonis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whiff IgE Ab [Units/volume] in Serum;Whiff IgE Qn;;ACTIVE;1.0j-a;2.73 +10940-5;Cow milk boiled Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow milk boiled IgE Ab [Units/volume] in Serum;Cow Milk Boiled IgE Qn;;ACTIVE;1.0j-a;2.73 +10941-3;Milk powder Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Milk powder IgE Ab [Units/volume] in Serum;Milk Powder IgE Qn;;ACTIVE;1.0j-a;2.73 +1094-2;K Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;K Ag [Presence] on Red Blood Cells from Blood product unit;K Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +10942-1;Echinochloa crus-galli Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockspur IgE Ab [Units/volume] in Serum;Cockspur IgE Qn;;ACTIVE;1.0j-a;2.73 +10943-9;Mink epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mink epithelium IgE Ab [Units/volume] in Serum;Mink Epith IgE Qn;;ACTIVE;1.0j-a;2.42 +10944-7;Octopus vulgaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Octopus IgE Ab [Units/volume] in Serum;Octopus IgE Qn;;ACTIVE;1.0j-a;2.73 +10945-4;Papain Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Papain IgE Ab [Units/volume] in Serum;Papain IgE Qn;;ACTIVE;1.0j-a;2.73 +10946-2;Passiflora edulis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Passion fruit IgE Ab [Units/volume] in Serum;Passion fruit IgE Qn;;ACTIVE;1.0j-a;2.73 +10947-0;Diospyros kaki Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Persimmon IgE Ab [Units/volume] in Serum;Persimmon IgE Qn;;ACTIVE;1.0j-a;2.73 +10948-8;Pigeon feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon feather IgE Ab [Units/volume] in Serum;Pigeon Feather IgE Qn;;ACTIVE;1.0j-a;2.73 +10949-6;Malassezia furfur Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Malassezia furfur IgE Ab [Units/volume] in Serum;M furfur IgE Qn;;ACTIVE;1.0j-a;2.73 +10950-4;Reindeer epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Reindeer epithelium IgE Ab [Units/volume] in Serum;Reindeer Epith IgE Qn;;ACTIVE;1.0j-a;2.42 +10951-2;Sericin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sericin IgE Ab [Units/volume] in Serum;Sericin IgE Qn;;ACTIVE;1.0j-a;2.42 +10952-0;Swine urine proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swine urine proteins IgE Ab [Units/volume] in Serum;Swine Urine Prot IgE Qn;;ACTIVE;1.0j-a;2.42 +10953-8;Phleum pratense Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy IgG Ab [Units/volume] in Serum;Timothy IgG Qn;;ACTIVE;1.0j-a;2.69 +10954-6;Pinus edulis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pine Nut IgE Ab [Units/volume] in Serum;Pine Nut IgE Qn;;ACTIVE;1.0j-a;2.73 +10955-3;Pinus palustris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Long Leaf Pine IgE Ab [Units/volume] in Serum;Long Leaf Pine IgE Qn;;ACTIVE;1.0j-a;2.73 +10956-1;Pinus echinata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Short Leaf Pine IgE Ab [Units/volume] in Serum;Short Leaf Pine IgE Qn;;ACTIVE;1.0j-a;2.42 +10957-9;Pinus elliottii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Slash Pine IgE Ab [Units/volume] in Serum;Slash Pine IgE Qn;;ACTIVE;1.0j-a;2.42 +10958-7;Pinus virginiana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Virginia Scrub Pine IgE Ab [Units/volume] in Serum;Virg Scrub Pine IgE Qn;;ACTIVE;1.0j-a;2.42 +1095-9;K Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;K Ag [Presence] on Red Blood Cells from Donor;K Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +10959-5;Pleuronectes platessa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Plaice IgE Ab [Units/volume] in Serum;Plaice IgE Qn;;ACTIVE;1.0j-a;2.73 +10960-3;Rabbit serum proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit serum proteins IgE Ab [Units/volume] in Serum;Rabbit Serum Prot IgE Qn;;ACTIVE;1.0j-a;2.73 +10961-1;Rabbit urine proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit urine proteins IgE Ab [Units/volume] in Serum;Rabbit Urine Prot IgE Qn;;ACTIVE;1.0j-a;2.73 +10962-9;Artemisia tridentata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Sagebrush tridenda IgE Ab [Units/volume] in Serum;Deprecated Sagbrsh IgE Qn;;DEPRECATED;1.0j-a;2.69 +10963-7;Spondylocladium citrovirens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spondylocladium citrovirens IgE Ab [Units/volume] in Serum;S citrovirens IgE Qn;;ACTIVE;1.0j-a;2.42 +10964-5;17-Hydroxyprogesterone^15M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --15 minutes post 250 ug corticotropin IM;17OHP 15M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10965-2;17-Hydroxyprogesterone^30M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;17OHP 30M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10966-0;Glucose^2.5H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --2.5 hours post 75 g glucose PO;Glucose 2.5h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0j-a;2.56 +1096-7;K Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;K Ag [Presence] on Red Blood Cells;K Ag RBC Ql;;ACTIVE;1.0;2.73 +10967-8;Glucose^3.5H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --3.5 hours post 75 g glucose PO;Glucose 3.5h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0j-a;2.56 +10968-6;Glucose^4.5H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --4.5 hours post 75 g glucose PO;Glucose 4.5h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0j-a;2.56 +10969-4;Cystine+Homocysteine;PrThr;Pt;Urine;Ord;;CHEM;1;Cystine+Homocysteine [Presence] in Urine;Cys+HCys Ur Ql;;ACTIVE;1.0j-a;2.73 +10970-2;Galactose 1 phosphate uridyl transferase;CCnc;Pt;Bld;Qn;;CHEM;1;Galactose 1 phosphate uridyl transferase [Enzymatic activity/volume] in Blood;Gal1PUT Bld-cCnc;;ACTIVE;1.0j-a;2.73 +10971-0;Lysozyme;MCnc;Pt;Urine;Qn;;CHEM;1;Lysozyme [Mass/volume] in Urine;Lysozyme Ur-mCnc;;ACTIVE;1.0j-a;2.73 +10972-8;Organic acids;MCnc;Pt;Urine;Qn;;CHEM;1;Organic acids [Mass/volume] in Urine;Organic Acids Ur-mCnc;;DISCOURAGED;1.0j-a;2.73 +10973-6;3 methoxy O desmethylencainide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;3 methoxy O desmethylencainide [Mass/volume] in Serum or Plasma;3Me-O-desmethylencainide SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +10974-4;5-Fluorocytosine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;5-Fluorocytosine [Mass/volume] in Urine;5-fluorocytosine Ur-mCnc;;ACTIVE;1.0j-a;2.42 +1097-5;K little p super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Kp sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Kp sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +10975-1;6-Monoacetylmorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Urine;6MAM Ur-mCnc;;ACTIVE;1.0j-a;2.73 +10976-9;6-Monoacetylmorphine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Urine;6MAM Ur Ql;;ACTIVE;1.0j-a;2.73 +10977-7;ALPRAZolam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Blood;Alpraz Bld-mCnc;;ACTIVE;1.0j-a;2.73 +10978-5;Amitriptyline+Nortriptyline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Mass/volume] in Urine;Amitrip+Nor Ur-mCnc;;ACTIVE;1.0j-a;2.73 +10979-3;Carisoprodol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carisoprodol [Mass/volume] in Urine;Carisoprodol Ur-mCnc;;ACTIVE;1.0j-a;2.73 +10980-1;Cephapirin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cephapirin [Mass/volume] in Serum or Plasma;Cephapirin SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +10981-9;cloNIDine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;cloNIDine [Mass/volume] in Urine;cloNIDine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +10982-7;Demeclocycline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Demeclocycline [Mass/volume] in Serum or Plasma;Demeclocycline SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +1098-3;K little p super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Kp sup(a) Ab [Presence] in Serum or Plasma from Donor;Kp sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +10983-5;Norparamethadione;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norparamethadione [Mass/volume] in Serum or Plasma;NOMO SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10984-3;Dicloxacillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dicloxacillin [Mass/volume] in Serum or Plasma;Dicloxacillin SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +10985-0;Doxapram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxapram [Mass/volume] in Serum or Plasma;Doxapram SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +10986-8;Doxycycline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxycycline [Mass/volume] in Serum or Plasma;Doxycycline SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10987-6;Fluconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fluconazole [Mass/volume] in Serum or Plasma;Fluconazole SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10988-4;fluvoxaMINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;fluvoxaMINE [Mass/volume] in Serum or Plasma;fluvoxaMINE SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10989-2;Itraconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Itraconazole [Mass/volume] in Serum or Plasma;Itraconaz SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +109-9;Cefotaxime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefotaxime [Susceptibility] by Disk diffusion (KB);Cefotaxime Islt KB;;ACTIVE;1.0;2.73 +10990-0;Ketoconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ketoconazole [Mass/volume] in Serum or Plasma;Ketoconazole SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1099-1;K little p super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Kp sup(a) Ab [Presence] in Serum or Plasma;Kp sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +10991-8;metroNIDAZOLE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;metroNIDAZOLE [Mass/volume] in Serum or Plasma;metroNIDAZOLE SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10992-6;Norclozapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norclozapine [Mass/volume] in Serum or Plasma;Norclozapine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10993-4;Nafcillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nafcillin [Mass/volume] in Serum or Plasma;Nafcillin SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +10994-2;Naltrexone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Naltrexone [Mass/volume] in Serum or Plasma;Naltrexone SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10995-9;Neomycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Neomycin [Mass/volume] in Serum or Plasma;Neomycin SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +10996-7;Normeperidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normeperidine [Mass/volume] in Serum or Plasma;Normeperidine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +10997-5;O-desmethylencainide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;O-desmethylencainide [Mass/volume] in Serum or Plasma;O-desmethylencainide SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +10998-3;oxyCODONE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;oxyCODONE [Presence] in Urine;oxyCODONE Ur Ql;;ACTIVE;1.0j-a;2.73 +10999-1;Paramethadione;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Paramethadione [Mass/volume] in Serum or Plasma;PMO SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11000-7;Promethazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Promethazine [Presence] in Urine;Promethazine Ur Ql;;ACTIVE;1.0j-a;2.73 +11001-5;Pyrazinamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pyrazinamide [Mass/volume] in Serum or Plasma;PZA SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11002-3;Scopolamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Scopolamine [Presence] in Urine;Scopolamine Ur Ql;;ACTIVE;1.0j-a;2.56 +11003-1;Ticlopidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ticlopidine [Mass/volume] in Serum or Plasma;Ticlopidine SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +11004-9;Tricyclic antidepressants;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Urine;Tricyclics Ur Ql;;ACTIVE;1.0j-a;2.73 +11005-6;Trimethoprim;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimethoprim [Mass/volume] in Serum or Plasma;Trimethoprim SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11006-4;Borrelia burgdorferi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia burgdorferi Ab [Presence] in Serum;B burgdor Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +1100-7;K little p super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Kp sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Kp sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11007-2;Borrelia burgdorferi Ag;ACnc;Pt;Urine;Qn;;MICRO;1;Borrelia burgdorferi Ag [Units/volume] in Urine;B burgdor Ag Ur-aCnc;;ACTIVE;1.0j-a;2.73 +11008-0;Cytomegalovirus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Cytomegalovirus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CMV IgG Titr CSF IF;;ACTIVE;1.0j-a;2.73 +11009-8;Epstein Barr virus capsid Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Epstein Barr virus capsid IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;EBV VCA IgG Titr CSF IF;;ACTIVE;1.0j-a;2.73 +11010-6;Epstein Barr virus capsid Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Epstein Barr virus capsid IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;EBV VCA IgM Titr CSF IF;;ACTIVE;1.0j-a;2.73 +11011-4;Hepatitis C virus RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HCV RNA SerPl NAA+probe-aCnc;;ACTIVE;1.0j-a;2.73 +11012-2;Reovirus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Reovirus Ab [Titer] in Serum by Complement fixation;Reovirus Ab Titr Ser CF;;ACTIVE;1.0j-a;2.70 +11013-0;DNA double strand Ab;Titr;Pt;Ser;Qn;;SERO;1;DNA double strand Ab [Titer] in Serum;dsDNA Ab Titr Ser;;ACTIVE;1.0j-a;2.73 +11014-8;Somatotropin Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Somatotropin Ab [Titer] in Serum or Plasma;GH Ab Titr SerPl;;ACTIVE;1.0j-a;2.73 +1101-5;K little p super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Kp sup(a) Ag [Presence] on Red Blood Cells from Donor;Kp sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11015-5;Somatotropin binding protein;SCnc;Pt;Ser/Plas;Qn;;SERO;1;Somatotropin binding protein [Moles/volume] in Serum or Plasma;GHBP SerPl-sCnc;;ACTIVE;1.0j-a;2.73 +11016-3;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Esterase stain.non-specific;PATH;1;Microscopic observation [Identifier] in Blood or Marrow by Esterase stain.non-specific;NSE Stn Bld/Mar;;ACTIVE;1.0j-a;2.19 +11017-1;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Chloracetate esterase stain;PATH;1;Microscopic observation [Identifier] in Blood or Marrow by Chloracetate esterase stain;CAE Stn Bld/Mar;;ACTIVE;1.0j-a;2.19 +11018-9;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Peroxidase stain;PATH;1;Microscopic observation [Identifier] in Blood or Marrow by Peroxidase stain;Peroxidase Stn Bld/Mar;;ACTIVE;1.0j-a;2.73 +11019-7;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Sudan black B stain;PATH;1;Microscopic observation [Identifier] in Blood or Marrow by Sudan black B stain;Sudan Black B Stn Bld/Mar;;ACTIVE;1.0j-a;2.19 +11020-5;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Tartrate-resistant acid phosphatase stain;PATH;1;Microscopic observation [Identifier] in Blood or Marrow by Tartrate-resistant acid phosphatase stain;TRAP Stn Bld/Mar;;ACTIVE;1.0j-a;2.73 +11021-3;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Terminal deoxynucleotidyl transferase stain;PATH;1;Microscopic observation [Identifier] in Blood or Marrow by Terminal deoxynucleotidyl transferase stain;TdT Stn Bld/Mar;;ACTIVE;1.0j-a;2.73 +11022-1;Barbiturates;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Barbiturates [Mass/volume] in Meconium;Barbiturates Mec-mCnc;;DISCOURAGED;1.0j-a;2.73 +1102-3;K little p super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Kp sup(a) Ag [Presence] on Red Blood Cells;Kp sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +11023-9;Benzodiazepines;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Meconium;Benzodiaz Mec-mCnc;;DISCOURAGED;1.0j-a;2.73 +11024-7;Benzodiazepines;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Serum or Plasma;Benzodiaz SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11025-4;Methadone;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Meconium;Methadone Mec-mCnc;;DISCOURAGED;1.0j-a;2.73 +11026-2;Methaqualone;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Methaqualone [Mass/volume] in Meconium;Methaqualone Mec-mCnc;;DISCOURAGED;1.0j-a;2.73 +11027-0;Propoxyphene;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Propoxyphene [Mass/volume] in Meconium;Propoxyph Mec-mCnc;;ACTIVE;1.0j-a;2.73 +11028-8;Zinc;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Body fluid;Zinc Fld-mCnc;;ACTIVE;1.0j-a;2.70 +11029-6;Consistency;Type;Pt;Stool;Nom;;SPEC;1;Consistency of Stool;Consistency Stl;;ACTIVE;1.0j-a;2.73 +11030-4;(Aspergillus fumigatus+Aspergillus niger) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus+Aspergillus niger IgE Ab [Units/volume] in Serum;A fumigatus+A niger IgE Qn;;ACTIVE;1.0j-a;2.73 +1103-1;K little p super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Kp sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Kp sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11031-2;Lymphocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Body fluid;Lymphocytes/leuk NFr Fld;;ACTIVE;1.0j-a;2.73 +11032-0;Glucose^45M post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --45 minutes post 50 g lactose PO;Glucose 45M p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11033-8;Thyrotropin^45M post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --45 minutes post dose TRH IV;TSH 45M p TRH IV SerPl-mCnc;;DISCOURAGED;1.0j-a;2.42 +11034-6;Acetylcholine receptor binding Ab;SCnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor binding Ab [Moles/volume] in Serum;AChR Bind Ab Ser-sCnc;;ACTIVE;1.0j-a;2.73 +11035-3;Adenylate kinase;CCnc;Pt;RBC;Qn;;CHEM;1;Adenylate kinase [Enzymatic activity/volume] in Red Blood Cells;Adenylate kinase RBC-cCnc;;ACTIVE;1.0j-a;2.44 +11036-1;Aldolase;CCnc;Pt;RBC;Qn;;CHEM;1;Deprecated Aldolase [Enzymatic activity/volume] in Red Blood Cells;Deprecated Aldolase RBC-cCnc;;DEPRECATED;1.0j-a;2.36 +11037-9;Alpha-N-acetylgalactosaminidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-N-acetylgalactosaminidase [Enzymatic activity/volume] in Serum or Plasma;A-NAGA SerPl-cCnc;;ACTIVE;1.0j-a;2.48 +11038-7;Beta+gamma tocopherol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta+gamma tocopherol [Mass/volume] in Serum or Plasma;Beta+Gamma Tocopherol SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11039-5;C reactive protein;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;C reactive protein [Presence] in Serum or Plasma;CRP SerPl Ql;;ACTIVE;1.0j-a;2.73 +11040-3;Cortisol.free;MCnc;Pt;Urine;Qn;;CHEM;1;Cortisol Free [Mass/volume] in Urine;Cortis F Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11041-1;Creatinine^post dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass/volume] in Serum or Plasma --post dialysis;Creat p dialysis SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11042-9;Creatinine^pre dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass/volume] in Serum or Plasma --pre dialysis;Creat pre dial SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11043-7;Cryofibrinogen;PrThr;Pt;Plas;Ord;;CHEM;1;Cryofibrinogen [Presence] in Plasma;Cryofib Plas Ql;;ACTIVE;1.0j-a;2.73 +11044-5;Diphosphoglycerate mutase;CCnc;Pt;RBC;Qn;;CHEM;1;Diphosphoglycerate mutase [Enzymatic activity/volume] in Red Blood Cells;DPGM RBC-cCnc;;ACTIVE;1.0j-a;2.44 +11045-2;Enolase;CCnc;Pt;RBC;Qn;;CHEM;1;Enolase [Enzymatic activity/volume] in Red Blood Cells;Enolase RBC-cCnc;;ACTIVE;1.0j-a;2.44 +11046-0;EPINEPHrine;MCnc;Pt;Urine;Qn;;CHEM;1;EPINEPHrine [Mass/volume] in Urine;Epineph Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11047-8;Glucose phosphate isomerase;CCnc;Pt;RBC;Qn;;CHEM;1;Glucose phosphate isomerase [Enzymatic activity/volume] in Red Blood Cells;GPI RBC-cCnc;;ACTIVE;1.0j-a;2.73 +11048-6;Glyceraldehyde 3 phosphate dehydrogenase;CCnc;Pt;RBC;Qn;;CHEM;1;Glyceraldehyde 3 phosphate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells;GAPD RBC-cCnc;;ACTIVE;1.0j-a;2.44 +1104-9;K little p super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Kp sup(b) Ab [Presence] in Serum or Plasma from Donor;Kp sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11049-4;Hydroxyproline;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Hydroxyproline [Mass/volume] in Urine;Deprecated OH-Proline Ur-mCnc;;DEPRECATED;1.0j-a;2.36 +11050-2;Immunoglobulin light chains.kappa;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Kappa light chains [Mass/volume] in Serum or Plasma;Kappa LC SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11051-0;Immunoglobulin light chains.lambda;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lambda light chains [Mass/volume] in Serum or Plasma;Lambda LC SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11052-8;Ketamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ketamine [Mass/volume] in Urine;Ketamine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11053-6;Lactate dehydrogenase;CCnc;Pt;RBC;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells;LDH RBC-cCnc;;ACTIVE;1.0j-a;2.44 +11054-4;Cholesterol.in LDL/Cholesterol.in HDL;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma;LDLc/HDLc SerPl;;ACTIVE;1.0j-a;2.73 +11055-1;Melatonin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Melatonin [Mass/volume] in Serum or Plasma;Melatonin SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1105-6;K little p super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Kp sup(b) Ab [Presence] in Serum or Plasma;Kp sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.56 +11056-9;Melatonin;VRat;24H;Urine;Qn;;CHEM;1;Melatonin [Flow] in 24 hour Urine;Melatonin 24h Ur-vRate;;ACTIVE;1.0j-a;2.70 +11057-7;Monophosphoglyceromutase;CCnc;Pt;RBC;Qn;;CHEM;1;Monophosphoglyceromutase [Enzymatic activity/volume] in Red Blood Cells;MPGM RBC-cCnc;;ACTIVE;1.0j-a;2.44 +11058-5;Phosphofructokinase;CCnc;Pt;RBC;Qn;;CHEM;1;Phosphofructokinase [Enzymatic activity/volume] in Red Blood Cells;PFK RBC-cCnc;;ACTIVE;1.0j-a;2.44 +11059-3;Phosphoglycerate kinase;CCnc;Pt;RBC;Qn;;CHEM;1;Phosphoglycerate kinase [Enzymatic activity/volume] in Red Blood Cells;PGK RBC-cCnc;;ACTIVE;1.0j-a;2.44 +11060-1;Reducing substances;PrThr;Pt;Stool;Ord;;CHEM;1;Reducing substances [Presence] in Stool;Reducing Subs Stl Ql;;ACTIVE;1.0j-a;2.73 +11061-9;11-Dehydro thromboxane beta 2;MRat;24H;Urine;Qn;;CHEM;1;11-Dehydro thromboxane beta 2 [Mass/time] in 24 hour Urine;11-dehydro TBX2 24h Ur-mRate;;ACTIVE;1.0j-a;2.70 +11062-7;Thyroxine.albumin bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4).albumin bound [Mass/volume] in Serum or Plasma;T4 Alb Bnd SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11063-5;Triosephosphate isomerase;CCnc;Pt;RBC;Qn;;CHEM;1;Triosephosphate isomerase [Enzymatic activity/volume] in Red Blood Cells;TPI RBC-cCnc;;ACTIVE;1.0j-a;2.73 +1106-4;K little p super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Kp sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Kp sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11064-3;Urea nitrogen^post dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Serum or Plasma --post dialysis;BUN p dialysis SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11065-0;Urea nitrogen^pre dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Serum or Plasma --pre dialysis;BUN pre dial SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11066-8;Uroporphyrinogen III synthase;CCnc;Pt;RBC;Qn;;CHEM;1;Uroporphyrinogen III synthase [Enzymatic activity/volume] in Red Blood Cells;URO-S RBC-cCnc;;ACTIVE;1.0j-a;2.73 +11067-6;Bleeding time;Time;Pt;^Patient;Qn;;COAG;1;Bleeding time;Bleeding time Patient;;ACTIVE;1.0j-a;2.73 +11068-4;Microscopic observation;Prid;Pt;Body fld;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Body fluid by Cyto stain;Cyto Fld;;ACTIVE;1.0j-a;2.73 +11069-2;Microscopic observation;Prid;Pt;Gast fld;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Gastric fluid by Cyto stain;Cyto Gast;;ACTIVE;1.0j-a;2.19 +110-7;Cefotaxime;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefotaxime [Susceptibility] by Serum bactericidal titer;Cefotaxime Titr SBT;;ACTIVE;1.0;2.32 +11070-0;Microscopic observation;Prid;Pt;Urine;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Urine by Cyto stain;Cyto Ur;;ACTIVE;1.0j-a;2.73 +11071-8;Butalbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Butalbital [Mass/volume] in Urine;Butalbital Ur-mCnc;;ACTIVE;1.0j-a;2.73 +1107-2;K little p super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Kp sup(b) Ag [Presence] on Red Blood Cells from Donor;Kp sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11072-6;Despropionylfentanyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Despropionylfentanyl [Mass/volume] in Serum or Plasma;Des-Pr-fentanyl SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +11073-4;Despropionylfentanyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Despropionylfentanyl [Mass/volume] in Urine;Des-Pr-fentanyl Ur-mCnc;;ACTIVE;1.0j-a;2.70 +11074-2;Norfentanyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norfentanyl [Mass/volume] in Serum or Plasma;Norfentanyl SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11075-9;Norfentanyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norfentanyl [Mass/volume] in Urine;Norfentanyl Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11076-7;Hepatitis C virus 5-1-1 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus 5-1-1 Ab [Presence] in Serum by Immunoblot;HCV5-1-1 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +11077-5;Hepatitis C virus superoxide dismutase Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus superoxide dismutase Ab [Presence] in Serum by Immunoblot;HCV SOD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +11078-3;HIV 2 gp80 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp80 Ab [Presence] in Serum by Immunoblot;HIV2 gp80 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +11079-1;HIV 2 p26 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p26 Ab [Presence] in Serum by Immunoblot;HIV2 p26 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +1108-0;K little p super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Kp sup(b) Ag [Presence] on Red Blood Cells;Kp sup(b) Ag RBC Ql;;ACTIVE;1.0;2.56 +11080-9;HIV 2 p53 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p53 Ab [Presence] in Serum by Immunoblot;HIV2 p53 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +11081-7;HIV 2 p56 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p56 Ab [Presence] in Serum by Immunoblot;HIV2 p56 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +11082-5;HIV 2 p68 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p68 Ab [Presence] in Serum by Immunoblot;HIV2 p68 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +11083-3;Human papilloma virus identified;Prid;Pt;Cvx;Nom;;MICRO;1;Human papilloma virus identified in Cervix;HPV Cvx;;ACTIVE;1.0j-a;2.73 +11084-1;Reagin Ab;Titr;Pt;Ser;Qn;;MICRO;1;Reagin Ab [Titer] in Serum;Reagin Ab Titr Ser;;ACTIVE;1.0j-a;2.73 +11085-8;Schistosoma sp identified;Prid;Pt;Stool;Nom;Concentration;MICRO;1;Schistosoma sp identified in Stool by Concentration;Schistosoma Stl Conc;;ACTIVE;1.0j-a;2.73 +11086-6;Streptococcus pneumoniae Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Serum;S pneum Ag Ser Ql;;ACTIVE;1.0j-a;2.73 +11087-4;Insulin Ab;Titr;Pt;Ser;Qn;;SERO;1;Insulin Ab [Titer] in Serum;Insulin Ab Titr Ser;;ACTIVE;1.0j-a;2.73 +11088-2;Neuronal nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Neuronal nuclear Ab [Presence] in Serum;Hu Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +11089-0;Neuronal nuclear Ab;PrThr;Pt;CSF;Ord;;SERO;1;Neuronal nuclear Ab [Presence] in Cerebral spinal fluid;Hu Ab CSF Ql;;ACTIVE;1.0j-a;2.73 +11090-8;Smith extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Smith extractable nuclear Ab [Units/volume] in Serum;ENA SM Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11091-6;Alpha chlordane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Alpha chlordane [Mass/volume] in Serum or Plasma;A-Chlordane SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11092-4;Barbiturates;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Barbiturates [Mass/mass] in Hair;Barbiturates Hair-mCnt;;ACTIVE;1.0j-a;2.73 +11093-2;Dichlorodiphenyldichloroethylene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dichlorodiphenyldichloroethylene [Mass/volume] in Serum or Plasma;DDE SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11094-0;Dichlorodiphenyltrichloroethane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dichlorodiphenyltrichloroethane [Mass/volume] in Serum or Plasma;DDT SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11095-7;Dieldrin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dieldrin [Mass/volume] in Serum or Plasma;Dieldrin SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11096-5;Gamma chlordane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gamma chlordane [Mass/volume] in Serum or Plasma;G-Chlordane SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11097-3;Lindane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lindane [Mass/volume] in Serum or Plasma;Lindane SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1109-8;L little b;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated L little b;Deprecated Lb Ser Ql;;DEPRECATED;1.0;2.34 +11098-1;Malaoxon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Malaoxon [Mass/volume] in Serum or Plasma;Malaoxon SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +11099-9;Methoxychlor;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methoxychlor [Mass/volume] in Serum or Plasma;Methoxychlor SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11100-5;Tetrachloroethylene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tetrachloroethylene [Mass/volume] in Blood;TTCE Bld-mCnc;;ACTIVE;1.0j-a;2.73 +11101-3;Bacteria;Naric;Pt;Synv fld;Qn;Microscopy.light.HPF;MICRO;1;Bacteria [#/area] in Synovial fluid by Microscopy high power field;Bacteria Snv HPF-#/area;;ACTIVE;1.0j-a;2.73 +11102-1;Charcot-leyden crystals;Prid;Pt;XXX;Nom;Trichrome stain;MICRO;1;Charcot-leyden crystals [type] in Specimen by Trichrome stain;CL Cry Spec Tri Stn;;ACTIVE;1.0j-a;2.73 +11103-9;Neutrophils.band form/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Band form neutrophils/100 cells in Bone marrow by Manual count;Neuts Band NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11104-7;Normoblasts.basophilic/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Normoblasts Basophilic/100 cells in Bone marrow by Manual count;Baso Normoblasts NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11105-4;Basophils/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Basophils/100 cells in Bone marrow by Manual count;Basophils NFr Mar Manual;;ACTIVE;1.0j-a;2.73 +1110-6;L little e super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Le sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Le sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11106-2;Eosinophils/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Eosinophils/100 cells in Bone marrow by Manual count;Eosinophil NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11107-0;Lymphocytes.variant/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Variant lymphocytes/100 cells in Bone marrow by Manual count;Variant Lymphs NFr Mar Manual;;ACTIVE;1.0j-a;2.73 +11108-8;Lymphocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Lymphocytes/100 cells in Bone marrow by Manual count;Lymphocytes NFr Mar Manual;;ACTIVE;1.0j-a;2.73 +11109-6;Mast cells/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Mast cells/100 cells in Bone marrow by Manual count;Masts NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11110-4;Megakaryocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Megakaryocytes/100 cells in Bone marrow by Manual count;Megakaryocytes NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11111-2;Metamyelocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Metamyelocytes/100 cells in Bone marrow by Manual count;Metamyelocytes NFr Mar Manual;;ACTIVE;1.0j-a;2.73 +11112-0;Monocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Monocytes/100 cells in Bone marrow by Manual count;Monocytes NFr Mar Manual;;ACTIVE;1.0j-a;2.73 +11113-8;Myeloblasts/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Myeloblasts/100 cells in Bone marrow by Manual count;Myeloblasts NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +1111-4;L little e super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Le sup(a) Ab [Presence] in Serum or Plasma from Donor;Le sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11114-6;Myelocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Myelocytes/100 cells in Bone marrow by Manual count;Myelocytes NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11115-3;Neutrophils/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Neutrophils/100 cells in Bone marrow by Manual count;Neutrophils NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11116-1;Normoblasts.orthochromic/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Normoblasts Orthochromic/100 cells in Bone marrow by Manual count;Ortho Normoblasts NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11117-9;Plasma cells.immature/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Plasma cells immature/100 cells in Bone marrow by Manual count;Imm Plasma Cells NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11118-7;Plasma cells/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Plasma cells/100 cells in Bone marrow by Manual count;Plasma Cells NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11119-5;Normoblasts.polychromatophilic/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Normoblasts Polychromatophilic/100 cells in Bone marrow by Manual count;Poly Normoblasts NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11120-3;Promyelocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Promyelocytes/100 cells in Bone marrow by Manual count;Promyelocytes NFr Mar Manual;;ACTIVE;1.0j-a;2.73 +11121-1;Prolymphocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Prolymphocytes/100 cells in Bone marrow by Manual count;Prolymphocytes NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +1112-2;L little e super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Le sup(a) Ab [Presence] in Serum or Plasma;Le sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +11122-9;Promonocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Promonocytes/100 cells in Bone marrow by Manual count;Promonycytes NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11123-7;Promyelocytes/100 leukocytes;NFr;Pt;Bone mar;Qn;Microscopy;HEM/BC;1;Deprecated Promyelocytes/100 cells in Bone marrow by Microscopy;Deprecated Promyelocytes Fr Mar Micro;;DEPRECATED;1.0j-a;2.70 +11124-5;Pronormoblasts/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Pronormoblasts/100 cells in Bone marrow by Manual count;Pronormoblasts NFr Mar Manual;;ACTIVE;1.0j-a;2.70 +11125-2;Platelet morphology finding;Prid;Pt;Bld;Nom;;HEM/BC;1;Platelet morphology finding [Identifier] in Blood;Plat morph Bld;;ACTIVE;1.0j-a;2.73 +11126-0;Platelets;Morph;Pt;Bone mar;Nom;;HEM/BC;1;Platelets [Morphology] in Bone marrow;Platelet Mar;;ACTIVE;1.0j-a;2.73 +11127-8;Erythrocytes;Morph;Pt;Bone mar;Nom;;HEM/BC;1;Erythrocytes [Morphology] in Bone marrow;RBC Mar;;ACTIVE;1.0j-a;2.73 +11128-6;Neutrophils.segmented/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Segmented neutrophils/100 cells in Bone marrow;Neuts Seg NFr Mar;;ACTIVE;1.0j-a;2.73 +11129-4;Pronormoblasts;NCnc;Pt;Bld;Qn;;HEM/BC;1;Pronormoblasts [#/volume] in Blood;Pronormoblasts # Bld;;ACTIVE;1.0j-a;2.42 +1113-0;L little e super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Le sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Le sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11130-2;Lymphocytes B;NCnc;Pt;Bld;Qn;;CELLMARK;1;B lymphocytes [#/volume] in Blood;B Lymphocytes # Bld;;ACTIVE;1.0j-a;2.73 +11131-0;Erythroblasts early/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Deprecated Normoblasts Basophilic/100 cells in Bone marrow by Microscopy;Deprecated Erythroblasts early Fr Mar;;DEPRECATED;1.0j-a;2.70 +11132-8;Bilirubin;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Bilirubin [Mass/volume] in Body fluid;Deprecated Bilirub Fld-mCnc;;DEPRECATED;1.0j-a;2.36 +11133-6;Catecholamines.free;MCnc;Pt;Urine;Qn;;CHEM;1;Catecholamines Free [Mass/volume] in Urine;FCA Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11134-4;Appearance;Aper;Pt;Body fld.spun;Nom;;SPEC;1;Appearance of Spun Body fluid;Appearance spun Fld;;ACTIVE;1.0j-a;2.73 +11135-1;Appearance;Aper;Pt;CSF.spun;Nom;;SPEC;1;Appearance of Spun Cerebral spinal fluid;Appearance spun CSF;;ACTIVE;1.0j-a;2.73 +11136-9;Erythroblasts late/100 erythrocytes;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Deprecated Normoblasts Orthochromic/100 cells in Bone marrow by Microscopy;Deprecated Erythroblasts late Fr Mar;;DEPRECATED;1.0j-a;2.70 +11137-7;Erythroblasts mid/100 erythrocytes;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Deprecated Normoblasts Polychromatophilic/100 cells in Bone marrow by Microscopy;Deprecated Erythroblasts mid Fr Mar;;DEPRECATED;1.0j-a;2.70 +11138-5;Myeloid cells/Erythroid cells;NRto;Pt;Bone mar;Qn;;HEM/BC;1;Myeloid cells/Erythroid cells [# Ratio] in Bone marrow;Myeloid cells/Erythroid Cells Mar;;ACTIVE;1.0j-a;2.26 +11139-3;Metanephrine;MCnc;Pt;Urine;Qn;;CHEM;1;Metanephrine [Mass/volume] in Urine;Metaneph Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11140-1;Metanephrine;SRat;24H;Urine;Qn;;CHEM;1;Metanephrine [Moles/time] in 24 hour Urine;Metaneph 24h Ur-sRate;;ACTIVE;1.0j-a;2.73 +11141-9;Phosphate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Phosphate/Creatinine [Mass Ratio] in Urine;Phosphate/Creat Ur;;ACTIVE;1.0j-a;2.73 +11142-7;Glucose^15M post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 minutes post 100 g glucose PO;Glucose 15M p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +11143-5;Glucose^45M post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --45 minutes post 100 g glucose PO;Glucose 45M p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +11144-3;Homovanillate;MCnc;Pt;Urine;Qn;;CHEM;1;Homovanillate [Mass/volume] in Urine;HVA Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11145-0;5-Hydroxyindoleacetate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate/Creatinine [Mass Ratio] in Urine;5OH-indoleacetate/Creat Ur;;ACTIVE;1.0j-a;2.73 +11146-8;Homovanillate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Homovanillate/Creatinine [Mass Ratio] in Urine;HVA/Creat Ur;;ACTIVE;1.0j-a;2.73 +11147-6;Myoglobin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Myoglobin/Creatinine [Mass Ratio] in Urine;Myoglobin/Creat Ur;;ACTIVE;1.0j-a;2.42 +1114-8;L little e super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Le sup(a) Ag [Presence] on Red Blood Cells from Donor;Le sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.73 +11148-4;Potassium/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Potassium/Creatinine [Mass Ratio] in Urine;Potassium/Creat Ur;;DISCOURAGED;1.0j-a;2.44 +11149-2;Sodium/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Sodium/Creatinine [Mass Ratio] in Urine;Sodium/Creat Ur;;DISCOURAGED;1.0j-a;2.44 +111-5;cefoTEtan;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;cefoTEtan [Susceptibility] by Minimum lethal concentration (MLC);cefoTEtan Islt MLC;;ACTIVE;1.0;2.19 +11150-0;Blasts/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Blasts/100 cells in Bone marrow;Blasts NFr Mar;;ACTIVE;1.0j-a;2.73 +11151-8;Hematocrit;VFr;Pt;BldCo;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Cord blood;Hct VFr BldCo;;ACTIVE;1.0j-a;2.70 +11152-6;Eosinophils/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Eosinophils/100 cells in Bone marrow;Eosinophil NFr Mar;;ACTIVE;1.0j-a;2.70 +11153-4;Hematocrit;VFr;Pt;Body fld;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Body fluid;Hct VFr Fld;;ACTIVE;1.0j-a;2.73 +11154-2;Cholinesterase;CCnc;Pt;Bld;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/volume] in Blood;Cholinesterase Bld-cCnc;;ACTIVE;1.0j-a;2.68 +1115-5;L little e super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Le sup(a) Ag [Presence] on Red Blood Cells;Le sup(a) Ag RBC Ql;;ACTIVE;1.0;2.73 +11155-9;Cortisol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Cortisol/Creatinine [Mass Ratio] in Urine;Cortis/Creat Ur;;ACTIVE;1.0j-a;2.73 +11156-7;Leukocyte morphology finding;Prid;Pt;Bld;Nom;;HEM/BC;1;Leukocyte morphology finding [Identifier] in Blood;WBC morph Bld;;ACTIVE;1.0j-a;2.73 +11157-5;Leukocytes;Morph;Pt;Bone mar;Nom;;HEM/BC;1;Leukocytes [Morphology] in Bone marrow;WBC Mar;;ACTIVE;1.0j-a;2.73 +11158-3;Appearance;Aper;Pt;Ser;Nom;;SPEC;1;Appearance of Serum;Appearance Ser;;ACTIVE;1.0j-a;2.73 +11159-1;Alkalase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alkalase IgE Ab [Units/volume] in Serum;Alkalase IgE Qn;;ACTIVE;1.0j-a;2.73 +11160-9;Beta lactoglobulin Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beta lactoglobulin IgG Ab [Units/volume] in Serum;B-Lactoglob IgG Qn;;ACTIVE;1.0j-a;2.73 +11161-7;Bran wheat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat Bran IgE Ab [Units/volume] in Serum;Wheat Bran IgE Qn;;ACTIVE;1.0j-a;2.73 +11162-5;Theobroma cacao Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cocoa IgE Ab [Units/volume] in Serum;Deprecated Cocoa IgE Qn;;DEPRECATED;1.0j-a;2.69 +1116-3;L little e super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Le sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Le sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11163-3;Carageenan Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Carageenan IgE Ab [Units/volume] in Serum;Carageenan IgE Qn;;ACTIVE;1.0j-a;2.73 +11164-1;Cheese cream Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cream Cheese IgE Ab [Units/volume] in Serum;Cream Cheese IgE Qn;;ACTIVE;1.0j-a;2.73 +11165-8;Chinchilla Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chinchilla IgE Ab [Units/volume] in Serum;Chinchilla IgE Qn;;ACTIVE;1.0j-a;2.42 +11166-6;Chortoglyphus arcuatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chortoglyphus arcuatus IgE Ab [Units/volume] in Serum;C arcuatus IgE Qn;;ACTIVE;1.0j-a;2.42 +11167-4;Cockatiel feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockatiel feather IgE Ab [Units/volume] in Serum;Cockatiel Feather IgE Qn;;ACTIVE;1.0j-a;2.73 +11168-2;Cupressus arizonica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Arizona Cypress IgE Ab [Units/volume] in Serum;Arizona Cypress IgE Qn;;ACTIVE;1.0j-a;2.73 +11169-0;Deer hair Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deer hair IgE Ab [Units/volume] in Serum;Deer Hair IgE Qn;;ACTIVE;1.0j-a;2.73 +11170-8;Dematiaceae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dematiaceae IgE Ab [Units/volume] in Serum;Dematiaceae IgE Qn;;ACTIVE;1.0j-a;2.42 +1117-1;L little e super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Le sup(b) Ab [Presence] in Serum or Plasma from Donor;Le sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11171-6;Erythromycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Erythromycin IgE Ab [Units/volume] in Serum;Erythromycin IgE Qn;;ACTIVE;1.0j-a;2.73 +11172-4;Ferret epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ferret epithelium IgE Ab [Units/volume] in Serum;Ferret Epith IgE Qn;;ACTIVE;1.0j-a;2.73 +11173-2;Ficus carica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fig IgE Ab [Units/volume] in Serum;Fig IgE Qn;;ACTIVE;1.0j-a;2.73 +11174-0;Sitophilus granarius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grain weevel IgE Ab [Units/volume] in Serum;Grain Weevel IgE Qn;;ACTIVE;1.0j-a;2.73 +11175-7;Helminthosporium sativum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Helminthosporium sativum IgE Ab [Units/volume] in Serum;H sativum IgE Qn;;ACTIVE;1.0j-a;2.73 +11176-5;Lactalbumin alpha Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin alpha IgG Ab [Units/volume] in Serum;A-Lactalb IgG Qn;;ACTIVE;1.0j-a;2.69 +11177-3;Lactalbumin beta Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin beta IgE Ab [Units/volume] in Serum;B-Lactalb IgE Qn;;ACTIVE;1.0j-a;2.73 +11178-1;Beta galactosidase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beta galactosidase IgE Ab [Units/volume] in Serum;B-Galactosidase IgE Qn;;ACTIVE;1.0j-a;2.73 +11179-9;Tilia cordata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Linden IgE Ab [Units/volume] in Serum;Linden IgE Qn;;ACTIVE;1.0j-a;2.73 +11180-7;Lupinus spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lupin IgE Ab [Units/volume] in Serum;Lupin IgE Qn;;ACTIVE;1.0j-a;2.73 +11181-5;Lycopodium spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lycopodium spp IgE Ab [Units/volume] in Serum;Lycopodium IgE Qn;;ACTIVE;1.0j-a;2.42 +11182-3;Lysozyme Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lysozyme IgE Ab [Units/volume] in Serum;Lysozyme IgE Qn;;ACTIVE;1.0j-a;2.73 +11183-1;Macadamia spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Macadamia IgE Ab [Units/volume] in Serum;Macadamia IgE Qn;;ACTIVE;1.0j-a;2.73 +11184-9;Trachurus japonicus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Scad IgE Ab [Units/volume] in Serum;Scad IgE Qn;;ACTIVE;1.0j-a;2.73 +11185-6;Maxatase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Maxatase IgE Ab [Units/volume] in Serum;Maxatase IgE Qn;;ACTIVE;1.0j-a;2.42 +11186-4;Setaria italica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Foxtail Millet IgE Ab [Units/volume] in Serum;Foxtail Millet IgE Qn;;ACTIVE;1.0j-a;2.42 +11187-2;Penicillium frequentans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium frequentans IgE Ab [Units/volume] in Serum;P frequentans IgE Qn;;ACTIVE;1.0j-a;2.73 +11188-0;Pepper cayenne Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cayenne IgE Ab [Units/volume] in Serum;Cayenne IgE Qn;;ACTIVE;1.0j-a;2.73 +1118-9;L little e super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Le sup(b) Ab [Presence] in Serum or Plasma;Le sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.56 +11189-8;Pepper jalapeno Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Jalepeno Pepper IgE Ab [Units/volume] in Serum;Jalepeno Pepper IgE Qn;;ACTIVE;1.0j-a;2.73 +11190-6;Mentha piperita Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mint IgE Ab [Units/volume] in Serum;Mint IgE Qn;;ACTIVE;1.0j-a;2.73 +11191-4;Pollachius virens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pollock IgE Ab [Units/volume] in Serum;Pollock IgE Qn;;ACTIVE;1.0j-a;2.73 +11192-2;Protamine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Protamine IgE Ab [Units/volume] in Serum;Protamine IgE Qn;;ACTIVE;1.0j-a;2.73 +11193-0;Cucurbita pepo seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pumpkin Seed IgE Ab [Units/volume] in Serum;Pumpkin Seed IgE Qn;;ACTIVE;1.0j-a;2.73 +11194-8;Brassica napus pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rape Pollen IgE Ab [Units/volume] in Serum;Rape Poln IgE Qn;;ACTIVE;1.0j-a;2.73 +11195-5;Brassica rapa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rapeseed IgE Ab [Units/volume] in Serum;Rapeseed IgE Qn;;ACTIVE;1.0j-a;2.73 +11196-3;Hoplostethus atlanticus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Orange roughy IgE Ab [Units/volume] in Serum;Orange roughy IgE Qn;;ACTIVE;1.0j-a;2.73 +1119-7;L little e super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Le sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Le sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11197-1;Sardina pilchardus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sardine (pilchard) IgE Ab [Units/volume] in Serum;Sardine (pilchard) IgE Qn;;ACTIVE;1.0j-a;2.73 +11198-9;Shark Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shark IgE Ab [Units/volume] in Serum;Shark IgE Qn;;ACTIVE;1.0j-a;2.73 +11199-7;Silver Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver IgE Ab [Units/volume] in Serum;Silver IgE Qn;;ACTIVE;1.0j-a;2.42 +11200-3;Helix aspersa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Escargot IgE Ab [Units/volume] in Serum;Escargot IgE Qn;;ACTIVE;1.0j-a;2.73 +11201-1;Succinylcholine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Succinylcholine IgE Ab [Units/volume] in Serum;Succinylcholine IgE Qn;;ACTIVE;1.0j-a;2.73 +11202-9;Artemisia dracunculus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tarragon IgE Ab [Units/volume] in Serum;Tarragon IgE Qn;;ACTIVE;1.0j-a;2.73 +11203-7;Trichosporon pullulans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trichosporon pullulans IgE Ab [Units/volume] in Serum;T pullulans IgE Qn;;ACTIVE;1.0j-a;2.73 +11204-5;Ulocladium chartarum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ulocladium chartarum IgE Ab [Units/volume] in Serum;U chartarum IgE Qn;;ACTIVE;1.0j-a;2.73 +1120-5;L little e super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Le sup(b) Ag [Presence] on Red Blood Cells from Donor;Le sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11205-2;Polistes spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Paper Wasp IgE Ab [Units/volume] in Serum;Deprecated Paper Wasp IgE Qn;;DEPRECATED;1.0j-a;2.69 +11206-0;18-Hydroxydeoxycorticosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;18-Hydroxydeoxycorticosterone [Mass/volume] in Serum or Plasma;18OH-DOC SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11207-8;Alpha-1-Fetoprotein;MCnc;Pt;Body fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Body fluid;AFP Fld-mCnc;;ACTIVE;1.0j-a;2.73 +11208-6;Atrial natriuretic factor;MCnc;Pt;Plas;Qn;;CHEM;1;Atrial natriuretic factor [Mass/volume] in Plasma;ANF Plas-mCnc;;ACTIVE;1.0j-a;2.73 +11209-4;Beta glucuronidase;CCnc;Pt;CSF;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/volume] in Cerebral spinal fluid;B-Glucuronidase CSF-cCnc;;ACTIVE;1.0j-a;2.73 +11210-2;Cancer Ag 125;ACnc;Pt;Body fld;Qn;;CHEM;1;Cancer Ag 125 [Units/volume] in Body fluid;Cancer Ag125 Fld-aCnc;;ACTIVE;1.0j-a;2.73 +11211-0;Carbon dioxide;SCnc;Pt;Body fld;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Body fluid;CO2 Fld-sCnc;;ACTIVE;1.0j-a;2.73 +11212-8;Coproporphyrin;MCnc;Pt;Urine;Qn;;CHEM;1;Coproporphyrin [Mass/volume] in Urine;Copro Ur-mCnc;;ACTIVE;1.0j-a;2.73 +1121-3;L little e super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Le sup(b) Ag [Presence] on Red Blood Cells;Le sup(b) Ag RBC Ql;;ACTIVE;1.0;2.73 +11213-6;Corticotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Corticotropin releasing hormone [Mass/volume] in Serum or Plasma;ACTH RH SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11214-4;Creatinine;ACnc;Pt;Urine;Ord;;CHEM;1;Deprecated Creatinine;Deprecated Creat Ur Ql;;DEPRECATED;1.0j-a;2.36 +11215-1;Delta aminolevulinate;MCnc;Pt;Urine;Qn;;CHEM;1;Delta aminolevulinate [Mass/volume] in Urine;D-ALA Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11216-9;Deoxypyridinoline;MCnc;Pt;Urine;Qn;;CHEM;1;Deoxypyridinoline [Mass/volume] in Urine;DPD Ur-mCnc;;DISCOURAGED;1.0j-a;2.44 +11217-7;Hexaporphyrin;MRat;24H;Urine;Qn;;CHEM;1;Deprecated Hexaporphyrin [Mass/time] in 24 hour Urine;Deprecated Hexapor 24h Ur-mRate;;DEPRECATED;1.0j-a;2.70 +11218-5;Albumin;MCnc;Pt;Urine;Qn;Detection limit <= 20 mg/L test strip;CHEM;1;Microalbumin [Mass/volume] in Urine by Test strip;Microalbumin Ur Test Str-mCnc;;ACTIVE;1.0j-a;2.73 +11219-3;Immunoglobulin light chains;PrThr;Pt;Ser;Ord;;CHEM;1;Immunoglobulin light chains [Presence] in Serum;BJ Protein Ser Ql;;ACTIVE;1.0j-a;2.73 +11220-1;Iodine.free;MRat;24H;Urine;Qn;;CHEM;1;Iodine Free [Mass/time] in 24 hour Urine;Iodine Free 24h Ur-mRate;;ACTIVE;1.0j-a;2.73 +1122-1;L little e super little x Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Le sup(x) Ab [Presence] in Serum or Plasma from Blood product unit;Le sup(x) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11221-9;Pentacarboxylporphyrins;MCnc;Pt;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/volume] in Urine;Penta-CP Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11222-7;Pentacarboxylporphyrins;PrThr;Pt;Urine;Ord;;CHEM;1;Pentacarboxylporphyrins [Presence] in Urine;Penta-CP Ur Ql;;ACTIVE;1.0j-a;2.56 +11223-5;Phenolphthalein;MCnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Phenolphthalein;Deprecated Phenolphthalein Ur Ql;;DEPRECATED;1.0j-a;2.36 +11224-3;Phosphoethanolamine;MCnc;Pt;CSF;Qn;;CHEM;1;Phosphoethanolamine [Mass/volume] in Cerebral spinal fluid;PETN CSF-mCnc;;ACTIVE;1.0j-a;2.42 +11225-0;Porphyrins;MCnc;Pt;Urine;Qn;;CHEM;1;Porphyrins [Mass/volume] in Urine;Porphyrins Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11226-8;Prorenin;ACnc;Pt;Plas;Qn;;CHEM;1;Prorenin [Units/volume] in Plasma;Prorenin Plas-aCnc;;ACTIVE;1.0j-a;2.70 +11227-6;Pyruvate kinase;PrThr;Pt;Bld;Ord;;CHEM;1;Pyruvate kinase [Presence] in Blood;PK Bld Ql;;ACTIVE;1.0j-a;2.73 +11228-4;Uroporphyrin;MCnc;Pt;Urine;Qn;;CHEM;1;Uroporphyrin [Mass/volume] in Urine;Uropor Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11229-2;3-O-Methyldopa;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;3-O-Methyldopa [Mass/volume] in Serum or Plasma;3-o-methyldopa SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +112-3;cefoTEtan;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefoTEtan [Susceptibility] by Minimum inhibitory concentration (MIC);cefoTEtan Islt MIC;;ACTIVE;1.0;2.73 +11230-0;Amobarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amobarbital [Mass/volume] in Urine;Amobarbital Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11231-8;Astemizole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Astemizole [Mass/volume] in Serum or Plasma;Astemizole SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +11232-6;Bromocriptine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromocriptine [Mass/volume] in Serum or Plasma;Bromocriptine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11233-4;Brompheniramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Brompheniramine [Mass/volume] in Serum or Plasma;Brompheniramine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11234-2;Propoxyphene;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Propoxyphene [Mass/mass] in Hair;Propoxyph Hair-mCnt;;ACTIVE;1.0j-a;2.70 +11235-9;fentaNYL;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;fentaNYL [Presence] in Urine;fentaNYL Ur Ql;;ACTIVE;1.0j-a;2.73 +11236-7;Gemfibrozil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gemfibrozil [Mass/volume] in Serum or Plasma;Gemfibrozil SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +11237-5;hydrALAZINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;hydrALAZINE [Mass/volume] in Serum or Plasma;hydrALAZINE SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +11238-3;Hydroxyalprazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hydroxyalprazolam [Mass/volume] in Urine;OH-Alpraz Ur-mCnc;;ACTIVE;1.0j-a;2.73 +1123-9;L little e super little x Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Le sup(x) Ab [Presence] in Serum or Plasma from Donor;Le sup(x) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11239-1;hydrOXYzine;MCnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated hydrOXYzine;Deprecated hydrOXYzine Ur Ql;;DEPRECATED;1.0j-a;2.36 +11240-9;hydrOXYzine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;hydrOXYzine [Mass/volume] in Urine;hydrOXYzine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +11241-7;Hyoscyamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hyoscyamine [Mass/volume] in Serum or Plasma;Hyoscyamine SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +11242-5;Mercaptopurine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mercaptopurine [Mass/volume] in Serum or Plasma;Mercaptopurine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11243-3;Methadone;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Methadone [Mass/mass] in Hair;Methadone Hair-mCnt;;ACTIVE;1.0j-a;2.70 +11244-1;Morphine.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Morphine Free [Mass/volume] in Serum or Plasma;Morphine Free SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11245-8;Orphenadrine;MCnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Orphenadrine;Deprecated Orphenadrine Ur Ql;;DEPRECATED;1.0j-a;2.36 +11246-6;oxyCODONE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;oxyCODONE [Mass/volume] in Urine;oxyCODONE Ur-mCnc;;ACTIVE;1.0j-a;2.73 +1124-7;L little e super little x Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Le sup(x) Ab [Presence] in Serum or Plasma;Le sup(x) Ab SerPl Ql;;ACTIVE;1.0;2.56 +11247-4;oxyMORphone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;oxyMORphone [Presence] in Urine;oxyMORphone Ur Ql;;ACTIVE;1.0j-a;2.73 +11248-2;Pergolide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pergolide [Mass/volume] in Serum or Plasma;Pergolide SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +11249-0;Phenacemide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenacemide [Mass/volume] in Serum or Plasma;Phenacemide SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11250-8;Phenylethylmalonate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenylethylmalonate [Mass/volume] in Serum or Plasma;Phenylethylmalonate SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +11251-6;Piroxicam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Piroxicam [Mass/volume] in Serum or Plasma;Piroxicam SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +11252-4;Scopolamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Scopolamine [Mass/volume] in Serum or Plasma;Scopolamine SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +11253-2;Tacrolimus;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Blood;Tacrolimus Bld-mCnc;;ACTIVE;1.0j-a;2.73 +1125-4;L little e Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Le Ab [Presence] in Serum or Plasma from Blood product unit;Le Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11254-0;Chlamydophila pneumoniae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae Ab [Titer] in Serum;C pneum Ab Titr Ser;;ACTIVE;1.0j-a;2.73 +11255-7;Haemophilus ducreyi;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Haemophilus ducreyi [Presence] in Specimen by Organism specific culture;H ducreyi Spec Ql Cult;;ACTIVE;1.0j-a;2.73 +11256-5;Haemophilus influenzae B Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae B IgG Ab [Mass/volume] in Serum;Haem influ B IgG Ser-mCnc;;ACTIVE;1.0j-a;2.73 +11257-3;Haemophilus influenzae B Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Haemophilus influenzae B IgG Ab [Mass/volume] in Serum by Immunoassay;Haem influ B IgG Ser IA-mCnc;;ACTIVE;1.0j-a;2.73 +11258-1;Hepatitis B virus DNA;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus DNA [Units/volume] in Serum;HBV DNA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11259-9;Hepatitis C virus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Presence] in Serum or Plasma by NAA with probe detection;HCV RNA SerPl Ql NAA+probe;;ACTIVE;1.0j-a;2.73 +11260-7;HTLV I Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;HTLV I Ab [Presence] in Serum by Immunoassay;HTLV I Ab Ser Ql IA;;ACTIVE;1.0j-a;2.73 +11261-5;Bacteria identified;Prid;Pt;Vag;Nom;Aerobic culture;MICRO;1;Bacteria identified in Vaginal fluid by Aerobe culture;Bacteria Vag Aerobe Cult;;ACTIVE;1.0j-a;2.73 +1126-2;L little e Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Le Ab [Presence] in Serum or Plasma from Donor;Le Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11262-3;Parainfluenza virus 3 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 IgG Ab [Titer] in Serum;HPIV3 IgG Titr Ser;;ACTIVE;1.0j-a;2.70 +11263-1;Parainfluenza virus 3 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 IgM Ab [Titer] in Serum;HPIV3 IgM Titr Ser;;ACTIVE;1.0j-a;2.70 +11264-9;Salmonella paratyphi A Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Salmonella paratyphi A Ab [Presence] in Serum by Agglutination;S Paraty A Ab Ser Ql Aggl;;ACTIVE;1.0j-a;2.73 +11265-6;Salmonella paratyphi B Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Salmonella paratyphi B Ab [Presence] in Serum by Agglutination;S Paraty B Ab Ser Ql Aggl;;ACTIVE;1.0j-a;2.73 +11266-4;Streptococcus agalactiae Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Streptococcus agalactiae Ag [Presence] in Specimen;Gp B Strep Ag Spec Ql;;ACTIVE;1.0j-a;2.73 +11267-2;Streptococcus.beta-hemolytic;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Streptococcus.beta-hemolytic [Presence] in Genital specimen by Organism specific culture;B-Hem Strep Genital Ql Cult;;ACTIVE;1.0j-a;2.73 +11268-0;Streptococcus pyogenes;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Streptococcus pyogenes [Presence] in Throat by Organism specific culture;S pyo Throat Ql Cult;;ACTIVE;1.0j-a;2.73 +11269-8;Streptococcus pyogenes Ag;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Streptococcus pyogenes Ag [Presence] in Serum by Agglutination;S pyo Ag Ser Ql Aggl;;ACTIVE;1.0j-a;2.56 +1127-0;L little e NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated Le NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated Le NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +11270-6;Viral inclusion bodies;Prid;Pt;XXX;Nom;Cyto stain;CYTO;1;Viral inclusion bodies [Identifier] in Specimen by Cyto stain;Vir Incl Bod Spec Cyto;;ACTIVE;1.0j-a;2.69 +11271-4;Hematocrit;VFr;Pt;BldCo;Qn;Automated count;HEM/BC;1;Hematocrit [Volume Fraction] of Cord blood by Automated count;Hct VFr BldCo Auto;;ACTIVE;1.0j-a;2.73 +11272-2;Erythrocyte mean corpuscular volume;EntVol;Pt;BldCo;Qn;Automated count;HEM/BC;1;MCV [Entitic volume] in Cord blood by Automated count;MCV BldCo Auto;;ACTIVE;1.0j-a;2.63 +11273-0;Erythrocytes;Morph;Pt;Bld;Nom;Automated count;HEM/BC;1;Erythrocytes [Morphology] in Blood by Automated count;RBC Bld Auto;;ACTIVE;1.0j-a;2.73 +11274-8;Elliptocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Elliptocytes [Presence] in Blood by Light microscopy;Elliptocytes Bld Ql Smear;;ACTIVE;1.0j-a;2.73 +11275-5;Lymphocytes.large granular/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Large granular lymphocytes/100 leukocytes in Blood by Manual count;Lg Gran Lymphs/leuk NFr Bld Manual;;ACTIVE;1.0j-a;2.70 +11276-3;Tubular cells;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Tubular cells [Presence] in Urine sediment by Light microscopy;Tubular Cells UrnS Ql Micro;;ACTIVE;1.0j-a;2.73 +11277-1;Epithelial cells.squamous;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Epithelial cells.squamous [#/area] in Urine sediment by Microscopy high power field;Squamous #/area UrnS HPF;;ACTIVE;1.0j-a;2.73 +11278-9;Bladder cells;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Bladder cells [#/area] in Urine sediment by Microscopy high power field;Bladder Cells #/area UrnS HPF;;ACTIVE;1.0j-a;2.40 +11279-7;Urine sediment comments;Find;Pt;Urine sed;Nar;Microscopy.light;UA;1;Urine sediment comments by Light microscopy Narrative;UrnS Cmnt Micro;;ACTIVE;1.0j-a;2.73 +11280-5;Cabot rings;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Cabot rings [Presence] in Blood by Light microscopy;Cabot rings Bld Ql Smear;;ACTIVE;1.0j-a;2.73 +11281-3;Auer rods;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Auer rods [Presence] in Blood by Light microscopy;Auer Bodies Bld Ql Smear;;ACTIVE;1.0j-a;2.73 +11282-1;Cells counted.total;Num;Pt;Bld;Qn;;HEM/BC;1;Cells Counted Total [#] in Blood;Total Cells Counted Bld;;ACTIVE;1.0j-a;2.73 +11283-9;Acuity assessment;Fcn;Enctr^frst;^Patient;Nom;;CLIN;2;Acuity assessment [Function] at First encounter;Acuity assess 1st enctr;;ACTIVE;1.0j-a;2.73 +11284-7;Acuity assessment practitioner identification;Type;Pt;Provider;Nom;;CLIN;2;Acuity assessment practitioner identification;Acuity assessment pract ID;;ACTIVE;1.0j-a;2.29 +11285-4;Acuity assessment practitioner profession;Type;Pt;Provider;Nom;;CLIN;2;Acuity assessment practitioner profession;Acuity assess pract profession;;ACTIVE;1.0j-a;2.27 +11286-2;Alcohol binge episodes per M;NRat;1Mo;^Patient;Qn;Reported;H&P.HX;2;Alcohol binge episodes per month - Reported;Alcohol binge episodes/M Reported;;ACTIVE;1.0j-a;2.50 +11287-0;Alcoholic drinks per drinking D;NRat;1D;^Patient;Qn;Reported;H&P.HX;2;Alcoholic drinks per drinking day - Reported;Alcoholic drinks/drinking D Reported;;ACTIVE;1.0j-a;2.73 +1128-8;L little e NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated Le NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated Le NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +11288-8;Arrival time documented;ClockTime;Pt;^Patient;Qn;;ED;2;Arrival time documented;Arrival time documented Clock time;;ACTIVE;1.0j-a;2.48 +11289-6;Body temperature;Temp;Enctr^frst;^Patient;Qn;;BDYTMP.ATOM;2;Body temperature at First encounter;Bdy temp 1st enctr;;ACTIVE;1.0j-a;2.73 +11290-4;Body temperature measurement site;Anat;Enctr^frst;XXX;Nom;;BDYTMP.ATOM;2;Body temperature measurement site at First encounter;Bdy temp measurement site 1st enctr;;ACTIVE;1.0j-a;2.73 +11291-2;Breaths;NRat;Enctr^frst;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate at First encounter;Resp rate 1st enctr;;ACTIVE;1.0j-a;2.44 +11292-0;Chief complaint;Prid;Pt;^Patient;Nom;Reported;H&P.HX;2;Deprecated Chief complaint: Prid: Pt: ^Patient: Nom: Reported;DeprecatedChief complaint;;DEPRECATED;1.0j-a;2.36 +11293-8;Class;Type;Pt;Referral source;Nom;;ED;2;Type of Referral source;Referral Source Class;;ACTIVE;1.0j-a;2.27 +11294-6;Current employment;Find;Pt;^Patient;Nar;Reported;ADMIN.PATIENT.DEMOG;2;Current employment Narrative - Reported;Current employment Reported;;ACTIVE;1.0j-a;2.66 +11295-3;Current employment;Find;Pt;^Patient;Nom;Reported;ADMIN.PATIENT.DEMOG;2;Current employment - Reported;Current employment Reported;;ACTIVE;1.0j-a;2.66 +1129-6;L little e NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated Le NOS Ab [Presence] in Serum or Plasma;Deprecated Le NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +11296-1;ED clinical finding practitioner ID;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED clinical finding practitioner identifier;ED clin find pract ID;;ACTIVE;1.0j-a;2.66 +11297-9;ED clinical finding practitioner profession;Type;Pt;Provider;Nom;;ED;2;ED clinical finding practitioner profession;ED clin find pract profession;;ACTIVE;1.0j-a;2.27 +11298-7;ED consultant practitioner ID;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED consultant practitioner identifier;ED consult pract ID;;ACTIVE;1.0j-a;2.66 +11299-5;ED consultant practitioner profession;Type;Pt;Provider;Nom;;ED;2;ED consultant practitioner profession;ED consult pract profession;;ACTIVE;1.0j-a;2.27 +11300-1;ED diagnosis;Imp;Pt;^Patient;Nom;;ED;2;ED diagnosis;ED Dx;;ACTIVE;1.0j-a;2.27 +11301-9;ED diagnosis;Type;Pt;^Patient;Nom;;ED;2;ED diagnosis type;ED Dx type;;ACTIVE;1.0j-a;2.40 +11302-7;ED discharge disposition;Type;Pt;^Patient;Nom;;ED;2;ED discharge disposition;ED dc dispo;;ACTIVE;1.0j-a;2.66 +11303-5;ED disposition consult &or referral;Type;Pt;^Patient;Nom;;ED;2;ED disposition consult/referral;ED dispo consult/referral;;ACTIVE;1.0j-a;2.27 +1130-4;L little e NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated Le NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated Le NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +11304-3;ED disposition diagnosis practitioner identification;Type;Pt;Provider;Nom;;ED;2;ED disposition diagnosis practitioner identification;ED dispo Dx pract ID;;ACTIVE;1.0j-a;2.27 +11305-0;ED disposition diagnosis practitioner profession;Type;Pt;Provider;Nom;;ED;2;ED disposition diagnosis practitioner profession;ED dispo Dx pract profession;;ACTIVE;1.0j-a;2.27 +11306-8;ED medication practitioner identification;Type;Pt;Provider;Nom;;ED;2;ED medication practitioner identification;ED medication pract ID;;ACTIVE;1.0j-a;2.27 +11307-6;ED medication practitioner profession;Type;Pt;Provider;Nom;;ED;2;ED medication practitioner profession;ED medication pract profession;;ACTIVE;1.0j-a;2.27 +11308-4;ED outcome observation practitioner identification;Type;Pt;Provider;Nom;;ED;2;ED outcome observation practitioner identification;ED outcome observ pract ID;;ACTIVE;1.0j-a;2.27 +11309-2;ED outcome observation practitioner profession;Type;Pt;Provider;Nom;;ED;2;ED outcome observation practitioner profession;ED outcome observ pract profession;;ACTIVE;1.0j-a;2.27 +113-1;cefoTEtan;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefoTEtan [Susceptibility] by Disk diffusion (KB);cefoTEtan Islt KB;;ACTIVE;1.0;2.73 +11310-0;ED patient satisfaction report type;Type;Pt;^Patient;Nom;;ED;2;ED patient satisfaction report type;ED patient satisfaction report type;;ACTIVE;1.0j-a;2.27 +11311-8;ED procedure practitioner profession;Type;Pt;Provider;Nom;;ED;2;ED procedure practitioner profession;ED procedure pract profession;;ACTIVE;1.0j-a;2.27 +1131-2;L little e NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated Le NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated Le NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +11312-6;ED procedure practitioner ID;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED procedure practitioner identifier;ED procedure pract ID;;ACTIVE;1.0j-a;2.66 +11313-4;ED procedure result observation;Imp;Pt;^Patient;Nom;;ED;2;ED procedure result observation [Interpretation];ED procedure result observation Imp;;ACTIVE;1.0j-a;2.50 +11314-2;ED procedure result type;Type;Pt;^Patient;Nom;;ED;2;ED procedure result type;ED procedure result type;;ACTIVE;1.0j-a;2.27 +11315-9;ED service level;Type;Pt;^Patient;Nom;;ED;2;ED service level;ED service level;;ACTIVE;1.0j-a;2.34 +11316-7;ED service level practitioner profession;Type;Pt;Provider;Nom;;ED;2;ED service level practitioner profession;ED service level pract profession;;ACTIVE;1.0j-a;2.27 +11317-5;ED service level practitioner identification;Type;Pt;Provider;Nom;;ED;2;ED service level practitioner identification;ED service level pract ID;;ACTIVE;1.0j-a;2.27 +11318-3;Ambulance transport agency;ID;Pt;EMS system;Nom;;ADMIN.ID;2;Ambulance transport agency EMS system;Ambulance transport agency EMS Sys;;ACTIVE;1.0j-a;2.66 +11319-1;Ambulance transport unit;ID;Pt;EMS system;Nom;;ADMIN.ID;2;Ambulance transport unit [Identifier] EMS system;Ambulance transport unit EMS Sys;;ACTIVE;1.0j-a;2.66 +1132-0;L little e NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated Le NOS Ag [Presence] on Red Blood Cells;Deprecated Le NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +11320-9;Feeding and dietary status;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Feeding and dietary status Narrative - Reported;Feeding and dietary status Reported;;ACTIVE;1.0j-a;2.40 +11321-7;Feeding and dietary status;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Feeding and dietary status - Reported;Feeding and dietary status Reported;;ACTIVE;1.0j-a;2.73 +11322-5;General health;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of General health Narrative;Hx of General health;;ACTIVE;1.0j-a;2.56 +11323-3;General health;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;General health - Reported;General health Reported;;ACTIVE;1.0j-a;2.27 +11324-1;Glasgow coma score.eye opening;Fcn;Enctr^frst;^Patient;Ord;;FUNCTION;2;Glasgow coma score eye opening at First encounter;GCS eye 1st enctr;;ACTIVE;1.0j-a;2.27 +11325-8;Glasgow coma score.motor;Fcn;Enctr^frst;^Patient;Ord;;FUNCTION;2;Glasgow coma score motor at First encounter;GCS motor 1st enctr;;ACTIVE;1.0j-a;2.27 +11326-6;Glasgow coma score.verbal;Fcn;Enctr^frst;^Patient;Ord;;FUNCTION;2;Glasgow coma score verbal at First encounter;GCS verbal 1st enctr;;ACTIVE;1.0j-a;2.27 +11327-4;Heart rate method;Type;Enctr^frst;XXX;Nom;;HRTRATE.ATOM;2;Heart rate method at First encounter;Heart rate method 1st enctr;;ACTIVE;1.0j-a;2.29 +11328-2;Heart rate;NRat;Enctr^frst;Arterial system;Qn;;HRTRATE.ATOM;2;Heart rate at First encounter;Heart rate 1st enctr;;ACTIVE;1.0j-a;2.42 +11329-0;History general;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;History general Narrative - Reported;Hx general Reported;;ACTIVE;1.0j-a;2.73 +11330-8;Alcohol use;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Alcohol use Narrative;Hx of Alcohol use;;ACTIVE;1.0j-a;2.56 +11331-6;Alcohol use;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Alcohol use;Hx of Alcohol use;;ACTIVE;1.0j-a;2.56 +11332-4;Cognitive function;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Cognitive function Narrative;Hx of Cogn func;;ACTIVE;1.0j-a;2.63 +11333-2;Cognitive function;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Cognitive function;Hx of Cogn func;;ACTIVE;1.0j-a;2.56 +11334-0;Growth+Development;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Growth+Development Narrative;Hx of Growth+Development;;ACTIVE;1.0j-a;2.56 +11335-7;Growth+Development;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Growth+Development;Hx of Growth+Development;;ACTIVE;1.0j-a;2.56 +11336-5;Hospitalization;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Hospitalization Narrative;Hx of Hospitalization;;ACTIVE;1.0j-a;2.63 +11337-3;Hospitalization;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Hospitalization;Hx of Hospitalization;;ACTIVE;1.0j-a;2.56 +1133-8;L little u super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Lu sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Lu sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11338-1;Major illnesses and injuries;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Major illnesses and injuries Narrative;Hx of Major illnesses and injuries;;ACTIVE;1.0j-a;2.56 +11339-9;Major illnesses and injuries;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Major illnesses and injuries;Hx of Major illnesses and injuries;;ACTIVE;1.0j-a;2.56 +11340-7;Occupation;Hx;Pt;^Patient;Nar;;ADMIN.PATIENT.DEMOG;2;History of Occupation Narrative;Hx of Occupation;;ACTIVE;1.0j-a;2.66 +11341-5;Occupation;Hx;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;History of Occupation;Hx of Occupation;;ACTIVE;1.0j-a;2.73 +11342-3;Other nonmedical drug use;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Other nonmedical drug use Narrative;Hx of Other nonmedical drug use;;ACTIVE;1.0j-a;2.56 +11343-1;Other nonmedical drug use;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Other nonmedical drug use;Hx of Other nonmedical drug use;;ACTIVE;1.0j-a;2.56 +11344-9;Other social factors;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Other social factors Narrative;Other social factors Hx;;ACTIVE;1.0j-a;2.56 +11345-6;Other social factors;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Other social factors;Hx of Other social factors;;ACTIVE;1.0j-a;2.56 +1134-6;L little u super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Lu sup(a) Ab [Presence] in Serum or Plasma from Donor;Lu sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11346-4;Outpatient visits;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Outpatient visits Narrative;Hx of Outpt visits;;ACTIVE;1.0j-a;2.63 +11347-2;Outpatient visits;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Outpatient visits;Hx of Outpt visits;;ACTIVE;1.0j-a;2.56 +11348-0;Past illness;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Past illness Narrative;Hx of Past illness;;ACTIVE;1.0j-a;2.63 +11349-8;Past illness;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Past illness;Hx of Past illness;;ACTIVE;1.0j-a;2.56 +11350-6;Sexual behavior;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Sexual behavior Narrative;Hx of Sexual behavior;;ACTIVE;1.0j-a;2.56 +11351-4;Sexual behavior;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Sexual behavior;Hx of Sexual behavior;;ACTIVE;1.0j-a;2.56 +11352-2;Symptoms & diseases;Hx;Pt;Allergic & Immunologic;Nar;;H&P.HX;2;History of Allergenic and Immunologic disorders Narrative;Hx of Allergy+Immunologic disorders;;ACTIVE;1.0j-a;2.56 +1135-3;L little u super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Lu sup(a) Ab [Presence] in Serum or Plasma;Lu sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +11353-0;Symptoms & diseases;Hx;Pt;Breasts;Nar;;H&P.HX;2;History of Breasts disorders Narrative;Hx of Brsts disorders;;ACTIVE;1.0j-a;2.56 +11354-8;Symptoms & diseases;Hx;Pt;Ears & Nose & Sinuses & Mouth & Thr;Nar;;H&P.HX;2;History of Ears and Nose and Sinuses and Mouth and Throat disorders Narrative;Hx of ENSMT disorders;;ACTIVE;1.0j-a;2.56 +11355-5;Symptoms & diseases;Hx;Pt;Gastrointestinal system;Nar;;H&P.HX;2;History of Gastrointestinal system disorders Narrative;Hx of GI disorders;;ACTIVE;1.0j-a;2.56 +11356-3;Symptoms & diseases;Hx;Pt;Genitourinary systems;Nar;;H&P.HX;2;History of Genitourinary systems disorders Narrative;Hx of GU disorders;;ACTIVE;1.0j-a;2.56 +11357-1;Symptoms & diseases;Hx;Pt;Integumentary system;Nar;;H&P.HX;2;History of Integumentary system disorders Narrative;Hx of Integumentary disorders;;ACTIVE;1.0j-a;2.56 +11358-9;Symptoms & diseases;Hx;Pt;Psychiatric;Nar;;H&P.HX;2;History of Psychiatric disorders Narrative;Hx of Psychiatric disorders;;ACTIVE;1.0j-a;2.56 +11359-7;Symptoms & diseases;Hx;Pt;Allergic & Immunologic;Nom;;H&P.HX;2;History of Allergenic and Immunologic disorders;Hx of Allergy+Immunologic disorders;;ACTIVE;1.0j-a;2.56 +11360-5;Symptoms & diseases;Hx;Pt;Breasts;Nom;;H&P.HX;2;History of Breasts disorders;Hx of Brsts disorders;;ACTIVE;1.0j-a;2.56 +1136-1;L little u super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Lu sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Lu sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11361-3;Symptoms & diseases;Hx;Pt;Ears & Nose & Sinuses & Mouth & Thr;Nom;;H&P.HX;2;History of Ears and Nose and Sinuses and Mouth and Throat disorders;Hx of ENSMT disorders;;ACTIVE;1.0j-a;2.56 +11362-1;Symptoms & diseases;Hx;Pt;Gastrointestinal system;Nom;;H&P.HX;2;History of Gastrointestinal system disorders;Hx of GI disorders;;ACTIVE;1.0j-a;2.56 +11363-9;Symptoms & diseases;Hx;Pt;Genitourinary systems;Nom;;H&P.HX;2;History of Genitourinary systems disorders;Hx of GU disorders;;ACTIVE;1.0j-a;2.56 +11364-7;Symptoms & diseases;Hx;Pt;Integumentary system;Nom;;H&P.HX;2;History of Integumentary system disorders;Hx of Integumentary disorders;;ACTIVE;1.0j-a;2.56 +11365-4;Symptoms & diseases;Hx;Pt;Psychiatric;Nom;;H&P.HX;2;History of Psychiatric disorders;Hx of Psychiatric disorders;;ACTIVE;1.0j-a;2.56 +11366-2;Tobacco use status;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Tobacco use Narrative;Hx of Tobacco use;;ACTIVE;1.0j-a;2.58 +11367-0;Tobacco use status;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Tobacco use;Hx of Tobacco use;;ACTIVE;1.0j-a;2.73 +11368-8;Illness or injury onset date and time;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Illness or injury onset date and time;Illness or injury onset date and time;;ACTIVE;1.0j-a;2.73 +11369-6;Immunization;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Immunization Narrative;Hx of Immunization;;ACTIVE;1.0j-a;2.63 +11370-4;Immunization status;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Immunization status - Reported;Immunization status Reported;;ACTIVE;1.0j-a;2.63 +11371-2;Initial visit for chief complaint;Type;Pt;^Patient;Nom;;H&P.HX;2;Initial visit for chief complaint;Initial visit for chief complaint;;ACTIVE;1.0j-a;2.29 +11372-0;Injury associated activity;Type;Pt;^Patient;Nom;;ED;2;Injury associated activity;Injury associated activity;;ACTIVE;1.0j-a;2.70 +11373-8;Injury cause;Type;Pt;^Patient;Nom;;ED;2;Injury cause;Injury cause;;ACTIVE;1.0j-a;2.27 +11374-6;Injury incident description;Find;Pt;^Patient;Nar;;ED;2;Injury incident description Narrative;Injury incident description;;ACTIVE;1.0j-a;2.40 +11375-3;Injury intent;Type;Pt;^Patient;Nom;;ED;2;Injury intent;Injury intent;;ACTIVE;1.0j-a;2.34 +11376-1;Injury location;Type;Pt;^Patient;Nom;;ED;2;Injury location;Injury location;;ACTIVE;1.0j-a;2.34 +11377-9;Intravascular diastolic;Pres;Enctr^frst;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure at First encounter;BP dias 1st enctr;;ACTIVE;1.0j-a;2.73 +11378-7;Intravascular systolic;Pres;Enctr^frst;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure at First encounter;BP sys 1st enctr;;ACTIVE;1.0j-a;2.73 +1137-9;L little u super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Lu sup(a) Ag [Presence] on Red Blood Cells from Donor;Lu sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.73 +11379-5;Highest level of education;Time;Pt;^Patient;Qn;Reported;H&P.HX;2;Deprecated Highest level of education [Time] - Reported;Deprecated High level of educ Time Repor;;DEPRECATED;1.0j-a;2.58 +11380-3;Marital status and living arrangements;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Marital status and living arrangements Narrative - Reported;Marital status+living arrang;;ACTIVE;1.0j-a;2.48 +11381-1;Marital status and living arrangements;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Marital status and living arrangements - Reported;Marital status+living arrang;;ACTIVE;1.0j-a;2.48 +11382-9;Medication allergy;Hx;Pt;^Patient;Nom;Reported;H&P.HX;2;Medication allergy - Reported;Medication allergy Reported;;ACTIVE;1.0j-a;2.27 +11383-7;Patient problem outcome;Find;Pt;^Patient;Nar;;H&P.HX;2;Patient problem outcome Narrative;Patient problem outcome;;ACTIVE;1.0j-a;2.40 +11384-5;Physical examination by organ systems;Find;Pt;^Patient;Nom;Observed;H&P.PX;2;Physical examination by organ systems;Physical exam by systems;;ACTIVE;1.0j-a;2.29 +11385-2;Physical findings;Find;Pt;Ankle;Nar;Observed;H&P.PX;2;Physical findings of Ankle Narrative;Phys find Ankle;;ACTIVE;1.0j-a;2.40 +11386-0;Physical findings;Find;Pt;Upper arm;Nar;Observed;H&P.PX;2;Physical findings of Upper arm Narrative;Phys find Upper arm;;ACTIVE;1.0j-a;2.40 +1138-7;L little u super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Lu sup(a) Ag [Presence] on Red Blood Cells;Lu sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +11387-8;Physical findings;Find;Pt;Axilla;Nar;Observed;H&P.PX;2;Physical findings of Axilla Narrative;Phys find Axilla;;ACTIVE;1.0j-a;2.40 +11388-6;Physical findings;Find;Pt;Buttocks;Nar;Observed;H&P.PX;2;Physical findings of Buttocks Narrative;Phys find Buttocks;;ACTIVE;1.0j-a;2.40 +11389-4;Physical findings;Find;Pt;Calf;Nar;Observed;H&P.PX;2;Physical findings of Calf Narrative;Phys find Calf;;ACTIVE;1.0j-a;2.40 +11390-2;Physical findings;Find;Pt;Cardiovascular system;Nar;Observed;H&P.PX;2;Physical findings of Cardiovascular system Narrative;Phys find CVS;;ACTIVE;1.0j-a;2.40 +11391-0;Physical findings;Find;Pt;Chest;Nar;Observed;H&P.PX;2;Physical findings of Chest Narrative;Phys find Chest;;ACTIVE;1.0j-a;2.40 +11392-8;Physical findings;Find;Pt;Chest wall;Nar;Observed;H&P.PX;2;Physical findings of Chest wall Narrative;Phys find Chest wall;;ACTIVE;1.0j-a;2.40 +11393-6;Physical findings;Find;Pt;Ears & Nose & Mouth & Throat;Nar;Observed;H&P.PX;2;Physical findings of Ears and Nose and Mouth and Throat Narrative;Phys find ENMT;;ACTIVE;1.0j-a;2.40 +11394-4;Physical findings;Find;Pt;Elbow;Nar;Observed;H&P.PX;2;Physical findings of Elbow Narrative;Phys find Elbow;;ACTIVE;1.0j-a;2.40 +1139-5;L little u super little a super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Lu sup(ab) Ab [Presence] in Serum or Plasma from Blood product unit;Lu sup(ab) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11395-1;Physical findings;Find;Pt;Extremities;Nar;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Extremities: Nar: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.36 +11396-9;Physical findings;Find;Pt;Extremities;Nar;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Extremities: Nar: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.66 +11397-7;Physical findings;Find;Pt;Foot;Nar;Observed;H&P.PX;2;Physical findings of Foot Narrative;Phys find Ft;;ACTIVE;1.0j-a;2.40 +11398-5;Physical findings;Find;Pt;Forearm;Nar;Observed;H&P.PX;2;Physical findings of Forearm Narrative;Phys find Forearm;;ACTIVE;1.0j-a;2.40 +11399-3;Physical findings;Find;Pt;Gastrointestinal system;Nar;Observed;H&P.PX;2;Physical findings of Gastrointestinal system Narrative;Phys find GI;;ACTIVE;1.0j-a;2.40 +11400-9;Physical findings;Find;Pt;Genitalia;Nar;Observed;H&P.PX;2;Physical findings of Genitalia Narrative;Phys find Genitalia;;ACTIVE;1.0j-a;2.40 +11401-7;Physical findings;Find;Pt;Genitalia.female;Nar;Observed;H&P.PX;2;Physical findings of Female genitalia Narrative;Phys find Female genitalia;;ACTIVE;1.0j-a;2.40 +11402-5;Physical findings;Find;Pt;Genitalia.male;Nar;Observed;H&P.PX;2;Physical findings of Male genitalia Narrative;Phys find Male genitalia;;ACTIVE;1.0j-a;2.40 +1140-3;L little u super little a super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Lu sup(ab) Ab [Presence] in Serum or Plasma from Donor;Lu sup(ab) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11403-3;Physical findings;Find;Pt;Groin;Nar;Observed;H&P.PX;2;Physical findings of Groin Narrative;Phys find Groin;;ACTIVE;1.0j-a;2.40 +11404-1;Physical findings;Find;Pt;Hand;Nar;Observed;H&P.PX;2;Physical findings of Hand Narrative;Phys find Hand;;ACTIVE;1.0j-a;2.40 +11405-8;Physical findings;Find;Pt;Heart;Nar;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Heart: Nar: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.36 +11406-6;Physical findings;Find;Pt;Hip;Nar;Observed;H&P.PX;2;Physical findings of Hip Narrative;Phys find Hip;;ACTIVE;1.0j-a;2.40 +11407-4;Physical findings;Find;Pt;Knee;Nar;Observed;H&P.PX;2;Physical findings of Knee Narrative;Phys find Knee;;ACTIVE;1.0j-a;2.40 +11408-2;Physical findings;Find;Pt;Mouth & Throat & Teeth;Nar;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Mouth & Throat & Teeth: Nar: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.36 +11409-0;Physical findings;Find;Pt;Mouth & Throat & Teeth;Nar;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Mouth & Throat & Teeth: Nar: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.66 +11410-8;Physical findings;Find;Pt;Musculoskeletal system;Nar;Observed;H&P.PX;2;Physical findings of Musculoskeletal system Narrative;Phys find Musculoskeletal;;ACTIVE;1.0j-a;2.40 +1141-1;L little u super little a super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Lu sup(ab) Ab [Presence] in Serum or Plasma;Lu sup(ab) Ab SerPl Ql;;ACTIVE;1.0;2.56 +11411-6;Physical findings;Find;Pt;Neck;Nar;Observed;H&P.PX;2;Physical findings of Neck Narrative;Phys find Neck;;ACTIVE;1.0j-a;2.40 +11412-4;Physical findings;Find;Pt;Respiratory system;Nar;Observed;H&P.PX;2;Physical findings of Respiratory system Narrative;Phys find Respiratory;;ACTIVE;1.0j-a;2.40 +11413-2;Physical findings;Find;Pt;Shoulder;Nar;Observed;H&P.PX;2;Physical findings of Shoulder Narrative;Phys find Should;;ACTIVE;1.0j-a;2.40 +11414-0;Physical findings;Find;Pt;Thigh;Nar;Observed;H&P.PX;2;Physical findings of Thigh Narrative;Phys find Thigh;;ACTIVE;1.0j-a;2.40 +11415-7;Physical findings;Find;Pt;Wrist;Nar;Observed;H&P.PX;2;Physical findings of Wrist Narrative;Phys find Wrist;;ACTIVE;1.0j-a;2.40 +11416-5;Physical findings;Find;Pt;Ankle;Nom;Observed;H&P.PX;2;Physical findings of Ankle;Phys find Ankle;;ACTIVE;1.0j-a;2.27 +11417-3;Physical findings;Find;Pt;Upper arm;Nom;Observed;H&P.PX;2;Physical findings of Upper arm;Phys find Upper arm;;ACTIVE;1.0j-a;2.27 +11418-1;Physical findings;Find;Pt;Axilla;Nom;Observed;H&P.PX;2;Physical findings of Axilla;Phys find Axilla;;ACTIVE;1.0j-a;2.27 +11419-9;Physical findings;Find;Pt;Buttocks;Nom;Observed;H&P.PX;2;Physical findings of Buttocks;Phys find Buttocks;;ACTIVE;1.0j-a;2.27 +11420-7;Physical findings;Find;Pt;Calf;Nom;Observed;H&P.PX;2;Physical findings of Calf;Phys find Calf;;ACTIVE;1.0j-a;2.27 +11421-5;Physical findings;Find;Pt;Cardiovascular system;Nom;Observed;H&P.PX;2;Physical findings of Cardiovascular system;Phys find CVS;;ACTIVE;1.0j-a;2.27 +11422-3;Physical findings;Find;Pt;Chest;Nom;Observed;H&P.PX;2;Physical findings of Chest;Phys find Chest;;ACTIVE;1.0j-a;2.27 +11423-1;Physical findings;Find;Pt;Chest wall;Nom;Observed;H&P.PX;2;Physical findings of Chest wall;Phys find Chest wall;;ACTIVE;1.0j-a;2.27 +11424-9;Physical findings;Find;Pt;Ears & Nose & Mouth & Throat;Nom;Observed;H&P.PX;2;Physical findings of Ears and Nose and Mouth and Throat;Phys find ENMT;;ACTIVE;1.0j-a;2.38 +11425-6;Physical findings;Find;Pt;Elbow;Nom;Observed;H&P.PX;2;Physical findings of Elbow;Phys find Elbow;;ACTIVE;1.0j-a;2.27 +11426-4;Physical findings;Find;Pt;Extremities;Nom;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Extremities: Nom: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.36 +11427-2;Physical findings;Find;Pt;Extremities;Nom;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Extremities: Nom: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.66 +11428-0;Physical findings;Find;Pt;Foot;Nom;Observed;H&P.PX;2;Physical findings of Foot;Phys find Ft;;ACTIVE;1.0j-a;2.27 +1142-9;L little u super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Lu sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Lu sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11429-8;Physical findings;Find;Pt;Forearm;Nom;Observed;H&P.PX;2;Physical findings of Forearm;Phys find Forearm;;ACTIVE;1.0j-a;2.27 +11430-6;Physical findings;Find;Pt;Gastrointestinal system;Nom;Observed;H&P.PX;2;Physical findings of Gastrointestinal system;Phys find GI;;ACTIVE;1.0j-a;2.27 +11431-4;Physical findings;Find;Pt;Genitalia;Nom;Observed;H&P.PX;2;Physical findings of Genitalia;Phys find Genitalia;;ACTIVE;1.0j-a;2.27 +11432-2;Physical findings;Find;Pt;Genitalia.female;Nom;Observed;H&P.PX;2;Physical findings of Female genitalia;Phys find Female genitalia;;ACTIVE;1.0j-a;2.27 +11433-0;Physical findings;Find;Pt;Genitalia.male;Nom;Observed;H&P.PX;2;Physical findings of Male genitalia;Phys find Male genitalia;;ACTIVE;1.0j-a;2.27 +11434-8;Physical findings;Find;Pt;Groin;Nom;Observed;H&P.PX;2;Physical findings of Groin;Phys find Groin;;ACTIVE;1.0j-a;2.27 +11435-5;Physical findings;Find;Pt;Hand;Nom;Observed;H&P.PX;2;Physical findings of Hand;Phys find Hand;;ACTIVE;1.0j-a;2.27 +11436-3;Physical findings;Find;Pt;Heart;Nom;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Heart: Nom: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.36 +1143-7;L little u super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Lu sup(b) Ab [Presence] in Serum or Plasma from Donor;Lu sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11437-1;Physical findings;Find;Pt;Hip;Nom;Observed;H&P.PX;2;Physical findings of Hip;Phys find Hip;;ACTIVE;1.0j-a;2.27 +11438-9;Physical findings;Find;Pt;Knee;Nom;Observed;H&P.PX;2;Physical findings of Knee;Phys find Knee;;ACTIVE;1.0j-a;2.27 +11439-7;Physical findings;Find;Pt;Mouth & Throat & Teeth;Nom;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Mouth & Throat & Teeth: Nom: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.66 +11440-5;Physical findings;Find;Pt;Mouth & Throat & Teeth;Nom;Observed;H&P.PX;2;Deprecated Physical findings: Find: Pt: Mouth & Throat & Teeth: Nom: Observed;DeprecatedPhysical findings;;DEPRECATED;1.0j-a;2.36 +11441-3;Physical findings;Find;Pt;Musculoskeletal system;Nom;Observed;H&P.PX;2;Physical findings of Musculoskeletal system;Phys find Musculoskeletal;;ACTIVE;1.0j-a;2.27 +11442-1;Physical findings;Find;Pt;Neck;Nom;Observed;H&P.PX;2;Physical findings of Neck;Phys find Neck;;ACTIVE;1.0j-a;2.27 +11443-9;Physical findings;Find;Pt;Respiratory system;Nom;Observed;H&P.PX;2;Physical findings of Respiratory system;Phys find Respiratory;;ACTIVE;1.0j-a;2.27 +11444-7;Physical findings;Find;Pt;Shoulder;Nom;Observed;H&P.PX;2;Physical findings of Shoulder;Phys find Should;;ACTIVE;1.0j-a;2.27 +1144-5;L little u super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Lu sup(b) Ab [Presence] in Serum or Plasma;Lu sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.56 +11445-4;Physical findings;Find;Pt;Thigh;Nom;Observed;H&P.PX;2;Physical findings of Thigh;Phys find Thigh;;ACTIVE;1.0j-a;2.27 +11446-2;Physical findings;Find;Pt;Wrist;Nom;Observed;H&P.PX;2;Physical findings of Wrist;Phys find Wrist;;ACTIVE;1.0j-a;2.27 +11447-0;Physical findings;Find;Pt;Hematologic+Lymphatic+Immunologic system;Nar;Observed;H&P.PX;2;Physical findings of Hematologic and Lymphatic and Immunologic System Narrative;Phys find Hem+Lymph+Immun;;ACTIVE;1.0j-a;2.40 +11448-8;Physical findings;Find;Pt;Hematologic+Lymphatic+Immunologic system;Nom;Observed;H&P.PX;2;Physical findings of Hematologic and Lymphatic and Immunologic System;Phys find Hem+Lymph+Immun;;ACTIVE;1.0j-a;2.38 +11449-6;Pregnancy status;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Pregnancy status - Reported;Pregnancy status Reported;;ACTIVE;1.0j-a;2.73 +11450-4;Problem list;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Problem list - Reported;Problem list Reported;;ACTIVE;1.0j-a;2.73 +11451-2;Psychiatric findings;Find;Pt;^Patient;Nar;Observed;H&P.PX;2;Psychiatric findings Narrative;Psychiatric findings;;ACTIVE;1.0j-a;2.40 +1145-2;L little u super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Lu sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Lu sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11452-0;Psychiatric findings;Find;Pt;^Patient;Nom;Observed;H&P.PX;2;Psychiatric findings;Psychiatric findings;;ACTIVE;1.0j-a;2.29 +11453-8;Receiving facility;Type;Pt;EMS system;Nom;;ED;2;Receiving facility EMS system;Receiving facility EMS Sys;;ACTIVE;1.0j-a;2.34 +11454-6;Responsiveness assessment;Fcn;Enctr^frst;^Patient;Ord;;FUNCTION;2;Responsiveness assessment at First encounter;Responsiveness assessment 1st enctr;;ACTIVE;1.0j-a;2.27 +11455-3;Review of symptoms and diseases;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Deprecated Review of symptoms and diseases: Find: Pt: ^Patient: Nar: Reported;DeprecatedReview of symptoms and disease;;DEPRECATED;1.0j-a;2.36 +11456-1;Review of symptoms and diseases;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Deprecated Review of symptoms and diseases: Find: Pt: ^Patient: Nom: Reported;DeprecatedReview of symptoms and disease;;DEPRECATED;1.0j-a;2.36 +11457-9;Safety equipment used;Type;Pt;^Patient;Nom;;ED;2;Safety equipment used;Safety equipment used;;ACTIVE;1.0j-a;2.63 +11458-7;Clostridium tetani immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Clostridium tetani immunization status;C tetani immunization status;;ACTIVE;1.0j-a;2.34 +11459-5;Transport mode;Type;Pt;EMS system;Nom;;ED;2;Transport mode EMS system;Transport mode EMS Sys;;ACTIVE;1.0j-a;2.63 +1146-0;L little u super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Lu sup(b) Ag [Presence] on Red Blood Cells from Donor;Lu sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11467-8;Bacillus anthracis Ab;ACnc;Pt;Ser;Qn;IB;MICRO;1;Bacillus anthracis Ab [Units/volume] in Serum by Immunoblot;B anthracis Ab Ser IB-aCnc;;ACTIVE;1.0j-a;2.69 +11468-6;Bacillus anthracis Ab;ACnc;Pt;XXX;Qn;IF;MICRO;1;Bacillus anthracis Ab [Units/volume] in Specimen by Immunofluorescence;B anthracis Ab Spec IF-aCnc;;ACTIVE;1.0j-a;2.69 +11469-4;Bacillus anthracis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bacillus anthracis [Presence] in Specimen by Organism specific culture;B anthracis Spec Ql Cult;;ACTIVE;1.0j-a;2.73 +11470-2;Clostridium botulinum toxin;ACnc;Pt;Stool;Qn;;MICRO;1;Clostridium botulinum toxin [Units/volume] in Stool;C bot Tox Stl-aCnc;;ACTIVE;1.0j-a;2.69 +11471-0;Cryptococcus neoformans Ag;Titr;Pt;XXX;Qn;;MICRO;1;Deprecated Cryptococcus neoformans Ag [Titer] in Unspecified specimen;Deprecated C neoform Ag Titr XXX;;DEPRECATED;1.0j-a;2.70 +11472-8;Cryptococcus neoformans Ag;ACnc;Pt;XXX;Ord;;MICRO;1;Deprecated Cryptococcus neoformans Ag [Presence] in Unspecified specimen;Deprecated C neoform Ag XXX Ql;;DEPRECATED;1.0j-a;2.69 +11473-6;Cryptococcus sp Ag;Titr;Pt;XXX;Qn;;MICRO;1;Cryptococcus sp Ag [Titer] in Specimen;Cryptoc Ag Titr Spec;;ACTIVE;1.0j-a;2.73 +11474-4;Hydatid cyst identified;Prid;Pt;XXX;Nom;Wet preparation;MICRO;1;Hydatid cyst identified in Specimen by Wet preparation;Hydatid Cyst Spec Wet Prep;;ACTIVE;1.0j-a;2.73 +11475-1;Microorganism identified;Prid;Pt;XXX;Nom;Culture;MICRO;1;Microorganism identified in Specimen by Culture;Microorganism Spec Cult;;ACTIVE;1.0j-a;2.73 +11476-9;Microscopic observation;Prid;Pt;Gast fld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Gastric fluid by Acid fast stain;Acid fast Stn Gast;;ACTIVE;1.0j-a;2.21 +11477-7;Microscopic observation;Prid;Pt;Sputum;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Sputum by Acid fast stain;Acid fast Stn Spt;;ACTIVE;1.0j-a;2.73 +1147-8;L little u super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Lu sup(b) Ag [Presence] on Red Blood Cells;Lu sup(b) Ag RBC Ql;;ACTIVE;1.0;2.56 +11478-5;Microscopic observation;Prid;Pt;Stool;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Stool by Acid fast stain;Acid fast Stn Stl;;ACTIVE;1.0j-a;2.73 +11479-3;Microscopic observation;Prid;Pt;Tiss;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Acid fast stain;Acid fast Stn Tiss;;ACTIVE;1.0j-a;2.73 +11480-1;Microscopic observation;Prid;Pt;Urine;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Urine by Acid fast stain;Acid fast Stn Ur;;ACTIVE;1.0j-a;2.73 +11481-9;Human papilloma virus identified;Prid;Pt;XXX;Nom;;MICRO;1;Human papilloma virus identified in Specimen;HPV Spec;;ACTIVE;1.0j-a;2.73 +11482-7;Rickettsia rickettsii RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Rickettsia rickettsii RNA [Presence] in Tissue by NAA with probe detection;R rickettsi RNA Tiss Ql NAA+probe;;ACTIVE;1.0j-a;2.63 +11483-5;Varicella zoster virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection;VZV DNA Spec Ql NAA+probe;;ACTIVE;1.0j-a;2.73 +11484-3;Virus identified;Prid;Pt;Amnio fld;Nom;Culture;MICRO;1;Virus identified in Amniotic fluid by Culture;Virus Amn Cult;;ACTIVE;1.0j-a;2.19 +11485-0;Anesthesia records;Find;-;^Patient;Doc;;DOC.MISC;2;Anesthesia records;Anesthesia records;;ACTIVE;1.0j-a;2.67 +1148-6;L little u NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated Lu NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated Lu NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +11486-8;Chemotherapy records;Find;-;^Patient;Doc;;DOC.MISC;2;Chemotherapy records;Chemotherapy records;;ACTIVE;1.0j-a;2.67 +11487-6;Consultation request.total;Find;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Consultation request (narrative);;;ACTIVE;1.0j-a;2.27 +11488-4;Consultation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Consult note;Consult note;;ACTIVE;1.0j-a;2.73 +11489-2;Dictating practitioner ID;ID;Pt;Provider;Nom;;ATTACH.CLINRPT;3;Dictating practitioner identifier;;;ACTIVE;1.0j-a;2.56 +114-9;cefoTEtan;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;cefoTEtan [Susceptibility] by Serum bactericidal titer;cefoTEtan Titr SBT;;ACTIVE;1.0;2.32 +11490-0;Discharge summary note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Discharge summary;MD D/C sum;;ACTIVE;1.0j-a;2.73 +11491-6;Emergency visit note.total;Find;Enctr;^Patient;Nar;;H&P.HX;2;Deprecated Provider-unspecified ED visit note;DeprecatedEmergency visit note.total;;DEPRECATED;1.0j-a;2.36 +11492-6;History and physical note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Provider-unspecifed, History and physical note;Hosp H&P note;;ACTIVE;1.0j-a;2.73 +11493-4;Hospital discharge studies summary;Find;Pt;^Patient;Nar;;H&P.HX;2;Hospital discharge studies summary Narrative;Hospital discharge studies summary;;ACTIVE;1.0j-a;2.63 +1149-4;L little u NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated Lu NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated Lu NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +11494-2;Initial assessment note;Find;Enctr^frst;^Patient;Doc;Physician;H&P.HX;2;Deprecated Physician Initial assessment note at First encounter;Deprecated Physician note 1st enctr;;DEPRECATED;1.0j-a;2.50 +11495-9;Initial assessment note;Find;Enctr^frst;^Patient;Doc;Physical therapy;H&P.HX;2;Deprecated Physical therapy Initial assessment note at First encounter;Deprecated PT note 1st enctr;;DEPRECATED;1.0j-a;2.50 +11496-7;Initial assessment note;Find;Enctr^frst;^Patient;Doc;Podiatry;H&P.HX;2;Deprecated Podiatry Initial assessment note at First encounter;Deprecated Podiatry note 1st enctr;;DEPRECATED;1.0j-a;2.50 +11497-5;Initial assessment note;Find;Enctr^frst;^Patient;Doc;Psychology;H&P.HX;2;Deprecated Psychology Initial assessment note at First encounter;Deprecated Psych note 1st enctr;;DEPRECATED;1.0j-a;2.50 +11498-3;Initial assessment note;Find;Enctr^frst;^Patient;Doc;Social work;H&P.HX;2;Deprecated Social work Initial assessment note at First encounter;Deprecated Social work note 1st enctr;;DEPRECATED;1.0j-a;2.50 +11499-1;Initial assessment note;Find;Enctr^frst;^Patient;Doc;Speech therapy;H&P.HX;2;Deprecated Speech therapy Initial assessment note at First encounter;Deprecated Speech therapy note 1st enctr;;DEPRECATED;1.0j-a;2.46 +11500-6;Initial assessment note;Find;Enctr^frst;^Patient;Doc;Occupational therapy;H&P.HX;2;Deprecated Occupational therapy Initial assessment note at First encounter;Deprecated OT note 1st enctr;;DEPRECATED;1.0j-a;2.50 +11501-6;Labor and delivery record.total;Find;Enctr;^Patient;Nar;;H&P.HX;2;Deprecated Labor and delivery records;DeprecatedLabor and delivery record.tota;;DEPRECATED;1.0j-a;2.36 +1150-2;L little u NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated Lu NOS Ab [Presence] in Serum or Plasma;Deprecated Lu NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +11502-2;Laboratory report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Laboratory report;Laboratory report;;ACTIVE;1.0j-a;2.73 +11503-0;Medical records;Find;-;^Patient;Doc;;DOC.MISC;2;Medical records;Medical records;;ACTIVE;1.0j-a;2.67 +11504-8;Surgical operation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Surgical operation note;Operative note;;ACTIVE;1.0j-a;2.63 +11505-5;Procedure note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician procedure note;MD Procedure note;;ACTIVE;1.0j-a;2.58 +11506-3;Progress note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Progress note;Prog note;;ACTIVE;1.0j-a;2.73 +11507-1;Progress note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Progress note;OT Prog note;;ACTIVE;1.0j-a;2.73 +11508-9;Progress note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Progress note;PT Prog note;;ACTIVE;1.0j-a;2.73 +11509-7;Progress note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Progress note;Podiatry Prog note;;ACTIVE;1.0j-a;2.73 +1151-0;L little u NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated Lu NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated Lu NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +11510-5;Progress note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Progress note;Psych Prog note;;ACTIVE;1.0j-a;2.73 +11511-3;Progress note.total;Find;Pt;^Patient;Nar;;H&P.HX;2;Deprecated Provider-unspecified progress note;DeprecatedProgress note.total;;DEPRECATED;1.0j-a;2.36 +11512-1;Progress note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Progress note;Speech-lang path Prog note;;ACTIVE;1.0j-a;2.73 +11513-9;Provider.signing;ID;Pt;Report;Nom;;ADMIN.ID;2;Provider.signing [Identifier] Report;Provider.signing Report;;ACTIVE;1.0j-a;2.73 +11514-7;Episode of care medical records;Find;Pt;^Patient;Doc;Chiropractic;DOC.MISC;2;Chiropractic Episode of care medical records;Chiropractic med records;;ACTIVE;1.0j-a;2.73 +11515-4;Episode of care medical records;Find;Pt;^Patient;Doc;Physical therapy;DOC.MISC;2;Physical therapy Episode of care medical records;PT med records;;ACTIVE;1.0j-a;2.73 +11516-2;Episode of care medical records;Find;Pt;^Patient;Doc;Physician;DOC.MISC;2;Physician Episode of care medical records;Physician med records;;ACTIVE;1.0j-a;2.73 +11517-0;Episode of care medical records;Find;Pt;^Patient;Doc;Podiatry;DOC.MISC;2;Podiatry Episode of care medical records;Podiatry med records;;ACTIVE;1.0j-a;2.73 +11518-8;Episode of care medical records;Find;Pt;^Patient;Doc;Psychology;DOC.MISC;2;Psychology Episode of care medical records;Psych med records;;ACTIVE;1.0j-a;2.73 +11519-6;Episode of care medical records;Find;Pt;^Patient;Doc;Social service;DOC.MISC;2;Social service Episode of care medical records;Social service med records;;ACTIVE;1.0j-a;2.73 +11520-4;Episode of care medical records;Find;Pt;^Patient;Doc;Speech therapy;DOC.MISC;2;Speech therapy Episode of care medical records;Speech therapy med records;;ACTIVE;1.0j-a;2.73 +11521-2;Episode of care medical records;Find;Pt;^Patient;Doc;Occupational therapy;DOC.MISC;2;Occupational therapy Episode of care medical records;OT med records;;ACTIVE;1.0j-a;2.73 +11522-0;Study report;Find;Pt;Heart;Doc;Cardiac echo;ATTACH.CLINRPT;3;Deprecated Cardiac echo study;Deprecated;;DEPRECATED;1.0j-a;2.58 +11523-8;Electroencephalography study;Find;Pt;^Patient;Doc;;NEURO;2;EEG study;EEG study;;ACTIVE;1.0j-a;2.72 +11524-6;EKG study;Find;Pt;Heart;Doc;EKG;CARD.PROC;2;EKG study;EKG study;;ACTIVE;1.0j-a;2.72 +11525-3;Multisection for pregnancy;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for pregnancy;US for pregnancy;;ACTIVE;1.0j-a;2.67 +11526-1;Pathology study;Find;Pt;^Patient;Doc;Pathology;PATH;1;Pathology study;Pathology study;;ACTIVE;1.0j-a;2.73 +11527-9;Psychiatry study;Find;Pt;^Patient;Doc;Psychiatry;CLIN;2;Psychiatry study;Psychiatry study;;ACTIVE;1.0j-a;2.72 +1152-8;L little u NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated Lu NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated Lu NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +11528-7;Study.total;Find;Pt;XXX;Doc;Radiology.XXX;ATTACH.CLINRPT;3;Deprecated Radiology Unspecified site and modality Study;Deprecated;;DEPRECATED;1.0j-a;2.40 +11529-5;Surgical pathology study;Find;Pt;^Patient;Doc;Surgical pathology;PATH;1;Surgical pathology study;Surgical pathology study;;ACTIVE;1.0j-a;2.73 +11530-3;Surgeon.assisting;ID;Pt;Surgical procedure;Nom;;ADMIN.ID;2;Surgeon.assisting [Identifier];Surgeon.assisting;;ACTIVE;1.0j-a;2.66 +11531-1;Surgeon.resident;ID;Pt;Surgical procedure;Nom;;ADMIN.ID;2;Surgeon.resident [Identifier];Surgeon.resident;;ACTIVE;1.0j-a;2.66 +11532-9;Surgeon.staff;ID;Pt;Surgical procedure;Nom;;ADMIN.ID;2;Surgeon.staff [Identifier];Surgeon.staff;;ACTIVE;1.0j-a;2.66 +11533-7;Surgical drains;Find;Pt;Surgical procedure;Nom;;CLIN;2;Surgical drains;Surgical drains;;ACTIVE;1.0j-a;2.29 +11534-5;Temperature charts;Find;-;^Patient;Doc;;DOC.MISC;2;Temperature charts;Temp charts;;ACTIVE;1.0j-a;2.67 +11535-2;Hospital discharge Dx;Imp;Pt;^Patient;Nar;;H&P.HX;2;Hospital discharge Dx Narrative;Hospital discharge Dx;;ACTIVE;1.0j-a;2.63 +1153-6;L little u NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated Lu NOS Ag [Presence] on Red Blood Cells;Deprecated Lu NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +11536-0;Notes;Find;Enctr;^Patient;Doc;Nursing;ATTACH.CLINRPT;3;Deprecated Nurse Notes;Deprecated;;DEPRECATED;1.0j-a;2.67 +11537-8;Surgical drains;Find;Pt;Surgical procedure;Nar;;CLIN;2;Surgical drains Narrative;Surgical drains;;ACTIVE;1.0j-a;2.63 +11538-6;Study.total;Find;Pt;Chest;Doc;CT;ATTACH.CLINRPT;3;Deprecated CT Chest study;Deprecated;;DEPRECATED;1.0j-a;2.40 +11539-4;Study.total;Find;Pt;Head;Doc;CT;ATTACH.CLINRPT;3;Deprecated CT Head study;Deprecated;;DEPRECATED;1.0j-a;2.46 +11540-2;Study.total;Find;Pt;Abdomen;Doc;CT;ATTACH.CLINRPT;3;Deprecated CT Abdomen study;Deprecated;;DEPRECATED;1.0j-a;2.40 +11541-0;Study report;Find;Pt;Brain;Doc;MRI;ATTACH.CLINRPT;3;Deprecated MRI Brain study;Deprecated;;DEPRECATED;1.0j-a;2.50 +11542-8;Subsequent visit evaluation note;Find;Pt;{Setting};Doc;{Provider};ATTACH.CLINRPT;3;Deprecated Provider-unspecified visit note;;;DEPRECATED;1.0j-a;2.36 +11543-6;Nursery records;Find;-;^Patient;Doc;;DOC.MISC;2;Nursery records;Nursery records;;ACTIVE;1.0j-a;2.67 +1154-4;little c Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;little c Ab [Presence] in Serum or Plasma from Blood product unit;little c Ab SerPl BPU Ql;;ACTIVE;1.0;2.73 +11544-4;Hospital discharge follow-up;Find;Pt;^Patient;Nar;;H&P.HX;2;Hospital discharge follow-up Narrative;Hospital discharge follow-up;;ACTIVE;1.0j-a;2.40 +11545-1;Microscopic observation;Prid;Pt;XXX;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Acid fast stain;Acid fast Stn Spec;;ACTIVE;1.0j-a;2.73 +11546-9;Microscopic observation;Prid;Pt;XXX;Nom;XXX stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Other stain;Other Stn Spec;;ACTIVE;1.0j-a;2.73 +11550-1;Borrelia burgdorferi;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Borrelia burgdorferi [Presence] in Specimen by Organism specific culture;B burgdor Spec Ql Cult;;ACTIVE;1.0j-a;2.73 +1155-1;little c Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;little c Ab [Presence] in Serum or Plasma from Donor;little c Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11551-9;Borrelia burgdorferi DNA;PrThr;Pt;CSF;Ord;Probe.amp;MICRO;1;Borrelia burgdorferi DNA [Presence] in Cerebral spinal fluid by Probe with amplification;B burgdor DNA CSF Ql Probe amp;;ACTIVE;1.0j-a;2.63 +11552-7;Microscopic exam;Imp;Pt;Tiss.FNA;Nom;Cytology;CYTO;1;Microscopic exam [Interpretation] of Tissue fine needle aspirate by Cytology;Microscopic Tiss FNA-Imp;;ACTIVE;1.0j-a;2.73 +11553-5;Microscopic exam;Imp;Pt;Sputum;Nom;Cytology;CYTO;1;Microscopic exam [Interpretation] of Sputum by Cytology;Microscopic Spt-Imp;;ACTIVE;1.0j-a;2.73 +11554-3;Magnesium;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Magnesium [Molecules/volume] in Serum or Plasma;Deprecated Magnesium SerPl-sCnc;;DEPRECATED;1.0j-a;2.36 +11555-0;Base excess;SCnc;Pt;Bld;Qn;Calculated;CHEM;1;Base excess in Blood by calculation;Base excess Bld Calc-sCnc;;ACTIVE;1.0j-a;2.73 +11556-8;Oxygen;PPres;Pt;Bld;Qn;;CHEM;1;Oxygen [Partial pressure] in Blood;pO2 Bld;;ACTIVE;1.0j-a;2.73 +11557-6;Carbon dioxide;PPres;Pt;Bld;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Blood;pCO2 Bld;;ACTIVE;1.0j-a;2.73 +11558-4;pH;LsCnc;Pt;Bld;Qn;;CHEM;1;pH of Blood;pH Bld;;ACTIVE;1.0j-a;2.73 +11559-2;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;CHEM;1;Fractional oxyhemoglobin in Blood;OxyHgb MFr Bld;;ACTIVE;1.0j-a;2.73 +115-6;cefOXitin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;cefOXitin [Susceptibility] by Minimum lethal concentration (MLC);cefOXitin Islt MLC;;ACTIVE;1.0;2.19 +11560-0;Acetylcholine receptor binding Ab;ACnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor binding Ab [Units/volume] in Serum;AChR Bind Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11561-8;Acetylcholine receptor blocking Ab;ACnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor blocking Ab [Units/volume] in Serum;AChR Block Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11562-6;Acetylcholine receptor modulation Ab;ACnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor modulation Ab [Units/volume] in Serum;AChR Mod Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11563-4;DNA double strand Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated DNA double strand Ab [Units/volume] in Serum;Deprecated dsDNA Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +11564-2;Intrinsic factor Ab;ACnc;Pt;Ser;Qn;;SERO;1;Intrinsic factor Ab [Units/volume] in Serum;IF Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11565-9;Jo-1 extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Jo-1 extractable nuclear Ab [Units/volume] in Serum;ENA Jo1 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11566-7;Liver kidney microsomal Ab;ACnc;Pt;Ser;Qn;;SERO;1;Liver kidney microsomal Ab [Units/volume] in Serum;LKM Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11567-5;Neutrophil cytoplasmic Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Neutrophil cytoplasmic Ab [Units/volume] in Serum;Deprecated ANCA Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +11568-3;Phosphatidylserine Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylserine IgG Ab [Presence] in Serum;PS IgG Ser Ql;;ACTIVE;1.0j-a;2.73 +1156-9;little c Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;little c Ab [Presence] in Serum or Plasma;little c Ab SerPl Ql;;ACTIVE;1.0;2.56 +11569-1;Phosphatidylserine Ab.IgM;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylserine IgM Ab [Presence] in Serum;PS IgM Ser Ql;;ACTIVE;1.0j-a;2.73 +11570-9;Platelet Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Platelet IgG Ab [Units/volume] in Serum;Platelet IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11571-7;Rheumatoid arthritis nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Rheumatoid arthritis nuclear Ab [Units/volume] in Serum;RA Nuc Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11572-5;Rheumatoid factor;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Rheumatoid factor [Units/volume] in Serum or Plasma;Rheumatoid fact SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +11573-3;Rheumatoid factor.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Rheumatoid factor IgM [Units/volume] in Serum;RF IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11574-1;Thyroperoxidase Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Thyroperoxidase Ab [Units/volume] in Serum;Deprecated Thyroperoxidase Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.36 +11575-8;Cefmetazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefmetazole [Susceptibility] by Gradient strip;Cefmetazole Islt Grad strip;;ACTIVE;1.0j-a;2.56 +11576-6;Erythromycin+sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Erythromycin+Sulfisoxazole [Susceptibility] by Gradient strip;Erythro+Sulf Islt Grad strip;;ACTIVE;1.0j-a;2.56 +1157-7;little c Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little c Ag [Presence] on Red Blood Cells from Blood product unit;little c Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11577-4;Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Sulfamethoxazole [Susceptibility] by Gradient strip;Sulfamethoxazole Islt Grad strip;;ACTIVE;1.0j-a;2.56 +11578-2;sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;sulfiSOXAZOLE [Susceptibility] by Gradient strip;Sulfisoxaz Islt Grad strip;;ACTIVE;1.0j-a;2.56 +11579-0;Thyrotropin;ACnc;Pt;Ser/Plas;Qn;Detection limit <= 0.05 mIU/L;CHEM;1;Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.05 mIU/L;TSH SerPl DL<=0.05 mIU/L-aCnc;;ACTIVE;1.0j-a;2.73 +11580-8;Thyrotropin;ACnc;Pt;Ser/Plas;Qn;Detection limit <= 0.005 mIU/L;CHEM;1;Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.005 mIU/L;TSH SerPl DL<=0.005 mIU/L-aCnc;;ACTIVE;1.0j-a;2.73 +11581-6;Ebola virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Ebola virus Ab [Units/volume] in Serum;EBOV Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11582-4;Wuchereria bancrofti Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Wuchereria bancrofti Ab [Units/volume] in Serum;W bancr Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11583-2;Aspergillus fumigatus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus 1 Ab [Presence] in Serum;A fumigatus1 Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +11584-0;Aureobasidium pullulans Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aureobasidium pullulans Ab [Presence] in Serum;A pullulans Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +1158-5;little c Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little c Ag [Presence] on Red Blood Cells from Donor;little c Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11585-7;Bordetella pertussis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis Ab [Units/volume] in Serum;B pert Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11586-5;Brucella abortus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella abortus Ab [Units/volume] in Serum;B abortus Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11587-3;Brucella canis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella canis Ab [Units/volume] in Serum;B canis Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11588-1;Brucella melitensis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella melitensis Ab [Units/volume] in Serum;B melitensis Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11589-9;Brucella suis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella suis Ab [Units/volume] in Serum;B suis Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11590-7;Coxsackievirus A10 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A10 Ab [Units/volume] in Serum;CV A10 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11591-5;Coxsackievirus A2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A2 Ab [Units/volume] in Serum;CV A2 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11592-3;Aspergillus fumigatus 6 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus 6 Ab [Presence] in Serum;A fumigatus6 Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +1159-3;little c Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;little c Ag [Presence] on Red Blood Cells;little c Ag RBC Ql;;ACTIVE;1.0;2.73 +11593-1;Coxsackievirus A4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A4 Ab [Units/volume] in Serum;CV A4 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11594-9;Echovirus 16 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 16 Ab [Units/volume] in Serum;ECV16 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11595-6;Echovirus 18 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 18 Ab [Units/volume] in Serum;ECV18 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11596-4;Shigella dysenteriae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Shigella dysenteriae Ab [Units/volume] in Serum;S dysenter Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11597-2;Treponema pallidum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Treponema pallidum Ab [Units/volume] in Serum;T pallidum Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11598-0;Toxoplasma gondii Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii Ab [Units/volume] in Serum;T gondii Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11599-8;Coxsackievirus A21 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A21 Ab [Units/volume] in Serum;CV A21 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11600-4;Shigella flexneri Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Shigella flexneri Ab [Units/volume] in Serum;S flexneri Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +1160-1;little e Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;little e Ab [Presence] in Serum or Plasma from Blood product unit;little e Ab SerPl BPU Ql;;ACTIVE;1.0;2.73 +11601-2;Echovirus 7 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 7 Ab [Units/volume] in Serum;ECV7 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11602-0;Shigella boydii Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Shigella boydii Ab [Units/volume] in Serum;S boydii Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11603-8;Salmonella sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella sp Ab [Units/volume] in Serum;Salmonella Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11604-6;Burkholderia pseudomallei Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Burkholderia pseudomallei Ab [Units/volume] in Serum;B pseudomal Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11605-3;Lymphocytic choriomeningitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Lymphocytic choriomeningitis virus Ab [Units/volume] in Serum;LCMV Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11606-1;Leptospira interrogans Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans Ab [Units/volume] in Serum;L inter Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11607-9;Junin virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Junin virus Ab [Units/volume] in Serum;JUNV Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11608-7;Japanese encephalitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Japanese encephalitis virus Ab [Units/volume] in Serum;JEV Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11609-5;HTLV I Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HTLV I Ab [Units/volume] in Serum;HTLV I Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11610-3;Heterophile Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Heterophile Ab [Units/volume] in Serum;Heteroph Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +11611-1;Shigella sonnei Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Shigella sonnei Ab [Units/volume] in Serum;S sonnei Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +11612-9;Abortions;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Abortions;Abortions;;ACTIVE;1.0j-a;2.40 +11613-7;Abortions.induced;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Abortions.induced;Abortions.induced;;ACTIVE;1.0j-a;2.48 +11614-5;Abortions.spontaneous;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Abortions.spontaneous;Abortions.spontaneous;;ACTIVE;1.0j-a;2.48 +11615-2;Activity;Find;Pt;Heart^Fetus;Nom;US;OB.US;2;Fetal Heart Activity US;Fet Hrt Activity US;;ACTIVE;1.0j-a;2.27 +11616-0;Activity;Find;Pt;Heart^Fetus;Nar;US;OB.US;2;Fetal Heart Narrative Activity US;Fet Hrt Activity US;;ACTIVE;1.0j-a;2.40 +11617-8;Activity;Find;Pt;Limbs^Fetus;Nom;US;OB.US;2;Fetal Limbs Activity US;Fet Limbs Activity US;;ACTIVE;1.0j-a;2.27 +11618-6;Activity;Find;Pt;Limbs^Fetus;Nar;US;OB.US;2;Fetal Limbs Narrative Activity US;Fet Limbs Activity US;;ACTIVE;1.0j-a;2.40 +1161-9;little e Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;little e Ab [Presence] in Serum or Plasma from Donor;little e Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11619-4;Activity;Find;Pt;Respiratory system^Fetus;Nom;US;OB.US;2;Fetal Respiratory Activity US;Fet Respiratory Activity US;;ACTIVE;1.0j-a;2.29 +11620-2;Activity;Find;Pt;Respiratory system^Fetus;Nar;US;OB.US;2;Fetal Respiratory Narrative Activity US;Fet Respiratory Activity US;;ACTIVE;1.0j-a;2.40 +11621-0;Activity;Find;Pt;Trunk^Fetus;Nom;US;OB.US;2;Fetal Trunk Activity US;Fet Trunk Activity US;;ACTIVE;1.0j-a;2.27 +11622-8;Activity;Find;Pt;Trunk^Fetus;Nar;US;OB.US;2;Fetal Trunk Narrative Activity US;Fet Trunk Activity US;;ACTIVE;1.0j-a;2.40 +11623-6;Amniotic fluid index;Len;Pt;Am fld space.quadrant four^Fetus;Qn;US.derived;OB.US;2;Fetal Quadrant four Amniotic fluid index derived by US;Fet Q4 AFI der US;;ACTIVE;1.0j-a;2.32 +11624-4;Amniotic fluid index;Len;Pt;Am fld space.quadrant one^Fetus;Qn;US.derived;OB.US;2;Fetal Quadrant four one Amniotic fluid index derived by US;Fet Q1 AFI der US;;ACTIVE;1.0j-a;2.48 +11625-1;Amniotic fluid index;Len;Pt;Am fld space.quadrant three^Fetus;Qn;US.derived;OB.US;2;Fetal Quadrant three Amniotic fluid index derived by US;Fet Q3 AFI der US;;ACTIVE;1.0j-a;2.48 +11626-9;Amniotic fluid index;Len;Pt;Am fld space.quadrant two^Fetus;Qn;US.derived;OB.US;2;Fetal Quadrant two Amniotic fluid index derived by US;Fet Q2 AFI der US;;ACTIVE;1.0j-a;2.48 +1162-7;little e Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;little e Ab [Presence] in Serum or Plasma;little e Ab SerPl Ql;;ACTIVE;1.0;2.56 +11627-7;Amniotic fluid index.sum;Len;Pt;Am fld space^Fetus;Qn;US.derived;OB.US;2;Fetal Amniotic fluid index.sum derived by US;Fet AFI sum der US;;ACTIVE;1.0j-a;2.48 +11628-5;Binocular distance;Len;Pt;Head^Fetus;Qn;US+Estimated from BPD;OB.US;2;Fetal Head Binocular distance estimated from Biparietal diameter on US;Fet Head Binoc D from BPD;;ACTIVE;1.0j-a;2.52 +11629-3;Binocular distance;Len;Pt;Head^Fetus;Qn;US.measured;OB.US;2;Fetal Head Binocular distance US;Fet Head Binoc D US.meas;;ACTIVE;1.0j-a;2.48 +11630-1;Biophysical profile.amniotic fluid volume;Fcn;Pt;^Fetus;Ord;US;OB.US;2;Fetal Biophysical profile.amniotic fluid volume US;Fet BPP.amn fld vol US;;ACTIVE;1.0j-a;2.27 +11631-9;Biophysical profile.body movement;Fcn;Pt;^Fetus;Ord;US;OB.US;2;Fetal Biophysical profile.body movement US;Fet BPP.body movement US;;ACTIVE;1.0j-a;2.27 +11632-7;Biophysical profile.breathing movement;Fcn;Pt;^Fetus;Ord;US;OB.US;2;Fetal Biophysical profile.breathing movement US;Fet BPP.breathing movement US;;ACTIVE;1.0j-a;2.27 +11633-5;Heart rate reactivity;Fcn;Pt;^Fetus;Ord;US;OB.US;2;Fetal Heart rate reactivity US;Fetal NST by US;;ACTIVE;1.0j-a;2.71 +11634-3;Biophysical profile.sum;Fcn;Pt;^Fetus;Ord;Derived;OB.US;2;Fetal Biophysical profile.sum Derived;Fet BPP.sum Derived;;ACTIVE;1.0j-a;2.27 +1163-5;little e Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little e Ag [Presence] on Red Blood Cells from Blood product unit;little e Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11635-0;Biophysical profile.tone;Fcn;Pt;^Fetus;Ord;US;OB.US;2;Fetal Biophysical profile.tone US;Fet BPP.tone US;;ACTIVE;1.0j-a;2.27 +11636-8;Births.live;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Births.live;Births.live;;ACTIVE;1.0j-a;2.48 +11637-6;Births.preterm;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Births.preterm;Births.preterm;;ACTIVE;1.0j-a;2.48 +11638-4;Births.still living;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Births.still living;Births.still living;;ACTIVE;1.0j-a;2.73 +11639-2;Births.term;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Births.term;Births.term;;ACTIVE;1.0j-a;2.73 +116-4;cefOXitin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefOXitin [Susceptibility] by Minimum inhibitory concentration (MIC);cefOXitin Islt MIC;;ACTIVE;1.0;2.73 +11640-0;Births.total;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Births total;Births.total;;ACTIVE;1.0j-a;2.48 +11641-8;A wave.max;Vel;Pt;Mitral valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Mitral valve Peak A wave US.doppler;Fet MV Peak A-wave DOP;;ACTIVE;1.0j-a;2.54 +11642-6;Blood flow.diastolic.atrial wave.max;Vel;Pt;Mitral valve;Qn;US.doppler;OB.US;2;Deprecated Mitral valve Blood flow.diastolic.atrial wave.max by US.doppler;Deprecated Blood flow.diastolic.atrial w;;DEPRECATED;1.0j-a;2.36 +1164-3;little e Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little e Ag [Presence] on Red Blood Cells from Donor;little e Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11643-4;A wave.max;Vel;Pt;Tricuspid valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Tricuspid valve Peak A wave US.doppler;Fet TV Peak A-wave DOP;;ACTIVE;1.0j-a;2.54 +11644-2;Blood flow.diastolic.atrial wave.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;OB.US;2;Deprecated Tricuspid valve Peak A velocity US.doppler;Deprecated TV Peak A US.dop;;DEPRECATED;1.0j-a;2.36 +11645-9;E wave.max;Vel;Pt;Mitral valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Mitral valve Peak E wave US.doppler;Fet MV Peak E-wave DOP;;ACTIVE;1.0j-a;2.54 +11646-7;Blood flow.diastolic.early wave.max;Vel;Pt;Mitral valve;Qn;US.doppler;OB.US;2;Deprecated Mitral valve Peak E velocity US.doppler;Deprecated MV Peak E US.dop;;DEPRECATED;1.0j-a;2.36 +11647-5;E wave.max;Vel;Pt;Tricuspid valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Tricuspid valve Peak E wave US.doppler;Fet TV Peak E-wave DOP;;ACTIVE;1.0j-a;2.54 +11648-3;Blood flow.diastolic.early wave.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;OB.US;2;Deprecated Tricuspid valve Peak E velocity US.doppler;Deprecated TV Peak E US.dop;;DEPRECATED;1.0j-a;2.36 +11649-1;E wave/A wave;VelRto;Pt;Mitral valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Mitral valve E-wave/A-wave US.doppler;Fet MV E-wave/A-wave DOP;;ACTIVE;1.0j-a;2.54 +1165-0;little e Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;little e Ag [Presence] on Red Blood Cells;little e Ag RBC Ql;;ACTIVE;1.0;2.73 +11650-9;Blood flow.diastolic.early wave/Atrial wave ratio;VelRto;Pt;Mitral valve;Qn;Doppler.measured;OB.US;2;Deprecated Mitral valve Blood flow.diastolic.early wave/Atrial wave Doppler.measured;Deprecated MV Bld flow.dias.E-wave/A;;DEPRECATED;1.0j-a;2.36 +11651-7;E wave/A wave;VelRto;Pt;Tricuspid valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Tricuspid valve E-wave/A-wave US.doppler;Fet TV E-wave/A-wave DOP;;ACTIVE;1.0j-a;2.54 +11652-5;Blood flow.diastolic.early wave/Atrial wave ratio;VelRto;Pt;Tricuspid valve;Qn;Doppler.measured;OB.US;2;Deprecated Tricuspid valve Blood flow.diastolic.early wave/Atrial wave Doppler.measured;Deprecated TV Bld flow.dias.E-wave/A;;DEPRECATED;1.0j-a;2.36 +11653-3;Blood flow velocity.diastolic.end;Vel;Pt;{Circulatory system};Qn;US.doppler;OB.US;2;Circulatory system End diastolic blood flow velocity US.doppler;Circ sys Bld flow vel.dias.end DOP;;ACTIVE;1.0j-a;2.67 +11654-1;Blood flow velocity.diastolic.min;Vel;Pt;Cerebral artery anterior^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery anterior Minimal flow velocity US.doppler;Fet Cerebral a Ant Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11655-8;Blood flow velocity.diastolic.min;Vel;Pt;Cerebral artery anterior;Qn;US.doppler;OB.US;2;Cerebral artery anterior Minimal flow velocity US.doppler;Cerebral a Ant Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11656-6;Blood flow velocity.diastolic.min;Vel;Pt;Cerebral artery middle^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery middle Minimal flow velocity US.doppler;Fet Cerebral a Middle Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11657-4;Blood flow velocity.diastolic.min;Vel;Pt;Cerebral artery middle;Qn;US.doppler;OB.US;2;Cerebral artery middle Minimal flow velocity US.doppler;Cerebral a Middle Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11658-2;Blood flow velocity.diastolic.min;Vel;Pt;Ovarian artery.left;Qn;US.doppler;OB.US;2;Ovarian artery - left Minimal flow velocity US.doppler;Ovarian a-L Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11659-0;Blood flow velocity.diastolic.min;Vel;Pt;Ovarian artery.right;Qn;US.doppler;OB.US;2;Ovarian artery - right Minimal flow velocity US.doppler;Ovarian a-R Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11660-8;Blood flow velocity.diastolic.min;Vel;Pt;Umbilical artery.at fetus^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at fetus Minimal flow velocity US.doppler;Fet Umb a at fetus Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11661-6;Blood flow velocity.diastolic.min;Vel;Pt;Umbilical artery.at placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at placenta Minimal flow velocity US.doppler;Fet Umb a.at plc Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11662-4;Blood flow velocity.diastolic.min;Vel;Pt;Umbilical artery.between fetus and placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery between fetus and placenta Minimal flow velocity US.doppler;Fet Umb a fetus-plc Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11663-2;Blood flow velocity.diastolic.min;Vel;Pt;Uterine artery.left;Qn;US.doppler;OB.US;2;Uterine artery - left Minimal flow velocity US.doppler;Uterine a-L Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11664-0;Blood flow velocity.diastolic.min;Vel;Pt;Uterine artery.right;Qn;US.doppler;OB.US;2;Uterine artery - right Minimal flow velocity US.doppler;Uterine a-R Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11665-7;Blood flow velocity.diastolic.min;Vel;Pt;{Circulatory system};Qn;US.doppler;OB.US;2;Circulatory system Minimal flow velocity US.doppler;Circ sys Vmin dias DOP;;ACTIVE;1.0j-a;2.67 +11666-5;Blood flow velocity.mean;Vel;Pt;Aorta ascending^Fetus;Qn;US.doppler;OB.US;2;Fetal Aorta ascending Mean blood flow velocity US.doppler;Fet Aorta ascending Vmean DOP;;ACTIVE;1.0j-a;2.67 +11667-3;Blood flow velocity.mean;Vel;Pt;Aorta ascending;Qn;US.doppler;OB.US;2;Aorta ascending Mean blood flow velocity US.doppler;Aorta ascending Vmean DOP;;ACTIVE;1.0j-a;2.67 +1166-8;little f Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;little f Ab [Presence] in Serum or Plasma from Blood product unit;little f Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11668-1;Blood flow velocity.mean;Vel;Pt;Aorta descending^Fetus;Qn;US.doppler;OB.US;2;Fetal Aorta descending Mean blood flow velocity US.doppler;Fet Aorta descending Vmean DOP;;ACTIVE;1.0j-a;2.67 +11669-9;Blood flow velocity.mean;Vel;Pt;Aorta descending;Qn;US.doppler;OB.US;2;Aorta descending Mean blood flow velocity US.doppler;Aorta descending Vmean DOP;;ACTIVE;1.0j-a;2.67 +11670-7;Blood flow velocity.mean;Vel;Pt;Aortic arch^Fetus;Qn;US.doppler;OB.US;2;Fetal Aortic arch Mean blood flow velocity US.doppler;Fet Ac arch Vmean DOP;;ACTIVE;1.0j-a;2.67 +11671-5;Blood flow velocity.mean;Vel;Pt;Aortic arch;Qn;US.doppler;OB.US;2;Aortic arch Mean blood flow velocity US.doppler;Ac arch Vmean DOP;;ACTIVE;1.0j-a;2.67 +11672-3;Blood flow velocity.mean;Vel;Pt;Cerebral artery anterior^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery anterior Mean blood flow velocity US.doppler;Fet Cerebral a Ant Vmean DOP;;ACTIVE;1.0j-a;2.67 +11673-1;Blood flow velocity.mean;Vel;Pt;Cerebral artery anterior;Qn;US.doppler;OB.US;2;Cerebral artery anterior Mean blood flow velocity US.doppler;Cerebral a Ant Vmean DOP;;ACTIVE;1.0j-a;2.67 +11674-9;Blood flow velocity.mean;Vel;Pt;Cerebral artery middle;Qn;US.doppler;OB.US;2;Cerebral artery middle Mean blood flow velocity US.doppler;Cerebral a Middle Vmean DOP;;ACTIVE;1.0j-a;2.67 +11675-6;Blood flow velocity.mean;Vel;Pt;Ductus arteriosus^Fetus;Qn;US.doppler;OB.US;2;Fetal Ductus arteriosus Mean blood flow velocity US.doppler;Fet DA Vmean DOP;;ACTIVE;1.0j-a;2.67 +1167-6;little f Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;little f Ab [Presence] in Serum or Plasma from Donor;little f Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11676-4;Blood flow velocity.mean;Vel;Pt;Ductus arteriosus;Qn;US.doppler;OB.US;2;Ductus arteriosus Mean blood flow velocity US.doppler;DA Vmean DOP;;ACTIVE;1.0j-a;2.68 +11677-2;Blood flow velocity.mean;Vel;Pt;Pulmonic valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Pulmonic valve Mean blood flow velocity US.doppler;Fet PV Vmean DOP;;ACTIVE;1.0j-a;2.67 +11678-0;Blood flow velocity.mean;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Mean blood flow velocity by US.doppler;PV Vmean DOP;;ACTIVE;1.0j-a;2.67 +11679-8;Blood flow velocity.mean;Vel;Pt;Heart.ventricle.left.outflow tract^Fetus;Qn;US.doppler;OB.US;2;Fetal Left ventricular outflow tract Mean blood flow velocity US.doppler;Fet LVOT Vmean DOP;;ACTIVE;1.0j-a;2.67 +11680-6;Blood flow.mean;Vel;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;OB.US;2;Deprecated Left ventricular outflow tract Mean blood flow Doppler.measured;Deprecated LVOT Vmean Dop.meas;;DEPRECATED;1.0j-a;2.36 +11681-4;Blood flow velocity.mean;Vel;Pt;Heart.ventricle.right.outflow tract^Fetus;Qn;US.doppler;OB.US;2;Fetal Right ventricular outflow tract Mean blood flow velocity US.doppler;Fet RVOT Vmean DOP;;ACTIVE;1.0j-a;2.67 +11682-2;Blood flow.mean;Vel;Pt;Heart.ventricle.right.outflow tract;Qn;US.doppler;OB.US;2;Deprecated Right ventricular outflow tract Mean blood flow Doppler.measured;Deprecated RVOT Vmean Dop.meas;;DEPRECATED;1.0j-a;2.36 +11683-0;Blood flow velocity.mean;Vel;Pt;Ovarian artery.left;Qn;US.doppler;OB.US;2;Ovarian artery - left Mean blood flow velocity US.doppler;Ovarian a-L Vmean DOP;;ACTIVE;1.0j-a;2.67 +1168-4;little f Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;little f Ab [Presence] in Serum or Plasma;little f Ab SerPl Ql;;ACTIVE;1.0;2.56 +11684-8;Blood flow velocity.mean;Vel;Pt;Ovarian artery.right;Qn;US.doppler;OB.US;2;Ovarian artery - right Mean blood flow velocity US.doppler;Ovarian a-R Vmean DOP;;ACTIVE;1.0j-a;2.67 +11685-5;Blood flow velocity.mean;Vel;Pt;Pulmonary artery.main^Fetus;Qn;US.doppler;OB.US;2;Fetal Main pulmonary artery Mean blood flow velocity US.doppler;Fet MPA Vmean DOP;;ACTIVE;1.0j-a;2.67 +11686-3;Blood flow velocity.mean;Vel;Pt;Pulmonary artery.main;Qn;US.doppler;OB.US;2;Main pulmonary artery Mean blood flow velocity US.doppler;MPA Vmean DOP;;ACTIVE;1.0j-a;2.67 +11687-1;Blood flow velocity.mean;Vel;Pt;Umbilical artery.at fetus^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at fetus Mean blood flow velocity US.doppler;Fet Umb a at fetus Vmean DOP;;ACTIVE;1.0j-a;2.67 +11688-9;Blood flow.mean;Vel;Pt;Umbilical artery.at placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at placenta Mean blood flow US.doppler;Fet Umb a.at plc Vmean DOP;;ACTIVE;1.0j-a;2.67 +11689-7;Blood flow.mean;Vel;Pt;Umbilical artery.between fetus and placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery between fetus and placenta Mean blood flow US.doppler;Fet Umb a fetus-plc Vmean DOP;;ACTIVE;1.0j-a;2.67 +11690-5;Blood flow.mean;Vel;Pt;Uterine artery.left;Qn;US.doppler;OB.US;2;Uterine artery - left Mean blood flow US.doppler;Uterine a-L Vmean DOP;;ACTIVE;1.0j-a;2.67 +11691-3;Blood flow.mean;Vel;Pt;Uterine artery.right;Qn;US.doppler;OB.US;2;Uterine artery - right Mean blood flow US.doppler;Uterine a-R Vmean DOP;;ACTIVE;1.0j-a;2.67 +1169-2;little f Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little f Ag [Presence] on Red Blood Cells from Blood product unit;little f Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11692-1;Blood flow velocity.mean.max;Vel;Pt;{Circulatory system};Qn;US.doppler;OB.US;2;Circulatory system Maximum blood flow velocity mean US.doppler;Circ sys VMax Bld flow.mean DOP;;ACTIVE;1.0j-a;2.67 +11693-9;Blood flow velocity.systolic.max;Vel;Pt;Aorta ascending^Fetus;Qn;US.doppler;OB.US;2;Fetal Aorta ascending Peak systolic flow velocity US.doppler;Fet Aorta ascending Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11694-7;Blood flow velocity.systolic.max;Vel;Pt;Aorta ascending;Qn;US.doppler;OB.US;2;Aorta ascending Peak systolic flow velocity US.doppler;Aorta ascending Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11695-4;Blood flow velocity.systolic.max;Vel;Pt;Aorta descending^Fetus;Qn;US.doppler;OB.US;2;Fetal Aorta descending Peak systolic flow velocity US.doppler;Fet Aorta descending Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11696-2;Blood flow velocity.systolic.max;Vel;Pt;Aorta descending;Qn;US.doppler;OB.US;2;Aorta descending Peak systolic flow velocity US.doppler;Aorta descending Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11697-0;Blood flow velocity.systolic.max;Vel;Pt;Aortic arch^Fetus;Qn;US.doppler;OB.US;2;Fetal Aortic arch Peak systolic flow velocity US.doppler;Fet Ac arch Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11698-8;Blood flow velocity.systolic.max;Vel;Pt;Aortic arch;Qn;US.doppler;OB.US;2;Aortic arch Peak systolic flow velocity US.doppler;Ac arch Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11699-6;Blood flow velocity.systolic.max;Vel;Pt;Cerebral artery anterior^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery anterior Peak systolic flow velocity US.doppler;Fet Cerebral a Ant Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11-7;Amikacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Amikacin [Susceptibility] by Minimum lethal concentration (MLC);Amikacin Islt MLC;;ACTIVE;1.0;2.19 +1170-0;little f Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little f Ag [Presence] on Red Blood Cells from Donor;little f Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11700-2;Blood flow velocity.systolic.max;Vel;Pt;Cerebral artery anterior;Qn;US.doppler;OB.US;2;Cerebral artery anterior Peak systolic flow velocity US.doppler;Cerebral a Ant Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11701-0;Blood flow velocity.systolic.max;Vel;Pt;Cerebral artery middle^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery middle Peak systolic flow velocity US.doppler;Fet Cerebral a Middle Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11702-8;Blood flow velocity.systolic.max;Vel;Pt;Cerebral artery middle;Qn;US.doppler;OB.US;2;Cerebral artery middle Peak systolic flow velocity US.doppler;Cerebral a Middle Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11703-6;Blood flow velocity.systolic.max;Vel;Pt;Ductus arteriosus^Fetus;Qn;US.doppler;OB.US;2;Fetal Ductus arteriosus Peak systolic flow velocity US.doppler;Fet DA Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11704-4;Blood flow velocity.systolic.max;Vel;Pt;Ductus arteriosus;Qn;US.doppler;OB.US;2;Ductus arteriosus Peak systolic flow velocity US.doppler;DA Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11705-1;Blood flow velocity.systolic.max;Vel;Pt;Aortic valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Aortic valve Peak systolic flow velocity US.doppler;Fet AV Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11706-9;Blood flow.systolic.max;Vel;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Peak systolic flow by US.doppler;AV Vmax sys DOP;;ACTIVE;1.0j-a;2.48 +11707-7;Blood flow velocity.systolic.max;Vel;Pt;Mitral valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Mitral valve Peak systolic flow velocity US.doppler;Fet MV Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11708-5;Blood flow velocity.systolic.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Peak systolic flow velocity by US.doppler;MV Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11709-3;Blood flow velocity.systolic.max;Vel;Pt;Pulmonic valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Pulmonic valve Peak systolic flow velocity US.doppler;Fet PV Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11710-1;Blood flow velocity.systolic.max;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US.DICOM;2;Pulmonic valve Peak systolic flow velocity by US.doppler;PV Vmax sys;;ACTIVE;1.0j-a;2.68 +11711-9;Blood flow velocity.systolic.max;Vel;Pt;Tricuspid valve^Fetus;Qn;US.doppler;OB.US;2;Fetal Tricuspid valve Peak systolic flow velocity US.doppler;Fet TV Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11712-7;Blood flow velocity.systolic.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Peak systolic flow velocity by US.doppler;TV Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11713-5;Blood flow velocity.systolic.max;Vel;Pt;Heart.ventricle.left.outflow tract^Fetus;Qn;US.doppler;OB.US;2;Fetal Left ventricular outflow tract Peak systolic flow velocity US.doppler;Fet LVOT Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11714-3;Blood flow.systolic.max;Vel;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;OB.US;2;Deprecated Left ventricular outflow tract Peak systolic flow Doppler.measured;Deprecated LVOT Vmax sys Dop.meas;;DEPRECATED;1.0j-a;2.36 +11715-0;Blood flow velocity.systolic.max;Vel;Pt;Heart.ventricle.right.outflow tract^Fetus;Qn;US.doppler;OB.US;2;Fetal Right ventricular outflow tract Peak systolic flow velocity US.doppler;Fet RVOT Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11716-8;Blood flow.systolic.max;Vel;Pt;Heart.ventricle.right.outflow tract;Qn;US.doppler;OB.US;2;Deprecated Right ventricular outflow tract Peak systolic flow Doppler.measured;Deprecated RVOT Vmax sys Dop.meas;;DEPRECATED;1.0j-a;2.36 +11717-6;Blood flow velocity.systolic.max;Vel;Pt;Ovarian artery.left;Qn;US.doppler;OB.US;2;Ovarian artery - left Peak systolic flow velocity US.doppler;Ovarian a-L Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +1171-8;little f Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;little f Ag [Presence] on Red Blood Cells;little f Ag RBC Ql;;ACTIVE;1.0;2.56 +11718-4;Blood flow velocity.systolic.max;Vel;Pt;Ovarian artery.right;Qn;US.doppler;OB.US;2;Ovarian artery - right Peak systolic flow velocity US.doppler;Ovarian a-R Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11719-2;Blood flow velocity.systolic.max;Vel;Pt;Pulmonary artery.main^Fetus;Qn;US.doppler;OB.US;2;Fetal Main pulmonary artery Peak systolic flow velocity US.doppler;Fet MPA Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +117-2;cefOXitin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefOXitin [Susceptibility] by Disk diffusion (KB);cefOXitin Islt KB;;ACTIVE;1.0;2.73 +11720-0;Blood flow velocity.systolic.max;Vel;Pt;Pulmonary artery.main;Qn;US.doppler;OB.US;2;Main pulmonary artery Peak systolic flow velocity US.doppler;MPA Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11721-8;Blood flow velocity.systolic.max;Vel;Pt;Umbilical artery.at fetus^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at fetus Peak systolic flow velocity US.doppler;Fet Umb a at fetus Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11722-6;Blood flow velocity.systolic.max;Vel;Pt;Umbilical artery.at placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at placenta Peak systolic flow velocity US.doppler;Fet Umb a.at plc Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11723-4;Blood flow velocity.systolic.max;Vel;Pt;Umbilical artery.between fetus and placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery between fetus and placenta Peak systolic flow velocity US.doppler;Fet Umb a fetus-plc Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11724-2;Blood flow velocity.systolic.max;Vel;Pt;Uterine artery.left;Qn;US.doppler;OB.US;2;Uterine artery - left Peak systolic flow velocity US.doppler;Uterine a-L Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11725-9;Blood flow velocity.systolic.max;Vel;Pt;Uterine artery.right;Qn;US.doppler;OB.US;2;Uterine artery - right Peak systolic flow velocity US.doppler;Uterine a-R Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +1172-6;little i -1 Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated little i-1 subtype [Presence] in Serum or Plasma from Blood product unit;Deprecated little i1 Ab SerPl BPU Ql;;DEPRECATED;1.0;2.40 +11726-7;Blood flow velocity.systolic.max;Vel;Pt;{Circulatory system};Qn;US.doppler;OB.US;2;Circulatory system Peak systolic flow velocity US.doppler;Circ sys Vmax sys DOP;;ACTIVE;1.0j-a;2.67 +11727-5;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated;OB.US;2;Fetal Body weight estimated by US;Fet Weight US+est;;ACTIVE;1.0j-a;2.73 +11728-3;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC;OB.US;2;Fetal Body weight estimated from Abdominal circumference on US;EFW from AC;;ACTIVE;1.0j-a;2.52 +11729-1;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter on US;EFW from AC+BPD;;ACTIVE;1.0j-a;2.52 +11730-9;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD&FL;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter and Femur length on US;EFW from AC+BPD+FL;;ACTIVE;1.0j-a;2.52 +11731-7;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD&FL&HC;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter and Femur length and Head circumference on US;EFW from AC+BPD+FL+HC;;ACTIVE;1.0j-a;2.52 +11732-5;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD&FL&HC.Hadlock 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter and Femur length and Head circumference on US by Hadlock 1985 method;EFW from AC+BPD+FL+HC.Hadlock85;;ACTIVE;1.0j-a;2.52 +11733-3;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD&FL&HC.Roberts 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter and Femur length and Head circumference on US by Roberts 1985 method;EFW from AC+BPD+FL+HC.Roberts85;;ACTIVE;1.0j-a;2.52 +1173-4;little i -1 Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated little i-1 subtype [Presence] in serum or plasma from donor;Deprecated little i1 Ab SerPl Donr Ql;;DEPRECATED;1.0;2.40 +11734-1;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD&FL.Hadlock 1984;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter and Femur length on US by Hadlock 1984 method;EFW from AC+BPD+FL.Hadlock84;;ACTIVE;1.0j-a;2.52 +11735-8;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD&FL.Hadlock 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter and Femur length on US by Hadlock 1985 method;EFW from AC+BPD+FL.Hadlock85;;ACTIVE;1.0j-a;2.52 +11736-6;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD&FL.Woo 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter and Femur length on US by Woo 1985 method;EFW from AC+BPD+FL.Woo85;;ACTIVE;1.0j-a;2.52 +11737-4;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD.Eik-Nes 1982;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter on US by Eik-Nes 1982 method;EFW from AC+BPD.Eik-Nes82;;ACTIVE;1.0j-a;2.52 +11738-2;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD.Hadlock 1984;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter on US by Hadlock 1984 method;EFW from AC+BPD.Hadlock84;;ACTIVE;1.0j-a;2.52 +11739-0;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD.Shepard 1982;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter on US by Shepard 1982 method;EFW from AC+BPD.Shepard82;;ACTIVE;1.0j-a;2.52 +11740-8;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD.Thurnau 1983;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter on US by Thurnau 1983 method;EFW from AC+BPD.Thurnau83;;ACTIVE;1.0j-a;2.52 +11741-6;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD.Warsof 1977;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter on US by Warsof 1977 method;EFW from AC+BPD.Warsof77;;ACTIVE;1.0j-a;2.52 +1174-2;little i -1 Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated little i-1 subtype [Presence] in serum;Deprecated little i1 Ab Ser Ql;;DEPRECATED;1.0;2.40 +11742-4;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&BPD.Weinberger 1984;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Biparietal diameter on US by Weinberger 1984 method;EFW from AC+BPD.Weinberger84;;ACTIVE;1.0j-a;2.52 +11743-2;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length on US;EFW from AC+FL;;ACTIVE;1.0j-a;2.52 +11744-0;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL&HC;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length and Head circumference on US;EFW from AC+FL+HC;;ACTIVE;1.0j-a;2.52 +11745-7;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL&HC.Hadlock 1984;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length and Head circumference on US by Hadlock 1984 method;EFW from AC+FL+HC.Hadlock84;;ACTIVE;1.0j-a;2.52 +11746-5;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL&HC.Hadlock 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length and Head circumference on US by Hadlock 1985 method;EFW from AC+FL+HC.Hadlock85;;ACTIVE;1.0j-a;2.52 +11747-3;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL&HC.Ott 1986;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length and Head circumference on US by Ott 1986 method;EFW from AC+FL+HC.Ott86;;ACTIVE;1.0j-a;2.52 +11748-1;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL&HC.Vintzileos 1987;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length and Head circumference on US by Vintzileos 1987 method;EFW from AC+FL+HC.Vintzileos87;;ACTIVE;1.0j-a;2.52 +11749-9;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL&HC.Weiner 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length and Head circumference on US by Weiner 1985 method;EFW from AC+FL+HC.Weiner85;;ACTIVE;1.0j-a;2.52 +11750-7;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL.Hadlock 1984;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length on US by Hadlock 1984 method;EFW from AC+FL.Hadlock84;;ACTIVE;1.0j-a;2.52 +11751-5;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL.Hadlock 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length on US by Hadlock 1985 method;EFW from AC+FL.Hadlock85;;ACTIVE;1.0j-a;2.52 +11752-3;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&FL.Woo 1985;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Femur length on US by Woo 1985 method;EFW from AC+FL.Woo85;;ACTIVE;1.0j-a;2.52 +11753-1;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&HC;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Head circumference on US;EFW from AC+HC;;ACTIVE;1.0j-a;2.52 +11754-9;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&HC.Hadlock 1984;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Head circumference on US by Hadlock 1984 method;EFW from AC+HC.Hadlock84;;ACTIVE;1.0j-a;2.52 +11755-6;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC&HC.Jordaan 1983;OB.US;2;Fetal Body weight estimated from Abdominal circumference and Head circumference on US by Jordaan 1983 method;EFW from AC+HC.Jordaan83;;ACTIVE;1.0j-a;2.52 +11756-4;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC.Campbell 1975;OB.US;2;Fetal Body weight estimated from Abdominal circumference on US by Campbell 1975 method;EFW from AC.Campbell75;;ACTIVE;1.0j-a;2.52 +11757-2;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC.Vintzileos 1987;OB.US;2;Fetal Body weight estimated from Abdominal circumference on US by Vintzileos 1987 method;EFW from AC.Vintzileos87;;ACTIVE;1.0j-a;2.52 +11758-0;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AC.Warsof 1977;OB.US;2;Fetal Body weight estimated from Abdominal circumference on US by Warsof 1977 method;EFW from AC.Warsof77;;ACTIVE;1.0j-a;2.52 +1175-9;little i -1 Ag;ACnc;Pt;RBC^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated little i-1 subtype [Presence] on Red Blood Cells from Blood product unit;Deprecated little i1 Ag RBC BPU Ql;;DEPRECATED;1.0;2.36 +11759-8;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AD&BPD;OB.US;2;Fetal Body weight estimated from Abdominal diameter and Biparietal diameter on US;EFW from AD+BPD;;ACTIVE;1.0j-a;2.52 +11760-6;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AD&BPD&FL;OB.US;2;Fetal Body weight estimated from Abdominal diameter and Biparietal diameter and Femur length on US;EFW from AD+BPD+FL;;ACTIVE;1.0j-a;2.52 +11761-4;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AD&BPD&FL.Rose 1987;OB.US;2;Fetal Body weight estimated from Abdominal diameter and Biparietal diameter and Femur length on US by Rose 1987 method;EFW from AD+BPD+FL.Rose87;;ACTIVE;1.0j-a;2.52 +11762-2;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AD&BPD.Rose 1987;OB.US;2;Fetal Body weight estimated from Abdominal diameter and Biparietal diameter on US by Rose 1987 method;EFW from AD+BPD.Rose87;;ACTIVE;1.0j-a;2.52 +11763-0;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AD&BPD.Vintzileos 1987;OB.US;2;Fetal Body weight estimated from Abdominal diameter and Biparietal diameter on US by Vintzileos 1987 method;EFW from AD+BPD.Vintzileos87;;ACTIVE;1.0j-a;2.52 +11764-8;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AD&FL;OB.US;2;Fetal Body weight estimated from Abdominal diameter and Femur length on US;EFW from AD+FL;;ACTIVE;1.0j-a;2.52 +11765-5;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from AD&FL.Rose 1987;OB.US;2;Fetal Body weight estimated from Abdominal diameter and Femur length on US by Rose 1987 method;EFW from AD+FL.Rose87;;ACTIVE;1.0j-a;2.52 +11766-3;Body weight percentile;Prctl;Pt;^Fetus;Qn;Per estimated gestational age;OB.US;2;Fetal Body weight percentile Per estimated gestational age;Fet Bdy weight Prctl Per est GA;;ACTIVE;1.0j-a;2.69 +1176-7;little i -1 Ag;ACnc;Pt;RBC^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated little i-1 subtype [Presence] on Red Blood Cells from donor;Deprecated little i1 Ag RBC Donr Ql;;DEPRECATED;1.0;2.36 +11767-1;Body weight percentile;Prctl;Pt;^Patient;Qn;Comp of est fetal wgt W std pop dist at same estga;OB.US;2;Deprecated Body weight percentile Comparison of estimated fetal weight with standard population distribution at same estimated gestational age;Deprecated Bdy weight Prctl Comp of EFW est GA;;DEPRECATED;1.0j-a;2.69 +11768-9;Body weight percentile range;Prctl;Pt;^Fetus;Ord;Categorization by comparison with standards;OB.US;2;Fetal Body weight percentile range Categorization by comparison with standards;Fet Bdy weight Prctl range Comp W std;;ACTIVE;1.0j-a;2.34 +11769-7;Body weight percentile range;Prctl;Pt;^Patient;Ord;Categorization by comparison with standards;OB.US;2;Body weight percentile range Categorization by comparison with standards;Bdy weight Prctl range Comp W std;;ACTIVE;1.0j-a;2.34 +11770-5;Body weight.10th;Prctl;Pt;^Population distribution;Qn;Estimated.pop birth wgt gestational age corr.ref;OB.US;2;[Percentile] Body weight.10th Estimated.pop birth wgt gestational age corr.ref;[Prctl] Bdy weight.10th GA Corr;;ACTIVE;1.0j-a;2.48 +11771-3;Body weight.25th;Prctl;Pt;^Population distribution;Qn;Estimated.pop birth wgt gestational age corr.ref;OB.US;2;[Percentile] Body weight.25th Estimated.pop birth wgt gestational age corr.ref;[Prctl] Bdy weight.25th GA Corr;;ACTIVE;1.0j-a;2.48 +11772-1;Body weight.50th;Prctl;Pt;^Population distribution;Qn;Estimated.pop birth wgt gestational age corr.ref;OB.US;2;[Percentile] Body weight.50th Estimated.pop birth wgt gestational age corr.ref;[Prctl] Bdy weight.50th GA Corr;;ACTIVE;1.0j-a;2.48 +11773-9;Body weight.75th;Prctl;Pt;^Population distribution;Qn;Estimated.pop birth wgt gestational age corr.ref;OB.US;2;[Percentile] Body weight.75th Estimated.pop birth wgt gestational age corr.ref;[Prctl] Bdy weight.75th GA Corr;;ACTIVE;1.0j-a;2.48 +11774-7;Body weight.90th;Prctl;Pt;^Population distribution;Qn;Estimated.pop birth wgt gestational age corr.ref;OB.US;2;[Percentile] Body weight.90th Estimated.pop birth wgt gestational age corr.ref;[Prctl] Bdy weight.90th GA Corr;;ACTIVE;1.0j-a;2.48 +1177-5;little i -1 Ag;ACnc;Pt;RBC^Patient;Ord;Aggl RBC;BLDBK;1;Deprecated little i-1 subtype [Presence] on Red Blood Cells;Deprecated little i1 Ag RBC Patient Ql;;DEPRECATED;1.0;2.36 +11775-4;Citation;Bib;Pt;Fetal body weight estimation formula;Nar;;OB.US;2;Fetal body weight estimation formula Narrative [Bibliographic Citation] Citation;EFW formula Citation;;ACTIVE;1.0j-a;2.73 +11776-2;Citation;Bib;Pt;Gestational age estimation formula;Nar;;OB.US;2;Gestational age estimation formula Narrative [Bibliographic Citation] Citation;GA est formula Citation;;ACTIVE;1.0j-a;2.40 +11777-0;Cross section;Area;Pt;Abdomen^Fetus;Qn;US.derived;OB.US;2;Fetal Abdomen [Area] Cross section derived by US;Fet Abd Area Xsection der US;;ACTIVE;1.0j-a;2.48 +11778-8;Delivery date;Date;Pt;^Patient;Qn;Clinical.estimated;OB.US;2;Delivery date Estimated;Deliv date Clin est;;ACTIVE;1.0j-a;2.73 +11779-6;Delivery date;Date;Pt;^Patient;Qn;Estimated from last menstrual period;OB.US;2;Delivery date Estimated from last menstrual period;Deliv date Est from LMP;;ACTIVE;1.0j-a;2.73 +11780-4;Delivery date;Date;Pt;^Patient;Qn;Estimated from ovulation date;OB.US;2;Delivery date Estimated from ovulation date;Deliv date Est from ovulation date;;ACTIVE;1.0j-a;2.50 +11781-2;Delivery date;Date;Pt;^Patient;Qn;US.composite.estimated;OB.US;2;Delivery date US composite estimate;Deliv date US.composite.est;;ACTIVE;1.0j-a;2.73 +11782-0;Diameter;Len;Pt;Bowel^Fetus;Qn;US.measured;OB.US;2;Fetal Bowel Diameter US;Fet Bowel Diam US.meas;;ACTIVE;1.0j-a;2.48 +1178-3;little i -2 Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated little i-2 subtype [Presence] in Serum or Plasma from Blood product unit;Deprecated little i2 Ab SerPl BPU Ql;;DEPRECATED;1.0;2.40 +11783-8;Diameter;Len;Pt;Bowel;Qn;US.measured;OB.US;2;Bowel Diameter US;Bowel Diam US.meas;;ACTIVE;1.0j-a;2.48 +11784-6;Diameter;Len;Pt;Cervical canal.external os;Qn;Palpation;OB.US;2;Cervical canal external os Diameter palpation;Cvx canal ext Os Diam Palpation;;ACTIVE;1.0j-a;2.48 +11785-3;Diameter;Len;Pt;Cervical canal.external os;Qn;US.measured;OB.US;2;Cervical canal external os Diameter US;Cvx canal ext Os Diam US.meas;;ACTIVE;1.0j-a;2.48 +11786-1;Diameter;Len;Pt;Cervical canal.internal os;Qn;Palpation;OB.US;2;Cervical canal internal os Diameter palpation;Cvx canal Int Os Diam Palpation;;ACTIVE;1.0j-a;2.48 +11787-9;Diameter;Len;Pt;Cervical canal.internal os;Qn;US.measured;OB.US;2;Cervical canal internal os Diameter US;Cvx canal Int Os Diam US.meas;;ACTIVE;1.0j-a;2.48 +11788-7;Diameter;Len;Pt;Cervical canal;Qn;Probe insertion.Hagar;OB.US;2;Cervical canal Diameter Probe insertion.Hagar;Cvx canal Diam Hagar prb;;ACTIVE;1.0j-a;2.48 +11789-5;Diameter;Len;Pt;Cervical canal;Qn;Probe insertion.Pratt;OB.US;2;Cervical canal Diameter Probe insertion.Pratt;Cvx canal Diam Pratt prb;;ACTIVE;1.0j-a;2.48 +11790-3;Diameter;Len;Pt;Colon.lumen^Fetus;Qn;US.measured;OB.US;2;Fetal Colon lumen Diameter US;Fet Colon.lumen Diam US.meas;;ACTIVE;1.0j-a;2.48 +1179-1;little i -2 Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated little i-2 subtype [Presence] in serum or plasmafrom donor;Deprecated little i2 Ab SerPl Donr Ql;;DEPRECATED;1.0;2.40 +11791-1;Diameter;Len;Pt;Colon.lumen;Qn;US.measured;OB.US;2;Colon lumen Diameter US;Colon.lumen Diam US.meas;;ACTIVE;1.0j-a;2.48 +11792-9;Diameter;Len;Pt;Eye^Fetus;Qn;US.measured;OB.US;2;Fetal Eye Diameter US;Fet Eye Diam US.meas;;ACTIVE;1.0j-a;2.48 +11793-7;Diameter;Len;Pt;Follicle;Qn;US.measured;OB.US;2;Follicle Diameter US;Follicle Diam US.meas;;ACTIVE;1.0j-a;2.48 +11794-5;Diameter;Len;Pt;Aortic valve^Fetus;Qn;US.measured;OB.US;2;Fetal Aortic valve Diameter US;Fet AV Diam US.meas;;ACTIVE;1.0j-a;2.48 +11795-2;Diameter;Len;Pt;Aortic valve;Qn;US.measured;CARD.US;2;Aortic valve Diameter by US;AV Diam US.meas;;ACTIVE;1.0j-a;2.48 +11796-0;Diameter;Len;Pt;Mitral valve^Fetus;Qn;US.measured;OB.US;2;Fetal Mitral valve Diameter US;Fet MV Diam US.meas;;ACTIVE;1.0j-a;2.48 +11797-8;Diameter;Len;Pt;Mitral valve;Qn;US.measured;CARD.US;2;Deprecated Mitral valve Diameter by US;Deprecated MV Diam US.meas;;DEPRECATED;1.0j-a;2.38 +11798-6;Diameter;Len;Pt;Pulmonic valve^Fetus;Qn;US.measured;OB.US;2;Fetal Pulmonic valve Diameter US;Fet PV Diam US.meas;;ACTIVE;1.0j-a;2.67 +11799-4;Diameter;Len;Pt;Pulmonic valve;Qn;US.measured;CARD.US;2;Pulmonic valve Diameter by US;PV Diam US.meas;;ACTIVE;1.0j-a;2.67 +118-0;cefOXitin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;cefOXitin [Susceptibility] by Serum bactericidal titer;cefOXitin Titr SBT;;ACTIVE;1.0;2.32 +11800-0;Diameter;Len;Pt;Tricuspid valve^Fetus;Qn;US.measured;OB.US;2;Fetal Tricuspid valve Diameter US;Fet TV Diam US.meas;;ACTIVE;1.0j-a;2.48 +11801-8;Diameter;Len;Pt;Tricuspid valve;Qn;US.measured;CARD.US;2;Tricuspid valve Diameter by US;TV Diam US.meas;;ACTIVE;1.0j-a;2.48 +11802-6;Diameter;Len;Pt;Heart.ventricle.left.outflow tract^Fetus;Qn;US.doppler;OB.US;2;Fetal Left ventricular outflow tract Diameter US.doppler;Fet LVOT Diam DOP;;ACTIVE;1.0j-a;2.48 +11803-4;Diameter;Len;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;OB.US;2;Left ventricular outflow tract Diameter US.doppler;LVOT Diam DOP;;ACTIVE;1.0j-a;2.48 +11804-2;Diameter;Len;Pt;Heart.ventricle.right.outflow tract^Fetus;Qn;US.measured;OB.US;2;Fetal Right ventricular outflow tract Diameter US;Fet RVOT Diam US.meas;;ACTIVE;1.0j-a;2.48 +11805-9;Diameter;Len;Pt;Heart.ventricle.right.outflow tract;Qn;US.measured;OB.US;2;Right ventricular outflow tract Diameter US;RVOT Diam US.meas;;ACTIVE;1.0j-a;2.48 +11806-7;Diameter;Len;Pt;Pulmonary artery^Fetus;Qn;US.measured;OB.US;2;Fetal Pulmonary artery Diameter US;Fet PA Diam US.meas;;ACTIVE;1.0j-a;2.48 +11807-5;Diameter;Len;Pt;Pulmonary artery;Qn;US.measured;OB.US;2;Pulmonary artery Diameter US;PA Diam US.meas;;ACTIVE;1.0j-a;2.48 +11808-3;Diameter;Len;Pt;Renal pelvis.left^Fetus;Qn;US.measured;OB.US;2;Fetal Renal pelvis - left Diameter US;Fet Renal pelvis-L Diam US.meas;;ACTIVE;1.0j-a;2.48 +1180-9;little i -2 Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated little i-2 subtype [Presence] in serum;Deprecated little i2 Ab Ser Ql;;DEPRECATED;1.0;2.40 +11809-1;Diameter;Len;Pt;Renal pelvis.left;Qn;US.measured;OB.US;2;Renal pelvis - left Diameter US;Renal pelvis-L Diam US.meas;;ACTIVE;1.0j-a;2.48 +11810-9;Diameter;Len;Pt;Renal pelvis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Renal pelvis - right Diameter US;Fet Renal pelvis-R Diam US.meas;;ACTIVE;1.0j-a;2.48 +11811-7;Diameter;Len;Pt;Renal pelvis.right;Qn;US.measured;OB.US;2;Renal pelvis - right Diameter US;Renal pelvis-R Diam US.meas;;ACTIVE;1.0j-a;2.48 +11812-5;Diameter;Len;Pt;Small bowel^Fetus;Qn;US.measured;OB.US;2;Fetal Small bowel Diameter US;Fet SB Diam US.meas;;ACTIVE;1.0j-a;2.48 +11813-3;Diameter;Len;Pt;Small bowel;Qn;US.measured;OB.US;2;Small bowel Diameter US;SB Diam US.meas;;ACTIVE;1.0j-a;2.48 +11814-1;Diameter;Len;Pt;Umbilical vein^Fetus;Qn;US.measured;OB.US;2;Fetal Umbilical vein Diameter US;Fet Umb v Diam US.meas;;ACTIVE;1.0j-a;2.48 +11815-8;Diameter;Len;Pt;Urinary bladder^Fetus;Qn;US.measured;OB.US;2;Fetal Urinary bladder Diameter US;Fet Bladder Diam US.meas;;ACTIVE;1.0j-a;2.48 +11816-6;Diameter;Len;Pt;Yolk sac^Fetus;Qn;US.measured;OB.US;2;Fetal Yolk sac Diameter US;Fet Yolk sac Diam US.meas;;ACTIVE;1.0j-a;2.48 +1181-7;little i -2 Ag;ACnc;Pt;RBC^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated little i-2 subtype [Presence] on Red Blood Cells from Blood product unit;Deprecated little i2 Ag RBC BPU Ql;;DEPRECATED;1.0;2.36 +11817-4;Diameter product.largest pocket;Area;Pt;Am fld space^Fetus;Qn;US.measured;OB.US;2;Fetal Amniotic fluid space Diameter largest pocket US;Fet AF space Area Diam lgst pk US.meas;;ACTIVE;1.0j-a;2.48 +11818-2;Diameter.anterior-posterior;Len;Pt;Abdomen^Fetus;Qn;US.measured;OB.US;2;Fetal Abdomen Diameter.anterior-posterior US;Fet Abd Diam AP US.meas;;ACTIVE;1.0j-a;2.27 +11819-0;Diameter.anterior-posterior;Len;Pt;Thorax^Fetus;Qn;US.measured;OB.US;2;Fetal Thorax Diameter.anterior-posterior US;Fet Thorax Diam AP US.meas;;ACTIVE;1.0j-a;2.48 +11820-8;Diameter.biparietal;Len;Pt;Head^Fetus;Qn;US.measured;OB.US;2;Fetal Head Diameter.biparietal US;Fet BPD US.meas;;ACTIVE;1.0j-a;2.73 +11821-6;Diameter.biparietal.mean;Len;Pt;Head^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Head Mean biparietal diameter Estimated from gestational age;Fet BPD.mean Est from GA;;ACTIVE;1.0j-a;2.48 +11822-4;Diameter.biparietal.mean;Len;Pt;Head^Fetus;Qn;US.estimated from cerebellar diameter;OB.US;2;Fetal Head Mean biparietal diameter estimated from Cerebellar diameter (US);Fet BPD.mean from cereb diam;;ACTIVE;1.0j-a;2.73 +11823-2;Diameter.biparietal/Diameter.occipital;LenRto;Pt;Head^Fetus;Qn;US.derived;OB.US;2;Fetal Head Diameter.biparietal/Diameter.occipital derived by US;Fet BPD/OFD der US;;ACTIVE;1.0j-a;2.73 +11824-0;Diameter.BPD.area-corrected;Len;Pt;Head^Fetus;Qn;US.derived;OB.US;2;Fetal Head Diameter.BPD.area-corrected derived by US;Fet Head BPD.area-corrected der US;;ACTIVE;1.0j-a;2.58 +1182-5;little i -2 Ag;ACnc;Pt;RBC^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated little i-2 subtype [Presence] on Red Blood Cells from donor;Deprecated little i2 Ag RBC Donr Ql;;DEPRECATED;1.0;2.36 +11825-7;Diameter.hilum-cortex;Len;Pt;Kidney.left^Fetus;Qn;US.measured;OB.US;2;Fetal Kidney - left Hilum-cortex diameter US;Fet Kidney-L Diam.hilum-cort US.meas;;ACTIVE;1.0j-a;2.48 +11826-5;Diameter.hilum-cortex;Len;Pt;Kidney.left;Qn;US.measured;OB.US;2;Kidney - left Hilum-cortex diameter US;Kidney-L Diam.hilum-cort US.meas;;ACTIVE;1.0j-a;2.48 +11827-3;Diameter.hilum-cortex;Len;Pt;Kidney.right^Fetus;Qn;US.measured;OB.US;2;Fetal Kidney - right Hilum-cortex diameter US;Fet Kidney-R Diam.hilum-cort US.meas;;ACTIVE;1.0j-a;2.48 +11828-1;Diameter.hilum-cortex;Len;Pt;Kidney.right;Qn;US.measured;OB.US;2;Kidney - right Hilum-cortex diameter US;Kidney-R Diam.hilum-cort US.meas;;ACTIVE;1.0j-a;2.48 +11829-9;Diameter.hilum-cortex;Len;Pt;Ovary.left;Qn;US.measured;OB.US;2;Ovary - left Hilum-cortex diameter US;Ovary-L Diam.hilum-cort US.meas;;ACTIVE;1.0j-a;2.48 +11830-7;Diameter.hilum-cortex;Len;Pt;Ovary.right;Qn;US.measured;OB.US;2;Ovary - right Hilum-cortex diameter US;Ovary-R Diam.hilum-cort US.meas;;ACTIVE;1.0j-a;2.48 +11831-5;Diameter.hilum-cortex.mean;Len;Pt;Kidney^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Kidney Mean width Estimated from gestational age;Fet Kidney Diam.hilum-cort Est from GA;;ACTIVE;1.0j-a;2.48 +11832-3;Diameter.largest pocket.max;Len;Pt;Am fld space^Fetus;Qn;US.measured;OB.US;2;Fetal Amniotic fluid space Maximum diameter largest pocket US;Fet AF space Diam.lgst pct max US.meas;;ACTIVE;1.0j-a;2.48 +1183-3;little i -2 Ag;ACnc;Pt;RBC^Patient;Ord;Aggl RBC;BLDBK;1;Deprecated little i-2 subtype [Presence] on Red Blood Cells;Deprecated little i2 Ag RBC Patient Ql;;DEPRECATED;1.0;2.36 +11833-1;Diameter.largest pocket.mean;Len;Pt;Am fld space^Fetus;Qn;US.measured;OB.US;2;Fetal Amniotic fluid space Mean diameter largest pocket US;Fet AF space Diam.lgst pct mean US.meas;;ACTIVE;1.0j-a;2.48 +11834-9;Diameter.long;Len;Pt;Kidney.left^Fetus;Qn;US.measured;OB.US;2;Fetal Kidney - left Longitudinal diameter US;Fet Kidney-L Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11835-6;Diameter.long;Len;Pt;Kidney.left;Qn;US.measured;OB.US;2;Kidney - left Longitudinal diameter US;Kidney-L Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11836-4;Diameter.long;Len;Pt;Kidney.right^Fetus;Qn;US.measured;OB.US;2;Fetal Kidney - right Longitudinal diameter US;Fet Kidney-R Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11837-2;Diameter.long;Len;Pt;Kidney.right;Qn;US.measured;OB.US;2;Kidney - right Longitudinal diameter US;Kidney-R Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11838-0;Diameter.long;Len;Pt;Liver^Fetus;Qn;US.measured;OB.US;2;Fetal Liver Longitudinal diameter US;Fet Liver Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11839-8;Diameter.long;Len;Pt;Liver;Qn;US.measured;OB.US;2;Liver Longitudinal diameter US;Liver Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11840-6;Diameter.long;Len;Pt;Ovary.left;Qn;US.measured;OB.US;2;Ovary - left Longitudinal diameter US;Ovary-L Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +1184-1;little i Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;little i Ab [Presence] in Serum or Plasma from Blood product unit;little i Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11841-4;Diameter.long;Len;Pt;Ovary.right;Qn;US.measured;OB.US;2;Ovary - right Longitudinal diameter US;Ovary-R Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11842-2;Diameter.long;Len;Pt;Uterus;Qn;US.measured;OB.US;2;Uterus Longitudinal diameter US;Uterus Long diameter US.meas;;ACTIVE;1.0j-a;2.54 +11843-0;Diameter.long.mean;Len;Pt;Kidney^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Kidney Mean longitudinal diameter Estimated from gestational age;Fet Kidney Diam.long.mean Est from GA;;ACTIVE;1.0j-a;2.48 +11844-8;Diameter.long.mean;Len;Pt;Liver^Fetus;Qn;Estimated from abdominal circumference;OB.US;2;Fetal Liver Mean longitudinal diameter Estimated from abdominal circumference;Fet Liver Diam.long.mean Est from AC;;ACTIVE;1.0j-a;2.48 +11845-5;Diameter.long.mean;Len;Pt;Liver^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Liver Mean longitudinal diameter Estimated from gestational age;Fet Liver Diam.long.mean Est from GA;;ACTIVE;1.0j-a;2.48 +11846-3;Diameter.max;Len;Pt;Ovary.largest follicle;Qn;US.measured;OB.US;2;Ovary largest follicle Maximum diameter US;Ovary.largest follicle Diam.max US.meas;;ACTIVE;1.0j-a;2.48 +11847-1;Diameter.max;Len;Pt;Ovary.left.largest follicle;Qn;US;OB.US;2;Ovary - left largest follicle Maximum diameter US;Ovary-L.largest follicle Diam.max US;;ACTIVE;1.0j-a;2.48 +11848-9;Diameter.max;Len;Pt;Ovary.right.largest follicle;Qn;US;OB.US;2;Ovary - right largest follicle Maximum diameter US;Ovary-R.largest follicle Diam.max US;;ACTIVE;1.0j-a;2.48 +11849-7;Diameter.mean;Len;Pt;Abdomen^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Abdomen Mean diameter Estimated from gestational age;Fet Abd Diam.mean Est from GA;;ACTIVE;1.0j-a;2.48 +11850-5;Diameter.mean;Len;Pt;Gestational sac;Qn;US.measured;OB.US;2;Gestational sac Mean diameter US;GS Diam.mean US.meas;;ACTIVE;1.0j-a;2.73 +11851-3;Diameter.occipito-frontal;Len;Pt;Head^Fetus;Qn;US.measured;OB.US;2;Fetal Head Diameter.occipito-frontal US;Fet Head OFD US.meas;;ACTIVE;1.0j-a;2.58 +11852-1;Diameter.outer to outer;Len;Pt;Head^Fetus;Qn;US.measured;OB.US;2;Fetal Head Diameter.outer to outer US;Fet Head Diam.O-O US.meas;;ACTIVE;1.0j-a;2.27 +11853-9;Diameter.perpendicular;Len;Pt;Kidney.left^Fetus;Qn;US.measured;OB.US;2;Fetal Kidney - left Thickeness US;Fet Kidney-L Thickeness US.meas;;ACTIVE;1.0j-a;2.48 +11854-7;Diameter.perpendicular;Len;Pt;Kidney.left;Qn;US.measured;OB.US;2;Kidney - left Thickeness US;Kidney-L Thickeness US.meas;;ACTIVE;1.0j-a;2.48 +11855-4;Diameter.perpendicular;Len;Pt;Kidney.right^Fetus;Qn;US.measured;OB.US;2;Fetal Kidney - right Thickeness US;Fet Kidney-R Thickeness US.meas;;ACTIVE;1.0j-a;2.48 +11856-2;Diameter.perpendicular;Len;Pt;Kidney.right;Qn;US.measured;OB.US;2;Kidney - right Thickeness US;Kidney-R Thickeness US.meas;;ACTIVE;1.0j-a;2.48 +11857-0;Diameter.perpendicular;Len;Pt;Ovary.left;Qn;US.measured;OB.US;2;Ovary - left Thickeness US;Ovary-L Thickeness US.meas;;ACTIVE;1.0j-a;2.48 +1185-8;little i Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;little i Ab [Presence] in Serum or Plasma from Donor;little i Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11858-8;Diameter.perpendicular;Len;Pt;Ovary.right;Qn;US.measured;OB.US;2;Ovary - right Thickeness US;Ovary-R Thickeness US.meas;;ACTIVE;1.0j-a;2.48 +11859-6;Diameter.perpendicular;Len;Pt;Uterus;Qn;US.measured;OB.US;2;Uterus Thickeness US;Uterus Thickeness US.meas;;ACTIVE;1.0j-a;2.48 +11860-4;Diameter.sagittal;Len;Pt;Cisterna magna^Fetus;Qn;US.measured;OB.US;2;Fetal Cisterna magna Diameter.sagittal US;Fet Cisterna magna Diam US.meas;;ACTIVE;1.0j-a;2.48 +11861-2;Diameter.sagittal.mean;Len;Pt;Cisterna magna^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Cisterna magna Mean sagittal diameter Estimated from gestational age;Fet Cisterna magna Diam Est from GA;;ACTIVE;1.0j-a;2.48 +11862-0;Diameter.transverse;Len;Pt;Abdomen^Fetus;Qn;US.measured;OB.US;2;Fetal Abdomen Diameter transverse US;Fetal TAD US.meas;;ACTIVE;1.0j-a;2.27 +11863-8;Diameter.transverse;Len;Pt;Cerebellum^Fetus;Qn;US.measured;OB.US;2;Fetal Cerebellum Diameter transverse US;Fetal TCD US.meas;;ACTIVE;1.0j-a;2.58 +11864-6;Diameter.transverse;Len;Pt;Thorax^Fetus;Qn;US.measured;OB.US;2;Fetal Thorax Diameter transverse US;Fet Thorax Diam transverse US.meas;;ACTIVE;1.0j-a;2.48 +11865-3;Diameter.transverse;Len;Pt;Uterus;Qn;US.measured;OB.US;2;Uterus Diameter transverse US;Uterus Diam transverse US.meas;;ACTIVE;1.0j-a;2.48 +1186-6;little i Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;little i Ab [Presence] in Serum or Plasma;little i Ab SerPl Ql;;ACTIVE;1.0;2.56 +11866-1;Diameter.transverse.mean;Len;Pt;Cerebellum^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Cerebellum Mean transverse diameter Estimated from gestational age;Fetal TCD Est from GA;;ACTIVE;1.0j-a;2.48 +11867-9;Effacement;Prctl;Pt;Cervix;Ord;Palpation;OBGYN;2;Effacement Cervix;Effacement Cervix;;ACTIVE;1.0j-a;2.73 +11868-7;Equation;Equ;Pt;Fetal body weight estimation formula;Nar;;OB.US;2;Fetal body weight estimation formula Narrative [Equation] Equation;EFW formula Eq'n;;ACTIVE;1.0j-a;2.40 +11869-5;Equation;Equ;Pt;Gestational age estimation formula;Nar;;OB.US;2;Gestational age estimation formula Narrative [Equation] Equation;GA est formula Eq'n;;ACTIVE;1.0j-a;2.40 +11870-3;Examination level.ultrasound;Type;Pt;^Patient;Nom;;OB.US;2;Examination level ultrasound;Exam level.US;;ACTIVE;1.0j-a;2.29 +11871-1;Femur length/Abdominal circumference;LenRto;Pt;^Fetus;Qn;US.derived;OB.US;2;Fetal Femur length/Abdominal circumference derived by US;Fet FL/AC der US;;ACTIVE;1.0j-a;2.48 +11872-9;Femur length/Biparietal diameter;LenRto;Pt;^Fetus;Qn;US.derived;OB.US;2;Fetal Femur length/Biparietal diameter derived by US;Fet FL/BDP der US;;ACTIVE;1.0j-a;2.48 +11873-7;Femur length/Head circumference;LenRto;Pt;^Fetus;Qn;US.derived;OB.US;2;Fetal Femur length/Head circumference derived by US;Fet FL/HC der US;;ACTIVE;1.0j-a;2.48 +1187-4;little i NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated little i NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated little i NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +11874-5;Fetal position;Type;Pt;Pelvis;Nom;Palpation;OB.US;2;Fetal position palpation;Fet positn Palpation;;ACTIVE;1.0j-a;2.38 +11875-2;Fetal position;Type;Pt;Pelvis;Nom;US;OB.US;2;Fetal position US;Fet positn US;;ACTIVE;1.0j-a;2.27 +11876-0;Fetal presentation;Type;Pt;Pelvis;Nom;Palpation;OB.US;2;Fetal presentation palpation;Fet pres Palpation;;ACTIVE;1.0j-a;2.38 +11877-8;Fetal presentation;Type;Pt;Pelvis;Nom;US;OB.US;2;Fetal presentation US;Fet pres US;;ACTIVE;1.0j-a;2.27 +11878-6;Fetuses;Num;Pt;^Patient;Qn;US;OB.US;2;Number of fetuses by US;# Fetuses US;;ACTIVE;1.0j-a;2.73 +11879-4;Follicles;Num;Pt;Ovary.left;Qn;US;OB.US;2;Ovary - left [#] Follicles US;Ovary-L Follicles US;;ACTIVE;1.0j-a;2.48 +11880-2;Follicles;Num;Pt;Ovary.right;Qn;US;OB.US;2;Ovary - right [#] Follicles US;Ovary-R Follicles US;;ACTIVE;1.0j-a;2.48 +11881-0;Fundal height;Len;Pt;Uterus;Qn;Tape measure;OB.US;2;Uterus Fundal height Tape measure;Uterus Fundal height Tape measure;;ACTIVE;1.0j-a;2.73 +1188-2;little i NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated little i NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated little i NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +11882-8;Fetal sex;Type;Pt;^Fetus;Nom;US;OB.US;2;Fetal Sex US;Fet Sex US;;ACTIVE;1.0j-a;2.73 +11883-6;Fetal sex;Type;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative Sex US;Fet Sex US;;ACTIVE;1.0j-a;2.66 +11884-4;Gestational age;Time;Pt;^Fetus;Qn;Clinical.estimated;OB.US;2;Gestational age Estimated;GA Clin est;;ACTIVE;1.0j-a;2.73 +11885-1;Gestational age;Time;Pt;^Fetus;Qn;Estimated from last menstrual period;OB.US;2;Gestational age Estimated from last menstrual period;GA Est from LMP;;ACTIVE;1.0j-a;2.73 +11886-9;Gestational age;Time;Pt;^Fetus;Qn;Estimated from ovulation date;OB.US;2;Gestational age Estimated from ovulation date;GA Est from ovulation date;;ACTIVE;1.0j-a;2.40 +11887-7;Gestational age;Time;Pt;^Fetus;Qn;Estimated from selected delivery date;OB.US;2;Gestational age Estimated from selected delivery date;GA Est from selected delivery date;;ACTIVE;1.0j-a;2.40 +11888-5;Gestational age;Time;Pt;^Fetus;Qn;US.composite.estimated;OB.US;2;Gestational age US composite estimate;GA US.composite.est;;ACTIVE;1.0j-a;2.73 +11889-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC;OB.US;2;Gestational age estimated from Abdominal circumference on US;GA from AC;;ACTIVE;1.0j-a;2.52 +1189-0;little i NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated little i NOS Ag [Presence] on Red Blood Cells;Deprecated little i NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +11890-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Campbell 1975;OB.US;2;Gestational age estimated from Abdominal circumference on US by Campbell 1975 method;GA from AC.Campbell75;;ACTIVE;1.0j-a;2.52 +11891-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Hadlock 1982;OB.US;2;Gestational age estimated from Abdominal circumference on US by Hadlock 1982 method;GA from AC.Hadlock82;;ACTIVE;1.0j-a;2.52 +11892-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Hadlock 1984;OB.US;2;Gestational age estimated from Abdominal circumference on US by Hadlock 1984 method;GA from AC.Hadlock84;;ACTIVE;1.0j-a;2.52 +11893-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Jeanty 1984;OB.US;2;Gestational age estimated from Abdominal circumference on US by Jeanty 1984 method;GA from AC.Jeanty84;;ACTIVE;1.0j-a;2.52 +11894-3;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from area corrected BPC;OB.US;2;Gestational age estimated from area corrected Biparietal circumference (US);GA from area cor BPC;;ACTIVE;1.0j-a;2.40 +11895-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BD;OB.US;2;Gestational age estimated from Binocular distance on US;GA from BD;;ACTIVE;1.0j-a;2.52 +11896-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BD.Jeanty 1984;OB.US;2;Gestational age estimated from Binocular distance on US by Jeanty 1984 method;GA from BD.Jeanty84;;ACTIVE;1.0j-a;2.52 +11897-6;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from BPC;OB.US;2;Gestational age estimated from Biparietal circumference (US);GA from BPC;;ACTIVE;1.0j-a;2.40 +11898-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD;OB.US;2;Gestational age estimated from Biparietal diameter on US;GA from BPD;;ACTIVE;1.0j-a;2.52 +11899-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Campbell 1975;OB.US;2;Gestational age estimated from Biparietal diameter on US by Campbell 1975 method;GA from BPD.Campbell75;;ACTIVE;1.0j-a;2.52 +11900-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Doubilet 1993;OB.US;2;Gestational age estimated from Biparietal diameter on US by Doubilet 1993 method;GA from BPD.Doubilet93;;ACTIVE;1.0j-a;2.52 +11901-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Hadlock 1982;OB.US;2;Gestational age estimated from Biparietal diameter on US by Hadlock 1982 method;GA from BPD.Hadlock82;;ACTIVE;1.0j-a;2.52 +11902-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Hadlock 1984;OB.US;2;Gestational age estimated from Biparietal diameter on US by Hadlock 1984 method;GA from BPD.Hadlock84;;ACTIVE;1.0j-a;2.52 +11903-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Hansmann 1985;OB.US;2;Gestational age estimated from Biparietal diameter on US by Hansmann 1985 method;GA from BPD.Hansmann85;;ACTIVE;1.0j-a;2.52 +11904-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Hobbins 1983;OB.US;2;Gestational age estimated from Biparietal diameter on US by Hobbins 1983 method;GA from BPD.Hobbins83;;ACTIVE;1.0j-a;2.52 +11905-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Jeanty 1984;OB.US;2;Gestational age estimated from Biparietal diameter on US by Jeanty 1984 method;GA from BPD.Jeanty84;;ACTIVE;1.0j-a;2.52 +11906-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Kurtz 1980;OB.US;2;Gestational age estimated from Biparietal diameter on US by Kurtz 1980 method;GA from BPD.Kurtz80;;ACTIVE;1.0j-a;2.52 +11907-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Sabbagha 1978;OB.US;2;Gestational age estimated from Biparietal diameter on US by Sabbagha 1978 method;GA from BPD.Sabbagha78;;ACTIVE;1.0j-a;2.52 +1190-8;little k Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;little k Ab [Presence] in Serum or Plasma from Blood product unit;little k Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +11908-1;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from cerebellum.Goldstein 1987;OB.US;2;Gestational age estimated from Cerebellar diameter by method of Goldstein 1987 (US);GA from cerebellum.Goldstein87;;ACTIVE;1.0j-a;2.40 +11909-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL;OB.US;2;Gestational age estimated from Crown rump length on US;GA from CRL;;ACTIVE;1.0j-a;2.73 +11910-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Hadlock 1992;OB.US;2;Gestational age estimated from Crown rump length on US by Hadlock 1992 method;GA from CRL.Hadlock92;;ACTIVE;1.0j-a;2.52 +11911-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Hansmann 1985;OB.US;2;Gestational age estimated from Crown rump length on US by Hansmann 1985 method;GA from CRL.Hansmann85;;ACTIVE;1.0j-a;2.52 +11912-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Jeanty 1984;OB.US;2;Gestational age estimated from Crown rump length on US by Jeanty 1984 method;GA from CRL.Jeanty84;;ACTIVE;1.0j-a;2.52 +11913-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Nelson 1981;OB.US;2;Gestational age estimated from Crown rump length on US by Nelson 1981 method;GA from CRL.Nelson81;;ACTIVE;1.0j-a;2.52 +11914-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Robinson 1975;OB.US;2;Gestational age estimated from Crown rump length on US by Robinson 1975 method;GA from CRL.Robinson75;;ACTIVE;1.0j-a;2.52 +11915-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Yeh 1988;OB.US;2;Gestational age estimated from Crown rump length on US by Yeh 1988 method;GA from CRL.Yeh88;;ACTIVE;1.0j-a;2.52 +1191-6;little k Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;little k Ab [Presence] in Serum or Plasma from Donor;little k Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +11916-4;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from fibula length;OB.US;2;Gestational age estimated from Fibula length (US);GA from Fib Length;;ACTIVE;1.0j-a;2.40 +11917-2;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from fibula length.Jeanty 1984;OB.US;2;Gestational age estimated from Fibula length by method of Jeanty 1984 (US);GA from Fib Length.Jeanty84;;ACTIVE;1.0j-a;2.40 +11918-0;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from fibula length.Merz 1987;OB.US;2;Gestational age estimated from Fibula length by method of Merz 1987 (US);GA from Fib Length.Merz.87;;ACTIVE;1.0j-a;2.40 +11919-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL;OB.US;2;Gestational age estimated from Femur length on US;GA from FL;;ACTIVE;1.0j-a;2.52 +11920-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Hadlock 1984;OB.US;2;Gestational age estimated from Femur length on US by Hadlock 1984 method;GA from FL.Hadlock84;;ACTIVE;1.0j-a;2.52 +11921-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Hansmann 1985;OB.US;2;Gestational age estimated from Femur length on US by Hansmann 1985 method;GA from FL.Hansmann85;;ACTIVE;1.0j-a;2.52 +11922-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Hohler 1982;OB.US;2;Gestational age estimated from Femur length on US by Hohler 1982 method;GA from FL.Hohler82;;ACTIVE;1.0j-a;2.52 +11923-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Jeanty 1984;OB.US;2;Gestational age estimated from Femur length on US by Jeanty 1984 method;GA from FL.Jeanty84;;ACTIVE;1.0j-a;2.52 +1192-4;little k Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;little k Ab [Presence] in Serum or Plasma;little k Ab SerPl Ql;;ACTIVE;1.0;2.56 +11924-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Merz 1987;OB.US;2;Gestational age estimated from Femur length on US by Merz 1987 method;GA from FL.Merz87;;ACTIVE;1.0j-a;2.52 +11925-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Obrien 1982;OB.US;2;Gestational age estimated from Femur length on US by Obrien 1982 method;GA from FL.Obrien82;;ACTIVE;1.0j-a;2.52 +11926-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Mercer 1987;OB.US;2;Gestational age estimated from Foot length on US by Mercer 1987 method;GA from FL.Mercer87;;ACTIVE;1.0j-a;2.52 +11927-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSD;OB.US;2;Gestational age estimated from Gestational sac diameter on US;GA from GSD;;ACTIVE;1.0j-a;2.52 +11928-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSD.Hellman 1969;OB.US;2;Gestational age estimated from Gestational sac diameter on US by Hellman 1969 method;GA from GSD.Hellman69;;ACTIVE;1.0j-a;2.52 +11929-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSD.Rempen 1991;OB.US;2;Gestational age estimated from Gestational sac diameter on US by Rempen 1991 method;GA from GSD.Rempen91;;ACTIVE;1.0j-a;2.52 +11930-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC;OB.US;2;Gestational age estimated from Head circumference on US;GA from HC;;ACTIVE;1.0j-a;2.52 +11931-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Hadlock 1982;OB.US;2;Gestational age estimated from Head circumference on US by Hadlock 1982 method;GA from HC.Hadlock82;;ACTIVE;1.0j-a;2.52 +1193-2;little k Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little k Ag [Presence] on Red Blood Cells from Blood product unit;little k Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +11932-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Hadlock 1984;OB.US;2;Gestational age estimated from Head circumference on US by Hadlock 1984 method;GA from HC.Hadlock84;;ACTIVE;1.0j-a;2.52 +11933-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Hoffbauer 1979;OB.US;2;Gestational age estimated from Head circumference on US by Hoffbauer 1979 method;GA from HC.Hoffbauer79;;ACTIVE;1.0j-a;2.52 +11934-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Jeanty 1984;OB.US;2;Gestational age estimated from Head circumference on US by Jeanty 1984 method;GA from HC.Jeanty84;;ACTIVE;1.0j-a;2.52 +11935-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HL;OB.US;2;Gestational age estimated from Humerus length on US;GA from HL;;ACTIVE;1.0j-a;2.52 +11936-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HL.Jeanty 1984;OB.US;2;Gestational age estimated from Humerus length on US by Jeanty 1984 method;GA from HL.Jeanty84;;ACTIVE;1.0j-a;2.52 +11937-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HL.Merz 1987;OB.US;2;Gestational age estimated from Humerus length on US by Merz 1987 method;GA from HL.Merz.87;;ACTIVE;1.0j-a;2.52 +11938-8;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from radius length;OB.US;2;Gestational age estimated from Radius length (US);GA from rad len;;ACTIVE;1.0j-a;2.40 +11939-6;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from radius length.Merz 1987;OB.US;2;Gestational age estimated from Radius length by method of Merz 1987 (US);GA from rad len.Merz.87;;ACTIVE;1.0j-a;2.40 +1194-0;little k Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little k Ag [Presence] on Red Blood Cells from Donor;little k Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +11940-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from tibia length;OB.US;2;Gestational age estimated from Tibia length on US;GA from tib len;;ACTIVE;1.0j-a;2.52 +11941-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from tibia length.Jeanty 1984;OB.US;2;Gestational age estimated from Tibia length on US by Jeanty 1984 method;GA from tib len.Jeanty84;;ACTIVE;1.0j-a;2.52 +11942-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from tibia length.Merz 1987;OB.US;2;Gestational age estimated from Tibia length on US by Merz 1987 method;GA from tib len.Merz87;;ACTIVE;1.0j-a;2.52 +11943-8;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from ulna length;OB.US;2;Gestational age estimated from Ulna length (US);GA from UL;;ACTIVE;1.0j-a;2.40 +11944-6;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from ulna length.Jeanty 1984;OB.US;2;Gestational age estimated from Ulna length by method of Jeanty 1984 (US);GA from UL.Jeanty84;;ACTIVE;1.0j-a;2.40 +11945-3;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from ulna length.Merz 1987;OB.US;2;Gestational age estimated from Ulna length by method of Merz 1987 (US);GA from UL.Merz.87;;ACTIVE;1.0j-a;2.40 +11946-1;Grade;Type;Pt;Placenta^Fetus;Ord;US;OB.US;2;Fetal Placenta Grade US;Fet Placenta Grade US;;ACTIVE;1.0j-a;2.27 +11947-9;Head circumference/Abdominal circumference;LenRto;Pt;^Fetus;Qn;US.derived;OB.US;2;Head circumference/Abdominal circumference derived by US;HC/AC der US;;ACTIVE;1.0j-a;2.73 +11948-7;Heart rate;NRat;Pt;^Fetus;Qn;US.measured;OB.US;2;Fetal Heart rate US;Fet Heart rate US.meas;;ACTIVE;1.0j-a;2.42 +11949-5;Identification criteria;Find;Pt;^Fetus;Nom;US;OB.US;2;Fetal Identification criteria US;Fet ID criteria US;;ACTIVE;1.0j-a;2.27 +11950-3;Identification criteria;Find;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative Identification criteria US;Fet ID criteria US;;ACTIVE;1.0j-a;2.40 +11951-1;Identifier;ID;Pt;^Fetus;Nom;*;OB.US;2;Fetal [Identifier] Identifier;Fet ID;;ACTIVE;1.0j-a;2.73 +11952-9;Insertion site;Find;Pt;Umbilical cord.placenta^Fetus;Nar;US;OB.US;2;Fetal Umbilical cord.placenta Narrative Insertion site US;Fet Umb cord.plc Insertion site US;;ACTIVE;1.0j-a;2.40 +11953-7;Institution inventory number;ID;Pt;OB ultrasound imaging device;Nom;;OB.US;2;OB ultrasound imaging device Institution inventory number;OB US Imaging device Inventory #;;ACTIVE;1.0j-a;2.27 +11954-5;Kidney length/Abdominal circumference;LenRto;Pt;Kidney^Fetus;Qn;US.derived;OB.US;2;Fetal Kidney length/Abdominal circumference derived by US;Fet Kidney len/AC der US;;ACTIVE;1.0j-a;2.48 +11955-2;Last menstrual period;TmStp;Pt;^Patient;Qn;Reported;OB.US;2;Deprecated Last menstrual period;DeprecatedLast menstrual period;;DEPRECATED;1.0j-a;2.36 +11956-0;Lateral ventricular body width/Hemispheric width;LenRto;Pt;Head^Fetus;Qn;US.derived;OB.US;2;Fetal Head Lateral ventricular body width/Hemispheric width derived by US;Fet Head LVW/HW der US;;ACTIVE;1.0j-a;2.48 +1195-7;little k Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;little k Ag [Presence] on Red Blood Cells;little k Ag RBC Ql;;ACTIVE;1.0;2.73 +11957-8;Length.crown rump;Len;Pt;^Fetus;Qn;US.measured;OB.US;2;Fetal Crown Rump length US;Fet CRL US.meas;;ACTIVE;1.0j-a;2.73 +11958-6;Long axis;Len;Pt;Cervical canal;Qn;Palpation;OB.US;2;Cervical canal [Length] palpation;Cvx canal Length Palpation;;ACTIVE;1.0j-a;2.48 +11959-4;Long axis;Len;Pt;Cervical canal;Qn;US.measured;OB.US;2;Cervical canal [Length] US;Cvx canal Length US.meas;;ACTIVE;1.0j-a;2.48 +11960-2;Long axis;Len;Pt;Cervix.externally palpable surface;Qn;Palpation;OB.US;2;Cervix externally palpable surface [Length] palpation;Cvx ext surf Length Palpation;;ACTIVE;1.0j-a;2.48 +11961-0;Long axis;Len;Pt;Cervix;Qn;US.measured;OB.US;2;Cervix [Length] US;Cervix Length US.meas;;ACTIVE;1.0j-a;2.48 +11962-8;Long axis;Len;Pt;Clavicle.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Clavicle diaphysis [Length] US;Fet Clavicle Length US.meas;;ACTIVE;1.0j-a;2.48 +11963-6;Long axis;Len;Pt;Femur.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Femur diaphysis [Length] US;Fet Femur Length US.meas;;ACTIVE;1.0j-a;2.27 +11964-4;Long axis;Len;Pt;Fibula.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Fibula diaphysis [Length] US;Fet Fibula Length US.meas;;ACTIVE;1.0j-a;2.48 +1196-5;Little NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated Little NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated Little NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +11965-1;Long axis;Len;Pt;Foot^Fetus;Qn;US.measured;OB.US;2;Fetal Foot [Length] US;Fet Ft Length US.meas;;ACTIVE;1.0j-a;2.48 +11966-9;Long axis;Len;Pt;Humerus.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Humerus diaphysis [Length] US;Fet Humerus Length US.meas;;ACTIVE;1.0j-a;2.27 +11967-7;Long axis;Len;Pt;Radius.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Radius diaphysis [Length] US;Fet Radius Length US.meas;;ACTIVE;1.0j-a;2.48 +11968-5;Long axis;Len;Pt;Tibia.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Tibia diaphysis [Length] US;Fet Tibia Length US.meas;;ACTIVE;1.0j-a;2.27 +11969-3;Long axis;Len;Pt;Ulna.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Ulna diaphysis [Length] US;Fet Ulna Length US.meas;;ACTIVE;1.0j-a;2.27 +11970-1;Long axis.mean;Len;Pt;Femur.diaphysis^Fetus;Qn;Estimated from gestational age.Merz 1987;OB.US;2;Fetal Femur diaphysis [Length] mean Estimated from gestational age.Merz. 1987;Fet Femur Length Est from GA.Merz87;;ACTIVE;1.0j-a;2.48 +11971-9;Long axis.mean;Len;Pt;Fibula.diaphysis^Fetus;Qn;Estimated from gestational age.Merz 1987;OB.US;2;Fetal Fibula diaphysis [Length] mean Estimated from gestational age.Merz. 1987;Fet Fibula Length Est from GA.Merz87;;ACTIVE;1.0j-a;2.48 +11972-7;Long axis.mean;Len;Pt;Humerus.diaphysis^Fetus;Qn;Estimated from gestational age.Merz 1987;OB.US;2;Fetal Humerus diaphysis [Length] mean Estimated from gestational age.Merz. 1987;Fet Humerus Length Est from GA.Merz87;;ACTIVE;1.0j-a;2.48 +1197-3;Little NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated Little NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated Little NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +11973-5;Long axis.mean;Len;Pt;Radius.diaphysis^Fetus;Qn;Estimated from gestational age.Merz 1987;OB.US;2;Fetal Radius diaphysis [Length] mean Estimated from gestational age.Merz. 1987;Fet Radius Length Est from GA.Merz87;;ACTIVE;1.0j-a;2.48 +11974-3;Long axis.mean;Len;Pt;Tibia.diaphysis^Fetus;Qn;Estimated from gestational age.Merz 1987;OB.US;2;Fetal Tibia diaphysis [Length] mean Estimated from gestational age.Merz. 1987;Fet Tibia Length Est from GA.Merz87;;ACTIVE;1.0j-a;2.48 +11975-0;Long axis.mean;Len;Pt;Ulna.diaphysis^Fetus;Qn;Estimated from gestational age.Merz 1987;OB.US;2;Fetal Ulna diaphysis [Length] mean Estimated from gestational age.Merz. 1987;Fet Ulna Length Est from GA.Merz87;;ACTIVE;1.0j-a;2.48 +11976-8;Ovulation date;Date;Pt;^Patient;Qn;Reported;OB.US;2;Ovulation date;Ovulation date;;ACTIVE;1.0j-a;2.50 +11977-6;Parity;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Parity;Parity;;ACTIVE;1.0j-a;2.73 +11978-4;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.derived;OB.US;2;Fetal Abdomen Circumference derived by US;Fet Abd Circum der US;;ACTIVE;1.0j-a;2.48 +11979-2;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.measured;OB.US;2;Fetal Abdomen Circumference US;Fet Abd Circum US.meas;;ACTIVE;1.0j-a;2.73 +119-8;Cefpodoxime;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefpodoxime [Susceptibility] by Minimum lethal concentration (MLC);Cefpodoxime Islt MLC;;ACTIVE;1.0;2.19 +11980-0;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.measured.ellipse overlay;OB.US;2;Fetal Abdomen Circumference measured by ellipse overlay (US);Fet Abd Circum by ellipse overlay;;ACTIVE;1.0j-a;2.48 +1198-1;Little NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated Little NOS Ab [Presence] in Serum or Plasma;Deprecated Little NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +11981-8;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.traced;OB.US;2;Fetal Abdomen Circumference US.traced;Fet Abd Circum US.traced;;ACTIVE;1.0j-a;2.48 +11982-6;Perimeter;Len;Pt;Head^Fetus;Qn;US.derived from OFD&O-O TD;OB.US;2;Fetal Head Circumference derived from occipital-frontal diameter and outer-outer transaxial diameter (US);Fet Head Circum by OFD+O-O TD;;ACTIVE;1.0j-a;2.48 +11983-4;Perimeter;Len;Pt;Head^Fetus;Qn;US.derived from OFD&O-I BPD;OB.US;2;Fetal Head Circumference derived from occipital-frontal diameter and outer-inner biparietal diameter (US);Fet Head Circum by OFD+O-I BPD;;ACTIVE;1.0j-a;2.48 +11984-2;Perimeter;Len;Pt;Head^Fetus;Qn;US.measured;OB.US;2;Fetal Head Circumference US;Fet Head Circum US.meas;;ACTIVE;1.0j-a;2.27 +11985-9;Perimeter;Len;Pt;Head^Fetus;Qn;US.measured.ellipse overlay;OB.US;2;Fetal Head Circumference measured by ellipse overlay (US);Fet Head Circum by ellipse overlay;;ACTIVE;1.0j-a;2.48 +11986-7;Perimeter;Len;Pt;Head^Fetus;Qn;US.traced;OB.US;2;Fetal Head Circumference US.traced;Fet Head Circum US.traced;;ACTIVE;1.0j-a;2.48 +11987-5;Perimeter;Len;Pt;Thorax^Fetus;Qn;US.derived;OB.US;2;Fetal Thorax Circumference derived by US;Fet Thorax Circum der US;;ACTIVE;1.0j-a;2.48 +11988-3;Perimeter;Len;Pt;Thorax^Fetus;Qn;US.measured;OB.US;2;Fetal Thorax Circumference US;Fet Thorax Circum US.meas;;ACTIVE;1.0j-a;2.48 +11989-1;Perimeter;Len;Pt;Thorax^Fetus;Qn;US.measured.ellipse overlay;OB.US;2;Fetal Thorax Circumference measured by ellipse overlay (US);Fet Thorax Circum by ellipse overlay;;ACTIVE;1.0j-a;2.48 +11990-9;Perimeter;Len;Pt;Thorax^Fetus;Qn;US.traced;OB.US;2;Fetal Thorax Circumference US.traced;Fet Thorax Circum US.traced;;ACTIVE;1.0j-a;2.48 +11991-7;Perimeter.mean;Len;Pt;Abdomen^Fetus;Qn;Estimated from gestational age;OB.US;2;Fetal Abdomen Mean perimeter Estimated from gestational age;Fet Abd Perimeter.mean Est from GA;;ACTIVE;1.0j-a;2.48 +11992-5;Position.heart;Find;Pt;Thorax^Fetus;Nom;US;OB.US;2;Fetal Heart position US;Fet Heart position US;;ACTIVE;1.0j-a;2.27 +11993-3;Position.heart;Find;Pt;Thorax^Fetus;Nar;US;OB.US;2;Fetal Narrative Heart position US;Fet Heart position US;;ACTIVE;1.0j-a;2.40 +11994-1;Position.placenta;Find;Pt;Uterus;Nom;US.measured;OB.US;2;Placenta position US;Placenta position US.meas;;ACTIVE;1.0j-a;2.27 +11995-8;Position.placenta;Find;Pt;Uterus;Nar;US.measured;OB.US;2;Narrative Placenta position US;Placenta position US.meas;;ACTIVE;1.0j-a;2.40 +11996-6;Pregnancies;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Pregnancies;Pregnancies;;ACTIVE;1.0j-a;2.73 +11997-4;Pulsatility index;VelRto;Pt;Cerebral artery anterior^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery anterior Pulsatility index US.doppler;Fet Cerebral a Ant PI DOP;;ACTIVE;1.0j-a;2.48 +11998-2;Pulsatility index;VelRto;Pt;Cerebral artery anterior;Qn;US.doppler;OB.US;2;Cerebral artery anterior Pulsatility index US.doppler;Cerebral a Ant PI DOP;;ACTIVE;1.0j-a;2.48 +1199-9;little p little k Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated pk Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated pk Ab SerPl BPU Ql;;DEPRECATED;1.0;2.63 +11999-0;Pulsatility index;VelRto;Pt;Cerebral artery middle^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery middle Pulsatility index US.doppler;Fet Cerebral a Middle PI DOP;;ACTIVE;1.0j-a;2.48 +12000-6;Pulsatility index;VelRto;Pt;Cerebral artery middle;Qn;US.doppler;OB.US;2;Cerebral artery middle Pulsatility index US.doppler;Cerebral a Middle PI DOP;;ACTIVE;1.0j-a;2.48 +12001-4;Pulsatility index;VelRto;Pt;Ovarian artery.left;Qn;US.doppler;OB.US;2;Ovarian artery - left Pulsatility index US.doppler;Ovarian a-L PI DOP;;ACTIVE;1.0j-a;2.48 +12002-2;Pulsatility index;VelRto;Pt;Ovarian artery.right;Qn;US.doppler;OB.US;2;Ovarian artery - right Pulsatility index US.doppler;Ovarian a-R PI DOP;;ACTIVE;1.0j-a;2.48 +12003-0;Pulsatility index;VelRto;Pt;Umbilical artery.at fetus^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at fetus Pulsatility index US.doppler;Fet Umb a at fetus PI DOP;;ACTIVE;1.0j-a;2.48 +12004-8;Pulsatility index;VelRto;Pt;Umbilical artery.at placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at placenta Pulsatility index US.doppler;Fet Umb a.at plc PI DOP;;ACTIVE;1.0j-a;2.48 +1200-5;little p little k Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated pk Ab [Presence] in Serum or Plasma from Donor;Deprecated pk Ab SerPl Donr Ql;;DEPRECATED;1.0;2.63 +12005-5;Pulsatility index;VelRto;Pt;Umbilical artery.between fetus and placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery between fetus and placenta Pulsatility index US.doppler;Fet Umb a fetus-plc PI DOP;;ACTIVE;1.0j-a;2.48 +12006-3;Pulsatility index;VelRto;Pt;Uterine artery.left;Qn;US.doppler;OB.US;2;Uterine artery - left Pulsatility index US.doppler;Uterine a-L PI DOP;;ACTIVE;1.0j-a;2.48 +12007-1;Pulsatility index;VelRto;Pt;Uterine artery.right;Qn;US.doppler;OB.US;2;Uterine artery - right Pulsatility index US.doppler;Uterine a-R PI DOP;;ACTIVE;1.0j-a;2.48 +12008-9;Pulsatility index;VelRto;Pt;^Patient;Qn;US.doppler;OB.US;2;Pulsatility index US.doppler;PI DOP;;ACTIVE;1.0j-a;2.48 +12009-7;RR duration;Time;Pt;Heart^Fetus;Qn;US.measured;OB.US;2;Fetal Heart R-R duration US;Fet Hrt R-R dur US.meas;;ACTIVE;1.0j-a;2.48 +12010-5;RR duration;Time;Pt;^Patient;Qn;US.measured;OB.US;2;R-R duration US;R-R dur US.meas;;ACTIVE;1.0j-a;2.48 +12011-3;Replicate summarization;Type;Pt;Measurement;*;;OB.US;2;Replicate summarization;Replicate sum;;ACTIVE;1.0j-a;2.29 +12012-1;Resistivity index;VelRto;Pt;Cerebral artery anterior^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery anterior Resistivity index US.doppler;Fet Cerebral a Ant RI DOP;;ACTIVE;1.0j-a;2.48 +1201-3;little p little k Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated pk Ab [Presence] in Serum or Plasma;Deprecated pk Ab SerPl Ql;;DEPRECATED;1.0;2.63 +12013-9;Resistivity index;VelRto;Pt;Cerebral artery anterior^Fetus;Qn;Doppler.calculated;OB.US;2;Deprecated Fetal Cerebral artery anterior Resistivity index Doppler.calculated;DeprecatedResistivity index;;DEPRECATED;1.0j-a;2.36 +12014-7;Resistivity index;VelRto;Pt;Cerebral artery middle;Qn;US.doppler;OB.US;2;Cerebral artery middle Resistivity index US.doppler;Cerebral a Middle RI DOP;;ACTIVE;1.0j-a;2.48 +12015-4;Resistivity index;VelRto;Pt;Cerebral artery middle^Patient;Qn;Doppler.calculated;OB.US;2;Deprecated Resistivity index of Cerebral artery middle Doppler.calculated;DeprecatedResistivity index;;DEPRECATED;1.0j-a;2.36 +12016-2;Resistivity index;VelRto;Pt;Ovarian artery.left;Qn;US.doppler;OB.US;2;Ovarian artery - left Resistivity index US.doppler;Ovarian a-L RI DOP;;ACTIVE;1.0j-a;2.48 +12017-0;Resistivity index;VelRto;Pt;Ovarian artery.right;Qn;US.doppler;OB.US;2;Ovarian artery - right Resistivity index US.doppler;Ovarian a-R RI DOP;;ACTIVE;1.0j-a;2.48 +12018-8;Resistivity index;VelRto;Pt;Umbilical artery.at fetus^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at fetus Resistivity index US.doppler;Fet Umb a at fetus RI DOP;;ACTIVE;1.0j-a;2.48 +12019-6;Resistivity index;VelRto;Pt;Umbilical artery.at placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at placenta Resistivity index US.doppler;Fet Umb a.at plc RI DOP;;ACTIVE;1.0j-a;2.48 +12020-4;Resistivity index;VelRto;Pt;Umbilical artery.between fetus and placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery between fetus and placenta Resistivity index US.doppler;Fet Umb a fetus-plc RI DOP;;ACTIVE;1.0j-a;2.48 +1202-1;little p little k Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated pk Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated pk Ag RBC BPU Ql;;DEPRECATED;1.0;2.63 +12021-2;Resistivity index;VelRto;Pt;Uterine artery.left;Qn;US.doppler;OB.US;2;Uterine artery - left Resistivity index US.doppler;Uterine a-L RI DOP;;ACTIVE;1.0j-a;2.48 +12022-0;Resistivity index;VelRto;Pt;Uterine artery.right;Qn;US.doppler;OB.US;2;Uterine artery - right Resistivity index US.doppler;Uterine a-R RI DOP;;ACTIVE;1.0j-a;2.48 +12023-8;Resistivity index;VelRto;Pt;^Patient;Qn;US.doppler;OB.US;2;Resistivity index US.doppler;RI DOP;;ACTIVE;1.0j-a;2.48 +12024-6;Minor axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US.M-mode+Measured;OB.US;2;Left ventricle [Length] Minor axis.diastole US.M-mode+Measured;LV Minor axis.dias US.M-mode+Meas;;ACTIVE;1.0j-a;2.67 +12025-3;Minor axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US.measured.real time two dimension;OB.US;2;Left ventricle [Length] Minor axis.diastole Measured by real time two dimension US;LV Minor axis.dias US.meas.RT 2D;;ACTIVE;1.0j-a;2.67 +12026-1;Short axis.systole;Len;Pt;Heart.ventricle.left;Qn;US.M-mode+Measured;OB.US;2;Left ventricle [Length] Short axis during systole US.M-mode+Measured;LV SAX dur sys US.M-mode+Meas;;ACTIVE;1.0j-a;2.54 +12027-9;Minor axis.systole;Len;Pt;Heart.ventricle.left;Qn;US.measured.real time two dimension;OB.US;2;Left ventricle [Length] Minor axis during systole Measured by real time two dimension US;LV Minor axis systole US.meas.RT 2D;;ACTIVE;1.0j-a;2.67 +12028-7;Study observation;Find;Pt;Abdomen^Fetus;Nom;US;OB.US;2;Fetal Abdomen Study observation US;US Abd Fetus Study;;ACTIVE;1.0j-a;2.44 +12029-5;Study observation;Find;Pt;Abdomen^Fetus;Nar;US;OB.US;2;Fetal Abdomen Narrative Study observation US;US Abd Fetus Study;;ACTIVE;1.0j-a;2.40 +12030-3;Study observation;Find;Pt;Abdominal wall^Fetus;Nom;US;OB.US;2;Fetal Abdominal wall Study observation US;US Abd wall Fetus Study;;ACTIVE;1.0j-a;2.44 +12031-1;Study observation;Find;Pt;Abdominal wall^Fetus;Nar;US;OB.US;2;Fetal Abdominal wall Narrative Study observation US;US Abd wall Fetus Study;;ACTIVE;1.0j-a;2.40 +12032-9;Study observation;Find;Pt;Aorta ascending^Fetus;Nom;US;OB.US;2;Fetal Aorta ascending Study observation US;US Aorta ascending Fetus Study;;ACTIVE;1.0j-a;2.44 +12033-7;Study observation;Find;Pt;Aorta ascending^Fetus;Nar;US;OB.US;2;Fetal Aorta ascending Narrative Study observation US;US Aorta ascending Fetus Study;;ACTIVE;1.0j-a;2.40 +12034-5;Study observation;Find;Pt;Aorta descending^Fetus;Nom;US;OB.US;2;Fetal Aorta descending Study observation US;US Aorta descending Fetus Study;;ACTIVE;1.0j-a;2.44 +12035-2;Study observation;Find;Pt;Aorta descending^Fetus;Nar;US;OB.US;2;Fetal Aorta descending Narrative Study observation US;US Aorta descending Fetus Study;;ACTIVE;1.0j-a;2.40 +12036-0;Study observation;Find;Pt;Aorta^Fetus;Nom;US;OB.US;2;Fetal Aorta Study observation US;US Aorta Fetus Study;;ACTIVE;1.0j-a;2.44 +12037-8;Study observation;Find;Pt;Aorta^Fetus;Nar;US;OB.US;2;Fetal Aorta Narrative Study observation US;US Aorta Fetus Study;;ACTIVE;1.0j-a;2.40 +12038-6;Study observation;Find;Pt;Aortic arch^Fetus;Nom;US;OB.US;2;Fetal Aortic arch Study observation US;US Ac arch Fetus Study;;ACTIVE;1.0j-a;2.44 +1203-9;little p little k Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated pk Ag [Presence] on Red Blood Cells from Donor;Deprecated pk Ag RBC Donr Ql;;DEPRECATED;1.0;2.63 +12039-4;Study observation;Find;Pt;Aortic arch^Fetus;Nar;US;OB.US;2;Fetal Aortic arch Narrative Study observation US;US Ac arch Fetus Study;;ACTIVE;1.0j-a;2.40 +12040-2;Study observation;Find;Pt;Cerebellum^Fetus;Nom;US;OB.US;2;Fetal Cerebellum Study observation US;US Cereb Fetus Study;;ACTIVE;1.0j-a;2.44 +12041-0;Study observation;Find;Pt;Cerebellum^Fetus;Nar;US;OB.US;2;Fetal Cerebellum Narrative Study observation US;US Cereb Fetus Study;;ACTIVE;1.0j-a;2.40 +12042-8;Study observation;Find;Pt;Cerebrum^Fetus;Nom;US;OB.US;2;Fetal Cerebrum Study observation US;US Cerebrum Fetus Study;;ACTIVE;1.0j-a;2.44 +12043-6;Study observation;Find;Pt;Cerebrum^Fetus;Nar;US;OB.US;2;Fetal Cerebrum Narrative Study observation US;US Cerebrum Fetus Study;;ACTIVE;1.0j-a;2.40 +12044-4;Study observation;Find;Pt;Cervix;Nom;Inspection;OB.US;2;Cervix Study observation Inspection;Inspect Cervix Study;;ACTIVE;1.0j-a;2.66 +12045-1;Study observation;Find;Pt;Cervix;Nom;Palpation;OB.US;2;Cervix Study observation palpation;Palpation Cervix Study;;ACTIVE;1.0j-a;2.66 +12046-9;Study observation;Find;Pt;Cervix;Nom;US;OB.US;2;Cervix Study observation US;US Cervix Study;;ACTIVE;1.0j-a;2.66 +1204-7;little p little k Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated pk Ag [Presence] on Red Blood Cells;Deprecated pk Ag RBC Ql;;DEPRECATED;1.0;2.63 +12047-7;Study observation;Find;Pt;Colon^Fetus;Nom;US;OB.US;2;Fetal Colon Study observation US;US Colon Fetus Study;;ACTIVE;1.0j-a;2.44 +12048-5;Study observation;Find;Pt;Colon^Fetus;Nar;US;OB.US;2;Fetal Colon Narrative Study observation US;US Colon Fetus Study;;ACTIVE;1.0j-a;2.40 +12049-3;Study observation;Find;Pt;Cranium^Fetus;Nom;US;OB.US;2;Fetal Cranium Study observation US;US Cranium Fetus Study;;ACTIVE;1.0j-a;2.44 +12050-1;Study observation;Find;Pt;Cranium^Fetus;Nar;US;OB.US;2;Fetal Cranium Narrative Study observation US;US Cranium Fetus Study;;ACTIVE;1.0j-a;2.40 +12051-9;Study observation;Find;Pt;Diaphragm^Fetus;Nom;US;OB.US;2;Fetal Diaphragm Study observation US;US Diaphragm Fetus Study;;ACTIVE;1.0j-a;2.44 +12052-7;Study observation;Find;Pt;Diaphragm^Fetus;Nar;US;OB.US;2;Fetal Diaphragm Narrative Study observation US;US Diaphragm Fetus Study;;ACTIVE;1.0j-a;2.40 +12053-5;Study observation;Find;Pt;Ductal arch^Fetus;Nom;US;OB.US;2;Fetal ductal arch Study observation US;US Ductal arch Fetus Study;;ACTIVE;1.0j-a;2.44 +1205-4;little p Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated little p Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated little p Ag RBC BPU Ql;;DEPRECATED;1.0;2.63 +12054-3;Study observation;Find;Pt;Ductal arch^Fetus;Nar;US;OB.US;2;Fetal ductal arch Narrative Study observation US;US Ductal arch Fetus Study;;ACTIVE;1.0j-a;2.40 +12055-0;Study observation;Find;Pt;Face^Fetus;Nom;US;OB.US;2;Fetal Face Study observation US;US Face Fetus Study;;ACTIVE;1.0j-a;2.44 +12056-8;Study observation;Find;Pt;Face^Fetus;Nar;US;OB.US;2;Fetal Face Narrative Study observation US;US Face Fetus Study;;ACTIVE;1.0j-a;2.40 +12057-6;Study observation;Find;Pt;Head.choroid plexus^Fetus;Nom;US;OB.US;2;Fetal Choroid plexus Study observation US;US Head.Choroid plexus Fetus Study;;ACTIVE;1.0j-a;2.44 +12058-4;Study observation;Find;Pt;Head.choroid plexus^Fetus;Nar;US;OB.US;2;Fetal Choroid plexus Narrative Study observation US;US Head.Choroid plexus Fetus Study;;ACTIVE;1.0j-a;2.40 +12059-2;Study observation;Find;Pt;Head.fourth ventricle^Fetus;Nom;US;OB.US;2;Fetal Fourth ventricle Study observation US;US Head.4th vent Fetus Study;;ACTIVE;1.0j-a;2.44 +120-6;Cefpodoxime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefpodoxime [Susceptibility] by Minimum inhibitory concentration (MIC);Cefpodoxime Islt MIC;;ACTIVE;1.0;2.73 +12060-0;Study observation;Find;Pt;Head.fourth ventricle^Fetus;Nar;US;OB.US;2;Fetal Fourth ventricle Narrative Study observation US;US Head.4th vent Fetus Study;;ACTIVE;1.0j-a;2.40 +12061-8;Study observation;Find;Pt;Head.intracranial anatomy^Fetus;Nom;US;OB.US;2;Fetal Intracranial anatomy Study observation US;US Head.IC Anatomy Fetus Study;;ACTIVE;1.0j-a;2.34 +1206-2;little p Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated little p Ag [Presence] on Red Blood Cells from Donor;Deprecated little p Ag RBC Donr Ql;;DEPRECATED;1.0;2.63 +12062-6;Study observation;Find;Pt;Head.intracranial anatomy^Fetus;Nar;US;OB.US;2;Fetal Intracranial anatomy Narrative Study observation US;US Head.IC Anatomy Fetus Study;;ACTIVE;1.0j-a;2.40 +12063-4;Study observation;Find;Pt;Head.lateral cerebral ventricles^Fetus;Nom;US;OB.US;2;Fetal Lateral cerebral ventricles Study observation US;US LV Fetus Study;;ACTIVE;1.0j-a;2.44 +12064-2;Study observation;Find;Pt;Head.lateral cerebral ventricles^Fetus;Nar;US;OB.US;2;Fetal Lateral cerebral ventricles Narrative Study observation US;US LV Fetus Study;;ACTIVE;1.0j-a;2.40 +12065-9;Study observation;Find;Pt;Posterior fossa^Fetus;Nom;US.measured;OB.US;2;Fetal Posterior fossa Study observation US;US.meas Post fossa Fetus Study;;ACTIVE;1.0j-a;2.44 +12066-7;Study observation;Find;Pt;Posterior fossa^Fetus;Nar;US.measured;OB.US;2;Fetal Posterior fossa Narrative Study observation US;US.meas Post fossa Fetus Study;;ACTIVE;1.0j-a;2.40 +12067-5;Study observation;Find;Pt;Head.third ventricle^Fetus;Nom;US.measured;OB.US;2;Fetal Head Third Ventricle Study observation US;US.meas Head.3rd Vent Fetus Study;;ACTIVE;1.0j-a;2.44 +12068-3;Study observation;Find;Pt;Head.third ventricle^Fetus;Nar;US.measured;OB.US;2;Fetal Head Third Ventricle Narrative Study observation US;US.meas Head.3rd Vent Fetus Study;;ACTIVE;1.0j-a;2.40 +12069-1;Study observation;Find;Pt;Head^Fetus;Nom;US;OB.US;2;Fetal Head Study observation US;US Head Fetus Study;;ACTIVE;1.0j-a;2.34 +1207-0;little p Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated little p Ag [Presence] on Red Blood Cells;Deprecated little p Ag RBC Ql;;DEPRECATED;1.0;2.63 +12070-9;Study observation;Find;Pt;Head^Fetus;Nar;US;OB.US;2;Fetal Head Narrative Study observation US;US Head Fetus Study;;ACTIVE;1.0j-a;2.40 +12071-7;Study observation;Find;Pt;Aortic valve^Fetus;Nom;US;OB.US;2;Fetal Aortic valve Study observation US;US AV Fetus Study;;ACTIVE;1.0j-a;2.44 +12072-5;Study observation;Find;Pt;Aortic valve^Fetus;Nar;US;OB.US;2;Fetal Aortic valve Narrative Study observation US;US AV Fetus Study;;ACTIVE;1.0j-a;2.40 +12073-3;Study observation;Find;Pt;Heart.atria^Fetus;Nom;US;OB.US;2;Fetal Atrium Study observation US;US Hrt.atria Fetus Study;;ACTIVE;1.0j-a;2.44 +12074-1;Study observation;Find;Pt;Heart.atria^Fetus;Nar;US;OB.US;2;Fetal Atrium Narrative Study observation US;US Hrt.atria Fetus Study;;ACTIVE;1.0j-a;2.40 +12075-8;Study observation;Find;Pt;Heart.chambers^Fetus;Nom;US;OB.US;2;Fetal Heart chambers Study observation US;US Hrt.chambers Fetus Study;;ACTIVE;1.0j-a;2.44 +12076-6;Study observation;Find;Pt;Heart.chambers^Fetus;Nar;US;OB.US;2;Fetal Heart chambers Narrative Study observation US;US Hrt.chambers Fetus Study;;ACTIVE;1.0j-a;2.40 +12077-4;Study observation;Find;Pt;Heart.great vessels^Fetus;Nom;US;OB.US;2;Fetal Heart great vessels Study observation US;US Hrt.great ves Fetus Study;;ACTIVE;1.0j-a;2.44 +12078-2;Study observation;Find;Pt;Heart.great vessels^Fetus;Nar;US;OB.US;2;Fetal Heart great vessels Narrative Study observation US;US Hrt.great ves Fetus Study;;ACTIVE;1.0j-a;2.40 +12079-0;Study observation;Find;Pt;Heart.interventricular septum^Fetus;Nom;US;OB.US;2;Fetal Interventricular septum Study observation US;US IVS Fetus Study;;ACTIVE;1.0j-a;2.44 +12080-8;Study observation;Find;Pt;Heart.interventricular septum^Fetus;Nar;US;OB.US;2;Fetal Interventricular septum Narrative Study observation US;US IVS Fetus Study;;ACTIVE;1.0j-a;2.40 +12081-6;Study observation;Find;Pt;Mitral valve^Fetus;Nom;US;OB.US;2;Fetal Mitral valve Study observation US;US MV Fetus Study;;ACTIVE;1.0j-a;2.44 +12082-4;Study observation;Find;Pt;Mitral valve^Fetus;Nar;US;OB.US;2;Fetal Mitral valve Narrative Study observation US;US MV Fetus Study;;ACTIVE;1.0j-a;2.40 +12083-2;Study observation;Find;Pt;Pulmonic valve^Fetus;Nom;US;OB.US;2;Fetal Pulmonic valve Study observation US;US PV Fetus Study;;ACTIVE;1.0j-a;2.67 +12084-0;Study observation;Find;Pt;Tricuspid valve^Fetus;Nom;US;OB.US;2;Fetal Tricuspid valve Study observation US;US TV Fetus Study;;ACTIVE;1.0j-a;2.44 +12085-7;Study observation;Find;Pt;Tricuspid valve^Fetus;Nar;US;OB.US;2;Fetal Tricuspid valve Narrative Study observation US;US TV Fetus Study;;ACTIVE;1.0j-a;2.40 +12086-5;Study observation;Find;Pt;Heart.valves^Fetus;Nom;US;OB.US;2;Fetal Heart valves Study observation US;US Hrt.valves Fetus Study;;ACTIVE;1.0j-a;2.44 +12087-3;Study observation;Find;Pt;Heart.valves^Fetus;Nar;US;OB.US;2;Fetal Heart valves Narrative Study observation US;US Hrt.valves Fetus Study;;ACTIVE;1.0j-a;2.40 +1208-8;little s Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;little s Ab [Presence] in Serum or Plasma from Blood product unit;little s Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12088-1;Study observation;Find;Pt;Heart.ventricle.left.outflow tract^Fetus;Nom;US;OB.US;2;Fetal Left ventricular outflow tract Study observation US;US LVOT Fetus Study;;ACTIVE;1.0j-a;2.44 +12089-9;Study observation;Find;Pt;Heart.ventricle.left.outflow tract^Fetus;Nar;US;OB.US;2;Fetal Left ventricular outflow tract Narrative Study observation US;US LVOT Fetus Study;;ACTIVE;1.0j-a;2.40 +12090-7;Study observation;Find;Pt;Heart.ventricle.right.outflow tract^Fetus;Nom;US;OB.US;2;Fetal Right ventricular outflow tract Study observation US;US RVOT Fetus Study;;ACTIVE;1.0j-a;2.44 +12091-5;Study observation;Find;Pt;Heart.ventricle.right.outflow tract^Fetus;Nar;US;OB.US;2;Fetal Right ventricular outflow tract Narrative Study observation US;US RVOT Fetus Study;;ACTIVE;1.0j-a;2.40 +12092-3;Study observation;Find;Pt;Intestine^Fetus;Nom;US;OB.US;2;Fetal Intestine Study observation US;US Intestine Fetus Study;;ACTIVE;1.0j-a;2.44 +12093-1;Study observation;Find;Pt;Intestine^Fetus;Nar;US;OB.US;2;Fetal Intestine Narrative Study observation US;US Intestine Fetus Study;;ACTIVE;1.0j-a;2.40 +12094-9;Study observation;Find;Pt;Kidney.left^Fetus;Nom;US;OB.US;2;Fetal Kidney - left Study observation US;US Kidney-L Fetus Study;;ACTIVE;1.0j-a;2.44 +12095-6;Study observation;Find;Pt;Kidney.left^Fetus;Nar;US;OB.US;2;Fetal Kidney - left Narrative Study observation US;US Kidney-L Fetus Study;;ACTIVE;1.0j-a;2.40 +1209-6;little s Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;little s Ab [Presence] in Serum or Plasma from Donor;little s Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12096-4;Study observation;Find;Pt;Kidney.right^Fetus;Nom;US;OB.US;2;Fetal Kidney - right Study observation US;US Kidney-R Fetus Study;;ACTIVE;1.0j-a;2.44 +12097-2;Study observation;Find;Pt;Kidney.right^Fetus;Nar;US;OB.US;2;Fetal Kidney - right Narrative Study observation US;US Kidney-R Fetus Study;;ACTIVE;1.0j-a;2.40 +12098-0;Study observation;Find;Pt;Kidney^Fetus;Nom;US;OB.US;2;Fetal Kidney Study observation US;US Kidney Fetus Study;;ACTIVE;1.0j-a;2.44 +12099-8;Study observation;Find;Pt;Kidney^Fetus;Nar;US;OB.US;2;Fetal Kidney Narrative Study observation US;US Kidney Fetus Study;;ACTIVE;1.0j-a;2.40 +12100-4;Study observation;Find;Pt;Limbs^Fetus;Nom;US;OB.US;2;Fetal Limbs Study observation US;US Limbs Fetus Study;;ACTIVE;1.0j-a;2.34 +12101-2;Study observation;Find;Pt;Limbs^Fetus;Nar;US;OB.US;2;Fetal Limbs Narrative Study observation US;US Limbs Fetus Study;;ACTIVE;1.0j-a;2.40 +12102-0;Study observation;Find;Pt;Nuchal fold^Fetus;Nom;US;OB.US;2;Fetal Nuchal fold Study observation US;US Nuchal fold Fetus Study;;ACTIVE;1.0j-a;2.44 +12103-8;Study observation;Find;Pt;Nuchal fold^Fetus;Nar;US;OB.US;2;Fetal Nuchal fold Narrative Study observation US;US Nuchal fold Fetus Study;;ACTIVE;1.0j-a;2.40 +1210-4;little s Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;little s Ab [Presence] in Serum or Plasma;little s Ab SerPl Ql;;ACTIVE;1.0;2.56 +12104-6;Study observation;Find;Pt;Pulmonary artery^Fetus;Nom;US;OB.US;2;Fetal Pulmonary artery Study observation US;US PA Fetus Study;;ACTIVE;1.0j-a;2.44 +12105-3;Study observation;Find;Pt;Pulmonary artery^Fetus;Nar;US;OB.US;2;Fetal Pulmonary artery Narrative Study observation US;US PA Fetus Study;;ACTIVE;1.0j-a;2.40 +12106-1;Study observation;Find;Pt;Pulmonary vein^Fetus;Nom;US;OB.US;2;Fetal Pulmonary vein Study observation US;US Pulm v Fetus Study;;ACTIVE;1.0j-a;2.44 +12107-9;Study observation;Find;Pt;Pulmonary vein^Fetus;Nar;US;OB.US;2;Fetal Pulmonary vein Narrative Study observation US;US Pulm v Fetus Study;;ACTIVE;1.0j-a;2.40 +12108-7;Study observation;Find;Pt;Small bowel^Fetus;Nom;US;OB.US;2;Fetal Small bowel Study observation US;US SB Fetus Study;;ACTIVE;1.0j-a;2.44 +12109-5;Study observation;Find;Pt;Small bowel^Fetus;Nar;US;OB.US;2;Fetal Small bowel Narrative Study observation US;US SB Fetus Study;;ACTIVE;1.0j-a;2.40 +12110-3;Study observation;Find;Pt;Spine^Fetus;Nom;US;OB.US;2;Fetal Spine Study observation US;US Spine Fetus Study;;ACTIVE;1.0j-a;2.44 +12111-1;Study observation;Find;Pt;Spine^Fetus;Nar;US;OB.US;2;Fetal Spine Narrative Study observation US;US Spine Fetus Study;;ACTIVE;1.0j-a;2.40 +1211-2;little s Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little s Ag [Presence] on Red Blood Cells from Blood product unit;little s Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12112-9;Study observation;Find;Pt;Stomach^Fetus;Nom;US;OB.US;2;Fetal Stomach Study observation US;US Stom Fetus Study;;ACTIVE;1.0j-a;2.44 +12113-7;Study observation;Find;Pt;Stomach^Fetus;Nar;US;OB.US;2;Fetal Stomach Narrative Study observation US;US Stom Fetus Study;;ACTIVE;1.0j-a;2.40 +12114-5;Study observation;Find;Pt;Thorax^Fetus;Nom;US;OB.US;2;Fetal Thorax Study observation US;US Thorax Fetus Study;;ACTIVE;1.0j-a;2.44 +12115-2;Study observation;Find;Pt;Thorax^Fetus;Nar;US;OB.US;2;Fetal Thorax Narrative Study observation US;US Thorax Fetus Study;;ACTIVE;1.0j-a;2.40 +12116-0;Study observation;Find;Pt;Umbilical cord^Fetus;Nom;US;OB.US;2;Fetal Umbilical cord Study observation US;US Umbilical cord Fetus Study;;ACTIVE;1.0j-a;2.73 +12117-8;Study observation;Find;Pt;Umbilical cord^Fetus;Nar;US;OB.US;2;Fetal Umbilical cord Narrative Study observation US;US Umbilical cord Fetus Study;;ACTIVE;1.0j-a;2.40 +12118-6;Study observation;Find;Pt;Urinary bladder^Fetus;Nom;US;OB.US;2;Fetal Urinary bladder Study observation US;US Bladder Fetus Study;;ACTIVE;1.0j-a;2.44 +12119-4;Study observation;Find;Pt;Urinary bladder^Fetus;Nar;US;OB.US;2;Fetal Urinary bladder Narrative Study observation US;US Bladder Fetus Study;;ACTIVE;1.0j-a;2.40 +1212-0;little s Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little s Ag [Presence] on Red Blood Cells from Donor;little s Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +12120-2;Study observation;Find;Pt;Vena cava.inferior^Fetus;Nom;US;OB.US;2;Fetal Inferior vena cava Study observation US;US IVC Fetus Study;;ACTIVE;1.0j-a;2.44 +12121-0;Study observation;Find;Pt;Vena cava.inferior^Fetus;Nar;US;OB.US;2;Fetal Inferior vena cava Narrative Study observation US;US IVC Fetus Study;;ACTIVE;1.0j-a;2.40 +12122-8;Study observation;Find;Pt;Vena cava.superior^Fetus;Nom;US;OB.US;2;Fetal Superior vena cava Study observation US;US SVC Fetus Study;;ACTIVE;1.0j-a;2.44 +12123-6;Study observation;Find;Pt;Vena cava.superior^Fetus;Nar;US;OB.US;2;Fetal Superior vena cava Narrative Study observation US;US SVC Fetus Study;;ACTIVE;1.0j-a;2.40 +12124-4;Study observation;Find;Pt;Vena cava^Fetus;Nom;US;OB.US;2;Fetal Vena cava Study observation US;US VC Fetus Study;;ACTIVE;1.0j-a;2.44 +12125-1;Study observation;Find;Pt;Vena cava^Fetus;Nar;US;OB.US;2;Fetal Vena cava Narrative Study observation US;US VC Fetus Study;;ACTIVE;1.0j-a;2.40 +12126-9;Study observation;Find;Pt;XXX;Nar;US;OB.US;2;Body region Narrative Study observation US;US Study;;ACTIVE;1.0j-a;2.69 +12127-7;Study observation;Find;Pt;Yolk sac^Fetus;Qn;US;OB.US;2;Deprecated Fetal Yolk sac Quantitative Study observation US;Deprecated US Yolk sac Fetus Study Qn;;DEPRECATED;1.0j-a;2.42 +12128-5;Study observation;Find;Pt;Yolk sac^Fetus;Nar;US;OB.US;2;Fetal Yolk sac Narrative Study observation US;US Yolk sac Fetus Study;;ACTIVE;1.0j-a;2.40 +12129-3;Study observation.general;Imp;Pt;^Fetus;Nom;US;OB.US;2;Fetal [Interpretation] Study observation general US;US Fetus Study [Imp];;ACTIVE;1.0j-a;2.50 +12130-1;Study observation.general;Imp;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation general US;US Fetus Study [Imp];;ACTIVE;1.0j-a;2.50 +12131-9;Study observation.general;Imp;Pt;^Patient;Nom;US;OB.US;2;[Interpretation] Study observation general US;US Study [Imp];;ACTIVE;1.0j-a;2.66 +12132-7;Study observation.general;Imp;Pt;^Patient;Nar;US;OB.US;2;Narrative [Interpretation] Study observation general US;US Study [Imp];;ACTIVE;1.0j-a;2.66 +12133-5;Systolic flow/Diastolic flow;VelRto;Pt;Cerebral artery anterior^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery anterior Systolic flow/Diastolic flow US.doppler;Fet Cerebral a Ant Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12134-3;Systolic flow/Diastolic flow;VelRto;Pt;Cerebral artery anterior;Qn;US.doppler;OB.US;2;Cerebral artery anterior Systolic flow/Diastolic flow US.doppler;Cerebral a Ant Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12135-0;Systolic flow/Diastolic flow;VelRto;Pt;Cerebral artery middle^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery middle Systolic flow/Diastolic flow US.doppler;Fet Cerebral a Middle Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12136-8;Systolic flow/Diastolic flow;VelRto;Pt;Cerebral artery middle;Qn;US.doppler;OB.US;2;Cerebral artery middle Systolic flow/Diastolic flow US.doppler;Cerebral a Middle Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12137-6;Systolic flow/Diastolic flow;VelRto;Pt;Ovarian artery.left;Qn;US.doppler;OB.US;2;Ovarian artery - left Systolic flow/Diastolic flow US.doppler;Ovarian a-L Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +1213-8;little s Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;little s Ag [Presence] on Red Blood Cells;little s Ag RBC Ql;;ACTIVE;1.0;2.73 +12138-4;Systolic flow/Diastolic flow;VelRto;Pt;Ovarian artery.right;Qn;US.doppler;OB.US;2;Ovarian artery - right Systolic flow/Diastolic flow US.doppler;Ovarian a-R Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12139-2;Systolic flow/Diastolic flow;VelRto;Pt;Umbilical artery.at fetus^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at fetus Systolic flow/Diastolic flow US.doppler;Fet Umb a at fetus Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +121-4;Cefpodoxime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefpodoxime [Susceptibility] by Disk diffusion (KB);Cefpodoxime Islt KB;;ACTIVE;1.0;2.19 +12140-0;Systolic flow/Diastolic flow;VelRto;Pt;Umbilical artery.at placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery at placenta Systolic flow/Diastolic flow US.doppler;Fet Umb a.at plc Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12141-8;Systolic flow/Diastolic flow;VelRto;Pt;Umbilical artery.between fetus and placenta^Fetus;Qn;US.doppler;OB.US;2;Fetal Umbilical artery between fetus and placenta Systolic flow/Diastolic flow US.doppler;Fet Umb a fetus-plc Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12142-6;Systolic flow/Diastolic flow;VelRto;Pt;Uterine artery.left;Qn;US.doppler;OB.US;2;Uterine artery - left Systolic flow/Diastolic flow US.doppler;Uterine a-L Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12143-4;Systolic flow/Diastolic flow;VelRto;Pt;Uterine artery.right;Qn;US.doppler;OB.US;2;Uterine artery - right Systolic flow/Diastolic flow US.doppler;Uterine a-R Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12144-2;Systolic flow/Diastolic flow;VelRto;Pt;^Patient;Qn;US.doppler;OB.US;2;Systolic flow/Diastolic flow US.doppler;Sys flow/Dias DOP;;ACTIVE;1.0j-a;2.48 +12145-9;Thickness;Len;Pt;Endometrium;Qn;US.measured;OB.US;2;Endometrium Thickness US;Endometrium Thickness US.meas;;ACTIVE;1.0j-a;2.48 +1214-6;LW Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;LW Ab [Presence] in Serum or Plasma from Blood product unit;LW Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12146-7;Thickness;Len;Pt;Nuchal fold^Fetus;Qn;US.measured;OB.US;2;Fetal Nuchal fold Thickness US;Fet Nuchal fold Thickness US.meas;;ACTIVE;1.0j-a;2.73 +12147-5;Thickness;Len;Pt;Placenta^Fetus;Qn;US.measured;OB.US;2;Fetal Placenta Thickness US;Fet Placenta Thickness US.meas;;ACTIVE;1.0j-a;2.48 +12148-3;Thickness.diastolic;Len;Pt;Heart.interventricular septum^Fetus;Qn;US.M-mode+Measured;OB.US;2;Fetal Interventricular septum Thickness diastolic US.M-mode+Measured;Fet IVS Thickness dias US.M-mode+Meas;;ACTIVE;1.0j-a;2.52 +12149-1;Thickness.diastolic;Len;Pt;Heart.interventricular septum^Fetus;Qn;US.measured.real time two dimension;OB.US;2;Fetal Interventricular septum Thickness diastolic Measured by real time two dimension US;Fet IVS Thickness dias US.meas.RT 2D;;ACTIVE;1.0j-a;2.48 +12150-9;Thickness.diastolic;Len;Pt;Heart.ventricle.posterior wall.left^Fetus;Qn;US.M-mode+Measured;OB.US;2;Fetal Left ventricular posterior wall Thickness diastolic US.M-mode+Measured;Fet LV.post wall Thick dia US.M-mode+Mea;;ACTIVE;1.0j-a;2.54 +12151-7;Thickness.diastolic;Len;Pt;Heart.ventricle.posterior wall.left^Fetus;Qn;US.measured.real time two dimension;OB.US;2;Fetal Left ventricular posterior wall Thickness diastolic Measured by real time two dimension US;Fet LV.post wall Thick dia US.meas.RT 2D;;ACTIVE;1.0j-a;2.54 +12152-5;Thickness.systolic;Len;Pt;Heart.interventricular septum^Fetus;Qn;US.M-mode+Measured;OB.US;2;Fetal Interventricular septum Thickness.systolic US.M-mode+Measured;Fet IVS Thickness.sys US.M-mode+Meas;;ACTIVE;1.0j-a;2.52 +1215-3;LW Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;LW Ab [Presence] in Serum or Plasma from Donor;LW Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12153-3;Thickness.systolic;Len;Pt;Heart.interventricular septum^Fetus;Qn;US.measured.real time two dimension;OB.US;2;Fetal Interventricular septum Thickness.systolic Measured by real time two dimension US;Fet IVS Thickness.sys US.meas.RT 2D;;ACTIVE;1.0j-a;2.48 +12154-1;Thickness.systolic;Len;Pt;Heart.ventricle.posterior wall.left^Fetus;Qn;US.M-mode+Measured;OB.US;2;Fetal Left ventricular posterior wall Thickness.systolic US.M-mode+Measured;Fet LV.post wall Thick sys US.M-mode+Mea;;ACTIVE;1.0j-a;2.54 +12155-8;Thickness.systolic;Len;Pt;Heart.ventricle.posterior wall.left^Fetus;Qn;US.measured.real time two dimension;OB.US;2;Fetal Left ventricular posterior wall Thickness.systolic Measured by real time two dimension US;Fet LV.post wall Thick sys US.meas.RT 2D;;ACTIVE;1.0j-a;2.73 +12156-6;Transducer site;Anat;Pt;^Patient;Nom;;OB.US;2;Transducer site;Transducer site;;ACTIVE;1.0j-a;2.27 +12157-4;Ultrasonographer gravidity number;Num;Pt;^Patient;Qn;;OB.US;2;Ultrasonographer gravidity number;Ultrasonographer grav #;;ACTIVE;1.0j-a;2.73 +12158-2;Ultrasound class;Type;Pt;OB ultrasound imaging device;Nom;;OB.US;2;OB ultrasound imaging device Class;OB US Imaging device Class;;ACTIVE;1.0j-a;2.29 +12159-0;Ultrasound scan quality;Type;Pt;^Patient;Nom;US;OB.US;2;Ultrasound scan quality;US scan quality;;ACTIVE;1.0j-a;2.29 +12160-8;Vendor model number;ID;Pt;OB ultrasound imaging device;Nom;;OB.US;2;OB ultrasound imaging device Vendor model number;OB US Imaging device Model #;;ACTIVE;1.0j-a;2.34 +1216-1;LW Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;LW Ab [Presence] in Serum or Plasma;LW Ab SerPl Ql;;ACTIVE;1.0;2.56 +12161-6;Vendor serial number;ID;Pt;OB ultrasound imaging device;Nom;;OB.US;2;OB ultrasound imaging device Vendor serial number;OB US Imaging device Serial #;;ACTIVE;1.0j-a;2.27 +12162-4;Volume;Vol;Pt;Kidney.left^Fetus;Qn;US.derived;OB.US;2;Fetal Kidney - left Volume derived by US;Fet Kidney-L Volume der US;;ACTIVE;1.0j-a;2.48 +12163-2;Volume;Vol;Pt;Kidney.right^Fetus;Qn;US.derived;OB.US;2;Fetal Kidney - right Volume derived by US;Fet Kidney-R Volume der US;;ACTIVE;1.0j-a;2.48 +12164-0;Volume;Vol;Pt;Ovary.left;Qn;US.derived;OB.US;2;Ovary - left Volume derived by US;Ovary-L Volume der US;;ACTIVE;1.0j-a;2.48 +12165-7;Volume;Vol;Pt;Ovary.right;Qn;US.derived;OB.US;2;Ovary - right Volume derived by US;Ovary-R Volume der US;;ACTIVE;1.0j-a;2.48 +12166-5;Volume;Vol;Pt;Yolk sac^Fetus;Qn;US.measured;OB.US;2;Fetal Yolk sac Volume US;Fet Yolk sac Volume US.meas;;ACTIVE;1.0j-a;2.48 +12167-3;Volume.amniotic fluid;Imp;Pt;Am fld space^Fetus;Nom;US;OB.US;2;Fetal Amniotic fluid space [Interpretation] Volume.amniotic fluid US;Fet AF space Imp Vol amnio fld US;;ACTIVE;1.0j-a;2.50 +12168-1;Volume^post void;Vol;Pt;Urinary bladder^Fetus;Qn;US.measured;OB.US;2;Fetal Urinary bladder Volume post void US;Fet Bladder Volume p vdg US.meas;;ACTIVE;1.0j-a;2.73 +12169-9;Volume.pre void;Vol;Pt;Urinary bladder^Fetus;Qn;US.measured;OB.US;2;Fetal Urinary bladder Volume.pre void US;Fet Bladder Vol pre void US.meas;;ACTIVE;1.0j-a;2.48 +12170-7;Width.hemisphere;Len;Pt;Head^Fetus;Qn;US.measured;OB.US;2;Fetal Head Hemisphere width US;Fet Head HW US.meas;;ACTIVE;1.0j-a;2.48 +12171-5;Width.transverse;Len;Pt;Head.lateral cerebral ventricles^Fetus;Qn;US.measured;OB.US;2;Fetal Lateral cerebral ventricles Transverse width US;Fet LV Width.transverse US.meas;;ACTIVE;1.0j-a;2.48 +12172-3;5-Hydroxyindoleacetate;PrThr;24H;Urine;Ord;;CHEM;1;5-Hydroxyindoleacetate [Presence] in 24 hour Urine;5OH-indoleacetate 24h Ur Ql;;ACTIVE;1.0j-a;2.73 +12173-1;Acid phosphatase.non-prostatic;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Non prostatic acid phosphatase [Enzymatic activity/volume] in Serum or Plasma;ACP Non-prost SerPl-cCnc;;ACTIVE;1.0j-a;2.73 +12174-9;Albumin/Globulin;MRto;Pt;Body fld;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Body fluid;Albumin/Glob Fld;;ACTIVE;1.0j-a;2.73 +12175-6;Albumin/Globulin;MCrto;Pt;Ser;Qn;;CHEM;1;Deprecated Albumin/Globulin [Mass ratio] in Serum;Deprecated Alb/Glob Ser-mRto;;DEPRECATED;1.0j-a;2.36 +12176-4;Amino acids;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amino acids [Moles/volume] in Serum or Plasma;Amino acids SerPl-sCnc;;ACTIVE;1.0j-a;2.73 +12177-2;Amino acids/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Amino acids/Creatinine [Ratio] in Urine;Amino acids/Creat Ur-Rto;;ACTIVE;1.0j-a;2.70 +12178-0;Bacteria;PrThr;Pt;Genital;Ord;Wet preparation;MICRO;1;Bacteria [Presence] in Genital specimen by Wet preparation;Bacteria Genital Ql Wet Prep;;ACTIVE;1.0j-a;2.56 +1217-9;LW Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;LW Ag [Presence] on Red Blood Cells from Blood product unit;LW Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12179-8;Basophils/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Body fluid by Manual count;Basophils/leuk NFr Fld Manual;;ACTIVE;1.0j-a;2.73 +12180-6;Calcium.ionized;SCnc;Pt;Ser/Plas;Qn;ISE;CHEM;1;Calcium.ionized [Moles/volume] in Serum or Plasma by Ion-selective membrane electrode (ISE);Ca-I SerPl ISE-sCnc;;ACTIVE;1.0j-a;2.73 +12181-4;Calcium;SCnc;Pt;Body fld;Qn;;CHEM;1;Calcium [Moles/volume] in Body fluid;Calcium Fld-sCnc;;ACTIVE;1.0j-a;2.73 +12182-2;Cells;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Cells [#/volume] in Body fluid by Manual count;Cells # Fld Manual;;ACTIVE;1.0j-a;2.73 +12183-0;Cholesterol;MCnc;Pt;Body fld;Qn;;CHEM;1;Cholesterol [Mass/volume] in Body fluid;Cholest Fld-mCnc;;ACTIVE;1.0j-a;2.73 +12184-8;Choriogonadotropin;PrThr;Pt;Body fld;Ord;;CHEM;1;Choriogonadotropin [Presence] in Body fluid;HCG Fld Ql;;ACTIVE;1.0j-a;2.73 +12185-5;Coagulation surface induced;Time;Pt;Bld^Control;Qn;Coag;COAG;1;aPTT in Control Blood by Coagulation assay;aPTT Cont Bld;;ACTIVE;1.0j-a;2.73 +12186-3;Colloid oncotic pressure;PPres;Pt;Plas;Qn;;CHEM;1;Colloid oncotic pressure [Partial pressure] in Plasma;COP Plas;;ACTIVE;1.0j-a;2.73 +1218-7;LW Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;LW Ag [Presence] on Red Blood Cells from Donor;LW Ag RBC Donr Ql;;ACTIVE;1.0;2.73 +12187-1;Creatine kinase.MB/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.MB/Creatine kinase.total in Serum or Plasma by Electrophoresis;CK MB CFr SerPl Elph;;ACTIVE;1.0j-a;2.73 +12188-9;Creatine kinase.MB/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;EIA;CHEM;1;Deprecated Creatine kinase.MB/Creatine kinase.total;Deprecated CK MB/CK Fr SerPl EIA;;DEPRECATED;1.0j-a;2.70 +12189-7;Creatine kinase.MB/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Creatine kinase.MB/Creatine kinase.total in Serum or Plasma by calculation;CK MB CFr SerPl Calc;;ACTIVE;1.0j-a;2.73 +12190-5;Creatinine;MCnc;Pt;Body fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Body fluid;Creat Fld-mCnc;;ACTIVE;1.0j-a;2.73 +12191-3;Creatinine;MCnc;Pt;Periton fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal fluid;Creat Prt-mCnc;;ACTIVE;1.0j-a;2.73 +12192-1;Creatinine^2H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal fluid --2 hours post peritoneal dialysis;Creat 2h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.34 +12193-9;Creatinine^4H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal fluid --4 hours post peritoneal dialysis;Creat 4h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.34 +12194-7;Creatinine^12H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal fluid --12 hours post peritoneal dialysis;Creat 12h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.34 +1219-5;LW Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;LW Ag [Presence] on Red Blood Cells;LW Ag RBC Ql;;ACTIVE;1.0;2.56 +12195-4;Creatinine renal clearance/1.73 sq M;ArVRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance/1.73 sq M in 24 hour Urine and Serum or Plasma;Creat Cl/1.73 sq M 24h Ur+SerPl-ArVRat;;ACTIVE;1.0j-a;2.73 +12196-2;Cryofibrinogen;PrThr;Pt;Plas;Ord;4H cold incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 4 hour cold incubation;Cryofib Plas Ql 4h Cold Inc;;ACTIVE;1.0j-a;2.56 +12197-0;Cryofibrinogen;PrThr;Pt;Plas;Ord;1D cold incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 1 day cold incubation;Cryofib Plas Ql 1D Cold Inc;;ACTIVE;1.0j-a;2.73 +12198-8;Cryofibrinogen;PrThr;Pt;Plas;Ord;2D cold incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 2 day cold incubation;Cryofib Plas Ql 2D Cold Inc;;ACTIVE;1.0j-a;2.73 +12199-6;Cryofibrinogen;PrThr;Pt;Plas;Ord;3D cold incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 3 day cold incubation;Cryofib Plas Ql 3D Cold Inc;;ACTIVE;1.0j-a;2.73 +12200-2;Cryoglobulin;PrThr;Pt;Ser;Ord;4H cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 4 hour cold incubation;Cryoglob Ser Ql 4h Cold Inc;;ACTIVE;1.0j-a;2.56 +12201-0;Cryoglobulin;PrThr;Pt;Ser;Ord;1D cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 1 day cold incubation;Cryoglob Ser Ql 1D Cold Inc;;ACTIVE;1.0j-a;2.73 +12202-8;Cryoglobulin;PrThr;Pt;Ser;Ord;2D cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 2 day cold incubation;Cryoglob Ser Ql 2D Cold Inc;;ACTIVE;1.0j-a;2.73 +1220-3;M little g Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Mg Ab [Presence] in Serum or Plasma from Blood product unit;Mg Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12203-6;Cryoglobulin;PrThr;Pt;Ser;Ord;3D cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 3 day cold incubation;Cryoglob Ser Ql 3D Cold Inc;;ACTIVE;1.0j-a;2.73 +12204-4;Cryoglobulin;PrThr;Pt;Ser;Ord;4D cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 4 day cold incubation;Cryoglob Ser Ql 4D Cold Inc;;ACTIVE;1.0j-a;2.56 +12205-1;Cryoglobulin;PrThr;Pt;Ser;Ord;5D cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 5 day cold incubation;Cryoglob Ser Ql 5D Cold Inc;;ACTIVE;1.0j-a;2.73 +12206-9;Cryoglobulin;PrThr;Pt;Ser;Ord;6D cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 6 day cold incubation;Cryoglob Ser Ql 6D Cold Inc;;ACTIVE;1.0j-a;2.73 +12207-7;Cryoglobulin;PrThr;Pt;Ser;Ord;1W cold incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 1 week cold incubation;Cryoglob Ser Ql 1W Cold Inc;;ACTIVE;1.0j-a;2.73 +12208-5;Eosinophils/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Cerebral spinal fluid by Manual count;Eosinophil/leuk NFr CSF Manual;;ACTIVE;1.0j-a;2.73 +12209-3;Eosinophils/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Body fluid by Manual count;Eosinophil/leuk NFr Fld Manual;;ACTIVE;1.0j-a;2.73 +12210-1;Eosinophils/100 leukocytes;NFr;Pt;Urine sed;Qn;Manual count;UA;1;Eosinophils/100 leukocytes in Urine sediment by Manual count;Eosinophil/leuk NFr UrnS Manual;;ACTIVE;1.0j-a;2.73 +1221-1;M little g Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Mg Ab [Presence] in Serum or Plasma from Donor;Mg Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12211-9;Epithelial cells;PrThr;Pt;Vag;Ord;Wet preparation;HEM/BC;1;Epithelial cells [Presence] in Vaginal fluid by Wet preparation;Epi Cells Vag Ql Wet Prep;;ACTIVE;1.0j-a;2.73 +12212-7;Epstein Barr virus nuclear Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus nuclear IgG Ab [Titer] in Serum by Immunofluorescence;EBV NA IgG Titr Ser IF;;ACTIVE;1.0j-a;2.73 +12213-5;Estradiol;MCnc;Pt;Ser;Qn;RIA;CHEM;1;Deprecated Estradiol [Mass/volume] in Serum or Plasma by RIA;Deprecated Estradiol Ser RIA-mCnc;;DEPRECATED;1.0j-a;2.70 +12214-3;Estradiol;MCnc;Pt;Ser;Qn;MEIA;CHEM;1;Deprecated Estradiol [Mass/volume] in Serum or Plasma by MEIA;Deprecated Estradiol Ser-mCnc;;DEPRECATED;1.0j-a;2.70 +12215-0;Fatty acids.very long chain;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain [Moles/volume] in Serum or Plasma;VLCFA SerPl-sCnc;;ACTIVE;1.0j-a;2.73 +12216-8;Gastrin;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Gastrin [Mass/volume] in Serum or Plasma;Deprecated Gastrin Ser-mCnc;;DEPRECATED;1.0j-a;2.70 +12217-6;Globulin;MCnc;Pt;Body fld;Qn;;CHEM;1;Globulin [Mass/volume] in Body fluid;Globulin Fld-mCnc;;ACTIVE;1.0j-a;2.73 +12218-4;Glucose^2H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal fluid --2 hours post peritoneal dialysis;Glucose 2h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.34 +12219-2;Glucose^4H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal fluid --4 hours post peritoneal dialysis;Glucose 4h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.34 +122-2;Cefpodoxime;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefpodoxime [Susceptibility] by Serum bactericidal titer;Cefpodoxime Titr SBT;;ACTIVE;1.0;2.32 +12220-0;Glucose^12H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal fluid --12 hours post peritoneal dialysis;Glucose 12h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.34 +12221-8;Heterophile Ab;PrThr;Pt;Ser;Ord;Sheep cell aggl;MICRO;1;Heterophile Ab [Presence] in Serum by Sheep Cell Agglutination;Heteroph Ab Ser Ql Shp Aggl;;ACTIVE;1.0j-a;2.73 +12222-6;Human papilloma virus Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Human papilloma virus Ag [Presence] in Genital specimen;HPV Ag Genital Ql;;ACTIVE;1.0j-a;2.56 +12223-4;Human papilloma virus 16+18 Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Human papilloma virus 16+18 Ag [Presence] in Genital specimen;HPV16+18 Ag Genital Ql;;ACTIVE;1.0j-a;2.56 +12224-2;Leukocytes;Naric;Pt;Nose;Qn;Microscopy.light.HPF;HEM/BC;1;Leukocytes [#/area] in Nose by Microscopy high power field;WBC #/area Nose HPF;;ACTIVE;1.0j-a;2.73 +12225-9;Leukocytes;Naric;Pt;Sputum;Qn;Microscopy.light.HPF;HEM/BC;1;Leukocytes [#/area] in Sputum by Microscopy high power field;WBC #/area Spt HPF;;ACTIVE;1.0j-a;2.40 +12226-7;Leukocytes;PrThr;Pt;Vag;Ord;Wet preparation;HEM/BC;1;Leukocytes [Presence] in Vaginal fluid by Wet preparation;WBC Vag Ql Wet Prep;;ACTIVE;1.0j-a;2.73 +12227-5;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Blood;WBC nRBC cor # Bld;;ACTIVE;1.0j-a;2.73 +12228-3;Triglyceride;MCnc;Pt;Body fld;Qn;;CHEM;1;Triglyceride [Mass/volume] in Body fluid;Trigl Fld-mCnc;;ACTIVE;1.0j-a;2.73 +1222-9;M little g Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Mg Ab [Presence] in Serum or Plasma;Mg Ab SerPl Ql;;ACTIVE;1.0;2.56 +12229-1;Macrophages/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Cerebral spinal fluid by Manual count;Macrophages/leuk NFr CSF Manual;;ACTIVE;1.0j-a;2.73 +12230-9;Macrophages/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Body fluid by Manual count;Macrophages/leuk NFr Fld Manual;;ACTIVE;1.0j-a;2.73 +12231-7;Prolactin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --baseline;Prolactin BS SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12232-5;Measles virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Specimen by Immunofluorescence;MeV Ag Spec Ql IF;;ACTIVE;1.0j-a;2.73 +12233-3;Mesothelial cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Cerebral spinal fluid by Manual count;Mesothl Cell/leuk NFr CSF Manual;;ACTIVE;1.0j-a;2.73 +12234-1;Mesothelial cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Body fluid by Manual count;Mesothl Cell/leuk NFr Fld Manual;;ACTIVE;1.0j-a;2.73 +12235-8;Microscopic observation;Prid;Pt;Urine sed;Nom;Microscopy.light;UA;1;Microscopic observation [Identifier] in Urine sediment by Light microscopy;Micro UrnS;;ACTIVE;1.0j-a;2.73 +12236-6;Mononuclear cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Cerebral spinal fluid by Manual count;Mononuc Cells/leuk NFr CSF Manual;;ACTIVE;1.0j-a;2.73 +1223-7;M little g Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Mg Ag [Presence] on Red Blood Cells from Blood product unit;Mg Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12237-4;Mumps virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Specimen by Immunofluorescence;MuV Ag Spec Ql IF;;ACTIVE;1.0j-a;2.69 +12238-2;Neutrophils/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Body fluid by Manual count;Neutrophils/leuk NFr Fld Manual;;ACTIVE;1.0j-a;2.73 +12239-0;Oligosaccharides;PrThr;Pt;Urine;Ord;;CHEM;1;Oligosaccharides [Presence] in Urine;Oligosaccharide Ur Ql;;ACTIVE;1.0j-a;2.73 +12240-8;Orotidine;SCnc;Pt;Urine;Qn;;CHEM;1;Orotidine [Moles/volume] in Urine;Orotidine Ur-sCnc;;ACTIVE;1.0j-a;2.42 +12241-6;Osmotic fragility;NFr;Pt;RBC;Qn;RBCs diluted;HEM/BC;1;Osmotic fragility of Red Blood Cells by Diluted RBC;OF NFr RBC Diluted;;ACTIVE;1.0j-a;2.73 +12242-4;Phosphate;MCnc;Pt;Body fld;Qn;;CHEM;1;Phosphate [Mass/volume] in Body fluid;Phosphate Fld-mCnc;;ACTIVE;1.0j-a;2.73 +12243-2;Platelets;Morph;Pt;Bld;Nom;Microscopy.light;HEM/BC;1;Deprecated Platelets [Morphology] in Blood;Deprecated Platelet Bld Smear;;DEPRECATED;1.0j-a;2.36 +12244-0;Polymorphonuclear cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Cerebral spinal fluid by Manual count;Polys/leuk NFr CSF Manual;;ACTIVE;1.0j-a;2.73 +1224-5;M little g Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Mg Ag [Presence] on Red Blood Cells from Donor;Mg Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +12245-7;Porphobilinogen;PrThr;24H;Urine;Ord;;CHEM;1;Porphobilinogen [Presence] in 24 hour Urine;PBG 24h Ur Ql;;ACTIVE;1.0j-a;2.73 +12246-5;Porphyrins;PrThr;24H;Urine;Ord;;CHEM;1;Porphyrins [Presence] in 24 hour Urine;Porphyrins 24h Ur Ql;;ACTIVE;1.0j-a;2.56 +12247-3;Pyruvate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyruvate [Mass/volume] in Serum or Plasma;Pyruvate SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12248-1;Epithelial cells.renal;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Epithelial cells.renal [Presence] in Urine sediment by Light microscopy;Renal Epi Cells UrnS Ql Micro;;ACTIVE;1.0j-a;2.73 +12249-9;Renin;MRat;Pt;Plas;Qn;;CHEM;1;Deprecated Renin [Enzymatic activity/volume] in Plasma;Deprecated Renin Plas-mRate;;DEPRECATED;1.0j-a;2.70 +12250-7;Reticulocytes/1000 erythrocytes^^hematocrit adjusted;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes/1000 erythrocytes hematocrit adjusted in Blood;Retics/1000 RBC Hct adj NFr;;DISCOURAGED;1.0j-a;2.73 +12251-5;Rubella virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Specimen by Immunofluorescence;RUBV Ag Spec Ql IF;;ACTIVE;1.0j-a;2.69 +1225-2;M little g Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Mg Ag [Presence] on Red Blood Cells;Mg Ag RBC Ql;;ACTIVE;1.0;2.56 +12252-3;Somatomedin C;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Insulin-Like growth factor-I [Mass/volume] in Serum or Plasma;Deprecated Somatomedin C Ser-mCnc;;DEPRECATED;1.0j-a;2.70 +12253-1;Somatotropin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --baseline;GH BS SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12254-9;Specimen volume;Vol;Pt;Body fld;Qn;;SPEC;1;Volume of Body fluid;Specimen vol Fld;;ACTIVE;1.0j-a;2.73 +12255-6;Specimen volume;Vol;5H;Urine;Qn;;SPEC;1;Volume of 5 hour Urine;Specimen vol 5h Ur;;ACTIVE;1.0j-a;2.73 +12256-4;Spermatozoa^post vasectomy;Naric;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Spermatozoa [#/area] in Semen by Microscopy high power field --post vasectomy;Sperm p vas #/area Smn HPF;;ACTIVE;1.0j-a;2.73 +12257-2;Spermatozoa.motile/100 spermatozoa^post vasectomy;NFr;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen by Microscopy high power field --post vasectomy;Sperm Motile p vas NFr Smn HPF;;ACTIVE;1.0j-a;2.73 +12258-0;Epithelial cells.squamous;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Epithelial cells.squamous [Presence] in Urine sediment by Light microscopy;Squamous UrnS Ql Micro;;ACTIVE;1.0j-a;2.73 +12259-8;Streptococcus pyogenes enzyme Ab;PrThr;Pt;Ser;Ord;Sheep cell aggl;MICRO;1;Streptococcus pyogenes enzyme Ab [Presence] in Serum by Sheep Cell Agglutination;S pyog.enz Ab Ser Ql Shp Aggl;;ACTIVE;1.0j-a;2.73 +1226-0;M Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;M Ab [Presence] in Serum or Plasma from Blood product unit;M Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12260-6;Sucrose hemolysis;PrThr;Pt;RBC;Ord;;HEM/BC;1;Sucrose hemolysis [Presence] of Red Blood Cells;Sucrose Hemolysis RBC Ql;;ACTIVE;1.0j-a;2.73 +12261-4;Toxoplasma gondii Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Toxoplasma gondii IgG Ab [Titer] in Serum by Immunoassay;T gondii IgG Titr Ser IA;;ACTIVE;1.0j-a;2.73 +12262-2;Toxoplasma gondii Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Toxoplasma gondii IgM Ab [Titer] in Serum by Immunoassay;T gondii IgM Titr Ser IA;;ACTIVE;1.0j-a;2.73 +12263-0;Epstein Barr virus early diffuse Ab;ACnc;Pt;CSF;Ord;IF;MICRO;1;Deprecated EBV [Presence] in Cerebral spinal fluid by Immunofluorescence;Deprecated EBV EA-D Ab CSF Ql IF;;DEPRECATED;1.0j-a;2.36 +12264-8;Epstein Barr virus early restricted Ab;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Epstein Barr virus early restricted Ab [Mass/volume] in Body fluid;Deprecated EBV EA-R Ab Fld-mCnc;;DEPRECATED;1.0j-a;2.40 +12265-5;Urea nitrogen;MCnc;Pt;Periton fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal fluid;Urea nit Prt-mCnc;;ACTIVE;1.0j-a;2.73 +12266-3;Urea nitrogen^2H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal fluid --2 hours post peritoneal dialysis;Urea nit 2h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.42 +12267-1;Urea nitrogen^4H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal fluid --4 hours post peritoneal dialysis;Urea nit 4h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.42 +12268-9;Urea nitrogen^12H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal fluid --12 hours post peritoneal dialysis;Urea nit 12h p PD Prt-mCnc;;ACTIVE;1.0j-a;2.42 +12269-7;Urobilinogen;PrThr;24H;Urine;Ord;;CHEM;1;Urobilinogen [Presence] in 24 hour Urine;Urobilinogen 24h Ur Ql;;ACTIVE;1.0j-a;2.73 +12270-5;Uroporphyrin;PrThr;24H;Urine;Ord;;CHEM;1;Uroporphyrin [Presence] in 24 hour Urine;Uropor 24h Ur Ql;;ACTIVE;1.0j-a;2.73 +12271-3;Varicella zoster virus Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Varicella zoster virus Ab [Presence] in Serum by Latex agglutination;VZV Ab Ser Ql LA;;ACTIVE;1.0j-a;2.73 +12272-1;Virus identified;Prid;Pt;XXX;Nom;IF;MICRO;1;Virus identified in Specimen by Immunofluorescence;Virus Spec IF;;ACTIVE;1.0j-a;2.73 +12273-9;Xanthochromia;PrThr;Pt;Body fld;Ord;;SPEC;1;Xanthochromia [Presence] of Body fluid Qualitative;Xanthochromia Fld Ql;;ACTIVE;1.0j-a;2.73 +12274-7;Xylose;MRat;5H;Urine;Qn;;CHEM;1;Xylose [Mass/time] in 5 hour Urine;Xylose 5h Ur-mRate;;ACTIVE;1.0j-a;2.70 +12275-4;Yeast;PrThr;Pt;Genital;Ord;Wet preparation;MICRO;1;Yeast [Presence] in Genital specimen by Wet preparation;Yeast Genital Ql Wet Prep;;ACTIVE;1.0j-a;2.73 +12276-2;Escherichia coli O157:H7;ACnc;Pt;Stool;Ord;Organism specific culture;MICRO;1;Deprecated Escherichia coli O157:H7 identified in Stool by Organism specific culture;Deprecated E coli O157H7 Stl Cult;;DEPRECATED;1.0j-a;2.36 +12277-0;DNA double strand Ab;PrThr;Pt;Ser;Ord;Farr;SERO;1;DNA double strand Ab [Presence] in Serum by Farr method;dsDNA Ab Ser Ql Farr;;ACTIVE;1.0j-a;2.73 +1227-8;M Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;M Ab [Presence] in Serum or Plasma from Donor;M Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12278-8;Neutrophils.band form/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Band form neutrophils/100 leukocytes in Cerebral spinal fluid by Manual count;Neuts Band/leuk NFr CSF Manual;;ACTIVE;1.0j-a;2.73 +12279-6;Spermatozoa Ab;ACnc;Pt;Semen;Qn;;FERT;1;Deprecated Spermatozoa Ab [Units/volume] in Semen;Deprecated Sperm Ab Smn-aCnc;;DEPRECATED;1.0j-a;2.69 +12280-4;Alanine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Alanine [Mass/volume] in Amniotic fluid;Alanine Amn-mCnc;;ACTIVE;1.0j-a;2.34 +12281-2;Bacteria identified;Prid;Pt;Cvx;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Cervix by Anaerobe culture;Bacteria Cvx Anaerobe Cult;;ACTIVE;1.0j-a;2.73 +12282-0;Warfarin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Warfarin [Presence] in Urine;Warfarin Ur Ql;;ACTIVE;1.0j-a;2.56 +12283-8;Corticotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Corticotropin releasing hormone [Units/volume] in Serum or Plasma;ACTH RH SerPl-aCnc;;DISCOURAGED;1.0j-a;2.69 +12284-6;Growth hormone-releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Growth hormone-releasing hormone [Units/volume] in Serum or Plasma;GHRH SerPl-aCnc;;DISCOURAGED;1.0j-a;2.69 +12285-3;HLA-DP;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DP [Type];HLA-DP;;ACTIVE;1.0j-a;2.73 +1228-6;M Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;M Ab [Presence] in Serum or Plasma;M Ab SerPl Ql;;ACTIVE;1.0;2.56 +12286-1;Drugs identified;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Drugs identified in Urine by Screen method;Drugs Ur Scn;;ACTIVE;1.0j-a;2.73 +12287-9;Drugs identified;Prid;Pt;Gast fld;Nom;Screen;DRUG/TOX;1;Drugs identified in Gastric fluid by Screen method;Drugs Gast Scn;;ACTIVE;1.0j-a;2.73 +12288-7;Diuretics;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Diuretics [Identifier] in Urine;Diuretics Ur;;ACTIVE;1.0j-a;2.73 +12289-5;Drugs identified;Prid;Pt;Vitr fld;Nom;Screen;DRUG/TOX;1;Drugs identified in Vitreous fluid by Screen method;Drugs Vitf Scn;;ACTIVE;1.0j-a;2.19 +12290-3;Procyclidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Procyclidine [Presence] in Urine;Procyclidine Ur Ql;;ACTIVE;1.0j-a;2.56 +12291-1;Mephentermine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mephentermine [Presence] in Urine;Mephentermine Ur Ql;;ACTIVE;1.0j-a;2.73 +12292-9;Dimethyltryptamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dimethyltryptamine [Presence] in Urine;Dimet-tryptamine Ur Ql;;ACTIVE;1.0j-a;2.56 +12293-7;Cotinine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cotinine [Presence] in Urine;Cotinine Ur Ql;;ACTIVE;1.0j-a;2.73 +1229-4;M Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;M Ag [Presence] on Red Blood Cells from Blood product unit;M Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12294-5;Nicotine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nicotine [Presence] in Urine;Nicotine Ur Ql;;ACTIVE;1.0j-a;2.73 +12295-2;Hallucinogens;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Hallucinogens [Identifier] in Urine;Hallucinogens Ur;;ACTIVE;1.0j-a;2.19 +12296-0;Mescaline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mescaline [Presence] in Urine;Mescaline Ur Ql;;ACTIVE;1.0j-a;2.56 +12297-8;Chlorate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Chlorate [Presence] in Blood;Chlorate Bld Ql;;ACTIVE;1.0j-a;2.56 +12298-6;Erythromycin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Erythromycin [Presence] in Urine;Erythromycin Ur Ql;;ACTIVE;1.0j-a;2.73 +12299-4;Ethinamate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethinamate [Presence] in Urine;Ethinamate Ur Ql;;ACTIVE;1.0j-a;2.56 +123-0;Cefprozil;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefprozil [Susceptibility] by Minimum lethal concentration (MLC);Cefprozil Islt MLC;;ACTIVE;1.0;2.19 +12300-0;Polythiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Polythiazide [Presence] in Urine;Polythiazide Ur Ql;;ACTIVE;1.0j-a;2.73 +12301-8;Procaine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Procaine [Presence] in Urine;Procaine Ur Ql;;ACTIVE;1.0j-a;2.73 +1230-2;M Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;M Ag [Presence] on Red Blood Cells from Donor;M Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +12302-6;Theobromine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Theobromine [Presence] in Serum or Plasma;Theobromine SerPl Ql;;ACTIVE;1.0j-a;2.73 +12303-4;Theobromine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Theobromine [Presence] in Urine;Theobromine Ur Ql;;ACTIVE;1.0j-a;2.56 +12304-2;Benzyl alcohol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Benzyl alcohol [Presence] in Serum or Plasma;Benzyl Alc SerPl Ql;;ACTIVE;1.0j-a;2.56 +12305-9;Chlordecone;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Chlordecone [Presence] in Blood;Chlordecone Bld Ql;;ACTIVE;1.0j-a;2.56 +12306-7;Cyclohexane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cyclohexane [Mass/volume] in Blood;Cyclohexane Bld-mCnc;;ACTIVE;1.0j-a;2.42 +12307-5;Dichloroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dichloroethane [Mass/volume] in Blood;DCA Bld-mCnc;;ACTIVE;1.0j-a;2.73 +12308-3;HYDROcodone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;HYDROcodone [Presence] in Urine;HYDROcodone Ur Ql;;ACTIVE;1.0j-a;2.73 +12309-1;Naltrexone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Naltrexone [Presence] in Urine;Naltrexone Ur Ql;;ACTIVE;1.0j-a;2.73 +1231-0;M Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;M Ag [Presence] on Red Blood Cells;M Ag RBC Ql;;ACTIVE;1.0;2.73 +12310-9;Phenytoin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenytoin [Presence] in Urine;Phenytoin Ur Ql;;ACTIVE;1.0j-a;2.73 +12311-7;Prazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Prazepam [Mass/volume] in Urine;Prazepam Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12312-5;Cyclopropane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cyclopropane [Mass/volume] in Blood;Cyclopropane Bld-mCnc;;ACTIVE;1.0j-a;2.73 +12313-3;Aprobarbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Aprobarbital [Presence] in Urine;Aprobarbital Ur Ql;;ACTIVE;1.0j-a;2.56 +12314-1;Clorazepate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Clorazepate [Presence] in Urine;Clorazepate Ur Ql;;ACTIVE;1.0j-a;2.56 +12315-8;Mephobarbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mephobarbital [Presence] in Urine;Mephobarbital Ur Ql;;ACTIVE;1.0j-a;2.73 +12316-6;Methopyrilene;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Methapyrilene [Presence] in Urine;Deprecated Methopyrilene Ur Ql;;DEPRECATED;1.0j-a;2.36 +12317-4;Phenolphthalein;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenolphthalein [Presence] in Urine;Phenolphthalein Ur Ql;;ACTIVE;1.0j-a;2.56 +12318-2;Spironolactone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Spironolactone [Presence] in Urine;Spironolactone Ur Ql;;ACTIVE;1.0j-a;2.73 +12319-0;Thioridazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Thioridazine [Presence] in Urine;Thioridazine Ur Ql;;ACTIVE;1.0j-a;2.73 +12320-8;Thiothixene;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Thiothixene [Presence] in Urine;Thiothixene Ur Ql;;ACTIVE;1.0j-a;2.73 +12321-6;Trifluoperazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trifluoperazine [Presence] in Urine;TriFperazine Ur Ql;;ACTIVE;1.0j-a;2.73 +12322-4;Triflupromazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Triflupromazine [Presence] in Urine;TriFpromazine Ur Ql;;ACTIVE;1.0j-a;2.56 +12323-2;Trimeprazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trimeprazine [Presence] in Urine;Trimeprazine Ur Ql;;ACTIVE;1.0j-a;2.56 +12324-0;hydrOXYzine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;hydrOXYzine [Presence] in Urine;hydrOXYzine Ur Ql;;ACTIVE;1.0j-a;2.73 +12325-7;Tetrahydrocortisone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tetrahydrocortisone [Presence] in Urine;THcortisone Ur Ql;;ACTIVE;1.0j-a;2.56 +12326-5;Diamorphine;PrThr;Pt;Unk sub;Ord;;DRUG/TOX;1;Diamorphine [Presence] in Unknown substance;DAM Usub Ql;;ACTIVE;1.0j-a;2.56 +12327-3;Ketamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ketamine [Presence] in Urine;Ketamine Ur Ql;;ACTIVE;1.0j-a;2.73 +1232-8;M little i super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Mi sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Mi sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12328-1;Beta blockers;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Beta blockers [Identifier] in Urine;Beta Blockers Ur;;ACTIVE;1.0j-a;2.19 +12329-9;chlorproPAMIDE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;chlorproPAMIDE [Presence] in Urine;chlorproPAMIDE Ur Ql;;ACTIVE;1.0j-a;2.56 +12330-7;Hypoglycemics.oral;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Hypoglycemics.oral [Identifier] in Urine;Oral Hypogly Ur;;ACTIVE;1.0j-a;2.19 +12331-5;Phenethylamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenethylamine [Presence] in Urine;Phenethylamine Ur Ql;;ACTIVE;1.0j-a;2.56 +12332-3;Antihistamines;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Antihistamines [Identifier] in Urine;Antihistamines Ur;;ACTIVE;1.0j-a;2.73 +12333-1;Butorphanol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Butorphanol [Presence] in Urine;Butorphanol Ur Ql;;ACTIVE;1.0j-a;2.73 +12334-9;Para aminophenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Para aminophenol [Mass/volume] in Urine;p-Aminophenol Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12335-6;Halothane;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Halothane [Presence] in Blood;Hal Bld Ql;;ACTIVE;1.0j-a;2.56 +1233-6;M little i super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Mi sup(a) Ag [Presence] on Red Blood Cells from Donor;Mi sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +12336-4;hydrALAZINE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;hydrALAZINE [Presence] in Serum or Plasma;hydrALAZINE SerPl Ql;;ACTIVE;1.0j-a;2.56 +12337-2;Dimethylsulfoxide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Dimethylsulfoxide [Presence] in Serum or Plasma;DMSO SerPl Ql;;ACTIVE;1.0j-a;2.56 +12338-0;Pentachlorophenol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Pentachlorophenol [Presence] in Serum or Plasma;Pentachlorophen SerPl Ql;;ACTIVE;1.0j-a;2.56 +12339-8;Diquat;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Diquat [Presence] in Urine;Diquat Ur Ql;;ACTIVE;1.0j-a;2.56 +12340-6;Ethylene;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Ethylene [Presence] in Blood;Ethylene Bld Ql;;ACTIVE;1.0j-a;2.56 +12341-4;Mazindol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Mazindol [Presence] in Serum or Plasma;Mazindol SerPl Ql;;ACTIVE;1.0j-a;2.56 +12342-2;oxyMORphone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;oxyMORphone [Presence] in Serum or Plasma;oxyMORphone SerPl Ql;;ACTIVE;1.0j-a;2.73 +12343-0;Thiazides;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Thiazides [Identifier] in Urine;Thiazides Ur;;ACTIVE;1.0j-a;2.19 +1234-4;M little i super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Mi sup(a) Ag [Presence] on Red Blood Cells;Mi sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +12344-8;Antipsychotics;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Antipsychotics [Identifier] in Serum or Plasma;Antipsychotics SerPl;;ACTIVE;1.0j-a;2.15 +12345-5;Cyclothiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cyclothiazide [Presence] in Urine;Cyclothiazide Ur Ql;;ACTIVE;1.0j-a;2.73 +12346-3;Methyclothiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methyclothiazide [Presence] in Urine;Methyclothiazide Ur Ql;;ACTIVE;1.0j-a;2.56 +12347-1;metOLazone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;metOLazone [Presence] in Urine;metOLazone Ur Ql;;ACTIVE;1.0j-a;2.73 +12348-9;Quinethazone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Quinethazone [Presence] in Urine;Quinethazone Ur Ql;;ACTIVE;1.0j-a;2.56 +12349-7;Trichlormethiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trichlormethiazide [Presence] in Urine;TCM Ur Ql;;ACTIVE;1.0j-a;2.73 +12350-5;Amphetamines;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Stool;Amphetamines Stl Ql;;ACTIVE;1.0j-a;2.56 +1235-1;M little i super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Mi sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Mi sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12351-3;Tetrahydrocannabinol;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Stool;THC Stl Ql;;ACTIVE;1.0j-a;2.56 +12352-1;Benzoylecgonine;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Benzoylecgonine [Presence] in Stool;BZE Stl Ql;;ACTIVE;1.0j-a;2.56 +12353-9;Methaqualone;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Methaqualone [Presence] in Stool;Methaqualone Stl Ql;;ACTIVE;1.0j-a;2.56 +12354-7;Opiates;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Opiates [Presence] in Stool;Opiates Stl Ql;;ACTIVE;1.0j-a;2.56 +12355-4;Phencyclidine;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Stool;PCP Stl Ql;;ACTIVE;1.0j-a;2.56 +12356-2;Methadone;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Methadone [Presence] in Stool;Methadone Stl Ql;;ACTIVE;1.0j-a;2.56 +12357-0;Propoxyphene;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Propoxyphene [Presence] in Stool;Propoxyph Stl Ql;;ACTIVE;1.0j-a;2.73 +12358-8;Barbiturates;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Stool;Barbiturates Stl Ql;;ACTIVE;1.0j-a;2.56 +12359-6;Benzodiazepines;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Stool;Benzodiaz Stl Ql;;ACTIVE;1.0j-a;2.56 +12360-4;Barbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Barbital [Presence] in Urine;Barbital Ur Ql;;ACTIVE;1.0j-a;2.73 +12361-2;Oxazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Oxazepam [Presence] in Urine;Oxazepam Ur Ql;;ACTIVE;1.0j-a;2.73 +12362-0;Oxazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Oxazepam [Presence] in Serum or Plasma;Oxazepam SerPl Ql;;ACTIVE;1.0j-a;2.73 +12363-8;carBAMazepine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;carBAMazepine [Presence] in Urine;carBAMazepine Ur Ql;;ACTIVE;1.0j-a;2.73 +12364-6;Benzodiazepines;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Gastric fluid;Benzodiaz Gast Ql;;ACTIVE;1.0j-a;2.56 +12365-3;dimenhyDRINATE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;dimenhyDRINATE [Presence] in Urine;dimenhyDRINATE Ur Ql;;ACTIVE;1.0j-a;2.56 +12366-1;Disopyramide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Disopyramide [Presence] in Urine;Disopyramide Ur Ql;;ACTIVE;1.0j-a;2.56 +12367-9;Mesoridazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mesoridazine [Presence] in Urine;Mesoridazine Ur Ql;;ACTIVE;1.0j-a;2.73 +12368-7;Phenacetin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenacetin [Presence] in Urine;Phenac Ur Ql;;ACTIVE;1.0j-a;2.56 +1236-9;M little i super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Mi sup(a) Ab [Presence] in Serum or Plasma from Donor;Mi sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12369-5;Sympathomimetics;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Sympathomimetics [Identifier] in Urine;Sympathomimetics Ur;;ACTIVE;1.0j-a;2.73 +12370-3;Thiopental;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiopental [Mass/volume] in Urine;Thiopental Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12371-1;Isopropyl ether;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isopropyl ether [Mass/volume] in Blood;Isopropyl Ether Bld-mCnc;;ACTIVE;1.0j-a;2.42 +12372-9;Dimethylacetamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dimethylacetamide [Mass/volume] in Urine;DMA Ur-mCnc;;ACTIVE;1.0j-a;2.34 +12373-7;Norchlordiazepoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Norchlordiazepoxide [Mass/volume] in Serum or Plasma;Deprecated Norchlordiazep SerPl-mCnc;;DEPRECATED;1.0j-a;2.36 +12374-5;cloBAZam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;cloBAZam [Mass/volume] in Urine;cloBAZam Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12375-2;Clozapine+Norclozapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloZAPine+Norclozapine [Mass/volume] in Serum or Plasma;cloZAPine+Nor SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12376-0;Norclozapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Norclozapine [Mass/volume] in Serum or Plasma;Deprecated Norclozapine SerPl-mCnc;;DEPRECATED;1.0j-a;2.36 +1237-7;M little i super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Mi sup(a) Ab [Presence] in Serum or Plasma;Mi sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +12377-8;Demoxepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Demoxepam [Mass/volume] in Serum or Plasma;Demoxepam SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12378-6;diazePAM;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;diazePAM [Presence] in Stool;diazePAM Stl Ql;;ACTIVE;1.0j-a;2.56 +12379-4;Halazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Halazepam [Mass/volume] in Serum or Plasma;Halazepam SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12380-2;LORazepam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;LORazepam [Presence] in Stool;LORazepam Stl Ql;;ACTIVE;1.0j-a;2.56 +12381-0;Oxazepam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Oxazepam [Presence] in Stool;Oxazepam Stl Ql;;ACTIVE;1.0j-a;2.56 +12382-8;Temazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Urine;Temazepam Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12383-6;Hydroxytriazolam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Hydroxytriazolam [Presence] in Stool;OH-Triazolam Stl Ql;;ACTIVE;1.0j-a;2.56 +12384-4;Triazolam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Triazolam [Presence] in Stool;Triazolam Stl Ql;;ACTIVE;1.0j-a;2.56 +1238-5;M NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated M NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated M NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +12385-1;Desmethyldoxepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Nordoxepin [Mass/volume] in Serum or Plasma;Deprecated Desmethyldoxepin SerPl-mCnc;;DEPRECATED;1.0j-a;2.36 +12386-9;Nordoxepin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nordoxepin [Mass/volume] in Urine;Nordoxepin Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12387-7;Primidone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Primidone [Mass/volume] in Urine;Primidone Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12388-5;Phenylethylmalonamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenylethylmalonamide [Mass/volume] in Serum or Plasma;PEMA SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12389-3;OLANZapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OLANZapine [Mass/volume] in Serum or Plasma;OLANZapine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12390-1;sulfaSALAzine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;sulfaSALAzine [Mass/volume] in Serum or Plasma;sulfaSALAzine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12391-9;dimenhyDRINATE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;dimenhyDRINATE [Mass/volume] in Serum or Plasma;dimenhyDRINATE SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12392-7;Itraconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Itraconazole [Mass/volume] in Serum or Plasma;Deprecated Itraconaz SerPl-mCnc;;DEPRECATED;1.0j-a;2.36 +1239-3;M NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated M NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated M NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +12393-5;Ketoconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Ketoconazole [Mass/volume] in Serum or Plasma;Deprecated Ketoconazole SerPl-mCnc;;DEPRECATED;1.0j-a;2.36 +12394-3;Butorphanol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Butorphanol [Mass/volume] in Serum or Plasma;Butorphanol SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12395-0;Butorphanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Butorphanol [Mass/volume] in Urine;Butorphanol Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12396-8;chlorproPAMIDE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;chlorproPAMIDE [Mass/volume] in Urine;chlorproPAMIDE Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12397-6;Colchicine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Colchicine [Mass/volume] in Serum or Plasma;Colchicine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12398-4;Diphenoxylate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diphenoxylate [Mass/volume] in Serum or Plasma;Diphenoxylate SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12399-2;Emetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Emetine [Mass/volume] in Serum or Plasma;Emetine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12400-8;Emetine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Emetine [Mass/volume] in Urine;Emetine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +1240-1;M NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated M NOS Ab [Presence] in Serum or Plasma;Deprecated M NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +12401-6;Ethinamate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethinamate [Mass/volume] in Serum or Plasma;Ethinamate SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12402-4;Griseofulvin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Griseofulvin [Mass/volume] in Serum or Plasma;Griseofulvin SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12403-2;Mephentermine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Mephentermine [Mass/volume] in Blood;Mephentermine Bld-mCnc;;ACTIVE;1.0j-a;2.73 +12404-0;Nitroglycerin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitroglycerin [Mass/volume] in Serum or Plasma;Nitroglycerin SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12405-7;Nabumetone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nabumetone [Mass/volume] in Serum or Plasma;Nabumetone SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12406-5;Nadolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nadolol [Mass/volume] in Serum or Plasma;Nadolol SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12407-3;6-Beta naltrexone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated 6-Beta naltrexone [Mass/volume] in Serum or Plasma;Deprecated 6B-Naltrexone SerPl-mCnc;;DEPRECATED;1.0j-a;2.58 +12408-1;Oxybutynin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxybutynin [Mass/volume] in Serum or Plasma;Oxybutynin SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12409-9;Pentoxyfylline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Pentoxyfylline [Mass/volume] in Serum or Plasma;Deprecated Pentoxyfylline SerPl-mCnc;;DEPRECATED;1.0j-a;2.36 +12410-7;Pimozide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pimozide [Mass/volume] in Serum or Plasma;Pimozide SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12411-5;Promazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Promazine [Mass/volume] in Serum or Plasma;Promazine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12412-3;Pyridine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pyridine [Mass/volume] in Serum or Plasma;Pyridine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12413-1;Resperine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Resperine [Mass/volume] in Serum or Plasma;Resperine SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12414-9;Resperine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Resperine [Mass/volume] in Urine;Resperine Ur-mCnc;;ACTIVE;1.0j-a;2.34 +12415-6;Selegiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Selegiline [Mass/volume] in Serum or Plasma;Selegiline SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12416-4;Sotalol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sotalol [Mass/volume] in Serum or Plasma;Sotalol SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12417-2;Sulindac;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulindac [Mass/volume] in Serum or Plasma;Sulindac SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12418-0;Terfenadine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Terfenadine [Mass/volume] in Serum or Plasma;Terfenadine SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +1241-9;M NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated M NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated M NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +12419-8;Terfenadine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Terfenadine [Mass/volume] in Urine;Terfenadine Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12420-6;Thiosulfate;MCnc;Pt;Urine;Qn;;CHEM;1;Thiosulfate [Mass/volume] in Urine;Thiosulfate Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12421-4;Thiosulfate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Thiosulfate/Creatinine [Mass Ratio] in Urine;Thiosulfate/Creat Ur;;DISCOURAGED;1.0j-a;2.73 +12422-2;Triflupromazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triflupromazine [Mass/volume] in Serum or Plasma;TriFpromazine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12423-0;Trimeprazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimeprazine [Mass/volume] in Serum or Plasma;Trimeprazine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12424-8;Triprolidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triprolidine [Mass/volume] in Serum or Plasma;Triprolidine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12425-5;Chlorzoxazone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorzoxazone [Mass/volume] in Serum or Plasma;Chlorzoxazone SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12426-3;Brodifacoum;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Brodifacoum [Mass/volume] in Serum or Plasma;Brodifacoum SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1242-7;M NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated M NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated M NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +12427-1;Chlormezanone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlormezanone [Mass/volume] in Serum or Plasma;Chlormezanone SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12428-9;Flurbiprofen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flurbiprofen [Mass/volume] in Serum or Plasma;Flurbiprofen SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12429-7;Succinylcholine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Succinylcholine [Mass/volume] in Urine;Succinylcholine Ur-mCnc;;ACTIVE;1.0j-a;2.34 +12430-5;Cumene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cumene [Mass/volume] in Serum or Plasma;Cumene SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12431-3;Norfenfluramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norfenfluramine [Mass/volume] in Serum or Plasma;Norfenfluramine SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12432-1;Hydroxytriazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Urine;OH-Triazolam Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12433-9;Bufotenine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bufotenine [Mass/volume] in Serum or Plasma;Bufotenine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12434-7;predniSONE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;predniSONE [Mass/volume] in Serum or Plasma;predniSONE SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1243-5;M NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated M NOS Ag [Presence] on Red Blood Cells;Deprecated M NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +12435-4;Naphthalene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Naphthalene [Mass/volume] in Serum or Plasma;Naphthalene SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12436-2;Naphthol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Naphthol [Mass/volume] in Serum or Plasma;Naphthol SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12437-0;traMADol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;traMADol [Mass/volume] in Serum or Plasma;traMADol SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12438-8;Nortramadol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortramadol [Mass/volume] in Serum or Plasma;Nortramadol SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12439-6;FLUoxetine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;FLUoxetine [Mass/volume] in Urine;FLUoxetine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12440-4;Midazolam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Midazolam [Presence] in Stool;Midazolam Stl Ql;;ACTIVE;1.0j-a;2.56 +12441-2;Tolmetin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tolmetin [Mass/volume] in Serum or Plasma;Tolmetin SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12442-0;Acetaminophen;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Acetaminophen [Mass/volume] in Specimen;APAP Spec-mCnc;;ACTIVE;1.0j-a;2.73 +1244-3;M1 Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;M1 Ab [Presence] in Serum or Plasma from Blood product unit;M1 Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12443-8;Trimipramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trimipramine [Mass/volume] in Urine;Trimipramine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12444-6;Nortrimipramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nortrimipramine [Mass/volume] in Urine;Nortrimipramine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12445-3;Norfluoxetine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norfluoxetine [Mass/volume] in Urine;Norfluoxetine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12446-1;Hydrocarbons.halogenated;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Halogenated organic molecules [Identifier] in Urine;Halog HC Ur;;ACTIVE;1.0j-a;2.19 +12447-9;Phenylethylmalonamide;MCnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Phenylethylmalonamide;Deprecated PEMA Ur Ql;;DEPRECATED;1.0j-a;2.36 +12448-7;Ketones^post CFst;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Ketones [Mass/volume] in Urine by Test strip --fasting;Ketones p fast Ur Strip-mCnc;;ACTIVE;1.0j-a;2.73 +12449-5;Ketones^1H post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Ketones [Mass/volume] in Urine by Test strip --1 hour post XXX challenge;Ketones 1h p chal Ur Strip-mCnc;;ACTIVE;1.0j-a;2.73 +1245-0;M1 Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;M1 Ab [Presence] in Serum or Plasma from Donor;M1 Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12450-3;Ketones^2H post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Ketones [Mass/volume] in Urine by Test strip --2 hours post XXX challenge;Ketones 2h p chal Ur Strip-mCnc;;ACTIVE;1.0j-a;2.73 +12451-1;Ketones^3H post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Ketones [Mass/volume] in Urine by Test strip --3 hours post XXX challenge;Ketones 3h p chal Ur Strip-mCnc;;ACTIVE;1.0j-a;2.73 +12452-9;Epithelial cells;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Epithelial cells [Presence] in Semen by Light microscopy;Epi Cells Smn Ql Micro;;ACTIVE;1.0j-a;2.73 +12453-7;Phosphate crystals.amorphous;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Phosphate crystals amorphous [Presence] in Urine sediment by Light microscopy;Amorph Phos Cry UrnS Ql Micro;;ACTIVE;1.0j-a;2.73 +12454-5;Urate crystals.amorphous;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Urate crystals amorphous [Presence] in Urine sediment by Light microscopy;Amorph Urate Cry UrnS Ql Micro;;ACTIVE;1.0j-a;2.73 +12455-2;Histoplasma capsulatum yeast phase Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum yeast phase Ab [Presence] in Cerebral spinal fluid;H capsul Yst Ab CSF Ql;;ACTIVE;1.0j-a;2.73 +12456-0;Histoplasma capsulatum mycelial phase Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Presence] in Cerebral spinal fluid;H capsul Myc Ab CSF Ql;;ACTIVE;1.0j-a;2.73 +12457-8;Specimen volume;Vol;Pt;Dial fld;Qn;;SPEC;1;Volume of Dialysis fluid;Specimen vol Dial fld;;ACTIVE;1.0j-a;2.21 +12458-6;Corticotropin^2nd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2nd specimen post XXX challenge;ACTH sp2 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12459-4;Corticotropin^3rd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3rd specimen post XXX challenge;ACTH sp3 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12460-2;Corticotropin^4th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --4th specimen post XXX challenge;ACTH sp4 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12461-0;Corticotropin^5th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --5th specimen post XXX challenge;ACTH sp5 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12462-8;Corticotropin^6th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --6th specimen post XXX challenge;ACTH sp6 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12463-6;Corticotropin^7th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --7th specimen post XXX challenge;ACTH sp7 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12464-4;Corticotropin^8th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --8th specimen post XXX challenge;ACTH sp8 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12465-1;Ethanol;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Vitreous fluid;Ethanol Vitf-mCnc;;ACTIVE;1.0j-a;2.34 +12466-9;Alpha 1 antitrypsin;MCnc;Pt;Amnio fld;Qn;Nephelometry;CHEM;1;Alpha 1 antitrypsin [Mass/volume] in Amniotic fluid by Nephelometry;A1AT Amn Neph-mCnc;;ACTIVE;1.0j-a;2.56 +12467-7;Amino acids;Prid;Pt;Urine;Nom;;CHEM;1;Amino acids [Identifier] in Urine;Amino acids Ur;;ACTIVE;1.0j-a;2.73 +1246-8;M1 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;M1 Ab [Presence] in Serum or Plasma;M1 Ab SerPl Ql;;ACTIVE;1.0;2.56 +12468-5;Amino acids;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Amino acids [Identifier] in Serum or Plasma;Amino acids SerPl;;ACTIVE;1.0j-a;2.73 +12469-3;Cystine crystals;Prid;Pt;Calculus;Nom;Microscopy.light;CHEM;1;Cystine crystals [type] in Stone by Light microscopy;Cystine Cry Stone Micro;;ACTIVE;1.0j-a;2.21 +12470-1;Homocysteine;MCnc;Pt;Urine;Qn;;CHEM;1;Homocysteine [Mass/volume] in Urine;Hcys Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12471-9;Amino beta guanidinopropionate;MCnc;Pt;Urine;Qn;;CHEM;1;Amino beta guanidinopropionate [Mass/volume] in Urine;AB-Gp Ur-mCnc;;DISCOURAGED;1.0j-a;2.44 +12472-7;Amino beta guanidinopropionate;MCnc;24H;Urine;Qn;;CHEM;1;Amino beta guanidinopropionate [Mass/volume] in 24 hour Urine;AB-Gp 24h Ur-mCnc;;DISCOURAGED;1.0j-a;2.44 +12473-5;Phosphoethanolamine;MRat;Pt;Urine;Qn;;CHEM;1;Phosphoethanolamine [Mass/time] in Urine;PETN Ur-mRate;;DISCOURAGED;1.0j-a;2.46 +12474-3;Carnosine;MCnc;24H;Urine;Qn;;CHEM;1;Carnosine [Mass/volume] in 24 hour Urine;Carnosine 24h Ur-mCnc;;DISCOURAGED;1.0j-a;2.44 +12475-0;Delta aminolevulinate;MRat;Pt;Urine;Qn;;CHEM;1;Delta aminolevulinate [Mass/time] in Urine;D-ALA Ur-mRate;;DISCOURAGED;1.0j-a;2.73 +1247-6;M1 Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;M1 Ag [Presence] on Red Blood Cells from Blood product unit;M1 Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12476-8;Bilirubin;MCnc;Pt;Amnio fld;Qn;Direct spectrophotometry;CHEM;1;Bilirubin.total [Mass/volume] in Amniotic fluid by Spectrophotometry direct;Bilirub Amn Spectrp dir-mCnc;;ACTIVE;1.0j-a;2.73 +12477-6;Dextromethamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dextromethamphetamine [Mass/volume] in Urine;D-methamphet Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12478-4;Levomethamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Levomethamphetamine [Mass/volume] in Urine;L-methamphet Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12479-2;Androsterone;MRat;Pt;Urine;Qn;;CHEM;1;Androsterone [Mass/time] in Urine;Androsterone Ur-mRate;;DISCOURAGED;1.0j-a;2.46 +124-8;Cefprozil;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefprozil [Susceptibility] by Minimum inhibitory concentration (MIC);Cefprozil Islt MIC;;ACTIVE;1.0;2.19 +12480-0;Angiotensin converting enzyme;CCnc;Pt;CSF;Qn;;CHEM;1;Angiotensin converting enzyme [Enzymatic activity/volume] in Cerebral spinal fluid;ACE CSF-cCnc;;ACTIVE;1.0j-a;2.73 +12481-8;Arsenic.inorganic;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic [Mass/volume] in Urine;Inorg Arsenic Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12482-6;Ascorbate;MCnc;Pt;WBC;Qn;;CHEM;1;Ascorbate [Mass/volume] in Leukocytes;Vit C WBC-mCnc;;ACTIVE;1.0j-a;2.42 +12483-4;Tungsten;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Tungsten [Presence] in Serum or Plasma;Tungsten SerPl Ql;;ACTIVE;1.0j-a;2.73 +1248-4;M1 Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;M1 Ag [Presence] on Red Blood Cells from Donor;M1 Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +12484-2;PHENobarbital;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;PHENobarbital [Presence] in Gastric fluid;Phenobarb Gast Ql;;ACTIVE;1.0j-a;2.56 +12485-9;Amobarbital;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Amobarbital [Presence] in Gastric fluid;Amobarbital Gast Ql;;ACTIVE;1.0j-a;2.56 +12486-7;Butabarbital;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Butabarbital [Presence] in Gastric fluid;Butabarbital Gast Ql;;ACTIVE;1.0j-a;2.56 +12487-5;Butalbital;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Butalbital [Presence] in Gastric fluid;Butalbital Gast Ql;;ACTIVE;1.0j-a;2.56 +12488-3;PENTobarbital;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;PENTobarbital [Presence] in Gastric fluid;Pentobarb Gast Ql;;ACTIVE;1.0j-a;2.56 +12489-1;Secobarbital;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Secobarbital [Presence] in Gastric fluid;Secobarbital Gast Ql;;ACTIVE;1.0j-a;2.56 +12490-9;Allyl-sec-butyl-barbiturate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Allyl-sec-butyl-barbiturate [Mass/volume] in Serum or Plasma;Talbutal SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12491-7;Methohexital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methohexital [Presence] in Serum or Plasma;Methohexital SerPl Ql;;ACTIVE;1.0j-a;2.56 +1249-2;M1 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;M1 Ag [Presence] on Red Blood Cells;M1 Ag RBC Ql;;ACTIVE;1.0;2.56 +12492-5;Thiamylal;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Thiamylal [Presence] in Serum or Plasma;Thiamylal SerPl Ql;;ACTIVE;1.0j-a;2.56 +12493-3;Hexobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hexobarbital [Mass/volume] in Serum or Plasma;Hexobarbital SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12494-1;Amobarbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Amobarbital [Presence] in Stool;Amobarbital Stl Ql;;ACTIVE;1.0j-a;2.56 +12495-8;Barbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Barbital [Presence] in Stool;Barbital Stl Ql;;ACTIVE;1.0j-a;2.56 +12496-6;Butabarbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Butabarbital [Presence] in Stool;Butabarbital Stl Ql;;ACTIVE;1.0j-a;2.56 +12497-4;Butalbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Butalbital [Presence] in Stool;Butalbital Stl Ql;;ACTIVE;1.0j-a;2.56 +12498-2;Metharbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Metharbital [Presence] in Stool;Metharbital Stl Ql;;ACTIVE;1.0j-a;2.56 +12499-0;PENTobarbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;PENTobarbital [Presence] in Stool;Pentobarb Stl Ql;;ACTIVE;1.0j-a;2.56 +12-5;Amikacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Amikacin [Susceptibility] by Minimum inhibitory concentration (MIC);Amikacin Islt MIC;;ACTIVE;1.0;2.73 +1250-0;Major crossmatch;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;Major crossmatch [Interpretation];Maj XM SerPl-Imp;;ACTIVE;1.0;2.73 +12500-5;Secobarbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Secobarbital [Presence] in Stool;Secobarbital Stl Ql;;ACTIVE;1.0j-a;2.56 +12501-3;PHENobarbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;PHENobarbital [Presence] in Stool;Phenobarb Stl Ql;;ACTIVE;1.0j-a;2.56 +12502-1;Allobarbital;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Allobarbital [Presence] in Stool;Allobarbital Stl Ql;;ACTIVE;1.0j-a;2.56 +12503-9;Hemoglobin.gastrointestinal^4th specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --4th specimen;Hemoccult sp4 Stl Ql;;ACTIVE;1.0j-a;2.73 +12504-7;Hemoglobin.gastrointestinal^5th specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --5th specimen;Hemoccult sp5 Stl Ql;;ACTIVE;1.0j-a;2.73 +12505-4;Cadmium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Red Blood Cells;Cadmium RBC-mCnc;;ACTIVE;1.0j-a;2.73 +12506-2;Calcitonin^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Calcit sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12507-0;Calcitonin^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Calcit sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12508-8;Calcitonin^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Calcit sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12509-6;Calcitonin^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Calcit sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12510-4;Calcitonin^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Calcit sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12511-2;Calcium;MCnc;4H;Urine;Qn;;CHEM;1;Calcium [Mass/volume] in 4 hour Urine;Calcium 4h Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12512-0;Calcium hydrogen phosphate dihydrate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Calcium hydrogen phosphate dihydrate crystals [Presence] in Urine sediment by Light microscopy;Ca H2 Phos dihyd Cry UrnS Ql Micro;;ACTIVE;1.0j-a;2.73 +12513-8;Bicarbonate;SCnc;Pt;Water;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Water;HCO3 Wat-sCnc;;ACTIVE;1.0j-a;2.34 +12514-6;Bicarbonate;SCnc;Pt;Dial fld;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Dialysis fluid;HCO3 Dial fld-sCnc;;ACTIVE;1.0j-a;2.34 +12515-3;Carcinoembryonic Ag;MCnc;Pt;Body fld;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Body fluid;CEA Fld-mCnc;;ACTIVE;1.0j-a;2.73 +12516-1;Catecholamines^2nd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Catecholamines [Mass/volume] in Urine --2nd specimen post XXX challenge;Catechols sp2 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.50 +12517-9;Catecholamines^3rd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Catecholamines [Mass/volume] in Urine --3rd specimen post XXX challenge;Catechols sp3 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.50 +1251-8;Major crossmatch;Imp;Pt;Ser/Plas;Nom;Immediate spin;BLDBK;1;Major crossmatch [Interpretation] by Immediate spin;Maj XM SerPl Imm Spin-Imp;;ACTIVE;1.0;2.73 +12518-7;Catecholamines^4th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Catecholamines [Mass/volume] in Urine --4th specimen post XXX challenge;Catechols sp4 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.50 +12519-5;Catecholamines^5th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Catecholamines [Mass/volume] in Urine --5th specimen post XXX challenge;Catechols sp5 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.50 +12520-3;Catecholamines^6th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Catecholamines [Mass/volume] in Urine --6th specimen post XXX challenge;Catechols sp6 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.50 +12521-1;Catecholamines^7th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Catecholamines [Mass/volume] in Urine --7th specimen post XXX challenge;Catechols sp7 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.50 +12522-9;Catecholamines^2nd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --2nd specimen post XXX challenge;Catechols sp2 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.50 +12523-7;Catecholamines^3rd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --3rd specimen post XXX challenge;Catechols sp3 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.50 +12524-5;Catecholamines^4th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --4th specimen post XXX challenge;Catechols sp4 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12525-2;Norepinephrine^1H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --1 hour post XXX challenge;Norepineph 1h p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +1252-6;Major crossmatch^post immediate spin;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;Major crossmatch [Interpretation] --post immediate spin;Maj XM p Imm Spin SerPl-Imp;;ACTIVE;1.0;2.09 +12526-0;Norepinephrine^2H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --2 hours post XXX challenge;Norepineph 2h p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +12527-8;Norepinephrine^3H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --3 hours post XXX challenge;Norepineph 3h p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +12528-6;Norepinephrine^4H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --4 hours post XXX challenge;Norepineph 4h p chal Plas-mCnc;;ACTIVE;1.0j-a;2.73 +12529-4;EPINEPHrine^2H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --2 hours post XXX challenge;Epineph 2h p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +12530-2;Chloride;SCnc;Pt;Water;Qn;;CHEM;1;Chloride [Moles/volume] in Water;Chloride Wat-sCnc;;ACTIVE;1.0j-a;2.34 +12531-0;Cholesterol;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Cholesterol [Mass/volume] in Body fluid;Deprecated Cholest Fld-mCnc;;DEPRECATED;1.0j-a;2.36 +12532-8;Meclizine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Meclizine [Presence] in Serum or Plasma;Meclizine SerPl Ql;;ACTIVE;1.0j-a;2.56 +12533-6;Thiazolidine-2-Thione-4-Carboxylic acid;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiazolidine-2-Thione-4-Carboxylic acid [Mass/volume] in Urine;TTCA Ur-mCnc;;ACTIVE;1.0j-a;2.34 +1253-4;Major crossmatch;Imp;Pt;Ser/Plas;Nom;Prewarmed;BLDBK;1;Major crossmatch [Interpretation] by Prewarmed;Maj XM SerPl Pwarm-Imp;;ACTIVE;1.0;2.10 +12534-4;Thiazolidine-2-Thione-4-Carboxylic acid/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Thiazolidine-2-Thione-4-Carboxylic acid/Creatinine [Mass Ratio] in Urine;TTCA/Creat Ur;;ACTIVE;1.0j-a;2.42 +12535-1;Amyl nitrite;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Amyl nitrite [Presence] in Blood;Amyl nitrite Bld Ql;;ACTIVE;1.0j-a;2.56 +12536-9;Butyl nitrate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Butyl nitrate [Presence] in Blood;Butyl nitrate Bld Ql;;ACTIVE;1.0j-a;2.56 +12537-7;Phenylglyoxylate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenylglyoxylate [Mass/volume] in Urine;Phenylglyoxylate Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12538-5;Nitrate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Nitrate [Mass/volume] in Blood;Nitrate Bld-mCnc;;ACTIVE;1.0j-a;2.42 +12539-3;2-Methylcitrate;MCnc;Pt;Urine;Qn;;CHEM;1;2-Methylcitrate [Mass/volume] in Urine;2Me-citrate Ur-mCnc;;DISCOURAGED;1.0j-a;2.73 +12540-1;2-Methylcitrate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Methylcitrate [Mass/volume] in Serum or Plasma;2Me-citrate SerPl-mCnc;;DISCOURAGED;1.0j-a;2.73 +12541-9;Meta methylhippurate+Para methylhippurate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Meta methylhippurate+Para methylhippurate [Mass/volume] in Urine;m+p-Methylhippurate Ur-mCnc;;ACTIVE;1.0j-a;2.73 +1254-2;Major crossmatch.re-crossmatch;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;Major crossmatch.re-crossmatch [Interpretation];Maj XM Re-Cross SerPl-Imp;;ACTIVE;1.0;2.09 +12542-7;N-methylacetamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;N-methylacetamide [Mass/volume] in Urine;NMA Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12543-5;Methyl formamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl formamide [Mass/volume] in Urine;Mehyl Formamide Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12544-3;Nefazodone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nefazodone [Mass/volume] in Serum or Plasma;Nefazodone SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12545-0;Zomepirac;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zomepirac [Mass/volume] in Serum or Plasma;Zomepirac SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12546-8;Quinethazone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Quinethazone [Presence] in Serum or Plasma;Quinethazone SerPl Ql;;ACTIVE;1.0j-a;2.56 +12547-6;Phorate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phorate [Mass/volume] in Serum or Plasma;Phorate SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12548-4;Tybamate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tybamate [Mass/volume] in Serum or Plasma;Tybamate SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12549-2;Turpentine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Turpentine [Mass/volume] in Serum or Plasma;Turpentine SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +125-5;Cefprozil;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefprozil [Susceptibility] by Disk diffusion (KB);Cefprozil Islt KB;;ACTIVE;1.0;2.19 +12550-0;Papaverine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Papaverine [Mass/volume] in Serum or Plasma;Papaverine SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12551-8;Isocarboxazid;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Isocarboxazid [Mass/volume] in Serum or Plasma;Isocarboxazid SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12552-6;Propylene glycol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propylene glycol [Mass/volume] in Serum or Plasma;Prop glycol SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12553-4;Stimulants;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Stimulants [Identifier] in Urine;Stimulants Ur;;ACTIVE;1.0j-a;2.73 +12554-2;Narcotics;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Narcotics and opioids [Identifier] in Urine;Narcotics Ur;;ACTIVE;1.0j-a;2.73 +12555-9;Turpentine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Turpentine [Mass/volume] in Urine;Turpentine Ur-mCnc;;ACTIVE;1.0j-a;2.34 +12556-7;Copper;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Blood;Copper Bld-mCnc;;ACTIVE;1.0j-a;2.73 +12557-5;Cortisol^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Cortis sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12558-3;Cortisol^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Cortis sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1255-9;Minor crossmatch;Imp;Pt;RBC;Nom;;BLDBK;1;Minor crossmatch [Interpretation];Min XM RBC-Imp;;ACTIVE;1.0;2.73 +12559-1;Cortisol^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Cortis sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12560-9;Cortisol^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Cortis sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12561-7;Cortisol^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Cortis sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12562-5;Cortisol^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Cortis sp7 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12563-3;Cortisol^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Cortis sp8 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12564-1;Cortisol^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Cortis sp9 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12565-8;Cortisol^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;Cortis sp10 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12566-6;Cortisol^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Cortis 30M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1256-7;N Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;N Ab [Presence] in Serum or Plasma from Blood product unit;N Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12567-4;Cortisol^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Cortis 1h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12568-2;Cortisol^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Cortis 20M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12569-0;Cortisol^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;Cortis 2.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.58 +12570-8;Cortisol^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --post XXX challenge;Cortis p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12571-6;Creatinine;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Creatinine [Mass/volume] in Body fluid;Deprecated Creat Fld-mCnc;;DEPRECATED;1.0j-a;2.36 +12572-4;Creatinine^2H dwell specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --2 hour dwell specimen;Creat 2H dwell spec DiafP-mCnc;;ACTIVE;1.0j-a;2.58 +12573-2;Creatinine^4H dwell specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --4 hour dwell specimen;Creat 4H dwell spec DiafP-mCnc;;ACTIVE;1.0j-a;2.58 +12574-0;Creatinine^24H specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --24 hour specimen;Creat 24h sp DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +1257-5;N Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;N Ab [Presence] in Serum or Plasma from Donor;N Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12575-7;Creatinine^baseline;MCnc;Pt;Dial fld prt;Qn;;CHAL;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --baseline;Creat BS DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12576-5;Creatinine^1st specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --1st specimen;Creat sp1 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12577-3;Creatinine^2nd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --2nd specimen;Creat sp2 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12578-1;Creatinine^3rd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --3rd specimen;Creat sp3 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12579-9;Creatinine^4th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --4th specimen;Creat sp4 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12580-7;Creatinine^5th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --5th specimen;Creat sp5 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12581-5;Creatinine^6th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --6th specimen;Creat sp6 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12582-3;Creatinine^7th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --7th specimen;Creat sp7 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +1258-3;N Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;N Ab [Presence] in Serum or Plasma;N Ab SerPl Ql;;ACTIVE;1.0;2.56 +12583-1;Creatinine^8th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --8th specimen;Creat sp8 DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12584-9;Creatinine;MCnc;Pt;Vitr fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Vitreous fluid;Creat Vitf-mCnc;;ACTIVE;1.0j-a;2.73 +12585-6;Creatinine;MRat;2H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 2 hour Urine;Creat 2h Ur-mRate;;ACTIVE;1.0j-a;2.73 +12586-4;Creatinine;MRat;4H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 4 hour Urine;Creat 4h Ur-mRate;;ACTIVE;1.0j-a;2.73 +12587-2;Creatinine;MRat;6H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 6 hour Urine;Creat 6h Ur-mRate;;ACTIVE;1.0j-a;2.40 +12588-0;Creatinine;MRat;8H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 8 hour Urine;Creat 8h Ur-mRate;;ACTIVE;1.0j-a;2.73 +12589-8;Creatinine;MRat;12H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 12 hour Urine;Creat 12h Ur-mRate;;ACTIVE;1.0j-a;2.73 +12590-6;Dehydroepiandrosterone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;DHEA sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1259-1;N Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;N Ag [Presence] on Red Blood Cells from Blood product unit;N Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12591-4;Dehydroepiandrosterone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;DHEA sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12592-2;Dehydroepiandrosterone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;DHEA sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12593-0;Dehydroepiandrosterone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;DHEA sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12594-8;Dehydroepiandrosterone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;DHEA sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12595-5;Estradiol;MCnc;Pt;Urine;Qn;;CHEM;1;Estradiol (E2) [Mass/volume] in Urine;Estradiol Ur-mCnc;;ACTIVE;1.0j-a;2.36 +12596-3;Estradiol^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Estradiol 3h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.36 +12597-1;Estrogen^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estrogen [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Estrogen sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12598-9;Fat.neutral;PrThr;Pt;Stool;Ord;;CHEM;1;Fat.neutral [Presence] in Stool;Neutral Fat Stl Ql;;ACTIVE;1.0j-a;2.73 +12599-7;Pristanate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pristanate (C15:0(CH3)4) [Mass/volume] in Serum or Plasma;Pristanate SerPl-mCnc;;DISCOURAGED;1.0j-a;2.73 +12600-3;Pristanate/Phytanate;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Pristanate (C15:0(CH3)4)/Phytanate (C16:0(CH3)4) [Mass Ratio] in Serum or Plasma;Pristanate/Phytanate SerPl;;ACTIVE;1.0j-a;2.73 +12601-1;Fluoride;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Fluoride [Mass/volume] in Dialysis fluid;Fluoride Dial fld-mCnc;;ACTIVE;1.0j-a;2.42 +12602-9;Hydroxyethylflurazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Urine;OH-Ethylfluraz Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12603-7;N-desalkylflurazepam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Stool;Desalkylfluraz Stl Ql;;ACTIVE;1.0j-a;2.56 +12604-5;Hydroxyethylflurazepam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Hydroxyethylflurazepam [Presence] in Stool;OH-Ethylfluraz Stl Ql;;ACTIVE;1.0j-a;2.56 +12605-2;Flurazepam;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Flurazepam [Presence] in Stool;Flurazepam Stl Ql;;ACTIVE;1.0j-a;2.56 +12606-0;Dolichol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dolichol [Mass/volume] in Serum or Plasma;Dolichol SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12607-8;Glucose^pre dialysis;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --pre dialysis;Glucose pre dial DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12608-6;Glucose^2H dwell specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --2 hour dwell specimen;Glucose 2H dwell spec DiafP-mCnc;;ACTIVE;1.0j-a;2.54 +1260-9;N Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;N Ag [Presence] on Red Blood Cells from Donor;N Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +12609-4;Glucose^4H dwell specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --4 hour dwell specimen;Glucose 4H dwell spec DiafP-mCnc;;ACTIVE;1.0j-a;2.54 +12610-2;Glucose^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Glucose 2h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12611-0;Glucose^4H specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --4 hour specimen;Glucose 4h spec SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12612-8;Glucose^2H specimen;MCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Mass/volume] in Dialysis fluid --2 hour specimen;Glucose 2h spec Dial fld-mCnc;;ACTIVE;1.0j-a;2.42 +12613-6;Glucose^4H specimen;MCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Mass/volume] in Dialysis fluid --4 hour specimen;Glucose 4h spec Dial fld-mCnc;;ACTIVE;1.0j-a;2.42 +12614-4;Glucose^7H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --7 hours post meal;Glucose 7h p meal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12615-1;Glucose^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Glucose sp1 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12616-9;Glucose^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Glucose sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1261-7;N Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;N Ag [Presence] on Red Blood Cells;N Ag RBC Ql;;ACTIVE;1.0;2.73 +12617-7;Glucose^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Glucose sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12618-5;Glucose^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Glucose sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12619-3;Glucose^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Glucose sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12620-1;Glucose^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Glucose sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12621-9;Glucose^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Glucose sp9 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12622-7;Glucose^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;Glucose sp10 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12623-5;Glucose^11th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --11th specimen post XXX challenge;Glucose sp11 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12624-3;Glucose^12th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12th specimen post XXX challenge;Glucose sp12 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +1262-5;N NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated N NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated N NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +12625-0;Glucose^13th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --13th specimen post XXX challenge;Glucose sp13 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12626-8;Glucose^14th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --14th specimen post XXX challenge;Glucose sp14 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12627-6;Glucose^15th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15th specimen post XXX challenge;Glucose sp15 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12628-4;Glucose;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid;Glucose DiafP-mCnc;;ACTIVE;1.0j-a;2.73 +12629-2;Glucose;MCnc;24H;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in 24 hour Peritoneal dialysis fluid;Glucose 24h DiafP-mCnc;;ACTIVE;1.0j-a;2.73 +126-3;Cefprozil;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefprozil [Susceptibility] by Serum bactericidal titer;Cefprozil Titr SBT;;ACTIVE;1.0;2.32 +12630-0;Glucose^1st specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --1st specimen;Glucose sp1 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12631-8;Glucose^2nd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --2nd specimen;Glucose sp2 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12632-6;Glucose^3rd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --3rd specimen;Glucose sp3 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +1263-3;N NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated N NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated N NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +12633-4;Glucose^4th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --4th specimen;Glucose sp4 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12634-2;Glucose^5th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --5th specimen;Glucose sp5 DiafP-mCnc;;ACTIVE;1.0j-a;2.73 +12635-9;Glucose^6th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --6th specimen;Glucose sp6 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12636-7;Glucose^7th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --7th specimen;Glucose sp7 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12637-5;Glucose^8th specimen post XXX challenge;MCnc;Pt;Dial fld prt;Qn;;CHAL;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --8th specimen post XXX challenge;Glucose sp8 p chal DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12638-3;Glucose^pre dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre dose lactose PO;Glucose pre Lac PO SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12639-1;Glucose^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Glucose 15M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12640-9;Glucose^6.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6.5 hours post XXX challenge;Glucose 6.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +1264-1;N NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated N NOS Ab [Presence] in Serum or Plasma;Deprecated N NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +12641-7;Glucose^7H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --7 hours post XXX challenge;Glucose 7h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12642-5;Glucose^7.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --7.5 hours post XXX challenge;Glucose 7.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12643-3;Glucose^8H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --8 hours post XXX challenge;Glucose 8h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12644-1;Glucose^9H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --9 hours post XXX challenge;Glucose 9h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12645-8;Glucose^10H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 hours post XXX challenge;Glucose 10h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12646-6;Glucose^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Glucose 1h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12647-4;Glucose^12H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12 hours post XXX challenge;Glucose 12h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12648-2;Glucose^15M post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 minutes post dose lactose PO;Glucose 15M p Lac PO SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12649-0;Glucose^6th specimen post dose lactose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6th specimen post dose lactose;Glucose sp6 p Lac SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12650-8;Glucose^3.5H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3.5 hours post dose lactose PO;Glucose 3.5h p Lac PO SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12651-6;Glucose^10M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 minutes pre XXX challenge;Glucose 10M pre chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12652-4;Glucose^2M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 minutes post XXX challenge;Glucose 2M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12653-2;Glucose^8M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --8 minutes post XXX challenge;Glucose 8M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12654-0;Glucose^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Glucose 10M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12655-7;Glucose^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Glucose 20M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12656-5;Glucose^4M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 minutes post XXX challenge;Glucose 4M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12657-3;Glucose^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;Glucose 40M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +1265-8;N NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated N NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated N NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +12658-1;Glucose^50M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --50 minutes post XXX challenge;Glucose 50M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12659-9;Glucose^70M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --70 minutes post XXX challenge;Glucose 70M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.70 +12660-7;Follitropin^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;FSH 3h p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.42 +12661-5;Follitropin^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;FSH 10M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.42 +12662-3;Follitropin^20M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge;FSH 20M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.42 +12663-1;Follitropin^40M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --40 minutes post XXX challenge;FSH 40M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.42 +12664-9;Follitropin^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;FSH sp2 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +12665-6;Follitropin^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;FSH sp3 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +1266-6;N NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated N NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated N NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +12666-4;Follitropin^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;FSH sp4 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +12667-2;Follitropin^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;FSH sp5 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +12668-0;Follitropin^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;FSH sp6 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +12669-8;Follitropin^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;FSH sp7 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +12670-6;Follitropin^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;FSH sp8 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +12671-4;Follitropin^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;FSH sp9 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.42 +12672-2;Lutropin^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;LH 10M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12673-0;Lutropin^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;LH 3h p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +1267-4;N NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated N NOS Ag [Presence] on Red Blood Cells;Deprecated N NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +12674-8;Lutropin^15M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --15 minutes pre XXX challenge;LH 15M pre chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12675-5;Lutropin^20M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge;LH 20M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12676-3;Lutropin^40M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --40 minutes post XXX challenge;LH 40M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12677-1;Lutropin^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;LH sp2 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12678-9;Lutropin^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;LH sp3 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12679-7;Lutropin^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;LH sp4 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12680-5;Lutropin^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;LH sp5 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12681-3;Lutropin^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;LH sp6 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +1268-2;NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated Not otherwise specified Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated Other Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +12682-1;Lutropin^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;LH sp7 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12683-9;Lutropin^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;LH sp8 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12684-7;Lutropin^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;LH sp9 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.34 +12685-4;Somatotropin^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;GH sp2 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12686-2;Somatotropin^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;GH sp3 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12687-0;Somatotropin^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;GH sp4 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12688-8;Somatotropin^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;GH sp5 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12689-6;Somatotropin^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;GH sp6 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +1269-0;NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated Not otherwise specified Ab [Presence] in Serum or Plasma from Donor;Deprecated Other Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +12690-4;Somatotropin^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;GH sp7 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12691-2;Somatotropin^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;GH sp8 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12692-0;Somatotropin^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;GH sp9 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12693-8;Somatotropin^10th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge;GH sp10 p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12694-6;Somatotropin^post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --post XXX challenge;GH p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12695-3;Somatotropin^15M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --15 minutes pre XXX challenge;GH 15M pre chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12696-1;Somatotropin^pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --pre XXX challenge;GH pre chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.73 +12697-9;Somatotropin^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;GH 10M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12698-7;Somatotropin^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;GH 15M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12699-5;Somatotropin^20M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge;GH 20M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12700-1;Somatotropin^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;GH 45M p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12701-9;Somatotropin^2.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge;GH 2.5h p chal SerPl-sCnc;;DISCOURAGED;1.0j-a;2.44 +12702-7;Antimony;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Antimony [Presence] in Serum or Plasma;Antimony SerPl Ql;;ACTIVE;1.0j-a;2.56 +12703-5;Gallium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gallium [Mass/volume] in Serum or Plasma;Gallium SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12704-3;Length;EntLen;Pt;Hair;Qn;;SPEC;1;Length of Hair;Length Hair Qn;;ACTIVE;1.0j-a;2.73 +12705-0;Strontium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Strontium [Mass/volume] in Urine;Strontium Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12706-8;Tellurium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tellurium [Mass/volume] in Serum or Plasma;Tellurium SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12707-6;Thorium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thorium [Mass/volume] in Serum or Plasma;Thorium SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1270-8;Unidentified Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Unidentified Ab [Presence] in Serum or Plasma;Unident Ab SerPl Ql;;ACTIVE;1.0;2.56 +12708-4;Tin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tin [Mass/volume] in Urine;Tin Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12709-2;Norastemizole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norastemizole [Mass/volume] in Serum or Plasma;Norastemizole SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +127-1;Cefsulodin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefsulodin [Susceptibility] by Minimum lethal concentration (MLC);Cefsulodin Islt MLC;;ACTIVE;1.0;2.19 +12710-0;Hemoglobin pattern;Imp;Pt;Bld;Nom;;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood;Hgb Fract Bld-Imp;;ACTIVE;1.0j-a;2.73 +12711-8;Hemoglobin A region;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin A region [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb A Reg Bld Ql Elph Alk;;ACTIVE;1.0j-a;2.73 +12712-6;Hemoglobin S+D+G region;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin S+D+G region [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb S+D+G Reg Bld Ql Elph Alk;;ACTIVE;1.0j-a;2.56 +12713-4;Hemoglobin C+E+O+A2 region;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin C+E+O+A2 region [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb C+E+O+A2 Bld Ql Elph Alk;;ACTIVE;1.0j-a;2.56 +12714-2;N-methylhistamine;MCnc;Pt;Urine;Qn;;CHEM;1;N-methylhistamine [Mass/volume] in Urine;Me-histamine Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12715-9;Homovanillate;MRat;Pt;Urine;Qn;;CHEM;1;Homovanillate [Mass/time] in Urine;HVA Ur-mRate;;DISCOURAGED;1.0j-a;2.73 +1271-6;O NOS Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated O group [Presence] [Presence] in Serum or Plasma from Blood product unit;Deprecated O Ab SerPl BPU Ql;;DEPRECATED;1.0;2.42 +12716-7;17-Hydroxyprogesterone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;17OHP sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12717-5;17-Hydroxyprogesterone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;17OHP sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12718-3;17-Hydroxyprogesterone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;17OHP sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12719-1;17-Hydroxyprogesterone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;17OHP sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12720-9;Hydroxyproline;MCnc;2H;Urine;Qn;;CHEM;1;Hydroxyproline [Mass/volume] in 2 hour Urine;OH-Proline 2h Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12721-7;Melatonin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Melatonin [Units/volume] in Serum or Plasma;Melatonin SerPl-aCnc;;DISCOURAGED;1.0j-a;2.73 +12722-5;Insulin-like growth factor binding protein 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor binding protein 1 [Mass/volume] in Serum or Plasma;IGF BP1 SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12723-3;Insulin-like growth factor binding protein 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor binding protein 2 [Mass/volume] in Serum or Plasma;IGF BP2 SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1272-4;O NOS Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated O group [Presence] in serum or plasma from donor;Deprecated O Ab SerPl Donr Ql;;DEPRECATED;1.0;2.42 +12724-1;Voltage-gated calcium channel Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Voltage-gated calcium channel IgG Ab [Units/volume] in Serum;VGCC IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +12725-8;IgA.secretory;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;IgA.secretory [Units/volume] in Serum or Plasma;SIgA SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12726-6;Leucine-enkephalin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Leucine-enkephalin [Units/volume] in Serum or Plasma;Leucine-Enkephalin SerPl-aCnc;;ACTIVE;1.0j-a;2.44 +12727-4;prednisoLONE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;prednisoLONE [Mass/volume] in Serum or Plasma;prednisoLONE SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12728-2;Alpha subunit;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha subunit [Units/volume] in Serum or Plasma;Alpha subunit SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12729-0;Interferon.gamma;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Interferon gamma [Units/volume] in Serum or Plasma;IGNF SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12730-8;Interferon.beta;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interferon beta [Units/volume] in Serum or Plasma;IFN-B SerPl-aCnc;;ACTIVE;1.0j-a;2.70 +12731-6;Interferon.alpha;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Interferon alpha [Units/volume] in Serum or Plasma;IFN-A SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +1273-2;O NOS Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated O group [Presence] in serum;Deprecated O Ab Ser Ql;;DEPRECATED;1.0;2.42 +12732-4;Interleukin 12;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 12 [Units/volume] in Serum or Plasma;Il12 SerPl-aCnc;;DISCOURAGED;1.0j-a;2.69 +12733-2;Tryptase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptase [Enzymatic activity/volume] in Serum or Plasma;Tryptase SerPl-cCnc;;ACTIVE;1.0j-a;2.73 +12734-0;Soluble liver Ab;ACnc;Pt;Ser;Qn;;SERO;1;Soluble liver Ab [Units/volume] in Serum;Soluble liver Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +12735-7;Collagen Ab;ACnc;Pt;Urine;Qn;;SERO;1;Collagen Ab [Units/volume] in Urine;Collagen Ab Ur-aCnc;;ACTIVE;1.0j-a;2.69 +12736-5;Hyaluronate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hyaluronate [Mass/volume] in Serum or Plasma;Hyaluronate SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12737-3;Endothelin;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Endothelin [Units/volume] in Serum or Plasma;Endothelin SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12738-1;Insulin^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --pre XXX challenge;Insulin pre chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12739-9;Insulin^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Insulin sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +1274-0;O NOS Ag;ACnc;Pt;RBC^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated O group [Presence] on Red Blood Cells from Blood product unit;Deprecated O Ag RBC BPU Ql;;DEPRECATED;1.0;2.42 +12740-7;Insulin^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Insulin sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12741-5;Insulin^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Insulin sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12742-3;Insulin^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Insulin sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12743-1;Insulin^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Insulin sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12744-9;Insulin^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Insulin sp7 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12745-6;Insulin^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Insulin sp8 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12746-4;Insulin^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Insulin sp9 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12747-2;Insulin^3.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --3.5 hours post XXX challenge;Insulin 3.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12748-0;Insulin^4.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --4.5 hours post XXX challenge;Insulin 4.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12749-8;Insulin^5.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --5.5 hours post XXX challenge;Insulin 5.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12750-6;Insulin^7H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --7 hours post XXX challenge;Insulin 7h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12751-4;Insulin^7.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --7.5 hours post XXX challenge;Insulin 7.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12752-2;Insulin^8H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --8 hours post XXX challenge;Insulin 8h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12753-0;Insulin^9H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --9 hours post XXX challenge;Insulin 9h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12754-8;Insulin^10H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --10 hours post XXX challenge;Insulin 10h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12755-5;Insulin^11H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --11 hour post XXX challenge;Insulin 11h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12756-3;Insulin^12H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --12 hours post XXX challenge;Insulin 12h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +1275-7;O NOS Ag;ACnc;Pt;RBC^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated O group [Presence] on Red Blood Cells from donor;Deprecated O Ag RBC Donr Ql;;DEPRECATED;1.0;2.42 +12757-1;Insulin^30M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --30 minutes pre XXX challenge;Insulin 30M pre chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12758-9;Insulin^15M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --15 minutes pre XXX challenge;Insulin 15M pre chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12759-7;Insulin^2M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --2 minutes post XXX challenge;Insulin 2M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12760-5;Insulin^4M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --4 minutes post XXX challenge;Insulin 4M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12761-3;Insulin^8M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --8 minutes post XXX challenge;Insulin 8M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12762-1;Insulin^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Insulin 15M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12763-9;Insulin^19M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --19 minutes post XXX challenge;Insulin 19M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12764-7;Insulin^22M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --22 minutes post XXX challenge;Insulin 22M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +1276-5;O NOS Ag;ACnc;Pt;RBC^Patient;Ord;Aggl RBC;BLDBK;1;Deprecated O group [Presence] on Red Blood Cells;Deprecated O Ag RBC Patient Ql;;DEPRECATED;1.0;2.42 +12765-4;Insulin^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;Insulin 40M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12766-2;Insulin^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Insulin 45M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12767-0;Insulin^50M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --50 minutes post XXX challenge;Insulin 50M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12768-8;Insulin^70M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --70 minutes post XXX challenge;Insulin 70M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12769-6;17-Ketosteroids.total neutral;MRat;24H;Urine;Qn;;CHEM;1;17-Ketosteroids.total neutral [Mass/time] in 24 hour Urine;17KS Neut 24h Ur-mRate;;ACTIVE;1.0j-a;2.73 +12770-4;Lead;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Lead [Mass/mass] in Tissue;Lead Tiss-mCnt;;ACTIVE;1.0j-a;2.40 +12771-2;Cholesterol.in HDL;PrThr;Pt;Ser/Plas;Ord;Electrophoresis;CHEM;1;Cholesterol in HDL [Presence] in Serum or Plasma by Electrophoresis;HDLc SerPl Ql Elph;;ACTIVE;1.0j-a;2.73 +12772-0;Cholesterol.in HDL;ACnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in HDL [Units/volume] in Serum or Plasma by Electrophoresis;HDLc SerPl Elph-aCnc;;ACTIVE;1.0j-a;2.69 +1277-3;P Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;P Ab [Presence] in Serum or Plasma from Blood product unit;P Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12773-8;Cholesterol.in LDL;ACnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in LDL [Units/volume] in Serum or Plasma by Electrophoresis;LDLc SerPl Elph-aCnc;;ACTIVE;1.0j-a;2.73 +12774-6;Mercury;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Red Blood Cells;Mercury RBC-mCnc;;ACTIVE;1.0j-a;2.73 +12775-3;Mercury;MCnc;Pt;Dentin;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Dentin;Mercury Dentin-mCnc;;ACTIVE;1.0j-a;2.34 +12776-1;Mucin-like carcinoma associated Ag;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Mucin-like carcinoma associated Ag [Units/volume] in Serum or Plasma;MCA Ag SerPl-aCnc;;ACTIVE;1.0j-a;2.68 +12777-9;Immunoglobulin light chains.kappa.free;ACnc;Pt;Urine;Qn;;CHEM;1;Kappa light chains.free [Units/volume] in Urine;Kappa LC Free Ur-aCnc;;DISCOURAGED;1.0j-a;2.69 +12778-7;Immunoglobulin light chains.lambda.free;ACnc;Pt;Urine;Qn;;CHEM;1;Lambda light chains.free [Units/volume] in Urine;Lambda LC Free Ur-aCnc;;DISCOURAGED;1.0j-a;2.69 +12779-5;Nickel;MRat;Pt;Urine;Qn;;DRUG/TOX;1;Nickel [Mass/time] in Urine;Nickel Ur-mRate;;DISCOURAGED;1.0j-a;2.73 +12780-3;Nickel;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Red Blood Cells;Nickel RBC-mCnc;;ACTIVE;1.0j-a;2.73 +1278-1;P Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;P Ab [Presence] in Serum or Plasma from Donor;P Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12781-1;Borrelia burgdorferi Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Borrelia burgdorferi Ab band pattern [Interpretation] in Serum by Immunoblot;B burgdor Ab Patrn Ser IB-Imp;;ACTIVE;1.0j-a;2.73 +12782-9;Protein fractions.oligoclonal bands;Imp;Pt;CSF;Nom;Electrophoresis;CHEM;1;Oligoclonal bands [Interpretation] in Cerebral spinal fluid by Electrophoresis;Oligoclonal Bands CSF Elph-Imp;;ACTIVE;1.0j-a;2.73 +12783-7;Protein fractions.oligoclonal bands;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Oligoclonal bands [Interpretation] in Serum or Plasma;Oligoclonal Bands SerPl-Imp;;ACTIVE;1.0j-a;2.73 +12784-5;Codeine.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Codeine Free [Mass/volume] in Serum or Plasma;Codeine Free SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12785-2;Dihydrocodeine.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dihydrocodeine Free [Mass/volume] in Serum or Plasma;DHC Free SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12786-0;HYDROcodone.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;HYDROcodone Free [Mass/volume] in Serum or Plasma;HYDROcodone Free SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12787-8;HYDROmorphone.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;HYDROmorphone Free [Mass/volume] in Serum or Plasma;HYDROmorphone Free SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12788-6;6-Monoacetylmorphine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Serum or Plasma;6MAM SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12789-4;oxyCODONE.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;oxyCODONE Free [Mass/volume] in Serum or Plasma;oxyCODONE Free SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12790-2;Oxalate^2nd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --2nd specimen post XXX challenge;Oxalate sp2 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12791-0;Oxalate^3rd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --3rd specimen post XXX challenge;Oxalate sp3 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12792-8;Oxalate^4th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --4th specimen post XXX challenge;Oxalate sp4 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12793-6;Oxalate^5th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --5th specimen post XXX challenge;Oxalate sp5 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12794-4;Oxalate^6th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --6th specimen post XXX challenge;Oxalate sp6 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12795-1;Oxalate^7th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --7th specimen post XXX challenge;Oxalate sp7 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12796-9;Oxalate^8th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --8th specimen post XXX challenge;Oxalate sp8 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12797-7;Oxalate^9th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --9th specimen post XXX challenge;Oxalate sp9 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +12798-5;Oxalate^10th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Oxalate [Mass/volume] in Urine --10th specimen post XXX challenge;Oxalate sp10 p chal Ur-mCnc;;ACTIVE;1.0j-a;2.40 +1279-9;P Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;P Ab [Presence] in Serum or Plasma;P Ab SerPl Ql;;ACTIVE;1.0;2.56 +12799-3;Parathyrin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Parathyrin Ab [Units/volume] in Serum;PTH Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +12800-9;Trimeprazine;MCnc;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Deprecated Trimeprazine;Deprecated Trimeprazine SerPl Ql;;DEPRECATED;1.0j-a;2.34 +12801-7;Methdilazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methdilazine [Mass/volume] in Serum or Plasma;Methdilazine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12802-5;Propiomazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propiomazine [Mass/volume] in Serum or Plasma;Propiomazine SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12803-3;Phenylalanine;PrThr;Pt;Bld;Ord;Guthrie test;CHEM;1;Phenylalanine [Presence] in Blood by Guthrie test;Phe Bld Ql Guthrie;;ACTIVE;1.0j-a;2.73 +12804-1;Acid phosphatase;CCnc;Pt;Body fld;Qn;;CHEM;1;Acid phosphatase [Enzymatic activity/volume] in Body fluid;ACP Fld-cCnc;;ACTIVE;1.0j-a;2.68 +12805-8;Alkaline phosphatase isoenzyme;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase isoenzyme [Units/volume] in Serum or Plasma;ALP Iso SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12806-6;Alkaline phosphatase.lung;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.lung [Enzymatic activity/volume] in Serum or Plasma;ALP Lung SerPl-cCnc;;ACTIVE;1.0j-a;2.68 +1280-7;P NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated P NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated P NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +12807-4;Phosphoserine;MCnc;Pt;CSF;Qn;;CHEM;1;Phosphoserine [Mass/volume] in Cerebral spinal fluid;Phosphoserine CSF-mCnc;;ACTIVE;1.0j-a;2.44 +12808-2;Uroporphyrin;MRat;Pt;Urine;Qn;;CHEM;1;Uroporphyrin [Mass/time] in Urine;Uropor Ur-mRate;;DISCOURAGED;1.0j-a;2.46 +12809-0;Coproporphyrin;MRat;Pt;Urine;Qn;;CHEM;1;Coproporphyrin [Mass/time] in Urine;Copro Ur-mRate;;DISCOURAGED;1.0j-a;2.46 +12810-8;Porphobilinogen deaminase;CCnc;Pt;Bld;Qn;;CHEM;1;Porphobilinogen deaminase [Enzymatic activity/volume] in Blood;PBG Deaminase Bld-cCnc;;ACTIVE;1.0j-a;2.66 +12811-6;Uroporphyrinogen III synthase;CCnc;Pt;Bld;Qn;;CHEM;1;Uroporphyrinogen III synthase [Enzymatic activity/volume] in Blood;URO-S Bld-cCnc;;ACTIVE;1.0j-a;2.68 +12812-4;Potassium^2nd specimen;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Potassium [Moles/volume] in Serum or Plasma --2nd specimen;Potassium sp2 SerPl-sCnc;;ACTIVE;1.0j-a;2.40 +12813-2;Potassium^3rd specimen;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Potassium [Moles/volume] in Serum or Plasma --3rd specimen;Potassium sp3 SerPl-sCnc;;ACTIVE;1.0j-a;2.40 +12814-0;Potassium;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Potassium [Moles/volume] in Vitreous fluid;Potassium Vitf-sCnc;;ACTIVE;1.0j-a;2.34 +1281-5;P NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated P NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated P NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +12815-7;Progesterone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Progest sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12816-5;Progesterone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Progest sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12817-3;Progesterone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Progest sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12818-1;Progesterone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Progest sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12819-9;Progesterone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Progest sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12820-7;Progesterone;MCnc;24H;Urine;Qn;;CHEM;1;Progesterone [Mass/volume] in 24 hour Urine;Progest 24h Ur-mCnc;;ACTIVE;1.0j-a;2.34 +12821-5;Progesterone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Progest 30M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12822-3;Progesterone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Progest 1h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1282-3;P NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated P NOS Ab [Presence] in Serum or Plasma;Deprecated P NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +12823-1;Prolactin^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Prolactin sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12824-9;Prolactin^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Prolactin sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12825-6;Prolactin^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Prolactin sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12826-4;Prolactin^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Prolactin sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12827-2;Prolactin^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Prolactin sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12828-0;Prolactin^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Prolactin sp7 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12829-8;Prolactin^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Prolactin sp8 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12830-6;Prolactin^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Prolactin sp9 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1283-1;P NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated P NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated P NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +12831-4;Prolactin^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;Prolactin sp10 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12832-2;Prolactin^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Prolactin 10M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12833-0;Prolactin^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Prolactin 20M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12834-8;Prolactin^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Prolactin 15M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12835-5;Prolactin^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Prolactin 45M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12836-3;Prostaglandin E2;MCnc;24H;Urine;Qn;;CHEM;1;Prostaglandin E2 [Mass/volume] in 24 hour Urine;Prostaglandin E2 24h Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12837-1;Prostaglandin E1;MCnc;24H;Urine;Qn;;CHEM;1;Prostaglandin E1 [Mass/volume] in 24 hour Urine;Prostaglandin E1 24h Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12838-9;Prostaglandin D2;MCnc;Pt;Urine;Qn;;CHEM;1;Prostaglandin D2 [Mass/volume] in Urine;Prostaglandin D2 Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12839-7;Prostaglandin D2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostaglandin D2 [Mass/volume] in Serum or Plasma;Prostaglandin D2 SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12840-5;Prostaglandin F2 alpha;SCnc;Pt;Urine;Qn;;CHEM;1;Prostaglandin F2 alpha [Moles/volume] in Urine;Prostaglandin F2A Ur-sCnc;;ACTIVE;1.0j-a;2.42 +12841-3;Prostate specific Ag.free/Prostate specific Ag.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma;PSA Free MFr SerPl;;ACTIVE;1.0j-a;2.73 +12842-1;Protein;MCnc;12H;Urine;Qn;;CHEM;1;Protein [Mass/volume] in 12 hour Urine;Prot 12h Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12843-9;Protein;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid;Prot DiafP-mCnc;;ACTIVE;1.0j-a;2.34 +12844-7;Protein^2nd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid --2nd specimen;Prot sp2 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12845-4;Protein^3rd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid --3rd specimen;Prot sp3 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12846-2;Protein^4th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid --4th specimen;Prot sp4 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12847-0;Protein^5th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid --5th specimen;Prot sp5 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12848-8;Protein^6th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid --6th specimen;Prot sp6 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +1284-9;P NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated P NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated P NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +12849-6;Protein^7th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid --7th specimen;Prot sp7 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12850-4;Protein^8th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal dialysis fluid --8th specimen;Prot sp8 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12851-2;Protein pattern;Imp;Pt;Ser/Plas;Nom;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in Serum or Plasma by Electrophoresis;Prot Pattern SerPl Elph-Imp;;ACTIVE;1.0j-a;2.73 +12852-0;Bovine inner ear Ag;PrThr;Pt;Ser/Plas;Ord;IB;SERO;1;Bovine inner ear Ag [Presence] in Serum or Plasma by Immunoblot;Bov Inner Ear Ag SerPl Ql IB;;ACTIVE;1.0j-a;2.58 +12853-8;Purkinje cells Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Purkinje cells Ab [Presence] in Serum by Immunoblot;Purkinje Cells Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12854-6;Neuronal nuclear type 1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Neuronal nuclear type 1 Ab [Units/volume] in Serum;Hu1 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +12855-3;HIV 1 p23 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p23 Ab [Presence] in Serum by Immunoblot;HIV1 p23 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +1285-6;P NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated P NOS Ag [Presence] on Red Blood Cells;Deprecated P NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +12856-1;HIV 1 p65 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p65 Ab [Presence] in Serum by Immunoblot;HIV1 p65 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12857-9;HIV 1 p28 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p28 Ab [Presence] in Serum by Immunoblot;HIV1 p28 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12858-7;HIV 1 p32 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p32 Ab [Presence] in Serum by Immunoblot;HIV1 p32 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12859-5;HIV 1 p18 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p18 Ab [Presence] in Serum by Immunoblot;HIV1 p18 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12860-3;Borrelia burgdorferi 39kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor39kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.73 +12861-1;Borrelia burgdorferi 88kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 88kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor88kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.58 +12862-9;Borrelia burgdorferi 66kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 66kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor66kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.73 +12863-7;Borrelia burgdorferi 41kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor41kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.73 +1286-4;P1 Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;P1 Ab [Presence] in Serum or Plasma from Blood product unit;P1 Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +12864-5;Borrelia burgdorferi 25kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 25kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor25kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.58 +12865-2;Borrelia burgdorferi 29kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 29kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor29kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.58 +12866-0;Borrelia burgdorferi 18kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 18kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor18kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.73 +12867-8;Borrelia burgdorferi 58kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 58kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor58kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.73 +12868-6;Borrelia burgdorferi 47kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 47kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor47kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.58 +12869-4;Borrelia burgdorferi 30kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 30kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor30kD Ab CSF Ql IB;;ACTIVE;1.0j-a;2.73 +12870-2;HIV 1 gp34 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp34 Ab [Presence] in Serum by Immunoblot;HIV1 gp34 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12871-0;HIV 1 p26 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p26 Ab [Presence] in Serum by Immunoblot;HIV1 p26 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +1287-2;P1 Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;P1 Ab [Presence] in Serum or Plasma from Donor;P1 Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +12872-8;HIV 1 p15 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p15 Ab [Presence] in Serum by Immunoblot;HIV1 p15 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12873-6;Borrelia burgdorferi 88kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 88kD Ab [Presence] in Serum by Immunoblot;B burgdor88kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12874-4;Borrelia burgdorferi 93kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 93kD Ab [Presence] in Serum by Immunoblot;B burgdor93kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12875-1;HIV 1 p64 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p64 Ab [Presence] in Serum by Immunoblot;HIV1 p64 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12876-9;HIV 1 p53 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p53 Ab [Presence] in Serum by Immunoblot;HIV1 p53 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12877-7;Borrelia burgdorferi 47kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 47kD Ab [Presence] in Serum by Immunoblot;B burgdor47kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12878-5;Borrelia burgdorferi 29kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 29kD Ab [Presence] in Serum by Immunoblot;B burgdor29kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12879-3;Borrelia burgdorferi 25kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 25kD Ab [Presence] in Serum by Immunoblot;B burgdor25kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +1288-0;P1 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;P1 Ab [Presence] in Serum or Plasma;P1 Ab SerPl Ql;;ACTIVE;1.0;2.56 +12880-1;Borrelia burgdorferi 58kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 58kD Ab [Presence] in Body fluid by Immunoblot;B burgdor58kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.73 +12881-9;Borrelia burgdorferi 47kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 47kD Ab [Presence] in Body fluid by Immunoblot;B burgdor47kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.58 +12882-7;Borrelia burgdorferi 29kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 29kD Ab [Presence] in Body fluid by Immunoblot;B burgdor29kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.58 +12883-5;Borrelia burgdorferi 18kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 18kD Ab [Presence] in Body fluid by Immunoblot;B burgdor18kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.73 +12884-3;Borrelia burgdorferi 39kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD Ab [Presence] in Body fluid by Immunoblot;B burgdor39kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.73 +12885-0;Borrelia burgdorferi 88kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 88kD Ab [Presence] in Body fluid by Immunoblot;B burgdor88kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.58 +12886-8;Borrelia burgdorferi 66kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 66kD Ab [Presence] in Body fluid by Immunoblot;B burgdor66kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.73 +12887-6;Borrelia burgdorferi 41kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD Ab [Presence] in Body fluid by Immunoblot;B burgdor41kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.73 +12888-4;Borrelia burgdorferi 25kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 25kD Ab [Presence] in Body fluid by Immunoblot;B burgdor25kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.58 +12889-2;Borrelia burgdorferi 30kD Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi 30kD Ab [Presence] in Body fluid by Immunoblot;B burgdor30kD Ab Fld Ql IB;;ACTIVE;1.0j-a;2.73 +128-9;Cefsulodin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefsulodin [Susceptibility] by Minimum inhibitory concentration (MIC);Cefsulodin Islt MIC;;ACTIVE;1.0;2.19 +12890-0;Borrelia burgdorferi 45kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 45kD Ab [Presence] in Serum by Immunoblot;B burgdor45kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12891-8;Borrelia burgdorferi 41kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD Ab [Presence] in Serum by Immunoblot;B burgdor41kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12892-6;Borrelia burgdorferi 30kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 30kD Ab [Presence] in Serum by Immunoblot;B burgdor30kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12893-4;HIV 1 gp105 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp105 Ab [Presence] in Serum by Immunoblot;HIV1 gp105 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12894-2;HIV 1 p68 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p68 Ab [Presence] in Serum by Immunoblot;HIV1 p68 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12895-9;HIV 1 p58 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p58 Ab [Presence] in Serum by Immunoblot;HIV1 p58 Ab Ser Ql IB;;ACTIVE;1.0j-a;2.58 +12896-7;Borrelia burgdorferi 58kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 58kD Ab [Presence] in Serum by Immunoblot;B burgdor58kD Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +12897-5;Myelin associated glycoprotein Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Myelin associated glycoprotein Ab [Presence] in Cerebral spinal fluid by Immunoblot;MAG Ab CSF Ql IB;;ACTIVE;1.0j-a;2.58 +1289-8;P1 Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;P1 Ag [Presence] on Red Blood Cells from Blood product unit;P1 Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +12898-3;Chloride;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Chloride [Moles/volume] in Vitreous fluid;Chloride Vitf-sCnc;;ACTIVE;1.0j-a;2.34 +12899-1;Acetylene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetylene [Mass/volume] in Serum or Plasma;Acetylene SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +12900-7;Renin^2nd specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --2nd specimen post XXX challenge;Renin sp2 p chal Plas-cCnc;;ACTIVE;1.0j-a;2.73 +12901-5;Renin^3rd specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --3rd specimen post XXX challenge;Renin sp3 p chal Plas-cCnc;;ACTIVE;1.0j-a;2.73 +12902-3;Renin^4th specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --4th specimen post XXX challenge;Renin sp4 p chal Plas-cCnc;;ACTIVE;1.0j-a;2.73 +12903-1;Renin^5th specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --5th specimen post XXX challenge;Renin sp5 p chal Plas-cCnc;;ACTIVE;1.0j-a;2.73 +12904-9;Renin^6th specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --6th specimen post XXX challenge;Renin sp6 p chal Plas-cCnc;;ACTIVE;1.0j-a;2.73 +12905-6;Renin^7th specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --7th specimen post XXX challenge;Renin sp7 p chal Plas-cCnc;;ACTIVE;1.0j-a;2.73 +1290-6;P1 Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;P1 Ag [Presence] on Red Blood Cells from Donor;P1 Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +12906-4;Renin^8th specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --8th specimen post XXX challenge;Renin sp8 p chal Plas-cCnc;;ACTIVE;1.0j-a;2.73 +12907-2;Sodium;SCnc;Pt;RBC;Qn;;CHEM;1;Sodium [Moles/volume] in Red Blood Cells;Sodium RBC-sCnc;;ACTIVE;1.0j-a;2.34 +12908-0;Sodium;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Sodium [Moles/volume] in Vitreous fluid;Sodium Vitf-sCnc;;ACTIVE;1.0j-a;2.34 +12909-8;Insulin-like growth factor-I^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;IGF-I 30M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12910-6;Insulin-like growth factor-I^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;IGF-I 1h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12911-4;Insulin-like growth factor-I^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;IGF-I 1.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +12912-2;Lipids;MCnc;Pt;Body fld;Qn;;CHEM;1;Lipids [Mass/volume] in Body fluid;Lipids Fld-mCnc;;ACTIVE;1.0j-a;2.42 +12913-0;Beta-N-acetylhexosaminidase;CCnc;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/volume] in Leukocytes;B-NAH WBC-cCnc;;ACTIVE;1.0j-a;2.73 +1291-4;P1 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;P1 Ag [Presence] on Red Blood Cells;P1 Ag RBC Ql;;ACTIVE;1.0;2.56 +12914-8;Beta-N-acetylhexosaminidase.A/Beta-N-acetylhexosaminidase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A/Beta-n-acetylhexosaminidase.total in Serum or Plasma;Hexosaminidase A CFr SerPl;;ACTIVE;1.0j-a;2.73 +12915-5;Beta galactosidase;CCnc;Pt;WBC;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/volume] in Leukocytes;B-Galactosidase WBC-cCnc;;ACTIVE;1.0j-a;2.73 +12916-3;Porphobilinogen synthase;CCnc;Pt;Bld;Qn;;CHEM;1;Porphobilinogen synthase [Enzymatic activity/volume] in Blood;PBG Synthase Bld-cCnc;;ACTIVE;1.0j-a;2.73 +12917-1;Porphobilinogen synthase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Porphobilinogen synthase [Enzymatic activity/volume] in Serum or Plasma;PBG Synthase SerPl-cCnc;;ACTIVE;1.0j-a;2.68 +12918-9;Monoamine oxidase;CCnc;Pt;PRP;Qn;;CHEM;1;Monoamine oxidase [Enzymatic activity/volume] in Platelet rich plasma;Monoamine Oxidase PRP-cCnc;;ACTIVE;1.0j-a;2.68 +12919-7;Monoamine oxidase;CCnc;Pt;Bld;Qn;;CHEM;1;Monoamine oxidase [Enzymatic activity/volume] in Blood;Monoamine Oxidase Bld-cCnc;;ACTIVE;1.0j-a;2.68 +12920-5;Sulfate;MCnc;24H;Urine;Qn;;CHEM;1;Sulfate [Mass/volume] in 24 hour Urine;Sulfate 24h Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12921-3;Testosterone^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Testost 3h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +1292-2;P2 Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated P2 Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated P2 Ab SerPl BPU Ql;;DEPRECATED;1.0;2.40 +12922-1;Testosterone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Testost 1h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.58 +12923-9;Thyroxine^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;T4 sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12924-7;Thyroxine^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;T4 sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12925-4;Thyroxine^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;T4 sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12926-2;Thyroxine^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;T4 sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12927-0;Thyroxine^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;T4 sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12928-8;Thyroxine^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;T4 sp7 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12929-6;Thyroxine^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;T4 sp8 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +1293-0;P2 Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated P2 Ab [Presence] on Red Blood Cells from donor;Deprecated P2 Ab SerPl Donr Ql;;DEPRECATED;1.0;2.40 +12930-4;Thyroxine^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;T4 sp9 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12931-2;Thyroxine^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;T4 1h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12932-0;Thyrotropin^post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --post XXX challenge;TSH p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12933-8;Thyrotropin^10M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --10 minutes post XXX challenge;TSH 10M p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12934-6;Thyrotropin^15M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --15 minutes post XXX challenge;TSH 15M p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12935-3;Thyrotropin^20M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --20 minutes post XXX challenge;TSH 20M p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12936-1;Thyrotropin^40M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --40 minutes post XXX challenge;TSH 40M p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12937-9;Thyrotropin^45M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --45 minutes post XXX challenge;TSH 45M p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12938-7;Thyrotropin^1.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1.5 hours post XXX challenge;TSH 1.5h p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12939-5;Thyrotropin^2H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --2 hours post XXX challenge;TSH 2h p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12940-3;Thyrotropin^30M pre XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --30 minutes pre XXX challenge;TSH 30M pre chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12941-1;Thyrotropin^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge;TSH sp2 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12942-9;Thyrotropin^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge;TSH sp3 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12943-7;Thyrotropin^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --4th specimen post XXX challenge;TSH sp4 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12944-5;Thyrotropin^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --5th specimen post XXX challenge;TSH sp5 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12945-2;Thyrotropin^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --6th specimen post XXX challenge;TSH sp6 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12946-0;Thyrotropin^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --7th specimen post XXX challenge;TSH sp7 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +12947-8;Thyrotropin^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --8th specimen post XXX challenge;TSH sp8 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +1294-8;P2 Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated P2 Ab;Deprecated P2 Ab Ser Ql;;DEPRECATED;1.0;2.36 +12948-6;Thyrotropin^9th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --9th specimen post XXX challenge;TSH sp9 p chal SerPl-aCnc;;ACTIVE;1.0j-a;2.36 +12949-4;Transferrin.carbohydrate deficient;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient [Mass/volume] in Serum or Plasma;CDT SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12950-2;Triglyceride;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Triglyceride [Mass/volume] in Body fluid;Deprecated Trigl Fld-mCnc;;DEPRECATED;1.0j-a;2.36 +12951-0;Triglyceride;MCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Triglyceride [Mass/volume] in Serum or Plasma by calculation;Trigl SerPl Calc-mCnc;;ACTIVE;1.0j-a;2.73 +12952-8;Thyroxine uptake^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Thyroxine (T4) uptake [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Deprecated T4U 1h p chal SerPl-mCnc;;DEPRECATED;1.0j-a;2.48 +12953-6;Triiodothyronine^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;T3 sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12954-4;Triiodothyronine^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;T3 sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1295-5;P2 Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated P2 Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated P2 Ag RBC BPU Ql;;DEPRECATED;1.0;2.63 +12955-1;Triiodothyronine^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;T3 sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12956-9;Triiodothyronine^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;T3 sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12957-7;Triiodothyronine^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;T3 sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12958-5;Triiodothyronine^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;T3 sp7 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12959-3;Triiodothyronine^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;T3 sp8 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12960-1;Alpha 1 antitrypsin fecal clearance;ACnc;Pt;Ser/Plas+Stool;Qn;;CHEM;1;Alpha 1 antitrypsin fecal clearance;A1AT Cl SerPl+Stl-aCnc;;ACTIVE;1.0j-a;2.69 +12961-9;Urea nitrogen;MCnc;Pt;BldA;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Arterial blood;BUN BldA-mCnc;;ACTIVE;1.0j-a;2.73 +12962-7;Urea nitrogen;MCnc;Pt;BldV;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Venous blood;BUN BldV-mCnc;;ACTIVE;1.0j-a;2.73 +1296-3;P2 Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated P2 Ag [Presence] on Red Blood Cells from Donor;Deprecated P2 Ag RBC Donr Ql;;DEPRECATED;1.0;2.63 +12963-5;Urea nitrogen;MCnc;Pt;BldP;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peripheral blood;BUN BldP-mCnc;;ACTIVE;1.0j-a;2.73 +12964-3;Urea nitrogen^baseline;MCnc;Pt;Bld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Blood --baseline;BUN BS Bld-mCnc;;ACTIVE;1.0j-a;2.40 +12965-0;Urea nitrogen^70M specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Serum or Plasma --70 minute specimen;BUN 70M spec SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12966-8;Urea nitrogen^2H specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Serum or Plasma --2 hour specimen;BUN 2h spec SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +12967-6;Urea nitrogen;MCnc;24H;Urine;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in 24 hour Urine;UUN 24h Ur-mCnc;;ACTIVE;1.0j-a;2.73 +12968-4;Urea nitrogen^4H specimen;MCnc;Pt;Dial fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Dialysis fluid --4 hour specimen;Urea nit 4h spec Dial fld-mCnc;;ACTIVE;1.0j-a;2.42 +12969-2;Urea nitrogen^baseline;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --baseline;Urea nit BS DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +129-7;Cefsulodin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefsulodin [Susceptibility] by Disk diffusion (KB);Cefsulodin Islt KB;;ACTIVE;1.0;2.19 +12970-0;Urea nitrogen^2H dwell specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --2 hour dwell specimen;Urea nit 2H dwell spec DiafP-mCnc;;ACTIVE;1.0j-a;2.54 +1297-1;P2 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated P2 Ag [Presence] on Red Blood Cells;Deprecated P2 Ag RBC Ql;;DEPRECATED;1.0;2.63 +12971-8;Urea nitrogen^4H dwell specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --4 hour dwell specimen;Urea nit 4H dwell spec DiafP-mCnc;;ACTIVE;1.0j-a;2.54 +12972-6;Urea nitrogen^1st specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --1st specimen;Urea nit sp1 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12973-4;Urea nitrogen^4th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --4th specimen;Urea nit sp4 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12974-2;Urea nitrogen^3rd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --3rd specimen;Urea nit sp3 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12975-9;Urea nitrogen^5th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --5th specimen;Urea nit sp5 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12976-7;Urea nitrogen^6th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --6th specimen;Urea nit sp6 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12977-5;Urea nitrogen^8th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --8th specimen;Urea nit sp8 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12978-3;Urea nitrogen^7th specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --7th specimen;Urea nit sp7 DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12979-1;Urea nitrogen^24H specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --24 hour specimen;Urea nit 24h sp DiafP-mCnc;;ACTIVE;1.0j-a;2.42 +12980-9;Urate;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Urate [Mass/volume] in Body fluid;Deprecated Urate Fld-mCnc;;DEPRECATED;1.0j-a;2.36 +12981-7;Urea nitrogen^post dialysis/pre dialysis;MRto;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass Ratio] in Peritoneal dialysis fluid --post dialysis/pre dialysis;Urea nit post/pre dialysis DiafP;;ACTIVE;1.0j-a;2.42 +12982-5;Vasopressin^2nd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Mass/volume] in Plasma --2nd specimen post XXX challenge;Vasopressin sp2 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +12983-3;Volatiles;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Volatiles and gases [Identifier] in Urine;Volatiles Ur;;ACTIVE;1.0j-a;2.73 +12984-1;2,4 toluenediamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2,4 toluenediamine [Mass/volume] in Blood;2,4Toluenediam Bld-mCnc;;ACTIVE;1.0j-a;2.42 +12985-8;2,6 toluenediamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2,6 toluenediamine [Mass/volume] in Blood;2,6Toluenediam Bld-mCnc;;ACTIVE;1.0j-a;2.42 +12986-6;2,5-Hexanedione;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2,5-Hexanedione [Mass/volume] in Blood;2,5Hexanedione Bld-mCnc;;ACTIVE;1.0j-a;2.42 +12987-4;Acetonitrile;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetonitrile [Mass/volume] in Urine;Acetonitrile Ur-mCnc;;ACTIVE;1.0j-a;2.42 +12988-2;Acrylamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acrylamide [Mass/volume] in Blood;Acrylamide Bld-mCnc;;ACTIVE;1.0j-a;2.42 +1298-9;Packed erythrocytes given;Vol;Pt;Dose;Qn;;BLDBK;1;Packed erythrocytes given [Volume];Packed RBC Gvn Vol Dose;;ACTIVE;1.0;2.42 +12989-0;Allyl alcohol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Allyl alcohol [Mass/volume] in Serum or Plasma;Allyl Alc SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12990-8;Polychlorinated biphenyl.Aroclor 1260;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Polychlorinated biphenyl.Aroclor 1260 [Mass/volume] in Serum or Plasma;PCB Aroclor1260 SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12991-6;Polychlorinated biphenyl.Aroclor 1254;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Polychlorinated biphenyl.Aroclor 1254 [Mass/volume] in Serum or Plasma;PCB Aroclor1254 SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12992-4;Isobutane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isobutane [Mass/volume] in Blood;Isobutane Bld-mCnc;;ACTIVE;1.0j-a;2.34 +12993-2;Hydrocarbons.chlorinated;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Hydrocarbons.chlorinated [Identifier] in Blood;Chlor HC Bld;;ACTIVE;1.0j-a;2.15 +12994-0;Oxychlordane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Oxychlordane [Mass/volume] in Blood;Oxychlordane Bld-mCnc;;ACTIVE;1.0j-a;2.73 +12995-7;Cyclohexanone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cyclohexanone [Mass/volume] in Blood;Cyclohexanone Bld-mCnc;;ACTIVE;1.0j-a;2.73 +12996-5;Dichlorodifluoroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dichlorodifluoroethane [Mass/volume] in Blood;DCDFE Bld-mCnc;;ACTIVE;1.0j-a;2.73 +1299-7;Platelets given;Vol;Pt;Dose;Qn;;BLDBK;1;Platelets given [Volume];Platelet Gvn Vol Dose;;ACTIVE;1.0;2.42 +12997-3;1,4-Dioxane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,4-Dioxane [Mass/volume] in Serum or Plasma;1,4Dioxane SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +12998-1;Methylene chloride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methylene chloride [Mass/volume] in Blood;DCM Bld-mCnc;;ACTIVE;1.0j-a;2.73 +12999-9;Epichlorohydrin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Epichlorohydrin [Mass/volume] in Serum or Plasma;Epichlorohydrin SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13000-5;Mandelate;MCnc;Pt;Urine;Qn;;CHEM;1;Mandelate [Mass/volume] in Urine;Mandelate Ur-mCnc;;ACTIVE;1.0j-a;2.73 +13001-3;Mandelate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Mandelate/Creatinine [Mass Ratio] in Urine;Mandelate/Creat Ur;;ACTIVE;1.0j-a;2.73 +13002-1;Mesityl oxide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Mesityl oxide [Mass/volume] in Blood;Mesityl Oxide Bld-mCnc;;ACTIVE;1.0j-a;2.73 +1300-3;PP1 Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated PP1 Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated PP1 Ab SerPl BPU Ql;;DEPRECATED;1.0;2.40 +13003-9;Hydrocarbons.halogenated;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Halogenated organic molecules [Identifier] in Blood;Halog HC Bld;;ACTIVE;1.0j-a;2.15 +13004-7;Hydrocarbons.halogenated.volatile;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Hydrocarbons.halogenated.volatile [Identifier] in Blood;Vol Halog HC Bld;;ACTIVE;1.0j-a;2.73 +13005-4;2,4,5-Trichlorophenoxyacetate;Type;Pt;Ser/Plas;Nom;;DRUG/TOX;1;2,4,5-Trichlorophenoxyacetate [Type] in Serum or Plasma;2,4,5T SerPl;;ACTIVE;1.0j-a;2.15 +13006-2;1,4-Dichlorobenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,4-Dichlorobenzene [Mass/volume] in Serum or Plasma;1,4DCB SerPl-mCnc;;ACTIVE;1.0j-a;2.42 +13007-0;Ethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethane [Mass/volume] in Blood;Ethane Bld-mCnc;;ACTIVE;1.0j-a;2.34 +13008-8;Methyl propyl ketone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methyl propyl ketone [Mass/volume] in Blood;MPK Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13009-6;Methyl ethyl ketone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl ethyl ketone [Mass/volume] in Urine;MEK Ur-mCnc;;ACTIVE;1.0j-a;2.73 +13010-4;Methyl amyl ketone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methyl amyl ketone [Mass/volume] in Blood;MAK Bld-mCnc;;ACTIVE;1.0j-a;2.73 +1301-1;PP1 Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated PP1 Ab [Presence] serum or plasma from donor;Deprecated PP1 Ab SerPl Donr Ql;;DEPRECATED;1.0;2.40 +13011-2;Methyl ethyl ketone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methyl ethyl ketone [Mass/volume] in Blood;MEK Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13012-0;Methyl isoamyl ketone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methyl isoamyl ketone [Mass/volume] in Blood;MIAK Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13013-8;Methyl isobutyl ketone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methyl isobutyl ketone [Mass/volume] in Blood;MIBK Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13014-6;Methyl butyl ketone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methyl butyl ketone [Mass/volume] in Blood;MNBK Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13015-3;Diisobutylketone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Diisobutylketone [Mass/volume] in Blood;Diisobutylketone Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13016-1;Nitrophenol;ACnc;Pt;Bld;Qn;;DRUG/TOX;1;Nitrophenol [Units/volume] in Blood;Nitrophenol Bld-aCnc;;ACTIVE;1.0j-a;2.69 +13017-9;Perchloroethylene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Tetrachloroethylene [Mass/volume] in Blood;Deprecated Perchloroethylene Bld-mCnc;;DEPRECATED;1.0j-a;2.36 +13018-7;Pesticides;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Pesticides [Identifier] in Urine;Pesticides Ur;;ACTIVE;1.0j-a;2.73 +13019-5;Pesticides;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Pesticides [Identifier] in Serum or Plasma;Pesticides SerPl;;ACTIVE;1.0j-a;2.73 +13020-3;Pesticides;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Pesticides [Identifier] in Blood;Pesticides Bld;;ACTIVE;1.0j-a;2.68 +13021-1;Pesticides;Prid;Pt;Gast fld;Nom;;DRUG/TOX;1;Pesticides [Identifier] in Gastric fluid;Pesticides Gast;;ACTIVE;1.0j-a;2.19 +13022-9;Propane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Propane [Mass/volume] in Blood;Propane Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13023-7;Trichlorofluoromethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichlorofluoromethane [Mass/volume] in Blood;TCFM Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13024-5;Trichlorofluoroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichlorofluoroethane [Mass/volume] in Blood;TCFE Bld-mCnc;;ACTIVE;1.0j-a;2.42 +13025-2;Trichlorotrifluoroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichlorotrifluoroethane [Mass/volume] in Blood;TCTFE Bld-mCnc;;ACTIVE;1.0j-a;2.73 +13026-0;Orthocresol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Orthocresol [Mass/volume] in Urine;Orthocresol Ur-mCnc;;ACTIVE;1.0j-a;2.73 +13027-8;Ethyl acetate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethyl acetate [Mass/volume] in Serum or Plasma;Ethyl Acetate SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13028-6;Xylose^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Xylose 1.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +1302-9;PP1 Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated PP1 Ab;Deprecated PP1 Ab Ser Ql;;DEPRECATED;1.0;2.36 +13029-4;Xylose^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Xylose 3h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.40 +13030-2;Xylose^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;Xylose 4h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13031-0;Xylose^5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --5 hours post XXX challenge;Xylose 5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13032-8;C peptide^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;C peptide sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13033-6;C peptide^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;C peptide sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13034-4;C peptide^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;C peptide sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13035-1;C peptide^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;C peptide sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13036-9;C peptide^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;C peptide sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1303-7;Reverse ABO group;Type;Pt;Bld;Nom;;BLDBK;1;Reverse ABO group [Type];Reverse ABO Group Bld;;ACTIVE;1.0;2.73 +13037-7;C peptide^post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --fasting;C peptide p fast SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13038-5;C peptide^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;C peptide 30M p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13039-3;C peptide^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;C peptide 1h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13040-1;C peptide^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;C peptide 1.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13041-9;C peptide^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;C peptide 2h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13042-7;C peptide^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;C peptide 2.5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13043-5;C peptide^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;C peptide 3h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13044-3;C peptide^5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --5 hours post XXX challenge;C peptide 5h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +1304-5;D Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;D Ab [Titer] in Serum or Plasma;D Ab Titr SerPl;;ACTIVE;1.0;2.73 +13045-0;C peptide^6H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --6 hours post XXX challenge;C peptide 6h p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13046-8;Lymphocytes.variant/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Blood;Variant Lymphs/leuk NFr Bld;;ACTIVE;1.0j-a;2.73 +13047-6;Plasma cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Plasma cells/100 leukocytes in Blood;Plasma Cells/leuk NFr Bld;;ACTIVE;1.0j-a;2.73 +13048-4;Sezary cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Sezary cells [Presence] in Blood by Light microscopy;Sezary Cells Bld Ql Smear;;ACTIVE;1.0j-a;2.56 +13049-2;von Willebrand factor Ag;ACnc;Pt;PPP;Qn;Imm;COAG;1;Deprecated von Willebrand factor (vWf) Ag [Units/volume] in Platelet poor plasma by Immunologic method;Deprecated vWF:Ag PPP Imm-aCnc;;DEPRECATED;1.0j-a;2.69 +130-5;Cefsulodin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefsulodin [Susceptibility] by Serum bactericidal titer;Cefsulodin Titr SBT;;ACTIVE;1.0;2.32 +13050-0;Protein C/Coagulation factor IX;MRto;Pt;PPP;Qn;;COAG;1;Protein C/Coagulation factor IX [Mass Ratio] in Platelet poor plasma;Prot C/Fact IX PPP;;ACTIVE;1.0j-a;2.42 +13051-8;Protein S;ACnc;Pt;PPP;Qn;;COAG;1;Deprecated Protein S [Units/volume] in Platelet poor plasma;Deprecated Prot S PPP-aCnc;;DEPRECATED;1.0j-a;2.69 +1305-2;D Ag;PrThr;Pt;Bld;Ord;;BLDBK;1;D Ag [Presence] in Blood;D Ag Bld Ql;;ACTIVE;1.0;2.73 +13052-6;Protein S/Coagulation factor IX;MRto;Pt;PPP;Qn;Coag;COAG;1;Protein S/Coagulation factor IX [Mass Ratio] in Platelet poor plasma by Coagulation assay;Prot S/Fact IX PPP;;ACTIVE;1.0j-a;2.42 +13053-4;Coagulation kaolin induced;ACnc;Pt;PPP;Qn;;COAG;1;Kaolin activated time [Units/volume] in Platelet poor plasma;KCT PPP-aCnc;;ACTIVE;1.0j-a;2.73 +13054-2;Fibrin+Fibrinogen fragments;ACnc;Pt;Urine;Qn;;COAG;1;Fibrin+Fibrinogen fragments [Units/volume] in Urine;FSP Ur-aCnc;;ACTIVE;1.0j-a;2.73 +13055-9;Heparin;ACnc;Pt;PPP;Qn;;COAG;1;Heparin [Units/volume] in Platelet poor plasma;Heparin PPP-aCnc;;DISCOURAGED;1.0j-a;2.73 +13056-7;Platelets;NCnc;Pt;Plas;Qn;Automated count;HEM/BC;1;Platelets [#/volume] in Plasma by Automated count;Platelet # Plas Auto;;ACTIVE;1.0j-a;2.73 +13057-5;Platelets;ACnc;Pt;Dial fld;Qn;;HEM/BC;1;Platelets [Units/volume] in Dialysis fluid;Platelet Dial fld-aCnc;;ACTIVE;1.0j-a;2.69 +13058-3;Coagulation surface induced^2nd specimen;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --2nd specimen;aPTT sp2 PPP;;ACTIVE;1.0j-a;2.73 +13059-1;Coagulation surface induced^3rd specimen;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --3rd specimen;aPTT sp3 PPP;;ACTIVE;1.0j-a;2.52 +1306-0;D NOS Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated D NOS Ab [Presence] in Serum or Plasma;Deprecated D NOS Ab SerPl Ql;;DEPRECATED;1.0;2.65 +13060-9;Coagulation surface induced^4th specimen;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --4th specimen;aPTT sp4 PPP;;ACTIVE;1.0j-a;2.52 +13061-7;Platelet Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Platelet IgM Ab [Units/volume] in Serum;Platelet IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13062-5;Platelet Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Platelet IgA Ab [Units/volume] in Serum;Platelet IgA Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13063-3;Drug induced platelet Ab;ACnc;Pt;Ser;Qn;;SERO;1;Drug induced platelet Ab [Units/volume] in Serum;Drug ind plt Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13064-1;Platelet associated Ab.IgA;ACnc;Pt;Bld;Qn;;SERO;1;Platelet associated IgA Ab [Units/volume] in Blood;PA IgA Bld-aCnc;;ACTIVE;1.0j-a;2.73 +13065-8;Platelet Ab.circulating;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Platelet Ab [Units/volume] in Serum;Deprecated Platelet Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13066-6;Nuclear Ab;ACnc;Pt;Body fld;Qn;IF;SERO;1;Nuclear Ab [Units/volume] in Body fluid by Immunofluorescence;ANA Fld IF-aCnc;;ACTIVE;1.0j-a;2.69 +13067-4;Nuclear Ab pattern;Imp;Pt;Body fld;Nom;IF;SERO;1;Nuclear Ab pattern [Interpretation] in Body fluid by Immunofluorescence;ANA Pat Fld IF-Imp;;ACTIVE;1.0j-a;2.73 +13068-2;Nuclear Ab pattern;Imp;Pt;Ser;Nom;IF;SERO;1;Nuclear Ab pattern [Interpretation] in Serum by Immunofluorescence;ANA Pat Ser IF-Imp;;ACTIVE;1.0j-a;2.73 +13069-0;Phosphatidylserine Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgA Ab [Units/volume] in Serum;PS IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13070-8;Phosphatidate Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidate IgG Ab [Units/volume] in Serum;Phosphatidate IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13071-6;Phosphatidate Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidate IgM Ab [Units/volume] in Serum;Phosphatidate IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13072-4;Phosphatidate Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidate IgA Ab [Units/volume] in Serum;Phosphatidate IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13073-2;Phosphatidylcholine Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgG Ab [Units/volume] in Serum;PC IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13074-0;Phosphatidylcholine Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgM Ab [Units/volume] in Serum;PC IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13075-7;Phosphatidylcholine Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgA Ab [Units/volume] in Serum;PC IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13076-5;Phosphatidylethanolamine Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgG Ab [Units/volume] in Serum;PE IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13077-3;Phosphatidylethanolamine Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgM Ab [Units/volume] in Serum;PE IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +1307-8;D NOS Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Deprecated D NOS Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated D NOS Ab SerPl BPU Ql;;DEPRECATED;1.0;2.65 +13078-1;Phosphatidylethanolamine Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgA Ab [Units/volume] in Serum;PE IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13079-9;Phosphatidylglycerol Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylglycerol IgG Ab [Units/volume] in Serum;PG IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13080-7;Phosphatidylglycerol Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylglycerol IgM Ab [Units/volume] in Serum;PG IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13081-5;Phosphatidylglycerol Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylglycerol IgA Ab [Units/volume] in Serum;PG IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13082-3;Phosphatidylinositol Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylinositol IgG Ab [Units/volume] in Serum;PI IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13083-1;Phosphatidylinositol Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylinositol IgM Ab [Units/volume] in Serum;PI IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13084-9;Phosphatidylinositol Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylinositol IgA Ab [Units/volume] in Serum;PI IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13085-6;C4 nephritic factor;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;C4 nephritic factor [Mass/volume] in Serum or Plasma;C4 NeF SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +1308-6;D NOS Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Deprecated D NOS Ab [Presence] in Serum or Plasma from Donor;Deprecated D NOS Ab SerPl Donr Ql;;DEPRECATED;1.0;2.65 +13086-4;C3 nephritic factor;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;C3 nephritic factor [Mass/volume] in Serum or Plasma;C3 NeF SerPl-mCnc;;ACTIVE;1.0j-a;2.73 +13087-2;Complement alternate pathway AH50;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement alternate pathway AH50 [Units/volume] in Serum or Plasma;AH50 SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +13088-0;Complement total hemolytic CH100;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement total hemolytic CH100 [Units/volume] in Serum or Plasma;CH100 SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +13089-8;Asialoganglioside GM1 Ab;ACnc;Pt;Ser;OrdQn;EIA;SERO;1;Deprecated Asialoganglioside GM1 Ab;Deprecated GM1 Asialo Ab Ser EIA;;DEPRECATED;1.0j-a;2.34 +13090-6;Asialoganglioside GM1 Ab.IgG;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Asialoganglioside GM1 Ab.IgG;Deprecated GM1 Asialo IgG Ser;;DEPRECATED;1.0j-a;2.36 +13091-4;Deoxyribonucleoprotein Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deoxyribonucleoprotein Ab [Units/volume] in Serum;DNP Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13092-2;Endomysium Ab;ACnc;Pt;Ser;Qn;;SERO;1;Endomysium Ab [Units/volume] in Serum;Endomysium Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13093-0;Monosialoganglioside GM1 Ab.IgM;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Monosialoganglioside GM1 Ab.IgM;Deprecated GM1 Monosialo IgM Ser;;DEPRECATED;1.0j-a;2.34 +1309-4;D NOS Ab;ACnc;Pt;Ser/Plas;Ord;Aggl RBC;BLDBK;1;Deprecated D NOS Ab [Presence] in Serum or Plasma by RBC Aggl;Deprecated D NOS Ab SerPl Ql;;DEPRECATED;1.0;2.66 +13094-8;Monosialoganglioside GM1 Ab.IgA;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Monosialoganglioside GM1 Ab.IgA in serum;Deprecated GM1 Monosialo IgA Ser;;DEPRECATED;1.0j-a;2.40 +13095-5;Monosialoganglioside GM1 Ab.IgA;ACnc;Pt;Ser/Plas;OrdQn;;SERO;1;Deprecated Monosialoganglioside GM1 Ab.IgA in serum or plasma;Deprecated GM1 Monosialo IgA SerPl;;DEPRECATED;1.0j-a;2.40 +13096-3;Myelin associated glycoprotein Ab.IgM;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Myelin associated glycoprotein Ab.IgM in serum;Deprecated MAG IgM Ser;;DEPRECATED;1.0j-a;2.40 +13097-1;PM-SCL extractable nuclear Ab;ACnc;Pt;Ser;OrdQn;EIA;SERO;1;Deprecated PM-SCL extractable nuclear Ab;Deprecated ENA PM-SCL Ab Ser EIA;;DEPRECATED;1.0j-a;2.36 +13098-9;Sulfatide Ab.IgG;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Sulfatide Ab.IgG;Deprecated Sulfatide IgG Ser;;DEPRECATED;1.0j-a;2.36 +13099-7;Sulfatide Ab.IgM;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Sulfatide Ab.IgM in serum;Deprecated Sulfatide IgM Ser;;DEPRECATED;1.0j-a;2.40 +13100-3;Sulfate-3-Glucuronyl paragloboside Ab.IgM;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Sulfate-3-Glucuronyl paragloboside Ab.IgM in serum;Deprecated SGPG IgM Ser;;DEPRECATED;1.0j-a;2.40 +13101-1;Sulfate-3-Glucuronyl paragloboside Ab.IgM;ACnc;Pt;CSF;OrdQn;;SERO;1;Deprecated Sulfate-3-Glucuronyl paragloboside Ab.IgM in CSF;Deprecated SGPG IgM CSF;;DEPRECATED;1.0j-a;2.40 +1310-2;D NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated D NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated D NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +13102-9;Disialylganglioside GD1b Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Disialylganglioside GD1b Ab in serum;Deprecated GD1b Disialyl Ab Ser;;DEPRECATED;1.0j-a;2.40 +13103-7;Disialylganglioside GD1b Ab.IgG;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Disialylganglioside GD1b Ab.IgG;Deprecated GD1b Disialyl IgG Ser;;DEPRECATED;1.0j-a;2.36 +13104-5;Disialylganglioside GD1b Ab.IgM;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Disialylganglioside GD1b Ab.IgM;Deprecated GD1b Disialyl IgM Ser;;DEPRECATED;1.0j-a;2.36 +13105-2;Tetrasialylganglioside GQ1b Ab.IgG;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Tetrasialylganglioside GQ1b Ab.IgG;Deprecated GQ1b Tetra IgG Ser;;DEPRECATED;1.0j-a;2.36 +13106-0;Tetrasialylganglioside GQ1b Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Tetrasialylganglioside GQ1b Ab in serum;Deprecated GQ1b Tetra Ab Ser;;DEPRECATED;1.0j-a;2.40 +13107-8;Disialylganglioside GD1a Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Disialylganglioside GD1a Ab;Deprecated GD1a Disialyl Ab Ser;;DEPRECATED;1.0j-a;2.36 +13108-6;Tetrasialylganglioside GQ1b Ab;ACnc;Pt;Ser/Plas;OrdQn;;SERO;1;Deprecated Tetrasialylganglioside GQ1b Ab in serum or plasma;Deprecated GQ1b Tetra Ab SerPl;;DEPRECATED;1.0j-a;2.40 +13109-4;Disialylganglioside GD1b Ab;ACnc;Pt;Ser/Plas;OrdQn;;SERO;1;Deprecated Disialylganglioside GD1b Ab in serum or plasma;Deprecated GD1b Disialyl Ab SerPl;;DEPRECATED;1.0j-a;2.40 +1311-0;D NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated D NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated D NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +13110-2;Beta tubulin Ab.IgM;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Beta tubulin Ab.IgM;Deprecated B-Tubulin IgM Ser;;DEPRECATED;1.0j-a;2.36 +13111-0;Nuclear Ab;ACnc;Pt;Ser;OrdQn;IF;SERO;1;Deprecated Nuclear Ab by Immunofluorescence;Deprecated ANA Ser IF;;DEPRECATED;1.0j-a;2.40 +13112-8;Nuclear Ab;ACnc;Pt;Ser;OrdQn;IF rat kidney substrate;SERO;1;Deprecated Nuclear Ab Immunofluorescence (rat kidney substrate);Deprecated ANA Ser IF Rat Kidney;;DEPRECATED;1.0j-a;2.40 +13113-6;Myelin associated glycoprotein Ab.IgM;ACnc;Pt;Ser/Plas;OrdQn;;SERO;1;Deprecated Myelin associated glycoprotein Ab.IgM in serum or plasma;Deprecated MAG IgM SerPl;;DEPRECATED;1.0j-a;2.40 +13114-4;Neuronal nuclear type 2 Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Neuronal nuclear type 2 Ab;Deprecated Hu2 Ab Ser;;DEPRECATED;1.0j-a;2.36 +13115-1;Neuronal nuclear type 1 Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Neuronal nuclear type 1 Ab;Deprecated Hu1 Ab Ser;;DEPRECATED;1.0j-a;2.36 +13116-9;Reticulin Ab.IgG;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Reticulin Ab.IgG;Deprecated Reticulin IgG Ser;;DEPRECATED;1.0j-a;2.36 +13117-7;Complement Sc5b-9 Ab;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement Sc5b-9 Ab [Units/volume] in Serum or Plasma;SC5b9 Ab SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +13118-5;Myelin associated glycoprotein Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Myelin associated glycoprotein Ab;Deprecated MAG Ab Ser;;DEPRECATED;1.0j-a;2.36 +13119-3;Myelin associated glycoprotein Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Myelin associated glycoprotein Ab [Presence] in Serum by Immunoblot;MAG Ab Ser Ql IB;;ACTIVE;1.0j-a;2.73 +13120-1;Ovary Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ovary Ab [Units/volume] in Serum;Ovary Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13121-9;Ribosomal P protein Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Ribosomal P protein Ab;Deprecated Ribosomal P protein Ab Ser;;DEPRECATED;1.0j-a;2.36 +13122-7;Sulfatide Ab.IgM;ACnc;Pt;Ser/Plas;OrdQn;;SERO;1;Deprecated Sulfatide Ab.IgM in serum or plasma;Deprecated Sulfatide IgM SerPl;;DEPRECATED;1.0j-a;2.40 +13123-5;Sulfate-3-Glucuronyl paragloboside Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Sulfate-3-Glucuronyl paragloboside Ab in serum;Deprecated SGPG Ab Ser;;DEPRECATED;1.0j-a;2.40 +13124-3;Sulfate-3-Glucuronyl paragloboside Ab;ACnc;Pt;Ser/Plas;OrdQn;;CHEM;1;Deprecated Sulfate-3-Glucuronyl paragloboside Ab in serum or plasma;Deprecated SGPG Ab SerPl;;DEPRECATED;1.0j-a;2.40 +13125-0;Hepatitis C virus c33c Ab;ACnc;Pt;Ser/Plas;Ord;IB;MICRO;1;Deprecated Hepatitis C virus c33c Ab [Presence] in Serum by Immunoblot (IB);Deprecated HCV C33c Ab SerPl Ql IB;;DEPRECATED;1.0j-a;2.36 +13126-8;Hepatitis B virus DNA;ACnc;Pt;Bld;Ord;IB;MICRO;1;Deprecated Hepatitis B virus DNA [Presence] in Blood by Immunoblot (IB);Deprecated HBV DNA Bld Ql IB;;DEPRECATED;1.0j-a;2.36 +13127-6;Cancer Ag DM-70K;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag DM/70K [Units/volume] in Serum or Plasma;Cancer Ag DM/70K SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +1312-8;D NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated D NOS Ag [Presence] on Red Blood Cells;Deprecated D NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +13128-4;Immunosuppressive acidic protein;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Immunosuppressive acidic protein [Units/volume] in Serum or Plasma;IAP SerPl-aCnc;;ACTIVE;1.0j-a;2.69 +13129-2;Pancreatic oncofetal Ag;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Pancreatic oncofetal Ag [Units/volume] in Serum or Plasma;POA Ag SerPl-aCnc;;ACTIVE;1.0j-a;2.69 +131-3;Cefsulodin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefsulodin [Mass/volume] in Serum or Plasma;Cefsulodin SerPl-mCnc;;ACTIVE;1.0;2.42 +13130-0;Motilin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Motilin [Units/volume] in Serum or Plasma;Motilin SerPl-aCnc;;DISCOURAGED;1.0j-a;2.69 +13131-8;Streptococcus pneumoniae 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Units/volume] in Serum;Deprecated S pneum 1 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13132-6;Streptococcus pneumoniae 4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Units/volume] in Serum;Deprecated S pneum4 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13133-4;Streptococcus pneumoniae Danish serotype 6B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B Ab [Units/volume] in Serum;S pneum Da 6B Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13134-2;Streptococcus pneumoniae 8 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Units/volume] in Serum;Deprecated S pneum8 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13135-9;Streptococcus pneumoniae 12 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Units/volume] in Serum;Deprecated S pneum12 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +1313-6;Rh immune globulin dosage.vials recommended;Num;Pt;^Patient;Qn;;BLDBK;1;Rh immune globulin dosage.vials recommended [#];Rh Ig Vials Recom Patient;;ACTIVE;1.0;2.73 +13136-7;Streptococcus pneumoniae Danish serotype 18C Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C Ab [Units/volume] in Serum;S pneum Da 18C Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13137-5;Streptococcus pneumoniae 19 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Units/volume] in Serum;Deprecated S pneum19 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13138-3;Streptococcus pneumoniae 23 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Units/volume] in Serum;Deprecated S pneum23 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13139-1;Streptococcus pneumoniae 1 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum 1 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13140-9;Streptococcus pneumoniae 1 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum 1 Ab sp2 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13141-7;Streptococcus pneumoniae 3 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum3 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13142-5;Streptococcus pneumoniae 3 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum3 Ab sp2 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13143-3;Streptococcus pneumoniae 4 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum4 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +1314-4;Rh immune globulin screen;Imp;Pt;Bld;Nom;;BLDBK;1;Rh immune globulin screen [interpretation];Rh Ig Scn Bld-Imp;;ACTIVE;1.0;2.73 +13144-1;Streptococcus pneumoniae 4 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum4 Ab sp2 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13145-8;Streptococcus pneumoniae Danish serotype 6B Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B Ab [Units/volume] in Serum --1st specimen;S pneum Da 6B Ab sp1 Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13146-6;Streptococcus pneumoniae Danish serotype 6B Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B Ab [Units/volume] in Serum --2nd specimen;S pneum Da 6B Ab sp2 Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13147-4;Streptococcus pneumoniae Danish serotype 7F Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Units/volume] in Serum --1st specimen;S pneum Da 7F Ab sp1 Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13148-2;Streptococcus pneumoniae Danish serotype 7F Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Units/volume] in Serum --2nd specimen;S pneum Da 7F Ab sp2 Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13149-0;Streptococcus pneumoniae 8 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum8 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13150-8;Streptococcus pneumoniae 8 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum8 Ab sp2 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +1315-1;S Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;S Ab [Presence] in Serum or Plasma from Blood product unit;S Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +13151-6;Streptococcus pneumoniae 9 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum9 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13152-4;Streptococcus pneumoniae 9 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum9 Ab sp2 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13153-2;Streptococcus pneumoniae 12 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum12 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13154-0;Streptococcus pneumoniae 12 Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum12 Ab 2:1 Ser-Rto;;DEPRECATED;1.0j-a;2.61 +13155-7;Streptococcus pneumoniae 14 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum14 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13156-5;Streptococcus pneumoniae 14 Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum14 Ab 2:1 Ser-Rto;;DEPRECATED;1.0j-a;2.66 +13157-3;Streptococcus pneumoniae Danish serotype 18C Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C Ab [Units/volume] in Serum --1st specimen;S pneum Da 18C Ab sp1 Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13158-1;Streptococcus pneumoniae Danish serotype 18C Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C Ab [Units/volume] in Serum --2nd specimen;S pneum Da 18C Ab sp2 Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13159-9;Streptococcus pneumoniae 19 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum19 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13160-7;Streptococcus pneumoniae 19 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum19 Ab sp2 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13161-5;Streptococcus pneumoniae 23 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum23 Ab sp1 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13162-3;Streptococcus pneumoniae 23 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum23 Ab sp2 Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13163-1;Streptococcus pneumoniae 12 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Units/volume] in Serum;Deprecated S pneum12 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13164-9;Human antimouse Ab;ACnc;Pt;Ser;Qn;;SERO;1;Human antimouse Ab [Units/volume] in Serum;Human Antimouse Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13165-6;Streptococcus pneumoniae 19 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Units/volume] in Serum;Deprecated S pneum19 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13166-4;Streptococcus pneumoniae 23 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Units/volume] in Serum;Deprecated S pneum23 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +13167-2;Streptococcus pneumoniae Danish serotype 7F Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Units/volume] in Serum;S pneum Da 7F Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13168-0;Streptococcus pneumoniae 6+26 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6+26 Ab [Units/volume] in Serum;Deprecated S pneum6+26 Ab Ser-aCnc;;DEPRECATED;1.0j-a;2.69 +1316-9;S Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;S Ab [Presence] in Serum or Plasma from Donor;S Ab SerPl Donr Ql;;ACTIVE;1.0;2.73 +13169-8;Interpretation;Imp;Pt;Ser/Plas;Nom;Immunoelectrophoresis;CHEM;1;Immunoelectrophoresis for Serum or Plasma;Interpretation SerPl IEP-Imp;;ACTIVE;1.0j-a;2.73 +13170-6;Immune complex;ACnc;Pt;Ser/Plas;Qn;Conglutinin assay;SERO;1;Immune complex [Units/volume] in Serum or Plasma by Conglutinin assay;IC SerPl Cong-aCnc;;ACTIVE;1.0j-a;2.69 +13171-4;Immune complex;ACnc;Pt;Ser/Plas;Qn;PEG assay;SERO;1;Immune complex [Units/volume] in Serum or Plasma by Polyethylene glycol (PEG) assay;IC SerPl PEG-aCnc;;ACTIVE;1.0j-a;2.69 +13172-2;Complement C1q Ag;ACnc;Pt;Ser/Plas;Qn;Raji cell assay;HEM/BC;1;Complement C1q Ag [Units/volume] in Serum or Plasma by Raji cell assay;C1q Ag SerPl Raji Cell-aCnc;;ACTIVE;1.0j-a;2.69 +13173-0;Fibronectin aggregate Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Fibronectin aggregate IgA Ab [Units/volume] in Serum;Fibronectin Aggr IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13174-8;Interpretation;Imp;Pt;CSF;Nom;Immunofixation;CHEM;1;Immunofixation for Cerebral spinal fluid;Interpretation CSF IFE-Imp;;ACTIVE;1.0j-a;2.73 +13175-5;Liver cytosol Ab;PrThr;Pt;Ser;Ord;;SERO;1;Liver cytosol Ab [Presence] in Serum;Liver Cytosol Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13176-3;Wasp venom Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wasp venom IgE Ab [Units/volume] in Serum;Wasp Venom IgE Qn;;ACTIVE;1.0j-a;2.73 +1317-7;S Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;S Ab [Presence] in Serum or Plasma;S Ab SerPl Ql;;ACTIVE;1.0;2.56 +13177-1;Elaeagnus angustifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Russian olive IgE Ab [Units/volume] in Serum;Russian olive IgE Qn;;ACTIVE;1.0j-a;2.73 +13178-9;Wasp venom Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wasp venom IgG Ab [Units/volume] in Serum;Wasp Venom IgG Qn;;ACTIVE;1.0j-a;2.69 +13179-7;Juglans regia Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;English Walnut IgG Ab [Units/volume] in Serum;English Walnut IgG Qn;;ACTIVE;1.0j-a;2.69 +13180-5;Formaldehyde Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Formaldehyde IgG Ab [Units/volume] in Serum;Formaldehyde IgG Qn;;ACTIVE;1.0j-a;2.73 +13181-3;Paspalum notatum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bahia grass IgG Ab [Units/volume] in Serum;Bahia grass IgG Qn;;ACTIVE;1.0j-a;2.69 +13182-1;Prosopis juliflora Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mesquite IgG Ab [Units/volume] in Serum;Mesquite IgG Qn;;ACTIVE;1.0j-a;2.69 +13183-9;Ulmus americana Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Elm IgG Ab [Units/volume] in Serum;White Elm IgG Qn;;ACTIVE;1.0j-a;2.73 +13184-7;Populus deltoides Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cottonwood IgG Ab [Units/volume] in Serum;Cottonwood IgG Qn;;ACTIVE;1.0j-a;2.73 +1318-5;S Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;S Ag [Presence] on Red Blood Cells from Blood product unit;S Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +13185-4;Urtica dioica Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nettle IgG Ab [Units/volume] in Serum;Nettle IgG Qn;;ACTIVE;1.0j-a;2.69 +13186-2;Rumex crispus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Dock IgG Ab [Units/volume] in Serum;Yellow Dock IgG Qn;;ACTIVE;1.0j-a;2.69 +13187-0;Franseria acanthicarpa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;False ragweed IgG Ab [Units/volume] in Serum;False ragweed IgG Qn;;ACTIVE;1.0j-a;2.69 +13188-8;Artemisia vulgaris Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mugwort IgG Ab [Units/volume] in Serum;Mugwort IgG Qn;;ACTIVE;1.0j-a;2.68 +13189-6;Plantago lanceolata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;English plantain IgG Ab [Units/volume] in Serum;Engl plantain IgG Qn;;ACTIVE;1.0j-a;2.69 +13190-4;Formaldehyde Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;ALLERGY;1;Formaldehyde IgM Ab [Units/volume] in Serum or Plasma;Formaldehyde IgM Qn;;ACTIVE;1.0j-a;2.73 +13191-2;Rheumatoid factor;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Deprecated Rheumatoid factor [Units/volume] in Serum;Deprecated Rheumatoid fact SerPl-aCnc;;DEPRECATED;1.0j-a;2.36 +13192-0;Adenovirus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Adenovirus Ab [Units/volume] in Cerebral spinal fluid;HAdV Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +1319-3;S Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;S Ag [Presence] on Red Blood Cells from Donor;S Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +13193-8;Aspergillus flavus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Aspergillus flavus Ab [Units/volume] in Cerebral spinal fluid;A flavus Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13194-6;Aspergillus glaucus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus glaucus Ab [Units/volume] in Serum;A glaucus Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13195-3;Ehrlichia chaffeensis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Ehrlichia chaffeensis Ab [Units/volume] in Serum;E chaffeensis Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13196-1;Ehrlichia sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia sp IgG Ab [Presence] in Serum;Ehrlichia IgG Ser Ql;;ACTIVE;1.0j-a;2.73 +13197-9;Ehrlichia sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia sp IgM Ab [Presence] in Serum;Ehrlichia IgM Ser Ql;;ACTIVE;1.0j-a;2.56 +13198-7;Thermoactinomyces sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Thermoactinomyces Ab [Units/volume] in Serum;Thermoactinomyces Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13199-5;Rickettsia conorii Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia conorii IgG Ab [Units/volume] in Serum;R conorii IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13200-1;Rickettsia conorii Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia conorii IgM Ab [Units/volume] in Serum;R conorii IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +1320-1;S Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;S Ag [Presence] on Red Blood Cells;S Ag RBC Ql;;ACTIVE;1.0;2.73 +13201-9;Blastomyces dermatitidis Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Blastomyces dermatitidis Ab [Units/volume] in Cerebral spinal fluid;B dermat Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13202-7;Borrelia burgdorferi Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor IgG CSF Ql IB;;ACTIVE;1.0j-a;2.73 +13203-5;Borrelia burgdorferi Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor IgM CSF Ql IB;;ACTIVE;1.0j-a;2.73 +13204-3;Borrelia burgdorferi Ab.IgG;ACnc;Pt;CSF;Qn;IF;MICRO;1;Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;B burgdor IgG CSF IF-aCnc;;ACTIVE;1.0j-a;2.73 +13205-0;Borrelia burgdorferi Ab.IgM;ACnc;Pt;CSF;Qn;IF;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;B burgdor IgM CSF IF-aCnc;;ACTIVE;1.0j-a;2.73 +13206-8;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor IgG Snv Ql IB;;ACTIVE;1.0j-a;2.58 +13207-6;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Synovial fluid by Immunoblot;B burgdor IgM Snv Ql IB;;ACTIVE;1.0j-a;2.58 +13208-4;Borrelia hermsii Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia hermsii IgG Ab [Units/volume] in Serum;B hermsii IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13209-2;Borrelia hermsii Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia hermsii IgM Ab [Units/volume] in Serum;B hermsii IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +132-1;cefTAZidime;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;cefTAZidime [Susceptibility] by Minimum lethal concentration (MLC);cefTAZidime Islt MLC;;ACTIVE;1.0;2.19 +13210-0;Brucella sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella sp IgG Ab [Units/volume] in Serum;Brucella IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13211-8;Brucella sp Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella sp IgA Ab [Units/volume] in Serum;Brucella IgA Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13212-6;Brucella abortus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Brucella abortus IgG Ab [Units/volume] in Cerebral spinal fluid;B abortus IgG CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13213-4;Brucella abortus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Brucella abortus IgM Ab [Units/volume] in Cerebral spinal fluid;B abortus IgM CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13214-2;Brucella canis Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Brucella canis IgG Ab [Units/volume] in Cerebral spinal fluid;B canis IgG CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13215-9;Brucella canis Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Brucella canis IgM Ab [Units/volume] in Cerebral spinal fluid;B canis IgM CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13216-7;Candida albicans immune complex;ACnc;Pt;Ser/Plas;Qn;;ALLERGY;1;Candida albicans immune complex [Units/volume] in Serum or Plasma;C albicans Immune Cmplx Qn;;ACTIVE;1.0j-a;2.73 +13217-5;Chlamydia trachomatis B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B Ab [Units/volume] in Serum;C trach B Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13218-3;Chlamydia trachomatis C Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis C Ab [Units/volume] in Serum;C trach C Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +1321-9;Transfusion duration;Time;*;^BPU;Qn;;BLDBK;1;Transfusion duration;Transf duration Time BPU;;ACTIVE;1.0;2.44 +13219-1;Chlamydia trachomatis G+F+K Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis G+F+K Ab [Units/volume] in Serum;C trach G+F+K Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13220-9;Chlamydia trachomatis C Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis C IgM Ab [Units/volume] in Serum;C trach C IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13221-7;Chlamydia trachomatis G+F+K Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis G+F+K IgM Ab [Units/volume] in Serum;C trach G+F+K IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13222-5;Chlamydia trachomatis C Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Chlamydia trachomatis C Ab [Units/volume] in Serum;Deprecated C trach C Ab SerPl-aCnc;;DEPRECATED;1.0j-a;2.69 +13223-3;Chlamydia trachomatis B Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Chlamydia trachomatis B Ab [Units/volume] in Serum;Deprecated C trach B Ab SerPl-aCnc;;DEPRECATED;1.0j-a;2.69 +13224-1;Chlamydia trachomatis G+F+K Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Chlamydia trachomatis G+F+K Ab [Units/volume] in Serum;Deprecated C trach G+F+K Ab SerPl-aCnc;;DEPRECATED;1.0j-a;2.69 +13225-8;Cytomegalovirus Ab.IgG^1st specimen;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma --1st specimen;CMV IgG sp1 SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +13226-6;Cytomegalovirus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Cytomegalovirus IgM Ab [Units/volume] in Cerebral spinal fluid;CMV IgM CSF-aCnc;;ACTIVE;1.0j-a;2.73 +1322-7;Transfusion volume;Vol;*;^BPU;Qn;;BLDBK;1;Transfusion volume;Transf Vol BPU;;ACTIVE;1.0;2.42 +13227-4;Corynebacterium diphtheriae Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae IgG Ab [Units/volume] in Serum;C diphtheriae IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13228-2;Eastern equine encephalitis virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Units/volume] in Cerebral spinal fluid;EEEV IgG CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13229-0;Eastern equine encephalitis virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Units/volume] in Cerebral spinal fluid;EEEV IgM CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13230-8;Saint Louis encephalitis virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Saint Louis encephalitis virus IgG Ab [Units/volume] in Cerebral spinal fluid;SLEV IgG CSF-aCnc;;ACTIVE;1.0j-a;2.73 +13231-6;Saint Louis encephalitis virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Units/volume] in Cerebral spinal fluid;SLEV IgM CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13232-4;Coxsackievirus A Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A Ab [Units/volume] in Cerebral spinal fluid;CV A Ab CSF-aCnc;;ACTIVE;1.0j-a;2.73 +13233-2;Coxsackievirus A2 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A2 Ab [Units/volume] in Cerebral spinal fluid;CV A2 Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13234-0;Coxsackievirus A4 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A4 Ab [Units/volume] in Cerebral spinal fluid;CV A4 Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +1323-5;U Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;U Ab [Presence] in Serum or Plasma from Blood product unit;U Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +13235-7;Coxsackievirus A16 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A16 Ab [Units/volume] in Cerebral spinal fluid;CV A16 Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13236-5;Epstein Barr virus early diffuse Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus early diffuse Ab [Presence] in Serum by Immunofluorescence;EBV EA-D Ab Ser Ql IF;;ACTIVE;1.0j-a;2.73 +13237-3;Epstein Barr virus early restricted Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus early restricted Ab [Presence] in Serum by Immunofluorescence;EBV EA-R Ab Ser Ql IF;;ACTIVE;1.0j-a;2.73 +13238-1;Epstein Barr virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus Ab [Units/volume] in Serum;EBV Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13239-9;Epstein Barr virus nuclear Ab.IgG;ACnc;Pt;Ser/Plas;Ord;;MICRO;1;Deprecated Epstein Barr virus nuclear IgG Ab [Presence] in Serum;Deprecated EBV NA IgG SerPl Ql;;DEPRECATED;1.0j-a;2.36 +13240-7;Phoma herbarum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phoma herbarum IgE Ab [Units/volume] in Serum;P herbarum IgE Qn;;ACTIVE;1.0j-a;2.73 +13241-5;Sporothrix schenckii Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Sporothrix schenckii IgG Ab [Units/volume] in Serum;S schenckii IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13242-3;Sporothrix schenckii Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Sporothrix schenckii IgM Ab [Units/volume] in Serum;S schenckii IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +1324-3;U Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;U Ab [Presence] in Serum or Plasma from Donor;U Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +13243-1;Sporothrix schenckii Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Sporothrix schenckii IgA Ab [Units/volume] in Serum;S schenckii IgA Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13244-9;Filaria Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Filaria IgG Ab [Units/volume] in Serum;Filaria IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13245-6;Filaria Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Filaria IgM Ab [Units/volume] in Serum;Filaria IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13246-4;Haemophilus influenzae B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae B Ab [Units/volume] in Serum;Haem influ B Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13247-2;HTLV I+II Ab;ACnc;Pt;CSF;Qn;;MICRO;1;HTLV I+II Ab [Units/volume] in Cerebral spinal fluid;HTLV I+II Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13248-0;Hepatitis D virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis D virus Ab [Presence] in Serum;HDV Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13249-8;Herpes simplex virus 1+2 Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Units/volume] in Cerebral spinal fluid;HSV1+2 IgG CSF-aCnc;;ACTIVE;1.0j-a;2.73 +1325-0;U Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;U Ab [Presence] in Serum or Plasma;U Ab SerPl Ql;;ACTIVE;1.0;2.56 +13250-6;Herpes virus 6 Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes virus 6 IgG+IgM Ab [Units/volume] in Serum;HHV6 IgG+IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13251-4;Herpes simplex virus 1 Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1 IgM Ab [Units/volume] in Cerebral spinal fluid;HSV1 IgM CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13252-2;Herpes simplex virus 2 Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 2 IgM Ab [Units/volume] in Cerebral spinal fluid;HSV2 IgM CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13253-0;Legionella non pneumophila sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella non-pneumophila Ab [Presence] in Serum;Legionella Non-pneum Ab Ser Ql;;ACTIVE;1.0j-a;2.56 +13254-8;Legionella pneumophila atypical Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila atypical Ab [Presence] in Serum;L pneumo Atyp Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13255-5;Legionella longbeachae 1+2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella longbeachae 1+2 Ab [Presence] in Serum;L longbeachae1+2 Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13256-3;Leishmania donovani Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania donovani IgG Ab [Units/volume] in Serum;L donovani IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13257-1;Leishmania donovani Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania donovani IgM Ab [Units/volume] in Serum;L donovani IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13258-9;Leishmania braziliensis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania brasilensis IgG Ab [Units/volume] in Serum;L braziliensis IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13259-7;Leishmania braziliensis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania brasilensis IgM Ab [Units/volume] in Serum;L braziliensis IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13260-5;Leishmania mexicana Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania mexicana IgG Ab [Units/volume] in Serum;L mexicana IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13261-3;Leishmania mexicana Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania mexicana IgM Ab [Units/volume] in Serum;L mexicana IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13262-1;Leishmania tropica Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania tropica IgG Ab [Units/volume] in Serum;L tropica IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13263-9;Leishmania tropica Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania tropica IgM Ab [Units/volume] in Serum;L tropica IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13264-7;Leptospira sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira sp IgG Ab [Titer] in Serum;Leptospira IgG Titr Ser;;ACTIVE;1.0j-a;2.70 +13265-4;Leptospira sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira sp IgM Ab [Titer] in Serum;Leptospira IgM Titr Ser;;ACTIVE;1.0j-a;2.70 +13266-2;Mumps virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Mumps virus IgG Ab [Units/volume] in Cerebral spinal fluid;MuV IgG CSF-aCnc;;ACTIVE;1.0j-a;2.73 +13267-0;Mumps virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Mumps virus IgM Ab [Units/volume] in Cerebral spinal fluid;MuV IgM CSF-aCnc;;ACTIVE;1.0j-a;2.73 +1326-8;U Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;U Ag [Presence] on Red Blood Cells from Blood product unit;U Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +13268-8;Mycoplasma pneumoniae Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Units/volume] in Serum --1st specimen;M pneumo Ab sp1 Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13269-6;Mycoplasma pneumoniae Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Units/volume] in Serum --2nd specimen;M pneumo Ab sp2 Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13270-4;Mycoplasma pneumoniae Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgA Ab [Units/volume] in Serum;M pneumo IgA Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13271-2;Neisseria meningitidis serogroup A Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup A Ab [Units/volume] in Serum;N men sg A Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13272-0;Neisseria meningitidis serogroup C Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup C Ab [Units/volume] in Serum;N men sg C Ab Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13273-8;Sporothrix schenckii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Sporothrix schenckii Ab [Presence] in Serum;S schenckii Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13274-6;Toxocara canis Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Toxocara canis Ab [Units/volume] in Cerebral spinal fluid;T canis Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13275-3;Toxocara canis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Toxocara canis IgM Ab [Units/volume] in Serum;T canis IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +1327-6;U Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;U Ag [Presence] on Red Blood Cells from Donor;U Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +13276-1;Toxocara canis Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Toxocara canis IgA Ab [Units/volume] in Serum;T canis IgA Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13277-9;Schistosoma sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Schistosoma sp IgG Ab [Units/volume] in Serum;Schistosoma IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13278-7;Schistosoma sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Schistosoma sp IgM Ab [Units/volume] in Serum;Schistosoma IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13279-5;Rubella virus Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Rubella virus IgG Ab [Units/volume] in Serum --1st specimen;RUBV IgG sp1 Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13280-3;Rubella virus Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Rubella virus IgG Ab [Units/volume] in Serum --2nd specimen;RUBV IgG sp2 Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13281-1;Rubella virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Rubella virus IgG Ab [Units/volume] in Cerebral spinal fluid;RUBV IgG CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13282-9;Rubella virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Rubella virus IgM Ab [Units/volume] in Cerebral spinal fluid;RUBV IgM CSF-aCnc;;ACTIVE;1.0j-a;2.73 +13283-7;Measles virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Measles virus IgM Ab [Units/volume] in Cerebral spinal fluid;MeV IgM CSF-aCnc;;ACTIVE;1.0j-a;2.73 +1328-4;U Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;U Ag [Presence] on Red Blood Cells;U Ag RBC Ql;;ACTIVE;1.0;2.56 +13284-5;Salmonella typhi H D Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella typhi H D Ab [Presence] in Serum;S Typhi H d Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13285-2;Salmonella typhi O D Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella typhi O D Ab [Presence] in Serum;S Typhi O D Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13286-0;Toxoplasma gondii Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Serum --2nd specimen;T gondii IgG sp2 Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13287-8;Toxoplasma gondii Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Toxoplasma gondii Ab [Units/volume] in Cerebral spinal fluid;T gondii Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13288-6;Treponema pallidum Ab;ACnc;Pt;Bld;Qn;IF;MICRO;1;Treponema pallidum Ab [Units/volume] in Blood by Immunofluorescence;T pallidum Ab Bld IF-aCnc;;ACTIVE;1.0j-a;2.73 +13289-4;Hantavirus hantaan Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus hantaan Ab [Units/volume] in Serum;HTNV Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13290-2;Trypanosoma cruzi Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Trypanosoma cruzi IgM Ab [Units/volume] in Serum;T cruzi IgM Ser-aCnc;;ACTIVE;1.0j-a;2.73 +13291-0;Trypanosoma cruzi Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Trypanosoma cruzi IgG Ab [Units/volume] in Serum;T cruzi IgG Ser-aCnc;;ACTIVE;1.0j-a;2.73 +1329-2;V Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;V Ab [Presence] in Serum or Plasma from Blood product unit;V Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +13292-8;Colorado tick fever virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Colorado tick fever virus IgG Ab [Units/volume] in Serum;CTFV IgG Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13293-6;Colorado tick fever virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Colorado tick fever virus IgM Ab [Units/volume] in Serum;CTFV IgM Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13294-4;Hepatitis E virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis E virus Ab [Presence] in Serum;HEV Ab Ser Ql;;ACTIVE;1.0j-a;2.73 +13295-1;Coxsackievirus A10 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A10 Ab [Units/volume] in Cerebral spinal fluid;CV A10 Ab CSF-aCnc;;ACTIVE;1.0j-a;2.69 +13296-9;Coxsackievirus A10 Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Coxsackievirus A10 Ab [Units/volume] in Serum;Deprecated CV A10 Ab SerPl-aCnc;;DEPRECATED;1.0j-a;2.69 +13297-7;Coxsackievirus A1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A1 Ab [Units/volume] in Serum;CV A1 Ab Ser-aCnc;;ACTIVE;1.0j-a;2.69 +13298-5;HLA-A;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-A [Type];HLA-A;;ACTIVE;1.0j-a;2.73 +13299-3;HLA-B;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-B [Type];HLA-B;;ACTIVE;1.0j-a;2.73 +13-3;Amikacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Amikacin [Susceptibility] by Disk diffusion (KB);Amikacin Islt KB;;ACTIVE;1.0;2.73 +1330-0;V Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;V Ab [Presence] in Serum or Plasma from Donor;V Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +13300-9;HLA-A+B;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-A+B [Type];HLA-A+B;;ACTIVE;1.0j-a;2.73 +13301-7;HLA-A+B+Bw;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-A+B+Bw [Type];HLA-A+B+Bw;;ACTIVE;1.0j-a;2.50 +13302-5;HLA-C;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-C [Type];HLA-C;;ACTIVE;1.0j-a;2.73 +13303-3;HLA-A+B+C;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-A+B+C (class I) [Type];HLA-A+B+C;;ACTIVE;1.0j-a;2.73 +13304-1;HLA-DR;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DR [Type];HLA-DR;;ACTIVE;1.0j-a;2.73 +13305-8;HLA-DQ;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DQ [Type];HLA-DQ;;ACTIVE;1.0j-a;2.73 +13306-6;HLA-DR beta;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DR beta [Type];HLA-DR Beta;;ACTIVE;1.0j-a;2.73 +13307-4;HLA-DQ alpha;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DQ alpha [Type];HLA-DQ Alpha;;ACTIVE;1.0j-a;2.73 +13308-2;DNA;Type;Pt;XXX;Nom;RFLP probe;SERO;1;Deprecated DNA;Deprecated DNA XXX RFLP Prb;;DEPRECATED;1.0j-a;2.69 +13309-0;Duffy group Ag;Type;Pt;RBC;Nom;;BLDBK;1;Duffy group Ag [Type] on Red Blood Cells;Duffy Group Ag RBC;;ACTIVE;1.0j-a;2.73 +13310-8;Kell group Ag;Type;Pt;RBC;Nom;;BLDBK;1;Kell group Ag [Type] on Red Blood Cells;Kell Group Ag RBC;;ACTIVE;1.0j-a;2.73 +13311-6;MNSs group Ag;Type;Pt;RBC;Nom;;BLDBK;1;MNS group Ag [Type] on Red Blood Cells;MNSS Group Ag RBC;;ACTIVE;1.0j-a;2.07 +13312-4;IgA Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;IgA IgG Ab [Units/volume] in Serum or Plasma;IgA IgG SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +13313-2;IgM Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;IgM IgM Ab [Units/volume] in Serum or Plasma;IgM Ab.IgM SerPl-aCnc;;ACTIVE;1.0j-a;2.73 +13314-0;Bacteria identified;Prid;Pt;Semen;Nom;;MICRO;1;Bacteria identified in Semen;Bacteria Smn;;ACTIVE;1.0j-a;2.73 +13315-7;Bacteria identified;Prid;24H;Urine;Nom;Culture;MICRO;1;Bacteria identified in 24 hour Urine by Culture;Bacteria 24h Ur Cult;;ACTIVE;1.0j-a;2.73 +13316-5;Enterococcus species.vancomycin resistant;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Vancomycin resistant enterococcus [Presence] in Specimen by Organism specific culture;VRE Spec Ql Cult;;ACTIVE;1.0j-a;2.73 +13317-3;Staphylococcus aureus.methicillin resistant isolate;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture;MRSA Spec Ql Cult;;ACTIVE;1.0j-a;2.73 +1331-8;V Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;V Ab [Presence] in Serum or Plasma;V Ab SerPl Ql;;ACTIVE;1.0;2.56 +13318-1;Escherichia coli enteroinvasive identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Escherichia coli enteroinvasive identified in Stool by Organism specific culture;E coli EIEC Stl Cult;;ACTIVE;1.0j-a;2.73 +13319-9;Ova & parasites identified^2nd specimen;Prid;Pt;Stool;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Stool by Light microscopy--2nd specimen;O+P sp2 Stl Micro;;ACTIVE;1.0j-a;2.73 +13320-7;Ova & parasites identified^3rd specimen;Prid;Pt;Stool;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Stool by Light microscopy--3rd specimen;O+P sp3 Stl Micro;;ACTIVE;1.0j-a;2.73 +13321-5;Human papilloma virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Human papilloma virus IgG Ab [Presence] in Serum;HPV IgG Ser Ql;;ACTIVE;1.0j-a;2.56 +13322-3;Human papilloma virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Human papilloma virus IgM Ab [Presence] in Serum;HPV IgM Ser Ql;;ACTIVE;1.0j-a;2.56 +13323-1;Herpes simplex virus 2 Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus 2 Ab [Units/volume] in Serum by Immunofluorescence;HSV2 Ab Ser IF-aCnc;;ACTIVE;1.0j-a;2.73 +13324-9;Herpes simplex virus 1 Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus 1 Ab [Units/volume] in Serum by Immunofluorescence;HSV1 Ab Ser IF-aCnc;;ACTIVE;1.0j-a;2.73 +13325-6;Bartonella sp identified;Prid;Pt;Bld;Nom;Microscopy.light;MICRO;1;Bartonella sp identified in Blood by Light microscopy;Bartonella Bld Smear;;ACTIVE;1.0j-a;1.0ma +1332-6;V Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;V Ag [Presence] on Red Blood Cells from Blood product unit;V Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +13326-4;Pneumocystis sp identified;Prid;Pt;XXX;Nom;Microscopy.light;MICRO;1;Pneumocystis sp identified in Specimen by Light microscopy;Pneumocystis Spec Micro;;ACTIVE;1.0j-a;2.73 +13327-2;Parainfluenza virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Parainfluenza virus Ag [Presence] in Specimen by Immunofluorescence;HPIV Ag Spec Ql IF;;ACTIVE;1.0j-a;2.73 +13328-0;Measles virus Ag;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Serum or Plasma by Immunofluorescence;MeV Ag SerPl Ql IF;;ACTIVE;1.0j-a;2.56 +13329-8;Escherichia coli labile toxin;PrThr;Pt;XXX;Ord;;MICRO;1;Escherichia coli labile toxin [Presence] in Specimen;E coli LT Spec Ql;;ACTIVE;1.0j-a;2.73 +13330-6;Barr bodies;PrThr;Pt;Cvx;Ord;Microscopy.light;HEM/BC;1;Barr bodies [Presence] in Cervix by Light microscopy;Barr Bod Cvx Ql Micro;;ACTIVE;1.0j-a;2.58 +13331-4;Cells.CD2+CD26+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD2+CD26+ cells/100 cells in Blood;CD2+CD26+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13332-2;Cells.CD4+CD25+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD25+ cells/100 cells in Blood;CD4+CD25+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13333-0;Cells.CD3+CD25+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD25+ cells/100 cells in Blood;CD3+CD25+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +1333-4;V Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;V Ag [Presence] on Red Blood Cells from Donor;V Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +13334-8;Cells.CD8+CD25+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD25+ cells/100 cells in Blood;CD8+CD25+ Cells NFr Bld;;ACTIVE;1.0j-a;2.70 +13335-5;Cells.CD4+CD29+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD29+ cells/100 cells in Blood;CD4+CD29+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13336-3;Cells.CD4+CD45RA+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45RA+ cells/100 cells in Blood;CD4+CD45RA+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13337-1;Cells.CD8+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+HLA-DR+ cells/100 cells in Blood;CD8+HLA-DR+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13338-9;Cells.CD8+CD57+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD57+ cells/100 cells in Blood;CD8+CD57+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13339-7;Cells.CD8+CD56+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD56+ cells/100 cells in Blood;CD8+CD56+ Cells NFr Bld;;ACTIVE;1.0j-a;2.70 +13340-5;Cells.CD3+CD38+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD38+ cells/100 cells in Blood;CD3+CD38+ Cells NFr Bld;;ACTIVE;1.0j-a;2.70 +13341-3;Cells.CD3+CD25+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD25+ cells/100 cells in Tissue;CD3+CD25+ Cells NFr Tiss;;ACTIVE;1.0j-a;2.70 +1334-2;V Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;V Ag [Presence] on Red Blood Cells;V Ag RBC Ql;;ACTIVE;1.0;2.56 +13342-1;Cells.CD3+CD26+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD26+ cells/100 cells in Blood;CD3+CD26+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13343-9;Cells.CD4+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+HLA-DR+ cells/100 cells in Blood;CD4+HLA-DR+ Cells NFr Bld;;ACTIVE;1.0j-a;2.70 +13344-7;Cells.CD8+CD38+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD38+ cells/100 cells in Blood;CD8+CD38+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13345-4;Cells.CD8+CD11b+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD11b+ cells/100 cells in Blood;CD8+CD11b+ Cells NFr Bld;;ACTIVE;1.0j-a;2.73 +13346-2;Cells.CD35/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD35 cells/100 cells in Blood;CD35 Cells NFr Bld;;ACTIVE;1.0j-a;2.70 +13347-0;RNA polymerase I+II+III Ab;PrThr;Pt;Ser;Ord;;SERO;1;RNA polymerase I+II+III Ab [Presence] in Serum;RNAp I+II+III Ab Ser Ql;;ACTIVE;1.0j-a;2.56 +13348-8;Monoclonal band observed;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Monoclonal band observed [Identifier] in Serum or Plasma;Monoclon Band Obs SerPl;;ACTIVE;1.0j-a;2.73 +13349-6;Leukocytes;NCnc;Pt;Stool;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Stool by Manual count;WBC # Stl Manual;;ACTIVE;1.0j-a;2.73 +13350-4;Eosinophils/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Deprecated Eosinophils/100 leukocytes in Cerebral spinal fluid by Manual count;Deprecated Eosinophil Fr CSF Manual;;DEPRECATED;1.0j-a;2.46 +13351-2;Leukocytes other;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Leukocytes other [#/volume] in Cerebral spinal fluid by Manual count;WBC Other # CSF Manual;;ACTIVE;1.0j-a;2.73 +13352-0;Neutrophils/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Deprecated Neutrophils/100 leukocytes in Body fluid by Manual count;Deprecated Neutrophils Fr Fld Manual;;DEPRECATED;1.0j-a;2.36 +13353-8;Eosinophils/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Deprecated Eosinophils/100 leukocytes in Body fluid by Manual count;Deprecated Eosinophil Fr Fld Manual;;DEPRECATED;1.0j-a;2.36 +13354-6;Neutrophils.band form/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Band form neutrophils/100 leukocytes in Body fluid by Manual count;Neuts Band/leuk NFr Fld Manual;;ACTIVE;1.0j-a;2.73 +13355-3;Unspecified cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Unspecified cells/100 leukocytes in Body fluid by Manual count;Unspecified Cells/leuk NFr Fld Manual;;ACTIVE;1.0j-a;2.73 +13356-1;Fat;PrThr;Pt;Body fld;Ord;;CHEM;1;Fat [Presence] in Body fluid;Fat Fld Ql;;ACTIVE;1.0j-a;2.73 +13357-9;Synovial cells;ACnc;Pt;Body fld;Qn;;HEM/BC;1;Synovial cells [Units/volume] in Body fluid;Synovial Cells Fld-aCnc;;ACTIVE;1.0j-a;2.73 +13358-7;Collection time;TmStp;Pt;Semen;Qn;;SPEC;1;Collection time of Semen;Collect Tme Smn;;ACTIVE;1.0j-a;2.73 +1335-9;Whole blood given;Vol;Pt;Dose;Qn;;BLDBK;1;Whole blood given [Volume];Whole Bld Gvn Vol Dose;;ACTIVE;1.0;2.73 +13359-5;Character;Aper;Pt;Semen;Nom;;SPEC;1;Character of Semen;Character Smn;;ACTIVE;1.0j-a;2.73 +13360-3;Color;Imp;Pt;Semen;Nom;;SPEC;1;Deprecated Color of Semen - impression;Deprecated Color Smn-Imp;;DEPRECATED;1.0j-a;2.40 +13361-1;Semen analysis panel;-;Pt;Semen;-;;PANEL.FERT;1;Semen analysis panel;Semen Analysis Pnl;;ACTIVE;1.0j-a;2.73 +13362-9;Collection duration;Time;*;Urine;Qn;;SPEC;1;Collection duration of Urine;Collect duration Time Ur;;ACTIVE;1.0j-a;2.73 +13363-7;Collection duration;Time;*;Stool;Qn;;SPEC;1;Collection duration of Stool;Collect duration Time Stl;;ACTIVE;1.0j-a;2.73 +13364-5;Amino beta guanidinopropionate;MCnc;Pt;Plas;Qn;;CHEM;1;Amino beta guanidinopropionate [Mass/volume] in Plasma;AB-Gp Plas-mCnc;;DISCOURAGED;1.0j-a;2.73 +13365-2;Amino beta guanidinopropionate;MCnc;Pt;CSF;Qn;;CHEM;1;Amino beta guanidinopropionate [Mass/volume] in Cerebral spinal fluid;AB-Gp CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +13366-0;Alpha aminoadipate;MCnc;Pt;CSF;Qn;;CHEM;1;Alpha aminoadipate [Mass/volume] in Cerebral spinal fluid;AAA CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +1336-7;X little g super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Xg sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Xg sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +13367-8;Beta aminoisobutyrate;MCnc;Pt;CSF;Qn;;CHEM;1;Beta aminoisobutyrate [Mass/volume] in Cerebral spinal fluid;B-AIB CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +13368-6;Beta alanine;MCnc;Pt;CSF;Qn;;CHEM;1;Beta alanine [Mass/volume] in Cerebral spinal fluid;B-Alanine CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +13369-4;Carnosine;MCnc;Pt;CSF;Qn;;CHEM;1;Carnosine [Mass/volume] in Cerebral spinal fluid;Carnosine CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +13370-2;Cystathionine;MCnc;Pt;CSF;Qn;;CHEM;1;Cystathionine [Mass/volume] in Cerebral spinal fluid;Cystathionin CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +13371-0;Cystine;MCnc;Pt;CSF;Qn;;CHEM;1;Cystine [Mass/volume] in Cerebral spinal fluid;Cystine CSF-mCnc;;ACTIVE;1.0j-a;2.42 +13372-8;Homocystine;MCnc;Pt;CSF;Qn;;CHEM;1;Homocystine [Mass/volume] in Cerebral spinal fluid;(Hcys)2 CSF-mCnc;;ACTIVE;1.0j-a;2.40 +13373-6;Hydroxylysine;MCnc;Pt;CSF;Qn;;CHEM;1;Hydroxylysine [Mass/volume] in Cerebral spinal fluid;OH-Lysine CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +13374-4;Hydroxyproline;MCnc;Pt;CSF;Qn;;CHEM;1;Hydroxyproline [Mass/volume] in Cerebral spinal fluid;OH-Proline CSF-mCnc;;ACTIVE;1.0j-a;2.42 +1337-5;X little g super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Xg sup(a) Ab [Presence] in Serum or Plasma from Donor;Xg sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +13375-1;Lysine;MCnc;Pt;CSF;Qn;;CHEM;1;Lysine [Mass/volume] in Cerebral spinal fluid;Lysine CSF-mCnc;;ACTIVE;1.0j-a;2.42 +13376-9;Methionine;MCnc;Pt;CSF;Qn;;CHEM;1;Methionine [Mass/volume] in Cerebral spinal fluid;Methionine CSF-mCnc;;ACTIVE;1.0j-a;2.42 +13377-7;1-Methylhistidine;MCnc;Pt;CSF;Qn;;CHEM;1;1-Methylhistidine [Mass/volume] in Cerebral spinal fluid;1Me-hist CSF-mCnc;;ACTIVE;1.0j-a;2.42 +13378-5;3-Methylhistidine;MCnc;Pt;CSF;Qn;;CHEM;1;3-Methylhistidine [Mass/volume] in Cerebral spinal fluid;3Me-histidine CSF-mCnc;;ACTIVE;1.0j-a;2.42 +13379-3;Ornithine;MCnc;Pt;CSF;Qn;;CHEM;1;Ornithine [Mass/volume] in Cerebral spinal fluid;Ornithine CSF-mCnc;;ACTIVE;1.0j-a;2.42 +13380-1;Sarcosine;MCnc;Pt;CSF;Qn;;CHEM;1;Sarcosine [Mass/volume] in Cerebral spinal fluid;Sarcosine CSF-mCnc;;DISCOURAGED;1.0j-a;2.44 +13381-9;Tyrosine;MCnc;Pt;CSF;Qn;;CHEM;1;Tyrosine [Mass/volume] in Cerebral spinal fluid;Tyrosine CSF-mCnc;;ACTIVE;1.0j-a;2.42 +13382-7;Amino beta guanidinopropionate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Amino beta guanidinopropionate [Mass/volume] in Amniotic fluid;AB-Gp Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +1338-3;X little g super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Xg sup(a) Ab [Presence] in Serum or Plasma;Xg sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +13383-5;Alpha aminobutyrate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha aminobutyrate [Mass/volume] in Amniotic fluid;A-Aminobutyr Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13384-3;Alpha aminoadipate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha aminoadipate [Mass/volume] in Amniotic fluid;AAA Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13385-0;Beta aminoisobutyrate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Beta aminoisobutyrate [Mass/volume] in Amniotic fluid;B-AIB Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13386-8;Anserine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Anserine [Mass/volume] in Amniotic fluid;Anserine Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13387-6;Arginine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Arginine [Mass/volume] in Amniotic fluid;Arginine Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13388-4;Asparagine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Asparagine [Mass/volume] in Amniotic fluid;Asparagine Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13389-2;Aspartate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Aspartate [Mass/volume] in Amniotic fluid;Aspartate Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +133-9;cefTAZidime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefTAZidime [Susceptibility] by Minimum inhibitory concentration (MIC);cefTAZidime Islt MIC;;ACTIVE;1.0;2.73 +13390-0;Beta alanine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Beta alanine [Mass/volume] in Amniotic fluid;B-Alanine Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +1339-1;X little g super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Xg sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Xg sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +13391-8;Carnosine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Carnosine [Mass/volume] in Amniotic fluid;Carnosine Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13392-6;Citrulline;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Citrulline [Mass/volume] in Amniotic fluid;Citrulline Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13393-4;Cystathionine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Cystathionine [Mass/volume] in Amniotic fluid;Cystathionin Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13394-2;Cystine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Cystine [Mass/volume] in Amniotic fluid;Cystine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13395-9;Glutamate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Glutamate [Mass/volume] in Amniotic fluid;Glutamate Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13396-7;Glutamine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Glutamine [Mass/volume] in Amniotic fluid;Glutamine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13397-5;Glycine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Glycine [Mass/volume] in Amniotic fluid;Glycine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13398-3;Histidine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Histidine [Mass/volume] in Amniotic fluid;Histidine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13399-1;Homocystine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Homocystine [Mass/volume] in Amniotic fluid;(Hcys)2 Amn-mCnc;;ACTIVE;1.0j-a;2.40 +13400-7;Hydroxylysine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Hydroxylysine [Mass/volume] in Amniotic fluid;OH-Lysine Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13401-5;Hydroxyproline;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Hydroxyproline [Mass/volume] in Amniotic fluid;OH-Proline Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13402-3;Isoleucine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Isoleucine [Mass/volume] in Amniotic fluid;Isoleucine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13403-1;Leucine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Leucine [Mass/volume] in Amniotic fluid;Leucine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13404-9;Lysine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Lysine [Mass/volume] in Amniotic fluid;Lysine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13405-6;Methionine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Methionine [Mass/volume] in Amniotic fluid;Methionine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13406-4;1-Methylhistidine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;1-Methylhistidine [Mass/volume] in Amniotic fluid;1Me-hist Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13407-2;3-Methylhistidine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Methylhistidine [Mass/volume] in Amniotic fluid;3Me-histidine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13408-0;Ornithine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Ornithine [Mass/volume] in Amniotic fluid;Ornithine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +1340-9;X little g super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Xg sup(a) Ag [Presence] on Red Blood Cells from Donor;Xg sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +13409-8;Phenylalanine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Phenylalanine [Mass/volume] in Amniotic fluid;Phe Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13410-6;Phosphoethanolamine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphoethanolamine [Mass/volume] in Amniotic fluid;PETN Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13411-4;Phosphoserine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphoserine [Mass/volume] in Amniotic fluid;Phosphoserine Amn-mCnc;;ACTIVE;1.0j-a;2.44 +13412-2;Proline;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Proline [Mass/volume] in Amniotic fluid;Proline Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13413-0;Sarcosine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Sarcosine [Mass/volume] in Amniotic fluid;Sarcosine Amn-mCnc;;DISCOURAGED;1.0j-a;2.44 +13414-8;Serine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Serine [Mass/volume] in Amniotic fluid;Serine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13415-5;Taurine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Taurine [Mass/volume] in Amniotic fluid;Taurine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13416-3;Threonine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Threonine [Mass/volume] in Amniotic fluid;Threonine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +1341-7;X little g super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Xg sup(a) Ag [Presence] on Red Blood Cells;Xg sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +13417-1;Tyrosine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Tyrosine [Mass/volume] in Amniotic fluid;Tyrosine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13418-9;Tryptophan;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Tryptophan [Mass/volume] in Amniotic fluid;Tryptophan Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13419-7;Valine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Valine [Mass/volume] in Amniotic fluid;Valine Amn-mCnc;;ACTIVE;1.0j-a;2.42 +13420-5;EPINEPHrine^2nd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --2nd specimen post XXX challenge;Epineph sp2 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13421-3;EPINEPHrine^3rd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --3rd specimen post XXX challenge;Epineph sp3 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13422-1;EPINEPHrine^4th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --4th specimen post XXX challenge;Epineph sp4 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13423-9;EPINEPHrine^5th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --5th specimen post XXX challenge;Epineph sp5 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13424-7;EPINEPHrine^6th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --6th specimen post XXX challenge;Epineph sp6 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +1342-5;Y little t super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Yt sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Yt sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +13425-4;EPINEPHrine^7th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --7th specimen post XXX challenge;Epineph sp7 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13426-2;Norepinephrine^2nd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --2nd specimen post XXX challenge;Norepineph sp2 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13427-0;Norepinephrine^3rd specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --3rd specimen post XXX challenge;Norepineph sp3 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13428-8;Norepinephrine^4th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --4th specimen post XXX challenge;Norepineph sp4 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13429-6;Norepinephrine^5th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --5th specimen post XXX challenge;Norepineph sp5 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13430-4;Norepinephrine^6th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --6th specimen post XXX challenge;Norepineph sp6 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13431-2;Norepinephrine^7th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --7th specimen post XXX challenge;Norepineph sp7 p chal Plas-mCnc;;ACTIVE;1.0j-a;2.42 +13432-0;DOPamine^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;DOPamine sp2 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +1343-3;Y little t super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Yt sup(a) Ab [Presence] in Serum or Plasma from Donor;Yt sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +13433-8;DOPamine^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;DOPamine sp3 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13434-6;DOPamine^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;DOPamine sp4 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13435-3;DOPamine^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;DOPamine sp5 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13436-1;DOPamine^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;DOPamine sp6 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13437-9;DOPamine^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;DOPamine sp7 p chal SerPl-mCnc;;ACTIVE;1.0j-a;2.34 +13438-7;Protein pattern;Imp;Pt;Urine;Nom;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in Urine by Electrophoresis;Prot Pattern Ur Elph-Imp;;ACTIVE;1.0j-a;2.73 +13439-5;Protein pattern;Imp;Pt;CSF;Nom;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in Cerebral spinal fluid by Electrophoresis;Prot Pattern CSF Elph-Imp;;ACTIVE;1.0j-a;2.73 +13440-3;Interpretation;Imp;Pt;Urine;Nom;Immunofixation;CHEM;1;Immunofixation for Urine;Interpretation Ur IFE-Imp;;ACTIVE;1.0j-a;2.73 +1344-1;Y little t super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Yt sup(a) Ab [Presence] in Serum or Plasma;Yt sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +13441-1;Creatinine renal clearance;VRat;4H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance in 4 hour Urine and Serum or Plasma;Creat Cl 4h Ur+SerPl-vRate;;ACTIVE;1.0j-a;2.66 +13442-9;Creatinine renal clearance;VRat;6H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance in 6 hour Urine and Serum or Plasma;Creat Cl 6h Ur+SerPl-vRate;;ACTIVE;1.0j-a;2.66 +13443-7;Creatinine renal clearance;VRat;8H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance in 8 hour Urine and Serum or Plasma;Creat Cl 8h Ur+SerPl-vRate;;ACTIVE;1.0j-a;2.73 +13444-5;Calcium/Albumin;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Calcium/Albumin [Mass Ratio] in Serum or Plasma;Calcium/Alb SerPl;;ACTIVE;1.0j-a;2.73 +13445-2;Creatinine renal clearance/1.73 sq M;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Deprecated Creatinine renal clearance/1.73 sq M in 24 hour;Deprecated CrCl/BSA 24H Ur+SerPl-vRate;;DEPRECATED;1.0j-a;2.36 +13446-0;Creatinine renal clearance/1.73 sq M;ArVRat;4H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance/1.73 sq M in 4 hour Urine and Serum or Plasma;Creat Cl/1.73 sq M 4h Ur+SerPl-ArVRat;;ACTIVE;1.0j-a;2.66 +13447-8;Creatinine renal clearance/1.73 sq M;ArVRat;6H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance/1.73 sq M in 6 hour Urine and Serum or Plasma;Creat Cl/1.73 sq M 6h Ur+SerPl-ArVRat;;ACTIVE;1.0j-a;2.66 +13448-6;Calcium/Osmolality;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Calcium/Osmolality [Ratio] in Serum or Plasma;Calcium/Osmolality SerPl-Rto;;ACTIVE;1.0j-a;2.69 +13449-4;Creatinine renal clearance/1.73 sq M;ArVRat;8H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance/1.73 sq M in 8 hour Urine and Serum or Plasma;Creat Cl/1.73 sq M 8h Ur+SerPl-ArVRat;;ACTIVE;1.0j-a;2.66 +13450-2;Creatinine renal clearance/1.73 sq M;ArVRat;12H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance/1.73 sq M in 12 hour Urine and Serum or Plasma;Creat Cl/1.73 sq M 12h Ur+SerPl-ArVRat;;ACTIVE;1.0j-a;2.73 +13451-0;Creatinine dialysis fluid clearance;VRat;Pt;Dial fld+Ser/Plas;Qn;;CHEM;1;Creatinine dialysis fluid clearance;Creat Cl Dial fld+SerPl-vRate;;ACTIVE;1.0j-a;2.73 +13452-8;Iron/Transferrin;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Iron/Transferrin [Mass Ratio] in Serum or Plasma;Iron/Transferrin SerPl;;ACTIVE;1.0j-a;2.73 +13453-6;Glucose mean value;ACnc;Pt;Bld;Qn;Estimated from glycated hemoglobin;CHEM;1;Deprecated Glucose mean value;Deprecated Mean Glucose Bld gHb Est-aCnc;;DEPRECATED;1.0j-a;2.69 +13454-4;Calcium-phosphorus product;SCncSq;Pt;Ser/Plas;Qn;;CHEM;1;Calcium-phosphorus product [(Moles/volume)*2] in Serum or Plasma;CaxP SerPl-SCncSq;;ACTIVE;1.0j-a;2.73 +13455-1;Lithium.plasma/Lithium.RBC;MRto;Pt;Bld;Qn;;DRUG/TOX;1;Lithium.plasma/Lithium.RBC [Mass Ratio] in Blood;Lithium SerPl/RBC Bld;;ACTIVE;1.0j-a;2.42 +13456-9;IgG synthesis rate;ACnc;Pt;Ser+CSF;Qn;;CHEM;1;IgG synthesis rate [Units/volume] in Serum and CSF;IgG Synth Rate Ser+CSF-aCnc;;ACTIVE;1.0j-a;2.73 +13457-7;Cholesterol.in LDL;MCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation;LDLc SerPl Calc-mCnc;;ACTIVE;1.0j-a;2.73 +1345-8;Y little t super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Yt sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Yt sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.73 +13458-5;Cholesterol.in VLDL;MCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Cholesterol in VLDL [Mass/volume] in Serum or Plasma by calculation;VLDLc SerPl Calc-mCnc;;ACTIVE;1.0j-a;2.73 +13459-3;Cholesterol.in LDL/Cholesterol.total;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL/Cholesterol.total [Mass Ratio] in Serum or Plasma;LDLc SerPl;;ACTIVE;1.0j-a;2.73 +13460-1;Cholesterol.in LDL/Cholesterol.in HDL;MCrto;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cholesterol.in LDL/Cholesterol.in HDL [Mass ratio] in Serum or Plasma;Deprecated LDLc/HDLc SerPl-mRto;;DEPRECATED;1.0j-a;2.36 +13461-9;Monoacetyldapsone/Dapsone;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Monoacetyldapsone/Dapsone [Mass Ratio] in Serum or Plasma;MADDS/DDS SerPl;;ACTIVE;1.0j-a;2.73 +13462-7;Apolipoprotein A-I/Apolipoprotein B;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein A-I/Apolipoprotein B [Mass Ratio] in Serum or Plasma;Apo A-I/Apo B SerPl;;ACTIVE;1.0j-a;2.73 +13463-5;Arsenic/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic/Creatinine [Mass Ratio] in Urine;Arsenic/Creat Ur;;ACTIVE;1.0j-a;2.73 +13464-3;Chromium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Chromium/Creatinine [Mass Ratio] in Urine;Chromium/Creat Ur;;ACTIVE;1.0j-a;2.73 +13465-0;Mercury/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Mercury/Creatinine [Mass Ratio] in Urine;Mercury/Creat Ur;;ACTIVE;1.0j-a;2.73 +1346-6;Y little t super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Yt sup(a) Ag [Presence] on Red Blood Cells from Donor;Yt sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +13466-8;Lead/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Lead/Creatinine [Mass Ratio] in Urine;Lead/Creat Ur;;ACTIVE;1.0j-a;2.73 +13467-6;Selenium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Selenium/Creatinine [Mass Ratio] in Urine;Selenium/Creat Ur;;ACTIVE;1.0j-a;2.73 +13468-4;Cobalt/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Cobalt/Creatinine [Mass Ratio] in Urine;Cobalt/Creat Ur;;ACTIVE;1.0j-a;2.73 +13469-2;Thallium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Thallium/Creatinine [Mass Ratio] in Urine;Thallium/Creat Ur;;ACTIVE;1.0j-a;2.73 +134-7;cefTAZidime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefTAZidime [Susceptibility] by Disk diffusion (KB);cefTAZidime Islt KB;;ACTIVE;1.0;2.73 +13470-0;Aluminum/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Aluminum/Creatinine [Mass Ratio] in Urine;Aluminum/Creat Ur;;ACTIVE;1.0j-a;2.73 +13471-8;Cadmium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Cadmium/Creatinine [Mass Ratio] in Urine;Cadmium/Creat Ur;;ACTIVE;1.0j-a;2.73 +13472-6;Nickel/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Nickel/Creatinine [Mass Ratio] in Urine;Nickel/Creat Ur;;ACTIVE;1.0j-a;2.73 +13473-4;Zinc/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Zinc/Creatinine [Mass Ratio] in Urine;Zinc/Creat Ur;;ACTIVE;1.0j-a;2.73 +1347-4;Y little t super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Yt sup(a) Ag [Presence] on Red Blood Cells;Yt sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +13474-2;Magnesium/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Magnesium/Creatinine [Mass Ratio] in Urine;Magnesium/Creat Ur;;ACTIVE;1.0j-a;2.73 +13475-9;Fluoride/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Fluoride/Creatinine [Mass Ratio] in Urine;Fluoride/Creat Ur;;ACTIVE;1.0j-a;2.73 +13476-7;Silver/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Silver/Creatinine [Mass Ratio] in Urine;Silver/Creat Ur;;ACTIVE;1.0j-a;2.42 +13477-5;Orthocresol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Orthocresol/Creatinine [Mass Ratio] in Urine;Orthocresol/Creat Ur;;ACTIVE;1.0j-a;2.73 +13478-3;Tetrahydrocannabinol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Tetrahydrocannabinol/Creatinine [Mass Ratio] in Urine;THC/Creat Ur;;ACTIVE;1.0j-a;2.73 +13479-1;Benzoylecgonine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Benzoylecgonine/Creatinine [Mass Ratio] in Urine;BZE/Creat Ur;;ACTIVE;1.0j-a;2.73 +13480-9;18-Hydroxydeoxycortisol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;18-Hydroxydeoxycortisol/Creatinine [Mass Ratio] in Urine;18OH-DC/Creat Ur;;ACTIVE;1.0j-a;2.42 +13481-7;Gonadotropin peptide/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Gonadotropin peptide/Creatinine [Mass Ratio] in Urine;GP/Creat Ur;;ACTIVE;1.0j-a;2.42 +1348-2;Y little t super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Yt sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Yt sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +13482-5;Aldosterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Aldosterone/Creatinine [Mass Ratio] in Urine;Aldost/Creat Ur;;ACTIVE;1.0j-a;2.73 +13483-3;Oxalate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Oxalate/Creatinine [Mass Ratio] in Urine;Oxalate/Creat Ur;;ACTIVE;1.0j-a;2.73 +13484-1;Creatine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Creatine/Creatinine [Mass Ratio] in Urine;Creatine/Creat Ur;;ACTIVE;1.0j-a;2.73 +13485-8;Beta-2-Microglobulin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Beta-2-Microglobulin/Creatinine [Mass Ratio] in Urine;B2 Microglob/Creat Ur;;ACTIVE;1.0j-a;2.73 +13486-6;Testosterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Testosterone/Creatinine [Mass Ratio] in Urine;Testost/Creat Ur;;ACTIVE;1.0j-a;2.42 +13487-4;Phenol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Phenol/Creatinine [Mass Ratio] in Urine;Phenol/Creat Ur;;ACTIVE;1.0j-a;2.73 +13488-2;Coagulation surface induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT in Control Platelet poor plasma by Coagulation assay;aPTT Cont PPP;;ACTIVE;1.0j-a;2.73 +13489-0;Follitropin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Follitropin/Creatinine [Mass Ratio] in Urine;FSH/Creat Ur;;DISCOURAGED;1.0j-a;2.42 +1349-0;Y little t super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Yt sup(b) Ab [Presence] in Serum or Plasma from Donor;Yt sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +13490-8;Lutropin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Lutropin/Creatinine [Mass Ratio] in Urine;LH/Creat Ur;;DISCOURAGED;1.0j-a;2.42 +13491-6;Cells.CD4+CD25+;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD4+CD25+ cells/100 cells in Blood;Deprecated CD4+CD25+ Cells Fr Bld;;DEPRECATED;1.0j-a;2.46 +13492-4;Cells.CD4+HLA-DR+;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD4+HLA-DR+ cells/100 cells in Blood;Deprecated CD4+HLA-DR+ Cells Fr Bld;;DEPRECATED;1.0j-a;2.46 +13493-2;Cells.CD8+CD25+;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD8+CD25+ cells/100 cells in Blood;Deprecated CD8+CD25+ Cells Fr Bld;;DEPRECATED;1.0j-a;2.46 +13494-0;Specimen volume;Vol;4H;Dial fld;Qn;;SPEC;1;Volume of 4 hour Dialysis fluid;Specimen vol 4h Dial fld;;ACTIVE;1.0j-a;2.42 +13495-7;Specimen volume;Vol;24H;Dial fld;Qn;;SPEC;1;Volume of 24 hour Dialysis fluid;Specimen vol 24h Dial fld;;ACTIVE;1.0j-a;2.40 +13496-5;Triple phosphate crystals;Prid;Pt;Calculus;Nom;Microscopy.light;CHEM;1;Triple phosphate crystals [type] in Stone by Light microscopy;Tri-Phos Cry Stone Micro;;ACTIVE;1.0j-a;2.73 +13497-3;Dextroamphetamine/Levoamphetamine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Dextroamphetamine/Levoamphetamine [Mass Ratio] in Urine;D-amphet/L-amphet Ur;;ACTIVE;1.0j-a;2.42 +13498-1;Dextromethamphetamine/Levomethamphetamine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Dextromethamphetamine/Levomethamphetamine [Mass Ratio] in Urine;D-methamphet/L-methamphet Ur;;ACTIVE;1.0j-a;2.73 +13499-9;HIV 1 Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;HIV 1 Ab band pattern [Interpretation] in Serum by Immunoblot;HIV1 Ab Patrn Ser IB-Imp;;ACTIVE;1.0j-a;2.73 +13500-4;Amino acid pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Amino acid pattern [Interpretation] in Serum or Plasma;Amino acid Pat SerPl-Imp;;ACTIVE;1.0j-a;2.73 +13501-2;Herpes simplex virus 2 Ab pattern;Imp;Pt;Ser;Nom;;MICRO;1;Herpes simplex virus 2 Ab pattern [Interpretation] in Serum;HSV2 Ab pattern Ser-Imp;;ACTIVE;1.0j-a;2.73 +13502-0;Borrelia burgdorferi Ab.IgG band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Borrelia burgdorferi IgG band pattern [Interpretation] in Serum by Immunoblot;B burgdor IgG Patrn Ser IB-Imp;;ACTIVE;1.0j-a;2.73 +13503-8;Borrelia burgdorferi Ab.IgM band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Borrelia burgdorferi IgM band pattern [Interpretation] in Serum by Immunoblot;B burgdor IgM Patrn Ser IB-Imp;;ACTIVE;1.0j-a;2.73 +13504-6;Borrelia burgdorferi Ab;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Deprecated Borrelia burgdorferi Ab [interpretation] in Serum;Deprecated B burgdor Ab SerPl-Imp;;DEPRECATED;1.0j-a;2.36 +13505-3;Herpes simplex virus 1+2 Ab pattern;Imp;Pt;Ser;Nom;;MICRO;1;Herpes simplex virus 1+2 Ab pattern [Interpretation] in Serum;HSV1+2 Ab pattern Ser-Imp;;ACTIVE;1.0j-a;2.73 +13506-1;Urea nitrogen renal clearance;VRat;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Urea nitrogen renal clearance in Urine and Serum or Plasma;UUN Cl Ur+SerPl-vRate;;ACTIVE;1.0j-a;2.73 +13507-9;Lupus erythematosus cells;PrThr;Pt;Bld;Ord;;HEM/BC;1;Lupus erythematosus cells [Presence] in Blood;LE Cells Bld Ql;;ACTIVE;1.0j-a;2.56 +1350-8;Y little t super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Yt sup(b) Ab [Presence] in Serum or Plasma;Yt sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.56 +13508-7;Hematocrit;VFr;Pt;CSF;Qn;Spun;HEM/BC;1;Hematocrit [Volume Fraction] of Cerebral spinal fluid by Centrifugation;Hct VFr CSF Spun;;ACTIVE;1.0k;2.73 +13509-5;Microscopic observation;Prid;Pt;Bld;Nom;Crystal violet stain;HEM/BC;1;Microscopic observation [Identifier] in Blood by Crystal violet stain;CV Stn Bld;;ACTIVE;1.0k;2.73 +13510-3;Microscopic observation;Prid;Pt;Bone mar;Nom;Myeloperoxidase stain;HEM/BC;1;Microscopic observation [Identifier] in Bone marrow by Myeloperoxidase stain;Myeloperoxidase Mar;;ACTIVE;1.0k;2.19 +13511-1;Cyanide ascorbate screen;PrThr;Pt;Bld;Ord;;HEM/BC;1;Cyanide ascorbate screen [Presence] in Blood;Cyanide Ascorbate Scn Bld Ql;;ACTIVE;1.0k;2.56 +13512-9;Microscopic observation;Prid;Pt;Bone mar;Nom;Butyrate esterase stain;HEM/BC;1;Microscopic observation [Identifier] in Bone marrow by Butyrate esterase stain;BE Stn Mar;;ACTIVE;1.0k;2.19 +13513-7;Iron.microscopic observation;Prid;Pt;Bone mar;Nom;Potassium ferrocyanide stain;HEM/BC;1;Iron.microscopic observation [Identifier] in Bone marrow by Potassium ferrocyanide stain;Iron Mar K Ferrocyanide Stn;;ACTIVE;1.0k;2.73 +13514-5;Hemoglobin pattern;Imp;Pt;Bld;Nar;Electrophoresis;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by Electrophoresis Narrative;Hgb Fract Bld Elph-Imp;;ACTIVE;1.0k;2.73 +13515-2;Hemoglobin pattern;Imp;Pt;Bld;Nar;Electrophoresis.citrate agar;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by Electrophesis citrate agar Narrative;Hgb Fract Bld Elph Citrate-Imp;;ACTIVE;1.0k;2.73 +1351-6;Y little t super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Yt sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Yt sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +13516-0;Neutrophils/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Cerebral spinal fluid by Manual count;Neutrophils/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +13517-8;Lymphocytes.variant/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Variant lymphocytes/100 leukocytes in Cerebral spinal fluid by Manual count;Variant Lymphs/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +13518-6;Lymphocytes.variant/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Variant lymphocytes/100 leukocytes in Body fluid by Manual count;Variant Lymphs/leuk NFr Fld Manual;;ACTIVE;1.0k;2.73 +13519-4;Basophils/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Cerebral spinal fluid by Manual count;Basophils/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +13520-2;Basophils/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Deprecated Basophils/100 leukocytes in Body fluid by Manual count;Deprecated Basophils Fr Fld Manual;;DEPRECATED;1.0k;2.36 +13521-0;Blasts/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Blasts/100 leukocytes in Cerebral spinal fluid by Manual count;Blasts/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +13522-8;Blasts/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Blasts/100 leukocytes in Body fluid by Manual count;Blasts/leuk NFr Fld Manual;;ACTIVE;1.0k;2.73 +13523-6;Leukocytes other/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Cerebral spinal fluid by Manual count;WBC Other/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +1352-4;Y little t super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Yt sup(b) Ag [Presence] on Red Blood Cells from Donor;Yt sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +13524-4;Leukocytes other/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Body fluid by Manual count;WBC Other/leuk NFr Fld Manual;;ACTIVE;1.0k;2.73 +13525-1;Nonhematic cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Nonhematic cells/100 leukocytes in Cerebral spinal fluid by Manual count;Nonhematic Cells/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +13526-9;Nonhematic cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Nonhematic cells/100 leukocytes in Body fluid by Manual count;Nonhematic Cells/leuk NFr Fld Manual;;ACTIVE;1.0k;2.73 +13527-7;Unidentified cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Unidentified cells/100 leukocytes in Cerebral spinal fluid by Manual count;Unident Cells/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +13528-5;Unidentified cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Unidentified cells/100 leukocytes in Body fluid by Manual count;Unident Cells/leuk NFr Fld Manual;;ACTIVE;1.0k;2.73 +13529-3;Erythrocytes.nucleated;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Cerebral spinal fluid by Manual count;nRBC # CSF Manual;;ACTIVE;1.0k;2.73 +13530-1;Erythrocytes.nucleated;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Body fluid by Manual count;nRBC # Fld Manual;;ACTIVE;1.0k;2.73 +13531-9;Fat.microscopic observation;PrThr;Pt;Sputum;Ord;Sudan III stain;PATH;1;Fat.microscopic observation [Presence] in Sputum by Sudan III stain;Fat Spt Ql Sudan III Stn;;ACTIVE;1.0k;2.56 +1353-2;Y little t super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Yt sup(b) Ag [Presence] on Red Blood Cells;Yt sup(b) Ag RBC Ql;;ACTIVE;1.0;2.56 +13532-7;Xanthochromia;PrThr;Pt;CSF;Ord;;SPEC;1;Xanthochromia [Presence] of Cerebral spinal fluid Qualitative;Xanthochromia CSF Ql;;ACTIVE;1.0k;2.73 +13533-5;Acid hemolysis;PrThr;Pt;Bld;Ord;;HEM/BC;1;Acid hemolysis [Presence] of Blood;Acid hemolysis Bld Ql;;ACTIVE;1.0k;2.73 +13534-3;Sucrose hemolysis;PrThr;Pt;Bld;Ord;;HEM/BC;1;Sucrose hemolysis [Presence] of Blood;Sucrose Hemolysis Bld Ql;;ACTIVE;1.0k;2.73 +13535-0;Sucrose hemolysis;NFr;Pt;RBC;Qn;;HEM/BC;1;Sucrose hemolysis of Red Blood Cells;Sucrose Hemolysis NFr RBC;;ACTIVE;1.0k;2.70 +13536-8;Globulin;MCnc;Pt;Plas;Qn;;CHEM;1;Globulin [Mass/volume] in Plasma;Globulin Plas-mCnc;;ACTIVE;1.0k;2.73 +13537-6;Protein;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Protein [Mass/volume] in Plasma;Deprecated Prot Plas-mCnc;;DEPRECATED;1.0k;2.66 +13538-4;Carbon dioxide;SCnc;Pt;Urine;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Urine;CO2 Ur-sCnc;;ACTIVE;1.0k;2.73 +13539-2;Phosphate;SCnc;Pt;Urine;Qn;;CHEM;1;Phosphate [Moles/volume] in Urine;Phosphate Ur-sCnc;;ACTIVE;1.0k;2.73 +135-4;cefTAZidime;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;cefTAZidime [Susceptibility] by Serum bactericidal titer;cefTAZidime Titr SBT;;ACTIVE;1.0;2.32 +1354-0;11-Deoxycorticosteroids^9H post 3 g metyraPONE PO overnight;MCnc;Pt;Plas;Qn;;CHAL;1;11-Deoxycorticosteroids [Mass/volume] in Plasma --9 hours post 3 g metyraPONE PO overnight;11DCOR 9h p 3 g MTP PO ON Plas-mCnc;;ACTIVE;1.0;2.42 +13540-0;Carbon dioxide;SCnc;Pt;CSF;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Cerebral spinal fluid;CO2 CSF-sCnc;;ACTIVE;1.0k;2.34 +13541-8;Carbon dioxide;SCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Carbon dioxide [Molecules/volume] in Body fluid;Deprecated CO2 Fld-sCnc;;DEPRECATED;1.0k;2.36 +13542-6;Phosphate;MCnc;Pt;CSF;Qn;;CHEM;1;Phosphate [Mass/volume] in Cerebral spinal fluid;Phosphate CSF-mCnc;;ACTIVE;1.0k;2.34 +13543-4;Phosphate;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Phosphate [Mass/volume] in Body fluid;Deprecated Phosphate Fld-mCnc;;DEPRECATED;1.0k;2.36 +13544-2;4-Hydroxyglutethimide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;4-Hydroxyglutethimide [Presence] in Serum or Plasma;4OH-glutethimide SerPl Ql;;ACTIVE;1.0k;2.56 +13545-9;ALPRAZolam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;ALPRAZolam [Presence] in Serum or Plasma;Alpraz SerPl Ql;;ACTIVE;1.0k;2.73 +13546-7;Amikacin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Body fluid;Amikacin Fld-mCnc;;ACTIVE;1.0k;2.70 +13547-5;Butriptyline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Butriptyline [Presence] in Serum or Plasma;Butrip SerPl Ql;;ACTIVE;1.0k;2.56 +13548-3;chlorproMAZINE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;chlorproMAZINE [Presence] in Serum or Plasma;chlorproMAZINE SerPl Ql;;ACTIVE;1.0k;2.73 +13549-1;clomiPRAMINE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;clomiPRAMINE [Presence] in Serum or Plasma;clomiPRAMINE SerPl Ql;;ACTIVE;1.0k;2.56 +13550-9;clonazePAM;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;clonazePAM [Presence] in Serum or Plasma;clonazePAM SerPl Ql;;ACTIVE;1.0k;2.73 +13551-7;Clorazepate;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Clorazepate [Presence] in Serum or Plasma;Clorazepate SerPl Ql;;ACTIVE;1.0k;2.56 +13552-5;cloZAPine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;cloZAPine [Presence] in Serum or Plasma;cloZAPine SerPl Ql;;ACTIVE;1.0k;2.73 +13553-3;Cocaethylene;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Cocaethylene [Presence] in Serum or Plasma;Cocaethylene SerPl Ql;;ACTIVE;1.0k;2.73 +13554-1;Cyclobenzaprine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Cyclobenzaprine [Presence] in Serum or Plasma;Cyclobenzaprine SerPl Ql;;ACTIVE;1.0k;2.56 +13555-8;D-pseudoephedrine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;D-pseudoephedrine [Presence] in Serum or Plasma;D-Pseudoephedrine SerPl Ql;;ACTIVE;1.0k;2.56 +13556-6;Demoxepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Demoxepam [Presence] in Serum or Plasma;Demoxepam SerPl Ql;;ACTIVE;1.0k;2.56 +1355-7;11-Deoxycorticosteroids^pre 3 g metyraPONE PO overnight;MCnc;Pt;Plas;Qn;;CHAL;1;11-Deoxycorticosteroids [Mass/volume] in Plasma --pre 3 g metyraPONE PO overnight;11DCOR pre 3 g MTP PO ON Plas-mCnc;;ACTIVE;1.0;2.42 +13557-4;Norsertraline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Norsertraline [Presence] in Serum or Plasma;Norsertraline SerPl Ql;;ACTIVE;1.0k;2.56 +13558-2;Disopyramide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Disopyramide [Presence] in Serum or Plasma;Disopyramide SerPl Ql;;ACTIVE;1.0k;2.73 +13559-0;Flecainide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Flecainide [Presence] in Serum or Plasma;Flecainide SerPl Ql;;ACTIVE;1.0k;2.56 +13560-8;fluvoxaMINE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;fluvoxaMINE [Presence] in Serum or Plasma;fluvoxaMINE SerPl Ql;;ACTIVE;1.0k;2.56 +13561-6;Gentamicin;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Cerebral spinal fluid;Gentamicin CSF-mCnc;;ACTIVE;1.0k;2.70 +13562-4;Gentamicin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Body fluid;Gentamicin Fld-mCnc;;ACTIVE;1.0k;2.70 +13563-2;Glutethimide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Glutethimide [Presence] in Serum or Plasma;Glutethimide SerPl Ql;;ACTIVE;1.0k;2.73 +13564-0;Ibuprofen;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ibuprofen [Presence] in Serum or Plasma;Ibuprofen SerPl Ql;;ACTIVE;1.0k;2.56 +1356-5;11-Deoxycortisol^8H post 30 mg/kg metyraPONE PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --8 hours post 30 mg/kg metyraPONE PO;11DC 8h p 30 mg/kg MTP PO SerPl-mCnc;;ACTIVE;1.0;2.40 +13565-7;LORazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;LORazepam [Presence] in Serum or Plasma;LORazepam SerPl Ql;;ACTIVE;1.0k;2.73 +13566-5;Mesoridazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Mesoridazine [Presence] in Serum or Plasma;Mesoridazine SerPl Ql;;ACTIVE;1.0k;2.73 +13567-3;Mexiletine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Mexiletine [Presence] in Serum or Plasma;Mexiletine SerPl Ql;;ACTIVE;1.0k;2.56 +13568-1;N-desalkylflurazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Serum or Plasma;Desalkylfluraz SerPl Ql;;ACTIVE;1.0k;2.73 +13569-9;Norchlordiazepoxide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Norchlordiazepoxide [Presence] in Serum or Plasma;Norchlordiazep SerPl Ql;;ACTIVE;1.0k;2.56 +13570-7;Norclomipramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Norclomipramine [Presence] in Serum or Plasma;Norclomipramine SerPl Ql;;ACTIVE;1.0k;2.56 +13571-5;Norclozapine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Norclozapine [Presence] in Serum or Plasma;Norclozapine SerPl Ql;;ACTIVE;1.0k;2.73 +13572-3;Nordiazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Nordiazepam [Presence] in Serum or Plasma;Nordiazepam SerPl Ql;;ACTIVE;1.0k;2.73 +1357-3;11-Deoxycortisol^post 750 mg metyraPONE Q4H X 6;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --post 750 mg metyraPONE q4h X 6;11DC p 750 mg MTP Q4h X 6 SerPl-mCnc;;ACTIVE;1.0;2.40 +13573-1;Nordoxepin;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Nordoxepin [Presence] in Serum or Plasma;Nordoxepin SerPl Ql;;ACTIVE;1.0k;2.73 +13574-9;Norfluoxetine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Norfluoxetine [Presence] in Serum or Plasma;Norfluoxetine SerPl Ql;;ACTIVE;1.0k;2.56 +13575-6;Normaprotiline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Normaprotiline [Presence] in Serum or Plasma;Normaprotiline SerPl Ql;;ACTIVE;1.0k;2.56 +13576-4;oxyCODONE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;oxyCODONE [Presence] in Serum or Plasma;oxyCODONE SerPl Ql;;ACTIVE;1.0k;2.73 +13577-2;PARoxetine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;PARoxetine [Presence] in Serum or Plasma;PARoxetine SerPl Ql;;ACTIVE;1.0k;2.73 +13578-0;Promazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Promazine [Presence] in Serum or Plasma;Promazine SerPl Ql;;ACTIVE;1.0k;2.56 +13579-8;Sertraline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Sertraline [Presence] in Serum or Plasma;Sertraline SerPl Ql;;ACTIVE;1.0k;2.73 +13580-6;Temazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Temazepam [Presence] in Serum or Plasma;Temazepam SerPl Ql;;ACTIVE;1.0k;2.73 +1358-1;Corticotropin^1.5H post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1.5 hours post dose insulin IV;ACTH 1.5h p Ins IV Plas-mCnc;;ACTIVE;1.0;2.40 +13581-4;Theophylline;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Cerebral spinal fluid;Theophylline CSF-mCnc;;ACTIVE;1.0k;2.70 +13582-2;Theophylline;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Body fluid;Theophylline Fld-mCnc;;ACTIVE;1.0k;2.70 +13583-0;Thioridazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Thioridazine [Presence] in Serum or Plasma;Thioridazine SerPl Ql;;ACTIVE;1.0k;2.73 +13584-8;Tobramycin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Body fluid;Tobramycin Fld-mCnc;;ACTIVE;1.0k;2.70 +13585-5;Trifluoperazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Trifluoperazine [Presence] in Serum or Plasma;TriFperazine SerPl Ql;;ACTIVE;1.0k;2.73 +13586-3;Vancomycin;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Cerebral spinal fluid;Vancomycin CSF-mCnc;;ACTIVE;1.0k;2.70 +13587-1;Vancomycin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Body fluid;Vancomycin Fld-mCnc;;ACTIVE;1.0k;2.73 +13588-9;Venlafaxine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Venlafaxine [Presence] in Serum or Plasma;Venlafaxine SerPl Ql;;ACTIVE;1.0k;2.56 +13589-7;Activated protein C resistance;PrThr;Pt;Bld;Ord;Probe.amp.tar;COAG;1;Activated protein C resistance [Presence] in Blood by NAA with probe detection;aPCR Bld Ql NAA+probe;;ACTIVE;1.0k;2.73 +13590-5;Activated protein C resistance;TRto;Pt;PPP;Qn;Coag;COAG;1;Activated protein C resistance [Time Ratio] in Platelet poor plasma by Coagulation assay;aPCR PPP;;ACTIVE;1.0k;2.73 +13591-3;Factor inhibitor XXX;ACnc;Pt;PPP;Qn;Coag;COAG;1;Factor inhibitor XXX [Units/volume] in Platelet poor plasma by Coagulation assay;Fact Inhib XXX PPP-aCnc;;ACTIVE;1.0k;2.73 +13592-1;Platelet aggregation.XXX induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation XXX induced in Platelet rich plasma;PA XXX PRP;;ACTIVE;1.0k;2.73 +13593-9;Platelet aggregation.prostaglandin induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation prostaglandin induced in Platelet rich plasma;PA PG PRP;;ACTIVE;1.0k;2.54 +13594-7;Prekallikrein;PrThr;Pt;PPP;Ord;;COAG;1;Prekallikrein (Fletcher Factor) [Presence] in Platelet poor plasma;PK PPP Ql;;ACTIVE;1.0k;2.73 +13595-4;Basophils/100 leukocytes;NFr;Pt;Nose;Qn;;HEM/BC;1;Basophils/100 leukocytes in Nose;Basophils/leuk NFr Nose;;ACTIVE;1.0k;2.73 +13596-2;Histiocytes;PrThr;Pt;Nose;Ord;Microscopy.light;HEM/BC;1;Histiocytes [Presence] in Nose by Light microscopy;Histiocytes Nose Ql Micro;;ACTIVE;1.0k;2.56 +13597-0;Neutrophils/100 leukocytes;NFr;Pt;Nose;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Nose;Neutrophils/leuk NFr Nose;;ACTIVE;1.0k;2.73 +13598-8;Promyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Deprecated Promyelocytes/100 leukocytes in Blood by Manual count;Deprecated Promyelocytes Fr Bld Manual;;DEPRECATED;1.0k;2.70 +1359-9;Corticotropin^1H post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 hour post 1 ug/kg CRH IV;ACTH 1h p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;1.0;2.40 +13599-6;Promonocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Promonocytes/100 leukocytes in Blood by Manual count;Promonycytes/leuk NFr Bld Manual;;ACTIVE;1.0k;2.73 +13600-2;11-Deoxycortisol^15M post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --15 minutes post 250 ug corticotropin;11DC 15M p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.70 +13601-0;11-Deoxycortisol^1H post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;11DC 1h p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13602-8;11-Deoxycortisol^30M post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;11DC 30M p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.70 +13603-6;17-Hydroxypregnenolone^15M post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --15 minutes post 250 ug corticotropin;17OH-Preg 15M p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13604-4;17-Hydroxypregnenolone^1H post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;17OH-Preg 1h p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13605-1;17-Hydroxypregnenolone^30M post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;17OH-Preg 30M p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13606-9;Glucose^3H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post 50 g lactose PO;Glucose 3h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0k;2.73 +1360-7;Corticotropin^1H post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 hour post dose insulin IV;ACTH 1h p Ins IV Plas-mCnc;;ACTIVE;1.0;2.40 +13607-7;Glucose^4H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 hours post 50 g lactose PO;Glucose 4h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0k;2.34 +13608-5;Insulin^1.5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO;Insulin 1.5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0k;2.73 +13609-3;Insulin^2.5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --2.5 hours post 75 g glucose PO;Insulin 2.5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0k;2.73 +13610-1;3-Beta-Androstanediol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Beta-Androstanediol [Mass/volume] in Serum or Plasma;3-B-androstanediol SerPl-mCnc;;ACTIVE;1.0k;2.70 +13611-9;6-Beta-Hydroxycortisol;MRat;24H;Urine;Qn;;CHEM;1;6-Beta-Hydroxycortisol [Mass/time] in 24 hour Urine;6B-OH-Cortisol 24h Ur-mRate;;ACTIVE;1.0k;2.73 +13612-7;Dehydroepiandrosterone;MRat;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Mass/time] in 24 hour Urine;DHEA 24h Ur-mRate;;ACTIVE;1.0k;2.73 +13613-5;Ethanolamine;MCnc;Pt;CSF;Qn;;CHEM;1;Ethanolamine [Mass/volume] in Cerebral spinal fluid;Ethanolamine CSF-mCnc;;ACTIVE;1.0k;2.42 +13614-3;Etiocholanolone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Etiocholanolone [Mass/volume] in Serum or Plasma;Etiocholanolone SerPl-mCnc;;ACTIVE;1.0k;2.70 +1361-5;Corticotropin^1M post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 minute post 1 ug/kg CRH IV;ACTH 1M p 1 u/kg CRH IV Plas-mCnc;;ACTIVE;1.0;2.40 +13615-0;Gamma aminobutyrate;MCnc;Pt;CSF;Qn;;CHEM;1;Gamma aminobutyrate [Mass/volume] in Cerebral spinal fluid;GABA CSF-mCnc;;DISCOURAGED;1.0k;2.44 +13616-8;Nitrite;MCnc;Pt;Water;Qn;;CHEM;1;Nitrite [Mass/volume] in Water;Nitrite Wat-mCnc;;ACTIVE;1.0k;2.70 +13617-6;Prostaglandin D2;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Prostaglandin D2 [Mass/volume] in Serum or Plasma;Deprecated Prostaglandin D2 Ser-mCnc;;DEPRECATED;1.0k;2.70 +13618-4;Tetrahydroaldosterone;MRat;24H;Urine;Qn;;CHEM;1;Tetrahydroaldosterone [Mass/time] in 24 hour Urine;THaldost 24h Ur-mRate;;ACTIVE;1.0k;2.73 +13619-2;Specimen volume;Vol;2H;Urine;Qn;;SPEC;1;Volume of 2 hour Urine;Specimen vol 2h Ur;;ACTIVE;1.0k;2.73 +136-2;Ceftizoxime;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ceftizoxime [Susceptibility] by Minimum lethal concentration (MLC);Ceftizoxime Islt MLC;;ACTIVE;1.0;2.19 +13620-0;Specimen volume;Vol;12H;Urine;Qn;;SPEC;1;Volume of 12 hour Urine;Specimen vol 12h Ur;;ACTIVE;1.0k;2.73 +13621-8;Coagulation thrombin induced;Time;Pt;-;Qn;Coag;COAG;1;Deprecated Thrombin time in Platelet poor plasma from control by Coagulation assay;Deprecated TT Qn;;DEPRECATED;1.0k;2.70 +13622-6;Acetaminophen;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetaminophen [Mass/volume] in Urine;APAP Ur-mCnc;;ACTIVE;1.0k;2.73 +1362-3;Corticotropin^30M post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes post 1 ug/kg CRH IV;ACTH 30M p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;1.0;2.40 +13623-4;Dextromethorphan;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dextromethorphan [Mass/volume] in Serum or Plasma;D-methorphan SerPl-mCnc;;ACTIVE;1.0k;2.73 +13624-2;DOXOrubicin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;DOXOrubicin [Mass/volume] in Serum or Plasma;DOXOrubicin SerPl-mCnc;;ACTIVE;1.0k;2.70 +13625-9;Methoxsalen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methoxsalen [Mass/volume] in Serum or Plasma;Methoxsalen SerPl-mCnc;;ACTIVE;1.0k;2.70 +13626-7;Mitotane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mitotane [Mass/volume] in Serum or Plasma;Mitotane SerPl-mCnc;;ACTIVE;1.0k;2.73 +13627-5;Erythrocytes;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Erythrocytes [Presence] in Semen by Light microscopy;RBC Smn Ql Micro;;ACTIVE;1.0k;2.73 +13628-3;Spermatozoa.motile/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Deprecated Spermatozoa Motile/100 spermatozoa in Semen;Deprecated Sperm Motile Fr Smn;;DEPRECATED;1.0k;2.70 +13629-1;Interleukin 1 beta;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 1 beta [Mass/volume] in Serum or Plasma;Il1Beta SerPl-mCnc;;ACTIVE;1.0k;2.73 +13630-9;Immune complex;ACnc;Pt;Ser/Plas;Qn;Conglutinin assay;SERO;1;Deprecated Immune complex [Units/volume] in Serum or Plasma by Conglutinin assay;Deprecated IC SerPl Cong-aCnc;;DEPRECATED;1.0k;2.70 +1363-1;Corticotropin^30M post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes post dose insulin IV;ACTH 30M p Ins IV Plas-mCnc;;ACTIVE;1.0;2.40 +13631-7;Immune complex;MCnc;Pt;Ser/Plas;Qn;PEG assay;SERO;1;Immune complex [Mass/volume] in Serum or Plasma by Polyethylene glycol (PEG) assay;IC SerPl PEG-mCnc;;ACTIVE;1.0k;2.70 +13632-5;Insulin receptor Ab;Titr;Pt;Ser;Qn;;SERO;1;Insulin receptor Ab [Titer] in Serum;Insulin Recep Ab Titr Ser;;ACTIVE;1.0k;2.70 +13633-3;Insulin receptor Ab;PrThr;Pt;Ser;Ord;;SERO;1;Insulin receptor Ab [Presence] in Serum;Insulin Recep Ab Ser Ql;;ACTIVE;1.0k;2.56 +13634-1;Rheumatoid factor;ACnc;Pt;Synv fld;Qn;;SERO;1;Rheumatoid factor [Units/volume] in Synovial fluid;Rheumatoid fact Snv-aCnc;;ACTIVE;1.0k;2.73 +13635-8;Ribosomal Ab;Titr;Pt;Ser;Qn;;SERO;1;Ribosomal Ab [Titer] in Serum;Ribosomal Ab Titr Ser;;ACTIVE;1.0k;2.73 +13636-6;Ribosomal P Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ribosomal P Ab [Units/volume] in Serum;Ribosomal P Ab Ser-aCnc;;ACTIVE;1.0k;2.73 +13637-4;Trichloroethane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trichloroethane [Mass/volume] in Serum or Plasma;TCE SerPl-mCnc;;ACTIVE;1.0k;2.70 +13638-2;Chlordecone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chlordecone [Mass/volume] in Blood;Chlordecone Bld-mCnc;;ACTIVE;1.0k;2.70 +13639-0;Chlordecone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlordecone [Mass/volume] in Serum or Plasma;Chlordecone SerPl-mCnc;;ACTIVE;1.0k;2.70 +13640-8;Vinyl chloride;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Vinyl chloride [Mass/volume] in Urine;Vinyl Chloride Ur-mCnc;;ACTIVE;1.0k;2.42 +13641-6;Codeine;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Codeine [Presence] in Urine by SAMHSA confirm method;Codeine Ur Ql SAMHSA Cfm;;ACTIVE;1.0k;2.73 +13642-4;Ethylene glycol;MCnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Ethylene glycol;Deprecated Ethylene Glycol Ur Ql;;DEPRECATED;1.0k;2.36 +13643-2;Lindane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lindane [Mass/volume] in Urine;Lindane Ur-mCnc;;ACTIVE;1.0k;2.73 +13644-0;1,3-Dimethylbenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,3-Dimethylbenzene [Mass/volume] in Blood;1,3DMB Bld-mCnc;;ACTIVE;1.0k;2.73 +13645-7;Manganese;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Water;Manganese Wat-mCnc;;ACTIVE;1.0k;2.70 +13646-5;Methaqualone;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Methaqualone [Mass/mass] in Hair;Methaqualone Hair-mCnt;;ACTIVE;1.0k;2.70 +13647-3;Methylene chloride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Methylene chloride [Mass/volume] in Blood;Deprecated DCM Bld-mCnc;;DEPRECATED;1.0k;2.70 +13648-1;Morphine;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Morphine [Presence] in Urine by SAMHSA confirm method;Morphine Ur Ql SAMHSA Cfm;;ACTIVE;1.0k;2.73 +1364-9;Corticotropin^45M post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --45 minutes post 1 ug/kg CRH IV;ACTH 45M p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;1.0;2.40 +13649-9;Nickel;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Water;Nickel Wat-mCnc;;ACTIVE;1.0k;2.70 +13650-7;1,2-Dimethylbenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,2-Dimethylbenzene [Mass/volume] in Blood;1,2DMB Bld-mCnc;;ACTIVE;1.0k;2.73 +13651-5;1,4-Dimethylbenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,4-Dimethylbenzene [Mass/volume] in Blood;1,4DMB Bld-mCnc;;ACTIVE;1.0k;2.73 +13652-3;Zinc;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Zinc [Mass/mass] in Hair;Zinc Hair-mCnt;;ACTIVE;1.0k;2.73 +13653-1;Epithelial cells.renal;NCnc;Pt;Urine sed;Qn;;UA;1;Epithelial cells.renal [#/volume] in Urine sediment;Renal Epi Cells # UrnS;;ACTIVE;1.0k;2.73 +13654-9;Epithelial cells.squamous;NCnc;Pt;Urine sed;Qn;;UA;1;Epithelial cells.squamous [#/volume] in Urine sediment;Squamous # UrnS;;ACTIVE;1.0k;2.73 +13655-6;Leukocytes;PrThr;Pt;Stool;Ord;Microscopy.light;HEM/BC;1;Leukocytes [Presence] in Stool by Light microscopy;WBC Stl Ql Micro;;ACTIVE;1.0k;2.73 +1365-6;Corticotropin^45M post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --45 minutes post dose insulin IV;ACTH 45M p Ins IV Plas-mCnc;;ACTIVE;1.0;2.40 +13656-4;Phosphate crystals.amorphous;NCnc;Pt;Urine sed;Qn;;UA;1;Phosphate crystals amorphous [#/volume] in Urine sediment;Amorph Phos Cry # UrnS;;ACTIVE;1.0k;2.73 +13657-2;Urate crystals.amorphous;NCnc;Pt;Urine sed;Qn;;UA;1;Urate crystals amorphous [#/volume] in Urine sediment;Amorph Urate Cry # UrnS;;ACTIVE;1.0k;2.73 +13658-0;Urobilinogen;PrThr;Pt;Urine;Ord;;CHEM;1;Urobilinogen [Presence] in Urine;Urobilinogen Ur Ql;;ACTIVE;1.0k;2.73 +13659-8;Epidermal growth factor receptor;MCnt;Pt;Tiss;Qn;;PATH;1;Epidermal growth factor receptor [Mass/mass] in Tissue;EGFR Tiss-mCnt;;ACTIVE;1.0k;2.70 +13660-6;Gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gonadotropin releasing hormone [Mass/volume] in Serum or Plasma;GnRH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13661-4;Ganglioside GD1b Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GD1b IgM Ab [Titer] in Serum;GD1b Gangl IgM Titr Ser;;ACTIVE;1.0k;2.73 +13662-2;Ganglioside GD1b Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GD1b IgG Ab [Titer] in Serum;GD1b Gangl IgG Titr Ser;;ACTIVE;1.0k;2.73 +13663-0;Asialoganglioside GM1 Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Asialoganglioside GM1 IgG Ab [Titer] in Serum;GM1 Asialo IgG Titr Ser;;ACTIVE;1.0k;2.73 +1366-4;Corticotropin^5M post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --5 minutes post 1 ug/kg CRH IV;ACTH 5M p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;1.0;2.40 +13664-8;Myelin associated glycoprotein-sulfated glucuronic paragloboside Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein/Sulfated glucuronic paragloboside IgM Ab [Titer] in Serum;MAG/SGPG IgM Titr Ser;;ACTIVE;1.0k;2.73 +13665-5;1-Methylhistidine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;1-Methylhistidine/Creatinine [Mass Ratio] in Urine;1Me-hist/Creat Ur;;ACTIVE;1.0k;2.73 +13666-3;Alpha aminoadipate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha aminoadipate/Creatinine [Mass Ratio] in Urine;AAA/Creat Ur;;ACTIVE;1.0k;2.73 +13667-1;Alpha aminobutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha aminobutyrate/Creatinine [Mass Ratio] in Urine;A-Aminobutyr/Creat Ur;;ACTIVE;1.0k;2.73 +13668-9;2-Ethyl-3-Hydroxypropionate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Ethyl-3-Hydroxypropionate/Creatinine [Mass Ratio] in Urine;2Ethyl3OH-Prop/Creat Ur;;DISCOURAGED;1.0k;2.70 +13669-7;2-Hydroxy-3-Methylvalerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxy-3-Methylvalerate/Creatinine [Mass Ratio] in Urine;2OH3Me-valerate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13670-5;2-Hydroxyadipate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyadipate/Creatinine [Mass Ratio] in Urine;2OH-adipate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13671-3;Alpha hydroxybutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha hydroxybutyrate/Creatinine [Mass Ratio] in Urine;A-OH-Butyr/Creat Ur;;ACTIVE;1.0k;2.70 +1367-2;Corticotropin^pre 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre 1 ug/kg CRH IV;ACTH pre 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;1.0;2.40 +13672-1;2-Hydroxyglutarate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyglutarate/Creatinine [Mass Ratio] in Urine;2OH-gluterate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13673-9;2-Hydroxyisocaproate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyisocaproate/Creatinine [Mass Ratio] in Urine;2OH-isocaproate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13674-7;2-Hydroxyisovalerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyisovalerate/Creatinine [Mass Ratio] in Urine;2OH-isovalerate/Creat Ur;;DISCOURAGED;1.0k;2.73 +13675-4;2-Methyl-3-Hydroxybutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-methyl-3-hydroxybutyrate (C5-OH)/Creatinine [Mass Ratio] in Urine;2Me3OH-butyrate/Creat Ur;;DISCOURAGED;1.0k;2.54 +13676-2;2-Oxo,3-Methylvalerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Oxo,3-Methylvalerate/Creatinine [Mass Ratio] in Urine;2Oxo3Me-valerate/Creat Ur;;DISCOURAGED;1.0k;2.42 +13677-0;2-Oxoadipate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Oxoadipate/Creatinine [Mass Ratio] in Urine;2-Oxoadipate/Creat Ur;;DISCOURAGED;1.0k;2.42 +13678-8;Alpha ketoglutarate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha ketoglutarate/Creatinine [Mass Ratio] in Urine;A-Ketoglut/Creat Ur;;ACTIVE;1.0k;2.70 +13679-6;2-Oxoisocaproate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Oxoisocaproate/Creatinine [Mass Ratio] in Urine;2Oxoisocaproate/Creat Ur;;DISCOURAGED;1.0k;2.73 +1368-0;Corticotropin^pre dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre dose insulin IV;ACTH pre Ins IV Plas-mCnc;;ACTIVE;1.0;2.40 +13680-4;2-Oxoisovalerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Oxoisovalerate/Creatinine [Mass Ratio] in Urine;2Oxoisovalerate/Creat Ur;;DISCOURAGED;1.0k;2.42 +13681-2;Beta aminoisobutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Beta aminoisobutyrate/Creatinine [Mass Ratio] in Urine;B-AIB/Creat Ur;;DISCOURAGED;1.0k;2.44 +13682-0;3-Hydroxy,3-Methylglutarate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;3-Hydroxy,3-Methylglutarate/Creatinine [Mass Ratio] in Urine;3OH3Me-glutarate/Creat Ur;;ACTIVE;1.0k;2.73 +13683-8;3-Hydroxyadipate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyadipate/Creatinine [Mass Ratio] in Urine;3OH-Adipate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13684-6;Beta hydroxybutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Beta hydroxybutyrate/Creatinine [Mass Ratio] in Urine;B-OH-Butyr/Creat Ur;;ACTIVE;1.0k;2.70 +13685-3;3-Hydroxyglutarate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyglutarate/Creatinine [Mass Ratio] in Urine;3OH-Glutarate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13686-1;3-Hydroxyisobutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyisobutyrate/Creatinine [Mass Ratio] in Urine;3OH-Isobutyrate/Creat Ur;;DISCOURAGED;1.0k;2.73 +13687-9;3-Hydroxyisovalerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyisovalerate/Creatinine [Mass Ratio] in Urine;3OH-Isovalerate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13688-7;3-Hydroxypropionate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxypropionate (3-OH-C3)/Creatinine [Mass Ratio] in Urine;3OH-Propionate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13689-5;3-Hydroxyvalerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyvalerate/Creatinine [Mass Ratio] in Urine;3OH-Valerate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13690-3;Vanillylmandelate/Creatinine;MCrto;Pt;Urine;Qn;;CHEM;1;Deprecated Vanillylmandelate/Creatinine [Mass ratio] in Urine;Deprecated VMA/creat Ur-mRto;;DEPRECATED;1.0k;2.70 +13691-1;3-Methylcrotonylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Methylcrotonylglycine/Creatinine [Mass Ratio] in Urine;3Me-crotonylglycine/Creat Ur;;ACTIVE;1.0k;2.73 +13692-9;3-Methylglutaconate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Methylglutaconate/Creatinine [Mass Ratio] in Urine;3Me-glutaconate/Creat Ur;;DISCOURAGED;1.0k;2.42 +13693-7;3-Methylglutarate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Methylglutarate/Creatinine [Mass Ratio] in Urine;3Me-glutarate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13694-5;3-Methylhistidine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Methylhistidine/Creatinine [Mass Ratio] in Urine;3Me-histidine/Creat Ur;;ACTIVE;1.0k;2.73 +13695-2;Gamma aminobutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Gamma aminobutyrate/Creatinine [Mass Ratio] in Urine;GABA/Creat Ur;;ACTIVE;1.0k;2.73 +13696-0;4-Hydroxyphenylacetate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;4-Hydroxyphenylacetate/Creatinine [Mass Ratio] in Urine;4OH-phenylacetate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13697-8;4-Hydroxyphenyllactate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxyphenyllactate/Creatinine [Mass Ratio] in Urine;4OH-phenyllactate/Creat Ur;;DISCOURAGED;1.0k;2.73 +1369-8;Ascorbate^post dose PO;MRat;24H;Urine;Qn;;CHAL;1;Ascorbate [Mass/time] in 24 hour Urine --post dose PO;Vit C p PO 24h Ur-mRate;;ACTIVE;1.0;2.42 +13698-6;4-Hydroxyphenylpyruvate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxyphenylpyruvate/Creatinine [Mass Ratio] in Urine;4OH-phenylpyruvate/Creat Ur;;DISCOURAGED;1.0k;2.70 +13699-4;5-Hydroxyhexanoate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;5-Hydroxyhexanoate/Creatinine [Mass Ratio] in Urine;5OH-Hexanoate/Creat Ur;;ACTIVE;1.0k;2.70 +137-0;Ceftizoxime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceftizoxime [Susceptibility] by Minimum inhibitory concentration (MIC);Ceftizoxime Islt MIC;;ACTIVE;1.0;2.73 +13700-0;5-Oxoproline/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;5-Oxoproline/Creatinine [Mass Ratio] in Urine;5Oxoproline/Creat Ur;;ACTIVE;1.0k;2.70 +13701-8;Acetoacetate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Acetoacetate/Creatinine [Mass Ratio] in Urine;Acetoacet/Creat Ur;;ACTIVE;1.0k;2.70 +13702-6;Aconitate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Aconitate/Creatinine [Mass Ratio] in Urine;Aconitate/Creat Ur;;ACTIVE;1.0k;2.70 +13703-4;Adipate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Adipate/Creatinine [Mass Ratio] in Urine;Adipate/Creat Ur;;ACTIVE;1.0k;2.73 +13704-2;Alanine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alanine/Creatinine [Mass Ratio] in Urine;Alanine/Creat Ur;;DISCOURAGED;1.0k;2.44 +13705-9;Albumin/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Albumin/Creatinine [Mass Ratio] in 24 hour Urine;Albumin/Creat 24h Ur;;ACTIVE;1.0k;2.73 +1370-6;Carotene^post 15000 U carotene QDx3 for 3D poly;MCnc;Pt;Ser;Qn;;CHAL;1;Carotene [Mass/volume] in Serum --post 15000 U carotene QDx3 for 3 day poly;Carotene p 15000 U BC QDx3 Ser-mCnc;;ACTIVE;1.0;2.34 +13706-7;Amylase/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Amylase/Creatinine [Mass Ratio] in Urine;Amylase/Creat Ur;;ACTIVE;1.0k;2.73 +13707-5;Anserine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Anserine/Creatinine [Mass Ratio] in Urine;Anserine/Creat Ur;;ACTIVE;1.0k;2.73 +13708-3;Arginine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Arginine/Creatinine [Mass Ratio] in Urine;Arginine/Creat Ur;;ACTIVE;1.0k;2.73 +13709-1;Argininosuccinate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Argininosuccinate/Creatinine [Mass Ratio] in Urine;Argininosuccinate/Creat Ur;;ACTIVE;1.0k;2.70 +13710-9;Asparagine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Asparagine/Creatinine [Mass Ratio] in Urine;Asparagine/Creat Ur;;ACTIVE;1.0k;2.73 +13711-7;Aspartate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Aspartate/Creatinine [Mass Ratio] in Urine;Aspartate/Creat Ur;;ACTIVE;1.0k;2.73 +13712-5;Azelate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Azelate/Creatinine [Mass Ratio] in Urine;Azelate/Creat Ur;;ACTIVE;1.0k;2.70 +13713-3;Benzoate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Benzoate/Creatinine [Mass Ratio] in Urine;Benzoate/Creat Ur;;DISCOURAGED;1.0k;2.44 +1371-4;Bromsulphthalein;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromsulphthalein [Mass/volume] in Serum or Plasma;Bromsulphthalein SerPl-mCnc;;ACTIVE;1.0;2.34 +13714-1;Beta alanine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Beta alanine/Creatinine [Mass Ratio] in Urine;B-Alanine/Creat Ur;;DISCOURAGED;1.0k;2.44 +13715-8;C peptide/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;C peptide/Creatinine [Mass Ratio] in 24 hour Urine;C peptide/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13716-6;C peptide/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;C peptide/Creatinine [Mass Ratio] in Urine;C peptide/Creat Ur;;ACTIVE;1.0k;2.42 +13717-4;Calcium/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Calcium/Creatinine [Mass Ratio] in 24 hour Urine;Calcium/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13718-2;Carnitine.free (C0)/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Carnitine free (C0)/Creatinine [Mass Ratio] in Urine;Carnitine Free/Creat Ur;;DISCOURAGED;1.0k;2.73 +13719-0;Carnitine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Carnitine/Creatinine [Mass Ratio] in Urine;Carnitine/Creat Ur;;DISCOURAGED;1.0k;2.73 +13720-8;Carnosine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Carnosine/Creatinine [Mass Ratio] in Urine;Carnosine/Creat Ur;;ACTIVE;1.0k;2.73 +13721-6;Chloride/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Chloride/Creatinine [Mass Ratio] in 24 hour Urine;Chloride/Creat 24h Ur;;ACTIVE;1.0k;2.73 +1372-2;Calcitonin^90s post 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --90 seconds post 0.5 ug/kg pentagastrin IV;Calcit 90S p 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;1.0;2.38 +13722-4;Citrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Citrate/Creatinine [Mass Ratio] in Urine;Citrate/Creat Ur;;ACTIVE;1.0k;2.73 +13723-2;Citrulline/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Citrulline/Creatinine [Mass Ratio] in Urine;Citrulline/Creat Ur;;DISCOURAGED;1.0k;2.44 +13724-0;Cystathionine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Cystathionine/Creatinine [Mass Ratio] in Urine;Cystathionin/Creat Ur;;DISCOURAGED;1.0k;2.44 +13725-7;Cystine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Cystine/Creatinine [Mass Ratio] in Urine;Cystine/Creat Ur;;ACTIVE;1.0k;2.73 +13726-5;Decadienediate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Decadienediate/Creatinine [Mass Ratio] in Urine;Decadienediate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13727-3;Decenedioate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Decenedioate/Creatinine [Mass Ratio] in Urine;Decenedioate/Creat Ur;;DISCOURAGED;1.0k;2.54 +13728-1;Delta aminolevulinate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Delta aminolevulinate/Creatinine [Mass Ratio] in Urine;D-ALA/Creat Ur;;ACTIVE;1.0k;2.73 +13729-9;Deoxypyridinoline/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Deoxypyridinoline/Creatinine [Mass Ratio] in Urine;DPD/Creat Ur;;DISCOURAGED;1.0k;2.73 +1373-0;Calcitonin^10M post 2.4 mg/kg calcium short IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --10 minutes post 2.4 mg/kg calcium short IV;Calcit 10M p 2.4 mg/kgCa sIV SerPl-mCnc;;ACTIVE;1.0;2.34 +13730-7;Deoxypyridinoline/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Deoxypyridinoline/Creatinine [Mass Ratio] in 24 hour Urine;DPD/Creat 24h Ur;;DISCOURAGED;1.0k;2.73 +13731-5;Deoxypyridinoline/Creatinine;MRto;2H;Urine;Qn;;CHEM;1;Deoxypyridinoline/Creatinine [Mass Ratio] in 2 hour Urine;DPD/Creat 2h Ur;;DISCOURAGED;1.0k;2.73 +13732-3;Dodecanedioate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Dodecanedioate/Creatinine [Mass Ratio] in Urine;DDDA/Creat Ur;;ACTIVE;1.0k;2.73 +13733-1;DOPamine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;DOPamine/Creatinine [Mass Ratio] in Urine;DOPamine/Creat Ur;;ACTIVE;1.0k;2.73 +13734-9;EPINEPHrine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;EPINEPHrine/Creatinine [Mass Ratio] in Urine;Epineph/Creat Ur;;ACTIVE;1.0k;2.73 +13735-6;Epinephrine+Norepinephrine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Epinephrine+Norepinephrine/Creatinine [Mass Ratio] in Urine;Epineph+Nor/Creat Ur;;ACTIVE;1.0k;2.73 +13736-4;Estradiol/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Estradiol (E2)/Creatinine [Mass Ratio] in 24 hour Urine;Estradiol/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13737-2;Estriol/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Estriol (E3)/Creatinine [Mass Ratio] in 24 hour Urine;Estriol/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13738-0;Estrogen/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Estrogen/Creatinine [Mass Ratio] in 24 hour Urine;Estrogen/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13739-8;Estrone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Estrone (E1)/Creatinine [Mass Ratio] in 24 hour Urine;Estrone/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13740-6;Ethanolamine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Ethanolamine/Creatinine [Mass Ratio] in Urine;Ethanolamine/Creat Ur;;ACTIVE;1.0k;2.73 +13741-4;Ethylmalonate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Ethylmalonate/Creatinine [Mass Ratio] in Urine;Ethylmalonate/Creat Ur;;ACTIVE;1.0k;2.73 +13742-2;Formate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Formate/Creatinine [Mass Ratio] in Urine;Formate/Creat Ur;;ACTIVE;1.0k;2.73 +13743-0;Fumarate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Fumarate/Creatinine [Mass Ratio] in Urine;Fumarate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13744-8;Galactose/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Galactose/Creatinine [Mass Ratio] in Urine;Galactose/Creat Ur;;ACTIVE;1.0k;2.44 +13745-5;Glutaconate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glutaconate/Creatinine [Mass Ratio] in Urine;Glutaconate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13746-3;Glutamate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glutamate/Creatinine [Mass Ratio] in Urine;Glutamate/Creat Ur;;ACTIVE;1.0k;2.73 +13747-1;Glutamine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glutamine/Creatinine [Mass Ratio] in Urine;Glutamine/Creat Ur;;ACTIVE;1.0k;2.73 +1374-8;Calcitonin^3H post 15 mg/kg calcium gluconate IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --3 hours post 15 mg/kg calcium gluconate IV;Calcit 3h p 15 mg/kg CaG IV SerPl-mCnc;;ACTIVE;1.0;2.34 +13748-9;Glutarate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glutarate/Creatinine [Mass Ratio] in Urine;Glutarate/Creat Ur;;ACTIVE;1.0k;2.73 +13749-7;Glycerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glycerate/Creatinine [Mass Ratio] in Urine;Glycerate/Creat Ur;;ACTIVE;1.0k;2.73 +13750-5;Glycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glycine/Creatinine [Mass Ratio] in Urine;Glycine/Creat Ur;;ACTIVE;1.0k;2.73 +13751-3;Glycolate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glycolate/Creatinine [Mass Ratio] in Urine;Glycolate/Creat Ur;;ACTIVE;1.0k;2.73 +13752-1;Glyoxylate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glyoxylate/Creatinine [Mass Ratio] in Urine;Glyoxylate/Creat Ur;;DISCOURAGED;1.0k;2.73 +13753-9;Hexanoylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Hexanoylglycine/Creatinine [Mass Ratio] in Urine;Hexanoylgly/Creat Ur;;ACTIVE;1.0k;2.73 +13754-7;Hippurate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Hippurate/Creatinine [Mass Ratio] in Urine;Hippurate/Creat Ur;;ACTIVE;1.0k;2.73 +1375-5;Calcitonin^4H post 15 mg/kg calcium gluconate IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --4 hours post 15 mg/kg calcium gluconate IV;Calcit 4h p 15 mg/kg CaG IV SerPl-mCnc;;ACTIVE;1.0;2.34 +13755-4;Histamine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Histamine/Creatinine [Mass Ratio] in Urine;Histamine/Creat Ur;;ACTIVE;1.0k;2.73 +13756-2;Histamine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Histamine/Creatinine [Mass Ratio] in 24 hour Urine;Histamine/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13757-0;Histidine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Histidine/Creatinine [Mass Ratio] in Urine;Histidine/Creat Ur;;ACTIVE;1.0k;2.73 +13758-8;Homocysteine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Homocysteine/Creatinine [Mass Ratio] in Urine;Hcys/Creat Ur;;DISCOURAGED;1.0k;2.73 +13759-6;Homocystine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Homocystine/Creatinine [Mass Ratio] in Urine;(Hcys)2/Creat Ur;;ACTIVE;1.0k;2.73 +13760-4;Homovanillate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Homovanillate/Creatinine [Mass Ratio] in 24 hour Urine;HVA/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13761-2;Hydroxydecanedioate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Hydroxydecanedioate/Creatinine [Mass Ratio] in Urine;OH-Decanedioate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13762-0;Hydroxylysine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Hydroxylysine/Creatinine [Mass Ratio] in Urine;OH-Lysine/Creat Ur;;DISCOURAGED;1.0k;2.44 +1376-3;Calcitonin^5M post 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --5 minutes post 0.5 ug/kg pentagastrin IV;Calcit 5M p 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;1.0;2.34 +13763-8;Hydroxyproline/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Hydroxyproline/Creatinine [Mass Ratio] in Urine;OH-Proline/Creat Ur;;ACTIVE;1.0k;2.73 +13764-6;Isocitrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Isocitrate/Creatinine [Mass Ratio] in Urine;Isocitrate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13765-3;Isoleucine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Isoleucine/Creatinine [Mass Ratio] in Urine;Isoleucine/Creat Ur;;ACTIVE;1.0k;2.73 +13766-1;Isovalerylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Isovalerylglycine/Creatinine [Mass Ratio] in Urine;Isovalerylgly/Creat Ur;;ACTIVE;1.0k;2.73 +13767-9;Lactate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Lactate/Creatinine [Mass Ratio] in Urine;Lactate/Creat Ur;;ACTIVE;1.0k;2.44 +13768-7;Leucine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Leucine/Creatinine [Mass Ratio] in Urine;Leucine/Creat Ur;;ACTIVE;1.0k;2.73 +13769-5;Lysine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Lysine/Creatinine [Mass Ratio] in Urine;Lysine/Creat Ur;;ACTIVE;1.0k;2.73 +13770-3;Malate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Malate/Creatinine [Mass Ratio] in Urine;Malate/Creat Ur;;DISCOURAGED;1.0k;2.44 +1377-1;Calcitonin^5M post 2.4 mg/kg calcium short IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --5 minutes post 2.4 mg/kg calcium short IV;Calcit 5M p 2.4 mg/kgCa sIV SerPl-mCnc;;ACTIVE;1.0;2.34 +13771-1;Metanephrines/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Metanephrines/Creatinine [Mass Ratio] in Urine;MetanephS/Creat Ur;;ACTIVE;1.0k;2.73 +13772-9;Methionine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Methionine/Creatinine [Mass Ratio] in Urine;Methionine/Creat Ur;;ACTIVE;1.0k;2.73 +13773-7;2-Methylcitrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Methylcitrate/Creatinine [Mass Ratio] in Urine;2Me-citrate/Creat Ur;;DISCOURAGED;1.0k;2.73 +13774-5;Methylhippurate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methylhippurate/Creatinine [Mass Ratio] in Urine;Methylhippurate/Creat Ur;;ACTIVE;1.0k;2.73 +13775-2;Methylmalonate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Methylmalonate/Creatinine [Mass Ratio] in 24 hour Urine;Methylmalonate/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13776-0;Methylmalonate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Methylmalonate/Creatinine [Mass Ratio] in Urine;Methylmalonate/Creat Ur;;ACTIVE;1.0k;2.73 +13777-8;Methylsuccinate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Methylsuccinate/Creatinine [Mass Ratio] in Urine;Me-succinate/Creat Ur;;ACTIVE;1.0k;2.73 +13778-6;Mevalonate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Mevalonate/Creatinine [Mass Ratio] in Urine;Mevalonate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13779-4;N-acetyl-L-aspartate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;N-acetyl-L-aspartate/Creatinine [Mass Ratio] in Urine;N-Ac-L-Asp/Creat Ur;;ACTIVE;1.0k;2.73 +13780-2;N-acetyltyrosine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;N-acetyltyrosine/Creatinine [Mass Ratio] in Urine;NAT/Creat Ur;;DISCOURAGED;1.0k;2.44 +13781-0;N-methylhistamine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;N-methylhistamine/Creatinine [Mass Ratio] in Urine;Me-histamine/Creat Ur;;ACTIVE;1.0k;2.73 +13782-8;Norepinephrine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Norepinephrine/Creatinine [Mass Ratio] in Urine;Norepineph/Creat Ur;;ACTIVE;1.0k;2.73 +13783-6;Normetanephrine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Normetanephrine/Creatinine [Mass Ratio] in Urine;Normetanephrine/Creat Ur;;ACTIVE;1.0k;2.73 +13784-4;Octanoate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Octanoate (C8:0)/Creatinine [Mass Ratio] in Urine;Octanoate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13785-1;Octenedioate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Octenedioate (C8:1)/Creatinine [Mass Ratio] in Urine;Octenedioate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13786-9;Ornithine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Ornithine/Creatinine [Mass Ratio] in Urine;Ornithine/Creat Ur;;ACTIVE;1.0k;2.73 +13787-7;Orotate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Orotate/Creatinine [Mass Ratio] in Urine;Orotate/Creat Ur;;ACTIVE;1.0k;2.73 +13788-5;Oxalate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Oxalate/Creatinine [Mass Ratio] in 24 hour Urine;Oxalate/Creat 24h Ur;;ACTIVE;1.0k;2.73 +1378-9;Calcitonin^pre 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --pre 0.5 ug/kg pentagastrin IV;Calcit pre 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;1.0;2.73 +13789-3;Phosphoethanolamine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Phosphoethanolamine/Creatinine [Mass Ratio] in Urine;PETN/Creat Ur;;ACTIVE;1.0k;2.73 +13790-1;Para nitrophenol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Para nitrophenol/Creatinine [Mass Ratio] in Urine;p-nitrophenol/Creat Ur;;ACTIVE;1.0k;2.44 +13791-9;Phenylacetate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Phenylacetate/Creatinine [Mass Ratio] in Urine;Phenylacetate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13792-7;Phenyllactate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Phenyllactate/Creatinine [Mass Ratio] in Urine;Phenyllactate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13793-5;Phenylpropionylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Phenylpropionylglycine/Creatinine [Mass Ratio] in Urine;PPG/Creat Ur;;ACTIVE;1.0k;2.73 +13794-3;Phenylpyruvate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Phenylpyruvate/Creatinine [Mass Ratio] in Urine;Phenylpyruvate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13795-0;Phosphate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Phosphate/Creatinine [Mass Ratio] in 24 hour Urine;Phosphate/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13796-8;Phosphoserine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Phosphoserine/Creatinine [Mass Ratio] in Urine;Phosphoserine/Creat Ur;;ACTIVE;1.0k;2.73 +1379-7;Calcitonin^pre 2.4 mg/kg calcium short IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --pre 2.4 mg/kg calcium short IV;Calcit pre 2.4 mg/kgCa sIV SerPl-mCnc;;ACTIVE;1.0;2.34 +13797-6;Porphobilinogen/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Porphobilinogen/Creatinine [Mass Ratio] in Urine;PBG/Creat Ur;;ACTIVE;1.0k;2.73 +13798-4;Potassium/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Potassium/Creatinine [Mass Ratio] in 24 hour Urine;Potassium/Creat 24h Ur;;DISCOURAGED;1.0k;2.44 +13799-2;Proline/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Proline/Creatinine [Mass Ratio] in Urine;Proline/Creat Ur;;ACTIVE;1.0k;2.73 +13800-8;Propionylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Propionylglycine/Creatinine [Mass Ratio] in Urine;Propionylgly/Creat Ur;;DISCOURAGED;1.0k;2.73 +13801-6;Protein/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Protein/Creatinine [Mass Ratio] in 24 hour Urine;Prot/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13802-4;Pyridinoline/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Pyridinoline/Creatinine [Mass Ratio] in Urine;PYD/Creat Ur;;DISCOURAGED;1.0k;2.44 +13803-2;Pyridinoline/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Pyridinoline/Creatinine [Mass Ratio] in 24 hour Urine;PYD/Creat 24h Ur;;DISCOURAGED;1.0k;2.73 +13804-0;Pyridinoline/Creatinine;MRto;2H;Urine;Qn;;CHEM;1;Pyridinoline/Creatinine [Mass Ratio] in 2 hour Urine;PYD/Creat 2h Ur;;DISCOURAGED;1.0k;2.73 +1380-5;Calcium/Phosphate parathyroid-challenge test;MRto;Pt;Ser;Qn;;CHAL;1;Calcium/Phosphate parathyroid-challenge test [Mass Ratio] in Serum;Calcium/Phos PTH Chall Ser;;ACTIVE;1.0;2.73 +13805-7;Pyruvate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Pyruvate/Creatinine [Mass Ratio] in Urine;Pyruvate/Creat Ur;;ACTIVE;1.0k;2.44 +13806-5;Sarcosine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Sarcosine/Creatinine [Mass Ratio] in Urine;Sarcosine/Creat Ur;;DISCOURAGED;1.0k;2.44 +13807-3;Sebacate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Sebacate (C8)/Creatinine [Mass Ratio] in Urine;Sebacate/Creat Ur;;DISCOURAGED;1.0k;2.44 +13808-1;Serine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Serine/Creatinine [Mass Ratio] in Urine;Serine/Creat Ur;;ACTIVE;1.0k;2.73 +13809-9;Sodium/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Sodium/Creatinine [Mass Ratio] in 24 hour Urine;Sodium/Creat 24h Ur;;DISCOURAGED;1.0k;2.44 +13810-7;Suberate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Suberate/Creatinine [Mass Ratio] in Urine;Suberate/Creat Ur;;DISCOURAGED;1.0k;2.73 +13811-5;Suberylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Suberylglycine/Creatinine [Mass Ratio] in Urine;Suberylgly/Creat Ur;;ACTIVE;1.0k;2.73 +13812-3;Succinate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Succinate/Creatinine [Mass Ratio] in Urine;Succinate/Creat Ur;;DISCOURAGED;1.0k;2.44 +1381-3;Calcium^10M post 2.4 mg/kg calcium short IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --10 minutes post 2.4 mg/kg calcium short IV;Calcium 10M p 2.4 mg/kgCa sIV SerPl-sCnc;;ACTIVE;1.0;2.34 +13813-1;Succinylacetone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Succinylacetone/Creatinine [Mass Ratio] in Urine;Succinylacetone/Creat Ur;;DISCOURAGED;1.0k;2.44 +13814-9;Taurine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Taurine/Creatinine [Mass Ratio] in Urine;Taurine/Creat Ur;;ACTIVE;1.0k;2.73 +13815-6;Threonine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Threonine/Creatinine [Mass Ratio] in Urine;Threonine/Creat Ur;;ACTIVE;1.0k;2.73 +13816-4;Tiglylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tiglylglycine/Creatinine [Mass Ratio] in Urine;Tiglylgly/Creat Ur;;DISCOURAGED;1.0k;2.73 +13817-2;Tryptophan/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tryptophan/Creatinine [Mass Ratio] in Urine;Tryptophan/Creat Ur;;ACTIVE;1.0k;2.73 +13818-0;Tyrosine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tyrosine/Creatinine [Mass Ratio] in Urine;Tyrosine/Creat Ur;;ACTIVE;1.0k;2.73 +13819-8;Uracil/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Uracil/Creatinine [Mass Ratio] in Urine;Uracil/Creat Ur;;ACTIVE;1.0k;2.42 +13820-6;Urate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Urate/Creatinine [Mass Ratio] in 24 hour Urine;Urate/Creat 24h Ur;;ACTIVE;1.0k;2.73 +1382-1;Calcium^5M post 2.4 mg/kg calcium short IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --5 minutes post 2.4 mg/kg calcium short IV;Calcium 5M p 2.4 mg/kgCa sIV SerPl-sCnc;;ACTIVE;1.0;2.34 +13821-4;Urea nitrogen/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Urea nitrogen/Creatinine [Mass Ratio] in 24 hour Urine;UUN/Creat 24h Ur;;ACTIVE;1.0k;2.70 +13822-2;Valine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Valine/Creatinine [Mass Ratio] in Urine;Valine/Creat Ur;;ACTIVE;1.0k;2.73 +13823-0;Antimony/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Antimony/Creatinine [Mass Ratio] in Urine;Antimony/Creat Ur;;ACTIVE;1.0k;2.73 +13824-8;Arsenic/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Arsenic/Creatinine [Mass Ratio] in 24 hour Urine;Arsenic/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13825-5;Arsenic.inorganic/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic/Creatinine [Mass Ratio] in Urine;Inorg Arsenic/Creat Ur;;ACTIVE;1.0k;2.73 +13826-3;Barium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Barium/Creatinine [Mass Ratio] in Urine;Barium/Creat Ur;;ACTIVE;1.0k;2.70 +13827-1;Beryllium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Beryllium/Creatinine [Mass Ratio] in Urine;Beryllium/Creat Ur;;ACTIVE;1.0k;2.73 +13828-9;Cadmium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Cadmium/Creatinine [Mass Ratio] in 24 hour Urine;Cadmium/Creat 24h Ur;;ACTIVE;1.0k;2.73 +13829-7;Copper/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Copper/Creatinine [Mass Ratio] in Urine;Copper/Creat Ur;;ACTIVE;1.0k;2.73 +13830-5;Phenylglyoxylate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Phenylglyoxylate/Creatinine [Mass Ratio] in Urine;Phenylglyoxylate/Creat Ur;;ACTIVE;1.0k;2.73 +13831-3;Vanadium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Vanadium/Creatinine [Mass Ratio] in Urine;Vanadium/Creat Ur;;ACTIVE;1.0k;2.73 +13832-1;Dimethylbenzene/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Dimethylbenzene/Creatinine [Mass Ratio] in Urine;DMB/Creat Ur;;ACTIVE;1.0k;2.70 +13833-9;Finch feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Finch feather IgE Ab [Units/volume] in Serum;Finch Feather IgE Qn;;ACTIVE;1.0k;2.73 +13834-7;IgE.total;ACnc;Pt;Ser;Qn;RAST;ALLERGY;1;Total IgE [Units/volume] in Serum by Radioallergosorbent test (RAST);Total IgE Qn RAST;;ACTIVE;1.0k;2.73 +13835-4;Monocytes/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Peritoneal fluid by Manual count;Monocytes/leuk NFr Prt Manual;;ACTIVE;1.0k;2.73 +13836-2;Neutrophils/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Peritoneal fluid by Manual count;Neutrophils/leuk NFr Prt Manual;;ACTIVE;1.0k;2.73 +13837-0;Blasts.CD10/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD10 blasts/100 blasts in Blood;CD10 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13838-8;Blasts.CD13/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD13 blasts/100 blasts in Blood;CD13 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +1383-9;Calcium^pre 2.4 mg/kg calcium short IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --pre 2.4 mg/kg calcium short IV;Calcium pre 2.4 mg/kgCa sIV SerPl-sCnc;;ACTIVE;1.0;2.34 +13839-6;Blasts.CD14/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD14 blasts/100 blasts in Blood;CD14 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13840-4;Blasts.CD19/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19 blasts/100 blasts in Blood;CD19 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13841-2;Blasts.CD2/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD2 blasts/100 blasts in Blood;CD2 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13842-0;Blasts.CD20/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20 blasts/100 blasts in Blood;CD20 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13843-8;Blasts.CD33/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD33 blasts/100 blasts in Blood;CD33 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13844-6;Blasts.CD34/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD34 blasts/100 blasts in Blood;CD34 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13845-3;Blasts.CD5/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5 blasts/100 blasts in Blood;CD5 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +13846-1;Blasts.CD7/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD7 blasts/100 blasts in Blood;CD7 Blasts NFr Bld;;ACTIVE;1.0k;2.70 +1384-7;Calcium^post calcium infusion;SCnc;Pt;Bld;Qn;;CHAL;1;Calcium [Moles/volume] in Blood --post calcium infusion;Calcium p Ca inf Bld-sCnc;;ACTIVE;1.0;2.34 +13847-9;Blasts.terminal deoxyribonucleotidyl transferase/100 blasts;NFr;Pt;Bld;Qn;Immunoperoxidase stain;CELLMARK;1;Terminal Deoxyribonucleotidyl Transferase blasts/100 blasts in Blood by Immunoperoxidase stain;TdT Blasts NFr Bld IP Stn;;ACTIVE;1.0k;2.70 +13848-7;Cells.CD3+CD26+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD26+ cells [#/volume] in Blood;CD3+CD26+ Cells # Bld;;ACTIVE;1.0k;2.42 +13849-5;Lymphocytes.CD3+CD26+/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD3+CD26+ cells/100 cells in Blood;Deprecated Lymphocytes.CD3+CD26+ Fr Bld;;DEPRECATED;1.0k;2.46 +13850-3;Cells.CD5+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD5+CD25+ cells [#/volume] in Blood;CD5+CD25+ Cells # Bld;;ACTIVE;1.0k;2.42 +13851-1;Cells.CD5+CD25+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5+CD25+ cells/100 cells in Blood;CD5+CD25+ Cells NFr Bld;;ACTIVE;1.0k;2.70 +13852-9;Aldosterone^1H post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM;Aldost 1h p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0k;2.73 +13853-7;Aldosterone^1H post 25 mg captopril PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --1 hour post 25 mg captopril PO;Aldost 1h p 25 mg Cpl PO SerPl-mCnc;;ACTIVE;1.0k;2.70 +1385-4;Catecholamines.free fractionated^1H post 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines Free fractionated [Mass/volume] in Plasma --1 hour post 300 ug cloNIDine PO;FCA Fract 1h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +13854-5;Aldosterone^2H post 25 mg captopril PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --2 hours post 25 mg captopril PO;Aldost 2h p 25 mg Cpl PO SerPl-mCnc;;ACTIVE;1.0k;2.70 +13855-2;Aldosterone^30M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;Aldost 30M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0k;2.70 +13856-0;Androstenedione^15M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --15 minutes post 250 ug corticotropin IM;Androst 15M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0k;2.70 +13857-8;Androstenedione^1H post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM;Androst 1h p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0k;2.73 +13858-6;Androstenedione^30M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;Androst 30M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0k;2.70 +13859-4;C peptide^10M post 1 mg glucagon IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --10 minutes post 1 mg glucagon IV;C peptide 10M p 1 mg Gc IV SerPl-mCnc;;ACTIVE;1.0k;2.70 +13860-2;C peptide^15M post 1 mg glucagon IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --15 minutes post 1 mg glucagon IV;C peptide 15M p 1 mg Gc PO SerPl-mCnc;;ACTIVE;1.0k;2.70 +13861-0;C peptide^5M post 1 mg glucagon IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --5 minutes post 1 mg glucagon IV;C peptide 5M p 1 mg Gc IV SerPl-mCnc;;ACTIVE;1.0k;2.73 +1386-2;Catecholamines.free fractionated^2H post 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines Free fractionated [Mass/volume] in Plasma --2 hours post 300 ug cloNIDine PO;FCA Fract 2h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.42 +13862-8;Dehydroepiandrosterone^15M post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --15 minutes post 250 ug corticotropin;DHEA 15M p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13863-6;Dehydroepiandrosterone^1H post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;DHEA 1h p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13864-4;Dehydroepiandrosterone^30M post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;DHEA 30M p 250 ug ACTH SerPl-mCnc;;ACTIVE;1.0k;2.73 +13865-1;Glucose^2.5H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.5 hours post 50 g lactose PO;Glucose 2.5h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0k;2.73 +13866-9;Glucose^5H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post 50 g lactose PO;Glucose 5h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0k;2.34 +13867-7;Renin^1H post 25 mg captopril PO;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --1 hour post 25 mg captopril PO;Renin 1h p 25 mg Cpl PO Plas-cCnc;;ACTIVE;1.0k;2.42 +13868-5;Renin^2H post 25 mg captopril PO;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --2 hours post 25 mg captopril PO;Renin 2h p 25 mg Cpl PO Plas-cCnc;;ACTIVE;1.0k;2.42 +13869-3;Thyrotropin^1.5H post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose TRH IV;TSH 1.5h p TRH IV SerPl-mCnc;;DISCOURAGED;1.0k;2.42 +1387-0;Catecholamines.free fractionated^3H post 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines Free fractionated [Mass/volume] in Plasma --3 hours post 300 ug cloNIDine PO;FCA Fract 3h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.42 +13870-1;Thyrotropin^15M post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --15 minutes post dose TRH IV;TSH 15M p TRH IV SerPl-mCnc;;DISCOURAGED;1.0k;2.73 +13871-9;Thyrotropin^2H post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --2 hours post dose TRH IV;TSH 2h p TRH IV SerPl-mCnc;;DISCOURAGED;1.0k;2.42 +13872-7;11-Deoxycortisol;MRat;24H;Urine;Qn;;CHEM;1;11-Deoxycortisol [Mass/time] in 24 hour Urine;11DC 24h Ur-mRate;;ACTIVE;1.0k;2.73 +13873-5;Albumin.glycated/Albumin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Albumin.glycated/Albumin.total in Serum or Plasma;Albumin Glycated MFr SerPl;;ACTIVE;1.0k;2.73 +13874-3;Alkaline phosphatase.liver 1;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.liver 1 [Enzymatic activity/volume] in Serum or Plasma;ALP Liver 1 SerPl-cCnc;;ACTIVE;1.0k;2.73 +13875-0;Alkaline phosphatase.liver 2;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.liver 2 [Enzymatic activity/volume] in Serum or Plasma;ALP Liver 2 SerPl-cCnc;;ACTIVE;1.0k;2.73 +13876-8;Beta-2 transferrin;PrThr;Pt;Body fld;Ord;;CHEM;1;Beta-2 transferrin [Presence] in Body fluid;B2 Transferrin Fld Ql;;ACTIVE;1.0k;2.73 +13877-6;Bilirubin;PrThr;Pt;Amnio fld;Ord;;CHEM;1;Bilirubin.total [Presence] in Amniotic fluid;Bilirub Amn Ql;;ACTIVE;1.0k;2.56 +13878-4;Collagen type 1 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Collagen type 1 IgG Ab [Units/volume] in Serum;Collagen1 IgG Ser-aCnc;;ACTIVE;1.0k;2.69 +13879-2;Collagen type 2 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Collagen type 2 IgG Ab [Units/volume] in Serum;Collagen2 IgG Ser-aCnc;;ACTIVE;1.0k;2.73 +138-8;Ceftizoxime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceftizoxime [Susceptibility] by Disk diffusion (KB);Ceftizoxime Islt KB;;ACTIVE;1.0;2.73 +13880-0;Collagen type 4 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Collagen type 4 IgG Ab [Units/volume] in Serum;Collagen4 IgG Ser-aCnc;;ACTIVE;1.0k;2.69 +13881-8;Deoxypyridinoline.free/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deoxypyridinoline Free/Creatinine [Molar ratio] in Urine;DPD Free/Creat Ur-sRto;;ACTIVE;1.0k;2.73 +13882-6;Androstanolone.free/Androstanolone.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Androstanolone Free/Androstanolone.total in Serum or Plasma;Androstanolone Free MFr SerPl;;ACTIVE;1.0k;2.73 +13883-4;Estradiol.bioavailable/Estradiol.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2).bioavailable/Estradiol (E2).total in Serum or Plasma;Estradiol Bioavail MFr SerPl;;ACTIVE;1.0k;2.73 +13884-2;Estradiol.bioavailable;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2).bioavailable [Mass/volume] in Serum or Plasma;Estradiol Bioavail SerPl-mCnc;;ACTIVE;1.0k;2.73 +13885-9;Estrogen/Creatinine;MCrto;24H;Urine;Qn;;CHEM;1;Deprecated Estrogen/Creatinine [Mass ratio] in 24 hour Urine;Deprecated Estrogen/creat 24H Ur-mRto;;DEPRECATED;1.0k;2.70 +13886-7;Lactate dehydrogenase 1/Lactate dehydrogenase.total;CFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 1/Lactate dehydrogenase.total in Urine by Electrophoresis;LDH1 CFr Ur Elph;;ACTIVE;1.0k;2.73 +13887-5;Lactate dehydrogenase 2/Lactate dehydrogenase.total;CFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 2/Lactate dehydrogenase.total in Urine by Electrophoresis;LDH2 CFr Ur Elph;;ACTIVE;1.0k;2.70 +1388-8;Catecholamines.free fractionated^pre 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines Free fractionated [Mass/volume] in Plasma --pre 300 ug cloNIDine PO;FCA Fract pre 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +13888-3;Lactate dehydrogenase 3/Lactate dehydrogenase.total;CFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 3/Lactate dehydrogenase.total in Urine by Electrophoresis;LDH3 CFr Ur Elph;;ACTIVE;1.0k;2.70 +13889-1;Lactate dehydrogenase 4/Lactate dehydrogenase.total;CFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 4/Lactate dehydrogenase.total in Urine by Electrophoresis;LDH4 CFr Ur Elph;;ACTIVE;1.0k;2.70 +13890-9;Lactate dehydrogenase 5/Lactate dehydrogenase.total;CFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 5/Lactate dehydrogenase.total in Urine by Electrophoresis;LDH5 CFr Ur Elph;;ACTIVE;1.0k;2.70 +13891-7;Motilin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Motilin [Mass/volume] in Serum or Plasma;Motilin SerPl-mCnc;;ACTIVE;1.0k;2.70 +13892-5;Nitrosonaphthol;PrThr;Pt;Urine;Ord;;CHEM;1;Nitrosonaphthol [Presence] in Urine;Nitrosonaphthol Ur Ql;;ACTIVE;1.0k;2.56 +13893-3;Phenylalanine;PrThr;Pt;Urine;Ord;;CHEM;1;Phenylalanine [Presence] in Urine;Phe Ur Ql;;ACTIVE;1.0k;2.73 +13894-1;Pregnenolone;MRat;24H;Urine;Qn;;CHEM;1;Pregnenolone [Mass/time] in 24 hour Urine;Preg 24h Ur-mRate;;ACTIVE;1.0k;2.73 +13895-8;Sodium;SCnc;Pt;Milk;Qn;;CHEM;1;Sodium [Moles/volume] in Milk;Sodium Mlk-sCnc;;ACTIVE;1.0k;2.70 +1389-6;Cortisol.free^24H post 40 ug corticotropin IM BID 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --24 hours post 40 ug corticotropin IM BID 3 day;Cortis F 1D p 40 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.34 +13896-6;Insulin-like growth factor-I;ACnc;Pt;Bld;Qn;;CHEM;1;Insulin-like growth factor-I [Units/volume] in Blood;IGF-I Bld-aCnc;;ACTIVE;1.0k;2.70 +13897-4;Thyrotropin.beta subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyrotropin.beta subunit [Mass/volume] in Serum or Plasma;TSH Beta SerPl-mCnc;;ACTIVE;1.0k;2.70 +13898-2;Trichloroacetate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trichloroacetate [Mass/volume] in Serum or Plasma;TCA SerPl-mCnc;;ACTIVE;1.0k;2.70 +13899-0;Triglyceride;MCnc;Pt;Body fld;Qn;;CHEM;1;Deprecated Triglyceride [Mass/volume] in fluid;Deprecated Trigl Fld-mCnc;;DEPRECATED;1.0k;2.70 +13900-6;Tumor necrosis factor.alpha;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Tumor necrosis factor.alpha [Mass/volume] in Serum or Plasma;Deprecated A-Tumor Necrosis Fact SerPl-m;;DEPRECATED;1.0k;2.70 +13901-4;Tyrosine;PrThr;Pt;Urine;Ord;;CHEM;1;Tyrosine [Presence] in Urine;Tyrosine Ur Ql;;ACTIVE;1.0k;2.73 +13902-2;Urate;MCnc;Pt;CSF;Qn;;CHEM;1;Urate [Mass/volume] in Cerebral spinal fluid;Urate CSF-mCnc;;ACTIVE;1.0k;2.70 +13903-0;Vasopressin;MCnc;Pt;Urine;Qn;;CHEM;1;Vasopressin [Mass/volume] in Urine;Vasopressin Ur-mCnc;;ACTIVE;1.0k;2.73 +1390-4;Cortisol.free^48H post 40 ug corticotropin IM BID 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --48 hours post 40 ug corticotropin IM BID 3 day;Cortis F 2D p 40 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.34 +13904-8;Meclizine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meclizine [Mass/volume] in Serum or Plasma;Meclizine SerPl-mCnc;;ACTIVE;1.0k;2.73 +13905-5;Meclofenamate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meclofenamate [Mass/volume] in Serum or Plasma;Meclofenamate SerPl-mCnc;;ACTIVE;1.0k;2.73 +13906-3;Mesoridazine;MCnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Mesoridazine;Deprecated Mesoridazine Ur Ql;;DEPRECATED;1.0k;2.36 +13907-1;Norethindrone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norethindrone [Mass/volume] in Serum or Plasma;Norethindrone SerPl-mCnc;;ACTIVE;1.0k;2.70 +13908-9;Oxipurinol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxipurinol [Mass/volume] in Serum or Plasma;Oxipurinol SerPl-mCnc;;ACTIVE;1.0k;2.73 +13909-7;Tamoxifen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tamoxifen [Mass/volume] in Serum or Plasma;Tamoxifen SerPl-mCnc;;ACTIVE;1.0k;2.73 +13910-5;HLA-B22;ACnc;Pt;Bld/Tiss;Ord;;HLA;1;Deprecated HLA-B22 [Presence];Deprecated HLA-B22 Ql;;DEPRECATED;1.0k;2.54 +13911-3;HLA-B27 related Ag;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B27 related Ag [Presence];HLA-B27 Related Ag Ql;;ACTIVE;1.0k;2.73 +1391-2;Cortisol.free^48H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --48 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis F 48h p 500 ug Dex 24h Ur-mCnc;;ACTIVE;1.0;2.34 +13912-1;HLA-B42;ACnc;Pt;Bld/Tiss;Ord;;HLA;1;Deprecated HLA-B42 [Presence];Deprecated HLA-B42 Ql;;DEPRECATED;1.0k;2.54 +13913-9;Adenovirus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Adenovirus Ab [Titer] in Serum by Immunofluorescence;HAdV Ab Titr Ser IF;;ACTIVE;1.0k;2.70 +13914-7;Adenovirus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Adenovirus IgG Ab [Units/volume] in Serum;HAdV IgG Ser-aCnc;;ACTIVE;1.0k;2.73 +13915-4;Adenovirus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Adenovirus IgM Ab [Titer] in Serum;HAdV IgM Titr Ser;;ACTIVE;1.0k;2.73 +13916-2;Bordetella parapertussis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bordetella parapertussis Ag [Presence] in Specimen by Immunofluorescence;B parapert Ag Spec Ql IF;;ACTIVE;1.0k;2.73 +13917-0;Coccidioides immitis Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coccidioides immitis Ab [Titer] in Cerebral spinal fluid by Complement fixation;C immitis Ab Titr CSF CF;;ACTIVE;1.0k;2.73 +13918-8;Eastern equine encephalitis virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum by Immunofluorescence;EEEV Ab Titr Ser IF;;ACTIVE;1.0k;2.73 +13919-6;Hepatitis B virus core Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis B virus core IgG Ab [Units/volume] in Serum by Immunoassay;HBV core IgG Ser IA-aCnc;;ACTIVE;1.0k;2.73 +1392-0;Cortisol.free^48H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --48 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis F 48h p 2 mg Dex 24h Ur-mCnc;;ACTIVE;1.0;2.34 +13920-4;HIV 2 p41 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p41 Ab [Presence] in Serum by Immunoblot;HIV2 p41 Ab Ser Ql IB;;ACTIVE;1.0k;2.73 +13921-2;Mumps virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Mumps virus [Presence] in Specimen by Organism specific culture;MuV Spec Ql Cult;;ACTIVE;1.0k;2.73 +13922-0;Trichinella spiralis Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trichinella spiralis IgA Ab [Presence] in Serum by Immunoassay;T spiralis IgA Ser Ql IA;;ACTIVE;1.0k;2.73 +13923-8;Trichinella spiralis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trichinella spiralis IgM Ab [Presence] in Serum by Immunoassay;T spiralis IgM Ser Ql IA;;ACTIVE;1.0k;2.73 +13924-6;Calcitonin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Calcitonin Ab [Presence] in Serum;Calcit Ab Ser Ql;;ACTIVE;1.0k;2.56 +13925-3;Soluble liver Ab;PrThr;Pt;Ser;Ord;;SERO;1;Soluble liver Ab [Presence] in Serum;Soluble liver Ab Ser Ql;;ACTIVE;1.0k;2.73 +13926-1;Glutamate decarboxylase 65 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Glutamate decarboxylase 65 Ab [Units/volume] in Serum;GAD65 Ab Ser-aCnc;;ACTIVE;1.0k;2.73 +13927-9;Pancreatic islet cell Ab;Titr;Pt;Ser;Qn;;SERO;1;Pancreatic islet cell Ab [Titer] in Serum;Panc Islet Cell Ab Titr Ser;;ACTIVE;1.0k;2.73 +13928-7;Parathyrin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Parathyrin Ab [Presence] in Serum;PTH Ab Ser Ql;;ACTIVE;1.0k;2.73 +13929-5;Rheumatoid factor;Titr;Pt;Synv fld;Qn;Sheep cell aggl;SERO;1;Rheumatoid factor [Titer] in Synovial fluid by Sheep Cell Agglutination;Rheumatoid fact Titr Snv Shp Aggl;;ACTIVE;1.0k;2.70 +13930-3;Rheumatoid factor;Titr;Pt;Synv fld;Qn;Aggl;SERO;1;Rheumatoid factor [Titer] in Synovial fluid by Agglutination;Rheumatoid fact Titr Snv Aggl;;ACTIVE;1.0k;2.73 +13931-1;Striated muscle Ab;PrThr;Pt;Ser;Ord;;SERO;1;Striated muscle Ab [Presence] in Serum;Stria Mus Ab Ser Ql;;ACTIVE;1.0k;2.73 +13932-9;Testes Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Testes IgG Ab [Titer] in Serum;Testes IgG Titr Ser;;ACTIVE;1.0k;2.70 +13933-7;Benzodiazepines;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/mass] in Hair;Benzodiaz Hair-mCnt;;ACTIVE;1.0k;2.73 +13934-5;Butanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Butanol [Mass/volume] in Blood;Butanol Bld-mCnc;;ACTIVE;1.0k;2.73 +13935-2;Dichlorodifluoromethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dichlorodifluoromethane [Mass/volume] in Blood;DCDFM Bld-mCnc;;ACTIVE;1.0k;2.73 +13936-0;Diethyl ether;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Diethyl ether [Mass/volume] in Blood;Diethyl Ether Bld-mCnc;;ACTIVE;1.0k;2.73 +13937-8;Ethyl acetate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethyl acetate [Mass/volume] in Blood;Ethyl Acetate Bld-mCnc;;ACTIVE;1.0k;2.73 +1393-8;Cortisol.free^72H post 40 ug corticotropin IM BID 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --72 hours post 40 ug corticotropin IM BID 3 day;Cortis F 72h p 40 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.34 +13938-6;Trichloroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichloroethane [Mass/volume] in Blood;TCE Bld-mCnc;;ACTIVE;1.0k;2.73 +13939-4;Trichlorotrifluoroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Trichlorotrifluoroethane [Mass/volume] in Blood;Deprecated TCTFE Bld-mCnc;;DEPRECATED;1.0k;2.70 +13940-2;Dimethylbenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dimethylbenzene [Mass/volume] in Blood;DMB Bld-mCnc;;ACTIVE;1.0k;2.73 +13941-0;Lymphocytes/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Body fluid by Manual count;Lymphocytes/leuk NFr Fld Manual;;ACTIVE;1.0k;2.73 +13942-8;Spermatozoa.motile;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Spermatozoa Motile [Presence] in Semen by Light microscopy;Sperm Motile Smn Ql Micro;;ACTIVE;1.0k;2.73 +13943-6;Fructose;PrThr;Pt;Semen;Ord;;CHEM;1;Fructose [Presence] in Semen;Fructose Smn Ql;;ACTIVE;1.0k;2.73 +13944-4;Phosphatase.leukocyte;CCnc;Pt;WBC^Control;Qn;Microscopy.light;HEM/BC;1;Leukocyte phosphatase [Enzymatic activity/volume] in Control Leukocytes by Light microscopy;LAP WBC Cont Micro-cCnc;;ACTIVE;1.0k;2.73 +13945-1;Erythrocytes;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Erythrocytes [#/area] in Urine sediment by Microscopy high power field;RBC #/area UrnS HPF;;ACTIVE;1.0k;2.73 +1394-6;Cortisol.free^pre 50 ug corticotropin IM 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --pre 50 ug corticotropin IM 3 day;Cortis F pre 50 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.34 +13946-9;Complement+Immunoglobulin;PrThr;Pt;RBC;Ord;;HEM/BC;1;Complement+Immunoglobulin [Presence] in Red Blood Cells;Comp+Ig RBC Ql;;ACTIVE;1.0k;2.73 +13947-7;Coccidioides immitis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coccidioides immitis IgG Ab [Presence] in Serum by Immunoassay;C immitis IgG Ser Ql IA;;ACTIVE;1.0k;2.73 +13948-5;Coccidioides immitis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coccidioides immitis IgM Ab [Presence] in Serum by Immunoassay;C immitis IgM Ser Ql IA;;ACTIVE;1.0k;2.73 +13949-3;Cytomegalovirus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Cytomegalovirus IgG Ab [Presence] in Serum or Plasma by Immunoassay;CMV IgG SerPl Ql IA;;ACTIVE;1.0k;2.73 +13950-1;Hepatitis A virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis A virus IgM Ab [Presence] in Serum or Plasma by Immunoassay;HAV IgM SerPl Ql IA;;ACTIVE;1.0k;2.73 +13951-9;Hepatitis A virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis A virus Ab [Presence] in Serum by Immunoassay;HAV Ab Ser Ql IA;;ACTIVE;1.0k;2.73 +13952-7;Hepatitis B virus core Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis B virus core Ab [Presence] in Serum or Plasma by Immunoassay;HBV core Ab SerPl Ql IA;;ACTIVE;1.0k;2.73 +1395-3;Cortisol.free^pre 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --pre 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis F pre 500 ug Dex 24h Ur-mCnc;;ACTIVE;1.0;2.73 +13953-5;Hepatitis B virus little e Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis B virus e Ab [Presence] in Serum or Plasma by Immunoassay;HBV e Ab SerPl Ql IA;;ACTIVE;1.0k;2.73 +13954-3;Hepatitis B virus little e Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis B virus e Ag [Presence] in Serum or Plasma by Immunoassay;HBV e Ag SerPl Ql IA;;ACTIVE;1.0k;2.73 +13955-0;Hepatitis C virus Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis C virus Ab [Presence] in Serum or Plasma by Immunoassay;HCV Ab SerPl Ql IA;;ACTIVE;1.0k;2.73 +13956-8;Mycobacterium tuberculosis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection;M tb DNA Spec Ql NAA+probe;;ACTIVE;1.0k;2.73 +13957-6;Clostridioides difficile toxin A;PrThr;Pt;Stool;Ord;IA;MICRO;1;Clostridioides difficile toxin A [Presence] in Stool by Immunoassay;C diff Tox A Stl Ql IA;;ACTIVE;1.0k;2.73 +13958-4;Arsenic;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Arsenic [Presence] in 24 hour Urine;Arsenic 24h Ur Ql;;ACTIVE;1.0k;2.56 +13959-2;Calcium.ionized;SCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Calcium.ionized [Moles/volume] in Serum or Plasma by calculation;Ca-I SerPl Calc-sCnc;;ACTIVE;1.0k;2.73 +139-6;Ceftizoxime;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ceftizoxime [Susceptibility] by Serum bactericidal titer;Ceftizoxime Titr SBT;;ACTIVE;1.0;2.32 +13960-0;Coproporphyrin;PrThr;24H;Urine;Ord;;CHEM;1;Coproporphyrin [Presence] in 24 hour Urine;Copro 24h Ur Ql;;ACTIVE;1.0k;2.56 +1396-1;Cortisol.free^pre 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --pre 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis F pre 2 mg Dex high 24h Ur-mCnc;;ACTIVE;1.0;2.34 +13961-8;Mercury;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Mercury [Presence] in 24 hour Urine;Mercury 24h Ur Ql;;ACTIVE;1.0k;2.56 +13962-6;Beta glucuronidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/volume] in Serum or Plasma;B-Glucuronidase SerPl-cCnc;;ACTIVE;1.0k;2.70 +13963-4;Orotate;SCnc;Pt;Urine;Qn;;CHEM;1;Orotate [Moles/volume] in Urine;Orotate Ur-sCnc;;ACTIVE;1.0k;2.73 +13964-2;Methylmalonate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonate [Moles/volume] in Serum or Plasma;Methylmalonate SerPl-sCnc;;ACTIVE;1.0k;2.73 +13965-9;Homocysteine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocysteine [Moles/volume] in Serum or Plasma;Hcys SerPl-sCnc;;ACTIVE;1.0k;2.73 +13966-7;Cystine;SRat;24H;Urine;Qn;;CHEM;1;Cystine [Moles/time] in 24 hour Urine;Cystine 24h Ur-sRate;;ACTIVE;1.0k;2.73 +13967-5;Sex hormone binding globulin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sex hormone binding globulin [Moles/volume] in Serum or Plasma;SHBG SerPl-sCnc;;ACTIVE;1.0k;2.73 +13968-3;Penicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Penicillin [Susceptibility] by Disk diffusion (KB);Penicillin Islt KB;;ACTIVE;1.0k;2.73 +13969-1;Creatine kinase.MB;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.MB [Mass/volume] in Serum or Plasma;CK MB SerPl-mCnc;;ACTIVE;1.0k;2.73 +13970-9;Delta tocopherol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Delta tocopherol [Mass/volume] in Serum or Plasma;D-Tocopherol SerPl-mCnc;;ACTIVE;1.0k;2.70 +13971-7;Histoplasma capsulatum Ag;ACnc;Pt;Urine;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Urine by Immunoassay;H capsul Ag Ur IA-aCnc;;ACTIVE;1.0k;2.73 +13972-5;Alpha 1 globulin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total in Cerebral spinal fluid by Electrophoresis;Alpha1 Glob MFr CSF Elph;;ACTIVE;1.0k;2.73 +13973-3;Prealbumin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Prealbumin/Protein.total in Cerebral spinal fluid by Electrophoresis;Prealb MFr CSF Elph;;ACTIVE;1.0k;2.73 +13974-1;Albumin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total in Cerebral spinal fluid by Electrophoresis;Albumin MFr CSF Elph;;ACTIVE;1.0k;2.73 +13975-8;Alpha 2 globulin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total in Cerebral spinal fluid by Electrophoresis;Alpha2 Glob MFr CSF Elph;;ACTIVE;1.0k;2.73 +13976-6;Beta globulin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total in Cerebral spinal fluid by Electrophoresis;B-Globulin MFr CSF Elph;;ACTIVE;1.0k;2.73 +13977-4;Gamma globulin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total in Cerebral spinal fluid by Electrophoresis;Gamma glob MFr CSF Elph;;ACTIVE;1.0k;2.73 +13978-2;Alpha 1 globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total in Serum or Plasma by Electrophoresis;Alpha1 Glob MFr SerPl Elph;;ACTIVE;1.0k;2.73 +1397-9;Cortisol^1.5H post 0.05-0.15 U insulin/kg IV post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1.5 hours post 0.05-0.15 U insulin/kg IV 12 hours fasting;Cortis 1.5h p U/kg Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +13979-0;Prealbumin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Prealbumin/Protein.total in Serum or Plasma by Electrophoresis;Prealb MFr SerPl Elph;;ACTIVE;1.0k;2.70 +13980-8;Albumin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total in Serum or Plasma by Electrophoresis;Albumin MFr SerPl Elph;;ACTIVE;1.0k;2.73 +13981-6;Alpha 2 globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total in Serum or Plasma by Electrophoresis;Alpha2 Glob MFr SerPl Elph;;ACTIVE;1.0k;2.73 +13982-4;Beta globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total in Serum or Plasma by Electrophoresis;B-Globulin MFr SerPl Elph;;ACTIVE;1.0k;2.73 +13983-2;Gamma globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total in Serum or Plasma by Electrophoresis;Gamma glob MFr SerPl Elph;;ACTIVE;1.0k;2.73 +13984-0;Alpha 1 globulin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total in 24 hour Urine by Electrophoresis;Alpha1 Glob 24h MFr Ur Elph;;ACTIVE;1.0k;2.73 +13985-7;Prealbumin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Prealbumin/Protein.total in 24 hour Urine by Electrophoresis;Prealb 24h MFr Ur Elph;;ACTIVE;1.0k;2.73 +13986-5;Albumin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total in 24 hour Urine by Electrophoresis;Albumin 24h MFr Ur Elph;;ACTIVE;1.0k;2.73 +1398-7;Cortisol^1.5H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1.5 hours post dose insulin IV;Cortis 1.5h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.73 +13987-3;Alpha 2 globulin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total in 24 hour Urine by Electrophoresis;Alpha2 Glob 24h MFr Ur Elph;;ACTIVE;1.0k;2.73 +13988-1;Beta globulin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total in 24 hour Urine by Electrophoresis;B-Globulin 24h MFr Ur Elph;;ACTIVE;1.0k;2.73 +13989-9;Gamma globulin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total in 24 hour Urine by Electrophoresis;Gamma glob 24h MFr Ur Elph;;ACTIVE;1.0k;2.73 +13990-7;Alpha 1 globulin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total in Urine by Electrophoresis;Alpha1 Glob MFr Ur Elph;;ACTIVE;1.0k;2.73 +13991-5;Prealbumin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Prealbumin/Protein.total in Urine by Electrophoresis;Prealb MFr Ur Elph;;ACTIVE;1.0k;2.73 +13992-3;Albumin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total in Urine by Electrophoresis;Albumin MFr Ur Elph;;ACTIVE;1.0k;2.73 +13993-1;Alpha 2 globulin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total in Urine by Electrophoresis;Alpha2 Glob MFr Ur Elph;;ACTIVE;1.0k;2.73 +13994-9;Beta globulin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total in Urine by Electrophoresis;B-Globulin MFr Ur Elph;;ACTIVE;1.0k;2.73 +1399-5;Cortisol^1H post 0.05-0.15 U insulin/kg IV post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post 0.05-0.15 U insulin/kg IV post 12H CFst;Cortis 1h p U/kg Ins IV SerPl-mCnc;;ACTIVE;1.0;2.73 +13995-6;Gamma globulin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total in Urine by Electrophoresis;Gamma glob MFr Ur Elph;;ACTIVE;1.0k;2.73 +13996-4;Hydroxyproline/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Hydroxyproline/Creatinine [Molar ratio] in 24 hour Urine;OH-Proline/Creat 24h Ur-sRto;;ACTIVE;1.0k;2.70 +13997-2;Neuronal nuclear type 1 Ab;Titr;Pt;Ser;Qn;;SERO;1;Neuronal nuclear type 1 Ab [Titer] in Serum;Hu1 Ab Titr Ser;;ACTIVE;1.0k;2.73 +13998-0;Neuronal nuclear type 2 Ab;Titr;Pt;Ser;Qn;;SERO;1;Neuronal nuclear type 2 Ab [Titer] in Serum;Hu2 Ab Titr Ser;;ACTIVE;1.0k;2.73 +13999-8;Transferrin.carbohydrate deficient;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient [Units/volume] in Serum or Plasma;CDT SerPl-aCnc;;ACTIVE;1.0k;2.70 +14000-4;Urea nitrogen;MCnc;Pt;CSF;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Cerebral spinal fluid;Urea nit CSF-mCnc;;ACTIVE;1.0k;2.70 +1400-1;Cortisol^1H post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post 1 ug/kg CRH IV;Cortis 1h p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14001-2;IgE;ACnc;Pt;BldCo;Qn;;CHEM;1;IgE [Units/volume] in Cord blood;IgE BldCo-aCnc;;ACTIVE;1.0k;2.70 +14002-0;IgM;ACnc;Pt;BldCo;Qn;;CHEM;1;IgM [Units/volume] in Cord blood;IgM BldCo-aCnc;;ACTIVE;1.0k;2.73 +14003-8;Carbon dioxide;PPres;Pt;BldCo;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Cord blood;pCO2 BldCo;;ACTIVE;1.0k;2.73 +14004-6;Prostaglandin A;MRat;24H;Urine;Qn;;CHEM;1;Prostaglandin A [Mass/time] in 24 hour Urine;Prostaglandin A 24h Ur-mRate;;ACTIVE;1.0k;2.70 +14005-3;Prostaglandin E1;MRat;24H;Urine;Qn;;CHEM;1;Prostaglandin E1 [Mass/time] in 24 hour Urine;Prostaglandin E1 24h Ur-mRate;;ACTIVE;1.0k;2.70 +14006-1;Prostaglandin E2;MRat;24H;Urine;Qn;;CHEM;1;Prostaglandin E2 [Mass/time] in 24 hour Urine;Prostaglandin E2 24h Ur-mRate;;ACTIVE;1.0k;2.73 +14007-9;Prostaglandin F2 alpha;MRat;24H;Urine;Qn;;CHEM;1;Prostaglandin F2 alpha [Mass/time] in 24 hour Urine;Prostaglandin F2A 24h Ur-mRate;;ACTIVE;1.0k;2.73 +14008-7;Phosphatidylcholine Ab.IgG;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylcholine IgG Ab [Units/volume] in Serum by Immunoassay;PC IgG Ser IA-aCnc;;ACTIVE;1.0k;2.73 +14009-5;Phosphatidylcholine Ab.IgM;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylcholine IgM Ab [Units/volume] in Serum by Immunoassay;PC IgM Ser IA-aCnc;;ACTIVE;1.0k;2.73 +14010-3;Phosphatidylcholine Ab.IgA;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylcholine IgA Ab [Units/volume] in Serum by Immunoassay;PC IgA Ser IA-aCnc;;ACTIVE;1.0k;2.73 +14011-1;Platelet associated Ab.IgA;ACnc;Pt;Bld;Qn;;SERO;1;Deprecated Platelet associated IgA Ab [Units/volume] in Blood;Deprecated PA IgA Bld-aCnc;;DEPRECATED;1.0k;2.70 +14012-9;Platelet associated Ab.IgG;ACnc;Pt;Bld;Qn;Flow cytometry;SERO;1;Platelet associated IgG Ab [Units/volume] in Blood by Flow cytometry (FC);PA IgG Bld FC-aCnc;;ACTIVE;1.0k;2.73 +14013-7;Platelet associated Ab.IgM;ACnc;Pt;Bld;Qn;Flow cytometry;SERO;1;Platelet associated IgM Ab [Units/volume] in Blood by Flow cytometry (FC);PA IgM Bld FC-aCnc;;ACTIVE;1.0k;2.73 +14014-5;Thyroxine.prealbumin bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4).prealbumin bound [Mass/volume] in Serum or Plasma;T4 PA Bnd SerPl-mCnc;;ACTIVE;1.0k;2.73 +14015-2;Thyroxine.prealbumin bound/Prealbumin;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4).prealbumin bound/Prealbumin [Mass Ratio] in Serum or Plasma;T4 PA Bnd/Prealb SerPl;;ACTIVE;1.0k;2.73 +14016-0;Thyroxine.thyroxine binding globulin bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine.thyroxine binding globulin bound [Mass/volume] in Serum or Plasma;T4 TBG Bnd SerPl-mCnc;;ACTIVE;1.0k;2.73 +14017-8;Cells.CD22/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD22 cells/100 cells in Blood;CD22 Cells NFr Bld;;ACTIVE;1.0k;2.73 +14018-6;Cells.CD23/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD23 cells/100 cells in Blood;CD23 Cells NFr Bld;;ACTIVE;1.0k;2.73 +1401-9;Cortisol^1H post 250 ug corticotropin IM rapid;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM rapid;Cortis 1h p 250 ug ACTH rIM SerPl-mCnc;;ACTIVE;1.0;2.40 +14019-4;HTLV I+II gp46 Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HTLV I+II gp46 Ab [Presence] in Serum or Plasma by Immunoblot;HTLV I+II gp46 Ab SerPl Ql IB;;ACTIVE;1.0k;2.73 +14020-2;HTLV I+II p19 Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HTLV I+II p19 Ab [Presence] in Serum or Plasma by Immunoblot;HTLV I+II p19 Ab SerPl Ql IB;;ACTIVE;1.0k;2.73 +14021-0;HTLV I+II p24 Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HTLV I+II p24 Ab [Presence] in Serum or Plasma by Immunoblot;HTLV I+II p24 Ab SerPl Ql IB;;ACTIVE;1.0k;2.73 +14022-8;HTLV I+II p26 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II p26 Ab [Presence] in Serum by Immunoblot;HTLV I+II p26 Ab Ser Ql IB;;ACTIVE;1.0k;2.73 +14023-6;HTLV I+II p28 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II p28 Ab [Presence] in Serum by Immunoblot;HTLV I+II p28 Ab Ser Ql IB;;ACTIVE;1.0k;2.73 +14024-4;HTLV I+II p32 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II p32 Ab [Presence] in Serum by Immunoblot;HTLV I+II p32 Ab Ser Ql IB;;ACTIVE;1.0k;2.73 +14025-1;HTLV I+II p36 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II p36 Ab [Presence] in Serum by Immunoblot;HTLV I+II p36 Ab Ser Ql IB;;ACTIVE;1.0k;2.73 +14026-9;HTLV I+II p53 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II p53 Ab [Presence] in Serum by Immunoblot;HTLV I+II p53 Ab Ser Ql IB;;ACTIVE;1.0k;2.73 +1402-7;Cortisol^1H post 250 ug corticotropin IV rapid;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IV rapid;Cortis 1h p 250 ug ACTH rIV SerPl-mCnc;;ACTIVE;1.0;2.73 +14027-7;HTLV I+II rgp21 Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HTLV I+II rgp21 Ab [Presence] in Serum or Plasma by Immunoblot;HTLV I+II rgp21 Ab SerPl Ql IB;;ACTIVE;1.0k;2.73 +14028-5;HTLV I+II rgp46-I Ab;ACnc;Pt;Ser;Ord;IB;MICRO;1;Deprecated HTLV I+II rgp46-I Ab [Presence] in Serum by Immunoblot (IB);Deprecated HTLV I+II rgp46-I Ab Ser Ql I;;DEPRECATED;1.0k;2.52 +14029-3;HTLV I+II rgp46-II Ab;ACnc;Pt;Ser;Ord;IB;MICRO;1;Deprecated HTLV I+II rgp46-II Ab [Presence] in Serum by Immunoblot (IB);Deprecated HTLV I+II rgp46-II Ab Ser Ql;;DEPRECATED;1.0k;2.52 +14030-1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA SM+RNP Ab Ser IA-aCnc;;ACTIVE;1.0k;2.73 +14031-9;Ciprofloxacin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ciprofloxacin [Mass/volume] in Serum or Plasma --peak;Ciprofloxacin Peak SerPl-mCnc;;ACTIVE;1.0k;2.42 +14032-7;Ciprofloxacin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ciprofloxacin [Mass/volume] in Serum or Plasma --trough;Ciprofloxacin Trough SerPl-mCnc;;ACTIVE;1.0k;2.70 +14033-5;1,4-Dioxane;MCnc;Pt;Bld;Qn;GC;DRUG/TOX;1;1,4-Dioxane [Mass/volume] in Blood by Gas chromatography;1,4Dioxane Bld GC-mCnc;;ACTIVE;1.0k;2.70 +14034-3;Rheumatoid factor;ACnc;Pt;CSF;Qn;;SERO;1;Rheumatoid factor [Units/volume] in Cerebral spinal fluid;Rheumatoid fact CSF-aCnc;;ACTIVE;1.0k;2.73 +1403-5;Cortisol^1H post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM;Cortis 1h p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.73 +14035-0;Cryptomeria japonica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Japanese Cedar IgE Ab [Units/volume] in Serum;Japanese Cedar IgE Qn;;ACTIVE;1.0k;2.73 +14036-8;Dermatophagoides microceras Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides microceras IgE Ab [Units/volume] in Serum;D microceras IgE Qn;;ACTIVE;1.0k;2.73 +14037-6;Fox Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fox IgE Ab [Units/volume] in Serum;Fox IgE Qn;;ACTIVE;1.0k;2.42 +14038-4;Todarodes pacificus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pacific Squid IgE Ab [Units/volume] in Serum;Pacific Squid IgE Qn;;ACTIVE;1.0k;2.73 +14039-2;Neutrophils/100 leukocytes;NFr;Pt;CSF;Qn;Microscopy;HEM/BC;1;Neutrophils/100 leukocytes in Cerebral spinal fluid by Microscopy;Neutrophils/leuk NFr CSF Micro;;ACTIVE;1.0k;2.73 +140-4;cefTRIAXone;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;cefTRIAXone [Susceptibility] by Minimum lethal concentration (MLC);cefTRIAXone Islt MLC;;ACTIVE;1.0;2.19 +14040-0;Carbon dioxide;SCnc;Pt;Stool;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Stool;CO2 Stl-sCnc;;ACTIVE;1.0k;2.73 +14041-8;Choriogonadotropin.beta subunit;ACnc;Pt;CSF;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Units/volume] in Cerebral spinal fluid;B-HCG CSF-aCnc;;ACTIVE;1.0k;2.73 +14042-6;Corticosterone;MRat;24H;Urine;Qn;;CHEM;1;Corticosterone [Mass/time] in 24 hour Urine;Corticoster 24h Ur-mRate;;ACTIVE;1.0k;2.70 +1404-3;Cortisol^1H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV;Cortis 1h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14043-4;Cortisol.free;MRat;12H;Urine;Qn;;CHEM;1;Cortisol Free [Mass/time] in 12 hour Urine;Cortis F 12h Ur-mRate;;ACTIVE;1.0k;2.70 +14044-2;Cortisone;MRat;24H;Urine;Qn;;CHEM;1;Cortisone [Mass/time] in 24 hour Urine;Cortisone 24h Ur-mRate;;ACTIVE;1.0k;2.73 +14045-9;D-lactate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;D-Lactate [Moles/volume] in Serum or Plasma;D-Lactate SerPl-sCnc;;ACTIVE;1.0k;2.73 +14046-7;D-lactate;SCnc;Pt;Urine;Qn;;CHEM;1;D-Lactate [Moles/volume] in Urine;D-Lactate Ur-sCnc;;ACTIVE;1.0k;2.70 +14047-5;Androstanolone.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstanolone Free [Mass/volume] in Serum or Plasma;Androstanolone Free SerPl-mCnc;;ACTIVE;1.0k;2.73 +14048-3;Elastase.pancreatic;MCnc;Pt;Ser;Qn;;CHEM;1;Elastase.pancreatic [Mass/volume] in Serum;Elastase Panc Ser-mCnc;;ACTIVE;1.0k;2.70 +14049-1;Epidermal growth factor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Epidermal growth factor [Mass/volume] in Serum or Plasma;EGF SerPl-mCnc;;ACTIVE;1.0k;2.73 +1405-0;Cortisol^1H post dose U/kg insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Deprecated Cortisol [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV;Deprecated Cortis 1H p U/kg Ins IV Plas-;;DEPRECATED;1.0;2.36 +14050-9;Epidermal growth factor receptor;SCnt;Pt;Tiss;Qn;;PATH;1;Epidermal growth factor receptor [Moles/mass] in Tissue;EGFR Tiss-sCnt;;ACTIVE;1.0k;2.70 +14051-7;Estrogen binding protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrogen binding protein [Mass/volume] in Serum or Plasma;Estrogen BP SerPl-mCnc;;ACTIVE;1.0k;2.70 +14052-5;Formate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Formate [Mass/volume] in Urine;Formate Ur-mCnc;;ACTIVE;1.0k;2.73 +14053-3;Homocystine;PrThr;Pt;Urine;Ord;;CHEM;1;Homocystine [Presence] in Urine;(Hcys)2 Ur Ql;;ACTIVE;1.0k;2.56 +14054-1;Prostaglandin D2;MRat;24H;Urine;Qn;;CHEM;1;Prostaglandin D2 [Mass/time] in 24 hour Urine;Prostaglandin D2 24h Ur-mRate;;ACTIVE;1.0k;2.73 +14055-8;Sodium;SCnt;Pt;Stool;Qn;;CHEM;1;Sodium [Moles/mass] in Stool;Sodium Stl-sCnt;;ACTIVE;1.0k;2.70 +14056-6;carBAMazepine 10,11-Epoxide.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbamazepine 10,11-epoxide free [Mass/volume] in Serum or Plasma;Carbamazepine EP Free SerPl-mCnc;;ACTIVE;1.0k;2.73 +14057-4;carBAMazepine.free;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;carBAMazepine free [Mass/volume] in Saliva (oral fluid);carBAMazepine free Sal-mCnc;;ACTIVE;1.0k;2.73 +14058-2;Ciprofloxacin^peak;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Ciprofloxacin [Mass/volume] in Serum or Plasma --peak;Deprecated Ciprofloxacin Peak Ser-mCnc;;DEPRECATED;1.0k;2.70 +14059-0;Ciprofloxacin^trough;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Ciprofloxacin [Mass/volume] in Serum or Plasma --trough;Deprecated Ciprofloxacin Trough Ser-mCnc;;DEPRECATED;1.0k;2.70 +14060-8;Cyclobenzaprine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cyclobenzaprine [Presence] in Urine;Cyclobenzaprine Ur Ql;;ACTIVE;1.0k;2.73 +14061-6;Cyclobenzaprine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cyclobenzaprine [Mass/volume] in Urine;Cyclobenzaprine Ur-mCnc;;ACTIVE;1.0k;2.73 +14062-4;Dexamethasone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dexamethasone [Mass/volume] in Serum or Plasma;Dexamethasone SerPl-mCnc;;ACTIVE;1.0k;2.73 +14063-2;Dezocine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dezocine [Presence] in Urine;Dezocine Ur Ql;;ACTIVE;1.0k;2.56 +14064-0;Diethylstilbestrol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diethylstilbestrol [Mass/volume] in Serum or Plasma;Diethylstilbestrol SerPl-mCnc;;ACTIVE;1.0k;2.70 +14065-7;Diflunisal;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diflunisal [Mass/volume] in Serum or Plasma;Diflunisal SerPl-mCnc;;ACTIVE;1.0k;2.42 +14066-5;Dihydrocodeine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dihydrocodeine [Presence] in Urine;DHC Ur Ql;;ACTIVE;1.0k;2.73 +14067-3;Dihydrocodeine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dihydrocodeine [Mass/volume] in Blood;DHC Bld-mCnc;;ACTIVE;1.0k;2.73 +1406-8;Cortisol^1M post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 minute post 1 ug/kg CRH IV;Cortis 1M p 1 u/kg CRH IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14068-1;Triamterene+hydroCHLOROthiazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triamterene+hydroCHLOROthiazide [Mass/volume] in Serum or Plasma;Dyazide SerPl-mCnc;;ACTIVE;1.0k;2.40 +14069-9;Estazolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Estazolam [Mass/volume] in Serum or Plasma;Estazolam SerPl-mCnc;;ACTIVE;1.0k;2.73 +14070-7;fluPHENAZine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;fluPHENAZine [Presence] in Urine;fluPHENAZine Ur Ql;;ACTIVE;1.0k;2.73 +14071-5;Ibuprofen;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ibuprofen [Presence] in Urine;Ibuprofen Ur Ql;;ACTIVE;1.0k;2.73 +14072-3;Monoacetyldapsone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Monoacetyldapsone [Mass/volume] in Serum or Plasma;MADDS SerPl-mCnc;;ACTIVE;1.0k;2.73 +14073-1;Phenytoin;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Phenytoin [Mass/volume] in Saliva (oral fluid);Phenytoin Sal-mCnc;;ACTIVE;1.0k;2.70 +14074-9;Spironolactone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Spironolactone [Mass/volume] in Serum or Plasma;Spironolactone SerPl-mCnc;;ACTIVE;1.0k;2.70 +14075-6;Sulfapyridine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfapyridine [Mass/volume] in Serum or Plasma;Sulfapyridine SerPl-mCnc;;ACTIVE;1.0k;2.73 +1407-6;Cortisol^24H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --24 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis 24h p 2 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14076-4;Complement total hemolytic CH100;PrThr;Pt;Ser/Plas;Ord;Immune diffusion;HEM/BC;1;Complement total hemolytic CH100 [Presence] in Serum or Plasma by Immune diffusion (ID);CH100 SerPl Ql ID;;ACTIVE;1.0k;2.70 +14077-2;Borrelia burgdorferi Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B burgdor IgG CSF IA-aCnc;;ACTIVE;1.0k;2.73 +14078-0;Borrelia burgdorferi Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B burgdor IgM CSF IA-aCnc;;ACTIVE;1.0k;2.73 +14079-8;Brucella canis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Brucella canis IgG Ab [Titer] in Serum by Immunofluorescence;B canis IgG Titr Ser IF;;ACTIVE;1.0k;2.70 +14080-6;Brucella canis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Brucella canis IgM Ab [Titer] in Serum by Immunofluorescence;B canis IgM Titr Ser IF;;ACTIVE;1.0k;2.70 +14081-4;Coliform bacteria;PrThr;Pt;Water;Ord;;MICRO;1;Coliform bacteria [Presence] in Water;Coliform Wat Ql;;ACTIVE;1.0k;2.56 +14082-2;Echinococcus sp Ab.IgG;ACnc;Pt;Ser;Qn;IB;MICRO;1;Echinococcus sp IgG Ab [Units/volume] in Serum by Immunoblot;Echinococcus IgG Ser IB-aCnc;;ACTIVE;1.0k;2.73 +14083-0;Epstein Barr virus early Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus early Ab [Titer] in Serum by Immunofluorescence;EBV EA Ab Titr Ser IF;;ACTIVE;1.0k;2.73 +1408-4;Cortisol^24H post 40 ug corticotropin IM BID 3 day;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --24 hours post 40 ug corticotropin IM BID 3 day;Cortis 1D p 40 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.40 +14084-8;Herpes simplex virus 1;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Herpes simplex virus 1 [Presence] in Isolate by Immunofluorescence;HSV1 Islt Ql IF;;ACTIVE;1.0k;2.73 +14085-5;Herpes simplex virus 2;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Herpes simplex virus 2 [Presence] in Isolate by Immunofluorescence;HSV2 Islt Ql IF;;ACTIVE;1.0k;2.73 +14086-3;Herpes simplex virus 1 Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV1 IgG Titr CSF IF;;ACTIVE;1.0k;2.70 +14087-1;Herpes simplex virus 1 Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 1 IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV1 IgM Titr CSF IF;;ACTIVE;1.0k;2.73 +14088-9;Herpes simplex virus 1 Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Deprecated Herpes simplex virus 1 IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Deprecated HSV1 IgM Titr CSF IF;;DEPRECATED;1.0k;2.70 +14089-7;Herpes simplex virus 2 Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV2 IgG Titr CSF IF;;ACTIVE;1.0k;2.70 +14090-5;Herpes simplex virus 2 Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 2 IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV2 IgM Titr CSF IF;;ACTIVE;1.0k;2.73 +14091-3;Herpes simplex virus 2 Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Deprecated Herpes simplex virus 2 IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Deprecated HSV2 IgM Titr CSF IF;;DEPRECATED;1.0k;2.70 +1409-2;Cortisol^24H post 500 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --24 hours post 500 ug corticotropin IM;Cortis 24h p 500 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.40 +14092-1;HIV 1 Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;HIV 1 Ab [Presence] in Serum by Immunofluorescence;HIV1 Ab Ser Ql IF;;ACTIVE;1.0k;2.73 +14093-9;Bacteria identified;Prid;Pt;Water;Nom;Culture;MICRO;1;Bacteria identified in Water by Culture;Bacteria Wat Cult;;ACTIVE;1.0k;2.73 +14094-7;Trypanosoma cruzi Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Trypanosoma cruzi IgG Ab [Titer] in Serum;T cruzi IgG Titr Ser;;ACTIVE;1.0k;2.73 +14095-4;Fibronectin aggregate Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Fibronectin aggregate IgG Ab [Units/volume] in Serum;Fibronectin Aggr IgG Ser-aCnc;;ACTIVE;1.0k;2.73 +14096-2;Intercalated disk Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Intercalated disk Ab [Titer] in Serum by Immunofluorescence;Intercal Dsk Ab Titr Ser IF;;ACTIVE;1.0k;2.70 +14097-0;Antimony;MRat;24H;Urine;Qn;;DRUG/TOX;1;Antimony [Mass/time] in 24 hour Urine;Antimony 24h Ur-mRate;;ACTIVE;1.0k;2.42 +14098-8;Dimethylsulfoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dimethylsulfoxide [Mass/volume] in Serum or Plasma;DMSO SerPl-mCnc;;ACTIVE;1.0k;2.73 +14099-6;Nickel;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Urine;Nickel Ur-mCnc;;ACTIVE;1.0k;2.73 +14-1;Amikacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Amikacin [Susceptibility] by Serum bactericidal titer;Amikacin Titr SBT;;ACTIVE;1.0;2.32 +1410-0;Cortisol^24H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --24 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis 24h p 500 ug Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14100-2;Strontium;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Strontium [Presence] in Urine;Strontium Ur Ql;;ACTIVE;1.0k;2.56 +14101-0;Strychnine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Strychnine [Mass/volume] in Gastric fluid;Strychnine Gast-mCnc;;ACTIVE;1.0k;2.42 +14102-8;Strychnine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Strychnine [Mass/volume] in Blood;Strychnine Bld-mCnc;;ACTIVE;1.0k;2.73 +14103-6;Epithelial cells;PrThr;Pt;Stool;Ord;Microscopy.light;HEM/BC;1;Epithelial cells [Presence] in Stool by Light microscopy;Epi Cells Stl Ql Micro;;ACTIVE;1.0k;2.56 +14104-4;Ustilago nuda+Ustilago tritici Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Barley smut+Wheat smut IgE Ab [Units/volume] in Serum;Barley+Wheat smut IgE Qn;;ACTIVE;1.0k;2.73 +14105-1;Leukocytes;PrThr;Pt;Nose;Ord;Microscopy.light;HEM/BC;1;Leukocytes [Presence] in Nose by Light microscopy;WBC Nose Ql Micro;;ACTIVE;1.0k;2.56 +14106-9;Lymphocytes;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Lymphocytes [#/volume] in Cerebral spinal fluid by Manual count;Lymphocytes # CSF Manual;;ACTIVE;1.0k;2.73 +14107-7;Neutrophils.segmented/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Segmented neutrophils/100 leukocytes in Cerebral spinal fluid by Manual count;Neuts Seg/leuk NFr CSF Manual;;ACTIVE;1.0k;2.73 +14108-5;Cells.CD16c+CD56+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD16C+CD56+ cells [#/volume] in Blood;CD16c+CD56+ Cells # Bld;;ACTIVE;1.0k;2.73 +14109-3;Cells.CD16c+CD56+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16C+CD56+ cells/100 cells in Blood;CD16c+CD56+ Cells NFr Bld;;ACTIVE;1.0k;2.70 +14110-1;Lymphocytes.CD22/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD22 cells/100 cells in Blood;Deprecated Lymphocytes.CD22 Fr Bld;;DEPRECATED;1.0k;2.46 +14111-9;Lymphocytes.CD23/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD23 cells/100 lymphocytes in Blood;Deprecated Lymphocytes.CD23 Fr Bld;;DEPRECATED;1.0k;2.46 +14112-7;Cells.CD25+CD19+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25+CD19+ cells/100 cells in Blood;CD25+CD19+ Cells NFr Bld;;ACTIVE;1.0k;2.70 +14113-5;Cells.CD56;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD56 cells [#/volume] in Blood;CD56 Cells # Bld;;ACTIVE;1.0k;2.73 +14114-3;17-Hydroxyprogesterone^1H post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM;17OHP 1h p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0k;2.73 +14115-0;Collagen crosslinked N-telopeptide/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Collagen crosslinked N-telopeptide/Creatinine [Molar ratio] in Urine;Collagen NTx/Creat Ur-sRto;;ACTIVE;1.0k;2.73 +14116-8;IgG synthesis rate;MRat;Pt;Ser+CSF;Qn;Calculated;CHEM;1;IgG synthesis rate [Mass/time] in Serum and CSF by calculation;IgG Synth Rate Ser+CSF Calc-mRate;;ACTIVE;1.0k;2.73 +14117-6;IgG clearance/Albumin clearance;Ratio;Pt;Ser+CSF;Qn;;CHEM;1;IgG clearance/Albumin clearance [Ratio] in Serum and CSF;IgG/Alb clear Ser+CSF-Rto;;ACTIVE;1.0k;2.73 +1411-8;Cortisol^26H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --26 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis 26h p 500 ug Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14118-4;Lactate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate [Mass/volume] in Serum or Plasma;Lactate SerPl-mCnc;;ACTIVE;1.0k;2.73 +14119-2;Lactate dehydrogenase 1/Lactate dehydrogenase 2;CRto;Pt;Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase 1/Lactate dehydrogenase 2 [Enzymatic activity ratio] in Serum or Plasma;LDH1/LDH2 SerPl-cRto;;ACTIVE;1.0k;2.73 +141-2;cefTRIAXone;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefTRIAXone [Susceptibility] by Minimum inhibitory concentration (MIC);cefTRIAXone Islt MIC;;ACTIVE;1.0;2.73 +14120-0;Prostate specific Ag.free/Prostate specific Ag.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma;Deprecated PSA Free Fr SerPl;;DEPRECATED;1.0k;2.70 +14121-8;Pyruvate;SCnc;Pt;Bld;Qn;;CHEM;1;Pyruvate [Moles/volume] in Blood;Pyruvate Bld-sCnc;;ACTIVE;1.0k;2.73 +14122-6;Pyruvate;SCnc;Pt;CSF;Qn;;CHEM;1;Pyruvate [Moles/volume] in Cerebral spinal fluid;Pyruvate CSF-sCnc;;ACTIVE;1.0k;2.73 +14123-4;Thyroxine.albumin bound/Albumin;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4).albumin bound/Albumin [Mass Ratio] in Serum or Plasma;T4 Alb Bnd/Alb SerPl;;ACTIVE;1.0k;2.73 +14124-2;Bacteria;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Bacteria [Presence] in Semen by Light microscopy;Bacteria Smn Ql Micro;;ACTIVE;1.0k;2.73 +14125-9;Entamoeba histolytica;PrThr;Pt;Stool;Ord;Trichrome stain;MICRO;1;Entamoeba histolytica [Presence] in Stool by Trichrome stain;E histolyt Stl Ql Tri Stn;;ACTIVE;1.0k;2.73 +1412-6;Cortisol^26H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --26 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis 26h p 2 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14126-7;HIV 1 gp120+gp160 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp120+gp160 Ab [Presence] in Serum by Immunoblot;HIV1 gp120+gp160 Ab Ser Ql IB;;ACTIVE;1.0k;2.73 +14127-5;Neisseria gonorrhoeae;PrThr;Pt;Anal;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Anal by Organism specific culture;N gonorrhoea Anal Ql Cult;;ACTIVE;1.0k;2.73 +14128-3;Rabies virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rabies virus Ab [Titer] in Serum;RABV Ab Titr Ser;;ACTIVE;1.0k;2.73 +14129-1;Respiratory syncytial virus;PrThr;Pt;Nose;Ord;Organism specific culture;MICRO;1;Respiratory syncytial virus [Presence] in Nose by Organism specific culture;RSV Nose Ql Cult;;ACTIVE;1.0k;2.73 +14130-9;Estrogen receptor;SCnt;Pt;Tiss;Qn;;PATH;1;Estrogen receptor [Moles/mass] in Tissue;ER Tiss-sCnt;;ACTIVE;1.0k;2.73 +14131-7;PM-1 Ab;PrThr;Pt;Ser;Ord;;SERO;1;PM-1 Ab [Presence] in Serum;PM1 Ab Ser Ql;;ACTIVE;1.0k;2.73 +14132-5;Color;Type;Pt;Gast fld;Nom;;SPEC;1;Color of Gastric fluid;Color Gast;;ACTIVE;1.0k;2.73 +14133-3;Maple silver Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Maple IgE Ab [Units/volume] in Serum;Silver Maple IgE Qn;;ACTIVE;1.0k;2.42 +1413-4;Cortisol^2D post 500 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2 days post 500 ug corticotropin IM;Cortis 2D p 500 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.73 +14134-1;Hemoglobin.free;MCnc;Pt;Ser;Qn;;HEM/BC;1;Deprecated Free Hemoglobin [Mass/volume] in Serum;Deprecated Hgb Free Ser-mCnc;;DEPRECATED;1.0k;2.70 +14135-8;Cells.CD3+CD8+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood;CD3+CD8+ Cells # Bld;;ACTIVE;1.0k;2.73 +14136-6;Cells.CD34;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD34 cells [#/volume] in Blood;CD34 Cells # Bld;;ACTIVE;1.0k;2.73 +14137-4;Glucose^5.5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5.5 hours post 75 g glucose PO;Glucose 5.5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0k;2.70 +14138-2;Ketones^30M post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --30 minutes post XXX challenge;Ketones 30M p chal Ur Ql;;ACTIVE;1.0k;2.73 +14139-0;Ketones^4H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --4 hours post XXX challenge;Ketones 4h p chal Ur Ql;;ACTIVE;1.0k;2.56 +14140-8;Ketones^5H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --5 hours post XXX challenge;Ketones 5h p chal Ur Ql;;ACTIVE;1.0k;2.56 +14141-6;Ketones^6H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --6 hours post XXX challenge;Ketones 6h p chal Ur Ql;;ACTIVE;1.0k;2.56 +1414-2;Cortisol^30M post 0.05-0.15 U insulin/kg IV post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 0.05-0.15 U insulin/kg IV post 12H CFst;Cortis 30M p U/kg Ins IV SerPl-mCnc;;ACTIVE;1.0;2.73 +14142-4;Somatotropin^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;GH 15M p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +14143-2;Somatotropin^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;GH 20M p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +14144-0;Somatotropin^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;GH 2h p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +14145-7;Somatotropin^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;GH 40M p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +14146-5;Somatotropin^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;GH 1h p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +14147-3;Somatotropin^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;GH 1.5h p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +14148-1;18-Hydroxycortisol;MRat;24H;Urine;Qn;;CHEM;1;18-Hydroxycortisol [Mass/time] in 24 hour Urine;18OH-Cortis 24h Ur-mRate;;ACTIVE;1.0k;2.73 +14149-9;Corticotropin.big fragment;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Corticotropin Big Fragment [Mass/volume] in Serum or Plasma;ACTH Big Frg SerPl-mCnc;;ACTIVE;1.0k;2.73 +14150-7;Beta glucuronidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Beta glucuronidase [Enzymatic activity/volume] in Serum or Plasma;Deprecated B-Glucuronidase SerPl-cCnc;;DEPRECATED;1.0k;2.70 +14151-5;Bicarbonate;SCnc;Pt;BldCo;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Cord blood;HCO3 BldCo-sCnc;;ACTIVE;1.0k;2.73 +14152-3;Bilirubin.glucuronidated+Bilirubin.albumin bound;MCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.direct [Mass/volume] in Body fluid;Bilirub Direct Fld-mCnc;;ACTIVE;1.0k;2.73 +14153-1;Carnitine esters/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Carnitine esters/Creatinine [Mass Ratio] in Urine;Carn esters/Creat Ur;;DISCOURAGED;1.0k;2.42 +14154-9;Cholesterol sulfate;MCnc;Pt;Ser;Qn;;CHEM;1;Cholesterol sulfate [Mass/volume] in Serum;Cholest Sulf Ser-mCnc;;ACTIVE;1.0k;2.70 +14155-6;Cholesterol.in LDL;Prctl;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL [Percentile];LDLc Prctl SerPl;;ACTIVE;1.0k;2.73 +14156-4;Coproporphyrin;MCnt;24H;Stool;Qn;;CHEM;1;Coproporphyrin [Mass/mass] in 24 hour Stool;Copro 24h Stl-mCnt;;ACTIVE;1.0k;2.73 +14157-2;Coproporphyrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Coproporphyrin [Mass/volume] in Serum or Plasma;Copro SerPl-mCnc;;ACTIVE;1.0k;2.73 +14158-0;Cortisol;MRat;24H;Urine;Qn;;CHEM;1;Cortisol [Mass/time] in 24 hour Urine;Cortis 24h Ur-mRate;;ACTIVE;1.0k;2.73 +1415-9;Cortisol^30M post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 1 ug/kg CRH IV;Cortis 30M p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14159-8;Cortisone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisone [Mass/volume] in Serum or Plasma;Cortisone SerPl-mCnc;;ACTIVE;1.0k;2.73 +14160-6;Estrone.unconjugated/Estrone.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Estrone (E1).unconjugated/Estrone (E1).total in Serum or Plasma;u Estrone MFr SerPl;;ACTIVE;1.0k;2.73 +14161-4;Formaldehyde;MFr;Pt;Flu.nonbiological;Qn;;DRUG/TOX;1;Deprecated Formaldehyde in Nonbiological fluid;Deprecated Formaldehyde MFr Fld.NB;;DEPRECATED;1.0k;2.70 +14162-2;Gamma melanocyte stimulating hormone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma melanocyte stimulating hormone [Mass/volume] in Serum or Plasma;G-MSH SerPl-mCnc;;ACTIVE;1.0k;2.73 +14163-0;IgA.secretory;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgA.secretory [Mass/volume] in Serum or Plasma;SIgA SerPl-mCnc;;ACTIVE;1.0k;2.73 +14164-8;Immunosuppressive acidic protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Immunosuppressive acidic protein [Mass/volume] in Serum or Plasma;IAP SerPl-mCnc;;ACTIVE;1.0k;2.70 +14165-5;Lactate;SCnc;Pt;Body fld;Qn;;CHEM;1;Lactate [Moles/volume] in Body fluid;Lactate Fld-sCnc;;ACTIVE;1.0k;2.73 +14166-3;Methane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methane [Mass/volume] in Blood;Methane Bld-mCnc;;ACTIVE;1.0k;2.70 +1416-7;Cortisol^30M post 250 ug corticotropin IM rapid;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM rapid;Cortis 30M p 250 ug ACTH rIM SerPl-mCnc;;ACTIVE;1.0;2.40 +14167-1;N-methylimidazoleacetate;MRat;24H;Urine;Qn;;CHEM;1;N-methylimidazoleacetate [Mass/time] in 24 hour Urine;N-MIAA 24h Ur-mRate;;ACTIVE;1.0k;2.70 +14168-9;Palatinase;CCnt;Pt;Tiss;Qn;;CHEM;1;Palatinase [Enzymatic activity/mass] in Tissue;Palatinase Tiss-cCnt;;ACTIVE;1.0k;2.73 +14169-7;Peptide histidine isoleucine;MCnc;Pt;Plas;Qn;;CHEM;1;Peptide histidine isoleucine [Mass/volume] in Plasma;PHIM Plas-mCnc;;ACTIVE;1.0k;2.70 +14170-5;Pituitary glycoprotein hormone.alpha subunit;MCnc;Pt;Ser;Qn;;CHEM;1;Pituitary glycoprotein hormone.alpha subunit [Mass/volume] in Serum;a-PGH Ser-mCnc;;ACTIVE;1.0k;2.73 +14171-3;Porphyrins;MCnt;24H;Stool;Qn;;CHEM;1;Porphyrins [Mass/mass] in 24 hour Stool;Porphyrins 24h Stl-mCnt;;ACTIVE;1.0k;2.70 +14172-1;Potassium;SCnc;Pt;Synv fld;Qn;;CHEM;1;Potassium [Moles/volume] in Synovial fluid;Potassium Snv-sCnc;;ACTIVE;1.0k;2.73 +14173-9;Progesterone.free;MRat;24H;Urine;Qn;;CHEM;1;Progesterone Free [Mass/time] in 24 hour Urine;Progest Free 24h Ur-mRate;;ACTIVE;1.0k;2.73 +14174-7;Prostaglandin F2 alpha;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostaglandin F2 alpha [Mass/volume] in Serum or Plasma;Prostaglandin F2A SerPl-mCnc;;ACTIVE;1.0k;2.73 +1417-5;Cortisol^30M post 250 ug corticotropin IV rapid;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IV rapid;Cortis 30M p 250 ug ACTH rIV SerPl-mCnc;;ACTIVE;1.0;2.40 +14175-4;Protoporphyrin;MCnt;24H;Stool;Qn;;CHEM;1;Protoporphyrin [Mass/mass] in 24 hour Stool;Protopor 24h Stl-mCnt;;ACTIVE;1.0k;2.73 +14176-2;Pyrroles;MCnc;Pt;Urine;Qn;;CHEM;1;Pyrroles [Mass/volume] in Urine;Pyrroles Ur-mCnc;;ACTIVE;1.0k;2.73 +14177-0;Growth hormone-releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Growth hormone-releasing hormone [Mass/volume] in Serum or Plasma;GHRH SerPl-mCnc;;ACTIVE;1.0k;2.73 +14178-8;Sucrase;CCnt;Pt;Tiss;Qn;;CHEM;1;Sucrase [Enzymatic activity/mass] in Tissue;Sucrase Tiss-cCnt;;ACTIVE;1.0k;2.73 +14179-6;Tissue polypeptide Ag;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tissue polypeptide Ag [Mass/volume] in Serum or Plasma;Tiss Polypept Ag SerPl-mCnc;;ACTIVE;1.0k;2.73 +14180-4;Uroporphyrin;MCnc;Pt;RBC;Qn;;CHEM;1;Uroporphyrin [Mass/volume] in Red Blood Cells;Uropor RBC-mCnc;;ACTIVE;1.0k;2.73 +14181-2;Uroporphyrin;MCnt;24H;Stool;Qn;;CHEM;1;Uroporphyrin [Mass/mass] in 24 hour Stool;Uropor 24h Stl-mCnt;;ACTIVE;1.0k;2.70 +14182-0;Thrombin antithrombin complex Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Thrombin antithrombin complex Ag [Mass/volume] in Platelet poor plasma by Immunoassay;TAT Ag PPP IA-mCnc;;ACTIVE;1.0k;2.73 +1418-3;Cortisol^30M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;Cortis 30M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.73 +14183-8;Aprobarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aprobarbital [Mass/volume] in Urine;Aprobarbital Ur-mCnc;;ACTIVE;1.0k;2.70 +14184-6;Atropine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Atropine [Presence] in Urine;Atropine Ur Ql;;ACTIVE;1.0k;2.56 +14185-3;methIMAzole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;methIMAzole [Mass/volume] in Serum or Plasma;methIMAzole SerPl-mCnc;;ACTIVE;1.0k;2.73 +14186-1;Methylprednisolone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylprednisolone [Mass/volume] in Serum or Plasma;Me-prednisolone SerPl-mCnc;;ACTIVE;1.0k;2.73 +14187-9;OKT3;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OKT3 [Mass/volume] in Serum or Plasma;OKT3 SerPl-mCnc;;ACTIVE;1.0k;2.70 +14188-7;Omeprazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Omeprazole [Mass/volume] in Serum or Plasma;Omeprazole SerPl-mCnc;;ACTIVE;1.0k;2.70 +14189-5;Phenyltoloxamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenyltoloxamine [Mass/volume] in Urine;Phenyltoloxamine Ur-mCnc;;ACTIVE;1.0k;2.70 +14190-3;Phenytoin.free;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Phenytoin Free [Mass/volume] in Saliva (oral fluid);Phenytoin Free Sal-mCnc;;ACTIVE;1.0k;2.73 +1419-1;Cortisol^30M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV;Cortis 30M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14191-1;Prazosin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prazosin [Mass/volume] in Serum or Plasma;Prazosin SerPl-mCnc;;ACTIVE;1.0k;2.73 +14192-9;Triazolam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Triazolam [Presence] in Urine;Triazolam Ur Ql;;ACTIVE;1.0k;2.73 +14193-7;Tripelennamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tripelennamine [Presence] in Urine;Tripelennamine Ur Ql;;ACTIVE;1.0k;2.56 +14194-5;Spermatozoa.progressive/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive/100 spermatozoa in Semen;Sperm Prog NFr Smn;;ACTIVE;1.0k;2.73 +14195-2;Complement C3b.inactive;MCnc;Pt;Plas;Qn;;HEM/BC;1;Complement C3b Inactive [Mass/volume] in Plasma;C3b Inactive Plas-mCnc;;ACTIVE;1.0k;2.70 +14196-0;Reticulocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes [#/volume] in Blood;Retics #;;ACTIVE;1.0k;2.73 +14197-8;Blastomyces dermatitidis exoantigen identification;Prid;Pt;Isolate;Nom;;MICRO;1;Blastomyces dermatitidis exoantigen [Identifier] in Isolate;B dermat XA ID Islt;;ACTIVE;1.0k;2.73 +14198-6;Chlamydophila psittaci Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila psittaci Ab [Titer] in Serum by Immunofluorescence;C psittaci Ab Titr Ser IF;;ACTIVE;1.0k;2.70 +14199-4;Chlamydia trachomatis B Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis B IgA Ab [Titer] in Serum by Immunofluorescence;C trach B IgA Titr Ser IF;;ACTIVE;1.0k;2.73 +142-0;cefTRIAXone;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefTRIAXone [Susceptibility] by Disk diffusion (KB);cefTRIAXone Islt KB;;ACTIVE;1.0;2.73 +14200-0;Chlamydia trachomatis B Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis B IgG Ab [Titer] in Serum by Immunofluorescence;C trach B IgG Titr Ser IF;;ACTIVE;1.0k;2.73 +14201-8;Chlamydia trachomatis B Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis B IgM Ab [Titer] in Serum by Immunofluorescence;C trach B IgM Titr Ser IF;;ACTIVE;1.0k;2.73 +14202-6;Chlamydia trachomatis C Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis C IgA Ab [Titer] in Serum by Immunofluorescence;C trach C IgA Titr Ser IF;;ACTIVE;1.0k;2.73 +14203-4;Chlamydia trachomatis C Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis C IgG Ab [Titer] in Serum by Immunofluorescence;C trach C IgG Titr Ser IF;;ACTIVE;1.0k;2.73 +14204-2;Chlamydia trachomatis C Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis C IgM Ab [Titer] in Serum by Immunofluorescence;C trach C IgM Titr Ser IF;;ACTIVE;1.0k;2.73 +14205-9;Coccidioides immitis Ag;PrThr;Pt;Isolate;Ord;Immune diffusion;MICRO;1;Coccidioides immitis Ag [Presence] in Isolate by Immune diffusion (ID);C immitis Ag Islt Ql ID;;ACTIVE;1.0k;2.56 +14206-7;Coccidioides immitis exoantigen identification;Prid;Pt;Isolate;Nom;;MICRO;1;Coccidioides immitis exoantigen [Identifier] in Isolate;C immitis XA ID Islt;;ACTIVE;1.0k;2.19 +14207-5;DNAse B Ab.Streptococcal;Titr;Pt;Ser;Qn;;MICRO;1;Streptococcal DNAse B [Titer] in Serum;Strep DNAse B Titr Ser;;ACTIVE;1.0k;2.73 +14208-3;Filaria Ab.IgG4;ACnc;Pt;Ser;Qn;;MICRO;1;Filaria IgG4 Ab [Units/volume] in Serum;Filaria IgG4 Ser-aCnc;;ACTIVE;1.0k;2.73 +1420-9;Cortisol^30M post dose U/kg insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Deprecated Cortisol [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV;Deprecated Cortis 30M p U/kg Ins IV Plas;;DEPRECATED;1.0;2.36 +14209-1;Francisella tularensis Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Francisella tularensis IgA Ab [Presence] in Serum;F tular IgA Ser Ql;;ACTIVE;1.0k;2.56 +14210-9;Giardia lamblia Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Giardia lamblia Ag [Presence] in Stool by Immunofluorescence;G lamblia Ag Stl Ql IF;;ACTIVE;1.0k;2.73 +14211-7;Hepatitis E virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis E virus IgG Ab [Presence] in Serum;HEV IgG Ser Ql;;ACTIVE;1.0k;2.73 +14212-5;Hepatitis E virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis E virus IgM Ab [Presence] in Serum;HEV IgM Ser Ql;;ACTIVE;1.0k;2.73 +14213-3;Herpes simplex virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus IgM Ab [Titer] in Serum by Immunofluorescence;HSV IgM Titr Ser IF;;ACTIVE;1.0k;2.73 +14214-1;Histoplasma capsulatum exoantigen identification;Prid;Pt;Isolate;Nom;;MICRO;1;Histoplasma capsulatum exoantigen [Identifier] in Isolate;H capsul XA ID Islt;;ACTIVE;1.0k;2.19 +14215-8;HTLV I g46 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I g46 Ab [Presence] in Serum;HTLV I g46 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14216-6;HTLV I gp46 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV 1 gp46 Ab [Presence] in Serum;HTLV1 gp46 Ab Ser Ql;;ACTIVE;1.0k;2.56 +1421-7;Cortisol^32H post 40 ug corticotropin IM BID 3 day;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --32 hours post 40 ug corticotropin IM BID 3 day;Cortis 32h p 40 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.73 +14217-4;HTLV I p19 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I p19 Ab [Presence] in Serum;HTLV I p19 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14218-2;HTLV I p24 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I p24 Ab [Presence] in Serum;HTLV I p24 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14219-0;HTLV I p26 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I p26 Ab [Presence] in Serum;HTLV I p26 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14220-8;HTLV I p28 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I p28 Ab [Presence] in Serum;HTLV I p28 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14221-6;HTLV I p32 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I p32 Ab [Presence] in Serum;HTLV I p32 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14222-4;HTLV I p36 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I p36 Ab [Presence] in Serum;HTLV I p36 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14223-2;HTLV I p53 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I p53 Ab [Presence] in Serum;HTLV I p53 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14224-0;HTLV I rgp21 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I rgp21 Ab [Presence] in Serum;HTLV I rgp21 Ab Ser Ql;;ACTIVE;1.0k;2.56 +1422-5;Cortisol^3D post 500 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --3 days post 500 ug corticotropin IM;Cortis 3D p 500 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.40 +14225-7;HTLV II g46 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV II g46 Ab [Presence] in Serum;HTLV II g46 Ab Ser Ql;;ACTIVE;1.0k;2.56 +14226-5;Nocardia sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Nocardia sp identified in Isolate by Organism specific culture;Nocardia Islt Cult;;ACTIVE;1.0k;2.19 +14227-3;Salmonella typhi H D Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella typhi H D Ab [Titer] in Serum;S Typhi H d Ab Titr Ser;;ACTIVE;1.0k;2.73 +14228-1;Cells.estrogen receptor/100 cells;NFr;Pt;Tiss;Qn;Immune stain;PATH;1;Cells.estrogen receptor/100 cells in Tissue by Immune stain;ER+ cells NFr Tiss ImStn;;ACTIVE;1.0k;2.73 +14229-9;P53 protein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;P53 protein Ag [Presence] in Tissue by Immune stain;P53 protein Ag Tiss Ql ImStn;;ACTIVE;1.0k;2.73 +14230-7;Cells.progesterone receptor/100 cells;NFr;Pt;Tiss;Qn;Immune stain;PATH;1;Cells.progesterone receptor/100 cells in Tissue by Immune stain;PR+ cells NFr Tiss ImStn;;ACTIVE;1.0k;2.73 +14231-5;H2a-H2b DNA Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;H2a-H2b DNA IgG Ab [Units/volume] in Serum;H2a-H2b DNA IgG Ser-aCnc;;ACTIVE;1.0k;2.69 +14232-3;Adrenal Ab;PrThr;Pt;Ser;Ord;;SERO;1;Adrenal Ab [Presence] in Serum;Adrenal Ab Ser Ql;;ACTIVE;1.0k;2.73 +1423-3;Cortisol^45M post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --45 minutes post 1 ug/kg CRH IV;Cortis 45M p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14233-1;Beta tubulin Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Beta tubulin IgG Ab [Titer] in Serum;B-Tubulin IgG Titr Ser;;ACTIVE;1.0k;2.70 +14234-9;Beta tubulin Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Beta tubulin IgM Ab [Titer] in Serum;B-Tubulin IgM Titr Ser;;ACTIVE;1.0k;2.70 +14235-6;Jo-1 extractable nuclear Ab;Titr;Pt;Ser;Qn;;SERO;1;Jo-1 extractable nuclear Ab [Titer] in Serum;ENA Jo1 Ab Titr Ser;;ACTIVE;1.0k;2.73 +14236-4;Mitochondria Ab;PrThr;Pt;Ser;Ord;;SERO;1;Mitochondria Ab [Presence] in Serum;Mitochondria Ab Ser Ql;;ACTIVE;1.0k;2.73 +14237-2;Myelin basic protein Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Myelin basic protein IgA Ab [Units/volume] in Serum;MBP IgA Ser-aCnc;;ACTIVE;1.0k;2.69 +14238-0;Myelin basic protein Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Myelin basic protein IgG Ab [Units/volume] in Serum;MBP IgG Ser-aCnc;;ACTIVE;1.0k;2.69 +14239-8;Myelin basic protein Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Myelin basic protein IgM Ab [Units/volume] in Serum;MBP IgM Ser-aCnc;;ACTIVE;1.0k;2.69 +14240-6;Neuronal nuclear Ab;ACnc;Pt;CSF;Qn;;SERO;1;Neuronal nuclear Ab [Units/volume] in Cerebral spinal fluid;Hu Ab CSF-aCnc;;ACTIVE;1.0k;2.70 +1424-1;Cortisol^45M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --45 minutes post dose insulin IV;Cortis 45M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14241-4;Parietal cell Ab;PrThr;Pt;Ser;Ord;;SERO;1;Parietal cell Ab [Presence] in Serum;PCA Ab Ser Ql;;ACTIVE;1.0k;2.73 +14242-2;Phosphatidylcholine Ab.IgA;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylcholine IgA Ab [Presence] in Serum;PC IgA Ser Ql;;ACTIVE;1.0k;2.73 +14243-0;Phosphatidylcholine Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylcholine IgG Ab [Presence] in Serum;PC IgG Ser Ql;;ACTIVE;1.0k;2.73 +14244-8;Phosphatidylcholine Ab.IgM;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylcholine IgM Ab [Presence] in Serum;PC IgM Ser Ql;;ACTIVE;1.0k;2.73 +14245-5;Phosphatidylserine Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgG Ab [Units/volume] in Serum;PS IgG Ser-aCnc;;ACTIVE;1.0k;2.73 +14246-3;Phosphatidylserine Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgM Ab [Units/volume] in Serum;PS IgM Ser-aCnc;;ACTIVE;1.0k;2.73 +14247-1;Purkinje cells Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Purkinje cells Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Purkinje Cells Ab CSF Ql IF;;ACTIVE;1.0k;2.73 +14248-9;Purkinje cells Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Purkinje cells Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Purkinje Cells Ab Titr CSF IF;;ACTIVE;1.0k;2.73 +14249-7;Purkinje cells Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Purkinje cells Ab [Presence] in Serum by Immunofluorescence;Purkinje Cells Ab Ser Ql IF;;ACTIVE;1.0k;2.73 +14250-5;Purkinje cells Ab.IgG;ACnc;Pt;Ser;Qn;IF;SERO;1;Purkinje cells IgG Ab [Units/volume] in Serum by Immunofluorescence;Purkinje Cells IgG Ser IF-aCnc;;ACTIVE;1.0k;2.73 +14251-3;Mitochondria M2 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Mitochondria M2 IgG Ab [Units/volume] in Serum;Mitochondria M2 IgG Ser-aCnc;;ACTIVE;1.0k;2.73 +14252-1;Smooth muscle Ab;PrThr;Pt;Ser;Ord;;SERO;1;Smooth muscle Ab [Presence] in Serum;Smooth muscle Ab Ser Ql;;ACTIVE;1.0k;2.73 +14253-9;Somatotropin Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Somatotropin Ab [Presence] in Serum or Plasma;GH Ab SerPl Ql;;ACTIVE;1.0k;2.73 +14254-7;Ganglioside GQ1b Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GQ1b IgG Ab [Titer] in Serum;GQ1b Gangl IgG Titr Ser;;ACTIVE;1.0k;2.73 +14255-4;Thyrotropin blocking Ab;ACnc;Pt;Ser;Qn;;SERO;1;Thyrotropin blocking Ab [Units/volume] in Serum;TSH Block Ab Ser-aCnc;;ACTIVE;1.0k;2.73 +14256-2;Tetrachlorodiphenylethane;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Tetrachlorodiphenylethane [Mass/mass] in Tissue;DDD Tiss-mCnt;;ACTIVE;1.0k;2.70 +14257-0;Tetrachlorodiphenylethane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tetrachlorodiphenylethane [Mass/volume] in Serum or Plasma;DDD SerPl-mCnc;;ACTIVE;1.0k;2.73 +1425-8;Cortisol^48H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --48 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis 48h p 2 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.73 +14258-8;1,4-Dioxane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,4-Dioxane [Mass/volume] in Blood;1,4Dioxane Bld-mCnc;;ACTIVE;1.0k;2.70 +14259-6;1-Pentanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1-Pentanol [Mass/volume] in Blood;1Pentanol Bld-mCnc;;ACTIVE;1.0k;2.73 +14260-4;Bromoform;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Bromoform [Mass/volume] in Blood;Bromoform Bld-mCnc;;ACTIVE;1.0k;2.70 +14261-2;Codeine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Codeine [Presence] in Gastric fluid;Codeine Gast Ql;;ACTIVE;1.0k;2.56 +14262-0;Dichlorodiphenyldichloroethylene;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Dichlorodiphenyldichloroethylene [Mass/mass] in Tissue;DDE Tiss-mCnt;;ACTIVE;1.0k;2.70 +14263-8;Dichlorodiphenyltrichloroethane;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Dichlorodiphenyltrichloroethane [Mass/mass] in Tissue;DDT Tiss-mCnt;;ACTIVE;1.0k;2.70 +14264-6;Enflurane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Enflurane [Mass/volume] in Blood;Enf Bld-mCnc;;ACTIVE;1.0k;2.73 +14265-3;Isobutyl acetate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isobutyl acetate [Mass/volume] in Blood;Isobutyl Acetate Bld-mCnc;;ACTIVE;1.0k;2.70 +1426-6;Cortisol^48H post 40 ug corticotropin IM BID 3 day;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --48 hours post 40 ug corticotropin IM BID 3 day;Cortis 2D p 40 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.40 +14266-1;Methoxyflurane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methoxyflurane [Mass/volume] in Blood;Methoxyflurane Bld-mCnc;;ACTIVE;1.0k;2.70 +14267-9;Methylenedioxymethamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Urine;MDMA Ur Ql;;ACTIVE;1.0k;2.73 +14268-7;Butyl acetate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Butyl acetate [Mass/volume] in Blood;Butyl acetate Bld-mCnc;;ACTIVE;1.0k;2.70 +14269-5;Sec-butyl acetate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Sec-butyl acetate [Mass/volume] in Blood;s-Butyl Acetate Bld-mCnc;;ACTIVE;1.0k;2.70 +14270-3;Tert-butyl acetate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tert-butyl acetate [Mass/volume] in Blood;t-Butyl Acetate Bld-mCnc;;ACTIVE;1.0k;2.70 +14271-1;Character;Aper;Pt;Synv fld;Nom;;SPEC;1;Character of Synovial fluid;Character Snv;;ACTIVE;1.0k;2.19 +14272-9;Liver kidney microsomal Ab;PrThr;Pt;Ser;Ord;;SERO;1;Liver kidney microsomal Ab [Presence] in Serum;LKM Ab Ser Ql;;ACTIVE;1.0k;2.73 +14273-7;Reticulin Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Reticulin IgA Ab [Presence] in Serum;Reticulin IgA Ser Ql;;ACTIVE;1.0k;2.73 +1427-4;Cortisol^48H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --48 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis 48h p 500 ug Dex SerPl-mCnc;;ACTIVE;1.0;2.73 +14274-5;Uroporphyrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Uroporphyrin [Mass/volume] in Serum or Plasma;Uropor SerPl-mCnc;;ACTIVE;1.0k;2.73 +14275-2;Immune complex;ACnc;Pt;Ser/Plas;Qn;C3b binding assay;SERO;1;Immune complex [Units/volume] in Serum or Plasma by C3b binding assay;IC SerPl C3B Bind-aCnc;;ACTIVE;1.0k;2.70 +14276-0;Hemoglobin F distribution;Imp;Pt;Bld;Nom;Kleihauer-Betke;HEM/BC;1;Hemoglobin F distribution [Interpretation] in Blood by Kleihauer-Betke method;Hgb F Dist Bld Kleih Betke-Imp;;ACTIVE;1.0k;2.73 +14277-8;Neutrophil cytoplasmic Ab.classic;Titr;Pt;Ser;Qn;IF;SERO;1;Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence;c-ANCA Titr Ser IF;;ACTIVE;1.0k;2.73 +14278-6;Neutrophil cytoplasmic Ab.perinuclear;Titr;Pt;Ser;Qn;IF;SERO;1;Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence;p-ANCA Titr Ser IF;;ACTIVE;1.0k;2.73 +1428-2;Cortisol^50H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --50 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis 50H p 500 ug Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14282-8;Acylcarnitine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acylcarnitine [Moles/volume] in Serum or Plasma;Acylcarnitine SerPl-sCnc;;ACTIVE;1.0k;2.73 +14283-6;Acylcarnitine;SCnc;Pt;Urine;Qn;;CHEM;1;Acylcarnitine [Moles/volume] in Urine;Acylcarnitine Ur-sCnc;;ACTIVE;1.0k;2.70 +14284-4;Beta glucuronidase;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta glucuronidase [Moles/volume] in Serum or Plasma;B-Glucuronidase SerPl-sCnc;;ACTIVE;1.0k;2.70 +14285-1;Carnitine.free (C0);SCnc;Pt;Urine;Qn;;CHEM;1;Carnitine free (C0) [Moles/volume] in Urine;Carnitine Free Ur-sCnc;;ACTIVE;1.0k;2.73 +14286-9;Carnitine.free (C0);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine free (C0) [Moles/volume] in Serum or Plasma;Carnitine Free SerPl-sCnc;;ACTIVE;1.0k;2.73 +14287-7;Carnitine;SCnc;Pt;Urine;Qn;;CHEM;1;Carnitine [Moles/volume] in Urine;Carnitine Ur-sCnc;;ACTIVE;1.0k;2.73 +14288-5;Carnitine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine [Moles/volume] in Serum or Plasma;Carnitine SerPl-sCnc;;ACTIVE;1.0k;2.73 +14289-3;Coproporphyrin;ACnc;24H;Urine;Ord;;CHEM;1;Deprecated Coproporphyrin [Presence] in 24 hour Urine;Deprecated Copro 24H Ur Ql;;DEPRECATED;1.0k;2.36 +1429-0;Cortisol^50H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --50 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis 50H p 2 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14290-1;Erythrocytes;ACnc;Pt;Urine sed;Qn;Manual count;UA;1;Deprecated Erythrocytes [Units/volume] in Urine sediment by Manual count;Deprecated RBC UrnS Manual-aCnc;;DEPRECATED;1.0k;2.70 +14291-9;Follitropin^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --baseline;FSH BS SerPl-sCnc;;DISCOURAGED;1.0k;2.42 +14292-7;IgE;SCnc;Pt;Ser;Qn;;CHEM;1;IgE [Moles/volume] in Serum;IgE Ser-sCnc;;ACTIVE;1.0k;2.73 +14293-5;Insulin^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --baseline;Insulin BS SerPl-sCnc;;ACTIVE;1.0k;2.73 +14294-3;Lysosomal enzymes screen;Prid;Pt;Plas+Urine;Nom;;CHEM;1;Lysosomal enzymes screen [Identifier] in Plasma and Urine;Lysosomal Enzymes Scn Plas+Ur;;ACTIVE;1.0k;2.38 +14295-0;Organic acids/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Organic acids/Creatinine [Molar ratio] in Urine;Organic Acids/Creat Ur-sRto;;ACTIVE;1.0k;2.73 +14296-8;Thyroperoxidase Ab;SCnc;Pt;Ser/Plas;Qn;;SERO;1;Thyroperoxidase Ab [Moles/volume] in Serum or Plasma;Thyroperoxidase Ab SerPl-sCnc;;DISCOURAGED;1.0k;2.73 +14297-6;Thyrotropin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyrotropin [Moles/volume] in Serum or Plasma;TSH SerPl-sCnc;;DISCOURAGED;1.0k;2.73 +14298-4;Plasma units available;Num;Pt;^BPU;Qn;;BLDBK;1;Plasma units available [#];Plasma Avail BPU;;ACTIVE;1.0k;2.69 +14299-2;Cryoprecipitate units available;Num;Pt;^BPU;Qn;;BLDBK;1;Cryoprecipitate units available [#];Cryoppt Avail BPU;;ACTIVE;1.0k;2.69 +14300-8;Plateletpheresis units available;Num;Pt;^BPU;Qn;;BLDBK;1;Plateletpheresis units available [#];Platpheresis Avail BPU;;ACTIVE;1.0k;2.73 +14301-6;Platelet concentrate units available;Num;Pt;^BPU;Qn;;BLDBK;1;Platelet concentrate units available [#];Platelet Conc Avail BPU;;ACTIVE;1.0k;2.69 +14302-4;Packed erythrocytes units available;Num;Pt;^BPU;Qn;;BLDBK;1;Packed erythrocytes units available [#];Packed RBC Avail BPU;;ACTIVE;1.0k;2.69 +14303-2;Transfuse plateletpheresis;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse plateletpheresis [Volume];Trans Platpheresis Vol Patient;;ACTIVE;1.0k;2.42 +14304-0;Measles virus Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Measles virus IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;MeV IgG sp1 Ser IA-aCnc;;ACTIVE;1.0k;2.73 +14305-7;Measles virus Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Measles virus IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;MeV IgG sp2 Ser IA-aCnc;;ACTIVE;1.0k;2.73 +14306-5;Varicella zoster virus Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;VZV IgG sp1 Ser IA-aCnc;;ACTIVE;1.0k;2.73 +14307-3;Varicella zoster virus Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;VZV IgG sp2 Ser IA-aCnc;;ACTIVE;1.0k;2.73 +1430-8;Cortisol^56H post 40 ug corticotropin IM BID 3 day;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --56 hours post 40 ug corticotropin IM BID 3 day;Cortis 56h p 40 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.40 +14308-1;Amphetamines;PrThr;Pt;Urine;Ord;Screen>1000 ng/mL;DRUG/TOX;1;Amphetamines [Presence] in Urine by Screen method >1000 ng/mL;Amphetamines Ur Ql Scn>1000 ng/mL;;ACTIVE;1.0k;2.73 +14309-9;Amphetamines;PrThr;Pt;Urine;Ord;Confirm>200 ng/mL;DRUG/TOX;1;Amphetamines [Presence] in Urine by Confirm method >200 ng/mL;Amphetamines Ur Ql Cfm>200 ng/mL;;ACTIVE;1.0k;2.73 +14310-7;Phencyclidine;PrThr;Pt;Urine;Ord;Screen>25 ng/mL;DRUG/TOX;1;Phencyclidine [Presence] in Urine by Screen method >25 ng/mL;PCP Ur Ql Scn>25 ng/mL;;ACTIVE;1.0k;2.73 +14311-5;Phencyclidine;PrThr;Pt;Urine;Ord;Confirm>20 ng/mL;DRUG/TOX;1;Phencyclidine [Presence] in Urine by Confirm method >20 ng/mL;PCP Ur Ql Cfm>20 ng/mL;;ACTIVE;1.0k;2.73 +14312-3;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Screen>50 ng/mL;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by Screen method >50 ng/mL;THC Ur Ql Scn>50 ng/mL;;ACTIVE;1.0k;2.73 +14313-1;Tetrahydrocannabinol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Urine by Confirmatory method;THC Ur Cfm-mCnc;;ACTIVE;1.0k;2.73 +14314-9;Benzoylecgonine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Benzoylecgonine [Presence] in Urine by Screen method;BZE Ur Ql Scn;;ACTIVE;1.0k;2.73 +14315-6;Benzoylecgonine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Benzoylecgonine [Presence] in Urine by Confirmatory method;BZE Ur Ql Cfm;;ACTIVE;1.0k;2.73 +1431-6;Cortisol^5M post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --5 minutes post 1 ug/kg CRH IV;Cortis 5M p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;1.0;2.73 +14316-4;Benzodiazepines;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Benzodiazepines [Presence] in Urine by Screen method;Benzodiaz Ur Ql Scn;;ACTIVE;1.0k;2.73 +14317-2;Microscopic observation;Prid;Pt;Genital;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Genital specimen by Wet preparation;Wet Prep Genital;;ACTIVE;1.0k;2.73 +14318-0;Microscopic observation;Prid;Pt;Cvx;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Cervix by Wet preparation;Wet Prep Cvx;;ACTIVE;1.0k;2.73 +14319-8;Microscopic observation;Prid;Pt;Vag;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Vaginal fluid by Wet preparation;Wet Prep Vag;;ACTIVE;1.0k;2.73 +14320-6;Bacteria identified;Prid;Pt;Urine;Nom;Culture @1:100;MICRO;1;Deprecated Bacteria identified in Urine by Culture @1:100;Deprecated Bacteria Ur Cult @1:100;;DEPRECATED;1.0k;2.36 +14321-4;Haemophilus influenzae B Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Haemophilus influenzae B Ag [Presence] in Cerebral spinal fluid by Latex agglutination;Haem influ B Ag CSF Ql LA;;ACTIVE;1.0k;2.73 +14322-2;Streptococcus pneumoniae Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Cerebral spinal fluid by Latex agglutination;S pneum Ag CSF Ql LA;;ACTIVE;1.0k;2.73 +14323-0;Streptococcus agalactiae Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Streptococcus agalactiae Ag [Presence] in Cerebral spinal fluid by Latex agglutination;Gp B Strep Ag CSF Ql LA;;ACTIVE;1.0k;2.73 +1432-4;Cortisol^72H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --72 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis 72h p 2 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14324-8;Escherichia coli K1 Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Escherichia coli K1 Ag [Presence] in Cerebral spinal fluid by Latex agglutination;E coli K1 Ag CSF Ql LA;;ACTIVE;1.0k;2.56 +14325-5;Bacteria identified;Prid;Pt;XXX;Nom;Environmental culture;MICRO;1;Bacteria identified in Specimen by Environmental culture;Bacteria Spec Envir Cult;;ACTIVE;1.0k;2.73 +14326-3;Eosinophils/100 leukocytes;NFr;Pt;Stool;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Stool by Manual count;Eosinophil/leuk NFr Stl Manual;;ACTIVE;1.0k;2.73 +14327-1;Epithelial cells.squamous;PrThr;Pt;Sputum;Ord;Microscopy.light;HEM/BC;1;Epithelial cells.squamous [Presence] in Sputum by Light microscopy;Squamous Spt Ql Micro;;ACTIVE;1.0k;2.73 +14328-9;Leukocytes;PrThr;Pt;Sputum;Ord;Microscopy.light;HEM/BC;1;Leukocytes [Presence] in Sputum by Light microscopy;WBC Spt Ql Micro;;ACTIVE;1.0k;2.73 +14329-7;Mucus;PrThr;Pt;Sputum;Ord;Microscopy.light;HEM/BC;1;Mucus [Presence] in Sputum by Light microscopy;Mucous Threads Spt Ql Micro;;ACTIVE;1.0k;2.56 +14330-5;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Stool;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Stool by Manual count;Polys/leuk NFr Stl Manual;;ACTIVE;1.0k;2.70 +14331-3;Erythrocytes;ACnc;Pt;Stool;Qn;Manual count;HEM/BC;1;Erythrocytes [Units/volume] in Stool by Manual count;RBC Stl Manual-aCnc;;DISCOURAGED;1.0k;2.69 +1433-2;Cortisol^72H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --72 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis 72h p 500 ug Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14332-1;Para aminosalicylate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Para aminosalicylate [Susceptibility] by Minimum inhibitory concentration (MIC);PAS Islt MIC;;ACTIVE;1.0k;2.19 +14333-9;Lead;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Lead [Presence] in 24 hour Urine;Lead 24h Ur Ql;;ACTIVE;1.0k;2.56 +14334-7;Lithium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lithium [Moles/volume] in Serum or Plasma;Lithium SerPl-sCnc;;ACTIVE;1.0k;2.73 +14335-4;Optical density;OD;Pt;Amnio fld;Qn;Spectrophotometry;CHEM;1;Optical density of Amniotic fluid by Spectrophotometry;OD Amn Spect;;ACTIVE;1.0k;2.70 +14336-2;Ethanol;MCnc;Pt;Ser/Plas;Qn;GC;DRUG/TOX;1;Ethanol [Mass/volume] in Serum or Plasma by Gas chromatography;Ethanol SerPl GC-mCnc;;ACTIVE;1.0k;2.73 +14337-0;Phenytoin.total/Phenytoin.free;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin.total/Phenytoin.free [Mass Ratio] in Serum or Plasma;Phenytoin Total/Free SerPl;;ACTIVE;1.0k;2.42 +14338-8;Prealbumin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prealbumin [Mass/volume] in Serum or Plasma;Prealb SerPl-mCnc;;ACTIVE;1.0k;2.73 +14339-6;IgG/Protein.total;MFr;Pt;CSF;Qn;;CHEM;1;IgG/Protein.total in Cerebral spinal fluid;IgG MFr CSF;;ACTIVE;1.0k;2.73 +1434-0;Cortisol^8H post 1 mg dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 hours post 1 mg dexamethasone PO overnight;Cortis 8h p 1 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.73 +14340-4;Gammopathy;Imp;Pt;Ser/Plas;Nom;Electrophoresis;CHEM;1;Gammopathy [Interpretation] in Serum or Plasma by Electrophoresis;Gammopathy SerPl Elph-Imp;;ACTIVE;1.0k;2.73 +14341-2;Globulin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Globulin/Protein.total in 24 hour Urine by Electrophoresis;Globulin 24h MFr Ur Elph;;ACTIVE;1.0k;2.73 +14342-0;Catecholamines/Creatinine;MCrto;Pt;Urine;Qn;;CHEM;1;Deprecated Catecholamines/Creatinine [Mass ratio] in Urine;Deprecated Catechol/creat Ur-mRto;;DEPRECATED;1.0k;2.70 +14343-8;Eosinophils/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Peritoneal fluid by Manual count;Eosinophil/leuk NFr Prt Manual;;ACTIVE;1.0k;2.73 +14344-6;Eosinophils/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Pleural fluid by Manual count;Eosinophil/leuk NFr Plr Manual;;ACTIVE;1.0k;2.73 +14345-3;Specific gravity;Rden;Pt;Amnio fld;Qn;Refractometry;CHEM;1;Specific gravity of Amniotic fluid by Refractometry;Sp Gr Amn Refractometry;;ACTIVE;1.0k;2.26 +14346-1;Specific gravity;Rden;Pt;CSF;Qn;Refractometry;CHEM;1;Specific gravity of Cerebral spinal fluid by Refractometry;Sp Gr CSF Refractometry;;ACTIVE;1.0k;2.26 +14347-9;Specific gravity;Rden;Pt;Gast fld;Qn;Refractometry;CHEM;1;Specific gravity of Gastric fluid by Refractometry;Sp Gr Gast Refractometry;;ACTIVE;1.0k;2.26 +14348-7;Specific gravity;Rden;Pt;Periton fld;Qn;Refractometry;CHEM;1;Specific gravity of Peritoneal fluid by Refractometry;Sp Gr Prt Refractometry;;ACTIVE;1.0k;2.73 +14349-5;Specific gravity;Rden;Pt;Plr fld;Qn;Refractometry;CHEM;1;Specific gravity of Pleural fluid by Refractometry;Sp Gr Plr Refractometry;;ACTIVE;1.0k;2.73 +14350-3;Specific gravity;Rden;Pt;Synv fld;Qn;Refractometry;CHEM;1;Specific gravity of Synovial fluid by Refractometry;Sp Gr Snv Refractometry;;ACTIVE;1.0k;2.73 +14351-1;Specific gravity;Rden;Pt;Stool;Qn;Refractometry;CHEM;1;Specific gravity of Stool by Refractometry;Sp Gr Stl Refractometry;;ACTIVE;1.0k;2.26 +14352-9;Specific gravity;Rden;Pt;Water;Qn;Refractometry;CHEM;1;Specific gravity of Water by Refractometry;Sp Gr Wat Refractometry;;ACTIVE;1.0k;2.26 +14353-7;Microscopic observation;Prid;Pt;Plr fld;Nom;Acid fast stain.Kinyoun modified;MICRO;1;Microscopic observation [Identifier] in Pleural fluid by Acid fast stain.Kinyoun modified;Acid fast Mod Kiny Stn Plr;;ACTIVE;1.0k;2.21 +14354-5;Microscopic observation;Prid;Pt;Wound;Nom;Acid fast stain.Kinyoun modified;MICRO;1;Microscopic observation [Identifier] in Wound by Acid fast stain.Kinyoun modified;Acid fast Mod Kiny Stn Wnd;;ACTIVE;1.0k;2.21 +14355-2;Microscopic observation;Prid;Pt;Cvx;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Cervix by KOH preparation;KOH Prep Cvx;;ACTIVE;1.0k;2.58 +14356-0;Microscopic observation;Prid;Pt;Vag;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Vaginal fluid by KOH preparation;KOH Prep Vag;;ACTIVE;1.0k;2.73 +1435-7;Cortisol^8H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis 8h p 2 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14357-8;Microscopic observation;Prid;Pt;CSF;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by Gram stain;Gram Stn CSF;;ACTIVE;1.0k;2.73 +14358-6;Microscopic observation;Prid;Pt;Asp;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Aspirate by Gram stain;Gram Stn Aspirate;;ACTIVE;1.0k;2.73 +14359-4;Microscopic observation;Prid;Pt;Periton fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Peritoneal fluid by Gram stain;Gram Stn Prt;;ACTIVE;1.0k;2.19 +14360-2;Microscopic observation;Prid;Pt;Plr fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Pleural fluid by Gram stain;Gram Stn Plr;;ACTIVE;1.0k;2.19 +14361-0;Microscopic observation;Prid;Pt;Vag;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Vaginal fluid by Gram stain;Gram Stn Vag;;ACTIVE;1.0k;2.73 +14362-8;Microscopic observation;Prid;Pt;Thrt;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Throat by Gram stain;Gram Stn Throat;;ACTIVE;1.0k;2.73 +14363-6;Microscopic observation;Prid;Pt;Synv fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Synovial fluid by Gram stain;Gram Stn Snv;;ACTIVE;1.0k;2.73 +14364-4;Microscopic observation;Prid;Pt;Eye;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Eye by Gram stain;Gram Stn Eye;;ACTIVE;1.0k;2.73 +1436-5;Cortisol^8H post 30 mg/kg metyraPONE PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 hours post 30 mg/kg metyraPONE PO;Cortis 8h p 30 mg/kg MTP PO SerPl-mCnc;;ACTIVE;1.0;2.40 +14365-1;Microscopic observation;Prid;Pt;Ear;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Ear by Gram stain;Gram Stn Ear;;ACTIVE;1.0k;2.73 +14366-9;Trichomonas vaginalis;PrThr;Pt;Cvx;Ord;Wet preparation;MICRO;1;Trichomonas vaginalis [Presence] in Cervix by Wet preparation;T vaginalis Cvx Ql Wet Prep;;ACTIVE;1.0k;2.73 +14367-7;Trichomonas vaginalis;PrThr;Pt;Vag;Ord;Wet preparation;MICRO;1;Trichomonas vaginalis [Presence] in Vaginal fluid by Wet preparation;T vaginalis Vag Ql Wet Prep;;ACTIVE;1.0k;2.73 +14368-5;Trichomonas vaginalis;PrThr;Pt;Urethra;Ord;Wet preparation;MICRO;1;Trichomonas vaginalis [Presence] in Urethra by Wet preparation;T vaginalis Urth Ql Wet Prep;;ACTIVE;1.0k;2.73 +14369-3;Yeast;PrThr;Pt;Cvx;Ord;Wet preparation;MICRO;1;Yeast [Presence] in Cervix by Wet preparation;Yeast Cvx Ql Wet Prep;;ACTIVE;1.0k;2.73 +14370-1;Yeast;PrThr;Pt;Vag;Ord;Wet preparation;MICRO;1;Yeast [Presence] in Vaginal fluid by Wet preparation;Yeast Vag Ql Wet Prep;;ACTIVE;1.0k;2.73 +14371-9;Yeast;PrThr;Pt;Urethra;Ord;Wet preparation;MICRO;1;Yeast [Presence] in Urethra by Wet preparation;Yeast Urth Ql Wet Prep;;ACTIVE;1.0k;2.73 +14372-7;Erythrocytes;NCnc;Pt;Gast fld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Gastric fluid by Manual count;RBC # Gast Manual;;ACTIVE;1.0k;2.44 +1437-3;Cortisol^8H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis 8h p 500 ug Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14373-5;Leukocytes;NCnc;Pt;Gast fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Gastric fluid by Manual count;WBC # Gast Manual;;ACTIVE;1.0k;2.44 +14374-3;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Pleural fluid by Manual count;Polys/leuk NFr Plr Manual;;ACTIVE;1.0k;2.73 +14375-0;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Peritoneal fluid by Manual count;Polys/leuk NFr Prt Manual;;ACTIVE;1.0k;2.73 +14376-8;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Synovial fluid by Manual count;Polys/leuk NFr Snv Manual;;ACTIVE;1.0k;2.73 +14377-6;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Semen;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Semen by Manual count;Polys/leuk NFr Smn Manual;;ACTIVE;1.0k;2.70 +14378-4;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Urine;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Urine by Manual count;Polys/leuk NFr Ur Manual;;ACTIVE;1.0k;2.70 +14379-2;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Gast fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Gastric fluid by Manual count;Polys/leuk NFr Gast Manual;;ACTIVE;1.0k;2.70 +143-8;cefTRIAXone;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;cefTRIAXone [Susceptibility] by Serum bactericidal titer;cefTRIAXone Titr SBT;;ACTIVE;1.0;2.32 +14380-0;Mononuclear cells/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Pleural fluid by Manual count;Mononuc Cells/leuk NFr Plr Manual;;ACTIVE;1.0k;2.73 +1438-1;Cortisol^8H post 40 ug corticotropin IM BID 3 day;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 hours post 40 ug corticotropin IM BID 3 day;Cortis 8h p 40 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.40 +14381-8;Mononuclear cells/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Peritoneal fluid by Manual count;Mononuc Cells/leuk NFr Prt Manual;;ACTIVE;1.0k;2.73 +14382-6;Mononuclear cells/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Synovial fluid by Manual count;Mononuc Cells/leuk NFr Snv Manual;;ACTIVE;1.0k;2.73 +14383-4;Mononuclear cells/100 leukocytes;NFr;Pt;Semen;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Semen by Manual count;Mononuc Cells/leuk NFr Smn Manual;;ACTIVE;1.0k;2.70 +14384-2;Mononuclear cells/100 leukocytes;NFr;Pt;Urine sed;Qn;Manual count;UA;1;Mononuclear cells/100 leukocytes in Urine sediment by Manual count;Mononuc Cells/leuk NFr UrnS Manual;;ACTIVE;1.0k;2.70 +14385-9;Mononuclear cells/100 leukocytes;NFr;Pt;Gast fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Gastric fluid by Manual count;Mononuc Cells/leuk NFr Gast Manual;;ACTIVE;1.0k;2.70 +14386-7;Glucose;MCnc;Pt;Gast fld;Qn;;CHEM;1;Glucose [Mass/volume] in Gastric fluid;Glucose Gast-mCnc;;ACTIVE;1.0k;2.34 +14387-5;Protein;MCnc;Pt;Gast fld;Qn;;CHEM;1;Protein [Mass/volume] in Gastric fluid;Prot Gast-mCnc;;ACTIVE;1.0k;2.34 +14388-3;Amylase;CCnc;Pt;Synv fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Synovial fluid;Amylase Snv-cCnc;;ACTIVE;1.0k;2.68 +14389-1;Amylase;CCnc;Pt;CSF;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Cerebral spinal fluid;Amylase CSF-cCnc;;ACTIVE;1.0k;2.68 +14390-9;Amylase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Dialysis fluid;Amylase Dial fld-cCnc;;ACTIVE;1.0k;2.68 +14391-7;Amylase;CCnc;Pt;Gast fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Gastric fluid;Amylase Gast-cCnc;;ACTIVE;1.0k;2.68 +14392-5;Amylase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Amniotic fluid;Amylase Amn-cCnc;;ACTIVE;1.0k;2.68 +14393-3;Urea nitrogen;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Amniotic fluid;Urea nit Amn-mCnc;;ACTIVE;1.0k;2.34 +14394-1;Urea nitrogen;MCnc;Pt;Plr fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Pleural fluid;Urea nit Plr-mCnc;;ACTIVE;1.0k;2.34 +14395-8;Urea nitrogen;MCnc;Pt;Periton fld;Qn;;CHEM;1;Deprecated Urea nitrogen [Mass/volume] in Peritoneal fluid;Deprecated Urea Nit Prt-mCnc;;DEPRECATED;1.0k;2.36 +14396-6;Urea nitrogen;MCnc;Pt;Synv fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Synovial fluid;Urea nit Snv-mCnc;;ACTIVE;1.0k;2.34 +14397-4;Urea nitrogen;MCnc;Pt;Gast fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Gastric fluid;Urea nit Gast-mCnc;;ACTIVE;1.0k;2.34 +14398-2;Creatinine;MCnc;Pt;CSF;Qn;;CHEM;1;Creatinine [Mass/volume] in Cerebral spinal fluid;Creat CSF-mCnc;;ACTIVE;1.0k;2.34 +1439-9;Cortisol^9.5H post 8 mg dexamethasone PO overnight high dose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9.5 hours post 8 mg dexamethasone PO overnight high dose;Cortis 9.5h p 8 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14399-0;Creatinine;MCnc;Pt;Plr fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Pleural fluid;Creat Plr-mCnc;;ACTIVE;1.0k;2.34 +14400-6;Creatinine;MCnc;Pt;Periton fld;Qn;;CHEM;1;Deprecated Creatinine [Mass/volume] in Peritoneal fluid;Deprecated Creat Prt-mCnc;;DEPRECATED;1.0k;2.36 +14401-4;Creatinine;MCnc;Pt;Synv fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Synovial fluid;Creat Snv-mCnc;;ACTIVE;1.0k;2.34 +14402-2;Creatinine;MCnc;Pt;Gast fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Gastric fluid;Creat Gast-mCnc;;ACTIVE;1.0k;2.34 +14403-0;Lactate dehydrogenase;CCnc;Pt;Gast fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Gastric fluid;LDH Gast-cCnc;;ACTIVE;1.0k;2.68 +14404-8;Phosphate;MCnc;Pt;Plr fld;Qn;;CHEM;1;Phosphate [Mass/volume] in Pleural fluid;Phosphate Plr-mCnc;;ACTIVE;1.0k;2.34 +14405-5;Phosphate;MCnc;Pt;Periton fld;Qn;;CHEM;1;Phosphate [Mass/volume] in Peritoneal fluid;Phosphate Prt-mCnc;;ACTIVE;1.0k;2.34 +14406-3;Phosphate;MCnc;Pt;Synv fld;Qn;;CHEM;1;Phosphate [Mass/volume] in Synovial fluid;Phosphate Snv-mCnc;;ACTIVE;1.0k;2.34 +1440-7;Cortisol^9H post 1 mg dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9 hours post 1 mg dexamethasone PO overnight;Cortis 9h p 1 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.73 +14407-1;Phosphate;MCnc;Pt;Gast fld;Qn;;CHEM;1;Phosphate [Mass/volume] in Gastric fluid;Phosphate Gast-mCnc;;ACTIVE;1.0k;2.34 +14408-9;Phosphate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphate [Mass/volume] in Amniotic fluid;Phosphate Amn-mCnc;;ACTIVE;1.0k;2.34 +14409-7;Aspartate aminotransferase;CCnc;Pt;Plr fld;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Pleural fluid;AST Plr-cCnc;;ACTIVE;1.0k;2.68 +14410-5;Aspartate aminotransferase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Peritoneal fluid;AST Prt-cCnc;;ACTIVE;1.0k;2.68 +14411-3;Aspartate aminotransferase;CCnc;Pt;Synv fld;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Synovial fluid;AST Snv-cCnc;;ACTIVE;1.0k;2.68 +14412-1;Aspartate aminotransferase;CCnc;Pt;Gast fld;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Gastric fluid;AST Gast-cCnc;;ACTIVE;1.0k;2.68 +14413-9;Aspartate aminotransferase;CCnc;Pt;Urine;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Urine;AST Ur-cCnc;;ACTIVE;1.0k;2.68 +14414-7;Aspartate aminotransferase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Dialysis fluid;AST Dial fld-cCnc;;ACTIVE;1.0k;2.68 +1441-5;Cortisol^9H post 3 g metyraPONE PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9 hours post 3 g metyraPONE PO overnight;Cortis 9h p 3 g MTP PO ON SerPl-mCnc;;ACTIVE;1.0;2.40 +14415-4;Calcium;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Calcium [Moles/volume] in Amniotic fluid;Calcium Amn-sCnc;;ACTIVE;1.0k;2.42 +14416-2;Calcium;SCnc;Pt;Plr fld;Qn;;CHEM;1;Calcium [Moles/volume] in Pleural fluid;Calcium Plr-sCnc;;ACTIVE;1.0k;2.42 +14417-0;Calcium;SCnc;Pt;Periton fld;Qn;;CHEM;1;Calcium [Moles/volume] in Peritoneal fluid;Calcium Prt-sCnc;;ACTIVE;1.0k;2.42 +14418-8;Calcium;SCnc;Pt;Synv fld;Qn;;CHEM;1;Calcium [Moles/volume] in Synovial fluid;Calcium Snv-sCnc;;ACTIVE;1.0k;2.42 +14419-6;Calcium;SCnc;Pt;Gast fld;Qn;;CHEM;1;Calcium [Moles/volume] in Gastric fluid;Calcium Gast-sCnc;;ACTIVE;1.0k;2.42 +14420-4;Bilirubin;MCnc;Pt;Dial fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Dialysis fluid;Bilirub Dial fld-mCnc;;ACTIVE;1.0k;2.38 +14421-2;Bilirubin;MCnc;Pt;Plr fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Pleural fluid;Bilirub Plr-mCnc;;ACTIVE;1.0k;2.38 +14422-0;Bilirubin;MCnc;Pt;Periton fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Peritoneal fluid;Bilirub Prt-mCnc;;ACTIVE;1.0k;2.73 +1442-3;Cortisol^9H post 8 mg dexamethasone PO overnight high dose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9 hours post 8 mg dexamethasone PO overnight high dose;Cortis 9h p 8 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14423-8;Bilirubin;MCnc;Pt;Synv fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Synovial fluid;Bilirub Snv-mCnc;;ACTIVE;1.0k;2.38 +14424-6;Bilirubin;MCnc;Pt;Gast fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Gastric fluid;Bilirub Gast-mCnc;;ACTIVE;1.0k;2.38 +14425-3;Globulin;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Globulin [Mass/volume] in Amniotic fluid;Globulin Amn-mCnc;;ACTIVE;1.0k;2.73 +14426-1;Globulin;MCnc;Pt;CSF;Qn;;CHEM;1;Globulin [Mass/volume] in Cerebral spinal fluid;Globulin CSF-mCnc;;ACTIVE;1.0k;2.42 +14427-9;Globulin;MCnc;Pt;Plr fld;Qn;;CHEM;1;Globulin [Mass/volume] in Pleural fluid;Globulin Plr-mCnc;;ACTIVE;1.0k;2.42 +14428-7;Globulin;MCnc;Pt;Periton fld;Qn;;CHEM;1;Globulin [Mass/volume] in Peritoneal fluid;Globulin Prt-mCnc;;ACTIVE;1.0k;2.42 +14429-5;Globulin;MCnc;Pt;Semen;Qn;;CHEM;1;Globulin [Mass/volume] in Semen;Globulin Smn-mCnc;;ACTIVE;1.0k;2.42 +14430-3;Globulin;MCnc;Pt;Synv fld;Qn;;CHEM;1;Globulin [Mass/volume] in Synovial fluid;Globulin Snv-mCnc;;ACTIVE;1.0k;2.42 +1443-1;Cortisol^pre 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 1 ug/kg CRH IV;Cortis pre 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14431-1;Globulin;MCnc;Pt;Urine;Qn;;CHEM;1;Globulin [Mass/volume] in Urine;Globulin Ur-mCnc;;ACTIVE;1.0k;2.73 +14432-9;Albumin/Globulin;MRto;Pt;Amnio fld;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Amniotic fluid;Albumin/Glob Amn;;ACTIVE;1.0k;2.44 +14433-7;Albumin/Globulin;MRto;Pt;CSF;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Cerebral spinal fluid;Albumin/Glob CSF;;ACTIVE;1.0k;2.44 +14434-5;Albumin/Globulin;MRto;Pt;Plr fld;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Pleural fluid;Albumin/Glob Plr;;ACTIVE;1.0k;2.44 +14435-2;Albumin/Globulin;MRto;Pt;Periton fld;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Peritoneal fluid;Albumin/Glob Prt;;ACTIVE;1.0k;2.44 +14436-0;Albumin/Globulin;MRto;Pt;Semen;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Semen;Albumin/Glob Smn;;ACTIVE;1.0k;2.44 +14437-8;Albumin/Globulin;MRto;Pt;Synv fld;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Synovial fluid;Albumin/Glob Snv;;ACTIVE;1.0k;2.44 +14438-6;Cholesterol;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Cholesterol [Mass/volume] in Amniotic fluid;Cholest Amn-mCnc;;ACTIVE;1.0k;2.42 +14439-4;Cholesterol;MCnc;Pt;CSF;Qn;;CHEM;1;Cholesterol [Mass/volume] in Cerebral spinal fluid;Cholest CSF-mCnc;;ACTIVE;1.0k;2.42 +14440-2;Cholesterol;MCnc;Pt;Plr fld;Qn;;CHEM;1;Deprecated Cholesterol [Mass/volume] in Pleural fluid;Deprecated Cholest Plr-mCnc;;DEPRECATED;1.0k;2.36 +14441-0;Cholesterol;MCnc;Pt;Periton fld;Qn;;CHEM;1;Cholesterol [Mass/volume] in Peritoneal fluid;Cholest Prt-mCnc;;ACTIVE;1.0k;2.73 +14442-8;Cholesterol;MCnc;Pt;Semen;Qn;;CHEM;1;Cholesterol [Mass/volume] in Semen;Cholest Smn-mCnc;;ACTIVE;1.0k;2.42 +14443-6;Cholesterol;MCnc;Pt;Synv fld;Qn;;CHEM;1;Cholesterol [Mass/volume] in Synovial fluid;Cholest Snv-mCnc;;ACTIVE;1.0k;2.42 +14444-4;Cholesterol;MCnc;Pt;Urine;Qn;;CHEM;1;Cholesterol [Mass/volume] in Urine;Cholest Ur-mCnc;;ACTIVE;1.0k;2.73 +14445-1;Triglyceride;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Triglyceride [Mass/volume] in Amniotic fluid;Trigl Amn-mCnc;;ACTIVE;1.0k;2.42 +14446-9;Triglyceride;MCnc;Pt;CSF;Qn;;CHEM;1;Triglyceride [Mass/volume] in Cerebral spinal fluid;Trigl CSF-mCnc;;ACTIVE;1.0k;2.42 +14447-7;Triglyceride;MCnc;Pt;Periton fld;Qn;;CHEM;1;Triglyceride [Mass/volume] in Peritoneal fluid;Trigl Prt-mCnc;;ACTIVE;1.0k;2.73 +14448-5;Triglyceride;MCnc;Pt;Semen;Qn;;CHEM;1;Triglyceride [Mass/volume] in Semen;Trigl Smn-mCnc;;ACTIVE;1.0k;2.42 +1444-9;Cortisol^pre 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 12 hour fast;Cortis pre 12h fast SerPl-mCnc;;ACTIVE;1.0;2.40 +14449-3;Triglyceride;MCnc;Pt;Synv fld;Qn;;CHEM;1;Triglyceride [Mass/volume] in Synovial fluid;Trigl Snv-mCnc;;ACTIVE;1.0k;2.73 +14450-1;Triglyceride;MCnc;Pt;Urine;Qn;;CHEM;1;Triglyceride [Mass/volume] in Urine;Trigl Ur-mCnc;;ACTIVE;1.0k;2.73 +14451-9;Virus identified;Prid;Pt;Eye;Nom;Culture;MICRO;1;Virus identified in Eye by Culture;Virus Eye Cult;;ACTIVE;1.0k;2.17 +14452-7;Virus identified;Prid;Pt;Cvx;Nom;Culture;MICRO;1;Virus identified in Cervix by Culture;Virus Cvx Cult;;ACTIVE;1.0k;2.58 +14453-5;Virus identified;Prid;Pt;Vag;Nom;Culture;MICRO;1;Virus identified in Vaginal fluid by Culture;Virus Vag Cult;;ACTIVE;1.0k;2.21 +14454-3;Virus identified;Prid;Pt;Nose;Nom;Culture;MICRO;1;Virus identified in Nose by Culture;Virus Nose Cult;;ACTIVE;1.0k;2.17 +14455-0;Virus identified;Prid;Pt;Plr fld;Nom;Culture;MICRO;1;Virus identified in Pleural fluid by Culture;Virus Plr Cult;;ACTIVE;1.0k;2.19 +1445-6;Cortisol^pre 1 mg dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 1 mg dexamethasone PO overnight;Cortis pre 1 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.73 +14456-8;Virus identified;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Virus identified in Peritoneal fluid by Culture;Virus Prt Cult;;ACTIVE;1.0k;2.19 +14457-6;Virus identified;Prid;Pt;Urine;Nom;Culture;MICRO;1;Virus identified in Urine by Culture;Virus Ur Cult;;ACTIVE;1.0k;2.19 +14458-4;Virus identified;Prid;Pt;Sputum;Nom;Culture;MICRO;1;Virus identified in Sputum by Culture;Virus Spt Cult;;ACTIVE;1.0k;2.73 +14459-2;Virus identified;Prid;Pt;Penis;Nom;Culture;MICRO;1;Virus identified in Penis by Culture;Virus Penis Cult;;ACTIVE;1.0k;2.21 +144-6;Cefuroxime.parenteral;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefuroxime Parenteral [Susceptibility] by Minimum lethal concentration (MLC);Cefuroxime Parenter Islt MLC;;ACTIVE;1.0;2.19 +14460-0;Virus identified;Prid;Pt;Urethra;Nom;Culture;MICRO;1;Virus identified in Urethra by Culture;Virus Urth Cult;;ACTIVE;1.0k;2.19 +14461-8;Chlamydia trachomatis;PrThr;Pt;Bld;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Blood by Organism specific culture;C trach Bld Ql Cult;;ACTIVE;1.0k;2.56 +14462-6;Chlamydia trachomatis;PrThr;Pt;CSF;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Cerebral spinal fluid by Organism specific culture;C trach CSF Ql Cult;;ACTIVE;1.0k;2.56 +14463-4;Chlamydia trachomatis;PrThr;Pt;Cvx;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Cervix by Organism specific culture;C trach Cvx Ql Cult;;ACTIVE;1.0k;2.73 +1446-4;Cortisol^pre 3 g metyraPONE PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 3 g metyraPONE PO overnight;Cortis pre 3 g MTP PO ON SerPl-mCnc;;ACTIVE;1.0;2.40 +14464-2;Chlamydia trachomatis;PrThr;Pt;Vag;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Vaginal fluid by Organism specific culture;C trach Vag Ql Cult;;ACTIVE;1.0k;2.73 +14465-9;Chlamydia trachomatis;PrThr;Pt;Urethra;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Urethra by Organism specific culture;C trach Urth Ql Cult;;ACTIVE;1.0k;2.73 +14466-7;Chlamydia trachomatis;ACnc;Pt;Penis;Ord;Organism specific culture;MICRO;1;Deprecated Chlamydia trachomatis [Presence] in Penis by Organism specific culture;Deprecated C trach Penis Ql Cult;;DEPRECATED;1.0k;2.52 +14467-5;Chlamydia trachomatis;PrThr;Pt;Urine sed;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Urine sediment by Organism specific culture;C trach UrnS Ql Cult;;ACTIVE;1.0k;2.73 +14468-3;Chlamydia trachomatis Ag;PrThr;Pt;Bld;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Blood by Immunoassay;C trach Ag Bld Ql IA;;ACTIVE;1.0k;2.56 +14469-1;Chlamydia trachomatis Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Cerebral spinal fluid by Immunoassay;C trach Ag CSF Ql IA;;ACTIVE;1.0k;2.56 +14470-9;Chlamydia trachomatis Ag;PrThr;Pt;Cvx;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Cervix by Immunoassay;C trach Ag Cvx Ql IA;;DISCOURAGED;1.0k;2.61 +14471-7;Chlamydia trachomatis Ag;PrThr;Pt;Vag;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Vaginal fluid by Immunoassay;C trach Ag Vag Ql IA;;DISCOURAGED;1.0k;2.61 +1447-2;Cortisol^pre 40 ug corticotropin IM 3 day;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 40 ug corticotropin IM 3 day;Cortis pre 40 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0;2.40 +14472-5;Chlamydia trachomatis Ag;PrThr;Pt;Urethra;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Urethra by Immunoassay;C trach Ag Urth Ql IA;;DISCOURAGED;1.0k;2.61 +14473-3;Chlamydia trachomatis Ag;ACnc;Pt;Penis;Ord;EIA;MICRO;1;Deprecated Chlamydia trachomatis Ag [Presence] in Penis by Immunoassay;Deprecated C trach Ag Penis Ql EIA;;DEPRECATED;1.0k;2.52 +14474-1;Chlamydia trachomatis Ag;PrThr;Pt;Urine sed;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Urine sediment by Immunoassay;C trach Ag UrnS Ql IA;;ACTIVE;1.0k;2.56 +14475-8;Bacteria identified;Prid;Pt;Cvx;Nom;Aerobic culture;MICRO;1;Bacteria identified in Cervix by Aerobe culture;Bacteria Cvx Aerobe Cult;;ACTIVE;1.0k;2.73 +14476-6;Microorganism identified;Prid;Pt;Vag;Nom;Aerobic culture;MICRO;1;Deprecated Bacteria identified in Vaginal fluid by Aerobe culture;Deprecated Microorganism Vag Aerobe Cult;;DEPRECATED;1.0k;2.36 +14477-4;Bacteria identified;Prid;Pt;Urethra;Nom;Aerobic culture;MICRO;1;Bacteria identified in Urethra by Aerobe culture;Bacteria Urth Aerobe Cult;;ACTIVE;1.0k;2.73 +14478-2;Bacteria identified;Prid;Pt;Penis;Nom;Aerobic culture;MICRO;1;Bacteria identified in Penis by Aerobe culture;Bacteria Penis Aerobe Cult;;ACTIVE;1.0k;2.73 +14479-0;Diphtheria sp identified;Prid;Pt;Thrt;Nom;Organism specific culture;MICRO;1;Diphtheria identified in Throat by Organism specific culture;Diphtheria Throat Cult;;ACTIVE;1.0k;2.17 +1448-0;Cortisol^pre 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis pre 500 ug Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14480-8;Diphtheria sp identified;Prid;Pt;Sputum;Nom;Organism specific culture;MICRO;1;Diphtheria identified in Sputum by Organism specific culture;Diphtheria Spt Cult;;ACTIVE;1.0k;2.19 +14481-6;Diphtheria sp identified;Prid;Pt;Nose;Nom;Organism specific culture;MICRO;1;Diphtheria identified in Nose by Organism specific culture;Diphtheria Nose Cult;;ACTIVE;1.0k;2.12 +14482-4;Diphtheria sp identified;Prid;Pt;Skin;Nom;Organism specific culture;MICRO;1;Diphtheria identified in Skin by Organism specific culture;Diphtheria Skin Cult;;ACTIVE;1.0k;2.21 +14483-2;Diphtheria sp identified;Prid;Pt;Bronchial;Nom;Organism specific culture;MICRO;1;Diphtheria identified in Bronchial specimen by Organism specific culture;Diphtheria Bronch Cult;;ACTIVE;1.0k;2.19 +14484-0;Mycoplasma sp & Ureaplasma sp;Prid;Pt;Cvx;Nom;Organism specific culture;MICRO;1;Mycoplasma sp and Ureaplasma sp [Identifier] in Cervix by Organism specific culture;Mycoplas+Ureoplas Cvx Cult;;ACTIVE;1.0k;2.73 +14485-7;Mycoplasma sp & Ureaplasma sp;Prid;Pt;Vag;Nom;Organism specific culture;MICRO;1;Mycoplasma sp and Ureaplasma sp [Identifier] in Vaginal fluid by Organism specific culture;Mycoplas+Ureoplas Vag Cult;;ACTIVE;1.0k;2.40 +14486-5;Mycoplasma sp & Ureaplasma sp;Prid;Pt;Penis;Nom;Organism specific culture;MICRO;1;Mycoplasma sp and Ureaplasma sp [Identifier] in Penis by Organism specific culture;Mycoplas+Ureoplas Penis Cult;;ACTIVE;1.0k;2.73 +14487-3;Mycoplasma sp & Ureaplasma sp;Prid;Pt;Urethra;Nom;Organism specific culture;MICRO;1;Mycoplasma sp and Ureaplasma sp [Identifier] in Urethra by Organism specific culture;Mycoplas+Ureoplas Urth Cult;;ACTIVE;1.0k;2.40 +14488-1;Virus identified;Prid;Pt;CSF;Nom;IF;MICRO;1;Virus identified in Cerebral spinal fluid by Immunofluorescence;Virus CSF IF;;ACTIVE;1.0k;1.0ma +14489-9;Virus identified;Prid;Pt;Bld;Nom;IF;MICRO;1;Virus identified in Blood by Immunofluorescence;Virus Bld IF;;ACTIVE;1.0k;1.0ma +14490-7;Virus identified;Prid;Pt;Semen;Nom;IF;MICRO;1;Virus identified in Semen by Immunofluorescence;Virus Smn IF;;ACTIVE;1.0k;2.19 +14491-5;Virus identified;Prid;Pt;Thrt;Nom;IF;MICRO;1;Virus identified in Throat by Immunofluorescence;Virus Throat IF;;ACTIVE;1.0k;2.17 +14492-3;Virus identified;Prid;Pt;Eye;Nom;IF;MICRO;1;Virus identified in Eye by Immunofluorescence;Virus Eye IF;;ACTIVE;1.0k;1.0ma +14493-1;Virus identified;Prid;Pt;Cvx;Nom;IF;MICRO;1;Virus identified in Cervix by Immunofluorescence;Virus Cvx IF;;ACTIVE;1.0k;2.58 +14494-9;Virus identified;Prid;Pt;Vag;Nom;IF;MICRO;1;Virus identified in Vaginal fluid by Immunofluorescence;Virus Vag IF;;ACTIVE;1.0k;2.21 +14495-6;Virus identified;Prid;Pt;Urine sed;Nom;IF;MICRO;1;Virus identified in Urine sediment by Immunofluorescence;Virus UrnS IF;;ACTIVE;1.0k;2.19 +14496-4;Virus identified;Prid;Pt;Sputum;Nom;IF;MICRO;1;Virus identified in Sputum by Immunofluorescence;Virus Spt IF;;ACTIVE;1.0k;2.19 +14497-2;Virus identified;Prid;Pt;Penis;Nom;IF;MICRO;1;Virus identified in Penis by Immunofluorescence;Virus Penis IF;;ACTIVE;1.0k;2.21 +1449-8;Cortisol^pre 8 mg dexamethasone PO overnight high dose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 8 mg dexamethasone PO overnight high dose;Cortis pre 8 mg Dex SerPl-mCnc;;ACTIVE;1.0;2.40 +14498-0;Virus identified;Prid;Pt;Urethra;Nom;IF;MICRO;1;Virus identified in Urethra by Immunofluorescence;Virus Urth IF;;ACTIVE;1.0k;2.19 +14499-8;Human papilloma virus Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Human papilloma virus Ag [Presence] in Cervix;HPV Ag Cvx Ql;;ACTIVE;1.0k;2.58 +14500-3;Human papilloma virus Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Human papilloma virus Ag [Presence] in Vaginal fluid;HPV Ag Vag Ql;;ACTIVE;1.0k;2.56 +14501-1;Human papilloma virus Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Human papilloma virus Ag [Presence] in Penis;HPV Ag Penis Ql;;ACTIVE;1.0k;2.56 +14502-9;Human papilloma virus Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Human papilloma virus Ag [Presence] in Urethra;HPV Ag Urth Ql;;ACTIVE;1.0k;2.56 +14503-7;Human papilloma virus 16+18 Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Human papilloma virus 16+18 Ag [Presence] in Cervix;HPV16+18 Ag Cvx Ql;;ACTIVE;1.0k;2.73 +14504-5;Human papilloma virus 16+18 Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Human papilloma virus 16+18 Ag [Presence] in Vaginal fluid;HPV16+18 Ag Vag Ql;;ACTIVE;1.0k;2.73 +14505-2;Human papilloma virus 16+18 Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Human papilloma virus 16+18 Ag [Presence] in Penis;HPV16+18 Ag Penis Ql;;ACTIVE;1.0k;2.56 +1450-6;Cortisol^pre 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis pre 2 mg Dex high SerPl-mCnc;;ACTIVE;1.0;2.40 +14506-0;Human papilloma virus 16+18 Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Human papilloma virus 16+18 Ag [Presence] in Urethra;HPV16+18 Ag Urth Ql;;ACTIVE;1.0k;2.56 +14507-8;Chlamydia trachomatis Ag;PrThr;Pt;Bld;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Blood by Immunofluorescence;C trach Ag Bld Ql IF;;ACTIVE;1.0k;2.56 +14508-6;Chlamydia trachomatis Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;C trach Ag CSF Ql IF;;ACTIVE;1.0k;2.56 +14509-4;Chlamydia trachomatis Ag;PrThr;Pt;Cvx;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Cervix by Immunofluorescence;C trach Ag Cvx Ql IF;;DISCOURAGED;1.0k;2.61 +14510-2;Chlamydia trachomatis Ag;PrThr;Pt;Vag;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Vaginal fluid by Immunofluorescence;C trach Ag Vag Ql IF;;DISCOURAGED;1.0k;2.61 +14511-0;Chlamydia trachomatis Ag;PrThr;Pt;Urethra;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Urethra by Immunofluorescence;C trach Ag Urth Ql IF;;DISCOURAGED;1.0k;2.61 +14512-8;Chlamydia trachomatis Ag;ACnc;Pt;Penis;Ord;IF;MICRO;1;Deprecated Chlamydia trachomatis Ag [Presence] in Penis by Immunofluorescence;Deprecated C trach Ag Penis Ql IF;;DEPRECATED;1.0k;2.52 +14513-6;Chlamydia trachomatis Ag;PrThr;Pt;Urine sed;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Urine sediment by Immunofluorescence;C trach Ag UrnS Ql IF;;ACTIVE;1.0k;2.56 +1451-4;Cortisol^pre dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre dose insulin IV;Cortis pre Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +14514-4;Pneumocystis jiroveci Ag;PrThr;Pt;Bld;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Blood by Immunofluorescence;P jiroveci Ag Bld Ql IF;;ACTIVE;1.0k;2.56 +14515-1;Pneumocystis jiroveci Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;P jiroveci Ag CSF Ql IF;;ACTIVE;1.0k;2.56 +14516-9;Pneumocystis jiroveci Ag;PrThr;Pt;Semen;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Semen by Immunofluorescence;P jiroveci Ag Smn Ql IF;;ACTIVE;1.0k;2.56 +14517-7;Pneumocystis jiroveci Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Stool by Immunofluorescence;P jiroveci Ag Stl Ql IF;;ACTIVE;1.0k;2.56 +14518-5;Pneumocystis jiroveci Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Throat by Immunofluorescence;P jiroveci Ag Throat Ql IF;;ACTIVE;1.0k;2.56 +14519-3;Pneumocystis jiroveci Ag;PrThr;Pt;Eye;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Eye by Immunofluorescence;P jiroveci Ag Eye Ql IF;;ACTIVE;1.0k;2.56 +14520-1;Pneumocystis jiroveci Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Nose by Immunofluorescence;P jiroveci Ag Nose Ql IF;;ACTIVE;1.0k;2.56 +14521-9;Pneumocystis jiroveci Ag;PrThr;Pt;Urine;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Urine by Immunofluorescence;P jiroveci Ag Ur Ql IF;;ACTIVE;1.0k;2.56 +1452-2;Creatinine^24H post 40 ug corticotropin IM BID 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --24 hours post 40 ug corticotropin IM BID 3 day;Creat 1D p 40 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.40 +14522-7;Pneumocystis jiroveci Ag;PrThr;Pt;Bronchial;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Bronchial specimen by Immunofluorescence;P jiroveci Ag Bronch Ql IF;;ACTIVE;1.0k;2.73 +14523-5;Rubella virus Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;RUBV Ag CSF Ql IF;;ACTIVE;1.0k;2.56 +14524-3;Rubella virus Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Throat by Immunofluorescence;RUBV Ag Throat Ql IF;;ACTIVE;1.0k;2.56 +14525-0;Rubella virus Ag;PrThr;Pt;Skin;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Skin by Immunofluorescence;RUBV Ag Skin Ql IF;;ACTIVE;1.0k;2.56 +14526-8;Rubella virus Ag;PrThr;Pt;Eye;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Eye by Immunofluorescence;RUBV Ag Eye Ql IF;;ACTIVE;1.0k;2.56 +14527-6;Rubella virus Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Nose by Immunofluorescence;RUBV Ag Nose Ql IF;;ACTIVE;1.0k;2.56 +14528-4;Rubella virus Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Sputum by Immunofluorescence;RUBV Ag Spt Ql IF;;ACTIVE;1.0k;2.56 +14529-2;Rubella virus Ag;PrThr;Pt;Cvx;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Cervix by Immunofluorescence;RUBV Ag Cvx Ql IF;;ACTIVE;1.0k;2.58 +145-3;Cefuroxime.parenteral;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefuroxime Parenteral [Susceptibility] by Minimum inhibitory concentration (MIC);Cefuroxime Parenter Islt MIC;;ACTIVE;1.0;2.73 +1453-0;Creatinine^48H post 40 ug corticotropin IM BID 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --48 hours post 40 ug corticotropin IM BID 3 day;Creat 2D p 40 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.40 +14530-0;Rubella virus Ag;PrThr;Pt;Vag;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Vaginal fluid by Immunofluorescence;RUBV Ag Vag Ql IF;;ACTIVE;1.0k;2.56 +14531-8;Rubella virus Ag;PrThr;Pt;Urine sed;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Urine sediment by Immunofluorescence;RUBV Ag UrnS Ql IF;;ACTIVE;1.0k;2.56 +14532-6;Rubella virus Ag;PrThr;Pt;Penis;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Penis by Immunofluorescence;RUBV Ag Penis Ql IF;;ACTIVE;1.0k;2.56 +14533-4;Rubella virus Ag;PrThr;Pt;Urethra;Ord;IF;MICRO;1;Rubella virus Ag [Presence] in Urethra by Immunofluorescence;RUBV Ag Urth Ql IF;;ACTIVE;1.0k;2.56 +14534-2;Measles virus Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;MeV Ag CSF Ql IF;;ACTIVE;1.0k;2.56 +14535-9;Measles virus Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Throat by Immunofluorescence;MeV Ag Throat Ql IF;;ACTIVE;1.0k;2.56 +14536-7;Measles virus Ag;PrThr;Pt;Skin;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Skin by Immunofluorescence;MeV Ag Skin Ql IF;;ACTIVE;1.0k;2.56 +14537-5;Measles virus Ag;PrThr;Pt;Eye;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Eye by Immunofluorescence;MeV Ag Eye Ql IF;;ACTIVE;1.0k;2.56 +14538-3;Measles virus Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Nose by Immunofluorescence;MeV Ag Nose Ql IF;;ACTIVE;1.0k;2.56 +14539-1;Measles virus Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Sputum by Immunofluorescence;MeV Ag Spt Ql IF;;ACTIVE;1.0k;2.56 +14540-9;Measles virus Ag;PrThr;Pt;Cvx;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Cervix by Immunofluorescence;MeV Ag Cvx Ql IF;;ACTIVE;1.0k;2.58 +14541-7;Measles virus Ag;PrThr;Pt;Vag;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Vaginal fluid by Immunofluorescence;MeV Ag Vag Ql IF;;ACTIVE;1.0k;2.56 +14542-5;Measles virus Ag;PrThr;Pt;Urine sed;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Urine sediment by Immunofluorescence;MeV Ag UrnS Ql IF;;ACTIVE;1.0k;2.56 +14543-3;Measles virus Ag;PrThr;Pt;Penis;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Penis by Immunofluorescence;MeV Ag Penis Ql IF;;ACTIVE;1.0k;2.56 +14544-1;Measles virus Ag;PrThr;Pt;Urethra;Ord;IF;MICRO;1;Measles virus Ag [Presence] in Urethra by Immunofluorescence;MeV Ag Urth Ql IF;;ACTIVE;1.0k;2.56 +14545-8;Mumps virus Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;MuV Ag CSF Ql IF;;ACTIVE;1.0k;2.56 +14546-6;Mumps virus Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Throat by Immunofluorescence;MuV Ag Throat Ql IF;;ACTIVE;1.0k;2.56 +14547-4;Mumps virus Ag;PrThr;Pt;Skin;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Skin by Immunofluorescence;MuV Ag Skin Ql IF;;ACTIVE;1.0k;2.56 +1454-8;Creatinine^48H post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --48 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Creat 48h p 500 ug Dex 24h Ur-mCnc;;ACTIVE;1.0;2.40 +14548-2;Mumps virus Ag;PrThr;Pt;Eye;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Eye by Immunofluorescence;MuV Ag Eye Ql IF;;ACTIVE;1.0k;2.56 +14549-0;Mumps virus Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Nose by Immunofluorescence;MuV Ag Nose Ql IF;;ACTIVE;1.0k;2.56 +14550-8;Mumps virus Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Sputum by Immunofluorescence;MuV Ag Spt Ql IF;;ACTIVE;1.0k;2.56 +14551-6;Mumps virus Ag;PrThr;Pt;Cvx;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Cervix by Immunofluorescence;MuV Ag Cvx Ql IF;;ACTIVE;1.0k;2.58 +14552-4;Mumps virus Ag;PrThr;Pt;Vag;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Vaginal fluid by Immunofluorescence;MuV Ag Vag Ql IF;;ACTIVE;1.0k;2.56 +14553-2;Mumps virus Ag;PrThr;Pt;Urine sed;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Urine sediment by Immunofluorescence;MuV Ag UrnS Ql IF;;ACTIVE;1.0k;2.56 +14554-0;Mumps virus Ag;PrThr;Pt;Penis;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Penis by Immunofluorescence;MuV Ag Penis Ql IF;;ACTIVE;1.0k;2.56 +1455-5;Creatinine^48H post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --48 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Creat 48h p 2 mg Dex 24h Ur-mCnc;;ACTIVE;1.0;2.40 +14555-7;Mumps virus Ag;PrThr;Pt;Urethra;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Urethra by Immunofluorescence;MuV Ag Urth Ql IF;;ACTIVE;1.0k;2.56 +14556-5;Mycobacterium tuberculosis DNA;PrThr;Pt;Sputum;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Sputum by NAA with probe detection;M tb DNA Spt Ql NAA+probe;;ACTIVE;1.0k;2.73 +14557-3;Mycobacterium tuberculosis DNA;PrThr;Pt;Bronchial;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Bronchial specimen by NAA with probe detection;M tb DNA Bronch Ql NAA+probe;;ACTIVE;1.0k;2.73 +14558-1;Mycobacterium tuberculosis DNA;PrThr;Pt;Gast fld;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Gastric fluid by NAA with probe detection;M tb DNA Gast Ql NAA+probe;;ACTIVE;1.0k;2.63 +14559-9;Mycobacterium tuberculosis DNA;PrThr;Pt;Plr fld;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Pleural fluid by NAA with probe detection;M tb DNA Plr Ql NAA+probe;;ACTIVE;1.0k;2.63 +14560-7;Mycobacterium tuberculosis DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Urine by NAA with probe detection;M tb DNA Ur Ql NAA+probe;;ACTIVE;1.0k;2.73 +14561-5;Mycobacterium tuberculosis DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;M tb DNA CSF Ql NAA+probe;;ACTIVE;1.0k;2.73 +14562-3;Mycobacterium tuberculosis DNA;PrThr;Pt;Semen;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Semen by NAA with probe detection;M tb DNA Smn Ql NAA+probe;;ACTIVE;1.0k;2.63 +1456-3;Creatinine^72H post 40 ug corticotropin IM BID 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --72 hours post 40 ug corticotropin IM BID 3 day;Creat 72h p 40 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.73 +14563-1;Hemoglobin.gastrointestinal^1st specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --1st specimen;Hemoccult sp1 Stl Ql;;ACTIVE;1.0k;2.73 +14564-9;Hemoglobin.gastrointestinal^2nd specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --2nd specimen;Hemoccult sp2 Stl Ql;;ACTIVE;1.0k;2.73 +14565-6;Hemoglobin.gastrointestinal^3rd specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --3rd specimen;Hemoccult sp3 Stl Ql;;ACTIVE;1.0k;2.73 +14566-4;Calcitriol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcitriol [Moles/volume] in Serum or Plasma;1,25(OH)2D3 SerPl-sCnc;;ACTIVE;1.0k;2.73 +14567-2;11-Deoxycortisol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma;11DC SerPl-sCnc;;ACTIVE;1.0k;2.34 +14568-0;17-Hydroxycorticosteroids;SRat;24H;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids [Moles/time] in 24 hour Urine;17OHCS 24h Ur-sRate;;ACTIVE;1.0k;2.40 +14569-8;17-Hydroxyprogesterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma;17OHP SerPl-sCnc;;ACTIVE;1.0k;2.73 +14570-6;17-Hydroxyprogesterone;SCnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone [Moles/volume] in Urine;17OHP Ur-sCnc;;ACTIVE;1.0k;2.42 +1457-1;Creatinine^pre 40 ug corticotropin IM 3 day;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --pre 40 ug corticotropin IM 3 day;Creat pre 40 ug ACTH IM 24h Ur-mCnc;;ACTIVE;1.0;2.40 +14571-4;17-Hydroxyprogesterone;SRat;24H;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone [Moles/time] in 24 hour Urine;17OHP 24h Ur-sRate;;ACTIVE;1.0k;2.42 +14572-2;17-Ketosteroids;SRat;24H;Urine;Qn;;CHEM;1;17-Ketosteroids [Moles/time] in 24 hour Urine;17KS 24h Ur-sRate;;ACTIVE;1.0k;2.40 +14573-0;5-Hydroxyindoleacetate;SRat;24H;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate [Moles/time] in 24 hour Urine;5OH-indoleacetate 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14574-8;8-Hydroxyamoxapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;8-Hydroxyamoxapine [Moles/volume] in Serum or Plasma;8OH-Amoxapine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14575-5;Blood group antibody investigation;Imp;Pt;Plas/RBC;Nom;;BLDBK;1;Blood group antibody investigation [Interpretation] in Plasma or RBC;Bld gp Ab Invest PlasRBC-Imp;;ACTIVE;1.0k;2.73 +14576-3;Blood group antibody investigation;Imp;Pt;Plas/RBC;Nom;Senior review;BLDBK;1;Blood group antibody investigation [Interpretation] in Plasma or RBC by Senior review;Bld gp Ab Invest PlasRBC Sr Rev-Imp;;ACTIVE;1.0k;2.73 +14577-1;ABO & Rh group;Type;Pt;Bld^Donor;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood from Donor;ABO + Rh Bld Donr;;ACTIVE;1.0k;2.72 +14578-9;ABO group;Type;Pt;Bld^BPU;Nom;;BLDBK;1;ABO group [Type] in Blood from Blood product unit;ABO Group Bld BPU;;ACTIVE;1.0k;2.73 +14579-7;ABO group;Type;Pt;Bld^Donor;Nom;;BLDBK;1;ABO group [Type] in Blood from Donor;ABO Group Bld Donr;;ACTIVE;1.0k;2.73 +14580-5;ABO group;Type;Pt;Bld^Newborn;Nom;;BLDBK;1;ABO group [Type] in Blood from Newborn;ABO Group Bld NB;;ACTIVE;1.0k;2.73 +14581-3;Acetaminophen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetaminophen [Moles/volume] in Serum or Plasma;APAP SerPl-sCnc;;ACTIVE;1.0k;2.73 +14582-1;Acetone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetone [Moles/volume] in Serum or Plasma;Acetone SerPl-sCnc;;ACTIVE;1.0k;2.73 +14583-9;Acidity.titratable;MCnc;Pt;Gast fld;Qn;;CHEM;1;Acidity.titratable [Mass/volume] in Gastric fluid;Titratable Acidity Gast-mCnc;;DISCOURAGED;1.0k;2.44 +14584-7;Adenosine monophosphate.cyclic;SRat;24H;Urine;Qn;;CHEM;1;Adenosine monophosphate.cyclic [Moles/time] in 24 hour Urine;cAMP 24h Ur-sRate;;ACTIVE;1.0k;2.42 +14585-4;Albumin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Albumin/Creatinine [Molar ratio] in Urine;Albumin/Creat Ur-sRto;;ACTIVE;1.0k;2.42 +14586-2;Aldosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aldosterone [Moles/volume] in Serum or Plasma;Aldost SerPl-sCnc;;ACTIVE;1.0k;2.73 +14587-0;Aldosterone;SRat;24H;Urine;Qn;;CHEM;1;Aldosterone [Moles/time] in 24 hour Urine;Aldost 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14588-8;Alkaline phosphatase isoenzymes;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Alkaline phosphatase isoenzymes [Interpretation] in Serum or Plasma;ALP Isos SerPl-Imp;;ACTIVE;1.0k;2.73 +1458-9;Creatinine^pre 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --pre 500 ug dexamethasone PO 2.5 day low dose q6h;Creat pre 500 ug Dex 24h Ur-mCnc;;ACTIVE;1.0;2.40 +14589-6;Amylase isoenzymes;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Amylase isoenzymes [Interpretation] in Serum or Plasma;Amylase Isos SerPl-Imp;;ACTIVE;1.0k;2.73 +14590-4;Alpha tocopherol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha tocopherol [Moles/volume] in Serum or Plasma;A-Tocopherol Vit E SerPl-sCnc;;ACTIVE;1.0k;2.73 +14591-2;ALPRAZolam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ALPRAZolam [Moles/volume] in Serum or Plasma;Alpraz SerPl-sCnc;;ACTIVE;1.0k;2.34 +14592-0;Aluminum;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in 24 hour Urine;Aluminum 24h Ur-sCnc;;ACTIVE;1.0k;2.34 +14593-8;Aluminum;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Serum or Plasma;Aluminum SerPl-sCnc;;ACTIVE;1.0k;2.34 +14594-6;Amitriptyline+Nortriptyline;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Presence] in Gastric fluid;Amitrip+Nor Gast Ql;;ACTIVE;1.0k;2.56 +14595-3;Amitriptyline+Nortriptyline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Presence] in Serum or Plasma;Amitrip+Nor SerPl Ql;;ACTIVE;1.0k;2.73 +14596-1;Amitriptyline+Nortriptyline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Presence] in Urine;Amitrip+Nor Ur Ql;;ACTIVE;1.0k;2.73 +1459-7;Creatinine^pre 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;24H;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in 24 hour Urine --pre 2 mg dexamethasone PO 2.5 day high dose q6h;Creat pre 2 mg Dex high 24h Ur-mCnc;;ACTIVE;1.0;2.73 +14597-9;Amitriptyline;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amitriptyline [Moles/volume] in Serum or Plasma;Amitrip SerPl-sCnc;;ACTIVE;1.0k;2.34 +14598-7;Amitriptyline+Nortriptyline;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Moles/volume] in Serum or Plasma;Amitrip+Nor SerPl-sCnc;;ACTIVE;1.0k;2.34 +14599-5;Ammonium;PrThr;Pt;Calculus;Ord;;CHEM;1;Ammonium [Presence] in Stone;Ammonium Stone Ql;;ACTIVE;1.0k;2.56 +14600-1;Amoxapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amoxapine [Moles/volume] in Serum or Plasma;Amoxapine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14601-9;Amoxapine+8-Hydroxyamoxapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amoxapine+8-Hydroxyamoxapine [Moles/volume] in Serum or Plasma;Amoxapine+8OH-Amox SerPl-sCnc;;ACTIVE;1.0k;2.40 +14602-7;Amoxapine+8-Hydroxyamoxapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Amoxapine+8-Hydroxyamoxapine [Molecules/volume] in Serum or Plasma;Deprecated Amoxapine+8OH-Amox SerPl-sCnc;;DEPRECATED;1.0k;2.36 +14603-5;Androstenedione;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstenedione [Moles/volume] in Serum or Plasma;Androst SerPl-sCnc;;ACTIVE;1.0k;2.73 +14604-3;Blood group antibodies identified;Prid;Pt;Ser/Plas^BPU;Nom;;BLDBK;1;Blood group antibodies identified in Serum or Plasma from Blood product unit;Blood group antibodies SerPl BPU;;ACTIVE;1.0k;2.73 +1460-5;Cobalamins^post dose cyanocobalamin;MRat;24H;Urine;Qn;;CHAL;1;Cobalamin (Vitamin B12) [Mass/time] in 24 hour Urine --post dose cyanocobalamin;Vit B12 p B12 24h Ur-mRate;;ACTIVE;1.0;2.42 +14605-0;Blood group antibodies identified;Prid;Pt;Ser/Plas^Donor;Nom;;BLDBK;1;Blood group antibodies identified in Serum or Plasma from Donor;Blood group antibodies SerPl Donr;;ACTIVE;1.0k;2.52 +14606-8;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;Prewarmed;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by Prewarmed;Bld gp Ab Scn SerPl Ql Pwarm;;ACTIVE;1.0k;2.73 +14607-6;Nuclear Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Nuclear Ab [Presence] in Body fluid;ANA Fld Ql;;ACTIVE;1.0k;2.73 +14608-4;Nuclear Ab;PrThr;Pt;Plr fld;Ord;;SERO;1;Nuclear Ab [Presence] in Pleural fluid;ANA Plr Ql;;ACTIVE;1.0k;2.56 +14609-2;Nuclear Ab;PrThr;Pt;Periton fld;Ord;;SERO;1;Nuclear Ab [Presence] in Peritoneal fluid;ANA Prt Ql;;ACTIVE;1.0k;2.56 +146-1;Cefuroxime.parenteral;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefuroxime Parenteral [Susceptibility] by Disk diffusion (KB);Cefuroxime Parenter Islt KB;;ACTIVE;1.0;2.73 +14610-0;Nuclear Ab;PrThr;Pt;Synv fld;Ord;;SERO;1;Nuclear Ab [Presence] in Synovial fluid;ANA Snv Ql;;ACTIVE;1.0k;2.56 +14611-8;Nuclear Ab pattern;Imp;Pt;Ser;Nom;;SERO;1;Nuclear Ab pattern [Interpretation] in Serum;ANA Pat Ser-Imp;;ACTIVE;1.0k;2.73 +14612-6;Nuclear Ab;Titr;Pt;Pericard fld;Qn;;SERO;1;Nuclear Ab [Titer] in Pericardial fluid;ANA Titr Pcar;;ACTIVE;1.0k;2.70 +1461-3;Epinephrine^1H post 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --1 hour post 300 ug cloNIDine PO;Epineph 1h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +14613-4;Nuclear Ab;Titr;Pt;Body fld;Qn;;SERO;1;Nuclear Ab [Titer] in Body fluid;ANA Titr Fld;;ACTIVE;1.0k;2.73 +14614-2;Nuclear Ab;Titr;Pt;Plr fld;Qn;;SERO;1;Nuclear Ab [Titer] in Pleural fluid;ANA Titr Plr;;ACTIVE;1.0k;2.70 +14615-9;Nuclear Ab;Titr;Pt;Periton fld;Qn;;SERO;1;Nuclear Ab [Titer] in Peritoneal fluid;ANA Titr Prt;;ACTIVE;1.0k;2.70 +14616-7;Nuclear Ab;Titr;Pt;Synv fld;Qn;;SERO;1;Nuclear Ab [Titer] in Synovial fluid;ANA Titr Snv;;ACTIVE;1.0k;2.70 +14617-5;Appearance;Aper;Pt;Pericard fld;Nom;;SPEC;1;Appearance of Pericardial fluid;Appearance Pcar;;ACTIVE;1.0k;2.73 +14618-3;Appearance;Aper;Pt;Calculus;Nom;;SPEC;1;Appearance of Stone;Appearance Stone;;ACTIVE;1.0k;2.73 +14619-1;Appearance;Aper;Pt;Plas;Nom;;SPEC;1;Appearance of Plasma;Appearance Plas;;ACTIVE;1.0k;2.73 +14620-9;Appearance;Aper;Pt;Plr fld;Nom;;SPEC;1;Appearance of Pleural fluid;Appearance Plr;;ACTIVE;1.0k;2.73 +1462-1;Epinephrine^2H post 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --2 hours post 300 ug cloNIDine PO;Epineph 2h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +14621-7;Appearance;Aper;Pt;Periton fld;Nom;;SPEC;1;Appearance of Peritoneal fluid;Appearance Prt;;ACTIVE;1.0k;2.73 +14622-5;Ascorbate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ascorbate [Moles/volume] in Serum or Plasma;Vit C SerPl-sCnc;;ACTIVE;1.0k;2.73 +14623-3;Barbital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Barbital [Presence] in Serum or Plasma;Barbital SerPl Ql;;ACTIVE;1.0k;2.56 +14624-1;Barbiturates;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Gastric fluid;Barbiturates Gast Ql;;ACTIVE;1.0k;2.56 +14625-8;Basophils/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Bronchial specimen by Manual count;Basophils/leuk NFr Bronch Manual;;ACTIVE;1.0k;2.73 +14626-6;Beta-2-Microglobulin;SCnc;Pt;Ser;Qn;;CHEM;1;Beta-2-Microglobulin [Moles/volume] in Serum;B2 Microglob Ser-sCnc;;ACTIVE;1.0k;2.73 +14627-4;Bicarbonate;SCnc;Pt;BldV;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Venous blood;HCO3 BldV-sCnc;;ACTIVE;1.0k;2.73 +14628-2;Bile acid;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bile acid [Moles/volume] in Serum or Plasma;Bile Ac SerPl-sCnc;;ACTIVE;1.0k;2.73 +14629-0;Bilirubin.glucuronidated+Bilirubin.albumin bound;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.direct [Moles/volume] in Serum or Plasma;Bilirub Direct SerPl-sCnc;;ACTIVE;1.0k;2.73 +14630-8;Bilirubin.non-glucuronidated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.indirect [Moles/volume] in Serum or Plasma;Bilirub Indirect SerPl-sCnc;;ACTIVE;1.0k;2.73 +14631-6;Bilirubin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Serum or Plasma;Bilirub SerPl-sCnc;;ACTIVE;1.0k;2.73 +14632-4;Buffy coat;Imp;Pt;Bld;Nom;Microscopy.light;HEM/BC;1;Deprecated Buffy coat;Deprecated Buffy coat Bld Smear-Imp;;DEPRECATED;1.0k;2.36 +14633-2;C peptide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;C peptide [Moles/volume] in Serum or Plasma;C peptide SerPl-sCnc;;ACTIVE;1.0k;2.73 +14634-0;C reactive protein;Titr;Pt;Ser/Plas;Qn;;CHEM;1;C reactive protein [Titer] in Serum or Plasma;CRP Titr SerPl;;ACTIVE;1.0k;2.73 +14635-7;Calcidiol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;25-hydroxyvitamin D3 [Moles/volume] in Serum or Plasma;25(OH)D3 SerPl-sCnc;;ACTIVE;1.0k;2.73 +14636-5;Calcium;PrThr;Pt;Calculus;Ord;;CHEM;1;Calcium [Presence] in Stone;Calcium Stone Ql;;ACTIVE;1.0k;2.56 +14637-3;Calcium;SRat;24H;Urine;Qn;;CHEM;1;Calcium [Moles/time] in 24 hour Urine;Calcium 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14638-1;Calculus analysis;Imp;Pt;Calculus;Nom;;CHEM;1;Calculus analysis [Interpretation] in Stone;Stone Analysis-Imp;;ACTIVE;1.0k;2.73 +1463-9;Epinephrine^3H post 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --3 hours post 300 ug cloNIDine PO;Epineph 3h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +14639-9;carBAMazepine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine [Moles/volume] in Serum or Plasma;carBAMazepine SerPl-sCnc;;ACTIVE;1.0k;2.73 +14640-7;Carbon dioxide;SCnc;Pt;Dial fld;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Dialysis fluid;CO2 Dial fld-sCnc;;ACTIVE;1.0k;2.73 +14641-5;Carbonate;PrThr;Pt;Calculus;Ord;;CHEM;1;Carbonate [Presence] in Stone;Carbonate Stone Ql;;ACTIVE;1.0k;2.56 +14642-3;Carotene;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carotene [Moles/volume] in Serum or Plasma;Carotene SerPl-sCnc;;ACTIVE;1.0k;2.73 +14643-1;Catecholamines.free;SRat;24H;Urine;Qn;;CHEM;1;Catecholamines Free [Moles/time] in 24 hour Urine;FCA 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14644-9;chlorproMAZINE;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;chlorproMAZINE [Presence] in Gastric fluid;chlorproMAZINE Gast Ql;;ACTIVE;1.0k;2.56 +14645-6;chlorproMAZINE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlorproMAZINE [Moles/volume] in Serum or Plasma;chlorproMAZINE SerPl-sCnc;;ACTIVE;1.0k;2.34 +14646-4;Cholesterol.in HDL;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL [Moles/volume] in Serum or Plasma;HDLc SerPl-sCnc;;ACTIVE;1.0k;2.73 +1464-7;Epinephrine^pre 300 ug cloNIDine PO;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --pre 300 ug cloNIDine PO;Epineph pre 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +14647-2;Cholesterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol [Moles/volume] in Serum or Plasma;Cholest SerPl-sCnc;;ACTIVE;1.0k;2.73 +14648-0;Chylomicrons;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chylomicrons [Moles/volume] in Serum or Plasma;Chylo SerPl-sCnc;;ACTIVE;1.0k;2.73 +14649-8;Cimetidine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Cimetidine [Presence] in Gastric fluid;Cimetidine Gast Ql;;ACTIVE;1.0k;2.56 +14650-6;Citrate;SRat;24H;Urine;Qn;;CHEM;1;Citrate [Moles/time] in 24 hour Urine;Citrate 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14651-4;cloBAZam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloBAZam [Moles/volume] in Serum or Plasma;cloBAZam SerPl-sCnc;;ACTIVE;1.0k;2.34 +14652-2;clomiPRAMINE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clomiPRAMINE [Moles/volume] in Serum or Plasma;clomiPRAMINE SerPl-sCnc;;ACTIVE;1.0k;2.34 +14653-0;clomiPRAMINE;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;clomiPRAMINE [Moles/volume] in Urine;clomiPRAMINE Ur-sCnc;;ACTIVE;1.0k;2.42 +1465-4;EPINEPHrine^supine;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --supine;Epineph sup Plas-mCnc;;ACTIVE;1.0;2.73 +14654-8;clomiPRAMINE+Norclomipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clomiPRAMINE+Norclomipramine [Moles/volume] in Serum or Plasma;clomiPRAMINE+Nor SerPl-sCnc;;ACTIVE;1.0k;2.69 +14655-5;clonazePAM;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clonazePAM [Moles/volume] in Serum or Plasma;clonazePAM SerPl-sCnc;;ACTIVE;1.0k;2.34 +14656-3;cloZAPine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloZAPine [Moles/volume] in Serum or Plasma;cloZAPine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14657-1;Clozapine+Norclozapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloZAPine+Norclozapine [Moles/volume] in Serum or Plasma;cloZAPine+Nor SerPl-sCnc;;ACTIVE;1.0k;2.34 +14658-9;Cold agglutinin;Titr;Pt;Ser/Plas;Qn;;SERO;1;Cold agglutinin [Titer] in Serum or Plasma;CA Titr SerPl;;ACTIVE;1.0k;2.73 +14659-7;Collection duration;Time;Pt;Urine;Qn;;SPEC;1;Deprecated Collection duration of Urine;Deprecated Collect Duration Ur Qn;;DEPRECATED;1.0k;2.36 +14660-5;Color;Type;Pt;Periton fld;Nom;;SPEC;1;Color of Peritoneal fluid;Color Prt;;ACTIVE;1.0k;2.73 +14661-3;Color;Type;Pt;Pericard fld;Nom;;SPEC;1;Color of Pericardial fluid;Color Pcar;;ACTIVE;1.0k;2.73 +1466-2;Follitropin^1.5H post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Follitropin [Mass/volume] in Serum or Plasma --1.5 hours post 100 g lutropin IV;Deprecated FSH 1.5H p 100 g LH IV SerPl;;DEPRECATED;1.0;2.32 +14662-1;Color;Type;Pt;Plr fld;Nom;;SPEC;1;Color of Pleural fluid;Color Plr;;ACTIVE;1.0k;2.73 +14663-9;Color;Type;Pt;Semen;Nom;Visual;SPEC;1;Deprecated Color of Semen by Visual;Deprecated Color Smn Visual;;DEPRECATED;1.0k;2.40 +14664-7;Color;Type;Pt;Synv fld;Nom;;SPEC;1;Color of Synovial fluid;Color Snv;;ACTIVE;1.0k;2.73 +14665-4;Copper;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Copper [Moles/volume] in Serum or Plasma;Copper SerPl-sCnc;;ACTIVE;1.0k;2.73 +14666-2;Copper;SRat;24H;Urine;Qn;;DRUG/TOX;1;Copper [Moles/time] in 24 hour Urine;Copper 24h Ur-sRate;;ACTIVE;1.0k;2.40 +14667-0;Coproporphyrin 1;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Coproporphyrin 1 [Moles/volume] in Serum or Plasma;Copro1 SerPl-sCnc;;ACTIVE;1.0k;2.34 +14668-8;Coproporphyrin 1;SCnc;Pt;Stool;Qn;;CHEM;1;Coproporphyrin 1 [Moles/volume] in Stool;Copro1 Stl-sCnc;;ACTIVE;1.0k;2.42 +14669-6;Coproporphyrin 1;SCnc;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 1 [Moles/volume] in Urine;Copro1 Ur-sCnc;;ACTIVE;1.0k;2.42 +1467-0;Follitropin^1.5H post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --1.5 hours post dose gonadotropin releasing hormone;FSH 1.5h p GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.73 +14670-4;Coproporphyrin 1/Porphyrins.total;SFr;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 1/Porphyrins.total in Urine;Copro1 SFr Ur;;ACTIVE;1.0k;2.70 +14671-2;Coproporphyrin 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Coproporphyrin 3 [Moles/volume] in Serum or Plasma;Copro3 SerPl-sCnc;;ACTIVE;1.0k;2.34 +14672-0;Coproporphyrin 3;SCnc;Pt;Stool;Qn;;CHEM;1;Coproporphyrin 3 [Moles/volume] in Stool;Copro3 Stl-sCnc;;ACTIVE;1.0k;2.42 +14673-8;Coproporphyrin 3;SCnc;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 3 [Moles/volume] in Urine;Copro3 Ur-sCnc;;ACTIVE;1.0k;2.42 +14674-6;Corticotropin;SCnc;Pt;Plas;Qn;;CHEM;1;Corticotropin [Moles/volume] in Plasma;ACTH Plas-sCnc;;ACTIVE;1.0k;2.73 +14675-3;Cortisol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Moles/volume] in Serum or Plasma;Cortis SerPl-sCnc;;ACTIVE;1.0k;2.73 +14676-1;Cortisol.free;SRat;24H;Urine;Qn;;CHEM;1;Cortisol Free [Moles/time] in 24 hour Urine;Cortis F 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14677-9;Cortisol^24H post 500 ug dexamethasone PO 2.5 day low dose q6h;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --24 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis 24h p 500 ug Dex SerPl-sCnc;;ACTIVE;1.0k;2.40 +14678-7;Cortisol^PM trough specimen;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Moles/volume] in Serum or Plasma --PM trough specimen;Cortis PM SerPl-sCnc;;ACTIVE;1.0k;2.73 +14679-5;Cortisol^AM peak specimen;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Moles/volume] in Serum or Plasma --AM peak specimen;Cortis AM peak SerPl-sCnc;;ACTIVE;1.0k;2.73 +14680-3;Creatine kinase isoenzymes;Imp;Pt;Ser/Plas;Nom;Electrophoresis;CHEM;1;Creatine kinase isoenzymes [Interpretation] in Serum or Plasma by Electrophoresis;CK Isos SerPl Elph-Imp;;ACTIVE;1.0k;2.73 +14681-1;Creatinine;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Moles/volume] in Peritoneal dialysis fluid;Creat DiafP-sCnc;;ACTIVE;1.0k;2.34 +14682-9;Creatinine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Moles/volume] in Serum or Plasma;Creat SerPl-sCnc;;ACTIVE;1.0k;2.73 +14683-7;Creatinine;SCnc;Pt;Urine;Qn;;CHEM;1;Creatinine [Moles/volume] in Urine;Creat Ur-sCnc;;ACTIVE;1.0k;2.73 +14684-5;Creatinine;SRat;24H;Urine;Qn;;CHEM;1;Creatinine [Moles/time] in 24 hour Urine;Creat 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14685-2;Cobalamins;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma;Vit B12 SerPl-sCnc;;ACTIVE;1.0k;2.73 +14686-0;Cystine;PrThr;Pt;Calculus;Ord;;CHEM;1;Cystine [Presence] in Stone;Cystine Stone Ql;;ACTIVE;1.0k;2.56 +14687-8;Transfusion date;TmStp;Pt;^Patient;Qn;;BLDBK;1;Transfusion date;Transf Date;;ACTIVE;1.0k;2.26 +1468-8;Follitropin^105M post 100 ug luteinizing releasing hormone IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --105 minutes post 100 ug luteinizing releasing hormone IV;FSH 105M p 100 ug LRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.69 +14688-6;Dehydroepiandrosterone sulfate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Moles/volume] in Serum or Plasma;DHEA-S SerPl-sCnc;;ACTIVE;1.0k;2.73 +14689-4;Delta aminolevulinate;SRat;24H;Urine;Qn;;CHEM;1;Delta aminolevulinate [Moles/time] in 24 hour Urine;D-ALA 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14690-2;N-desalkylflurazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Moles/volume] in Serum or Plasma;Desalkylfluraz SerPl-sCnc;;ACTIVE;1.0k;2.73 +14691-0;Desipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desipramine [Moles/volume] in Serum or Plasma;Desipramine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14692-8;Desipramine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Desipramine [Moles/volume] in Urine;Desipramine Ur-sCnc;;ACTIVE;1.0k;2.42 +14693-6;Norclobazam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norclobazam [Moles/volume] in Serum or Plasma;Norclobazam SerPl-sCnc;;ACTIVE;1.0k;2.34 +14694-4;Norclomipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norclomipramine [Moles/volume] in Serum or Plasma;Norclomipramine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14695-1;Nordoxepin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nordoxepin [Moles/volume] in Serum or Plasma;Nordoxepin SerPl-sCnc;;ACTIVE;1.0k;2.34 +1469-6;Follitropin^15M post 100 ug luteinizing releasing hormone IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --15 minutes post 100 ug luteinizing releasing hormone IV;FSH 15M p 100 ug LRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.69 +14696-9;Deuteroporphyrin;SCnc;Pt;Stool;Qn;;CHEM;1;Deuteroporphyrin [Moles/volume] in Stool;Deuteropor Stl-sCnc;;ACTIVE;1.0k;2.42 +14697-7;diazePAM;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;diazePAM [Moles/volume] in Serum or Plasma;diazePAM SerPl-sCnc;;ACTIVE;1.0k;2.34 +14698-5;Digoxin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digoxin [Moles/volume] in Serum or Plasma;Digoxin SerPl-sCnc;;ACTIVE;1.0k;2.73 +14699-3;diphenhydrAMINE+dimenhyDRINATE;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;diphenhydrAMINE+dimenhyDRINATE [Presence] in Gastric fluid;Diphenhyd+Dimenhyd Gast Ql;;ACTIVE;1.0k;2.69 +14700-9;diphenhydrAMINE+dimenhyDRINATE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;diphenhydrAMINE+dimenhyDRINATE [Presence] in Serum or Plasma;Diphenhyd+Dimenhyd SerPl Ql;;ACTIVE;1.0k;2.69 +14701-7;diphenhydrAMINE+dimenhyDRINATE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;diphenhydrAMINE+dimenhyDRINATE [Presence] in Urine;Diphenhyd+Dimenhyd Ur Ql;;ACTIVE;1.0k;2.73 +14702-5;Disopyramide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Disopyramide [Moles/volume] in Serum or Plasma;Disopyramide SerPl-sCnc;;ACTIVE;1.0k;2.34 +14703-3;DOPamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;DOPamine [Moles/volume] in Serum or Plasma;DOPamine SerPl-sCnc;;ACTIVE;1.0k;2.73 +1470-4;Follitropin^1H post 100 ug luteinizing releasing hormone IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --1 hour post 100 ug luteinizing releasing hormone IV;FSH 1h p 100 ug LRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.69 +14704-1;Doxepin;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Doxepin [Presence] in Gastric fluid;Doxepin Gast Ql;;ACTIVE;1.0k;2.56 +14705-8;Doxepin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxepin [Moles/volume] in Serum or Plasma;Doxepin SerPl-sCnc;;ACTIVE;1.0k;2.73 +14706-6;Doxepin;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Doxepin [Moles/volume] in Urine;Doxepin Ur-sCnc;;ACTIVE;1.0k;2.42 +14707-4;Doxepin+Nordoxepin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxepin+Nordoxepin [Moles/volume] in Serum or Plasma;Doxepin+Nor SerPl-sCnc;;ACTIVE;1.0k;2.34 +14708-2;Endomysium Ab;Titr;Pt;Ser;Qn;;SERO;1;Endomysium Ab [Titer] in Serum;Endomysium Ab Titr Ser;;ACTIVE;1.0k;2.73 +14709-0;Eosinophils/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Bronchial specimen by Manual count;Eosinophil/leuk NFr Bronch Manual;;ACTIVE;1.0k;2.73 +14710-8;Ephedrine+Pseudoephedrine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Presence] in Gastric fluid;Ephedrin+Pseudo Gast Ql;;ACTIVE;1.0k;2.56 +14711-6;EPINEPHrine;SCnc;Pt;Plas;Qn;;CHEM;1;EPINEPHrine [Moles/volume] in Plasma;Epineph Plas-sCnc;;ACTIVE;1.0k;2.34 +1471-2;Follitropin^1H post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --1 hour post dose gonadotropin releasing hormone;FSH 1h p GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.73 +14712-4;EPINEPHrine;SRat;24H;Urine;Qn;;CHEM;1;EPINEPHrine [Moles/time] in 24 hour Urine;Epineph 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14713-2;Erythrocytes;NCnc;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Pericardial fluid by Manual count;RBC # Pcar Manual;;ACTIVE;1.0k;2.73 +14714-0;Erythropoietin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Erythropoietin (EPO) [Moles/volume] in Serum or Plasma;EPO SerPl-sCnc;;DISCOURAGED;1.0k;2.73 +14715-7;Estradiol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2) [Moles/volume] in Serum or Plasma;Estradiol SerPl-sCnc;;ACTIVE;1.0k;2.73 +14716-5;Estriol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3) [Moles/volume] in Serum or Plasma;Estriol SerPl-sCnc;;ACTIVE;1.0k;2.73 +14717-3;Estriol;SCnc;Pt;Urine;Qn;;CHEM;1;Estriol (E3) [Moles/volume] in Urine;Estriol Ur-sCnc;;ACTIVE;1.0k;2.34 +14718-1;Estriol;SRat;24H;Urine;Qn;;CHEM;1;Estriol (E3) [Moles/time] in 24 hour Urine;Estriol 24h Ur-sRate;;ACTIVE;1.0k;2.42 +14719-9;Ethanol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethanol [Moles/volume] in Serum or Plasma;Ethanol SerPl-sCnc;;ACTIVE;1.0k;2.73 +1472-0;Follitropin^2H post 100 ug luteinizing releasing hormone IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --2 hours post 100 ug luteinizing releasing hormone IV;FSH 2h p 100 ug LRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.69 +14720-7;Ethosuximide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethosuximide [Moles/volume] in Serum or Plasma;Ethosuximide SerPl-sCnc;;ACTIVE;1.0k;2.34 +14721-5;Ethylene glycol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethylene glycol [Moles/volume] in Serum or Plasma;Ethylene Glycol SerPl-sCnc;;ACTIVE;1.0k;2.73 +14722-3;Extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Extractable nuclear Ab [Presence] in Serum;ENA Ab Ser Ql;;ACTIVE;1.0k;2.73 +14723-1;Ferritin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ferritin [Moles/volume] in Serum or Plasma;Ferritin SerPl-sCnc;;ACTIVE;1.0k;2.73 +14724-9;Ferritin;Imp;Pt;Bld;Nom;;CHEM;1;Ferritin [Interpretation] in Blood;Ferritin Bld-Imp;;ACTIVE;1.0k;2.73 +14725-6;Fluid;Type;Pt;Body fld;Nom;;SPEC;1;[Type] of Body fluid;Body fld type;;ACTIVE;1.0k;2.73 +14726-4;Fluoride;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fluoride [Moles/volume] in Serum or Plasma;Fluoride SerPl-sCnc;;ACTIVE;1.0k;2.73 +14727-2;FLUoxetine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;FLUoxetine [Presence] in Gastric fluid;FLUoxetine Gast Ql;;ACTIVE;1.0k;2.56 +14728-0;FLUoxetine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;FLUoxetine [Moles/volume] in Serum or Plasma;FLUoxetine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14729-8;Flurazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flurazepam [Moles/volume] in Serum or Plasma;Flurazepam SerPl-sCnc;;ACTIVE;1.0k;2.34 +14730-6;Flurazepam+N-desalkylflurazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flurazepam+N-desalkylflurazepam [Moles/volume] in Serum or Plasma;Flurazepam+Desalkyl SerPl-sCnc;;ACTIVE;1.0k;2.34 +14731-4;Folate;SCnc;Pt;RBC;Qn;;CHEM;1;Folate [Moles/volume] in Red Blood Cells;Folate RBC-sCnc;;ACTIVE;1.0k;2.73 +14732-2;Folate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Folate [Moles/volume] in Serum or Plasma;Folate SerPl-sCnc;;ACTIVE;1.0k;2.73 +14733-0;Folate+Cyanocobalamin;Imp;Pt;Ser/Bld;Nom;;CHEM;1;Folate+Cyanocobalamin [Interpretation] in Serum or Blood;Folate+Vit B12 SerBld-Imp;;ACTIVE;1.0k;2.26 +14734-8;Follitropin;SRat;24H;Urine;Qn;;CHEM;1;Follitropin [Moles/time] in 24 hour Urine;FSH 24h Ur-sRate;;DISCOURAGED;1.0k;2.42 +14735-5;Gastrin^10M post 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --10 minutes post 0.2 U/kg secretin;Gastrin 10M p 0.2 U/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +14736-3;Gastrin^15M post 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --15 minutes post 0.2 U/kg secretin;Gastrin 15M p 0.2 U/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +14737-1;Gastrin^20M post 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --20 minutes post 0.2 U/kg secretin;Gastrin 20M p 0.2 U/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +1473-8;Follitropin^30M post 100 ug luteinizing releasing hormone IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --30 minutes post 100 ug luteinizing releasing hormone IV;FSH 30M p 100 ug LRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.69 +14738-9;Gastrin^25M post 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --25 minutes post 0.2 U/kg secretin;Gastrin 25M p 0.2 U/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +14739-7;Gastrin^2M post 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --2 minutes post 0.2 U/kg secretin;Gastrin 2M p 0.2 U/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +14740-5;Gastrin^30M post 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --30 minutes post 0.2 U/kg secretin;Gastrin 30M p 0.2 U/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +14741-3;Gastrin^5M post 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --5 minutes post 0.2 U/kg secretin;Gastrin 5M p 0.2 u/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +14742-1;Gastrin^pre 0.2 U/kg secretin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --pre 0.2 U/kg secretin;Gastrin pre 0.2 u/kg SCT SerPl-sCnc;;ACTIVE;1.0k;2.40 +14743-9;Glucose;SCnc;Pt;BldC;Qn;Glucometer;CHEM;1;Glucose [Moles/volume] in Capillary blood by Glucometer;Glucose BldC Glucomtr-sCnc;;ACTIVE;1.0k;2.73 +14744-7;Glucose;SCnc;Pt;CSF;Qn;;CHEM;1;Glucose [Moles/volume] in Cerebral spinal fluid;Glucose CSF-sCnc;;ACTIVE;1.0k;2.73 +14745-4;Glucose;SCnc;Pt;Body fld;Qn;;CHEM;1;Glucose [Moles/volume] in Body fluid;Glucose Fld-sCnc;;ACTIVE;1.0k;2.73 +1474-6;Follitropin^30M post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --30 minutes post dose gonadotropin releasing hormone;FSH 30M p GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.73 +14746-2;Glucose;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Moles/volume] in Peritoneal dialysis fluid;Glucose DiafP-sCnc;;ACTIVE;1.0k;2.34 +14747-0;Glucose;SCnc;Pt;Plr fld;Qn;;CHEM;1;Glucose [Moles/volume] in Pleural fluid;Glucose Plr-sCnc;;ACTIVE;1.0k;2.34 +14748-8;Glucose;SCnc;Pt;Periton fld;Qn;;CHEM;1;Glucose [Moles/volume] in Peritoneal fluid;Glucose Prt-sCnc;;ACTIVE;1.0k;2.34 +14749-6;Glucose;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Moles/volume] in Serum or Plasma;Glucose SerPl-sCnc;;ACTIVE;1.0k;2.73 +14750-4;Glucose;SCnc;Pt;Synv fld;Qn;;CHEM;1;Glucose [Moles/volume] in Synovial fluid;Glucose Snv-sCnc;;ACTIVE;1.0k;2.34 +14751-2;Glucose^1.5H post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post 50 g lactose PO;Glucose 1.5h p 50 g Lac PO SerPl-sCnc;;ACTIVE;1.0k;2.34 +14752-0;Glucose^1.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose glucose;Glucose 1.5h p Glc SerPl-sCnc;;ACTIVE;1.0k;2.34 +1475-3;Follitropin^45M post 100 ug luteinizing releasing hormone IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --45 minutes post 100 ug luteinizing releasing hormone IV;FSH 45M p 100 ug LRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.69 +14753-8;Glucose^1H post 100 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post 100 g glucose PO;Glucose 1h p 100 g Glc PO SerPl-sCnc;;ACTIVE;1.0k;2.73 +14754-6;Glucose^1H post 50 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post 50 g glucose PO;Glucose 1h p 50 g Glc PO SerPl-sCnc;;ACTIVE;1.0k;2.73 +14755-3;Glucose^1H post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post 50 g lactose PO;Glucose 1h p 50 g Lac PO SerPl-sCnc;;ACTIVE;1.0k;2.73 +14756-1;Glucose^1H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post dose glucose;Glucose 1h p Glc SerPl-sCnc;;ACTIVE;1.0k;2.73 +14757-9;Glucose^2H post 100 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post 100 g glucose PO;Glucose 2h p 100 g Glc PO SerPl-sCnc;;ACTIVE;1.0k;2.73 +14758-7;Glucose^2H post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post 50 g lactose PO;Glucose 2h p 50 g Lac PO SerPl-sCnc;;ACTIVE;1.0k;2.34 +14759-5;Glucose^2H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post dose glucose;Glucose 2h p Glc SerPl-sCnc;;ACTIVE;1.0k;2.73 +14760-3;Glucose^2H post meal;SCnc;Pt;BldC;Qn;;CHAL;1;Glucose [Moles/volume] in Capillary blood --2 hours post meal;Glucose 2h p meal BldC-sCnc;;ACTIVE;1.0k;2.73 +1476-1;Follitropin^75M post 100 ug luteinizing releasing hormone IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --75 minutes post 100 ug luteinizing releasing hormone IV;FSH 75M p 100 ug LRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.69 +14761-1;Glucose^2H post meal;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post meal;Glucose 2h p meal SerPl-sCnc;;ACTIVE;1.0k;2.73 +14762-9;Glucose^30M post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post 50 g lactose PO;Glucose 30M p 50 g Lac PO SerPl-sCnc;;ACTIVE;1.0k;2.34 +14763-7;Glucose^30M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose glucose;Glucose 30M p Glc SerPl-sCnc;;ACTIVE;1.0k;2.73 +14764-5;Glucose^3H post 100 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post 100 g glucose PO;Glucose 3h p 100 g Glc PO SerPl-sCnc;;ACTIVE;1.0k;2.73 +14765-2;Glucose^3H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post dose glucose;Glucose 3h p Glc SerPl-sCnc;;ACTIVE;1.0k;2.73 +14766-0;Glucose^4H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4 hours post dose glucose;Glucose 4h p Glc SerPl-sCnc;;ACTIVE;1.0k;2.73 +14767-8;Glucose^5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5 hours post dose glucose;Glucose 5h p Glc SerPl-sCnc;;ACTIVE;1.0k;2.73 +14768-6;Glucose^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --baseline;Glucose BS SerPl-sCnc;;ACTIVE;1.0k;2.73 +14769-4;Glucose^pre 12H CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre 12 hour fast;Glucose pre 12h fast SerPl-sCnc;;ACTIVE;1.0k;2.34 +14770-2;Glucose^post CFst;SCnc;Pt;BldC;Qn;Glucometer;CHAL;1;Fasting glucose [Moles/volume] in Capillary blood by Glucometer;Glucose p fast BldC Glucomtr-sCnc;;ACTIVE;1.0k;2.73 +14771-0;Glucose^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fasting glucose [Moles/volume] in Serum or Plasma;Glucose p fast SerPl-sCnc;;ACTIVE;1.0k;2.73 +14772-8;Gold;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gold [Moles/volume] in Serum or Plasma;Gold SerPl-sCnc;;ACTIVE;1.0k;2.34 +14773-6;Granulocytes/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Granulocytes/100 leukocytes in Bronchial specimen by Manual count;Granulocytes/leuk NFr Bronch Manual;;ACTIVE;1.0k;2.70 +14774-4;Haloperidol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Haloperidol [Moles/volume] in Serum or Plasma;Haloperidol SerPl-sCnc;;ACTIVE;1.0k;2.34 +14775-1;Hemoglobin;MCnc;Pt;BldA;Qn;Oximetry;HEM/BC;1;Hemoglobin [Mass/volume] in Arterial blood by Oximetry;Hgb BldA Oximetry-mCnc;;ACTIVE;1.0k;2.73 +14776-9;Heptacarboxylate;SCnc;Pt;Plas;Qn;;CHEM;1;Heptacarboxylate [Moles/volume] in Plasma;Heptacarboxylate Plas-sCnc;;ACTIVE;1.0k;2.34 +14777-7;Heptacarboxylate;SCnc;Pt;Stool;Qn;;CHEM;1;Heptacarboxylate [Moles/volume] in Stool;Heptacarboxylate Stl-sCnc;;ACTIVE;1.0k;2.42 +14778-5;Heptacarboxylate;SCnc;Pt;Urine;Qn;;CHEM;1;Heptacarboxylate [Moles/volume] in Urine;Heptacarboxylate Ur-sCnc;;ACTIVE;1.0k;2.42 +1477-9;Follitropin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --baseline;FSH BS SerPl-mCnc;;DISCOURAGED;1.0;2.73 +14779-3;Hexacarboxylate;SCnc;Pt;Plas;Qn;;CHEM;1;Hexacarboxylate [Moles/volume] in Plasma;Hexacarboxylate Plas-sCnc;;ACTIVE;1.0k;2.34 +14780-1;Hexacarboxylate;SCnc;Pt;Stool;Qn;;CHEM;1;Hexacarboxylate [Moles/volume] in Stool;Hexacarboxylate Stl-sCnc;;ACTIVE;1.0k;2.42 +14781-9;Hexacarboxylate;SCnc;Pt;Urine;Qn;;CHEM;1;Hexacarboxylate [Moles/volume] in Urine;Hexacarboxylate Ur-sCnc;;ACTIVE;1.0k;2.42 +14782-7;Homovanillate;SCnc;Pt;Urine;Qn;;CHEM;1;Homovanillate [Moles/volume] in Urine;HVA Ur-sCnc;;ACTIVE;1.0k;2.34 +14783-5;Homovanillate;SRat;24H;Urine;Qn;;CHEM;1;Homovanillate [Moles/time] in 24 hour Urine;HVA 24h Ur-sRate;;ACTIVE;1.0k;2.40 +14784-3;Hydroxyproline.free;SRat;24H;Urine;Qn;;CHEM;1;Hydroxyproline Free [Moles/time] in 24 hour Urine;OH-Proline Free 24h Ur-sRate;;ACTIVE;1.0k;2.42 +14785-0;Hydroxyproline;SRat;24H;Urine;Qn;;CHEM;1;Hydroxyproline [Moles/time] in 24 hour Urine;OH-Proline 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14786-8;Arthropod identified;Prid;Pt;XXX;Nom;Micro/Micro;MICRO;1;Deprecated Arthropod identified in Unspecified specimen;Deprecated Insect XXX;;DEPRECATED;1.0k;2.69 +1478-7;Follitropin^pre dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --pre dose gonadotropin releasing hormone;FSH pre GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.73 +14787-6;Arthropod identified;Prid;Pt;XXX;Nom;Perm mount;MICRO;1;Arthropod identified in Specimen by Permanent mount;Insect Spec Perm Mount;;ACTIVE;1.0k;2.69 +14788-4;Helminth+Arthropod identified;Prid;Pt;XXX;Nom;Rearing/Culture;MICRO;1;Helminth+Arthropod identified in Specimen by Rearing/Culture;Worm+Insect Spec Rearing/Cult;;ACTIVE;1.0k;2.69 +14789-2;Helminth identified;Prid;Pt;XXX;Nom;Macro/Micro ID;MICRO;1;Helminth identified in Specimen by Macro/micro identification;Worm Spec Macro/micro Id;;ACTIVE;1.0k;2.73 +147-9;Cefuroxime.parenteral;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefuroxime Parenteral [Susceptibility] by Serum bactericidal titer;Cefuroxime Parenter Titr SBT;;ACTIVE;1.0;2.32 +14790-0;Helminth identified;Prid;Pt;XXX;Nom;Perm mount;MICRO;1;Helminth identified in Specimen by Permanent mount;Worm Spec Perm Mount;;ACTIVE;1.0k;2.69 +14791-8;Imipramine+Desipramine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Imipramine+Desipramine [Presence] in Gastric fluid;Imipramine+Desipr Gast Ql;;ACTIVE;1.0k;2.56 +14792-6;Imipramine+Desipramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Imipramine+Desipramine [Presence] in Serum or Plasma;Imipramine+Desipr SerPl Ql;;ACTIVE;1.0k;2.56 +14793-4;Imipramine+Desipramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Imipramine+Desipramine [Presence] in Urine;Imipramine+Desipr Ur Ql;;ACTIVE;1.0k;2.73 +14794-2;Imipramine+Desipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imipramine+Desipramine [Moles/volume] in Serum or Plasma;Imipramine+Desipr SerPl-sCnc;;ACTIVE;1.0k;2.34 +1479-5;Galactose^1.5H post 40 g galactose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Galactose [Mass/volume] in Blood --1.5 hours post 40 g galactose PO;Galactose 4.5h p 40 g Gal PO Bld-mCnc;;ACTIVE;1.0;2.40 +14795-9;Immunoglobulin light chains;Imp;Pt;Urine;Nom;;CHEM;1;Immunoglobulin light chains [Interpretation] in Urine;BJ Protein Ur-Imp;;ACTIVE;1.0k;2.73 +14796-7;Insulin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin [Moles/volume] in Serum or Plasma;Insulin SerPl-sCnc;;ACTIVE;1.0k;2.73 +14797-5;Iron;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Iron [Interpretation] in Serum or Plasma;Iron SerPl-Imp;;ACTIVE;1.0k;2.26 +14798-3;Iron;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Moles/volume] in Serum or Plasma;Iron SerPl-sCnc;;ACTIVE;1.0k;2.73 +14799-1;Iron;SRat;24H;Urine;Qn;;CHEM;1;Iron [Moles/time] in 24 hour Urine;Iron 24h Ur-sRate;;ACTIVE;1.0k;2.40 +14800-7;Iron binding capacity;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron binding capacity [Moles/volume] in Serum or Plasma;TIBC SerPl-sCnc;;ACTIVE;1.0k;2.73 +14801-5;Iron saturation;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Iron saturation [Molar fraction] in Serum or Plasma;Iron Satn SFr SerPl;;ACTIVE;1.0k;2.73 +14802-3;Isopropanol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Isopropanol [Moles/volume] in Serum or Plasma;Isopropanol SerPl-sCnc;;ACTIVE;1.0k;2.73 +1480-3;Galactose^1H post 40 g galactose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Galactose [Mass/volume] in Blood --1 hour post 40 g galactose PO;Galactose 1h p 40 g Gal PO Bld-mCnc;;ACTIVE;1.0;2.40 +14803-1;Lactate dehydrogenase;CCnc;Pt;Body fld;Qn;Reaction: lactate to pyruvate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Body fluid by Lactate to pyruvate reaction;LDH Fld L to P-cCnc;;ACTIVE;1.0k;2.73 +14804-9;Lactate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;Reaction: lactate to pyruvate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction;LDH SerPl L to P-cCnc;;ACTIVE;1.0k;2.73 +14805-6;Lactate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;Reaction: pyruvate to lactate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Pyruvate to lactate reaction;LDH SerPl P to L-cCnc;;ACTIVE;1.0k;2.73 +14806-4;Lactose.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Lactose.PO [Mass] of Dose;Lactose PO Dose;;ACTIVE;1.0k;2.73 +14807-2;Lead;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Lead [Moles/volume] in Blood;Lead Bld-sCnc;;ACTIVE;1.0k;2.73 +14808-0;Lead;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lead [Moles/volume] in Urine;Lead Ur-sCnc;;ACTIVE;1.0k;2.73 +14809-8;Lead;SRat;24H;Urine;Qn;;DRUG/TOX;1;Lead [Moles/time] in 24 hour Urine;Lead 24h Ur-sRate;;ACTIVE;1.0k;2.40 +14810-6;Leukocytes;NCnc;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Bronchial specimen by Manual count;WBC # Bronch Manual;;ACTIVE;1.0k;2.19 +1481-1;Galactose^2H post 40 g galactose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Galactose [Mass/volume] in Blood --2 hours post 40 g galactose PO;Galactose 2h p 400 g Gal PO Bld-mCnc;;ACTIVE;1.0;2.40 +14811-4;Leukocytes;NCnc;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Pericardial fluid by Manual count;WBC # Pcar Manual;;ACTIVE;1.0k;2.73 +14812-2;Lidocaine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lidocaine [Moles/volume] in Serum or Plasma;Lidocain SerPl-sCnc;;ACTIVE;1.0k;2.73 +14813-0;Lipoprotein.alpha;SCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lipoprotein.alpha [Moles/volume] in Serum or Plasma by Electrophoresis;HDL SerPl Elph-sCnc;;ACTIVE;1.0k;2.40 +14814-8;Lipoprotein.beta;SCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lipoprotein.beta [Moles/volume] in Serum or Plasma by Electrophoresis;LDL SerPl Elph-sCnc;;ACTIVE;1.0k;2.40 +14815-5;Lipoprotein.beta;SCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Lipoprotein.beta [Moles/volume] in Serum or Plasma by calculation;LDL SerPl Calc-sCnc;;ACTIVE;1.0k;2.73 +14816-3;Lipoprotein.pre-beta;SCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lipoprotein.pre-beta [Moles/volume] in Serum or Plasma by Electrophoresis;VLDL SerPl Elph-sCnc;;ACTIVE;1.0k;2.73 +14817-1;LORazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;LORazepam [Moles/volume] in Serum or Plasma;LORazepam SerPl-sCnc;;ACTIVE;1.0k;2.34 +14818-9;Lymphocytes/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Pericardial fluid by Manual count;Lymphocytes/leuk NFr Pcar Manual;;ACTIVE;1.0k;2.73 +14819-7;Lymphocytes/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Bronchial specimen by Manual count;Lymphocytes/leuk NFr Bronch Manual;;ACTIVE;1.0k;2.73 +14820-5;Lymphocytes/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Pleural fluid by Manual count;Lymphocytes/leuk NFr Plr Manual;;ACTIVE;1.0k;2.73 +14821-3;Lymphocytes/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Peritoneal fluid by Manual count;Lymphocytes/leuk NFr Prt Manual;;ACTIVE;1.0k;2.73 +14822-1;Lymphocytes/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Synovial fluid by Manual count;Lymphocytes/leuk NFr Snv Manual;;ACTIVE;1.0k;2.73 +14823-9;Macrophages/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Bronchial specimen by Manual count;Macrophages/leuk NFr Bronch Manual;;ACTIVE;1.0k;2.70 +14824-7;Magnesium;PrThr;Pt;Calculus;Ord;;CHEM;1;Magnesium [Presence] in Stone;Magnesium Stone Ql;;ACTIVE;1.0k;2.56 +14825-4;Maprotiline;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Maprotiline [Moles/volume] in Serum or Plasma;Maprotiline SerPl-sCnc;;ACTIVE;1.0k;2.34 +14826-2;Meperidine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Meperidine [Presence] in Gastric fluid;Meperidine Gast Ql;;ACTIVE;1.0k;2.56 +14827-0;Mesoporphyrin;SCnc;Pt;Stool;Qn;;CHEM;1;Mesoporphyrin [Moles/volume] in Stool;Mesopor Stl-sCnc;;ACTIVE;1.0k;2.42 +14828-8;Mesothelial cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Pericardial fluid by Manual count;Mesothl Cell/leuk NFr Pcar Manual;;ACTIVE;1.0k;2.73 +1482-9;Galactose^30M post 40 g galactose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Galactose [Mass/volume] in Blood --30 minutes post 40 g galactose PO;Galactose 30M p 40 g Gal PO Bld-mCnc;;ACTIVE;1.0;2.40 +14829-6;Mesothelial cells/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Pleural fluid by Manual count;Mesothl Cell/leuk NFr Plr Manual;;ACTIVE;1.0k;2.73 +14830-4;Mesothelial cells/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Peritoneal fluid by Manual count;Mesothl Cell/leuk NFr Prt Manual;;ACTIVE;1.0k;2.73 +14831-2;Metanephrine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Metanephrine/Creatinine [Molar ratio] in Urine;Metaneph/Creat Ur-sRto;;ACTIVE;1.0k;2.73 +14832-0;Metanephrines;SCnc;Pt;Urine;Qn;;CHEM;1;Metanephrines [Moles/volume] in Urine;MetanephS Ur-sCnc;;ACTIVE;1.0k;2.34 +14833-8;Metanephrines;SRat;24H;Urine;Qn;;CHEM;1;Metanephrines [Moles/time] in 24 hour Urine;MetanephS 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14834-6;Methamphetamine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methamphetamine [Presence] in Gastric fluid;Methamphet Gast Ql;;ACTIVE;1.0k;2.56 +14835-3;Methanol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methanol [Moles/volume] in Serum or Plasma;Methanol SerPl-sCnc;;ACTIVE;1.0k;2.73 +14836-1;Methotrexate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma;MTX SerPl-sCnc;;ACTIVE;1.0k;2.73 +1483-7;Galactose^post 40 g dose PO;MRat;5H;Urine;Qn;;CHAL;1;Galactose [Mass/time] in 5 hour Urine --post 40 g dose PO;Galactose p 40 g PO 5h Ur-mRate;;ACTIVE;1.0;2.44 +14837-9;Methsuximide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methsuximide [Moles/volume] in Serum or Plasma;Methsuximide SerPl-sCnc;;ACTIVE;1.0k;2.34 +14838-7;Toxoplasma gondii;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Toxoplasma gondii [Presence] in Tissue by Organism specific culture;T gondii Tiss Ql Cult;;ACTIVE;1.0k;2.56 +14839-5;Trypanosoma sp identified;Prid;Pt;Bld.buffy coat;Nom;Microscopy.light;MICRO;1;Trypanosoma sp identified in Buffy Coat by Light microscopy;Trypanos Buffy Coat Micro;;ACTIVE;1.0k;2.12 +14840-3;Trypanosoma sp identified;Prid;Pt;CSF;Nom;Wet preparation;MICRO;1;Trypanosoma sp identified in Cerebral spinal fluid by Wet preparation;Trypanos CSF Wet Prep;;ACTIVE;1.0k;1.0ma +14841-1;Microscopic observation;Prid;Pt;XXX;Nom;Iron hematoxylin stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Iron hematoxylin stain;IH Stn Spec;;ACTIVE;1.0k;2.69 +14842-9;Microscopic observation;Prid;Pt;XXX;Nom;Kinyoun iron hematoxylin stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Kinyoun iron hematoxylin stain;Kinyoun IH Stn Spec;;ACTIVE;1.0k;2.69 +14843-7;6-Monoacetylmorphine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Gastric fluid;6MAM Gast Ql;;ACTIVE;1.0k;2.56 +14844-5;6-Monoacetylmorphine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Serum or Plasma;6MAM SerPl Ql;;ACTIVE;1.0k;2.56 +1484-5;Gastrin^10M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --10 minutes post 0.2 U/kg secretin;Gastrin 10M p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0;2.34 +14845-2;6-Monoacetylmorphine;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Monoacetylmorphine [Presence] in Urine;Deprecated 6MAM Ur Ql;;DEPRECATED;1.0k;2.40 +14846-0;N-acetylprocainamide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;N-acetylprocainamide [Moles/volume] in Serum or Plasma;NAPA SerPl-sCnc;;ACTIVE;1.0k;2.34 +14847-8;Neutrophils/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Pericardial fluid by Manual count;Neutrophils/leuk NFr Pcar Manual;;ACTIVE;1.0k;2.73 +14848-6;Neutrophils/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Pleural fluid by Manual count;Neutrophils/leuk NFr Plr Manual;;ACTIVE;1.0k;2.73 +14849-4;Nitrazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitrazepam [Moles/volume] in Serum or Plasma;Nitrazepam SerPl-sCnc;;ACTIVE;1.0k;2.34 +14850-2;Nitrazepam;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nitrazepam [Moles/volume] in Urine;Nitrazepam Ur-sCnc;;ACTIVE;1.0k;2.42 +14851-0;Norclozapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norclozapine [Moles/volume] in Serum or Plasma;Norclozapine SerPl-sCnc;;ACTIVE;1.0k;2.34 +1485-2;Gastrin^15M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --15 minutes post 0.2 U/kg secretin;Gastrin 15M p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0;2.34 +14852-8;Norepinephrine;SCnc;Pt;Plas;Qn;;CHEM;1;Norepinephrine [Moles/volume] in Plasma;Norepineph Plas-sCnc;;ACTIVE;1.0k;2.73 +14853-6;Norepinephrine;SCnc;Pt;Urine;Qn;;CHEM;1;Norepinephrine [Moles/volume] in Urine;Norepineph Ur-sCnc;;ACTIVE;1.0k;2.73 +14854-4;Norepinephrine;SRat;24H;Urine;Qn;;CHEM;1;Norepinephrine [Moles/time] in 24 hour Urine;Norepineph 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14855-1;Norfluoxetine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norfluoxetine [Moles/volume] in Serum or Plasma;Norfluoxetine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14856-9;Nortriptyline;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortriptyline [Moles/volume] in Serum or Plasma;Nortrip SerPl-sCnc;;ACTIVE;1.0k;2.34 +14857-7;Leukocytes other/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Pericardial fluid by Manual count;WBC Other/leuk NFr Pcar Manual;;ACTIVE;1.0k;2.70 +14858-5;Leukocytes other/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Pleural fluid by Manual count;WBC Other/leuk NFr Plr Manual;;ACTIVE;1.0k;2.70 +14859-3;Leukocytes other/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Peritoneal fluid by Manual count;WBC Other/leuk NFr Prt Manual;;ACTIVE;1.0k;2.70 +1486-0;Gastrin^20M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --20 minutes post 0.2 U/kg secretin;Gastrin 20M p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0;2.34 +14860-1;Leukocytes other/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Synovial fluid by Manual count;WBC Other/leuk NFr Snv Manual;;ACTIVE;1.0k;2.73 +14861-9;Oxalate;PrThr;Pt;Calculus;Ord;;CHEM;1;Oxalate [Presence] in Stone;Oxalate Stone Ql;;ACTIVE;1.0k;2.56 +14862-7;Oxalate;SRat;24H;Urine;Qn;;CHEM;1;Oxalate [Moles/time] in 24 hour Urine;Oxalate 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14863-5;oxyCODONE;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;oxyCODONE [Presence] in Gastric fluid;oxyCODONE Gast Ql;;ACTIVE;1.0k;2.56 +14864-3;Oxygen;PPres;Pt;BldCo;Qn;;CHEM;1;Oxygen [Partial pressure] in Cord blood;pO2 BldCo;;ACTIVE;1.0k;2.73 +14865-0;Parathyrin;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Parathyrin [Interpretation] in Serum or Plasma;PTH SerPl-Imp;;ACTIVE;1.0k;2.73 +14866-8;Parathyrin.intact;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.intact [Moles/volume] in Serum or Plasma;PTH-Intact SerPl-sCnc;;ACTIVE;1.0k;2.73 +14867-6;PARoxetine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PARoxetine [Moles/volume] in Serum or Plasma;PARoxetine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14868-4;Pathologist report;Imp;Pt;Plas/RBC;Nom;;BLDBK;1;Pathologist report of Plasma or RBC tests;Path Report PlasRBC-Imp;;ACTIVE;1.0k;2.08 +14869-2;Pathologist review;Imp;Pt;Bld;Nom;Pathologist comment;BLDBK;1;Pathologist review of Blood tests;Path Rev Bld -Imp;;ACTIVE;1.0k;2.73 +148-7;Cephalexin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cephalexin [Susceptibility] by Minimum lethal concentration (MLC);Cephalexin Islt MLC;;ACTIVE;1.0;2.19 +14870-0;Pentacarboxylate;SCnc;Pt;Plas;Qn;;CHEM;1;Pentacarboxylate [Moles/volume] in Plasma;Pentacarboxylate Plas-sCnc;;ACTIVE;1.0k;2.34 +14871-8;Pentacarboxylate;SCnc;Pt;Stool;Qn;;CHEM;1;Pentacarboxylate [Moles/volume] in Stool;Pentacarboxylate Stl-sCnc;;ACTIVE;1.0k;2.42 +14872-6;Pentacarboxylate;SCnc;Pt;Urine;Qn;;CHEM;1;Pentacarboxylate [Moles/volume] in Urine;Pentacarboxylate Ur-sCnc;;ACTIVE;1.0k;2.42 +14873-4;pH;LsCnc;Pt;BldCo;Qn;;CHEM;1;pH of Cord blood;pH BldCo;;ACTIVE;1.0k;2.73 +14874-2;PHENobarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PHENobarbital [Moles/volume] in Serum or Plasma;Phenobarb SerPl-sCnc;;ACTIVE;1.0k;2.73 +14875-9;Phenylalanine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenylalanine [Moles/volume] in Serum or Plasma;Phe SerPl-sCnc;;ACTIVE;1.0k;2.73 +14876-7;Phenylpropanolamine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Phenylpropanolamine [Presence] in Gastric fluid;PPA Gast Ql;;ACTIVE;1.0k;2.56 +14877-5;Phenytoin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin [Moles/volume] in Serum or Plasma;Phenytoin SerPl-sCnc;;ACTIVE;1.0k;2.73 +1487-8;Gastrin^25M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --25 minutes post 0.2 U/kg secretin;Gastrin 25M p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0;2.34 +14878-3;Phosphate;PrThr;Pt;Calculus;Ord;;CHEM;1;Phosphate [Presence] in Stone;Phosphate Stone Ql;;ACTIVE;1.0k;2.56 +14879-1;Phosphate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphate [Moles/volume] in Serum or Plasma;Phosphate SerPl-sCnc;;ACTIVE;1.0k;2.73 +14880-9;Phosphate;SCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Phosphate [Molecules/volume] in Urine;Deprecated Phosphate Ur-sCnc;;DEPRECATED;1.0k;2.36 +14881-7;Phosphate;SRat;24H;Urine;Qn;;CHEM;1;Phosphate [Moles/time] in 24 hour Urine;Phosphate 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14882-5;Porphobilinogen;SRat;24H;Urine;Qn;;CHEM;1;Porphobilinogen [Moles/time] in 24 hour Urine;PBG 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14883-3;Porphyrins;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Porphyrins [Interpretation] in Serum or Plasma;Porphyrins SerPl-Imp;;ACTIVE;1.0k;2.73 +14884-1;Porphyrins;Imp;Pt;Stool;Nom;;CHEM;1;Porphyrins [Interpretation] in Stool;Porphyrins Stl-Imp;;ACTIVE;1.0k;2.73 +14885-8;Pregnanediol;SRat;24H;Urine;Qn;;CHEM;1;Pregnanediol [Moles/time] in 24 hour Urine;Pregnanediol 24h Ur-sRate;;ACTIVE;1.0k;2.42 +1488-6;Gastrin^30M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --30 minutes post 0.2 U/kg secretin;Gastrin 30M p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0;2.34 +14886-6;Pregnanetriol;SRat;24H;Urine;Qn;;CHEM;1;Pregnanetriol [Moles/time] in 24 hour Urine;Pregntrl 24h Ur-sRate;;ACTIVE;1.0k;2.58 +14887-4;Primidone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Primidone [Moles/volume] in Serum or Plasma;Primidone SerPl-sCnc;;ACTIVE;1.0k;2.73 +14888-2;Procainamide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procainamide [Moles/volume] in Serum or Plasma;Procainamide SerPl-sCnc;;ACTIVE;1.0k;2.34 +14889-0;Procainamide+N-acetylprocainamide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procainamide+N-acetylprocainamide [Moles/volume] in Serum or Plasma;Procainamide+NAPA SerPl-sCnc;;ACTIVE;1.0k;2.34 +14890-8;Progesterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Progesterone [Moles/volume] in Serum or Plasma;Progest SerPl-sCnc;;ACTIVE;1.0k;2.73 +14891-6;Propranolol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propranolol [Moles/volume] in Serum or Plasma;Propranolol SerPl-sCnc;;ACTIVE;1.0k;2.34 +14892-4;Propranolol;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propranolol [Moles/volume] in Urine;Propranolol Ur-sCnc;;ACTIVE;1.0k;2.42 +14893-2;Propranolol;SRat;24H;Urine;Qn;;DRUG/TOX;1;Propranolol [Moles/time] in 24 hour Urine;Propranolol 24h Ur-sRate;;ACTIVE;1.0k;2.42 +1489-4;Gastrin^5M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --5 minutes post 0.2 U/kg secretin;Gastrin 5M p 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0;2.34 +14894-0;Propylene glycol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Propylene glycol [Presence] in Serum or Plasma;Prop glycol SerPl Ql;;ACTIVE;1.0k;2.56 +14895-7;Protein pattern;Imp;Pt;Ser/Plas;Nom;Immunofixation;CHEM;1;Protein Fractions [Interpretation] in Serum or Plasma by Immunofixation;Prot Pattern SerPl IFE-Imp;;ACTIVE;1.0k;2.73 +14896-5;Protein pattern;Imp;Pt;Urine;Nom;Immunofixation;CHEM;1;Protein Fractions [Interpretation] in Urine by Immunofixation;Prot Pattern Ur IFE-Imp;;ACTIVE;1.0k;2.73 +14897-3;Protein;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Protein [Mass/volume] in Plasma;Deprecated Prot Plas-mCnc;;DEPRECATED;1.0k;2.40 +14898-1;Protriptyline;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Protriptyline [Moles/volume] in Serum or Plasma;Protrip SerPl-sCnc;;ACTIVE;1.0k;2.34 +14899-9;quiNIDine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNIDine [Moles/volume] in Serum or Plasma;quiNIDine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14900-5;raNITIdine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;raNITIdine [Presence] in Gastric fluid;raNITIdine Gast Ql;;ACTIVE;1.0k;2.56 +14901-3;raNITIdine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;raNITIdine [Presence] in Serum or Plasma;raNITIdine SerPl Ql;;ACTIVE;1.0k;2.56 +1490-2;Gastrin^pre 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --pre 0.2 U/kg secretin;Gastrin pre 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0;2.73 +14902-1;raNITIdine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;raNITIdine [Presence] in Urine;raNITIdine Ur Ql;;ACTIVE;1.0k;2.73 +14903-9;Folate;Imp;Pt;Bld;Nom;;CHEM;1;Folate [Interpretation] in Blood;Folate Bld-Imp;;ACTIVE;1.0k;2.26 +14904-7;Reagin Ab;PrThr;Pt;XXX;Ord;VDRL;MICRO;1;Reagin Ab [Presence] in Specimen by VDRL;VDRL Spec Ql;;ACTIVE;1.0k;2.73 +14905-4;Retinol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinol [Moles/volume] in Serum or Plasma;Vit A SerPl-sCnc;;ACTIVE;1.0k;2.73 +14906-2;Rh;Type;Pt;BldCo;Nom;;BLDBK;1;Rh [Type] in Cord blood;Rh BldCo;;ACTIVE;1.0k;2.73 +14907-0;Rh;Type;Pt;Bld^BPU;Nom;;BLDBK;1;Rh [Type] in Blood from Blood product unit;Rh Bld BPU;;ACTIVE;1.0k;2.73 +14908-8;Rh;Type;Pt;Bld^Newborn;Nom;;BLDBK;1;Rh [Type] in Blood from Newborn;Rh Bld NB;;ACTIVE;1.0k;2.73 +14909-6;Salicylates;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylates [Moles/volume] in Serum or Plasma;Salicylates SerPl-sCnc;;ACTIVE;1.0k;2.73 +1491-0;Glucose^30M post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --30 minutes post 100 g glucose PO;Glucose 30M p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +14910-4;Serotonin;SCnc;Pt;Ser;Qn;;CHEM;1;Serotonin [Moles/volume] in Serum;Serotonin Ser-sCnc;;ACTIVE;1.0k;2.34 +14911-2;Sertraline;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sertraline [Moles/volume] in Serum or Plasma;Sertraline SerPl-sCnc;;ACTIVE;1.0k;2.34 +14912-0;Smudge cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Smudge cells/100 leukocytes in Blood by Manual count;Smudge Cells/leuk NFr Bld Manual;;ACTIVE;1.0k;2.73 +14913-8;Testosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone [Moles/volume] in Serum or Plasma;Testost SerPl-sCnc;;ACTIVE;1.0k;2.73 +14914-6;Testosterone.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone Free [Moles/volume] in Serum or Plasma;Testost Free SerPl-sCnc;;ACTIVE;1.0k;2.73 +14915-3;Theophylline;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline [Moles/volume] in Serum or Plasma;Theophylline SerPl-sCnc;;ACTIVE;1.0k;2.73 +14916-1;Thiocyanate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thiocyanate [Moles/volume] in Serum or Plasma;Thiocyanate SerPl-sCnc;;ACTIVE;1.0k;2.34 +14917-9;Thioridazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thioridazine [Moles/volume] in Serum or Plasma;Thioridazine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14918-7;Thyroglobulin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroglobulin [Moles/volume] in Serum or Plasma;Thyroglob SerPl-sCnc;;ACTIVE;1.0k;2.34 +14919-5;Thyrotropin binding inhibitory immunoglobulins;PrThr;Pt;Ser;Ord;;CHEM;1;Thyrotropin binding inhibitory immunoglobulins [Presence] in Serum;TSH BII Ser Ql;;ACTIVE;1.0k;2.73 +14920-3;Thyroxine.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma;T4 Free SerPl-sCnc;;ACTIVE;1.0k;2.73 +14921-1;Thyroxine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4) [Moles/volume] in Serum or Plasma;T4 SerPl-sCnc;;ACTIVE;1.0k;2.73 +14922-9;Toxoplasma gondii Ab.IgA+IgE;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxoplasma gondii IgA+IgE Ab [Units/volume] in Serum by Immunoassay;T gondii IgA+IgE Ser IA-aCnc;;ACTIVE;1.0k;2.56 +14923-7;Toxoplasma gondii Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Toxoplasma gondii Ab [Units/volume] in Specimen;T gondii Ab Spec-aCnc;;ACTIVE;1.0k;2.69 +14924-5;Transfusion reaction;Imp;Pt;Plas/RBC;Nar;;BLDBK;1;Transfusion reaction [Interpretation] in Plasma or RBC Narrative;Transf React PlasRBC-Imp;;ACTIVE;1.0k;2.73 +14925-2;traZODone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;traZODone [Moles/volume] in Serum or Plasma;traZODone SerPl-sCnc;;ACTIVE;1.0k;2.34 +14926-0;Triazolam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triazolam [Moles/volume] in Serum or Plasma;Triazolam SerPl-sCnc;;ACTIVE;1.0k;2.34 +14927-8;Triglyceride;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride [Moles/volume] in Serum or Plasma;Trigl SerPl-sCnc;;ACTIVE;1.0k;2.73 +1492-8;Glucose^1.5H post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 0.5 g/kg glucose IV;Glucose 1.5h p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.34 +14928-6;Triiodothyronine.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma;T3Free SerPl-sCnc;;ACTIVE;1.0k;2.73 +14929-4;Triiodothyronine.reverse;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3).reverse [Moles/volume] in Serum or Plasma;T3Reverse SerPl-sCnc;;ACTIVE;1.0k;2.73 +14930-2;Triiodothyronine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma;T3 SerPl-sCnc;;ACTIVE;1.0k;2.73 +14931-0;Trimipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimipramine [Moles/volume] in Serum or Plasma;Trimipramine SerPl-sCnc;;ACTIVE;1.0k;2.34 +14932-8;Urate;PrThr;Pt;Calculus;Ord;;CHEM;1;Urate [Presence] in Stone;Urate Stone Ql;;ACTIVE;1.0k;2.73 +14933-6;Urate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urate [Moles/volume] in Serum or Plasma;Urate SerPl-sCnc;;ACTIVE;1.0k;2.73 +14934-4;Urate;SCnc;Pt;Urine;Qn;;CHEM;1;Urate [Moles/volume] in Urine;Urate Ur-sCnc;;ACTIVE;1.0k;2.73 +14935-1;Urate;SRat;24H;Urine;Qn;;CHEM;1;Urate [Moles/time] in 24 hour Urine;Urate 24h Ur-sRate;;ACTIVE;1.0k;2.73 +1493-6;Glucose^1.5H post 0.05-0.15 U insulin/kg IV post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 0.05-0.15 U insulin/kg IV 12 hours fasting;Glucose 1.5h p U/kg Ins IV SerPl-mCnc;;ACTIVE;1.0;2.34 +14936-9;Urea nitrogen;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Moles/volume] in Peritoneal dialysis fluid;Urea nit DiafP-sCnc;;ACTIVE;1.0k;2.70 +14937-7;Urea nitrogen;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Moles/volume] in Serum or Plasma;BUN SerPl-sCnc;;ACTIVE;1.0k;2.73 +14938-5;Urea nitrogen;SCnc;Pt;Urine;Qn;;CHEM;1;Urea nitrogen [Moles/volume] in Urine;UUN Ur-sCnc;;ACTIVE;1.0k;2.70 +14939-3;Urea nitrogen;SRat;24H;Urine;Qn;;CHEM;1;Urea nitrogen [Moles/time] in 24 hour Urine;UUN 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14940-1;Uroporphyrin 1 isomer;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Uroporphyrin 1 isomer [Moles/volume] in Serum or Plasma;Uropor1 SerPl-sCnc;;ACTIVE;1.0k;2.34 +14941-9;Uroporphyrin 1 isomer;SCnc;Pt;Stool;Qn;;CHEM;1;Uroporphyrin 1 isomer [Moles/volume] in Stool;Uropor1 Stl-sCnc;;ACTIVE;1.0k;2.42 +14942-7;Uroporphyrin 1 isomer;SCnc;Pt;Urine;Qn;;CHEM;1;Uroporphyrin 1 isomer [Moles/volume] in Urine;Uropor1 Ur-sCnc;;ACTIVE;1.0k;2.42 +14943-5;Uroporphyrin 3 isomer;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Uroporphyrin 3 isomer [Moles/volume] in Serum or Plasma;Uropor3 SerPl-sCnc;;ACTIVE;1.0k;2.34 +1494-4;Glucose^1.5H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 100 g glucose PO;Glucose 1.5h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.34 +14944-3;Uroporphyrin 3 isomer;SCnc;Pt;Stool;Qn;;CHEM;1;Uroporphyrin 3 isomer [Moles/volume] in Stool;Uropor3 Stl-sCnc;;ACTIVE;1.0k;2.42 +14945-0;Uroporphyrin 3 isomer;SCnc;Pt;Urine;Qn;;CHEM;1;Uroporphyrin 3 isomer [Moles/volume] in Urine;Uropor3 Ur-sCnc;;ACTIVE;1.0k;2.42 +14946-8;Valproate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate [Moles/volume] in Serum or Plasma;Valproate SerPl-sCnc;;ACTIVE;1.0k;2.73 +14947-6;Vanillylmandelate;SRat;24H;Urine;Qn;;CHEM;1;Vanillylmandelate [Moles/time] in 24 hour Urine;VMA 24h Ur-sRate;;ACTIVE;1.0k;2.73 +14948-4;Vanillylmandelate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Vanillylmandelate/Creatinine [Molar ratio] in Urine;VMA/Creat Ur-sRto;;ACTIVE;1.0k;2.73 +14949-2;Vasopressin;SCnc;Pt;Plas;Qn;;CHEM;1;Vasopressin [Moles/volume] in Plasma;Vasopressin Plas-sCnc;;ACTIVE;1.0k;2.73 +149-5;Cephalexin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cephalexin [Susceptibility] by Minimum inhibitory concentration (MIC);Cephalexin Islt MIC;;ACTIVE;1.0;2.19 +14950-0;Viscosity;Visc;Pt;Synv fld;Ord;;SPEC;1;Viscosity of Synovial fluid Qualitative;Visc Snv Ql;;ACTIVE;1.0k;2.73 +1495-1;Glucose^1.5H post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1.5 hours post 100 g glucose PO;Glucose 1.5h p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.34 +14951-8;Volatile drugs positive;Prid;Pt;Ser/Plas;Nom;Screen;DRUG/TOX;1;Volatile drugs positive [Identifier] in Serum or Plasma by Screen method;Volatile Drugs Pos SerPl Scn;;ACTIVE;1.0k;2.73 +14952-6;Xylose^1H post 25 g xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --1 hour post 25 g xylose PO;Xylose 1h p 25 g Xyl PO Bld-sCnc;;ACTIVE;1.0k;2.40 +14953-4;Xylose^2H post 25 g xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --2 hours post 25 g xylose PO;Xylose 2h p 25 g Xyl PO Bld-sCnc;;ACTIVE;1.0k;2.40 +14954-2;Xylose^post dose PO;SRat;5H;Urine;Qn;;CHAL;1;Xylose [Moles/time] in 5 hour Urine --post dose PO;Xylose p PO 5h Ur-sRate;;ACTIVE;1.0k;2.40 +14955-9;Zinc;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zinc [Moles/volume] in Serum or Plasma;Zinc SerPl-sCnc;;ACTIVE;1.0k;2.73 +14956-7;Albumin;MRat;24H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/time] in 24 hour Urine;Microalbumin 24h Ur-mRate;;ACTIVE;1.0k;2.73 +14957-5;Albumin;MCnc;Pt;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/volume] in Urine;Microalbumin Ur-mCnc;;ACTIVE;1.0k;2.73 +14958-3;Albumin/Creatinine;MRto;24H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin/Creatinine [Mass Ratio] in 24 hour Urine;Microalbumin/Creat 24h Ur;;ACTIVE;1.0k;2.73 +14959-1;Albumin/Creatinine;MRto;Pt;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin/Creatinine [Mass Ratio] in Urine;Microalbumin/Creat Ur;;ACTIVE;1.0k;2.73 +14960-9;Estradiol.free/Estradiol.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2) Free/Estradiol (E2).total in Serum or Plasma;Estradiol Free MFr SerPl;;ACTIVE;1.0k;2.73 +14961-7;Abnormal blood cells.CD10/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD10 Abnormal blood cells/Abnormal blood cells.total in Blood;CD10 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +14962-5;Abnormal blood cells.CD13/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD13 Abnormal blood cells/Abnormal blood cells.total in Blood;CD13 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +14963-3;Abnormal blood cells.CD14/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD14 Abnormal blood cells/Abnormal blood cells.total in Blood;CD14 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +14964-1;Abnormal blood cells.CD19/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19 Abnormal blood cells/Abnormal blood cells.total in Blood;CD19 Abn Bld Cells NFr;;ACTIVE;1.0k;2.73 +14965-8;Abnormal blood cells.CD2/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD2 Abnormal blood cells/Abnormal blood cells.total in Blood;CD2 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +14966-6;Abnormal blood cells.CD20/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20 Abnormal blood cells/Abnormal blood cells.total in Blood;CD20 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +14967-4;Abnormal blood cells.CD33/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD33 Abnormal blood cells/Abnormal blood cells.total in Blood;CD33 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +14968-2;Abnormal blood cells.CD5/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5 Abnormal blood cells/Abnormal blood cells.total in Blood;CD5 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +1496-9;Glucose^1.5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO;Glucose 1.5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +14969-0;Abnormal blood cells.CD7/Abnormal blood cells.total;NFr;Pt;Bld;Qn;;CELLMARK;1;CD7 Abnormal blood cells/Abnormal blood cells.total in Blood;CD7 Abn Bld Cells NFr;;ACTIVE;1.0k;2.70 +14970-8;Estrone.bioavailable;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrone (E1).bioavailable [Mass/volume] in Serum or Plasma;Estrone Bioavail SerPl-mCnc;;ACTIVE;1.0k;2.73 +14971-6;Estrone.bioavailable/Estrone.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Estrone (E1).bioavailable/Estrone (E1).total in Serum or Plasma;Estrone Bioavail MFr SerPl;;ACTIVE;1.0k;2.73 +14972-4;Mycobacterium sp DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Mycobacterium sp DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Mycobacterium DNA CSF Ql NAA+probe;;ACTIVE;1.0k;2.63 +14973-2;Mycobacterium sp DNA;PrThr;Pt;Sputum;Ord;Probe.amp.tar;MICRO;1;Mycobacterium sp DNA [Presence] in Sputum by NAA with probe detection;Mycobacterium DNA Spt Ql NAA+probe;;ACTIVE;1.0k;2.73 +14974-0;Mycobacterium sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium sp DNA [Presence] in Specimen by NAA with probe detection;Mycobacterium DNA Spec Ql NAA+probe;;ACTIVE;1.0k;2.73 +14975-7;Human antimouse Ab;MCnc;Pt;Ser;Qn;;SERO;1;Human antimouse Ab [Mass/volume] in Serum;Human Antimouse Ab Ser-mCnc;;ACTIVE;1.0k;2.73 +14976-5;Lecithin/Sphingomyelin;Ratio;Pt;Amnio fld;Qn;;CHEM;1;Lecithin/Sphingomyelin [Ratio] in Amniotic fluid;Lecithin/Sphingomyelin Amn-Rto;;ACTIVE;1.0k;2.73 +1497-7;Glucose^1.5H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose insulin IV;Glucose 1.5h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.73 +14977-3;Immunoglobulin light chains.free;Type;Pt;Urine;Nom;;CHEM;1;Immunoglobulin light chains.free [Type] in Urine;BJ Protein Free Ur;;ACTIVE;1.0k;2.26 +14978-1;cycloSPORINE;MCnc;Pt;Bld;Qn;IA;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood by Immunoassay;cycloSPORINE Bld IA-mCnc;;ACTIVE;1.0k;2.73 +14979-9;Coagulation surface induced;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay;aPTT PPP;;ACTIVE;1.0k;2.73 +14980-7;A variant subtype Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;A variant subtype Ab [Presence] in Serum or Plasma from Blood product unit;A Var Subtyp Ab SerPl BPU Ql;;ACTIVE;1.0k;2.56 +14981-5;A variant subtype Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;A variant subtype Ab [Presence] in Serum or Plasma from Donor;A Var Subtyp Ab SerPl Donr Ql;;ACTIVE;1.0k;2.56 +14982-3;A variant subtype Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;A variant subtype Ab [Presence] in Serum or Plasma;A Var Subtyp Ab SerPl Ql;;ACTIVE;1.0k;2.56 +14983-1;I (int) subtype;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;I (intermediate) subtype [Presence] on Red Blood Cells from Blood product unit;I (Int) Subtyp RBC BPU Ql;;ACTIVE;1.0k;2.56 +14984-9;I (int) subtype;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;I (intermediate) subtype [Presence] on Red Blood Cells from Donor;I (Int) Subtyp RBC Donr Ql;;ACTIVE;1.0k;2.56 +1498-5;Glucose^10M post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 minutes post 0.5 g/kg glucose IV;Glucose 10M p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.73 +14985-6;I (int) subtype;PrThr;Pt;RBC;Ord;;BLDBK;1;I (intermediate) subtype [Presence] on Red Blood Cells;I (Int) Subtyp RBC Ql;;ACTIVE;1.0k;2.56 +14986-4;little i-1 subtype;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little i-1 subtype [Presence] on Red Blood Cells from Blood product unit;little i1 subtype RBC BPU Ql;;ACTIVE;1.0k;2.56 +14987-2;little i-1 subtype;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little i-1 subtype [Presence] on Red Blood Cells from Donor;little i1 subtype RBC Donr Ql;;ACTIVE;1.0k;2.56 +14988-0;little i-1 subtype;PrThr;Pt;RBC;Ord;;BLDBK;1;little i-1 subtype [Presence] on Red Blood Cells;little i1 subtype RBC Ql;;ACTIVE;1.0k;2.56 +14989-8;little i-2 subtype;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little i-2 subtype [Presence] on Red Blood Cells from Blood product unit;little i2 subtype RBC BPU Ql;;ACTIVE;1.0k;2.56 +14990-6;little i-2 subtype;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little i-2 subtype [Presence] on Red Blood Cells from Donor;little i2 subtype RBC Donr Ql;;ACTIVE;1.0k;2.56 +14991-4;little i-2 subtype;PrThr;Pt;RBC;Ord;;BLDBK;1;little i-2 subtype [Presence] on Red Blood Cells;little i2 subtype RBC Ql;;ACTIVE;1.0k;2.56 +14992-2;O group;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;O group [Presence] on Red Blood Cells from Blood product unit;O Group RBC BPU Ql;;ACTIVE;1.0k;2.56 +1499-3;Glucose^1H post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post 0.5 g/kg glucose IV;Glucose 1h p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.73 +14993-0;O group;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;O group [Presence] on Red Blood Cells from Donor;O Group RBC Donr Ql;;ACTIVE;1.0k;2.56 +14994-8;O group;PrThr;Pt;RBC;Ord;;BLDBK;1;O group [Presence] on Red Blood Cells;O Group RBC Ql;;ACTIVE;1.0k;2.56 +14995-5;Glucose^2H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post 75 g glucose PO;Glucose 2h p 75 g Glc PO SerPl-sCnc;;ACTIVE;1.0k;2.73 +14996-3;Glucose^pre 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre 75 g glucose PO;Glucose pre 75 g Glc PO SerPl-sCnc;;ACTIVE;1.0k;2.34 +14997-1;Thyrotropin^30M post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --30 minutes post dose TRH IV;TSH 30M p TRH IV SerPl-aCnc;;ACTIVE;1.0k;2.73 +14998-9;Thyrotropin^1H post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1 hour post dose TRH IV;TSH 1h p TRH IV SerPl-aCnc;;ACTIVE;1.0k;2.73 +14999-7;Thyrotropin^baseline;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --baseline;TSH BS SerPl-aCnc;;ACTIVE;1.0k;2.73 +15000-3;Thyrotropin^pre dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --pre dose TRH IV;TSH pre TRH IV SerPl-aCnc;;ACTIVE;1.0k;2.73 +15001-1;Xylose^1H post 25 g xylose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --1 hour post 25 g xylose PO;Xylose 1h p 25 g Xyl PO SerPl-sCnc;;ACTIVE;1.0k;2.34 +15002-9;Xylose^2H post 25 g xylose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --2 hours post 25 g xylose PO;Xylose 2h p 25 g Xyl PO SerPl-sCnc;;ACTIVE;1.0k;2.34 +15003-7;11-Hydroxyandrosterone;SRat;24H;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone [Moles/time] in 24 hour Urine;11OH-Androst 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15004-5;11-Hydroxyetiocholanolone;SRat;24H;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone [Moles/time] in 24 hour Urine;11OH-Etioch 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15005-2;11-Ketoandrosterone;SRat;24H;Urine;Qn;;CHEM;1;11-Ketoandrosterone [Moles/time] in 24 hour Urine;11Ketoandros 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15006-0;11-Ketoetiocholanolone;SRat;24H;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone [Moles/time] in 24 hour Urine;11Ketoetioch 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15007-8;2,3-Diphosphoglycerate;SCnc;Pt;RBC;Qn;;CHEM;1;2,3-Diphosphoglycerate [Moles/volume] in Red Blood Cells;2,3DPG RBC-sCnc;;ACTIVE;1.0k;2.34 +1500-8;Glucose^1H post 0.05-0.15 U insulin/kg IV post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post 0.05-0.15 U insulin/kg IV post 12H CFst;Glucose 1h p U/kg Ins IV SerPl-mCnc;;ACTIVE;1.0;2.34 +15008-6;3-Alpha-Androstanediol glucuronide;SCnc;Pt;Ser;Qn;;CHEM;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Serum;3A-diol G Ser-sCnc;;ACTIVE;1.0k;2.73 +15009-4;5-Hydroxyindoleacetate;SCnc;Pt;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate [Moles/volume] in Urine;5OH-indoleacetate Ur-sCnc;;ACTIVE;1.0k;2.73 +15010-2;Aldosterone;SCnc;Pt;Urine;Qn;;CHEM;1;Aldosterone [Moles/volume] in Urine;Aldost Ur-sCnc;;ACTIVE;1.0k;2.70 +15011-0;Aldosterone^supine;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --supine;Aldost sup SerPl-sCnc;;ACTIVE;1.0k;2.70 +15012-8;Aldosterone^upright;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aldosterone [Moles/volume] in Serum or Plasma --upright;Aldost upr SerPl-sCnc;;ACTIVE;1.0k;2.70 +15013-6;Alkaline phosphatase.bone/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.bone/Alkaline phosphatase.total in Serum or Plasma;ALP Bone CFr SerPl;;ACTIVE;1.0k;2.73 +15014-4;Alkaline phosphatase.intestinal/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.intestinal/Alkaline phosphatase.total in Serum or Plasma;ALP Intest CFr SerPl;;ACTIVE;1.0k;2.73 +15015-1;Alkaline phosphatase.liver/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.liver/Alkaline phosphatase.total in Serum or Plasma;ALP Liver CFr SerPl;;ACTIVE;1.0k;2.73 +1501-6;Glucose^1H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post 100 g glucose PO;Glucose 1h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15016-9;Alkaline phosphatase.placental/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.placental/Alkaline phosphatase.total in Serum or Plasma;ALP Plac CFr SerPl;;ACTIVE;1.0k;2.73 +15017-7;Alkaline phosphatase.regan/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.regan/Alkaline phosphatase.total in Serum or Plasma;ALP Regan CFr SerPl;;ACTIVE;1.0k;2.70 +15018-5;Alkaline phosphatase.renal/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.renal/Alkaline phosphatase.total in Serum or Plasma;ALP Renal CFr SerPl;;ACTIVE;1.0k;2.70 +15019-3;Alpha-1-Fetoprotein;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Moles/volume] in Amniotic fluid;AFP Amn-sCnc;;ACTIVE;1.0k;2.73 +15020-1;Amylase.P1/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.P1/Amylase.total in Serum or Plasma;Amylase P1 CFr SerPl;;ACTIVE;1.0k;2.73 +15021-9;Amylase.P2/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.P2/Amylase.total in Serum or Plasma;Amylase P2 CFr SerPl;;ACTIVE;1.0k;2.73 +15022-7;Amylase.P3/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.P3/Amylase.total in Serum or Plasma;Amylase P3 CFr SerPl;;ACTIVE;1.0k;2.73 +15023-5;Amylase.S1/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S1/Amylase.total in Serum or Plasma;Amylase S1 CFr SerPl;;ACTIVE;1.0k;2.73 +1502-4;Glucose^1H post 100 g glucose PO;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --1 hour post 100 g glucose PO;Deprecated Glucose 1H p 100 g Glc PO Ser;;DEPRECATED;1.0;2.36 +15024-3;Amylase.S2/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S2/Amylase.total in Serum or Plasma;Amylase S2 CFr SerPl;;ACTIVE;1.0k;2.73 +15025-0;Amylase.S3/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S3/Amylase.total in Serum or Plasma;Amylase S3 CFr SerPl;;ACTIVE;1.0k;2.73 +15026-8;Androstanediol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstanediol [Moles/volume] in Serum or Plasma;Androstanediol SerPl-sCnc;;ACTIVE;1.0k;2.40 +15027-6;Androstenedione;SCnc;Pt;Urine;Qn;;CHEM;1;Androstenedione [Moles/volume] in Urine;Androst Ur-sCnc;;ACTIVE;1.0k;2.42 +15028-4;Androstenedione;SRat;24H;Urine;Qn;;CHEM;1;Androstenedione [Moles/time] in 24 hour Urine;Androst 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15029-2;Androsterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androsterone [Moles/volume] in Serum or Plasma;Androsterone SerPl-sCnc;;ACTIVE;1.0k;2.40 +150-3;Cephalexin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cephalexin [Susceptibility] by Disk diffusion (KB);Cephalexin Islt KB;;ACTIVE;1.0;2.21 +15030-0;Androsterone;SRat;24H;Urine;Qn;;CHEM;1;Androsterone [Moles/time] in 24 hour Urine;Androsterone 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15031-8;Angiotensin I;SCnc;Pt;Plas;Qn;;CHEM;1;Angiotensin I [Moles/volume] in Plasma;Angiotensin I Plas-sCnc;;ACTIVE;1.0k;2.73 +1503-2;Glucose^1H post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1 hour post 100 g glucose PO;Glucose 1h p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15032-6;Angiotensin II;SCnc;Pt;Plas;Qn;;CHEM;1;Angiotensin II [Moles/volume] in Plasma;Angiotensin II Plas-sCnc;;ACTIVE;1.0k;2.42 +15033-4;Ascorbate;SRat;24H;Urine;Qn;;CHEM;1;Ascorbate [Moles/time] in 24 hour Urine;Vit C 24h Ur-sRate;;ACTIVE;1.0k;2.40 +15034-2;Bromide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromide [Moles/volume] in Serum or Plasma;Bromide SerPl-sCnc;;ACTIVE;1.0k;2.73 +15035-9;Calcitonin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcitonin [Moles/volume] in Serum or Plasma;Calcit SerPl-sCnc;;ACTIVE;1.0k;2.73 +15036-7;Catecholamines;SRat;24H;Urine;Qn;;CHEM;1;Catecholamines [Moles/time] in 24 hour Urine;Catechols 24h Ur-sRate;;ACTIVE;1.0k;2.50 +15037-5;Chymotrypsin;SCnt;Pt;Stool;Qn;;CHEM;1;Chymotrypsin [Moles/mass] in Stool;Chymotryp Stl-sCnt;;ACTIVE;1.0k;2.42 +15038-3;Citrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Citrate [Moles/volume] in Serum or Plasma;Citrate SerPl-sCnc;;ACTIVE;1.0k;2.73 +15039-1;Cobalamin;SCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Cobalamin [Molecules/volume] in Serum;Deprecated Cobalamin Ser-sCnc;;DEPRECATED;1.0k;2.36 +1504-0;Glucose^1H post 50 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO;Glucose 1h p 50 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15040-9;Coproporphyrin;SRat;24H;Stool;Qn;;CHEM;1;Coproporphyrin [Moles/time] in 24 hour Stool;Copro 24h Stl-sRate;;ACTIVE;1.0k;2.42 +15041-7;Coproporphyrin;SRat;24H;Urine;Qn;;CHEM;1;Coproporphyrin [Moles/time] in 24 hour Urine;Copro 24h Ur-sRate;;ACTIVE;1.0k;2.73 +15042-5;Corticotropin;ACnc;Pt;Ser;Qn;;CHEM;1;Corticotropin [Units/volume] in Serum;ACTH Ser-aCnc;;DISCOURAGED;1.0k;2.69 +15043-3;Cortisol;SCnc;Pt;Urine;Qn;;CHEM;1;Cortisol [Moles/volume] in Urine;Cortis Ur-sCnc;;ACTIVE;1.0k;2.73 +15044-1;Cortisol.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol Free [Moles/volume] in Serum or Plasma;Cortis F SerPl-sCnc;;ACTIVE;1.0k;2.73 +15045-8;Creatine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatine [Moles/volume] in Serum or Plasma;Creatine SerPl-sCnc;;ACTIVE;1.0k;2.73 +15046-6;Creatine;SCnc;Pt;Urine;Qn;;CHEM;1;Creatine [Moles/volume] in Urine;Creatine Ur-sCnc;;ACTIVE;1.0k;2.73 +15047-4;Creatine;SRat;24H;Urine;Qn;;CHEM;1;Creatine [Moles/time] in 24 hour Urine;Creatine 24h Ur-sRate;;ACTIVE;1.0k;2.73 +15048-2;Creatine kinase.BB/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.BB/Creatine kinase.total in Serum or Plasma by Electrophoresis;CK BB CFr SerPl Elph;;ACTIVE;1.0k;2.73 +15049-0;Creatine kinase.MM/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.MM/Creatine kinase.total in Serum or Plasma by Electrophoresis;CK MM CFr SerPl Elph;;ACTIVE;1.0k;2.73 +15050-8;Creatinine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Amniotic fluid;Creat Amn-sCnc;;ACTIVE;1.0k;2.73 +15051-6;Creatinine;SCnc;Pt;Dial fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Dialysis fluid;Creat Dial fld-sCnc;;ACTIVE;1.0k;2.70 +15052-4;Cobalamins.unsaturated binding capacity;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cobalamin (Vitamin B12).unsaturated Binding Capacity [Moles/volume] in Serum or Plasma;Vit B12 USB SerPl-sCnc;;ACTIVE;1.0k;2.38 +15053-2;Dehydroepiandrosterone sulfate;SRat;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Moles/time] in 24 hour Urine;DHEA-S 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15054-0;Dehydroepiandrosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Moles/volume] in Serum or Plasma;DHEA SerPl-sCnc;;ACTIVE;1.0k;2.73 +15055-7;Deoxypyridinoline;SRat;24H;Urine;Qn;;CHEM;1;Deoxypyridinoline [Moles/time] in 24 hour Urine;DPD 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15056-5;Deoxypyridinoline;SRat;24H;Urine;Qn;;CHEM;1;Deprecated Deoxypyridinoline [Molecules/time] in 24 hour Urine;Deprecated DPD 24H Ur-sRate;;DEPRECATED;1.0k;2.36 +1505-7;Glucose^1H post 50 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1 hour post 50 g glucose PO;Glucose 1h p 50 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15057-3;Androstanolone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstanolone [Moles/volume] in Serum or Plasma;Androstanolone SerPl-sCnc;;ACTIVE;1.0k;2.73 +15058-1;DOPamine;SCnc;Pt;Urine;Qn;;CHEM;1;DOPamine [Moles/volume] in Urine;DOPamine Ur-sCnc;;ACTIVE;1.0k;2.73 +15059-9;DOPamine;SRat;24H;Urine;Qn;;CHEM;1;DOPamine [Moles/time] in 24 hour Urine;DOPamine 24h Ur-sRate;;ACTIVE;1.0k;2.73 +15060-7;Enolase.neuron specific;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Enolase.neuron specific [Mass/volume] in Serum or Plasma;NSE SerPl-mCnc;;ACTIVE;1.0k;2.73 +15061-5;Erythropoietin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Erythropoietin (EPO) [Units/volume] in Serum or Plasma;EPO SerPl-aCnc;;ACTIVE;1.0k;2.73 +15062-3;Estradiol.unconjugated;SRat;24H;Urine;Qn;;CHEM;1;Estradiol (E2).unconjugated [Moles/time] in 24 hour Urine;u Estradiol 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15063-1;Estriol.conjugated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3).conjugated [Moles/volume] in Serum or Plasma;Estriol Conj SerPl-sCnc;;ACTIVE;1.0k;2.40 +15064-9;Estriol.unconjugated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3).unconjugated [Moles/volume] in Serum or Plasma;u Estriol SerPl-sCnc;;ACTIVE;1.0k;2.73 +1506-5;Glucose^1H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g lactose PO;Glucose 1h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15065-6;Etiocholanolone;SRat;24H;Urine;Qn;;CHEM;1;Etiocholanolone [Moles/time] in 24 hour Urine;Etiocholanolone 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15066-4;Fatty acids.nonesterified;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma;NEFA SerPl-sCnc;;ACTIVE;1.0k;2.73 +15067-2;Follitropin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin [Units/volume] in Serum or Plasma;FSH SerPl-aCnc;;ACTIVE;1.0k;2.73 +15068-0;Follitropin;ARat;24H;Urine;Qn;;CHEM;1;Follitropin [Units] in 24 hour Urine;FSH 24h Ur;;ACTIVE;1.0k;2.73 +15069-8;Fructosamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fructosamine [Moles/volume] in Serum or Plasma;Fructosamine SerPl-sCnc;;ACTIVE;1.0k;2.73 +15070-6;Fructose;SRat;24H;Urine;Qn;;CHEM;1;Fructose [Moles/time] in 24 hour Urine;Fructose 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15071-4;Galactose;SRat;24H;Urine;Qn;;CHEM;1;Galactose [Moles/time] in 24 hour Urine;Galactose 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15072-2;Gastrin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gastrin [Moles/volume] in Serum or Plasma;Gastrin SerPl-sCnc;;ACTIVE;1.0k;2.73 +1507-3;Glucose^1H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post 75 g glucose PO;Glucose 1h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15073-0;Glucagon;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucagon [Moles/volume] in Serum or Plasma;Glucagon SerPl-sCnc;;ACTIVE;1.0k;2.40 +15074-8;Glucose;SCnc;Pt;Bld;Qn;;CHEM;1;Glucose [Moles/volume] in Blood;Glucose Bld-sCnc;;ACTIVE;1.0k;2.73 +15075-5;Glucose;SCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Moles/volume] in Dialysis fluid;Glucose Dial fld-sCnc;;ACTIVE;1.0k;2.73 +15076-3;Glucose;SCnc;Pt;Urine;Qn;;CHEM;1;Glucose [Moles/volume] in Urine;Glucose Ur-sCnc;;ACTIVE;1.0k;2.73 +15077-1;Glucose;SRat;24H;Urine;Qn;;CHEM;1;Glucose [Moles/time] in 24 hour Urine;Glucose 24h Ur-sRate;;ACTIVE;1.0k;2.73 +15078-9;Lactate;SRat;24H;Urine;Qn;;CHEM;1;Lactate [Moles/time] in 24 hour Urine;Lactate 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15079-7;Lutropin;ACnc;Pt;Urine;Qn;;CHEM;1;Lutropin [Units/volume] in Urine;LH Ur-aCnc;;ACTIVE;1.0k;2.44 +15080-5;Lutropin;ARat;24H;Urine;Qn;;CHEM;1;Lutropin [Units] in 24 hour Urine;LH 24h Ur;;ACTIVE;1.0k;2.66 +1508-1;Glucose^1H post 75 g glucose PO;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --1 hour post 75 g glucose PO;Deprecated Glucose 1H p 75 g Glc PO Ser-;;DEPRECATED;1.0;2.36 +15081-3;Prolactin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin [Units/volume] in Serum or Plasma;Prolactin SerPl-aCnc;;ACTIVE;1.0k;2.73 +15082-1;Methemoglobin;MCnc;Pt;Bld;Qn;;CHEM;1;Methemoglobin [Mass/volume] in Blood;MetHgb Bld-mCnc;;ACTIVE;1.0k;2.73 +15083-9;Normetanephrine;SRat;24H;Urine;Qn;;CHEM;1;Normetanephrine [Moles/time] in 24 hour Urine;Normetanephrine 24h Ur-sRate;;ACTIVE;1.0k;2.73 +15084-7;Osteocalcin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Osteocalcin [Moles/volume] in Serum or Plasma;Osteocalcin SerPl-sCnc;;ACTIVE;1.0k;2.70 +15085-4;Oxalate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Oxalate [Moles/volume] in Serum or Plasma;Oxalate SerPl-sCnc;;ACTIVE;1.0k;2.73 +15086-2;Oxalate;SCnc;Pt;Urine;Qn;;CHEM;1;Oxalate [Moles/volume] in Urine;Oxalate Ur-sCnc;;ACTIVE;1.0k;2.73 +15087-0;Parathyrin related protein;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin related protein [Moles/volume] in Serum or Plasma;PTH Related Prot SerPl-sCnc;;ACTIVE;1.0k;2.73 +15088-8;Parathyrin.C-terminal;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.C-terminal [Moles/volume] in Serum or Plasma;PTH-C SerPl-sCnc;;ACTIVE;1.0k;2.40 +15089-6;Phospholipid;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phospholipid [Moles/volume] in Serum or Plasma;Phospholipid SerPl-sCnc;;ACTIVE;1.0k;2.40 +15090-4;Porphyrins;SRat;24H;Stool;Qn;;CHEM;1;Porphyrins [Moles/time] in 24 hour Stool;Porphyrins 24h Stl-sRate;;ACTIVE;1.0k;2.42 +15091-2;Pregnanediol;SCnc;Pt;Urine;Qn;;CHEM;1;Pregnanediol [Moles/volume] in Urine;Pregnanediol Ur-sCnc;;ACTIVE;1.0k;2.42 +15092-0;Pregnanetriol;SCnc;Pt;Urine;Qn;;CHEM;1;Pregnanetriol [Moles/volume] in Urine;Pregntrl Ur-sCnc;;ACTIVE;1.0k;2.58 +15093-8;Protoporphyrin.free;SCnc;Pt;Bld;Qn;;CHEM;1;Protoporphyrin Free [Moles/volume] in Blood;FEP Bld-sCnc;;ACTIVE;1.0k;2.73 +15094-6;Testosterone;SCnc;Pt;Urine;Qn;;CHEM;1;Testosterone [Moles/volume] in Urine;Testost Ur-sCnc;;ACTIVE;1.0k;2.42 +15095-3;Testosterone;SRat;24H;Urine;Qn;;CHEM;1;Testosterone [Moles/time] in 24 hour Urine;Testost 24h Ur-sRate;;ACTIVE;1.0k;2.42 +15096-1;Uroporphyrin;SRat;24H;Urine;Qn;;CHEM;1;Uroporphyrin [Moles/time] in 24 hour Urine;Uropor 24h Ur-sRate;;ACTIVE;1.0k;2.73 +15097-9;Vanillylmandelate;SCnc;Pt;Urine;Qn;;CHEM;1;Vanillylmandelate [Moles/volume] in Urine;VMA Ur-sCnc;;ACTIVE;1.0k;2.73 +15098-7;Amikacin^random;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Moles/volume] in Serum or Plasma --random;Amikacin Rand SerPl-sCnc;;DISCOURAGED;1.0k;2.73 +1509-9;Glucose^1H post 75 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1 hour post 75 g glucose PO;Glucose 1h p 75 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15099-5;Amiodarone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amiodarone [Moles/volume] in Serum or Plasma;Amiodarone SerPl-sCnc;;ACTIVE;1.0k;2.73 +15100-1;Barbiturates;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Barbiturates [Moles/volume] in Serum or Plasma;Barbiturates SerPl-sCnc;;ACTIVE;1.0k;2.34 +15101-9;Chloramphenicol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloramphenicol [Moles/volume] in Serum or Plasma;Chloramphen SerPl-sCnc;;ACTIVE;1.0k;2.34 +15102-7;Codeine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Codeine [Moles/volume] in Serum or Plasma;Codeine SerPl-sCnc;;ACTIVE;1.0k;2.40 +15103-5;cycloSPORINE;SCnc;Pt;Ser;Qn;;DRUG/TOX;1;cycloSPORINE [Moles/volume] in Serum;cycloSPORINE Ser-sCnc;;DISCOURAGED;1.0k;2.73 +15104-3;Digitoxin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digitoxin [Moles/volume] in Serum or Plasma;Digitoxin SerPl-sCnc;;ACTIVE;1.0k;2.42 +15105-0;Flecainide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flecainide [Moles/volume] in Serum or Plasma;Flecainide SerPl-sCnc;;ACTIVE;1.0k;2.42 +15106-8;Gentamicin^random;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Moles/volume] in Serum or Plasma --random;Gentamicin Rand SerPl-sCnc;;DISCOURAGED;1.0k;2.73 +1510-7;Glucose^1H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV;Glucose 1h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15107-6;Imipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imipramine [Moles/volume] in Serum or Plasma;Imipramine SerPl-sCnc;;ACTIVE;1.0k;2.34 +15108-4;Methadone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methadone [Moles/volume] in Serum or Plasma;Methadone SerPl-sCnc;;ACTIVE;1.0k;2.73 +15109-2;Midazolam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Midazolam [Moles/volume] in Serum or Plasma;Midazolam SerPl-sCnc;;ACTIVE;1.0k;2.42 +151-1;Cephalexin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cephalexin [Susceptibility] by Serum bactericidal titer;Cephalexin Titr SBT;;ACTIVE;1.0;2.32 +15110-0;Morphine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Morphine [Moles/volume] in Serum or Plasma;Morphine SerPl-sCnc;;ACTIVE;1.0k;2.73 +15111-8;Tricyclic antidepressants;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tricyclic antidepressants [Moles/volume] in Serum or Plasma;Tricyclics SerPl-sCnc;;ACTIVE;1.0k;2.34 +15112-6;Phosphatase.leukocyte;ACnc;Pt;WBC;Qn;;HEM/BC;1;Leukocyte phosphatase [Units/volume] in Leukocytes;LAP WBC-aCnc;;ACTIVE;1.0k;2.73 +15113-4;Aluminum;SCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Dialysis fluid;Aluminum Dial fld-sCnc;;ACTIVE;1.0k;2.42 +15114-2;Arsenic;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Arsenic [Moles/volume] in Blood;Arsenic Bld-sCnc;;ACTIVE;1.0k;2.73 +1511-5;Glucose^1H post dose U/kg insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV;Deprecated Glucose 1H p U/kg Ins IV Plas;;DEPRECATED;1.0;2.36 +15115-9;Arsenic;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic [Moles/volume] in Urine;Arsenic Ur-sCnc;;ACTIVE;1.0k;2.34 +15116-7;Arsenic;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Arsenic [Molecules/volume] in Urine;Deprecated Arsenic Ur-sCnc;;DEPRECATED;1.0k;2.36 +15117-5;Cadmium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cadmium [Moles/volume] in Blood;Cadmium Bld-sCnc;;ACTIVE;1.0k;2.34 +15118-3;Chromium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chromium [Moles/volume] in Blood;Chromium Bld-sCnc;;ACTIVE;1.0k;2.34 +15119-1;Cobalt;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cobalt [Moles/volume] in Blood;Cobalt Bld-sCnc;;ACTIVE;1.0k;2.73 +15120-9;Ethanol;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethanol [Moles/volume] in Blood;Ethanol Bld-sCnc;;ACTIVE;1.0k;2.73 +15121-7;Lipoprotein.alpha/Lipoprotein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.alpha/total Lipoprotein in Serum or Plasma;HDL MFr SerPl;;ACTIVE;1.0k;2.73 +15122-5;Lipoprotein.beta/Lipoprotein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.beta/total Lipoprotein in Serum or Plasma;LDL MFr SerPl;;ACTIVE;1.0k;2.73 +1512-3;Glucose^1M post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 minute post 0.5 g/kg glucose IV;Glucose 1M p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.34 +15123-3;Lipoprotein.pre-beta/Lipoprotein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.pre-beta/total Lipoprotein in Serum or Plasma;VLDL MFr SerPl;;ACTIVE;1.0k;2.73 +15124-1;Albumin/Protein.total;MFr;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total in Synovial fluid by Electrophoresis;Albumin MFr Snv Elph;;ACTIVE;1.0k;2.70 +15125-8;Alpha 1 globulin/Protein.total;MFr;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total in Synovial fluid by Electrophoresis;Alpha1 Glob MFr Snv Elph;;ACTIVE;1.0k;2.70 +15126-6;Alpha 2 globulin/Protein.total;MFr;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total in Synovial fluid by Electrophoresis;Alpha2 Glob MFr Snv Elph;;ACTIVE;1.0k;2.70 +15127-4;Beta globulin/Protein.total;MFr;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total in Synovial fluid by Electrophoresis;B-Globulin MFr Snv Elph;;ACTIVE;1.0k;2.70 +15128-2;Gamma globulin/Protein.total;MFr;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total in Synovial fluid by Electrophoresis;Gamma glob MFr Snv Elph;;ACTIVE;1.0k;2.70 +15129-0;Fibrin D-dimer;MCnc;Pt;PPP;Qn;EIA;COAG;1;Deprecated Fibrin D-dimer EIA;Deprecated D Dimer PPP EIA-mCnc;;DEPRECATED;1.0k;2.36 +15130-8;Methionine+Tryptophan;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Methionine+Tryptophan [Presence] in Serum or Plasma;Met+Trp SerPl Ql;;ACTIVE;1.0k;2.73 +1513-1;Glucose^20M post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20 minutes post 0.5 g/kg glucose IV;Glucose 20M p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.34 +15131-6;Isoleucine+Leucine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Isoleucine+Leucine [Presence] in Serum or Plasma;Ile+Leu SerPl Ql;;ACTIVE;1.0k;2.73 +15132-4;Beta aminoisobutyrate+Proline;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Beta aminoisobutyrate+Proline [Presence] in Serum or Plasma;B-AIB+Pro SerPl Ql;;ACTIVE;1.0k;2.73 +15133-2;Anserine+Carnosine+Cysteine+Histidine+Ornithine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Anserine+Carnosine+Cysteine+Histidine+Ornithine [Presence] in Serum or Plasma;Amino Acids mixE SerPl Ql;;ACTIVE;1.0k;2.73 +15134-0;Glutamate+Glutamine+Threonine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Glutamate+Glutamine+Threonine [Presence] in Serum or Plasma;Glu+Gln+Thr SerPl Ql;;ACTIVE;1.0k;2.73 +15135-7;Aspartate+Citrulline+Glycine+Homocystine+Hydroxyproline;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Aspartate+Citrulline+Glycine+Homocystine+Hydroxyproline [Presence] in Serum or Plasma;Amino Acids mixD SerPl Ql;;ACTIVE;1.0k;2.73 +15136-5;Arginine+Argininosuccinate+Lysine+Serine+Taurine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Arginine+Argininosuccinate+Lysine+Serine+Taurine [Presence] in Serum or Plasma;Amino Acids mixC SerPl Ql;;ACTIVE;1.0k;2.73 +15137-3;Alanine+Ethanolamine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alanine+Ethanolamine [Presence] in Serum or Plasma;Ala+Etn SerPl Ql;;ACTIVE;1.0k;2.73 +15138-1;Isoleucine+Leucine;PrThr;Pt;Urine;Ord;;CHEM;1;Isoleucine+Leucine [Presence] in Urine;Ile+Leu Ur Ql;;ACTIVE;1.0k;2.73 +15139-9;Anserine+Carnosine+Cysteine+Histidine+Ornithine;PrThr;Pt;Urine;Ord;;CHEM;1;Anserine+Carnosine+Cysteine+Histidine+Ornithine [Presence] in Urine;Amino Acids mixE Ur Ql;;ACTIVE;1.0k;2.73 +15140-7;Arginine+Argininosuccinate+Lysine+Serine+Taurine;PrThr;Pt;Urine;Ord;;CHEM;1;Arginine+Argininosuccinate+Lysine+Serine+Taurine [Presence] in Urine;Amino Acids mixC Ur Ql;;ACTIVE;1.0k;2.73 +15141-5;Beta aminoisobutyrate+Proline;PrThr;Pt;Urine;Ord;;CHEM;1;Beta aminoisobutyrate+Proline [Presence] in Urine;B-AIB+Pro Ur Ql;;ACTIVE;1.0k;2.73 +15142-3;Alanine+Ethanolamine;PrThr;Pt;Urine;Ord;;CHEM;1;Alanine+Ethanolamine [Presence] in Urine;Ala+Etn Ur Ql;;ACTIVE;1.0k;2.73 +15143-1;Aspartate+Citrulline+Glycine+Homocystine+Hydroxyproline;PrThr;Pt;Urine;Ord;;CHEM;1;Aspartate+Citrulline+Glycine+Homocystine+Hydroxyproline [Presence] in Urine;Amino Acids mixD Ur Ql;;ACTIVE;1.0k;2.73 +15144-9;Glutamate+Glutamine+Threonine;PrThr;Pt;Urine;Ord;;CHEM;1;Glutamate+Glutamine+Threonine [Presence] in Urine;Glu+Gln+Thr Ur Ql;;ACTIVE;1.0k;2.73 +15145-6;Methionine+Tryptophan;PrThr;Pt;Urine;Ord;;CHEM;1;Methionine+Tryptophan [Presence] in Urine;Met+Trp Ur Ql;;ACTIVE;1.0k;2.73 +15146-4;Acetone;ACnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acetone [Units/volume] in Body fluid;Acetone Fld-aCnc;;DISCOURAGED;1.0k;2.69 +15147-2;Acetone;ARat;24H;Urine;Ord;;DRUG/TOX;1;Deprecated Acetone [Units] in 24 hour Urine Qualitative;Deprecated Acetone 24h Ur;;DEPRECATED;1.0k;2.40 +15148-0;Alkaline phosphatase;CCnc;Pt;Body fld;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Body fluid;ALP Fld-cCnc;;ACTIVE;1.0k;2.73 +1514-9;Glucose^2H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post 100 g glucose PO;Glucose 2h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15149-8;Ammonia;SCnc;Pt;Body fld;Qn;;CHEM;1;Ammonia [Moles/volume] in Body fluid;Ammonia Fld-sCnc;;ACTIVE;1.0k;2.73 +15150-6;Anisocytosis;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Anisocytosis [Presence] in Blood by Automated count;Anisocytosis Bld Ql Auto;;ACTIVE;1.0k;2.73 +15151-4;Aspergillus fumigatus 3 Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus fumigatus 3 Ab [Presence] in Serum by Immune diffusion (ID);A fumigatus3 Ab Ser Ql ID;;ACTIVE;1.0k;2.73 +15152-2;Bilirubin.glucuronidated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.conjugated [Mass/volume] in Serum or Plasma;Bilirub Conj SerPl-mCnc;;ACTIVE;1.0k;2.73 +15153-0;Bilirubin.non-glucuronidated;MCnc;Pt;Ser/Plas;Qn;Differential light absorption;CHEM;1;Deprecated Indirect bilirubin [Mass/volume] in Serum or Plasma;Deprecated Bilirub Indirect SerPl-mCnc;;DEPRECATED;1.0k;2.70 +15154-8;Blasts;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Blasts [Presence] in Blood by Automated count;Blasts Bld Ql Auto;;ACTIVE;1.0k;2.73 +15155-5;Calcium;MCnc;Pt;Body fld;Qn;;CHEM;1;Calcium [Mass/volume] in Body fluid;Calcium Fld-mCnc;;ACTIVE;1.0k;2.73 +1515-6;Glucose^2H post 100 g glucose PO;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --2 hours post 100 g glucose PO;Deprecated Glucose 2H p 100 g Glc PO Ser;;DEPRECATED;1.0;2.36 +15156-3;Cancer Ag 125;ACnc;Pt;Body fld;Qn;Dilution;CHEM;1;Cancer Ag 125 [Units/volume] in Body fluid by Dilution;Cancer Ag125 Fld Dil-aCnc;;ACTIVE;1.0k;2.68 +15157-1;Cancer Ag 125;ACnc;Pt;Ser/Plas;Qn;Dilution;CHEM;1;Cancer Ag 125 [Units/volume] in Serum or Plasma by Dilution;Cancer Ag125 SerPl Dil-aCnc;;ACTIVE;1.0k;2.68 +15158-9;Chloride;SCnc;Pt;Stool;Qn;;CHEM;1;Chloride [Moles/volume] in Stool;Chloride Stl-sCnc;;ACTIVE;1.0k;2.73 +15159-7;Coagulation factor.extrinsic pathway;Imp;Pt;PPP;Nar;;COAG;1;Coagulation factor extrinsic pathway [Interpretation] in Platelet poor plasma Narrative;Extrins clotting path PPP-Imp;;ACTIVE;1.0k;2.73 +15160-5;Coagulation factor.intrinsic factor;Imp;Pt;PPP;Nar;;COAG;1;Coagulation factor Intrinsic Factor [Interpretation] in Platelet poor plasma Narrative;Coag Fact Intrinsic PPP-Imp;;ACTIVE;1.0k;2.73 +15161-3;Complement C1 esterase inhibitor.functional;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Complement C1 esterase inhibitor.functional [Presence] in Serum or Plasma;C1INH Functional SerPl Ql;;ACTIVE;1.0k;2.73 +15162-1;Complement C1q;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C1q [Mass/volume] in Body fluid;C1q Fld-mCnc;;ACTIVE;1.0k;2.44 +15163-9;Complement C2;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C2 [Mass/volume] in Body fluid;C2 Fld-mCnc;;ACTIVE;1.0k;2.44 +1516-4;Glucose^2H post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --2 hours post 100 g glucose PO;Glucose 2h p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15164-7;Complement C3;MCnc;Pt;Synv fld;Qn;;HEM/BC;1;Complement C3 [Mass/volume] in Synovial fluid;C3 Snv-mCnc;;ACTIVE;1.0k;2.73 +15165-4;Complement C4;MCnc;Pt;Synv fld;Qn;;HEM/BC;1;Complement C4 [Mass/volume] in Synovial fluid;C4 Snv-mCnc;;ACTIVE;1.0k;2.73 +15166-2;Complement C5;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C5 [Mass/volume] in Body fluid;C5 Fld-mCnc;;ACTIVE;1.0k;2.44 +15167-0;Complement C6;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C6 [Mass/volume] in Body fluid;C6 Fld-mCnc;;ACTIVE;1.0k;2.44 +15168-8;Complement total hemolytic C50;ACnc;Pt;Body fld;Qn;IA;HEM/BC;1;Complement total hemolytic C50 [Units/volume] in Body fluid by Immunoassay;Comp C50 Fld IA-aCnc;;ACTIVE;1.0k;2.69 +15169-6;Complement total hemolytic C50;ACnc;Pt;Ser/Plas;Qn;IA;HEM/BC;1;Complement total hemolytic C50 [Units/volume] in Serum or Plasma by Immunoassay;Comp C50 SerPl IA-aCnc;;ACTIVE;1.0k;2.73 +15170-4;Complement total hemolytic C50;ACnc;Pt;Synv fld;Qn;IA;HEM/BC;1;Complement total hemolytic C50 [Units/volume] in Synovial fluid by Immunoassay;Comp C50 Snv IA-aCnc;;ACTIVE;1.0k;2.69 +15171-2;Cryoglobulin.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin.IgA [Units/volume] in Serum;Cryoglob IgA Ser-aCnc;;ACTIVE;1.0k;2.73 +1517-2;Glucose^2H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post 50 g lactose PO;Glucose 2h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15172-0;Cryoglobulin.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin.IgG [Units/volume] in Serum;Cryoglob IgG Ser-aCnc;;ACTIVE;1.0k;2.73 +15173-8;Cryoglobulin.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin.IgM [Units/volume] in Serum;Cryoglob IgM Ser-aCnc;;ACTIVE;1.0k;2.73 +15174-6;Cryoglobulin/Serum.total;VFr;Pt;Ser;Qn;Spun Westergren tube;CHEM;1;Cryocrit of Serum by Spun Westergren;Cryocrit Ser Spun Westergren;;ACTIVE;1.0k;2.73 +15175-3;Cryoproteins;Imp;Pt;Ser/Plas;Nom;Electrophoresis.agarose gel;CHEM;1;Cryoproteins [Interpretation] in Serum or Plasma by Electrophoresis agarose gel;Cryoproteins SerPl AG Elph-Imp;;ACTIVE;1.0k;2.73 +15176-1;Cryoproteins identified;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Cryoproteins identified in Serum or Plasma;Cryoproteins SerPl;;ACTIVE;1.0k;2.19 +15177-9;DNA double strand Ab;ACnc;Pt;Body fld;Qn;;SERO;1;DNA double strand Ab [Units/volume] in Body fluid;dsDNA Ab Fld-aCnc;;ACTIVE;1.0k;2.42 +15178-7;Complement factor B;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement factor B [Mass/volume] in Body fluid;Comp Fact B Fld-mCnc;;ACTIVE;1.0k;2.34 +15179-5;Fibrin D-dimer;PrThr;Pt;PPP;Ord;;COAG;1;Fibrin D-dimer [Presence] in Platelet poor plasma;D Dimer PPP Ql;;ACTIVE;1.0k;2.73 +1518-0;Glucose^2H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post 75 g glucose PO;Glucose 2h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15180-3;Hypochromia;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Hypochromia [Presence] in Blood by Automated count;Hypochromia Bld Ql Auto;;ACTIVE;1.0k;2.73 +15181-1;IgA;MCnc;Pt;Body fld;Qn;;CHEM;1;IgA [Mass/volume] in Body fluid;IgA Fld-mCnc;;ACTIVE;1.0k;2.73 +15182-9;IgA;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgA [Presence] in Serum by Immunoelectrophoresis;IgA Ser Ql IEP;;ACTIVE;1.0k;2.73 +15183-7;IgG;MCnc;Pt;Body fld;Qn;;CHEM;1;IgG [Mass/volume] in Body fluid;IgG Fld-mCnc;;ACTIVE;1.0k;2.73 +15184-5;IgG;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgG [Presence] in Serum by Immunoelectrophoresis;IgG Ser Ql IEP;;ACTIVE;1.0k;2.73 +15185-2;IgM;MCnc;Pt;Body fld;Qn;;CHEM;1;IgM [Mass/volume] in Body fluid;IgM Fld-mCnc;;ACTIVE;1.0k;2.73 +15186-0;IgM;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgM [Presence] in Serum by Immunoelectrophoresis;IgM Ser Ql IEP;;ACTIVE;1.0k;2.73 +15187-8;Immunoglobulin light chains.lambda;MCnc;24H;Urine;Qn;;CHEM;1;Lambda light chains [Mass/volume] in 24 hour Urine;Lambda LC 24h Ur-mCnc;;ACTIVE;1.0k;2.73 +15188-6;Immunoglobulin light chains.kappa;MCnc;24H;Urine;Qn;;CHEM;1;Kappa light chains [Mass/volume] in 24 hour Urine;Kappa LC 24h Ur-mCnc;;ACTIVE;1.0k;2.73 +15189-4;Immunoglobulin light chains.kappa/Immunoglobulin light chains.lambda;MRto;Pt;Ser;Qn;;CHEM;1;Kappa light chains/Lambda light chains [Mass Ratio] in Serum;Kappa LC/Lambda Ser;;ACTIVE;1.0k;2.73 +15190-2;Leukocytes other;Prid;Pt;Bld;Nom;Automated count;HEM/BC;1;Leukocytes other [Identifier] in Blood by Automated count;WBC Other Bld Auto;;ACTIVE;1.0k;2.07 +15191-0;Lupus anticoagulant neutralization.dilute phospholipid;PrThr;Pt;PPP;Ord;;COAG;1;Lupus anticoagulant neutralization dilute phospholipid [Presence] in Platelet poor plasma;LA Nt dPL PPP Ql;;DISCOURAGED;1.0k;2.73 +15192-8;Lymphocytes.variant;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Variant lymphocytes [Presence] in Blood by Automated count;Variant Lymphs Bld Ql Auto;;ACTIVE;1.0k;2.73 +15193-6;Cells.CD3-CD16+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3-CD16+ cells [#/volume] in Blood;CD3-CD16+ Cells # Bld;;ACTIVE;1.0k;2.42 +15194-4;Cells.CD3-CD16+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3-CD16+ cells/100 cells in Blood;CD3-CD16+ Cells NFr Bld;;ACTIVE;1.0k;2.70 +15195-1;Cells.CD3-CD19+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3-CD19+ cells [#/volume] in Blood;CD3-CD19+ Cells # Bld;;ACTIVE;1.0k;2.73 +15196-9;Cells.CD3-CD19+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3-CD19+ cells/100 cells in Blood;CD3-CD19+ Cells NFr Bld;;ACTIVE;1.0k;2.73 +15197-7;Lymphocytes.clefted/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes clefted/100 leukocytes in Blood by Manual count;Cleft Lymphs/leuk NFr Bld Manual;;ACTIVE;1.0k;2.73 +1519-8;Glucose^2H post 75 g glucose PO;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --2 hours post 75 g glucose PO;Deprecated Glucose 2H p 75 g Glc PO Ser-;;DEPRECATED;1.0;2.36 +15198-5;Macrocytes;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Macrocytes [Presence] in Blood by Automated count;Macrocytes Bld Ql Auto;;ACTIVE;1.0k;2.73 +15199-3;Microcytes;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Microcytes [Presence] in Blood by Automated count;Microcytes Bld Ql Auto;;ACTIVE;1.0k;2.73 +15200-9;Osmolality;Osmol;Pt;Body fld;Qn;;CHEM;1;Osmolality of Body fluid;Osmolality Fld;;ACTIVE;1.0k;2.73 +15201-7;Platelets.large fragments;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Platelets Large Fragments [#/volume] in Blood by Manual count;Platelets Lg Frg # Bld Manual;;ACTIVE;1.0k;2.73 +15202-5;Potassium;SCnc;Pt;Stool;Qn;;CHEM;1;Potassium [Moles/volume] in Stool;Potassium Stl-sCnc;;ACTIVE;1.0k;2.73 +15203-3;Rheumatoid factor;ACnc;Pt;Body fld;Qn;Nephelometry;SERO;1;Rheumatoid factor [Units/volume] in Body fluid by Nephelometry;Rheumatoid fact Fld Neph-aCnc;;ACTIVE;1.0k;2.73 +15204-1;Rheumatoid factor;Titr;Pt;Ser;Qn;Nephelometry;SERO;1;Rheumatoid factor [Titer] in Serum by Nephelometry;Rheumatoid fact Titr Ser Neph;;ACTIVE;1.0k;2.73 +15205-8;Rheumatoid factor;ACnc;Pt;Ser;Qn;Nephelometry;SERO;1;Rheumatoid factor [Units/volume] in Serum by Nephelometry;Rheumatoid fact Ser Neph-aCnc;;ACTIVE;1.0k;2.73 +1520-6;Glucose^2H post 75 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --2 hours post 75 g glucose PO;Glucose 2h p 75 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15206-6;Rheumatoid factor;ACnc;Pt;Synv fld;Qn;Nephelometry;SERO;1;Rheumatoid factor [Units/volume] in Synovial fluid by Nephelometry;Rheumatoid fact Snv Neph-aCnc;;ACTIVE;1.0k;2.73 +15207-4;Sodium;SCnc;Pt;Stool;Qn;;CHEM;1;Sodium [Moles/volume] in Stool;Sodium Stl-sCnc;;ACTIVE;1.0k;2.73 +15208-2;Taurine;PrThr;Pt;Nose;Ord;;CHEM;1;Taurine [Presence] in Nose;Taurine Nose Ql;;ACTIVE;1.0k;2.56 +15209-0;Saccharomonospora viridis Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Saccharomonospora viridis Ab [Presence] in Serum by Immune diffusion (ID);S viridis Ab Ser Ql ID;;ACTIVE;1.0k;2.73 +15210-8;Thyroglobulin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Thyroglobulin Ab [Presence] in Serum;Thyroglob Ab Ser Ql;;ACTIVE;1.0k;2.73 +15211-6;Biopsy;Imp;Pt;Thyroid;Nar;;PATH;1;Biopsy [Interpretation] in Thyroid Narrative;Biopsy Thyroid-Imp;;ACTIVE;1.0k;2.36 +15212-4;Triacylglycerol lipase;CCnc;Pt;Body fld;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Body fluid;Lipase Fld-cCnc;;ACTIVE;1.0k;2.73 +15213-2;(Cat dander+Dog dander+Guinea pig epithelium+Mouse+Rat) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 2 (Cat dander+Dog dander+Guinea pig epithelium+Mouse+Rat) IgE Ab [Presence] in Serum by Multidisk;Epid Allerg Mix2 IgE Ql;;ACTIVE;1.0k;2.65 +1521-4;Glucose^2H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post meal;Glucose 2h p meal SerPl-mCnc;;ACTIVE;1.0;2.73 +15214-0;(Guinea pig epithelium+Hamster epithelium+Mouse+Rabbit epithelium+Rat) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 70 (Guinea pig epithelium+Hamster epithelium+Mouse+Rabbit epithelium+Rat) IgE Ab [Presence] in Serum by Multidisk;Epidermal Mix 70 IgE Ql;;ACTIVE;1.0k;2.65 +15215-7;(Chicken feather+Duck feather+Goose feather+Turkey feather) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 71 (Chicken feather+Duck feather+Goose feather+Turkey feather) IgE Ab [Presence] in Serum by Multidisk;Epid Allerg Mix71 IgE Ql;;ACTIVE;1.0k;2.73 +15216-5;(Budgerigar feather+Canary feather+Finch feather+Parakeet feather+Parrot feather) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 72 (Budgerigar feather+Canary feather+Finch feather+Parakeet feather+Parrot feather) IgE Ab [Presence] in Serum by Multidisk;Epid Allerg Mix72 IgE Ql;;ACTIVE;1.0k;2.65 +15217-3;(Arachis hypogaea+Bertholletia excelsa+Cocos nucifera+Corylus avellana+Prunus dulcis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 1 (Peanut+Brazil nut+Coconut+Hazelnut+Almond) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix1 IgE Ql;;ACTIVE;1.0k;2.73 +15218-1;(Gadus morhua+Mytilus edulis+Pandalus borealis+Salmo salar+Thunnus albacares) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 2 (Cod+Blue Mussel+Shrimp+Salmon+Tuna) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix2 IgE Ql;;ACTIVE;1.0k;2.73 +15219-9;(Avena sativa+Fagopyrum esculentum+Sesamum indicum+Triticum aestivum+Zea mays) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 3 (Oat+Buckwheat+Sesame seed+Wheat+Corn) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix3 IgE Ql;;ACTIVE;1.0k;2.73 +15220-7;(Arachis hypogaea+Cow milk+Egg white+Glycine max+Triticum aestivum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix A (Peanut+Cow milk+Egg white+Soybean+Wheat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix A IgE Ql;;ACTIVE;1.0k;2.73 +15221-5;(Fagopyrum esculentum+Glycine max+Oryza sativa+Sesamum indicum+Triticum aestivum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix F (Buckwheat+Soybean+Rice+Sesame seed+Wheat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix F IgE Ql;;ACTIVE;1.0k;2.65 +1522-2;Glucose^30M post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post 0.5 g/kg glucose IV;Glucose 30M p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15222-3;(Cancer pagurus+Fagopyrum esculentum+Pandalus borealis+Sesamum indicum+Zea mays) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix E (Crab+Buckwheat+Shrimp+Sesame seed+Corn) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix E IgE Ql;;ACTIVE;1.0k;2.65 +15223-1;(Artemisia dracunculus+Levisticum officinale+Origanum majorana) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix B (Tarragon+Lovage+Marjoram) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix B IgE Ql;;ACTIVE;1.0k;2.65 +15224-9;(Carum carvi+Elettaria cardamomum+Mace+Syzygium aromaticum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 71 (Caraway+Cardamon+Mace+Clove) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix71 IgE Ql;;ACTIVE;1.0k;2.73 +15225-6;(Foeniculum vulgare seed+Ocimum basilicum+Pimpinella anisum+Zingiber officinale) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 72 (Fennel seed+Basil+Anise+Ginger) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix72 IgE Ql;;ACTIVE;1.0k;2.65 +15226-4;(Beef+Chicken meat+Pork+Pleuronectes platessa) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix G (Beef+Chicken meat+Pork+Plaice) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix G IgE Ql;;ACTIVE;1.0k;2.65 +15227-2;(Clupea harengus+Gadus morhua+Pleuronectes platessa+Scomber scombrus) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 74 (Herring+Cod+Plaice+Mackerel) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix74 IgE Ql;;ACTIVE;1.0k;2.65 +15228-0;(Anthoxanthum odoratum+Holcus lanatus+Lolium perenne+Phragmites communis+Secale cereale) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 4 (Sweet vernal grass+Velvet grass+Perennial rye grass+Common reed+Rye) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix4 IgE Ql;;ACTIVE;1.0k;2.65 +15229-8;(Anthoxanthum odoratum+Lolium perenne+Phleum pratense+Secale cereale+Holcus lanatus) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 3 (Sweet vernal grass+Perennial rye grass+Timothy+Rye+Velvet grass) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix3 IgE Ql;;ACTIVE;1.0k;2.65 +1523-0;Glucose^30M post 0.05-0.15 U insulin/kg IV post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post 0.05-0.15 U insulin/kg IV post 12H CFst;Glucose 30M p U/kg Ins IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15230-6;(Bromus inermis+Cynodon dactylon+Holcus lanatus+Paspalum notatum+Phleum pratense+Sorghum halepense) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix C (Brome+Bermuda grass+Velvet grass+Bahia grass+Timothy+Johnson grass) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix C IgE Ql;;ACTIVE;1.0k;2.65 +15231-4;(Blatella germanica+Dermatophagoides farinae+Dermatophagoides pteronyssinus+House dust Greer) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Dust Allergen Mix A (Cockroach+American house dust mite+European house dust mite+House dust Greer) IgE Ab [Presence] in Serum by Multidisk;Dust Allerg Mix A IgE Ql;;ACTIVE;1.0k;2.65 +15232-2;(Ambrosia elatior+Artemisia vulgaris+Cryptomeria japonica+Dactylis glomerata+Phleum pratense) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix A (Common ragweed+Mugwort+Japanese cedar+Orchard grass+Timothy) IgE Ab [Presence] in Serum by Multidisk;Region Allerg Mix A IgE Ql;;ACTIVE;1.0k;2.71 +15233-0;(Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Penicillium notatum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix A (Alternaria alternata+Aspergillus fumigatus+Candida albicans+Setomelanomma rostrata+Penicillium notatum) IgE Ab [Presence] in Serum by Multidisk;Mold Allerg Mix A IgE Ql;;ACTIVE;1.0k;2.73 +15234-8;(Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Setomelanomma rostrata+Penicillium notatum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 2 (Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Setomelanomma rostrata+Penicillium notatum) IgE Ab [Presence] in Serum by Multidisk;Mold Allerg Mix2 IgE Ql;;ACTIVE;1.0k;2.73 +15235-5;(Chicken feather+Cow dander+Goose feather+Horse dander) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 1 (Chicken feather+Cow dander+Goose feather+Horse dander) IgE Ab [Presence] in Serum by Multidisk;Occup Allerg Mix1 IgE Ql;;ACTIVE;1.0k;2.65 +15236-3;(Acarus siro+Lepidoglyphus destructor+Gasterophilus intestinalis+Sitophilus granarius) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 2 (Acarus siro+Lepidoglyphus destructor+Horse bot fly+Grain weevel) IgE Ab [Presence] in Serum by Multidisk;Occup Allerg Mix2 IgE Ql;;ACTIVE;1.0k;2.65 +15237-1;(Alternaria alternata+Aspergillus fumigatus+Rye pollen+Wheat pollen) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 3 (Alternaria alternata+Aspergillus fumigatus+rye pollen+wheat pollen) IgE Ab [Presence] in Serum by Multidisk;Occup Allerg Mix3 IgE Ql;;ACTIVE;1.0k;2.65 +15238-9;(Amylase+Glycine max+Sitophilus granarius+Triticum sativum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 4 (Amylase+Soybean+Grain weevel+Wheat) IgE Ab [Presence] in Serum by Multidisk;Occup Allerg Mix4 IgE Ql;;ACTIVE;1.0k;2.65 +15239-7;(Hexamethylene diisocyanate (HDI)+Diphenylmethane diisocyanate (MDI)+Toluene diisocyanate (TDI)+Phthalic anhydride) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 5 (Isocyanate HDI+MDI+TDI+Phthalic anhydride) IgE Ab [Presence] in Serum by Multidisk;Occup Allerg Mix5 IgE Ql;;ACTIVE;1.0k;2.65 +15240-5;(Chloramin T+Ethylene oxide+Formaldehyde+Phthalic anhydride) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 6 (Chloramin T+Ethylene oxide+Formaldehyde+Phthalic anhydride) IgE Ab [Presence] in Serum by Multidisk;Occup Allerg Mix6 IgE Ql;;ACTIVE;1.0k;2.65 +15241-3;(Beef+Chicken meat+Egg yolk+Pork+Turkey meat) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 10 (Beef+Chicken meat+Egg yolk+Pork+Turkey meat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix10 IgE Ql;;ACTIVE;1.0k;2.73 +15242-1;(Brassica oleracea var italica+Daucus carota+Phaseolus vulgaris+Pisum sativum+Zea mays) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 11 (Broccoli+Carrot+White bean+Peas+Corn) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix11 IgE Ql;;ACTIVE;1.0k;2.65 +15243-9;(Agaricus hortensis+Cucurbita pepo+Oryza sativa+Secale cereale+Solanum tuberosum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 12 (Mushroom+Pumpkin+Rice+Rye+Potato) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix12 IgE Ql;;ACTIVE;1.0k;2.65 +15244-7;(Daucus carota+Phaseolus vulgaris+Pisum sativum+Solanum tuberosum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 13 (Carrot+White bean+Peas+Potato) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix13 IgE Ql;;ACTIVE;1.0k;2.65 +15245-4;(Brassica oleracea var capitata+Capsicum annuum+Lycopersicon lycopersicum+Spinacia oleracea) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 14 (Cabbage+Paprika+Tomato+Spinach) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix14 IgE Ql;;ACTIVE;1.0k;2.65 +15246-2;(Citrus sinensis+Malus sylvestris+Musa spp+Prunus persica) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 15 (Orange+Apple+Banana+Peach) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix15 IgE Ql;;ACTIVE;1.0k;2.65 +15247-0;(Ananas comosus+Citrus limon+Fragaria vesca+Persea americana) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix H (Pineapple+Lemon+Strawberry+Avocado) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix H IgE Ql;;ACTIVE;1.0k;2.65 +1524-8;Glucose^30M post 0.1 U/kg insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post 0.1 U/kg insulin;Glucose 30M p 0.1 U/kg Ins SerPl-mCnc;;ACTIVE;1.0;2.73 +15248-8;(Arachis hypogaea+Glycine max+Pisum sativum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 18 (Peanut+Soybean+Peas) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix18 IgE Ql;;ACTIVE;1.0k;2.73 +15249-6;(Cucumis sativus+Daucus carota+Solanum tuberosum+Spinacia oleracea) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 19 (Cucumber+Carrot+Potato+Spinach) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix19 IgE Ql;;ACTIVE;1.0k;2.65 +15250-4;(Hordeum vulgare+Oryza sativa+Secale cereale+Triticum aestivum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 20 (Barley+Rice+Rye+Wheat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix20 IgE Ql;;ACTIVE;1.0k;2.65 +15251-2;(Actinidia chinensis+Ananas comosus+Cucumis melo+Musa spp+Prunus persica) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 21 (Kiwi+Pineapple+Melon+Banana+Peach) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix21 IgE Ql;;ACTIVE;1.0k;2.65 +15252-0;(Anacardium occidentale+Carya illinoinensis+Juglans spp+Pistacia vera) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 22 (Cashew+Pecan or Hickory nut+Walnut+Pistachio) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix22 IgE Ql;;ACTIVE;1.0k;2.73 +15253-8;(Allium cepa+Allium sativum+Apium graveolens+Lycopersicon lycopersicum+Yeast) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 7 (Onion+Garlic+Celery+Tomato+Yeast) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix7 IgE Ql;;ACTIVE;1.0k;2.65 +15254-6;(Bertholletia excelsa+Citrus sinensis+Corylus avellana+Malus sylvestris+Theobroma cacao) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 8 (Brazil nut+Orange+Hazelnut+Apple+Cocoa) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix8 IgE Ql;;ACTIVE;1.0k;2.73 +1525-5;Glucose^30M post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post 100 g glucose PO;Glucose 30M p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15255-3;(Actinidia chinensis+Cucumis melo+Musa spp+Prunus dulcis+Vitis vinifera) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 9 (Kiwi+Melon+Banana+Almond+Grape) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix9 IgE Ql;;ACTIVE;1.0k;2.65 +15256-1;(Artemisia vulgaris+Betula verrucosa+Parietaria judaica+phleum pratense+Plantago lanceolata) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 1 (Mugwort+Silver birch+Pellitory+Timothy+English plantain) IgE Ab [Presence] in Serum by Multidisk;Region Allerg Mix1 IgE Ql;;ACTIVE;1.0k;2.65 +15257-9;(Alternaria alternata+Cat dander+Dermatophagoides farinae+Dog dander+Horse dander) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 2 (Alternaria alternata+Cat dander+American house dust mite+Dog dander+Horse dander) IgE Ab [Presence] in Serum by Multidisk;Region Allerg Mix2 IgE Ql;;ACTIVE;1.0k;2.65 +15258-7;(Ambrosia elatior+Chenopodium album+Cynodon dactylon+Lolium perenne+Paspalum notatum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix B (Common ragweed+Goosefoot or Lambs quarters+Bermuda grass+Perennial rye grass+Bahia grass) IgE Ab [Presence] in Serum by Multidisk;Region Allerg Mix B IgE Ql;;ACTIVE;1.0k;2.73 +15259-5;(Cynodon dactylon+Lolium perenne+Bromus inermis+Ambrosia elatior+Artemisia vulgaris+Plantago lanceolata) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 4 (Bermuda grass+Perennial rye grass+Brome+Common ragweed+Mugwort+English plantain) IgE Ab [Presence] in Serum by Multidisk;Region Allerg Mix4 IgE Ql;;ACTIVE;1.0k;2.65 +15260-3;(Alnus incana+Betula verrucosa+Corylus avellana+Fraxinus americana) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 10 (Grey alder+Silver birch+Hazelnut+White ash) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix10 IgE Ql;;ACTIVE;1.0k;2.65 +15261-1;(Ambrosia elatior+Ambrosia psilostachya+Ambrosia trifida) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 209 (Common ragweed+Western ragweed+Giant ragweed) IgE Ab [Presence] in Serum by Multidisk;Weed Allerg Mix209 IgE Ql;;ACTIVE;1.0k;2.65 +15262-9;(Acer negundo+Betula verrucosa+Quercus alba+Ulmus americana+Juglans californica) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 1 (Boxelder+Silver birch+White oak+White elm+California walnut) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix1 IgE Ql;;ACTIVE;1.0k;2.73 +1526-3;Glucose^30M post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post 50 g lactose PO;Glucose 30M p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15263-7;(Cottonwood+Elm+Maple+Oak+Pecan tree) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix D (Cottonwood+Elm+Maple+Oak+Pecan tree) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix D IgE Ql;;ACTIVE;1.0k;2.65 +15264-5;(Juniperus sabinoides+Quercus alba+Ulmus americana+Populus deltoides+Prosopis juliflora) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 3 (Mountain juniper+White oak+White elm+Cottonwood+Mesquite) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix3 IgE Ql;;ACTIVE;1.0k;2.73 +15265-2;(Platanus occidentalis+Populus deltoides+Quercus alba+Salix caprea+Ulmus americana) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix E (American sycamore+Cottonwood+White oak+Willow+White elm) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix E IgE Ql;;ACTIVE;1.0k;2.65 +15266-0;(Alnus incana+Corylus avellana+Ulmus americana+Salix caprea+Populus deltoides) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 5 (Grey alder+Hazelnut+White elm+Willow+Cottonwood) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix5 IgE Ql;;ACTIVE;1.0k;2.65 +15267-8;(Acer negundo+Betula verrucosa+Fagus grandifolia+Quercus alba+Juglans californica) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 6 (Boxelder+Silver birch+American beech+White oak+California walnut) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix6 IgE Ql;;ACTIVE;1.0k;2.65 +15268-6;(Olea europaea+Salix caprea+Pinus strobus+Eucalyptus spp+Acacia longifolia+Melaleuca leucadendron) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 7 (Olive+Willow+Eastern white pine+Eucalyptus spp+Wattle+Cajeput) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix7 IgE Ql;;ACTIVE;1.0k;2.65 +15269-4;(Alnus incana+Betula verrucosa+Corylus avellana+Quercus alba+Salix caprea) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 9 (Grey alder+Silver birch+Hazelnut+White oak+Willow) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix 9 IgE Ql;;ACTIVE;1.0k;2.65 +15270-2;(Acer negundo+Betula verrucosa+Corylus avellana+Quercus alba+Platanus acerifolia) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 8 (Boxelder+Silver birch+Hazelnut+White oak+London plane or Maple leaf sycamore) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix8 IgE Ql;;ACTIVE;1.0k;2.73 +1527-1;Glucose^30M post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post 75 g glucose PO;Glucose 30M p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15271-0;(Ambrosia elatior+Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Salsola kali) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 1 (Common ragweed+Mugwort+Goosefoot or Lambs quarters+English plantain+Saltwort) IgE Ab [Presence] in Serum by Multidisk;Weed Allerg Mix1 IgE Ql;;ACTIVE;1.0k;2.73 +15272-8;(Ambrosia psilostachya+Artemisia vulgaris+Atriplex lentiformis+Chenopodium album+Plantago lanceolata) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 2 (Western ragweed+Mugwort+Lenscale+Goosefoot or Lambs quarters+English plantain) IgE Ab [Presence] in Serum by Multidisk;Weed Allerg Mix2 IgE Ql;;ACTIVE;1.0k;2.73 +15273-6;(Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Solidago virgaurea+Urtica dioica) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 3 (Mugwort+Goosefoot or Lambs quarters+English plantain+Goldenrod+Nettle) IgE Ab [Presence] in Serum by Multidisk;Weed Allerg Mix3 IgE Ql;;ACTIVE;1.0k;2.65 +15274-4;(Ambrosia elatior+Artemisia vulgaris+Chrysanthemum leucathemum+Taraxacum vulgare+Solidago virgaurea) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 5 (Common ragweed+Mugwort+Ox-eye daisy+Dandelion+Goldenrod) IgE Ab [Presence] in Serum by Multidisk;Weed Allerg Mix5 IgE Ql;;ACTIVE;1.0k;2.73 +15275-1;(Plantago lanceolata+Chenopodium album+Salsola kali+Rumex acetosella) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 6 (English plantain+Goosefoot or Lambs quarters+Saltwort+Sheep sorrel) IgE Ab [Presence] in Serum by Multidisk;Weed Allerg Mix6 IgE Ql;;ACTIVE;1.0k;2.65 +15276-9;(Chrysanthemum leucanthemum+Taraxacum vulgare+Plantago lanceolata+Chenopodium album+Solidago virgaurea) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 7 (Ox-eye daisy+Dandelion+English plantain+Goosefoot or Lambs quarters+Goldenrod) IgE Ab [Presence] in Serum by Multidisk;Weed Allerg Mix7 IgE Ql;;ACTIVE;1.0k;2.65 +15277-7;Turkey feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Turkey feather IgE Ab [Units/volume] in Serum;Deprecated Turkey Feather IgE Qn;;DEPRECATED;1.0k;2.69 +15278-5;Levisticum officinale Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lovage IgE Ab [Units/volume] in Serum;Lovage IgE Qn;;ACTIVE;1.0k;2.42 +15279-3;Elettaria cardamomum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cardamon IgE Ab [Units/volume] in Serum;Cardamon IgE Qn;;ACTIVE;1.0k;2.73 +15280-1;Mace Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mace IgE Ab [Units/volume] in Serum;Mace IgE Qn;;ACTIVE;1.0k;2.73 +15281-9;Gasterophilus intestinalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse Bot Fly IgE Ab [Units/volume] in Serum;Horse Bot Fly IgE Qn;;ACTIVE;1.0k;2.73 +15282-7;Secale cereale pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cultivated Rye IgE Ab [Units/volume] in Serum;Deprecated Cultivated Rye IgE Qn;;DEPRECATED;1.0k;2.69 +15283-5;Betula verrucosa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch IgE Ab [Units/volume] in Serum;Silver Birch IgE Qn;;ACTIVE;1.0k;2.73 +15284-3;Alnus incana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grey Alder IgE Ab [Units/volume] in Serum;Grey Alder IgE Qn;;ACTIVE;1.0k;2.73 +15285-0;Platanus acerifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;London Plane IgE Ab [Units/volume] in Serum;London Plane IgE Qn;;ACTIVE;1.0k;2.73 +15286-8;Height;Len;Pt;Kidney.left;Qn;US.measured;US.URO;2;Kidney - left Height by US;Height Kidney-L US.meas;;ACTIVE;1.0k;2.48 +15287-6;Width;Len;Pt;Kidney.left;Qn;US.measured;US.URO;2;Kidney - left Width by US;Width Kidney-L US.meas;;ACTIVE;1.0k;2.48 +15288-4;Length;Len;Pt;Kidney.left;Qn;US.measured;US.URO;2;Kidney - left Length by US;Length Kidney-L US.meas;;ACTIVE;1.0k;2.48 +1528-9;Glucose^30M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV;Glucose 30M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15289-2;Height;Len;Pt;Kidney.right;Qn;US.measured;US.URO;2;Kidney - right Height by US;Height Kidney-R US.meas;;ACTIVE;1.0k;2.48 +152-9;Cephaloglycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cephaloglycin [Susceptibility] by Minimum lethal concentration (MLC);Cephaloglycin Islt MLC;;ACTIVE;1.0;2.19 +15290-0;Width;Len;Pt;Kidney.right;Qn;US.measured;US.URO;2;Kidney - right Width by US;Width Kidney-R US.meas;;ACTIVE;1.0k;2.48 +15291-8;Length;Len;Pt;Kidney.right;Qn;US.measured;US.URO;2;Kidney - right Length by US;Length Kidney-R US.meas;;ACTIVE;1.0k;2.48 +15292-6;Height;Len;Pt;Testis.left;Qn;US.measured;US.URO;2;Testis - left Height by US;Height Testis-L US.meas;;ACTIVE;1.0k;2.48 +15293-4;Width;Len;Pt;Testis.left;Qn;US.measured;US.URO;2;Testis - left Width by US;Width Testis-L US.meas;;ACTIVE;1.0k;2.48 +15294-2;Length;Len;Pt;Testis.left;Qn;US.measured;US.URO;2;Testis - left Length by US;Length Testis-L US.meas;;ACTIVE;1.0k;2.48 +15295-9;Height;Len;Pt;Testis.right;Qn;US.measured;US.URO;2;Testis - right Height by US;Height Testis-R US.meas;;ACTIVE;1.0k;2.48 +15296-7;Width;Len;Pt;Testis.right;Qn;US.measured;US.URO;2;Testis - right Width by US;Width Testis-R US.meas;;ACTIVE;1.0k;2.48 +1529-7;Glucose^30M post dose U/kg insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV;Deprecated Glucose 30M p U/kg Ins IV Pla;;DEPRECATED;1.0;2.36 +15297-5;Length;Len;Pt;Testis.right;Qn;US.measured;US.URO;2;Testis - right Length by US;Length Testis-R US.meas;;ACTIVE;1.0k;2.48 +15298-3;Height;Len;Pt;Urinary bladder;Qn;US.measured;US.URO;2;Urinary bladder Height by US;Height Bladder US.meas;;ACTIVE;1.0k;2.48 +15299-1;Width;Len;Pt;Urinary bladder;Qn;US.measured;US.URO;2;Urinary bladder Width by US;Width Bladder US.meas;;ACTIVE;1.0k;2.48 +15300-7;Length;Len;Pt;Urinary bladder;Qn;US.measured;US.URO;2;Urinary bladder Length by US;Length Bladder US.meas;;ACTIVE;1.0k;2.48 +15301-5;Height;Len;Pt;Prostate;Qn;US.measured;US.URO;2;Prostate Height by US;Height Prostate US.meas;;ACTIVE;1.0k;2.48 +15302-3;Width;Len;Pt;Prostate;Qn;US.measured;US.URO;2;Prostate Width by US;Width Prostate US.meas;;ACTIVE;1.0k;2.48 +15303-1;Length;Len;Pt;Prostate;Qn;US.measured;US.URO;2;Prostate Length by US;Length Prostate US.meas;;ACTIVE;1.0k;2.48 +15304-9;Volume;Vol;Pt;Kidney.left;Qn;US.derived.HWL;US.URO;2;Kidney - left Volume by derived from height, width and length (US);Volume Kidney-L from HWL;;ACTIVE;1.0k;2.48 +1530-5;Glucose^3H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post 100 g glucose PO;Glucose 3h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15305-6;Volume;Vol;Pt;Kidney.right;Qn;US.derived.HWL;US.URO;2;Kidney - right Volume by derived from height, width and length (US);Volume Kidney-R from HWL;;ACTIVE;1.0k;2.48 +15306-4;Volume;Vol;Pt;Testis.left;Qn;US.derived.HWL;US.URO;2;Testis - left Volume by derived from height, width and length (US);Volume Testis-L from HWL;;ACTIVE;1.0k;2.48 +15307-2;Volume;Vol;Pt;Testis.right;Qn;US.derived.HWL;US.URO;2;Testis - right Volume by derived from height, width and length (US);Volume Testis-R from HWL;;ACTIVE;1.0k;2.48 +15308-0;Volume;Vol;Pt;Prostate;Qn;US.derived.HWL;US.URO;2;Prostate Volume by derived from height, width and length (US);Volume Prostate from HWL;;ACTIVE;1.0k;2.48 +15309-8;Volume;Vol;Pt;Urinary bladder;Qn;US.derived.HWL;US.URO;2;Urinary bladder Volume by derived from height, width and length (US);Volume Bladder from HWL;;ACTIVE;1.0k;2.48 +15310-6;Volume;Vol;Pt;Kidney.left;Qn;US.derived.ROT;US.URO;2;Kidney - left Volume by derived.from ROT (US);Volume Kidney-L US.derived.ROT;;ACTIVE;1.0k;2.48 +15311-4;Volume;Vol;Pt;Kidney.right;Qn;US.derived.ROT;US.URO;2;Kidney - right Volume by derived.from ROT (US);Volume Kidney-R US.derived.ROT;;ACTIVE;1.0k;2.48 +15312-2;Volume;Vol;Pt;Testis.left;Qn;US.derived.ROT;US.URO;2;Testis - left Volume by derived.from ROT (US);Volume Testis-L US.derived.ROT;;ACTIVE;1.0k;2.48 +1531-3;Glucose^3H post 100 g glucose PO;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --3 hours post 100 g glucose PO;Deprecated Glucose 3H p 100 g Glc PO Ser;;DEPRECATED;1.0;2.36 +15313-0;Volume;Vol;Pt;Testis.right;Qn;US.derived.ROT;US.URO;2;Testis - right Volume by derived.from ROT (US);Volume Testis-R US.derived.ROT;;ACTIVE;1.0k;2.48 +15314-8;Volume;Vol;Pt;Prostate;Qn;US.derived.ROT;US.URO;2;Prostate Volume by derived.from ROT (US);Volume Prostate US.derived.ROT;;ACTIVE;1.0k;2.48 +15315-5;Volume;Vol;Pt;Prostate;Qn;US.derived.PLN;US.URO;2;Prostate Volume by derived by planimetry (US);Volume Prostate US.derived.PLN;;ACTIVE;1.0k;2.48 +15316-3;Stepsize;Len;Pt;Volume.planimetry;Qn;Reported;US.URO;2;Volume planimetry Stepsize by - Reported;Stepsize Vol.planimetry Reported;;ACTIVE;1.0k;2.48 +15317-1;Volume;Vol;Pt;Kidney.left;Qn;US.derived.AUT;US.URO;2;Kidney - left Volume by derived by automated ultrasound testing (US);Volume Kidney-L by AUT;;ACTIVE;1.0k;2.48 +15318-9;Volume;Vol;Pt;Kidney.right;Qn;US.derived.AUT;US.URO;2;Kidney - right Volume by derived by automated ultrasound testing (US);Volume Kidney-R by AUT;;ACTIVE;1.0k;2.48 +15319-7;Volume;Vol;Pt;Testis.left;Qn;US.derived.AUT;US.URO;2;Testis - left Volume by derived by automated ultrasound testing (US);Volume Testis-L by AUT;;ACTIVE;1.0k;2.48 +15320-5;Volume;Vol;Pt;Testis.right;Qn;US.derived.AUT;US.URO;2;Testis - right Volume by derived by automated ultrasound testing (US);Volume Testis-R by AUT;;ACTIVE;1.0k;2.48 +1532-1;Glucose^3H post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --3 hours post 100 g glucose PO;Glucose 3h p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15321-3;Volume;Vol;Pt;Urinary bladder;Qn;US.derived.EMP;US.URO;2;Urinary bladder Volume by derived by EMP (US);Volume Bladder by EMP;;ACTIVE;1.0k;2.48 +15323-9;Prostate specific Ag/Prostate volume;Ratio;Pt;Ser+Prostate;Qn;Calculated.HWL;US.URO;2;Prostate specific Ag/Prostate volume calculated from height, width and length;PSA/Prostate vol HWL Calc;;ACTIVE;1.0k;2.48 +15324-7;Prostate specific Ag/Prostate volume;Ratio;Pt;Ser+Prostate;Qn;Calculated.PLN;US.URO;2;Prostate specific Ag/Prostate volume calculated from planimetry;PSA/Prostate vol PLN Calc;;ACTIVE;1.0k;2.48 +15325-4;Prostate specific Ag/Prostate volume;Ratio;Pt;Ser+Prostate;Qn;Calculated;US.URO;2;Prostate specific Ag/Prostate volume calculated;PSA/Prostate vol Calc;;ACTIVE;1.0k;2.73 +15326-2;Volume;Vol;Pt;Prostate.adenoma;Qn;US.derived.HWL;US.URO;2;Prostate Adenoma Volume by derived from height, width and length (US);Volume Prostate.adenoma from HWL;;ACTIVE;1.0k;2.48 +15327-0;Volume;Vol;Pt;Prostate.adenoma;Qn;US.derived.planimetry;US.URO;2;Prostate Adenoma Volume by derived by planimetry (US);Volume Prostate.adenoma US.derived.PLN;;ACTIVE;1.0k;2.48 +15328-8;Blood flow.systolic.max^baseline;VelRat;Pt;Penile cavernosal artery;Qn;US.doppler;US.URO;2;Penile cavernosal artery Peak systolic flow--baseline by US.doppler;Vmax sys BS CA DOP;;ACTIVE;1.0k;2.61 +15329-6;Blood flow.systolic.max^post XXX challenge;VelRat;Pt;Penile cavernosal artery;Qn;US.doppler;US.URO;2;Penile cavernosal artery Peak systolic flow--post XXX challenge by US.doppler;Vmax sys p chal CA DOP;;ACTIVE;1.0k;2.61 +15330-4;Blood flow.diastolic.end^baseline;VelRat;Pt;Penile cavernosal artery;Qn;US.doppler;US.URO;2;Penile cavernosal artery End diastolic blood flow--baseline by US.doppler;Bld flow.dias.end BS CA DOP;;ACTIVE;1.0k;2.61 +15331-2;Blood flow.diastolic.end^post XXX challenge;VelRat;Pt;Penile cavernosal artery;Qn;US.doppler;US.URO;2;Penile cavernosal artery End diastolic blood flow--post XXX challenge by US.doppler;Bld flow.dias.end p chal CA DOP;;ACTIVE;1.0k;2.61 +15332-0;Resistance.index^baseline;VelRto;Pt;Penile cavernosal artery;Qn;US.calculated;US.URO;2;Penile cavernosal artery Resistance index--baseline by US.calculated;RI BS CA US Calc;;ACTIVE;1.0k;2.61 +15333-8;Resistance.index^post XXX challenge;VelRto;Pt;Penile cavernosal artery;Qn;US.calculated;US.URO;2;Penile cavernosal artery Resistance index--post XXX challenge by US.calculated;RI p chal CA US Calc;;ACTIVE;1.0k;2.61 +15334-6;Challenge;Type;Pt;^Patient;Nom;;US.URO;2;Challenge;Challenge;;ACTIVE;1.0k;2.27 +15335-3;Pulsativity.index;VelRto;Pt;Penile cavernosal artery;Qn;US.calculated;US.URO;2;Penile cavernosal artery Pulsativity index by US.calculated;PI CA US Calc;;ACTIVE;1.0k;2.48 +15336-1;Antibiotic XXX;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Other Antibiotic [Susceptibility] by Serum bactericidal titer;Other Antibiotic Titr SBT;;ACTIVE;1.0k;2.32 +15337-9;Antibiotic XXX^peak;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Other Antibiotic [Susceptibility] by Serum bactericidal titer --peak;Other Antibiotic Peak Titr SBT;;ACTIVE;1.0k;2.32 +15338-7;Antibiotic XXX^trough;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Other Antibiotic [Susceptibility] by Serum bactericidal titer --trough;Other Antibiotic Trough Titr SBT;;ACTIVE;1.0k;2.32 +1533-9;Glucose^3H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post 75 g glucose PO;Glucose 3h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15339-5;Trogoderma angustum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Berlin Beetle IgE Ab [Units/volume] in Serum;Berlin Beetle IgE Qn;;ACTIVE;1.0k;2.42 +15340-3;Cedar italian Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Italian Cedar IgE Ab [Units/volume] in Serum;Italian Cedar IgE Qn;;ACTIVE;1.0k;2.42 +15341-1;Simulium venustum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Fly IgE Ab [Units/volume] in Serum;Black Fly IgE Qn;;ACTIVE;1.0k;2.73 +15342-9;Vespa crabro Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European Hornet IgE Ab [Units/volume] in Serum;European Hornet IgE Qn;;ACTIVE;1.0k;2.73 +15343-7;Blood group antibody screen;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Blood group antibody screen [Titer] in Serum or Plasma;Bld gp Ab Scn Titr SerPl;;ACTIVE;1.0k;2.73 +15344-5;little i Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;little i Ab [Titer] in Serum or Plasma;little i Ab Titr SerPl;;ACTIVE;1.0k;2.70 +15345-2;Aldosterone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Aldost 1h p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +15346-0;Aldosterone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Aldost 30M p chal SerPl-mCnc;;ACTIVE;1.0k;2.70 +1534-7;Glucose^3M post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 minutes post 0.5 g/kg glucose IV;Glucose 3M p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15347-8;Somatotropin^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;GH 30M p chal SerPl-mCnc;;ACTIVE;1.0k;2.73 +15348-6;Alkaline phosphatase.liver 1/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.liver 1/Alkaline phosphatase.total in Serum or Plasma;ALP Liver 1 CFr SerPl;;ACTIVE;1.0k;2.73 +15349-4;Alkaline phosphatase.liver 2/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.liver 2/Alkaline phosphatase.total in Serum or Plasma;ALP Liver 2 CFr SerPl;;ACTIVE;1.0k;2.73 +15350-2;Amylase;CRat;2H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/time] in 2 hour Urine;Amylase 2h Ur-cRate;;ACTIVE;1.0k;2.70 +15351-0;Apolipoprotein E2;PrThr;Pt;Bld;Ord;;CHEM;1;Apolipoprotein E2 [Presence] in Blood;Apo E2 Bld Ql;;ACTIVE;1.0k;2.73 +15352-8;Apolipoprotein E3;PrThr;Pt;Bld;Ord;;CHEM;1;Apolipoprotein E3 [Presence] in Blood;Apo E3 Bld Ql;;ACTIVE;1.0k;2.73 +15353-6;Apolipoprotein E4;PrThr;Pt;Bld;Ord;;CHEM;1;Apolipoprotein E4 [Presence] in Blood;Apo E4 Bld Ql;;ACTIVE;1.0k;2.73 +1535-4;Glucose^40M post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --40 minutes post 0.5 g/kg glucose IV;Glucose 40M p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.34 +15354-4;Bombesin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Bombesin Ag [Presence] in Tissue by Immune stain;Bombesin Ag Tiss Ql ImStn;;ACTIVE;1.0k;2.56 +15355-1;Estrone sulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrone sulfate [Mass/volume] in Serum or Plasma;Estrone Sulfate SerPl-mCnc;;ACTIVE;1.0k;2.73 +15356-9;Globulin;MRat;24H;Urine;Qn;;CHEM;1;Globulin [Mass/time] in 24 hour Urine;Globulin 24h Ur-mRate;;ACTIVE;1.0k;2.73 +15357-7;Iron;MCnt;Pt;Tiss;Qn;;CHEM;1;Iron [Mass/mass] in Tissue;Iron Tiss-mCnt;;ACTIVE;1.0k;2.73 +15358-5;Macroamylase;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Macroamylase [Presence] in Serum or Plasma;Macroamylase SerPl Ql;;ACTIVE;1.0k;2.73 +15359-3;Coagulation dilute Russell viper venom induced actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;dRVVT actual/normal (normalized LA screen);Screen dRVVT/normal;;ACTIVE;1.0k;2.73 +15360-1;Coagulation dilute Russell viper venom induced actual/Normal;PrThr;Pt;PPP;Ord;Coag;COAG;1;dRVVT actual/normal [Presence] in Platelet poor plasma by Coagulation assay;dRVVT Act/Nor PPP Ql;;DISCOURAGED;1.0k;2.73 +15361-9;Coagulation surface induced.factor substitution^immediately after 1:4 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:4 addition of normal plasma;aPTT imm 1:4 NP PPP;;ACTIVE;1.0k;2.73 +1536-2;Glucose^45M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose insulin IV;Glucose 45M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.34 +15362-7;Coagulation surface induced.inhibitor sensitive;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.inhibitor sensitive in Platelet poor plasma by Coagulation assay;aPTT Inhib Sens PPP;;ACTIVE;1.0k;2.73 +15363-5;Busulfan;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Busulfan [Mass/volume] in Serum or Plasma;Busulfan SerPl-mCnc;;ACTIVE;1.0k;2.73 +15364-3;Codeine;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Codeine [Mass/volume] in Meconium;Codeine Mec-mCnc;;DISCOURAGED;1.0k;2.52 +15365-0;Codeine;MCnc;Pt;Meconium;Ord;;DRUG/TOX;1;Deprecated Codeine;Deprecated Codeine Mec Ql;;DEPRECATED;1.0k;2.36 +15366-8;Dextroamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dextroamphetamine [Mass/volume] in Urine;D-amphet Ur-mCnc;;ACTIVE;1.0k;2.73 +15367-6;Ganciclovir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ganciclovir [Mass/volume] in Serum or Plasma;Ganciclovir SerPl-mCnc;;ACTIVE;1.0k;2.73 +15368-4;Hypoglycemics.sulfonyluric;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Hypoglycemics.sulfonyluric [Identifier] in Serum or Plasma;Sulfonyluric Hypogly SerPl;;ACTIVE;1.0k;2.73 +15369-2;Lithium.saliva/Lithium.serum;RelRto;Pt;Ser+Saliva;Qn;;DRUG/TOX;1;Lithium.saliva/Lithium.serum;Lithium Sal/SerPl;;ACTIVE;1.0k;2.44 +153-7;Cephaloglycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cephaloglycin [Susceptibility] by Minimum inhibitory concentration (MIC);Cephaloglycin Islt MIC;;ACTIVE;1.0;2.19 +1537-0;Glucose^4H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 hours post 100 g glucose PO;Glucose 4h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15370-0;Morphine;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Morphine [Mass/volume] in Meconium;Morphine Mec-mCnc;;DISCOURAGED;1.0k;2.52 +15371-8;Morphine;MCnc;Pt;Meconium;Ord;;DRUG/TOX;1;Deprecated Morphine;Deprecated Morphine Mec Ql;;DEPRECATED;1.0k;2.36 +15372-6;Nordiazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Urine;Nordiazepam Ur-mCnc;;ACTIVE;1.0k;2.73 +15373-4;Phenyltoloxamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phenyltoloxamine [Mass/volume] in Blood;Phenyltoloxamine Bld-mCnc;;ACTIVE;1.0k;2.70 +15374-2;Sulfonylurea;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Sulfonylurea [Presence] in Serum or Plasma;Sulfonylurea SerPl Ql;;ACTIVE;1.0k;2.73 +15375-9;Valproate.free;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Valproate Free [Mass/volume] in Saliva (oral fluid);Valproate Free Sal-mCnc;;ACTIVE;1.0k;2.73 +15376-7;Spermatozoa.abnormal/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Abnormal/100 spermatozoa in Semen;Sperm Abnorm NFr Smn;;ACTIVE;1.0k;2.73 +15377-5;Cytomegalovirus Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Cytomegalovirus Ab [Presence] in Serum by Latex agglutination;CMV Ab Ser Ql LA;;ACTIVE;1.0k;2.56 +15378-3;Fungus identified;Prid;Pt;Isolate;Nom;Culture;MICRO;1;Fungus identified in Isolate by Culture;Fungus Islt Cult;;ACTIVE;1.0k;2.73 +15379-1;Haemophilus influenzae B Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Haemophilus influenzae B Ag [Presence] in Urine;Haem influ B Ag Ur Ql;;ACTIVE;1.0k;2.56 +15380-9;Leishmania braziliensis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania brasilensis IgG Ab [Titer] in Serum;L braziliensis IgG Titr Ser;;ACTIVE;1.0k;2.73 +15381-7;Leishmania braziliensis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania brasilensis IgM Ab [Titer] in Serum;L braziliensis IgM Titr Ser;;ACTIVE;1.0k;2.73 +15382-5;Leishmania donovani Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania donovani IgG Ab [Titer] in Serum;L donovani IgG Titr Ser;;ACTIVE;1.0k;2.73 +15383-3;Leishmania donovani Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania donovani IgM Ab [Titer] in Serum;L donovani IgM Titr Ser;;ACTIVE;1.0k;2.73 +15384-1;Leishmania mexicana Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania mexicana IgG Ab [Titer] in Serum;L mexicana IgG Titr Ser;;ACTIVE;1.0k;2.73 +15385-8;Leishmania mexicana Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania mexicana IgM Ab [Titer] in Serum;L mexicana IgM Titr Ser;;ACTIVE;1.0k;2.73 +15386-6;Leishmania tropica Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania tropica IgG Ab [Titer] in Serum;L tropica IgG Titr Ser;;ACTIVE;1.0k;2.73 +15387-4;Leishmania tropica Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania tropica IgM Ab [Titer] in Serum;L tropica IgM Titr Ser;;ACTIVE;1.0k;2.73 +1538-8;Glucose^4H post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --4 hours post 100 g glucose PO;Glucose 4h p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15388-2;Mycoplasma hominis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Mycoplasma hominis [Presence] in Specimen by Organism specific culture;M hominis Spec Ql Cult;;ACTIVE;1.0k;2.73 +15389-0;Parainfluenza virus 1 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 1 IgG Ab [Presence] in Serum;HPIV1 IgG Ser Ql;;ACTIVE;1.0k;2.56 +15390-8;Parainfluenza virus 1 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 1 IgM Ab [Presence] in Serum;HPIV1 IgM Ser Ql;;ACTIVE;1.0k;2.56 +15391-6;Parainfluenza virus 1 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1 IgM Ab [Titer] in Serum;HPIV1 IgM Titr Ser;;ACTIVE;1.0k;2.70 +15392-4;Parainfluenza virus 2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 2 IgG Ab [Presence] in Serum;HPIV2 IgG Ser Ql;;ACTIVE;1.0k;2.56 +15393-2;Parainfluenza virus 2 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 2 IgM Ab [Titer] in Serum;HPIV2 IgM Titr Ser;;ACTIVE;1.0k;2.70 +15394-0;Parainfluenza virus 3 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 3 IgG Ab [Presence] in Serum;HPIV3 IgG Ser Ql;;ACTIVE;1.0k;2.56 +15395-7;Parainfluenza virus 3 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 3 IgM Ab [Presence] in Serum;HPIV3 IgM Ser Ql;;ACTIVE;1.0k;2.56 +1539-6;Glucose^4H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 hours post 75 g glucose PO;Glucose 4h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15396-5;Toxoplasma sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Toxoplasma gondii IgG Ab [Units/volume] in Serum;Deprecated Toxoplasma IgG Ser-aCnc;;DEPRECATED;1.0k;2.69 +15397-3;Trypanosoma cruzi Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Trypanosoma cruzi IgM Ab [Titer] in Serum;T cruzi IgM Titr Ser;;ACTIVE;1.0k;2.73 +15398-1;Neuronal nuclear Ab;Titr;Pt;Ser;Qn;;SERO;1;Neuronal nuclear Ab [Titer] in Serum;Hu Ab Titr Ser;;ACTIVE;1.0k;2.73 +15399-9;Neuronal nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear IgG Ab [Units/volume] in Serum by Immunofluorescence;Hu IgG Ser IF-aCnc;;ACTIVE;1.0k;2.69 +15400-5;Platelet Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Platelet IgG Ab [Presence] in Serum;Platelet IgG Ser Ql;;ACTIVE;1.0k;2.73 +15401-3;Drugs identified;Prid;Pt;Bld;Nom;Screen;DRUG/TOX;1;Drugs identified in Blood by Screen method;Drugs Bld Scn;;ACTIVE;1.0k;2.73 +15402-1;Ethanol;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Ethanol [Presence] in Meconium;Ethanol Mec Ql;;ACTIVE;1.0k;2.73 +15403-9;Isopropanol;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Isopropanol [Presence] in Meconium;Isopropanol Mec Ql;;ACTIVE;1.0k;2.56 +1540-4;Glucose^5H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post 100 g glucose PO;Glucose 5h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15404-7;Levomethamphetamine/Amphetamines.total;MFr;Pt;Urine;Qn;;DRUG/TOX;1;Levomethamphetamine/Amphetamines.total in Urine;L-methamphet MFr Ur;;ACTIVE;1.0k;2.73 +15405-4;Methamphetamine;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Methamphetamine [Mass/volume] in Meconium;Methamphet Mec-mCnc;;DISCOURAGED;1.0k;2.52 +15406-2;Methamphetamine;MCnc;Pt;Meconium;Ord;;DRUG/TOX;1;Deprecated Methamphetamine;Deprecated Methamphet Mec Ql;;DEPRECATED;1.0k;2.36 +15407-0;Methanol;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Methanol [Presence] in Meconium;Methanol Mec Ql;;ACTIVE;1.0k;2.56 +15408-8;Thallium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Thallium [Mass/mass] in Hair;Thallium Hair-mCnt;;ACTIVE;1.0k;2.70 +15409-6;Thallium;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Thallium [Mass/mass] in Nail;Thallium Nail-mCnt;;ACTIVE;1.0k;2.73 +15410-4;Varicella zoster virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Varicella zoster virus IgG Ab [Presence] in Serum by Immunoassay;VZV IgG Ser Ql IA;;ACTIVE;1.0k;2.73 +15411-2;Ergosterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ergosterol [Mass/volume] in Serum or Plasma;Ergosterol SerPl-mCnc;;ACTIVE;1.0k;2.34 +1541-2;Glucose^5H post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --5 hours post 100 g glucose PO;Glucose 5h p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15412-0;Service comment 21;Imp;Pt;XXX;Nom;;MISC;1;Service comment 21;Service Cmnt 21-Imp;;ACTIVE;1.0k;2.73 +15413-8;Service comment 22;Imp;Pt;XXX;Nom;;MISC;1;Service comment 22;Service Cmnt 22-Imp;;ACTIVE;1.0k;2.69 +15414-6;Service comment 23;Imp;Pt;XXX;Nom;;MISC;1;Service comment 23;Service Cmnt 23-Imp;;ACTIVE;1.0k;2.69 +15415-3;Service comment 24;Imp;Pt;XXX;Nom;;MISC;1;Service comment 24;Service Cmnt 24-Imp;;ACTIVE;1.0k;2.69 +15416-1;Service comment 25;Imp;Pt;XXX;Nom;;MISC;1;Service comment 25;Service Cmnt 25-Imp;;ACTIVE;1.0k;2.69 +15417-9;Service comment 26;Imp;Pt;XXX;Nom;;MISC;1;Service comment 26;Service Cmnt 26-Imp;;ACTIVE;1.0k;2.73 +15418-7;Service comment 27;Imp;Pt;XXX;Nom;;MISC;1;Service comment 27;Service Cmnt 27-Imp;;ACTIVE;1.0k;2.69 +15419-5;Service comment 28;Imp;Pt;XXX;Nom;;MISC;1;Service comment 28;Service Cmnt 28-Imp;;ACTIVE;1.0k;2.69 +1542-0;Glucose^5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post 75 g glucose PO;Glucose 5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15420-3;Service comment 29;Imp;Pt;XXX;Nom;;MISC;1;Service comment 29;Service Cmnt 29-Imp;;ACTIVE;1.0k;2.69 +15421-1;Service comment 30;Imp;Pt;XXX;Nom;;MISC;1;Service comment 30;Service Cmnt 30-Imp;;ACTIVE;1.0k;2.73 +15422-9;Service comment 31;Imp;Pt;XXX;Nom;;MISC;1;Service comment 31;Service Cmnt 31-Imp;;ACTIVE;1.0k;2.73 +15423-7;Service comment 32;Imp;Pt;XXX;Nom;;MISC;1;Service comment 32;Service Cmnt 32-Imp;;ACTIVE;1.0k;2.73 +15424-5;Service comment 33;Imp;Pt;XXX;Nom;;MISC;1;Service comment 33;Service Cmnt 33-Imp;;ACTIVE;1.0k;2.73 +15425-2;Service comment 34;Imp;Pt;XXX;Nom;;MISC;1;Service comment 34;Service Cmnt 34-Imp;;ACTIVE;1.0k;2.73 +15426-0;Service comment 35;Imp;Pt;XXX;Nom;;MISC;1;Service comment 35;Service Cmnt 35-Imp;;ACTIVE;1.0k;2.73 +15427-8;Service comment 36;Imp;Pt;XXX;Nom;;MISC;1;Service comment 36;Service Cmnt 36-Imp;;ACTIVE;1.0k;2.73 +15428-6;Service comment 37;Imp;Pt;XXX;Nom;;MISC;1;Service comment 37;Service Cmnt 37-Imp;;ACTIVE;1.0k;2.73 +15429-4;Service comment 38;Imp;Pt;XXX;Nom;;MISC;1;Service comment 38;Service Cmnt 38-Imp;;ACTIVE;1.0k;2.73 +15430-2;Service comment 39;Imp;Pt;XXX;Nom;;MISC;1;Service comment 39;Service Cmnt 39-Imp;;ACTIVE;1.0k;2.73 +15431-0;Service comment 40;Imp;Pt;XXX;Nom;;MISC;1;Service comment 40;Service Cmnt 40-Imp;;ACTIVE;1.0k;2.73 +15432-8;Testosterone.free/Testosterone.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone Free/Testosterone.total in Serum or Plasma;Testost Free MFr SerPl;;ACTIVE;1.0k;2.73 +15433-6;Anaplasma marginale Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Anaplasma marginale Ab [Presence] in Serum by Agglutination;A marginale Ab Ser Ql Aggl;;ACTIVE;1.0k;2.67 +15434-4;Avian adenovirus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Avian adenovirus Ab [Presence] in Serum by Immune diffusion (ID);FAdV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15435-1;Avian adenovirus 2 Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Avian adenovirus 2 Ab [Presence] in Serum by Immune diffusion (ID);FAdV2 Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15436-9;Avian encephalomyelitis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Avian encephalomyelitis virus Ab [Presence] in Serum by Immunoassay;AEV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15437-7;Avian encephalomyelitis virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Avian encephalomyelitis virus Ab [Presence] in Serum by Immune diffusion (ID);AEV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +1543-8;Glucose^5M post 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 minutes post 0.5 g/kg glucose IV;Glucose 5M p .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15438-5;Avian hemorrhagic enteritis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Avian hemorrhagic enteritis virus Ab [Presence] in Serum by Immunoassay;AAV2 Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15439-3;Infectious bronchitis virus Ark-99 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Infectious bronchitis virus Ark-99 Ab [Titer] in Serum by Hemagglutination inhibition;IBV Ark99 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15440-1;Infectious bronchitis virus Mass-41 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Infectious bronchitis virus Mass-41 Ab [Titer] in Serum by Hemagglutination inhibition;IBV Mass41 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15441-9;Infectious bronchitis virus Conn-42 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Infectious bronchitis virus Conn-42 Ab [Titer] in Serum by Hemagglutination inhibition;IBV Conn42 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15442-7;Avian infectious laryngotracheitis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Avian infectious laryngotracheitis virus Ab [Presence] in Serum by Immunoassay;ILT Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15443-5;Avian infectious laryngotracheitis virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Avian infectious laryngotracheitis virus Ab [Presence] in Serum by Immune diffusion (ID);ILT Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15444-3;Influenza virus A Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Influenza virus A Ab [Presence] in Serum by Immune diffusion (ID);FLUAV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15445-0;Avian leukosis virus Ag;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian leukosis virus Ag [Titer] in Serum by Immunoassay;ALV Ag Titr Ser IA;;ACTIVE;1.0k;2.70 +1544-6;Glucose^6H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 hours post 100 g glucose PO;Glucose 6h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15446-8;Avian leukosis virus Ag;Titr;Pt;Eggylk;Qn;IA;MICRO;1;Avian leukosis virus Ag [Titer] in Egg yolk by Immunoassay;ALV Ag Titr Egg Yolk IA;;ACTIVE;1.0k;2.70 +15447-6;Avian paramyxovirus 1 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Avian paramyxovirus 1 Ab [Presence] in Serum by Immunoassay;APMV1 Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15448-4;Avian paramyxovirus 1 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian paramyxovirus 1 Ab [Titer] in Serum by Hemagglutination inhibition;APMV1 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15449-2;Avian paramyxovirus 2 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian paramyxovirus 2 Ab [Titer] in Serum by Hemagglutination inhibition;APMV2 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +154-5;Cephaloglycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cephaloglycin [Susceptibility] by Disk diffusion (KB);Cephaloglycin Islt KB;;ACTIVE;1.0;2.19 +15450-0;Avian paramyxovirus 3 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian paramyxovirus 3 Ab [Titer] in Serum by Hemagglutination inhibition;APMV3 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15451-8;Avian pox virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Avian pox virus Ab [Presence] in Serum by Immune diffusion (ID);FWPV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15452-6;Avian reovirus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Avian reovirus Ab [Presence] in Serum by Immune diffusion (ID);AVREOV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +1545-3;Glucose^6H post 100 g glucose PO;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Glucose [Mass/volume] in Serum or Plasma --6 hours post 100 g glucose PO;Deprecated Glucose 6H p 100 g Glc PO Ser;;DEPRECATED;1.0;2.36 +15453-4;Avian reovirus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Avian reovirus Ab [Presence] in Serum by Immunoassay;AVREOV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15454-2;Reticuloendotheliosis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Reticuloendotheliosis virus Ab [Presence] in Serum by Immunoassay;REV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15455-9;Bluetongue virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Bluetongue virus Ab [Presence] in Serum by Immune diffusion (ID);BTV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15456-7;Bluetongue virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bluetongue virus Ab [Presence] in Serum by Immunoassay;BTV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15457-5;Bordetella avium Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Bordetella avium Ab [Titer] in Serum by Agglutination;B avium Ab Titr Ser Aggl;;ACTIVE;1.0k;2.70 +15458-3;Bordetella avium Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bordetella avium Ab [Presence] in Serum by Immunoassay;B avium Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15459-1;Bovine herpesvirus 1 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bovine herpesvirus 1 neutralizing antibody [Titer] in Serum by Neutralization test;BoHV1 NAb Titr Ser Nt;;ACTIVE;1.0k;2.72 +15460-9;Bovine leukemia virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bovine leukemia virus Ab [Presence] in Serum by Immunoassay;BLV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +1546-1;Glucose^6H post 100 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --6 hours post 100 g glucose PO;Glucose 6h p 100 g Glc PO Ur-mCnc;;ACTIVE;1.0;2.73 +15461-7;Bovine leukemia virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Bovine leukemia virus Ab [Presence] in Serum by Immune diffusion (ID);BLV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15462-5;Bovine diarrhea virus 1 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bovine diarrhea virus 1 neutralizing antibody [Titer] in Serum by Neutralization test;BVDV1 NAb Titr Ser Nt;;ACTIVE;1.0k;2.72 +15463-3;Bovine diarrhea virus 2 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bovine diarrhea virus 2 neutralizing antibody [Titer] in Serum by Neutralization test;BVDV2 NAb Titr Ser Nt;;ACTIVE;1.0k;2.72 +15464-1;Caprine arthritis encephalitis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Caprine arthritis encephalitis virus Ab [Presence] in Serum by Immunoassay;CAEV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15465-8;Caprine arthritis encephalitis virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Caprine arthritis encephalitis virus Ab [Presence] in Serum by Immune diffusion (ID);CAEV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15466-6;Epizootic hemorrhagic disease virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Epizootic hemorrhagic disease virus Ab [Presence] in Serum by Immune diffusion (ID);EHDV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15467-4;Equine herpesvirus 1 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Equine herpesvirus 1 neutralizing antibody [Titer] in Serum by Neutralization test;EHV1 NAb Titr Ser Nt;;ACTIVE;1.0k;2.72 +15468-2;Equine infectious anemia virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Equine infectious anemia virus Ab [Presence] in Serum by Immune diffusion (ID);EIAV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15469-0;Equine influenza virus A1 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Equine influenza virus A1 Ab [Titer] in Serum by Hemagglutination inhibition;EIV A1 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15470-8;Equine influenza virus A2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Equine influenza virus A2 Ab [Presence] in Serum;EIV A2 Ab Ser Ql;;ACTIVE;1.0k;2.67 +15471-6;Equine influenza virus A2 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Equine influenza virus A2 Ab [Titer] in Serum by Hemagglutination inhibition;EIV A2 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15472-4;Equine influenza virus Ag;PrThr;Pt;Nose;Ord;IA;MICRO;1;Equine influenza virus Ag [Presence] in Nose by Immunoassay;EIV Ag Nose Ql IA;;ACTIVE;1.0k;2.67 +15473-2;Equine arteritis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Equine arteritis virus neutralizing antibody [Titer] in Serum by Neutralization test;EAV NAb Titr Ser Nt;;ACTIVE;1.0k;2.72 +15474-0;Infectious bursal disease virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Infectious bursal disease virus Ab [Presence] in Serum by Immune diffusion (ID);IBDV Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15475-7;Infectious bursal disease virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Infectious bursal disease virus Ab [Presence] in Serum by Immunoassay;IBDV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15476-5;Leptospira interrogans serovar Bratislava Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Bratislava Ab [Titer] in Serum by Agglutination;L inter Brat Ab Titr Ser Aggl;;ACTIVE;1.0k;2.70 +15477-3;Leptospira interrogans serovar Canicola Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Canicola Ab [Titer] in Serum by Agglutination;L inter Canic Ab Titr Ser Aggl;;ACTIVE;1.0k;2.70 +15478-1;Leptospira interrogans serovar Grippotyphosa Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Grippotyphosa Ab [Titer] in Serum by Agglutination;L inter Grip Ab Titr Ser Aggl;;ACTIVE;1.0k;2.70 +1547-9;Glucose^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --baseline;Glucose BS SerPl-mCnc;;ACTIVE;1.0;2.73 +15479-9;Leptospira interrogans serovar Hardjo Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Hardjo Ab [Titer] in Serum by Agglutination;L inter Hard Ab Titr Ser Aggl;;ACTIVE;1.0k;2.70 +15480-7;Leptospira interrogans serovar Icterohaemorrhagiae Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Icterohaemorrhagiae Ab [Titer] in Serum by Agglutination;L inter Icter Ab Titr Ser Aggl;;ACTIVE;1.0k;2.70 +15481-5;Leptospira interrogans serovar Pomona Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Pomona Ab [Titer] in Serum by Agglutination;L inter Pomon Ab Titr Ser Aggl;;ACTIVE;1.0k;2.70 +15482-3;Mycobacterium avium subspecies paratuberculosis Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Presence] in Serum by Immune diffusion (ID);M avium paraTB Ab Ser Ql ID;;ACTIVE;1.0k;2.67 +15483-1;Mycobacterium avium subspecies paratuberculosis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Presence] in Serum by Immunoassay;M avium paraTB Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15484-9;Mycoplasma gallisepticum Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Mycoplasma gallisepticum Ab [Presence] in Serum by Agglutination;M gallisep Ab Ser Ql Aggl;;ACTIVE;1.0k;2.67 +15485-6;Mycoplasma gallisepticum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma gallisepticum Ab [Presence] in Serum by Immunoassay;M gallisep Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15486-4;Mycoplasma gallisepticum rRNA;PrThr;Pt;Nose/Trac;Ord;Probe;MICRO;1;Mycoplasma gallisepticum rRNA [Presence] in Nose or Trachea by Probe;M gallisep rRNA Nose/Trachea Ql Probe;;ACTIVE;1.0k;2.67 +1548-7;Glucose^pre 0.5 g/kg glucose IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre 0.5 g/kg glucose IV;Glucose pre .5 g/kg Glc IV SerPl-mCnc;;ACTIVE;1.0;2.34 +15487-2;Mycoplasma meleagridis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma meleagridis Ab [Presence] in Serum by Immunoassay;M meleagridis Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15488-0;Mycoplasma meleagridis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Mycoplasma meleagridis Ab [Presence] in Serum by Agglutination;M meleagridis Ab Ser Ql Aggl;;ACTIVE;1.0k;2.67 +15489-8;Mycoplasma synoviae Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma synoviae Ab [Presence] in Serum by Immunoassay;M synoviae Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15490-6;Mycoplasma synoviae Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Mycoplasma synoviae Ab [Presence] in Serum by Agglutination;M synoviae Ab Ser Ql Aggl;;ACTIVE;1.0k;2.67 +15491-4;Mycoplasma synoviae rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Mycoplasma synoviae rRNA [Presence] in Serum by Probe;M synoviae rRNA Ser Ql Probe;;ACTIVE;1.0k;2.67 +15492-2;Neospora caninum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Neospora caninum Ab [Presence] in Serum by Immunoassay;N caninum Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15493-0;Parainfluenza virus 3 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Serum by Hemagglutination inhibition;HPIV3 Ab Titr Ser HAI;;ACTIVE;1.0k;2.70 +15494-8;Pasteurella multocida Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Pasteurella multocida Ab [Presence] in Serum by Immunoassay;P multoc Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +1549-5;Glucose^pre 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --pre 100 g glucose PO;Glucose pre 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15495-5;Porcine reproductive and respiratory syndrome virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;PRRSV Ab [Presence] in Serum by Immunoassay;PRRSV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15496-3;Porcine reproductive and respiratory syndrome virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;PRRSV Ab [Presence] in Serum by Immunofluorescence;PRRSV Ab Ser Ql IF;;ACTIVE;1.0k;2.67 +15497-1;Pseudorabies virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Pseudorabies virus Ab [Presence] in Serum by Immunoassay;PRV Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15498-9;Pseudorabies virus Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Pseudorabies virus Ab [Presence] in Serum by Latex agglutination;PRV Ab Ser Ql LA;;ACTIVE;1.0k;2.67 +15499-7;Pseudorabies virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Pseudorabies virus neutralizing antibody [Titer] in Serum by Neutralization test;PRV NAb Titr Ser Nt;;ACTIVE;1.0k;2.72 +15500-2;Pseudorabies virus.ClinEase gene deletion Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Pseudorabies virus Clinease gene deletion Ab [Presence] in Serum by Immunoassay;PRV Clinease Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15501-0;Pseudorabies virus.HerdCheck gene deletion Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Pseudorabies virus Herdcheck gene deletion Ab [Presence] in Serum by Immunoassay;PRV Herdcheck Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15502-8;Pseudorabies virus.OmniMark gene deletion Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Pseudorabies virus Omnimark gene deletion Ab [Presence] in Serum by Immunoassay;PRV Omnimark Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +1550-3;Glucose^pre 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre 12 hour fast;Glucose pre 12h fast SerPl-mCnc;;ACTIVE;1.0;2.34 +15503-6;Pseudorabies virus.Tolvid gene deletion Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Pseudorabies virus Tolvid gene deletion Ab [Presence] in Serum by Immunoassay;PRV Tolvid Ab Ser Ql IA;;ACTIVE;1.0k;2.67 +15504-4;Salmonella arizonae Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Salmonella arizonae Ab [Presence] in Serum by Agglutination;S arizonae Ab Ser Ql Aggl;;ACTIVE;1.0k;2.67 +15505-1;Salmonella pullorum Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Salmonella pullorum Ab [Presence] in Serum by Agglutination;S pullorum Ab Ser Ql Aggl;;ACTIVE;1.0k;2.67 +15506-9;Salmonella typhimurium Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Salmonella typhimurium Ab [Presence] in Serum by Agglutination;S Typhimur Ab Ser Ql Aggl;;ACTIVE;1.0k;2.73 +15507-7;Progress note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Progress note;ED Prog note;;ACTIVE;1.0k;2.73 +15508-5;Labor and delivery records;Find;-;^Patient;Doc;;DOC.MISC;2;Labor and delivery records;Labor and delivery records;;ACTIVE;1.0k;2.67 +15509-3;Rationale for scheduled transport;Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Rationale for scheduled transport;;;ACTIVE;1.0k;2.27 +15510-1;Distance transported;Len;Pt;Ambulance transport;Qn;;ATTACH.AMB;3;Ambulance transport, Distance transported Length;;;ACTIVE;1.0k;2.48 +1551-1;Glucose^pre 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre 50 g lactose PO;Glucose pre 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0;2.34 +15511-9;Origination site information;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Origination site information Set;;;ACTIVE;1.0l;2.40 +15512-7;Destination site information;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Destination site information Set;;;ACTIVE;1.0l;2.40 +15513-5;Reason for scheduled trip;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Reason for scheduled trip Set;;;ACTIVE;1.0l;2.40 +15514-3;Ordering practitioner ID;Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Ordering practitioner identifier type;;;ACTIVE;1.0l;2.38 +15515-0;Medical reason for transport;Imp;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Medical reason for transport;;;ACTIVE;1.0l;2.27 +15516-8;Justification for extra attendants;Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Justification for extra attendants;;;ACTIVE;1.0l;1.0ma +15517-6;Transport direction;Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Transport direction;;;ACTIVE;1.0l;2.24 +15518-4;Haliotis spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Abalone IgE Ab RAST class [Presence] in Serum;Abalone IgE RAST Ql;;ACTIVE;1.0l;2.73 +15519-2;Acacia longifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wattle IgE Ab RAST class [Presence] in Serum;Wattle IgE RAST Ql;;ACTIVE;1.0l;2.73 +155-2;Cephaloglycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cephaloglycin [Susceptibility] by Serum bactericidal titer;Cephaloglycin Titr SBT;;ACTIVE;1.0;2.32 +15520-0;Corticotropin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Corticotropin IgE Ab RAST class [Presence] in Serum;ACTH IgE RAST Ql;;ACTIVE;1.0l;2.58 +15521-8;Alnus rhombifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Alder IgE Ab RAST class [Presence] in Serum;White Alder IgE RAST Ql;;ACTIVE;1.0l;2.73 +15522-6;Alder Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Alder Ab.IgE.RAST class;Deprecated Alder IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15523-4;Alnus rugosa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Smooth Alder IgE Ab RAST class [Presence] in Serum;Smooth Alder IgE RAST Ql;;ACTIVE;1.0l;2.58 +15524-2;Medicago sativa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alfalfa IgE Ab RAST class [Presence] in Serum;Alfalfa IgE RAST Ql;;ACTIVE;1.0l;2.73 +15525-9;Alkalase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alkalase IgE Ab RAST class [Presence] in Serum;Alkalase IgE RAST Ql;;ACTIVE;1.0l;2.58 +15526-7;Pimenta dioica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Allspice IgE Ab RAST class [Presence] in Serum;Allspice IgE RAST Ql;;ACTIVE;1.0l;2.73 +15527-5;Prunus dulcis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Almond IgE Ab RAST class [Presence] in Serum;Almond IgE RAST Ql;;ACTIVE;1.0l;2.73 +15528-3;Prunus dulcis tree Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Almond Tree IgE Ab RAST class [Presence] in Serum;Almond Tree IgE RAST Ql;;ACTIVE;1.0l;2.58 +1552-9;Glucose^pre 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre 75 g glucose PO;Glucose pre 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15529-1;Lactalbumin alpha Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactalbumin alpha IgE Ab RAST class [Presence] in Serum;A-Lactalb IgE RAST Ql;;ACTIVE;1.0l;2.73 +15530-9;Alternaria alternata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alternaria alternata IgE Ab RAST class [Presence] in Serum;A alternata IgE RAST Ql;;ACTIVE;1.0l;2.73 +15531-7;Alternaria alternata Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Alternaria alternata IgE Ab RAST class in Serum;Deprecated A alternata IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15532-5;Amoxicillin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Amoxicillin IgE Ab RAST class [Presence] in Serum;Amoxicillin IgE RAST Ql;;ACTIVE;1.0l;2.73 +15533-3;Ampicillin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ampicillin IgE Ab RAST class [Presence] in Serum;Ampicillin IgE RAST Ql;;ACTIVE;1.0l;2.73 +15534-1;Engraulis encrasicolus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Anchovy IgE Ab RAST class [Presence] in Serum;Anchovy IgE RAST Ql;;ACTIVE;1.0l;2.73 +15535-8;Anisakis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Anisakis IgE Ab RAST class [Presence] in Serum;Anisakis IgE RAST Ql;;ACTIVE;1.0l;2.73 +15536-6;Pimpinella anisum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Anise IgE Ab RAST class [Presence] in Serum;Anise IgE RAST Ql;;ACTIVE;1.0l;2.73 +1553-7;Glucose^pre dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre dose insulin IV;Glucose pre Ins IV SerPl-mCnc;;ACTIVE;1.0;2.34 +15537-4;Solenopsis invicta Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Imported Fire Ant IgE Ab RAST class [Presence] in Serum;Red Imp Fire Ant IgE RAST Ql;;ACTIVE;1.0l;2.73 +15538-2;Solenopsis invicta Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Red Imported Fire Ant IgE Ab RAST class in Serum;Deprecated Red Imp Fire Ant IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15539-0;Malus sylvestris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Apple IgE Ab RAST class [Presence] in Serum;Apple IgE RAST Ql;;ACTIVE;1.0l;2.73 +15540-8;Malus sylvestris tree Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Apple Tree IgE Ab RAST class [Presence] in Serum;Apple Tree IgE RAST Ql;;ACTIVE;1.0l;2.58 +15541-6;Prunus armeniaca Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Apricot IgE Ab RAST class [Presence] in Serum;Apricot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15542-4;Maranta arundinacea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Arrowroot IgE Ab RAST class [Presence] in Serum;Arrowroot IgE RAST Ql;;ACTIVE;1.0l;2.58 +15543-2;Cynara scolymus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Artichoke IgE Ab RAST class [Presence] in Serum;Artichoke IgE RAST Ql;;ACTIVE;1.0l;2.73 +15544-0;Ascaris sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ascaris sp IgE Ab RAST class [Presence] in Serum;Ascaris IgE RAST Ql;;ACTIVE;1.0l;2.73 +1554-5;Glucose^post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12 hours fasting;Glucose p 12h fast SerPl-mCnc;;ACTIVE;1.0;2.73 +15545-7;Fraxinus velutina Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Arizona Ash IgE Ab RAST class [Presence] in Serum;Arizona Ash IgE RAST Ql;;ACTIVE;1.0l;2.73 +15546-5;Fraxinus americana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Ash IgE Ab RAST class [Presence] in Serum;White Ash IgE RAST Ql;;ACTIVE;1.0l;2.73 +15547-3;Asparagus officinalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Asparagus IgE Ab RAST class [Presence] in Serum;Asparagus IgE RAST Ql;;ACTIVE;1.0l;2.73 +15548-1;Populus tremula Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspen IgE Ab RAST class [Presence] in Serum;Aspen IgE RAST Ql;;ACTIVE;1.0l;2.73 +15549-9;Aspergillus fumigatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus IgE Ab RAST class [Presence] in Serum;A fumigatus IgE RAST Ql;;ACTIVE;1.0l;2.73 +15550-7;Aspergillus niger Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus niger IgE Ab RAST class [Presence] in Serum;A niger IgE RAST Ql;;ACTIVE;1.0l;2.73 +15551-5;Persea americana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Avocado IgE Ab RAST class [Presence] in Serum;Avocado IgE RAST Ql;;ACTIVE;1.0l;2.73 +1555-2;Glucose^post 12H CFst;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --12 hours fasting;Glucose p 12h fast Ur-mCnc;;ACTIVE;1.0;2.73 +15552-3;Baccharis spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Groundsel Tree IgE Ab RAST class [Presence] in Serum;Groundsel Tree IgE RAST Ql;;ACTIVE;1.0l;2.73 +15553-1;Phyllostachys pubescens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bamboo shoot IgE Ab RAST class [Presence] in Serum;Bamboo shoot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15554-9;Musa spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Banana IgE Ab RAST class [Presence] in Serum;Banana IgE RAST Ql;;ACTIVE;1.0l;2.73 +15555-6;Hordeum vulgare Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Barley IgE Ab RAST class [Presence] in Serum;Barley IgE RAST Ql;;ACTIVE;1.0l;2.73 +15556-4;Hordeum vulgare pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Barley Pollen IgE Ab RAST class [Presence] in Serum;Barley Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +15557-2;Ocimum basilicum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Basil IgE Ab RAST class [Presence] in Serum;Basil IgE RAST Ql;;ACTIVE;1.0l;2.73 +15558-0;Micropterus salmoides Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bass, Black IgE Ab RAST class [Presence] in Serum;Bass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15559-8;Bassia hyssopifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fivehook Bassia IgE Ab RAST class [Presence] in Serum;Fivehook Bassia IgE RAST Ql;;ACTIVE;1.0l;2.58 +1556-0;Glucose^post CFst;MCnc;Pt;BldC;Qn;;CHAL;1;Fasting glucose [Mass/volume] in Capillary blood;Glucose p fast BldC-mCnc;;ACTIVE;1.0;2.73 +15560-6;Myrica spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bayberry IgE Ab RAST class [Presence] in Serum;Bayberry IgE RAST Ql;;ACTIVE;1.0l;2.73 +15561-4;Laurus nobilis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bayleaf IgE Ab RAST class [Presence] in Serum;Bayleaf IgE RAST Ql;;ACTIVE;1.0l;2.73 +15562-2;Ricinus communis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Castor Bean IgE Ab RAST class [Presence] in Serum;Castor Bean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15563-0;Coffee bean green Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Green Coffee Bean IgE Ab RAST class [Presence] in Serum;Green Coffee Bean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15564-8;Bean green Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Green Bean IgE Ab RAST class [Presence] in Serum;Green Bean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15565-5;Bean kidney red Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Kidney Bean IgE Ab RAST class [Presence] in Serum;Red Kidney Bean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15566-3;Phaseolus limensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lima Bean IgE Ab RAST class [Presence] in Serum;Lima Bean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15567-1;Bean pinto Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pinto Bean IgE Ab RAST class [Presence] in Serum;Pinto Bean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15568-9;Glycine max Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Soybean IgE Ab RAST class [Presence] in Serum;Soybean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15569-7;Bean white Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Bean IgE Ab RAST class [Presence] in Serum;White Bean IgE RAST Ql;;ACTIVE;1.0l;2.73 +15570-5;Apis mellifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee IgE Ab RAST class [Presence] in Serum;Honey bee IgE RAST Ql;;ACTIVE;1.0l;2.73 +15571-3;Fagus grandifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;American Beech IgE Ab RAST class [Presence] in Serum;Amer Beech IgE RAST Ql;;ACTIVE;1.0l;2.73 +15572-1;Beef Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Beef IgE Ab RAST class [Presence] in Serum;Beef IgE RAST Ql;;ACTIVE;1.0l;2.73 +15573-9;Beet Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Beet IgE Ab RAST class [Presence] in Serum;Beet IgE RAST Ql;;ACTIVE;1.0l;2.73 +15574-7;Beta vulgaris seed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sugar Beet Seed (Beta vulgaris seed) IgE Ab RAST class [Presence] in Serum;Sugar Beet Seed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15575-4;Trogoderma angustum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Berlin Beetle IgE Ab RAST class [Presence] in Serum;Berlin Beetle IgE RAST Ql;;ACTIVE;1.0l;2.58 +15576-2;Lactalbumin beta Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactalbumin beta IgE Ab RAST class [Presence] in Serum;B-Lactalb IgE RAST Ql;;ACTIVE;1.0l;2.73 +15577-0;Beta lactoglobulin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Beta lactoglobulin IgE Ab RAST class [Presence] in Serum;B-Lactoglob IgE RAST Ql;;ACTIVE;1.0l;2.73 +1557-8;Glucose^post CFst;MCnc;Pt;BldV;Qn;;CHAL;1;Fasting glucose [Mass/volume] in Venous blood;Glucose p fast BldV-mCnc;;ACTIVE;1.0;2.73 +15578-8;Birch Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Birch Ab.IgE.RAST class;Deprecated Birch IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15579-6;Betula verrucosa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch IgE Ab RAST class [Presence] in Serum;Silver Birch IgE RAST Ql;;ACTIVE;1.0l;2.73 +15580-4;Rubus fruticosus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blackberry IgE Ab RAST class [Presence] in Serum;Blackberry IgE RAST Ql;;ACTIVE;1.0l;2.73 +15581-2;Blomia tropicalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blomia tropicalis IgE Ab RAST class [Presence] in Serum;B tropicalis IgE RAST Ql;;ACTIVE;1.0l;2.73 +15582-0;Chironomus thummi Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bloodworm IgE Ab RAST class [Presence] in Serum;Bloodworm IgE RAST Ql;;ACTIVE;1.0l;2.73 +15583-8;Vaccinium myrtillus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blueberry IgE Ab RAST class [Presence] in Serum;Blueberry IgE RAST Ql;;ACTIVE;1.0l;2.73 +15584-6;Botrytis cinerea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Botrytis cinerea IgE Ab RAST class [Presence] in Serum;B cinerea IgE RAST Ql;;ACTIVE;1.0l;2.73 +15585-3;Acer negundo Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Boxelder IgE Ab RAST class [Presence] in Serum;Boxelder IgE RAST Ql;;ACTIVE;1.0l;2.73 +1558-6;Glucose^post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Fasting glucose [Mass/volume] in Serum or Plasma;Glucose p fast SerPl-mCnc;;ACTIVE;1.0;2.73 +15586-1;Bertholletia excelsa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Brazil Nut IgE Ab RAST class [Presence] in Serum;Brazil Nut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15587-9;Brassica oleracea var italica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Broccoli IgE Ab RAST class [Presence] in Serum;Broccoli IgE RAST Ql;;ACTIVE;1.0l;2.73 +15588-7;Bromelin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bromelin IgE Ab RAST class [Presence] in Serum;Bromelin IgE RAST Ql;;ACTIVE;1.0l;2.58 +15589-5;Brassica oleracea var gemmifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Brussel Sprouts IgE Ab RAST class [Presence] in Serum;Brussel Sprouts IgE RAST Ql;;ACTIVE;1.0l;2.73 +15590-3;Bovine serum albumin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bovine serum albumin (BSA) IgE Ab RAST class [Presence] in Serum;BSA IgE RAST Ql;;ACTIVE;1.0l;2.58 +15591-1;Fagopyrum esculentum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Buckwheat IgE Ab RAST class [Presence] in Serum;Buckwheat IgE RAST Ql;;ACTIVE;1.0l;2.73 +15592-9;Budgerigar feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Budgerigar feather IgE Ab RAST class [Presence] in Serum;Budgie Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +15593-7;Bombus terrestris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bumble Bee IgE Ab RAST class [Presence] in Serum;Bumble Bee IgE RAST Ql;;ACTIVE;1.0l;2.73 +1559-4;Insulin^1.5H post dose TOLBUTamide IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --1.5 hours post dose TOLBUTamide IV;Insulin 1.5M p TBM IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15594-5;Hymenoclea salsola Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Burrobrush IgE Ab RAST class [Presence] in Serum;Burrobrush IgE RAST Ql;;ACTIVE;1.0l;2.58 +15595-2;Iva xanthifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Burweed marshelder IgE Ab RAST class [Presence] in Serum;Burweed marshelder IgE RAST Ql;;ACTIVE;1.0l;2.73 +15596-0;Brassica oleracea var capitata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cabbage IgE Ab RAST class [Presence] in Serum;Cabbage IgE RAST Ql;;ACTIVE;1.0l;2.73 +15597-8;Theobroma cacao Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cocoa IgE Ab RAST class [Presence] in Serum;Cocoa IgE RAST Ql;;ACTIVE;1.0l;2.73 +15598-6;Canary feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canary feather IgE Ab RAST class [Presence] in Serum;Canary Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +15599-4;Candida albicans Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Candida albicans IgE Ab RAST class [Presence] in Serum;C albicans IgE RAST Ql;;ACTIVE;1.0l;2.73 +156-0;Cephaloridine;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cephaloridine [Susceptibility] by Minimum lethal concentration (MLC);Cephaloridine Islt MLC;;ACTIVE;1.0;2.19 +15600-0;Cucumis melo spp Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Melon IgE Ab RAST class in Serum;Deprecated Melon IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15601-8;Averrhoa carambola Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Starfruit IgE Ab RAST class [Presence] in Serum;Starfruit IgE RAST Ql;;ACTIVE;1.0l;2.58 +1560-2;Insulin^1H post dose TOLBUTamide IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --1 hour post dose TOLBUTamide IV;Insulin 1h p TBM IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15602-6;Carum carvi Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Caraway IgE Ab RAST class [Presence] in Serum;Caraway IgE RAST Ql;;ACTIVE;1.0l;2.73 +15603-4;Amaranthus palmeri Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Careless Weed IgE Ab RAST class [Presence] in Serum;Careless Weed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15604-2;Ceratonia siliqua Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Carob IgE Ab RAST class [Presence] in Serum;Carob IgE RAST Ql;;ACTIVE;1.0l;2.73 +15605-9;Daucus carota Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Carrot IgE Ab RAST class [Presence] in Serum;Carrot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15606-7;Casein Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Casein IgE Ab RAST class [Presence] in Serum;Casein IgE RAST Ql;;ACTIVE;1.0l;2.73 +15607-5;Anacardium occidentale Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cashew nut IgE Ab RAST class [Presence] in Serum;Cashew nut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15608-3;Cat Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Cat IgE Ab RAST class in Serum;Deprecated Cat IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15609-1;Cat dander Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cat dander IgE Ab RAST class [Presence] in Serum;Cat Dander IgE RAST Ql;;ACTIVE;1.0l;2.73 +1561-0;Insulin^1H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --1 hour post 75 g glucose PO;Insulin 1h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15610-9;Cat epithelium Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Cat epithelium IgE Ab RAST class in Serum;Deprecated Cat Epith IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15611-7;Ictalurus punctatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Catfish IgE Ab RAST class [Presence] in Serum;Catfish IgE RAST Ql;;ACTIVE;1.0l;2.73 +15612-5;Brassica oleracea var botrytis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cauliflower IgE Ab RAST class [Presence] in Serum;Cauliflower IgE RAST Ql;;ACTIVE;1.0l;2.73 +15613-3;Cedar italian Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Italian Cedar IgE Ab RAST class [Presence] in Serum;Italian Cedar IgE RAST Ql;;ACTIVE;1.0l;2.58 +15614-1;Cryptomeria japonica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Japanese Cedar IgE Ab RAST class [Presence] in Serum;Japanese Cedar IgE RAST Ql;;ACTIVE;1.0l;2.73 +15615-8;Juniperus sabinoides Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mountain Juniper IgE Ab RAST class [Presence] in Serum;Mt Juniper IgE RAST Ql;;ACTIVE;1.0l;2.73 +15616-6;Juniperus virginiana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Cedar IgE Ab RAST class [Presence] in Serum;Red Cedar IgE RAST Ql;;ACTIVE;1.0l;2.73 +15617-4;Tamarix spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saltcedar IgE Ab RAST class [Presence] in Serum;Saltcedar IgE RAST Ql;;ACTIVE;1.0l;2.58 +15618-2;Apium graveolens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Celery IgE Ab RAST class [Presence] in Serum;Celery IgE RAST Ql;;ACTIVE;1.0l;2.73 +15619-0;Acremonium sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Acremonium sp IgE Ab RAST class [Presence] in Serum;Acremonium IgE RAST Ql;;ACTIVE;1.0l;2.73 +15620-8;Chaetomium globosum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chaetomium globosum IgE Ab RAST class [Presence] in Serum;C globosum IgE RAST Ql;;ACTIVE;1.0l;2.73 +15621-6;Matricaria chamomilla Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chamomile IgE Ab RAST class [Presence] in Serum;Chamomile IgE RAST Ql;;ACTIVE;1.0l;2.58 +15622-4;Cheese American Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;American Cheese IgE Ab RAST class [Presence] in Serum;American Cheese IgE RAST Ql;;ACTIVE;1.0l;2.73 +15623-2;Cheese cheddar type Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cheese cheddar type IgE Ab RAST class [Presence] in Serum;Cheddar IgE RAST Ql;;ACTIVE;1.0l;2.73 +15624-0;Cheese cottage Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cottage Cheese IgE Ab RAST class [Presence] in Serum;Cottage Cheese IgE RAST Ql;;ACTIVE;1.0l;2.73 +15625-7;Cheese mozzarella Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mozzarella Cheese IgE Ab RAST class [Presence] in Serum;Mozzarella IgE RAST Ql;;ACTIVE;1.0l;2.73 +15626-5;Cheese parmesan Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parmesan Cheese IgE Ab RAST class [Presence] in Serum;Parmesan IgE RAST Ql;;ACTIVE;1.0l;2.73 +15627-3;Cheese swiss Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Swiss Cheese IgE Ab RAST class [Presence] in Serum;Swiss Cheese IgE RAST Ql;;ACTIVE;1.0l;2.73 +1562-8;Insulin^2.5H post dose TOLBUTamide IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --2.5 hours post dose TOLBUTamide IV;Insulin 2.5h p TBM IV SerPl-mCnc;;ACTIVE;1.0;2.40 +15628-1;Prunus avium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cherry IgE Ab RAST class [Presence] in Serum;Cherry IgE RAST Ql;;ACTIVE;1.0l;2.73 +15629-9;Castanea sativa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chestnut IgE Ab RAST class [Presence] in Serum;Chestnut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15630-7;Aesculus hippocastanum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse Chestnut IgE Ab RAST class [Presence] in Serum;Horse Chestnut IgE RAST Ql;;ACTIVE;1.0l;2.58 +15631-5;Castanea sativa Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Chestnut IgE Ab RAST class in Serum;Deprecated Chestnut IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15632-3;Castanea sativa pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chestnut Pollen IgE Ab RAST class [Presence] in Serum;Chestnut Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +15633-1;Chicken feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken feather IgE Ab RAST class [Presence] in Serum;Chicken Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +15634-9;Chicken meat Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken meat IgE Ab RAST class [Presence] in Serum;Chicken Meat IgE RAST Ql;;ACTIVE;1.0l;2.73 +15635-6;Cichorium intybus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicory IgE Ab RAST class [Presence] in Serum;Chicory IgE RAST Ql;;ACTIVE;1.0l;2.58 +1563-6;Insulin^2H post dose TOLBUTamide IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --2 hours post dose TOLBUTamide IV;Insulin 2h p TBM IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15636-4;Chinchilla Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chinchilla IgE Ab RAST class [Presence] in Serum;Chinchilla IgE RAST Ql;;ACTIVE;1.0l;2.58 +15637-2;Chloramin T Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chloramin T IgE Ab RAST class [Presence] in Serum;Chloramin T IgE RAST Ql;;ACTIVE;1.0l;2.58 +15638-0;Chortoglyphus arcuatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chortoglyphus arcuatus IgE Ab RAST class [Presence] in Serum;C arcuatus IgE RAST Ql;;ACTIVE;1.0l;2.58 +15639-8;Chymofast Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Chymofast IgE Ab RAST class in Serum;Deprecated Chymofast IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15640-6;Chymopapain Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chymopapain IgE Ab RAST class [Presence] in Serum;Chymopapain IgE RAST Ql;;ACTIVE;1.0l;2.58 +15641-4;Cinnamomum spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cinnamon IgE Ab RAST class [Presence] in Serum;Cinnamon IgE RAST Ql;;ACTIVE;1.0l;2.73 +15642-2;Cladosporium herbarum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cladosporium herbarum IgE Ab RAST class [Presence] in Serum;C herbarum IgE RAST Ql;;ACTIVE;1.0l;2.73 +15643-0;Ruditapes spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Clam IgE Ab RAST class [Presence] in Serum;Clam IgE RAST Ql;;ACTIVE;1.0l;2.73 +1564-4;Insulin^2H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --2 hours post 75 g glucose PO;Insulin 2h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15644-8;Syzygium aromaticum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Clove IgE Ab RAST class [Presence] in Serum;Clove IgE RAST Ql;;ACTIVE;1.0l;2.73 +15645-5;Clover Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Clover IgE Ab RAST class [Presence] in Serum;Clover IgE RAST Ql;;ACTIVE;1.0l;2.73 +15646-3;Xanthium commune Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cocklebur IgE Ab RAST class [Presence] in Serum;Cocklebur IgE RAST Ql;;ACTIVE;1.0l;2.73 +15647-1;Blatella germanica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cockroach IgE Ab RAST class [Presence] in Serum;Roach IgE RAST Ql;;ACTIVE;1.0l;2.73 +15648-9;Theobroma cacao Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Cocoa IgE Ab RAST class in Serum;Deprecated Cocoa IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15649-7;Cocos nucifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Coconut IgE Ab RAST class [Presence] in Serum;Coconut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15650-5;Gadus morhua Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Codfish IgE Ab RAST class [Presence] in Serum;Codfish IgE RAST Ql;;ACTIVE;1.0l;2.73 +1565-1;Insulin^30M post dose TOLBUTamide IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --30 minutes post dose TOLBUTamide IV;Insulin 30M p TBM IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15651-3;Coffea spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Coffee IgE Ab RAST class [Presence] in Serum;Coffee IgE RAST Ql;;ACTIVE;1.0l;2.73 +15652-1;Cola Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cola IgE Ab RAST class [Presence] in Serum;Cola IgE RAST Ql;;ACTIVE;1.0l;2.73 +15653-9;Zea mays Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Corn IgE Ab RAST class [Presence] in Serum;Corn IgE RAST Ql;;ACTIVE;1.0l;2.73 +15654-7;Zea mays pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cultivated Corn IgE Ab RAST class [Presence] in Serum;Cultivated Corn IgE RAST Ql;;ACTIVE;1.0l;2.73 +15655-4;Cotton cultivated Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cultivated Cotton IgE Ab RAST class [Presence] in Serum;Cultivated Cotton IgE RAST Ql;;ACTIVE;1.0l;2.58 +15656-2;Cotton fibers Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cotton fibers IgE Ab RAST class [Presence] in Serum;Cotton Fibers IgE RAST Ql;;ACTIVE;1.0l;2.73 +15657-0;Cotton western Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cotton western IgE Ab RAST class [Presence] in Serum;West Cotton IgE RAST Ql;;ACTIVE;1.0l;2.73 +15658-8;Cottonseed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cottonseed IgE Ab RAST class [Presence] in Serum;Cottonseed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15659-6;Populus deltoides Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cottonwood IgE Ab RAST class [Presence] in Serum;Cottonwood IgE RAST Ql;;ACTIVE;1.0l;2.73 +15660-4;Populus fremontii Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Western Cottonwood IgE Ab RAST class [Presence] in Serum;West Cottonwood IgE RAST Ql;;ACTIVE;1.0l;2.58 +15661-2;Cow dander Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cow dander IgE Ab RAST class [Presence] in Serum;Cow Dander IgE RAST Ql;;ACTIVE;1.0l;2.73 +15662-0;Cow epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cow epithelium IgE Ab RAST class [Presence] in Serum;Cow Epith IgE RAST Ql;;ACTIVE;1.0l;2.58 +15663-8;Cancer pagurus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Crab IgE Ab RAST class [Presence] in Serum;Crab IgE RAST Ql;;ACTIVE;1.0l;2.73 +15664-6;Vaccinium oxycoccos Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cranberry IgE Ab RAST class [Presence] in Serum;Cranberry IgE RAST Ql;;ACTIVE;1.0l;2.73 +15665-3;Astacus astacus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Crawfish IgE Ab RAST class [Presence] in Serum;Crawfish IgE RAST Ql;;ACTIVE;1.0l;2.73 +15666-1;Cryptococcus terreus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cryptococcus terreus IgE Ab RAST class [Presence] in Serum;C terreus IgE RAST Ql;;ACTIVE;1.0l;2.58 +15667-9;Cucumis sativus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cucumber IgE Ab RAST class [Presence] in Serum;Cucumber IgE RAST Ql;;ACTIVE;1.0l;2.73 +15668-7;Curry Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Curry IgE Ab RAST class [Presence] in Serum;Curry IgE RAST Ql;;ACTIVE;1.0l;2.73 +1566-9;Insulin^3H post dose TOLBUTamide IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --3 hours post dose TOLBUTamide IV;Insulin 3h p TBM IV SerPl-mCnc;;ACTIVE;1.0;2.73 +15669-5;Curvularia lunata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Curvularia lunata IgE Ab RAST class [Presence] in Serum;C lunata IgE RAST Ql;;ACTIVE;1.0l;2.73 +15670-3;Curvularia specifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Curvularia specifera IgE Ab RAST class [Presence] in Serum;C specifera IgE RAST Ql;;ACTIVE;1.0l;2.73 +15671-1;Cupressus arizonica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Arizona Cypress IgE Ab RAST class [Presence] in Serum;Arizona Cypress IgE RAST Ql;;ACTIVE;1.0l;2.73 +15672-9;Taxodium distichum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bald Cypress IgE Ab RAST class [Presence] in Serum;Bald Cypress IgE RAST Ql;;ACTIVE;1.0l;2.73 +15673-7;Cupressus sempervirens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Italian Cypress IgE Ab RAST class [Presence] in Serum;Italian Cypress IgE RAST Ql;;ACTIVE;1.0l;2.73 +15674-5;Bellis perennis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Daisy IgE Ab RAST class [Presence] in Serum;Daisy IgE RAST Ql;;ACTIVE;1.0l;2.58 +15675-2;Chrysanthemum leucanthemum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ox-eye daisy IgE Ab RAST class [Presence] in Serum;Ox-eye daisy IgE RAST Ql;;ACTIVE;1.0l;2.73 +15676-0;Taraxacum vulgare Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dandelion IgE Ab RAST class [Presence] in Serum;Dandelion IgE RAST Ql;;ACTIVE;1.0l;2.73 +1567-7;Insulin^3H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --3 hours post 75 g glucose PO;Insulin 3h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15677-8;Daphnia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Daphnia (fish feed) IgE Ab RAST class [Presence] in Serum;Daphnia IgE RAST Ql;;ACTIVE;1.0l;2.58 +15678-6;Phoenix canariensis pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Date Palm Pollen IgE Ab RAST class [Presence] in Serum;Date Palm Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +15679-4;Deer epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Deer epithelium IgE Ab RAST class [Presence] in Serum;Deer Epith IgE RAST Ql;;ACTIVE;1.0l;2.58 +15680-2;Dermatophagoides farinae Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;American house dust mite IgE Ab RAST class [Presence] in Serum;D farinae IgE RAST Ql;;ACTIVE;1.0l;2.73 +15681-0;Dermatophagoides microceras Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dermatophagoides microceras IgE Ab RAST class [Presence] in Serum;D microceras IgE RAST Ql;;ACTIVE;1.0l;2.73 +15682-8;Dermatophagoides pteronyssinus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European house dust mite IgE Ab RAST class [Presence] in Serum;D pteronyss IgE RAST Ql;;ACTIVE;1.0l;2.73 +15683-6;Anethum graveolens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dill IgE Ab RAST class [Presence] in Serum;Dill IgE RAST Ql;;ACTIVE;1.0l;2.73 +15684-4;Rumex crispus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yellow Dock IgE Ab RAST class [Presence] in Serum;Yellow Dock IgE RAST Ql;;ACTIVE;1.0l;2.73 +1568-5;Insulin^4H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --4 hours post 75 g glucose PO;Insulin 4h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15685-1;Dog dander Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog dander IgE Ab RAST class [Presence] in Serum;Dog Dander IgE RAST Ql;;ACTIVE;1.0l;2.73 +15686-9;Dog epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog epithelium IgE Ab RAST class [Presence] in Serum;Dog Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +15687-7;Duck feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Duck feather IgE Ab RAST class [Presence] in Serum;Duck Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +15688-5;Echinococcus sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Echinococcus sp IgE Ab RAST class [Presence] in Serum;Echinococcus IgE RAST Ql;;ACTIVE;1.0l;2.73 +15689-3;Egg white Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Egg white IgE Ab RAST class [Presence] in Serum;Egg White IgE RAST Ql;;ACTIVE;1.0l;2.73 +15690-1;Egg whole Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Whole Egg IgE Ab RAST class [Presence] in Serum;Whole Egg IgE RAST Ql;;ACTIVE;1.0l;2.73 +15691-9;Egg yolk Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Egg yolk IgE Ab RAST class [Presence] in Serum;Egg Yolk IgE RAST Ql;;ACTIVE;1.0l;2.73 +15692-7;Solanum melongena Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Eggplant IgE Ab RAST class [Presence] in Serum;Eggplant IgE RAST Ql;;ACTIVE;1.0l;2.73 +1569-3;Insulin^5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --5 hours post 75 g glucose PO;Insulin 5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15693-5;Iva ciliata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rough Marsh Elder IgE Ab RAST class [Presence] in Serum;Marsh Elder IgE RAST Ql;;ACTIVE;1.0l;2.73 +15694-3;Sambucus nigra Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Elder IgE Ab RAST class [Presence] in Serum;Elder IgE RAST Ql;;ACTIVE;1.0l;2.73 +15695-0;Sambucus nigra Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Elderberry IgE Ab RAST class in Serum;Deprecated Elderberry IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15696-8;Elk meat Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Elk or Moose Meat IgE Ab RAST class [Presence] in Serum;Elk Meat IgE RAST Ql;;ACTIVE;1.0l;2.58 +15697-6;Ulmus americana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Elm IgE Ab RAST class [Presence] in Serum;White Elm IgE RAST Ql;;ACTIVE;1.0l;2.73 +15698-4;Ulmus pumila Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chinese Elm IgE Ab RAST class [Presence] in Serum;Chinese Elm IgE RAST Ql;;ACTIVE;1.0l;2.73 +15699-2;Cichorium endivia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Endive IgE Ab RAST class [Presence] in Serum;Endive IgE RAST Ql;;ACTIVE;1.0l;2.58 +15700-8;Epicoccum purpurascens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Epicoccum purpurascens IgE Ab RAST class [Presence] in Serum;E purpurascens IgE RAST Ql;;ACTIVE;1.0l;2.73 +1570-1;Insulin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --baseline;Insulin BS SerPl-mCnc;;ACTIVE;1.0;2.73 +15701-6;Epidermophyton floccosum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Epidermophyton floccosum IgE Ab RAST class [Presence] in Serum;E floccosum IgE RAST Ql;;ACTIVE;1.0l;2.73 +15702-4;Ethylene oxide Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ethylene oxide IgE Ab RAST class [Presence] in Serum;Ethylene Oxide IgE RAST Ql;;ACTIVE;1.0l;2.73 +15703-2;Eucalyptus spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gum-Tree IgE Ab RAST class [Presence] in Serum;Gum-Tree IgE RAST Ql;;ACTIVE;1.0l;2.73 +15704-0;Euroglyphus maynei Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Euroglyphus maynei IgE Ab RAST class [Presence] in Serum;E maynei IgE RAST Ql;;ACTIVE;1.0l;2.73 +15705-7;Anthemis cotula Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog Fennel IgE Ab RAST class [Presence] in Serum;Dog Fennel IgE RAST Ql;;ACTIVE;1.0l;2.73 +15706-5;Foeniculum vulgare fresh Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fennel Fresh IgE Ab RAST class [Presence] in Serum;Fennel Fresh IgE RAST Ql;;ACTIVE;1.0l;2.73 +15707-3;Foeniculum vulgare seed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fennel Seed IgE Ab RAST class [Presence] in Serum;Fennel Seed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15708-1;Ferret epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ferret epithelium IgE Ab RAST class [Presence] in Serum;Ferret Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +15709-9;Festuca elatior Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Meadow Fescue IgE Ab RAST class [Presence] in Serum;Meadow Fescue IgE RAST Ql;;ACTIVE;1.0l;2.73 +15710-7;Finch feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Finch feather IgE Ab RAST class [Presence] in Serum;Finch Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +15711-5;Pseudotsuga taxifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Douglas Fir IgE Ab RAST class [Presence] in Serum;Douglas Fir IgE RAST Ql;;ACTIVE;1.0l;2.73 +15712-3;Kochia scoparia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Firebush IgE Ab RAST class [Presence] in Serum;Firebush IgE RAST Ql;;ACTIVE;1.0l;2.73 +15713-1;Fiscus sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fiscus sp IgE Ab RAST class [Presence] in Serum;Fiscus IgE RAST Ql;;ACTIVE;1.0l;2.58 +15714-9;Ctenocephalides sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Flea IgE Ab RAST class [Presence] in Serum;Flea IgE RAST Ql;;ACTIVE;1.0l;2.73 +15715-6;Flounder Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Flounder IgE Ab RAST class [Presence] in Serum;Flounder IgE RAST Ql;;ACTIVE;1.0l;2.73 +15716-4;Simulium venustum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Fly IgE Ab RAST class [Presence] in Serum;Black Fly IgE RAST Ql;;ACTIVE;1.0l;2.58 +15717-2;Tabanus spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse Fly IgE Ab RAST class [Presence] in Serum;Horse Fly IgE RAST Ql;;ACTIVE;1.0l;2.73 +15718-0;Formaldehyde Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Formaldehyde IgE Ab RAST class [Presence] in Serum;Formaldehyde IgE RAST Ql;;ACTIVE;1.0l;2.73 +1571-9;Insulin^pre dose TOLBUTamide IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --pre dose TOLBUTamide IV;Insulin pre TBM IV SerPl-mCnc;;ACTIVE;1.0;2.40 +15719-8;Fox Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fox IgE Ab RAST class [Presence] in Serum;Fox IgE RAST Ql;;ACTIVE;1.0l;2.58 +15720-6;Alopercurus pratensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Meadow Foxtail IgE Ab RAST class [Presence] in Serum;Meadow Foxtail IgE RAST Ql;;ACTIVE;1.0l;2.73 +15721-4;Fusarium culmorum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fusarium culmorum IgE Ab RAST class [Presence] in Serum;F culmorum IgE RAST Ql;;ACTIVE;1.0l;2.58 +15722-2;Fusarium moniliforme Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fusarium moniliforme IgE Ab RAST class [Presence] in Serum;F moniliforme IgE RAST Ql;;ACTIVE;1.0l;2.73 +15723-0;Fusarium solani Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fusarium solani IgE Ab RAST class [Presence] in Serum;F solani IgE RAST Ql;;ACTIVE;1.0l;2.73 +15724-8;Allium sativum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Garlic IgE Ab RAST class [Presence] in Serum;Garlic IgE RAST Ql;;ACTIVE;1.0l;2.73 +15725-5;Gelatin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gelatin IgE Ab RAST class [Presence] in Serum;Gelatin IgE RAST Ql;;ACTIVE;1.0l;2.73 +15726-3;Geotrichum candidum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Geotrichum candidum IgE Ab RAST class [Presence] in Serum;G candidum IgE RAST Ql;;ACTIVE;1.0l;2.73 +1572-7;Insulin^pre 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --pre 75 g glucose PO;Insulin pre 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0;2.40 +15727-1;Gerbil Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gerbil IgE Ab RAST class [Presence] in Serum;Gerbil IgE RAST Ql;;ACTIVE;1.0l;2.73 +15728-9;Zingiber officinale Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ginger IgE Ab RAST class [Presence] in Serum;Ginger IgE RAST Ql;;ACTIVE;1.0l;2.73 +15729-7;Gluten Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gluten IgE Ab RAST class [Presence] in Serum;Gluten IgE RAST Ql;;ACTIVE;1.0l;2.73 +15730-5;Glycyphagus domesticus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Glycyphagus domesticus IgE Ab RAST class [Presence] in Serum;G domesticus IgE RAST Ql;;ACTIVE;1.0l;2.73 +15731-3;Goat epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Goat epithelium IgE Ab RAST class [Presence] in Serum;Goat Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +15732-1;Goat milk Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Goat milk IgE Ab RAST class [Presence] in Serum;Goat Milk IgE RAST Ql;;ACTIVE;1.0l;2.73 +15733-9;Solidago virgaurea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Goldenrod IgE Ab RAST class [Presence] in Serum;Goldenrod IgE RAST Ql;;ACTIVE;1.0l;2.73 +15734-7;Goose feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Goose feather IgE Ab RAST class [Presence] in Serum;Goose Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +1573-5;Insulin^post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --12 hours fasting;Insulin p 12h fast SerPl-mCnc;;ACTIVE;1.0;2.73 +15735-4;Vitis vinifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Grape IgE Ab RAST class [Presence] in Serum;Grape IgE RAST Ql;;ACTIVE;1.0l;2.73 +15736-2;Citrus paradisis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Grapefruit IgE Ab RAST class [Presence] in Serum;Grapefruit IgE RAST Ql;;ACTIVE;1.0l;2.73 +15737-0;Paspalum notatum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bahia grass IgE Ab RAST class [Presence] in Serum;Bahia grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15738-8;Cynodon dactylon Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bermuda grass IgE Ab RAST class [Presence] in Serum;Bermuda grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15739-6;Poa compressa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canadian blue grass IgE Ab RAST class [Presence] in Serum;Can blue grass IgE RAST Ql;;ACTIVE;1.0l;2.58 +15740-4;Bromus inermis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Brome IgE Ab RAST class [Presence] in Serum;Brome IgE RAST Ql;;ACTIVE;1.0l;2.73 +15741-2;Arrhenatherum elatius Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;False oat grass IgE Ab RAST class [Presence] in Serum;False oat grass IgE RAST Ql;;ACTIVE;1.0l;2.58 +15742-0;Bouteloua gracilis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gramma grass (Bouteloua gracilis) IgE Ab RAST class [Presence] in Serum;Gramma grass IgE RAST Ql;;ACTIVE;1.0l;2.58 +1574-3;17-Ketogenic steroids^24H post 40 ug corticotropin IM BID 3 day;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --24 hours post 40 ug corticotropin IM BID 3 day;17KGS 1D p 40 ug ACTH IM 24h Ur-mRate;;ACTIVE;1.0;2.42 +15743-8;Sorghum halepense Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Johnson grass IgE Ab RAST class [Presence] in Serum;Johnson grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15744-6;Poa pratensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Kentucky blue grass IgE Ab RAST class [Presence] in Serum;Kent blue grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15745-3;Grass koehlers Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Koehlers grass IgE Ab RAST class [Presence] in Serum;Koehlers grass IgE RAST Ql;;ACTIVE;1.0l;2.58 +15746-1;Dactylis glomerata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cocksfoot IgE Ab RAST class [Presence] in Serum;Cocksfoot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15747-9;Agropyron repens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Quack grass IgE Ab RAST class [Presence] in Serum;Quack grass IgE RAST Ql;;ACTIVE;1.0l;2.58 +15748-7;Agrostis stolonifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red top grass IgE Ab RAST class [Presence] in Serum;Red top grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15749-5;Lolium perenne Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Perennial rye grass IgE Ab RAST class [Presence] in Serum;Per rye grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +1575-0;17-Ketogenic steroids^48H post 40 ug corticotropin IM BID 3 day;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --48 hours post 40 ug corticotropin IM BID 3 day;17KGS 2D p 40 ug ACTH IM 24h Ur-mRate;;ACTIVE;1.0;2.42 +15750-3;Lolium perenne Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Grass rye Italian IgE Ab RAST class in Serum;Deprecated Per rye grass IgE RAST Ql;;DEPRECATED;1.0l;2.40 +15751-1;Elymus triticoides Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wild rye grass IgE Ab RAST class [Presence] in Serum;Wild rye grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15752-9;Distichlis spicata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Salt grass IgE Ab RAST class [Presence] in Serum;Salt grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15753-7;Grass sorghum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sorghum grass IgE Ab RAST class [Presence] in Serum;Sorghum grass IgE RAST Ql;;ACTIVE;1.0l;2.58 +15754-5;Sorghum sudanense Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sudan grass IgE Ab RAST class [Presence] in Serum;Sudan grass IgE RAST Ql;;ACTIVE;1.0l;2.58 +15755-2;Anthoxanthum odoratum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sweet Vernal grass IgE Ab RAST class [Presence] in Serum;Sw Vernal grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15756-0;Holcus lanatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Velvet grass IgE Ab RAST class [Presence] in Serum;Velvet grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15757-8;Cyamopsis tetragonoloba Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Guar gum IgE Ab RAST class [Presence] in Serum;Guar gum IgE RAST Ql;;ACTIVE;1.0l;2.73 +15758-6;Psidium guajava Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Guava IgE Ab RAST class [Presence] in Serum;Guava IgE RAST Ql;;ACTIVE;1.0l;2.73 +15759-4;Guinea pig epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Guinea pig epithelium IgE Ab RAST class [Presence] in Serum;Guinea Pig Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +15760-2;Gum arabic Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gum arabic IgE Ab RAST class [Presence] in Serum;Gum Arabic IgE RAST Ql;;ACTIVE;1.0l;2.73 +15761-0;Liquidambar styraciflua Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sweet gum IgE Ab RAST class [Presence] in Serum;Sweet gum IgE RAST Ql;;ACTIVE;1.0l;2.73 +15762-8;Celtis occidentalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hackberry tree IgE Ab RAST class [Presence] in Serum;Hackberry tree IgE RAST Ql;;ACTIVE;1.0l;2.73 +15763-6;Melanogrammus aeglefinus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Haddock IgE Ab RAST class [Presence] in Serum;Haddock IgE RAST Ql;;ACTIVE;1.0l;2.73 +15764-4;Hippoglossus hippoglossus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Halibut IgE Ab RAST class [Presence] in Serum;Halibut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15765-1;Hamster epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hamster epithelium IgE Ab RAST class [Presence] in Serum;Hmtr Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +15766-9;Corylus avellana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hazelnut IgE Ab RAST class [Presence] in Serum;Hazelnut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15767-7;Corylus avellana pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hazelnut Pollen IgE Ab RAST class [Presence] in Serum;Hazelnut Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +1576-8;17-Ketogenic steroids^48H post 500 ug dexamethasone PO 2.5 day low dose q6h;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --48 hours post 500 ug dexamethasone PO 2.5 day low dose q6h;17KGS 48h p 500 ug Dex 24h Ur-mRate;;ACTIVE;1.0;2.73 +15768-5;Helminthosporium sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Helminthosporium sp IgE Ab RAST class [Presence] in Serum;Helminthosporium IgE RAST Ql;;ACTIVE;1.0l;2.73 +15769-3;Setomelanomma rostrata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Setomelanomma rostrata IgE Ab RAST class [Presence] in Serum;S rostrata IgE RAST Ql;;ACTIVE;1.0l;2.73 +15770-1;Tsuga canadensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Eastern Hemlock IgE Ab RAST class [Presence] in Serum;East Hemlock IgE RAST Ql;;ACTIVE;1.0l;2.58 +15771-9;Amaranthus tuberculatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Water Hemp IgE Ab RAST class [Presence] in Serum;Water Hemp IgE RAST Ql;;ACTIVE;1.0l;2.73 +15772-7;Clupea harengus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Herring IgE Ab RAST class [Presence] in Serum;Herring IgE RAST Ql;;ACTIVE;1.0l;2.73 +15773-5;Carya illinoinensis nut Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pecan or Hickory Nut IgE Ab RAST class [Presence] in Serum;Pecan/Hick Nut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15774-3;Carya illinoinensis tree Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pecan or Hickory Tree IgE Ab RAST class [Presence] in Serum;Pecan/Hick Tree IgE RAST Ql;;ACTIVE;1.0l;2.73 +15775-0;Carya laciniosa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Shellbark Hickory IgE Ab RAST class [Presence] in Serum;Shellbark Hickory IgE RAST Ql;;ACTIVE;1.0l;2.58 +1577-6;17-Ketogenic steroids^48H post 2 mg dexamethasone PO 2.5 day high dose q6h;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --48 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;17KGS 48h p 2 mg Dex 24h Ur-mRate;;ACTIVE;1.0;2.42 +15776-8;Carya tomentosa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Hickory IgE Ab RAST class [Presence] in Serum;White Hickory IgE RAST Ql;;ACTIVE;1.0l;2.73 +15777-6;Honey Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey IgE Ab RAST class [Presence] in Serum;Honey IgE RAST Ql;;ACTIVE;1.0l;2.73 +15778-4;Honeysuckle Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honeysuckle IgE Ab RAST class [Presence] in Serum;Honeysuckle IgE RAST Ql;;ACTIVE;1.0l;2.58 +15779-2;Humulus lupus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hop IgE Ab RAST class [Presence] in Serum;Hop IgE RAST Ql;;ACTIVE;1.0l;2.73 +157-8;Cephaloridine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cephaloridine [Susceptibility] by Minimum inhibitory concentration (MIC);Cephaloridine Islt MIC;;ACTIVE;1.0;2.19 +15780-0;Carpinus betulus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horn beam IgE Ab RAST class [Presence] in Serum;Horn beam IgE RAST Ql;;ACTIVE;1.0l;2.58 +15781-8;Hornet Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hornet IgE Ab RAST class [Presence] in Serum;Hornet IgE RAST Ql;;ACTIVE;1.0l;2.58 +15782-6;Dolichovespula maculata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Whitefaced Hornet IgE Ab RAST class [Presence] in Serum;Whitefaced Hornet IgE RAST Ql;;ACTIVE;1.0l;2.73 +15783-4;Dolichovespula arenaria Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yellow Hornet IgE Ab RAST class [Presence] in Serum;Yellow Hornet IgE RAST Ql;;ACTIVE;1.0l;2.73 +1578-4;17-Ketogenic steroids^72H post 40 ug corticotropin IM BID 3 day;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --72 hours post 40 ug corticotropin IM BID 3 day;17KGS 72h p 40 ug ACTH IM 24h Ur-mRate;;ACTIVE;1.0;2.42 +15784-2;Horse dander Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse dander IgE Ab RAST class [Presence] in Serum;Horse Dander IgE RAST Ql;;ACTIVE;1.0l;2.73 +15785-9;Horse epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse epithelium IgE Ab RAST class [Presence] in Serum;Horse Epith IgE RAST Ql;;ACTIVE;1.0l;2.58 +15786-7;Horse serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse serum proteins IgE Ab RAST class [Presence] in Serum;Horse Serum Prot IgE RAST Ql;;ACTIVE;1.0l;2.58 +15787-5;Armoracia rusticana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horseradish IgE Ab RAST class [Presence] in Serum;Horseradish IgE RAST Ql;;ACTIVE;1.0l;2.73 +15788-3;House dust Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;House dust IgE Ab RAST class [Presence] in Serum;House Dust IgE RAST Ql;;ACTIVE;1.0l;2.73 +15789-1;House dust Greer Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;House dust Greer IgE Ab RAST class [Presence] in Serum;House Dust Greer IgE RAST Ql;;ACTIVE;1.0l;2.73 +15790-9;House dust Hausstaub Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;House dust Hausstaub IgE Ab RAST class [Presence] in Serum;House Dust Hauss IgE RAST Ql;;ACTIVE;1.0l;2.58 +15791-7;House dust Hollister Stier Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;House dust Hollister Stier IgE Ab RAST class [Presence] in Serum;House Dust HS IgE RAST Ql;;ACTIVE;1.0l;2.73 +1579-2;17-Ketogenic steroids^pre 50 ug corticotropin IM 3 day;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --pre 50 ug corticotropin IM 3 day;17KGS pre 50 ug ACTH IM 24h Ur-mRate;;ACTIVE;1.0;2.42 +15792-5;Insulin bovine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Insulin bovine IgE Ab RAST class [Presence] in Serum;Insulin Bovine IgE RAST Ql;;ACTIVE;1.0l;2.73 +15793-3;Insulin human Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Insulin human IgE Ab RAST class [Presence] in Serum;Insulin Human IgE RAST Ql;;ACTIVE;1.0l;2.73 +15794-1;Insulin porcine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Insulin porcine IgE Ab RAST class [Presence] in Serum;Insulin Porcine IgE RAST Ql;;ACTIVE;1.0l;2.73 +15795-8;Allenrolfea occidentalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Iodinebush IgE Ab RAST class [Presence] in Serum;Iodinebush IgE RAST Ql;;ACTIVE;1.0l;2.58 +15796-6;Hexamethylene diisocyanate (HDI) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Isocyanate HDI IgE Ab RAST class [Presence] in Serum;Isocyanate HDI IgE RAST Ql;;ACTIVE;1.0l;2.73 +15797-4;Diphenylmethane diisocyanate (MDI) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Isocyanate MDI IgE Ab RAST class [Presence] in Serum;Isocyanate MDI IgE RAST Ql;;ACTIVE;1.0l;2.73 +15798-2;Toluene diisocyanate (TDI) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Isocyanate TDI IgE Ab RAST class [Presence] in Serum;Isocyanate TDI IgE RAST Ql;;ACTIVE;1.0l;2.73 +15799-0;Ispaghula laxative Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ispaghula laxative IgE Ab RAST class [Presence] in Serum;Ispaghula IgE RAST Ql;;ACTIVE;1.0l;2.73 +15-8;Amoxicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Amoxicillin [Susceptibility] by Minimum lethal concentration (MLC);Amoxicillin Islt MLC;;ACTIVE;1.0;2.19 +1580-0;17-Ketogenic steroids^pre 500 ug dexamethasone PO 2.5 day low dose q6h;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --pre 500 ug dexamethasone PO 2.5 day low dose q6h;17KGS pre 500 ug Dex 24h Ur-mRate;;ACTIVE;1.0;2.42 +15800-6;Juniper Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Juniper IgE Ab RAST class [Presence] in Serum;Juniper IgE RAST Ql;;ACTIVE;1.0l;2.58 +15801-4;Kapok Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Kapok IgE Ab RAST class [Presence] in Serum;Kapok IgE RAST Ql;;ACTIVE;1.0l;2.58 +15802-2;Actinidia chinensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Kiwifruit IgE Ab RAST class [Presence] in Serum;Kiwifruit IgE RAST Ql;;ACTIVE;1.0l;2.73 +15803-0;Lamb Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lamb IgE Ab RAST class [Presence] in Serum;Lamb IgE RAST Ql;;ACTIVE;1.0l;2.73 +15804-8;Mutton Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Mutton IgE Ab RAST class in Serum;Deprecated Mutton IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15805-5;Chenopodium album Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Goosefoot IgE Ab RAST class [Presence] in Serum;Goosefoot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15806-3;Latex Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex IgE Ab RAST class [Presence] in Serum;Ltx IgE RAST Ql;;ACTIVE;1.0l;2.73 +15807-1;Latex glove extract Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex glove extract IgE Ab RAST class [Presence] in Serum;Ltx Glv Ext IgE RAST Ql;;ACTIVE;1.0l;2.73 +15808-9;Latex glove extract ammoniated Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex glove extract ammoniated IgE Ab RAST class [Presence] in Serum;Ltx Glv Ext Ammon IgE RAST Ql;;ACTIVE;1.0l;2.73 +15809-7;Latex glove extract buffered Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex glove extract buffered IgE Ab RAST class [Presence] in Serum;Ltx Glv Ext Buff IgE RAST Ql;;ACTIVE;1.0l;2.58 +15810-5;Legume Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Legume IgE Ab RAST class [Presence] in Serum;Legume IgE RAST Ql;;ACTIVE;1.0l;2.58 +15811-3;Citrus limon Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lemon IgE Ab RAST class [Presence] in Serum;Lemon IgE RAST Ql;;ACTIVE;1.0l;2.73 +15812-1;Atriplex lentiformis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lenscale IgE Ab RAST class [Presence] in Serum;Lenscale IgE RAST Ql;;ACTIVE;1.0l;2.73 +15813-9;Lens esculenta Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lentils IgE Ab RAST class [Presence] in Serum;Lentils IgE RAST Ql;;ACTIVE;1.0l;2.73 +15814-7;Lepidoglyphus destructor Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lepidoglyphus destructor IgE Ab RAST class [Presence] in Serum;L destructor IgE RAST Ql;;ACTIVE;1.0l;2.73 +15815-4;Lactuca sativa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lettuce IgE Ab RAST class [Presence] in Serum;Lettuce IgE RAST Ql;;ACTIVE;1.0l;2.73 +15816-2;Syringa vulgaris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lilac IgE Ab RAST class [Presence] in Serum;Lilac IgE RAST Ql;;ACTIVE;1.0l;2.58 +15817-0;Lilium longiflorum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Easter lily IgE Ab RAST class [Presence] in Serum;Easter lily IgE RAST Ql;;ACTIVE;1.0l;2.58 +1581-8;17-Ketogenic steroids^pre 2 mg dexamethasone PO 2.5 day high dose q6h;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --pre 2 mg dexamethasone PO 2.5 day high dose q6h;17KGS pre 2 mg Dex high 24h Ur-mRate;;ACTIVE;1.0;2.42 +15818-8;Citrus aurantifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lime IgE Ab RAST class [Presence] in Serum;Lime IgE RAST Ql;;ACTIVE;1.0l;2.73 +15819-6;Tilia cordata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Linden IgE Ab RAST class [Presence] in Serum;Linden IgE RAST Ql;;ACTIVE;1.0l;2.73 +15820-4;Liver beef Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Liver beef IgE Ab RAST class [Presence] in Serum;Liver Beef IgE RAST Ql;;ACTIVE;1.0l;2.58 +15821-2;Homarus gammarus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lobster IgE Ab RAST class [Presence] in Serum;Lobster IgE RAST Ql;;ACTIVE;1.0l;2.73 +15822-0;Palinurus spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spiny lobster IgE Ab RAST class [Presence] in Serum;Spiny lobster IgE RAST Ql;;ACTIVE;1.0l;2.73 +15823-8;Robinia pseudoacacia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Locust IgE Ab RAST class [Presence] in Serum;Black Locust IgE RAST Ql;;ACTIVE;1.0l;2.73 +15824-6;Lupinus spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lupin IgE Ab RAST class [Presence] in Serum;Lupin IgE RAST Ql;;ACTIVE;1.0l;2.58 +15825-3;Lycopodium spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lycopodium spp IgE Ab RAST class [Presence] in Serum;Lycopodium IgE RAST Ql;;ACTIVE;1.0l;2.58 +1582-6;Lactose^1H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Mass/volume] in Serum or Plasma --1 hour post 50 g lactose PO;Lactose 1h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15826-1;Lysozyme Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lysozyme IgE Ab RAST class [Presence] in Serum;Lysozyme IgE RAST Ql;;ACTIVE;1.0l;2.58 +15827-9;Scomber scombrus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mackerel IgE Ab RAST class [Presence] in Serum;Mackerel IgE RAST Ql;;ACTIVE;1.0l;2.73 +15828-7;Scomber japonicus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chub Mackerel IgE Ab RAST class [Presence] in Serum;Chub Mackerel IgE RAST Ql;;ACTIVE;1.0l;2.58 +15829-5;Trachurus japonicus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Scad IgE Ab RAST class [Presence] in Serum;Scad IgE RAST Ql;;ACTIVE;1.0l;2.73 +15830-3;Zea mays Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Corn IgE Ab RAST class in Serum;Deprecated Corn IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15831-1;Malt Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Malt IgE Ab RAST class [Presence] in Serum;Malt IgE RAST Ql;;ACTIVE;1.0l;2.73 +15832-9;Mangifera indica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mango IgE Ab RAST class [Presence] in Serum;Mango IgE RAST Ql;;ACTIVE;1.0l;2.73 +15833-7;Acer macrophyllum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Coastal Maple IgE Ab RAST class [Presence] in Serum;Coastal Maple IgE RAST Ql;;ACTIVE;1.0l;2.73 +1583-4;Lactose^2H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Mass/volume] in Serum or Plasma --2 hours post 50 g lactose PO;Lactose 2h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0;2.34 +15834-5;Acer rubrum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Maple IgE Ab RAST class [Presence] in Serum;Red Maple IgE RAST Ql;;ACTIVE;1.0l;2.73 +15835-2;Maple silver Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Maple IgE Ab RAST class [Presence] in Serum;Silver Maple IgE RAST Ql;;ACTIVE;1.0l;2.58 +15836-0;Maple sugar Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Maple sugar IgE Ab RAST class [Presence] in Serum;Maple sugar IgE RAST Ql;;ACTIVE;1.0l;2.73 +15837-8;Mare milk Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mare milk IgE Ab RAST class [Presence] in Serum;Mare Milk IgE RAST Ql;;ACTIVE;1.0l;2.58 +15838-6;Origanum majorana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Marjoram IgE Ab RAST class [Presence] in Serum;Marjoram IgE RAST Ql;;ACTIVE;1.0l;2.73 +15839-4;Maxatase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Maxatase IgE Ab RAST class [Presence] in Serum;Maxatase IgE RAST Ql;;ACTIVE;1.0l;2.58 +15840-2;Lepidorhombus whiffiagonis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Whiff IgE Ab RAST class [Presence] in Serum;Whiff IgE RAST Ql;;ACTIVE;1.0l;2.58 +15841-0;Melaleuca leucadendron Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cajeput tree IgE Ab RAST class [Presence] in Serum;Cajeput tree IgE RAST Ql;;ACTIVE;1.0l;2.73 +1584-2;Lactose^30M post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Mass/volume] in Serum or Plasma --30 minutes post 50 g lactose PO;Lactose 30M p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0;2.73 +15842-8;Cucumis melo spp Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Melon IgE Ab RAST class in Serum;Deprecated Melon IgE RAST Ql;;DEPRECATED;1.0l;2.66 +15843-6;Prosopis juliflora Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mesquite IgE Ab RAST class [Presence] in Serum;Mesquite IgE RAST Ql;;ACTIVE;1.0l;2.73 +15844-4;Chenopodium ambrosioides Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mexican tea IgE Ab RAST class [Presence] in Serum;Mexican tea IgE RAST Ql;;ACTIVE;1.0l;2.73 +15845-1;Cladotanytarsus lewisi Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Green Nimitti IgE Ab RAST class [Presence] in Serum;Green Nimitti IgE RAST Ql;;ACTIVE;1.0l;2.73 +15846-9;Milk Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Milk IgE Ab RAST class [Presence] in Serum;Milk IgE RAST Ql;;ACTIVE;1.0l;2.73 +15847-7;Cow milk boiled Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cow milk boiled IgE Ab RAST class [Presence] in Serum;Cow Milk Boiled IgE RAST Ql;;ACTIVE;1.0l;2.73 +15848-5;Milk powder Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Milk powder IgE Ab RAST class [Presence] in Serum;Milk Powder IgE RAST Ql;;ACTIVE;1.0l;2.73 +15849-3;Panicum milliaceum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common Millet IgE Ab RAST class [Presence] in Serum;Common Millet IgE RAST Ql;;ACTIVE;1.0l;2.73 +15850-1;Setaria italica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Foxtail Millet IgE Ab RAST class [Presence] in Serum;Foxtail Millet IgE RAST Ql;;ACTIVE;1.0l;2.58 +15851-9;Echinochloa crus-galli Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cockspur IgE Ab RAST class [Presence] in Serum;Cockspur IgE RAST Ql;;ACTIVE;1.0l;2.73 +15852-7;Mink epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mink epithelium IgE Ab RAST class [Presence] in Serum;Mink Epith IgE RAST Ql;;ACTIVE;1.0l;2.58 +15853-5;Mentha piperita Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mint IgE Ab RAST class [Presence] in Serum;Mint IgE RAST Ql;;ACTIVE;1.0l;2.73 +15854-3;Cheese mold type Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cheese mold type IgE Ab RAST class [Presence] in Serum;Cheese Mold IgE RAST Ql;;ACTIVE;1.0l;2.73 +15855-0;Chrysonilia sitophila Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chrysonilia sitophila IgE Ab RAST class [Presence] in Serum;C sitophila IgE RAST Ql;;ACTIVE;1.0l;2.58 +15856-8;Aedes communis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aedes mosquito IgE Ab RAST class [Presence] in Serum;Aedes mosquito IgE RAST Ql;;ACTIVE;1.0l;2.73 +15857-6;Moth Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Moth IgE Ab RAST class [Presence] in Serum;Moth IgE RAST Ql;;ACTIVE;1.0l;2.73 +15858-4;Ephestia kuehniella Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mediterranean flour moth IgE Ab RAST class [Presence] in Serum;Med flour moth IgE RAST Ql;;ACTIVE;1.0l;2.58 +1585-9;Lactose^pre 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Mass/volume] in Serum or Plasma --pre 12 hour fast;Lactose pre 12h fast SerPl-mCnc;;ACTIVE;1.0;2.34 +15859-2;Mouse epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mouse epithelium IgE Ab RAST class [Presence] in Serum;Mouse Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +158-6;Cephaloridine;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cephaloridine [Susceptibility] by Disk diffusion (KB);Cephaloridine Islt KB;;ACTIVE;1.0;2.19 +15860-0;Mouse serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mouse serum proteins IgE Ab RAST class [Presence] in Serum;Mouse Serum Prot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15861-8;Mouse urine proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mouse urine proteins IgE Ab RAST class [Presence] in Serum;Mouse Urine Prot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15862-6;Mucor racemosus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mucor racemosus IgE Ab RAST class [Presence] in Serum;M racemosus IgE RAST Ql;;ACTIVE;1.0l;2.73 +15863-4;Artemisia vulgaris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mugwort IgE Ab RAST class [Presence] in Serum;Mugwort IgE RAST Ql;;ACTIVE;1.0l;2.73 +15864-2;Morus alba Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White mulberry IgE Ab RAST class [Presence] in Serum;White mulberry IgE RAST Ql;;ACTIVE;1.0l;2.73 +15865-9;Morus alba Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated White mulberry IgE Ab RAST class in Serum;Deprecated White mulberry IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15866-7;Agaricus hortensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mushroom IgE Ab RAST class [Presence] in Serum;Mushroom IgE RAST Ql;;ACTIVE;1.0l;2.73 +1586-7;Lead^post EDTA therapy;MCnc;Pt;Urine;Qn;;CHAL;1;Lead [Mass/volume] in Urine --post EDTA therapy;Lead p EDTA Ur-mCnc;;ACTIVE;1.0;2.40 +15867-5;Cucumis melo spp Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Melon IgE Ab Ab RAST class in Serum;Deprecated Melon IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15868-3;Mussel Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Blue mussel IgE Ab RAST class in Serum;Deprecated Mussel IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15869-1;Mytilus edulis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blue mussel IgE Ab RAST class [Presence] in Serum;Blue mussel IgE RAST Ql;;ACTIVE;1.0l;2.73 +15870-9;Mustard Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mustard IgE Ab RAST class [Presence] in Serum;Mustard IgE RAST Ql;;ACTIVE;1.0l;2.73 +15871-7;Prunus persica var nucipersica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Nectarine IgE Ab RAST class [Presence] in Serum;Nectarine IgE RAST Ql;;ACTIVE;1.0l;2.73 +15872-5;Urtica dioica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Nettle IgE Ab RAST class [Presence] in Serum;Nettle IgE RAST Ql;;ACTIVE;1.0l;2.73 +15873-3;Nigrospora sphaerica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Nigrospora sphaerica IgE Ab RAST class [Presence] in Serum;N sphaerica IgE RAST Ql;;ACTIVE;1.0l;2.73 +15874-1;Nutmeg Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Nutmeg IgE Ab RAST class [Presence] in Serum;Nutmeg IgE RAST Ql;;ACTIVE;1.0l;2.73 +1587-5;Lutropin^1.5H post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --1.5 hours post 100 g lutropin IV;Deprecated LH 1.5H p 100 g LH IV SerPl;;DEPRECATED;1.0;2.32 +15875-8;Quercus alba Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Oak IgE Ab RAST class [Presence] in Serum;White Oak IgE RAST Ql;;ACTIVE;1.0l;2.73 +15876-6;Quercus kelloggii Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;California Black Oak IgE Ab RAST class [Presence] in Serum;Calif Black Oak IgE RAST Ql;;ACTIVE;1.0l;2.73 +15877-4;Quercus parvula Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Coastal Oak IgE Ab RAST class [Presence] in Serum;Coastal Oak IgE RAST Ql;;ACTIVE;1.0l;2.73 +15878-2;Quercus gambelii Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gamble Oak IgE Ab RAST class [Presence] in Serum;Gamble Oak IgE RAST Ql;;ACTIVE;1.0l;2.73 +15879-0;Chenopodium botrys Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Jerusalem oak IgE Ab RAST class [Presence] in Serum;Jerusalem oak IgE RAST Ql;;ACTIVE;1.0l;2.58 +15880-8;Quercus virginiana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Virginia Live Oak IgE Ab RAST class [Presence] in Serum;Virg Live Oak IgE RAST Ql;;ACTIVE;1.0l;2.73 +15881-6;Quercus rubra Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Oak IgE Ab RAST class [Presence] in Serum;Red Oak IgE RAST Ql;;ACTIVE;1.0l;2.73 +15882-4;Quercus lobata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Valley Oak IgE Ab RAST class [Presence] in Serum;Valley Oak IgE RAST Ql;;ACTIVE;1.0l;2.58 +1588-3;Lutropin^1.5H post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --1.5 hours post dose gonadotropin releasing hormone;LH 1.5h p GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.34 +15883-2;Quercus virginiana Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Virginia Live Oak IgE Ab RAST class in Serum;Deprecated Virg Live Oak IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15884-0;Quercus alba Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated White Oak IgE Ab RAST class in Serum;Deprecated White Oak IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15885-7;Avena sativa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oat IgE Ab RAST class [Presence] in Serum;Oat IgE RAST Ql;;ACTIVE;1.0l;2.73 +15886-5;Avena sativa cultivated Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oat pollen IgE Ab RAST class [Presence] in Serum;Oat Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +15887-3;Avena sativa cultivated Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Oat pollen IgE Ab RAST class in Serum;Deprecated Oat Poln IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15888-1;Octopus vulgaris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Octopus IgE Ab RAST class [Presence] in Serum;Octopus IgE RAST Ql;;ACTIVE;1.0l;2.73 +15889-9;Oidiodendrum spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oidiodendrum spp IgE Ab RAST class [Presence] in Serum;Oidiodendrum IgE RAST Ql;;ACTIVE;1.0l;2.58 +15890-7;Abelmoschus esculentus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Okra IgE Ab RAST class [Presence] in Serum;Okra IgE RAST Ql;;ACTIVE;1.0l;2.73 +1589-1;Lutropin^105M post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --105 minutes post 100 g lutropin IV;Deprecated LH 105M p 100 g LH IV SerPl;;DEPRECATED;1.0;2.32 +15891-5;Olive Ab.IgE.RAST class;Threshold;Pt;Ser;Ord;;ALLERGY;1;Deprecated Olive IgE Ab RAST class [Presence] in Serum;Deprecated Olive IgE RAST Ql;;DEPRECATED;1.0l;2.54 +15892-3;Olea europaea pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Olive Pollen IgE Ab RAST class [Presence] in Serum;Olive Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +15893-1;Allium cepa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Onion IgE Ab RAST class [Presence] in Serum;Onion IgE RAST Ql;;ACTIVE;1.0l;2.73 +15894-9;Citrus sinensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Orange IgE Ab RAST class [Presence] in Serum;Orange IgE RAST Ql;;ACTIVE;1.0l;2.73 +15895-6;Origanum vulgare Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oregano IgE Ab RAST class [Presence] in Serum;Oregano IgE RAST Ql;;ACTIVE;1.0l;2.73 +15896-4;Iris germanica var florentina Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Orris root IgE Ab RAST class [Presence] in Serum;Orris root IgE RAST Ql;;ACTIVE;1.0l;2.73 +15897-2;Ovalbumin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ovalbumin IgE Ab RAST class [Presence] in Serum;Ovalb IgE RAST Ql;;ACTIVE;1.0l;2.73 +15898-0;Ovomucoid Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ovomucoid IgE Ab RAST class [Presence] in Serum;Ovomucoid IgE RAST Ql;;ACTIVE;1.0l;2.73 +15899-8;Ostrea edulis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oyster IgE Ab RAST class [Presence] in Serum;Oyster IgE RAST Ql;;ACTIVE;1.0l;2.73 +15900-4;Syagrus romanzoffianum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Queen Palm IgE Ab RAST class [Presence] in Serum;Queen Palm IgE RAST Ql;;ACTIVE;1.0l;2.73 +15901-2;Carica papaya Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Papaya (Carica papaya) IgE Ab RAST class [Presence] in Serum;Papaya IgE RAST Ql;;ACTIVE;1.0l;2.73 +15902-0;Capsicum annuum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Paprika IgE Ab RAST class [Presence] in Serum;Paprika IgE RAST Ql;;ACTIVE;1.0l;2.73 +15903-8;Parakeet feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parakeet feather IgE Ab RAST class [Presence] in Serum;Parakeet Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +15904-6;Budgerigar droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Budgerigar droppings IgE Ab RAST class [Presence] in Serum;Budgie Drop IgE RAST Ql;;ACTIVE;1.0l;2.73 +15905-3;Budgerigar feather Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Budgerigar feather IgE Ab RAST class in Serum;Deprecated Budgie Feather IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15906-1;Budgerigar serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Budgerigar serum proteins IgE Ab RAST class [Presence] in Serum;Budgie Serum Prot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15907-9;Parrot droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parrot droppings IgE Ab RAST class [Presence] in Serum;Parrot Drop IgE RAST Ql;;ACTIVE;1.0l;2.58 +15908-7;Parrot feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parrot feather IgE Ab RAST class [Presence] in Serum;Parrot Feather IgE RAST Ql;;ACTIVE;1.0l;2.58 +1590-9;Lutropin^15M post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --15 minutes post 100 g lutropin IV;Deprecated LH 15M p 100 g LH IV SerP;;DEPRECATED;1.0;2.32 +15909-5;Parrot serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parrot serum proteins IgE Ab RAST class [Presence] in Serum;Parrot Serum Prot IgE RAST Ql;;ACTIVE;1.0l;2.58 +15910-3;Petroselinum crispum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parsley IgE Ab RAST class [Presence] in Serum;Parsley IgE RAST Ql;;ACTIVE;1.0l;2.73 +15911-1;Pastinaca sativa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parsnip IgE Ab RAST class [Presence] in Serum;Parsnip IgE RAST Ql;;ACTIVE;1.0l;2.58 +15912-9;Passiflora edulis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Passion fruit IgE Ab RAST class [Presence] in Serum;Passion fruit IgE RAST Ql;;ACTIVE;1.0l;2.73 +15913-7;Pisum sativum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pea IgE Ab RAST class [Presence] in Serum;Pea IgE RAST Ql;;ACTIVE;1.0l;2.73 +15914-5;Vigna sinensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black-eye pea IgE Ab RAST class [Presence] in Serum;Black-eye Pea IgE RAST Ql;;ACTIVE;1.0l;2.73 +15915-2;Cicer arietinus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chick Pea IgE Ab RAST class [Presence] in Serum;Chick Pea IgE RAST Ql;;ACTIVE;1.0l;2.73 +15916-0;Prunus persica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peach IgE Ab RAST class [Presence] in Serum;Peach IgE RAST Ql;;ACTIVE;1.0l;2.73 +1591-7;Lutropin^1H post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --1 hour post 100 g lutropin IV;Deprecated LH 1H p 100 g LH IV SerPl;;DEPRECATED;1.0;2.32 +15917-8;Arachis hypogaea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut IgE Ab RAST class [Presence] in Serum;Peanut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15918-6;Pyrus communis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pear IgE Ab RAST class [Presence] in Serum;Pear IgE RAST Ql;;ACTIVE;1.0l;2.73 +15919-4;Carya illinoinensis nut Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Pecan or Hickory Nut IgE Ab RAST class in Serum;Deprecated Pecan/Hick Nut IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15920-2;Carya illinoinensis tree Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Pecan or Hickory Tree IgE Ab RAST class in Serum;Deprecated Pecan/Hick Tree IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15921-0;Penicillin G Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillin G IgE Ab RAST class [Presence] in Serum;Penicillin G IgE RAST Ql;;ACTIVE;1.0l;2.73 +15922-8;Penicillin V Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillin V IgE Ab RAST class [Presence] in Serum;Penicillin V IgE RAST Ql;;ACTIVE;1.0l;2.73 +15923-6;Penicillium frequentans Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillium frequentans IgE Ab RAST class [Presence] in Serum;P frequentans IgE RAST Ql;;ACTIVE;1.0l;2.73 +15924-4;Penicillium notatum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillium notatum IgE Ab RAST class [Presence] in Serum;P notatum IgE RAST Ql;;ACTIVE;1.0l;2.73 +1592-5;Lutropin^1H post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --1 hour post dose gonadotropin releasing hormone;LH 1h p GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.34 +15925-1;Piper nigrum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Pepper IgE Ab RAST class [Presence] in Serum;Black Pepper IgE RAST Ql;;ACTIVE;1.0l;2.73 +15926-9;Pepper cayenne Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cayenne IgE Ab RAST class [Presence] in Serum;Cayenne IgE RAST Ql;;ACTIVE;1.0l;2.73 +15927-7;Capsicum frutescens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chili Pepper IgE Ab RAST class [Presence] in Serum;Chili Pepper IgE RAST Ql;;ACTIVE;1.0l;2.73 +15928-5;Pepper green Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Green Pepper IgE Ab RAST class [Presence] in Serum;Green Pepper IgE RAST Ql;;ACTIVE;1.0l;2.73 +15929-3;Schinus molle Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pepper tree IgE Ab RAST class [Presence] in Serum;Pepper tree IgE RAST Ql;;ACTIVE;1.0l;2.73 +15930-1;Perca spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Perch IgE Ab RAST class [Presence] in Serum;Perch IgE RAST Ql;;ACTIVE;1.0l;2.73 +15931-9;Phoma betae Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Phoma betae IgE Ab RAST class [Presence] in Serum;P betae IgE RAST Ql;;ACTIVE;1.0l;2.73 +15932-7;Phospholipase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Phospholipase IgE Ab RAST class [Presence] in Serum;Phospholipase IgE RAST Ql;;ACTIVE;1.0l;2.58 +1593-3;Lutropin^2H post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --2 hours post 100 g lutropin IV;Deprecated LH 2H p 100 g LH IV SerPl;;DEPRECATED;1.0;2.32 +15933-5;Phthalic anhydride Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Phthalic anhydride IgE Ab RAST class [Presence] in Serum;PAN IgE RAST Ql;;ACTIVE;1.0l;2.73 +15934-3;Pigeon droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon droppings IgE Ab RAST class [Presence] in Serum;Pigeon Drop IgE RAST Ql;;ACTIVE;1.0l;2.73 +15935-0;Pigeon feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon feather IgE Ab RAST class [Presence] in Serum;Pigeon Feather IgE RAST Ql;;ACTIVE;1.0l;2.73 +15936-8;Pigweed common Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common Pigweed IgE Ab RAST class [Presence] in Serum;Common Pigweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15937-6;Pigweed rough Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rough Pigweed IgE Ab RAST class [Presence] in Serum;Rough Pigweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15938-4;Pigweed spiny Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spiny Pigweed IgE Ab RAST class [Presence] in Serum;Spiny Pigweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15939-2;Pinus nigra Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Austrian Pine IgE Ab RAST class [Presence] in Serum;Austrian Pine IgE RAST Ql;;ACTIVE;1.0l;2.58 +159-4;Cephaloridine;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cephaloridine [Susceptibility] by Serum bactericidal titer;Cephaloridine Titr SBT;;ACTIVE;1.0;2.32 +15940-0;Pinus taeda Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Loblolly Pine IgE Ab RAST class [Presence] in Serum;Loblolly Pine IgE RAST Ql;;ACTIVE;1.0l;2.73 +1594-1;Lutropin^2H post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --2 hours post dose gonadotropin releasing hormone;LH 2h p GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.34 +15941-8;Pinus palustris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Long Leaf Pine IgE Ab RAST class [Presence] in Serum;Long Leaf Pine IgE RAST Ql;;ACTIVE;1.0l;2.73 +15942-6;Pinus radiata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pine IgE Ab RAST class [Presence] in Serum;Pine IgE RAST Ql;;ACTIVE;1.0l;2.73 +15943-4;Pinus edulis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pine Nut IgE Ab RAST class [Presence] in Serum;Pine Nut IgE RAST Ql;;ACTIVE;1.0l;2.73 +15944-2;Pinus echinata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Short Leaf Pine IgE Ab RAST class [Presence] in Serum;Short Leaf Pine IgE RAST Ql;;ACTIVE;1.0l;2.58 +15945-9;Pinus elliottii Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Slash Pine IgE Ab RAST class [Presence] in Serum;Slash Pine IgE RAST Ql;;ACTIVE;1.0l;2.58 +15946-7;Pinus virginiana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Virginia Scrub Pine IgE Ab RAST class [Presence] in Serum;Virg Scrub Pine IgE RAST Ql;;ACTIVE;1.0l;2.58 +15947-5;Pinus strobus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Eastern White Pine IgE Ab RAST class [Presence] in Serum;East White Pine IgE RAST Ql;;ACTIVE;1.0l;2.73 +15948-3;Ananas comosus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pineapple IgE Ab RAST class [Presence] in Serum;Pineapple IgE RAST Ql;;ACTIVE;1.0l;2.73 +15949-1;Pistacia vera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pistachio IgE Ab RAST class [Presence] in Serum;Pistachio IgE RAST Ql;;ACTIVE;1.0l;2.73 +15950-9;Malassezia furfur Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Malassezia furfur IgE Ab RAST class [Presence] in Serum;M furfur IgE RAST Ql;;ACTIVE;1.0l;2.73 +15951-7;Pleuronectes platessa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Plaice IgE Ab RAST class [Presence] in Serum;Plaice IgE RAST Ql;;ACTIVE;1.0l;2.73 +15952-5;Plantago lanceolata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;English plantain IgE Ab RAST class [Presence] in Serum;Engl plantain IgE RAST Ql;;ACTIVE;1.0l;2.73 +15953-3;Prunus domestica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Plum IgE Ab RAST class [Presence] in Serum;Plum IgE RAST Ql;;ACTIVE;1.0l;2.73 +15954-1;Populus nigra Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Cottonwood IgE Ab RAST class [Presence] in Serum;Black Cottonwood IgE RAST Ql;;ACTIVE;1.0l;2.73 +15955-8;Papaver somniferum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Poppy Seed IgE Ab RAST class [Presence] in Serum;Poppy Seed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15956-6;Pork Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pork IgE Ab RAST class [Presence] in Serum;Pork IgE RAST Ql;;ACTIVE;1.0l;2.73 +15957-4;Solanum tuberosum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Potato IgE Ab RAST class [Presence] in Serum;Potato IgE RAST Ql;;ACTIVE;1.0l;2.73 +1595-8;Lutropin^30M post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --30 minutes post 100 g lutropin IV;Deprecated LH 30M p 100 g LH IV SerPl;;DEPRECATED;1.0;2.32 +15958-2;Ipomoea batatas Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sweet potato IgE Ab RAST class [Presence] in Serum;Sweet potato IgE RAST Ql;;ACTIVE;1.0l;2.73 +15959-0;Iva axillaris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Povertyweed IgE Ab RAST class [Presence] in Serum;Povertyweed IgE RAST Ql;;ACTIVE;1.0l;2.58 +15960-8;Ligustrum vulgare Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Privet IgE Ab RAST class [Presence] in Serum;Privet IgE RAST Ql;;ACTIVE;1.0l;2.73 +15961-6;Protamine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Protamine IgE Ab RAST class [Presence] in Serum;Protamine IgE RAST Ql;;ACTIVE;1.0l;2.58 +15962-4;Prune Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Prune IgE Ab RAST class [Presence] in Serum;Prune IgE RAST Ql;;ACTIVE;1.0l;2.73 +15963-2;Psyllium seed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Psyllium seed IgE Ab RAST class [Presence] in Serum;Psyllium seed IgE RAST Ql;;ACTIVE;1.0l;2.58 +15964-0;Aureobasidium pullulans Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aureobasidium pullulans IgE Ab RAST class [Presence] in Serum;A pullulans IgE RAST Ql;;ACTIVE;1.0l;2.73 +15965-7;Pullularia pullulans Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Pullularia pullulans IgE Ab RAST class in Serum;Deprecated P pullulans IgE RAST Ql;;DEPRECATED;1.0l;2.40 +1596-6;Lutropin^30M post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --30 minutes post dose gonadotropin releasing hormone;LH 30M p GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.34 +15966-5;Cucurbita pepo Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pumpkin IgE Ab RAST class [Presence] in Serum;Pumpkin IgE RAST Ql;;ACTIVE;1.0l;2.73 +15967-3;Cucurbita pepo seed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pumpkin Seed IgE Ab RAST class [Presence] in Serum;Pumpkin Seed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15968-1;Chrysanthemum cinerariifolium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pyrethrum IgE Ab RAST class [Presence] in Serum;Pyrethrum IgE RAST Ql;;ACTIVE;1.0l;2.73 +15969-9;Rabbit meat Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rabbit meat IgE Ab RAST class [Presence] in Serum;Rabbit Meat IgE RAST Ql;;ACTIVE;1.0l;2.73 +15970-7;Chrysothamnus nauseosus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rabbit Bush IgE Ab RAST class [Presence] in Serum;Rabbit Bush IgE RAST Ql;;ACTIVE;1.0l;2.58 +15971-5;Rabbit epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rabbit epithelium IgE Ab RAST class [Presence] in Serum;Rabbit Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +15972-3;Rabbit serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rabbit serum proteins IgE Ab RAST class [Presence] in Serum;Rabbit Serum Prot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15973-1;Rabbit urine proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rabbit urine proteins IgE Ab RAST class [Presence] in Serum;Rabbit Urine Prot IgE RAST Ql;;ACTIVE;1.0l;2.73 +1597-4;Lutropin^45M post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --45 minutes post 100 g lutropin IV;Deprecated LH 45M p 100 g LH IV SerP;;DEPRECATED;1.0;2.32 +15974-9;Raphanus sativus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Radish IgE Ab RAST class [Presence] in Serum;Radish IgE RAST Ql;;ACTIVE;1.0l;2.73 +15975-6;Ambrosia elatior Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common Ragweed IgE Ab RAST class [Presence] in Serum;Common Ragweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15976-4;Ambrosia dumosa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Desert Ragweed IgE Ab RAST class [Presence] in Serum;Desert Ragweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15977-2;Franseria acanthicarpa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;False ragweed IgE Ab RAST class [Presence] in Serum;False ragweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15978-0;Ambrosia trifida Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Giant Ragweed IgE Ab RAST class [Presence] in Serum;Giant Ragweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15979-8;Ambrosia elatior Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Common Ragweed IgE Ab RAST class in Serum;Deprecated Common Ragweed IgE RAST Ql;;DEPRECATED;1.0l;2.36 +15980-6;Ambrosia bidentata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Southern Ragweed IgE Ab RAST class [Presence] in Serum;Southern Ragweed IgE RAST Ql;;ACTIVE;1.0l;2.58 +15981-4;Ambrosia psilostachya Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Western Ragweed IgE Ab RAST class [Presence] in Serum;West Ragweed IgE RAST Ql;;ACTIVE;1.0l;2.73 +1598-2;Lutropin^75M post 100 g lutropin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Lutropin [Mass/volume] in Serum or Plasma --75 minutes post 100 g lutropin IV;Deprecated LH 75M p 100 g LH IV SerP;;DEPRECATED;1.0;2.32 +15982-2;Brassica rapa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rapeseed IgE Ab RAST class [Presence] in Serum;Rapeseed IgE RAST Ql;;ACTIVE;1.0l;2.73 +15983-0;Rubus idaeus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Raspberry IgE Ab RAST class [Presence] in Serum;Raspberry IgE RAST Ql;;ACTIVE;1.0l;2.73 +15984-8;Rat epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rat epithelium IgE Ab RAST class [Presence] in Serum;Rat Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +15985-5;Rat serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rat serum proteins IgE Ab RAST class [Presence] in Serum;Rat Serum Prot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15986-3;Rat urine proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rat urine proteins IgE Ab RAST class [Presence] in Serum;Rat Urine Prot IgE RAST Ql;;ACTIVE;1.0l;2.73 +15987-1;Sequoia spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Redwood IgE Ab RAST class [Presence] in Serum;Redwood IgE RAST Ql;;ACTIVE;1.0l;2.58 +15988-9;Phalaris arundinacea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canary grass IgE Ab RAST class [Presence] in Serum;Canary grass IgE RAST Ql;;ACTIVE;1.0l;2.73 +15989-7;Phragmites communis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common Reed IgE Ab RAST class [Presence] in Serum;Common Reed IgE RAST Ql;;ACTIVE;1.0l;2.73 +1599-0;Lutropin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --baseline;LH BS SerPl-mCnc;;DISCOURAGED;1.0;2.34 +15990-5;Reindeer epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Reindeer epithelium IgE Ab RAST class [Presence] in Serum;Reindeer Epith IgE RAST Ql;;ACTIVE;1.0l;2.58 +15991-3;Rhizopus nigricans Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rhizopus nigricans IgE Ab RAST class [Presence] in Serum;R nigricans IgE RAST Ql;;ACTIVE;1.0l;2.73 +15992-1;Rhodotorula spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rhodotorula spp IgE Ab RAST class [Presence] in Serum;Rhodatorula IgE RAST Ql;;ACTIVE;1.0l;2.73 +15993-9;Rheum spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rhubarb IgE Ab RAST class [Presence] in Serum;Rhubarb IgE RAST Ql;;ACTIVE;1.0l;2.73 +15994-7;Oryza sativa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rice IgE Ab RAST class [Presence] in Serum;Rice IgE RAST Ql;;ACTIVE;1.0l;2.73 +15995-4;Zizania spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wild Rice IgE Ab RAST class [Presence] in Serum;Wild Rice IgE RAST Ql;;ACTIVE;1.0l;2.73 +15996-2;Rosa spp hip Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rose Hip IgE Ab RAST class [Presence] in Serum;Rose Hip IgE RAST Ql;;ACTIVE;1.0l;2.58 +15997-0;Secale cereale pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cultivated Rye IgE Ab RAST class [Presence] in Serum;Cultivated Rye IgE RAST Ql;;ACTIVE;1.0l;2.73 +15998-8;Secale cereale Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rye IgE Ab RAST class [Presence] in Serum;Rye IgE RAST Ql;;ACTIVE;1.0l;2.73 +15999-6;Secale cereale pollen Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Cultivated Rye IgE Ab RAST class in Serum;Deprecated Cultivated Rye IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16000-2;Lolium perenne Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated rye Perennial IgE Ab RAST class in Serum;Deprecated Per rye grass IgE RAST Ql;;DEPRECATED;1.0l;2.40 +16001-0;Carthamus tinctorius Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Safflower IgE Ab RAST class [Presence] in Serum;Safflower IgE RAST Ql;;ACTIVE;1.0l;2.73 +16002-8;Salvia officinalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sage IgE Ab RAST class [Presence] in Serum;Sage IgE RAST Ql;;ACTIVE;1.0l;2.73 +16003-6;Artemisia tridentata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common Sagebrush IgE Ab RAST class [Presence] in Serum;Sagbrsh IgE RAST Ql;;ACTIVE;1.0l;2.73 +16004-4;Artemisia tridentata Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Sagebrush IgE Ab RAST class in Serum;Deprecated Sagbrsh IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16005-1;Saline fish feed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saline fish feed IgE Ab RAST class [Presence] in Serum;Saline Fish Feed IgE RAST Ql;;ACTIVE;1.0l;2.58 +1600-6;Lutropin^pre dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --pre dose gonadotropin releasing hormone;LH pre GnRH SerPl-mCnc;;DISCOURAGED;1.0;2.34 +16006-9;Salmo salar Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Salmon IgE Ab RAST class [Presence] in Serum;Salmon IgE RAST Ql;;ACTIVE;1.0l;2.73 +16007-7;Saltbush Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saltbush IgE Ab RAST class [Presence] in Serum;Saltbush IgE RAST Ql;;ACTIVE;1.0l;2.73 +16008-5;Sardina pilchardus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sardine (pilchard) IgE Ab RAST class [Presence] in Serum;Sardine (pilchard) IgE RAST Ql;;ACTIVE;1.0l;2.73 +16009-3;Savinase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Savinase IgE Ab RAST class [Presence] in Serum;Savinase IgE RAST Ql;;ACTIVE;1.0l;2.58 +16010-1;Atriplex lentiformis Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Lenscale IgE Ab RAST class in Serum;Deprecated Lenscale IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16011-9;Pecten spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Scallop IgE Ab RAST class [Presence] in Serum;Scallop IgE RAST Ql;;ACTIVE;1.0l;2.73 +16012-7;Cytisus scoparius Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Scotch broom IgE Ab RAST class [Presence] in Serum;Scotch broom IgE RAST Ql;;ACTIVE;1.0l;2.73 +16013-5;Sericin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sericin IgE Ab RAST class [Presence] in Serum;Sericin IgE RAST Ql;;ACTIVE;1.0l;2.58 +1601-4;Norepinephrine^supine;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --supine;Norepineph sup Plas-mCnc;;ACTIVE;1.0;2.73 +16014-3;Sesamum indicum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sesame Seed IgE Ab RAST class [Presence] in Serum;Sesame Seed IgE RAST Ql;;ACTIVE;1.0l;2.73 +16015-0;Sheep epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sheep epithelium IgE Ab RAST class [Presence] in Serum;Sheep Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +16016-8;Rumex acetosella Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sheep Sorrel IgE Ab RAST class [Presence] in Serum;Sheep Sorrel IgE RAST Ql;;ACTIVE;1.0l;2.73 +16017-6;Sheep wool Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sheep wool IgE Ab RAST class [Presence] in Serum;Sheep Wool IgE RAST Ql;;ACTIVE;1.0l;2.73 +16018-4;Pandalus borealis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Shrimp IgE Ab RAST class [Presence] in Serum;Shrimp IgE RAST Ql;;ACTIVE;1.0l;2.73 +16019-2;Silk Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silk IgE Ab RAST class [Presence] in Serum;Silk IgE RAST Ql;;ACTIVE;1.0l;2.73 +160-2;Cephalothin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cephalothin [Susceptibility] by Minimum lethal concentration (MLC);Cephalothin Islt MLC;;ACTIVE;1.0;2.19 +16020-0;Silk waste Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silk waste IgE Ab RAST class [Presence] in Serum;Silk Waste IgE RAST Ql;;ACTIVE;1.0l;2.73 +16021-8;Silver Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver IgE Ab RAST class [Presence] in Serum;Silver IgE RAST Ql;;ACTIVE;1.0l;2.58 +1602-2;Norepinephrine^10M post standing;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --10 minutes post standing;Norepineph 10M p Sta Plas-mCnc;;ACTIVE;1.0;2.42 +16022-6;Ustilago cynodontis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bermuda grass smut IgE Ab RAST class [Presence] in Serum;Bermuda grass smut IgE RAST Ql;;ACTIVE;1.0l;2.73 +16023-4;Sphacelotheca cruenta Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Johnson grass smut IgE Ab RAST class [Presence] in Serum;Johnson grass smut IgE RAST Ql;;ACTIVE;1.0l;2.73 +16024-2;Helix aspersa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Escargot IgE Ab RAST class [Presence] in Serum;Escargot IgE RAST Ql;;ACTIVE;1.0l;2.73 +16025-9;Snapper red Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Snapper IgE Ab RAST class [Presence] in Serum;Red Snapper IgE RAST Ql;;ACTIVE;1.0l;2.73 +16026-7;Solea solea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sole IgE Ab RAST class [Presence] in Serum;Sole IgE RAST Ql;;ACTIVE;1.0l;2.73 +16027-5;Spinacia oleracea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spinach IgE Ab RAST class [Presence] in Serum;Spinach IgE RAST Ql;;ACTIVE;1.0l;2.73 +16028-3;Spondylocladium citrovirens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spondylocladium citrovirens IgE Ab RAST class [Presence] in Serum;S citrovirens IgE RAST Ql;;ACTIVE;1.0l;2.58 +16029-1;Picea excelsa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spruce IgE Ab RAST class [Presence] in Serum;Spruce IgE RAST Ql;;ACTIVE;1.0l;2.73 +1603-0;Norepinephrine^1H post 300 ug clonidine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --1 hour post 300 ug cloNIDine PO;Norepineph 1h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +16030-9;Squash Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Squash IgE Ab RAST class [Presence] in Serum;Squash IgE RAST Ql;;ACTIVE;1.0l;2.73 +16031-7;Loligo sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Squid IgE Ab RAST class [Presence] in Serum;Squid IgE RAST Ql;;ACTIVE;1.0l;2.73 +16032-5;Todarodes pacificus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pacific Squid IgE Ab RAST class [Presence] in Serum;Pacific Squid IgE RAST Ql;;ACTIVE;1.0l;2.73 +16033-3;Stemphylium botryosum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Stemphylium botryosum IgE Ab RAST class [Presence] in Serum;S botryosum IgE RAST Ql;;ACTIVE;1.0l;2.73 +16034-1;Stemphylium solani Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Stemphylium solani IgE Ab RAST class [Presence] in Serum;S solani IgE RAST Ql;;ACTIVE;1.0l;2.73 +16035-8;Acarus siro Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Acarus siro IgE Ab RAST class [Presence] in Serum;A siro IgE RAST Ql;;ACTIVE;1.0l;2.73 +16037-4;Tyrophagus putrescentiae Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tyrophagus putrescentiae IgE Ab RAST class [Presence] in Serum;T putrescentiae IgE RAST Ql;;ACTIVE;1.0l;2.58 +16038-2;Fragaria vesca Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Strawberry IgE Ab RAST class [Presence] in Serum;Strawberry IgE RAST Ql;;ACTIVE;1.0l;2.73 +16039-0;Succinylcholine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Succinylcholine IgE Ab RAST class [Presence] in Serum;Succinylcholine IgE RAST Ql;;ACTIVE;1.0l;2.58 +16040-8;Saccharum officinarum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sugar Cane IgE Ab RAST class [Presence] in Serum;Sugar Cane IgE RAST Ql;;ACTIVE;1.0l;2.73 +16041-6;Helianthus annuus pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sunflower Pollen IgE Ab RAST class [Presence] in Serum;Sunflower Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +16042-4;Helianthus annuus seed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sunflower Seed IgE Ab RAST class [Presence] in Serum;Sunflower Seed IgE RAST Ql;;ACTIVE;1.0l;2.73 +16043-2;Swine epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Swine epithelium IgE Ab RAST class [Presence] in Serum;Swine Epith IgE RAST Ql;;ACTIVE;1.0l;2.73 +16044-0;Swine urine proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Swine urine proteins IgE Ab RAST class [Presence] in Serum;Swine Urine Prot IgE RAST Ql;;ACTIVE;1.0l;2.58 +16045-7;Xiphias gladius Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Swordfish IgE Ab RAST class [Presence] in Serum;Swordfish IgE RAST Ql;;ACTIVE;1.0l;2.73 +16046-5;Platanus occidentalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;American Sycamore IgE Ab RAST class [Presence] in Serum;Amer Sycamore IgE RAST Ql;;ACTIVE;1.0l;2.73 +16047-3;Citrus reticulata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mandarin IgE Ab RAST class [Presence] in Serum;Mandarin IgE RAST Ql;;ACTIVE;1.0l;2.73 +1604-8;Norepinephrine^2H post 300 ug clonidine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --2 hours post 300 ug cloNIDine PO;Norepineph 2h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +16048-1;Manihot esculenta crantz Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tapioca IgE Ab RAST class [Presence] in Serum;Tapioca IgE RAST Ql;;ACTIVE;1.0l;2.73 +16049-9;Artemisia dracunculus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tarragon IgE Ab RAST class [Presence] in Serum;Tarragon IgE RAST Ql;;ACTIVE;1.0l;2.73 +16050-7;Camellia sinensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tea IgE Ab RAST class [Presence] in Serum;Tea IgE RAST Ql;;ACTIVE;1.0l;2.73 +16051-5;Tetramin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tetramin IgE Ab RAST class [Presence] in Serum;Tetramin IgE RAST Ql;;ACTIVE;1.0l;2.58 +16052-3;Salsola kali Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saltwort IgE Ab RAST class [Presence] in Serum;Saltwort IgE RAST Ql;;ACTIVE;1.0l;2.73 +16053-1;Thymus vulgaris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Thyme IgE Ab RAST class [Presence] in Serum;Thyme IgE RAST Ql;;ACTIVE;1.0l;2.73 +16054-9;Phleum pratense Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy IgE Ab RAST class [Presence] in Serum;Timothy IgE RAST Ql;;ACTIVE;1.0l;2.73 +1605-5;Norepinephrine^3H post 300 ug clonidine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --3 hours post 300 ug cloNIDine PO;Norepineph 3h p 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +16055-6;Nicotiana tabacum cigarette Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Tobacco IgE Ab RAST class in Serum;Deprecated Cigarette Tobacco IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16056-4;Nicotiana tabacum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tobacco IgE Ab RAST class [Presence] in Serum;Tobacco IgE RAST Ql;;ACTIVE;1.0l;2.73 +16057-2;Lycopersicon lycopersicum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tomato IgE Ab RAST class [Presence] in Serum;Tomato IgE RAST Ql;;ACTIVE;1.0l;2.73 +16058-0;Astragalus spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tragacanth IgE Ab RAST class [Presence] in Serum;Tragacanth IgE RAST Ql;;ACTIVE;1.0l;2.73 +16059-8;Trichoderma viride Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichoderma viride IgE Ab RAST class [Presence] in Serum;T viride IgE RAST Ql;;ACTIVE;1.0l;2.73 +16060-6;Trichophyton Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichophyton sp IgE Ab RAST class [Presence] in Serum;Trichophyton IgE RAST Ql;;ACTIVE;1.0l;2.73 +16061-4;Trichophyton rubrum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichophyton rubrum IgE Ab RAST class [Presence] in Serum;T rubrum IgE RAST Ql;;ACTIVE;1.0l;2.73 +16062-2;Trichosporon spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichosporon spp IgE Ab RAST class [Presence] in Serum;Trichosporon IgE RAST Ql;;ACTIVE;1.0l;2.73 +1606-3;Norepinephrine^pre 300 ug clonidine PO;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --pre 300 ug cloNIDine PO;Norepineph pre 300 ug CLN PO Plas-mCnc;;ACTIVE;1.0;2.73 +16063-0;Trimellitic anhydride Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trimellitic anhydride (TMA) IgE Ab RAST class [Presence] in Serum;TMA IgE RAST Ql;;ACTIVE;1.0l;2.73 +16064-8;Oncorhynchus mykiss Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trout IgE Ab RAST class [Presence] in Serum;Trout IgE RAST Ql;;ACTIVE;1.0l;2.73 +16065-5;Thunnus albacares Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tuna IgE Ab RAST class [Presence] in Serum;Tuna IgE RAST Ql;;ACTIVE;1.0l;2.73 +16066-3;Turkey meat Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Turkey meat IgE Ab RAST class [Presence] in Serum;Turkey Meat IgE RAST Ql;;ACTIVE;1.0l;2.73 +16067-1;Turnip Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Turnip IgE Ab RAST class [Presence] in Serum;Turnip IgE RAST Ql;;ACTIVE;1.0l;2.73 +16069-7;Ulocladium chartarum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ulocladium chartarum IgE Ab RAST class [Presence] in Serum;U chartarum IgE RAST Ql;;ACTIVE;1.0l;2.73 +16070-5;Ustilago nuda Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Barley smut IgE Ab RAST class [Presence] in Serum;Barley smut IgE RAST Ql;;ACTIVE;1.0l;2.73 +1607-1;Osmolality^post 12H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--12 hours post fluid fast;Osmolality p 12h FFST Ur;;ACTIVE;1.0;2.40 +16071-3;Vanilla planifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Vanilla IgE Ab RAST class [Presence] in Serum;Vanilla IgE RAST Ql;;ACTIVE;1.0l;2.73 +16072-1;Veal Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Veal IgE Ab RAST class [Presence] in Serum;Veal IgE RAST Ql;;ACTIVE;1.0l;2.73 +16073-9;Wall pellitory Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wall pellitory IgE Ab RAST class [Presence] in Serum;Pellitory IgE RAST Ql;;ACTIVE;1.0l;2.73 +16074-7;Juglans spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Walnut IgE Ab RAST class [Presence] in Serum;Walnut IgE RAST Ql;;ACTIVE;1.0l;2.73 +16075-4;Juglans nigra Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Walnut IgE Ab RAST class [Presence] in Serum;Black Walnut IgE RAST Ql;;ACTIVE;1.0l;2.73 +16076-2;Juglans nigra pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Walnut Pollen IgE Ab RAST class [Presence] in Serum;Black Walnut Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +16077-0;Juglans regia pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;English Walnut Pollen IgE Ab RAST class [Presence] in Serum;Eng Walnut Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +16078-8;Juglans california pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;California Walnut Pollen IgE Ab RAST class [Presence] in Serum;Calif Walnut Poln IgE RAST Ql;;ACTIVE;1.0l;2.73 +16079-6;Juglans california pollen Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated California Walnut Pollen IgE Ab RAST class in Serum;Deprecated Calif Walnut Poln IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16080-4;Polistes spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Paper wasp IgE Ab RAST class [Presence] in Serum;Paper Wasp IgE RAST Ql;;ACTIVE;1.0l;2.73 +16081-2;Polistes spp Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Paper Wasp IgE Ab RAST class in Serum;Deprecated Paper Wasp IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16082-0;Vespula spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yellow Jacket IgE Ab RAST class [Presence] in Serum;Yellow Jacket IgE RAST Ql;;ACTIVE;1.0l;2.73 +16083-8;Citrullus lanatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Watermelon IgE Ab RAST class [Presence] in Serum;Watermelon IgE RAST Ql;;ACTIVE;1.0l;2.73 +16084-6;Sitophilus granarius Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Grain weevel IgE Ab RAST class [Presence] in Serum;Grain Weevel IgE RAST Ql;;ACTIVE;1.0l;2.73 +16085-3;Triticum aestivum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat IgE Ab RAST class [Presence] in Serum;Wheat IgE RAST Ql;;ACTIVE;1.0l;2.73 +16086-1;Triticum aestivum pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cultivated Wheat IgE Ab RAST class [Presence] in Serum;Cultivated Wheat IgE RAST Ql;;ACTIVE;1.0l;2.73 +16087-9;Triticum aestivum pollen Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Cultivated Wheat IgE Ab RAST class in Serum;Deprecated Cultivated Wheat IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16088-7;Puccinia graminis triticu Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat Stem Rust IgE Ab RAST class [Presence] in Serum;Wheat Stem Rust IgE RAST Ql;;ACTIVE;1.0l;2.58 +1608-9;Osmolality^post 8H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--8 hours post fluid fast;Osmolality p 8h FFST Ur;;ACTIVE;1.0;2.40 +16089-5;Cow whey Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cow whey IgE Ab RAST class [Presence] in Serum;Cow Whey IgE RAST Ql;;ACTIVE;1.0l;2.73 +16090-3;Whitefish Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Whitefish IgE Ab RAST class [Presence] in Serum;Whitefish IgE RAST Ql;;ACTIVE;1.0l;2.73 +16091-1;Salix caprea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Willow IgE Ab RAST class [Presence] in Serum;Willow IgE RAST Ql;;ACTIVE;1.0l;2.73 +16092-9;Salix nigra Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Willow IgE Ab RAST class [Presence] in Serum;Black Willow IgE RAST Ql;;ACTIVE;1.0l;2.73 +16093-7;Salix discolor Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pussy Willow IgE Ab RAST class [Presence] in Serum;Pussy Willow IgE RAST Ql;;ACTIVE;1.0l;2.58 +16094-5;Atriplex canescens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wingscale IgE Ab RAST class [Presence] in Serum;Wingscale IgE RAST Ql;;ACTIVE;1.0l;2.73 +16095-2;Artemisia absinthium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wormwood IgE Ab RAST class [Presence] in Serum;Wormwood IgE RAST Ql;;ACTIVE;1.0l;2.73 +16096-0;Saccharomyces cerevisiae Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Baker's yeast IgE Ab RAST class [Presence] in Serum;Baker's yeast IgE RAST Ql;;ACTIVE;1.0l;2.73 +1609-7;Prolactin^1.5H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1.5 hours post dose insulin IV;Prolactin 1.5h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16097-8;Yeast bakers Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Bakers Yeast IgE Ab RAST class in Serum;Deprecated Bakers Yeast IgE RAST Ql;;DEPRECATED;1.0l;2.36 +16098-6;Yeast brewer's Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Brewer's yeast IgE Ab RAST class [Presence] in Serum;Brewer's yeast IgE RAST Ql;;ACTIVE;1.0l;2.73 +16099-4;Ethionamide;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ethionamide [Susceptibility] by Minimum inhibitory concentration (MIC);Ethionamide Islt MIC;;ACTIVE;1.0l;2.73 +161-0;Cephalothin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cephalothin [Susceptibility] by Minimum inhibitory concentration (MIC);Cephalothin Islt MIC;;ACTIVE;1.0;2.73 +16100-0;Rifabutin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Rifabutin [Susceptibility] by Minimum inhibitory concentration (MIC);Rifabutin Islt MIC;;ACTIVE;1.0l;2.73 +16101-8;Cuminum cyminum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cumin IgE Ab [Units/volume] in Serum;Cumin IgE Qn;;ACTIVE;1.0l;2.73 +16102-6;Gelatin bovine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bovine Gelatin IgE Ab [Units/volume] in Serum;Bovine Gelatin IgE Qn;;ACTIVE;1.0l;2.73 +16103-4;Gelatin porcine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Porcine Gelatin IgE Ab [Units/volume] in Serum;Porcine Gelatin IgE Qn;;ACTIVE;1.0l;2.73 +16104-2;Broussonetia papyrifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paper Mulberry IgE Ab [Units/volume] in Serum;Paper Mulberry IgE Qn;;ACTIVE;1.0l;2.73 +1610-5;Prolactin^1H post dose L-Dopa PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1 hour post dose L-dopa PO;Prolactin 1h p L-D PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16105-9;Pheasant Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pheasant IgE Ab [Units/volume] in Serum;Pheasant IgE Qn;;ACTIVE;1.0l;2.42 +16106-7;Cells.CD8+CD28+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+CD28+ cells [#/volume] in Blood;CD8+CD28+ Cells # Bld;;ACTIVE;1.0l;2.73 +16107-5;Cells.CD8+HLA-DR+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+HLA-DR+ cells [#/volume] in Blood;CD8+HLA-DR+ Cells # Bld;;ACTIVE;1.0l;2.73 +16108-3;17-Hydroxyprogesterone^45M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --45 minutes post 250 ug corticotropin IM;17OHP 45M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0l;2.70 +16109-1;Prolactin^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Prolactin 2h p chal SerPl-mCnc;;ACTIVE;1.0l;2.70 +16110-9;11-Deoxycorticosterone;MRat;24H;Urine;Qn;;CHEM;1;11-Deoxycorticosterone [Mass/time] in 24 hour Urine;11DOC 24h Ur-mRate;;ACTIVE;1.0l;2.70 +16111-7;Epinephrine+Norepinephrine;MRat;24H;Urine;Qn;;CHEM;1;Epinephrine+Norepinephrine [Mass/time] in 24 hour Urine;Epineph+Nor 24h Ur-mRate;;ACTIVE;1.0l;2.73 +16112-5;Estrogen receptor;Imp;Pt;Tiss;Nom;;PATH;1;Estrogen receptor [Interpretation] in Tissue;ER Tiss-Imp;;ACTIVE;1.0l;2.73 +1611-3;Prolactin^1H post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1 hour post dose TRH IV;Prolactin 1h p TRH IV SerPl-mCnc;;ACTIVE;1.0;2.73 +16113-3;Progesterone receptor;Imp;Pt;Tiss;Nom;;PATH;1;Progesterone receptor [Interpretation] in Tissue;PR Tiss-Imp;;ACTIVE;1.0l;2.73 +16114-1;Amitriptyline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Urine;Amitrip Ur-mCnc;;ACTIVE;1.0l;2.73 +16115-8;Doxepin;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Doxepin [Mass/mass] in Tissue;Doxepin Tiss-mCnt;;ACTIVE;1.0l;2.70 +16116-6;Tetrahydrocortisone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Tetrahydrocortisone [Mass/time] in 24 hour Urine;THcortisone 24h Ur-mRate;;ACTIVE;1.0l;2.73 +16117-4;Babesia microti Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Babesia microti IgG Ab [Titer] in Serum;B microti IgG Titr Ser;;ACTIVE;1.0l;2.73 +16118-2;Babesia microti Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Babesia microti IgM Ab [Titer] in Serum;B microti IgM Titr Ser;;ACTIVE;1.0l;2.73 +16119-0;Brucella abortus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Brucella abortus IgG Ab [Titer] in Serum;B abortus IgG Titr Ser;;ACTIVE;1.0l;2.73 +16120-8;Brucella abortus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Brucella abortus IgM Ab [Titer] in Serum;B abortus IgM Titr Ser;;ACTIVE;1.0l;2.73 +1612-1;Prolactin^1H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV;Prolactin 1h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16121-6;Colorado tick fever virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Colorado tick fever virus IgG Ab [Titer] in Serum;CTFV IgG Titr Ser;;ACTIVE;1.0l;2.73 +16122-4;Colorado tick fever virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Colorado tick fever virus IgM Ab [Titer] in Serum;CTFV IgM Titr Ser;;ACTIVE;1.0l;2.73 +16123-2;Cryptococcus sp Ab;Titr;Pt;CSF;Qn;;MICRO;1;Cryptococcus sp Ab [Titer] in Cerebral spinal fluid;Cryptoc Ab Titr CSF;;ACTIVE;1.0l;2.73 +16124-0;Cryptococcus sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Cryptococcus sp Ab [Titer] in Serum;Cryptoc Ab Titr Ser;;ACTIVE;1.0l;2.73 +16125-7;Helicobacter pylori Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Helicobacter pylori IgA Ab [Presence] in Serum;H pylori IgA Ser Ql;;ACTIVE;1.0l;2.73 +16126-5;Helicobacter pylori Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Helicobacter pylori IgG Ab [Presence] in Serum;H pylori IgG Ser Ql;;ACTIVE;1.0l;2.73 +16127-3;Helicobacter pylori Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Helicobacter pylori IgM Ab [Presence] in Serum;H pylori IgM Ser Ql;;ACTIVE;1.0l;2.73 +16128-1;Hepatitis C virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus Ab [Presence] in Serum;HCV Ab Ser Ql;;ACTIVE;1.0l;2.73 +16129-9;Hepatitis C virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus IgG Ab [Presence] in Serum;HCV IgG Ser Ql;;ACTIVE;1.0l;2.73 +16130-7;Herpes simplex virus 1 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Specimen by NAA with probe detection;HSV1 DNA Spec Ql NAA+probe;;ACTIVE;1.0l;2.73 +16131-5;Herpes simplex virus 2 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Specimen by NAA with probe detection;HSV2 DNA Spec Ql NAA+probe;;ACTIVE;1.0l;2.73 +16132-3;HIV 1 p15+p18 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p15+p18 Ab [Presence] in Serum by Immunoblot;HIV1 p15+p18 Ab Ser Ql IB;;ACTIVE;1.0l;2.58 +16133-1;Legionella pneumophila Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo IgM Titr Ser IF;;ACTIVE;1.0l;2.73 +16134-9;Neisseria meningitidis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Neisseria meningitidis [Presence] in Specimen by Organism specific culture;N men Spec Ql Cult;;ACTIVE;1.0l;2.69 +16135-6;Beta 2 glycoprotein 1 Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum;B2 Glycoprot1 IgG Ser-aCnc;;ACTIVE;1.0l;2.73 +16136-4;Beta 2 glycoprotein 1 Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum;B2 Glycoprot1 IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +16137-2;Centromere Ab;PrThr;Pt;Ser;Ord;;SERO;1;Centromere Ab [Presence] in Serum;Centromere Ab Ser Ql;;ACTIVE;1.0l;2.73 +16138-0;Ganglioside GM1 Ab.IgA;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 IgA Ab [Titer] in Serum;GM1 Gangl IgA Titr Ser;;ACTIVE;1.0l;2.73 +1613-9;Prolactin^2H post dose L-Dopa PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --2 hours post dose L-dopa PO;Prolactin 2h p L-D PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16139-8;Neuronal nuclear Ab;Titr;Pt;CSF;Qn;;SERO;1;Neuronal nuclear Ab [Titer] in Cerebral spinal fluid;Hu Ab Titr CSF;;ACTIVE;1.0l;2.73 +16140-6;Tellurium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tellurium [Mass/volume] in Blood;Tellurium Bld-mCnc;;ACTIVE;1.0l;2.73 +16141-4;Nitrogen;MRat;24H;Stool;Qn;;CHEM;1;Nitrogen [Mass/time] in 24 hour Stool;N2 24h Stl-mRate;;ACTIVE;1.0l;2.42 +16142-2;Fat;MRat;24H;Stool;Qn;;CHEM;1;Fat [Mass/time] in 24 hour Stool;Fat 24h Stl-mRate;;ACTIVE;1.0l;2.73 +16143-0;Butane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Butane [Mass/volume] in Blood;Deprecated Butane Bld-mCnc;;DEPRECATED;1.0l;2.36 +16144-8;Droperidol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Droperidol [Presence] in Serum or Plasma;Droperidol SerPl Ql;;ACTIVE;1.0l;2.56 +16145-5;Mescaline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mescaline [Mass/volume] in Serum or Plasma;Mescaline SerPl-mCnc;;ACTIVE;1.0l;2.42 +16146-3;Psilocin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Psilocin [Mass/volume] in Serum or Plasma;Psilocin SerPl-mCnc;;ACTIVE;1.0l;2.73 +1614-7;Prolactin^30M post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --30 minutes post dose TRH IV;Prolactin 30M p TRH IV SerPl-mCnc;;ACTIVE;1.0;2.73 +16147-1;Aldosterone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Aldost sp3 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16148-9;Aldosterone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Aldost sp4 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16149-7;Aldosterone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Aldost sp5 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16150-5;Carboxy tetrahydrocannabinol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Serum or Plasma;CarboxyTHC SerPl-mCnc;;ACTIVE;1.0l;2.73 +16151-3;Dechlorane;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Dechlorane [Presence] in Serum or Plasma;Dechlorane SerPl Ql;;ACTIVE;1.0l;2.56 +16152-1;Gastrin^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Gastrin sp2 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16153-9;Gastrin^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Gastrin sp3 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +1615-4;Prolactin^30M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV;Prolactin 30M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16154-7;Gastrin^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Gastrin sp4 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16155-4;Gastrin^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Gastrin sp5 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16156-2;Gastrin^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Gastrin sp6 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16157-0;Gastrin^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Gastrin sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16158-8;Gastrin^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Gastrin sp8 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16159-6;Gastrin^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Gastrin sp9 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16160-4;Gastrin^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;Gastrin sp10 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16161-2;Gastrin^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --post XXX challenge;Gastrin p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +1616-2;Prolactin^30M post dose U/kg insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Deprecated Prolactin [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV;Deprecated Prolactin 30M p U/kg Ins IV P;;DEPRECATED;1.0;2.36 +16162-0;Parathyrin.intact^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;PTH-Intact 30M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16163-8;Parathyrin.intact^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;PTH-Intact 1h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16164-6;Parathyrin.intact^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;PTH-Intact 2h p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16165-3;Glucose^10 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 AM specimen;Glucose 10 AM SerPl-mCnc;;ACTIVE;1.0l;2.34 +16166-1;Glucose^11 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --11 AM specimen;Glucose 11 AM SerPl-mCnc;;ACTIVE;1.0l;2.34 +16167-9;Glucose^2 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 PM specimen;Glucose 2 PM SerPl-mCnc;;ACTIVE;1.0l;2.34 +16168-7;Glucose^3 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 PM specimen;Glucose 3 PM SerPl-mCnc;;ACTIVE;1.0l;2.34 +16169-5;Glucose^4 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 PM specimen;Glucose 4 PM SerPl-mCnc;;ACTIVE;1.0l;2.73 +1617-0;Prolactin^3H post dose L-Dopa PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --3 hours post dose L-dopa PO;Prolactin 3h p L-D PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16170-3;Glucose^5 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 PM specimen;Glucose 5 PM SerPl-mCnc;;ACTIVE;1.0l;2.73 +16171-1;Cocaethylene;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cocaethylene [Mass/mass] in Hair;Cocaethylene Hair-mCnt;;ACTIVE;1.0l;2.73 +16172-9;Magnesium;MCnt;Pt;Hair;Qn;;CHEM;1;Magnesium [Mass/mass] in Hair;Magnesium Hair-mCnt;;ACTIVE;1.0l;2.73 +16173-7;Amyl ether;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Amyl ether [Mass/volume] in Blood;Amyl ether Bld-mCnc;;ACTIVE;1.0l;2.34 +16174-5;Bartonella henselae Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Bartonella henselae IgG Ab [Presence] in Cerebral spinal fluid;B henselae IgG CSF Ql;;ACTIVE;1.0l;2.56 +16175-2;Bartonella henselae Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Bartonella henselae IgM Ab [Presence] in Cerebral spinal fluid;B henselae IgM CSF Ql;;ACTIVE;1.0l;2.56 +16176-0;Bartonella quintana Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Bartonella quintana IgG Ab [Units/volume] in Cerebral spinal fluid;B quintana IgG CSF-aCnc;;ACTIVE;1.0l;2.69 +16177-8;Bartonella quintana Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Bartonella quintana IgM Ab [Units/volume] in Cerebral spinal fluid;B quintana IgM CSF-aCnc;;ACTIVE;1.0l;2.69 +16178-6;Beryllium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Beryllium [Mass/mass] in Tissue;Beryllium Tiss-mCnt;;ACTIVE;1.0l;2.42 +16179-4;Polychlorinated biphenyl;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Mass/mass] in Tissue;PCB Tiss-mCnt;;ACTIVE;1.0l;2.46 +16180-2;Zinc;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Zinc [Mass/mass] in Tissue;Zinc Tiss-mCnt;;ACTIVE;1.0l;2.40 +16181-0;Tricyclic antidepressants;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Tricyclic antidepressants [Mass/volume] in Urine by Confirmatory method;Tricyclics Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16182-8;Alkaline phosphatase isoenzymes;CCnc;Pt;Ser/Plas;Qn;Heat stability;CHEM;1;Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Heat stability;ALP Isos SerPl HS-cCnc;;ACTIVE;1.0l;2.73 +16183-6;Phenolphthalein;MCnc;Pt;Stool;Qn;;DRUG/TOX;1;Phenolphthalein [Mass/volume] in Stool;Phenolphthalein Stl-mCnc;;ACTIVE;1.0l;2.73 +16184-4;Temazepam;MCnc;Pt;Stool;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Stool;Temazepam Stl-mCnc;;ACTIVE;1.0l;2.42 +16185-1;chlordiazePOXIDE;MCnc;Pt;Stool;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Stool;Chlordiazep Stl-mCnc;;ACTIVE;1.0l;2.42 +16186-9;Hydroxyalprazolam;MCnc;Pt;Stool;Qn;;DRUG/TOX;1;Hydroxyalprazolam [Mass/volume] in Stool;OH-Alpraz Stl-mCnc;;ACTIVE;1.0l;2.42 +16187-7;ALPRAZolam;MCnc;Pt;Stool;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Stool;Alpraz Stl-mCnc;;ACTIVE;1.0l;2.42 +1618-8;Prolactin^45M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --45 minutes post dose insulin IV;Prolactin 45M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16188-5;Creatinine^2H specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass/volume] in Serum or Plasma --2 hour specimen;Creat 2h spec SerPl-mCnc;;ACTIVE;1.0l;2.73 +16189-3;Creatinine^4H specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass/volume] in Serum or Plasma --4 hour specimen;Creat 4h spec SerPl-mCnc;;ACTIVE;1.0l;2.34 +16190-1;Amobarbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Amobarbital [Presence] in Urine by Confirmatory method;Amobarbital Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16191-9;Butabarbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Butabarbital [Presence] in Urine by Confirmatory method;Butabarbital Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16192-7;PHENobarbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;PHENobarbital [Presence] in Urine by Confirmatory method;Phenobarb Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16193-5;PENTobarbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;PENTobarbital [Presence] in Urine by Confirmatory method;Pentobarb Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16194-3;Secobarbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Secobarbital [Presence] in Urine by Confirmatory method;Secobarbital Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16195-0;Benzodiazepines;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Benzodiazepines [Presence] in Urine by Confirmatory method;Benzodiaz Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1619-6;Prolactin^pre dose L-dopa PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --pre dose L-dopa PO;Prolactin pre L-D PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16196-8;Morphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Morphine [Presence] in Urine by Confirmatory method;Morphine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16197-6;Codeine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Codeine [Presence] in Urine by Confirmatory method;Codeine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16198-4;Diamorphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Diamorphine [Presence] in Urine by Confirmatory method;DAM Ur Ql Cfm;;ACTIVE;1.0l;2.56 +16199-2;Methadone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methadone [Presence] in Urine by Confirmatory method;Methadone Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16200-8;Propoxyphene;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Propoxyphene [Presence] in Urine by Confirmatory method;Propoxyph Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16201-6;Oxazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Oxazepam [Mass/volume] in Urine by Confirmatory method;Oxazepam Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16202-4;Nordiazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Nordiazepam [Presence] in Urine by Confirmatory method;Nordiazepam Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16203-2;ALPRAZolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;ALPRAZolam [Presence] in Urine by Confirmatory method;Alpraz Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1620-4;Prolactin^pre dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --pre dose TRH IV;Prolactin pre TRH IV SerPl-mCnc;;ACTIVE;1.0;2.73 +16204-0;clonazePAM;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;clonazePAM [Presence] in Urine by Confirmatory method;clonazePAM Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16205-7;LORazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;LORazepam [Presence] in Urine by Confirmatory method;LORazepam Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16206-5;Temazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Temazepam [Presence] in Urine by Confirmatory method;Temazepam Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16207-3;Meperidine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Meperidine [Presence] in Urine by Confirmatory method;Meperidine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16208-1;Buprenorphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Buprenorphine [Presence] in Urine by Confirmatory method;Buprenorphine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16209-9;Chlorpheniramine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Chlorpheniramine [Presence] in Urine by Confirmatory method;Chlorphenir Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16210-7;Diethylpropion;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Diethylpropion [Presence] in Urine by Confirmatory method;Diethylpropion Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16211-5;Dihydrocodeine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Dihydrocodeine [Presence] in Urine by Confirmatory method;DHC Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1621-2;Prolactin^pre dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --pre dose insulin IV;Prolactin pre Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16212-3;Ethylamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ethylamphetamine [Presence] in Urine by Confirmatory method;Ethylamphet Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16213-1;Levorphanol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Levorphanol [Presence] in Urine by Confirmatory method;Levorphanol Ur Ql Cfm;;ACTIVE;1.0l;2.56 +16214-9;Lysergate diethylamide;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Lysergate diethylamide [Presence] in Urine by Confirmatory method;LSD Ur Ql Cfm;;ACTIVE;1.0l;2.56 +16215-6;Mephobarbital;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Mephobarbital [Mass/volume] in Serum or Plasma by Confirmatory method;Mephobarbital SerPl Cfm-mCnc;;ACTIVE;1.0l;2.40 +16216-4;MethylePHEDrine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;MethylePHEDrine [Presence] in Urine by Confirmatory method;Me-ePHEDrine Ur Ql Cfm;;ACTIVE;1.0l;2.56 +16217-2;Methyprylon;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methyprylon [Presence] in Urine by Confirmatory method;Methyprylon Ur Ql Cfm;;ACTIVE;1.0l;2.56 +16218-0;Nalbuphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Nalbuphine [Presence] in Urine by Confirmatory method;Nalbuphine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16219-8;Pentazocine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Pentazocine [Presence] in Urine by Confirmatory method;Pentazocine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1622-0;Renin^5H post 600 ug furosemide PO;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --5 hours post 600 ug furosemide PO;Renin 5h p 600 ug Fur PO Plas-cCnc;;ACTIVE;1.0;2.42 +16220-6;Phenmetrazine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Phenmetrazine [Presence] in Urine by Confirmatory method;Phenmetrazine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16221-4;Phenothiazines;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Phenothiazines [Presence] in Urine by Confirmatory method;Phenothiaz Ur Ql Cfm;;ACTIVE;1.0l;2.70 +16222-2;Phentermine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Phentermine [Presence] in Urine by Confirmatory method;Phentermine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16223-0;Thiopental;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Thiopental [Presence] in Urine by Confirmatory method;Thiopental Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16224-8;Triazolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Triazolam [Presence] in Urine by Confirmatory method;Triazolam Ur Ql Cfm;;ACTIVE;1.0l;2.56 +16225-5;Amitriptyline;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Amitriptyline [Presence] in Urine by Confirmatory method;Amitrip Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16226-3;Benzoylecgonine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Urine by Confirmatory method;BZE Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16227-1;diazePAM;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/volume] in Urine by Confirmatory method;diazePAM Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16228-9;Nordiazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Mass/volume] in Urine by Confirmatory method;Nordiazepam Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16229-7;clonazePAM;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;clonazePAM [Mass/volume] in Urine by Confirmatory method;clonazePAM Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16230-5;N-desalkylflurazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Urine by Confirmatory method;Desalkylfluraz Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16231-3;Flurazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flurazepam [Mass/volume] in Urine by Confirmatory method;Flurazepam Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16232-1;Triazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Triazolam [Mass/volume] in Urine by Confirmatory method;Triazolam Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16233-9;Midazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Midazolam [Mass/volume] in Urine by Confirmatory method;Midazolam Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16234-7;Amphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amphetamine [Mass/volume] in Urine by Confirmatory method;Amphet Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16235-4;Methamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methamphetamine [Mass/volume] in Urine by Confirmatory method;Methamphet Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16236-2;Butabarbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butabarbital [Mass/volume] in Urine by Confirmatory method;Butabarbital Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16237-0;Butalbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butalbital [Mass/volume] in Urine by Confirmatory method;Butalbital Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1623-8;Renin^pre 600 ug furosemide PO;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --pre 600 ug furosemide PO;Renin pre 600 ug Fur PO Plas-cCnc;;ACTIVE;1.0;2.42 +16238-8;Secobarbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Secobarbital [Mass/volume] in Urine by Confirmatory method;Secobarbital Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16239-6;Amobarbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amobarbital [Mass/volume] in Urine by Confirmatory method;Amobarbital Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16240-4;PENTobarbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;PENTobarbital [Mass/volume] in Urine by Confirmatory method;Pentobarb Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16241-2;PHENobarbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;PHENobarbital [Mass/volume] in Urine by Confirmatory method;Phenobarb Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16242-0;Propoxyphene;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Propoxyphene [Mass/volume] in Urine by Confirmatory method;Propoxyph Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16243-8;Cannabinoids;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Cannabinoids [Mass/volume] in Blood by Confirmatory method;Cannabinoids Bld Cfm-mCnc;;ACTIVE;1.0l;2.73 +16244-6;Methaqualone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methaqualone [Mass/volume] in Urine by Confirmatory method;Methaqualone Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16245-3;Hydroxyethylflurazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Serum or Plasma by Confirmatory method;OH-Ethylfluraz SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +1624-6;Retinol^3H post 5000 units;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Retinol [Mass/volume] in Serum or Plasma --3 hours post 5000 units;Vit A 3h p 5000 U SerPl-mCnc;;ACTIVE;1.0;2.40 +16246-1;Methadone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methadone [Mass/volume] in Urine by Confirmatory method;Methadone Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16247-9;Dextromethorphan;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Dextromethorphan [Mass/volume] in Serum or Plasma by Confirmatory method;D-methorphan SerPl Cfm-mCnc;;ACTIVE;1.0l;2.40 +16248-7;6-Monoacetylmorphine.free;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;6-monoacetylmorphine free [Mass/volume] in Serum or Plasma by Confirmatory method;6MAM Free SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +16249-5;oxyCODONE;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;oxyCODONE [Mass/volume] in Urine by Confirmatory method;oxyCODONE Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16250-3;Codeine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Codeine [Mass/volume] in Urine by Confirmatory method;Codeine Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16251-1;Morphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Morphine [Mass/volume] in Urine by Confirmatory method;Morphine Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16252-9;HYDROcodone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;HYDROcodone [Mass/volume] in Urine by Confirmatory method;HYDROcodone Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1625-3;Retinol^6H post 5000 units;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Retinol [Mass/volume] in Serum or Plasma --6 hours post 5000 units;Vit A 6h p 5000 U SerPl-mCnc;;ACTIVE;1.0;2.40 +16253-7;Meperidine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Meperidine [Mass/volume] in Urine by Confirmatory method;Meperidine Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16254-5;Phencyclidine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phencyclidine [Mass/volume] in Urine by Confirmatory method;PCP Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16255-2;Troponin I.cardiac;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Troponin I.cardiac [Units/volume] in Serum or Plasma;Troponin I SerPl-aCnc;;DISCOURAGED;1.0l;2.73 +16257-8;Sodium urate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Sodium urate crystals [Presence] in Stone by Infrared spectroscopy;Na Urate Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16258-6;Ammonium urate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Ammonium urate crystals [Presence] in Stone by Infrared spectroscopy;Amm Urate Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16259-4;Urate dihydrate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Urate dihydrate crystals [Presence] in Stone by Infrared spectroscopy;Urate dihyd Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16260-2;Triamterene crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Triamterene crystals [Presence] in Stone by Infrared spectroscopy;Triamterene Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +1626-1;Retinol^pre 5000 units;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Retinol [Mass/volume] in Serum or Plasma --pre 5000 units;Vit A pre 5000 U SerPl-mCnc;;ACTIVE;1.0;2.40 +16261-0;Calcium bilirubinate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Calcium bilirubinate crystals [Presence] in Stone by Infrared spectroscopy;Ca Bilirub Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16262-8;Newberyite crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Newberyite crystals [Presence] in Stone by Infrared spectroscopy;Newberyite Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16263-6;Calcium oxalate dihydrate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Calcium oxalate dihydrate crystals [Presence] in Stone by Infrared spectroscopy;COD Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16264-4;Calcium oxalate monohydrate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Calcium oxalate monohydrate crystals [Presence] in Stone by Infrared spectroscopy;COM Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16265-1;Triple phosphate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Triple phosphate crystals [Presence] in Stone by Infrared spectroscopy;Tri-Phos Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16266-9;Calcium hydrogen phosphate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Calcium hydrogen phosphate crystals [Presence] in Stone by Infrared spectroscopy;CaHPO4 Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16267-7;Calcium carbonate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Calcium carbonate crystals [Presence] in Stone by Infrared spectroscopy;Ca Carbonate Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16268-5;Calcium phosphate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Calcium phosphate crystals [Presence] in Stone by Infrared spectroscopy;Ca Phos Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16269-3;Urate crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Urate crystals [Presence] in Stone by Infrared spectroscopy;Urate Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16270-1;Calcium^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Calcium 1h p chal SerPl-mCnc;;ACTIVE;1.0l;2.70 +16271-9;Calcium^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Calcium 30M p chal SerPl-mCnc;;ACTIVE;1.0l;2.70 +16272-7;Calcium^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Calcium 2h p chal SerPl-mCnc;;ACTIVE;1.0l;2.70 +16273-5;Calcium;MCnt;Pt;RBC;Qn;;CHEM;1;Calcium [Mass/mass] in Red Blood Cells;Calcium RBC-mCnt;;ACTIVE;1.0l;2.73 +16274-3;Cells.CD4/Cells.C4;MCrto;Pt;Plas;Qn;;CELLMARK;1;Deprecated Cells.CD4/Cells.C4;Deprecated CD4 Cells Plas-mRto;;DEPRECATED;1.0l;2.36 +16275-0;Bartonella sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Bartonella sp DNA [Presence] in Blood by NAA with probe detection;Bartonella DNA Bld Ql NAA+probe;;ACTIVE;1.0l;2.73 +16276-8;Bartonella henselae DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Bartonella henselae DNA [Presence] in Blood by NAA with probe detection;B henselae DNA Bld Ql NAA+probe;;ACTIVE;1.0l;2.73 +16277-6;Bartonella quintana DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Bartonella quintana DNA [Presence] in Blood by NAA with probe detection;B quintana DNA Bld Ql NAA+probe;;ACTIVE;1.0l;2.73 +16278-4;Mycobacterium tuberculosis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Blood by NAA with probe detection;M tb DNA Bld Ql NAA+probe;;ACTIVE;1.0l;2.73 +1627-9;Somatotropin^1.5H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose insulin IV;GH 1.5h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16279-2;Toxoplasma gondii DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Blood by NAA with probe detection;T gondii DNA Bld Ql NAA+probe;;ACTIVE;1.0l;2.73 +162-8;Cephalothin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cephalothin [Susceptibility] by Disk diffusion (KB);Cephalothin Islt KB;;ACTIVE;1.0;2.73 +16280-0;Human papilloma virus DNA;PrThr;Pt;XXX;Ord;Probe.amp;MICRO;1;Human papilloma virus DNA [Presence] in Specimen by Probe with amplification;HPV DNA Spec Ql Probe amp;;ACTIVE;1.0l;2.73 +16281-8;traZODone;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;traZODone [Units/volume] in Urine;traZODone Ur-aCnc;;DISCOURAGED;1.0l;2.73 +16282-6;Acetaminophen;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetaminophen [Units/volume] in Urine;APAP Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16283-4;Escherichia coli verotoxin;PrThr;Pt;XXX;Ord;;MICRO;1;Escherichia coli verotoxin [Presence] in Specimen;E coli VTN Spec Ql;;ACTIVE;1.0l;2.73 +16284-2;Polio virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Polio virus Ab [Units/volume] in Serum;PV Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +16285-9;Creatinine/Protein;MRto;Pt;Urine;Qn;;CHEM;1;Creatinine/Protein [Mass Ratio] in Urine;Creat/Prot Ur;;ACTIVE;1.0l;2.73 +16286-7;Testosterone.free/Testosterone.total;NFr;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Testosterone Free/Testosterone.total in Serum or Plasma;Deprecated Testost Free Fr SerPl;;DEPRECATED;1.0l;2.46 +1628-7;Somatotropin^1H post 1 g/kg glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post 1 g/kg glucose PO;GH 1h p 1 g/kg Glc PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16287-5;Sulfatide Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Sulfatide Ab;Deprecated Sulfatide Ab Ser;;DEPRECATED;1.0l;2.36 +16288-3;Monosialoganglioside GM1 Ab.IgG+IgM;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Monosialoganglioside GM1 Ab.IgG+IgM;Deprecated GM1 Monosialo IgG+IgM Ser;;DEPRECATED;1.0l;2.36 +16289-1;Monosialoganglioside GM1 Ab;ACnc;Pt;Ser;OrdQn;;SERO;1;Deprecated Monosialoganglioside GM1 Ab;Deprecated GM1 Monosialo Ab Ser;;DEPRECATED;1.0l;2.36 +16290-9;Neutrophils;PrThr;Pt;Stool;Ord;;HEM/BC;1;Neutrophils [Presence] in Stool;Neutrophils Stl Ql;;ACTIVE;1.0l;2.73 +16291-7;Herpes simplex virus 1;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 1 [Presence] in Specimen by Organism specific culture;HSV1 Spec Ql Cult;;ACTIVE;1.0l;2.73 +16292-5;1,4-Dioxane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;1,4-Dioxane [Mass/volume] in Urine;1,4Dioxane Ur-mCnc;;ACTIVE;1.0l;2.42 +16293-3;11-Deoxycorticosteroids;MCnc;Pt;Plas;Qn;;CHEM;1;11-Deoxycorticosteroids [Mass/volume] in Plasma;11DCOR Plas-mCnc;;ACTIVE;1.0l;2.42 +16294-1;11-Deoxycorticosterone^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --post XXX challenge;11DOC p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +1629-5;Somatotropin^1H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV;GH 1h p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16295-8;11-Deoxycortisol^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --post XXX challenge;11DC p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16296-6;11-Hydroxyandrosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Hydroxyandrosterone [Mass/volume] in Serum or Plasma;11OH-Androst SerPl-mCnc;;ACTIVE;1.0l;2.42 +16297-4;17-Hydroxypregnenolone;MCnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxypregnenolone [Mass/volume] in Urine;17OH-Preg Ur-mCnc;;ACTIVE;1.0l;2.42 +16298-2;17-Hydroxypregnenolone^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;17OH-Preg 45M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16299-0;17-Hydroxypregnenolone^6H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --6 hours post XXX challenge;17OH-Preg 6h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16300-6;17-Ketogenic steroids;MRat;72H;Urine;Qn;;CHEM;1;17-Ketogenic steroids [Mass/time] in 72 hour Urine;17KGS 72h Ur-mRate;;ACTIVE;1.0l;2.42 +16301-4;17-Ketogenic steroids^baseline;MRat;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine --baseline;17KGS BS 24h Ur-mRate;;ACTIVE;1.0l;2.42 +16302-2;1-Methylhistidine;PrThr;Pt;Urine;Ord;;CHEM;1;1-Methylhistidine [Presence] in Urine;1Me-hist Ur Ql;;ACTIVE;1.0l;2.56 +1630-3;Somatotropin^2H post 1 g/kg glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post 1 g/kg glucose PO;GH 2h p 1 g/kg Glc PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16303-0;2-Hexanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2-Hexanol [Mass/volume] in Urine;2Hexanol Ur-mCnc;;ACTIVE;1.0l;2.42 +16304-8;2-Hexanol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;2-Hexanol/Creatinine [Mass Ratio] in Urine;2Hexanol/Creat Ur;;ACTIVE;1.0l;2.44 +16305-5;2-Methoxyethanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Methoxyethanol [Mass/volume] in Blood;2Methoxyethanol Bld-mCnc;;ACTIVE;1.0l;2.42 +16306-3;3-Methylhistidine;PrThr;Pt;Urine;Ord;;CHEM;1;3-Methylhistidine [Presence] in Urine;3Me-histidine Ur Ql;;ACTIVE;1.0l;2.56 +16307-1;Acetate;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Acetate [Mass/volume] in Dialysis fluid;Acetate Dial fld-mCnc;;ACTIVE;1.0l;2.44 +16308-9;acetaZOLAMIDE;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetazolamide [Units/volume] in Serum or Plasma;acetaZOLAMIDE SerPl-aCnc;;DISCOURAGED;1.0l;2.73 +16309-7;acetaZOLAMIDE;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetazolamide [Units/volume] in Urine;acetaZOLAMIDE Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16310-5;Acetone;PrThr;Pt;Body fld;Ord;;DRUG/TOX;1;Acetone [Presence] in Body fluid;Acetone Fld Ql;;ACTIVE;1.0l;2.73 +1631-1;Somatotropin^30M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV;GH 30M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16311-3;Acetone;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acetone [Mass/volume] in Body fluid;Acetone Fld-mCnc;;ACTIVE;1.0l;2.42 +16312-1;Acetonitrile;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetonitrile [Mass/volume] in Serum or Plasma;Acetonitrile SerPl-mCnc;;ACTIVE;1.0l;2.42 +16313-9;Acetylene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acetylene [Mass/volume] in Blood;Acetylene Bld-mCnc;;ACTIVE;1.0l;2.42 +16314-7;Acetylsalicylate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Acetylsalicylate [Presence] in Urine;Acetylsalicylate Ur Ql;;ACTIVE;1.0l;2.56 +16315-4;Acid phosphatase;CCnc;Pt;Bld;Qn;Tartrate inhibited;CHEM;1;Acid phosphatase [Enzymatic activity/volume] in Blood by Tartrate inhibited;ACP Bld Tart Inhib-cCnc;;ACTIVE;1.0l;2.68 +16316-2;Acid phosphatase.tartrate resistant;CCnc;Pt;Bld;Qn;;CHEM;1;Acid phosphatase tartrate resistant [Enzymatic activity/volume] in Blood;ACP TRAP Bld-cCnc;;ACTIVE;1.0l;2.68 +16317-0;Acid phosphatase.prostatic;PrThr;Pt;Vag;Ord;;CHEM;1;Prostatic acid phosphatase [Presence] in Vaginal fluid;PACP Vag Ql;;ACTIVE;1.0l;2.56 +16318-8;Acrylamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acrylamide [Mass/volume] in Urine;Acrylamide Ur-mCnc;;ACTIVE;1.0l;2.42 +16319-6;Acrylamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acrylamide [Mass/volume] in Serum or Plasma;Acrylamide SerPl-mCnc;;ACTIVE;1.0l;2.73 +16320-4;Acyclovir;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Acyclovir [Susceptibility] by Serum bactericidal titer;Acyclovir Titr SBT;;ACTIVE;1.0l;2.32 +16321-2;Acyl carnitine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Acyl carnitine [Mass/volume] in Serum or Plasma;Deprecated Acyl carnitine SerPl-mCnc;;DEPRECATED;1.0l;2.36 +16322-0;Biperiden;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Biperiden [Mass/volume] in Serum or Plasma;Biperiden SerPl-mCnc;;ACTIVE;1.0l;2.42 +16323-8;Alanine;PrThr;Pt;Urine;Ord;;CHEM;1;Alanine [Presence] in Urine;Alanine Ur Ql;;ACTIVE;1.0l;2.56 +16324-6;Alanine aminotransferase;CCnc;Pt;RBC;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Red Blood Cells;ALT RBC-cCnc;;ACTIVE;1.0l;2.68 +16325-3;Alanine aminotransferase/Aspartate aminotransferase;CRto;Pt;Ser/Plas;Qn;;CHEM;1;Alanine aminotransferase/Aspartate aminotransferase [Enzymatic activity ratio] in Serum or Plasma;ALT/AST SerPl-cRto;;ACTIVE;1.0l;2.73 +16327-9;Allyl alcohol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Allyl alcohol [Mass/volume] in Blood;Allyl Alc Bld-mCnc;;ACTIVE;1.0l;2.42 +16328-7;Benzyl alcohol;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Benzyl alcohol [Presence] in Blood;Benzyl Alc Bld Ql;;ACTIVE;1.0l;2.56 +1632-9;Somatotropin^3H post 1 g/kg glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3 hours post 1 g/kg glucose PO;GH 3h p 1 g/kg Glc PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16329-5;Aldosterone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Aldost sp6 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16330-3;Aldosterone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Aldost sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16331-1;Aldosterone^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Aldost sp8 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16332-9;Aldosterone^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Aldost sp9 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16333-7;Aldrin;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Aldrin [Mass/volume] in Blood;Aldrin Bld-mCnc;;ACTIVE;1.0l;2.68 +16334-5;Alfentanil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alfentanil [Mass/volume] in Urine;Alfentanil Ur-mCnc;;ACTIVE;1.0l;2.73 +16335-2;Hydrocarbons.aliphatic;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Hydrocarbons Aliphatic [Identifier] in Blood;Aliph HC Bld;;ACTIVE;1.0l;2.17 +16336-0;Alkaline phosphatase.placental;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Alkaline phosphatase.placental [Enzymatic activity/volume] in Serum or Plasma;Deprecated ALP Plac SerPl-cCnc;;DEPRECATED;1.0l;2.36 +1633-7;Somatotropin^45M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --45 minutes post dose insulin IV;GH 45M p Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16337-8;Alkaline phosphatase;CCnc;Pt;Urine;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Urine;ALP Ur-cCnc;;ACTIVE;1.0l;2.68 +16338-6;Alpha aminoadipate;PrThr;Pt;Urine;Ord;;CHEM;1;Alpha aminoadipate [Presence] in Urine;AAA Ur Ql;;ACTIVE;1.0l;2.56 +16339-4;Alpha aminoisobutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;Alpha aminoisobutyrate [Presence] in Urine;A-AIB Ur Ql;;ACTIVE;1.0l;2.56 +16340-2;Alpha aminoisobutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Alpha aminoisobutyrate [Mass/volume] in Urine;A-AIB Ur-mCnc;;ACTIVE;1.0l;2.34 +16341-0;Alpha aminoisobutyrate;PrThr;Pt;Plas;Ord;;CHEM;1;Alpha aminoisobutyrate [Presence] in Plasma;A-AIB Plas Ql;;ACTIVE;1.0l;2.56 +16342-8;Alpha aminoisobutyrate;MCnc;Pt;Plas;Qn;;CHEM;1;Alpha aminoisobutyrate [Mass/volume] in Plasma;A-AIB Plas-mCnc;;ACTIVE;1.0l;2.34 +16343-6;Alpha aminoisobutyrate;MCnc;Pt;CSF;Qn;;CHEM;1;Alpha aminoisobutyrate [Mass/volume] in Cerebral spinal fluid;A-AIB CSF-mCnc;;ACTIVE;1.0l;2.34 +16344-4;Alpha aminoisobutyrate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha aminoisobutyrate [Mass/volume] in Amniotic fluid;A-AIB Amn-mCnc;;ACTIVE;1.0l;2.34 +1634-5;Somatotropin^52H post 250 ug L-Dopa TID 2day PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --52 hours post 250 ug L-dopa TID 2day PO;GH 52h p 250 ug L-D TID 2D PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16345-1;Alpha aminobutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;Alpha aminobutyrate [Presence] in Urine;A-Aminobutyr Ur Ql;;ACTIVE;1.0l;2.56 +16346-9;Alpha chlordane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alpha chlordane [Mass/volume] in Urine;A-Chlordane Ur-mCnc;;ACTIVE;1.0l;2.42 +16347-7;Alpha chlordane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Alpha chlordane [Mass/volume] in Blood;A-Chlordane Bld-mCnc;;ACTIVE;1.0l;2.73 +16348-5;Alpha hydroxyalprazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Urine by Confirmatory method;A-OH Alpraz Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16349-3;Aluminum;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Body fluid;Aluminum Fld-mCnc;;ACTIVE;1.0l;2.42 +16350-1;Amantadine;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Amantadine [Susceptibility] by Serum bactericidal titer;Amantadine Titr SBT;;ACTIVE;1.0l;2.32 +16351-9;aMILoride;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;aMILoride [Units/volume] in Serum or Plasma;aMILoride SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +1635-2;Somatotropin^pre 1 g/kg glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre 1 g/kg glucose PO;GH pre 1 g/kg Glc PO SerPl-mCnc;;ACTIVE;1.0;2.73 +16352-7;aMILoride;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;aMILoride [Units/volume] in Urine;aMILoride Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16353-5;Amino beta guanidinopropionate;PrThr;Pt;Urine;Ord;;CHEM;1;Amino beta guanidinopropionate [Presence] in Urine;AB-Gp Ur Ql;;ACTIVE;1.0l;2.56 +16354-3;Amino beta guanidinopropionate;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Amino beta guanidinopropionate [Mass/volume] in Urine;Deprecated AB-Gp Ur-mCnc;;DEPRECATED;1.0l;2.36 +16355-0;Amino beta guanidinopropionate;PrThr;Pt;Plas;Ord;;CHEM;1;Amino beta guanidinopropionate [Presence] in Plasma;AB-Gp Plas Ql;;ACTIVE;1.0l;2.56 +16356-8;Amino beta guanidinopropionate;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Amino beta guanidinopropionate [Mass/volume] in Plasma;Deprecated AB-Gp Plas-mCnc;;DEPRECATED;1.0l;2.36 +16357-6;Amino beta guanidinopropionate;MCnc;Pt;CSF;Qn;;CHEM;1;Deprecated Amino beta guanidinopropionate [Mass/volume] in Cerebral spinal fluid;Deprecated AB-Gp CSF-mCnc;;DEPRECATED;1.0l;2.36 +16358-4;Amino beta guanidinopropionate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Deprecated Amino beta guanidinopropionate [Mass/volume] in Amniotic fluid;Deprecated AB-Gp Amn-mCnc;;DEPRECATED;1.0l;2.36 +16359-2;Amiodarone+Desethylamiodarone;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Amiodarone+Desethylamiodarone [Mass/volume] in Serum or Plasma;Deprecated Amiodarone+Deseth Ser-mCnc;;DEPRECATED;1.0l;2.36 +163-6;Cephalothin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cephalothin [Susceptibility] by Serum bactericidal titer;Cephalothin Titr SBT;;ACTIVE;1.0;2.32 +1636-0;Somatotropin^pre 250 ug L-Dopa TID 2day PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre 250 ug L-dopa TID 2day PO;GH pre 250 ug L-D TID 2D PO SerPl-mCnc;;ACTIVE;1.0;2.40 +16360-0;Amitriptyline^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Serum or Plasma --peak;Amitrip Peak SerPl-mCnc;;ACTIVE;1.0l;2.40 +16361-8;Amitriptyline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Serum or Plasma --trough;Amitrip Trough SerPl-mCnc;;ACTIVE;1.0l;2.40 +16362-6;Ammonia;SCnc;Pt;Plas;Qn;;CHEM;1;Ammonia [Moles/volume] in Plasma;Ammonia Plas-sCnc;;ACTIVE;1.0l;2.73 +16363-4;Ammonia;SCnt;Pt;Tiss;Qn;;CHEM;1;Ammonia [Moles/mass] in Tissue;Ammonia Tiss-sCnt;;ACTIVE;1.0l;2.42 +16364-2;Amobarbital;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Amobarbital [Mass/volume] in Gastric fluid;Amobarbital Gast-mCnc;;ACTIVE;1.0l;2.42 +16365-9;Amoxicillin+Clavulanate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Amoxicillin+Clavulanate [Mass/volume] in Serum or Plasma;Deprecated Amoxicillin+Clav SerPl-mCnc;;DEPRECATED;1.0l;2.65 +16366-7;Diethylpropion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diethylpropion [Mass/volume] in Serum or Plasma;Diethylpropion SerPl-mCnc;;ACTIVE;1.0l;2.34 +16367-5;Amphetamine/Methamphetamine;MCrto;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Amphetamine/Methamphetamine [Mass ratio] in Urine Qualitative;Deprecated Amphet/Methamphet Ur;;DEPRECATED;1.0l;2.40 +16369-1;Amphetamines;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Amphetamines [Presence] in Urine by Confirmatory method;Amphetamines Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16370-9;Amphotericin B;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amphotericin B [Mass/volume] in Urine;Amphotericin B Ur-mCnc;;ACTIVE;1.0l;2.42 +16373-3;Amyl ether;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Amyl ether [Presence] in Blood;Amyl ether Bld Ql;;ACTIVE;1.0l;2.56 +16374-1;Amyl nitrite;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amyl nitrite [Mass/volume] in Serum or Plasma;Amyl nitrite SerPl-mCnc;;ACTIVE;1.0l;2.34 +1637-8;Somatotropin^pre dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre dose insulin IV;GH pre Ins IV SerPl-mCnc;;ACTIVE;1.0;2.40 +16378-2;Androstenedione^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Androst sp2 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16379-0;Androstenedione^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Androst sp3 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16380-8;Androstenedione^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Androst sp4 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16381-6;Androstenedione^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Androst sp5 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16382-4;Androstenedione^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Androst sp6 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16383-2;Androstenedione^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Androst sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16384-0;Androstenedione^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Androst sp8 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16385-7;Androstenedione^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Androst sp9 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +1638-6;Testosterone^96H post 5000 U HCG IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --96 hours post 5000 U HCG IM;Testost 96h p 5000 U HCG IM SerPl-mCnc;;ACTIVE;1.0;2.34 +16386-5;Rifabutin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Deprecated Rifabutin [Susceptibility] by Minimum inhibitory concentration (MIC);Deprecated Rifabutin Islt MIC;;DEPRECATED;1.0l;2.36 +16387-3;Rifabutin+Ethambutol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Rifabutin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC);Rifabutin+Ethambutol Islt MIC;;ACTIVE;1.0l;2.19 +16388-1;Anticonvulsants;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Anticonvulsants [Identifier] in Urine;Anticonvulsants Ur;;ACTIVE;1.0l;2.73 +16389-9;Antidepressants;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Antidepressants [Identifier] in Serum or Plasma;Antidepressants SerPl;;ACTIVE;1.0l;2.73 +16390-7;Antidiuretics;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Antidiuretics [Identifier] in Urine;Antidiuretics Ur;;ACTIVE;1.0l;2.19 +16391-5;Antimony;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Antimony [Presence] in Urine;Antimony Ur Ql;;ACTIVE;1.0l;2.56 +16392-3;Nuclear Ab;PrThr;Pt;Ser;Ord;Rodent substrate;SERO;1;Nuclear Ab [Presence] in Serum by Rodent substrate;ANA Ser Ql Rodent subst;;ACTIVE;1.0l;2.73 +16393-1;Nuclear Ab;ACnc;Pt;Ser;Qn;Rodent substrate;SERO;1;Nuclear Ab [Units/volume] in Serum by Rodent substrate;ANA Ser Rodent subst-aCnc;;ACTIVE;1.0l;2.69 +1639-4;Testosterone^pre 5000 U HCG IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --pre 5000 U HCG IM;Testost pre 5000 U CG IM SerPl-mCnc;;ACTIVE;1.0;2.34 +16394-9;Nuclear Ab;PrThr;Pt;Body fld;Ord;IF;SERO;1;Nuclear Ab [Presence] in Body fluid by Immunofluorescence;ANA Fld Ql IF;;ACTIVE;1.0l;2.56 +16395-6;Antipsychotics;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Antipsychotics [Identifier] in Urine;Antipsychotics Ur;;ACTIVE;1.0l;2.73 +16400-4;Appearance;Aper;Pt;Semin plas;Nom;;SPEC;1;Appearance of Seminal plasma;Appearance Semin plas;;ACTIVE;1.0l;2.73 +16401-2;Arginine;PrThr;Pt;Urine;Ord;;CHEM;1;Arginine [Presence] in Urine;Arginine Ur Ql;;ACTIVE;1.0l;2.56 +1640-2;Thyrotropin^30M post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --30 minutes post dose TRH IV;TSH 30M p TRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.73 +16402-0;Aromatic solvents;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Aromatic solvents [Identifier] in Blood;Arom Solvents Bld;;ACTIVE;1.0l;2.07 +16403-8;Arsenic;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Arsenic [Presence] in Serum or Plasma;Arsenic SerPl Ql;;ACTIVE;1.0l;2.56 +16404-6;Arsenic;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Arsenic [Presence] in Urine;Arsenic Ur Ql;;ACTIVE;1.0l;2.56 +16405-3;Arylamidase;PrThr;Pt;Urine;Ord;;CHEM;1;Arylamidase [Presence] in Urine;Arylamidase Ur Ql;;ACTIVE;1.0l;2.56 +16406-1;Arylamidase;CCnc;Pt;Urine;Qn;;CHEM;1;Arylamidase [Enzymatic activity/volume] in Urine;Arylamidase Ur-cCnc;;ACTIVE;1.0l;2.68 +16407-9;Asbestos identified;Prid;Pt;Sputum;Nom;Microscopy.light;DRUG/TOX;1;Asbestos identified in Sputum by Light microscopy;Asbestos Spt Micro;;ACTIVE;1.0l;2.19 +16408-7;Ascorbate;MCnc;Pt;Urine;Qn;;CHEM;1;Ascorbate [Mass/volume] in Urine;Vit C Ur-mCnc;;ACTIVE;1.0l;2.73 +16409-5;Ascorbate^post dose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Ascorbate [Mass/volume] in Serum or Plasma --post dose;Vit C p dose SerPl-mCnc;;ACTIVE;1.0l;2.34 +1641-0;Thyrotropin^1H post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --1 hour post dose TRH IV;TSH 1h p TRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.73 +16410-3;Asparagine;PrThr;Pt;Urine;Ord;;CHEM;1;Asparagine [Presence] in Urine;Asparagine Ur Ql;;ACTIVE;1.0l;2.73 +16411-1;Aspartate;PrThr;Pt;Urine;Ord;;CHEM;1;Aspartate [Presence] in Urine;Aspartate Ur Ql;;ACTIVE;1.0l;2.56 +16412-9;Aspartate aminotransferase;CCnc;Pt;RBC;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Red Blood Cells;AST RBC-cCnc;;ACTIVE;1.0l;2.68 +16414-5;Aspergillus amstelodami Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus amstelodami Ab [Units/volume] in Serum;A amstelodami Ab Qn;;ACTIVE;1.0l;2.69 +16415-2;Aspergillus flavus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Aspergillus flavus Ab [Presence] in Cerebral spinal fluid;A flavus Ab CSF Ql;;ACTIVE;1.0l;2.73 +16416-0;Aspergillus terreus Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus terreus Ab [Units/volume] in Serum;A terreus Ab Qn;;ACTIVE;1.0l;2.69 +16417-8;Aspergillus versicolor Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus versicolor Ab [Units/volume] in Serum;A versicolor Ab Qn;;ACTIVE;1.0l;2.69 +16418-6;Azatadine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Azatadine [Presence] in Urine;Azatadine Ur Ql;;ACTIVE;1.0l;2.56 +16419-4;azaTHIOprine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;azaTHIOprine [Mass/volume] in Serum or Plasma;azaTHIOprine SerPl-mCnc;;ACTIVE;1.0l;2.73 +16420-2;Azithromycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Azithromycin [Mass/volume] in Serum or Plasma;Azithromycin SerPl-mCnc;;ACTIVE;1.0l;2.73 +16421-0;Azithromycin+Ethambutol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Azithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC);Azithro+Ethambut Islt MIC;;ACTIVE;1.0l;2.19 +16422-8;Azlocillin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Azlocillin [Mass/volume] in Urine;Azlocillin Ur-mCnc;;ACTIVE;1.0l;2.34 +16423-6;Aztreonam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aztreonam [Mass/volume] in Urine;Aztreonam Ur-mCnc;;ACTIVE;1.0l;2.42 +16424-4;Salicylazosulfapyridine;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated sulfaSALAzine [Mass/volume] in Serum or Plasma;Deprecated Salicylazosulfapyridine Ser;;DEPRECATED;1.0l;2.36 +16425-1;Babesia sp Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Babesia sp IgM Ab [Units/volume] in Serum by Immunofluorescence;Babesia IgM Ser IF-aCnc;;ACTIVE;1.0l;2.69 +16426-9;Babesia sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Babesia sp IgM Ab [Titer] in Serum;Babesia IgM Titr Ser;;ACTIVE;1.0l;2.70 +16427-7;Babesia microti Ab;Titr;Pt;Ser;Qn;;MICRO;1;Babesia microti Ab [Titer] in Serum;B microti Ab Titr Ser;;ACTIVE;1.0l;2.70 +1642-8;Thyrotropin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --baseline;TSH BS SerPl-mCnc;;DISCOURAGED;1.0;2.73 +16428-5;Bacitracin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bacitracin [Mass/volume] in Serum or Plasma;Bacitracin SerPl-mCnc;;ACTIVE;1.0l;2.42 +16429-3;Barbiturates;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Barbiturates [Presence] in Urine by Confirmatory method;Barbiturates Ur Ql Cfm;;ACTIVE;1.0l;2.73 +16430-1;Barbiturates;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Barbiturates [Units/volume] in Urine;Barbiturates Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16431-9;Barium;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Barium [Presence] in Urine;Barium Ur Ql;;ACTIVE;1.0l;2.56 +16432-7;Barium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Barium [Mass/volume] in Blood;Barium Bld-mCnc;;ACTIVE;1.0l;2.73 +16433-5;Basement membrane Ab;PrThr;Pt;Ser;Ord;;SERO;1;Basement membrane Ab [Presence] in Serum;BM Ab Ser Ql;;ACTIVE;1.0l;2.73 +16434-3;Basement membrane Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Basement membrane Ab [Units/volume] in Serum by Immunofluorescence;BM Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +16435-0;Bean white Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated White Bean IgE Ab [Units/volume] in Serum;Deprecated White Bean IgE Qn;;DEPRECATED;1.0l;2.69 +1643-6;Thyrotropin^pre dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --pre dose TRH IV;TSH pre TRH IV SerPl-mCnc;;DISCOURAGED;1.0;2.42 +16436-8;Bean wax Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Bean string IgE Ab [Units/volume] in Serum;Deprecated Wax Bean IgE Qn;;DEPRECATED;1.0l;2.69 +16437-6;Bendroflumethiazide;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Bendroflumethiazide [Units/volume] in Urine;Bendroflumethiaz Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16438-4;Benzaldehyde;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Benzaldehyde [Presence] in Urine;Benzaldehyde Ur Ql;;ACTIVE;1.0l;2.56 +16439-2;Benzene;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Benzene [Presence] in Blood;Benzene Bld Ql;;ACTIVE;1.0l;2.56 +164-4;Cephapirin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cephapirin [Susceptibility] by Minimum lethal concentration (MLC);Cephapirin Islt MLC;;ACTIVE;1.0;2.19 +16440-0;Benzene ring Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Benzene ring IgE Ab [Units/volume] in Serum;Benzene ring IgE Qn;;ACTIVE;1.0l;2.42 +16441-8;Benzene ring Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Benzene ring IgG Ab [Units/volume] in Serum;Benzene ring IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +16442-6;Benzene ring Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Benzene ring IgM Ab [Units/volume] in Serum;Benzene ring IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16443-4;Benzonatate;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Benzonatate [Mass/volume] in Serum;Benzonatate Ser-mCnc;;ACTIVE;1.0l;2.42 +1644-4;Triglyceride^post 12H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triglyceride [Mass/volume] in Serum or Plasma --12 hours fasting;Trigl p 12h fast SerPl-mCnc;;ACTIVE;1.0;2.73 +16444-2;Benzophenone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzophenone [Mass/volume] in Serum or Plasma;Benzophenone SerPl-mCnc;;ACTIVE;1.0l;2.34 +16446-7;Benzoylecgonine;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Benzoylecgonine [Presence] in Serum or Plasma by Confirmatory method;BZE SerPl Ql Cfm;;ACTIVE;1.0l;2.73 +16447-5;Cocaine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cocaine [Units/volume] in Serum or Plasma;Cocaine SerPl-aCnc;;DISCOURAGED;1.0l;2.73 +16448-3;Cocaine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Cocaine [Units/volume] in Urine;Cocaine Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16449-1;Benzthiazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzthiazide [Mass/volume] in Serum or Plasma;Benzthiazide SerPl-mCnc;;ACTIVE;1.0l;2.42 +16450-9;Benzylhydrazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzylhydrazine [Mass/volume] in Serum or Plasma;Benzylhydrazine SerPl-mCnc;;ACTIVE;1.0l;2.34 +1645-1;Xylose^2H post 25 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --2 hours post 25 g xylose PO;Xylose 2h p 25 g Xyl PO Bld-mCnc;;ACTIVE;1.0;2.73 +16451-7;Beryllium;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Beryllium [Presence] in Urine;Beryllium Ur Ql;;ACTIVE;1.0l;2.56 +16452-5;Beta alanine;PrThr;Pt;Urine;Ord;;CHEM;1;Beta alanine [Presence] in Urine;B-Alanine Ur Ql;;ACTIVE;1.0l;2.56 +16453-3;Beta aminoisobutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;Beta aminoisobutyrate [Presence] in Urine;B-AIB Ur Ql;;ACTIVE;1.0l;2.56 +16454-1;Beta galactosidase;CCnc;Pt;Bld;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/volume] in Blood;B-Galactosidase Bld-cCnc;;ACTIVE;1.0l;2.73 +16455-8;Beta hydroxybutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;Beta hydroxybutyrate [Moles/volume] in Cerebral spinal fluid;B-OH-Butyr CSF-sCnc;;ACTIVE;1.0l;2.34 +16456-6;Beta hydroxybutyrate;SCnc;Pt;Urine;Qn;;CHEM;1;Beta hydroxybutyrate [Moles/volume] in Urine;B-OH-Butyr Ur-sCnc;;ACTIVE;1.0l;2.73 +16457-4;Beta-N-acetylhexosaminidase.A;CCnc;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A [Enzymatic activity/volume] in Leukocytes;Hexosaminidase A WBC-cCnc;;ACTIVE;1.0l;2.73 +16458-2;Bethanechol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bethanechol [Mass/volume] in Serum or Plasma;Bethanechol SerPl-mCnc;;ACTIVE;1.0l;2.34 +16459-0;Bicarbonate;SCnc;Pt;Body fld;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Body fluid;HCO3 Fld-sCnc;;ACTIVE;1.0l;2.34 +16460-8;Bicarbonate;SCnc;Pt;CSF;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Cerebral spinal fluid;HCO3 CSF-sCnc;;ACTIVE;1.0l;2.34 +16461-6;Bicarbonate;SCnc;Pt;RBC;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Red Blood Cells;HCO3 RBC-sCnc;;ACTIVE;1.0l;2.34 +16462-4;Bicarbonate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Amniotic fluid;HCO3 Amn-sCnc;;ACTIVE;1.0l;2.34 +16463-2;Bile acid.dihydroxy;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bile acid.dihydroxy [Mass/volume] in Serum or Plasma;Di-OH Bile Ac SerPl-mCnc;;ACTIVE;1.0l;2.67 +16464-0;Bile acid;ACnc;Pt;Exhl gas;Qn;;CHEM;1;Bile acid [Units/volume] in Exhaled gas;Bile Ac ExG-aCnc;;ACTIVE;1.0l;2.69 +16465-7;Bile acid;MCnc;Pt;Urine;Qn;;CHEM;1;Bile acid [Mass/volume] in Urine;Bile Ac Ur-mCnc;;ACTIVE;1.0l;2.73 +16466-5;Bile acid.trihydroxy;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bile acid.trihydroxy [Mass/volume] in Serum or Plasma;Tri-OH Bile Ac SerPl-mCnc;;ACTIVE;1.0l;2.67 +16467-3;Bismuth;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Bismuth [Presence] in Blood;Bismuth Bld Ql;;ACTIVE;1.0l;2.56 +16468-1;Bismuth;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Bismuth [Presence] in Urine;Bismuth Ur Ql;;ACTIVE;1.0l;2.56 +1646-9;Xylose^post dose PO;MRat;5H;Urine;Qn;;CHAL;1;Xylose [Mass/time] in 5 hour Urine --post dose PO;Xylose p PO 5h Ur-mRate;;ACTIVE;1.0;2.73 +16469-9;Bismuth/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Bismuth/Creatinine [Mass Ratio] in Urine;Bismuth/Creat Ur;;ACTIVE;1.0l;2.73 +16470-7;Blastomyces dermatitidis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Serum by Complement fixation;B dermat Ab Ser Ql CF;;ACTIVE;1.0l;2.73 +16471-5;Blastomyces dermatitidis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Blastomyces dermatitidis Ab [Units/volume] in Serum;B dermat Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +16472-3;Blastomyces dermatitidis rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Blastomyces dermatitidis rRNA [Presence] in Serum by Probe;B dermat rRNA Ser Ql Probe;;ACTIVE;1.0l;2.63 +16473-1;Bordetella parapertussis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella parapertussis Ab [Units/volume] in Serum;B parapert Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +16474-9;Bordetella pertussis Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Bordetella pertussis Ab [Units/volume] in Serum by Complement fixation;B pert Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16475-6;Borrelia burgdorferi Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid by Immunoassay;B burgdor Ab CSF Ql IA;;ACTIVE;1.0l;2.73 +16476-4;Borrelia burgdorferi Ab;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Borrelia burgdorferi Ab [Presence] in Body fluid by Immunoassay;B burgdor Ab Fld Ql IA;;ACTIVE;1.0l;2.56 +1647-7;Tuberculosis reaction wheal^3D post 25 TU ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tuberculosis reaction wheal [Diameter] --3 days post 25 TU intradermal;TB Wheal 3D p 25 TU Diam;;ACTIVE;1.0;2.26 +16477-2;Borrelia burgdorferi Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Borrelia burgdorferi Ab [Presence] in Body fluid;B burgdor Ab Fld Ql;;ACTIVE;1.0l;2.56 +16478-0;Borrelia burgdorferi Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia burgdorferi IgA Ab [Presence] in Serum by Immunoassay;B burgdor IgA Ser Ql IA;;ACTIVE;1.0l;2.73 +16479-8;Borrelia burgdorferi Ab.IgA;PrThr;Pt;CSF;Ord;IA;MICRO;1;Borrelia burgdorferi IgA Ab [Presence] in Cerebral spinal fluid by Immunoassay;B burgdor IgA CSF Ql IA;;ACTIVE;1.0l;2.56 +16480-6;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Serum or Plasma by Immunoassay;B burgdor IgG SerPl Ql IA;;ACTIVE;1.0l;2.73 +16481-4;Borrelia burgdorferi Ab.IgG;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Borrelia burgdorferi IgG Ab [Units/volume] in Body fluid by Immunoassay;B burgdor IgG Fld IA-aCnc;;ACTIVE;1.0l;2.73 +16482-2;Borrelia burgdorferi Ab.IgM;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Body fluid by Immunoassay;B burgdor IgM Fld IA-aCnc;;ACTIVE;1.0l;2.73 +16483-0;Borrelia hermsii;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Borrelia hermsii [Presence] in Specimen by Organism specific culture;B hermsii Spec Ql Cult;;ACTIVE;1.0l;2.69 +16484-8;Boysenberry Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Boysenberry IgE Ab [Units/volume] in Serum;Boysenberrry IgE Qn;;ACTIVE;1.0l;2.42 +1648-5;Tuberculosis reaction wheal^3D post 5 TU ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tuberculosis reaction wheal [Diameter] --3 days post 5 TU intradermal;TB Wheal 3D p 5 TU Diam;;ACTIVE;1.0;2.73 +16485-5;Bromodiphenhydramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bromodiphenhydramine [Mass/volume] in Urine;Bromodiphenhyd Ur-mCnc;;ACTIVE;1.0l;2.42 +16486-3;Brucella abortus Ab.IgA+IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella abortus IgA+IgG+IgM Ab [Units/volume] in Serum;B abortus IgA+IgG+IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16487-1;Brucella abortus Ab.IgG;ACnc;Pt;Ser;Qn;Aggl;MICRO;1;Brucella abortus IgG Ab [Units/volume] in Serum by Agglutination;B abortus IgG Ser Aggl-aCnc;;ACTIVE;1.0l;2.73 +16488-9;Brucella abortus Ab.IgG;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Brucella abortus IgG Ab [Units/volume] in Serum by Complement fixation;B abortus IgG Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16489-7;Brucella melitensis Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Brucella melitensis Ab [Units/volume] in Serum by Latex agglutination;B melitensis Ab Ser LA-aCnc;;ACTIVE;1.0l;2.69 +16490-5;Brucella suis Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Brucella suis Ab [Units/volume] in Serum by Latex agglutination;B suis Ab Ser LA-aCnc;;ACTIVE;1.0l;2.69 +16491-3;Brush border Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Brush border Ab [Presence] in Serum by Immunofluorescence;Brush border Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +16492-1;Bufotenine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Bufotenine [Units/volume] in Urine;Bufotenine Ur-aCnc;;DISCOURAGED;1.0l;2.69 +1649-3;Calcitriol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcitriol [Mass/volume] in Serum or Plasma;1,25(OH)2D3 SerPl-mCnc;;ACTIVE;1.0;2.73 +16493-9;Bufotenine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bufotenine [Units/volume] in Serum or Plasma;Bufotenine SerPl-aCnc;;DISCOURAGED;1.0l;2.73 +16494-7;Bumetanide;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Bumetanide [Units/volume] in Urine;Bumetanide Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16495-4;Buprenorphine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Buprenorphine [Units/volume] in Serum or Plasma;Buprenorphine SerPl-aCnc;;DISCOURAGED;1.0l;2.73 +16496-2;Buprenorphine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Buprenorphine [Units/volume] in Urine;Buprenorphine Ur-aCnc;;DISCOURAGED;1.0l;2.73 +16497-0;Butabarbital;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Butabarbital [Mass/volume] in Gastric fluid;Butabarbital Gast-mCnc;;ACTIVE;1.0l;2.42 +16498-8;Butalbital;ACnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Butalbital [Units/volume] in Gastric fluid;Butalbital Gast-aCnc;;DISCOURAGED;1.0l;2.69 +16499-6;Butorphanol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butorphanol [Mass/volume] in Urine by Confirmatory method;Butorphanol Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16500-1;Butyrate;MCnc;Pt;Stool;Qn;;CHEM;1;Butyrate (C4) [Mass/volume] in Stool;Butyrate Stl-mCnc;;ACTIVE;1.0l;2.34 +1650-1;1,4-Alpha glucan branching enzyme;CCnc;Pt;WBC;Qn;;CHEM;1;1,4-Alpha glucan branching enzyme [Enzymatic activity/volume] in Leukocytes;GLGB WBC-cCnc;;ACTIVE;1.0;2.14 +16501-9;C peptide^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;C peptide sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16502-7;C peptide^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;C peptide sp8 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16503-5;C reactive protein;MCnc;Pt;Body fld;Qn;;CHEM;1;C reactive protein [Mass/volume] in Body fluid;CRP Fld-mCnc;;ACTIVE;1.0l;2.73 +16504-3;Calcitonin^1.5M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --1.5 minutes post XXX challenge;Calcit 1.5M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16505-0;Calcitonin^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Calcit 10M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16506-8;Calcitonin^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Calcit 3h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16507-6;Calcitonin^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;Calcit 4h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16508-4;Calcitonin^5M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --5 minutes post XXX challenge;Calcit 5M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16509-2;Calcitonin^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Calcit sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +165-1;Cephapirin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cephapirin [Susceptibility] by Minimum inhibitory concentration (MIC);Cephapirin Islt MIC;;ACTIVE;1.0;2.19 +16510-0;Calcitonin^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Calcit sp8 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16511-8;Calcitonin^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Calcit sp9 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16512-6;Calcium.ionized^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium.ionized [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;Ca-I sp2 p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16513-4;Calcium.ionized^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium.ionized [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;Ca-I sp3 p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16514-2;Calcium.ionized^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium.ionized [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;Ca-I sp4 p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16515-9;Calcium.ionized^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium.ionized [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;Ca-I sp5 p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16516-7;Calcium.ionized^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium.ionized [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;Ca-I sp6 p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16517-5;Calcium.ionized^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium.ionized [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;Ca-I sp7 p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16518-3;Calcium;MRat;2H;Urine;Qn;;CHEM;1;Calcium [Mass/time] in 2 hour Urine;Calcium 2h Ur-mRate;;ACTIVE;1.0l;2.73 +1651-9;1-Methylhistidine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;1-Methylhistidine [Presence] in Serum or Plasma;1Me-hist SerPl Ql;;ACTIVE;1.0;2.56 +16519-1;Calcium^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;Calcium 10M p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16520-9;Calcium^2nd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --2nd specimen post XXX challenge;Calcium sp2 p chal Ur-sCnc;;ACTIVE;1.0l;2.34 +16521-7;Calcium^3rd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --3rd specimen post XXX challenge;Calcium sp3 p chal Ur-sCnc;;ACTIVE;1.0l;2.34 +16522-5;Calcium^4th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --4th specimen post XXX challenge;Calcium sp4 p chal Ur-sCnc;;ACTIVE;1.0l;2.34 +16523-3;Calcium^5M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge;Calcium 5M p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16524-1;Calcium^6H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --6 hours post XXX challenge;Calcium 6h p chal SerPl-sCnc;;ACTIVE;1.0l;2.34 +16525-8;Calcium/Phosphate;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Calcium/Phosphate [Mass Ratio] in Serum or Plasma;Calcium/Phosphate SerPl;;ACTIVE;1.0l;2.73 +16526-6;Calcium/Protein;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Calcium/Protein [Mass Ratio] in Serum or Plasma;Calcium/Prot SerPl;;ACTIVE;1.0l;2.42 +1652-7;1-Methylhistidine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;1-Methylhistidine [Mass/volume] in Serum or Plasma;1Me-hist SerPl-mCnc;;ACTIVE;1.0;2.73 +16527-4;Calcium/Sodium;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Calcium/Sodium [Mass Ratio] in Serum or Plasma;Calcium/Sodium SerPl;;ACTIVE;1.0l;2.42 +16528-2;Campylobacter coli rRNA;ACnc;Pt;Ser;Qn;Probe;MICRO;1;Campylobacter coli rRNA [Units/volume] in Serum by Probe;C coli rRNA Ser Probe-aCnc;;ACTIVE;1.0l;2.69 +16529-0;Campylobacter jejuni rRNA;ACnc;Pt;Ser;Qn;Probe;MICRO;1;Campylobacter jejuni rRNA [Units/volume] in Serum by Probe;C jejuni rRNA Ser Probe-aCnc;;ACTIVE;1.0l;2.69 +16530-8;Campylobacter jejuni rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Campylobacter jejuni rRNA [Presence] in Serum by Probe;C jejuni rRNA Ser Ql Probe;;ACTIVE;1.0l;2.63 +16531-6;Campylobacter lari rRNA;ACnc;Pt;Ser;Qn;Probe;MICRO;1;Campylobacter lari rRNA [Units/volume] in Serum by Probe;C lari rRNA Ser Probe-aCnc;;ACTIVE;1.0l;2.69 +16532-4;Campylobacter lari rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Campylobacter lari rRNA [Presence] in Serum by Probe;C lari rRNA Ser Ql Probe;;ACTIVE;1.0l;2.63 +16533-2;Helicobacter pylori Ab;Titr;Pt;Ser;Qn;;MICRO;1;Helicobacter pylori Ab [Titer] in Serum;H pylori Ab Titr Ser;;ACTIVE;1.0l;2.70 +16534-0;Campylobacter sp rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Campylobacter sp rRNA [Presence] in Serum by Probe;Campylobacter rRNA Ser Ql Probe;;ACTIVE;1.0l;2.63 +1653-5;1-Methylhistidine;MCnc;Pt;Urine;Qn;;CHEM;1;1-Methylhistidine [Mass/volume] in Urine;1Me-hist Ur-mCnc;;ACTIVE;1.0;2.42 +16535-7;Canary droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Canary droppings IgE Ab [Units/volume] in Serum;Canary Drop IgE Qn;;ACTIVE;1.0l;2.42 +16536-5;Canary serum proteins Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Canary serum proteins Ab [Units/volume] in Serum;Canary Serum Prot Ab Qn;;ACTIVE;1.0l;2.69 +16537-3;Candida albicans Ab;ACnc;Pt;Ser;Qn;Immune diffusion;MICRO;1;Candida albicans Ab [Units/volume] in Serum by Immune diffusion (ID);C albicans Ab Ser ID-aCnc;;ACTIVE;1.0l;2.69 +16538-1;Candida sp Ab.IgA;ACnc;Pt;Saliva;Qn;;MICRO;1;Candida sp IgA Ab [Units/volume] in Saliva (oral fluid);Candida IgA Sal-aCnc;;ACTIVE;1.0l;2.69 +16539-9;Candida sp Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Candida sp Ag [Presence] in Serum;Candida Ag Ser Ql;;ACTIVE;1.0l;2.73 +16540-7;Cannabinoids;ACnc;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Deprecated Cannabinoids [Presence] in Serum or Plasma by Confirm method;Deprecated Cannabinoids SerPl Ql Cfm;;DEPRECATED;1.0l;2.36 +16542-3;Cannabinoids;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Cannabinoids [Mass/volume] in Serum or Plasma by Confirmatory method;Cannabinoids SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +1654-3;1-Naphthalene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;1-Naphthalene [Mass/volume] in Urine;1Naphthalene Ur-mCnc;;ACTIVE;1.0;2.42 +16543-1;Cannabinoids;MCnc;Pt;Unk sub;Qn;Confirm;DRUG/TOX;1;Cannabinoids [Mass/volume] in Unknown substance by Confirmatory method;Cannabinoids Usub Cfm-mCnc;;ACTIVE;1.0l;2.36 +16544-9;Canrenone;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Canrenone [Units/volume] in Urine;Canrenone Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16545-6;Capreomycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Capreomycin [Mass/volume] in Serum or Plasma;Capreomycin SerPl-mCnc;;ACTIVE;1.0l;2.42 +16546-4;Captopril;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Captopril [Mass/volume] in Serum or Plasma;Captopril SerPl-mCnc;;ACTIVE;1.0l;2.42 +16547-2;Carbamate pesticides;Type;Pt;Urine;Nom;;DRUG/TOX;1;Carbamate pesticides [Type] in Urine;Carbamate pesticides Ur;;ACTIVE;1.0l;2.19 +16548-0;carBAMazepine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;carBAMazepine [Mass/volume] in Urine;carBAMazepine Ur-mCnc;;ACTIVE;1.0l;2.73 +16549-8;Carbinoxamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Carbinoxamine [Presence] in Urine;Carbinoxamine Ur Ql;;ACTIVE;1.0l;2.56 +1655-0;11-Deoxy/11-Oxy steroids;MCrto;Pt;Urine;Qn;;CHEM;1;Deprecated 11-Deoxy/11-Oxy steroids in Urine;Deprecated 11-Deoxy/11-Oxy Ur-mRto;;DEPRECATED;1.0;2.36 +16550-6;Carbohydrates;Prid;Pt;Urine;Nom;;CHEM;1;Carbohydrates [Identifier] in Urine;Carbohydrates Ur;;ACTIVE;1.0l;2.73 +16551-4;Carbon dioxide;SCnc;Pt;BldC;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Capillary blood;CO2 BldC-sCnc;;ACTIVE;1.0l;2.73 +16553-0;Carnitine;MCnt;Pt;Tiss;Qn;;CHEM;1;Carnitine [Mass/mass] in Tissue;Carnitine Tiss-mCnt;;DISCOURAGED;1.0l;2.42 +16555-5;Carnitine;MCnc;Pt;CSF;Qn;;CHEM;1;Carnitine [Mass/volume] in Cerebral spinal fluid;Carnitine CSF-mCnc;;DISCOURAGED;1.0l;2.42 +16556-3;Carnitine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Carnitine [Mass/volume] in Amniotic fluid;Carnitine Amn-mCnc;;DISCOURAGED;1.0l;2.42 +16557-1;Carnosine;PrThr;Pt;Urine;Ord;;CHEM;1;Carnosine [Presence] in Urine;Carnosine Ur Ql;;ACTIVE;1.0l;2.56 +16558-9;Catecholamines^2H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --2 hours post XXX challenge;Catechols 2h p chal Plas-mCnc;;ACTIVE;1.0l;2.73 +16559-7;Catecholamines^3H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --3 hours post XXX challenge;Catechols 3h p chal Plas-mCnc;;ACTIVE;1.0l;2.73 +16560-5;Catecholamines^5th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --5th specimen post XXX challenge;Catechols sp5 p chal Plas-mCnc;;ACTIVE;1.0l;2.50 +16561-3;Catecholamines^6th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --6th specimen post XXX challenge;Catechols sp6 p chal Plas-mCnc;;ACTIVE;1.0l;2.50 +16562-1;Cathartic laxatives;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Cathartic laxatives [Identifier] in Urine;Cathartic laxatives Ur;;ACTIVE;1.0l;2.19 +16563-9;Cathepsin D;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Cathepsin D in Serum or Plasma;Cathepsin D SFr SerPl;;ACTIVE;1.0l;2.70 +16564-7;Cefaclor;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefaclor [Mass/volume] in Serum or Plasma;Cefaclor SerPl-mCnc;;ACTIVE;1.0l;2.42 +16565-4;Cefadroxil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefadroxil [Mass/volume] in Serum or Plasma;Cefadroxil SerPl-mCnc;;ACTIVE;1.0l;2.42 +16566-2;ceFAZolin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;ceFAZolin [Mass/volume] in Urine;ceFAZolin Ur-mCnc;;ACTIVE;1.0l;2.42 +16567-0;Cefixime;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefixime [Mass/volume] in Serum or Plasma;Cefixime SerPl-mCnc;;ACTIVE;1.0l;2.42 +1656-8;11-Deoxycorticosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma;11DOC SerPl-mCnc;;ACTIVE;1.0;2.73 +16568-8;Cefuroxime Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cefuroxime IgE Ab [Units/volume] in Serum;Cefuroxime IgE Qn;;ACTIVE;1.0l;2.42 +16569-6;cefTRIAXone Ab.IgE;MCnc;Pt;Ser;Qn;;ALLERGY;1;cefTRIAXone IgE Ab [Mass/volume] in Serum;cefTRIAXone IgE-mCnc;;ACTIVE;1.0l;2.34 +16570-4;Centromere Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Centromere Ab [Presence] in Serum by Immunofluorescence;Centromere Ab Ser Ql IF;;ACTIVE;1.0l;2.73 +16571-2;Cephadrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cephadrine [Mass/volume] in Serum or Plasma;Cephadrine SerPl-mCnc;;ACTIVE;1.0l;2.42 +16572-0;Cephaloridine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cephaloridine [Mass/volume] in Serum or Plasma;Cephaloridine SerPl-mCnc;;ACTIVE;1.0l;2.42 +16573-8;Cerebroside sulfatase;ACnc;Pt;Ser/Plas;Ord;;CHEM;1;Deprecated Cerebroside sulfatase [Presence] in Serum or Plasma;Deprecated Arylsulfatase A SerPl Ql;;DEPRECATED;1.0l;2.36 +16574-6;Cerebroside sulfatase;CCnt;Pt;Tiss;Qn;;CHEM;1;Deprecated Cerebroside sulfatase [Enzymatic activity/mass] in Tissue;Deprecated Arylsulfatase A Tiss-cCnt;;DEPRECATED;1.0l;2.36 +16575-3;Cerebroside sulfatase B;CCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Cerebroside sulfatase B in urine;Deprecated Cerebroside sulfatase B Ur;;DEPRECATED;1.0l;2.40 +1657-6;11-Deoxycortisol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma;11DC SerPl-mCnc;;ACTIVE;1.0;2.73 +16576-1;Cerebroside sulfatase B;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Deprecated Cerebroside sulfatase B in amniotic fluid;Deprecated Arylsulfatase A Amn-cCnc;;DEPRECATED;1.0l;2.40 +16577-9;Cerebroside sulfatase B;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cerebroside sulfatase B in serum or plasma;Deprecated Cerebroside sulfatase B SerPl;;DEPRECATED;1.0l;2.40 +16578-7;Cerebroside sulfatase B;CCnt;Pt;Tiss;Qn;;CHEM;1;Deprecated Cerebroside sulfatase B in tissue;Deprecated Cerebroside sulfatase B Tiss;;DEPRECATED;1.0l;2.40 +16579-5;Cerebroside sulfatase B;CCnc;Pt;Bld;Qn;;CHEM;1;Deprecated Cerebroside sulfatase B in blood;Deprecated Arylsulfatase A Bld-cCnc;;DEPRECATED;1.0l;2.40 +16580-3;Cerebroside sulfatase B;CCnc;Pt;WBC;Qn;;CHEM;1;Deprecated Cerebroside sulfatase B in leukocytes;Deprecated Cerebroside sulfatase B WBC;;DEPRECATED;1.0l;2.40 +16581-1;Chlamydophila pneumoniae Ab.IgA;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydophila pneumoniae IgA Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C pneum IgA Titr CSF IF;;ACTIVE;1.0l;2.70 +16582-9;Chlamydophila pneumoniae Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydophila pneumoniae IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C pneum IgG Titr CSF IF;;ACTIVE;1.0l;2.70 +16583-7;Chlamydophila pneumoniae Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydophila pneumoniae IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C pneum IgM Titr CSF IF;;ACTIVE;1.0l;2.70 +1658-4;11-Hydroxyandrostenedione;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Hydroxyandrostenedione [Mass/volume] in Serum or Plasma;11OH-Ad SerPl-mCnc;;ACTIVE;1.0;2.42 +16584-5;Chlamydophila pneumoniae rRNA;PrThr;Pt;Sputum;Ord;Probe;MICRO;1;Chlamydophila pneumoniae rRNA [Presence] in Sputum by Probe;C pneum rRNA Spt Ql Probe;;ACTIVE;1.0l;2.63 +16585-2;Chlamydophila pneumoniae rRNA;PrThr;Pt;Ser/Plas;Ord;Probe;MICRO;1;Chlamydophila pneumoniae rRNA [Presence] in Serum or Plasma by Probe;C pneum rRNA SerPl Ql Probe;;ACTIVE;1.0l;2.63 +16586-0;Chlamydophila psittaci Ab.IgA;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydophila psittaci IgA Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C psittaci IgA Titr CSF IF;;ACTIVE;1.0l;2.70 +16587-8;Chlamydophila psittaci Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydophila psittaci IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C psittaci IgG Titr CSF IF;;ACTIVE;1.0l;2.70 +16588-6;Chlamydophila psittaci Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydophila psittaci IgM Ab [Units/volume] in Cerebral spinal fluid;C psittaci IgM CSF-aCnc;;ACTIVE;1.0l;2.69 +16589-4;Chlamydia sp Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Chlamydia sp Ab [Units/volume] in Serum by Immunofluorescence;Chlamydia Ab Ser IF-aCnc;;ACTIVE;1.0l;2.73 +16590-2;Chlamydia sp Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Chlamydia sp Ab [Units/volume] in Serum by Complement fixation;Chlamydia Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16591-0;Chlamydia sp Ab.IgG;ACnc;Pt;CSF;Qn;IF;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;Chlamydia IgG CSF IF-aCnc;;ACTIVE;1.0l;2.69 +1659-2;11-Hydroxyandrosterone;MCnc;Pt;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone [Mass/volume] in Urine;11OH-Androst Ur-mCnc;;ACTIVE;1.0;2.73 +16592-8;Chlamydia sp Ab.IgM;ACnc;Pt;CSF;Qn;IF;MICRO;1;Chlamydia sp IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;Chlamydia IgM CSF IF-aCnc;;ACTIVE;1.0l;2.73 +16593-6;Chlamydia sp Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Urine;Chlamydia Ag Ur Ql;;ACTIVE;1.0l;2.56 +16594-4;Chlamydia trachomatis Ab.IgA;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydia trachomatis IgA Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C trach IgA Titr CSF IF;;ACTIVE;1.0l;2.70 +16595-1;Chlamydia trachomatis Ab.IgG;ACnc;Pt;CSF;Qn;IF;MICRO;1;Chlamydia trachomatis IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;C trach IgG CSF IF-aCnc;;ACTIVE;1.0l;2.69 +16596-9;Chlamydia trachomatis Ab.IgM;ACnc;Pt;CSF;Qn;IF;MICRO;1;Chlamydia trachomatis IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;C trach IgM CSF IF-aCnc;;ACTIVE;1.0l;2.69 +16597-7;Chlamydia trachomatis B Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B IgG Ab [Units/volume] in Serum;C trach B IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +16598-5;Chlamydia trachomatis C Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis C IgG Ab [Units/volume] in Serum;C trach C IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +16599-3;Chlamydia trachomatis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Blood by NAA with probe detection;C trach DNA Bld Ql NAA+probe;;ACTIVE;1.0l;2.63 +16-6;Amoxicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Amoxicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Amoxicillin Islt MIC;;ACTIVE;1.0;2.73 +1660-0;11-Hydroxyetiocholanolone;MCnc;Pt;Ser;Qn;;CHEM;1;11-Hydroxyetiocholanolone [Mass/volume] in Serum;11OH-Etioch Ser-mCnc;;ACTIVE;1.0;2.42 +16600-9;Chlamydia trachomatis rRNA;PrThr;Pt;Genital;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Genital specimen by Probe;C trach rRNA Genital Ql Probe;;ACTIVE;1.0l;2.73 +16601-7;Chlamydia trachomatis rRNA;PrThr;Pt;Urine;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Urine by Probe;C trach rRNA Ur Ql Probe;;DISCOURAGED;1.0l;2.73 +16602-5;Chlamydia trachomatis rRNA;ACnc;Pt;Urine;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Urine by DNA probe;Deprecated C trach rRNA Ur Ql Prb;;DEPRECATED;1.0l;2.36 +16603-3;Chloramphenicol^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloramphenicol [Mass/volume] in Serum or Plasma --peak;Chloramphen Peak SerPl-mCnc;;ACTIVE;1.0l;2.34 +16604-1;Chloramphenicol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloramphenicol [Mass/volume] in Serum or Plasma --trough;Chloramphen Trough SerPl-mCnc;;ACTIVE;1.0l;2.34 +16605-8;Chlorocycline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorocycline [Mass/volume] in Urine;Chlorocycline Ur-mCnc;;ACTIVE;1.0l;2.34 +16606-6;Chlorine;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Chlorine [Mass/volume] in Dialysis fluid;Chlorine Dial fld-mCnc;;ACTIVE;1.0l;2.44 +16607-4;Chlorine;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Chlorine [Mass/volume] in Water;Chlorine Wat-mCnc;;ACTIVE;1.0l;2.34 +16608-2;Chlorpheniramine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorpheniramine [Units/volume] in Urine;Chlorphenir Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16609-0;Chlorphentermine;ACnc;Pt;Bld;Qn;;DRUG/TOX;1;Chlorphentermine [Units/volume] in Blood;Chlorphentermin Bld-aCnc;;DISCOURAGED;1.0l;2.69 +16610-8;Chlorphentermine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorphentermine [Units/volume] in Urine;Chlorphentermin Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16611-6;Chlorpyrifos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorpyrifos [Mass/volume] in Urine;Chlorpyrifos Ur-mCnc;;ACTIVE;1.0l;2.73 +16612-4;Chlorthalidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorthalidone [Mass/volume] in Serum or Plasma;Chlorthalidone SerPl-mCnc;;ACTIVE;1.0l;2.73 +16613-2;Cholesterol crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Cholesterol crystals [Presence] in Stone by Infrared spectroscopy;Cholest Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16614-0;Cholesterol crystals;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Cholesterol crystals [Presence] in Body fluid by Light microscopy;Cholest Cry Fld Ql Micro;;ACTIVE;1.0l;2.73 +16615-7;Cholesterol.total/Cholesterol.in LDL;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.total/Cholesterol in LDL [Mass Ratio] in Serum or Plasma;Cholest/LDLc SerPl;;ACTIVE;1.0l;2.42 +16616-5;Cholesterol.in HDL/Cholesterol.in LDL;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL/Cholesterol in LDL [Mass Ratio] in Serum or Plasma;HDLc/LDLc SerPl;;ACTIVE;1.0l;2.73 +16617-3;Choriogonadotropin.intact;SCnc;Pt;Semen;Qn;;CHEM;1;Choriogonadotropin.intact [Moles/volume] in Semen;HCG Intact Smn-sCnc;;ACTIVE;1.0l;2.70 +1661-8;11-Ketoandrosterone;MCnc;Pt;Ser;Qn;;CHEM;1;11-Ketoandrosterone [Mass/volume] in Serum;11Ketoandros Ser-mCnc;;ACTIVE;1.0;2.73 +16618-1;Cladosporium herbarum Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum Ab [Units/volume] in Serum;C herbarum Ab Qn;;ACTIVE;1.0l;2.69 +16619-9;Clarithromycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clarithromycin [Mass/volume] in Serum or Plasma;Clarithro SerPl-mCnc;;ACTIVE;1.0l;2.42 +16620-7;Clarithromycin+Ethambutol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clarithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC);Clarithro+Ethamb Islt MIC;;ACTIVE;1.0l;2.19 +16621-5;Clindamycin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clindamycin [Mass/volume] in Serum or Plasma --peak;Clindamycin Peak SerPl-mCnc;;ACTIVE;1.0l;2.42 +16622-3;Clindamycin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clindamycin [Mass/volume] in Serum or Plasma --trough;Clindamycin Trough SerPl-mCnc;;ACTIVE;1.0l;2.42 +16623-1;Clofazimine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clofazimine [Susceptibility] by Minimum inhibitory concentration (MIC);Clofazamine Islt MIC;;ACTIVE;1.0l;2.73 +16624-9;clomiPRAMINE;ACnc;Pt;Milk;Qn;;DRUG/TOX;1;clomiPRAMINE [Units/volume] in Milk;clomiPRAMINE Mlk-aCnc;;DISCOURAGED;1.0l;2.69 +16625-6;clomiPRAMINE;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;clomiPRAMINE [Mass/volume] in Milk;clomiPRAMINE Mlk-mCnc;;ACTIVE;1.0l;2.42 +1662-6;11-Ketoetiocholanolone;MCnc;Pt;Ser;Qn;;CHEM;1;11-Ketoetiocholanolone [Mass/volume] in Serum;11Ketoetioch Ser-mCnc;;ACTIVE;1.0;2.73 +16626-4;Clostridium tetani Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani Ab [Units/volume] in Serum --1st specimen;C tetani Ab sp1 Ser-aCnc;;DISCOURAGED;1.0l;2.73 +16627-2;Clostridium tetani Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani Ab [Units/volume] in Serum --2nd specimen;C tetani Ab sp2 Ser-aCnc;;DISCOURAGED;1.0l;2.73 +16628-0;Cloxacillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cloxacillin [Mass/volume] in Serum or Plasma;Cloxacillin SerPl-mCnc;;ACTIVE;1.0l;2.42 +16629-8;Coagulation surface induced;Time;Pt;Bld^Control;Qn;Coag;COAG;1;Deprecated Activated partial thrombplastin time (aPTT) in Blood from control by Coagulation assay;Deprecated aPTT Bld Cont Qn;;DEPRECATED;1.0l;2.36 +16630-6;Coagulation surface induced;Time;Pt;Bld^Control;Qn;Coag.saline 1:1;COAG;1;aPTT in Control Blood by Coagulation 1:1 saline;aPTT Cont Bld 1:1 saline;;ACTIVE;1.0l;2.73 +16631-4;Coagulation surface induced;Time;Pt;Bld;Qn;Coag.saline 1:1;COAG;1;aPTT in Blood by Coagulation 1:1 saline;aPTT Bld 1:1 saline;;ACTIVE;1.0l;2.73 +16632-2;Cocaethylene;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cocaethylene [Mass/volume] in Urine by Confirmatory method;Cocaethylene Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16633-0;Cocaine;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Cocaine [Presence] in Blood;Cocaine Bld Ql;;ACTIVE;1.0l;2.73 +1663-4;11-Oxycorticosterone;MCnc;Pt;Ser;Qn;;CHEM;1;11-Oxycorticosterone [Mass/volume] in Serum;11oxyCorticosterone Ser-mCnc;;ACTIVE;1.0;2.42 +16634-8;Coccidioides immitis Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coccidioides immitis Ab [Units/volume] in Cerebral spinal fluid;C immitis Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +16635-5;Coccidioides immitis Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coccidioides immitis IgA Ab [Units/volume] in Serum by Immunoassay;C immitis IgA Ser IA-aCnc;;ACTIVE;1.0l;2.69 +16636-3;Coccidioides immitis Ab.IgA;ACnc;Pt;CSF;Qn;;MICRO;1;Coccidioides immitis IgA Ab [Units/volume] in Cerebral spinal fluid;C immitis IgA CSF-aCnc;;ACTIVE;1.0l;2.69 +16637-1;Coccidioides immitis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coccidioides immitis IgE Ab [Units/volume] in Serum;C immitis IgE Qn;;ACTIVE;1.0l;2.42 +16638-9;Coccidioides immitis Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Coccidioides immitis IgG Ab [Units/volume] in Cerebral spinal fluid;C immitis IgG CSF-aCnc;;ACTIVE;1.0l;2.73 +16639-7;Coccidioides immitis Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Coccidioides immitis IgM Ab [Units/volume] in Cerebral spinal fluid;C immitis IgM CSF-aCnc;;ACTIVE;1.0l;2.73 +16640-5;Coccidioides reaction wheal;Diam;Pt;Skin;Qn;;CHALSKIN;1;Coccidioides reaction wheal [Diameter];Coccidioides wheal Diam;;ACTIVE;1.0l;2.42 +16641-3;Cockatiel droppings Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockatiel droppings Ab [Units/volume] in Serum;Cockatiel Drop Ab Qn;;ACTIVE;1.0l;2.69 +1664-2;17-Hydroxycorticosteroids;MCnc;Pt;Amnio fld;Qn;;CHEM;1;17-Hydroxycorticosteroids [Mass/volume] in Amniotic fluid;17OHCS Amn-mCnc;;ACTIVE;1.0;2.42 +16642-1;Cockatiel droppings Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockatiel droppings IgG Ab [Units/volume] in Serum;Cockatiel Drop IgG Qn;;ACTIVE;1.0l;2.68 +16643-9;Cockatoo droppings Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockatoo droppings Ab [Units/volume] in Serum;Cockatoo Drop Ab Qn;;ACTIVE;1.0l;2.69 +16644-7;Codeine.free;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Codeine Free [Presence] in Serum or Plasma by Confirmatory method;Codeine Free SerPl Ql Cfm;;ACTIVE;1.0l;2.73 +16645-4;Colistin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Colistin [Mass/volume] in Serum or Plasma;Colistin SerPl-mCnc;;ACTIVE;1.0l;2.42 +16647-0;Collagen Ab;ACnc;Pt;Ser;Qn;;SERO;1;Collagen Ab [Units/volume] in Serum;Collagen Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +16648-8;Copper;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Body fluid;Copper Fld-mCnc;;ACTIVE;1.0l;2.42 +16649-6;Coproporphyrinogen oxidase;CCnc;Pt;RBC;Qn;;CHEM;1;Coproporphyrinogen oxidase [Enzymatic activity/volume] in Red Blood Cells;COPROgen-oxidase RBC-cCnc;;ACTIVE;1.0l;2.44 +16650-4;Coriandrum sativum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cilantro IgE Ab [Units/volume] in Serum;Cilantro IgE Qn;;ACTIVE;1.0l;2.73 +16651-2;Corticosterone^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Corticosterone [Mass/volume] in Serum or Plasma --post XXX challenge;Corticoster p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16652-0;Corticotropin;MCnc;Pt;Amnio fld;Qn;RIA;CHEM;1;Corticotropin [Mass/volume] in Amniotic fluid by Radioimmunoassay (RIA);ACTH Amn RIA-mCnc;;ACTIVE;1.0l;2.42 +16653-8;Corticotropin.canine;MCnc;Pt;Plas;Qn;;CHEM;1;Corticotropin Canine [Mass/volume] in Plasma;ACTH Canine Plas-mCnc;;ACTIVE;1.0l;2.42 +16654-6;Corticotropin^1.5H post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --1.5 hours post XXX challenge;ACTH 1.5h p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16655-3;Corticotropin^10M post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --10 minutes post XXX challenge;ACTH 10M p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16656-1;Corticotropin^15M post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --15 minutes post XXX challenge;ACTH 15M p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16657-9;Corticotropin^1H post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --1 hour post XXX challenge;ACTH 1h p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16658-7;Corticotropin^1M post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --1 minute post XXX challenge;ACTH 1M p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +1665-9;17-Hydroxycorticosteroids;MCnc;Pt;Plas;Qn;;CHEM;1;17-Hydroxycorticosteroids [Mass/volume] in Plasma;17OHCS Plas-mCnc;;ACTIVE;1.0;2.42 +16659-5;Corticotropin^2.5H post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --2.5 hours post XXX challenge;ACTH 2.5h p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16660-3;Corticotropin^20M post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --20 minutes post XXX challenge;ACTH 20M p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16661-1;Corticotropin^2H post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --2 hours post XXX challenge;ACTH 2h p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16662-9;Corticotropin^30M post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --30 minutes post XXX challenge;ACTH 30M p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16663-7;Corticotropin^3H post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --3 hours post XXX challenge;ACTH 3h p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16664-5;Corticotropin^45M post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --45 minutes post XXX challenge;ACTH 45M p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16665-2;Corticotropin^5M post XXX challenge;MCnc;Pt;Plas;Qn;RIA;CHAL;1;Corticotropin [Mass/volume] in Plasma by Radioimmunoassay (RIA) --5 minutes post XXX challenge;ACTH 5M p chal Plas RIA-mCnc;;ACTIVE;1.0l;2.40 +16666-0;Corticotropin^9th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --9th specimen post XXX challenge;ACTH sp9 p chal Plas-mCnc;;ACTIVE;1.0l;2.73 +1666-7;17-Hydroxycorticosteroids;MCnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids [Mass/volume] in Urine;17OHCS Ur-mCnc;;ACTIVE;1.0;2.73 +16667-8;Cortisol.free;MRat;48H;Urine;Qn;;CHEM;1;Cortisol Free [Mass/time] in 48 hour Urine;Cortis F 48h Ur-mRate;;ACTIVE;1.0l;2.42 +16668-6;Cortisol.free;MRat;72H;Urine;Qn;;CHEM;1;Cortisol Free [Mass/time] in 72 hour Urine;Cortis F 72h Ur-mRate;;ACTIVE;1.0l;2.42 +16669-4;Cortisol^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Cortis 10M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16670-2;Cortisol^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Cortis 15M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16671-0;Cortisol^1M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 minute post XXX challenge;Cortis 1M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16672-8;Cortisol^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;Cortis 40M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16673-6;Cortisol^50M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --50 minutes post XXX challenge;Cortis 50M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16674-4;Cortisol^70M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --70 minutes post XXX challenge;Cortis 70M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +1667-5;17-Hydroxyketosteroids;MCnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxyketosteroids [Mass/volume] in Urine;17OHKS Ur-mCnc;;ACTIVE;1.0;2.42 +16675-1;Cortisol^80M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --80 minutes post XXX challenge;Cortis 80M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16676-9;Corynebacterium diphtheriae;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Corynebacterium diphtheriae [Presence] in Specimen by Organism specific culture;C diphtheriae Spec Ql Cult;;ACTIVE;1.0l;2.73 +16677-7;Coxiella burnetii Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii IgG Ab [Units/volume] in Serum;C burnet IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +16678-5;Coxiella burnetii Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii IgM Ab [Units/volume] in Serum;C burnet IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16679-3;Coxsackievirus A Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A Ab [Units/volume] in Serum;CV A Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +16680-1;Coxsackievirus A Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A IgG Ab [Units/volume] in Serum;CV A IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +16681-9;Coxsackievirus A Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A IgM Ab [Units/volume] in Serum;CV A IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16682-7;Coxsackievirus A2 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A2 Ab [Titer] in Cerebral spinal fluid;CV A2 Ab Titr CSF;;ACTIVE;1.0l;2.73 +1668-3;17-Hydroxyprogesterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma;17OHP SerPl-mCnc;;ACTIVE;1.0;2.73 +16683-5;Coxsackievirus A4 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A4 Ab [Titer] in Cerebral spinal fluid;CV A4 Ab Titr CSF;;ACTIVE;1.0l;2.73 +16684-3;Coxsackievirus B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B Ab [Units/volume] in Serum;CV B Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +16685-0;Coxsackievirus B Ab.IgG;ACnc;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B IgG Ab [Units/volume] in Serum by Neutralization test;CV B IgG Ser Nt-aCnc;;ACTIVE;1.0l;2.69 +16686-8;Coxsackievirus B Ab.IgM;ACnc;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B IgM Ab [Units/volume] in Serum by Neutralization test;CV B IgM Ser Nt-aCnc;;ACTIVE;1.0l;2.69 +16687-6;Creatine;MCnc;Pt;Vitr fld;Qn;;CHEM;1;Creatine [Mass/volume] in Vitreous fluid;Creatine Vitf-mCnc;;ACTIVE;1.0l;2.42 +16688-4;Creatine kinase;CCnc;Pt;Body fld;Qn;;CHEM;1;Creatine kinase [Enzymatic activity/volume] in Body fluid;CK Fld-cCnc;;ACTIVE;1.0l;2.68 +16689-2;Creatinine;MRat;48H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 48 hour Urine;Creat 48h Ur-mRate;;ACTIVE;1.0l;2.40 +166-9;Cephapirin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cephapirin [Susceptibility] by Disk diffusion (KB);Cephapirin Islt KB;;ACTIVE;1.0;2.19 +16690-0;Creatinine;MRat;72H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 72 hour Urine;Creat 72h Ur-mRate;;ACTIVE;1.0l;2.40 +1669-1;17-Hydroxyprogesterone;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated 17-Hydroxyprogesterone [Mass/volume] in Serum;Deprecated 17OHP Ser-mCnc;;DEPRECATED;1.0;2.69 +16691-8;Cresols;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Cresols [Identifier] in Specimen;Cresols Spec;;ACTIVE;1.0l;2.69 +16692-6;Cryptococcus sp Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Cryptococcus sp Ag [Presence] in Body fluid;Cryptoc Ag Fld Ql;;ACTIVE;1.0l;2.56 +16693-4;Cryptococcus sp Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Cryptococcus sp Ag [Presence] in Urine;Cryptoc Ag Ur Ql;;ACTIVE;1.0l;2.56 +16694-2;Cumene;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Cumene [Presence] in Blood;Cumene Bld Ql;;ACTIVE;1.0l;2.56 +16695-9;Cobalamins;MCnc;Pt;Bld;Qn;;CHEM;1;Cobalamin (Vitamin B12) [Mass/volume] in Blood;Vit B12 Bld-mCnc;;ACTIVE;1.0l;2.73 +16696-7;Cobalamins^post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Cobalamin (Vitamin B12) [Mass/volume] in Urine --post XXX challenge;Vit B12 p chal Ur-mCnc;;ACTIVE;1.0l;2.42 +16697-5;Cyclohexane;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Cyclohexane [Presence] in Blood;Cyclohexane Bld Ql;;ACTIVE;1.0l;2.56 +16698-3;Cyclohexanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cyclohexanol [Mass/volume] in Blood;Cyclohexanol Bld-mCnc;;ACTIVE;1.0l;2.42 +16699-1;Cyclohexanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cyclohexanol [Mass/volume] in Urine;Cyclohexanol Ur-mCnc;;ACTIVE;1.0l;2.42 +16700-7;Cyclohexanol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Cyclohexanol/Creatinine [Mass Ratio] in Urine;Cyclohexanol/Creat Ur;;ACTIVE;1.0l;2.44 +16701-5;Cyclopropane;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Cyclopropane [Presence] in Blood;Cyclopropane Bld Ql;;ACTIVE;1.0l;2.56 +16702-3;cycloSERINE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;cycloSERINE [Mass/volume] in Urine;cycloSERINE Ur-mCnc;;ACTIVE;1.0l;2.42 +16703-1;cycloSPORINE;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Plasma;cycloSPORINE Plas-mCnc;;ACTIVE;1.0l;2.73 +16704-9;Cyproheptadine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyproheptadine [Mass/volume] in Serum or Plasma;Cyproheptadine SerPl-mCnc;;ACTIVE;1.0l;2.73 +16705-6;Cystathionine;PrThr;Pt;Urine;Ord;;CHEM;1;Cystathionine [Presence] in Urine;Cystathionin Ur Ql;;ACTIVE;1.0l;2.56 +16706-4;Taenia solium larva Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Taenia solium larva IgM Ab [Units/volume] in Cerebral spinal fluid;T sol lar IgM CSF-aCnc;;ACTIVE;1.0l;2.69 +16707-2;Taenia solium larva Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Taenia solium larva IgM Ab [Units/volume] in Serum;T sol lar IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16708-0;Taenia solium larva Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Taenia solium larva Ab [Units/volume] in Cerebral spinal fluid;T sol lar Ab CSF-aCnc;;ACTIVE;1.0l;2.73 +1670-9;17-Hydroxyprogesterone;MCnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone [Mass/volume] in Urine;17OHP Ur-mCnc;;ACTIVE;1.0;2.73 +16709-8;Cystine;ACnc;Pt;Urine;Qn;;CHEM;1;Cystine [Units/volume] in Urine;Cystine Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16710-6;Cystine crystals;PrThr;Pt;Calculus;Ord;Infrared spectroscopy;CHEM;1;Cystine crystals [Presence] in Stone by Infrared spectroscopy;Cystine Cry Stone Ql IR;;ACTIVE;1.0l;2.73 +16711-4;Cystine+Homocystine;PrThr;Pt;Urine;Ord;;CHEM;1;Cystine+Homocystine [Presence] in Urine;Cys+(Hcys)2 Ur Ql;;ACTIVE;1.0l;2.56 +16712-2;Cytomegalovirus Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Cytomegalovirus Ab [Units/volume] in Body fluid;CMV Ab Fld-aCnc;;ACTIVE;1.0l;2.69 +16713-0;Cytomegalovirus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Cytomegalovirus Ab [Units/volume] in Cerebral spinal fluid;CMV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +16714-8;Cytomegalovirus Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Cytomegalovirus Ab [Units/volume] in Serum by Latex agglutination;CMV Ab Ser LA-aCnc;;ACTIVE;1.0l;2.69 +16715-5;Cytomegalovirus Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IF;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma by Immunofluorescence;CMV IgG SerPl IF-aCnc;;ACTIVE;1.0l;2.73 +16716-3;Cytomegalovirus Ab.IgG^2nd specimen;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma by Immunoassay --2nd specimen;CMV IgG sp2 SerPl IA-aCnc;;ACTIVE;1.0l;2.73 +1671-7;17-Ketogenic steroids;MCnc;Pt;Bld;Qn;;CHEM;1;17-Ketogenic steroids [Mass/volume] in Blood;17KGS Bld-mCnc;;ACTIVE;1.0;2.42 +16717-1;Cytomegalovirus Ag;PrThr;Pt;Urine;Ord;IA;MICRO;1;Cytomegalovirus Ag [Presence] in Urine by Immunoassay;CMV Ag Ur Ql IA;;ACTIVE;1.0l;2.56 +16718-9;Cytomegalovirus Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Cytomegalovirus Ag [Presence] in Blood;CMV Ag Bld Ql;;ACTIVE;1.0l;2.73 +16719-7;Cytomegalovirus inclusion bodies;PrThr;Pt;Urine;Ord;Microscopic observation;MICRO;1;Cytomegalovirus inclusion bodies [Presence] in Urine by Microscopic observation;CMV Incl Bod Ur Ql Microscopic;;ACTIVE;1.0l;2.56 +16720-5;Dechlorane;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Dechlorane [Presence] in Blood;Dechlorane Bld Ql;;ACTIVE;1.0l;2.56 +16721-3;Dehydroepiandrosterone sulfate;MCnc;Pt;Saliva;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Saliva (oral fluid);DHEA-S Sal-mCnc;;ACTIVE;1.0l;2.73 +16722-1;Dehydroepiandrosterone sulfate^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;DHEA-S sp10 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16723-9;Dehydroepiandrosterone sulfate^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;DHEA-S sp2 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16724-7;Dehydroepiandrosterone sulfate^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;DHEA-S sp3 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +1672-5;17-Ketogenic steroids;MCnc;Pt;Bld;Qn;;CHEM;1;Deprecated 17-Ketogenic steroids [Mass/volume] in Blood;Deprecated 17KGS Bld-mCnc;;DEPRECATED;1.0;2.36 +16725-4;Dehydroepiandrosterone sulfate^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;DHEA-S sp4 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16726-2;Dehydroepiandrosterone sulfate^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;DHEA-S sp5 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16727-0;Dehydroepiandrosterone sulfate^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;DHEA-S sp6 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16728-8;Dehydroepiandrosterone sulfate^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;DHEA-S sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16729-6;Dehydroepiandrosterone sulfate^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;DHEA-S sp8 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16730-4;Dehydroepiandrosterone sulfate^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;DHEA-S sp9 p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +16731-2;Dehydroepiandrosterone.unconjugated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Dehydroepiandrosterone.unconjugated [Mass/volume] in Serum or Plasma;Deprecated u DHEA SerPl-mCnc;;DEPRECATED;1.0l;2.36 +16732-0;Dehydroepiandrosterone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;DHEA sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +1673-3;17-Ketogenic steroids;MRat;24H;Urine;Qn;;CHEM;1;17-Ketogenic steroids [Mass/time] in 24 hour Urine;17KGS 24h Ur-mRate;;ACTIVE;1.0;2.73 +16733-8;Dehydroepiandrosterone^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;DHEA sp9 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16734-6;Dehydroepiandrosterone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --baseline;DHEA BS SerPl-mCnc;;ACTIVE;1.0l;2.73 +16735-3;Dehydroepiandrosterone^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --post XXX challenge;DHEA p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16736-1;Dengue virus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Dengue virus 1 Ab [Titer] in Serum;DENV1 Ab Titr Ser;;ACTIVE;1.0l;2.70 +16737-9;Dengue virus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Dengue virus 2 Ab [Titer] in Serum;DENV2 Ab Titr Ser;;ACTIVE;1.0l;2.70 +16738-7;Dengue virus 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Dengue virus 3 Ab [Titer] in Serum;DENV3 Ab Titr Ser;;ACTIVE;1.0l;2.70 +16739-5;Dengue virus 4 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Dengue virus 4 Ab [Titer] in Serum;DENV4 Ab Titr Ser;;ACTIVE;1.0l;2.70 +16740-3;Dengue virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus Ab [Presence] in Serum;DENV Ab Ser Ql;;ACTIVE;1.0l;2.73 +1674-1;18-Hydroxycorticosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;18-Hydroxycorticosterone [Mass/volume] in Serum or Plasma;18OHB SerPl-mCnc;;ACTIVE;1.0;2.73 +16741-1;Dermatophagoides farinae Ab.IgG;PrThr;Pt;Bld;Ord;;ALLERGY;1;American house dust mite IgG Ab [Presence] in Blood;D farinae IgG Bld Ql;;ACTIVE;1.0l;2.56 +16742-9;Dermatophagoides pteronyssinus Ab.IgG;PrThr;Pt;Bld;Ord;;ALLERGY;1;European house dust mite IgG Ab [Presence] in Blood;D pteronyss IgG Bld Ql;;ACTIVE;1.0l;2.56 +16743-7;Nordiazepam;ACnc;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Deprecated Nordiazepam [Presence] in Serum or Plasma;Deprecated Nordiazepam SerPl Ql;;DEPRECATED;1.0l;2.36 +16744-5;Nordiazepam;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Nordiazepam [Presence] in Urine;Deprecated Nordiazepam Ur Ql;;DEPRECATED;1.0l;2.36 +16745-2;Desmethylmethsuximide;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Desmethylmethsuximide [Mass/volume] in Serum or Plasma;Deprecated Desmethylmethsuximide Ser;;DEPRECATED;1.0l;2.40 +16746-0;Nortrimipramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortrimipramine [Mass/volume] in Serum or Plasma;Nortrimipramine SerPl-mCnc;;ACTIVE;1.0l;2.73 +16747-8;Dextromoramide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Dextromoramide [Presence] in Serum or Plasma;D-moramide SerPl Ql;;ACTIVE;1.0l;2.56 +16748-6;Propoxyphene;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Propoxyphene [Presence] in Serum or Plasma by Confirmatory method;Propoxyph SerPl Ql Cfm;;ACTIVE;1.0l;2.56 +16749-4;Propoxyphene+Norpropoxyphene;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Units/volume] in Urine;Propoxyph+Nor Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16750-2;Dezocine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dezocine [Mass/volume] in Serum or Plasma;Dezocine SerPl-mCnc;;ACTIVE;1.0l;2.42 +16751-0;Dezocine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dezocine [Mass/volume] in Blood;Dezocine Bld-mCnc;;ACTIVE;1.0l;2.42 +16752-8;Diacetate;ACnc;Pt;Urine;Ord;;CHEM;1;Deprecated Diacetate [Presence] in Urine;Deprecated Diacetate Ur Ql;;DEPRECATED;1.0l;2.34 +16753-6;Dialtrazene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Dialtrazene;Deprecated Dialtrazene SerPl-mCnc;;DEPRECATED;1.0l;2.36 +16754-4;Diamorphine;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Diamorphine [Mass/volume] in Unknown substance;DAM Usub-mCnc;;ACTIVE;1.0l;2.42 +16755-1;Diamorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Diamorphine [Mass/volume] in Urine by Confirmatory method;DAM Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16756-9;Diamorphine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Diamorphine [Mass/volume] in Serum or Plasma by Confirmatory method;DAM SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +16757-7;Diazepam+Nordiazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;diazePAM+Nordiazepam [Mass/volume] in Serum or Plasma;diazePAM+Nor SerPl-mCnc;;ACTIVE;1.0l;2.73 +1675-8;2,3-Diphosphoglycerate;MCnc;Pt;RBC;Qn;;CHEM;1;2,3-Diphosphoglycerate [Mass/volume] in Red Blood Cells;2,3DPG RBC-mCnc;;ACTIVE;1.0;2.34 +16758-5;Dicamba;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dicamba [Mass/volume] in Serum or Plasma;Dicamba SerPl-mCnc;;ACTIVE;1.0l;2.73 +16759-3;Dicamba;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dicamba [Mass/volume] in Urine;Dicamba Ur-mCnc;;ACTIVE;1.0l;2.42 +16760-1;Dicarboxylporphyrin;MCnc;Pt;Bld;Qn;;CHEM;1;Deprecated Dicarboxylporphyrin [Mass/volume] in Blood;Deprecated Di-CP Bld-mCnc;;DEPRECATED;1.0l;2.42 +16761-9;Protoporphyrin;MCnc;Pt;Stool;Qn;;CHEM;1;Protoporphyrin [Mass/volume] in Stool;Protopor Stl-mCnc;;ACTIVE;1.0l;2.42 +16762-7;Dichlorobenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dichlorobenzene [Mass/volume] in Blood;DCB Bld-mCnc;;ACTIVE;1.0l;2.42 +16763-5;Dichlorodiphenyldichloroethylene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dichlorodiphenyldichloroethylene [Mass/volume] in Urine;DDE Ur-mCnc;;ACTIVE;1.0l;2.42 +16764-3;Dichlorodiphenyldichloroethylene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dichlorodiphenyldichloroethylene [Mass/volume] in Blood;DDE Bld-mCnc;;ACTIVE;1.0l;2.73 +16765-0;Dichlorodiphenyltrichloroethane;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Dichlorodiphenyltrichloroethane [Mass/volume] in Milk;DDT Mlk-mCnc;;ACTIVE;1.0l;2.42 +1676-6;2,3-Diphosphoglycerate;MCnc;Pt;Ser;Qn;;CHEM;1;2,3-Diphosphoglycerate [Mass/volume] in Serum;2,3DPG Ser-mCnc;;ACTIVE;1.0;2.42 +16766-8;Dichloroethane;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Dichloroethane [Presence] in Blood;DCA Bld Ql;;ACTIVE;1.0l;2.56 +16767-6;2,4-Dichlorophenoxyacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated 2,4-Dichlorophenoxyacetate [Mass/volume] in Urine;Deprecated 2,4D Ur-mCnc;;DEPRECATED;1.0l;2.36 +16768-4;Dichlorvos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dichlorvos [Mass/volume] in Urine;Dichlorvos Ur-mCnc;;ACTIVE;1.0l;2.73 +16769-2;Dicloxacillin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dicloxacillin [Mass/volume] in Urine;Dicloxacillin Ur-mCnc;;ACTIVE;1.0l;2.42 +167-7;Cephapirin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cephapirin [Susceptibility] by Serum bactericidal titer;Cephapirin Titr SBT;;ACTIVE;1.0;2.32 +16770-0;Dicoumarol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dicoumarol [Mass/volume] in Urine;Dicoumarol Ur-mCnc;;ACTIVE;1.0l;2.34 +16771-8;Dicyclomine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dicyclomine [Mass/volume] in Serum or Plasma;Dicyclomine SerPl-mCnc;;ACTIVE;1.0l;2.73 +16772-6;Dieldrin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dieldrin [Mass/volume] in Urine;Dieldrin Ur-mCnc;;ACTIVE;1.0l;2.42 +16773-4;Dieldrin;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dieldrin [Mass/volume] in Blood;Dieldrin Bld-mCnc;;ACTIVE;1.0l;2.73 +1677-4;Alpha hydroxybutyrate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha hydroxybutyrate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma;A-OH-Butyr Dehydrog SerPl-cCnc;;ACTIVE;1.0;2.68 +16774-2;Diethylcarbamazepine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diethylcarbamazepine [Mass/volume] in Serum or Plasma;Diethylcarbamazepine SerPl-mCnc;;ACTIVE;1.0l;2.42 +16775-9;Dihydrocodeine.free;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Dihydrocodeine Free [Presence] in Serum or Plasma by Confirmatory method;DHC Free SerPl Ql Cfm;;ACTIVE;1.0l;2.73 +16776-7;dilTIAZem;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;dilTIAZem [Mass/volume] in Urine;dilTIAZem Ur-mCnc;;ACTIVE;1.0l;2.42 +16777-5;Dimethylacetamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dimethylacetamide [Presence] in Urine;DMA Ur Ql;;ACTIVE;1.0l;2.56 +16778-3;Dinitrophenol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Dinitrophenol [Presence] in Serum or Plasma;Dinitrophenol SerPl Ql;;ACTIVE;1.0l;2.56 +16779-1;Dinitrophenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dinitrophenol [Mass/volume] in Urine;Dinitrophenol Ur-mCnc;;ACTIVE;1.0l;2.42 +16780-9;Disopyramide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Disopyramide [Mass/volume] in Urine;Disopyramide Ur-mCnc;;ACTIVE;1.0l;2.42 +16781-7;Disulfiram;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Disulfiram [Presence] in Urine;Disulfiram Ur Ql;;ACTIVE;1.0l;2.56 +1678-2;20-Hydroxyprogesterone;MCnc;Pt;Ser;Qn;;CHEM;1;20-Hydroxyprogesterone [Mass/volume] in Serum;20OHP Ser-mCnc;;ACTIVE;1.0;2.42 +16782-5;DNA double strand Ab;ACnc;Pt;Ser;Qn;Farr;SERO;1;Deprecated DNA double strand Ab [Presence] in Serum by Farr method;Deprecated dsDNA Ab Ser Farr-aCnc;;DEPRECATED;1.0l;2.69 +16784-1;DOPamine^2nd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;DOPamine [Mass/volume] in Urine --2nd specimen post XXX challenge;DOPamine sp2 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +16785-8;DOPamine^3rd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;DOPamine [Mass/volume] in Urine --3rd specimen post XXX challenge;DOPamine sp3 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +16786-6;DOPamine^4th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;DOPamine [Mass/volume] in Urine --4th specimen post XXX challenge;DOPamine sp4 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +16787-4;DOPamine^5th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;DOPamine [Mass/volume] in Urine --5th specimen post XXX challenge;DOPamine sp5 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +16788-2;DOPamine^6th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;DOPamine [Mass/volume] in Urine --6th specimen post XXX challenge;DOPamine sp6 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +16789-0;DOPamine^7th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;DOPamine [Mass/volume] in Urine --7th specimen post XXX challenge;DOPamine sp7 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +1679-0;24r-Hydroxycalcidiol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;24r-Hydroxycalcidiol [Mass/volume] in Serum or Plasma;24R-OH-Calcidiol SerPl-mCnc;;ACTIVE;1.0;2.73 +16790-8;Doxepin+Desmethyldoxepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Doxepin+Desmethyldoxepin [Mass/volume] in Serum or Plasma;Deprecated Doxepin+Desmethy SerPl;;DEPRECATED;1.0l;2.40 +16791-6;Doxylamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxylamine [Mass/volume] in Serum or Plasma;Doxylamine SerPl-mCnc;;ACTIVE;1.0l;2.73 +16792-4;Doxylamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Doxylamine [Mass/volume] in Urine;Doxylamine Ur-mCnc;;ACTIVE;1.0l;2.73 +16793-2;Drugs identified;Prid;Pt;Unk sub;Nom;Screen;DRUG/TOX;1;Drugs identified in Unknown substance by Screen method;Drugs Usub Scn;;ACTIVE;1.0l;2.73 +16794-0;Echinococcus sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Echinococcus sp IgM Ab [Units/volume] in Serum;Echinococcus IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16795-7;Echovirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus Ab [Units/volume] in Serum;ECV Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +16796-5;Echovirus Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus Ab [Units/volume] in Serum by Complement fixation;ECV Ab Ser CF-aCnc;;ACTIVE;1.0l;2.73 +16797-3;Echovirus 1 Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 1 Ab [Units/volume] in Serum by Complement fixation;ECV1 Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16798-1;Echovirus 14 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 14 Ab [Units/volume] in Serum;ECV14 Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +16799-9;Echovirus 140 Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Deprecated Echovirus 140 Ab by complement fixation;Deprecated Echovirus 140 Ab Ser CF-aCnc;;DEPRECATED;1.0l;2.69 +16800-5;Echovirus 19 Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 19 Ab [Units/volume] in Serum by Complement fixation;ECV19 Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16801-3;Echovirus 3 Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 3 Ab [Units/volume] in Serum by Complement fixation;ECV3 Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16802-1;Echovirus 30 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 30 Ab [Units/volume] in Serum;ECV30 Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +16803-9;Echovirus 4 Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 4 Ab [Units/volume] in Serum by Complement fixation;ECV4 Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16804-7;Echovirus 40 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 40 Ab [Units/volume] in Serum;ECV40 Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +16805-4;Echovirus 6 Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 6 Ab [Units/volume] in Serum by Complement fixation;ECV6 Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16806-2;Echovirus 6+18+30 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 6+18+30 Ab [Units/volume] in Serum;ECV6+18+30 Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +16807-0;Echovirus 9 Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 9 Ab [Units/volume] in Serum by Complement fixation;ECV9 Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +1680-8;3-Alpha-Androstanediol glucuronide;MCnc;Pt;Ser;Qn;;CHEM;1;3-Alpha-Androstanediol glucuronide [Mass/volume] in Serum;3A-diol G Ser-mCnc;;DISCOURAGED;1.0;2.73 +16808-8;Anaplasma phagocytophilum Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Anaplasma phagocytophilum IgG Ab [Units/volume] in Serum;A phagocytoph IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +16809-6;Anaplasma phagocytophilum Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Anaplasma phagocytophilum IgM Ab [Units/volume] in Serum;A phagocytoph IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16811-2;Arachidate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Arachidate (C20:0) [Mass/volume] in Serum or Plasma;Arachidate SerPl-mCnc;;DISCOURAGED;1.0l;2.44 +16812-0;Emetine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Emetine [Presence] in Serum or Plasma;Emetine SerPl Ql;;ACTIVE;1.0l;2.56 +16813-8;Emetine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Emetine [Units/volume] in Serum or Plasma;Emetine SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +16814-6;Endomysium Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Endomysium Ab [Presence] in Serum by Immunofluorescence;Endomysium Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +16815-3;Endomysium Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Endomysium Ab [Units/volume] in Serum by Immunofluorescence;Endomysium Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +1681-6;Beta hydroxybutyrate dehydrogenase;CCnc;Pt;Bld;Qn;;CHEM;1;Beta hydroxybutyrate dehydrogenase [Enzymatic activity/volume] in Blood;B-OH-Butyr Dehydrog Bld-cCnc;;ACTIVE;1.0;2.68 +16816-1;Enoxacin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Enoxacin [Mass/volume] in Urine;Enoxacin Ur-mCnc;;ACTIVE;1.0l;2.42 +16817-9;Entamoeba histolytica Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Entamoeba histolytica Ab [Presence] in Serum by Immune diffusion (ID);E histolyt Ab Ser Ql ID;;ACTIVE;1.0l;2.73 +16818-7;Entamoeba histolytica Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Entamoeba histolytica Ab [Units/volume] in Cerebral spinal fluid;E histolyt Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +16819-5;Entamoeba histolytica Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Entamoeba histolytica Ab [Units/volume] in Serum by Immunofluorescence;E histolyt Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +16820-3;Entamoeba histolytica Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Entamoeba histolytica Ab [Units/volume] in Serum by Complement fixation;E histolyt Ab Ser CF-aCnc;;ACTIVE;1.0l;2.69 +16821-1;EPINEPHrine^4H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --4 hours post XXX challenge;Epineph 4h p chal Plas-mCnc;;ACTIVE;1.0l;2.73 +16822-9;Epithelial cells;PrThr;Pt;Nose;Ord;Microscopy.light;HEM/BC;1;Epithelial cells [Presence] in Nose by Light microscopy;Epi Cells Nose Ql Micro;;ACTIVE;1.0l;2.73 +16823-7;Epstein Barr virus early Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus early Ab [Units/volume] in Serum by Immunoassay;EBV EA Ab Ser IA-aCnc;;ACTIVE;1.0l;2.73 +1682-4;Beta hydroxybutyrate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta hydroxybutyrate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma;B-OH-Butyr Dehydrog SerPl-cCnc;;ACTIVE;1.0;2.68 +16824-5;Epstein Barr virus nuclear Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Epstein Barr virus nuclear Ab [Presence] in Cerebral spinal fluid;EBV NA Ab CSF Ql;;ACTIVE;1.0l;2.56 +16825-2;Epstein Barr virus nuclear Ab.IgG;PrThr;Pt;Body fld;Ord;;MICRO;1;Epstein Barr virus nuclear IgG Ab [Presence] in Body fluid;EBV NA IgG Fld Ql;;ACTIVE;1.0l;2.56 +16826-0;Epstein Barr virus capsid Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Cerebral spinal fluid;EBV VCA IgG CSF-aCnc;;ACTIVE;1.0l;2.69 +16827-8;Epstein Barr virus capsid Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Epstein Barr virus capsid IgG Ab [Presence] in Cerebral spinal fluid;EBV VCA IgG CSF Ql;;ACTIVE;1.0l;2.56 +16828-6;Erythrocytes;NCnc;Pt;Semin plas;Qn;Manual count;FERT;1;Erythrocytes [#/volume] in Seminal plasma by Manual count;RBC # Semin plas Manual;;ACTIVE;1.0l;2.73 +16829-4;Erythromycin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Erythromycin [Mass/volume] in Urine;Erythromycin Ur-mCnc;;ACTIVE;1.0l;2.42 +16830-2;Erythromycin+Ethambutol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Erythromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC);Erythro+Ethamb Islt MIC;;ACTIVE;1.0l;2.19 +1683-2;3-Hydroxyisovalerate;MCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxyisovalerate [Mass/volume] in Urine;3OH-Isovalerate Ur-mCnc;;DISCOURAGED;1.0;2.42 +16832-8;Escherichia coli enterotoxic identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Escherichia coli enterotoxic identified in Stool by Organism specific culture;E coli ETEC Stl Cult;;ACTIVE;1.0l;2.73 +16833-6;Escherichia coli K1 Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Escherichia coli K1 Ag [Presence] in Specimen by Immunoassay;E coli K1 Ag Spec Ql IA;;ACTIVE;1.0l;2.69 +16834-4;Escherichia coli K1 Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Escherichia coli K1 Ag [Presence] in Specimen by Latex agglutination;E coli K1 Ag Spec Ql LA;;ACTIVE;1.0l;2.69 +16835-1;Escherichia coli shiga-like toxin identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Escherichia coli shiga-like toxin identified in Stool by Organism specific culture;E coli SXT Stl Cult;;ACTIVE;1.0l;2.73 +16836-9;Escherichia coli verotoxic identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Escherichia coli verotoxic identified in Stool by Organism specific culture;E coli VT Stl Cult;;ACTIVE;1.0l;2.19 +16838-5;Estriol;MCnc;Pt;Body fld;Qn;;CHEM;1;Estriol (E3) [Mass/volume] in Body fluid;Estriol Fld-mCnc;;ACTIVE;1.0l;2.52 +1684-0;3-Methoxy-4-Hydroxyphenylglycol;MCnc;Pt;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Mass/volume] in Urine;3Me4OH-phenylglycol Ur-mCnc;;ACTIVE;1.0;2.42 +16840-1;Ethacrynate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethacrynate [Mass/volume] in Serum or Plasma;Ethacrynate SerPl-mCnc;;ACTIVE;1.0l;2.34 +16841-9;Ethambutol+rifAMPin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ethambutol+rifAMPin [Susceptibility] by Minimum inhibitory concentration (MIC);Ethambutol+rifAMPin Islt MIC;;ACTIVE;1.0l;2.19 +16842-7;Ethanol;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Unknown substance;Ethanol Usub-mCnc;;ACTIVE;1.0l;2.73 +16843-5;Ethanol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Body fluid;Ethanol Fld-mCnc;;ACTIVE;1.0l;2.34 +16844-3;Ethinamate;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Ethinamate [Presence] in Serum or Plasma by Confirmatory method;Ethinamate SerPl Ql Cfm;;ACTIVE;1.0l;2.56 +16845-0;Ethionamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethionamide [Mass/volume] in Serum or Plasma;Ethionamide SerPl-mCnc;;ACTIVE;1.0l;2.42 +16847-6;Ethoheptazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ethoheptazine [Presence] in Serum or Plasma;Ethoheptazine SerPl Ql;;ACTIVE;1.0l;2.56 +16848-4;Ethoheptazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethoheptazine [Mass/volume] in Serum or Plasma;Ethoheptazine SerPl-mCnc;;ACTIVE;1.0l;2.34 +16849-2;Ethyl benzene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethyl benzene [Mass/volume] in Urine;Ethyl Benzene Ur-mCnc;;ACTIVE;1.0l;2.73 +168-5;Cephradine;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cephradine [Susceptibility] by Minimum lethal concentration (MLC);Cephradine Islt MLC;;ACTIVE;1.0;2.19 +16850-0;Ethylene oxide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethylene oxide [Mass/volume] in Blood;Ethylene Oxide Bld-mCnc;;ACTIVE;1.0l;2.42 +16851-8;Ethylmorphine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethylmorphine [Units/volume] in Urine;EMP Ur-aCnc;;DISCOURAGED;1.0l;2.69 +16852-6;Etodolac;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Etodolac [Mass/volume] in Serum or Plasma;Etodolac SerPl-mCnc;;ACTIVE;1.0l;2.73 +16853-4;Fat;Mass;Pt;Stool;Qn;;CHEM;1;Fat [Mass] in Stool;Fat Stl Qn;;ACTIVE;1.0l;2.73 +16855-9;Fat;MRat;48H;Stool;Qn;;CHEM;1;Fat [Mass/time] in 48 hour Stool;Fat 48h Stl-mRate;;ACTIVE;1.0l;2.73 +16856-7;Fat.microscopic observation;Prid;Pt;Synv fld;Nom;Sudan IV stain;PATH;1;Fat.microscopic observation [Identifier] in Synovial fluid by Sudan IV stain;Fat Snv Sudan IV Stn;;ACTIVE;1.0l;2.19 +1685-7;3-Methylhistidine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;3-Methylhistidine [Presence] in Serum or Plasma;3Me-histidine SerPl Ql;;ACTIVE;1.0;2.56 +16857-5;Fenclorvos;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Fenclorvos [Presence] in Blood;Fenclorvos Bld Ql;;ACTIVE;1.0l;2.56 +16858-3;fentaNYL;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;fentaNYL [Mass/volume] in Body fluid;fentaNYL Fld-mCnc;;ACTIVE;1.0l;2.73 +16859-1;Fibrinogen;PrThr;Pt;PPP;Ord;;COAG;1;Fibrinogen [Presence] in Platelet poor plasma;Fibrinogen PPP Ql;;ACTIVE;1.0l;2.73 +16860-9;Fibrinopeptide A Ag;ACnc;Pt;Periton fld;Qn;IA;COAG;1;Fibrinopeptide A Ag [Units/volume] in Peritoneal fluid by Immunoassay;FpA Ag Prt IA-aCnc;;ACTIVE;1.0l;2.69 +16861-7;Fibrinopeptide A Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide A Ag [Units/volume] in Platelet poor plasma by Immunoassay;FpA Ag PPP IA-aCnc;;ACTIVE;1.0l;2.69 +16862-5;Fibrinopeptide B Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B Ag [Units/volume] in Platelet poor plasma by Immunoassay;FpB Ag PPP IA-aCnc;;ACTIVE;1.0l;2.69 +16863-3;Fibrinopeptide B beta (1-14) Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (1-14) Ag [Units/volume] in Platelet poor plasma by Immunoassay;FpB Beta1-14 Ag PPP IA-aCnc;;ACTIVE;1.0l;2.69 +16864-1;Fibrinopeptide B beta (1-42) Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (1-42) Ag [Units/volume] in Platelet poor plasma by Immunoassay;FpB Beta1-42 Ag PPP IA-aCnc;;ACTIVE;1.0l;2.69 +1686-5;3-Methylhistidine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methylhistidine [Mass/volume] in Serum or Plasma;3Me-histidine SerPl-mCnc;;ACTIVE;1.0;2.73 +16865-8;Fibrinopeptide B beta (15-42) Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (15-42) Ag [Units/volume] in Platelet poor plasma by Immunoassay;FpB Beta15-42 Ag PPP IA-aCnc;;ACTIVE;1.0l;2.69 +16866-6;Fibrinopeptide B beta (43-47) Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (43-47) Ag [Units/volume] in Platelet poor plasma by Immunoassay;FpB Beta43-47 Ag PPP IA-aCnc;;ACTIVE;1.0l;2.69 +16867-4;Fibronectin aggregate Ab.IgG;MCnc;Pt;Ser;Qn;;SERO;1;Fibronectin aggregate IgG Ab [Mass/volume] in Serum;Fibronectin Aggr IgG Ser-mCnc;;ACTIVE;1.0l;2.73 +16868-2;Finch droppings Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Finch droppings IgE Ab [Presence] in Serum;Finch Drop IgE Ql;;ACTIVE;1.0l;2.56 +16869-0;Flubiprofen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Flurbiprofen [Mass/volume] in Serum or Plasma;Deprecated Flubiprofen SerPl-mCnc;;DEPRECATED;1.0l;2.36 +16870-8;Fluconazole;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fluconazole [Mass/volume] in Urine;Fluconazole Ur-mCnc;;ACTIVE;1.0l;2.42 +16871-6;Fluoride;ACnc;Pt;Bone;Qn;;DRUG/TOX;1;Fluoride [Units/volume] in Bone;Fluoride Bone-aCnc;;DISCOURAGED;1.0l;2.69 +16872-4;Fluorocarbons;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Fluorocarbons [Identifier] in Serum or Plasma;Fluorocarbons SerPl;;ACTIVE;1.0l;2.19 +1687-3;3-Methylhistidine;MCnc;Pt;Urine;Qn;;CHEM;1;3-Methylhistidine [Mass/volume] in Urine;3Me-histidine Ur-mCnc;;ACTIVE;1.0;2.42 +16873-2;Follitropin^105M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Moles/volume] in Serum or Plasma --105 minutes post XXX challenge;FSH 105M p chal SerPl-sCnc;;DISCOURAGED;1.0l;2.42 +16874-0;Formate+Formaldehyde;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Formate+Formaldehyde [Mass/volume] in Blood;Formate+Formaldehyde Bld-mCnc;;ACTIVE;1.0l;2.42 +16875-7;Francisella tularensis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Francisella tularensis Ab [Titer] in Serum;F tular Ab Titr Ser;;ACTIVE;1.0l;2.70 +16876-5;Francisella tularensis Ab.IgA;PrThr;Pt;Ser;Ord;LA;MICRO;1;Francisella tularensis IgA Ab [Presence] in Serum by Latex agglutination;F tular IgA Ser Ql LA;;ACTIVE;1.0l;2.56 +16877-3;Francisella tularensis Ab.IgG;PrThr;Pt;Ser;Ord;LA;MICRO;1;Francisella tularensis IgG Ab [Presence] in Serum by Latex agglutination;F tular IgG Ser Ql LA;;ACTIVE;1.0l;2.56 +16878-1;Francisella tularensis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Francisella tularensis IgM Ab [Units/volume] in Serum;F tular IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +16879-9;Francisella tularensis Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Francisella tularensis Ag [Presence] in Serum by Immunofluorescence;F tular Ag Ser Ql IF;;ACTIVE;1.0l;2.56 +1688-1;4-Pyridoxate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Pyridoxate [Mass/volume] in Serum or Plasma;4Pyridoxate SerPl-mCnc;;ACTIVE;1.0;2.73 +16881-5;Gallium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Gallium [Mass/volume] in Blood;Gallium Bld-mCnc;;ACTIVE;1.0l;2.34 +16882-3;Gamma aminobutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;Gamma aminobutyrate [Presence] in Urine;GABA Ur Ql;;ACTIVE;1.0l;2.56 +16883-1;Gamma aminobutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Gamma aminobutyrate [Mass/volume] in Urine;Deprecated GABA Ur-mCnc;;DEPRECATED;1.0l;2.36 +16884-9;Gamma aminobutyrate;ACnc;Pt;Plas;Ord;;CHEM;1;Deprecated Gamma aminobutyrate [Presence] in Serum or Plasma;Deprecated GABA Plas Ql;;DEPRECATED;1.0l;2.36 +16885-6;Gamma aminobutyrate;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Gamma aminobutyrate [Mass/volume] in Serum or Plasma;Deprecated GABA Plas-mCnc;;DEPRECATED;1.0l;2.36 +16886-4;Gamma aminobutyrate;MCnc;Pt;CSF;Qn;;CHEM;1;Deprecated Gamma aminobutyrate [Mass/volume] in Cerebral spinal fluid;Deprecated GABA CSF-mCnc;;DEPRECATED;1.0l;2.36 +16887-2;Gamma aminobutyrate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Gamma aminobutyrate [Mass/volume] in Amniotic fluid;GABA Amn-mCnc;;DISCOURAGED;1.0l;2.44 +16888-0;Gamma chlordane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Gamma chlordane [Mass/volume] in Urine;G-Chlordane Ur-mCnc;;ACTIVE;1.0l;2.42 +16890-6;Gastrin^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Gastrin 10M p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16891-4;Gastrin^11th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --11th specimen post XXX challenge;Gastrin sp11 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16892-2;Gastrin^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Gastrin 15M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16893-0;Gastrin^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Gastrin 20M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16894-8;Gastrin^25M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --25 minutes post XXX challenge;Gastrin 25M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16895-5;Gastrin^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Gastrin 30M p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16896-3;Gastrin^5M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --5 minutes post XXX challenge;Gastrin 5M p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +16898-9;Giardia lamblia 65 Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia 65 Ag [Presence] in Stool;G lamblia65 Ag Stl Ql;;ACTIVE;1.0l;2.73 +1689-9;5'-Nucleotidase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;5'-Nucleotidase [Enzymatic activity/volume] in Amniotic fluid;5NT Amn-cCnc;;ACTIVE;1.0;2.68 +16899-7;Giardia lamblia Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Giardia lamblia Ag [Presence] in Specimen;G lamblia Ag Spec Ql;;ACTIVE;1.0l;2.73 +16900-3;Gliadin Ab;ACnc;Pt;Saliva;Qn;;SERO;1;Gliadin Ab [Units/volume] in Saliva (oral fluid);Gliadin Ab Sal-aCnc;;ACTIVE;1.0l;2.73 +16901-1;Gliadin Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Gliadin IgA Ab [Presence] in Serum;Gliadin IgA Ser Ql;;ACTIVE;1.0l;2.73 +16902-9;Gliadin Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Gliadin IgG Ab [Presence] in Serum;Gliadin IgG Ser Ql;;ACTIVE;1.0l;2.73 +16903-7;Glucose;MCnc;Pt;Vitr fld;Qn;;CHEM;1;Glucose [Mass/volume] in Vitreous fluid;Glucose Vitf-mCnc;;ACTIVE;1.0l;2.73 +16904-5;Glucose^1st specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --1st specimen post XXX challenge;Glucose sp1 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16905-2;Glucose^2nd specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --2nd specimen post XXX challenge;Glucose sp2 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16906-0;Glucose^3rd specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --3rd specimen post XXX challenge;Glucose sp3 p chal Ur Ql;;ACTIVE;1.0l;2.56 +1690-7;5'-Nucleotidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;5'-Nucleotidase [Enzymatic activity/volume] in Serum or Plasma;5NT SerPl-cCnc;;ACTIVE;1.0;2.73 +16907-8;Glucose^4th specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --4th specimen post XXX challenge;Glucose sp4 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16908-6;Glucose^5th specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --5th specimen post XXX challenge;Glucose sp5 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16909-4;Glucose^6th specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --6th specimen post XXX challenge;Glucose sp6 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16910-2;Glucose^7th specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --7th specimen post XXX challenge;Glucose sp7 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16911-0;Glucose^8th specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --8th specimen post XXX challenge;Glucose sp8 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16912-8;Glucose^9th specimen post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Glucose [Presence] in Urine --9th specimen post XXX challenge;Glucose sp9 p chal Ur Ql;;ACTIVE;1.0l;2.56 +16913-6;Glucose^post CFst;PrThr;Pt;Urine;Ord;;CHAL;1;Fasting glucose [Presence] in Urine;Glucose p fast Ur Ql;;ACTIVE;1.0l;2.73 +16914-4;Glucose^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --post XXX challenge;Glucose p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +1691-5;5,10-Methylenetetrahydrofolate reductase;CCnc;Pt;Ser;Qn;;CHEM;1;5,10-Methylenetetrahydrofolate reductase [Enzymatic activity/volume] in Serum;MTHFR Ser-cCnc;;ACTIVE;1.0;2.73 +16915-1;Glucose^post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --post meal;Glucose p meal SerPl-mCnc;;ACTIVE;1.0l;2.34 +16916-9;Glutamate;PrThr;Pt;Urine;Ord;;CHEM;1;Glutamate [Presence] in Urine;Glutamate Ur Ql;;ACTIVE;1.0l;2.56 +16917-7;Glutamine;PrThr;Pt;Urine;Ord;;CHEM;1;Glutamine [Presence] in Urine;Glutamine Ur Ql;;ACTIVE;1.0l;2.56 +16918-5;Glutathione;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutathione [Mass/volume] in Serum or Plasma;Glutathione SerPl-mCnc;;ACTIVE;1.0l;2.34 +16919-3;Glycine;PrThr;Pt;Urine;Ord;;CHEM;1;Glycine [Presence] in Urine;Glycine Ur Ql;;ACTIVE;1.0l;2.56 +16920-1;Glycoproteins;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Glycoproteins [Presence] in Serum or Plasma;Glycoprots SerPl Ql;;ACTIVE;1.0l;2.56 +16921-9;Stenotaphrum secundatum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;St. Augustine grass IgE Ab [Units/volume] in Serum;St. Augustine grass IgE Qn;;ACTIVE;1.0l;2.42 +16922-7;Elymus triticoides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wild rye grass IgE Ab [Units/volume] in Serum;Wild rye grass IgE Qn;;ACTIVE;1.0l;2.73 +1692-3;5-Hydroxyindoleacetate;MCnc;Pt;CSF;Qn;;CHEM;1;5-Hydroxyindoleacetate [Mass/volume] in Cerebral spinal fluid;5OH-indoleacetate CSF-mCnc;;ACTIVE;1.0;2.42 +16923-5;guaiFENesin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;guaiFENesin [Mass/volume] in Serum or Plasma;guaiFENesin SerPl-mCnc;;ACTIVE;1.0l;2.73 +16924-3;Haemophilus influenzae Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae IgG Ab [Units/volume] in Serum;Haem influ IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +16925-0;Haemophilus influenzae A Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Haemophilus influenzae A Ag [Presence] in Urine;Haem influ A Ag Ur Ql;;ACTIVE;1.0l;2.56 +16926-8;Haemophilus influenzae A Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Haemophilus influenzae A Ag [Presence] in Cerebral spinal fluid;Haem influ A Ag CSF Ql;;ACTIVE;1.0l;2.56 +16927-6;Haemophilus influenzae B Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae B IgG Ab [Units/volume] in Serum;Haem influ B IgG Ser-aCnc;;ACTIVE;1.0l;2.73 +16928-4;Hantavirus puumala Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus puumala IgG+IgM Ab [Units/volume] in Serum;PUUV IgG+IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +16929-2;Helicobacter pylori Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Helicobacter pylori Ab [Units/volume] in Serum by Immunofluorescence;H pylori Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +169-3;Cephradine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cephradine [Susceptibility] by Minimum inhibitory concentration (MIC);Cephradine Islt MIC;;ACTIVE;1.0;2.19 +16930-0;Helminth Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Helminth IgE Ab [Units/volume] in Serum;Worm IgE Qn;;ACTIVE;1.0l;2.42 +1693-1;5-Hydroxyindoleacetate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Hydroxyindoleacetate [Mass/volume] in Serum or Plasma;5OH-indoleacetate SerPl-mCnc;;ACTIVE;1.0;2.73 +16931-8;Hematocrit/Hemoglobin;Ratio;Pt;Bld;Qn;Automated count;HEM/BC;1;Hematocrit/Hemoglobin [Ratio] of Blood by Automated count;Hct/Hgb Bld Auto-Rto;;ACTIVE;1.0l;2.73 +16932-6;Hemoglobin A3/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A3/Hemoglobin.total in Blood by Electrophoresis;Hgb A3 MFr Bld Elph;;ACTIVE;1.0l;2.70 +16933-4;Hepatitis B virus core Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus core Ab [Presence] in Serum;HBV core Ab Ser Ql;;ACTIVE;1.0l;2.73 +16934-2;Hepatitis B virus polymerase DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Hepatitis B virus polymerase DNA [Presence] in Blood by NAA with probe detection;HBV DNAp Bld Ql NAA+probe;;ACTIVE;1.0l;2.73 +16935-9;Hepatitis B virus surface Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus surface Ab [Units/volume] in Serum;HBV surface Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +16936-7;Hepatitis C virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis C virus IgG Ab [Units/volume] in Serum;HCV IgG Ser-aCnc;;ACTIVE;1.0l;2.73 +16937-5;Hepatitis G virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Hepatitis G virus RNA [Presence] in Serum by NAA with probe detection;HGV RNA Ser Ql NAA+probe;;ACTIVE;1.0l;2.73 +16938-3;Heptacarboxylporphyrin;MCnc;Pt;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/volume] in Stool;Hepta-CP Stl-mCnc;;ACTIVE;1.0l;2.42 +16939-1;Heptachlor;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Heptachlor [Mass/volume] in Urine;Heptachlor Ur-mCnc;;ACTIVE;1.0l;2.34 +16940-9;Heptachlorepoxide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Heptachlorepoxide [Mass/volume] in Urine;Heptachlorepoxide Ur-mCnc;;ACTIVE;1.0l;2.42 +16941-7;Herbicide;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Herbicide [Identifier] in Specimen;Herbicide Spec;;ACTIVE;1.0l;2.69 +16942-5;Herpes simplex virus Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Herpes simplex virus Ab [Presence] in Serum by Immunoblot;HSV Ab Ser Ql IB;;ACTIVE;1.0l;2.73 +16943-3;Herpes simplex virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus IgG Ab [Units/volume] in Cerebral spinal fluid;HSV IgG CSF-aCnc;;ACTIVE;1.0l;2.69 +16944-1;Herpes simplex virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus IgM Ab [Units/volume] in Serum;HSV IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +16945-8;Herpes simplex virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Specimen;HSV Ag Spec Ql;;ACTIVE;1.0l;2.69 +16947-4;Herpes simplex virus 1 Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Herpes simplex virus 1 Ab [Presence] in Cerebral spinal fluid by Immunoblot;HSV1 Ab CSF Ql IB;;ACTIVE;1.0l;2.58 +16948-2;Herpes simplex virus 1 Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1 IgG Ab [Units/volume] in Cerebral spinal fluid;HSV1 IgG CSF-aCnc;;ACTIVE;1.0l;2.73 +1694-9;5-Hydroxyindoleacetate;MCnc;Pt;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate [Mass/volume] in Urine;5OH-indoleacetate Ur-mCnc;;ACTIVE;1.0;2.73 +16949-0;Herpes simplex virus 1 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 IgG Ab [Units/volume] in Serum --1st specimen;HSV1 IgG sp1 Ser-aCnc;;ACTIVE;1.0l;2.73 +16950-8;Herpes simplex virus 1 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 IgG Ab [Units/volume] in Serum --2nd specimen;HSV1 IgG sp2 Ser-aCnc;;ACTIVE;1.0l;2.69 +16952-4;Herpes simplex virus 1 DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HSV1 DNA CSF Ql NAA+probe;;ACTIVE;1.0l;2.73 +16953-2;Herpes simplex virus 1 DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Serum or Plasma by NAA with probe detection;HSV1 DNA SerPl Ql NAA+probe;;ACTIVE;1.0l;2.73 +16954-0;Herpes simplex virus 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 2 Ab [Presence] in Serum;HSV2 Ab Ser Ql;;ACTIVE;1.0l;2.73 +16955-7;Herpes simplex virus 2 Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Herpes simplex virus 2 IgG Ab [Presence] in Serum by Immunoblot;HSV2 IgG Ser Ql IB;;ACTIVE;1.0l;2.73 +1695-6;5-Hydroxyindoleacetate;MRat;24H;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate [Mass/time] in 24 hour Urine;5OH-indoleacetate 24h Ur-mRate;;ACTIVE;1.0;2.73 +16956-5;Herpes simplex virus 2 Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Cerebral spinal fluid;HSV2 IgG CSF-aCnc;;ACTIVE;1.0l;2.73 +16957-3;Herpes simplex virus 2 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Serum --1st specimen;HSV2 IgG sp1 Ser-aCnc;;ACTIVE;1.0l;2.73 +16958-1;Herpes simplex virus 2 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Serum --2nd specimen;HSV2 IgG sp2 Ser-aCnc;;ACTIVE;1.0l;2.69 +16959-9;Herpes simplex virus 2 DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Serum or Plasma by NAA with probe detection;HSV2 DNA SerPl Ql NAA+probe;;ACTIVE;1.0l;2.73 +16960-7;Herpes simplex virus 2 DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HSV2 DNA CSF Ql NAA+probe;;ACTIVE;1.0l;2.73 +16962-3;Heterophile Ab;PrThr;Pt;Synv fld;Ord;LA;MICRO;1;Heterophile Ab [Presence] in Synovial fluid by Latex agglutination;Heteroph Ab Snv Ql LA;;ACTIVE;1.0l;2.56 +16963-1;Hexacarboxylporphyrin;MCnc;Pt;Bld;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/volume] in Blood;Hexa-CP Bld-mCnc;;ACTIVE;1.0l;2.73 +1696-4;5-Methyltetrahydrofolate homocysteine methyltransferase;CCnc;Pt;Ser;Qn;;CHEM;1;5-Methyltetrahydrofolate homocysteine methyltransferase [Enzymatic activity/volume] in Serum;5MTHF-Hcys-MT Ser-cCnc;;ACTIVE;1.0;2.68 +16964-9;Hexacarboxylporphyrin;MCnc;Pt;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/volume] in Stool;Hexa-CP Stl-mCnc;;ACTIVE;1.0l;2.42 +16965-6;Lindane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Lindane [Mass/volume] in Blood;Lindane Bld-mCnc;;ACTIVE;1.0l;2.73 +16966-4;Hexachloroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hexachloroethane [Mass/volume] in Blood;HCE Bld-mCnc;;ACTIVE;1.0l;2.42 +16967-2;Hexokinase 1;CCnc;Pt;RBC;Qn;;CHEM;1;Hexokinase 1 [Enzymatic activity/volume] in Red Blood Cells;Hexokinase1 RBC-cCnc;;ACTIVE;1.0l;2.44 +16968-0;Hexokinase 3;CCnc;Pt;RBC;Qn;;CHEM;1;Hexokinase 3 [Enzymatic activity/volume] in Red Blood Cells;Hexokinase3 RBC-cCnc;;ACTIVE;1.0l;2.44 +16969-8;Histone H2a+H2b Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Histone H2a+H2b Ab [Units/volume] in Serum by Immunofluorescence;Histone H2a+H2b Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +16970-6;Histoplasma capsulatum Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Histoplasma capsulatum Ab [Presence] in Serum by Complement fixation;H capsul Ab Ser Ql CF;;ACTIVE;1.0l;2.56 +16971-4;Histoplasma capsulatum Ab.IgA;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum IgA Ab [Presence] in Serum by Immune diffusion (ID);H capsul IgA Ser Ql ID;;ACTIVE;1.0l;2.56 +1697-2;6-Phosphogluconate dehydrogenase;CCnc;Pt;RBC;Qn;;CHEM;1;6-Phosphogluconate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells;6PGD RBC-cCnc;;ACTIVE;1.0;2.44 +16972-2;Histoplasma capsulatum Ab.IgE;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum IgE Ab [Presence] in Serum by Immune diffusion (ID);H capsul IgE Ser Ql ID;;ACTIVE;1.0l;2.56 +16973-0;Histoplasma capsulatum Ab.IgM;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum IgM Ab [Presence] in Serum by Immune diffusion (ID);H capsul IgM Ser Ql ID;;ACTIVE;1.0l;2.56 +16974-8;HIV 1 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;HIV 1 Ab [Presence] in Cerebral spinal fluid;HIV1 Ab CSF Ql;;ACTIVE;1.0l;2.56 +16975-5;HIV 1 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 IgG Ab [Presence] in Serum;HIV1 IgG Ser Ql;;ACTIVE;1.0l;2.73 +16976-3;HIV 1 Ag;ACnc;Pt;Ser;Qn;;MICRO;1;HIV 1 Ag [Units/volume] in Serum;HIV1 Ag Ser-aCnc;;ACTIVE;1.0l;2.73 +16977-1;HIV 1 Ag;PrThr;Pt;CSF;Ord;;MICRO;1;HIV 1 Ag [Presence] in Cerebral spinal fluid;HIV1 Ag CSF Ql;;ACTIVE;1.0l;2.56 +16978-9;HIV 1 p24 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HIV 1 p24 Ab [Units/volume] in Serum;HIV1 p24 Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +16979-7;HIV 1 p24 Ag;ACnc;Pt;CSF;Qn;;MICRO;1;HIV 1 p24 Ag [Units/volume] in Cerebral spinal fluid;HIV1 p24 Ag CSF-aCnc;;ACTIVE;1.0l;2.69 +1698-0;8-Hydroxyamoxapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;8-Hydroxyamoxapine [Mass/volume] in Serum or Plasma;8OH-Amoxapine SerPl-mCnc;;ACTIVE;1.0;2.73 +16980-5;HTLV II DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;HTLV II DNA [Presence] in Specimen by NAA with probe detection;HTLV II DNA Spec Ql NAA+probe;;ACTIVE;1.0l;2.73 +16981-3;HTLV I DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;HTLV I DNA [Presence] in Specimen by NAA with probe detection;HTLV I DNA Spec Ql NAA+probe;;ACTIVE;1.0l;2.73 +16982-1;HTLV I+II Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II Ab [Presence] in Serum by Immunoblot;HTLV I+II Ab Ser Ql IB;;ACTIVE;1.0l;2.73 +16983-9;hydrALAZINE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;hydrALAZINE [Presence] in Urine;hydrALAZINE Ur Ql;;ACTIVE;1.0l;2.56 +16984-7;Hydrastine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Hydrastine [Presence] in Urine;Hydrastine Ur Ql;;ACTIVE;1.0l;2.56 +16985-4;Hydrogen/Expired gas^1.5H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose glucose;Breath H2 1.5h p Glc;;ACTIVE;1.0l;2.42 +16986-2;Hydrogen/Expired gas^1H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose glucose;Breath H2 1h p Glc;;ACTIVE;1.0l;2.42 +16987-0;Hydrogen/Expired gas^2.5H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.5 hours post dose glucose;Breath H2 2.5h p Glc;;ACTIVE;1.0l;2.42 +16988-8;Hydrogen/Expired gas^2H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose glucose;Breath H2 2h p Glc;;ACTIVE;1.0l;2.42 +16989-6;Hydrogen/Expired gas^3.5H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3.5 hours post dose glucose;Breath H2 3.5h p Glc;;ACTIVE;1.0l;2.42 +16990-4;Hydrogen/Expired gas^3H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3 hours post dose glucose;Breath H2 3h p Glc;;ACTIVE;1.0l;2.42 +16991-2;Hydrogen/Expired gas^4.5H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --4.5 hours post dose glucose;Breath H2 4.5h p Glc;;ACTIVE;1.0l;2.42 +16992-0;Hydrogen/Expired gas^4H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --4 hours post dose glucose;Breath H2 4h p Glc;;ACTIVE;1.0l;2.42 +16993-8;Hydrogen/Expired gas^5.5H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --5.5 hours post dose glucose;Breath H2 5.5h p Glc;;ACTIVE;1.0l;2.42 +16994-6;Hydrogen/Expired gas^5H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --5 hours post dose glucose;Breath H2 5h p Glc;;ACTIVE;1.0l;2.42 +16995-3;Hydrogen/Expired gas^6H post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --6 hours post dose glucose;Breath H2 6h p Glc;;ACTIVE;1.0l;2.42 +16996-1;Hydrogen/Expired gas^pre dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --pre dose glucose;Breath H2 pre Glc;;ACTIVE;1.0l;2.42 +16997-9;Hydrogen/Expired gas^post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post dose glucose;Breath H2 p Glc;;ACTIVE;1.0l;2.42 +1699-8;Alpha-L-iduronidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Alpha-L-iduronidase [Enzymatic activity/mass] in Tissue;A-L-Iduronidase Tiss-cCnt;;ACTIVE;1.0;2.42 +16998-7;HYDROmorphone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;HYDROmorphone [Mass/volume] in Urine by Confirmatory method;HYDROmorphone Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +16999-5;Hydroquinone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hydroquinone [Mass/volume] in Urine;Hydroquinone Ur-mCnc;;ACTIVE;1.0l;2.42 +17000-1;Hydroxylysine;PrThr;Pt;Urine;Ord;;CHEM;1;Hydroxylysine [Presence] in Urine;OH-Lysine Ur Ql;;ACTIVE;1.0l;2.56 +17001-9;Hydroxyproline;PrThr;Pt;Urine;Ord;;CHEM;1;Hydroxyproline [Presence] in Urine;OH-Proline Ur Ql;;ACTIVE;1.0l;2.56 +17002-7;Hydroxytriazolam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Serum or Plasma by Confirmatory method;OH-Triazolam SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +17003-5;Serotonin;MCnc;Pt;Urine;Qn;;CHEM;1;Serotonin [Mass/volume] in Urine;Serotonin Ur-mCnc;;ACTIVE;1.0l;2.73 +1700-4;Acetaldehyde;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acetaldehyde [Mass/volume] in Blood;Acetaldehyde Bld-mCnc;;ACTIVE;1.0;2.73 +17004-3;Hypoxanthine;MCnc;Pt;Urine;Qn;;CHEM;1;Hypoxanthine [Mass/volume] in Urine;Hypoxanthine Ur-mCnc;;ACTIVE;1.0l;2.42 +17005-0;IgA subclass 1;MCnc;Pt;CSF;Qn;;CHEM;1;IgA subclass 1 [Mass/volume] in Cerebral spinal fluid;IgA1 CSF-mCnc;;ACTIVE;1.0l;2.42 +17006-8;IgA subclass 2;MCnc;Pt;CSF;Qn;;CHEM;1;IgA subclass 2 [Mass/volume] in Cerebral spinal fluid;IgA2 CSF-mCnc;;ACTIVE;1.0l;2.42 +17007-6;IgG;PrThr;Pt;Ser;Ord;;CHEM;1;IgG [Presence] in Serum;IgG Ser Ql;;ACTIVE;1.0l;2.73 +17008-4;IgG/Beta tubulin;MRto;Pt;Ser;Qn;;CHEM;1;IgG/Beta tubulin [Mass Ratio] in Serum;IgG/B-Tubulin Ser;;ACTIVE;1.0l;2.42 +17009-2;IgM;PrThr;Pt;Ser;Ord;;CHEM;1;IgM [Presence] in Serum;IgM Ser Ql;;ACTIVE;1.0l;2.73 +170-1;Cephradine;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cephradine [Susceptibility] by Disk diffusion (KB);Cephradine Islt KB;;ACTIVE;1.0;2.19 +17010-0;Imipenem;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imipenem [Mass/volume] in Serum or Plasma;Imipenem SerPl-mCnc;;ACTIVE;1.0l;2.73 +1701-2;Acetaldehyde;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetaldehyde [Mass/volume] in Serum or Plasma;Acetaldehyde SerPl-mCnc;;ACTIVE;1.0;2.73 +17012-6;Influenza virus A Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Influenza virus A Ab [Units/volume] in Cerebral spinal fluid;FLUAV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +17013-4;Influenza virus A+B Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Influenza virus A+B Ab [Units/volume] in Serum by Immunofluorescence;FLUAV+FLUBV Ab Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17014-2;Influenza virus B Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Influenza virus B Ab [Units/volume] in Cerebral spinal fluid;FLUBV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +17015-9;Influenza virus B Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus B IgG Ab [Units/volume] in Serum;FLUBV IgG Ser-aCnc;;ACTIVE;1.0l;2.73 +17016-7;Influenza virus B Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus B IgM Ab [Units/volume] in Serum;FLUBV IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +17017-5;Insulin^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Insulin 10M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +17018-3;Insulin^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Insulin 20M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +17019-1;Insulin-like growth factor-I^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;IGF-I 2h p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +1702-0;Acetoacetate;MCnc;Pt;Urine;Qn;;CHEM;1;Acetoacetate [Mass/volume] in Urine;Acetoacet Ur-mCnc;;ACTIVE;1.0;2.73 +17020-9;Intercellular substance Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Intercellular substance Ab [Presence] in Serum by Immunofluorescence;ICS Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17021-7;Intercellular substance Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Intercellular substance Ab [Units/volume] in Serum by Immunofluorescence;ICS Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17022-5;Interleukin 1+2;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 1+2 [Units/volume] in Serum or Plasma;Il1+2 SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +17023-3;Interleukin 7;ACnc;Pt;Ser;Qn;;CHEM;1;Deprecated Interleukin 7 [Units/volume] in Serum or Plasma;Deprecated Il7 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17024-1;Iodine.inorganic;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iodine.inorganic [Mass/volume] in Serum or Plasma;Inorg Iodine SerPl-mCnc;;ACTIVE;1.0l;2.73 +17025-8;Iron;MCnc;Pt;Water;Qn;;CHEM;1;Iron [Mass/volume] in Water;Iron Wat-mCnc;;ACTIVE;1.0l;2.34 +17026-6;Isocyanate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate IgE Ab [Units/volume] in Serum;Isocyanate IgE Qn;;ACTIVE;1.0l;2.42 +17027-4;Isocyanate Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate IgG Ab [Units/volume] in Serum;Isocyanate IgG Qn;;ACTIVE;1.0l;2.69 +17028-2;Isocyanate Ab.IgM;ACnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate IgM Ab [Units/volume] in Serum;Isocyanate IgM Qn;;ACTIVE;1.0l;2.69 +17029-0;Isoleucine;PrThr;Pt;Urine;Ord;;CHEM;1;Isoleucine [Presence] in Urine;Isoleucine Ur Ql;;ACTIVE;1.0l;2.56 +17030-8;Isopropyl ether;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Isopropyl ether [Presence] in Blood;Isopropyl Ether Bld Ql;;ACTIVE;1.0l;2.73 +17031-6;Jo-1 extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA Jo1 Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17032-4;Jo-1 extractable nuclear Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunofluorescence;ENA Jo1 Ab Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17033-2;Ketamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ketamine [Presence] in Urine by Confirmatory method;Ketamine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +17034-0;Ketoprofen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ketoprofen [Mass/volume] in Serum or Plasma;Ketoprofen SerPl-mCnc;;ACTIVE;1.0l;2.73 +17035-7;Ketorolac;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ketorolac [Mass/volume] in Serum or Plasma;Ketorolac SerPl-mCnc;;ACTIVE;1.0l;2.73 +17036-5;La Crosse virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;La Crosse virus Ab [Titer] in Serum;LACV Ab Titr Ser;;ACTIVE;1.0l;2.73 +17037-3;La Crosse virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;La Crosse virus Ab [Titer] in Cerebral spinal fluid;LACV Ab Titr CSF;;ACTIVE;1.0l;2.70 +1703-8;Acetoacetate;MCnc;Pt;CSF;Qn;;CHEM;1;Acetoacetate [Mass/volume] in Cerebral spinal fluid;Acetoacet CSF-mCnc;;ACTIVE;1.0;2.42 +17038-1;La Crosse virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;La Crosse virus IgG Ab [Titer] in Serum;LACV IgG Titr Ser;;ACTIVE;1.0l;2.73 +17039-9;La Crosse virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;La Crosse virus IgM Ab [Titer] in Serum;LACV IgM Titr Ser;;ACTIVE;1.0l;2.73 +17040-7;Labetalol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Labetalol [Presence] in Serum or Plasma;Labetalol SerPl Ql;;ACTIVE;1.0l;2.56 +17041-5;Lactate dehydrogenase;PrThr;Pt;Urine;Ord;;CHEM;1;Lactate dehydrogenase [Presence] in Urine;LDH Ur Ql;;ACTIVE;1.0l;2.73 +17042-3;Lactoglobulin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactoglobulin IgE Ab [Units/volume] in Serum;Lactoglob IgE Qn;;ACTIVE;1.0l;2.73 +17043-1;Lactose;MCnc;Pt;Urine;Qn;;CHEM;1;Lactose [Mass/volume] in Urine;Lactose Ur-mCnc;;ACTIVE;1.0l;2.42 +17044-9;Lamellar bodies;PrThr;Pt;Amnio fld;Ord;;HEM/BC;1;Lamellar bodies [Presence] in Amniotic fluid;Lamellar Bod Amn Ql;;ACTIVE;1.0l;2.56 +17045-6;Latex Ab.IgE;ACnc;Pt;Bld;Qn;;ALLERGY;1;Latex IgE Ab [Units/volume] in Blood;Ltx IgE Bld Qn;;ACTIVE;1.0l;2.42 +1704-6;Acetoacetate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Acetoacetate [Presence] in Serum or Plasma;Acetoacet SerPl Ql;;ACTIVE;1.0;2.56 +17046-4;Latex Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex IgG Ab [Units/volume] in Serum;Ltx IgG Qn;;ACTIVE;1.0l;2.73 +17047-2;Latex Bencard Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex Bencard IgE Ab [Units/volume] in Serum;Ltx Bencard IgE Qn;;ACTIVE;1.0l;2.42 +17048-0;Latex glove extract Ab.IgE;ACnc;Pt;Bld;Qn;;ALLERGY;1;Latex glove extract IgE Ab [Units/volume] in Blood;Ltx Glv Ext IgE Bld Qn;;ACTIVE;1.0l;2.42 +17049-8;Latex glove extract ammoniated Ab.IgE;ACnc;Pt;Bld;Qn;;ALLERGY;1;Latex glove extract ammoniated IgE Ab [Units/volume] in Blood;Ltx Glv Ext Ammon IgE Bld Qn;;ACTIVE;1.0l;2.42 +17050-6;Latex glove extract buffered Ab.IgE;ACnc;Pt;Bld;Qn;;ALLERGY;1;Latex glove extract buffered IgE Ab [Units/volume] in Blood;Ltx Glv Ext Buff IgE Bld Qn;;ACTIVE;1.0l;2.42 +17051-4;Laxatives;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Laxatives [Identifier] in Urine;Laxatives Ur;;ACTIVE;1.0l;2.19 +17052-2;Lead;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Lead [Presence] in Blood;Lead Bld Ql;;ACTIVE;1.0l;2.73 +1705-3;Acetoacetate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acetoacetate [Mass/volume] in Serum or Plasma;Acetoacet SerPl-mCnc;;ACTIVE;1.0;2.73 +17053-0;Legionella longbeachae 1 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella longbeachae 1 IgG Ab [Presence] in Serum;L longbeachae1 IgG Ser Ql;;ACTIVE;1.0l;2.56 +17054-8;Legionella longbeachae 1 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella longbeachae 1 IgM Ab [Presence] in Serum;L longbeachae1 IgM Ser Ql;;ACTIVE;1.0l;2.56 +17055-5;Legionella longbeachae 2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella longbeachae 2 IgG Ab [Presence] in Serum;L longbeachae2 IgG Ser Ql;;ACTIVE;1.0l;2.56 +17056-3;Legionella longbeachae 2 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella longbeachae 2 IgM Ab [Presence] in Serum;L longbeachae2 IgM Ser Ql;;ACTIVE;1.0l;2.56 +17057-1;Legionella pneumophila Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Legionella pneumophila Ag [Presence] in Specimen;L pneumo Ag Spec Ql;;ACTIVE;1.0l;2.73 +17058-9;Legionella pneumophila Ag;PrThr;Pt;Urine;Ord;LA;MICRO;1;Legionella pneumophila Ag [Presence] in Urine by Latex agglutination;L pneumo Ag Ur Ql LA;;ACTIVE;1.0l;2.56 +17059-7;Legionella pneumophila Ag;PrThr;Pt;Urine;Ord;IF;MICRO;1;Legionella pneumophila Ag [Presence] in Urine by Immunofluorescence;L pneumo Ag Ur Ql IF;;ACTIVE;1.0l;2.56 +17060-5;Legionella pneumophila 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1 Ab [Titer] in Serum;L pneumo1 Ab Titr Ser;;ACTIVE;1.0l;2.73 +1706-1;Acetonitrile;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acetonitrile [Mass/volume] in Blood;Acetonitrile Bld-mCnc;;ACTIVE;1.0;2.42 +17061-3;Legionella pneumophila 1 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1 IgM Ab [Units/volume] in Serum;L pneumo1 IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +17062-1;Legionella pneumophila 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 2 Ab [Titer] in Serum;L pneumo2 Ab Titr Ser;;ACTIVE;1.0l;2.70 +17063-9;Legionella pneumophila 2 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 2 IgM Ab [Units/volume] in Serum;L pneumo2 IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +17064-7;Legionella pneumophila 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 3 Ab [Titer] in Serum;L pneumo3 Ab Titr Ser;;ACTIVE;1.0l;2.70 +17065-4;Legionella pneumophila 3 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 3 IgM Ab [Units/volume] in Serum;L pneumo3 IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +17066-2;Legionella pneumophila 4 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 4 Ab [Titer] in Serum;L pneumo4 Ab Titr Ser;;ACTIVE;1.0l;2.70 +17067-0;Legionella pneumophila 4 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 4 IgM Ab [Units/volume] in Serum;L pneumo4 IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +17068-8;Legionella pneumophila 5 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 5 Ab [Titer] in Serum;L pneumo5 Ab Titr Ser;;ACTIVE;1.0l;2.70 +17069-6;Legionella pneumophila 5 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 5 IgM Ab [Units/volume] in Serum;L pneumo5 IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +17070-4;Legionella pneumophila 6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 6 Ab [Titer] in Serum;L pneumo6 Ab Titr Ser;;ACTIVE;1.0l;2.70 +17071-2;Legionella pneumophila 7 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 7 Ab [Presence] in Serum;L pneumo7 Ab Ser Ql;;ACTIVE;1.0l;2.56 +17072-0;Legionella pneumophila 8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 8 Ab [Presence] in Serum;L pneumo8 Ab Ser Ql;;ACTIVE;1.0l;2.56 +17073-8;Legionella pneumophila 9 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 9 Ab [Presence] in Serum;L pneumo9 Ab Ser Ql;;ACTIVE;1.0l;2.56 +17074-6;Leucine;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Leucine [Units/volume] in Amniotic fluid;Leucine Amn-aCnc;;DISCOURAGED;1.0l;2.69 +17075-3;Lidocaine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lidocaine [Mass/volume] in Urine;Lidocain Ur-mCnc;;ACTIVE;1.0l;2.73 +17076-1;Lidocaine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Lidocaine [Mass/volume] in Body fluid;Lidocain Fld-mCnc;;ACTIVE;1.0l;2.42 +17077-9;Lindane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Lindane [Mass/volume] in Blood;Deprecated Lindane Bld-mCnc;;DEPRECATED;1.0l;2.36 +17078-7;Fatty acids.esterified;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.esterified [Mass/volume] in Serum or Plasma;EFA SerPl-mCnc;;ACTIVE;1.0l;2.34 +1707-9;Acetylcholine;MCnc;Pt;Ser;Qn;;CHEM;1;Acetylcholine [Mass/volume] in Serum;ACh Ser-mCnc;;ACTIVE;1.0;2.42 +17079-5;Fatty acids.long chain;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Fatty acids.long chain [Identifier] in Serum or Plasma;LCFA SerPl;;ACTIVE;1.0l;2.09 +17080-3;Fatty acids.very long chain;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Fatty acids.very long chain [Identifier] in Serum or Plasma;VLCFA SerPl;;ACTIVE;1.0l;2.73 +17081-1;Triglyceride^post CFst;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Triglyceride [Mass/volume] in Serum or Plasma --post CFst;Deprecated Trigl p fast Ser-mCnc;;DEPRECATED;1.0l;2.36 +17082-9;Lipoprotein.alpha;MCnc;Pt;Body fld;Qn;;CHEM;1;Lipoprotein.alpha [Mass/volume] in Body fluid;HDL Fld-mCnc;;ACTIVE;1.0l;2.42 +17083-7;Lipoprotein.beta;MCnc;Pt;Body fld;Qn;;CHEM;1;Lipoprotein.beta [Mass/volume] in Body fluid;LDL Fld-mCnc;;ACTIVE;1.0l;2.42 +17084-5;Lipoprotein.pre-beta;MCnc;Pt;Body fld;Qn;;CHEM;1;Lipoprotein.pre-beta [Mass/volume] in Body fluid;VLDL Fld-mCnc;;ACTIVE;1.0l;2.42 +17085-2;Lipoprotein;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lipoproteins [Presence] in Serum or Plasma;LP SerPl Ql;;ACTIVE;1.0l;2.56 +17086-0;Lithium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Lithium [Mass/volume] in Body fluid;Lithium Fld-mCnc;;ACTIVE;1.0l;2.42 +1708-7;Acetylcholinesterase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Acetylcholinesterase [Enzymatic activity/volume] in Amniotic fluid;AChE Amn-cCnc;;ACTIVE;1.0;2.73 +17087-8;Loperamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Loperamide [Mass/volume] in Serum or Plasma;Loperamide SerPl-mCnc;;ACTIVE;1.0l;2.40 +17088-6;LORazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;LORazepam [Mass/volume] in Urine by Confirmatory method;LORazepam Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +17089-4;Lorcainide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lorcainide [Mass/volume] in Serum or Plasma;Lorcainide SerPl-mCnc;;ACTIVE;1.0l;2.42 +17090-2;Loxapine+8-Hydroxyloxapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Loxapine+8-Hydroxyloxapine [Mass/volume] in Serum or Plasma;Loxapine+8OH-Lox SerPl-mCnc;;ACTIVE;1.0l;2.40 +17091-0;Lumpfish roe Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lumpfish roe IgE Ab [Units/volume] in Serum;Lumpfish Roe IgE Qn;;ACTIVE;1.0l;2.42 +17092-8;Lupus erythematosus factor;PrThr;Pt;Ser;Ord;LA;SERO;1;Lupus erythematosus factor [Presence] in Serum by Latex agglutination;LE Scn Ser Ql LA;;ACTIVE;1.0l;2.73 +17094-4;Lutropin^105M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --105 minutes post XXX challenge;LH 105M p chal SerPl-sCnc;;DISCOURAGED;1.0l;2.34 +1709-5;Acetylcholinesterase;CCnc;Pt;RBC;Qn;;CHEM;1;Acetylcholinesterase [Enzymatic activity/volume] in Red Blood Cells;AChE RBC-cCnc;;DISCOURAGED;1.0;2.68 +17095-1;Lutropin^75M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Moles/volume] in Serum or Plasma --75 minutes post XXX challenge;LH 75M p chal SerPl-sCnc;;DISCOURAGED;1.0l;2.44 +17096-9;Lymphocytes.kappa/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;Kappa lymphocytes/100 lymphocytes in Blood;Lymphs Kappa/lymph NFr Bld;;ACTIVE;1.0l;2.73 +17097-7;Cells.CD10+CD20+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD10+CD20+ cells/100 cells in Blood;CD10+CD20+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17098-5;Cells.CD100/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD100 cells/100 cells in Blood;CD100 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17099-3;Cells.CD102/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD102 cells/100 cells in Blood;CD102 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17100-9;Cells.CD103/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD103 cells/100 cells in Blood;CD103 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17101-7;Cells.CD104/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD104 cells/100 cells in Blood;CD104 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17102-5;Cells.CD105/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD105 cells/100 cells in Blood;CD105 Cells NFr Bld;;ACTIVE;1.0l;2.70 +1710-3;Acetylcholinesterase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acetylcholinesterase [Enzymatic activity/volume] in Serum or Plasma;AChE SerPl-cCnc;;ACTIVE;1.0;2.68 +17103-3;Cells.CD106/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD106 cells/100 cells in Blood;CD106 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17104-1;Cells.CD107a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD107a cells/100 cells in Blood;CD107a Cells NFr Bld;;ACTIVE;1.0l;2.70 +17105-8;Cells.CD107b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD107b cells/100 cells in Blood;CD107b Cells NFr Bld;;ACTIVE;1.0l;2.70 +17106-6;Cells.CD115/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD115 cells/100 cells in Blood;CD115 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17107-4;Cells.CD117/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD117 cells/100 cells in Blood;CD117 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17108-2;Cells.CD118/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD118 cells/100 cells in Blood;CD118 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17109-0;Cells.CD11a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11a cells/100 cells in Blood;CD11a Cells NFr Bld;;ACTIVE;1.0l;2.70 +17110-8;Cells.CD11b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11b cells/100 cells in Blood;CD11b Cells NFr Bld;;ACTIVE;1.0l;2.73 +1711-1;Acid phosphatase;CCnc;Pt;Bld;Qn;;CHEM;1;Acid phosphatase [Enzymatic activity/volume] in Blood;ACP Bld-cCnc;;ACTIVE;1.0;2.73 +17111-6;Cells.CD12/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD12 cells/100 cells in Blood;CD12 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17112-4;Cells.CD120a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD120A cells/100 cells in Blood;CD120A Cells NFr Bld;;ACTIVE;1.0l;2.70 +17113-2;Cells.CD120b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD120B cells/100 cells in Blood;CD120B Cells NFr Bld;;ACTIVE;1.0l;2.70 +17114-0;Cells.CD122/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD122 cells/100 cells in Blood;CD122 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17115-7;Cells.CD126/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD126 cells/100 cells in Blood;CD126 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17116-5;Cells.CD128/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD128 cells/100 cells in Blood;CD128 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17117-3;Cells.CD15/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD15 cells/100 cells in Blood;CD15 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17118-1;Cells.CD16b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16B cells/100 cells in Blood;CD16B Cells NFr Bld;;ACTIVE;1.0l;2.70 +17119-9;Cells.CD16-CD34+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16-CD34+ cells/100 cells in Blood;CD16-CD34 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17120-7;Cells.CD17/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD17 cells/100 cells in Blood;CD17 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17121-5;Cells.CD18/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD18 cells/100 cells in Blood;CD18 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17122-3;Cells.CD19+Kappa+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+Kappa+ cells/100 cells in Blood;CD19+Kappa+ Cells NFr Bld;;ACTIVE;1.0l;2.73 +17123-1;Cells.CD19+Lambda+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+Lambda+ cells/100 cells in Blood;CD19+Lambda+ Cells NFr Bld;;ACTIVE;1.0l;2.73 +17124-9;Cells.CD2+CD20+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD2+CD20+ cells/100 cells in Blood;CD2+CD20+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17125-6;Cells.CD22+CD19+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD22+CD19+ cells/100 cells in Blood;CD22+CD19+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17126-4;Cells.CD24/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD24 cells/100 cells in Blood;CD24 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17127-2;Cells.CD26/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD26 cells/100 cells in Blood;CD26 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17128-0;Cells.CD27/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27 cells/100 cells in Blood;CD27 Cells NFr Bld;;ACTIVE;1.0l;2.73 +1712-9;Acid phosphatase.prostatic;CCnc;Pt;Vag;Qn;;CHEM;1;Prostatic acid phosphatase [Enzymatic activity/volume] in Vaginal fluid;PACP Vag-cCnc;;ACTIVE;1.0;2.68 +17129-8;Cells.CD28/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD28 cells/100 cells in Blood;CD28 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17130-6;Cells.CD29/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD29 cells/100 cells in Blood;CD29 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17131-4;Cells.CD3+CD69+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD69+ cells/100 cells in Blood;CD3+CD69+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17132-2;Cells.CD3+IL2R1+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+IL2R1+ cells/100 cells in Blood;CD3+IL2R1+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17133-0;Cells.CD3+CD16+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD16+ cells/100 cells in Blood;CD3+CD16+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17135-5;Cells.CD3+CD56+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD56+ cells/100 cells in Blood;CD3+CD56+ Cells NFr Bld;;ACTIVE;1.0l;2.73 +17136-3;Cells.CD3+DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+DR+ cells/100 cells in Blood;CD3+DR+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +1713-7;Acid phosphatase.prostatic;CCnc;Pt;Semen;Qn;;CHEM;1;Prostatic acid phosphatase [Enzymatic activity/volume] in Semen;PACP Smn-cCnc;;ACTIVE;1.0;2.68 +17137-1;Cells.CD30/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD30 cells/100 cells in Blood;CD30 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17138-9;Cells.CD31/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD31 cells/100 cells in Blood;CD31 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17139-7;Cells.CD32/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD32 cells/100 cells in Blood;CD32 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17140-5;Cells.CD34+DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD34+DR+ cells/100 cells in Blood;CD34+DR+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17141-3;Cells.CD36/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD36 cells/100 cells in Blood;CD36 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17142-1;Cells.CD37/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD37 cells/100 cells in Blood;CD37 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17143-9;Cells.CD39/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD39 cells/100 cells in Blood;CD39 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17144-7;Cells.CD4+CD69+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD69+ cells/100 cells in Blood;CD4+CD69+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +1714-5;Acid phosphatase.prostatic;CCnc;Pt;Ser;Qn;;CHEM;1;Prostatic acid phosphatase [Enzymatic activity/volume] in Serum;PACP Ser-cCnc;;ACTIVE;1.0;2.73 +17145-4;Cells.CD4+2H4/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD4+2H4 cells/100 cells in Blood;Deprecated Cells.CD4+2H4 Fr Bld;;DEPRECATED;1.0l;2.70 +17146-2;Cells.CD4+CD8+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD8+ cells/100 cells in Blood;CD4+CD8+ Cells NFr Bld;;ACTIVE;1.0l;2.73 +17147-0;Cells.CD40/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD40 cells/100 cells in Blood;CD40 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17148-8;Cells.CD41/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD41 cells/100 cells in Blood;CD41 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17149-6;Cells.CD42a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD42a cells/100 cells in Blood;CD42a Cells NFr Bld;;ACTIVE;1.0l;2.70 +17150-4;Cells.CD42b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD42b cells/100 cells in Blood;CD42b Cells NFr Bld;;ACTIVE;1.0l;2.73 +17151-2;Cells.CD42c/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD42c cells/100 cells in Blood;CD42c Cells NFr Bld;;ACTIVE;1.0l;2.70 +1715-2;Acid phosphatase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acid phosphatase [Enzymatic activity/volume] in Serum or Plasma;ACP SerPl-cCnc;;ACTIVE;1.0;2.73 +17152-0;Cells.CD42d/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD42d cells/100 cells in Blood;CD42d Cells NFr Bld;;ACTIVE;1.0l;2.70 +17153-8;Cells.CD4+CD45RA+/Cells.CD8;NRto;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45RA+ cells/CD8 Cells [# Ratio] in Blood;CD4+CD45RA+ Cells/CD8 cells Bld;;ACTIVE;1.0l;2.73 +17154-6;Cells.CD43/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD43 cells/100 cells in Blood;CD43 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17155-3;Cells.CD44/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD44 cells/100 cells in Blood;CD44 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17156-1;Cells.CD44R/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD44R cells/100 cells in Blood;CD44R Cells NFr Bld;;ACTIVE;1.0l;2.70 +17157-9;Cells.CD45RA/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45RA cells/100 cells in Blood;CD45RA Cells NFr Bld;;ACTIVE;1.0l;2.73 +17158-7;Cells.CD45RB/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45RB cells/100 cells in Blood;CD45RB Cells NFr Bld;;ACTIVE;1.0l;2.70 +17159-5;Cells.CD45RO/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45RO cells/100 cells in Blood;CD45RO Cells NFr Bld;;ACTIVE;1.0l;2.70 +1716-0;Acidity.titratable;MCnc;Pt;Urine;Qn;;CHEM;1;Acidity.titratable [Mass/volume] in Urine;Titratable Acidity Ur-mCnc;;DISCOURAGED;1.0;2.44 +17160-3;Cells.CD46/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD46 cells/100 cells in Blood;CD46 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17161-1;Cells.CD47/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD47 cells/100 cells in Blood;CD47 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17162-9;Cells.CD48/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD48 cells/100 cells in Blood;CD48 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17163-7;Cells.CD49a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD49a cells/100 cells in Blood;CD49a Cells NFr Bld;;ACTIVE;1.0l;2.70 +17164-5;Cells.CD49b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD49b cells/100 cells in Blood;CD49b Cells NFr Bld;;ACTIVE;1.0l;2.70 +17165-2;Cells.CD49c/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD49c cells/100 cells in Blood;CD49c Cells NFr Bld;;ACTIVE;1.0l;2.70 +17166-0;Cells.CD49d/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD49d cells/100 cells in Blood;CD49d Cells NFr Bld;;ACTIVE;1.0l;2.70 +17167-8;Cells.CD49e/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD49e cells/100 cells in Blood;CD49e Cells NFr Bld;;ACTIVE;1.0l;2.70 +17168-6;Cells.CD49f/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD49f cells/100 cells in Blood;CD49f Cells NFr Bld;;ACTIVE;1.0l;2.70 +17169-4;Cells.CD5+CD2-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5+CD2- cells/100 cells in Blood;CD5+CD2- Cells NFr Bld;;ACTIVE;1.0l;2.70 +17170-2;Cells.CD50/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD50 cells/100 cells in Blood;CD50 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17171-0;Cells.CD51/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD51 cells/100 cells in Blood;CD51 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17172-8;Cells.CD52/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD52 cells/100 cells in Blood;CD52 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17173-6;Cells.CD53/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD53 cells/100 cells in Blood;CD53 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17174-4;Cells.CD54/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD54 cells/100 cells in Blood;CD54 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17175-1;Cells.CD55/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD55 cells/100 cells in Blood;CD55 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17176-9;Cells.CD58/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD58 cells/100 cells in Blood;CD58 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17177-7;Cells.CD59/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD59 cells/100 cells in Blood;CD59 Cells NFr Bld;;ACTIVE;1.0l;2.73 +1717-8;Acylcarnitine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acylcarnitine [Mass/volume] in Serum or Plasma;Acylcarnitine SerPl-mCnc;;DISCOURAGED;1.0;2.73 +17178-5;Cells.CD6/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD6 cells/100 cells in Blood;CD6 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17179-3;Cells.CD62E/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD62E cells/100 cells in Blood;CD62E Cells NFr Bld;;ACTIVE;1.0l;2.70 +17180-1;Cells.CD62L/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD62L cells/100 cells in Blood;CD62L Cells NFr Bld;;ACTIVE;1.0l;2.70 +17181-9;Cells.CD62P/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD62P cells/100 cells in Blood;CD62P Cells NFr Bld;;ACTIVE;1.0l;2.70 +17182-7;Cells.CD63/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD63 cells/100 cells in Blood;CD63 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17183-5;Cells.CD64/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD64 cells/100 cells in Blood;CD64 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17184-3;Cells.CD66a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD66a cells/100 cells in Blood;CD66a Cells NFr Bld;;ACTIVE;1.0l;2.70 +17185-0;Cells.CD66b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD66b cells/100 cells in Blood;CD66b Cells NFr Bld;;ACTIVE;1.0l;2.70 +1718-6;Acyl CoA dehydrogenase;CCnc;Pt;Ser;Qn;;CHEM;1;Acyl CoA dehydrogenase [Enzymatic activity/volume] in Serum;ACAD Ser-cCnc;;ACTIVE;1.0;2.73 +17186-8;Cells.CD66c/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD66c cells/100 cells in Blood;CD66c Cells NFr Bld;;ACTIVE;1.0l;2.70 +17187-6;Cells.CD66d/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD66d cells/100 cells in Blood;CD66d Cells NFr Bld;;ACTIVE;1.0l;2.70 +17188-4;Cells.CD66e/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD66e cells/100 cells in Blood;CD66e Cells NFr Bld;;ACTIVE;1.0l;2.70 +17189-2;Cells.CD68/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD68 cells/100 cells in Blood;CD68 Cells NFr Bld;;ACTIVE;1.0l;2.70 +171-9;Cephradine;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cephradine [Susceptibility] by Serum bactericidal titer;Cephradine Titr SBT;;ACTIVE;1.0;2.32 +17190-0;Cells.CD69/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD69 cells/100 cells in Blood;CD69 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17191-8;Cells.CD3-CD7+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3-CD7+cells/100 cells in Blood;CD3-CD7+ Cells NFr Bld;;ACTIVE;1.0l;2.70 +17192-6;Cells.CD72/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD72 cells/100 cells in Blood;CD72 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17193-4;Cells.CD73/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD73 cells/100 cells in Blood;CD73 Cells NFr Bld;;ACTIVE;1.0l;2.70 +1719-4;Adenine;MCnc;Pt;Ser;Qn;;CHEM;1;Adenine [Mass/volume] in Serum;Adenine Ser-mCnc;;DISCOURAGED;1.0;2.44 +17194-2;Cells.CD74/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD74 cells/100 cells in Blood;CD74 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17195-9;Cells.CD77/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD77 cells/100 cells in Blood;CD77 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17196-7;Cells.CD79a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD79a cells/100 cells in Blood;CD79a Cells NFr Bld;;ACTIVE;1.0l;2.70 +17197-5;Cells.CD79b/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD79b cells/100 cells in Blood;CD79b Cells NFr Bld;;ACTIVE;1.0l;2.73 +17198-3;Cells.CD8+CD28+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD28+ cells/100 cells in Blood;CD8+CD28+ Cells NFr Bld;;ACTIVE;1.0l;2.73 +17199-1;Cells.CD80/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD80 cells/100 cells in Blood;CD80 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17200-7;Cells.CD82/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD82 cells/100 cells in Blood;CD82 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17201-5;Cells.CD83/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD83 cells/100 cells in Blood;CD83 Cells NFr Bld;;ACTIVE;1.0l;2.70 +1720-2;Adenine phosphoribosyltransferase;CCnc;Pt;RBC;Qn;;CHEM;1;Adenine phosphoribosyltransferase [Enzymatic activity/volume] in Red Blood Cells;APRT RBC-cCnc;;ACTIVE;1.0;2.44 +17202-3;Cells.CD85/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD85 cells/100 cells in Blood;CD85 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17203-1;Cells.CD86/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD86 cells/100 cells in Blood;CD86 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17204-9;Cells.CD87/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD87 cells/100 cells in Blood;CD87 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17205-6;Cells.CD88/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD88 cells/100 cells in Blood;CD88 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17206-4;Cells.CD9/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD9 cells/100 cells in Blood;CD9 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17207-2;Cells.CD91/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD91 cells/100 cells in Blood;CD91 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17208-0;Cells.CD93/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD93 cells/100 cells in Blood;CD93 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17209-8;Cells.CD94/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD94 cells/100 cells in Blood;CD94 Cells NFr Bld;;ACTIVE;1.0l;2.70 +1721-0;Adenosine triphosphate;MCnc;Pt;Bld;Qn;;CHEM;1;Adenosine triphosphate [Mass/volume] in Blood;ATP Bld-mCnc;;ACTIVE;1.0;2.73 +17210-6;Cells.CD95/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD95 cells/100 cells in Blood;CD95 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17211-4;Cells.CD96/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD96 cells/100 cells in Blood;CD96 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17212-2;Cells.CD97/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD97 cells/100 cells in Blood;CD97 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17213-0;Cells.CD98/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD98 cells/100 cells in Blood;CD98 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17214-8;Cells.CD99/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD99 cells/100 cells in Blood;CD99 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17215-5;Lymphocytes.CV/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;CV lymphocytes/100 lymphocytes in Blood;Lymphs CV/lymph NFr Bld;;ACTIVE;1.0l;2.70 +17216-3;Cells.cytoplasmic CD3/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD3 cells/100 cells in Blood;cyCD3 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17217-1;Cells.cytoplasmic CD79/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD79 cells/100 cells in Blood;cyCD79 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17218-9;Cells.cytoplasmic Ig mu/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic Ig mu cells/100 cells in Blood;CyIg mu Cells NFr Bld;;ACTIVE;1.0l;2.70 +17219-7;Cells.cytoplasmic Ig/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic Ig cells/100 cells in Blood;CyIg Cells NFr Bld;;ACTIVE;1.0l;2.73 +17220-5;Cells.FMC7/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;FMC7 cells/100 cells in Blood;FMC7 Cells NFr Bld;;ACTIVE;1.0l;2.73 +17221-3;Cells.CD235a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD235a cells/100 cells in Blood;CD235a Cells NFr Bld;;ACTIVE;1.0l;2.73 +17222-1;Lymphocytes.HLE/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;HLE lymphocytes/100 lymphocytes in Blood;Lymphs HLE/lymph NFr Bld;;ACTIVE;1.0l;2.70 +17223-9;Cells.CD14/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD14 cells/100 cells in Blood;Deprecated CD14 Cells Fr Bld;;DEPRECATED;1.0l;2.46 +17224-7;Lymphocytes.lambda/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;Lambda lymphocytes/100 lymphocytes in Blood;Lymphs Lambda/lymph NFr Bld;;ACTIVE;1.0l;2.73 +17225-4;Lymphocytes.SmIg/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;SMIg lymphocytes/100 lymphocytes in Blood;Lymphs SmIg/lymph NFr Bld;;ACTIVE;1.0l;2.73 +17226-2;Cells.SmIg-CD79/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;SmIg-Cd79 cells/100 cells in Blood;SmIg-CD79 Cells NFr Bld;;ACTIVE;1.0l;2.70 +17227-0;Lymphocytes/100 leukocytes;NFr;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Lymphocytes/100 leukocytes in Synovial fluid by Automated count;Lymphocytes/leuk NFr Snv Auto;;ACTIVE;1.0l;2.73 +1722-8;Adenosine deaminase;CCnc;Pt;Bld;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Blood;Adenosine deaminase Bld-cCnc;;ACTIVE;1.0;2.73 +17228-8;Lymphocytic choriomeningitis virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Lymphocytic choriomeningitis virus Ab [Titer] in Cerebral spinal fluid;LCMV Ab Titr CSF;;ACTIVE;1.0l;2.70 +17229-6;Lymphocytic choriomeningitis virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Titer] in Cerebral spinal fluid;LCMV IgM Titr CSF;;ACTIVE;1.0l;2.70 +17230-4;Lysine;PrThr;Pt;Urine;Ord;;CHEM;1;Lysine [Presence] in Urine;Lysine Ur Ql;;ACTIVE;1.0l;2.56 +17231-2;Lysosomal enzymes;Prid;Pt;Plas;Nom;;CHEM;1;Lysosomal enzymes [Identifier] in Plasma;Lysosomal Enzymes Plas;;ACTIVE;1.0l;2.15 +17232-0;Lysozyme;CCnc;Pt;Tear;Qn;;CHEM;1;Lysozyme [Enzymatic activity/volume] in Tear;Lysozyme Tear-cCnc;;ACTIVE;1.0l;2.68 +17234-6;Magnesium.plasma/Magnesium.RBC;SRto;Pt;Bld;Qn;;CHEM;1;Magnesium.plasma/Magnesium.RBC [Molar ratio] in Blood;Magnesium SerPl/RBC Bld-sRto;;ACTIVE;1.0l;2.42 +17235-3;Magnesium;SCnc;Pt;WBC;Qn;;CHEM;1;Magnesium [Moles/volume] in Leukocytes;Magnesium WBC-sCnc;;ACTIVE;1.0l;2.73 +1723-6;Adenosine deaminase binding protein;MCnc;Pt;Urine;Qn;;CHEM;1;Adenosine deaminase binding protein [Mass/volume] in Urine;Adenosine deaminase BP Ur-mCnc;;DISCOURAGED;1.0;2.44 +17236-1;Magnesium;SCnc;Pt;Stool;Qn;;CHEM;1;Magnesium [Moles/volume] in Stool;Magnesium Stl-sCnc;;ACTIVE;1.0l;2.73 +17237-9;Magnesium;SCnt;Pt;Hair;Qn;;CHEM;1;Magnesium [Moles/mass] in Hair;Magnesium Hair-sCnt;;ACTIVE;1.0l;2.40 +17238-7;Malignin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Malignin Ab [Units/volume] in Serum;Malignin Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +17241-1;Prolactin^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Prolactin 3h p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +17242-9;Prolactin^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;Prolactin 40M p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +17243-7;Prolactin^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --pre XXX challenge;Prolactin pre chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +1724-4;Adenosine diphosphate;MCnc;Pt;Ser;Qn;;CHEM;1;Adenosine diphosphate [Mass/volume] in Serum;ADP Ser-mCnc;;ACTIVE;1.0;2.44 +17244-5;Manganese;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Manganese [Mass/mass] in Hair;Manganese Hair-mCnt;;ACTIVE;1.0l;2.73 +17245-2;Meclizine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Meclizine [Mass/volume] in Serum or Plasma;Deprecated Meclizine SerPl-mCnc;;DEPRECATED;1.0l;2.36 +17246-0;Mefenamate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mefenamate [Mass/volume] in Serum or Plasma;Mefenamate SerPl-mCnc;;ACTIVE;1.0l;2.73 +17247-8;Melanin;ACnc;Pt;Urine;Qn;;CHEM;1;Melanin [Units/volume] in Urine;Melanin Ur-aCnc;;DISCOURAGED;1.0l;2.69 +17248-6;Melanin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Melanin [Units/volume] in Serum or Plasma;Melanin SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +17249-4;Menthol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Menthol [Mass/volume] in Blood;Menthol Bld-mCnc;;ACTIVE;1.0l;2.34 +17250-2;Mephobarbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mephobarbital [Mass/volume] in Urine by Confirmatory method;Mephobarbital Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +1725-1;Adenosine monophosphate deaminase;CCnc;Pt;Ser;Qn;;CHEM;1;Adenosine monophosphate deaminase [Enzymatic activity/volume] in Serum;AMP deaminase Ser-cCnc;;ACTIVE;1.0;2.68 +17251-0;Mepivacaine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Mepivacaine [Presence] in Serum or Plasma;Mepivacaine SerPl Ql;;ACTIVE;1.0l;2.56 +17252-8;Mercaptopurine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Mercaptopurine [Presence] in Serum or Plasma;Mercaptopurine SerPl Ql;;ACTIVE;1.0l;2.56 +17253-6;Mercury;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Milk;Mercury Mlk-mCnc;;ACTIVE;1.0l;2.34 +17254-4;Mercury;MCnc;Pt;Food;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Food;Mercury Food-mCnc;;ACTIVE;1.0l;2.34 +17255-1;Mercury;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Dialysis fluid;Mercury Dial fld-mCnc;;ACTIVE;1.0l;2.34 +17256-9;Mesoridazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mesoridazine [Mass/volume] in Urine;Mesoridazine Ur-mCnc;;ACTIVE;1.0l;2.73 +17257-7;Mesothelial cells;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Mesothelial cells [Presence] in Body fluid by Light microscopy;Mesothl Cell Fld Ql Micro;;ACTIVE;1.0l;2.73 +17258-5;Metandienone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metandienone [Mass/volume] in Serum or Plasma;Metandienone SerPl-mCnc;;ACTIVE;1.0l;2.34 +17259-3;Methadone.long acting metabolite;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methadone.long acting metabolite [Mass/volume] in Serum or Plasma;LA Methadone Metab SerPl-mCnc;;ACTIVE;1.0l;2.40 +17260-1;Methamphetamine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Methamphetamine [Mass/volume] in Serum or Plasma by Confirmatory method;Methamphet SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +17261-9;Methapyrilene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methapyrilene [Mass/volume] in Urine;Methapyrilene Ur-mCnc;;ACTIVE;1.0l;2.42 +17263-5;Methemalbumin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Methemalbumin [Presence] in Serum or Plasma;Methemalb SerPl Ql;;ACTIVE;1.0l;2.56 +17264-3;Methionine;PrThr;Pt;Urine;Ord;;CHEM;1;Methionine [Presence] in Urine;Methionine Ur Ql;;ACTIVE;1.0l;2.56 +17265-0;Methocarbamol;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methocarbamol [Units/volume] in Serum or Plasma;Methocarbamol SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +17266-8;Methotrexate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Urine;MTX Ur-mCnc;;ACTIVE;1.0l;2.42 +17267-6;Methoxychlor;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methoxychlor [Mass/volume] in Urine;Methoxychlor Ur-mCnc;;ACTIVE;1.0l;2.42 +17268-4;Methsuximide+Desmethylmethsuximide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Methsuximide+Normethsuximide [Mass/volume] in Serum or Plasma;Deprecated Methsuximide+Desmethyl SerPl;;DEPRECATED;1.0l;2.36 +1726-9;Adenosine monophosphate.cyclic;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adenosine monophosphate.cyclic [Mass/volume] in Serum or Plasma;cAMP SerPl-mCnc;;ACTIVE;1.0;2.73 +17269-2;Methyl isobutyl ketone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl isobutyl ketone [Mass/volume] in Urine;MIBK Ur-mCnc;;ACTIVE;1.0l;2.73 +172-7;Chloramphenicol;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Chloramphenicol [Susceptibility] by Minimum lethal concentration (MLC);Chloramphen Islt MLC;;ACTIVE;1.0;2.19 +17270-0;Methylacrylate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylacrylate [Mass/volume] in Serum or Plasma;Me-acrylate SerPl-mCnc;;ACTIVE;1.0l;2.73 +17271-8;1,1,1-Trichloroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated 1,1,1-Trichloroethane [Mass/volume] in Serum or Plasma;Deprecated 1,1,1TCE Bld-mCnc;;DEPRECATED;1.0l;2.36 +17272-6;Methylenedianiline;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methylenedianiline [Mass/volume] in Blood;4,4-MDA Bld-mCnc;;ACTIVE;1.0l;2.42 +17273-4;MethylePHEDrine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;MethylePHEDrine [Units/volume] in Urine;Me-ePHEDrine Ur-aCnc;;DISCOURAGED;1.0l;2.69 +17274-2;Methylergonovine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylergonovine [Mass/volume] in Serum or Plasma;Me-ergonovine SerPl-mCnc;;ACTIVE;1.0l;2.42 +17275-9;Methylfentanyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylfentanyl [Mass/volume] in Serum or Plasma;Me-fentanyl SerPl-mCnc;;ACTIVE;1.0l;2.42 +17276-7;2-Methylpentane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Methylpentane [Mass/volume] in Blood;2Me-pentane Bld-mCnc;;ACTIVE;1.0l;2.42 +1727-7;Adenosine monophosphate.cyclic;MRat;24H;Urine;Qn;;CHEM;1;Adenosine monophosphate.cyclic [Mass/time] in 24 hour Urine;cAMP 24h Ur-mRate;;ACTIVE;1.0;2.42 +17277-5;metOLazone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;metOLazone [Mass/volume] in Serum or Plasma;metOLazone SerPl-mCnc;;ACTIVE;1.0l;2.73 +17278-3;Miconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Miconazole [Mass/volume] in Serum or Plasma;Miconazole SerPl-mCnc;;ACTIVE;1.0l;2.40 +17279-1;Bacteria identified;Prid;Pt;Plr fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Pleural fluid by Aerobe culture;Bacteria Plr Aerobe Cult;;ACTIVE;1.0l;2.73 +17280-9;Plasmodium sp identified;Prid;Pt;Tiss;Nom;Thick film;MICRO;1;Plasmodium sp identified in Tissue by Thick film;Plasmodium Tiss Thick Film;;ACTIVE;1.0l;2.65 +17281-7;Microscopic observation;Prid;Pt;Sputum;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Sputum by KOH preparation;KOH Prep Spt;;ACTIVE;1.0l;2.58 +17282-5;Minoxidil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Minoxidil [Mass/volume] in Serum or Plasma;Minoxidil SerPl-mCnc;;ACTIVE;1.0l;2.73 +17283-3;Mirtazapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mirtazapine [Mass/volume] in Serum or Plasma;Mirtazapine SerPl-mCnc;;ACTIVE;1.0l;2.73 +17284-1;Mitochondria Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Mitochondria Ab [Presence] in Serum by Immunofluorescence;Mitochondria Ab Ser Ql IF;;ACTIVE;1.0l;2.73 +1728-5;Adenosine monophosphate.cyclic/Creatinine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Adenosine monophosphate.cyclic/Creatinine [Mass Ratio] in Serum or Plasma;cAMP/Creat SerPl;;ACTIVE;1.0;2.73 +17285-8;Mitochondria Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Mitochondria Ab [Units/volume] in Serum by Immunofluorescence;Mitochondria Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17286-6;Monocytes/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Synovial fluid by Manual count;Monocytes/leuk NFr Snv Manual;;ACTIVE;1.0l;2.73 +17287-4;Monocytes/100 leukocytes;NFr;Pt;Urine;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Urine by Manual count;Monocytes/leuk NFr Ur Manual;;ACTIVE;1.0l;2.73 +17288-2;Ganglioside GM1 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Ganglioside GM1 Ab [Presence] in Serum by Immunofluorescence;GM1 Gangl Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17289-0;Monosodium glutamate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Monosodium glutamate (MSG) IgE Ab [Units/volume] in Serum;MSG IgE Qn;;ACTIVE;1.0l;2.73 +17290-8;Morphine;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Morphine [Presence] in Serum or Plasma by Confirmatory method;Morphine SerPl Ql Cfm;;ACTIVE;1.0l;2.73 +17291-6;Morus alba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Mulberry tree IgE Ab [Units/volume] in Serum;Deprecated White mulberry IgE Qn;;DEPRECATED;1.0l;2.69 +17292-4;Mumps virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Mumps virus Ab [Units/volume] in Cerebral spinal fluid;MuV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +1729-3;Adenosine triphosphatase;CCnc;Pt;RBC;Qn;;CHEM;1;Adenosine triphosphatase [Enzymatic activity/volume] in Red Blood Cells;ATPase RBC-cCnc;;ACTIVE;1.0;2.44 +17293-2;Mumps virus Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus IgG+IgM Ab [Units/volume] in Serum;MuV IgG+IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +17294-0;Mushroom toxins;Prid;Pt;Urine;Nom;;MICRO;1;Mushroom toxins [Identifier] in Urine;Mushroom Tox Ur;;ACTIVE;1.0l;2.19 +17296-5;Mycobacterium tuberculosis complex rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium tuberculosis complex rRNA [Presence] in Specimen by Probe;M TB Cmplx rRNA Spec Ql Probe;;ACTIVE;1.0l;2.73 +17297-3;Mycobacterium tuberculosis rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Mycobacterium tuberculosum rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated M TB rRNA XXX Ql Prb;;DEPRECATED;1.0l;2.69 +17298-1;Mycobacterium tuberculosis rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Mycobacterium tuberculosis rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated M TB rRNA XXX Ql Prb;;DEPRECATED;1.0l;2.69 +17299-9;Mycoplasma fermentans Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma fermentans Ab [Presence] in Serum;M fermentans Ab Ser Ql;;ACTIVE;1.0l;2.56 +17300-5;Mycoplasma hominis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Mycoplasma hominis Ab [Titer] in Serum by Complement fixation;M hominis Ab Titr Ser CF;;ACTIVE;1.0l;2.70 +1730-1;Adenosine triphosphatase;CCnc;Pt;Semen;Qn;;CHEM;1;Adenosine triphosphatase [Enzymatic activity/volume] in Semen;ATPase Smn-cCnc;;ACTIVE;1.0;2.68 +17301-3;Mycoplasma hominis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma hominis Ab [Presence] in Serum;M hominis Ab Ser Ql;;ACTIVE;1.0l;2.56 +17302-1;Mycoplasma pneumoniae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma pneumoniae Ab [Presence] in Serum;M pneumo Ab Ser Ql;;ACTIVE;1.0l;2.73 +17303-9;Mycoplasma pneumoniae Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Units/volume] in Cerebral spinal fluid;M pneumo Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +17304-7;Mycoplasma pneumoniae Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgG+IgM Ab [Units/volume] in Serum;M pneumo IgG+IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +17305-4;Myelin Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Myelin IgA Ab [Presence] in Serum;Myelin IgA Ser Ql;;ACTIVE;1.0l;2.56 +17306-2;Myelin Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Myelin IgG Ab [Presence] in Serum;Myelin IgG Ser Ql;;ACTIVE;1.0l;2.73 +17307-0;Myelin Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Myelin IgM Ab [Presence] in Serum;Myelin IgM Ser Ql;;ACTIVE;1.0l;2.56 +17308-8;Myelin associated glycoprotein Ab;ACnc;Pt;Ser;Qn;IB;SERO;1;Myelin associated glycoprotein Ab [Units/volume] in Serum by Immunoblot;MAG Ab Ser IB-aCnc;;ACTIVE;1.0l;2.73 +17310-4;Myelin associated glycoprotein Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Myelin associated glycoprotein Ab [Presence] in Serum by Immunofluorescence;MAG Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17311-2;Myelin associated glycoprotein Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein IgA Ab [Units/volume] in Serum;MAG IgA Ser-aCnc;;ACTIVE;1.0l;2.69 +17312-0;Myelin associated glycoprotein Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein IgG Ab [Units/volume] in Serum;MAG IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +17313-8;Myelin associated glycoprotein Ab.IgG;ACnc;Pt;Ser;Qn;IF;SERO;1;Myelin associated glycoprotein IgG Ab [Units/volume] in Serum by Immunofluorescence;MAG IgG Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17314-6;Myelin associated glycoprotein Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Myelin associated glycoprotein IgM Ab [Units/volume] in Serum by Immunoassay;MAG IgM Ser IA-aCnc;;ACTIVE;1.0l;2.73 +17315-3;Myelin basic protein Ab;MCnc;Pt;Ser;Qn;;SERO;1;Myelin basic protein Ab [Mass/volume] in Serum;MBP Ab Ser-mCnc;;ACTIVE;1.0l;2.42 +17316-1;Myeloperoxidase Ab;PrThr;Pt;Ser;Ord;;SERO;1;Myeloperoxidase Ab [Presence] in Serum;Myeloperoxidase Ab Ser Ql;;ACTIVE;1.0l;2.73 +17317-9;N-acetylprocainamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;N-acetylprocainamide [Mass/volume] in Urine;NAPA Ur-mCnc;;ACTIVE;1.0l;2.42 +17318-7;Nalbuphine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nalbuphine [Mass/volume] in Serum or Plasma;Nalbuphine SerPl-mCnc;;ACTIVE;1.0l;2.73 +1731-9;Adenylate kinase;CCnc;Pt;Ser;Qn;;CHEM;1;Adenylate kinase [Enzymatic activity/volume] in Serum;Adenylate kinase Ser-cCnc;;ACTIVE;1.0;2.68 +17319-5;Nalidixate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nalidixate [Mass/volume] in Serum or Plasma;Nalidixate SerPl-mCnc;;ACTIVE;1.0l;2.42 +17320-3;Nefazodone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nefazodone [Mass/volume] in Urine;Nefazodone Ur-mCnc;;ACTIVE;1.0l;2.42 +17321-1;Neisseria meningitidis serogroups A+Y Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Neisseria meningitidis serogroups A+Y Ag [Presence] in Urine;N men sg A+Y Ag Ur Ql;;ACTIVE;1.0l;2.64 +17322-9;Neisseria meningitidis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Neisseria meningitidis Ab [Presence] in Serum;N men Ab Ser Ql;;ACTIVE;1.0l;2.73 +17323-7;Neisseria meningitidis Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Neisseria meningitidis Ag [Presence] in Urine;N men Ag Ur Ql;;ACTIVE;1.0l;2.56 +17324-5;Neisseria meningitidis Ag;ACnc;Pt;CSF;Qn;LA;MICRO;1;Neisseria meningitidis Ag [Units/volume] in Cerebral spinal fluid by Latex agglutination;N men Ag CSF LA-aCnc;;ACTIVE;1.0l;2.69 +17325-2;Neisseria meningitidis serogroups C+w135 Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Neisseria meningitidis serogroups C+w135 Ag [Presence] in Urine;N men sg C+W135 Ag Ur Ql;;ACTIVE;1.0l;2.64 +17326-0;Neisseria meningitidis serogroup A Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;N men sg A Ag CSF Ql IF;;ACTIVE;1.0l;2.64 +1732-7;Adenylosuccinate lyase;CCnc;Pt;Ser;Qn;;CHEM;1;Adenylosuccinate lyase [Enzymatic activity/volume] in Serum;ADSL Ser-cCnc;;ACTIVE;1.0;2.68 +17327-8;Neisseria meningitidis serogroup B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup B Ab [Units/volume] in Serum;N men sg B Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +17328-6;Neisseria meningitidis serogroup B Ag;PrThr;Pt;Urine;Ord;LA;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Urine by Latex agglutination;N men sg B Ag Ur Ql LA;;ACTIVE;1.0l;2.64 +17329-4;Neisseria meningitidis serogroup C Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;N men sg C Ag CSF Ql IF;;ACTIVE;1.0l;2.64 +17330-2;Neisseria meningitidis serogroup Y Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroup Y Ag [Presence] in Cerebral spinal fluid;N men sg Y Ag CSF Ql;;ACTIVE;1.0l;2.64 +17331-0;Neisseria meningitidis polyvalent Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis polyvalent Ab [Units/volume] in Serum;N men Polyval Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +17332-8;Neisseria meningitidis polyvalent Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis polyvalent Ag [Presence] in Cerebral spinal fluid;N men Polyval Ag CSF Ql;;ACTIVE;1.0l;2.56 +17333-6;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;Ser/Plas;Ord;LA;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Serum or Plasma by Latex agglutination;N men sg W135 Ag SerPl Ql LA;;ACTIVE;1.0l;2.64 +17334-4;Neopterin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Neopterin/Creatinine [Mass Ratio] in Urine;Neopterin/Creat Ur;;ACTIVE;1.0l;2.73 +1733-5;Adipate;MCnc;Pt;Urine;Qn;;CHEM;1;Adipate [Mass/volume] in Urine;Adipate Ur-mCnc;;ACTIVE;1.0;2.73 +17335-1;Neostigmine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Neostigmine [Mass/volume] in Serum or Plasma;Neostigmine SerPl-mCnc;;ACTIVE;1.0l;2.34 +17336-9;Neuronal Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Neuronal Ab [Presence] in Serum by Immunofluorescence;Neuronal Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17337-7;Neuronal Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Neuronal Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Neuronal Ab CSF Ql IF;;ACTIVE;1.0l;2.56 +17338-5;Neuronal Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Neuronal Ab [Units/volume] in Serum by Immunofluorescence;Neuronal Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17339-3;Neuronal Ab;ACnc;Pt;CSF;Qn;IF;SERO;1;Neuronal Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;Neuronal Ab CSF IF-aCnc;;ACTIVE;1.0l;2.69 +17340-1;Neuronal Ab.IgG;PrThr;Pt;Body fld;Ord;IA;SERO;1;Neuronal IgG Ab [Presence] in Body fluid by Immunoassay;Neuronal IgG Fld Ql IA;;ACTIVE;1.0l;2.56 +17341-9;Neuronal nuclear Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Neuronal nuclear Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Hu Ab CSF Ql IF;;ACTIVE;1.0l;2.73 +17342-7;Neuronal nuclear type 2 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Neuronal nuclear type 2 Ab [Units/volume] in Serum;Hu2 Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +1734-3;Aldosterone renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Aldosterone renal clearance in 24 hour Urine and Serum or Plasma;Aldost Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +17343-5;Neuronal nuclear type 2 Ab;PrThr;Pt;CSF;Ord;;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Cerebral spinal fluid;Hu2 Ab CSF Ql;;ACTIVE;1.0l;2.73 +17344-3;Neuronal nuclear type 2 Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear type 2 Ab [Units/volume] in Serum by Immunofluorescence;Hu2 Ab Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17345-0;Neutrophil Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Neutrophil Ab [Units/volume] in Serum;Deprecated Neutrophil Ab Ser-aCnc;;DEPRECATED;1.0l;2.69 +17346-8;Neutrophil Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil Ab [Presence] in Serum by Immunofluorescence;Neutrophil Ab Ser Ql IF;;ACTIVE;1.0l;2.73 +17347-6;Neutrophil Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Neutrophil Ab [Units/volume] in Serum by Immunofluorescence;Neutrophil Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17348-4;Neutrophil Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil IgA Ab [Units/volume] in Serum;Neutrophil IgA Ser-aCnc;;ACTIVE;1.0l;2.73 +17349-2;Neutrophil Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil IgG Ab [Units/volume] in Serum;Neutrophil IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +173-5;Chloramphenicol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Chloramphenicol [Susceptibility] by Minimum inhibitory concentration (MIC);Chloramphen Islt MIC;;ACTIVE;1.0;2.73 +1735-0;Alanine;MCnc;Pt;CSF;Qn;;CHEM;1;Alanine [Mass/volume] in Cerebral spinal fluid;Alanine CSF-mCnc;;DISCOURAGED;1.0;2.44 +17350-0;Neutrophil Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil IgM Ab [Units/volume] in Serum;Neutrophil IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +17351-8;Neutrophil cytoplasmic Ab;PrThr;Pt;Ser;Ord;;SERO;1;Neutrophil cytoplasmic Ab [Presence] in Serum;ANCA Ab Ser Ql;;ACTIVE;1.0l;2.73 +17352-6;Neutrophil cytoplasmic Ab;Imp;Pt;Ser;Nom;;SERO;1;Neutrophil cytoplasmic Ab [Interpretation] in Serum;ANCA Ab Ser-Imp;;ACTIVE;1.0l;2.73 +17353-4;Neutrophil cytoplasmic Ab.classic;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil cytoplasmic Ab.classic [Presence] in Serum by Immunofluorescence;c-ANCA Ser Ql IF;;ACTIVE;1.0l;2.73 +17354-2;Neutrophil cytoplasmic Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Neutrophil cytoplasmic IgA Ab [Presence] in Serum;ANCA IgA Ser Ql;;ACTIVE;1.0l;2.56 +17355-9;Neutrophil cytoplasmic Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Neutrophil cytoplasmic IgG Ab [Presence] in Serum;ANCA IgG Ser Ql;;ACTIVE;1.0l;2.73 +17356-7;Neutrophil cytoplasmic Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Neutrophil cytoplasmic IgM Ab [Presence] in Serum;ANCA IgM Ser Ql;;ACTIVE;1.0l;2.56 +17357-5;Neutrophil cytoplasmic Ab.perinuclear;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil cytoplasmic Ab.perinuclear [Presence] in Serum by Immunofluorescence;p-ANCA Ser Ql IF;;ACTIVE;1.0l;2.73 +17358-3;Neutrophil cytoplasmic Ab.atypical;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil Cytoplasmic Ab atypical [Units/volume] in Serum;Atyp ANCA Ser-aCnc;;ACTIVE;1.0l;2.73 +17359-1;Neutrophils;NCnc;Pt;Semen;Qn;Manual count;FERT;1;Neutrophils [#/volume] in Semen by Manual count;Neutrophils # Smn Manual;;ACTIVE;1.0l;2.42 +17360-9;Heptane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Heptane [Mass/volume] in Blood;Heptane Bld-mCnc;;ACTIVE;1.0l;2.73 +17361-7;Hexane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Hexane [Mass/volume] in Blood;Deprecated Hexane Bld-mCnc;;DEPRECATED;1.0l;2.36 +17362-5;Nicotinamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nicotinamide [Presence] in Urine;Nicotinamide Ur Ql;;ACTIVE;1.0l;2.56 +17363-3;Nitrazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Nitrazepam [Mass/volume] in Serum or Plasma by Confirmatory method;Nitrazepam SerPl Cfm-mCnc;;ACTIVE;1.0l;2.42 +17364-1;Nitrophenol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nitrophenol [Presence] in Urine;Nitrophenol Ur Ql;;ACTIVE;1.0l;2.56 +17365-8;Nitroprusside;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitroprusside [Mass/volume] in Serum or Plasma;Nitroprusside SerPl-mCnc;;ACTIVE;1.0l;2.42 +17366-6;Nizatidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nizatidine [Mass/volume] in Serum or Plasma;Nizatidine SerPl-mCnc;;ACTIVE;1.0l;2.42 +17367-4;Nomifensine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nomifensine [Mass/volume] in Serum or Plasma;Nomifensine SerPl-mCnc;;ACTIVE;1.0l;2.42 +1736-8;Alanine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alanine [Presence] in Serum or Plasma;Alanine SerPl Ql;;ACTIVE;1.0;2.73 +17368-2;Norepinephrine^standing;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --standing;Norepineph stand Plas-mCnc;;ACTIVE;1.0l;2.42 +17369-0;Norepinephrine^2nd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Urine --2nd specimen post XXX challenge;Norepineph sp2 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +17370-8;Norepinephrine^3rd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Urine --3rd specimen post XXX challenge;Norepineph sp3 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +17371-6;Norepinephrine^4th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Urine --4th specimen post XXX challenge;Norepineph sp4 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +17372-4;Norepinephrine^5th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Urine --5th specimen post XXX challenge;Norepineph sp5 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +17373-2;Norepinephrine^6th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Urine --6th specimen post XXX challenge;Norepineph sp6 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +17374-0;Norepinephrine^7th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Urine --7th specimen post XXX challenge;Norepineph sp7 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +17375-7;Norflunitrazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Norflunitrazepam [Mass/volume] in Blood;Norflunitrazepam Bld-mCnc;;ACTIVE;1.0l;2.73 +1737-6;Alanine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alanine [Mass/volume] in Serum or Plasma;Alanine SerPl-mCnc;;DISCOURAGED;1.0;2.73 +17376-5;Norpropoxyphene;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Norpropoxyphene [Presence] in Urine by Confirmatory method;Norpropoxyph Ur Ql Cfm;;ACTIVE;1.0l;2.73 +17377-3;Norpropoxyphene;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norpropoxyphene [Mass/volume] in Urine by Confirmatory method;Norpropoxyph Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +17378-1;Novobiocin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Novobiocin [Mass/volume] in Serum or Plasma;Novobiocin SerPl-mCnc;;ACTIVE;1.0l;2.42 +17379-9;Propanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Propanol [Mass/volume] in Blood;Propanol Bld-mCnc;;ACTIVE;1.0l;2.73 +17380-7;Nuclear Ab.histone reactive;PrThr;Pt;Ser;Ord;;SERO;1;Nuclear Ab.histone reactive [Presence] in Serum;ANA Histone Reactive Ser Ql;;ACTIVE;1.0l;2.56 +17381-5;Uroporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Uroporphyrin [Mass/time] in 24 hour Stool;Uropor 24h Stl-mRate;;ACTIVE;1.0l;2.73 +17382-3;Octadecanoate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octadecanoate (C18:0) [Mass/volume] in Serum or Plasma;Octadecanoate SerPl-mCnc;;DISCOURAGED;1.0l;2.44 +1738-4;Alanine;MCnc;Pt;Urine;Qn;;CHEM;1;Alanine [Mass/volume] in Urine;Alanine Ur-mCnc;;DISCOURAGED;1.0;2.73 +17384-9;Opiates;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Opiates [Mass/volume] in Urine by Confirmatory method;Opiates Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +17385-6;Organic acids;ACnc;Pt;Urine;Qn;;CHEM;1;Organic acids [Units/volume] in Urine;Organic Acids Ur-aCnc;;DISCOURAGED;1.0l;2.69 +17386-4;Organic acids;ACnc;Pt;Bld;Qn;;CHEM;1;Organic acids [Units/volume] in Blood;Organic Acids Bld-aCnc;;DISCOURAGED;1.0l;2.69 +17387-2;Organic acids;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Organic acids [Units/volume] in Serum or Plasma;Organic Acids SerPl-aCnc;;DISCOURAGED;1.0l;2.73 +17388-0;Organochlorine pesticides;Type;Pt;Urine;Nom;;DRUG/TOX;1;Organochlorine pesticides [Type] in Urine;OC Pesticides Ur;;ACTIVE;1.0l;2.19 +17389-8;Ornithine;PrThr;Pt;Urine;Ord;;CHEM;1;Ornithine [Presence] in Urine;Ornithine Ur Ql;;ACTIVE;1.0l;2.56 +17390-6;Orphenadrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Orphenadrine [Mass/volume] in Urine;Orphenadrine Ur-mCnc;;ACTIVE;1.0l;2.42 +17391-4;Orthocresol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Orthocresol [Mass/volume] in Blood;Orthocresol Bld-mCnc;;ACTIVE;1.0l;2.42 +1739-2;Alanine;MRat;24H;Urine;Qn;;CHEM;1;Alanine [Mass/time] in 24 hour Urine;Alanine 24h Ur-mRate;;DISCOURAGED;1.0;2.73 +17392-2;Osmium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Osmium [Mass/volume] in Urine;Osmium Ur-mCnc;;ACTIVE;1.0l;2.34 +17393-0;Ovary Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ovary Ab [Presence] in Serum;Ovary Ab Ser Ql;;ACTIVE;1.0l;2.73 +17394-8;Oxychlordane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxychlordane [Mass/volume] in Urine;Oxychlordane Ur-mCnc;;ACTIVE;1.0l;2.42 +17395-5;oxyMORphone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;oxyMORphone [Mass/volume] in Urine by Confirmatory method;oxyMORphone Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +17396-3;Oxytetracycline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxytetracycline [Mass/volume] in Serum or Plasma;Oxytetracycline SerPl-mCnc;;ACTIVE;1.0l;2.42 +17397-1;Oxytriphylline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxytriphylline [Mass/volume] in Serum or Plasma;Oxytriphylline SerPl-mCnc;;ACTIVE;1.0l;2.34 +17398-9;Human papilloma virus 11 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 11 Ag [Presence] in Specimen;HPV11 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17399-7;Human papilloma virus 16 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 16 Ag [Presence] in Specimen;HPV16 Ag Spec Ql;;ACTIVE;1.0l;2.73 +17-4;Amoxicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Amoxicillin [Susceptibility] by Disk diffusion (KB);Amoxicillin Islt KB;;ACTIVE;1.0;2.73 +1740-0;Alanine aminopeptidase;MCnc;Pt;Ser;Qn;;CHEM;1;Alanine aminopeptidase [Mass/volume] in Serum;AAP Ser-mCnc;;DISCOURAGED;1.0;2.44 +17400-3;Human papilloma virus 16+18 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 16+18 Ag [Presence] in Specimen;HPV16+18 Ag Spec Ql;;ACTIVE;1.0l;2.73 +17401-1;Human papilloma virus 18 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 18 Ag [Presence] in Specimen;HPV18 Ag Spec Ql;;ACTIVE;1.0l;2.73 +17402-9;Human papilloma virus 31 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 31 Ag [Presence] in Specimen;HPV31 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17403-7;Human papilloma virus 31+33+35 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 31+33+35 Ag [Presence] in Specimen;HPV31+33+35 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17404-5;Human papilloma virus 33 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 33 Ag [Presence] in Specimen;HPV33 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17405-2;Human papilloma virus 42 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 42 Ag [Presence] in Specimen;HPV42 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17406-0;Human papilloma virus 43 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 43 Ag [Presence] in Specimen;HPV43 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17407-8;Human papilloma virus 44 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 44 Ag [Presence] in Specimen;HPV44 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17408-6;Human papilloma virus 45 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 45 Ag [Presence] in Specimen;HPV45 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17409-4;Human papilloma virus 5 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 5 Ag [Presence] in Specimen;HPV5 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17410-2;Human papilloma virus 51 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 51 Ag [Presence] in Specimen;HPV51 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17411-0;Human papilloma virus 6 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 6 Ag [Presence] in Specimen;HPV6 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17412-8;Human papilloma virus 6+11 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 6+11 Ag [Presence] in Specimen;HPV6+11 Ag Spec Ql;;ACTIVE;1.0l;2.73 +17413-6;Papova virus SV40 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Papova virus SV 40 Ab [Units/volume] in Serum;SV40 Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +17414-4;Parainfluenza virus 1+2+3 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Parainfluenza virus 1+2+3 Ag [Presence] in Specimen;HPIV1+2+3 Ag Spec Ql;;ACTIVE;1.0l;2.69 +17415-1;Parainfluenza virus A Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus A Ab [Units/volume] in Serum;HPIVA Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +17416-9;Parakeet droppings Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parakeet droppings Ab [Units/volume] in Serum;Parakeet Drop Ab Qn;;ACTIVE;1.0l;2.73 +17417-7;Parakeet droppings Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parakeet droppings IgG Ab [Units/volume] in Serum;Parakeet Drop IgG Qn;;ACTIVE;1.0l;2.69 +1741-8;Alanine aminotransferase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Amniotic fluid;ALT Amn-cCnc;;ACTIVE;1.0;2.68 +17418-5;Parakeet serum Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parakeet serum Ab [Units/volume] in Serum;Parakeet Serum Ab Qn;;ACTIVE;1.0l;2.73 +17419-3;Parathion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Parathion [Mass/volume] in Urine;Parathion Ur-mCnc;;ACTIVE;1.0l;2.73 +17420-1;Parrot droppings Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parrot droppings Ab [Units/volume] in Serum;Parrot Drop Ab Qn;;ACTIVE;1.0l;2.69 +17421-9;Parrot serum Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parrot serum Ab [Units/volume] in Serum;Parrot Serum Ab Qn;;ACTIVE;1.0l;2.69 +17422-7;Parvovirus B19 Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgG+IgM Ab [Units/volume] in Serum;B19V IgG+IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +17423-5;Parvovirus B19 Ab.IgM;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Parvovirus B19 IgM Ab [Presence] in Serum;Deprecated B19V IgM Ser Ql;;DEPRECATED;1.0l;2.36 +17424-3;1,4-Dichlorobenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,4-Dichlorobenzene [Mass/volume] in Blood;1,4DCB Bld-mCnc;;ACTIVE;1.0l;2.73 +1742-6;Alanine aminotransferase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma;ALT SerPl-cCnc;;ACTIVE;1.0;2.73 +17426-8;Penicillium roqueforti Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium roqueforti IgE Ab [Units/volume] in Serum;P roqueforte IgE Qn;;ACTIVE;1.0l;2.42 +17427-6;Penicillium sp Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium sp Ab [Units/volume] in Serum;Penicillium Ab Qn;;ACTIVE;1.0l;2.69 +17428-4;Pentacarboxylporphyrins;MRat;24H;Stool;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/time] in 24 hour Stool;Penta-CP 24h Stl-mRate;;ACTIVE;1.0l;2.42 +17429-2;Pentachlorophenol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pentachlorophenol [Mass/volume] in Blood;Pentachlorophen Bld-mCnc;;ACTIVE;1.0l;2.73 +174-3;Chloramphenicol;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Chloramphenicol [Susceptibility] by Disk diffusion (KB);Chloramphen Islt KB;;ACTIVE;1.0;2.73 +17430-0;Pentane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pentane [Mass/volume] in Blood;Pentane Bld-mCnc;;ACTIVE;1.0l;2.73 +17431-8;PENTobarbital;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;PENTobarbital [Mass/volume] in Gastric fluid;Pentobarb Gast-mCnc;;ACTIVE;1.0l;2.42 +17432-6;Tetrachloroethylene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tetrachloroethylene [Mass/volume] in Serum or Plasma;TTCE SerPl-mCnc;;ACTIVE;1.0l;2.42 +17433-4;pH;LsCnc;Pt;XXX;Qn;;CHEM;1;pH of Specimen;pH Spec;;ACTIVE;1.0l;2.73 +1743-4;Alanine aminotransferase;CCnc;Pt;Ser/Plas;Qn;With P-5'-P;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma by With P-5'-P;ALT SerPl w P-5'-P-cCnc;;ACTIVE;1.0;2.73 +17434-2;Phenazopyridine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenazopyridine [Mass/volume] in Serum or Plasma;Phenazopyridine SerPl-mCnc;;ACTIVE;1.0l;2.73 +17435-9;Pheniramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pheniramine [Mass/volume] in Urine;Pheniramine Ur-mCnc;;ACTIVE;1.0l;2.42 +17436-7;PHENobarbital;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;PHENobarbital [Mass/volume] in Gastric fluid;Phenobarb Gast-mCnc;;ACTIVE;1.0l;2.42 +17437-5;Phenolphthalein;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenolphthalein [Mass/volume] in Urine;Phenolphthalein Ur-mCnc;;ACTIVE;1.0l;2.73 +17438-3;Phenolphthalein;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phenolphthalein [Mass/volume] in Blood;Phenolphthalein Bld-mCnc;;ACTIVE;1.0l;2.73 +17439-1;Phenols;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phenols [Mass/volume] in Blood;Phenols Bld-mCnc;;ACTIVE;1.0l;2.42 +17440-9;Phenothiazines;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenothiazines [Units/volume] in Serum or Plasma;Phenothiaz SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +17441-7;Phenothiazines;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenothiazines [Units/volume] in Urine;Phenothiaz Ur-aCnc;;DISCOURAGED;1.0l;2.69 +1744-2;Alanine aminotransferase;CCnc;Pt;Ser/Plas;Qn;No addition of P-5'-P;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma by No addition of P-5'-P;ALT SerPl w/o P-5'-P-cCnc;;ACTIVE;1.0;2.73 +17442-5;Phenylephrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenylephrine [Mass/volume] in Serum or Plasma;Phenylephrine SerPl-mCnc;;ACTIVE;1.0l;2.73 +17443-3;Phenylpropanolamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenylpropanolamine [Mass/volume] in Urine;PPA Ur-mCnc;;ACTIVE;1.0l;2.73 +17444-1;Phenytoin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenytoin [Mass/volume] in Urine;Phenytoin Ur-mCnc;;ACTIVE;1.0l;2.73 +17445-8;Phoma herbarum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phoma herbarum IgG Ab [Units/volume] in Serum;P herbarum IgG Qn;;ACTIVE;1.0l;2.69 +17446-6;Phoma sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phoma sp IgE Ab [Units/volume] in Serum;Phoma IgE Qn;;ACTIVE;1.0l;2.73 +17447-4;Phosphate;PrThr;Pt;Stool;Ord;;CHEM;1;Phosphate [Presence] in Stool;Phosphate Stl Ql;;ACTIVE;1.0l;2.56 +17448-2;Phosphatidylethanolamine Ab.IgA;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylethanolamine IgA Ab [Presence] in Serum;PE IgA Ser Ql;;ACTIVE;1.0l;2.73 +17449-0;Phosphatidylethanolamine Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylethanolamine IgG Ab [Presence] in Serum;PE IgG Ser Ql;;ACTIVE;1.0l;2.73 +17450-8;Phosphatidylethanolamine Ab.IgM;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylethanolamine IgM Ab [Presence] in Serum;PE IgM Ser Ql;;ACTIVE;1.0l;2.73 +17451-6;Phosphatidylglycerol Ab.IgA;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylglycerol IgA Ab [Presence] in Serum;PG IgA Ser Ql;;ACTIVE;1.0l;2.56 +17452-4;Phosphatidylglycerol Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylglycerol IgG Ab [Presence] in Serum;PG IgG Ser Ql;;ACTIVE;1.0l;2.56 +17453-2;Phosphatidylglycerol Ab.IgM;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylglycerol IgM Ab [Presence] in Serum;PG IgM Ser Ql;;ACTIVE;1.0l;2.56 +17454-0;Phosphatidylinositol Ab.IgA;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylinositol IgA Ab [Presence] in Serum;PI IgA Ser Ql;;ACTIVE;1.0l;2.73 +17455-7;Phosphatidylinositol Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylinositol IgG Ab [Presence] in Serum;PI IgG Ser Ql;;ACTIVE;1.0l;2.56 +17456-5;Phosphatidylinositol Ab.IgM;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylinositol IgM Ab [Presence] in Serum;PI IgM Ser Ql;;ACTIVE;1.0l;2.73 +17457-3;Phosphoethanolamine;PrThr;Pt;Urine;Ord;;CHEM;1;Phosphoethanolamine [Presence] in Urine;PETN Ur Ql;;ACTIVE;1.0l;2.56 +17458-1;Phosphoethanolamine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Phosphoethanolamine [Presence] in Serum or Plasma;PETN SerPl Ql;;ACTIVE;1.0l;2.56 +1745-9;Albumin;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Albumin [Mass/volume] in Amniotic fluid;Albumin Amn-mCnc;;ACTIVE;1.0;2.34 +17459-9;Phospholipid Ab.IgA;ACnc;Pt;Ser;Qn;IA;COAG;1;Phospholipid IgA Ab [Units/volume] in Serum by Immunoassay;Phospholipid IgA Ser IA-aCnc;;ACTIVE;1.0l;2.73 +17460-7;Phosphoserine;PrThr;Pt;Urine;Ord;;CHEM;1;Phosphoserine [Presence] in Urine;Phosphoserine Ur Ql;;ACTIVE;1.0l;2.56 +17461-5;Phosphoserine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Phosphoserine [Presence] in Serum or Plasma;Phosphoserine SerPl Ql;;ACTIVE;1.0l;2.73 +17462-3;Picloram;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Picloram [Mass/volume] in Urine;Picloram Ur-mCnc;;ACTIVE;1.0l;2.73 +17463-1;Pigeon droppings Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon droppings Ab [Units/volume] in Serum;Pigeon Drop Ab Qn;;ACTIVE;1.0l;2.69 +17464-9;Pigeon feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon feather IgE Ab [Presence] in Serum;Pigeon Feather IgE Ql;;ACTIVE;1.0l;2.56 +17465-6;Pigeon serum Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon serum IgE Ab [Presence] in Serum;Pigeon Serum IgE Ql;;ACTIVE;1.0l;2.56 +17466-4;Plasminogen activator inhibitor 1 Ag;ACnc;Pt;PPP;Qn;EIA;COAG;1;Deprecated Plasminogen activator inhibitor 1 Ag [Units/volume] in Platelet poor plasma by Immunologic method;Deprecated PAI1 Ag PPP EIA-aCnc;;DEPRECATED;1.0l;2.69 +1746-7;Albumin;MCnc;Pt;CSF;Qn;;CHEM;1;Albumin [Mass/volume] in Cerebral spinal fluid;Albumin CSF-mCnc;;ACTIVE;1.0;2.73 +17467-2;Plasminogen activator inhibitor 2 Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator inhibitor 2 Ag [Units/volume] in Platelet poor plasma by Immunoassay;PAI2 Ag PPP IA-aCnc;;ACTIVE;1.0l;2.69 +17468-0;Plutonium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Plutonium [Mass/volume] in Urine;Plutonium Ur-mCnc;;ACTIVE;1.0l;2.34 +17469-8;PM-1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;PM-1 Ab [Units/volume] in Serum;PM1 Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +17470-6;PM-1 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;PM-1 Ab [Presence] in Serum by Immunofluorescence;PM1 Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17471-4;PM-1 Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;PM-1 Ab [Units/volume] in Serum by Immunofluorescence;PM1 Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17472-2;Polybrominated biphenyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Polybrominated biphenyl [Mass/volume] in Serum or Plasma;PBB SerPl-mCnc;;ACTIVE;1.0l;2.68 +17473-0;Polymyxin B;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Polymyxin B [Mass/volume] in Serum or Plasma;Polymyxin B SerPl-mCnc;;ACTIVE;1.0l;2.42 +17474-8;Porphobilinogen;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Porphobilinogen [Moles/volume] in Serum or Plasma;PBG SerPl-sCnc;;ACTIVE;1.0l;2.42 +1747-5;Albumin;MCnc;Pt;Body fld;Qn;;CHEM;1;Albumin [Mass/volume] in Body fluid;Albumin Fld-mCnc;;ACTIVE;1.0;2.73 +17475-5;Porphyrins;ACnc;Pt;Urine;Qn;;CHEM;1;Porphyrins [Units/volume] in Urine;Porphyrins Ur-aCnc;;DISCOURAGED;1.0l;2.69 +17476-3;Porphyrins;ACnc;Pt;RBC;Qn;;CHEM;1;Porphyrins [Units/volume] in Red Blood Cells;Porphyrins RBC-aCnc;;DISCOURAGED;1.0l;2.69 +17477-1;Porphyrins;ACnc;Pt;Stool;Qn;;CHEM;1;Porphyrins [Units/volume] in Stool;Porphyrins Stl-aCnc;;DISCOURAGED;1.0l;2.69 +17478-9;Porphyrins;PrThr;Pt;Body fld;Ord;;CHEM;1;Porphyrins [Presence] in Body fluid;Porphyrins Fld Ql;;ACTIVE;1.0l;2.56 +17479-7;Prazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Prazepam [Mass/volume] in Urine by Confirmatory method;Prazepam Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +17480-5;Pregnenolone;MCnc;Pt;Urine;Qn;;CHEM;1;Pregnenolone [Mass/volume] in Urine;Preg Ur-mCnc;;ACTIVE;1.0l;2.42 +17481-3;Probenecid;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Probenecid [Units/volume] in Urine;Probenecid Ur-aCnc;;DISCOURAGED;1.0l;2.69 +17482-1;Procainamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Procainamide [Mass/volume] in Urine;Procainamide Ur-mCnc;;ACTIVE;1.0l;2.42 +1748-3;Albumin;MCnc;Pt;Plr fld;Qn;;CHEM;1;Albumin [Mass/volume] in Pleural fluid;Albumin Plr-mCnc;;ACTIVE;1.0;2.73 +17483-9;Progesterone;MCnc;Pt;Urine;Qn;;CHEM;1;Progesterone [Mass/volume] in Urine;Progest Ur-mCnc;;ACTIVE;1.0l;2.73 +17484-7;Progesterone^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Progest 1.5h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17485-4;Progesterone^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Progest 15M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17486-2;Progesterone^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Progest 2h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17487-0;Progesterone^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Progest 45M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17488-8;Progesterone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Progest sp7 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17489-6;Progesterone^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Progest sp8 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17490-4;Progesterone^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Progest sp9 p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +1749-1;Albumin;MCnc;Pt;Periton fld;Qn;;CHEM;1;Albumin [Mass/volume] in Peritoneal fluid;Albumin Prt-mCnc;;ACTIVE;1.0;2.73 +17491-2;Proinsulin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Mass/volume] in Serum or Plasma --baseline;Proinsulin BS SerPl-mCnc;;ACTIVE;1.0l;2.42 +17492-0;Proline;PrThr;Pt;Urine;Ord;;CHEM;1;Proline [Presence] in Urine;Proline Ur Ql;;ACTIVE;1.0l;2.56 +17493-8;Prostaglandin E;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostaglandin E [Mass/volume] in Serum or Plasma;Prostaglandin E SerPl-mCnc;;ACTIVE;1.0l;2.56 +17494-6;Prostaglandin F2 alpha;MCnc;Pt;Urine;Qn;;CHEM;1;Prostaglandin F2 alpha [Mass/volume] in Urine;Prostaglandin F2A Ur-mCnc;;ACTIVE;1.0l;2.42 +17495-3;Prostaglandins;MCnc;Pt;Urine;Qn;;CHEM;1;Prostaglandins [Mass/volume] in Urine;Prostaglandins Ur-mCnc;;ACTIVE;1.0l;2.42 +17496-1;Alpha 1 globulin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin [Mass/volume] in Body fluid by Electrophoresis;Alpha1 Glob Fld Elph-mCnc;;ACTIVE;1.0l;2.73 +17497-9;Alpha 2 globulin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin [Mass/volume] in Body fluid by Electrophoresis;Alpha2 Glob Fld Elph-mCnc;;ACTIVE;1.0l;2.73 +17498-7;Beta globulin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta globulin [Mass/volume] in Body fluid by Electrophoresis;B-Globulin Fld Elph-mCnc;;ACTIVE;1.0l;2.73 +17499-5;Gamma globulin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Gamma globulin [Mass/volume] in Body fluid by Electrophoresis;Gamma glob Fld Elph-mCnc;;ACTIVE;1.0l;2.73 +175-0;Chloramphenicol;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Chloramphenicol [Susceptibility] by Serum bactericidal titer;Chloramphen Titr SBT;;ACTIVE;1.0;2.32 +17501-8;Protoporphyrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Protoporphyrin [Mass/volume] in Serum or Plasma;Protopor SerPl-mCnc;;ACTIVE;1.0l;2.73 +17502-6;Pseudomonas aeruginosa Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Pseudomonas aeruginosa Ab [Units/volume] in Serum;P aeruginosa Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +17504-2;Psilocybin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Psilocybin [Presence] in Urine;Psilocybin Ur Ql;;ACTIVE;1.0l;2.56 +17505-9;Psilocybin/Psilocin;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Psilocybin/Psilocin [Mass Ratio] in Serum or Plasma;Psilocybin/Psilocin SerPl;;ACTIVE;1.0l;2.73 +17506-7;Quinacrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Quinacrine [Mass/volume] in Serum or Plasma;Quinacrine SerPl-mCnc;;ACTIVE;1.0l;2.42 +17507-5;quiNIDine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;quiNIDine [Mass/volume] in Urine;quiNIDine Ur-mCnc;;ACTIVE;1.0l;2.73 +17508-3;quiNINE;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;quiNINE [Units/volume] in Urine;quiNINE Ur-aCnc;;DISCOURAGED;1.0l;2.69 +1750-9;Albumin;MCnc;Pt;Semen;Qn;;CHEM;1;Albumin [Mass/volume] in Semen;Albumin Smn-mCnc;;ACTIVE;1.0;2.34 +17509-1;Ragweed marsh Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Marsh Ragweed IgE Ab [Units/volume] in Serum;Marsh Ragweed IgE Qn;;ACTIVE;1.0l;2.42 +17510-9;Raisin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Raisin IgE Ab [Units/volume] in Serum;Raisin IgE Qn;;ACTIVE;1.0l;2.42 +17511-7;Red dye Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red dye IgE Ab [Units/volume] in Serum;Red Dye IgE Qn;;ACTIVE;1.0l;2.73 +17512-5;Redfish Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Redfish IgE Ab [Units/volume] in Serum;Redfish IgE Qn;;ACTIVE;1.0l;2.42 +17513-3;Renin^5H post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --5 hours post XXX challenge;Renin 5h p chal Plas-cCnc;;ACTIVE;1.0l;2.42 +17514-1;Renin^9th specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --9th specimen post XXX challenge;Renin sp9 p chal Plas-cCnc;;ACTIVE;1.0l;2.42 +17515-8;Renin^baseline;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --baseline;Renin BS Plas-cCnc;;ACTIVE;1.0l;2.73 +17516-6;Renin^supine;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --supine;Renin sup Plas-cCnc;;ACTIVE;1.0l;2.68 +1751-7;Albumin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Albumin [Mass/volume] in Serum or Plasma;Albumin SerPl-mCnc;;ACTIVE;1.0;2.73 +17517-4;Respiratory syncytial virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Respiratory syncytial virus IgG Ab [Titer] in Cerebral spinal fluid;RSV IgG Titr CSF;;ACTIVE;1.0l;2.70 +17518-2;Respiratory syncytial virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus IgG Ab [Titer] in Serum;RSV IgG Titr Ser;;ACTIVE;1.0l;2.70 +17519-0;Respiratory syncytial virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Respiratory syncytial virus IgM Ab [Titer] in Cerebral spinal fluid;RSV IgM Titr CSF;;ACTIVE;1.0l;2.70 +17520-8;Respiratory syncytial virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Respiratory syncytial virus identified in Specimen by Organism specific culture;RSV Spec Cult;;ACTIVE;1.0l;2.73 +17521-6;Reticulin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Reticulin Ab [Presence] in Serum;Reticulin Ab Ser Ql;;ACTIVE;1.0l;2.73 +17522-4;Reticulin Ab.IgA;Titr;Pt;Ser;Qn;IF;SERO;1;Reticulin IgA Ab [Titer] in Serum by Immunofluorescence;Reticulin IgA Titr Ser IF;;ACTIVE;1.0l;2.73 +17523-2;Reticulin Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Reticulin IgG Ab [Titer] in Serum;Reticulin IgG Titr Ser;;ACTIVE;1.0l;2.70 +17524-0;Reticulin Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Reticulin IgG Ab [Titer] in Serum by Immunofluorescence;Reticulin IgG Titr Ser IF;;ACTIVE;1.0l;2.73 +1752-5;Albumin;MCnc;Pt;Synv fld;Qn;;CHEM;1;Albumin [Mass/volume] in Synovial fluid;Albumin Snv-mCnc;;ACTIVE;1.0;2.73 +17525-7;Retinoate esters;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinoate esters [Mass/volume] in Serum or Plasma;Retinoate Ester SerPl-mCnc;;ACTIVE;1.0l;2.42 +17526-5;Retinyl esters;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinyl esters [Mass/volume] in Serum or Plasma;Vit A Ester SerPl-mCnc;;ACTIVE;1.0l;2.52 +17527-3;Retinol.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinol Free [Mass/volume] in Serum or Plasma;Vit A Free SerPl-mCnc;;ACTIVE;1.0l;2.73 +17528-1;Retinol^3H post dose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Retinol [Mass/volume] in Serum or Plasma --3 hours post dose;Vit A 3h p SerPl-mCnc;;ACTIVE;1.0l;2.73 +17529-9;Retinol^6H post dose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Retinol [Mass/volume] in Serum or Plasma --6 hours post dose;Vit A 6h p SerPl-mCnc;;ACTIVE;1.0l;2.40 +17530-7;Retrovirus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Retrovirus identified in Specimen by Organism specific culture;Retrovirus Spec Cult;;ACTIVE;1.0l;2.69 +17531-5;Rh;Type;Pt;Amnio fld;Nom;;BLDBK;1;Rh [Type] in Amniotic fluid;Rh Amn;;ACTIVE;1.0l;2.19 +17532-3;Rheumatoid arthritis nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Rheumatoid arthritis nuclear Ab [Presence] in Serum;RA Nuc Ab Ser Ql;;ACTIVE;1.0l;2.73 +1753-3;Albumin;PrThr;Pt;Urine;Ord;;CHEM;1;Albumin [Presence] in Urine;Albumin Ur Ql;;ACTIVE;1.0;2.73 +17533-1;Rheumatoid arthritis nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Rheumatoid arthritis nuclear Ab [Presence] in Serum by Immunofluorescence;RA Nuc Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17534-9;Rheumatoid factor;ACnc;Pt;Body fld;Qn;IA;SERO;1;Rheumatoid factor [Units/volume] in Body fluid by Immunoassay;Rheumatoid fact Fld IA-aCnc;;ACTIVE;1.0l;2.56 +17535-6;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA RNP Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17536-4;Ribonucleoprotein extractable nuclear Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum by Immunofluorescence;ENA RNP Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17537-2;Rickettsia spotted fever group RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Rickettsia spotted fever group RNA [Presence] in Serum by NAA with probe detection;Rick SF RNA Ser Ql NAA+probe;;ACTIVE;1.0l;2.63 +17538-0;Rickettsia spotted fever group RNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Rickettsia spotted fever group RNA [Presence] in Serum by Probe;Rick SF RNA Ser Ql Probe;;ACTIVE;1.0l;2.63 +17539-8;Rickettsia typhi Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Rickettsia typhi Ab [Units/volume] in Serum by Latex agglutination;R typhi Ab Ser LA-aCnc;;ACTIVE;1.0l;2.69 +17540-6;Rickettsia typhi Ab.IgA;ACnc;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhi IgA Ab [Units/volume] in Serum by Immunofluorescence;R typhi IgA Ser IF-aCnc;;ACTIVE;1.0l;2.69 +1754-1;Albumin;MCnc;Pt;Urine;Qn;;CHEM;1;Albumin [Mass/volume] in Urine;Albumin Ur-mCnc;;ACTIVE;1.0;2.73 +17541-4;Rickettsia typhi Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rickettsia typhi IgG Ab [Presence] in Serum by Immunoassay;R typhi IgG Ser Ql IA;;ACTIVE;1.0l;2.56 +17544-8;Bartonella quintana Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Bartonella quintana IgG Ab [Presence] in Cerebral spinal fluid;B quintana IgG CSF Ql;;ACTIVE;1.0l;2.56 +17545-5;Bartonella quintana Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Bartonella quintana IgM Ab [Presence] in Cerebral spinal fluid;B quintana IgM CSF Ql;;ACTIVE;1.0l;2.56 +17546-3;Bartonella quintana rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Bartonella quintana rRNA [Presence] in Specimen by Probe;B quintana rRNA Spec Ql Probe;;ACTIVE;1.0l;2.73 +17547-1;Rotavirus Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Rotavirus Ag [Presence] in Stool;RV Ag Stl Ql;;ACTIVE;1.0l;2.73 +17548-9;Rotavirus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Rotavirus RNA [Presence] in Specimen by Probe;RV RNA Spec Ql Probe;;ACTIVE;1.0l;2.69 +17549-7;Rubella virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Rubella virus Ab [Units/volume] in Cerebral spinal fluid;RUBV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +17550-5;Rubella virus Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Rubella virus Ab [Units/volume] in Serum by Latex agglutination;RUBV Ab Ser LA-aCnc;;ACTIVE;1.0l;2.73 +17551-3;Rubella virus Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Rubella virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;RUBV IgG CSF IA-aCnc;;ACTIVE;1.0l;2.73 +17552-1;Rubella virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Rubella virus IgM Ab [Presence] in Cerebral spinal fluid;RUBV IgM CSF Ql;;ACTIVE;1.0l;2.56 +17553-9;Measles virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Measles virus Ab [Units/volume] in Cerebral spinal fluid;MeV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +17554-7;Measles virus Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus IgA Ab [Units/volume] in Serum;MeV IgA Ser-aCnc;;ACTIVE;1.0l;2.69 +17555-4;Measles virus Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus Ab [Units/volume] in Serum --1st specimen;MeV Ab sp1 Ser-aCnc;;ACTIVE;1.0l;2.69 +17556-2;Measles virus Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus Ab [Units/volume] in Serum --2nd specimen;MeV Ab sp2 Ser-aCnc;;ACTIVE;1.0l;2.69 +17557-0;Saccharomonospora viridis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Saccharomonospora viridis IgG Ab [Units/volume] in Serum;S viridis IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +1755-8;Albumin;MRat;24H;Urine;Qn;;CHEM;1;Albumin [Mass/time] in 24 hour Urine;Albumin 24h Ur-mRate;;ACTIVE;1.0;2.73 +17558-8;Saint Louis encephalitis virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Units/volume] in Cerebral spinal fluid;SLEV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +17559-6;Salicylates;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Salicylates [Presence] in Blood;Salicylates Bld Ql;;ACTIVE;1.0l;2.56 +17560-4;Salicylates;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Salicylates [Presence] in Gastric fluid;Salicylates Gast Ql;;ACTIVE;1.0l;2.56 +17561-2;Salmo salar roe Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Salmon roe IgE Ab [Units/volume] in Serum;Salmon roe IgE Qn;;ACTIVE;1.0l;2.42 +17562-0;Salmonella sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella sp Ab [Presence] in Serum;Salmonella Ab Ser Ql;;ACTIVE;1.0l;2.73 +17563-8;Salmonella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Salmonella sp identified in Specimen by Organism specific culture;Salmonella Spec Cult;;ACTIVE;1.0l;2.73 +17564-6;Salmonella typhi O D Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella typhi O D Ab [Presence] in Serum by Latex agglutination;S Typhi O D Ab Ser Ql LA;;ACTIVE;1.0l;2.56 +17565-3;Salmonella typhi H D Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella typhi H D Ab [Presence] in Serum by Latex agglutination;S Typhi H d Ab Ser Ql LA;;ACTIVE;1.0l;2.56 +1756-6;Albumin.CSF/Albumin.SerPl;RelRto;Pt;Ser/Plas+CSF;Qn;;CHEM;1;Albumin in CSF/Albumin in Serum or Plasma;Alb CSF/SerPl;;ACTIVE;1.0;2.73 +17566-1;Salmonella typhi O Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella typhi O Ab [Presence] in Serum;S Typhi O Ab Ser Ql;;ACTIVE;1.0l;2.73 +17567-9;Sasapyrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sasapyrine [Mass/volume] in Serum or Plasma;Sasapyrine SerPl-mCnc;;ACTIVE;1.0l;2.42 +17568-7;Sarcosine;PrThr;Pt;Urine;Ord;;CHEM;1;Sarcosine [Presence] in Urine;Sarcosine Ur Ql;;ACTIVE;1.0l;2.56 +17569-5;SCL-70 extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA Scl70 Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17570-3;SCL-70 extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;SCL-70 extractable nuclear IgG Ab [Presence] in Serum by Immunoassay;ENA Scl70 IgG Ser Ql IA;;ACTIVE;1.0l;2.73 +17571-1;Scopolamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Scopolamine [Mass/volume] in Urine;Scopolamine Ur-mCnc;;ACTIVE;1.0l;2.42 +17572-9;2-Butanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Butanol [Mass/volume] in Blood;2Butanol Bld-mCnc;;ACTIVE;1.0l;2.73 +17573-7;Secobarbital;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Secobarbital [Mass/volume] in Gastric fluid;Secobarbital Gast-mCnc;;ACTIVE;1.0l;2.42 +1757-4;Albumin renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Albumin renal clearance in 24 hour Urine and Serum or Plasma;Albumin Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.73 +17574-5;Selenium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Body fluid;Selenium Fld-mCnc;;ACTIVE;1.0l;2.42 +17575-2;Serine;PrThr;Pt;Urine;Ord;;CHEM;1;Serine [Presence] in Urine;Serine Ur Ql;;ACTIVE;1.0l;2.56 +17576-0;Shigella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Shigella sp identified in Specimen by Organism specific culture;Shigella Spec Cult;;ACTIVE;1.0l;2.73 +17577-8;Ganglioside GQ1a Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GQ1a IgM Ab [Presence] in Serum;GQ1a Gangl IgM Ser Ql;;ACTIVE;1.0l;2.56 +17578-6;Ganglioside GQ1b Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GQ1b Ab [Presence] in Serum;GQ1b Gangl Ab Ser Ql;;ACTIVE;1.0l;2.56 +17579-4;Ganglioside GQ1b Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GQ1b IgG Ab [Presence] in Serum;GQ1b Gangl IgG Ser Ql;;ACTIVE;1.0l;2.56 +17580-2;Ganglioside GQ1b Ab.IgG;PrThr;Pt;CSF;Ord;;SERO;1;Ganglioside GQ1b IgG Ab [Presence] in Cerebral spinal fluid;GQ1b Gangl IgG CSF Ql;;ACTIVE;1.0l;2.56 +17581-0;Ganglioside GQ1b Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GQ1b IgM Ab [Presence] in Serum;GQ1b Gangl IgM Ser Ql;;ACTIVE;1.0l;2.56 +1758-2;Albumin.glycated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Albumin.glycated [Mass/volume] in Serum or Plasma;Albumin Glycated SerPl-mCnc;;ACTIVE;1.0;2.73 +17582-8;Silver;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Dialysis fluid;Silver Dial fld-mCnc;;ACTIVE;1.0l;2.42 +17583-6;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA SS-A Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17584-4;Sjogrens syndrome-A extractable nuclear Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Units/volume] in Serum by Immunofluorescence;ENA SS-A Ab Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17585-1;Sjogrens syndrome-A extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear IgG Ab [Presence] in Serum by Immunoassay;ENA SS-A IgG Ser Ql IA;;ACTIVE;1.0l;2.73 +17586-9;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA SS-B Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17587-7;Sjogrens syndrome-B extractable nuclear Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum by Immunofluorescence;ENA SS-B Ab Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17588-5;Sjogrens syndrome-B extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Sjogrens syndrome-B extractable nuclear IgG Ab [Presence] in Serum by Immunoassay;ENA SS-B IgG Ser Ql IA;;ACTIVE;1.0l;2.73 +17589-3;Smith extractable nuclear Ab;Titr;Pt;Ser;Qn;Immune diffusion;SERO;1;Smith extractable nuclear Ab [Titer] in Serum by Immune diffusion (ID);ENA SM Ab Titr Ser ID;;ACTIVE;1.0l;2.70 +1759-0;Albumin/Globulin;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Serum or Plasma;Albumin/Glob SerPl;;ACTIVE;1.0;2.73 +17590-1;Smith extractable nuclear Ab;Titr;Pt;Ser;Qn;IA;SERO;1;Smith extractable nuclear Ab [Titer] in Serum by Immunoassay;ENA SM Ab Titr Ser IA;;ACTIVE;1.0l;2.73 +17591-9;Smith extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Smith extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA SM Ab Ser Ql IF;;ACTIVE;1.0l;2.56 +17592-7;Smith extractable nuclear Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Smith extractable nuclear Ab [Units/volume] in Serum by Immunofluorescence;ENA SM Ab Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17593-5;Smooth muscle Ab;PrThr;Pt;Sweat;Ord;;SERO;1;Smooth muscle Ab [Presence] in Sweat;Smooth muscle Ab Sweat Ql;;ACTIVE;1.0l;2.56 +17594-3;Somatotropin^1.5H post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Deprecated GH 1.5H p chal Ser-mCnc;;DEPRECATED;1.0l;2.36 +17595-0;Somatotropin^1H post XXX challenge;MCnc;Pt;Ser;Qn;;CHAL;1;Deprecated Somatotropin [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Deprecated GH 1H p chal Ser-mCnc;;DEPRECATED;1.0l;2.36 +17597-6;Somatotropin^52H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --52 hours post XXX challenge;GH 52h p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +17598-4;Specific gravity;Rden;Pt;Synv fld;Qn;;CHEM;1;Specific gravity of Synovial fluid;Sp Gr Snv;;ACTIVE;1.0l;2.73 +17599-2;Specimen volume;Vol;24H;Dial fld prt;Qn;;SPEC;1;Volume of 24 hour Peritoneal dialysis fluid;Specimen vol 24h DiafP;;ACTIVE;1.0l;2.40 +17600-8;Specimen volume;Vol;6H;Urine;Qn;;SPEC;1;Volume of 6 hour Urine;Specimen vol 6h Ur;;ACTIVE;1.0l;2.42 +17601-6;Specimen volume;Vol;24H;Sputum;Qn;;SPEC;1;Volume of 24 hour Sputum;Specimen vol 24h Spt;;ACTIVE;1.0l;2.42 +17602-4;Specimen volume;Vol;Pt;Semin plas;Qn;;SPEC;1;Volume of Seminal plasma;Specimen vol Semin plas;;ACTIVE;1.0l;2.73 +17603-2;Specimen volume;Vol;24H;Stool;Qn;;SPEC;1;Volume of 24 hour Stool;Specimen vol 24h Stl;;ACTIVE;1.0l;2.42 +17604-0;Specimen volume;Vol;24H;Sweat;Qn;;SPEC;1;Volume of 24 hour Sweat;Specimen vol 24h Sweat;;ACTIVE;1.0l;2.42 +17605-7;Specimen volume;Vol;24H;XXX;Qn;;SPEC;1;Volume of 24 hour Specimen;Vol 24h Spec;;ACTIVE;1.0l;2.73 +17606-5;Specimen volume;Vol;Pt;Stool;Qn;;SPEC;1;Volume of Stool;Specimen vol Stl;;ACTIVE;1.0l;2.73 +17607-3;Specimen volume;Vol;Pt;CSF;Qn;;SPEC;1;Volume of Cerebral spinal fluid;Specimen vol CSF;;ACTIVE;1.0l;2.73 +1760-8;Alcohol dehydrogenase;CCnc;Pt;Ser;Qn;;CHEM;1;Alcohol dehydrogenase [Enzymatic activity/volume] in Serum;ADH Ser-cCnc;;ACTIVE;1.0;2.68 +17608-1;Specimen weight;MRat;48H;Stool;Qn;;SPEC;1;Weight [Mass/time] of 48 hour Stool;Specimen wt 48h Stl-mRate;;ACTIVE;1.0l;2.44 +17609-9;Specimen weight;MRat;72H;Stool;Qn;;SPEC;1;Weight [Mass/time] of 72 hour Stool;Specimen wt 72h Stl-mRate;;ACTIVE;1.0l;2.73 +17610-7;Spermatozoa.motile^30M post collection;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Motile [Presence] in Semen --30 minutes post collection;Sperm Motile 30M p coll Smn Ql;;ACTIVE;1.0l;2.73 +17611-5;Stimulants;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Stimulants [Identifier] in Serum or Plasma;Stimulants SerPl;;ACTIVE;1.0l;2.07 +17612-3;Streptococcus pneumoniae 1 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum1 Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17613-1;Streptococcus pneumoniae 1 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum1 Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17614-9;Streptococcus pneumoniae 12 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Presence] in Serum;Deprecated S pneum12 Ab Ser Ql;;DEPRECATED;1.0l;2.61 +17615-6;Streptococcus pneumoniae 12f Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12f Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum12f Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +1761-6;Aldolase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aldolase [Enzymatic activity/volume] in Serum or Plasma;Aldolase SerPl-cCnc;;ACTIVE;1.0;2.73 +17616-4;Streptococcus pneumoniae 12f Ab^2nd specimen/Streptococcus pneumoniae 12f Ab^1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12f Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum12f Ab Ser-Rto;;DEPRECATED;1.0l;2.66 +17617-2;Streptococcus pneumoniae 14 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Units/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum14 Ab sp1 Ser IA-aCnc;;DEPRECATED;1.0l;2.69 +17618-0;Streptococcus pneumoniae 14 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum14 Ab sp2 Ser IA-aCnc;;DEPRECATED;1.0l;2.69 +17619-8;Streptococcus pneumoniae 14 Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Ratio] in Serum by Immunoassay --2nd specimen/1st specimen;Deprecated S pneum14 Ab 2:1 Ser IA-Rto;;DEPRECATED;1.0l;2.66 +17620-6;Streptococcus pneumoniae 18c Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 56 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum18c Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17621-4;Streptococcus pneumoniae 18c Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 56 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum18c Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17622-2;Streptococcus pneumoniae 18 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptocuccus pneumoniae 18 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum18 Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17623-0;Streptococcus pneumoniae 19f Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19f Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum19f Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +1762-4;Aldosterone;MCnc;Pt;Bld;Qn;;CHEM;1;Aldosterone [Mass/volume] in Blood;Aldost Bld-mCnc;;ACTIVE;1.0;2.73 +17624-8;Streptococcus pneumoniae 23f Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23f Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum23f Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17625-5;Streptococcus pneumoniae 23f Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23f Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum23f Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17626-3;Streptococcus pneumoniae 3 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum3 Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17627-1;Streptococcus pneumoniae 3 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Units/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum3 Ab sp1 Ser IA-aCnc;;DEPRECATED;1.0l;2.69 +17628-9;Streptococcus pneumoniae 3 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum3 Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17629-7;Streptococcus pneumoniae 3 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum3 Ab sp2 Ser IA-aCnc;;DEPRECATED;1.0l;2.69 +17630-5;Streptococcus pneumoniae 3 Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum3 Ab 2:1 Ser-Rto;;DEPRECATED;1.0l;2.66 +17631-3;Streptococcus pneumoniae 36a+6b Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 36a+6b IgG Ab [Units/volume] in Serum;Deprecated S pneum36a+6b IgG Ser-aCnc;;DEPRECATED;1.0l;2.69 +1763-2;Aldosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aldosterone [Mass/volume] in Serum or Plasma;Aldost SerPl-mCnc;;ACTIVE;1.0;2.73 +17632-1;Streptococcus pneumoniae 4 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Units/volume] in Serum;Deprecated S pneum4 IgG Ser-aCnc;;DEPRECATED;1.0l;2.69 +17633-9;Streptococcus pneumoniae 4 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum4 Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17634-7;Streptococcus pneumoniae 4 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum4 Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17635-4;Streptococcus pneumoniae Danish serotype 18C Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Units/volume] in Serum;S pneum Da 18C IgG Ser-aCnc;;ACTIVE;1.0l;2.73 +17636-2;Streptococcus pneumoniae 6b Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 26 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum6b Ab sp1 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17637-0;Streptococcus pneumoniae 6b Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 26 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum6b Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +17638-8;Streptococcus pneumoniae Danish serotype 7F Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pneum Da 7F Ab sp1 Ser IA-aCnc;;ACTIVE;1.0l;2.69 +17639-6;Streptococcus pneumoniae Danish serotype 7F Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 7F Ab sp2 Ser IA-aCnc;;ACTIVE;1.0l;2.69 +1764-0;Aldosterone;MCnc;Pt;Urine;Qn;;CHEM;1;Aldosterone [Mass/volume] in Urine;Aldost Ur-mCnc;;ACTIVE;1.0;2.73 +17640-4;Streptococcus pneumoniae Danish serotype 7F Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Ratio] in Serum by Immunoassay --2nd specimen/1st specimen;S pneum Da 7F Ab 2:1 Ser IA-Rto;;ACTIVE;1.0l;2.61 +17641-2;Streptococcus pneumoniae 8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Presence] in Serum;Deprecated S pneum8 Ab Ser Ql;;DEPRECATED;1.0l;2.66 +17642-0;Streptococcus pneumoniae 8 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Presence] in Serum by Immunoassay;Deprecated S pneum8 Ab Ser Ql IA;;DEPRECATED;1.0l;2.66 +17643-8;Streptococcus pneumoniae 9 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Presence] in Serum by Immunoassay;Deprecated S pneum9 Ab Ser Ql IA;;DEPRECATED;1.0l;2.66 +17644-6;Streptococcus pneumoniae 9 Ab^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;Deprecated S pneum9 Ab 1:2 Ser IA-Rto;;DEPRECATED;1.0l;2.66 +17645-3;Streptococcus pneumoniae 9 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Units/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum9 Ab sp1 Ser IA-aCnc;;DEPRECATED;1.0l;2.69 +17646-1;Streptococcus pneumoniae 9 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum9 Ab sp2 Ser IA-aCnc;;DEPRECATED;1.0l;2.69 +17647-9;Streptococcus pneumoniae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Ab [Units/volume] in Serum;S pneum Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +17648-7;Streptococcus pneumoniae Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Ab [Units/volume] in Serum by Immunoassay;S pneum Ab Ser IA-aCnc;;ACTIVE;1.0l;2.69 +17649-5;Streptococcus pneumoniae Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae IgG Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;S pneum IgG 1:2 Ser IA-Rto;;ACTIVE;1.0l;2.56 +17650-3;Streptococcus pneumoniae Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pneum IgG sp1 Ser IA-aCnc;;ACTIVE;1.0l;2.69 +17651-1;Streptococcus pneumoniae Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pneum IgG sp2 Ser IA-aCnc;;ACTIVE;1.0l;2.69 +17652-9;Streptococcus pneumoniae Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Specimen by Latex agglutination;S pneum Ag Spec Ql LA;;ACTIVE;1.0l;2.73 +17653-7;Streptococcus pneumoniae group A Ag;ACnc;Pt;XXX;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae group A Ag;Deprecated S pneumA Ag XXX Ql;;DEPRECATED;1.0l;2.69 +17654-5;Streptococcus pneumoniae group B Ab;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Streptococcus pneumoniae group B Ab by Immunoassay;Deprecated S pneumB Ab Ser Ql EIA;;DEPRECATED;1.0l;2.40 +17655-2;Streptococcus pneumoniae group B Ag;ACnc;Pt;Urine;Ord;IF;MICRO;1;Deprecated Streptococcus pneumoniae group B Ag in urine by immunofluorescence;Deprecated S pneumB Ag Ur Ql IF;;DEPRECATED;1.0l;2.40 +17656-0;Streptococcus pyogenes;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Streptococcus pyogenes [Presence] in Specimen by Organism specific culture;S pyo Spec Ql Cult;;ACTIVE;1.0l;2.73 +1765-7;Aldosterone;MRat;24H;Urine;Qn;;CHEM;1;Aldosterone [Mass/time] in 24 hour Urine;Aldost 24h Ur-mRate;;ACTIVE;1.0;2.73 +17657-8;Streptolysin O Ab;ACnc;Pt;Synv fld;Qn;;MICRO;1;Streptolysin O Ab [Units/volume] in Synovial fluid;ASO Ab Snv-aCnc;;ACTIVE;1.0l;2.68 +17658-6;Strontium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Strontium/Creatinine [Mass Ratio] in Urine;Strontium/Creat Ur;;ACTIVE;1.0l;2.73 +17659-4;Strychnine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Strychnine [Units/volume] in Serum or Plasma;Strychnine SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +17660-2;Strychnine;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Strychnine [Units/volume] in Urine;Strychnine Ur-aCnc;;DISCOURAGED;1.0l;2.69 +17661-0;Succinylcholine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Succinylcholine [Mass/volume] in Serum or Plasma;Succinylcholine SerPl-mCnc;;ACTIVE;1.0l;2.34 +17662-8;Succinylpurines;PrThr;Pt;Urine;Ord;;CHEM;1;Succinylpurines [Presence] in Urine;Succinylpurines Ur Ql;;ACTIVE;1.0l;2.56 +17663-6;sulfADIAZINE Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;sulfADIAZINE IgE Ab [Units/volume] in Serum;sulfADIAZINE IgE Qn;;ACTIVE;1.0l;2.42 +17664-4;Sulfalazine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sulfalazine IgE Ab [Units/volume] in Serum;Sulfalazine IgE Qn;;ACTIVE;1.0l;2.42 +1766-5;Aldosterone receptors;Num;Pt;WBC;Qn;;CHEM;1;Aldosterone receptors [#] in Leukocytes;Num Aldost Recep WBC;;ACTIVE;1.0;2.69 +17665-1;Sulfamedraxozole Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sulfamedraxozole IgE Ab [Units/volume] in Serum;Sulfamedraxozole IgE Qn;;ACTIVE;1.0l;2.73 +17666-9;Sulfate;MCnc;Pt;Dial fld;Qn;;CHEM;1;Sulfate [Mass/volume] in Dialysis fluid;Sulfate Dial fld-mCnc;;ACTIVE;1.0l;2.44 +17667-7;Sulfate.organic/Sulfate.total;MFr;Pt;Urine;Qn;;CHEM;1;Sulfate.organic/Sulfate.total in Urine;Sulfate Organic MFr Ur;;ACTIVE;1.0l;2.70 +17668-5;Sulfatide Ab.IgG;ACnc;Pt;Ser;Qn;IF;SERO;1;Sulfatide IgG Ab [Units/volume] in Serum by Immunofluorescence;Sulfatide IgG Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17669-3;Sulfatide Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Sulfatide IgG Ab [Units/volume] in Serum by Immunoassay;Sulfatide IgG Ser IA-aCnc;;ACTIVE;1.0l;2.69 +17670-1;Sulfatide Ab.IgM;ACnc;Pt;Ser;Qn;IF;SERO;1;Sulfatide IgM Ab [Units/volume] in Serum by Immunofluorescence;Sulfatide IgM Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17671-9;Sulfatide Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Sulfatide IgM Ab [Units/volume] in Serum by Immunoassay;Sulfatide IgM Ser IA-aCnc;;ACTIVE;1.0l;2.73 +17672-7;Sulfide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sulfide [Mass/volume] in Urine;Sulfide Ur-mCnc;;ACTIVE;1.0l;2.34 +1767-3;Aldosterone^supine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --supine;Aldost sup SerPl-mCnc;;ACTIVE;1.0;2.73 +17673-5;sulfiSOXAZOLE Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;sulfiSOXAZOLE IgE Ab [Units/volume] in Serum;Sulfisoxaz IgE Qn;;ACTIVE;1.0l;2.42 +17674-3;Sulfonamide;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfonamide [Units/volume] in Serum or Plasma;Sulfonamide SerPl-aCnc;;DISCOURAGED;1.0l;2.69 +17675-0;Sulfonamide;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Sulfonamide [Units/volume] in Urine;Sulfonamide Ur-aCnc;;DISCOURAGED;1.0l;2.69 +17676-8;Sulindac sulfide metabolite;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulindac sulfide metabolite [Mass/volume] in Serum or Plasma;Sulindac Metab SerPl-mCnc;;ACTIVE;1.0l;2.42 +17677-6;Helianthus annuus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Helianthus annuus Ab.IgE;Deprecated Sunflower IgE Qn;;DEPRECATED;1.0l;2.69 +17678-4;Taurine;PrThr;Pt;Urine;Ord;;CHEM;1;Taurine [Presence] in Urine;Taurine Ur Ql;;ACTIVE;1.0l;2.56 +17679-2;Taurine;PrThr;Pt;CSF;Ord;;CHEM;1;Taurine [Presence] in Cerebral spinal fluid;Taurine CSF Ql;;ACTIVE;1.0l;2.56 +176-8;Chlortetracycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Chlortetracycline [Susceptibility] by Minimum lethal concentration (MLC);Chlortetracycline Islt MLC;;ACTIVE;1.0;2.19 +1768-1;Aldosterone^upright;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aldosterone [Mass/volume] in Serum or Plasma --upright;Aldost upr SerPl-mCnc;;ACTIVE;1.0;2.73 +17681-8;Tellurium;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tellurium [Presence] in Urine;Tellurium Ur Ql;;ACTIVE;1.0l;2.56 +17682-6;Terpineol;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Terpineol [Presence] in Blood;Terpineol Bld Ql;;ACTIVE;1.0l;2.56 +17683-4;2-Methyl-2-Propanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Methyl-2-Propanol [Mass/volume] in Blood;2Me2Propanol Bld-mCnc;;ACTIVE;1.0l;2.73 +17685-9;Testosterone.free;MCnc;Pt;Dial fld;Qn;;CHEM;1;Testosterone Free [Mass/volume] in Dialysis fluid;Testost Free Dial fld-mCnc;;ACTIVE;1.0l;2.34 +17686-7;Testosterone.weakly bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone.weakly bound [Mass/volume] in Serum or Plasma;Testost Wkly Bnd SerPl-mCnc;;ACTIVE;1.0l;2.40 +17687-5;Testosterone/Epitestosterone;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone/Epitestosterone [Mass Ratio] in Serum or Plasma;Testost/Epitestost SerPl;;ACTIVE;1.0l;2.73 +17688-3;Testosterone^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Testost 1.5h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17689-1;Testosterone^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Testost 15M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17690-9;Testosterone^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Testost 2h p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17691-7;Testosterone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Testost 30M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17692-5;Testosterone^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Testost 45M p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17693-3;Testosterone^4D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --4 days post XXX challenge;Testost 4D p chal SerPl-mCnc;;ACTIVE;1.0l;2.34 +17694-1;Coproporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Deprecated Coproporphyrin [Mass/time] in 24 hour Stool;Deprecated Copro 24H Stl-mRate;;DEPRECATED;1.0l;2.36 +17695-8;Tetrachlorodiphenylethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tetrachlorodiphenylethane [Mass/volume] in Blood;DDD Bld-mCnc;;ACTIVE;1.0l;2.73 +17696-6;Tetrachlorodiphenylethane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tetrachlorodiphenylethane [Mass/volume] in Urine;DDD Ur-mCnc;;ACTIVE;1.0l;2.63 +17697-4;Tetrachloroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tetrachloroethane [Mass/volume] in Blood;Tetrachloroethane Bld-mCnc;;ACTIVE;1.0l;2.73 +17698-2;Tetraethyl lead;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tetraethyl lead [Mass/volume] in Blood;Tetraethyl Lead Bld-mCnc;;ACTIVE;1.0l;2.34 +1769-9;Fatty acids.nonesterified;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.nonesterified [Mass/volume] in Serum or Plasma;NEFA SerPl-mCnc;;ACTIVE;1.0;2.73 +17699-0;Thebaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thebaine [Mass/volume] in Serum or Plasma;Thebaine SerPl-mCnc;;ACTIVE;1.0l;2.34 +17700-6;Theophylline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Urine;Theophylline Ur-mCnc;;ACTIVE;1.0l;2.42 +17701-4;Thiazides;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiazides [Mass/volume] in Urine;Thiazides Ur-mCnc;;ACTIVE;1.0l;2.42 +17703-0;Thorium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thorium [Mass/volume] in Urine;Thorium Ur-mCnc;;ACTIVE;1.0l;2.42 +17704-8;Threonine;PrThr;Pt;Urine;Ord;;CHEM;1;Threonine [Presence] in Urine;Threonine Ur Ql;;ACTIVE;1.0l;2.56 +17705-5;Thyroglobulin Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Thyroglobulin IgM Ab [Units/volume] in Serum;Thyroglob IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +17706-3;Thyroperoxidase Ab;Titr;Pt;CSF;Qn;LA;SERO;1;Thyroperoxidase Ab [Titer] in Cerebral spinal fluid by Latex agglutination;Thyroperoxidase Ab Titr CSF LA;;ACTIVE;1.0l;2.73 +1770-7;Aliphatic carboxylate C14-C26.absorption;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aliphatic carboxylate, C14-C26.absorption [Mass/volume] in Serum or Plasma;Al Carb C14-C26 Abs SerPl-mCnc;;DISCOURAGED;1.0;2.44 +17707-1;Thyroperoxidase Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Thyroperoxidase IgM Ab [Units/volume] in Serum or Plasma;Thyroperoxidase IgM SerPl-aCnc;;ACTIVE;1.0l;2.69 +17708-9;Thyroid stimulating immunoglobulins;PrThr;Pt;Ser;Ord;;CHEM;1;Thyroid stimulating immunoglobulins [Presence] in Serum;TSI Ser Ql;;ACTIVE;1.0l;2.73 +17709-7;Ticlopidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ticlopidine [Presence] in Urine;Ticlopidine Ur Ql;;ACTIVE;1.0l;2.56 +17710-5;Tin/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Tin/Creatinine [Mass Ratio] in Urine;Tin/Creat Ur;;ACTIVE;1.0l;2.42 +17712-1;Toluene diisocyanate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Toluene diisocyanate [Mass/volume] in Blood;TDI Bld-mCnc;;ACTIVE;1.0l;2.34 +17713-9;Topiramate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Topiramate [Mass/volume] in Serum or Plasma;Topiramate SerPl-mCnc;;ACTIVE;1.0l;2.73 +17714-7;Toxaphene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Toxaphene [Mass/volume] in Serum or Plasma;Toxaphene SerPl-mCnc;;ACTIVE;1.0l;2.34 +1771-5;Aliphatic carboxylate C14-C26.esters;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aliphatic carboxylate, C14-C26.esters [Mass/volume] in Serum or Plasma;Al Carb C14-C26 Ester SerPl-mCnc;;DISCOURAGED;1.0;2.44 +17715-4;Toxocara canis Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Toxocara canis Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;T canis Ab CSF IA-aCnc;;ACTIVE;1.0l;2.69 +17716-2;Toxoplasma gondii Ab.IgE;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgE Ab [Units/volume] in Serum;T gondii IgE Ser-aCnc;;ACTIVE;1.0l;2.73 +17717-0;Toxoplasma gondii Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Toxoplasma gondii IgG+IgM Ab [Presence] in Serum;T gondii IgG+IgM Ser Ql;;ACTIVE;1.0l;2.73 +17718-8;traMADol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;traMADol [Presence] in Urine by Confirmatory method;traMADol Ur Ql Cfm;;ACTIVE;1.0l;2.73 +17719-6;traMADol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;traMADol [Mass/volume] in Urine;traMADol Ur-mCnc;;ACTIVE;1.0l;2.73 +17720-4;Trans nonachlor;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trans nonachlor [Mass/volume] in Urine;Trans Nonachlor Ur-mCnc;;ACTIVE;1.0l;2.42 +17721-2;Trans nonachlor;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trans nonachlor [Mass/volume] in Blood;Trans Nonachlor Bld-mCnc;;ACTIVE;1.0l;2.73 +1772-3;Aliphatic carboxylate C14-C26.esters;MCnc;Pt;Stool;Qn;;CHEM;1;Aliphatic carboxylate, C14-C26.esters [Mass/volume] in Stool;Al Carb C14-C26 Ester Stl-mCnc;;DISCOURAGED;1.0;2.44 +17723-8;Treponema pallidum Ab;PrThr;Pt;Ser;Ord;Immobilization;MICRO;1;Treponema pallidum Ab [Presence] in Serum by Immobilization;T pallidum Ab Ser Ql Immob;;ACTIVE;1.0l;2.56 +17724-6;Treponema pallidum Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Treponema pallidum Ab [Units/volume] in Serum by Immunofluorescence;T pallidum Ab Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17725-3;Treponema pallidum Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Treponema pallidum Ab [Units/volume] in Serum by Latex agglutination;T pallidum Ab Ser LA-aCnc;;ACTIVE;1.0l;2.73 +17726-1;Treponema pallidum Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Treponema pallidum IgG Ab [Presence] in Serum by Immunofluorescence;T pallidum IgG Ser Ql IF;;ACTIVE;1.0l;2.73 +17727-9;Treponema pallidum Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Treponema pallidum IgG Ab [Units/volume] in Serum by Immunofluorescence;T pallidum IgG Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17728-7;Treponema pallidum Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Treponema pallidum IgM Ab [Units/volume] in Serum by Immunofluorescence;T pallidum IgM Ser IF-aCnc;;ACTIVE;1.0l;2.73 +17729-5;Treponema pallidum Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Treponema pallidum IgM Ab [Presence] in Serum by Immunofluorescence;T pallidum IgM Ser Ql IF;;ACTIVE;1.0l;2.73 +17730-3;Triamterene;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Triamterene [Units/volume] in Urine;Triamterene Ur-aCnc;;DISCOURAGED;1.0l;2.69 +1773-1;Fatty acids.very long chain.C24:0/C22:0;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate)/C22:0 (Docosanoate) [Mass Ratio] in Serum or Plasma;VLCFA C24:0/C22:0 SerPl;;ACTIVE;1.0;2.73 +17732-9;Trichinella spiralis Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Trichinella spiralis Ab [Presence] in Serum by Latex agglutination;T spiralis Ab Ser Ql LA;;ACTIVE;1.0l;2.56 +17733-7;Trichinella spiralis Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Trichinella spiralis IgA Ab [Presence] in Serum;T spiralis IgA Ser Ql;;ACTIVE;1.0l;2.56 +17734-5;Trichinella spiralis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Trichinella spiralis IgG Ab [Units/volume] in Serum;T spiralis IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +17735-2;Trichinella spiralis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Trichinella spiralis IgM Ab [Presence] in Serum;T spiralis IgM Ser Ql;;ACTIVE;1.0l;2.56 +17736-0;Trichloroacetate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichloroacetate [Mass/volume] in Blood;TCA Bld-mCnc;;ACTIVE;1.0l;2.73 +17737-8;Trichloroethane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trichloroethane [Mass/volume] in Urine;TCE Ur-mCnc;;ACTIVE;1.0l;2.42 +17738-6;Chloral hydrate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chloral hydrate [Presence] in Urine;Chloral Hydrate Ur Ql;;ACTIVE;1.0l;2.56 +17739-4;Chloral hydrate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Chloral hydrate [Presence] in Urine by Confirmatory method;Chloral Hydrate Ur Ql Cfm;;ACTIVE;1.0l;2.56 +17740-2;Trichlorophenoxyacetate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Trichlorophenoxyacetate [Presence] in Blood;TCPA Bld Ql;;ACTIVE;1.0l;2.56 +17741-0;Trichlorophenoxyacetate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trichlorophenoxyacetate [Mass/volume] in Serum or Plasma;TCPA SerPl-mCnc;;ACTIVE;1.0l;2.42 +17742-8;Trichlorothiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trichlorothiazide [Presence] in Urine;TCT Ur Ql;;ACTIVE;1.0l;2.56 +17743-6;Triiodothyronine resin uptake (T3RU)^1H post XXX challenge;NFr;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine resin uptake (T3RU) in Serum or Plasma --1 hour post XXX challenge;T3RU 1h p chal NFr SerPl;;ACTIVE;1.0l;2.70 +17744-4;Trimellitic anhydride Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trimellitic anhydride (TMA) IgG Ab [Units/volume] in Serum;TMA IgG Qn;;ACTIVE;1.0l;2.69 +17745-1;Trimellitic anhydride Ab.IgM;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trimellitic anhydride (TMA) IgM Ab [Units/volume] in Serum;TMA IgM Qn;;ACTIVE;1.0l;2.69 +17746-9;Trimeprazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Trimeprazine [Presence] in Serum or Plasma;Trimeprazine SerPl Ql;;ACTIVE;1.0l;2.56 +17747-7;Trimethoprim;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trimethoprim [Mass/volume] in Urine;Trimethoprim Ur-mCnc;;ACTIVE;1.0l;2.42 +17748-5;Trimethylamine;PrThr;Pt;Urine;Ord;;CHEM;1;Trimethylamine [Presence] in Urine;Trimet-amine Ur Ql;;ACTIVE;1.0l;2.56 +1774-9;Fatty acids.very long chain.C26:0/C22:0;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate)/C22:0 (Docosanoate) [Mass Ratio] in Serum or Plasma;VLCFA C26:0/C22:0 SerPl;;ACTIVE;1.0;2.73 +17749-3;Tromethamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tromethamine [Mass/volume] in Serum or Plasma;Tromethamine SerPl-mCnc;;ACTIVE;1.0l;2.34 +17750-1;Trypsinogen;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Trypsinogen [Enzymatic activity/volume] in Serum or Plasma;Trypsinogen SerPl-cCnc;;ACTIVE;1.0l;2.73 +17751-9;Tryptamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tryptamine [Mass/volume] in Serum or Plasma;Tryptamine SerPl-mCnc;;ACTIVE;1.0l;2.42 +17752-7;Tryptophan;PrThr;Pt;Urine;Ord;;CHEM;1;Tryptophan [Presence] in Urine;Tryptophan Ur Ql;;ACTIVE;1.0l;2.73 +17753-5;Tungsten;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tungsten [Mass/volume] in Serum or Plasma;Tungsten SerPl-mCnc;;ACTIVE;1.0l;2.73 +17754-3;Tyrosine;PrThr;Pt;Bld;Ord;;CHEM;1;Tyrosine [Presence] in Blood;Tyrosine Bld Ql;;ACTIVE;1.0l;2.56 +17755-0;Urate;MRat;2H;Urine;Qn;;CHEM;1;Urate [Mass/time] in 2 hour Urine;Urate 2h Ur-mRate;;ACTIVE;1.0l;2.42 +1775-6;Alkaline phosphatase;MCnc;Pt;Body fld;Qn;;CHEM;1;Alkaline phosphatase [Mass/volume] in Body fluid;ALP Fld-mCnc;;ACTIVE;1.0;2.34 +17756-8;Urate;MRat;4H;Urine;Qn;;CHEM;1;Urate [Mass/time] in 4 hour Urine;Urate 4h Ur-mRate;;ACTIVE;1.0l;2.42 +17757-6;Urea nitrogen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid;Urea nit DiafP-mCnc;;ACTIVE;1.0l;2.34 +17758-4;Urea nitrogen;MCnc;Pt;Vitr fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Vitreous fluid;Urea nit Vitf-mCnc;;ACTIVE;1.0l;2.34 +17759-2;Urea nitrogen^post dialysis;MCnc;Pt;BldA;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Arterial blood --post dialysis;BUN p dialysis BldA-mCnc;;ACTIVE;1.0l;2.42 +177-6;Chlortetracycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Chlortetracycline [Susceptibility] by Minimum inhibitory concentration (MIC);Chlortetracycline Islt MIC;;ACTIVE;1.0;2.19 +17760-0;Urea nitrogen^pre dialysis;MCnc;Pt;BldV;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Venous blood --pre dialysis;BUN pre dial BldV-mCnc;;ACTIVE;1.0l;2.42 +17761-8;Urobilinogen;MRat;48H;Stool;Qn;;CHEM;1;Urobilinogen [Mass/time] in 48 hour Stool;Urobilinogen 48h Stl-mRate;;ACTIVE;1.0l;2.42 +17762-6;Valproate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Valproate [Mass/volume] in Urine;Valproate Ur-mCnc;;ACTIVE;1.0l;2.42 +17763-4;Varicella zoster virus Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Serum by Immunofluorescence;VZV IgG Ser IF-aCnc;;ACTIVE;1.0l;2.73 +1776-4;Alkaline phosphatase;MCnc;Pt;Urine;Qn;;CHEM;1;Alkaline phosphatase [Mass/volume] in Urine;ALP Ur-mCnc;;ACTIVE;1.0;2.34 +17764-2;Varicella zoster virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Cerebral spinal fluid;VZV IgG CSF-aCnc;;ACTIVE;1.0l;2.73 +17765-9;Varicella zoster virus Ab.IgG;ACnc;Pt;CSF;Qn;IF;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;VZV IgG CSF IF-aCnc;;ACTIVE;1.0l;2.69 +17766-7;Varicella zoster virus Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Varicella zoster virus IgM Ab [Units/volume] in Serum by Immunofluorescence;VZV IgM Ser IF-aCnc;;ACTIVE;1.0l;2.69 +17767-5;Verapamil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Verapamil [Mass/volume] in Urine;Verapamil Ur-mCnc;;ACTIVE;1.0l;2.73 +17768-3;Vinyl chloride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Vinyl chloride [Mass/volume] in Blood;Vinyl Chloride Bld-mCnc;;ACTIVE;1.0l;2.42 +17769-1;Western equine encephalitis virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Western equine encephalitis virus Ab [Titer] in Cerebral spinal fluid;WEEV Ab Titr CSF;;ACTIVE;1.0l;2.70 +17770-9;Western equine encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum;WEEV Ab Titr Ser;;ACTIVE;1.0l;2.70 +17771-7;Whitefish roe Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whitefish roe IgE Ab [Units/volume] in Serum;Whitefish Roe IgE Qn;;ACTIVE;1.0l;2.42 +1777-2;Alkaline phosphatase.bone;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.bone [Enzymatic activity/volume] in Serum or Plasma;ALP Bone SerPl-cCnc;;ACTIVE;1.0;2.73 +17772-5;Dimethylbenzene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dimethylbenzene [Mass/volume] in Urine;DMB Ur-mCnc;;ACTIVE;1.0l;2.42 +17773-3;Yeast;PrThr;Pt;Stool;Ord;Microscopy.light;MICRO;1;Yeast [Presence] in Stool by Light microscopy;Yeast Stl Ql Micro;;ACTIVE;1.0l;2.56 +17774-1;Yellow dye Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow dye IgE Ab [Units/volume] in Serum;Yellow Dye IgE Qn;;ACTIVE;1.0l;2.42 +17775-8;Yersinia sp Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia sp IgA Ab [Units/volume] in Serum;Yersinia IgA Ser-aCnc;;ACTIVE;1.0l;2.69 +17776-6;Yersinia sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia sp IgG Ab [Units/volume] in Serum;Yersinia IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +17777-4;Yersinia sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia sp IgM Ab [Units/volume] in Serum;Yersinia IgM Ser-aCnc;;ACTIVE;1.0l;2.73 +17778-2;Zinc;MCnc;Pt;WBC;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Leukocytes;Zinc WBC-mCnc;;ACTIVE;1.0l;2.42 +1778-0;Alkaline phosphatase.intestinal;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.intestinal [Enzymatic activity/volume] in Serum or Plasma;ALP Intest SerPl-cCnc;;ACTIVE;1.0;2.73 +17780-8;Helicobacter pylori Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Helicobacter pylori Ag [Presence] in Stool by Immunoassay;H pylori Ag Stl Ql IA;;ACTIVE;1.0l;2.73 +17781-6;21-Hydroxylase Ab;ACnc;Pt;Ser;Qn;;SERO;1;21-Hydroxylase Ab [Units/volume] in Serum;21Hydroxylase Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +17782-4;Lipoprotein.beta.subparticle;EntLen;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.beta.subparticle [Entitic length] in Serum or Plasma;LDL SerPl Qn;;ACTIVE;1.0l;2.73 +17783-2;Hemosiderin;PrThr;Pt;Urine;Ord;Microscopy.light;HEM/BC;1;Hemosiderin [Presence] in Urine by Light microscopy;Hemosiderin Ur Ql Micro;;ACTIVE;1.0l;2.73 +17784-0;Parasite identified;Prid;Pt;Bld;Nom;Microscopy.light;MICRO;1;Parasite identified in Blood by Light microscopy;Parasite Bld Smear;;ACTIVE;1.0l;2.73 +17785-7;Radioactive iodine.thyroid/Radioactive iodine.dose;Ratio;Pt;Thyroid;Qn;;CHEM;1;Radioactive iodine.thyroid/Radioactive iodine dose [Ratio];RAI Uptake Thyroid-Rto;;ACTIVE;1.0l;2.15 +17786-5;Thyrotropin^post dose TRH;Imp;Pt;XXX;Nom;;CHAL;1;Thyrotropin [Interpretation] in Specimen--post dose TRH;TSH p TRH Spec-Imp;;ACTIVE;1.0l;2.69 +17787-3;Study report;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;Deprecated NM Thyroid gland Study report;Deprecated NM Thyroid Study report;;DEPRECATED;1.0l;2.64 +17788-1;Large unstained cells/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Large unstained cells/100 leukocytes in Blood by Automated count;LUC/leuk NFr Bld Auto;;ACTIVE;1.0l;2.73 +17789-9;Large unstained cells;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Large unstained cells [#/volume] in Blood by Automated count;LUC # Bld Auto;;ACTIVE;1.0l;2.73 +17790-7;Leukocytes.left shift;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Leukocytes Left Shift [Presence] in Blood by Automated count;WBC Left Shift Bld Ql Auto;;ACTIVE;1.0l;2.73 +17791-5;Sjogrens syndrome-B extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum;ENA SS-B Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +17792-3;Sjogrens syndrome-A extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Units/volume] in Serum;ENA SS-A Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +17793-1;Immunoglobulin light chains;MCnc;24H;Urine;Qn;;CHEM;1;Immunoglobulin light chains [Mass/volume] in 24 hour Urine;BJ Protein 24h Ur-mCnc;;ACTIVE;1.0l;2.73 +17794-9;Osmolality;Osmol;Pt;Hyperal solution;Qn;;CHEM;1;Osmolality of Hyperal solution;Osmolality Hyperal Soln;;ACTIVE;1.0l;2.42 +17795-6;Potassium;SCnc;Pt;Hyperal solution;Qn;;CHEM;1;Potassium [Moles/volume] in Hyperal solution;Potassium Hyperal Soln-sCnc;;ACTIVE;1.0l;2.73 +17796-4;Sodium;SCnc;Pt;Hyperal solution;Qn;;CHEM;1;Sodium [Moles/volume] in Hyperal solution;Sodium Hyperal Soln-sCnc;;ACTIVE;1.0l;2.34 +17797-2;Thyroid colloidal Ab;ACnc;Pt;Ser;Qn;;SERO;1;Thyroid colloidal Ab [Units/volume] in Serum;Thyroid Colloidal Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +1779-8;Alkaline phosphatase.liver;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.liver [Enzymatic activity/volume] in Serum or Plasma;ALP Liver SerPl-cCnc;;ACTIVE;1.0;2.73 +17798-0;Amikacin;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Cerebral spinal fluid;Amikacin CSF-mCnc;;ACTIVE;1.0l;2.42 +17799-8;Promyelocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Promyelocytes/100 leukocytes in Body fluid;Promyelocytes/leuk NFr Fld;;ACTIVE;1.0l;2.73 +17800-4;Myelocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Myelocytes/100 leukocytes in Body fluid;Myelocytes/leuk NFr Fld;;ACTIVE;1.0l;2.73 +17801-2;Metamyelocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Metamyelocytes/100 leukocytes in Body fluid;Metamyelocytes/leuk NFr Fld;;ACTIVE;1.0l;2.73 +17802-0;Prolymphocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Prolymphocytes/100 leukocytes in Body fluid;Prolymphocytes/leuk NFr Fld;;ACTIVE;1.0l;2.70 +17803-8;Plasma cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Plasma cells/100 leukocytes in Body fluid;Plasma Cells/leuk NFr Fld;;ACTIVE;1.0l;2.73 +17804-6;Promonocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Promonocytes/100 leukocytes in Body fluid;Promonycytes/leuk NFr Fld;;ACTIVE;1.0l;2.70 +17805-3;Procainamide;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Procainamide [Mass/volume] in Body fluid;Procainamide Fld-mCnc;;ACTIVE;1.0l;2.42 +1780-6;Alkaline phosphatase.placental;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.placental [Enzymatic activity/volume] in Serum or Plasma;ALP Plac SerPl-cCnc;;ACTIVE;1.0;2.73 +17806-1;N-acetylprocainamide;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;N-acetylprocainamide [Mass/volume] in Body fluid;NAPA Fld-mCnc;;ACTIVE;1.0l;2.42 +17807-9;cycloSPORINE;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Body fluid;cycloSPORINE Fld-mCnc;;ACTIVE;1.0l;2.66 +17808-7;Tobramycin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Urine;Tobramycin Ur-mCnc;;ACTIVE;1.0l;2.42 +17809-5;Hematocrit;VFr;Pt;Urine;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Urine;Hct VFr Ur;;ACTIVE;1.0l;2.70 +17810-3;Prealbumin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Prealbumin/Protein.total in Body fluid by Electrophoresis;Prealb MFr Fld Elph;;ACTIVE;1.0l;2.70 +17811-1;Alpha 1 globulin/Protein.total;MFr;XXX;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total by Electrophoresis in Urine collected for unspecified duration;Alpha1 Glob ?Tm MFr Ur Elph;;ACTIVE;1.0l;2.73 +17812-9;Alpha 1 globulin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total in Body fluid by Electrophoresis;Alpha1 Glob MFr Fld Elph;;ACTIVE;1.0l;2.73 +17813-7;Alpha 2 globulin/Protein.total;MFr;XXX;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total by Electrophoresis in Urine collected for unspecified duration;Alpha2 Glob ?Tm MFr Ur Elph;;ACTIVE;1.0l;2.73 +1781-4;Alkaline phosphatase.regan;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.regan [Enzymatic activity/volume] in Serum or Plasma;ALP Regan SerPl-cCnc;;ACTIVE;1.0;2.40 +17814-5;Alpha 2 globulin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total in Body fluid by Electrophoresis;Alpha2 Glob MFr Fld Elph;;ACTIVE;1.0l;2.73 +17815-2;Beta globulin/Protein.total;MFr;XXX;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total by Electrophoresis in Urine collected for unspecified duration;B-Globulin ?Tm MFr Ur Elph;;ACTIVE;1.0l;2.73 +17816-0;Beta globulin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total in Body fluid by Electrophoresis;B-Globulin MFr Fld Elph;;ACTIVE;1.0l;2.73 +17817-8;Gamma globulin/Protein.total;MFr;XXX;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total by Electrophoresis in Urine collected for unspecified duration;Gamma glob ?Tm MFr Ur Elph;;ACTIVE;1.0l;2.73 +17818-6;Gamma globulin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total in Body fluid by Electrophoresis;Gamma glob MFr Fld Elph;;ACTIVE;1.0l;2.73 +17819-4;Albumin/Protein.total;MFr;XXX;Urine;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total by Electrophoresis in Urine collected for unspecified duration;Albumin ?Tm MFr Ur Elph;;ACTIVE;1.0l;2.73 +17820-2;Albumin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total in Body fluid by Electrophoresis;Albumin MFr Fld Elph;;ACTIVE;1.0l;2.70 +17821-0;Protein fractions.oligoclonal bands;Imp;Pt;Body fld;Nar;Electrophoresis;CHEM;1;Oligoclonal bands [Interpretation] in Body fluid by Electrophoresis Narrative;Oligoclonal Bands Fld Elph-Imp;;ACTIVE;1.0l;2.54 +1782-2;Alkaline phosphatase.renal;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.renal [Enzymatic activity/volume] in Serum or Plasma;ALP Renal SerPl-cCnc;;ACTIVE;1.0;2.68 +17822-8;Cells.CD3+CD4+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 cells in Body fluid;CD3+CD4+ Cells NFr Fld;;ACTIVE;1.0l;2.73 +17823-6;Cells.CD45/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD45 (Lymphs) cells/100 cells in Body fluid;CD45 Cells NFr Fld;;ACTIVE;1.0l;2.70 +17824-4;Cells.CD3+CD8+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells/100 cells in Body fluid;CD3+CD8+ Cells NFr Fld;;ACTIVE;1.0l;2.73 +17825-1;Cells.CD41a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD41a cells/100 cells in Blood;CD41a Cells NFr Bld;;ACTIVE;1.0l;2.70 +17826-9;Cells.CD3/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3 cells/100 cells in Body fluid;CD3 Cells NFr Fld;;ACTIVE;1.0l;2.73 +17827-7;Cells.CD2/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD2 cells/100 cells in Body fluid;CD2 Cells NFr Fld;;ACTIVE;1.0l;2.70 +17828-5;Cells.CD16/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD16 cells/100 cells in Body fluid;CD16 Cells NFr Fld;;ACTIVE;1.0l;2.70 +17829-3;Cells.CD19/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19 cells/100 cells in Body fluid;CD19 Cells NFr Fld;;ACTIVE;1.0l;2.70 +1783-0;Alkaline phosphatase;CCnc;Pt;Bld;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Blood;ALP Bld-cCnc;;ACTIVE;1.0;2.73 +17830-1;Centromere Ab;ACnc;Pt;Body fld;Qn;;SERO;1;Centromere Ab [Units/volume] in Body fluid;Centromere Ab Fld-aCnc;;ACTIVE;1.0l;2.69 +17831-9;5-Fluorocytosine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Deprecated 5-Fluorocytosine [Susceptibility] by Minimum inhibitory concentration (MIC);Deprecated 5-fluorocytosine Islt MIC;;DEPRECATED;1.0l;2.36 +17832-7;5-Fluorocytosine;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Deprecated 5-Fluorocytosine [Susceptibility] by Minimum lethal concentration (MLC);Deprecated 5-fluorocytosine Islt MLC;;DEPRECATED;1.0l;2.36 +17833-5;Basophils/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Basophils/100 leukocytes in Synovial fluid;Basophils/leuk NFr Snv;;ACTIVE;1.0l;2.73 +17834-3;Eosinophils/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Synovial fluid;Eosinophil/leuk NFr Snv;;ACTIVE;1.0l;2.73 +17835-0;Monocytes/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Synovial fluid;Monocytes/leuk NFr Snv;;ACTIVE;1.0l;2.73 +17836-8;Neutrophils/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Synovial fluid;Neutrophils/leuk NFr Snv;;ACTIVE;1.0l;2.73 +17837-6;Acid phosphatase.tartrate resistant;CCnc;Pt;Ser;Qn;;CHEM;1;Acid phosphatase tartrate resistant [Enzymatic activity/volume] in Serum;ACP TRAP Ser-cCnc;;ACTIVE;1.0l;2.73 +17838-4;Alkaline phosphatase.bone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.bone [Mass/volume] in Serum or Plasma;ALP Bone SerPl-mCnc;;ACTIVE;1.0l;2.73 +17839-2;Alpha fucosidase;CCnc;Pt;Bld;Qn;;CHEM;1;Alpha fucosidase [Enzymatic activity/volume] in Blood;A-Fucosidase Bld-cCnc;;ACTIVE;1.0l;2.42 +178-4;Chlortetracycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Chlortetracycline [Susceptibility] by Disk diffusion (KB);Chlortetracycline Islt KB;;ACTIVE;1.0;2.21 +17840-0;Alpha-L-iduronidase;CCnc;Pt;Bld;Qn;;CHEM;1;Alpha-L-iduronidase [Enzymatic activity/volume] in Blood;A-L-Iduronidase Bld-cCnc;;ACTIVE;1.0l;2.68 +17841-8;Amylase;CRat;12H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/time] in 12 hour Urine;Amylase 12h Ur-cRate;;ACTIVE;1.0l;2.42 +17842-6;Cancer Ag 27-29;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag 27-29 [Units/volume] in Serum or Plasma;Cancer Ag27-29 SerPl-aCnc;;ACTIVE;1.0l;2.73 +17843-4;Cancer Ag 72-4;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag 72-4 [Units/volume] in Serum or Plasma;Cancer Ag72-4 SerPl-aCnc;;ACTIVE;1.0l;2.73 +17844-2;Estradiol.albumin bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2).albumin bound [Mass/volume] in Serum or Plasma;Estradiol Albumin Bnd SerPl-mCnc;;ACTIVE;1.0l;2.40 +17845-9;Lipoprotein.alpha;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lipoprotein.alpha [Presence] in Serum or Plasma;HDL SerPl Ql;;ACTIVE;1.0l;2.73 +17846-7;Lipoprotein.beta;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lipoprotein.beta [Presence] in Serum or Plasma;LDL SerPl Ql;;ACTIVE;1.0l;2.73 +17847-5;Lipoprotein.pre-beta;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lipoprotein.pre-beta [Presence] in Serum or Plasma;VLDL SerPl Ql;;ACTIVE;1.0l;2.73 +1784-8;Alpha amino acid nitrogen;MCnc;Pt;Plas;Qn;;CHEM;1;Alpha amino acid nitrogen [Mass/volume] in Plasma;A-AA Nitrogen Plas-mCnc;;ACTIVE;1.0;2.73 +17848-3;Reticulocytes/1000 erythrocytes;NFr;Pt;Bld;Qn;Manual;HEM/BC;1;Reticulocytes/1000 erythrocytes in Blood by Manual;Retics/1000 RBC NFr Manual;;DISCOURAGED;1.0l;2.73 +17849-1;Reticulocytes/100 erythrocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Reticulocytes/100 erythrocytes in Blood by Automated count;Retics/100 RBC NFr Auto;;ACTIVE;1.0l;2.73 +17850-9;Herpes simplex virus 1 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 1 IgG Ab [Presence] in Serum;HSV1 IgG Ser Ql;;ACTIVE;1.0l;2.73 +17851-7;Herpes simplex virus 2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 2 IgG Ab [Presence] in Serum;HSV2 IgG Ser Ql;;ACTIVE;1.0l;2.73 +17852-5;Ureaplasma urealyticum;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Ureaplasma urealyticum [Presence] in Specimen by Organism specific culture;U urealyticum Spec Ql Cult;;ACTIVE;1.0l;2.73 +17853-3;Ganglioside GM1b Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GM1b IgG Ab [Titer] in Serum;GM1b Gangl IgG Titr Ser;;ACTIVE;1.0l;2.73 +17854-1;Ganglioside GM1b Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GM1b IgM Ab [Titer] in Serum;GM1b Gangl IgM Titr Ser;;ACTIVE;1.0l;2.73 +1785-5;Alpha amino acid nitrogen;MRat;24H;Urine;Qn;;CHEM;1;Alpha amino acid nitrogen [Mass/time] in 24 hour Urine;A-AA Nitrogen 24h Ur-mRate;;ACTIVE;1.0;2.42 +17855-8;Hemoglobin A1c/Hemoglobin.total;MFr;Pt;Bld;Qn;Calculated;CHEM;1;Hemoglobin A1c/Hemoglobin.total in Blood by calculation;HbA1c MFr Bld Calc;;ACTIVE;1.0l;2.73 +17856-6;Hemoglobin A1c/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;CHEM;1;Hemoglobin A1c/Hemoglobin.total in Blood by HPLC;HbA1c MFr Bld HPLC;;ACTIVE;1.0l;2.73 +17857-4;Rheumatoid factor;Titr;Pt;Ser;Qn;;SERO;1;Rheumatoid factor [Titer] in Serum;Rheumatoid fact Titr Ser;;ACTIVE;1.0l;2.73 +17858-2;Gamma glutamyl transferase;CCnc;Pt;Body fld;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/volume] in Body fluid;GGT Fld-cCnc;;ACTIVE;1.0l;2.73 +17859-0;Helicobacter pylori Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Helicobacter pylori IgG Ab [Presence] in Serum or Plasma by Immunoassay;H pylori IgG SerPl Ql IA;;ACTIVE;1.0l;2.73 +17860-8;3-Methylhistidine;MCnc;24H;Urine;Qn;;CHEM;1;3-Methylhistidine [Mass/volume] in 24 hour Urine;3Me-histidine 24h Ur-mCnc;;ACTIVE;1.0l;2.42 +17861-6;Calcium;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Mass/volume] in Serum or Plasma;Calcium SerPl-mCnc;;ACTIVE;1.0l;2.73 +17862-4;Calcium;MCnc;Pt;Urine;Qn;;CHEM;1;Calcium [Mass/volume] in Urine;Calcium Ur-mCnc;;ACTIVE;1.0l;2.73 +1786-3;Alpha aminobutyrate;MCnc;Pt;CSF;Qn;;CHEM;1;Alpha aminobutyrate [Mass/volume] in Cerebral spinal fluid;A-Aminobutyr CSF-mCnc;;DISCOURAGED;1.0;2.44 +17863-2;Calcium.ionized;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium.ionized [Mass/volume] in Serum or Plasma;Ca-I SerPl-mCnc;;ACTIVE;1.0l;2.73 +17864-0;Calcium.ionized;MCnc;Pt;Ser/Plas;Qn;ISE;CHEM;1;Calcium.ionized [Mass/volume] in Serum or Plasma by Ion-selective membrane electrode (ISE);Ca-I SerPl ISE-mCnc;;ACTIVE;1.0l;2.73 +17865-7;Glucose^post 8H CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --8 hours fasting;Glucose p 8h fast SerPl-mCnc;;ACTIVE;1.0l;2.73 +17866-5;Carnitine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Carnitine/Creatinine [Ratio] in Urine;Carnitine/Creat Ur-Rto;;ACTIVE;1.0l;2.73 +17867-3;Carnitine.free (C0)/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Carnitine free (C0)/Creatinine [Ratio] in Urine;Carnitine Free/Creat Ur-Rto;;ACTIVE;1.0l;2.73 +17868-1;Acylcarnitine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Acylcarnitine/Creatinine [Ratio] in Urine;Acylcarnitine/Creat Ur-Rto;;ACTIVE;1.0l;2.73 +17869-9;Orotate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Orotate/Creatinine [Molar ratio] in Urine;Orotate/Creat Ur-sRto;;ACTIVE;1.0l;2.73 +17870-7;Orotidine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Orotidine/Creatinine [Molar ratio] in Urine;Orotidine/Creat Ur-sRto;;ACTIVE;1.0l;2.42 +1787-1;Alpha aminobutyrate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alpha aminobutyrate [Presence] in Serum or Plasma;A-Aminobutyr SerPl Ql;;ACTIVE;1.0;2.56 +17871-5;Hemoglobin H;PrThr;Pt;Bld;Ord;Heat denaturation;HEM/BC;1;Hemoglobin H [Presence] in Blood by Heat denaturation;Hgb H Bld Ql Heat Denat;;ACTIVE;1.0l;2.56 +17872-3;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Confirm>25 ng/mL;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by Confirm method >25 ng/mL;THC Ur Ql Cfm>25 ng/mL;;ACTIVE;1.0l;2.73 +17873-1;Bacteria identified^^^2;Prid;Pt;Bone;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Bone by Aerobe culture;Bacteria Bone Aerobe Cult org #2;;ACTIVE;1.0l;2.17 +17874-9;Bacteria identified^^^3;Prid;Pt;Bone;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Bone by Aerobe culture;Bacteria Bone Aerobe Cult org #3;;ACTIVE;1.0l;2.17 +17875-6;Bacteria identified^^^4;Prid;Pt;Bone;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Bone by Aerobe culture;Bacteria Bone Aerobe Cult org #4;;ACTIVE;1.0l;2.17 +17876-4;Bacteria identified^^^5;Prid;Pt;Bone;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Bone by Aerobe culture;Bacteria Bone Aerobe Cult org #5;;ACTIVE;1.0l;2.17 +17877-2;Bacteria identified^^^6;Prid;Pt;Bone;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Bone by Aerobe culture;Bacteria Bone Aerobe Cult org #6;;ACTIVE;1.0l;2.17 +17878-0;Bacteria identified^^^2;Prid;Pt;Bronchial;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Bronchial specimen by Aerobe culture;Bacteria Bronch Aerobe Cult org #2;;ACTIVE;1.0l;2.19 +17879-8;Bacteria identified^^^3;Prid;Pt;Bronchial;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Bronchial specimen by Aerobe culture;Bacteria Bronch Aerobe Cult org #3;;ACTIVE;1.0l;2.19 +17880-6;Bacteria identified^^^4;Prid;Pt;Bronchial;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Bronchial specimen by Aerobe culture;Bacteria Bronch Aerobe Cult org #4;;ACTIVE;1.0l;2.19 +17881-4;Bacteria identified^^^5;Prid;Pt;Bronchial;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Bronchial specimen by Aerobe culture;Bacteria Bronch Aerobe Cult org #5;;ACTIVE;1.0l;2.19 +17882-2;Bacteria identified^^^6;Prid;Pt;Bronchial;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Bronchial specimen by Aerobe culture;Bacteria Bronch Aerobe Cult org #6;;ACTIVE;1.0l;2.19 +17883-0;Bacteria identified^^^2;Prid;Pt;Genital;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Genital specimen by Aerobe culture;Bacteria Genital Aerobe Cult org #2;;ACTIVE;1.0l;2.73 +17884-8;Bacteria identified^^^3;Prid;Pt;Genital;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Genital specimen by Aerobe culture;Bacteria Genital Aerobe Cult org #3;;ACTIVE;1.0l;2.21 +17885-5;Bacteria identified^^^4;Prid;Pt;Genital;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Genital specimen by Aerobe culture;Bacteria Genital Aerobe Cult org #4;;ACTIVE;1.0l;2.21 +17886-3;Bacteria identified^^^5;Prid;Pt;Genital;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Genital specimen by Aerobe culture;Bacteria Genital Aerobe Cult org #5;;ACTIVE;1.0l;2.21 +17887-1;Bacteria identified^^^6;Prid;Pt;Genital;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Genital specimen by Aerobe culture;Bacteria Genital Aerobe Cult org #6;;ACTIVE;1.0l;2.21 +17888-9;Bacteria identified^^^2;Prid;Pt;Nose;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Nose by Aerobe culture;Bacteria Nose Aerobe Cult org #2;;ACTIVE;1.0l;2.73 +1788-9;Alpha aminobutyrate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha aminobutyrate [Mass/volume] in Serum or Plasma;A-Aminobutyr SerPl-mCnc;;DISCOURAGED;1.0;2.73 +17889-7;Bacteria identified^^^3;Prid;Pt;Nose;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Nose by Aerobe culture;Bacteria Nose Aerobe Cult org #3;;ACTIVE;1.0l;2.17 +17890-5;Bacteria identified^^^4;Prid;Pt;Nose;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Nose by Aerobe culture;Bacteria Nose Aerobe Cult org #4;;ACTIVE;1.0l;2.17 +17891-3;Bacteria identified^^^5;Prid;Pt;Nose;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Nose by Aerobe culture;Bacteria Nose Aerobe Cult org #5;;ACTIVE;1.0l;2.17 +17892-1;Bacteria identified^^^6;Prid;Pt;Nose;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Nose by Aerobe culture;Bacteria Nose Aerobe Cult org #6;;ACTIVE;1.0l;2.17 +17893-9;Bacteria identified^^^2;Prid;Pt;Sputum;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Sputum by Aerobe culture;Bacteria Spt Aerobe Cult org #2;;ACTIVE;1.0l;2.19 +17894-7;Bacteria identified^^^3;Prid;Pt;Sputum;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Sputum by Aerobe culture;Bacteria Spt Aerobe Cult org #3;;ACTIVE;1.0l;2.19 +17895-4;Bacteria identified^^^4;Prid;Pt;Sputum;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Sputum by Aerobe culture;Bacteria Spt Aerobe Cult org #4;;ACTIVE;1.0l;2.19 +17896-2;Bacteria identified^^^5;Prid;Pt;Sputum;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Sputum by Aerobe culture;Bacteria Spt Aerobe Cult org #5;;ACTIVE;1.0l;2.19 +1789-7;Alpha aminobutyrate;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Alpha aminobutyrate [Mass/volume] in Serum;Deprecated A-Aminobutyr Ser-mCnc;;DEPRECATED;1.0;2.36 +17897-0;Bacteria identified^^^6;Prid;Pt;Sputum;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Sputum by Aerobe culture;Bacteria Spt Aerobe Cult org #6;;ACTIVE;1.0l;2.19 +17898-8;Bacteria identified;Prid;Pt;Thrt;Nom;Aerobic culture;MICRO;1;Bacteria identified in Throat by Aerobe culture;Bacteria Throat Aerobe Cult;;ACTIVE;1.0l;2.73 +17899-6;Bacteria identified^^^2;Prid;Pt;Thrt;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Throat by Aerobe culture;Bacteria Throat Aerobe Cult org #2;;ACTIVE;1.0l;2.73 +17900-2;Bacteria identified^^^3;Prid;Pt;Thrt;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Throat by Aerobe culture;Bacteria Throat Aerobe Cult org #3;;ACTIVE;1.0l;2.17 +17901-0;Bacteria identified^^^4;Prid;Pt;Thrt;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Throat by Aerobe culture;Bacteria Throat Aerobe Cult org #4;;ACTIVE;1.0l;2.17 +17902-8;Bacteria identified^^^5;Prid;Pt;Thrt;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Throat by Aerobe culture;Bacteria Throat Aerobe Cult org #5;;ACTIVE;1.0l;2.17 +17903-6;Bacteria identified^^^6;Prid;Pt;Thrt;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Throat by Aerobe culture;Bacteria Throat Aerobe Cult org #6;;ACTIVE;1.0l;2.17 +17904-4;Bacteria identified^^^2;Prid;Pt;Tiss;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Tissue by Aerobe culture;Bacteria Tiss Aerobe Cult org #2;;ACTIVE;1.0l;2.22 +1790-5;Alpha aminobutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Alpha aminobutyrate [Mass/volume] in Urine;A-Aminobutyr Ur-mCnc;;DISCOURAGED;1.0;2.73 +17905-1;Bacteria identified^^^3;Prid;Pt;Tiss;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Tissue by Aerobe culture;Bacteria Tiss Aerobe Cult org #3;;ACTIVE;1.0l;2.22 +17906-9;Bacteria identified^^^4;Prid;Pt;Tiss;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Tissue by Aerobe culture;Bacteria Tiss Aerobe Cult org #4;;ACTIVE;1.0l;2.22 +17907-7;Bacteria identified^^^5;Prid;Pt;Tiss;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Tissue by Aerobe culture;Bacteria Tiss Aerobe Cult org #5;;ACTIVE;1.0l;2.22 +17908-5;Bacteria identified^^^6;Prid;Pt;Tiss;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Tissue by Aerobe culture;Bacteria Tiss Aerobe Cult org #6;;ACTIVE;1.0l;2.22 +17909-3;Bacteria identified;Prid;Pt;Wound.deep;Nom;Aerobic culture;MICRO;1;Bacteria identified in Wound deep by Aerobe culture;Bacteria Deep Wnd Aerobe Cult;;ACTIVE;1.0l;2.73 +17910-1;Bacteria identified^^^2;Prid;Pt;Wound.deep;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Wound deep by Aerobe culture;Bacteria Deep Wnd Aerobe Cult org #2;;ACTIVE;1.0l;2.19 +17911-9;Bacteria identified^^^3;Prid;Pt;Wound.deep;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Wound deep by Aerobe culture;Bacteria Deep Wnd Aerobe Cult org #3;;ACTIVE;1.0l;2.19 +17912-7;Bacteria identified^^^4;Prid;Pt;Wound.deep;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Wound deep by Aerobe culture;Bacteria Deep Wnd Aerobe Cult org #4;;ACTIVE;1.0l;2.19 +1791-3;Alpha aminoadipate;PrThr;Pt;Plas;Ord;;CHEM;1;Alpha aminoadipate [Presence] in Plasma;AAA Plas Ql;;ACTIVE;1.0;2.56 +17913-5;Bacteria identified^^^5;Prid;Pt;Wound.deep;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Wound deep by Aerobe culture;Bacteria Deep Wnd Aerobe Cult org #5;;ACTIVE;1.0l;2.19 +17914-3;Bacteria identified^^^6;Prid;Pt;Wound.deep;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Wound deep by Aerobe culture;Bacteria Deep Wnd Aerobe Cult org #6;;ACTIVE;1.0l;2.19 +17915-0;Bacteria identified;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult;;ACTIVE;1.0l;2.73 +17916-8;Bacteria identified^^^2;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult org #2;;ACTIVE;1.0l;2.19 +17917-6;Bacteria identified^^^3;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult org #3;;ACTIVE;1.0l;2.19 +17918-4;Bacteria identified^^^4;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult org #4;;ACTIVE;1.0l;2.19 +17919-2;Bacteria identified^^^5;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult org #5;;ACTIVE;1.0l;2.19 +179-2;Chlortetracycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Chlortetracycline [Susceptibility] by Serum bactericidal titer;Chlortetracycline Titr SBT;;ACTIVE;1.0;2.32 +17920-0;Bacteria identified^^^6;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult org #6;;ACTIVE;1.0l;2.19 +1792-1;Alpha aminoadipate;MCnc;Pt;Plas;Qn;;CHEM;1;Alpha aminoadipate [Mass/volume] in Plasma;AAA Plas-mCnc;;DISCOURAGED;1.0;2.73 +17921-8;Bacteria identified^^^2;Prid;Pt;Nose;Nom;Anaerobic culture;MICRO;1;Bacteria # 2 identified in Nose by Anaerobe culture;Bacteria Nose Anaerobe Cult org #2;;ACTIVE;1.0l;2.17 +17922-6;Bacteria identified^^^3;Prid;Pt;Nose;Nom;Anaerobic culture;MICRO;1;Bacteria # 3 identified in Nose by Anaerobe culture;Bacteria Nose Anaerobe Cult org #3;;ACTIVE;1.0l;2.17 +17923-4;Bacteria identified^^^2;Prid;Pt;Tiss;Nom;Anaerobic culture;MICRO;1;Bacteria # 2 identified in Tissue by Anaerobe culture;Bacteria Tiss Anaerobe Cult org #2;;ACTIVE;1.0l;2.22 +17924-2;Bacteria identified^^^3;Prid;Pt;Tiss;Nom;Anaerobic culture;MICRO;1;Bacteria # 3 identified in Tissue by Anaerobe culture;Bacteria Tiss Anaerobe Cult org #3;;ACTIVE;1.0l;2.22 +17925-9;Bacteria identified;Prid;Pt;Wound.deep;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Wound deep by Anaerobe culture;Bacteria Deep Wnd Anaerobe Cult;;ACTIVE;1.0l;2.73 +17926-7;Bacteria identified^^^2;Prid;Pt;Wound.deep;Nom;Anaerobic culture;MICRO;1;Bacteria # 2 identified in Wound deep by Anaerobe culture;Bacteria Deep Wnd Anaerobe Cult org #2;;ACTIVE;1.0l;2.19 +17927-5;Bacteria identified^^^3;Prid;Pt;Wound.deep;Nom;Anaerobic culture;MICRO;1;Bacteria # 3 identified in Wound deep by Anaerobe culture;Bacteria Deep Wnd Anaerobe Cult org #3;;ACTIVE;1.0l;2.19 +17928-3;Bacteria identified;Prid;Pt;Bld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Blood by Aerobe culture;Bacteria Bld Aerobe Cult;;ACTIVE;1.0l;2.73 +17929-1;Bacteria identified^^^2;Prid;Pt;Bld;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Blood by Aerobe culture;Bacteria Bld Aerobe Cult org #2;;ACTIVE;1.0l;2.17 +17930-9;Bacteria identified^^^3;Prid;Pt;Bld;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Blood by Aerobe culture;Bacteria Bld Aerobe Cult org #3;;ACTIVE;1.0l;2.17 +17931-7;Bacteria identified^^^4;Prid;Pt;Bld;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Blood by Aerobe culture;Bacteria Bld Aerobe Cult org #4;;ACTIVE;1.0l;2.17 +17932-5;Bacteria identified^^^5;Prid;Pt;Bld;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Blood by Aerobe culture;Bacteria Bld Aerobe Cult org #5;;ACTIVE;1.0l;2.17 +17933-3;Bacteria identified^^^6;Prid;Pt;Bld;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Blood by Aerobe culture;Bacteria Bld Aerobe Cult org #6;;ACTIVE;1.0l;2.17 +17934-1;Bacteria identified;Prid;Pt;Bld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Blood by Anaerobe culture;Bacteria Bld Anaerobe Cult;;ACTIVE;1.0l;2.73 +17935-8;Bacteria identified^^^2;Prid;Pt;Bld;Nom;Anaerobic culture;MICRO;1;Bacteria # 2 identified in Blood by Anaerobe culture;Bacteria Bld Anaerobe Cult org #2;;ACTIVE;1.0l;2.17 +17936-6;Bacteria identified^^^3;Prid;Pt;Bld;Nom;Anaerobic culture;MICRO;1;Bacteria # 3 identified in Blood by Anaerobe culture;Bacteria Bld Anaerobe Cult org #3;;ACTIVE;1.0l;2.17 +17937-4;Bacteria identified^^^2;Prid;Pt;Burn;Nom;Culture;MICRO;1;Bacteria # 2 identified in Burn by Culture;Bacteria Burn Cult org #2;;ACTIVE;1.0l;2.21 +17938-2;Bacteria identified^^^3;Prid;Pt;Burn;Nom;Culture;MICRO;1;Bacteria # 3 identified in Burn by Culture;Bacteria Burn Cult org #3;;ACTIVE;1.0l;2.21 +1793-9;Alpha aminoadipate;MCnc;Pt;Urine;Qn;;CHEM;1;Alpha aminoadipate [Mass/volume] in Urine;AAA Ur-mCnc;;DISCOURAGED;1.0;2.73 +17939-0;Bacteria identified^^^4;Prid;Pt;Burn;Nom;Culture;MICRO;1;Bacteria # 4 identified in Burn by Culture;Bacteria Burn Cult org #4;;ACTIVE;1.0l;2.21 +17940-8;Bacteria identified^^^5;Prid;Pt;Burn;Nom;Culture;MICRO;1;Bacteria # 5 identified in Burn by Culture;Bacteria Burn Cult org #5;;ACTIVE;1.0l;2.21 +17941-6;Bacteria identified^^^6;Prid;Pt;Burn;Nom;Culture;MICRO;1;Bacteria # 6 identified in Burn by Culture;Bacteria Burn Cult org #6;;ACTIVE;1.0l;2.21 +17942-4;Bacteria identified^^^2;Prid;Pt;Line;Nom;Intravascular line culture;MICRO;1;Bacteria # 2 identified in Line specimen by IV Line culture;Bacteria Line IV Ln Cult org #2;;ACTIVE;1.0l;2.21 +17943-2;Bacteria identified^^^3;Prid;Pt;Line;Nom;Intravascular line culture;MICRO;1;Bacteria # 3 identified in Line specimen by IV Line culture;Bacteria Line IV Ln Cult org #3;;ACTIVE;1.0l;2.21 +17944-0;Bacteria identified^^^4;Prid;Pt;Line;Nom;Intravascular line culture;MICRO;1;Bacteria # 4 identified in Line specimen by IV Line culture;Bacteria Line IV Ln Cult org #4;;ACTIVE;1.0l;2.21 +17945-7;Bacteria identified^^^5;Prid;Pt;Line;Nom;Intravascular line culture;MICRO;1;Bacteria # 5 identified in Line specimen by IV Line culture;Bacteria Line IV Ln Cult org #5;;ACTIVE;1.0l;2.21 +17946-5;Bacteria identified^^^6;Prid;Pt;Line;Nom;Intravascular line culture;MICRO;1;Bacteria # 6 identified in Line specimen by IV Line culture;Bacteria Line IV Ln Cult org #6;;ACTIVE;1.0l;2.21 +1794-7;Amylase;CCnc;Pt;Duod fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Duodenal fluid;Amylase Duod fl-cCnc;;ACTIVE;1.0;2.73 +17947-3;Fungus identified^^^2;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus # 2 identified in Specimen by Culture;Fungus Spec Cult org #2;;ACTIVE;1.0l;2.73 +17948-1;Fungus identified^^^3;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus # 3 identified in Specimen by Culture;Fungus Spec Cult org #3;;ACTIVE;1.0l;2.73 +17949-9;Fungus identified^^^4;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus # 4 identified in Specimen by Culture;Fungus Spec Cult org #4;;ACTIVE;1.0l;2.73 +17950-7;Microorganism identified;Prid;Pt;Body fld;Nom;Aerobic culture;MICRO;1;Deprecated Bacteria identified in Body fluid by Aerobe culture;Deprecated Microorganism Fld Aerobe Cult;;DEPRECATED;1.0l;2.36 +17951-5;Bacteria identified^^^2;Prid;Pt;Body fld;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Body fluid by Aerobe culture;Bacteria Fld Aerobe Cult org #2;;ACTIVE;1.0l;2.19 +17952-3;Bacteria identified^^^3;Prid;Pt;Body fld;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Body fluid by Aerobe culture;Bacteria Fld Aerobe Cult org #3;;ACTIVE;1.0l;2.73 +17953-1;Bacteria identified^^^4;Prid;Pt;Body fld;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Body fluid by Aerobe culture;Bacteria Fld Aerobe Cult org #4;;ACTIVE;1.0l;2.19 +1795-4;Amylase;CCnc;Pt;Body fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Body fluid;Amylase Fld-cCnc;;ACTIVE;1.0;2.73 +17954-9;Bacteria identified^^^5;Prid;Pt;Body fld;Nom;Aerobic culture;MICRO;1;Bacteria # 5 identified in Body fluid by Aerobe culture;Bacteria Fld Aerobe Cult org #5;;ACTIVE;1.0l;2.19 +17955-6;Bacteria identified^^^6;Prid;Pt;Body fld;Nom;Aerobic culture;MICRO;1;Bacteria # 6 identified in Body fluid by Aerobe culture;Bacteria Fld Aerobe Cult org #6;;ACTIVE;1.0l;2.19 +17956-4;Bacteria identified;Prid;Pt;Body fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Body fluid by Anaerobe culture;Bacteria Fld Anaerobe Cult;;ACTIVE;1.0l;2.73 +17957-2;Bacteria identified^^^2;Prid;Pt;Body fld;Nom;Anaerobic culture;MICRO;1;Bacteria # 2 identified in Body fluid by Anaerobe culture;Bacteria Fld Anaerobe Cult org #2;;ACTIVE;1.0l;2.19 +17958-0;Bacteria identified^^^3;Prid;Pt;Body fld;Nom;Anaerobic culture;MICRO;1;Bacteria # 3 identified in Body fluid by Anaerobe culture;Bacteria Fld Anaerobe Cult org #3;;ACTIVE;1.0l;2.19 +17959-8;Bacteria identified^^^2;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Bacteria # 2 identified in Peritoneal fluid by Culture;Bacteria Prt Cult org #2;;ACTIVE;1.0l;2.19 +17960-6;Bacteria identified^^^3;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Bacteria # 3 identified in Peritoneal fluid by Culture;Bacteria Prt Cult org #3;;ACTIVE;1.0l;2.19 +17961-4;Bacteria identified^^^4;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Bacteria # 4 identified in Peritoneal fluid by Culture;Bacteria Prt Cult org #4;;ACTIVE;1.0l;2.19 +1796-2;Amylase;CCnc;Pt;Plr fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Pleural fluid;Amylase Plr-cCnc;;ACTIVE;1.0;2.73 +17962-2;Bacteria identified^^^5;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Bacteria # 5 identified in Peritoneal fluid by Culture;Bacteria Prt Cult org #5;;ACTIVE;1.0l;2.19 +17963-0;Bacteria identified^^^6;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Bacteria # 6 identified in Peritoneal fluid by Culture;Bacteria Prt Cult org #6;;ACTIVE;1.0l;2.19 +17964-8;Bacteria identified^^^2;Prid;Pt;Stool;Nom;Culture;MICRO;1;Bacteria # 2 identified in Stool by Culture;Bacteria Stl Cult org #2;;ACTIVE;1.0l;2.73 +17965-5;Bacteria identified^^^3;Prid;Pt;Stool;Nom;Culture;MICRO;1;Bacteria # 3 identified in Stool by Culture;Bacteria Stl Cult org #3;;ACTIVE;1.0l;2.73 +17966-3;Bacteria identified^^^4;Prid;Pt;Stool;Nom;Culture;MICRO;1;Bacteria # 4 identified in Stool by Culture;Bacteria Stl Cult org #4;;ACTIVE;1.0l;2.73 +17967-1;Bacteria identified^^^5;Prid;Pt;Stool;Nom;Culture;MICRO;1;Bacteria # 5 identified in Stool by Culture;Bacteria Stl Cult org #5;;ACTIVE;1.0l;2.73 +17968-9;Bacteria identified^^^6;Prid;Pt;Stool;Nom;Culture;MICRO;1;Bacteria # 6 identified in Stool by Culture;Bacteria Stl Cult org #6;;ACTIVE;1.0l;2.19 +17969-7;Bacteria identified;Prid;Pt;Urine;Nom;Aerobic culture;MICRO;1;Deprecated Bacteria identified in Urine by Aerobe culture;Deprecated Bacteria Ur Aerobe Cult;;DEPRECATED;1.0l;2.42 +1797-0;Amylase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Peritoneal fluid;Amylase Prt-cCnc;;ACTIVE;1.0;2.73 +17970-5;Bacteria identified^^^2;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria # 2 identified in Urine by Culture;Bacteria Ur Cult org #2;;ACTIVE;1.0l;2.73 +17971-3;Bacteria identified^^^3;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria # 3 identified in Urine by Culture;Bacteria Ur Cult org #3;;ACTIVE;1.0l;2.73 +17972-1;Bacteria identified^^^4;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria # 4 identified in Urine by Culture;Bacteria Ur Cult org #4;;ACTIVE;1.0l;2.73 +17973-9;Bacteria identified^^^5;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria # 5 identified in Urine by Culture;Bacteria Ur Cult org #5;;ACTIVE;1.0l;2.30 +17974-7;Bacteria identified^^^6;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria # 6 identified in Urine by Culture;Bacteria Ur Cult org #6;;ACTIVE;1.0l;2.30 +17975-4;Virus identified^^^2;Prid;Pt;XXX;Nom;Culture;MICRO;1;Virus # 2 identified in Specimen by Culture;Virus Spec Cult org #2;;ACTIVE;1.0l;2.69 +17976-2;Virus identified^^^3;Prid;Pt;XXX;Nom;Culture;MICRO;1;Virus # 3 identified in Specimen by Culture;Virus Spec Cult org #3;;ACTIVE;1.0l;2.69 +17977-0;Area;Area;Pt;Heart.atrium.left;Qn;US.2D.A4C;CARD.US;2;Left atrial Area by US.2D.A4C;LA Area A4C;;ACTIVE;1.0l;2.67 +17978-8;A wave.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Peak A wave by US.doppler;MV Peak A-wave DOP;;ACTIVE;1.0l;2.54 +17979-6;A-C duration;Time;Pt;Mitral valve.leaflet.anterior;Qn;US.M-mode;CARD.US;2;Anterior mitral valve leaflet A-C interval by US.M-mode;AML A-C interval M-mode;;ACTIVE;1.0l;2.54 +17980-4;A-C slope;Vel;Pt;Mitral valve.leaflet.anterior;Qn;US.M-mode;CARD.US;2;Anterior mitral valve leaflet A-C slope [Velocity] by US.M-mode;AML A-C slope M-mode;;ACTIVE;1.0l;2.54 +17981-2;Acceleration;Time;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Acceleration by US.doppler;AV Accel Time DOP;;ACTIVE;1.0l;2.48 +17982-0;Acceleration;Time;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Acceleration by US.doppler;PV Accel Time DOP;;ACTIVE;1.0l;2.48 +17983-8;Acceleration;Time;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Acceleration by US.doppler;TV Accel Time DOP;;ACTIVE;1.0l;2.48 +17984-6;Aortic valve area method;Prid;Pt;Aortic valve;Nom;*;CARD.US;2;Aortic valve area method;AV AV area method;;ACTIVE;1.0l;2.27 +17985-3;AP dimension.left atrium/AP dimension.aorta root;LenRto;Pt;Heart.atrium.left;Qn;US;CARD.US;2;Left atrial AP dimension.left atrium/AP dimension.aorta root by US;LA AP dim.LA/AP dim.aorta root US;;ACTIVE;1.0l;2.48 +17986-1;Apical 2 chamber.diastole.max;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod;CARD.US;2;Left ventricular Maximum Apical 2 chamber.diastole [Volume] by US 2D modified;LV Apical 2CH dias.max Vol US.2D.mod;;ACTIVE;1.0l;2.48 +17987-9;Apical 2 chamber.systole.min;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod;CARD.US;2;Left ventricular Apical 2 chamber.systole.minimum [Volume] by US 2D modified;LV Apical 2CH sys.min Vol US.2D.mod;;ACTIVE;1.0l;2.48 +1798-8;Amylase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Serum or Plasma;Amylase SerPl-cCnc;;ACTIVE;1.0;2.73 +17988-7;Apical 4 chamber;Area;Pt;Heart.atrium.right;Qn;US.2D;CARD.US;2;Right atrial Apical 4 chamber [Area] by US 2D;RA Apical 4CH Area 2D US;;ACTIVE;1.0l;2.48 +17989-5;Apical 4 chamber.diastole.max;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod;CARD.US;2;Left ventricular Maximum Apical 4 chamber.diastole [Volume] by US 2D modified;LV Apical 4CH dias.max Vol US.2D.mod;;ACTIVE;1.0l;2.67 +17990-3;Apical 4 chamber.systole.min;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod;CARD.US;2;Left ventricular Apical 4 chamber.systole.minimum [Volume] by US 2D modified;LV Apical 4CH sys.min Vol US.2D.mod;;ACTIVE;1.0l;2.48 +17991-1;Cardiac echo LV volume method;Prid;Pt;Heart.ventricle.left;Nom;*;CARD.US;2;Left ventricular Cardiac echo volume method;LV Cardiac echo vol method;;ACTIVE;1.0l;2.27 +17992-9;Cardiac output;VRat;Pt;Aorta.root;Qn;US.doppler;CARD.US;2;Aorta root Cardiac output by US.doppler;AO root Output DOP;;ACTIVE;1.0l;2.48 +17993-7;Cardiac output;VRat;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Cardiac output by US.doppler;MV Output DOP;;ACTIVE;1.0l;2.48 +17994-5;Cardiac output;VRat;Pt;Pulmonary artery;Qn;US;CARD.US;2;Pulmonary artery Cardiac output by US;PA Output US;;ACTIVE;1.0l;2.48 +17995-2;Coarctation.pressure gradient.max;PressDiff;Pt;Aorta;Qn;US.doppler;CARD.US;2;Aorta Maximum coarctation pressure gradient by US.doppler;Aorta Max Coarct Pres Grad DOP;;ACTIVE;1.0l;2.73 +1799-6;Amylase;CCnc;Pt;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Urine;Amylase Ur-cCnc;;ACTIVE;1.0;2.73 +17996-0;Cusp separation.max;Len;Pt;Aortic valve;Qn;US;CARD.US;2;Aortic valve Maximum cusp separation [Length] by US;AV Cusp sep.max US;;ACTIVE;1.0l;2.48 +17997-8;D-E excursion;Len;Pt;Mitral valve.leaflet.anterior;Qn;US.M-mode;CARD.US;2;Anterior mitral valve leaflet D-E excursion [Length] by US.M-mode;AML D-E excursion M-mode;;ACTIVE;1.0l;2.54 +17998-6;Regurgitant jet deceleration;Time;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Regurgitant jet deceleration [Time] by US.doppler;AV Regurg jet decel Time DOP;;ACTIVE;1.0l;2.67 +17999-4;Deceleration;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Deceleration [Time] by US.doppler;MV Decel Time DOP;;ACTIVE;1.0l;2.48 +1-8;Acyclovir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Acyclovir [Susceptibility];Acyclovir Susc Islt;;ACTIVE;1.0;2.73 +180-0;Cinoxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cinoxacin [Susceptibility] by Minimum lethal concentration (MLC);Cinoxacin Islt MLC;;ACTIVE;1.0;2.19 +18000-0;Deceleration;Time;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Deceleration [Time] by US.doppler;TV Decel Time DOP;;ACTIVE;1.0l;2.48 +18001-8;Deceleration.pressure.half time;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Deceleration.pressure.half time by US.doppler;MV Decel.pres.1/2T DOP;;ACTIVE;1.0l;2.48 +1800-2;Amylase;CRat;24H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/time] in 24 hour Urine;Amylase 24h Ur-cRate;;ACTIVE;1.0;2.73 +18002-6;Deceleration slope;Accel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Deceleration slope [Acceleration] by US.doppler;MV Decel slope DOP;;ACTIVE;1.0l;2.29 +18003-4;Regurgitant deceleration time slope;Accel;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Regurgitant deceleration time slope by US.doppler;AV Regurg decel time slope DOP;;ACTIVE;1.0l;2.67 +18004-2;Defect.diameter;Len;Pt;Heart.atrium.septum;Qn;US;CARD.US;2;Atrial septum Defect diameter by US;AS Defect.diam US;;ACTIVE;1.0l;2.48 +18005-9;Defect.diameter;Len;Pt;Heart.ventricle.septum;Qn;US;CARD.US;2;Ventricular septal Defect diameter by US;VS Defect.diam US;;ACTIVE;1.0l;2.48 +18006-7;Diameter;Len;Pt;Vena cava.inferior;Qn;US;CARD.US;2;Inferior vena cava Diameter by US;IVC Diam US;;ACTIVE;1.0l;2.73 +18007-5;Diameter;Len;Pt;Vena cava.superior;Qn;US;CARD.US;2;Superior vena cava Diameter by US;SVC Diam US;;ACTIVE;1.0l;2.48 +18008-3;Defect.pressure gradient.systole.max;PressDiff;Pt;Heart.ventricle.septum;Qn;US.doppler;CARD.US;2;Ventricular septal Defect.pressure gradient.systole.maximum by US.doppler;VS Defect.press grad.sys.max DOP;;ACTIVE;1.0l;2.67 +18009-1;Defect.pressure gradient.systole.mean;PressDiff;Pt;Heart.ventricle.septum;Qn;US.doppler;CARD.US;2;Ventricular septal Defect.pressure gradient.systole.mean by US.doppler;VS Defect.press grad.sys.mean DOP;;ACTIVE;1.0l;2.67 +1801-0;Amylase renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Amylase renal clearance in 24 hour Urine and Serum or Plasma;Amylase Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +18010-9;Diameter;Len;Pt;Aorta;Qn;US;CARD.US;2;Aorta Diameter by US;Aorta Diam US;;ACTIVE;1.0l;2.48 +18011-7;Diameter;Len;Pt;Aorta.thoracic.arch;Qn;US;CARD.US;2;Aorta arch and Neck Diameter by US;TA arch Diam US;;ACTIVE;1.0l;2.48 +18012-5;Diameter;Len;Pt;Aorta.thoracic.ascending;Qn;US;CARD.US;2;Ascending thoracic aorta Diameter by US;ATA Diam US;;ACTIVE;1.0l;2.54 +18013-3;Diameter;Len;Pt;Aorta.thoracic.descending;Qn;US;CARD.US;2;Descending thoracic aorta Diameter by US;DTA Diam US;;ACTIVE;1.0l;2.54 +18014-1;Diameter;Len;Pt;Aorta.isthmus;Qn;US;CARD.US;2;Aorta isthmus Diameter by US;Aorta.isthmus Diam US;;ACTIVE;1.0l;2.48 +18015-8;Diameter;Len;Pt;Aorta.root.annulo-aortic junction;Qn;US;CARD.US;2;Aorta root annulo-aortic junction Diameter by US;AO.root.annulo-AO junc Diam US;;ACTIVE;1.0l;2.73 +18016-6;Diameter;Len;Pt;Aortic valve.annulus;Qn;US;CARD.US;2;Aortic valve annulus Diameter by US;AV ann Diam US;;ACTIVE;1.0l;2.27 +18017-4;Diameter;Len;Pt;Mitral valve.annulus;Qn;US;CARD.US;2;Mitral valve annulus Diameter by US;MV ann Diam US;;ACTIVE;1.0l;2.27 +18018-2;Diameter;Len;Pt;Heart.ventricle.left.outflow tract;Qn;US;CARD.US;2;Left ventricular outflow tract Diameter by US;LVOT Diam US;;ACTIVE;1.0l;2.73 +18019-0;Diameter;Len;Pt;Pulmonary artery.left;Qn;US;CARD.US;2;Left pulmonary artery Diameter by US;PA-L Diam US;;ACTIVE;1.0l;2.54 +18020-8;Diameter;Len;Pt;Pulmonary artery.main;Qn;US;CARD.US;2;Main pulmonary artery Diameter by US;MPA Diam US;;ACTIVE;1.0l;2.48 +18021-6;Diameter;Len;Pt;Pulmonary artery.right;Qn;US;CARD.US;2;Right pulmonary artery Diameter by US;PA-R Diam US;;ACTIVE;1.0l;2.54 +18022-4;Diameter;Len;Pt;Pulmonic valve.annulus;Qn;US;CARD.US;2;Pulmonic valve annulus Diameter by US;PV ann Diam US;;ACTIVE;1.0l;2.54 +18023-2;Diameter;Len;Pt;Tricuspid valve.annulus;Qn;US;CARD.US;2;Tricuspid valve annulus Diameter by US;TV ann Diam US;;ACTIVE;1.0l;2.48 +18024-0;Diameter.anterior-posterior.systole;Len;Pt;Heart.atrium.left;Qn;US.M-mode;CARD.US;2;Left atrial Diameter anterior-posterior systole by US.M-mode;LA Diam AP sys M-mode;;ACTIVE;1.0l;2.54 +18025-7;Diameter.anterior-posterior.systole/Diameter.aorta root;LenRto;Pt;Heart;Qn;US;CARD.US;2;Heart Diameter anterior-posterior systole/Aortic root diameter by US;Hrt Diam AP sys/OA root US;;ACTIVE;1.0l;2.48 +18026-5;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular End-diastolic volume by US;LV ED vol US;;ACTIVE;1.0l;2.52 +18027-3;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by single-plane ellipse method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by single-plane ellipse method;LV ED vol US.2D+SP-EL;;ACTIVE;1.0l;2.52 +1802-8;Amylase.P1;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.P1 [Enzymatic activity/volume] in Serum or Plasma;Amylase P1 SerPl-cCnc;;ACTIVE;1.0;2.73 +18028-1;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane ellipse method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by biplane ellipse method;LV ED vol US.2D+BP-EL;;ACTIVE;1.0l;2.52 +18029-9;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod;CARD.US;2;Left ventricular End-diastolic volume by US 2D modified;LV ED vol US.2D.mod;;ACTIVE;1.0l;2.52 +18030-7;A wave.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Peak A wave by US.doppler;TV Peak A-wave DOP;;ACTIVE;1.0l;2.54 +18031-5;E wave.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Peak E wave by US.doppler;TV Peak E-wave DOP;;ACTIVE;1.0l;2.54 +18032-3;Pressure half time.diastole;Time;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Pressure half time during diastole by US.doppler;TV PHT dias DOP;;ACTIVE;1.0l;2.67 +18033-1;Diastole-systole;Vol;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Diastole-systole [Volume] by US;LV Dia-sys Vol US;;ACTIVE;1.0l;2.67 +18034-9;Regurgitation dP/dT (1 M/S to 3 M/S).systole;PresRat;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve regurgitant jet dP/dT (1 M/S to 3 M/S).systole [Pressure rate] by US.doppler;TV reg dP/dT (1 M/S to 3 M/S).syst DOP;;ACTIVE;1.0l;2.67 +18035-6;Regurgitation dP/dT (1M/S to 3 M/S);PresRat;Pt;Mitral valve;Qn;US.doppler.CW;CARD.US;2;Mitral valve regurgitant jet dP/dT (1M/S to 3 M/S) [Pressure rate] by US.doppler continuous wave;MV reg dP/dT (1M/S to 3 M/S) DOP.CW;;ACTIVE;1.0l;2.67 +1803-6;Amylase.P2;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.P2 [Enzymatic activity/volume] in Serum or Plasma;Amylase P2 SerPl-cCnc;;ACTIVE;1.0;2.73 +18036-4;E point to septal separation;Time;Pt;Mitral valve.leaflet.anterior;Qn;US.M-mode;CARD.US;2;Anterior mitral valve leaflet E point to septal separation [Time] by US.M-mode;AML EPSS Time M-mode;;ACTIVE;1.0l;2.54 +18037-2;E wave.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Peak E wave by US.doppler;MV Peak E-wave DOP;;ACTIVE;1.0l;2.54 +18038-0;E wave.max/A wave.max;VelRto;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Peak E wave/Peak A wave by US.doppler;MV Peak E-wave/Peak A wave DOP;;ACTIVE;1.0l;2.69 +18039-8;E wave.max/A wave.max;VelRto;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Peak E wave/Peak A wave by US.doppler;TV Peak E-wave/Peak A wave DOP;;ACTIVE;1.0l;2.69 +18040-6;E-F slope;Vel;Pt;Mitral valve.leaflet.anterior;Qn;US.M-mode;CARD.US;2;Anterior mitral valve leaflet E-F slope [Velocity] by US.M-mode;AML E-F slope M-mode;;ACTIVE;1.0l;2.54 +18041-4;Ejection time;Time;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Ejection time by US.doppler;AV Ejection time DOP;;ACTIVE;1.0l;2.54 +18042-2;Ejection time;Time;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Ejection time by US.doppler;PV Ejection time DOP;;ACTIVE;1.0l;2.54 +18043-0;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Ejection fraction by US;LV EF US;;ACTIVE;1.0l;2.73 +1804-4;Amylase.P3;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.P3 [Enzymatic activity/volume] in Serum or Plasma;Amylase P3 SerPl-cCnc;;ACTIVE;1.0;2.73 +18044-8;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by single-plane ellipse method;CARD.US;2;Left ventricular Ejection fraction by US.2D+Calculated by single-plane ellipse method;LV EF US.2D+SP-EL;;ACTIVE;1.0l;2.52 +18045-5;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane ellipse method;CARD.US;2;Left ventricular Ejection fraction by US.2D+Calculated by biplane ellipse method;LV EF US.2D+BP-EL;;ACTIVE;1.0l;2.52 +18046-3;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D.mod;CARD.US;2;Left ventricular Ejection fraction by US 2D modified;LV EF US.2D.mod;;ACTIVE;1.0l;2.52 +18047-1;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane;CARD.US;2;Left ventricular Ejection fraction by US 2D modified biplane;LV EF US.2D.MOD-BP;;ACTIVE;1.0l;2.73 +18048-9;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane;CARD.US;2;Left ventricular Ejection fraction by US 2D modified single-plane;LV EF US.2D.MOD-SP;;ACTIVE;1.0l;2.52 +18049-7;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Teichholz method;CARD.US;2;Left ventricular Ejection fraction by US.M-mode+Calculated by Teichholz method;LV EF US.M-mode+Teichholz;;ACTIVE;1.0l;2.52 +18050-5;Fractional collapse^inspiration;LenFr;Pt;Vena cava.inferior;Qn;US;CARD.US;2;Inferior vena cava Fractional collapse by US --inspiration;IVC Fract collapse insp US;;ACTIVE;1.0l;2.48 +1805-1;Amylase.pancreatic;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma;Amylase P SerPl-cCnc;;ACTIVE;1.0;2.73 +18051-3;Fractional shortening.minor axis;LenFr;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Fractional shortening minor axis by US;LV FS US;;ACTIVE;1.0l;2.73 +18052-1;Fractional thickening.freewall;LenFr;Pt;Heart.ventricle.right.anterior wall;Qn;US;CARD.US;2;Right ventricular anterior wall Fractional thickening freewall by US;RV.ant wall Fract thickening.freewall US;;ACTIVE;1.0l;2.54 +18053-9;Thickening.fractional change;LenFr;Pt;Heart.ventricle.left.posterior wall;Qn;US;CARD.US;2;Left ventricular posterior wall Thickening.fractional change by US;LVPW Thick.fract chng US;;ACTIVE;1.0l;2.27 +18054-7;"Fractional thickness; fractional change";LenFr;Pt;Heart.interventricular septum;Qn;US.2D;CARD.US;2;"Interventricular septum Fractional thickness; fractional change by US 2D";"IVS Fract thickness;change 2D US";;ACTIVE;1.0l;2.48 +18055-4;Pressure gradient.diastole.max;PressDiff;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Maximum pressure gradient during diastole by US.doppler;TV Max press grad dias DOP;;ACTIVE;1.0l;2.67 +18056-2;Pressure gradient.diastole.mean;PressDiff;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Mean pressure gradient dur diastole by US.doppler;TV Mean press grad dias DOP;;ACTIVE;1.0l;2.67 +18057-0;Pressure gradient.max;PressDiff;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Peak pressure gradient by US.doppler;MV Peak press grad DOP;;ACTIVE;1.0l;2.67 +18058-8;Pressure gradient.max;PressDiff;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Peak pressure gradient by US.doppler;PV Peak press grad DOP;;ACTIVE;1.0l;2.67 +18059-6;Pressure gradient.mean;PressDiff;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Mean pressure gradient by US.doppler;MV Mean press grad DOP;;ACTIVE;1.0l;2.67 +18060-4;Pressure gradient.mean;PressDiff;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Mean pressure gradient by US.doppler;PV Mean press grad DOP;;ACTIVE;1.0l;2.73 +18061-2;Pressure gradient.systole.max;PressDiff;Pt;Aortic valve;Qn;US.doppler.derived.full Bernoulli;CARD.US;2;Aortic valve Maximum pressure gradient dur systole by US.doppler derived full Bernoulli;AV Max press grad sys DOP V1V2;;ACTIVE;1.0l;2.67 +18062-0;Pressure gradient.systole.max;PressDiff;Pt;Aortic valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US;2;Aortic valve Maximum pressure gradient dur systole by US.doppler+Calculated by simplified Bernoulli;AV Max press grad sys Simp Bern;;ACTIVE;1.0l;2.73 +18063-8;Gradient.systole.mean;Pres;Pt;Aortic valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US;2;Deprecated Aortic valve Mean systole gradient [Pressure] by US.doppler+Calculated by simplified Bernoulli;Deprecated AV Mean grad systole Simp Bern;;DEPRECATED;1.0l;2.67 +18064-6;Pressure gradient.systole.max;PressDiff;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US;2;Left ventricular outflow tract Maximum pressure gradient dur systole by US.doppler;LVOT Max press grad sys DOP;;ACTIVE;1.0l;2.67 +18065-3;Regurgitant pressure gradient.systole.max;Pres;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Maximum regurgitant pressure gradient dur systole by US.doppler;TV Max regurg press grad sys DOP;;ACTIVE;1.0l;2.67 +18066-1;Pressure gradient.systole.mean;PressDiff;Pt;Aortic valve;Qn;US.doppler.derived.full Bernoulli;CARD.US;2;Aortic valve Mean systole pressure gradient by US.doppler derived full Bernoulli;AV Mean press grad sys DOP V1V2;;ACTIVE;1.0l;2.73 +18067-9;Image quality;Type;Pt;Cardiac echo imaging device;Nom;US;CARD.US;2;Cardiac echo imaging device Image quality by US;Card Echo Device Image Qual US;;ACTIVE;1.0l;2.56 +18068-7;Pre ejection time;Time;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Pre ejection time by US;LV Pre eject time US;;ACTIVE;1.0l;2.54 +1806-9;Amylase.S1;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S1 [Enzymatic activity/volume] in Serum or Plasma;Amylase S1 SerPl-cCnc;;ACTIVE;1.0;2.73 +18069-5;Intrachamber.systole.mean;Pres;Pt;Heart.atrium.right;Qn;Estimated from jugular venous distention;CARD.US;2;Right atrial Intrachamber mean systole pressure by Estimated from jugular venous distention;RA Intrachamber.sys.mean press JVD est;;ACTIVE;1.0l;2.40 +18070-3;Intrachamber.systole.mean;Pres;Pt;Heart.atrium.right;Qn;US;CARD.US;2;Right atrial Intrachamber mean systole pressure by US;RA Intrachamber.sys.mean press US;;ACTIVE;1.0l;2.40 +18071-1;Isovolumic relaxation time;Time;Pt;Heart.ventricle.left;Qn;US.doppler;CARD.US;2;Left ventricular Isovolumic relaxation time by US.doppler;LV Isovolumic relaxation time DOP;;ACTIVE;1.0l;2.54 +18072-9;Major axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D.A2C;CARD.US;2;Left ventricular Major axis diastole [Length] by US.2D.A2C;LV Major axis dias A2C;;ACTIVE;1.0l;2.68 +18073-7;Major axis.systole;Len;Pt;Heart.ventricle.left;Qn;US.2D.A2C;CARD.US;2;Left ventricular Major axis during systole [Length] by US.2D.A2C;LV Major axis dur sys A2C;;ACTIVE;1.0l;2.67 +18074-5;Major axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D.A4C;CARD.US;2;Left ventricular Major axis diastole [Length] by US.2D.A4C;LV Major axis dias A4C;;ACTIVE;1.0l;2.67 +18075-2;Major axis.systole;Len;Pt;Heart.ventricle.left;Qn;US.2D.A4C;CARD.US;2;Left ventricular Major axis during systole [Length] by US.2D.A4C;LV Major axis dur sys A4C;;ACTIVE;1.0l;2.67 +18076-0;Major axis.apical.systole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Major axis apical systole [Length] by US 2D;LV Major axis apical sys 2D US;;ACTIVE;1.0l;2.48 +1807-7;Amylase.S2;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S2 [Enzymatic activity/volume] in Serum or Plasma;Amylase S2 SerPl-cCnc;;ACTIVE;1.0;2.73 +18077-8;Major axis.apical.diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Major axis apical diastole [Length] by US 2D;LV Major axis apical dias 2D US;;ACTIVE;1.0l;2.48 +18078-6;Major axis.diastole.max;Len;Pt;Heart.ventricle.right;Qn;US.2D;CARD.US;2;Right ventricular Major axis diastole maximum [Length] by US 2D;RV Major axis dias max 2D US;;ACTIVE;1.0l;2.48 +18079-4;Major axis.systole.min;Len;Pt;Heart.ventricle.right;Qn;US.2D;CARD.US;2;Right ventricular Minimum major axis during systole [Length] by US 2D;RV Minimum major axis sys 2D US;;ACTIVE;1.0l;2.67 +18080-2;Blood flow velocity.systole.max;Vel;Pt;Heart.ventricle.right.outflow tract;Qn;US.doppler;CARD.US;2;Right ventricular outflow tract Maximum blood flow velocity during systole by US.doppler;RVOT Vmax sys DOP;;ACTIVE;1.0l;2.67 +18081-0;Minor axis.end diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D.A4C;CARD.US;2;Left ventricular Minor axis at end diastole [Length] by US.2D.A4C;LV ED minor axis A4C;;ACTIVE;1.0l;2.67 +18082-8;Minor axis.end systole.apical 4 chamber;Len;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US;2;Left ventricular Minor axis at end systole.apical 4 chamber [Length] by US.M-mode;LV ES minor axis A4C M-mode;;ACTIVE;1.0l;2.54 +18083-6;Internal diameter.minor axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Internal diameter minor axis diastole by US 2D;LV Diam dias, short 2D US;;ACTIVE;1.0l;2.48 +18084-4;Minor axis.end diastole;Len;Pt;Heart.ventricle.right;Qn;US.2D;CARD.US;2;Right ventricular Minor axis at end diastole [Length] by US 2D;RV ED minor axis 2D US;;ACTIVE;1.0l;2.54 +1808-5;Amylase.S3;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S3 [Enzymatic activity/volume] in Serum or Plasma;Amylase S3 SerPl-cCnc;;ACTIVE;1.0;2.73 +18085-1;Internal diameter.minor axis.systole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Internal diameter minor axis systole by US 2D;LV Diam sys, short 2D US;;ACTIVE;1.0l;2.48 +18086-9;Minor axis.end systole;Len;Pt;Heart.ventricle.right;Qn;US.2D;CARD.US;2;Right ventricular Minor axis at end systole [Length] by US 2D;RV ES minor axis 2D US;;ACTIVE;1.0l;2.54 +18087-7;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Myocardial mass by US;LV Myo mass US;;ACTIVE;1.0l;2.54 +18088-5;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US;2;Left ventricular Myocardial mass by US.M-mode;LV Myo mass M-mode;;ACTIVE;1.0l;2.54 +18089-3;Orifice area;Area;Pt;Aortic valve;Qn;US;CARD.US;2;Aortic valve Orifice area by US;AV Orifice area US;;ACTIVE;1.0l;2.67 +18090-1;Orifice area;Area;Pt;Aortic valve;Qn;US.continuity;CARD.US;2;Aortic valve Orifice area by US.continuity;AV Orifice area US.cont;;ACTIVE;1.0l;2.67 +18091-9;Orifice area;Area;Pt;Aortic valve;Qn;US.continuity.VTI+Area;CARD.US;2;Aortic valve Orifice area by US.continuity.VTI+Area;AV Orifice area US.cont.VTI+area;;ACTIVE;1.0l;2.73 +18092-7;Orifice area;Area;Pt;Aortic valve;Qn;US.continuity.VTI+Diameter;CARD.US;2;Aortic valve Orifice area by US.continuity.VTI+Diameter;AV Orifice area US.cont.VTI+diam;;ACTIVE;1.0l;2.67 +1809-3;Amylase.salivary;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.salivary [Enzymatic activity/volume] in Serum or Plasma;Amylase S SerPl-cCnc;;ACTIVE;1.0;2.73 +18093-5;Orifice area;Area;Pt;Aortic valve;Qn;US.continuity.Vmax+Area;CARD.US;2;Aortic valve Orifice area by US.continuity.Vmax+Area;AV Orifice area US.cont VMAX+area;;ACTIVE;1.0l;2.67 +18094-3;Orifice area;Area;Pt;Aortic valve;Qn;US.continuity.Vmax+Diameter;CARD.US;2;Aortic valve Orifice area by US.continuity.Vmax+Diameter;AV Orifice area US.cont.VMAX+diam;;ACTIVE;1.0l;2.67 +18095-0;Crossection;Area;Pt;Pulmonary artery.main;Qn;US;CARD.US;2;Main pulmonary artery Crossection [Area] by US;MPA Xsection Area US;;ACTIVE;1.0l;2.48 +18096-8;Orifice area;Area;Pt;Pulmonic valve;Qn;US.continuity;CARD.US;2;Pulmonic valve Orifice area by US.continuity;PV Orifice area US.cont;;ACTIVE;1.0l;2.67 +18097-6;Orifice area.min;Area;Pt;Mitral valve;Qn;US.doppler.pressure half time;CARD.US;2;Mitral valve Minimum orifice area by US.doppler pressure half time;MV Orifice area min DOP PHT;;ACTIVE;1.0l;2.67 +18098-4;Orifice area.minor axis.min;Area;Pt;Mitral valve;Qn;US.2D;CARD.US;2;Mitral valve Minimum orifice area minor axis by US 2D;MV Orifice area.minor axis.min 2D US;;ACTIVE;1.0l;2.67 +18099-2;Plane.diastole;Area;Pt;Heart.ventricle.left;Qn;US.2D.A2C;CARD.US;2;Left ventricular Plane.diastole [Area] by US.2D.A2C;LV Plane.dia Area A2C;;ACTIVE;1.0l;2.67 +18100-8;Plane.systole;Area;Pt;Heart.ventricle.left;Qn;US.2D.A2C;CARD.US;2;Left ventricular Plane.systole [Area] by US.2D.A2C;LV Plane.sys Area A2C;;ACTIVE;1.0l;2.67 +1810-1;Amylase/Creatinine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Amylase/Creatinine [Mass Ratio] in Serum or Plasma;Amylase/Creat SerPl;;ACTIVE;1.0;2.44 +18101-6;Plane.diastole;Area;Pt;Heart.ventricle.left;Qn;US.2D.A4C;CARD.US;2;Left ventricular Plane.diastole [Area] by US.2D.A4C;LV Plane.dia Area A4C;;ACTIVE;1.0l;2.67 +18102-4;Plane.systole;Area;Pt;Heart.ventricle.left;Qn;US.2D.A4C;CARD.US;2;Left ventricular Plane.systole [Area] by US.2D.A4C;LV Plane.sys Area A4C;;ACTIVE;1.0l;2.67 +18103-2;Planimetry.parasternal short axis;Area;Pt;Heart.ventricle.left.outflow tract;Qn;US.2D;CARD.US;2;Left ventricular outflow tract Planimetry parasternal short axis [Area] by US 2D;LVOT PLN parasternal short Area 2D US;;ACTIVE;1.0l;2.48 +18104-0;Pressure half time;Time;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Pressure half time by US.doppler;AV PHT DOP;;ACTIVE;1.0l;2.54 +18105-7;Regurgitant blood flow pressure half-time;Time;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Regurgitant blood flow pressure half-time by US.doppler;AV Regurg PHT DOP;;ACTIVE;1.0l;2.67 +18106-5;Procedure;Prid;Pt;Cardiac echo study;Nom;*;CARD.US;2;Cardiac echo study Procedure;Cardiac Echo Study Procedure;;ACTIVE;1.0l;2.29 +18107-3;Procedure stress method;Type;Pt;Cardiac echo study;Nom;*;CARD.US;2;Cardiac echo study Procedure stress method;Cardiac Echo Study Proced stress method;;ACTIVE;1.0l;2.73 +18108-1;Prosthetic valve type;Prid;Pt;Aortic valve;Nom;US;CARD.US;2;Aortic valve Prosthetic valve type by US;AV Prosth valve typ US;;ACTIVE;1.0l;2.27 +18109-9;Prosthetic valve type;Prid;Pt;Mitral valve;Nom;US;CARD.US;2;Mitral valve Prosthetic valve type by US;MV Prosth valve typ US;;ACTIVE;1.0l;2.27 +18110-7;Prosthetic valve type;Prid;Pt;Pulmonic valve;Nom;US;CARD.US;2;Pulmonic valve Prosthetic valve type by US;PV Prosth valve typ US;;ACTIVE;1.0l;2.27 +18111-5;Prosthetic valve type;Prid;Pt;Tricuspid valve;Nom;US;CARD.US;2;Tricuspid valve Prosthetic valve type by US;TV Prosth valve typ US;;ACTIVE;1.0l;2.27 +18112-3;Regurgitation degree;Arb;Pt;Aortic valve;Ord;US.doppler;CARD.US;2;Aortic valve Regurgitation degree by US.doppler;AV Reg deg DOP;;ACTIVE;1.0l;2.29 +18113-1;Regurgitation degree;Arb;Pt;Mitral valve;Ord;US.doppler;CARD.US;2;Mitral valve Regurgitation degree by US.doppler;MV Reg deg DOP;;ACTIVE;1.0l;2.29 +18114-9;Regurgitation degree;Arb;Pt;Pulmonic valve;Ord;US.doppler;CARD.US;2;Pulmonic valve Regurgitation degree by US.doppler;PV Reg deg DOP;;ACTIVE;1.0l;2.29 +18115-6;Regurgitation degree;Arb;Pt;Tricuspid valve;Ord;US.doppler;CARD.US;2;Tricuspid valve Regurgitation degree by US.doppler;TV Reg deg DOP;;ACTIVE;1.0l;2.73 +18116-4;Segmental wall appearance;Find;Pt;Heart.ventricle.left;Nom;US;CARD.US;2;Left ventricular Segmental wall appearance by US;LV Seg wall appear US;;ACTIVE;1.0l;2.34 +18117-2;Segmental wall motion;Find;Pt;Heart.ventricle.left;Ord;US;CARD.US;2;Left ventricular Segmental wall motion by US;LV SWM US Ql;;ACTIVE;1.0l;2.73 +18118-0;Segmental wall motion;Find;Pt;Heart.ventricle.left;Nar;US;CARD.US;2;Left ventricular Segmental wall motion Narrative by US;LV SWM US;;ACTIVE;1.0l;2.40 +1811-9;Amylase/Creatinine renal clearance;Ratio;24H;Urine+Ser/Plas;Qn;;CHEM;1;Amylase/Creatinine renal clearance [Ratio] in 24 hour Urine and Serum or Plasma;Amylase/Cr Cl 24h Ur+SerPl-Rto;;ACTIVE;1.0;2.73 +18119-8;Segmental wall motion;Find;Pt;Heart.ventricle.left.apical anterior;Ord;US;CARD.US;2;Left ventricular apical anterior Segmental wall motion by US;LV.apical ant SWM US;;ACTIVE;1.0l;2.54 +18120-6;Segmental wall motion;Find;Pt;Heart.ventricle.left.apical septum;Ord;US;CARD.US;2;Left ventricular apical septum Segmental wall motion by US;LV.apical septum SWM US;;ACTIVE;1.0l;2.54 +18121-4;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal anterior;Ord;US;CARD.US;2;Left ventricular basal anterior Segmental wall motion by US;LV.basal ant SWM US;;ACTIVE;1.0l;2.54 +18122-2;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal anterior septum;Ord;US;CARD.US;2;Left ventricular basal anterior septum Segmental wall motion by US;LV.basal ant septum SWM US;;ACTIVE;1.0l;2.54 +18123-0;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal inferior;Ord;US;CARD.US;2;Left ventricular basal inferior Segmental wall motion by US;LV.basal inf SWM US;;ACTIVE;1.0l;2.54 +18124-8;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal lateral;Ord;US;CARD.US;2;Left ventricular basal lateral Segmental wall motion by US;LV.basal lat SWM US;;ACTIVE;1.0l;2.54 +18125-5;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal posterior;Ord;US;CARD.US;2;Left ventricular basal posterior Segmental wall motion by US;LV.basal post SWM US;;ACTIVE;1.0l;2.54 +18126-3;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal septum;Ord;US;CARD.US;2;Left ventricular basal septum Segmental wall motion by US;LV.basal sept SWM US;;ACTIVE;1.0l;2.54 +1812-7;Alpha fucosidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Alpha fucosidase [Enzymatic activity/mass] in Tissue;A-Fucosidase Tiss-cCnt;;ACTIVE;1.0;2.42 +18127-1;Segmental wall motion;Find;Pt;Heart.ventricle.left.inferior apical;Ord;US;CARD.US;2;Left ventricular inferior apical Segmental wall motion by US;LV.inf apical SWM US;;ACTIVE;1.0l;2.54 +18128-9;Segmental wall motion;Find;Pt;Heart.ventricle.left.lateral apical;Ord;US;CARD.US;2;Left ventricular lateral apical Segmental wall motion by US;LV.apical lat SWM US;;ACTIVE;1.0l;2.54 +18129-7;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid anterior;Ord;US;CARD.US;2;Left ventricular mid anterior Segmental wall motion by US;LV.mid ant SWM US;;ACTIVE;1.0l;2.54 +18130-5;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid anterior septum;Ord;US;CARD.US;2;Left ventricular mid anterior septum Segmental wall motion by US;LV.mid ant septum SWM US;;ACTIVE;1.0l;2.54 +18131-3;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid inferior;Ord;US;CARD.US;2;Left ventricular mid inferior Segmental wall motion by US;LV.mid inf SWM US;;ACTIVE;1.0l;2.54 +18132-1;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid lateral;Ord;US;CARD.US;2;Left ventricular mid lateral Segmental wall motion by US;LV.mid lat SWM US;;ACTIVE;1.0l;2.54 +18133-9;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid posterior;Ord;US;CARD.US;2;Left ventricular mid posterior Segmental wall motion by US;LV.mid post SWM US;;ACTIVE;1.0l;2.54 +18134-7;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid septum;Ord;US;CARD.US;2;Left ventricular mid septum Segmental wall motion by US;LV.mid sept SWM US;;ACTIVE;1.0l;2.54 +1813-5;Alpha galactosidase A;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha galactosidase A [Enzymatic activity/volume] in Serum or Plasma;A-Galactosidase A SerPl-cCnc;;ACTIVE;1.0;2.73 +18135-4;Minor axis.mitral level.diastole;Area;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Minor axis.mitral level.diastole [Area] by US 2D;LV Minor axis.mitral.dias Area 2D US;;ACTIVE;1.0l;2.48 +18136-2;Minor axis.mitral level.systole;Area;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Minor axis.mitral level.systole [Area] by US 2D;LV Minor axis.mitral.sys Area 2D US;;ACTIVE;1.0l;2.48 +18137-0;Minor axis.papillary level.diastole;Area;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Minor axis.papillary level.diastole [Area] by US 2D;LV Minor axis.papillary.dias Area 2D US;;ACTIVE;1.0l;2.48 +18138-8;Minor axis.papillary level.systole;Area;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Minor axis.papillary level.systole [Area] by US 2D;LV Minor axis.papillary.sys Area 2D US;;ACTIVE;1.0l;2.48 +18139-6;Stage;Prid;Pt;Stress study;Nom;US;CARD.US;2;Stress study Stage by US;Stress Study Stage US;;ACTIVE;1.0l;2.27 +18140-4;Study observation;Find;Pt;Cardiovascular.central;Nom;US;CARD.US;2;Central cardiovascular Study observation by US;US Cent CV Study;;ACTIVE;1.0l;2.27 +18141-2;Study observation;Find;Pt;Cardiovascular.central;Nar;US;CARD.US;2;Central cardiovascular Study observation Narrative by US;US Cent CV Study;;ACTIVE;1.0l;2.40 +18142-0;Study observation;Find;Pt;Heart.chambers;Nom;US;CARD.US;2;Heart chambers Study observation by US;US Hrt.chambers Study;;ACTIVE;1.0l;2.73 +1814-3;Acid alpha glucosidase;CCnc;Pt;Semen;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/volume] in Semen;Acid A-Glucosidase Smn-cCnc;;ACTIVE;1.0;2.68 +18143-8;Study observation;Find;Pt;Heart.chambers;Nar;US;CARD.US;2;Heart chambers Study observation Narrative by US;US Hrt.chambers Study;;ACTIVE;1.0l;2.40 +18144-6;Study observation;Find;Pt;Heart.valves;Nar;US;CARD.US;2;Heart valves Study observation Narrative by US;US Hrt.valves Study;;ACTIVE;1.0l;2.40 +18145-3;Study observation;Find;Pt;Heart.valves;Nom;US;CARD.US;2;Heart valves Study observation by US;US Hrt.valves Study;;ACTIVE;1.0l;2.27 +18146-1;Study observation.overall;Imp;Pt;Cardiovascular.central;Nar;US;CARD.US;2;Central cardiovascular Overall Study observation Narrative by US;US Cent CV Study [Imp];;ACTIVE;1.0l;2.40 +18147-9;Study observation.overall;Imp;Pt;Cardiovascular.central;Nom;US;CARD.US;2;Central cardiovascular Overall Study observation by US;US Cent CV Study [Imp];;ACTIVE;1.0l;2.40 +18148-7;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular End-systolic volume by US;LV ES vol US;;ACTIVE;1.0l;2.73 +18149-5;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by single-plane ellipse method;CARD.US;2;Left ventricular End-systolic volume by US.2D+Calculated by single-plane ellipse method;LV ES vol US.2D+SP-EL;;ACTIVE;1.0l;2.52 +1815-0;Acid alpha glucosidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/mass] in Tissue;Acid A-Glucosidase Tiss-cCnt;;ACTIVE;1.0;2.73 +18150-3;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane ellipse method;CARD.US;2;Left ventricular End-systolic volume by US.2D+Calculated by biplane ellipse method;LV ES vol US.2D+BP-EL;;ACTIVE;1.0l;2.52 +18151-1;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod;CARD.US;2;Left ventricular End-systolic volume by US 2D modified;LV ES vol US.2D.mod;;ACTIVE;1.0l;2.52 +18152-9;Thickness.diastole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US;CARD.US;2;Left ventricular posterior wall Thickness during diastole by US;LVPW Thickness dia US;;ACTIVE;1.0l;2.73 +18153-7;Thickness.diastole;Len;Pt;Heart.ventricle.right.anterior wall;Qn;US;CARD.US;2;Right ventricular anterior wall Thickness during diastole by US;RV.ant wall Thickness dia US;;ACTIVE;1.0l;2.67 +18154-5;Thickness.diastole;Len;Pt;Heart.interventricular septum;Qn;US;CARD.US;2;Interventricular septum Thickness during diastole by US;IVS Thickness dia US;;ACTIVE;1.0l;2.67 +18155-2;Thickness.septal wall/Thickness.posterior wall;LenRto;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Thickness septal wall/Thickness posterior wall by US;LV SWT/PWT US;;ACTIVE;1.0l;2.48 +18156-0;Thickness.systole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US;CARD.US;2;Left ventricular posterior wall Thickness during systole by US;LVPW Thickness sys US;;ACTIVE;1.0l;2.67 +18157-8;Thickness.systole;Len;Pt;Heart.ventricle.right.anterior wall;Qn;US;CARD.US;2;Right ventricular anterior wall Thickness during systole by US;RV.ant wall Thickness sys US;;ACTIVE;1.0l;2.67 +18158-6;Thickness.systole;Len;Pt;Heart.interventricular septum;Qn;US;CARD.US;2;Interventricular septum Thickness during systole by US;IVS Thickness sys US;;ACTIVE;1.0l;2.67 +18159-4;Transducer site;Prid;Pt;Cardiac echo study;Nom;*;CARD.US;2;Cardiac echo study Transducer site;Cardiac Echo Study Transducer site;;ACTIVE;1.0l;2.27 +18160-2;Ultrasound class;Type;Pt;Cardiac echo imaging device;Nom;*;CARD.US;2;Cardiac echo imaging device Class;Card Echo Device Class;;ACTIVE;1.0l;2.56 +18161-0;Blood flow velocity.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Maximum blood flow velocity by US.doppler;TV Vmax DOP;;ACTIVE;1.0l;2.67 +18162-8;Blood flow velocity.max;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Maximum blood flow velocity by US.doppler;PV Vmax DOP;;ACTIVE;1.0l;2.67 +18163-6;Blood flow velocity.systole.max;Vel;Pt;Aorta.root;Qn;US.doppler;CARD.US;2;Aorta root Maximum blood flow velocity during systole by US.doppler;AO root Vmax sys DOP;;ACTIVE;1.0l;2.67 +18164-4;Blood flow.systole.max;Vel;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US;2;Deprecated Left ventricular outflow tract Peak systolic flow velocity by US.doppler;Deprecated LVOT Vmax sys DOP;;DEPRECATED;1.0l;2.67 +18165-1;Regurgitant blood flow velocity.diastole.max;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Maximum regurgitant blood flow velocity during diastole by US.doppler;PV reg Vmax dias DOP;;ACTIVE;1.0l;2.67 +18166-9;Regurgitant blood flow velocity.systole.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Maximum regurgitant blood flow velocity during systole by US.doppler;TV reg Vmax sys DOP;;ACTIVE;1.0l;2.68 +18167-7;Blood flow velocity.systole.mean;Vel;Pt;Aorta.root;Qn;US.doppler;CARD.US;2;Aorta root Mean flow velocity during systole by US.doppler;AO root Mean flow vel sys DOP;;ACTIVE;1.0l;2.67 +1816-8;Acid alpha glucosidase;CCnc;Pt;WBC;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/volume] in Leukocytes;Acid A-Glucosidase WBC-cCnc;;ACTIVE;1.0;2.38 +18168-5;Blood velocity-time integral;Len;Pt;Aorta.root;Qn;US.doppler;CARD.US;2;Aorta root Blood velocity-time integral by US.doppler;AO root VTI DOP;;ACTIVE;1.0l;2.70 +18169-3;Blood velocity-time integral;Len;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Blood velocity-time integral by US.doppler;AV VTI DOP;;ACTIVE;1.0l;2.70 +18170-1;Blood velocity-time integral;Len;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US;2;Left ventricular outflow tract Blood velocity-time integral by US.doppler;LVOT VTI DOP;;ACTIVE;1.0l;2.73 +18171-9;Blood velocity-time integral;Len;Pt;Heart.ventricle.right.outflow tract;Qn;US.doppler;CARD.US;2;Right ventricular outflow tract Blood velocity-time integral by US.doppler;RVOT VTI DOP;;ACTIVE;1.0l;2.70 +18172-7;Blood velocity-time integral;Len;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Blood velocity-time integral by US.doppler;MV VTI DOP;;ACTIVE;1.0l;2.70 +18173-5;Blood velocity-time integral;Len;Pt;Pulmonary artery;Qn;US.doppler;CARD.US;2;Pulmonary artery Blood velocity-time integral by US.doppler;PA VTI DOP;;ACTIVE;1.0l;2.70 +18174-3;Blood velocity-time integral;Len;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Blood velocity-time integral by US.doppler;PV VTI DOP;;ACTIVE;1.0l;2.70 +18175-0;Blood velocity-time integral.diastole;Len;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Velocity-time integral during diastole by US.doppler;TV VTI dia DOP;;ACTIVE;1.0l;2.70 +1817-6;Alpha ketoglutarate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha ketoglutarate [Mass/volume] in Serum or Plasma;A-Ketoglut SerPl-mCnc;;DISCOURAGED;1.0;2.44 +18176-8;Vendor model number;ID;Pt;Cardiac echo imaging device;Nom;;CARD.US;2;Cardiac echo imaging device Vendor model number;Card Echo Device Model #;;ACTIVE;1.0l;2.56 +18177-6;Vendor serial number;ID;Pt;Cardiac echo imaging device;Nom;;CARD.US;2;Cardiac echo imaging device Vendor serial number;Card Echo Device Serial #;;ACTIVE;1.0l;2.56 +18178-4;Wall motion index;Arb;Pt;Heart.ventricle.left;Ord;US;CARD.US;2;Left ventricular Wall motion index by US;LV Wall motion index US;;ACTIVE;1.0l;2.27 +18179-2;Wall segment;Prid;Pt;Heart.ventricle.left;Nom;US;CARD.US;2;Left ventricular Wall segment [Identifier] by US;LV Wall seg US;;ACTIVE;1.0l;2.27 +181-8;Cinoxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cinoxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Cinoxacin Islt MIC;;ACTIVE;1.0;2.73 +18180-0;Albumin;MRat;2H;Ser;Qn;;CHEM;1;Deprecated Albumin;Deprecated Albumin 2H Ser-mRate;;DEPRECATED;1.0l;2.36 +18182-6;Osmolality;Osmol;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Osmolality of Serum or Plasma by calculation;Osmolality SerPl Calc;;ACTIVE;1.0l;2.73 +18183-4;Melatonin;MRat;24H;Urine;Qn;;CHEM;1;Melatonin [Mass/time] in 24 hour Urine;Melatonin 24h Ur-mRate;;ACTIVE;1.0l;2.73 +1818-4;Alpha mannosidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha mannosidase [Enzymatic activity/volume] in Serum or Plasma;A-Mannosidase SerPl-cCnc;;ACTIVE;1.0;2.48 +18184-2;Erythrocyte sedimentation rate;Vel;Pt;Bld;Qn;Westergren.2H reading;HEM/BC;1;Erythrocyte sedimentation rate by 2H Westergren method;ESR Bld Qn Westrgrn 2h;;ACTIVE;1.0l;2.73 +18185-9;Gestational age;Time;Pt;^Fetus;Qn;;OB.US;2;Gestational age;GA;;ACTIVE;1.0l;2.73 +18186-7;Calcium;MRat;12H;Urine;Qn;;CHEM;1;Calcium [Mass/time] in 12 hour Urine;Calcium 12h Ur-mRate;;ACTIVE;1.0l;2.73 +18187-5;LORazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;LORazepam [Presence] in Urine;LORazepam Ur Ql;;ACTIVE;1.0l;2.73 +18188-3;Acebutolol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Acebutolol [Mass/volume] in Specimen;Acebutolol Spec-mCnc;;ACTIVE;1.0l;2.69 +18189-1;Acetone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Acetone [Mass/time] in 24 hour Urine;Acetone 24h Ur-mRate;;ACTIVE;1.0l;2.73 +18190-9;Acid phosphatase.tartrate resistant;PrThr;Pt;XXX;Ord;;CHEM;1;Acid phosphatase tartrate resistant [Presence] in Specimen;ACP TRAP Spec Ql;;ACTIVE;1.0l;2.73 +18191-7;Amino acids;Prid;24H;Urine;Nom;;CHEM;1;Amino acids [Identifier] in 24 hour Urine;Amino acids 24h Ur;;ACTIVE;1.0l;2.73 +1819-2;Alpha mannosidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Alpha mannosidase [Enzymatic activity/mass] in Tissue;A-Mannosidase Tiss-cCnt;;ACTIVE;1.0;2.42 +18192-5;Bacteria;PrThr;Pt;Nose;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Nose by Light microscopy;Bacteria Nose Ql Micro;;ACTIVE;1.0l;2.73 +18194-1;Barium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Barium [Mass/time] in 24 hour Urine;Barium 24h Ur-mRate;;ACTIVE;1.0l;2.42 +18195-8;Glucosylceramidase;PrThr;Pt;Tiss;Ord;;CHEM;1;Glucosylceramidase [Presence] in Tissue;Glucosylceramidase Tiss Ql;;ACTIVE;1.0l;2.63 +18196-6;Beta-N-acetylhexosaminidase.A;PrThr;Pt;Tiss;Ord;;CHEM;1;Beta-N-acetylhexosaminidase.A [Presence] in Tissue;Hexosaminidase A Tiss Ql;;ACTIVE;1.0l;2.56 +18197-4;Blastomyces dermatitidis Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Cerebral spinal fluid;B dermat Ab CSF Ql;;ACTIVE;1.0l;2.73 +18198-2;Blastomyces dermatitidis Ab.IgE;PrThr;Pt;Ser;Ord;;MICRO;1;Blastomyces dermatitidis IgE Ab [Presence] in Serum;B dermat IgE Ser Ql;;ACTIVE;1.0l;2.56 +18199-0;Blastomyces dermatitidis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Blastomyces dermatitidis IgG Ab [Presence] in Serum;B dermat IgG Ser Ql;;ACTIVE;1.0l;2.56 +18-2;Amoxicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Amoxicillin [Susceptibility] by Serum bactericidal titer;Amoxicillin Titr SBT;;ACTIVE;1.0;2.32 +1820-0;Alpha melanocyte stimulating hormone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha melanocyte stimulating hormone [Mass/volume] in Serum or Plasma;A-MSH SerPl-mCnc;;ACTIVE;1.0;2.73 +18200-6;Blastomyces dermatitidis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Blastomyces dermatitidis IgM Ab [Presence] in Serum;B dermat IgM Ser Ql;;ACTIVE;1.0l;2.56 +18201-4;Borrelia burgdorferi Ab.IgA;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi IgA Ab [Presence] in Serum by Immunoblot;B burgdor IgA Ser Ql IB;;ACTIVE;1.0l;2.58 +18202-2;Borrelia burgdorferi Ab.IgA;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi IgA Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor IgA CSF Ql IB;;ACTIVE;1.0l;2.58 +18203-0;Borrelia burgdorferi Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi IgG+IgM Ab [Presence] in Serum by Immunoblot;B burgdor IgG+IgM Ser Ql IB;;ACTIVE;1.0l;2.73 +18204-8;Caffeine renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Caffeine renal clearance in 24 hour Urine and Serum or Plasma;Caffeine Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0l;2.66 +18205-5;Carbon disulfide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Carbon disulfide [Presence] in Urine;Carbon diS Ur Ql;;ACTIVE;1.0l;2.56 +18206-3;Catecholamines^7th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --7th specimen post XXX challenge;Catechols sp7 p chal Plas-mCnc;;ACTIVE;1.0l;2.50 +18208-9;Cocaine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cocaine [Mass/volume] in Specimen;Cocaine Spec-mCnc;;ACTIVE;1.0l;2.73 +18209-7;Ubiquinone 10;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Coenzyme Q10 [Units/volume] in Serum or Plasma;Ubiquinone10 SerPl-aCnc;;DISCOURAGED;1.0l;2.73 +18210-5;Complement C1 esterase inhibitor bound Ab.IgG;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor bound IgG Ab [Mass/volume] in Serum or Plasma;C1INH Bnd IgG SerPl-mCnc;;ACTIVE;1.0l;2.34 +18211-3;Complement C1 esterase inhibitor bound Ab.IgM;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor bound IgM Ab [Mass/volume] in Serum or Plasma;C1INH Bnd IgM SerPl-mCnc;;ACTIVE;1.0l;2.34 +18212-1;Complement C1 esterase inhibitor free Ab.IgG;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor free IgG Ab [Mass/volume] in Serum or Plasma;C1INH Free IgG SerPl-mCnc;;ACTIVE;1.0l;2.34 +18213-9;Complement C1 esterase inhibitor free Ab.IgM;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor free IgM Ab [Mass/volume] in Serum or Plasma;C1INH Free IgM SerPl-mCnc;;ACTIVE;1.0l;2.34 +18214-7;Delta 5-Pregnanetriol;MCnc;Pt;Urine;Qn;;CHEM;1;Delta 5-Pregnanetriol [Mass/volume] in Urine;D5Pregnanetriol Ur-mCnc;;ACTIVE;1.0l;2.42 +18215-4;Delta alanine;MCnc;Pt;Urine;Qn;;CHEM;1;Delta alanine [Mass/volume] in Urine;D-Alanine Ur-mCnc;;DISCOURAGED;1.0l;2.44 +18216-2;Dezocine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Dezocine [Presence] in Urine by Confirmatory method;Dezocine Ur Ql Cfm;;ACTIVE;1.0l;2.56 +18217-0;Epidermis Ab.IgA;PrThr;Pt;Tiss;Ord;;SERO;1;Epidermis IgA Ab [Presence] in Tissue;Epidis IgA Tiss Ql;;ACTIVE;1.0l;2.56 +1821-8;Alpha naphthylesterase;CCnc;Pt;Ser;Qn;;CHEM;1;Alpha naphthylesterase [Enzymatic activity/volume] in Serum;A-Naphthylesterase Ser-cCnc;;ACTIVE;1.0;2.68 +18218-8;Epidermis Ab.IgM;PrThr;Pt;Tiss;Ord;;SERO;1;Epidermis IgM Ab [Presence] in Tissue;Epidis IgM Tiss Ql;;ACTIVE;1.0l;2.56 +18219-6;EPINEPHrine^2nd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Urine --2nd specimen post XXX challenge;Epineph sp2 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +18220-4;EPINEPHrine^3rd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Urine --3rd specimen post XXX challenge;Epineph sp3 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +18221-2;EPINEPHrine^4th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Urine --4th specimen post XXX challenge;Epineph sp4 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +18222-0;EPINEPHrine^5th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Urine --5th specimen post XXX challenge;Epineph sp5 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +18223-8;EPINEPHrine^6th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Urine --6th specimen post XXX challenge;Epineph sp6 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +18224-6;EPINEPHrine^7th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Urine --7th specimen post XXX challenge;Epineph sp7 p chal Ur-mCnc;;ACTIVE;1.0l;2.34 +18225-3;Erythrocyte shape;Morph;Pt;Bld;Nom;;HEM/BC;1;Erythrocyte shape [Morphology] in Blood;RBC Shape Bld;;ACTIVE;1.0l;2.73 +1822-6;Alpha thymosin;MCnc;Pt;Ser;Qn;;CHEM;1;Alpha thymosin [Mass/volume] in Serum;A-Thymosin Ser-mCnc;;ACTIVE;1.0;2.42 +18226-1;Erythrocyte size;Morph;Pt;Bld;Nom;;HEM/BC;1;Erythrocyte size [Morphology] in Blood;RBC Size Bld;;ACTIVE;1.0l;2.73 +18227-9;Glucose;MRat;6H;Urine;Qn;;CHEM;1;Glucose [Mass/time] in 6 hour Urine;Glucose 6h Ur-mRate;;ACTIVE;1.0l;2.42 +18228-7;Glucose-6-Phosphate dehydrogenase;PrThr;Pt;Tiss;Ord;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Presence] in Tissue;G6PD Tiss Ql;;ACTIVE;1.0l;2.56 +18229-5;Heparan sulfate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Heparan sulfate [Presence] in Serum or Plasma;Heparan sulfate SerPl Ql;;ACTIVE;1.0l;2.56 +18230-3;Histone H2a+H2b Ab;ACnc;Pt;Ser;Qn;;SERO;1;Histone H2a+H2b Ab [Units/volume] in Serum;Histone H2a+H2b Ab Ser-aCnc;;ACTIVE;1.0l;2.73 +18231-1;Histone H2a+H2b Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Histone H2a+H2b Ab [Presence] in Serum by Immunofluorescence;Histone H2a+H2b Ab Ser Ql IF;;ACTIVE;1.0l;2.73 +18232-9;Hydrocorticosterone;PrThr;Pt;Urine;Ord;;CHEM;1;Hydrocorticosterone [Presence] in Urine;Hydrocorticostern Ur Ql;;ACTIVE;1.0l;2.56 +18233-7;Influenza virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Influenza virus Ab [Units/volume] in Cerebral spinal fluid;FLUV Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +1823-4;Alpha tocopherol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha tocopherol [Mass/volume] in Serum or Plasma;A-Tocopherol Vit E SerPl-mCnc;;ACTIVE;1.0;2.73 +18234-5;Insulin;PrThr;Pt;Unk sub;Ord;;CHEM;1;Insulin [Presence] in Unknown substance;Insulin Usub Ql;;ACTIVE;1.0l;2.56 +18235-2;Ketone solvents;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Ketone solvents [Identifier] in Blood;Ketone Solvents Bld;;ACTIVE;1.0l;2.15 +18236-0;Lead;PrThr;Pt;Tiss;Ord;;DRUG/TOX;1;Lead [Presence] in Tissue;Lead Tiss Ql;;ACTIVE;1.0l;2.56 +18237-8;Legionella pneumophila atypical Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila atypical IgM Ab [Presence] in Serum;L pneumo Atyp IgM Ser Ql;;ACTIVE;1.0l;2.56 +18238-6;Lithium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Lithium [Mass/mass] in Tissue;Lithium Tiss-mCnt;;ACTIVE;1.0l;2.42 +18239-4;Lupus erythematosus factor;MCnc;Pt;Bld;Qn;LA;SERO;1;Lupus erythematosus factor [Mass/volume] in Blood by Latex agglutination;LE Scn Bld LA-mCnc;;ACTIVE;1.0l;2.34 +18240-2;1,3-Dichlorobenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,3-Dichlorobenzene [Mass/volume] in Blood;1,3DCB Bld-mCnc;;ACTIVE;1.0l;2.73 +18241-0;cefOXitin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;cefOXitin IgE Ab [Units/volume] in Serum;cefOXitin IgE Qn;;ACTIVE;1.0l;2.42 +1824-2;Alpha-1-Antichymotrypsin;MCnc;Pt;Ser;Qn;;CHEM;1;Alpha-1-Antichymotrypsin [Mass/volume] in Serum;A1ACT Ser-mCnc;;ACTIVE;1.0;2.73 +18242-8;Methyprylon;MRat;24H;Urine;Qn;;DRUG/TOX;1;Methyprylon [Mass/time] in 24 hour Urine;Methyprylon 24h Ur-mRate;;ACTIVE;1.0l;2.42 +18243-6;Mycoplasma pneumoniae Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Units/volume] in Cerebral spinal fluid;M pneumo IgG CSF-aCnc;;ACTIVE;1.0l;2.69 +18244-4;Niacin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Niacin [Mass/volume] in Serum or Plasma;Niacin SerPl-mCnc;;ACTIVE;1.0l;2.73 +18245-1;Nickel;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Specimen;Nickel Spec-mCnc;;ACTIVE;1.0l;2.69 +18246-9;Nitrogen;MCnc;Pt;Stool;Qn;;CHEM;1;Nitrogen [Mass/volume] in Stool;N2 Stl-mCnc;;ACTIVE;1.0l;2.42 +18247-7;Nitrogen;MCnc;Pt;Dial fld;Qn;;CHEM;1;Nitrogen [Mass/volume] in Dialysis fluid;N2 Dial fld-mCnc;;ACTIVE;1.0l;2.42 +18248-5;Nordiazepam;MCnc;Pt;Stool;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Stool;Nordiazepam Stl-mCnc;;ACTIVE;1.0l;2.42 +18249-3;Para aminobenzoate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Para aminobenzoate [Mass/volume] in Serum or Plasma;pABA SerPl-mCnc;;ACTIVE;1.0l;2.73 +18250-1;Pentacarboxylporphyrins;MCnc;Pt;Bld;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/volume] in Blood;Penta-CP Bld-mCnc;;ACTIVE;1.0l;2.40 +18251-9;Polychlorinated biphenyl;PrThr;Pt;Tiss;Ord;;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Presence] in Tissue;PCB Tiss Ql;;ACTIVE;1.0l;2.56 +18252-7;predniSONE;MRat;24H;Urine;Qn;;DRUG/TOX;1;predniSONE [Mass/time] in 24 hour Urine;predniSONE 24h Ur-mRate;;ACTIVE;1.0l;2.42 +18253-5;Serotonin;MRat;24H;Urine;Qn;;CHEM;1;Serotonin [Mass/time] in 24 hour Urine;Serotonin 24h Ur-mRate;;ACTIVE;1.0l;2.73 +18254-3;Silicate;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Silicate [Mass/volume] in Body fluid;Silicate Fld-mCnc;;ACTIVE;1.0l;2.34 +18255-0;Sulfonylurea;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfonylurea [Mass/volume] in Serum or Plasma;Sulfonylurea SerPl-mCnc;;ACTIVE;1.0l;2.42 +18256-8;Sulfonylurea;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sulfonylurea [Mass/volume] in Urine;Sulfonylurea Ur-mCnc;;ACTIVE;1.0l;2.42 +18257-6;Coproporphyrin;MCnc;Pt;Bld;Qn;;CHEM;1;Coproporphyrin [Mass/volume] in Blood;Copro Bld-mCnc;;ACTIVE;1.0l;2.73 +18258-4;Trimethoprim Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trimethoprim IgE Ab [Units/volume] in Serum;Trimethoprim IgE Qn;;ACTIVE;1.0l;2.73 +1825-9;Alpha 1 antitrypsin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma;A1AT SerPl-mCnc;;ACTIVE;1.0;2.73 +18259-2;Vasoactive intestinal peptide;MRat;24H;Urine;Qn;;CHEM;1;Vasoactive intestinal peptide [Mass/time] in 24 hour Urine;VIP 24h Ur-mRate;;ACTIVE;1.0l;2.73 +182-6;Cinoxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cinoxacin [Susceptibility] by Disk diffusion (KB);Cinoxacin Islt KB;;ACTIVE;1.0;2.73 +18260-0;Zinc;PrThr;Pt;Tiss;Ord;;DRUG/TOX;1;Zinc [Presence] in Tissue;Zinc Tiss Ql;;ACTIVE;1.0l;2.56 +18261-8;Cholesterol.in LDL;MCnc;Pt;Ser/Plas.ultracentrifugate;Qn;;CHEM;1;Cholesterol in LDL [Mass/volume] in Serum or Plasma ultracentrifugate;LDLc SerPl.Ultracent-mCnc;;ACTIVE;1.0l;2.73 +18262-6;Cholesterol.in LDL;MCnc;Pt;Ser/Plas;Qn;Direct assay;CHEM;1;Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay;LDLc SerPl Direct Assay-mCnc;;ACTIVE;1.0l;2.73 +18263-4;Cholesterol.in HDL;MCnc;Pt;Ser/Plas.ultracentrifugate;Qn;;CHEM;1;Cholesterol in HDL [Mass/volume] in Serum or Plasma ultracentrifugate;HDLc SerPl.Ultracent-mCnc;;ACTIVE;1.0l;2.73 +18264-2;Bilirubin.glucuronidated+Bilirubin.albumin bound;MCnc;Pt;Ser/Plas;Qn;Incubation.1M;CHEM;1;Deprecated Direct bilirubin [Mass/volume] in Serum or Plasma;Deprecated Bilirub Direct SerPl 1m Inc-m;;DEPRECATED;1.0l;2.70 +18265-9;Acetaminophen;PrThr;Pt;Body fld;Ord;;DRUG/TOX;1;Acetaminophen [Presence] in Body fluid;APAP Fld Ql;;ACTIVE;1.0l;2.56 +18266-7;Cells.CD3+CD4+/Cells.CD3+CD8+;NRto;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Body fluid;CD3+CD4+ Cells/CD3+CD8+ Cells Fld;;ACTIVE;1.0l;2.73 +1826-7;Alpha 1 antitrypsin.MM;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin MM [Mass/volume] in Serum or Plasma;A1AT MM SerPl-mCnc;;ACTIVE;1.0;2.40 +18267-5;Cells.CD16+CD56+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16+CD56+ cells/100 cells in Blood;CD16+CD56+ Cells NFr Bld;;ACTIVE;1.0l;2.73 +18268-3;Cells.CD16+CD56+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD16+CD56+ cells/100 cells in Body fluid;CD16+CD56+ Cells NFr Fld;;ACTIVE;1.0l;2.70 +18269-1;Immune complex;ACnc;Pt;Body fld;Qn;;SERO;1;Immune complex [Units/volume] in Body fluid;IC Fld-aCnc;;ACTIVE;1.0l;2.69 +18270-9;carBAMazepine 10,11-Epoxide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbamazepine 10,11-Epoxide [Moles/volume] in Serum or Plasma;Carbamazepine EP SerPl-sCnc;;ACTIVE;1.0l;2.34 +18271-7;Alpha 1 antitrypsin fecal clearance;VRat;24H;Ser/Plas+Stool;Qn;;CHEM;1;Alpha 1 antitrypsin fecal clearance in 24 hour;A1AT Cl 24h SerPl+Stl-vRate;;ACTIVE;1.0l;2.73 +18272-5;RNA Ab;ACnc;Pt;Ser;Qn;;SERO;1;RNA Ab [Units/volume] in Serum;RNA Ab Ser-aCnc;;ACTIVE;1.0l;2.69 +18273-3;Blood group antibody screen;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma from Blood product unit;Bld gp Ab Scn SerPl BPU Ql;;ACTIVE;1.0l;2.73 +18274-1;Blood group antibody screen;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma from Donor;Bld gp Ab Scn SerPl Donr Ql;;ACTIVE;1.0l;2.73 +1827-5;Alpha 1 antitrypsin.MS;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin MS [Mass/volume] in Serum or Plasma;A1AT MS SerPl-mCnc;;ACTIVE;1.0;2.40 +18275-8;Blood group antigens present;Prid;Pt;RBC^Donor;Nom;;BLDBK;1;Blood group antigens present [Identifier] on Red Blood Cells from Donor;Antigens Present RBC Donr;;ACTIVE;1.0l;2.24 +18276-6;Blood group antigens absent;Prid;Pt;RBC^Donor;Nom;;BLDBK;1;Blood group antigens absent [Identifier] on Red Blood Cells from Donor;Antigens Absent RBC Donr;;ACTIVE;1.0l;2.24 +18277-4;Hemoglobin F;PrThr;Pt;Gast fld;Ord;Apt-Downey;HEM/BC;1;Hemoglobin F [Presence] in Gastric fluid by Apt-Downey method;Hgb F Gast Ql Apt-Downey;;ACTIVE;1.0l;2.56 +18278-2;Hemoglobin F;PrThr;Pt;Meconium;Ord;Apt-Downey;HEM/BC;1;Hemoglobin F [Presence] in Meconium by Apt-Downey method;Hgb F Mec Ql Apt-Downey;;ACTIVE;1.0l;2.56 +18279-0;Hemoglobin F;ACnc;Pt;Stool;Ord;Apt-Downey;HEM/BC;1;Deprecated Hemoglobin F [Presence] in Stool by Apt-Downey method;Deprecated Hgb F Stl Ql Apt-Downey;;DEPRECATED;1.0l;2.36 +18280-8;Background stain;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Background stain [Presence] in Blood by Light microscopy;Background Stn Bld Ql Smear;;ACTIVE;1.0l;2.56 +18281-6;Calcium^^corrected for total protein;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Moles/volume] corrected for total protein in Serum or Plasma;Calcium TP cor SerPl-sCnc;;ACTIVE;1.0l;2.70 +18282-4;Cannabinoids;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Urine by Screen method;Cannabinoids Ur Ql Scn;;ACTIVE;1.0l;2.73 +1828-3;Alpha 1 antitrypsin.MZ;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin MZ [Mass/volume] in Serum or Plasma;A1AT MZ SerPl-mCnc;;ACTIVE;1.0;2.40 +18283-2;Cells.CD11/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11 cells/100 cells in Blood;CD11 Cells NFr Bld;;ACTIVE;1.0l;2.73 +18284-0;Cells.CD198/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD198 cells/100 cells in Blood;CD198 Cells NFr Bld;;ACTIVE;1.0l;2.70 +18285-7;Cells.CDA/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CDA cells/100 cells in Blood;CDA Cells NFr Bld;;ACTIVE;1.0l;2.70 +18286-5;Donath Landsteiner Ab;PrThr;Pt;Bld;Ord;;BLDBK;1;Donath Landsteiner Ab [Presence] in Blood;D-L Ab Bld Ql;;ACTIVE;1.0l;2.73 +18287-3;Donath Landsteiner Ab;PrThr;Pt;Ser+RBC^Control;Ord;;BLDBK;1;Donath Landsteiner Ab [Presence] in Control Serum and RBC;D-L Ab Ser+RBC Cont Ql;;ACTIVE;1.0l;2.73 +18288-1;Donath Landsteiner Ab;Titr;Pt;Ser+RBC^Control;Qn;;BLDBK;1;Donath Landsteiner Ab [Titer] in Control Serum and RBC;D-L Ab Titr Ser+RBC Cont;;ACTIVE;1.0l;2.70 +18289-9;Erythrocytes;Morph;Pt;CSF;Nom;Microscopy.light;HEM/BC;1;Erythrocytes [Morphology] in Cerebral spinal fluid by Light microscopy;RBC CSF Micro;;ACTIVE;1.0l;2.07 +18290-7;Erythrocytes;Morph;Pt;Synv fld;Nom;Microscopy.light;HEM/BC;1;Erythrocytes [Morphology] in Synovial fluid by Light microscopy;RBC Snv Micro;;ACTIVE;1.0l;2.19 +1829-1;Alpha 1 antitrypsin.SS;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin SS [Mass/volume] in Serum or Plasma;A1AT SS SerPl-mCnc;;ACTIVE;1.0;2.73 +18291-5;Hemoglobin F/Hemoglobin.total;MFr;Pt;Bld^Newborn;Qn;;HEM/BC;1;Hemoglobin F/Hemoglobin.total in Blood from Newborn;Hgb F MFr Bld NB;;ACTIVE;1.0l;2.73 +18292-3;Hemoglobin.fetal/Hemoglobin.total^post amniocentesis;SFr;Pt;Bld;Ord;Kleihauer-Betke;HEM/BC;1;Deprecated Hemoglobin.fetal/Hemoglobin.total^post amniocentesis;Deprecated Hgb F Fr Bld Kleih Betke;;DEPRECATED;1.0l;2.46 +18293-1;Hemoglobin.fetal/Hemoglobin.total^post partum;SFr;Pt;Bld;Ord;Kleihauer-Betke;HEM/BC;1;Deprecated Hemoglobin.fetal/Hemoglobin.total^post partum;Deprecated Hgb F p partum Fr Bld KB;;DEPRECATED;1.0l;2.46 +18294-9;Hemoglobin.fetal/Hemoglobin.total^pre amniocentesis;SFr;Pt;Bld;Ord;Kleihauer-Betke;HEM/BC;1;Deprecated Hemoglobin.fetal/Hemoglobin.total^pre amniocentesis;Deprecated Hgb F Fr Bld Kleih Betke;;DEPRECATED;1.0l;2.46 +18295-6;Hemoglobin.fetal/Hemoglobin.total^pre partum;SFr;Pt;Bld;Ord;Kleihauer-Betke;HEM/BC;1;Deprecated Hemoglobin.fetal/Hemoglobin.total^pre partum;Deprecated Hgb F pre partum Fr Bld KB;;DEPRECATED;1.0l;2.46 +18296-4;Glucose^post dose glucose;Imp;Pt;Ser/Plas;Nom;;CHAL;1;Glucose [Interpretation] in Serum or Plasma--post dose glucose;Glucose p Glc SerPl-Imp;;ACTIVE;1.0l;2.26 +18297-2;Acid hemolysis;MCnc;Pt;RBC;Qn;;HEM/BC;1;Acid hemolysis [Mass/volume] of Red Blood Cells;Acid hemolysis RBC-mCnc;;DISCOURAGED;1.0l;2.44 +18298-0;High titer low avidity Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;High titer low avidity Ab [Presence] in Serum or Plasma;HTLA Ab SerPl Ql;;ACTIVE;1.0l;2.56 +18299-8;IgA;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgA [Presence] in Serum by Immunofixation;IgA Ser Ql IFE;;ACTIVE;1.0l;2.73 +18300-4;IgA;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgA [Presence] in Urine by Immunofixation;IgA Ur Ql IFE;;ACTIVE;1.0l;2.73 +18301-2;IgG;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgG [Presence] in Serum by Immunofixation;IgG Ser Ql IFE;;ACTIVE;1.0l;2.73 +18302-0;IgG;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgG [Presence] in Urine by Immunofixation;IgG Ur Ql IFE;;ACTIVE;1.0l;2.73 +18303-8;IgM;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgM [Presence] in Serum by Immunofixation;IgM Ser Ql IFE;;ACTIVE;1.0l;2.73 +18304-6;IgM;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgM [Presence] in Urine by Immunofixation;IgM Ur Ql IFE;;ACTIVE;1.0l;2.73 +18305-3;Amoeba identified;Prid;Pt;Asp;Nom;Iron hematoxylin stain;MICRO;1;Amoeba identified in Aspirate by Iron hematoxylin stain;Amoeba Aspirate IH Stn;;ACTIVE;1.0l;2.17 +18306-1;Hydatid cyst identified;Prid;Pt;Asp;Nom;Iron hematoxylin stain;MICRO;1;Hydatid cyst identified in Aspirate by Iron hematoxylin stain;Hydatid Cyst Aspirate IH Stn;;ACTIVE;1.0l;2.17 +18307-9;Ova & parasites identified;Prid;Pt;Stool;Nom;Iron hematoxylin stain;MICRO;1;Ova and parasites identified in Stool by Iron hematoxylin stain;O+P Stl IH Stn;;ACTIVE;1.0l;2.38 +18308-7;Pneumocystis sp identified;Prid;Pt;Lung tiss;Nom;Immune stain;MICRO;1;Pneumocystis sp identified in Lung tissue by Immune stain;Pneumocystis Lung tiss ImStn;;ACTIVE;1.0l;2.63 +1830-9;Alpha 1 antitrypsin.SZ;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin SZ [Mass/volume] in Serum or Plasma;A1AT SZ SerPl-mCnc;;ACTIVE;1.0;2.73 +18309-5;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Bld;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Blood by Manual count;nRBC/100 WBC Bld Manual-Rto;;ACTIVE;1.0l;2.73 +18310-3;Hemoglobin.other/Hemoglobin.total;Imp;Pt;Bld;Nom;;HEM/BC;1;Deprecated Hemoglobin.other/Hemoglobin.total [interpretation] in Blood;Deprecated Hgb Other Bld-Imp;;DEPRECATED;1.0l;2.46 +18311-1;Pelger Huet cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Pelger Huet cells [Presence] in Blood by Light microscopy;Pelger Huet Cells Bld Ql Smear;;ACTIVE;1.0l;2.73 +18312-9;Platelet satellitism;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Platelet satellitism [Presence] in Blood by Light microscopy;Platelet Satel Bld Ql Smear;;ACTIVE;1.0l;2.73 +18313-7;Coagulation;PrThr;Pt;Semen;Ord;Visual;FERT;1;Coagulation of Semen by Visual observation;Coag Smn Ql Visual;;ACTIVE;1.0l;2.73 +18314-5;Morphology;Imp;Pt;Bld;Nar;;HEM/BC;1;Morphology [Interpretation] in Blood Narrative;Morphology Bld-Imp;;ACTIVE;1.0l;2.73 +1831-7;Alpha 1 antitrypsin.ZZ;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin ZZ [Mass/volume] in Serum or Plasma;A1AT ZZ SerPl-mCnc;;ACTIVE;1.0;2.73 +18319-4;Neutrophils.vacuolated;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Neutrophils.vacuolated [Presence] in Blood by Light microscopy;Neuts Vac Bld Ql Smear;;ACTIVE;1.0l;2.73 +18320-2;Globulin;MCnc;Pt;Urine;Qn;Calculated;CHEM;1;Globulin [Mass/volume] in Urine by calculation;Globulin Ur Calc-mCnc;;ACTIVE;1.0l;2.42 +18321-0;Benzidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzidine [Mass/volume] in Serum or Plasma;Benzidine SerPl-mCnc;;ACTIVE;1.0l;2.42 +18322-8;Norketamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norketamine [Mass/volume] in Urine;Norketamine Ur-mCnc;;ACTIVE;1.0l;2.73 +18323-6;Smith extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Smith extractable nuclear IgG Ab [Units/volume] in Serum;ENA SM IgG Ser-aCnc;;ACTIVE;1.0l;2.73 +18324-4;Cockatiel serum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockatiel serum IgE Ab [Units/volume] in Serum;Cockatiel Serum IgE Qn;;ACTIVE;1.0l;2.42 +1832-5;Alpha-1-Fetoprotein;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Amniotic fluid;AFP Amn-mCnc;;ACTIVE;1.0;2.73 +18325-1;oxyMORphone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;oxyMORphone [Presence] in Urine by Confirmatory method;oxyMORphone Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18326-9;Microscopic observation;Prid;Pt;Cvx;Nom;XXX stain;MICRO;1;Microscopic observation [Identifier] in Cervix by Other stain;Other Stn Cvx;;ACTIVE;1.0l;2.73 +18327-7;Microscopic observation;Prid;Pt;Duod fld;Nom;XXX stain;MICRO;1;Microscopic observation [Identifier] in Duodenal fluid by Other stain;Other Stn Duod fl;;ACTIVE;1.0l;2.21 +18328-5;Microscopic observation;Prid;Pt;Body fld;Nom;XXX stain;CYTO;1;Microscopic observation [Identifier] in Body fluid by Other stain;Other Stn Fld;;ACTIVE;1.0l;2.73 +18329-3;Neutrophil cytoplasmic Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic IgA Ab [Units/volume] in Serum;ANCA IgA Ser-aCnc;;ACTIVE;1.0l;2.69 +18330-1;Neutrophil cytoplasmic Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic IgG Ab [Units/volume] in Serum;ANCA IgG Ser-aCnc;;ACTIVE;1.0l;2.69 +18331-9;Neutrophil cytoplasmic Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic IgM Ab [Units/volume] in Serum;ANCA IgM Ser-aCnc;;ACTIVE;1.0l;2.69 +18332-7;Thyroperoxidase Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Thyroperoxidase IgG Ab [Units/volume] in Serum or Plasma;Thyroperoxidase IgG SerPl-aCnc;;ACTIVE;1.0l;2.73 +1833-3;Alpha-1-Fetoprotein;MCnc;Pt;CSF;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Cerebral spinal fluid;AFP CSF-mCnc;;ACTIVE;1.0;2.73 +18333-5;Echovirus 7 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Echovirus 7 Ab [Units/volume] in Cerebral spinal fluid;ECV7 Ab CSF-aCnc;;ACTIVE;1.0l;2.69 +18334-3;Naltrexone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Naltrexone [Presence] in Urine by Confirmatory method;Naltrexone Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18335-0;Antihistamines;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Antihistamines [Presence] in Urine by Confirmatory method;Antihistamines Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18336-8;Methyl tert-butyl ether;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methyl tert-butyl ether [Mass/volume] in Blood;MTBE Bld-mCnc;;ACTIVE;1.0l;2.73 +18337-6;Hydroxyitraconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxyitraconazole [Mass/volume] in Serum or Plasma;OH-Itraconaz SerPl-mCnc;;ACTIVE;1.0l;2.73 +18338-4;Nortramadol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nortramadol [Mass/volume] in Urine;Nortramadol Ur-mCnc;;ACTIVE;1.0l;2.73 +18339-2;Nortramadol;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Nortramadol [Presence] in Serum or Plasma by Confirmatory method;Nortramadol SerPl Ql Cfm;;ACTIVE;1.0l;2.56 +183-4;Cinoxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cinoxacin [Susceptibility] by Serum bactericidal titer;Cinoxacin Titr SBT;;ACTIVE;1.0;2.32 +18340-0;Nortramadol;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Nortramadol [Mass/volume] in Serum or Plasma by Confirmatory method;Nortramadol SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +1834-1;Alpha-1-Fetoprotein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma;AFP SerPl-mCnc;;ACTIVE;1.0;2.73 +18341-8;Propylene glycol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propylene glycol [Mass/volume] in Urine;Prop glycol Ur-mCnc;;ACTIVE;1.0l;2.42 +18342-6;Glucose^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Glucose 3h p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +18343-4;6-Monoacetylmorphine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Serum or Plasma by Screen method;6MAM SerPl Ql Scn;;ACTIVE;1.0l;2.73 +18344-2;Beta-N-acetylhexosaminidase;CCnc;Pt;Platelets;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/volume] in Platelets;B-NAH Plts-cCnc;;ACTIVE;1.0l;2.73 +18345-9;Protein S Ag/Coagulation factor VII Ag;MRto;Pt;PPP;Qn;Coag;COAG;1;Protein S Ag/Coagulation factor VII Ag [Mass Ratio] in Platelet poor plasma by Coagulation assay;Prot S Ag/Fact VII Ag PPP;;ACTIVE;1.0l;2.73 +18346-7;Streptococcus pneumoniae 18c Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 56 IgG Ab [Units/volume] in Serum;Deprecated S pneum18c IgG Ser-aCnc;;DEPRECATED;1.0l;2.69 +18347-5;Streptococcus pneumoniae 12 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum12 Ab sp2 Ser-aCnc;;DEPRECATED;1.0l;2.69 +18348-3;Toxoplasma gondii Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Toxoplasma gondii IgM Ab [Units/volume] in Cerebral spinal fluid;T gondii IgM CSF-aCnc;;ACTIVE;1.0l;2.69 +18349-1;Cells.CD8+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+CD25+ cells [#/volume] in Blood;CD8+CD25+ Cells # Bld;;ACTIVE;1.0l;2.70 +18350-9;Cells.CD8+CD57+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+CD57+ cells [#/volume] in Blood;CD8+CD57+ Cells # Bld;;ACTIVE;1.0l;2.73 +18351-7;11-Deoxycortisol^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;11DC sp2 p chal SerPl-mCnc;;ACTIVE;1.0l;2.73 +18352-5;Specimen volume;Vol;4H;Urine;Qn;;SPEC;1;Volume of 4 hour Urine;Specimen vol 4h Ur;;ACTIVE;1.0l;2.73 +18353-3;Glucose^6H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 hours post 50 g lactose PO;Glucose 6h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0l;2.34 +18354-1;Glucose^12H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12 hours post 50 g lactose PO;Glucose 12h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0l;2.34 +18355-8;Methylenedioxyamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Urine;MDA Ur-mCnc;;ACTIVE;1.0l;2.73 +18356-6;Methylenedioxymethamphetamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Serum or Plasma;MDMA SerPl-mCnc;;ACTIVE;1.0l;2.73 +18357-4;Methylenedioxymethamphetamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Blood;MDMA Bld-mCnc;;ACTIVE;1.0l;2.73 +1835-8;Alpha-2-Macroglobulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-2-Macroglobulin [Mass/volume] in Serum or Plasma;A2 Macroglob SerPl-mCnc;;ACTIVE;1.0;2.73 +18358-2;Methylenedioxymethamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Urine by Confirmatory method;MDMA Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +18359-0;Methylenedioxyamphetamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Blood;MDA Bld-mCnc;;ACTIVE;1.0l;2.73 +18360-8;8-Hydroxyamoxapine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;8-Hydroxyamoxapine [Mass/volume] in Urine;8OH-Amoxapine Ur-mCnc;;ACTIVE;1.0l;2.42 +18361-6;Adenosine monophosphate.cyclic/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Adenosine monophosphate.cyclic/Creatinine [Mass Ratio] in Urine;cAMP/Creat Ur;;ACTIVE;1.0l;2.73 +18362-4;Retinol binding protein;MRat;24H;Urine;Qn;;CHEM;1;Retinol binding protein [Mass/time] in 24 hour Urine;Retinol Bind Prot 24h Ur-mRate;;ACTIVE;1.0l;2.69 +18363-2;Carnitine.free (C0);ACnt;Pt;Tiss;Qn;;CHEM;1;Carnitine free (C0) [Units/mass] in Tissue;Carnitine Free Tiss-aCnt;;DISCOURAGED;1.0l;2.42 +18364-0;Chondroitin sulfate;MCnc;Pt;Ser;Qn;;CHEM;1;Chondroitin sulfate [Mass/volume] in Serum;Chondrotin Sulf Ser-mCnc;;ACTIVE;1.0l;2.42 +18365-7;Cortisol.free;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol Free [Mass/volume] in Saliva (oral fluid);Cortis F Sal-mCnc;;ACTIVE;1.0l;2.73 +1836-6;Retinol binding protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinol binding protein [Mass/volume] in Serum or Plasma;Retinol Bind Prot SerPl-mCnc;;ACTIVE;1.0;2.73 +18366-5;Cytochrome C oxidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/mass] in Tissue;CyC Oxidase Tiss-cCnt;;ACTIVE;1.0l;2.42 +18367-3;Iodine.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iodine Free [Mass/volume] in Serum or Plasma;Iodine Free SerPl-mCnc;;ACTIVE;1.0l;2.73 +18368-1;Magnesium;SRat;2H;Urine;Qn;;CHEM;1;Magnesium [Moles/time] in 2 hour Urine;Magnesium 2h Ur-sRate;;ACTIVE;1.0l;2.73 +18369-9;Magnesium;SRat;4H;Urine;Qn;;CHEM;1;Magnesium [Moles/time] in 4 hour Urine;Magnesium 4h Ur-sRate;;ACTIVE;1.0l;2.73 +18370-7;Nitrite;MCnc;Pt;Bld;Qn;;CHEM;1;Nitrite [Mass/volume] in Blood;Nitrite Bld-mCnc;;ACTIVE;1.0l;2.44 +18371-5;Methyl parathion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl parathion [Mass/volume] in Urine;Methyl Parathion Ur-mCnc;;ACTIVE;1.0l;2.73 +18372-3;Potassium;SRat;6H;Urine;Qn;;CHEM;1;Potassium [Moles/time] in 6 hour Urine;Potassium 6h Ur-sRate;;ACTIVE;1.0l;2.42 +18373-1;Protein;MRat;6H;Urine;Qn;;UA;1;Protein [Mass/time] in 6 hour Urine;Prot 6h Ur-mRate;;ACTIVE;1.0l;2.73 +1837-4;Alpha-N-acetylglucosaminidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-N-acetylglucosaminidase [Enzymatic activity/volume] in Serum or Plasma;A-NAG SerPl-cCnc;;ACTIVE;1.0;2.70 +18374-9;Riboflavin;MCnc;24H;Urine;Qn;;CHEM;1;Riboflavin [Mass/volume] in 24 hour Urine;Vit B2 24h Ur-mCnc;;ACTIVE;1.0l;2.42 +18375-6;Serotonin;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Serotonin [Mass/volume] in Urine;Deprecated Serotonin Ur-mCnc;;DEPRECATED;1.0l;2.36 +18376-4;Sodium;SRat;6H;Urine;Qn;;CHEM;1;Sodium [Moles/time] in 6 hour Urine;Sodium 6h Ur-sRate;;ACTIVE;1.0l;2.42 +18377-2;Sodium;SRat;12H;Urine;Qn;;CHEM;1;Sodium [Moles/time] in 12 hour Urine;Sodium 12h Ur-sRate;;ACTIVE;1.0l;2.73 +18378-0;Transcortin;MCnc;Pt;CSF;Qn;;CHEM;1;Transcortin [Mass/volume] in Cerebral spinal fluid;Transcortin CSF-mCnc;;ACTIVE;1.0l;2.42 +18379-8;Urate;MRat;6H;Urine;Qn;;CHEM;1;Urate [Mass/time] in 6 hour Urine;Urate 6h Ur-mRate;;ACTIVE;1.0l;2.42 +18380-6;Uroporphyrinogen decarboxylase;EntCat;Pt;RBC;Qn;;CHEM;1;Uroporphyrinogen decarboxylase [Entitic Catalytic Activity] in Red Blood Cells;URO-D RBC Qn;;ACTIVE;1.0l;2.73 +18381-4;Uroporphyrinogen decarboxylase;CCnc;Pt;Bld;Qn;;CHEM;1;Uroporphyrinogen decarboxylase [Enzymatic activity/volume] in Blood;URO-D Bld-cCnc;;ACTIVE;1.0l;2.68 +1838-2;Alpha-N-acetylglucosaminidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Alpha-N-acetylglucosaminidase [Enzymatic activity/mass] in Tissue;A-NAG Tiss-cCnt;;ACTIVE;1.0;2.42 +18382-2;Specimen.dry weight;MRat;24H;Stool;Qn;;SPEC;1;Dry weight [Mass/time] of 24 hour Stool;Dry Spec Wt 24h Stl-mRate;;ACTIVE;1.0l;2.73 +18383-0;Alfentanil;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Alfentanil [Presence] in Urine;Alfentanil Ur Ql;;ACTIVE;1.0l;2.56 +18384-8;Butabarbital;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Butabarbital [Mass/volume] in Serum or Plasma by Confirmatory method;Butabarbital SerPl Cfm-mCnc;;ACTIVE;1.0l;2.73 +18385-5;Butalbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Butalbital [Presence] in Urine by Confirmatory method;Butalbital Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18386-3;Chlorothiazide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Chlorothiazide [Presence] in Serum or Plasma;Chlorothiazide SerPl Ql;;ACTIVE;1.0l;2.56 +18387-1;Diamorphine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diamorphine [Mass/volume] in Serum or Plasma;DAM SerPl-mCnc;;ACTIVE;1.0l;2.73 +18388-9;diazePAM;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;diazePAM [Presence] in Urine by Confirmatory method;diazePAM Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18389-7;Methaqualone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methaqualone [Presence] in Urine by Confirmatory method;Methaqualone Ur Ql Cfm;;ACTIVE;1.0l;2.70 +1839-0;Ammonia;SCnc;Pt;Bld;Qn;;CHEM;1;Ammonia [Moles/volume] in Blood;Ammonia Bld-sCnc;;ACTIVE;1.0;2.73 +18390-5;Opiates;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Opiates [Presence] in Urine by Confirmatory method;Opiates Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18391-3;Paraldehyde;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Paraldehyde [Mass/volume] in Urine;Paraldehyde Ur-mCnc;;ACTIVE;1.0l;2.42 +18392-1;Phencyclidine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Urine by Confirmatory method;PCP Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18393-9;quiNIDine+Quinine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;quiNIDine+Quinine [Presence] in Urine;quiNIDine+Quinine Ur Ql;;ACTIVE;1.0l;2.56 +18394-7;HLA-A24(9);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A24(9) [Presence];HLA-A24(9) Ql;;ACTIVE;1.0l;2.56 +18395-4;Aspergillus niger Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Aspergillus niger Ab [Presence] in Cerebral spinal fluid;A niger Ab CSF Ql;;ACTIVE;1.0l;2.73 +18396-2;HIV 1 p24 Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1 p24 Ag [Presence] in Serum or Plasma by Immunoassay;HIV1 p24 Ag SerPl Ql IA;;ACTIVE;1.0l;2.73 +18397-0;Polio virus 1 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Polio virus 1 Ab [Titer] in Cerebral spinal fluid by Complement fixation;PV1 Ab Titr CSF CF;;ACTIVE;1.0l;2.73 +18398-8;Polio virus 2 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Polio virus 2 Ab [Titer] in Cerebral spinal fluid by Complement fixation;PV2 Ab Titr CSF CF;;ACTIVE;1.0l;2.73 +18399-6;Polio virus 3 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Polio virus 3 Ab [Titer] in Cerebral spinal fluid by Complement fixation;PV3 Ab Titr CSF CF;;ACTIVE;1.0l;2.73 +18400-2;Spermatozoa Ab.IgA;ACnc;Pt;Cvm;Qn;;FERT;1;Spermatozoa IgA Ab [Units/volume] in Cervical mucus;Sperm IgA Cerv mucus-aCnc;;ACTIVE;1.0l;2.69 +18401-0;Spermatozoa Ab.IgG;ACnc;Pt;Cvm;Qn;;FERT;1;Spermatozoa IgG Ab [Units/volume] in Cervical mucus;Sperm IgG Cerv mucus-aCnc;;ACTIVE;1.0l;2.69 +18402-8;Spermatozoa Ab.IgA;ACnc;Pt;Semen;Qn;;FERT;1;Spermatozoa IgA Ab [Units/volume] in Semen;Sperm IgA Smn-aCnc;;ACTIVE;1.0l;2.73 +18403-6;Spermatozoa Ab.IgG;ACnc;Pt;Semen;Qn;;FERT;1;Spermatozoa IgG Ab [Units/volume] in Semen;Sperm IgG Smn-aCnc;;ACTIVE;1.0l;2.73 +18404-4;Spermatozoa Ab.IgM;ACnc;Pt;Semen;Qn;;FERT;1;Spermatozoa IgM Ab [Units/volume] in Semen;Sperm IgM Smn-aCnc;;ACTIVE;1.0l;2.73 +18405-1;Arsenate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenate [Mass/volume] in Urine;Arsenate Ur-mCnc;;ACTIVE;1.0l;2.42 +18406-9;Arsenic trioxide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic trioxide [Mass/volume] in Urine;Arsenic trioxide Ur-mCnc;;ACTIVE;1.0l;2.42 +18407-7;Leukocytes;NRat;12H;Urine sed;Qn;Microscopy.light;UA;1;Leukocytes in 12 hour Urine sediment by Light microscopy;WBC 12h UrnS Micro-nRate;;ACTIVE;1.0l;2.27 +1840-8;Ammonia;SCnc;Pt;CSF;Qn;;CHEM;1;Ammonia [Moles/volume] in Cerebral spinal fluid;Ammonia CSF-sCnc;;ACTIVE;1.0;2.73 +18408-5;Cells.CD3+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+HLA-DR+ cells/100 cells in Blood;CD3+HLA-DR+ Cells NFr Bld;;ACTIVE;1.0l;2.73 +18409-3;Curvularia lunata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Curvularia lunata IgG Ab [Units/volume] in Serum;C lunata IgG Qn;;ACTIVE;1.0l;2.73 +18410-1;Epicoccum purpurascens Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Epicoccum purpurascens IgG Ab [Units/volume] in Serum;E purpurascens IgG Qn;;ACTIVE;1.0l;2.73 +18411-9;Rhizopus nigricans Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rhizopus nigricans IgG Ab [Units/volume] in Serum;R nigricans IgG Qn;;ACTIVE;1.0l;2.73 +18412-7;Stemphylium botryosum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Stemphylium botryosum IgG Ab [Units/volume] in Serum;S botryosum IgG Qn;;ACTIVE;1.0l;2.73 +18413-5;HLA-DR16;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR16 [Presence];HLA-DR16 Ql;;ACTIVE;1.0l;2.73 +18414-3;Psilocin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Psilocin [Presence] in Urine;Psilocin Ur Ql;;ACTIVE;1.0l;2.73 +18415-0;Psilocin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Psilocin [Mass/volume] in Urine;Psilocin Ur-mCnc;;ACTIVE;1.0l;2.73 +1841-6;Ammonia;SCnc;Pt;Ser;Qn;;CHEM;1;Ammonia [Moles/volume] in Serum;Ammonia Ser-sCnc;;DISCOURAGED;1.0;2.73 +18416-8;Aspergillus nidulans Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus nidulans IgG Ab [Units/volume] in Serum;A nidulans IgG Qn;;ACTIVE;1.0l;2.73 +18417-6;Bean black Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Bean IgG Ab [Units/volume] in Serum;Black Bean IgG Qn;;ACTIVE;1.0l;2.69 +18418-4;Casein Ab.IgA;ACnc;Pt;Ser;Qn;;ALLERGY;1;Casein IgA Ab [Units/volume] in Serum;Casein IgA Qn;;ACTIVE;1.0l;2.69 +18419-2;Cephalosporine mold Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cephalosporine mold IgG Ab [Units/volume] in Serum;Cephalospor Mold IgG Qn;;ACTIVE;1.0l;2.73 +184-2;Ciprofloxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ciprofloxacin [Susceptibility] by Minimum lethal concentration (MLC);Ciprofloxacin Islt MLC;;ACTIVE;1.0;2.19 +18420-0;Chaetomium globosum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chaetomium globosum IgG Ab [Units/volume] in Serum;C globosum IgG Qn;;ACTIVE;1.0l;2.73 +18421-8;Fusarium oxysporum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium oxysporum IgG Ab [Units/volume] in Serum;F oxysporum IgG Qn;;ACTIVE;1.0l;2.73 +18422-6;Microcytes;PrThr;Pt;Urine;Ord;Microscopy.light;HEM/BC;1;Microcytes [Presence] in Urine by Light microscopy;Microcytes Ur Ql Micro;;ACTIVE;1.0l;2.73 +18423-4;Phthalic anhydride Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phthalic anhydride IgG Ab [Units/volume] in Serum;PAN IgG Qn;;ACTIVE;1.0l;2.69 +1842-4;Ammonia;SCnc;Pt;Urine;Qn;;CHEM;1;Ammonia [Moles/volume] in Urine;Ammonia Ur-sCnc;;ACTIVE;1.0;2.73 +18424-2;Phthalic anhydride Ab.IgM;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phthalic anhydride IgM Ab [Units/volume] in Serum;PAN IgM Qn;;ACTIVE;1.0l;2.69 +18425-9;Squash zucchini Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Zucchini IgG Ab [Units/volume] in Serum;Zucchini IgG Qn;;ACTIVE;1.0l;2.73 +18426-7;Aspergillus sp Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Aspergillus sp Ab [Presence] in Cerebral spinal fluid;Aspergillus Ab CSF Ql;;ACTIVE;1.0l;2.56 +18427-5;Epstein Barr virus early Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Epstein Barr virus early Ab [Presence] in Body fluid;EBV EA Ab Fld Ql;;ACTIVE;1.0l;2.56 +18428-3;Epstein Barr virus nuclear Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Epstein Barr virus nuclear IgG Ab [Presence] in Cerebral spinal fluid;EBV NA IgG CSF Ql;;ACTIVE;1.0l;2.56 +18429-1;Rickettsia rickettsii Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Rickettsia rickettsii IgG Ab [Units/volume] in Cerebral spinal fluid;R rickettsi IgG CSF-aCnc;;ACTIVE;1.0l;2.69 +18430-9;Rickettsia rickettsii Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Rickettsia rickettsii IgM Ab [Units/volume] in Cerebral spinal fluid;R rickettsi IgM CSF-aCnc;;ACTIVE;1.0l;2.69 +18431-7;Amphetamines;PrThr;Pt;Stool;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Stool by Screen method;Amphetamines Stl Ql Scn;;ACTIVE;1.0l;2.56 +1843-2;Ammonia nitrogen;MRat;24H;Urine;Qn;;CHEM;1;Ammonia nitrogen [Mass/time] in 24 hour Urine;Ammonia nitrogen 24h Ur-mRate;;ACTIVE;1.0;2.73 +18432-5;Tetrahydrocannabinol;PrThr;Pt;Stool;Ord;Screen;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Stool by Screen method;THC Stl Ql Scn;;ACTIVE;1.0l;2.56 +18433-3;1,3-Dichlorobenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated 1,3-Dichlorobenzene [Mass/volume] in Blood;Deprecated 1,3DCB Bld-mCnc;;DEPRECATED;1.0l;2.36 +18434-1;1,2-Dichlorobenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,2-Dichlorobenzene [Mass/volume] in Blood;1,2DCB Bld-mCnc;;ACTIVE;1.0l;2.73 +18435-8;SUFentanil;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;SUFentanil [Presence] in Urine;SUFentanil Ur Ql;;ACTIVE;1.0l;2.56 +18436-6;Acetylcarnitine (C2);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acetylcarnitine (C2) [Mass/volume] in Serum or Plasma;Acetylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18437-4;Acrylylcarnitine (C3:1);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acrylylcarnitine (C3:1) [Mass/volume] in Serum or Plasma;Acrylylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18438-2;Propionylcarnitine (C3);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Propionylcarnitine (C3) [Mass/volume] in Serum or Plasma;Propionylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18439-0;Butyrylcarnitine (C4);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Butyrylcarnitine (C4) [Mass/volume] in Serum or Plasma;Butyrylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +1844-0;Ammonium ion;SCnc;Pt;BldA;Qn;;CHEM;1;Ammonium ion [Moles/volume] in Arterial blood;Ammonium Ion BldA-sCnc;;ACTIVE;1.0;2.42 +18440-8;Crotonylcarnitine (C4:1);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Crotonylcarnitine (C4:1) [Mass/volume] in Serum or Plasma;Crotonylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.42 +18441-6;Isovalerylcarnitine (C5);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isovalerylcarnitine (C5) [Mass/volume] in Serum or Plasma;Isovalerylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18442-4;3-Hydroxybutyrylcarnitine (C4-OH);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH) [Mass/volume] in Serum or Plasma;3OH-Butyrcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18443-2;Hexanoylcarnitine (C6);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexanoylcarnitine (C6) [Mass/volume] in Serum or Plasma;Hexanoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18444-0;3-Hydroxyisovalerylcarnitine (C5-OH);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH) [Mass/volume] in Serum or Plasma;3OH-Isovalerylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18445-7;Benzoylcarnitine (BzCn);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Benzoylcarnitine (BzCn) [Mass/volume] in Serum or Plasma;Benzoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18446-5;Methylmalonylcarnitine (C4-DC);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC) [Mass/volume] in Serum or Plasma;Me-malonylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18447-3;Octenoylcarnitine (C8:1);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octenoylcarnitine (C8:1) [Mass/volume] in Serum or Plasma;Octenoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18448-1;Octanoylcarnitine (C8);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octanoylcarnitine (C8) [Mass/volume] in Serum or Plasma;Octanoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18449-9;Glutarylcarnitine (C5-DC);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutarylcarnitine (C5-DC) [Mass/volume] in Serum or Plasma;Glutarylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18450-7;Adipoylcarnitine (C6-DC);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adipoylcarnitine (C6-DC) [Mass/volume] in Serum or Plasma;Adipoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18451-5;Cis-4-decenoylcarnitine (Cis 4 C10:1);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;cis-4-Decenoylcarnitine (Cis 4 C10:1) [Mass/volume] in Serum or Plasma;Cis4Decenoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.42 +18452-3;Decanoylcarnitine (C10);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decanoylcarnitine (C10) [Mass/volume] in Serum or Plasma;Decanoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18453-1;Suberylcarnitine (C8-DC);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Suberylcarnitine (C8-DC) [Mass/volume] in Serum or Plasma;Suberylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18454-9;Dodecenoylcarnitine (C12:1);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1) [Mass/volume] in Serum or Plasma;Dodecenoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18455-6;Dodecanoylcarnitine (C12);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dodecanoylcarnitine (C12) [Mass/volume] in Serum or Plasma;Dodecanoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18456-4;Tetradecadienoylcarnitine (C14:2);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2) [Mass/volume] in Serum or Plasma;Tdecadienoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +1845-7;Ammonium ion;SCnc;Pt;Plas;Qn;;CHEM;1;Ammonium ion [Moles/volume] in Plasma;Ammonium Ion Plas-sCnc;;ACTIVE;1.0;2.34 +18457-2;Tetradecenoylcarnitine (C14:1);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1) [Mass/volume] in Serum or Plasma;Tdecenoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18458-0;3-Hydroxytetradecadienoylcarnitine (C14:2-OH);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Mass/volume] in Serum or Plasma;3OH-Tdecadienoylcar SerPl-mCnc;;DISCOURAGED;1.0l;2.42 +18459-8;3-Hydroxytetradecenoylcarnitine (C14:1-OH);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Mass/volume] in Serum or Plasma;3OH-Tdecenoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18460-6;Palmitoylcarnitine (C16);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Mass/volume] in Serum or Plasma;Palmitoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18461-4;3-Hydroxypalmitoylcarnitine (C16-OH);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Mass/volume] in Serum or Plasma;3OH-Palmitoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18462-2;Linoleoylcarnitine (C18:2);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Linoleoylcarnitine (C18:2) [Mass/volume] in Serum or Plasma;Linoleoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18463-0;Oleoylcarnitine (C18:1);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Oleoylcarnitine (C18:1) [Mass/volume] in Serum or Plasma;Oleoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18464-8;3-Hydroxylinoleoylcarnitine (C18:2-OH);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxylinoleoylcarnitine (C18:2-OH) [Mass/volume] in Serum or Plasma;3OH-Linoleoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +1846-5;Amylo-alpha-1,6-glucosidase;CCnc;Pt;RBC;Qn;;CHEM;1;Amylo-alpha-1,6-glucosidase [Enzymatic activity/volume] in Red Blood Cells;AGL RBC-cCnc;;ACTIVE;1.0;2.54 +18465-5;3-Hydroxyoleoylcarnitine (C18:1-OH);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyoleoylcarnitine (C18:1-OH) [Mass/volume] in Serum or Plasma;3OH-Oleoylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18466-3;Dicarboxyoleylcarnitine (C18:1-DC);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxyoleylcarnitine (C18:1-DC) [Mass/volume] in Serum or Plasma;Dicarboxyoleylcarn SerPl-mCnc;;DISCOURAGED;1.0l;2.73 +18467-1;Venlafaxine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Venlafaxine [Mass/volume] in Urine;Venlafaxine Ur-mCnc;;ACTIVE;1.0l;2.73 +18468-9;Aspergillus fumigatus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Aspergillus fumigatus Ab [Presence] in Cerebral spinal fluid;A fumigatus Ab CSF Ql;;ACTIVE;1.0l;2.56 +18469-7;Methyclothiazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyclothiazide [Mass/volume] in Serum or Plasma;Methyclothiazide SerPl-mCnc;;ACTIVE;1.0l;2.44 +18470-5;Norclomipramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norclomipramine [Mass/volume] in Urine;Norclomipramine Ur-mCnc;;ACTIVE;1.0l;2.73 +18471-3;Metoclopramide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Metoclopramide [Mass/volume] in Urine;Metoclopramide Ur-mCnc;;ACTIVE;1.0l;2.42 +18472-1;Organophosphate pesticides;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Organophosphate pesticides [Identifier] in Urine;OP Pesticides Ur;;ACTIVE;1.0l;2.19 +1847-3;Amyloid associated protein;MCnc;Pt;Ser;Qn;;CHEM;1;Amyloid associated protein [Mass/volume] in Serum;AA Prot Ser-mCnc;;ACTIVE;1.0;2.73 +18473-9;HYDROmorphone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;HYDROmorphone [Presence] in Urine by Confirmatory method;HYDROmorphone Ur Ql Cfm;;ACTIVE;1.0l;2.73 +18474-7;HER2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;HER2 Ag [Presence] in Tissue by Immune stain;Her2 Ag Tiss Ql ImStn;;ACTIVE;1.0l;2.73 +18475-4;Phenylalanine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phenylalanine/Creatinine [Molar ratio] in Urine;Phe/Creat Ur-sRto;;ACTIVE;1.0l;2.73 +18476-2;Uroporphyrinogen decarboxylase;PrThr;Pt;RBC;Ord;;CHEM;1;Uroporphyrinogen decarboxylase [Presence] in Red Blood Cells;URO-D RBC Ql;;ACTIVE;1.0l;2.73 +18477-0;Lithium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Lithium [Moles/time] in 24 hour Urine;Lithium 24h Ur-sRate;;ACTIVE;1.0l;2.70 +18478-8;Human papilloma virus 16+18 DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 16+18 DNA [Presence] in Tissue by Probe;HPV16+18 DNA Tiss Ql Probe;;ACTIVE;1.0l;2.73 +18479-6;Human papilloma virus 31+35+51 DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 31+35+51 DNA [Presence] in Tissue by Probe;HPV31+35+51 DNA Tiss Ql Probe;;ACTIVE;1.0l;2.73 +18480-4;Human papilloma virus 6+11 DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 6+11 DNA [Presence] in Tissue by Probe;HPV6+11 DNA Tiss Ql Probe;;ACTIVE;1.0l;2.73 +1848-1;Androstanolone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstanolone [Mass/volume] in Serum or Plasma;Androstanolone SerPl-mCnc;;ACTIVE;1.0;2.73 +18481-2;Streptococcus pyogenes Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Streptococcus pyogenes Ag [Presence] in Throat;S pyo Ag Throat Ql;;ACTIVE;1.0l;2.73 +18482-0;Yeast;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Yeast [Presence] in Specimen by Organism specific culture;Yeast Spec Ql Cult;;ACTIVE;1.0l;2.73 +18483-8;Yeast;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Yeast [Presence] in Genital specimen by Organism specific culture;Yeast Genital Ql Cult;;ACTIVE;1.0l;2.73 +18484-6;Ku Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ku Ab [Presence] in Serum;Ku Ab Ser Ql;;ACTIVE;1.0l;2.73 +18485-3;Mi-2 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Mi-2 Ab [Presence] in Serum;MI2 Ab Ser Ql;;ACTIVE;1.0l;2.73 +18486-1;Methylenediamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methylenediamine [Presence] in Urine;Me-enediam Ur Ql;;ACTIVE;1.0l;2.73 +18487-9;Broad casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Broad casts [#/area] in Urine sediment by Microscopy low power field;Broad Casts #/area UrnS LPF;;ACTIVE;1.0l;2.73 +18488-7;Calcium;MCnc;24H;Urine;Qn;;CHEM;1;Calcium [Mass/volume] in 24 hour Urine;Calcium 24h Ur-mCnc;;ACTIVE;1.0l;2.73 +18489-5;Valproate.protein bound;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate.protein bound [Mass/volume] in Serum or Plasma;PB Valproate SerPl-mCnc;;ACTIVE;1.0l;2.73 +18490-3;Chlamydia trachomatis G+F+K Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis G+F+K IgA Ab [Titer] in Serum by Immunofluorescence;C trach G+F+K IgA Titr Ser IF;;ACTIVE;1.0l;2.70 +18491-1;Chlamydia trachomatis G+F+K Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis G+F+K IgG Ab [Titer] in Serum by Immunofluorescence;C trach G+F+K IgG Titr Ser IF;;ACTIVE;1.0l;2.70 +18492-9;Chlamydia trachomatis G+F+K Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis G+F+K IgM Ab [Titer] in Serum by Immunofluorescence;C trach G+F+K IgM Titr Ser IF;;ACTIVE;1.0l;2.70 +18493-7;Ova & parasites identified^3rd specimen;Prid;Pt;Stool;Nom;Concentration;MICRO;1;Ova and parasites identified in Stool by Concentration--3rd specimen;O+P sp3 Stl Conc;;ACTIVE;1.0l;2.73 +18494-5;Ova & parasites identified^2nd specimen;Prid;Pt;Stool;Nom;Concentration;MICRO;1;Ova and parasites identified in Stool by Concentration--2nd specimen;O+P sp2 Stl Conc;;ACTIVE;1.0l;2.73 +18495-2;Ova & parasites identified^3rd specimen;Prid;Pt;Stool;Nom;Trichrome stain;MICRO;1;Ova and parasites identified in Stool by Trichrome stain--3rd specimen;O+P sp3 Stl Tri Stn;;ACTIVE;1.0l;2.73 +18496-0;Ova & parasites identified^2nd specimen;Prid;Pt;Stool;Nom;Trichrome stain;MICRO;1;Ova and parasites identified in Stool by Trichrome stain--2nd specimen;O+P sp2 Stl Tri Stn;;ACTIVE;1.0l;2.73 +18497-8;Microscopic observation;Prid;Pt;Thyroid.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Thyroid fine needle aspirate by Cyto stain;Cyto Thyroid FNA;;ACTIVE;1.0l;2.73 +18498-6;Microscopic observation;Prid;Pt;Breast.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Breast fine needle aspirate by Cyto stain;Cyto Breast FNA;;ACTIVE;1.0l;2.73 +1849-9;Androstanolone;MCnc;Pt;Semen;Qn;;CHEM;1;Androstanolone [Mass/volume] in Semen;Androstanolone Smn-mCnc;;ACTIVE;1.0;2.42 +18499-4;Microscopic observation;Prid;Pt;Nipple discharge;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Nipple discharge by Cyto stain;Cyto Nipple dis;;ACTIVE;1.0l;2.73 +18500-9;Microscopic observation;Prid;Pt;Cvx;Nom;Cyto stain.thin prep;CYTO;1;Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep;Thin Prep Cvx;;ACTIVE;1.0l;2.73 +18501-7;Microscopic observation;Prid;Pt;Buccal smear;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Buccal smear by Cyto stain;Cyto Buccal Smear;;ACTIVE;1.0l;1.0ma +18502-5;Microscopic observation;Prid;Pt;Deep tissue.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Deep tissue fine needle aspirate by Cyto stain;Cyto Deep Tiss FNA;;ACTIVE;1.0l;2.19 +18503-3;Microscopic observation;Prid;Pt;Superficial tissue.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Superficial tissue fine needle aspirate by Cyto stain;Cyto Superf Tiss FNA;;ACTIVE;1.0l;2.19 +18504-1;PP interval;Time;Stdy^mean;Heart;Qn;EKG;EKG.MEAS;2;PP interval mean;PP Interv Mean;;ACTIVE;1.0l;2.48 +18505-8;RR interval;Time;Stdy^mean;Heart;Qn;EKG;EKG.MEAS;2;R-R interval (Mean value during study) by EKG;R-R interval Mean;;ACTIVE;1.0l;2.54 +18506-6;P wave axis.horizontal plane;Angle;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;P wave axis horizontal plane Reference beat;P wave Ax HP RefB;;ACTIVE;1.0l;2.48 +1850-7;Androstanediol;MCnc;Pt;Urine;Qn;;CHEM;1;Androstanediol [Mass/volume] in Urine;Androstanediol Ur-mCnc;;ACTIVE;1.0;2.42 +18507-4;QRS axis.horizontal plane;Angle;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;QRS axis.horizontal plane Reference beat;QRS axis HP RefB;;ACTIVE;1.0l;2.48 +18508-2;R wave axis.horizontal plane;Angle;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave axis.horizontal plane;R wave axis HP;;ACTIVE;1.0l;2.48 +18509-0;T wave axis.horizontal plane;Angle;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;T wave axis.horizontal plane Reference beat;T wave axis HP RefB;;ACTIVE;1.0l;2.48 +18510-8;ST segment axis.horizontal plane;Angle;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST segment axis.horizontal plane;ST Seg axis HP;;ACTIVE;1.0l;2.48 +18511-6;P wave onset;Time;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;P wave onset [Time] Reference beat;P wave Onset Time RefB;;ACTIVE;1.0l;2.48 +18512-4;P wave offset;Time;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;P wave offset [Time] Reference beat;P wave Offset Time RefB;;ACTIVE;1.0l;2.48 +18513-2;QRS onset;Time;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;QRS onset [Time] Reference beat;QRS Onset Time RefB;;ACTIVE;1.0l;2.48 +18514-0;QRS offset;Time;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;QRS offset [Time] Reference beat;QRS Offset Time RefB;;ACTIVE;1.0l;2.48 +1851-5;Androstenedione;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Androstenedione [Mass/volume] in Amniotic fluid;Androst Amn-mCnc;;ACTIVE;1.0;2.34 +18515-7;T wave offset;Time;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;T wave offset [Time] Reference beat;T wave Offset Time RefB;;ACTIVE;1.0l;2.48 +18516-5;P wave axis.frontal plane;Angle;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;P wave axis frontal plane Reference beat;P wave Ax FP RefB;;ACTIVE;1.0l;2.48 +18517-3;QRS axis.frontal plane;Angle;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;QRS axis.frontal plane Reference beat;QRS axis FP RefB;;ACTIVE;1.0l;2.48 +18518-1;T wave axis.frontal plane;Angle;Pt;Reference beat;Qn;EKG;EKG.MEAS;2;T wave axis.frontal plane Reference beat;T wave axis FP RefB;;ACTIVE;1.0l;2.48 +18519-9;Reference beat;Type;Pt;Reference beat;Nom;EKG;EKG.MEAS;2;Reference beat;RefB;;ACTIVE;1.0l;2.29 +18520-7;PR interval;Time;Pt;Lead AVF;Qn;EKG;EKG.MEAS;2;P-R Interval Lead AVF;P-R interval L-AVF;;ACTIVE;1.0l;2.48 +18521-5;PR interval;Time;Pt;Lead AVL;Qn;EKG;EKG.MEAS;2;P-R Interval Lead AVL;P-R interval L-AVL;;ACTIVE;1.0l;2.48 +18522-3;PR interval;Time;Pt;Lead AVR;Qn;EKG;EKG.MEAS;2;P-R Interval Lead AVR;P-R interval L-AVR;;ACTIVE;1.0l;2.48 +1852-3;Androstenedione;MCnc;Pt;BldC;Qn;;CHEM;1;Androstenedione [Mass/volume] in Capillary blood;Androst BldC-mCnc;;ACTIVE;1.0;2.34 +18523-1;PR interval;Time;Pt;Lead I;Qn;EKG;EKG.MEAS;2;P-R Interval Lead I;P-R interval L-I;;ACTIVE;1.0l;2.48 +18524-9;PR interval;Time;Pt;Lead II;Qn;EKG;EKG.MEAS;2;P-R Interval Lead II;P-R interval L-II;;ACTIVE;1.0l;2.48 +18525-6;PR interval;Time;Pt;Lead III;Qn;EKG;EKG.MEAS;2;P-R Interval Lead III;P-R interval L-III;;ACTIVE;1.0l;2.48 +18526-4;PR interval;Time;Pt;Lead V1;Qn;EKG;EKG.MEAS;2;P-R Interval Lead V1;P-R interval L-V1;;ACTIVE;1.0l;2.48 +18527-2;PR interval;Time;Pt;Lead V2;Qn;EKG;EKG.MEAS;2;P-R Interval Lead V2;P-R interval L-V2;;ACTIVE;1.0l;2.48 +18528-0;PR interval;Time;Pt;Lead V3;Qn;EKG;EKG.MEAS;2;P-R Interval Lead V3;P-R interval L-V3;;ACTIVE;1.0l;2.48 +18529-8;PR interval;Time;Pt;Lead V4;Qn;EKG;EKG.MEAS;2;P-R Interval Lead V4;P-R interval L-V4;;ACTIVE;1.0l;2.48 +18530-6;PR interval;Time;Pt;Lead V5;Qn;EKG;EKG.MEAS;2;P-R Interval Lead V5;P-R interval L-V5;;ACTIVE;1.0l;2.48 +1853-1;Androstenedione;MCnc;Pt;Semen;Qn;;CHEM;1;Androstenedione [Mass/volume] in Semen;Androst Smn-mCnc;;ACTIVE;1.0;2.34 +18531-4;PR interval;Time;Pt;Lead V6;Qn;EKG;EKG.MEAS;2;P-R Interval Lead V6;P-R interval L-V6;;ACTIVE;1.0l;2.48 +18532-2;QT interval;Time;Pt;Lead AVF;Qn;EKG;EKG.MEAS;2;Q-T interval Lead AVF;Q-T interval L-AVF;;ACTIVE;1.0l;2.48 +18533-0;QT interval;Time;Pt;Lead AVL;Qn;EKG;EKG.MEAS;2;Q-T interval Lead AVL;Q-T interval L-AVL;;ACTIVE;1.0l;2.48 +18534-8;QT interval;Time;Pt;Lead AVR;Qn;EKG;EKG.MEAS;2;Q-T interval Lead AVR;Q-T interval L-AVR;;ACTIVE;1.0l;2.48 +18535-5;QT interval;Time;Pt;Lead I;Qn;EKG;EKG.MEAS;2;Q-T interval Lead I;Q-T interval L-I;;ACTIVE;1.0l;2.48 +18536-3;QT interval;Time;Pt;Lead II;Qn;EKG;EKG.MEAS;2;Q-T interval Lead II;Q-T interval L-II;;ACTIVE;1.0l;2.48 +18537-1;QT interval;Time;Pt;Lead III;Qn;EKG;EKG.MEAS;2;Q-T interval Lead III;Q-T interval L-III;;ACTIVE;1.0l;2.48 +18538-9;QT interval;Time;Pt;Lead V1;Qn;EKG;EKG.MEAS;2;Q-T interval Lead V1;Q-T interval L-V1;;ACTIVE;1.0l;2.48 +18539-7;QT interval;Time;Pt;Lead V2;Qn;EKG;EKG.MEAS;2;Q-T interval Lead V2;Q-T interval L-V2;;ACTIVE;1.0l;2.48 +18540-5;QT interval;Time;Pt;Lead V3;Qn;EKG;EKG.MEAS;2;Q-T interval Lead V3;Q-T interval L-V3;;ACTIVE;1.0l;2.48 +18541-3;QT interval;Time;Pt;Lead V4;Qn;EKG;EKG.MEAS;2;Q-T interval Lead V4;Q-T interval L-V4;;ACTIVE;1.0l;2.48 +18542-1;QT interval;Time;Pt;Lead V5;Qn;EKG;EKG.MEAS;2;Q-T interval Lead V5;Q-T interval L-V5;;ACTIVE;1.0l;2.48 +18543-9;QT interval;Time;Pt;Lead V6;Qn;EKG;EKG.MEAS;2;Q-T interval Lead V6;Q-T interval L-V6;;ACTIVE;1.0l;2.48 +18544-7;ST amplitude.J point+20 ms;Elpot;Pt;Lead AVF;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead AVF;J Pnt ST Amp+20ms L-AVF;;ACTIVE;1.0l;2.48 +18545-4;ST amplitude.J point+20 ms;Elpot;Pt;Lead AVL;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead AVL;J Pnt ST Amp+20ms L-AVL;;ACTIVE;1.0l;2.48 +18546-2;ST amplitude.J point+20 ms;Elpot;Pt;Lead AVR;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead AVR;J Pnt ST Amp+20ms L-AVR;;ACTIVE;1.0l;2.48 +18547-0;ST amplitude.J point+20 ms;Elpot;Pt;Lead I;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead I;J Pnt ST Amp+20ms L-I;;ACTIVE;1.0l;2.48 +18548-8;ST amplitude.J point+20 ms;Elpot;Pt;Lead II;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead II;J Pnt ST Amp+20ms L-II;;ACTIVE;1.0l;2.48 +1854-9;Androstenedione;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstenedione [Mass/volume] in Serum or Plasma;Androst SerPl-mCnc;;ACTIVE;1.0;2.73 +18549-6;ST amplitude.J point+20 ms;Elpot;Pt;Lead III;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead III;J Pnt ST Amp+20ms L-III;;ACTIVE;1.0l;2.48 +18550-4;ST amplitude.J point+20 ms;Elpot;Pt;Lead V1;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead V1;J Pnt ST Amp+20ms L-V1;;ACTIVE;1.0l;2.48 +18551-2;ST amplitude.J point+20 ms;Elpot;Pt;Lead V2;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead V2;J Pnt ST Amp+20ms L-V2;;ACTIVE;1.0l;2.48 +18552-0;ST amplitude.J point+20 ms;Elpot;Pt;Lead V3;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead V3;J Pnt ST Amp+20ms L-V3;;ACTIVE;1.0l;2.48 +18553-8;ST amplitude.J point+20 ms;Elpot;Pt;Lead V4;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead V4;J Pnt ST Amp+20ms L-V4;;ACTIVE;1.0l;2.48 +18554-6;ST amplitude.J point+20 ms;Elpot;Pt;Lead V5;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead V5;J Pnt ST Amp+20ms L-V5;;ACTIVE;1.0l;2.48 +18555-3;ST amplitude.J point+20 ms;Elpot;Pt;Lead V6;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+20 ms Lead V6;J Pnt ST Amp+20ms L-V6;;ACTIVE;1.0l;2.48 +1855-6;Androstenedione;MCnc;Pt;Urine;Qn;;CHEM;1;Androstenedione [Mass/volume] in Urine;Androst Ur-mCnc;;ACTIVE;1.0;2.34 +18556-1;ST amplitude.J point+60 ms;Elpot;Pt;Lead AVF;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead AVF;J Pnt ST Amp+60ms L-AVF;;ACTIVE;1.0l;2.48 +18557-9;ST amplitude.J point+60 ms;Elpot;Pt;Lead AVL;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead AVL;J Pnt ST Amp+60ms L-AVL;;ACTIVE;1.0l;2.48 +18558-7;ST amplitude.J point+60 ms;Elpot;Pt;Lead AVR;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead AVR;J Pnt ST Amp+60ms L-AVR;;ACTIVE;1.0l;2.48 +18559-5;ST amplitude.J point+60 ms;Elpot;Pt;Lead I;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead I;J Pnt ST Amp+60ms L-I;;ACTIVE;1.0l;2.48 +18560-3;ST amplitude.J point+60 ms;Elpot;Pt;Lead II;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead II;J Pnt ST Amp+60ms L-II;;ACTIVE;1.0l;2.48 +18561-1;ST amplitude.J point+60 ms;Elpot;Pt;Lead III;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead III;J Pnt ST Amp+60ms L-III;;ACTIVE;1.0l;2.48 +18562-9;ST amplitude.J point+60 ms;Elpot;Pt;Lead V1;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead V1;J Pnt ST Amp+60ms L-V1;;ACTIVE;1.0l;2.48 +18563-7;ST amplitude.J point+60 ms;Elpot;Pt;Lead V2;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead V2;J Pnt ST Amp+60ms L-V2;;ACTIVE;1.0l;2.48 +1856-4;Androsterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androsterone [Mass/volume] in Serum or Plasma;Androsterone SerPl-mCnc;;ACTIVE;1.0;2.73 +18564-5;ST amplitude.J point+60 ms;Elpot;Pt;Lead V3;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead V3;J Pnt ST Amp+60ms L-V3;;ACTIVE;1.0l;2.48 +18565-2;ST amplitude.J point+60 ms;Elpot;Pt;Lead V4;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead V4;J Pnt ST Amp+60ms L-V4;;ACTIVE;1.0l;2.48 +18566-0;ST amplitude.J point+60 ms;Elpot;Pt;Lead V5;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead V5;J Pnt ST Amp+60ms L-V5;;ACTIVE;1.0l;2.48 +18567-8;ST amplitude.J point+60 ms;Elpot;Pt;Lead V6;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+60 ms Lead V6;J Pnt ST Amp+60ms L-V6;;ACTIVE;1.0l;2.48 +18568-6;ST amplitude.J point+80 ms;Elpot;Pt;Lead AVF;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead AVF;J Pnt ST Amp+80ms L-AVF;;ACTIVE;1.0l;2.48 +18569-4;ST amplitude.J point+80 ms;Elpot;Pt;Lead AVL;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead AVL;J Pnt ST Amp+80ms L-AVL;;ACTIVE;1.0l;2.48 +18570-2;ST amplitude.J point+80 ms;Elpot;Pt;Lead AVR;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead AVR;J Pnt ST Amp+80ms L-AVR;;ACTIVE;1.0l;2.48 +18571-0;ST amplitude.J point+80 ms;Elpot;Pt;Lead I;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead I;J Pnt ST Amp+80ms L-I;;ACTIVE;1.0l;2.48 +1857-2;Angiotensin converting enzyme;CCnc;Pt;Bld;Qn;;CHEM;1;Angiotensin converting enzyme [Enzymatic activity/volume] in Blood;ACE Bld-cCnc;;ACTIVE;1.0;2.73 +18572-8;ST amplitude.J point+80 ms;Elpot;Pt;Lead II;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead II;J Pnt ST Amp+80ms L-II;;ACTIVE;1.0l;2.48 +18573-6;ST amplitude.J point+80 ms;Elpot;Pt;Lead III;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead III;J Pnt ST Amp+80ms L-III;;ACTIVE;1.0l;2.48 +18574-4;ST amplitude.J point+80 ms;Elpot;Pt;Lead V1;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead V1;J Pnt ST Amp+80ms L-V1;;ACTIVE;1.0l;2.48 +18575-1;ST amplitude.J point+80 ms;Elpot;Pt;Lead V2;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead V2;J Pnt ST Amp+80ms L-V2;;ACTIVE;1.0l;2.48 +18576-9;ST amplitude.J point+80 ms;Elpot;Pt;Lead V3;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead V3;J Pnt ST Amp+80ms L-V3;;ACTIVE;1.0l;2.48 +18577-7;ST amplitude.J point+80 ms;Elpot;Pt;Lead V4;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead V4;J Pnt ST Amp+80ms L-V4;;ACTIVE;1.0l;2.48 +18578-5;ST amplitude.J point+80 ms;Elpot;Pt;Lead V5;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead V5;J Pnt ST Amp+80ms L-V5;;ACTIVE;1.0l;2.48 +18579-3;ST amplitude.J point+80 ms;Elpot;Pt;Lead V6;Qn;EKG;EKG.MEAS;2;ST amplitude.J point+80 ms Lead V6;J Pnt ST Amp+80ms L-V6;;ACTIVE;1.0l;2.48 +1858-0;Angiotensin I;MCnc;Pt;Plas;Qn;;CHEM;1;Angiotensin I [Mass/volume] in Plasma;Angiotensin I Plas-mCnc;;ACTIVE;1.0;2.73 +18580-1;Origination site;Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Origination site;;;ACTIVE;1.0l;2.27 +18581-9;Origination site;Addr;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Origination site Address;;;ACTIVE;1.0l;2.24 +18582-7;Destination site;Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Destination site Name;;;ACTIVE;1.0l;2.27 +18583-5;Destination site;Addr;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Destination site Address;;;ACTIVE;1.0l;2.24 +18584-3;Body weight^at ambulance transport;Cmplx;Pt;^Patient;Set;;ATTACH.AMB;3;Body weight at ambulance transport Set;;;ACTIVE;1.0l;2.40 +18588-4;Purpose of stretcher;Find;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Purpose of stretcher (narrative);;;ACTIVE;1.0l;2.27 +18589-2;Admitted at destination facility;Find;Pt;^Patient;Ord;;ED;2;Admitted at destination facility;Admitted at destination facility;;ACTIVE;1.0l;2.64 +185-9;Ciprofloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Ciprofloxacin Islt MIC;;ACTIVE;1.0;2.73 +18591-8;Confined to bed^before Ambulance transport;Find;Pt;^Patient;Ord;;ATTACH.AMB;3;Confined to bed before ambulance transport;;;ACTIVE;1.0l;2.27 +18592-6;Confined to bed^after Ambulance transport;Find;Pt;^Patient;Ord;;ATTACH.AMB;3;Confined to bed after ambulance transport;;;ACTIVE;1.0l;2.27 +18593-4;Discharged from origin institution;Find;Pt;Ambulance transport;Ord;;ATTACH.AMB;3;Ambulance transport, Discharged from origin institution;;;ACTIVE;1.0l;2.27 +18594-2;Rehabilitation.psychiatric service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Psychiatric service attachment;Rehab.psych therapy service Doc;;ACTIVE;1.0l;2.73 +1859-8;Angiotensin II;MCnc;Pt;CSF;Qn;;CHEM;1;Angiotensin II [Mass/volume] in Cerebral spinal fluid;Angiotensin II CSF-mCnc;;ACTIVE;1.0;2.42 +18598-3;Control number identification.claims attachment;ID;Pt;^Patient;Nom;;ATTACH;3;Control number identification.claims attachment;;;ACTIVE;1.0l;2.27 +18600-7;Primary practitioner ID;ID;Pt;Provider;Nom;;ATTACH;3;Primary practitioner identifier;;;ACTIVE;1.0l;2.56 +18601-5;Primary practitioner profession;Type;Pt;Provider;Nom;;ATTACH;3;Primary practitioner profession;;;ACTIVE;1.0l;2.27 +18602-3;ED practitioner ID;ID;Pt;Provider;Nom;;ATTACH;3;ED practitioner identifier;;;ACTIVE;1.0l;2.56 +18605-6;Medication.current;Cmplx;Pt;^Patient;Set;Reported;ATTACH.MEDS;3;Medication current Set;;;ACTIVE;1.0l;2.73 +1860-6;Angiotensin II;MCnc;Pt;Plas;Qn;;CHEM;1;Angiotensin II [Mass/volume] in Plasma;Angiotensin II Plas-mCnc;;ACTIVE;1.0;2.73 +18606-4;Name + ID;ID;Pt;Medication.current;Nom;;ATTACH.MEDS;3;Current medication, Name and Identifier;;;ACTIVE;1.0l;2.40 +18607-2;Medication XXX;Dosage;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication Dose;;;ACTIVE;1.0l;2.27 +18608-0;Timing + Quantity;TQ2;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication, Timing + Quantity;;;ACTIVE;1.0l;2.42 +18609-8;Route;Prid;Pt;Medication.current;Nom;;ATTACH.MEDS;3;Current medication, Route;;;ACTIVE;1.0l;2.27 +18610-6;Medication.administered;Cmplx;Pt;^Patient;Set;;ATTACH.MEDS;3;Medication administered Set;;;ACTIVE;1.0l;2.63 +18611-4;Name + ID;ID;Pt;Medication.administered;Nom;;ATTACH.MEDS;3;Administered medication, Name and Identifier;;;ACTIVE;1.0l;2.40 +18612-2;Route;Prid;Pt;Medication.administered;Nom;;ATTACH.MEDS;3;Administered medication, Route;;;ACTIVE;1.0l;2.73 +1861-4;Angiotensinogen;MCnc;Pt;Plas;Qn;;CHEM;1;Angiotensinogen [Mass/volume] in Plasma;Angiotensinogen Plas-mCnc;;ACTIVE;1.0;2.42 +18614-8;Timing;TQ2;Pt;Medication.administered;Qn;;ATTACH.MEDS;3;Administered medication, Timing;;;ACTIVE;1.0l;2.27 +18615-5;Medication XXX;Dosage;Pt;Medication.administered;Qn;;ATTACH.MEDS;3;Medication administered Dose;;;ACTIVE;1.0l;2.27 +18616-3;Strength;Prid;Pt;Medication.administered;Nom;;ATTACH.MEDS;3;Administered medication, Strength;;;ACTIVE;1.0l;2.27 +18617-1;Medication.discharge;Cmplx;Pt;^Patient;Set;;ATTACH.MEDS;3;Medication discharge Set;;;ACTIVE;1.0l;2.40 +18618-9;Name + ID;ID;Pt;Medication.discharge;Nom;;ATTACH.MEDS;3;Discharge medication, Name and Identifier;;;ACTIVE;1.0l;2.40 +18619-7;Medication XXX;Dosage;Pt;Medication.discharge;Qn;;ATTACH.MEDS;3;Discharge medication Dose;;;ACTIVE;1.0l;2.27 +18620-5;Timing + Quantity;TQ2;Pt;Medication.discharge;Qn;;ATTACH.MEDS;3;Discharge medication, Timing + Quantity;;;ACTIVE;1.0l;2.42 +18621-3;Route;Prid;Pt;Medication.discharge;Nom;;ATTACH.MEDS;3;Discharge medication, Route;;;ACTIVE;1.0l;2.27 +1862-2;Aniline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aniline [Mass/volume] in Serum or Plasma;Aniline SerPl-mCnc;;ACTIVE;1.0;2.42 +18622-1;Amount dispensed;Num;Pt;Medication.discharge;Qn;;ATTACH.MEDS;3;Discharge medication, Amount dispensed;;;ACTIVE;1.0l;2.27 +18623-9;Refills;Num;Pt;Medication.discharge;Qn;;ATTACH.MEDS;3;Discharge medication, Refills;;;ACTIVE;1.0l;2.27 +18624-7;ED problem;Find;Pt;^Patient;Nar;Reported;ATTACH.ED;3;ED problem (narrative);;;ACTIVE;1.0l;2.27 +18626-2;New &or revised;Type;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, New/revised;Deprecated;;DEPRECATED;1.0l;2.66 +18627-0;Date.onset or exacerbation;Date;Pt;Primary Dx for psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;1.0l;2.66 +18628-8;Date.start;TmStp;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, start date;;;DEPRECATED;1.0l;2.36 +18629-6;Clinical discipline;Type;Pt;Psychiatric rehabilitation treatment plan;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Clinical discipline - Psychiatric rehabilitation treatment plan;;;DEPRECATED;1.0l;2.40 +1863-0;Anion gap 4;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Anion gap 4 in Serum or Plasma;Anion Gap4 SerPl-sCnc;;ACTIVE;1.0;2.73 +18630-4;Diagnosis.primary;Imp;Pt;^Patient;Nom;;ATTACH.REHAB;3;Primary diagnosis;;;ACTIVE;1.0l;2.70 +18631-2;Diagnosis.addressed by plan;Imp;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;1.0l;2.66 +18632-0;Author of treatment plan;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Author of treatment plan Set;;;ACTIVE;1.0l;2.40 +18633-8;Author name;Pn;Pt;Psychiatric rehabilitation treatment plan;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Author name;Deprecated;;DEPRECATED;1.0l;2.66 +18634-6;Author profession;Prid;Pt;Psychiatric rehabilitation treatment plan;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;1.0l;2.66 +18635-3;Signature date;TmStp;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;1.0l;2.66 +18637-9;Visit frequency;TQ2;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;1.0l;2.66 +18638-7;Visit duration;Time;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Visit duration Time;Deprecated;;DEPRECATED;1.0l;2.66 +18639-5;Date range (from_through) described by plan;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;1.0l;2.40 +18640-3;Start date;Date;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Start date;Deprecated;;DEPRECATED;1.0l;2.66 +18641-1;Date.end;Date;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, End date;Deprecated;;DEPRECATED;1.0l;2.66 +18642-9;Date range;Cmplx;Enctr;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Date range (from/through) Set;;;ACTIVE;1.0l;2.40 +18643-7;Start date;Date;Pt;Hospitalization leading to psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;1.0l;2.66 +18644-5;End date;Date;Procedure;Hospitalization leading to psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;1.0l;2.66 +18645-2;Continuation status;Type;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Continuation status;Deprecated;;DEPRECATED;1.0l;2.66 +18646-0;Date attending MD referred patient for;Date;Pt;Psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;1.0l;2.66 +18647-8;Date attending MD signed;TmStp;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;1.0l;2.66 +1864-8;Anserine;MCnc;Pt;CSF;Qn;;CHEM;1;Anserine [Mass/volume] in Cerebral spinal fluid;Anserine CSF-mCnc;;DISCOURAGED;1.0;2.44 +18648-6;Date rehabilitation professional signed;TmStp;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date rehabilitation professional signed Date and time;Deprecated;;DEPRECATED;1.0l;2.66 +18649-4;Signature of responsible attending physician on file;Arb;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;1.0l;2.66 +18650-2;Signature of responsible rehabilitation professional on file;Arb;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;1.0l;2.66 +18651-0;Medication administered;Cmplx;Pt;Psychiatric rehabilitation treatment;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Medication administered Set;;;ACTIVE;1.0l;2.40 +18652-8;Prognosis for rehabilitation;Imp;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;1.0l;2.66 +18653-6;Estimated date of completion;Date;Pt;Psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;1.0l;2.66 +18654-4;Date of last plan of treatment certification;Date;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;1.0l;2.66 +1865-5;Anserine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Anserine [Presence] in Serum or Plasma;Anserine SerPl Ql;;ACTIVE;1.0;2.73 +18655-1;Past medical history+Level of function;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18656-9;Initial evaluation note;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan Initial evaluation note (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18657-7;Plan of treatment;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18658-5;Progress note+attainment of goals;Find;Pt;Psychiatric rehabilitation treatment;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18659-3;Reason to continue;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18660-1;Justification;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Justification (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18661-9;Psychiatric symptoms;Find;Pt;Psychiatric rehabilitation treatment;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18662-7;Chief complaint+Reason for referral+Reason for relapse if known;Find;Pt;Alcohol-substance abuse rehabilitation treatment;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Chief complaint+Reason for referral+Reason for relapse if known (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +1866-3;Anserine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Anserine [Mass/volume] in Serum or Plasma;Anserine SerPl-mCnc;;DISCOURAGED;1.0;2.73 +18663-5;History of present alcohol &or substance abuse;Hx;Pt;^Patient;Nar;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse, rehabilitation plan, History of present alcohol/substance abuse (narrative);;;ACTIVE;1.0l;2.56 +18664-3;Follow-up approach;Cmplx;Pt;Rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Rehabilitation treatment plan, Follow-up approach Set;;;ACTIVE;1.0l;2.40 +18665-0;Agency that will follow up;Prid;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Agency that will follow up Identifier;Deprecated;;DEPRECATED;1.0l;2.66 +18666-8;Person that will follow up after;Prid;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Person that will follow up after Identifier;Deprecated;;DEPRECATED;1.0l;2.66 +18667-6;Methodology for follow up;Txt;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Methodology for follow up (narrative) Text;Deprecated;;DEPRECATED;1.0l;2.66 +18668-4;Frequency of assessments for follow up;Num;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Frequency of assessments for follow up #;Deprecated;;DEPRECATED;1.0l;2.66 +18669-2;Level of patient participation;Txt;Pt;Rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Rehabilitation treatment plan, Level of patient participation Text;Deprecated;;DEPRECATED;1.0l;2.66 +186-7;Ciprofloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ciprofloxacin [Susceptibility] by Disk diffusion (KB);Ciprofloxacin Islt KB;;ACTIVE;1.0;2.73 +18670-0;Date of next planned rehabilitation treatment;Cmplx;Pt;Rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Rehabilitation treatment plan, Date of next planned rehabilitation treatment Set;;;ACTIVE;1.0l;2.40 +1867-1;Anserine;MCnc;Pt;Urine;Qn;;CHEM;1;Anserine [Mass/volume] in Urine;Anserine Ur-mCnc;;DISCOURAGED;1.0;2.73 +18671-8;Next plan of treatment;Txt;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Next plan of treatment (narrative) Text;Deprecated;;DEPRECATED;1.0l;2.66 +18672-6;Alcohol or substance abuse symptoms with physiological dependence indicator;Find;Pt;^Patient;Ord;;ATTACH.REHAB.ABUSE;3;Alcohol or substance abuse symptoms with physiological dependence indicator;;;ACTIVE;1.0l;2.27 +18673-4;Rehabilitation problem remission status;Prid;Pt;^Patient;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, rehabilitation problem remission status;Deprecated;;DEPRECATED;1.0l;2.66 +18674-2;Longest period of sobriety for abused substance;Time;Pt;^Patient;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, longest period of sobriety for abused substance (composite);;;ACTIVE;1.0l;2.00 +18675-9;Substance abused;Type;Pt;^Patient;Nar;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, abused substance;;;ACTIVE;1.0l;2.27 +18676-7;Longest period of sobriety;Time;Pt;^Patient;Qn;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, longest period of sobriety;;;ACTIVE;1.0l;2.69 +18677-5;Rehabilitation.service claims attachment;Cmplx;-;^Patient;Set;;ATTACH.REHAB;3;Deprecated Service claims attachment;Deprecated;;DEPRECATED;1.0l;2.66 +18679-1;ED claims attachment;Cmplx;Enctr;^Patient;Set;;ATTACH.ED;3;ED claims attachment (composite);;;ACTIVE;1.0l;2.27 +18682-5;Note;Find;Pt;Ambulance;Doc;Emergency medicine;DOC.ONTOLOGY;2;Ambulance records;Ambulance records;;ACTIVE;1.0l;2.74 +18684-1;Blood pressure;Cmplx;Enctr^frst;^Patient;Set;;ATTACH.ED;3;First Blood pressure Set;;;ACTIVE;1.0l;2.73 +18685-8;Blood pressure special circumstances;Type;Enctr^frst;^Patient;Nom;;ATTACH.ED;3;First Blood pressure special circumstances;;;ACTIVE;1.0l;2.21 +18686-6;Respiration rate;Cmplx;Enctr^frst;^Patient;Set;;ATTACH.ED;3;First Respiration rate Set;;;ACTIVE;1.0l;2.73 +18687-4;Respiration rate special circumstances;Type;Enctr^frst;^Patient;Nom;;ATTACH.ED;3;First Respiration rate special circumstances;;;ACTIVE;1.0l;2.27 +18688-2;Body temperature;Cmplx;Enctr^frst;^Patient;Set;;ATTACH.ED;3;First Body temperature Set;;;ACTIVE;1.0l;2.40 +1868-9;Antithrombin Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Antithrombin Ag [Mass/volume] in Platelet poor plasma by Immunoassay;AT III Ag PPP IA-mCnc;;ACTIVE;1.0;2.73 +18689-0;Body temperature special circumstances;Type;Enctr^frst;^Patient;Nom;;ATTACH.ED;3;First Body temperature special circumstances;;;ACTIVE;1.0l;2.27 +18690-8;Body weight;Cmplx;Enctr^frst;^Patient;Set;;ATTACH.ED;3;First Body weight Set;;;ACTIVE;1.0l;2.40 +18692-4;Body weight special circumstances;Type;Enctr^frst;^Patient;Nom;;ATTACH.ED;3;First Body weight special circumstances;;;ACTIVE;1.0l;2.27 +18693-2;ED consultant practitioner;Cmplx;Pt;Provider;Set;;ATTACH.ED;3;ED consultant practitioner Set;;;ACTIVE;1.0l;2.40 +18694-0;ED consultant practitioner name;Pn;Pt;Provider;Nom;;ATTACH.ED;3;ED consultant practitioner name;;;ACTIVE;1.0l;2.27 +18695-7;ED clinical finding type;Type;Pt;^Patient;Nom;;ATTACH.ED;3;ED clinical finding type;;;ACTIVE;1.0l;2.27 +18696-5;ED clinical finding;Find;Pt;^Patient;Nar;;ATTACH.ED;3;ED clinical finding (narrative);;;ACTIVE;1.0l;2.27 +1869-7;Apolipoprotein A-I;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein A-I [Mass/volume] in Serum or Plasma;Apo A-I SerPl-mCnc;;ACTIVE;1.0;2.73 +18697-3;ED clinical finding data source;Type;Pt;^Patient;Nom;;ATTACH.ED;3;ED clinical finding data source;;;ACTIVE;1.0l;2.27 +18698-1;ED clinical finding information;Cmplx;Pt;^Patient;Set;;ATTACH.ED;3;ED clinical finding (composite);;;ACTIVE;1.0l;1.0ma +18699-9;ED practitioner;Cmplx;Pt;Provider;Set;;ATTACH.ED;3;ED practitioner Set;;;ACTIVE;1.0l;2.40 +18700-5;ED practitioner name;Pn;Pt;Provider;Nom;;ATTACH.ED;3;ED practitioner name;;;ACTIVE;1.0l;2.27 +18701-3;ED practitioner profession;Type;Pt;Provider;Nom;;ATTACH.ED;3;ED practitioner profession;;;ACTIVE;1.0l;2.27 +18702-1;ED practitioner role;Type;Pt;Provider;Nom;;ATTACH.ED;3;ED practitioner role;;;ACTIVE;1.0l;2.27 +18703-9;ED diagnostic procedure results;Cmplx;Pt;^Patient;Set;;ATTACH.ED;3;ED diagnostic procedure results Set;;;ACTIVE;1.0l;2.40 +18704-7;ED referring practitioner;Cmplx;Pt;Provider;Set;;ATTACH.ED;3;ED referring practitioner Set;;;ACTIVE;1.0l;2.40 +1870-5;Apolipoprotein A-II;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein A-II [Mass/volume] in Serum or Plasma;Apo A-II SerPl-mCnc;;ACTIVE;1.0;2.70 +18705-4;ED referring practitioner name;Pn;Pt;Provider;Nom;;ATTACH.ED;3;ED referring practitioner name;;;ACTIVE;1.0l;2.27 +18706-2;ED referring practitioner ID;ID;Pt;Provider;Nom;;ATTACH.ED;3;ED referring practitioner identifier;;;ACTIVE;1.0l;2.73 +18707-0;ED referring practitioner profession;Type;Pt;Provider;Nom;;ATTACH.ED;3;ED referring practitioner profession;;;ACTIVE;1.0l;2.27 +18708-8;Heart rate;Cmplx;Enctr^frst;Arterial system;Set;;ATTACH.ED;3;First Heart rate Set;;;ACTIVE;1.0l;2.40 +18709-6;Heart rate special circumstances;Type;Enctr^frst;^Patient;Nom;;ATTACH.ED;3;First Heart rate special circumstances;;;ACTIVE;1.0l;2.29 +18710-4;Primary practitioner;Cmplx;Pt;Provider;Set;;ATTACH.ED;3;Primary practitioner Set;;;ACTIVE;1.0l;2.40 +18711-2;Primary practitioner name;Pn;Pt;Provider;Nom;;ATTACH.ED;3;Primary practitioner name;;;ACTIVE;1.0l;2.27 +1871-3;Apolipoprotein B-100;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B-100 [Mass/volume] in Serum or Plasma;Apo B100 SerPl-mCnc;;ACTIVE;1.0;2.73 +18716-1;Allergy studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Allergy studies (set);;;ACTIVE;1.0l;2.73 +18717-9;Blood bank studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Blood bank studies (set);;;ACTIVE;1.0l;2.73 +18718-7;Cell marker studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Cell marker studies (set);;;ACTIVE;1.0l;2.73 +18719-5;Chemistry studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Chemistry studies (set);;;ACTIVE;1.0l;2.73 +18720-3;Coagulation studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Coagulation studies (set);;;ACTIVE;1.0l;2.73 +1872-1;Apolipoprotein B-150;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B-150 [Mass/volume] in Serum or Plasma;Apo B150 SerPl-mCnc;;ACTIVE;1.0;2.40 +18721-1;Therapeutic drug monitoring studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Therapeutic drug monitoring studies (set);;;ACTIVE;1.0l;2.27 +18722-9;Fertility studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Fertility studies (set);;;ACTIVE;1.0l;2.27 +18723-7;Hematology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Hematology studies (set);;;ACTIVE;1.0l;2.73 +18724-5;HLA studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;HLA studies (set);;;ACTIVE;1.0l;2.27 +18725-2;Microbiology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Microbiology studies (set);;;ACTIVE;1.0l;2.73 +18726-0;Radiology studies;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Radiology studies (set);;;ACTIVE;1.0l;2.27 +18727-8;Serology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Serology studies (set);;;ACTIVE;1.0l;2.73 +18728-6;Toxicology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Toxicology studies (set);;;ACTIVE;1.0l;2.27 +18729-4;Urinalysis studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Urinalysis studies (set);;;ACTIVE;1.0l;2.73 +18730-2;Author ID;ID;Pt;Psychiatric rehabilitation treatment plan;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;1.0l;2.66 +18733-6;Progress note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending Progress note;Attend Prog note;;ACTIVE;1.0l;2.73 +18734-4;Initial evaluation note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Initial evaluation note;OT Initial eval note;;ACTIVE;1.0l;2.50 +18735-1;Initial evaluation note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Initial evaluation note;PT Initial eval note;;ACTIVE;1.0l;2.50 +18736-9;Initial evaluation note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Initial evaluation note;MD Initial eval note;;ACTIVE;1.0l;2.58 +18737-7;Initial evaluation note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Initial evaluation note;Podiatry Initial eval note;;ACTIVE;1.0l;2.50 +18738-5;Initial evaluation note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Initial evaluation note;Psych Initial eval note;;ACTIVE;1.0l;2.50 +1873-9;Apolipoprotein B-48;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B-48 [Mass/volume] in Serum or Plasma;Apo B48 SerPl-mCnc;;ACTIVE;1.0;2.40 +18739-3;Initial evaluation note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Initial evaluation note;SW Initial eval note;;ACTIVE;1.0l;2.65 +18740-1;Initial evaluation note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Initial evaluation note;Speech-lang path Initial eval note;;ACTIVE;1.0l;2.50 +18741-9;Subsequent visit evaluation note;Find;Pt;{Setting};Doc;Attending physician;ATTACH.CLINRPT;3;Deprecated Attending physician progress note;;;DEPRECATED;1.0l;2.36 +18742-7;Arthroscopy study;Find;Pt;XXX;Doc;Arthroscopy;DOC.MISC;2;Arthroscopy study;Arthroscopy study;;ACTIVE;1.0l;2.72 +18743-5;Autopsy report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Autopsy report;Autopsy report;;ACTIVE;1.0l;2.73 +18744-3;Bronchoscopy study;Find;Pt;Respiratory system;Doc;Bronchoscopy;CLIN;2;Bronchoscopy study;Bronchoscopy study;;ACTIVE;1.0l;2.72 +18745-0;Cardiac catheterization study;Find;Pt;Heart;Doc;Cardiac catheterization;CARD.PROC;2;Cardiac catheterization study;Cardiac catheterization study;;ACTIVE;1.0l;2.72 +18746-8;Colonoscopy study;Find;Pt;Lower GI tract;Doc;Colonoscopy;ENDO.GI;2;Colonoscopy study;Colonoscopy study;;ACTIVE;1.0l;2.73 +1874-7;Apolipoprotein B/Apolipoprotein A-I;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B/Apolipoprotein A-I [Mass Ratio] in Serum or Plasma;Apo B/Apo A-I SerPl;;ACTIVE;1.0;2.73 +18747-6;Study;Find;Pt;XXX;Doc;CT;ATTACH.CLINRPT;3;Deprecated CT Unspecified system Study;Deprecated;;DEPRECATED;1.0l;2.58 +18748-4;Diagnostic imaging study;Find;Pt;^Patient;Doc;Diagnostic imaging;DOC.MISC;2;Diagnostic imaging study;Diagnostic imaging study;;ACTIVE;1.0l;2.72 +18749-2;Electromyogram study;Find;Pt;XXX;Doc;Electromyogram;DOC.MISC;2;Electromyogram study;Electromyogram study;;ACTIVE;1.0l;2.72 +187-5;Ciprofloxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ciprofloxacin [Susceptibility] by Serum bactericidal titer;Ciprofloxacin Titr SBT;;ACTIVE;1.0;2.32 +18750-0;Cardiac electrophysiology study;Find;Pt;Heart;Doc;Electrophysiology;CARD.PROC;2;Cardiac electrophysiology study;Card Electrophysiology study;;ACTIVE;1.0l;2.72 +18751-8;Endoscopy study;Find;Pt;^Patient;Doc;Endoscopy;ENDO.GI;2;Endoscopy study;Endoscopy study;;ACTIVE;1.0l;2.72 +18752-6;Exercise stress test study;Find;Pt;^Patient;Doc;;CLIN;2;Exercise stress test study;Exercise stress test study;;ACTIVE;1.0l;2.72 +18753-4;Flexible sigmoidoscopy study;Find;Pt;Lower GI tract;Doc;Flexible sigmoidoscopy;ENDO.GI;2;Flexible sigmoidoscopy study;Flex sigmoidoscopy study;;ACTIVE;1.0l;2.72 +1875-4;Apolipoprotein C-I;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein C-I [Mass/volume] in Serum or Plasma;Apo C-I SerPl-mCnc;;ACTIVE;1.0;2.40 +18754-2;Ambulatory cardiac rhythm monitor study;Find;Pt;Heart;Doc;Holter monitor;CARD.PROC;2;Ambulatory cardiac rhythm monitor (Holter) study;Holter monitor study;;ACTIVE;1.0l;2.72 +18755-9;Study report;Find;Pt;XXX;Doc;MRI;ATTACH.CLINRPT;3;Deprecated MRI Unspecified site study;Deprecated;;DEPRECATED;1.0l;2.58 +18756-7;Study report;Find;Pt;Spine.XXX;Doc;MR;DOC.MISC;2;Deprecated MR Spine study;Deprecated MR Spine study;;DEPRECATED;1.0l;2.72 +18757-5;Study report;Find;Pt;XXX;Doc;Radnuc;ATTACH.CLINRPT;3;Deprecated Nuclear medicine study;Deprecated;;DEPRECATED;1.0l;2.58 +18758-3;Study;Find;Pt;XXX;Doc;PET scan;ATTACH.CLINRPT;3;Deprecated PET scan Unspecified system Study;Deprecated;;DEPRECATED;1.0l;2.58 +18759-1;Polysomnography study;Find;Pt;Respiratory system;Doc;Spirometry;CLIN;2;Spirometry study;Spirometry study;;ACTIVE;1.0l;2.72 +18760-9;Study;Find;Pt;XXX;Doc;US;ATTACH.CLINRPT;3;Deprecated US Unspecified system Study;Deprecated;;DEPRECATED;1.0l;2.58 +18761-7;Transfer summary note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Transfer summary note;Transfer sum note;;ACTIVE;1.0l;2.58 +1876-2;Apolipoprotein C-II;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein C-II [Mass/volume] in Serum or Plasma;Apo C-II SerPl-mCnc;;ACTIVE;1.0;2.40 +18762-5;Subsequent evaluation note;Find;Pt;{Setting};Doc;Chiropractor;ATTACH.CLINRPT;3;Deprecated Chiropractor Progress note;Deprecated;;DEPRECATED;1.0l;2.52 +18763-3;Initial evaluation note;Find;Pt;{Setting};Doc;Consultant;DOC.ONTOLOGY;2;Consultant Initial evaluation note;Consultant Initial eval note;;ACTIVE;1.0l;2.65 +18764-1;Subsequent evaluation note;Find;Pt;{Setting};Doc;Nurse practitioner;ATTACH.CLINRPT;3;Deprecated Nurse practitioner Progress note;Deprecated;;DEPRECATED;1.0l;2.52 +18765-8;Subsequent visit evaluation note;Find;Pt;{Setting};Doc;Podiatry;ATTACH.CLINRPT;3;Deprecated Podiatry visit note;;;DEPRECATED;1.0l;2.36 +18766-6;Subsequent visit evaluation note;Find;Pt;{Setting};Doc;Psychology;ATTACH.CLINRPT;3;Deprecated Psychology visit note;;;DEPRECATED;1.0l;2.36 +18767-4;Blood gas studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Blood gas studies (set);;;ACTIVE;1.0l;2.73 +18768-2;Cell counts+Differential studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Cell counts+Differential studies (set);;;ACTIVE;1.0l;2.27 +18769-0;Microbial susceptibility tests;Susc;Pt;^Patient;Set;;ATTACH.LAB;3;Microbial susceptibility tests Set;;;ACTIVE;1.0l;2.73 +1877-0;Apolipoprotein C-III;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein C-III [Mass/volume] in Serum or Plasma;Apo C-III SerPl-mCnc;;ACTIVE;1.0;2.70 +18770-8;Dictating practitioner name;Pn;Pt;Provider;Nom;;ATTACH.CLINRPT;3;Dictating practitioner name;;;ACTIVE;1.0l;2.27 +18771-6;Provider.signing name;Pn;Pt;Report;Nom;;ADMIN;2;Provider signing name;Provider signing name;;ACTIVE;1.0l;2.73 +18772-4;Surgeon.resident name;Pn;Pt;Surgical procedure;Nom;;ATTACH.CLINRPT;3;Surgeon.resident name;;;ACTIVE;1.0l;2.27 +18773-2;Surgeon.staff name;Pn;Pt;Surgical procedure;Nom;;ATTACH.CLINRPT;3;Surgeon.staff name;;;ACTIVE;1.0l;2.27 +18774-0;Staff practitioner name;Pn;Pt;Provider;Nom;;ATTACH.CLINRPT;3;Staff practitioner name;;;ACTIVE;1.0l;2.73 +18775-7;Staff practitioner ID;ID;Pt;Provider;Nom;;ATTACH.CLINRPT;3;Staff practitioner identifier;;;ACTIVE;1.0l;2.56 +18776-5;Plan of care note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Plan of care note;Plan of care note;;ACTIVE;1.0l;2.67 +18777-3;Diagnosis.primary;Imp;Pt;Psychiatric rehabilitation treatment;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;1.0l;2.66 +18779-9;Comparison.study;TmStp;Pt;XXX;Qn;Radiology;ATTACH.CLINRPT;3;Radiology Comparison study - date and time;;;ACTIVE;1.0l;1.0ma +18780-7;Ordering practitioner ID;Type;Pt;Provider;Nom;;ATTACH.CLINRPT;3;Ordering practitioner identifier;;;ACTIVE;1.0l;2.56 +18781-5;Ordering practitioner name;Pn;Pt;Provider;Nom;;ATTACH.CLINRPT;3;Ordering practitioner name;;;ACTIVE;1.0l;2.73 +18782-3;Study observation;Find;Pt;XXX;Nar;Radiology;ATTACH.CLINRPT;3;Radiology Study observation (narrative);;;ACTIVE;1.0l;2.63 +18783-1;Study recommendation;Imp;Pt;^Patient;Nar;Radiology;ATTACH.CLINRPT;3;Radiology Study recommendation (narrative);;;ACTIVE;1.0l;2.63 +18785-6;Reason for study;Find;Pt;Report;Nar;Radiology;ATTACH.CLINRPT;3;Radiology Reason for study (narrative);;;ACTIVE;1.0l;2.63 +1878-8;Apolipoprotein A-III;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein A-III [Mass/volume] in Serum or Plasma;Apo A-III SerPl-mCnc;;ACTIVE;1.0;2.40 +18789-8;Include all data of the selected type within the date window associated with the service;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type within the date window associated with the service;;;ACTIVE;1.0l;2.44 +18790-6;Include all data of the selected type on or before the date of service;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type on or before the date of service;;;ACTIVE;1.0l;2.44 +18791-4;Include all data of the selected type within or aligned to an encounter by the same service or encounter;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type within or aligned to an encounter by the same service or encounter;;;ACTIVE;1.0l;2.44 +18792-2;Include all data of the selected type on or after the date of service;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type on or after the date of service;;;ACTIVE;1.0l;2.44 +18793-0;Use no fixed time limit on data (any of the selected type are relevant no matter when obtained);Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Use no fixed time limit on data (any of the selected type are relevant no matter when obtained);;;ACTIVE;1.0l;2.27 +18794-8;Send all items of the specified type within the time window;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send all items of the specified type within the time window;;;DISCOURAGED;1.0l;2.50 +18795-5;Send all items of the specified type within the time window relevant to the service;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send all items of the specified type within the time window relevant to the service;;;DISCOURAGED;1.0l;2.50 +1879-6;Apolipoprotein E2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein E2 [Mass/volume] in Serum or Plasma;Apo E2 SerPl-mCnc;;ACTIVE;1.0;2.50 +18796-3;Send all abnormals within the time window;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send all abnormals within the time window;;;DISCOURAGED;1.0l;2.50 +18797-1;Send the first abnormals within the time window;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send the first abnormals within the time window;;;DISCOURAGED;1.0l;2.50 +18798-9;Send the last abnormals within the time window;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send the last abnormals within the time window;;;DISCOURAGED;1.0l;2.50 +18799-7;Send the first (i.e., oldest) result for each kind of observation in the time window;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send the first (i.e., oldest) result for each kind of observation in the time window;;;DISCOURAGED;1.0l;2.50 +18800-3;Send the worst abnormal result for each kind of observation in the time window;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send the worst abnormal result for each kind of observation in the time window;;;DISCOURAGED;1.0l;2.50 +18802-9;Send the last (most recent) within the time window;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send the last (most recent) within the time window;;;DISCOURAGED;1.0l;2.50 +18803-7;Include all data of the selected type that represents observations made 30D or fewer before the starting date of service;Scope.modifier.time window;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type that represents observations made 30 days or fewer before the starting date of service;;;ACTIVE;1.0l;2.44 +1880-4;Beta 2 glycoprotein 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta 2 glycoprotein 1 [Mass/volume] in Serum or Plasma;B2 Glycoprot1 SerPl-mCnc;;ACTIVE;1.0;2.40 +18804-5;Include all data of the selected type that represents observations made 3Mo or fewer before the starting date of service;Scope.modifier.time window;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type that represents observations made 3 months or fewer before the starting date of service;;;ACTIVE;1.0l;2.44 +18805-2;Include all data of the selected type that represents observations made six Mo or fewer before the starting date of service;Scope.modifier.time window;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type that represents observations made six months or fewer before the starting date of service;;;ACTIVE;1.0l;2.44 +18806-0;Include all data of the selected type that represents observations made nine Mo or fewer before the starting date of service;Scope.modifier.time window;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type that represents observations made nine months or fewer before the starting date of service;;;ACTIVE;1.0l;2.44 +18807-8;Include all data of the selected type that represents observations made one year or less before the starting date of service;Scope.modifier.time window;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type that represents observations made one year or less before the starting date of service;;;ACTIVE;1.0l;2.44 +18810-2;Study observation.overall;Find;Pt;Heart;Nar;EKG;EKG.IMP;2;EKG Study observation overall (narrative);EKG Study;;ACTIVE;1.0l;2.29 +1881-2;Apolipoprotein LPA;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein LPA [Mass/volume] in Serum or Plasma;Apo Lp(a) SerPl-mCnc;;ACTIVE;1.0;2.73 +18812-8;Ordering practitioner;ID;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Ordering practitioner Identifier;;;ACTIVE;1.0l;2.56 +18813-6;Ordering practitioner;Pn;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Ordering practitioner name;;;ACTIVE;1.0l;2.24 +18814-4;Reason for scheduled trip;Imp;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Reason for scheduled trip;;;ACTIVE;1.0l;2.26 +18815-1;Reason for scheduled trip additional service information;Imp;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Reason for scheduled trip additional service information (narrative);;;ACTIVE;1.0l;2.27 +18816-9;Medication name + ID;ID;Pt;^Patient;Nom;;ATTACH.MEDS;3;Medication name + identifier;;;ACTIVE;1.0l;2.27 +18817-7;Medication XXX;Dosage;Pt;^Patient;Qn;;ATTACH.MEDS;3;Medication dose;;;ACTIVE;1.0l;2.73 +18818-5;Medication timing + Quantity;TQ2;Pt;^Patient;Qn;;ATTACH.MEDS;3;Medication timing + Quantity;;;ACTIVE;1.0l;2.27 +18819-3;Medication route;Prid;Pt;Psychiatric rehabilitation treatment;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;1.0l;2.66 +1882-0;Apolipoprotein LPQ;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein LPQ [Mass/volume] in Serum or Plasma;Apo Lp(q) SerPl-mCnc;;ACTIVE;1.0;2.40 +18820-1;Diagnosis.primary;ID;Pt;Psychiatric rehabilitation treatment;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;1.0l;2.66 +18821-9;Diagnosis.addressed by plan;ID;Pt;^Patient;Nom;;ATTACH.REHAB;3;Diagnosis addressed by plan;;;ACTIVE;1.0l;2.27 +18822-7;Diagnosis.addressed by plan;Txt;Pt;^Patient;Nar;;ATTACH.REHAB;3;Diagnosis addressed by plan (narrative);;;ACTIVE;1.0l;2.27 +18823-5;Rehabilitation.alcohol &or substance abuse service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Alcohol and/or substance abuse service attachment;Rehab.alcohol/subs service Doc;;ACTIVE;1.0l;2.73 +18824-3;Rehabilitation.cardiac service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Cardiac service attachment;Rehab.cardiac service Doc;;ACTIVE;1.0l;2.73 +18825-0;Rehabilitation.medical social services attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Medical social services attachment;Rehab.med social services Doc;;ACTIVE;1.0l;2.73 +18826-8;Rehabilitation.occupational therapy service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Occupational therapy service attachment;Rehab.OT service Doc;;ACTIVE;1.0l;2.73 +188-3;Clarithromycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Clarithromycin [Susceptibility] by Minimum lethal concentration (MLC);Clarithro Islt MLC;;ACTIVE;1.0;2.19 +18833-4;Body weight;Mass;Enctr^frst;^Patient;Qn;Measured;ATTACH.CLINRPT;3;First Body weight;;;ACTIVE;1.0l;2.73 +18834-2;Comparison.study;Imp;Pt;XXX;Nar;Radiology;ATTACH.CLINRPT;3;Radiology Comparison study (narrative);;;ACTIVE;1.0l;2.63 +18835-9;Aortic valve area method;Prid;Pt;Aortic valve;Nar;*;CARD.US;2;Aortic valve area method Narrative;AV AV area method;;ACTIVE;1.0l;2.40 +18836-7;Procedure;Find;Pt;Cardiac stress study;Doc;;DOC.MISC;2;Cardiac stress study Procedure;Cardiac stress study Procedure;;ACTIVE;1.0l;2.67 +18837-5;Segmental wall appearance;Find;Pt;Heart.ventricle.left;Nar;US;CARD.US;2;Left ventricle Segmental wall appearance by US Narrative;LV Seg wall appear US;;ACTIVE;1.0l;2.40 +1883-8;Apolipoprotein A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein A [Mass/volume] in Serum or Plasma;Apo A SerPl-mCnc;;ACTIVE;1.0;2.73 +18838-3;Transducer site;Prid;Pt;Cardiac echo study;Nar;*;CARD.US;2;Cardiac echo study Transducer site Narrative;Cardiac Echo Study Transducer site;;ACTIVE;1.0l;2.40 +18839-1;Ultrasound class;Type;Pt;Cardiac echo imaging device;Nar;*;CARD.US;2;Cardiac echo imaging device Class Narrative;Card Echo Device Class;;ACTIVE;1.0l;2.56 +18840-9;Wall motion index;Arb;Pt;Heart.ventricle.left;Nar;US;CARD.US;2;Left ventricular Wall motion index by US Narrative;LV Wall motion index NAR US;;ACTIVE;1.0l;2.40 +18841-7;Hospital consultations;Find;Pt;^Patient;Doc;;DOC.MISC;2;Hospital consultations Document;Hospital consultations Doc;;ACTIVE;1.0l;2.67 +18842-5;Discharge summary note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Discharge summary;D/C sum;;ACTIVE;1.0l;2.73 +18843-3;Comparison.study;Imp;Pt;Heart;Nar;EKG;EKG.ATOM;2;EKG Comparison study (narrative);Comparison study Imp EKG;;ACTIVE;1.0l;2.29 +18844-1;EKG impression;Imp;Pt;Heart;Nar;EKG;EKG.ATOM;2;EKG impression Narrative;EKG impression;;ACTIVE;1.0l;2.40 +18845-8;Reference beat type;Prid;Pt;Heart;Nar;EKG;ATTACH.CLINRPT;3;Reference beat type (narrative) by EKG;;;ACTIVE;1.0l;2.27 +1884-6;Apolipoprotein B;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B [Mass/volume] in Serum or Plasma;Apo B SerPl-mCnc;;ACTIVE;1.0;2.73 +18846-6;Examination level.ultrasound;Type;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Examination level ultrasound (narrative);;;ACTIVE;1.0l;1.0ma +18847-4;Fetal position;Type;Pt;Pelvis;Nar;Palpation;OB.US;2;Narrative Fetal position palpation;Fet positn Palpation;;ACTIVE;1.0l;2.40 +18848-2;Fetal position;Type;Pt;Pelvis;Nar;US;OB.US;2;Narrative Fetal position US;Fet positn US;;ACTIVE;1.0l;2.40 +18849-0;Fetal presentation;Type;Pt;Pelvis;Nar;Palpation;OB.US;2;Narrative Fetal presentation palpation;Fet pres Palpation;;ACTIVE;1.0l;2.40 +18850-8;Fetal presentation;Type;Pt;Pelvis;Nar;US;OB.US;2;Narrative Fetal presentation US;Fet pres US;;ACTIVE;1.0l;2.40 +18851-6;Grade;Type;Pt;Placenta^Fetus;Nar;US;OB.US;2;Fetal Placenta Grade US (narrative);Fet Placenta Grade - NAR US;;ACTIVE;1.0l;2.38 +18852-4;Surgical drains;Find;Pt;Surgery^Patient;Nar;;ATTACH.CLINRPT;3;Deprecated Operative note - surgical drains (narrative);;;DEPRECATED;1.0l;2.36 +1885-3;Apolipoprotein C;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein C [Mass/volume] in Serum or Plasma;Apo C SerPl-mCnc;;ACTIVE;1.0;2.40 +18855-7;5-Fluorocytosine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;5-Fluorocytosine [Susceptibility];5-fluorocytosine Susc Islt;;ACTIVE;1.0l;2.73 +18857-3;Almecillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Almecillin [Susceptibility];Almecillin Susc Islt;;ACTIVE;1.0l;2.19 +18859-9;Amdinocillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amdinocillin [Susceptibility];Amdinocillin Susc Islt;;ACTIVE;1.0l;2.19 +18860-7;Amikacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amikacin [Susceptibility];Amikacin Susc Islt;;ACTIVE;1.0l;2.73 +1886-1;Apolipoprotein E;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein E [Mass/volume] in Serum or Plasma;Apo E SerPl-mCnc;;ACTIVE;1.0;2.70 +18861-5;Amoxicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amoxicillin [Susceptibility];Amoxicillin Susc Islt;;ACTIVE;1.0l;2.73 +18862-3;Amoxicillin+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility];Amoxicillin+Clav Susc Islt;;ACTIVE;1.0l;2.73 +18863-1;Amphotericin B;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amphotericin B [Susceptibility];Amphotericin B Susc Islt;;ACTIVE;1.0l;2.73 +18864-9;Ampicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ampicillin [Susceptibility];Ampicillin Susc Islt;;ACTIVE;1.0l;2.73 +18865-6;Ampicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility];Ampicillin+Sulbac Susc Islt;;ACTIVE;1.0l;2.73 +18866-4;Azithromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Azithromycin [Susceptibility];Azithromycin Susc Islt;;ACTIVE;1.0l;2.73 +18867-2;Azlocillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Azlocillin [Susceptibility];Azlocillin Susc Islt;;ACTIVE;1.0l;2.19 +18868-0;Aztreonam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Aztreonam [Susceptibility];Aztreonam Susc Islt;;ACTIVE;1.0l;2.73 +18869-8;Bacampicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Bacampicillin [Susceptibility];Bacampicillin Susc Islt;;ACTIVE;1.0l;2.19 +18870-6;Bacitracin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Bacitracin [Susceptibility];Bacitracin Susc Islt;;ACTIVE;1.0l;2.19 +18871-4;Butirosin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Butirosin [Susceptibility];Butirosin Susc Islt;;ACTIVE;1.0l;2.19 +18872-2;Capreomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Capreomycin [Susceptibility];Capreomycin Susc Islt;;ACTIVE;1.0l;2.19 +18873-0;Carbenicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Carbenicillin [Susceptibility];Carbenicillin Susc Islt;;ACTIVE;1.0l;2.73 +18874-8;Cefaclor;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefaclor [Susceptibility];Cefaclor Susc Islt;;ACTIVE;1.0l;2.73 +18875-5;Cefadroxil;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefadroxil [Susceptibility];Cefadroxil Susc Islt;;ACTIVE;1.0l;2.19 +18876-3;Cefamandole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefamandole [Susceptibility];Cefamandole Susc Islt;;ACTIVE;1.0l;2.19 +18877-1;Cefatrizine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefatrizine [Susceptibility];Cefatrizine Susc Islt;;ACTIVE;1.0l;2.19 +18878-9;ceFAZolin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;ceFAZolin [Susceptibility];ceFAZolin Susc Islt;;ACTIVE;1.0l;2.73 +1887-9;Appearance;Aper;Pt;Amnio fld;Nom;;SPEC;1;Appearance of Amniotic fluid;Appearance Amn;;ACTIVE;1.0;2.73 +18879-7;Cefepime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefepime [Susceptibility];Cefepime Susc Islt;;ACTIVE;1.0l;2.73 +18880-5;Cefixime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefixime [Susceptibility];Cefixime Susc Islt;;ACTIVE;1.0l;2.73 +18881-3;Cefmetazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefmetazole [Susceptibility];Cefmetazole Susc Islt;;ACTIVE;1.0l;2.73 +18882-1;Cefodizime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefodizime [Susceptibility];Cefodizime Susc Islt;;ACTIVE;1.0l;2.19 +18883-9;Cefonicid;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefonicid [Susceptibility];Cefonocid Susc Islt;;ACTIVE;1.0l;2.73 +18884-7;Cefoperazone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefoperazone [Susceptibility];Cefoperazone Susc Islt;;ACTIVE;1.0l;2.73 +18885-4;Ceforanide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceforanide [Susceptibility];Ceforanide Susc Islt;;ACTIVE;1.0l;2.19 +18886-2;Cefotaxime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefotaxime [Susceptibility];Cefotaxime Susc Islt;;ACTIVE;1.0l;2.73 +1888-7;Aquacobalamin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aquacobalamin [Mass/volume] in Serum or Plasma;Vit B12a SerPl-mCnc;;ACTIVE;1.0;2.38 +18887-0;cefoTEtan;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefoTEtan [Susceptibility];cefoTEtan Susc Islt;;ACTIVE;1.0l;2.73 +18888-8;cefOXitin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefOXitin [Susceptibility];cefOXitin Susc Islt;;ACTIVE;1.0l;2.73 +18889-6;Cefpirome;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefpirome [Susceptibility];Cefpirome Susc Islt;;ACTIVE;1.0l;2.19 +18890-4;Cefpodoxime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefpodoxime [Susceptibility];Cefpodoxime Susc Islt;;ACTIVE;1.0l;2.73 +18891-2;Cefprozil;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefprozil [Susceptibility];Cefprozil Susc Islt;;ACTIVE;1.0l;2.73 +18892-0;Cefsulodin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefsulodin [Susceptibility];Cefsulodin Susc Islt;;ACTIVE;1.0l;2.19 +18893-8;cefTAZidime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefTAZidime [Susceptibility];cefTAZidime Susc Islt;;ACTIVE;1.0l;2.73 +18894-6;Ceftizoxime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceftizoxime [Susceptibility];Ceftizoxime Susc Islt;;ACTIVE;1.0l;2.73 +1889-5;Arachidonate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Arachidonate (C20:4w6) [Mass/volume] in Serum or Plasma;AA SerPl-mCnc;;DISCOURAGED;1.0;2.73 +18895-3;cefTRIAXone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefTRIAXone [Susceptibility];cefTRIAXone Susc Islt;;ACTIVE;1.0l;2.73 +18896-1;Cefuroxime.parenteral;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefuroxime Parenteral [Susceptibility];Cefuroxime Parenter Susc Islt;;ACTIVE;1.0l;2.73 +18897-9;Cephalexin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cephalexin [Susceptibility];Cephalexin Susc Islt;;ACTIVE;1.0l;2.19 +18898-7;Cephaloglycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cephaloglycin [Susceptibility];Cephaloglycin Susc Islt;;ACTIVE;1.0l;2.19 +18899-5;Cephaloridine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cephaloridine [Susceptibility];Cephaloridine Susc Islt;;ACTIVE;1.0l;2.19 +18900-1;Cephalothin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cephalothin [Susceptibility];Cephalothin Susc Islt;;ACTIVE;1.0l;2.73 +18901-9;Cephapirin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cephapirin [Susceptibility];Cephapirin Susc Islt;;ACTIVE;1.0l;2.19 +18902-7;Cephradine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cephradine [Susceptibility];Cephradine Susc Islt;;ACTIVE;1.0l;2.19 +1890-3;Arginase;CCnc;Pt;RBC;Qn;;CHEM;1;Arginase [Enzymatic activity/volume] in Red Blood Cells;Arginase RBC-cCnc;;ACTIVE;1.0;2.73 +18903-5;Chloramphenicol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Chloramphenicol [Susceptibility];Chloramphen Susc Islt;;ACTIVE;1.0l;2.73 +18904-3;Chlortetracycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Chlortetracycline [Susceptibility];Chlortetracycline Susc Islt;;ACTIVE;1.0l;2.19 +18905-0;Cinoxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cinoxacin [Susceptibility];Cinoxacin Susc Islt;;ACTIVE;1.0l;2.73 +18906-8;Ciprofloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ciprofloxacin [Susceptibility];Ciprofloxacin Susc Islt;;ACTIVE;1.0l;2.73 +18907-6;Clarithromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clarithromycin [Susceptibility];Clarithro Susc Islt;;ACTIVE;1.0l;2.73 +18908-4;Clindamycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clindamycin [Susceptibility];Clindamycin Susc Islt;;ACTIVE;1.0l;2.73 +18909-2;Clotrimazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clotrimazole [Susceptibility];Clotrimazole Susc Islt;;ACTIVE;1.0l;2.19 +189-1;Clarithromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clarithromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Clarithro Islt MIC;;ACTIVE;1.0;2.73 +18910-0;Cloxacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cloxacillin [Susceptibility];Cloxacillin Susc Islt;;ACTIVE;1.0l;2.19 +1891-1;Arginine;MCnc;Pt;CSF;Qn;;CHEM;1;Arginine [Mass/volume] in Cerebral spinal fluid;Arginine CSF-mCnc;;DISCOURAGED;1.0;2.44 +18911-8;Colistimethate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Colistimethate;Colistimethate Susc Islt;;ACTIVE;1.0l;2.19 +18912-6;Colistin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Colistin [Susceptibility];Colistin Susc Islt;;ACTIVE;1.0l;2.73 +18913-4;Cyclacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cyclacillin [Susceptibility];Cyclacillin Susc Islt;;ACTIVE;1.0l;2.19 +18914-2;cycloSERINE;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cycloSERINE [Susceptibility];cycloSERINE Susc Islt;;ACTIVE;1.0l;2.19 +18915-9;Demeclocycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Demeclocycline [Susceptibility];Demeclocycline Susc Islt;;ACTIVE;1.0l;2.19 +18916-7;Dicloxacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Dicloxacillin [Susceptibility];Dicloxacillin Susc Islt;;ACTIVE;1.0l;2.73 +18917-5;Doxycycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Doxycycline [Susceptibility];Doxycycline Susc Islt;;ACTIVE;1.0l;2.73 +18918-3;Enoxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Enoxacin [Susceptibility];Enoxacin Susc Islt;;ACTIVE;1.0l;2.73 +18919-1;Erythromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Erythromycin [Susceptibility];Erythromycin Susc Islt;;ACTIVE;1.0l;2.73 +18920-9;Erythromycin+sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Erythromycin+Sulfisoxazole [Susceptibility];Erythro+Sulf Susc Islt;;ACTIVE;1.0l;2.73 +18921-7;Ethambutol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ethambutol [Susceptibility];Ethambutol Susc Islt;;ACTIVE;1.0l;2.73 +18922-5;Ethionamide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ethionamide [Susceptibility];Ethionamide Susc Islt;;ACTIVE;1.0l;2.73 +18923-3;Floxacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Floxacillin [Susceptibility];Floxacillin Susc Islt;;ACTIVE;1.0l;2.19 +18924-1;Fluconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Fluconazole [Susceptibility];Fluconazole Susc Islt;;ACTIVE;1.0l;2.73 +18925-8;5-Fluorocytosine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Deprecated 5-Fluorocytosine [Susceptibility];Deprecated 5-fluorocytosine Susc Islt;;DEPRECATED;1.0l;2.36 +18926-6;Framycetin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Framycetin [Susceptibility];Framycetin Susc Islt;;ACTIVE;1.0l;2.19 +18927-4;Fusidate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Fusidate [Susceptibility];Fusidate Susc Islt;;ACTIVE;1.0l;2.19 +18928-2;Gentamicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Gentamicin [Susceptibility];Gentamicin Susc Islt;;ACTIVE;1.0l;2.73 +1892-9;Arginine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Arginine [Presence] in Serum or Plasma;Arginine SerPl Ql;;ACTIVE;1.0;2.73 +18929-0;Gentamicin.high potency;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Gentamicin.high potency [Susceptibility];Gentamicin Synergy Susc Islt;;ACTIVE;1.0l;2.73 +18930-8;Gramicidin D;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Gramicidin D [Susceptibility];Gramicidin D Susc Islt;;ACTIVE;1.0l;2.19 +18931-6;Hetacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Hetacillin [Susceptibility];Hetacillin Susc Islt;;ACTIVE;1.0l;2.19 +18932-4;Imipenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Imipenem [Susceptibility];Imipenem Susc Islt;;ACTIVE;1.0l;2.73 +18933-2;Imipenem+Cilastatin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Deprecated Imipenem+Cilastatin [Susceptibility];Deprecated Imipenem+Cilastatin Susc Islt;;DEPRECATED;1.0l;2.36 +18934-0;Isoniazid;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Isoniazid [Susceptibility];Isoniazid Susc Islt;;ACTIVE;1.0l;2.73 +18935-7;Kanamycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Kanamycin [Susceptibility];Kanamycin Susc Islt;;ACTIVE;1.0l;2.73 +18936-5;Kanamycin.high potency;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Kanamycin.high potency [Susceptibility];Kanamycin High Pot Susc Islt;;ACTIVE;1.0l;2.19 +1893-7;Arginine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Arginine [Mass/volume] in Serum or Plasma;Arginine SerPl-mCnc;;DISCOURAGED;1.0;2.73 +18937-3;Ketoconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ketoconazole [Susceptibility];Ketoconazole Susc Islt;;ACTIVE;1.0l;2.19 +18938-1;Lincomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Lincomycin [Susceptibility];Lincomycin Susc Islt;;ACTIVE;1.0l;2.19 +18939-9;Lomefloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Lomefloxacin [Susceptibility];Lomefloxacin Susc Islt;;ACTIVE;1.0l;2.73 +18940-7;Loracarbef;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Loracarbef [Susceptibility];Loracarbef Susc Islt;;ACTIVE;1.0l;2.19 +18941-5;Lymecycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Lymecycline [Susceptibility];Lymecycline Susc Islt;;ACTIVE;1.0l;2.19 +18942-3;Meclocycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Meclocycline [Susceptibility];Meclocycline Susc Islt;;ACTIVE;1.0l;2.19 +18943-1;Meropenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Meropenem [Susceptibility];Meropenem Susc Islt;;ACTIVE;1.0l;2.73 +18944-9;Methacycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Methacycline [Susceptibility];Methacycline Susc Islt;;ACTIVE;1.0l;2.19 +1894-5;Arginine;MCnc;Pt;Urine;Qn;;CHEM;1;Arginine [Mass/volume] in Urine;Arginine Ur-mCnc;;DISCOURAGED;1.0;2.44 +18945-6;Methicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Methicillin [Susceptibility];Methicillin Susc Islt;;ACTIVE;1.0l;2.19 +18946-4;metroNIDAZOLE;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;metroNIDAZOLE [Susceptibility];metroNIDAZOLE Susc Islt;;ACTIVE;1.0l;2.73 +18947-2;Mezlocillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Mezlocillin [Susceptibility];Mezlocillin Susc Islt;;ACTIVE;1.0l;2.73 +18948-0;Minocycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Minocycline [Susceptibility];Minocycline Susc Islt;;ACTIVE;1.0l;2.73 +18949-8;Miocamycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Miocamycin [Susceptibility];Miocamycin Susc Islt;;ACTIVE;1.0l;2.19 +18950-6;Moxalactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Moxalactam [Susceptibility];Moxalactam Susc Islt;;ACTIVE;1.0l;2.73 +18951-4;Nafcillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nafcillin [Susceptibility];Nafcillin Susc Islt;;ACTIVE;1.0l;2.19 +1895-2;Arginine;MRat;24H;Urine;Qn;;CHEM;1;Arginine [Mass/time] in 24 hour Urine;Arginine 24h Ur-mRate;;DISCOURAGED;1.0;2.44 +18952-2;Nalidixate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nalidixate [Susceptibility];Nalidixate Susc Islt;;ACTIVE;1.0l;2.73 +18953-0;Neomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Neomycin [Susceptibility];Neomycin Susc Islt;;ACTIVE;1.0l;2.73 +18954-8;Netilmicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Netilmicin [Susceptibility];Netilmicin Susc Islt;;ACTIVE;1.0l;2.19 +18955-5;Nitrofurantoin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nitrofurantoin [Susceptibility];Nitrofurantoin Susc Islt;;ACTIVE;1.0l;2.73 +18956-3;Norfloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Norfloxacin [Susceptibility];Norfloxacin Susc Islt;;ACTIVE;1.0l;2.73 +18957-1;Novobiocin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Novobiocin [Susceptibility];Novobiocin Susc Islt;;ACTIVE;1.0l;2.19 +18958-9;Nystatin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nystatin [Susceptibility];Nystatin Susc Islt;;ACTIVE;1.0l;2.21 +18959-7;Ofloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ofloxacin [Susceptibility];Ofloxacin Susc Islt;;ACTIVE;1.0l;2.73 +1896-0;Argininosuccinate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Argininosuccinate [Mass/volume] in Serum or Plasma;Argininosuccinate SerPl-mCnc;;DISCOURAGED;1.0;2.44 +18960-5;Oleandomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Oleandomycin [Susceptibility];Oleandomycin Susc Islt;;ACTIVE;1.0l;2.19 +18961-3;Oxacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Oxacillin [Susceptibility];Oxacillin Susc Islt;;ACTIVE;1.0l;2.73 +18962-1;Oxytetracycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Oxytetracycline [Susceptibility];Oxytetracycline Susc Islt;;ACTIVE;1.0l;2.19 +18963-9;Pefloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pefloxacin [Susceptibility];Pefloxacin Susc Islt;;ACTIVE;1.0l;2.19 +18964-7;Penicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Penicillin [Susceptibility];Penicillin Susc Islt;;ACTIVE;1.0l;2.73 +18965-4;Penicillin G;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Penicillin G [Susceptibility];Penicillin G Susc Islt;;ACTIVE;1.0l;2.73 +18966-2;Penicillin V;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Penicillin V [Susceptibility];Penicillin V Susc Islt;;ACTIVE;1.0l;2.73 +18967-0;Phenethicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Phenethicillin [Susceptibility];Phenethicillin Susc Islt;;ACTIVE;1.0l;2.19 +18968-8;Pipemidate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pipemidate [Susceptibility];Pipemidate Susc Islt;;ACTIVE;1.0l;2.19 +18969-6;Piperacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Piperacillin [Susceptibility];Piperacillin Susc Islt;;ACTIVE;1.0l;2.73 +18970-4;Piperacillin+Tazobactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Piperacillin+Tazobactam [Susceptibility];Pip+Tazo Susc Islt;;ACTIVE;1.0l;2.73 +18971-2;Pivampicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pivampicillin [Susceptibility];Pivampicillin Susc Islt;;ACTIVE;1.0l;2.19 +18972-0;Polymyxin B;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Polymyxin B [Susceptibility];Polymyxin B Susc Islt;;ACTIVE;1.0l;2.73 +18973-8;Pyrazinamide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pyrazinamide [Susceptibility];PZA Susc Islt;;ACTIVE;1.0l;2.73 +18974-6;rifAMPin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;rifAMPin [Susceptibility];rifAMPin Susc Islt;;ACTIVE;1.0l;2.73 +18975-3;Ristocetin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ristocetin [Susceptibility];Ristocetin Susc Islt;;ACTIVE;1.0l;2.19 +18976-1;Rolitetracycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Rolitetracycline [Susceptibility];Rolitetracycline Susc Islt;;ACTIVE;1.0l;2.19 +18977-9;Rosoxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Rosoxacin [Susceptibility];Rosoxacin Susc Islt;;ACTIVE;1.0l;2.19 +1897-8;Argininosuccinate;MCnc;Pt;Urine;Qn;;CHEM;1;Argininosuccinate [Mass/volume] in Urine;Argininosuccinate Ur-mCnc;;ACTIVE;1.0;2.68 +18978-7;Roxithromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Roxithromycin [Susceptibility];Roxithromycin Susc Islt;;ACTIVE;1.0l;2.19 +18979-5;Sisomicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sisomicin [Susceptibility];Sisomicin Susc Islt;;ACTIVE;1.0l;2.19 +18980-3;Spectinomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Spectinomycin [Susceptibility];Spectinomycin Susc Islt;;ACTIVE;1.0l;2.73 +18981-1;Spiramycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Spiramycin [Susceptibility];Spiramycin Susc Islt;;ACTIVE;1.0l;2.19 +18982-9;Streptomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Streptomycin [Susceptibility];Streptomycin Susc Islt;;ACTIVE;1.0l;2.73 +18983-7;Streptomycin.high potency;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Streptomycin.high potency [Susceptibility];Streptomycin High Pot Susc Islt;;ACTIVE;1.0l;2.73 +18984-5;sulfADIAZINE;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;sulfADIAZINE [Susceptibility];sulfADIAZINE Susc Islt;;ACTIVE;1.0l;2.19 +18985-2;Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sulfamethoxazole [Susceptibility];Sulfamethoxazole Susc Islt;;ACTIVE;1.0l;2.19 +1898-6;Argininosuccinate lyase;CCnc;Pt;Ser;Qn;;CHEM;1;Argininosuccinate lyase [Enzymatic activity/volume] in Serum;ASA Lyase Ser-cCnc;;ACTIVE;1.0;2.68 +18986-0;sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;sulfiSOXAZOLE [Susceptibility];Sulfisoxaz Susc Islt;;ACTIVE;1.0l;2.73 +18987-8;Sulfonamide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sulfonamide [Susceptibility];Sulfonamide Susc Islt;;ACTIVE;1.0l;2.19 +18988-6;Talampicillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Talampicillin [Susceptibility];Talampicillin Susc Islt;;ACTIVE;1.0l;2.19 +18989-4;Teicoplanin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Teicoplanin [Susceptibility];Teicoplanin Susc Islt;;ACTIVE;1.0l;2.19 +18990-2;Temafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Temafloxacin [Susceptibility];Temafloxacin Susc Islt;;ACTIVE;1.0l;2.19 +18991-0;Temocillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Temocillin [Susceptibility];Temocillin Susc Islt;;ACTIVE;1.0l;2.19 +18992-8;Terbinafine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Terbinafine [Susceptibility];Terbinafine Susc Islt;;ACTIVE;1.0l;2.19 +18993-6;Tetracycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tetracycline [Susceptibility];Tetracycline Susc Islt;;ACTIVE;1.0l;2.73 +1899-4;Argininosuccinate synthase;CCnt;Pt;Tiss;Qn;;CHEM;1;Argininosuccinate synthase [Enzymatic activity/mass] in Tissue;ASA Synthase Tiss-cCnt;;ACTIVE;1.0;2.42 +18994-4;Ticarcillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ticarcillin [Susceptibility];Ticarcillin Susc Islt;;ACTIVE;1.0l;2.73 +18995-1;Ticarcillin+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ticarcillin+Clavulanate [Susceptibility];Ticarcillin+Clav Susc Islt;;ACTIVE;1.0l;2.73 +18996-9;Tobramycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tobramycin [Susceptibility];Tobramycin Susc Islt;;ACTIVE;1.0l;2.73 +18997-7;Trimethoprim;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Trimethoprim [Susceptibility];Trimethoprim Susc Islt;;ACTIVE;1.0l;2.73 +18998-5;Trimethoprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility];TMP SMX Susc Islt;;ACTIVE;1.0l;2.73 +18999-3;Troleandomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Troleandomycin [Susceptibility];Troleandomycin Susc Islt;;ACTIVE;1.0l;2.19 +19-0;Amoxicillin+Clavulanate;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility] by Minimum lethal concentration (MLC);Amoxicillin+Clav Islt MLC;;ACTIVE;1.0;2.19 +1900-0;Arylamidase;CCnc;Pt;Ser;Qn;;CHEM;1;Arylamidase [Enzymatic activity/volume] in Serum;Arylamidase Ser-cCnc;;ACTIVE;1.0;2.73 +19000-9;Vancomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Vancomycin [Susceptibility];Vancomycin Susc Islt;;ACTIVE;1.0l;2.73 +19001-7;Viomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Viomycin [Susceptibility];Viomycin Susc Islt;;ACTIVE;1.0l;2.19 +19002-5;Rehabilitation.physical therapy service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Physical therapy service attachment;Rehab.PT service Doc;;ACTIVE;1.0l;2.73 +19003-3;Rehabilitation.respiratory therapy service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Respiratory therapy service attachment;Rehab.resp therapy service Doc;;ACTIVE;1.0l;2.73 +19004-1;Rehabilitation.skilled nursing service attachment;Find;Pt;{Setting};Doc;{Role};ATTACH.REHAB;3;Deprecated Skilled nursing service attachment;Deprecated;;DEPRECATED;1.0l;2.66 +19005-8;Imaging study;Imp;Pt;XXX;Nar;Radiology;ATTACH.CLINRPT;3;Radiology Imaging study [Impression] (narrative);;;ACTIVE;1.0l;2.63 +19006-6;Image quality;Type;Pt;Cardiac echo imaging device;Nar;US;CARD.US;2;Cardiac echo imaging device Image quality Narrative by US;Card Echo Device Image Qual US;;ACTIVE;1.0l;2.56 +19007-4;Diagnosis.primary;Cmplx;Pt;Psychiatric rehabilitation treatment;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Primary diagnosis Set;;;ACTIVE;1.0l;2.40 +19008-2;Transducer site;Anat;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Transducer site Narrative;;;ACTIVE;1.0l;2.40 +19009-0;Medication.current;Find;Pt;^Patient;Nar;Reported;ATTACH.MEDS;3;Medication current (narrative);;;ACTIVE;1.0l;2.73 +19010-8;Medication.discharge;Find;Pt;^Patient;Nar;;ATTACH.MEDS;3;Medication discharge (narrative);;;ACTIVE;1.0l;2.24 +19011-6;Medication.administered;Find;Pt;^Patient;Nar;;ATTACH.MEDS;3;Medication administered (narrative);;;ACTIVE;1.0l;2.24 +19012-4;Substitution instruction;Prid;Pt;Medication.discharge;Nom;;ATTACH.MEDS;3;Discharge medication, Substitution instruction;;;ACTIVE;1.0l;2.27 +19013-2;Medications.current.report request;Find;Pt;^Patient;Nom;;ATTACH.MEDS;3;Medications current report request;;;ACTIVE;1.0l;2.27 +19014-0;Medications.discharge.report request;Find;Pt;^Patient;Nom;;ATTACH.MEDS;3;Medications discharge report request;;;ACTIVE;1.0l;2.27 +19015-7;Medications.administered.report request;Find;Pt;^Patient;Nom;;ATTACH.MEDS;3;Medications administered report request;;;ACTIVE;1.0l;2.27 +19016-5;X12 277, all requests for information that are included in this transaction are stated for individual services;Scope.modifier.selection item;Pt;X12^277;-;;ATTACH.MODIFIER;3;Deprecated X12 277, all requests for information that are included in this transaction are stated for individual services;Deprecated;;DEPRECATED;1.0l;2.66 +1901-8;Arylsulfatase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Arylsulfatase [Enzymatic activity/volume] in Serum or Plasma;Arylsulfatase SerPl-cCnc;;ACTIVE;1.0;2.68 +19021-5;Study observation;Find;Pt;Cervix;Nar;Palpation;OB.US;2;Palpitation Cervix Study observation (narrative);Palpation Cervix Study;;ACTIVE;1.0l;2.29 +19022-3;Neisseria meningitidis serogroups C+w135 Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroups C+w135 Ag [Presence] in Cerebral spinal fluid;N men sg C+W135 Ag CSF Ql;;ACTIVE;1.0l;2.64 +19023-1;Granulocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Granulocytes/100 leukocytes in Blood by Automated count;Granulocytes/leuk NFr Bld Auto;;ACTIVE;1.0l;2.73 +1902-6;Ascorbate;MCnc;Pt;Bld;Qn;;CHEM;1;Ascorbate [Mass/volume] in Blood;Vit C Bld-mCnc;;ACTIVE;1.0;2.40 +1903-4;Ascorbate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ascorbate [Mass/volume] in Serum or Plasma;Vit C SerPl-mCnc;;ACTIVE;1.0;2.73 +1904-2;Ascorbate;PrThr;Pt;Urine;Ord;;CHEM;1;Ascorbate [Presence] in Urine;Vit C Ur Ql;;ACTIVE;1.0;2.73 +19044-7;Artemia salina Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fish Feed IgE Ab RAST class [Presence] in Serum;Fish Feed IgE RAST Ql;;ACTIVE;1.0l;2.58 +19045-4;Salmo salar Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Salmon IgG Ab RAST class [Presence] in Serum;Salmon IgG RAST Ql;;ACTIVE;1.0l;2.73 +19046-2;Bovine serum albumin Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Bovine serum albumin (BSA) IgE Ab RAST class in Serum;Deprecated BSA IgE RAST Ql;;DEPRECATED;1.0l;2.36 +19047-0;Thunnus albacares Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tuna IgG Ab RAST class [Presence] in Serum;Tuna IgG RAST Ql;;ACTIVE;1.0l;2.73 +19048-8;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Bld;Qn;;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Blood;nRBC/100 WBC Bld-Rto;;ACTIVE;1.0l;2.73 +19049-6;Metanephrine;MRat;24H;Urine;Qn;;CHEM;1;Metanephrine [Mass/time] in 24 hour Urine;Metaneph 24h Ur-mRate;;ACTIVE;1.0l;2.73 +19050-4;Metanephrines;MCnc;24H;Urine;Qn;;CHEM;1;Metanephrines [Mass/volume] in 24 hour Urine;MetanephS 24h Ur-mCnc;;ACTIVE;1.0l;2.73 +19051-2;Saquinavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Saquinavir [Mass/volume] in Serum or Plasma;Saquinavir SerPl-mCnc;;ACTIVE;1.0l;2.73 +19052-0;Borrelia burgdorferi DNA;PrThr;Pt;Urine;Ord;Probe.amp;MICRO;1;Borrelia burgdorferi DNA [Presence] in Urine by Probe with amplification;B burgdor DNA Ur Ql Probe amp;;ACTIVE;1.0l;2.73 +19053-8;Brucella sp Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Brucella sp Ab [Titer] in Serum by Agglutination;Brucella Ab Titr Ser Aggl;;ACTIVE;1.0l;2.73 +19054-6;Mycoplasma pneumoniae;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Mycoplasma pneumoniae [Presence] in Specimen by Organism specific culture;M pneumo Spec Ql Cult;;ACTIVE;1.0l;2.73 +19055-3;Carboxy tetrahydrocannabinol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol/Creatinine [Mass Ratio] in Urine;CarboxyTHC/Creat Ur;;ACTIVE;1.0l;2.73 +19056-1;Mercury;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mercury [Presence] in Urine;Mercury Ur Ql;;ACTIVE;1.0l;2.56 +19057-9;ABO & Rh group;Type;Pt;Bld^Newborn;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood from Newborn;ABO + Rh Bld NB;;ACTIVE;1.0l;2.73 +19058-7;Allergens identified;Prid;Pt;Ser;Nom;;ALLERGY;1;Allergens identified in Serum;Allergens;;ACTIVE;1.0l;2.73 +1905-9;Ascorbate;MRat;24H;Urine;Qn;;CHEM;1;Ascorbate [Mass/time] in 24 hour Urine;Vit C 24h Ur-mRate;;ACTIVE;1.0;2.42 +19059-5;Amphetamines cutoff;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amphetamines cutoff [Mass/volume] in Urine;Amphetamines CtO Ur-mCnc;;ACTIVE;1.0l;2.73 +19060-3;Antibodies identified;Prid;Pt;Ser/Plas;Nom;;BLDBK;1;Deprecated Blood group antibodies identified in Serum or Plasma;Deprecated Antibodies SerPl;;DEPRECATED;1.0l;2.36 +19064-5;Benzodiazepines cutoff;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzodiazepines cutoff [Mass/volume] in Urine;Benzodiaz CtO Ur-mCnc;;ACTIVE;1.0l;2.73 +19065-2;Benzoylecgonine cutoff;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzoylecgonine cutoff [Mass/volume] in Urine;BZE CtO Ur-mCnc;;ACTIVE;1.0l;2.44 +19066-0;Blood bank comment;Imp;Pt;^Patient;Nom;;BLDBK;1;Blood bank comment;Blood Bank Cmnt Patient-Imp;;ACTIVE;1.0l;2.73 +1906-7;Asparagine;MCnc;Pt;CSF;Qn;;CHEM;1;Asparagine [Mass/volume] in Cerebral spinal fluid;Asparagine CSF-mCnc;;DISCOURAGED;1.0;2.44 +19071-0;Blood removed from patient;Vol;Pt;Bld;Qn;;BLDBK;1;Blood removed from patient [Volume];Bld from Patient Vol;;ACTIVE;1.0l;2.73 +19072-8;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma;Ca-I adj pH7.4 SerPl-sCnc;;ACTIVE;1.0l;2.73 +19073-6;Cannabinoids cutoff;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cannabinoids cutoff [Mass/volume] in Urine;Cannabinoids CtO Ur-mCnc;;ACTIVE;1.0l;2.73 +19074-4;Carnitine esters;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine esters [Moles/volume] in Serum or Plasma;Carn esters SerPl-sCnc;;ACTIVE;1.0l;2.73 +1907-5;Asparagine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Asparagine [Presence] in Serum or Plasma;Asparagine SerPl Ql;;ACTIVE;1.0;2.56 +19075-1;Cells counted.total;Num;Pt;CSF;Qn;;HEM/BC;1;Cells Counted Total [#] in Cerebral spinal fluid;Total Cells Counted CSF;;ACTIVE;1.0l;2.73 +19076-9;Cells counted.total;Num;Pt;XXX;Qn;;HEM/BC;1;Cells Counted Total [#] in Specimen;Total Cells Counted Spec;;ACTIVE;1.0l;2.73 +19077-7;Cells identified;Prid;Pt;Body fld;Nom;;HEM/BC;1;Cells identified in Body fluid;Cells Fld;;ACTIVE;1.0l;2.73 +19078-5;Cells.CD23/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD23 cells/100 cells in Specimen;CD23 Cells NFr Spec;;ACTIVE;1.0l;2.73 +19079-3;Cells.CD43/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD43 cells/100 cells in Specimen;CD43 Cells NFr Spec;;ACTIVE;1.0l;2.73 +19080-1;Choriogonadotropin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin [Units/volume] in Serum or Plasma;HCG SerPl-aCnc;;ACTIVE;1.0l;2.73 +1908-3;Asparagine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Asparagine [Mass/volume] in Serum or Plasma;Asparagine SerPl-mCnc;;DISCOURAGED;1.0;2.73 +19085-0;Collection duration;Time;*;Urine;Qn;;SPEC;1;Deprecated Collection duration of Urine - time unspecified;Deprecated Collect Duration Ur Qn;;DEPRECATED;1.0l;2.70 +19086-8;Collection end date;Date;Pt;Urine;Qn;;SPEC;1;Collection of urine specimen end date;Collect End Date Ur;;ACTIVE;1.0l;2.73 +19087-6;Collection end time;TmStp;Pt;Urine;Qn;;SPEC;1;Collection of urine specimen end time;Collect End Tme Ur;;ACTIVE;1.0l;2.73 +19088-4;Collection start date;Date;Pt;Urine;Qn;;SPEC;1;Collection of urine specimen start date;Collect Start Date Ur;;ACTIVE;1.0l;2.73 +19089-2;Collection start time;TmStp;Pt;Urine;Qn;;SPEC;1;Collection of urine specimen start time;Collect Start Tme Ur;;ACTIVE;1.0l;2.73 +190-9;Clarithromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clarithromycin [Susceptibility] by Disk diffusion (KB);Clarithro Islt KB;;ACTIVE;1.0;2.73 +19090-0;Colony count;NCnc;Pt;Urine;Qn;;MICRO;1;Colony count [#/volume] in Urine;CC # Ur;;ACTIVE;1.0l;2.73 +1909-1;Asparagine;MCnc;Pt;Urine;Qn;;CHEM;1;Asparagine [Mass/volume] in Urine;Asparagine Ur-mCnc;;DISCOURAGED;1.0;2.73 +19091-8;Colony count;Num;Pt;Urine;Qn;VC;MICRO;1;Colony count [#] in Urine by Visual count;CC Ur VC;;ACTIVE;1.0l;2.73 +19092-6;Cotinine cutoff;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cotinine cutoff [Mass/volume] in Urine;Cotinine CtO Ur-mCnc;;ACTIVE;1.0l;2.34 +19096-7;Electrolytes;Imp;24H;Urine;Nar;;CHEM;1;Electrolytes - single valence [Interpretation] in 24 hour Urine Narrative;Electrolytes 24h Ur-Imp;;ACTIVE;1.0l;2.26 +19098-3;Erythrocytes;PrThr;Pt;Amnio fld;Ord;;HEM/BC;1;Erythrocytes [Presence] in Amniotic fluid;RBC Amn Ql;;ACTIVE;1.0l;2.73 +19099-1;Events counted;Num;Pt;XXX;Qn;;CELLMARK;1;Events counted [#] in Specimen;Events Counted Spec;;ACTIVE;1.0l;2.73 +19101-5;Fungus colony count;NCnc;Pt;XXX;Qn;Culture;MICRO;1;Fungus colony count [#/volume] in Specimen by Culture;Fungus CC # Spec Cult;;ACTIVE;1.0l;2.69 +19102-3;Genetic screen;Find;Pt;XXX;Nar;Molgen;MOLPATH;1;Genetic screen in Specimen by Molecular genetics method Narrative;Genetic scn Spec;;ACTIVE;1.0l;2.73 +19104-9;Glucose^1H post dose glucose;Imp;Pt;Ser/Plas;Nom;;CHAL;1;Glucose [Interpretation] in Serum or Plasma--1 hour post dose glucose;Glucose 1h p Glc SerPl-Imp;;ACTIVE;1.0l;2.26 +19105-6;Glucose^3H post dose glucose;Imp;Pt;Ser/Plas;Nom;;CHAL;1;Glucose [Interpretation] in Serum or Plasma--3 hours post dose glucose;Glucose 3h p Glc SerPl-Imp;;ACTIVE;1.0l;2.73 +19106-4;Herpes simplex virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus IgG Ab [Presence] in Serum;HSV IgG Ser Ql;;ACTIVE;1.0l;2.70 +19107-2;Histoplasma capsulatum Ag;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Serum by Radioimmunoassay (RIA);H capsul Ag Ser RIA-aCnc;;ACTIVE;1.0l;2.73 +19108-0;Histoplasma capsulatum Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum Ag [Presence] in Serum;H capsul Ag Ser Ql;;ACTIVE;1.0l;2.73 +1910-9;Asparagine;MRat;24H;Urine;Qn;;CHEM;1;Asparagine [Mass/time] in 24 hour Urine;Asparagine 24h Ur-mRate;;DISCOURAGED;1.0;2.73 +19109-8;Histoplasma capsulatum Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Histoplasma capsulatum Ag [Presence] in Specimen;H capsul Ag Spec Ql;;ACTIVE;1.0l;2.73 +19110-6;HIV 1 gp41+gp43 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp41+gp43 Ab [Presence] in Serum by Immunoblot;HIV1 gp41+gp43 Ab Ser Ql IB;;ACTIVE;1.0l;2.58 +19111-4;Hospital number;ID;Pt;^Mother;Nom;;ADMIN.ID;2;Mother's hospital number;Mother's hospital #;;ACTIVE;1.0l;2.73 +19113-0;IgE;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;IgE [Units/volume] in Serum or Plasma;IgE SerPl-aCnc;;ACTIVE;1.0l;2.73 +19114-8;Lamellar bodies;NCnc;Pt;Amnio fld;Qn;;HEM/BC;1;Lamellar bodies [#/volume] in Amniotic fluid;Lamellar Bod # Amn;;ACTIVE;1.0l;2.73 +1911-7;Aspartate;MCnc;Pt;CSF;Qn;;CHEM;1;Aspartate [Mass/volume] in Cerebral spinal fluid;Aspartate CSF-mCnc;;DISCOURAGED;1.0;2.44 +19122-1;Cells.CD42/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD42 cells/100 cells in Blood;CD42 Cells NFr Bld;;ACTIVE;1.0l;2.73 +19123-9;Magnesium;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Magnesium [Mass/volume] in Serum or Plasma;Magnesium SerPl-mCnc;;ACTIVE;1.0l;2.73 +19124-7;Magnesium;MCnc;Pt;Urine;Qn;;CHEM;1;Magnesium [Mass/volume] in Urine;Magnesium Ur-mCnc;;ACTIVE;1.0l;2.73 +1912-5;Aspartate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Aspartate [Presence] in Serum or Plasma;Aspartate SerPl Ql;;ACTIVE;1.0;2.73 +19125-4;Meconium;PrThr;Pt;Amnio fld;Ord;;CHEM;1;Meconium [Presence] in Amniotic fluid;Meconium Amn Ql;;ACTIVE;1.0l;2.73 +19126-2;Bacteria identified;Prid;Pt;Bone mar;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bone marrow by Aerobe culture;Bacteria Mar Aerobe Cult;;ACTIVE;1.0l;2.73 +19127-0;Bacteria identified;Prid;Pt;Sputum;Nom;Acute respiratory distress culture;MICRO;1;Bacteria identified in Sputum by Acute Respiratoy Distress (ARDS) culture;Bacteria Spt ARDS Cult;;ACTIVE;1.0l;2.19 +19128-8;Bacteria identified;Prid;Pt;Ctp;Nom;Culture;MICRO;1;Bacteria identified in Catheter tip by Culture;Bacteria Cath Tip Cult;;ACTIVE;1.0l;2.73 +19129-6;Microscopic observation;Prid;Pt;Tiss;Nom;Biopsy culture;MICRO;1;Deprecated Microscopic observation [Identifier] in Tissue by Biopsy culture;Deprecated Biopsy Culture Smear Tiss;;DEPRECATED;1.0l;2.61 +19132-0;Name;Pn;Pt;^Mother;Nom;;CLIN;2;Mother's name;Mother's name;;ACTIVE;1.0l;2.73 +1913-3;Aspartate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aspartate [Mass/volume] in Serum or Plasma;Aspartate SerPl-mCnc;;DISCOURAGED;1.0;2.73 +19133-8;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg A+C+W135+Y Ag CSF Ql LA;;ACTIVE;1.0l;2.73 +19134-6;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg B+E coli K1 Ag CSF Ql LA;;ACTIVE;1.0l;2.73 +19137-9;Neuronal nuclear Ab;ACnc;Pt;Ser;Qn;IB;SERO;1;Neuronal nuclear Ab [Units/volume] in Serum by Immunoblot;Hu Ab Ser IB-aCnc;;ACTIVE;1.0l;2.73 +19138-7;Opiates cutoff;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Opiates cutoff [Mass/volume] in Urine;Opiates CtO Ur-mCnc;;ACTIVE;1.0l;2.73 +19139-5;Pathologist name;Pn;Pt;Provider;Nom;;CLIN;2;Pathologist name;Pathologist name;;ACTIVE;1.0l;2.73 +19140-3;Phospholipid Ab;PrThr;Pt;Ser;Ord;;COAG;1;Phospholipid Ab [Presence] in Serum;Phospholipid Ab Ser Ql;;ACTIVE;1.0l;2.56 +1914-1;Aspartate;MCnc;Pt;Urine;Qn;;CHEM;1;Aspartate [Mass/volume] in Urine;Aspartate Ur-mCnc;;DISCOURAGED;1.0;2.73 +19141-1;Propoxyphene;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Propoxyphene [Presence] in Urine;Propoxyph Ur Ql;;ACTIVE;1.0l;2.73 +19144-5;Reason for drug test;Imp;Pt;^Patient;Nom;;DRUG/TOX;1;Reason for drug test [Interpretation];Reason for Drg Tst Patient-Imp;;ACTIVE;1.0l;2.73 +19145-2;Referral lab test name;Type;Pt;Referral lab test;Nar;;MISC;1;Referral lab test name;Ref Lab Test Name;;ACTIVE;1.0l;2.73 +19146-0;Referral lab test results;Find;Pt;Referral lab test;Nar;;MISC;1;Referral lab test results;Ref Lab Test Results;;ACTIVE;1.0l;2.73 +19147-8;Referral lab test reference range;Find;Pt;Referral lab test;Nom;;MISC;1;Referral lab test reference range;Ref Lab Test Ref Range;;ACTIVE;1.0l;2.73 +19148-6;Rh immune globulin candidate (yes/no);Arb;Pt;^Patient;Ord;;BLDBK;1;RhoGam candidate (yes/no);RhoGam candidate;;ACTIVE;1.0l;2.73 +19149-4;Rifabutin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Rifabutin [Susceptibility];Rifabutin Susc Islt;;ACTIVE;1.0l;2.73 +19150-2;Specimen creatinine acceptable;Arb;Pt;Urine;Ord;;DRUG/TOX;1;Specimen creatinine acceptable [Presence] in Urine;Acceptable Creat Ur Ql;;ACTIVE;1.0l;2.73 +19151-0;Specimen drawn;TmStp;Pt;Ser/Plas;Qn;;SPEC;1;Specimen drawn [Date and time] of Serum or Plasma;Specimen drawn SerPl;;ACTIVE;1.0l;2.73 +19152-8;Specimen specific gravity acceptable;Arb;Pt;Urine;Ord;;DRUG/TOX;1;Specimen specific gravity acceptable [Presence] in Urine;Acceptible Sp Gr Ur Ql;;ACTIVE;1.0l;2.73 +19153-6;Specimen volume;Vol;XXX;Urine;Qn;;SPEC;1;Volume in Urine collected for unspecified duration;Specimen vol ?Tm Ur;;ACTIVE;1.0l;2.73 +19156-9;Susceptibility method;Prid;Pt;XXX;Nom;*;ABXBACT;1;Susceptibility method [Identifier] in Specimen;Susc Meth Spec;;ACTIVE;1.0l;2.73 +19157-7;Tube number;ID;Pt;CSF;Nom;;SPEC;1;Tube number of Cerebral spinal fluid;Tube # CSF;;ACTIVE;1.0l;2.73 +1915-8;Aspartate;MRat;24H;Urine;Qn;;CHEM;1;Aspartate [Mass/time] in 24 hour Urine;Aspartate 24h Ur-mRate;;DISCOURAGED;1.0;2.73 +19158-5;Urea nitrogen comment;Imp;24H;Urine;Nar;;CHEM;1;Urea nitrogen comment - 24 hour Urine Narrative;UUN 24h Ur-Imp;;ACTIVE;1.0l;2.26 +19159-3;Urinalysis specimen collection method;Prid;Pt;Urine;Nom;*;UA;1;Urinalysis specimen collection method;Urn Spec Collect Meth Ur;;ACTIVE;1.0l;2.73 +19161-9;Urobilinogen;ACnc;Pt;Urine;Qn;Test strip;UA;1;Urobilinogen [Units/volume] in Urine by Test strip;Urobilinogen Ur Strip-aCnc;;ACTIVE;1.0l;2.73 +19162-7;Varicella zoster virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Varicella zoster virus IgG Ab [Presence] in Serum;VZV IgG Ser Ql;;ACTIVE;1.0l;2.73 +19163-5;Cancer Ag 19-9;ACnc;Pt;Plr fld;Qn;;CHEM;1;Cancer Ag 19-9 [Units/volume] in Pleural fluid;Cancer Ag19-9 Plr-aCnc;;ACTIVE;1.0l;2.73 +19164-3;Cancer Ag 72-4;ACnc;Pt;Plr fld;Qn;;CHEM;1;Cancer Ag 72-4 [Units/volume] in Pleural fluid;Cancer Ag72-4 Plr-aCnc;;ACTIVE;1.0l;2.68 +19165-0;Cancer Ag 125;ACnc;Pt;Plr fld;Qn;;CHEM;1;Cancer Ag 125 [Units/volume] in Pleural fluid;Cancer Ag125 Plr-aCnc;;ACTIVE;1.0l;2.68 +1916-6;Aspartate aminotransferase/Alanine aminotransferase;CRto;Pt;Ser/Plas;Qn;;CHEM;1;Aspartate aminotransferase/Alanine aminotransferase [Enzymatic activity ratio] in Serum or Plasma;AST/ALT SerPl-cRto;;ACTIVE;1.0;2.73 +19166-8;Carcinoembryonic Ag;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Carcinoembryonic Ag [Units/volume] in Serum or Plasma;CEA SerPl-aCnc;;ACTIVE;1.0l;2.73 +19167-6;Carcinoembryonic Ag;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carcinoembryonic Ag [Moles/volume] in Serum or Plasma;CEA SerPl-sCnc;;ACTIVE;1.0l;2.40 +19168-4;Carcinoembryonic Ag;ACnc;Pt;Plr fld;Qn;;CHEM;1;Carcinoembryonic Ag [Units/volume] in Pleural fluid;CEA Plr-aCnc;;ACTIVE;1.0l;2.42 +19169-2;Carcinoembryonic Ag;MCnc;Pt;Plr fld;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Pleural fluid;CEA Plr-mCnc;;ACTIVE;1.0l;2.73 +191-7;Clarithromycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Clarithromycin [Susceptibility] by Serum bactericidal titer;Clarithro Titr SBT;;ACTIVE;1.0;2.32 +19170-0;Carcinoembryonic Ag;SCnc;Pt;Plr fld;Qn;;CHEM;1;Carcinoembryonic Ag [Moles/volume] in Pleural fluid;CEA Plr-sCnc;;ACTIVE;1.0l;2.42 +19171-8;Alpha-1-Fetoprotein;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Amniotic fluid;AFP Amn-aCnc;;ACTIVE;1.0l;2.73 +19172-6;Alpha-1-Fetoprotein;ACnc;Pt;Plr fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Pleural fluid;AFP Plr-aCnc;;ACTIVE;1.0l;2.42 +19173-4;Alpha-1-Fetoprotein;SCnc;Pt;Plr fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Moles/volume] in Pleural fluid;AFP Plr-sCnc;;ACTIVE;1.0l;2.42 +1917-4;Aspartate aminotransferase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Amniotic fluid;AST Amn-cCnc;;ACTIVE;1.0;2.68 +19174-2;Choriogonadotropin.beta subunit;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Units/volume] in Amniotic fluid;B-HCG Amn-aCnc;;ACTIVE;1.0l;2.42 +19175-9;Choriogonadotropin.beta subunit;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Moles/volume] in Amniotic fluid;B-HCG Amn-sCnc;;ACTIVE;1.0l;2.42 +19176-7;Alpha-1-Fetoprotein;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma;AFP SerPl-aCnc;;ACTIVE;1.0l;2.73 +19177-5;Alpha-1-Fetoprotein;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Moles/volume] in Serum or Plasma;AFP SerPl-sCnc;;ACTIVE;1.0l;2.40 +19178-3;Choriogonadotropin.beta subunit.free;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Units/volume] in Amniotic fluid;B-HCG Free Amn-aCnc;;ACTIVE;1.0l;2.42 +19179-1;Choriogonadotropin.beta subunit.free;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Moles/volume] in Amniotic fluid;B-HCG Free Amn-sCnc;;ACTIVE;1.0l;2.42 +19180-9;Choriogonadotropin.beta subunit.free;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Units/volume] in Serum or Plasma;B-HCG Free SerPl-aCnc;;ACTIVE;1.0l;2.73 +1918-2;Aspartate aminotransferase;CCnc;Pt;CSF;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Cerebral spinal fluid;AST CSF-cCnc;;ACTIVE;1.0;2.68 +19182-5;Cytokeratin 19;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cytokeratin 19 [Units/volume] in Serum or Plasma;CK 19 SerPl-aCnc;;ACTIVE;1.0l;2.68 +19183-3;Cytokeratin 19;ACnc;Pt;Plr fld;Qn;;CHEM;1;Cytokeratin 19 [Units/volume] in Pleural fluid;CK 19 Plr-aCnc;;ACTIVE;1.0l;2.68 +19184-1;Tissue polypeptide specific Ag;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Tissue polypeptide specific Ag [Units/volume] in Serum or Plasma;TPS Ag SerPl-aCnc;;ACTIVE;1.0l;2.68 +19185-8;Tissue polypeptide specific Ag;ACnc;Pt;Plr fld;Qn;;CHEM;1;Tissue polypeptide specific Ag [Units/volume] in Pleural fluid;TPS Ag Plr-aCnc;;ACTIVE;1.0l;2.68 +19186-6;Cancer Ag 15-3;ACnc;Pt;Plr fld;Qn;;CHEM;1;Cancer Ag 15-3 [Units/volume] in Pleural fluid;Cancer Ag15-3 Plr-aCnc;;ACTIVE;1.0l;2.68 +19187-4;Cancer Ag 27-29;ACnc;Pt;Plr fld;Qn;;CHEM;1;Cancer Ag 27-29 [Units/volume] in Pleural fluid;Cancer Ag27-29 Plr-aCnc;;ACTIVE;1.0l;2.68 +19188-2;Mucin-like carcinoma associated Ag;ACnc;Pt;Plr fld;Qn;;CHEM;1;Mucin-like carcinoma associated Ag [Units/volume] in Pleural fluid;MCA Ag Plr-aCnc;;ACTIVE;1.0l;2.68 +19189-0;Cancer Ag 549;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag 549 [Units/volume] in Serum or Plasma;Cancer Ag549 SerPl-aCnc;;ACTIVE;1.0l;2.68 +1919-0;Aspartate aminotransferase;CCnc;Pt;Body fld;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Body fluid;AST Fld-cCnc;;ACTIVE;1.0;2.73 +19190-8;Cancer Ag 549;ACnc;Pt;Plr fld;Qn;;CHEM;1;Cancer Ag 549 [Units/volume] in Pleural fluid;Cancer Ag549 Plr-aCnc;;ACTIVE;1.0l;2.68 +19193-2;Enolase.neuron specific;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Enolase.neuron specific [Units/volume] in Serum or Plasma;NSE SerPl-aCnc;;ACTIVE;1.0l;2.68 +19194-0;Enolase.neuron specific;ACnc;Pt;Plr fld;Qn;;CHEM;1;Enolase.neuron specific [Units/volume] in Pleural fluid;NSE Plr-aCnc;;ACTIVE;1.0l;2.68 +19195-7;Prostate specific Ag;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostate specific Ag [Units/volume] in Serum or Plasma;PSA SerPl-aCnc;;ACTIVE;1.0l;2.73 +19197-3;Prostate specific Ag;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostate specific Ag [Moles/volume] in Serum or Plasma;PSA SerPl-sCnc;;ACTIVE;1.0l;2.40 +19198-1;Prostate specific Ag;ACnc;Pt;Semen;Qn;;CHEM;1;Prostate specific Ag [Units/volume] in Semen;PSA Smn-aCnc;;ACTIVE;1.0l;2.42 +19199-9;Prostate specific Ag;MCnc;Pt;Semen;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in Semen;PSA Smn-mCnc;;ACTIVE;1.0l;2.42 +19200-5;Prostate specific Ag;SCnc;Pt;Semen;Qn;;CHEM;1;Prostate specific Ag [Moles/volume] in Semen;PSA Smn-sCnc;;ACTIVE;1.0l;2.42 +19201-3;Prostate specific Ag.free;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostate Specific Ag Free [Units/volume] in Serum or Plasma;PSA Free SerPl-aCnc;;ACTIVE;1.0l;2.73 +19203-9;Prostate specific Ag.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostate Specific Ag Free [Moles/volume] in Serum or Plasma;PSA Free SerPl-sCnc;;ACTIVE;1.0l;2.40 +19204-7;Prostate specific Ag.free;ACnc;Pt;Semen;Qn;;CHEM;1;Prostate Specific Ag Free [Units/volume] in Semen;PSA Free Smn-aCnc;;ACTIVE;1.0l;2.42 +19205-4;Prostate specific Ag.free;MCnc;Pt;Semen;Qn;;CHEM;1;Prostate Specific Ag Free [Mass/volume] in Semen;PSA Free Smn-mCnc;;ACTIVE;1.0l;2.42 +19206-2;Prostate specific Ag.free;SCnc;Pt;Semen;Qn;;CHEM;1;Prostate Specific Ag Free [Moles/volume] in Semen;PSA Free Smn-sCnc;;ACTIVE;1.0l;2.42 +19207-0;Squamous cell carcinoma Ag;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Squamous cell carcinoma Ag [Units/volume] in Serum or Plasma;SCC Ag SerPl-aCnc;;ACTIVE;1.0l;2.68 +1920-8;Aspartate aminotransferase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma;AST SerPl-cCnc;;ACTIVE;1.0;2.73 +19208-8;Squamous cell carcinoma Ag;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Squamous cell carcinoma Ag [Moles/volume] in Serum or Plasma;SCC Ag SerPl-sCnc;;ACTIVE;1.0l;2.40 +19209-6;Squamous cell carcinoma Ag;ACnc;Pt;Plr fld;Qn;;CHEM;1;Squamous cell carcinoma Ag [Units/volume] in Pleural fluid;SCC Ag Plr-aCnc;;ACTIVE;1.0l;2.68 +19210-4;Squamous cell carcinoma Ag;SCnc;Pt;Plr fld;Qn;;CHEM;1;Squamous cell carcinoma Ag [Moles/volume] in Pleural fluid;SCC Ag Plr-sCnc;;ACTIVE;1.0l;2.42 +19211-2;Oxygen;PPres;Pt;BldMV;Qn;;CHEM;1;Oxygen [Partial pressure] in Mixed venous blood;pO2 BldMV;;ACTIVE;1.0l;2.73 +19212-0;Carbon dioxide;PPres;Pt;BldMV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Mixed venous blood;pCO2 BldMV;;ACTIVE;1.0l;2.73 +19213-8;pH;LsCnc;Pt;BldMV;Qn;;CHEM;1;pH of Mixed venous blood;pH BldMV;;ACTIVE;1.0l;2.73 +19214-6;Oxygen^^saturation adjusted to 0.5;PPres;Pt;BldA;Qn;;CHEM;1;Oxygen [Partial pressure] saturation adjusted to 0.5 in Arterial blood;pO2 satn adj to 0.5 BldA;;ACTIVE;1.0l;2.73 +19215-3;Oxygen^^saturation adjusted to 0.5;PPres;Pt;BldC;Qn;;CHEM;1;Oxygen [Partial pressure] saturation adjusted to 0.5 in Capillary blood;pO2 satn adj to 0.5 BldC;;ACTIVE;1.0l;2.30 +1921-6;Atrial natriuretic factor;MCnc;Pt;BldA;Qn;;CHEM;1;Atrial natriuretic factor [Mass/volume] in Arterial blood;ANF BldA-mCnc;;ACTIVE;1.0;2.42 +19216-1;Oxygen^^saturation adjusted to 0.5;PPres;Pt;BldV;Qn;;CHEM;1;Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood;pO2 satn adj to 0.5 BldV;;ACTIVE;1.0l;2.73 +19217-9;Oxygen^^saturation adjusted to 0.5;PPres;Pt;BldMV;Qn;;CHEM;1;Oxygen [Partial pressure] saturation adjusted to 0.5 in Mixed venous blood;pO2 satn adj to 0.5 BldMV;;ACTIVE;1.0l;2.30 +19218-7;Oxygen content;SCnc;Pt;BldA;Qn;;CHEM;1;Oxygen content in Arterial blood;O2 Ct BldA-sCnc;;ACTIVE;1.0l;2.73 +19219-5;Oxygen content;SCnc;Pt;BldC;Qn;;CHEM;1;Oxygen content in Capillary blood;O2 Ct BldC-sCnc;;ACTIVE;1.0l;2.73 +19220-3;Oxygen content;SCnc;Pt;BldV;Qn;;CHEM;1;Oxygen content in Venous blood;O2 Ct BldV-sCnc;;ACTIVE;1.0l;2.73 +19221-1;Oxygen content;SCnc;Pt;BldMV;Qn;;CHEM;1;Oxygen content in Mixed venous blood;O2 Ct BldMV-sCnc;;ACTIVE;1.0l;2.73 +19223-7;Carbon dioxide;SCnc;Pt;BldMV;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Mixed venous blood;CO2 BldMV-sCnc;;ACTIVE;1.0l;2.73 +1922-4;Base deficit;SCnc;Pt;BldA;Qn;;CHEM;1;Base deficit in Arterial blood;Base deficit BldA-sCnc;;ACTIVE;1.0;2.73 +19224-5;Oxygen saturation;MFr;Pt;BldMV;Qn;;HEMODYN.MOLEC;2;Oxygen saturation in Mixed venous blood;SaO2 % BldMV;;ACTIVE;1.0l;2.73 +19225-2;Deoxyhemoglobin/Hemoglobin.total;MFr;Pt;BldA;Qn;;HEM/BC;1;Deoxyhemoglobin/Hemoglobin.total in Arterial blood;DO-Hgb MFr BldA;;ACTIVE;1.0l;2.73 +19226-0;Deoxyhemoglobin/Hemoglobin.total;MFr;Pt;BldC;Qn;;HEM/BC;1;Deoxyhemoglobin/Hemoglobin.total in Capillary blood;DO-Hgb MFr BldC;;ACTIVE;1.0l;2.70 +19227-8;Deoxyhemoglobin/Hemoglobin.total;MFr;Pt;BldV;Qn;;HEM/BC;1;Deoxyhemoglobin/Hemoglobin.total in Venous blood;DO-Hgb MFr BldV;;ACTIVE;1.0l;2.73 +19228-6;Deoxyhemoglobin/Hemoglobin.total;MFr;Pt;BldMV;Qn;;HEM/BC;1;Deoxyhemoglobin/Hemoglobin.total in Mixed venous blood;DO-Hgb MFr BldMV;;ACTIVE;1.0l;2.70 +19229-4;Bicarbonate;SCnc;Pt;BldMV;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Mixed venous blood;HCO3 BldMV-sCnc;;ACTIVE;1.0l;2.73 +19230-2;Bicarbonate^^standard;SCnc;Pt;BldA;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Arterial blood;HCO3 std BldA-sCnc;;ACTIVE;1.0l;2.73 +19231-0;Bicarbonate^^standard;SCnc;Pt;BldC;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Capillary blood;HCO3 std BldC-sCnc;;ACTIVE;1.0l;2.56 +1923-2;Base deficit;SCnc;Pt;BldC;Qn;;CHEM;1;Base deficit in Capillary blood;Base deficit BldC-sCnc;;ACTIVE;1.0;2.73 +19232-8;Bicarbonate^^standard;SCnc;Pt;BldV;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Venous blood;HCO3 std BldV-sCnc;;ACTIVE;1.0l;2.73 +19233-6;Bicarbonate^^standard;SCnc;Pt;BldMV;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Mixed venous blood;HCO3 std BldMV-sCnc;;ACTIVE;1.0l;2.56 +19234-4;Base excess;SCnc;Pt;BldMV;Qn;Calculated;CHEM;1;Base excess in Mixed venous blood by calculation;Base excess BldMV Calc-sCnc;;ACTIVE;1.0l;2.73 +19235-1;Base excess^^standard;SCnc;Pt;BldA;Qn;Calculated;CHEM;1;Base excess standard in Arterial blood by calculation;Base excess std BldA Calc-sCnc;;ACTIVE;1.0l;2.73 +19236-9;Base excess^^standard;SCnc;Pt;BldC;Qn;Calculated;CHEM;1;Base excess standard in Capillary blood by calculation;Base excess std BldC Calc-sCnc;;ACTIVE;1.0l;2.73 +19237-7;Base excess^^standard;SCnc;Pt;BldV;Qn;Calculated;CHEM;1;Base excess standard in Venous blood by calculation;Base excess std BldV Calc-sCnc;;ACTIVE;1.0l;2.73 +19238-5;Base excess^^standard;SCnc;Pt;BldMV;Qn;Calculated;CHEM;1;Base excess standard in Mixed venous blood by calculation;Base excess std BldMV Calc-sCnc;;ACTIVE;1.0l;2.42 +19239-3;Lactate;SCnc;Pt;BldC;Qn;;CHEM;1;Lactate [Moles/volume] in Capillary blood;Lactate BldC-sCnc;;ACTIVE;1.0l;2.73 +1924-0;Base deficit;SCnc;Pt;BldV;Qn;;CHEM;1;Base deficit in Venous blood;Base deficit BldV-sCnc;;ACTIVE;1.0;2.73 +19240-1;Lactate;SCnc;Pt;BldMV;Qn;;CHEM;1;Lactate [Moles/volume] in Mixed venous blood;Lactate BldMV-sCnc;;ACTIVE;1.0l;2.73 +19242-7;Corticotropin^post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --post XXX challenge;ACTH p chal Plas-mCnc;;ACTIVE;1.0l;2.73 +19243-5;Brucella abortus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella abortus Ab [Units/volume] in Serum by Immunoassay;B abortus Ab Ser IA-aCnc;;ACTIVE;1.0l;2.69 +19244-3;Character;Aper;Pt;Urine;Nom;;SPEC;1;Character of Urine;Character Ur;;ACTIVE;1.0l;2.73 +19245-0;clonazePAM;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;clonazePAM [Presence] in Urine;clonazePAM Ur Ql;;ACTIVE;1.0l;2.73 +19247-6;Doxepin+Metabolites;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Doxepin+Metabolites [Mass/volume] in Urine;Doxepin+Metab Ur-mCnc;;ACTIVE;1.0l;2.73 +19248-4;Lactate dehydrogenase 2;CCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 2 [Enzymatic activity/volume] in Serum or Plasma by Electrophoresis;LDH2 SerPl Elph-cCnc;;ACTIVE;1.0l;2.68 +19249-2;Lactose^3H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Mass/volume] in Serum or Plasma --3 hours post 50 g lactose PO;Lactose 3h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0l;2.34 +192-5;Clindamycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Clindamycin [Susceptibility] by Minimum lethal concentration (MLC);Clindamycin Islt MLC;;ACTIVE;1.0;2.19 +19250-0;Lipoprotein.alpha;MCnc;Pt;Plr fld;Qn;;CHEM;1;Lipoprotein.alpha [Mass/volume] in Pleural fluid;HDL Plr-mCnc;;ACTIVE;1.0l;2.73 +19251-8;Prolactin^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --post XXX challenge;Prolactin p chal SerPl-mCnc;;ACTIVE;1.0l;2.40 +19252-6;Megakaryocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Megakaryocytes/100 leukocytes in Blood;Megakaryocytes/leuk NFr Bld;;ACTIVE;1.0l;2.73 +19253-4;Trichinella spiralis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trichinella spiralis Ab [Presence] in Serum by Immunoassay;T spiralis Ab Ser Ql IA;;ACTIVE;1.0l;2.73 +19254-2;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;Bld;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood;pO2 temp adj Bld;;ACTIVE;1.0l;2.73 +19255-9;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldA;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Arterial blood;pO2 temp adj BldA;;ACTIVE;1.0l;2.73 +19256-7;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldC;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Capillary blood;pO2 temp adj BldC;;ACTIVE;1.0l;2.73 +1925-7;Base excess;SCnc;Pt;BldA;Qn;Calculated;CHEM;1;Base excess in Arterial blood by calculation;Base excess BldA Calc-sCnc;;ACTIVE;1.0;2.73 +19257-5;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldMV;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Mixed venous blood;pO2 temp adj BldMV;;ACTIVE;1.0l;2.73 +19258-3;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldV;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood;pO2 temp adj BldV;;ACTIVE;1.0l;2.73 +19259-1;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Specimen by Latex agglutination;N men sg A+C+W135+Y Ag Spec Ql LA;;ACTIVE;1.0l;2.73 +19260-9;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Specimen by Latex agglutination;N men sg B+E coli K1 Ag Spec Ql LA;;ACTIVE;1.0l;2.73 +19261-7;Amphetamines;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Urine by Screen method;Amphetamines Ur Ql Scn;;ACTIVE;1.0l;2.73 +19262-5;Amphetamines tested for;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Amphetamines tested for in Urine by Screen method Nominal;Amphetamines Tested Ur Scn;;ACTIVE;1.0l;2.73 +19263-3;Amphetamines tested for;Prid;Pt;Urine;Nar;Screen;DRUG/TOX;1;Amphetamines tested for in Urine by Screen method Narrative;Amphetamines Tested Ur Scn;;ACTIVE;1.0l;2.21 +1926-5;Base excess;SCnc;Pt;BldC;Qn;Calculated;CHEM;1;Base excess in Capillary blood by calculation;Base excess BldC Calc-sCnc;;ACTIVE;1.0;2.73 +19265-8;Amphetamines positive;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Amphetamines [Identifier] in Urine by Confirmatory method;Amphetamines Pos Ur Cfm;;ACTIVE;1.0l;2.73 +19266-6;Amphetamines cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Amphetamines cutoff [Mass/volume] in Urine for Screen method;Amphetamines CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19267-4;Amphetamines cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amphetamines cutoff [Mass/volume] in Urine for Confirmatory method;Amphetamines CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.36 +19268-2;Amphetamines screen method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Amphetamines screen method [Identifier] in Urine;Amphetamines Scn Meth Ur;;ACTIVE;1.0l;2.73 +19269-0;Amphetamines confirm method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Amphetamines confirm method [Identifier] in Urine;Amphetamines Cfm Meth Ur;;ACTIVE;1.0l;2.42 +19270-8;Barbiturates;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Urine by Screen method;Barbiturates Ur Ql Scn;;ACTIVE;1.0l;2.73 +19271-6;Barbiturates tested for;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Barbiturates tested for in Urine by Screen method Nominal;Barbiturates Tested Ur Scn;;ACTIVE;1.0l;2.73 +19272-4;Barbiturates tested for;Prid;Pt;Urine;Nar;Screen;DRUG/TOX;1;Barbiturates tested for in Urine by Screen method Narrative;Barbiturates Tested Ur Scn;;ACTIVE;1.0l;2.19 +1927-3;Base excess;SCnc;Pt;BldV;Qn;Calculated;CHEM;1;Base excess in Venous blood by calculation;Base excess BldV Calc-sCnc;;ACTIVE;1.0;2.73 +19274-0;Barbiturates positive;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Barbiturates positive [Identifier] in Urine by Confirmatory method;Barbiturates Pos Ur Cfm;;ACTIVE;1.0l;2.36 +19275-7;Barbiturates cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Barbiturates cutoff [Mass/volume] in Urine for Screen method;Barbiturates CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19276-5;Barbiturates cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Barbiturates cutoff [Mass/volume] in Urine for Confirmatory method;Barbiturates CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19277-3;Barbiturates screen method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Barbiturates screen method [Identifier] in Urine;Barbiturates Scn Meth Ur;;ACTIVE;1.0l;2.19 +19278-1;Barbiturates confirm method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Barbiturates confirm method [Identifier] in Urine;Barbiturates Cfm Meth Ur;;ACTIVE;1.0l;2.42 +19279-9;Benzodiazepines tested for;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Benzodiazepines tested for in Urine by Screen method Nominal;Benzodiaz Tested Ur Scn;;ACTIVE;1.0l;2.73 +19280-7;Benzodiazepines tested for;Prid;Pt;Urine;Nar;Screen;DRUG/TOX;1;Benzodiazepines tested for in Urine by Screen method Narrative;Benzodiaz Tested Ur Scn;;ACTIVE;1.0l;2.19 +1928-1;Immunoglobulin light chains;PrThr;Pt;Urine;Ord;;CHEM;1;Immunoglobulin light chains [Presence] in Urine;BJ Protein Ur Ql;;ACTIVE;1.0;2.73 +19282-3;Benzodiazepines positive;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Benzodiazepines positive [Identifier] in Urine by Confirmatory method;Benzodiaz Pos Ur Cfm;;ACTIVE;1.0l;2.36 +19283-1;Benzodiazepines cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Benzodiazepines cutoff [Mass/volume] in Urine for Screen method;Benzodiaz CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19284-9;Benzodiazepines cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Benzodiazepines cutoff [Mass/volume] in Urine for Confirmatory method;Benzodiaz CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19285-6;Benzodiazepines screen method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Benzodiazepines screen method [Identifier] in Urine;Benzodiaz Scn Meth Ur;;ACTIVE;1.0l;2.19 +19286-4;Benzodiazepines confirm method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Benzodiazepines confirm method [Identifier] in Urine;Benzodiaz Cfm Meth Ur;;ACTIVE;1.0l;2.73 +19287-2;Cannabinoids tested for;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Cannabinoids tested for in Urine by Screen method Nominal;Cannabinoids Tested Ur Scn;;ACTIVE;1.0l;2.73 +19288-0;Cannabinoids tested for;Prid;Pt;Urine;Nar;Screen;DRUG/TOX;1;Cannabinoids tested for in Urine by Screen method Narrative;Cannabinoids Tested Ur Scn;;ACTIVE;1.0l;2.19 +19289-8;Cannabinoids;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cannabinoids [Presence] in Urine by Confirmatory method;Cannabinoids Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19290-6;Cannabinoids positive;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Cannabinoids positive [Identifier] in Urine by Confirmatory method;Cannabinoids Pos Ur Cfm;;ACTIVE;1.0l;2.36 +19291-4;Cannabinoids cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Cannabinoids cutoff [Mass/volume] in Urine for Screen method;Cannabinoids CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19292-2;Cannabinoids cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cannabinoids cutoff [Mass/volume] in Urine for Confirmatory method;Cannabinoids CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19293-0;Cannabinoids screen method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Cannabinoids screen method [Identifier] in Urine;Cannabinoids Scn Meth Ur;;ACTIVE;1.0l;2.73 +19294-8;Cannabinoids confirm method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Cannabinoids confirm method [Identifier] in Urine;Cannabinoids Cfm Meth Ur;;ACTIVE;1.0l;2.42 +19295-5;Opiates;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Urine by Screen method;Opiates Ur Ql Scn;;ACTIVE;1.0l;2.73 +19296-3;Opiates tested for;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Opiates tested for in Urine by Screen method Nominal;Opiates Tested Ur Scn;;ACTIVE;1.0l;2.73 +19297-1;Opiates tested for;Prid;Pt;Urine;Nar;Screen;DRUG/TOX;1;Opiates tested for in Urine by Screen method Narrative;Opiates Tested Ur Scn;;ACTIVE;1.0l;2.19 +19298-9;Opiates positive;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Opiates positive [Identifier] in Urine by Confirmatory method;Opiates Pos Ur Cfm;;ACTIVE;1.0l;2.73 +1929-9;Immunoglobulin light chains;MCnc;Pt;Urine;Qn;;CHEM;1;Immunoglobulin light chains [Mass/volume] in Urine;BJ Protein Ur-mCnc;;ACTIVE;1.0;2.73 +19299-7;Opiates cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Opiates cutoff [Mass/volume] in Urine for Screen method;Opiates CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19300-3;Opiates cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Opiates cutoff [Mass/volume] in Urine for Confirmatory method;Opiates CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19301-1;Opiates screen method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Opiates screen method [Identifier] in Urine;Opiates Scn Meth Ur;;ACTIVE;1.0l;2.19 +19302-9;Opiates confirm method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Opiates confirm method [Identifier] in Urine;Opiates Cfm Meth Ur;;ACTIVE;1.0l;2.42 +19303-7;Thiazides;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Thiazides [Presence] in Urine by Screen method;Thiazides Ur Ql Scn;;ACTIVE;1.0l;2.56 +19304-5;Thiazides tested for;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Thiazides tested for in Urine by Screen method Nominal;Thiazides Tested Ur Scn;;ACTIVE;1.0l;2.19 +19305-2;Thiazides tested for;Prid;Pt;Urine;Nar;Screen;DRUG/TOX;1;Thiazides tested for in Urine by Screen method Narrative;Thiazides Tested Ur Scn;;ACTIVE;1.0l;2.19 +19306-0;Thiazides;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Thiazides [Presence] in Urine by Confirmatory method;Thiazides Ur Ql Cfm;;ACTIVE;1.0l;2.56 +1930-7;Benzoate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzoate [Mass/volume] in Serum or Plasma;Benzoate SerPl-mCnc;;ACTIVE;1.0;2.34 +19307-8;Thiazides positive;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Thiazides positive [Identifier] in Urine by Confirmatory method;Thiazides Pos Ur Cfm;;ACTIVE;1.0l;2.36 +19308-6;Thiazides cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Thiazides cutoff [Mass/volume] in Urine for Screen method;Thiazides CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19309-4;Thiazides cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Thiazides cutoff [Mass/volume] in Urine for Confirmatory method;Thiazides CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19310-2;Thiazides screen method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Thiazides screen method [Identifier] in Urine;Thiazides Scn Meth Ur;;ACTIVE;1.0l;2.19 +19311-0;Thiazides confirm method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Thiazides confirm method [Identifier] in Urine;Thiazides Cfm Meth Ur;;ACTIVE;1.0l;2.42 +19312-8;Tricyclic antidepressants;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Urine by Screen method;Tricyclics Ur Ql Scn;;ACTIVE;1.0l;2.73 +19313-6;Tricyclic antidepressants tested for;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Tricyclic antidepressants tested for in Urine by Screen method Nominal;Tricyclics Tested Ur Scn;;ACTIVE;1.0l;2.73 +19314-4;Tricyclic antidepressants tested for;Prid;Pt;Urine;Nar;Screen;DRUG/TOX;1;Tricyclic antidepressants tested for in Urine by Screen method Narrative;Tricyclics Tested Ur Scn;;ACTIVE;1.0l;2.19 +1931-5;Beta alanine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Beta alanine [Presence] in Serum or Plasma;B-Alanine SerPl Ql;;ACTIVE;1.0;2.56 +19315-1;Tricyclic antidepressants;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Urine by Confirmatory method;Tricyclics Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19316-9;Tricyclic antidepressants positive;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Tricyclic antidepressants positive [Identifier] in Urine by Confirmatory method;Tricyclics Pos Ur Cfm;;ACTIVE;1.0l;2.36 +19317-7;Tricyclic antidepressants cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Tricyclic antidepressants cutoff [Mass/volume] in Urine for Screen method;Tricyclics CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19318-5;Tricyclic antidepressants cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Tricyclic antidepressants cutoff [Mass/volume] in Urine for Confirmatory method;Tricyclics CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19319-3;Tricyclic antidepressants screen method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Tricyclic antidepressants screen method [Identifier] in Urine;Tricyclics Scn Meth Ur;;ACTIVE;1.0l;2.73 +19320-1;Tricyclic antidepressants confirm method;Prid;Pt;Urine;Nom;*;DRUG/TOX;1;Tricyclic antidepressants confirm method [Identifier] in Urine;Tricyclics Cfm Meth Ur;;ACTIVE;1.0l;2.42 +19321-9;6-Monoacetylmorphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Urine by Screen method;6MAM Ur Ql Scn;;ACTIVE;1.0l;2.73 +19322-7;6-Monoacetylmorphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Urine by Confirmatory method;6MAM Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1932-3;Beta alanine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta alanine [Mass/volume] in Serum or Plasma;B-Alanine SerPl-mCnc;;ACTIVE;1.0;2.73 +19323-5;6-Monoacetylmorphine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) cutoff [Mass/volume] in Urine for Screen method;6MAM CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19324-3;6-Monoacetylmorphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) cutoff [Mass/volume] in Urine for Confirmatory method;6MAM CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.36 +19325-0;Alpha hydroxyalprazolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Alpha hydroxyalprazolam [Presence] in Urine by Screen method;A-OH Alpraz Ur Ql Scn;;ACTIVE;1.0l;2.56 +19326-8;Alpha hydroxyalprazolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam [Presence] in Urine by Confirmatory method;A-OH Alpraz Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19328-4;Alpha hydroxyalprazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Urine;A-OH Alpraz Ur-mCnc;;ACTIVE;1.0l;2.73 +19329-2;Alpha hydroxyalprazolam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Alpha hydroxyalprazolam cutoff [Mass/volume] in Urine for Screen method;A-OH Alpraz CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +193-3;Clindamycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clindamycin [Susceptibility] by Minimum inhibitory concentration (MIC);Clindamycin Islt MIC;;ACTIVE;1.0;2.73 +19330-0;Alpha hydroxyalprazolam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam cutoff [Mass/volume] in Urine for Confirmatory method;A-OH Alpraz CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1933-1;Beta alanine;MCnc;Pt;Urine;Qn;;CHEM;1;Beta alanine [Mass/volume] in Urine;B-Alanine Ur-mCnc;;DISCOURAGED;1.0;2.73 +19331-8;Amitriptyline;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Amitriptyline [Presence] in Urine by Screen method;Amitrip Ur Ql Scn;;ACTIVE;1.0l;2.73 +19333-4;Amitriptyline cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Amitriptyline cutoff [Mass/volume] in Urine for Screen method;Amitrip CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19334-2;Amitriptyline cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amitriptyline cutoff [Mass/volume] in Urine for Confirmatory method;Amitrip CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19335-9;Amitriptyline+Nortriptyline;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Amitriptyline+Nortriptyline [Presence] in Urine by Screen method;Amitrip+Nor Ur Ql Scn;;ACTIVE;1.0l;2.56 +19336-7;Amitriptyline+Nortriptyline;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Amitriptyline+Nortriptyline [Presence] in Urine by Confirmatory method;Amitrip+Nor Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19337-5;Amitriptyline+Nortriptyline cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Amitriptyline+Nortriptyline cutoff [Mass/volume] in Urine for Screen method;Amitrip+Nor CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19338-3;Amitriptyline+Nortriptyline cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amitriptyline+Nortriptyline cutoff [Mass/volume] in Urine for Confirmatory method;Amitrip+Nor CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19339-1;Amobarbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Amobarbital [Presence] in Urine by Screen method;Amobarbital Ur Ql Scn;;ACTIVE;1.0l;2.73 +19341-7;Amobarbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Amobarbital cutoff [Mass/volume] in Urine for Screen method;Amobarbital CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19342-5;Amobarbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amobarbital cutoff [Mass/volume] in Urine for Confirmatory method;Amobarbital CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19343-3;Amphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Amphetamine [Presence] in Urine by Screen method;Amphet Ur Ql Scn;;ACTIVE;1.0l;2.73 +19344-1;Amphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Amphetamine [Presence] in Urine by Confirmatory method;Amphet Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19346-6;Amphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amphetamine [Mass/volume] in Urine;Amphet Ur-mCnc;;ACTIVE;1.0l;2.73 +19347-4;Amphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Amphetamine cutoff [Mass/volume] in Urine for Screen method;Amphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.34 +19348-2;Amphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amphetamine cutoff [Mass/volume] in Urine for Confirmatory method;Amphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1934-9;Beta aminoisobutyrate;PrThr;Pt;Plas;Ord;;CHEM;1;Beta aminoisobutyrate [Presence] in Plasma;B-AIB Plas Ql;;ACTIVE;1.0;2.56 +19349-0;Aprobarbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Aprobarbital [Presence] in Urine by Screen method;Aprobarbital Ur Ql Scn;;ACTIVE;1.0l;2.56 +19350-8;Aprobarbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Aprobarbital [Presence] in Urine by Confirmatory method;Aprobarbital Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19351-6;Aprobarbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Aprobarbital cutoff [Mass/volume] in Urine for Screen method;Aprobarbital CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19352-4;Aprobarbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Aprobarbital cutoff [Mass/volume] in Urine for Confirmatory method;Aprobarbital CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19353-2;Barbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Barbital [Presence] in Urine by Screen method;Barbital Ur Ql Scn;;ACTIVE;1.0l;2.73 +19354-0;Barbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Barbital [Presence] in Urine by Confirmatory method;Barbital Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19355-7;Barbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Barbital cutoff [Mass/volume] in Urine for Screen method;Barbital CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.34 +1935-6;Beta aminoisobutyrate;MCnc;Pt;Plas;Qn;;CHEM;1;Beta aminoisobutyrate [Mass/volume] in Plasma;B-AIB Plas-mCnc;;DISCOURAGED;1.0;2.73 +19356-5;Barbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Barbital cutoff [Mass/volume] in Urine for Confirmatory method;Barbital CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.36 +19357-3;Benzoylecgonine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Benzoylecgonine cutoff [Mass/volume] in Urine for Screen method;BZE CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19358-1;Benzoylecgonine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Benzoylecgonine cutoff [Mass/volume] in Urine for Confirmatory method;BZE CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19359-9;Cocaine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Cocaine [Presence] in Urine by Screen method;Cocaine Ur Ql Scn;;ACTIVE;1.0l;2.73 +19360-7;Cocaine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Urine by Confirmatory method;Cocaine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19361-5;Cocaine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Benzoylmethylecgonine [Mass/volume] in Urine;Deprecated Cocaine Ur-mCnc;;DEPRECATED;1.0l;2.40 +19362-3;Cocaine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Cocaine cutoff [Mass/volume] in Urine for Screen method;Cocaine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19363-1;Cocaine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cocaine cutoff [Mass/volume] in Urine for Confirmatory method;Cocaine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1936-4;Beta aminoisobutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Beta aminoisobutyrate [Mass/volume] in Urine;B-AIB Ur-mCnc;;DISCOURAGED;1.0;2.73 +19364-9;Bromazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Bromazepam [Presence] in Urine by Screen method;Bromazepam Ur Ql Scn;;ACTIVE;1.0l;2.56 +19365-6;Bromazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Bromazepam [Presence] in Urine by Confirmatory method;Bromazepam Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19366-4;Bromazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Bromazepam cutoff [Mass/volume] in Urine for Screen method;Bromazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19367-2;Bromazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Bromazepam cutoff [Mass/volume] in Urine for Confirmatory method;Bromazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19368-0;Butabarbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Butabarbital [Presence] in Urine by Screen method;Butabarbital Ur Ql Scn;;ACTIVE;1.0l;2.73 +19370-6;Butabarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Butabarbital [Mass/volume] in Urine;Butabarbital Ur-mCnc;;ACTIVE;1.0l;2.73 +19371-4;Butabarbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Butabarbital cutoff [Mass/volume] in Urine for Screen method;Butabarbital CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +1937-2;Beta endorphin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta endorphin [Mass/volume] in Serum or Plasma;B-Endorphin SerPl-mCnc;;ACTIVE;1.0;2.73 +19372-2;Butabarbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butabarbital cutoff [Mass/volume] in Urine for Confirmatory method;Butabarbital CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19373-0;Butalbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Butalbital [Presence] in Urine by Screen method;Butalbital Ur Ql Scn;;ACTIVE;1.0l;2.73 +19375-5;Butalbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Butalbital cutoff [Mass/volume] in Urine for Screen method;Butalbital CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19376-3;Butalbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butalbital cutoff [Mass/volume] in Urine for Confirmatory method;Butalbital CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19377-1;Butorphanol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Butorphanol [Presence] in Urine by Screen method;Butorphanol Ur Ql Scn;;ACTIVE;1.0l;2.73 +19378-9;Butorphanol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Butorphanol [Presence] in Urine by Confirmatory method;Butorphanol Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19379-7;Butorphanol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Butorphanol cutoff [Mass/volume] in Urine for Screen method;Butorphanol CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +1938-0;Beta fructofuranosidase;CCnc;Pt;RBC;Qn;;CHEM;1;Beta fructofuranosidase [Enzymatic activity/volume] in Red Blood Cells;B-Fructofuranosidase RBC-cCnc;;ACTIVE;1.0;2.44 +19380-5;Butorphanol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butorphanol cutoff [Mass/volume] in Urine for Confirmatory method;Butorphanol CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19381-3;Carboxy tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Urine by Screen method;CarboxyTHC Ur Ql Scn;;ACTIVE;1.0l;2.73 +19382-1;Carboxy tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Urine by Confirmatory method;CarboxyTHC Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19383-9;Carboxy tetrahydrocannabinol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Carboxy tetrahydrocannabinol cutoff [Mass/volume] in Urine for Screen method;CarboxyTHC CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19384-7;Carboxy tetrahydrocannabinol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Carboxy tetrahydrocannabinol cutoff [Mass/volume] in Urine for Confirmatory method;CarboxyTHC CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.36 +19385-4;chlordiazePOXIDE;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;chlordiazePOXIDE [Presence] in Urine by Screen method;Chlordiazep Ur Ql Scn;;ACTIVE;1.0l;2.56 +19386-2;chlordiazePOXIDE;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Presence] in Urine by Confirmatory method;Chlordiazep Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19387-0;chlordiazePOXIDE cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;chlordiazePOXIDE cutoff [Mass/volume] in Urine for Screen method;Chlordiazep CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19388-8;chlordiazePOXIDE cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE cutoff [Mass/volume] in Urine for Confirmatory method;Chlordiazep CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19389-6;Chlorpheniramine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Chlorpheniramine [Presence] in Urine by Screen method;Chlorphenir Ur Ql Scn;;ACTIVE;1.0l;2.73 +19391-2;Chlorpheniramine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Chlorpheniramine [Mass/volume] in Urine by Confirmatory method;Chlorphenir Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19392-0;Chlorpheniramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorpheniramine [Mass/volume] in Urine;Chlorphenir Ur-mCnc;;ACTIVE;1.0l;2.42 +19393-8;Chlorpheniramine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Chlorpheniramine cutoff [Mass/volume] in Urine for Screen method;Chlorphenir CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19394-6;Chlorpheniramine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Chlorpheniramine cutoff [Mass/volume] in Urine for Confirmatory method;Chlorphenir CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19395-3;chlorproMAZINE;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;chlorproMAZINE [Presence] in Urine by Screen method;chlorproMAZINE Ur Ql Scn;;ACTIVE;1.0l;2.73 +19396-1;chlorproMAZINE;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;chlorproMAZINE [Presence] in Urine by Confirmatory method;chlorproMAZINE Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19397-9;chlorproMAZINE cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;chlorproMAZINE cutoff [Mass/volume] in Urine for Screen method;chlorproMAZINE CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +1939-8;Beta fructofuranosidase;CCnc;Pt;Ser;Qn;;CHEM;1;Beta fructofuranosidase [Enzymatic activity/volume] in Serum;B-Fructofuranosidase Ser-cCnc;;ACTIVE;1.0;2.68 +19398-7;chlorproMAZINE cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;chlorproMAZINE cutoff [Mass/volume] in Urine for Confirmatory method;chlorproMAZINE CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19399-5;clonazePAM;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;clonazePAM [Presence] in Urine by Screen method;clonazePAM Ur Ql Scn;;ACTIVE;1.0l;2.56 +19402-7;clonazePAM;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;clonazePAM [Mass/volume] in Urine;clonazePAM Ur-mCnc;;ACTIVE;1.0l;2.73 +19403-5;clonazePAM cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;clonazePAM cutoff [Mass/volume] in Urine for Screen method;clonazePAM CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19404-3;clonazePAM cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;clonazePAM cutoff [Mass/volume] in Urine for Confirmatory method;clonazePAM CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19405-0;Cocaethylene;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Cocaethylene [Presence] in Urine by Screen method;Cocaethylene Ur Ql Scn;;ACTIVE;1.0l;2.56 +1940-6;Beta galactosidase;CCnc;Pt;RBC;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/volume] in Red Blood Cells;B-Galactosidase RBC-cCnc;;ACTIVE;1.0;2.44 +19406-8;Cocaethylene;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cocaethylene [Presence] in Urine by Confirmatory method;Cocaethylene Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19408-4;Cocaethylene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cocaethylene [Mass/volume] in Urine;Cocaethylene Ur-mCnc;;ACTIVE;1.0l;2.73 +19409-2;Cocaethylene cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Cocaethylene cutoff [Mass/volume] in Urine for Screen method;Cocaethylene CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +194-1;Clindamycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clindamycin [Susceptibility] by Disk diffusion (KB);Clindamycin Islt KB;;ACTIVE;1.0;2.73 +19410-0;Cocaethylene cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cocaethylene cutoff [Mass/volume] in Urine for Confirmatory method;Cocaethylene CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19411-8;Codeine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Codeine [Presence] in Urine by Screen method;Codeine Ur Ql Scn;;ACTIVE;1.0l;2.73 +19413-4;Codeine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Codeine cutoff [Mass/volume] in Urine for Screen method;Codeine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +1941-4;Beta galactosidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/volume] in Serum or Plasma;B-Galactosidase SerPl-cCnc;;ACTIVE;1.0;2.40 +19414-2;Codeine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Codeine cutoff [Mass/volume] in Urine for Confirmatory method;Codeine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19415-9;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by Screen method;THC Ur Ql Scn;;ACTIVE;1.0l;2.73 +19416-7;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by Confirmatory method;THC Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19417-5;Tetrahydrocannabinol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Tetrahydrocannabinol cutoff [Mass/volume] in Urine for Screen method;THC CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19418-3;Tetrahydrocannabinol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Tetrahydrocannabinol cutoff [Mass/volume] in Urine for Confirmatory method;THC CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19419-1;Dextroamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Dextroamphetamine [Presence] in Urine by Screen method;D-amphet Ur Ql Scn;;ACTIVE;1.0l;2.70 +19420-9;Dextroamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Dextroamphetamine [Presence] in Urine by Confirmatory method;D-amphet Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19421-7;Dextroamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Dextroamphetamine cutoff [Mass/volume] in Urine for Screen method;D-amphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +1942-2;Beta galactosidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/mass] in Tissue;B-Galactosidase Tiss-cCnt;;ACTIVE;1.0;2.73 +19422-5;Dextroamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dextroamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;D-amphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19423-3;Dextromethamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Dextromethamphetamine [Presence] in Urine by Screen method;D-methamphet Ur Ql Scn;;ACTIVE;1.0l;2.56 +19424-1;Dextromethamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Dextromethamphetamine [Presence] in Urine by Confirmatory method;D-methamphet Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19425-8;Dextromethamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dextromethamphetamine [Mass/volume] in Urine by Confirmatory method;D-methamphet Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19426-6;Dextromethamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Dextromethamphetamine [Mass/volume] in Urine;Deprecated D-methamphet Ur-mCnc;;DEPRECATED;1.0l;2.36 +19427-4;Dextromethamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Dextromethamphetamine cutoff [Mass/volume] in Urine for Screen method;D-methamphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19428-2;Dextromethamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dextromethamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;D-methamphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19429-0;Propoxyphene;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Propoxyphene [Presence] in Urine by Screen method;Propoxyph Ur Ql Scn;;ACTIVE;1.0l;2.73 +1943-0;Glucosylceramidase;CCnc;Pt;WBC;Qn;;CHEM;1;Glucosylceramidase [Enzymatic activity/volume] in Leukocytes;Glucosylceramidase WBC-cCnc;;ACTIVE;1.0;2.73 +19431-6;Propoxyphene cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Propoxyphene cutoff [Mass/volume] in Urine for Screen method;Propoxyph CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19432-4;Propoxyphene cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Propoxyphene cutoff [Mass/volume] in Urine for Confirmatory method;Propoxyph CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19433-2;Propoxyphene+Norpropoxyphene;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Presence] in Urine by Screen method;Propoxyph+Nor Ur Ql Scn;;ACTIVE;1.0l;2.73 +19434-0;Propoxyphene+Norpropoxyphene;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Presence] in Urine by Confirmatory method;Propoxyph+Nor Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19435-7;Propoxyphene+Norpropoxyphene;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Mass/volume] in Urine by Confirmatory method;Propoxyph+Nor Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19436-5;Propoxyphene+Norpropoxyphene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Mass/volume] in Urine;Propoxyph+Nor Ur-mCnc;;ACTIVE;1.0l;2.73 +19437-3;Propoxyphene+Norpropoxyphene cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Propoxyphene + Norpropoxyphene cutoff [Mass/volume] in Urine for Screen method;Propoxyph+Nor CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19438-1;Propoxyphene+Norpropoxyphene cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Propoxyphene + Norpropoxyphene cutoff [Mass/volume] in Urine for Confirmatory method;Propoxyph+Nor CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19439-9;Diamorphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Diamorphine [Presence] in Urine by Screen method;DAM Ur Ql Scn;;ACTIVE;1.0l;2.56 +19441-5;Diamorphine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Diamorphine cutoff [Mass/volume] in Urine for Screen method;DAM CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19442-3;Diamorphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Diamorphine cutoff [Mass/volume] in Urine for Confirmatory method;DAM CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19443-1;diazePAM;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;diazePAM [Presence] in Urine by Screen method;diazePAM Ur Ql Scn;;ACTIVE;1.0l;2.56 +19444-9;diazePAM cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;diazePAM cutoff [Mass/volume] in Urine for Screen method;diazePAM CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19445-6;diazePAM cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;diazePAM cutoff [Mass/volume] in Urine for Confirmatory method;diazePAM CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19446-4;Dihydrocodeine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Dihydrocodeine [Presence] in Urine by Screen method;DHC Ur Ql Scn;;ACTIVE;1.0l;2.56 +1944-8;Beta glucuronidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/mass] in Tissue;B-Glucuronidase Tiss-cCnt;;ACTIVE;1.0;2.42 +19448-0;Dihydrocodeine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dihydrocodeine [Mass/volume] in Urine by Confirmatory method;DHC Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19449-8;Dihydrocodeine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dihydrocodeine [Mass/volume] in Urine;DHC Ur-mCnc;;ACTIVE;1.0l;2.73 +19450-6;Dihydrocodeine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Dihydrocodeine cutoff [Mass/volume] in Urine for Screen method;DHC CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19451-4;Dihydrocodeine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dihydrocodeine cutoff [Mass/volume] in Urine for Confirmatory method;DHC CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19452-2;Dimetamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Dimetamphetamine [Presence] in Urine by Screen method;Dimetamphet Ur Ql Scn;;ACTIVE;1.0l;2.56 +19453-0;Dimetamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Dimetamphetamine [Presence] in Urine by Confirmatory method;Dimetamphet Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19454-8;Dimetamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Dimetamphetamine cutoff [Mass/volume] in Urine for Screen method;Dimetamphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +1945-5;Beta glucuronidase;CCnc;Pt;Urine;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/volume] in Urine;B-Glucuronidase Ur-cCnc;;ACTIVE;1.0;2.42 +19455-5;Dimetamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dimetamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;Dimetamphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19456-3;Ethylamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Ethylamphetamine [Presence] in Urine by Screen method;Ethylamphet Ur Ql Scn;;ACTIVE;1.0l;2.56 +19458-9;Ethylamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethylamphetamine [Mass/volume] in Urine by Confirmatory method;Ethylamphet Ur Cfm-mCnc;;ACTIVE;1.0l;2.36 +19459-7;Ethylamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethylamphetamine [Mass/volume] in Urine;Ethylamphet Ur-mCnc;;ACTIVE;1.0l;2.34 +19460-5;Ethylamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Ethylamphetamine cutoff [Mass/volume] in Urine for Screen method;Ethylamphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19461-3;Ethylamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethylamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;Ethylamphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19462-1;Ethylmorphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Ethylmorphine [Presence] in Urine by Screen method;EMP Ur Ql Scn;;ACTIVE;1.0l;2.56 +1946-3;Beta hydroxybutyrate;MCnc;Pt;CSF;Qn;;CHEM;1;Beta hydroxybutyrate [Mass/volume] in Cerebral spinal fluid;B-OH-Butyr CSF-mCnc;;ACTIVE;1.0;2.73 +19463-9;Ethylmorphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ethylmorphine [Presence] in Urine by Confirmatory method;EMP Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19464-7;Ethylmorphine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Ethylmorphine cutoff [Mass/volume] in Urine for Screen method;EMP CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19465-4;Ethylmorphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethylmorphine cutoff [Mass/volume] in Urine for Confirmatory method;EMP CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19466-2;Flunitrazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Flunitrazepam [Presence] in Urine by Screen method;Flunitrazepam Ur Ql Scn;;ACTIVE;1.0l;2.73 +19467-0;Flunitrazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Flunitrazepam [Presence] in Urine by Confirmatory method;Flunitrazepam Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19468-8;Flunitrazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Flunitrazepam cutoff [Mass/volume] in Urine for Screen method;Flunitrazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19469-6;Flunitrazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flunitrazepam cutoff [Mass/volume] in Urine for Confirmatory method;Flunitrazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19470-4;FLUoxetine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;FLUoxetine [Presence] in Urine by Screen method;FLUoxetine Ur Ql Scn;;ACTIVE;1.0l;2.73 +1947-1;Beta hydroxybutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Beta hydroxybutyrate [Mass/volume] in Urine;B-OH-Butyr Ur-mCnc;;ACTIVE;1.0;2.73 +19471-2;FLUoxetine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;FLUoxetine [Presence] in Urine by Confirmatory method;FLUoxetine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19472-0;FLUoxetine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;FLUoxetine cutoff [Mass/volume] in Urine for Screen method;FLUoxetine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19473-8;FLUoxetine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;FLUoxetine cutoff [Mass/volume] in Urine for Confirmatory method;FLUoxetine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19474-6;Flurazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Flurazepam [Presence] in Urine by Screen method;Flurazepam Ur Ql Scn;;ACTIVE;1.0l;2.56 +19475-3;Flurazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Flurazepam [Presence] in Urine by Confirmatory method;Flurazepam Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19476-1;Flurazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Flurazepam cutoff [Mass/volume] in Urine for Screen method;Flurazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19477-9;Flurazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flurazepam cutoff [Mass/volume] in Urine for Confirmatory method;Flurazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19478-7;Haloperidol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Haloperidol [Presence] in Urine by Screen method;Haloperidol Ur Ql Scn;;ACTIVE;1.0l;2.73 +19479-5;Haloperidol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Haloperidol [Presence] in Urine by Confirmatory method;Haloperidol Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19480-3;Haloperidol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Haloperidol cutoff [Mass/volume] in Urine for Screen method;Haloperidol CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19481-1;Haloperidol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Haloperidol cutoff [Mass/volume] in Urine for Confirmatory method;Haloperidol CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19482-9;HYDROcodone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;HYDROcodone [Presence] in Urine by Screen method;HYDROcodone Ur Ql Scn;;ACTIVE;1.0l;2.73 +19483-7;HYDROcodone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;HYDROcodone [Presence] in Urine by Confirmatory method;HYDROcodone Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19484-5;HYDROcodone cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;HYDROcodone cutoff [Mass/volume] in Urine for Screen method;HYDROcodone CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19485-2;HYDROcodone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;HYDROcodone cutoff [Mass/volume] in Urine for Confirmatory method;HYDROcodone CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19486-0;HYDROmorphone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;HYDROmorphone [Presence] in Urine by Screen method;HYDROmorphone Ur Ql Scn;;ACTIVE;1.0l;2.56 +19487-8;HYDROmorphone cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;HYDROmorphone cutoff [Mass/volume] in Urine for Screen method;HYDROmorphone CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19488-6;HYDROmorphone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;HYDROmorphone cutoff [Mass/volume] in Urine for Confirmatory method;HYDROmorphone CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1948-9;Beta hydroxybutyrate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Beta hydroxybutyrate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma;Deprecated B-OH-Butyr Dehydrog SerPl-cCn;;DEPRECATED;1.0;2.36 +19489-4;Hydroxyalprazolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hydroxyalprazolam [Presence] in Urine by Screen method;OH-Alpraz Ur Ql Scn;;ACTIVE;1.0l;2.73 +19490-2;Hydroxyalprazolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Hydroxyalprazolam [Presence] in Urine by Confirmatory method;OH-Alpraz Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19491-0;Hydroxyalprazolam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Hydroxyalprazolam cutoff [Mass/volume] in Urine for Screen method;OH-Alpraz CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19492-8;Hydroxyalprazolam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxyalprazolam cutoff [Mass/volume] in Urine for Confirmatory method;OH-Alpraz CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19493-6;Hydroxyethylflurazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hydroxyethylflurazepam [Presence] in Urine by Screen method;OH-Ethylfluraz Ur Ql Scn;;ACTIVE;1.0l;2.56 +19494-4;Hydroxyethylflurazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Presence] in Urine by Confirmatory method;OH-Ethylfluraz Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19495-1;Hydroxyethylflurazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Hydroxyethylflurazepam cutoff [Mass/volume] in Urine for Screen method;OH-Ethylfluraz CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19496-9;Hydroxyethylflurazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam cutoff [Mass/volume] in Urine for Confirmatory method;OH-Ethylfluraz CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1949-7;Beta lipotropin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta lipotropin [Mass/volume] in Serum or Plasma;B-Lipotropin SerPl-mCnc;;ACTIVE;1.0;2.34 +19497-7;Hydroxytriazolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hydroxytriazolam [Presence] in Urine by Screen method;OH-Triazolam Ur Ql Scn;;ACTIVE;1.0l;2.56 +19499-3;Ketamine;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Ketamine [Mass/volume] in Urine by Screen method;Ketamine Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19500-8;Ketamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ketamine cutoff [Mass/volume] in Urine for Confirmatory method;Ketamine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19501-6;Ketamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Ketamine cutoff [Mass/volume] in Urine for Screen method;Ketamine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19502-4;Methotrimeprazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methotrimeprazine [Presence] in Urine by Screen method;Methotrimeprazine Ur Ql Scn;;ACTIVE;1.0l;2.56 +19503-2;Methotrimeprazine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methotrimeprazine [Presence] in Urine by Confirmatory method;Methotrimeprazine Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19504-0;Methotrimeprazine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methotrimeprazine cutoff [Mass/volume] in Urine for Screen method;Methotrimeprazine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.52 +1950-5;Beta melanocyte stimulating hormone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta melanocyte stimulating hormone [Mass/volume] in Serum or Plasma;B-MSH SerPl-mCnc;;ACTIVE;1.0;2.73 +19505-7;Methotrimeprazine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methotrimeprazine cutoff [Mass/volume] in Urine for Confirmatory method;Methotrimeprazine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.52 +19506-5;Levomepromazine;ACnc;Pt;Urine;Ord;Screen;DRUG/TOX;1;Deprecated Levomepromazine [Presence] in Urine by Screen method;Deprecated L-Mepromazine Ur Ql Scn;;DEPRECATED;1.0l;2.36 +19507-3;Levomepromazine;ACnc;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Deprecated Levomepromazine [Presence] in Urine by Confirm method;Deprecated L-Mepromazine Ur Ql Cfm;;DEPRECATED;1.0l;2.36 +19508-1;Levomepromazine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Deprecated Levomepromazine cutoff [Mass/volume] in Urine for Screen method;Deprecated L-Mepromazine CtO Ur Scn-mCnc;;DEPRECATED;1.0l;2.36 +19509-9;Levomepromazine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated Levomepromazine cutoff [Mass/volume] in Urine for Confirm method;Deprecated L-Mepromazine CtO Ur Cfm-mCnc;;DEPRECATED;1.0l;2.36 +19510-7;Levomethamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Levomethamphetamine [Presence] in Urine by Screen method;L-methamphet Ur Ql Scn;;ACTIVE;1.0l;2.73 +19511-5;Levomethamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Levomethamphetamine [Presence] in Urine by Confirmatory method;L-methamphet Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19512-3;Levomethamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Levomethamphetamine [Mass/volume] in Urine by Confirmatory method;L-methamphet Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1951-3;Beta-2-Microglobulin;MCnc;Pt;CSF;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Cerebral spinal fluid;B2 Microglob CSF-mCnc;;ACTIVE;1.0;2.73 +19514-9;Levomethamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Levomethamphetamine cutoff [Mass/volume] in Urine for Screen method;L-methamphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19515-6;Levomethamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Levomethamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;L-methamphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19516-4;Levorphanol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Levorphanol [Presence] in Urine by Screen method;Levorphanol Ur Ql Scn;;ACTIVE;1.0l;2.56 +19518-0;Levorphanol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Levorphanol cutoff [Mass/volume] in Urine for Screen method;Levorphanol CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19519-8;Levorphanol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Levorphanol cutoff [Mass/volume] in Urine for Confirmatory method;Levorphanol CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19520-6;LORazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;LORazepam [Presence] in Urine by Screen method;LORazepam Ur Ql Scn;;ACTIVE;1.0l;2.56 +1952-1;Beta-2-Microglobulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Serum or Plasma;B2 Microglob SerPl-mCnc;;ACTIVE;1.0;2.73 +19522-2;LORazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;LORazepam cutoff [Mass/volume] in Urine for Screen method;LORazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19523-0;LORazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;LORazepam cutoff [Mass/volume] in Urine for Confirmatory method;LORazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19524-8;Lormetazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Lormetazepam [Presence] in Urine by Screen method;Lormetazepam Ur Ql Scn;;ACTIVE;1.0l;2.56 +19525-5;Lormetazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Lormetazepam [Presence] in Urine by Confirmatory method;Lormetazepam Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19526-3;Lormetazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Lormetazepam cutoff [Mass/volume] in Urine for Screen method;Lormetazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19527-1;Lormetazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Lormetazepam cutoff [Mass/volume] in Urine for Confirmatory method;Lormetazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19528-9;Lysergate diethylamide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Lysergate diethylamide [Presence] in Urine by Screen method;LSD Ur Ql Scn;;ACTIVE;1.0l;2.73 +19530-5;Lysergate diethylamide cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Lysergate diethylamide cutoff [Mass/volume] in Urine for Screen method;LSD CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.34 +19531-3;Lysergate diethylamide cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Lysergate diethylamide cutoff [Mass/volume] in Urine for Confirmatory method;LSD CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.36 +19532-1;Meperidine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Meperidine [Presence] in Urine by Screen method;Meperidine Ur Ql Scn;;ACTIVE;1.0l;2.73 +19534-7;Meperidine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Meperidine cutoff [Mass/volume] in Urine for Screen method;Meperidine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19535-4;Meperidine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Meperidine cutoff [Mass/volume] in Urine for Confirmatory method;Meperidine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19536-2;Mephobarbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Mephobarbital [Presence] in Urine by Screen method;Mephobarbital Ur Ql Scn;;ACTIVE;1.0l;2.56 +19537-0;Mephobarbital;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Mephobarbital [Presence] in Urine by Confirmatory method;Mephobarbital Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1953-9;Beta-2-Microglobulin;MCnc;Pt;Urine;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Urine;B2 Microglob Ur-mCnc;;ACTIVE;1.0;2.73 +19539-6;Mephobarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mephobarbital [Mass/volume] in Urine;Mephobarbital Ur-mCnc;;ACTIVE;1.0l;2.42 +19540-4;Mephobarbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Mephobarbital cutoff [Mass/volume] in Urine for Screen method;Mephobarbital CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19541-2;Mephobarbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mephobarbital cutoff [Mass/volume] in Urine for Confirmatory method;Mephobarbital CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19542-0;Mescaline;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Mescaline [Presence] in Urine by Screen method;Mescaline Ur Ql Scn;;ACTIVE;1.0l;2.56 +19543-8;Mescaline;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Mescaline [Presence] in Urine by Confirmatory method;Mescaline Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19544-6;Mescaline cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Mescaline cutoff [Mass/volume] in Urine for Screen method;Mescaline CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19545-3;Mescaline cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mescaline cutoff [Mass/volume] in Urine for Confirmatory method;Mescaline CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19546-1;Mesoridazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Mesoridazine [Presence] in Urine by Screen method;Mesoridazine Ur Ql Scn;;ACTIVE;1.0l;2.73 +1954-7;Beta-N-acetylhexosaminidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/volume] in Serum or Plasma;B-NAH SerPl-cCnc;;ACTIVE;1.0;2.73 +19547-9;Mesoridazine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Mesoridazine [Presence] in Urine by Confirmatory method;Mesoridazine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19548-7;Mesoridazine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Mesoridazine cutoff [Mass/volume] in Urine for Screen method;Mesoridazine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19549-5;Mesoridazine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mesoridazine cutoff [Mass/volume] in Urine for Confirmatory method;Mesoridazine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19550-3;Methadone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methadone [Presence] in Urine by Screen method;Methadone Ur Ql Scn;;ACTIVE;1.0l;2.73 +19552-9;Methadone cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methadone cutoff [Mass/volume] in Urine for Screen method;Methadone CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19553-7;Methadone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methadone cutoff [Mass/volume] in Urine for Confirmatory method;Methadone CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1955-4;Beta-N-acetylhexosaminidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/mass] in Tissue;B-NAH Tiss-cCnt;;ACTIVE;1.0;2.42 +19554-5;Methamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methamphetamine [Presence] in Urine by Screen method;Methamphet Ur Ql Scn;;ACTIVE;1.0l;2.73 +19555-2;Methamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methamphetamine [Presence] in Urine by Confirmatory method;Methamphet Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19556-0;Methamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methamphetamine cutoff [Mass/volume] in Urine for Screen method;Methamphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19557-8;Methamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;Methamphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19558-6;Methaqualone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methaqualone [Presence] in Urine by Screen method;Methaqualone Ur Ql Scn;;ACTIVE;1.0l;2.73 +19559-4;Methaqualone cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methaqualone cutoff [Mass/volume] in Urine for Screen method;Methaqualone CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19560-2;Methaqualone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methaqualone cutoff [Mass/volume] in Urine for Confirmatory method;Methaqualone CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19561-0;Methylenediamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methylenediamine [Presence] in Urine by Screen method;Me-enediam Ur Ql Scn;;ACTIVE;1.0l;2.56 +1956-2;Beta-N-acetylhexosaminidase.A;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A [Enzymatic activity/volume] in Serum or Plasma;Hexosaminidase A SerPl-cCnc;;ACTIVE;1.0;2.73 +19562-8;Methylenediamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methylenediamine [Presence] in Urine by Confirmatory method;Me-enediam Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19563-6;Methylenediamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methylenediamine cutoff [Mass/volume] in Urine for Screen method;Me-enediam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19564-4;Methylenediamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenediamine cutoff [Mass/volume] in Urine for Confirmatory method;Me-enediam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19565-1;Methylenedioxyamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Urine by Screen method;MDA Ur Ql Scn;;ACTIVE;1.0l;2.73 +19566-9;Methylenedioxyamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Urine by Confirmatory method;MDA Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19567-7;Methylenedioxyamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methylenedioxyamphetamine cutoff [Mass/volume] in Urine for Screen method;MDA CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19568-5;Methylenedioxymethamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Urine by Screen method;MDMA Ur Ql Scn;;ACTIVE;1.0l;2.73 +19569-3;Methylenedioxymethamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Urine by Confirmatory method;MDMA Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1957-0;Beta-N-acetylhexosaminidase.B;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B [Enzymatic activity/volume] in Serum or Plasma;Hexosaminidase B SerPl-cCnc;;ACTIVE;1.0;2.73 +19570-1;Methylenedioxymethamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Urine;MDMA Ur-mCnc;;ACTIVE;1.0l;2.73 +19571-9;Methylenedioxymethamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methylenedioxymethamphetamine cutoff [Mass/volume] in Urine for Screen method;MDMA CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19572-7;Methylenedioxymethamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;MDMA CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19573-5;MethylePHEDrine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;MethylePHEDrine [Presence] in Urine by Screen method;Me-ePHEDrine Ur Ql Scn;;ACTIVE;1.0l;2.56 +19575-0;MethylePHEDrine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;MethylePHEDrine cutoff [Mass/volume] in Urine for Screen method;Me-ePHEDrine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19576-8;MethylePHEDrine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;MethylePHEDrine cutoff [Mass/volume] in Urine for Confirmatory method;Me-ePHEDrine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19577-6;Methylphenidate;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methylphenidate [Presence] in Urine by Screen method;Me-phenidate Ur Ql Scn;;ACTIVE;1.0l;2.73 +19578-4;Methylphenidate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methylphenidate [Presence] in Urine by Confirmatory method;Me-phenidate Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19579-2;Methylphenidate cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methylphenidate cutoff [Mass/volume] in Urine for Screen method;Me-phenidate CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +195-8;Clindamycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Clindamycin [Susceptibility] by Serum bactericidal titer;Clindamycin Titr SBT;;ACTIVE;1.0;2.32 +19580-0;Methylphenidate cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylphenidate cutoff [Mass/volume] in Urine for Confirmatory method;Me-phenidate CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19581-8;Methyprylon;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methyprylon [Presence] in Urine by Screen method;Methyprylon Ur Ql Scn;;ACTIVE;1.0l;2.56 +19583-4;Methyprylon cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methyprylon cutoff [Mass/volume] in Urine for Screen method;Methyprylon CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19584-2;Methyprylon cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methyprylon cutoff [Mass/volume] in Urine for Confirmatory method;Methyprylon CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19585-9;Midazolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Midazolam [Presence] in Urine by Screen method;Midazolam Ur Ql Scn;;ACTIVE;1.0l;2.73 +19586-7;Midazolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Midazolam [Presence] in Urine by Confirmatory method;Midazolam Ur Ql Cfm;;ACTIVE;1.0l;2.73 +1958-8;Beta-N-acetylhexosaminidase.I;CCnc;Pt;Ser;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.I [Enzymatic activity/volume] in Serum;Hexosaminidase I Ser-cCnc;;ACTIVE;1.0;2.42 +19588-3;Midazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Midazolam [Mass/volume] in Urine;Midazolam Ur-mCnc;;ACTIVE;1.0l;2.73 +19589-1;Midazolam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Midazolam cutoff [Mass/volume] in Urine for Screen method;Midazolam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19590-9;Midazolam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Midazolam cutoff [Mass/volume] in Urine for Confirmatory method;Midazolam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19591-7;6-Monoacetylmorphine;ACnc;Pt;Urine;Ord;Screen;DRUG/TOX;1;Deprecated 6-Monoacetylmorphine [Presence] in Urine by Screen method;Deprecated 6MAM Ur Ql Scn;;DEPRECATED;1.0l;2.36 +19592-5;6-Monoacetylmorphine;ACnc;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Deprecated 6-Monoacetylmorphine [Presence] in Urine by Confirm method;Deprecated 6MAM Ur Ql Cfm;;DEPRECATED;1.0l;2.36 +19593-3;6-Monoacetylmorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Urine by Confirmatory method;6MAM Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19594-1;6-Monoacetylmorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Monoacetylmorphine [Mass/volume] in Urine;Deprecated 6MAM Ur-mCnc;;DEPRECATED;1.0l;2.40 +19595-8;6-Monoacetylmorphine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Deprecated 6-Monoacetylmorphine cutoff [Mass/volume] in Urine for Screen method;Deprecated 6MAM CtO Ur Scn-mCnc;;DEPRECATED;1.0l;2.36 +1959-6;Bicarbonate;SCnc;Pt;Bld;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Blood;HCO3 Bld-sCnc;;ACTIVE;1.0;2.73 +19596-6;6-Monoacetylmorphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated 6-Monoacetylmorphine cutoff [Mass/volume] in Urine for Confirm method;Deprecated 6MAM CtO Ur Cfm-mCnc;;DEPRECATED;1.0l;2.36 +19597-4;Morphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Morphine [Presence] in Urine by Screen method;Morphine Ur Ql Scn;;ACTIVE;1.0l;2.73 +19599-0;Morphine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Morphine cutoff [Mass/volume] in Urine for Screen method;Morphine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19600-6;Morphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Morphine cutoff [Mass/volume] in Urine for Confirmatory method;Morphine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19601-4;Morphine.free;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Morphine Free [Presence] in Urine by Screen method;Morphine Free Ur Ql Scn;;ACTIVE;1.0l;2.56 +19602-2;Morphine.free;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Morphine Free [Presence] in Urine by Confirmatory method;Morphine Free Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19603-0;Morphine.free cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Morphine Free cutoff [Mass/volume] in Urine for Screen method;Morphine Free CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +1960-4;Bicarbonate;SCnc;Pt;BldA;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Arterial blood;HCO3 BldA-sCnc;;ACTIVE;1.0;2.73 +19604-8;Morphine.free cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Morphine Free cutoff [Mass/volume] in Urine for Confirmatory method;Morphine Free CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19605-5;Nalbuphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Nalbuphine [Presence] in Urine by Screen method;Nalbuphine Ur Ql Scn;;ACTIVE;1.0l;2.56 +19607-1;Nalbuphine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Nalbuphine cutoff [Mass/volume] in Urine for Screen method;Nalbuphine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19608-9;Nalbuphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nalbuphine cutoff [Mass/volume] in Urine for Confirmatory method;Nalbuphine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19609-7;Naltrexone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Naltrexone [Presence] in Urine by Screen method;Naltrexone Ur Ql Scn;;ACTIVE;1.0l;2.73 +19610-5;Naltrexone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naltrexone [Mass/volume] in Urine by Confirmatory method;Naltrexone Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19611-3;Naltrexone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Naltrexone [Mass/volume] in Urine;Naltrexone Ur-mCnc;;ACTIVE;1.0l;2.73 +1961-2;Bicarbonate;SCnc;Pt;BldC;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Capillary blood;HCO3 BldC-sCnc;;ACTIVE;1.0;2.73 +19612-1;Naltrexone cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Naltrexone cutoff [Mass/volume] in Urine for Screen method;Naltrexone CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19613-9;Naltrexone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naltrexone cutoff [Mass/volume] in Urine for Confirmatory method;Naltrexone CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19614-7;N-desalkylflurazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Urine by Screen method;Desalkylfluraz Ur Ql Scn;;ACTIVE;1.0l;2.73 +19615-4;N-desalkylflurazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Urine by Confirmatory method;Desalkylfluraz Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19617-0;N-desalkylflurazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Urine;Desalkylfluraz Ur-mCnc;;ACTIVE;1.0l;2.73 +19618-8;N-desalkylflurazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;N-desalkylflurazepam cutoff [Mass/volume] in Urine for Screen method;Desalkylfluraz CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19619-6;N-desalkylflurazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam cutoff [Mass/volume] in Urine for Confirmatory method;Desalkylfluraz CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +1962-0;Bicarbonate;SCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Bicarbonate [Moles/volume] in Plasma;Deprecated HCO3 Plas-sCnc;;DEPRECATED;1.0;2.70 +19620-4;Nitrazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Nitrazepam [Presence] in Urine by Screen method;Nitrazepam Ur Ql Scn;;ACTIVE;1.0l;2.56 +19621-2;Nitrazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Nitrazepam [Presence] in Urine by Confirmatory method;Nitrazepam Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19622-0;Nitrazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Nitrazepam cutoff [Mass/volume] in Urine for Screen method;Nitrazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19623-8;Nitrazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nitrazepam cutoff [Mass/volume] in Urine for Confirmatory method;Nitrazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19624-6;Nordiazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Nordiazepam [Presence] in Urine by Screen method;Nordiazepam Ur Ql Scn;;ACTIVE;1.0l;2.73 +19626-1;Nordiazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Nordiazepam cutoff [Mass/volume] in Urine for Screen method;Nordiazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19627-9;Nordiazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nordiazepam cutoff [Mass/volume] in Urine for Confirmatory method;Nordiazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19628-7;Norfluoxetine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norfluoxetine [Presence] in Urine by Screen method;Norfluoxetine Ur Ql Scn;;ACTIVE;1.0l;2.73 +19629-5;Norfluoxetine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Norfluoxetine [Presence] in Urine by Confirmatory method;Norfluoxetine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19630-3;Norfluoxetine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Norfluoxetine cutoff [Mass/volume] in Urine for Screen method;Norfluoxetine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19631-1;Norfluoxetine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norfluoxetine cutoff [Mass/volume] in Urine for Confirmatory method;Norfluoxetine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19632-9;Norpropoxyphene;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norpropoxyphene [Presence] in Urine by Screen method;Norpropoxyph Ur Ql Scn;;ACTIVE;1.0l;2.56 +19635-2;Norpropoxyphene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/volume] in Urine;Norpropoxyph Ur-mCnc;;ACTIVE;1.0l;2.73 +19636-0;Norpropoxyphene cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Norpropoxyphene cutoff [Mass/volume] in Urine for Screen method;Norpropoxyph CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19637-8;Norpropoxyphene cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norpropoxyphene cutoff [Mass/volume] in Urine for Confirmatory method;Norpropoxyph CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +1963-8;Bicarbonate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Serum or Plasma;HCO3 SerPl-sCnc;;ACTIVE;1.0;2.73 +19638-6;Oxazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Oxazepam [Presence] in Urine by Screen method;Oxazepam Ur Ql Scn;;ACTIVE;1.0l;2.56 +19639-4;Oxazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Oxazepam [Presence] in Urine by Confirmatory method;Oxazepam Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19640-2;Oxazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Oxazepam cutoff [Mass/volume] in Urine for Screen method;Oxazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19641-0;Oxazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Oxazepam cutoff [Mass/volume] in Urine for Confirmatory method;Oxazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19642-8;oxyCODONE;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;oxyCODONE [Presence] in Urine by Screen method;oxyCODONE Ur Ql Scn;;ACTIVE;1.0l;2.73 +19643-6;oxyCODONE;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;oxyCODONE [Presence] in Urine by Confirmatory method;oxyCODONE Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19644-4;oxyCODONE cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;oxyCODONE cutoff [Mass/volume] in Urine for Screen method;oxyCODONE CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19645-1;oxyCODONE cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;oxyCODONE cutoff [Mass/volume] in Urine for Confirmatory method;oxyCODONE CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +1964-6;Bicarbonate;SCnc;Pt;Urine;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Urine;HCO3 Ur-sCnc;;ACTIVE;1.0;2.73 +19646-9;oxyMORphone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;oxyMORphone [Presence] in Urine by Screen method;oxyMORphone Ur Ql Scn;;ACTIVE;1.0l;2.73 +19648-5;oxyMORphone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;oxyMORphone [Mass/volume] in Urine;oxyMORphone Ur-mCnc;;ACTIVE;1.0l;2.73 +19649-3;oxyMORphone cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;oxyMORphone cutoff [Mass/volume] in Urine for Screen method;oxyMORphone CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19650-1;oxyMORphone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;oxyMORphone cutoff [Mass/volume] in Urine for Confirmatory method;oxyMORphone CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19651-9;Para hydroxyamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Para hydroxyamphetamine [Presence] in Urine by Screen method;P-OH-Amphet Ur Ql Scn;;ACTIVE;1.0l;2.56 +19652-7;Para hydroxyamphetamine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Para hydroxyamphetamine [Presence] in Urine by Confirmatory method;P-OH-Amphet Ur Ql Cfm;;ACTIVE;1.0l;2.56 +1965-3;Bile;PrThr;Pt;Stool;Ord;;CHEM;1;Bile [Presence] in Stool;Bile Stl Ql;;ACTIVE;1.0;2.56 +19653-5;Para hydroxyamphetamine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Para hydroxyamphetamine cutoff [Mass/volume] in Urine for Screen method;P-OH-Amphet CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19654-3;Para hydroxyamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Para hydroxyamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;P-OH-Amphet CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19655-0;PENTobarbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;PENTobarbital [Presence] in Urine by Screen method;Pentobarb Ur Ql Scn;;ACTIVE;1.0l;2.73 +19657-6;PENTobarbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;PENTobarbital cutoff [Mass/volume] in Urine for Screen method;Pentobarb CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19658-4;PENTobarbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;PENTobarbital cutoff [Mass/volume] in Urine for Confirmatory method;Pentobarb CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19659-2;Phencyclidine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Urine by Screen method;PCP Ur Ql Scn;;ACTIVE;1.0l;2.73 +196-6;Cloxacillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cloxacillin [Susceptibility] by Minimum lethal concentration (MLC);Cloxacillin Islt MLC;;ACTIVE;1.0;2.19 +19660-0;Phencyclidine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Phencyclidine cutoff [Mass/volume] in Urine for Screen method;PCP CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +1966-1;Bile acid;MCnc;Pt;Exhl gas;Qn;;CHEM;1;Bile acid [Mass/volume] in Exhaled gas;Bile Ac ExG-mCnc;;ACTIVE;1.0;2.34 +19661-8;Phencyclidine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phencyclidine cutoff [Mass/volume] in Urine for Confirmatory method;PCP CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19662-6;Phenmetrazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Phenmetrazine [Presence] in Urine by Screen method;Phenmetrazine Ur Ql Scn;;ACTIVE;1.0l;2.56 +19664-2;Phenmetrazine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Phenmetrazine cutoff [Mass/volume] in Urine for Screen method;Phenmetrazine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19665-9;Phenmetrazine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phenmetrazine cutoff [Mass/volume] in Urine for Confirmatory method;Phenmetrazine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19666-7;PHENobarbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;PHENobarbital [Presence] in Urine by Screen method;Phenobarb Ur Ql Scn;;ACTIVE;1.0l;2.73 +19668-3;PHENobarbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;PHENobarbital cutoff [Mass/volume] in Urine for Screen method;Phenobarb CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19669-1;PHENobarbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;PHENobarbital cutoff [Mass/volume] in Urine for Confirmatory method;Phenobarb CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19670-9;Phenothiazines;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Phenothiazines [Presence] in Urine by Screen method;Phenothiaz Ur Ql Scn;;ACTIVE;1.0l;2.73 +19672-5;Phenothiazines cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Phenothiazines cutoff [Mass/volume] in Urine for Screen method;Phenothiaz CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.52 +19673-3;Phenothiazines cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phenothiazines cutoff [Mass/volume] in Urine for Confirmatory method;Phenothiaz CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.52 +19674-1;Phentermine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Phentermine [Presence] in Urine by Screen method;Phentermine Ur Ql Scn;;ACTIVE;1.0l;2.73 +19676-6;Phentermine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Phentermine cutoff [Mass/volume] in Urine for Screen method;Phentermine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19677-4;Phentermine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phentermine cutoff [Mass/volume] in Urine for Confirmatory method;Phentermine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19678-2;Prazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Prazepam [Presence] in Urine by Screen method;Prazepam Ur Ql Scn;;ACTIVE;1.0l;2.56 +1967-9;Bile acid;MCnc;Pt;Ser;Qn;;CHEM;1;Bile acid [Mass/volume] in Serum;Bile Ac Ser-mCnc;;ACTIVE;1.0;2.73 +19679-0;Prazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Prazepam [Presence] in Urine by Confirmatory method;Prazepam Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19680-8;Prazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Prazepam cutoff [Mass/volume] in Urine for Screen method;Prazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19681-6;Prazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Prazepam cutoff [Mass/volume] in Urine for Confirmatory method;Prazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19682-4;Psilocin;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Psilocin [Presence] in Urine by Screen method;Psilocin Ur Ql Scn;;ACTIVE;1.0l;2.56 +19683-2;Psilocin;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Psilocin [Presence] in Urine by Confirmatory method;Psilocin Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19684-0;Psilocin cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Psilocin cutoff [Mass/volume] in Urine for Screen method;Psilocin CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19685-7;Psilocin cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Psilocin cutoff [Mass/volume] in Urine for Confirmatory method;Psilocin CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19686-5;Psilocybin;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Psilocybin [Presence] in Urine by Screen method;Psilocybin Ur Ql Scn;;ACTIVE;1.0l;2.56 +1968-7;Bilirubin.glucuronidated+Bilirubin.albumin bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.direct [Mass/volume] in Serum or Plasma;Bilirub Direct SerPl-mCnc;;ACTIVE;1.0;2.73 +19687-3;Psilocybin;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Psilocybin [Presence] in Urine by Confirmatory method;Psilocybin Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19688-1;Psilocybin;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Psilocybin [Mass/volume] in Urine by Confirmatory method;Psilocybin Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19689-9;Psilocybin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Psilocybin [Mass/volume] in Urine;Deprecated Psilocybin Ur-mCnc;;DEPRECATED;1.0l;2.36 +19690-7;Psilocybin cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Psilocybin cutoff [Mass/volume] in Urine for Screen method;Psilocybin CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19691-5;Psilocybin cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Psilocybin cutoff [Mass/volume] in Urine for Confirmatory method;Psilocybin CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19692-3;Secobarbital;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Secobarbital [Presence] in Urine by Screen method;Secobarbital Ur Ql Scn;;ACTIVE;1.0l;2.73 +1969-5;Bilirubin renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Bilirubin.total renal clearance in 24 hour Urine and Serum or Plasma;Bilirub Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +19695-6;Secobarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Secobarbital [Mass/volume] in Urine;Secobarbital Ur-mCnc;;ACTIVE;1.0l;2.73 +19696-4;Secobarbital cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Secobarbital cutoff [Mass/volume] in Urine for Screen method;Secobarbital CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19697-2;Secobarbital cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Secobarbital cutoff [Mass/volume] in Urine for Confirmatory method;Secobarbital CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19698-0;Temazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Temazepam [Presence] in Urine by Screen method;Temazepam Ur Ql Scn;;ACTIVE;1.0l;2.73 +19700-4;Temazepam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Temazepam cutoff [Mass/volume] in Urine for Screen method;Temazepam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19701-2;Temazepam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Temazepam cutoff [Mass/volume] in Urine for Confirmatory method;Temazepam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19702-0;Tetrahydrocannabinol;ACnc;Pt;Urine;Ord;Screen;DRUG/TOX;1;Deprecated Tetrahydrocannabinol [Presence] in Urine by Screen method;Deprecated THC Ur Ql Scn;;DEPRECATED;1.0l;2.36 +1970-3;Bilirubin.albumin bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.delta [Mass/volume] in Serum or Plasma;Bilirub Delta SerPl-mCnc;;ACTIVE;1.0;2.73 +19703-8;Tetrahydrocannabinol;ACnc;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Deprecated Tetrahydrocannabinol [Presence] in Urine by Confirm method;Deprecated THC Ur Ql Cfm;;DEPRECATED;1.0l;2.36 +19704-6;Tetrahydrocannabinol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Deprecated Tetrahydrocannabinol cutoff [Mass/volume] in Urine for Screen method;Deprecated THC CtO Ur Scn-mCnc;;DEPRECATED;1.0l;2.36 +19705-3;Tetrahydrocannabinol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated Tetrahydrocannabinol cutoff [Mass/volume] in Urine for Confirm method;Deprecated THC CtO Ur Cfm-mCnc;;DEPRECATED;1.0l;2.36 +19706-1;Thioridazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Thioridazine [Presence] in Urine by Screen method;Thioridazine Ur Ql Scn;;ACTIVE;1.0l;2.73 +19707-9;Thioridazine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Thioridazine [Presence] in Urine by Confirmatory method;Thioridazine Ur Ql Cfm;;ACTIVE;1.0l;2.73 +19708-7;Thioridazine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Thioridazine cutoff [Mass/volume] in Urine for Screen method;Thioridazine CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19709-5;Thioridazine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Thioridazine cutoff [Mass/volume] in Urine for Confirmatory method;Thioridazine CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19710-3;traMADol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;traMADol [Presence] in Urine by Screen method;traMADol Ur Ql Scn;;ACTIVE;1.0l;2.73 +1971-1;Bilirubin.non-glucuronidated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.indirect [Mass/volume] in Serum or Plasma;Bilirub Indirect SerPl-mCnc;;ACTIVE;1.0;2.73 +19712-9;traMADol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;traMADol cutoff [Mass/volume] in Urine for Screen method;traMADol CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.73 +19713-7;traMADol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;traMADol cutoff [Mass/volume] in Urine for Confirmatory method;traMADol CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.73 +19714-5;Triazolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Triazolam [Presence] in Urine by Screen method;Triazolam Ur Ql Scn;;ACTIVE;1.0l;2.56 +19716-0;Triazolam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Triazolam cutoff [Mass/volume] in Urine for Screen method;Triazolam CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.42 +19717-8;Triazolam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Triazolam cutoff [Mass/volume] in Urine for Confirmatory method;Triazolam CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19718-6;Trichlorothiazide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Trichlorothiazide [Presence] in Urine by Screen method;TCT Ur Ql Scn;;ACTIVE;1.0l;2.56 +19719-4;Trichlorothiazide;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Trichlorothiazide [Presence] in Urine by Confirmatory method;TCT Ur Ql Cfm;;ACTIVE;1.0l;2.56 +19720-2;Trichlorothiazide;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Trichlorothiazide [Mass/volume] in Urine by Confirmatory method;TCT Ur Cfm-mCnc;;ACTIVE;1.0l;2.42 +19721-0;Trichlorothiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trichlorothiazide [Mass/volume] in Urine;TCT Ur-mCnc;;ACTIVE;1.0l;2.42 +19722-8;Trichlorothiazide cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Trichlorothiazide cutoff [Mass/volume] in Urine for Screen method;TCT CtO Ur Scn-mCnc;;ACTIVE;1.0l;2.44 +19723-6;Trichlorothiazide cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Trichlorothiazide cutoff [Mass/volume] in Urine for Confirmatory method;TCT CtO Ur Cfm-mCnc;;ACTIVE;1.0l;2.44 +19724-4;Triplochiton scleroxylon Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Abachi Wood Dust IgE Ab [Units/volume] in Serum;Abachi Wood Dust IgE Qn;;ACTIVE;1.0l;2.42 +19725-1;Aspergillus flavus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus flavus IgG Ab [Presence] in Serum;A flavus IgG Ser Ql;;ACTIVE;1.0l;2.73 +19726-9;Aspergillus fumigatus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus IgG Ab [Presence] in Serum;A fumigatus IgG Ser Ql;;ACTIVE;1.0l;2.73 +19727-7;Aspergillus niger Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus niger IgG Ab [Presence] in Serum;A niger IgG Ser Ql;;ACTIVE;1.0l;2.73 +19728-5;Beet Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beet IgE Ab [Units/volume] in Serum;Beet IgE Qn;;ACTIVE;1.0l;2.73 +1972-9;Bilirubin;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Amniotic fluid;Bilirub Amn-mCnc;;ACTIVE;1.0;2.73 +19729-3;Lathyrus sativus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blue vetch IgE Ab [Units/volume] in Serum;Blue vetch IgE Qn;;ACTIVE;1.0l;2.42 +19730-1;Budgerigar droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Budgerigar droppings IgE Ab [Units/volume] in Serum;Deprecated Budgie Drop IgE Qn;;DEPRECATED;1.0l;2.69 +19731-9;Budgerigar serum proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Budgerigar serum proteins IgE Ab [Units/volume] in Serum;Deprecated Budgie Serum Prot IgE Qn;;DEPRECATED;1.0l;2.69 +19732-7;Cat serum albumin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cat serum albumin IgE Ab [Units/volume] in Serum;Cat Serum Alb IgE Qn;;ACTIVE;1.0l;2.42 +19733-5;Cefaclor Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cefaclor IgE Ab [Units/volume] in Serum;Cefaclor IgE Qn;;ACTIVE;1.0l;2.73 +19734-3;Chicken droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicken droppings IgE Ab [Units/volume] in Serum;Chicken Drop IgE Qn;;ACTIVE;1.0l;2.73 +19735-0;Dactylis glomerata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cocksfoot IgE Ab [Units/volume] in Serum;Deprecated Cocksfoot IgE Qn;;DEPRECATED;1.0l;2.69 +19736-8;Coralbumin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coralbumin IgE Ab [Units/volume] in Serum;Coralb IgE Qn;;ACTIVE;1.0l;2.42 +1973-7;Bilirubin;MCnc;Pt;CSF;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Cerebral spinal fluid;Bilirub CSF-mCnc;;ACTIVE;1.0;2.38 +19737-6;Cotton fibers Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cotton fibers IgE Ab [Units/volume] in Serum;Cotton Fibers IgE Qn;;ACTIVE;1.0l;2.73 +19738-4;Dog serum albumin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog serum albumin IgE Ab [Units/volume] in Serum;Dog Serum Alb IgE Qn;;ACTIVE;1.0l;2.42 +19739-2;Trigonella foenum-graecum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fenugreek IgE Ab [Units/volume] in Serum;Fenugreek IgE Qn;;ACTIVE;1.0l;2.42 +197-4;Cloxacillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cloxacillin [Susceptibility] by Minimum inhibitory concentration (MIC);Cloxacillin Islt MIC;;ACTIVE;1.0;2.19 +19740-0;Fox epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fox epithelium IgE Ab [Units/volume] in Serum;Fox Epith IgE Qn;;ACTIVE;1.0l;2.42 +19741-8;Merluccius merluccius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hake IgE Ab [Units/volume] in Serum;Hake IgE Qn;;ACTIVE;1.0l;2.73 +19742-6;Hexahydrophthalic anhydride Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hexahydrophthalic anhydride (HHPA) IgE Ab [Units/volume] in Serum;HHPA IgE Qn;;ACTIVE;1.0l;2.54 +19743-4;Horse meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse meat IgE Ab [Units/volume] in Serum;Horse Meat IgE Qn;;ACTIVE;1.0l;2.42 +19744-2;Artocarpus heterophyllus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Jackfruit IgE Ab [Units/volume] in Serum;Jackfruit IgE Qn;;ACTIVE;1.0l;2.73 +1974-5;Bilirubin;MCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Body fluid;Bilirub Fld-mCnc;;ACTIVE;1.0;2.73 +19745-9;Linum usitatissimum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Flax IgE Ab [Units/volume] in Serum;Deprecated Flax IgE Qn;;DEPRECATED;1.0l;2.69 +19746-7;Maleic anhydride Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Maleic anhydride IgE Ab [Units/volume] in Serum;Maleic Anhydride IgE Qn;;ACTIVE;1.0l;2.42 +19747-5;Tenebrio mollitor Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mealworm IgE Ab [Units/volume] in Serum;Mealworm IgE Qn;;ACTIVE;1.0l;2.42 +19748-3;Methyltetrahydrophthalic anhydride Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Methyltetrahydrophthalic anhydride (MTHPA) IgE Ab [Units/volume] in Serum;MTHPA IgE Qn;;ACTIVE;1.0l;2.54 +19749-1;Saccharopolyspora rectivirgula Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saccharopolyspora rectivirgula IgG Ab [Presence] in Serum;S rectivirgula IgG Ql;;ACTIVE;1.0l;2.56 +19750-9;Mentha piperita Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Mint IgE Ab [Units/volume] in Serum;Deprecated Mint IgE Qn;;DEPRECATED;1.0l;2.69 +19751-7;Mouse epithelium+Serum proteins+Urine proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse epithelium, serum proteins + urine proteins IgE Ab [Units/volume] in Serum;Mouse Epith+Ser+Ur Prot IgE Qn;;ACTIVE;1.0l;2.73 +1975-2;Bilirubin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Serum or Plasma;Bilirub SerPl-mCnc;;ACTIVE;1.0;2.73 +19752-5;Pigeon serum Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon serum IgG Ab [Presence] in Serum;Pigeon Serum IgG Ql;;ACTIVE;1.0l;2.73 +19753-3;Rat epithelium+Serum proteins+Urine proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rat epithelium, serum proteins + urine proteins IgE Ab [Units/volume] in Serum;Rat Epith+Ser+Ur IgE Qn;;ACTIVE;1.0l;2.73 +19754-1;Ribes sylvestre Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Currant IgE Ab [Units/volume] in Serum;Red Currant IgE Qn;;ACTIVE;1.0l;2.42 +19755-8;Crocus sativus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saffron IgE Ab [Units/volume] in Serum;Saffron IgE Qn;;ACTIVE;1.0l;2.73 +19756-6;Sheep milk Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep milk IgE Ab [Units/volume] in Serum;Sheep Milk IgE Qn;;ACTIVE;1.0l;2.73 +19757-4;Sheep whey Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep whey IgE Ab [Units/volume] in Serum;Sheep Whey IgE Qn;;ACTIVE;1.0l;2.42 +19758-2;Silk waste Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silk waste IgE Ab [Units/volume] in Serum;Silk Waste IgE Qn;;ACTIVE;1.0l;2.73 +19759-0;Swine serum albumin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swine serum albumin IgE Ab [Units/volume] in Serum;Swine Serum Alb IgE Qn;;ACTIVE;1.0l;2.42 +1976-0;Bilirubin;PrThr;Pt;Stool;Ord;;CHEM;1;Bilirubin.total [Presence] in Stool;Bilirub Stl Ql;;ACTIVE;1.0;2.73 +19760-8;Clostridium tetani toxoid Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clostridium tetani toxoid IgE Ab [Units/volume] in Serum;C tetani Toxoid IgE Qn;;ACTIVE;1.0l;2.73 +19761-6;Thermoactinomyces vulgaris Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Thermoactinomyces vulgaris IgG Ab [Presence] in Serum;T vulgaris IgG Ser Ql;;ACTIVE;1.0l;2.56 +19762-4;General categories;Imp;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;General categories [Interpretation] of Cervical or vaginal smear or scraping by Cyto stain;Gen Categ Cvx/Vag Cyto-Imp;;ACTIVE;1.0l;2.73 +19763-2;Specimen source;Prid;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Specimen source [Identifier] in Cervical or vaginal smear or scraping by Cyto stain;Specimen source Cvx/Vag Cyto;;ACTIVE;1.0l;2.73 +19764-0;Statement of adequacy;Imp;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Statement of adequacy [Interpretation] of Cervical or vaginal smear or scraping by Cyto stain;Stat of Adq Cvx/Vag Cyto-Imp;;ACTIVE;1.0l;2.73 +19765-7;Microscopic observation;Prid;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Cervical or vaginal smear or scraping by Cyto stain;Cyto Cvx/Vag;;ACTIVE;1.0l;2.73 +19766-5;Microscopic observation;Prid;Pt;Cvx/Vag;Nar;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Cervical or vaginal smear or scraping by Cyto stain Narrative;Cyto Cvx/Vag;;ACTIVE;1.0l;2.73 +19767-3;Cytologist;ID;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Cytologist who read Cyto stain of Cervical or vaginal smear or scraping;Cytologist Cvx/Vag Cyto;;ACTIVE;1.0l;2.73 +19768-1;Reviewing cytologist;ID;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Reviewing cytologist who read Cyto stain of Cervical or vaginal smear or scraping;Reviewing cytologist;;ACTIVE;1.0l;2.73 +19769-9;Pathologist;ID;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Pathologist who read Cyto stain of Cervical or vaginal smear or scraping;Pathologist Cvx/Vag Cyto;;ACTIVE;1.0l;2.73 +19770-7;Specimen source;Prid;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Deprecated Specimen source [Identifier] in Cervical or vaginal smear or scraping by Cyto stain;Deprecated Specimen source Cvx/Vag Cyto;;DEPRECATED;1.0l;2.36 +19771-5;Screen techniques;Prid;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Screening techniques [Identifier] in Cervical or vaginal smear or scraping by Cyto stain;Screen Tech Cvx/Vag Cyto;;ACTIVE;1.0l;2.73 +19772-3;Preparation techniques;Type;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Preparation techniques [Type] in Cervical or vaginal smear or scraping by Cyto stain;Prep Tech Cvx/Vag Cyto;;ACTIVE;1.0l;2.73 +19773-1;Recommended follow-up;Prid;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Recommended follow-up [Identifier] in Cervical or vaginal smear or scraping by Cyto stain;Recom F/U Cvx/Vag Cyto;;ACTIVE;1.0l;2.73 +19774-9;Cytology study comment;Imp;Pt;Cvx/Vag;Nar;Cyto stain;CYTO;1;Cytology study comment Cervical or vaginal smear or scraping Cyto stain;Cytology Cmnt Cvx/Vag Cyto-Imp;;ACTIVE;1.0l;2.73 +19775-6;Relevant Hx and Px for procedure;Find;Pt;^Patient;Nar;Endoscopy;ENDO.GI;2;Relevant Hx and Px for procedure Narrative Endoscopy;Relevant H&P Endoscopy;;ACTIVE;1.0l;2.40 +19776-4;Relevant Hx and Px for procedure;Find;Pt;^Patient;Nom;Endoscopy;ENDO.GI;2;Relevant Hx and Px for procedure Endoscopy;Relevant H&P Endoscopy;;ACTIVE;1.0l;2.27 +19777-2;Indications;Find;Pt;^Patient;Nom;Endoscopy;ENDO.GI;2;Indications Endoscopy;Indications Endoscopy;;ACTIVE;1.0l;2.27 +1977-8;Bilirubin;PrThr;Pt;Urine;Ord;;CHEM;1;Bilirubin.total [Presence] in Urine;Bilirub Ur Ql;;ACTIVE;1.0;2.73 +19778-0;Indications description;Find;Pt;^Patient;Nar;Endoscopy;ENDO.GI;2;Indications description Narrative Endoscopy;Indications description Endoscopy;;ACTIVE;1.0l;2.40 +19779-8;Procedure;Type;Pt;Endoscopy study;Nom;Endoscopy;ENDO.GI;2;Procedure Endoscopy;Procedure Endoscopy;;ACTIVE;1.0l;2.29 +19780-6;Procedure description;Desc;Pt;Endoscopy study;Nar;Endoscopy;ENDO.GI;2;Procedure description Narrative Endoscopy;Proc desc Endoscopy;;ACTIVE;1.0l;2.40 +19781-4;Procedure monitoring parameters;Type;Stdy;Endoscopy study;Nom;;ENDO.GI;2;Procedure monitoring parameters Endoscopy study;Proc monit parameters Endoscopy stdy;;ACTIVE;1.0l;2.29 +19782-2;Procedure monitoring description;Desc;Stdy;Endoscopy study;Nar;;ENDO.GI;2;Procedure monitoring description Endoscopy study Narrative;Proc monit desc Endoscopy stdy;;ACTIVE;1.0l;2.40 +19783-0;Class;Type;Pt;Endoscopy device;Nom;;ENDO.GI;2;Type of Endoscopy device;Endoscopy device Class;;ACTIVE;1.0l;2.27 +19784-8;Institution inventory number;ID;Pt;Endoscopy device;Nom;;ENDO.GI;2;Endoscopy device Institution inventory number;Endoscopy device Inventory #;;ACTIVE;1.0l;2.50 +19785-5;Vendor model number;ID;Pt;Endoscopy device;Nom;;ENDO.GI;2;Endoscopy device Vendor model number;Model # Endoscopy device;;ACTIVE;1.0l;2.50 +1978-6;Bilirubin;MCnc;Pt;Urine;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Urine;Bilirub Ur-mCnc;;ACTIVE;1.0;2.73 +19786-3;Vendor serial number;ID;Pt;Endoscopy device;Nom;;ENDO.GI;2;Endoscopy device Vendor serial number;Serial # Endoscopy device;;ACTIVE;1.0l;2.50 +19787-1;Cleaning method;Type;Pt;Endoscopy device;Nom;;ENDO.GI;2;Cleaning method Endoscopy device;Cleaning method Endoscopy device;;ACTIVE;1.0l;2.73 +19788-9;Date and time of cleaning;TmStp;Pt;Endoscopy device;Qn;;ENDO.GI;2;Date and time of cleaning Endoscopy device;Date+time of cleaning Endoscopy device;;ACTIVE;1.0l;2.56 +19789-7;Medications;Prid;Stdy;^Patient;Nom;;ENDO.GI;2;Medications [Identifier];Medications;;ACTIVE;1.0l;2.27 +19790-5;Medication administration;Find;Stdy;^Patient;Nar;;ENDO.GI;2;Medication administration Narrative;Medication administration;;ACTIVE;1.0l;2.40 +19791-3;Insertion depth;Len;Stdy;Gastrointestinal tract.upper;Qn;EGD;ENDO.GI;2;Insertion depth Gastrointestinal tract upper EGD;Insert depth UGI EGD;;ACTIVE;1.0l;2.56 +19792-1;Examination extent landmark;Anat;Stdy;Gastrointestinal tract.upper;Nom;EGD;ENDO.GI;2;Examination extent landmark Gastrointestinal tract upper EGD;Exam extent landmark UGI EGD;;ACTIVE;1.0l;2.56 +19793-9;Examination extent landmark;Desc;Stdy;Biliary duct;Nar;ERCP;ENDO.GI;2;Examination extent landmark [Description] Biliary duct Narrative ERCP;Exam extent landmark BD ERCP;;ACTIVE;1.0l;2.40 +1979-4;Biopterin;MCnc;24H;Urine;Qn;;CHEM;1;Biopterin [Mass/volume] in 24 hour Urine;Biopterin 24h Ur-mCnc;;ACTIVE;1.0;2.42 +19794-7;Examination extent landmark;Anat;Stdy;Pancreatic duct;Nom;ERCP;ENDO.GI;2;Examination extent landmark Pancreatic duct ERCP;Exam extent landmark PD ERCP;;ACTIVE;1.0l;2.29 +19795-4;Insertion depth;Len;Stdy;Gastrointestinal tract.lower;Qn;Flexible sigmoidoscopy;ENDO.GI;2;Insertion depth Gastrointestinal tract lower Flexible sigmoidoscopy;Insert depth LGI FSIG;;ACTIVE;1.0l;2.56 +19796-2;Examination extent landmark;Anat;Stdy;Gastrointestinal tract.lower;Nom;Flexible sigmoidoscopy;ENDO.GI;2;Examination extent landmark Gastrointestinal tract lower Flexible sigmoidoscopy;Exam extent landmark LGI FSIG;;ACTIVE;1.0l;2.56 +19797-0;Examination extent landmark;Desc;Stdy;Abdomen;Nar;Lap;ENDO.GI;2;Examination extent landmark [Description] Abdomen Narrative Laparoscopy;Exam extent landmark Abd LAP;;ACTIVE;1.0l;2.40 +19798-8;Limitations of examination;Type;Stdy;Endoscopy procedure;Nom;;ENDO.GI;2;Limitations of examination Endoscopy procedure;Limits of exam Endoscopy;;ACTIVE;1.0l;2.29 +19799-6;Limitations of examination;Desc;Stdy;Endoscopy procedure;Nar;;ENDO.GI;2;Limitations of examination [Description] Endoscopy procedure Narrative;Limits of exam Endoscopy;;ACTIVE;1.0l;2.40 +19800-2;Number of specimens obtained;Num;Stdy;Gastrointestinal tract.upper;Qn;EGD;ENDO.GI;2;Number of specimens obtained Gastrointestinal tract upper EGD;# spec obtained UGI EGD;;ACTIVE;1.0l;2.56 +19801-0;Specimen obtained;Anat;Stdy;Gastrointestinal tract.upper;Nom;EGD;ENDO.GI;2;Specimen obtained [Anatomy] Gastrointestinal tract upper EGD;Specimen obtained UGI EGD;;ACTIVE;1.0l;2.56 +1980-2;Biotin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Biotin [Mass/volume] in Serum or Plasma;Biotin SerPl-mCnc;;ACTIVE;1.0;2.73 +19802-8;Specimen obtained;Type;Stdy;Gastrointestinal tract.upper;Nom;EGD;ENDO.GI;2;Specimen obtained Gastrointestinal tract upper EGD;Specimen type obtained UGI EGD;;ACTIVE;1.0l;2.56 +19803-6;Specimen site;Type;Stdy;*;Nar;;ENDO.GI;2;Specimen site Narrative;Specimen site;;ACTIVE;1.0l;2.73 +19804-4;Study observation;Find;Stdy;Endoscopy procedure;Nom;;ENDO.GI;2;Endoscopy procedure Study observation;Endoscopy study;;ACTIVE;1.0l;2.38 +19805-1;Study observation;Find;Stdy;Endoscopy procedure;Nar;;ENDO.GI;2;Endoscopy procedure Study observation Narrative;Endoscopy study;;ACTIVE;1.0l;2.40 +19806-9;Diagnosis;Imp;Stdy;Gastrointestinal tract.upper;Nom;;ENDO.GI;2;Diagnosis Gastrointestinal tract upper;Dx UGI;;ACTIVE;1.0l;2.56 +19807-7;Diagnosis;Imp;Stdy;Biliary duct+Pancreatic duct;Nom;;ENDO.GI;2;Diagnosis Biliary duct and Pancreatic duct;Dx BD+PD;;ACTIVE;1.0l;2.38 +19808-5;Diagnosis;Imp;Stdy;Gastrointestinal tract.lower;Nom;;ENDO.GI;2;Diagnosis Gastrointestinal tract lower;Dx LGI;;ACTIVE;1.0l;2.56 +19809-3;Diagnosis;Imp;Stdy;Abdomen;Nom;;ENDO.GI;2;Diagnosis Abdomen;Dx Abd;;ACTIVE;1.0l;2.27 +1981-0;Biotinidase;PrThr;Pt;Bld;Ord;;CHEM;1;Biotinidase [Presence] in Blood;Biotinidase Bld Ql;;ACTIVE;1.0;2.73 +19810-1;Diagnosis;Imp;Stdy;Endoscopy procedure.XXX;Nom;;ENDO.GI;2;Diagnosis Endoscopy Procedure;Dx Endoscopy proc;;ACTIVE;1.0l;2.27 +19811-9;Diagnosis;Imp;Stdy;Endoscopy procedure.XXX;Nar;;ENDO.GI;2;Diagnosis Endoscopy Procedure Narrative;Dx Endoscopy proc;;ACTIVE;1.0l;2.40 +19812-7;Therapeutic intervention;Desc;Stdy;Endoscopy procedure;Nom;;ENDO.GI;2;Therapeutic intervention Endoscopy procedure;Therapeutic intervention Endoscopy;;ACTIVE;1.0l;2.29 +19813-5;Therapeutic intervention;Desc;Stdy;Endoscopy procedure;Nar;;ENDO.GI;2;Therapeutic intervention [Description] Endoscopy procedure Narrative;Therapeutic intervention Endoscopy;;ACTIVE;1.0l;2.40 +19814-3;Therapeutic results;Imp;Stdy;Endoscopy procedure;Nom;;ENDO.GI;2;Therapeutic results [Interpretation] Endoscopy procedure;Therapeutic results Imp Endoscopy;;ACTIVE;1.0l;2.50 +19815-0;Therapeutic results;Desc;Stdy;Endoscopy procedure;Nar;;ENDO.GI;2;Therapeutic results [Description] Endoscopy procedure Narrative;Therapeutic results Endoscopy;;ACTIVE;1.0l;2.40 +19816-8;Images taken;Arb;Stdy;Endoscopy procedure;Ord;;ENDO.GI;2;Images taken Endoscopy procedure;Images taken Endoscopy;;ACTIVE;1.0l;2.27 +19817-6;Complications;Type;Stdy;^Patient;Nom;;ENDO.GI;2;Complications;Complications;;ACTIVE;1.0l;2.27 +19818-4;Complications;Desc;Stdy;^Patient;Nar;;ENDO.GI;2;Deprecated Complications - description;DeprecatedComplications;;DEPRECATED;1.0l;2.40 +19819-2;Instructions post GI procedure;Instrct;Pt;^Patient;Nar;;ENDO.GI;2;Post GI procedure instructions [Instructions] Narrative;Post GI proc instructions;;ACTIVE;1.0l;2.40 +198-2;Cloxacillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cloxacillin [Susceptibility] by Disk diffusion (KB);Cloxacillin Islt KB;;ACTIVE;1.0;2.21 +19820-0;Return visit post GI procedure;Instrct;Pt;^Patient;Nar;;ENDO.GI;2;Return visit post GI procedure [Instructions] Narrative;Return visit p GI proc;;ACTIVE;1.0l;2.40 +19821-8;Return visit post GI procedure;TmStp;Pt;^Patient;Qn;;ENDO.GI;2;Return visit post GI procedure [Date and time];Return visit p GI proc TmStp;;ACTIVE;1.0l;2.27 +19822-6;Return visit clinic post GI procedure;Loc;Pt;^Patient;Nar;;ENDO.GI;2;Return visit clinic post GI procedure [Location] Narrative;Return visit clinic p GI proc;;ACTIVE;1.0l;2.40 +19823-4;Return visit post GI procedure;Tele;Pt;^Patient;Nom;;ENDO.GI;2;Return visit post GI procedure [Telephone number];Return visit p GI proc Tele;;ACTIVE;1.0l;2.27 +19824-2;Return visit conditions;Find;Pt;^Patient;Nom;;ENDO.GI;2;Return visit conditions;Return visit conditions;;ACTIVE;1.0l;2.50 +19825-9;Facility location;Prid;Pt;Endoscopy procedure;Nom;;ENDO.GI;2;Facility location [Identifier] Endoscopy procedure;Facility location Endoscopy;;ACTIVE;1.0l;2.27 +19826-7;Informed consent obtained;Arb;Pt;^Patient;Ord;;ENDO.GI;2;Informed consent obtained;Informed consent obtained;;ACTIVE;1.0l;2.27 +19827-5;Apnea monitor alarm type;Type;Pt;Apnea monitor;Nom;;PULM;2;Apnea monitor alarm type;Apnea monitor alarm type;;ACTIVE;1.0l;2.29 +1982-8;Biotinidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Biotinidase [Enzymatic activity/volume] in Serum or Plasma;Biotinidase SerPl-cCnc;;ACTIVE;1.0;2.73 +19828-3;Breaths max setting;NRat;Pt;Ventilator XXX;Qn;;PULM;2;Breaths maximum setting Ventilator;Breaths max setting Vent;;ACTIVE;1.0l;2.42 +19829-1;Breaths max setting;NRat;Pt;Ventilator.alarm;Qn;;PULM;2;Breaths maximum setting Ventilator alarm;Breaths max setting Vent alarm;;ACTIVE;1.0l;2.42 +19830-9;Breaths max setting;NRat;Pt;Apnea monitor;Qn;;PULM;2;Breaths maximum setting Apnea monitor;Breaths max setting Apnea Monitor;;ACTIVE;1.0l;2.42 +19831-7;Breaths min setting;NRat;Pt;Ventilator;Qn;;PULM;2;Breath rate minimum setting Ventilator;Breaths min setting Vent;;ACTIVE;1.0l;2.66 +19832-5;Breaths min setting;NRat;Pt;Ventilator.alarm;Qn;;PULM;2;Breath rate minimum setting Ventilator alarm;Breaths min setting Vent alarm;;ACTIVE;1.0l;2.42 +19833-3;Breaths min setting;NRat;Pt;Apnea monitor;Qn;;PULM;2;Breath rate minimum setting Apnea monitor;Breaths min setting Apnea Monitor;;ACTIVE;1.0l;2.42 +19834-1;Breaths setting;NRat;Pt;Ventilator;Qn;;PULM;2;Breath rate setting Ventilator;Breaths setting Vent;;ACTIVE;1.0l;2.73 +19835-8;Breaths setting;NRat;Pt;Ventilator.synchronized intermittent mandatory;Qn;;PULM;2;Breath rate setting Ventilator synchronized intermittent mandatory;Breaths setting SIMV;;ACTIVE;1.0l;2.73 +1983-6;Bradykinin;MCnc;Pt;Ser/Plas;Qn;;COAG;1;Bradykinin [Mass/volume] in Serum or Plasma;Bradykinin SerPl-mCnc;;ACTIVE;1.0;2.42 +19836-6;Breaths setting;NRat;Pt;Ventilator.intermitten mandatory;Qn;;PULM;2;Breath rate setting Intermittent mandatory ventilator;Breaths setting IMV;;ACTIVE;1.0l;2.42 +19837-4;Breaths setting;NRat;Pt;Ventilator.neonatal;Qn;;PULM;2;Breath rate setting Neonatal ventilator;Breaths setting Neo Vent;;ACTIVE;1.0l;2.42 +19838-2;Breaths.sigh setting;NRat;Pt;Ventilator;Qn;;PULM;2;Sigh rate setting Ventilator;Breaths.sigh setting Vent;;ACTIVE;1.0l;2.42 +19839-0;Breaths.spontaneous^on ventilator;NRat;Pt;Respiratory system;Qn;;PULM;2;Breath rate spontaneous --on ventilator;Breaths.spontaneous on vent;;ACTIVE;1.0l;2.73 +19840-8;Breaths.spontaneous+mechanical^on ventilator;NRat;Pt;Respiratory system;Qn;;PULM;2;Breath rate spontaneous and mechanical --on ventilator;Breaths.spont+mech on vent;;ACTIVE;1.0l;2.73 +19841-6;Breaths^at maximum voluntary ventilation;NRat;Pt;Respiratory system;Qn;Spirometry;PULM;2;Respiratory rate by Spirometry --at maximum voluntary ventilation;Resp rate @ max vol vent Spirometry;;ACTIVE;1.0l;2.42 +19842-4;Breaths^at maximum voluntary ventilation;NRat;Pt;Respiratory system;Qn;;PULM;2;Respiratory rate --at maximum voluntary ventilation;Resp rate @ max vol vent;;ACTIVE;1.0l;2.42 +19843-2;Capacity.functional residual;Vol;Pt;Respiratory system;Qn;;PULM;2;Functional residual capacity;FRC;;ACTIVE;1.0l;2.48 +1984-4;Bromide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromide [Mass/volume] in Serum or Plasma;Bromide SerPl-mCnc;;ACTIVE;1.0;2.73 +19844-0;Capacity.functional residual;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Functional residual capacity by Helium rebreathing;FRC He Rebreath;;ACTIVE;1.0l;2.48 +19845-7;Capacity.functional residual;Vol;Pt;Respiratory system;Qn;Helium single breath;PULM;2;Functional residual capacity by Helium single breath;FRC He SB;;ACTIVE;1.0l;2.48 +19846-5;Capacity.functional residual;Vol;Pt;Respiratory system;Qn;Plethysmograph.body box;PULM;2;Functional residual capacity by Plethysmograph body box;FRC Plethysmograph;;ACTIVE;1.0l;2.48 +19847-3;Capacity.functional residual;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;Functional residual capacity Predicted;FRC Predicted;;ACTIVE;1.0l;2.40 +19848-1;Capacity.inspiratory;Vol;Pt;Respiratory system;Qn;;PULM;2;Inspiratory capacity;IC;;ACTIVE;1.0l;2.48 +19849-9;Capacity.inspiratory;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Inspiratory capacity by Helium rebreathing;IC He Rebreath;;ACTIVE;1.0l;2.48 +19850-7;Capacity.inspiratory;Vol;Pt;Respiratory system;Qn;Helium single breath;PULM;2;Inspiratory capacity by Helium single breath;IC He SB;;ACTIVE;1.0l;2.48 +1985-1;Bromide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bromide [Mass/volume] in Urine;Bromide Ur-mCnc;;ACTIVE;1.0;2.73 +19851-5;Capacity.inspiratory;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;Inspiratory capacity Predicted;IC Predicted;;ACTIVE;1.0l;2.73 +19852-3;Capacity.inspiratory;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Inspiratory capacity by Spirometry;IC Spirometry;;ACTIVE;1.0l;2.48 +19853-1;Capacity.inspiratory.bs/Capacity.inspiratory.preop;RelVol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Inspiratory capacity bs/Inspiratory capacity pre-operative by Spirometry;IC bs/pre-op Spirometry;;ACTIVE;1.0l;2.48 +19854-9;Capacity.inspiratory.bs/Capacity.inspiratory.preop;RelVol;Pt;Respiratory system;Qn;;PULM;2;Inspiratory capacity bs/Inspiratory capacity pre-operative;IC bs/pre-op;;ACTIVE;1.0l;2.48 +19855-6;Capacity.inspiratory/predicted;RelVol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Inspiratory capacity measured/predicted by Spirometry;IC meas/pred Spirometry;;ACTIVE;1.0l;2.66 +19856-4;Capacity.inspiratory/predicted;RelVol;Pt;Respiratory system;Qn;;PULM;2;Inspiratory capacity measured/predicted;IC meas/pred;;ACTIVE;1.0l;2.66 +19857-2;Capacity.total;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Total lung capacity by Helium rebreathing;TLC He Rebreath;;ACTIVE;1.0l;2.48 +19858-0;Capacity.total;Vol;Pt;Respiratory system;Qn;Helium single breath;PULM;2;Total lung capacity by Helium single breath;TLC He SB;;ACTIVE;1.0l;2.48 +19859-8;Capacity.total;Vol;Pt;Respiratory system;Qn;Plethysmograph.body box;PULM;2;Total lung capacity by Plethysmograph body box;TLC Plethysmograph;;ACTIVE;1.0l;2.48 +19860-6;Capacity.total;Vol;Pt;Respiratory system;Qn;Chest xray.calculated;PULM;2;Total lung capacity by Chest xray.calculated;TLC Chest Xray.calc;;ACTIVE;1.0l;2.48 +19861-4;Capacity.total;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;Total lung capacity Predicted;TLC Predicted;;ACTIVE;1.0l;2.40 +19862-2;Capacity.total;Vol;Pt;Respiratory system;Qn;;PULM;2;Total lung capacity;TLC;;ACTIVE;1.0l;2.73 +19863-0;Vital capacity;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Vital capacity [Volume] Respiratory system by Helium rebreathing;VC Vol Respiratory He Rebreath;;ACTIVE;1.0l;2.48 +19864-8;Vital capacity;Vol;Pt;Respiratory system;Qn;Helium single breath;PULM;2;Vital capacity [Volume] Respiratory system by Helium single breath;VC Vol Respiratory He SB;;ACTIVE;1.0l;2.48 +19865-5;Vital capacity;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;Vital capacity [Volume] Respiratory system Predicted;VC Vol Respiratory Predicted;;ACTIVE;1.0l;2.40 +19866-3;Vital capacity;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Vital capacity [Volume] Respiratory system by Spirometry;VC Vol Respiratory Spirometry;;ACTIVE;1.0l;2.40 +19867-1;Vital capacity;Vol;Pt;Respiratory system;Qn;;PULM;2;Vital capacity [Volume] Respiratory system;VC Vol Respiratory;;ACTIVE;1.0l;2.48 +19868-9;Forced vital capacity;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Forced vital capacity [Volume] Respiratory system by Spirometry;FVC Vol Respiratory Spirometry;;ACTIVE;1.0l;2.73 +1986-9;C peptide;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;C peptide [Mass/volume] in Serum or Plasma;C peptide SerPl-mCnc;;ACTIVE;1.0;2.73 +19869-7;Forced vital capacity;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;Forced vital capacity [Volume] Respiratory system Predicted;FVC Vol Respiratory Predicted;;ACTIVE;1.0l;2.73 +19870-5;Forced vital capacity;Vol;Pt;Respiratory system;Qn;;PULM;2;Forced vital capacity [Volume] Respiratory system;FVC Vol Respiratory;;ACTIVE;1.0l;2.73 +19871-3;Forced vital capacity/Forced vital capacity.predicted^pre bronchodilation;RelVol;Pt;Respiratory system;Qn;;PULM;2;FVC pre bronchodilation measured/predicted;FVC pre BD meas/pred;;ACTIVE;1.0l;2.73 +19872-1;Forced vital capacity/Forced vital capacity.predicted;RelVol;Pt;Respiratory system;Qn;;PULM;2;FVC measured/predicted;FVC meas/pred;;ACTIVE;1.0l;2.66 +19873-9;Forced vital capacity/Forced vital capacity.predicted^post bronchodilation;RelVol;Pt;Respiratory system;Qn;;PULM;2;FVC post bronchodilation measured/predicted;FVC p BD meas/pred;;ACTIVE;1.0l;2.66 +19874-7;Forced vital capacity^post bronchodilation;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Forced vital capacity [Volume] Respiratory system by Spirometry --post bronchodilation;FVC p BD Vol Respiratory Spirometry;;ACTIVE;1.0l;2.40 +19875-4;Forced vital capacity^post bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Forced vital capacity [Volume] Respiratory system --post bronchodilation;FVC p BD Vol Respiratory;;ACTIVE;1.0l;2.73 +19876-2;Forced vital capacity^pre bronchodilation;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation;FVC pre BD Vol Respiratory Spirometry;;ACTIVE;1.0l;2.40 +1987-7;C peptide;MCnc;Pt;Urine;Qn;;CHEM;1;C peptide [Mass/volume] in Urine;C peptide Ur-mCnc;;ACTIVE;1.0;2.73 +19877-0;Forced vital capacity^pre bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Forced vital capacity [Volume] Respiratory system --pre bronchodilation;FVC pre BD Vol Respiratory;;ACTIVE;1.0l;2.73 +19878-8;Carbon dioxide;PPres;8H^max;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] (8 hour maximum) in Capillary blood Transcutaneous CO2 monitor;pCO2 8h Max BldC TcCo2;;ACTIVE;1.0l;2.54 +19879-6;Carbon dioxide;PPres;8H^max;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] (8 hour maximum) in Capillary blood;pCO2 8h Max BldC;;ACTIVE;1.0l;2.54 +19880-4;Carbon dioxide;PPres;8H^min;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] (8 hour minimum) in Capillary blood Transcutaneous CO2 monitor;pCO2 8h Min BldC TcCo2;;ACTIVE;1.0l;2.54 +19881-2;Carbon dioxide;PPres;8H^min;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] (8 hour minimum) in Capillary blood;pCO2 8h Min BldC;;ACTIVE;1.0l;2.54 +19882-0;Carbon dioxide;PPres;Pt;Ventilator airway circuit;Qn;Infrared absorption;PULM;2;Carbon dioxide [Partial pressure] in Ventilator airway circuit by Infrared absorption;pCO2 Vent airway circuit IR Abs;;ACTIVE;1.0l;2.30 +19883-8;Carbon dioxide;PPres;Pt;Ventilator airway circuit;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Ventilator airway circuit;pCO2 Vent airway circuit;;ACTIVE;1.0l;2.30 +19884-6;Carbon dioxide;PPres;Pt;Bld.preductal;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Blood Preductal by Transcutaneous CO2 monitor;pCO2 Bld Preductal TcCo2;;ACTIVE;1.0l;2.34 +1988-5;C reactive protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;C reactive protein [Mass/volume] in Serum or Plasma;CRP SerPl-mCnc;;ACTIVE;1.0;2.73 +19885-3;Carbon dioxide;PPres;Pt;Bld.preductal;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Blood Preductal;pCO2 Bld Preductal;;ACTIVE;1.0l;2.30 +19886-1;Carbon dioxide;PPres;Pt;Bld.postductal;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Blood Postductal by Transcutaneous CO2 monitor;pCO2 Bld Postductal TcCo2;;ACTIVE;1.0l;2.34 +19887-9;Carbon dioxide;PPres;Pt;Bld.postductal;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Blood Postductal;pCO2 Bld Postductal;;ACTIVE;1.0l;2.30 +19888-7;Carbon dioxide/Gas.total.at end expiration;VFr;Pt;Exhl gas;Qn;Infrared absorption;PULM;2;Carbon dioxide/Gas.total.at end expiration in Exhaled gas by Infrared absorption;CO2 VFr ExG IR Abs;;ACTIVE;1.0l;2.34 +19889-5;Carbon dioxide/Gas.total.at end expiration;VFr;Pt;Exhl gas;Qn;;PULM;2;Carbon dioxide/Gas.total.at end expiration in Exhaled gas;CO2 VFr ExG;;ACTIVE;1.0l;2.73 +19890-3;Carbon dioxide^at end expiration;PPres;Pt;Exhl gas;Qn;Calculated;PULM;2;Carbon dioxide [Partial pressure] in Exhaled gas by Calculated --at end expiration;pCO2 end exp ExG Calc;;ACTIVE;1.0l;2.56 +19891-1;Carbon dioxide^at end expiration;PPres;Pt;Exhl gas;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Exhaled gas --at end expiration;pCO2 end exp ExG;;ACTIVE;1.0l;2.56 +19892-9;Carbon dioxide^during bronchodilation;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --during bronchodilation;pCO2 during BD BldC TcCo2;;ACTIVE;1.0l;2.34 +1989-3;Calcidiol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma;25(OH)D3 SerPl-mCnc;;ACTIVE;1.0;2.73 +19893-7;Carbon dioxide^during bronchodilation;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --during bronchodilation;pCO2 during BD BldC;;ACTIVE;1.0l;2.73 +19894-5;Carbon dioxide^during chest physiotherapy;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --during chest physiotherapy;pCO2 during chest PT BldC TcCo2;;ACTIVE;1.0l;2.34 +19895-2;Carbon dioxide^during chest physiotherapy;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --during chest physiotherapy;pCO2 during chest PT BldC;;ACTIVE;1.0l;2.30 +19896-0;Carbon dioxide^during XXX treatment;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --during XXX treatment;pCO2 during XXX Tx BldC;;ACTIVE;1.0l;2.30 +19897-8;Carbon dioxide^during XXX treatment;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --during XXX treatment;pCO2 during XXX Tx BldC TcCo2;;ACTIVE;1.0l;2.34 +19898-6;Carbon dioxide^post bronchodilation;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --post bronchodilation;pCO2 p BD BldC TcCo2;;ACTIVE;1.0l;2.34 +19899-4;Carbon dioxide^post bronchodilation;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --post bronchodilation;pCO2 p BD BldC;;ACTIVE;1.0l;2.30 +199-0;Cloxacillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cloxacillin [Susceptibility] by Serum bactericidal titer;Cloxacillin Titr SBT;;ACTIVE;1.0;2.32 +19900-0;Carbon dioxide^post chest physiotherapy;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --post chest physiotherapy;pCO2 p chest PT BldC TcCo2;;ACTIVE;1.0l;2.34 +1990-1;Cholecalciferol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholecalciferol (Vit D3) [Mass/volume] in Serum or Plasma;Vitamin D3 SerPl-mCnc;;ACTIVE;1.0;2.73 +19901-8;Carbon dioxide^post chest physiotherapy;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --post chest physiotherapy;pCO2 p chest PT BldC;;ACTIVE;1.0l;2.73 +19902-6;Carbon dioxide^post XXX treatment;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --post XXX treatment;pCO2 p XXX Tx BldC TcCo2;;ACTIVE;1.0l;2.34 +19903-4;Carbon dioxide^post XXX treatment;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --post XXX treatment;pCO2 p XXX Tx BldC;;ACTIVE;1.0l;2.30 +19904-2;Carbon dioxide^pre bronchodilation;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --pre bronchodilation;pCO2 pre BD BldC TcCo2;;ACTIVE;1.0l;2.34 +19905-9;Carbon dioxide^pre bronchodilation;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --pre bronchodilation;pCO2 pre BD BldC;;ACTIVE;1.0l;2.30 +19906-7;Carbon dioxide^pre chest physiotherapy;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --pre chest physiotherapy;pCO2 pre chest PT BldC TcCo2;;ACTIVE;1.0l;2.34 +19907-5;Carbon dioxide^pre chest physiotherapy;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --pre chest physiotherapy;pCO2 pre chest PT BldC;;ACTIVE;1.0l;2.30 +19908-3;Carbon dioxide^pre XXX treatment;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor --pre XXX treatment;pCO2 pre XXX Tx BldC TcCo2;;ACTIVE;1.0l;2.34 +19909-1;Carbon dioxide^pre XXX treatment;PPres;Pt;BldC;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood --pre XXX treatment;pCO2 pre XXX Tx BldC;;ACTIVE;1.0l;2.30 +19910-9;Diffusion capacity.carbon monoxide;FldConduct;Pt;Respiratory system;Qn;Predicted;PULM;2;Diffusion capacity.carbon monoxide Predicted;Diff cap.CO Predicted;;ACTIVE;1.0l;2.73 +19911-7;Diffusion capacity.carbon monoxide;FldConduct;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity.carbon monoxide;Diff cap.CO;;ACTIVE;1.0l;2.73 +19912-5;Diffusion capacity.carbon monoxide^^adjusted for hemoglobin;FldConduct;Pt;Respiratory system;Qn;Helium single breath;PULM;2;Diffusion capacity.carbon monoxide adjusted for hemoglobin by Helium single breath;Diff cap.CO Hgb adj He SB;;ACTIVE;1.0l;2.70 +19913-3;Diffusion capacity.carbon monoxide^^adjusted for hemoglobin;FldConduct;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity.carbon monoxide adjusted for hemoglobin;Diff cap.CO Hgb adj;;ACTIVE;1.0l;2.70 +19914-1;Diffusion capacity/Alveolar volume;Inverse VI;Pt;Respiratory system;Qn;Single breath.carbon monoxide+Helium;PULM;2;Diffusion capacity/Alveolar volume by Single breath.carbon monoxide+Helium;Diff cap/Alv vol SB.CO+He;;ACTIVE;1.0l;2.27 +19915-8;Diffusion capacity/Alveolar volume;Inverse VI;Pt;Respiratory system;Qn;Predicted;PULM;2;Diffusion capacity/Alveolar volume Predicted;Diff cap/Alv vol Predicted;;ACTIVE;1.0l;2.27 +19916-6;Diffusion capacity/Alveolar volume;Inverse VI;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity/Alveolar volume;Diff cap/Alv vol;;ACTIVE;1.0l;2.27 +19917-4;Diffusion capacity^^adjusted to body conditions;FldConduct;Pt;Respiratory system;Qn;Single breath.carbon monoxide+Helium;PULM;2;Diffusion capacity adjusted to body conditions by Single breath.carbon monoxide+Helium;Diff cap Body cond adj SB.CO+He;;ACTIVE;1.0l;2.48 +19918-2;Diffusion capacity^^adjusted to body conditions;FldConduct;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity adjusted to body conditions;Diff cap Body cond adj;;ACTIVE;1.0l;2.48 +1991-9;Calciferol binding proteins;MCnc;Pt;Ser;Qn;;CHEM;1;Calciferol binding proteins [Mass/volume] in Serum;Calciferol BP Ser-mCnc;;ACTIVE;1.0;2.73 +19919-0;Endotracheal suction catheter types;Type;Pt;*;Nom;;PULM;2;Endotracheal suction catheter types;Endotracheal suction catheter types;;ACTIVE;1.0l;2.27 +19920-8;Expiration setting;Time;Pt;Ventilator;Qn;;PULM;2;Expiration setting [Time] Ventilator;Expiration setting Time Vent;;ACTIVE;1.0l;2.48 +19921-6;Expiratory reserve;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Expiratory reserve by Helium rebreathing;Expiratory reserve He Rebreath;;ACTIVE;1.0l;2.48 +19922-4;Expiratory reserve;Vol;Pt;Respiratory system;Qn;Helium single breath;PULM;2;Expiratory reserve by Helium single breath;Expiratory reserve He SB;;ACTIVE;1.0l;2.48 +19923-2;Expiratory reserve;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;Expiratory reserve Predicted;Expiratory reserve Predicted;;ACTIVE;1.0l;2.40 +19924-0;Expiratory reserve;Vol;Pt;Respiratory system;Qn;;PULM;2;Expiratory reserve;Expiratory reserve;;ACTIVE;1.0l;2.48 +19925-7;Volume expired during 1.0 s of forced expiration/Forced vital capacity;VRto;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV1/FVC Predicted;FEV1/FVC Predicted;;ACTIVE;1.0l;2.73 +19926-5;Volume expired during 1.0 s of forced expiration/Forced vital capacity;VRto;Pt;Respiratory system;Qn;;PULM;2;FEV1/FVC;FEV1/FVC;;ACTIVE;1.0l;2.73 +1992-7;Calcitonin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcitonin [Mass/volume] in Serum or Plasma;Calcit SerPl-mCnc;;ACTIVE;1.0;2.73 +19927-3;Gas flow at 25-75% of forced expiration;VRat;Pt;Respiratory system;Qn;;PULM;2;Gas flow FEV 25%-75%;Gas flow FEV 25-75%;;ACTIVE;1.0l;2.73 +19928-1;Gas delivery source;Type;Pt;Respiratory system;Nom;;PULM;2;Gas delivery source Respiratory system;Gas deliv source Respiratory;;ACTIVE;1.0l;2.73 +19929-9;Gas flow;VRat;Pt;Respiratory system.airway;Qn;Rebreathing;PULM;2;Gas flow Respiratory system airway by Rebreathing;Gas flow Airway Rebreath;;ACTIVE;1.0l;2.40 +19930-7;Gas flow;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Gas flow Respiratory system airway;Gas flow Airway;;ACTIVE;1.0l;2.73 +19931-5;Gas flow.peak inspiratory setting;VRat;Pt;Ventilator;Qn;;PULM;2;Peak inspiratory gas flow setting Ventilator;Gas flow.peak inspiratory setting Vent;;ACTIVE;1.0l;2.73 +19932-3;Gas flow.constant setting;VRat;Pt;Ventilator;Qn;;PULM;2;Constant gas flow setting Ventilator;Gas flow.constant setting Vent;;ACTIVE;1.0l;2.40 +19933-1;Gas flow.constant^baseline setting;VRat;Pt;Ventilator;Qn;;PULM;2;Constant gas flow Ventilator --baseline setting;Gas flow.constant baseline setting Vent;;ACTIVE;1.0l;2.40 +19934-9;Gas flow.delivered setting;VRat;Pt;Ventilator;Qn;;PULM;2;Delivered gas flow setting Ventilator;Gas flow.delivered setting Vent;;ACTIVE;1.0l;2.40 +1993-5;Calcium renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Calcium renal clearance in 24 hour Urine and Serum or Plasma;Calcium Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +19935-6;Expiratory gas flow.max;VRat;Pt;Respiratory system.airway;Qn;Peak flow meter;PULM;2;Maximum expiratory gas flow Respiratory system airway by Peak flow meter;PEF Airway PFM;;ACTIVE;1.0l;2.73 +19936-4;Gas flow.max;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Deprecated Maximum gas flow Respiratory system airway;Deprecated Gas flow.max Airway;;DEPRECATED;1.0l;2.44 +19937-2;Expiratory gas flow.max^post therapy;VRat;Pt;Respiratory system.airway;Qn;Peak flow meter;PULM;2;Maximum expiratory gas flow Respiratory system airway by Peak flow meter --post therapy;PEF p therapy Airway PFM;;ACTIVE;1.0l;2.44 +19938-0;Expiratory gas flow.max^post therapy;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow Respiratory system airway --post therapy;PEF p therapy Airway;;ACTIVE;1.0l;2.44 +19939-8;Gas flow.min^pre therapy;VRat;Pt;Respiratory system.airway;Qn;Peak flow meter;PULM;2;Deprecated Minimum gas flow Respiratory system airway by Peak flow meter --pre therapy;Deprecated Gas flow.min pre therapy Airw;;DEPRECATED;1.0l;2.40 +19940-6;Gas flow.min^pre therapy;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Deprecated Minimum gas flow Respiratory system airway --pre therapy;Deprecated Gas flow.min pre therapy Airw;;DEPRECATED;1.0l;2.40 +19941-4;Gas flow.oxygen;VRat;Pt;Oxygen delivery system;Qn;;PULM;2;Oxygen gas flow Oxygen delivery system;Gas flow.O2 O2 delivery sys;;ACTIVE;1.0l;2.73 +19942-2;Gas flow.oxygen setting;VRat;Pt;Oxymiser;Qn;;PULM;2;Oxygen gas flow setting Oxymiser;Gas flow.O2 setting Oxymiser;;ACTIVE;1.0l;2.73 +1994-3;Calcium.ionized;SCnc;Pt;Bld;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Blood;Ca-I Bld-sCnc;;ACTIVE;1.0;2.73 +19943-0;Gas flow.secondary gas setting;VRat;Pt;Ventilator;Qn;;PULM;2;Secondary gas flow setting Ventilator;Gas flow.secondary gas setting Vent;;ACTIVE;1.0l;2.40 +19944-8;Gas flow^at 25-75% of forced expiration;VRat;Pt;Respiratory system.airway;Qn;Predicted;PULM;2;Deprecated Gas flow^at 25-75% of forced expiration: VRat: Pt: Respiratory system.airway: Qn: Predicted;DeprecatedGas flow^at 25-75% of forced e;;DEPRECATED;1.0l;2.40 +19945-5;Gas flow at 25-75% of forced expiration;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Gas flow FEV 25%-75% airway;Gas flow FEV 25-75% airway;;ACTIVE;1.0l;2.40 +19946-3;Heart rate max setting;NRat;Pt;Apnea monitor.alarm;Qn;;PULM;2;Maximum heart rate setting Apnea Monitor Alarm;Heart rate max set Apnea Monitor.alarm;;ACTIVE;1.0l;2.42 +19947-1;Heart rate min setting;NRat;Pt;Apnea monitor.alarm;Qn;;PULM;2;Heart rate minimum setting Apnea Monitor Alarm;Heart rate min set Apnea Monitor.alarm;;ACTIVE;1.0l;2.42 +19948-9;Oxyhemoglobin/Hemoglobin.total;MFr;8H^max;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin in 8 hour maximum by Pulse oximetry;Deprecated OxyHgb 8H Max % PulseOx;;DEPRECATED;1.0l;2.32 +19949-7;Oxyhemoglobin/Hemoglobin.total;MFr;8H^max;BldA;Qn;;PULM;2;Oxyhemoglobin/Hemoglobin.total (8 hour maximum) in Arterial blood;OxyHgb 8h Max % BldA;;ACTIVE;1.0l;2.54 +1995-0;Calcium.ionized;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Serum or Plasma;Ca-I SerPl-sCnc;;ACTIVE;1.0;2.73 +19950-5;Oxyhemoglobin/Hemoglobin.total;MFr;8H^min;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin in 8 hour minimum by Pulse oximetry;Deprecated OxyHgb 8H Min % PulseOx;;DEPRECATED;1.0l;2.32 +19951-3;Oxyhemoglobin/Hemoglobin.total;MFr;8H^min;BldA;Qn;;PULM;2;Oxyhemoglobin/Hemoglobin.total (8 hour minimum) in Arterial blood;OxyHgb 8h Min % BldA;;ACTIVE;1.0l;2.54 +19952-1;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;Bld.preductal;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin in Blood Preductal by Pulse oximetry;Deprecated OxyHgb % Bld Preductal PulseO;;DEPRECATED;1.0l;2.32 +19953-9;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;Bld.preductal;Qn;;PULM;2;Fractional oxyhemoglobin in Blood Preductal;OxyHgb % Bld Preductal;;ACTIVE;1.0l;2.30 +19954-7;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;Bld.postductal;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin in Blood Postductal by Pulse oximetry;Deprecated OxyHgb % Bld Postductal Pulse;;DEPRECATED;1.0l;2.32 +19955-4;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;Bld.postductal;Qn;;PULM;2;Fractional oxyhemoglobin in Blood Postductal;OxyHgb % Bld Postductal;;ACTIVE;1.0l;2.30 +19956-2;Oxyhemoglobin/Hemoglobin.total^during bronchodilation;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --during bronchodilation;Deprecated OxyHgb during BD % PulseOx;;DEPRECATED;1.0l;2.32 +19957-0;Oxyhemoglobin/Hemoglobin.total^during bronchodilation;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --during bronchodilation;OxyHgb during BD % BldA;;ACTIVE;1.0l;2.30 +19958-8;Oxyhemoglobin/Hemoglobin.total^during treatment;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --during treatment;Deprecated OxyHgb during Tx % PulseOx;;DEPRECATED;1.0l;2.32 +19959-6;Oxyhemoglobin/Hemoglobin.total^during treatment;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --during treatment;OxyHgb during Tx % BldA;;ACTIVE;1.0l;2.30 +19960-4;Oxyhemoglobin/Hemoglobin.total^on room air;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --on room air;Deprecated OxyHgb room air % PulseOx;;DEPRECATED;1.0l;2.32 +19961-2;Oxyhemoglobin/Hemoglobin.total^on room air;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --on room air;OxyHgb room air % BldA;;ACTIVE;1.0l;2.30 +19962-0;Oxyhemoglobin/Hemoglobin.total^post bronchodilation;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --post bronchodilation;Deprecated OxyHgb p BD % PulseOx;;DEPRECATED;1.0l;2.32 +19963-8;Oxyhemoglobin/Hemoglobin.total^post bronchodilation;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --post bronchodilation;OxyHgb p BD % BldA;;ACTIVE;1.0l;2.30 +19964-6;Oxyhemoglobin/Hemoglobin.total^post treatment;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --post treatment;Deprecated OxyHgb p Tx % PulseOx;;DEPRECATED;1.0l;2.32 +19965-3;Oxyhemoglobin/Hemoglobin.total^post treatment;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --post treatment;OxyHgb p Tx % BldA;;ACTIVE;1.0l;2.30 +19966-1;Oxyhemoglobin/Hemoglobin.total^pre bronchodilation;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --pre bronchodilation;Deprecated OxyHgb pre BD % PulseOx;;DEPRECATED;1.0l;2.32 +19967-9;Oxyhemoglobin/Hemoglobin.total^pre bronchodilation;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --pre bronchodilation;OxyHgb pre BD % BldA;;ACTIVE;1.0l;2.30 +1996-8;Calcium;SCnc;Pt;Bld;Qn;;CHEM;1;Calcium [Moles/volume] in Blood;Calcium Bld-sCnc;;ACTIVE;1.0;2.73 +19968-7;Oxyhemoglobin/Hemoglobin.total^pre physiotherapy;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --pre physiotherapy;Deprecated OxyHgb pre PT % PulseOx;;DEPRECATED;1.0l;2.32 +19969-5;Oxyhemoglobin/Hemoglobin.total^pre physiotherapy;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --pre physiotherapy;OxyHgb pre PT % BldA;;ACTIVE;1.0l;2.30 +19970-3;Oxyhemoglobin/Hemoglobin.total^pre treatment;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --pre treatment;Deprecated OxyHgb pre Tx % PulseOx;;DEPRECATED;1.0l;2.32 +19971-1;Oxyhemoglobin/Hemoglobin.total^pre treatment;MFr;Pt;BldA;Qn;;PULM;2;Fractional oxyhemoglobin in Arterial blood --pre treatment;OxyHgb pre Tx % BldA;;ACTIVE;1.0l;2.30 +19972-9;Humidifier types;Type;Pt;*;Nom;;PULM;2;Humidifier types;Humidifier types;;ACTIVE;1.0l;2.27 +19973-7;Inspiration setting;Time;Pt;Ventilator;Qn;;PULM;2;Inspiration setting [Time] Ventilator;Inspiration setting Time Vent;;ACTIVE;1.0l;2.73 +19974-5;Inspiration/Expiration setting;TRto;Pt;Ventilator;Qn;;PULM;2;Inspiration/Expiration setting Ventilator;Insp/Expiration setting Vent;;ACTIVE;1.0l;2.73 +19975-2;Max^during inspiration on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;Airway pressure monitor;PULM;2;Deprecated Maximum [Pressure] Respiratory system airway opening by Airway pressure monitor --at inspiration on ventilator;Deprecated Max at insp on vent Airway op;;DEPRECATED;1.0l;2.50 +1997-6;Calcium;SCnc;Pt;CSF;Qn;;CHEM;1;Calcium [Moles/volume] in Cerebral spinal fluid;Calcium CSF-sCnc;;ACTIVE;1.0;2.34 +19976-0;Max^during inspiration on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;;PULM;2;Maximum [Pressure] Respiratory system airway opening --during inspiration on ventilator;Max dur insp on vent Airway opening;;ACTIVE;1.0l;2.73 +19977-8;Max^during inspiration on ventilator;Pres;Pt;Trachea.airway;Qn;Airway pressure monitor;PULM;2;Deprecated Maximum [Pressure] Trachea airway by Airway pressure monitor --at inspiration on ventilator;Deprecated Max at insp on vent Trachea.a;;DEPRECATED;1.0l;2.50 +19978-6;Max^during inspiration on ventilator;Pres;Pt;Trachea.airway;Qn;;PULM;2;Maximum [Pressure] Trachea airway --during inspiration on ventilator;Max dur insp on vent Trachea.airway;;ACTIVE;1.0l;2.50 +19979-4;Nasal cannula type;Type;Pt;*;Nom;;PULM;2;Nasal cannula type;Nasal cannula type;;ACTIVE;1.0l;2.27 +19980-2;Oxygen;PPres;8H^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (8 hour maximum) in Capillary blood Transcutaneous O2 monitor;pO2 8h Max BldC TcO2;;ACTIVE;1.0l;2.70 +19981-0;Oxygen;PPres;8H^max;BldC;Qn;;PULM;2;Oxygen [Partial pressure] (8 hour maximum) in Capillary blood;pO2 8h Max BldC;;ACTIVE;1.0l;2.54 +19982-8;Oxygen;PPres;8H^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (8 hour minimum) in Capillary blood Transcutaneous O2 monitor;pO2 8h Min BldC TcO2;;ACTIVE;1.0l;2.54 +19983-6;Oxygen;PPres;8H^min;BldC;Qn;;PULM;2;Oxygen [Partial pressure] (8 hour minimum) in Capillary blood;pO2 8h Min BldC;;ACTIVE;1.0l;2.54 +1998-4;Calcium;SCnc;Pt;Dial fld;Qn;;CHEM;1;Calcium [Moles/volume] in Dialysis fluid;Calcium Dial fld-sCnc;;ACTIVE;1.0;2.34 +19984-4;Oxygen;PPres;Pt;Respiratory system.alveolus;Qn;Calculated;PULM;2;Oxygen [Partial pressure] Respiratory system alveolus Calculated;pO2 Aveolus Calc;;ACTIVE;1.0l;2.40 +19985-1;Oxygen;PPres;Pt;Bld.preductal;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Blood Preductal by Transcutaneous O2 monitor;pO2 Bld Preductal TcO2;;ACTIVE;1.0l;2.34 +19986-9;Oxygen;PPres;Pt;Bld.preductal;Qn;;PULM;2;Oxygen [Partial pressure] in Blood Preductal;pO2 Bld Preductal;;ACTIVE;1.0l;2.30 +19987-7;Oxygen;PPres;Pt;Bld.postductal;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Blood Postductal by Transcutaneous O2 monitor;pO2 Bld Postductal TcO2;;ACTIVE;1.0l;2.34 +19988-5;Oxygen;PPres;Pt;Bld.postductal;Qn;;PULM;2;Oxygen [Partial pressure] in Blood Postductal;pO2 Bld Postductal;;ACTIVE;1.0l;2.30 +19989-3;Oxygen max setting;VRat;Pt;Ventilator.alarm;Qn;;PULM;2;Maximum oxygen setting Ventilator alarm;O2 max setting Vent alarm;;ACTIVE;1.0l;2.29 +19990-1;Oxygen min setting;VRat;Pt;Ventilator.alarm;Qn;;PULM;2;Minimum oxygen setting Ventilator alarm;O2 min setting Vent alarm;;ACTIVE;1.0l;2.29 +19991-9;Oxygen.alveolar - arterial;PPresDiff;Pt;Respiratory system;Qn;;PULM;2;Alveolar-arterial oxygen Partial pressure difference;O2 A-a PPresDiff Respiratory;;ACTIVE;1.0l;2.73 +1999-2;Calcium;SCnc;Pt;Semen;Qn;;CHEM;1;Calcium [Moles/volume] in Semen;Calcium Smn-sCnc;;ACTIVE;1.0;2.42 +19992-7;Oxygen/Gas.total;VFr;Pt;Inhl gas;Qn;Helium single breath;PULM;2;Oxygen/Gas total Inhaled gas by Helium single breath;FIO2 He SB;;ACTIVE;1.0l;2.69 +19993-5;Oxygen/Gas.total;VFr;Pt;Inhl gas;Qn;Gas dilution.rebreathing;PULM;2;Oxygen/Gas total Inhaled gas by Gas dilution.rebreath;FIO2 Gas Dil.rebreath;;ACTIVE;1.0l;2.73 +19994-3;Oxygen/Gas.total setting;VFr;Pt;Ventilator;Qn;;PULM;2;Oxygen/Total gas setting [Volume Fraction] Ventilator;O2/Total gas setting VFr Vent;;ACTIVE;1.0l;2.73 +19995-0;Oxygen/Inspired gas^on ventilator;VFr;Pt;Respiratory system;Qn;Oxygen analyzer;PULM;2;Oxygen/Inspired gas Respiratory system by O2 Analyzer --on ventilator;FIO2 on vent O2 Analyzer;;ACTIVE;1.0l;2.30 +19996-8;Oxygen/Inspired gas^on ventilator;VFr;Pt;Respiratory system;Qn;;PULM;2;Oxygen/Inspired gas Respiratory system --on ventilator;FIO2 on vent;;ACTIVE;1.0l;2.73 +19997-6;Oxygen^during bronchodilation;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --during bronchodilation;pO2 during BD BldC TcO2;;ACTIVE;1.0l;2.34 +19998-4;Oxygen^during bronchodilation;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --during bronchodilation;pO2 during BD BldC;;ACTIVE;1.0l;2.30 +19999-2;Oxygen^during chest physiotherapy;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --during chest physiotherapy;pO2 during chest PT BldC TcO2;;ACTIVE;1.0l;2.34 +20000-6;Oxygen^during chest physiotherapy;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --during chest physiotherapy;pO2 during chest PT BldC;;ACTIVE;1.0l;2.30 +20001-4;Oxygen^during treatment;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --during treatment;pO2 during Tx BldC TcO2;;ACTIVE;1.0l;2.34 +20002-2;Oxygen^on oxygen.high flow & asleep;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on high flow oxygen and asleep;pO2 asleep high O2 Max BldC TcO2;;ACTIVE;1.0l;2.54 +20003-0;Oxygen^on oxygen.high flow & asleep;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on high flow oxygen and asleep;pO2 asleep high O2 Min BldC TcO2;;ACTIVE;1.0l;2.54 +20004-8;Oxygen^on oxygen.high flow & awake;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on high flow oxygen and awake;pO2 awake high O2 Max BldC TcO2;;ACTIVE;1.0l;2.54 +20005-5;Oxygen^on oxygen.high flow & awake;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on high flow oxygen and awake;pO2 awake high O2 Min BldC TcO2;;ACTIVE;1.0l;2.54 +20006-3;Oxygen^on oxygen.high flow & eating;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on high flow oxygen and eating;pO2 eating high O2 Max BldC TcO2;;ACTIVE;1.0l;2.54 +20007-1;Oxygen^on oxygen.high flow & eating;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on high flow oxygen and eating;pO2 eating high O2 Min BldC TcO2;;ACTIVE;1.0l;2.54 +2000-8;Calcium;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Moles/volume] in Serum or Plasma;Calcium SerPl-sCnc;;ACTIVE;1.0;2.73 +20008-9;Oxygen^on oxygen.low flow & asleep;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on low flow oxygen and asleep;pO2 asleep low O2 Max BldC TcO2;;ACTIVE;1.0l;2.54 +20009-7;Oxygen^on oxygen.low flow & asleep;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on low flow oxygen and asleep;pO2 asleep low O2 Min BldC TcO2;;ACTIVE;1.0l;2.54 +20010-5;Oxygen^on oxygen.low flow & awake;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on low flow oxygen and awake;pO2 awake low O2 Max BldC TcO2;;ACTIVE;1.0l;2.54 +20011-3;Oxygen^on oxygen.low flow & awake;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on low flow oxygen and awake;pO2 awake low O2 Min BldC TcO2;;ACTIVE;1.0l;2.54 +20012-1;Oxygen^on oxygen.low flow & eating;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on low flow oxygen and eating;pO2 eating low O2 Max BldC TcO2;;ACTIVE;1.0l;2.54 +20013-9;Oxygen^on oxygen.low flow & eating;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on low flow oxygen and eating;pO2 eating low O2 Min BldC TcO2;;ACTIVE;1.0l;2.54 +20014-7;Oxygen^on room air and asleep;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on room air and asleep;pO2 asleep room air Max BldC TcO2;;ACTIVE;1.0l;2.54 +20015-4;Oxygen^on room air and asleep;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on room air and asleep;pO2 asleep room air Min BldC TcO2;;ACTIVE;1.0l;2.54 +2001-6;Calcium;SCnc;24H;Stool;Qn;;CHEM;1;Calcium [Moles/volume] in 24 hour Stool;Calcium 24h Stl-sCnc;;ACTIVE;1.0;2.42 +20016-2;Oxygen^on room air and awake;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on room air and awake;pO2 awake room air Max BldC TcO2;;ACTIVE;1.0l;2.73 +20017-0;Oxygen^on room air and awake;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on room air and awake;pO2 awake room air Min BldC TcO2;;ACTIVE;1.0l;2.54 +20018-8;Oxygen^on room air and eating;PPres;Stdy^max;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Maximum value during study) Capillary blood Transcutaneous O2 monitor --on room air and eating;pO2 eating room air Max BldC TcO2;;ACTIVE;1.0l;2.54 +20019-6;Oxygen^on room air and eating;PPres;Stdy^min;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] (Minimum value during study) Capillary blood Transcutaneous O2 monitor --on room air and eating;pO2 eating room air Min BldC TcO2;;ACTIVE;1.0l;2.54 +20020-4;Oxygen^post bronchodilation;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --post bronchodilation;pO2 p BD BldC TcO2;;ACTIVE;1.0l;2.34 +20021-2;Oxygen^post bronchodilation;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --post bronchodilation;pO2 p BD BldC;;ACTIVE;1.0l;2.30 +20022-0;Oxygen^post chest physiotherapy;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --post chest physiotherapy;pO2 p chest PT BldC TcO2;;ACTIVE;1.0l;2.34 +20023-8;Oxygen^post chest physiotherapy;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --post chest physiotherapy;pO2 p chest PT BldC;;ACTIVE;1.0l;2.30 +2002-4;Calcium;SCnc;Pt;Stool;Qn;;CHEM;1;Calcium [Moles/volume] in Stool;Calcium Stl-sCnc;;ACTIVE;1.0;2.42 +20024-6;Oxygen^post treatment;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --post treatment;pO2 p Tx BldC TcO2;;ACTIVE;1.0l;2.34 +20025-3;Oxygen^post treatment;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --post treatment;pO2 p Tx BldC;;ACTIVE;1.0l;2.30 +20026-1;Oxygen^pre bronchodilation;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --pre bronchodilation;pO2 pre BD BldC TcO2;;ACTIVE;1.0l;2.34 +20027-9;Oxygen^pre bronchodilation;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --pre bronchodilation;pO2 pre BD BldC;;ACTIVE;1.0l;2.30 +20028-7;Oxygen^pre chest physiotherapy;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --pre chest physiotherapy;pO2 pre chest PT BldC TcO2;;ACTIVE;1.0l;2.34 +20029-5;Oxygen^pre chest physiotherapy;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --pre chest physiotherapy;pO2 pre chest PT BldC;;ACTIVE;1.0l;2.30 +20030-3;Oxygen^pre treatment;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor --pre treatment;pO2 pre Tx BldC TcO2;;ACTIVE;1.0l;2.34 +20031-1;Oxygen^pre treatment;PPres;Pt;BldC;Qn;;PULM;2;Oxygen [Partial pressure] in Capillary blood --pre treatment;pO2 pre Tx BldC;;ACTIVE;1.0l;2.30 +2003-2;Calcium;SCnc;Pt;Urine;Ord;;CHEM;1;Deprecated Calcium;Deprecated Calcium Ur Ql;;DEPRECATED;1.0;2.36 +20032-9;Peak inspiratory flow^at 0.5 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Respiratory system airway opening by Airway pressure monitor --at 0.5 liter per second on ventilator;Deprecated Pmax @ 0.5 L/s on vent Airway;;DEPRECATED;1.0l;2.34 +20033-7;Peak inspiratory flow^at 0.5 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;;PULM;2;Peak inspiratory flow Respiratory system airway opening --at 0.5 liter per second on ventilator;Pmax @ 0.5 L/s on vent Airway opening;;ACTIVE;1.0l;2.48 +20034-5;Peak inspiratory flow^at 0.5 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Trachea airway by Airway pressure monitor --at 0.5 liter per second on ventilator;Deprecated Pmax @ 0.5 L/s on vent Trache;;DEPRECATED;1.0l;2.34 +20035-2;Peak inspiratory flow^at 0.5 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;;PULM;2;Peak inspiratory flow Trachea airway --at 0.5 liter per second on ventilator;Pmax @ 0.5 L/s on vent Trachea.airway;;ACTIVE;1.0l;2.27 +20036-0;Peak inspiratory flow^at 1.0 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Respiratory system airway opening by Airway pressure monitor --at 1.0 liter per second on ventilator;Deprecated Pmax @ 1.0 L/s on vent Airway;;DEPRECATED;1.0l;2.34 +20037-8;Peak inspiratory flow^at 1.0 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;;PULM;2;Peak inspiratory flow Respiratory system airway opening --at 1.0 liter per second on ventilator;Pmax @ 1.0 L/s on vent Airway opening;;ACTIVE;1.0l;2.27 +20038-6;Peak inspiratory flow^at 1.0 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Trachea airway by Airway pressure monitor --at 1.0 liter per second on ventilator;Deprecated Pmax @ 1.0 L/s on vent Trache;;DEPRECATED;1.0l;2.34 +20039-4;Peak inspiratory flow^at 1.0 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;;PULM;2;Peak inspiratory flow Trachea airway --at 1.0 liter per second on ventilator;Pmax @ 1.0 L/s on vent Trachea.airway;;ACTIVE;1.0l;2.27 +2004-0;Calcium;SCnc;Pt;Urine;Qn;;CHEM;1;Calcium [Moles/volume] in Urine;Calcium Ur-sCnc;;ACTIVE;1.0;2.73 +20040-2;Peak inspiratory flow^at 1.5 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Respiratory system airway opening by Airway pressure monitor --at 1.5 liter per second on ventilator;Deprecated Pmax @ 1.5 L/s on vent Airway;;DEPRECATED;1.0l;2.34 +20041-0;Peak inspiratory flow^at 1.5 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;;PULM;2;Peak inspiratory flow Respiratory system airway opening --at 1.5 liter per second on ventilator;Pmax @ 1.5 L/s on vent Airway opening;;ACTIVE;1.0l;2.27 +20042-8;Peak inspiratory flow^at 1.5 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Trachea airway by Airway pressure monitor --at 1.5 liter per second on ventilator;Deprecated Pmax @ 1.5 L/s on vent Trache;;DEPRECATED;1.0l;2.34 +20043-6;Peak inspiratory flow^at 1.5 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;;PULM;2;Peak inspiratory flow Trachea airway --at 1.5 liter per second on ventilator;Pmax @ 1.5 L/s on vent Trachea.airway;;ACTIVE;1.0l;2.27 +20044-4;Peak inspiratory flow^at 2.0 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Respiratory system airway opening by Airway pressure monitor --at 2.0 liter per second on ventilator;Deprecated Pmax @ 2.0 L/s on vent Airway;;DEPRECATED;1.0l;2.34 +20045-1;Peak inspiratory flow^at 2.0 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;;PULM;2;Peak inspiratory flow Respiratory system airway opening --at 2.0 liter per second on ventilator;Pmax @ 2.0 L/s on vent Airway opening;;ACTIVE;1.0l;2.27 +20046-9;Peak inspiratory flow^at 2.0 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Trachea airway by Airway pressure monitor --at 2.0 liter per second on ventilator;Deprecated Pmax @ 2.0 L/s on vent Trache;;DEPRECATED;1.0l;2.34 +20047-7;Peak inspiratory flow^at 2.0 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;;PULM;2;Peak inspiratory flow Trachea airway --at 2.0 liter per second on ventilator;Pmax @ 2.0 L/s on vent Trachea.airway;;ACTIVE;1.0l;2.27 +20048-5;Peak inspiratory flow^at 2.5 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Respiratory system airway opening by Airway pressure monitor --at 2.5 liter per second on ventilator;Deprecated Pmax @ 2.5 L/s on vent Airway;;DEPRECATED;1.0l;2.34 +20049-3;Peak inspiratory flow^at 2.5 liter per second on ventilator;Pres;Pt;Respiratory system.airway opening;Qn;;PULM;2;Peak inspiratory flow Respiratory system airway opening --at 2.5 liter per second on ventilator;Pmax @ 2.5 L/s on vent Airway opening;;ACTIVE;1.0l;2.27 +20050-1;Peak inspiratory flow^at 2.5 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;Airway pressure monitor;PULM;2;Deprecated Peak inspiratory flow Trachea airway by Airway pressure monitor --at 2.5 liter per second on ventilator;Deprecated Pmax @ 2.5 L/s on vent Trache;;DEPRECATED;1.0l;2.34 +20051-9;Peak inspiratory flow^at 2.5 liter per second on ventilator;Pres;Pt;Trachea.airway;Qn;;PULM;2;Peak inspiratory flow Trachea airway --at 2.5 liter per second on ventilator;Pmax @ 2.5 L/s on vent Trachea.airway;;ACTIVE;1.0l;2.27 +20052-7;Pressure;Pres;Pt;Atmosphere;Qn;Mercury column;PULM;2;Pressure Atmosphere by Mercury column;Press Atmosphere Mercury Column;;ACTIVE;1.0l;2.48 +20053-5;Pressure;Pres;Pt;Atmosphere;Qn;;PULM;2;Atmospheric pressure;Atmospheric press;;ACTIVE;1.0l;2.73 +20054-3;Pressure max setting;Pres;Pt;Ventilator.alarm;Qn;;PULM;2;Pressure maximum setting Ventilator alarm;Pressure max setting Vent alarm;;ACTIVE;1.0l;2.48 +20055-0;Pressure min setting;Pres;Pt;Ventilator.alarm;Qn;;PULM;2;Pressure minimum setting Ventilator alarm;Pressure min setting Vent alarm;;ACTIVE;1.0l;2.48 +20056-8;Pressure.airway^at mean expiratory flow on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure --at mean expiratory flow on ventilator;PAW @ mean exp flow on vent;;ACTIVE;1.0l;2.73 +2005-7;Calcium^post 12H CFst;SRat;2H;Urine;Qn;;CHAL;1;Calcium [Moles/time] in 2 hour Urine --12 hours fasting;Calcium p 12h fast 2h Ur-sRate;;ACTIVE;1.0;2.40 +20057-6;Pressure.airway^at peak inspiratory flow max setting;Pres;Pt;Ventilator;Qn;;PULM;2;Airway pressure Ventilator --at peak inspiratory flow maximum setting;PAW @ peak insp flow max setting Vent;;ACTIVE;1.0l;2.34 +20058-4;Pressure.airway^at peak inspiratory flow setting;Pres;Pt;Ventilator;Qn;;PULM;2;Airway pressure Ventilator --at peak inspiratory flow setting;PAW @ peak insp flow setting Vent;;ACTIVE;1.0l;2.73 +20059-2;Pressure.airway^at zero inspiratory flow on ventilator;Pres;Pt;Respiratory system.airway;Qn;Airway pressure monitor;PULM;2;Airway pressure by Airway pressure monitor --at zero inspiratory flow on ventilator;PAW @ zero insp flow on vent APM;;ACTIVE;1.0l;2.48 +200-6;Colistimethate;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Colistimethate by Minimum lethal concentration (MLC);Colistimethate Islt MLC;;ACTIVE;1.0;2.19 +20060-0;Pressure.airway^at zero inspiratory flow on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure --at zero inspiratory flow on ventilator;PAW @ zero insp flow on vent;;ACTIVE;1.0l;2.48 +20061-8;Pressure.airway^on ventilator.pressure targeted control;Pres;Pt;Respiratory system.airway;Qn;Airway pressure monitor;PULM;2;Airway pressure by Airway pressure monitor --on ventilator.pressure targeted control;PAW on vent pres target cont APM;;ACTIVE;1.0l;2.48 +20062-6;Pressure.airway^on ventilator.pressure targeted control;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure --on ventilator.pressure targeted control;PAW on vent pres target cont;;ACTIVE;1.0l;2.73 +20063-4;Pressure.airway^on ventilator.volume targeted assist & control;Pres;Pt;Respiratory system.airway;Qn;Airway pressure monitor;PULM;2;Airway pressure by Airway pressure monitor --on ventilator.volume targeted assist and control;PAW on vent vol target assist+cont APM;;ACTIVE;1.0l;2.48 +20064-2;Pressure.airway^on ventilator.volume targeted assist & control;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure --on ventilator.volume targeted assist and control;PAW on vent vol target assist+cont;;ACTIVE;1.0l;2.48 +2006-5;Cancer Ag 125;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 125 [Presence] in Serum or Plasma;Cancer Ag125 SerPl Ql;;ACTIVE;1.0;2.73 +20065-9;Pressure.airway^on ventilator.volume targeted control;Pres;Pt;Respiratory system.airway;Qn;Airway pressure monitor;PULM;2;Airway pressure by Airway pressure monitor --on ventilator.volume targeted control;PAW on vent vol target cont APM;;ACTIVE;1.0l;2.48 +20066-7;Pressure.airway^on ventilator.volume targeted control;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure --on ventilator.volume targeted control;PAW on vent vol target cont;;ACTIVE;1.0l;2.73 +20067-5;Pressure.drive max setting;Pres;Pt;Ventilator.servo;Qn;;PULM;2;Maximum drive pressure setting Servo ventilator;Drive Pres Max Servo vent;;ACTIVE;1.0l;2.48 +20068-3;Pressure.drive min setting;Pres;Pt;Ventilator.servo;Qn;;PULM;2;Minimum drive pressure setting Servo ventilator;Drive Pres Min Servo vent;;ACTIVE;1.0l;2.48 +20069-1;Pressure.inflation.mean;Pres;Pt;Respiratory system;Qn;Calculated;PULM;2;Mean inflation pressure Respiratory system Calculated;Infl Pres Mean Respiratory Calc;;ACTIVE;1.0l;2.48 +20070-9;Pressure.inspiratory min setting;Pres;Pt;Ventilator.alarm;Qn;;PULM;2;Minimum inspiratory pressure setting Ventilator alarm;Insp Press Min Vent alarm;;ACTIVE;1.0l;2.48 +20071-7;Pressure.mean;Pres;Pt;Respiratory system.airway;Qn;Calculated;PULM;2;Mean pressure Respiratory system airway Calculated;Mean Pres Airway Calc;;ACTIVE;1.0l;2.73 +20072-5;Pressure.mean max setting;Pres;Pt;Ventilator.alarm;Qn;;PULM;2;Maximum mean pressure setting Ventilator alarm;Mean Press Max Vent alarm;;ACTIVE;1.0l;2.48 +2007-3;Cancer Ag 15-3;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 15-3 [Presence] in Serum or Plasma;Cancer Ag15-3 SerPl Ql;;ACTIVE;1.0;2.73 +20073-3;Pressure.mean min setting;Pres;Pt;Ventilator.alarm;Qn;;PULM;2;Minimum mean pressure setting Ventilator alarm;Mean Pres Min Vent alarm;;ACTIVE;1.0l;2.48 +20074-1;Pressure.negative inspiratory setting;Pres;Pt;Ventilator;Qn;;PULM;2;Negative inspiratory pressure setting Ventilator;Neg Insp Pres Vent;;ACTIVE;1.0l;2.48 +20075-8;Pressure.positive end expiratory;Pres;Pt;Respiratory system;Qn;;PULM;2;PEEP Respiratory system;PEEP Respiratory;;ACTIVE;1.0l;2.73 +20076-6;Pressure.positive end expiratory min setting;Pres;Pt;Ventilator.alarm;Qn;;PULM;2;Minimum PEEP setting Ventilator alarm;Min PEEP setting Vent alarm;;ACTIVE;1.0l;2.73 +20077-4;Pressure.positive end expiratory setting;Pres;Pt;Ventilator;Qn;;PULM;2;Positive end expiratory pressure setting Ventilator;PEEP setting Vent;;ACTIVE;1.0l;2.73 +20078-2;Pressure.pulmonary airway max setting;Pres;Pt;Ventilator;Qn;;PULM;2;Maximum positive end expiratory pressure setting Ventilator;PEEP max setting Vent;;ACTIVE;1.0l;2.73 +20079-0;Pressure.support setting;Pres;Pt;Ventilator;Qn;;PULM;2;Pressure support setting Ventilator;Pressure support setting Vent;;ACTIVE;1.0l;2.73 +20080-8;Pulmonary function test method;Type;Pt;Respiratory system;Nom;*;PULM;2;Pulmonary function test method;Pulmonary function test method;;ACTIVE;1.0l;2.42 +2008-1;Cancer Ag 19-5;ACnc;Pt;Ser/Plas;Ord;;CHEM;1;Deprecated Cancer Ag 19-5 [Presence] in Serum or Plasma;Deprecated Cancer Ag19-5 SerPl Ql;;DEPRECATED;1.0;2.40 +20081-6;Pulse oximetry site;Anat;Pt;*;Nom;;PULM;2;Pulse oximetry site;Pulse oximetry site;;ACTIVE;1.0l;2.73 +20082-4;Rescuscitator types;Type;Pt;*;Nom;;PULM;2;Rescuscitator types;Rescuscitator types;;ACTIVE;1.0l;2.27 +20083-2;Resistance.airway;FldResist;Stdy^mean;Respiratory system.airway;Qn;Plethysmograph.body box;PULM;2;Airway resistance mean by Plethysmograph body box;Airway resist Mean Plethysmograph;;ACTIVE;1.0l;2.56 +20084-0;Resistance.airway;FldResist;Stdy^mean;Respiratory system.airway;Qn;;PULM;2;Airway resistance mean;Airway resist Mean;;ACTIVE;1.0l;2.56 +20085-7;Resistance.airway;FldResist;Stdy^mean;Respiratory system.airway;Qn;Calculated;PULM;2;Airway resistance mean Calculated;Airway resist Mean Calc;;ACTIVE;1.0l;2.56 +20086-5;Respiration.pause setting;Time;Pt;Ventilator;Qn;;PULM;2;Respiration pause setting [Time] Ventilator;Respiration pause setting Time Vent;;ACTIVE;1.0l;2.48 +20087-3;Respiratory mask;Type;Pt;*;Nom;;PULM;2;Respiratory mask;Resp mask;;ACTIVE;1.0l;2.29 +20088-1;Respiratory test prediction method;Type;Pt;Respiratory system;Nom;*;PULM;2;Respiratory test prediction method;Respiratory test prediction method;;ACTIVE;1.0l;2.42 +20089-9;Secondary gas/Gas.total setting;VFr;Pt;Ventilator;Qn;;PULM;2;Secondary gas/Total gas setting [Volume Fraction] Ventilator;Secondary gas/Total gas setting VFr Vent;;ACTIVE;1.0l;2.34 +20090-7;Sighs/Respiratory event setting;NRto;Pt;Ventilator;Qn;;PULM;2;Sighs/Respiratory event setting Ventilator;Sighs/Resp event setting Vent;;ACTIVE;1.0l;2.50 +20091-5;Temperature;Temp;Pt;Inhl gas;Qn;Body hood;PULM;2;Temperature Inhaled gas by Body hood;Temp IhG Body Hood;;ACTIVE;1.0l;2.48 +20092-3;Temperature;Temp;Pt;Inhl gas;Qn;;PULM;2;Temperature Inhaled gas;Temp IhG;;ACTIVE;1.0l;2.48 +20093-1;Temperature;Temp;Pt;Humidifier;Qn;;PULM;2;Temperature Humidifier;Temp Humidifier;;ACTIVE;1.0l;2.73 +20094-9;Temperature;Temp;Pt;Airway.proximal;Qn;;PULM;2;Temperature Proximal airway;Temp Prox airway;;ACTIVE;1.0l;2.48 +20095-6;Temperature;Temp;Pt;Airway.distal;Qn;;PULM;2;Temperature Distal airway;Temp Dis airway;;ACTIVE;1.0l;2.48 +20096-4;Temperature.airway max setting;Temp;Pt;Ventilator.alarm;Qn;;PULM;2;Maximum airway temperature setting Ventilator alarm;Airway Temp Max Vent alarm;;ACTIVE;1.0l;2.48 +20097-2;Temperature.airway min setting;Temp;Pt;Ventilator.alarm;Qn;;PULM;2;Minimum temperature airway setting Ventilator alarm;Airway Temp Min Vent alarm;;ACTIVE;1.0l;2.48 +20098-0;Temperature setting;Temp;Pt;Humidifier;Qn;;PULM;2;Temperature setting Humidifier;Temp setting Humidifier;;ACTIVE;1.0l;2.48 +2009-9;Cancer Ag 19-9;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 19-9 [Presence] in Serum or Plasma;Cancer Ag19-9 SerPl Ql;;ACTIVE;1.0;2.73 +20099-8;Tidal volume max setting;Vol;Pt;Ventilator.alarm;Qn;;PULM;2;Maximum tidal volume setting Ventilator alarm;VT max setting Vent alarm;;ACTIVE;1.0l;2.48 +20100-4;Tidal volume min setting;Vol;Pt;Ventilator.alarm;Qn;;PULM;2;Minimum tidal volume setting Ventilator alarm;VT min setting Vent alarm;;ACTIVE;1.0l;2.48 +20101-2;Tidal volume.expired/Pressure.peak inspiratory^on ventilator;Compli;Pt;Respiratory system;Qn;Calculated;PULM;2;Deprecated Tidal volume expired/Peak inspiratory pressure Calculated --on ventilator;Deprecated Vet/PIP on vent Calc;;DEPRECATED;1.0l;2.42 +20102-0;Tidal volume.expired/Pressure.peak inspiratory^on ventilator;Compli;Pt;Respiratory system;Qn;;PULM;2;Tidal volume expired/Peak inspiratory pressure --on ventilator;VT.expired/PIP on vent;;ACTIVE;1.0l;2.50 +20103-8;Tidal volume.expired/Pressure.plateau^post 1.5-2.0 s inspiratory hold on ventilator;Compli;Pt;Respiratory system;Qn;;PULM;2;Tidal volume expired/Plateau pressure --post 1.5-2.0 seconds inspiratory hold on ventilator;CES p 1.5-2.0 s insp hold on vent;;ACTIVE;1.0l;2.48 +20104-6;Tidal volume.expired/Pressure.plateau^post 1.5-2.0 s inspiratory hold on ventilator;Compli;Pt;Respiratory system;Qn;Calculated;PULM;2;Deprecated Tidal volume expired/Plateau pressure Calculated --post 1.5-2.0 seconds inspiratory hold on ventilator;Deprecated CES p 1.5-2.0 s insp hold on;;DEPRECATED;1.0l;2.42 +20105-3;Tidal volume.expired.spontaneous^^uncorrected for compressible gas volume setting;Vol;Pt;Ventilator;Qn;;PULM;2;Tidal volume expired spontaneous uncorrected for compressible gas volume setting Ventilator;Spont VT Compres gas vol set uncor Vent;;ACTIVE;1.0l;2.48 +20106-1;Tidal volume.expired.spontaneous^on ventilator^corrected for compressible gas volume;Vol;Pt;Respiratory system.airway;Qn;;PULM;2;Tidal volume expired spontaneous corrected for compressible gas volume Respiratory system airway --on ventilator;Spont VT on vent corrected Airway;;ACTIVE;1.0l;2.48 +2010-7;Cancer Ag 19-9;ACnc;Pt;Ser/Plas;Ord;;CHEM;1;Deprecated Cancer Ag 19-9 [Presence] in Serum or Plasma;Deprecated Cancer Ag19-9 SerPl Ql;;DEPRECATED;1.0;2.36 +20107-9;Tidal volume.expired.spontaneous+mechanical^on ventilator;Vol;Pt;Respiratory system.airway;Qn;;PULM;2;Tidal volume expired spontaneous+mechanical Respiratory system airway --on ventilator;Spont+mech Vet on vent Airway;;ACTIVE;1.0l;2.48 +20108-7;Tidal volume.expired.spontaneous+mechanical^on ventilator^corrected for compressible gas volume;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume expired spontaneous+mechanical corrected for compressible gas volume --on ventilator;Spont+mech Vet on vent corrected;;ACTIVE;1.0l;2.48 +20109-5;Tidal volume.inspired.spontaneous+mechanical^on ventilator;Vol;Pt;Respiratory system;Qn;Measured;PULM;2;Tidal volume inspired spontaneous+mechanical Measured --on ventilator;Spont+mech Vit on vent Measured;;ACTIVE;1.0l;2.48 +20110-3;Tidal volume.inspired.spontaneous+mechanical^on ventilator;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume inspired spontaneous+mechanical --on ventilator;Spont+mech Vit on vent;;ACTIVE;1.0l;2.48 +20111-1;Tidal volume.inspired.spontaneous+mechanical^on ventilator^corrected for compressible gas volume;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume inspired spontaneous+mechanical corrected for compressible gas volume --on ventilator;Spont+mech Vit on vent corrected;;ACTIVE;1.0l;2.73 +20112-9;Tidal volume setting;Vol;Pt;Ventilator;Qn;;PULM;2;Tidal volume setting Ventilator;VT setting Vent;;ACTIVE;1.0l;2.73 +20113-7;Tidal volume setting;VRat;Pt;Ventilator;Qn;;PULM;2;Tidal volume rate setting Ventilator;VT rate setting Vent;;ACTIVE;1.0l;2.73 +20114-5;Tidal volume.sigh.spontaneous+mechanical^on ventilator;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume sigh spontaneous+mechanical --on ventilator;Spont+mech VT sigh on vent;;ACTIVE;1.0m;2.48 +2011-5;Cancer Ag 242;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 242 [Presence] in Serum or Plasma;Cancer Ag242 SerPl Ql;;ACTIVE;1.0;2.56 +20115-2;Tidal volume.spontaneous/Body weight^on ventilator;VCnt;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.spontaneous/Body weight [Volume/mass] --on ventilator;Spont VT/BW on vent VCnt;;ACTIVE;1.0m;2.48 +20116-0;Tidal volume.spontaneous^on ventilator;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.spontaneous --on ventilator;Spont VT on vent;;ACTIVE;1.0m;2.73 +20117-8;Tidal volume.spontaneous+mechanical/Body weight^on ventilator;VCnt;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.spontaneous+mechanical/Body weight [Volume/mass] --on ventilator;Spont+mech VT/BW on vent VCnt;;ACTIVE;1.0m;2.48 +20118-6;Tidal volume.spontaneous+mechanical^on ventilator;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.spontaneous+mechanical --on ventilator;Spont+mech VT on vent;;ACTIVE;1.0m;2.48 +20119-4;Tidal volume.spontaneous+mechanical^on ventilator^corrected for compressible gas volume;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.spontaneous+mechanical corrected for compressible gas volume --on ventilator;Spont+mech VT on vent corrected;;ACTIVE;1.0m;2.48 +20120-2;Tidal volume.spontaneous+mechanical/Body weight^on ventilator^corrected for compressible gas volume;VCnt;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.spontaneous+mechanical/Body weight [Volume/mass] corrected for compressible gas volume --on ventilator;Spont+mech VT/BW on vent corrected VCnt;;ACTIVE;1.0m;2.48 +20121-0;Tidal volume.spontaneous+mechanical^on ventilator^uncorrected for compressible gas volume;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.spontaneous+mechanical uncorrected for compressible gas volume --on ventilator;Spont+mech VT on vent uncorrected;;ACTIVE;1.0m;2.48 +20122-8;Transcutaneous monitor site;Anat;Pt;*;Nom;;PULM;2;Transcutaneous monitor site;Transcutaneous monitor site;;ACTIVE;1.0m;2.27 +2012-3;Cancer Ag 27-29;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 27-29 [Presence] in Serum or Plasma;Cancer Ag27-29 SerPl Ql;;ACTIVE;1.0;2.73 +20123-6;Tubing types;Type;Pt;*;Nom;;PULM;2;Tubing types;Tubing types;;ACTIVE;1.0m;2.27 +20124-4;Ventilation mode;Type;Pt;Ventilator;Nom;*;PULM;2;Ventilation mode Ventilator;Ventilation mode Vent;;ACTIVE;1.0m;2.73 +20125-1;Ventilator type;Type;Pt;*;Nom;;PULM;2;Ventilator type;Vent type;;ACTIVE;1.0m;2.73 +20126-9;Ventilator.wave form;Type;Pt;*;Nom;;PULM;2;Ventilator wave form;Waveform Vent;;ACTIVE;1.0m;2.73 +20127-7;Volume;Vol;Pt;Gas^breathing circuit;Qn;Gas dilution.rebreathing;PULM;2;Volume Gas from Breathing circuit by Gas dilution.rebreath;Volume breath circuit Gas Dil.rebreath;;ACTIVE;1.0m;2.48 +20128-5;Volume;Vol;Pt;Gas^breathing circuit;Qn;;PULM;2;Volume Gas from Breathing circuit;Volume Gas Breath circuit;;ACTIVE;1.0m;2.48 +20129-3;Volume;Vol;Pt;Breathing bag;Qn;Gas dilution.rebreathing;PULM;2;Volume Breathing bag by Gas dilution.rebreath;Volume Breathing Bag Gas Dil.rebreath;;ACTIVE;1.0m;2.48 +20130-1;Volume;Vol;Pt;Breathing bag;Qn;;PULM;2;Volume Breathing bag;Volume Breathing Bag;;ACTIVE;1.0m;2.48 +2013-1;Cancer Ag 50;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 50 [Presence] in Serum or Plasma;Cancer Ag50 SerPl Ql;;ACTIVE;1.0;2.56 +20131-9;Volume;Vol;Pt;Thoracic gas;Qn;Plethysmograph.body box;PULM;2;Volume Thoracic gas by Plethysmograph body box;Volume Thoracic gas Plethysmograph;;ACTIVE;1.0m;2.48 +20132-7;Volume;Vol;Pt;Thoracic gas;Qn;;PULM;2;Volume Thoracic gas;Volume Thoracic gas;;ACTIVE;1.0m;2.48 +20133-5;Volume max setting;VRat;Pt;Ventilator.alarm;Qn;;PULM;2;Maximum volume setting Ventilator alarm;Vol max Vent alarm;;ACTIVE;1.0m;2.27 +20134-3;Volume min setting;VRat;Pt;Ventilator.alarm;Qn;;PULM;2;Minimum volume setting Ventilator alarm;Vol min Vent alarm;;ACTIVE;1.0m;2.27 +20135-0;Volume at 25-75% of forced expiration.post bronchodilation/Volume at 25-75% of forced expiration.predicted;RelVol;Pt;Respiratory system;Qn;;PULM;2;FEV 25%-75% post bronchodilation measured/predicted;FEV 25-75% p BD meas/pred;;ACTIVE;1.0m;2.66 +20136-8;Volume at 25-75% of forced expiration.pre bronchodilation/Volume at 25-75% of forced expiration.predicted;RelVol;Pt;Respiratory system;Qn;;PULM;2;FEV 25%-75% pre bronchodilation measured/predicted;FEV 25-75% pre BD meas/pred;;ACTIVE;1.0m;2.66 +20137-6;Volume at 25-75% of forced expiration/Volume at 25-75% of forced expiration.predicted;RelVol;Pt;Respiratory system;Qn;;PULM;2;FEV 25%-75% measured/predicted;FEV 25-75% meas/pred;;ACTIVE;1.0m;2.66 +20138-4;Volume.compressed gas;Vol;Pt;Ventilator airway circuit;Qn;;PULM;2;Volume compressed gas Ventilator airway circuit;Vol compressed gas Vent airway circuit;;ACTIVE;1.0m;2.48 +20139-2;Volume.expired;Vol;1M;Respiratory system;Qn;;PULM;2;Volume expired 1 minute;Vol exp 1M;;ACTIVE;1.0m;2.73 +201-4;Colistimethate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Colistimethate by Minimum inhibitory concentration (MIC);Colistimethate Islt MIC;;ACTIVE;1.0;2.73 +20140-0;Volume.expired;Vol;Pt;Respiratory system;Qn;;PULM;2;Volume expired;Vol exp;;ACTIVE;1.0m;2.48 +20141-8;Volume.expired per minute/Body weight^on ventilator;VRatCnt;Pt;Respiratory system;Qn;;PULM;2;Volume expired per minute/Body weight --on ventilator;Vol.exp/M/BW on vent;;ACTIVE;1.0m;2.73 +20142-6;Volume.forced expiration.total;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV;FEV;;ACTIVE;1.0m;2.73 +20143-4;Volume.residual;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Residual volume by Helium rebreathing;Residual vol He Rebreath;;ACTIVE;1.0m;2.48 +20144-2;Volume.residual;Vol;Pt;Respiratory system;Qn;Helium single breath;PULM;2;Residual volume by Helium single breath;Residual vol He SB;;ACTIVE;1.0m;2.48 +20145-9;Volume.residual;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;Residual volume Predicted;Residual vol Predicted;;ACTIVE;1.0m;2.48 +20146-7;Volume.residual;Vol;Pt;Respiratory system;Qn;;PULM;2;Residual volume;Residual vol;;ACTIVE;1.0m;2.73 +20147-5;Volume expired during 0.5 s of forced expiration;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV.5 Predicted;FEV.5 Predicted;;ACTIVE;1.0m;2.40 +20148-3;Volume expired during 0.5 s of forced expiration;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV.5;FEV.5;;ACTIVE;1.0m;2.40 +2014-9;Cancer Ag 549;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 549 [Presence] in Serum or Plasma;Cancer Ag549 SerPl Ql;;ACTIVE;1.0;2.56 +20149-1;Volume expired during 1.0 s of forced expiration;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV1 Predicted;FEV1 Predicted;;ACTIVE;1.0m;2.73 +20150-9;Volume expired during 1.0 s of forced expiration;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1;FEV1;;ACTIVE;1.0m;2.73 +20151-7;Volume expired during 1.0 s of forced expiration measured/Predicted;RelVol;Pt;Respiratory system;Qn;Calculation;PULM;2;Deprecated FEV1/Predicted by Calculation;Deprecated FEV1/Predicted Calcn;;DEPRECATED;1.0m;2.42 +20152-5;Volume expired during 1.0 s of forced expiration/Predicted;RelVol;Pt;Respiratory system;Qn;;PULM;2;FEV1 measured/predicted;FEV1 meas/pred;;ACTIVE;1.0m;2.73 +20153-3;Volume expired during 1.0 s of forced expiration/Volume.forced expiration.total;VFr;Pt;Respiratory system;Qn;;PULM;2;FEV1/FEV total;FEV1/FEV total VFr;;ACTIVE;1.0m;2.40 +20154-1;Volume expired during 1.0 s of forced expiration^post bronchodilation;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV1 Predicted --post bronchodilation;FEV1 p BD Predicted;;ACTIVE;1.0m;2.64 +20155-8;Volume expired during 1.0 s of forced expiration^post bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --post bronchodilation;FEV1 p BD;;ACTIVE;1.0m;2.73 +2015-6;Cancer Ag 72-4;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cancer Ag 72-4 [Presence] in Serum or Plasma;Cancer Ag72-4 SerPl Ql;;ACTIVE;1.0;2.73 +20156-6;Volume expired during 1.0 s of forced expiration^pre bronchodilation;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV1 Predicted --pre bronchodilation;FEV1 pre BD Predicted;;ACTIVE;1.0m;2.64 +20157-4;Volume expired during 1.0 s of forced expiration^pre bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --pre bronchodilation;FEV1 pre BD;;ACTIVE;1.0m;2.73 +20158-2;Voluntary ventilation.max;VRat;Pt;Respiratory system;Qn;Predicted;PULM;2;Maximum voluntary ventilation Predicted;MVV Predicted;;ACTIVE;1.0m;2.73 +20159-0;Voluntary ventilation.max;VRat;Pt;Respiratory system;Qn;;PULM;2;Maximum voluntary ventilation;MVV;;ACTIVE;1.0m;2.48 +20160-8;Voluntary ventilation.max^post bronchodilator;VRat;Pt;Respiratory system;Qn;;PULM;2;Maximum voluntary ventilation --post bronchodilator;MVV p BD;;ACTIVE;1.0m;2.48 +20161-6;Voluntary ventilation.max^post bronchodilator/Voluntary ventilation.max predicted;RelVRat;Pt;Respiratory system;Qn;;PULM;2;Maximum voluntary ventilation [Flow] --post bronchodilator/Voluntary ventilation.maximum predicted;MVV p BD/Pred RelVRat;;ACTIVE;1.0m;2.40 +20162-4;Voluntary ventilation.max^pre bronchodilator;VRat;Pt;Respiratory system;Qn;Measured;PULM;2;Maximum voluntary ventilation Measured --pre bronchodilator;MVV pre BD Measured;;ACTIVE;1.0m;2.48 +20163-2;Voluntary ventilation.max^pre bronchodilator;VRat;Pt;Respiratory system;Qn;;PULM;2;Maximum voluntary ventilation --pre bronchodilator;MVV pre BD;;ACTIVE;1.0m;2.48 +2016-4;Carbamoyl phosphate synthetase;CCnc;Pt;Ser;Qn;;CHEM;1;Carbamoyl phosphate synthetase [Enzymatic activity/volume] in Serum;CPS Ser-cCnc;;ACTIVE;1.0;2.68 +20164-0;Voluntary ventilation.max^pre bronchodilator/Voluntary ventilation.max predicted;RelVRat;Pt;Respiratory system;Qn;;PULM;2;Maximum voluntary ventilation [Flow] --pre bronchodilator/Voluntary ventilation.maximum predicted;MVV pre BD/Pred RelVRat;;ACTIVE;1.0m;2.73 +20165-7;Region;Area;Pt;Region of interest.XXX;Qn;US.2D;CARD.US;2;Region of interest Region [Area] by US 2D;ROI Region Area 2D US;;ACTIVE;1.0m;2.48 +20166-5;Diameter;Len;Pt;Circulatory system.XXX;Qn;US.2D;CARD.US;2;Diameter by US 2D;Diam 2D US;;ACTIVE;1.0m;2.48 +20167-3;Acceleration slope;Vel;Pt;{Circulatory system};Qn;US.doppler;CARD.US;2;Circulatory system Acceleration slope by US.doppler;Circ sys Accel slope DOP;;ACTIVE;1.0m;2.29 +20168-1;Acceleration;Time;Pt;{Circulatory system};Qn;US.doppler;CARD.US;2;Circulatory system Acceleration by US.doppler;Circ sys Accel Time DOP;;ACTIVE;1.0m;2.48 +20169-9;Acceleration;Time;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Deprecated Circulatory system Acceleration by US.doppler;Deprecated Circ sys Accel Time US.dop;;DEPRECATED;1.0m;2.36 +20170-7;Acceleration 2;Time;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Acceleration 2 by US;Accel 2 Time US;;ACTIVE;1.0m;2.48 +20171-5;Acceleration/Acceleration 2;TRto;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Acceleration/Acceleration 2 by US;Accel/Accel 2 US;;ACTIVE;1.0m;2.48 +2017-2;Carbamoyl phosphate synthetase(ammonia);CCnt;Pt;Tiss;Qn;;CHEM;1;Carbamoyl phosphate synthetase (ammonia) [Enzymatic activity/mass] in Tissue;CPS (ammonia) Tiss-cCnt;;ACTIVE;1.0;2.42 +20172-3;Regurgitant blood flow velocity.end diastole;Vel;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Regurgitant blood flow velocity at end diastole by US.doppler;AV ED regurg velocity DOP;;ACTIVE;1.0m;2.68 +20173-1;Regurgitant blood flow velocity.diastole.max;Vel;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Maximum regurgitant blood flow velocity during diastole by US.doppler;AV reg Vmax dias DOP;;ACTIVE;1.0m;2.68 +20174-9;Acceleration slope;Vel;Pt;Aortic valve;Qn;US;CARD.US;2;Aortic valve Acceleration slope by US;AV Accel slope US;;ACTIVE;1.0m;2.27 +20175-6;Deceleration slope;Vel;Pt;Aortic valve;Qn;US;CARD.US;2;Aortic valve Deceleration slope [Velocity] by US;AV Decel slope US;;ACTIVE;1.0m;2.27 +20176-4;Deceleration;Time;Pt;Aortic valve;Qn;US;CARD.US;2;Aortic valve Deceleration [Time] by US;AV Decel Time US;;ACTIVE;1.0m;2.48 +20177-2;Crossection;Area;Pt;Aorta.root;Qn;US.calculated;CARD.US;2;Aorta root Crossection [Area] by US.calculated;AO root Xsection Area US Calc;;ACTIVE;1.0m;2.48 +20178-0;Crossection;Area;Pt;Aorta.root;Qn;US.2D;CARD.US;2;Aorta root Crossection [Area] by US 2D;AO root Xsection Area 2D US;;ACTIVE;1.0m;2.48 +20179-8;RR interval^at aortic flow measurement;Time;Pt;Heart;Qn;US;CARD.US;2;R-R interval by US --at aortic flow measurement;R-R interval @ AV flow US;;ACTIVE;1.0m;2.48 +2018-0;Carbon dioxide;PPres;Pt;Amnio fld;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Amniotic fluid;pCO2 Amn;;ACTIVE;1.0;2.30 +20180-6;Area;Area;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Area by US;ROI Area US;;ACTIVE;1.0m;2.48 +20181-4;Area 2;Area;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Area 2 by US;ROI Area 2 US;;ACTIVE;1.0m;2.48 +20182-2;Area.XXX/Area 2.XXX;AreaRto;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Area/Area 2 by US;ROI Area/Area 2 US;;ACTIVE;1.0m;2.69 +20183-0;Blood flow velocity.max^at stenosis;Vel;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Maximum blood flow velocity by US.doppler --at stenosis;AV Vmax @ stenosis DOP;;ACTIVE;1.0m;2.67 +20184-8;Intravascular diastolic;Pres;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Diastolic blood pressure by US;BP dias US;;ACTIVE;1.0m;2.40 +20185-5;Intravascular end systolic.XXX;Pres;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;End systolic blood pressure by US;BP end sys US;;ACTIVE;1.0m;2.40 +20186-3;Intravascular peak systolic.XXX;Pres;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Peak systolic blood pressure by US;BP peak sys US;;ACTIVE;1.0m;2.73 +20187-1;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane ellipse method;CARD.US;2;Left ventricular Cardiac index by US.2D+Calculated by biplane ellipse method;LV Cardiac index US.2D+BP-EL;;ACTIVE;1.0m;2.52 +20188-9;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by bullet method;CARD.US;2;Left ventricular Cardiac index by US.2D+Calculated by bullet method;LV Cardiac index US.2D+bullet;;ACTIVE;1.0m;2.52 +20189-7;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.XXX;Qn;US.cubed.calculated;CARD.US;2;Ventricular Cardiac index by US.cubed.calculated;Hrt ventr Cardiac index US.cubed;;ACTIVE;1.0m;2.34 +20190-5;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.2D.LVOT area.calculated;CARD.US;2;Left ventricular Cardiac index by US 2D left ventricular outflow tract area calculated;LV Cardiac index US.2D.LVOT area;;ACTIVE;1.0m;2.48 +20191-3;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane ellipse.calculated;CARD.US;2;Left ventricular Cardiac index by US 2D modified biplane ellipse calculated;LV Cardiac index US.2D.MOD-BP-EL;;ACTIVE;1.0m;2.48 +20192-1;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.modified Simpson.calculated;CARD.US;2;Left ventricular Cardiac index by US.modified Simpson.calculated;LV Cardiac index US.Mod Simp;;ACTIVE;1.0m;2.48 +20193-9;Cardiac output/Body surface area.2 chamber;ArVRat;Pt;Heart.ventricle.left;Qn;US.mod.single-plane.calculated;CARD.US;2;Left ventricular Cardiac index 2 chamber by US.modified.single-plane.calculated;LV Cardiac index 2cham US.MOD-SP;;ACTIVE;1.0m;2.48 +20194-7;Cardiac output/Body surface area.4 chamber;ArVRat;Pt;Heart.ventricle.left;Qn;US.mod.single-plane.calculated;CARD.US;2;Left ventricular Cardiac index 4 chamber by US.modified.single-plane.calculated;LV Cardiac index 4cham US.MOD-SP;;ACTIVE;1.0m;2.48 +20195-4;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.2D.mitral valve.calculated;CARD.US;2;Left ventricular Cardiac index by US 2D mitral valve calculated;LV Cardiac index US.2D.MV;;ACTIVE;1.0m;2.48 +20196-2;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;US.2D.pulmonic valve.calculated;CARD.US;2;Right ventricular Cardiac index by US 2D pulmonic valve calculated;RV Cardiac index US.2D.PV;;ACTIVE;1.0m;2.48 +20197-0;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by single-plane ellipse method;CARD.US;2;Left ventricular Cardiac index by US.2D+Calculated by single-plane ellipse method;LV Cardiac index US.2D+SP-EL;;ACTIVE;1.0m;2.52 +2019-8;Carbon dioxide;PPres;Pt;BldA;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Arterial blood;pCO2 BldA;;ACTIVE;1.0;2.73 +20198-8;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US+Calculated by Teichholz method;CARD.US;2;Left ventricular Cardiac index by US+Calculated by Teichholz method;LV Cardiac index US+Teichholz;;ACTIVE;1.0m;2.52 +20199-6;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;US.2D.tricuspid valve.calculated;CARD.US;2;Right ventricular Cardiac index by US 2D tricuspid valve calculated;RV Cardiac index US.2D.TV;;ACTIVE;1.0m;2.48 +20200-2;Circumference.XXX/Circumference 2.XXX;CircFr;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Circumference/Circumference 2 by US;ROI Circumf/Circumf 2 CircFr US;;ACTIVE;1.0m;2.48 +20201-0;Circulatory system;Prid;Pt;*;Nom;;CARD.US;2;Circulatory system [Identifier];Circ sys;;ACTIVE;1.0m;2.27 +20202-8;Circumference;Circ;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Circumference by US;ROI Circumf US;;ACTIVE;1.0m;2.48 +20203-6;Circumference 2;Circ;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Circumference 2 by US;ROI Circumf 2 US;;ACTIVE;1.0m;2.48 +20204-4;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane ellipse method;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated by biplane ellipse method;LV Output US.2D+BP-EL;;ACTIVE;1.0m;2.52 +20205-1;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by bullet method;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated by bullet method;LV Output US.2D+bullet;;ACTIVE;1.0m;2.52 +2020-6;Carbon dioxide;PPres;Pt;BldC;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Capillary blood;pCO2 BldC;;ACTIVE;1.0;2.73 +20206-9;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.cubed.calculated;CARD.US;2;Left ventricular Cardiac output by US.cubed.calculated;LV Output US.cubed;;ACTIVE;1.0m;2.48 +20207-7;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D.left ventricular outflow tract.calculated;CARD.US;2;Left ventricular Cardiac output by US 2D left ventricular outflow tract calculated;LV Output US.2D.LVOT;;ACTIVE;1.0m;2.48 +20208-5;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane.calculated;CARD.US;2;Left ventricular Cardiac output by US 2D modified biplane calculated;LV Output US.2D.MOD-BP;;ACTIVE;1.0m;2.48 +20209-3;Cardiac output;VRat;Pt;Heart.ventricle.XXX;Qn;US.2D+Calculated by modified Simpson method;CARD.US;2;Ventricular Cardiac output by US.2D+Calculated by modified Simpson method;Hrt ventr Output US.2D+mod Simpson;;ACTIVE;1.0m;2.52 +20210-1;Cardiac output.2 chamber;VRat;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane.calculated;CARD.US;2;Left ventricular Cardiac output.2 chamber by US 2D modified single-plane calculated;LV Output.2CH US.2D.MOD-SP;;ACTIVE;1.0m;2.48 +20211-9;Cardiac output.4 chamber;VRat;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane.calculated;CARD.US;2;Left ventricular Cardiac output.4 chamber by US 2D modified single-plane calculated;LV Output 4CH US.2D.MOD-SP;;ACTIVE;1.0m;2.48 +20212-7;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by single-plane ellipse method;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated by single-plane ellipse method;LV Output US.2D+SP-EL;;ACTIVE;1.0m;2.52 +20213-5;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US+Calculated by Teichholz method;CARD.US;2;Left ventricular Cardiac output by US+Calculated by Teichholz method;LV Output US+Teichholz;;ACTIVE;1.0m;2.52 +2021-4;Carbon dioxide;PPres;Pt;BldV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Venous blood;pCO2 BldV;;ACTIVE;1.0;2.73 +20214-3;Cardiac output;VRat;Pt;Heart.ventricle.right;Qn;US.2D.tricuspid valve;CARD.US;2;Right ventricular Cardiac output by US 2D tricuspid valve;RV Output US.2D.TV;;ACTIVE;1.0m;2.48 +20215-0;Deceleration.max;Vel;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Maximum deceleration [Velocity] by US;Decel.max Vel US;;ACTIVE;1.0m;2.29 +20216-8;Deceleration slope;Vel;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Deceleration slope [Velocity] by US;Decel slope US;;ACTIVE;1.0m;2.27 +20217-6;Deceleration;Time;Pt;{Circulatory system};Qn;US;CARD.US;2;Circulatory system Deceleration [Time] by US;Circ sys Decel Time US;;ACTIVE;1.0m;2.48 +20218-4;Deceleration;Vel;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Deceleration [Velocity] by US;Decel Vel US;;ACTIVE;1.0m;2.29 +20219-2;Deceleration 2;Vel;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Deceleration 2 [Velocity] by US;Decel 2 Vel US;;ACTIVE;1.0m;2.29 +202-2;Colistimethate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Colistimethate by Disk diffusion (KB);Colistimethate Islt KB;;ACTIVE;1.0;2.19 +20220-0;Deceleration.XXX/Deceleration 2.XXX;TRto;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Deceleration/Deceleration 2 by US;Decel/Decel 2 US;;ACTIVE;1.0m;2.69 +20221-8;Ejection time;Time;Pt;Heart.ventricle.XXX;Qn;US.doppler;CARD.US;2;Ventricular Ejection time by US.doppler;Hrt ventr Ejection time DOP;;ACTIVE;1.0m;2.54 +2022-2;Carbon dioxide;PPres;Pt;CSF;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Cerebral spinal fluid;pCO2 CSF;;ACTIVE;1.0;2.30 +20222-6;Ejection time;Time;Pt;Heart.ventricle.XXX;Qn;US;CARD.US;2;Ventricular Ejection time by US;Hrt ventr Ejection time US;;ACTIVE;1.0m;2.54 +20223-4;Ejection time 2;Time;Pt;Heart.ventricle.XXX;Qn;US;CARD.US;2;Ventricular Ejection time 2 by US;Hrt ventr Ejection time 2 US;;ACTIVE;1.0m;2.54 +20224-2;Ejection time/Ejection time 2;TRto;Pt;Heart.ventricle.left;Qn;US.calculated;CARD.US;2;Left ventricular Ejection time/Ejection time 2 by US.calculated;LV Ejection time/Ejection time 2 US Calc;;ACTIVE;1.0m;2.69 +20225-9;Regurgitant blood flow velocity.diastole.min.end;Vel;Pt;Pulmonic valve;Qn;US;CARD.US;2;Pulmonic valve Minimum end diastole regurgitant blood flow velocity by US;PV Regurg Vmin dias end US;;ACTIVE;1.0m;2.68 +20226-7;Flow.XXX;Area;Pt;Circulatory system.XXX;Qn;US+Calculated;CARD.US;2;Flow [Area] by US+Calculated;Flow Area US+Calc;;ACTIVE;1.0m;2.52 +20227-5;Height;Len;Pt;Region of interest.XXX;Qn;US.M-mode;CARD.US;2;Region of interest Height by US.M-mode;ROI Height M-mode;;ACTIVE;1.0m;2.54 +20228-3;Laterality;Type;Pt;Anatomic part.*;Nom;;CARD.US;2;Anatomic part Laterality;Anatomic part Laterality;;ACTIVE;1.0m;2.73 +20229-1;Length.XXX/Length 2.XXX;LenFr;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Length/Length 2 by US;ROI Length/Length 2 US;;ACTIVE;1.0m;2.48 +2023-0;Carbon dioxide;PPres;Pt;Body fld;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Body fluid;pCO2 Fld;;ACTIVE;1.0;2.30 +20230-9;Length;Len;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Length by US;ROI Length US;;ACTIVE;1.0m;2.48 +20231-7;Length 2;Len;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Length 2 by US;ROI Length 2 US;;ACTIVE;1.0m;2.48 +20232-5;Blood flow velocity.mean;Vel;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US;2;Left ventricular outflow tract Mean blood flow velocity by US.doppler;LVOT Vmean DOP;;ACTIVE;1.0m;2.67 +20233-3;Pressure gradient.systole.mean;PressDiff;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US;2;Left ventricular outflow tract Mean systole pressure gradient by US.doppler;LVOT Mean press grad sys DOP;;ACTIVE;1.0m;2.73 +20234-1;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by bullet method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by bullet method;LV ED vol US.2D+bullet;;ACTIVE;1.0m;2.52 +20235-8;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.cubed.calculated;CARD.US;2;Left ventricular End-diastolic volume by US.cubed.calculated;LV ED vol US.cubed;;ACTIVE;1.0m;2.52 +20236-6;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane ellipse.calculated;CARD.US;2;Left ventricular End-diastolic volume by US 2D modified biplane ellipse calculated;LV ED vol US.2D.MOD-BP-EL;;ACTIVE;1.0m;2.52 +20237-4;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by modified Simpson method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by modified Simpson method;LV ED vol US.2D+mod Simpson;;ACTIVE;1.0m;2.52 +20238-2;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Teichholz method;CARD.US;2;Left ventricular End-diastolic volume by US.M-mode+Calculated by Teichholz method;LV ED vol US.M-mode+Teichholz;;ACTIVE;1.0m;2.52 +20239-0;Plane.apical.diastole;Area;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Apical plane diastole [Area] by US 2D;LV Plane apical dias Area 2D US;;ACTIVE;1.0m;2.48 +20240-8;Short axis.papillary level.diastole;Area;Pt;Heart.ventricle.left.epicardium;Qn;US.2D;CARD.US;2;Left ventricular epicardium Short axis papillary level diastole [Area] by US 2D;LV.epi SAX PM dias Area 2D US;;ACTIVE;1.0m;2.48 +20241-6;Plane.apical.systole;Area;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Apical plane systole [Area] by US 2D;LV Plane apical sys Area 2D US;;ACTIVE;1.0m;2.48 +20242-4;Short axis.papillary level.systole;Area;Pt;Heart.ventricle.left.epicardium;Qn;US.2D;CARD.US;2;Left ventricular epicardium Short axis papillary level systole [Area] by US 2D;LV.epi SAX PM sys Area 2D US;;ACTIVE;1.0m;2.48 +20243-2;Internal diameter.minor axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Deprecated Internal diameter.minor axis.diastole of Heart ventricle Left US 2D;Deprecated LV Diam dias, short 2D US;;DEPRECATED;1.0m;2.36 +20244-0;Internal diameter.minor axis.systole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Deprecated Internal diameter.minor axis.systole of Heart ventricle Left US 2D;DeprecatedInternal diameter.minor axis.s;;DEPRECATED;1.0m;2.36 +20245-7;Region crossection;Area;Pt;Heart.ventricle.left.outflow tract;Qn;US+Calculated;CARD.US;2;Left ventricular outflow tract Region crossection [Area] by US+Calculated;LVOT Region Xsection Area US+Calc;;ACTIVE;1.0m;2.52 +20246-5;Pre ejection period;Time;Pt;Heart.ventricle.left;Qn;US.measured;CARD.US;2;Deprecated Pre ejection period of Heart ventricle Left US;DeprecatedPre ejection period;;DEPRECATED;1.0m;2.36 +20247-3;Pressure gradient.max;PressDiff;Pt;Circulatory system.XXX;Qn;US+Calculated;CARD.US;2;Peak pressure gradient by US+Calculated;Peak press grad US+Calc;;ACTIVE;1.0m;2.67 +2024-8;Carbon dioxide.dissolved;SCnc;Pt;Plas;Qn;;CHEM;1;Carbon dioxide dissolved [Moles/volume] in Plasma;dis CO2 Plas-sCnc;;ACTIVE;1.0;2.73 +20248-1;Pressure gradient 2.max;PressDiff;Pt;Circulatory system.XXX;Qn;US+Calculated;CARD.US;2;Maximum pressure gradient 2 by US+Calculated;Max press grad 2 US+Calc;;ACTIVE;1.0m;2.67 +20249-9;Regurgitant pressure gradient.max;PressDiff;Pt;Aortic valve;Qn;US+Calculated;CARD.US;2;Aortic valve Maximum regurgitant pressure gradient by US+Calculated;AV Max regurg press gradient US+Calc;;ACTIVE;1.0m;2.67 +20250-7;Regurgitant pressure gradient.max;PressDiff;Pt;Mitral valve;Qn;US+Calculated;CARD.US;2;Mitral valve Maximum regurgitant pressure gradient by US+Calculated;MV Max regurg press gradient US+Calc;;ACTIVE;1.0m;2.67 +20251-5;Regurgitant pressure gradient.max;PressDiff;Pt;Pulmonic valve;Qn;US.calculated;CARD.US;2;Pulmonic valve Maximum regurgitant pressure gradient by US.calculated;PV Max regurg press gradient US Calc;;ACTIVE;1.0m;2.67 +20252-3;Systole.max/Systole 2.max;VelRto;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Maximum systole/Systole 2 maximum by US.doppler;Sys.max/Sys 2 DOP;;ACTIVE;1.0m;2.29 +20253-1;Blood flow.max;Vel;Pt;Tricuspid valve.regurgitant jet;Qn;US.doppler;CARD.US;2;Deprecated Tricuspid valve regurgitant jet Peak systolic flow by US.doppler;Deprecated TV reg Vmax sys US.dop;;DEPRECATED;1.0m;2.36 +20254-9;Regurgitant blood flow 2.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Peak regurgitant blood flow 2 by US.doppler;TV Regurg bld flow 2.max DOP;;ACTIVE;1.0m;2.67 +2025-5;Carbon dioxide.dissolved;SCnc;Pt;RBC;Qn;;CHEM;1;Carbon dioxide dissolved [Moles/volume] in Red Blood Cells;dis CO2 RBC-sCnc;;ACTIVE;1.0;2.73 +20255-6;Pressure gradient.mean;PressDiff;Pt;Circulatory system.XXX;Qn;US+Calculated;CARD.US;2;Mean pressure gradient by US+Calculated;Mean press grad US+Calc;;ACTIVE;1.0m;2.67 +20256-4;Pressure gradient.mean;PressDiff;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Mean pressure gradient by US.doppler;Mean press grad DOP;;ACTIVE;1.0m;2.67 +20257-2;Pressure gradient 2.mean;PressDiff;Pt;Circulatory system.XXX;Qn;US+Calculated;CARD.US;2;Mean pressure gradient 2 by US+Calculated;Press Grad 2.mean US+Calc;;ACTIVE;1.0m;2.67 +20258-0;Pressure gradient 2.mean;PressDiff;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Mean pressure gradient 2 by US;Press Grad 2.mean US;;ACTIVE;1.0m;2.67 +20259-8;Pressure gradient.mean.XXX/Pressure gradient 2.mean.XXX;PresRto;Pt;Circulatory system.XXX;Qn;US.doppler.calculated;CARD.US;2;Mean pressure gradient/Mean pressure gradient 2 by US.doppler calculated;Mean press grade/Mean press grade 2 DOP;;ACTIVE;1.0m;2.69 +20260-6;Systole.mean/Systole 2.mean;VelRto;Pt;Circulatory system.XXX;Qn;US.doppler.calculated;CARD.US;2;Mean sytole/Systole 2 mean by US.doppler calculated;Sys.mean/Sys 2 DOP;;ACTIVE;1.0m;2.29 +20261-4;Regurgitant blood flow velocity.mean;Vel;Pt;Tricuspid valve;Qn;US;CARD.US;2;Tricuspid valve Mean regurgitant blood flow velocity by US;TV Regurg Vmean US;;ACTIVE;1.0m;2.67 +20262-2;Regurgitant blood flow 2.mean;Vel;Pt;Tricuspid valve;Qn;US;CARD.US;2;Tricuspid valve Mean Regurgitant blood flow 2 by US;TV Regurg Bld flow 2.mean US;;ACTIVE;1.0m;2.67 +2026-3;Carbon dioxide;SCnc;Pt;BldA;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Arterial blood;CO2 BldA-sCnc;;ACTIVE;1.0;2.73 +20263-0;RR interval^at mitral flow measurement;Time;Pt;Heart;Qn;US;CARD.US;2;R-R interval by US --at mitral flow measurement;R-R interval @ MV flow US;;ACTIVE;1.0m;2.48 +20264-8;Region crossection;Area;Pt;Mitral valve.annulus;Qn;US+Calculated;CARD.US;2;Mitral valve annulus Region crossection [Area] by US+Calculated;MV ann Region Xsection Area US+Calc;;ACTIVE;1.0m;2.73 +20265-5;Slope;Vel;Pt;Circulatory system.XXX;Qn;US.M-mode;CARD.US;2;Slope [Velocity] by US.M-mode;Slope M-mode;;ACTIVE;1.0m;2.54 +20266-3;Slope 2;Vel;Pt;Circulatory system.XXX;Qn;US.M-mode;CARD.US;2;Slope 2 [Velocity] by US.M-mode;Slope 2 M-mode;;ACTIVE;1.0m;2.54 +20267-1;Slope.XXX/Slope 2.XXX;VelRto;Pt;Circulatory system.XXX;Qn;US.M-mode+Calculated;CARD.US;2;Slope/Slope 2 by US.M-mode+Calculated;Slope/Slope 2 US.M-mode+Calc;;ACTIVE;1.0m;2.69 +20268-9;Regurgitant blood flow velocity.systole.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Maximum regurgitant blood flow velocity during systole by US.doppler;MV reg Vmax sys DOP;;ACTIVE;1.0m;2.68 +20269-7;Acceleration slope;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Acceleration slope by US.doppler;MV Accel slope DOP;;ACTIVE;1.0m;2.29 +20270-5;Acceleration;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Acceleration by US.doppler;MV Accel Time DOP;;ACTIVE;1.0m;2.48 +2027-1;Carbon dioxide;SCnc;Pt;BldV;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Venous blood;CO2 BldV-sCnc;;ACTIVE;1.0;2.73 +20271-3;Filling period.diastole;Time;Pt;Mitral valve;Qn;US;CARD.US;2;Mitral valve Diastolic filling period by US;MV Dias fill period US;;ACTIVE;1.0m;2.48 +20272-1;Diameter;Len;Pt;Mitral valve;Qn;US;CARD.US;2;Mitral valve Diameter by US;MV Diam US;;ACTIVE;1.0m;2.48 +20273-9;Diameter 2;Len;Pt;Mitral valve;Qn;US;CARD.US;2;Mitral valve Diameter 2 by US;MV Diam 2 US;;ACTIVE;1.0m;2.27 +20274-7;Flow;Area;Pt;Mitral valve;Qn;US+Calculated;CARD.US;2;Mitral valve Flow [Area] by US+Calculated;MV Flow Area US+Calc;;ACTIVE;1.0m;2.52 +20275-4;Deceleration.pressure half-time;Len;Pt;Mitral valve;Qn;US.doppler.calculated;CARD.US;2;Deprecated Deceleration.pressure.half time of Mitral valve US.doppler;DeprecatedDeceleration.pressure half-tim;;DEPRECATED;1.0m;2.36 +20276-2;Blood flow velocity.systole.max^for peak half-time calculation;Vel;Pt;Mitral valve;Qn;US;CARD.US;2;Mitral valve Maximum blood flow velocity during systole by US --for peak half-time calculation;MV Vmax sys for peak 1/2T calc US;;ACTIVE;1.0m;2.67 +20277-0;Blood flow velocity.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Maximum blood flow velocity by US.doppler;MV Vmax DOP;;ACTIVE;1.0m;2.58 +20278-8;Blood velocity.mean;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Mean blood velocity by US.doppler;MV Bld vel.mean DOP;;ACTIVE;1.0m;2.29 +20279-6;Area orifice;Area;Pt;Mitral valve;Qn;US.2D;CARD.US;2;Deprecated Orifice.minor axis.min [Area] of Mitral valve US 2D;DeprecatedArea orifice;;DEPRECATED;1.0m;2.36 +20280-4;Pressure half time.XXX;Time;Pt;Circulatory system.XXX;Qn;US+Calculated;CARD.US;2;Pressure half time by US+Calculated;PHT US+Calc;;ACTIVE;1.0m;2.54 +20281-2;Acceleration slope;Vel;Pt;Pulmonary artery;Qn;US;CARD.US;2;Pulmonary artery Acceleration slope by US;PA Accel slope US;;ACTIVE;1.0m;2.27 +20282-0;Deceleration slope;Vel;Pt;Pulmonary artery;Qn;US;CARD.US;2;Pulmonary artery Deceleration slope [Velocity] by US;PA Decel slope US;;ACTIVE;1.0m;2.27 +20283-8;Deceleration;Time;Pt;Pulmonary artery;Qn;US;CARD.US;2;Pulmonary artery Deceleration [Time] by US;PA Decel Time US;;ACTIVE;1.0m;2.48 +20284-6;Blood flow velocity.mean;Vel;Pt;Pulmonic valve.distal;Qn;US.doppler;CARD.US;2;Pulmonic valve distal Mean blood flow velocity by US.doppler;Pulmonic valve.distal Vmean DOP;;ACTIVE;1.0m;2.67 +20285-3;Pre ejection period;Time;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Deprecated Left ventricular Pre ejection period by US;Deprecated LV Pre ejection period US;;DEPRECATED;1.0m;2.36 +20286-1;RR interval^at pulmonic flow measurement;Time;Pt;Heart;Qn;US;CARD.US;2;R-R interval by US --at pulmonic flow measurement;R-R interval @ PV flow US;;ACTIVE;1.0m;2.48 +20287-9;Region orifice area;Area;Pt;Pulmonic valve;Qn;US.doppler.VTI+Area.calculated;CARD.US;2;Pulmonic valve Region orifice area by US.doppler VTI + area calculated;PV Region orifice area DOP.VTI+area;;ACTIVE;1.0m;2.67 +20288-7;Region orifice area;Area;Pt;Pulmonic valve;Qn;US.doppler.VTI+Diameter.calculated;CARD.US;2;Pulmonic valve Region orifice area by US.doppler VTI + diameter calculated;PV Region orifice area DOP.VTI+diam;;ACTIVE;1.0m;2.67 +2028-9;Carbon dioxide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Serum or Plasma;CO2 SerPl-sCnc;;ACTIVE;1.0;2.73 +20289-5;Region orifice area;Area;Pt;Pulmonic valve;Qn;US.doppler.Vmax+Area.calculated;CARD.US;2;Pulmonic valve Region orifice area by US.doppler Vmax + area calculated;PV Region orifice area DOP.VMAX+area;;ACTIVE;1.0m;2.67 +20290-3;Region orifice area;Area;Pt;Pulmonic valve;Qn;US.doppler.Vmax+Diameter.calculated;CARD.US;2;Pulmonic valve Region orifice area by US.doppler Vmax + diameter calculated;PV Region orifice area DOP.Vmax+diam;;ACTIVE;1.0m;2.67 +20291-1;Pulmonic flow/Systemic flow;VRatRto;Pt;Circulatory system.XXX;Qn;US.doppler.VTI+Aorta.calculated;CARD.US;2;Pulmonic flow/Systemic flow by US.doppler VTI + aorta calculated;Pulmonic/Systemic DOP.VTI+AO;;ACTIVE;1.0m;2.69 +20292-9;Pulmonic flow/Systemic flow;VRatRto;Pt;Circulatory system.XXX;Qn;US.doppler.VTI+LVOT.calculated;CARD.US;2;Pulmonic flow/Systemic flow by US.doppler VTI + left ventricular outflow tract calculated;Pulmonic/Systemic DOP.VTI+LVOT;;ACTIVE;1.0m;2.69 +20293-7;Pulmonic flow/Systemic flow;VRatRto;Pt;Circulatory system.XXX;Qn;US.doppler.Vmax+Aorta.calculated;CARD.US;2;Pulmonic flow/Systemic flow by US.doppler Vmax + aorta calculated;Pulmonic/Systemic DOP.VMAX+AO;;ACTIVE;1.0m;2.69 +20294-5;Pulmonic flow/Systemic flow;VRatRto;Pt;Circulatory system.XXX;Qn;US.doppler.Vmax+LVOT.calculated;CARD.US;2;Pulmonic flow/Systemic flow by US.doppler Vmax + left ventricular outflow tract calculated;Pulmonic/Systemic DOP.VMAX+LVOT;;ACTIVE;1.0m;2.69 +20295-2;Q-wave to closure;Time;Pt;Pulmonic valve;Qn;US.measured;CARD.US;2;Pulmonic valve Q-wave to closure [Time] by US;PV Q-wave to closure Time US.meas;;ACTIVE;1.0m;2.54 +20296-0;Q-wave to open;Time;Pt;Tricuspid valve;Qn;US.measured;CARD.US;2;Tricuspid valve Q-wave to open [Time] by US;TV Q-wave to open Time US.meas;;ACTIVE;1.0m;2.54 +2029-7;Carboxyhemoglobin;SFr;Pt;RBC;Ord;;CHEM;1;Deprecated Carboxyhemoglobin;Deprecated COHgb Fr RBC;;DEPRECATED;1.0;2.46 +20297-8;Intrachamber.diastole;Pres;Pt;Heart.atrium.right;Qn;Estimated from jugular venous distention;CARD.US;2;Right atrial Intrachamber diastole pressure by Estimated from jugular venous distention;RA Intrachamber.dias pres JVD est;;ACTIVE;1.0m;2.40 +20298-6;Region of interest;Prid;Pt;*;Nom;;CARD.US;2;Region of interest;ROI;;ACTIVE;1.0m;2.29 +20299-4;Pressure gradient.max;PressDiff;Pt;Heart.ventricle.right;Qn;US.doppler;CARD.US;2;Right ventricular Peak pressure gradient by US.doppler;RV Peak press grad DOP;;ACTIVE;1.0m;2.67 +203-0;Colistimethate;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Colistimethate [Susceptibility] by Serum bactericidal titer;Colistimethate Titr SBT;;ACTIVE;1.0;2.34 +20300-0;Pressure gradient.mean;PressDiff;Pt;Heart.ventricle.right;Qn;US.doppler;CARD.US;2;Right ventricular Mean pressure gradient by US.doppler;RV Mean press grad DOP;;ACTIVE;1.0m;2.67 +20301-8;Pre ejection time;Time;Pt;Heart.ventricle.right;Qn;US;CARD.US;2;Right ventricular Pre ejection time by US;RV Pre eject time US;;ACTIVE;1.0m;2.54 +20302-6;Blood flow velocity.mean;Vel;Pt;Heart.ventricle.right.outflow tract;Qn;US.doppler;CARD.US;2;Right ventricular outflow tract Mean blood flow velocity by US.doppler;RVOT Vmean DOP;;ACTIVE;1.0m;2.67 +20303-4;Pressure gradient.systole.mean;PressDiff;Pt;Heart.ventricle.right.outflow tract;Qn;US.doppler;CARD.US;2;Right ventricular outflow tract Mean systole pressure gradient by US.doppler;RVOT Mean press grad sys DOP;;ACTIVE;1.0m;2.67 +20304-2;Minor axis.max;Len;Pt;Heart.ventricle.right;Qn;US.2D;CARD.US;2;Right ventricular Minor axis.maximum [Length] by US 2D;RV Minor axis.max 2D US;;ACTIVE;1.0m;2.48 +2030-5;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldA;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Arterial blood;COHgb MFr BldA;;ACTIVE;1.0;2.73 +20305-9;Diameter.systole;Len;Pt;Heart.ventricle.right;Qn;US;CARD.US;2;Right ventricular Diameter during systole by US;RV Diam sys US;;ACTIVE;1.0m;2.67 +20306-7;Region crossection;Area;Pt;Heart.ventricle.right.outflow tract;Qn;US+Calculated;CARD.US;2;Right ventricular outflow tract Region crossection [Area] by US+Calculated;RVOT Region Xsection Area US+Calc;;ACTIVE;1.0m;2.52 +20307-5;Diameter;Len;Pt;Heart.ventricle.right.outflow tract;Qn;US.2D;CARD.US;2;Right ventricular outflow tract Diameter by US 2D;RVOT Diam 2D US;;ACTIVE;1.0m;2.48 +20308-3;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated;CARD.US;2;Left ventricular Stroke volume index by US.2D+Calculated;LV SVI US.2D+Calc;;ACTIVE;1.0m;2.52 +20309-1;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.aortic root.calculated;CARD.US;2;Left ventricular Stroke volume index by US 2D aortic root calculated;LV SVI US.2D.AO root;;ACTIVE;1.0m;2.48 +20310-9;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane ellipse method;CARD.US;2;Left ventricular Stroke volume index by US.2D+Calculated by biplane ellipse method;LV SVI US.2D+BP-EL;;ACTIVE;1.0m;2.52 +20311-7;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by bullet method;CARD.US;2;Left ventricular Stroke volume index by US.2D+Calculated by bullet method;LV SVI US.2D+bullet;;ACTIVE;1.0m;2.52 +20312-5;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.cubed.calculated;CARD.US;2;Left ventricular Stroke volume index by US.cubed.calculated;LV SVI US.cubed;;ACTIVE;1.0m;2.48 +2031-3;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldC;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Capillary blood;COHgb MFr BldC;;ACTIVE;1.0;2.73 +20313-3;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.LVOT area.calculated;CARD.US;2;Left ventricular Stroke volume index by US 2D left ventricular outflow tract area calculated;LV SVI US.2D.LVOT area;;ACTIVE;1.0m;2.29 +20314-1;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane ellipse.calculated;CARD.US;2;Left ventricular Stroke volume index by US 2D modified biplane ellipse calculated;LV SVI US.2D.MOD-BP-EL;;ACTIVE;1.0m;2.29 +20315-8;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.modified Simpson.calculated;CARD.US;2;Left ventricular Stroke volume index by US.modified Simpson.calculated;LV SVI US.Mod Simp;;ACTIVE;1.0m;2.48 +20316-6;Stroke volume/Body surface area.2 chamber;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane ellipse.calculated;CARD.US;2;Left ventricular Stroke volume index 2 chamber by US 2D modified single-plane ellipse calculated;LV Stroke index 2cham US.2D.MOD-SP-EL;;ACTIVE;1.0m;2.29 +20317-4;Stroke volume/Body surface area.4 chamber;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane ellipse.calculated;CARD.US;2;Left ventricular Stroke volume index 4 chamber by US 2D modified single-plane ellipse calculated;LV Stroke index 4cham US.2D.MOD-SP-EL;;ACTIVE;1.0m;2.30 +20318-2;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.mitral valve.calculated;CARD.US;2;Left ventricular Stroke volume index by US 2D mitral valve calculated;LV SVI US.2D.MV;;ACTIVE;1.0m;2.48 +20319-0;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.pulmonic valve flow area.calculated;CARD.US;2;Left ventricular Stroke volume index by US 2D pulmonic valve flow area calculated;LV SVI US.2D.PV flow area;;ACTIVE;1.0m;2.29 +20320-8;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by single-plane ellipse method;CARD.US;2;Left ventricular Stroke volume index by US.2D+Calculated by single-plane ellipse method;LV SVI US.2D+SP-EL;;ACTIVE;1.0m;2.52 +2032-1;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldV;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Venous blood;COHgb MFr BldV;;ACTIVE;1.0;2.73 +20321-6;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.Teichholz;CARD.US;2;Left ventricular Stroke volume index by US.Teichholz;LV SVI US.Teich;;ACTIVE;1.0m;2.67 +20322-4;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D.tricuspid valve.calculated;CARD.US;2;Left ventricular Stroke volume index by US 2D tricuspid valve calculated;LV SVI US.2D.TV;;ACTIVE;1.0m;2.29 +20323-2;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated;LV SV US.2D+Calc;;ACTIVE;1.0m;2.52 +20324-0;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.aortic root.calculated;CARD.US;2;Left ventricular Stroke volume by US 2D aortic root calculated;LV SV US.2D.AO root;;ACTIVE;1.0m;2.50 +20325-7;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane ellipse method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by biplane ellipse method;LV SV US.2D+BP-EL;;ACTIVE;1.0m;2.52 +20326-5;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by bullet method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by bullet method;LV SV US.2D+bullet;;ACTIVE;1.0m;2.52 +20327-3;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.cubed.calculated;CARD.US;2;Left ventricular Stroke volume by US.cubed.calculated;LV SV US.cubed;;ACTIVE;1.0m;2.48 +20328-1;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.LVOT area.calculated;CARD.US;2;Left ventricular Stroke volume by US 2D left ventricular outflow tract area calculated;LV SV US.2D.LVOT area;;ACTIVE;1.0m;2.48 +20329-9;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane ellipse.calculated;CARD.US;2;Left ventricular Stroke volume by US 2D modified biplane ellipse calculated;LV SV US.2D.MOD-BP-EL;;ACTIVE;1.0m;2.48 +20330-7;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by modified Simpson method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by modified Simpson method;LV SV US.2D+mod Simpson;;ACTIVE;1.0m;2.52 +20331-5;Cardiac output/Heart rate.2 chamber;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane.calculated;CARD.US;2;Left ventricular Stroke volume 2 chamber by US 2D modified single-plane calculated;LV Stroke volume.2cham US.2D.MOD-SP;;ACTIVE;1.0m;2.48 +20332-3;Cardiac output/Heart rate.4 chamber;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane.calculated;CARD.US;2;Left ventricular Cardiac output/Heart rate 4 chamber by US 2D modified single-plane calculated;LV Output/Heart rate.4cham US.2D.MOD-SP;;ACTIVE;1.0m;2.48 +20333-1;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mitral valve flow area.calculated;CARD.US;2;Left ventricular Stroke volume by US 2D mitral valve flow area calculated;LV SV US.2D.MV flow area;;ACTIVE;1.0m;2.44 +20334-9;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;US.2D.pulmonic valve flow area.calculated;CARD.US;2;Right ventricular Stroke volume by US 2D pulmonic valve flow area calculated;RV SV US.2D.PV flow area;;ACTIVE;1.0m;2.44 +20335-6;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by single-plane ellipse method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by single-plane ellipse method;LV SV US.2D+SP-EL;;ACTIVE;1.0m;2.52 +20336-4;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.Teichholz.calculated;CARD.US;2;Left ventricular Stroke volume by US.Teichholz.calculated;LV SV US.Teich;;ACTIVE;1.0m;2.67 +20337-2;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;US.2D.tricuspid valve.calculated;CARD.US;2;Right ventricular Stroke volume by US 2D tricuspid valve calculated;RV SV US.2D.TV;;ACTIVE;1.0m;2.48 +20338-0;Time;Time;Pt;Circulatory system.XXX;Qn;US.M-mode;CARD.US;2;Time by US.M-mode;Time M-mode;;ACTIVE;1.0m;2.54 +2033-9;Carbonate;MCnc;Pt;BldA;Qn;;CHEM;1;Carbonate [Mass/volume] in Arterial blood;Carbonate BldA-mCnc;;ACTIVE;1.0;2.34 +20339-8;Time;Time;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Time by US;Time US;;ACTIVE;1.0m;2.48 +20340-6;Time 2;Time;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Time 2 by US;Time 2 US;;ACTIVE;1.0m;2.48 +20341-4;Time.XXX/Time 2.XXX;TRto;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Time/Time 2 by US;Time/Time 2 US;;ACTIVE;1.0m;2.27 +20342-2;RR interval^at tricuspid flow measurement;Time;Pt;Heart;Qn;US;CARD.US;2;R-R interval by US --at tricuspid flow measurement;R-R interval @ TV flow US;;ACTIVE;1.0m;2.48 +20343-0;Acceleration slope;Vel;Pt;Tricuspid valve;Qn;US;CARD.US;2;Tricuspid valve Acceleration slope by US;TV Accel slope US;;ACTIVE;1.0m;2.27 +20344-8;Region crossection;Area;Pt;Tricuspid valve.annulus;Qn;US.calculated;CARD.US;2;Tricuspid valve annulus Region crossection [Area] by US.calculated;TV ann Region Xsection Area US Calc;;ACTIVE;1.0m;2.48 +20345-5;Deceleration slope;Vel;Pt;Tricuspid valve;Qn;US;CARD.US;2;Tricuspid valve Deceleration slope [Velocity] by US;TV Decel slope US;;ACTIVE;1.0m;2.27 +20346-3;Filling period.diastole;Time;Pt;Heart.atrium.right;Qn;US.measured;CARD.US;2;Right atrial Diastolic filling period by US;RA Dias fill period US.meas;;ACTIVE;1.0m;2.48 +2034-7;Carbonate;MCnc;Pt;BldV;Qn;;CHEM;1;Carbonate [Mass/volume] in Venous blood;Carbonate BldV-mCnc;;ACTIVE;1.0;2.34 +20347-1;Flow;Area;Pt;Tricuspid valve;Qn;US.calculated;CARD.US;2;Tricuspid valve Flow [Area] by US.calculated;TV Flow Area US Calc;;ACTIVE;1.0m;2.27 +20348-9;Diameter.4 chamber;Len;Pt;Tricuspid valve.orifice;Qn;US.measured;CARD.US;2;Tricuspid valve orifice Diameter.4 chamber by US;TV orifice Diam 4CH US.meas;;ACTIVE;1.0m;2.48 +20349-7;Pressure half time.velocity.max;Time;Pt;Tricuspid valve;Qn;US;CARD.US;2;Tricuspid valve Pressure half time velocity maximum by US;TV PHT vel max US;;ACTIVE;1.0m;2.54 +20350-5;Blood flow velocity.mean;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Mean blood flow velocity by US.doppler;TV Vmean DOP;;ACTIVE;1.0m;2.67 +20351-3;Blood flow velocity.max;Vel;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Maximum blood flow velocity by US.doppler;Vmax DOP;;ACTIVE;1.0m;2.67 +20352-1;Blood flow velocity.mean;Vel;Pt;{Circulatory system};Qn;US.doppler;CARD.US;2;Circulatory system Mean blood flow velocity by US.doppler;Circ sys Vmean DOP;;ACTIVE;1.0m;2.67 +20353-9;Pressure gradient;PressDiff;Pt;Region of interest.XXX;Qn;US.doppler;CARD.US;2;Region of interest Pressure gradient by US.doppler;ROI Press grad DOP;;ACTIVE;1.0m;2.67 +2035-4;Carbonate;MCnc;Pt;Plas;Qn;;CHEM;1;Carbonate [Mass/volume] in Plasma;Carbonate Plas-mCnc;;ACTIVE;1.0;2.34 +20354-7;Blood velocity-time integral;Vel;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Blood velocity-time integral by US.doppler;VTI DOP;;ACTIVE;1.0m;2.54 +20355-4;Blood flow 2.max;Vel;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Peak blood flow 2 by US.doppler;Bld flow 2.max DOP;;ACTIVE;1.0m;2.48 +20356-2;Blood flow 2.mean;Vel;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Mean blood flow 2 by US.doppler;Bld flow 2.mean DOP;;ACTIVE;1.0m;2.48 +20357-0;Pressure gradient 2;PressDiff;Pt;Region of interest.XXX;Qn;US.doppler;CARD.US;2;Region of interest Pressure gradient 2 by US.doppler;ROI Press grad 2 DOP;;ACTIVE;1.0m;2.67 +20358-8;Blood velocity-time integral 2;Vel;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Blood velocity-time integral 2 by US.doppler;VTI 2 DOP;;ACTIVE;1.0m;2.54 +20359-6;Region;Area;Pt;Heart.valve.XXX;Qn;US.doppler.VTI+Area.calculated;CARD.US;2;Heart valve Region [Area] by US.doppler VTI + area calculated;Valve Region Area DOP.VTI+area;;ACTIVE;1.0m;2.32 +20360-4;Region;Area;Pt;Heart.valve.XXX;Qn;US.doppler.VTI+Diameter.calculated;CARD.US;2;Heart valve Region [Area] by US.doppler VTI + diameter calculated;Valve Region Area DOP.VTI+diam;;ACTIVE;1.0m;2.32 +20361-2;Region;Area;Pt;Heart.valve.XXX;Qn;US.doppler.velocity+Area.calculated;CARD.US;2;Heart valve Region [Area] by US.doppler velocity + area calculated;Valve Region Area DOP.vel+area;;ACTIVE;1.0m;2.32 +2036-2;Carbonate dehydratase;CCnc;Pt;RBC;Qn;;CHEM;1;Carbonate dehydratase [Enzymatic activity/volume] in Red Blood Cells;Carbonate dehydratase RBC-cCnc;;ACTIVE;1.0;2.44 +20362-0;Region;Area;Pt;Heart.valve.XXX;Qn;US.doppler.velocity+Diameter.calculated;CARD.US;2;Heart valve Region [Area] by US.doppler velocity + diameter calculated;Valve Region Area DOP.vel+diam;;ACTIVE;1.0m;2.32 +20363-8;Velocity slope;Vel;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Velocity slope by US;Vel slope US;;ACTIVE;1.0m;2.27 +20364-6;Velocity slope 2;Vel;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Velocity slope 2 by US;Vel slope 2 US;;ACTIVE;1.0m;2.27 +20365-3;Volume.XXX/Volume 2.XXX;VFr;Pt;Region of interest.XXX;Qn;US.calculated;CARD.US;2;Region of interest Volume/Volume 2 by US.calculated;ROI Vol/Vol 2 VFr US Calc;;ACTIVE;1.0m;2.34 +20366-1;Volume;Vol;Pt;Region of interest.XXX;Qn;US.2D+Calculated by area-length method;CARD.US;2;Region of interest Volume by US.2D+Calculated by area-length method;ROI Volume US.2D+A-L;;ACTIVE;1.0m;2.52 +20367-9;Volume 2;Vol;Pt;Region of interest.XXX;Qn;US.2D+Calculated by area-length method;CARD.US;2;Region of interest Volume 2 by US.2D+Calculated by area-length method;ROI Vol 2 US.2D+A-L;;ACTIVE;1.0m;2.52 +20368-7;Blood flow velocity.max;Vel;Pt;Heart.interventricular septum.defect;Qn;US.doppler;CARD.US;2;Interventricular septal defect Maximum blood flow velocity by US.doppler;IVS defect Vmax DOP;;ACTIVE;1.0m;2.67 +20369-5;Velocity slope.XXX/Velocity slope 2.XXX;VelRto;Pt;Circulatory system.XXX;Qn;US.doppler.calculated;CARD.US;2;Velocity slope/Velocity slope 2 by US.doppler calculated;Vel slope/Vel slope 2 DOP;;ACTIVE;1.0m;2.69 +2037-0;Carcinoembryonic Ag;MCnc;Pt;CSF;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Cerebral spinal fluid;CEA CSF-mCnc;;ACTIVE;1.0;2.73 +20370-3;Velocity-time integral.XXX;Len;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Velocity-time integral.XXX by US.doppler;VTI.XXX DOP;;ACTIVE;1.0m;2.40 +20371-1;Velocity-time integral.XXX/Velocity-time integral 2.XXX;LenRto;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Velocity-time integral.XXX/Velocity-time integral 2 by US.doppler;VTI.XXX/VTI 2 DOP;;ACTIVE;1.0m;2.67 +20372-9;Velocity-time integral 2.XXX;Len;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Velocity-time integral 2 XXX by US.doppler;VTI 2.XXX DOP;;ACTIVE;1.0m;2.40 +20373-7;Amikacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin Islt SlowMyco;;ACTIVE;1.0m;2.73 +20374-5;Ampicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility] by Method for Slow-growing mycobacteria;Ampicillin+Sulbac Islt SlowMyco;;ACTIVE;1.0m;2.26 +20375-2;Clarithromycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clarithromycin [Susceptibility] by Method for Slow-growing mycobacteria;Clarithro Islt SlowMyco;;ACTIVE;1.0m;2.73 +20376-0;Clofazimine;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clofazimine [Susceptibility] by Method for Slow-growing mycobacteria;Clofazamine Islt SlowMyco;;ACTIVE;1.0m;2.26 +20377-8;Ciprofloxacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ciprofloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Ciprofloxacin Islt SlowMyco;;ACTIVE;1.0m;2.73 +20378-6;Ceftizoxime;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ceftizoxime [Susceptibility] by Method for Slow-growing mycobacteria;Ceftizoxime Islt SlowMyco;;ACTIVE;1.0m;2.26 +20379-4;Doxycycline;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Doxycycline [Susceptibility] by Method for Slow-growing mycobacteria;Doxycycline Islt SlowMyco;;ACTIVE;1.0m;2.26 +20380-2;Erythromycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Erythromycin [Susceptibility] by Method for Slow-growing mycobacteria;Erythromycin Islt SlowMyco;;ACTIVE;1.0m;2.26 +20381-0;Ethambutol;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol Islt SlowMyco;;ACTIVE;1.0m;2.26 +20382-8;Ethionamide;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethionamide [Susceptibility] by Method for Slow-growing mycobacteria;Ethionamide Islt SlowMyco;;ACTIVE;1.0m;2.26 +20383-6;Isoniazid;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid Islt SlowMyco;;ACTIVE;1.0m;2.26 +20384-4;Ofloxacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ofloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Ofloxacin Islt SlowMyco;;ACTIVE;1.0m;2.26 +20385-1;rifAMPin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;rifAMPin [Susceptibility] by Method for Slow-growing mycobacteria;rifAMPin Islt SlowMyco;;ACTIVE;1.0m;2.26 +20386-9;Rifabutin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Rifabutin [Susceptibility] by Method for Slow-growing mycobacteria;Rifabutin Islt SlowMyco;;ACTIVE;1.0m;2.26 +20387-7;Trimethoprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility] by Method for Slow-growing mycobacteria;TMP SMX Islt SlowMyco;;ACTIVE;1.0m;2.73 +2038-8;Carcinoembryonic Ag;MCnc;Pt;Semen;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Semen;CEA Smn-mCnc;;ACTIVE;1.0;2.42 +20388-5;Nitrofurazone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nitrofurazone [Susceptibility];Nitrofurazone Susc Islt;;ACTIVE;1.0m;2.50 +20389-3;Mupirocin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Mupirocin [Susceptibility];Mupirocin Susc Islt;;ACTIVE;1.0m;2.21 +20390-1;Silver sulfADIAZINE;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Silver sulfADIAZINE [Susceptibility];Silvadene Susc Islt;;ACTIVE;1.0m;2.73 +20391-9;Mafenide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Mafenide [Susceptibility];Mafenide Susc Islt;;ACTIVE;1.0m;2.21 +20392-7;Sample icteric;PrThr;Pt;Ser/Plas;Ord;;SPEC;1;Sample icteric [Presence] of Serum or Plasma Qualitative;Sample Icteric SerPl Ql;;ACTIVE;1.0m;2.73 +20393-5;Sample hemolyzed;PrThr;Pt;Ser/Plas;Ord;;SPEC;1;Sample hemolyzed [Presence] of Serum or Plasma Qualitative;Sample Hemolyzed SerPl Ql;;ACTIVE;1.0m;2.73 +20394-3;Sample lipemic;PrThr;Pt;Ser/Plas;Ord;;SPEC;1;Sample lipemic [Presence] of Serum or Plasma Qualitative;Sample Lipemic SerPl Ql;;ACTIVE;1.0m;2.73 +20395-0;Sample integrity;Type;Pt;Ser/Plas;Nom;;SPEC;1;Sample integrity [Type] of Serum or Plasma;Sample Integrity SerPl;;ACTIVE;1.0m;2.73 +2039-6;Carcinoembryonic Ag;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Serum or Plasma;CEA SerPl-mCnc;;ACTIVE;1.0;2.73 +20396-8;levoFLOXacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;levoFLOXacin [Susceptibility] by Minimum inhibitory concentration (MIC);levoFLOXacin Islt MIC;;ACTIVE;1.0m;2.73 +20397-6;Sparfloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sparfloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Sparfloxacin Islt MIC;;ACTIVE;1.0m;2.19 +20398-4;Nuclear Ab pattern.homogeneous;Titr;Pt;Ser;Qn;;SERO;1;Homogenous nuclear Ab pattern [Titer] in Serum;ANA Homogen Titr Ser;;ACTIVE;1.0m;2.73 +20399-2;Nuclear Ab pattern.nucleolar;Titr;Pt;Ser;Qn;;SERO;1;Nucleolar nuclear Ab pattern [Titer] in Serum;ANA nucleolar Titr Ser;;ACTIVE;1.0m;2.73 +20400-8;Nuclear Ab pattern.smooth nuclear envelope;Titr;Pt;Ser;Qn;;SERO;1;Smooth nuclear envelope nuclear Ab pattern [Titer] in Serum;ANA smooth nucl env Titr Ser;;ACTIVE;1.0m;2.70 +20401-6;Nuclear Ab pattern.speckled;Titr;Pt;Ser;Qn;;SERO;1;Speckled nuclear Ab pattern [Titer] in Serum;ANA Speckled Titr Ser;;ACTIVE;1.0m;2.73 +20402-4;Cells.CD16+CD56+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD16+CD56+ cells [#/volume] in Blood;CD16+CD56+ Cells # Bld;;ACTIVE;1.0m;2.73 +20403-2;Fibronectin.fetal;MCnc;Pt;Vag;Qn;;CHEM;1;Fibronectin.fetal [Mass/volume] in Vaginal fluid;Fibronectin Fetal Vag-mCnc;;ACTIVE;1.0m;2.73 +2040-4;Cardiolipin;MCnc;Pt;Ser;Qn;;COAG;1;Cardiolipin [Mass/volume] in Serum;Cardiolipin Ser-mCnc;;ACTIVE;1.0;2.34 +20404-0;Fibronectin.fetal;PrThr;Pt;Vag;Ord;;CHEM;1;Fibronectin.fetal [Presence] in Vaginal fluid;Fibronectin Fetal Vag Ql;;ACTIVE;1.0m;2.73 +20405-7;Urobilinogen;MCnc;Pt;Urine;Qn;Test strip;UA;1;Urobilinogen [Mass/volume] in Urine by Test strip;Urobilinogen Ur Strip-mCnc;;ACTIVE;1.0m;2.73 +20406-5;Glucose;MFr;Pt;Urine;Qn;Test strip;UA;1;Deprecated Glucose [Mass/volume] in Urine by Test strip;Deprecated Glucose Fr Ur Strip;;DEPRECATED;1.0m;2.70 +20407-3;Nitrite;MCnc;Pt;Urine;Qn;Test strip;UA;1;Nitrite [Mass/volume] in Urine by Test strip;Nitrite Ur Strip-mCnc;;ACTIVE;1.0m;2.73 +20408-1;Leukocytes;NCnc;Pt;Urine;Qn;Test strip;UA;1;Leukocytes [#/volume] in Urine by Test strip;WBC # Ur Strip;;ACTIVE;1.0m;2.73 +20409-9;Erythrocytes;NCnc;Pt;Urine;Qn;Test strip;UA;1;Erythrocytes [#/volume] in Urine by Test strip;RBC # Ur Strip;;ACTIVE;1.0m;2.73 +20410-7;Amphetamines;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amphetamines [Mass/volume] in Urine by Confirmatory method;Amphetamines Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20411-5;Barbiturates;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Barbiturates [Mass/volume] in Urine by Confirmatory method;Barbiturates Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +2041-2;Carnitine acyltransferase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine acyltransferase [Enzymatic activity/volume] in Serum or Plasma;Carnitine AcT SerPl-cCnc;;ACTIVE;1.0;2.68 +20412-3;Benzodiazepines;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Urine by Confirmatory method;Benzodiaz Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20413-1;Cannabinoids;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cannabinoids [Mass/volume] in Urine by Confirmatory method;Cannabinoids Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20414-9;Thiazides;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Thiazides [Mass/volume] in Urine by Confirmatory method;Thiazides Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20415-6;Choriogonadotropin.beta subunit;ACnc;Pt;Ser/Plas;Qn;EIA.3rd IS;CHEM;1;Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma by Immunoassay (EIA) 3rd IS;B-HCG SerPl EIA 3rd IS-aCnc;;ACTIVE;1.0m;2.73 +20416-4;Hepatitis C virus RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HCV RNA # SerPl NAA+probe;;ACTIVE;1.0m;2.73 +20417-2;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Serum;H capsul Myc Ab Titr Ser;;ACTIVE;1.0m;2.70 +20418-0;Histoplasma capsulatum yeast phase Ab;Titr;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum yeast phase Ab [Titer] in Serum;H capsul Yst Ab Titr Ser;;ACTIVE;1.0m;2.73 +20419-8;Lutropin;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHEM;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP;LH SerPl IRP1-aCnc;;ACTIVE;1.0m;2.73 +2042-0;Carnitine.free (C0);PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Carnitine free (C0) [Presence] in Serum or Plasma;Carnitine Free SerPl Ql;;ACTIVE;1.0;2.73 +20420-6;Acid phosphatase.prostatic;MCnc;Pt;Ser;Qn;;CHEM;1;Prostatic acid phosphatase [Mass/volume] in Serum;PACP Ser-mCnc;;ACTIVE;1.0m;2.73 +20421-4;Barbiturates;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Serum or Plasma by Screen method;Barbiturates SerPl Ql Scn;;ACTIVE;1.0m;2.73 +20422-2;Alpha 1 antitrypsin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma;Deprecated A1AT SerPl-mCnc;;DEPRECATED;1.0m;2.36 +20423-0;Beta lactamase organism identified;Prid;Pt;Isolate;Nom;;MICRO;1;Beta lactamase organism identified in Isolate;B-Lactamase Organism Islt;;ACTIVE;1.0m;2.73 +20424-8;Cardiolipin Ab.IgG;Imp;Pt;Ser;Nom;;COAG;1;Cardiolipin IgG Ab [Interpretation] in Serum;Cardiolipin IgG Ser-Imp;;ACTIVE;1.0m;2.73 +20425-5;Cardiolipin Ab.IgM;Imp;Pt;Ser;Nom;;COAG;1;Cardiolipin IgM Ab [Interpretation] in Serum;Cardiolipin IgM Ser-Imp;;ACTIVE;1.0m;2.73 +20426-3;Alkaline phosphatase.bile;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.bile [Enzymatic activity/volume] in Serum or Plasma;ALP Bile SerPl-cCnc;;ACTIVE;1.0m;2.68 +20427-1;Acetylcholine receptor Ab;SCnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor Ab [Moles/volume] in Serum;AChR Ab Ser-sCnc;;ACTIVE;1.0m;2.73 +20428-9;Phospholipid Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Phospholipid IgG Ab [Presence] in Serum;Phospholipid IgG Ser Ql;;ACTIVE;1.0m;2.73 +20429-7;Phospholipid Ab.IgM;PrThr;Pt;Ser;Ord;;COAG;1;Phospholipid IgM Ab [Presence] in Serum;Phospholipid IgM Ser Ql;;ACTIVE;1.0m;2.73 +20430-5;Culture medium;Type;Pt;Isolate;Nom;;MICRO;1;Culture medium [Type] in Isolate;Cult Medium Islt;;ACTIVE;1.0m;2.73 +20431-3;Microscopic observation;Prid;Pt;XXX;Nom;Smear;MICRO;1;Microscopic observation [Identifier] in Specimen by Smear;Smear Spec;;ACTIVE;1.0m;2.73 +20432-1;Epstein Barr virus nuclear Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus nuclear Ab [Presence] in Serum by Immunofluorescence;EBV NA Ab Ser Ql IF;;ACTIVE;1.0m;2.73 +20433-9;Follitropin;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHEM;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP;FSH SerPl IRP2-aCnc;;ACTIVE;1.0m;2.73 +20434-7;Prolactin;ACnc;Pt;Ser/Plas;Qn;3rd IS;CHEM;1;Prolactin [Units/volume] in Serum or Plasma by 3rd IS;Prolactin SerPl 3rd IS-aCnc;;DISCOURAGED;1.0m;2.73 +20435-4;Unidentified extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Unidentified extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA Unident Ab Ser Ql ID;;ACTIVE;1.0m;2.56 +20436-2;Glucose^2H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post dose glucose;Glucose 2h p Glc SerPl-mCnc;;ACTIVE;1.0m;2.73 +20437-0;Glucose^3H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post dose glucose;Glucose 3h p Glc SerPl-mCnc;;ACTIVE;1.0m;2.73 +2043-8;Carnitine.free (C0);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine free (C0) [Mass/volume] in Serum or Plasma;Carnitine Free SerPl-mCnc;;DISCOURAGED;1.0;2.73 +20438-8;Glucose^1H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post dose glucose;Glucose 1h p Glc SerPl-mCnc;;ACTIVE;1.0m;2.73 +20439-6;Glucose^30M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose glucose;Glucose 30M p Glc SerPl-mCnc;;ACTIVE;1.0m;2.73 +20440-4;Glucose^1.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose glucose;Glucose 1.5h p Glc SerPl-mCnc;;ACTIVE;1.0m;2.73 +20441-2;Glucose^post 50 g glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --post 50 g glucose;Glucose p 50 g Glc SerPl-mCnc;;ACTIVE;1.0m;2.73 +20442-0;Hepatitis B virus DNA;NCnc;Pt;Ser;Qn;Probe.amp.sig;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Serum by Probe with signal amplification;HBV DNA # Ser Probe+sig amp;;ACTIVE;1.0m;2.73 +20444-6;Herpes simplex virus 1+2 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection;HSV1+2 DNA Spec Ql NAA+probe;;ACTIVE;1.0m;2.73 +20445-3;Herpes virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Herpes virus identified in Specimen by Organism specific culture;HHV Spec Cult;;ACTIVE;1.0m;2.73 +2044-6;Carnitine;MCnc;Pt;Semen;Qn;;CHEM;1;Carnitine [Mass/volume] in Semen;Carnitine Smn-mCnc;;DISCOURAGED;1.0;2.42 +20446-1;Herpes simplex virus Ab.IgG;Imp;Pt;Ser;Nom;IA;MICRO;1;Herpes simplex virus IgG Ab [Interpretation] in Serum by Immunoassay;HSV IgG Ser IA-Imp;;ACTIVE;1.0m;2.73 +20447-9;HIV 1 RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HIV1 RNA # SerPl NAA+probe;;ACTIVE;1.0m;2.73 +20448-7;Insulin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin [Units/volume] in Serum or Plasma;Insulin SerPl-aCnc;;ACTIVE;1.0m;2.73 +20449-5;Borrelia burgdorferi Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia burgdorferi Ab [Presence] in Serum by Immunoassay;B burgdor Ab Ser Ql IA;;ACTIVE;1.0m;2.73 +20450-3;Alpha-1-Fetoprotein;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] in Serum or Plasma;AFP MoM SerPl;;ACTIVE;1.0m;2.73 +20451-1;Thyroxine;PrThr;Pt;Bld;Ord;;CHEM;1;Thyroxine (T4) [Presence] in Blood;T4 Bld Ql;;ACTIVE;1.0m;2.56 +20452-9;Thyrotropin;PrThr;Pt;Bld;Ord;;CHEM;1;Thyrotropin [Presence] in Blood;TSH Bld Ql;;ACTIVE;1.0m;2.56 +2045-3;Carnitine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Carnitine [Presence] in Serum or Plasma;Carnitine SerPl Ql;;ACTIVE;1.0;2.73 +20453-7;Epithelial cells;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Epithelial cells [Presence] in Urine sediment by Light microscopy;Epi Cells UrnS Ql Micro;;ACTIVE;1.0m;2.73 +20454-5;Protein;PrThr;Pt;Urine;Ord;Test strip;UA;1;Protein [Presence] in Urine by Test strip;Prot Ur Ql Strip;;ACTIVE;1.0m;2.73 +20455-2;Leukocytes;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Leukocytes [Presence] in Urine sediment by Light microscopy;WBC UrnS Ql Micro;;ACTIVE;1.0m;2.73 +20456-0;Fungi.yeastlike;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Fungi.yeastlike [Presence] in Urine sediment by Light microscopy;Yeast Like Fungi UrnS Ql Micro;;ACTIVE;1.0m;2.73 +20457-8;Fungi.filamentous;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Fungi.filamentous [Presence] in Urine sediment by Light microscopy;Filament Fungi UrnS Ql Micro;;ACTIVE;1.0m;2.73 +20458-6;Rubella virus Ab.IgG;Imp;Pt;Ser;Nom;;MICRO;1;Rubella virus IgG Ab [Interpretation] in Serum;RUBV IgG Ser-Imp;;ACTIVE;1.0m;2.73 +20459-4;Streptococcus agalactiae Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Streptococcus agalactiae Ag [Presence] in Specimen by Latex agglutination;Gp B Strep Ag Spec Ql LA;;ACTIVE;1.0m;2.73 +20460-2;Cefuroxime.oral;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefuroxime Oral [Susceptibility] by Minimum inhibitory concentration (MIC);Cefuroxime Oral Islt MIC;;ACTIVE;1.0m;2.73 +2046-1;Carnitine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine [Mass/volume] in Serum or Plasma;Carnitine SerPl-mCnc;;DISCOURAGED;1.0;2.73 +20461-0;Pyrazinamide;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Pyrazinamide [Susceptibility] by Method for Slow-growing mycobacteria;PZA Islt SlowMyco;;ACTIVE;1.0m;2.73 +20462-8;Streptomycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Streptomycin [Susceptibility] by Method for Slow-growing mycobacteria;Streptomycin Islt SlowMyco;;ACTIVE;1.0m;2.73 +20463-6;Mycobacterium avium complex rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium avium complex rRNA [Presence] in Specimen by NAA with probe detection;M avium Cmplx rRNA Spec Ql NAA+probe;;ACTIVE;1.0m;2.73 +20464-4;Toxoplasma gondii Ab;Imp;Pt;Ser;Nom;;MICRO;1;Toxoplasma gondii Ab [Interpretation] in Serum;T gondii Ab Ser-Imp;;ACTIVE;1.0m;2.73 +20465-1;Choriogonadotropin;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin [Multiple of the median] in Serum or Plasma;HCG MoM SerPl;;ACTIVE;1.0m;2.73 +20466-9;Estriol.unconjugated;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3).unconjugated [Multiple of the median] in Serum or Plasma;u Estriol MoM SerPl;;ACTIVE;1.0m;2.73 +20467-7;Blood bank alert;Imp;Pt;^Patient;Nom;;BLDBK;1;Blood bank alert;Blood Bank Alert Patient-Imp;;ACTIVE;1.0m;2.08 +20468-5;Thiamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thiamine [Moles/volume] in Serum or Plasma;Vit B1 SerPl-sCnc;;ACTIVE;1.0m;2.73 +20469-3;Acetone;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Acetone [Presence] in Serum or Plasma by Screen method;Acetone SerPl Ql Scn;;ACTIVE;1.0m;2.73 +20470-1;Ethanol;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Ethanol [Presence] in Serum or Plasma by Screen method;Ethanol SerPl Ql Scn;;ACTIVE;1.0m;2.73 +20471-9;Isopropanol;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Isopropanol [Presence] in Serum or Plasma by Screen method;Isopropanol SerPl Ql Scn;;ACTIVE;1.0m;2.56 +20472-7;Eosinophils;PrThr;Pt;XXX;Ord;Wright stain;HEM/BC;1;Eosinophils [Presence] in Specimen by Wright stain;Eosinophil Spec Ql Wright Stn;;ACTIVE;1.0m;2.73 +20473-5;Polymorphonuclear cells;PrThr;Pt;XXX;Ord;Wright stain;HEM/BC;1;Polymorphonuclear cells [Presence] in Specimen by Wright stain;Polys Spec Ql Wright Stn;;ACTIVE;1.0m;2.73 +20474-3;Bacteria identified;Prid;Pt;Tiss;Nom;Biopsy culture;MICRO;1;Bacteria identified in Tissue by Biopsy culture;Bacteria Tiss Bx Cult;;ACTIVE;1.0m;2.73 +20475-0;Cytomegalovirus Ab.IgG;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Cytomegalovirus IgG Ab [Interpretation] in Serum or Plasma;CMV IgG SerPl-Imp;;ACTIVE;1.0m;2.73 +20476-8;Cells.CD1a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD1a cells/100 cells in Blood;CD1a Cells NFr Bld;;ACTIVE;1.0m;2.70 +20477-6;Cells.CD33+CD44+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD33+CD44+ cells/100 cells in Blood;CD33+CD44+ Cells NFr Bld;;ACTIVE;1.0m;2.70 +20478-4;Cells.CD61/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD61 cells/100 cells in Blood;CD61 Cells NFr Bld;;ACTIVE;1.0m;2.73 +2047-9;Carnitine;MCnc;Pt;Urine;Qn;;CHEM;1;Carnitine [Mass/volume] in Urine;Carnitine Ur-mCnc;;DISCOURAGED;1.0;2.73 +20479-2;Measles virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Measles virus IgG Ab [Presence] in Serum;MeV IgG Ser Ql;;ACTIVE;1.0m;2.73 +204-8;Colistin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Colistin [Susceptibility] by Minimum lethal concentration (MLC);Colistin Islt MLC;;ACTIVE;1.0;2.19 +20480-0;Benzoylecgonine;ACnc;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Deprecated Benzoylecgonine [Presence] in Meconium by Screen method;Deprecated BZE Mec Ql Scn;;DEPRECATED;1.0m;2.36 +20481-8;Opiates;ACnc;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Deprecated Opiates [Presence] in Meconium by Screen method;Deprecated Opiates Mec Ql Scn;;DEPRECATED;1.0m;2.36 +20482-6;Granulocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Granulocytes [#/volume] in Blood by Automated count;Granulocytes # Bld Auto;;ACTIVE;1.0m;2.73 +20483-4;Mitochondria Ab;Titr;Pt;Ser;Qn;;SERO;1;Mitochondria Ab [Titer] in Serum;Mitochondria Ab Titr Ser;;ACTIVE;1.0m;2.73 +20484-2;Cardiolipin Ab.IgG;Titr;Pt;Ser;Qn;;COAG;1;Cardiolipin IgG Ab [Titer] in Serum;Cardiolipin IgG Titr Ser;;ACTIVE;1.0m;2.70 +20485-9;Cardiolipin Ab.IgM;Titr;Pt;Ser;Qn;;COAG;1;Cardiolipin IgM Ab [Titer] in Serum;Cardiolipin IgM Titr Ser;;ACTIVE;1.0m;2.73 +20486-7;Haemophilus influenzae B Ag;ACnc;Pt;CSF;Qn;;MICRO;1;Haemophilus influenzae B Ag [Units/volume] in Cerebral spinal fluid;Haem influ B Ag CSF-aCnc;;ACTIVE;1.0m;2.69 +2048-7;Carnitine/Creatinine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine/Creatinine [Mass Ratio] in Serum or Plasma;Carnitine/Creat SerPl;;DISCOURAGED;1.0;2.42 +20487-5;Neisseria meningitidis serogroups A+Y Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroups A+Y Ag [Presence] in Cerebral spinal fluid;N men sg A+Y Ag CSF Ql;;ACTIVE;1.0m;2.64 +20488-3;Streptococcus agalactiae Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Streptococcus agalactiae Ag [Presence] in Cerebral spinal fluid;Gp B Strep Ag CSF Ql;;ACTIVE;1.0m;2.73 +20489-1;Streptococcus pneumoniae Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Cerebral spinal fluid;S pneum Ag CSF Ql;;ACTIVE;1.0m;2.73 +20490-9;Epstein Barr virus capsid Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Titer] in Serum;EBV VCA IgG Titr Ser;;ACTIVE;1.0m;2.73 +20491-7;Epstein Barr virus capsid Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgM Ab [Titer] in Serum;EBV VCA IgM Titr Ser;;ACTIVE;1.0m;2.73 +20492-5;Hemoglobin pattern imp;Imp;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Deprecated Hemoglobin pattern [interpretation] in Blood by Electrophoresis Narrative;Deprecated Hgb Bld Elph-Imp;;DEPRECATED;1.0m;2.36 +20493-3;Histiocytes/100 cells;NFr;Pt;Body fld;Qn;Microscopy.light;HEM/BC;1;Histiocytes/100 cells in Body fluid by Light microscopy;Histiocytes NFr Fld Micro;;ACTIVE;1.0m;2.73 +20494-1;Lymphocytes/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Deprecated Lymphocytes/100 leukocytes in Body fluid by Manual count;Deprecated Lymphocytes Fr Fld Manual;;DEPRECATED;1.0m;2.36 +2049-5;Carnosine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Carnosine [Presence] in Serum or Plasma;Carnosine SerPl Ql;;ACTIVE;1.0;2.73 +20495-8;Gliadin Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Gliadin IgA Ab [Units/volume] in Serum by Immunoassay;Gliadin IgA Ser IA-aCnc;;ACTIVE;1.0m;2.73 +20496-6;Gliadin Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Gliadin IgG Ab [Units/volume] in Serum by Immunoassay;Gliadin IgG Ser IA-aCnc;;ACTIVE;1.0m;2.73 +20497-4;Histoplasma capsulatum mycelial phase Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Units/volume] in Serum by Complement fixation;H capsul Myc Ab Ser CF-aCnc;;ACTIVE;1.0m;2.69 +20498-2;Histoplasma capsulatum yeast phase Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Histoplasma capsulatum yeast phase Ab [Units/volume] in Serum by Complement fixation;H capsul Yst Ab Ser CF-aCnc;;ACTIVE;1.0m;2.69 +20499-0;Phosphatidylglycerol/Surfactant.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylglycerol/Surfactant.total in Amniotic fluid;PG MFr Amn;;ACTIVE;1.0m;2.73 +20500-5;Hydroxyalprazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxyalprazolam [Mass/volume] in Urine by Confirmatory method;OH-Alpraz Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20501-3;Hydroxytriazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Urine by Confirmatory method;OH-Triazolam Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20502-1;Clue cells;PrThr;Pt;Vag;Ord;Wet preparation;MICRO;1;Clue cells [Presence] in Vaginal fluid by Wet preparation;Clue Cells Vag Ql Wet Prep;;ACTIVE;1.0m;2.73 +2050-3;Carnosine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnosine [Mass/volume] in Serum or Plasma;Carnosine SerPl-mCnc;;DISCOURAGED;1.0;2.44 +20503-9;Cells.CD22+CD11c+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD22+CD11c+ cells/100 cells in Blood;CD22+CD11c+ Cells NFr Bld;;ACTIVE;1.0m;2.70 +20504-7;Histiocytes/100 cells;NFr;Pt;CSF;Qn;;HEM/BC;1;Histiocytes/100 cells in Cerebral spinal fluid;Histiocytes NFr CSF;;ACTIVE;1.0m;2.73 +20505-4;Bilirubin;MCnc;Pt;Urine;Qn;Test strip;UA;1;Bilirubin.total [Mass/volume] in Urine by Test strip;Bilirub Ur Strip-mCnc;;ACTIVE;1.0m;2.73 +20506-2;Specimen drawn from;Type;Pt;^Patient;Nom;;SPEC;1;Specimen drawn from;Specimen drawn from Patient;;ACTIVE;1.0m;2.73 +20507-0;Reagin Ab;PrThr;Pt;Ser;Ord;RPR;MICRO;1;Reagin Ab [Presence] in Serum by RPR;RPR Ser Ql;;ACTIVE;1.0m;2.73 +20508-8;Reagin Ab;ACnc;Pt;Ser/Plas;Qn;RPR;MICRO;1;Reagin Ab [Units/volume] in Serum or Plasma by RPR;RPR SerPl-aCnc;;ACTIVE;1.0m;2.73 +20509-6;Hemoglobin;MCnc;Pt;Bld;Qn;Calculated;HEM/BC;1;Hemoglobin [Mass/volume] in Blood by calculation;Hgb Bld Calc-mCnc;;ACTIVE;1.0m;2.73 +20510-4;Lipoprotein pattern;Imp;Pt;Ser/Plas;Nom;Electrophoresis;CHEM;1;Lipoprotein fractions [Interpretation] in Serum or Plasma by Electrophoresis;LP SerPl Elph-Imp;;ACTIVE;1.0m;2.73 +2051-1;Carnosine;MCnc;Pt;Urine;Qn;;CHEM;1;Carnosine [Mass/volume] in Urine;Carnosine Ur-mCnc;;DISCOURAGED;1.0;2.44 +20511-2;Creatinine;Imp;Pt;Urine;Nom;;CHEM;1;Creatinine [Interpretation] in Urine;Creat Ur-Imp;;ACTIVE;1.0m;2.26 +20512-0;Turbidity;PrThr;Pt;CSF;Ord;;SPEC;1;Turbidity [Presence] of Cerebral spinal fluid Qualitative;Turbidity CSF Ql;;ACTIVE;1.0m;2.73 +20513-8;Turbidity;PrThr;Pt;Body fld;Ord;;SPEC;1;Turbidity [Presence] of Body fluid Qualitative;Turbidity Fld Ql;;ACTIVE;1.0m;2.73 +20514-6;6-Monoacetylmorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated 6-Monoacetylmorphine [Mass/volume] in Urine Confirm;Deprecated 6MAM Ur Cfm-mCnc;;DEPRECATED;1.0m;2.40 +20515-3;Amitriptyline;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amitriptyline [Mass/volume] in Urine by Confirmatory method;Amitrip Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20516-1;Amitriptyline+Nortriptyline;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Amitriptyline+Nortriptyline [Mass/volume] in Urine by Confirmatory method;Amitrip+Nor Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20517-9;Aprobarbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Aprobarbital [Mass/volume] in Urine by Confirmatory method;Aprobarbital Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20518-7;Barbital;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Barbital [Mass/volume] in Urine by Confirmatory method;Barbital Ur Cfm-mCnc;;ACTIVE;1.0m;2.36 +20519-5;Cocaine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cocaine [Mass/volume] in Urine by Confirmatory method;Cocaine Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20520-3;Bromazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Bromazepam [Mass/volume] in Urine by Confirmatory method;Bromazepam Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20521-1;Carboxy tetrahydrocannabinol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Urine by Confirmatory method;CarboxyTHC Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20522-9;chlordiazePOXIDE;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Urine by Confirmatory method;Chlordiazep Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20523-7;chlorproMAZINE;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;chlorproMAZINE [Mass/volume] in Urine by Confirmatory method;chlorproMAZINE Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20524-5;Tetrahydrocannabinol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated Tetrahydrocannabinol [Mass/volume] in Urine by Confirm method;Deprecated THC Ur Cfm-mCnc;;DEPRECATED;1.0m;2.36 +20525-2;Dextroamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dextroamphetamine [Mass/volume] in Urine by Confirmatory method;D-amphet Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20526-0;Dimetamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dimetamphetamine [Mass/volume] in Urine by Confirmatory method;Dimetamphet Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20527-8;Ethylmorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethylmorphine [Mass/volume] in Urine by Confirmatory method;EMP Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20528-6;Flunitrazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flunitrazepam [Mass/volume] in Urine by Confirmatory method;Flunitrazepam Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +2052-9;Carotene;MCnc;Pt;Bld;Qn;;CHEM;1;Carotene [Mass/volume] in Blood;Carotene Bld-mCnc;;ACTIVE;1.0;2.40 +20529-4;FLUoxetine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;FLUoxetine [Mass/volume] in Urine by Confirmatory method;FLUoxetine Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20530-2;Haloperidol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Haloperidol [Mass/volume] in Urine by Confirmatory method;Haloperidol Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20531-0;Hydroxyalprazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated Hydroxyalprazolam [Mass/volume] in Urine by Confirm method;Deprecated OH-Alpraz Ur Cfm-mCnc;;DEPRECATED;1.0m;2.36 +20532-8;Hydroxyethylflurazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Urine by Confirmatory method;OH-Ethylfluraz Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20533-6;Hydroxytriazolam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Hydroxytriazolam [Presence] in Urine by Confirmatory method;OH-Triazolam Ur Ql Cfm;;ACTIVE;1.0m;2.73 +20534-4;Hydroxytriazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated Hydroxytriazolam [Mass/volume] in Urine by Confirm method;Deprecated OH-Triazolam Ur Cfm-mCnc;;DEPRECATED;1.0m;2.36 +20535-1;Hydroxytriazolam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxytriazolam cutoff [Mass/volume] in Urine for Confirmatory method;OH-Triazolam CtO Ur Cfm-mCnc;;ACTIVE;1.0m;2.44 +20536-9;Hydroxytriazolam cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Hydroxytriazolam cutoff [Mass/volume] in Urine for Screen method;OH-Triazolam CtO Ur Scn-mCnc;;ACTIVE;1.0m;2.44 +2053-7;Carotene;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carotene [Mass/volume] in Serum or Plasma;Carotene SerPl-mCnc;;ACTIVE;1.0;2.73 +20537-7;Ketamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ketamine [Mass/volume] in Urine by Confirmatory method;Ketamine Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20538-5;Methotrimeprazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methotrimeprazine [Mass/volume] in Urine by Confirmatory method;Methotrimeprazine Ur Cfm-mCnc;;ACTIVE;1.0m;2.52 +20539-3;Levomepromazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated Levomepromazine [Mass/volume] in Urine by Confirm method;Deprecated L-Mepromazine Ur Cfm-mCnc;;DEPRECATED;1.0m;2.36 +20540-1;Levorphanol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Levorphanol [Mass/volume] in Urine by Confirmatory method;Levorphanol Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20541-9;Lormetazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Lormetazepam [Mass/volume] in Urine by Confirmatory method;Lormetazepam Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20542-7;Lysergate diethylamide;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Lysergate diethylamide [Mass/volume] in Urine by Confirmatory method;LSD Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20543-5;Mescaline;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mescaline [Mass/volume] in Urine by Confirmatory method;Mescaline Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20544-3;Mesoridazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mesoridazine [Mass/volume] in Urine by Confirmatory method;Mesoridazine Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +2054-5;Catalase;CCnc;Pt;RBC;Qn;;CHEM;1;Catalase [Enzymatic activity/volume] in Red Blood Cells;Catalase RBC-cCnc;;ACTIVE;1.0;2.44 +20545-0;Methylenedioxyamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Urine by Confirmatory method;MDA Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20546-8;Methylenedioxyamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;MDA CtO Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20547-6;MethylePHEDrine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;MethylePHEDrine [Mass/volume] in Urine by Confirmatory method;Me-ePHEDrine Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20548-4;Methylphenidate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylphenidate [Mass/volume] in Urine by Confirmatory method;Me-phenidate Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20549-2;Methyprylon;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methyprylon [Mass/volume] in Urine by Confirmatory method;Methyprylon Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +205-5;Colistin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Colistin [Susceptibility] by Minimum inhibitory concentration (MIC);Colistin Islt MIC;;ACTIVE;1.0;2.73 +20550-0;Morphine.free;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Morphine Free [Mass/volume] in Urine by Confirmatory method;Morphine Free Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20551-8;Nalbuphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nalbuphine [Mass/volume] in Urine by Confirmatory method;Nalbuphine Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +2055-2;Catecholamines;MCnc;Pt;Bld;Qn;;CHEM;1;Catecholamines [Mass/volume] in Blood;Catechols Bld-mCnc;;ACTIVE;1.0;2.50 +20552-6;Nitrazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nitrazepam [Mass/volume] in Urine by Confirmatory method;Nitrazepam Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20553-4;Norfluoxetine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norfluoxetine [Mass/volume] in Urine by Confirmatory method;Norfluoxetine Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20554-2;Para hydroxyamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Para hydroxyamphetamine [Mass/volume] in Urine by Confirmatory method;P-OH-Amphet Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20555-9;Phenmetrazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phenmetrazine [Mass/volume] in Urine by Confirmatory method;Phenmetrazine Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20556-7;Phenothiazines;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phenothiazines [Mass/volume] in Urine by Confirmatory method;Phenothiaz Ur Cfm-mCnc;;ACTIVE;1.0m;2.52 +20557-5;Phentermine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phentermine [Mass/volume] in Urine by Confirmatory method;Phentermine Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20558-3;Psilocin;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Psilocin [Mass/volume] in Urine by Confirmatory method;Psilocin Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20559-1;Temazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Temazepam [Mass/volume] in Urine by Confirmatory method;Temazepam Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +2056-0;Catecholamines;MCnc;Pt;Plas;Qn;;CHEM;1;Catecholamines [Mass/volume] in Plasma;Catechols Plas-mCnc;;ACTIVE;1.0;2.73 +20560-9;Thioridazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Thioridazine [Mass/volume] in Urine by Confirmatory method;Thioridazine Ur Cfm-mCnc;;ACTIVE;1.0m;2.42 +20561-7;traMADol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;traMADol [Mass/volume] in Urine by Confirmatory method;traMADol Ur Cfm-mCnc;;ACTIVE;1.0m;2.73 +20562-5;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventricular Stroke volume;LV SV;;ACTIVE;1.0m;2.73 +20563-3;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Blood;COHgb MFr Bld;;ACTIVE;1.0m;2.73 +20564-1;Oxygen saturation;MFr;Pt;Bld;Qn;;HEMODYN.MOLEC;2;Oxygen saturation in Blood;SaO2 % Bld;;ACTIVE;1.0m;2.73 +20565-8;Carbon dioxide;SCnc;Pt;Bld;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Blood;CO2 Bld-sCnc;;ACTIVE;1.0m;2.73 +20566-6;Colony count;NCnc;Pt;Ctp;Qn;Culture;MICRO;1;Colony count [#/volume] in Catheter tip by Culture;CC # Cath Tip Cult;;ACTIVE;1.0m;2.42 +20567-4;Ferritin;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Ferritin [Mass/volume] in Serum or Plasma by Immunoassay;Ferritin SerPl IA-mCnc;;ACTIVE;1.0m;2.73 +20568-2;Prolactin;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Prolactin [Mass/volume] in Serum or Plasma by Immunoassay;Prolactin SerPl IA-mCnc;;ACTIVE;1.0m;2.73 +20569-0;Creatine kinase.MB/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.MB/Creatine kinase.total in Serum or Plasma;CK MB CFr SerPl;;ACTIVE;1.0m;2.73 +20570-8;Hematocrit;VFr;Pt;Bld;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Blood;Hct VFr Bld;;ACTIVE;1.0m;2.73 +20571-6;Hepatitis C virus RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.sig;MICRO;1;Hepatitis C virus RNA [#/volume] (viral load) in Serum or Plasma by Probe with signal amplification;HCV RNA # SerPl Probe+sig amp;;ACTIVE;1.0m;2.73 +20572-4;Hemoglobin A/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A/Hemoglobin.total in Blood by Electrophoresis;Hgb A MFr Bld Elph;;ACTIVE;1.0m;2.73 +20573-2;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Serum by Complement fixation;H capsul Myc Ab Titr Ser CF;;ACTIVE;1.0m;2.73 +20574-0;Histoplasma capsulatum yeast phase Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Histoplasma capsulatum yeast phase Ab [Titer] in Serum by Complement fixation;H capsul Yst Ab Titr Ser CF;;ACTIVE;1.0m;2.73 +20575-7;Hepatitis A virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis A virus Ab [Presence] in Serum;HAV Ab Ser Ql;;ACTIVE;1.0m;2.73 +20576-5;Galactose 1 phosphate uridyl transferase;PrThr;Pt;Bld;Ord;;CHEM;1;Galactose 1 phosphate uridyl transferase [Presence] in Blood;Gal1PUT Bld Ql;;ACTIVE;1.0m;2.73 +20577-3;Protein;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Deprecated Protein [Mass/volume] in Serum or Plasma by electrophoresis;Deprecated Prot SerPl Elph-mCnc;;DEPRECATED;1.0m;2.40 +2057-8;Catecholamines;MCnc;Pt;Urine;Qn;;CHEM;1;Catecholamines [Mass/volume] in Urine;Catechols Ur-mCnc;;ACTIVE;1.0;2.73 +20578-1;Vancomycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Serum or Plasma;Vancomycin SerPl-mCnc;;ACTIVE;1.0m;2.73 +20579-9;Methanol;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Methanol [Presence] in Serum or Plasma by Screen method;Methanol SerPl Ql Scn;;ACTIVE;1.0m;2.56 +20584-9;Leukocytes;NCnc;Pt;XXX;Qn;Automated count;CELLMARK;1;Leukocytes [#/volume] in Specimen by Automated count;WBC # Spec Auto;;ACTIVE;1.0m;2.73 +20585-6;Lymphocytes;NCnc;Pt;XXX;Qn;Automated count;HEM/BC;1;Lymphocytes [#/volume] in Specimen by Automated count;Lymphocytes # Spec Auto;;ACTIVE;1.0m;2.73 +2058-6;Catecholamines;MRat;24H;Urine;Qn;;CHEM;1;Catecholamines [Mass/time] in 24 hour Urine;Catechols 24h Ur-mRate;;ACTIVE;1.0;2.73 +20586-4;Cells.CD1/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD1 cells/100 cells in Specimen;CD1 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20587-2;Cells.CD10/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD10 cells/100 cells in Specimen;CD10 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20588-0;Cells.CD13/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD13 cells/100 cells in Specimen;CD13 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20589-8;Cells.CD14/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD14 cells/100 cells in Specimen;CD14 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20590-6;Cells.CD15/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD15 cells/100 cells in Specimen;CD15 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20591-4;Cells.CD16+CD57-/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD16+CD57- cells/100 cells in Specimen;CD16+CD57- Cells NFr Spec;;ACTIVE;1.0m;2.70 +20592-2;Cells.CD19;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD19 cells [#/volume] in Specimen;CD19 Cells # Spec;;ACTIVE;1.0m;2.73 +20593-0;Cells.CD19/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19 cells/100 cells in Specimen;CD19 Cells NFr Spec;;ACTIVE;1.0m;2.73 +2059-4;Cerebroside sulfatase;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cerebroside sulfatase [Presence] in Serum or Plasma;Arylsulfatase A SerPl Ql;;ACTIVE;1.0;2.56 +20594-8;Cells.CD2/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD2 cells/100 cells in Specimen;CD2 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20595-5;Cells.CD20/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD20 cells/100 cells in Specimen;CD20 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20596-3;Cells.CD22/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD22 cells/100 cells in Specimen;CD22 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20597-1;Cells.CD24/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD24 cells/100 cells in Specimen;CD24 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20598-9;Cells.CD3;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD3 cells [#/volume] in Specimen;CD3 Cells # Spec;;ACTIVE;1.0m;2.73 +20599-7;Cells.CD3/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3 cells/100 cells in Specimen;CD3 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20600-3;Cells.CD30/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD30 cells/100 cells in Specimen;CD30 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20601-1;Cells.CD33/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD33 cells/100 cells in Specimen;CD33 Cells NFr Spec;;ACTIVE;1.0m;2.73 +2060-2;Cerebroside sulfatase;CCnt;Pt;Tiss;Qn;;CHEM;1;Cerebroside sulfatase [Enzymatic activity/mass] in Tissue;Arylsulfatase A Tiss-cCnt;;ACTIVE;1.0;2.42 +20602-9;Cells.CD34/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD34 cells/100 cells in Specimen;CD34 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20603-7;Cells.CD38/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD38 cells/100 cells in Specimen;CD38 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20604-5;Cells.CD3-CD16+CD56+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Specimen;CD3-CD16+CD56+ Cells # Spec;;ACTIVE;1.0m;2.73 +20605-2;Cells.CD4;NCnc;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD4 cells [#/volume] in Unspecified specimen;Deprecated CD4 Cells # XXX;;DEPRECATED;1.0m;2.70 +20606-0;Cells.CD4/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD4 cells/100 cells in Unspecified specimen;Deprecated CD4 Cells NFr XXX;;DEPRECATED;1.0m;2.70 +20607-8;Cells.CD3+CD4+/Cells.CD3+CD8+;NRto;Pt;XXX;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Specimen;CD3+CD4+ Cells/CD3+CD8+ Cells Spec;;ACTIVE;1.0m;2.73 +20608-6;Cells.CD41/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD41 cells/100 cells in Specimen;CD41 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20609-4;Cells.CD42/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD42 cells/100 cells in Specimen;CD42 Cells NFr Spec;;ACTIVE;1.0m;2.70 +2061-0;Cerebroside sulfatase;CCnc;Pt;Urine;Qn;;CHEM;1;Cerebroside sulfatase [Enzymatic activity/volume] in Urine;Arylsulfatase A Ur-cCnc;;ACTIVE;1.0;2.73 +20610-2;Cells.CD45/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD45 (Lymphs) cells/100 cells in Specimen;CD45 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20611-0;Cells.CD5/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD5 cells/100 cells in Specimen;CD5 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20612-8;Cells.CD7/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD7 cells/100 cells in Specimen;CD7 Cells NFr Spec;;ACTIVE;1.0m;2.73 +20613-6;Cells.CD8;NCnc;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD8 cells [#/volume] in Unspecified specimen;Deprecated CD8 Cells # XXX;;DEPRECATED;1.0m;2.70 +20614-4;Cells.CD8/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD8 cells/100 cells in Unspecified specimen;Deprecated CD8 Cells NFr XXX;;DEPRECATED;1.0m;2.70 +20615-1;Lymphocytes.IgD/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;IgD lymphocytes/100 lymphocytes in Specimen;Lymphs IgD/lymph NFr Spec;;ACTIVE;1.0m;2.73 +20616-9;Lymphocytes.IgM/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;IgM lymphocytes/100 lymphocytes in Specimen;Lymphs IgM/lymph NFr Spec;;ACTIVE;1.0m;2.73 +20617-7;Lymphocytes.kappa/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;Kappa lymphocytes/100 lymphocytes in Specimen;Lymphs Kappa/lymph NFr Spec;;ACTIVE;1.0m;2.73 +20618-5;Lymphocytes.lambda/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;Lambda lymphocytes/100 lymphocytes in Specimen;Lymphs Lambda/lymph NFr Spec;;ACTIVE;1.0m;2.73 +20619-3;Lymphocytes/100 leukocytes;NFr;Pt;XXX;Qn;Automated count;CELLMARK;1;Lymphocytes/100 leukocytes in Specimen by Automated count;Lymphocytes/leuk NFr Spec Auto;;ACTIVE;1.0m;2.70 +20620-1;Cells.CD16+CD56+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD16+CD56+ cells/100 cells in Specimen;CD16+CD56+ Cells NFr Spec;;ACTIVE;1.0m;2.73 +20621-9;Albumin/Creatinine;PrThr;Pt;Urine;Ord;Test strip;CHEM;1;Albumin/Creatinine [Presence] in Urine by Test strip;Albumin/Creat Ur Ql Strip;;ACTIVE;1.0m;2.73 +20622-7;Cortisol;MCnc;24H;Urine;Qn;;CHEM;1;Cortisol [Mass/volume] in 24 hour Urine;Cortis 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +20623-5;Coproporphyrin;MCnc;24H;Urine;Qn;;CHEM;1;Coproporphyrin [Mass/volume] in 24 hour Urine;Copro 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +20624-3;Creatinine;MCnc;24H;Urine;Qn;;CHEM;1;Creatinine [Mass/volume] in 24 hour Urine;Creat 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +20625-0;Lead;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Lead [Mass/volume] in 24 hour Urine;Lead 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +20626-8;Reducing substances;ACnc;Pt;Urine;Qn;Test strip;UA;1;Reducing substances [Units/volume] in Urine by Test strip;Reducing Subs Ur Strip-aCnc;;ACTIVE;1.0m;2.73 +20627-6;Turbidity;PrThr;Pt;Urine;Ord;;SPEC;1;Turbidity [Presence] of Urine Qualitative;Turbidity Ur Ql;;ACTIVE;1.0m;2.73 +2062-8;Cerebroside sulfatase;PrThr;Pt;WBC;Ord;;CHEM;1;Cerebroside sulfatase [Presence] in Leukocytes;Arylsulfatase A WBC Ql;;ACTIVE;1.0;2.56 +20628-4;Blasts.terminal deoxyribonucleotidyl transferase/100 blasts;NFr;Pt;XXX;Qn;Immunoperoxidase stain;CELLMARK;1;Terminal Deoxyribonucleotidyl Transferase blasts/100 blasts in Specimen by Immunoperoxidase stain;TdT Blasts NFr Spec IP Stn;;ACTIVE;1.0m;2.70 +20629-2;levoFLOXacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;levoFLOXacin [Susceptibility];levoFLOXacin Susc Islt;;ACTIVE;1.0m;2.73 +206-3;Colistin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Colistin [Susceptibility] by Disk diffusion (KB);Colistin Islt KB;;ACTIVE;1.0;2.73 +20631-8;Lymphocytes.activated T cells/100 lymphocytes.small;NFr;Pt;Bld;Qn;;CELLMARK;1;Activated T cells lymphocytes/100 lymphocytes.small in Blood;Activ T Lymphs NFr Bld;;ACTIVE;1.0m;2.70 +20632-6;Lymphocytes.activated T cells/100 lymphocytes.small;NFr;Pt;XXX;Qn;;CELLMARK;1;Activated T cells lymphocytes/100 lymphocytes.small in Specimen;Activ T Lymphs NFr Spec;;ACTIVE;1.0m;2.73 +20633-4;1-Methylhistidine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in Serum or Plasma;1Me-hist SerPl-sCnc;;ACTIVE;1.0m;2.73 +20634-2;Alpha aminobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in Serum or Plasma;A-Aminobutyr SerPl-sCnc;;ACTIVE;1.0m;2.73 +20635-9;3-Methylhistidine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in Serum or Plasma;3Me-histidine SerPl-sCnc;;ACTIVE;1.0m;2.73 +2063-6;Cerebroside sulfatase;CCnc;Pt;WBC;Qn;;CHEM;1;Cerebroside sulfatase [Enzymatic activity/volume] in Leukocytes;Arylsulfatase A WBC-cCnc;;ACTIVE;1.0;2.73 +20636-7;Alanine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alanine [Moles/volume] in Serum or Plasma;Alanine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20637-5;Arginine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Arginine [Moles/volume] in Serum or Plasma;Arginine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20638-3;Asparagine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Asparagine [Moles/volume] in Serum or Plasma;Asparagine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20639-1;Aspartate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aspartate [Moles/volume] in Serum or Plasma;Aspartate SerPl-sCnc;;ACTIVE;1.0m;2.73 +20640-9;Citrulline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Citrulline [Moles/volume] in Serum or Plasma;Citrulline SerPl-sCnc;;ACTIVE;1.0m;2.73 +20641-7;Cysteine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cysteine [Moles/volume] in Serum or Plasma;Cysteine SerPl-sCnc;;ACTIVE;1.0m;2.70 +20642-5;Glutamate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamate [Moles/volume] in Serum or Plasma;Glutamate SerPl-sCnc;;ACTIVE;1.0m;2.73 +20643-3;Glutamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamine [Moles/volume] in Serum or Plasma;Glutamine SerPl-sCnc;;ACTIVE;1.0m;2.73 +2064-4;Ceruloplasmin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ceruloplasmin [Mass/volume] in Serum or Plasma;Ceruloplasmin SerPl-mCnc;;ACTIVE;1.0;2.73 +20644-1;Glycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycine [Moles/volume] in Serum or Plasma;Glycine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20645-8;Histidine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Histidine [Moles/volume] in Serum or Plasma;Histidine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20646-6;Homocystine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocystine [Moles/volume] in Serum or Plasma;(Hcys)2 SerPl-sCnc;;ACTIVE;1.0m;2.73 +20647-4;Hydroxyproline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in Serum or Plasma;OH-Proline SerPl-sCnc;;ACTIVE;1.0m;2.73 +20648-2;Isoleucine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isoleucine [Moles/volume] in Serum or Plasma;Isoleucine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20649-0;Leucine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Leucine [Moles/volume] in Serum or Plasma;Leucine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20650-8;Lysine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lysine [Moles/volume] in Serum or Plasma;Lysine SerPl-sCnc;;ACTIVE;1.0m;2.73 +2065-1;Chenodeoxycholate;MCnc;Pt;Ser;Qn;;CHEM;1;Chenodeoxycholate [Mass/volume] in Serum;CDCAe Ser-mCnc;;DISCOURAGED;1.0;2.73 +20651-6;Methionine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methionine [Moles/volume] in Serum or Plasma;Methionine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20652-4;Ornithine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ornithine [Moles/volume] in Serum or Plasma;Ornithine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20653-2;Phenylalanine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Phenylalanine [Molecules/volume] in Serum or Plasma;Deprecated Phe SerPl-sCnc;;DEPRECATED;1.0m;2.70 +20654-0;Phosphoserine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphoserine [Moles/volume] in Serum or Plasma;Phosphoserine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20655-7;Proline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Proline [Moles/volume] in Serum or Plasma;Proline SerPl-sCnc;;ACTIVE;1.0m;2.73 +20656-5;Serine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Serine [Moles/volume] in Serum or Plasma;Serine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20657-3;Taurine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurine [Moles/volume] in Serum or Plasma;Taurine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20658-1;Threonine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Threonine [Moles/volume] in Serum or Plasma;Threonine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20659-9;Tryptophan;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptophan [Moles/volume] in Serum or Plasma;Tryptophan SerPl-sCnc;;ACTIVE;1.0m;2.73 +20660-7;Tyrosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tyrosine [Moles/volume] in Serum or Plasma;Tyrosine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20661-5;Valine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Valine [Moles/volume] in Serum or Plasma;Valine SerPl-sCnc;;ACTIVE;1.0m;2.73 +20662-3;Allergens tested for;Prid;Pt;Ser;Nom;;ALLERGY;1;Allergens tested for in Serum;Allergens Tested;;ACTIVE;1.0m;2.73 +20663-1;Tricyclic antidepressants;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Tricyclic antidepressants [Mass/volume] in Urine by Screen method;Tricyclics Ur Scn-mCnc;;ACTIVE;1.0m;2.73 +20664-9;Barbiturates;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Barbiturates [Mass/volume] in Urine by Screen method;Barbiturates Ur Scn-mCnc;;ACTIVE;1.0m;2.73 +20665-6;Echovirus 14 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 14 neutralizing antibody [Titer] in Serum by Neutralization test;ECV14 NAb Titr Ser Nt;;ACTIVE;1.0m;2.72 +20666-4;Echovirus Ab;Imp;Pt;Ser;Nom;;MICRO;1;Echovirus Ab [Interpretation] in Serum;ECV Ab Ser-Imp;;ACTIVE;1.0m;2.26 +2066-9;Chenodeoxycholylglycine;MCnc;Pt;Ser;Qn;;CHEM;1;Chenodeoxycholylglycine [Mass/volume] in Serum;CDCG Ser-mCnc;;ACTIVE;1.0;2.34 +20669-8;Cardiolipin Ab.IgA;Titr;Pt;Ser;Qn;;COAG;1;Cardiolipin IgA Ab [Titer] in Serum;Cardiolipin IgA Titr Ser;;ACTIVE;1.0m;2.70 +20671-4;Amino acids;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Deprecated Amino acids [interpretation] in Serum or Plasma;Deprecated Amino acids SerPl-Imp;;DEPRECATED;1.0m;2.48 +20672-2;Actinobacillus pleuropneumoniae serotype;Prid;Pt;Isolate;Nom;;MICRO;1;Actinobacillus pleuropneumoniae serotype [Identifier] in Isolate;A pleuropn Sertyp Islt;;ACTIVE;1.0m;2.19 +20673-0;Actinobacillus pleuropneumoniae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinobacillus pleuropneumoniae Ab [Presence] in Serum;A pleuropn Ab Ser Ql;;ACTIVE;1.0m;2.56 +20674-8;Avian adenovirus 2 Ag;PrThr;Pt;Tiss;Ord;Immune diffusion;MICRO;1;Avian adenovirus 2 Ag [Presence] in Tissue by Immune diffusion (ID);FAdV2 Ag Tiss Ql ID;;ACTIVE;1.0m;2.56 +20675-5;Bovine adenovirus 3 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine adenovirus 3 Ag [Presence] in Tissue by Immunofluorescence;BAdV3 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20676-3;Bovine adenovirus 5 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine adenovirus 5 Ag [Presence] in Tissue by Immunofluorescence;BAdV5 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +2067-7;Chenodeoxycholylglycine.conjugated;MCnc;Pt;Ser;Qn;;CHEM;1;Chenodeoxycholylglycine.conjugated [Mass/volume] in Serum;CDCG Conj Ser-mCnc;;ACTIVE;1.0;2.34 +20677-1;Equine adenovirus Ag;PrThr;Pt;Lung;Ord;IF;MICRO;1;Equine adenovirus Ag [Presence] in Lung by Immunofluorescence;EAdV Ag Lung Ql IF;;ACTIVE;1.0m;2.56 +20678-9;Alkaloid identified;Prid;Pt;Urine;Nom;TLC;DRUG/TOX;1;Alkaloid identified in Urine by Thin layer chromatography (TLC);Alkaloid Ur TLC;;ACTIVE;1.0m;2.19 +20679-7;Alkaloid identified;Prid;Pt;Plant;Nom;TLC;DRUG/TOX;1;Alkaloid identified in Plant by Thin layer chromatography (TLC);Alkaloid Plant TLC;;ACTIVE;1.0m;2.15 +20680-5;Alkaloid identified;Prid;Pt;Ingesta;Nom;TLC;DRUG/TOX;1;Alkaloid identified in Ingesta by Thin layer chromatography (TLC);Alkaloid Ingesta TLC;;ACTIVE;1.0m;2.15 +20681-3;Alpha tocopherol;MCnt;Pt;Tiss;Qn;;CHEM;1;Alpha tocopherol [Mass/mass] in Tissue;A-Tocopherol Vit E Tiss-mCnt;;ACTIVE;1.0m;2.73 +20682-1;Ammonia;MCnc;Pt;Urine;Qn;;CHEM;1;Ammonia [Mass/volume] in Urine;Ammonia Ur-mCnc;;ACTIVE;1.0m;2.73 +20683-9;Ammonia;MCnc;Pt;Ingesta;Qn;;CHEM;1;Ammonia [Mass/volume] in Ingesta;Ammonia Ingesta-mCnc;;ACTIVE;1.0m;2.42 +20684-7;Ammonia;MCnc;Pt;Ser;Qn;;CHEM;1;Ammonia [Mass/volume] in Serum;Ammonia Ser-mCnc;;DISCOURAGED;1.0m;2.40 +2068-5;Chloride;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Chloride [Moles/volume] in Amniotic fluid;Chloride Amn-sCnc;;ACTIVE;1.0;2.34 +20685-4;Anaplasma marginale Ab;PrThr;Pt;Ser;Ord;Aggl.card;MICRO;1;Anaplasma marginale Ab [Presence] in Serum by Card agglutination;A marginale Ab Ser Ql Card aggl;;ACTIVE;1.0m;2.56 +20686-2;Anaplasma marginale Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Anaplasma marginale Ab [Presence] in Serum by Complement fixation;A marginale Ab Ser Ql CF;;ACTIVE;1.0m;2.56 +20687-0;Arsenic;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Gastric fluid;Arsenic Gast-mCnc;;ACTIVE;1.0m;2.73 +20688-8;Aspergillus sp identified;Prid;Pt;Litter;Nom;Organism specific culture;MICRO;1;Aspergillus sp identified in Litter by Organism specific culture;Aspergillus Litter Cult;;ACTIVE;1.0m;2.21 +20689-6;Babesia caballi Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Babesia caballi Ab [Presence] in Serum by Complement fixation;B caballi Ab Ser Ql CF;;ACTIVE;1.0m;2.67 +20690-4;Theileria equi Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Theileria equi Ab [Presence] in Serum by Complement fixation;T equi Ab Ser Ql CF;;ACTIVE;1.0m;2.67 +20691-2;Bacillus anthracis;ACnc;Pt;XXX;Ord;Organism specific culture;MICRO;1;Deprecated Bacillus anthracis [Presence] in Unspecified specimen by Organism specific culture;Deprecated B anthracis XXX Ql Cult;;DEPRECATED;1.0m;2.69 +20692-0;Bacillus cereus;PrThr;Pt;Food;Ord;Culture.FDA method;MICRO;1;Bacillus cereus [Presence] in Food by Culture FDA method;B cereus Food Ql Cult FDA;;ACTIVE;1.0m;2.56 +2069-3;Chloride;SCnc;Pt;Bld;Qn;;CHEM;1;Chloride [Moles/volume] in Blood;Chloride Bld-sCnc;;ACTIVE;1.0;2.73 +20693-8;Bacteria identified;Prid;Pt;Litter;Nom;Aerobic culture;MICRO;1;Bacteria identified in Litter by Aerobe culture;Bacteria Litter Aerobe Cult;;ACTIVE;1.0m;2.73 +20694-6;Bacteria identified;Prid;Pt;^Embryo;Nom;Aerobic culture;MICRO;1;Bacteria identified in Embryo by Aerobe culture;Bacteria Embryo Aerobe Cult;;ACTIVE;1.0m;2.19 +20695-3;Bacteria;NCnc;Pt;Mmlk;Qn;;MICRO;1;Bacteria [#/volume] in Mother's milk;Bacteria # Mother Milk;;ACTIVE;1.0m;2.42 +20696-1;Bifidobacterium sp;NCnc;Pt;Milk;Qn;Organism specific culture;MICRO;1;Bifidobacterium sp [#/volume] in Milk by Organism specific culture;Bifidobacterium # Mlk Cult;;ACTIVE;1.0m;2.42 +20697-9;Amines.biogenic;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Amines.biogenic [Mass/mass] in Feed;Biogenic Amines Feed-mCnt;;ACTIVE;1.0m;2.42 +20698-7;Bluetongue virus serotype;Prid;Pt;Isolate;Nom;;MICRO;1;Bluetongue virus serotype [Identifier] in Isolate;BTV Sertyp Islt;;ACTIVE;1.0m;2.19 +20699-5;Bluetongue virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Bluetongue virus Ab [Presence] in Serum by Complement fixation;BTV Ab Ser Ql CF;;ACTIVE;1.0m;2.56 +20700-1;Bluetongue virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Bluetongue virus RNA [Presence] in Tissue by NAA with probe detection;BTV RNA Tiss Ql NAA+probe;;ACTIVE;1.0m;2.63 +2070-1;Chloride;SCnc;Pt;CSF;Qn;;CHEM;1;Chloride [Moles/volume] in Cerebral spinal fluid;Chloride CSF-sCnc;;ACTIVE;1.0;2.73 +20701-9;Bluetongue virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bluetongue virus Ag [Presence] in Tissue by Immunofluorescence;BTV Ag Tiss Ql IF;;ACTIVE;1.0m;2.56 +20702-7;Bluetongue virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bluetongue virus [Presence] in Specimen by Organism specific culture;BTV Spec Ql Cult;;ACTIVE;1.0m;2.69 +20703-5;Border disease virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Border disease virus Ag [Presence] in Tissue by Immunofluorescence;Border DV Ag Tiss Ql IF;;ACTIVE;1.0m;2.56 +20704-3;Border disease virus Ag;PrThr;Pt;Bld;Ord;IF;MICRO;1;Border disease virus Ag [Presence] in Blood by Immunofluorescence;Border DV Ag Bld Ql IF;;ACTIVE;1.0m;2.56 +20705-0;Clostridium botulinum toxin;Prid;Pt;Ser;Nom;Animal inoculation;MICRO;1;Clostridium botulinum toxin [Identifier] in Serum by Animal inoculation;C bot Tox Ser Anim Inoc;;ACTIVE;1.0m;2.09 +20706-8;Clostridium botulinum toxin;Prid;Pt;XXX;Nom;Animal inoculation;MICRO;1;Clostridium botulinum toxin [Identifier] in Specimen by Animal inoculation;C bot Tox Spec Anim Inoc;;ACTIVE;1.0m;2.69 +20707-6;Bovine leukosis virus Ab;ACnc;Pt;Ser;Ord;ID;MICRO;1;Deprecated Bovine leukemia virus Ab [Presence] in Serum by Immune diffusion (ID);Deprecated BLV Ab Ser Ql;;DEPRECATED;1.0m;2.67 +20708-4;Bovine papular stomatitis virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine papular stomatitis virus Ag [Presence] in Tissue by Immunofluorescence;BPSV Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20709-2;Bovine diarrhea virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Bovine diarrhea virus RNA [Presence] in Tissue by NAA with probe detection;BVDV RNA Tiss Ql NAA+probe;;ACTIVE;1.0m;2.67 +207-1;Colistin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Colistin [Susceptibility] by Serum bactericidal titer;Colistin Titr SBT;;ACTIVE;1.0;2.32 +20710-0;Bovine diarrhea virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Bovine diarrhea virus RNA [Presence] in Serum by NAA with probe detection;BVDV RNA Ser Ql NAA+probe;;ACTIVE;1.0m;2.67 +20711-8;Bovine diarrhea virus Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Bovine diarrhea virus Ag [Presence] in Nose by Immunofluorescence;BVDV Ag Nose Ql IF;;ACTIVE;1.0m;2.67 +20712-6;Bovine diarrhea virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine diarrhea virus Ag [Presence] in Tissue by Immunofluorescence;BVDV Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20713-4;Bovine diarrhea virus Ag;PrThr;Pt;Bld;Ord;IF;MICRO;1;Bovine diarrhea virus Ag [Presence] in Blood by Immunofluorescence;BVDV Ag Bld Ql IF;;ACTIVE;1.0m;2.67 +20714-2;Bovine diarrhea virus Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Bovine diarrhea virus Ag [Presence] in Stool by Immunofluorescence;BVDV Ag Stl Ql IF;;ACTIVE;1.0m;2.67 +20715-9;Bovine diarrhea virus Ag;PrThr;Pt;Ser;Ord;Immune stain;MICRO;1;Bovine diarrhea virus Ag [Presence] in Serum by Immune stain;BVDV Ag Ser Ql ImStn;;ACTIVE;1.0m;2.67 +20716-7;Bovine diarrhea virus;PrThr;Pt;Ser;Ord;Organism specific culture;MICRO;1;Bovine diarrhea virus [Presence] in Serum by Organism specific culture;BVDV Ser Ql Cult;;ACTIVE;1.0m;2.67 +20717-5;Bovine diarrhea virus 2 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine diarrhea virus 2 Ag [Presence] in Tissue by Immunofluorescence;BVDV2 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20718-3;Bromide;MCnc;Pt;Ocular fld;Qn;;DRUG/TOX;1;Bromide [Mass/volume] in Ocular fluid;Bromide Ocflu-mCnc;;ACTIVE;1.0m;2.42 +2071-9;Chloride;SCnc;Pt;Dial fld;Qn;;CHEM;1;Chloride [Moles/volume] in Dialysis fluid;Chloride Dial fld-sCnc;;ACTIVE;1.0;2.34 +20719-1;Brucella abortus Ab;Titr;Pt;Ser;Qn;Aggl.standard tube;MICRO;1;Brucella abortus Ab [Titer] in Serum by Tube agglutination;B abortus Ab Titr Ser Tube aggl;;ACTIVE;1.0m;2.73 +20720-9;Brucella abortus Ab;PrThr;Pt;Milk;Ord;Aggl.serial ring test;MICRO;1;Brucella abortus Ab [Presence] in Milk by Serial ring agglutination;B abortus Ab Mlk Ql Ser ring aggl;;ACTIVE;1.0m;2.67 +20721-7;Brucella abortus Ab;PrThr;Pt;Semen;Ord;Aggl;MICRO;1;Brucella abortus Ab [Presence] in Semen by Agglutination;B abortus Ab Smn Ql Aggl;;ACTIVE;1.0m;2.67 +20722-5;Brucella abortus Ab;Titr;Pt;Ser;Qn;Aggl.rivanol;MICRO;1;Brucella abortus Ab [Titer] in Serum by Rivanol agglutination;B abortus Ab Titr Ser Rivanol aggl;;ACTIVE;1.0m;2.70 +20723-3;Brucella abortus Ab;PrThr;Pt;Ser;Ord;Aggl.rapid;MICRO;1;Brucella abortus Ab [Presence] in Serum by Rapid agglutination;B abortus Ab Ser Ql Rapid aggl;;ACTIVE;1.0m;2.67 +20724-1;Brucella abortus Ab;PrThr;Pt;Whey;Ord;Aggl.ring test;MICRO;1;Brucella abortus Ab [Presence] in Whey by Ring agglutination;B abortus Ab whey Ql Ring aggl;;ACTIVE;1.0m;2.67 +20725-8;Brucella abortus Ab;PrThr;Pt;Milk;Ord;Aggl.ring test;MICRO;1;Brucella abortus Ab [Presence] in Milk by Ring agglutination;B abortus Ab Mlk Ql Ring aggl;;ACTIVE;1.0m;2.67 +20726-6;Brucella abortus Ab;PrThr;Pt;Ser;Ord;Aggl.card;MICRO;1;Brucella abortus Ab [Presence] in Serum by Card agglutination;B abortus Ab Ser Ql Card aggl;;ACTIVE;1.0m;2.67 +2072-7;Chloride;SCnc;Pt;Body fld;Qn;;CHEM;1;Chloride [Moles/volume] in Body fluid;Chloride Fld-sCnc;;ACTIVE;1.0;2.73 +20727-4;Brucella abortus Ab;PrThr;Pt;Ser;Ord;Aggl.plate.buffered acidified;MICRO;1;Brucella abortus Ab [Presence] in Serum by Acidified buffered plate agglutination;B abortus Ab Ser Ql Buff plate aggl;;ACTIVE;1.0m;2.67 +20728-2;Brucella abortus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Brucella abortus Ab [Presence] in Serum by Complement fixation;B abortus Ab Ser Ql CF;;ACTIVE;1.0m;2.67 +20729-0;Brucella abortus Ab;Titr;Pt;Ser;Qn;Aggl.plate;MICRO;1;Brucella abortus Ab [Titer] in Serum by Plate agglutination;B abortus Ab Titr Ser Plate aggl;;ACTIVE;1.0m;2.70 +20730-8;Brucella abortus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella abortus Ab [Presence] in Serum by Immunoassay;B abortus Ab Ser Ql IA;;ACTIVE;1.0m;2.67 +20731-6;Brucella abortus Ab;PrThr;Pt;Ser;Ord;EIA.RST;MICRO;1;Brucella abortus Ab [Presence] in Serum by Immunoassay (EIA) RST;B abortus Ab Ser Ql EIA RST;;ACTIVE;1.0m;2.67 +20732-4;Brucella ovis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella ovis Ab [Presence] in Serum by Immunoassay;B ovis Ab Ser Ql IA;;ACTIVE;1.0m;2.67 +20733-2;Brucella ovis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Brucella ovis Ab [Presence] in Serum by Complement fixation;B ovis Ab Ser Ql CF;;ACTIVE;1.0m;2.67 +20734-0;Brucella sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Brucella sp identified in Tissue by Organism specific culture;Brucella Tiss Cult;;ACTIVE;1.0m;2.22 +2073-5;Chloride;SCnc;Pt;RBC;Qn;;CHEM;1;Chloride [Moles/volume] in Red Blood Cells;Chloride RBC-sCnc;;ACTIVE;1.0;2.34 +20735-7;Brucella sp identified;Prid;Pt;Milk;Nom;Organism specific culture;MICRO;1;Brucella sp identified in Milk by Organism specific culture;Brucella Mlk Cult;;ACTIVE;1.0m;2.19 +20736-5;Cache valley virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Cache valley virus neutralizing antibody [Presence] in Serum by Neutralization test;CVV NAb Ser Ql Nt;;ACTIVE;1.0m;2.72 +20737-3;Cadmium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Cadmium [Mass/mass] in Tissue;Cadmium Tiss-mCnt;;ACTIVE;1.0m;2.40 +20738-1;Campylobacter sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Campylobacter sp identified in Isolate by Organism specific culture;Campylobacter Islt Cult;;ACTIVE;1.0m;2.19 +20739-9;Campylobacter sp identified;Prid;Pt;Body fld;Nom;Organism specific culture;MICRO;1;Campylobacter sp identified in Body fluid by Organism specific culture;Campylobacter Fld Cult;;ACTIVE;1.0m;2.19 +20740-7;Campylobacter sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Campylobacter sp identified in Tissue by Organism specific culture;Campylobacter Tiss Cult;;ACTIVE;1.0m;2.22 +20741-5;Canarypox virus Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Canarypox virus Ag [Presence] in Serum by Immunofluorescence;CNPV Ag Ser Ql IF;;ACTIVE;1.0m;2.56 +20742-3;Canine distemper virus Ag;PrThr;Pt;Cnjt;Ord;IF;MICRO;1;Canine distemper virus Ag [Presence] in Conjunctival specimen by Immunofluorescence;CDV Ag Conjunct Ql IF;;ACTIVE;1.0m;2.67 +2074-3;Chloride;SCnc;Pt;Saliva;Qn;;CHEM;1;Chloride [Moles/volume] in Saliva (oral fluid);Chloride Sal-sCnc;;ACTIVE;1.0;2.42 +20743-1;Caprine arthritis encephalitis virus Ab;ACnc;Pt;Ser;Ord;ID;MICRO;1;Deprecated Caprine arthritis encephalitis virus Ab [Presence] in Serum by Immune diffusion (ID);Deprecated CAEV Ab Ser Ql;;DEPRECATED;1.0m;2.67 +20744-9;Caprine arthritis encephalitis virus Ab;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Caprine arthritis encephalitis virus Ab [Presence] in Serum by Immunoassay;Deprecated CAEV Ab Ser Ql EIA;;DEPRECATED;1.0m;2.67 +20745-6;Carbamates;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Carbamates [Presence] in Gastric fluid by Screen method;Carbamates Gast Ql Scn;;ACTIVE;1.0m;2.73 +20746-4;Carbamates;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Carbamates [Presence] in Specimen by Screen method;Carbamates Spec Ql Scn;;ACTIVE;1.0m;2.69 +20747-2;Carbamates;PrThr;Pt;Ingesta;Ord;Screen;DRUG/TOX;1;Carbamates [Presence] in Ingesta by Screen method;Carbamates Ingesta Ql Scn;;ACTIVE;1.0m;2.56 +20748-0;Carbamates;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Carbamates [Presence] in Tissue by Screen method;Carbamates Tiss Ql Scn;;ACTIVE;1.0m;2.56 +20749-8;Carbamates;PrThr;Pt;Feed;Ord;Screen;DRUG/TOX;1;Carbamates [Presence] in Feed by Screen method;Carbamates Feed Ql Scn;;ACTIVE;1.0m;2.56 +2075-0;Chloride;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chloride [Moles/volume] in Serum or Plasma;Chloride SerPl-sCnc;;ACTIVE;1.0;2.73 +20750-6;Chicken anemia virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Chicken anemia virus neutralizing antibody [Presence] in Serum by Neutralization test;CAV NAb Ser Ql Nt;;ACTIVE;1.0m;2.72 +20751-4;Chicken anemia virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chicken anemia virus Ab [Presence] in Serum by Immunoassay;CAV Ab Ser Ql IA;;ACTIVE;1.0m;2.67 +20752-2;Chlamydophila psittaci;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Chlamydophila psittaci [Presence] in Specimen by Organism specific culture;C psittaci Spec Ql Cult;;ACTIVE;1.0m;2.73 +20753-0;Chlamydophila psittaci Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Chlamydophila psittaci Ag [Presence] in Tissue by Immunofluorescence;C psittaci Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20754-8;Chlamydophila psittaci Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Chlamydophila psittaci Ab [Presence] in Serum by Complement fixation;C psittaci Ab Ser Ql CF;;ACTIVE;1.0m;2.67 +20755-5;Chlamydia sp Ag;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Body fluid by Immunoassay;Chlamydia Ag Fld Ql IA;;ACTIVE;1.0m;2.56 +20756-3;Chlamydia sp Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Stool by Immunoassay;Chlamydia Ag Stl Ql IA;;ACTIVE;1.0m;2.56 +20757-1;Chlamydia sp Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Tissue by Immunofluorescence;Chlamydia Ag Tiss Ql IF;;ACTIVE;1.0m;2.56 +20758-9;Cholinesterase;CCnt;Pt;Brain;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/mass] in Brain;Cholinesterase Brain-cCnt;;ACTIVE;1.0m;2.40 +20759-7;Chromium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Chromium [Mass/mass] in Tissue;Chromium Tiss-mCnt;;ACTIVE;1.0m;2.40 +20760-5;Clostridium chauvoei Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Clostridium chauvoei Ag [Presence] in Tissue by Immunofluorescence;C chauvoei Ag Tiss Ql IF;;ACTIVE;1.0m;2.56 +20761-3;Clostridioides difficile;PrThr;Pt;Stool;Ord;Aggl;MICRO;1;Clostridioides difficile [Presence] in Stool by Agglutination;C diff Stl Ql Aggl;;ACTIVE;1.0m;2.73 +20762-1;Clostridioides difficile;PrThr;Pt;Stool;Ord;Aerobic culture;MICRO;1;Clostridioides difficile [Presence] in Stool by Aerobe culture;C diff Stl Ql Aerobe Cult;;ACTIVE;1.0m;2.73 +20763-9;Clostridium novyii Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Clostridium novyii Ag [Presence] in Tissue by Immunofluorescence;C novyii Ag Tiss Ql IF;;ACTIVE;1.0m;2.56 +20764-7;Clostridium perfringens genotype;Prid;Pt;Isolate;Nom;;MICRO;1;Clostridium perfringens genotype [Identifier] in Isolate;C perfringens Gentyp Islt;;ACTIVE;1.0m;2.72 +20765-4;Clostridium septicum Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Clostridium septicum Ag [Presence] in Tissue by Immunofluorescence;C septicum Ag Tiss Ql IF;;ACTIVE;1.0m;2.56 +20766-2;Clostridium sordellii Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Clostridium sordellii Ag [Presence] in Tissue by Immunofluorescence;C sordellii Ag Tiss Ql IF;;ACTIVE;1.0m;2.56 +20767-0;Coccidioides immitis;PrThr;Pt;Isolate;Ord;;MICRO;1;Coccidioides immitis [Presence] in Isolate;C immitis Islt Ql;;ACTIVE;1.0m;2.56 +2076-8;Chloride;SCnt;Pt;Stool;Qn;;CHEM;1;Chloride [Moles/mass] in Stool;Chloride Stl-sCnt;;ACTIVE;1.0;2.73 +20768-8;Coccidioides immitis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Coccidioides immitis Ab [Presence] in Serum by Complement fixation;C immitis Ab Ser Ql CF;;ACTIVE;1.0m;2.73 +20769-6;Coliform bacteria;NCnc;Pt;Water;Qn;Viability count;MICRO;1;Coliform bacteria [#/volume] in Water by Viability count;Coliform # Wat Viab Cnt;;ACTIVE;1.0m;2.19 +20770-4;Coliform bacteria;NCnc;Pt;Envir;Qn;Viability count;MICRO;1;Coliform bacteria [#/volume] by Viability count;Coliform # Viab Cnt;;ACTIVE;1.0m;2.42 +20771-2;Coliform bacteria;NCnt;Pt;Egg;Qn;Viability count;MICRO;1;Coliform bacteria [#/mass] in Egg by Viability count;Coliform Egg Viab Cnt;;ACTIVE;1.0m;2.66 +20772-0;Coliform colony count;NCnc;Pt;Milk;Qn;;MICRO;1;Coliform colony count [#/volume] in Milk;Coliform CC # Mlk;;ACTIVE;1.0m;2.42 +20773-8;Colony count;NCnc;Pt;Milk;Qn;Culture.standard plate count;MICRO;1;Colony count [#/volume] in Milk by Culture Standard Plate Count;CC # Mlk Cult Std Plate Cnt;;ACTIVE;1.0m;2.42 +20774-6;Colony count;ACnc;Pt;XXX;Qn;VC;MICRO;1;Colony count [Units/volume] in Specimen by Visual count;CC Spec VC-aCnc;;ACTIVE;1.0m;2.73 +20775-3;Colony count;ACnc;Pt;XXX;Qn;Viability count.FDA method;MICRO;1;Colony count [Units/volume] in Specimen by Viability count FDA method;CC Spec Viab Cnt FDA-aCnc;;ACTIVE;1.0m;2.69 +2077-6;Chloride;SCnc;Pt;Sweat;Qn;;CHEM;1;Chloride [Moles/volume] in Sweat;Chloride Sweat-sCnc;;ACTIVE;1.0;2.73 +20776-1;Caprine parapoxvirus Ab;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Caprine parapoxvirus Ab [Presence] in Tissue by Immunofluorescence;Caprine Parapox Ab Tiss Ql IF;;ACTIVE;1.0m;2.67 +20777-9;Caprine parapoxvirus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Caprine parapoxvirus Ab [Presence] in Serum by Complement fixation;Caprine Parapox Ab Ser Ql CF;;ACTIVE;1.0m;2.67 +20778-7;Copper;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Specimen;Copper Spec-mCnc;;ACTIVE;1.0m;2.73 +20779-5;Bovine coronavirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine coronavirus Ag [Presence] in Tissue by Immunofluorescence;BCV Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20780-3;Cryptosporidium sp;PrThr;Pt;Tlgi/Tsmi;Ord;Acid fast stain;MICRO;1;Cryptosporidium sp [Presence] in Large intestine or small intestine Tissue by Acid fast stain;Cryptosp TLGI/TSMI Ql Acid fast Stn;;ACTIVE;1.0m;2.56 +20781-1;Cryptosporidium sp;PrThr;Pt;Stool;Ord;Acid fast stain;MICRO;1;Cryptosporidium sp [Presence] in Stool by Acid fast stain;Cryptosp Stl Ql Acid fast Stn;;ACTIVE;1.0m;2.73 +20782-9;Cyanide;MCnt;Pt;Plant;Qn;;DRUG/TOX;1;Cyanide [Mass/mass] in Plant;Cyanide Plant-mCnt;;ACTIVE;1.0m;2.42 +20783-7;Cyanide;ACnt;Pt;Plant;Ord;;DRUG/TOX;1;Cyanide [Units/mass] in Plant Qualitative;Cyanide Plant Ql;;ACTIVE;1.0m;2.07 +2078-4;Chloride;SCnc;Pt;Urine;Qn;;CHEM;1;Chloride [Moles/volume] in Urine;Chloride Ur-sCnc;;ACTIVE;1.0;2.73 +20784-5;Cyanide;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cyanide [Mass/volume] in Specimen;Cyanide Spec-mCnc;;ACTIVE;1.0m;2.69 +20785-2;Drugs identified;Prid;Pt;Ser/Plas;Nom;Screen;DRUG/TOX;1;Drugs identified in Serum or Plasma by Screen method;Drugs SerPl Scn;;ACTIVE;1.0m;2.73 +20786-0;Drugs identified;Prid;Pt;Tiss;Nom;Screen;DRUG/TOX;1;Drugs identified in Tissue by Screen method;Drugs Tiss Scn;;ACTIVE;1.0m;2.22 +20787-8;Drugs identified;Prid;Pt;XXX;Nom;Screen;DRUG/TOX;1;Drugs identified in Specimen by Screen method;Drugs Spec Scn;;ACTIVE;1.0m;2.73 +20788-6;Duck enteritis virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Duck enteritis virus neutralizing antibody [Presence] in Serum by Neutralization test;DVE NAb Ser Ql Nt;;ACTIVE;1.0m;2.72 +20789-4;Escherichia coli serotype;Prid;Pt;Isolate;Nom;;MICRO;1;Escherichia coli serotype [Identifier] in Isolate;E coli Sertyp Islt;;ACTIVE;1.0m;2.73 +20790-2;Eastern equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Serum by Hemagglutination inhibition;EEEV Ab Ser Ql HAI;;ACTIVE;1.0m;2.56 +20791-0;Eastern equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Serum by Immunofluorescence;EEEV Ab Ser Ql IF;;ACTIVE;1.0m;2.56 +2079-2;Chloride;SRat;24H;Urine;Qn;;CHEM;1;Chloride [Moles/time] in 24 hour Urine;Chloride 24h Ur-sRate;;ACTIVE;1.0;2.73 +20792-8;Eastern equine encephalitis virus Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;EEEV Ab CSF Ql IF;;ACTIVE;1.0m;2.56 +20793-6;Eastern equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Serum by Complement fixation;EEEV Ab Ser Ql CF;;ACTIVE;1.0m;2.56 +20794-4;Eastern equine encephalitis virus Ab;PrThr;Pt;CSF;Ord;Comp fix;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Cerebral spinal fluid by Complement fixation;EEEV Ab CSF Ql CF;;ACTIVE;1.0m;2.56 +20795-1;Eastern equine encephalitis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Eastern equine encephalitis virus neutralizing antibody [Titer] in Serum by Neutralization test;EEEV NAb Titr Ser Nt;;ACTIVE;1.0m;2.72 +20796-9;Endophyte identified;Prid;Pt;Plant;Nom;;MICRO;1;Endophyte identified in Plant;Endophyte Plant;;ACTIVE;1.0m;1.0n +20797-7;Endotoxin identified;Prid;Pt;XXX;Nom;;MICRO;1;Endotoxin identified in Specimen;Endotoxin Spec;;ACTIVE;1.0m;2.69 +20798-5;Clostridium perfringens enterotoxin;PrThr;Pt;Tiss;Ord;;MICRO;1;Clostridium perfringens enterotoxin [Presence] in Tissue;C perfringens Etx Tiss Ql;;ACTIVE;1.0m;2.56 +20799-3;Clostridium perfringens enterotoxin;PrThr;Pt;Body fld;Ord;;MICRO;1;Clostridium perfringens enterotoxin [Presence] in Body fluid;C perfringens Etx Fld Ql;;ACTIVE;1.0m;2.56 +20-8;Amoxicillin+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);Amoxicillin+Clav Islt MIC;;ACTIVE;1.0;2.73 +2080-0;Cholate;MCnc;Pt;Ser;Qn;;CHEM;1;Cholate [Mass/volume] in Serum;Cholate Ser-mCnc;;DISCOURAGED;1.0;2.73 +20800-9;Clostridium perfringens enterotoxin;PrThr;Pt;Small intes fixed;Ord;;MICRO;1;Clostridium perfringens enterotoxin [Presence] in Small intestine Fixed;C perfringens Etx Fsmi Ql;;ACTIVE;1.0m;2.56 +20801-7;Encephalitozoon cuniculi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Encephalitozoon cuniculi Ab [Presence] in Serum;E cuniculi Ab Ser Ql;;ACTIVE;1.0m;2.56 +20802-5;Epizootic hemorrhagic disease virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Epizootic hemorrhagic disease virus neutralizing antibody [Presence] in Serum by Neutralization test;EHDV NAb Ser Ql Nt;;ACTIVE;1.0m;2.72 +20803-3;Epizootic hemorrhagic disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epizootic hemorrhagic disease virus Ab [Presence] in Serum;EHDV Ab Ser Ql;;ACTIVE;1.0m;2.56 +20804-1;Epizootic hemorrhagic disease virus Ag;PrThr;Pt;Bld;Ord;IF;MICRO;1;Epizootic hemorrhagic disease virus Ag [Presence] in Blood by Immunofluorescence;EHDV Ag Bld Ql IF;;ACTIVE;1.0m;2.56 +20805-8;Epizootic hemorrhagic disease virus Ag;ACnt;Pt;Lung;Ord;IF;MICRO;1;Epizootic hemorrhagic disease virus Ag [Units/mass] in Lung Qualitative by Immunofluorescence;EHDV Ag Lung Ql IF;;ACTIVE;1.0m;1.0n +20806-6;Saint Louis encephalitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Saint Louis encephalitis virus Ab [Presence] in Serum;SLEV Ab Ser Ql;;ACTIVE;1.0m;2.56 +20807-4;Equine arteritis virus;PrThr;Pt;Bld;Ord;Organism specific culture;MICRO;1;Equine arteritis virus [Presence] in Blood by Organism specific culture;EAV Bld Ql Cult;;ACTIVE;1.0m;2.56 +20808-2;Ergot alkaloid;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ergot alkaloid [Mass/volume] in Specimen;Ergot Alkaloid Spec-mCnc;;ACTIVE;1.0m;2.69 +20809-0;Ergot alkaloid;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Ergot alkaloid [Mass/mass] in Feed;Ergot Alkaloid Feed-mCnt;;ACTIVE;1.0m;2.42 +20810-8;Anaplasma phagocytophilum Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Ehrlichia equi Ab [Presence] in Serum;Deprecated A phagocytoph Ab Ser Ql;;DEPRECATED;1.0m;2.40 +20811-6;Escherichia coli;PrThr;Pt;XXX;Ord;Culture.FDA method;MICRO;1;Escherichia coli [Presence] in Specimen by Culture FDA method;E coli Spec Ql Cult FDA;;ACTIVE;1.0m;2.69 +20812-4;Escherichia coli 987P;PrThr;Pt;Tsmi;Ord;IF;MICRO;1;Escherichia coli 987P [Presence] in Small intestine Tissue by Immunofluorescence;E coli987p TSMI Ql IF;;ACTIVE;1.0m;2.56 +20813-2;Escherichia coli F41;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Escherichia coli F41 [Presence] in Isolate by Agglutination;E coli F41 Islt Ql Aggl;;ACTIVE;1.0m;2.56 +20814-0;Escherichia coli F41;PrThr;Pt;Tsmi;Ord;IF;MICRO;1;Escherichia coli F41 [Presence] in Small intestine Tissue by Immunofluorescence;E coli F41 TSMI Ql IF;;ACTIVE;1.0m;2.56 +20815-7;Escherichia coli K88;PrThr;Pt;Tsmi;Ord;Aggl;MICRO;1;Escherichia coli K88 [Presence] in Small intestine Tissue by Agglutination;E coli K88 TSMI Ql Aggl;;ACTIVE;1.0m;2.56 +20816-5;Escherichia coli K88;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Escherichia coli K88 [Presence] in Isolate by Agglutination;E coli K88 Islt Ql Aggl;;ACTIVE;1.0m;2.56 +20817-3;Escherichia coli K88;PrThr;Pt;Tsmi;Ord;IF;MICRO;1;Escherichia coli K88 [Presence] in Small intestine Tissue by Immunofluorescence;E coli K88 TSMI Ql IF;;ACTIVE;1.0m;2.56 +2081-8;Cholecystokinin;MCnc;Pt;Plas;Qn;;CHEM;1;Cholecystokinin [Mass/volume] in Plasma;CCK Plas-mCnc;;ACTIVE;1.0;2.73 +20818-1;Escherichia coli K99;PrThr;Pt;Tsmi;Ord;Aggl;MICRO;1;Escherichia coli K99 [Presence] in Small intestine Tissue by Agglutination;E coli K99 TSMI Ql Aggl;;ACTIVE;1.0m;2.56 +20819-9;Escherichia coli K99;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Escherichia coli K99 [Presence] in Isolate by Agglutination;E coli K99 Islt Ql Aggl;;ACTIVE;1.0m;2.56 +20820-7;Escherichia coli K99;ACnc;Pt;Tsmi;Ord;Aggl;MICRO;1;Deprecated Escherichia coli K99 [Presence] in Small intestine Tissue by Agglutination;Deprecated E coli K99 TSMI Ql Aggl;;DEPRECATED;1.0m;2.36 +20821-5;Escherichia coli K99;PrThr;Pt;Stool;Ord;Aggl;MICRO;1;Escherichia coli K99 [Presence] in Stool by Agglutination;E coli K99 Stl Ql Aggl;;ACTIVE;1.0m;2.56 +20822-3;Escherichia coli K99;PrThr;Pt;Tsmi;Ord;IF;MICRO;1;Escherichia coli K99 [Presence] in Small intestine Tissue by Immunofluorescence;E coli K99 TSMI Ql IF;;ACTIVE;1.0m;2.56 +20823-1;Escherichia coli O157:H7;PrThr;Pt;Mlk.raw;Ord;Organism specific culture;MICRO;1;Escherichia coli O157:H7 [Presence] in Raw milk by Organism specific culture;E coli O157H7 RawMilk Ql Cult;;ACTIVE;1.0m;2.67 +20824-9;Freezing point;Temp;Pt;Milk;Qn;;SPEC;1;Freezing point of Milk;Freezing Pnt Mlk;;ACTIVE;1.0m;2.42 +20825-6;Fumonisin;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Fumonisin [Mass/mass] in Feed;Fumonisin Feed-mCnt;;ACTIVE;1.0m;2.42 +2082-6;Cholestanol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholestanol [Mass/volume] in Serum or Plasma;Cholestanol SerPl-mCnc;;ACTIVE;1.0;2.40 +20826-4;Gallotannin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gallotannin [Mass/volume] in Serum or Plasma;Gallotannin SerPl-mCnc;;ACTIVE;1.0m;2.34 +20827-2;Gallotannin;MCnt;Pt;Gast fld;Qn;;DRUG/TOX;1;Gallotannin [Mass/mass] in Gastric fluid;Gallotannin Gast-mCnt;;ACTIVE;1.0m;2.19 +20828-0;Gallotannin;MCnt;Pt;Plant;Qn;;DRUG/TOX;1;Gallotannin [Mass/mass] in Plant;Gallotannin Plant-mCnt;;ACTIVE;1.0m;2.19 +20829-8;Glycol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Glycol [Mass/mass] in Tissue;Glycol Tiss-mCnt;;ACTIVE;1.0m;2.42 +20830-6;Glycol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Glycol [Mass/volume] in Urine;Glycol Ur-mCnc;;ACTIVE;1.0m;2.34 +20831-4;Glycolate;MCnt;Pt;Tiss;Qn;;CHEM;1;Glycolate [Mass/mass] in Tissue;Glycolate Tiss-mCnt;;ACTIVE;1.0m;2.42 +20832-2;Gossypol;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Gossypol [Mass/mass] in Feed;Gossypol Feed-mCnt;;ACTIVE;1.0m;2.42 +20833-0;Haemophilus paragallinarum serotype;Prid;Pt;Isolate;Nom;;MICRO;1;Haemophilus paragallinarum serotype [Identifier] in Isolate;H paragallinar Sertyp Islt;;ACTIVE;1.0m;2.19 +2083-4;Cholesterol esterase;CCnc;Pt;Ser;Qn;;CHEM;1;Cholesterol esterase [Enzymatic activity/volume] in Serum;Cholest Est Ser-cCnc;;ACTIVE;1.0;2.68 +20834-8;Herbicide;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Deprecated Herbicide [Identifier] in Unspecified specimen;Deprecated Herbicide XXX;;DEPRECATED;1.0m;2.69 +20835-5;Herbicide;Prid;Pt;Ingesta;Nom;;DRUG/TOX;1;Herbicide [Identifier] in Ingesta;Herbicide Ingesta;;ACTIVE;1.0m;2.15 +20836-3;Herbicide;Prid;Pt;Tiss;Nom;;DRUG/TOX;1;Herbicide [Identifier] in Tissue;Herbicide Tiss;;ACTIVE;1.0m;2.22 +20837-1;Herbicide;Prid;Pt;Feed;Nom;;DRUG/TOX;1;Herbicide [Identifier] in Feed;Herbicide Feed;;ACTIVE;1.0m;2.15 +20838-9;Herbicide;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Herbicide [Presence] in Gastric fluid by Screen method;Herbicide Gast Ql Scn;;ACTIVE;1.0m;2.56 +20839-7;Herbicide;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Herbicide [Presence] in Specimen by Screen method;Herbicide Spec Ql Scn;;ACTIVE;1.0m;2.69 +20840-5;Herbicide;PrThr;Pt;Ingesta;Ord;Screen;DRUG/TOX;1;Herbicide [Presence] in Ingesta by Screen method;Herbicide Ingesta Ql Scn;;ACTIVE;1.0m;2.56 +20841-3;Herbicide;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Herbicide [Presence] in Tissue by Screen method;Herbicide Tiss Ql Scn;;ACTIVE;1.0m;2.56 +2084-2;Cholesterol esters;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol esters [Mass/volume] in Serum or Plasma;Cholest Ester SerPl-mCnc;;ACTIVE;1.0;2.73 +20842-1;Herbicide;PrThr;Pt;Feed;Ord;Screen;DRUG/TOX;1;Herbicide [Presence] in Feed by Screen method;Herbicide Feed Ql Scn;;ACTIVE;1.0m;2.56 +20843-9;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;Trac;Ord;IF;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Trachea by Immunofluorescence;ILT Ag Trachea Ql IF;;ACTIVE;1.0m;2.56 +20844-7;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;Lung tiss;Ord;IF;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Lung tissue by Immunofluorescence;ILT Ag Lung tiss Ql IF;;ACTIVE;1.0m;2.56 +20845-4;Bovine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bovine herpesvirus 1 Ab [Presence] in Serum by Immunoassay;BoHV1 Ab Ser Ql IA;;ACTIVE;1.0m;2.67 +20846-2;Bovine herpesvirus 1 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Tissue by Immunofluorescence;BoHV1 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20847-0;Bovine herpesvirus 2 Ag;PrThr;Pt;Exudate;Ord;IF;MICRO;1;Bovine herpesvirus 2 Ag [Presence] in Exudate by Immunofluorescence;BoHV2 Ag Exudate Ql IF;;ACTIVE;1.0m;2.67 +20848-8;Bovine herpesvirus 2 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine herpesvirus 2 Ag [Presence] in Tissue by Immunofluorescence;BoHV2 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20849-6;Bovine herpesvirus 4 Ag;PrThr;Pt;Body fld;Ord;IF;MICRO;1;Bovine herpesvirus 4 Ag [Presence] in Body fluid by Immunofluorescence;BoHV4 Ag Fld Ql IF;;ACTIVE;1.0m;2.67 +20850-4;Bovine herpesvirus 4 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine herpesvirus 4 Ag [Presence] in Tissue by Immunofluorescence;BoHV4 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20851-2;Bovine herpesvirus 5 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine herpesvirus 5 Ag [Presence] in Tissue by Immunofluorescence;BoHV5 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20852-0;Duck enteritis virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Duck enteritis virus Ag [Presence] in Tissue by Immunofluorescence;DVE Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20853-8;Equine herpesvirus 1 Ag;PrThr;Pt;Tracheal swab;Ord;IF;MICRO;1;Equine herpesvirus 1 Ag [Presence] in Tracheal swab by Immunofluorescence;EHV1 Ag Tracheal Swb Ql IF;;ACTIVE;1.0m;2.67 +20854-6;Equine herpesvirus 1 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Equine herpesvirus 1 Ag [Presence] in Tissue by Immunofluorescence;EHV1 Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20855-3;IgG.bovine;MCnc;Pt;Ser;Qn;Immune diffusion;CHEM;1;IgG.bovine [Mass/volume] in Serum by Immune diffusion (ID);IgG Bovine Ser ID-mCnc;;ACTIVE;1.0m;2.42 +20856-1;IgG.equine;MCnc;Pt;Body Fld^Fetus;Qn;Immune diffusion;CHEM;1;IgG.equine [Mass/volume] in Body fluid from Fetus by Immune diffusion (ID);IgG Equine Fld Fetus ID-mCnc;;ACTIVE;1.0m;2.67 +20857-9;IgG.equine;MCnc;Pt;Col;Qn;Immune diffusion;CHEM;1;IgG.equine [Mass/volume] in Colostrum by Immune diffusion (ID);IgG Equine Col ID-mCnc;;ACTIVE;1.0m;2.42 +20858-7;Infectious bronchitis virus genotype;Prid;Pt;Isolate;Nom;PAGE;MICRO;1;Infectious bronchitis virus genotype [Identifier] in Isolate by Polyacrylamide gel electrophoresis (PAGE);IBV Gentyp Islt PAGE;;ACTIVE;1.0m;2.72 +2085-9;Cholesterol.in HDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL [Mass/volume] in Serum or Plasma;HDLc SerPl-mCnc;;ACTIVE;1.0;2.73 +20859-5;Infectious bronchitis virus serotype;Prid;Pt;Isolate;Nom;Neut;MICRO;1;Infectious bronchitis virus serotype [Identifier] in Isolate by Neutralization test;IBV Sertyp Islt Nt;;ACTIVE;1.0m;2.19 +20860-3;Infectious bronchitis virus;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Infectious bronchitis virus [Presence] in Tissue by Organism specific culture;IBV Tiss Ql Cult;;ACTIVE;1.0m;2.56 +20861-1;Infectious bronchitis virus genotype;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Infectious bronchitis virus genotype [Identifier] in Isolate by NAA with probe detection;IBV Gentyp Islt NAA+probe;;ACTIVE;1.0m;2.72 +20862-9;Influenza virus A Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Influenza virus A Ab [Presence] in Serum by Hemagglutination inhibition;FLUAV Ab Ser Ql HAI;;ACTIVE;1.0m;2.56 +20863-7;Iodine;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Iodine [Mass/volume] in Water;Iodine Wat-mCnc;;ACTIVE;1.0m;2.34 +20864-5;Iodine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Iodine [Mass/volume] in Milk;Iodine Mlk-mCnc;;ACTIVE;1.0m;2.42 +20865-2;Iodine;MCnt;Pt;Liver;Qn;;DRUG/TOX;1;Iodine [Mass/mass] in Liver;Iodine Liver-mCnt;;ACTIVE;1.0m;2.42 +20866-0;Lactobacillus acidophilus colony count;NCnc;Pt;Milk;Qn;Organism specific culture;MICRO;1;Lactobacillus acidophilus colony count [#/volume] in Milk by Organism specific culture;L acidophilus CC # Mlk Cult;;ACTIVE;1.0m;2.42 +2086-7;Cholesterol.in HDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cholesterol.in HDL [Mass/volume] in Serum or Plasma;Deprecated HDLc SerPl-mCnc;;DEPRECATED;1.0;2.36 +20867-8;Lead;MCnt;Pt;Bone;Qn;;DRUG/TOX;1;Lead [Mass/mass] in Bone;Lead Bone-mCnt;;ACTIVE;1.0m;2.40 +20868-6;Leptospira sp;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Leptospira sp [Presence] in Tissue by Immunofluorescence;Leptospira Tiss Ql IF;;ACTIVE;1.0m;2.56 +20869-4;Leptospira sp;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Leptospira sp [Presence] in Tissue by Organism specific culture;Leptospira Tiss Ql Cult;;ACTIVE;1.0m;2.56 +20870-2;Listeria sp;PrThr;Pt;Milk;Ord;Organism specific culture;MICRO;1;Listeria sp [Presence] in Milk by Organism specific culture;Listeria Mlk Ql Cult;;ACTIVE;1.0m;2.56 +20871-0;Listeria sp;PrThr;Pt;Cheese;Ord;Organism specific culture;MICRO;1;Listeria sp [Presence] in Cheese by Organism specific culture;Listeria Cheese Ql Cult;;ACTIVE;1.0m;2.56 +20872-8;Magnesium;MCnc;Pt;Ocular fld;Qn;;CHEM;1;Magnesium [Mass/volume] in Ocular fluid;Magnesium Ocflu-mCnc;;ACTIVE;1.0m;2.42 +20873-6;Alcelaphine herpesvirus 1 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Alcelaphine herpesvirus 1 neutralizing antibody [Presence] in Serum by Neutralization test;AHV1 NAb Ser Ql Nt;;ACTIVE;1.0m;2.72 +20874-4;Manganese;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Manganese [Mass/mass] in Tissue;Manganese Tiss-mCnt;;ACTIVE;1.0m;2.42 +2087-5;Cholesterol.in IDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in IDL [Mass/volume] in Serum or Plasma;IDLc SerPl-mCnc;;ACTIVE;1.0;2.73 +20875-1;Manganese;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Manganese [Mass/mass] in Feed;Manganese Feed-mCnt;;ACTIVE;1.0m;2.42 +20876-9;Mercury;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Mercury [Mass/mass] in Feed;Mercury Feed-mCnt;;ACTIVE;1.0m;2.40 +20877-7;Bacteria identified;Prid;Pt;Isolate;Nom;Animal inoculation;MICRO;1;Bacteria identified in Isolate by Animal inoculation;Bacteria Islt Anim Inoc;;ACTIVE;1.0m;2.19 +20878-5;Bacteria identified;Prid;Pt;Isolate;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Isolate by Anaerobe culture;Bacteria Islt Anaerobe Cult;;ACTIVE;1.0m;2.73 +20879-3;Bacteria identified;Prid;Pt;Milk;Nom;Aerobic culture;MICRO;1;Bacteria identified in Milk by Aerobe culture;Bacteria Mlk Aerobe Cult;;ACTIVE;1.0m;2.19 +20881-9;Microscopic observation;Prid;Pt;Tiss;Nom;Microscopy.electron.thin section;MICRO;1;Microscopic observation [Identifier] in Tissue by Electron microscopy thin sectiion;EM Thin Tiss;;ACTIVE;1.0m;2.22 +20882-7;Microscopic observation;Prid;Pt;Stool;Nom;Microscopy.electron.negative stain;MICRO;1;Microscopic observation [Identifier] in Stool by Electron microscopy negative stain;EM Negative Stn Stl;;ACTIVE;1.0m;2.19 +2088-3;Cholesterol.in IDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cholesterol.in IDL [Mass/volume] in Serum or Plasma;Deprecated IDLc SerPl-mCnc;;DEPRECATED;1.0;2.36 +20883-5;Microscopic observation;Prid;Pt;Urine;Nom;Dark field examination;MICRO;1;Microscopic observation [Identifier] in Urine by Dark field examination;Dark Field Ur;;ACTIVE;1.0m;2.19 +20884-3;Microscopic observation;Prid;Pt;Stool;Nom;Dark field examination;MICRO;1;Microscopic observation [Identifier] in Stool by Dark field examination;Dark Field Stl;;ACTIVE;1.0m;2.19 +20885-0;Microscopic observation;Prid;Pt;Gast fld;Nom;Dark field examination;MICRO;1;Microscopic observation [Identifier] in Gastric fluid by Dark field examination;Dark Field Gast;;ACTIVE;1.0m;2.19 +20886-8;Molybdenum;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Molybdenum [Mass/volume] in Specimen;Molybdenum Spec-mCnc;;ACTIVE;1.0m;2.69 +20887-6;Molybdenum;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Molybdenum [Mass/mass] in Tissue;Molybdenum Tiss-mCnt;;ACTIVE;1.0m;2.40 +20888-4;Molybdenum;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Molybdenum [Mass/mass] in Feed;Molybdenum Feed-mCnt;;ACTIVE;1.0m;2.40 +20889-2;Monensin;MCnt;Pt;Gast fld;Qn;;DRUG/TOX;1;Monensin [Mass/mass] in Gastric fluid;Monensin Gast-mCnt;;ACTIVE;1.0m;2.42 +208-9;Cyclacillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cyclacillin [Susceptibility] by Minimum lethal concentration (MLC);Cyclacillin Islt MLC;;ACTIVE;1.0;2.19 +20890-0;Monensin;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Monensin [Mass/mass] in Feed;Monensin Feed-mCnt;;ACTIVE;1.0m;2.42 +2089-1;Cholesterol.in LDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL [Mass/volume] in Serum or Plasma;LDLc SerPl-mCnc;;ACTIVE;1.0;2.73 +20891-8;Mushroom identified;Prid;Pt;^Mushroom specimen;Nom;;MICRO;1;Mushroom identified;Mushroom identified;;ACTIVE;1.0m;2.26 +20892-6;Mycobacterium avium subspecies paratuberculosis;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Mycobacterium avium ss paratuberculosis [Presence] in Tissue by Organism specific culture;M avium paraTB Tiss Ql Cult;;ACTIVE;1.0m;2.56 +20893-4;Mycobacterium avium subspecies paratuberculosis;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Mycobacterium avium ss paratuberculosis [Presence] in Stool by Organism specific culture;M avium paraTB Stl Ql Cult;;ACTIVE;1.0m;2.56 +20894-2;Mycobacterium avium subspecies paratuberculosis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Presence] in Serum by Complement fixation;M avium paraTB Ab Ser Ql CF;;ACTIVE;1.0m;2.56 +20895-9;Mycoplasma gallisepticum Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Mycoplasma gallisepticum Ag [Presence] in Tissue by Immune stain;M gallisep Ag Tiss Ql ImStn;;ACTIVE;1.0m;2.56 +20896-7;Mycoplasma sp;PrThr;Pt;Tiss;Ord;Organism specific culture.NPIP method;MICRO;1;Mycoplasma sp [Presence] in Tissue by Culture NPIP (National Poultry Improvement Plan);Mycoplasma Tiss Ql Cult NPIP;;ACTIVE;1.0m;2.56 +20897-5;Mycoplasma sp serotype;Prid;Pt;Isolate;Nom;;MICRO;1;Mycoplasma sp serotype [Identifier] in Isolate;Mycoplasma Sertyp Islt;;ACTIVE;1.0m;2.67 +20898-3;Mycoplasma sp;PrThr;Pt;Milk;Ord;Organism specific culture;MICRO;1;Mycoplasma sp [Presence] in Milk by Organism specific culture;Mycoplasma Mlk Ql Cult;;ACTIVE;1.0m;2.56 +20899-1;Mycoplasma sp;PrThr;Pt;Exudate;Ord;Organism specific culture;MICRO;1;Mycoplasma sp [Presence] in Exudate by Organism specific culture;Mycoplasma Exudate Ql Cult;;ACTIVE;1.0m;2.56 +20900-7;Mycoplasma sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma sp Ab [Presence] in Serum by Immunoassay;Mycoplasma Ab Ser Ql IA;;ACTIVE;1.0m;2.56 +20901-5;Mycoplasma sp Ag;PrThr;Pt;Isolate;Ord;Immune stain;MICRO;1;Mycoplasma sp Ag [Presence] in Isolate by Immune stain;Mycoplasma Ag Islt Ql ImStn;;ACTIVE;1.0m;2.56 +20902-3;Mycoplasma sp+Ureaplasma sp;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Mycoplasma sp+Ureaplasma sp [Presence] in Tissue by Organism specific culture;Mycoplas+Ureoplas Tiss Ql Cult;;ACTIVE;1.0m;2.56 +20903-1;Mycotoxin identified;Prid;Pt;Feed;Nom;;MICRO;1;Mycotoxin identified in Feed;Mycotoxin Feed;;ACTIVE;1.0m;1.0n +20904-9;Neospora caninum Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Neospora caninum Ab [Presence] in Serum by Immunofluorescence;N caninum Ab Ser Ql IF;;ACTIVE;1.0m;2.56 +20905-6;Oleandrin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oleandrin [Mass/volume] in Urine;Oleandrin Ur-mCnc;;ACTIVE;1.0m;2.34 +20906-4;Oleandrin;MCnc;Pt;Ingesta;Qn;;DRUG/TOX;1;Oleandrin [Mass/volume] in Ingesta;Oleandrin Ingesta-mCnc;;ACTIVE;1.0m;2.34 +20907-2;Organochlorine pesticides;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Organochlorine pesticides [Identifier] in Blood;OC Pesticides Bld;;ACTIVE;1.0m;2.07 +20908-0;Organochlorine pesticides;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Organochlorine pesticides [Identifier] in Specimen;OC Pesticides Spec;;ACTIVE;1.0m;2.69 +2090-9;Cholesterol.in LDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cholesterol.in LDL [Mass/volume] in Serum or Plasma;Deprecated LDLc SerPl-mCnc;;DEPRECATED;1.0;2.36 +20909-8;Organochlorine pesticides;Prid;Pt;Gast fld;Nom;;DRUG/TOX;1;Organochlorine pesticides [Identifier] in Gastric fluid;OC Pesticides Gast;;ACTIVE;1.0m;2.19 +20910-6;Organochlorine pesticides;Prid;Pt;Milk;Nom;;DRUG/TOX;1;Organochlorine pesticides [Identifier] in Milk;OC Pesticides Mlk;;ACTIVE;1.0m;2.19 +20911-4;Organochlorine pesticides;Prid;Pt;Tiss;Nom;;DRUG/TOX;1;Organochlorine pesticides [Identifier] in Tissue;OC Pesticides Tiss;;ACTIVE;1.0m;2.22 +20912-2;Organochlorine pesticides;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Organochlorine pesticides [Presence] in Blood by Screen method;OC Pesticides Bld Ql Scn;;ACTIVE;1.0m;2.68 +20913-0;Organochlorine pesticides;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Organochlorine pesticides [Presence] in Specimen by Screen method;OC Pesticides Spec Ql Scn;;ACTIVE;1.0m;2.69 +20914-8;Organochlorine pesticides;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Organochlorine pesticides [Presence] in Gastric fluid by Screen method;OC Pesticides Gast Ql Scn;;ACTIVE;1.0m;2.56 +20915-5;Organochlorine pesticides;PrThr;Pt;Milk;Ord;Screen;DRUG/TOX;1;Organochlorine pesticides [Presence] in Milk by Screen method;OC Pesticides Mlk Ql Scn;;ACTIVE;1.0m;2.56 +20916-3;Organochlorine pesticides;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Organochlorine pesticides [Presence] in Tissue by Screen method;OC Pesticides Tiss Ql Scn;;ACTIVE;1.0m;2.56 +2091-7;Cholesterol.in VLDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL [Mass/volume] in Serum or Plasma;VLDLc SerPl-mCnc;;ACTIVE;1.0;2.73 +20917-1;Organophosphate pesticides;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Organophosphate pesticides [Presence] in Blood by Screen method;OP Pesticides Bld Ql Scn;;ACTIVE;1.0m;2.68 +20918-9;Organophosphate pesticides;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Organophosphate pesticides [Presence] in Specimen by Screen method;OP Pesticides Spec Ql Scn;;ACTIVE;1.0m;2.69 +20919-7;Organophosphate pesticides;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Organophosphate pesticides [Presence] in Gastric fluid by Screen method;OP Pesticides Gast Ql Scn;;ACTIVE;1.0m;2.56 +20920-5;Organophosphate pesticides;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Organophosphate pesticides [Presence] in Tissue by Screen method;OP Pesticides Tiss Ql Scn;;ACTIVE;1.0m;2.56 +20921-3;Organophosphate pesticides;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Organophosphate pesticides [Identifier] in Specimen;OP Pesticides Spec;;ACTIVE;1.0m;2.73 +20922-1;Organophosphate pesticides;Prid;Pt;Gast fld;Nom;;DRUG/TOX;1;Organophosphate pesticides [Identifier] in Gastric fluid;OP Pesticides Gast;;ACTIVE;1.0m;2.19 +20923-9;Organophosphate pesticides;Prid;Pt;Tiss;Nom;;DRUG/TOX;1;Organophosphate pesticides [Identifier] in Tissue;OP Pesticides Tiss;;ACTIVE;1.0m;2.22 +20924-7;Ova & parasites identified;Prid;Pt;Stool;Nom;Sedimentation;MICRO;1;Ova and parasites identified in Stool by Parasite sedimentation;O+P Stl Sedimentation;;ACTIVE;1.0m;2.73 +2092-5;Cholesterol.in VLDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cholesterol.in VLDL [Mass/volume] in Serum or Plasma;Deprecated VLDLc SerPl-mCnc;;DEPRECATED;1.0;2.36 +20925-4;Ova & parasites identified;Prid;Pt;Stool;Nom;Concentration.McMaster;MICRO;1;Ova and parasites identified in Stool by McMaster concentration;O+P Stl McMaster Conc;;ACTIVE;1.0m;2.38 +20926-2;Ova & parasites identified;Prid;Pt;Stool;Nom;Concentration.Baermann;MICRO;1;Ova and parasites identified in Stool by Baermann concentration;O+P Stl Baermann Conc;;ACTIVE;1.0m;2.70 +20927-0;Oxalate;MCnt;Pt;Tiss;Qn;;CHEM;1;Oxalate [Mass/mass] in Tissue;Oxalate Tiss-mCnt;;ACTIVE;1.0m;2.42 +20928-8;Oxalate;MCnt;Pt;Plant;Qn;;CHEM;1;Oxalate [Mass/mass] in Plant;Oxalate Plant-mCnt;;ACTIVE;1.0m;2.42 +20929-6;Paraquat;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Paraquat [Mass/volume] in Gastric fluid;Paraquat Gast-mCnc;;ACTIVE;1.0m;2.42 +20930-4;Paraquat;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Paraquat [Mass/mass] in Tissue;Paraquat Tiss-mCnt;;ACTIVE;1.0m;2.42 +20931-2;Parasites;NCnc;Pt;Gast fld;Qn;;MICRO;1;Parasites [#/volume] in Gastric fluid;Parasites # Gast;;ACTIVE;1.0m;2.73 +20932-0;Parasite identified;Prid;Pt;XXX;Nom;Inspection;MICRO;1;Parasite identified in Specimen by Inspection;Parasite Spec Inspect;;ACTIVE;1.0m;2.73 +2093-3;Cholesterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol [Mass/volume] in Serum or Plasma;Cholest SerPl-mCnc;;ACTIVE;1.0;2.73 +20933-8;Parasite identified;Prid;Pt;Ser;Nom;Microscopy.light;MICRO;1;Parasite identified in Serum by Light microscopy;Parasite Ser Micro;;ACTIVE;1.0m;2.73 +20934-6;Bovine parvovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine parvovirus Ag [Presence] in Tissue by Immunofluorescence;BPV Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20935-3;Pasteurella multocida serotype;Prid;Pt;Isolate;Nom;Immune diffusion;MICRO;1;Pasteurella multocida serotype [Identifier] in Isolate by Immune diffusion (ID);P multoc Sertyp Islt ID;;ACTIVE;1.0m;2.19 +20936-1;Pentachlorophenol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Pentachlorophenol [Mass/mass] in Tissue;Pentachlorophen Tiss-mCnt;;ACTIVE;1.0m;2.42 +20937-9;Pentachlorophenol;MCnt;Pt;Tiss fat;Qn;;DRUG/TOX;1;Pentachlorophenol [Mass/mass] in Fat;Pentachlorophen Fat-mCnt;;ACTIVE;1.0m;2.42 +20938-7;Phenols;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Phenols [Mass/volume] in Gastric fluid;Phenols Gast-mCnc;;ACTIVE;1.0m;2.42 +20939-5;Phosphide;MCnt;Pt;GI cnt;Qn;;DRUG/TOX;1;Phosphide [Mass/mass] in Gastrointestinal content;Phosphide GiCnt-mCnt;;ACTIVE;1.0m;2.21 +20940-3;Phosphide;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Phosphide [Mass/mass] in Feed;Phosphide Feed-mCnt;;ACTIVE;1.0m;2.42 +2094-1;Cholesterol.non-esterified;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.non-esterified [Mass/volume] in Serum or Plasma;NE Cholest SerPl-mCnc;;ACTIVE;1.0;2.73 +20941-1;Phosphate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Phosphate [Mass/volume] in Serum or Plasma;Deprecated Phosphate SerPl-mCnc;;DEPRECATED;1.0m;2.36 +20942-9;Plant identified;Type;Pt;Plant;Nom;;DRUG/TOX;1;Plant identified [Type] in Plant;Plant identified;;ACTIVE;1.0m;2.26 +20943-7;Bovine respiratory syncytial virus Ag;PrThr;Pt;Lung;Ord;Immune stain;MICRO;1;Bovine respiratory syncytial virus Ag [Presence] in Lung by Immune stain;BRSV Ag Lung Ql ImStn;;ACTIVE;1.0m;2.56 +20944-5;Bovine respiratory syncytial virus Ag;PrThr;Pt;Lung;Ord;IA;MICRO;1;Bovine respiratory syncytial virus Ag [Presence] in Lung by Immunoassay;BRSV Ag Lung Ql IA;;ACTIVE;1.0m;2.67 +20945-2;Bovine respiratory syncytial virus Ag;PrThr;Pt;Lung;Ord;IF;MICRO;1;Bovine respiratory syncytial virus Ag [Presence] in Lung by Immunofluorescence;BRSV Ag Lung Ql IF;;ACTIVE;1.0m;2.67 +20946-0;Retinol;MCnt;Pt;Liver;Qn;;CHEM;1;Retinol [Mass/mass] in Liver;Vit A Liver-mCnt;;ACTIVE;1.0m;2.42 +20947-8;Retinol;MCnt;Pt;Feed;Qn;;CHEM;1;Retinol [Mass/mass] in Feed;Vit A Feed-mCnt;;ACTIVE;1.0m;2.42 +20948-6;Retinol;MCnt;Pt;Tiss;Qn;;CHEM;1;Retinol [Mass/mass] in Tissue;Vit A Tiss-mCnt;;ACTIVE;1.0m;2.42 +20949-4;Rickettsia sp;PrThr;Pt;Bld;Ord;Microscopy.light;MICRO;1;Rickettsia sp [Presence] in Blood by Light microscopy;Rickettsia Bld Ql Smear;;ACTIVE;1.0m;2.56 +20950-2;Bovine rotavirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine rotavirus Ag [Presence] in Tissue by Immunofluorescence;BRV Ag Tiss Ql IF;;ACTIVE;1.0m;2.67 +20951-0;Salmonella sp serotype;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Salmonella sp serotype [Identifier] in Isolate by Agglutination;Salmonella Sertyp Islt Aggl;;ACTIVE;1.0m;2.73 +20952-8;Salmonella sp identified;Prid;Pt;Egg;Nom;Organism specific culture;MICRO;1;Salmonella sp identified in Egg by Organism specific culture;Salmonella Egg Cult;;ACTIVE;1.0m;2.67 +20953-6;Salmonella sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Salmonella sp identified in Tissue by Organism specific culture;Salmonella Tiss Cult;;ACTIVE;1.0m;2.67 +20954-4;Salmonella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Deprecated Salmonella sp identified in Unspecified specimen by Organism specific culture;Deprecated Salmonella XXX Cult;;DEPRECATED;1.0m;2.69 +20955-1;Salmonella sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Salmonella sp identified in Stool by Organism specific culture;Salmonella Stl Cult;;ACTIVE;1.0m;2.67 +20956-9;Sarcocystis neurona Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Sarcocystis neurona Ab [Presence] in Body fluid by Immunoblot;S neurona Ab Fld Ql IB;;ACTIVE;1.0m;2.58 +20957-7;Sarcocystis neurona Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Sarcocystis neurona Ab [Presence] in Serum by Immunoblot;S neurona Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +2095-8;Cholesterol.in HDL/Cholesterol.total;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma;HDLc SerPl;;ACTIVE;1.0;2.73 +20958-5;Sarcocystis neurona Ab;PrThr;Pt;Bld;Ord;IB;MICRO;1;Sarcocystis neurona Ab [Presence] in Blood by Immunoblot;S neurona Ab Bld Ql IB;;ACTIVE;1.0m;2.58 +20959-3;Sarcocystis neurona Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Sarcocystis neurona Ag [Presence] in Tissue by Immune stain;S neurona Ag Tiss Ql ImStn;;ACTIVE;1.0m;2.56 +20960-1;Selenium;MCnt;Pt;Gast fld;Qn;;DRUG/TOX;1;Selenium [Mass/mass] in Gastric fluid;Selenium Gast-mCnt;;ACTIVE;1.0m;2.40 +20961-9;Selenium;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Selenium [Mass/mass] in Feed;Selenium Feed-mCnt;;ACTIVE;1.0m;2.40 +20962-7;Serpulina hyodysenteria;PrThr;Pt;Spiral colon;Ord;Organism specific culture;MICRO;1;Serpulina hyodysenteria [Presence] in Spiral colon by Organism specific culture;S hyodysenter Sp Colon Ql Cult;;ACTIVE;1.0m;2.67 +20963-5;Serpulina hyodysenteria;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Serpulina hyodysenteria [Presence] in Stool by Organism specific culture;S hyodysenter Stl Ql Cult;;ACTIVE;1.0m;2.67 +20964-3;Shigella sp identified;Prid;Pt;Feed;Nom;Organism specific culture;MICRO;1;Shigella sp identified in Feed by Organism specific culture;Shigella Feed Cult;;ACTIVE;1.0m;1.0n +20965-0;Somatic cells;NCnc;Pt;Milk;Qn;;MICRO;1;Somatic cells [#/volume] in Milk;Somatic Cells # Mlk;;ACTIVE;1.0m;2.42 +2096-6;Cholesterol/Triglyceride;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol/Triglyceride [Mass Ratio] in Serum or Plasma;Cholest/Trigl SerPl;;ACTIVE;1.0;2.73 +20966-8;Staphylococcus sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Staphylococcus sp identified in Specimen by Organism specific culture;Staphylococcus Spec Cult;;ACTIVE;1.0m;2.73 +20967-6;Staphylococcus sp identified;Prid;Pt;Milk;Nom;Organism specific culture;MICRO;1;Staphylococcus sp identified in Milk by Organism specific culture;Staphylococcus Mlk Cult;;ACTIVE;1.0m;2.19 +20968-4;Staphylococcus sp identified;Prid;Pt;Cheese;Nom;Organism specific culture;MICRO;1;Staphylococcus sp identified in Cheese by Organism specific culture;Staphylococcus Cheese Cult;;ACTIVE;1.0m;1.0n +20969-2;Strychnine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Strychnine [Presence] in Gastric fluid;Strychnine Gast Ql;;ACTIVE;1.0m;2.56 +209-7;Cyclacillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cyclacillin [Susceptibility] by Minimum inhibitory concentration (MIC);Cyclacillin Islt MIC;;ACTIVE;1.0;2.19 +20970-0;Strychnine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Strychnine [Presence] in Specimen;Strychnine Spec Ql;;ACTIVE;1.0m;2.69 +20972-6;Strychnine;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Strychnine [Mass/mass] in Tissue;Strychnine Tiss-mCnt;;ACTIVE;1.0m;2.42 +20973-4;Sulfate;MCnc;Pt;Gast fld;Qn;;CHEM;1;Sulfate [Mass/volume] in Gastric fluid;Sulfate Gast-mCnc;;ACTIVE;1.0m;2.44 +2097-4;Cholinesterase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/volume] in Amniotic fluid;Cholinesterase Amn-cCnc;;ACTIVE;1.0;2.68 +20974-2;Sulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sulfate [Mass/volume] in Serum or Plasma;Sulfate SerPl-mCnc;;ACTIVE;1.0m;2.44 +20975-9;Thallium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Thallium [Mass/mass] in Tissue;Thallium Tiss-mCnt;;ACTIVE;1.0m;2.40 +20976-7;Tritrichomonas foetus;PrThr;Pt;Preputial wash;Ord;Organism specific culture;MICRO;1;Tritrichomonas foetus [Presence] in Preputial wash by Organism specific culture;T foet Preput Wash Ql Cult;;ACTIVE;1.0m;2.56 +20977-5;Urea;MCnc;Pt;Bld;Qn;;CHEM;1;Urea [Mass/volume] in Blood;Urea Bld-mCnc;;ACTIVE;1.0m;2.42 +20978-3;Urea;MCnc;Pt;Gast fld;Qn;;CHEM;1;Urea [Mass/volume] in Gastric fluid;Urea Gast-mCnc;;ACTIVE;1.0m;2.42 +20979-1;Urea;MCnt;Pt;Feed;Qn;;CHEM;1;Urea [Mass/mass] in Feed;Urea Feed-mCnt;;ACTIVE;1.0m;2.42 +20980-9;Venezuelan equine encephalitis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Venezuelan equine encephalitis virus neutralizing antibody [Titer] in Serum by Neutralization test;VEEV NAb Titr Ser Nt;;ACTIVE;1.0m;2.72 +20981-7;Verotoxin identified;Prid;Pt;Isolate;Nom;;MICRO;1;Verotoxin identified in Isolate;Verotoxin Islt;;ACTIVE;1.0m;2.73 +2098-2;Cholinesterase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/volume] in Serum or Plasma;Cholinesterase SerPl-cCnc;;ACTIVE;1.0;2.73 +20982-5;Western equine encephalitis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Western equine encephalitis virus neutralizing antibody [Titer] in Serum by Neutralization test;WEEV NAb Titr Ser Nt;;ACTIVE;1.0m;2.72 +20983-3;Western equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Western equine encephalitis virus Ab [Presence] in Serum by Immunofluorescence;WEEV Ab Ser Ql IF;;ACTIVE;1.0m;2.56 +20984-1;Western equine encephalitis virus Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Western equine encephalitis virus Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;WEEV Ab CSF Ql IF;;ACTIVE;1.0m;2.56 +20985-8;Western equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Western equine encephalitis virus Ab [Presence] in Serum by Complement fixation;WEEV Ab Ser Ql CF;;ACTIVE;1.0m;2.56 +20986-6;Western equine encephalitis virus Ab;PrThr;Pt;CSF;Ord;Comp fix;MICRO;1;Western equine encephalitis virus Ab [Presence] in Cerebral spinal fluid by Complement fixation;WEEV Ab CSF Ql CF;;ACTIVE;1.0m;2.56 +20987-4;Yersinia sp identified;Prid;Pt;Dairy product;Nom;Organism specific culture;MICRO;1;Yersinia sp identified in Dairy product by Organism specific culture;Yersinia Dairy Prod Cult;;ACTIVE;1.0m;2.73 +20988-2;Zinc phosphide;MCnt;Pt;GI cnt;Qn;;DRUG/TOX;1;Zinc phosphide [Mass/mass] in Gastrointestinal content;Zinc Phosphide GiCnt-mCnt;;ACTIVE;1.0m;2.21 +20989-0;Zinc phosphide;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Zinc phosphide [Mass/mass] in Specimen;Zinc Phosphide Spec-mCnt;;ACTIVE;1.0m;2.69 +2099-0;Cholinesterase;CCnc;Pt;RBC;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/volume] in Red Blood Cells;Cholinesterase RBC-cCnc;;ACTIVE;1.0;2.73 +20990-8;APC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;APC gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +20991-6;Antithrombin;Imp;Pt;PPP;Nom;;COAG;1;Antithrombin [Interpretation] in Platelet poor plasma;AT III PPP-Imp;;ACTIVE;1.0m;2.73 +20992-4;Bordetella pertussis Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Bordetella pertussis Ab [Presence] in Specimen;B pert Ab Spec Ql;;ACTIVE;1.0m;2.73 +20993-2;Chlamydia trachomatis rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis DNA [Presence] in Unspecified specimen by DNA probe;Deprecated C trach rRNA XXX Ql Prb;;DEPRECATED;1.0m;2.69 +20994-0;Choriogonadotropin;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Choriogonadotropin [Interpretation] in Serum or Plasma;HCG SerPl-Imp;;ACTIVE;1.0m;2.73 +20995-7;Cortisol^1H post dose corticotropin;Imp;Pt;Ser/Plas;Nom;;CHAL;1;Cortisol [Interpretation] in Serum or Plasma--1 hour post dose corticotropin;Cortis 1h p ACTH SerPl-Imp;;ACTIVE;1.0m;2.73 +20996-5;Coxsackievirus B1+B2+B3+B4+B5+B6 Ab;Imp;Pt;Ser;Nom;;MICRO;1;Coxsackievirus B1+B2+B3+B4+B5+B6 Ab [Interpretation] in Serum;CV B blend Ab Ser-Imp;;ACTIVE;1.0m;2.26 +20997-3;Cryptosporidium;-;-;-;-;;MICRO;1;Deprecated Cryptosporidium sp Ag [Presence] in Unspecified specimen by Immunofluorescence;Deprecated Cryptosporidium;;DEPRECATED;1.0m;2.66 +20998-1;Cell fractions;Imp;Pt;CSF;Nom;;HEM/BC;1;Cell Fractions/Differential [Interpretation] in Cerebral spinal fluid;Cell Fract CSF-Imp;;ACTIVE;1.0m;2.73 +20999-9;Cell fractions;Imp;Pt;Body fld;Nom;;HEM/BC;1;Cell Fractions/Differential [Interpretation] in Body fluid;Cell Fract Fld-Imp;;ACTIVE;1.0m;2.73 +21000-5;Erythrocyte distribution width;EntVol;Pt;RBC;Qn;Automated count;HEM/BC;1;Erythrocyte distribution width [Entitic volume] by Automated count;RDW RBC Auto;;ACTIVE;1.0m;2.73 +21001-3;Coagulation factor VIII;Imp;Pt;XXX;Nom;;COAG;1;Coagulation factor VIII [Interpretation] in Specimen;Fact VIII Spec-Imp;;ACTIVE;1.0m;2.69 +21002-1;Fibrinogen;Imp;Pt;PPP;Nom;;COAG;1;Fibrinogen [Interpretation] in Platelet poor plasma;Fibrinogen PPP-Imp;;ACTIVE;1.0m;2.26 +21003-9;Fungus identified;Prid;Pt;XXX;Nom;Fungus stain;MICRO;1;Fungus identified in Specimen by Fungus stain;Fungus Spec Fungus Stn;;ACTIVE;1.0m;2.73 +21004-7;Glucose tolerance;Imp;Pt;Ser/Plas;Nom;;CHAL;1;Glucose tolerance [Interpretation] in Serum or Plasma;GTT SerPl-Imp;;ACTIVE;1.0m;2.73 +21005-4;Hepatitis B virus core Ab;ACnc;Pt;Ser^Donor;Qn;IA;MICRO;1;Hepatitis B virus core Ab [Units/volume] in Serum from Donor by Immunoassay;HBV core Ab Ser Donr IA-aCnc;;ACTIVE;1.0m;2.69 +2100-6;Cholylglycine;MCnc;Pt;Ser;Qn;;CHEM;1;Cholylglycine [Mass/volume] in Serum;Cholylglycine Ser-mCnc;;ACTIVE;1.0;2.73 +21006-2;Hepatitis B virus surface Ab;ACnc;Pt;Ser^Donor;Qn;IA;MICRO;1;Hepatitis B virus surface Ab [Units/volume] in Serum from Donor by Immunoassay;HBV surface Ab Ser Donr IA-aCnc;;ACTIVE;1.0m;2.73 +21007-0;HIV 1 Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;HIV 1 Ab [Presence] in Serum from Donor;HIV1 Ab Ser Donr Ql;;ACTIVE;1.0m;2.73 +21008-8;HIV 1 RNA;NCnc;Pt;Ser/Plas;Qn;Probe;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by Probe;HIV1 RNA # SerPl Probe;;ACTIVE;1.0m;2.73 +21009-6;HIV 1;Imp;Pt;Ser;Nom;IB;MICRO;1;Deprecated HIV 1 Ab band pattern [interpretation] in Serum by Immunoblot (IB);Deprecated HIV1 Ser IB-Imp;;DEPRECATED;1.0m;2.36 +21010-4;Cells.CD1;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD1 cells [#/volume] in Blood;CD1 Cells # Bld;;ACTIVE;1.0m;2.40 +21011-2;Cells.CD13;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD13 cells [#/volume] in Blood;CD13 Cells # Bld;;ACTIVE;1.0m;2.40 +21012-0;Cells.CD15;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD15 cells [#/volume] in Blood;CD15 Cells # Bld;;ACTIVE;1.0m;2.40 +21013-8;Cells.CD22;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD22 cells [#/volume] in Blood;CD22 Cells # Bld;;ACTIVE;1.0m;2.40 +2101-4;Cholylglycine.conjugated;MCnc;Pt;Ser;Qn;;CHEM;1;Cholylglycine.conjugated [Mass/volume] in Serum;Cholylglycine Conj Ser-mCnc;;ACTIVE;1.0;2.42 +21014-6;Cells.CD24;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD24 cells [#/volume] in Blood;CD24 Cells # Bld;;ACTIVE;1.0m;2.73 +21015-3;Cells.CD33;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD33 cells [#/volume] in Blood;CD33 Cells # Bld;;ACTIVE;1.0m;2.42 +21016-1;Cells.CD41;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD41 cells [#/volume] in Blood;CD41 Cells # Bld;;ACTIVE;1.0m;2.40 +21017-9;Cells.CD57;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD57 cells [#/volume] in Blood;CD57 Cells # Bld;;ACTIVE;1.0m;2.73 +21018-7;Cells.CD61;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD61 cells [#/volume] in Blood;CD61 Cells # Bld;;ACTIVE;1.0m;2.65 +21019-5;Metanephrine;MCnc;24H;Urine;Qn;;CHEM;1;Metanephrine [Mass/volume] in 24 hour Urine;Metaneph 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21020-3;Bacteria identified;Prid;Pt;XXX;Nom;Anaerobic+Aerobic culture;MICRO;1;Bacteria identified in Specimen by Anaerobe+Aerobe culture;Bacteria Spec Anaerobe+Aerobe Cult;;ACTIVE;1.0m;2.73 +21021-1;Microscopic observation;Prid;Pt;Bronchial;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Bronchial specimen by Gram stain;Gram Stn Bronch;;ACTIVE;1.0m;2.19 +2102-2;Chondroitin sulfate;MCnc;Pt;Urine;Qn;;CHEM;1;Chondroitin sulfate [Mass/volume] in Urine;Chondrotin Sulf Ur-mCnc;;ACTIVE;1.0;2.42 +21022-9;Microscopic observation;Prid;Pt;Dial fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Dialysis fluid by Gram stain;Gram Stn Dial fld;;ACTIVE;1.0m;2.21 +21023-7;Neutrophil cytoplasmic Ab;Titr;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic Ab [Titer] in Serum;ANCA Ab Titr Ser;;ACTIVE;1.0m;2.73 +21024-5;Pathologist interpretation;Imp;Pt;CSF;Nom;;PATH;1;Pathologist interpretation of Cerebral spinal fluid tests;Path Interp CSF-Imp;;ACTIVE;1.0m;2.73 +21025-2;Pathologist interpretation;Imp;Pt;Body fld;Nom;;PATH;1;Pathologist interpretation of Body fluid tests;Path Interp Fld-Imp;;ACTIVE;1.0m;2.73 +21026-0;Pathologist interpretation;Imp;Pt;Bld;Nom;;PATH;1;Pathologist interpretation of Blood tests;Path Interp Bld-Imp;;ACTIVE;1.0m;2.73 +21027-8;Platelet aggregation;Imp;Pt;PPP;Nom;;COAG;1;Platelet aggregation [Interpretation] in Platelet poor plasma;PA PPP-Imp;;ACTIVE;1.0m;2.73 +21028-6;Protein;Imp;24H;Urine;Nom;;CHEM;1;Protein [Interpretation] in 24 hour Urine;Prot 24h Ur-Imp;;ACTIVE;1.0m;2.73 +2103-0;Choriomammotropin;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Choriomammotropin [Mass/volume] in Amniotic fluid;Choriomammotropin Amn-mCnc;;ACTIVE;1.0;2.42 +21030-2;Reagin Ab;PrThr;Pt;Ser^Donor;Ord;VDRL;MICRO;1;Reagin Ab [Presence] in Serum from Donor by VDRL;VDRL Ser Donr Ql;;ACTIVE;1.0m;2.56 +21031-0;Saint Louis encephalitis virus;Imp;Pt;XXX;Nom;;MICRO;1;Saint Louis encephalitis virus [Interpretation] in Specimen;SLEV Spec-Imp;;ACTIVE;1.0m;2.73 +21032-8;Coagulation thrombin induced;Imp;Pt;Bld;Nom;;COAG;1;Thrombin time [Interpretation] in Blood;TT Bld-Imp;;ACTIVE;1.0m;2.73 +21033-6;Yeast.budding;PrThr;Pt;Urine sed;Ord;;UA;1;Yeast.budding [Presence] in Urine sediment;Yeast Budding UrnS Ql;;ACTIVE;1.0m;2.73 +21034-4;11-Deoxycortisol^evening specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --evening specimen;11DC evening SerPl-mCnc;;ACTIVE;1.0m;2.40 +21035-1;11-Deoxycortisol^morning specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --morning specimen;11DC AM SerPl-mCnc;;ACTIVE;1.0m;2.52 +21036-9;17-Hydroxycorticosteroids;MRat;24H;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids [Mass/time] in 24 hour Urine;17OHCS 24h Ur-mRate;;ACTIVE;1.0m;2.73 +21037-7;17-Hydroxypregnenolone;MRat;24H;Urine;Qn;;CHEM;1;17-Hydroxypregnenolone [Mass/time] in 24 hour Urine;17OH-Preg 24h Ur-mRate;;ACTIVE;1.0m;2.70 +21038-5;17-Ketosteroids;MCnc;24H;Urine;Qn;;CHEM;1;17-Ketosteroids [Mass/volume] in 24 hour Urine;17KS 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21039-3;18-Hydroxycortisol;MCnc;24H;Urine;Qn;;CHEM;1;18-Hydroxycortisol [Mass/volume] in 24 hour Urine;18OH-Cortis 24h Ur-mCnc;;ACTIVE;1.0m;2.70 +21040-1;Alpha ketoglutarate/Creatinine;MCrto;Pt;Urine;Qn;;CHEM;1;Deprecated Alpha ketoglutarate/Creatinine [Mass ratio] in Urine;Deprecated A-Ketoglut/creat Ur-mRto;;DEPRECATED;1.0m;2.70 +21041-9;3-Hydroxydodecanedioate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydodecanedioate (3-OH-D-C12)/Creatinine [Mass Ratio] in Urine;3OH-dodecanedioate/Creat Ur;;DISCOURAGED;1.0m;2.70 +21042-7;3-Hydroxydodecanoate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydodecanoate (3-OH-C12:0)/Creatinine [Mass Ratio] in Urine;3OH-dodecanoate/Creat Ur;;DISCOURAGED;1.0m;2.70 +21043-5;3-Methoxy-4-Hydroxyphenylglycol;MCnc;24H;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Mass/volume] in 24 hour Urine;3Me4OH-phenylglycol 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21044-3;5-Alpha tetrahydrocortisol;MRat;24H;Urine;Qn;;CHEM;1;5-Alpha tetrahydrocortisol [Mass/time] in 24 hour Urine;5-A THF 24h Ur-mRate;;ACTIVE;1.0m;2.70 +21045-0;5-Hydroxytryptophan;MRat;24H;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Mass/time] in 24 hour Urine;5OH-Tryptophan 24h Ur-mRate;;ACTIVE;1.0m;2.70 +21046-8;7-Aminoflunitrazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;7-Aminoflunitrazepam [Mass/volume] in Serum or Plasma;7Aminoflunitrazepam SerPl-mCnc;;ACTIVE;1.0m;2.73 +21047-6;8-Hydroxyloxapine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;8-Hydroxyloxapine [Mass/volume] in Urine;8OH-Loxapine Ur-mCnc;;ACTIVE;1.0m;2.73 +2104-8;Choriomammotropin;MCnc;Pt;Ser;Qn;;CHEM;1;Choriomammotropin [Mass/volume] in Serum;Choriomammotropin Ser-mCnc;;ACTIVE;1.0;2.73 +21048-4;Acetaldehyde;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetaldehyde [Mass/volume] in Urine;Acetaldehyde Ur-mCnc;;ACTIVE;1.0m;2.73 +21049-2;Acetone;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Acetone [Mass/mass] in Tissue;Acetone Tiss-mCnt;;ACTIVE;1.0m;2.70 +210-5;Cyclacillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cyclacillin [Susceptibility] by Disk diffusion (KB);Cyclacillin Islt KB;;ACTIVE;1.0;2.19 +21050-0;6-Monoacetylmorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Acetylmorphine [Mass/volume] in Urine;Deprecated 6MAM Ur-mCnc;;DEPRECATED;1.0m;2.70 +21051-8;Acrylaldehyde;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acrylaldehyde [Mass/volume] in Serum or Plasma;Acrylaldehyde SerPl-mCnc;;ACTIVE;1.0m;2.70 +21052-6;Adenosine monophosphate.cyclic.nephrogenous;SCnc;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Adenosine monophosphate.cyclic.nephrogenous [Moles/volume] in Urine and Serum or Plasma;cAMP Nephrogenous Ur+SerPl-sCnc;;ACTIVE;1.0m;2.73 +21053-4;Adenovirus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Adenovirus IgG Ab [Titer] in Serum;HAdV IgG Titr Ser;;ACTIVE;1.0m;2.73 +21054-2;Adenovirus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Adenovirus IgM Ab [Presence] in Serum;HAdV IgM Ser Ql;;ACTIVE;1.0m;2.56 +2105-5;Choriogonadotropin;SCnc;Pt;Semen;Qn;;CHEM;1;Choriogonadotropin [Moles/volume] in Semen;HCG Smn-sCnc;;ACTIVE;1.0;2.42 +21055-9;Adenovirus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Serum or Plasma by NAA with probe detection;HAdV DNA SerPl Ql NAA+probe;;ACTIVE;1.0m;2.73 +21056-7;Alanine+Cystine+Histidine+Homocysteine+Leucine+Phenylalanine+Tyrosine;PrThr;Pt;Urine;Ord;;CHEM;1;Alanine+Cystine+Histidine+Homocysteine+Leucine+Phenylalanine+Tyrosine [Presence] in Urine;Amino Acids mixA Ur Ql;;ACTIVE;1.0m;2.56 +21057-5;Alanine+Histidine+Leucine+Phenylalanine+Tyrosine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alanine+Histidine+Leucine+Phenylalanine+Tyrosine [Presence] in Serum or Plasma;Amino Acids mixB SerPl Ql;;ACTIVE;1.0m;2.56 +21058-3;Albumin^2H post peritoneal dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Albumin [Mass/volume] in Serum or Plasma --2 hours post peritoneal dialysis;Albumin 2h p PD SerPl-mCnc;;ACTIVE;1.0m;2.73 +21059-1;Albumin;MCnc;24H;Urine;Qn;;CHEM;1;Albumin [Mass/volume] in 24 hour Urine;Albumin 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21060-9;Alnus incana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Grey Alder IgE Ab RAST class [Presence] in Serum;Grey Alder IgE RAST Ql;;ACTIVE;1.0m;2.73 +21061-7;Medicago sativa Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alfalfa IgG Ab RAST class [Presence] in Serum;Alfalfa IgG RAST Ql;;ACTIVE;1.0m;2.58 +21062-5;Allobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Allobarbital [Mass/volume] in Serum or Plasma;Allobarbital SerPl-mCnc;;ACTIVE;1.0m;2.70 +2106-3;Choriogonadotropin (pregnancy test);PrThr;Pt;Urine;Ord;;CHEM;1;Choriogonadotropin (pregnancy test) [Presence] in Urine;HCG Preg Ur Ql;;ACTIVE;1.0;2.73 +21063-3;Prunus dulcis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Almond IgG Ab RAST class [Presence] in Serum;Almond IgG RAST Ql;;ACTIVE;1.0m;2.73 +21064-1;Acid alpha glucosidase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/volume] in Amniotic fluid;Acid A-Glucosidase Amn-cCnc;;ACTIVE;1.0m;2.42 +21065-8;Alternaria alternata Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alternaria alternata IgG Ab RAST class [Presence] in Serum;A alternata IgG RAST Ql;;ACTIVE;1.0m;2.73 +21066-6;Ampicillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ampicillin [Mass/volume] in Specimen;Ampicillin Spec-mCnc;;ACTIVE;1.0m;2.73 +21067-4;Monomorium minimum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Ant IgE Ab RAST class [Presence] in Serum;Black Ant IgE RAST Ql;;ACTIVE;1.0m;2.73 +21068-2;Pogonomyrmex barbatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Ant IgE Ab RAST class [Presence] in Serum;Red Ant IgE RAST Ql;;ACTIVE;1.0m;2.73 +21070-8;Antibiotic XXX;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Other Antibiotic [Susceptibility] by Minimum inhibitory concentration (MIC);Other Antibiotic Islt MIC;;ACTIVE;1.0m;2.73 +2107-1;Choriogonadotropin;SCnc;Pt;Urine;Qn;;CHEM;1;Choriogonadotropin [Moles/volume] in Urine;HCG Ur-sCnc;;ACTIVE;1.0;2.73 +21071-6;Antimony;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Antimony [Mass/volume] in 24 hour Urine;Antimony 24h Ur-mCnc;;ACTIVE;1.0m;2.42 +21072-4;Malus sylvestris Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Apple IgG Ab RAST class [Presence] in Serum;Apple IgG RAST Ql;;ACTIVE;1.0m;2.73 +21073-2;Prunus armeniaca Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Apricot IgG Ab RAST class [Presence] in Serum;Apricot IgG RAST Ql;;ACTIVE;1.0m;2.58 +21074-0;Arsenic;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in 24 hour Urine;Arsenic 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21075-7;Ascaris lumbricoides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ascaris lumbricoides IgE Ab [Units/volume] in Serum;A lumbric IgE Qn;;ACTIVE;1.0m;2.73 +21076-5;Ascaris lumbricoides Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ascaris lumbricoides IgE Ab RAST class [Presence] in Serum;A lumbric IgE RAST Ql;;ACTIVE;1.0m;2.58 +21077-3;Fraxinus nigra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Ash IgE Ab [Units/volume] in Serum;Black Ash IgE Qn;;ACTIVE;1.0m;2.42 +21078-1;Fraxinus pennsylvanica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Green Ash IgE Ab [Units/volume] in Serum;Green Ash IgE Qn;;ACTIVE;1.0m;2.73 +21079-9;Fraxinus pennsylvanica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Green Ash IgE Ab RAST class [Presence] in Serum;Green Ash IgE RAST Ql;;ACTIVE;1.0m;2.73 +21080-7;Asialoganglioside GM1 Ab;Titr;Pt;Ser;Qn;;SERO;1;Asialoganglioside GM1 Ab [Titer] in Serum;GM1 Asialo Ab Titr Ser;;ACTIVE;1.0m;2.73 +21081-5;ASPA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ASPA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ASPA gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21082-3;Asparagus officinalis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Asparagus IgG Ab RAST class [Presence] in Serum;Asparagus IgG RAST Ql;;ACTIVE;1.0m;2.58 +21083-1;Populus tremula Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Aspen IgE Ab RAST class in Serum;Deprecated Aspen IgE RAST Ql;;DEPRECATED;1.0m;2.36 +21084-9;Aspergillus flavus Ab;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Aspergillus flavus Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);A flavus Ab CSF Ql ID;;ACTIVE;1.0m;2.73 +21085-6;Aspergillus fumigatus Ab;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Aspergillus fumigatus Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);A fumigatus Ab CSF Ql ID;;ACTIVE;1.0m;2.73 +21086-4;Aspergillus niger Ab;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Aspergillus niger Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);A niger Ab CSF Ql ID;;ACTIVE;1.0m;2.73 +21087-2;Aspergillus terreus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus terreus IgE Ab RAST class [Presence] in Serum;A terreus IgE RAST Ql;;ACTIVE;1.0m;2.73 +21088-0;Azinphos-methyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Azinphos-methyl [Mass/volume] in Urine;Azinphos-Mehyl Ur-mCnc;;ACTIVE;1.0m;2.73 +2108-9;Choriogonadotropin.alpha subunit;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Choriogonadotropin.alpha subunit [Presence] in Serum or Plasma;A-HCG SerPl Ql;;ACTIVE;1.0;2.73 +21089-8;Babesia microti DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Babesia microti DNA [Presence] in Blood by NAA with probe detection;B microti DNA Bld Ql NAA+probe;;ACTIVE;1.0m;2.73 +21090-6;Musa spp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Banana IgG Ab RAST class [Presence] in Serum;Banana IgG RAST Ql;;ACTIVE;1.0m;2.73 +21091-4;Barbiturates present;Prid;Pt;Ser/Plas;Nom;Screen;DRUG/TOX;1;Barbiturates present [Identifier] in Serum or Plasma by Screen method;Barbiturates Present SerPl Scn;;ACTIVE;1.0m;2.73 +21092-2;Hordeum vulgare Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Barley IgG Ab RAST class [Presence] in Serum;Barley IgG RAST Ql;;ACTIVE;1.0m;2.73 +21093-0;Basement membrane Ab.IgG;Imp;Pt;Ser;Nom;IF;SERO;1;Basement membrane IgG Ab [Interpretation] in Serum by Immunofluorescence;BM IgG Ser IF-Imp;;ACTIVE;1.0m;2.26 +21094-8;Basophils/100 leukocytes;NFr;Pt;Sputum;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Sputum by Manual count;Basophils/leuk NFr Spt Manual;;ACTIVE;1.0m;2.73 +21095-5;BCL2 gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;BCL2 gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;BCL2 gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21096-3;Bean black Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Bean IgE Ab [Units/volume] in Serum;Black Bean IgE Qn;;ACTIVE;1.0m;2.73 +2109-7;Choriogonadotropin.alpha subunit;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.alpha subunit [Moles/volume] in Serum or Plasma;A-HCG SerPl-sCnc;;ACTIVE;1.0;2.40 +21097-1;Bean black Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Bean IgE Ab RAST class [Presence] in Serum;Black Bean IgE RAST Ql;;ACTIVE;1.0m;2.73 +21098-9;Bean green Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Green Bean IgG Ab RAST class [Presence] in Serum;Green Bean IgG RAST Ql;;ACTIVE;1.0m;2.58 +21099-7;Bean kidney red Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Kidney Bean IgG Ab RAST class [Presence] in Serum;Red Kidney Bean IgG RAST Ql;;ACTIVE;1.0m;2.58 +21100-3;Vigna radiata Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mung Bean IgG Ab RAST class [Presence] in Serum;Mung Bean IgG RAST Ql;;ACTIVE;1.0m;2.58 +21101-1;Bean pinto Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pinto Bean IgG Ab RAST class [Presence] in Serum;Pinto Bean IgG RAST Ql;;ACTIVE;1.0m;2.58 +21102-9;Glycine max Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Soybean IgG Ab RAST class [Presence] in Serum;Soybean IgG RAST Ql;;ACTIVE;1.0m;2.73 +21104-5;Glycine max dust Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Soybean dust IgE Ab RAST class [Presence] in Serum;Soybean dust IgE RAST Ql;;ACTIVE;1.0m;2.58 +2110-5;Choriogonadotropin.beta subunit (pregnancy test);PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Choriogonadotropin.beta subunit (pregnancy test) [Presence] in Serum or Plasma;B-HCG Preg SerPl Ql;;ACTIVE;1.0;2.73 +21105-2;Bean yellow Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yellow Bean IgG Ab RAST class [Presence] in Serum;Yellow Bean IgG RAST Ql;;ACTIVE;1.0m;2.58 +21106-0;Beef Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Beef IgG Ab RAST class [Presence] in Serum;Beef IgG RAST Ql;;ACTIVE;1.0m;2.73 +21107-8;Bendiocarb;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bendiocarb [Mass/volume] in Urine;Bendiocarb Ur-mCnc;;ACTIVE;1.0m;2.73 +21108-6;Beta 2 glycoprotein 1 Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Beta 2 glycoprotein 1 IgA Ab [Units/volume] in Serum;B2 Glycoprot1 IgA Ser-aCnc;;ACTIVE;1.0m;2.73 +21109-4;Beta lactoglobulin Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Beta lactoglobulin IgG Ab RAST class [Presence] in Serum;B-Lactoglob IgG RAST Ql;;ACTIVE;1.0m;2.58 +21110-2;Beta-N-acetylhexosaminidase.B/Beta-N-acetylhexosaminidase.total;CFr;Pt;Bld;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B/Beta-n-acetylhexosaminidase.total in Blood;Hexosaminidase B CFr Bld;;ACTIVE;1.0m;2.70 +21111-0;Beta-N-acetylhexosaminidase.B/Beta-N-acetylhexosaminidase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B/Beta-n-acetylhexosaminidase.total in Serum or Plasma;Hexosaminidase B CFr SerPl;;ACTIVE;1.0m;2.70 +21112-8;Birth date;TmStp;Pt;^Patient;Qn;;MISC;1;Birth date;Birth date;;ACTIVE;1.0m;2.73 +2111-3;Choriogonadotropin.beta subunit;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Moles/volume] in Serum or Plasma;B-HCG SerPl-sCnc;;ACTIVE;1.0;2.73 +21113-6;Bismuth;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Bismuth [Mass/volume] in 24 hour Urine;Bismuth 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21114-4;Blasts/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Blasts/100 leukocytes in Blood by Automated count;Deprecated Blasts Fr Bld Auto;;DEPRECATED;1.0m;2.70 +21115-1;Vaccinium myrtillus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blueberry IgG Ab RAST class [Presence] in Serum;Blueberry IgG RAST Ql;;ACTIVE;1.0m;2.58 +21116-9;Borrelia burgdorferi 66kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 66kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor66kD IgM Ser Ql IB;;ACTIVE;1.0m;2.73 +21117-7;Borrelia burgdorferi 93kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 93kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor93kD IgM Ser Ql IB;;ACTIVE;1.0m;2.73 +21118-5;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Synv fld;Ord;IA;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Synovial fluid by Immunoassay;B burgdor IgG Snv Ql IA;;ACTIVE;1.0m;2.56 +21119-3;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Synv fld;Ord;IA;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Synovial fluid by Immunoassay;B burgdor IgM Snv Ql IA;;ACTIVE;1.0m;2.56 +21120-1;Borrelia burgdorferi DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Urine by NAA with probe detection;B burgdor DNA Ur Ql NAA+probe;;ACTIVE;1.0m;2.73 +2112-1;Choriogonadotropin.beta subunit (pregnancy test);PrThr;Pt;Urine;Ord;;CHEM;1;Choriogonadotropin.beta subunit (pregnancy test) [Presence] in Urine;B-HCG Preg Ur Ql;;ACTIVE;1.0;2.73 +21121-9;Borrelia hermsii Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Borrelia hermsii IgG Ab [Titer] in Serum by Immunofluorescence;B hermsii IgG Titr Ser IF;;ACTIVE;1.0m;2.73 +21122-7;Borrelia hermsii Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Borrelia hermsii IgM Ab [Titer] in Serum by Immunofluorescence;B hermsii IgM Titr Ser IF;;ACTIVE;1.0m;2.73 +21123-5;Bran wheat Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat Bran IgE Ab RAST class [Presence] in Serum;Wheat Bran IgE RAST Ql;;ACTIVE;1.0m;2.73 +21124-3;Brassica oleracea var italica Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Broccoli IgG Ab RAST class [Presence] in Serum;Broccoli IgG RAST Ql;;ACTIVE;1.0m;2.73 +21125-0;Brush border Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Brush border Ab [Titer] in Serum by Immunofluorescence;Brush border Ab Titr Ser IF;;ACTIVE;1.0m;2.70 +21126-8;Brassica oleracea var gemmifera Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Brussel Sprouts IgG Ab RAST class [Presence] in Serum;Brussel Sprouts IgG RAST Ql;;ACTIVE;1.0m;2.58 +21127-6;Brassica oleracea var capitata Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cabbage IgG Ab RAST class [Presence] in Serum;Cabbage IgG RAST Ql;;ACTIVE;1.0m;2.58 +21128-4;Cadmium;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Cadmium [Mass/mass] in Nail;Cadmium Nail-mCnt;;ACTIVE;1.0m;2.73 +21129-2;Cadmium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Serum or Plasma;Cadmium SerPl-mCnc;;ACTIVE;1.0m;2.40 +211-3;Cyclacillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cyclacillin [Susceptibility] by Serum bactericidal titer;Cyclacillin Titr SBT;;ACTIVE;1.0;2.32 +21130-0;Cadmium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in 24 hour Urine;Cadmium 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21131-8;Calcitonin^10M post 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --10 minutes post 0.5 ug/kg pentagastrin IV;Calcit 10M p 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;1.0m;2.34 +21132-6;Calcitonin^1M post 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --1 minute post 0.5 ug/kg pentagastrin IV;Calcit 1M p 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;1.0m;2.34 +21133-4;Calcitonin^2M post 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --2 minutes post 0.5 ug/kg pentagastrin IV;Calcit 2M p 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;1.0m;2.34 +21134-2;Calcitonin^3M post 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --3 minutes post 0.5 ug/kg pentagastrin IV;Calcit 3M p 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;1.0m;2.34 +21135-9;Canrenone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Canrenone [Mass/volume] in Serum or Plasma;Canrenone SerPl-mCnc;;ACTIVE;1.0m;2.73 +21136-7;Cucumis melo spp Ab.IgG.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Melon IgG Ab RAST class in Serum;Deprecated Melon IgG RAST Ql;;DEPRECATED;1.0m;2.36 +21137-5;Carageenan Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Carageenan IgE Ab RAST class [Presence] in Serum;Carageenan IgE RAST Ql;;ACTIVE;1.0m;2.73 +21138-3;Carbaryl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carbaryl [Mass/volume] in Urine;Carbaryl Ur-mCnc;;ACTIVE;1.0m;2.73 +2113-9;Choriogonadotropin.beta subunit;MRat;24H;Urine;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Mass/time] in 24 hour Urine;B-HCG 24h Ur-mRate;;ACTIVE;1.0;2.42 +21139-1;Carbofuran;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carbofuran [Mass/volume] in Urine;Carbofuran Ur-mCnc;;ACTIVE;1.0m;2.73 +21140-9;Carbophenothion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carbophenothion [Mass/volume] in Urine;Carbophenothion Ur-mCnc;;ACTIVE;1.0m;2.73 +21141-7;Elettaria cardamomum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cardamon IgE Ab RAST class [Presence] in Serum;Cardamon IgE RAST Ql;;ACTIVE;1.0m;2.73 +21142-5;Carisoprodol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Carisoprodol [Presence] in Urine;Carisoprodol Ur Ql;;ACTIVE;1.0m;2.73 +21143-3;Carp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Carp IgE Ab [Units/volume] in Serum;Carp IgE Qn;;ACTIVE;1.0m;2.42 +21144-1;Carp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Carp IgE Ab RAST class [Presence] in Serum;Carp IgE RAST Ql;;ACTIVE;1.0m;2.58 +21145-8;Daucus carota Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Carrot IgG Ab RAST class [Presence] in Serum;Carrot IgG RAST Ql;;ACTIVE;1.0m;2.58 +21146-6;Casein Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Casein IgG Ab RAST class [Presence] in Serum;Casein IgG RAST Ql;;ACTIVE;1.0m;2.73 +2114-7;Choriogonadotropin.beta subunit;SCnc;Pt;Urine;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Moles/volume] in Urine;B-HCG Ur-sCnc;;ACTIVE;1.0;2.42 +21147-4;Brassica oleracea var botrytis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cauliflower IgG Ab RAST class [Presence] in Serum;Cauliflower IgG RAST Ql;;ACTIVE;1.0m;2.58 +21148-2;Cedar white Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Cedar IgE Ab [Units/volume] in Serum;White Cedar IgE Qn;;ACTIVE;1.0m;2.42 +21149-0;Cefaclor Ab.IgE;ACnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Cefaclor IgE Ab [Units/volume] in Serum;Deprecated Cefaclor IgE Ser-aCnc;;DEPRECATED;1.0m;2.69 +21150-8;Cefaclor Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cefaclor IgE Ab RAST class [Presence] in Serum;Cefaclor IgE RAST Ql;;ACTIVE;1.0m;2.58 +21151-6;cefTAZidime;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;cefTAZidime [Mass/volume] in Specimen;cefTAZidime Spec-mCnc;;ACTIVE;1.0m;2.70 +21152-4;Apium graveolens Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Celery IgG Ab RAST class [Presence] in Serum;Celery IgG RAST Ql;;ACTIVE;1.0m;2.58 +21153-2;Cells.CD10/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD10 cells/100 cells in Unspecified specimen;Deprecated CD10 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +2115-4;Choriogonadotropin.beta subunit.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Moles/volume] in Serum or Plasma;B-HCG Free SerPl-sCnc;;ACTIVE;1.0;2.73 +21154-0;Cells.CD11c/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11c cells/100 cells in Specimen;CD11c Cells NFr Spec;;ACTIVE;1.0m;2.73 +21155-7;Cells.CD13/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD13 cells/100 cells in Unspecified specimen;Deprecated CD13 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21156-5;Cells.CD14/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD14 cells/100 cells in Unspecified specimen;Deprecated CD14 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21157-3;Cells.CD19/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD19 cells/100 cells in Unspecified specimen;Deprecated CD19 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21158-1;Cells.CD20/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD20 cells/100 cells in Unspecified specimen;Deprecated CD20 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21159-9;Cells.CD23/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD23 cells/gated cells in Unspecified specimen;Deprecated CD23 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21160-7;Cells.CD3/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD3 cells/100 cells in Unspecified specimen;Deprecated CD3 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21161-5;Cells.CD33/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD33 cells/100 cells in Unspecified specimen;Deprecated CD33 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +2116-2;Choriogonadotropin.intact;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Choriogonadotropin.intact [Presence] in Serum or Plasma;HCG Intact SerPl Ql;;ACTIVE;1.0;2.73 +21162-3;Cells.CD34/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD34 cells/100 cells in Unspecified specimen;Deprecated CD34 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21163-1;Cells.CD38/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD38 cells/100 cells in Unspecified specimen;Deprecated CD38 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21164-9;Cells.CD4/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD4 cells/gated cells in Unspecified specimen;Deprecated CD4 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21165-6;Cells.CD5/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD5 cells/100 cells in Unspecified specimen;Deprecated CD5 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21166-4;Cells.CD56/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD56 cells/100 cells in Specimen;CD56 Cells NFr Spec;;ACTIVE;1.0m;2.73 +21167-2;Cells.CD61/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD61 cells/100 cells in Specimen;CD61 Cells NFr Spec;;ACTIVE;1.0m;2.73 +21168-0;Cells.CD7/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD7 cells/100 cells in Unspecified specimen;Deprecated CD7 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21169-8;Cells.CD71/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD71 cells/100 cells in Specimen;CD71 Cells NFr Spec;;ACTIVE;1.0m;2.73 +2117-0;Choriogonadotropin.intact;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.intact [Moles/volume] in Serum or Plasma;HCG Intact SerPl-sCnc;;ACTIVE;1.0;2.73 +21170-6;Cells.CD8/Gated cells.total;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD8 cells/gated cells in Unspecified specimen;Deprecated CD8 Cells Fr XXX;;DEPRECATED;1.0m;2.70 +21171-4;Cells.FMC7/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;FMC7 cells/100 cells in Specimen;FMC7 Cells NFr Spec;;ACTIVE;1.0m;2.73 +21172-2;Cells.XXX/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;XXX cells/100 cells in Specimen;Other cells NFr Spec;;ACTIVE;1.0m;2.73 +21173-0;Cephaeline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cephaeline [Mass/volume] in Serum or Plasma;Cephaeline SerPl-mCnc;;ACTIVE;1.0m;2.73 +21174-8;Cephaeline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cephaeline [Mass/volume] in Urine;Cephaeline Ur-mCnc;;ACTIVE;1.0m;2.73 +21175-5;Cephalexin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cephalexin [Mass/volume] in Specimen;Cephalexin Spec-mCnc;;ACTIVE;1.0m;2.69 +21176-3;Cerebroventricular lining cells;PrThr;Pt;CSF;Ord;Microscopy.light;CYTO;1;Cerebroventricular lining cells [Presence] in Cerebral spinal fluid by Light microscopy;Cerebrov Lin Cell CSF Ql Micro;;ACTIVE;1.0m;2.73 +21177-1;CFTR gene mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated CFTR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Deprecated CFTR gene Mut Anal Bld/T;;DEPRECATED;1.0m;2.36 +21178-9;Cheese cheddar type Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cheese cheddar type IgG Ab RAST class [Presence] in Serum;Cheddar IgG RAST Ql;;ACTIVE;1.0m;2.58 +21179-7;Cheese cream Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cream Cheese IgE Ab RAST class [Presence] in Serum;Cream Cheese IgE RAST Ql;;ACTIVE;1.0m;2.73 +21180-5;Cheese roquefort Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Roquefort Cheese IgE Ab RAST class [Presence] in Serum;Roquefort IgE RAST Ql;;ACTIVE;1.0m;2.73 +21181-3;Prunus avium Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cherry IgG Ab RAST class [Presence] in Serum;Cherry IgG RAST Ql;;ACTIVE;1.0m;2.58 +21182-1;Chicken Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken IgG Ab RAST class [Presence] in Serum;Chicken IgG RAST Ql;;ACTIVE;1.0m;2.58 +21183-9;Chicken meat Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken meat IgG Ab RAST class [Presence] in Serum;Chicken Meat IgG RAST Ql;;ACTIVE;1.0m;2.73 +21184-7;Chlamydophila pneumoniae;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Chlamydophila pneumoniae [Presence] in Specimen by Organism specific culture;C pneum Spec Ql Cult;;ACTIVE;1.0m;2.73 +21185-4;Chlamydia sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia sp IgG Ab [Presence] in Serum;Chlamydia IgG Ser Ql;;ACTIVE;1.0m;2.73 +21186-2;Chlamydia sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia sp IgM Ab [Presence] in Serum;Chlamydia IgM Ser Ql;;ACTIVE;1.0m;2.56 +21187-0;Chlamydia trachomatis DNA;PrThr;Pt;Cnjt;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Conjunctival specimen by NAA with probe detection;C trach DNA Conjunct Ql NAA+probe;;ACTIVE;1.0m;2.73 +2118-8;Choriogonadotropin (pregnancy test);PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma;HCG Preg SerPl Ql;;ACTIVE;1.0;2.73 +21188-8;Chlamydia trachomatis rRNA;PrThr;Pt;Cnjt;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Conjunctival specimen by Probe;C trach rRNA Conjunct Ql Probe;;ACTIVE;1.0m;2.73 +21189-6;Chlamydia trachomatis DNA;PrThr;Pt;Cvm;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Cervical mucus by NAA with probe detection;C trach DNA Cerv mucus Ql NAA+probe;;DISCOURAGED;1.0m;2.73 +21190-4;Chlamydia trachomatis DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Cervix by NAA with probe detection;C trach DNA Cvx Ql NAA+probe;;ACTIVE;1.0m;2.73 +21191-2;Chlamydia trachomatis DNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Urethra by NAA with probe detection;C trach DNA Urth Ql NAA+probe;;ACTIVE;1.0m;2.73 +21192-0;Chlamydia trachomatis rRNA;PrThr;Pt;Urethra;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Urethra by Probe;C trach rRNA Urth Ql Probe;;DISCOURAGED;1.0m;2.73 +21193-8;Chlordiazepoxide+Norchlordiazepoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlordiazePOXIDE+Norchlordiazepoxide [Mass/volume] in Serum or Plasma;Chlordiazep+Nor SerPl-mCnc;;ACTIVE;1.0m;2.73 +21194-6;Chloride;SCnc;24H;Urine;Qn;;CHEM;1;Chloride [Moles/volume] in 24 hour Urine;Chloride 24h Ur-sCnc;;ACTIVE;1.0m;2.73 +21195-3;Chlorzoxazone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorzoxazone [Mass/volume] in Urine;Chlorzoxazone Ur-mCnc;;ACTIVE;1.0m;2.42 +2119-6;Choriogonadotropin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin [Moles/volume] in Serum or Plasma;HCG SerPl-sCnc;;ACTIVE;1.0;2.73 +21196-1;Chocolate Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chocolate IgG Ab RAST class [Presence] in Serum;Chocolate IgG RAST Ql;;ACTIVE;1.0m;2.73 +21197-9;Cholesterol esters/Cholesterol.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol esters/Cholesterol.total in Serum or Plasma;Cholest Ester MFr SerPl;;ACTIVE;1.0m;2.73 +21198-7;Choriogonadotropin.beta subunit;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma;B-HCG SerPl-aCnc;;ACTIVE;1.0m;2.73 +21199-5;Chromium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Body fluid;Chromium Fld-mCnc;;ACTIVE;1.0m;2.73 +21200-1;Chromium;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Chromium [Mass/mass] in Nail;Chromium Nail-mCnt;;ACTIVE;1.0m;2.73 +21201-9;Chromium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in 24 hour Urine;Chromium 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21202-7;Cinnamomum spp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cinnamon IgG Ab RAST class [Presence] in Serum;Cinnamon IgG RAST Ql;;ACTIVE;1.0m;2.58 +21203-5;Citrate;MCnc;24H;Urine;Qn;;CHEM;1;Citrate [Mass/volume] in 24 hour Urine;Citrate 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +2120-4;Chylomicrons;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chylomicrons [Mass/volume] in Serum or Plasma;Chylo SerPl-mCnc;;ACTIVE;1.0;2.73 +21204-3;Ruditapes spp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Clam IgG Ab RAST class [Presence] in Serum;Clam IgG RAST Ql;;ACTIVE;1.0m;2.58 +21205-0;Syzygium aromaticum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Clove IgG Ab RAST class [Presence] in Serum;Clove IgG RAST Ql;;ACTIVE;1.0m;2.58 +21206-8;Clover sweet Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sweet Clover IgE Ab [Units/volume] in Serum;Sweet Clover IgE Qn;;ACTIVE;1.0m;2.42 +21207-6;CCR5 gene targeted mutation analysis;Prid;Pt;Bld;Nom;Molgen;MOLPATH.MUT;1;CCR5 gene mutations found [Identifier] in Blood by Molecular genetics method Nominal;CCR5 gene Mut Anl Bld;;ACTIVE;1.0m;2.63 +21208-4;Cobalt;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in 24 hour Urine;Cobalt 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21209-2;Coccidioides immitis Ab;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Coccidioides immitis Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);C immitis Ab CSF Ql ID;;ACTIVE;1.0m;2.73 +212-1;cycloSERINE;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;cycloSERINE [Susceptibility] by Minimum lethal concentration (MLC);cycloSERINE Islt MLC;;ACTIVE;1.0;2.19 +21210-0;Cockatiel droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cockatiel droppings IgE Ab RAST class [Presence] in Serum;Cockatiel Drop IgE RAST Ql;;ACTIVE;1.0m;2.73 +21211-8;Cockatiel feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cockatiel feather IgE Ab RAST class [Presence] in Serum;Cockatiel Feather IgE RAST Ql;;ACTIVE;1.0m;2.73 +2121-2;Chylomicrons;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Chylomicrons [Presence] in Serum or Plasma;Chylo SerPl Ql;;ACTIVE;1.0;2.73 +21212-6;Cocos nucifera Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Coconut IgG Ab RAST class [Presence] in Serum;Coconut IgG RAST Ql;;ACTIVE;1.0m;2.58 +21213-4;Gadus morhua Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Codfish IgG Ab RAST class [Presence] in Serum;Codfish IgG RAST Ql;;ACTIVE;1.0m;2.73 +21214-2;Coffea spp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Coffee IgG Ab RAST class [Presence] in Serum;Coffee IgG RAST Ql;;ACTIVE;1.0m;2.58 +21215-9;Collagen crosslinked N-telopeptide;SCnc;Pt;Ser;Qn;;CHEM;1;Collagen crosslinked N-telopeptide [Moles/volume] in Serum;Collagen NTx Ser-sCnc;;ACTIVE;1.0m;2.73 +21216-7;Collagen crosslinked N-telopeptide/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Collagen crosslinked N-telopeptide/Creatinine [Molar ratio] in 24 hour Urine;Collagen NTx/Creat 24h Ur-sRto;;ACTIVE;1.0m;2.73 +21217-5;Complement C4d;MCnc;Pt;Plas;Qn;;HEM/BC;1;Complement C4d [Mass/volume] in Plasma;C4d Plas-mCnc;;ACTIVE;1.0m;2.73 +21218-3;Complement total hemolytic CH50;ACnc;Pt;CSF;Qn;;HEM/BC;1;Complement total hemolytic CH50 [Units/volume] in Cerebral spinal fluid;CH50 CSF-aCnc;;ACTIVE;1.0m;2.70 +21219-1;Copper;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Copper [Mass/volume] in 24 hour Urine;Copper 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +2122-0;Chymopapain;MCnc;Pt;Ser;Qn;;CHEM;1;Chymopapain [Mass/volume] in Serum;Chymopapain Ser-mCnc;;ACTIVE;1.0;2.34 +21220-9;Coriandrum sativum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cilantro IgE Ab RAST class [Presence] in Serum;Cilantro IgE RAST Ql;;ACTIVE;1.0m;2.73 +21221-7;Zea mays Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Corn IgG Ab RAST class [Presence] in Serum;Corn IgG RAST Ql;;ACTIVE;1.0m;2.73 +21222-5;Cortisol^11 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --11 PM specimen;Cortis 11 PM SerPl-mCnc;;ACTIVE;1.0m;2.73 +21223-3;Cortisol^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Cortis sp1 p chal SerPl-mCnc;;ACTIVE;1.0m;2.73 +21224-1;Cortisol^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Cortis 2h p chal SerPl-mCnc;;ACTIVE;1.0m;2.58 +21225-8;Cortisol^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Cortis 3h p chal SerPl-mCnc;;ACTIVE;1.0m;2.58 +21226-6;Cortisol^4 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --4 PM specimen;Cortis 4 PM SerPl-mCnc;;ACTIVE;1.0m;2.73 +21227-4;Cotton linters Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cotton linters IgE Ab RAST class [Presence] in Serum;Cotton Linters IgE RAST Ql;;ACTIVE;1.0m;2.73 +21228-2;Cottonseed Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cottonseed IgG Ab RAST class [Presence] in Serum;Cottonseed IgG RAST Ql;;ACTIVE;1.0m;2.58 +21229-0;Coumaphos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Coumaphos [Mass/volume] in Urine;Coumaphos Ur-mCnc;;ACTIVE;1.0m;2.73 +21230-8;Cow milk Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cow milk IgG Ab RAST class [Presence] in Serum;Cow Milk IgG RAST Ql;;ACTIVE;1.0m;2.73 +21231-6;Cancer pagurus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Crab IgG Ab RAST class [Presence] in Serum;Crab IgG RAST Ql;;ACTIVE;1.0m;2.58 +21232-4;Creatinine;MCnc;Pt;BldA;Qn;;CHEM;1;Creatinine [Mass/volume] in Arterial blood;Creat BldA-mCnc;;ACTIVE;1.0m;2.73 +21233-2;Cryptosporidium sp Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Cryptosporidium sp Ag [Presence] in Stool;Cryptosp Ag Stl Ql;;ACTIVE;1.0m;2.73 +21234-0;Cucumis sativus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cucumber IgG Ab RAST class [Presence] in Serum;Cucumber IgG RAST Ql;;ACTIVE;1.0m;2.58 +21235-7;Cuminum cyminum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cumin IgE Ab RAST class [Presence] in Serum;Cumin IgE RAST Ql;;ACTIVE;1.0m;2.73 +21236-5;Cyclohexanone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cyclohexanone [Mass/volume] in Urine;Cyclohexanone Ur-mCnc;;ACTIVE;1.0m;2.73 +21237-3;Cytomegalovirus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Cytomegalovirus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CMV IgM Titr CSF IF;;ACTIVE;1.0m;2.73 +2123-8;Chymotrypsin;CCnc;Pt;Body fld;Qn;;CHEM;1;Chymotrypsin [Enzymatic activity/volume] in Body fluid;Chymotryp Fld-cCnc;;ACTIVE;1.0;2.68 +21238-1;Deer hair Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Deer hair IgE Ab RAST class [Presence] in Serum;Deer Hair IgE RAST Ql;;ACTIVE;1.0m;2.58 +21239-9;Desalkylhalazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desalkylhalazepam [Mass/volume] in Serum or Plasma;Desalkylhalazepam SerPl-mCnc;;ACTIVE;1.0m;2.70 +21240-7;Dextromethorphan;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dextromethorphan [Mass/volume] in Urine;D-methorphan Ur-mCnc;;ACTIVE;1.0m;2.73 +21241-5;Diazepam+Nordiazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;diazePAM+Nordiazepam [Mass/volume] in Urine;diazePAM+Nor Ur-mCnc;;ACTIVE;1.0m;2.42 +21242-3;Protoporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Protoporphyrin [Mass/time] in unspecified time Stool;Protopor ?Tm Stl-mRate;;ACTIVE;1.0m;2.70 +21243-1;Diethyl ether;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Diethyl ether [Mass/volume] in Urine;Diethyl Ether Ur-mCnc;;ACTIVE;1.0m;2.73 +21244-9;Diethylpropion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Diethylpropion [Mass/volume] in Serum or Plasma;Deprecated Diethylpropion SerPl-mCnc;;DEPRECATED;1.0m;2.36 +21245-6;Diisobutylketone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Diisobutylketone [Mass/volume] in Urine;Diisobutylketone Ur-mCnc;;ACTIVE;1.0m;2.73 +2124-6;Chymotrypsin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chymotrypsin [Mass/volume] in Serum or Plasma;Chymotryp SerPl-mCnc;;ACTIVE;1.0;2.42 +21246-4;Dimethoate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dimethoate [Mass/volume] in Urine;Dimethoate Ur-mCnc;;ACTIVE;1.0m;2.73 +21247-2;DMD gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DMD gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;DMD gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21248-0;DOBUTamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dobutamine [Mass/volume] in Serum or Plasma;DOBUTamine SerPl-mCnc;;ACTIVE;1.0m;2.42 +21249-8;Dolichol;MCnc;Pt;Urine;Qn;;CHEM;1;Dolichol [Mass/volume] in Urine;Dolichol Ur-mCnc;;ACTIVE;1.0m;2.42 +21250-6;Doxycycline;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Doxycycline [Mass/volume] in Specimen;Doxycycline Spec-mCnc;;ACTIVE;1.0m;2.73 +21251-4;Echinococcus granulosus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Echinococcus granulosus IgE Ab RAST class [Presence] in Serum;E granulosus IgE RAST Ql;;ACTIVE;1.0m;2.58 +21252-2;Echinococcus granulosus Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Echinococcus granulosus IgG Ab [Presence] in Serum by Immunoblot;E granulosus IgG Ser Ql IB;;ACTIVE;1.0m;2.73 +2125-3;Chymotrypsin;MCnt;Pt;Stool;Qn;;CHEM;1;Chymotrypsin [Mass/mass] in Stool;Chymotryp Stl-mCnt;;ACTIVE;1.0;2.73 +21253-0;Egg white Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Egg white IgG Ab RAST class [Presence] in Serum;Egg White IgG RAST Ql;;ACTIVE;1.0m;2.73 +21254-8;Egg yolk Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Egg yolk IgG Ab RAST class [Presence] in Serum;Egg Yolk IgG RAST Ql;;ACTIVE;1.0m;2.73 +21255-5;Solanum melongena Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Eggplant IgG Ab RAST class [Presence] in Serum;Eggplant IgG RAST Ql;;ACTIVE;1.0m;2.73 +21256-3;Iva xanthifolia Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Elder marsh IgE Ab RAST class in Serum;Deprecated Burweed marshelder IgE RAST Q;;DEPRECATED;1.0m;2.40 +21257-1;Iva xanthifolia Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Burweed marshelder IgE Ab RAST class in Serum;Deprecated Burweed marshelder IgE RAST Q;;DEPRECATED;1.0m;2.36 +21258-9;Cichorium endivia Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Endive IgG Ab RAST class [Presence] in Serum;Endive IgG RAST Ql;;ACTIVE;1.0m;2.58 +21259-7;Entamoeba histolytica Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Entamoeba histolytica Ab [Titer] in Serum by Hemagglutination;E histolyt Ab Titr Ser HA;;ACTIVE;1.0m;2.70 +21260-5;Epstein Barr virus nuclear Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus nuclear Ab [Titer] in Serum by Immunofluorescence;EBV NA Ab Titr Ser IF;;ACTIVE;1.0m;2.73 +2126-1;Citrate;MCnc;Pt;Semen;Qn;;CHEM;1;Citrate [Mass/volume] in Semen;Citrate Smn-mCnc;;ACTIVE;1.0;2.42 +21261-3;Erythromycin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Erythromycin IgE Ab RAST class [Presence] in Serum;Erythromycin IgE RAST Ql;;ACTIVE;1.0m;2.73 +21262-1;Escherichia coli shiga-like toxin;PrThr;Pt;Stool;Ord;IA;MICRO;1;Escherichia coli shiga-like toxin [Presence] in Stool by Immunoassay;E coli SXT Stl Ql IA;;ACTIVE;1.0m;2.73 +21263-9;Estradiol;MRat;24H;Urine;Qn;;CHEM;1;Estradiol (E2) [Mass/time] in 24 hour Urine;Estradiol 24h Ur-mRate;;ACTIVE;1.0m;2.42 +21264-7;Estriol.unconjugated^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3).unconjugated [Multiple of the median] adjusted in Serum or Plasma;u Estriol adj MoM SerPl;;ACTIVE;1.0m;2.73 +21265-4;Estriol.unconjugated^^unadjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3).unconjugated [Multiple of the median] unadjusted in Serum or Plasma;u Estriol unadj MoM SerPl;;DISCOURAGED;1.0m;2.73 +21266-2;Ethion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethion [Mass/volume] in Urine;Ethion Ur-mCnc;;ACTIVE;1.0m;2.73 +21267-0;O-Ethyl O-(p-nitrophenyl) phenylphosphonothionate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;O-Ethyl O-(p-nitrophenyl) phenylphosphonothionate [Mass/volume] in Urine;EPN Ur-mCnc;;ACTIVE;1.0m;2.73 +21268-8;Fenchlorphos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fenchlorphos [Mass/volume] in Urine;Fenchlorphos Ur-mCnc;;ACTIVE;1.0m;2.73 +21269-6;Fenthion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fenthion [Mass/volume] in Urine;Fenthion Ur-mCnc;;ACTIVE;1.0m;2.73 +21270-4;Ficus carica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fig IgE Ab RAST class [Presence] in Serum;Fig IgE RAST Ql;;ACTIVE;1.0m;2.73 +21271-2;Chamerion angustifolium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fireweed IgE Ab [Units/volume] in Serum;Fireweed IgE Qn;;ACTIVE;1.0m;2.42 +21272-0;Chamerion angustifolium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fireweed IgE Ab RAST class [Presence] in Serum;Fireweed IgE RAST Ql;;ACTIVE;1.0m;2.58 +21273-8;Linum usitatissimum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Flax IgE Ab RAST class [Presence] in Serum;Flax IgE RAST Ql;;ACTIVE;1.0m;2.73 +21274-6;Flounder Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Flounder IgG Ab RAST class [Presence] in Serum;Flounder IgG RAST Ql;;ACTIVE;1.0m;2.58 +21275-3;Follitropin^15M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --15 minutes post dose gonadotropin releasing hormone;FSH 15M p GnRH SerPl-aCnc;;ACTIVE;1.0m;2.70 +21276-1;Follitropin^1H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1 hour post XXX challenge;FSH 1h p chal SerPl-aCnc;;ACTIVE;1.0m;2.73 +21277-9;Follitropin^2H post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --2 hours post dose gonadotropin releasing hormone;FSH 2h p GnRH SerPl-aCnc;;ACTIVE;1.0m;2.70 +21278-7;Follitropin^45M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --45 minutes post dose gonadotropin releasing hormone;FSH 45M p GnRH SerPl-aCnc;;ACTIVE;1.0m;2.70 +2127-9;Citrate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Citrate [Mass/volume] in Serum or Plasma;Citrate SerPl-mCnc;;ACTIVE;1.0;2.73 +21279-5;Follitropin^1.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1.5 hours post XXX challenge;FSH 1.5h p chal SerPl-aCnc;;ACTIVE;1.0m;2.70 +21280-3;Fonofos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fonofos [Mass/volume] in Urine;Fonofos Ur-mCnc;;ACTIVE;1.0m;2.73 +21281-1;Fusarium oxysporum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fusarium oxysporum IgE Ab RAST class [Presence] in Serum;F oxysporum IgE RAST Ql;;ACTIVE;1.0m;2.73 +21282-9;Ganglioside GD1a Ab.IgM;Titr;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1a IgM Ab [Titer] in Serum by Immunoassay;GD1a Gangl IgM Titr Ser IA;;ACTIVE;1.0m;2.73 +21283-7;Ganglioside GD1a Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1a IgG Ab [Titer] in Serum by Immunoassay;GD1a Gangl IgG Titr Ser IA;;ACTIVE;1.0m;2.73 +21284-5;Gardnerella vaginalis;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Gardnerella vaginalis [Presence] in Genital specimen by Organism specific culture;G vaginalis Genital Ql Cult;;ACTIVE;1.0m;2.73 +21285-2;Allium sativum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Garlic IgG Ab RAST class [Presence] in Serum;Garlic IgG RAST Ql;;ACTIVE;1.0m;2.58 +21286-0;Gastrin^1.5H post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --1.5 hours post 0.2 U/kg secretin;Gastrin 1.5h p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +2128-7;Citrate;MCnc;Pt;Urine;Qn;;CHEM;1;Citrate [Mass/volume] in Urine;Citrate Ur-mCnc;;ACTIVE;1.0;2.73 +21287-8;Gastrin^1H post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --1 hour post 0.2 U/kg secretin;Gastrin 1h p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21288-6;Gastrin^2.5H post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --2.5 hours post 0.2 U/kg secretin;Gastrin 2.5h p 0.2 ug/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21289-4;Gastrin^2H post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --2 hours post 0.2 U/kg secretin;Gastrin 2h p 0.5 U/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21290-2;Gastrin^3.5H post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --3.5 hours post 0.2 U/kg secretin;Gastrin 3.5h p 0.2 U/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21291-0;Gastrin^3H post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --3 hours post 0.2 U/kg secretin;Gastrin 3h p 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21292-8;Gastrin^40M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --40 minutes post 0.2 U/kg secretin;Gastrin 40M p 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21293-6;Gastrin^45M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --45 minutes post 0.2 U/kg secretin;Gastrin 45M p 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21294-4;Gastrin^4H post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --4 hours post 0.2 U/kg secretin;Gastrin 4h p 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +2129-5;Citrulline;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Citrulline [Presence] in Serum or Plasma;Citrulline SerPl Ql;;ACTIVE;1.0;2.73 +21295-1;Gastrin^50M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --50 minutes post 0.2 U/kg secretin;Gastrin 50M p 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21296-9;Gastrin^7M post 0.2 U/kg secretin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --7 minutes post 0.2 U/kg secretin;Gastrin 7M p 0.2 u/kg SCT SerPl-mCnc;;ACTIVE;1.0m;2.34 +21297-7;Gelatin bovine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bovine Gelatin IgE Ab RAST class [Presence] in Serum;Bovine Gelatin IgE RAST Ql;;ACTIVE;1.0m;2.73 +21298-5;Gelatin porcine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Porcine Gelatin IgE Ab RAST class [Presence] in Serum;Porcine Gelatin IgE RAST Ql;;ACTIVE;1.0m;2.73 +21299-3;Gestational age method;Prid;Pt;^Fetus;Nom;*;OB.US;2;Gestational age method;GA method;;ACTIVE;1.0m;2.73 +21300-9;Giardia lamblia Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Giardia lamblia IgA Ab [Titer] in Serum by Immunofluorescence;G lamblia IgA Titr Ser IF;;ACTIVE;1.0m;2.73 +21301-7;Giardia lamblia Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Giardia lamblia IgM Ab [Titer] in Serum by Immunofluorescence;G lamblia IgM Titr Ser IF;;ACTIVE;1.0m;2.73 +21302-5;Giardia lamblia Ag^2nd specimen;PrThr;Pt;Stool;Ord;IA;MICRO;1;Giardia lamblia Ag [Presence] in Stool by Immunoassay --2nd specimen;G lamblia Ag sp2 Stl Ql IA;;ACTIVE;1.0m;2.73 +2130-3;Citrulline;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Citrulline [Mass/volume] in Serum or Plasma;Citrulline SerPl-mCnc;;DISCOURAGED;1.0;2.73 +21303-3;Giardia lamblia Ag^3rd specimen;PrThr;Pt;Stool;Ord;IA;MICRO;1;Giardia lamblia Ag [Presence] in Stool by Immunoassay --3rd specimen;G lamblia Ag sp3 Stl Ql IA;;ACTIVE;1.0m;2.73 +21304-1;Zingiber officinale Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ginger IgG Ab RAST class [Presence] in Serum;Ginger IgG RAST Ql;;ACTIVE;1.0m;2.58 +21305-8;Glucose;MCnc;24H;Urine;Qn;;CHEM;1;Glucose [Mass/volume] in 24 hour Urine;Glucose 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21306-6;Glucose;MRat;8H;Urine;Qn;;CHEM;1;Glucose [Mass/time] in 8 hour Urine;Glucose 8h Ur-mRate;;ACTIVE;1.0m;2.70 +21307-4;Glucose;MRat;10H;Urine;Qn;;CHEM;1;Glucose [Mass/time] in 10 hour Urine;Glucose 10h Ur-mRate;;ACTIVE;1.0m;2.70 +21308-2;Glucose^105M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --105 minutes post XXX challenge;Glucose 105M p chal SerPl-mCnc;;ACTIVE;1.0m;2.73 +21309-0;Glucose^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Glucose 45M p chal SerPl-mCnc;;ACTIVE;1.0m;2.70 +21310-8;Glucose^75M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --75 minutes post XXX challenge;Glucose 75M p chal SerPl-mCnc;;ACTIVE;1.0m;2.73 +2131-1;Citrulline;MCnc;Pt;Urine;Qn;;CHEM;1;Citrulline [Mass/volume] in Urine;Citrulline Ur-mCnc;;DISCOURAGED;1.0;2.73 +21311-6;Gluten Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gluten IgG Ab RAST class [Presence] in Serum;Gluten IgG RAST Ql;;ACTIVE;1.0m;2.73 +21312-4;Gold;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Gold [Mass/volume] in Body fluid;Gold Fld-mCnc;;ACTIVE;1.0m;2.42 +21313-2;Grain elevator dust Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Grain elevator dust IgE Ab RAST class [Presence] in Serum;Grain Elevat Dust IgE RAST Ql;;ACTIVE;1.0m;2.58 +21314-0;Vitis vinifera Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Grape IgG Ab RAST class [Presence] in Serum;Grape IgG RAST Ql;;ACTIVE;1.0m;2.58 +21315-7;Citrus paradisis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Grapefruit IgG Ab RAST class [Presence] in Serum;Grapefruit IgG RAST Ql;;ACTIVE;1.0m;2.73 +21316-5;Grepafloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Grepafloxacin [Susceptibility] by Gradient strip;Grepafloxacin Islt Grad strip;;ACTIVE;1.0m;2.56 +21317-3;Baccharis spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Groundsel Tree IgE Ab [Units/volume] in Serum;Deprecated Groundsel Tree IgE Qn;;DEPRECATED;1.0m;2.69 +21318-1;Baccharis spp Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Groundsel Tree IgE Ab RAST class in Serum;Deprecated Groundsel Tree IgE RAST Ql;;DEPRECATED;1.0m;2.36 +21319-9;Melanogrammus aeglefinus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Haddock IgG Ab RAST class [Presence] in Serum;Haddock IgG RAST Ql;;ACTIVE;1.0m;2.58 +21320-7;Haemophilus influenzae B Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Haemophilus influenzae B Ag [Presence] in Specimen by Latex agglutination;Haem influ B Ag Spec Ql LA;;ACTIVE;1.0m;2.73 +21321-5;Hippoglossus hippoglossus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Halibut IgG Ab RAST class [Presence] in Serum;Halibut IgG RAST Ql;;ACTIVE;1.0m;2.58 +21322-3;Hantavirus puumala Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Hantavirus puumala IgG Ab [Titer] in Serum by Immunofluorescence;PUUV IgG Titr Ser IF;;ACTIVE;1.0m;2.70 +21323-1;Hantavirus puumala Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Hantavirus puumala IgM Ab [Titer] in Serum by Immunofluorescence;PUUV IgM Titr Ser IF;;ACTIVE;1.0m;2.70 +21324-9;Helminthosporium sativum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Helminthosporium sativum IgE Ab RAST class [Presence] in Serum;H sativum IgE RAST Ql;;ACTIVE;1.0m;2.73 +21325-6;Helminthosporium sp Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Helminthosporium sp IgE Ab RAST class in Serum;Deprecated Helminthosporium IgE RAST Ql;;DEPRECATED;1.0m;2.36 +21326-4;Herpes simplex virus 1 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 IgM Ab [Titer] in Serum;HSV1 IgM Titr Ser;;ACTIVE;1.0m;2.73 +21327-2;Herpes simplex virus 2 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 IgM Ab [Titer] in Serum;HSV2 IgM Titr Ser;;ACTIVE;1.0m;2.73 +21328-0;Beta-N-acetylhexosaminidase A & B;Imp;Pt;Bld;Nom;;CHEM;1;Beta-N-acetylhexosaminidase A and B [Interpretation] in Blood;Hexosaminidase A & B Bld-Imp;;ACTIVE;1.0m;2.38 +2132-9;Cobalamins;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma;Vit B12 SerPl-mCnc;;ACTIVE;1.0;2.73 +21329-8;Carya ovata Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Shagbark Hickory IgE Ab RAST class [Presence] in Serum;Shagbark Hickory IgE RAST Ql;;ACTIVE;1.0m;2.73 +21330-6;Histoplasma capsulatum Ab;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);H capsul Ab CSF Ql ID;;ACTIVE;1.0m;2.73 +21331-4;HIV 1 p24 Ab;Titr;Pt;Ser;Qn;IB;MICRO;1;HIV 1 p24 Ab [Titer] in Serum by Immunoblot;HIV1 p24 Ab Titr Ser IB;;ACTIVE;1.0m;2.70 +21332-2;HIV 1 p41 Ab;Titr;Pt;Ser;Qn;IB;MICRO;1;HIV 1 p41 Ab [Titer] in Serum by Immunoblot;HIV1 p41 Ab Titr Ser IB;;ACTIVE;1.0m;2.70 +21333-0;HIV 1 RNA;NCnc;Pt;Ser;Qn;;MICRO;1;HIV 1 RNA [#/volume] in Serum;HIV1 RNA # Ser;;ACTIVE;1.0m;2.70 +21334-8;HIV 2 gp105 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp105 Ab [Presence] in Serum by Immunoblot;HIV2 gp105 Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +21335-5;HIV 2 gp120 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp120 Ab [Presence] in Serum by Immunoblot;HIV 2 gp120 Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +21336-3;HIV 2 gp15 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp15 Ab [Presence] in Serum by Immunoblot;HIV2 gp15 Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +2133-7;Collagenase;CCnc;Pt;Ser;Qn;;CHEM;1;Collagenase [Enzymatic activity/volume] in Serum;Collagenase Ser-cCnc;;ACTIVE;1.0;2.68 +21337-1;HIV 2 gp34 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp34 Ab [Presence] in Serum by Immunoblot;HIV2 gp34 Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +21338-9;HIV 2 p31 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p31 Ab [Presence] in Serum by Immunoblot;HIV2 p31 Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +21339-7;HIV 2 p55 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p55 Ab [Presence] in Serum by Immunoblot;HIV2 p55 Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +21340-5;HIV 2 p58 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p58 Ab [Presence] in Serum by Immunoblot;HIV2 p58 Ab Ser Ql IB;;ACTIVE;1.0m;2.58 +21341-3;HLA-DR locus;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DR locus [Type];HLA-DR locus;;ACTIVE;1.0m;2.50 +21342-1;HLA-DR locus 2;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DR locus 2 [Type];HLA-DR locus 2;;ACTIVE;1.0m;2.50 +21343-9;HLA-DR+DQ;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DR+DQ [Type];HLA-DR+DQ;;ACTIVE;1.0m;2.73 +21344-7;House dust Greer Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;House dust Greer IgG Ab RAST class [Presence] in Serum;House Dust Greer IgG RAST Ql;;ACTIVE;1.0m;2.58 +2134-5;Coproporphyrin;SCnc;Pt;RBC;Qn;;CHEM;1;Coproporphyrin [Moles/volume] in Red Blood Cells;Copro RBC-sCnc;;ACTIVE;1.0;2.73 +21345-4;HTLV I+II Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;HTLV I+II Ab [Presence] in Cerebral spinal fluid by Immunoblot;HTLV I+II Ab CSF Ql IB;;ACTIVE;1.0m;2.73 +21346-2;HTLV I+II Ab band pattern;Imp;Pt;CSF;Nom;IB;MICRO;1;HTLV I+II Ab band pattern [Interpretation] in Cerebral spinal fluid by Immunoblot;HTLV I+II Ab Patrn CSF IB-Imp;;ACTIVE;1.0m;2.73 +21347-0;HTLV I+II Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;HTLV I+II Ab band pattern [Interpretation] in Serum by Immunoblot;HTLV I+II Ab Patrn Ser IB-Imp;;ACTIVE;1.0m;2.73 +21348-8;HTLV I+II Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;HTLV I+II IgG Ab [Presence] in Serum by Immunoassay;HTLV I+II IgG Ser Ql IA;;ACTIVE;1.0m;2.73 +21349-6;IgA;PrThr;Pt;CSF;Ord;Immunofixation;CHEM;1;IgA [Presence] in Cerebral spinal fluid by Immunofixation;IgA CSF Ql IFE;;ACTIVE;1.0m;2.56 +21350-4;IgG;PrThr;Pt;CSF;Ord;Immunofixation;CHEM;1;IgG [Presence] in Cerebral spinal fluid by Immunofixation;IgG CSF Ql IFE;;ACTIVE;1.0m;2.56 +21351-2;IgM;PrThr;Pt;CSF;Ord;Immunofixation;CHEM;1;IgM [Presence] in Cerebral spinal fluid by Immunofixation;IgM CSF Ql IFE;;ACTIVE;1.0m;2.56 +2135-2;Coproporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Coproporphyrin [Mass/time] in 24 hour Stool;Copro 24h Stl-mRate;;ACTIVE;1.0;2.73 +21352-0;Intercellular substance Ab.IgG;Imp;Pt;Ser;Nom;IF;SERO;1;Intercellular substance IgG Ab [Interpretation] in Serum by Immunofluorescence;ICS IgG Ser IF-Imp;;ACTIVE;1.0m;2.73 +21353-8;Juniperus occidentalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Western Juniper IgE Ab RAST class [Presence] in Serum;West Juniper IgE RAST Ql;;ACTIVE;1.0m;2.73 +21354-6;Karaya gum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Karaya gum IgE Ab RAST class [Presence] in Serum;Karaya Gum IgE RAST Ql;;ACTIVE;1.0m;2.73 +21355-3;Ketones^2.5H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --2.5 hours post XXX challenge;Ketones 2.5h p chal Ur Ql;;ACTIVE;1.0m;2.56 +21356-1;Ketones^3.5H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --3.5 hours post XXX challenge;Ketones 3.5h p chal Ur Ql;;ACTIVE;1.0m;2.56 +21357-9;Ketones^1.5H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --1.5 hours post XXX challenge;Ketones 1.5h p chal Ur Ql;;ACTIVE;1.0m;2.56 +21358-7;Lactalbumin alpha Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactalbumin alpha IgG Ab RAST class [Presence] in Serum;A-Lactalb IgG RAST Ql;;ACTIVE;1.0m;2.58 +21359-5;Beta galactosidase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Beta galactosidase IgE Ab RAST class [Presence] in Serum;B-Galactosidase IgE RAST Ql;;ACTIVE;1.0m;2.73 +2136-0;Coproporphyrin;PrThr;Pt;Urine;Ord;;CHEM;1;Coproporphyrin [Presence] in Urine;Copro Ur Ql;;ACTIVE;1.0;2.73 +21360-3;Lamb Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lamb IgG Ab RAST class [Presence] in Serum;Lamb IgG RAST Ql;;ACTIVE;1.0m;2.73 +21361-1;Laxatives present;Prid;Pt;Stool;Nom;Screen;DRUG/TOX;1;Laxatives present [Identifier] in Stool by Screen method;Laxatives Present Stl Scn;;ACTIVE;1.0m;2.19 +21362-9;Legionella pneumophila Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo IgG Titr Ser IF;;ACTIVE;1.0m;2.73 +21363-7;Legionella pneumophila DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection;L pneumo DNA Spec Ql NAA+probe;;ACTIVE;1.0m;2.73 +21364-5;Citrus limon Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lemon IgG Ab RAST class [Presence] in Serum;Lemon IgG RAST Ql;;ACTIVE;1.0m;2.73 +21365-2;Leptin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Leptin [Mass/volume] in Serum or Plasma;Leptin SerPl-mCnc;;ACTIVE;1.0m;2.73 +21366-0;Lactuca sativa Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lettuce IgG Ab RAST class [Presence] in Serum;Lettuce IgG RAST Ql;;ACTIVE;1.0m;2.58 +21367-8;levoFLOXacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;levoFLOXacin [Susceptibility] by Disk diffusion (KB);levoFLOXacin Islt KB;;ACTIVE;1.0m;2.73 +21368-6;levoFLOXacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;levoFLOXacin [Mass/volume] in Serum or Plasma;levoFLOXacin SerPl-mCnc;;ACTIVE;1.0m;2.73 +21369-4;Glycyrrhiza lepidota Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Licorice IgE Ab RAST class [Presence] in Serum;Licorice IgE RAST Ql;;ACTIVE;1.0m;2.73 +21370-2;Citrus aurantifolia Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lime IgG Ab RAST class [Presence] in Serum;Lime IgG RAST Ql;;ACTIVE;1.0m;2.73 +21371-0;Homarus gammarus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lobster IgG Ab RAST class [Presence] in Serum;Lobster IgG RAST Ql;;ACTIVE;1.0m;2.73 +21372-8;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Cerebral spinal fluid by Manual count;Lymph Abn/leuk NFr CSF Manual;;ACTIVE;1.0m;2.73 +21373-6;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Synovial fluid by Manual count;Lymph Abn/leuk NFr Snv Manual;;ACTIVE;1.0m;2.70 +21374-4;Cells.CD8+CD38+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+CD38+ cells [#/volume] in Blood;CD8+CD38+ Cells # Bld;;ACTIVE;1.0m;2.73 +21375-1;Lymphocytes.kappa/Lymphocytes.lambda;NRto;Pt;Bld;Qn;;CELLMARK;1;Kappa lymphocytes/Lymphocytes.lambda [# Ratio] in Blood;Lymphs Kappa/Lambda Bld;;ACTIVE;1.0m;2.73 +21376-9;Macadamia spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Macadamia IgE Ab RAST class [Presence] in Serum;Macadamia IgE RAST Ql;;ACTIVE;1.0m;2.73 +21377-7;Magnesium;MCnc;Pt;Bld;Qn;;CHEM;1;Magnesium [Mass/volume] in Blood;Magnesium Bld-mCnc;;ACTIVE;1.0m;2.73 +2137-8;Coproporphyrin;MRat;24H;Urine;Qn;;CHEM;1;Coproporphyrin [Mass/time] in 24 hour Urine;Copro 24h Ur-mRate;;ACTIVE;1.0;2.73 +21378-5;Malathion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Malathion [Mass/volume] in Urine;Malathion Ur-mCnc;;ACTIVE;1.0m;2.73 +21379-3;Malt Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Malt IgG Ab RAST class [Presence] in Serum;Malt IgG RAST Ql;;ACTIVE;1.0m;2.73 +21380-1;Prolactin;MRat;24H;Urine;Qn;;CHEM;1;Prolactin [Mass/time] in 24 hour Urine;Prolactin 24h Ur-mRate;;ACTIVE;1.0m;2.70 +21381-9;Prolactin^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Prolactin 1.5h p chal SerPl-mCnc;;ACTIVE;1.0m;2.70 +21382-7;Manganese;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in 24 hour Urine;Manganese 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21383-5;Mercury;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in 24 hour Urine;Mercury 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21384-3;Mesothelial cells;PrThr;Pt;Periton fld;Ord;Microscopy.light;HEM/BC;1;Mesothelial cells [Presence] in Peritoneal fluid by Light microscopy;Mesothl Cell Prt Ql Micro;;ACTIVE;1.0m;2.56 +21385-0;Metasystox;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Metasystox [Mass/volume] in Urine;Metasystox Ur-mCnc;;ACTIVE;1.0m;2.73 +2138-6;Coproporphyrinogen oxidase;CCnc;Pt;Ser;Qn;;CHEM;1;Coproporphyrinogen oxidase [Enzymatic activity/volume] in Serum;COPROgen-oxidase Ser-cCnc;;ACTIVE;1.0;2.68 +21386-8;Methamphetamine;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Methamphetamine [Presence] in Urine by SAMHSA confirm method;Methamphet Ur Ql SAMHSA Cfm;;ACTIVE;1.0m;2.56 +21387-6;Methylhippurate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylhippurate [Mass/volume] in Urine;Methylhippurate Ur-mCnc;;ACTIVE;1.0m;2.73 +21388-4;Mevinphos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mevinphos [Mass/volume] in Urine;Mevinphos Ur-mCnc;;ACTIVE;1.0m;2.73 +21389-2;Saccharopolyspora rectivirgula Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saccharopolyspora rectivirgula IgE Ab [Units/volume] in Serum;S rectivirgula IgE Qn;;ACTIVE;1.0m;2.42 +213-9;cycloSERINE;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cycloSERINE [Susceptibility] by Minimum inhibitory concentration (MIC);cycloSERINE Islt MIC;;ACTIVE;1.0;2.19 +21390-0;Saccharopolyspora rectivirgula Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saccharopolyspora rectivirgula IgE Ab RAST class [Presence] in Serum;S rectivirgula IgE RAST Ql;;ACTIVE;1.0m;2.58 +21391-8;Microscopic observation;Prid;Pt;Bone;Nom;Acid phosphatase stain;PATH;1;Microscopic observation [Identifier] in Bone by Acid phosphatase stain;ACP Stn Bone;;ACTIVE;1.0m;2.07 +21392-6;Panicum milliaceum Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Common Millet IgE Ab RAST class in Serum;Deprecated Common Millet IgE RAST Ql;;DEPRECATED;1.0m;2.36 +21393-4;Monkey epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Monkey epithelium IgE Ab RAST class [Presence] in Serum;Monkey Epith IgE RAST Ql;;ACTIVE;1.0m;2.58 +2139-4;Corticosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Corticosterone [Mass/volume] in Serum or Plasma;Corticoster SerPl-mCnc;;ACTIVE;1.0;2.73 +21394-2;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Body fluid by Manual count;Monos+Macros/leuk NFr Fld Manual;;ACTIVE;1.0m;2.73 +21395-9;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Synovial fluid by Manual count;Monos+Macros/leuk NFr Snv Manual;;ACTIVE;1.0m;2.73 +21396-7;Mononuclear cells;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Mononuclear cells [#/volume] in Cerebral spinal fluid by Manual count;Mononuc Cells # CSF Manual;;ACTIVE;1.0m;2.70 +21397-5;Mononuclear cells;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Mononuclear cells [#/volume] in Body fluid by Manual count;Mononuc Cells # Fld Manual;;ACTIVE;1.0m;2.70 +21398-3;Mononuclear cells;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Mononuclear cells [#/volume] in Synovial fluid by Manual count;Mononuc Cells # Snv Manual;;ACTIVE;1.0m;2.73 +21399-1;Broussonetia papyrifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Paper Mulberry IgE Ab RAST class [Presence] in Serum;Paper Mulberry IgE RAST Ql;;ACTIVE;1.0m;2.73 +21400-7;Morus rubra Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red mulberry IgE Ab RAST class [Presence] in Serum;Red mulberry IgE RAST Ql;;ACTIVE;1.0m;2.58 +21401-5;Mumps virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Mumps virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;MuV IgG Titr CSF IF;;ACTIVE;1.0m;2.73 +2140-2;Corticotropin;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Corticotropin [Mass/volume] in Amniotic fluid;ACTH Amn-mCnc;;ACTIVE;1.0;2.42 +21402-3;Mumps virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Mumps virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;MuV IgM Titr CSF IF;;ACTIVE;1.0m;2.73 +21403-1;Agaricus hortensis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mushroom IgG Ab RAST class [Presence] in Serum;Mushroom IgG RAST Ql;;ACTIVE;1.0m;2.58 +21404-9;Mustard Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mustard IgG Ab RAST class [Presence] in Serum;Mustard IgG RAST Ql;;ACTIVE;1.0m;2.58 +21405-6;Mycobacterium sp DNA;PrThr;Pt;Bronchial;Ord;Probe.amp.tar;MICRO;1;Mycobacterium sp DNA [Presence] in Bronchial specimen by NAA with probe detection;Mycobacterium DNA Bronch Ql NAA+probe;;ACTIVE;1.0m;2.63 +21406-4;Mycoplasma pneumoniae Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma pneumoniae IgM Ab [Presence] in Serum;M pneumo IgM Ser Ql;;ACTIVE;1.0m;2.73 +21407-2;Myelin Ab.IgA;Titr;Pt;Ser;Qn;;SERO;1;Myelin IgA Ab [Titer] in Serum;Myelin IgA Titr Ser;;ACTIVE;1.0m;2.70 +21408-0;Myelin Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Myelin IgG Ab [Titer] in Serum;Myelin IgG Titr Ser;;ACTIVE;1.0m;2.73 +21409-8;Myelin Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Myelin IgM Ab [Titer] in Serum;Myelin IgM Titr Ser;;ACTIVE;1.0m;2.70 +2141-0;Corticotropin;MCnc;Pt;Plas;Qn;;CHEM;1;Corticotropin [Mass/volume] in Plasma;ACTH Plas-mCnc;;ACTIVE;1.0;2.73 +21410-6;Myelin associated glycoprotein Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein IgM Ab [Titer] in Serum;MAG IgM Titr Ser;;ACTIVE;1.0m;2.73 +21411-4;Myelin associated glycoprotein Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein IgM Ab [Units/volume] in Serum;MAG IgM Ser-aCnc;;ACTIVE;1.0m;2.69 +21412-2;Myocardium Ab pattern;Imp;Pt;Ser;Nom;;SERO;1;Myocardium Ab pattern [Interpretation] in Serum;Myocardium Ab pattern Ser-Imp;;ACTIVE;1.0m;2.26 +21413-0;N-Acetylgalactosamine-4-Sulfatase;CCnc;Pt;Urine;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/volume] in Urine;Arylsulfatase B Ur-cCnc;;ACTIVE;1.0m;2.70 +21414-8;Neisseria gonorrhoeae DNA;PrThr;Pt;Cvm;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Cervical mucus by NAA with probe detection;N gonorrhoea DNA Cerv mucus Ql NAA+probe;;DISCOURAGED;1.0m;2.73 +21415-5;Neisseria gonorrhoeae DNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Urethra by NAA with probe detection;N gonorrhoea DNA Urth Ql NAA+probe;;ACTIVE;1.0m;2.73 +21416-3;Neisseria gonorrhoeae DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection;N gonorrhoea DNA Ur Ql NAA+probe;;ACTIVE;1.0m;2.73 +21417-1;Neurokinin A;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Neurokinin A [Units/volume] in Serum or Plasma;Neurokinin A SerPl-aCnc;;ACTIVE;1.0m;2.73 +21418-9;Neutrophil Ab;PrThr;Pt;Ser;Ord;;SERO;1;Neutrophil Ab [Presence] in Serum;Neutrophil Ab Ser Ql;;ACTIVE;1.0m;2.73 +21419-7;Neutrophil cytoplasmic Ab pattern;Imp;Pt;Ser;Nom;IF;SERO;1;Neutrophil cytoplasmic Ab pattern [Interpretation] in Serum by Immunofluorescence;ANCA Ab pattern Ser IF-Imp;;ACTIVE;1.0m;2.73 +21420-5;Nitrate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nitrate [Mass/volume] in Urine;Nitrate Ur-mCnc;;ACTIVE;1.0m;2.73 +21421-3;Norketamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norketamine [Mass/volume] in Serum or Plasma;Norketamine SerPl-mCnc;;ACTIVE;1.0m;2.73 +21422-1;Normetanephrine;MCnc;24H;Urine;Qn;;CHEM;1;Normetanephrine [Mass/volume] in 24 hour Urine;Normetanephrine 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21423-9;Nuclear Ab;Titr;Pt;Ser;Qn;IF rat liver substrate;SERO;1;Nuclear Ab [Titer] in Serum by Immunofluorescence (IF) rat liver;ANA Titr Ser IF Rat Liv;;ACTIVE;1.0m;2.73 +21424-7;Nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Nuclear IgG Ab [Presence] in Serum by Immunofluorescence;Nuclear IgG Ser Ql IF;;ACTIVE;1.0m;2.73 +21425-4;Nutmeg Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Nutmeg IgG Ab RAST class [Presence] in Serum;Nutmeg IgG RAST Ql;;ACTIVE;1.0m;2.73 +21426-2;Avena sativa Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oat IgG Ab RAST class [Presence] in Serum;Oat IgG RAST Ql;;ACTIVE;1.0m;2.73 +21427-0;Avena sativa Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Oat IgE Ab RAST class in Serum;Deprecated Oat IgE RAST Ql;;DEPRECATED;1.0m;2.36 +2142-8;Cortisol;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid);Cortis Sal-mCnc;;ACTIVE;1.0;2.73 +21428-8;Olea europaea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive IgE Ab [Units/volume] in Serum;Olive IgE Qn;;ACTIVE;1.0m;2.73 +21429-6;Olea europaea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Olive IgE Ab RAST class [Presence] in Serum;Olive IgE RAST Ql;;ACTIVE;1.0m;2.73 +21430-4;Allium cepa Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Onion IgG Ab RAST class [Presence] in Serum;Onion IgG RAST Ql;;ACTIVE;1.0m;2.73 +21431-2;Opiates;PrThr;Pt;Urine;Ord;Screen>2000 ng/mL;DRUG/TOX;1;Opiates [Presence] in Urine by Screen method >2000 ng/mL;Opiates Ur Ql Scn>2000 ng/mL;;ACTIVE;1.0m;2.73 +21432-0;Citrus sinensis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Orange IgG Ab RAST class [Presence] in Serum;Orange IgG RAST Ql;;ACTIVE;1.0m;2.73 +21433-8;Citrus sinensis tree Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Orange Tree IgE Ab RAST class [Presence] in Serum;Orange Tree IgE RAST Ql;;ACTIVE;1.0m;2.73 +21434-6;Origanum vulgare Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oregano IgG Ab RAST class [Presence] in Serum;Oregano IgG RAST Ql;;ACTIVE;1.0m;2.58 +21435-3;Osteocalcin.bovine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Osteocalcin.bovine [Mass/volume] in Serum or Plasma;Osteocalcin Bovine SerPl-mCnc;;ACTIVE;1.0m;2.42 +2143-6;Cortisol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma;Cortis SerPl-mCnc;;ACTIVE;1.0;2.73 +21436-1;Ovary Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Ovary Ab [Presence] in Serum by Immunofluorescence;Ovary Ab Ser Ql IF;;ACTIVE;1.0m;2.73 +21437-9;Oxychlordane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxychlordane [Mass/volume] in Serum or Plasma;Oxychlordane SerPl-mCnc;;ACTIVE;1.0m;2.73 +21438-7;Ostrea edulis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oyster IgG Ab RAST class [Presence] in Serum;Oyster IgG RAST Ql;;ACTIVE;1.0m;2.58 +21439-5;Papain Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Papain IgE Ab RAST class [Presence] in Serum;Papain IgE RAST Ql;;ACTIVE;1.0m;2.58 +21440-3;Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA;PrThr;Pt;Cvx;Ord;Probe;MICRO;1;Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence] in Cervix by Probe;HPV I/H Risk DNA Cvx Ql Probe;;ACTIVE;1.0m;2.73 +21441-1;Human papilloma virus 6+11+42+43+44 DNA;PrThr;Pt;Cvx;Ord;Probe;MICRO;1;Human papilloma virus 6+11+42+43+44 DNA [Presence] in Cervix by Probe;HPV Low Risk DNA Cvx Ql Probe;;ACTIVE;1.0m;2.73 +21442-9;Parainfluenza virus identified;Prid;Pt;Nose;Nom;Organism specific culture;MICRO;1;Parainfluenza virus identified in Nose by Organism specific culture;HPIV Nose Cult;;ACTIVE;1.0m;2.21 +21443-7;Paraoxon;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Paraoxon [Mass/volume] in Urine;Paraoxon Ur-mCnc;;ACTIVE;1.0m;2.73 +2144-4;Cortisol;MCnc;Pt;Urine;Qn;;CHEM;1;Cortisol [Mass/volume] in Urine;Cortis Ur-mCnc;;ACTIVE;1.0;2.73 +21444-5;Petroselinum crispum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parsley IgG Ab RAST class [Presence] in Serum;Parsley IgG RAST Ql;;ACTIVE;1.0m;2.58 +21445-2;Pisum sativum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pea IgG Ab RAST class [Presence] in Serum;Pea IgG RAST Ql;;ACTIVE;1.0m;2.58 +21446-0;Prunus persica Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peach IgG Ab RAST class [Presence] in Serum;Peach IgG RAST Ql;;ACTIVE;1.0m;2.58 +21447-8;Arachis hypogaea Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut IgG Ab RAST class [Presence] in Serum;Peanut IgG RAST Ql;;ACTIVE;1.0m;2.73 +21448-6;Pyrus communis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pear IgG Ab RAST class [Presence] in Serum;Pear IgG RAST Ql;;ACTIVE;1.0m;2.58 +21449-4;Piper nigrum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Black Pepper IgG Ab RAST class [Presence] in Serum;Black Pepper IgG RAST Ql;;ACTIVE;1.0m;2.58 +21450-2;Pepper cayenne Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cayenne IgG Ab RAST class [Presence] in Serum;Cayenne IgG RAST Ql;;ACTIVE;1.0m;2.58 +2145-1;Cortisol.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol Free [Mass/volume] in Serum or Plasma;Cortis F SerPl-mCnc;;ACTIVE;1.0;2.73 +21451-0;Capsicum frutescens Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chili Pepper IgG Ab RAST class [Presence] in Serum;Chili Pepper IgG RAST Ql;;ACTIVE;1.0m;2.58 +21452-8;Pepper green Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Green Pepper IgG Ab RAST class [Presence] in Serum;Green Pepper IgG RAST Ql;;ACTIVE;1.0m;2.58 +21453-6;Pepper jalapeno Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Jalepeno Pepper IgE Ab RAST class [Presence] in Serum;Jalepeno Pepper IgE RAST Ql;;ACTIVE;1.0m;2.73 +21454-4;Pepper white Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Pepper IgG Ab RAST class [Presence] in Serum;White Pepper IgG RAST Ql;;ACTIVE;1.0m;2.73 +21455-1;Mentha piperita Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Mint IgE Ab RAST class in Serum;Deprecated Mint IgE RAST Ql;;DEPRECATED;1.0m;2.36 +21456-9;Pheasant Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pheasant IgE Ab RAST class [Presence] in Serum;Pheasant IgE RAST Ql;;ACTIVE;1.0m;2.58 +21457-7;Phorate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phorate [Mass/volume] in Urine;Phorate Ur-mCnc;;ACTIVE;1.0m;2.73 +21458-5;Phosphate;MCnc;24H;Urine;Qn;;CHEM;1;Phosphate [Mass/volume] in 24 hour Urine;Phosphate 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21459-3;Salicornia spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pickleweed IgE Ab RAST class [Presence] in Serum;Pickleweed IgE RAST Ql;;ACTIVE;1.0m;2.58 +21460-1;Stizostedion vitreum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Walleye Pike IgE Ab RAST class [Presence] in Serum;Walleye Pike IgE RAST Ql;;ACTIVE;1.0m;2.73 +21461-9;(Pinus contorta+Pinus ponderosa ) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lodgepole Pine+Pondersosa Pine IgE Ab [Units/volume] in Serum;Lodgepol+Pond Pine IgE Qn;;ACTIVE;1.0m;2.73 +21462-7;(Pinus contorta+Pinus ponderosa ) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lodgepole Pine+Pondersosa Pine IgE Ab RAST class [Presence] in Serum;Lodgepol+Pond Pine IgE RAST Ql;;ACTIVE;1.0m;2.73 +21463-5;Ananas comosus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pineapple IgG Ab RAST class [Presence] in Serum;Pineapple IgG RAST Ql;;ACTIVE;1.0m;2.58 +21464-3;Plasminogen activator urokinase type;PrThr;Pt;Tiss;Ord;;COAG;1;Plasminogen activator urokinase type [Presence] in Tissue;uPA Tiss Ql;;ACTIVE;1.0m;2.56 +21465-0;Plasmodium falciparum Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium falciparum Ab [Titer] in Serum by Immunofluorescence;P falciparum Ab Titr Ser IF;;ACTIVE;1.0m;2.73 +21466-8;Plasmodium malariae Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium malariae Ab [Titer] in Serum by Immunofluorescence;P malariae Ab Titr Ser IF;;ACTIVE;1.0m;2.73 +21467-6;Plasmodium ovale Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium ovale Ab [Titer] in Serum by Immunofluorescence;P ovale Ab Titr Ser IF;;ACTIVE;1.0m;2.73 +21468-4;Plasmodium vivax Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium vivax Ab [Titer] in Serum by Immunofluorescence;P vivax Ab Titr Ser IF;;ACTIVE;1.0m;2.73 +2146-9;Cortisol.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cortisol Free [Mass/volume] in Serum or Plasma;Deprecated Cortis F SerPl-mCnc;;DEPRECATED;1.0;2.36 +21469-2;Prunus domestica Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Plum IgG Ab RAST class [Presence] in Serum;Plum IgG RAST Ql;;ACTIVE;1.0m;2.58 +214-7;cycloSERINE;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cycloSERINE [Susceptibility] by Disk diffusion (KB);cycloSERINE Islt KB;;ACTIVE;1.0;2.19 +21470-0;Pollachius virens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pollock IgE Ab RAST class [Presence] in Serum;Pollock IgE RAST Ql;;ACTIVE;1.0m;2.73 +21471-8;Punica granatum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pomegranate IgE Ab [Units/volume] in Serum;Pomegranate IgE Qn;;ACTIVE;1.0m;2.73 +21472-6;Punica granatum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pomegranate IgE Ab RAST class [Presence] in Serum;Pomegranate IgE RAST Ql;;ACTIVE;1.0m;2.73 +21473-4;Populus alba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Poplar IgE Ab [Units/volume] in Serum;White Poplar IgE Qn;;ACTIVE;1.0m;2.73 +21474-2;Populus alba Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Poplar IgE Ab RAST class [Presence] in Serum;White Poplar IgE RAST Ql;;ACTIVE;1.0m;2.73 +21475-9;Pork Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pork IgG Ab RAST class [Presence] in Serum;Pork IgG RAST Ql;;ACTIVE;1.0m;2.73 +21476-7;Potassium;SCnc;24H;Urine;Qn;;CHEM;1;Potassium [Moles/volume] in 24 hour Urine;Potassium 24h Ur-sCnc;;ACTIVE;1.0m;2.73 +2147-7;Cortisol.free;MRat;24H;Urine;Qn;;CHEM;1;Cortisol Free [Mass/time] in 24 hour Urine;Cortis F 24h Ur-mRate;;ACTIVE;1.0;2.73 +21477-5;Solanum tuberosum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Potato IgE Ab [Units/volume] in Serum;Deprecated Potato IgE Qn;;DEPRECATED;1.0m;2.69 +21478-3;Solanum tuberosum Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Potato IgE Ab RAST class in Serum;Deprecated Potato IgE RAST Ql;;DEPRECATED;1.0m;2.36 +21479-1;Solanum tuberosum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Potato IgG Ab RAST class [Presence] in Serum;Potato IgG RAST Ql;;ACTIVE;1.0m;2.73 +21480-9;Propoxur;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propoxur [Mass/volume] in Urine;Propoxur Ur-mCnc;;ACTIVE;1.0m;2.73 +21481-7;Propranolol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Propranolol [Mass/volume] in Gastric fluid;Propranolol Gast-mCnc;;ACTIVE;1.0m;2.70 +21482-5;Protein;MCnc;24H;Urine;Qn;;CHEM;1;Protein [Mass/volume] in 24 hour Urine;Prot 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21483-3;quiNIDine^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNIDine [Mass/volume] in Serum or Plasma --peak;quiNIDine Peak SerPl-mCnc;;ACTIVE;1.0m;2.70 +21484-1;Race;Type;Pt;^Mother;Nom;;CLIN;2;Mother's race;Mother's race;;ACTIVE;1.0m;2.73 +2148-5;Creatine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatine [Mass/volume] in Serum or Plasma;Creatine SerPl-mCnc;;ACTIVE;1.0;2.73 +21485-8;Raphanus sativus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Radish IgG Ab RAST class [Presence] in Serum;Radish IgG RAST Ql;;ACTIVE;1.0m;2.58 +21486-6;Brassica napus pollen Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rape Pollen IgE Ab RAST class [Presence] in Serum;Rape Poln IgE RAST Ql;;ACTIVE;1.0m;2.73 +21487-4;Ribosomal P Ab;ACnc;Pt;CSF;Qn;;SERO;1;Ribosomal P Ab [Units/volume] in Cerebral spinal fluid;Ribosomal P Ab CSF-aCnc;;ACTIVE;1.0m;2.73 +21488-2;Oryza sativa Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rice IgG Ab RAST class [Presence] in Serum;Rice IgG RAST Ql;;ACTIVE;1.0m;2.73 +21489-0;Rickettsia (Proteus OX19) Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Rickettsia (Proteus OX19) Ab [Titer] in Serum by Latex agglutination;Proteus OX19 Ab Titr Ser LA;;ACTIVE;1.0m;2.70 +21490-8;Rickettsia (Proteus OX2) Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Rickettsia (Proteus OX2) Ab [Titer] in Serum by Latex agglutination;Proteus OX2 Ab Titr Ser LA;;ACTIVE;1.0m;2.70 +21491-6;Rickettsia (Proteus OXK) Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Rickettsia (Proteus OXK) Ab [Titer] in Serum by Latex agglutination;Proteus OXK Ab Titr Ser LA;;ACTIVE;1.0m;2.70 +21492-4;Rickettsia conorii Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia conorii IgG Ab [Titer] in Serum;R conorii IgG Titr Ser;;ACTIVE;1.0m;2.70 +2149-3;Creatine;MCnc;Pt;Urine;Qn;;CHEM;1;Creatine [Mass/volume] in Urine;Creatine Ur-mCnc;;ACTIVE;1.0;2.73 +21493-2;Rickettsia conorii Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia conorii IgM Ab [Titer] in Serum;R conorii IgM Titr Ser;;ACTIVE;1.0m;2.70 +21494-0;Rickettsia spotted fever group Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Rick SF IgG Titr CSF IF;;ACTIVE;1.0m;2.70 +21495-7;Rickettsia spotted fever group Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia spotted fever group IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Rick SF IgM Titr CSF IF;;ACTIVE;1.0m;2.70 +21496-5;Rickettsia typhus group Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia typhus group IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Rick Typhus IgG Titr CSF IF;;ACTIVE;1.0m;2.73 +21497-3;Rickettsia typhus group Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia typhus group IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Rick Typhus IgM Titr CSF IF;;ACTIVE;1.0m;2.73 +21498-1;Orientia tsutsugamushi Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi IgG Ab [Titer] in Serum;O tsut IgG Titr Ser;;ACTIVE;1.0m;2.70 +21499-9;Hoplostethus atlanticus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Orange roughy IgE Ab RAST class [Presence] in Serum;Orange roughy IgE RAST Ql;;ACTIVE;1.0m;2.73 +21500-4;Measles virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Measles virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;MeV IgG Titr CSF IF;;ACTIVE;1.0m;2.73 +2150-1;Creatine;MRat;24H;Urine;Qn;;CHEM;1;Creatine [Mass/time] in 24 hour Urine;Creatine 24h Ur-mRate;;ACTIVE;1.0;2.73 +21501-2;Measles virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Measles virus IgG Ab [Titer] in Serum by Immunofluorescence;MeV IgG Titr Ser IF;;ACTIVE;1.0m;2.73 +21502-0;Measles virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Measles virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;MeV IgM Titr CSF IF;;ACTIVE;1.0m;2.73 +21503-8;Measles virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Measles virus IgM Ab [Presence] in Serum;MeV IgM Ser Ql;;ACTIVE;1.0m;2.73 +21504-6;Secale cereale Ab.IgG.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Rye IgG Ab RAST class in Serum;Deprecated Rye IgG RAST Ql;;DEPRECATED;1.0m;2.36 +21505-3;Secale cereale Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rye IgG Ab RAST class [Presence] in Serum;Rye IgG RAST Ql;;ACTIVE;1.0m;2.73 +21506-1;Carthamus tinctorius Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Safflower IgG Ab RAST class [Presence] in Serum;Safflower IgG RAST Ql;;ACTIVE;1.0m;2.58 +21507-9;Salvia officinalis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sage IgG Ab RAST class [Presence] in Serum;Sage IgG RAST Ql;;ACTIVE;1.0m;2.58 +21508-7;Artemisia californica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;California Sagebrush IgE Ab RAST class [Presence] in Serum;Calif Sagbrsh IgE RAST Ql;;ACTIVE;1.0m;2.73 +21509-5;Saint Louis encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Saint Louis encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;SLEV IgG Titr CSF IF;;ACTIVE;1.0m;2.73 +21510-3;Saint Louis encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Saint Louis encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;SLEV IgM Titr CSF IF;;ACTIVE;1.0m;2.73 +21511-1;Salmonella paratyphi A H Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella paratyphi A H Ab [Titer] in Serum by Agglutination;S paraty A H Ab Titr Ser Aggl;;ACTIVE;1.0m;2.73 +21512-9;Salmonella paratyphi A H Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Salmonella paratyphi A H Ab [Titer] in Serum by Immunofluorescence;S paraty A H Ab Titr Ser IF;;ACTIVE;1.0m;2.70 +21513-7;Salmonella paratyphi B H Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella paratyphi B H Ab [Titer] in Serum by Agglutination;S paraty B H Ab Titr Ser Aggl;;ACTIVE;1.0m;2.73 +21514-5;Salmonella paratyphi B H Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Salmonella paratyphi B H Ab [Titer] in Serum by Immunofluorescence;S paraty B H Ab Titr Ser IF;;ACTIVE;1.0m;2.70 +21515-2;Saltbush annual Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Annual Saltbush IgE Ab RAST class [Presence] in Serum;Annual Saltbush IgE RAST Ql;;ACTIVE;1.0m;2.58 +21516-0;Pecten spp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Scallop IgG Ab RAST class [Presence] in Serum;Scallop IgG RAST Ql;;ACTIVE;1.0m;2.58 +21517-8;Schistosoma sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Schistosoma sp IgE Ab RAST class [Presence] in Serum;Schistosoma IgE RAST Ql;;ACTIVE;1.0m;2.58 +21518-6;SCL-70 extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;SCL-70 extractable nuclear IgG Ab [Presence] in Serum;ENA Scl70 IgG Ser Ql;;ACTIVE;1.0m;2.73 +2151-9;Creatine kinase;CCnc;Pt;CSF;Qn;;CHEM;1;Creatine kinase [Enzymatic activity/volume] in Cerebral spinal fluid;CK CSF-cCnc;;ACTIVE;1.0;2.73 +21519-4;Sesamum indicum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sesame Seed IgG Ab RAST class [Presence] in Serum;Sesame Seed IgG RAST Ql;;ACTIVE;1.0m;2.73 +21520-2;Shark Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Shark IgE Ab RAST class [Presence] in Serum;Shark IgE RAST Ql;;ACTIVE;1.0m;2.73 +21521-0;Pandalus borealis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Shrimp IgG Ab RAST class [Presence] in Serum;Shrimp IgG RAST Ql;;ACTIVE;1.0m;2.73 +21522-8;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear IgG Ab [Units/volume] in Serum;ENA SM+RNP IgG Ser-aCnc;;ACTIVE;1.0m;2.73 +21523-6;Smith extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Smith extractable nuclear IgG Ab [Presence] in Serum;ENA SM IgG Ser Ql;;ACTIVE;1.0m;2.73 +21524-4;Snapper red Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Snapper IgG Ab RAST class [Presence] in Serum;Red Snapper IgG RAST Ql;;ACTIVE;1.0m;2.58 +21525-1;Sodium;SCnc;24H;Urine;Qn;;CHEM;1;Sodium [Moles/volume] in 24 hour Urine;Sodium 24h Ur-sCnc;;ACTIVE;1.0m;2.73 +21526-9;Sodium;MCnc;24H;Urine;Qn;;CHEM;1;Sodium [Mass/volume] in 24 hour Urine;Sodium 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +2152-7;Creatine kinase.BB;CCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.BB [Enzymatic activity/volume] in Serum or Plasma by Electrophoresis;CK BB SerPl Elph-cCnc;;ACTIVE;1.0;2.73 +21527-7;Sodium;MRat;24H;Urine;Qn;;CHEM;1;Sodium [Mass/time] in 24 hour Urine;Sodium 24h Ur-mRate;;ACTIVE;1.0m;2.73 +21528-5;Solea solea Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sole IgG Ab RAST class [Presence] in Serum;Sole IgG RAST Ql;;ACTIVE;1.0m;2.58 +21529-3;Specimen volume;Vol;8H;Urine;Qn;;SPEC;1;Volume of 8 hour Urine;Specimen vol 8h Ur;;ACTIVE;1.0m;2.42 +21530-1;Specimen volume;Vol;10H;Urine;Qn;;SPEC;1;Volume of 10 hour Urine;Specimen vol 10h Ur;;ACTIVE;1.0m;2.42 +21531-9;Spermatozoa.motile/100 spermatozoa^1H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --1 hour post ejaculation;Sperm Motile 1h p ejac NFr Smn;;ACTIVE;1.0m;2.73 +21532-7;Spermatozoa.motile/100 spermatozoa^2H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --2 hours post ejaculation;Sperm Motile 2h p ejac NFr Smn;;ACTIVE;1.0m;2.73 +21533-5;Spermatozoa.motile/100 spermatozoa^3H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --3 hours post ejaculation;Sperm Motile 3h p ejac NFr Smn;;ACTIVE;1.0m;2.73 +21534-3;Spermatozoa.motile/100 spermatozoa^4H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --4 hours post ejaculation;Sperm Motile 4h p ejac NFr Smn;;ACTIVE;1.0m;2.73 +2153-5;Creatine kinase.macromolecular;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.macromolecular [Enzymatic activity/volume] in Serum or Plasma;CK Macro SerPl-cCnc;;ACTIVE;1.0;2.73 +21535-0;Spermatozoa.motile/100 spermatozoa^6H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --6 hours post ejaculation;Sperm Motile 6h p Ejac NFr Smn;;ACTIVE;1.0m;2.70 +21536-8;Acid sphingomyelinase;CCnc;Pt;Bld;Qn;;CHEM;1;Acid sphingomyelinase [Enzymatic activity/volume] in Blood;Acid sphingomyelinase Bld-cCnc;;ACTIVE;1.0m;2.42 +21537-6;Spinacia oleracea Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spinach IgG Ab RAST class [Presence] in Serum;Spinach IgG RAST Ql;;ACTIVE;1.0m;2.73 +21538-4;Picea pungens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blue Spruce IgE Ab RAST class [Presence] in Serum;Blue Spruce IgE RAST Ql;;ACTIVE;1.0m;2.58 +21539-2;Squash summer Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Summer Squash IgE Ab RAST class [Presence] in Serum;Summer Squash IgE RAST Ql;;ACTIVE;1.0m;2.73 +215-4;cycloSERINE;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;cycloSERINE [Susceptibility] by Serum bactericidal titer;cycloSERINE Titr SBT;;ACTIVE;1.0;2.32 +21540-0;Squash zucchini Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Zucchini IgE Ab RAST class [Presence] in Serum;Zucchini IgE RAST Ql;;ACTIVE;1.0m;2.73 +21541-8;Squash zucchini Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Zucchini IgG Ab RAST class [Presence] in Serum;Zucchini IgG RAST Ql;;ACTIVE;1.0m;2.58 +21542-6;Fragaria vesca Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Strawberry IgG Ab RAST class [Presence] in Serum;Strawberry IgG RAST Ql;;ACTIVE;1.0m;2.73 +2154-3;Creatine kinase.MB;CCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.MB [Enzymatic activity/volume] in Serum or Plasma by Electrophoresis;CK MB SerPl Elph-cCnc;;ACTIVE;1.0;2.73 +21543-4;Saccharum officinarum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sugar Cane IgG Ab RAST class [Presence] in Serum;Sugar Cane IgG RAST Ql;;ACTIVE;1.0m;2.58 +21544-2;Sulfamethoxazole Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sulfamethoxazole IgE Ab RAST class [Presence] in Serum;Sulfamethoxazole IgE RAST Ql;;ACTIVE;1.0m;2.73 +21545-9;Sulfatide Ab.IgG;Titr;Pt;CSF;Qn;;SERO;1;Sulfatide IgG Ab [Titer] in Cerebral spinal fluid;Sulfatide IgG Titr CSF;;ACTIVE;1.0m;2.70 +21546-7;Sulfatide Ab.IgM;Titr;Pt;CSF;Qn;;SERO;1;Sulfatide IgM Ab [Titer] in Cerebral spinal fluid;Sulfatide IgM Titr CSF;;ACTIVE;1.0m;2.70 +21547-5;Helianthus annuus seed Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sunflower Seed IgG Ab RAST class [Presence] in Serum;Sunflower Seed IgG RAST Ql;;ACTIVE;1.0m;2.73 +21548-3;Ipomoea batatas Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sweet potato IgG Ab RAST class [Presence] in Serum;Sweet potato IgG RAST Ql;;ACTIVE;1.0m;2.73 +21549-1;Liquidambar styraciflua Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Sweetgum IgE Ab RAST class in Serum;Deprecated Sweetgum IgE RAST Ql;;DEPRECATED;1.0m;2.36 +2155-0;Creatine kinase.MM;CCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.MM [Enzymatic activity/volume] in Serum or Plasma by Electrophoresis;CK MM SerPl Elph-cCnc;;ACTIVE;1.0;2.73 +21550-9;Synovial lining cells;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Synovial lining cells [Presence] in Synovial fluid by Light microscopy;Synoviocytes Snv Ql Micro;;ACTIVE;1.0m;2.73 +21551-7;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(15;17)(PML,RARA) Bld/T Ql";;ACTIVE;1.0m;2.73 +21552-5;Citrus reticulata Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mandarin IgG Ab RAST class [Presence] in Serum;Mandarin IgG RAST Ql;;ACTIVE;1.0m;2.58 +21553-3;Camellia sinensis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tea IgG Ab RAST class [Presence] in Serum;Tea IgG RAST Ql;;ACTIVE;1.0m;2.58 +21554-1;Terbufos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Terbufos [Mass/volume] in Urine;Terbufos Ur-mCnc;;ACTIVE;1.0m;2.73 +21555-8;Testosterone^^adjusted for sex hormone binding globulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone [Mass/volume] adjusted for sex hormone binding globulin in Serum or Plasma;Testost SHBG adj SerPl-mCnc;;ACTIVE;1.0m;2.73 +21556-6;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Screen>20 ng/mL;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by Screen method >20 ng/mL;THC Ur Ql Scn>20 ng/mL;;ACTIVE;1.0m;2.73 +21557-4;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Screen>100 ng/mL;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by Screen method >100 ng/mL;THC Ur Ql Scn>100 ng/mL;;ACTIVE;1.0m;2.73 +21558-2;Thallium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in 24 hour Urine;Thallium 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21559-0;Theophylline;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Gastric fluid;Theophylline Gast-mCnc;;ACTIVE;1.0m;2.70 +21560-8;Thermoactinomyces candidus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Thermoactinomyces candidus Ab [Presence] in Serum;T candidus Ab Ser Ql;;ACTIVE;1.0m;2.73 +21561-6;Laceyella sacchari Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Laceyella sacchari Ab [Presence] in Serum;Laceyella sacchari Ab Ser Ql;;ACTIVE;1.0m;2.74 +21562-4;Thiocyanate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Thiocyanate/Creatinine [Mass Ratio] in Urine;Thiocyanate/Creat Ur;;ACTIVE;1.0m;2.73 +21563-2;Thiopurine methyltransferase;CCnc;Pt;RBC;Qn;;CHEM;1;Thiopurine methyltransferase [Enzymatic activity/volume] in Red Blood Cells;TPMT RBC-cCnc;;ACTIVE;1.0m;2.73 +21564-0;Thiosulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thiosulfate [Mass/volume] in Serum or Plasma;Thiosulfate SerPl-mCnc;;ACTIVE;1.0m;2.73 +21565-7;tiaGABine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;tiaGABine [Mass/volume] in Serum or Plasma;tiaGABine SerPl-mCnc;;ACTIVE;1.0m;2.73 +21566-5;TOLAZamide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;TOLAZamide [Presence] in Serum or Plasma;TOLAZamide SerPl Ql;;ACTIVE;1.0m;2.73 +21567-3;TOLBUTamide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;TOLBUTamide [Presence] in Serum or Plasma;TOLBUTamide SerPl Ql;;ACTIVE;1.0m;2.73 +2156-8;Creatine kinase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Creatine kinase [Enzymatic activity/volume] in Amniotic fluid;CK Amn-cCnc;;ACTIVE;1.0;2.68 +21568-1;Lycopersicon lycopersicum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tomato IgG Ab RAST class [Presence] in Serum;Tomato IgG RAST Ql;;ACTIVE;1.0m;2.73 +21569-9;Toxoplasma gondii Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Toxoplasma gondii IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;T gondii IgG Titr CSF IF;;ACTIVE;1.0m;2.73 +21570-7;Toxoplasma gondii Ab.IgG;PrThr;Pt;Ser;Ord;Dye test;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Serum by Sabin dye test;T gondii IgG Ser Ql Dye Test;;ACTIVE;1.0m;2.73 +21571-5;Toxoplasma gondii Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Toxoplasma gondii IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;T gondii IgM Titr CSF IF;;ACTIVE;1.0m;2.73 +21572-3;Transferrin.carbohydrate deficient.asialo/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.asialo/Transferrin.total in Serum or Plasma;CDT Asialo/Tf MFr SerPl;;ACTIVE;1.0m;2.73 +21573-1;Transferrin.carbohydrate deficient.disialo/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma;CDT Disialo/Tf MFr SerPl;;ACTIVE;1.0m;2.70 +21574-9;Transferrin.carbohydrate deficient.monosialo/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.monosialo/Transferrin.total in Serum or Plasma;CDT Monosialo/Tf MFr SerPl;;ACTIVE;1.0m;2.73 +21575-6;Transferrin.carbohydrate deficient.pentasialo/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.pentasialo/Transferrin.total in Serum or Plasma;CDT Pentasialo/Tf MFr SerPl;;ACTIVE;1.0m;2.70 +2157-6;Creatine kinase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase [Enzymatic activity/volume] in Serum or Plasma;CK SerPl-cCnc;;ACTIVE;1.0;2.73 +21576-4;Transferrin.carbohydrate deficient.tetrasialo/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.tetrasialo/Transferrin.total in Serum or Plasma;CDT Tetrasialo/Tf MFr SerPl;;ACTIVE;1.0m;2.70 +21577-2;Transferrin.carbohydrate deficient.trisialo/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.trisialo/Transferrin.total in Serum or Plasma;CDT Trisialo/Tf MFr SerPl;;ACTIVE;1.0m;2.70 +21578-0;Ailanthus altissima Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tree of Heaven IgE Ab RAST class [Presence] in Serum;Tree of Heaven IgE RAST Ql;;ACTIVE;1.0m;2.73 +21579-8;Trichloroethylene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichloroethylene [Mass/volume] in Blood;TCY Bld-mCnc;;ACTIVE;1.0m;2.73 +21580-6;Trimethobenzamide;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Trimethobenzamide [Mass/volume] in Specimen;Trimethobenzamide Spec-mCnc;;ACTIVE;1.0m;2.70 +21581-4;Oncorhynchus mykiss Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trout IgG Ab RAST class [Presence] in Serum;Trout IgG RAST Ql;;ACTIVE;1.0m;2.58 +21582-2;Tryptase;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptase [Mass/volume] in Serum or Plasma;Tryptase SerPl-mCnc;;ACTIVE;1.0m;2.73 +21583-0;Turkey Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Turkey IgG Ab RAST class [Presence] in Serum;Turkey IgG RAST Ql;;ACTIVE;1.0m;2.73 +2158-4;Creatine kinase.total/Creatine kinase.MB;CRto;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.total/Creatine kinase.MB [Enzymatic activity ratio] in Serum or Plasma;CK/CK MB SerPl-cRto;;ACTIVE;1.0;2.73 +21584-8;Turkey feather Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Turkey feather IgE Ab RAST class [Presence] in Serum;Turkey Feather IgE RAST Ql;;ACTIVE;1.0m;2.73 +21585-5;Uranium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Uranium [Mass/volume] in 24 hour Urine;Uranium 24h Ur-mCnc;;ACTIVE;1.0m;2.70 +21586-3;Uranium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Uranium [Mass/time] in 24 hour Urine;Uranium 24h Ur-mRate;;ACTIVE;1.0m;2.70 +21587-1;Urate;MCnc;24H;Urine;Qn;;CHEM;1;Urate [Mass/volume] in 24 hour Urine;Urate 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21588-9;Urobilinogen;MCnt;Pt;Stool;Qn;;CHEM;1;Urobilinogen [Mass/mass] in Stool;Urobilinogen Stl-mCnt;;ACTIVE;1.0m;2.70 +21589-7;Ustilago nuda+Ustilago tritici Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Barley smut+Wheat smut IgE Ab RAST class [Presence] in Serum;Barley+Wheat smut IgE RAST Ql;;ACTIVE;1.0m;2.73 +21590-5;Valproate.bound/Valproate.total;MFr;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate.bound/Valproate.total in Serum or Plasma;Valproate Bnd MFr SerPl;;ACTIVE;1.0m;2.73 +21591-3;Vanilla planifolia Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Vanilla IgG Ab RAST class [Presence] in Serum;Vanilla IgG RAST Ql;;ACTIVE;1.0m;2.58 +2159-2;Creatinine;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Amniotic fluid;Creat Amn-mCnc;;ACTIVE;1.0;2.73 +21592-1;Varicella zoster virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Varicella zoster virus Ab [Titer] in Cerebral spinal fluid;VZV Ab Titr CSF;;ACTIVE;1.0m;2.73 +21594-7;Varicella zoster virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus Ab [Titer] in Serum;VZV Ab Titr Ser;;ACTIVE;1.0m;2.73 +21595-4;Varicella zoster virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Varicella zoster virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;VZV IgG Titr CSF IF;;ACTIVE;1.0m;2.70 +21596-2;Varicella zoster virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Varicella zoster virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;VZV IgM Titr CSF IF;;ACTIVE;1.0m;2.73 +21597-0;Varicella zoster virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Varicella zoster virus IgM Ab [Presence] in Serum;VZV IgM Ser Ql;;ACTIVE;1.0m;2.73 +21598-8;Varicella zoster virus DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;VZV DNA CSF Ql NAA+probe;;ACTIVE;1.0m;2.73 +21599-6;Venison Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Venison IgE Ab RAST class [Presence] in Serum;Venison IgE RAST Ql;;ACTIVE;1.0m;2.73 +21-6;Amoxicillin+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility] by Disk diffusion (KB);Amoxicillin+Clav Islt KB;;ACTIVE;1.0;2.73 +2160-0;Creatinine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass/volume] in Serum or Plasma;Creat SerPl-mCnc;;ACTIVE;1.0;2.73 +21600-2;Juglans regia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;English Walnut IgE Ab RAST class [Presence] in Serum;English Walnut IgE RAST Ql;;ACTIVE;1.0m;2.73 +21601-0;Citrullus lanatus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Watermelon IgG Ab RAST class [Presence] in Serum;Watermelon IgG RAST Ql;;ACTIVE;1.0m;2.58 +21602-8;Triticum aestivum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat IgG Ab RAST class [Presence] in Serum;Wheat IgG RAST Ql;;ACTIVE;1.0m;2.73 +21603-6;Wheat dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat dust IgE Ab [Units/volume] in Serum;Wheat Dust IgE Qn;;ACTIVE;1.0m;2.73 +21604-4;Wheat dust Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat dust IgE Ab RAST class [Presence] in Serum;Wheat Dust IgE RAST Ql;;ACTIVE;1.0m;2.58 +21605-1;Whitefish Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Whitefish IgG Ab RAST class [Presence] in Serum;Whitefish IgG RAST Ql;;ACTIVE;1.0m;2.58 +21606-9;Xylose^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Xylose sp2 p chal SerPl-mCnc;;ACTIVE;1.0m;2.70 +21607-7;Saccharomyces cerevisiae Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Baker's yeast IgG Ab RAST class [Presence] in Serum;Baker's yeast IgG RAST Ql;;ACTIVE;1.0m;2.73 +21608-5;Yeast brewer's Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Brewer's yeast IgG Ab RAST class [Presence] in Serum;Brewer's yeast IgG RAST Ql;;ACTIVE;1.0m;2.58 +21609-3;Yogurt Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yogurt IgE Ab RAST class [Presence] in Serum;Yogurt IgE RAST Ql;;ACTIVE;1.0m;2.73 +21610-1;Zinc;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in 24 hour Urine;Zinc 24h Ur-mCnc;;ACTIVE;1.0m;2.73 +21611-9;Age;Time;Pt;^Patient;Qn;Estimated;MISC;1;Age estimated;Age Time Patient Est;;ACTIVE;1.0m;2.71 +21612-7;Age;Time;Pt;^Patient;Qn;Reported;MISC;1;Age - Reported;Age - Reported;;ACTIVE;1.0m;2.73 +21613-5;Chlamydia trachomatis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection;C trach DNA Spec Ql NAA+probe;;ACTIVE;1.0m;2.73 +21614-3;CDKN2A gene deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;CDKN2A gene deletion [Presence] in Blood or Tissue by Molecular genetics method;CDKN2A Del Bld/T Ql;;ACTIVE;1.0m;2.73 +21615-0;CDKN2B gene deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;CDKN2B gene deletion [Presence] in Blood or Tissue by Molecular genetics method;CDKN2B gene Del Bld/T Ql;;ACTIVE;1.0m;2.13 +21616-8;APC gene mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated APC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Deprecated APC gene Mut Anal Bld/T;;DEPRECATED;1.0m;2.36 +21617-6;APC gene.p.Ile1307Lys;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;APC gene p.Ile1307Lys [Presence] in Blood or Tissue by Molecular genetics method;APC p.I1307K Bld/T Ql;;ACTIVE;1.0m;2.56 +2161-8;Creatinine;MCnc;Pt;Urine;Qn;;CHEM;1;Creatinine [Mass/volume] in Urine;Creat Ur-mCnc;;ACTIVE;1.0;2.73 +21618-4;APC gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APC gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;APC gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21619-2;APOE gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APOE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;APOE gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +216-2;Demeclocycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Demeclocycline [Susceptibility] by Minimum lethal concentration (MLC);Demeclocycline Islt MLC;;ACTIVE;1.0;2.19 +21620-0;STS gene deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;STS gene deletion [Presence] in Blood or Tissue by Molecular genetics method;STS gene Del Bld/T Ql;;ACTIVE;1.0m;2.13 +21622-6;ASPA gene.p.Glu285Ala;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ASPA gene p.Glu285Ala [Presence] in Blood or Tissue by Molecular genetics method;ASPA p.E285A Bld/T Ql;;ACTIVE;1.0m;2.56 +21623-4;ASPA gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ASPA gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;ASPA gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21624-2;ATM gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ATM gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ATM gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21625-9;ATM gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ATM gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;ATM gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +2162-6;Creatinine;MRat;24H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 24 hour Urine;Creat 24h Ur-mRate;;ACTIVE;1.0;2.73 +21626-7;ATP7B gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ATP7B gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ATP7B gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21627-5;ATP7B gene.c.2010_2016del;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene c.2010_2016del [Presence] in Blood or Tissue by Molecular genetics method;ATP7B c.2010_2016del Bld/T Ql;;ACTIVE;1.0m;2.56 +21628-3;ATP7B gene.c.2337delC;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene c.2337delC [Presence] in Blood or Tissue by Molecular genetics method;ATP7B c.2337delC Bld/T Ql;;ACTIVE;1.0m;2.56 +21629-1;ATP7B gene.c.2487insT;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene c.2487insT [Presence] in Blood or Tissue by Molecular genetics method;ATP7B c.2487insT Bld/T Ql;;ACTIVE;1.0m;2.56 +21630-9;ATP7B gene.c.1711G>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene c.1711G>C [Presence] in Blood or Tissue by Molecular genetics method;ATP7B c.1711G>C Bld/T Ql;;ACTIVE;1.0m;2.56 +21631-7;ATP7B gene.p.Gly1267Arg;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene p.Gly1267Arg [Presence] in Blood or Tissue by Molecular genetics method;ATP7B p.G1267R Bld/T Ql;;ACTIVE;1.0m;2.56 +21632-5;ATP7B gene.p.His1070Gln;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene p.His1070Gln [Presence] in Blood or Tissue by Molecular genetics method;ATP7B p.H1070Q Bld/T Ql;;ACTIVE;1.0m;2.56 +21633-3;ATP7B gene.p.His714Gln;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene p.His714Gln [Presence] in Blood or Tissue by Molecular genetics method;ATP7B p.H714Q Bld/T Ql;;ACTIVE;1.0m;2.56 +2163-4;Creatinine renal clearance;VRat;12H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance in 12 hour Urine and Serum or Plasma;Creat Cl 12h Ur+SerPl-vRate;;ACTIVE;1.0;2.73 +21634-1;ATP7B gene.p.Asn915Ser;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene p.Asn915Ser [Presence] in Blood or Tissue by Molecular genetics method;ATP7B p.N915S Bld/T Ql;;ACTIVE;1.0m;2.56 +21635-8;ATP7B gene.p.Arg778Leu;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ATP7B gene p.Arg778Leu [Presence] in Blood or Tissue by Molecular genetics method;ATP7B p.R778L Bld/T Ql;;ACTIVE;1.0m;2.56 +21636-6;BRCA1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BRCA1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BRCA1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21637-4;BRCA1 gene.c.185delAG;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;BRCA1 gene.c.185 del AG [presence] in Blood or Tissue by Molecular genetics method;BRCA1 c.185delAG Bld/T Ql;;ACTIVE;1.0m;2.56 +21638-2;BRCA1 gene.c.5382insC;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;BRCA1 gene c.5382insC [Presence] in Blood or Tissue by Molecular genetics method;BRCA1 c.5382insC Bld/T Ql;;ACTIVE;1.0m;2.56 +21639-0;BRCA1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BRCA1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;BRCA1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21640-8;BRCA2 gene.c.6174delT;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;BRCA2 gene c.6174delT [Presence] in Blood or Tissue by Molecular genetics method;BRCA2 c.6174delT Bld/T Ql;;ACTIVE;1.0m;2.56 +21641-6;CACNA1S gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CACNA1S gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CACNA1S gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +2164-2;Creatinine renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance in 24 hour Urine and Serum or Plasma;Creat Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.73 +21642-4;CACNA1S gene.p.Arg1239Gly;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CACNA1S gene p.Arg1239Gly [Presence] in Blood or Tissue by Molecular genetics method;CACNA1S p.R1239G Bld/T Ql;;ACTIVE;1.0m;2.56 +21643-2;CACNA1S gene.p.Arg1239His;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CACNA1S gene p.Arg1239His [Presence] in Blood or Tissue by Molecular genetics method;CACNA1S p.R1239h Bld/T Ql;;ACTIVE;1.0m;2.56 +21644-0;CACNA1S gene.p.Arg528His;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CACNA1S gene p.Arg528His [Presence] in Blood or Tissue by Molecular genetics method;CACNA1S p.R528h Bld/T Ql;;ACTIVE;1.0m;2.56 +21645-7;CACNA1S gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CACNA1S gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CACNA1S gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21646-5;CBS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CBS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CBS gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21647-3;CBS gene.p.G307S;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated CBS gene p.G307S [Presence] in Blood or Tissue by Molecular genetics method;Deprecated CBS p.G307S Bld/T Ql;;DEPRECATED;1.0m;2.40 +21648-1;CBS gene.p.I278T;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated CBS gene p.I278T [Presence] in Blood or Tissue by Molecular genetics method;Deprecated CBS p.I278T Bld/T Ql;;DEPRECATED;1.0m;2.40 +21649-9;CBS gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CBS gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CBS gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21650-7;CCR5 gene mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated CCR5 gene mutations found [Identifier] in Blood by Molecular genetics method Nominal;Deprecated CCR5 gene Mut Anal Bld/T;;DEPRECATED;1.0m;2.36 +21651-5;CCR5 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CCR5 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CCR5 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21652-3;CDH1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CDH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CDH1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21653-1;CDH1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CDH1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CDH1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21654-9;CFTR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CFTR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CFTR Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21655-6;CFTR gene.p.Phe508del;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene.p.Phe508del [Presence] in Blood or Tissue by Molecular genetics method;CFTR p.F508del Bld/T Ql;;ACTIVE;1.0m;2.56 +21656-4;CFTR gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CFTR gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CFTR Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21657-2;COL2A1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COL2A1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;COL2A1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21658-0;COL2A1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COL2A1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;COL2A1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +2165-9;Cryofibrinogen;MCnc;Pt;Bld;Qn;;CHEM;1;Cryofibrinogen [Mass/volume] in Blood;Cryofib Bld-mCnc;;ACTIVE;1.0;2.73 +21659-8;CTNNB1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CTNNB1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CTNNB1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21660-6;CTNNB1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CTNNB1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CTNNB1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21661-4;CYP2D6 gene deletion;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene deletion [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CYP2D6 Del Bld/T;;ACTIVE;1.0m;2.73 +21662-2;CYP2D6 gene.c.2637delA;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene c.2637delA [Presence] in Blood or Tissue by Molecular genetics method;CYP2D6 c.2637delA Bld/T Ql;;ACTIVE;1.0m;2.67 +21663-0;CYP2D6 gene mutation analysis G-A NT1 X4;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated CYP2D6 gene G-A NT1 X4 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Deprecated CYP2D6 gene G-A NT1 X4 Bld/T;;DEPRECATED;1.0m;2.67 +21664-8;CYP2D6 gene.p.Gly169Ter;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene p.Gly169Ter [Presence] in Blood or Tissue by Molecular genetics method;CYP2D6 p.G169X Bld/T Ql;;ACTIVE;1.0m;2.67 +21665-5;EGFR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;EGFR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;EGFR gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21666-3;EGFR gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;EGFR gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;EGFR gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +2166-7;Cryoglobulin;MCnc;Pt;Bld;Qn;;CHEM;1;Cryoglobulin [Mass/volume] in Blood;Cryoglob Bld-mCnc;;DISCOURAGED;1.0;2.73 +21667-1;F5 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F5 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;F5 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21668-9;F5 gene.p.Arg506Gln;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method;F5 p.R506Q Bld/T Ql;;ACTIVE;1.0m;2.73 +21669-7;F5 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F5 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;F5 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21670-5;F7 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F7 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;F7 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21671-3;F7 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F7 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;F7 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21672-1;F8 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F8 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;F8 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21673-9;F8 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F8 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;F8 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21674-7;FGFR2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGFR2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FGFR2 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +2167-5;Cryoglobulin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cryoglobulin [Presence] in Serum or Plasma;Cryoglob SerPl Ql;;DISCOURAGED;1.0;2.56 +21675-4;FGFR2 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGFR2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;FGFR2 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21676-2;FGFR3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGFR3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FGFR3 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21677-0;FGFR3 gene.p.Gly375Cys;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;FGFR3 gene p.Gly375Cys [Presence] in Blood or Tissue by Molecular genetics method;FGFR3 p.G375C Bld/T Ql;;ACTIVE;1.0m;2.56 +21678-8;FGFR3 gene.p.Gly380Arg;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;FGFR3 gene p.Gly380Arg [Presence] in Blood or Tissue by Molecular genetics method;FGFR3 p.G380R Bld/T Ql;;ACTIVE;1.0m;2.56 +21679-6;FGFR3 gene.p.Lys650Glu;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;FGFR3 gene p.Lys650Glu [Presence] in Blood or Tissue by Molecular genetics method;FGFR3 p.K650E Bld/T Ql;;ACTIVE;1.0m;2.56 +21680-4;G6PD gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;G6PD gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;G6PD gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21681-2;G6PD gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;G6PD gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;G6PD gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21682-0;Gauchers disease type 1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gaucher 1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;Gau1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +2168-3;Cryoglobulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cryoglobulin [Mass/volume] in Serum or Plasma;Cryoglob SerPl-mCnc;;DISCOURAGED;1.0;2.73 +21683-8;Gauchers disease type 2 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gaucher 2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;Gau2 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21684-6;Gauchers disease type 3 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gaucher 3 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;Gau3 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21685-3;HADHB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HADHB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HADHB gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21686-1;HADHB gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HADHB gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HADHB gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21687-9;HBA1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HBA1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HBA1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21688-7;HBA1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HBA1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HBA1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21689-5;HBB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HBB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HBB gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21690-3;HBB gene.p.Glu6Val;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HBB gene p.Glu6Val [Presence] in Blood or Tissue by Molecular genetics method;HBB p.E6V Bld/T Ql;;ACTIVE;1.0m;2.56 +2169-1;Cobalamins renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Cobalamin (Vitamin B12) renal clearance in 24 hour Urine and Serum or Plasma;Vit B12 Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +21691-1;HBB gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HBB gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HBB gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21692-9;PRSS1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PRSS1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PRSS1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21693-7;Hereditary pancreatitis gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HP gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HP gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21694-5;HFE gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HFE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HFE gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21695-2;HFE gene.p.Cys282Tyr;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HFE gene.p.Cys282Tyr [Presence] in Blood or Tissue by Molecular genetics method;HFE p.C282Y Bld/T Ql;;ACTIVE;1.0m;2.73 +21696-0;HFE gene.p.His63Asp;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HFE gene p.His63Asp [Presence] in Blood or Tissue by Molecular genetics method;HFE p.H63D Bld/T Ql;;ACTIVE;1.0m;2.73 +21697-8;HFE gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HFE gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HFE gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21698-6;HRAS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HRAS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HRAS gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21699-4;HRAS gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HRAS gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HRAS gene Mut Tested Bld/T;;ACTIVE;1.0m;2.27 +217-0;Demeclocycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Demeclocycline [Susceptibility] by Minimum inhibitory concentration (MIC);Demeclocycline Islt MIC;;ACTIVE;1.0;2.19 +21700-0;Kallmann syndrome gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Kallmann syndrome gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KMS gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21701-8;Kallmann syndrome gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Kallmann syndrome gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;KMS gene Mut Tested Bld/T;;ACTIVE;1.0m;2.67 +21702-6;KRAS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KRAS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KRAS gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21703-4;KRAS gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KRAS gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;KRAS gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21704-2;MT-ATP6 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MT-ATP6 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MT-ATP6 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21705-9;MT-ND4 gene.m.11696G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND4 gene m.11696G>A [Presence] in Blood or Tissue by Molecular genetics method;MT-ND4 m.11696G>A Bld/T Ql;;ACTIVE;1.0m;2.56 +21706-7;MT-ND4 gene.p.R304H;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated MT-ND4 gene p.R304H [Presence] in Blood or Tissue by Molecular genetics method;Deprecated MT-ND4 p.R304h Bld/T Ql;;DEPRECATED;1.0m;2.40 +21707-5;MT-ND4 gene.p.Thr109Ala;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND4 gene p.Thr109Ala [Presence] in Blood or Tissue by Molecular genetics method;MT-ND4 p.T109A Bld/T Ql;;ACTIVE;1.0m;2.56 +21708-3;MT-ATP6 gene.p.L156R;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated MT-ATP6 gene p.L156R [Presence] in Blood or Tissue by Molecular genetics method;Deprecated MT-ATP6 p.L156R Bld/T Ql;;DEPRECATED;1.0m;2.40 +2170-9;Cyanocobalamin.true;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Cobalamin [Mass/volume] in Serum;Deprecated Cyanocobalamin.true Ser-mCnc;;DEPRECATED;1.0;2.36 +21709-1;MTHFR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MTHFR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MTHFR gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21710-9;MTHFR gene.p.Ala677Val;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated MTHFR gene p.Ala677Val [Presence] in Blood or Tissue by Molecular genetics method;Deprecated MTHFR p.A677V Bld/T Ql;;DEPRECATED;1.0m;2.65 +21711-7;MTHFR gene.p.Cys677Glu;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated MTHFR gene p.Cys677Glu [Presence] in Blood or Tissue by Molecular genetics method;Deprecated MTHFR p.C677E Bld/T Ql;;DEPRECATED;1.0m;2.65 +21712-5;MTHFR gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MTHFR gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MTHFR gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21713-3;MT-TK gene.m.8344A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TK gene m.8344A>G [Presence] in Blood or Tissue by Molecular genetics method;MT-TK m.8344A>G Bld/T Ql;;ACTIVE;1.0m;2.56 +21714-1;MT-TL1 gene.m.3243A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TL1 gene m.3243A>G [Presence] in Blood or Tissue by Molecular genetics method;MT-TL1 m.3243A>G Bld/T Ql;;ACTIVE;1.0m;2.56 +21715-8;MXI1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MXI1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MXI1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21716-6;NB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NB gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +2171-7;Cobalamins.unsaturated binding capacity;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cobalamin (Vitamin B12).unsaturated Binding Capacity [Mass/volume] in Serum or Plasma;Vit B12 USB SerPl-mCnc;;ACTIVE;1.0;2.73 +21717-4;NF1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NF1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NF1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21718-2;NF1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NF1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;NF1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21719-0;NRAS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NRAS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NRAS gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21720-8;NRAS gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NRAS gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;NRAS gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21721-6;OTC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;OTC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;OTC gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21722-4;OTC gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;OTC gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;OTC gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21723-2;SERPINA1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SERPINA1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SERPINA1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21724-0;SERPINA1 gene.p.Glu264Val;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;SERPINA1 gene p.Glu264Val [Presence] in Blood or Tissue by Molecular genetics method;SERPINA1 p.E264V Bld/T Ql;;ACTIVE;1.0m;2.56 +2172-5;Cystathionine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cystathionine [Presence] in Serum or Plasma;Cystathionin SerPl Ql;;ACTIVE;1.0;2.56 +21725-7;SERPINA1 gene.p.Glu342Lys;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;SERPINA1 gene p.Glu342Lys [Presence] in Blood or Tissue by Molecular genetics method;SERPINA1 p.E342K Bld/T Ql;;ACTIVE;1.0m;2.73 +21726-5;SERPINA1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SERPINA1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;SERPINA1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21727-3;PMP22 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PMP22 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PMP22 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21728-1;PMP22 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PMP22 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;PMP22 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21729-9;PSAP gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PSAP gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PSAP gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21730-7;PSAP gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PSAP gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;PSAP gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21731-5;RB1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RB1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;RB1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21732-3;RB1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RB1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;RB1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +2173-3;Cystathionine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystathionine [Mass/volume] in Serum or Plasma;Cystathionin SerPl-mCnc;;DISCOURAGED;1.0;2.73 +21733-1;RET gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RET gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;RET gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21734-9;RET gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RET gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;RET gene Mut Tested Bld/T;;ACTIVE;1.0m;2.73 +21735-6;SNCA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SNCA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SNCA gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +21736-4;SNCA gene.p.Ala30Pro;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;SNCA gene p.Ala30Pro [Presence] in Blood or Tissue by Molecular genetics method;SNCA p.A30P Bld/T Ql;;ACTIVE;1.0m;2.73 +21737-2;SNCA gene.p.Ala53Thr;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;SNCA gene p.Ala53Thr [Presence] in Blood or Tissue by Molecular genetics method;SNCA p.A53T Bld/T Ql;;ACTIVE;1.0m;2.56 +21738-0;SNCA gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SNCA gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;SNCA gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21739-8;TP53 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TP53 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TP53 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21740-6;TRAF3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TRAF3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TRAF3 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.63 +2174-1;Cystathionine;MCnc;Pt;Urine;Qn;;CHEM;1;Cystathionine [Mass/volume] in Urine;Cystathionin Ur-mCnc;;DISCOURAGED;1.0;2.73 +21741-4;TRAF3 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TRAF3 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;TRAF3 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21742-2;WT1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;WT1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;WT1 gene Mut Anl Bld/T;;ACTIVE;1.0m;2.73 +21743-0;WT1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;WT1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;WT1 gene Mut Tested Bld/T;;ACTIVE;1.0m;2.13 +21744-8;CCND1 gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;CCND1 gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;CCND1 gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21745-5;BCL2 gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;Deprecated BCL2 gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;Deprecated BCL2 gene Rear Bld/T Ql;;DEPRECATED;1.0m;2.36 +21746-3;BCL6 gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;BCL6 gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;BCL6 gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21747-1;Immunoglobulin heavy chain gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;HC gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;HC gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21748-9;Immunoglobulin kappa light chain gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;Kappa LC gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;Kappa LC gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21749-7;Immunoglobulin lambda light chain gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;Lambda LC gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;Lambda LC gene Rear Bld/T Ql;;ACTIVE;1.0m;2.21 +21750-5;MYC gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;MYC gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;MYC gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21751-3;TCRB gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;TCRB gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;TCRB gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21752-1;TCRD gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;TCRD gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;TCRD gene Rear Bld/T Ql;;ACTIVE;1.0m;2.21 +21753-9;TCRG gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;TCRG gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;TCRG gene Rear Bld/T Ql;;ACTIVE;1.0m;2.73 +21754-7;AR gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;AR gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;AR gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21755-4;CACNA1A gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;CACNA1A gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;CACNA1A gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.56 +21756-2;ATN1 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;ATN1 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;ATN1 gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21757-0;DMPK gene.CTG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;DMPK gene CTG repeats [Presence] in Blood or Tissue by Molecular genetics method;DMPK gene CTG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +2175-8;Cystine;PrThr;Pt;Bld;Ord;;CHEM;1;Cystine [Presence] in Blood;Cystine Bld Ql;;ACTIVE;1.0;2.56 +21759-6;FMR1 gene.CGG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;FMR1 gene CGG repeats [Presence] in Blood or Tissue by Molecular genetics method;FMR1 gene CGG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21760-4;FRAXE gene.CGG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;FRAXE gene CGG repeats [Presence] in Blood or Tissue by Molecular genetics method;FRAXE gene CGG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21761-2;FRAXE gene.CGG repeats;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRINUC;1;Deprecated FRAXE gene CGG repeats [Presence] in Blood or Tissue by Molecular genetics method;Deprecated FRAXE gene CGG Rpt Bld/T Ql;;DEPRECATED;1.0m;2.36 +21762-0;FXN gene.GAA repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;FXN gene GAA repeats [Presence] in Blood or Tissue by Molecular genetics method;FXN gene GAA Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21763-8;HTT gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;HTT gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;HTT gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21764-6;MJD gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;MJD gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;MJD gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21765-3;SCA1 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA1 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA1 gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +2176-6;Cystine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cystine [Presence] in Serum or Plasma;Cystine SerPl Ql;;ACTIVE;1.0;2.73 +21766-1;SCA2 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA2 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA2 gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21767-9;SCA7 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA7 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA7 gene CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.73 +21768-7;Spinocerebellar ataxia gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SCA gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;SCA gene Mut Tested Bld/T;;ACTIVE;1.0m;2.21 +21769-5;Spinocerebellar ataxia genes.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA genes CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA genes CAG Rpt Bld/T Ql;;ACTIVE;1.0m;2.56 +21770-3;Chromosome 12 trisomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 12 trisomy [Presence] in Blood or Tissue by Cytogenetics;Chr 12 Ts Bld/T Ql;;ACTIVE;1.0m;2.73 +21771-1;Chromosome 21 trisomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 21 trisomy [Presence] in Blood or Tissue by Cytogenetics;Chr 21 Ts Bld/T Ql;;ACTIVE;1.0m;2.73 +21772-9;Chromosome 7 trisomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 7 trisomy [Presence] in Blood or Tissue by Cytogenetics;Chr 7 Ts Bld/T Ql;;ACTIVE;1.0m;2.66 +21773-7;Chromosome 8 trisomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 8 trisomy [Presence] in Blood or Tissue by Cytogenetics;Chr 8 Ts Bld/T Ql;;ACTIVE;1.0m;2.66 +2177-4;Cystine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystine [Mass/volume] in Serum or Plasma;Cystine SerPl-mCnc;;ACTIVE;1.0;2.73 +21774-5;Chromosome 9 trisomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 9 trisomy [Presence] in Blood or Tissue by Cytogenetics;Chr 9 Ts Bld/T Ql;;ACTIVE;1.0m;2.66 +21775-2;"Cells.t(1;13)(p36.13;q14.1)(PAX7,FOXO1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(1;13)(p36.13;q14.1)(PAX7,FOXO1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(1;13)(PAX7,FOXO1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21776-0;"Cells.t(1;19)(q23.3;p13.3)(PBX1,TCF3)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(1;19)(q23.3;p13.3)(PBX1,TCF3) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(1;19)(PBX1,TCF3) NFr Bld/T";;ACTIVE;1.0m;2.70 +21777-8;"Cells.t(11;14)(q13;q32)(CCND1,IGH)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(11;14)(q13;q32)(CCND1,IGH) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(11;14)(CCND1,IGH) NFr Bld/T";;ACTIVE;1.0m;2.73 +21778-6;"Cells.t(11;19)(q23;p13.3)(MLL,MLLT1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(11;19)(q23;p13.3)(MLL,MLLT1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(11;19)(MLL,MLLT1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21779-4;"Cells.t(11;22)(q24;q12.2)(FLI1,EWSR1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(11;22)(q24;q12.2)(FLI1,EWSR1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(11;22)(FLI1,EWSR1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21780-2;"Cells.t(11;22)(p13;q12.2)(WT1,EWSR1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(11;22)(p13;q12.2)(WT1,EWSR1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(11;22)(WT1,EWSR1) NFr Bld/T";;ACTIVE;1.0m;2.73 +21781-0;"Cells.t(12;16)(q13;p11.2)(DDIT3,FUS)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(12;16)(q13;p11.2)(DDIT3,FUS) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(12;16)(DDIT3,FUS) NFr Bld/T";;ACTIVE;1.0m;2.70 +2178-2;Cystine;MCnc;Pt;Urine;Qn;;CHEM;1;Cystine [Mass/volume] in Urine;Cystine Ur-mCnc;;ACTIVE;1.0;2.73 +21782-8;"Cells.t(12;21)(p13;q22.3)(ETV6,RUNX1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(12;21)(p13;q22.3)(ETV6,RUNX1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(12;21)(ETV6,RUNX1) NFr Bld/T";;ACTIVE;1.0m;2.73 +21783-6;"Cells.t(12;22)(q13;q12.2)(ATF1,EWSR1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(12;22)(q13;q12.2)(ATF1,EWSR1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(12;22)(ATF1,EWSR1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21784-4;"Cells.t(14;18)(q32;q21.3)(IGH,BCL2)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(14;18)(IGH,BCL2) NFr Bld/T";;ACTIVE;1.0m;2.73 +21785-1;"Cells.t(15;17)(q24.1;q21.1)(PML,RARA)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(15;17)(PML,RARA) NFr Bld/T";;ACTIVE;1.0m;2.73 +21786-9;"Cells.t(2;13)(q36.1;q14.4)(PAX3,FOXO1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(2;13)(q36.1;q14.4)(PAX3,FOXO1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(2;13)(PAX3,FOXO1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21787-7;"Cells.t(2;5)(p23;q35.1)(ALK,NPM1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(2;5)(p23;q35.1)(ALK,NPM1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(2;5)(ALK,NPM1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21788-5;"Cells.t(21;22)(q22.3;q12.2)(ERG,EWSR1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(21;22)(q22.3;q12.2)(ERG,EWSR1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(21;22)(ERG,EWSR1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21789-3;"Cells.t(4;11)(q21.3;q23)(AFF1,MLL)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(4;11)(q21.3;q23)(AFF1,MLL) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(4;11)(AFF1,MLL) NFr Bld/T";;ACTIVE;1.0m;2.70 +2179-0;Cystine;MRat;24H;Urine;Qn;;CHEM;1;Cystine [Mass/time] in 24 hour Urine;Cystine 24h Ur-mRate;;ACTIVE;1.0;2.73 +21790-1;"Cells.t(5;12)(q33.1;p13)(PDGFRB,ETV6)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(5;12)(q33.1;p13)(PDGFRB,ETV6) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(5;12)(PDGFRB,ETV6) NFr Bld/T";;ACTIVE;1.0m;2.70 +21791-9;"Cells.t(6;9)(p22;q34)(DEK,NUP214)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(6;9)(p22;q34)(DEK,NUP214) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(6;9)(DEK,NUP214) NFr Bld/T";;ACTIVE;1.0m;2.70 +21792-7;"Cells.t(8;14)(q24;q32)(MYC,IGH)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(8;14)(q24;q32)(MYC,IGH) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(8;14)(MYC,IGH) NFr Bld/T";;ACTIVE;1.0m;2.70 +21793-5;"Cells.t(8;21)(q22;q22.3)(RUNX1T1,RUNX1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(8;21)(RUNX1T1,RUNX1) NFr Bld/T";;ACTIVE;1.0m;2.73 +21794-3;"Cells.t(9;11)(p22;q23)(MLLT3,MLL)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;11)(p22;q23)(MLLT3,MLL) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(9;11)(MLLT3,MLL) NFr Bld/T";;ACTIVE;1.0m;2.70 +21795-0;"Cells.t(9;22)(q34.1;q11)(ABL1,BCR)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(9;22)(ABL1,BCR) NFr Bld/T";;ACTIVE;1.0m;2.73 +21796-8;"Cells.t(9;22)(q22;q12.2)(NR4A3,EWSR1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q22;q12.2)(NR4A3,EWSR1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(9;22)(NR4A3,EWSR1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21797-6;"Cells.t(X;18)(q11.2;p11.23)(SS18,SSX1)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(X;18)(q11.2;p11.23)(SS18,SSX1) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(X;18)(SS18,SSX1) NFr Bld/T";;ACTIVE;1.0m;2.70 +21798-4;"Cells.t(X;18)(q11.2;p11.22)(SS18,SSX2)/Cells.total";NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(X;18)(q11.2;p11.22)(SS18,SSX2) cells/Cells.total in Blood or Tissue by Molecular genetics method";"t(X;18)(SS18,SSX2) NFr Bld/T";;ACTIVE;1.0m;2.70 +21799-2;"t(1;13)(p36.13;q14.1)(PAX7,FOXO1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(1;13)(p36.13;q14.1)(PAX7,FOXO1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(1;13)(PAX7,FOXO1) Bld/T Ql";;ACTIVE;1.0m;2.52 +21800-8;"t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(1;19)(PBX1,TCF3) Bld/T Ql";;ACTIVE;1.0m;2.73 +21801-6;"t(11;14)(q13;q32)(CCND1,IGH) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;14)(q13;q32)(CCND1,IGH) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(11;14)(CCND1,IGH) Bld/T Ql";;ACTIVE;1.0m;2.73 +21802-4;"t(11;19)(q23;p13.3)(MLL,MLLT1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;19)(q23;p13.3)(MLL,MLLT1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(11;19)(MLL,MLLT1) Bld/T Ql";;ACTIVE;1.0m;2.73 +21803-2;"t(11;22)(q24;q12.2)(FLI1,EWSR1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;22)(q24;q12.2)(FLI1,EWSR1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(11;22)(FLI1,EWSR1) Bld/T Ql";;ACTIVE;1.0m;2.40 +21804-0;"t(11;22)(p13;q12.2)(WT1,EWSR1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;22)(p13;q12.2)(WT1,EWSR1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(11;22)(WT1,EWSR1) Bld/T Ql";;ACTIVE;1.0m;2.40 +21805-7;"t(12;16)(q13;p11.2)(DDIT3,FUS) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(12;16)(q13;p11.2)(DDIT3,FUS) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(12;16)(DDIT3,FUS) Bld/T Ql";;ACTIVE;1.0m;2.40 +21806-5;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(12;21)(ETV6,RUNX1) Bld/T Ql";;ACTIVE;1.0m;2.73 +21807-3;"t(12;22)(q13;q12.2)(ATF1,EWSR1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(12;22)(q13;q12.2)(ATF1,EWSR1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(12;22)(ATF1,EWSR1) Bld/T Ql";;ACTIVE;1.0m;2.73 +2180-8;Cystine+Cysteine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystine+Cysteine [Mass/volume] in Serum or Plasma;Cys+Cysteine SerPl-mCnc;;ACTIVE;1.0;2.42 +21808-1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(14;18)(IGH,BCL2) Bld/T Ql";;ACTIVE;1.0m;2.73 +21809-9;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points [Presence] in Blood or Tissue by Molecular genetics method";"t(14;18)(IGH,BCL2) Major Bld/T Ql";;ACTIVE;1.0m;2.50 +21810-7;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points [Presence] in Blood or Tissue by Molecular genetics method";"t(14;18)(IGH,BCL2) Minor Bld/T Ql";;ACTIVE;1.0m;2.50 +21811-5;t(15,17) (PML,RARA) gene translocation;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;Deprecated t(15,17)(PML,RARA) Translocation [Presence] in Blood or Tissue by Molecular genetics method;Deprecated t(15,17) (PML,RARA) Bld/T Ql;;DEPRECATED;1.0m;2.36 +21812-3;"t(2;13)(q36.1;q14.4)(PAX3,FOXO1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(2;13)(q36.1;q14.4)(PAX3,FOXO1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(2;13)(PAX3,FKHR) Bld/T Ql";;ACTIVE;1.0m;2.40 +21813-1;"t(2;5)(p23;q35.1)(ALK,NPM1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(2;5)(p23;q35.1)(ALK,NPM1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(2;5)(ALK,NPM1) Bld/T Ql";;ACTIVE;1.0m;2.73 +21814-9;"t(21;22)(q22.3;q12.2)(ERG,EWSR1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(21;22)(q22.3;q12.2)(ERG,EWSR1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(21;22)(ERG,EWSR1) Bld/T Ql";;ACTIVE;1.0m;2.40 +21815-6;"t(4;11)(q21.3;q23)(AFF1,MLL) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(4;11)(q21.3;q23)(AFF1,MLL) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(4;11)(AFF1,MLL) Bld/T Ql";;ACTIVE;1.0m;2.52 +2181-6;Cystinyl aminopeptidase;CCnc;Pt;Ser;Qn;;CHEM;1;Cystinyl aminopeptidase [Enzymatic activity/volume] in Serum;Cystinyl AP Ser-cCnc;;ACTIVE;1.0;2.68 +21816-4;"t(5;12)(q33.1;p13)(PDGFRB,ETV6) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(5;12)(q33.1;p13)(PDGFRB,ETV6) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(5;12)(PDGFRB,ETV6) Bld/T Ql";;ACTIVE;1.0m;2.73 +21817-2;"t(6;9)(p22;q34)(DEK,NUP214) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(6;9)(p22;q34)(DEK,NUP214) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(6;9)(DEK,NUP214) Bld/T Ql";;ACTIVE;1.0m;2.52 +21818-0;"t(8;14)(q24;q32)(MYC,IGH) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(8;14)(q24;q32)(MYC,IGH) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(8;14)(MYC,IGH) Bld/T Ql";;ACTIVE;1.0m;2.73 +21819-8;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(8;21)(RUNX1T1,RUNX1) Bld/T Ql";;ACTIVE;1.0m;2.73 +21820-6;"t(9;11)(p22;q23)(MLLT3,MLL) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;11)(p22;q23)(MLLT3,MLL) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(9;11)(MLLT3,MLL) Bld/T Ql";;ACTIVE;1.0m;2.40 +21821-4;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(9;22)(ABL1,BCR) Bld/T Ql";;ACTIVE;1.0m;2.73 +21822-2;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript major break points";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript major break points [Presence] in Blood or Tissue by Molecular genetics method";"t(9;22)(ABL1,BCR) Major Bld/T Ql";;ACTIVE;1.0m;2.73 +21823-0;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript minor break points";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript minor break points [Presence] in Blood or Tissue by Molecular genetics method";"t(9;22)(ABL1,BCR) Minor Bld/T Ql";;ACTIVE;1.0m;2.73 +2182-4;Cytochrome B reductase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Cytochrome B reductase [Enzymatic activity/volume] in Amniotic fluid;CyB Reduct Amn-cCnc;;ACTIVE;1.0;2.68 +21824-8;"t(9;22)(q22;q12.2)(NR4A3,EWSR1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q22;q12.2)(NR4A3,EWSR1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(9;22)(NR4A3,EWSR1) Bld/T Ql";;ACTIVE;1.0m;2.52 +21825-5;"t(X;18)(q11.2;p11.23)(SS18,SSX1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(X;18)(q11.2;p11.23)(SS18,SSX1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(X;18)(SS18,SSX1) Bld/T Ql";;ACTIVE;1.0m;2.52 +21826-3;"t(X;18)(q11.2;p11.22)(SS18,SSX2) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(X;18)(q11.2;p11.22)(SS18,SSX2) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(X;18)(SS18,SSX2) Bld/T Ql";;ACTIVE;1.0m;2.52 +21827-1;Transmitted record type;Type;Pt;NAACCR message;Nom;;TUMRRGT;2;Transmitted record type NAACCR message;Transmitted record type NAACCR Message;;ACTIVE;1.0m;2.27 +21828-9;Cancer registry;Type;Pt;NAACCR message;Nom;;TUMRRGT;2;Cancer registry NAACCR message;Cancer reg NAACCR Message;;ACTIVE;1.0m;2.29 +21829-7;Institution data source;ID;Pt;Registry message;Nom;;TUMRRGT;2;Institution data source Registry message;Inst data source Registry Message;;ACTIVE;1.0m;2.32 +21830-5;Version;Type;Pt;NAACCR message;Nom;;TUMRRGT;2;Version NAACCR message;Version NAACCR Message;;ACTIVE;1.0m;2.29 +21831-3;Unique tumor case ID;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Unique tumor case ID Cancer;Unique tumor case ID Cancer;;ACTIVE;1.0m;2.27 +2183-2;Cytochrome B5 reductase;CCnc;Pt;Ser;Qn;;CHEM;1;Cytochrome B5 reductase [Enzymatic activity/volume] in Serum;CyB5 Reduct Ser-cCnc;;ACTIVE;1.0;2.68 +21832-1;Coding system 1970&80&90;Type;Pt;Census tract at cancer XXX Dx;Nom;;TUMRRGT;2;Coding system 1970/80/90 Census tract at cancer diagnosis;Coding sys 1970/80/90 Census tract;;ACTIVE;1.0m;2.32 +21833-9;Alternate census tract at cancer XXX Dx;ID;Pt;^Patient;Nom;;TUMRRGT;2;Alternate census tract at cancer diagnosis;Alternate census tract at cancer Dx;;ACTIVE;1.0m;2.32 +21834-7;Coding system;Type;Pt;Census tract at cancer XXX Dx.alternate;Nom;;TUMRRGT;2;Coding system Census tract at cancer diagnosis alternate;Coding sys Census tract Alt;;ACTIVE;1.0m;2.29 +21835-4;Coding system.current;Type;Pt;Race;Nom;;TUMRRGT;2;Coding system.current Race;Coding sys.current Race;;ACTIVE;1.0m;2.29 +21836-2;Coding system.original;Type;Pt;Race;Nom;;TUMRRGT;2;Coding system.original Race;Coding sys.original Race;;ACTIVE;1.0m;2.29 +21837-0;Hispanic origin;Type;Pt;^Patient;Nom;Best estimate;TUMRRGT;2;Hispanic origin Best estimate;Hispanic origin Best Est;;ACTIVE;1.0m;2.29 +21838-8;Ethnicity;Type;Pt;^Patient;Nom;Computed;TUMRRGT;2;Ethnicity Computed;Ethnicity Computed;;ACTIVE;1.0m;2.73 +21839-6;Derivation method;Type;Pt;Ethnicity computation;Nom;*;TUMRRGT;2;Derivation method Computed Ethnicity;Derivation method Computed Ethnicity;;ACTIVE;1.0m;2.32 +2184-0;Cytochrome C oxidase;CCnc;Pt;Plas;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/volume] in Plasma;CyC Oxidase Plas-cCnc;;ACTIVE;1.0;2.68 +21840-4;Sex;Type;Pt;^Patient;Nom;NAACCR v.11;TUMRRGT;2;Sex [NAACCR v.11];Sex NAACCR v.11;;ACTIVE;1.0m;2.73 +21841-2;Age at cancer Dx;Num;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Age at cancer diagnosis;Cancer diagnosis age;;ACTIVE;1.0m;2.70 +21842-0;Birthplace;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Birthplace;Birthplace;;ACTIVE;1.0m;2.67 +21843-8;Usual occupation;Hx;Pt;^Patient;Nom;;TUMRRGT;2;History of Usual occupation;Hx of Usual occupation;;ACTIVE;1.0m;2.63 +21844-6;Usual industry;Hx;Pt;^Patient;Nom;;TUMRRGT;2;History of Usual industry;Hx of Usual industry;;ACTIVE;1.0m;2.63 +21845-3;Information source;Type;Pt;Usual occupation Hx;Nom;*;TUMRRGT;2;Source of information Usual occupational Hx;Source of info Usual Occupation Hx;;ACTIVE;1.0m;2.32 +21846-1;Information source;Type;Pt;Usual industry Hx;Nom;*;TUMRRGT;2;Source of information Usual industry Hx;Source of info Usual Industry Hx;;ACTIVE;1.0m;2.32 +21847-9;Usual occupation;Find;Pt;^Patient;Nar;;TUMRRGT;2;Usual occupation Narrative;Usual occupation;;ACTIVE;1.0m;2.40 +21848-7;Usual industry;Find;Pt;^Patient;Nar;;TUMRRGT;2;Usual industry Narrative;Usual industry;;ACTIVE;1.0m;2.40 +21849-5;Coding system;Type;Pt;Occupation & Industry Hx;Nom;;TUMRRGT;2;Coding system Occupational and Industry Hx;Coding sys Occupation+Industry Hx;;ACTIVE;1.0m;2.38 +21850-3;Cancer;Hx;Pt;^Family member;Nar;;TUMRRGT;2;Family history of Cancer Narrative;Family hx of Cancer;;ACTIVE;1.0m;2.56 +21851-1;Address at cancer XXX Dx;Xad;Pt;^Patient;Nom;;TUMRRGT;2;Address at cancer diagnosis;Address at cancer Dx;;ACTIVE;1.0m;2.27 +21852-9;Census tract certainty 1970&80&90;Type;Pt;Census tract;Nom;*;TUMRRGT;2;Census tract certainty 1970and80and90;Census tract certainty 1970/80/90;;ACTIVE;1.0m;2.38 +21853-7;Sequence number central.patient;Arb;Pt;Cancer.XXX;Ord;;TUMRRGT;2;Sequence number central.patient Cancer;Seq # central.patient Cancer;;ACTIVE;1.0m;2.32 +21854-5;Date first Dx;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date first Dx Cancer;Date first Dx Cancer;;ACTIVE;1.0m;2.50 +21855-2;Primary site;Anat;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Primary site Cancer;Primary site Cancer;;ACTIVE;1.0m;2.73 +21856-0;Histology ICD-O-2;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Histology ICD-O-2 Cancer;Histology ICD-O-2 Cancer;;ACTIVE;1.0m;2.27 +2185-7;Cytochrome C oxidase;CCnc;Pt;Platelets;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/volume] in Platelets;CyC Oxidase Plts-cCnc;;ACTIVE;1.0;2.61 +21857-8;Behavior ICD-O-2;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Behavior ICD-O-2 Cancer;Behavior ICD-O-2 Cancer;;ACTIVE;1.0m;2.32 +21858-6;Grade;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Grade Cancer;Grade Cancer;;ACTIVE;1.0m;2.73 +21859-4;Coding system.original;Type;Pt;Cancer.XXX.anatomic site;Nom;;TUMRRGT;2;Coding system.original Cancer site;Coding sys.original Cancer site;;ACTIVE;1.0m;2.29 +21860-2;Coding system.original;Type;Pt;Cancer.XXX.morphology;Nom;;TUMRRGT;2;Coding system.original Cancer morphology;Coding sys.original Cancer morph;;ACTIVE;1.0m;2.29 +21861-0;Dx confirmed by;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Dx confirmed by Cancer;Dx confirmed by Cancer;;ACTIVE;1.0m;2.29 +21862-8;Source of document used to abstract;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Source of document used to abstract Cancer;Source doc used to abstract Cancer;;ACTIVE;1.0m;2.29 +21863-6;Date last screened;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date last screened Cancer;Date last screened Cancer;;ACTIVE;1.0m;2.50 +21864-4;Most recent screening result for;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Most recent screening result for Cancer;Most recent screening result for Cancer;;ACTIVE;1.0m;2.29 +2186-5;Cytochrome C oxidase;CCnc;Pt;WBC;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/volume] in Leukocytes;CyC Oxidase WBC-cCnc;;ACTIVE;1.0;2.15 +21865-1;Hospital.reporting;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Hospital.reporting [Identifier] Cancer;Hospital.reporting Cancer;;ACTIVE;1.0m;2.27 +21866-9;Patient ID.hospital;ID;Pt;^Patient;Nom;;TUMRRGT;2;Patient ID.hospital;Patient ID.hospital;;ACTIVE;1.0m;2.73 +21867-7;Sequence number.hospital;Arb;Pt;Cancer.XXX;Ord;;TUMRRGT;2;Sequence number.hospital Cancer;Seq #.hospital Cancer;;ACTIVE;1.0m;2.32 +21868-5;User ID.hospital assigned;ID;Pt;Abstractor;Nom;;TUMRRGT;2;User ID.hospital assigned Abstractor;Hospital ID Abstractor;;ACTIVE;1.0m;2.73 +21869-3;Hospital admission.first contact;TmStp;Pt;Cancer;Qn;;TUMRRGT;2;Hospital admission.first contact [Date and time] Cancer;Hosp adm 1st contact Cancer;;ACTIVE;1.0m;2.32 +21870-1;Date of inpatient admission;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date of inpatient admission Cancer;Date of inpt adm Cancer;;ACTIVE;1.0m;2.32 +21871-9;Date of inpatient discharge;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date of inpatient discharge Cancer;Date of inpt disch Cancer;;ACTIVE;1.0m;2.32 +21872-7;Relationship between this hospital and cancer Dx;Type;Episode;Cancer.XXX;Nom;;TUMRRGT;2;Relationship between this hospital and cancer Dx;Rel between hosp and cancer Dx;;ACTIVE;1.0m;2.32 +2187-3;Cytosol aminopeptidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cytosol aminopeptidase [Enzymatic activity/volume] in Serum or Plasma;Cytosol AP SerPl-cCnc;;ACTIVE;1.0;2.73 +21873-5;Y first seen at this hospital for;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Year first seen at this hospital for [Date] Cancer;Y first seen this hospital for Cancer;;ACTIVE;1.0m;2.50 +21874-3;Cancer conference.presentation status at reporting facility;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Cancer conference.presentation status at reporting facility;Presentation at CA Conf;;ACTIVE;1.0m;2.32 +21875-0;Cancer conference;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Cancer conference [Date and time];CA Conf;;ACTIVE;1.0m;2.32 +21876-8;Surgery procedure for primary site at facility.YYY;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery procedure for primary site at facility.YYY Cancer;Surg proc for prime site Cancer;;ACTIVE;1.0m;2.34 +21877-6;Surgery procedure for regional nodes at facility.YYY;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery procedure for regional nodes at facility.YYY Cancer;Surg proc for reg nodes Cancer;;ACTIVE;1.0m;2.34 +21878-4;Other regional disease at facility.YYY most definitive procedure;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Other regional disease at facility.YYY most definitive procedure Cancer;Other reg dis at facility most def proc;;ACTIVE;1.0m;2.27 +21879-2;Surgery.regional nodes examined at facility.YYY most definitive procedure;Num;Surg;Cancer.XXX;Qn;;TUMRRGT;2;Surgery.regional nodes examined at facility.YYY most definitive procedure [#] Surgery Cancer;Surg.reg nodes exam most def proc Cancer;;ACTIVE;1.0m;2.52 +218-8;Demeclocycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Demeclocycline [Susceptibility] by Disk diffusion (KB);Demeclocycline Islt KB;;ACTIVE;1.0;2.19 +21880-0;Radiation Rx therapy;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Radiation treatment therapy Cancer;Radiation Rx therapy Cancer;;ACTIVE;1.0m;2.29 +2188-1;Cytosol aminopeptidase;PrThr;Pt;Urine;Ord;;CHEM;1;Cytosol aminopeptidase [Presence] in Urine;Cytosol AP Ur Ql;;ACTIVE;1.0;2.56 +21881-8;Chemotherapy Rx at facility.YYY;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Chemotherapy treatment at facility.YYY Cancer;Chemotherapy Rx at facility Cancer;;ACTIVE;1.0m;2.32 +21882-6;Hormone Rx at facility.YYY;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Hormone treatment at facility.YYY Cancer;Hormone Rx at facility Cancer;;ACTIVE;1.0m;2.32 +21883-4;Transplant Rx at facility.YYY;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Transplant treatment at facility.YYY Cancer;Transplant Rx at facility Cancer;;ACTIVE;1.0m;2.32 +21884-2;Other Rx at facility.YYY;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Other treatment at facility.YYY Cancer;Other Rx at facility Cancer;;ACTIVE;1.0m;2.32 +21885-9;Surgery.not cancer Rx at facility.YYY;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery.not cancer treatment at facility.YYY;Surgery.not cancer Rx;;ACTIVE;1.0m;2.34 +21886-7;Breast-prostate staging.NAACCR;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Breast-prostate staging.NAACCR;Breast-prostate staging.NAACCR Cancer;;ACTIVE;1.0m;2.29 +21887-5;SEER summary stage 1977;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;SEER summary stage 1977 Cancer;SEER SS1977 Cancer;;ACTIVE;1.0m;2.32 +21888-3;Stage.summary abbreviated at Dx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Summary stage abbreviated at Dx Cancer;SS abbreviated at Dx Cancer;;ACTIVE;1.0m;2.32 +21889-1;Size;Len;Pt;Tumor;Qn;;TUMRRGT;2;Size Tumor;Size Tumor;;ACTIVE;1.0m;2.73 +21890-9;Extension;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Extension Cancer;Extension Cancer;;ACTIVE;1.0m;2.29 +21891-7;Extent of disease;Type;Pt;Prostate cancer.XXX;Nom;;TUMRRGT;2;Extent of disease Prostate cancer;EOD Prostate cancer;;ACTIVE;1.0m;2.29 +21892-5;Lymph node involvement;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Lymph node involvement Cancer;LN involved Cancer;;ACTIVE;1.0m;2.58 +21893-3;Regional lymph nodes positive;Num;Pt;Specimen;Qn;;TUMRRGT;2;Regional lymph nodes positive [#] Specimen;Reg LN positive Spec;;ACTIVE;1.0m;2.61 +21894-1;Regional lymph nodes examined;Num;Pt;Specimen;Qn;;TUMRRGT;2;Regional lymph nodes examined [#] Specimen;Reg LN examined Spec;;ACTIVE;1.0m;2.56 +21895-8;Extent of disease.NAACCR.old 13 digit;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Extent of disease.NAACCR.old 13 digit;EOD.NAACCR.old 13 digit Cancer;;ACTIVE;1.0m;2.27 +21896-6;Extent of disease.NAACCR.old 2 digit;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Extent of disease.NAACCR.old 2 digit;EOD.NAACCR.old 2 digit Cancer;;ACTIVE;1.0m;2.27 +21897-4;Extent of disease.NAACCR.old 4 digit;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Extent of disease.NAACCR.old 4 digit;EOD.NAACCR.old 4 digit Cancer;;ACTIVE;1.0m;2.27 +21898-2;Version used;Type;Pt;Extent of disease coding system;Nom;;TUMRRGT;2;Version used Extent of disease coding system;Version EOD coding sys;;ACTIVE;1.0m;2.32 +2189-9;Cytosol aminopeptidase;CCnc;Pt;Urine;Qn;;CHEM;1;Cytosol aminopeptidase [Enzymatic activity/volume] in Urine;Cytosol AP Ur-cCnc;;ACTIVE;1.0;2.68 +21899-0;Primary tumor.pathology;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Primary tumor.pathology Cancer;Primary tumor.pathology Cancer;;ACTIVE;1.0m;2.32 +21900-6;Regional lymph nodes.pathology;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Regional lymph nodes.pathology [Class] Cancer;Reg LN.pathology Cancer;;ACTIVE;1.0m;2.32 +21901-4;Distant metastases.pathology;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Distant metastases.pathology [Class] Cancer;Distant metastases.pathology Cancer;;ACTIVE;1.0m;2.27 +21902-2;Stage group.pathology;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Stage group.pathology Cancer;Stg grp.pathology Cancer;;ACTIVE;1.0m;2.73 +21903-0;Descriptor.pathology;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Descriptor.pathology Cancer Narrative;Descript.pathology Cancer;;ACTIVE;1.0m;2.40 +21904-8;Stager.pathology;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Stager.pathology Cancer;Stager.pathology Cancer;;ACTIVE;1.0m;2.27 +21905-5;Primary tumor.clinical;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Primary tumor.clinical [Class] Cancer;Primary tumor.clinical Cancer;;ACTIVE;1.0m;2.27 +21906-3;Regional lymph nodes.clinical;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Regional lymph nodes.clinical [Class] Cancer;Reg LN.clinical Cancer;;ACTIVE;1.0m;2.32 +2190-7;Dehydroepiandrosterone sulfate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Amniotic fluid;DHEA-S Amn-mCnc;;ACTIVE;1.0;2.42 +21907-1;Distant metastases.clinical;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Distant metastases.clinical [Class] Cancer;Distant metastases.clinical Cancer;;ACTIVE;1.0m;2.27 +21908-9;Stage group.clinical;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Stage group.clinical Cancer;Stg grp.clinical Cancer;;ACTIVE;1.0m;2.32 +21909-7;Descriptor.clinical;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Descriptor.clinical Cancer Narrative;Descript.clinical Cancer;;ACTIVE;1.0m;2.40 +21910-5;Stager.clinical;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Stager.clinical Cancer;Stager.clinical Cancer;;ACTIVE;1.0m;2.27 +21911-3;Primary tumor.other;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Primary tumor.other [Class] Cancer;Primary tumor.other Cancer;;ACTIVE;1.0m;2.27 +21912-1;Regional lymph nodes.other;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Regional lymph nodes.other [Class] Cancer;Reg LN.other Cancer;;ACTIVE;1.0m;2.32 +21913-9;Distant metastases.other;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Distant metastases.other [Class] Cancer;Distant metastases.other Cancer;;ACTIVE;1.0m;2.27 +21914-7;Stage group.other;Class;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Stage group.other Cancer;Stg grp.other Cancer;;ACTIVE;1.0m;2.32 +2191-5;Dehydroepiandrosterone sulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma;DHEA-S SerPl-mCnc;;ACTIVE;1.0;2.73 +21915-4;Stager.other;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Stager.other Cancer;Stager.other Cancer;;ACTIVE;1.0m;2.27 +21916-2;Descriptor.other;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Descriptor.other Cancer Narrative;Descript.other Cancer;;ACTIVE;1.0m;2.40 +21917-0;Version used;ID;Pt;TNM classification;Nom;;TUMRRGT;2;Version used [Identifier] TNM classification;Version TNM Classification;;ACTIVE;1.0m;2.32 +21918-8;Other staging classification;Class;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Other staging classification Cancer Narrative;Other staging classification Cancer;;ACTIVE;1.0m;2.40 +21919-6;Date 1st positive Bx;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st positive Bx Cancer;Date 1st positive Bx Cancer;;ACTIVE;1.0m;2.50 +21920-4;Site of distant metastasis;Anat;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Site of distant metastasis Cancer;Site of distant mets Cancer;;ACTIVE;1.0m;2.29 +21921-2;Pediatric stage;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Pediatric stage Cancer;Pediatric stage Cancer;;ACTIVE;1.0m;2.27 +21922-0;Coding system used;Prid;Pt;Cancer.XXX pediatric staging;Nom;;TUMRRGT;2;Coding system used Cancer pediatric staging;Coding sys used Cancer Ped stage;;ACTIVE;1.0m;2.32 +2192-3;Dehydroepiandrosterone sulfate;MRat;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/time] in 24 hour Urine;DHEA-S 24h Ur-mRate;;ACTIVE;1.0;2.73 +21923-8;Pediatric cancer stager;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Pediatric cancer stager;Pediatric cancer stager;;ACTIVE;1.0m;2.27 +21924-6;Tumor marker;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Tumor marker Cancer;Tumor marker Cancer;;ACTIVE;1.0m;2.73 +21925-3;Date 1st surgery treatment;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st surgery treatment Cancer;Date 1st surgery Cancer;;ACTIVE;1.0m;2.50 +21926-1;Date 1st radiation treatment;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st radiation treatment Cancer;Date 1st radiation Cancer;;ACTIVE;1.0m;2.50 +21927-9;Date 1st chemotherapy treatment;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st chemotherapy treatment Cancer;Date 1st chemo Cancer;;ACTIVE;1.0m;2.50 +21928-7;Date 1st hormone treatment;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st hormone treatment Cancer;Date 1st hormone Cancer;;ACTIVE;1.0m;2.50 +21929-5;Date 1st immunotherapy treatment;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st immunotherapy treatment Cancer;Date 1st BRM Cancer;;ACTIVE;1.0m;2.50 +21930-3;Date 1st other treatment;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st other treatment Cancer;Date 1st other Tx Cancer;;ACTIVE;1.0m;2.50 +2193-1;Dehydroepiandrosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma;DHEA SerPl-mCnc;;ACTIVE;1.0;2.73 +21931-1;Date 1st cancer Rx (any).SEERS;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st cancer treatment (any).SEERS;Date 1st cancer Rx (any).SEERS;;ACTIVE;1.0m;2.73 +21932-9;Date 1st cancer Rx (any).COC;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st cancer treatment (any).COC;Date 1st cancer Rx (any).COC;;ACTIVE;1.0m;2.50 +21933-7;Date non cancer directed surgery Rx as part of 1st cancer;Date;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date non cancer directed surgery treatment as part of 1st cancer;Date non CDS Rx as part of 1st cancer;;ACTIVE;1.0m;2.50 +21934-5;Surgery site.primary;Anat;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery site.primary Cancer;Surgery site.primary Cancer;;ACTIVE;1.0m;2.27 +21935-2;Surgery scope;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery scope Cancer;Surgery scope Cancer;;ACTIVE;1.0m;2.32 +21936-0;Surgery.other regional disease;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery.other regional disease Cancer;Surgery.other reg disease Cancer;;ACTIVE;1.0m;2.32 +21937-8;Surgery regional nodes examined;Num;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Surgery regional nodes examined [#] Cancer;Surgery reg nodes examined Cancer;;ACTIVE;1.0m;2.32 +21938-6;Surgical approach;Type;Pt;Surgical procedure;Nom;;TUMRRGT;2;Surgical approach;Surgical approach;;ACTIVE;1.0m;2.72 +21939-4;Surgical margins cancer involvement;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgical margins cancer involvement;Surg margins cancer invol;;ACTIVE;1.0m;2.29 +21940-2;Surgery reconstruction;Prid;Pt;Surgical procedure;Nom;;TUMRRGT;2;Surgery reconstruction;Surgery reconstruction;;ACTIVE;1.0m;2.72 +21941-0;Reason for no cancer directed surgery;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Reason for no cancer directed surgery;Reason for no CDS;;ACTIVE;1.0m;2.29 +21942-8;Non cancer directed surgery summary;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Non cancer directed surgery summary;Non CDS summary;;ACTIVE;1.0m;2.29 +21943-6;Radiation Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Radiation treatment Cancer;Radiation Rx Cancer;;ACTIVE;1.0m;2.29 +21944-4;Lung & leukemia CNS radiation status;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Lung and leukemia CNS radiation status Cancer;Lung/Leukemia CNS Rad status Cancer;;ACTIVE;1.0m;2.38 +21945-1;Surgery-radiation sequence;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery-radiation sequence Cancer;Surgery-radiation sequence Cancer;;ACTIVE;1.0m;2.29 +21946-9;Chemotherapy Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Chemotherapy treatment Cancer;Chemotherapy Rx Cancer;;ACTIVE;1.0m;2.29 +21947-7;Hormone Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Hormone treatment Cancer;Hormone Rx Cancer;;ACTIVE;1.0m;2.29 +21948-5;Biological response modifier Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Biological response modifier treatment Cancer;Biological response modifier Rx Cancer;;ACTIVE;1.0m;2.29 +2194-9;Dehydroepiandrosterone;PrThr;Pt;Urine;Ord;;CHEM;1;Dehydroepiandrosterone (DHEA) [Presence] in Urine;DHEA Ur Ql;;ACTIVE;1.0;2.73 +21949-3;Other Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Other treatment Cancer;Other Rx Cancer;;ACTIVE;1.0m;2.29 +21950-1;Reason for no radiation Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Reason for no radiation treatment Cancer;Reason for no radiation Rx Cancer;;ACTIVE;1.0m;2.29 +21951-9;Reason for no chemotherapy Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Reason for no chemotherapy treatment Cancer;Reason for no chemotherapy Rx Cancer;;ACTIVE;1.0m;2.29 +21952-7;Reason for no hormone Rx;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Reason for no hormone treatment Cancer;Reason for no hormone Rx Cancer;;ACTIVE;1.0m;2.29 +21953-5;Coding system for Rx;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Coding system for treatment [Identifier] Cancer;Coding sys for Rx Cancer;;ACTIVE;1.0m;2.27 +21954-3;Protocol eligibility status;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Protocol eligibility status Cancer;Protocol eligibility status Cancer;;ACTIVE;1.0m;2.29 +21955-0;Source of protocol in which patient enrolled;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Source of protocol in which patient enrolled Cancer;Source protocol patient enrolled Cancer;;ACTIVE;1.0m;2.29 +2195-6;Dehydroepiandrosterone;MCnc;Pt;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Urine;DHEA Ur-mCnc;;ACTIVE;1.0;2.73 +21956-8;Referred to support services;Arb;Pt;Cancer.XXX;Ord;;TUMRRGT;2;Referred to support services Cancer;Referred to support services Cancer;;ACTIVE;1.0m;2.27 +21957-6;Method for calculating time interval of 1st course of treatment;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Method for calculating time interval of first course of treatment;1st course calc method;;ACTIVE;1.0m;2.42 +21958-4;Regional radiation Rx;EngCnt;Pt;Dose;Qn;;TUMRRGT;2;Regional radiation treatment Dose;Reg radiation Rx Dose;;ACTIVE;1.0m;2.70 +21959-2;Number of radiation Rx;Num;Pt;Radiation.Rx;Qn;;TUMRRGT;2;Number of radiation treatment;# radiation Rx;;ACTIVE;1.0m;2.48 +219-6;Demeclocycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Demeclocycline [Susceptibility] by Serum bactericidal titer;Demeclocycline Titr SBT;;ACTIVE;1.0;2.32 +21960-0;Duration;Time;Episode^frst;Radiation.Rx;Qn;;TUMRRGT;2;Duration first episode Radiation treatment;Duration 1st episode Radiation Rx;;ACTIVE;1.0m;2.70 +21961-8;Organ target(s);Anat;Episode^frst;Radiation.Rx;Nom;;TUMRRGT;2;Organ target(s) First episode Radiation treatment;Organ target(s) 1st episode Radiation Rx;;ACTIVE;1.0m;2.32 +21962-6;Where performed;Type;Pt;Radiation.Rx;Nom;;TUMRRGT;2;Where performed Radiation treatment;Where performed Radiation Rx;;ACTIVE;1.0m;2.29 +21963-4;Curative intent of Rx;Type;Pt;Radiation.Rx;Nom;;TUMRRGT;2;Curative intent of treatment Radiation treatment;Intent of Rx Radiation Rx;;ACTIVE;1.0m;2.29 +2196-4;Dehydroepiandrosterone.unconjugated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA).unconjugated [Mass/volume] in Serum or Plasma;u DHEA SerPl-mCnc;;ACTIVE;1.0;2.73 +21964-2;Modality;Prid;Pt;Radiation.Rx;Nom;;TUMRRGT;2;Modality Radiation treatment;Modality Radiation Rx;;ACTIVE;1.0m;2.32 +21965-9;Completion status;Type;Pt;Radiation.Rx;Nom;;TUMRRGT;2;Completion status Radiation treatment;Completion status Radiation Rx;;ACTIVE;1.0m;2.29 +21966-7;Regional outcomes of;Type;Pt;Radiation.Rx;Nom;;TUMRRGT;2;Regional outcomes of Radiation treatment;Reg outcomes of Radiation Rx;;ACTIVE;1.0m;2.32 +21967-5;Chemotherapy;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Chemotherapy Cancer;Chemotherapy Cancer;;ACTIVE;1.0m;2.32 +21968-3;Surgery;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery Cancer;Surgery Cancer;;ACTIVE;1.0m;2.29 +21969-1;Dx &or stage;ID;Pt;Procedure;Nom;;TUMRRGT;2;Dx/Stage Procedure;Dx/Stage Procedure;;ACTIVE;1.0m;2.27 +21970-9;2nd course treatment start date;Date;Pt;Subsequent cancer Rx;Qn;;TUMRRGT;2;2nd course treatment start date Cancer Rx;2nd crs Tx start date Cancer Rx;;ACTIVE;1.0m;2.50 +21971-7;2nd course treatment;Type;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;2nd course treatment Cancer Rx;2nd course Tx Cancer Rx;;ACTIVE;1.0m;2.29 +2197-2;Dehydroepiandrosterone.unconjugated;MRat;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA).unconjugated [Mass/time] in 24 hour Urine;u DHEA 24h Ur-mRate;;ACTIVE;1.0;2.42 +21972-5;2nd course treatment.surgery.other regional disease;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;2nd course surgery.other regional disease Cancer;2nd crs Surg.other reg dis Cancer;;ACTIVE;1.0m;2.32 +21973-3;3rd course treatment;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;3rd course treatment Cancer Rx;3rd course Tx Cancer Rx;;ACTIVE;1.0m;2.32 +21974-1;Surgery reconstruction;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;Surgery reconstruction Cancer Rx;Surgery reconstruction Cancer Rx;;ACTIVE;1.0m;2.32 +21975-8;Date last contact;Date;Pt;^Patient;Qn;;TUMRRGT;2;Date last contact;Date last contact;;ACTIVE;1.0m;2.50 +21976-6;Cancer outcome status;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Cancer outcome status;Cancer outcome status;;ACTIVE;1.0m;2.29 +21977-4;Survival quality;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Survival quality Cancer;Survival quality Cancer;;ACTIVE;1.0m;2.29 +21978-2;Source of follow-up information;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Source of follow-up information Cancer;Source follow-up info Cancer;;ACTIVE;1.0m;2.29 +21979-0;Planned &or next follow-up;Type;Pt;^Patient;Nom;;TUMRRGT;2;Planned/next follow-up;Planned/next follow-up;;ACTIVE;1.0m;2.29 +2198-0;Delta aminolevulinate;MCnc;Pt;Plas;Qn;;CHEM;1;Delta aminolevulinate [Mass/volume] in Plasma;D-ALA Plas-mCnc;;ACTIVE;1.0;2.42 +21980-8;Other follow-up method;Type;Pt;^Patient;Nar;;TUMRRGT;2;Other follow-up method Narrative;Other follow-up method;;ACTIVE;1.0m;2.40 +21981-6;Recurrence date;Date;Episode^frst;Cancer.XXX;Qn;;TUMRRGT;2;Recurrence date first episode Cancer;Recur date 1st episode Cancer;;ACTIVE;1.0m;2.50 +21982-4;Recurrence distant site(s);Anat;Episode^frst;Cancer.XXX;Nom;;TUMRRGT;2;Recurrence distant site(s) first episode Cancer;Recur distant site(s) 1st episode Cancer;;ACTIVE;1.0m;2.32 +21983-2;Recurrence type;Type;Episode^frst;Cancer.XXX;Nom;;TUMRRGT;2;Recurrence type first episode Cancer;Recur type 1st episode Cancer;;ACTIVE;1.0m;2.32 +21984-0;Cause of death;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Deprecated Cause of death;Deprecated Cause of death;;DEPRECATED;1.0m;2.54 +21985-7;ICD revision number;ID;Pt;Cause of death;Nom;;TUMRRGT;2;ICD revision number [Identifier] Cause of death;ICD revision # Cause of Death;;ACTIVE;1.0m;2.27 +21986-5;Autopsy status;Type;Pt;^Patient;Nom;;TUMRRGT;2;Autopsy status;Autopsy status;;ACTIVE;1.0m;2.29 +21987-3;Geographic place of death;Type;Pt;^Patient;Nom;;TUMRRGT;2;Geographic place of death;Geographic place of death;;ACTIVE;1.0m;2.29 +21988-1;Site.ICD-O-1;Anat;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Site.ICD-O-1 Cancer;Site.ICD-O-1 Cancer;;ACTIVE;1.0m;2.27 +21989-9;Morphology.ICD-O-1;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Morphology.ICD-O-1 Cancer;Morphology.ICD-O-1 Cancer;;ACTIVE;1.0m;2.32 +21990-7;ICD-O-1 to ICD-O-2 conversion method;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;ICD-O-1 to ICD-O-2 conversion method;ICD-O-1 to ICD-O-2 conversion method;;ACTIVE;1.0m;2.42 +21991-5;Age&site&morphology override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Age and Site and Morphology override flag Cancer case;Age/Site/Morph O/R Cancer case;;ACTIVE;1.0m;2.38 +21992-3;Sequence number&diagnosis confirm override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Sequence numberanddiagnosis confirm override flag Cancer case;Seq #/Dx confirm O/R Cancer case;;ACTIVE;1.0m;2.38 +21993-1;Site&laterality&sequence number override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Site and laterality and sequence number override flag Cancer case;Site/lat/seq # O/R Cancer case;;ACTIVE;1.0m;2.38 +21994-9;Surgery&diagnosis confirm override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Surgery and diagnosis confirm override flag Cancer case;Surgery/Dx confirm O/R Cancer case;;ACTIVE;1.0m;2.38 +21995-6;Site&type override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Siteandtype override flag Cancer case;Site/type O/R Cancer case;;ACTIVE;1.0m;2.38 +21996-4;Histology override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Histology override flag Cancer case;Histology O/R Cancer case;;ACTIVE;1.0m;2.27 +21997-2;Report source override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Report source override flag Cancer case;Report source O/R Cancer case;;ACTIVE;1.0m;2.27 +2199-8;Delta aminolevulinate;MCnc;Pt;Ser;Qn;;CHEM;1;Delta aminolevulinate [Mass/volume] in Serum;D-ALA Ser-mCnc;;ACTIVE;1.0;2.42 +21998-0;Ill defined site override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Ill defined site override flag Cancer case;Ill defined site O/R Cancer case;;ACTIVE;1.0m;2.27 +21999-8;Leukemia & lymphoma override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Leukemia and lymphoma override flag Cancer case;Leukemia/Lymphoma O/R Cancer case;;ACTIVE;1.0m;2.38 +22000-4;Site & behavior override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Site and behavior override flag Cancer case;Site/Behavior O/R Cancer case;;ACTIVE;1.0m;2.38 +22001-2;Site & extent of disease & diagnosis date override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Site and extent of disease and diagnosis date override flag Cancer case;Site/EOD/Dx date O/R Cancer case;;ACTIVE;1.0m;2.38 +22002-0;Site & laterality & extent of disease override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Site and laterality and extent of disease override flag Cancer case;Site/Lat/EOD O/R Cancer case;;ACTIVE;1.0m;2.38 +22003-8;Site & laterality & morphology override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Site and laterality and morphology override flag Cancer case;Site/lat/morph O/R Cancer case;;ACTIVE;1.0m;2.38 +2200-4;Delta aminolevulinate;MRat;24H;Urine;Qn;;CHEM;1;Delta aminolevulinate [Mass/time] in 24 hour Urine;D-ALA 24h Ur-mRate;;ACTIVE;1.0;2.73 +22004-6;CRC checksum;Num;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;CRC checksum;CRC checksum;;ACTIVE;1.0m;2.32 +22005-3;Date case completed;Date;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date case completed Cancer case;Date case completed Cancer case;;ACTIVE;1.0m;2.50 +22006-1;Date case last changed;Date;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date case last changed Cancer case;Date case last changed Cancer case;;ACTIVE;1.0m;2.50 +22007-9;Date case report exported;Date;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date case report exported Cancer case;Date case report exported Cancer case;;ACTIVE;1.0m;2.50 +22008-7;Date case report received;Date;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date case report received Cancer case;Date case report received Cancer case;;ACTIVE;1.0m;2.50 +22009-5;Date case report loaded;Date;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date case report loaded Cancer case;Date case report loaded Cancer case;;ACTIVE;1.0m;2.50 +22010-3;Date tumor record available;TmStp;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date tumor record available Cancer case;Date tumor record available Cancer case;;ACTIVE;1.0m;2.27 +22011-1;Coding system.current.SEER;ID;Pt;Cancer registry;Nom;;TUMRRGT;2;Coding system.current.SEER [Identifier] Cancer registry;Coding sys.current.SEER Cancer Registry;;ACTIVE;1.0m;2.27 +2201-2;Deoxycholate;MCnc;Pt;Ser;Qn;;CHEM;1;Deoxycholate [Mass/volume] in Serum;DO-cholate Ser-mCnc;;DISCOURAGED;1.0;2.73 +22012-9;Coding system.original.SEER;ID;Pt;Cancer registry;Nom;;TUMRRGT;2;Coding system.original.SEER [Identifier] Cancer registry;Coding sys.original.SEER Cancer Registry;;ACTIVE;1.0m;2.27 +22013-7;Coding system.current.COC;ID;Pt;Cancer registry;Nom;;TUMRRGT;2;Coding system.current. Commission on Cancer (COC) [Identifier] Cancer registry;Coding sys.current.COC Cancer Registry;;ACTIVE;1.0m;2.27 +22014-5;Coding system.original.COC;ID;Pt;Cancer registry;Nom;;TUMRRGT;2;Coding system.original.Commission on Cancer (COC) [Identifier] Cancer registry;Coding sys.original.COC Cancer Registry;;ACTIVE;1.0m;2.27 +22015-2;Follow-up expectation;Type;Pt;Cancer case.XXX;Nom;;TUMRRGT;2;Follow-up expectation Cancer case;Follow-up expectation Cancer case;;ACTIVE;1.0m;2.29 +22016-0;SEER record number;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;SEER record number Cancer case;SEER record # Cancer case;;ACTIVE;1.0m;2.27 +22017-8;State defined narrative;Find;Pt;^Patient;Nar;;TUMRRGT;2;State defined narrative Narrative;State defined narrative;;ACTIVE;1.0m;2.40 +22018-6;Military patient number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Military patient number;Military patient #;;ACTIVE;1.0m;2.66 +22019-4;Death certificate number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Death certificate number;Death certificate #;;ACTIVE;1.0m;2.66 +2202-0;Deoxycholylglycine;MCnc;Pt;Ser;Qn;;CHEM;1;Deoxycholylglycine [Mass/volume] in Serum;DO-cholylgly Ser-mCnc;;ACTIVE;1.0;2.34 +22020-2;Maiden name;Pn;Pt;^Patient;Nom;;TUMRRGT;2;Patient maiden name;Patient maiden name;;ACTIVE;1.0m;2.73 +22021-0;Institution referred from;ID;Pt;Cancer registry;Nom;;ADMIN.ID;2;Institution referred from Cancer registry;Inst referred from Cancer Registry;;ACTIVE;1.0m;2.66 +22022-8;Institution referred to;ID;Pt;Cancer registry;Nom;;ADMIN.ID;2;Institution referred to Cancer registry;Inst referred to Cancer Registry;;ACTIVE;1.0m;2.66 +22023-6;Last follow-up hospital;ID;Pt;Cancer registry;Nom;;ADMIN.ID;2;Last follow-up hospital [Identifier] Cancer registry;Last follow-up hospital Cancer Registry;;ACTIVE;1.0n;2.66 +22024-4;Following registry;ID;Pt;Cancer registry;Nom;;ADMIN.ID;2;Following registry [Identifier] Cancer registry;Following registry Cancer Registry;;ACTIVE;1.0n;2.66 +22025-1;Physician managing;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Physician managing [Identifier];Physician managing;;ACTIVE;1.0n;2.66 +22026-9;Physician follow up;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Physician follow up [Identifier];Physician follow up;;ACTIVE;1.0n;2.66 +22027-7;Surgeon primary;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Surgeon primary [Identifier];Surgeon primary;;ACTIVE;1.0n;2.66 +22028-5;Physician;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Physician [Identifier];Physician;;ACTIVE;1.0n;2.73 +22029-3;Physical exam.total;Find;Pt;^Patient;Nar;;TUMRRGT;2;Physical exam Narrative;Physical exam.total;;ACTIVE;1.0n;2.63 +22030-1;Xray/Scan.total;Find;Pt;^Patient;Nar;;TUMRRGT;2;Xray/Scan.total Narrative;Xray/Scan.total;;ACTIVE;1.0n;2.40 +22031-9;Scopic exam.total;Find;Pt;^Patient;Nar;;TUMRRGT;2;Scopic exam Narrative;Scopic exam.total;;ACTIVE;1.0n;2.40 +22032-7;Lab tests.total;Find;Pt;^Patient;Nar;;TUMRRGT;2;Lab tests Narrative;Lab tests.total;;ACTIVE;1.0n;2.40 +22033-5;Operations (?).total;Find;Pt;^Patient;Nar;;TUMRRGT;2;Operations (?).total Narrative;Operations (?).total;;ACTIVE;1.0n;2.40 +22034-3;Pathology report.total;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Pathology report Cancer Narrative;Path report.total Cancer;;ACTIVE;1.0n;2.40 +22035-0;Primary site;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Primary site Cancer Narrative;Primary site Cancer;;ACTIVE;1.0n;2.73 +22036-8;Histology;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Histology Cancer Narrative;Histology Cancer;;ACTIVE;1.0n;2.40 +22037-6;Staging;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Staging Cancer Narrative;Staging Cancer;;ACTIVE;1.0n;2.40 +2203-8;Dermatan sulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dermatan sulfate [Mass/volume] in Serum or Plasma;Dermatan Sulfate SerPl-mCnc;;ACTIVE;1.0;2.34 +22038-4;Surgery Rx;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Surgery treatment Cancer Narrative;Surgery Rx Cancer;;ACTIVE;1.0n;2.40 +22039-2;Radiation beam Rx;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Radiation beam treatment Cancer Narrative;Radiation beam Rx Cancer;;ACTIVE;1.0n;2.40 +220-4;Dicloxacillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Dicloxacillin [Susceptibility] by Minimum lethal concentration (MLC);Dicloxacillin Islt MLC;;ACTIVE;1.0;2.19 +22040-0;Radiation other Rx;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Radiation other treatment Cancer Narrative;Radiation other Rx Cancer;;ACTIVE;1.0n;2.40 +22041-8;Chemotherapy Rx;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Chemotherapy treatment Cancer Narrative;Chemotherapy Rx Cancer;;ACTIVE;1.0n;2.40 +22042-6;Hormone Rx;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Hormone treatment Cancer Narrative;Hormone Rx Cancer;;ACTIVE;1.0n;2.40 +22043-4;Transplant Rx;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Transplant treatment Cancer Narrative;Transplant Rx Cancer;;ACTIVE;1.0n;2.40 +22044-2;Other Rx;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Other treatment Cancer Narrative;Other Rx Cancer;;ACTIVE;1.0n;2.40 +22045-9;Remarks recorded;Find;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Remarks recorded Cancer Narrative;Remarks recorded Cancer;;ACTIVE;1.0n;2.73 +2204-6;Dermatan sulfate;MCnc;Pt;Urine;Qn;;CHEM;1;Dermatan sulfate [Mass/volume] in Urine;Dermatan Sulfate Ur-mCnc;;ACTIVE;1.0;2.34 +22046-7;Place of 1st Dx;Loc;Pt;Cancer.XXX;Nar;;TUMRRGT;2;Place of 1st Dx [Location] Cancer Narrative;Place of 1st Dx Cancer;;ACTIVE;1.0n;2.40 +22047-5;Record ID battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Record ID battery;DeprecatedRecord ID battery;;DEPRECATED;1.0n;2.66 +22048-3;Patient demographics battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Patient demographics battery;DeprecatedPatient demographics battery;;DEPRECATED;1.0n;2.66 +22049-1;Cancer identification battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Cancer identification battery;DeprecatedCancer identification battery;;DEPRECATED;1.0n;2.66 +22050-9;Hospital specific battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Hospital specific battery;DeprecatedHospital specific battery;;DEPRECATED;1.0n;2.66 +22051-7;State & prognostic factors battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated State & prognostic factors battery;DeprecatedState & prognostic factors bat;;DEPRECATED;1.0n;2.66 +22052-5;Treatment battery.first;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Treatment battery.first;DeprecatedTreatment battery.first;;DEPRECATED;1.0n;2.66 +2205-3;Diacetate;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Diacetate [Mass/volume] in Serum;Deprecated Diacetate Ser-mCnc;;DEPRECATED;1.0;2.34 +22053-3;Treatment battery.subsequent;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Treatment battery.subsequent;DeprecatedTreatment battery.subsequent;;DEPRECATED;1.0n;2.66 +22054-1;Followup&recurrent&death battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Followup&recurrent&death battery;DeprecatedFollowup&recurrent&death batte;;DEPRECATED;1.0n;2.66 +22055-8;Overrides&conversion&system administration battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Overrides&conversion&system administration battery [Complex] Multi;Deprecated Overrides&conv&system adminis;;DEPRECATED;1.0n;2.66 +22056-6;Special use battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Special use battery;DeprecatedSpecial use battery;;DEPRECATED;1.0n;2.66 +22057-4;Patient confidential battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Patient confidential battery [Complex] Multi;Deprecated Patient confidential battery;;DEPRECATED;1.0n;2.66 +22058-2;Hospital confidential battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Hospital confidential battery;DeprecatedHospital confidential battery;;DEPRECATED;1.0n;2.66 +22059-0;Other confidential battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Other confidential battery;DeprecatedOther confidential battery;;DEPRECATED;1.0n;2.66 +22060-8;Text diagnosis battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Text diagnosis battery;DeprecatedText diagnosis battery;;DEPRECATED;1.0n;2.66 +2206-1;Dicarboxylate C6-C8-C10;MCnc;Pt;Ser;Qn;;CHEM;1;Dicarboxylate, C6-C8-C10 [Mass/volume] in Serum;Dicarboxy C6-C8-C10 Ser-mCnc;;ACTIVE;1.0;2.34 +22061-6;Text treatment battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Text treatment battery;DeprecatedText treatment battery;;DEPRECATED;1.0n;2.66 +22062-4;Text miscellaneous battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Text miscellaneous battery;DeprecatedText miscellaneous battery;;DEPRECATED;1.0n;2.66 +22063-2;Correction comments battery;Cmplx;Pt;-;Multi;;TUMRRGT;2;Deprecated Correction comments battery [Complex] Multi;Deprecated Correction comments battery;;DEPRECATED;1.0n;2.66 +22064-0;Alpha 1 globulin;MCnc;Pt;Urine;Qn;;CHEM;1;Alpha 1 globulin [Mass/volume] in Urine;Alpha1 Glob Ur-mCnc;;ACTIVE;1.0n;2.73 +22065-7;Propoxyphene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Propoxyphene [Mass/volume] in Urine;Deprecated Propoxyph Ur-mCnc;;DEPRECATED;1.0n;2.70 +22066-5;PRSS1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PRSS1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;PRSS1 gene Mut Tested Bld/T;;ACTIVE;1.0n;2.13 +22067-3;NB gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NB gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;NB gene Mut Tested Bld/T;;ACTIVE;1.0n;2.13 +22068-1;MXI1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MXI1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MXI1 gene Mut Tested Bld/T;;ACTIVE;1.0n;2.27 +22069-9;MT-ATP6 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MT-ATP6 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MT-ATP6 gene Mut Tested Bld/T;;ACTIVE;1.0n;2.34 +22070-7;Hereditary pancreatitis gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HP gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HP gene Mut Anl Bld/T;;ACTIVE;1.0n;2.73 +22071-5;Gauchers disease type 3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gaucher 3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Gau3 gene Mut Anl Bld/T;;ACTIVE;1.0n;2.63 +22072-3;Gauchers disease type 2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gaucher 2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Gau2 gene Mut Anl Bld/T;;ACTIVE;1.0n;2.63 +22073-1;Gauchers disease type 1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gaucher 1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Gau1 gene Mut Anl Bld/T;;ACTIVE;1.0n;2.63 +22074-9;FGFR3 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGFR3 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;FGFR3 gene Mut Tested Bld/T;;ACTIVE;1.0n;2.13 +22075-6;DMD gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DMD gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;DMD gene Mut Tested Bld/T;;ACTIVE;1.0n;2.13 +22076-4;CMKBR5 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated CCR5 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;Deprecated CMKBR5 gene Mut Tested Bld/T;;DEPRECATED;1.0n;2.36 +22077-2;Acanthamoeba sp Ab;PrThr;Pt;Crn;Ord;;MICRO;1;Acanthamoeba sp Ab [Presence] in Cornea;Acanthamoeba Ab Crn Ql;;ACTIVE;1.0n;2.56 +22078-0;Acanthamoeba sp Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Acanthamoeba sp Ab [Presence] in Cerebral spinal fluid;Acanthamoeba Ab CSF Ql;;ACTIVE;1.0n;2.56 +2207-9;Dicarboxylate C6-C8-C10;MCnc;Pt;Urine;Qn;;CHEM;1;Dicarboxylate, C6-C8-C10 [Mass/volume] in Urine;Dicarboxy C6-C8-C10 Ur-mCnc;;ACTIVE;1.0;2.34 +22079-8;Actinomyces sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Actinomyces sp Ab [Titer] in Serum;Actinomyces Ab Titr Ser;;ACTIVE;1.0n;2.70 +22080-6;Adenovirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Adenovirus Ab [Titer] in Serum;HAdV Ab Titr Ser;;ACTIVE;1.0n;2.73 +22081-4;Afipia felis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Afipia felis IgG Ab [Titer] in Serum;A felis IgG Titr Ser;;ACTIVE;1.0n;2.70 +22082-2;Afipia felis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Afipia felis IgM Ab [Titer] in Serum;A felis IgM Titr Ser;;ACTIVE;1.0n;2.70 +22083-0;Alcelaphine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Alcelaphine herpesvirus 1 Ab [Presence] in Serum;AHV1 Ab Ser Ql;;ACTIVE;1.0n;2.67 +22084-8;Anaplasma marginale Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Anaplasma marginale Ab [Presence] in Serum;A marginale Ab Ser Ql;;ACTIVE;1.0n;2.56 +22085-5;Aspergillus fumigatus 3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus 3 Ab [Presence] in Serum;A fumigatus3 Ab Ser Ql;;ACTIVE;1.0n;2.73 +22086-3;Aspergillus niger Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus niger Ab [Presence] in Serum;A niger Ab Ser Ql;;ACTIVE;1.0n;2.73 +2208-7;Diethyl ether;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diethyl ether [Mass/volume] in Serum or Plasma;Diethyl Ether SerPl-mCnc;;ACTIVE;1.0;2.73 +22087-1;Aspergillus sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Aspergillus sp Ab [Titer] in Serum;Aspergillus Ab Titr Ser;;ACTIVE;1.0n;2.70 +22088-9;Avian adenovirus 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian adenovirus 2 Ab [Presence] in Serum;FAdV2 Ab Ser Ql;;ACTIVE;1.0n;2.67 +22089-7;Avian adenovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian adenovirus Ab [Presence] in Serum;FAdV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22090-5;Avian encephalomyelitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian encephalomyelitis virus Ab [Presence] in Serum;AEV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22091-3;Avian hemorrhagic enteritis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian hemorrhagic enteritis virus Ab [Presence] in Serum;AAV2 Ab Ser Ql;;ACTIVE;1.0n;2.67 +22092-1;Infectious bronchitis virus Ark-99 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Ark-99 Ab [Titer] in Serum;IBV Ark99 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22093-9;Infectious bronchitis virus Conn-42 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Conn-42 Ab [Titer] in Serum;IBV Conn42 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22094-7;Infectious bronchitis virus Mass-41 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Mass-41 Ab [Titer] in Serum;IBV Mass41 Ab Titr Ser;;ACTIVE;1.0n;2.70 +2209-5;Dihydrofolate;MCnc;Pt;Ser;Qn;;CHEM;1;Dihydrofolate [Mass/volume] in Serum;Dihydrofolate Ser-mCnc;;ACTIVE;1.0;2.34 +22095-4;Avian infectious laryngotracheitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian infectious laryngotracheitis virus Ab [Presence] in Serum;ILT Ab Ser Ql;;ACTIVE;1.0n;2.56 +22096-2;Influenza virus A Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A Ab [Presence] in Serum;FLUAV Ab Ser Ql;;ACTIVE;1.0n;2.73 +22097-0;Avian paramyxovirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian paramyxovirus 1 Ab [Presence] in Serum;APMV1 Ab Ser Ql;;ACTIVE;1.0n;2.67 +22098-8;Avian paramyxovirus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 1 Ab [Titer] in Serum;APMV1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22099-6;Avian paramyxovirus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 2 Ab [Titer] in Serum;APMV2 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22100-2;Avian paramyxovirus 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 3 Ab [Titer] in Serum;APMV3 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22101-0;Avian pox virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian pox virus Ab [Presence] in Serum;FWPV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22102-8;Avian reovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian reovirus Ab [Presence] in Serum;AVREOV Ab Ser Ql;;ACTIVE;1.0n;2.56 +2210-3;Dihydrolipoamide acetyl transferase;CCnt;Pt;Tiss;Qn;;CHEM;1;Dihydrolipoamide acetyl transferase [Enzymatic activity/mass] in Tissue;DL AcT Tiss-cCnt;;ACTIVE;1.0;2.42 +22103-6;Reticuloendotheliosis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Reticuloendotheliosis virus Ab [Presence] in Serum;REV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22104-4;Babesia caballi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia caballi Ab [Presence] in Serum;B caballi Ab Ser Ql;;ACTIVE;1.0n;2.67 +22105-1;Theileria equi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Theileria equi Ab [Presence] in Serum;T equi Ab Ser Ql;;ACTIVE;1.0n;2.67 +22106-9;Babesia sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Babesia sp Ab [Titer] in Serum;Babesia Ab Titr Ser;;ACTIVE;1.0n;2.70 +22107-7;Babesia sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Babesia sp IgG Ab [Titer] in Serum;Babesia IgG Titr Ser;;ACTIVE;1.0n;2.70 +22108-5;Babesia sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Babesia sp IgM Ab [Units/volume] in Serum;Babesia IgM Ser-aCnc;;ACTIVE;1.0n;2.69 +22109-3;Bacillus anthracis Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Bacillus anthracis Ab [Units/volume] in Specimen;B anthracis Ab Spec-aCnc;;ACTIVE;1.0n;2.69 +22110-1;Bartonella henselae Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella henselae IgG Ab [Titer] in Serum;B henselae IgG Titr Ser;;ACTIVE;1.0n;2.73 +2211-1;Dihydrolipoamide dehydrogenase;CCnt;Pt;Tiss;Qn;;CHEM;1;Dihydrolipoamide dehydrogenase [Enzymatic activity/mass] in Tissue;DL Dehydrog Tiss-cCnt;;ACTIVE;1.0;2.42 +22111-9;Bartonella henselae Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella henselae IgM Ab [Titer] in Serum;B henselae IgM Titr Ser;;ACTIVE;1.0n;2.73 +22112-7;Blastomyces dermatitidis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Blastomyces dermatitidis Ab [Titer] in Serum;B dermat Ab Titr Ser;;ACTIVE;1.0n;2.73 +22113-5;Bluetongue virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bluetongue virus Ab [Presence] in Serum;BTV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22114-3;Bordetella avium Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella avium Ab [Presence] in Serum;B avium Ab Ser Ql;;ACTIVE;1.0n;2.67 +22115-0;Bordetella avium Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bordetella avium Ab [Titer] in Serum;B avium Ab Titr Ser;;ACTIVE;1.0n;2.70 +22116-8;Bordetella pertussis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis Ab [Titer] in Serum;B pert Ab Titr Ser;;ACTIVE;1.0n;2.70 +22117-6;Bordetella pertussis Ab;Titr;Pt;XXX;Qn;;MICRO;1;Bordetella pertussis Ab [Titer] in Specimen;B pert Ab Titr Spec;;ACTIVE;1.0n;2.70 +22118-4;Borrelia burgdorferi Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid;B burgdor Ab CSF Ql;;ACTIVE;1.0n;2.73 +22119-2;Borrelia burgdorferi Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Cerebral spinal fluid;B burgdor Ab CSF-aCnc;;ACTIVE;1.0n;2.73 +221-2;Dicloxacillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Dicloxacillin [Susceptibility] by Minimum inhibitory concentration (MIC);Dicloxacillin Islt MIC;;ACTIVE;1.0;2.19 +22120-0;Borrelia burgdorferi Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Body fluid;B burgdor Ab Fld-aCnc;;ACTIVE;1.0n;2.73 +22121-8;Borrelia burgdorferi Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Serum;B burgdor Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22122-6;Borrelia burgdorferi Ab;Titr;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi Ab [Titer] in Serum;B burgdor Ab Titr Ser;;ACTIVE;1.0n;2.70 +22123-4;Borrelia burgdorferi Ab.IgA;PrThr;Pt;CSF;Ord;;MICRO;1;Borrelia burgdorferi IgA Ab [Presence] in Cerebral spinal fluid;B burgdor IgA CSF Ql;;ACTIVE;1.0n;2.56 +22124-2;Borrelia burgdorferi Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia burgdorferi IgA Ab [Presence] in Serum;B burgdor IgA Ser Ql;;ACTIVE;1.0n;2.56 +22125-9;Borrelia burgdorferi Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Cerebral spinal fluid;B burgdor IgG CSF Ql;;ACTIVE;1.0n;2.56 +22126-7;Borrelia burgdorferi Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid;B burgdor IgG CSF-aCnc;;ACTIVE;1.0n;2.73 +22127-5;Borrelia burgdorferi Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Borrelia burgdorferi IgG Ab [Units/volume] in Body fluid;B burgdor IgG Fld-aCnc;;ACTIVE;1.0n;2.69 +22128-3;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Serum;B burgdor IgG Ser Ql;;ACTIVE;1.0n;2.73 +2212-9;Dihydropteridine reductase;CCnc;Pt;Ser;Qn;;CHEM;1;Dihydropteridine reductase [Enzymatic activity/volume] in Serum;DHP Reduct Ser-cCnc;;ACTIVE;1.0;2.68 +22129-1;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Synv fld;Ord;;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Synovial fluid;B burgdor IgG Snv Ql;;ACTIVE;1.0n;2.56 +22130-9;Borrelia burgdorferi Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi IgG Ab [Titer] in Serum;B burgdor IgG Titr Ser;;ACTIVE;1.0n;2.70 +22131-7;Borrelia burgdorferi Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia burgdorferi IgG+IgM Ab [Presence] in Serum;B burgdor IgG+IgM Ser Ql;;ACTIVE;1.0n;2.73 +22132-5;Borrelia burgdorferi Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Cerebral spinal fluid;B burgdor IgM CSF Ql;;ACTIVE;1.0n;2.56 +22133-3;Borrelia burgdorferi Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid;B burgdor IgM CSF-aCnc;;ACTIVE;1.0n;2.73 +22134-1;Borrelia burgdorferi Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Body fluid;B burgdor IgM Fld-aCnc;;ACTIVE;1.0n;2.69 +22135-8;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Serum;B burgdor IgM Ser Ql;;ACTIVE;1.0n;2.73 +22136-6;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Synv fld;Ord;;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Synovial fluid;B burgdor IgM Snv Ql;;ACTIVE;1.0n;2.56 +2213-7;Dimethadione;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dimethadione [Mass/volume] in Serum or Plasma;DMO SerPl-mCnc;;ACTIVE;1.0;2.73 +22137-4;Borrelia burgdorferi Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi IgM Ab [Titer] in Serum;B burgdor IgM Titr Ser;;ACTIVE;1.0n;2.70 +22138-2;Borrelia hermsii Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Borrelia hermsii IgG Ab [Titer] in Serum;B hermsii IgG Titr Ser;;ACTIVE;1.0n;2.70 +22139-0;Borrelia hermsii Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Borrelia hermsii IgM Ab [Titer] in Serum;B hermsii IgM Titr Ser;;ACTIVE;1.0n;2.70 +22140-8;Bovine diarrhea virus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bovine diarrhea virus 1 Ab [Titer] in Serum;BVDV1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22141-6;Bovine diarrhea virus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bovine diarrhea virus 2 Ab [Titer] in Serum;BVDV2 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22142-4;Bovine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bovine herpesvirus 1 Ab [Presence] in Serum;BoHV1 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22143-2;Bovine herpesvirus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bovine herpesvirus 1 Ab [Titer] in Serum;BoHV1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22144-0;Bovine leukemia virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bovine leukemia virus Ab [Presence] in Serum;BLV Ab Ser Ql;;ACTIVE;1.0n;2.67 +2214-5;Dinitrobenzene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dinitrobenzene [Mass/volume] in Urine;Dinitrobenz Ur-mCnc;;ACTIVE;1.0;2.42 +22145-7;Bovine leukosis virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Bovine leukemia virus Ab [Presence] in Serum;Deprecated BLV Ab Ser Ql;;DEPRECATED;1.0n;2.67 +22146-5;Brucella abortus Ab;PrThr;Pt;Milk;Ord;;MICRO;1;Brucella abortus Ab [Presence] in Milk;B abortus Ab Mlk Ql;;ACTIVE;1.0n;2.67 +22147-3;Brucella abortus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella abortus Ab [Presence] in Serum;B abortus Ab Ser Ql;;ACTIVE;1.0n;2.56 +22148-1;Brucella abortus Ab;PrThr;Pt;Semen;Ord;;MICRO;1;Brucella abortus Ab [Presence] in Semen;B abortus Ab Smn Ql;;ACTIVE;1.0n;2.67 +22149-9;Brucella abortus Ab;PrThr;Pt;Whey;Ord;;MICRO;1;Brucella abortus Ab [Presence] in Whey;B abortus Ab whey Ql;;ACTIVE;1.0n;2.67 +22150-7;Brucella abortus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Brucella abortus Ab [Titer] in Serum;B abortus Ab Titr Ser;;ACTIVE;1.0n;2.70 +22151-5;Brucella abortus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella abortus IgM Ab [Units/volume] in Serum;B abortus IgM Ser-aCnc;;ACTIVE;1.0n;2.73 +2215-2;Dipalmitoylphosphatidylcholine;MCnc;Pt;Ser;Qn;;CHEM;1;Dipalmitoylphosphatidylcholine [Mass/volume] in Serum;DPPC Ser-mCnc;;ACTIVE;1.0;2.34 +22152-3;Brucella canis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Brucella canis Ab [Titer] in Serum;B canis Ab Titr Ser;;ACTIVE;1.0n;2.70 +22153-1;Brucella canis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella canis IgG Ab [Units/volume] in Serum;B canis IgG Ser-aCnc;;ACTIVE;1.0n;2.69 +22154-9;Brucella canis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Brucella canis IgG Ab [Titer] in Serum;B canis IgG Titr Ser;;ACTIVE;1.0n;2.70 +22155-6;Brucella canis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella canis IgM Ab [Units/volume] in Serum;B canis IgM Ser-aCnc;;ACTIVE;1.0n;2.69 +22156-4;Brucella canis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Brucella canis IgM Ab [Titer] in Serum;B canis IgM Titr Ser;;ACTIVE;1.0n;2.70 +22157-2;Brucella melitensis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Brucella melitensis Ab [Titer] in Serum;B melitensis Ab Titr Ser;;ACTIVE;1.0n;2.70 +22158-0;Brucella ovis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella ovis Ab [Presence] in Serum;B ovis Ab Ser Ql;;ACTIVE;1.0n;2.67 +22159-8;Brucella sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Brucella sp Ab [Titer] in Serum;Brucella Ab Titr Ser;;ACTIVE;1.0n;2.73 +2216-0;DOPamine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;DOPamine [Mass/volume] in Serum or Plasma;DOPamine SerPl-mCnc;;ACTIVE;1.0;2.73 +22160-6;Brucella suis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Brucella suis Ab [Titer] in Serum;B suis Ab Titr Ser;;ACTIVE;1.0n;2.70 +22161-4;Cache valley virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Cache valley virus Ab [Presence] in Serum;CVV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22162-2;Candida albicans Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Candida albicans Ab [Presence] in Serum;C albicans Ab Ser Ql;;ACTIVE;1.0n;2.73 +22163-0;Candida albicans Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Candida albicans Ab [Units/volume] in Serum;C albicans Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22164-8;Caprine arthritis encephalitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Caprine arthritis encephalitis virus Ab [Presence] in Serum;CAEV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22165-5;Caprine arthritis encephalitis virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Caprine arthritis encephalitis virus Ab [Presence] in Serum;Deprecated CAEV Ab Ser Ql;;DEPRECATED;1.0n;2.67 +22166-3;Caprine parapoxvirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Caprine parapoxvirus Ab [Presence] in Serum;Caprine Parapox Ab Ser Ql;;ACTIVE;1.0n;2.67 +22167-1;Caprine parapoxvirus Ab;PrThr;Pt;Tiss;Ord;;MICRO;1;Caprine parapoxvirus Ab [Presence] in Tissue;Caprine Parapox Ab Tiss Ql;;ACTIVE;1.0n;2.67 +22168-9;Chicken anemia virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chicken anemia virus Ab [Presence] in Serum;CAV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22169-7;Chlamydophila pneumoniae Ab.IgA;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydophila pneumoniae IgA Ab [Titer] in Cerebral spinal fluid;C pneum IgA Titr CSF;;ACTIVE;1.0n;2.70 +22170-5;Chlamydophila pneumoniae Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae IgA Ab [Titer] in Serum;C pneum IgA Titr Ser;;ACTIVE;1.0n;2.73 +22171-3;Chlamydophila pneumoniae Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydophila pneumoniae IgG Ab [Titer] in Cerebral spinal fluid;C pneum IgG Titr CSF;;ACTIVE;1.0n;2.70 +22172-1;Chlamydophila pneumoniae Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae IgG Ab [Titer] in Serum;C pneum IgG Titr Ser;;ACTIVE;1.0n;2.73 +22173-9;Chlamydophila pneumoniae Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydophila pneumoniae IgM Ab [Titer] in Cerebral spinal fluid;C pneum IgM Titr CSF;;ACTIVE;1.0n;2.70 +22174-7;Chlamydophila pneumoniae Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae IgM Ab [Titer] in Serum;C pneum IgM Titr Ser;;ACTIVE;1.0n;2.73 +22175-4;Chlamydophila psittaci Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila psittaci Ab [Presence] in Serum;C psittaci Ab Ser Ql;;ACTIVE;1.0n;2.67 +22176-2;Chlamydophila psittaci Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci Ab [Titer] in Serum;C psittaci Ab Titr Ser;;ACTIVE;1.0n;2.70 +22177-0;Chlamydophila psittaci Ab.IgA;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydophila psittaci IgA Ab [Titer] in Cerebral spinal fluid;C psittaci IgA Titr CSF;;ACTIVE;1.0n;2.70 +2217-8;DOPamine;MCnc;Pt;Urine;Qn;;CHEM;1;DOPamine [Mass/volume] in Urine;DOPamine Ur-mCnc;;ACTIVE;1.0;2.73 +22178-8;Chlamydophila psittaci Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci IgA Ab [Titer] in Serum;C psittaci IgA Titr Ser;;ACTIVE;1.0n;2.73 +22179-6;Chlamydophila psittaci Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydophila psittaci IgG Ab [Titer] in Cerebral spinal fluid;C psittaci IgG Titr CSF;;ACTIVE;1.0n;2.70 +22180-4;Chlamydophila psittaci Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci IgG Ab [Titer] in Serum;C psittaci IgG Titr Ser;;ACTIVE;1.0n;2.73 +22181-2;Chlamydophila psittaci Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci IgM Ab [Titer] in Serum;C psittaci IgM Titr Ser;;ACTIVE;1.0n;2.73 +22182-0;Chlamydia sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia sp Ab [Titer] in Serum;Chlamydia Ab Titr Ser;;ACTIVE;1.0n;2.70 +22183-8;Chlamydia sp Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Cerebral spinal fluid;Chlamydia IgG CSF-aCnc;;ACTIVE;1.0n;2.69 +22184-6;Chlamydia sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgG Ab [Titer] in Serum;Chlamydia IgG Titr Ser;;ACTIVE;1.0n;2.73 +22185-3;Chlamydia sp Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydia sp IgM Ab [Units/volume] in Cerebral spinal fluid;Chlamydia IgM CSF-aCnc;;ACTIVE;1.0n;2.69 +2218-6;DOPamine;MRat;24H;Urine;Qn;;CHEM;1;DOPamine [Mass/time] in 24 hour Urine;DOPamine 24h Ur-mRate;;ACTIVE;1.0;2.73 +22186-1;Chlamydia sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgM Ab [Titer] in Serum;Chlamydia IgM Titr Ser;;ACTIVE;1.0n;2.70 +22187-9;Chlamydia trachomatis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis Ab [Titer] in Serum;C trach Ab Titr Ser;;ACTIVE;1.0n;2.70 +22188-7;Chlamydia trachomatis Ab.IgA;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydia trachomatis IgA Ab [Titer] in Cerebral spinal fluid;C trach IgA Titr CSF;;ACTIVE;1.0n;2.70 +22189-5;Chlamydia trachomatis Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis IgA Ab [Titer] in Serum;C trach IgA Titr Ser;;ACTIVE;1.0n;2.73 +22190-3;Chlamydia trachomatis Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydia trachomatis IgG Ab [Units/volume] in Cerebral spinal fluid;C trach IgG CSF-aCnc;;ACTIVE;1.0n;2.69 +22191-1;Chlamydia trachomatis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis IgG Ab [Titer] in Serum;C trach IgG Titr Ser;;ACTIVE;1.0n;2.73 +22192-9;Chlamydia trachomatis Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydia trachomatis IgM Ab [Units/volume] in Cerebral spinal fluid;C trach IgM CSF-aCnc;;ACTIVE;1.0n;2.69 +22193-7;Chlamydia trachomatis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis IgM Ab [Titer] in Serum;C trach IgM Titr Ser;;ACTIVE;1.0n;2.73 +2219-4;Dopamine beta-hydroxylase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dopamine beta-hydroxylase [Enzymatic activity/volume] in Serum or Plasma;Dopamine B-Hydroxylae SerPl-cCnc;;ACTIVE;1.0;2.69 +22194-5;Chlamydia trachomatis B Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B IgA Ab [Titer] in Serum;C trach B IgA Titr Ser;;ACTIVE;1.0n;2.70 +22195-2;Chlamydia trachomatis B Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B IgG Ab [Titer] in Serum;C trach B IgG Titr Ser;;ACTIVE;1.0n;2.70 +22196-0;Chlamydia trachomatis B Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B IgM Ab [Titer] in Serum;C trach B IgM Titr Ser;;ACTIVE;1.0n;2.70 +22197-8;Chlamydia trachomatis C Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis C IgA Ab [Titer] in Serum;C trach C IgA Titr Ser;;ACTIVE;1.0n;2.70 +22198-6;Chlamydia trachomatis C Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis C IgG Ab [Titer] in Serum;C trach C IgG Titr Ser;;ACTIVE;1.0n;2.70 +22199-4;Chlamydia trachomatis C Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis C IgM Ab [Titer] in Serum;C trach C IgM Titr Ser;;ACTIVE;1.0n;2.70 +222-0;Dicloxacillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Dicloxacillin [Susceptibility] by Disk diffusion (KB);Dicloxacillin Islt KB;;ACTIVE;1.0;2.19 +22200-0;Chlamydia trachomatis G+F+K Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis G+F+K IgA Ab [Titer] in Serum;C trach G+F+K IgA Titr Ser;;ACTIVE;1.0n;2.70 +22201-8;Chlamydia trachomatis G+F+K Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis G+F+K IgG Ab [Titer] in Serum;C trach G+F+K IgG Titr Ser;;ACTIVE;1.0n;2.70 +2220-2;Elastase.pancreatic.free;CCnc;Pt;Ser;Qn;;CHEM;1;Elastase.pancreatic Free [Enzymatic activity/volume] in Serum;Elastase Panc Free Ser-cCnc;;ACTIVE;1.0;2.68 +22202-6;Chlamydia trachomatis G+F+K Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis G+F+K IgM Ab [Titer] in Serum;C trach G+F+K IgM Titr Ser;;ACTIVE;1.0n;2.70 +22203-4;Clostridium tetani Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani IgG Ab [Units/volume] in Serum;C tetani IgG Ser-aCnc;;DISCOURAGED;1.0n;2.73 +22204-2;Coccidioides immitis Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Coccidioides immitis Ab [Presence] in Cerebral spinal fluid;C immitis Ab CSF Ql;;ACTIVE;1.0n;2.56 +22205-9;Coccidioides immitis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coccidioides immitis Ab [Presence] in Serum;C immitis Ab Ser Ql;;ACTIVE;1.0n;2.56 +22206-7;Coccidioides immitis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coccidioides immitis Ab [Units/volume] in Serum;C immitis Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22207-5;Coccidioides immitis Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coccidioides immitis Ab [Titer] in Cerebral spinal fluid;C immitis Ab Titr CSF;;ACTIVE;1.0n;2.70 +22208-3;Coccidioides immitis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coccidioides immitis Ab [Titer] in Serum;C immitis Ab Titr Ser;;ACTIVE;1.0n;2.70 +22209-1;Coccidioides immitis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Coccidioides immitis IgG Ab [Presence] in Serum;C immitis IgG Ser Ql;;ACTIVE;1.0n;2.73 +2221-0;Elastase.pancreatic;CCnc;Pt;Ser;Qn;;CHEM;1;Elastase.pancreatic [Enzymatic activity/volume] in Serum;Elastase Panc Ser-cCnc;;ACTIVE;1.0;2.73 +22210-9;Coccidioides immitis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Coccidioides immitis IgM Ab [Presence] in Serum;C immitis IgM Ser Ql;;ACTIVE;1.0n;2.73 +22211-7;Coxiella burnetii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii Ab [Titer] in Serum;C burnet Ab Titr Ser;;ACTIVE;1.0n;2.73 +22212-5;Coxsackievirus A10 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A10 Ab [Titer] in Cerebral spinal fluid;CV A10 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22213-3;Coxsackievirus A10 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A10 Ab [Titer] in Serum;CV A10 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22214-1;Coxsackievirus A16 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A16 Ab [Titer] in Cerebral spinal fluid;CV A16 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22215-8;Coxsackievirus A16 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A16 Ab [Titer] in Serum;CV A16 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22216-6;Coxsackievirus A2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A2 Ab [Titer] in Serum;CV A2 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22217-4;Coxsackievirus A21 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A21 Ab [Titer] in Serum;CV A21 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22218-2;Coxsackievirus A4 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A4 Ab [Titer] in Serum;CV A4 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22219-0;Coxsackievirus A7 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A7 Ab [Titer] in Cerebral spinal fluid;CV A7 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22220-8;Coxsackievirus A7 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A7 Ab [Titer] in Serum;CV A7 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22221-6;Coxsackievirus A9 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A9 Ab [Titer] in Cerebral spinal fluid;CV A9 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22222-4;Coxsackievirus A9 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A9 Ab [Titer] in Serum;CV A9 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22223-2;Coxsackievirus B Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B IgG Ab [Units/volume] in Serum;CV B IgG Ser-aCnc;;ACTIVE;1.0n;2.69 +22224-0;Coxsackievirus B Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B IgM Ab [Units/volume] in Serum;CV B IgM Ser-aCnc;;ACTIVE;1.0n;2.69 +22225-7;Coxsackievirus B1 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B1 Ab [Titer] in Cerebral spinal fluid;CV B1 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22226-5;Coxsackievirus B1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B1 Ab [Titer] in Serum;CV B1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22227-3;Coxsackievirus B2 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B2 Ab [Titer] in Cerebral spinal fluid;CV B2 Ab Titr CSF;;ACTIVE;1.0n;2.73 +2222-8;Elastase.pancreatic 2;CCnc;Pt;Ser;Qn;;CHEM;1;Elastase.pancreatic 2 [Enzymatic activity/volume] in Serum;Elastase Panc2 Ser-cCnc;;ACTIVE;1.0;2.68 +22228-1;Coxsackievirus B2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B2 Ab [Titer] in Serum;CV B2 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22229-9;Coxsackievirus B3 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B3 Ab [Titer] in Cerebral spinal fluid;CV B3 Ab Titr CSF;;ACTIVE;1.0n;2.70 +22230-7;Coxsackievirus B3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B3 Ab [Titer] in Serum;CV B3 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22231-5;Coxsackievirus B4 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B4 Ab [Titer] in Cerebral spinal fluid;CV B4 Ab Titr CSF;;ACTIVE;1.0n;2.70 +22232-3;Coxsackievirus B4 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B4 Ab [Titer] in Serum;CV B4 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22233-1;Coxsackievirus B5 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B5 Ab [Titer] in Cerebral spinal fluid;CV B5 Ab Titr CSF;;ACTIVE;1.0n;2.70 +22234-9;Coxsackievirus B5 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B5 Ab [Titer] in Serum;CV B5 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22235-6;Coxsackievirus B6 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B6 Ab [Titer] in Cerebral spinal fluid;CV B6 Ab Titr CSF;;ACTIVE;1.0n;2.70 +2223-6;Elastase.leukocyte;CCnc;Pt;Plas;Qn;;CHEM;1;Elastase.leukocyte [Enzymatic activity/volume] in Plasma;Elastase Leukocyte Plas-cCnc;;ACTIVE;1.0;2.68 +22236-4;Coxsackievirus B6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B6 Ab [Titer] in Serum;CV B6 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22237-2;Cryptococcus neoformans Ab;Titr;Pt;Ser;Qn;;MICRO;1;Cryptococcus neoformans Ab [Titer] in Serum;C neoform Ab Titr Ser;;ACTIVE;1.0n;2.73 +22238-0;Taenia solium larva Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Taenia solium larva Ab [Presence] in Serum;T sol lar Ab Ser Ql;;ACTIVE;1.0n;2.73 +22239-8;Cytomegalovirus Ab;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Cytomegalovirus Ab [Presence] in Serum or Plasma;CMV Ab SerPl Ql;;ACTIVE;1.0n;2.73 +22240-6;Cytomegalovirus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Cytomegalovirus Ab [Titer] in Cerebral spinal fluid;CMV Ab Titr CSF;;ACTIVE;1.0n;2.70 +22241-4;Cytomegalovirus Ab;Titr;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus Ab [Titer] in Serum or Plasma;CMV Ab Titr SerPl;;ACTIVE;1.0n;2.70 +22242-2;Cytomegalovirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Cytomegalovirus Ab [Titer] in Serum;Deprecated CMV Ab Titr Ser;;DEPRECATED;1.0n;2.70 +22243-0;Cytomegalovirus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Cerebral spinal fluid;CMV IgG CSF-aCnc;;ACTIVE;1.0n;2.69 +2224-4;Enolase;CCnc;Pt;Ser;Qn;;CHEM;1;Enolase [Enzymatic activity/volume] in Serum;Enolase Ser-cCnc;;ACTIVE;1.0;2.68 +22244-8;Cytomegalovirus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Cytomegalovirus IgG Ab [Presence] in Serum or Plasma;CMV IgG SerPl Ql;;ACTIVE;1.0n;2.73 +22245-5;Cytomegalovirus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Cytomegalovirus IgG Ab [Titer] in Cerebral spinal fluid;CMV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22246-3;Cytomegalovirus Ab.IgG;Titr;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgG Ab [Titer] in Serum or Plasma;CMV IgG Titr SerPl;;ACTIVE;1.0n;2.73 +22247-1;Cytomegalovirus Ab.IgG^2nd specimen;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma --2nd specimen;CMV IgG sp2 SerPl-aCnc;;ACTIVE;1.0n;2.69 +22248-9;Cytomegalovirus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Cytomegalovirus IgM Ab [Titer] in Cerebral spinal fluid;CMV IgM Titr CSF;;ACTIVE;1.0n;2.70 +22249-7;Cytomegalovirus Ab.IgM;Titr;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgM Ab [Titer] in Serum or Plasma;CMV IgM Titr SerPl;;ACTIVE;1.0n;2.73 +22250-5;Dengue virus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus 1 Ab [Presence] in Serum;DENV1 Ab Ser Ql;;ACTIVE;1.0n;2.56 +2225-1;Enolase.neuron specific;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Enolase.neuron specific [Enzymatic activity/volume] in Serum or Plasma;NSE SerPl-cCnc;;ACTIVE;1.0;2.73 +22251-3;Dengue virus 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus 2 Ab [Presence] in Serum;DENV2 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22252-1;Dengue virus 3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus 3 Ab [Presence] in Serum;DENV3 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22253-9;Dengue virus 4 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus 4 Ab [Presence] in Serum;DENV4 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22254-7;Duck enteritis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Duck enteritis virus Ab [Presence] in Serum;DVE Ab Ser Ql;;ACTIVE;1.0n;2.56 +22255-4;Eastern equine encephalitis virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Cerebral spinal fluid;EEEV Ab CSF Ql;;ACTIVE;1.0n;2.56 +22256-2;Eastern equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Serum;EEEV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22257-0;Eastern equine encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum;EEEV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22258-8;Eastern equine encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid;EEEV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22259-6;Eastern equine encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Titer] in Serum;EEEV IgG Titr Ser;;ACTIVE;1.0n;2.73 +22260-4;Eastern equine encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid;EEEV IgM Titr CSF;;ACTIVE;1.0n;2.70 +22261-2;Eastern equine encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Titer] in Serum;EEEV IgM Titr Ser;;ACTIVE;1.0n;2.73 +22262-0;Eastern equine encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Eastern equine encephalitis virus Ab [Titer] in Serum;Deprecated EEEV Ab Titr Ser;;DEPRECATED;1.0n;2.70 +22263-8;Ebola virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Ebola virus Ab [Titer] in Serum;EBOV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22264-6;Echinococcus granulosus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Echinococcus granulosus IgG Ab [Presence] in Serum;E granulosus IgG Ser Ql;;ACTIVE;1.0n;2.73 +22265-3;Echinococcus sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Echinococcus sp IgG Ab [Units/volume] in Serum;Echinococcus IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +22266-1;Echovirus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 1 Ab [Titer] in Serum;ECV1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22267-9;Echovirus 11 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Echovirus 11 Ab [Titer] in Cerebral spinal fluid;ECV11 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22268-7;Echovirus 11 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 11 Ab [Titer] in Serum;ECV11 Ab Titr Ser;;ACTIVE;1.0n;2.73 +2226-9;Enteroglucagon;MCnc;Pt;Ser;Qn;;CHEM;1;Enteroglucagon [Mass/volume] in Serum;Enteroglucagon Ser-mCnc;;ACTIVE;1.0;2.42 +22269-5;Echovirus 14 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 14 Ab [Titer] in Serum;ECV14 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22270-3;Echovirus 140 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Echovirus 140 Ab;Deprecated ECV140 Ab Ser-aCnc;;DEPRECATED;1.0n;2.69 +22271-1;Echovirus 16 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 16 Ab [Titer] in Serum;ECV16 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22272-9;Echovirus 18 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 18 Ab [Titer] in Serum;ECV18 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22273-7;Echovirus 19 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 19 Ab [Titer] in Serum;ECV19 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22274-5;Echovirus 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 3 Ab [Titer] in Serum;ECV3 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22275-2;Echovirus 30 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Echovirus 30 Ab [Titer] in Cerebral spinal fluid;ECV30 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22276-0;Echovirus 4 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Echovirus 4 Ab [Titer] in Cerebral spinal fluid;ECV4 Ab Titr CSF;;ACTIVE;1.0n;2.70 +2227-7;Enteropeptidase;CCnc;Pt;Plas;Qn;;CHEM;1;Enteropeptidase [Enzymatic activity/volume] in Plasma;Enteropeptidase Plas-cCnc;;ACTIVE;1.0;2.68 +22277-8;Echovirus 4 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 4 Ab [Titer] in Serum;ECV4 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22278-6;Echovirus 6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 6 Ab [Titer] in Serum;ECV6 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22279-4;Echovirus 7 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 7 Ab [Titer] in Serum;ECV7 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22280-2;Echovirus 9 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Echovirus 9 Ab [Titer] in Cerebral spinal fluid;ECV9 Ab Titr CSF;;ACTIVE;1.0n;2.73 +22281-0;Echovirus 9 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 9 Ab [Titer] in Serum;ECV9 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22282-8;Echovirus NOS Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus NOS Ab [Titer] in Serum;ECV NOS Ab Titr Ser;;ACTIVE;1.0n;2.70 +22283-6;Ehrlichia chaffeensis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia chaffeensis IgG Ab [Presence] in Serum;E chaffeensis IgG Ser Ql;;ACTIVE;1.0n;2.73 +22284-4;Ehrlichia chaffeensis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Ehrlichia chaffeensis IgG Ab [Units/volume] in Serum;E chaffeensis IgG Ser-aCnc;;ACTIVE;1.0n;2.69 +2228-5;Enterotoxin;MCnc;Pt;Ser;Qn;;MICRO;1;Enterotoxin [Mass/volume] in Serum;Etx Ser-mCnc;;ACTIVE;1.0;2.34 +22285-1;Entamoeba histolytica Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Entamoeba histolytica Ab [Presence] in Serum;E histolyt Ab Ser Ql;;ACTIVE;1.0n;2.73 +22286-9;Entamoeba histolytica Ab;Titr;Pt;Ser;Qn;;MICRO;1;Entamoeba histolytica Ab [Titer] in Serum;E histolyt Ab Titr Ser;;ACTIVE;1.0n;2.70 +22287-7;Entamoeba histolytica Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Entamoeba histolytica IgA Ab [Units/volume] in Serum;E histolyt IgA Ser-aCnc;;ACTIVE;1.0n;2.69 +22288-5;Entamoeba histolytica Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Entamoeba histolytica IgG Ab [Units/volume] in Serum;E histolyt IgG Ser-aCnc;;ACTIVE;1.0n;2.69 +22289-3;Entamoeba histolytica Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Entamoeba histolytica IgM Ab [Units/volume] in Serum;E histolyt IgM Ser-aCnc;;ACTIVE;1.0n;2.69 +22290-1;Epstein Barr virus capsid Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgA Ab [Titer] in Serum;EBV VCA IgA Titr Ser;;ACTIVE;1.0n;2.73 +22291-9;Epstein Barr virus capsid Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Titer] in Cerebral spinal fluid;EBV VCA IgG Titr CSF;;ACTIVE;1.0n;2.70 +22292-7;Epstein Barr virus capsid Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus capsid IgM Ab [Titer] in Cerebral spinal fluid;EBV VCA IgM Titr CSF;;ACTIVE;1.0n;2.70 +2229-3;Epiandrosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Epiandrosterone [Mass/volume] in Serum or Plasma;Epiandrosterone SerPl-mCnc;;ACTIVE;1.0;2.42 +22293-5;Epstein Barr virus early Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus early Ab [Units/volume] in Serum;EBV EA Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22294-3;Epstein Barr virus early Ab;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus early Ab [Titer] in Serum;EBV EA Ab Titr Ser;;ACTIVE;1.0n;2.73 +22295-0;Epstein Barr virus early Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus early IgG Ab [Presence] in Serum;EBV EA IgG Ser Ql;;ACTIVE;1.0n;2.73 +22296-8;Epstein Barr virus nuclear Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus nuclear Ab [Presence] in Serum;EBV NA Ab Ser Ql;;ACTIVE;1.0n;2.73 +22297-6;Epstein Barr virus nuclear Ab;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus nuclear Ab [Titer] in Serum;EBV NA Ab Titr Ser;;ACTIVE;1.0n;2.73 +22298-4;Epstein Barr virus nuclear Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus nuclear IgG Ab [Titer] in Serum;EBV NA IgG Titr Ser;;ACTIVE;1.0n;2.73 +22299-2;Equine arteritis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Equine arteritis virus Ab [Titer] in Serum;EAV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22300-8;Equine herpesvirus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Equine herpesvirus 1 Ab [Titer] in Serum;EHV1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +2230-1;EPINEPHrine;MCnc;Pt;Plas;Qn;;CHEM;1;EPINEPHrine [Mass/volume] in Plasma;Epineph Plas-mCnc;;ACTIVE;1.0;2.73 +22301-6;Equine infectious anemia virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Equine infectious anemia virus Ab [Presence] in Serum;EIAV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22302-4;Equine influenza virus A1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Equine influenza virus A1 Ab [Titer] in Serum;EIV A1 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22303-2;Equine influenza virus A2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Equine influenza virus A2 Ab [Titer] in Serum;EIV A2 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22304-0;Giardia lamblia Ab;Titr;Pt;Ser;Qn;;MICRO;1;Giardia lamblia Ab [Titer] in Serum;G lamblia Ab Titr Ser;;ACTIVE;1.0n;2.73 +22305-7;Giardia lamblia Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Giardia lamblia IgA Ab [Titer] in Serum;G lamblia IgA Titr Ser;;ACTIVE;1.0n;2.70 +22306-5;Giardia lamblia Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Giardia lamblia IgG Ab [Titer] in Serum;G lamblia IgG Titr Ser;;ACTIVE;1.0n;2.73 +22307-3;Giardia lamblia Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Giardia lamblia IgM Ab [Titer] in Serum;G lamblia IgM Titr Ser;;ACTIVE;1.0n;2.70 +22308-1;Hantavirus puumala Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Hantavirus puumala IgG Ab [Titer] in Serum;PUUV IgG Titr Ser;;ACTIVE;1.0n;2.70 +22309-9;Hantavirus puumala Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Hantavirus puumala IgM Ab [Titer] in Serum;PUUV IgM Titr Ser;;ACTIVE;1.0n;2.70 +22310-7;Helicobacter pylori Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Helicobacter pylori Ab [Presence] in Serum;H pylori Ab Ser Ql;;ACTIVE;1.0n;2.73 +22311-5;Helicobacter pylori Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Helicobacter pylori Ab [Titer] in Serum;Deprecated H pylori Ab Titr Ser;;DEPRECATED;1.0n;2.36 +22312-3;Hepatitis A virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis A virus Ab [Units/volume] in Serum;HAV Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22313-1;Hepatitis A virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis A virus IgG Ab [Units/volume] in Serum;HAV IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +22314-9;Hepatitis A virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis A virus IgM Ab [Presence] in Serum;HAV IgM Ser Ql;;ACTIVE;1.0n;2.73 +22315-6;Hepatitis A virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis A virus IgM Ab [Units/volume] in Serum;HAV IgM Ser-aCnc;;ACTIVE;1.0n;2.73 +22316-4;Hepatitis B virus core Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus core Ab [Units/volume] in Serum;HBV core Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22317-2;Hepatitis B virus core Ab;ACnc;Pt;Ser^Donor;Qn;;MICRO;1;Hepatitis B virus core Ab [Units/volume] in Serum from Donor;HBV core Ab Ser Donr-aCnc;;ACTIVE;1.0n;2.69 +22318-0;Hepatitis B virus core Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus core IgG Ab [Units/volume] in Serum;HBV core IgG Ser-aCnc;;ACTIVE;1.0n;2.69 +2231-9;EPINEPHrine;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated EPINEPHrine [Mass/volume] in Plasma;Deprecated Epineph Ser-mCnc;;DEPRECATED;1.0;2.36 +22319-8;Hepatitis B virus core Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus core IgM Ab [Units/volume] in Serum;HBV core IgM Ser-aCnc;;ACTIVE;1.0n;2.73 +22320-6;Hepatitis B virus little e Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus e Ab [Presence] in Serum;HBV e Ab Ser Ql;;ACTIVE;1.0n;2.73 +22321-4;Hepatitis B virus little e Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus e Ab [Units/volume] in Serum;HBV e Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22322-2;Hepatitis B virus surface Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus surface Ab [Presence] in Serum;HBV surface Ab Ser Ql;;ACTIVE;1.0n;2.73 +22323-0;Hepatitis B virus surface Ab;ACnc;Pt;Ser^Donor;Qn;;MICRO;1;Hepatitis B virus surface Ab [Units/volume] in Serum from Donor;HBV surface Ab Ser Donr-aCnc;;ACTIVE;1.0n;2.73 +22324-8;Hepatitis C virus 100-3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus 100-3 Ab [Presence] in Serum;HCV100-3 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22325-5;Hepatitis C virus 22-3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus 22-3 Ab [Presence] in Serum;HCV22-3 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22326-3;Hepatitis C virus 5-1-1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus 5-1-1 Ab [Presence] in Serum;HCV5-1-1 Ab Ser Ql;;ACTIVE;1.0n;2.56 +2232-7;EPINEPHrine;MRat;24H;Urine;Qn;;CHEM;1;EPINEPHrine [Mass/time] in 24 hour Urine;Epineph 24h Ur-mRate;;ACTIVE;1.0;2.73 +22327-1;Hepatitis C virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis C virus Ab [Units/volume] in Serum;HCV Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22328-9;Hepatitis C virus superoxide dismutase Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus superoxide dismutase Ab [Presence] in Serum;HCV SOD Ab Ser Ql;;ACTIVE;1.0n;2.56 +22329-7;Hepatitis C virus c33c Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus c33c Ab [Presence] in Serum;HCV C33c Ab Ser Ql;;ACTIVE;1.0n;2.56 +22330-5;Hepatitis D virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis D virus Ab [Units/volume] in Serum;HDV Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22331-3;Herpes simplex virus 1 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 1 Ab [Presence] in Cerebral spinal fluid;HSV1 Ab CSF Ql;;ACTIVE;1.0n;2.56 +22332-1;Herpes simplex virus 1 Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Herpes simplex virus 1 Ab [Units/volume] in Serum;Deprecated HSV1 Ab SerPl-aCnc;;DEPRECATED;1.0n;2.69 +22333-9;Herpes simplex virus 1 Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1 IgG Ab [Titer] in Cerebral spinal fluid;HSV1 IgG Titr CSF;;ACTIVE;1.0n;2.70 +22334-7;Herpes simplex virus 1 Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1 IgM Ab [Titer] in Cerebral spinal fluid;HSV1 IgM Titr CSF;;ACTIVE;1.0n;2.70 +2233-5;Epitestosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Epitestosterone [Mass/volume] in Serum or Plasma;Epitestost SerPl-mCnc;;ACTIVE;1.0;2.73 +22335-4;Herpes simplex virus 2 Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Herpes simplex virus 2 Ab [Units/volume] in Serum;Deprecated HSV2 Ab SerPl-aCnc;;DEPRECATED;1.0n;2.69 +22336-2;Herpes simplex virus 2 Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Herpes simplex virus 2 IgG Ab [Presence] in Serum;Deprecated HSV2 IgG Ser Ql;;DEPRECATED;1.0n;2.36 +22337-0;Herpes simplex virus 2 Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Titer] in Cerebral spinal fluid;HSV2 IgG Titr CSF;;ACTIVE;1.0n;2.70 +22338-8;Herpes simplex virus 2 Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 2 IgM Ab [Titer] in Cerebral spinal fluid;HSV2 IgM Titr CSF;;ACTIVE;1.0n;2.70 +22339-6;Herpes simplex virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus Ab [Presence] in Serum;HSV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22340-4;Herpes simplex virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus Ab [Titer] in Cerebral spinal fluid;HSV Ab Titr CSF;;ACTIVE;1.0n;2.70 +22341-2;Herpes simplex virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus Ab [Titer] in Serum;HSV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22342-0;Herpes simplex virus Ab.IgG;Imp;Pt;Ser;Nom;;MICRO;1;Herpes simplex virus IgG Ab [Interpretation] in Serum;HSV IgG Ser-Imp;;ACTIVE;1.0n;2.73 +2234-3;Epitestosterone;PrThr;Pt;Urine;Ord;;CHEM;1;Epitestosterone [Presence] in Urine;Epitestost Ur Ql;;ACTIVE;1.0;2.56 +22343-8;Herpes simplex virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus IgM Ab [Titer] in Serum;HSV IgM Titr Ser;;ACTIVE;1.0n;2.73 +22344-6;Heterophile Ab after absorption;Titr;Pt;Ser;Qn;;MICRO;1;Heterophile Ab after absorption [Titer] in Serum;Heteroph Ab Abs Titr Ser;;ACTIVE;1.0n;2.70 +22345-3;Histoplasma capsulatum Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum Ab [Presence] in Cerebral spinal fluid;H capsul Ab CSF Ql;;ACTIVE;1.0n;2.56 +22346-1;Histoplasma capsulatum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum Ab [Presence] in Serum;H capsul Ab Ser Ql;;ACTIVE;1.0n;2.73 +22347-9;Histoplasma capsulatum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum Ab [Titer] in Serum;H capsul Ab Titr Ser;;ACTIVE;1.0n;2.70 +22348-7;Histoplasma capsulatum Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum IgA Ab [Presence] in Serum;H capsul IgA Ser Ql;;ACTIVE;1.0n;2.56 +22349-5;Histoplasma capsulatum Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum IgA Ab [Units/volume] in Serum;H capsul IgA Ser-aCnc;;ACTIVE;1.0n;2.73 +2235-0;Epitestosterone;MCnc;Pt;Urine;Qn;;CHEM;1;Epitestosterone [Mass/volume] in Urine;Epitestost Ur-mCnc;;ACTIVE;1.0;2.73 +22350-3;Histoplasma capsulatum Ab.IgE;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum IgE Ab [Presence] in Serum;H capsul IgE Ser Ql;;ACTIVE;1.0n;2.56 +22351-1;Histoplasma capsulatum Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum IgG Ab [Units/volume] in Serum;H capsul IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +22352-9;Histoplasma capsulatum Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum IgM Ab [Presence] in Serum;H capsul IgM Ser Ql;;ACTIVE;1.0n;2.73 +22353-7;Histoplasma capsulatum Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum IgM Ab [Units/volume] in Serum;H capsul IgM Ser-aCnc;;ACTIVE;1.0n;2.73 +22354-5;Histoplasma capsulatum mycelial phase Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Units/volume] in Serum;H capsul Myc Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22355-2;Histoplasma capsulatum yeast phase Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum yeast phase Ab [Units/volume] in Serum;H capsul Yst Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22356-0;HIV 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HIV 1 Ab [Units/volume] in Serum;HIV1 Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22357-8;HIV 1+2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HIV 1+2 Ab [Units/volume] in Serum;HIV1+2 Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22358-6;HIV 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HIV 2 Ab [Units/volume] in Serum;HIV 2 Ab Ser-aCnc;;ACTIVE;1.0n;2.73 +22359-4;HTLV I Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I Ab [Presence] in Serum;HTLV I Ab Ser Ql;;ACTIVE;1.0n;2.56 +22360-2;HTLV I Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I IgG Ab [Presence] in Serum;HTLV I IgG Ser Ql;;ACTIVE;1.0n;2.56 +22361-0;HTLV I+II Ab;PrThr;Pt;CSF;Ord;;MICRO;1;HTLV I+II Ab [Presence] in Cerebral spinal fluid;HTLV I+II Ab CSF Ql;;ACTIVE;1.0n;2.73 +22362-8;HTLV I+II Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II Ab [Presence] in Serum;HTLV I+II Ab Ser Ql;;ACTIVE;1.0n;2.73 +22363-6;HTLV I+II Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HTLV I+II Ab [Units/volume] in Serum;HTLV I+II Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22364-4;Infectious bursal disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Infectious bursal disease virus Ab [Presence] in Serum;IBDV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22365-1;Influenza virus A Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A Ab [Titer] in Serum;FLUAV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22366-9;Influenza virus A+B Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A+B Ab [Titer] in Serum;FLUAV+FLUBV Ab Titr Ser;;ACTIVE;1.0n;2.73 +22367-7;Influenza virus B Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus B Ab [Titer] in Serum;FLUBV Ab Titr Ser;;ACTIVE;1.0n;2.70 +2236-8;Calciferol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calciferol (Vit D2) [Mass/volume] in Serum or Plasma;Vitamin D2 SerPl-mCnc;;ACTIVE;1.0;2.73 +22368-5;Influenza virus C Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus C Ab [Titer] in Serum;FLUCV Ab Titr Ser;;ACTIVE;1.0n;2.73 +22369-3;Japanese encephalitis virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Japanese encephalitis virus Ab [Presence] in Cerebral spinal fluid;JEV Ab CSF Ql;;ACTIVE;1.0n;2.56 +22370-1;Japanese encephalitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Japanese encephalitis virus Ab [Presence] in Serum;JEV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22371-9;Junin virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Junin virus Ab [Presence] in Serum;JUNV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22372-7;La Crosse virus Ab;ACnc;Pt;Ser;OrdQn;;MICRO;1;Deprecated La Crosse virus Ab;Deprecated LACV Ab Ser;;DEPRECATED;1.0n;2.36 +22373-5;La Crosse virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;La Crosse virus IgG Ab [Titer] in Cerebral spinal fluid;LACV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22374-3;La Crosse virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated La Crosse virus IgG Ab [Titer] in Serum;Deprecated LACV IgG Titr Ser;;DEPRECATED;1.0n;2.70 +22375-0;La Crosse virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;La Crosse virus IgM Ab [Titer] in Cerebral spinal fluid;LACV IgM Titr CSF;;ACTIVE;1.0n;2.70 +2237-6;Erythropoietin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Erythropoietin (EPO) [Mass/volume] in Serum or Plasma;EPO SerPl-mCnc;;DISCOURAGED;1.0;2.73 +22376-8;La Crosse virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated La Crosse virus IgM Ab [Titer] in Serum;Deprecated LACV IgM Titr Ser;;DEPRECATED;1.0n;2.70 +22377-6;Lassa virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Lassa virus IgG Ab [Presence] in Serum;LASV IgG Ser Ql;;ACTIVE;1.0n;2.56 +22378-4;Lassa virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Lassa virus IgG Ab [Titer] in Serum;LASV IgG Titr Ser;;ACTIVE;1.0n;2.70 +22379-2;Lassa virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Lassa virus IgM Ab [Presence] in Serum;LASV IgM Ser Ql;;ACTIVE;1.0n;2.56 +223-8;Dicloxacillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Dicloxacillin [Susceptibility] by Serum bactericidal titer;Dicloxacillin Titr SBT;;ACTIVE;1.0;2.32 +22380-0;Lassa virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Lassa virus IgM Ab [Titer] in Serum;LASV IgM Titr Ser;;ACTIVE;1.0n;2.70 +22381-8;Legionella pneumophila 1 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1 IgG Ab [Titer] in Serum;L pneumo1 IgG Titr Ser;;ACTIVE;1.0n;2.70 +22382-6;Legionella pneumophila 1 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1 IgM Ab [Titer] in Serum;L pneumo1 IgM Titr Ser;;ACTIVE;1.0n;2.73 +22383-4;Legionella pneumophila 2 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 2 IgG Ab [Titer] in Serum;L pneumo2 IgG Titr Ser;;ACTIVE;1.0n;2.70 +2238-4;Estradiol;MCnc;Pt;Saliva;Qn;;CHEM;1;Estradiol (E2) [Mass/volume] in Saliva (oral fluid);Estradiol Sal-mCnc;;ACTIVE;1.0;2.73 +22384-2;Legionella pneumophila 2 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 2 IgM Ab [Titer] in Serum;L pneumo2 IgM Titr Ser;;ACTIVE;1.0n;2.73 +22385-9;Legionella pneumophila 3 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 3 IgG Ab [Titer] in Serum;L pneumo3 IgG Titr Ser;;ACTIVE;1.0n;2.73 +22386-7;Legionella pneumophila 3 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 3 IgM Ab [Titer] in Serum;L pneumo3 IgM Titr Ser;;ACTIVE;1.0n;2.73 +22387-5;Legionella pneumophila 4 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 4 IgG Ab [Titer] in Serum;L pneumo4 IgG Titr Ser;;ACTIVE;1.0n;2.73 +22388-3;Legionella pneumophila 4 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 4 IgM Ab [Titer] in Serum;L pneumo4 IgM Titr Ser;;ACTIVE;1.0n;2.73 +22389-1;Legionella pneumophila 5 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 5 IgG Ab [Titer] in Serum;L pneumo5 IgG Titr Ser;;ACTIVE;1.0n;2.73 +22390-9;Legionella pneumophila 5 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 5 IgM Ab [Titer] in Serum;L pneumo5 IgM Titr Ser;;ACTIVE;1.0n;2.73 +22391-7;Legionella pneumophila 6 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 6 IgG Ab [Titer] in Serum;L pneumo6 IgG Titr Ser;;ACTIVE;1.0n;2.73 +2239-2;Estradiol;MCnc;Pt;Semen;Qn;;CHEM;1;Estradiol (E2) [Mass/volume] in Semen;Estradiol Smn-mCnc;;ACTIVE;1.0;2.36 +22392-5;Legionella pneumophila 6 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 6 IgM Ab [Titer] in Serum;L pneumo6 IgM Titr Ser;;ACTIVE;1.0n;2.73 +22393-3;Legionella pneumophila 7 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 7 Ab [Titer] in Serum;L pneumo7 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22394-1;Legionella pneumophila 8 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 8 Ab [Titer] in Serum;L pneumo8 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22395-8;Legionella pneumophila 9 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 9 Ab [Titer] in Serum;L pneumo9 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22396-6;Legionella pneumophila Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila Ab [Titer] in Serum;L pneumo Ab Titr Ser;;ACTIVE;1.0n;2.70 +22397-4;Legionella pneumophila Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila IgG Ab [Titer] in Serum;L pneumo IgG Titr Ser;;ACTIVE;1.0n;2.70 +22398-2;Legionella pneumophila Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila IgM Ab [Titer] in Serum;L pneumo IgM Titr Ser;;ACTIVE;1.0n;2.73 +22399-0;Legionella sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella sp Ab [Titer] in Serum;Legionella Ab Titr Ser;;ACTIVE;1.0n;2.73 +22-4;Amoxicillin+Clavulanate;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility] by Serum bactericidal titer;Amoxicillin+Clav Titr SBT;;ACTIVE;1.0;2.32 +2240-0;Estradiol.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2) Free [Mass/volume] in Serum or Plasma;Estradiol Free SerPl-mCnc;;ACTIVE;1.0;2.73 +22400-6;Leptospira interrogans serovar Bratislava Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Bratislava Ab [Titer] in Serum;L inter Brat Ab Titr Ser;;ACTIVE;1.0n;2.70 +22401-4;Leptospira interrogans serovar Canicola Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Canicola Ab [Titer] in Serum;L inter Canic Ab Titr Ser;;ACTIVE;1.0n;2.70 +22402-2;Leptospira interrogans serovar Grippotyphosa Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Grippotyphosa Ab [Titer] in Serum;L inter Grip Ab Titr Ser;;ACTIVE;1.0n;2.70 +22403-0;Leptospira interrogans serovar Hardjo Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Hardjo Ab [Titer] in Serum;L inter Hard Ab Titr Ser;;ACTIVE;1.0n;2.70 +22404-8;Leptospira interrogans serovar Icterohaemorrhagiae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Icterohaemorrhagiae Ab [Titer] in Serum;L inter Icter Ab Titr Ser;;ACTIVE;1.0n;2.70 +22405-5;Leptospira interrogans serovar Pomona Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Pomona Ab [Titer] in Serum;L inter Pomon Ab Titr Ser;;ACTIVE;1.0n;2.70 +22406-3;Listeria monocytogenes Ab;Titr;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes Ab [Titer] in Serum;L monocytog Ab Titr Ser;;ACTIVE;1.0n;2.70 +22407-1;little d little s DNA (Crithidia lucilia) Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated DNA double strand Ab [Presence] in Serum by IF Crithidia luciliae;Deprecated dsDNA Ab Ser Ql;;DEPRECATED;1.0n;2.36 +22408-9;Lymphocytic choriomeningitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Lymphocytic choriomeningitis virus Ab [Titer] in Serum;LCMV Ab Titr Ser;;ACTIVE;1.0n;2.73 +22409-7;Lymphocytic choriomeningitis virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Titer] in Cerebral spinal fluid;LCMV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22410-5;Lymphocytic choriomeningitis virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Titer] in Serum;LCMV IgG Titr Ser;;ACTIVE;1.0n;2.73 +22411-3;Lymphocytic choriomeningitis virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Titer] in Serum;LCMV IgM Titr Ser;;ACTIVE;1.0n;2.70 +22412-1;Saccharopolyspora rectivirgula Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Saccharopolyspora rectivirgula Ab [Presence] in Serum;S rectivirgula Ab Ser Ql;;ACTIVE;1.0n;2.73 +22413-9;Mumps virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Mumps virus Ab [Titer] in Cerebral spinal fluid;MuV Ab Titr CSF;;ACTIVE;1.0n;2.70 +22414-7;Mumps virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mumps virus Ab [Titer] in Serum;MuV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22415-4;Mumps virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Mumps virus IgG Ab [Presence] in Serum;MuV IgG Ser Ql;;ACTIVE;1.0n;2.73 +22416-2;Mumps virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Mumps virus IgG Ab [Titer] in Cerebral spinal fluid;MuV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22417-0;Mumps virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Mumps virus IgG Ab [Titer] in Serum;MuV IgG Titr Ser;;ACTIVE;1.0n;2.73 +2241-8;Estradiol.free;SCnt;Pt;Tiss;Qn;;CHEM;1;Estradiol (E2) Free [Moles/mass] in Tissue;Estradiol Free Tiss-sCnt;;ACTIVE;1.0;2.42 +22418-8;Mumps virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Mumps virus IgM Ab [Presence] in Serum;MuV IgM Ser Ql;;ACTIVE;1.0n;2.73 +22419-6;Mumps virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Mumps virus IgM Ab [Titer] in Cerebral spinal fluid;MuV IgM Titr CSF;;ACTIVE;1.0n;2.70 +22420-4;Mumps virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Mumps virus IgM Ab [Titer] in Serum;MuV IgM Titr Ser;;ACTIVE;1.0n;2.73 +22421-2;Mycobacterium avium subspecies paratuberculosis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Presence] in Serum;M avium paraTB Ab Ser Ql;;ACTIVE;1.0n;2.56 +22422-0;Mycoplasma gallisepticum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma gallisepticum Ab [Presence] in Serum;M gallisep Ab Ser Ql;;ACTIVE;1.0n;2.67 +22423-8;Mycoplasma hominis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma hominis Ab [Titer] in Serum;M hominis Ab Titr Ser;;ACTIVE;1.0n;2.70 +22424-6;Mycoplasma meleagridis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma meleagridis Ab [Presence] in Serum;M meleagridis Ab Ser Ql;;ACTIVE;1.0n;2.67 +22425-3;Mycoplasma pneumoniae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum;M pneumo Ab Titr Ser;;ACTIVE;1.0n;2.73 +2242-6;Estradiol.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Estradiol Free [Mass/volume] in Serum or Plasma;Deprecated Estradiol Free SerPl-mCnc;;DEPRECATED;1.0;2.36 +22426-1;Mycoplasma pneumoniae Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Titer] in Serum;M pneumo IgG Titr Ser;;ACTIVE;1.0n;2.73 +22427-9;Mycoplasma pneumoniae Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgM Ab [Titer] in Serum;M pneumo IgM Titr Ser;;ACTIVE;1.0n;2.73 +22428-7;Mycoplasma sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma sp Ab [Presence] in Serum;Mycoplasma Ab Ser Ql;;ACTIVE;1.0n;2.73 +22429-5;Mycoplasma synoviae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma synoviae Ab [Presence] in Serum;M synoviae Ab Ser Ql;;ACTIVE;1.0n;2.56 +22430-3;Neisseria gonorrhoeae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Neisseria gonorrhoeae Ab [Titer] in Serum;N gonorrhoea Ab Titr Ser;;DISCOURAGED;1.0n;2.73 +22431-1;Neisseria meningitidis serogroup Y Ab;Titr;Pt;XXX;Qn;;MICRO;1;Neisseria meningitidis serogroup Y Ab [Titer] in Specimen;N men sg Y Ab Titr Spec;;ACTIVE;1.0n;2.70 +22432-9;Neospora caninum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Neospora caninum Ab [Presence] in Serum;N caninum Ab Ser Ql;;ACTIVE;1.0n;2.67 +22433-7;Neospora caninum Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Neospora caninum Ab [Presence] in Serum;Deprecated N caninum Ab Ser Ql;;DEPRECATED;1.0n;2.36 +2243-4;Estradiol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2) [Mass/volume] in Serum or Plasma;Estradiol SerPl-mCnc;;ACTIVE;1.0;2.73 +22434-5;Human papilloma virus Ab;PrThr;Pt;Tiss;Ord;;MICRO;1;Human papilloma virus Ab [Presence] in Tissue;HPV Ab Tiss Ql;;ACTIVE;1.0n;2.56 +22435-2;Paracoccidioides brasiliensis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Paracoccidioides brasiliensis Ab [Titer] in Serum;P brasilien Ab Titr Ser;;ACTIVE;1.0n;2.70 +22436-0;Paragonimus sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Paragonimus sp Ab [Titer] in Serum;Paragonimus Ab Titr Ser;;ACTIVE;1.0n;2.70 +22437-8;Parainfluenza virus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Serum;HPIV1 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22438-6;Parainfluenza virus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Serum;HPIV2 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22439-4;Parainfluenza virus 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Serum;HPIV3 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22440-2;Pasteurella multocida Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Pasteurella multocida Ab [Presence] in Serum;P multoc Ab Ser Ql;;ACTIVE;1.0n;2.67 +22441-0;Plasmodium falciparum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium falciparum Ab [Titer] in Serum;P falciparum Ab Titr Ser;;ACTIVE;1.0n;2.73 +2244-2;Estradiol;MCnc;Pt;Saliva;Qn;;CHEM;1;Deprecated Estradiol [Mass/volume] in Saliva;Deprecated Estradiol Saliva-mCnc;;DEPRECATED;1.0;2.36 +22442-8;Plasmodium malariae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium malariae Ab [Titer] in Serum;P malariae Ab Titr Ser;;ACTIVE;1.0n;2.70 +22443-6;Plasmodium ovale Ab;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium ovale Ab [Titer] in Serum;P ovale Ab Titr Ser;;ACTIVE;1.0n;2.70 +22444-4;Plasmodium vivax Ab;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium vivax Ab [Titer] in Serum;P vivax Ab Titr Ser;;ACTIVE;1.0n;2.70 +22445-1;Polio virus 1 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Polio virus 1 Ab [Titer] in Cerebral spinal fluid;PV1 Ab Titr CSF;;ACTIVE;1.0n;2.70 +22446-9;Polio virus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 1 Ab [Titer] in Serum;PV1 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22447-7;Polio virus 2 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Polio virus 2 Ab [Titer] in Cerebral spinal fluid;PV2 Ab Titr CSF;;ACTIVE;1.0n;2.70 +22448-5;Polio virus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 2 Ab [Titer] in Serum;PV2 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22449-3;Polio virus 3 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Polio virus 3 Ab [Titer] in Cerebral spinal fluid;PV3 Ab Titr CSF;;ACTIVE;1.0n;2.70 +22450-1;Polio virus 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 3 Ab [Titer] in Serum;PV3 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22451-9;Porcine reproductive and respiratory syndrome virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;PRRSV Ab [Presence] in Serum;PRRSV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22452-7;Pseudorabies virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Pseudorabies virus Ab [Presence] in Serum;PRV Ab Ser Ql;;ACTIVE;1.0n;2.67 +22453-5;Pseudorabies virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Pseudorabies virus Ab [Titer] in Serum;PRV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22454-3;Pseudorabies virus.ClinEase gene deletion Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Pseudorabies virus Clinease gene deletion Ab [Presence] in Serum;PRV Clinease Ab Ser Ql;;ACTIVE;1.0n;2.67 +22455-0;Pseudorabies virus.HerdCheck gene deletion Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Pseudorabies virus Herdcheck gene deletion Ab [Presence] in Serum;PRV Herdcheck Ab Ser Ql;;ACTIVE;1.0n;2.67 +22456-8;Pseudorabies virus.OmniMark gene deletion Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Pseudorabies virus Omnimark gene deletion Ab [Presence] in Serum;PRV Omnimark Ab Ser Ql;;ACTIVE;1.0n;2.67 +22457-6;Pseudorabies virus.Tolvid gene deletion Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Pseudorabies virus Tolvid gene deletion Ab [Presence] in Serum;PRV Tolvid Ab Ser Ql;;ACTIVE;1.0n;2.67 +22458-4;Rabies virus Ab;ACnc;Pt;Tiss;Qn;;MICRO;1;Rabies virus Ab [Units/volume] in Tissue;RABV Ab Tiss-aCnc;;ACTIVE;1.0n;2.69 +2245-9;Estradiol;SCnt;Pt;Tiss;Qn;;CHEM;1;Estradiol (E2) [Moles/mass] in Tissue;Estradiol Tiss-sCnt;;ACTIVE;1.0;2.42 +22459-2;Reagin Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Reagin Ab [Presence] in Cerebral spinal fluid;Reagin Ab CSF Ql;;ACTIVE;1.0n;2.73 +224-6;Doxycycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Doxycycline [Susceptibility] by Minimum lethal concentration (MLC);Doxycycline Islt MLC;;ACTIVE;1.0;2.19 +22460-0;Reagin Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Reagin Ab [Units/volume] in Cerebral spinal fluid;Reagin Ab CSF-aCnc;;ACTIVE;1.0n;2.69 +22461-8;Reagin Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Reagin Ab [Presence] in Serum;Reagin Ab Ser Ql;;ACTIVE;1.0n;2.73 +22462-6;Reagin Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Reagin Ab [Units/volume] in Serum;Reagin Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22463-4;Reagin Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;Reagin Ab [Presence] in Serum from Donor;Reagin Ab Ser Donr Ql;;ACTIVE;1.0n;2.73 +22464-2;Reagin Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Reagin Ab [Presence] in Specimen;Reagin Ab Spec Ql;;ACTIVE;1.0n;2.73 +22465-9;Reovirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Reovirus Ab [Titer] in Serum;Reovirus Ab Titr Ser;;ACTIVE;1.0n;2.70 +22466-7;Respiratory syncytial virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus Ab [Titer] in Serum;RSV Ab Titr Ser;;ACTIVE;1.0n;2.70 +2246-7;Estradiol.unconjugated;MRat;24H;Urine;Qn;;CHEM;1;Estradiol (E2).unconjugated [Mass/time] in 24 hour Urine;u Estradiol 24h Ur-mRate;;ACTIVE;1.0;2.42 +22467-5;Respiratory syncytial virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus IgM Ab [Titer] in Serum;RSV IgM Titr Ser;;ACTIVE;1.0n;2.70 +22468-3;Rickettsia (Proteus OX19) Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia (Proteus OX19) Ab [Presence] in Serum;Proteus OX19 Ab Ser Ql;;ACTIVE;1.0n;2.73 +22469-1;Rickettsia (Proteus OX19) Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia (Proteus OX19) Ab [Titer] in Serum;Proteus OX19 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22470-9;Rickettsia (Proteus OX2) Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia (Proteus OX2) Ab [Presence] in Serum;Proteus OX2 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22471-7;Rickettsia (Proteus OX2) Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia (Proteus OX2) Ab [Titer] in Serum;Proteus OX2 Ab Titr Ser;;ACTIVE;1.0n;2.73 +22472-5;Rickettsia (Proteus OXK) Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia (Proteus OXK) Ab [Presence] in Serum;Proteus OXK Ab Ser Ql;;ACTIVE;1.0n;2.56 +22473-3;Rickettsia (Proteus OXK) Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia (Proteus OXK) Ab [Titer] in Serum;Proteus OXK Ab Titr Ser;;ACTIVE;1.0n;2.73 +22474-1;Rickettsia spotted fever group Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia spotted fever group Ab [Presence] in Serum;Rick SF Ab Ser Ql;;ACTIVE;1.0n;2.56 +2247-5;Estriol.conjugated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3).conjugated [Mass/volume] in Serum or Plasma;Estriol Conj SerPl-mCnc;;ACTIVE;1.0;2.40 +22475-8;Rickettsia spotted fever group Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group Ab [Titer] in Serum;Rick SF Ab Titr Ser;;ACTIVE;1.0n;2.70 +22476-6;Rickettsia spotted fever group Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Cerebral spinal fluid;Rick SF IgG Titr CSF;;ACTIVE;1.0n;2.70 +22477-4;Rickettsia spotted fever group Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Serum;Rick SF IgG Titr Ser;;ACTIVE;1.0n;2.73 +22478-2;Rickettsia spotted fever group Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia spotted fever group IgM Ab [Titer] in Cerebral spinal fluid;Rick SF IgM Titr CSF;;ACTIVE;1.0n;2.70 +22479-0;Rickettsia spotted fever group Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group IgM Ab [Titer] in Serum;Rick SF IgM Titr Ser;;ACTIVE;1.0n;2.73 +22480-8;Rickettsia typhus group Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia typhus group IgG Ab [Titer] in Cerebral spinal fluid;Rick Typhus IgG Titr CSF;;ACTIVE;1.0n;2.70 +22481-6;Rickettsia typhus group Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia typhus group IgM Ab [Titer] in Cerebral spinal fluid;Rick Typhus IgM Titr CSF;;ACTIVE;1.0n;2.70 +22482-4;Rickettsia rickettsii Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia rickettsii IgG Ab [Titer] in Serum;R rickettsi IgG Titr Ser;;ACTIVE;1.0n;2.73 +2248-3;Estriol;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Estriol (E3) [Mass/volume] in Amniotic fluid;Estriol Amn-mCnc;;ACTIVE;1.0;2.73 +22483-2;Rickettsia rickettsii Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia rickettsii IgM Ab [Titer] in Serum;R rickettsi IgM Titr Ser;;ACTIVE;1.0n;2.73 +22484-0;Rickettsia sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia sp Ab [Titer] in Serum;Rickettsia Ab Titr Ser;;ACTIVE;1.0n;2.70 +22485-7;Orientia tsutsugamushi Ab;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Ab [Titer] in Serum;O tsut Ab Titr Ser;;ACTIVE;1.0n;2.70 +22486-5;Rickettsia typhi Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi Ab [Units/volume] in Serum;R typhi Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22487-3;Rickettsia typhi Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi IgA Ab [Units/volume] in Serum;R typhi IgA Ser-aCnc;;ACTIVE;1.0n;2.69 +22488-1;Rickettsia typhi Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia typhi IgG Ab [Presence] in Serum;R typhi IgG Ser Ql;;ACTIVE;1.0n;2.73 +22489-9;Rickettsia typhi Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Serum;R typhi IgG Titr Ser;;ACTIVE;1.0n;2.73 +22490-7;Rickettsia typhi Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi IgM Ab [Titer] in Serum;R typhi IgM Titr Ser;;ACTIVE;1.0n;2.73 +2249-1;Estriol.unconjugated;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Estriol (E3).unconjugated [Mass/volume] in Amniotic fluid;u Estriol Amn-mCnc;;ACTIVE;1.0;2.73 +22491-5;Rickettsia typhus group Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia typhus group Ab [Presence] in Serum;Rick Typhus Ab Ser Ql;;ACTIVE;1.0n;2.56 +22492-3;Rickettsia typhus group Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhus group Ab [Titer] in Serum;Rick Typhus Ab Titr Ser;;ACTIVE;1.0n;2.70 +22493-1;Rickettsia typhus group Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhus group IgG Ab [Titer] in Serum;Rick Typhus IgG Titr Ser;;ACTIVE;1.0n;2.70 +22494-9;Rickettsia typhus group Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhus group IgM Ab [Titer] in Serum;Rick Typhus IgM Titr Ser;;ACTIVE;1.0n;2.70 +22495-6;Rotavirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rotavirus Ab [Titer] in Serum;RV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22496-4;Rubella virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rubella virus Ab [Presence] in Serum;RUBV Ab Ser Ql;;ACTIVE;1.0n;2.73 +22497-2;Rubella virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rubella virus Ab [Titer] in Serum;RUBV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22498-0;Measles virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Measles virus Ab [Titer] in Cerebral spinal fluid;MeV Ab Titr CSF;;ACTIVE;1.0n;2.70 +22499-8;Measles virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Measles virus Ab [Titer] in Serum;MeV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22500-3;Measles virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Measles virus IgG Ab [Units/volume] in Cerebral spinal fluid;MeV IgG CSF-aCnc;;ACTIVE;1.0n;2.73 +22501-1;Measles virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Measles virus IgG Ab [Titer] in Cerebral spinal fluid;MeV IgG Titr CSF;;ACTIVE;1.0n;2.73 +22502-9;Measles virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Measles virus IgG Ab [Titer] in Serum;MeV IgG Titr Ser;;ACTIVE;1.0n;2.73 +22503-7;Measles virus Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus IgG Ab [Units/volume] in Serum --1st specimen;MeV IgG sp1 Ser-aCnc;;ACTIVE;1.0n;2.69 +22504-5;Measles virus Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus IgG Ab [Units/volume] in Serum --2nd specimen;MeV IgG sp2 Ser-aCnc;;ACTIVE;1.0n;2.69 +22505-2;Measles virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Measles virus IgM Ab [Titer] in Cerebral spinal fluid;MeV IgM Titr CSF;;ACTIVE;1.0n;2.70 +22506-0;Measles virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Measles virus IgM Ab [Titer] in Serum;MeV IgM Titr Ser;;ACTIVE;1.0n;2.73 +22507-8;Saint Louis encephalitis virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Saint Louis encephalitis virus Ab [Presence] in Cerebral spinal fluid;SLEV Ab CSF Ql;;ACTIVE;1.0n;2.56 +22508-6;Saint Louis encephalitis virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Saint Louis encephalitis virus Ab [Presence] in Serum;Deprecated SLEV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +2250-9;Estriol.unconjugated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3).unconjugated [Mass/volume] in Serum or Plasma;u Estriol SerPl-mCnc;;ACTIVE;1.0;2.73 +22509-4;Saint Louis encephalitis virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Cerebral spinal fluid;SLEV Ab Titr CSF;;ACTIVE;1.0n;2.70 +22510-2;Saint Louis encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum;SLEV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22511-0;Saint Louis encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Saint Louis encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid;SLEV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22512-8;Saint Louis encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus IgG Ab [Titer] in Serum;SLEV IgG Titr Ser;;ACTIVE;1.0n;2.73 +22513-6;Saint Louis encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid;SLEV IgM Titr CSF;;ACTIVE;1.0n;2.70 +22514-4;Saint Louis encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Titer] in Serum;SLEV IgM Titr Ser;;ACTIVE;1.0n;2.73 +22515-1;Salmonella arizonae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella arizonae Ab [Presence] in Serum;S arizonae Ab Ser Ql;;ACTIVE;1.0n;2.67 +22516-9;Salmonella paratyphi A Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi A Ab [Presence] in Serum;S Paraty A Ab Ser Ql;;ACTIVE;1.0n;2.56 +2251-7;Estriol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3) [Mass/volume] in Serum or Plasma;Estriol SerPl-mCnc;;ACTIVE;1.0;2.73 +22517-7;Salmonella paratyphi A H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi A H Ab [Presence] in Serum;S paraty A H Ab Ser Ql;;ACTIVE;1.0n;2.73 +22518-5;Salmonella paratyphi A H Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi A H Ab [Titer] in Serum;S paraty A H Ab Titr Ser;;ACTIVE;1.0n;2.70 +22519-3;Salmonella paratyphi A O Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi A O Ab [Presence] in Serum;S paraty A O Ab Ser Ql;;ACTIVE;1.0n;2.56 +22520-1;Salmonella paratyphi B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi B Ab [Presence] in Serum;S Paraty B Ab Ser Ql;;ACTIVE;1.0n;2.56 +22521-9;Salmonella paratyphi B H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi B H Ab [Presence] in Serum;S paraty B H Ab Ser Ql;;ACTIVE;1.0n;2.73 +22522-7;Salmonella paratyphi B H Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi B H Ab [Titer] in Serum;S paraty B H Ab Titr Ser;;ACTIVE;1.0n;2.70 +22523-5;Salmonella paratyphi B O Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi B O Ab [Presence] in Serum;S paraty B O Ab Ser Ql;;ACTIVE;1.0n;2.56 +22524-3;Salmonella paratyphi C H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi C H Ab [Presence] in Serum;S paraty C H Ab Ser Ql;;ACTIVE;1.0n;2.56 +2252-5;Estriol;MCnc;Pt;Urine;Qn;;CHEM;1;Estriol (E3) [Mass/volume] in Urine;Estriol Ur-mCnc;;ACTIVE;1.0;2.42 +22525-0;Salmonella paratyphi C O Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella paratyphi C O Ab [Presence] in Serum;S paraty C O Ab Ser Ql;;ACTIVE;1.0n;2.56 +22526-8;Salmonella pullorum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella pullorum Ab [Presence] in Serum;S pullorum Ab Ser Ql;;ACTIVE;1.0n;2.67 +22527-6;Salmonella sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella sp Ab [Titer] in Serum;Salmonella Ab Titr Ser;;ACTIVE;1.0n;2.70 +22528-4;Salmonella typhi D Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Salmonella typhi D Ab [Presence] in Serum;Deprecated S typhi D Ab Ser Ql;;DEPRECATED;1.0n;2.40 +22529-2;Salmonella typhi H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella typhi H Ab [Presence] in Serum;S Typhi H Ab Ser Ql;;ACTIVE;1.0n;2.73 +225-3;Doxycycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Doxycycline [Susceptibility] by Minimum inhibitory concentration (MIC);Doxycycline Islt MIC;;ACTIVE;1.0;2.73 +22530-0;Salmonella typhi little d Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Salmonella typhi H D Ab [Presence] in Serum;Deprecated S typhi d Ab Ser Ql;;DEPRECATED;1.0n;2.36 +22531-8;Salmonella typhimurium Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella typhimurium Ab [Presence] in Serum;S Typhimur Ab Ser Ql;;ACTIVE;1.0n;2.67 +22532-6;Sarcocystis neurona Ab;PrThr;Pt;Bld;Ord;;MICRO;1;Sarcocystis neurona Ab [Presence] in Blood;S neurona Ab Bld Ql;;ACTIVE;1.0n;2.56 +2253-3;Estriol;MRat;24H;Urine;Qn;;CHEM;1;Estriol (E3) [Mass/time] in 24 hour Urine;Estriol 24h Ur-mRate;;ACTIVE;1.0;2.42 +22533-4;Sarcocystis neurona Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Sarcocystis neurona Ab [Presence] in Body fluid;S neurona Ab Fld Ql;;ACTIVE;1.0n;2.56 +22534-2;Sarcocystis neurona Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Sarcocystis neurona Ab [Presence] in Serum;S neurona Ab Ser Ql;;ACTIVE;1.0n;2.56 +22535-9;Schistosoma japonicum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Schistosoma japonicum Ab [Titer] in Serum;S japonicum Ab Titr Ser;;ACTIVE;1.0n;2.70 +22536-7;Schistosoma mansoni Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Schistosoma mansoni Ab [Presence] in Serum;S mansoni Ab Ser Ql;;ACTIVE;1.0n;2.56 +22537-5;Shigella boydii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Shigella boydii Ab [Titer] in Serum;S boydii Ab Titr Ser;;ACTIVE;1.0n;2.73 +22538-3;Shigella dysenteriae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Shigella dysenteriae Ab [Titer] in Serum;S dysenter Ab Titr Ser;;ACTIVE;1.0n;2.73 +22539-1;Shigella flexneri Ab;Titr;Pt;Ser;Qn;;MICRO;1;Shigella flexneri Ab [Titer] in Serum;S flexneri Ab Titr Ser;;ACTIVE;1.0n;2.70 +22540-9;Shigella sonnei Ab;Titr;Pt;Ser;Qn;;MICRO;1;Shigella sonnei Ab [Titer] in Serum;S sonnei Ab Titr Ser;;ACTIVE;1.0n;2.73 +2254-1;Estrogen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrogen [Mass/volume] in Serum or Plasma;Estrogen SerPl-mCnc;;ACTIVE;1.0;2.73 +22541-7;Streptococcus pneumoniae 1 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Units/volume] in Serum;Deprecated S pneum 1 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22542-5;Streptococcus pneumoniae 12 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Units/volume] in Serum;Deprecated S pneum12 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22543-3;Streptococcus pneumoniae 14 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Units/volume] in Serum;Deprecated S pneum14 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22544-1;Streptococcus pneumoniae 14 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum14 Ab sp1 Ser-aCnc;;DEPRECATED;1.0n;2.69 +22545-8;Streptococcus pneumoniae 14 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum14 Ab sp2 Ser-aCnc;;DEPRECATED;1.0n;2.69 +22546-6;Streptococcus pneumoniae 14 Ab^2nd specimen/Streptococcus pneumoniae 14 Ab^1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum14 Ab Ser-Rto;;DEPRECATED;1.0n;2.66 +22547-4;Streptococcus pneumoniae 19 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Units/volume] in Serum;Deprecated S pneum19 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22548-2;Streptococcus pneumoniae 23 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Units/volume] in Serum;Deprecated S pneum23 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22549-0;Streptococcus pneumoniae 3 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Units/volume] in Serum;Deprecated S pneum3 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22550-8;Streptococcus pneumoniae 6+26 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6+26 IgG Ab [Units/volume] in Serum;Deprecated S pneum6+26 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22551-6;Streptococcus pneumoniae 7 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 7 IgG Ab [Units/volume] in Serum;Deprecated S pneum7 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22552-4;Streptococcus pneumoniae Danish serotype 7F Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Units/volume] in Serum;S pneum Da 7F IgG Ser-aCnc;;ACTIVE;1.0n;2.69 +22553-2;Streptococcus pneumoniae 7f Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 51 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum7f Ab sp1 Ser-aCnc;;DEPRECATED;1.0n;2.69 +22554-0;Streptococcus pneumoniae 7f Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 51 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum7f Ab sp2 Ser-aCnc;;DEPRECATED;1.0n;2.69 +22555-7;Streptococcus pneumoniae Danish serotype 7F Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 7F Ab 2:1 Ser-Rto;;ACTIVE;1.0n;2.61 +22556-5;Streptococcus pneumoniae 8 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Units/volume] in Serum;Deprecated S pneum8 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22557-3;Streptococcus pneumoniae 9 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Presence] in Serum;Deprecated S pneum9 Ab Ser Ql;;DEPRECATED;1.0n;2.66 +2255-8;Estrogen;MCnc;Pt;Urine;Qn;;CHEM;1;Estrogen [Mass/volume] in Urine;Estrogen Ur-mCnc;;ACTIVE;1.0;2.42 +22558-1;Streptococcus pneumoniae 9 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Units/volume] in Serum;Deprecated S pneum9 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22559-9;Streptococcus pneumoniae 9n Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9n Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum9n Ab sp1 Ser-aCnc;;DEPRECATED;1.0n;2.69 +22560-7;Streptococcus pneumoniae 9 Ab^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Ratio] in Serum --1st specimen/2nd specimen;Deprecated S pneum9 Ab 1:2 Ser-Rto;;DEPRECATED;1.0n;2.66 +22561-5;Streptococcus pneumoniae 9n Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9n Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum9n Ab sp2 Ser-aCnc;;DEPRECATED;1.0n;2.69 +22562-3;Streptococcus pneumoniae Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae IgG Ab [Units/volume] in Serum --1st specimen;S pneum IgG sp1 Ser-aCnc;;ACTIVE;1.0n;2.69 +22563-1;Streptococcus pneumoniae Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;S pneum IgG 1:2 Ser-Rto;;ACTIVE;1.0n;2.73 +22564-9;Streptococcus pneumoniae Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae IgG Ab [Units/volume] in Serum --2nd specimen;S pneum IgG sp2 Ser-aCnc;;ACTIVE;1.0n;2.69 +22565-6;Streptococcus pneumoniae group B Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae group B Ab;Deprecated S pneumB Ab Ser Ql;;DEPRECATED;1.0n;2.36 +2256-6;Estrogen;MRat;24H;Urine;Qn;;CHEM;1;Estrogen [Mass/time] in 24 hour Urine;Estrogen 24h Ur-mRate;;ACTIVE;1.0;2.73 +22566-4;Streptococcus pyogenes enzyme Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcus pyogenes enzyme Ab [Presence] in Serum;S pyog.enz Ab Ser Ql;;ACTIVE;1.0n;2.73 +22567-2;Streptococcus pyogenes enzyme Ab;Titr;Pt;Ser;Qn;;MICRO;1;Streptococcus pyogenes enzyme Ab [Titer] in Serum;S pyog.enz Ab Titr Ser;;ACTIVE;1.0n;2.73 +22568-0;Streptolysin O Ab;Titr;Pt;Ser;Qn;;MICRO;1;Streptolysin O Ab [Titer] in Serum;ASO Ab Titr Ser;;ACTIVE;1.0n;2.73 +22569-8;Strongyloides sp Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Strongyloides sp Ab [Units/volume] in Serum;Deprecated Strongyloides Ab SerPl-aCnc;;DEPRECATED;1.0n;2.69 +22570-6;Taenia solium Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Taenia solium adult Ab [Units/volume] in Serum;Deprecated T sol Ab SerPl-aCnc;;DEPRECATED;1.0n;2.69 +22571-4;Teichoate Ab;Titr;Pt;Ser;Qn;;MICRO;1;Teichoate Ab [Titer] in Serum;Teichoate Ab Titr Ser;;ACTIVE;1.0n;2.73 +22572-2;Saccharomonospora viridis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Saccharomonospora viridis Ab [Presence] in Serum;S viridis Ab Ser Ql;;ACTIVE;1.0n;2.73 +22573-0;Thermoactinomyces vulgaris Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Thermoactinomyces vulgaris Ab [Presence] in Serum;T vulgaris Ab Ser Ql;;ACTIVE;1.0n;2.73 +2257-4;Estrone;MCnc;Pt;Semen;Qn;;CHEM;1;Estrone (E1) [Mass/volume] in Semen;Estrone Smn-mCnc;;ACTIVE;1.0;2.42 +22574-8;Toxocara canis Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Toxocara canis IgA Ab [Units/volume] in Serum;Deprecated T canis IgA Ser-aCnc;;DEPRECATED;1.0n;2.69 +22575-5;Toxocara canis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Toxocara canis IgG Ab [Units/volume] in Serum;T canis IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +22576-3;Toxocara canis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Toxocara canis IgM Ab [Units/volume] in Serum;Deprecated T canis IgM Ser-aCnc;;DEPRECATED;1.0n;2.69 +22577-1;Toxoplasma gondii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Toxoplasma gondii Ab [Presence] in Serum;T gondii Ab Ser Ql;;ACTIVE;1.0n;2.73 +22578-9;Toxoplasma gondii Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgA Ab [Units/volume] in Serum;T gondii IgA Ser-aCnc;;ACTIVE;1.0n;2.73 +22579-7;Toxoplasma gondii Ab.IgA+IgE;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgA+IgE Ab [Units/volume] in Serum;T gondii IgA+IgE Ser-aCnc;;ACTIVE;1.0n;2.42 +22580-5;Toxoplasma gondii Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Serum;T gondii IgG Ser Ql;;ACTIVE;1.0n;2.73 +22581-3;Toxoplasma gondii Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Titer] in Cerebral spinal fluid;T gondii IgG Titr CSF;;ACTIVE;1.0n;2.70 +2258-2;Estrone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrone (E1) [Mass/volume] in Serum or Plasma;Estrone SerPl-mCnc;;ACTIVE;1.0;2.73 +22582-1;Toxoplasma gondii Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Titer] in Serum;T gondii IgG Titr Ser;;ACTIVE;1.0n;2.73 +22583-9;Toxoplasma gondii Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Toxoplasma gondii IgM Ab [Titer] in Cerebral spinal fluid;T gondii IgM Titr CSF;;ACTIVE;1.0n;2.70 +22584-7;Toxoplasma gondii Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgM Ab [Titer] in Serum;T gondii IgM Titr Ser;;ACTIVE;1.0n;2.70 +22585-4;Treponema pallidum Ab;ACnc;Pt;Bld;Qn;;MICRO;1;Treponema pallidum Ab [Units/volume] in Blood;T pallidum Ab Bld-aCnc;;ACTIVE;1.0n;2.73 +22586-2;Treponema pallidum Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Treponema pallidum Ab [Presence] in Cerebral spinal fluid;T pallidum Ab CSF Ql;;ACTIVE;1.0n;2.56 +22587-0;Treponema pallidum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Treponema pallidum Ab [Presence] in Serum;T pallidum Ab Ser Ql;;ACTIVE;1.0n;2.73 +22588-8;Treponema pallidum Ab;ACnc;Pt;Ser/Plas;Ord;;MICRO;1;Deprecated Treponema pallidum Ab [Presence] in Serum;Deprecated T pallidum Ab SerPl Ql;;DEPRECATED;1.0n;2.36 +22589-6;Treponema pallidum Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Treponema pallidum Ab [Units/volume] in Serum;Deprecated T pallidum Ab SerPl-aCnc;;DEPRECATED;1.0n;2.69 +2259-0;Estrone;MCnc;Pt;Urine;Qn;;CHEM;1;Estrone (E1) [Mass/volume] in Urine;Estrone Ur-mCnc;;ACTIVE;1.0;2.42 +22590-4;Treponema pallidum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Treponema pallidum Ab [Titer] in Serum;T pallidum Ab Titr Ser;;ACTIVE;1.0n;2.70 +22591-2;Treponema pallidum Ab.IgG;ACnc;Pt;Ser/Plas;Ord;;MICRO;1;Deprecated Treponema pallidum IgG Ab [Presence] in Serum;Deprecated T pallidum IgG SerPl Ql;;DEPRECATED;1.0n;2.36 +22592-0;Treponema pallidum Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Treponema pallidum IgG Ab [Units/volume] in Serum;T pallidum IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +22593-8;Treponema pallidum Ab.IgM;ACnc;Pt;Ser/Plas;Ord;;MICRO;1;Deprecated Treponema pallidum IgM Ab [Presence] in Serum;Deprecated T pallidum IgM SerPl Ql;;DEPRECATED;1.0n;2.36 +22594-6;Treponema pallidum Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Treponema pallidum IgM Ab [Units/volume] in Serum;T pallidum IgM Ser-aCnc;;ACTIVE;1.0n;2.73 +22595-3;Trichinella spiralis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trichinella spiralis Ab [Presence] in Serum;T spiralis Ab Ser Ql;;ACTIVE;1.0n;2.56 +22596-1;Trichinella spiralis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Trichinella spiralis Ab [Titer] in Serum;T spiralis Ab Titr Ser;;ACTIVE;1.0n;2.70 +22597-9;Trichinella spiralis Ab.IgA;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Trichinella spiralis IgA Ab [Presence] in Serum;Deprecated T spiralis IgA Ser Ql;;DEPRECATED;1.0n;2.36 +22598-7;Trichinella spiralis Ab.IgM;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Trichinella spiralis IgM Ab [Presence] in Serum;Deprecated T spiralis IgM Ser Ql;;DEPRECATED;1.0n;2.36 +22599-5;Trypanosoma cruzi Ab;Titr;Pt;Ser;Qn;;MICRO;1;Trypanosoma cruzi Ab [Titer] in Serum;T cruzi Ab Titr Ser;;ACTIVE;1.0n;2.70 +22600-1;Varicella zoster virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Varicella zoster virus Ab [Presence] in Serum;VZV Ab Ser Ql;;ACTIVE;1.0n;2.73 +22601-9;Varicella zoster virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Varicella zoster virus IgG Ab [Titer] in Cerebral spinal fluid;VZV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22602-7;Varicella zoster virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus IgG Ab [Titer] in Serum;VZV IgG Titr Ser;;ACTIVE;1.0n;2.73 +22603-5;Varicella zoster virus Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Serum --1st specimen;VZV IgG sp1 Ser-aCnc;;ACTIVE;1.0n;2.69 +22604-3;Varicella zoster virus Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Serum --2nd specimen;VZV IgG sp2 Ser-aCnc;;ACTIVE;1.0n;2.69 +22605-0;Varicella zoster virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Varicella zoster virus IgM Ab [Titer] in Cerebral spinal fluid;VZV IgM Titr CSF;;ACTIVE;1.0n;2.70 +22606-8;Varicella zoster virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus IgM Ab [Titer] in Serum;VZV IgM Titr Ser;;ACTIVE;1.0n;2.73 +22607-6;Venezuelan equine encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Venezuelan equine encephalitis virus Ab [Titer] in Serum;VEEV Ab Titr Ser;;ACTIVE;1.0n;2.70 +2260-8;Estrone.unconjugated;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Estrone (E1).unconjugated [Mass/volume] in Amniotic fluid;u Estrone Amn-mCnc;;ACTIVE;1.0;2.42 +22608-4;Escherichia coli verotoxin 1 Ab;Titr;Pt;Stool;Qn;;MICRO;1;Escherichia coli verotoxin 1 Ab [Titer] in Stool;E coli VTN1 Ab Titr Stl;;ACTIVE;1.0n;2.70 +22609-2;Escherichia coli verotoxin 2 Ab;Titr;Pt;Stool;Qn;;MICRO;1;Escherichia coli verotoxin 2 Ab [Titer] in Stool;E coli VTN2 Ab Titr Stl;;ACTIVE;1.0n;2.70 +226-1;Doxycycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Doxycycline [Susceptibility] by Disk diffusion (KB);Doxycycline Islt KB;;ACTIVE;1.0;2.73 +22610-0;Western equine encephalitis virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Western equine encephalitis virus Ab [Presence] in Cerebral spinal fluid;WEEV Ab CSF Ql;;ACTIVE;1.0n;2.73 +22611-8;Western equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Western equine encephalitis virus Ab [Presence] in Serum;WEEV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22612-6;Western equine encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Western equine encephalitis virus Ab [Titer] in Serum;Deprecated WEEV Ab Titr Ser;;DEPRECATED;1.0n;2.70 +22613-4;Western equine encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Western equine encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid;WEEV IgG Titr CSF;;ACTIVE;1.0n;2.70 +22614-2;Western equine encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus IgG Ab [Titer] in Serum;WEEV IgG Titr Ser;;ACTIVE;1.0n;2.73 +22615-9;Western equine encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Western equine encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid;WEEV IgM Titr CSF;;ACTIVE;1.0n;2.70 +2261-6;Estrone.unconjugated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrone (E1).unconjugated [Mass/volume] in Serum or Plasma;u Estrone SerPl-mCnc;;ACTIVE;1.0;2.73 +22616-7;Western equine encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus IgM Ab [Titer] in Serum;WEEV IgM Titr Ser;;ACTIVE;1.0n;2.73 +22617-5;Wuchereria bancrofti Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Wuchereria bancrofti Ab [Presence] in Serum;W bancr Ab Ser Ql;;ACTIVE;1.0n;2.56 +22618-3;Yellow fever virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yellow fever virus Ab [Titer] in Serum;YFV Ab Titr Ser;;ACTIVE;1.0n;2.73 +22619-1;Yersinia enterocolitica Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica IgA Ab [Units/volume] in Serum;Y enterocol IgA Ser-aCnc;;ACTIVE;1.0n;2.69 +22620-9;Yersinia enterocolitica Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica IgG Ab [Units/volume] in Serum;Y enterocol IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +22621-7;Yersinia enterocolitica Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica IgM Ab [Units/volume] in Serum;Y enterocol IgM Ser-aCnc;;ACTIVE;1.0n;2.69 +22622-5;Xylose^1H post 25 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Deprecated Xylose [Mass/volume] in Blood --1 hour post 25 g xylose PO;Deprecated Xylose 1H p 25 g Xyl PO Bld-m;;DEPRECATED;1.0n;2.36 +22623-3;Xylose^2H post 25 g xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Deprecated Xylose [Molecules/volume] in Blood --2 hours post 25 g xylose PO;Deprecated Xylose 2H p 25 g Xyl PO Bld-s;;DEPRECATED;1.0n;2.36 +2262-4;Estrone.unconjugated;MRat;24H;Urine;Qn;;CHEM;1;Estrone (E1).unconjugated [Mass/time] in 24 hour Urine;u Estrone 24h Ur-mRate;;ACTIVE;1.0;2.42 +22624-1;Xylose^2H post 5 g xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --2 hours post 5 g xylose PO;Xylose 2h p 5 g Xyl PO Bld-sCnc;;ACTIVE;1.0n;2.40 +22625-8;Xylose^2H post dose xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --2 hours post dose xylose PO;Xylose 2h p Xyl PO Bld-sCnc;;ACTIVE;1.0n;2.40 +22626-6;Xylose^post 25 g xylose PO;MRat;5H;Urine;Qn;;CHAL;1;Xylose [Mass/time] in 5 hour Urine --post 25 g xylose PO;Xylose p 25 g Xyl PO 5h Ur-mRate;;ACTIVE;1.0n;2.73 +22627-4;Xylose^post 5 g xylose PO;MRat;5H;Urine;Qn;;CHAL;1;Xylose [Mass/time] in 5 hour Urine --post 5 g xylose PO;Xylose p 5 g Xyl PO 5h Ur-mRate;;ACTIVE;1.0n;2.70 +22628-2;Xylose^post 25 g xylose PO;SRat;5H;Urine;Qn;;CHAL;1;Xylose [Moles/time] in 5 hour Urine --post 25 g xylose PO;Xylose p 25 g Xyl PO 5h Ur-sRate;;ACTIVE;1.0n;2.70 +22629-0;Xylose^post 5 g xylose PO;SRat;5H;Urine;Qn;;CHAL;1;Xylose [Moles/time] in 5 hour Urine --post 5 g xylose PO;Xylose p 5 g Xyl PO 5h Ur-sRate;;ACTIVE;1.0n;2.70 +22630-8;Xylose/Xylose.dose^post 25 g xylose PO;SFr;5H;Urine;Qn;;CHAL;1;Xylose/Xylose dose in 5 hour Urine --post 25 g xylose PO;Xylose p 25 g Xyl PO 5h SFr Ur;;ACTIVE;1.0n;2.73 +22631-6;Xylose/Xylose.dose^post 5 g xylose PO;SFr;5H;Urine;Qn;;CHAL;1;Xylose/Xylose dose in 5 hour Urine --post 5 g xylose PO;Xylose p 5 g Xyl PO 5h SFr Ur;;ACTIVE;1.0n;2.70 +2263-2;Ethanolamine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ethanolamine [Mass/volume] in Serum or Plasma;Ethanolamine SerPl-mCnc;;ACTIVE;1.0;2.73 +22632-4;Xylose/Xylose.dose^post dose xylose PO;SFr;5H;Urine;Qn;;CHAL;1;Xylose/Xylose dose in 5 hour Urine --post dose xylose PO;Xylose p Xyl PO 5h SFr Ur;;ACTIVE;1.0n;2.70 +22633-2;Path report.site of origin;Anat;Pt;Specimen;Nar;;TUMRRGT;2;Pathology report site of origin Narrative;Path report.site of origin Spec;;ACTIVE;1.0n;2.73 +22634-0;Path report.gross observation;Find;Pt;Specimen;Nar;;TUMRRGT;2;Pathology report gross observation Narrative;Path report.gross Spec;;ACTIVE;1.0n;2.73 +22635-7;Path report.microscopic observation;Prid;Pt;Specimen;Nar;XXX stain;TUMRRGT;2;Pathology report microscopic observation Narrative Other stain;Path report.microscopic Spec Other Stn;;ACTIVE;1.0n;2.73 +22636-5;Path report.relevant Hx;Find;Pt;Specimen;Nar;;TUMRRGT;2;Pathology report relevant history Narrative;Path report.relevant Hx Spec;;ACTIVE;1.0n;2.73 +22637-3;Path report.final diagnosis;Imp;Pt;Specimen;Nar;;TUMRRGT;2;Pathology report final diagnosis Narrative;Path report.final Dx Spec;;ACTIVE;1.0n;2.73 +22638-1;Path report.comments;Imp;Pt;Specimen;Nar;;TUMRRGT;2;Pathology report comments [Interpretation] Narrative;Path report.comments Imp Spec;;ACTIVE;1.0n;2.73 +22639-9;Path report.supplemental reports;Find;Pt;Specimen;Nar;;TUMRRGT;2;Pathology report supplemental reports Narrative;Path report.supplemental reports Spec;;ACTIVE;1.0n;2.73 +2264-0;Ethanolamine;MCnc;Pt;Urine;Qn;;CHEM;1;Ethanolamine [Mass/volume] in Urine;Ethanolamine Ur-mCnc;;ACTIVE;1.0;2.42 +22640-7;Path report.staging evidence;Find;Pt;Specimen;Nar;;TUMRRGT;2;Pathology report staging evidence Narrative;Path report.staging evidence Spec;;ACTIVE;1.0n;2.40 +22641-5;Glutamine;SCnc;Pt;CSF;Qn;;CHEM;1;Glutamine [Moles/volume] in Cerebral spinal fluid;Glutamine CSF-sCnc;;ACTIVE;1.0n;2.73 +22642-3;Tyrosine;SCnc;Pt;CSF;Qn;;CHEM;1;Tyrosine [Moles/volume] in Cerebral spinal fluid;Tyrosine CSF-sCnc;;ACTIVE;1.0n;2.73 +22643-1;Threonine;SCnc;Pt;CSF;Qn;;CHEM;1;Threonine [Moles/volume] in Cerebral spinal fluid;Threonine CSF-sCnc;;ACTIVE;1.0n;2.73 +22644-9;Serine;SCnc;Pt;CSF;Qn;;CHEM;1;Serine [Moles/volume] in Cerebral spinal fluid;Serine CSF-sCnc;;ACTIVE;1.0n;2.73 +22645-6;Proline;SCnc;Pt;CSF;Qn;;CHEM;1;Proline [Moles/volume] in Cerebral spinal fluid;Proline CSF-sCnc;;ACTIVE;1.0n;2.73 +22646-4;Phenylalanine;SCnc;Pt;CSF;Qn;;CHEM;1;Phenylalanine [Moles/volume] in Cerebral spinal fluid;Phe CSF-sCnc;;ACTIVE;1.0n;2.73 +22647-2;Ornithine;SCnc;Pt;CSF;Qn;;CHEM;1;Ornithine [Moles/volume] in Cerebral spinal fluid;Ornithine CSF-sCnc;;ACTIVE;1.0n;2.73 +22648-0;Methionine;SCnc;Pt;CSF;Qn;;CHEM;1;Methionine [Moles/volume] in Cerebral spinal fluid;Methionine CSF-sCnc;;ACTIVE;1.0n;2.73 +22649-8;Valine;SCnc;Pt;CSF;Qn;;CHEM;1;Valine [Moles/volume] in Cerebral spinal fluid;Valine CSF-sCnc;;ACTIVE;1.0n;2.73 +22650-6;Glycine;SCnc;Pt;CSF;Qn;;CHEM;1;Glycine [Moles/volume] in Cerebral spinal fluid;Glycine CSF-sCnc;;ACTIVE;1.0n;2.73 +22651-4;Lysine;SCnc;Pt;CSF;Qn;;CHEM;1;Lysine [Moles/volume] in Cerebral spinal fluid;Lysine CSF-sCnc;;ACTIVE;1.0n;2.73 +22652-2;Glutamate;SCnc;Pt;CSF;Qn;;CHEM;1;Glutamate [Moles/volume] in Cerebral spinal fluid;Glutamate CSF-sCnc;;ACTIVE;1.0n;2.73 +22653-0;Cystine;SCnc;Pt;CSF;Qn;;CHEM;1;Cystine [Moles/volume] in Cerebral spinal fluid;Cystine CSF-sCnc;;ACTIVE;1.0n;2.73 +22654-8;Citrulline;SCnc;Pt;CSF;Qn;;CHEM;1;Citrulline [Moles/volume] in Cerebral spinal fluid;Citrulline CSF-sCnc;;ACTIVE;1.0n;2.73 +22655-5;Aspartate;SCnc;Pt;CSF;Qn;;CHEM;1;Aspartate [Moles/volume] in Cerebral spinal fluid;Aspartate CSF-sCnc;;ACTIVE;1.0n;2.73 +22656-3;Arginine;SCnc;Pt;CSF;Qn;;CHEM;1;Arginine [Moles/volume] in Cerebral spinal fluid;Arginine CSF-sCnc;;ACTIVE;1.0n;2.73 +2265-7;Ethylmalonate;MCnc;Pt;Urine;Qn;;CHEM;1;Ethylmalonate [Mass/volume] in Urine;Ethylmalonate Ur-mCnc;;ACTIVE;1.0;2.73 +22657-1;Alanine;SCnc;Pt;CSF;Qn;;CHEM;1;Alanine [Moles/volume] in Cerebral spinal fluid;Alanine CSF-sCnc;;ACTIVE;1.0n;2.73 +22658-9;Alloisoleucine;SCnc;Pt;CSF;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in Cerebral spinal fluid;Alloisoleucine CSF-sCnc;;ACTIVE;1.0n;2.73 +22659-7;Isoleucine;SCnc;Pt;CSF;Qn;;CHEM;1;Isoleucine [Moles/volume] in Cerebral spinal fluid;Isoleucine CSF-sCnc;;ACTIVE;1.0n;2.73 +22660-5;Homocystine;SCnc;Pt;CSF;Qn;;CHEM;1;Homocystine [Moles/volume] in Cerebral spinal fluid;(Hcys)2 CSF-sCnc;;ACTIVE;1.0n;2.73 +22661-3;Coproporphyrin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Coproporphyrin [Moles/volume] in Serum or Plasma;Copro SerPl-sCnc;;ACTIVE;1.0n;2.70 +22662-1;Uroporphyrin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Uroporphyrin [Moles/volume] in Serum or Plasma;Uropor SerPl-sCnc;;ACTIVE;1.0n;2.70 +22663-9;Estrone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrone (E1) [Moles/volume] in Serum or Plasma;Estrone SerPl-sCnc;;ACTIVE;1.0n;2.73 +22664-7;Urea;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea [Moles/volume] in Serum or Plasma;Urea SerPl-sCnc;;ACTIVE;1.0n;2.70 +2266-5;Etiocholanolone;PrThr;Pt;Urine;Ord;;CHEM;1;Etiocholanolone [Presence] in Urine;Etiocholanolone Ur Ql;;ACTIVE;1.0;2.56 +22665-4;Bilirubin.albumin bound;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.delta [Moles/volume] in Serum or Plasma;Bilirub Delta SerPl-sCnc;;ACTIVE;1.0n;2.70 +22666-2;Busulfan;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Busulfan [Moles/volume] in Serum or Plasma;Busulfan SerPl-sCnc;;ACTIVE;1.0n;2.70 +22667-0;Fatty acids.nonesterified;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Fatty acids.nonesterified [Molecules/volume] in Serum or Plasma;Deprecated NEFA SerPl-sCnc;;DEPRECATED;1.0n;2.70 +22668-8;Propylene glycol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propylene glycol [Moles/volume] in Serum or Plasma;Prop glycol SerPl-sCnc;;ACTIVE;1.0n;2.70 +22669-6;Glutamate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Glutamate [Molecules/volume] in Serum or Plasma;Deprecated Glutamate SerPl-sCnc;;DEPRECATED;1.0n;2.70 +22670-4;Alloisoleucine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in Serum or Plasma;Alloisoleucine SerPl-sCnc;;ACTIVE;1.0n;2.73 +22671-2;Phytanate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phytanate (C16:0(CH3)4) [Moles/volume] in Serum or Plasma;Phytanate SerPl-sCnc;;ACTIVE;1.0n;2.73 +22672-0;Cystine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystine [Moles/volume] in Serum or Plasma;Cystine SerPl-sCnc;;ACTIVE;1.0n;2.73 +2267-3;Etiocholanolone;MCnc;Pt;Urine;Qn;;CHEM;1;Etiocholanolone [Mass/volume] in Urine;Etiocholanolone Ur-mCnc;;ACTIVE;1.0;2.73 +22673-8;Homocystine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Homocystine [Molecules/volume] in Serum or Plasma;Deprecated Homocystine SerPl-sCnc;;DEPRECATED;1.0n;2.70 +22674-6;Transferrin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin [Moles/volume] in Serum or Plasma;Transferrin SerPl-sCnc;;ACTIVE;1.0n;2.73 +22675-3;Angiotensin converting enzyme;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma;Deprecated ACE SerPl-cCnc;;DEPRECATED;1.0n;2.70 +22676-1;7-Dehydrocholesterol;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;7-Dehydrocholesterol [Presence] in Serum or Plasma;7-DHC SerPl Ql;;ACTIVE;1.0n;2.56 +22677-9;Aspartate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Aspartate [Molecules/volume] in Serum or Plasma;Deprecated Aspartate SerPl-sCnc;;DEPRECATED;1.0n;2.70 +22678-7;Ethylene glycol;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethylene glycol [Moles/volume] in Urine;Ethylene Glycol Ur-sCnc;;ACTIVE;1.0n;2.70 +22679-5;Lysine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Lysine/Creatinine [Molar ratio] in Urine;Lysine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22680-3;Mercury/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Mercury/Creatinine [Molar ratio] in Urine;Mercury/Creat Ur-sRto;;ACTIVE;1.0n;2.70 +2268-1;Etiocholanolone;MRat;24H;Urine;Qn;;CHEM;1;Etiocholanolone [Mass/time] in 24 hour Urine;Etiocholanolone 24h Ur-mRate;;ACTIVE;1.0;2.73 +22681-1;Methionine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Methionine/Creatinine [Molar ratio] in Urine;Methionine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22682-9;Ornithine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Ornithine/Creatinine [Molar ratio] in Urine;Ornithine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22683-7;Phenylalanine/Creatinine;SCrto;Pt;Urine;Qn;;CHEM;1;Deprecated Phenylalanine/Creatinine [Molecular ratio] in Urine;Deprecated Phe/creat Ur-sRto;;DEPRECATED;1.0n;2.70 +22684-5;Serine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Serine/Creatinine [Molar ratio] in Urine;Serine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22685-2;Tyrosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tyrosine/Creatinine [Molar ratio] in Urine;Tyrosine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22686-0;Protoporphyrin;SRat;24H;Urine;Qn;;CHEM;1;Protoporphyrin [Moles/time] in 24 hour Urine;Protopor 24h Ur-sRate;;ACTIVE;1.0n;2.70 +22687-8;Cystine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Cystine/Creatinine [Molar ratio] in Urine;Cystine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22688-6;Threonine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Threonine/Creatinine [Molar ratio] in Urine;Threonine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22689-4;Zinc;SRat;24H;Urine;Qn;;DRUG/TOX;1;Zinc [Moles/time] in 24 hour Urine;Zinc 24h Ur-sRate;;ACTIVE;1.0n;2.70 +22690-2;Proline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Proline/Creatinine [Molar ratio] in Urine;Proline/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22691-0;Aspartate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Aspartate/Creatinine [Molar ratio] in Urine;Aspartate/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22692-8;Valine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Valine/Creatinine [Molar ratio] in Urine;Valine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22693-6;Leucine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Leucine/Creatinine [Molar ratio] in Urine;Leucine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22694-4;Citrulline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Citrulline/Creatinine [Molar ratio] in Urine;Citrulline/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22695-1;Carnitine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Carnitine/Creatinine [Molar ratio] in Urine;Carnitine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22696-9;Cadmium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Cadmium/Creatinine [Molar ratio] in Urine;Cadmium/Creat Ur-sRto;;ACTIVE;1.0n;2.70 +22697-7;Arginine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Arginine/Creatinine [Molar ratio] in Urine;Arginine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22698-5;Alanine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alanine/Creatinine [Molar ratio] in Urine;Alanine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +2269-9;Complement factor B;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement factor B [Mass/volume] in Serum or Plasma;Comp Fact B SerPl-mCnc;;ACTIVE;1.0;2.73 +22699-3;Alloisoleucine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alloisoleucine/Creatinine [Molar ratio] in Urine;Alloisoleucine/Creat Ur-sRto;;ACTIVE;1.0n;2.70 +22700-9;Urea;SCnc;Pt;Urine;Qn;;CHEM;1;Urea [Moles/volume] in Urine;Urea Ur-sCnc;;ACTIVE;1.0n;2.73 +22701-7;Salicylates;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Salicylates [Moles/volume] in Urine;Salicylates Ur-sCnc;;ACTIVE;1.0n;2.70 +22702-5;Ketones;SCnc;Pt;Urine;Qn;Test strip;UA;1;Ketones [Moles/volume] in Urine by Test strip;Ketones Ur Strip-sCnc;;ACTIVE;1.0n;2.73 +22703-3;Histidine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Histidine/Creatinine [Molar ratio] in Urine;Histidine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22704-1;Carnitine.free (C0)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Carnitine free (C0)/Creatinine [Molar ratio] in Urine;Carnitine Free/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22705-8;Glucose;SCnc;Pt;Urine;Qn;Test strip;UA;1;Glucose [Moles/volume] in Urine by Test strip;Glucose Ur Strip-sCnc;;ACTIVE;1.0n;2.73 +22706-6;Isoleucine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Isoleucine/Creatinine [Molar ratio] in Urine;Isoleucine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +2270-7;Fat;PrThr;Pt;Stool;Ord;;CHEM;1;Fat [Presence] in Stool;Fat Stl Ql;;ACTIVE;1.0;2.73 +22707-4;Homocystine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homocystine/Creatinine [Molar ratio] in Urine;(Hcys)2/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22708-2;Homovanillate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homovanillate/Creatinine [Molar ratio] in Urine;HVA/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22709-0;Glycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glycine/Creatinine [Molar ratio] in Urine;Glycine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22710-8;Glutamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutamine/Creatinine [Molar ratio] in Urine;Glutamine/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22711-6;Glutamate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutamate/Creatinine [Molar ratio] in Urine;Glutamate/Creat Ur-sRto;;ACTIVE;1.0n;2.73 +22712-4;Adenosine monophosphate.cyclic;SCnc;Pt;Urine;Qn;;CHEM;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine;cAMP Ur-sCnc;;ACTIVE;1.0n;2.73 +22713-2;Lysine;SCnc;Pt;XXX;Qn;;CHEM;1;Lysine [Moles/volume] in Specimen;Lysine Spec-sCnc;;ACTIVE;1.0n;2.73 +22714-0;Isoleucine;SCnc;Pt;XXX;Qn;;CHEM;1;Isoleucine [Moles/volume] in Specimen;Isoleucine Spec-sCnc;;ACTIVE;1.0n;2.73 +2271-5;Fat;MRat;72H;Stool;Qn;;CHEM;1;Fat [Mass/time] in 72 hour Stool;Fat 72h Stl-mRate;;ACTIVE;1.0;2.73 +22715-7;Homocystine;SCnc;Pt;XXX;Qn;;CHEM;1;Homocystine [Moles/volume] in Specimen;(Hcys)2 Spec-sCnc;;ACTIVE;1.0n;2.73 +22716-5;Methionine;SCnc;Pt;XXX;Qn;;CHEM;1;Methionine [Moles/volume] in Specimen;Methionine Spec-sCnc;;ACTIVE;1.0n;2.73 +22717-3;Histidine;SCnc;Pt;XXX;Qn;;CHEM;1;Histidine [Moles/volume] in Specimen;Histidine Spec-sCnc;;ACTIVE;1.0n;2.73 +22718-1;Glycine;SCnc;Pt;XXX;Qn;;CHEM;1;Glycine [Moles/volume] in Specimen;Glycine Spec-sCnc;;ACTIVE;1.0n;2.73 +22719-9;Leucine;SCnc;Pt;XXX;Qn;;CHEM;1;Leucine [Moles/volume] in Specimen;Leucine Spec-sCnc;;ACTIVE;1.0n;2.73 +22720-7;Glutamine;SCnc;Pt;XXX;Qn;;CHEM;1;Glutamine [Moles/volume] in Specimen;Glutamine Spec-sCnc;;ACTIVE;1.0n;2.73 +22721-5;Glutamate;SCnc;Pt;XXX;Qn;;CHEM;1;Glutamate [Moles/volume] in Specimen;Glutamate Spec-sCnc;;ACTIVE;1.0n;2.73 +22722-3;Citrulline;SCnc;Pt;XXX;Qn;;CHEM;1;Citrulline [Moles/volume] in Specimen;Citrulline Spec-sCnc;;ACTIVE;1.0n;2.73 +2272-3;Fat;PrThr;Pt;Urine;Ord;;CHEM;1;Fat [Presence] in Urine;Fat Ur Ql;;ACTIVE;1.0;2.73 +22723-1;Aspartate;SCnc;Pt;XXX;Qn;;CHEM;1;Aspartate [Moles/volume] in Specimen;Aspartate Spec-sCnc;;ACTIVE;1.0n;2.73 +22724-9;Alanine;SCnc;Pt;XXX;Qn;;CHEM;1;Alanine [Moles/volume] in Specimen;Alanine Spec-sCnc;;ACTIVE;1.0n;2.73 +22725-6;Ornithine;SCnc;Pt;XXX;Qn;;CHEM;1;Ornithine [Moles/volume] in Specimen;Ornithine Spec-sCnc;;ACTIVE;1.0n;2.73 +22726-4;Creatinine;SCnc;Pt;XXX;Qn;;CHEM;1;Creatinine [Moles/volume] in Specimen;Creat Spec-sCnc;;ACTIVE;1.0n;2.73 +22727-2;Arginine;SCnc;Pt;XXX;Qn;;CHEM;1;Arginine [Moles/volume] in Specimen;Arginine Spec-sCnc;;ACTIVE;1.0n;2.73 +22728-0;Cystine;SCnc;Pt;XXX;Qn;;CHEM;1;Cystine [Moles/volume] in Specimen;Cystine Spec-sCnc;;ACTIVE;1.0n;2.70 +22729-8;Valine;SCnc;Pt;XXX;Qn;;CHEM;1;Valine [Moles/volume] in Specimen;Valine Spec-sCnc;;ACTIVE;1.0n;2.70 +22730-6;Alloisoleucine;SCnc;Pt;XXX;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in Specimen;Alloisoleucine Spec-sCnc;;ACTIVE;1.0n;2.70 +2273-1;Fatty acids.esterified;MCnc;Pt;Bld;Qn;;CHEM;1;Fatty acids.esterified [Mass/volume] in Blood;EFA Bld-mCnc;;ACTIVE;1.0;2.34 +22731-4;Triglyceride;SCnc;Pt;XXX;Qn;;CHEM;1;Triglyceride [Moles/volume] in Specimen;Trigl Spec-sCnc;;ACTIVE;1.0n;2.73 +22732-2;Salicylates;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Salicylates [Moles/volume] in Specimen;Salicylates Spec-sCnc;;ACTIVE;1.0n;2.70 +22733-0;Phosphate;SCnc;Pt;XXX;Qn;;CHEM;1;Phosphate [Moles/volume] in Specimen;Phosphate Spec-sCnc;;ACTIVE;1.0n;2.73 +22734-8;Ethylene glycol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ethylene glycol [Moles/volume] in Specimen;Ethylene Glycol Spec-sCnc;;ACTIVE;1.0n;2.70 +22735-5;Bicarbonate;SCnc;Pt;XXX;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Specimen;HCO3 Spec-sCnc;;ACTIVE;1.0n;2.73 +22736-3;Acetaminophen;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Acetaminophen [Moles/volume] in Specimen;APAP Spec-sCnc;;ACTIVE;1.0n;2.70 +22737-1;Phenylalanine;SCnc;Pt;XXX;Qn;;CHEM;1;Phenylalanine [Moles/volume] in Specimen;Phe Spec-sCnc;;ACTIVE;1.0n;2.73 +22738-9;Urea;SCnc;Pt;XXX;Qn;;CHEM;1;Urea [Moles/volume] in Specimen;Urea Spec-sCnc;;ACTIVE;1.0n;2.70 +22739-7;Tyrosine;SCnc;Pt;XXX;Qn;;CHEM;1;Tyrosine [Moles/volume] in Specimen;Tyrosine Spec-sCnc;;ACTIVE;1.0n;2.70 +22740-5;Threonine;SCnc;Pt;XXX;Qn;;CHEM;1;Threonine [Moles/volume] in Specimen;Threonine Spec-sCnc;;ACTIVE;1.0n;2.73 +22741-3;Serine;SCnc;Pt;XXX;Qn;;CHEM;1;Serine [Moles/volume] in Specimen;Serine Spec-sCnc;;ACTIVE;1.0n;2.73 +22742-1;Propylene glycol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Propylene glycol [Moles/volume] in Specimen;Prop glycol Spec-sCnc;;ACTIVE;1.0n;2.70 +22743-9;Proline;SCnc;Pt;XXX;Qn;;CHEM;1;Proline [Moles/volume] in Specimen;Proline Spec-sCnc;;ACTIVE;1.0n;2.70 +22744-7;Copper;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Copper [Moles/volume] in Specimen;Copper Spec-sCnc;;ACTIVE;1.0n;2.70 +22745-4;Ethanol;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethanol [Moles/volume] in Urine;Ethanol Ur-sCnc;;ACTIVE;1.0n;2.73 +22746-2;Gentamicin^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Moles/volume] in Serum or Plasma --peak;Gentamicin Peak SerPl-sCnc;;ACTIVE;1.0n;2.73 +22747-0;Gentamicin^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Moles/volume] in Serum or Plasma --trough;Gentamicin Trough SerPl-sCnc;;ACTIVE;1.0n;2.73 +22748-8;Cholesterol.in LDL;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL [Moles/volume] in Serum or Plasma;LDLc SerPl-sCnc;;ACTIVE;1.0n;2.73 +2274-9;Fatty acids.nonesterified;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Fatty acids.nonesterified [Mass/volume] in Plasma;Deprecated NEFA Plas-mCnc;;DEPRECATED;1.0;2.40 +22749-6;Amylase.pancreatic;CCnc;Pt;Urine;Qn;;CHEM;1;Amylase.pancreatic [Enzymatic activity/volume] in Urine;Amylase P Ur-cCnc;;ACTIVE;1.0n;2.70 +22750-4;Tobramycin^random;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Moles/volume] in Serum or Plasma --random;Tobramycin Rand SerPl-sCnc;;DISCOURAGED;1.0n;2.73 +22751-2;Tobramycin^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Moles/volume] in Serum or Plasma --peak;Tobramycin Peak SerPl-sCnc;;ACTIVE;1.0n;2.73 +22752-0;Tobramycin^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Moles/volume] in Serum or Plasma --trough;Tobramycin Trough SerPl-sCnc;;ACTIVE;1.0n;2.73 +22753-8;Iron binding capacity.unsaturated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron binding capacity.unsaturated [Moles/volume] in Serum or Plasma;UIBC SerPl-sCnc;;ACTIVE;1.0n;2.73 +22754-6;Dibucaine number;ACnc;Pt;Ser;Qn;;CHEM;1;Deprecated Dibucaine number in Serum or Plasma;Deprecated Dibucaine Number Ser-aCnc;;DEPRECATED;1.0n;2.69 +22755-3;Haemophilus influenzae B Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae B Ab [Mass/volume] in Serum;Haem influ B Ab Ser-mCnc;;ACTIVE;1.0n;2.40 +2275-6;Fatty acids;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids [Mass/volume] in Serum or Plasma;FA SerPl-mCnc;;ACTIVE;1.0;2.34 +22756-1;HLA-DR;ACnc;Pt;CSF;Qn;;HLA;1;HLA-DR [Units/volume] in Cerebral spinal fluid;HLA-DR CSF-aCnc;;ACTIVE;1.0n;2.69 +22757-9;Metanephrine;MRat;24H;Urine;Qn;;CHEM;1;Deprecated Metanephrine [Mass/time] in 24 hour Urine;Deprecated Metaneph 24H Ur-mRate;;DEPRECATED;1.0n;2.36 +22758-7;Plasminogen activator inhibitor 1 Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator inhibitor 1 Ag [Mass/volume] in Platelet poor plasma by Immunoassay;PAI1 Ag PPP IA-mCnc;;ACTIVE;1.0n;2.73 +22759-5;Platelet Ab;Titr;Pt;Ser;Qn;;SERO;1;Platelet Ab [Titer] in Serum;Platelet Ab Titr Ser;;ACTIVE;1.0n;2.70 +22760-3;Potassium;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Potassium [Mass/volume] in Serum or Plasma;Potassium SerPl-mCnc;;DISCOURAGED;1.0n;2.73 +22761-1;Pristanate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pristanate (C15:0(CH3)4) [Moles/volume] in Serum or Plasma;Pristanate SerPl-sCnc;;ACTIVE;1.0n;2.73 +22762-9;Streptococcus pneumoniae 12 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Units/volume] in Serum;Deprecated S pneum12 IgG Ser-aCnc;;DEPRECATED;1.0n;2.69 +22763-7;Ammonia;MCnc;Pt;Plas;Qn;;CHEM;1;Ammonia [Mass/volume] in Plasma;Ammonia Plas-mCnc;;ACTIVE;1.0n;2.73 +2276-4;Ferritin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ferritin [Mass/volume] in Serum or Plasma;Ferritin SerPl-mCnc;;ACTIVE;1.0;2.73 +22764-5;Actinobacillus pleuropneumoniae Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Actinobacillus pleuropneumoniae Ab [Presence] in Serum by Complement fixation;A pleuropn Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +22765-2;Adult fly identified;Prid;Pt;XXX;Nom;;MICRO;1;Adult fly identified in Specimen;Adult Fly Spec;;ACTIVE;1.0n;2.69 +22766-0;African horse sickness virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;African horse sickness virus Ab [Presence] in Serum by Immunoassay;AHSV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22767-8;African horse sickness virus Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;African horse sickness virus Ab [Presence] in Serum by Immunoblot;AHSV Ab Ser Ql IB;;ACTIVE;1.0n;2.58 +22768-6;African horse sickness virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;African horse sickness virus Ab [Presence] in Serum by Complement fixation;AHSV Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +22769-4;African horse sickness virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;African horse sickness virus neutralizing antibody [Titer] in Serum by Neutralization test;AHSV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +22770-2;African horse sickness virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;African horse sickness virus Ab [Titer] in Serum;AHSV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22771-0;African horse sickness virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;African horse sickness virus Ab [Presence] in Serum;AHSV Ab Ser Ql;;ACTIVE;1.0n;2.56 +2277-2;Ferrochelatase;CCnc;Pt;Ser;Qn;;CHEM;1;Ferrochelatase [Enzymatic activity/volume] in Serum;Ferrochelatase Ser-cCnc;;ACTIVE;1.0;2.68 +22772-8;African horse sickness virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;African horse sickness virus Ag [Presence] in Tissue by Immunoassay;AHSV Ag Tiss Ql IA;;ACTIVE;1.0n;2.56 +22773-6;African horse sickness virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;African horse sickness virus Ag [Presence] in Specimen by Immunoassay;AHSV Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +22774-4;African horse sickness virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;African horse sickness virus RNA [Presence] in Tissue by NAA with probe detection;AHSV RNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22775-1;African horse sickness virus serotype;Prid;Pt;Ser;Nom;Neut;MICRO;1;African horse sickness virus serotype [Identifier] in Serum by Neutralization test;AHSV Sertyp Ser Nt;;ACTIVE;1.0n;1.0n +22776-9;African horse sickness virus serotype;Prid;Pt;XXX;Nom;Neut;MICRO;1;African horse sickness virus serotype [Identifier] in Specimen by Neutralization test;AHSV Sertyp Spec Nt;;ACTIVE;1.0n;2.69 +22777-7;African swine fever virus Ab;PrThr;Pt;Body fld;Ord;IA;MICRO;1;African swine fever virus Ab [Presence] in Body fluid by Immunoassay;ASFV Ab Fld Ql IA;;ACTIVE;1.0n;2.56 +22778-5;African swine fever virus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;African swine fever virus Ab [Presence] in Body fluid;ASFV Ab Fld Ql;;ACTIVE;1.0n;2.56 +22779-3;African swine fever virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;African swine fever virus Ab [Presence] in Serum;ASFV Ab Ser Ql;;ACTIVE;1.0n;2.56 +2278-0;Fibrinopeptide B;MCnc;Pt;Ser;Qn;;COAG;1;Fibrinopeptide B [Mass/volume] in Serum;FpB Ser-mCnc;;ACTIVE;1.0;2.42 +22780-1;African swine fever virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;African swine fever virus Ab [Presence] in Serum by Immunoassay;ASFV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22781-9;African swine fever virus Ag;PrThr;Pt;XXX;Ord;Aggl;MICRO;1;African swine fever virus Ag [Presence] in Specimen by Agglutination;ASFV Ag Spec Ql Aggl;;ACTIVE;1.0n;2.69 +22782-7;African swine fever virus Ag;PrThr;Pt;Tiss;Ord;Aggl;MICRO;1;African swine fever virus Ag [Presence] in Tissue by Agglutination;ASFV Ag Tiss Ql Aggl;;ACTIVE;1.0n;2.56 +22783-5;African swine fever virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;African swine fever virus Ag [Presence] in Tissue by Immunofluorescence;ASFV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +22784-3;African swine fever virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;African swine fever virus Ag [Presence] in Specimen by Immunofluorescence;ASFV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22785-0;African swine fever virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;African swine fever virus DNA [Presence] in Tissue by NAA with probe detection;ASFV DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22786-8;Alcelaphine herpesvirus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Alcelaphine herpesvirus 1 Ab [Titer] in Serum;AHV1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +22787-6;Alcelaphine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Alcelaphine herpesvirus 1 Ab [Presence] in Serum by Immunofluorescence;AHV1 Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +22788-4;Alcelaphine herpesvirus 1 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Alcelaphine herpesvirus 1 neutralizing antibody [Titer] in Serum by Neutralization test;AHV1 NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +22789-2;Alcelaphine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Alcelaphine herpesvirus 1 Ag [Presence] in Specimen by Immunofluorescence;AHV1 Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +227-9;Doxycycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Doxycycline [Susceptibility] by Serum bactericidal titer;Doxycycline Titr SBT;;ACTIVE;1.0;2.32 +22790-0;Alcelaphine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Alcelaphine herpesvirus 1 Ag [Presence] in Specimen by Immune stain;AHV1 Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +22791-8;Alcelaphine herpesvirus 1 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Alcelaphine herpesvirus 1 DNA [Presence] in Tissue by NAA with probe detection;AHV1 DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22792-6;Aleutian disease virus Ab;PrThr;Pt;Ser;Ord;CIE;MICRO;1;Aleutian disease virus Ab [Presence] in Serum by Counterimmunoelectrophoresis (CIE);ADV Ab Ser Ql CIE;;ACTIVE;1.0n;2.56 +22793-4;Aleutian disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aleutian disease virus Ab [Presence] in Serum;ADV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22794-2;Anaplasma marginale Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Anaplasma marginale Ab [Presence] in Serum by Immunofluorescence;A marginale Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +22795-9;Anaplasma marginale Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Anaplasma marginale Ab [Presence] in Serum by Immunoassay;A marginale Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22796-7;Anaplasma marginale Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Anaplasma marginale Ag [Presence] in Tissue by Immunofluorescence;A marginale Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +22797-5;Anaplasma marginale DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Anaplasma marginale DNA [Presence] in Tissue by NAA with probe detection;A marginale DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +2279-8;Fibrinopeptide A;MCnc;Pt;Periton fld;Qn;;COAG;1;Fibrinopeptide A [Mass/volume] in Peritoneal fluid;FpA Prt-mCnc;;ACTIVE;1.0;2.42 +22798-3;Anaplasma marginale rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Anaplasma marginale rRNA [Presence] in Tissue by Probe;A marginale rRNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +22799-1;Anaplasma sp identified;Prid;Pt;Tiss;Nom;Modified Giemsa;MICRO;1;Anaplasma sp identified in Tissue by Modified Giemsa stain;Anaplasma Tiss Mod Giemsa;;ACTIVE;1.0n;2.22 +22800-7;Anaplasma sp identified;Prid;Pt;Bld;Nom;Modified Giemsa;MICRO;1;Anaplasma sp identified in Blood by Modified Giemsa stain;Anaplasma Bld Mod Giemsa;;ACTIVE;1.0n;1.0n +22801-5;Infectious bronchitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Ab [Titer] in Serum;IBV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22802-3;Infectious bronchitis virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Infectious bronchitis virus Ab [Titer] in Serum by Hemagglutination inhibition;IBV Ab Titr Ser HAI;;ACTIVE;1.0n;2.70 +22803-1;Infectious bronchitis virus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Infectious bronchitis virus Ab [Titer] in Serum by Immunoassay;IBV Ab Titr Ser IA;;ACTIVE;1.0n;2.70 +22804-9;Infectious bronchitis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Infectious bronchitis virus neutralizing antibody [Titer] in Serum by Neutralization test;IBV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +22805-6;Infectious bronchitis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Infectious bronchitis virus Ag [Presence] in Specimen by Neutralization test;IBV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +2280-6;Fibronectin;MCnc;Pt;Plas;Qn;;CHEM;1;Fibronectin [Mass/volume] in Plasma;Fibronectin Plas-mCnc;;ACTIVE;1.0;2.42 +22806-4;Infectious bronchitis virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Infectious bronchitis virus Ag [Presence] in Tissue by Immune stain;IBV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +22807-2;Infectious bronchitis virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Infectious bronchitis virus Ag [Presence] in Specimen by Immunofluorescence;IBV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22808-0;Infectious bronchitis virus;PrThr;Pt;XXX;Ord;Microscopy.electron;MICRO;1;Infectious bronchitis virus [Presence] in Specimen by Electron microscopy;IBV Spec Ql EM;;ACTIVE;1.0n;2.69 +22809-8;Infectious bronchitis virus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Infectious bronchitis virus RNA [Presence] in Specimen by Probe;IBV RNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +22810-6;Infectious bronchitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Infectious bronchitis virus RNA [Presence] in Specimen by NAA with probe detection;IBV RNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +22811-4;Avian infectious laryngotracheitis virus;PrThr;Pt;XXX;Ord;Microscopy.electron;MICRO;1;Avian infectious laryngotracheitis virus [Presence] in Specimen by Electron microscopy;ILT Spec Ql EM;;ACTIVE;1.0n;2.69 +22812-2;Avian infectious laryngotracheitis virus;ACnc;Pt;Trac;Ord;Microscopy.electron;MICRO;1;Deprecated Avian infectious laryngotracheitis virus [Presence] in Unspecified specimen by Electron microscopy;Deprecated ILT Trachea Ql EM;;DEPRECATED;1.0n;2.36 +22813-0;Avian infectious laryngotracheitis virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Avian infectious laryngotracheitis virus Ab [Titer] in Serum by Immunofluorescence;ILT Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +2281-4;Flavin adenine dinucleotide;MCnc;Pt;Ser;Qn;;CHEM;1;Flavin adenine dinucleotide [Mass/volume] in Serum;FAD Ser-mCnc;;ACTIVE;1.0;2.73 +22814-8;Avian infectious laryngotracheitis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Avian infectious laryngotracheitis virus neutralizing antibody [Titer] in Serum by Neutralization test;ILT NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +22815-5;Avian infectious laryngotracheitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian infectious laryngotracheitis virus Ab [Titer] in Serum;ILT Ab Titr Ser;;ACTIVE;1.0n;2.70 +22816-3;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Specimen by Neutralization test;ILT Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +22817-1;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;Trac;Ord;Immune diffusion;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Trachea by Immune diffusion (ID);ILT Ag Trachea Ql ID;;ACTIVE;1.0n;2.56 +22818-9;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;Trac;Ord;IA;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Trachea by Immunoassay;ILT Ag Trachea Ql IA;;ACTIVE;1.0n;2.56 +22819-7;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Specimen by Immune diffusion (ID);ILT Ag Spec Ql ID;;ACTIVE;1.0n;2.69 +22820-5;Avian orthoreovirus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Avian orthoreovirus Ag [Presence] in Specimen;ARV Ag Spec Ql;;ACTIVE;1.0n;2.69 +22821-3;Influenza virus A Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Influenza virus A Ab [Titer] in Serum;Deprecated FLUAV Ab Titr Ser;;DEPRECATED;1.0n;2.70 +2282-2;Folate;MCnc;Pt;Bld;Qn;;CHEM;1;Folate [Mass/volume] in Blood;Folate Bld-mCnc;;ACTIVE;1.0;2.73 +22822-1;Influenza virus A Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Influenza virus A Ab [Presence] in Serum by Immunoassay;FLUAV Ab Ser Ql IA;;ACTIVE;1.0n;2.73 +22823-9;Influenza virus A Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Influenza virus A Ab [Titer] in Serum by Agglutination;FLUAV Ab Titr Ser Aggl;;ACTIVE;1.0n;2.70 +22824-7;Influenza virus A Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV Ab Titr Ser HAI;;ACTIVE;1.0n;2.70 +22825-4;Influenza virus A Ag;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Influenza virus A Ag [Presence] in Specimen by Immune diffusion (ID);FLUAV Ag Spec Ql ID;;ACTIVE;1.0n;2.69 +22826-2;Influenza virus A identified;Prid;Pt;XXX;Nom;Bioassay;MICRO;1;Influenza virus A identified in Specimen by Bioassay;FLUAV Spec Bioassay;;ACTIVE;1.0n;2.69 +22827-0;Influenza virus A subtype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Influenza virus A subtype [Identifier] in Specimen by NAA with probe detection;FLUAV Subtyp Spec NAA+probe;;ACTIVE;1.0n;2.73 +22828-8;Influenza virus A subtype;Prid;Pt;XXX;Nom;Immune diffusion;MICRO;1;Influenza virus A subtype [Identifier] in Specimen by Immune diffusion (ID);FLUAV Subtyp Spec ID;;ACTIVE;1.0n;2.69 +22829-6;Avian paramyxovirus 1 Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Avian paramyxovirus 1 Ab [Presence] in Serum by Hemagglutination inhibition;APMV1 Ab Ser Ql HAI;;ACTIVE;1.0n;2.56 +2283-0;Folate;MCnc;Pt;RBC;Qn;;CHEM;1;Folate [Mass/volume] in Red Blood Cells;Folate RBC-mCnc;;ACTIVE;1.0;2.73 +22830-4;Avian paramyxovirus 1 Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Avian paramyxovirus 1 Ab [Titer] in Serum by Agglutination;APMV1 Ab Titr Ser Aggl;;ACTIVE;1.0n;2.70 +22831-2;Avian paramyxovirus 1 Ag;PrThr;Pt;XXX;Ord;HAI;MICRO;1;Avian paramyxovirus 1 Ag [Presence] in Specimen by Hemagglutination inhibition;APMV1 Ag Spec Ql HAI;;ACTIVE;1.0n;2.69 +22832-0;Avian paramyxovirus 1 identified;Prid;Pt;XXX;Nom;Bioassay;MICRO;1;Avian paramyxovirus 1 identified in Specimen by Bioassay;APMV1 Spec Bioassay;;ACTIVE;1.0n;2.69 +22833-8;Avian paramyxovirus 1;ACnc;Pt;XXX;Qn;Bioassay;MICRO;1;Avian paramyxovirus 1 [Units/volume] in Specimen by Bioassay;APMV1 Spec Bioassay-aCnc;;ACTIVE;1.0n;2.69 +22834-6;Avian metapneumovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian metapneumovirus Ab [Presence] in Serum;aMPV Ab Ser Ql;;ACTIVE;1.0n;2.58 +22835-3;Avian pneumovirus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Avian pneumovirus Ab [Presence] in Serum;Deprecated TRTV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +22836-1;Avian pox virus;PrThr;Pt;Tiss;Ord;Microscopy.electron;MICRO;1;Avian pox virus [Presence] in Tissue by Electron microscopy;FWPV Tiss Ql EM;;ACTIVE;1.0n;2.56 +22837-9;Avian pox virus Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Avian pox virus Ab [Presence] in Serum by Agglutination;FWPV Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +22838-7;Avian pox virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Avian pox virus Ab [Presence] in Serum by Immunofluorescence;FWPV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +22839-5;Avian pox virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Avian pox virus neutralizing antibody [Presence] in Serum by Neutralization test;FWPV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +22840-3;Avian pox virus Ab;PrThr;Pt;Ser;Ord;Immune stain;MICRO;1;Avian pox virus Ab [Presence] in Serum by Immune stain;FWPV Ab Ser Ql ImStn;;ACTIVE;1.0n;2.56 +22841-1;Avian pox virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Avian pox virus Ab [Presence] in Serum by Immunoassay;FWPV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22842-9;Avian pox virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Avian pox virus DNA [Presence] in Tissue by NAA with probe detection;FWPV DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22843-7;Avian pox virus DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Avian pox virus DNA [Presence] in Tissue by Probe;FWPV DNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +22844-5;Babesia bigemina Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia bigemina Ab [Presence] in Serum;B bigemina Ab Ser Ql;;ACTIVE;1.0n;2.64 +22845-2;Babesia bigemina Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Babesia bigemina Ab [Presence] in Serum by Immunofluorescence;B bigemina Ab Ser Ql IF;;ACTIVE;1.0n;2.64 +22846-0;Babesia bigemina Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Babesia bigemina Ab [Presence] in Serum by Immunoassay;B bigemina Ab Ser Ql IA;;ACTIVE;1.0n;2.64 +22847-8;Babesia bovis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia bovis Ab [Presence] in Serum;B bovis Ab Ser Ql;;ACTIVE;1.0n;2.64 +2284-8;Folate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Folate [Mass/volume] in Serum or Plasma;Folate SerPl-mCnc;;ACTIVE;1.0;2.73 +22848-6;Babesia bovis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Babesia bovis Ab [Presence] in Serum by Immunoassay;B bovis Ab Ser Ql IA;;ACTIVE;1.0n;2.64 +22849-4;Babesia bovis Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Babesia bovis Ab [Presence] in Serum by Immunofluorescence;B bovis Ab Ser Ql IF;;ACTIVE;1.0n;2.64 +22850-2;Babesia caballi Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Babesia caballi Ab [Presence] in Serum by Immunoassay;B caballi Ab Ser Ql IA;;ACTIVE;1.0n;2.64 +22851-0;Babesia caballi Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Babesia caballi Ab [Presence] in Serum by Immunofluorescence;B caballi Ab Ser Ql IF;;ACTIVE;1.0n;2.64 +22852-8;Babesia caballi Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Babesia caballi Ab [Presence] in Serum;Deprecated Bab caballi Ab Ser Ql;;DEPRECATED;1.0n;2.36 +22853-6;Babesia caballi rRNA;PrThr;Pt;Bld;Ord;Probe;MICRO;1;Babesia caballi rRNA [Presence] in Blood by Probe;B caballi rRNA Bld Ql Probe;;ACTIVE;1.0n;2.64 +22854-4;Babesia divergens Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Babesia divergens Ab [Presence] in Serum by Immunofluorescence;B divergens Ab Ser Ql IF;;ACTIVE;1.0n;2.64 +2285-5;Follitropin;SCnc;Pt;Semen;Qn;;CHEM;1;Follitropin [Moles/volume] in Semen;FSH Smn-sCnc;;DISCOURAGED;1.0;2.42 +22855-1;Babesia divergens Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia divergens Ab [Presence] in Serum;B divergens Ab Ser Ql;;ACTIVE;1.0n;2.64 +22856-9;Babesia sp rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Babesia sp rRNA [Presence] in Tissue by Probe;Babesia rRNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +22857-7;Babesia sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Babesia sp DNA [Presence] in Tissue by NAA with probe detection;Babesia DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22858-5;Babesia sp identified;Prid;Pt;Tiss;Nom;Giemsa stain;MICRO;1;Babesia sp identified in Tissue by Giemsa stain;Babesia Tiss Gie Stn;;ACTIVE;1.0n;2.22 +22859-3;Bacillus anthracis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bacillus anthracis Ab [Titer] in Serum;B anthracis Ab Titr Ser;;ACTIVE;1.0n;2.70 +22860-1;Bacillus anthracis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bacillus anthracis Ab [Presence] in Serum;B anthracis Ab Ser Ql;;ACTIVE;1.0n;2.56 +22861-9;Bacillus anthracis Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Bacillus anthracis Ab [Presence] in Serum by Immune diffusion (ID);B anthracis Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +22862-7;Bacillus anthracis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Bacillus anthracis Ab [Presence] in Serum by Agglutination;B anthracis Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +2286-3;Follitropin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin [Moles/volume] in Serum or Plasma;FSH SerPl-sCnc;;DISCOURAGED;1.0;2.73 +22863-5;Bacillus anthracis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bacillus anthracis Ab [Presence] in Serum by Immunoassay;B anthracis Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22864-3;Bacillus anthracis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Bacillus anthracis Ab [Presence] in Serum by Complement fixation;B anthracis Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +22865-0;Bacillus anthracis Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Bacillus anthracis Ab [Titer] in Serum by Immune diffusion (ID);B anthracis Ab Titr Ser ID;;ACTIVE;1.0n;2.70 +22866-8;Bacillus anthracis Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bacillus anthracis Ag [Presence] in Tissue by Immunofluorescence;B anthracis Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +22867-6;Bacillus anthracis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bacillus anthracis Ag [Presence] in Specimen by Immunofluorescence;B anthracis Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22868-4;Bluetongue virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Bluetongue virus neutralizing antibody [Presence] in Serum by Neutralization test;BTV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +22869-2;Bluetongue virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bluetongue virus Ag [Presence] in Specimen by Immunofluorescence;BTV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +228-7;Enoxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Enoxacin [Susceptibility] by Minimum lethal concentration (MLC);Enoxacin Islt MLC;;ACTIVE;1.0;2.19 +22870-0;Bluetongue virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bluetongue virus Ag [Presence] in Specimen by Immunoassay;BTV Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +2287-1;Follitropin;MRat;24H;Urine;Qn;;CHEM;1;Follitropin [Mass/time] in 24 hour Urine;FSH 24h Ur-mRate;;DISCOURAGED;1.0;2.73 +22871-8;Bluetongue virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Bluetongue virus Ag [Presence] in Specimen by Neutralization test;BTV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +22872-6;Bluetongue virus Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Bluetongue virus Ag [Presence] in Blood;BTV Ag Bld Ql;;ACTIVE;1.0n;2.56 +22873-4;Bluetongue virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Bluetongue virus Ag [Presence] in Specimen by Immune stain;BTV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +22874-2;Bluetongue virus serotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Bluetongue virus serotype [Identifier] in Specimen by NAA with probe detection;BTV Sertyp Spec NAA+probe;;ACTIVE;1.0n;2.69 +22875-9;Border disease virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Border disease virus Ab [Units/volume] in Serum by Immunoassay;Border DV Ab Ser IA-aCnc;;ACTIVE;1.0n;2.69 +22876-7;Border disease virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Border disease virus Ab [Units/volume] in Serum;Border DV Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22877-5;Border disease virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Border disease virus Ab [Titer] in Serum;Border DV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22878-3;Border disease virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Border disease virus neutralizing antibody [Titer] in Serum by Neutralization test;Border DV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +22879-1;Border disease virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Border disease virus Ag [Presence] in Specimen by Immunofluorescence;Border DV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22880-9;Border disease virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Border disease virus Ag [Presence] in Specimen by Immune stain;Border DV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +22881-7;Border disease virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Border disease virus Ag [Presence] in Tissue by Immunoassay;Border DV Ag Tiss Ql IA;;ACTIVE;1.0n;2.56 +22882-5;Border disease virus Ag;PrThr;Pt;Bld;Ord;IA;MICRO;1;Border disease virus Ag [Presence] in Blood by Immunoassay;Border DV Ag Bld Ql IA;;ACTIVE;1.0n;2.56 +22883-3;Border disease virus RNA;PrThr;Pt;Tiss^Fetus;Ord;Probe.amp.tar;MICRO;1;Border disease virus RNA [Presence] in Tissue from Fetus by NAA with probe detection;Border DV RNA Tiss Fetus Ql NAA+probe;;ACTIVE;1.0n;2.63 +22884-1;Border disease virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Border disease virus RNA [Presence] in Tissue by NAA with probe detection;Border DV RNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22885-8;Border disease virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Border disease virus RNA [Presence] in Blood by NAA with probe detection;Border DV RNA Bld Ql NAA+probe;;ACTIVE;1.0n;2.63 +22886-6;Bordetella bronchiseptica Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella bronchiseptica Ab [Presence] in Serum;B bronch Ab Ser Ql;;ACTIVE;1.0n;2.56 +22887-4;Bordetella bronchiseptica Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Bordetella bronchiseptica Ab [Presence] in Serum by Agglutination;B bronch Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +22888-2;Bordetella bronchiseptica Ag;PrThr;Pt;XXX;Ord;Aggl;MICRO;1;Bordetella bronchiseptica Ag [Presence] in Specimen by Agglutination;B bronch Ag Spec Ql Aggl;;ACTIVE;1.0n;2.69 +2288-9;Follitropin.alpha subunit;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin.alpha subunit [Moles/volume] in Serum or Plasma;A-FSH SerPl-sCnc;;DISCOURAGED;1.0;2.44 +22889-0;Bovine diarrhea virus Ab;PrThr;Pt;Milk;Ord;;MICRO;1;Bovine diarrhea virus Ab [Presence] in Milk;BVDV Ab Mlk Ql;;ACTIVE;1.0n;2.56 +22890-8;Bovine diarrhea virus Ab;PrThr;Pt;Milk;Ord;IA;MICRO;1;Bovine diarrhea virus Ab [Presence] in Milk by Immunoassay;BVDV Ab Mlk Ql IA;;ACTIVE;1.0n;2.56 +22891-6;Bovine diarrhea virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bovine diarrhea virus Ab [Titer] in Serum;BVDV Ab Titr Ser;;ACTIVE;1.0n;2.70 +22892-4;Bovine diarrhea virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bovine diarrhea virus neutralizing antibody [Titer] in Serum by Neutralization test;BVDV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +22893-2;Bovine diarrhea virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Bovine diarrhea virus neutralizing antibody [Presence] in Serum by Neutralization test;BVDV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +22894-0;Bovine diarrhea virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bovine diarrhea virus Ab [Presence] in Serum by Immunoassay;BVDV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22895-7;Bovine diarrhea virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bovine diarrhea virus Ab [Presence] in Serum;BVDV Ab Ser Ql;;ACTIVE;1.0n;2.56 +22896-5;Bovine diarrhea virus Ag;PrThr;Pt;Bld;Ord;IA;MICRO;1;Bovine diarrhea virus Ag [Presence] in Blood by Immunoassay;BVDV Ag Bld Ql IA;;ACTIVE;1.0n;2.56 +2289-7;Follitropin.beta subunit;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin.beta subunit [Moles/volume] in Serum or Plasma;B-FSH SerPl-sCnc;;DISCOURAGED;1.0;2.44 +22897-3;Bovine diarrhea virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Bovine diarrhea virus Ag [Presence] in Specimen by Immune stain;BVDV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +22898-1;Bovine diarrhea virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bovine diarrhea virus Ag [Presence] in Specimen by Immunofluorescence;BVDV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22899-9;Bovine diarrhea virus RNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Bovine diarrhea virus RNA [Presence] in Tissue by Probe;BVDV RNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +22900-5;Bovine diarrhea virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bovine diarrhea virus RNA [Presence] in Specimen by NAA with probe detection;BVDV RNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +22901-3;Bovine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Bovine herpesvirus 1 Ab [Presence] in Serum by Immunofluorescence;BoHV1 Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +22902-1;Bovine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Bovine herpesvirus 1 Ab [Presence] in Serum by Immune diffusion (ID);BoHV1 Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +22903-9;Bovine herpesvirus 1 Ab;PrThr;Pt;Milk;Ord;IA;MICRO;1;Bovine herpesvirus 1 Ab [Presence] in Milk by Immunoassay;BoHV1 Ab Mlk Ql IA;;ACTIVE;1.0n;2.56 +22904-7;Bovine herpesvirus 1 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Bovine herpesvirus 1 neutralizing antibody [Presence] in Serum by Neutralization test;BoHV1 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +2290-5;Follitropin/Lutropin;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin/Lutropin [Molar ratio] in Serum or Plasma;FSH/LH SerPl-sRto;;DISCOURAGED;1.0;2.73 +22905-4;Bovine herpesvirus 1 Ab;PrThr;Pt;Milk;Ord;;MICRO;1;Bovine herpesvirus 1 Ab [Presence] in Milk;BoHV1 Ab Mlk Ql;;ACTIVE;1.0n;2.56 +22906-2;Bovine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Specimen by Immunoassay;BoHV1 Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +22907-0;Bovine herpesvirus 1 Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Nose by Immunofluorescence;BoHV1 Ag Nose Ql IF;;ACTIVE;1.0n;2.56 +22908-8;Bovine herpesvirus 1 Ag;ACnc;Pt;XXX;Qn;Neut;MICRO;1;Bovine herpesvirus 1 Ag [Units/volume] in Specimen by Neutralization test;BoHV1 Ag Spec Nt-aCnc;;ACTIVE;1.0n;2.69 +22909-6;Bovine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Specimen by Immune stain;BoHV1 Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +22910-4;Bovine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Specimen by Immunofluorescence;BoHV1 Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22911-2;Bovine herpesvirus 1 Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Genital specimen by Immunofluorescence;BoHV1 Ag Genital Ql IF;;ACTIVE;1.0n;2.56 +22912-0;Bovine herpesvirus 1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Tissue by Immune stain;BoHV1 Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +2291-3;Formate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Formate [Mass/volume] in Blood;Formate Bld-mCnc;;ACTIVE;1.0;2.73 +22913-8;Bovine herpesvirus 1 DNA;PrThr;Pt;Semen;Ord;Probe.amp.tar;MICRO;1;Bovine herpesvirus 1 DNA [Presence] in Semen by NAA with probe detection;BoHV1 DNA Smn Ql NAA+probe;;ACTIVE;1.0n;2.63 +22914-6;Bovine herpesvirus 1 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Bovine herpesvirus 1 DNA [Presence] in Tissue by NAA with probe detection;BoHV1 DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22915-3;Bovine leukemia virus Ab;PrThr;Pt;Milk;Ord;;MICRO;1;Bovine leukemia virus Ab [Presence] in Milk;BLV Ab Mlk Ql;;ACTIVE;1.0n;2.56 +22916-1;Bovine leukemia virus Ab;PrThr;Pt;Milk;Ord;IA;MICRO;1;Bovine leukemia virus Ab [Presence] in Milk by Immunoassay;BLV Ab Mlk Ql IA;;ACTIVE;1.0n;2.56 +22917-9;Bovine leukemia virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bovine leukemia virus Ag [Presence] in Specimen;BLV Ag Spec Ql;;ACTIVE;1.0n;2.69 +22918-7;Bovine leukemia virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Bovine leukemia virus RNA [Presence] in Blood by NAA with probe detection;BLV RNA Bld Ql NAA+probe;;ACTIVE;1.0n;2.63 +22919-5;Bovine leukemia virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Bovine leukemia virus RNA [Presence] in Tissue by NAA with probe detection;BLV RNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +22920-3;Brucella abortus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Brucella abortus Ab [Presence] in Serum by Immunofluorescence;B abortus Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +2292-1;Formate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Formate [Mass/volume] in Serum or Plasma;Formate SerPl-mCnc;;ACTIVE;1.0;2.73 +22921-1;Brucella abortus Ab;ACnc;Pt;Ser;Qn;Aggl;MICRO;1;Brucella abortus Ab [Units/volume] in Serum by Agglutination;B abortus Ab Ser Aggl-aCnc;;ACTIVE;1.0n;2.69 +22922-9;Brucella abortus Ab.IgG1;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella abortus IgG1 Ab [Presence] in Serum by Immunoassay;B abortus IgG1 Ser Ql IA;;ACTIVE;1.0n;2.56 +22923-7;Brucella abortus Ab.IgG1;PrThr;Pt;Milk;Ord;IA;MICRO;1;Brucella abortus IgG1 Ab [Presence] in Milk by Immunoassay;B abortus IgG1 Mlk Ql IA;;ACTIVE;1.0n;2.56 +22924-5;Brucella abortus Ab.IgG1;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella abortus IgG1 Ab [Presence] in Serum;B abortus IgG1 Ser Ql;;ACTIVE;1.0n;2.56 +22925-2;Brucella abortus Ab.IgG1;PrThr;Pt;Milk;Ord;;MICRO;1;Brucella abortus IgG1 Ab [Presence] in Milk;B abortus IgG1 Mlk Ql;;ACTIVE;1.0n;2.56 +22926-0;Brucella abortus rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Brucella abortus rRNA [Presence] in Specimen by Probe;B abortus rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +22927-8;Brucella abortus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Brucella abortus DNA [Presence] in Specimen by NAA with probe detection;B abortus DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +22928-6;Brucella canis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella canis Ab [Presence] in Serum;B canis Ab Ser Ql;;ACTIVE;1.0n;2.56 +22929-4;Brucella canis Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Brucella canis Ab [Presence] in Serum by Immune diffusion (ID);B canis Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +22930-2;Brucella canis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Brucella canis Ab [Presence] in Serum by Agglutination;B canis Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +22931-0;Brucella melitensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella melitensis Ab [Presence] in Serum;B melitensis Ab Ser Ql;;ACTIVE;1.0n;2.56 +22932-8;Brucella melitensis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella melitensis Ab [Presence] in Serum by Immunoassay;B melitensis Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22933-6;Brucella melitensis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Brucella melitensis Ab [Presence] in Serum by Agglutination;B melitensis Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +22934-4;Brucella melitensis Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Brucella melitensis Ab [Units/volume] in Serum by Complement fixation;B melitensis Ab Ser CF-aCnc;;ACTIVE;1.0n;2.69 +22935-1;Brucella melitensis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Brucella melitensis Ab [Presence] in Serum by Complement fixation;B melitensis Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +22936-9;Brucella melitensis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Brucella melitensis DNA [Presence] in Specimen by NAA with probe detection;B melitensis DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +22937-7;Brucella ovis Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Brucella ovis Ab [Units/volume] in Serum by Complement fixation;B ovis Ab Ser CF-aCnc;;ACTIVE;1.0n;2.69 +22938-5;Brucella ovis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Brucella ovis Ab [Presence] in Serum by Agglutination;B ovis Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +2293-9;Fructokinase;CCnc;Pt;Ser;Qn;;CHEM;1;Fructokinase [Enzymatic activity/volume] in Serum;Fructokinase Ser-cCnc;;ACTIVE;1.0;2.68 +22939-3;Brucella ovis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella ovis Ab [Units/volume] in Serum;B ovis Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +22940-1;Brucella ovis Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Brucella ovis Ab [Presence] in Serum by Immune diffusion (ID);B ovis Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +22941-9;Brucella reaction wheal^2D post 0.1 mL brucellin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Brucella reaction wheal [Diameter] --2 days post 0.1 mL brucellin intradermal;Wheal 2D p .1mL Brucellin Diam;;ACTIVE;1.0n;2.42 +22942-7;Brucella reaction wheal^3D post 0.1 mL brucellin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Brucella reaction wheal [Diameter] --3 days post 0.1 mL brucellin intradermal;Wheal 3D p .1mL Brucellin Diam;;ACTIVE;1.0n;2.42 +22943-5;Brucella sp Ag;PrThr;Pt;Placenta;Ord;IF;MICRO;1;Brucella sp Ag [Presence] in Placenta by Immunofluorescence;Brucella Ag Placenta Ql IF;;ACTIVE;1.0n;2.63 +22944-3;Brucella sp Ag;PrThr;Pt;Vag;Ord;Immune stain;MICRO;1;Brucella sp Ag [Presence] in Vaginal fluid by Immune stain;Brucella Ag Vag Ql ImStn;;ACTIVE;1.0n;2.56 +22945-0;Brucella sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Brucella sp Ag [Presence] in Tissue by Immune stain;Brucella Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +22946-8;Brucella sp Ag;PrThr;Pt;Tiss^Fetus;Ord;IF;MICRO;1;Brucella sp Ag [Presence] in Tissue from Fetus by Immunofluorescence;Brucella Ag Tiss Fetus Ql IF;;ACTIVE;1.0n;2.56 +2294-7;Fructosamine;CCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Fructosamine;Deprecated Fructosamine Ser-cCnc;;DEPRECATED;1.0;2.36 +22947-6;Brucella sp Ag;PrThr;Pt;Vag;Ord;IF;MICRO;1;Brucella sp Ag [Presence] in Vaginal fluid by Immunofluorescence;Brucella Ag Vag Ql IF;;ACTIVE;1.0n;2.56 +22948-4;Brucella sp Ag;PrThr;Pt;Tiss^Fetus;Ord;Immune stain;MICRO;1;Brucella sp Ag [Presence] in Tissue from Fetus by Immune stain;Brucella Ag Tiss Fetus Ql ImStn;;ACTIVE;1.0n;2.56 +22949-2;Brucella sp Ag;PrThr;Pt;Placenta;Ord;Immune stain;MICRO;1;Brucella sp Ag [Presence] in Placenta by Immune stain;Brucella Ag Placenta Ql ImStn;;ACTIVE;1.0n;2.63 +229-5;Enoxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Enoxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Enoxacin Islt MIC;;ACTIVE;1.0;2.19 +22950-0;Brucella suis Ab;PrThr;Pt;Ser;Ord;Aggl.plate;MICRO;1;Brucella suis Ab [Presence] in Serum by Plate agglutination;B suis Ab Ser Ql Plate aggl;;ACTIVE;1.0n;2.56 +22951-8;Brucella suis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella suis Ab [Presence] in Serum;B suis Ab Ser Ql;;ACTIVE;1.0n;2.56 +22952-6;Brucella suis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella suis Ab [Presence] in Serum by Immunoassay;B suis Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22953-4;Brucella suis Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Brucella suis Ab [Units/volume] in Serum by Complement fixation;B suis Ab Ser CF-aCnc;;ACTIVE;1.0n;2.69 +2295-4;Fructose;MCnc;Pt;Semen;Qn;;CHEM;1;Fructose [Mass/volume] in Semen;Fructose Smn-mCnc;;ACTIVE;1.0;2.73 +22954-2;Brucella suis rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Brucella suis rRNA [Presence] in Specimen by Probe;B suis rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +22955-9;Brucella suis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Brucella suis DNA [Presence] in Specimen by NAA with probe detection;B suis DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +22956-7;Burkholderia mallei Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Burkholderia mallei Ab [Presence] in Serum;B mallei Ab Ser Ql;;ACTIVE;1.0n;2.56 +22957-5;Burkholderia mallei Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Burkholderia mallei Ab [Presence] in Serum;Deprecated B mallei Ab Ser Ql;;DEPRECATED;1.0n;2.36 +22958-3;Burkholderia mallei Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Burkholderia mallei Ab [Presence] in Serum by Immunoassay;B mallei Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22959-1;Burkholderia mallei Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Burkholderia mallei Ab [Presence] in Serum by Complement fixation;B mallei Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +22960-9;Burkholderia mallei reaction^1D post 0.1 mL mallein ID;Aper;Pt;Skin;Nom;;CHALSKIN;1;Burkholderia mallei reaction [Appearance] -1D post 0.1 mL mallein intradermal-;B mallei Rx 1D p .1mL Mallein;;ACTIVE;1.0n;2.21 +22961-7;Burkholderia mallei reaction^2D post 0.1 mL mallein ID;Aper;Pt;Skin;Nom;;CHALSKIN;1;Burkholderia mallei reaction [Appearance] -2D post 0.1 mL mallein intradermal-;B mallei Rx 2D p .1mL Mallein;;ACTIVE;1.0n;2.21 +2296-2;Fructose;MCnc;Pt;Ser;Qn;;CHEM;1;Fructose [Mass/volume] in Serum;Fructose Ser-mCnc;;ACTIVE;1.0;2.42 +22962-5;Campylobacter fetus Ab;PrThr;Pt;Genital muc;Ord;;MICRO;1;Campylobacter fetus Ab [Presence] in Genital mucus;C fetus Ab Genital mucus Ql;;ACTIVE;1.0n;2.56 +22963-3;Campylobacter fetus Ab;PrThr;Pt;Genital muc;Ord;Aggl;MICRO;1;Campylobacter fetus Ab [Presence] in Genital mucus by Agglutination;C fetus Ab Genital mucus Ql Aggl;;ACTIVE;1.0n;2.56 +22964-1;Campylobacter fetus Ag;PrThr;Pt;Genital fld;Ord;IF;MICRO;1;Campylobacter fetus Ag [Presence] in Genital fluid by Immunofluorescence;C fetus Ag Genital fl Ql IF;;ACTIVE;1.0n;2.56 +22965-8;Campylobacter fetus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Campylobacter fetus Ag [Presence] in Specimen by Immunofluorescence;C fetus Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22966-6;Campylobacter fetus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Campylobacter fetus Ag [Presence] in Tissue by Immunofluorescence;C fetus Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +22967-4;Campylobacter fetus subspecies venerealis Ab;PrThr;Pt;Genital muc;Ord;;MICRO;1;Campylobacter fetus ss venerealis Ab [Presence] in Genital mucus;C fetus Vener Ab Genital mucus Ql;;ACTIVE;1.0n;2.56 +22968-2;Campylobacter fetus subspecies venerealis Ab;PrThr;Pt;Genital muc;Ord;Aggl;MICRO;1;Campylobacter fetus ss venerealis Ab [Presence] in Genital mucus by Agglutination;C fetus Vener Ab Genital mucus Ql Aggl;;ACTIVE;1.0n;2.56 +22969-0;Campylobacter fetus subspecies venerealis Ab.IgA;PrThr;Pt;Genital muc;Ord;IA;MICRO;1;Campylobacter fetus ss venerealis IgA Ab [Presence] in Genital mucus by Immunoassay;C fetus Vener IgA Genital mucus Ql IA;;ACTIVE;1.0n;2.56 +2297-0;Fructose;MRat;24H;Urine;Qn;;CHEM;1;Fructose [Mass/time] in 24 hour Urine;Fructose 24h Ur-mRate;;ACTIVE;1.0;2.42 +22970-8;Campylobacter fetus subspecies venerealis Ab.IgA;PrThr;Pt;Genital muc;Ord;;MICRO;1;Campylobacter fetus ss venerealis IgA Ab [Presence] in Genital mucus;C fetus Vener IgA Genital mucus Ql;;ACTIVE;1.0n;2.56 +22971-6;Caprine arthritis encephalitis virus;PrThr;Pt;XXX;Ord;Microscopy.electron;MICRO;1;Caprine arthritis encephalitis virus [Presence] in Specimen by Electron microscopy;CAEV Spec Ql EM;;ACTIVE;1.0n;2.69 +22972-4;Caprine arthritis encephalitis virus Ab;PrThr;Pt;Milk;Ord;;MICRO;1;Caprine arthritis encephalitis virus Ab [Presence] in Milk;CAEV Ab Mlk Ql;;ACTIVE;1.0n;2.56 +22973-2;Caprine arthritis encephalitis virus Ab;PrThr;Pt;Milk;Ord;IA;MICRO;1;Caprine arthritis encephalitis virus Ab [Presence] in Milk by Immunoassay;CAEV Ab Mlk Ql IA;;ACTIVE;1.0n;2.56 +22974-0;Caprine arthritis encephalitis virus Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Caprine arthritis encephalitis virus Ab [Presence] in Serum by Agglutination;CAEV Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +22975-7;Caprine arthritis encephalitis virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Caprine arthritis encephalitis virus Ag [Presence] in Specimen by Immune stain;CAEV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +22976-5;Caprine arthritis encephalitis virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Caprine arthritis encephalitis virus Ag [Presence] in Specimen by Immunofluorescence;CAEV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22977-3;Caprine arthritis encephalitis virus DNA;PrThr;Pt;XXX;Ord;PAGE;MICRO;1;Caprine arthritis encephalitis virus DNA [Presence] in Specimen by Polyacrylamide gel electrophoresis (PAGE);CAEV DNA Spec Ql PAGE;;ACTIVE;1.0n;2.69 +22978-1;Caprine arthritis encephalitis virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Caprine arthritis encephalitis virus DNA [Presence] in Specimen by NAA with probe detection;CAEV DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +22979-9;Caprine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Caprine herpesvirus 1 Ab [Presence] in Serum;CpHV1 Ab Ser Ql;;ACTIVE;1.0n;2.56 +22980-7;Caprine herpesvirus 1 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Caprine herpesvirus 1 neutralizing antibody [Presence] in Serum by Neutralization test;CpHV1 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +22981-5;Capripox virus;PrThr;Pt;Tiss;Ord;Animal inoculation;MICRO;1;Capripox virus [Presence] in Tissue by Animal inoculation;Capripox Tiss Ql Anim Inoc;;ACTIVE;1.0n;2.56 +22982-3;Capripox virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Capripox virus Ab [Presence] in Serum;Capripox Ab Ser Ql;;ACTIVE;1.0n;2.56 +22983-1;Capripox virus Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Capripox virus Ab [Presence] in Serum by Immunoblot;Capripox Ab Ser Ql IB;;ACTIVE;1.0n;2.58 +22984-9;Capripox virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Capripox virus neutralizing antibody [Presence] in Serum by Neutralization test;Capripox NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +22985-6;Capripox virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Capripox virus Ab [Presence] in Serum;Deprecated Capripox Ab Ser Ql;;DEPRECATED;1.0n;2.36 +22986-4;Capripox virus Ag;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Capripox virus Ag [Presence] in Specimen by Immune diffusion (ID);Capripox Ag Spec Ql ID;;ACTIVE;1.0n;2.69 +22987-2;Capripox virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Capripox virus Ag [Presence] in Tissue by Immune stain;Capripox Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +2298-8;Aldolase;CCnc;Pt;Ser;Qn;;CHEM;1;Deprecated FRUCTOSE ALDOLASE [Enzymatic activity/volume] in Serum;Deprecated Aldolase Ser-cCnc;;DEPRECATED;1.0;2.40 +22988-0;Capripox virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Capripox virus Ag [Presence] in Specimen by Immunoassay;Capripox Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +22989-8;Capripox virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Capripox virus Ag [Presence] in Specimen by Immunofluorescence;Capripox Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +22990-6;Capripox virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Capripox virus Ag [Presence] in Tissue by Immunoassay;Capripox Ag Tiss Ql IA;;ACTIVE;1.0n;2.56 +22991-4;Capripox virus DNA;PrThr;Pt;XXX;Ord;RFLP;MICRO;1;Capripox virus DNA [Presence] in Specimen by RFLP;Capripox DNA Spec Ql RFLP;;ACTIVE;1.0n;2.69 +22992-2;Chlamydophila psittaci;PrThr;Pt;XXX;Ord;Giemsa stain;MICRO;1;Chlamydophila psittaci [Presence] in Specimen by Giemsa stain;C psittaci Spec Ql Gie Stn;;ACTIVE;1.0n;2.69 +22993-0;Chlamydophila psittaci;PrThr;Pt;Placenta;Ord;Microscopy.electron;MICRO;1;Chlamydophila psittaci [Presence] in Placenta by Electron microscopy;C psittaci Placenta Ql EM;;ACTIVE;1.0n;2.63 +22994-8;Chlamydophila psittaci Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Chlamydophila psittaci Ab [Presence] in Serum by Agglutination;C psittaci Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +22995-5;Chlamydophila psittaci Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Chlamydophila psittaci Ab [Presence] in Serum by Immune diffusion (ID);C psittaci Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +2299-6;Aldolase;CCnc;Pt;RBC;Qn;;CHEM;1;Aldolase [Enzymatic activity/volume] in Red Blood Cells;Aldolase RBC-cCnc;;ACTIVE;1.0;2.44 +22996-3;Chlamydophila psittaci Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydophila psittaci Ab [Presence] in Serum by Immunoassay;C psittaci Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +22997-1;Chlamydophila psittaci Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Chlamydophila psittaci Ag [Presence] in Specimen by Immune stain;C psittaci Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +22998-9;Chlamydophila psittaci Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Chlamydophila psittaci Ag [Presence] in Tissue by Immune stain;C psittaci Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +22999-7;Chlamydophila psittaci Ag;PrThr;Pt;Stool;Ord;Immune stain;MICRO;1;Chlamydophila psittaci Ag [Presence] in Stool by Immune stain;C psittaci Ag Stl Ql ImStn;;ACTIVE;1.0n;2.56 +23000-3;Chlamydophila psittaci Ag;PrThr;Pt;Exudate;Ord;Immune stain;MICRO;1;Chlamydophila psittaci Ag [Presence] in Exudate by Immune stain;C psittaci Ag Exudate Ql ImStn;;ACTIVE;1.0n;2.56 +23001-1;Chlamydophila psittaci DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chlamydophila psittaci DNA [Presence] in Specimen by NAA with probe detection;C psittaci DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.73 +2300-2;Aldolase;CCnc;Pt;Ser;Qn;;CHEM;1;Deprecated FRUCTOSE BIPHOSPHATE ALDOLASE [Enzymatic activity/volume] in Serum;Deprecated Aldolase Ser-cCnc;;DEPRECATED;1.0;2.40 +23002-9;Classical swine fever virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Classical swine fever virus Ab [Presence] in Serum by Immunoassay;CSFV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23003-7;Classical swine fever virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Classical swine fever virus neutralizing antibody [Presence] in Serum by Neutralization test;CSFV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23004-5;Classical swine fever virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Classical swine fever virus Ab [Presence] in Serum;CSFV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23005-2;Classical swine fever virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Classical swine fever virus Ag [Presence] in Tissue by Immunofluorescence;CSFV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23006-0;Classical swine fever virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Classical swine fever virus Ag [Presence] in Specimen by Immunofluorescence;CSFV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23007-8;Classical swine fever virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Classical swine fever virus Ag [Presence] in Tissue by Immune stain;CSFV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23008-6;Classical swine fever virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Classical swine fever virus RNA [Presence] in Specimen by NAA with probe detection;CSFV RNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23009-4;Cowdria ruminantium;PrThr;Pt;Brain;Ord;Giemsa stain;MICRO;1;Cowdria ruminantium [Presence] in Brain by Giemsa stain;C rumin Brain Ql Gie Stn;;ACTIVE;1.0n;2.56 +2301-0;Aldolase;CCnc;Pt;Bld;Qn;;CHEM;1;Deprecated Aldolase;Deprecated Aldolase Bld-cCnc;;DEPRECATED;1.0;2.36 +23010-2;Cowdria ruminantium Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Cowdria ruminantium Ab [Presence] in Serum by Immunofluorescence;C rumin Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23011-0;Cowdria ruminantium Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Cowdria ruminantium Ab [Presence] in Serum by Immunoassay;C rumin Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23012-8;Cowdria ruminantium Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Cowdria ruminantium Ab [Presence] in Serum;C rumin Ab Ser Ql;;ACTIVE;1.0n;2.56 +23013-6;Cowdria ruminantium Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Cowdria ruminantium Ab [Presence] in Serum by Immunoblot;C rumin Ab Ser Ql IB;;ACTIVE;1.0n;2.58 +23014-4;Cowdria ruminantium DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cowdria ruminantium DNA [Presence] in Specimen by NAA with probe detection;C rumin DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23015-1;Cowdria ruminantium rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Cowdria ruminantium rRNA [Presence] in Specimen by Probe;C rumin rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +23016-9;Coxiella burnetii;PrThr;Pt;Placenta;Ord;Microscopy.light;MICRO;1;Coxiella burnetii [Presence] in Placenta by Light microscopy;C burnet Placenta Ql Micro;;ACTIVE;1.0n;2.63 +23017-7;Coxiella burnetii Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Coxiella burnetii Ab [Presence] in Serum by Complement fixation;C burnet Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23018-5;Coxiella burnetii Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii Ab [Presence] in Serum by Immunofluorescence;C burnet Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23019-3;Coxiella burnetii Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coxiella burnetii Ab [Presence] in Serum by Immunoassay;C burnet Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23020-1;Coxiella burnetii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxiella burnetii Ab [Presence] in Serum;C burnet Ab Ser Ql;;ACTIVE;1.0n;2.56 +23021-9;Coxiella burnetii Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Coxiella burnetii Ag [Presence] in Tissue by Immunoassay;C burnet Ag Tiss Ql IA;;ACTIVE;1.0n;2.56 +23022-7;Coxiella burnetii Ag;PrThr;Pt;Placenta;Ord;IF;MICRO;1;Coxiella burnetii Ag [Presence] in Placenta by Immunofluorescence;C burnet Ag Placenta Ql IF;;ACTIVE;1.0n;2.63 +23023-5;Coxiella burnetii Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Coxiella burnetii Ag [Presence] in Specimen by Immunofluorescence;C burnet Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23024-3;Coxiella burnetii DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Coxiella burnetii DNA [Presence] in Specimen by NAA with probe detection;C burnet DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.73 +23025-0;Dermatophilus congolensis;PrThr;Pt;Skin;Ord;Giemsa stain;MICRO;1;Dermatophilus congolensis [Presence] in Skin by Giemsa stain;D congo Skin Ql Gie Stn;;ACTIVE;1.0n;2.56 +23026-8;Dermatophilus congolensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Dermatophilus congolensis Ab [Presence] in Serum;D congo Ab Ser Ql;;ACTIVE;1.0n;2.56 +23027-6;Dermatophilus congolensis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Dermatophilus congolensis Ab [Presence] in Serum by Immunoassay;D congo Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +2302-8;Fumarase;CCnc;Pt;Ser;Qn;;CHEM;1;Fumarase [Enzymatic activity/volume] in Serum;Fumarase Ser-cCnc;;ACTIVE;1.0;2.68 +23028-4;Dermatophilus congolensis Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Dermatophilus congolensis Ag [Presence] in Tissue by Immunofluorescence;D congo Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23029-2;Dirofilaria immitis Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Dirofilaria immitis Ag [Presence] in Blood;D immitis Ag Bld Ql;;ACTIVE;1.0n;2.56 +230-3;Enoxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Enoxacin [Susceptibility] by Disk diffusion (KB);Enoxacin Islt KB;;ACTIVE;1.0;2.19 +23030-0;Duck enteritis virus;PrThr;Pt;Tiss;Ord;Microscopy.electron;MICRO;1;Duck enteritis virus [Presence] in Tissue by Electron microscopy;DVE Tiss Ql EM;;ACTIVE;1.0n;2.56 +23031-8;Duck enteritis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Duck enteritis virus Ag [Presence] in Specimen by Neutralization test;DVE Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23032-6;Duck enteritis virus Ag;PrThr;Pt;XXX;Ord;Aggl;MICRO;1;Duck enteritis virus Ag [Presence] in Specimen by Agglutination;DVE Ag Spec Ql Aggl;;ACTIVE;1.0n;2.69 +23033-4;Duck hepatitis virus 1 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Duck hepatitis virus 1 neutralizing antibody [Presence] in Serum by Neutralization test;DHV1 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23034-2;Duck hepatitis virus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Duck hepatitis virus 1 Ab [Presence] in Serum;DHV1 Ab Ser Ql;;ACTIVE;1.0n;2.56 +23035-9;Duck hepatitis virus 1 Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Duck hepatitis virus 1 Ag [Presence] in Specimen by Neutralization test;DHV1 Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +2303-6;Fumarate;MCnc;Pt;Urine;Qn;;CHEM;1;Fumarate [Mass/volume] in Urine;Fumarate Ur-mCnc;;DISCOURAGED;1.0;2.73 +23036-7;Duck hepatitis virus 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Duck hepatitis virus 2 Ab [Presence] in Serum;DHV2 Ab Ser Ql;;ACTIVE;1.0n;2.56 +23037-5;Duck hepatitis virus 2 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Duck hepatitis virus 2 neutralizing antibody [Presence] in Serum by Neutralization test;DHV2 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23038-3;Duck hepatitis virus 2 Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Duck hepatitis virus 2 Ag [Presence] in Specimen by Neutralization test;DHV2 Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23039-1;Duck hepatitis virus 3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Duck hepatitis virus 3 Ab [Presence] in Serum;DHV3 Ab Ser Ql;;ACTIVE;1.0n;2.56 +23040-9;Duck hepatitis virus 3 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Duck hepatitis virus 3 neutralizing antibody [Presence] in Serum by Neutralization test;DHV3 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23041-7;Duck hepatitis virus 3 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Duck hepatitis virus 3 Ag [Presence] in Specimen by Immunofluorescence;DHV3 Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23042-5;Eastern equine encephalitis virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum by Hemagglutination inhibition;EEEV Ab Titr Ser HAI;;ACTIVE;1.0n;2.70 +23043-3;Eastern equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Eastern equine encephalitis virus Ab [Presence] in Serum by Agglutination;EEEV Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +2304-4;Fumarylacetoacetate;MCnc;Pt;Ser;Qn;;CHEM;1;Fumarylacetoacetate [Mass/volume] in Serum;Fumarylacetoacetate Ser-mCnc;;ACTIVE;1.0;2.34 +23044-1;Eastern equine encephalitis virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Eastern equine encephalitis virus neutralizing antibody [Presence] in Serum by Neutralization test;EEEV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23045-8;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Serum by Immunoassay;EEEV IgM Ser Ql IA;;ACTIVE;1.0n;2.56 +23046-6;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Serum;EEEV IgM Ser Ql;;ACTIVE;1.0n;2.56 +23047-4;Eastern equine encephalitis virus Ag;PrThr;Pt;Brain;Ord;Comp fix;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Brain by Complement fixation;EEEV Ag Brain Ql CF;;ACTIVE;1.0n;2.56 +23048-2;Eastern equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Specimen by Immunofluorescence;EEEV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23049-0;Eastern equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Specimen by Complement fixation;EEEV Ag Spec Ql CF;;ACTIVE;1.0n;2.69 +23050-8;Eastern equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Specimen by Neutralization test;EEEV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +2305-1;Galactokinase;CCnc;Pt;RBC;Qn;;CHEM;1;Galactokinase [Enzymatic activity/volume] in Red Blood Cells;Galactokinase RBC-cCnc;;ACTIVE;1.0;2.73 +23051-6;Eastern equine encephalitis virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Eastern equine encephalitis virus RNA [Presence] in Tissue by NAA with probe detection;EEEV RNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23052-4;Eastern equine encephalitis virus RNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Eastern equine encephalitis virus RNA [Presence] in Tissue by Probe;EEEV RNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +23053-2;Echinococcus sp Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Echinococcus sp Ag [Presence] in Stool by Immunoassay;Echinococcus Ag Stl Ql IA;;ACTIVE;1.0n;2.56 +23054-0;Ehrlichia canis Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Ehrlichia canis Ab [Presence] in Serum by Immunofluorescence;E canis Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23055-7;Ehrlichia risticii Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Ehrlichia risticii Ab [Presence] in Serum by Immunofluorescence;E risticii Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23056-5;Ehrlichia risticii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia risticii Ab [Presence] in Serum;E risticii Ab Ser Ql;;ACTIVE;1.0n;2.56 +23057-3;Ephemeral fever virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Ephemeral fever virus neutralizing antibody [Presence] in Serum by Neutralization test;Ephemeral FV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23058-1;Ephemeral fever virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ephemeral fever virus Ab [Presence] in Serum;Ephemeral FV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23059-9;Epizootic hemorrhagic disease virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epizootic hemorrhagic disease virus Ab [Presence] in Serum by Immunoassay;EHDV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23060-7;Epizootic hemorrhagic disease virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Epizootic hemorrhagic disease virus Ab [Presence] in Serum by Complement fixation;EHDV Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23061-5;Epizootic hemorrhagic disease virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Epizootic hemorrhagic disease virus Ag [Presence] in Specimen;EHDV Ag Spec Ql;;ACTIVE;1.0n;2.69 +23062-3;Epizootic hemorrhagic disease virus Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Epizootic hemorrhagic disease virus Ag [Presence] in Blood;EHDV Ag Bld Ql;;ACTIVE;1.0n;2.56 +23063-1;Epizootic hemorrhagic disease virus Alberta Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epizootic hemorrhagic disease virus Alberta Ab [Presence] in Serum;EHDV Alberta Ab Ser Ql;;ACTIVE;1.0n;2.56 +23064-9;Epizootic hemorrhagic disease virus Alberta Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Epizootic hemorrhagic disease virus Alberta Ab [Presence] in Serum by Immune diffusion (ID);EHDV Alberta Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +23065-6;Epizootic hemorrhagic disease virus New Jersey Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epizootic hemorrhagic disease virus New Jersey Ab [Presence] in Serum;EHDV New Jersey Ab Ser Ql;;ACTIVE;1.0n;2.56 +23066-4;Epizootic hemorrhagic disease virus New Jersey Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Epizootic hemorrhagic disease virus New Jersey Ab [Presence] in Serum by Immune diffusion (ID);EHDV New Jersey Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +23067-2;Epizootic hemorrhagic disease virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Epizootic hemorrhagic disease virus RNA [Presence] in Blood by NAA with probe detection;EHDV RNA Bld Ql NAA+probe;;ACTIVE;1.0n;2.63 +23068-0;Equine arteritis virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Equine arteritis virus Ab [Presence] in Serum by Immune diffusion (ID);EAV Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +2306-9;Galactose;PrThr;Pt;Bld;Ord;;CHEM;1;Galactose [Presence] in Blood;Galactose Bld Ql;;ACTIVE;1.0;2.73 +23069-8;Equine arteritis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Equine arteritis virus Ab [Titer] in Serum by Complement fixation;EAV Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23070-6;Equine arteritis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Equine arteritis virus Ab [Presence] in Serum by Immunoassay;EAV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23071-4;Equine arteritis virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Equine arteritis virus neutralizing antibody [Presence] in Serum by Neutralization test;EAV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23072-2;Equine arteritis virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Equine arteritis virus Ab [Presence] in Serum by Immunofluorescence;EAV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23073-0;Equine arteritis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Equine arteritis virus Ab [Presence] in Serum;EAV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23074-8;Equine arteritis virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Equine arteritis virus Ag [Presence] in Specimen by Immunofluorescence;EAV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23075-5;Equine arteritis virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Equine arteritis virus Ag [Presence] in Specimen by Immune stain;EAV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +23076-3;Equine arteritis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Equine arteritis virus Ag [Presence] in Specimen by Neutralization test;EAV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +2307-7;Galactose;MCnc;Pt;Bld;Qn;;CHEM;1;Galactose [Mass/volume] in Blood;Galactose Bld-mCnc;;ACTIVE;1.0;2.40 +23077-1;Equine arteritis virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Equine arteritis virus Ag [Presence] in Tissue by Immunofluorescence;EAV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23078-9;Equine arteritis virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Equine arteritis virus Ag [Presence] in Tissue by Immune stain;EAV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23079-7;Equine arteritis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Equine arteritis virus RNA [Presence] in Specimen by NAA with probe detection;EAV RNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23080-5;Equine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Equine herpesvirus 1 Ag [Presence] in Specimen by Immunofluorescence;EHV1 Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23081-3;Equine herpesvirus 1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Equine herpesvirus 1 Ag [Presence] in Tissue by Immune stain;EHV1 Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23082-1;Equine herpesvirus 1 DNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 1 DNA [Presence] in Nose by NAA with probe detection;EHV1 DNA Nose Ql NAA+probe;;ACTIVE;1.0n;2.63 +23083-9;Equine herpesvirus 1 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 1 DNA [Presence] in Specimen by NAA with probe detection;EHV1 DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23084-7;Equine herpesvirus 1 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 1 DNA [Presence] in Tissue by NAA with probe detection;EHV1 DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +2308-5;Galactose;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Galactose [Mass/volume] in Serum or Plasma;Galactose SerPl-mCnc;;ACTIVE;1.0;2.73 +23085-4;Equine herpesvirus 1+4 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Equine herpesvirus 1+4 neutralizing antibody [Presence] in Serum by Neutralization test;EHV1+4 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23086-2;Equine herpesvirus 1+4 Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Equine herpesvirus 1+4 Ab [Titer] in Serum by Immunoassay;EHV1+4 Ab Titr Ser IA;;ACTIVE;1.0n;2.70 +23087-0;Equine herpesvirus 1+4 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Equine herpesvirus 1+4 Ab [Presence] in Serum;EHV1+4 Ab Ser Ql;;ACTIVE;1.0n;2.56 +23088-8;Equine herpesvirus 1+4 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Equine herpesvirus 1+4 Ab [Titer] in Serum;EHV1+4 Ab Titr Ser;;ACTIVE;1.0n;2.70 +23089-6;Equine herpesvirus 1+4 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Equine herpesvirus 1+4 neutralizing antibody [Titer] in Serum by Neutralization test;EHV1+4 NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23090-4;Equine herpesvirus 1+4 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Equine herpesvirus 1+4 Ab [Titer] in Serum by Complement fixation;EHV1+4 Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23091-2;Equine herpesvirus 1+4 Ag;PrThr;Pt;Body fld;Ord;IF;MICRO;1;Equine herpesvirus 1+4 Ag [Presence] in Body fluid by Immunofluorescence;EHV1+4 Ag Fld Ql IF;;ACTIVE;1.0n;2.56 +23092-0;Equine herpesvirus 4 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Equine herpesvirus 4 Ag [Presence] in Specimen by Immunofluorescence;EHV4 Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +2309-3;Galactose;PrThr;Pt;Urine;Ord;;CHEM;1;Galactose [Presence] in Urine;Galactose Ur Ql;;ACTIVE;1.0;2.73 +23093-8;Equine herpesvirus 4 DNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 4 DNA [Presence] in Nose by NAA with probe detection;EHV4 DNA Nose Ql NAA+probe;;ACTIVE;1.0n;2.63 +23094-6;Equine herpesvirus 4 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 4 DNA [Presence] in Tissue by NAA with probe detection;EHV4 DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23095-3;Equine herpesvirus 4 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 4 DNA [Presence] in Specimen by NAA with probe detection;EHV4 DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23096-1;Equine infectious anemia virus Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Equine infectious anemia virus Ab [Presence] in Serum by Immunoblot;EIAV Ab Ser Ql IB;;ACTIVE;1.0n;2.58 +23097-9;Equine infectious anemia virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Equine infectious anemia virus Ab [Presence] in Serum by Immunoassay;EIAV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23098-7;Equine infectious anemia virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Equine infectious anemia virus Ag [Presence] in Specimen by Immunofluorescence;EIAV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23099-5;Equine infectious anemia virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Equine infectious anemia virus Ag [Presence] in Specimen by Immunoassay;EIAV Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +23100-1;Equine influenza virus A1 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Equine influenza virus A1 Ab [Presence] in Serum by Complement fixation;EIV A1 Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +2310-1;Galactose;MCnc;Pt;Urine;Qn;;CHEM;1;Galactose [Mass/volume] in Urine;Galactose Ur-mCnc;;ACTIVE;1.0;2.42 +23101-9;Equine influenza virus A1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Equine influenza virus A1 Ab [Presence] in Serum;EIV A1 Ab Ser Ql;;ACTIVE;1.0n;2.56 +23102-7;Equine influenza virus A1 Ag;Titr;Pt;XXX;Qn;HAI;MICRO;1;Equine influenza virus A1 Ag [Titer] in Specimen by Hemagglutination inhibition;EIV A1 Ag Titr Spec HAI;;ACTIVE;1.0n;2.70 +23103-5;Equine influenza virus A2 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Equine influenza virus A2 Ab [Presence] in Serum by Complement fixation;EIV A2 Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23104-3;Equine influenza virus A2 Ag;Titr;Pt;XXX;Qn;HAI;MICRO;1;Equine influenza virus A2 Ag [Titer] in Specimen by Hemagglutination inhibition;EIV A2 Ag Titr Spec HAI;;ACTIVE;1.0n;2.70 +23105-0;Fly larvae identified;Prid;Pt;XXX;Nom;;MICRO;1;Fly larvae identified in Specimen;Fly Larvae Spec;;ACTIVE;1.0n;2.69 +23106-8;Foot and mouth disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Foot and mouth disease virus Ab [Presence] in Serum;FMDV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23107-6;Foot and mouth disease virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Foot and mouth disease virus neutralizing antibody [Presence] in Serum by Neutralization test;FMDV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23108-4;Foot and mouth disease virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Foot and mouth disease virus Ab [Presence] in Serum by Immunoassay;FMDV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23109-2;Foot and mouth disease virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Foot and mouth disease virus Ab [Presence] in Serum by Immune diffusion (ID);FMDV Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +231-1;Enoxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Enoxacin [Susceptibility] by Serum bactericidal titer;Enoxacin Titr SBT;;ACTIVE;1.0;2.32 +23110-0;Foot and mouth disease virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Foot and mouth disease virus Ag [Presence] in Tissue by Immunoassay;FMDV Ag Tiss Ql IA;;ACTIVE;1.0n;2.56 +23111-8;Foot and mouth disease virus Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Foot and mouth disease virus Ag [Presence] in Throat by Immunoassay;FMDV Ag Throat Ql IA;;ACTIVE;1.0n;2.56 +23112-6;Foot and mouth disease virus Ag;PrThr;Pt;Tiss;Ord;Comp fix;MICRO;1;Foot and mouth disease virus Ag [Presence] in Tissue by Complement fixation;FMDV Ag Tiss Ql CF;;ACTIVE;1.0n;2.56 +23113-4;Foot and mouth disease virus Ag;PrThr;Pt;Thrt;Ord;Comp fix;MICRO;1;Foot and mouth disease virus Ag [Presence] in Throat by Complement fixation;FMDV Ag Throat Ql CF;;ACTIVE;1.0n;2.56 +23114-2;Foot and mouth disease virus RNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Foot and mouth disease virus RNA [Presence] in Tissue by Probe;FMDV RNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +23115-9;Foot and mouth disease virus serotype;Prid;Pt;XXX;Nom;Comp fix;MICRO;1;Foot and mouth disease virus serotype [Identifier] in Specimen by Complement fixation;FMDV Sertyp Spec CF;;ACTIVE;1.0n;2.69 +23116-7;Foot and mouth disease virus serotype;Prid;Pt;Tiss;Nom;IA;MICRO;1;Foot and mouth disease virus serotype [Identifier] in Tissue by Immunoassay;FMDV Sertyp Tiss IA;;ACTIVE;1.0n;2.56 +23117-5;Foot and mouth disease virus serotype;Prid;Pt;Ser;Nom;IA;MICRO;1;Foot and mouth disease virus serotype [Identifier] in Serum by Immunoassay;FMDV Sertyp Ser IA;;ACTIVE;1.0n;2.56 +23118-3;Foot and mouth disease virus serotype;Prid;Pt;Ser;Nom;Neut;MICRO;1;Foot and mouth disease virus serotype [Identifier] in Serum by Neutralization test;FMDV Sertyp Ser Nt;;ACTIVE;1.0n;1.0n +2311-9;Galactose renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Galactose renal clearance in 24 hour Urine and Serum or Plasma;Galactose Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +23119-1;Foot and mouth disease virus serotype;Prid;Pt;Tiss;Nom;Comp fix;MICRO;1;Foot and mouth disease virus serotype [Identifier] in Tissue by Complement fixation;FMDV Sertyp Tiss CF;;ACTIVE;1.0n;2.22 +23120-9;Foot and mouth disease virus serotype;Prid;Pt;XXX;Nom;IA;MICRO;1;Foot and mouth disease virus serotype [Identifier] in Specimen by Immunoassay;FMDV Sertyp Spec IA;;ACTIVE;1.0n;2.69 +23121-7;Foot and mouth disease virus serotype;Prid;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;Foot and mouth disease virus serotype [Identifier] in Tissue by NAA with probe detection;FMDV Sertyp Tiss NAA+probe;;ACTIVE;1.0n;2.63 +23122-5;Francisella tularensis A DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Francisella tularensis A DNA [Presence] in Tissue by NAA with probe detection;F tular A DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23123-3;Francisella tularensis A rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Francisella tularensis A rRNA [Presence] in Tissue by Probe;F tular A rRNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +23124-1;Francisella tularensis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Francisella tularensis Ab [Presence] in Serum by Immunoassay;F tular Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23125-8;Francisella tularensis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Francisella tularensis Ab [Titer] in Serum by Agglutination;F tular Ab Titr Ser Aggl;;ACTIVE;1.0n;2.73 +23126-6;Francisella tularensis Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Francisella tularensis Ag [Presence] in Tissue by Immune stain;F tular Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +2312-7;Galactose 1 phosphate;MCnc;Pt;RBC;Qn;;CHEM;1;Galactose 1 phosphate [Mass/volume] in Red Blood Cells;Gal1PO4 RBC-mCnc;;ACTIVE;1.0;2.73 +23127-4;Francisella tularensis Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Francisella tularensis Ag [Presence] in Tissue by Immunofluorescence;F tular Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23128-2;Francisella tularensis B DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Francisella tularensis B DNA [Presence] in Tissue by NAA with probe detection;F tular B DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23129-0;Francisella tularensis B rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Francisella tularensis B rRNA [Presence] in Tissue by Probe;F tular B rRNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +23130-8;Francisella tularensis DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Francisella tularensis DNA [Presence] in Tissue by NAA with probe detection;F tular DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23131-6;Francisella tularensis rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Francisella tularensis rRNA [Presence] in Tissue by Probe;F tular rRNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +23132-4;Histoplasma capsulatum farciminosum Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Histoplasma farciminosum Ab [Presence] in Serum by Immunofluorescence;H capsul farci Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23133-2;Histoplasma capsulatum farciminosum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Histoplasma farciminosum Ab [Presence] in Serum by Immunoassay;H capsul farci Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23134-0;Histoplasma capsulatum farciminosum Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Histoplasma farciminosum Ab [Presence] in Serum by Hemagglutination;H capsul farci Ab Ser Ql HA;;ACTIVE;1.0n;2.56 +2313-5;Galactose 1 phosphate uridyl transferase;PrThr;Pt;RBC;Ord;;CHEM;1;Galactose 1 phosphate uridyl transferase [Presence] in Red Blood Cells;Gal1PUT RBC Ql;;ACTIVE;1.0;2.56 +23135-7;Histoplasma capsulatum farciminosum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma farciminosum Ab [Presence] in Serum;H capsul farci Ab Ser Ql;;ACTIVE;1.0n;2.56 +23136-5;Histoplasma capsulatum farciminosum reaction wheal^1D post dose ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Histoplasma capsulatum farciminosum reaction wheal [Diameter] --1 day post dose intradermal;Wheal 1D p ID Diam;;ACTIVE;1.0n;2.42 +23137-3;Histoplasma capsulatum farciminosum reaction wheal^2D post dose ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Histoplasma capsulatum farciminosum reaction wheal [Diameter] --2 days post dose intradermal;Wheal 2D p ID Diam;;ACTIVE;1.0n;2.42 +23138-1;Histoplasma capsulatum farciminosum reaction wheal^3D post dose ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Histoplasma capsulatum farciminosum reaction wheal [Diameter] --3 days post dose intradermal;Wheal 3D p ID Diam;;ACTIVE;1.0n;2.42 +23139-9;Infectious bursal disease virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Infectious bursal disease virus Ab [Titer] in Serum;IBDV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23140-7;Infectious bursal disease virus Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Infectious bursal disease virus Ab [Titer] in Serum by Immune diffusion (ID);IBDV Ab Titr Ser ID;;ACTIVE;1.0n;2.70 +23141-5;Infectious bursal disease virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Infectious bursal disease virus neutralizing antibody [Titer] in Serum by Neutralization test;IBDV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23142-3;Infectious bursal disease virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Infectious bursal disease virus Ag [Presence] in Specimen by Neutralization test;IBDV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +2314-3;Galactose 1 phosphate uridyl transferase;CCnc;Pt;RBC;Qn;;CHEM;1;Galactose 1 phosphate uridyl transferase [Enzymatic activity/volume] in Red Blood Cells;Gal1PUT RBC-cCnc;;ACTIVE;1.0;2.73 +23143-1;Infectious bursal disease virus Ag;PrThr;Pt;Bursa of Fabricius;Ord;Immune diffusion;MICRO;1;Infectious bursal disease virus Ag [Presence] in Bursa of Fabricius by Immune diffusion (ID);IBDV Ag Bursa of Fab Ql ID;;ACTIVE;1.0n;2.56 +23144-9;Japanese encephalitis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Japanese encephalitis virus neutralizing antibody [Titer] in Serum by Neutralization test;JEV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23145-6;Japanese encephalitis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Japanese encephalitis virus Ab [Titer] in Serum by Complement fixation;JEV Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23146-4;Japanese encephalitis virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Japanese encephalitis virus Ab [Presence] in Serum by Hemagglutination inhibition;JEV Ab Ser Ql HAI;;ACTIVE;1.0n;2.56 +23147-2;Japanese encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Japanese encephalitis virus Ab [Titer] in Serum;JEV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23148-0;Japanese encephalitis virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Japanese encephalitis virus Ag [Presence] in Specimen by Immunofluorescence;JEV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23149-8;Japanese encephalitis virus Ag;PrThr;Pt;XXX;Ord;HAI;MICRO;1;Japanese encephalitis virus Ag [Presence] in Specimen by Hemagglutination inhibition;JEV Ag Spec Ql HAI;;ACTIVE;1.0n;2.69 +2315-0;Galactosylceramidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Galactosylceramidase [Enzymatic activity/mass] in Tissue;GALC Tiss-cCnt;;ACTIVE;1.0;2.42 +23150-6;Leishmania donovani Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Leishmania donovani Ag [Presence] in Tissue by Immune stain;L donovani Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23151-4;Leishmania reaction wheal^3D post 0.1 mL leishmanin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Leishmania reaction wheal [Diameter] --3 days post 0.1 mL leishmanin intradermal;Wheal 3D p .1mL Leishmanin Diam;;ACTIVE;1.0n;2.42 +23152-2;Leishmania sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania sp Ab [Titer] in Serum;Leishmania Ab Titr Ser;;ACTIVE;1.0n;2.70 +23153-0;Leishmania sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leishmania sp Ab [Presence] in Serum by Immunoassay;Leishmania Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23154-8;Leishmania sp Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Leishmania sp Ab [Titer] in Serum by Hemagglutination;Leishmania Ab Titr Ser HA;;ACTIVE;1.0n;2.70 +23155-5;Leishmania sp Ab;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;MICRO;1;Leishmania sp Ab [Presence] in Serum by Immunoelectrophoresis;Leishmania Ab Ser Ql IEP;;ACTIVE;1.0n;2.56 +23156-3;Leishmania sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania sp Ab [Titer] in Serum by Immunofluorescence;Leishmania Ab Titr Ser IF;;ACTIVE;1.0n;2.73 +23157-1;Leishmania sp Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leishmania sp Ab [Presence] in Serum by Agglutination;Leishmania Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23158-9;Leishmania sp rRNA;Prid;Pt;XXX;Nom;Probe;MICRO;1;Leishmania sp rRNA [Identifier] in Specimen by Probe;Leishmania rRNA Spec Probe;;ACTIVE;1.0n;2.69 +23159-7;Leishmania sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Leishmania sp DNA [Identifier] in Specimen by NAA with probe detection;Leishmania DNA Spec NAA+probe;;ACTIVE;1.0n;2.69 +23160-5;Leishmania sp identified;Prid;Pt;Tiss;Nom;IF;MICRO;1;Leishmania sp identified in Tissue by Immunofluorescence;Leishmania Tiss IF;;ACTIVE;1.0n;2.22 +23161-3;Leishmania sp identified;Prid;Pt;Tiss;Nom;Electrophoresis;MICRO;1;Leishmania sp identified in Tissue by Electrophoresis;Leishmania Tiss Elph;;ACTIVE;1.0n;2.22 +23162-1;Leishmania sp identified;Prid;Pt;Tiss;Nom;PAGE;MICRO;1;Leishmania sp identified in Tissue by Polyacrylamide gel electrophoresis (PAGE);Leishmania Tiss PAGE;;ACTIVE;1.0n;2.22 +23163-9;Leptospira interrogans serovar Australis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Australis Ab [Presence] in Serum by Agglutination;L inter Austral Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23164-7;Leptospira interrogans serovar Australis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Australis Ab [Presence] in Serum;L inter Austral Ab Ser Ql;;ACTIVE;1.0n;2.56 +23165-4;Leptospira interrogans serovar Autumnalis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Autumnalis Ab [Presence] in Serum by Agglutination;L inter Autum Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23166-2;Leptospira interrogans serovar Autumnalis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Autumnalis Ab [Presence] in Serum;L inter Autum Ab Ser Ql;;ACTIVE;1.0n;2.56 +23167-0;Leptospira borgpetersenii serovar Ballum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira borgpetersenii sv Ballum Ab [Presence] in Serum;L borgp Ball Ab Ser Ql;;ACTIVE;1.0n;2.56 +2316-8;Galactosylgalactosylglucosylceramidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Galactosylgalactosylglucosylceramidase [Enzymatic activity/mass] in Tissue;GalGalGlucCeramidase Tiss-cCnt;;ACTIVE;1.0;2.42 +23168-8;Leptospira borgpetersenii serovar Ballum Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira borgpetersenii sv Ballum Ab [Presence] in Serum by Agglutination;L borgp Ball Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23169-6;Leptospira interrogans serovar Bataviae Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Bataviae Ab [Presence] in Serum by Agglutination;L inter Batav Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23170-4;Leptospira interrogans serovar Bataviae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Bataviae Ab [Presence] in Serum;L inter Batav Ab Ser Ql;;ACTIVE;1.0n;2.56 +23171-2;Leptospira interrogans serovar Bratislava Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Bratislava Ab [Presence] in Serum by Agglutination;L inter Brat Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23172-0;Leptospira interrogans serovar Bratislava Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Bratislava Ab [Presence] in Serum;L inter Brat Ab Ser Ql;;ACTIVE;1.0n;2.56 +23173-8;Leptospira interrogans serovar Canicola Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Canicola Ab [Presence] in Serum;L inter Canic Ab Ser Ql;;ACTIVE;1.0n;2.56 +23174-6;Leptospira interrogans serovar Canicola Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Canicola Ab [Presence] in Serum by Agglutination;L inter Canic Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23175-3;Leptospira interrogans serovar Copenhageni Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Copenhageni Ab [Presence] in Serum;L inter Copen Ab Ser Ql;;ACTIVE;1.0n;2.56 +2317-6;Gamma aminobutyrate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Gamma aminobutyrate [Presence] in Serum or Plasma;GABA SerPl Ql;;ACTIVE;1.0;2.56 +23176-1;Leptospira interrogans serovar Copenhageni Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Copenhageni Ab [Presence] in Serum by Agglutination;L inter Copen Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23177-9;Leptospira interrogans serovar Grippotyphosa Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Grippotyphosa Ab [Presence] in Serum;L inter Grip Ab Ser Ql;;ACTIVE;1.0n;2.56 +23178-7;Leptospira interrogans serovar Grippotyphosa Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Grippotyphosa Ab [Presence] in Serum by Agglutination;L inter Grip Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23179-5;Leptospira interrogans serovar Hardjo Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leptospira interrogans sv Hardjo Ab [Presence] in Serum by Immunoassay;L inter Hard Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23180-3;Leptospira interrogans serovar Hardjo Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Hardjo Ab [Presence] in Serum by Agglutination;L inter Hard Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23181-1;Leptospira interrogans serovar Hardjo Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Hardjo Ab [Presence] in Serum;L inter Hard Ab Ser Ql;;ACTIVE;1.0n;2.56 +23182-9;Leptospira interrogans serovar Hebdomadis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Hebdomadis Ab [Presence] in Serum by Agglutination;L inter Hebdo Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23183-7;Leptospira interrogans serovar Hebdomadis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Hebdomadis Ab [Presence] in Serum;L inter Hebdo Ab Ser Ql;;ACTIVE;1.0n;2.56 +2318-4;Gamma aminobutyrate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma aminobutyrate [Mass/volume] in Serum or Plasma;GABA SerPl-mCnc;;DISCOURAGED;1.0;2.44 +23184-5;Leptospira interrogans serovar Icterohaemorrhagiae Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Icterohaemorrhagiae Ab [Presence] in Serum by Agglutination;L inter Icter Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23185-2;Leptospira interrogans serovar Icterohaemorrhagiae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Icterohaemorrhagiae Ab [Presence] in Serum;L inter Icter Ab Ser Ql;;ACTIVE;1.0n;2.56 +23186-0;Leptospira interrogans Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leptospira interrogans Ab [Presence] in Serum by Immunoassay;L inter Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23187-8;Leptospira interrogans Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans Ab [Presence] in Serum;L inter Ab Ser Ql;;ACTIVE;1.0n;2.56 +23188-6;Leptospira interrogans Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans Ab [Presence] in Serum by Agglutination;L inter Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23189-4;Leptospira interrogans serovar Mitis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Mitis Ab [Presence] in Serum;L inter Mitis Ab Ser Ql;;ACTIVE;1.0n;2.56 +23190-2;Leptospira interrogans serovar Mitis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Mitis Ab [Presence] in Serum by Agglutination;L inter Mitis Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23191-0;Leptospira interrogans serovar Pomona Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Pomona Ab [Presence] in Serum;L inter Pomon Ab Ser Ql;;ACTIVE;1.0n;2.56 +2319-2;Gamma aminobutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Gamma aminobutyrate [Mass/volume] in Urine;GABA Ur-mCnc;;DISCOURAGED;1.0;2.44 +23192-8;Leptospira interrogans serovar Pomona Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Pomona Ab [Presence] in Serum by Agglutination;L inter Pomon Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23193-6;Leptospira borgpetersenii serovar Sejroe Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira borgpetersenii sv Sejroe Ab [Presence] in Serum;L borgp Sej Ab Ser Ql;;ACTIVE;1.0n;2.56 +23194-4;Leptospira borgpetersenii serovar Sejroe Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira borgpetersenii sv Sejroe Ab [Presence] in Serum by Agglutination;L borgp Sej Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23195-1;Leptospira sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leptospira sp Ab [Presence] in Serum by Immunoassay;Leptospira Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23196-9;Leptospira sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira sp Ab [Presence] in Serum;Leptospira Ab Ser Ql;;ACTIVE;1.0n;2.73 +23197-7;Leptospira sp Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira sp Ab [Presence] in Serum by Agglutination;Leptospira Ab Ser Ql Aggl;;ACTIVE;1.0n;2.73 +23198-5;Leptospira sp Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira sp Ab [Titer] in Serum by Agglutination;Leptospira Ab Titr Ser Aggl;;ACTIVE;1.0n;2.73 +23199-3;Leptospira sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leptospira sp IgG Ab [Presence] in Serum by Immunoassay;Leptospira IgG Ser Ql IA;;ACTIVE;1.0n;2.56 +23-2;Amphotericin B;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Amphotericin B [Susceptibility] by Minimum lethal concentration (MLC);Amphotericin B Islt MLC;;ACTIVE;1.0;2.19 +2320-0;Gamma glutamyl cysteine synthetase;CCnc;Pt;RBC;Qn;;CHEM;1;Gamma glutamyl cysteine synthetase [Enzymatic activity/volume] in Red Blood Cells;GGCS RBC-cCnc;;ACTIVE;1.0;2.44 +23200-9;Leptospira sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira sp IgG Ab [Presence] in Serum;Leptospira IgG Ser Ql;;ACTIVE;1.0n;2.56 +23201-7;Leptospira sp Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leptospira sp IgM Ab [Presence] in Serum by Immunoassay;Leptospira IgM Ser Ql IA;;ACTIVE;1.0n;2.73 +23202-5;Leptospira sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira sp IgM Ab [Presence] in Serum;Leptospira IgM Ser Ql;;ACTIVE;1.0n;2.73 +23203-3;Leptospira sp Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Leptospira sp Ag [Presence] in Tissue by Immunofluorescence;Leptospira Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23204-1;Leptospira sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Leptospira sp Ag [Presence] in Tissue by Immune stain;Leptospira Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23205-8;Leptospira sp DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Leptospira sp DNA [Presence] in Body fluid by NAA with probe detection;Leptospira DNA Fld Ql NAA+probe;;ACTIVE;1.0n;2.63 +23206-6;Leptospira sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Leptospira sp DNA [Presence] in Tissue by NAA with probe detection;Leptospira DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23207-4;Leptospira sp subtype;Prid;Pt;XXX;Nom;;MICRO;1;Leptospira subtype [Identifier] in Specimen;Leptospira Subtyp Spec;;ACTIVE;1.0n;2.69 +23208-2;Leptospira borgpetersenii serovar Tarrasovi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira borgpetersenii sv Tarrasovi Ab [Presence] in Serum;L borgp Tarra Ab Ser Ql;;ACTIVE;1.0n;2.56 +23209-0;Leptospira borgpetersenii serovar Tarrasovi Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira borgpetersenii sv Tarrasovi Ab [Presence] in Serum by Agglutination;L borgp Tarra Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23210-8;Listeria sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Listeria sp Ab [Presence] in Serum;Listeria Ab Ser Ql;;ACTIVE;1.0n;2.56 +23211-6;Listeria sp Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Listeria sp Ab [Presence] in Serum by Agglutination;Listeria Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23212-4;Lumpy skin disease virus;PrThr;Pt;Tiss;Ord;Microscopy.electron;MICRO;1;Lumpy skin disease virus [Presence] in Tissue by Electron microscopy;LSDV Tiss Ql EM;;ACTIVE;1.0n;2.56 +23213-2;Lumpy skin disease virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Lumpy skin disease virus Ab [Titer] in Serum by Immunofluorescence;LSDV Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23214-0;Lumpy skin disease virus Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Lumpy skin disease virus Ab [Presence] in Serum by Immunoblot;LSDV Ab Ser Ql IB;;ACTIVE;1.0n;2.58 +23215-7;Lumpy skin disease virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Lumpy skin disease virus neutralizing antibody [Presence] in Serum by Neutralization test;LSDV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23216-5;Lumpy skin disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Lumpy skin disease virus Ab [Presence] in Serum;LSDV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23217-3;Lumpy skin disease virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Lumpy skin disease virus Ab [Titer] in Serum;LSDV Ab Titr Ser;;ACTIVE;1.0n;2.70 +2321-8;Gamma glutamyl cysteine synthetase;CCnc;Pt;Ser;Qn;;CHEM;1;Gamma glutamyl cysteine synthetase [Enzymatic activity/volume] in Serum;GGCS Ser-cCnc;;ACTIVE;1.0;2.68 +23218-1;Lumpy skin disease virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Lumpy skin disease virus Ag [Presence] in Tissue by Immunoassay;LSDV Ag Tiss Ql IA;;ACTIVE;1.0n;2.56 +23219-9;Lumpy skin disease virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Lumpy skin disease virus Ag [Presence] in Specimen by Immunoassay;LSDV Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +23220-7;Lumpy skin disease virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Lumpy skin disease virus Ag [Presence] in Specimen;LSDV Ag Spec Ql;;ACTIVE;1.0n;2.69 +23221-5;Lumpy skin disease virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Lumpy skin disease virus Ag [Presence] in Specimen by Immunofluorescence;LSDV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23222-3;Lumpy skin disease virus Ag;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Lumpy skin disease virus Ag [Presence] in Specimen by Immune diffusion (ID);LSDV Ag Spec Ql ID;;ACTIVE;1.0n;2.69 +23223-1;Lumpy skin disease virus DNA;PrThr;Pt;XXX;Ord;RFLP;MICRO;1;Lumpy skin disease virus DNA [Presence] in Specimen by RFLP;LSDV DNA Spec Ql RFLP;;ACTIVE;1.0n;2.69 +23224-9;Mareks disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mareks disease virus Ab [Presence] in Serum;GaHV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23225-6;Mareks disease virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mareks disease virus Ab [Presence] in Serum by Immunoassay;GaHV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +2322-6;Gamma glutamyl transferase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/volume] in Amniotic fluid;GGT Amn-cCnc;;ACTIVE;1.0;2.68 +23226-4;Mareks disease virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Mareks disease virus Ab [Presence] in Serum by Immunofluorescence;GaHV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23227-2;Mareks disease virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Mareks disease virus neutralizing antibody [Presence] in Serum by Neutralization test;GaHV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23228-0;Mareks disease virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Mareks disease virus Ab [Presence] in Serum by Immune diffusion (ID);GaHV Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +23229-8;Mareks disease virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Mareks disease virus Ag [Presence] in Specimen by Immunofluorescence;GaHV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23230-6;Mareks disease virus Ag;PrThr;Pt;Feather;Ord;Immune diffusion;MICRO;1;Mareks disease virus Ag [Presence] in Feather by Immune diffusion (ID);GaHV Ag Feather Ql ID;;ACTIVE;1.0n;2.56 +23231-4;Mareks disease virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mareks disease virus DNA [Presence] in Specimen by NAA with probe detection;GaHV DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23232-2;Mite identified;Prid;Pt;Skin;Nom;Flotation;MICRO;1;Mite identified in Skin by Flotation;Mite Skin Flotation;;ACTIVE;1.0n;2.21 +23233-0;Mite identified;Prid;Pt;Skin;Nom;Sedimentation;MICRO;1;Mite identified in Skin by Parasite sedimentation;Mite Skin Sedimentation;;ACTIVE;1.0n;2.21 +2323-4;Gamma glutamyl transferase;CCnc;Pt;Semen;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/volume] in Semen;GGT Smn-cCnc;;ACTIVE;1.0;2.73 +23234-8;Mycobacterium avium subspecies avium Ab;PrThr;Pt;Bld;Ord;;MICRO;1;Mycobacterium avium ss avium Ab [Presence] in Blood;M avium av Ab Bld Ql;;ACTIVE;1.0n;2.56 +23235-5;Mycobacterium avium subspecies avium Ab;PrThr;Pt;Bld;Ord;Aggl;MICRO;1;Mycobacterium avium ss avium Ab [Presence] in Blood by Agglutination;M avium av Ab Bld Ql Aggl;;ACTIVE;1.0n;2.56 +23236-3;Mycobacterium avium subspecies avium rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Mycobacterium avium ss avium rRNA [Presence] in Tissue by Probe;M avium av rRNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +23237-1;Mycobacterium avium subspecies avium identified;Prid;Pt;XXX;Nom;Bioassay;MICRO;1;Mycobacterium avium ss avium identified in Specimen by Bioassay;M avium av Spec Bioassay;;ACTIVE;1.0n;2.69 +23238-9;Mycobacterium avium subspecies avium serotype;Prid;Pt;XXX;Nom;;MICRO;1;Mycobacterium avium ss avium serotype [Identifier] in Specimen;M avium av Sertyp Spec;;ACTIVE;1.0n;2.69 +23239-7;Mycobacterium bovis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycobacterium bovis Ab [Presence] in Serum;M bovis Ab Ser Ql;;ACTIVE;1.0n;2.56 +23240-5;Mycobacterium bovis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycobacterium bovis Ab [Presence] in Serum by Immunoassay;M bovis Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23241-3;Mycobacterium bovis Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Mycobacterium bovis Ag [Presence] in Tissue by Immune stain;M bovis Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +2324-2;Gamma glutamyl transferase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma;GGT SerPl-cCnc;;ACTIVE;1.0;2.73 +23242-1;Mycobacterium bovis Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Mycobacterium bovis Ag [Presence] in Blood;M bovis Ag Bld Ql;;ACTIVE;1.0n;2.73 +23243-9;Mycobacterium avium subspecies paratuberculosis;PrThr;Pt;Stool;Ord;Acid fast stain.Ziehl-Neelsen;MICRO;1;Mycobacterium avium ss paratuberculosis [Presence] in Stool by Acid fast stain.Ziehl-Neelsen;M avium paraTB Stl Ql ZN Stn;;ACTIVE;1.0n;2.56 +23244-7;Mycobacterium avium subspecies paratuberculosis;PrThr;Pt;Tiss;Ord;Acid fast stain.Ziehl-Neelsen;MICRO;1;Mycobacterium avium ss paratuberculosis [Presence] in Tissue by Acid fast stain.Ziehl-Neelsen;M avium paraTB Tiss Ql ZN Stn;;ACTIVE;1.0n;2.56 +23245-4;Mycobacterium avium subspecies paratuberculosis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium avium ss paratuberculosis DNA [Presence] in Specimen by NAA with probe detection;M avium paraTB DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23246-2;Mycobacterium avium subspecies paratuberculosis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Mycobacterium avium ss paratuberculosis DNA [Presence] in Stool by NAA with probe detection;M avium paraTB DNA Stl Ql NAA+probe;;ACTIVE;1.0n;2.63 +23247-0;Mycobacterium sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Mycobacterium sp DNA [Presence] in Tissue by NAA with probe detection;Mycobacterium DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23248-8;Mycoplasma agalactiae Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Mycoplasma agalactiae neutralizing antibody [Presence] in Serum by Neutralization test;M agalactiae NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23249-6;Mycoplasma agalactiae Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma agalactiae Ab [Presence] in Serum by Complement fixation;M agalactiae Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23250-4;Mycoplasma agalactiae Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma agalactiae Ab [Presence] in Serum by Immunoassay;M agalactiae Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23251-2;Mycoplasma agalactiae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma agalactiae Ab [Presence] in Serum;M agalactiae Ab Ser Ql;;ACTIVE;1.0n;2.56 +23252-0;Mycoplasma agalactiae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma agalactiae DNA [Presence] in Specimen by NAA with probe detection;M agalactiae DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23253-8;Mycoplasma arginini Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma arginini Ab [Presence] in Serum;M arginini Ab Ser Ql;;ACTIVE;1.0n;2.56 +23254-6;Mycoplasma arginini Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma arginini Ab [Presence] in Serum by Complement fixation;M arginini Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23255-3;Mycoplasma bovis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma bovis Ab [Presence] in Serum;Mp bovis Ab Ser Ql;;ACTIVE;1.0n;2.56 +23256-1;Mycoplasma bovis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma bovis Ab [Presence] in Serum by Complement fixation;Mp bovis Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23257-9;Mycoplasma capricolum subspecies capricolum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma capricolum ss capricolum Ab [Presence] in Serum by Immunoassay;M cap capric Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23258-7;Mycoplasma capricolum subspecies capricolum Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma capricolum ss capricolum Ab [Presence] in Serum by Complement fixation;M cap capric Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +2325-9;Gamma glutamyl transferase/Aspartate aminotransferase;CRto;Pt;Ser/Plas;Qn;;CHEM;1;Gamma glutamyl transferase/Aspartate aminotransferase [Enzymatic activity ratio] in Serum or Plasma;GGT/AST SerPl-cRto;;ACTIVE;1.0;2.73 +23259-5;Mycoplasma capricolum subspecies capricolum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma capricolum ss capricolum Ab [Presence] in Serum;M cap capric Ab Ser Ql;;ACTIVE;1.0n;2.56 +23260-3;Mycoplasma capricolum subspecies capripneumonia Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Presence] in Serum by Agglutination;M cap caprip Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23261-1;Mycoplasma capricolum subspecies capripneumonia Ab;ACnc;Pt;Ser;Ord;Aggl;MICRO;1;Deprecated Mycoplasma capricolum ss capripneumonia Ab [Presence] in Serum by Agglutination;Deprecated M cap caprip Ab Ser Ql Aggl;;DEPRECATED;1.0n;2.36 +23262-9;Mycoplasma capricolum subspecies capripneumonia Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Titer] in Serum;M cap caprip Ab Titr Ser;;ACTIVE;1.0n;2.70 +23263-7;Mycoplasma capricolum subspecies capripneumonia Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Presence] in Serum by Immunoassay;M cap caprip Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23264-5;Mycoplasma capricolum subspecies capripneumonia Ab;PrThr;Pt;Bld;Ord;Aggl;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Presence] in Blood by Agglutination;M cap caprip Ab Bld Ql Aggl;;ACTIVE;1.0n;2.56 +23265-2;Mycoplasma capricolum subspecies capripneumonia Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Titer] in Serum by Complement fixation;M cap caprip Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23266-0;Mycoplasma capricolum subspecies capripneumonia Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Presence] in Serum by Complement fixation;M cap caprip Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +2326-7;Gastric inhibitory polypeptide;MCnc;Pt;Plas;Qn;;CHEM;1;Gastric inhibitory polypeptide [Mass/volume] in Plasma;GIP Plas-mCnc;;ACTIVE;1.0;2.73 +23267-8;Mycoplasma capricolum subspecies capripneumonia Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Mycoplasma capricolum ss capripneumonia Ag [Presence] in Specimen by Neutralization test;M cap caprip Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23268-6;Mycoplasma capricolum subspecies capripneumonia Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Mycoplasma capricolum ss capripneumonia Ag [Presence] in Specimen by Immunofluorescence;M cap caprip Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23269-4;Mycoplasma capricolum subspecies capripneumonia Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Mycoplasma capricolum ss capripneumonia Ag [Presence] in Specimen;M cap caprip Ag Spec Ql;;ACTIVE;1.0n;2.69 +23270-2;Mycoplasma capricolum subspecies capripneumonia Ag;PrThr;Pt;Tiss;Ord;;MICRO;1;Mycoplasma capricolum ss capripneumonia Ag [Presence] in Tissue;M cap caprip Ag Tiss Ql;;ACTIVE;1.0n;2.56 +23271-0;Mycoplasma capricolum subspecies capripneumonia rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycoplasma capricolum ss capripneumonia rRNA [Presence] in Specimen by Probe;M cap caprip rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +23272-8;Mycoplasma capricolum subspecies capripneumonia rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma capricolum ss capripneumonia rRNA [Presence] in Specimen by NAA with probe detection;M cap caprip rRNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23273-6;Mycoplasma gallisepticum Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Mycoplasma gallisepticum Ab [Presence] in Serum by Hemagglutination;M gallisep Ab Ser Ql HA;;ACTIVE;1.0n;2.56 +23274-4;Mycoplasma gallisepticum Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Mycoplasma gallisepticum Ab [Titer] in Serum by Hemagglutination;M gallisep Ab Titr Ser HA;;ACTIVE;1.0n;2.70 +2327-5;Gastrin releasing polypeptide;MCnc;Pt;CSF;Qn;;CHEM;1;Gastrin releasing polypeptide [Mass/volume] in Cerebral spinal fluid;GRP CSF-mCnc;;ACTIVE;1.0;2.42 +23275-1;Mycoplasma gallisepticum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma gallisepticum Ab [Titer] in Serum;M gallisep Ab Titr Ser;;ACTIVE;1.0n;2.70 +23276-9;Mycoplasma gallisepticum Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Mycoplasma gallisepticum Ag [Presence] in Specimen by Immunofluorescence;M gallisep Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23277-7;Mycoplasma gallisepticum Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Mycoplasma gallisepticum Ag [Presence] in Specimen by Immune stain;M gallisep Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +23278-5;Mycoplasma gallisepticum Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Mycoplasma gallisepticum Ag [Presence] in Specimen by Neutralization test;M gallisep Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23279-3;Mycoplasma gallisepticum DNA;PrThr;Pt;Nose/Trac;Ord;Probe.amp.tar;MICRO;1;Mycoplasma gallisepticum DNA [Presence] in Nose or Trachea by NAA with probe detection;M gallisep DNA Nose/Trachea Ql NAA+probe;;ACTIVE;1.0n;2.63 +23280-1;Mycoplasma meleagridis Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Mycoplasma meleagridis Ab [Presence] in Serum by Hemagglutination;M meleagridis Ab Ser Ql HA;;ACTIVE;1.0n;2.56 +23281-9;Mycoplasma mycoides subspecies capri Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma mycoides ss capri Ab [Presence] in Serum by Complement fixation;M myc capri Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23282-7;Mycoplasma mycoides subspecies capri Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma mycoides ss capri Ab [Presence] in Serum;M myc capri Ab Ser Ql;;ACTIVE;1.0n;2.56 +2328-3;Gastrin releasing polypeptide;SCnc;Pt;CSF;Qn;;CHEM;1;Gastrin releasing polypeptide [Moles/volume] in Cerebral spinal fluid;GRP CSF-sCnc;;ACTIVE;1.0;2.42 +23283-5;Mycoplasma mycoides subspecies mycoides large colony Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma mycoides ss mycoides large colony Ab [Presence] in Serum by Complement fixation;M myc my lc Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23284-3;Mycoplasma mycoides subspecies mycoides large colony Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma mycoides ss mycoides large colony Ab [Presence] in Serum by Immunoassay;M myc my lc Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23285-0;Mycoplasma mycoides subspecies mycoides small colony Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ab [Presence] in Serum;M myc my sc Ab Ser Ql;;ACTIVE;1.0n;2.56 +23286-8;Mycoplasma mycoides subspecies mycoides small colony Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ab [Presence] in Serum by Immunoblot;M myc my sc Ab Ser Ql IB;;ACTIVE;1.0n;2.58 +23287-6;Mycoplasma mycoides subspecies mycoides small colony Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ab [Presence] in Serum by Immunoassay;M myc my sc Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23288-4;Mycoplasma mycoides subspecies mycoides small colony Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ab [Presence] in Serum by Complement fixation;M myc my sc Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23289-2;Mycoplasma mycoides subspecies mycoides small colony Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ab [Presence] in Serum by Agglutination;M myc my sc Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +232-9;Erythromycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Erythromycin [Susceptibility] by Minimum lethal concentration (MLC);Erythromycin Islt MLC;;ACTIVE;1.0;2.19 +23290-0;Mycoplasma mycoides subspecies mycoides small colony Ag;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ag [Presence] in Specimen by Immune diffusion (ID);M myc my sc Ag Spec Ql ID;;ACTIVE;1.0n;2.69 +2329-1;Gastrin releasing polypeptide;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gastrin releasing polypeptide [Mass/volume] in Serum or Plasma;GRP SerPl-mCnc;;ACTIVE;1.0;2.73 +23291-8;Mycoplasma mycoides subspecies mycoides small colony Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ag [Presence] in Specimen by Immunofluorescence;M myc my sc Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23292-6;Mycoplasma mycoides subspecies mycoides small colony Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ag [Presence] in Tissue by Immune stain;M myc my sc Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23293-4;Mycoplasma mycoides subspecies mycoides small colony DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma mycoides ss mycoides small colony DNA [Presence] in Specimen by NAA with probe detection;M myc my sc DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23294-2;Mycoplasma putrefaciens Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma putrefaciens Ab [Presence] in Serum by Immunoassay;M putrefaciens Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23295-9;Mycoplasma putrefaciens Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma putrefaciens Ab [Presence] in Serum by Complement fixation;M putrefaciens Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23296-7;Mycoplasma putrefaciens Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma putrefaciens Ab [Presence] in Serum;M putrefaciens Ab Ser Ql;;ACTIVE;1.0n;2.56 +23297-5;Mycoplasma sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Mycoplasma sp Ab [Presence] in Serum by Complement fixation;Mycoplasma Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23298-3;Mycoplasma sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Mycoplasma sp Ag [Presence] in Specimen by Immunofluorescence;Mycoplasma Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23299-1;Mycoplasma sp Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Mycoplasma sp Ag [Presence] in Specimen;Mycoplasma Ag Spec Ql;;ACTIVE;1.0n;2.69 +23300-7;Mycoplasma sp rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycoplasma sp rRNA [Presence] in Specimen by Probe;Mycoplasma rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +23301-5;Mycoplasma sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma sp DNA [Presence] in Specimen by NAA with probe detection;Mycoplasma DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.73 +23302-3;Mycoplasma synoviae Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Mycoplasma synoviae Ab [Presence] in Serum by Hemagglutination;M synoviae Ab Ser Ql HA;;ACTIVE;1.0n;2.56 +23303-1;Myxoma virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Myxoma virus Ab [Presence] in Serum by Immune diffusion (ID);MYXV Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +23304-9;Myxoma virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Myxoma virus Ab [Presence] in Serum;MYXV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23305-6;Myxoma virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Myxoma virus Ab [Titer] in Serum;MYXV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23306-4;Myxoma virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Myxoma virus Ab [Titer] in Serum by Immunofluorescence;MYXV Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23307-2;Myxoma virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Myxoma virus Ab [Presence] in Serum by Complement fixation;MYXV Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23308-0;Myxoma virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Myxoma virus neutralizing antibody [Presence] in Serum by Neutralization test;MYXV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +2330-9;Gastrin.34 residue fragment;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gastrin.34 residue fragment [Mass/volume] in Serum or Plasma;Gastrin34 Residu Frg SerPl-mCnc;;ACTIVE;1.0;2.42 +23309-8;Myxoma virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Myxoma virus Ab [Presence] in Serum by Immunofluorescence;MYXV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23310-6;Myxoma virus Ag;PrThr;Pt;Skin;Ord;Immune diffusion;MICRO;1;Myxoma virus Ag [Presence] in Skin by Immune diffusion (ID);MYXV Ag Skin Ql ID;;ACTIVE;1.0n;2.56 +23311-4;Myxoma virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Myxoma virus Ag [Presence] in Specimen by Immunofluorescence;MYXV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23312-2;Nairobi sheep disease virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Nairobi sheep disease virus Ab [Presence] in Serum;Deprecated NSDV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23313-0;Nairobi sheep disease virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Nairobi sheep disease virus Ab [Titer] in Serum;NSDV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23314-8;Nairobi sheep disease virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Nairobi sheep disease virus Ab [Presence] in Serum by Immune diffusion (ID);NSDV Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +23315-5;Nairobi sheep disease virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Nairobi sheep disease virus Ab [Presence] in Serum by Immunofluorescence;NSDV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23316-3;Nairobi sheep disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Nairobi sheep disease virus Ab [Presence] in Serum;NSDV Ab Ser Ql;;ACTIVE;1.0n;2.56 +2331-7;Gastrin.17 residue fragment;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gastrin.17 residue fragment [Mass/volume] in Serum or Plasma;Gastrin17 Residu Frg SerPl-mCnc;;ACTIVE;1.0;2.42 +23317-1;Nairobi sheep disease virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Nairobi sheep disease virus Ab [Titer] in Serum;Deprecated NSDV Ab Titr Ser;;DEPRECATED;1.0n;2.36 +23318-9;Nairobi sheep disease virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Nairobi sheep disease virus Ag [Presence] in Specimen by Complement fixation;NSDV Ag Spec Ql CF;;ACTIVE;1.0n;2.69 +23319-7;Nairobi sheep disease virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Nairobi sheep disease virus Ag [Presence] in Specimen by Immunofluorescence;NSDV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23320-5;Nairobi sheep disease virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Nairobi sheep disease virus Ag [Presence] in Specimen by Immunoassay;NSDV Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +23321-3;Ovine herpesvirus 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ovine herpesvirus 2 Ab [Presence] in Serum;OvHV2 Ab Ser Ql;;ACTIVE;1.0n;2.56 +23322-1;Ovine herpesvirus 2 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Ovine herpesvirus 2 Ab [Presence] in Serum by Complement fixation;OvHV2 Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23323-9;Ovine herpesvirus 2 Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Ovine herpesvirus 2 Ab [Presence] in Serum;Deprecated OvHV2 Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23324-7;Ovine herpesvirus 2 Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Ovine herpesvirus 2 Ab [Presence] in Serum by Immunofluorescence;OvHV2 Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +2332-5;Gastrin.14 residue fragment;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gastrin.14 residue fragment [Mass/volume] in Serum or Plasma;Gastrin14 Residu Frg SerPl-mCnc;;ACTIVE;1.0;2.42 +23325-4;Ovine herpesvirus 2 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ovine herpesvirus 2 Ab [Presence] in Serum by Immunoassay;OvHV2 Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23326-2;Ovine herpesvirus 2 Ab;PrThr;Pt;Ser;Ord;Immune stain;MICRO;1;Ovine herpesvirus 2 Ab [Presence] in Serum by Immune stain;OvHV2 Ab Ser Ql ImStn;;ACTIVE;1.0n;2.56 +23327-0;Ovine herpesvirus 2 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Ovine herpesvirus 2 DNA [Presence] in Tissue by NAA with probe detection;OvHV2 DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23328-8;Ovine progressive pneumonia virus Ab;PrThr;Pt;Milk;Ord;;MICRO;1;Ovine progressive pneumonia virus Ab [Presence] in Milk;OPPV Ab Mlk Ql;;ACTIVE;1.0n;2.56 +23329-6;Ovine progressive pneumonia virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ovine progressive pneumonia virus Ab [Presence] in Serum;OPPV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23330-4;Ovine progressive pneumonia virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ovine progressive pneumonia virus Ab [Presence] in Serum by Immunoassay;OPPV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23331-2;Ovine progressive pneumonia virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Ovine progressive pneumonia virus Ab [Presence] in Serum;Deprecated OPPV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23332-0;Ovine progressive pneumonia virus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Ovine progressive pneumonia virus Ab [Presence] in Serum by Immune diffusion (ID);OPPV Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +2333-3;Gastrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gastrin [Mass/volume] in Serum or Plasma;Gastrin SerPl-mCnc;;ACTIVE;1.0;2.73 +23333-8;Ovine progressive pneumonia virus Ab;PrThr;Pt;Milk;Ord;IA;MICRO;1;Ovine progressive pneumonia virus Ab [Presence] in Milk by Immunoassay;OPPV Ab Mlk Ql IA;;ACTIVE;1.0n;2.56 +23334-6;Ovine progressive pneumonia virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Ovine progressive pneumonia virus Ag [Presence] in Specimen by Immunofluorescence;OPPV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23335-3;Ovine progressive pneumonia virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Ovine progressive pneumonia virus Ag [Presence] in Specimen by Immune stain;OPPV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +23336-1;Ovine progressive pneumonia virus DNA;PrThr;Pt;XXX;Ord;PAGE;MICRO;1;Ovine progressive pneumonia virus DNA [Presence] in Specimen by Polyacrylamide gel electrophoresis (PAGE);OPPV DNA Spec Ql PAGE;;ACTIVE;1.0n;2.69 +23337-9;Ovine progressive pneumonia virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ovine progressive pneumonia virus DNA [Presence] in Specimen by NAA with probe detection;OPPV DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23338-7;Ovine pulmonary adenomatosis retrovirus RNA;PrThr;Pt;Lung tiss;Ord;Probe.amp.tar;MICRO;1;Ovine pulmonary adenomatosis retrovirus RNA [Presence] in Lung tissue by NAA with probe detection;OPAV RNA Lung tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23339-5;Paratuberculosis reaction wheal^3D post 0.1 mL avian tuberculin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Paratuberculosis reaction wheal [Diameter] --3 days post 0.1 mL avian tuberculin intradermal;MAP Wheal 3D p .1mL Av PPD Diam;;ACTIVE;1.0n;2.73 +23340-3;Paratuberculosis reaction wheal^3D post 0.1 mL johnin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Paratuberculosis reaction wheal [Diameter] --3 days post 0.1 mL johnin intradermal;MAP Wheal 3D p .1mL Johnin Diam;;ACTIVE;1.0n;2.42 +2334-1;Hemoglobin.gastrointestinal;PrThr;Pt;Gast fld;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Gastric fluid;Gastrocult Gast Ql;;ACTIVE;1.0;2.73 +23341-1;Pasteurella multocida Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Pasteurella multocida Ab [Titer] in Serum by Immunoassay;P multoc Ab Titr Ser IA;;ACTIVE;1.0n;2.70 +23342-9;Pasteurella multocida Ab;Titr;Pt;Ser;Qn;;MICRO;1;Pasteurella multocida Ab [Titer] in Serum;P multoc Ab Titr Ser;;ACTIVE;1.0n;2.70 +23343-7;Pasteurella multocida Ag;Titr;Pt;XXX;Qn;Aggl;MICRO;1;Pasteurella multocida Ag [Titer] in Specimen by Agglutination;P multoc Ag Titr Spec Aggl;;ACTIVE;1.0n;2.70 +23344-5;Pasteurella multocida rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Pasteurella multocida rRNA [Presence] in Specimen by Probe;P multoc rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +23345-2;Pasteurella multocida serotype;Prid;Pt;XXX;Nom;Aggl;MICRO;1;Pasteurella multocida serotype [Identifier] in Specimen by Agglutination;P multoc Sertyp Spec Aggl;;ACTIVE;1.0n;2.69 +23346-0;Pasteurella multocida serotype;Prid;Pt;XXX;Nom;Immunoelectrophoresis;MICRO;1;Pasteurella multocida serotype [Identifier] in Specimen by Immunoelectrophoresis;P multoc Sertyp Spec IEP;;ACTIVE;1.0n;2.69 +23347-8;Pasteurella multocida serotype;Prid;Pt;XXX;Nom;IF;MICRO;1;Pasteurella multocida serotype [Identifier] in Specimen by Immunofluorescence;P multoc Sertyp Spec IF;;ACTIVE;1.0n;2.69 +23348-6;Pasteurella multocida serotype;Prid;Pt;XXX;Nom;Aggl;MICRO;1;Deprecated Pasteurella multocida serotype [Identifier] in Unspecified specimen by Agglutination;Deprecated P multoc Sertyp XXX Aggl;;DEPRECATED;1.0n;2.69 +23349-4;Pasteurella multocida toxin;PrThr;Pt;XXX;Ord;IA;MICRO;1;Pasteurella multocida toxin [Presence] in Specimen by Immunoassay;P multoc Tox Spec Ql IA;;ACTIVE;1.0n;2.69 +23350-2;Peste des petits ruminants virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Peste des petits ruminants virus Ab [Titer] in Serum;PPRV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23351-0;Peste des petits ruminants virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Peste des petits ruminants virus Ab [Presence] in Serum;PPRV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23352-8;Peste des petits ruminants virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Peste des petits ruminants virus neutralizing antibody [Titer] in Serum by Neutralization test;PPRV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23353-6;Peste des petits ruminants virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Peste des petits ruminants virus Ab [Presence] in Serum;Deprecated PPRV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23354-4;Peste des petits ruminants virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Peste des petits ruminants virus Ab [Presence] in Serum by Immunoassay;PPRV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23355-1;Peste des petits ruminants virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Peste des petits ruminants virus Ag [Presence] in Tissue by Immunoassay;PPRV Ag Tiss Ql IA;;ACTIVE;1.0n;2.56 +23356-9;Peste des petits ruminants virus Ag;PrThr;Pt;Tiss;Ord;Immunoelectrophoresis;MICRO;1;Peste des petits ruminants virus Ag [Presence] in Tissue by Immunoelectrophoresis;PPRV Ag Tiss Ql IEP;;ACTIVE;1.0n;2.56 +23357-7;Peste des petits ruminants virus Ag;PrThr;Pt;Tiss;Ord;Immune diffusion;MICRO;1;Peste des petits ruminants virus Ag [Presence] in Tissue by Immune diffusion (ID);PPRV Ag Tiss Ql ID;;ACTIVE;1.0n;2.56 +2335-8;Hemoglobin.gastrointestinal;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool;Hemoccult Stl Ql;;ACTIVE;1.0;2.73 +23358-5;Peste des petits ruminants virus RNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Peste des petits ruminants virus RNA [Presence] in Tissue by Probe;PPRV RNA Tiss Ql Probe;;ACTIVE;1.0n;2.63 +23359-3;Peste des petits ruminants virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Peste des petits ruminants virus RNA [Presence] in Tissue by NAA with probe detection;PPRV RNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23360-1;Porcine enterovirus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Porcine enterovirus Ag [Presence] in Specimen by Neutralization test;PEV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23361-9;Porcine enterovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Porcine enterovirus Ab [Presence] in Serum;PEV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23362-7;Porcine enterovirus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Porcine enterovirus neutralizing antibody [Presence] in Serum by Neutralization test;PEV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23363-5;Porcine enterovirus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Porcine enterovirus Ab [Presence] in Serum by Immunoassay;PEV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23364-3;Porcine enterovirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Porcine enterovirus Ag [Presence] in Specimen by Immunofluorescence;PEV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23365-0;Porcine parvovirus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Porcine parvovirus Ab [Presence] in Serum by Hemagglutination inhibition;PPV Ab Ser Ql HAI;;ACTIVE;1.0n;2.56 +2336-6;Globulin;MCnc;Pt;Ser;Qn;;CHEM;1;Globulin [Mass/volume] in Serum;Globulin Ser-mCnc;;ACTIVE;1.0;2.73 +23366-8;Porcine parvovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Porcine parvovirus Ab [Presence] in Serum;PPV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23367-6;Porcine reproductive and respiratory syndrome virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;PRRSV Ab [Presence] in Serum by Complement fixation;PRRSV Ab Ser Ql CF;;ACTIVE;1.0n;2.64 +23368-4;Porcine reproductive and respiratory syndrome virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;PRRSV neutralizing antibody [Presence] in Serum by Neutralization test;PRRSV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23369-2;Porcine reproductive and respiratory syndrome virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;PRRSV Ag [Presence] in Specimen by Immune stain;PRRSV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +233-7;Erythromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Erythromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Erythromycin Islt MIC;;ACTIVE;1.0;2.73 +23370-0;Porcine reproductive and respiratory syndrome virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;PRRSV Ag [Presence] in Tissue by Immune stain;PRRSV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.64 +23371-8;Porcine reproductive and respiratory syndrome virus RNA;PrThr;Pt;Semen;Ord;Probe.amp.tar;MICRO;1;PRRSV RNA [Presence] in Semen by NAA with probe detection;PRRSV RNA Smn Ql NAA+probe;;ACTIVE;1.0n;2.64 +23372-6;Porcine respiratory coronavirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Porcine respiratory coronavirus Ab [Presence] in Serum;PRCoV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23373-4;Porcine respiratory coronavirus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Porcine respiratory coronavirus neutralizing antibody [Presence] in Serum by Neutralization test;PRCoV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +2337-4;Glucagon;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Glucagon [Mass/volume] in Amniotic fluid;Glucagon Amn-mCnc;;ACTIVE;1.0;2.42 +23374-2;Porcine respiratory coronavirus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Porcine respiratory coronavirus Ab [Presence] in Serum by Immunoassay;PRCoV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23375-9;Porcine respiratory coronavirus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Porcine respiratory coronavirus Ab [Presence] in Serum;Deprecated PRCoV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23376-7;Porcine respiratory coronavirus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Porcine respiratory coronavirus Ag [Presence] in Specimen by Immune stain;PRCoV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +23377-5;Porcine respiratory coronavirus Ag;PrThr;Pt;Tsmi;Ord;Immune stain;MICRO;1;Porcine respiratory coronavirus Ag [Presence] in Small intestine Tissue by Immune stain;PRCoV Ag TSMI Ql ImStn;;ACTIVE;1.0n;2.56 +23378-3;Porcine respiratory coronavirus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Porcine respiratory coronavirus RNA [Presence] in Specimen by Probe;PRCoV RNA Spec Ql Probe;;ACTIVE;1.0n;2.73 +23379-1;Prion protein.abnormal;PrThr;Pt;Brain;Ord;IB;MICRO;1;Abnormal Prion Protein [Presence] in Brain by Immunoblot;Abn Prion Prot Brain Ql IB;;ACTIVE;1.0n;2.58 +23380-9;Prion protein.abnormal;PrThr;Pt;Brain;Ord;Immune stain;MICRO;1;Abnormal Prion Protein [Presence] in Brain by Immune stain;Abn Prion Prot Brain Ql ImStn;;ACTIVE;1.0n;2.73 +23381-7;Prion protein.abnormal;PrThr;Pt;Brain;Ord;Microscopy.electron;MICRO;1;Abnormal Prion Protein [Presence] in Brain by Electron microscopy;Abn Prion Prot Brain Ql EM;;ACTIVE;1.0n;2.56 +2338-2;Glucagon;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucagon [Mass/volume] in Serum or Plasma;Glucagon SerPl-mCnc;;ACTIVE;1.0;2.73 +23382-5;Pseudorabies virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Pseudorabies virus neutralizing antibody [Presence] in Serum by Neutralization test;PRV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23383-3;Pseudorabies virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Pseudorabies virus Ag [Presence] in Specimen by Immune stain;PRV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +23384-1;Pseudorabies virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Pseudorabies virus Ag [Presence] in Specimen by Immunoassay;PRV Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +23385-8;Pseudorabies virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Pseudorabies virus Ag [Presence] in Specimen by Immunofluorescence;PRV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23386-6;Pseudorabies virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Pseudorabies virus Ag [Presence] in Specimen by Neutralization test;PRV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23387-4;Pseudorabies virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Pseudorabies virus DNA [Presence] in Specimen by NAA with probe detection;PRV DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23388-2;Rabies virus;PrThr;Pt;Brain;Ord;Microscopy.light;MICRO;1;Rabies virus [Presence] in Brain by Light microscopy;RABV Brain Ql Micro;;ACTIVE;1.0n;2.56 +23389-0;Rabies virus Ag;PrThr;Pt;Brain;Ord;IA;MICRO;1;Rabies virus Ag [Presence] in Brain by Immunoassay;RABV Ag Brain Ql IA;;ACTIVE;1.0n;2.56 +2339-0;Glucose;MCnc;Pt;Bld;Qn;;CHEM;1;Glucose [Mass/volume] in Blood;Glucose Bld-mCnc;;ACTIVE;1.0;2.73 +23390-8;Rabies virus Ag;PrThr;Pt;Brain;Ord;Immune stain;MICRO;1;Rabies virus Ag [Presence] in Brain by Immune stain;RABV Ag Brain Ql ImStn;;ACTIVE;1.0n;2.56 +23391-6;Rabies virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Rabies virus Ag [Presence] in Specimen by Immune stain;RABV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +23392-4;Rabies virus DNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Rabies virus DNA by probe;Deprecated RABV DNA XXX Ql Prb;;DEPRECATED;1.0n;2.69 +23393-2;Rabies virus DNA;ACnc;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Deprecated Rabies virus DNA by amplified target;Deprecated RABV DNA XXX Ql PCR;;DEPRECATED;1.0n;2.69 +23394-0;Reticuloendotheliosis virus Ab;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Reticuloendotheliosis virus Ab [Presence] in Serum by Immunoassay;Deprecated REV Ab Ser Ql EIA;;DEPRECATED;1.0n;2.36 +23395-7;Reticuloendotheliosis virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Reticuloendotheliosis virus Ab [Presence] in Serum;Deprecated REV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23396-5;Rift valley fever virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Rift valley fever virus neutralizing antibody [Titer] in Serum by Neutralization test;RVFV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23397-3;Rift valley fever virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rift valley fever virus Ab [Presence] in Serum;RVFV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23398-1;Rift valley fever virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Rift valley fever virus Ab [Titer] in Serum by Hemagglutination inhibition;RVFV Ab Titr Ser HAI;;DISCOURAGED;1.0n;2.70 +23399-9;Rift valley fever virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rift valley fever virus Ab [Presence] in Serum by Immunoassay;RVFV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23400-5;Rift valley fever virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rift valley fever virus Ab [Titer] in Serum;RVFV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23401-3;Rift valley fever virus Ag;PrThr;Pt;Tiss;Ord;Neut;MICRO;1;Rift valley fever virus Ag [Presence] in Tissue by Neutralization test;RVFV Ag Tiss Ql Nt;;ACTIVE;1.0n;2.56 +23402-1;Rift valley fever virus Ag;PrThr;Pt;Bld;Ord;Neut;MICRO;1;Rift valley fever virus Ag [Presence] in Blood by Neutralization test;RVFV Ag Bld Ql Nt;;ACTIVE;1.0n;2.56 +23403-9;Rift valley fever virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Rift valley fever virus Ag [Presence] in Specimen by Immunofluorescence;RVFV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23404-7;Rift valley fever virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Rift valley fever virus Ag [Presence] in Tissue by Immunofluorescence;RVFV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23405-4;Rift valley fever virus Ag;PrThr;Pt;Tiss;Ord;Immune diffusion;MICRO;1;Rift valley fever virus Ag [Presence] in Tissue by Immune diffusion (ID);RVFV Ag Tiss Ql ID;;ACTIVE;1.0n;2.56 +23406-2;Rift valley fever virus Ag;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Rift valley fever virus Ag [Presence] in Serum by Immune diffusion (ID);RVFV Ag Ser Ql ID;;ACTIVE;1.0n;2.56 +23407-0;Rinderpest virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Rinderpest virus neutralizing antibody [Presence] in Serum by Neutralization test;RPV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +2340-8;Glucose;MCnc;Pt;Bld;Qn;Test strip.automated;CHEM;1;Glucose [Mass/volume] in Blood by Automated test strip;Glucose Bld Strip.auto-mCnc;;ACTIVE;1.0;2.73 +23408-8;Rinderpest virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rinderpest virus Ab [Titer] in Serum;RPV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23409-6;Rinderpest virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Rinderpest virus neutralizing antibody [Titer] in Serum by Neutralization test;RPV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23410-4;Rinderpest virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rinderpest virus Ab [Presence] in Serum by Immunoassay;RPV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23411-2;Rinderpest virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rinderpest virus Ab [Presence] in Serum;RPV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23412-0;Rinderpest virus Ag;ACnc;Pt;Tiss;Qn;IA;MICRO;1;Rinderpest virus Ag [Units/volume] in Tissue by Immunoassay;RPV Ag Tiss IA-aCnc;;ACTIVE;1.0n;2.69 +23413-8;Rinderpest virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Rinderpest virus Ag [Presence] in Specimen by Immunofluorescence;RPV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23414-6;Rinderpest virus Ag;PrThr;Pt;Exudate;Ord;Immunoelectrophoresis;MICRO;1;Rinderpest virus Ag [Presence] in Exudate by Immunoelectrophoresis;RPV Ag Exudate Ql IEP;;ACTIVE;1.0n;2.56 +23415-3;Rinderpest virus Ag;PrThr;Pt;Exudate;Ord;Immune diffusion;MICRO;1;Rinderpest virus Ag [Presence] in Exudate by Immune diffusion (ID);RPV Ag Exudate Ql ID;;ACTIVE;1.0n;2.56 +2341-6;Glucose;MCnc;Pt;Bld;Qn;Test strip manual;CHEM;1;Glucose [Mass/volume] in Blood by Test strip manual;Glucose Bld Manual Strip-mCnc;;ACTIVE;1.0;2.73 +23416-1;Rinderpest virus Ag;ACnc;Pt;XXX;Qn;IA;MICRO;1;Rinderpest virus Ag [Units/volume] in Specimen by Immunoassay;RPV Ag Spec IA-aCnc;;ACTIVE;1.0n;2.69 +23417-9;Rinderpest virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rinderpest virus RNA [Presence] in Specimen by NAA with probe detection;RPV RNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23418-7;Salmonella abortus equi Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Salmonella abortus equi Ab [Presence] in Serum by Agglutination;S Abortusequi Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23419-5;Salmonella abortus equi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella abortus equi Ab [Presence] in Serum;S Abortusequi Ab Ser Ql;;ACTIVE;1.0n;2.56 +23420-3;Salmonella abortus ovis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Salmonella abortus ovis Ab [Presence] in Serum by Complement fixation;S Abortusovis Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23421-1;Salmonella abortus ovis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella abortus ovis Ab [Presence] in Serum;S Abortusovis Ab Ser Ql;;ACTIVE;1.0n;2.56 +23422-9;Salmonella enteritidis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella enteritidis IgG Ab [Presence] in Serum;S Enteritid IgG Ser Ql;;ACTIVE;1.0n;2.56 +23423-7;Salmonella enteritidis Ab.IgG;PrThr;Pt;Eggylk;Ord;IA;MICRO;1;Salmonella enteritidis IgG Ab [Presence] in Egg yolk by Immunoassay;S Enteritid IgG Egg Yolk Ql IA;;ACTIVE;1.0n;2.56 +2342-4;Glucose;MCnc;Pt;CSF;Qn;;CHEM;1;Glucose [Mass/volume] in Cerebral spinal fluid;Glucose CSF-mCnc;;ACTIVE;1.0;2.73 +23424-5;Salmonella enteritidis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Salmonella enteritidis IgG Ab [Presence] in Serum by Immunoassay;S Enteritid IgG Ser Ql IA;;ACTIVE;1.0n;2.56 +23425-2;Salmonella enteritidis Ab.IgG;PrThr;Pt;Eggylk;Ord;;MICRO;1;Salmonella enteritidis IgG Ab [Presence] in Egg yolk;S Enteritid IgG Egg Yolk Ql;;ACTIVE;1.0n;2.56 +23426-0;Salmonella gallinarum Ab;PrThr;Pt;Bld;Ord;Aggl;MICRO;1;Salmonella gallinarum Ab [Presence] in Blood by Agglutination;S Gallinarum Ab Bld Ql Aggl;;ACTIVE;1.0n;2.56 +23427-8;Salmonella gallinarum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella gallinarum Ab [Presence] in Serum;S Gallinarum Ab Ser Ql;;ACTIVE;1.0n;2.56 +23428-6;Salmonella gallinarum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Salmonella gallinarum Ab [Presence] in Serum by Immunoassay;S Gallinarum Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23429-4;Salmonella gallinarum Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Salmonella gallinarum Ab [Presence] in Serum by Agglutination;S Gallinarum Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23430-2;Salmonella gallinarum Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Salmonella gallinarum Ab [Presence] in Serum;Deprecated S gallinarum Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23431-0;Salmonella gallinarum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Salmonella gallinarum DNA [Presence] in Specimen by NAA with probe detection;S Gallinarum DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +2343-2;Glucose;MCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Mass/volume] in Dialysis fluid;Glucose Dial fld-mCnc;;ACTIVE;1.0;2.73 +23432-8;Salmonella gallinarum rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Salmonella gallinarum rRNA [Presence] in Specimen by Probe;S Gallinarum rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +23433-6;Salmonella pullorum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Salmonella pullorum Ab [Presence] in Serum by Immune diffusion (ID);S pullorum Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +23434-4;Salmonella pullorum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Salmonella pullorum Ab [Presence] in Serum by Immunoassay;S pullorum Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23435-1;Salmonella pullorum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Salmonella pullorum DNA [Presence] in Specimen by NAA with probe detection;S pullorum DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23436-9;Salmonella pullorum rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Salmonella pullorum rRNA [Presence] in Specimen by Probe;S pullorum rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +23437-7;Swine influenza virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Swine influenza virus Ab [Presence] in Serum;SIV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23438-5;Swine influenza virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Swine influenza virus Ab [Presence] in Serum by Hemagglutination inhibition;SIV Ab Ser Ql HAI;;ACTIVE;1.0n;2.56 +23439-3;Swine vesicular disease virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Swine vesicular disease virus Ab [Presence] in Serum;Deprecated SVD Ab Ser Ql;;DEPRECATED;1.0n;2.36 +2344-0;Glucose;MCnc;Pt;Body fld;Qn;;CHEM;1;Glucose [Mass/volume] in Body fluid;Glucose Fld-mCnc;;ACTIVE;1.0;2.73 +23440-1;Swine vesicular disease virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Swine vesicular disease virus neutralizing antibody [Presence] in Serum by Neutralization test;SVD NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23441-9;Swine vesicular disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Swine vesicular disease virus Ab [Presence] in Serum;SVD Ab Ser Ql;;ACTIVE;1.0n;2.56 +23442-7;Swine vesicular disease virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Swine vesicular disease virus Ab [Presence] in Serum by Immunoassay;SVD Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23443-5;Swine vesicular disease virus Ab;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;MICRO;1;Swine vesicular disease virus Ab [Presence] in Serum by Immunoelectrophoresis;SVD Ab Ser Ql IEP;;ACTIVE;1.0n;2.56 +23444-3;Swine vesicular disease virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Swine vesicular disease virus Ag [Presence] in Specimen by Immunoassay;SVD Ag Spec Ql IA;;ACTIVE;1.0n;2.69 +23445-0;Swine vesicular disease virus Ag;PrThr;Pt;Skin;Ord;Comp fix;MICRO;1;Swine vesicular disease virus Ag [Presence] in Skin by Complement fixation;SVD Ag Skin Ql CF;;ACTIVE;1.0n;2.56 +23446-8;Swine vesicular disease virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Swine vesicular disease virus Ag [Presence] in Specimen by Complement fixation;SVD Ag Spec Ql CF;;ACTIVE;1.0n;2.69 +23447-6;Swine vesicular disease virus Ag;PrThr;Pt;Skin;Ord;IA;MICRO;1;Swine vesicular disease virus Ag [Presence] in Skin by Immunoassay;SVD Ag Skin Ql IA;;ACTIVE;1.0n;2.56 +23448-4;Swine vesicular disease virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Swine vesicular disease virus RNA [Presence] in Tissue by NAA with probe detection;SVD RNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.63 +23449-2;Taenia hydatigena Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Taenia hydatigena Ag [Presence] in Stool by Immunoassay;T hydatigena Ag Stl Ql IA;;ACTIVE;1.0n;2.56 +234-5;Erythromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Erythromycin [Susceptibility] by Disk diffusion (KB);Erythromycin Islt KB;;ACTIVE;1.0;2.73 +23450-0;Taenia sp Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Taenia sp Ag [Presence] in Stool by Immunoassay;Taenia Ag Stl Ql IA;;ACTIVE;1.0n;2.56 +23451-8;Taenia sp eggs;PrThr;Pt;Stool;Ord;Probe;MICRO;1;Taenia sp eggs [Presence] in Stool by Probe;Taenia Eggs Stl Ql Probe;;ACTIVE;1.0n;2.63 +23452-6;Taenia sp eggs;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Taenia sp eggs [Presence] in Stool by NAA with probe detection;Taenia Eggs Stl Ql NAA+probe;;ACTIVE;1.0n;2.63 +23453-4;Taylorella equigenitalis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Taylorella equigenitalis Ab [Presence] in Serum by Complement fixation;T equigenit Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23454-2;Taylorella equigenitalis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Taylorella equigenitalis Ab [Presence] in Serum;T equigenit Ab Ser Ql;;ACTIVE;1.0n;2.56 +23455-9;Taylorella equigenitalis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Taylorella equigenitalis Ag [Presence] in Specimen by Immunofluorescence;T equigenit Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23456-7;Taylorella equigenitalis Ag;PrThr;Pt;XXX;Ord;Aggl;MICRO;1;Taylorella equigenitalis Ag [Presence] in Specimen by Agglutination;T equigenit Ag Spec Ql Aggl;;ACTIVE;1.0n;2.69 +2345-7;Glucose;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma;Glucose SerPl-mCnc;;ACTIVE;1.0;2.73 +23457-5;Taylorella equigenitalis Ag;ACnc;Pt;XXX;Ord;Aggl;MICRO;1;Deprecated Taylorella equigenitalis Ag [Presence] in Unspecified specimen by Agglutination;Deprecated T equigenit Ag XXX Ql Aggl;;DEPRECATED;1.0n;2.69 +23458-3;Taylorella equigenitalis DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Taylorella equigenitalis DNA [Presence] in Genital specimen by NAA with probe detection;T equigenit DNA Genital Ql NAA+probe;;ACTIVE;1.0n;2.63 +23459-1;Theileria annulata Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Theileria annulata Ab [Presence] in Serum;T annulata Ab Ser Ql;;ACTIVE;1.0n;2.56 +23460-9;Theileria annulata Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Theileria annulata Ab [Presence] in Serum by Immunofluorescence;T annulata Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23461-7;Theileria annulata Ab;Titr;Pt;Ser;Qn;;MICRO;1;Theileria annulata Ab [Titer] in Serum;T annulata Ab Titr Ser;;ACTIVE;1.0n;2.70 +23462-5;Theileria annulata Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Theileria annulata Ab [Titer] in Serum by Immunofluorescence;T annulata Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23463-3;Theileria annulata rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Theileria annulata rRNA [Presence] in Serum by Probe;T annulata rRNA Ser Ql Probe;;ACTIVE;1.0n;2.63 +23464-1;Theileria equi Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Theileria equi Ab [Presence] in Serum by Immunoassay;T equi Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +2346-5;Glucose;MCnc;Pt;Plr fld;Qn;;CHEM;1;Glucose [Mass/volume] in Pleural fluid;Glucose Plr-mCnc;;ACTIVE;1.0;2.73 +23465-8;Theileria equi rRNA;PrThr;Pt;Bld;Ord;Probe;MICRO;1;Theileria equi rRNA [Presence] in Blood by Probe;T equi rRNA Bld Ql Probe;;ACTIVE;1.0n;2.63 +23466-6;Theileria equi Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Theileria equi Ab [Presence] in Serum by Immunofluorescence;T equi Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23467-4;Theileria mutans Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Theileria mutans Ab [Titer] in Serum by Immunofluorescence;T mutans Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23468-2;Theileria mutans Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Theileria mutans Ab [Presence] in Serum by Immunoassay;T mutans Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23469-0;Theileria mutans Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Theileria mutans Ab [Presence] in Serum by Immunofluorescence;T mutans Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23470-8;Theileria mutans Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Theileria mutans Ab [Presence] in Serum;T mutans Ab Ser Ql;;ACTIVE;1.0n;2.56 +23471-6;Theileria mutans Ab;Titr;Pt;Ser;Qn;;MICRO;1;Theileria mutans Ab [Titer] in Serum;T mutans Ab Titr Ser;;ACTIVE;1.0n;2.70 +23472-4;Theileria mutans rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Theileria mutans rRNA [Presence] in Serum by Probe;T mutans rRNA Ser Ql Probe;;ACTIVE;1.0n;2.63 +2347-3;Glucose;MCnc;Pt;Periton fld;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal fluid;Glucose Prt-mCnc;;ACTIVE;1.0;2.73 +23473-2;Theileria mutans DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Theileria mutans DNA [Presence] in Serum by NAA with probe detection;T mutans DNA Ser Ql NAA+probe;;ACTIVE;1.0n;2.63 +23474-0;Theileria parva Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Theileria parva Ab [Presence] in Serum;T parva Ab Ser Ql;;ACTIVE;1.0n;2.56 +23475-7;Theileria parva Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Theileria parva Ab [Presence] in Serum by Immunofluorescence;T parva Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23476-5;Theileria parva Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Theileria parva Ab [Titer] in Serum by Immunofluorescence;T parva Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23477-3;Theileria parva Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Theileria parva Ab [Presence] in Serum by Immunoassay;T parva Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23478-1;Theileria parva Ab;Titr;Pt;Ser;Qn;;MICRO;1;Theileria parva Ab [Titer] in Serum;T parva Ab Titr Ser;;ACTIVE;1.0n;2.70 +23479-9;Theileria parva rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Theileria parva rRNA [Presence] in Serum by Probe;T parva rRNA Ser Ql Probe;;ACTIVE;1.0n;2.63 +23480-7;Theileria parva DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Theileria parva DNA [Presence] in Serum by NAA with probe detection;T parva DNA Ser Ql NAA+probe;;ACTIVE;1.0n;2.63 +2348-1;Glucose;MCnc;Pt;Synv fld;Qn;;CHEM;1;Glucose [Mass/volume] in Synovial fluid;Glucose Snv-mCnc;;ACTIVE;1.0;2.73 +23481-5;Theileria parva rRNA;ACnc;Pt;Ser;Ord;Probe;MICRO;1;Deprecated Theileria parva rRNA [Presence] in Serum by DNA probe;Deprecated T parva rRNA Ser Ql Prb;;DEPRECATED;1.0n;2.36 +23482-3;Theileria sp;PrThr;Pt;Bld;Ord;Giemsa stain;MICRO;1;Theileria sp [Presence] in Blood by Giemsa stain;Theileria Bld Ql Gie Stn;;ACTIVE;1.0n;2.56 +23483-1;Theileria sp;PrThr;Pt;Tiss;Ord;Giemsa stain;MICRO;1;Theileria sp [Presence] in Tissue by Giemsa stain;Theileria Tiss Ql Gie Stn;;ACTIVE;1.0n;2.56 +23484-9;Toxoplasma sp Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Toxoplasma gondii Ab [Presence] in Serum;Deprecated Toxoplasma Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23485-6;Toxoplasma gondii Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Toxoplasma gondii Ab [Presence] in Serum by Agglutination;T gondii Ab Ser Ql Aggl;;ACTIVE;1.0n;2.73 +23486-4;Toxoplasma gondii Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Toxoplasma gondii Ab [Presence] in Serum by Latex agglutination;T gondii Ab Ser Ql LA;;ACTIVE;1.0n;2.56 +23487-2;Transmissible gastroenteritis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Transmissible gastroenteritis virus Ab [Presence] in Serum;TGEV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23488-0;Transmissible gastroenteritis virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Transmissible gastroenteritis virus neutralizing antibody [Presence] in Serum by Neutralization test;TGEV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23489-8;Transmissible gastroenteritis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Transmissible gastroenteritis virus Ab [Titer] in Serum;TGEV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23490-6;Transmissible gastroenteritis virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Transmissible gastroenteritis virus Ab [Presence] in Serum;Deprecated TGEV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23491-4;Transmissible gastroenteritis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Transmissible gastroenteritis virus Ab [Presence] in Serum by Immunoassay;TGEV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23492-2;Transmissible gastroenteritis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Transmissible gastroenteritis virus neutralizing antibody [Titer] in Serum by Neutralization test;TGEV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23493-0;Transmissible gastroenteritis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Transmissible gastroenteritis virus Ag [Presence] in Specimen by Neutralization test;TGEV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23494-8;Transmissible gastroenteritis virus Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Transmissible gastroenteritis virus Ag [Presence] in Stool by Immunoassay;TGEV Ag Stl Ql IA;;ACTIVE;1.0n;2.56 +23495-5;Transmissible gastroenteritis virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Transmissible gastroenteritis virus Ag [Presence] in Specimen by Immune stain;TGEV Ag Spec Ql ImStn;;ACTIVE;1.0n;2.69 +23496-3;Transmissible gastroenteritis virus Ag;PrThr;Pt;Tsmi;Ord;Immune stain;MICRO;1;Transmissible gastroenteritis virus Ag [Presence] in Small intestine Tissue by Immune stain;TGEV Ag TSMI Ql ImStn;;ACTIVE;1.0n;2.56 +23497-1;Transmissible gastroenteritis virus Ag;PrThr;Pt;Tsmi;Ord;IF;MICRO;1;Transmissible gastroenteritis virus Ag [Presence] in Small intestine Tissue by Immunofluorescence;TGEV Ag TSMI Ql IF;;ACTIVE;1.0n;2.56 +23498-9;Transmissible gastroenteritis virus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Transmissible gastroenteritis virus RNA [Presence] in Specimen by Probe;TGEV RNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +2349-9;Glucose;PrThr;Pt;Urine;Ord;;CHEM;1;Glucose [Presence] in Urine;Glucose Ur Ql;;ACTIVE;1.0;2.73 +23499-7;Trichinella spiralis;PrThr;Pt;Tiss;Ord;Microscopy.light;MICRO;1;Trichinella spiralis [Presence] in Tissue by Light microscopy;T spiralis Tiss Ql Micro;;ACTIVE;1.0n;2.56 +23500-2;Tritrichomonas foetus Ab;PrThr;Pt;Genital muc;Ord;;MICRO;1;Tritrichomonas foetus Ab [Presence] in Genital mucus;T foet Ab Genital mucus Ql;;ACTIVE;1.0n;2.56 +23501-0;Tritrichomonas foetus Ab;PrThr;Pt;Genital muc;Ord;Aggl;MICRO;1;Tritrichomonas foetus Ab [Presence] in Genital mucus by Agglutination;T foet Ab Genital mucus Ql Aggl;;ACTIVE;1.0n;2.56 +23502-8;Tritrichomonas foetus Ag;PrThr;Pt;Tiss^Fetus;Ord;Immune stain;MICRO;1;Tritrichomonas foetus Ag [Presence] in Tissue from Fetus by Immune stain;T foet Ag Tiss Fetus Ql ImStn;;ACTIVE;1.0n;2.56 +23503-6;Tritrichomonas foetus Ag;PrThr;Pt;Placenta;Ord;Immune stain;MICRO;1;Tritrichomonas foetus Ag [Presence] in Placenta by Immune stain;T foet Ag Placenta Ql ImStn;;ACTIVE;1.0n;2.63 +23504-4;Tritrichomonas foetus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Tritrichomonas foetus DNA [Presence] in Specimen by NAA with probe detection;T foet DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23505-1;Tritrichomonas foetus DNA;PrThr;Pt;Genital fld;Ord;Probe.amp.tar;MICRO;1;Tritrichomonas foetus DNA [Presence] in Genital fluid by NAA with probe detection;T foet DNA Genital fl Ql NAA+probe;;ACTIVE;1.0n;2.63 +23506-9;Tritrichomonas foetus reaction wheal^post 0.1 mL tricin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tritrichomonas foetus reaction wheal [Diameter] --post 0.1 mL tricin intradermal;Wheal p Tricin Diam;;ACTIVE;1.0n;2.42 +2350-7;Glucose;MCnc;Pt;Urine;Qn;;CHEM;1;Glucose [Mass/volume] in Urine;Glucose Ur-mCnc;;ACTIVE;1.0;2.73 +23507-7;Trypanosoma brucei DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Trypanosoma brucei DNA [Presence] in Blood by NAA with probe detection;T brucei DNA Bld Ql NAA+probe;;ACTIVE;1.0n;2.63 +23508-5;Trypanosoma congolense DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Trypanosoma congolense DNA [Presence] in Blood by NAA with probe detection;T congolense DNA Bld Ql NAA+probe;;ACTIVE;1.0n;2.63 +23509-3;Trypanosoma equiperdum;PrThr;Pt;Body fld;Ord;Microscopy.light;MICRO;1;Trypanosoma equiperdum [Presence] in Body fluid by Light microscopy;T equiperdum Fld Ql Micro;;ACTIVE;1.0n;2.56 +23510-1;Trypanosoma equiperdum Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Trypanosoma equiperdum Ab [Titer] in Serum by Complement fixation;T equiperdum Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23511-9;Trypanosoma equiperdum Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Trypanosoma equiperdum Ab [Presence] in Serum by Complement fixation;T equiperdum Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23512-7;Trypanosoma equiperdum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trypanosoma equiperdum Ab [Presence] in Serum by Immunoassay;T equiperdum Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23513-5;Trypanosoma equiperdum Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Trypanosoma equiperdum Ab [Presence] in Serum by Immunofluorescence;T equiperdum Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23514-3;Trypanosoma equiperdum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Trypanosoma equiperdum Ab [Presence] in Serum by Immune diffusion (ID);T equiperdum Ab Ser Ql ID;;ACTIVE;1.0n;2.56 +2351-5;Glucose;MRat;24H;Urine;Qn;;CHEM;1;Glucose [Mass/time] in 24 hour Urine;Glucose 24h Ur-mRate;;ACTIVE;1.0;2.73 +23515-0;Trypanosoma equiperdum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma equiperdum Ab [Presence] in Serum;T equiperdum Ab Ser Ql;;ACTIVE;1.0n;2.56 +23516-8;Trypanosoma equiperdum Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Trypanosoma equiperdum Ab [Presence] in Serum;Deprecated T equiperdum Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23517-6;Trypanosoma equiperdum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Trypanosoma equiperdum Ab [Titer] in Serum;T equiperdum Ab Titr Ser;;ACTIVE;1.0n;2.70 +23518-4;Trypanosoma evansi;PrThr;Pt;Asp;Ord;Thick film;MICRO;1;Trypanosoma evansi [Presence] in Aspirate by Thick film;T evansi Aspirate Ql Thick Film;;ACTIVE;1.0n;2.56 +23519-2;Trypanosoma evansi;PrThr;Pt;Asp;Ord;Thin film;MICRO;1;Trypanosoma evansi [Presence] in Aspirate by Thin film;T evansi Aspirate Ql Thin Film;;ACTIVE;1.0n;2.56 +235-2;Erythromycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Erythromycin [Susceptibility] by Serum bactericidal titer;Erythromycin Titr SBT;;ACTIVE;1.0;2.32 +23520-0;Trypanosoma evansi;PrThr;Pt;Asp;Ord;Wet preparation;MICRO;1;Trypanosoma evansi [Presence] in Aspirate by Wet preparation;T evansi Aspirate Ql Wet Prep;;ACTIVE;1.0n;2.56 +23521-8;Trypanosoma evansi Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Trypanosoma evansi Ab [Units/volume] in Serum;T evansi Ab Ser-aCnc;;ACTIVE;1.0n;2.69 +23522-6;Trypanosoma evansi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma evansi Ab [Presence] in Serum;T evansi Ab Ser Ql;;ACTIVE;1.0n;2.56 +2352-3;Glucose CSF/Glucose plas;RelMCnc;Pt;Plas+CSF;Qn;;CHEM;1;Glucose in CSF/Glucose plas;Glucose CSF/SerPl;;ACTIVE;1.0;2.42 +23523-4;Trypanosoma evansi Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Trypanosoma evansi Ab [Presence] in Serum by Agglutination;T evansi Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23524-2;Trypanosoma evansi Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trypanosoma evansi Ab [Units/volume] in Serum by Immunoassay;T evansi Ab Ser IA-aCnc;;ACTIVE;1.0n;2.69 +23525-9;Trypanosoma evansi Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Trypanosoma evansi Ab [Presence] in Serum;Deprecated T evansi Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23526-7;Trypanosoma evansi Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Trypanosoma evansi Ab [Presence] in Serum by Immunofluorescence;T evansi Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23527-5;Trypanosoma evansi Ag;ACnc;Pt;Bld;Ord;Aggl;MICRO;1;Deprecated Trypanosoma evansi Ab [Presence] in Serum by Agglutination;Deprecated T evansi Ag Bld Ql Aggl;;DEPRECATED;1.0n;2.36 +23528-3;Trypanosoma evansi Ag;PrThr;Pt;Bld;Ord;IA;MICRO;1;Trypanosoma evansi Ag [Presence] in Blood by Immunoassay;T evansi Ag Bld Ql IA;;ACTIVE;1.0n;2.56 +23529-1;Trypanosoma evansi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Trypanosoma evansi DNA [Presence] in Specimen by NAA with probe detection;T evansi DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23530-9;Trypanosoma evansi rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Trypanosoma evansi rRNA [Presence] in Specimen by Probe;T evansi rRNA Spec Ql Probe;;ACTIVE;1.0n;2.69 +2353-1;Glucose phosphate isomerase;CCnc;Pt;Ser;Qn;;CHEM;1;Glucose phosphate isomerase [Enzymatic activity/volume] in Serum;GPI Ser-cCnc;;ACTIVE;1.0;2.73 +23531-7;Trypanosoma sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trypanosoma sp Ab [Presence] in Serum by Immunoassay;Trypanos Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23532-5;Trypanosoma sp Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Trypanosoma sp Ab [Presence] in Serum by Agglutination;Trypanos Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23533-3;Trypanosoma sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma sp Ab [Presence] in Serum;Trypanos Ab Ser Ql;;ACTIVE;1.0n;2.56 +23534-1;Trypanosoma sp Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Trypanosoma sp Ab [Presence] in Serum by Immunofluorescence;Trypanos Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23535-8;Trypanosoma sp Ag;PrThr;Pt;Bld;Ord;IA;MICRO;1;Trypanosoma sp Ag [Presence] in Blood by Immunoassay;Trypanos Ag Bld Ql IA;;ACTIVE;1.0n;2.56 +23536-6;Trypanosoma sp identified;Prid;Pt;Bld;Nom;Concentration;MICRO;1;Trypanosoma sp identified in Blood by Concentration;Trypanos Bld Conc;;ACTIVE;1.0n;1.0n +23537-4;Tuberculosis reaction wheal^2D post dose mammalian tuberculin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tuberculosis reaction wheal [Diameter] --2 days post dose mammalian tuberculin intradermal;TB Wheal 2D p Mam Tuberc Diam;;ACTIVE;1.0n;2.73 +23538-2;Tuberculosis reaction wheal^3D post dose avian tuberculin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tuberculosis reaction wheal [Diameter] --3 days post dose avian tuberculin intradermal;TB Wheal 3D p Av PPD Diam;;ACTIVE;1.0n;2.73 +23539-0;Tuberculosis reaction wheal^3D post dose mammalian tuberculin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tuberculosis reaction wheal [Diameter] --3 days post dose mammalian tuberculin intradermal;TB Wheal 3D p Mam Tuberc Diam;;ACTIVE;1.0n;2.42 +23540-8;Turkey enteritis coronavirus;PrThr;Pt;Ser;Ord;IF;MICRO;1;Turkey enteritis coronavirus [Presence] in Serum by Immunofluorescence;TCoV Ser Ql IF;;ACTIVE;1.0n;2.56 +23541-6;Venezuelan equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Venezuelan equine encephalitis virus Ab [Presence] in Serum by Complement fixation;VEEV Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23542-4;Venezuelan equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Venezuelan equine encephalitis virus Ab [Presence] in Serum by Hemagglutination inhibition;VEEV Ab Ser Ql HAI;;ACTIVE;1.0n;2.56 +23543-2;Venezuelan equine encephalitis virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Venezuelan equine encephalitis virus Ab [Titer] in Serum by Hemagglutination inhibition;VEEV Ab Titr Ser HAI;;ACTIVE;1.0n;2.70 +23544-0;Venezuelan equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Venezuelan equine encephalitis virus Ab [Presence] in Serum;VEEV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23545-7;Venezuelan equine encephalitis virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Venezuelan equine encephalitis virus neutralizing antibody [Presence] in Serum by Neutralization test;VEEV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23546-5;Venezuelan equine encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Venezuelan equine encephalitis virus IgM Ab [Presence] in Serum;VEEV IgM Ser Ql;;ACTIVE;1.0n;2.56 +23547-3;Venezuelan equine encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Venezuelan equine encephalitis virus IgM Ab [Presence] in Serum by Immunoassay;VEEV IgM Ser Ql IA;;ACTIVE;1.0n;2.56 +23548-1;Venezuelan equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Specimen by Neutralization test;VEEV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +2354-9;Glucose-6-Phosphatase;CCnc;Pt;Ser;Qn;;CHEM;1;Glucose-6-Phosphatase [Enzymatic activity/volume] in Serum;G6Pas Ser-cCnc;;ACTIVE;1.0;2.68 +23549-9;Venezuelan equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Specimen by Immunofluorescence;VEEV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23550-7;Venezuelan equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;HAI;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Specimen by Hemagglutination inhibition;VEEV Ag Spec Ql HAI;;ACTIVE;1.0n;2.69 +23551-5;Venezuelan equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Specimen by Complement fixation;VEEV Ag Spec Ql CF;;ACTIVE;1.0n;2.69 +23552-3;Venezuelan equine encephalitis virus subtype;Prid;Pt;XXX;Nom;Neut;MICRO;1;Venezuelan equine encephalitis virus subtype [Identifier] in Specimen by Neutralization test;VEEE subtyp Spec Nt;;ACTIVE;1.0n;2.69 +23553-1;Venezuelan equine encephalitis virus subtype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Venezuelan equine encephalitis virus subtype [Identifier] in Specimen by NAA with probe detection;VEEE subtyp Spec NAA+probe;;ACTIVE;1.0n;2.69 +23554-9;Venezuelan equine encephalitis virus subtype;Prid;Pt;XXX;Nom;IF;MICRO;1;Venezuelan equine encephalitis virus subtype [Identifier] in Specimen by Immunofluorescence;VEEE subtyp Spec IF;;ACTIVE;1.0n;2.69 +23555-6;Vesicular stomatitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Vesicular stomatitis virus Ab [Presence] in Serum;VSV Ab Ser Ql;;ACTIVE;1.0n;2.56 +2355-6;Glucose-6-Phosphatase;CCnt;Pt;Tiss;Qn;;CHEM;1;Glucose-6-Phosphatase [Enzymatic activity/mass] in Tissue;G6Pas Tiss-cCnt;;ACTIVE;1.0;2.42 +23556-4;Vesicular stomatitis virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Vesicular stomatitis virus Ab [Presence] in Serum;Deprecated VSV Ab Ser Ql;;DEPRECATED;1.0n;2.36 +23557-2;Vesicular stomatitis virus Ag;PrThr;Pt;Skin;Ord;IA;MICRO;1;Vesicular stomatitis virus Ag [Presence] in Skin by Immunoassay;VSV Ag Skin Ql IA;;ACTIVE;1.0n;2.56 +23558-0;Vesicular stomatitis virus Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Vesicular stomatitis virus Ag [Presence] in Throat by Immunoassay;VSV Ag Throat Ql IA;;ACTIVE;1.0n;2.56 +23559-8;Vesicular stomatitis virus Ag;PrThr;Pt;Skin;Ord;Comp fix;MICRO;1;Vesicular stomatitis virus Ag [Presence] in Skin by Complement fixation;VSV Ag Skin Ql CF;;ACTIVE;1.0n;2.56 +23560-6;Vesicular stomatitis virus Ag;PrThr;Pt;Thrt;Ord;Comp fix;MICRO;1;Vesicular stomatitis virus Ag [Presence] in Throat by Complement fixation;VSV Ag Throat Ql CF;;ACTIVE;1.0n;2.56 +23561-4;Vesicular stomatitis Indiana virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Vesicular stomatitis Indiana virus Ab [Presence] in Serum;VSIV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23562-2;Vesicular stomatitis Indiana virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Vesicular stomatitis Indiana virus neutralizing antibody [Presence] in Serum by Neutralization test;VSIV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23563-0;Vesicular stomatitis Indiana virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Vesicular stomatitis Indiana virus Ab [Presence] in Serum by Immunoassay;VSIV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +2356-4;Glucose-6-Phosphate dehydrogenase;PrThr;Pt;RBC;Ord;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Presence] in Red Blood Cells;G6PD RBC Ql;;ACTIVE;1.0;2.73 +23564-8;Vesicular stomatitis Indiana virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Vesicular stomatitis Indiana virus Ab [Presence] in Serum by Complement fixation;VSIV Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23565-5;Vesicular stomatitis New Jersey virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Vesicular stomatitis New Jersey virus Ab [Presence] in Serum;VSNJV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23566-3;Vesicular stomatitis New Jersey virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Vesicular stomatitis New Jersey virus Ab [Presence] in Serum by Immunoassay;VSNJV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23567-1;Vesicular stomatitis New Jersey virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Vesicular stomatitis New Jersey virus neutralizing antibody [Presence] in Serum by Neutralization test;VSNJV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23568-9;Vesicular stomatitis New Jersey virus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Vesicular stomatitis New Jersey virus Ab [Presence] in Serum by Complement fixation;VSNJV Ab Ser Ql CF;;ACTIVE;1.0n;2.56 +23569-7;Vesicular stomatitis virus serotype;Prid;Pt;XXX;Nom;Comp fix;MICRO;1;Vesicular stomatitis virus serotype [Identifier] in Specimen by Complement fixation;VSV Sertyp Spec CF;;ACTIVE;1.0n;2.69 +23570-5;Vesicular stomatitis virus serotype;Prid;Pt;Tiss;Nom;Comp fix;MICRO;1;Vesicular stomatitis virus serotype [Identifier] in Tissue by Complement fixation;VSV Sertyp Tiss CF;;ACTIVE;1.0n;2.22 +23571-3;Vesicular stomatitis virus serotype;Prid;Pt;Tiss;Nom;IA;MICRO;1;Vesicular stomatitis virus serotype [Identifier] in Tissue by Immunoassay;VSV Sertyp Tiss IA;;ACTIVE;1.0n;2.56 +2357-2;Glucose-6-Phosphate dehydrogenase;CCnc;Pt;RBC;Qn;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells;G6PD RBC-cCnc;;ACTIVE;1.0;2.73 +23572-1;Vesicular stomatitis virus serotype;Prid;Pt;XXX;Nom;IA;MICRO;1;Vesicular stomatitis virus serotype [Identifier] in Specimen by Immunoassay;VSV Sertyp Spec IA;;ACTIVE;1.0n;2.69 +23573-9;Rabbit hemorrhagic disease virus;PrThr;Pt;Tiss;Ord;Microscopy.electron;MICRO;1;Rabbit hemorrhagic disease virus [Presence] in Tissue by Electron microscopy;RHDV Tiss Ql EM;;ACTIVE;1.0n;2.68 +23574-7;Rabbit hemorrhagic disease virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rabbit hemorrhagic disease virus Ab [Presence] in Serum;RHDV Ab Ser Ql;;ACTIVE;1.0n;2.68 +23575-4;Rabbit hemorrhagic disease virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rabbit hemorrhagic disease virus Ab [Titer] in Serum;RHDV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23576-2;Rabbit hemorrhagic disease virus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Rabbit hemorrhagic disease virus Ab [Titer] in Serum by Immunoassay;RHDV Ab Titr Ser IA;;ACTIVE;1.0n;2.70 +23577-0;Rabbit hemorrhagic disease virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rabbit hemorrhagic disease virus Ab [Presence] in Serum by Immunoassay;RHDV Ab Ser Ql IA;;ACTIVE;1.0n;2.68 +23578-8;Rabbit hemorrhagic disease virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Rabbit hemorrhagic disease virus Ab [Titer] in Serum by Hemagglutination inhibition;RHDV Ab Titr Ser HAI;;ACTIVE;1.0n;2.70 +23579-6;Rabbit hemorrhagic disease virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Rabbit hemorrhagic disease virus Ag [Presence] in Tissue by Immunofluorescence;RHDV Ag Tiss Ql IF;;ACTIVE;1.0n;2.68 +2358-0;Glucose-6-Phosphate dehydrogenase;PrThr;Pt;Ser;Ord;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Presence] in Serum;G6PD Ser Ql;;ACTIVE;1.0;2.73 +23580-4;Rabbit hemorrhagic disease virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Rabbit hemorrhagic disease virus Ag [Presence] in Tissue by Immunoassay;RHDV Ag Tiss Ql IA;;ACTIVE;1.0n;2.68 +23581-2;Rabbit hemorrhagic disease virus Ag;PrThr;Pt;Tiss;Ord;Aggl;MICRO;1;Rabbit hemorrhagic disease virus Ag [Presence] in Tissue by Agglutination;RHDV Ag Tiss Ql Aggl;;ACTIVE;1.0n;2.68 +23582-0;Rabbit hemorrhagic disease virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Rabbit hemorrhagic disease virus Ag [Presence] in Tissue by Immune stain;RHDV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.68 +23583-8;Western equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Western equine encephalitis virus Ab [Presence] in Serum by Agglutination;WEEV Ab Ser Ql Aggl;;ACTIVE;1.0n;2.56 +23584-6;Western equine encephalitis virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum by Hemagglutination inhibition;WEEV Ab Titr Ser HAI;;ACTIVE;1.0n;2.70 +23585-3;Western equine encephalitis virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Western equine encephalitis virus neutralizing antibody [Presence] in Serum by Neutralization test;WEEV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23586-1;Western equine encephalitis virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Western equine encephalitis virus Ab [Presence] in Serum by Hemagglutination inhibition;WEEV Ab Ser Ql HAI;;ACTIVE;1.0n;2.56 +23587-9;Western equine encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Western equine encephalitis virus IgM Ab [Presence] in Serum;WEEV IgM Ser Ql;;ACTIVE;1.0n;2.56 +23588-7;Western equine encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Western equine encephalitis virus IgM Ab [Presence] in Serum by Immunoassay;WEEV IgM Ser Ql IA;;ACTIVE;1.0n;2.56 +23589-5;Western equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Western equine encephalitis virus Ag [Presence] in Specimen by Neutralization test;WEEV Ag Spec Ql Nt;;ACTIVE;1.0n;2.69 +23590-3;Western equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Western equine encephalitis virus Ag [Presence] in Specimen by Immunofluorescence;WEEV Ag Spec Ql IF;;ACTIVE;1.0n;2.69 +23591-1;Western equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Western equine encephalitis virus Ag [Presence] in Specimen by Complement fixation;WEEV Ag Spec Ql CF;;ACTIVE;1.0n;2.69 +23592-9;African swine fever virus Ab;PrThr;Pt;Ser;Ord;Immune stain;MICRO;1;African swine fever virus Ab [Presence] in Serum by Immune stain;ASFV Ab Ser Ql ImStn;;ACTIVE;1.0n;2.56 +23593-7;Bovine leukemia virus;PrThr;Pt;Bld;Ord;Organism specific culture;MICRO;1;Bovine leukemia virus [Presence] in Blood by Organism specific culture;BLV Bld Ql Cult;;ACTIVE;1.0n;2.56 +23594-5;Brucella sp identified;Prid;Pt;Semen;Nom;Organism specific culture;MICRO;1;Brucella sp identified in Semen by Organism specific culture;Brucella Smn Cult;;ACTIVE;1.0n;2.19 +23595-2;Dermatophilus congolensis;PrThr;Pt;Exudate;Ord;Giemsa stain;MICRO;1;Dermatophilus congolensis [Presence] in Exudate by Giemsa stain;D congo Exudate Ql Gie Stn;;ACTIVE;1.0n;2.56 +23596-0;Dermatophilus congolensis;PrThr;Pt;Exudate;Ord;Carbol-fuchsin stain;MICRO;1;Dermatophilus congolensis [Presence] in Exudate by Carbol-fuchsin stain;D congo Exudate Ql CF Stn;;ACTIVE;1.0n;2.56 +23597-8;Dermatophilus congolensis;PrThr;Pt;Exudate;Ord;Methylene blue stain;MICRO;1;Dermatophilus congolensis [Presence] in Exudate by Methylene blue stain;D congo Exudate Ql MB Stn;;ACTIVE;1.0n;2.56 +2359-8;Glucose-6-Phosphate dehydrogenase;CCnc;Pt;Ser;Qn;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Enzymatic activity/volume] in Serum;G6PD Ser-cCnc;;ACTIVE;1.0;2.73 +23598-6;Dermatophilus congolensis Ag;PrThr;Pt;Exudate;Ord;IF;MICRO;1;Dermatophilus congolensis Ag [Presence] in Exudate by Immunofluorescence;D congo Ag Exudate Ql IF;;ACTIVE;1.0n;2.56 +23599-4;Leptospira sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Leptospira sp identified in Tissue by Organism specific culture;Leptospira Tiss Cult;;ACTIVE;1.0n;2.22 +236-0;Erythromycin+sulfiSOXAZOLE;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Erythromycin+Sulfisoxazole [Susceptibility] by Minimum lethal concentration (MLC);Erythro+Sulf Islt MLC;;ACTIVE;1.0;2.19 +23600-0;Leptospira sp identified;Prid;Pt;Milk;Nom;Organism specific culture;MICRO;1;Leptospira sp identified in Milk by Organism specific culture;Leptospira Mlk Cult;;ACTIVE;1.0n;2.19 +23601-8;Mareks disease virus serotype;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Mareks disease virus serotype [Identifier] in Tissue by Organism specific culture;GaHV Sertyp Tiss Cult;;ACTIVE;1.0n;2.22 +23602-6;Salmonella enteritidis;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Salmonella enteritidis [Presence] in Stool by Organism specific culture;S Enteritid Stl Ql Cult;;ACTIVE;1.0n;2.56 +23603-4;Taylorella equigenitalis;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Taylorella equigenitalis [Presence] in Genital specimen by Organism specific culture;T equigenit Genital Ql Cult;;ACTIVE;1.0n;2.56 +23604-2;Tritrichomonas foetus;PrThr;Pt;Body fld;Ord;Organism specific culture;MICRO;1;Tritrichomonas foetus [Presence] in Body fluid by Organism specific culture;T foet Fld Ql Cult;;ACTIVE;1.0n;2.56 +23605-9;Tritrichomonas foetus;PrThr;Pt;Placenta;Ord;Organism specific culture;MICRO;1;Tritrichomonas foetus [Presence] in Placenta by Organism specific culture;T foet Placenta Ql Cult;;ACTIVE;1.0n;2.63 +2360-6;Glucose-6-Phosphate dehydrogenase;CCnc;Pt;WBC;Qn;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Enzymatic activity/volume] in Leukocytes;G6PD WBC-cCnc;;ACTIVE;1.0;2.15 +23606-7;Tritrichomonas foetus;PrThr;Pt;Genital fld;Ord;Organism specific culture;MICRO;1;Tritrichomonas foetus [Presence] in Genital fluid by Organism specific culture;T foet Genital fl Ql Cult;;ACTIVE;1.0n;2.56 +23607-5;Capreomycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Capreomycin [Susceptibility] by Method for Slow-growing mycobacteria;Capreomycin Islt SlowMyco;;ACTIVE;1.0n;2.73 +23608-3;cycloSERINE;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cycloSERINE [Susceptibility] by Method for Slow-growing mycobacteria;cycloSERINE Islt SlowMyco;;ACTIVE;1.0n;2.73 +23609-1;Kanamycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Kanamycin [Susceptibility] by Method for Slow-growing mycobacteria;Kanamycin Islt SlowMyco;;ACTIVE;1.0n;2.26 +23610-9;Sparfloxacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Sparfloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Sparfloxacin Islt SlowMyco;;ACTIVE;1.0n;2.26 +23611-7;Para aminosalicylate;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Para aminosalicylate [Susceptibility] by Method for Slow-growing mycobacteria;PAS Islt SlowMyco;;ACTIVE;1.0n;2.73 +23612-5;Azithromycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Azithromycin [Susceptibility] by Method for Slow-growing mycobacteria;Azithromycin Islt SlowMyco;;ACTIVE;1.0n;2.26 +23613-3;Imipenem;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Imipenem [Susceptibility] by Method for Slow-growing mycobacteria;Imipenem Islt SlowMyco;;ACTIVE;1.0n;2.73 +2361-4;Glucosylceramidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Glucosylceramidase [Enzymatic activity/mass] in Tissue;Glucosylceramidase Tiss-cCnt;;ACTIVE;1.0;2.42 +23614-1;Trimethoprim;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Trimethoprim [Susceptibility] by Method for Slow-growing mycobacteria;Trimethoprim Islt SlowMyco;;ACTIVE;1.0n;2.26 +23615-8;Vancomycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Vancomycin [Susceptibility] by Method for Slow-growing mycobacteria;Vancomycin Islt SlowMyco;;ACTIVE;1.0n;2.26 +23616-6;Viomycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Viomycin [Susceptibility] by Method for Slow-growing mycobacteria;Viomycin Islt SlowMyco;;ACTIVE;1.0n;2.26 +23617-4;Ethionamide;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ethionamide [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ethionamide Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23618-2;Ampicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ampicillin+Sulbactam [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ampicillin+Sulbac Islt SlowMy;;DEPRECATED;1.0n;2.36 +23619-0;Clarithromycin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Clarithromycin [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Clarithro Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23620-8;Clofazimine;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Clofazimine [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Clofazamine Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23621-6;Ciprofloxacin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ciprofloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ciprofloxacin Islt SlowMyco;;DEPRECATED;1.0n;2.36 +2362-2;Glutamate;MCnc;Pt;CSF;Qn;;CHEM;1;Glutamate [Mass/volume] in Cerebral spinal fluid;Glutamate CSF-mCnc;;ACTIVE;1.0;2.42 +23622-4;Ceftizoxime;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ceftizoxime [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ceftizoxime Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23623-2;Doxycycline;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Doxycycline [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Doxycycline Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23624-0;Amikacin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Amikacin [Susceptibility] by Slow-growing mycobacteria;Deprecated Amikacin Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23625-7;Ethambutol;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ethambutol [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ethambutol Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23626-5;Streptomycin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Streptomycin [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Streptomycin Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23627-3;Clofazimine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clofazimine [Susceptibility];Clofazamine Susc Islt;;ACTIVE;1.0n;2.19 +23628-1;Sparfloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sparfloxacin [Susceptibility];Sparfloxacin Susc Islt;;ACTIVE;1.0n;2.19 +23629-9;Para aminosalicylate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Para aminosalicylate [Susceptibility];PAS Susc Islt;;ACTIVE;1.0n;2.19 +2363-0;Glutamate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Glutamate [Presence] in Serum or Plasma;Glutamate SerPl Ql;;ACTIVE;1.0;2.73 +23630-7;Rifabutin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Rifabutin [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Rifabutin Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23631-5;Trimethoprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Trimethoprim+Sulfamethoxazole [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated TMP SMX Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23632-3;Pyrazinamide;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Pyrazinamide [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated PZA Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23633-1;Erythromycin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Erythromycin [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Erythromycin Islt SlowMyco;;DEPRECATED;1.0n;2.36 +23634-9;Erythropoietin given;ACnc;Pt;Dose;Qn;;DRUGDOSE;1;Erythropoietin (EPO) given [Units/volume] of Dose;EPO Gvn Dose-aCnc;;ACTIVE;1.0n;2.70 +23635-6;Erythropoietin given;ACnt;Pt;Dose;Qn;;DRUGDOSE;1;Erythropoietin (EPO) given [Units/mass] of Dose;EPO Gvn Dose-aCnt;;ACTIVE;1.0n;2.70 +23636-4;Cefdinir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefdinir [Susceptibility];Cefdinir Susc Islt;;ACTIVE;1.0n;2.19 +23637-2;Cefdinir;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefdinir [Susceptibility] by Minimum inhibitory concentration (MIC);Cefdinir Islt MIC;;ACTIVE;1.0n;2.19 +23638-0;Grepafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Grepafloxacin [Susceptibility];Grepafloxacin Susc Islt;;ACTIVE;1.0n;2.73 +23639-8;Grepafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Grepafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Grepafloxacin Islt MIC;;ACTIVE;1.0n;2.19 +23640-6;Quinupristin+Dalfopristin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Quinupristin+Dalfopristin [Susceptibility];Quinupristin+Dalfoprist Susc Islt;;ACTIVE;1.0n;2.73 +23641-4;Quinupristin+Dalfopristin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Quinupristin+Dalfopristin [Susceptibility] by Minimum inhibitory concentration (MIC);Quinupristin+Dalfoprist Islt MIC;;ACTIVE;1.0n;2.73 +23642-2;Trovafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Trovafloxacin [Susceptibility];Trovafloxacin Susc Islt;;ACTIVE;1.0n;2.73 +23643-0;Trovafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Trovafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Trovafloxacin Islt MIC;;ACTIVE;1.0n;2.19 +23644-8;Actinobacillus pleuropneumoniae serotype 1 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 1 Ab [Presence] in Serum by Immunoassay;A pleuropn 1 Ab Ser Ql IA;;ACTIVE;1.0n;2.61 +23645-5;Actinobacillus pleuropneumoniae serotype 3 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 3 Ab [Presence] in Serum by Immunoassay;A pleuropn 3 Ab Ser Ql IA;;ACTIVE;1.0n;2.61 +23646-3;Actinobacillus pleuropneumoniae serotype 5 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 5 Ab [Presence] in Serum by Immunoassay;A pleuropn 5 Ab Ser Ql IA;;ACTIVE;1.0n;2.61 +23647-1;Actinobacillus pleuropneumoniae serotype 7 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 7 Ab [Presence] in Serum by Immunoassay;A pleuropn 7 Ab Ser Ql IA;;ACTIVE;1.0n;2.61 +2364-8;Glutamate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamate [Mass/volume] in Serum or Plasma;Glutamate SerPl-mCnc;;ACTIVE;1.0;2.73 +23648-9;Actinobacillus pleuropneumoniae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Actinobacillus pleuropneumoniae Ab [Titer] in Serum;A pleuropn Ab Titr Ser;;ACTIVE;1.0n;2.70 +23649-7;Actinobacillus pleuropneumoniae biovar 2 serotype;Prid;Pt;XXX;Nom;Aggl;MICRO;1;Actinobacillus pleuropneumoniae biovar 2 serotype [Identifier] in Specimen by Agglutination;A pleuropn bv2 Sertyp Spec Aggl;;ACTIVE;1.0n;2.69 +23650-5;Actinobacillus pleuropneumoniae serotype;Prid;Pt;XXX;Nom;Aggl;MICRO;1;Actinobacillus pleuropneumoniae serotype [Identifier] in Specimen by Agglutination;A pleuropn Sertyp Spec Aggl;;ACTIVE;1.0n;2.69 +23651-3;Actinobacillus suis serotype;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Actinobacillus suis serotype [Identifier] in Isolate by Agglutination;A suis Sertyp Islt Aggl;;ACTIVE;1.0n;2.19 +23652-1;Aeromonas salmonicida DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Aeromonas salmonicida DNA [Presence] in Tissue by NAA with probe detection;A salmonicida DNA Tiss Ql NAA+probe;;ACTIVE;1.0n;2.67 +23653-9;Aflatoxin;MCnc;Pt;XXX;Qn;;MICRO;1;Aflatoxin [Mass/volume] in Specimen;Aflatoxin Spec-mCnc;;ACTIVE;1.0n;2.69 +23654-7;Aflatoxin;MCnt;Pt;Feed;Qn;;MICRO;1;Aflatoxin [Mass/mass] in Feed;Aflatoxin Feed-mCnt;;ACTIVE;1.0n;2.67 +2365-5;Glutamate;MCnc;Pt;Urine;Qn;;CHEM;1;Glutamate [Mass/volume] in Urine;Glutamate Ur-mCnc;;ACTIVE;1.0;2.73 +23655-4;Aflatoxin;MCnt;Pt;Tiss;Qn;;MICRO;1;Aflatoxin [Mass/mass] in Tissue;Aflatoxin Tiss-mCnt;;ACTIVE;1.0n;2.67 +23656-2;Ammonia;MCnc;Pt;XXX;Qn;;CHEM;1;Ammonia [Mass/volume] in Specimen;Ammonia Spec-mCnc;;ACTIVE;1.0n;2.73 +23657-0;Anaplasma marginale Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Anaplasma marginale Ab [Titer] in Serum by Complement fixation;A marginale Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23658-8;Antibiotic XXX;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Other Antibiotic [Susceptibility];Other Antibiotic Susc Islt;;ACTIVE;1.0n;2.73 +23659-6;Apramycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Apramycin [Susceptibility];Apramycin Susc Islt;;ACTIVE;1.0n;2.19 +23660-4;Aspergillus sp Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Aspergillus sp Ab [Titer] in Serum by Immunoassay;Aspergillus Ab Titr Ser IA;;ACTIVE;1.0n;2.70 +23661-2;Avian paramyxovirus 1 Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian paramyxovirus 1 Ab [Titer] in Serum by Immunoassay;APMV1 Ab Titr Ser IA;;ACTIVE;1.0n;2.70 +23662-0;Babesia bigemina Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Babesia bigemina Ab [Presence] in Serum by Complement fixation;B bigemina Ab Ser Ql CF;;ACTIVE;1.0n;2.64 +2366-3;Glutamate;MRat;24H;Urine;Qn;;CHEM;1;Glutamate [Mass/time] in 24 hour Urine;Glutamate 24h Ur-mRate;;ACTIVE;1.0;2.73 +23663-8;Babesia bovis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Babesia bovis Ab [Presence] in Serum by Complement fixation;B bovis Ab Ser Ql CF;;ACTIVE;1.0n;2.64 +23664-6;Babesia canis Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia canis Ab [Titer] in Serum by Immunofluorescence;B canis Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23665-3;Babesia divergens Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Babesia divergens Ab [Presence] in Serum by Complement fixation;B divergens Ab Ser Ql CF;;ACTIVE;1.0n;2.64 +23666-1;Babesia sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Babesia sp Ab [Titer] in Serum by Complement fixation;Babesia Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23667-9;Bacteria identified;Prid;Pt;XXX;Nom;;MICRO;1;Bacteria identified in Specimen;Bacteria Spec;;ACTIVE;1.0n;2.73 +23668-7;Bartonella henselae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella henselae Ab [Titer] in Serum;B henselae Ab Titr Ser;;ACTIVE;1.0n;2.70 +23669-5;Biochanin A;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Biochanin A [Mass/volume] in Serum or Plasma;Biochanin A SerPl-mCnc;;ACTIVE;1.0n;2.34 +23670-3;Blastomyces sp Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Blastomyces dermatitidis Ab [Presence] in Serum;Deprecated Blastomyces Ab Ser Ql;;DEPRECATED;1.0n;2.36 +2367-1;Glutamate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma;GLDH SerPl-cCnc;;ACTIVE;1.0;2.68 +23671-1;Bluetongue virus 10 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bluetongue virus 10 neutralizing antibody [Titer] in Serum by Neutralization test;BTV10 NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23672-9;Bluetongue virus 11 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bluetongue virus 11 neutralizing antibody [Titer] in Serum by Neutralization test;BTV11 NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23673-7;Bluetongue virus 13 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bluetongue virus 13 neutralizing antibody [Titer] in Serum by Neutralization test;BTV13 NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23674-5;Bluetongue virus 17 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bluetongue virus 17 neutralizing antibody [Titer] in Serum by Neutralization test;BTV17 NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23675-2;Bluetongue virus 2 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bluetongue virus 2 neutralizing antibody [Titer] in Serum by Neutralization test;BTV2 NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23676-0;Borrelia burgdorferi Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Borrelia burgdorferi Ab [Presence] in Serum by Immunofluorescence;B burgdor Ab Ser Ql IF;;ACTIVE;1.0n;2.73 +23677-8;Bovine leukemia virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Bovine leukemia virus Ab [Titer] in Serum by Complement fixation;BLV Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23678-6;Bovine parainfluenza virus 3 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Bovine parainfluenza virus 3 Ag [Presence] in Tissue by Immunofluorescence;BPIV3 Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23679-4;Bovine respiratory syncytial virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bovine respiratory syncytial virus Ag [Presence] in Specimen;BRSV Ag Spec Ql;;ACTIVE;1.0n;2.69 +23680-2;Bromide;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Bromide [Mass/volume] in Specimen;Bromide Spec-mCnc;;ACTIVE;1.0n;2.69 +23681-0;Brucella canis Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Brucella canis Ab [Presence] in Serum by Immunofluorescence;B canis Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23682-8;Brucella canis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Brucella canis Ab [Titer] in Serum by Agglutination;B canis Ab Titr Ser Aggl;;ACTIVE;1.0n;2.70 +23683-6;Brucella canis Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Brucella canis Ab [Titer] in Serum by Immunofluorescence;B canis Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23684-4;Brucella ovis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Brucella ovis Ab [Titer] in Serum;B ovis Ab Titr Ser;;ACTIVE;1.0n;2.70 +23685-1;Canine adenovirus 1 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Canine adenovirus 1 neutralizing antibody [Presence] in Serum by Neutralization test;CAdV1 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23686-9;Canine adenovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Canine adenovirus Ag [Presence] in Tissue by Immunofluorescence;CAdV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23687-7;Canine coronavirus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Canine coronavirus Ab [Presence] in Serum by Immunofluorescence;CCV Ab Ser Ql IF;;ACTIVE;1.0n;2.67 +23688-5;Canine coronavirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Canine coronavirus Ag [Presence] in Tissue by Immunofluorescence;CCV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +2368-9;Glutamate dehydrogenase.NAD;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamate dehydrogenase.NAD [Enzymatic activity/volume] in Serum or Plasma;NAD GluDH SerPl-cCnc;;ACTIVE;1.0;2.68 +23689-3;Canine distemper virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Canine distemper virus Ab [Presence] in Serum by Immunofluorescence;CDV Ab Ser Ql IF;;ACTIVE;1.0n;2.67 +23690-1;Canine distemper virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Canine distemper virus Ab [Titer] in Serum;CDV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23691-9;Canine distemper virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Canine distemper virus IgG Ab [Titer] in Serum by Immunofluorescence;CDV IgG Titr Ser IF;;ACTIVE;1.0n;2.70 +23692-7;Canine distemper virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Canine distemper virus IgG Ab [Titer] in Serum;CDV IgG Titr Ser;;ACTIVE;1.0n;2.70 +23693-5;Canine distemper virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Canine distemper virus IgM Ab [Titer] in Serum by Immunofluorescence;CDV IgM Titr Ser IF;;ACTIVE;1.0n;2.70 +23694-3;Canine distemper virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Canine distemper virus IgM Ab [Titer] in Serum;CDV IgM Titr Ser;;ACTIVE;1.0n;2.70 +23695-0;Canine distemper virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Canine distemper virus Ag [Presence] in Tissue by Immunofluorescence;CDV Ag Tiss Ql IF;;ACTIVE;1.0n;2.67 +23696-8;Canine distemper virus Ag;PrThr;Pt;Cnjt;Ord;;MICRO;1;Canine distemper virus Ag [Presence] in Conjunctival specimen;CDV Ag Conjunct Ql;;ACTIVE;1.0n;2.56 +2369-7;Glutamate dehydrogenase.NADP;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamate dehydrogenase.NADP [Enzymatic activity/volume] in Serum or Plasma;NADP GluDH SerPl-cCnc;;ACTIVE;1.0;2.68 +23697-6;Canine herpesvirus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Canine herpesvirus neutralizing antibody [Presence] in Serum by Neutralization test;CaHV NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23698-4;Canine herpesvirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Canine herpesvirus Ag [Presence] in Tissue by Immunofluorescence;CaHV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23699-2;Canine parainfluenza virus 2 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Canine parainfluenza virus 2 Ag [Presence] in Tissue by Immunofluorescence;Canine PIV2 Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23700-8;Canine parvovirus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Canine parvovirus Ab [Presence] in Serum by Immunofluorescence;CPV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23701-6;Canine parvovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Canine parvovirus Ab [Presence] in Serum;CPV Ab Ser Ql;;ACTIVE;1.0n;2.67 +23702-4;Canine parvovirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Canine parvovirus Ab [Titer] in Serum;CPV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23703-2;Canine parvovirus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Canine parvovirus IgG Ab [Titer] in Serum;CPV IgG Titr Ser;;ACTIVE;1.0n;2.70 +23704-0;Canine parvovirus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Canine parvovirus IgM Ab [Titer] in Serum;CPV IgM Titr Ser;;ACTIVE;1.0n;2.70 +2370-5;Glutamine;MCnc;Pt;CSF;Qn;;CHEM;1;Glutamine [Mass/volume] in Cerebral spinal fluid;Glutamine CSF-mCnc;;ACTIVE;1.0;2.34 +23705-7;Canine parvovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Canine parvovirus Ag [Presence] in Tissue by Immunofluorescence;CPV Ag Tiss Ql IF;;ACTIVE;1.0n;2.67 +23706-5;Canine parvovirus Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Canine parvovirus Ag [Presence] in Stool by Immunofluorescence;CPV Ag Stl Ql IF;;ACTIVE;1.0n;2.67 +23707-3;Canine parvovirus DNA;PrThr;Pt;Stool;Ord;Probe;MICRO;1;Canine parvovirus DNA [Presence] in Stool by Probe;CPV DNA Stl Ql Probe;;ACTIVE;1.0n;2.63 +23708-1;Caprine arthritis encephalitis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Caprine arthritis encephalitis virus Ag [Presence] in Specimen;CAEV Ag Spec Ql;;ACTIVE;1.0n;2.69 +23709-9;Ceftiofur;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceftiofur [Susceptibility];Ceftiofur Susc Islt;;ACTIVE;1.0n;2.19 +23710-7;Dirofilaria immitis Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Dirofilaria immitis Ag [Presence] in Serum by Immunoassay;D immitis Ag Ser Ql IA;;ACTIVE;1.0n;2.56 +23711-5;Ehrlichia canis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia canis Ab [Titer] in Serum;E canis Ab Titr Ser;;ACTIVE;1.0n;2.70 +23712-3;Enrofloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Enrofloxacin [Susceptibility];Enrofloxacin Susc Islt;;ACTIVE;1.0n;2.19 +2371-3;Glutamine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Glutamine [Presence] in Serum or Plasma;Glutamine SerPl Ql;;ACTIVE;1.0;2.73 +23713-1;Ethylene glycol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ethylene glycol [Presence] in Serum or Plasma;Ethylene Glycol SerPl Ql;;ACTIVE;1.0n;2.56 +23714-9;Fat;MCnc;Pt;Milk;Qn;;CHEM;1;Fat [Mass/volume] in Milk;Fat Mlk-mCnc;;ACTIVE;1.0n;2.34 +23715-6;Feline calicivirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline calicivirus Ab [Titer] in Serum;FCV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23716-4;Feline coronavirus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Feline coronavirus Ab [Presence] in Serum by Immunoassay;FCoV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23717-2;Feline coronavirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Feline coronavirus Ab [Presence] in Serum;FCoV Ab Ser Ql;;ACTIVE;1.0n;2.56 +23718-0;Feline coronavirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline coronavirus Ab [Titer] in Serum;FCoV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23719-8;Feline herpesvirus 1 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Feline herpesvirus 1 neutralizing antibody [Presence] in Serum by Neutralization test;FeHV1 NAb Ser Ql Nt;;ACTIVE;1.0n;2.72 +23720-6;Feline herpesvirus 1 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Feline herpesvirus 1 Ag [Presence] in Tissue by Immunofluorescence;FeHV1 Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +2372-1;Glutamine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamine [Mass/volume] in Serum or Plasma;Glutamine SerPl-mCnc;;ACTIVE;1.0;2.73 +23721-4;Feline herpesvirus 1 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Feline herpesvirus 1 DNA [Presence] in Specimen by NAA with probe detection;FeHV1 DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.69 +23722-2;Feline herpesvirus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Feline herpesvirus neutralizing antibody [Titer] in Serum by Neutralization test;FeHV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23723-0;Feline immunodeficiency virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Feline immunodeficiency virus Ab [Presence] in Serum by Immunoassay;FIV Ab Ser Ql IA;;ACTIVE;1.0n;2.67 +23724-8;Feline immunodeficiency virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Feline immunodeficiency virus Ab [Presence] in Serum;FIV Ab Ser Ql;;ACTIVE;1.0n;2.67 +23725-5;Feline immunodeficiency virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Feline immunodeficiency virus Ab [Titer] in Serum by Immunofluorescence;FIV Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23726-3;Feline infectious peritonitis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Feline infectious peritonitis virus Ab [Presence] in Serum by Immunoassay;FIPV Ab Ser Ql IA;;ACTIVE;1.0n;2.67 +23727-1;Feline infectious peritonitis virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Feline infectious peritonitis virus Ab [Presence] in Serum by Immunofluorescence;FIPV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23728-9;Feline infectious peritonitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Feline infectious peritonitis virus Ab [Presence] in Serum;FIPV Ab Ser Ql;;ACTIVE;1.0n;2.67 +23729-7;Feline infectious peritonitis virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Feline infectious peritonitis virus Ag [Presence] in Tissue by Immunofluorescence;FIPV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23730-5;Feline infectious peritonitis virus Ag;PrThr;Pt;Tsmi;Ord;IF;MICRO;1;Feline infectious peritonitis virus Ag [Presence] in Small intestine Tissue by Immunofluorescence;FIPV Ag TSMI Ql IF;;ACTIVE;1.0n;2.67 +23731-3;Feline leukemia provirus;PrThr;Pt;XXX;Ord;;MICRO;1;Feline leukemia provirus [Presence] in Specimen;FeLV provirus Spec Ql;;ACTIVE;1.0n;2.69 +23732-1;Feline leukemia virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Feline leukemia virus Ab [Presence] in Serum by Immunoassay;FeLV Ab Ser Ql IA;;ACTIVE;1.0n;2.56 +23733-9;Feline leukemia virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Feline leukemia virus Ab [Presence] in Serum by Immunofluorescence;FeLV Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23734-7;Feline leukemia virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Feline leukemia virus Ab [Presence] in Serum;FeLV Ab Ser Ql;;ACTIVE;1.0n;2.67 +23735-4;Feline leukemia virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Feline leukemia virus neutralizing antibody [Titer] in Serum by Neutralization test;FeLV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23736-2;Feline leukemia virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Feline leukemia virus Ag [Presence] in Tissue by Immunofluorescence;FeLV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23737-0;Feline panleukopenia virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline panleukopenia virus Ab [Titer] in Serum;FPLV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23738-8;Feline herpesvirus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline herpesvirus 1 Ab [Titer] in Serum;FeHV1 Ab Titr Ser;;ACTIVE;1.0n;2.70 +2373-9;Glutamine;MCnc;Pt;Urine;Qn;;CHEM;1;Glutamine [Mass/volume] in Urine;Glutamine Ur-mCnc;;ACTIVE;1.0;2.73 +23739-6;Feline syncytial virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline syncytial virus Ab [Titer] in Serum;FSV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23740-4;Florfenicol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Florfenicol [Susceptibility];Florfenicol Susc Islt;;ACTIVE;1.0n;2.19 +23741-2;Francisella tularensis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Francisella tularensis Ab [Titer] in Serum by Complement fixation;F tular Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23742-0;Fumonisin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Fumonisin [Mass/volume] in Specimen;Fumonisin Spec-mCnc;;ACTIVE;1.0n;2.69 +23743-8;Genistein;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Genistein [Units/volume] in Serum or Plasma;Genistein SerPl-aCnc;;ACTIVE;1.0n;2.69 +23744-6;Giardia lamblia Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Giardia lamblia Ag [Presence] in Specimen by Immunofluorescence;G lamblia Ag Spec Ql IF;;ACTIVE;1.0n;2.73 +23745-3;Gossypol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Gossypol [Mass/volume] in Specimen;Gossypol Spec-mCnc;;ACTIVE;1.0n;2.69 +23746-1;Gossypol.free;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Gossypol Free [Mass/volume] in Specimen;Gossypol free Spec-mCnc;;ACTIVE;1.0n;2.69 +2374-7;Glutamine;MRat;24H;Urine;Qn;;CHEM;1;Glutamine [Mass/time] in 24 hour Urine;Glutamine 24h Ur-mRate;;ACTIVE;1.0;2.73 +23747-9;Heavy metals;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Heavy metals [Presence] in Specimen;Heavy Metals Spec Ql;;ACTIVE;1.0n;2.69 +23748-7;Histoplasma sp Ab;ACnc;Pt;Ser;Ord;Immune diffusion;MICRO;1;Deprecated Histoplasma capsulatum Ab [Presence] in Serum by Immune diffusion (ID);Deprecated Histoplasma Ab Ser Ql ID;;DEPRECATED;1.0n;2.36 +23749-5;Lead;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Specimen;Lead Spec-mCnc;;ACTIVE;1.0n;2.73 +23750-3;Leptospira sp Ag;PrThr;Pt;Urine;Ord;IF;MICRO;1;Leptospira sp Ag [Presence] in Urine by Immunofluorescence;Leptospira Ag Ur Ql IF;;ACTIVE;1.0n;2.56 +23751-1;Metaldehyde;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Metaldehyde [Mass/volume] in Specimen;Metaldehyde Spec-mCnc;;ACTIVE;1.0n;2.69 +23752-9;Mite identified;Prid;Pt;Skin;Nom;;MICRO;1;Mite identified in Skin;Mite Skin;;ACTIVE;1.0n;2.21 +23753-7;Mycoplasma hyopneumoniae Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Mycoplasma hyopneumoniae Ab [Presence] in Serum by Immunofluorescence;M hyopneumo Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +2375-4;Glutaryl CoA dehydrogenase;CCnt;Pt;Tiss;Qn;;CHEM;1;Glutaryl CoA dehydrogenase [Enzymatic activity/mass] in Tissue;GCDH Tiss-cCnt;;ACTIVE;1.0;2.42 +23754-5;Mycoplasma sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma sp Ab [Titer] in Serum;Mycoplasma Ab Titr Ser;;ACTIVE;1.0n;2.73 +23755-2;Mycoplasma synoviae Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Mycoplasma synoviae Ab [Titer] in Serum by Hemagglutination;M synoviae Ab Titr Ser HA;;ACTIVE;1.0n;2.70 +23756-0;Neospora caninum Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Neospora caninum Ab [Units/volume] in Serum by Immunoassay;N caninum Ab Ser IA-aCnc;;ACTIVE;1.0n;2.69 +23757-8;Neospora caninum Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Neospora caninum Ab [Titer] in Serum by Immunofluorescence;N caninum Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23758-6;Neospora caninum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Neospora caninum Ab [Titer] in Serum;N caninum Ab Titr Ser;;ACTIVE;1.0n;2.70 +23759-4;Neospora caninum Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Neospora caninum Ag [Presence] in Tissue by Immune stain;N caninum Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23760-2;Neospora caninum Ag;PrThr;Pt;Tiss fixed;Ord;Immune stain;MICRO;1;Neospora caninum Ag [Presence] in Fixed tissue by Immune stain;N caninum Ag Ftis Ql ImStn;;ACTIVE;1.0n;2.56 +23761-0;Neutrophils/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Blood by Manual count;Neutrophils/leuk NFr Bld Manual;;ACTIVE;1.0n;2.73 +2376-2;Glutathione peroxidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutathione peroxidase [Enzymatic activity/volume] in Serum or Plasma;Glutathione Px SerPl-cCnc;;ACTIVE;1.0;2.68 +23762-8;Nitrate+Nitrite;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nitrate+Nitrite [Mass/volume] in Specimen;Nitrate+Nitrite Spec-mCnc;;ACTIVE;1.0n;2.69 +23763-6;Pasteurella multocida serotype;Prid;Pt;Isolate;Nom;;MICRO;1;Pasteurella multocida serotype [Identifier] in Isolate;P multoc Sertyp Islt;;ACTIVE;1.0n;2.19 +23764-4;Pesticides;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Pesticides [Identifier] in Specimen;Pesticides Spec;;ACTIVE;1.0n;2.69 +23765-1;Porcine adenovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Porcine adenovirus Ag [Presence] in Tissue by Immunofluorescence;PAdV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23766-9;Porcine circovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Porcine circovirus Ag [Presence] in Tissue by Immunofluorescence;PCV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23767-7;Porcine circovirus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Porcine circovirus Ag [Presence] in Tissue by Immune stain;PCV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23768-5;Porcine influenza virus A Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Porcine influenza virus A Ab [Titer] in Serum by Hemagglutination inhibition;Porcine FLUAV Ab Titr Ser HAI;;ACTIVE;1.0n;2.70 +23769-3;Porcine influenza virus A Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Porcine influenza virus A Ag [Presence] in Tissue by Immune stain;Porcine FLUAV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.64 +2377-0;Glutathione peroxidase;CCnc;Pt;RBC;Qn;;CHEM;1;Glutathione peroxidase [Enzymatic activity/volume] in Red Blood Cells;Glutathione Px RBC-cCnc;;ACTIVE;1.0;2.44 +23770-1;Porcine parvovirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Porcine parvovirus Ab [Titer] in Serum;PPV Ab Titr Ser;;ACTIVE;1.0n;2.70 +23771-9;Porcine parvovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Porcine parvovirus Ag [Presence] in Tissue by Immunofluorescence;PPV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23772-7;Porcine reproductive and respiratory syndrome virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;PRRSV Ab [Titer] in Serum by Immunofluorescence;PRRSV Ab Titr Ser IF;;ACTIVE;1.0n;2.70 +23773-5;Porcine rotavirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Porcine rotavirus Ag [Presence] in Tissue by Immunofluorescence;PoRV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23774-3;Pseudorabies virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Pseudorabies virus Ag [Presence] in Tissue by Immunofluorescence;PRV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23775-0;Rhodococcus equi Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rhodococcus equi Ab [Titer] in Serum;R equi Ab Titr Ser;;ACTIVE;1.0n;2.70 +23776-8;Rickettsia spotted fever group Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia spotted fever group Ab [Presence] in Serum by Immunofluorescence;Rick SF Ab Ser Ql IF;;ACTIVE;1.0n;2.56 +23777-6;Salmonella pullorum Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella pullorum Ab [Titer] in Serum by Agglutination;S pullorum Ab Titr Ser Aggl;;ACTIVE;1.0n;2.70 +23778-4;Salmonella typhimurium Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella typhimurium Ab [Titer] in Serum by Agglutination;S Typhimur Ab Titr Ser Aggl;;ACTIVE;1.0n;2.70 +23779-2;Selenium;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Specimen;Selenium Spec-mCnc;;ACTIVE;1.0n;2.73 +237-8;Erythromycin+sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Erythromycin+Sulfisoxazole [Susceptibility] by Minimum inhibitory concentration (MIC);Erythro+Sulf Islt MIC;;ACTIVE;1.0;2.19 +23780-0;Strychnine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Strychnine [Mass/volume] in Specimen;Strychnine Spec-mCnc;;ACTIVE;1.0n;2.69 +23781-8;Swine influenza virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Swine influenza virus Ag [Presence] in Tissue by Immunofluorescence;SIV Ag Tiss Ql IF;;ACTIVE;1.0n;2.56 +23782-6;Swine influenza virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Swine influenza virus Ag [Presence] in Tissue by Immune stain;SIV Ag Tiss Ql ImStn;;ACTIVE;1.0n;2.56 +23783-4;Taylorella equigenitalis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Taylorella equigenitalis Ab [Titer] in Serum by Complement fixation;T equigenit Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23784-2;Toxoplasma gondii Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Toxoplasma gondii Ab [Titer] in Serum by Hemagglutination;T gondii Ab Titr Ser HA;;ACTIVE;1.0n;2.70 +23785-9;Trypanosoma cruzi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma cruzi Ab [Presence] in Serum;T cruzi Ab Ser Ql;;ACTIVE;1.0n;2.73 +23786-7;Urea;MCnc;Pt;XXX;Qn;;CHEM;1;Urea [Mass/volume] in Specimen;Urea Spec-mCnc;;ACTIVE;1.0n;2.69 +23787-5;Venezuelan equine encephalitis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Venezuelan equine encephalitis virus Ab [Titer] in Serum by Complement fixation;VEEV Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +2378-8;Glutathione reductase;CCnc;Pt;RBC;Qn;;CHEM;1;Glutathione reductase [Enzymatic activity/volume] in Red Blood Cells;GR RBC-cCnc;;ACTIVE;1.0;2.44 +23788-3;Vesicular stomatitis Indiana virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Vesicular stomatitis Indiana virus Ab [Titer] in Serum by Complement fixation;VSIV Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23789-1;Vesicular stomatitis Indiana virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Vesicular stomatitis Indiana virus neutralizing antibody [Titer] in Serum by Neutralization test;VSIV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23790-9;Vesicular stomatitis New Jersey virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Vesicular stomatitis New Jersey virus Ab [Titer] in Serum by Complement fixation;VSNJV Ab Titr Ser CF;;ACTIVE;1.0n;2.70 +23791-7;Vesicular stomatitis New Jersey virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Vesicular stomatitis New Jersey virus neutralizing antibody [Titer] in Serum by Neutralization test;VSNJV NAb Titr Ser Nt;;ACTIVE;1.0n;2.72 +23792-5;Western equine encephalitis virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Western equine encephalitis virus Ab [Presence] in Specimen;WEEV Ab Spec Ql;;ACTIVE;1.0n;2.69 +23793-3;Canine parvovirus Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Canine parvovirus Ag [Presence] in Stool by Immunoassay;CPV Ag Stl Ql IA;;ACTIVE;1.0n;2.56 +23794-1;(Avena sativa+Hordeum vulgare+Oryza sativa+Secale cereale+Triticum aestivum+Zea mays) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix C (Oat+Barley+Rice+Rye+Wheat+Corn) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix C IgE Ql;;ACTIVE;1.0n;2.56 +23795-8;(Blatella germanica+Dermatophagoides farinae+Dermatophagoides pteronyssinus+House dust Hollister Stier) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Dust Allergen Mix 2 (Cockroach+American house dust mite+European house dust mite+House dust Hollister Stier) IgE Ab [Presence] in Serum by Multidisk;Dust Allerg Mix2 IgE Ql;;ACTIVE;1.0n;2.73 +2379-6;Glutathione S-transferase;CCnc;Pt;RBC;Qn;;CHEM;1;Glutathione S-transferase [Enzymatic activity/volume] in Red Blood Cells;GST RBC-cCnc;;ACTIVE;1.0;2.44 +23796-6;(Acer negundo+Betula verrucosa+Quercus alba+Ulmus americana+Juglans californica) Ab.IgE;ACnc;Pt;Ser;Ord;Multidisk;ALLERGY;1;Deprecated Tree Allergen Mix 1 (Boxelder+Silver birch+White oak+White elm+California walnut) IgE Ab [Presence] in Serum by Multiple allergens;Deprecated Tree Allerg Mix1 IgE Ql;;DEPRECATED;1.0n;2.36 +23797-4;(Acer negundo+Quercus alba+Ulmus americana+Populus deltoides+Carya illinoinensis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 2 (Boxelder+White oak+White elm+Cottonwood+Pecan/Hickory) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix2 IgE Ql;;ACTIVE;1.0n;2.73 +23798-2;(Cat dander+Cow dander+Dog dander+Horse dander) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 1 (Cat dander+Cow dander+Dog dander+Horse dander) IgE Ab [Presence] in Serum by Multidisk;Epid Allerg Mix1 IgE Ql;;ACTIVE;1.0n;2.73 +23799-0;(Chicken feather+Duck feather+Goose feather+Parrot feather) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 73 (Chicken feather+Duck feather+Goose feather+Parrot feather) IgE Ab [Presence] in Serum by Multidisk;Epid Allerg Mix73 IgE Ql;;ACTIVE;1.0n;2.73 +23800-6;(Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 1 (Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) IgE Ab [Presence] in Serum by Multidisk;Mold Allerg Mix1 IgE Ql;;ACTIVE;1.0n;2.73 +23801-4;(Arachis hypogaea+Cow milk+Egg white+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 5 (Peanut+Cow milk+Egg white+Cod+Soybean+Wheat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix5 IgE Ql;;ACTIVE;1.0n;2.73 +23802-2;(Cynodon dactylon+Lolium perenne+Phleum pratense+Poa pratensis+Sorghum halepense) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix D (Bermuda grass+Perennial rye grass+Timothy+Kentucky blue grass+Johnson grass) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix D IgE Ql;;ACTIVE;1.0n;2.73 +23803-0;(Dactylis glomerata+Festuca elatior+Lolium perenne+Phleum pratense+Poa pratensis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 1 (Orchard grass+Meadow Fescue+Perennial rye grass+Timothy+Kentucky blue grass) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix1 IgE Ql;;ACTIVE;1.0n;2.73 +2380-4;Glutathione synthase;CCnc;Pt;RBC;Qn;;CHEM;1;Glutathione synthase [Enzymatic activity/volume] in Red Blood Cells;Glutathione Synthase RBC-cCnc;;ACTIVE;1.0;2.44 +23804-8;(Gadus morhua+Mytilus edulis+Pandalus borealis+Salmo salar+Thunnus albacares) Ab.IgE;ACnc;Pt;Ser;Ord;Multidisk;ALLERGY;1;Deprecated Food Allergen Mix 2 (Cod+Blue Mussel+Shrimp+Salmon+Tuna) IgE Ab [Presence] in Serum by Multiple allergens;Deprecated Food Allerg Mix2 IgE Ql;;DEPRECATED;1.0n;2.36 +23805-5;5-Fluorocytosine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;5-Fluorocytosine [Mass/volume] in Specimen;5-fluorocytosine Spec-mCnc;;ACTIVE;1.0n;2.69 +23806-3;Albumin^2H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Albumin [Mass/volume] in Peritoneal fluid --2 hours post peritoneal dialysis;Albumin 2h p PD Prt-mCnc;;ACTIVE;1.0n;2.42 +23807-1;Albumin^4H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Albumin [Mass/volume] in Peritoneal fluid --4 hours post peritoneal dialysis;Albumin 4h p PD Prt-mCnc;;ACTIVE;1.0n;2.42 +23808-9;Aldosterone.free;MRat;24H;Urine;Qn;;CHEM;1;Aldosterone free [Mass/time] in 24 hour Urine;Aldost Free 24h Ur-mRate;;ACTIVE;1.0n;2.40 +23809-7;Alloisoleucine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alloisoleucine [Mass/volume] in Serum or Plasma;Alloisoleucine SerPl-mCnc;;DISCOURAGED;1.0n;2.44 +23810-5;Alpha fucosidase;ACnc;Pt;WBC;Qn;;CHEM;1;Alpha fucosidase [Units/volume] in Leukocytes;A-Fucosidase WBC-aCnc;;DISCOURAGED;1.0n;2.69 +23811-3;Alpha-1-Fetoprotein^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] adjusted in Serum or Plasma;AFP adj MoM SerPl;;ACTIVE;1.0n;2.73 +2381-2;Glutathione.oxidized;MCnc;Pt;RBC;Qn;;CHEM;1;Glutathione.oxidized [Mass/volume] in Red Blood Cells;GSS RBC-mCnc;;ACTIVE;1.0;2.42 +23812-1;Alpha-1-Fetoprotein^^unadjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] unadjusted in Serum or Plasma;AFP unadj MoM SerPl;;DISCOURAGED;1.0n;2.73 +23813-9;Alternaria sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alternaria sp IgE Ab RAST class [Presence] in Serum;Alternaria IgE RAST Ql;;ACTIVE;1.0n;2.58 +23814-7;Amantadine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amantadine [Mass/volume] in Urine;Amantadine Ur-mCnc;;ACTIVE;1.0n;2.42 +23815-4;Androstanediol;MRat;24H;Urine;Qn;;CHEM;1;Androstanediol [Mass/time] in 24 hour Urine;Androstanediol 24h Ur-mRate;;ACTIVE;1.0n;2.42 +23816-2;Antibiotic XXX;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Other Antibiotic [Mass/volume] in Serum or Plasma;Other Antibiotic SerPl-mCnc;;ACTIVE;1.0n;2.42 +23817-0;Antibiotic XXX^peak;Susc;Pt;Isolate+Ser;Ord;MLC;ABXBACT;1;Deprecated Other Antibiotic [Susceptibility] by Minimum lethal concentration (MLC) --peak;Deprecated Other Antibiotic Peak MLC;;DEPRECATED;1.0n;2.36 +23818-8;Antibiotic XXX^trough;Susc;Pt;Isolate+Ser;Ord;MLC;ABXBACT;1;Deprecated Other Antibiotic [Susceptibility] by Minimum lethal concentration (MLC) --trough;Deprecated Other Antibiotic Trough MLC;;DEPRECATED;1.0n;2.36 +23819-6;Antibody coated bacteria;PrThr;Pt;Urine;Ord;IF;MICRO;1;Antibody coated bacteria [Presence] in Urine by Immunofluorescence;Ab Coated Bacteria Ur Ql IF;;ACTIVE;1.0n;2.56 +2382-0;Glutathione.reduced;MCnc;Pt;RBC;Qn;;CHEM;1;Glutathione.reduced [Mass/volume] in Red Blood Cells;GSH RBC-mCnc;;ACTIVE;1.0;2.73 +23820-4;Aspergillus flavus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus flavus Ab [Presence] in Serum by Immune diffusion (ID);A flavus Ab Ser Ql ID;;ACTIVE;1.0n;2.73 +23821-2;Aspergillus fumigatus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus fumigatus Ab [Presence] in Serum by Immune diffusion (ID);A fumigatus Ab Ser Ql ID;;ACTIVE;1.0n;2.73 +23822-0;Azinphos-methyl;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Azinphos-methyl [Mass/volume] in Blood;Azinphos-Mehyl Bld-mCnc;;ACTIVE;1.0n;2.73 +23823-8;Basophils/100 leukocytes;NFr;Pt;XXX;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Specimen by Manual count;Basophils/leuk NFr Spec Manual;;ACTIVE;1.0n;2.73 +23824-6;Beta-N-acetylhexosaminidase.A/Beta-N-acetylhexosaminidase.total;CFr;Pt;Ser;Qn;;CHEM;1;Deprecated Beta-N-acetylhexosaminidase.A/Beta-n-acetylhexosaminidase.total in Serum;Deprecated Hexosaminidase A Fr Ser;;DEPRECATED;1.0n;2.70 +23825-3;Beta-N-acetylhexosaminidase.A/Beta-N-acetylhexosaminidase.total;CFr;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A/Beta-n-acetylhexosaminidase.total in Leukocytes;Hexosaminidase A CFr WBC;;ACTIVE;1.0n;2.73 +23826-1;Bordetella pertussis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection;B pert DNA Spec Ql NAA+probe;;ACTIVE;1.0n;2.73 +23827-9;Bordetella pertussis.filamentous hemagglutinin Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgA Ab [Units/volume] in Serum;B pert FHA IgA Ser-aCnc;;ACTIVE;1.0n;2.73 +23828-7;Bordetella pertussis.filamentous hemagglutinin Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgG Ab [Units/volume] in Serum;B pert FHA IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +23829-5;Bordetella pertussis.filamentous hemagglutinin Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgM Ab [Units/volume] in Serum;B pert FHA IgM Ser-aCnc;;ACTIVE;1.0n;2.68 +23830-3;Bordetella pertussis.pertussis toxin Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis.pertussis toxin IgA Ab [Units/volume] in Serum;B pert.PT IgA Ser-aCnc;;ACTIVE;1.0n;2.73 +23831-1;Bordetella pertussis.pertussis toxin Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis.pertussis toxin IgG Ab [Units/volume] in Serum;B pert.PT IgG Ser-aCnc;;ACTIVE;1.0n;2.73 +23832-9;Bordetella pertussis.pertussis toxin Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis.pertussis toxin IgM Ab [Units/volume] in Serum;B pert.PT IgM Ser-aCnc;;ACTIVE;1.0n;2.73 +23833-7;Borrelia burgdorferi Ab index;PrThr;Pt;Ser+CSF;Ord;;MICRO;1;Borrelia burgdorferi Ab index [Presence] in Serum and CSF;B burgdor Ab Indx Ser+CSF Ql;;ACTIVE;1.0n;2.73 +23834-5;Canary droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canary droppings IgE Ab RAST class [Presence] in Serum;Canary Drop IgE RAST Ql;;ACTIVE;1.0n;2.58 +23835-2;Carbon disulfide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carbon disulfide [Mass/volume] in Urine;Carbon diS Ur-mCnc;;ACTIVE;1.0n;2.42 +23836-0;Carbon disulfide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbon disulfide [Mass/volume] in Serum or Plasma;Carbon diS SerPl-mCnc;;ACTIVE;1.0n;2.42 +23837-8;Chicken serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken serum proteins IgE Ab RAST class [Presence] in Serum;Chicken Serum Prot IgE RAST Ql;;ACTIVE;1.0n;2.58 +2383-8;Glutathione;MCnc;Pt;RBC;Qn;;CHEM;1;Glutathione [Mass/volume] in Red Blood Cells;Glutathione RBC-mCnc;;ACTIVE;1.0;2.73 +23838-6;Chlamydia trachomatis rRNA;PrThr;Pt;Genital fld;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Genital fluid by Probe;C trach rRNA Genital fl Ql Probe;;ACTIVE;1.0n;2.73 +23839-4;Cholinesterase;ACnc;Pt;RBC;Qn;Calculated;CHEM;1;Deprecated Cholinesterase [Enzymatic activity/volume] in Red Blood Cells;Deprecated Cholinesterase RBC Calc-aCnc;;DEPRECATED;1.0n;2.69 +23840-2;Choriogonadotropin.beta subunit^^unadjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Multiple of the median] unadjusted in Serum or Plasma;B-HCG unadj MoM SerPl;;DISCOURAGED;1.0n;2.73 +23841-0;Choriogonadotropin.beta subunit^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Multiple of the median] adjusted in Serum or Plasma;B-HCG adj MoM SerPl;;ACTIVE;1.0n;2.73 +23842-8;Cobalt;MCnc;Pt;Synv fld;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Synovial fluid;Cobalt Snv-mCnc;;ACTIVE;1.0n;2.42 +23843-6;Cockatiel droppings Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Cockatiel droppings Ab [Presence] in Serum by Immune diffusion (ID);Cockatiel Drop Ab Ql ID;;ACTIVE;1.0n;2.73 +23844-4;C3 nephritic factor;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;C3 nephritic factor [Units/volume] in Serum or Plasma;C3 NeF SerPl-aCnc;;ACTIVE;1.0n;2.73 +23845-1;Coproporphyrin 1;MRat;24H;Stool;Qn;;CHEM;1;Coproporphyrin 1 [Mass/time] in 24 hour Stool;Copro1 24h Stl-mRate;;ACTIVE;1.0n;2.73 +2384-6;Glyceraldehyde 3 phosphate dehydrogenase;CCnc;Pt;Ser;Qn;;CHEM;1;Glyceraldehyde 3 phosphate dehydrogenase [Enzymatic activity/volume] in Serum;GAPD Ser-cCnc;;ACTIVE;1.0;2.68 +23846-9;Coproporphyrin 3;MRat;24H;Stool;Qn;;CHEM;1;Coproporphyrin 3 [Mass/time] in 24 hour Stool;Copro3 24h Stl-mRate;;ACTIVE;1.0n;2.73 +23847-7;Cotton fibers Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cotton fibers IgE Ab [Units/volume] in Serum;Deprecated Cotton Fibers IgE Qn;;DEPRECATED;1.0n;2.69 +23848-5;Creosol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Creosol [Mass/volume] in Specimen;Creosol Spec-mCnc;;ACTIVE;1.0n;2.69 +23849-3;Creosol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Creosol [Mass/volume] in Serum or Plasma;Creosol SerPl-mCnc;;ACTIVE;1.0n;2.34 +23850-1;Creosol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Creosol [Mass/volume] in Urine;Creosol Ur-mCnc;;ACTIVE;1.0n;2.73 +23851-9;Cyclohexanone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyclohexanone [Mass/volume] in Serum or Plasma;Cyclohexanone SerPl-mCnc;;ACTIVE;1.0n;2.73 +23852-7;Deuteroporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Deuteroporphyrin [Mass/time] in unspecified time Stool;Deuteropor ?Tm Stl-mRate;;ACTIVE;1.0n;2.19 +2385-3;Glycerate;MCnc;Pt;Ser;Qn;;CHEM;1;Glycerate [Mass/volume] in Serum;Glycerate Ser-mCnc;;ACTIVE;1.0;2.34 +23853-5;Dimethylformamide/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Dimethylformamide/Creatinine [Mass Ratio] in Urine;DMF/Creat Ur;;ACTIVE;1.0n;2.44 +23854-3;Dioxin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dioxin [Mass/volume] in Serum or Plasma;Dioxin SerPl-mCnc;;ACTIVE;1.0n;2.34 +23855-0;Echinococcus granulosus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Echinococcus granulosus IgE Ab [Units/volume] in Serum;E granulosus IgE Qn;;ACTIVE;1.0n;2.42 +23856-8;Endrin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Endrin [Mass/volume] in Serum or Plasma;Endrin SerPl-mCnc;;ACTIVE;1.0n;2.42 +23857-6;Epidermis Ab;Imp;Pt;Tiss;Nom;IF;SERO;1;Epidermis Ab [Interpretation] in Tissue by Immunofluorescence;Epidis Ab Tiss IF-Imp;;ACTIVE;1.0n;2.26 +23858-4;Epstein Barr virus DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;EBV DNA CSF Ql NAA+probe;;ACTIVE;1.0n;2.73 +23859-2;Erythrocytes;NCnc;Pt;XXX;Qn;Microscopy.light;HEM/BC;1;Erythrocytes [#/volume] in Specimen by Light microscopy;RBC # Spec Micro;;ACTIVE;1.0n;2.69 +238-6;Erythromycin+sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Erythromycin+Sulfisoxazole [Susceptibility] by Disk diffusion (KB);Erythro+Sulf Islt KB;;ACTIVE;1.0;2.19 +23860-0;Erythrocytes;NCnc;Pt;Body fld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Body fluid by Automated count;RBC # Fld Auto;;ACTIVE;1.0n;2.73 +2386-1;Glycerate;MCnc;Pt;Urine;Qn;;CHEM;1;Glycerate [Mass/volume] in Urine;Glycerate Ur-mCnc;;ACTIVE;1.0;2.34 +23861-8;Ethanol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Ethanol [Mass/mass] in Tissue;Ethanol Tiss-mCnt;;ACTIVE;1.0n;2.42 +23862-6;Famotidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Famotidine [Mass/volume] in Serum or Plasma;Famotidine SerPl-mCnc;;ACTIVE;1.0n;2.42 +23863-4;Finch droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Finch droppings IgE Ab RAST class [Presence] in Serum;Finch Drop IgE RAST Ql;;ACTIVE;1.0n;2.58 +23864-2;Flunitrazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flunitrazepam [Mass/volume] in Serum or Plasma;Flunitrazepam SerPl-mCnc;;ACTIVE;1.0n;2.73 +23865-9;Fluoxetine+Norfluoxetine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;FLUoxetine+Norfluoxetine [Presence] in Urine;FLUoxetine+Nor Ur Ql;;ACTIVE;1.0n;2.56 +23866-7;Glutaraldehyde;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Glutaraldehyde [Presence] in Urine;Glutaraldehyde Ur Ql;;ACTIVE;1.0n;2.56 +23867-5;Hantavirus sin nombre Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Hantavirus sin nombre IgG Ab [Titer] in Serum;SNV IgG Titr Ser;;ACTIVE;1.0n;2.73 +23868-3;Hantavirus sin nombre Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Hantavirus sin nombre IgM Ab [Titer] in Serum;SNV IgM Titr Ser;;ACTIVE;1.0n;2.73 +23869-1;Hepatitis B virus DNA;MCnc;Pt;Ser;Qn;Probe;MICRO;1;Hepatitis B virus DNA [Mass/volume] (viral load) in Serum by Probe;HBV DNA Ser Probe-mCnc;;ACTIVE;1.0n;2.73 +23870-9;Hepatitis C virus 100+5-1-1 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus 100+5-1-1 Ab [Presence] in Serum by Immunoblot;HCV100+5-1-1 Ab Ser Ql IB;;ACTIVE;1.0n;2.73 +23871-7;Hepatitis C virus NS5 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus NS5 Ab [Presence] in Serum by Immunoblot;HCV NS5 Ab Ser Ql IB;;ACTIVE;1.0n;2.73 +23872-5;Heptacarboxylporphyrin I;MRat;XXX;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin I [Mass/time] in unspecified time Stool;Hepta-CP I ?Tm Stl-mRate;;ACTIVE;1.0n;2.19 +23873-3;Heptacarboxylporphyrin III;MRat;XXX;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin III [Mass/time] in unspecified time Stool;Hepta-CP3 ?Tm Stl-mRate;;ACTIVE;1.0n;2.19 +23874-1;Hexacarboxylporphyrin I;MRat;XXX;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin I [Mass/time] in unspecified time Stool;Hexa-CP I ?Tm Stl-mRate;;ACTIVE;1.0n;2.73 +23875-8;Hexacarboxylporphyrin III;MRat;XXX;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin III [Mass/time] in unspecified time Stool;Hexa-CPr3 ?Tm Stl-mRate;;ACTIVE;1.0n;2.73 +23876-6;HIV 1 RNA;ACnc;Pt;Plas;Qn;Probe.amp.sig;MICRO;1;HIV 1 RNA [Units/volume] (viral load) in Plasma by Probe with signal amplification;HIV1 RNA Plas Probe+sig amp-aCnc;;ACTIVE;1.0n;2.73 +23877-4;Anaplasma phagocytophilum Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Anaplasma phagocytophilum IgG Ab [Titer] in Serum by Immunofluorescence;A phagocytoph IgG Titr Ser IF;;ACTIVE;1.0n;2.73 +23878-2;Anaplasma phagocytophilum Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Anaplasma phagocytophilum IgM Ab [Titer] in Serum by Immunofluorescence;A phagocytoph IgM Titr Ser IF;;ACTIVE;1.0n;2.73 +2387-9;Glycerol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycerol [Mass/volume] in Serum or Plasma;Glycerol SerPl-mCnc;;ACTIVE;1.0;2.42 +23879-0;Immune complex;ACnc;Pt;Body fld;Qn;C1q binding assay;SERO;1;Immune complex [Units/volume] in Body fluid by C1q binding assay;IC Fld C1Q Bind-aCnc;;ACTIVE;1.0n;2.69 +23880-8;Immune complex;ACnc;Pt;Body fld;Qn;Raji cell assay;SERO;1;Immune complex [Units/volume] in Body fluid by Raji cell assay;IC Fld Raji Cell-aCnc;;ACTIVE;1.0n;2.69 +23881-6;Immune complex;MCnc;Pt;Body fld;Qn;PEG assay;SERO;1;Immune complex [Mass/volume] in Body fluid by Polyethylene glycol (PEG) assay;IC Fld PEG-mCnc;;ACTIVE;1.0n;2.42 +23882-4;Immune complex;ACnc;Pt;Body fld;Qn;Conglutinin assay;SERO;1;Immune complex [Units/volume] in Body fluid by Conglutinin assay;IC Fld Cong-aCnc;;ACTIVE;1.0n;2.69 +23883-2;Inhibin A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin A [Mass/volume] in Serum or Plasma;Inhibin A SerPl-mCnc;;ACTIVE;1.0n;2.73 +23884-0;Interleukin 2 receptor;PrThr;Pt;Tiss;Ord;ICA;CHEM;1;Interleukin 2 receptor [Presence] in Tissue by Immunocytochemical assay;Il2Recep Tiss Ql ICA;;ACTIVE;1.0n;2.56 +23885-7;Isoheptacarboxylporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Isoheptacarboxylporphyrin [Mass/time] in unspecified time Stool;Isohepta-CP ?Tm Stl-mRate;;ACTIVE;1.0n;2.73 +23886-5;Isohexacarboxylporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Isohexacarboxylporphyrin [Mass/time] in unspecified time Stool;Isohexa-CP ?Tm Stl-mRate;;ACTIVE;1.0n;2.73 +2388-7;Glycerol;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Glycerol [Mass/volume] in Serum or Plasma;Deprecated Glycerol Ser-mCnc;;DEPRECATED;1.0;2.36 +23887-3;Isopentacarboxylporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Isopentacarboxylporphyrin [Mass/time] in unspecified time Stool;Isopenta-CP ?Tm Stl-mRate;;ACTIVE;1.0n;2.73 +23888-1;Isopropanol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Isopropanol [Mass/volume] in Gastric fluid;Isopropanol Gast-mCnc;;ACTIVE;1.0n;2.42 +23889-9;Kanamycin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Kanamycin [Mass/volume] in Specimen;Kanamycin Spec-mCnc;;ACTIVE;1.0n;2.69 +23890-7;Lead;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Lead [Mass/mass] in Specimen;Lead Spec-mCnt;;ACTIVE;1.0n;2.69 +23891-5;Magnesium;SCnc;24H;Stool;Qn;;CHEM;1;Magnesium [Moles/volume] in 24 hour Stool;Magnesium 24h Stl-sCnc;;ACTIVE;1.0n;2.42 +23892-3;Magnesium;SRat;24H;Stool;Qn;;CHEM;1;Magnesium [Moles/time] in 24 hour Stool;Magnesium 24h Stl-sRate;;ACTIVE;1.0n;2.42 +23893-1;Malaoxon;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Malaoxon [Mass/volume] in Blood;Malaoxon Bld-mCnc;;ACTIVE;1.0n;2.34 +23894-9;Maple Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Maple IgE Ab RAST class [Presence] in Serum;Maple IgE RAST Ql;;ACTIVE;1.0n;2.73 +2389-5;Glycine;MCnc;Pt;CSF;Qn;;CHEM;1;Glycine [Mass/volume] in Cerebral spinal fluid;Glycine CSF-mCnc;;ACTIVE;1.0;2.73 +23895-6;Mattress dust Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mattress dust IgE Ab RAST class [Presence] in Serum;Mattress Dust IgE RAST Ql;;ACTIVE;1.0n;2.58 +23896-4;Mercury;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Mercury [Mass/mass] in Specimen;Mercury Spec-mCnt;;ACTIVE;1.0o;2.73 +23897-2;Mesothelial cells;PrThr;Pt;XXX;Ord;Microscopy.light;HEM/BC;1;Mesothelial cells [Presence] in Specimen by Light microscopy;Mesothl Cell Spec Ql Micro;;ACTIVE;1.0o;2.69 +23898-0;Mesothelial cells;PrThr;Pt;CSF;Ord;Microscopy.light;HEM/BC;1;Mesothelial cells [Presence] in Cerebral spinal fluid by Light microscopy;Mesothl Cell CSF Ql Micro;;ACTIVE;1.0o;2.56 +23899-8;Methanol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methanol [Mass/volume] in Gastric fluid;Methanol Gast-mCnc;;ACTIVE;1.0o;2.42 +23900-4;Methanol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Methanol [Mass/mass] in Tissue;Methanol Tiss-mCnt;;ACTIVE;1.0o;2.42 +23901-2;Microscopic observation;Prid;Pt;Body fld;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Body fluid by Wet preparation;Wet Prep Fld;;ACTIVE;1.0o;2.19 +23902-0;Monocyte+Macrophage/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Deprecated Monocytes+Macrophages/100 leukocytes in Body fluid by Manual count;Deprecated Hgb F Fr Fld Manual;;DEPRECATED;1.0o;2.36 +2390-3;Glycine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Glycine [Presence] in Serum or Plasma;Glycine SerPl Ql;;ACTIVE;1.0;2.56 +23903-8;Monocytes+Macrophages/100 leukocytes;NFr;Pt;XXX;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Specimen by Manual count;Monos+Macros/leuk NFr Spec Manual;;ACTIVE;1.0o;2.73 +23904-6;Monocytes+Macrophages/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Cerebral spinal fluid by Manual count;Monos+Macros/leuk NFr CSF Manual;;ACTIVE;1.0o;2.73 +23905-3;Mycophenolate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mycophenolate [Mass/volume] in Serum or Plasma;Mycophenolate SerPl-mCnc;;ACTIVE;1.0o;2.73 +23906-1;Mycophenolate glucuronide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mycophenolate glucuronide [Mass/volume] in Serum or Plasma;Mycophenolate-G SerPl-mCnc;;ACTIVE;1.0o;2.73 +23907-9;Myelin associated glycoprotein-sulfated glucuronic paragloboside Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein/Sulfated glucuronic paragloboside IgM Ab [Units/volume] in Serum;MAG/SGPG IgM Ser-aCnc;;ACTIVE;1.0o;2.69 +23908-7;Neisseria gonorrhoeae rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Neisseria gonorrhoeae DNA [Presence] in Unspecified specimen by DNA probe;Deprecated N gonorrhoea rRNA XXX Ql Prb;;DEPRECATED;1.0o;2.69 +23909-5;Trisetum paniceum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wild Oats IgE Ab RAST class [Presence] in Serum;Wild Oats IgE RAST Ql;;ACTIVE;1.0o;2.58 +23910-3;Osmotic fragility^0.0% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.0% sodium chloride;OF 0% NaCl NFr RBC;;ACTIVE;1.0o;2.70 +2391-1;Glycine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycine [Mass/volume] in Serum or Plasma;Glycine SerPl-mCnc;;ACTIVE;1.0;2.73 +23911-1;Osmotic fragility^0.30% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.30% sodium chloride;OF .30% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23912-9;Osmotic fragility^0.35% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.35% sodium chloride;OF .35% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23913-7;Osmotic fragility^0.40% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.40% sodium chloride;OF .40% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23914-5;Osmotic fragility^0.45% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.45% sodium chloride;OF .45% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23915-2;Osmotic fragility^0.50% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.50% sodium chloride;OF .50% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23916-0;Osmotic fragility^0.55% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.55% sodium chloride;OF .55% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23917-8;Osmotic fragility^0.60% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.60% sodium chloride;OF .60% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23918-6;Osmotic fragility^0.60% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.60% sodium chloride 24 hour 37 degree C incubation;OF .60% NaCl 24h Inc NFr RBC;;ACTIVE;1.0o;2.73 +23919-4;Osmotic fragility^0.65% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.65% sodium chloride;OF .65% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23920-2;Osmotic fragility^0.65% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.65% sodium chloride 24 hour 37 degree C incubation;OF .65% NaCl 24h Inc NFr RBC;;ACTIVE;1.0o;2.73 +23921-0;Osmotic fragility^0.75% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.75% sodium chloride 24 hour 37 degree C incubation;OF .75% NaCl 24h Inc NFr RBC;;ACTIVE;1.0o;2.73 +23922-8;Osmotic fragility^0.85% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.85% sodium chloride;OF .85% NaCl NFr RBC;;ACTIVE;1.0o;2.73 +23923-6;Parakeet droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parakeet droppings IgE Ab RAST class [Presence] in Serum;Parakeet Drop IgE RAST Ql;;ACTIVE;1.0o;2.58 +23924-4;Parakeet serum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parakeet serum IgE Ab RAST class [Presence] in Serum;Parakeet Serum IgE RAST Ql;;ACTIVE;1.0o;2.58 +23925-1;Penicillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Deprecated Penicillin [Susceptibility] by Gradient strip;Deprecated Penicillin Islt Grad strip;;DEPRECATED;1.0o;2.58 +23926-9;Pepper bell Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bell Pepper IgE Ab RAST class [Presence] in Serum;Bell Pepper IgE RAST Ql;;ACTIVE;1.0o;2.73 +23927-7;Pepper white Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Pepper IgE Ab RAST class [Presence] in Serum;White Pepper IgE RAST Ql;;ACTIVE;1.0o;2.73 +23928-5;Protoporphyrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Protoporphyrin [Mass/volume] in Serum or Plasma;Deprecated Protopor SerPl-mCnc;;DEPRECATED;1.0o;2.36 +2392-9;Glycine;MCnc;Pt;Urine;Qn;;CHEM;1;Glycine [Mass/volume] in Urine;Glycine Ur-mCnc;;ACTIVE;1.0;2.73 +23929-3;Ribonucleoprotein extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Ribonucleoprotein extractable nuclear IgG Ab [Presence] in Serum;ENA RNP IgG Ser Ql;;ACTIVE;1.0o;2.73 +23930-1;Salmonella typhi O D Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella typhi O D Ab [Titer] in Serum by Agglutination;S Typhi O D Ab Titr Ser Aggl;;ACTIVE;1.0o;2.73 +23931-9;Salmonella typhi O D;Titr;Pt;Ser;Qn;IF;MICRO;1;Salmonella typhi O D [Titer] in Serum by Immunofluorescence;S Typhi O D Titr Ser IF;;ACTIVE;1.0o;2.70 +23932-7;Squash zucchini Ab.IgE.RAST class;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Zucchini IgE Ab RAST class in Serum;Deprecated Zucchini IgE RAST Qn;;DEPRECATED;1.0o;2.69 +23933-5;Staphylococcus aureus enterotoxin B;PrThr;Pt;XXX;Ord;;MICRO;1;Staphylococcus aureus enterotoxin B [Presence] in Specimen;S aureus Etx B Spec Ql;;ACTIVE;1.0o;2.69 +23934-3;Staphylococcus aureus enterotoxin B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Staphylococcus aureus enterotoxin B Ab [Presence] in Serum;S aureus Etx B Ab Ser Ql;;ACTIVE;1.0o;2.73 +23935-0;Staphylococcus aureus toxic shock syndrome toxin 1;PrThr;Pt;XXX;Ord;;MICRO;1;Staphylococcus aureus toxic shock syndrome toxin 1 [Presence] in Specimen;S aureus TSST-1 Spec Ql;;ACTIVE;1.0o;2.69 +23936-8;Staphylococcus aureus toxic shock syndrome toxin 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Staphylococcus aureus toxic shock syndrome toxin 1 Ab [Presence] in Serum;S aureus TSST-1 Ab Ser Ql;;ACTIVE;1.0o;2.73 +2393-7;Glycine;MRat;24H;Urine;Qn;;CHEM;1;Glycine [Mass/time] in 24 hour Urine;Glycine 24h Ur-mRate;;ACTIVE;1.0;2.73 +23937-6;Trans nonachlor;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trans nonachlor [Mass/volume] in Serum or Plasma;Trans Nonachlor SerPl-mCnc;;ACTIVE;1.0o;2.73 +23938-4;Trapa natans Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Water Chestnut IgE Ab RAST class [Presence] in Serum;Water Chestnut IgE RAST Ql;;ACTIVE;1.0o;2.73 +23939-2;Xylose^1H post 5 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --1 hour post 5 g xylose PO;Xylose 1h p 5 g Xyl PO Bld-mCnc;;ACTIVE;1.0o;2.40 +239-4;Erythromycin+sulfiSOXAZOLE;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Erythromycin+Sulfisoxazole [Susceptibility] by Serum bactericidal titer;Erythro+Sulf Titr SBT;;ACTIVE;1.0;2.32 +23940-0;Xylose^1H post dose xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --1 hour post dose xylose PO;Xylose 1h p Xyl PO Bld-mCnc;;ACTIVE;1.0o;2.73 +23941-8;Xylose^2H post 25 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Deprecated Xylose [Mass/volume] in Blood --2 hours post 25 g xylose PO;Deprecated Xylose 2H p 25 g Xyl PO Bld-m;;DEPRECATED;1.0o;2.36 +23942-6;Xylose^2H post 5 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --2 hours post 5 g xylose PO;Xylose 2h p 5 g Xyl PO Bld-mCnc;;ACTIVE;1.0o;2.40 +23943-4;Xylose^2H post dose xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --2 hours post dose xylose PO;Xylose 2h p Xyl PO Bld-mCnc;;ACTIVE;1.0o;2.73 +23944-2;Xylose^1H post 25 g xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Deprecated Xylose [Molecules/volume] in Blood --1 hour post 25 g xylose PO;Deprecated Xylose 1H p 25 g Xyl PO Bld-s;;DEPRECATED;1.0o;2.36 +2394-5;Glycogen synthase;CCnc;Pt;Ser;Qn;;CHEM;1;Glycogen synthase [Enzymatic activity/volume] in Serum;Glycogen Synthase Ser-cCnc;;ACTIVE;1.0;2.68 +23945-9;Xylose^1H post 5 g xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --1 hour post 5 g xylose PO;Xylose 1h p 5 g Xyl PO Bld-sCnc;;ACTIVE;1.0o;2.40 +23946-7;Xylose^1H post dose xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --1 hour post dose xylose PO;Xylose 1h p Xyl PO Bld-sCnc;;ACTIVE;1.0o;2.40 +23947-5;Isoniazid;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Isoniazid [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Isoniazid Islt SlowMyco;;DEPRECATED;1.0o;2.36 +23948-3;Ofloxacin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ofloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ofloxacin Islt SlowMyco;;DEPRECATED;1.0o;2.36 +23949-1;rifAMPin;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated rifAMPin [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated rifAMPin Islt SlowMyco;;DEPRECATED;1.0o;2.36 +23950-9;Adenovirus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Adenovirus Ab [Titer] in Cerebral spinal fluid by Complement fixation;HAdV Ab Titr CSF CF;;ACTIVE;1.0o;2.73 +23951-7;Asialoganglioside GM1 Ab.IgG;Titr;Pt;CSF;Qn;IA;SERO;1;Asialoganglioside GM1 IgG Ab [Titer] in Cerebral spinal fluid by Immunoassay;GM1 Asialo IgG Titr CSF IA;;ACTIVE;1.0o;2.70 +2395-2;Glycolate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycolate [Mass/volume] in Serum or Plasma;Glycolate SerPl-mCnc;;DISCOURAGED;1.0;2.44 +23952-5;Asialoganglioside GM1 Ab.IgM;Titr;Pt;CSF;Qn;IA;SERO;1;Asialoganglioside GM1 IgM Ab [Titer] in Cerebral spinal fluid by Immunoassay;GM1 Asialo IgM Titr CSF IA;;ACTIVE;1.0o;2.70 +23953-3;Aspergillus sp Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Aspergillus sp Ab [Titer] in Cerebral spinal fluid by Complement fixation;Aspergillus Ab Titr CSF CF;;ACTIVE;1.0o;2.73 +23954-1;Bartonella henselae Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Bartonella henselae IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B henselae IgG Titr CSF IF;;ACTIVE;1.0o;2.73 +23955-8;Bartonella henselae Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Bartonella henselae IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B henselae IgM Titr CSF IF;;ACTIVE;1.0o;2.73 +23956-6;Aspergillus sp Ab;Titr;Pt;CSF;Qn;;MICRO;1;Aspergillus sp Ab [Titer] in Cerebral spinal fluid;Aspergillus Ab Titr CSF;;ACTIVE;1.0o;2.73 +23957-4;Bartonella henselae Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Bartonella henselae IgG Ab [Titer] in Cerebral spinal fluid;B henselae IgG Titr CSF;;ACTIVE;1.0o;2.70 +23958-2;Dengue virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Dengue virus IgG Ab [Units/volume] in Serum;DENV IgG Ser-aCnc;;ACTIVE;1.0o;2.69 +23959-0;Blastomyces dermatitidis Ab;Titr;Pt;CSF;Qn;;MICRO;1;Blastomyces dermatitidis Ab [Titer] in Cerebral spinal fluid;B dermat Ab Titr CSF;;ACTIVE;1.0o;2.70 +2396-0;Glycolate;MCnc;Pt;Urine;Qn;;CHEM;1;Glycolate [Mass/volume] in Urine;Glycolate Ur-mCnc;;DISCOURAGED;1.0;2.44 +23960-8;Bartonella quintana Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Bartonella quintana IgM Ab [Titer] in Cerebral spinal fluid;B quintana IgM Titr CSF;;ACTIVE;1.0o;2.70 +23961-6;Bartonella quintana Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Bartonella quintana IgG Ab [Titer] in Cerebral spinal fluid;B quintana IgG Titr CSF;;ACTIVE;1.0o;2.70 +23962-4;Bartonella henselae Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Bartonella henselae IgM Ab [Titer] in Cerebral spinal fluid;B henselae IgM Titr CSF;;ACTIVE;1.0o;2.70 +23963-2;Brucella abortus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Brucella abortus IgG Ab [Titer] in Cerebral spinal fluid;B abortus IgG Titr CSF;;ACTIVE;1.0o;2.70 +23964-0;Brucella abortus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Brucella abortus IgM Ab [Titer] in Cerebral spinal fluid;B abortus IgM Titr CSF;;ACTIVE;1.0o;2.70 +23965-7;Burkholderia pseudomallei Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Burkholderia pseudomallei IgG Ab [Titer] in Serum;B pseudomal IgG Titr Ser;;ACTIVE;1.0o;2.70 +23966-5;Borrelia burgdorferi Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Borrelia burgdorferi IgG Ab [Titer] in Cerebral spinal fluid;B burgdor IgG Titr CSF;;ACTIVE;1.0o;2.70 +23967-3;Chlamydia sp Ab;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydia sp Ab [Titer] in Cerebral spinal fluid;Chlamydia Ab Titr CSF;;ACTIVE;1.0o;2.70 +23968-1;Dengue virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Dengue virus IgM Ab [Units/volume] in Serum;DENV IgM Ser-aCnc;;ACTIVE;1.0o;2.69 +23969-9;Echovirus 7 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Echovirus 7 Ab [Titer] in Cerebral spinal fluid;ECV7 Ab Titr CSF;;ACTIVE;1.0o;2.73 +23970-7;Epstein Barr virus nuclear Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus nuclear IgG Ab [Titer] in Cerebral spinal fluid;EBV NA IgG Titr CSF;;ACTIVE;1.0o;2.70 +23971-5;Epstein Barr virus early Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus early IgG Ab [Titer] in Serum;EBV EA IgG Titr Ser;;ACTIVE;1.0o;2.73 +23972-3;Epstein Barr virus early Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus early IgG Ab [Titer] in Cerebral spinal fluid;EBV EA IgG Titr CSF;;ACTIVE;1.0o;2.70 +23973-1;Burkholderia pseudomallei Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Burkholderia pseudomallei IgM Ab [Titer] in Serum;B pseudomal IgM Titr Ser;;ACTIVE;1.0o;2.70 +23974-9;Bartonella quintana Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Bartonella quintana IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B quintana IgG Titr CSF IF;;ACTIVE;1.0o;2.70 +23975-6;Bartonella quintana Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Bartonella quintana IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B quintana IgM Titr CSF IF;;ACTIVE;1.0o;2.70 +23976-4;Blastomyces dermatitidis Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Blastomyces dermatitidis Ab [Titer] in Cerebral spinal fluid by Complement fixation;B dermat Ab Titr CSF CF;;ACTIVE;1.0o;2.73 +23977-2;Borrelia burgdorferi Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Borrelia burgdorferi Ag [Presence] in Specimen by Immunofluorescence;B burgdor Ag Spec Ql IF;;ACTIVE;1.0o;2.69 +2397-8;Glycoproteins;PrThr;Pt;Urine;Ord;;CHEM;1;Glycoproteins [Presence] in Urine;Glycoprots Ur Ql;;ACTIVE;1.0;2.56 +23978-0;Borrelia burgdorferi Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Borrelia burgdorferi IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B burgdor IgG Titr CSF IF;;ACTIVE;1.0o;2.73 +23979-8;Borrelia burgdorferi Ab.IgG band pattern;Imp;Pt;CSF;Nom;IB;MICRO;1;Borrelia burgdorferi IgG band pattern [Interpretation] in Cerebral spinal fluid by Immunoblot;B burgdor IgG Patrn CSF IB-Imp;;ACTIVE;1.0o;2.73 +23980-6;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Body fluid by Immunoblot;B burgdor IgG Fld Ql IB;;ACTIVE;1.0o;2.73 +23981-4;Borrelia burgdorferi Ab.IgG band pattern;Imp;Pt;Body fld;Nom;IB;MICRO;1;Borrelia burgdorferi IgG band pattern [Interpretation] in Body fluid by Immunoblot;B burgdor IgG Patrn Fld IB-Imp;;ACTIVE;1.0o;2.73 +23982-2;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Body fluid by Immunoblot;B burgdor IgM Fld Ql IB;;ACTIVE;1.0o;2.73 +23983-0;Borrelia burgdorferi Ab.IgM band pattern;Imp;Pt;Body fld;Nom;IB;MICRO;1;Borrelia burgdorferi IgM band pattern [Interpretation] in Body fluid by Immunoblot;B burgdor IgM Patrn Fld IB-Imp;;ACTIVE;1.0o;2.73 +23984-8;Borrelia burgdorferi Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Borrelia burgdorferi IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B burgdor IgM Titr CSF IF;;ACTIVE;1.0o;2.73 +23985-5;Borrelia burgdorferi Ab.IgM band pattern;Imp;Pt;CSF;Nom;IB;MICRO;1;Borrelia burgdorferi IgM band pattern [Interpretation] in Cerebral spinal fluid by Immunoblot;B burgdor IgM Patrn CSF IB-Imp;;ACTIVE;1.0o;2.73 +2398-6;Glycosaminoglycans;PrThr;Pt;Urine;Ord;;CHEM;1;Glycosaminoglycans [Presence] in Urine;GAG Ur Ql;;ACTIVE;1.0;2.73 +23986-3;Brucella abortus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Brucella abortus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B abortus IgG Titr CSF IF;;ACTIVE;1.0o;2.70 +23987-1;Brucella abortus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Brucella abortus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B abortus IgM Titr CSF IF;;ACTIVE;1.0o;2.70 +23988-9;Burkholderia pseudomallei Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Burkholderia pseudomallei IgG Ab [Titer] in Serum by Immunofluorescence;B pseudomal IgG Titr Ser IF;;ACTIVE;1.0o;2.70 +23989-7;Burkholderia pseudomallei Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Burkholderia pseudomallei IgM Ab [Titer] in Serum by Immunofluorescence;B pseudomal IgM Titr Ser IF;;ACTIVE;1.0o;2.70 +23990-5;Chlamydia sp Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Chlamydia sp Ab [Titer] in Cerebral spinal fluid by Complement fixation;Chlamydia Ab Titr CSF CF;;ACTIVE;1.0o;2.70 +23991-3;Dengue virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Dengue virus IgG Ab [Units/volume] in Serum by Immunoassay;DENV IgG Ser IA-aCnc;;ACTIVE;1.0o;2.73 +23992-1;Dengue virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Dengue virus IgM Ab [Units/volume] in Serum by Immunoassay;DENV IgM Ser IA-aCnc;;ACTIVE;1.0o;2.73 +23993-9;Echovirus 7 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Echovirus 7 Ab [Titer] in Cerebral spinal fluid by Complement fixation;ECV7 Ab Titr CSF CF;;ACTIVE;1.0o;2.73 +2399-4;Glycosaminoglycans;MCnc;Pt;Urine;Qn;;CHEM;1;Glycosaminoglycans [Mass/volume] in Urine;GAG Ur-mCnc;;ACTIVE;1.0;2.73 +23994-7;Epstein Barr virus nuclear Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Epstein Barr virus nuclear IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;EBV NA IgG Titr CSF IF;;ACTIVE;1.0o;2.70 +23995-4;Epstein Barr virus early Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus early IgG Ab [Titer] in Serum by Immunofluorescence;EBV EA IgG Titr Ser IF;;ACTIVE;1.0o;2.73 +23996-2;Epstein Barr virus early Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Epstein Barr virus early IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;EBV EA IgG Titr CSF IF;;ACTIVE;1.0o;2.73 +23997-0;Ganglioside GD1a Ab.IgG;Titr;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1a IgG Ab [Titer] in Cerebral spinal fluid by Immunoassay;GD1a Gangl IgG Titr CSF IA;;ACTIVE;1.0o;2.70 +23998-8;Ganglioside GD1a Ab.IgM;Titr;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1a IgM Ab [Titer] in Cerebral spinal fluid by Immunoassay;GD1a Gangl IgM Titr CSF IA;;ACTIVE;1.0o;2.70 +23999-6;Ganglioside GD1b Ab.IgG;Titr;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1b IgG Ab [Titer] in Cerebral spinal fluid by Immunoassay;GD1b Gangl IgG Titr CSF IA;;ACTIVE;1.0o;2.70 +24-0;Amphotericin B;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Amphotericin B [Susceptibility] by Minimum inhibitory concentration (MIC);Amphotericin B Islt MIC;;ACTIVE;1.0;2.73 +2400-0;Guanine deaminase;CCnc;Pt;Bld;Qn;;CHEM;1;Guanine deaminase [Enzymatic activity/volume] in Blood;Guanine Deaminase Bld-cCnc;;ACTIVE;1.0;2.68 +24000-2;Ganglioside GD1b Ab.IgM;Titr;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1b IgM Ab [Titer] in Cerebral spinal fluid by Immunoassay;GD1b Gangl IgM Titr CSF IA;;ACTIVE;1.0o;2.70 +24001-0;Ganglioside GQ1b Ab.IgG;Titr;Pt;CSF;Qn;IA;SERO;1;Ganglioside GQ1b IgG Ab [Titer] in Cerebral spinal fluid by Immunoassay;GQ1b Gangl IgG Titr CSF IA;;ACTIVE;1.0o;2.70 +24002-8;Microscopic observation;Prid;Pt;Bronchial;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Bronchial specimen by Acid fast stain;Acid fast Stn Bronch;;ACTIVE;1.0o;2.73 +24003-6;Brucella sp identified;Prid;Pt;Bone mar;Nom;Organism specific culture;MICRO;1;Brucella sp identified in Bone marrow by Organism specific culture;Brucella Mar Cult;;ACTIVE;1.0o;2.19 +24004-4;Chlamydophila pneumoniae Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila pneumoniae IgM Ab [Presence] in Serum;C pneum IgM Ser Ql;;ACTIVE;1.0o;2.73 +24005-1;Chlamydia sp identified;Prid;Pt;Bronchial;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Bronchial specimen by Organism specific culture;Chlamydia Bronch Cult;;ACTIVE;1.0o;2.19 +24006-9;Eastern equine encephalitis virus Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Eastern equine encephalitis virus IgG and IgM [Interpretation] in Serum;EEEV IgG+IgM Ser-Imp;;ACTIVE;1.0o;2.73 +24007-7;Epstein Barr virus early Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus early IgG Ab [Units/volume] in Serum;EBV EA IgG Ser-aCnc;;ACTIVE;1.0o;2.73 +24008-5;Echovirus 14 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 14 Ab [Titer] in Serum by Complement fixation;ECV14 Ab Titr Ser CF;;ACTIVE;1.0o;2.70 +24009-3;Fungus identified;Prid;Pt;Bronchial;Nom;Culture;MICRO;1;Fungus identified in Bronchial specimen by Culture;Fungus Bronch Cult;;ACTIVE;1.0o;2.73 +24010-1;Haemophilus influenzae B Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Haemophilus influenzae B Ag [Presence] in Cerebral spinal fluid;Haem influ B Ag CSF Ql;;ACTIVE;1.0o;2.56 +24011-9;Hepatitis C virus Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Hepatitis C virus Ab band pattern [Interpretation] in Serum by Immunoblot;HCV Ab Patrn Ser IB-Imp;;ACTIVE;1.0o;2.73 +24012-7;HIV 1 Ag;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 Ag [Presence] in Serum;HIV1 Ag Ser Ql;;ACTIVE;1.0o;2.73 +24013-5;HIV 1 RNA;Imp;Pt;Ser;Nom;;MICRO;1;HIV 1 RNA [Interpretation] in Serum;HIV1 RNA Ser-Imp;;ACTIVE;1.0o;2.73 +24014-3;Herpes simplex virus 2 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Titer] in Serum;HSV2 IgG Titr Ser;;ACTIVE;1.0o;2.73 +24015-0;Influenza virus A+B Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Influenza virus A+B Ag [Presence] in Specimen;FLUAV+FLUBV Ag Spec Ql;;ACTIVE;1.0o;2.73 +24016-8;La Crosse virus Ab;Imp;Pt;Ser;Nom;;MICRO;1;La Crosse virus Ab [Interpretation] in Serum;LACV Ab Ser-Imp;;ACTIVE;1.0o;2.73 +24017-6;Neisseria meningitidis serogroup B Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Cerebral spinal fluid;N men sg B Ag CSF Ql;;ACTIVE;1.0o;2.64 +2401-8;Guanine deaminase;CCnc;Pt;Ser;Qn;;CHEM;1;Guanine deaminase [Enzymatic activity/volume] in Serum;Guanine Deaminase Ser-cCnc;;ACTIVE;1.0;2.68 +24018-4;Neisseria meningitidis serogroup B Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Urine;N men sg B Ag Ur Ql;;ACTIVE;1.0o;2.73 +24019-2;Neisseria meningitdis B Ag;ACnc;Pt;Urine;Ord;;MICRO;1;Deprecated Neisseria meningitidis B Ag [Presence] in Urine;Deprecated N men B Ag Ur Ql;;DEPRECATED;1.0o;2.36 +240-2;Ethambutol;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ethambutol [Susceptibility] by Minimum lethal concentration (MLC);Ethambutol Islt MLC;;ACTIVE;1.0;2.19 +24020-0;Streptococcus agalactiae Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Streptococcus agalactiae Ag [Presence] in Urine;Gp B Strep Ag Ur Ql;;ACTIVE;1.0o;2.73 +24021-8;Streptococcus pneumoniae 12 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Mass/volume] in Serum;Deprecated S pneum12 Ab Ser-mCnc;;DEPRECATED;1.0o;2.70 +24022-6;Streptococcus pneumoniae 14 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Mass/volume] in Serum;Deprecated S pneum14 Ab Ser-mCnc;;DEPRECATED;1.0o;2.70 +24023-4;Streptococcus pneumoniae 3 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Mass/volume] in Serum;Deprecated S pneum3 Ab Ser-mCnc;;DEPRECATED;1.0o;2.70 +24025-9;Streptococcus pneumoniae 8 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Mass/volume] in Serum;Deprecated S pneum8 Ab Ser-mCnc;;DEPRECATED;1.0o;2.70 +2402-6;Guanosine monophosphate.cyclic;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Guanosine monophosphate.cyclic [Mass/volume] in Serum or Plasma;cGMP SerPl-mCnc;;ACTIVE;1.0;2.34 +24027-5;Streptococcus pneumoniae Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Urine;S pneum Ag Ur Ql;;ACTIVE;1.0o;2.73 +24028-3;Toxocara canis Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Toxocara canis IgA Ab [Presence] in Serum;T canis IgA Ser Ql;;ACTIVE;1.0o;2.56 +24029-1;Toxocara canis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Toxocara canis IgG Ab [Presence] in Serum;T canis IgG Ser Ql;;ACTIVE;1.0o;2.56 +24030-9;Toxocara canis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Toxocara canis IgM Ab [Presence] in Serum;T canis IgM Ser Ql;;ACTIVE;1.0o;2.56 +24031-7;14-3-3 Ag;PrThr;Pt;CSF;Ord;IB;SERO;1;14-3-3 Ag [Presence] in Cerebral spinal fluid by Immunoblot;14-3-3 Ag CSF Ql IB;;ACTIVE;1.0o;2.73 +24032-5;Rifabutin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Rifabutin [Mass/volume] in Serum or Plasma;Rifabutin SerPl-mCnc;;ACTIVE;1.0o;2.42 +24033-3;Bordetella pertussis.filamentous hemagglutinin Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgG Ab [Units/volume] in Serum by Immunoassay;B pert FHA IgG Ser IA-aCnc;;ACTIVE;1.0o;2.73 +2403-4;Hemopexin;MCnc;Pt;Ser;Qn;;CHEM;1;Hemopexin [Mass/volume] in Serum;Hemopexin Ser-mCnc;;ACTIVE;1.0;2.34 +24034-1;Bordetella pertussis.filamentous hemagglutinin Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgA Ab [Units/volume] in Serum by Immunoassay;B pert FHA IgA Ser IA-aCnc;;ACTIVE;1.0o;2.73 +24035-8;Bordetella pertussis.filamentous hemagglutinin Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgM Ab [Units/volume] in Serum by Immunoassay;B pert FHA IgM Ser IA-aCnc;;ACTIVE;1.0o;2.68 +24036-6;Borrelia sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Borrelia sp Ag [Presence] in Specimen by Immunofluorescence;Borrelia Ag Spec Ql IF;;ACTIVE;1.0o;2.69 +24037-4;Coccidioides immitis rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Coccidioides immitis rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated C immitis rRNA XXX Ql Prb;;DEPRECATED;1.0o;2.69 +24038-2;Cryoglobulin type;Prid;Pt;Ser;Nom;Electrophoresis;CHEM;1;Cryoglobulin type [Identifier] in Serum by Electrophoresis;Cryoglob Typ Ser Elph;;ACTIVE;1.0o;2.21 +24039-0;Taenia solium larva Ab.IgG band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Taenia solium larva IgG band pattern [Interpretation] in Serum by Immunoblot;T sol lar IgG Patrn Ser IB-Imp;;ACTIVE;1.0o;2.73 +24040-8;Taenia solium larva Ab.IgG band pattern;Imp;Pt;CSF;Nom;IB;MICRO;1;Taenia solium larva IgG band pattern [Interpretation] in Cerebral spinal fluid by Immunoblot;T sol lar IgG Patrn CSF IB-Imp;;ACTIVE;1.0o;2.67 +24041-6;Cytomegalovirus DNA;ACnc;Pt;XXX;Qn;Probe.amp.sig;MICRO;1;Cytomegalovirus DNA [Units/volume] (viral load) in Specimen by Probe with signal amplification;CMV DNA Spec Probe+sig amp-aCnc;;ACTIVE;1.0o;2.73 +2404-2;Hemopexin;MCnc;Pt;Urine;Qn;;CHEM;1;Hemopexin [Mass/volume] in Urine;Hemopexin Ur-mCnc;;ACTIVE;1.0;2.42 +24042-4;Ehrlichia chaffeensis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ehrlichia chaffeensis DNA [Presence] in Specimen by NAA with probe detection;E chaffeensis DNA Spec Ql NAA+probe;;ACTIVE;1.0o;2.73 +24043-2;Acetyl-CoA:glucosamine acetyltransferase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Acetyl-CoA:glucosamine acetyltransferase [Enzymatic activity/mass] in Fibroblast;AcCoA:Glucosamine AT Fib-cCnt;;ACTIVE;1.0o;2.70 +24044-0;Acetyl-CoA:glucosamine acetyltransferase;CCnt;Pt;WBC;Qn;;CHEM;1;Acetyl-CoA:glucosamine acetyltransferase [Enzymatic activity/mass] in Leukocytes;AcCoA:Glucosamine AT WBC-cCnt;;ACTIVE;1.0o;2.70 +24045-7;Alpha fucosidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha fucosidase [Enzymatic activity/volume] in Serum or Plasma;A-Fucosidase SerPl-cCnc;;ACTIVE;1.0o;2.70 +24046-5;Alpha fucosidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alpha fucosidase [Enzymatic activity/mass] in Fibroblast;A-Fucosidase Fib-cCnt;;ACTIVE;1.0o;2.70 +24047-3;Alpha fucosidase;CCnt;Pt;WBC;Qn;;CHEM;1;Alpha fucosidase [Enzymatic activity/mass] in Leukocytes;A-Fucosidase WBC-cCnt;;ACTIVE;1.0o;2.70 +24048-1;Alpha galactosidase A;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alpha galactosidase A [Enzymatic activity/mass] in Fibroblast;A-Galactosidase A Fib-cCnt;;ACTIVE;1.0o;2.70 +24049-9;Alpha galactosidase A;CCnt;Pt;WBC;Qn;;CHEM;1;Alpha galactosidase A [Enzymatic activity/mass] in Leukocytes;A-Galactosidase A WBC-cCnt;;ACTIVE;1.0o;2.73 +24050-7;Acid alpha glucosidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/mass] in Fibroblast;Acid A-Glucosidase Fib-cCnt;;ACTIVE;1.0o;2.70 +24051-5;Acid alpha glucosidase;CCnt;Pt;WBC;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/mass] in Leukocytes;Acid A-Glucosidase WBC-cCnt;;ACTIVE;1.0o;2.73 +24052-3;Alpha mannosidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alpha mannosidase [Enzymatic activity/mass] in Fibroblast;A-Mannosidase Fib-cCnt;;ACTIVE;1.0o;2.70 +24053-1;Alpha mannosidase;CCnt;Pt;WBC;Qn;;CHEM;1;Alpha mannosidase [Enzymatic activity/mass] in Leukocytes;A-Mannosidase WBC-cCnt;;ACTIVE;1.0o;2.70 +24054-9;Alpha-N-acetylgalactosaminidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alpha-N-acetylgalactosaminidase [Enzymatic activity/mass] in Fibroblast;A-NAGA Fib-cCnt;;ACTIVE;1.0o;2.70 +24055-6;Alpha-N-acetylgalactosaminidase;CCnt;Pt;WBC;Qn;;CHEM;1;Alpha-N-acetylgalactosaminidase [Enzymatic activity/mass] in Leukocytes;A-NAGA WBC-cCnt;;ACTIVE;1.0o;2.70 +24056-4;Alpha-L-iduronidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alpha-L-iduronidase [Enzymatic activity/mass] in Fibroblast;A-L-Iduronidase Fib-cCnt;;ACTIVE;1.0o;2.70 +24057-2;Alpha-L-iduronidase;CCnt;Pt;WBC;Qn;;CHEM;1;Alpha-L-iduronidase [Enzymatic activity/mass] in Leukocytes;A-L-Iduronidase WBC-cCnt;;ACTIVE;1.0o;2.70 +24058-0;Aspartylglucosaminidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Aspartylglucosaminidase [Enzymatic activity/mass] in Fibroblast;AGA Fib-cCnt;;ACTIVE;1.0o;2.70 +2405-9;Heparan sulfate;PrThr;Pt;Urine;Ord;;CHEM;1;Heparan sulfate [Presence] in Urine;Heparan sulfate Ur Ql;;ACTIVE;1.0;2.56 +24059-8;Aspartylglucosaminidase;CCnt;Pt;WBC;Qn;;CHEM;1;Aspartylglucosaminidase [Enzymatic activity/mass] in Leukocytes;AGA WBC-cCnt;;ACTIVE;1.0o;2.70 +24060-6;Beta galactosidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/mass] in Fibroblast;B-Galactosidase Fib-cCnt;;ACTIVE;1.0o;2.70 +24061-4;Beta galactosidase;CCnt;Pt;WBC;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/mass] in Leukocytes;B-Galactosidase WBC-cCnt;;ACTIVE;1.0o;2.73 +24064-8;Beta glucuronidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/mass] in Fibroblast;B-Glucuronidase Fib-cCnt;;ACTIVE;1.0o;2.70 +24065-5;Beta glucuronidase;CCnt;Pt;WBC;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/mass] in Leukocytes;B-Glucuronidase WBC-cCnt;;ACTIVE;1.0o;2.70 +24066-3;Beta mannosidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta mannosidase [Enzymatic activity/volume] in Serum or Plasma;B-Mannosidase SerPl-cCnc;;ACTIVE;1.0o;2.70 +2406-7;Heparan sulfate;MCnc;Pt;Urine;Qn;;CHEM;1;Heparan sulfate [Mass/volume] in Urine;Heparan sulfate Ur-mCnc;;ACTIVE;1.0;2.42 +24067-1;Beta mannosidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Beta mannosidase [Enzymatic activity/mass] in Fibroblast;B-Mannosidase Fib-cCnt;;ACTIVE;1.0o;2.70 +24068-9;Beta mannosidase;CCnt;Pt;WBC;Qn;;CHEM;1;Beta mannosidase [Enzymatic activity/mass] in Leukocytes;B-Mannosidase WBC-cCnt;;ACTIVE;1.0o;2.70 +24069-7;Beta N-acetylhexosaminidase.B/Beta N-acetyl hexosaminidase.total;CFr;Pt;Ser;Qn;;CHEM;1;Deprecated Beta-N-acetylhexosaminidase.B/Beta-n-acetylhexosaminidase.total in Serum;Deprecated Hexosaminidase B Fr Ser;;DEPRECATED;1.0o;2.46 +24070-5;Beta-N-acetylhexosaminidase.B/Beta-N-acetylhexosaminidase.total;CFr;Pt;Fibroblasts;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B/Beta-n-acetylhexosaminidase.total in Fibroblast;Hexosaminidase B CFr Fib;;ACTIVE;1.0o;2.70 +24071-3;Beta-N-acetylhexosaminidase.B/Beta-N-acetylhexosaminidase.total;CFr;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B/Beta-n-acetylhexosaminidase.total in Leukocytes;Hexosaminidase B CFr WBC;;ACTIVE;1.0o;2.70 +24072-1;Beta-N-acetylhexosaminidase.B;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B [Enzymatic activity/mass] in Fibroblast;Hexosaminidase B Fib-cCnt;;ACTIVE;1.0o;2.70 +24073-9;Beta-N-acetylhexosaminidase.B;CCnt;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B [Enzymatic activity/mass] in Leukocytes;Hexosaminidase B WBC-cCnt;;ACTIVE;1.0o;2.70 +24074-7;Beta-N-acetylhexosaminidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/mass] in Fibroblast;B-NAH Fib-cCnt;;ACTIVE;1.0o;2.70 +2407-5;Heptacarboxylporphyrin;MCnc;Pt;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/volume] in Urine;Hepta-CP Ur-mCnc;;ACTIVE;1.0;2.73 +24075-4;Beta-N-acetylhexosaminidase;CCnt;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/mass] in Leukocytes;B-NAH WBC-cCnt;;ACTIVE;1.0o;2.73 +24076-2;Cerebroside sulfatase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cerebroside sulfatase [Enzymatic activity/volume] in Serum or Plasma;Arylsulfatase A SerPl-cCnc;;ACTIVE;1.0o;2.70 +24077-0;Cerebroside sulfatase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Cerebroside sulfatase [Enzymatic activity/mass] in Fibroblast;Arylsulfatase A Fib-cCnt;;ACTIVE;1.0o;2.70 +24078-8;Cerebroside sulfatase;CCnt;Pt;WBC;Qn;;CHEM;1;Cerebroside sulfatase [Enzymatic activity/mass] in Leukocytes;Arylsulfatase A WBC-cCnt;;ACTIVE;1.0o;2.73 +24079-6;Cholesterol esterase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Cholesterol esterase [Enzymatic activity/mass] in Fibroblast;Cholest Est Fib-cCnt;;ACTIVE;1.0o;2.70 +24080-4;Cholesterol esterase;CCnt;Pt;WBC;Qn;;CHEM;1;Cholesterol esterase [Enzymatic activity/mass] in Leukocytes;Cholest Est WBC-cCnt;;ACTIVE;1.0o;2.70 +24081-2;Dihydroxyacetone phosphate acylcoa acyl transferase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Dihydroxyacetone phosphate acylcoa acyl transferase [Enzymatic activity/mass] in Fibroblast;DHAP AcylCoA AT Fib-cCnt;;ACTIVE;1.0o;2.70 +24082-0;Galactose 1 phosphate uridyl transferase;CCnt;Pt;RBC;Qn;;CHEM;1;Galactose 1 phosphate uridyl transferase [Enzymatic activity/mass] in Red Blood Cells;Gal1PUT RBC-cCnt;;ACTIVE;1.0o;2.73 +2408-3;Hexachlorophene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hexachlorophene [Mass/volume] in Blood;HCP Bld-mCnc;;ACTIVE;1.0;2.73 +24083-8;Galactosylceramidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Galactosylceramidase [Enzymatic activity/mass] in Fibroblast;GALC Fib-cCnt;;ACTIVE;1.0o;2.70 +24084-6;Galactosylceramidase;CCnt;Pt;WBC;Qn;;CHEM;1;Galactosylceramidase [Enzymatic activity/mass] in Leukocytes;GALC WBC-cCnt;;ACTIVE;1.0o;2.73 +24085-3;Heparan-N-sulfatase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Heparan-N-sulfatase [Enzymatic activity/mass] in Fibroblast;Heparan-N-Sulfatase Fib-cCnt;;ACTIVE;1.0o;2.70 +24086-1;Heparan-N-sulfatase;CCnt;Pt;WBC;Qn;;CHEM;1;Heparan-N-sulfatase [Enzymatic activity/mass] in Leukocytes;Heparan-N-Sulfatase WBC-cCnt;;ACTIVE;1.0o;2.70 +24087-9;Iduronate-2-Sulfatase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iduronate-2-Sulfatase [Enzymatic activity/volume] in Serum or Plasma;Iduronate2Sulfatas SerPl-cCnc;;ACTIVE;1.0o;2.70 +24088-7;Iduronate-2-Sulfatase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Iduronate-2-Sulfatase [Enzymatic activity/mass] in Fibroblast;Iduronate2Sulfatas Fib-cCnt;;ACTIVE;1.0o;2.70 +24089-5;Iduronate-2-Sulfatase;CCnt;Pt;WBC;Qn;;CHEM;1;Iduronate-2-Sulfatase [Enzymatic activity/mass] in Leukocytes;Iduronate2Sulfatas WBC-cCnt;;ACTIVE;1.0o;2.70 +24090-3;Alpha-N-acetylglucosaminidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Alpha-N-acetylglucosaminidase [Enzymatic activity/volume] in Serum or Plasma;Deprecated A-NAG SerPl-cCnc;;DEPRECATED;1.0o;2.70 +2409-1;Hexokinase;CCnc;Pt;Plas;Qn;;CHEM;1;Hexokinase [Enzymatic activity/volume] in Plasma;Hexokinase Plas-cCnc;;ACTIVE;1.0;2.68 +24091-1;Alpha-N-acetylglucosaminidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alpha-N-acetylglucosaminidase [Enzymatic activity/mass] in Fibroblast;A-NAG Fib-cCnt;;ACTIVE;1.0o;2.70 +24092-9;Alpha-N-acetylglucosaminidase;CCnt;Pt;WBC;Qn;;CHEM;1;Alpha-N-acetylglucosaminidase [Enzymatic activity/mass] in Leukocytes;A-NAG WBC-cCnt;;ACTIVE;1.0o;2.70 +24093-7;N-Acetylgalactosamine-4-Sulfatase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/mass] in Fibroblast;Arylsulfatase B Fib-cCnt;;ACTIVE;1.0o;2.70 +24094-5;N-Acetylgalactosamine-4-Sulfatase;CCnt;Pt;WBC;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/mass] in Leukocytes;Arylsulfatase B WBC-cCnt;;ACTIVE;1.0o;2.70 +24095-2;N-Acetylgalactosamine-6-Sulfatase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;N-Acetylgalactosamine-6-Sulfatase [Enzymatic activity/mass] in Fibroblast;GALNS Fib-cCnt;;ACTIVE;1.0o;2.70 +24096-0;N-Acetylgalactosamine-6-Sulfatase;CCnt;Pt;WBC;Qn;;CHEM;1;N-Acetylgalactosamine-6-Sulfatase [Enzymatic activity/mass] in Leukocytes;GALNS WBC-cCnt;;ACTIVE;1.0o;2.70 +24097-8;N-Acetylglucosamine-6-Sulfatase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;N-Acetylglucosamine-6-Sulfatase [Enzymatic activity/mass] in Fibroblast;NAG6Sulfatase Fib-cCnt;;ACTIVE;1.0o;2.70 +24098-6;N-Acetylglucosamine-6-Sulfatase;CCnt;Pt;WBC;Qn;;CHEM;1;N-Acetylglucosamine-6-Sulfatase [Enzymatic activity/mass] in Leukocytes;NAG6Sulfatase WBC-cCnt;;ACTIVE;1.0o;2.70 +24099-4;Sialidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Sialidase [Enzymatic activity/mass] in Fibroblast;Sialidase Fib-cCnt;;ACTIVE;1.0o;2.70 +241-0;Ethambutol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC);Ethambutol Islt MIC;;ACTIVE;1.0;2.73 +24100-0;Acid sphingomyelinase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Acid sphingomyelinase [Enzymatic activity/mass] in Fibroblast;Acid sphingomyelinase Fib-cCnt;;ACTIVE;1.0o;2.70 +24101-8;Acid sphingomyelinase;CCnt;Pt;WBC;Qn;;CHEM;1;Acid sphingomyelinase [Enzymatic activity/mass] in Leukocytes;Acid sphingomyelinase WBC-cCnt;;ACTIVE;1.0o;2.70 +24102-6;Corynebacterium spp toxin;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Corynebacterium toxin [Presence] in Specimen by Immune diffusion (ID);Corynebacterium Tox Spec Ql ID;;ACTIVE;1.0o;2.69 +24103-4;Plasma cells;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Plasma cells [#/volume] in Blood by Manual count;Plasma Cells # Bld Manual;;ACTIVE;1.0o;2.73 +24104-2;Lymphoma cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphoma cells/100 leukocytes in Blood by Manual count;Lymphoma Cells/leuk NFr Bld Manual;;ACTIVE;1.0o;2.73 +24105-9;Lymphoma cells;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphoma cells [#/volume] in Blood by Manual count;Lymphoma Cells # Bld Manual;;ACTIVE;1.0o;2.73 +24106-7;Hairy cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Hairy cells/100 leukocytes in Blood by Manual count;Hairy Cells/leuk NFr Bld Manual;;ACTIVE;1.0o;2.70 +24107-5;Hairy cells;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Hairy cells [#/volume] in Blood by Manual count;Hairy Cells # Bld Manual;;ACTIVE;1.0o;2.40 +24108-3;Cancer Ag 19-9;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag 19-9 [Units/volume] in Serum or Plasma;Cancer Ag19-9 SerPl-aCnc;;ACTIVE;1.0o;2.73 +2410-9;Hexokinase;CCnc;Pt;RBC;Qn;;CHEM;1;Hexokinase [Enzymatic activity/volume] in Red Blood Cells;Hexokinase RBC-cCnc;;ACTIVE;1.0;2.44 +24109-1;Progesterone;SCnc;Pt;Saliva;Qn;;CHEM;1;Progesterone [Moles/volume] in Saliva (oral fluid);Progest Sal-sCnc;;ACTIVE;1.0o;2.42 +24110-9;Treponema pallidum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Treponema pallidum Ab [Presence] in Serum by Immunoassay;T pallidum Ab Ser Ql IA;;ACTIVE;1.0o;2.73 +24111-7;Neisseria gonorrhoeae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection;N gonorrhoea DNA Spec Ql NAA+probe;;ACTIVE;1.0o;2.73 +24112-5;Trichomonas vaginalis rRNA;ACnc;Pt;Genital;Ord;Probe;MICRO;1;Deprecated Trichomonas vaginalis rRNA [Presence] in Genital specimen by DNA probe;Deprecated T vaginalis rRNA Genital Ql P;;DEPRECATED;1.0o;2.36 +24113-3;Hepatitis B virus core Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis B virus core IgM Ab [Presence] in Serum or Plasma by Immunoassay;HBV core IgM SerPl Ql IA;;ACTIVE;1.0o;2.73 +24114-1;Epstein Barr virus capsid Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epstein Barr virus capsid IgG Ab [Presence] in Serum by Immunoassay;EBV VCA IgG Ser Ql IA;;ACTIVE;1.0o;2.73 +24115-8;Epstein Barr virus capsid Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epstein Barr virus capsid IgM Ab [Presence] in Serum by Immunoassay;EBV VCA IgM Ser Ql IA;;ACTIVE;1.0o;2.73 +24116-6;Rubella virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Rubella virus IgM Ab [Presence] in Serum or Plasma by Immunoassay;RUBV IgM SerPl Ql IA;;ACTIVE;1.0o;2.73 +2411-7;Hexokinase 1/Hexokinase.total;CFr;Pt;RBC;Qn;;CHEM;1;Hexokinase 1/Hexokinase.total in Red Blood Cells;Hexokinase1 CFr RBC;;ACTIVE;1.0;2.73 +24117-4;Ross river virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ross River virus IgG Ab [Presence] in Serum by Immunoassay;RRV IgG Ser Ql IA;;ACTIVE;1.0o;2.56 +24118-2;Barmah forest virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Barmah forest virus IgM Ab [Presence] in Serum by Immunoassay;BFV IgM Ser Ql IA;;ACTIVE;1.0o;2.56 +24119-0;Cytomegalovirus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Cytomegalovirus IgM Ab [Presence] in Serum or Plasma by Immunoassay;CMV IgM SerPl Ql IA;;ACTIVE;1.0o;2.73 +24120-8;Ross river virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ross River virus IgM Ab [Presence] in Serum by Immunoassay;RRV IgM Ser Ql IA;;ACTIVE;1.0o;2.56 +24121-6;Barmah forest virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Barmah forest virus IgG Ab [Presence] in Serum by Immunoassay;BFV IgG Ser Ql IA;;ACTIVE;1.0o;2.56 +24122-4;Leukocytes;NCnc;Pt;Urine;Qn;Manual count;UA;1;Leukocytes [#/volume] in Urine by Manual count;WBC # Ur Manual;;ACTIVE;1.0o;2.73 +24123-2;Epithelial cells;NCnc;Pt;Urine;Qn;Manual count;UA;1;Epithelial cells [#/volume] in Urine by Manual count;Epi Cells # Ur Manual;;ACTIVE;1.0o;2.73 +24124-0;Casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Casts [Presence] in Urine sediment by Light microscopy;Casts UrnS Ql Micro;;ACTIVE;1.0o;2.73 +2412-5;Hexokinase 3/Hexokinase.total;CFr;Pt;RBC;Qn;;CHEM;1;Hexokinase 3/Hexokinase.total in Red Blood Cells;Hexokinase3 CFr RBC;;ACTIVE;1.0;2.70 +24125-7;Androgen.free index;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Androgen free Index in Serum or Plasma;Androgen FAI SerPl-sRto;;ACTIVE;1.0o;2.73 +24126-5;Adenovirus type;Prid;Pt;XXX;Nom;Neut;MICRO;1;Adenovirus type [Identifier] in Specimen by Neutralization test;Adenovirus Typ Spec Nt;;ACTIVE;1.0o;2.69 +24127-3;Bordetella pertussis.pertussis toxin Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis.pertussis toxin IgG Ab [Units/volume] in Serum by Immunoassay;B pert.PT IgG Ser IA-aCnc;;ACTIVE;1.0o;2.73 +24128-1;Bordetella pertussis.pertussis toxin Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis.pertussis toxin IgA Ab [Units/volume] in Serum by Immunoassay;B pert.PT IgA Ser IA-aCnc;;ACTIVE;1.0o;2.73 +24129-9;Bordetella pertussis.pertussis toxin Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis.pertussis toxin IgM Ab [Units/volume] in Serum by Immunoassay;B pert.PT IgM Ser IA-aCnc;;ACTIVE;1.0o;2.73 +24130-7;Bordetella pertussis.secretory Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bordetella pertussis secretory IgA Ab [Presence] in Specimen by Immunoassay;B pert secr IgA Spec Ql IA;;ACTIVE;1.0o;2.69 +24131-5;(Avena sativa+Fagopyrum esculentum+Sesamum indicum+Triticum aestivum+Zea mays) Ab.IgE;ACnc;Pt;Ser;Ord;Multidisk;ALLERGY;1;Deprecated Food Allergen Mix 3 (Oat+Buckwheat+Sesame seed+Wheat+Corn) IgE Ab [Presence] in Serum by Multiple allergens;Deprecated Food Allerg Mix3 IgE Ql;;DEPRECATED;1.0o;2.36 +24132-3;(Anthoxanthum odoratum+Lolium perenne+Phragmites communis+Secale cereale+Holcus lanatus) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix B (Sweet vernal grass+Perennial rye grass+Common reed+Rye+Velvet grass) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix B IgE Ql;;ACTIVE;1.0o;2.56 +2413-3;Hippuran renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Hippuran renal clearance in 24 hour Urine and Serum or Plasma;Hippuran Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +24133-1;(Alnus incana+Corylus avellana+Ulmus americana+Salix caprea+Populus deltoides) Ab.IgE;ACnc;Pt;Ser;Ord;Multidisk;ALLERGY;1;Deprecated Tree Allergen Mix 5 (Grey alder+Hazelnut+White elm+Willow+Cottonwood) IgE Ab [Presence] in Serum by Multiple allergens;Deprecated Tree Allerg Mix5 IgE Ql;;DEPRECATED;1.0o;2.36 +24134-9;(Acer negundo+Betula verrucosa+Fagus grandifolia+Quercus alba+Juglans californica) Ab.IgE;ACnc;Pt;Ser;Ord;Multidisk;ALLERGY;1;Deprecated Tree Allergen Mix 6 (Boxelder+Silver birch+American beech+White oak+California walnut) IgE Ab [Presence] in Serum by Multiple allergens;Deprecated Tree Allerg Mix6 IgE Ql;;DEPRECATED;1.0o;2.36 +24135-6;(Alnus incana+Betula verrucosa+Corylus avellana+Quercus alba+Salix caprea) Ab.IgE;ACnc;Pt;Ser;Ord;Multidisk;ALLERGY;1;Deprecated Tree Allergen Mix 9 (Grey alder+Silver birch+Hazelnut+White oak+Willow) IgE Ab [Presence] in Serum by Multiple allergens;Deprecated Tree Allerg Mix9 IgE Ql;;DEPRECATED;1.0o;2.36 +24136-4;Juglans nigra Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Walnut IgG Ab [Units/volume] in Serum;Black Walnut IgG Qn;;ACTIVE;1.0o;2.73 +24137-2;Carya tomentosa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Hickory IgG Ab [Units/volume] in Serum;White Hickory IgG Qn;;ACTIVE;1.0o;2.73 +24138-0;Sorghum halepense Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Johnson grass IgG Ab [Units/volume] in Serum;Johnson grass IgG Qn;;ACTIVE;1.0o;2.69 +24139-8;Blatella germanica Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach IgG Ab [Units/volume] in Serum;Roach IgG Qn;;ACTIVE;1.0o;2.73 +24140-6;Fraxinus americana Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Ash IgG Ab [Units/volume] in Serum;White Ash IgG Qn;;ACTIVE;1.0o;2.73 +2414-1;Hippurate;MRat;24H;Urine;Qn;;DRUG/TOX;1;Hippurate [Mass/time] in 24 hour Urine;Hippurate 24h Ur-mRate;;ACTIVE;1.0;2.19 +24141-4;Iva ciliata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rough Marsh Elder IgG Ab [Units/volume] in Serum;Marsh Elder IgG Qn;;ACTIVE;1.0o;2.72 +24142-2;Morus rubra Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red mulberry IgG Ab [Units/volume] in Serum;Red mulberry IgG Qn;;ACTIVE;1.0o;2.73 +24143-0;Rumex acetosella Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep Sorrel IgG Ab [Units/volume] in Serum;Sheep Sorrel IgG Qn;;ACTIVE;1.0o;2.69 +24144-8;Bromus inermis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brome IgG Ab [Units/volume] in Serum;Brome IgG Qn;;ACTIVE;1.0o;2.73 +24145-5;Platanus occidentalis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;American Sycamore IgG Ab [Units/volume] in Serum;Amer Sycamore IgG Qn;;ACTIVE;1.0o;2.69 +24146-3;Acnida tamariscina Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Western Water Hemp IgG Ab [Units/volume] in Serum;West Water Hemp IgG Qn;;ACTIVE;1.0o;2.73 +24147-1;(Chicken feather+Duck feather+Goose feather) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix A (Chicken feather+Duck feather+Goose feather) IgE Ab [Units/volume] in Serum by Multidisk;Epid Allerg Mix A IgE Qn;;ACTIVE;1.0o;2.73 +24148-9;Poa pratensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kentucky blue grass IgG Ab [Units/volume] in Serum;Kent blue grass IgG Qn;;ACTIVE;1.0o;2.69 +24149-7;(Brassica oleracea var botrytis+Brassica oleracea var capitata+Brassica oleracea var gemmifera+Brassica oleracea var italica) Ab.IgG;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix D (Cauliflower+Cabbage+Brussel sprouts+Broccoli) IgG Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix D IgG Qn;;ACTIVE;1.0o;2.69 +24150-5;Acer rubrum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Maple IgG Ab [Units/volume] in Serum;Red Maple IgG Qn;;ACTIVE;1.0o;2.69 +24151-3;Ambrosia trifida Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Giant Ragweed IgG Ab [Units/volume] in Serum;Giant Ragweed IgG Qn;;ACTIVE;1.0o;2.73 +24152-1;Alternaria alternata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated ALTERNARIA ALTERNATA+ALTERNARIA TENUIS IgG Ab [Units/volume] in Serum;Deprecated A alternata IgG Qn;;DEPRECATED;1.0o;2.69 +24153-9;Kamut flour Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kamut flour IgG Ab [Units/volume] in Serum;Kamut Flour IgG Qn;;ACTIVE;1.0o;2.69 +24154-7;Chenopodium album Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goosefoot IgG Ab [Units/volume] in Serum;Goosefoot IgG Qn;;ACTIVE;1.0o;2.69 +24155-4;Mangifera indica Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mango IgG Ab [Units/volume] in Serum;Mango IgG Qn;;ACTIVE;1.0o;2.69 +24156-2;Maple syrup Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Maple syrup IgG Ab [Units/volume] in Serum;Maple Syrup IgG Qn;;ACTIVE;1.0o;2.69 +24157-0;Quercus virginiana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Virginia Live Oak IgE Ab [Units/volume] in Serum;Deprecated Virg Live Oak IgE Qn;;DEPRECATED;1.0o;2.69 +2415-8;Histamine;MCnc;Pt;Bld;Qn;;CHEM;1;Histamine [Mass/volume] in Blood;Histamine Bld-mCnc;;ACTIVE;1.0;2.73 +24158-8;Pepper white+Pepper black Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White+Black Pepper IgG Ab [Units/volume] in Serum;White+Black Pepper IgG Qn;;ACTIVE;1.0o;2.69 +24159-6;Pepper white+Pepper black Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White+Black Pepper IgE Ab [Units/volume] in Serum;White+Black Pepper IgE Qn;;ACTIVE;1.0o;2.42 +24160-4;Bean wax Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Wax Bean IgE Ab [Units/volume] in Serum;Deprecated Wax Bean IgE Qn;;DEPRECATED;1.0o;2.69 +24161-2;Cucumis melo spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Melon IgE Ab [Units/volume] in Serum;Deprecated Melon IgE Qn;;DEPRECATED;1.0o;2.69 +24162-0;Aspergillus fumigatus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus IgG Ab RAST class [Presence] in Serum;A fumigatus IgG RAST Ql;;ACTIVE;1.0o;2.73 +24163-8;(Beef+Chicken+Pork) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix fx73 (Beef+Chicken+Pork) IgE Ab [Presence] in Serum by Multidisk;Food Allergen Mix fx73 IgE Ql;;ACTIVE;1.0o;2.73 +24164-6;Citrus reticulata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Mandarin IgE Ab [Units/volume] in Serum;Deprecated Mandarin IgE Qn;;DEPRECATED;1.0o;2.69 +24165-3;Beta vulgaris seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Beet Seed (Beta vulgaris seed) IgE Ab [Units/volume] in Serum;Sugar Beet Seed IgE Qn;;ACTIVE;1.0o;2.73 +2416-6;Histamine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Histamine [Mass/volume] in Serum or Plasma;Histamine SerPl-mCnc;;ACTIVE;1.0;2.73 +24166-1;Pinus radiata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Monterey Pine IgE Ab [Units/volume] in Serum;Deprecated Monterey Pine IgE Qn;;DEPRECATED;1.0o;2.69 +24167-9;Rat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Rat epithelium, serum proteins & urine proteins IgE Ab [Units/volume] in Serum;Deprecated Rat IgE Qn;;DEPRECATED;1.0o;2.69 +24168-7;Cat hair+Cat dander Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cat hair + Cat dander IgG Ab [Units/volume] in Serum;Deprecated Cat Hair+Dander IgG Qn;;DEPRECATED;1.0o;2.69 +24169-5;Polio virus 1 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 1 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;PV1 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24170-3;Polio virus 1 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 1 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;PV1 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24171-1;Polio virus 2 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 2 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;PV2 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24172-9;Polio virus 2 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 2 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;PV2 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24173-7;Polio virus 3 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 3 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;PV3 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +2417-4;Histamine;MCnc;Pt;Urine;Qn;;CHEM;1;Histamine [Mass/volume] in Urine;Histamine Ur-mCnc;;ACTIVE;1.0;2.73 +24174-5;Polio virus 3 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 3 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;PV3 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24175-2;Adenovirus Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Adenovirus Ab [Titer] in Serum by Complement fixation --1st specimen;HAdV Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24176-0;Adenovirus Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Adenovirus Ab [Titer] in Serum by Complement fixation --2nd specimen;HAdV Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24177-8;Coxsackievirus B1 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B1 Ab [Titer] in Serum by Complement fixation --1st specimen;CV B1 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24178-6;Coxsackievirus B1 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B1 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV B1 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24179-4;Coxsackievirus B1 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B1 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;CV B1 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24180-2;Coxsackievirus B1 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B1 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;CV B1 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24181-0;Coxsackievirus B2 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B2 Ab [Titer] in Serum by Complement fixation --1st specimen;CV B2 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +2418-2;Histidine;PrThr;Pt;Bld;Ord;;CHEM;1;Histidine [Presence] in Blood;Histidine Bld Ql;;ACTIVE;1.0;2.73 +24182-8;Coxsackievirus B2 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B2 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV B2 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24183-6;Coxsackievirus B2 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B2 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;CV B2 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24184-4;Coxsackievirus B2 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B2 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;CV B2 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24185-1;Coxsackievirus B3 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B3 Ab [Titer] in Serum by Complement fixation --1st specimen;CV B3 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24186-9;Coxsackievirus B3 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B3 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV B3 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24187-7;Coxsackievirus B3 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B3 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;CV B3 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24188-5;Coxsackievirus B3 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B3 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;CV B3 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24189-3;Coxsackievirus B4 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B4 Ab [Titer] in Serum by Complement fixation --1st specimen;CV B4 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +2419-0;Histidine;MCnc;Pt;Bld;Qn;;CHEM;1;Histidine [Mass/volume] in Blood;Histidine Bld-mCnc;;ACTIVE;1.0;2.42 +24190-1;Coxsackievirus B4 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B4 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV B4 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24191-9;Coxsackievirus B4 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B4 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;CV B4 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24192-7;Coxsackievirus B4 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B4 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;CV B4 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24193-5;Coxsackievirus B5 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B5 Ab [Titer] in Serum by Complement fixation --1st specimen;CV B5 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24194-3;Coxsackievirus B5 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B5 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV B5 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24195-0;Coxsackievirus B5 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B5 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;CV B5 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24196-8;Coxsackievirus B5 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B5 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;CV B5 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24197-6;Coxsackievirus B6 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B6 Ab [Titer] in Serum by Complement fixation --1st specimen;CV B6 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24198-4;Coxsackievirus B6 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B6 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV B6 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24199-2;Coxsackievirus B6 Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B6 neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;CV B6 NAb sp1 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24200-8;Coxsackievirus B6 Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B6 neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;CV B6 NAb sp2 Titr Ser Nt;;ACTIVE;1.0o;2.72 +24201-6;Saint Louis encephalitis virus Ab^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum by Immunofluorescence --1st specimen;SLEV Ab sp1 Titr Ser IF;;ACTIVE;1.0o;2.70 +24202-4;Saint Louis encephalitis virus Ab^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum by Immunofluorescence --2nd specimen;SLEV Ab sp2 Titr Ser IF;;ACTIVE;1.0o;2.70 +24203-2;Legionella pneumophila Ab^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila Ab [Titer] in Serum by Immunofluorescence --1st specimen;L pneumo Ab sp1 Titr Ser IF;;ACTIVE;1.0o;2.70 +24204-0;Legionella pneumophila Ab^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila Ab [Titer] in Serum by Immunofluorescence --2nd specimen;L pneumo Ab sp2 Titr Ser IF;;ACTIVE;1.0o;2.70 +24205-7;Rickettsia typhi Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Serum by Immunofluorescence --1st specimen;R typhi IgG sp1 Titr Ser IF;;ACTIVE;1.0o;2.70 +24206-5;Rickettsia typhi Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Serum by Immunofluorescence --2nd specimen;R typhi IgG sp2 Titr Ser IF;;ACTIVE;1.0o;2.70 +24207-3;Rickettsia spotted fever group Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Serum by Immunofluorescence --1st specimen;Rick SF IgG sp1 Titr Ser IF;;ACTIVE;1.0o;2.73 +2420-8;Histidine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Histidine [Mass/volume] in Serum or Plasma;Histidine SerPl-mCnc;;ACTIVE;1.0;2.73 +24208-1;Rickettsia spotted fever group Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Serum by Immunofluorescence --2nd specimen;Rick SF IgG sp2 Titr Ser IF;;ACTIVE;1.0o;2.70 +24209-9;La Crosse virus Ab^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;La Crosse virus Ab [Titer] in Serum by Immunofluorescence --1st specimen;LACV Ab sp1 Titr Ser IF;;ACTIVE;1.0o;2.70 +24210-7;La Crosse virus Ab^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;La Crosse virus Ab [Titer] in Serum by Immunofluorescence --2nd specimen;LACV Ab sp2 Titr Ser IF;;ACTIVE;1.0o;2.70 +24211-5;Western equine encephalitis virus Ab^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum by Immunofluorescence --1st specimen;WEEV Ab sp1 Titr Ser IF;;ACTIVE;1.0o;2.70 +24212-3;Western equine encephalitis virus Ab^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum by Immunofluorescence --2nd specimen;WEEV Ab sp2 Titr Ser IF;;ACTIVE;1.0o;2.70 +24213-1;Eastern equine encephalitis virus Ab^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum by Immunofluorescence --1st specimen;EEEV Ab sp1 Titr Ser IF;;ACTIVE;1.0o;2.70 +24214-9;Eastern equine encephalitis virus Ab^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum by Immunofluorescence --2nd specimen;EEEV Ab sp2 Titr Ser IF;;ACTIVE;1.0o;2.70 +24215-6;Influenza virus A Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus A Ab [Titer] in Serum by Complement fixation --1st specimen;FLUAV Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +2421-6;Histidine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Histidine [Presence] in Serum or Plasma;Histidine SerPl Ql;;ACTIVE;1.0;2.73 +24216-4;Influenza virus A Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus A Ab [Titer] in Serum by Complement fixation --2nd specimen;FLUAV Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24217-2;Influenza virus B Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus B Ab [Titer] in Serum by Complement fixation --1st specimen;FLUBV Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24218-0;Influenza virus B Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus B Ab [Titer] in Serum by Complement fixation --2nd specimen;FLUBV Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24219-8;Parainfluenza virus 1 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Serum by Complement fixation --1st specimen;HPIV1 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24220-6;Parainfluenza virus 2 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Serum by Complement fixation --1st specimen;HPIV2 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24221-4;Parainfluenza virus 2 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Serum by Complement fixation --2nd specimen;HPIV2 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24222-2;Parainfluenza virus 3 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Serum by Complement fixation --1st specimen;HPIV3 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24223-0;Parainfluenza virus 3 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Serum by Complement fixation --2nd specimen;HPIV3 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +2422-4;Histidine;PrThr;Pt;Urine;Ord;;CHEM;1;Histidine [Presence] in Urine;Histidine Ur Ql;;ACTIVE;1.0;2.56 +24224-8;Respiratory syncytial virus Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Respiratory syncytial virus Ab [Titer] in Serum by Complement fixation --1st specimen;RSV Ab sp1 Titr Ser CF;;DISCOURAGED;1.0o;2.70 +24225-5;Respiratory syncytial virus Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Respiratory syncytial virus Ab [Titer] in Serum by Complement fixation --2nd specimen;RSV Ab sp2 Titr Ser CF;;DISCOURAGED;1.0o;2.70 +24226-3;Coxsackievirus A10 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A10 Ab [Titer] in Serum by Complement fixation --1st specimen;CV A10 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24227-1;Coxsackievirus A10 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A10 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV A10 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24228-9;Coxsackievirus A16 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A16 Ab [Titer] in Serum by Complement fixation --1st specimen;CV A16 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24229-7;Coxsackievirus A16 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A16 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV A16 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24230-5;Coxsackievirus A7 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A7 Ab [Titer] in Serum by Complement fixation --1st specimen;CV A7 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24231-3;Coxsackievirus A7 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A7 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV A7 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +2423-2;Histidine;MCnc;Pt;Urine;Qn;;CHEM;1;Histidine [Mass/volume] in Urine;Histidine Ur-mCnc;;ACTIVE;1.0;2.42 +24232-1;Coxsackievirus A9 Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A9 Ab [Titer] in Serum by Complement fixation --1st specimen;CV A9 Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24233-9;Coxsackievirus A9 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A9 Ab [Titer] in Serum by Complement fixation --2nd specimen;CV A9 Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24234-7;Mycoplasma pneumoniae Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum --1st specimen;M pneumo IgG sp1 Ser-aCnc;;ACTIVE;1.0o;2.69 +24235-4;Mycoplasma pneumoniae Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum --2nd specimen;M pneumo IgG sp2 Ser-aCnc;;ACTIVE;1.0o;2.69 +24236-2;Mycoplasma pneumoniae Ab^1st specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum by Complement fixation --1st specimen;M pneumo Ab sp1 Titr Ser CF;;ACTIVE;1.0o;2.70 +24237-0;Mycoplasma pneumoniae Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum by Complement fixation --2nd specimen;M pneumo Ab sp2 Titr Ser CF;;ACTIVE;1.0o;2.70 +24238-8;Chlamydia sp Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Serum --1st specimen;Chlamydia IgG sp1 Ser-aCnc;;ACTIVE;1.0o;2.69 +24239-6;Chlamydia sp Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Serum --2nd specimen;Chlamydia IgG sp2 Ser-aCnc;;ACTIVE;1.0o;2.69 +2424-0;Histidine;MRat;24H;Urine;Qn;;CHEM;1;Histidine [Mass/time] in 24 hour Urine;Histidine 24h Ur-mRate;;ACTIVE;1.0;2.42 +24240-4;Mumps virus Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus IgG Ab [Units/volume] in Serum --1st specimen;MuV IgG sp1 Ser-aCnc;;ACTIVE;1.0o;2.73 +24241-2;Mumps virus Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus IgG Ab [Units/volume] in Serum --2nd specimen;MuV IgG sp2 Ser-aCnc;;ACTIVE;1.0o;2.73 +24242-0;Toxoplasma gondii Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Serum --1st specimen;T gondii IgG sp1 Ser-aCnc;;ACTIVE;1.0o;2.73 +24243-8;Polio virus 1 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 1 Ab [Titer] in Serum --1st specimen;PV1 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24244-6;Polio virus 1 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 1 Ab [Titer] in Serum --2nd specimen;PV1 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24245-3;Polio virus 2 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 2 Ab [Titer] in Serum --1st specimen;PV2 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24246-1;Polio virus 2 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 2 Ab [Titer] in Serum --2nd specimen;PV2 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24247-9;Polio virus 3 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 3 Ab [Titer] in Serum --1st specimen;PV3 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24248-7;Polio virus 3 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus 3 Ab [Titer] in Serum --2nd specimen;PV3 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24249-5;Adenovirus Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Adenovirus Ab [Titer] in Serum --1st specimen;HAdV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24250-3;Adenovirus Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Adenovirus Ab [Titer] in Serum --2nd specimen;HAdV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24251-1;Coxsackievirus B1 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B1 Ab [Titer] in Serum --1st specimen;CV B1 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24252-9;Coxsackievirus B1 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B1 Ab [Titer] in Serum --2nd specimen;CV B1 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24255-2;Coxsackievirus B2 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B2 Ab [Titer] in Serum --1st specimen;CV B2 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24256-0;Coxsackievirus B2 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B2 Ab [Titer] in Serum --2nd specimen;CV B2 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +2425-7;Histidine ammonia lyase;CCnc;Pt;Ser;Qn;;CHEM;1;Histidine ammonia lyase [Enzymatic activity/volume] in Serum;HAL Ser-cCnc;;ACTIVE;1.0;2.68 +24259-4;Coxsackievirus B3 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B3 Ab [Titer] in Serum --1st specimen;CV B3 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24260-2;Coxsackievirus B3 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B3 Ab [Titer] in Serum --2nd specimen;CV B3 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24263-6;Coxsackievirus B4 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B4 Ab [Titer] in Serum --1st specimen;CV B4 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24264-4;Coxsackievirus B4 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B4 Ab [Titer] in Serum --2nd specimen;CV B4 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +2426-5;Homocarnosine;MCnc;Pt;CSF;Qn;;CHEM;1;Homocarnosine [Mass/volume] in Cerebral spinal fluid;Homocarnosine CSF-mCnc;;ACTIVE;1.0;2.34 +24267-7;Coxsackievirus B5 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B5 Ab [Titer] in Serum --1st specimen;CV B5 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24268-5;Coxsackievirus B5 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B5 Ab [Titer] in Serum --2nd specimen;CV B5 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24271-9;Coxsackievirus B6 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B6 Ab [Titer] in Serum --1st specimen;CV B6 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24272-7;Coxsackievirus B6 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B6 Ab [Titer] in Serum --2nd specimen;CV B6 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +2427-3;Homocitrulline;MCnc;Pt;Urine;Qn;;CHEM;1;Homocitrulline [Mass/volume] in Urine;Homocitrulline Ur-mCnc;;DISCOURAGED;1.0;2.44 +24275-0;Saint Louis encephalitis virus Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum --1st specimen;SLEV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24276-8;Saint Louis encephalitis virus Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum --2nd specimen;SLEV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24277-6;Legionella pneumophila Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila Ab [Titer] in Serum --1st specimen;L pneumo Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24278-4;Legionella pneumophila Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila Ab [Titer] in Serum --2nd specimen;L pneumo Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24279-2;Rickettsia typhi Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Serum --1st specimen;R typhi IgG sp1 Titr Ser;;ACTIVE;1.0o;2.70 +242-8;Ethambutol;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ethambutol [Susceptibility] by Disk diffusion (KB);Ethambutol Islt KB;;ACTIVE;1.0;2.21 +24280-0;Rickettsia typhi Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Serum --2nd specimen;R typhi IgG sp2 Titr Ser;;ACTIVE;1.0o;2.70 +2428-1;Homocysteine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocysteine [Mass/volume] in Serum or Plasma;Hcys SerPl-mCnc;;ACTIVE;1.0;2.73 +24281-8;Rickettsia spotted fever group Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Serum --1st specimen;Rick SF IgG sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24282-6;Rickettsia spotted fever group Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Serum --2nd specimen;Rick SF IgG sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24283-4;La Crosse virus Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;La Crosse virus Ab [Titer] in Serum --1st specimen;LACV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24284-2;La Crosse virus Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;La Crosse virus Ab [Titer] in Serum --2nd specimen;LACV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24285-9;Western equine encephalitis virus Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum --1st specimen;WEEV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24286-7;Western equine encephalitis virus Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum --2nd specimen;WEEV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24287-5;Eastern equine encephalitis virus Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum --1st specimen;EEEV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24288-3;Eastern equine encephalitis virus Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum --2nd specimen;EEEV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24289-1;Influenza virus A Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A Ab [Titer] in Serum --1st specimen;FLUAV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24290-9;Influenza virus A Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A Ab [Titer] in Serum --2nd specimen;FLUAV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24291-7;Influenza virus B Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus B Ab [Titer] in Serum --1st specimen;FLUBV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24292-5;Influenza virus B Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus B Ab [Titer] in Serum --2nd specimen;FLUBV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24293-3;Parainfluenza virus 1 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Serum --1st specimen;HPIV1 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24294-1;Parainfluenza virus 2 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Serum --1st specimen;HPIV2 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24295-8;Parainfluenza virus 2 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Serum --2nd specimen;HPIV2 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24296-6;Parainfluenza virus 3 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Serum --1st specimen;HPIV3 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24297-4;Parainfluenza virus 3 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Serum --2nd specimen;HPIV3 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24298-2;Respiratory syncytial virus Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus Ab [Titer] in Serum --1st specimen;RSV Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +2429-9;Homocystine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Homocystine [Presence] in Serum or Plasma;(Hcys)2 SerPl Ql;;ACTIVE;1.0;2.73 +24299-0;Respiratory syncytial virus Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus Ab [Titer] in Serum --2nd specimen;RSV Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24300-6;Coxsackievirus A10 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A10 Ab [Titer] in Serum --1st specimen;CV A10 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24301-4;Coxsackievirus A10 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A10 Ab [Titer] in Serum --2nd specimen;CV A10 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24302-2;Coxsackievirus A16 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A16 Ab [Titer] in Serum --1st specimen;CV A16 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24303-0;Coxsackievirus A16 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A16 Ab [Titer] in Serum --2nd specimen;CV A16 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24304-8;Coxsackievirus A7 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A7 Ab [Titer] in Serum --1st specimen;CV A7 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24305-5;Coxsackievirus A7 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A7 Ab [Titer] in Serum --2nd specimen;CV A7 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24306-3;Coxsackievirus A9 Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A9 Ab [Titer] in Serum --1st specimen;CV A9 Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +2430-7;Homocystine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocystine [Mass/volume] in Serum or Plasma;(Hcys)2 SerPl-mCnc;;ACTIVE;1.0;2.73 +24307-1;Coxsackievirus A9 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A9 Ab [Titer] in Serum --2nd specimen;CV A9 Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24310-5;Mycoplasma pneumoniae Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum --1st specimen;M pneumo Ab sp1 Titr Ser;;ACTIVE;1.0o;2.70 +24311-3;Mycoplasma pneumoniae Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum --2nd specimen;M pneumo Ab sp2 Titr Ser;;ACTIVE;1.0o;2.70 +24312-1;Treponema pallidum Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Treponema pallidum Ab [Presence] in Serum by Agglutination;T pallidum Ab Ser Ql Aggl;;ACTIVE;1.0o;2.73 +24313-9;Hepatitis 1996 panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis 1996 panel - Serum;Hepatitis 1996 Pnl Ser;;ACTIVE;1.0o;2.73 +24314-7;TORCH 1996 panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;TORCH 1996 panel - Serum;TORCH 1996 Pnl Ser;;ACTIVE;1.0o;2.73 +2431-5;Homocystine;MCnc;Pt;Urine;Qn;;CHEM;1;Homocystine [Mass/volume] in Urine;(Hcys)2 Ur-mCnc;;ACTIVE;1.0;2.73 +24315-4;Cytomegalovirus Ab.IgG & IgM panel;-;Pt;Ser/Plas;Qn;;PANEL.MICRO;1;Cytomegalovirus IgG and IgM panel - Serum or Plasma;CMV IgG+IgM Pnl SerPl;;ACTIVE;1.0o;2.73 +24316-2;Epstein Barr virus capsid Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Epstein Barr virus capsid IgG and IgM panel - Serum;EBV VCA IgG+IgM Pnl Ser;;ACTIVE;1.0o;2.73 +24317-0;Hemogram & platelets WO differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Hemogram and platelets WO differential panel - Blood;CBC WO diff Bld;;DISCOURAGED;1.0o;2.73 +24318-8;Manual Differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Manual Differential panel - Blood;Manual diff Bld;;DISCOURAGED;1.0o;2.73 +24319-6;Cardiolipin Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Cardiolipin IgG and IgM panel - Serum;Cardiolipin IgG+IgM Pnl Ser;;ACTIVE;1.0o;2.73 +24320-4;Basic metabolic 1998 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Basic metabolic 1998 panel - Serum or Plasma;Bas Metab 1998 Pnl SerPl;;ACTIVE;1.0o;2.73 +24321-2;Basic metabolic 2000 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Basic metabolic 2000 panel - Serum or Plasma;Bas Metab 2000 Pnl SerPl;;ACTIVE;1.0o;2.73 +24322-0;Comprehensive metabolic 1998 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Comprehensive metabolic 1998 panel - Serum or Plasma;Comp Metab 1998 Pnl SerPl;;ACTIVE;1.0o;2.73 +2432-3;Homogentisate;PrThr;Pt;Urine;Ord;;CHEM;1;Homogentisate [Presence] in Urine;Homogentisate Ur Ql;;ACTIVE;1.0;2.73 +24323-8;Comprehensive metabolic 2000 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Comprehensive metabolic 2000 panel - Serum or Plasma;Comp Metab 2000 Pnl SerPl;;ACTIVE;1.0o;2.73 +24324-6;Hepatic function 1996 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Hepatic function 1996 panel - Serum or Plasma;Hep Func 1996 Pnl SerPl;;ACTIVE;1.0o;2.73 +24325-3;Hepatic function 2000 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Hepatic function 2000 panel - Serum or Plasma;Hep Func 2000 Pnl SerPl;;ACTIVE;1.0o;2.73 +24326-1;Electrolytes 1998 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Electrolytes 1998 panel - Serum or Plasma;Lytes 1998 Pnl SerPl;;ACTIVE;1.0o;2.73 +24327-9;Electrolytes 3 panel;-;Pt;Body fld;Qn;;PANEL.CHEM;1;Electrolytes 3 panel - Body fluid;Lytes 3 Pnl Fld;;ACTIVE;1.0o;2.73 +24328-7;Electrolytes 3 panel;-;Pt;Stool;Qn;;PANEL.CHEM;1;Electrolytes 3 panel - Stool;Lytes 3 Pnl Stl;;ACTIVE;1.0o;2.73 +24329-5;Electrolytes 3 panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Electrolytes 3 panel - Urine;Lytes 3 Pnl Ur;;ACTIVE;1.0o;2.73 +2433-1;Homogentisate;MCnc;Pt;Urine;Qn;;CHEM;1;Homogentisate [Mass/volume] in Urine;Homogentisate Ur-mCnc;;ACTIVE;1.0;2.42 +24331-1;Lipid 1996 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Lipid 1996 panel - Serum or Plasma;Lipid 1996 Pnl SerPl;;ACTIVE;1.0o;2.73 +24332-9;Alkaline phosphatase isoenz panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Alkaline phosphatase isoenz panel - Serum or Plasma;ALP Iso Pnl SerPl;;ACTIVE;1.0o;2.73 +24333-7;Amylase isoenz 3 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Amylase isoenzyme 3 panel - Serum or Plasma;Amylase Iso3 Pnl SerPl;;ACTIVE;1.0o;2.73 +24334-5;Amylase isoenz 7 panel;-;Pt;Ser;Qn;;PANEL.CHEM;1;Amylase isoenzyme 7 panel - Serum;Amylase Iso7 Pnl Ser;;ACTIVE;1.0o;2.42 +24335-2;Creatine kinase panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Creatine kinase panel - Serum or Plasma;CK Pnl SerPl;;ACTIVE;1.0o;2.73 +24336-0;Gas panel;-;Pt;BldA;Qn;;PANEL.CHEM;1;Gas panel - Arterial blood;Gas Pnl BldA;;ACTIVE;1.0o;2.73 +24337-8;Gas panel;-;Pt;BldC;Qn;;PANEL.CHEM;1;Gas panel - Capillary blood;Gas Pnl BldC;;ACTIVE;1.0o;2.73 +24338-6;Gas panel;-;Pt;Bld;Qn;;PANEL.CHEM;1;Gas panel - Blood;Gas Pnl Bld;;ACTIVE;1.0o;2.73 +24339-4;Gas panel;-;Pt;BldV;Qn;;PANEL.CHEM;1;Gas panel - Venous blood;Gas Pnl BldV;;ACTIVE;1.0o;2.73 +24340-2;Gas panel;-;Pt;Body fld;Qn;;PANEL.CHEM;1;Gas panel - Body fluid;Gas Pnl Fld;;ACTIVE;1.0o;2.42 +24341-0;Gas & CO panel;-;Pt;BldA;Qn;;PANEL.CHEM;1;Gas and Carbon monoxide panel - Arterial blood;Gas + CO Pnl BldA;;ACTIVE;1.0o;2.73 +24342-8;Gas & CO panel;-;Pt;BldC;Qn;;PANEL.CHEM;1;Gas and Carbon monoxide panel - Capillary blood;Gas + CO Pnl BldC;;ACTIVE;1.0o;2.42 +24343-6;Gas & CO panel;-;Pt;Bld;Qn;;PANEL.CHEM;1;Gas and Carbon monoxide panel - Blood;Gas + CO Pnl Bld;;ACTIVE;1.0o;2.67 +24344-4;Gas & CO panel;-;Pt;BldV;Qn;;PANEL.CHEM;1;Gas and Carbon monoxide panel - Venous blood;Gas + CO Pnl BldV;;ACTIVE;1.0o;2.73 +24345-1;Gas & CO panel;-;Pt;Body fld;Qn;;PANEL.CHEM;1;Deprecated Gas & CO panel;Deprecated Gas + CO Pnl Fld;;DEPRECATED;1.0o;2.36 +24346-9;Parathyrin.intact & Calcium panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Parathyrin.intact and Calcium panel - Serum or Plasma;PTH-Intact + Ca Pnl SerPl;;ACTIVE;1.0o;2.73 +24347-7;Parathyrin.mid molecule & Calcium panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Parathyrin.mid molecule and Calcium panel - Serum or Plasma;PTH Mid Mol + Ca Pnl SerPl;;ACTIVE;1.0o;2.42 +24348-5;Free T4 & TSH panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Free T4 and TSH panel - Serum or Plasma;T4 Free+ TSH Pnl SerPl;;ACTIVE;1.0o;2.73 +2434-9;Homovanillate;MCnc;Pt;CSF;Qn;;CHEM;1;Homovanillate [Mass/volume] in Cerebral spinal fluid;HVA CSF-mCnc;;ACTIVE;1.0;2.34 +24349-3;Drugs of abuse 5 panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Drugs of abuse 5 panel - Urine;Drugs of Abuse 5 Pnl Ur;;ACTIVE;1.0o;2.73 +24350-1;Volatiles panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Volatiles panel - Urine;Volatiles Pnl Ur;;ACTIVE;1.0o;2.42 +24351-9;Protein fractions panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Protein electrophoresis panel - Serum or Plasma;Prot Elph Pnl SerPl;;ACTIVE;1.0o;2.73 +24352-7;Protein fractions panel;-;Pt;CSF;Qn;;PANEL.CHEM;1;Protein electrophoresis panel - Cerebral spinal fluid;Prot Elph Pnl CSF;;ACTIVE;1.0o;2.73 +24353-5;Glucose tolerance 2H gestational panel;-;-;Urine+Ser/Plas;Qn;;PANEL.CHAL;1;Glucose tolerance 2 hours gestational panel - Urine and Serum or Plasma;GTT gest 2h Pnl Ur+SerPl;;ACTIVE;1.0o;2.73 +24355-0;Urinalysis macroscopic panel;-;Pt;Urine;-;;PANEL.UA;1;Deprecated Urinalysis macroscopic panel in Urine;Deprecated UA Macroscopic Pnl Ur;;DEPRECATED;1.0o;2.36 +2435-6;Homovanillate;MCnc;Pt;Ser;Qn;;CHEM;1;Homovanillate [Mass/volume] in Serum;HVA Ser-mCnc;;ACTIVE;1.0;2.34 +24356-8;Urinalysis complete panel;-;Pt;Urine;-;;PANEL.UA;1;Urinalysis complete panel - Urine;Urinalysis complete pnl Ur;;ACTIVE;1.0o;2.73 +24357-6;Urinalysis macro (dipstick) panel;-;Pt;Urine;-;;PANEL.UA;1;Urinalysis macro (dipstick) panel - Urine;UA Dipstick Pnl Ur;;ACTIVE;1.0o;2.73 +24358-4;Hemogram WO platelets panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Hemogram without Platelets panel - Blood;CBC WO Platelets Bld;;DISCOURAGED;1.0o;2.73 +24359-2;Hemogram WO Platelets & W Manual Differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Hemogram without Platelets and with Manual Differential panel - Blood;CBC WO platelets W man diff Bld;;DISCOURAGED;1.0o;2.42 +243-6;Ethambutol;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ethambutol [Susceptibility] by Serum bactericidal titer;Ethambutol Titr SBT;;ACTIVE;1.0;2.32 +24360-0;Hemoglobin & Hematocrit panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Hemoglobin and Hematocrit panel - Blood;Hgb+Hct Pnl Bld;;ACTIVE;1.0o;2.73 +24361-8;Hemogram, platelets & Differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Deprecated Hemogram, platelets & Differential panel in Blood;Deprecated CBC, Platelets + Diff Bld;;DEPRECATED;1.0o;2.36 +24362-6;Renal function 2000 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Renal function 2000 panel - Serum or Plasma;Renal Func 2000 Pnl SerPl;;ACTIVE;1.0o;2.73 +24363-4;Acute hepatitis 2000 panel;-;Pt;Ser;-;;PANEL.MICRO;1;Acute hepatitis 2000 panel - Serum;Acute Hep 2000 Pnl Ser;;ACTIVE;1.0o;2.73 +2436-4;Homovanillate;MRat;24H;Urine;Qn;;CHEM;1;Homovanillate [Mass/time] in 24 hour Urine;HVA 24h Ur-mRate;;ACTIVE;1.0;2.73 +24364-2;Obstetric 1996 panel;-;Pt;Ser+Bld;-;;PANEL.OBS;1;Obstetric 1996 panel - Serum and Blood;Obstetric 1996 Pnl Ser+Bld;;ACTIVE;1.0o;2.73 +24365-9;Urinalysis microscopic panel;-;Pt;Urine sed;-;;PANEL.UA;1;Urinalysis microscopic panel - Urine sediment;UA Microscopic Pnl UrnS;;DISCOURAGED;1.0o;2.73 +24369-1;RR interval^during XXX measurement;Time;Pt;Heart;Qn;EKG;CARD.US;2;R-R interval by EKG --during XXX measurement;R-R interval during XXX meas EKG;;ACTIVE;1.0o;2.50 +24370-9;Intravascular peak systolic^during MR max vel measurement;Pres;Pt;Arterial system.XXX;Qn;;CARD.US;2;Peak systolic blood pressure --during mitral regurgitation maximum velocity measurement;BP peak sys MR MaxV;;ACTIVE;1.0o;2.70 +24371-7;Intravascular peak systolic^during AS max vel measurement;Pres;Pt;Arterial system.XXX;Qn;;CARD.US;2;Peak systolic blood pressure --during aorta stenosis maximum velocity measurement;BP peak sys AS MaxV;;ACTIVE;1.0o;2.70 +2437-2;Hydrogen/Expired gas^post 50 g glucose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post 50 g glucose PO;Breath H2 p 50 g Glc PO;;ACTIVE;1.0;2.42 +24372-5;Intravascular peak systolic^during RVSP max vel measurement;Pres;Pt;Arterial system.XXX;Qn;;CARD.US;2;Peak systolic blood pressure --during right ventricular septal defect maximum velocity measurement;BP peak sys RVSP Max V;;ACTIVE;1.0o;2.70 +24373-3;Ferritin;MCnc;Pt;Bld;Qn;;CHEM;1;Ferritin [Mass/volume] in Blood;Ferritin Bld-mCnc;;ACTIVE;1.0o;2.40 +24374-1;Platelet associated Ab;PrThr;Pt;Bld;Ord;;SERO;1;Platelet associated Ab [Presence] in Blood;PA Ab Bld Ql;;ACTIVE;1.0o;2.73 +24375-8;Platelet Ab;PrThr;Pt;Ser;Ord;;SERO;1;Platelet Ab [Presence] in Serum;Platelet Ab Ser Ql;;ACTIVE;1.0o;2.73 +24376-6;von Willebrand factor multimers;ACnc;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf) multimers in Platelet poor plasma by Immunoassay;vWF multimers PPP IA-aCnc;;ACTIVE;1.0o;2.73 +24377-4;Platelet aggregation.adenosine diphosphate induced;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ADP induced [Presence] in Platelet rich plasma;PA ADP PRP Ql;;ACTIVE;1.0o;2.73 +24378-2;Platelet aggregation.EPINEPHrine induced;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation EPINEPHrine induced [Presence] in Platelet rich plasma;PA Epineph PRP Ql;;ACTIVE;1.0o;2.73 +24379-0;Platelet aggregation.collagen induced;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation collagen induced [Presence] in Platelet rich plasma;PA Coll PRP Ql;;ACTIVE;1.0o;2.73 +2438-0;Hydrogen sulfide;MCnc;Pt;Bld;Ord;;CHEM;1;Deprecated Hydrogen sulfide;Deprecated Hydrogen Sulfide Bld Ql;;DEPRECATED;1.0;2.36 +24380-8;Platelet aggregation.ristocetin induced;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ristocetin induced [Presence] in Platelet rich plasma;PA Rist PRP Ql;;ACTIVE;1.0o;2.73 +24381-6;Platelet aggregation.arachidonate induced;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation arachidonate induced [Presence] in Platelet rich plasma;PA AA PRP Ql;;ACTIVE;1.0o;2.73 +24382-4;Neutrophil associated Ab;Prid;Pt;Ser;Nom;;SERO;1;Neutrophil associated Ab [Identifier] in Serum;Neut Assoc Ab Ser;;ACTIVE;1.0o;2.07 +24383-2;Intrinsic factor Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Intrinsic factor Ab [Presence] in Serum by Immunoassay;IF Ab Ser Ql IA;;ACTIVE;1.0o;2.56 +24384-0;little c Ab;ACnc;Pt;Ser/Plas;Qn;;BLDBK;1;little c Ab [Units/volume] in Serum or Plasma;little c Ab SerPl-aCnc;;ACTIVE;1.0o;2.70 +24385-7;Cardiolipin Ab.IgG;PrThr;Pt;Ser;Ord;IA;COAG;1;Cardiolipin IgG Ab [Presence] in Serum by Immunoassay;Cardiolipin IgG Ser Ql IA;;ACTIVE;1.0o;2.73 +24386-5;Cardiolipin Ab.IgM;PrThr;Pt;Ser;Ord;IA;COAG;1;Cardiolipin IgM Ab [Presence] in Serum by Immunoassay;Cardiolipin IgM Ser Ql IA;;ACTIVE;1.0o;2.73 +24387-3;Brucella sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella sp IgG Ab [Presence] in Serum by Immunoassay;Brucella IgG Ser Ql IA;;ACTIVE;1.0o;2.73 +24388-1;Brucella sp Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella sp IgM Ab [Presence] in Serum by Immunoassay;Brucella IgM Ser Ql IA;;ACTIVE;1.0o;2.73 +24389-9;Cortisol^pre 250 ug corticotropin IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin IM;Cortis pre 250 ug ACTH IM SerPl-sCnc;;ACTIVE;1.0o;2.70 +24390-7;Cortisol^30M post 250 ug corticotropin IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;Cortis 30M p 250 ug ACTH IM SerPl-sCnc;;ACTIVE;1.0o;2.70 +24391-5;Cortisol^1H post 250 ug corticotropin IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM;Cortis 1h p 250 ug ACTH IM SerPl-sCnc;;ACTIVE;1.0o;2.70 +24392-3;Cortisol^pre 1 mg dexamethasone PO overnight;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre 1 mg dexamethasone PO overnight;Cortis pre 1 mg Dex SerPl-sCnc;;ACTIVE;1.0o;2.70 +24393-1;Cortisol^10H post 1 mg dexamethasone PO overnight;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --10 hours post 1 mg dexamethasone PO overnight;Cortis 10h p 1 mg Dex SerPl-sCnc;;ACTIVE;1.0o;2.70 +24394-9;Cortisol^17H post 1 mg dexamethasone PO overnight;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --17 hours post 1 mg dexamethasone PO overnight;Cortis 17h p 1 mg Dex SerPl-sCnc;;ACTIVE;1.0o;2.70 +24395-6;Cortisol^24H post 1 mg dexamethasone PO overnight;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --24 hours post 1 mg dexamethasone PO overnight;Cortis 24h p 1 mg Dex SerPl-sCnc;;ACTIVE;1.0o;2.70 +24396-4;Brucella sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella sp IgG Ab [Presence] in Serum;Brucella IgG Ser Ql;;ACTIVE;1.0o;2.73 +24397-2;Brucella sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella sp IgM Ab [Presence] in Serum;Brucella IgM Ser Ql;;ACTIVE;1.0o;2.73 +2439-8;Hydroxycalcidiol;MCnc;Pt;Ser;Qn;;CHEM;1;Hydroxycalcidiol [Mass/volume] in Serum;OH-Calcidiol Ser-mCnc;;ACTIVE;1.0;2.42 +24398-0;Toxoplasma sp Ab.IgM;ACnc;Pt;Ser;Qn;EIA;MICRO;1;Deprecated Toxoplasma gondii IgM Ab [Units/volume] in Serum by Immunoassay;Deprecated Toxoplasma IgM Ser EIA-aCnc;;DEPRECATED;1.0o;2.70 +24399-8;Toxoplasma sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Toxoplasma gondii IgM Ab [Units/volume] in Serum;Deprecated Toxoplasma IgM Ser-aCnc;;DEPRECATED;1.0o;2.70 +24400-4;Neuronal nuclear type 1 Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Neuronal nuclear type 1 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Hu1 Ab Titr CSF IF;;ACTIVE;1.0o;2.73 +24401-2;Neuronal nuclear type 2 Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Neuronal nuclear type 2 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Hu2 Ab Titr CSF IF;;ACTIVE;1.0o;2.73 +24402-0;Chlamydophila pneumoniae+Chlamydophila psittaci DNA;PrThr;Pt;XXX;Ord;Probe.amp;MICRO;1;Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Specimen by Probe with amplification;C pn+psitt DNA Spec Ql Probe amp;;ACTIVE;1.0o;2.69 +24403-8;Neuronal nuclear type 1 Ab;Titr;Pt;CSF;Qn;IB;SERO;1;Neuronal nuclear type 1 Ab [Titer] in Cerebral spinal fluid by Immunoblot;Hu1 Ab Titr CSF IB;;ACTIVE;1.0o;2.70 +24404-6;Neuronal nuclear type 2 Ab;Titr;Pt;CSF;Qn;IB;SERO;1;Neuronal nuclear type 2 Ab [Titer] in Cerebral spinal fluid by Immunoblot;Hu2 Ab Titr CSF IB;;ACTIVE;1.0o;2.70 +24405-3;Aeromonas salmonicida;PrThr;Pt;XXX;Ord;;MICRO;1;Aeromonas salmonicida [Presence] in Specimen;A salmonicida Spec Ql;;ACTIVE;1.0o;2.69 +2440-6;Hydroxocobalamin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxocobalamin [Mass/volume] in Serum or Plasma;Vit B12b SerPl-mCnc;;ACTIVE;1.0;2.42 +24406-1;Aeromonas salmonicida serotype;Prid;Pt;Isolate;Nom;;MICRO;1;Aeromonas salmonicida serotype [Identifier] in Isolate;A salmonicida Sertyp Islt;;ACTIVE;1.0o;2.67 +24407-9;Androstenedione^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --baseline;Androst BS SerPl-mCnc;;ACTIVE;1.0o;2.73 +24408-7;Babesia canis;PrThr;Pt;Bld;Ord;Giemsa stain;MICRO;1;Babesia canis [Presence] in Blood by Giemsa stain;B canis Bld Ql Gie Stn;;ACTIVE;1.0o;2.64 +24409-5;Brachyspira sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Brachyspira sp identified in Specimen by Organism specific culture;Brachyspira Spec Cult;;ACTIVE;1.0o;2.69 +24410-3;Brucella canis Ab;PrThr;Pt;Ser;Ord;Aggl.plate;MICRO;1;Brucella canis Ab [Presence] in Serum by Plate agglutination;B canis Ab Ser Ql Plate aggl;;ACTIVE;1.0o;2.56 +24411-1;Canine parvovirus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Canine parvovirus Ab [Presence] in Serum by Hemagglutination inhibition;CPV Ab Ser Ql HAI;;ACTIVE;1.0o;2.67 +24412-9;Coccidia identified;Prid;Pt;Tsmi;Nom;Giemsa stain;MICRO;1;Coccidia identified in Small intestine Tissue by Giemsa stain;Coccidia TSMI Gie Stn;;ACTIVE;1.0o;2.00 +24413-7;Eperythrozoon sp;PrThr;Pt;Bld;Ord;Giemsa stain;MICRO;1;Eperythrozoon sp [Presence] in Blood by Giemsa stain;Eperythrozoon Bld Ql Gie Stn;;ACTIVE;1.0o;2.56 +2441-4;Hydroxylysine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Hydroxylysine [Presence] in Serum or Plasma;OH-Lysine SerPl Ql;;ACTIVE;1.0;2.56 +24414-5;Estradiol^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --baseline;Estradiol BS SerPl-mCnc;;ACTIVE;1.0o;2.73 +24415-2;Feline panleukopenia virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Feline panleukopenia virus Ag [Presence] in Tissue by Immunofluorescence;FPLV Ag Tiss Ql IF;;ACTIVE;1.0o;2.67 +24416-0;Filovirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Filovirus Ab [Titer] in Serum;Filovirus Ab Titr Ser;;DISCOURAGED;1.0o;2.70 +24417-8;Follitropin^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;FSH sp1 p chal SerPl-mCnc;;DISCOURAGED;1.0o;2.42 +24418-6;Formononetin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Formononetin [Mass/volume] in Serum or Plasma;Formononetin SerPl-mCnc;;ACTIVE;1.0o;2.34 +24419-4;Path report.gross observation;Find;Pt;Specimen;Nom;;TUMRRGT;2;Pathology report gross observation;Path report.gross Spec;;ACTIVE;1.0o;2.73 +24420-2;Haemophilus somnus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Haemophilus somnus Ab [Titer] in Serum;H somnus Ab Titr Ser;;ACTIVE;1.0o;2.70 +24421-0;Haemobartonella felis;PrThr;Pt;Bld;Ord;Microscopy.light;MICRO;1;Haemobartonella felis [Presence] in Blood by Light microscopy;H felis Bld Ql Smear;;ACTIVE;1.0o;2.56 +2442-2;Hydroxylysine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxylysine [Mass/volume] in Serum or Plasma;OH-Lysine SerPl-mCnc;;ACTIVE;1.0;2.73 +24422-8;Hydrocarbons.chlorinated;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Hydrocarbons.chlorinated [Identifier] in Specimen;Chlor HC Spec;;ACTIVE;1.0o;2.69 +24427-7;Mycobacterium avium subspecies paratuberculosis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Mycobacterium avium ss paratuberculosis [Presence] in Specimen by Organism specific culture;M avium paraTB Spec Ql Cult;;ACTIVE;1.0o;2.69 +24428-5;Mycoplasma hyopneumoniae Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma hyopneumoniae Ab [Presence] in Serum by Immunoassay;M hyopneumo Ab Ser Ql IA;;ACTIVE;1.0o;2.56 +24429-3;Parasite identified;Prid;Pt;Bld;Nom;;MICRO;1;Parasite identified in Blood;Parasite Bld;;ACTIVE;1.0o;2.73 +2443-0;Hydroxylysine;MCnc;Pt;Urine;Qn;;CHEM;1;Hydroxylysine [Mass/volume] in Urine;OH-Lysine Ur-mCnc;;DISCOURAGED;1.0;2.73 +24430-1;Streptococcus suis serotype;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Streptococcus suis serotype [Identifier] in Isolate by Agglutination;S suis Sertyp Islt Aggl;;ACTIVE;1.0o;2.19 +24431-9;IgA.canine;MCnc;Pt;Ser;Qn;Immune diffusion;SERO;1;IgA.canine [Mass/volume] in Serum by Immune diffusion (ID);IgA Canine Ser ID-mCnc;;ACTIVE;1.0o;2.42 +24432-7;IgG.canine;MCnc;Pt;Ser;Qn;Immune diffusion;SERO;1;IgG.canine [Mass/volume] in Serum by Immune diffusion (ID);IgG Canine Ser ID-mCnc;;ACTIVE;1.0o;2.42 +24433-5;IgG.equine;MCnc;Pt;Ser;Qn;;CHEM;1;IgG.equine [Mass/volume] in Serum;IgG Equine Ser-mCnc;;ACTIVE;1.0o;2.42 +24434-3;IgM.canine;MCnc;Pt;Ser;Qn;Immune diffusion;SERO;1;IgM.canine [Mass/volume] in Serum by Immune diffusion (ID);IgM Canine Ser ID-mCnc;;ACTIVE;1.0o;2.42 +24435-0;2-Methylbutyrylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methylbutyrylglycine/Creatinine [Molar ratio] in Urine;2Me-butyrylglycine/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24436-8;3-Methylcrotonylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methylcrotonylglycine/Creatinine [Molar ratio] in Urine;3Me-crotonylglycine/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24437-6;Butyrylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Butyrylglycine/Creatinine [Molar ratio] in Urine;Butyrylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24438-4;Hexanoylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexanoylglycine/Creatinine [Molar ratio] in Urine;Hexanoylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24439-2;Isobutyrylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Isobutyrylglycine/Creatinine [Molar ratio] in Urine;Isobutyrylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +244-4;Floxacillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Floxacillin [Susceptibility] by Minimum lethal concentration (MLC);Floxacillin Islt MLC;;ACTIVE;1.0;2.19 +24440-0;Isovalerylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Isovalerylglycine/Creatinine [Molar ratio] in Urine;Isovalerylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24441-8;Phenylpropionylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phenylpropionylglycine/Creatinine [Molar ratio] in Urine;PPG/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24442-6;Propionylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Propionylglycine/Creatinine [Molar ratio] in Urine;Propionylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24443-4;Suberylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Suberylglycine/Creatinine [Molar ratio] in Urine;Suberylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24444-2;Tiglylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tiglylglycine/Creatinine [Molar ratio] in Urine;Tiglylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24445-9;Valerylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Valerylglycine/Creatinine [Molar ratio] in Urine;Valerylgly/Creat Ur-sRto;;ACTIVE;1.0o;2.70 +24446-7;Porphobilinogen;MCnc;Pt;Urine;Qn;;CHEM;1;Porphobilinogen [Mass/volume] in Urine;PBG Ur-mCnc;;ACTIVE;1.0o;2.73 +24447-5;Magnesium;MRat;24H;Urine;Qn;;CHEM;1;Magnesium [Mass/time] in 24 hour Urine;Magnesium 24h Ur-mRate;;ACTIVE;1.0o;2.73 +2444-8;Hydroxymethylglutaryl CoA lyase;CCnc;Pt;Ser;Qn;;CHEM;1;Hydroxymethylglutaryl CoA lyase [Enzymatic activity/volume] in Serum;HMG-CoA Lyase Ser-cCnc;;ACTIVE;1.0;2.68 +24448-3;Carnitine;SRat;24H;Urine;Qn;;CHEM;1;Carnitine [Moles/time] in 24 hour Urine;Carnitine 24h Ur-sRate;;ACTIVE;1.0o;2.70 +24449-1;Carnitine esters;SCnc;Pt;Urine;Qn;;CHEM;1;Carnitine esters [Moles/volume] in Urine;Carn esters Ur-sCnc;;ACTIVE;1.0o;2.40 +24450-9;Carnitine esters;SCnt;Pt;Tiss;Qn;;CHEM;1;Carnitine esters [Moles/mass] in Tissue;Carn esters Tiss-sCnt;;ACTIVE;1.0o;2.40 +24451-7;Carnitine;SCnt;Pt;Tiss;Qn;;CHEM;1;Carnitine [Moles/mass] in Tissue;Carnitine Tiss-sCnt;;ACTIVE;1.0o;2.40 +24452-5;Carnitine.free (C0);SCnt;Pt;Tiss;Qn;;CHEM;1;Carnitine free (C0) [Moles/mass] in Tissue;Carnitine Free Tiss-sCnt;;ACTIVE;1.0o;2.40 +24453-3;Carnitine;SCnt;Pt;Tiss;-;;CHEM;1;Deprecated Carnitine (C0) [Molecules/mass] in Tissue;Deprecated Carnitine Tiss;;DEPRECATED;1.0o;2.66 +24454-1;Collection duration;Time;*;Gast fld;Qn;;SPEC;1;Collection duration of Gastric fluid;Collect duration Time Gast;;ACTIVE;1.0o;2.44 +2445-5;Hydroxyproline;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Hydroxyproline [Presence] in Serum or Plasma;OH-Proline SerPl Ql;;ACTIVE;1.0;2.73 +24456-6;Deoxypyridinoline/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Deoxypyridinoline/Creatinine [Molar ratio] in 24 hour Urine;DPD/Creat 24h Ur-sRto;;ACTIVE;1.0o;2.73 +24457-4;Tryptophan;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Tryptophan [Molecules/volume] in Serum or Plasma;Deprecated Tryptophan SerPl-sCnc;;DEPRECATED;1.0o;2.36 +24458-2;Interleukin 2 receptor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 receptor [Mass/volume] in Serum or Plasma;Il2Recep SerPl-mCnc;;ACTIVE;1.0o;2.73 +24459-0;Thyrotropin^20M post dose TRH;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --20 minutes post dose TRH;TSH 20M p TRH SerPl-mCnc;;DISCOURAGED;1.0o;2.42 +24461-6;Fatty acids;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids [Moles/volume] in Serum or Plasma;FA SerPl-sCnc;;ACTIVE;1.0o;2.73 +24462-4;Heptacarboxylporphyrin;MRat;24H;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/time] in 24 hour Urine;Hepta-CP 24h Ur-mRate;;ACTIVE;1.0o;2.73 +2446-3;Hydroxyproline;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxyproline [Mass/volume] in Serum or Plasma;OH-Proline SerPl-mCnc;;ACTIVE;1.0;2.73 +24463-2;Keratan sulfate;PrThr;Pt;Urine;Ord;;CHEM;1;Keratan sulfate [Presence] in Urine;Keratan Sulfate Ur Ql;;ACTIVE;1.0o;2.56 +24464-0;Chondroitin sulfate;PrThr;Pt;Urine;Ord;;CHEM;1;Chondroitin sulfate [Presence] in Urine;Chondrotin Sulf Ur Ql;;ACTIVE;1.0o;2.56 +24465-7;Urea nitrogen;MRat;12H;Urine;Qn;;CHEM;1;Urea nitrogen [Mass/time] in 12 hour Urine;UUN 12h Ur-mRate;;ACTIVE;1.0o;2.73 +24466-5;Cells.CD56/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD56 cells/100 cells in Unspecified specimen;Deprecated CD56 Cells Fr XXX;;DEPRECATED;1.0o;2.70 +24467-3;Cells.CD3+CD4+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells [#/volume] in Blood;CD3+CD4+ Cells # Bld;;ACTIVE;1.0o;2.73 +24468-1;Cells.CD14+CD16+CD59+;PrThr;Pt;Ser;Ord;;CELLMARK;1;CD14+CD16+CD59+ cells [Presence] in Serum;CD14+CD16+CD59+ Cells Ser Ql;;ACTIVE;1.0o;2.56 +24469-9;Hemoglobin XXX/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin XXX/Hemoglobin.total in Blood by Electrophoresis;Hgb XXX MFr Bld Elph;;ACTIVE;1.0o;2.73 +24470-7;Hemoglobin A2+XXX/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A2+XXX/Hemoglobin.total in Blood by Electrophoresis;Hgb A2+XXX MFr Bld Elph;;ACTIVE;1.0o;2.70 +2447-1;Hydroxyproline;MRat;24H;Urine;Qn;;CHEM;1;Hydroxyproline [Mass/time] in 24 hour Urine;OH-Proline 24h Ur-mRate;;ACTIVE;1.0;2.73 +24471-5;Platelet function.collagen+EPINEPHrine induced;Time;Pt;Bld;Qn;;COAG;1;Platelet function (closure time) collagen+EPINEPHrine induced [Time] in Blood;Closure Tme Coll+Epinep Bld;;ACTIVE;1.0o;2.73 +24472-3;Platelet function.collagen+Adenosine diphosphate induced;Time;Pt;Bld;Qn;;COAG;1;Platelet function (closure time) collagen+ADP induced [Time] in Blood;Closure Tme Coll+ADP Bld;;ACTIVE;1.0o;2.73 +24473-1;Cells.CD23/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD23 cells/100 cells in Unspecified specimen;Deprecated CD23 Cells Fr XXX;;DEPRECATED;1.0o;2.70 +24474-9;Cancer associated serum Ag;ACnc;Pt;Ser;Qn;;CHEM;1;Cancer associated serum Ag [Units/volume] in Serum;CASA Ser-aCnc;;ACTIVE;1.0o;2.73 +24475-6;F2 gene.c.20210G>A;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F2 gene c.20210G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal;F2 c.20210G>A Geno Bld/T;;ACTIVE;1.0o;2.73 +24476-4;F2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;F2 gene Mut Anl Bld/T;;ACTIVE;1.0o;2.73 +24477-2;F2 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;F2 gene Mut Tested Bld/T;;ACTIVE;1.0o;2.73 +24478-0;(Dactylis glomerata+Festuca elatior+Lolium perenne+Phleum pratense+Poa pratensis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 1 (Orchard grass+Meadow Fescue+Perennial rye grass+Timothy+Kentucky blue grass) IgE Ab RAST class [Presence] in Serum by Multidisk;Grass Allerg Mix1 IgE RAST Ql;;ACTIVE;1.0o;2.56 +24479-8;(Acer negundo+Betula verrucosa+Quercus alba+Ulmus americana+Juglans californica) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 1 (Boxelder+Silver birch+White oak+White elm+California walnut) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix1 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24480-6;(Ambrosia elatior+Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Salsola kali) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 1 (Common ragweed+Mugwort+Goosefoot or Lambs quarters+English plantain+Saltwort) IgE Ab [Units/volume] in Serum by Multidisk;Weed Allerg Mix1 IgE Qn;;ACTIVE;1.0o;2.73 +24481-4;(Ambrosia elatior+Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Salsola kali) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 1 (Common ragweed+Mugwort+Goosefoot or Lambs quarters+English plantain+Saltwort) IgE Ab RAST class [Presence] in Serum by Multidisk;Weed Allerg Mix1 IgE RAST Ql;;ACTIVE;1.0o;2.56 +24482-2;(Hordeum vulgare+Oryza sativa+Secale cereale+Triticum aestivum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 20 (Barley+Rice+Rye+Wheat) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix20 IgE RAST Ql;;ACTIVE;1.0o;2.56 +24483-0;(Cat dander+Cow dander+Dog dander+Horse dander) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 1 (Cat dander+Cow dander+Dog dander+Horse dander) IgE Ab RAST class [Presence] in Serum by Multidisk;Epid Allerg Mix1 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24484-8;(Arachis hypogaea+Cow milk+Egg white+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 5 (Peanut+Cow milk+Egg white+Cod+Soybean+Wheat) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix5 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24485-5;(Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 1 (Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) IgE Ab RAST class [Presence] in Serum by Multidisk;Mold Allerg Mix1 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24486-3;(Cynodon dactylon+Lolium perenne+Phleum pratense+Poa pratensis+Sorghum halepense+Paspalum notatum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 2 (Bermuda grass+Perennial rye grass+Timothy+Kentucky blue grass+Johnson grass+Bahia grass) IgE Ab RAST class [Presence] in Serum by Multidisk;Grass Allerg Mix2 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24487-1;(Gadus morhua+Mytilus edulis+Pandalus borealis+Salmo salar+Thunnus albacares) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 2 (Cod+Blue Mussel+Shrimp+Salmon+Tuna) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix2 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24488-9;(Chicken feather+Duck feather+Goose feather+Parrot feather) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 73 (Chicken feather+Duck feather+Goose feather+Parrot feather) IgE Ab RAST class [Presence] in Serum by Multidisk;Epid Allerg Mix73 IgE RAST Ql;;ACTIVE;1.0o;2.56 +2448-9;Hydroxyproline.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxyproline Free [Mass/volume] in Serum or Plasma;OH-Proline Free SerPl-mCnc;;ACTIVE;1.0;2.73 +24489-7;(Acer negundo+Quercus alba+Ulmus americana+Populus deltoides+Carya illinoinensis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 2 (Boxelder+White oak+White elm+Cottonwood+Pecan/Hickory) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix2 IgE RAST Ql;;ACTIVE;1.0o;2.56 +24490-5;(Juniperus sabinoides+Quercus alba+Ulmus americana+Populus deltoides+Prosopis juliflora) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 3 (Mountain juniper+White oak+White elm+Cottonwood+Mesquite) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix3 IgE RAST Ql;;ACTIVE;1.0o;2.56 +24491-3;(Quercus alba+Ulmus americana+Platanus acerifolia+Salix caprea+Populus deltoides) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 4 (White oak+White elm+London plane or Maple leaf sycamore+Willow+Cottonwood) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix4 IgE Qn;;ACTIVE;1.0o;2.73 +24492-1;(Quercus alba+Ulmus americana+Platanus acerifolia+Salix caprea+Populus deltoides) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 4 (White oak+White elm+London plane or Maple leaf sycamore+Willow+Cottonwood) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix4 IgE RAST Ql;;ACTIVE;1.0o;2.56 +24493-9;(Ambrosia psilostachya+Artemisia vulgaris+Atriplex lentiformis+Chenopodium album+Plantago lanceolata) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 2 (Western ragweed+Mugwort+Lenscale+Goosefoot or Lambs quarters+English plantain) IgE Ab [Units/volume] in Serum by Multidisk;Weed Allerg Mix2 IgE Qn;;ACTIVE;1.0o;2.73 +24494-7;(Ambrosia psilostachya+Artemisia vulgaris+Atriplex lentiformis+Chenopodium album+Plantago lanceolata) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 2 (Western ragweed+Mugwort+Lenscale+Goosefoot or Lambs quarters+English plantain) IgE Ab RAST class [Presence] in Serum by Multidisk;Weed Allerg Mix2 IgE RAST Ql;;ACTIVE;1.0o;2.56 +24495-4;(Chicken feather+Duck feather+Goose feather+Turkey feather) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 71 (Chicken feather+Duck feather+Goose feather+Turkey feather) IgE Ab RAST class [Presence] in Serum by Multidisk;Epid Allerg Mix71 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24496-2;(Avena sativa+Hordeum vulgare+Oryza sativa+Secale cereale+Triticum aestivum+Zea mays) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix C (Oat+Barley+Rice+Rye+Wheat+Corn) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix C IgE RAST Ql;;ACTIVE;1.0o;2.56 +2449-7;Hydroxyproline.free;MCnc;Pt;Urine;Qn;;CHEM;1;Hydroxyproline Free [Mass/volume] in Urine;OH-Proline Free Ur-mCnc;;ACTIVE;1.0;2.73 +24497-0;Canary serum proteins Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Canary serum proteins Ab [Presence] in Serum by Immune diffusion (ID);Canary Serum Prot Ab Ql ID;;ACTIVE;1.0o;2.56 +24498-8;Chicken serum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Chicken serum Ab [Presence] in Serum by Immune diffusion (ID);Chicken Serum Ab Ql ID;;ACTIVE;1.0o;2.73 +24499-6;Cryptostroma corticale Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Cryptostroma corticale Ab [Presence] in Serum by Immune diffusion (ID);C corticale Ab Ser Ql ID;;ACTIVE;1.0o;2.56 +24500-1;Parrot serum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Parrot serum Ab [Presence] in Serum by Immune diffusion (ID);Parrot Serum Ab Ql ID;;ACTIVE;1.0o;2.73 +24501-9;Parrot droppings Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Parrot droppings Ab [Presence] in Serum by Immune diffusion (ID);Parrot Drop Ab Ql ID;;ACTIVE;1.0o;2.73 +24502-7;Parakeet serum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Parakeet serum Ab [Presence] in Serum by Immune diffusion (ID);Parakeet Serum Ab Ql ID;;ACTIVE;1.0o;2.73 +24503-5;Parakeet droppings Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Parakeet droppings Ab [Presence] in Serum by Immune diffusion (ID);Parakeet Drop Ab Ql ID;;ACTIVE;1.0o;2.73 +24504-3;Pullularia sp Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Pullularia sp Ab [Presence] in Serum by Immune diffusion (ID);Pullaria Ab Ql ID;;ACTIVE;1.0o;2.56 +2450-5;Hydroxyproline.free;MRat;24H;Urine;Qn;;CHEM;1;Hydroxyproline Free [Mass/time] in 24 hour Urine;OH-Proline Free 24h Ur-mRate;;ACTIVE;1.0;2.73 +24505-0;Pigeon droppings Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Pigeon droppings Ab [Presence] in Serum by Immune diffusion (ID);Pigeon Drop Ab Ql ID;;ACTIVE;1.0o;2.73 +24506-8;(Blatella germanica+Dermatophagoides farinae+Dermatophagoides pteronyssinus+House dust Hollister Stier) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Dust Allergen Mix 2 (Cockroach+American house dust mite+European house dust mite+House dust Hollister Stier) IgE Ab RAST class [Presence] in Serum by Multidisk;Dust Allerg Mix2 IgE RAST Ql;;ACTIVE;1.0o;2.73 +24507-6;Aspergillus clavatus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus clavatus Ab [Presence] in Serum by Immune diffusion (ID);A clavatus Ab Ser Ql ID;;ACTIVE;1.0o;2.56 +24508-4;Aspergillus nidulans Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus nidulans Ab [Presence] in Serum by Immune diffusion (ID);A nidulans Ab Ser Ql ID;;ACTIVE;1.0o;2.73 +24509-2;Aspergillus terreus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus terreus Ab [Presence] in Serum by Immune diffusion (ID);A terreus Ab Ser Ql ID;;ACTIVE;1.0o;2.73 +245-1;Floxacillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Floxacillin [Susceptibility] by Minimum inhibitory concentration (MIC);Floxacillin Islt MIC;;ACTIVE;1.0;2.19 +24510-0;Vespa crabro Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European Hornet IgE Ab RAST class [Presence] in Serum;European Hornet IgE RAST Ql;;ACTIVE;1.0o;2.58 +24511-8;Pascopyrum smithii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Western wheatgrass IgE Ab [Units/volume] in Serum;West wheatgrass IgE Qn;;ACTIVE;1.0o;2.42 +24512-6;(Citharexylum caudatum+Juniperus monosperma+Juniperus scopulorum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix C (Berry juniper+Oneseed juniper+Rocky mountain juniper) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix C IgE Qn;;ACTIVE;1.0o;2.73 +2451-3;Hydroxyproline;MCnc;Pt;Urine;Qn;;CHEM;1;Hydroxyproline [Mass/volume] in Urine;OH-Proline Ur-mCnc;;ACTIVE;1.0;2.73 +24513-4;(Citharexylum caudatum+Juniperus monosperma+Juniperus scopulorum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix C (Berry juniper+Oneseed juniper+Rocky mountain juniper) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix C IgE RAST Ql;;ACTIVE;1.0o;2.73 +24514-2;Maple syrup Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Maple syrup IgE Ab RAST class [Presence] in Serum;Maple Syrup IgE RAST Ql;;ACTIVE;1.0o;2.58 +24515-9;(Anthoxanthum odoratum+Cynodon dactylon+Lolium perenne+Phleum pratense+Sorghum halepense) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix A (Sweet vernal grass+Bermuda grass+Perennial rye grass+Timothy+Johnson grass) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allerg Mix A IgE Qn;;ACTIVE;1.0o;2.73 +24516-7;Pascopyrum smithii Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Western wheatgrass IgE Ab RAST class [Presence] in Serum;West wheatgrass IgE RAST Ql;;ACTIVE;1.0o;2.58 +24517-5;Phoma sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phoma sp IgG Ab [Units/volume] in Serum;Phoma IgG Qn;;ACTIVE;1.0o;2.73 +24518-3;Calcium/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Calcium/Creatinine [Molar ratio] in Urine;Calcium/Creat Ur-sRto;;ACTIVE;1.0o;2.73 +24519-1;Phosphate;SCnc;Pt;Bld;Qn;;CHEM;1;Phosphate [Moles/volume] in Blood;Phosphate Bld-sCnc;;ACTIVE;1.0o;2.70 +24520-9;Phosphate;SCnc;Pt;RBC;Qn;;CHEM;1;Phosphate [Moles/volume] in Red Blood Cells;Phosphate RBC-sCnc;;ACTIVE;1.0o;2.70 +2452-1;Hypoxanthine;MCnc;Pt;Body fld;Qn;;CHEM;1;Hypoxanthine [Mass/volume] in Body fluid;Hypoxanthine Fld-mCnc;;ACTIVE;1.0;2.42 +24521-7;EPINEPHrine;SCnc;Pt;Urine;Qn;;CHEM;1;EPINEPHrine [Moles/volume] in Urine;Epineph Ur-sCnc;;ACTIVE;1.0o;2.73 +24522-5;EPINEPHrine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;EPINEPHrine/Creatinine [Molar ratio] in Urine;Epineph/Creat Ur-sRto;;ACTIVE;1.0o;2.70 +24523-3;Norepinephrine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Norepinephrine/Creatinine [Molar ratio] in Urine;Norepineph/Creat Ur-sRto;;ACTIVE;1.0o;2.70 +24524-1;DOPamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;DOPamine/Creatinine [Molar ratio] in Urine;DOPamine/Creat Ur-sRto;;ACTIVE;1.0o;2.70 +24525-8;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Cardiac index by US;LV Cardiac index US;;ACTIVE;1.0o;2.48 +24526-6;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Cardiac output by US;LV Output US;;ACTIVE;1.0o;2.48 +24527-4;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US.2D.mod.single-plane;CARD.US;2;Left ventricular Myocardial mass by US 2D modified single-plane;LV Myo mass US.2D.MOD-SP;;ACTIVE;1.0o;2.54 +24528-2;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane;CARD.US;2;Left ventricular Myocardial mass by US 2D modified biplane;LV Myo mass US.2D.MOD-BP;;ACTIVE;1.0o;2.54 +24529-0;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.mod.biplane;CARD.US;2;Left ventricular End-systolic volume by US 2D modified biplane;LV ES vol US.2D.MOD-BP;;ACTIVE;1.0o;2.52 +24530-8;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Teichholz method;CARD.US;2;Left ventricular End-systolic volume by US.M-mode+Calculated by Teichholz method;LV ES vol US.M-mode+Teichholz;;ACTIVE;1.0o;2.52 +24531-6;Multisection;Find;Pt;Abdomen>Retroperitoneum;Doc;US;RAD;2;US Retroperitoneum;US Retroperitoneum;;ACTIVE;1.0o;2.61 +24532-4;Multisection;Find;Pt;Abdomen>Right upper quadrant;Doc;US;RAD;2;US Abdomen RUQ;US Abd RUQ;;ACTIVE;1.0o;2.73 +24533-2;Multisection^W contrast IV;Find;Pt;Abdomen>Abdominal vessels;Doc;MR.angio;RAD;2;MRA Abdominal vessels W contrast IV;MRA Abd ves W contr IV;;ACTIVE;1.0o;2.61 +24534-0;Multisection;Find;Pt;Abdomen>Abdominal vessels;Doc;US.doppler;RAD;2;US.doppler Abdominal vessels;DOP Abd ves;;ACTIVE;1.0o;2.61 +24535-7;Views;Find;Pt;Lower extremity>Acetabulum;Doc;XR;RAD;2;XR Acetabulum Views;XR Acetabulum Views;;ACTIVE;1.0o;2.64 +24536-5;Views;Find;Pt;Upper extremity>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular Joint Views;XR AC joint Views;;ACTIVE;1.0o;2.73 +24537-3;Guidance for aspiration of amniotic fluid;Find;Pt;Pelvis>Uterus;Doc;US;RAD;2;US Guidance for aspiration of amniotic fluid of Uterus;US Guided Uterus Amn fld asp;;ACTIVE;1.0o;2.64 +24538-1;Multisection;Find;Pt;Lower extremity>Ankle;Doc;MR;RAD;2;MR Ankle;MR Ankle;;ACTIVE;1.0o;2.73 +2453-9;Hypoxanthine;MCnc;Pt;Ser;Qn;;CHEM;1;Hypoxanthine [Mass/volume] in Serum;Hypoxanthine Ser-mCnc;;ACTIVE;1.0;2.42 +24539-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Ankle;Doc;MR;RAD;2;MR Ankle WO and W contrast IV;MR Ankle WO+W contr IV;;ACTIVE;1.0o;2.61 +24540-7;Views 2;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle 2 Views;XR Ankle 2V;;ACTIVE;1.0o;2.61 +24541-5;Views;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle Views;XR Ankle Views;;ACTIVE;1.0o;2.64 +24542-3;Multisection;Find;Pt;Pelvis>Anus;Doc;US;RAD;2;US Anus;US Anus;;ACTIVE;1.0o;2.61 +24543-1;Guidance for angioplasty^W contrast IA;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Thoracic and abdominal aorta-- W contrast IA;RFA Guided TA + AA Angio--W contr IA;;ACTIVE;1.0o;2.64 +24544-9;Multisection;Find;Pt;Chest>Aorta.thoracic;Doc;CT;RAD;2;CT Thoracic Aorta;CT TA;;ACTIVE;1.0o;2.73 +24545-6;Multisection^W contrast IV;Find;Pt;Chest>Aorta.thoracic;Doc;CT;RAD;2;CT Thoracic Aorta W contrast IV;CT TA W contr IV;;ACTIVE;1.0o;2.61 +24546-4;Views^W contrast IA;Find;Pt;Aorta.thoracic.arch;Doc;RF.angio;RAD;2;Deprecated RFA Aortic arch W contrast IA;Deprecated TA arch RFA W contr IA;;DEPRECATED;1.0o;2.61 +2454-7;Hypoxanthine phosphoribosyltransferase;CCnc;Pt;RBC;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase [Enzymatic activity/volume] in Red Blood Cells;HPRT RBC-cCnc;;ACTIVE;1.0;2.44 +24547-2;Multisection;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;US;RAD;2;US Thoracic and abdominal aorta;US TA + AA;;ACTIVE;1.0o;2.61 +24548-0;Multisection;Find;Pt;Abdomen+Pelvis>Appendix;Doc;US;RAD;2;US Appendix;US Appendix;;ACTIVE;1.0o;2.73 +24549-8;Multisection^W contrast IV;Find;Pt;Upper extremity>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels W contrast IV;MRA UE ves W contr IV;;ACTIVE;1.0o;2.61 +24550-6;Views^W contrast IV;Find;Pt;Upper extremity>Upper extremity veins;Doc;RF.angio;RAD;2;RFA Upper extremity veins Views W contrast IV;RFA UE vv Views W contr IV;;ACTIVE;1.0o;2.64 +24551-4;Views^W contrast IA;Find;Pt;XXX>AV fistula;Doc;RF.angio;RAD;2;RFA AV fistula Views W contrast IA;RFA AVF Views W contr IA;;ACTIVE;1.0o;2.64 +24552-2;Views^W contrast intra stent;Find;Pt;XXX>Stent;Doc;RF;RAD;2;RF Stent Views W contrast intra stent;RF Stent Views W contr intra stnt;;ACTIVE;1.0o;2.64 +24553-0;Guidance for removal of embolus^W contrast IV;Find;Pt;Head>Intracranial vessel;Doc;RF.angio;RAD;2;RFA Guidance for embolectomy of Intracranial vessel-- W contrast IV;RFA Guided IC ves Embolec--W contr IV;;ACTIVE;1.0o;2.67 +2455-4;Hypoxanthine phosphoribosyltransferase;CCnt;Pt;Tiss;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase [Enzymatic activity/mass] in Tissue;HPRT Tiss-cCnt;;ACTIVE;1.0;2.42 +24554-8;Guidance for embolization^W contrast IA;Find;Pt;XXX>Artery;Doc;RF.angio;RAD;2;RFA Guidance for embolization of Artery-- W contrast IA;RFA Guided Artery Embol--W contr IA;;ACTIVE;1.0o;2.64 +24555-5;Guidance for placement of stent;Find;Pt;XXX>Artery;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Artery;RFA Guided Artery Stent place;;ACTIVE;1.0o;2.64 +24556-3;Multisection;Find;Pt;Abdomen;Doc;MR;RAD;2;MR Abdomen;MR Abd;;ACTIVE;1.0o;2.73 +24557-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen;Doc;MR;RAD;2;MR Abdomen WO and W contrast IV;MR Abd WO+W contr IV;;ACTIVE;1.0o;2.73 +24558-9;Multisection;Find;Pt;Abdomen;Doc;US;RAD;2;US Abdomen;US Abd;;ACTIVE;1.0o;2.73 +24559-7;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Abdomen;US Guided Abd Drain+cath place;;ACTIVE;1.0o;2.66 +24560-5;View AP L-lateral-decubitus;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen AP left lateral-decubitus;XR port Abd AP L-lat decub;;ACTIVE;1.0o;2.61 +24561-3;View AP L-lateral-decubitus;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP left lateral-decubitus;XR Abd AP L-lat decub;;ACTIVE;1.0o;2.61 +2456-2;Iduronate-2-Sulfatase;CCnt;Pt;Tiss;Qn;;CHEM;1;Iduronate-2-Sulfatase [Enzymatic activity/mass] in Tissue;Iduronate2Sulfatas Tiss-cCnt;;ACTIVE;1.0;2.42 +24562-1;Views L-lateral-decubitus + R-lateral-decubitus;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Left lateral-decubitus and Right lateral-decubitus;XR Abd L+R Lat Decub;;ACTIVE;1.0o;2.61 +24563-9;View AP R-lateral-decubitus;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP right lateral-decubitus;XR Abd AP R-lat decub;;ACTIVE;1.0o;2.61 +24564-7;View AP upright;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen AP upright;XR port Abd AP upr;;ACTIVE;1.0o;2.61 +24565-4;Views AP (KUB & upright) & upright chest;Find;Pt;Chest+Abdomen;Nar;XR;RAD;2;Deprecated Chest and Abdomen Narrative X-ray;Deprecated Chest+Abd XR;;DEPRECATED;1.0o;2.40 +24566-2;Multisection;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Retroperitoneum;CT Retroperitoneum;;ACTIVE;1.0o;2.61 +24567-0;Multisection^W contrast;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;Deprecated Abdomen>Retroperitoneum CT W contrast;Deprecated Abd>Retroperitoneum CT W cont;;DEPRECATED;1.0o;2.58 +24568-8;Guidance for atherectomy^W contrast IV;Find;Pt;XXX>AV fistula;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of AV fistula-- W contrast IV;RFA Guided AVF Atherect--W contr IV;;ACTIVE;1.0o;2.64 +24569-6;Views^W contrast IV;Find;Pt;XXX>AV shunt;Doc;RF.angio;RAD;2;RFA AV shunt Views W contrast IV;RFA AV shunt Views W contr IV;;ACTIVE;1.0o;2.64 +2457-0;IgA;MCnc;Pt;CSF;Qn;;CHEM;1;IgA [Mass/volume] in Cerebral spinal fluid;IgA CSF-mCnc;;ACTIVE;1.0;2.73 +24570-4;Guidance for removal of calculus^W contrast retrograde intra biliary;Find;Pt;Abdomen>Biliary duct.common;Doc;RF;RAD;2;RF Guidance for removal of calculus from Biliary duct common-- W contrast retrograde intra biliary;RF Guided CBD Calc rem--W contr retro IB;;ACTIVE;1.0o;2.64 +24571-2;Views for patency of biliary structures+ejection fraction^W sincalide+W radionuclide IV;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Biliary ducts and Gallbladder Views for patency of biliary structures and ejection fraction W sincalide and W radionuclide IV;NM BDs+GB Bil Pat+EF W Sinc+RNC IV;;ACTIVE;1.0o;2.64 +24572-0;Views for patency of biliary structures^W Tc-99m IV;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Biliary ducts and Gallbladder Views for patency of biliary structures W Tc-99m IV;NM BDs+GB Views for bil pat W Tc99mIV;;ACTIVE;1.0o;2.64 +24573-8;Views^W contrast IV;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;XR;RAD;2;XR Biliary ducts and Gallbladder Views W contrast IV;XR BDs+GB Views W contr IV;;ACTIVE;1.0o;2.64 +24574-6;Views^during surgery W contrast biliary duct;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;RF;RAD;2;RF Biliary ducts and Gallbladder Views during surgery W contrast biliary duct;RF BDs+GB Views in Surg W contr BD;;ACTIVE;1.0o;2.64 +24575-3;Views^W contrast percutaneous transhepatic;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;RF;RAD;2;RF Biliary ducts and Gallbladder Views W contrast percutaneous transhepatic;RF BDs+GB Views W contr PC transhepatic;;ACTIVE;1.0o;2.64 +24576-1;Views^W contrast IA;Find;Pt;Pelvis>Urinary bladder arteries;Doc;RF.angio;RAD;2;RFA Urinary bladder arteries Views W contrast IA;RFA Bladder aa Views W contr IA;;ACTIVE;1.0o;2.64 +24577-9;Views^during surgery;Find;Pt;XXX>Bone;Doc;XR;RAD;2;XR Bone Views during surgery;XR Bone Views in Surg;;ACTIVE;1.0o;2.64 +24578-7;Multisection^W radionuclide IV;Find;Pt;XXX>Bones;Doc;NM.SPECT;RAD;2;SPECT Bones;SPECT Bones W RNC IV;;ACTIVE;1.0o;2.61 +24579-5;Views survey;Find;Pt;XXX>Bones.long;Doc;XR;RAD;2;XR Long bones Survey Views;XR Bones.long Survey;;ACTIVE;1.0o;2.64 +24580-3;Guidance for angioplasty^W contrast IA;Find;Pt;Chest>Brachiocephalic artery;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Brachiocephalic artery-- W contrast IA;RFA Guided BrachCeph a Angio--W contr IA;;ACTIVE;1.0o;2.64 +24581-1;Views^W contrast IA;Find;Pt;Chest>Subclavian artery & Upper extremity>Brachial artery;Doc;RF.angio;RAD;2;RFA Subclavian artery and Brachial artery Views W contrast IA;RFA Subclav a+Brach a Views W contr IA;;ACTIVE;1.0o;2.64 +24582-9;Multisection;Find;Pt;Chest>Brachial plexus;Doc;MR;RAD;2;MR Brachial plexus;MR Brachial plexus;;ACTIVE;1.0o;2.61 +24583-7;Multisection^WO & W contrast IV;Find;Pt;Chest>Brachial plexus;Doc;MR;RAD;2;MR Brachial plexus WO and W contrast IV;MR Brachial plexus WO+W contr IV;;ACTIVE;1.0o;2.61 +24584-5;Multisection^W contrast IV;Find;Pt;Chest>Thoracic inlet vessels;Doc;MR.angio;RAD;2;MRA Thoracic inlet vessels W contrast IV;MRA TI ves W contr IV;;ACTIVE;1.0o;2.61 +24585-2;Guidance for stereotactic biopsy^W contrast IV;Find;Pt;Head;Doc;CT;RAD;2;CT Guidance for stereotactic biopsy of Head-- W contrast IV;CT Guided Head Str Bx--W contr IV;;ACTIVE;1.0o;2.64 +24586-0;Multisection^W anesthesia;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain W anesthesia;MR Brain W anesthesia;;ACTIVE;1.0o;2.61 +24587-8;Multisection^WO & W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain WO and W contrast IV;MR Brain WO+W contr IV;;ACTIVE;1.0o;2.73 +2458-8;IgA;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgA [Mass/volume] in Serum or Plasma;IgA SerPl-mCnc;;ACTIVE;1.0;2.73 +24588-6;Multisection^WO & W contrast IV+W anesthesia;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain WO and W contrast IV and W anesthesia;MR Brain WO+W contr IV+Anesthesia;;ACTIVE;1.0o;2.61 +24589-4;Multisection^W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain W contrast IV;MR Brain W contr IV;;ACTIVE;1.0o;2.61 +24590-2;Multisection;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain;MR Brain;;ACTIVE;1.0o;2.73 +24591-0;Views brain death protocol^W Tc-99m HMPAO IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Brain death protocol Views W Tc-99m HMPAO IV;NM Brain BD protocol W Tc99mHMPAO IV;;ACTIVE;1.0o;2.64 +24592-8;Views^W 99m Tc DISIDA or MIBIDA;Find;Pt;Brain;Nar;Radnuc;RAD;2;Deprecated Views^W 99m Tc DISIDA or MIBIDA;Deprecated Brain RI;;DEPRECATED;1.0o;2.36 +24593-6;Multisection^W contrast IV;Find;Pt;Head>Head vessels;Doc;MR.angio;RAD;2;MRA Head vessels W contrast IV;MRA Head ves W contr IV;;ACTIVE;1.0o;2.61 +24594-4;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for aspiration of cyst of Breast;MG Guided Brst Cyst asp;;ACTIVE;1.0o;2.64 +24595-1;Guidance for needle localization of mass;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for needle localization of mass of Breast;MG Guided Brst Needle loc mass;;ACTIVE;1.0o;2.64 +2459-6;IgA.monoclonal;MCnc;Pt;Ser;Qn;;CHEM;1;IgA.monoclonal [Mass/volume] in Serum;M-IgA Ser-mCnc;;ACTIVE;1.0;2.73 +24596-9;Multisection;Find;Pt;^Breast specimen;Doc;US;RAD;2;US Breast specimen;US Brst spec;;ACTIVE;1.0o;2.61 +24597-7;Views;Find;Pt;^Breast specimen;Doc;MG;RAD;2;MG Breast specimen Views;MG Brst spec Views;;ACTIVE;1.0o;2.73 +24598-5;Guidance for percutaneous aspiration of fluid;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for fluid aspiration of Breast;MG Guided Brst PC fluid asp;;ACTIVE;1.0o;2.64 +24599-3;Multisection limited;Find;Pt;Breast;Doc;US;RAD;2;US Breast limited;US Brst Ltd;;ACTIVE;1.0o;2.61 +24600-9;Guidance for needle localization;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for needle localization of Breast;US Guided Brst Needle loc;;ACTIVE;1.0o;2.64 +24601-7;Multisection;Find;Pt;Breast;Doc;US;RAD;2;US Breast;US Brst;;ACTIVE;1.0o;2.73 +24602-5;Guidance for percutaneous biopsy;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for biopsy of Breast;MG Guided Brst Bx;;ACTIVE;1.0o;2.64 +24603-3;Guidance for percutaneous biopsy;Find;Pt;Breast;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for biopsy of Breast;MG.stereo Guided Brst Bx;;ACTIVE;1.0o;2.64 +2460-4;IgD;MCnc;Pt;Ser;Qn;;CHEM;1;IgD [Mass/volume] in Serum;IgD Ser-mCnc;;ACTIVE;1.0;2.73 +24604-1;Views limited diagnostic;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Diagnostic Limited Views;MG Brst Views Dx Ltd;;ACTIVE;1.0o;2.64 +24605-8;Views diagnostic;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Diagnostic;MG Brst Dx;;ACTIVE;1.0o;2.73 +24606-6;Views screening;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Screening;MG Brst screening;;ACTIVE;1.0o;2.73 +24609-0;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for percutaneous biopsy.core needle of Breast;MG Guided Brst PC Bx CN;;ACTIVE;1.0o;2.64 +24610-8;Views limited;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Limited Views;MG Brst Views Ltd;;ACTIVE;1.0o;2.64 +24611-6;Confirmatory consultation note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Consultation 2nd opinion;OP Confirm consult note;;ACTIVE;1.0o;2.54 +2461-2;IgD.monoclonal;MCnc;Pt;Ser;Qn;;CHEM;1;IgD.monoclonal [Mass/volume] in Serum;M-IgD Ser-mCnc;;ACTIVE;1.0;2.42 +24612-4;Views;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus Views;XR Heel Views;;ACTIVE;1.0o;2.73 +24613-2;Guidance for placement of catheter in artery;Find;Pt;Cardiovascular.central artery;Doc;RF.angio;RAD;2;Deprecated RFA Guidance for placement of catheter in artery in Central cardiovascular artery;Deprecated Cent CV a RFA Cath plac guid;;DEPRECATED;1.0o;2.61 +24614-0;Guidance for angioplasty^W contrast IA;Find;Pt;Neck>Carotid artery.extracranial;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Carotid artery extracranial-- W contrast IA;RFA Guided Carot a.EC Angio--W contr IA;;ACTIVE;1.0o;2.64 +24615-7;Guidance for angioplasty^W contrast IA;Find;Pt;Head>Carotid artery.intracranial;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Carotid artery.intracranial-- W contrast IA;RFA Guided Carot a.IC Angio--W contr IA;;ACTIVE;1.0o;2.64 +24616-5;Multisection;Find;Pt;Head+Neck>Carotid arteries;Doc;US;RAD;2;US Carotid arteries;US Carotid aa;;ACTIVE;1.0o;2.73 +24617-3;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries;Doc;RF.angio;RAD;2;RFA Carotid arteries Views W contrast IA;RFA Carotid aa Views W contr IA;;ACTIVE;1.0o;2.64 +24619-9;Views;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Views;XR Wrist Views;;ACTIVE;1.0o;2.64 +2462-0;IgE;MCnc;Pt;Ser;Qn;;CHEM;1;IgE [Mass/volume] in Serum;IgE Ser-mCnc;;ACTIVE;1.0;2.73 +24620-7;Views for patency check^W contrast via catheter;Find;Pt;XXX>Catheter;Doc;RF;RAD;2;RF Catheter Views for patency check W contrast via catheter;RF Catheter Vs patency W contr via cath;;ACTIVE;1.0o;2.73 +24621-5;Guidance for percutaneous drainage+placement of drainage catheter;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for percutaneous drainage and placement of drainage catheter of Unspecified body region;RF Guided PC drn+cath place;;ACTIVE;1.0o;2.66 +24622-3;Views^W contrast IA;Find;Pt;Abdomen>Celiac artery;Doc;RF.angio;RAD;2;RFA Celiac artery Views W contrast IA;RFA Celiac a Views W contr IA;;ACTIVE;1.0o;2.64 +24623-1;Guidance for nerve block;Find;Pt;Abdomen>Celiac plexus;Doc;CT;RAD;2;CT Guidance for nerve block of Celiac plexus;CT Guided Celiac plexus Nerve block;;ACTIVE;1.0o;2.64 +24624-9;Guidance for change of central venous catheter^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for change of CV catheter in Vein-- W contrast IV;RFA Guided Vein CVC change--W contr IV;;ACTIVE;1.0o;2.64 +24625-6;Guidance for placement of central venous catheter^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for placement of CV catheter in Vein-- W contrast IV;RFA Guided Vein CVC place--W contr IV;;ACTIVE;1.0o;2.64 +24626-4;Guidance for reposition of central venous catheter^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for reposition of CV catheter in Vein-- W contrast IV;RFA Guided Vein CVC repos--W contr IV;;ACTIVE;1.0o;2.64 +24627-2;Multisection;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest;CT Chest;;ACTIVE;1.0o;2.73 +24628-0;Multisection^W contrast IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest W contrast IV;CT Chest W contr IV;;ACTIVE;1.0o;2.73 +24629-8;Multisection;Find;Pt;Chest;Doc;MR;RAD;2;MR Chest;MR Chest;;ACTIVE;1.0o;2.61 +24630-6;Multisection;Find;Pt;Chest;Doc;US;RAD;2;US Chest;US Chest;;ACTIVE;1.0o;2.73 +24631-4;Views for placement check of central venous catheter;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views for central venous catheter placement check;RF Views for CVC place ck;;ACTIVE;1.0o;2.64 +24632-2;Views AP;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Views AP;XR port Chest Views AP;;ACTIVE;1.0o;2.73 +24634-8;Views^W inspiration + W expiration;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Views W inspiration and expiration;XR port Chest Views W insp+exp;;ACTIVE;1.0o;2.64 +24635-5;Views PA upright^W inspiration + W expiration;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA upright Views W inspiration and expiration;XR Chest Views PA Upr W insp+exp;;ACTIVE;1.0o;2.64 +24636-3;View AP L-lateral-decubitus;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest AP left lateral-decubitus;XR port Chest AP L-lat decub;;ACTIVE;1.0o;2.61 +24637-1;View AP L-lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP left lateral-decubitus;XR Chest AP L-lat decub;;ACTIVE;1.0o;2.61 +2463-8;IgE.monoclonal;MCnc;Pt;Ser;Qn;;CHEM;1;IgE.monoclonal [Mass/volume] in Serum;M-IgE Ser-mCnc;;ACTIVE;1.0;2.73 +24638-9;View L-lateral upright;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Left lateral upright;XR port Chest L-lat upr;;ACTIVE;1.0o;2.61 +24639-7;View L-lateral upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Left lateral upright;XR Chest L-lat upr;;ACTIVE;1.0o;2.61 +24640-5;View apical lordotic;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Apical lordotic;XR Chest Apical lord;;ACTIVE;1.0o;2.73 +24641-3;View L-oblique;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Left oblique;XR port Chest L-obl;;ACTIVE;1.0o;2.61 +24642-1;Views AP + PA upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP and PA upright;XR Chest AP+PA Upr;;ACTIVE;1.0o;2.61 +24643-9;Views PA + lateral + oblique upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and Oblique upright;XR Chest PA+Lat+Obl Upr;;ACTIVE;1.0o;2.61 +24644-7;Views PA + lateral upright;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest PA and Lateral upright;XR port Chest PA+Lat Upr;;ACTIVE;1.0o;2.61 +24645-4;Views PA + R-lateral + R-oblique + L-oblique upright;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest PA and Right lateral and Right oblique and Left oblique upright;XR port Chest PA+R-Lat+R-Obl+L-Obl Upr;;ACTIVE;1.0o;2.61 +2464-6;IgG;MCnc;Pt;CSF;Qn;;CHEM;1;IgG [Mass/volume] in Cerebral spinal fluid;IgG CSF-mCnc;;ACTIVE;1.0;2.73 +24646-2;Views PA + R-lateral + R-oblique + L-oblique upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Right lateral and Right oblique and Left oblique upright;XR Chest PA+R-Lat+R-Obl+L-Obl Upr;;ACTIVE;1.0o;2.61 +24647-0;Views PA + lateral upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral upright;XR Chest PA+Lat Upr;;ACTIVE;1.0o;2.61 +24648-8;View PA upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA upright;XR Chest PA upr;;ACTIVE;1.0o;2.73 +24649-6;Views R-lateral-decubitus + L-lateral-decubitus;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Right lateral-decubitus and Left lateral-decubitus;XR port Chest R+L-Lat Decub;;ACTIVE;1.0o;2.61 +24650-4;Views R-lateral-decubitus + L-lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Right lateral-decubitus and Left lateral-decubitus;XR Chest R+L-Lat Decub;;ACTIVE;1.0o;2.61 +24651-2;Views R-oblique + L-oblique upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Right oblique and Left oblique upright;XR Chest R-Obl+L-Obl Upr;;ACTIVE;1.0o;2.61 +24652-0;View AP R-lateral-decubitus;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest AP right lateral-decubitus;XR port Chest AP R-lat decub;;ACTIVE;1.0o;2.61 +2465-3;IgG;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgG [Mass/volume] in Serum or Plasma;IgG SerPl-mCnc;;ACTIVE;1.0;2.73 +24653-8;Views AP + AP R-lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP and AP right lateral-decubitus;XR Chest AP+AP R-Lat Debub;;ACTIVE;1.0o;2.61 +24654-6;Views AP + AP R-lateral-decubitus;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest AP and AP right lateral-decubitus;XR port Chest AP+AP R-Lat Debub;;ACTIVE;1.0o;2.61 +24655-3;Image intensifier^during surgery;Find;Pt;Chest;Doc;RF;RAD;2;RF Chest Image intensifier during surgery;RF Chest Image intensifier in Surg;;DISCOURAGED;1.0o;2.61 +24656-1;View^during surgery;Find;Pt;Chest;Doc;RF;RAD;2;RF Chest Single view during surgery;RF Chest 1V in Surg;;ACTIVE;1.0o;2.64 +24657-9;Multisection;Find;Pt;Chest;Doc;XR.tomography;RAD;2;XR tomography Chest;XR tomo Chest;;ACTIVE;1.0o;2.61 +24658-7;Views^W contrast IA;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;RF.angio;RAD;2;RFA Thoracic and abdominal aorta Views W contrast IA;RFA TA + AA Views W contr IA;;ACTIVE;1.0o;2.64 +24659-5;Multisection^W contrast IV;Find;Pt;Chest>Chest vessels;Doc;MR.angio;RAD;2;MRA Chest vessels W contrast IV;MRA Chest ves W contr IV;;ACTIVE;1.0o;2.61 +24660-3;Multisection;Find;Pt;Chest>Aorta.thoracic;Doc;MR.angio;RAD;2;MRA Thoracic Aorta;MRA TA;;ACTIVE;1.0o;2.61 +2466-1;IgG subclass 1;MCnc;Pt;Ser;Qn;;CHEM;1;IgG subclass 1 [Mass/volume] in Serum;IgG1 Ser-mCnc;;ACTIVE;1.0;2.73 +24661-1;Views^W contrast intra pleural space;Find;Pt;Chest>Pleural space;Doc;RF;RAD;2;RF Pleural space Views W contrast intra pleural space;RF Pl space Views W contr intra PS;;ACTIVE;1.0o;2.73 +24662-9;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Pleural space;Doc;US;RAD;2;US Guidance for fluid aspiration of Pleural space;US Guided Pl space PC fluid asp;;ACTIVE;1.0o;2.64 +24663-7;Views^W radionuclide IT;Find;Pt;Head+Neck>Cerebral cisterns;Doc;NM;RAD;2;NM Cerebral cisterns Views W radionuclide IT;NM Cerebral cist Views W RNC IT;;ACTIVE;1.0o;2.64 +24664-5;Views;Find;Pt;Chest>Clavicle;Doc;XR;RAD;2;XR Clavicle Views;XR Clavicle Views;;ACTIVE;1.0o;2.64 +24665-2;Views;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Sacrum and Coccyx Views;XR Sacrum+Coccyx Views;;ACTIVE;1.0o;2.73 +24666-0;Views^W air contrast PR+W barium contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views W air and barium contrast PR;RF Colon Views W Air+Ba PR;;ACTIVE;1.0o;2.64 +24667-8;Views^W contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views W contrast PR;RF Colon Views W contr PR;;ACTIVE;1.0o;2.64 +24668-6;View for transit^post solid contrast PO;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Single view for transit Post solid contrast;RF Colon 1V for transit p solid contr PO;;ACTIVE;1.0o;2.64 +24669-4;Views^W water soluble contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views W water soluble contrast PR;RF Colon Views W H2O sol contr PR;;ACTIVE;1.0o;2.64 +24670-2;Guidance for biopsy of cyst;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for biopsy of cyst of Unspecified body region;US Guided Cyst Bx;;ACTIVE;1.0o;2.64 +24671-0;Guidance for percutaneous aspiration of cyst;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for aspiration of cyst of Unspecified body region;RF Guided Cyst asp;;ACTIVE;1.0o;2.64 +24672-8;Multisection for motion;Find;Pt;Chest>Diaphragm;Doc;US;RAD;2;US Diaphragm for motion;US Diaphragm for motion;;ACTIVE;1.0o;2.61 +24673-6;Views^W contrast PO+hypotonic agent per ng;Find;Pt;Abdomen>Duodenum;Doc;RF;RAD;2;Deprecated Duodenum Radio fluoroscopy W contrast PO and hypotonic agent per ng;Deprecated Flr W contr PO+Hypo Agent NG;;DEPRECATED;1.0o;2.61 +24674-4;Multisection;Find;Pt;Upper extremity>Elbow;Doc;MR;RAD;2;MR Elbow;MR Elbow;;ACTIVE;1.0o;2.61 +24675-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Elbow;Doc;MR;RAD;2;MR Elbow WO and W contrast IV;MR Elbow WO+W contr IV;;ACTIVE;1.0o;2.61 +24676-9;Views;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow Views;XR Elbow Views;;ACTIVE;1.0o;2.64 +24677-7;Multisection transvaginal;Find;Pt;Pelvis;Doc;US;RAD;2;US Pelvis transvaginal;US Pelvis Transvag;;ACTIVE;1.0o;2.73 +24678-5;Views^W contrast PO;Find;Pt;Chest>Esophagus;Doc;RF;RAD;2;RF Esophagus Views W contrast PO;RF Esophagus Views W contr PO;;ACTIVE;1.0o;2.73 +2467-9;IgG subclass 2;MCnc;Pt;Ser;Qn;;CHEM;1;IgG subclass 2 [Mass/volume] in Serum;IgG2 Ser-mCnc;;ACTIVE;1.0;2.73 +24679-3;Views^W gastrografin PO;Find;Pt;Chest>Esophagus;Doc;RF;RAD;2;RF Esophagus Views W gastrografin PO;RF Esophagus Views W Gastrografin PO;;ACTIVE;1.0o;2.64 +24680-1;Guidance for dilation;Find;Pt;Chest>Esophagus;Doc;RF;RAD;2;RF Guidance for dilation of Esophagus;RF Guided Esophagus Dilation;;ACTIVE;1.0o;2.64 +24681-9;Views^W contrast PO+during swallowing;Find;Pt;Neck>Hypopharynx & Chest>Esophagus;Doc;RF.video;RAD;2;RF videography Hypopharynx and Esophagus Views;RF vid Hypoph+Esophagus cont PO Swal fn;;ACTIVE;1.0o;2.64 +24682-7;Views^W liquid contrast PO+W paste contrast PO+during swallowing;Find;Pt;Neck>Hypopharynx & Chest>Esophagus;Doc;RF.video;RAD;2;RF videography Hypopharynx and Esophagus Views W liquid and paste contrast PO during swallowing;RF vid Hypoph+Esophagus Liq+Pst Swal fn;;ACTIVE;1.0o;2.64 +24683-5;Views^W Tc-99m SC PO;Find;Pt;Chest>Esophagus & Abdomen>Stomach;Doc;NM;RAD;2;NM Esophagus+Stomach Views W Tc-99m SC PO;NM Esophagus+Stom Views W Tc99mSC PO;;ACTIVE;1.0o;2.64 +24684-3;Guidance for removal of embolus^W contrast IA;Find;Pt;XXX>Extracranial vessels;Doc;RF.angio;RAD;2;RFA Guidance for embolectomy of Extracranial vessels-- W contrast IA;RFA Guided EC vess Embolec--W contr IA;;ACTIVE;1.0o;2.67 +24685-0;Views^W contrast IV;Find;Pt;XXX>Peripheral veins;Doc;RF.angio;RAD;2;RFA Peripheral veins Views W contrast IV;RFA Periph vv Views W contr IV;;ACTIVE;1.0o;2.64 +24686-8;Views;Find;Pt;Lower extremity;Doc;XR;RAD;2;XR Lower extremity Views;XR LE Views;;ACTIVE;1.0o;2.64 +2468-7;IgG subclass 3;MCnc;Pt;Ser;Qn;;CHEM;1;IgG subclass 3 [Mass/volume] in Serum;IgG3 Ser-mCnc;;ACTIVE;1.0;2.73 +24687-6;Multisection;Find;Pt;Lower extremity>Lower extremity joint;Doc;MR;RAD;2;MR Lower Extremity Joint;MR LE joint;;ACTIVE;1.0o;2.73 +24688-4;Multisection;Find;Pt;Upper extremity;Doc;MR;RAD;2;MR Upper extremity;MR UE;;ACTIVE;1.0o;2.61 +24689-2;Views;Find;Pt;Upper extremity;Doc;XR;RAD;2;XR Upper extremity Views;XR UE Views;;ACTIVE;1.0o;2.64 +246-9;Floxacillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Floxacillin [Susceptibility] by Disk diffusion (KB);Floxacillin Islt KB;;ACTIVE;1.0;2.19 +24690-0;Multisection;Find;Pt;Extremity;Doc;CT;RAD;2;CT Extremity;CT Extr;;ACTIVE;1.0o;2.73 +24691-8;Multisection^W contrast IV;Find;Pt;Extremity;Doc;CT;RAD;2;CT Extremity W contrast IV;CT Extr W contr IV;;ACTIVE;1.0o;2.61 +24692-6;Guidance for drainage+placement of drainage catheter;Find;Pt;Extremity;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Extremity;US Guided Extr Drain+cath place;;ACTIVE;1.0o;2.66 +24693-4;Multisection;Find;Pt;Extremity;Doc;US;RAD;2;US Extremity;US Extr;;ACTIVE;1.0o;2.73 +24694-2;Multisection^WO & W contrast IV;Find;Pt;Head>Face;Doc;MR;RAD;2;MR Face WO and W contrast IV;MR Face WO+W contr IV;;ACTIVE;1.0o;2.61 +2469-5;IgG subclass 4;MCnc;Pt;Ser;Qn;;CHEM;1;IgG subclass 4 [Mass/volume] in Serum;IgG4 Ser-mCnc;;ACTIVE;1.0;2.73 +24695-9;Views;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones Views;XR Face Views;;ACTIVE;1.0o;2.73 +24696-7;Multisection;Find;Pt;Head>Facial bones;Doc;CT;RAD;2;CT Facial bones;CT Face;;ACTIVE;1.0o;2.73 +24697-5;Multisection^W contrast IV;Find;Pt;Head>Facial bones;Doc;CT;RAD;2;CT Facial bones W contrast IV;CT Face W contr IV;;ACTIVE;1.0o;2.61 +24698-3;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity>Femoral artery;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Femoral artery-- W contrast IA;RFA Guided Fem a Angio--W contr IA;;ACTIVE;1.0o;2.64 +24699-1;View runoff^W contrast IA;Find;Pt;Lower extremity>Femoral artery;Doc;RF.angio;RAD;2;RFA Femoral artery Runoff W contrast IA;RFA Fem a Runoff W contr IA;;ACTIVE;1.0o;2.61 +24700-7;Views for leg length;Find;Pt;Lower extremity>Femur+Tibia;Doc;XR;RAD;2;XR Femur and Tibia Views for leg length;XR Femur+Tib Views for leg length;;ACTIVE;1.0o;2.73 +24701-5;Views for bone density;ArMass;Pt;Lower extremity>Femur;Qn;DXA;RAD;2;DXA Femur [Mass/Area] Bone density;DXA Femur ArMass BMD;;ACTIVE;1.0o;2.64 +24702-3;Multisection;Find;Pt;Lower extremity>Thigh;Doc;MR;RAD;2;MR Thigh;MR Thigh;;ACTIVE;1.0o;2.61 +2470-3;IgG/Albumin;MRto;Pt;CSF;Qn;;CHEM;1;IgG/Albumin [Mass Ratio] in Cerebral spinal fluid;IgG/Alb CSF;;ACTIVE;1.0;2.73 +24703-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Thigh;Doc;MR;RAD;2;MR Thigh WO and W contrast IV;MR Thigh WO+W contr IV;;ACTIVE;1.0o;2.61 +24704-9;Views;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur Views;XR Femur Views;;ACTIVE;1.0o;2.73 +24705-6;Multisection;Find;Pt;Upper extremity>Finger;Doc;MR;RAD;2;MR Finger;MR Finger;;ACTIVE;1.0o;2.61 +24706-4;Views;Find;Pt;Upper extremity>Finger;Doc;XR;RAD;2;XR Finger Views;XR Finger Views;;ACTIVE;1.0o;2.64 +24707-2;Multisection;Find;Pt;Lower extremity>Foot;Doc;MR;RAD;2;MR Foot;MR Foot;;ACTIVE;1.0o;2.61 +24708-0;Views^W standing;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Views W standing;XR Foot Views W Stand;;ACTIVE;1.0o;2.64 +24709-8;Views;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Views;XR Foot Views;;ACTIVE;1.0o;2.64 +24710-6;Multisection;Find;Pt;Upper extremity>Forearm;Doc;MR;RAD;2;MR Forearm;MR Forearm;;ACTIVE;1.0o;2.61 +2471-1;IgM;MCnc;Pt;CSF;Qn;;CHEM;1;IgM [Mass/volume] in Cerebral spinal fluid;IgM CSF-mCnc;;ACTIVE;1.0;2.73 +24711-4;Multisection;Find;Pt;Abdomen>Gallbladder;Doc;US;RAD;2;US Gallbladder;US GB;;ACTIVE;1.0o;2.73 +24712-2;Views^W contrast PO;Find;Pt;Abdomen>Gallbladder;Doc;XR;RAD;2;XR Gallbladder Views W contrast PO;XR GB Views W contr PO;;ACTIVE;1.0o;2.64 +24713-0;Views^48H post contrast PO intrabiliary;Find;Pt;Abdomen>Gallbladder;Doc;XR;RAD;2;XR Gallbladder Views 48H post contrast PO;XR GB Views 48H p con PO IB;;ACTIVE;1.0o;2.64 +24714-8;Views for gastrointestinal bleeding^W Tc-99m tagged RBC IV;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;NM;RAD;2;NM Gastrointestinal tract Views for gastrointestinal bleeding W Tc-99m tagged RBC IV;NM GI tract Vs GI bleed W Tc99m RBC IV;;ACTIVE;1.0o;2.64 +24715-5;View^W contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Gastrointestinal tract upper Single view W contrast PO;RF UGI 1V W contr PO;;ACTIVE;1.0o;2.73 +24716-3;Guidance for placement of decompression tube;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;RF;RAD;2;RF Guidance for placement of decompression tube in Gastrointestinal tract;RF Guided GI tract Decompr tube place;;ACTIVE;1.0o;2.64 +24717-1;Loopogram;Find;Pt;Abdomen>Ileal conduit;Doc;XR;RAD;2;Deprecated XR Ileal conduit Loopogram;Deprecated XR Ileal conduit Loopogram;;DEPRECATED;1.0o;2.64 +24718-9;Guidance for transjugular biopsy^W contrast IV;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;RF Guidance for transjugular biopsy of Liver-- W contrast IV;RF Guided Liver TJ Bx--W contr IV;;ACTIVE;1.0o;2.64 +24719-7;Multisection;Find;Pt;Pelvis>Groin;Doc;US;RAD;2;US Groin;US Groin;;ACTIVE;1.0o;2.73 +24720-5;Multisection;Find;Pt;Upper extremity>Hand;Doc;MR;RAD;2;MR Hand;MR Hand;;ACTIVE;1.0o;2.61 +24721-3;Views 2;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand 2 Views;XR Hand 2V;;ACTIVE;1.0o;2.61 +24722-1;Views 3;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand 3 Views;XR Hand 3V;;ACTIVE;1.0o;2.61 +24723-9;View arthritis;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand Arthritis;XR Hand Arthritis;;ACTIVE;1.0o;2.73 +24724-7;Views bone age;Find;Pt;Upper extremity>Wrist+Hand;Doc;XR;RAD;2;XR Wrist and Hand Bone age Views;XR Wrist+Hand Views bone Age;;ACTIVE;1.0o;2.64 +24725-4;Multisection;Find;Pt;Head;Doc;CT;RAD;2;CT Head;CT Head;;ACTIVE;1.0o;2.73 +24726-2;Multisection^WO & W contrast IV;Find;Pt;Head;Doc;CT;RAD;2;CT Head WO and W contrast IV;CT Head WO+W contr IV;;ACTIVE;1.0o;2.73 +24727-0;Multisection^W contrast IV;Find;Pt;Head;Doc;CT;RAD;2;CT Head W contrast IV;CT Head W contr IV;;ACTIVE;1.0o;2.61 +24728-8;Multisection;Find;Pt;Head;Doc;CT.perfusion;RAD;2;CT perfusion Head;CT.perfusion Head;;ACTIVE;1.0o;2.61 +2472-9;IgM;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgM [Mass/volume] in Serum or Plasma;IgM SerPl-mCnc;;ACTIVE;1.0;2.73 +24729-6;Multisection^WO & W contrast IV;Find;Pt;Head;Doc;CT.perfusion;RAD;2;CT perfusion Head WO and W contrast IV;CT.perfusion Head WO+W contr IV;;ACTIVE;1.0o;2.61 +24730-4;Views^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views;NM Brain Views W RNC IV;;ACTIVE;1.0o;2.64 +24731-2;Multisection;Find;Pt;Head;Doc;US;RAD;2;US Head;US Head;;ACTIVE;1.0o;2.61 +24732-0;Multisection^during surgery;Find;Pt;Head;Doc;US;RAD;2;US Head during surgery;US Head in Surg;;ACTIVE;1.0o;2.61 +24733-8;Multisection;Find;Pt;Head>Head vessels;Doc;US.doppler;RAD;2;US.doppler Head vessels;DOP Head ves;;ACTIVE;1.0o;2.61 +24734-6;Multisection^W contrast IT;Find;Pt;Head+Neck>Cerebral cisterns;Doc;CT;RAD;2;CT Cerebral cisterns W contrast IT;CT Cerebral cist W contr IT;;ACTIVE;1.0o;2.61 +24735-3;Multisection;Find;Pt;Head>Internal auditory canal+Posterior fossa;Doc;MR;RAD;2;MR Internal auditory canal and Posterior fossa;MR IAC+Post fossa;;ACTIVE;1.0o;2.61 +2473-7;IgM.monoclonal;MCnc;Pt;Ser;Qn;;CHEM;1;IgM.monoclonal [Mass/volume] in Serum;M-IgM Ser-mCnc;;ACTIVE;1.0;2.73 +24740-3;Multisection^WO & W contrast IV;Find;Pt;Head>Internal auditory canal+Posterior fossa;Doc;MR;RAD;2;MR Internal auditory canal and Posterior fossa WO and W contrast IV;MR IAC+Post fossa WO+W contr IV;;ACTIVE;1.0o;2.61 +2474-5;Indicans;PrThr;Pt;Urine;Ord;;CHEM;1;Indicans [Presence] in Urine;Indicans Ur Ql;;ACTIVE;1.0;2.73 +24745-2;Views;Find;Pt;Head>Petrous part of temporal bone;Doc;XR;RAD;2;XR Petrous part of temporal bone Views;XR Petr part temp bone Views;;ACTIVE;1.0o;2.64 +24746-0;Multisection;Find;Pt;Head.sagittal sinus;Doc;MR;RAD;2;Deprecated Head Sagittal Sinus MR;Deprecated Head.SS MR;;DEPRECATED;1.0o;2.58 +24747-8;Multisection^W contrast IV;Find;Pt;Head.sagittal sinus;Doc;MR.angio;RAD;2;Deprecated Head Sagittal Sinus MR angiogram W contrast IV;Deprecated Head.SS MR.angio W contr IV;;DEPRECATED;1.0o;2.58 +24748-6;Multisection;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart;MR Hrt;;ACTIVE;1.0o;2.61 +24750-2;Views^at rest+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views at rest and W Tl-201 IV;NM Hrt Views Rest+W Tl201 IV;;ACTIVE;1.0o;2.64 +24751-0;Views^W TI-201 subtraction Tc-99m IV;Find;Pt;Neck>Parathyroid gland;Doc;NM;RAD;2;NM Parathyroid gland Views W TI-201 subtraction Tc-99m IV;NM Parathyroid gland Vs W TI201-Tc99m IV;;ACTIVE;1.0o;2.64 +2475-2;Indicans;MCnc;Pt;Urine;Qn;;CHEM;1;Indicans [Mass/volume] in Urine;Indicans Ur-mCnc;;ACTIVE;1.0;2.44 +24752-8;Views;Find;Pt;Chest>Heart;Doc;RF.video;RAD;2;RF videography Heart Views;RF video Hrt Views;;ACTIVE;1.0o;2.64 +24753-6;Multisection^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region W contrast IV;CT W contr IV;;ACTIVE;1.0o;2.69 +24754-4;Administration of vasodilator into catheter;Find;Pt;XXX>Vein;Doc;;DOC.MISC;2;Administration of vasodilator into catheter Vein;VD admin into cath Vein;;ACTIVE;1.0o;2.63 +24755-1;Guidance for atherectomy^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Vein-- W contrast IV;RFA Guided Vein Atherect--W contr IV;;ACTIVE;1.0o;2.64 +24756-9;Guidance for placement of stent;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Vein;RFA Guided Vein Stent place;;ACTIVE;1.0o;2.64 +24757-7;Multisection;Find;Pt;Coronary arteries;Doc;CT.fast;RAD;2;Deprecated Coronary arteries CT fast;Deprecated Coronary aa CT.Fast;;DEPRECATED;1.0o;2.58 +2476-0;Indolamine;MCnc;Pt;Ser;Qn;;CHEM;1;Indolamine [Mass/volume] in Serum;Indolamine Ser-mCnc;;DISCOURAGED;1.0;2.44 +24760-1;Multisection;Find;Pt;Lower extremity>Hip;Doc;US;RAD;2;US Hip;US Hip;;ACTIVE;1.0o;2.61 +24761-9;View;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Single view;XR Hip 1V;;ACTIVE;1.0o;2.64 +24762-7;Views;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Views;XR Hip Views;;ACTIVE;1.0o;2.64 +24764-3;Views^W contrast IS;Find;Pt;Lower extremity>Hip;Doc;RF;RAD;2;RF Hip Arthrogram;RF Hip Views W contr IS;;ACTIVE;1.0o;2.64 +24765-0;Views 2;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus 2 Views;XR Humerus 2V;;ACTIVE;1.0o;2.61 +24766-8;Guidance for angioplasty^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Iliac artery-- W contrast IA;RFA Guided Iliac a Angio--W contr IA;;ACTIVE;1.0o;2.64 +24767-6;Multisection;Find;Pt;Head>Internal auditory canal;Doc;XR.tomography;RAD;2;XR tomography Internal auditory canal;XR tomo IAC;;ACTIVE;1.0o;2.61 +24769-2;Guidance for injection;Find;Pt;XXX>Joint space;Doc;CT;RAD;2;CT Guidance for injection of Joint space;CT Guided Joint space Inj;;ACTIVE;1.0o;2.64 +247-7;Floxacillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Floxacillin [Susceptibility] by Serum bactericidal titer;Floxacillin Titr SBT;;ACTIVE;1.0;2.32 +24770-0;Views^W In-111 intrajoint;Find;Pt;XXX>Joint;Doc;NM;RAD;2;NM Joint Views W In-111 intrajoint;NM Joint Views W In-111 Intrajoint;;ACTIVE;1.0o;2.64 +24771-8;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Joint space;Doc;RF;RAD;2;RF Guidance for arthrocentesis of Joint space;RF Guided Joint space Arthrocentesis;;ACTIVE;1.0o;2.66 +24772-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for biopsy of Kidney;US Guided Kidney Bx;;ACTIVE;1.0o;2.64 +24773-4;Views^W radionuclide transplant scan;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views W radionuclide transplant scan;NM Kidney Views W RNC Transplant Scan;;ACTIVE;1.0o;2.64 +24774-2;Multisection;Find;Pt;Kidney.bilateral+Collecting system;Nar;CT;RAD;2;Deprecated Kidney - bilateral and Collecting system CT;Deprecated KD-Bl+CS CT;;DEPRECATED;1.0o;2.40 +24775-9;Multisection^W contrast IV;Find;Pt;Kidney.bilateral+Collecting system;Nar;CT;RAD;2;Deprecated Kidney - bilateral and Collecting system CT W contrast IV;Deprecated KD-Bl+CS CT W contr IV;;DEPRECATED;1.0o;2.40 +24776-7;Views^W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views;NM Kidney Views W RNC IV;;ACTIVE;1.0o;2.64 +24777-5;Multisection;Find;Pt;Kidney.bilateral+Collecting system;Nar;US;RAD;2;Deprecated Kidney - bilateral and Collecting system US;Deprecated;;DEPRECATED;1.0o;2.40 +2477-8;Indole;MCnc;Pt;Ser;Qn;;CHEM;1;Indole [Mass/volume] in Serum;Indole Ser-mCnc;;DISCOURAGED;1.0;2.44 +24778-3;Views 3 serial^WO & W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR;RAD;2;XR Kidney - bilateral 3 Serial Views WO and W contrast IV;XR Kdny-Bl 3V Serial WO+W contr IV;;ACTIVE;1.0o;2.64 +24779-1;Guidance for percutaneous placement of nephrostomy tube^W contrast via tube;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Guidance for percutaneous placement of nephrostomy tube of Kidney - bilateral-- W contrast via tube;RF Kdny-Bl NT place W contr via tube;;ACTIVE;1.0o;2.64 +24780-9;Views^W contrast via nephrostomy tube;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Kidney - bilateral Views W contrast via nephrostomy tube;RF Kdny-Bl Views W contr via NT;;ACTIVE;1.0o;2.64 +24781-7;Guidance for percutaneous exchange of nephrostomy tube^W contrast;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Guidance for exchange of nephrostomy tube of Kidney - bilateral-- W contrast;RF Kdny-Bl neph tube exchange W contr;;ACTIVE;1.0o;2.64 +24782-5;Guidance for percutaneous placement of nephroureteral stent^W contrast via stent;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Guidance for percutaneous placement of nephroureteral stent of Kidney - bilateral-- W contrast via stent;RF Guided Bl PCNUS place W cont via st;;ACTIVE;1.0o;2.64 +24783-3;Views for urodynamics;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Kidney - bilateral Views for urodynamics;RF Kdny-Bl Vs for urodynamics;;ACTIVE;1.0o;2.64 +24784-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR.tomography;RAD;2;XR tomography Kidney - bilateral WO and W contrast IV;XR tomo Kdny-Bl WO+W contr IV;;ACTIVE;1.0o;2.61 +24785-8;View 1;Find;Pt;Kidney.bilateral+Collecting system;Nar;XR.tomo;RAD;2;deprecated Kidney - bilateral & Collecting system X-ray tomograph Single view;deprecated KD-Bl+CS XRTomo 1V;;DEPRECATED;1.0o;2.36 +2478-6;Inhibin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin [Mass/volume] in Serum or Plasma;Inhibin SerPl-mCnc;;ACTIVE;1.0;2.73 +24786-6;Multisection^W & WO contrast IV;Find;Pt;Kidney.bilateral+Collecting system;Nar;XR.tomo;RAD;2;Deprecated Kidney Bilateral & Collecting system X-ray tomograph Multisection W & WO contrast IV;Deprecated KD-Bl+CS XR.Tomo W+WO contr I;;DEPRECATED;1.0o;2.36 +24787-4;Multisection^WO contrast+10M post contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR.tomography;RAD;2;XR tomography Kidney - bilateral WO contrast and 10M post contrast IV;XR tomo Kdny-Bl WO contr+10m p contr IV;;ACTIVE;1.0o;2.61 +24788-2;Views^W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR;RAD;2;XR Kidney - bilateral Views W contrast IV;XR Kdny-Bl Views W contr IV;;ACTIVE;1.0o;2.64 +24789-0;Multisection;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR.tomography;RAD;2;XR tomography Kidney - bilateral;XR tomo Kdny-Bl;;ACTIVE;1.0o;2.61 +24790-8;Multisection^W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR.tomography;RAD;2;XR tomography Kidney - bilateral W contrast IV;XR tomo Kdny-Bl W contr IV;;ACTIVE;1.0o;2.61 +24791-6;Multisection;Find;Pt;Kidney.bilateral+Collecting system;Nar;XR.tomo;RAD;2;Deprecated Kidney Bilateral & Collecting system X-ray tomograph Multisection;Deprecated KD-Bl+CS XR.Tomo;;DEPRECATED;1.0o;2.36 +24792-4;Views AP + AP L-lateral-decubitus;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen AP and AP left lateral-decubitus;XR port Abd AP+AP L-Lat Decub;;ACTIVE;1.0o;2.61 +24793-2;Views AP + lateral;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen AP and Lateral;XR port Abd AP+Lat;;ACTIVE;1.0o;2.61 +2479-4;Inosine;MCnc;Pt;Ser;Qn;;CHEM;1;Inosine [Mass/volume] in Serum;Inosine Ser-mCnc;;DISCOURAGED;1.0;2.44 +24794-0;Views AP + lateral;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP and Lateral;XR Abd AP+Lat;;ACTIVE;1.0o;2.61 +24795-7;Views supine + upright;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen Supine and Upright;XR port Abd Sup+Upr;;ACTIVE;1.0o;2.61 +24796-5;Views AP + AP L-lateral-decubitus;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP and AP left lateral-decubitus;XR Abd AP+AP L-Lat Decub;;ACTIVE;1.0o;2.61 +24797-3;Views AP + oblique prone;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP and Oblique prone;XR Abd AP+Obl Prone;;ACTIVE;1.0o;2.61 +24798-1;Views supine + upright;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Supine and Upright;XR Abd Sup+Upr;;ACTIVE;1.0o;2.61 +24799-9;View AP;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP;XR Abd AP;;ACTIVE;1.0o;2.73 +24800-5;Views^W contrast IS;Find;Pt;Lower extremity>Knee;Doc;RF;RAD;2;RF Knee Arthrogram;RF Knee Views W contr IS;;ACTIVE;1.0o;2.64 +24801-3;View Merchants;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Merchants;XR Knee Merchants;;ACTIVE;1.0o;2.73 +2480-2;Inositol.free;MCnc;Pt;Ser;Qn;;CHEM;1;Inositol Free [Mass/volume] in Serum;Inositol Free Ser-mCnc;;ACTIVE;1.0;2.42 +24802-1;Multisection;Find;Pt;Lower extremity>Knee;Doc;MR;RAD;2;MR Knee;MR Knee;;ACTIVE;1.0o;2.73 +24803-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Knee;Doc;MR;RAD;2;MR Knee WO and W contrast IV;MR Knee WO+W contr IV;;ACTIVE;1.0o;2.61 +24804-7;Views^W radionuclide IV;Find;Pt;Lower extremity>Knee;Doc;NM;RAD;2;NM Knee Views;NM Knee Views W RNC IV;;ACTIVE;1.0o;2.64 +24805-4;Views AP + lateral^W standing;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral W standing;XR Knee AP+Lat W Stand;;ACTIVE;1.0o;2.61 +24806-2;Views 2;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee 2 Views;XR Knee 2V;;ACTIVE;1.0o;2.61 +24807-0;View AP^W standing;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP W standing;XR Knee AP W Stand;;ACTIVE;1.0o;2.61 +24808-8;Views AP + PA^W standing;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and PA W standing;XR Knee AP+PA W Stand;;DISCOURAGED;1.0o;2.61 +24809-6;Views^W standing;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Views W standing;XR Knee Views W Stand;;ACTIVE;1.0o;2.64 +2481-0;Insulin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Insulin Ab [Presence] in Serum;Insulin Ab Ser Ql;;ACTIVE;1.0;2.73 +24811-2;Guidance for percutaneous aspiration of fluid;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Liver;CT Guided Liver PC fluid asp;;ACTIVE;1.0o;2.64 +24812-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for biopsy of Liver;CT Guided Liver Bx;;ACTIVE;1.0o;2.64 +24813-8;Guidance for biopsy.core needle;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for core needle biopsy of Liver;CT Guided Liver CN Bx;;ACTIVE;1.0o;2.64 +24814-6;Multisection;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Liver;CT Liver;;ACTIVE;1.0o;2.73 +24815-3;Multisection^W contrast IV;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Liver W contrast IV;CT Liver W contr IV;;ACTIVE;1.0o;2.61 +24816-1;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;US Guidance for biopsy of Liver;US Guided Liver Bx;;ACTIVE;1.0o;2.64 +24817-9;Multisection^W Tc-99m IV;Find;Pt;Abdomen>Liver;Doc;NM.SPECT;RAD;2;SPECT Liver W Tc-99m IV;SPECT Liver W Tc99mIV;;ACTIVE;1.0o;2.61 +24818-7;Multisection;Find;Pt;Chest>Diaphragm & Abdomen>Liver;Doc;US;RAD;2;US Diaphragm and Liver;US Diaphragm+Liver;;ACTIVE;1.0o;2.61 +24819-5;Views^W Tc-99m calcium colloid IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM;RAD;2;Deprecated Liver and Spleen NM W Tc-99m calcium colloid IV;Deprecated Liver+Spleen NM W Tc99mCa col;;DEPRECATED;1.0o;2.58 +24820-3;Multisection^W contrast IV;Find;Pt;Lower extremity>Lower leg vessels;Doc;MR.angio;RAD;2;MRA Lower leg vessels W contrast IV;MRA Lower leg ves W contr IV;;ACTIVE;1.0o;2.61 +24821-1;Multisection;Find;Pt;Lower extremity>Lower leg;Doc;MR;RAD;2;MR Lower leg;MR Lower leg;;ACTIVE;1.0o;2.61 +24822-9;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Lung;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Lung;CT Guided Lung PC fluid asp;;ACTIVE;1.0o;2.64 +24823-7;Guidance for percutaneous biopsy;Find;Pt;Chest>Lung;Doc;CT;RAD;2;CT Guidance for biopsy of Lung;CT Guided Lung Bx;;ACTIVE;1.0o;2.64 +24824-5;Views portable^W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Portable Views;NM Lung Views port W RNC IV;;ACTIVE;1.0o;2.64 +24825-2;Views^W contrast intrabronchial;Find;Pt;Chest>Lung;Doc;XR;RAD;2;XR Lung Views W contrast intrabronchial;XR Lung Views W contr IB;;ACTIVE;1.0o;2.64 +24826-0;Views^W radionuclide intra lymphatic;Find;Pt;XXX>Lymphatic vessels;Doc;NM;RAD;2;NM Lymphatic vessels Views W radionuclide intra lymphatic;NM Lymph ves Views W RNC Intra Lymph;;ACTIVE;1.0o;2.73 +24827-8;Views^W contrast intra lymphatic;Find;Pt;XXX>Lymphatic vessels;Doc;RF.angio;RAD;2;RFA Lymphatic vessels Views W contrast intra lymphatic;RFA Lymph ves Views W contr IL;;ACTIVE;1.0o;2.64 +2482-8;Insulin Ab;MCnc;Pt;Ser;Qn;;SERO;1;Insulin Ab [Mass/volume] in Serum;Insulin Ab Ser-mCnc;;ACTIVE;1.0;2.73 +24828-6;View panoramic;Find;Pt;Head>Mandible;Doc;XR.tomography;RAD;2;XR tomography Mandible Panoramic;XR tomo Mandible Panoramic;;ACTIVE;1.0o;2.61 +24829-4;Views;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible Views;XR Mandible Views;;ACTIVE;1.0o;2.64 +24830-2;Views;Find;Pt;Head>Mastoid;Doc;XR;RAD;2;XR Mastoid Views;XR Mastoid Views;;ACTIVE;1.0o;2.64 +24831-0;Views for Meckel's diverticulum^W Tc-99m M04 IV;Find;Pt;Abdomen>Small bowel;Doc;NM;RAD;2;NM Small bowel Views for Meckel's diverticulum W Tc-99m M04 IV;NM Sm bowel Meckel's div W Tc99mM04 IV;;ACTIVE;1.0o;2.64 +24832-8;Guidance for angioplasty^W contrast IA;Find;Pt;Abdomen>Mesenteric artery;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Mesenteric artery-- W contrast IA;RFA Guided Mesent a Angio--W contr IA;;ACTIVE;1.0o;2.64 +24833-6;Views^W contrast IA;Find;Pt;Abdomen>Mesenteric artery;Doc;RF.angio;RAD;2;RFA Mesenteric artery Views W contrast IA;RFA Mesenteric a Views W contr IA;;ACTIVE;1.0o;2.64 +24834-4;Views;Find;Pt;Head>Nasal bones;Doc;XR;RAD;2;XR Nasal bones Views;XR Nasal bones Views;;ACTIVE;1.0o;2.64 +24835-1;Multisection;Find;Pt;Head+Neck>Nasopharynx & Neck;Doc;CT;RAD;2;CT Nasopharynx and Neck;CT Nasopharynx+Neck;;ACTIVE;1.0o;2.61 +2483-6;Insulin-like growth factor binding protein 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma;IGF BP3 SerPl-mCnc;;ACTIVE;1.0;2.73 +24836-9;Multisection^W contrast IV;Find;Pt;Head+Neck>Nasopharynx & Neck;Doc;CT;RAD;2;CT Nasopharynx and Neck W contrast IV;CT Nasopharynx+Neck W contr IV;;ACTIVE;1.0o;2.73 +24837-7;Guidance for percutaneous aspiration of fluid;Find;Pt;Neck;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Neck;CT Guided Neck PC fluid asp;;ACTIVE;1.0o;2.64 +24838-5;Guidance for percutaneous biopsy;Find;Pt;Neck;Doc;CT;RAD;2;CT Guidance for biopsy of Neck;CT Guided Neck Bx;;ACTIVE;1.0o;2.64 +24839-3;Multisection;Find;Pt;Neck;Doc;MR;RAD;2;MR Neck;MR Neck;;ACTIVE;1.0o;2.73 +24840-1;Multisection^WO & W contrast IV;Find;Pt;Neck;Doc;MR;RAD;2;MR Neck WO and W contrast IV;MR Neck WO+W contr IV;;ACTIVE;1.0o;2.61 +24841-9;Multisection^W contrast IV;Find;Pt;Neck;Doc;MR;RAD;2;MR Neck W contrast IV;MR Neck W contr IV;;ACTIVE;1.0o;2.61 +24842-7;Multisection;Find;Pt;Neck;Doc;US;RAD;2;US Neck;US Neck;;ACTIVE;1.0o;2.73 +24843-5;View lateral;Find;Pt;Neck;Doc;XR;RAD;2;XR Neck Lateral;XR Neck Lat;;ACTIVE;1.0o;2.73 +2484-4;Insulin-like growth factor-I;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma;IGF-I SerPl-mCnc;;ACTIVE;1.0;2.73 +24844-3;Multisection^W contrast IV;Find;Pt;Neck>Neck vessels;Doc;MR.angio;RAD;2;MRA Neck vessels W contrast IV;MRA Neck ves W contr IV;;ACTIVE;1.0o;2.61 +24845-0;Views^W contrast intra larynx;Find;Pt;Neck;Doc;RF;RAD;2;RF Neck Views W contrast intra larynx;RF Neck Vs W contr intra Larynx;;ACTIVE;1.0o;2.64 +24846-8;Views;Find;Pt;Head>Optic foramen;Doc;XR;RAD;2;XR Optic foramen Views;XR Optic foramen Views;;ACTIVE;1.0o;2.64 +24848-4;Multisection;Find;Pt;Head>Orbit.bilateral;Doc;CT;RAD;2;CT Orbit - bilateral;CT Orbit-Bl;;ACTIVE;1.0o;2.61 +24849-2;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit.bilateral;Doc;CT;RAD;2;CT Orbit - bilateral WO and W contrast IV;CT Orbit-Bl WO+W contr IV;;ACTIVE;1.0o;2.61 +248-5;Fluconazole;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Fluconazole [Susceptibility] by Minimum lethal concentration (MLC);Fluconazole Islt MLC;;ACTIVE;1.0;2.19 +24850-0;Multisection^W contrast IV;Find;Pt;Head>Orbit.bilateral;Doc;CT;RAD;2;CT Orbit - bilateral W contrast IV;CT Orbit-Bl W contr IV;;ACTIVE;1.0o;2.61 +2485-1;Insulin-like growth factor-II;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor-II [Mass/volume] in Serum or Plasma;IGF-II SerPl-mCnc;;ACTIVE;1.0;2.73 +24851-8;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit.bilateral;Doc;MR;RAD;2;MR Orbit - bilateral WO and W contrast IV;MR Orbit-Bl WO+W contr IV;;ACTIVE;1.0o;2.61 +24852-6;Multisection^W contrast IV;Find;Pt;Head>Orbit.bilateral;Doc;MR;RAD;2;MR Orbit - bilateral W contrast IV;MR Orbit-Bl W contr IV;;ACTIVE;1.0o;2.61 +24853-4;Multisection;Find;Pt;Eye+Orbit.bilateral;Doc;US;EYE.US;2;US Eye+Orbit - bilateral;US Eye+Orbit-Bl;;ACTIVE;1.0o;2.64 +24854-2;Views;Find;Pt;Head>Orbit.bilateral;Doc;XR;RAD;2;XR Orbit - bilateral Views;XR Orbit-Bl Views;;ACTIVE;1.0o;2.64 +24855-9;Views;Find;Pt;Head+Neck>Oropharynx;Doc;RF.video;RAD;2;RF videography Oropharynx Views;RF video Oropharynx Views;;ACTIVE;1.0o;2.64 +24856-7;Guidance for percutaneous aspiration of fluid;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Pancreas;CT Guided Pancreas PC fluid asp;;ACTIVE;1.0o;2.64 +24857-5;Multisection;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Pancreas;CT Pancreas;;ACTIVE;1.0o;2.73 +24858-3;Multisection^W contrast IV;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Pancreas W contrast IV;CT Pancreas W contr IV;;ACTIVE;1.0o;2.61 +24859-1;Multisection;Find;Pt;Abdomen>Pancreas;Doc;US;RAD;2;US Pancreas;US Pancreas;;ACTIVE;1.0o;2.73 +24860-9;Views^W contrast IA;Find;Pt;Abdomen>Pancreatic artery;Doc;RF.angio;RAD;2;RFA Pancreatic artery Views W contrast IA;RFA Panc a Views W contr IA;;ACTIVE;1.0o;2.64 +24861-7;Views 2;Find;Pt;Lower extremity>Patella;Doc;XR;RAD;2;XR Patella 2 Views;XR Patella 2V;;ACTIVE;1.0o;2.61 +24862-5;Views^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.internal;Doc;RF.angio;RAD;2;RFA Iliac artery Internal Views W contrast IA;RFA Iliac a.Int Views W contr IA;;ACTIVE;1.0o;2.64 +24863-3;Guidance for percutaneous aspiration of fluid;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Pelvis;CT Guided Pelvis PC fluid asp;;ACTIVE;1.0o;2.64 +24864-1;Guidance for percutaneous biopsy;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for biopsy of Pelvis;CT Guided Pelvis Bx;;ACTIVE;1.0o;2.64 +24865-8;Multisection;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis;CT Pelvis;;ACTIVE;1.0o;2.73 +24866-6;Multisection^W contrast IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis W contrast IV;CT Pelvis W contr IV;;ACTIVE;1.0o;2.73 +24867-4;Multisection;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis;MR Pelvis;;ACTIVE;1.0o;2.73 +24868-2;Guidance for drainage+placement of drainage catheter;Find;Pt;Pelvis;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Pelvis;US Guided Pelvis Drain+cath place;;ACTIVE;1.0o;2.66 +2486-9;Somatomedins;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatomedins [Mass/volume] in Serum or Plasma;Somatomedins SerPl-mCnc;;DISCOURAGED;1.0;2.44 +24869-0;Multisection;Find;Pt;Pelvis;Doc;US;RAD;2;US Pelvis;US Pelvis;;ACTIVE;1.0o;2.73 +24870-8;Multisection;Find;Pt;Pelvis>Pelvis vessels;Doc;US.doppler;RAD;2;US.doppler Pelvis vessels;DOP Pelvis ves;;ACTIVE;1.0o;2.61 +24871-6;View pelvimetry;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Pelvimetry;XR Pelvis Pelvimetry;;ACTIVE;1.0o;2.61 +24872-4;Multisection;Find;Pt;Pelvis & Lower extremity>Hip;Doc;MR;RAD;2;MR Pelvis and Hip;MR Pelvis and Hip;;ACTIVE;1.0o;2.61 +24873-2;Multisection^W contrast IV;Find;Pt;Pelvis>Pelvis vessels;Doc;MR.angio;RAD;2;MRA Pelvis vessels W contrast IV;MRA Pelvis ves W contr IV;;ACTIVE;1.0o;2.61 +24874-0;Views^W contrast IA;Find;Pt;XXX>Peripheral arteries;Doc;RF.angio;RAD;2;RFA Peripheral arteries Views W contrast IA;RFA Periph aa Views W contr IA;;ACTIVE;1.0o;2.64 +24875-7;Peripheral plane;Find;Pt;Peripheral vessel;Doc;US.doppler;RAD;2;Deprecated Peripheral vessel US.doppler Peripheral plane;Deprecated Periph ves DOP Periph plane;;DEPRECATED;1.0o;2.58 +24876-5;Views for shunt patency^W Tc-99m DTPA IT;Find;Pt;Head+Neck+Chest+Abdomen+Pelvis;Doc;NM;RAD;2;NM Head to Pelvis Views for shunt patency W Tc-99m DTPA IT;NM Head Pelv shunt pat W Tc99mDTPA IT;;ACTIVE;1.0o;2.64 +2487-7;Inter alpha trypsin inhibitor;MCnc;Pt;Ser;Qn;;CHEM;1;Inter alpha trypsin inhibitor [Mass/volume] in Serum;Inter A-Trypsin Inhib Ser-mCnc;;ACTIVE;1.0;2.42 +24877-3;Multisection;Find;Pt;Head>Petrous part of temporal bone;Doc;CT;RAD;2;CT Petrous part of temporal bone;CT Petr part temp bone;;ACTIVE;1.0o;2.61 +24878-1;Multisection^W contrast IV;Find;Pt;Head>Petrous part of temporal bone;Doc;CT;RAD;2;CT Petrous part of temporal bone W contrast IV;CT Petr part temp bone W contr IV;;ACTIVE;1.0o;2.61 +24879-9;Multisection^WO & W contrast IV;Find;Pt;Head>Pituitary+Sella turcica;Doc;MR;RAD;2;MR Pituitary and Sella turcica WO and W contrast IV;MR Pit+Sella turc WO+W contr IV;;ACTIVE;1.0o;2.61 +24880-7;Multisection;Find;Pt;Head>Pituitary+Sella turcica;Doc;MR;RAD;2;MR Pituitary and Sella turcica;MR Pit+Sella turc;;ACTIVE;1.0o;2.61 +24881-5;Multisection;Find;Pt;Lower extremity>Popliteal space;Doc;US;RAD;2;US Popliteal space;US Popliteal space;;ACTIVE;1.0o;2.61 +24882-3;Guidance for percutaneous transluminal angioplasty^W contrast IA;Find;Pt;Lower extremity>Popliteal artery;Doc;RF.angio;RAD;2;RFA Guidance for percutaneous transluminal angioplasty of Popliteal artery-- W contrast IA;RFA Guided Pop a PTA--W contr IA;;ACTIVE;1.0o;2.64 +24883-1;Guidance for percutaneous biopsy;Find;Pt;Pelvis>Prostate;Doc;US;RAD;2;US Guidance for percutaneous biopsy of Prostate;US Guided Prostate Bx;;ACTIVE;1.0o;2.64 +24884-9;Multisection transrectal;Find;Pt;Pelvis>Prostate;Doc;US;RAD;2;US Prostate transrectal;US Prostate transrectal;;ACTIVE;1.0o;2.73 +2488-5;Intrinsic factor;MCnc;Pt;Ser;Qn;;CHEM;1;Intrinsic factor [Mass/volume] in Serum;IF Ser-mCnc;;DISCOURAGED;1.0;2.44 +24885-6;Guidance for repair;Find;Pt;Pseudoaneurysm/AV fistula;Doc;US;RAD;2;Deprecated US Guidance for repair of Pseudoaneurysm/AV fistula;Deprecated PA/AV fistula US Repair guid;;DEPRECATED;1.0o;2.58 +24886-4;Views^W contrast in pulmonary artery;Find;Pt;Pulmonary arteries;Nar;XR.fluor.angio;RAD;2;Deprecated Pulmonary artery Bilateral X-ray fluoroscopy angio W contrast IA;Deprecated PAA XRA;;DEPRECATED;1.0o;2.46 +24887-2;Guidance for removal of embolus^W contrast IA;Find;Pt;Chest>Pulmonary arteries;Doc;RF.angio;RAD;2;RFA Guidance for embolectomy of Pulmonary arteries-- W contrast IA;RFA Guided PA Embolec--W contr IA;;ACTIVE;1.0o;2.67 +24888-0;Views ventilation+perfusion^W Xe-133 IH+W Tc-99m MAA IV;Find;Pt;Chest>Pulmonary system;Doc;NM;RAD;2;NM Pulmonary system Ventilation and Perfusion W Xe-133 IH and W Tc-99m MAA IV;NM Pulm system VP W 133Xe IH+Tc99mMAA IV;;ACTIVE;1.0o;2.61 +24889-8;Multisection for pyloric stenosis;Find;Pt;Abdomen>Pylorus;Doc;US;RAD;2;US Pylorus for pyloric stenosis;US Pylorus for Pyloric Stenosis;;ACTIVE;1.0o;2.61 +24890-6;Views for bone density;ArMass;Pt;Upper extremity>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna [Mass/Area] Bone density;DXA Radius+Ulna ArMass BMD;;ACTIVE;1.0o;2.64 +24891-4;Views;Find;Pt;Upper extremity>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna Views;XR Radius+Ulna Views;;ACTIVE;1.0o;2.64 +24892-2;Multisection;Find;Pt;Pelvis>Rectum;Doc;US;RAD;2;US Rectum;US Rectum;;ACTIVE;1.0o;2.61 +2489-3;Intrinsic factor blocking Ab;Titr;Pt;Ser;Qn;;CHEM;1;Intrinsic factor blocking Ab [Titer] in Serum;IF Block Ab Titr Ser;;ACTIVE;1.0;2.73 +24893-0;View^post contrast PR+during defecation;Find;Pt;Pelvis>Rectum;Doc;RF;RAD;2;RF Rectum Single view post contrast PR during defecation;RF Rectum 1V p contr PR during def;;ACTIVE;1.0o;2.64 +24894-8;Views^W contrast PR+W contrast intra bladder+during defecation+during voiding;Find;Pt;Pelvis>Rectum+Urinary bladder;Doc;RF;RAD;2;RF Rectum and Urinary bladder Views W contrast PR and intra bladder during defecation and voiding;RF Rect+Blad Vs W contr PR+IB def+void;;ACTIVE;1.0o;2.64 +24896-3;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Kidney;US Guided Kidney Drain+cath place;;ACTIVE;1.0o;2.66 +24899-7;Views;Find;Pt;Chest>Ribs;Doc;XR;RAD;2;XR Ribs Views;XR Ribs Views;;ACTIVE;1.0o;2.73 +24900-3;Views;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint Views;XR SIJ Views;;ACTIVE;1.0o;2.73 +2490-1;Inulin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Inulin [Mass/volume] in Serum or Plasma;Inulin SerPl-mCnc;;ACTIVE;1.0;2.34 +24901-1;Guidance for injection;Find;Pt;Pelvis>Sacroiliac joint;Doc;CT;RAD;2;CT Guidance for injection of Sacroiliac Joint;CT Guided SIJ Inj;;ACTIVE;1.0o;2.64 +24902-9;Views^W contrast intra salivary duct;Find;Pt;Head>Salivary gland;Doc;RF;RAD;2;RF Salivary gland Views W contrast intra salivary duct;RF Salivary gland Views W contr intra SD;;ACTIVE;1.0o;2.64 +24903-7;Views;Find;Pt;Chest>Scapula;Doc;XR;RAD;2;XR Scapula Views;XR Scapula Views;;ACTIVE;1.0o;2.64 +24904-5;Multisection^WO & W contrast IV;Find;Pt;Head>Pituitary+Sella turcica;Doc;CT;RAD;2;CT Pituitary and Sella turcica WO and W contrast IV;CT Pit+Sella turc WO+W contr IV;;ACTIVE;1.0o;2.61 +24905-2;Multisection;Find;Pt;Upper extremity>Shoulder;Doc;MR;RAD;2;MR Shoulder;MR Should;;ACTIVE;1.0o;2.73 +24906-0;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Shoulder;Doc;MR;RAD;2;MR Shoulder WO and W contrast IV;MR Should WO+W contr IV;;ACTIVE;1.0o;2.61 +24907-8;Multisection;Find;Pt;Upper extremity>Shoulder;Doc;US;RAD;2;US Shoulder;US Should;;ACTIVE;1.0o;2.73 +24908-6;Views 3;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder 3 Views;XR Should 3V;;ACTIVE;1.0o;2.61 +24909-4;Views;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Views;XR Should Views;;ACTIVE;1.0o;2.73 +24910-2;Views^W contrast IS;Find;Pt;Upper extremity>Shoulder;Doc;RF;RAD;2;RF Shoulder Arthrogram;RF Should Views W contr IS;;ACTIVE;1.0o;2.64 +24911-0;Views;Find;Pt;XXX>Shunt;Doc;RF;RAD;2;RF Shunt Views;RF Shunt Views;;ACTIVE;1.0o;2.64 +24912-8;Views^W contrast intra sinus tract;Find;Pt;XXX>Sinus tract;Doc;RF;RAD;2;RF Sinus tract Views W contrast intra sinus tract;RF Sinus tr Views W contr intra ST;;ACTIVE;1.0o;2.64 +24913-6;Multisection limited;Find;Pt;Head>Sinuses;Doc;CT;RAD;2;CT Sinuses limited;CT Sinuses Ltd;;ACTIVE;1.0o;2.61 +24914-4;Multisection;Find;Pt;Head>Sinuses;Doc;MR;RAD;2;MR Sinuses;MR Sinuses;;ACTIVE;1.0o;2.61 +24915-1;Multisection^W contrast IV;Find;Pt;Head>Sinuses;Doc;MR;RAD;2;MR Sinuses W contrast IV;MR Sinuses W contr IV;;ACTIVE;1.0o;2.61 +24916-9;Views;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Views;XR Sinuses Views;;ACTIVE;1.0o;2.64 +24917-7;View;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Single view;XR Skull 1V;;ACTIVE;1.0o;2.64 +24918-5;Views 3;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull 3 Views;XR Skull 3V;;ACTIVE;1.0o;2.73 +2491-9;Inulin renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Inulin renal clearance in 24 hour Urine and Serum or Plasma;Inulin Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +24919-3;Views AP + lateral;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull AP and Lateral;XR Skull AP+Lat;;ACTIVE;1.0o;2.61 +24920-1;View lateral;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Lateral;XR Skull Lat;;ACTIVE;1.0o;2.61 +24921-9;View Waters;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Waters;XR Skull Waters;;ACTIVE;1.0o;2.61 +24922-7;Views 5;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull 5 Views;XR Skull 5V;;ACTIVE;1.0o;2.61 +24923-5;Views^W positive contrast via enteroclysis tube;Find;Pt;Abdomen>Small bowel;Doc;RF;RAD;2;RF Small bowel Views W positive contrast via enteroclysis tube;RF SB Views W pos contr enterocly tube;;ACTIVE;1.0o;2.64 +24924-3;Views^W contrast PO;Find;Pt;Abdomen>Small bowel;Doc;RF;RAD;2;RF Small bowel Views W contrast PO;RF SB Views W contr PO;;ACTIVE;1.0o;2.64 +24925-0;Views^W contrast IA;Find;Pt;XXX>Spinal artery;Doc;RF.angio;RAD;2;RFA Spinal artery Views W contrast IA;RFA Spinal a Views W contr IA;;ACTIVE;1.0o;2.64 +24926-8;Multisection;Find;Pt;XXX>Spine;Doc;US;RAD;2;US Spine;US Spine;;DISCOURAGED;1.0o;2.61 +2492-7;Iodine;MRat;24H;Urine;Qn;;CHEM;1;Iodine [Mass/time] in 24 hour Urine;Iodine 24h Ur-mRate;;ACTIVE;1.0;2.73 +24927-6;Views^W contrast intradisc;Find;Pt;XXX>Spine;Doc;RF;RAD;2;RF Spine Views W contrast intradisc;RF Spine Views W contr ID;;DISCOURAGED;1.0o;2.64 +24928-4;Views AP + lateral;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine AP and Lateral;XR Spine AP+Lat;;DISCOURAGED;1.0o;2.61 +24929-2;Views for scoliosis^W flexion + W extension;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Views for scoliosis W flexion and W extension;XR T+L-Spine Views for scoli W FE;;ACTIVE;1.0o;2.64 +249-3;Fluconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Fluconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Fluconazole Islt MIC;;ACTIVE;1.0;2.73 +24930-0;Views for scoliosis;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Views for scoliosis;XR T+L-Spine Views for scoli;;ACTIVE;1.0o;2.73 +24931-8;Guidance for injection;Find;Pt;XXX>Spine facet joint;Doc;RF;RAD;2;RF Guidance for injection of Spine facet joint;RF Guided Spine FJ Inj;;ACTIVE;1.0o;2.65 +24932-6;Multisection;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine;CT C-spine;;ACTIVE;1.0o;2.73 +24933-4;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine W contrast IV;CT C-spine W contr IV;;ACTIVE;1.0o;2.61 +24934-2;Multisection^W contrast IT;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine W contrast IT;CT C-spine W contr IT;;ACTIVE;1.0o;2.61 +2493-5;Iodine.free;MCnc;Pt;Urine;Qn;;CHEM;1;Iodine Free [Mass/volume] in Urine;Iodine Free Ur-mCnc;;ACTIVE;1.0;2.73 +24935-9;Multisection;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine;MR C-spine;;ACTIVE;1.0o;2.73 +24936-7;Multisection^W anesthesia;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine W anesthesia;MR C-spine W anesthesia;;ACTIVE;1.0o;2.61 +24937-5;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine WO and W contrast IV;MR C-spine WO+W contr IV;;ACTIVE;1.0o;2.73 +24938-3;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine W contrast IV;MR C-spine W contr IV;;ACTIVE;1.0o;2.61 +24939-1;Views 5;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 5 Views;XR C-spine 5V;;ACTIVE;1.0o;2.73 +24940-9;View;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Single view;XR C-spine 1V;;ACTIVE;1.0o;2.64 +24941-7;Views 3;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 3 Views;XR C-spine 3V;;ACTIVE;1.0o;2.61 +24942-5;Views AP + lateral;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Lateral;XR C-spine AP+Lat;;ACTIVE;1.0o;2.73 +2494-3;Iodine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iodine [Mass/volume] in Serum or Plasma;Iodine SerPl-mCnc;;ACTIVE;1.0;2.73 +24943-3;View lateral;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Lateral;XR C-spine Lat;;ACTIVE;1.0o;2.61 +24944-1;View Swimmers;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Swimmers;XR C-spine Swimmers;;ACTIVE;1.0o;2.61 +24945-8;Views^W flexion + W extension;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Views W flexion and W extension;XR C-spine Views W FE;;ACTIVE;1.0o;2.73 +24946-6;Views;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Views;XR C-spine Views;;ACTIVE;1.0o;2.64 +24947-4;Views^W contrast IT;Find;Pt;Neck>Spine.cervical;Doc;RF;RAD;2;RF Cervical spine Views W contrast IT;RF C-spine Views W contr IT;;ACTIVE;1.0o;2.64 +24948-2;View AP;Find;Pt;Neck>Spine.cervical.odontoid+Spine.cervical.axis;Doc;XR;RAD;2;XR Spine Cervical Odontoid and Cervical axis AP;XR C-spine.odontoid+axis AP 1V;;ACTIVE;1.0o;2.61 +2495-0;Iodine;MCnc;Pt;Urine;Qn;;CHEM;1;Iodine [Mass/volume] in Urine;Iodine Ur-mCnc;;ACTIVE;1.0;2.73 +24963-1;Multisection;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine;CT L-spine;;ACTIVE;1.0o;2.73 +24964-9;Multisection^W contrast IV;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine W contrast IV;CT L-spine W contr IV;;ACTIVE;1.0o;2.61 +24965-6;Multisection^W contrast IT;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine W contrast IT;CT L-spine W contr IT;;ACTIVE;1.0o;2.61 +24966-4;Views for bone density;ArMass;Pt;Abdomen>Spine.lumbar;Qn;DXA;RAD;2;DXA Lumbar spine [Mass/Area] Bone density;DXA L-spine ArMass BMD;;ACTIVE;1.0o;2.64 +24967-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine WO and W contrast IV;MR L-spine WO+W contr IV;;ACTIVE;1.0o;2.73 +2496-8;Iodohippuran renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Iodohippuran renal clearance in 24 hour Urine and Serum or Plasma;Iodohippuran Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +24968-0;Multisection;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine;MR L-spine;;ACTIVE;1.0o;2.73 +24969-8;View lateral;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Lateral;XR L-spine Lat;;ACTIVE;1.0o;2.73 +24970-6;Views AP + lateral;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP and Lateral;XR L-spine AP+Lat;;ACTIVE;1.0o;2.73 +24971-4;Views^W flexion + W extension;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views W flexion and W extension;XR L-spine Views W FE;;ACTIVE;1.0o;2.64 +24972-2;Views;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views;XR L-spine Views;;ACTIVE;1.0o;2.64 +24973-0;Guidance for percutaneous aspiration of fluid;Find;Pt;Abdomen>Spine.lumbar space;Doc;RF;RAD;2;RF Guidance for fluid aspiration of Lumbar spine space;RF Guided L-spine space PC fluid asp;;ACTIVE;1.0o;2.73 +24974-8;Views^W contrast IT;Find;Pt;Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Lumbar spine Views W contrast IT;RF L-spine Views W contr IT;;ACTIVE;1.0o;2.64 +24975-5;Views;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacroiliac joint.bilateral;Doc;XR;RAD;2;XR Spine.lumbar and Sacroiliac joint - bilateral Views;XR L-spine+SIJ-Bl Views;;ACTIVE;1.0o;2.73 +2497-6;Iron;MCnt;Pt;Hair;Qn;;CHEM;1;Iron [Mass/mass] in Hair;Iron Hair-mCnt;;ACTIVE;1.0;2.19 +24977-1;Multisection^W anesthesia;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine W anesthesia;MR L-spine W anesthesia;;ACTIVE;1.0o;2.61 +24978-9;Multisection;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine;CT T-spine;;ACTIVE;1.0o;2.73 +24979-7;Multisection^W contrast IV;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine W contrast IV;CT T-spine W contr IV;;ACTIVE;1.0o;2.61 +24980-5;Multisection;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine;MR T-spine;;ACTIVE;1.0o;2.73 +24981-3;Multisection^WO & W contrast IV;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine WO and W contrast IV;MR T-spine WO+W contr IV;;ACTIVE;1.0o;2.73 +24982-1;Multisection^W contrast IV;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine W contrast IV;MR T-spine W contr IV;;ACTIVE;1.0o;2.61 +24983-9;Views;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Views;XR T-spine Views;;ACTIVE;1.0o;2.64 +2498-4;Iron;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma;Iron SerPl-mCnc;;ACTIVE;1.0;2.73 +24984-7;Views 2;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine 2 Views;XR T+L-Spine 2V;;ACTIVE;1.0o;2.61 +24985-4;Views^W contrast IT;Find;Pt;Chest>Spine.thoracic;Doc;RF;RAD;2;RF Thoracic spine Views W contrast IT;RF T-spine Views W contr IT;;ACTIVE;1.0o;2.64 +24986-2;Guidance for percutaneous biopsy;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Guidance for biopsy of Spine;CT Guided Spine Bx;;DISCOURAGED;1.0o;2.64 +24987-0;Multisection^W contrast IV;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Spine W contrast IV;CT Spine W contr IV;;DISCOURAGED;1.0o;2.61 +24988-8;Multisection;Find;Pt;Abdomen>Spleen;Doc;CT;RAD;2;CT Spleen;CT Spleen;;ACTIVE;1.0o;2.61 +24989-6;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Spleen;Doc;CT;RAD;2;CT Spleen WO and W contrast IV;CT Spleen WO+W contr IV;;ACTIVE;1.0o;2.61 +24990-4;Multisection;Find;Pt;Abdomen>Spleen;Doc;US;RAD;2;US Spleen;US Spleen;;ACTIVE;1.0o;2.61 +24991-2;Views^W contrast IA;Find;Pt;Abdomen>Splenic vein+Portal vein;Doc;RF.angio;RAD;2;RFA Splenic vein and Portal vein Views W contrast IA;RFA Splenic v+Portal v Views W contr IA;;ACTIVE;1.0o;2.64 +2499-2;Iron;MRat;24H;Urine;Qn;;CHEM;1;Iron [Mass/time] in 24 hour Urine;Iron 24h Ur-mRate;;ACTIVE;1.0;2.73 +24992-0;Views^W contrast IA;Find;Pt;Abdomen>Splenic artery;Doc;RF.angio;RAD;2;RFA Splenic artery Views W contrast IA;RFA Splenic a Views W contr IA;;ACTIVE;1.0o;2.64 +24993-8;Views;Find;Pt;Chest>Sternoclavicular joints;Doc;XR;RAD;2;Deprecated X-ray;Deprecated XR;;DEPRECATED;1.0o;2.58 +24994-6;Views;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum Views;XR Sternum Views;;ACTIVE;1.0o;2.64 +24995-3;Guidance for placement of tube;Find;Pt;Abdomen>Stomach;Doc;RF;RAD;2;RF Guidance for placement of tube in Stomach;RF Guided Stom Tube place;;ACTIVE;1.0o;2.64 +24996-1;Guidance for percutaneous replacement of gastrostomy;Find;Pt;Abdomen>Stomach;Doc;RF;RAD;2;RF Guidance for percutaneous replacement of gastrostomy of Stomach;RF Guided Stom PEG replace;;ACTIVE;1.0o;2.64 +24997-9;Views for gastric emptying solid phase^W Tc-99m SC PO;Find;Pt;Abdomen>Stomach;Doc;NM;RAD;2;NM Stomach Views for gastric emptying solid phase W Tc-99m SC PO;NM Stom Views for SPGE W Tc99mSC PO;;ACTIVE;1.0o;2.73 +24998-7;Views for placement check of gastrostomy tube^W contrast via GI tube;Find;Pt;Abdomen>Stomach;Doc;RF;RAD;2;RF Placement check of gastrostomy tube W contrast via GI tube;RF GT plac Ck W contr via GI tb;;ACTIVE;1.0o;2.61 +24999-5;Multisection;Find;Pt;Head>Temporomandibular joint;Doc;MR;RAD;2;MR Temporomandibular joint;MR TMJ;;ACTIVE;1.0o;2.61 +25000-1;Views;Find;Pt;Head>Temporomandibular joint;Doc;XR;RAD;2;XR Temporomandibular joint Views;XR TMJ Views;;ACTIVE;1.0o;2.64 +25001-9;Views^W Tc-99m pertechnetate IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;NM;RAD;2;NM Scrotum and testicle Views W Tc-99m pertechnetate IV;NM Scrotum+Test Views W Tc99mP IV;;ACTIVE;1.0o;2.64 +25002-7;Multisection;Find;Pt;Pelvis>Scrotum+Testicle;Doc;US;RAD;2;US Scrotum and testicle;US Scrotum+Test;;ACTIVE;1.0o;2.73 +25003-5;Multisection^W contrast IV;Find;Pt;Lower extremity>Thigh vessels;Doc;MR.angio;RAD;2;MRA Thigh vessels W contrast IV;MRA Thigh ves W contr IV;;ACTIVE;1.0o;2.61 +25004-3;Multisection;Find;Pt;Thigh;Nar;MRI;RAD;2;Deprecated Thigh MRI Multisection;Deprecated Thigh MRI;;DEPRECATED;1.0o;2.46 +25005-0;Views^W contrast;Find;Pt;XXX>Three vessels;Doc;RF.angio;RAD;2;RFA Three vessels Views W contrast;RFA 3 vess Views W contr;;DISCOURAGED;1.0o;2.64 +25006-8;Views;Find;Pt;Upper extremity>Thumb;Doc;XR;RAD;2;XR Thumb Views;XR Thumb Views;;ACTIVE;1.0o;2.73 +2500-7;Iron binding capacity;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron binding capacity [Mass/volume] in Serum or Plasma;TIBC SerPl-mCnc;;ACTIVE;1.0;2.73 +25007-6;Views^W I-131 IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views W I-131 IV;NM Thyroid Views W I-131 IV;;ACTIVE;1.0o;2.64 +25008-4;Views+views uptake^W I-131 IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views and Views uptake W I-131 IV;NM Thyroid Views+views uptake W I-131 IV;;ACTIVE;1.0o;2.64 +25009-2;Guidance for percutaneous biopsy;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;US Guidance for biopsy of Thyroid gland;US Guided Thyroid Bx;;ACTIVE;1.0o;2.64 +250-1;Fluconazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Fluconazole [Susceptibility] by Disk diffusion (KB);Fluconazole Islt KB;;ACTIVE;1.0;2.21 +25010-0;Multisection;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;US Thyroid gland;US Thyroid;;ACTIVE;1.0o;2.73 +25011-8;Views;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula Views;XR Tib+Fib Views;;ACTIVE;1.0o;2.73 +25012-6;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity>Tibial artery;Doc;RF.angio;RAD;2;Deprecated RFA Guidance for angioplasty of Tibial artery-- W contrast IA;Deprecated RFA Tibl a Angio guide W contr IA;;DEPRECATED;1.0o;2.64 +25013-4;Views;Find;Pt;Lower extremity>Toes;Doc;XR;RAD;2;XR Toes Views;XR Toes Views;;ACTIVE;1.0o;2.73 +25014-2;Views^W contrast;Find;Pt;XXX>Two vessels;Doc;RF.angio;RAD;2;RFA Two vessels Views W contrast;RFA 2 vess Views W contr;;DISCOURAGED;1.0o;2.64 +2501-5;Iron binding capacity.unsaturated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron binding capacity.unsaturated [Mass/volume] in Serum or Plasma;UIBC SerPl-mCnc;;ACTIVE;1.0;2.73 +25015-9;Replacement of percutaneous gastrojejunostomy;Find;Pt;Upper GI tract;Doc;;DOC.MISC;2;Replacement of percutaneous gastrojejunostomy Upper GI tract Document;Replac of PGJ Upr GI Tract Doc;;ACTIVE;1.0o;2.63 +25016-7;Views^W contrast intra urethra;Find;Pt;Pelvis>Urethra;Doc;RF;RAD;2;RF Urethra Views W contrast intra urethra;RF Urethra Views W contr intra ureth;;ACTIVE;1.0o;2.64 +25017-5;Views^W contrast intra bladder;Find;Pt;Pelvis>Urinary bladder+Urethra;Doc;RF;RAD;2;RF Urinary bladder and Urethra Views W contrast intra bladder;RF Bladder+Urethra Views W contr IUB;;ACTIVE;1.0o;2.64 +25018-3;Views^W radionuclide IV;Find;Pt;Pelvis>Urinary bladder;Doc;NM;RAD;2;NM Urinary bladder Views;NM Bladder Views W RNC IV;;ACTIVE;1.0o;2.64 +25019-1;Multisection;Find;Pt;Pelvis>Urinary bladder;Doc;US;RAD;2;US Urinary bladder;US Bladder;;ACTIVE;1.0o;2.73 +25020-9;Views^W contrast retrograde via urethra;Find;Pt;Pelvis>Urinary bladder+Urethra;Doc;RF;RAD;2;RF Urinary bladder and Urethra Views W contrast retrograde via urethra;RF Bladder+Urethra Views W contr RU;;ACTIVE;1.0o;2.64 +25021-7;Views^W voiding;Find;Pt;Urinary bladder+Urethra;Nar;XR.fluor;RAD;2;Deprecated Urinary Bladder & Urethra Fluoroscopy W voiding;Deprecated Bladder+Urethra Flr W vdg;;DEPRECATED;1.0o;2.36 +25022-5;Views^W contrast IU;Find;Pt;Pelvis>Uterus+Fallopian tubes;Doc;RF;RAD;2;RF Uterus and Fallopian tubes Views W contrast IU;RF Uterus+FT Views W contr IU;;ACTIVE;1.0o;2.64 +2502-3;Iron saturation;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Iron saturation [Mass Fraction] in Serum or Plasma;Iron Satn MFr SerPl;;ACTIVE;1.0;2.73 +25023-3;Views^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Vein Views W contrast IV;RFA Vein Views W contr IV;;ACTIVE;1.0o;2.64 +25024-1;Guidance for placement of peripherally-inserted central venous catheter;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for placement of peripherally-inserted central venous catheter in Vein;RFA Guided Vein PICC place;;ACTIVE;1.0o;2.64 +25025-8;Views^W contrast IV;Find;Pt;Chest+Abdomen>Vena cava.superior &or Vena cava.inferior;Doc;RF.angio;RAD;2;RFA Vena cava Views W contrast IV;RFA Vena cava Views W contr IV;;ACTIVE;1.0o;2.64 +25026-6;Guidance for placement of venous filter^W contrast IV;Find;Pt;Abdomen>Vena cava.inferior;Doc;RF.angio;RAD;2;RFA Guidance for placement of venous filter in Inferior vena cava-- W contrast IV;RFA Guided IVC Filter place--W contr IV;;ACTIVE;1.0o;2.64 +25027-4;Guidance for placement of large bore central venous catheter;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for placement of large bore CV catheter in Vein;Guided Vein LB CVC place;;ACTIVE;1.0o;2.64 +25028-2;Guidance for placement of catheter for infusion of thrombolytic^W contrast intravascular;Find;Pt;XXX>Vessel;Doc;RF.angio;RAD;2;RFA Guidance for placement of catheter for infusion of thrombolytic in Vessel-- W contrast intravascular;RFA Guide Ves Cath throm adm W con vasc;;ACTIVE;1.0o;2.64 +25029-0;Guidance for placement of catheter for vasoconstrictor infusion;Find;Pt;XXX>Vessels;Doc;RF.angio;RAD;2;RFA Guidance for placement of catheter for vasoconstrictor infusion in Vessels;RFA Guided Vesl Cath plac VC inf;;ACTIVE;1.0o;2.64 +25030-8;Views^W contrast IA;Find;Pt;Abdomen>Abdominal arteries;Doc;RF.angio;RAD;2;RFA Abdominal arteries Views W contrast IA;RFA Abdominal aa Views W contr IA;;ACTIVE;1.0o;2.64 +2503-1;Iron.chelated;MCnc;Pt;Urine;Qn;;CHEM;1;Iron.chelated [Mass/volume] in Urine;Iron Chelated Ur-mCnc;;ACTIVE;1.0;2.40 +25031-6;Views^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Views;NM Bone Views W RNC IV;;ACTIVE;1.0o;2.64 +25032-4;Views^W In-111 tagged WBC IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Views W In-111 tagged WBC IV;NM Bone Views W In-111 WBC IV;;ACTIVE;1.0o;2.64 +25033-2;Multisection;Find;Pt;Upper extremity>Wrist;Doc;MR;RAD;2;MR Wrist;MR Wrist;;ACTIVE;1.0o;2.61 +25034-0;Views^W contrast IS;Find;Pt;Upper extremity>Wrist;Doc;RF;RAD;2;RF Wrist Arthrogram;RF Wrist Views W contr IS;;ACTIVE;1.0o;2.64 +25035-7;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Wrist;Doc;MR;RAD;2;MR Wrist WO and W contrast IV;MR Wrist WO+W contr IV;;ACTIVE;1.0o;2.61 +25036-5;Multisection;Find;Pt;Upper extremity>Wrist;Doc;US;RAD;2;US Wrist;US Wrist;;ACTIVE;1.0o;2.61 +25037-3;Views;Find;Pt;Wrist;Nar;XR;RAD;2;Deprecated Wrist X-ray;Deprecated Wrist XR;;DEPRECATED;1.0o;2.46 +25038-1;Courtesy consultation.XXX;Find;Pt;XXX;Doc;;DOC.MISC;2;Courtesy consultation Document;Courtesy consult Doc;;ACTIVE;1.0o;2.69 +25039-9;Multisection limited;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region limited;CT Ltd Unsp region;;ACTIVE;1.0o;2.64 +25040-7;Multisection;Find;Pt;XXX;Doc;CT.3D;RAD;2;Deprecated Unspecified body region CT 3D;Deprecated XXX CT.3D;;DEPRECATED;1.0o;2.58 +25041-5;Guidance for aspiration or biopsy^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for aspiration or biopsy of Unspecified body region-- W contrast IV;CT Guided Asp or Bx--W contr IV;;DISCOURAGED;1.0o;2.64 +25042-3;Guidance for aspiration or biopsy;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for aspiration or biopsy of Unspecified body region;CT Guided Asp or Bx;;DISCOURAGED;1.0o;2.64 +25043-1;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Unspecified body region;CT Guided PC fluid asp;;ACTIVE;1.0o;2.64 +25044-9;Guidance for percutaneous biopsy;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for biopsy of Unspecified body region;CT Guided Bx;;ACTIVE;1.0o;2.64 +25045-6;Multisection;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region;CT Unsp region;;ACTIVE;1.0o;2.64 +25046-4;Multisection^W anesthesia;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region W anesthesia;CT W anesthesia;;ACTIVE;1.0o;2.69 +25047-2;Multisection^W conscious sedation;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region W conscious sedation;CT W conscious sedation;;ACTIVE;1.0o;2.69 +2504-9;Iron;MCnc;Pt;Urine;Qn;;CHEM;1;Iron [Mass/volume] in Urine;Iron Ur-mCnc;;ACTIVE;1.0;2.73 +25049-8;Views multiple sagittal & coronal;Find;Pt;XXX;Nar;CT.3D;RAD;2;Deprecated Unspecified body region CT 3D multiple sagittal & coronal;Deprecated XXX CT.3D Sagittal & coronal;;DEPRECATED;1.0o;2.36 +25050-6;Multisection sagittal & coronal disarticulation;Find;Pt;XXX;Doc;CT.3D;RAD;2;Deprecated Unspecified body region CT 3D sagittal and coronal disarticulation;Deprecated XXX CT.3D Sagittal+Coronal di;;DEPRECATED;1.0o;2.58 +25051-4;Multisectional sagittal;Find;Pt;XXX;Doc;CT;RAD;2;Deprecated Unspecified body region CT Multisectional sagittal;Deprecated XXX CT Multisectional sagitta;;DEPRECATED;1.0o;2.58 +25052-2;Multisection sagittal & coronal;Find;Pt;XXX;Doc;CT;RAD;2;Deprecated Unspecified body region CT sagittal and coronal;Deprecated XXX CT Sagittal+Coronal;;DEPRECATED;1.0o;2.58 +25053-0;Guidance for radiosurgery;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for radiosurgery of Unspecified body region;CT Guided Radiosurg;;ACTIVE;1.0o;2.64 +25054-8;Guidance for radiosurgery^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for radiosurgery of Unspecified body region-- W contrast IV;CT Guided Radiosurg--W contr IV;;ACTIVE;1.0o;2.64 +25055-5;Multisection additional sequence;Find;Pt;XXX;Doc;MR;RAD;2;Deprecated Unspecified body region MR additional sequence;Deprecated;;DEPRECATED;1.0o;2.58 +2505-6;Iron/Iron binding capacity.total;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Iron/Iron binding capacity.total [Mass Ratio] in Serum or Plasma;Iron/TIBC SerPl;;DISCOURAGED;1.0;2.73 +25056-3;Multisection;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region;MR Unsp region;;ACTIVE;1.0o;2.64 +25057-1;Multisection^W conscious sedation;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region W conscious sedation;MR W conscious sedation;;ACTIVE;1.0o;2.69 +25058-9;Multisection^W contrast IV;Find;Pt;XXX;Doc;MR.angio;RAD;2;MRA Unspecified body region W contrast IV;MRA W contr IV;;ACTIVE;1.0o;2.69 +25059-7;Guidance for percutaneous biopsy;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for biopsy of Unspecified body region;US Guided Bx;;ACTIVE;1.0o;2.64 +25060-5;No charge;Find;Pt;XXX;Doc;US;RAD;2;US Unspecified body region No charge;US No charge;;ACTIVE;1.0o;2.64 +25061-3;Multisection;Find;Pt;XXX;Doc;US;RAD;2;US Unspecified body region;US Unsp region;;ACTIVE;1.0o;2.64 +25062-1;View comparison;Find;Pt;XXX;Doc;XR;RAD;2;XR Unspecified body region Comparison view;XR Comparison;;ACTIVE;1.0o;2.64 +25063-9;View^W contrast IA;Find;Pt;XXX>Vessel;Doc;RF.angio;RAD;2;RFA Vessel Single view W contrast IA;RFA Ves 1V W contr IA;;ACTIVE;1.0o;2.64 +2506-4;Isocitrate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isocitrate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma;Isocitrate Dehydrog SerPl-cCnc;;ACTIVE;1.0;2.68 +25064-7;Views for angioplasty^W contrast IA;Find;Pt;XXX>Vessel;Doc;RF.angio;RAD;2;RFA Vessel Views for angioplasty W contrast IA;RFA Ves Vs angioplasty W contr IA;;ACTIVE;1.0o;2.64 +25065-4;View;Find;15M;XXX;Doc;RF;RAD;2;RF 15 minutes;RF 15M;;ACTIVE;1.0o;2.64 +25066-2;View;Find;30M;XXX;Doc;RF;RAD;2;RF 30 minutes;RF 30M;;ACTIVE;1.0o;2.64 +25067-0;View;Find;45M;XXX;Doc;RF;RAD;2;RF 45 minutes;RF 45M;;ACTIVE;1.0o;2.64 +25068-8;View;Find;1H;XXX;Doc;RF;RAD;2;RF 1 hour;RF 1h;;ACTIVE;1.0o;2.64 +25069-6;Guidance for percutaneous biopsy;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for biopsy of Unspecified body region;RF Guided Bx;;ACTIVE;1.0o;2.64 +25070-4;Views^during surgery;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views during surgery;RF Views in Surg;;ACTIVE;1.0o;2.64 +25071-2;Multisection;Find;Pt;XXX;Doc;XR.tomography;RAD;2;XR tomography Unspecified body region;XR tomo Unsp region;;ACTIVE;1.0o;2.64 +2507-2;Isoleucine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Isoleucine [Presence] in Serum or Plasma;Isoleucine SerPl Ql;;ACTIVE;1.0;2.73 +25072-0;Guidance for placement of infusion port;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for placement of infusion port;Guided Unsp region Infusion port place;;ACTIVE;1.0o;2.64 +25073-8;Guidance for removal of foreign body;Find;Pt;XXX>Vessel;Doc;RF.angio;RAD;2;RFA Guidance for removal of foreign body from Vessel;RFA Guided Ves FB removal;;ACTIVE;1.0o;2.64 +25074-6;Views;Find;Pt;Head>Zygomatic arch;Doc;XR;RAD;2;XR Zygomatic arch Views;XR Zygomatic arch Views;;ACTIVE;1.0o;2.64 +25076-1;Views^W contrast IA;Find;Pt;Abdomen>Hepatic artery;Doc;RF.angio;RAD;2;RFA Hepatic artery Views W contrast IA;RFA Hep a Views W contr IA;;ACTIVE;1.0o;2.64 +25077-9;Guidance for placement of catheter^W contrast IA;Find;Pt;Abdomen>Hepatic artery;Doc;RF.angio;RAD;2;RFA Guidance for placement of catheter in Hepatic artery-- W contrast IA;RFA Guided Hep a Cath place--W contr IA;;ACTIVE;1.0o;2.64 +25078-7;Guidance for placement of stent;Find;Pt;Abdomen>Intrahepatic portal system;Doc;RF;RAD;2;RF Guidance for placement of stent in Intrahepatic portal system;RF Guided IHP Stent place;;ACTIVE;1.0o;2.64 +25079-5;Views^W contrast IA;Find;Pt;Abdomen>Renal arteries;Doc;RF.angio;RAD;2;RFA Renal arteries Views W contrast IA;RFA Renal aa Views W contr IA;;ACTIVE;1.0o;2.64 +2508-0;Isoleucine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isoleucine [Mass/volume] in Serum or Plasma;Isoleucine SerPl-mCnc;;ACTIVE;1.0;2.73 +25080-3;Views for renin sampling^W contrast IV;Find;Pt;Abdomen>Renal vein.bilateral;Doc;RF.angio;RAD;2;RFA Renal vein - bilateral Views for renin sampling W contrast IV;RFA Renal v-Bl Vs renin samp W contr IV;;ACTIVE;1.0o;2.64 +25081-1;Guidance for angioplasty^W contrast IA;Find;Pt;Abdomen>Renal vessel;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Renal vessel-- W contrast IA;RFA Guided Renal ves Angio--W contr IA;;ACTIVE;2.00;2.64 +25082-9;2-Methyl-3-Hydroxybutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-methyl-3-hydroxybutyrate (C5-OH)/Creatinine [Molar ratio] in Urine;2Me3OH-butyrate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25083-7;2-Oxo,3-Methylvalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Oxo,3-Methylvalerate/Creatinine [Molar ratio] in Urine;2Oxo3Me-valerate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25084-5;2-Oxoisocaproate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Oxoisocaproate/Creatinine [Molar ratio] in Urine;2Oxoisocaproate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25085-2;2-Oxoisovalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Oxoisovalerate/Creatinine [Molar ratio] in Urine;2Oxoisovalerate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25086-0;Beta aminoisobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Beta aminoisobutyrate/Creatinine [Molar ratio] in Urine;B-AIB/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25087-8;3-Methylglutaconate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methylglutaconate/Creatinine [Molar ratio] in Urine;3Me-glutaconate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25088-6;4-Hydroxyphenylacetate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;4-Hydroxyphenylacetate/Creatinine [Molar ratio] in Urine;4OH-phenylacetate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25089-4;4-Hydroxyphenyllactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxyphenyllactate/Creatinine [Molar ratio] in Urine;4OH-phenyllactate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25090-2;Benzoate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Benzoate/Creatinine [Molar ratio] in Urine;Benzoate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25091-0;C peptide/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;C peptide/Creatinine [Molar ratio] in Urine;C peptide/Creat Ur-sRto;;ACTIVE;2.00;2.70 +25092-8;Cystathionine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Cystathionine/Creatinine [Molar ratio] in Urine;Cystathionin/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25093-6;Decadienediate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Decadienediate/Creatinine [Molar ratio] in Urine;Decadienediate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25094-4;Decenedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Decenedioate/Creatinine [Molar ratio] in Urine;Decenedioate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25095-1;Deoxypyridinoline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deoxypyridinoline/Creatinine [Molar ratio] in Urine;DPD/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25096-9;Deoxypyridinoline/Creatinine;SRto;2H;Urine;Qn;;CHEM;1;Deoxypyridinoline/Creatinine [Molar ratio] in 2 hour Urine;DPD/Creat 2h Ur-sRto;;ACTIVE;2.00;2.73 +25097-7;Dodecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dodecanedioate/Creatinine [Molar ratio] in Urine;DDDA/Creat Ur-sRto;;ACTIVE;2.00;2.73 +2509-8;Isoleucine;MCnc;Pt;Urine;Qn;;CHEM;1;Isoleucine [Mass/volume] in Urine;Isoleucine Ur-mCnc;;ACTIVE;1.0;2.73 +25098-5;Ethanolamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Ethanolamine/Creatinine [Molar ratio] in Urine;Ethanolamine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25099-3;Ethylmalonate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Ethylmalonate/Creatinine [Molar ratio] in Urine;Ethylmalonate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25100-9;Formate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Formate/Creatinine [Molar ratio] in Urine;Formate/Creat Ur-sRto;;ACTIVE;2.00;2.70 +25101-7;Fumarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Fumarate/Creatinine [Molar ratio] in Urine;Fumarate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25102-5;Galactose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Galactose/Creatinine [Molar ratio] in Urine;Galactose/Creat Ur-sRto;;ACTIVE;2.00;2.70 +25103-3;Glutaconate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutaconate/Creatinine [Molar ratio] in Urine;Glutaconate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25104-1;Glutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutarate/Creatinine [Molar ratio] in Urine;Glutarate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25105-8;Glycerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glycerate/Creatinine [Molar ratio] in Urine;Glycerate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +2510-6;Isoleucine;MRat;24H;Urine;Qn;;CHEM;1;Isoleucine [Mass/time] in 24 hour Urine;Isoleucine 24h Ur-mRate;;ACTIVE;1.0;2.73 +25106-6;Glycolate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glycolate/Creatinine [Molar ratio] in Urine;Glycolate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25107-4;Glyoxylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glyoxylate/Creatinine [Molar ratio] in Urine;Glyoxylate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25108-2;Hydroxydecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hydroxydecanedioate/Creatinine [Molar ratio] in Urine;OH-Decanedioate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25109-0;Hydroxylysine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hydroxylysine/Creatinine [Molar ratio] in Urine;OH-Lysine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25110-8;Hydroxyproline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hydroxyproline/Creatinine [Molar ratio] in Urine;OH-Proline/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25111-6;Isocitrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Isocitrate/Creatinine [Molar ratio] in Urine;Isocitrate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25112-4;Lactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Lactate/Creatinine [Molar ratio] in Urine;Lactate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25113-2;Malate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Malate/Creatinine [Molar ratio] in Urine;Malate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +2511-4;Keratan sulfate;MCnc;Pt;Bld;Qn;;CHEM;1;Keratan sulfate [Mass/volume] in Blood;Keratan Sulfate Bld-mCnc;;ACTIVE;1.0;2.42 +25114-0;2-Methylcitrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methylcitrate/Creatinine [Molar ratio] in Urine;2Me-citrate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25115-7;Methylmalonate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Methylmalonate/Creatinine [Molar ratio] in 24 hour Urine;Methylmalonate/Creat 24h Ur-sRto;;ACTIVE;2.00;2.73 +25116-5;Methylmalonate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Methylmalonate/Creatinine [Molar ratio] in Urine;Methylmalonate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25117-3;Methylsuccinate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Methylsuccinate/Creatinine [Molar ratio] in Urine;Me-succinate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25118-1;Mevalonate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Mevalonate/Creatinine [Molar ratio] in Urine;Mevalonate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25119-9;N-acetyltyrosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N-acetyltyrosine/Creatinine [Molar ratio] in Urine;NAT/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25120-7;Octanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Octanoate (C8:0)/Creatinine [Molar ratio] in Urine;Octanoate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25121-5;Octenedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Octenedioate (C8:1)/Creatinine [Molar ratio] in Urine;Octenedioate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +2512-2;Keratan sulfate;MCnc;Pt;Urine;Qn;;CHEM;1;Keratan sulfate [Mass/volume] in Urine;Keratan Sulfate Ur-mCnc;;ACTIVE;1.0;2.42 +25122-3;Phosphoethanolamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phosphoethanolamine/Creatinine [Molar ratio] in Urine;PETN/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25123-1;Para nitrophenol/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Para nitrophenol/Creatinine [Molar ratio] in Urine;p-nitrophenol/Creat Ur-sRto;;ACTIVE;2.00;2.70 +25124-9;Phenylacetate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Phenylacetate/Creatinine [Molar ratio] in Urine;Phenylacetate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25125-6;Phenyllactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phenyllactate/Creatinine [Molar ratio] in Urine;Phenyllactate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25126-4;Phenylpyruvate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phenylpyruvate/Creatinine [Molar ratio] in Urine;Phenylpyruvate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25127-2;Phosphate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Phosphate/Creatinine [Molar ratio] in 24 hour Urine;Phosphate/Creat 24h Ur-sRto;;ACTIVE;2.00;2.70 +25128-0;Phosphoserine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phosphoserine/Creatinine [Molar ratio] in Urine;Phosphoserine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25129-8;Pyridinoline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pyridinoline/Creatinine [Molar ratio] in Urine;PYD/Creat Ur-sRto;;ACTIVE;2.00;2.73 +2513-0;Ketones;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Ketones [Presence] in Serum or Plasma;Ketones SerPl Ql;;ACTIVE;1.0;2.73 +25130-6;Pyridinoline/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Pyridinoline/Creatinine [Molar ratio] in 24 hour Urine;PYD/Creat 24h Ur-sRto;;ACTIVE;2.00;2.73 +25131-4;Pyridinoline/Creatinine;SRto;2H;Urine;Qn;;CHEM;1;Pyridinoline/Creatinine [Molar ratio] in 2 hour Urine;PYD/Creat 2h Ur-sRto;;ACTIVE;2.00;2.73 +25132-2;Pyruvate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pyruvate/Creatinine [Molar ratio] in Urine;Pyruvate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25133-0;Sarcosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sarcosine/Creatinine [Molar ratio] in Urine;Sarcosine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25134-8;Sebacate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sebacate (C8)/Creatinine [Molar ratio] in Urine;Sebacate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25135-5;Suberate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Suberate/Creatinine [Molar ratio] in Urine;Suberate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25136-3;Succinate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Succinate/Creatinine [Molar ratio] in Urine;Succinate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25137-1;Succinylacetone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Succinylacetone/Creatinine [Molar ratio] in Urine;Succinylacetone/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25138-9;Taurine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Taurine/Creatinine [Molar ratio] in Urine;Taurine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25139-7;Tryptophan/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tryptophan/Creatinine [Molar ratio] in Urine;Tryptophan/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25140-5;Uracil/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Uracil/Creatinine [Molar ratio] in Urine;Uracil/Creat Ur-sRto;;ACTIVE;2.00;2.73 +25141-3;Carnitine esters/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Carnitine esters/Creatinine [Molar ratio] in Urine;Carn esters/Creat Ur-sRto;;ACTIVE;2.00;2.70 +25142-1;5-Fluorocytosine^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;5-Fluorocytosine [Mass/volume] in Serum or Plasma --peak;5-fluorocytosine Peak SerPl-mCnc;;ACTIVE;2.00;2.70 +25143-9;5-Fluorocytosine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;5-Fluorocytosine [Mass/volume] in Serum or Plasma --trough;5-fluorocytosine Trough SerPl-mCnc;;ACTIVE;2.00;2.70 +25144-7;Ammonium urate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Ammonium urate crystals [#/area] in Urine sediment by Microscopy high power field;Amm Urate Cry #/area UrnS HPF;;ACTIVE;2.00;2.73 +25145-4;Bacteria;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Bacteria [Presence] in Urine sediment by Light microscopy;Bacteria UrnS Ql Micro;;ACTIVE;2.00;2.73 +25146-2;Bilirubin crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Bilirubin crystals [#/area] in Urine sediment by Microscopy high power field;Bilirub Cry #/area UrnS HPF;;ACTIVE;2.00;2.70 +25147-0;Calcium carbonate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Calcium carbonate crystals [#/area] in Urine sediment by Microscopy high power field;Ca Carbonate Cry #/area UrnS HPF;;ACTIVE;2.00;2.73 +2514-8;Ketones;PrThr;Pt;Urine;Ord;Test strip;CHEM;1;Ketones [Presence] in Urine by Test strip;Ketones Ur Ql Strip;;ACTIVE;1.0;2.73 +25148-8;Calcium oxalate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Calcium oxalate crystals [#/area] in Urine sediment by Microscopy high power field;CaOx Cry #/area UrnS HPF;;ACTIVE;2.00;2.73 +25149-6;Calcium phosphate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Calcium phosphate crystals [#/area] in Urine sediment by Microscopy high power field;Ca Phos Cry #/area UrnS HPF;;ACTIVE;2.00;2.73 +25150-4;Calcium sulfate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Calcium sulfate crystals [#/area] in Urine sediment by Microscopy high power field;Ca Sulfate Cry #/area UrnS HPF;;ACTIVE;2.00;2.70 +25153-8;Cholesterol crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Cholesterol crystals [#/area] in Urine sediment by Microscopy high power field;Cholest Cry #/area UrnS HPF;;ACTIVE;2.00;2.70 +25154-6;Crystals.unidentified;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Unidentified crystals [#/area] in Urine sediment by Microscopy high power field;Unident Crys #/area UrnS HPF;;ACTIVE;2.00;2.73 +2515-5;Kynurenate;MCnc;Pt;Urine;Qn;;CHEM;1;Kynurenate [Mass/volume] in Urine;Kynuren Ur-mCnc;;DISCOURAGED;1.0;2.44 +25155-3;Cystine crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Cystine crystals [#/area] in Urine sediment by Microscopy high power field;Cystine Cry #/area UrnS HPF;;ACTIVE;2.00;2.73 +25156-1;Eosinophils;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Eosinophils [Presence] in Urine sediment by Light microscopy;Eosinophil UrnS Ql Micro;;ACTIVE;2.00;2.73 +25157-9;Epithelial casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Epithelial casts [Presence] in Urine sediment by Light microscopy;Epith Casts UrnS Ql Micro;;ACTIVE;2.00;2.73 +25158-7;Oval fat bodies (globules);PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Oval fat bodies (globules) [Presence] in Urine sediment by Light microscopy;Oval fat bodies UrnS Ql Micro;;ACTIVE;2.00;2.73 +25159-5;Fatty casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Fatty casts [Presence] in Urine sediment by Light microscopy;Fatty Casts UrnS Ql Micro;;ACTIVE;2.00;2.73 +25160-3;Granular casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Granular casts [Presence] in Urine sediment by Light microscopy;Gran Casts UrnS Ql Micro;;ACTIVE;2.00;2.73 +25161-1;Hippurate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Hippurate crystals [#/area] in Urine sediment by Microscopy high power field;Hippurate Cry #/area UrnS HPF;;ACTIVE;2.00;2.70 +25162-9;Hyaline casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Hyaline casts [Presence] in Urine sediment by Light microscopy;Hyaline Casts UrnS Ql Micro;;ACTIVE;2.00;2.73 +2516-3;L-iditol dehydrogenase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;L-iditol dehydrogenase [Enzymatic activity/volume] in Amniotic fluid;L-Iditol Dehydrog Amn-cCnc;;ACTIVE;1.0;2.68 +25163-7;Leucine crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Leucine crystals [#/area] in Urine sediment by Microscopy high power field;Leucine Cry #/area UrnS HPF;;ACTIVE;2.00;2.73 +25164-5;Cells.CD21;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD21 cells [#/volume] in Blood;CD21 Cells # Bld;;ACTIVE;2.00;2.70 +25165-2;Cells.CD23;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD23 cells [#/volume] in Blood;CD23 Cells # Bld;;ACTIVE;2.00;2.70 +25166-0;Uroporphyrin;SCnc;Pt;Urine;Qn;;CHEM;1;Uroporphyrin [Moles/volume] in Urine;Uropor Ur-sCnc;;ACTIVE;2.00;2.70 +25167-8;Coproporphyrin;SCnc;Pt;Urine;Qn;;CHEM;1;Coproporphyrin [Moles/volume] in Urine;Copro Ur-sCnc;;ACTIVE;2.00;2.70 +25168-6;Perhexiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Perhexiline [Mass/volume] in Serum or Plasma;Phex SerPl-mCnc;;ACTIVE;2.00;2.70 +25169-4;Nickel;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Nickel [Moles/volume] in Blood;Nickel Bld-sCnc;;ACTIVE;2.00;2.70 +25170-2;Mercury;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Blood;Mercury Bld-sCnc;;ACTIVE;2.00;2.73 +2517-1;L-iditol dehydrogenase;CCnc;Pt;Ser;Qn;;CHEM;1;L-iditol dehydrogenase [Enzymatic activity/volume] in Serum;L-Iditol Dehydrog Ser-cCnc;;ACTIVE;1.0;2.68 +25171-0;Bromide;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Bromide [Moles/volume] in Blood;Bromide Bld-sCnc;;ACTIVE;2.00;2.70 +25172-8;Fluoride;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Fluoride [Moles/volume] in Blood;Fluoride Bld-sCnc;;ACTIVE;2.00;2.70 +25173-6;Thallium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Thallium [Moles/volume] in Blood;Thallium Bld-sCnc;;ACTIVE;2.00;2.70 +25174-4;Amikacin 8.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 8 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25175-1;Amikacin 16.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 16 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 16 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25176-9;Amikacin 32.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 32 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 32 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25177-7;Amikacin 12.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 12 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 12 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25178-5;Amikacin 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25179-3;Amikacin 6.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 6 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25180-1;Ciprofloxacin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ciprofloxacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ciprofloxacin 2 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25181-9;Ciprofloxacin 4.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ciprofloxacin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ciprofloxacin 4 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25182-7;Kanamycin 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Kanamycin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Kanamycin 5 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25183-5;Ethionamide 11.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethionamide 11 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethionamide 11 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25184-3;rifAMPin 14.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;rifAMPin 14 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;rifAMPin 14 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25185-0;Streptomycin 6.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Streptomycin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Streptomycin 6 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25186-8;Pyrazinamide 25.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Pyrazinamide 25 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;PZA 25 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25187-6;Ethambutol 7.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol 7.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol 7.5 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25188-4;Ciprofloxacin 8.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ciprofloxacin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ciprofloxacin 8 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +2518-9;Lactate;SCnc;Pt;BldA;Qn;;CHEM;1;Lactate [Moles/volume] in Arterial blood;Lactate BldA-sCnc;;ACTIVE;1.0;2.73 +25189-2;Ciprofloxacin 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ciprofloxacin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ciprofloxacin 5 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +251-9;Fluconazole;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Fluconazole [Susceptibility] by Serum bactericidal titer;Fluconazole Titr SBT;;ACTIVE;1.0;2.32 +25190-0;Clarithromycin 8.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clarithromycin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clarithro 8 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25191-8;Clarithromycin 16.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clarithromycin 16 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clarithro 16 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25192-6;Clarithromycin 32.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clarithromycin 32 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clarithro 32 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25194-2;Ethambutol 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol 5 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25195-9;Ethambutol 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol 10 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25196-7;Ethionamide 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethionamide 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethionamide 5 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +2519-7;Lactate;SCnc;Pt;BldV;Qn;;CHEM;1;Lactate [Moles/volume] in Venous blood;Lactate BldV-sCnc;;ACTIVE;1.0;2.73 +25198-3;Ethionamide 15.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethionamide 15 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethionamide 15 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25199-1;Rifabutin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Rifabutin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Rifabutin 1 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25200-7;Rifabutin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Rifabutin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Rifabutin 2 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25201-5;Rifabutin 4.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Rifabutin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Rifabutin 4 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25202-3;rifAMPin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;rifAMPin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;rifAMPin 1 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25203-1;rifAMPin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;rifAMPin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;rifAMPin 2 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25204-9;rifAMPin 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;rifAMPin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;rifAMPin 5 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +2520-5;Lactate;SCnc;Pt;CSF;Qn;;CHEM;1;Lactate [Moles/volume] in Cerebral spinal fluid;Lactate CSF-sCnc;;ACTIVE;1.0;2.73 +25205-6;Streptomycin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Streptomycin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Streptomycin 2 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25206-4;Streptomycin 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Streptomycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Streptomycin 10 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25207-2;cycloSERINE 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cycloSERINE 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;cycloSERINE 10 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25208-0;cycloSERINE 20.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cycloSERINE 20 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;cycloSERINE 20 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25209-8;cycloSERINE 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cycloSERINE 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;cycloSERINE 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25210-6;Capreomycin 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Capreomycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Capreomycin 10 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25211-4;Capreomycin 20.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Capreomycin 20 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Capreomycin 20 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25212-2;Capreomycin 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Capreomycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Capreomycin 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +2521-3;Lactate;PrThr;Pt;Gast fld;Ord;;CHEM;1;Lactate [Presence] in Gastric fluid;Lactate Gast Ql;;ACTIVE;1.0;2.56 +25213-0;Kanamycin 6.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Kanamycin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Kanamycin 6 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25214-8;Kanamycin 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Kanamycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Kanamycin 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25215-5;Para aminosalicylate 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Para aminosalicylate 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;PAS 2 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25216-3;Para aminosalicylate 8.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Para aminosalicylate 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;PAS 8 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25217-1;Isoniazid 0.1 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid 0.1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid 0.1 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25218-9;Isoniazid 0.2 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid 0.2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid 0.2 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25219-7;Isoniazid 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid 1 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25220-5;cefOXitin 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cefOXitin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;cefOXitin 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +2522-1;Lactate;SCnc;Pt;Plr fld;Qn;;CHEM;1;Lactate [Moles/volume] in Pleural fluid;Lactate Plr-sCnc;;ACTIVE;1.0;2.42 +25221-3;Imipenem 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Imipenem 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Imipenem 10 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25222-1;Cefmetazole 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Cefmetazole 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Cefmetazole 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25223-9;Doxycycline 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Doxycycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Doxycycline 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25224-7;Erythromycin 15.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Erythromycin 15 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Erythromycin 15 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25225-4;Minocycline 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Minocycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Minocycline 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25226-2;sulfiSOXAZOLE 300.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;sulfiSOXAZOLE 300 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Sulfisoxaz 300 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25227-0;Tobramycin 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Tobramycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Tobramycin 10 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25228-8;Vancomycin 30.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Vancomycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Vancomycin 30 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.26 +25229-6;Pyrazinamide 100.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Pyrazinamide 100 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;PZA 100 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25230-4;Ethambutol 2.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol 2.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol 2.5 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25231-2;Ethionamide 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethionamide 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethionamide 10 ug/mL Islt SlowMyco;;ACTIVE;2.00;2.73 +25232-0;Nafcillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nafcillin [Mass/volume] in Specimen;Nafcillin Spec-mCnc;;ACTIVE;2.00;2.70 +25233-8;Azithromycin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Azithromycin [Mass/volume] in Specimen;Azithromycin Spec-mCnc;;ACTIVE;2.00;2.70 +25234-6;Aztreonam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Aztreonam [Mass/volume] in Specimen;Aztreonam Spec-mCnc;;ACTIVE;2.00;2.73 +25235-3;ceFAZolin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;ceFAZolin [Mass/volume] in Specimen;ceFAZolin Spec-mCnc;;ACTIVE;2.00;2.73 +25236-1;Cefixime;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cefixime [Mass/volume] in Specimen;Cefixime Spec-mCnc;;ACTIVE;2.00;2.70 +25237-9;Cefonicid;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cefonicid [Mass/volume] in Specimen;Cefonocid Spec-mCnc;;ACTIVE;2.00;2.70 +25238-7;Cefotaxime;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cefotaxime [Mass/volume] in Specimen;Cefotaxime Spec-mCnc;;ACTIVE;2.00;2.70 +2523-9;Lactate;SCnc;Pt;Periton fld;Qn;;CHEM;1;Lactate [Moles/volume] in Peritoneal fluid;Lactate Prt-sCnc;;ACTIVE;1.0;2.73 +25239-5;cefoTEtan;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;cefoTEtan [Mass/volume] in Specimen;cefoTEtan Spec-mCnc;;ACTIVE;2.00;2.70 +25240-3;cefOXitin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;cefOXitin [Mass/volume] in Specimen;cefOXitin Spec-mCnc;;ACTIVE;2.00;2.73 +25241-1;Cefpodoxime;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cefpodoxime [Mass/volume] in Specimen;Cefpodoxime Spec-mCnc;;ACTIVE;2.00;2.70 +25242-9;Cefsulodin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cefsulodin [Mass/volume] in Specimen;Cefsulodin Spec-mCnc;;ACTIVE;2.00;2.70 +25243-7;Ceftizoxime;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ceftizoxime [Mass/volume] in Specimen;Ceftizoxime Spec-mCnc;;ACTIVE;2.00;2.70 +25244-5;cefTRIAXone;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;cefTRIAXone [Mass/volume] in Specimen;cefTRIAXone Spec-mCnc;;ACTIVE;2.00;2.73 +25245-2;Cefuroxime.parenteral;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cefuroxime Parenteral [Mass/volume] in Specimen;Cefuroxime Parenter Spec-mCnc;;ACTIVE;2.00;2.70 +25246-0;Cephalothin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cephalothin [Mass/volume] in Specimen;Cephalothin Spec-mCnc;;ACTIVE;2.00;2.70 +2524-7;Lactate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate [Moles/volume] in Serum or Plasma;Lactate SerPl-sCnc;;ACTIVE;1.0;2.73 +25247-8;Chloramphenicol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Chloramphenicol [Mass/volume] in Specimen;Chloramphen Spec-mCnc;;ACTIVE;2.00;2.70 +25248-6;Ciprofloxacin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ciprofloxacin [Mass/volume] in Specimen;Ciprofloxacin Spec-mCnc;;ACTIVE;2.00;2.70 +25249-4;Clindamycin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Clindamycin [Mass/volume] in Specimen;Clindamycin Spec-mCnc;;ACTIVE;2.00;2.73 +25250-2;Cloxacillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cloxacillin [Mass/volume] in Specimen;Cloxacillin Spec-mCnc;;ACTIVE;2.00;2.70 +25251-0;cycloSERINE;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;cycloSERINE [Mass/volume] in Specimen;cycloSERINE Spec-mCnc;;ACTIVE;2.00;2.73 +25252-8;Dicloxacillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Dicloxacillin [Mass/volume] in Specimen;Dicloxacillin Spec-mCnc;;ACTIVE;2.00;2.70 +25253-6;Clarithromycin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Clarithromycin [Mass/volume] in Specimen;Clarithro Spec-mCnc;;ACTIVE;2.00;2.70 +2525-4;Lactate;SCnc;Pt;Synv fld;Qn;;CHEM;1;Lactate [Moles/volume] in Synovial fluid;Lactate Snv-sCnc;;ACTIVE;1.0;2.34 +25254-4;Ticarcillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ticarcillin [Mass/volume] in Specimen;Ticarcillin Spec-mCnc;;ACTIVE;2.00;2.70 +25255-1;Fluconazole;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Fluconazole [Mass/volume] in Specimen;Fluconazole Spec-mCnc;;ACTIVE;2.00;2.70 +25256-9;Ganciclovir;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ganciclovir [Mass/volume] in Specimen;Ganciclovir Spec-mCnc;;ACTIVE;2.00;2.70 +25257-7;Imipenem;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Imipenem [Mass/volume] in Specimen;Imipenem Spec-mCnc;;ACTIVE;2.00;2.70 +25258-5;Itraconazole;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Itraconazole [Mass/volume] in Specimen;Itraconaz Spec-mCnc;;ACTIVE;2.00;2.73 +25259-3;Ketoconazole;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ketoconazole [Mass/volume] in Specimen;Ketoconazole Spec-mCnc;;ACTIVE;2.00;2.73 +25261-9;Nalidixate;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nalidixate [Mass/volume] in Specimen;Nalidixate Spec-mCnc;;ACTIVE;2.00;2.70 +2526-2;Lactate;MRat;24H;Urine;Qn;;CHEM;1;Lactate [Mass/time] in 24 hour Urine;Lactate 24h Ur-mRate;;ACTIVE;1.0;2.42 +25262-7;Neomycin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Neomycin [Mass/volume] in Specimen;Neomycin Spec-mCnc;;ACTIVE;2.00;2.70 +25263-5;Netilmicin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Netilmicin [Mass/volume] in Specimen;Netilmicin Spec-mCnc;;ACTIVE;2.00;2.70 +25264-3;Ofloxacin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ofloxacin [Mass/volume] in Specimen;Ofloxacin Spec-mCnc;;ACTIVE;2.00;2.70 +25265-0;Oxacillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Oxacillin [Mass/volume] in Specimen;Oxacillin Spec-mCnc;;ACTIVE;2.00;2.70 +25266-8;Oxytetracycline;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Oxytetracycline [Mass/volume] in Specimen;Oxytetracycline Spec-mCnc;;ACTIVE;2.00;2.70 +25267-6;Penicillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Penicillin [Mass/volume] in Specimen;Penicillin Spec-mCnc;;ACTIVE;2.00;2.73 +25268-4;Piperacillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Piperacillin [Mass/volume] in Specimen;Piperacillin Spec-mCnc;;ACTIVE;2.00;2.73 +25269-2;Polymyxin B;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Polymyxin B [Mass/volume] in Specimen;Polymyxin B Spec-mCnc;;ACTIVE;2.00;2.70 +252-7;5-Fluorocytosine;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;5-Fluorocytosine [Susceptibility] by Minimum lethal concentration (MLC);5-fluorocytosine Islt MLC;;ACTIVE;1.0;2.21 +2527-0;Lactate dehydrogenase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Amniotic fluid;LDH Amn-cCnc;;ACTIVE;1.0;2.68 +25270-0;Pyrazinamide;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Pyrazinamide [Mass/volume] in Specimen;PZA Spec-mCnc;;ACTIVE;2.00;2.70 +25271-8;Sulfamethoxazole;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Sulfamethoxazole [Mass/volume] in Specimen;Sulfamethoxazole Spec-mCnc;;ACTIVE;2.00;2.70 +25272-6;Tetracycline;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Tetracycline [Mass/volume] in Specimen;Tetracycline Spec-mCnc;;ACTIVE;2.00;2.70 +25273-4;Trimethoprim+Sulfamethoxazole;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Deprecated Trimethoprim+Sulfamethoxazole [Mass/volume] in Unspecified specimen;Deprecated TMP SMX XXX-mCnc;;DEPRECATED;2.00;2.70 +25274-2;Amoxicillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Amoxicillin [Mass/volume] in Specimen;Amoxicillin Spec-mCnc;;ACTIVE;2.00;2.70 +25275-9;Erythromycin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Erythromycin [Mass/volume] in Specimen;Erythromycin Spec-mCnc;;ACTIVE;2.00;2.73 +25276-7;Streptococcus pneumoniae 9 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum9 IgG 2:1 Ser-Rto;;DEPRECATED;2.00;2.66 +25277-5;Streptococcus pneumoniae 8 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum8 IgG 2:1 Ser-Rto;;DEPRECATED;2.00;2.66 +25278-3;Streptococcus pneumoniae Danish serotype 7F Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 7F IgG 2:1 Ser-Rto;;ACTIVE;2.00;2.61 +25279-1;Streptococcus pneumoniae Danish serotype 6B Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 6B IgG sp1 Ser-aCnc;;ACTIVE;2.00;2.70 +25280-9;Streptococcus pneumoniae Danish serotype 6B Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 6B IgG 2:1 Ser-Rto;;ACTIVE;2.00;2.61 +25281-7;Streptococcus pneumoniae 4 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum4 IgG 2:1 Ser-Rto;;DEPRECATED;2.00;2.66 +25282-5;Streptococcus pneumoniae 3 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum3 IgG 2:1 Ser-Rto;;DEPRECATED;2.00;2.66 +25283-3;Streptococcus pneumoniae 23 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum23 IgG 2:1 Ser-Rto;;DEPRECATED;2.00;2.66 +25284-1;Streptococcus pneumoniae 19 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum19 IgG 2:1 Ser-Rto;;DEPRECATED;2.00;2.66 +25285-8;Streptococcus pneumoniae Danish serotype 18C Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 18C IgG 2:1 Ser-Rto;;ACTIVE;2.00;2.61 +25286-6;Streptococcus pneumoniae 1 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum 1 IgG 2:1 Ser-Rto;;DEPRECATED;2.00;2.66 +25287-4;Streptococcus pneumoniae 19 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum19 IgG sp1 Ser-aCnc;;DEPRECATED;2.00;2.70 +2528-8;Lactate dehydrogenase;CCnc;Pt;CSF;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Cerebral spinal fluid;LDH CSF-cCnc;;DISCOURAGED;1.0;2.73 +25288-2;Streptococcus pneumoniae 19 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum19 IgG sp2 Ser-aCnc;;DEPRECATED;2.00;2.70 +25289-0;Streptococcus pneumoniae Danish serotype 18C Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 18C IgG sp2 Ser-aCnc;;ACTIVE;2.00;2.70 +25290-8;Streptococcus pneumoniae 14 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum14 IgG sp1 Ser-aCnc;;DEPRECATED;2.00;2.70 +25291-6;Streptococcus pneumoniae 14 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum14 IgG sp2 Ser-aCnc;;DEPRECATED;2.00;2.70 +25292-4;Streptococcus pneumoniae 12 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum12 IgG sp1 Ser-aCnc;;DEPRECATED;2.00;2.70 +25293-2;Streptococcus pneumoniae 12 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum12 IgG sp2 Ser-aCnc;;DEPRECATED;2.00;2.70 +25294-0;Streptococcus pneumoniae 1 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum 1 IgG sp2 Ser-aCnc;;DEPRECATED;2.00;2.70 +25295-7;Streptococcus pneumoniae Danish serotype 6B Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Units/volume] in Serum;S pneum Da 6B IgG Ser-aCnc;;ACTIVE;2.00;2.70 +2529-6;Lactate dehydrogenase;CCnc;Pt;Body fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Body fluid;LDH Fld-cCnc;;DISCOURAGED;1.0;2.73 +25296-5;Streptococcus pneumoniae Danish serotype 7F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Mass/volume] in Serum;S pneum Da 7F IgG Ser-mCnc;;ACTIVE;2.00;2.73 +25297-3;Parainfluenza virus 1 Ab^2nd specimen;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Serum by Complement fixation --2nd specimen;HPIV1 Ab sp2 Titr Ser CF;;ACTIVE;2.00;2.70 +25298-1;Rubella virus Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Rubella virus IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;RUBV IgG 1:2 Ser-Rto;;ACTIVE;2.00;2.73 +25299-9;Measles virus Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Measles virus IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;MeV IgG 1:2 Ser-Rto;;ACTIVE;2.00;2.10 +25300-5;Toxoplasma gondii Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;T gondii IgG 1:2 Ser-Rto;;ACTIVE;2.00;2.10 +25301-3;Alanine;SRat;24H;Urine;Qn;;CHEM;1;Alanine [Moles/time] in 24 hour Urine;Alanine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25302-1;Alanine aminotransferase;CCnc;Pt;Body fld;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Body fluid;ALT Fld-cCnc;;ACTIVE;2.00;2.73 +25303-9;Alpha 1 antitrypsin;MCnt;Pt;Stool;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/mass] in Stool;A1AT Stl-mCnt;;ACTIVE;2.00;2.73 +2530-4;Lactate dehydrogenase;CCnc;Pt;Plr fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid;LDH Plr-cCnc;;DISCOURAGED;1.0;2.73 +25304-7;Alpha aminoadipate;SRat;24H;Urine;Qn;;CHEM;1;Alpha aminoadipate [Moles/time] in 24 hour Urine;AAA 24h Ur-sRate;;ACTIVE;2.00;2.73 +25305-4;Alpha aminobutyrate;SRat;24H;Urine;Qn;;CHEM;1;Alpha aminobutyrate [Moles/time] in 24 hour Urine;A-Aminobutyr 24h Ur-sRate;;ACTIVE;2.00;2.73 +25306-2;Alternaria alternata Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Alternaria alternata IgG Ab [Units/volume] in Serum;Deprecated A alternata IgG Ser-aCnc;;DEPRECATED;2.00;2.69 +25307-0;Alternaria alternata Ab.IgG.RAST class;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Alternaria alternata IgG Ab RAST class in Serum;Deprecated A alternata IgG RAST Ser Ql;;DEPRECATED;2.00;2.36 +25308-8;Ammonia;SRat;24H;Urine;Qn;;CHEM;1;Ammonia [Moles/time] in 24 hour Urine;Ammonia 24h Ur-sRate;;ACTIVE;2.00;2.73 +25309-6;Amobarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amobarbital [Moles/volume] in Serum or Plasma;Amobarbital SerPl-sCnc;;ACTIVE;2.00;2.34 +25310-4;Amoxicillin+Clavulanate;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility] by Method for Slow-growing mycobacteria;Amoxicillin+Clav Islt SlowMyco;;ACTIVE;2.00;2.26 +25311-2;Amylase;CCnc;24H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in 24 hour Urine;Amylase 24h Ur-cCnc;;ACTIVE;2.00;2.73 +2531-2;Lactate dehydrogenase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Peritoneal fluid;LDH Prt-cCnc;;DISCOURAGED;1.0;2.73 +25312-0;Amylase.pancreatic/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.pancreatic/Amylase.total in Serum or Plasma;Amylase P CFr SerPl;;ACTIVE;2.00;2.70 +25313-8;Amylase.salivary/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.salivary/Amylase.total in Serum or Plasma;Amylase S CFr SerPl;;ACTIVE;2.00;2.70 +25314-6;Androstenediol;SRat;24H;Urine;Qn;;CHEM;1;Androstenediol [Moles/time] in 24 hour Urine;Androstenediol 24h Ur-sRate;;ACTIVE;2.00;2.44 +25315-3;11-Deoxycortisol;SRat;24H;Urine;Qn;;CHEM;1;11-Deoxycortisol [Moles/time] in 24 hour Urine;11DC 24h Ur-sRate;;ACTIVE;2.00;2.42 +25316-1;17-Hydroxypregnenolone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;17-Hydroxypregnenolone [Moles/volume] in Serum or Plasma;17OH-Preg SerPl-sCnc;;ACTIVE;2.00;2.40 +25317-9;17-Ketosteroids;SCnc;24H;Urine;Qn;;CHEM;1;17-Ketosteroids [Moles/volume] in 24 hour Urine;17KS 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25318-7;1-Methylhistidine;SRat;24H;Urine;Qn;;CHEM;1;1-Methylhistidine [Moles/time] in 24 hour Urine;1Me-hist 24h Ur-sRate;;ACTIVE;2.00;2.73 +25319-5;3-Methylhistidine;SRat;24H;Urine;Qn;;CHEM;1;3-Methylhistidine [Moles/time] in 24 hour Urine;3Me-histidine 24h Ur-sRate;;ACTIVE;2.00;2.73 +2532-0;Lactate dehydrogenase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma;LDH SerPl-cCnc;;DISCOURAGED;1.0;2.73 +25320-3;Anserine;SRat;24H;Urine;Qn;;CHEM;1;Anserine [Moles/time] in 24 hour Urine;Anserine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25321-1;Antimony;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Antimony [Moles/volume] in Serum or Plasma;Antimony SerPl-sCnc;;ACTIVE;2.00;2.34 +25322-9;Arginine;SRat;24H;Urine;Qn;;CHEM;1;Arginine [Moles/time] in 24 hour Urine;Arginine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25323-7;Arsenic;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Arsenic [Moles/volume] in Serum or Plasma;Arsenic SerPl-sCnc;;ACTIVE;2.00;2.40 +25324-5;Arsenic/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic/Creatinine [Molar ratio] in Urine;Arsenic/Creat Ur-sRto;;ACTIVE;2.00;2.42 +25325-2;Ascaris sp Ab.IgE;ACnc;Pt;Ser;Qn;IA;ALLERGY;1;Ascaris sp IgE Ab [Units/volume] in Serum by Immunoassay;Ascaris IgE Qn IA;;ACTIVE;2.00;2.56 +25326-0;Asparagine;SRat;24H;Urine;Qn;;CHEM;1;Asparagine [Moles/time] in 24 hour Urine;Asparagine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25327-8;Aspartate;SRat;24H;Urine;Qn;;CHEM;1;Aspartate [Moles/time] in 24 hour Urine;Aspartate 24h Ur-sRate;;ACTIVE;2.00;2.73 +25328-6;Aspergillus versicolor Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus versicolor IgE Ab RAST class [Presence] in Serum;A versicolor IgE RAST Ql;;ACTIVE;2.00;2.73 +25329-4;Aureobasidium pullulans Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Aureobasidium pullulans IgE Ab RAST class in Serum;Deprecated A pullulans IgE RAST Ql;;DEPRECATED;2.00;2.36 +25331-0;Bordetella pertussis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis IgG Ab [Titer] in Serum;B pert IgG Titr Ser;;ACTIVE;2.00;2.70 +25332-8;Bordetella pertussis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis IgM Ab [Titer] in Serum;B pert IgM Titr Ser;;ACTIVE;2.00;2.70 +25333-6;Campylobacter fetus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Campylobacter fetus Ab [Titer] in Serum;C fetus Ab Titr Ser;;ACTIVE;2.00;2.70 +25335-1;Coxiella burnetii Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii IgG Ab [Titer] in Serum;C burnet IgG Titr Ser;;ACTIVE;2.00;2.70 +25336-9;Coxiella burnetii Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii IgM Ab [Titer] in Serum;C burnet IgM Titr Ser;;ACTIVE;2.00;2.70 +25337-7;Taenia solium larva Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Taenia solium larva IgG Ab [Units/volume] in Serum;T sol lar IgG Ser-aCnc;;ACTIVE;2.00;2.73 +2533-8;Lactate dehydrogenase;CCnc;Pt;Synv fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Synovial fluid;LDH Snv-cCnc;;DISCOURAGED;1.0;2.73 +25338-5;Dengue virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus IgM Ab [Presence] in Serum;DENV IgM Ser Ql;;ACTIVE;2.00;2.73 +25339-3;Echinococcus sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echinococcus sp Ab [Presence] in Serum;Echinococcus Ab Ser Ql;;ACTIVE;2.00;2.56 +25342-7;Fasciola sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Fasciola sp Ab [Titer] in Serum;Fasciola Ab Titr Ser;;ACTIVE;2.00;2.70 +25343-5;Fasciola sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Fasciola sp IgG Ab [Units/volume] in Serum;Fasciola IgG Ser-aCnc;;ACTIVE;2.00;2.69 +25344-3;Filaria Ab;Titr;Pt;Ser;Qn;;MICRO;1;Filaria Ab [Titer] in Serum;Filaria Ab Titr Ser;;ACTIVE;2.00;2.70 +25345-0;Beet red Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Beet IgE Ab RAST class [Presence] in Serum;Red Beet IgE RAST Ql;;ACTIVE;2.00;2.73 +2534-6;Lactate dehydrogenase;CCnc;Pt;Urine;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Urine;LDH Ur-cCnc;;ACTIVE;1.0;2.73 +25346-8;Beta alanine;SRat;24H;Urine;Qn;;CHEM;1;Beta alanine [Moles/time] in 24 hour Urine;B-Alanine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25347-6;Filaria Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Filaria IgG Ab [Units/volume] in Serum;Deprecated Filaria IgG Ser-aCnc;;DEPRECATED;2.00;2.69 +25348-4;Beta aminoisobutyrate;SRat;24H;Urine;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/time] in 24 hour Urine;B-AIB 24h Ur-sRate;;ACTIVE;2.00;2.73 +25349-2;Betula verrucosa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch IgG Ab [Units/volume] in Serum;Silver Birch IgG Qn;;ACTIVE;2.00;2.69 +253-5;5-Fluorocytosine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;5-Fluorocytosine [Susceptibility] by Minimum inhibitory concentration (MIC);5-fluorocytosine Islt MIC;;ACTIVE;1.0;2.73 +25350-0;Betula verrucosa Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch IgG Ab RAST class [Presence] in Serum;Silver Birch IgG RAST Ql;;ACTIVE;2.00;2.58 +25351-8;Bismuth;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bismuth [Moles/volume] in Serum or Plasma;Bismuth SerPl-sCnc;;ACTIVE;2.00;2.73 +25352-6;Bordetella pertussis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Bordetella pertussis IgG Ab [Titer] in Serum by Immunofluorescence;B pert IgG Titr Ser IF;;ACTIVE;2.00;2.70 +2535-3;Lactate dehydrogenase 1;CCnc;Pt;Ser/Plas;Qn;Chemical separation;CHEM;1;Lactate dehydrogenase 1 [Enzymatic activity/volume] in Serum or Plasma by Chemical separation;LDH1 SerPl Chem Sepn-cCnc;;ACTIVE;1.0;2.73 +25353-4;Bordetella pertussis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Bordetella pertussis IgM Ab [Titer] in Serum by Immunofluorescence;B pert IgM Titr Ser IF;;ACTIVE;2.00;2.70 +25354-2;Bran wheat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat Bran IgG Ab [Units/volume] in Serum;Wheat Bran IgG Qn;;ACTIVE;2.00;2.69 +25355-9;Bran wheat Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat Bran IgG Ab RAST class [Presence] in Serum;Wheat Bran IgG RAST Ql;;ACTIVE;2.00;2.58 +25356-7;Budgerigar droppings Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Budgerigar droppings IgE Ab RAST class in Serum;Deprecated Budgie Drop IgE RAST Ql;;DEPRECATED;2.00;2.36 +25357-5;Butabarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Butabarbital [Moles/volume] in Serum or Plasma;Butabarbital SerPl-sCnc;;ACTIVE;2.00;2.73 +25358-3;C peptide;SRat;24H;Urine;Qn;;CHEM;1;C peptide [Moles/time] in 24 hour Urine;C peptide 24h Ur-sRate;;ACTIVE;2.00;2.42 +25359-1;Cadmium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cadmium [Moles/volume] in Serum or Plasma;Cadmium SerPl-sCnc;;ACTIVE;2.00;2.42 +25360-9;Cadmium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cadmium [Moles/volume] in Urine;Cadmium Ur-sCnc;;ACTIVE;2.00;2.34 +2536-1;Lactate dehydrogenase 1/Lactate dehydrogenase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 1/Lactate dehydrogenase.total in Serum or Plasma by Electrophoresis;LDH1 CFr SerPl Elph;;ACTIVE;1.0;2.73 +25361-7;Caffeine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Caffeine [Moles/volume] in Serum or Plasma;Caffeine SerPl-sCnc;;ACTIVE;2.00;2.73 +25362-5;Calcium;SCnc;24H;Urine;Qn;;CHEM;1;Calcium [Moles/volume] in 24 hour Urine;Calcium 24h Ur-sCnc;;ACTIVE;2.00;2.73 +25363-3;Campylobacter fetus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Campylobacter fetus Ab [Titer] in Serum by Complement fixation;C fetus Ab Titr Ser CF;;ACTIVE;2.00;2.70 +25364-1;Campylobacter jejuni Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Campylobacter jejuni Ab [Titer] in Serum by Complement fixation;C jejuni Ab Titr Ser CF;;ACTIVE;2.00;2.70 +25365-8;Carnosine;SRat;24H;Urine;Qn;;CHEM;1;Carnosine [Moles/time] in 24 hour Urine;Carnosine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25366-6;cefOXitin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cefOXitin [Susceptibility] by Method for Slow-growing mycobacteria;cefOXitin Islt SlowMyco;;ACTIVE;2.00;2.73 +25367-4;cefTRIAXone;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cefTRIAXone [Susceptibility] by Method for Slow-growing mycobacteria;cefTRIAXone Islt SlowMyco;;ACTIVE;2.00;2.26 +25368-2;Cheese blue Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blue Cheese IgE Ab RAST class [Presence] in Serum;Blue Cheese IgE RAST Ql;;ACTIVE;2.00;2.73 +25369-0;Chlamydia sp Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgA Ab [Units/volume] in Serum;Chlamydia IgA Ser-aCnc;;ACTIVE;2.00;2.69 +25370-8;Chocolate Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chocolate IgE Ab RAST class [Presence] in Serum;Chocolate IgE RAST Ql;;ACTIVE;2.00;2.73 +25371-6;Cholesterol.in VLDL;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL [Moles/volume] in Serum or Plasma;VLDLc SerPl-sCnc;;ACTIVE;2.00;2.73 +25372-4;Choriogonadotropin;ACnc;Pt;Urine;Qn;;CHEM;1;Choriogonadotropin [Units/volume] in Urine;HCG Ur-aCnc;;ACTIVE;2.00;2.73 +25373-2;Choriogonadotropin.beta subunit.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma;B-HCG Free SerPl-mCnc;;ACTIVE;2.00;2.73 +25374-0;Chromium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chromium [Moles/volume] in Serum or Plasma;Chromium SerPl-sCnc;;ACTIVE;2.00;2.34 +25375-7;Chymotrypsin;CCnt;Pt;Stool;Qn;;CHEM;1;Chymotrypsin [Enzymatic activity/mass] in Stool;Chymotryp Stl-cCnt;;ACTIVE;2.00;2.73 +25376-5;Citrulline;SRat;24H;Urine;Qn;;CHEM;1;Citrulline [Moles/time] in 24 hour Urine;Citrulline 24h Ur-sRate;;ACTIVE;2.00;2.73 +25377-3;Coagulation calcium ion induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Recalcification time in Control Platelet poor plasma by Coagulation assay;Recal time Cont PPP;;ACTIVE;2.00;2.44 +25378-1;Cobalt;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cobalt [Moles/volume] in Serum or Plasma;Cobalt SerPl-sCnc;;ACTIVE;2.00;2.34 +2537-9;Lactate dehydrogenase 1;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase 1 [Enzymatic activity/volume] in Serum or Plasma;LDH1 SerPl-cCnc;;ACTIVE;1.0;2.73 +25379-9;Cobalt;SRat;24H;Urine;Qn;;DRUG/TOX;1;Cobalt [Moles/time] in 24 hour Urine;Cobalt 24h Ur-sRate;;ACTIVE;2.00;2.40 +25380-7;Dactylis glomerata Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Cocksfoot IgE Ab RAST class in Serum;Deprecated Cocksfoot IgE RAST Ql;;DEPRECATED;2.00;2.36 +25381-5;Corticosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Corticosterone [Moles/volume] in Serum or Plasma;Corticoster SerPl-sCnc;;ACTIVE;2.00;2.40 +25382-3;Cortisone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisone [Moles/volume] in Serum or Plasma;Cortisone SerPl-sCnc;;ACTIVE;2.00;2.42 +25383-1;Cow milk Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cow milk IgE Ab RAST class [Presence] in Serum;Cow Milk IgE RAST Ql;;ACTIVE;2.00;2.73 +25384-9;Coxiella burnetii Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii IgG Ab [Titer] in Serum by Immunofluorescence;C burnet IgG Titr Ser IF;;ACTIVE;2.00;2.73 +25385-6;Coxiella burnetii Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii IgM Ab [Titer] in Serum by Immunofluorescence;C burnet IgM Titr Ser IF;;ACTIVE;2.00;2.70 +25386-4;Creatinine;SCnc;Pt;Body fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Body fluid;Creat Fld-sCnc;;ACTIVE;2.00;2.73 +2538-7;Lactate dehydrogenase 2;CCnc;Pt;Ser/Plas;Qn;Chemical separation;CHEM;1;Lactate dehydrogenase 2 [Enzymatic activity/volume] in Serum or Plasma by Chemical separation;LDH2 SerPl Chem Sepn-cCnc;;ACTIVE;1.0;2.73 +25387-2;Cyanide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyanide [Moles/volume] in Serum or Plasma;Cyanide SerPl-sCnc;;ACTIVE;2.00;2.34 +25388-0;Cystathionine;SRat;24H;Urine;Qn;;CHEM;1;Cystathionine [Moles/time] in 24 hour Urine;Cystathionin 24h Ur-sRate;;ACTIVE;2.00;2.73 +25389-8;Taenia solium larva Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Taenia solium larva IgG Ab [Units/volume] in Serum by Immunoassay;T sol lar IgG Ser IA-aCnc;;ACTIVE;2.00;2.73 +25390-6;Cytokeratin 19;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cytokeratin 19 [Mass/volume] in Serum or Plasma;CK 19 SerPl-mCnc;;ACTIVE;2.00;2.73 +25391-4;Dehydroepiandrosterone;SRat;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Moles/time] in 24 hour Urine;DHEA 24h Ur-sRate;;ACTIVE;2.00;2.42 +25392-2;Dengue virus Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Dengue virus IgM Ab [Presence] in Serum by Immunoblot;DENV IgM Ser Ql IB;;ACTIVE;2.00;2.58 +25393-0;Desethylamiodarone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desethylamiodarone [Moles/volume] in Serum or Plasma;Desethylamiodarone SerPl-sCnc;;ACTIVE;2.00;2.42 +25394-8;Nortrimipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortrimipramine [Moles/volume] in Serum or Plasma;Nortrimipramine SerPl-sCnc;;ACTIVE;2.00;2.34 +2539-5;Lactate dehydrogenase 2/Lactate dehydrogenase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 2/Lactate dehydrogenase.total in Serum or Plasma by Electrophoresis;LDH2 CFr SerPl Elph;;ACTIVE;1.0;2.73 +25395-5;Dog serum albumin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog serum albumin IgE Ab RAST class [Presence] in Serum;Dog Serum Alb IgE RAST Ql;;ACTIVE;2.00;2.58 +25396-3;Duck meat Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Duck meat IgE Ab RAST class [Presence] in Serum;Duck Meat IgE RAST Ql;;ACTIVE;2.00;2.73 +25397-1;Echinococcus sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Echinococcus sp Ab [Presence] in Serum by Immunoassay;Echinococcus Ab Ser Ql IA;;ACTIVE;2.00;2.73 +25398-9;Echinococcus sp Ab;ACnc;Pt;Ser;Qn;CIE;MICRO;1;Echinococcus sp Ab [Units/volume] in Serum by Counterimmunoelectrophoresis (CIE);Echinococcus Ab Ser CIE-aCnc;;ACTIVE;2.00;2.69 +25399-7;Endomysium Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Endomysium Ab [Titer] in Serum by Immunofluorescence;Endomysium Ab Titr Ser IF;;ACTIVE;2.00;2.73 +25400-3;Entamoeba histolytica Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Entamoeba histolytica Ab [Titer] in Serum by Immunofluorescence;E histolyt Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25401-1;Estradiol;SRat;24H;Urine;Qn;;CHEM;1;Estradiol (E2) [Moles/time] in 24 hour Urine;Estradiol 24h Ur-sRate;;ACTIVE;2.00;2.42 +25402-9;Estrogen;SRat;24H;Urine;Qn;;CHEM;1;Estrogen [Moles/time] in 24 hour Urine;Estrogen 24h Ur-sRate;;ACTIVE;2.00;2.40 +2540-3;Lactate dehydrogenase 2;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase 2 [Enzymatic activity/volume] in Serum or Plasma;LDH2 SerPl-cCnc;;ACTIVE;1.0;2.73 +25403-7;Estrone;SCnc;Pt;Urine;Qn;;CHEM;1;Estrone (E1) [Moles/volume] in Urine;Estrone Ur-sCnc;;ACTIVE;2.00;2.42 +25404-5;Ethambutol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ethambutol [Presence] in Serum or Plasma;Ethambutol SerPl Ql;;ACTIVE;2.00;2.56 +25405-2;Ethanolamine;SRat;24H;Urine;Qn;;CHEM;1;Ethanolamine [Moles/time] in 24 hour Urine;Ethanolamine 24h Ur-sRate;;ACTIVE;2.00;2.42 +25406-0;Fasciola sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Fasciola sp Ab [Titer] in Serum by Immunofluorescence;Fasciola Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25407-8;Fasciola sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Fasciola sp IgG Ab [Units/volume] in Serum by Immunoassay;Fasciola IgG Ser IA-aCnc;;ACTIVE;2.00;2.69 +25408-6;Trigonella foenum-graecum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fenugreek IgE Ab RAST class [Presence] in Serum;Fenugreek IgE RAST Ql;;ACTIVE;2.00;2.58 +25409-4;Filaria Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Filaria Ab [Titer] in Serum by Immunofluorescence;Filaria Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25410-2;Filaria Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Filaria IgG Ab [Units/volume] in Serum by Immunoassay;Filaria IgG Ser IA-aCnc;;ACTIVE;2.00;2.69 +2541-1;Lactate dehydrogenase 3;CCnc;Pt;Ser/Plas;Qn;Chemical separation;CHEM;1;Lactate dehydrogenase 3 [Enzymatic activity/volume] in Serum or Plasma by Chemical separation;LDH3 SerPl Chem Sepn-cCnc;;ACTIVE;1.0;2.73 +25411-0;Fleroxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Fleroxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Fleroxacin Islt MIC;;ACTIVE;2.00;2.19 +25412-8;Flunitrazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flunitrazepam [Moles/volume] in Serum or Plasma;Flunitrazepam SerPl-sCnc;;ACTIVE;2.00;2.42 +25413-6;Fluoride;SRat;24H;Urine;Qn;;DRUG/TOX;1;Fluoride [Moles/time] in 24 hour Urine;Fluoride 24h Ur-sRate;;ACTIVE;2.00;2.42 +25414-4;Gasterophilus intestinalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse Bot Fly IgE Ab RAST class [Presence] in Serum;Horse Bot Fly IgE RAST Ql;;ACTIVE;2.00;2.73 +25415-1;Folate;SCnc;Pt;Bld;Qn;;CHEM;1;Folate [Moles/volume] in Blood;Folate Bld-sCnc;;ACTIVE;2.00;2.73 +25416-9;Herpes virus 6 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 6 IgG Ab [Titer] in Serum by Immunofluorescence;HHV6 IgG Titr Ser IF;;ACTIVE;2.00;2.73 +25417-7;Herpes virus 6 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 6 IgM Ab [Titer] in Serum by Immunofluorescence;HHV6 IgM Titr Ser IF;;ACTIVE;2.00;2.73 +25418-5;Mumps virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mumps virus IgG Ab [Units/volume] in Serum by Immunoassay;MuV IgG Ser IA-aCnc;;ACTIVE;2.00;2.73 +25419-3;Mumps virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mumps virus IgM Ab [Units/volume] in Serum by Immunoassay;MuV IgM Ser IA-aCnc;;ACTIVE;2.00;2.73 +25420-1;Rubella virus Ab.IgM;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rubella virus IgM Ab [Presence] in Serum by Latex agglutination;RUBV IgM Ser Ql LA;;ACTIVE;2.00;2.56 +25421-9;Measles virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Measles virus IgM Ab [Units/volume] in Serum by Immunoassay;MeV IgM Ser IA-aCnc;;ACTIVE;2.00;2.73 +25422-7;Schistosoma sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Schistosoma sp Ab [Titer] in Serum by Immunofluorescence;Schistosoma Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25423-5;Trichinella spiralis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichinella spiralis IgG Ab [Units/volume] in Serum by Immunoassay;T spiralis IgG Ser IA-aCnc;;ACTIVE;2.00;2.69 +25424-3;Trypanosoma sp Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Trypanosoma sp Ab [Units/volume] in Serum by Immunofluorescence;Trypanos Ab Ser IF-aCnc;;ACTIVE;2.00;2.69 +25425-0;Gabapentin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gabapentin [Moles/volume] in Serum or Plasma;Gabapentin SerPl-sCnc;;ACTIVE;2.00;2.73 +25426-8;Galactose;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Galactose [Moles/volume] in Serum or Plasma;Galactose SerPl-sCnc;;ACTIVE;2.00;2.34 +25427-6;Gamma aminobutyrate;SRat;24H;Urine;Qn;;CHEM;1;Gamma aminobutyrate [Moles/time] in 24 hour Urine;GABA 24h Ur-sRate;;ACTIVE;2.00;2.73 +25428-4;Glucose;PrThr;Pt;Urine;Ord;Test strip;UA;1;Glucose [Presence] in Urine by Test strip;Glucose Ur Ql Strip;;ACTIVE;2.00;2.73 +2542-9;Lactate dehydrogenase 3/Lactate dehydrogenase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 3/Lactate dehydrogenase.total in Serum or Plasma by Electrophoresis;LDH3 CFr SerPl Elph;;ACTIVE;1.0;2.73 +25429-2;Glutamate;SRat;24H;Urine;Qn;;CHEM;1;Glutamate [Moles/time] in 24 hour Urine;Glutamate 24h Ur-sRate;;ACTIVE;2.00;2.73 +254-3;5-Fluorocytosine;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;5-Fluorocytosine [Susceptibility] by Disk diffusion (KB);5-fluorocytosine Islt KB;;ACTIVE;1.0;2.21 +25430-0;Glutamine;SRat;24H;Urine;Qn;;CHEM;1;Glutamine [Moles/time] in 24 hour Urine;Glutamine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25431-8;Glycine;SRat;24H;Urine;Qn;;CHEM;1;Glycine [Moles/time] in 24 hour Urine;Glycine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25432-6;Haemophilus influenzae Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae Ab [Mass/volume] in Serum;Haem influ Ab Ser-mCnc;;ACTIVE;2.00;2.40 +25433-4;Hemoglobin.free;SCnc;Pt;Plas;Qn;;HEM/BC;1;Free Hemoglobin [Moles/volume] in Plasma;Hgb Free Plas-sCnc;;ACTIVE;2.00;2.70 +25434-2;Heptacarboxylporphyrin;SRat;24H;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin [Moles/time] in 24 hour Urine;Hepta-CP 24h Ur-sRate;;ACTIVE;2.00;2.73 +25435-9;Herpes simplex virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus IgM Ab [Presence] in Serum;HSV IgM Ser Ql;;ACTIVE;2.00;2.73 +2543-7;Lactate dehydrogenase 3;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase 3 [Enzymatic activity/volume] in Serum or Plasma;LDH3 SerPl-cCnc;;ACTIVE;1.0;2.73 +25438-3;Hexacarboxylporphyrin;SRat;24H;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin [Moles/time] in 24 hour Urine;Hexa-CP 24h Ur-sRate;;ACTIVE;2.00;2.73 +25439-1;Histamine;SRat;24H;Urine;Qn;;CHEM;1;Histamine [Moles/time] in 24 hour Urine;Histamine 24h Ur-sRate;;ACTIVE;2.00;2.40 +25440-9;Histidine;SRat;24H;Urine;Qn;;CHEM;1;Histidine [Moles/time] in 24 hour Urine;Histidine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25441-7;Homocystine;SRat;24H;Urine;Qn;;CHEM;1;Homocystine [Moles/time] in 24 hour Urine;(Hcys)2 24h Ur-sRate;;ACTIVE;2.00;2.73 +25442-5;Horse meat Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse meat IgE Ab RAST class [Presence] in Serum;Horse Meat IgE RAST Ql;;ACTIVE;2.00;2.58 +25443-3;Hydroxylysine;SRat;24H;Urine;Qn;;CHEM;1;Hydroxylysine [Moles/time] in 24 hour Urine;OH-Lysine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25444-1;IgA;PrThr;Pt;Urine;Ord;Immunoelectrophoresis;CHEM;1;IgA [Presence] in Urine by Immunoelectrophoresis;IgA Ur Ql IEP;;ACTIVE;2.00;2.56 +2544-5;Lactate dehydrogenase 4;CCnc;Pt;Ser/Plas;Qn;Chemical separation;CHEM;1;Lactate dehydrogenase 4 [Enzymatic activity/volume] in Serum or Plasma by Chemical separation;LDH4 SerPl Chem Sepn-cCnc;;ACTIVE;1.0;2.73 +25445-8;IgG;PrThr;Pt;Urine;Ord;Immunoelectrophoresis;CHEM;1;IgG [Presence] in Urine by Immunoelectrophoresis;IgG Ur Ql IEP;;ACTIVE;2.00;2.56 +25446-6;IgM;PrThr;Pt;Urine;Ord;Immunoelectrophoresis;CHEM;1;IgM [Presence] in Urine by Immunoelectrophoresis;IgM Ur Ql IEP;;ACTIVE;2.00;2.56 +25447-4;Insulin.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin Free [Moles/volume] in Serum or Plasma;Insulin Free SerPl-sCnc;;ACTIVE;2.00;2.73 +25448-2;Iodine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iodine [Moles/volume] in Serum or Plasma;Iodine SerPl-sCnc;;ACTIVE;2.00;2.42 +25449-0;Iodine;SRat;24H;Urine;Qn;;CHEM;1;Iodine [Moles/time] in 24 hour Urine;Iodine 24h Ur-sRate;;ACTIVE;2.00;2.42 +25450-8;Isoleucine;SRat;24H;Urine;Qn;;CHEM;1;Isoleucine [Moles/time] in 24 hour Urine;Isoleucine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25451-6;Isoniazid;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Isoniazid [Moles/volume] in Serum or Plasma;Isoniazid SerPl-sCnc;;ACTIVE;2.00;2.34 +2545-2;Lactate dehydrogenase 4/Lactate dehydrogenase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 4/Lactate dehydrogenase.total in Serum or Plasma by Electrophoresis;LDH4 CFr SerPl Elph;;ACTIVE;1.0;2.73 +25452-4;Itraconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Itraconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Itraconaz Islt MIC;;ACTIVE;2.00;2.73 +25453-2;Lactalbumin alpha Ab.IgA;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin alpha IgA Ab [Units/volume] in Serum;A-Lactalb IgA Qn;;ACTIVE;2.00;2.69 +25454-0;Lactalbumin alpha Ab.IgA.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactalbumin alpha IgA Ab RAST class [Presence] in Serum;A-Lactalb IgA RAST Ql;;ACTIVE;2.00;2.58 +25455-7;Lactoglobulin Ab.IgA;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactoglobulin IgA Ab [Units/volume] in Serum;Lactoglob IgA Qn;;ACTIVE;2.00;2.69 +25456-5;Lactoglobulin Ab.IgA.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactoglobulin IgA Ab RAST class [Presence] in Serum;Lactoglob IgA RAST Ql;;ACTIVE;2.00;2.58 +25457-3;Lactoglobulin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactoglobulin IgE Ab RAST class [Presence] in Serum;Lactoglob IgE RAST Ql;;ACTIVE;2.00;2.58 +25458-1;lamoTRIgine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;lamoTRIgine [Moles/volume] in Serum or Plasma;lamoTRIgine SerPl-sCnc;;ACTIVE;2.00;2.73 +25459-9;Lead;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lead [Moles/volume] in Serum or Plasma;Lead SerPl-sCnc;;ACTIVE;2.00;2.73 +2546-0;Lactate dehydrogenase 4;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase 4 [Enzymatic activity/volume] in Serum or Plasma;LDH4 SerPl-cCnc;;ACTIVE;1.0;2.73 +25460-7;Leucine;SRat;24H;Urine;Qn;;CHEM;1;Leucine [Moles/time] in 24 hour Urine;Leucine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25461-5;Lithium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Lithium [Moles/volume] in Blood;Lithium Bld-sCnc;;ACTIVE;2.00;2.73 +25462-3;Lithium;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Lithium [Moles/volume] in Red Blood Cells;Lithium RBC-sCnc;;ACTIVE;2.00;2.73 +25463-1;Lithium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lithium [Moles/volume] in Urine;Lithium Ur-sCnc;;ACTIVE;2.00;2.73 +25464-9;Lysine;SRat;24H;Urine;Qn;;CHEM;1;Lysine [Moles/time] in 24 hour Urine;Lysine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25465-6;Maleic anhydride Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Maleic anhydride IgE Ab RAST class [Presence] in Serum;Maleic Anhydride IgE RAST Ql;;ACTIVE;2.00;2.58 +25466-4;Manganese;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Manganese [Moles/volume] in Blood;Manganese Bld-sCnc;;ACTIVE;2.00;2.40 +25467-2;Manganese;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Manganese [Moles/volume] in Serum or Plasma;Manganese SerPl-sCnc;;ACTIVE;2.00;2.34 +25468-0;Mephenytoin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mephenytoin [Moles/volume] in Serum or Plasma;Mephenytoin SerPl-sCnc;;ACTIVE;2.00;2.34 +25469-8;Meprobamate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meprobamate [Moles/volume] in Serum or Plasma;Meprobamate SerPl-sCnc;;ACTIVE;2.00;2.34 +25470-6;Mercury;SCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Saliva (oral fluid);Mercury Sal-sCnc;;ACTIVE;2.00;2.42 +25471-4;Mercury;SRat;24H;Urine;Qn;;DRUG/TOX;1;Mercury [Moles/time] in 24 hour Urine;Mercury 24h Ur-sRate;;ACTIVE;2.00;2.40 +25472-2;Mesoridazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mesoridazine [Moles/volume] in Serum or Plasma;Mesoridazine SerPl-sCnc;;ACTIVE;2.00;2.42 +25473-0;Metanephrine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Metanephrine [Moles/volume] in Serum or Plasma;Metaneph SerPl-sCnc;;ACTIVE;2.00;2.73 +25474-8;Metanephrines;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Metanephrines [Moles/volume] in Serum or Plasma;MetanephS SerPl-sCnc;;ACTIVE;2.00;2.73 +25475-5;Methaqualone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methaqualone [Moles/volume] in Serum or Plasma;Methaqualone SerPl-sCnc;;ACTIVE;2.00;2.34 +25476-3;Methionine;SRat;24H;Urine;Qn;;CHEM;1;Methionine [Moles/time] in 24 hour Urine;Methionine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25477-1;Methionine sulfoxide;SRat;24H;Urine;Qn;;CHEM;1;Methionine sulfoxide [Moles/time] in 24 hour Urine;MSO 24h Ur-sRate;;ACTIVE;2.00;2.42 +2547-8;Lactate dehydrogenase 5;CCnc;Pt;Ser/Plas;Qn;Chemical separation;CHEM;1;Lactate dehydrogenase 5 [Enzymatic activity/volume] in Serum or Plasma by Chemical separation;LDH5 SerPl Chem Sepn-cCnc;;ACTIVE;1.0;2.73 +25478-9;Methyprylon;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyprylon [Moles/volume] in Serum or Plasma;Methyprylon SerPl-sCnc;;ACTIVE;2.00;2.34 +25479-7;Saccharopolyspora rectivirgula Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saccharopolyspora rectivirgula IgG Ab [Units/volume] in Serum;S rectivirgula IgG Qn;;ACTIVE;2.00;2.69 +25480-5;Saccharopolyspora rectivirgula Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saccharopolyspora rectivirgula IgG Ab RAST class [Presence] in Serum;S rectivirgula IgG RAST Ql;;ACTIVE;2.00;2.58 +25481-3;Molybdenum;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Molybdenum [Moles/volume] in Serum or Plasma;Molybdenum SerPl-sCnc;;ACTIVE;2.00;2.42 +25484-7;Nefazodone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nefazodone [Moles/volume] in Serum or Plasma;Nefazodone SerPl-sCnc;;ACTIVE;2.00;2.42 +25485-4;Neurospora sitophila Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Neurospora sitophila IgE Ab RAST class [Presence] in Serum;N sitophila IgE RAST Ql;;ACTIVE;2.00;2.58 +2548-6;Lactate dehydrogenase 5/Lactate dehydrogenase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 5/Lactate dehydrogenase.total in Serum or Plasma by Electrophoresis;LDH5 CFr SerPl Elph;;ACTIVE;1.0;2.73 +25486-2;Nickel;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nickel [Moles/volume] in Serum or Plasma;Nickel SerPl-sCnc;;ACTIVE;2.00;2.34 +25487-0;Nickel;SRat;24H;Urine;Qn;;DRUG/TOX;1;Nickel [Moles/time] in 24 hour Urine;Nickel 24h Ur-sRate;;ACTIVE;2.00;2.40 +25488-8;Nicotinamide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nicotinamide [Moles/volume] in Serum or Plasma;Nicotinamide SerPl-sCnc;;ACTIVE;2.00;2.42 +25489-6;Normetanephrine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Normetanephrine [Moles/volume] in Serum or Plasma;Normetanephrine SerPl-sCnc;;ACTIVE;2.00;2.73 +25490-4;Olive green Ab.IgE.RAST class;Threshold;Pt;Ser;Ord;;ALLERGY;1;Deprecated Green Olive IgE Ab RAST class [Presence] in Serum;Deprecated Green Olive IgE RAST Ql;;DEPRECATED;2.00;2.54 +25491-2;Ornithine;SRat;24H;Urine;Qn;;CHEM;1;Ornithine [Moles/time] in 24 hour Urine;Ornithine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25492-0;Oxipurinol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxipurinol [Moles/volume] in Serum or Plasma;Oxipurinol SerPl-sCnc;;ACTIVE;2.00;2.44 +25493-8;Penicillium brevicompactum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillium brevicompactum IgE Ab RAST class [Presence] in Serum;P brevicompactum IgE RAST Ql;;ACTIVE;2.00;2.58 +2549-4;Lactate dehydrogenase 5;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase 5 [Enzymatic activity/volume] in Serum or Plasma;LDH5 SerPl-cCnc;;ACTIVE;1.0;2.73 +25494-6;Pentacarboxylporphyrins;SRat;24H;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins [Moles/time] in 24 hour Urine;Penta-CP 24h Ur-sRate;;ACTIVE;2.00;2.73 +25495-3;Phenylalanine;SRat;24H;Urine;Qn;;CHEM;1;Phenylalanine [Moles/time] in 24 hour Urine;Phe 24h Ur-sRate;;ACTIVE;2.00;2.73 +25496-1;Triplochiton scleroxylon Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Abachi Wood Dust IgE Ab RAST class [Presence] in Serum;Abachi Wood Dust IgE RAST Ql;;ACTIVE;2.00;2.58 +25497-9;Acarus siro Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Acarus siro IgE Ab RAST class in Serum;Deprecated A siro IgE RAST Ql;;DEPRECATED;2.00;2.36 +25498-7;Adenosine monophosphate.cyclic;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adenosine monophosphate.cyclic [Moles/volume] in Serum or Plasma;cAMP SerPl-sCnc;;ACTIVE;2.00;2.73 +25499-5;Adrenal cortex Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Adrenal cortex Ab [Titer] in Serum by Immunofluorescence;Adrenal cortex Ab Titr Ser IF;;ACTIVE;2.00;2.73 +255-0;5-Fluorocytosine;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;5-Fluorocytosine [Susceptibility] by Serum bactericidal titer;5-fluorocytosine Titr SBT;;ACTIVE;1.0;2.32 +25500-0;Phenylbutazone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenylbutazone [Moles/volume] in Serum or Plasma;Phenylbutazone SerPl-sCnc;;ACTIVE;2.00;2.34 +25501-8;Phosphate;SCnc;Pt;Body fld;Qn;;CHEM;1;Phosphate [Moles/volume] in Body fluid;Phosphate Fld-sCnc;;ACTIVE;2.00;2.70 +2550-2;Lactate/Pyruvate;SRto;Pt;Bld;Qn;;CHEM;1;Lactate/Pyruvate [Molar ratio] in Blood;Lactate/Pyruvate Bld-sRto;;ACTIVE;1.0;2.73 +25502-6;Phosphoethanolamine;SCnc;Pt;Urine;Qn;;CHEM;1;Phosphoethanolamine [Moles/volume] in Urine;PETN Ur-sCnc;;ACTIVE;2.00;2.42 +25503-4;Phosphoserine;SRat;24H;Urine;Qn;;CHEM;1;Phosphoserine [Moles/time] in 24 hour Urine;Phosphoserine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25504-2;Pinus radiata Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Monterey Pine IgE Ab RAST class in Serum;Deprecated Monterey Pine IgE RAST Ql;;DEPRECATED;2.00;2.36 +25505-9;Pituitary glycoprotein hormone.alpha subunit;ACnc;Pt;Ser;Qn;;CHEM;1;Pituitary glycoprotein hormone.alpha subunit [Units/volume] in Serum;a-PGH Ser-aCnc;;DISCOURAGED;2.00;2.69 +25506-7;Potassium;SCnt;Pt;Stool;Qn;;CHEM;1;Potassium [Moles/mass] in Stool;Potassium Stl-sCnt;;ACTIVE;2.00;2.73 +25507-5;Pregnenolone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pregnenolone [Moles/volume] in Serum or Plasma;Preg SerPl-sCnc;;ACTIVE;2.00;2.73 +25508-3;Progesterone^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;Progest sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25509-1;Progesterone^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;Progest sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +2551-0;Lactoferrin;MCnc;Pt;Ser;Qn;;CHEM;1;Lactoferrin [Mass/volume] in Serum;Lactoferrin Ser-mCnc;;ACTIVE;1.0;2.73 +25510-9;Proline;SRat;24H;Urine;Qn;;CHEM;1;Proline [Moles/time] in 24 hour Urine;Proline 24h Ur-sRate;;ACTIVE;2.00;2.73 +25511-7;Propafenone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propafenone [Moles/volume] in Serum or Plasma;Propafenone SerPl-sCnc;;ACTIVE;2.00;2.34 +25512-5;Protoporphyrin;SRat;24H;Stool;Qn;;CHEM;1;Protoporphyrin [Moles/time] in 24 hour Stool;Protopor 24h Stl-sRate;;ACTIVE;2.00;2.42 +25513-3;Renin^1st specimen post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --1st specimen post XXX challenge;Renin sp1 p chal Plas-cCnc;;ACTIVE;2.00;2.73 +25514-1;Rubella virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Rubella virus IgG Ab [Presence] in Serum;RUBV IgG Ser Ql;;ACTIVE;2.00;2.73 +25517-4;Crocus sativus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saffron IgE Ab RAST class [Presence] in Serum;Saffron IgE RAST Ql;;ACTIVE;2.00;2.73 +25518-2;Sarcosine;SRat;24H;Urine;Qn;;CHEM;1;Sarcosine [Moles/time] in 24 hour Urine;Sarcosine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25520-8;Secobarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Secobarbital [Moles/volume] in Serum or Plasma;Secobarbital SerPl-sCnc;;ACTIVE;2.00;2.34 +25521-6;Selenium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Selenium [Moles/volume] in Serum or Plasma;Selenium SerPl-sCnc;;ACTIVE;2.00;2.73 +25522-4;Seminal fluid Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Seminal fluid IgE Ab RAST class [Presence] in Serum;Seminal Fld IgE RAST Ql;;ACTIVE;2.00;2.73 +25523-2;Serine;SRat;24H;Urine;Qn;;CHEM;1;Serine [Moles/time] in 24 hour Urine;Serine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25524-0;Serotonin;SCnc;Pt;Bld;Qn;;CHEM;1;Serotonin [Moles/volume] in Blood;Serotonin Bld-sCnc;;ACTIVE;2.00;2.42 +25525-7;Serpula lacrymans Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dry-rot Fungus IgE Ab RAST class [Presence] in Serum;S lacrymans IgE RAST Ql;;ACTIVE;2.00;2.58 +25526-5;Silicon;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Silicon [Moles/volume] in Serum or Plasma;Silicon SerPl-sCnc;;ACTIVE;2.00;2.42 +25527-3;Silver;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Silver [Moles/volume] in Serum or Plasma;Silver SerPl-sCnc;;ACTIVE;2.00;2.34 +2552-8;Lactose;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactose [Mass/volume] in Serum or Plasma;Lactose SerPl-mCnc;;ACTIVE;1.0;2.73 +25528-1;Insulin-like growth factor;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma;IGF SerPl-sCnc;;ACTIVE;2.00;2.73 +25529-9;Somatotropin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Moles/volume] in Serum or Plasma;GH SerPl-sCnc;;DISCOURAGED;2.00;2.73 +25530-7;Specimen weight;MRat;24H;Stool;Qn;;SPEC;1;Weight [Mass/time] of 24 hour Stool;Specimen wt 24h Stl-mRate;;ACTIVE;2.00;2.73 +25531-5;Streptococcus pneumoniae Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Ab [Mass/volume] in Serum;S pneum Ab Ser-mCnc;;ACTIVE;2.00;2.73 +25532-3;Swine serum albumin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Swine serum albumin IgE Ab RAST class [Presence] in Serum;Swine Serum Alb IgE RAST Ql;;ACTIVE;2.00;2.58 +25533-1;Taurine;SRat;24H;Urine;Qn;;CHEM;1;Taurine [Moles/time] in 24 hour Urine;Taurine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25534-9;Teicoplanin^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Teicoplanin [Moles/volume] in Serum or Plasma --peak;Teicoplanin Peak SerPl-sCnc;;ACTIVE;2.00;2.44 +25535-6;Teicoplanin^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Teicoplanin [Moles/volume] in Serum or Plasma --trough;Teicoplanin Trough SerPl-sCnc;;ACTIVE;2.00;2.44 +2553-6;Lactose;PrThr;Pt;Urine;Ord;;CHEM;1;Lactose [Presence] in Urine;Lactose Ur Ql;;ACTIVE;1.0;2.56 +25536-4;Clostridium tetani toxoid Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Clostridium tetani toxoid IgE Ab RAST class [Presence] in Serum;C tetani Toxoid IgE RAST Ql;;ACTIVE;2.00;2.58 +25537-2;Thallium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thallium [Moles/volume] in Serum or Plasma;Thallium SerPl-sCnc;;ACTIVE;2.00;2.40 +25538-0;Thermoactinomyces vulgaris Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Thermoactinomyces vulgaris IgG Ab [Units/volume] in Serum;T vulgaris IgG Ser-aCnc;;ACTIVE;2.00;2.69 +25539-8;Thermoactinomyces vulgaris Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Thermoactinomyces vulgaris IgG Ab RAST class [Presence] in Serum;T vulgaris IgG RAST Ql;;ACTIVE;2.00;2.58 +25540-6;Threonine;SRat;24H;Urine;Qn;;CHEM;1;Threonine [Moles/time] in 24 hour Urine;Threonine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25541-4;Topiramate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Topiramate [Moles/volume] in Serum or Plasma;Topiramate SerPl-sCnc;;ACTIVE;2.00;2.34 +25542-2;Toxoplasma gondii Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Toxoplasma gondii IgM Ab [Presence] in Serum;T gondii IgM Ser Ql;;ACTIVE;2.00;2.73 +25543-0;Triacylglycerol lipase;CRat;24H;Urine;Qn;;CHEM;1;Lipase [Enzymatic activity/time] in 24 hour Urine;Lipase 24h Ur-cRate;;ACTIVE;2.00;2.40 +2554-4;Lactose;MRat;24H;Urine;Qn;;CHEM;1;Lactose [Mass/time] in 24 hour Urine;Lactose 24h Ur-mRate;;ACTIVE;1.0;2.42 +25546-3;Tryptophan;SRat;24H;Urine;Qn;;CHEM;1;Tryptophan [Moles/time] in 24 hour Urine;Tryptophan 24h Ur-sRate;;ACTIVE;2.00;2.73 +25547-1;Tyrosine;SRat;24H;Urine;Qn;;CHEM;1;Tyrosine [Moles/time] in 24 hour Urine;Tyrosine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25548-9;Urate;SCnc;Pt;Body fld;Qn;;CHEM;1;Urate [Moles/volume] in Body fluid;Urate Fld-sCnc;;ACTIVE;2.00;2.73 +25549-7;Urea;SCnc;Pt;Body fld;Qn;;CHEM;1;Urea [Moles/volume] in Body fluid;Urea Fld-sCnc;;ACTIVE;2.00;2.70 +25550-5;Urea;SRat;24H;Urine;Qn;;CHEM;1;Urea [Moles/time] in 24 hour Urine;Urea 24h Ur-sRate;;ACTIVE;2.00;2.73 +2555-1;Lecithin cholesterol acyltransferase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lecithin cholesterol acyltransferase [Enzymatic activity/volume] in Serum or Plasma;LCAT SerPl-cCnc;;ACTIVE;1.0;2.68 +25551-3;Urobilinogen;PrThr;Pt;Body fld;Ord;;CHEM;1;Urobilinogen [Presence] in Body fluid;Urobilinogen Fld Ql;;ACTIVE;2.00;2.56 +25552-1;Uroporphyrin;SRat;24H;Stool;Qn;;CHEM;1;Uroporphyrin [Moles/time] in 24 hour Stool;Uropor 24h Stl-sRate;;ACTIVE;2.00;2.42 +25553-9;Valine;SRat;24H;Urine;Qn;;CHEM;1;Valine [Moles/time] in 24 hour Urine;Valine 24h Ur-sRate;;ACTIVE;2.00;2.73 +25554-7;Tenebrio mollitor Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mealworm IgE Ab RAST class [Presence] in Serum;Mealworm IgE RAST Ql;;ACTIVE;2.00;2.58 +25555-4;Wuchereria bancrofti Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Wuchereria bancrofti Ag [Presence] in Serum;W bancr Ag Ser Ql;;ACTIVE;2.00;2.56 +25556-2;Xylose;SCnc;Pt;Urine;Qn;;CHEM;1;Xylose [Moles/volume] in Urine;Xylose Ur-sCnc;;ACTIVE;2.00;2.34 +25557-0;Zinc;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Zinc [Moles/volume] in Red Blood Cells;Zinc RBC-sCnc;;ACTIVE;2.00;2.73 +25558-8;Zinc;SCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Zinc [Molecules/volume] in Serum or Plasma;Deprecated Zinc Ser-sCnc;;DEPRECATED;2.00;2.36 +25559-6;Zolpidem;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zolpidem [Moles/volume] in Serum or Plasma;Zolpidem SerPl-sCnc;;ACTIVE;2.00;2.42 +25560-4;Allobarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Allobarbital [Moles/volume] in Serum or Plasma;Allobarbital SerPl-sCnc;;ACTIVE;2.00;2.44 +25561-2;11-Deoxycorticosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Deoxycorticosterone [Moles/volume] in Serum or Plasma;11DOC SerPl-sCnc;;ACTIVE;2.00;2.40 +25562-0;Angiotensin II^supine;SCnc;Pt;Plas;Qn;;CHAL;1;Angiotensin II [Moles/volume] in Plasma --supine;Angiotensin II sup Plas-sCnc;;ACTIVE;2.00;2.68 +25563-8;Angiotensin II^upright;SCnc;Pt;Plas;Qn;;CHEM;1;Angiotensin II [Moles/volume] in Plasma --upright;Angiotensin II upr Plas-sCnc;;ACTIVE;2.00;2.42 +25564-6;Bilirubin.glucuronidated+Bilirubin.albumin bound;SCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.direct [Moles/volume] in Body fluid;Bilirub Direct Fld-sCnc;;ACTIVE;2.00;2.70 +25565-3;Bougainvillea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bougainvillea IgE Ab [Units/volume] in Serum;Bougainvillea IgE Qn;;ACTIVE;2.00;2.42 +25566-1;Bougainvillea Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bougainvillea IgE Ab RAST class [Presence] in Serum;Bougainvillea IgE RAST Ql;;ACTIVE;2.00;2.58 +25567-9;Budgerigar serum proteins Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Budgerigar serum proteins IgE Ab RAST class in Serum;Deprecated Budgie Serum Prot IgE RAST Ql;;DEPRECATED;2.00;2.36 +25568-7;C peptide^10th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge;C peptide sp10 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +2556-9;Lecithin phosphorus;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Lecithin phosphorus [Mass/volume] in Amniotic fluid;Lecithin Phosphorus Amn-mCnc;;ACTIVE;1.0;2.34 +25569-5;C peptide^11th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --11th specimen post XXX challenge;C peptide sp11 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25570-3;C peptide^12th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --12th specimen post XXX challenge;C peptide sp12 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25571-1;C peptide^13th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --13th specimen post XXX challenge;C peptide sp13 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25572-9;C peptide^14th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --14th specimen post XXX challenge;C peptide sp14 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25573-7;C peptide^15th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --15th specimen post XXX challenge;C peptide sp15 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25574-5;C peptide^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;C peptide sp1 p chal SerPl-sCnc;;ACTIVE;2.00;2.73 +25575-2;C peptide^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;C peptide sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25576-0;C peptide^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;C peptide sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +2557-7;Lecithin/Sphingomyelin;MRto;Pt;Amnio fld;Qn;;CHEM;1;Lecithin/Sphingomyelin [Mass Ratio] in Amniotic fluid;Lecithin/Sphingomyelin Amn;;ACTIVE;1.0;2.73 +25577-8;C peptide^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;C peptide sp4 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25578-6;C peptide^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;C peptide sp5 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25579-4;C peptide^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;C peptide sp6 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25580-2;C peptide^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;C peptide sp7 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25581-0;C peptide^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;C peptide sp8 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25582-8;C peptide^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;C peptide sp9 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25583-6;Calcium;SCnc;Pt;RBC;Qn;;CHEM;1;Calcium [Moles/volume] in Red Blood Cells;Calcium RBC-sCnc;;ACTIVE;2.00;2.70 +25584-4;Calcium^5H post 500 mg calcium PO;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --5 hours post 500 mg calcium PO;Calcium 5h p 500 mg Ca PO Ur-sCnc;;ACTIVE;2.00;2.70 +2558-5;Leucine;MCnc;Pt;Bld;Ord;;CHEM;1;Deprecated Leucine;Deprecated Leucine Bld Ql;;DEPRECATED;1.0;2.36 +25585-1;Cat serum albumin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cat serum albumin IgE Ab RAST class [Presence] in Serum;Cat Serum Alb IgE RAST Ql;;ACTIVE;2.00;2.58 +25586-9;Chicken droppings Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken droppings IgE Ab RAST class [Presence] in Serum;Chicken Drop IgE RAST Ql;;ACTIVE;2.00;2.73 +25587-7;Chromogranin A;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chromogranin A [Moles/volume] in Serum or Plasma;CgA SerPl-sCnc;;ACTIVE;2.00;2.73 +25589-3;Citalopram;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Citalopram [Moles/volume] in Serum or Plasma;Citalopram SerPl-sCnc;;ACTIVE;2.00;2.73 +2559-3;Leucine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Leucine [Presence] in Serum or Plasma;Leucine SerPl Ql;;ACTIVE;1.0;2.73 +25593-5;Rotavirus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Rotavirus IgG Ab [Presence] in Serum;RV IgG Ser Ql;;ACTIVE;2.00;2.56 +25594-3;Schistosoma sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Schistosoma sp IgG Ab [Units/volume] in Serum;Deprecated Schistosoma IgG Ser-aCnc;;DEPRECATED;2.00;2.69 +25595-0;Econazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Econazole [Susceptibility];Econazole Susc Islt;;ACTIVE;2.00;2.19 +25596-8;Fosfomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Fosfomycin [Susceptibility];Fosfomycin Susc Islt;;ACTIVE;2.00;2.73 +25597-6;Josamycine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Josamycine [Susceptibility];Josamycine Susc Islt;;ACTIVE;2.00;2.19 +25598-4;Cladosporium cladosporioides Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium cladosporioides IgG Ab [Units/volume] in Serum;C cladosporioides IgG Qn;;ACTIVE;2.00;2.69 +25599-2;Rotavirus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rotavirus IgG Ab [Units/volume] in Serum;RV IgG Ser-aCnc;;ACTIVE;2.00;2.69 +25600-8;Rotavirus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rotavirus IgM Ab [Units/volume] in Serum;RV IgM Ser-aCnc;;ACTIVE;2.00;2.69 +2560-1;Leucine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Leucine [Mass/volume] in Serum or Plasma;Leucine SerPl-mCnc;;ACTIVE;1.0;2.73 +25601-6;Rotavirus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Rotavirus IgM Ab [Presence] in Serum;RV IgM Ser Ql;;ACTIVE;2.00;2.56 +25603-2;Rickettsia prowazekii Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia prowazekii IgG Ab [Titer] in Serum;R prowazek IgG Titr Ser;;ACTIVE;2.00;2.70 +25604-0;Rickettsia prowazekii Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia prowazekii IgM Ab [Titer] in Serum;R prowazek IgM Titr Ser;;ACTIVE;2.00;2.70 +25607-3;Miconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Miconazole [Susceptibility];Miconazole Susc Islt;;ACTIVE;2.00;2.19 +25608-1;Nitroxoline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nitroxoline [Susceptibility];Nitroxoline Susc Islt;;ACTIVE;2.00;2.19 +25609-9;Cochineal extract Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cochineal extract IgE Ab [Units/volume] in Serum;Chocineal IgE Qn;;ACTIVE;2.00;2.73 +25610-7;Cochineal extract Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cochineal extract IgE Ab RAST class [Presence] in Serum;Chocineal IgE RAST Ql;;ACTIVE;2.00;2.73 +25611-5;Blatta orientalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oriental Cockroach IgE Ab [Units/volume] in Serum;Oriental Roach IgE Qn;;ACTIVE;2.00;2.42 +25612-3;Blatta orientalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oriental Cockroach IgE Ab RAST class [Presence] in Serum;Oriental Roach IgE RAST Ql;;ACTIVE;2.00;2.58 +25613-1;Periplaneta fuliginosa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Smoky Brown Cockroach IgE Ab [Units/volume] in Serum;Smky Brwn Roach IgE Qn;;ACTIVE;2.00;2.42 +25614-9;Periplaneta fuliginosa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Smoky Brown Cockroach IgE Ab RAST class [Presence] in Serum;Smky Brwn Roach IgE RAST Ql;;ACTIVE;2.00;2.58 +25615-6;Conalbumin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Conalbumin IgE Ab [Units/volume] in Serum;Conalb IgE Qn;;ACTIVE;2.00;2.42 +25616-4;Conalbumin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Conalbumin IgE Ab RAST class [Presence] in Serum;Conalb IgE RAST Ql;;ACTIVE;2.00;2.58 +25617-2;Cortisol^1H post 250 ug cortrosyn IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Cortisol [Molecules/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM;Deprecated Cortis SerPl-sCnc;;DEPRECATED;2.00;2.36 +25618-0;Cortisol^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;Cortis sp1 p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +2561-9;Leucine;MCnc;Pt;Urine;Qn;;CHEM;1;Leucine [Mass/volume] in Urine;Leucine Ur-mCnc;;ACTIVE;1.0;2.73 +25619-8;Cortisol^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;Cortis sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +25620-6;Cortisol^30M post 250 ug cortrosyn IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Cortisol [Molecules/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;Deprecated Cortis SerPl-sCnc;;DEPRECATED;2.00;2.36 +25621-4;Cortisol^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;Cortis sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +25622-2;Cortisol^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;Cortis sp4 p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +25623-0;Cortisol^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;Cortis sp5 p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +25624-8;Cortisol^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;Cortis sp6 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25625-5;Cortisol^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;Cortis sp7 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25626-3;Cortisol^8H post 2 mg dexamethasone PO 2.5 day high dose q6h;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --8 hours post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis 8h p 2 mg Dex SerPl-sCnc;;ACTIVE;2.00;2.40 +2562-7;Leucine;MRat;24H;Urine;Qn;;CHEM;1;Leucine [Mass/time] in 24 hour Urine;Leucine 24h Ur-mRate;;ACTIVE;1.0;2.73 +25627-1;Cortisol^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;Cortis sp8 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25628-9;Cortisol^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;Cortis sp9 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25629-7;Cortisol^pre 250 ug cortrosyn IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Cortisol [Molecules/volume] in Serum or Plasma --pre 250 ug corticotropin IM;Deprecated Cortis SerPl-sCnc;;DEPRECATED;2.00;2.36 +25630-5;Parvovirus B19 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Titer] in Serum;B19V IgG Titr Ser;;ACTIVE;2.00;2.73 +25631-3;Parvovirus B19 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Titer] in Serum;B19V IgM Titr Ser;;ACTIVE;2.00;2.73 +25632-1;Plasmodium sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium sp Ab [Titer] in Serum;Plasmodium Ab Titr Ser;;ACTIVE;2.00;2.70 +25633-9;Leishmania donovani Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania donovani Ab [Titer] in Serum;L donovani Ab Titr Ser;;ACTIVE;2.00;2.70 +25634-7;Ribes sylvestre Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red Currant IgE Ab RAST class [Presence] in Serum;Red Currant IgE RAST Ql;;ACTIVE;2.00;2.58 +2563-5;Leukocyte esterase;CCnc;Pt;WBC;Qn;;CHEM;1;Leukocyte esterase [Enzymatic activity/volume] in Leukocytes;Leukocyte esterase WBC-cCnc;;ACTIVE;1.0;2.73 +25637-0;Econazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Econazole [Susceptibility] by Minimum inhibitory concentration (MIC);Econazole Islt MIC;;ACTIVE;2.00;2.19 +25638-8;Eosinophil cationic protein;MCnc;Pt;Ser;Qn;;ALLERGY;1;Eosinophil cationic protein (ECP) [Mass/volume] in Serum;ECP-mCnc;;ACTIVE;2.00;2.73 +25639-6;Follitropin;ACnc;Pt;Urine;Qn;2nd IRP;CHEM;1;Follitropin [Units/volume] in Urine by 2nd IRP;FSH Ur IRP2-aCnc;;ACTIVE;2.00;2.68 +25640-4;Follitropin^1.5H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1.5 hours post 100 ug luteinizing releasing hormone IV;FSH 1.5h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +25641-2;Follitropin^1H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1 hour post 100 ug luteinizing releasing hormone IV;FSH 1h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +25642-0;Follitropin^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --1st specimen post XXX challenge;FSH sp1 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +2564-3;Linoleate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Linoleate (C18:2w6) [Mass/volume] in Serum or Plasma;Linoleate SerPl-mCnc;;DISCOURAGED;1.0;2.44 +25643-8;Follitropin^2H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --2 hours post 100 ug luteinizing releasing hormone IV;FSH 2h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +25644-6;Follitropin^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --2nd specimen post XXX challenge;FSH sp2 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +25645-3;Follitropin^30M post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --30 minutes post 100 ug luteinizing releasing hormone IV;FSH 30M p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +25646-1;Follitropin^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --3rd specimen post XXX challenge;FSH sp3 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +25647-9;Follitropin^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --4th specimen post XXX challenge;FSH sp4 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +25648-7;Follitropin^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --5th specimen post XXX challenge;FSH sp5 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +25649-5;Follitropin^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --6th specimen post XXX challenge;FSH sp6 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +2565-0;Cholesterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Cholesterol [Mass/volume] in Serum or Plasma;Deprecated Cholest SerPl-mCnc;;DEPRECATED;1.0;2.36 +25650-3;Follitropin^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --7th specimen post XXX challenge;FSH sp7 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +25651-1;Follitropin^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --8th specimen post XXX challenge;FSH sp8 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +25652-9;Follitropin^9th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;2nd IRP;CHAL;1;Follitropin [Units/volume] in Serum or Plasma by 2nd IRP --9th specimen post XXX challenge;FSH sp9 p chal SerPl IRP2-aCnc;;ACTIVE;2.00;2.38 +25653-7;Fosfomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Fosfomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Fosfomycin Islt MIC;;ACTIVE;2.00;2.73 +25654-5;Gastrin^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;Gastrin sp1 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25655-2;Gastrin^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;Gastrin sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25656-0;Gastrin^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;Gastrin sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25657-8;Gastrin^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;Gastrin sp4 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25658-6;Gastrin^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;Gastrin sp5 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25659-4;Gastrin^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;Gastrin sp6 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25660-2;Gastrin^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;Gastrin sp7 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25661-0;Gastrin^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;Gastrin sp8 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25662-8;Gastrin^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;Gastrin sp9 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25663-6;Glucose^15M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose glucose;Glucose 15M p Glc SerPl-sCnc;;ACTIVE;2.00;2.34 +25664-4;Glucose^1H post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1 hour post dose glucose;Glucose 1h p Glc Ur-mCnc;;ACTIVE;2.00;2.73 +25665-1;Glucose^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Glucose 1h p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25666-9;Glucose^2.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose glucose;Glucose 2.5h p Glc SerPl-sCnc;;ACTIVE;2.00;2.34 +25667-7;Glucose^2H post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --2 hours post dose glucose;Glucose 2h p Glc Ur-mCnc;;ACTIVE;2.00;2.73 +2566-8;Fatty acids.nonesterified;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Fatty acids.nonesterified [Mass/volume] in Serum or Plasma;Deprecated NEFA SerPl-mCnc;;DEPRECATED;1.0;2.36 +25668-5;Glucose^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Glucose 2h p chal SerPl-sCnc;;ACTIVE;2.00;2.73 +25669-3;Glucose^3.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3.5 hours post dose glucose;Glucose 3.5h p Glc SerPl-sCnc;;ACTIVE;2.00;2.34 +25670-1;Glucose^30M post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --30 minutes post dose glucose;Glucose 30M p Glc Ur-mCnc;;ACTIVE;2.00;2.73 +25671-9;Glucose^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Glucose 30M p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +25672-7;Glucose^4.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4.5 hours post dose glucose;Glucose 4.5h p Glc SerPl-sCnc;;ACTIVE;2.00;2.34 +25673-5;Glucose^45M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose glucose;Glucose 45M p Glc SerPl-sCnc;;ACTIVE;2.00;2.34 +25674-3;Glucose^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;Glucose 45M p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25675-0;Glucose^4H post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --4 hours post dose glucose;Glucose 4h p Glc Ur-mCnc;;ACTIVE;2.00;2.73 +2567-6;Phospholipid phosphorus;MCnc;Pt;Ser;Qn;;CHEM;1;Phospholipid phosphorus [Mass/volume] in Serum;Phospholipid P Ser-mCnc;;ACTIVE;1.0;2.73 +25676-8;Glucose^5.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5.5 hours post dose glucose;Glucose 5.5h p Glc SerPl-sCnc;;ACTIVE;2.00;2.34 +25677-6;Glucose^6H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --6 hours post dose glucose;Glucose 6h p Glc SerPl-sCnc;;ACTIVE;2.00;2.34 +25678-4;Glucose^1.5H post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1.5 hours post dose glucose;Glucose 1.5h p Glc Ur-mCnc;;ACTIVE;2.00;2.34 +25679-2;Glucose^1.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge;Glucose 1.5h p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +256-8;Foscarnet;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Foscarnet [Susceptibility];Foscarnet Susc Islt;;ACTIVE;1.0;2.73 +25680-0;Glucose^pre 50 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre 50 g glucose PO;Glucose pre 50 g Glc PO SerPl-sCnc;;ACTIVE;2.00;2.34 +25681-8;Immunoglobulin light chains.kappa;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;Kappa light chains [Presence] in Serum by Immunoelectrophoresis;Kappa LC Ser Ql IEP;;ACTIVE;2.00;2.73 +25682-6;Immunoglobulin light chains.kappa;MRat;24H;Urine;Qn;;CHEM;1;Kappa light chains [Mass/time] in 24 hour Urine;Kappa LC 24h Ur-mRate;;ACTIVE;2.00;2.73 +25683-4;Immunoglobulin light chains.lambda;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;Lambda light chains [Presence] in Serum by Immunoelectrophoresis;Lambda LC Ser Ql IEP;;ACTIVE;2.00;2.73 +2568-4;Phospholipid;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phospholipid [Mass/volume] in Serum or Plasma;Phospholipid SerPl-mCnc;;ACTIVE;1.0;2.73 +25684-2;Immunoglobulin light chains.lambda;MRat;24H;Urine;Qn;;CHEM;1;Lambda light chains [Mass/time] in 24 hour Urine;Lambda LC 24h Ur-mRate;;ACTIVE;2.00;2.73 +25685-9;Insulin^10th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge;Insulin sp10 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25686-7;Insulin^11th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --11th specimen post XXX challenge;Insulin sp11 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25687-5;Insulin^12th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --12th specimen post XXX challenge;Insulin sp12 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25688-3;Insulin^13th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --13th specimen post XXX challenge;Insulin sp13 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25689-1;Insulin^14th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --14th specimen post XXX challenge;Insulin sp14 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25690-9;Insulin^15th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --15th specimen post XXX challenge;Insulin sp15 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25691-7;Insulin^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;Insulin sp1 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +2569-2;Lipids;MCnc;Pt;Ser;Qn;;CHEM;1;Lipids [Mass/volume] in Serum;Lipids Ser-mCnc;;ACTIVE;1.0;2.73 +25692-5;Insulin^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;Insulin sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25693-3;Insulin^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;Insulin sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25694-1;Insulin^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;Insulin sp4 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25695-8;Insulin^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;Insulin sp5 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25696-6;Insulin^7.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --7.5 hours post XXX challenge;Insulin 7.5h p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25697-4;Insulin^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;Insulin sp7 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25698-2;Insulin^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;Insulin sp8 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25699-0;Insulin^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;Insulin sp9 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25-7;Amphotericin B;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Amphotericin B [Susceptibility] by Disk diffusion (KB);Amphotericin B Islt KB;;ACTIVE;1.0;2.21 +2570-0;Fat;MCnc;Pt;Stool;Qn;;CHEM;1;Fat [Mass/volume] in Stool;Fat Stl-mCnc;;ACTIVE;1.0;2.73 +25700-6;Interpretation;Imp;Pt;Ser/Plas;Nom;Immunofixation;CHEM;1;Immunofixation for Serum or Plasma;Interpretation SerPl IFE-Imp;;ACTIVE;2.00;2.73 +25701-4;Artocarpus heterophyllus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Jackfruit IgE Ab RAST class [Presence] in Serum;Jackfruit IgE RAST Ql;;ACTIVE;2.00;2.73 +25702-2;Josamycine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Josamycine [Susceptibility] by Minimum inhibitory concentration (MIC);Josamycine Islt MIC;;ACTIVE;2.00;2.19 +25703-0;Ziziphus jujuba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Jujube IgE Ab [Units/volume] in Serum;Jujube IgE Qn;;ACTIVE;2.00;2.73 +25704-8;Ziziphus jujuba Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Jujube IgE Ab RAST class [Presence] in Serum;Jujube IgE RAST Ql;;ACTIVE;2.00;2.58 +25705-5;Ketones^1H post 50 g glucose PO;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --1 hour post 50 g glucose PO;Ketones 1h p 50 g Glc PO Ur Ql;;ACTIVE;2.00;2.56 +25706-3;Ketones^2H post dose glucose;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Ketones [Mass/volume] in Urine by Test strip --2 hours post dose glucose;Ketones 2h p Glc Ur Strip-mCnc;;ACTIVE;2.00;2.34 +25707-1;Ketones^4H post dose glucose;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Ketones [Mass/volume] in Urine by Test strip --4 hours post dose glucose;Ketones 4h p Glc Ur Strip-mCnc;;ACTIVE;2.00;2.34 +25708-9;Leishmania donovani Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania donovani Ab [Titer] in Serum by Immunofluorescence;L donovani Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25709-7;Leptospira interrogans serovar Canicola Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Leptospira interrogans sv Canicola Ab [Titer] in Serum by Complement fixation;L inter Canic Ab Titr Ser CF;;ACTIVE;2.00;2.70 +25710-5;Leptospira interrogans serovar Grippotyphosa Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Leptospira interrogans sv Grippotyphosa Ab [Titer] in Serum by Complement fixation;L inter Grip Ab Titr Ser CF;;ACTIVE;2.00;2.70 +25711-3;Leptospira interrogans serovar Icterohaemorrhagiae Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Leptospira interrogans sv Icterohaemorrhagiae Ab [Titer] in Serum by Complement fixation;L inter Icter Ab Titr Ser CF;;ACTIVE;2.00;2.70 +25712-1;Leptospira interrogans serovar Pomona Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Leptospira interrogans sv Pomona Ab [Titer] in Serum by Complement fixation;L inter Pomon Ab Titr Ser CF;;ACTIVE;2.00;2.70 +25713-9;Linum usitatissimum Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Flax IgE Ab RAST class in Serum;Deprecated Flax IgE RAST Ql;;DEPRECATED;2.00;2.36 +25714-7;Litchi chinensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Litchi IgE Ab [Units/volume] in Serum;Litchi IgE Qn;;ACTIVE;2.00;2.42 +25715-4;Litchi chinensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Litchi IgE Ab RAST class [Presence] in Serum;Litchi IgE RAST Ql;;ACTIVE;2.00;2.58 +25716-2;Lutropin;ACnc;Pt;Urine;Qn;1st IRP;CHEM;1;Lutropin [Units/volume] in Urine by 1st IRP;LH Ur IRP1-aCnc;;ACTIVE;2.00;2.44 +25717-0;Lutropin^1.5H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1.5 hours post 100 ug luteinizing releasing hormone IV;LH 1.5h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +2571-8;Triglyceride;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride [Mass/volume] in Serum or Plasma;Trigl SerPl-mCnc;;ACTIVE;1.0;2.73 +25718-8;Lutropin^1H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1 hour post 100 ug luteinizing releasing hormone IV;LH 1h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +25719-6;Lutropin^2H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --2 hours post 100 ug luteinizing releasing hormone IV;LH 2h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +25720-4;Lutropin^30M post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --30 minutes post 100 ug luteinizing releasing hormone IV;LH 30M p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.00;2.69 +25721-2;Mianserin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mianserin [Moles/volume] in Serum or Plasma;Mianserin SerPl-sCnc;;ACTIVE;2.00;2.42 +25722-0;Miconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Miconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Miconazole Islt MIC;;ACTIVE;2.00;2.19 +25723-8;Nitroxoline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Nitroxoline [Susceptibility] by Minimum inhibitory concentration (MIC);Nitroxoline Islt MIC;;ACTIVE;2.00;2.19 +25724-6;Norsertraline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Norsertraline [Mass/volume] in Serum or Plasma;Deprecated Norsertraline SerPl-mCnc;;DEPRECATED;2.00;2.36 +25725-3;Ovary Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Ovary Ab [Titer] in Serum by Immunofluorescence;Ovary Ab Titr Ser IF;;ACTIVE;2.00;2.73 +2572-6;Lipoprotein lipase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein lipase [Enzymatic activity/volume] in Serum or Plasma;LPL SerPl-cCnc;;ACTIVE;1.0;2.73 +25726-1;OXcarbazepine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OXcarbazepine [Moles/volume] in Serum or Plasma;OXcarbazepine SerPl-sCnc;;ACTIVE;2.00;2.73 +25728-7;Parkinsonia florida Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Palo verde IgE Ab RAST class [Presence] in Serum;Palo verde IgE RAST Ql;;ACTIVE;2.00;2.58 +25729-5;Parvovirus B19 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Parvovirus B19 IgG Ab [Titer] in Serum by Immunofluorescence;B19V IgG Titr Ser IF;;ACTIVE;2.00;2.70 +25730-3;Parvovirus B19 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Parvovirus B19 IgM Ab [Titer] in Serum by Immunofluorescence;B19V IgM Titr Ser IF;;ACTIVE;2.00;2.70 +25731-1;Plasmodium sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium sp Ab [Titer] in Serum by Immunofluorescence;Plasmodium Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25732-9;Pregnanetriolone;SRat;24H;Urine;Qn;;CHEM;1;Pregnanetriolone [Moles/time] in 24 hour Urine;Pregntrlone 24h Ur-sRate;;ACTIVE;2.00;2.58 +25733-7;Procollagen type III;ACnc;Pt;Ser;Qn;;CHEM;1;Procollagen type III [Units/volume] in Serum;Procollagen III Ser-aCnc;;ACTIVE;2.00;2.68 +2573-4;Lipoprotein.alpha;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.alpha [Mass/volume] in Serum or Plasma;HDL SerPl-mCnc;;ACTIVE;1.0;2.73 +25734-5;Prolactin^10M post 200 ug TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --10 minutes post 200 ug TRH IV;Prolactin 10M p 200 ug TRH IV SerPl-mCnc;;ACTIVE;2.00;2.70 +25735-2;Prolactin^1H post 200 ug TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1 hour post 200 ug TRH IV;Prolactin 1h p 200 ug TRH IV SerPl-mCnc;;ACTIVE;2.00;2.70 +25736-0;Prolactin^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Prolactin sp1 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +25737-8;Prolactin^20M post 200 ug TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --20 minutes post 200 ug TRH IV;Prolactin 20M p 200 ug TRH IV SerPl-mCnc;;ACTIVE;2.00;2.70 +25738-6;Prolactin^2H post 200 ug TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --2 hours post 200 ug TRH IV;Prolactin 2h p 200 ug TRH IV SerPl-mCnc;;ACTIVE;2.00;2.70 +25739-4;Prolactin^30M post 200 ug TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --30 minutes post 200 ug TRH IV;Prolactin 30M p 200 ug TRH IV SerPl-mCnc;;ACTIVE;2.00;2.70 +25740-2;Prolactin^40M post 200 ug TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --40 minutes post 200 ug TRH IV;Prolactin 40M p 200 ug TRH IV SerPl-mCnc;;ACTIVE;2.00;2.70 +25741-0;Prolactin^50M post 200 ug TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --50 minutes post 200 ug TRH IV;Prolactin 50M p 200 ug TRH IV SerPl-mCnc;;ACTIVE;2.00;2.70 +2574-2;Lipoprotein.beta;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.beta [Mass/volume] in Serum or Plasma;LDL SerPl-mCnc;;ACTIVE;1.0;2.73 +25742-8;Prothrombin fragment 1+2;SCnc;Pt;Ser/Plas;Qn;;COAG;1;Prothrombin Fragment 1.2 [Moles/volume] in Serum or Plasma;Pro Frg1+2 SerPl-sCnc;;ACTIVE;2.00;2.73 +25743-6;Chenopodium quinoa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Quinoa IgE Ab [Units/volume] in Serum;Quinoa IgE Qn;;ACTIVE;2.00;2.73 +25744-4;Chenopodium quinoa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Quinoa IgE Ab RAST class [Presence] in Serum;Quinoa IgE RAST Ql;;ACTIVE;2.00;2.73 +25745-1;Rheumatoid factor;PrThr;Pt;Body fld;Ord;Sheep cell aggl;SERO;1;Rheumatoid factor [Presence] in Body fluid by Sheep Cell Agglutination;Rheumatoid fact Fld Ql Shp Aggl;;ACTIVE;2.00;2.56 +25746-9;Rheumatoid factor;Titr;Pt;Body fld;Qn;Sheep cell aggl;SERO;1;Rheumatoid factor [Titer] in Body fluid by Sheep Cell Agglutination;Rheumatoid fact Titr Fld Shp Aggl;;ACTIVE;2.00;2.70 +25747-7;Ribosomal Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Ribosomal Ab [Presence] in Serum by Immunoassay;Ribosomal Ab Ser Ql IA;;ACTIVE;2.00;2.56 +25748-5;Ribosomal Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Ribosomal Ab [Titer] in Serum by Immunofluorescence;Ribosomal Ab Titr Ser IF;;ACTIVE;2.00;2.73 +25749-3;Rickettsia conorii Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia conorii IgG Ab [Titer] in Serum by Immunofluorescence;R conorii IgG Titr Ser IF;;ACTIVE;2.00;2.70 +25750-1;Rickettsia conorii Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia conorii IgM Ab [Titer] in Serum by Immunofluorescence;R conorii IgM Titr Ser IF;;ACTIVE;2.00;2.70 +25751-9;Rickettsia prowazekii Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia prowazekii IgG Ab [Titer] in Serum by Immunofluorescence;R prowazek IgG Titr Ser IF;;ACTIVE;2.00;2.70 +25752-7;Rickettsia prowazekii Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia prowazekii IgM Ab [Titer] in Serum by Immunofluorescence;R prowazek IgM Titr Ser IF;;ACTIVE;2.00;2.70 +25753-5;Rotavirus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rotavirus IgG Ab [Presence] in Serum by Immunoassay;RV IgG Ser Ql IA;;ACTIVE;2.00;2.56 +25754-3;Rotavirus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rotavirus IgG Ab [Units/volume] in Serum by Immunoassay;RV IgG Ser IA-aCnc;;ACTIVE;2.00;2.69 +25755-0;Rotavirus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rotavirus IgM Ab [Presence] in Serum by Immunoassay;RV IgM Ser Ql IA;;ACTIVE;2.00;2.56 +25756-8;Rotavirus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rotavirus IgM Ab [Units/volume] in Serum by Immunoassay;RV IgM Ser IA-aCnc;;ACTIVE;2.00;2.69 +25757-6;Schistosoma sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Schistosoma sp IgG Ab [Units/volume] in Serum by Immunoassay;Schistosoma IgG Ser IA-aCnc;;ACTIVE;2.00;2.73 +25758-4;Insulin-like growth factor^10th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge;IGF sp10 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +2575-9;Lipoprotein.pre-beta;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.pre-beta [Mass/volume] in Serum or Plasma;VLDL SerPl-mCnc;;ACTIVE;1.0;2.73 +25759-2;Insulin-like growth factor^11th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --11th specimen post XXX challenge;IGF sp11 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +257-6;Framycetin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Framycetin [Susceptibility] by Minimum lethal concentration (MLC);Framycetin Islt MLC;;ACTIVE;1.0;2.19 +25760-0;Insulin-like growth factor^12th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --12th specimen post XXX challenge;IGF sp12 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25761-8;Insulin-like growth factor^13th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --13th specimen post XXX challenge;IGF sp13 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25762-6;Insulin-like growth factor^14th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --14th specimen post XXX challenge;IGF sp14 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25763-4;Insulin-like growth factor^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;IGF sp1 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25764-2;Insulin-like growth factor^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;IGF sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25765-9;Insulin-like growth factor^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;IGF sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25766-7;Insulin-like growth factor^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;IGF sp4 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +2576-7;Lipoprotein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoproteins [Mass/volume] in Serum or Plasma;LP SerPl-mCnc;;ACTIVE;1.0;2.73 +25767-5;Insulin-like growth factor^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;IGF sp5 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25768-3;Insulin-like growth factor^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;IGF sp6 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25769-1;Insulin-like growth factor^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;IGF sp7 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25770-9;Insulin-like growth factor^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;IGF sp8 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25771-7;Insulin-like growth factor^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;IGF sp9 p chal SerPl-sCnc;;ACTIVE;2.00;2.40 +25772-5;Somatotropin^11th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --11th specimen post XXX challenge;GH sp11 p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +25773-3;Somatotropin^12th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --12th specimen post XXX challenge;GH sp12 p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +25774-1;Somatotropin^13th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --13th specimen post XXX challenge;GH sp13 p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +2577-5;Lithocholate;MCnc;Pt;Ser;Qn;;CHEM;1;Lithocholate [Mass/volume] in Serum;Lithocholate Ser-mCnc;;DISCOURAGED;1.0;2.44 +25775-8;Somatotropin^14th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --14th specimen post XXX challenge;GH sp14 p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +25776-6;Somatotropin^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;GH sp1 p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +25777-4;Somatotropin^40M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --40 minutes post XXX challenge;GH 40M p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +25778-2;Somatotropin^50M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --50 minutes post XXX challenge;GH 50M p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +25779-0;Stachybotrys chartarum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Stachybotrys chartarum IgG Ab [Units/volume] in Serum;S chartarum IgG Qn;;ACTIVE;2.00;2.73 +25780-8;Stachybotrys chartarum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Stachybotrys chartarum IgG Ab RAST class [Presence] in Serum;S chartarum IgG RAST Ql;;ACTIVE;2.00;2.58 +2578-3;Lutropin;SCnc;Pt;Semen;Qn;;CHEM;1;Lutropin [Moles/volume] in Semen;LH Smn-sCnc;;DISCOURAGED;1.0;2.34 +25788-1;Streptolysin O Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Streptolysin O Ab [Units/volume] in Serum by Latex agglutination;ASO Ab Ser LA-aCnc;;ACTIVE;2.00;2.73 +25789-9;Thyrotropin^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1st specimen post XXX challenge;TSH sp1 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +25790-7;Thyroxine.free^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;T4 Free sp1 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +2579-1;Lutropin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin [Moles/volume] in Serum or Plasma;LH SerPl-sCnc;;DISCOURAGED;1.0;2.73 +25791-5;Thyroxine.free^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;T4 Free sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25792-3;Thyroxine.free^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;T4 Free sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25793-1;Thyroxine.free^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;T4 Free sp4 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25794-9;Thyroxine.free^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;T4 Free sp5 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25795-6;Thyroxine.free^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;T4 Free sp6 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25796-4;Thyroxine.free^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;T4 Free sp7 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25797-2;Thyroxine.free^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;T4 Free sp8 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25798-0;Thyroxine.free^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;T4 Free sp9 p chal SerPl-sCnc;;ACTIVE;2.00;2.34 +25799-8;Tissue polypeptide specific Ag;ACnc;Pt;Urine;Qn;;CHEM;1;Tissue polypeptide specific Ag [Units/volume] in Urine;TPS Ag Ur-aCnc;;ACTIVE;2.00;2.68 +25800-4;Tobramycin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Tobramycin [Susceptibility] by Method for Slow-growing mycobacteria;Tobramycin Islt SlowMyco;;ACTIVE;2.00;2.73 +25801-2;Trichophyton mentagrophytes var interdigitale Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trichophyton mentagrophytes var interdigitale IgE Ab [Units/volume] in Serum;T ment interdigi IgE Qn;;ACTIVE;2.00;2.73 +25802-0;Trichophyton mentagrophytes var interdigitale Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichophyton mentagrophytes var interdigitale IgE Ab RAST class [Presence] in Serum;T ment interdigi IgE RAST Ql;;ACTIVE;2.00;2.73 +25803-8;Triiodothyronine.free^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;T3Free sp1 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25804-6;Triiodothyronine.free^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;T3Free sp2 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25805-3;Triiodothyronine.free^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;T3Free sp3 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25806-1;Triiodothyronine.free^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;T3Free sp4 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25807-9;Triiodothyronine.free^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;T3Free sp5 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25808-7;Triiodothyronine.free^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;T3Free sp6 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +2580-9;Lutropin;SCnc;Pt;Urine;Qn;;CHEM;1;Lutropin [Moles/volume] in Urine;LH Ur-sCnc;;DISCOURAGED;1.0;2.34 +25809-5;Triiodothyronine.free^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;T3Free sp7 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25810-3;Triiodothyronine.free^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;T3Free sp8 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25811-1;Triiodothyronine.free^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;T3Free sp9 p chal SerPl-sCnc;;ACTIVE;2.00;2.44 +25812-9;Trimipramine+Nortrimipramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimipramine+Nortrimipramine [Moles/volume] in Serum or Plasma;Trimipram+Nor SerPl-sCnc;;ACTIVE;2.00;2.40 +25813-7;Trypanosoma cruzi Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Trypanosoma cruzi Ab [Titer] in Serum by Immunofluorescence;T cruzi Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25814-5;Lathyrus sativus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Blue vetch IgE Ab [Units/volume] in Serum;Deprecated Blue vetch IgE Qn;;DEPRECATED;2.00;2.69 +25815-2;Lathyrus sativus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Blue vetch IgE Ab RAST class [Presence] in Serum;Blue vetch IgE RAST Ql;;ACTIVE;2.00;2.58 +25816-0;Vigabatrin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vigabatrin [Moles/volume] in Serum or Plasma;Vigabatrin SerPl-sCnc;;ACTIVE;2.00;2.42 +2581-7;Gonadotropin releasing hormone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gonadotropin releasing hormone [Moles/volume] in Serum or Plasma;GnRH SerPl-sCnc;;ACTIVE;1.0;2.73 +25817-8;Xylose^1.5H post dose xylose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --1.5 hours post dose xylose PO;Xylose 1.5h p Xyl PO SerPl-sCnc;;ACTIVE;2.00;2.40 +25818-6;Xylose^1H post dose xylose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --1 hour post dose xylose PO;Xylose 1h p Xyl PO SerPl-sCnc;;ACTIVE;2.00;2.40 +25819-4;Xylose^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --baseline;Xylose BS SerPl-sCnc;;ACTIVE;2.00;2.40 +25820-2;Cysteate;SRat;24H;Urine;Qn;;CHEM;1;Cysteate [Moles/time] in 24 hour Urine;Cysteate 24h Ur-sRate;;ACTIVE;2.00;2.42 +25821-0;Staphylococcus aureus enterotoxin A Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Staphylococcus aureus enterotoxin A IgE Ab [Units/volume] in Serum;S aureus Etx A IgE Qn;;ACTIVE;2.00;2.73 +25822-8;Staphylococcus aureus enterotoxin B Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Staphylococcus aureus enterotoxin B IgE Ab [Units/volume] in Serum;S aureus Etx B IgE Qn;;ACTIVE;2.00;2.73 +25823-6;Staphylococcus aureus enterotoxin B Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Staphylococcus aureus enterotoxin B IgE Ab RAST class [Presence] in Serum;S aureus Etx B IgE RAST Ql;;ACTIVE;2.00;2.73 +25824-4;Staphylococcus aureus enterotoxin C Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Staphylococcus aureus enterotoxin C IgE Ab [Units/volume] in Serum;S aureus Etx C IgE Qn;;ACTIVE;2.00;2.42 +2582-5;Lutropin.alpha subunit;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin.alpha subunit [Moles/volume] in Serum or Plasma;A-LH SerPl-sCnc;;DISCOURAGED;1.0;2.34 +25825-1;Staphylococcus aureus enterotoxin C Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Staphylococcus aureus enterotoxin C IgE Ab RAST class [Presence] in Serum;S aureus Etx C IgE RAST Ql;;ACTIVE;2.00;2.58 +25826-9;Staphylococcus aureus enterotoxin D Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Staphylococcus aureus enterotoxin D IgE Ab [Units/volume] in Serum;S aureus Etx D IgE Qn;;ACTIVE;2.00;2.42 +25827-7;Staphylococcus aureus enterotoxin D Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Staphylococcus aureus enterotoxin D IgE Ab RAST class [Presence] in Serum;S aureus Etx D IgE RAST Ql;;ACTIVE;2.00;2.58 +25828-5;Parkinsonia florida Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Palo verde IgE Ab [Units/volume] in Serum;Palo verde IgE Qn;;ACTIVE;2.00;2.42 +25829-3;Glucosylceramidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Glucosylceramidase [Enzymatic activity/mass] in Fibroblast;Glucosylceramidase Fib-cCnt;;ACTIVE;2.00;2.70 +25830-1;Beta glucosidase activator;Imp;Pt;Fibroblasts;Nom;;CHEM;1;Beta glucosidase activator [Interpretation] in Fibroblast;B-Glucosidase Act Fib-Imp;;ACTIVE;2.00;2.26 +25831-9;Beta-N-acetylhexosaminidase.A;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A [Enzymatic activity/mass] in Fibroblast;Hexosaminidase A Fib-cCnt;;ACTIVE;2.00;2.70 +25832-7;Beta-N-acetylhexosaminidase.A activator;Imp;Pt;Fibroblasts;Nom;;CHEM;1;Beta-N-acetylhexosaminidase.A activator [Interpretation] in Fibroblast;Hexosaminidase A Act Fib-Imp;;ACTIVE;2.00;2.26 +2583-3;Lutropin.beta subunit;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin.beta subunit [Moles/volume] in Serum or Plasma;B-LH SerPl-sCnc;;DISCOURAGED;1.0;2.34 +25833-5;Cerebroside sulfatase activator;Imp;Pt;Fibroblasts;Nom;;CHEM;1;Cerebroside sulfatase activator [Interpretation] in Fibroblast;Cerebro Sulfatase Act Fib-Imp;;ACTIVE;2.00;2.26 +25834-3;Cancer associated retinopathy Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Cancer associated retinopathy Ab [Presence] in Serum by Immunoblot;CAR Ab Ser Ql IB;;ACTIVE;2.00;2.73 +25835-0;HIV 1 RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA [Presence] in Serum or Plasma by NAA with probe detection;HIV1 RNA SerPl Ql NAA+probe;;ACTIVE;2.00;2.73 +25836-8;HIV 1 RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Specimen by NAA with probe detection;HIV1 RNA # Spec NAA+probe;;ACTIVE;2.00;2.73 +25837-6;Herpes simplex virus 1 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus 1 Ab [Titer] in Serum by Immunofluorescence;HSV1 Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25838-4;Herpes simplex virus 1 Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 1 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV1 Ab Titr CSF IF;;ACTIVE;2.00;2.73 +25839-2;Herpes simplex virus 2 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus 2 Ab [Titer] in Serum by Immunofluorescence;HSV2 Ab Titr Ser IF;;ACTIVE;2.00;2.70 +258-4;Framycetin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Framycetin [Susceptibility] by Minimum inhibitory concentration (MIC);Framycetin Islt MIC;;ACTIVE;1.0;2.19 +25840-0;Herpes simplex virus 2 Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 2 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV2 Ab Titr CSF IF;;ACTIVE;2.00;2.73 +2584-1;Lysine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lysine [Presence] in Serum or Plasma;Lysine SerPl Ql;;ACTIVE;1.0;2.73 +25841-8;HIV 2 proviral DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HIV 2 proviral DNA [Presence] in Blood by NAA with probe detection;HIV 2 proviral DNA Bld Ql NAA+probe;;ACTIVE;2.00;2.73 +25842-6;HIV 2 proviral DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;HIV 2 proviral DNA [Presence] in Specimen by NAA with probe detection;HIV 2 proviral DNA Spec Ql NAA+probe;;ACTIVE;2.00;2.73 +25843-4;Alanine;SCnc;24H;Urine;Qn;;CHEM;1;Alanine [Moles/volume] in 24 hour Urine;Alanine 24h Ur-sCnc;;ACTIVE;2.00;2.34 +25844-2;Alanine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Alanine/Creatinine [Molar ratio] in 24 hour Urine;Alanine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25845-9;Aldosterone;SCnc;24H;Urine;Qn;;CHEM;1;Aldosterone [Moles/volume] in 24 hour Urine;Aldost 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25846-7;Alpha aminoadipate;SCnc;24H;Urine;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in 24 hour Urine;AAA 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25847-5;Alpha aminoadipate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Alpha aminoadipate/Creatinine [Molar ratio] in 24 hour Urine;AAA/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25848-3;Alpha aminobutyrate;SCnc;24H;Urine;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in 24 hour Urine;A-Aminobutyr 24h Ur-sCnc;;ACTIVE;2.00;2.73 +25849-1;Alpha aminobutyrate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Alpha aminobutyrate/Creatinine [Molar ratio] in 24 hour Urine;A-Aminobutyr/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25850-9;Ammonia;SCnc;24H;Urine;Qn;;CHEM;1;Ammonia [Moles/volume] in 24 hour Urine;Ammonia 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25851-7;Ammonia/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Ammonia/Creatinine [Molar ratio] in 24 hour Urine;Ammonia/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25852-5;17-Hydroxycorticosteroids;SCnc;24H;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids [Moles/volume] in 24 hour Urine;17OHCS 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25853-3;1-Methylhistidine;SCnc;24H;Urine;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in 24 hour Urine;1Me-hist 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25854-1;1-Methylhistidine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;1-Methylhistidine/Creatinine [Molar ratio] in 24 hour Urine;1Me-hist/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25855-8;3-Alpha-Androstanediol glucuronide;SRat;24H;Urine;Qn;;CHEM;1;3-Alpha-Androstanediol glucuronide [Moles/time] in 24 hour Urine;3A-diol G 24h Ur-sRate;;ACTIVE;2.00;2.42 +25856-6;3-Methylhistidine;SCnc;24H;Urine;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in 24 hour Urine;3Me-histidine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25857-4;3-Methylhistidine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Methylhistidine/Creatinine [Molar ratio] in 24 hour Urine;3Me-histidine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2585-8;Lysine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lysine [Mass/volume] in Serum or Plasma;Lysine SerPl-mCnc;;ACTIVE;1.0;2.73 +25858-2;Anserine;SCnc;24H;Urine;Qn;;CHEM;1;Anserine [Moles/volume] in 24 hour Urine;Anserine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25859-0;Anserine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Anserine/Creatinine [Molar ratio] in 24 hour Urine;Anserine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25860-8;Arginine;SCnc;24H;Urine;Qn;;CHEM;1;Arginine [Moles/volume] in 24 hour Urine;Arginine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25861-6;Arginine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Arginine/Creatinine [Molar ratio] in 24 hour Urine;Arginine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25862-4;Asparagine;SCnc;24H;Urine;Qn;;CHEM;1;Asparagine [Moles/volume] in 24 hour Urine;Asparagine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25863-2;Asparagine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Asparagine/Creatinine [Molar ratio] in 24 hour Urine;Asparagine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25864-0;Aspartate;SCnc;24H;Urine;Qn;;CHEM;1;Aspartate [Moles/volume] in 24 hour Urine;Aspartate 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25865-7;Aspartate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Aspartate/Creatinine [Molar ratio] in 24 hour Urine;Aspartate/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2586-6;Lysine;MCnc;Pt;Urine;Qn;;CHEM;1;Lysine [Mass/volume] in Urine;Lysine Ur-mCnc;;ACTIVE;1.0;2.42 +25866-5;Leptospira borgpetersenii serovar Sejroe Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira borgpetersenii sv Sejroe Ab [Titer] in Serum;L borgp Sej Ab Titr Ser;;ACTIVE;2.00;2.70 +25867-3;Echinococcus sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echinococcus sp Ab [Titer] in Serum;Echinococcus Ab Titr Ser;;ACTIVE;2.00;2.70 +25868-1;Beta alanine;SCnc;24H;Urine;Qn;;CHEM;1;Beta alanine [Moles/volume] in 24 hour Urine;B-Alanine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25869-9;Beta alanine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Beta alanine/Creatinine [Molar ratio] in 24 hour Urine;B-Alanine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25870-7;Beta aminoisobutyrate;SCnc;24H;Urine;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/volume] in 24 hour Urine;B-AIB 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25871-5;Beta aminoisobutyrate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Beta aminoisobutyrate/Creatinine [Molar ratio] in 24 hour Urine;B-AIB/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25872-3;C peptide;SCnc;24H;Urine;Qn;;CHEM;1;C peptide [Moles/volume] in 24 hour Urine;C peptide 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25873-1;Calcium^pre 500 mg calcium PO;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --pre 500 mg calcium PO;Calcium pre 500 mg Ca PO Ur-sCnc;;ACTIVE;2.00;2.70 +2587-4;Lysine;MRat;24H;Urine;Qn;;CHEM;1;Lysine [Mass/time] in 24 hour Urine;Lysine 24h Ur-mRate;;ACTIVE;1.0;2.42 +25874-9;Carnosine;SCnc;24H;Urine;Qn;;CHEM;1;Carnosine [Moles/volume] in 24 hour Urine;Carnosine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25875-6;Carnosine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Carnosine/Creatinine [Molar ratio] in 24 hour Urine;Carnosine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25876-4;Citrate;SCnc;24H;Urine;Qn;;CHEM;1;Citrate [Moles/volume] in 24 hour Urine;Citrate 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25877-2;Citrulline;SCnc;24H;Urine;Qn;;CHEM;1;Citrulline [Moles/volume] in 24 hour Urine;Citrulline 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25878-0;Citrulline/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Citrulline/Creatinine [Molar ratio] in 24 hour Urine;Citrulline/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25879-8;Copper;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Copper [Moles/volume] in 24 hour Urine;Copper 24h Ur-sCnc;;ACTIVE;2.00;2.34 +25880-6;Copper/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Copper/Creatinine [Molar ratio] in Urine;Copper/Creat Ur-sRto;;ACTIVE;2.00;2.42 +25881-4;Coproporphyrin;SCnc;24H;Urine;Qn;;CHEM;1;Coproporphyrin [Moles/volume] in 24 hour Urine;Copro 24h Ur-sCnc;;ACTIVE;2.00;2.34 +2588-2;Lysolecithin acyltransferase;CCnc;Pt;RBC;Qn;;CHEM;1;Lysolecithin acyltransferase [Enzymatic activity/volume] in Red Blood Cells;Lysolecithin AT RBC-cCnc;;ACTIVE;1.0;2.44 +25882-2;Cortisol.free;SCnc;24H;Urine;Qn;RIA;CHEM;1;Cortisol Free [Moles/volume] in 24 hour Urine by Radioimmunoassay (RIA);Cortis F 24h Ur RIA-sCnc;;ACTIVE;2.00;2.42 +25883-0;Cortisol.free;SCnc;24H;Urine;Qn;HPLC;CHEM;1;Cortisol Free [Moles/volume] in 24 hour Urine by HPLC;Cortis F 24h Ur HPLC-sCnc;;ACTIVE;2.00;2.73 +25884-8;Cortisol.free;SRat;24H;Urine;Qn;RIA;CHEM;1;Cortisol Free [Moles/time] in 24 hour Urine by Radioimmunoassay (RIA);Cortis F 24h Ur RIA-sRate;;ACTIVE;2.00;2.42 +25885-5;Cortisol.free;SRat;24H;Urine;Qn;HPLC;CHEM;1;Cortisol Free [Moles/time] in 24 hour Urine by HPLC;Cortis F 24h Ur HPLC-sRate;;ACTIVE;2.00;2.42 +25886-3;Creatinine;SCnc;24H;Urine;Qn;;CHEM;1;Creatinine [Moles/volume] in 24 hour Urine;Creat 24h Ur-sCnc;;ACTIVE;2.00;2.73 +25887-1;Cystathionine;SCnc;24H;Urine;Qn;;CHEM;1;Cystathionine [Moles/volume] in 24 hour Urine;Cystathionin 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25888-9;Cystathionine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Cystathionine/Creatinine [Molar ratio] in 24 hour Urine;Cystathionin/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25889-7;Cysteate;SCnc;24H;Urine;Qn;;CHEM;1;Cysteate [Moles/volume] in 24 hour Urine;Cysteate 24h Ur-sCnc;;ACTIVE;2.00;2.42 +2589-0;Lysozyme;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lysozyme [Mass/volume] in Serum or Plasma;Lysozyme SerPl-mCnc;;ACTIVE;1.0;2.73 +25890-5;Cysteate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Cysteate/Creatinine [Molar ratio] in 24 hour Urine;Cysteate/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25891-3;Cysteine;SCnc;24H;Urine;Qn;;CHEM;1;Cysteine [Moles/volume] in 24 hour Urine;Cysteine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25892-1;Cysteine;SRat;24H;Urine;Qn;;CHEM;1;Cysteine [Moles/time] in 24 hour Urine;Cysteine 24h Ur-sRate;;ACTIVE;2.00;2.42 +25893-9;Cysteine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Cysteine/Creatinine [Molar ratio] in 24 hour Urine;Cysteine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25894-7;Cystine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Cystine/Creatinine [Molar ratio] in 24 hour Urine;Cystine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.73 +25895-4;Dehydroepiandrosterone;SCnc;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Moles/volume] in 24 hour Urine;DHEA 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25896-2;Delta aminolevulinate;SCnc;24H;Urine;Qn;;CHEM;1;Delta aminolevulinate [Moles/volume] in 24 hour Urine;D-ALA 24h Ur-sCnc;;ACTIVE;2.00;2.73 +25897-0;Delta aminolevulinate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Delta aminolevulinate/Creatinine [Molar ratio] in 24 hour Urine;D-ALA/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25898-8;Deoxypyridinoline;SCnc;24H;Urine;Qn;;CHEM;1;Deoxypyridinoline [Moles/volume] in 24 hour Urine;DPD 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25899-6;D-Lactate^1st specimen post exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;D-Lactate [Moles/volume] in Serum or Plasma --1st specimen post excercise;D-Lactate sp1 p Exc SerPl-sCnc;;ACTIVE;2.00;2.70 +25900-2;D-Lactate^2nd specimen post exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;D-Lactate [Moles/volume] in Serum or Plasma --2nd specimen post excercise;D-Lactate sp2 p Exc SerPl-sCnc;;ACTIVE;2.00;2.70 +25901-0;D-Lactate^3rd specimen post exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;D-Lactate [Moles/volume] in Serum or Plasma --3rd specimen post excercise;D-Lactate sp3 p Exc SerPl-sCnc;;ACTIVE;2.00;2.70 +25902-8;D-Lactate^4th specimen post exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;D-Lactate [Moles/volume] in Serum or Plasma --4th specimen post excercise;D-Lactate sp4 p Exc SerPl-sCnc;;ACTIVE;2.00;2.70 +25903-6;D-Lactate^5th specimen post exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;D-Lactate [Moles/volume] in Serum or Plasma --5th specimen post excercise;D-Lactate sp5 p Exc SerPl-sCnc;;ACTIVE;2.00;2.70 +25904-4;D-Lactate^6th specimen post exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;D-Lactate [Moles/volume] in Serum or Plasma --6th specimen post excercise;D-Lactate sp6 p Exc SerPl-sCnc;;ACTIVE;2.00;2.70 +25905-1;D-lactate^pre exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;D-Lactate [Moles/volume] in Serum or Plasma --Pre excercise;D-Lactate pre Exc SerPl-sCnc;;ACTIVE;2.00;2.70 +25906-9;DOPamine;SCnc;24H;Urine;Qn;;CHEM;1;DOPamine [Moles/volume] in 24 hour Urine;DOPamine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25907-7;Elastase.pancreatic;MCnt;Pt;Stool;Qn;;CHEM;1;Elastase.pancreatic [Mass/mass] in Stool;Elastase Panc Stl-mCnt;;ACTIVE;2.00;2.73 +2590-8;Lysozyme;MRat;24H;Urine;Qn;;CHEM;1;Lysozyme [Mass/time] in 24 hour Urine;Lysozyme 24h Ur-mRate;;ACTIVE;1.0;2.42 +25908-5;EPINEPHrine;SCnc;24H;Urine;Qn;;CHEM;1;EPINEPHrine [Moles/volume] in 24 hour Urine;Epineph 24h Ur-sCnc;;ACTIVE;2.00;2.34 +25909-3;EPINEPHrine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;EPINEPHrine/Creatinine [Molar ratio] in 24 hour Urine;Epineph/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25910-1;Ethanolamine;SCnc;24H;Urine;Qn;;CHEM;1;Ethanolamine [Moles/volume] in 24 hour Urine;Ethanolamine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25911-9;Ethanolamine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Ethanolamine/Creatinine [Molar ratio] in 24 hour Urine;Ethanolamine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25912-7;Fluoride;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Fluoride [Moles/volume] in 24 hour Urine;Fluoride 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25913-5;Fluoride/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Fluoride/Creatinine [Molar ratio] in 24 hour Urine;Fluoride/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25914-3;Gamma aminobutyrate;SCnc;24H;Urine;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in 24 hour Urine;GABA 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25915-0;Gamma aminobutyrate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Gamma aminobutyrate/Creatinine [Molar ratio] in 24 hour Urine;GABA/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2591-6;Macroamylase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Macroamylase [Enzymatic activity/volume] in Serum or Plasma;Macroamylase SerPl-cCnc;;ACTIVE;1.0;2.73 +25916-8;Glucose;SCnc;24H;Urine;Qn;;CHEM;1;Glucose [Moles/volume] in 24 hour Urine;Glucose 24h Ur-sCnc;;ACTIVE;2.00;2.34 +25917-6;Glutamate;SCnc;24H;Urine;Qn;;CHEM;1;Glutamate [Moles/volume] in 24 hour Urine;Glutamate 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25918-4;Glutamate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Glutamate/Creatinine [Molar ratio] in 24 hour Urine;Glutamate/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25919-2;Glutamine;SCnc;24H;Urine;Qn;;CHEM;1;Glutamine [Moles/volume] in 24 hour Urine;Glutamine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +259-2;Framycetin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Framycetin [Susceptibility] by Disk diffusion (KB);Framycetin Islt KB;;ACTIVE;1.0;2.19 +25920-0;Glutamine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Glutamine/Creatinine [Molar ratio] in 24 hour Urine;Glutamine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25921-8;Glycine;SCnc;24H;Urine;Qn;;CHEM;1;Glycine [Moles/volume] in 24 hour Urine;Glycine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25922-6;Glycine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Glycine/Creatinine [Molar ratio] in 24 hour Urine;Glycine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25923-4;Heptacarboxylporphyrin;SCnc;24H;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin [Moles/volume] in 24 hour Urine;Hepta-CP 24h Ur-sCnc;;ACTIVE;2.00;2.42 +2592-4;Macroglobulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Macroglobulin [Mass/volume] in Serum or Plasma;Macroglob SerPl-mCnc;;ACTIVE;1.0;2.40 +25924-2;Hexacarboxylporphyrin;SCnc;24H;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin [Moles/volume] in 24 hour Urine;Hexa-CP 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25925-9;Histamine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Histamine/Creatinine [Molar ratio] in 24 hour Urine;Histamine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.73 +25926-7;Histidine;SCnc;24H;Urine;Qn;;CHEM;1;Histidine [Moles/volume] in 24 hour Urine;Histidine 24h Ur-sCnc;;ACTIVE;2.00;2.73 +25927-5;Histidine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Histidine/Creatinine [Molar ratio] in 24 hour Urine;Histidine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25928-3;Homocystine;SCnc;24H;Urine;Qn;;CHEM;1;Homocystine [Moles/volume] in 24 hour Urine;(Hcys)2 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25929-1;Homocystine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Homocystine/Creatinine [Molar ratio] in 24 hour Urine;(Hcys)2/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25930-9;Homovanillate;SCnc;24H;Urine;Qn;;CHEM;1;Homovanillate [Moles/volume] in 24 hour Urine;HVA 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25931-7;Homovanillate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Homovanillate/Creatinine [Molar ratio] in 24 hour Urine;HVA/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2593-2;Magnesium;SCnc;Pt;Bld;Qn;;CHEM;1;Magnesium [Moles/volume] in Blood;Magnesium Bld-sCnc;;ACTIVE;1.0;2.46 +25932-5;Hydroxylysine;SCnc;24H;Urine;Qn;;CHEM;1;Hydroxylysine [Moles/volume] in 24 hour Urine;OH-Lysine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25933-3;Hydroxylysine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Hydroxylysine/Creatinine [Molar ratio] in 24 hour Urine;OH-Lysine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25934-1;Hydroxyproline;SCnc;24H;Urine;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in 24 hour Urine;OH-Proline 24h Ur-sCnc;;ACTIVE;2.00;2.34 +25935-8;Hydroxyproline/Creatinine;SCrto;24H;Urine;Qn;;CHEM;1;Deprecated Hydroxyproline/Creatinine [Molecular ratio] in 24 hour Urine;Deprecated OH-Proline/creat 24H Ur-sRto;;DEPRECATED;2.00;2.66 +25936-6;Iodine;SCnc;24H;Urine;Qn;;CHEM;1;Iodine [Moles/volume] in 24 hour Urine;Iodine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25937-4;Iron;SCnc;24H;Urine;Qn;;CHEM;1;Iron [Moles/volume] in 24 hour Urine;Iron 24h Ur-sCnc;;ACTIVE;2.00;2.70 +25938-2;Isoleucine;SCnc;24H;Urine;Qn;;CHEM;1;Isoleucine [Moles/volume] in 24 hour Urine;Isoleucine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25939-0;Isoleucine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Isoleucine/Creatinine [Molar ratio] in 24 hour Urine;Isoleucine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2594-0;Magnesium;SCnc;Pt;CSF;Qn;;CHEM;1;Magnesium [Moles/volume] in Cerebral spinal fluid;Magnesium CSF-sCnc;;ACTIVE;1.0;2.34 +25940-8;Leptospira borgpetersenii serovar Sejroe Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Leptospira borgpetersenii sv Sejroe Ab [Titer] in Serum by Complement fixation;L borgp Sej Ab Titr Ser CF;;ACTIVE;2.00;2.70 +25941-6;Leucine;SCnc;24H;Urine;Qn;;CHEM;1;Leucine [Moles/volume] in 24 hour Urine;Leucine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25942-4;Leucine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Leucine/Creatinine [Molar ratio] in 24 hour Urine;Leucine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25943-2;Lutropin^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --1st specimen post XXX challenge;LH sp1 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25944-0;Lutropin^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --2nd specimen post XXX challenge;LH sp2 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25945-7;Lutropin^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --3rd specimen post XXX challenge;LH sp3 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25946-5;Lutropin^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --4th specimen post XXX challenge;LH sp4 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25947-3;Lutropin^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --5th specimen post XXX challenge;LH sp5 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25948-1;Lutropin^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --6th specimen post XXX challenge;LH sp6 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25949-9;Lutropin^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --7th specimen post XXX challenge;LH sp7 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25950-7;Lutropin^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --8th specimen post XXX challenge;LH sp8 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25951-5;Lutropin^9th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;1st IRP;CHAL;1;Lutropin [Units/volume] in Serum or Plasma by 1st IRP --9th specimen post XXX challenge;LH sp9 p chal SerPl IRP1-aCnc;;ACTIVE;2.00;2.68 +25952-3;Lysine;SCnc;24H;Urine;Qn;;CHEM;1;Lysine [Moles/volume] in 24 hour Urine;Lysine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25953-1;Lysine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Lysine/Creatinine [Molar ratio] in 24 hour Urine;Lysine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25954-9;Magnesium;SCnc;24H;Urine;Qn;;CHEM;1;Magnesium [Moles/volume] in 24 hour Urine;Magnesium 24h Ur-sCnc;;ACTIVE;2.00;2.70 +25955-6;Metanephrine;SCnc;24H;Urine;Qn;;CHEM;1;Metanephrine [Moles/volume] in 24 hour Urine;Metaneph 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25956-4;Methionine;SCnc;24H;Urine;Qn;;CHEM;1;Methionine [Moles/volume] in 24 hour Urine;Methionine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +2595-7;Magnesium;SCnc;Pt;Dial fld;Qn;;CHEM;1;Magnesium [Moles/volume] in Dialysis fluid;Magnesium Dial fld-sCnc;;ACTIVE;1.0;2.42 +25957-2;Methionine sulfoxide;SCnc;24H;Urine;Qn;;CHEM;1;Methionine sulfoxide [Moles/volume] in 24 hour Urine;MSO 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25958-0;Methionine sulfoxide/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Methionine sulfoxide/Creatinine [Molar ratio] in 24 hour Urine;MSO/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25959-8;Methionine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Methionine/Creatinine [Molar ratio] in 24 hour Urine;Methionine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25960-6;Methyltetrahydrophthalic anhydride Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Methyltetrahydrophthalic anhydride (MTHPA) IgE Ab RAST class [Presence] in Serum;MTHPA IgE RAST Ql;;ACTIVE;2.00;2.58 +25961-4;Nickel;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Nickel [Moles/volume] in 24 hour Urine;Nickel 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25962-2;Nickel/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Nickel/Creatinine [Molar ratio] in 24 hour Urine;Nickel/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25963-0;Norepinephrine;SCnc;24H;Urine;Qn;;CHEM;1;Norepinephrine [Moles/volume] in 24 hour Urine;Norepineph 24h Ur-sCnc;;ACTIVE;2.00;2.34 +25964-8;Normetanephrine;SCnc;24H;Urine;Qn;;CHEM;1;Normetanephrine [Moles/volume] in 24 hour Urine;Normetanephrine 24h Ur-sCnc;;ACTIVE;2.00;2.73 +2596-5;Magnesium;SCnc;Pt;Body fld;Qn;;CHEM;1;Magnesium [Moles/volume] in Body fluid;Magnesium Fld-sCnc;;ACTIVE;1.0;2.34 +25965-5;Ornithine;SCnc;24H;Urine;Qn;;CHEM;1;Ornithine [Moles/volume] in 24 hour Urine;Ornithine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25966-3;Ornithine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Ornithine/Creatinine [Molar ratio] in 24 hour Urine;Ornithine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25967-1;Penicillium roqueforti Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillium roqueforti IgE Ab RAST class [Presence] in Serum;P roqueforte IgE RAST Ql;;ACTIVE;2.00;2.58 +25968-9;Pentacarboxylporphyrins;SCnc;24H;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins [Moles/volume] in 24 hour Urine;Penta-CP 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25969-7;Phenylalanine;SCnc;24H;Urine;Qn;;CHEM;1;Phenylalanine [Moles/volume] in 24 hour Urine;Phe 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25970-5;Phenylalanine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Phenylalanine/Creatinine [Molar ratio] in 24 hour Urine;Phe/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25971-3;5-Hydroxyindoleacetate;SCnc;24H;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate [Moles/volume] in 24 hour Urine;5OH-indoleacetate 24h Ur-sCnc;;ACTIVE;2.00;2.34 +25972-1;Adenosine monophosphate.cyclic/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Adenosine monophosphate.cyclic/Creatinine [Molar ratio] in 24 hour Urine;cAMP/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2597-3;Magnesium;SCnc;Pt;RBC;Qn;;CHEM;1;Magnesium [Moles/volume] in Red Blood Cells;Magnesium RBC-sCnc;;ACTIVE;1.0;2.73 +25973-9;Phosphate;SCnc;24H;Urine;Qn;;CHEM;1;Phosphate [Moles/volume] in 24 hour Urine;Phosphate 24h Ur-sCnc;;ACTIVE;2.00;2.73 +25974-7;Phosphoserine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Phosphoserine/Creatinine [Molar ratio] in 24 hour Urine;Phosphoserine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25975-4;Proline;SCnc;24H;Urine;Qn;;CHEM;1;Proline [Moles/volume] in 24 hour Urine;Proline 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25976-2;Proline/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Proline/Creatinine [Molar ratio] in 24 hour Urine;Proline/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25977-0;Pyridinoline;SCnc;24H;Urine;Qn;;CHEM;1;Pyridinoline [Moles/volume] in 24 hour Urine;PYD 24h Ur-sCnc;;ACTIVE;2.00;2.70 +25978-8;Sarcosine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Sarcosine/Creatinine [Molar ratio] in 24 hour Urine;Sarcosine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25979-6;Serine;SCnc;24H;Urine;Qn;;CHEM;1;Serine [Moles/volume] in 24 hour Urine;Serine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25980-4;Serine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Serine/Creatinine [Molar ratio] in 24 hour Urine;Serine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2598-1;Magnesium;SCnc;Pt;Urine;Qn;;CHEM;1;Magnesium [Moles/volume] in Urine;Magnesium Ur-sCnc;;ACTIVE;1.0;2.73 +25981-2;Serotonin;SCnc;24H;Urine;Qn;;CHEM;1;Serotonin [Moles/volume] in 24 hour Urine;Serotonin 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25982-0;Sheep milk Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sheep milk IgE Ab RAST class [Presence] in Serum;Sheep Milk IgE RAST Ql;;ACTIVE;2.00;2.73 +25983-8;Sheep whey Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sheep whey IgE Ab RAST class [Presence] in Serum;Sheep Whey IgE RAST Ql;;ACTIVE;2.00;2.58 +25984-6;Somatotropin^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;GH 30M p chal SerPl-sCnc;;DISCOURAGED;2.00;2.44 +25985-3;Taurine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Taurine/Creatinine [Molar ratio] in 24 hour Urine;Taurine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25986-1;Testosterone;SCnc;24H;Urine;Qn;;CHEM;1;Testosterone [Moles/volume] in 24 hour Urine;Testost 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25987-9;Testosterone.free;SCnc;Pt;Ser/Plas;Qn;RIA;CHEM;1;Testosterone Free [Moles/volume] in Serum or Plasma by Radioimmunoassay (RIA);Testost Free SerPl RIA-sCnc;;ACTIVE;2.00;2.73 +25988-7;Threonine;SCnc;24H;Urine;Qn;;CHEM;1;Threonine [Moles/volume] in 24 hour Urine;Threonine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25989-5;Threonine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Threonine/Creatinine [Molar ratio] in 24 hour Urine;Threonine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25990-3;Thyrotropin^30M post dose TRH IN;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Moles/volume] in Serum or Plasma --30 minutes post dose TRH IN;TSH 30M p TRH IN SerPl-sCnc;;DISCOURAGED;2.00;2.42 +25991-1;Thyrotropin^pre dose TRH IN;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Moles/volume] in Serum or Plasma --pre dose TRH IN;TSH pre TRH IN SerPl-sCnc;;DISCOURAGED;2.00;2.42 +25992-9;Triacylglycerol lipase;CCnc;24H;Urine;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in 24 hour Urine;Lipase 24h Ur-cCnc;;ACTIVE;2.00;2.68 +25993-7;Trichinella spiralis Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Trichinella spiralis Ab [Titer] in Serum by Immunofluorescence;T spiralis Ab Titr Ser IF;;ACTIVE;2.00;2.70 +25994-5;Tryptophan/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Tryptophan/Creatinine [Molar ratio] in 24 hour Urine;Tryptophan/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25995-2;Tyrosine;SCnc;24H;Urine;Qn;;CHEM;1;Tyrosine [Moles/volume] in 24 hour Urine;Tyrosine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +25996-0;Tyrosine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Tyrosine/Creatinine [Molar ratio] in 24 hour Urine;Tyrosine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +25997-8;Urate;SCnc;24H;Urine;Qn;;CHEM;1;Urate [Moles/volume] in 24 hour Urine;Urate 24h Ur-sCnc;;ACTIVE;2.00;2.70 +25998-6;Urea;SCnc;24H;Urine;Qn;;CHEM;1;Urea [Moles/volume] in 24 hour Urine;Urea 24h Ur-sCnc;;ACTIVE;2.00;2.73 +2599-9;Magnesium;SRat;24H;Urine;Qn;;CHEM;1;Magnesium [Moles/time] in 24 hour Urine;Magnesium 24h Ur-sRate;;ACTIVE;1.0;2.73 +25999-4;Urea/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Urea/Creatinine [Molar ratio] in 24 hour Urine;Urea/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +2-6;Almecillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Almecillin [Susceptibility] by Minimum lethal concentration (MLC);Almecillin Islt MLC;;ACTIVE;1.0;2.19 +260-0;Framycetin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Framycetin [Susceptibility] by Serum bactericidal titer;Framycetin Titr SBT;;ACTIVE;1.0;2.32 +26000-0;Uroporphyrin;SCnc;24H;Urine;Qn;;CHEM;1;Uroporphyrin [Moles/volume] in 24 hour Urine;Uropor 24h Ur-sCnc;;ACTIVE;2.00;2.34 +26001-8;Valine;SCnc;24H;Urine;Qn;;CHEM;1;Valine [Moles/volume] in 24 hour Urine;Valine 24h Ur-sCnc;;ACTIVE;2.00;2.42 +26002-6;Valine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Valine/Creatinine [Molar ratio] in 24 hour Urine;Valine/Creat 24h Ur-sRto;;ACTIVE;2.00;2.42 +26003-4;Vanillylmandelate;SCnc;24H;Urine;Qn;;CHEM;1;Vanillylmandelate [Moles/volume] in 24 hour Urine;VMA 24h Ur-sCnc;;ACTIVE;2.00;2.73 +26004-2;Vanillylmandelate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Vanillylmandelate/Creatinine [Molar ratio] in 24 hour Urine;VMA/Creat 24h Ur-sRto;;ACTIVE;2.00;2.73 +2600-5;Magnesium.ionized;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Magnesium Ionized [Moles/volume] in Serum or Plasma;Mg Ionized SerPl-sCnc;;ACTIVE;1.0;2.73 +26005-9;Xylose^2H post dose xylose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --2 hours post dose xylose PO;Xylose 2h p Xyl PO SerPl-sCnc;;ACTIVE;2.00;2.40 +26006-7;Borrelia burgdorferi Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Borrelia burgdorferi Ab [Presence] in Serum by Hemagglutination;B burgdor Ab Ser Ql HA;;ACTIVE;2.00;2.56 +26007-5;Echinococcus sp Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Echinococcus sp Ab [Presence] in Serum by Hemagglutination;Echinococcus Ab Ser Ql HA;;ACTIVE;2.00;2.56 +26008-3;Echinococcus sp Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Echinococcus sp Ab [Titer] in Serum by Hemagglutination;Echinococcus Ab Titr Ser HA;;ACTIVE;2.00;2.70 +26009-1;Treponema pallidum Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Treponema pallidum Ab [Titer] in Serum by Hemagglutination;T pallidum Ab Titr Ser HA;;ACTIVE;2.00;2.70 +26010-9;Alkaline phosphatase.other fractions/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.other fractions/Alkaline phosphatase.total in Serum or Plasma;ALP Other CFr SerPl;;ACTIVE;2.00;2.73 +26011-7;Macroamylase/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Macroamylase/Amylase.total in Serum or Plasma;Macroamylase CFr SerPl;;ACTIVE;2.00;2.73 +26012-5;17-Hydroxycorticosteroids^1D post XXX challenge;SRat;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Moles/time] in 24 hour Urine --1 day post XXX challenge;17OHCS 1D p chal 24h Ur-sRate;;ACTIVE;2.00;2.40 +2601-3;Magnesium;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Magnesium [Moles/volume] in Serum or Plasma;Magnesium SerPl-sCnc;;ACTIVE;1.0;2.73 +26013-3;17-Hydroxycorticosteroids^2D post XXX challenge;SRat;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Moles/time] in 24 hour Urine --2 days post XXX challenge;17OHCS 2D p chal 24h Ur-sRate;;ACTIVE;2.00;2.40 +26014-1;Arbovirus NOS Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Arbovirus NOS Ab [Titer] in Serum by Complement fixation;Arbovirus NOS Ab Titr Ser CF;;ACTIVE;2.00;2.70 +26015-8;Cholesterol.in HDL 2;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 2 [Moles/volume] in Serum or Plasma;HDL2c SerPl-sCnc;;ACTIVE;2.00;2.73 +26016-6;Cholesterol.in HDL 2;MCnc;Pt;Ser/Plas.ultracentrifugate;Qn;;CHEM;1;Cholesterol in HDL 2 [Mass/volume] in Serum or Plasma ultracentrifugate;HDL2c SerPl.Ultracent-mCnc;;ACTIVE;2.00;2.73 +26017-4;Cholesterol.in HDL 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 3 [Moles/volume] in Serum or Plasma;HDL3c SerPl-sCnc;;ACTIVE;2.00;2.70 +26018-2;Cladosporium cladosporioides Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cladosporium cladosporioides IgG Ab RAST class [Presence] in Serum;C cladosporioides IgG RAST Ql;;ACTIVE;2.00;2.73 +26019-0;Creatine kinase.macromolecular.type 1/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Creatine Kinase.macromolecular type 1/Creatine kinase.total in Serum or Plasma;CK Macro1 CFr SerPl;;ACTIVE;2.00;2.73 +26020-8;Creatine kinase.macromolecular.type 2/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Creatine Kinase.macromolecular type 2/Creatine kinase.total in Serum or Plasma;CK Macro2 CFr SerPl;;ACTIVE;2.00;2.73 +2602-1;Malate dehydrogenase;CCnc;Pt;Ser;Qn;;CHEM;1;Malate dehydrogenase [Enzymatic activity/volume] in Serum;Malate Dehydrog Ser-cCnc;;ACTIVE;1.0;2.68 +26021-6;Nordiazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nordiazepam [Moles/volume] in Serum or Plasma;Nordiazepam SerPl-sCnc;;ACTIVE;2.00;2.34 +26022-4;Enterovirus NOS Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Enterovirus NOS Ab [Titer] in Serum by Complement fixation;EV Ab Titr Ser CF;;ACTIVE;2.00;2.70 +26023-2;Extractable nuclear Ab identified;Prid;Pt;Ser;Nom;;SERO;1;Extractable nuclear Ab identified in Serum;ENA Ser;;ACTIVE;2.00;2.73 +26024-0;Gastrin^post meal;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --post meal;Gastrin p meal SerPl-sCnc;;ACTIVE;2.00;2.40 +26025-7;Festuca elatior Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Meadow Fescue IgE Ab RAST class in Serum;Deprecated Meadow Fescue IgE RAST Ql;;DEPRECATED;2.00;2.36 +26026-5;Hexahydrophthalic anhydride Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hexahydrophthalic anhydride (HHPA) IgE Ab RAST class [Presence] in Serum;HHPA IgE RAST Ql;;ACTIVE;2.00;2.58 +26027-3;Histiocytes;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Histiocytes [#/area] in Urine sediment by Microscopy high power field;Histiocytes #/area UrnS HPF;;ACTIVE;2.00;2.40 +26028-1;HLA-B27;PrThr;Pt;Bld/Tiss;Ord;Flow cytometry;HLA;1;HLA-B27 [Presence] by Flow cytometry (FC);HLA-B27 Ql FC;;ACTIVE;2.00;2.73 +26029-9;Lactoferrin bovine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactoferrin bovine IgE Ab [Units/volume] in Serum;Lactoferrin Bovine IgE Qn;;ACTIVE;2.00;2.42 +26030-7;Lactoferrin bovine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactoferrin bovine IgE Ab RAST class [Presence] in Serum;Lactoferrin Bovine IgE RAST Ql;;ACTIVE;2.00;2.58 +26031-5;Sialate.lipid bound;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sialate.lipid bound [Moles/volume] in Serum or Plasma;LASA SerPl-sCnc;;ACTIVE;2.00;2.70 +26032-3;Pepsin Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pepsin IgE Ab RAST class [Presence] in Serum;Pepsin IgE RAST Ql;;ACTIVE;2.00;2.58 +26033-1;Pronormoblasts/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Pronormoblasts/100 cells in Bone marrow;Pronormoblasts NFr Mar;;ACTIVE;2.00;2.70 +26034-9;Protein;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Deprecated Protein [Mass/volume] in Urine;Deprecated Prot Ur Elph-mCnc;;DEPRECATED;2.00;2.36 +26035-6;Serotonin;SCnc;Pt;Plas;Qn;;CHEM;1;Serotonin [Moles/volume] in Plasma;Serotonin Plas-sCnc;;ACTIVE;2.00;2.42 +26036-4;Staphylococcus aureus enterotoxin A Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Staphylococcus aureus enterotoxin A IgE Ab RAST class [Presence] in Serum;S aureus Etx A IgE RAST Ql;;ACTIVE;2.00;2.73 +26037-2;Trichophyton mentagrophytes var goetzii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trichophyton mentagrophytes var goetzii IgE Ab [Units/volume] in Serum;T ment goetzii IgE Qn;;ACTIVE;2.00;2.73 +26038-0;Trichophyton mentagrophytes var goetzii Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichophyton mentagrophytes var goetzii IgE Ab RAST class [Presence] in Serum;T ment goetzii IgE RAST Ql;;ACTIVE;2.00;2.73 +2603-9;Malonate;MCnc;Pt;Ser;Qn;;CHEM;1;Malonate [Mass/volume] in Serum;Malonate Ser-mCnc;;ACTIVE;1.0;2.44 +26039-8;Norflunitrazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norflunitrazepam [Moles/volume] in Serum or Plasma;Norflunitrazepam SerPl-sCnc;;ACTIVE;2.00;2.42 +26040-6;Norcitalopram;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norcitalopram [Moles/volume] in Serum or Plasma;Norcitalopram SerPl-sCnc;;ACTIVE;2.00;2.42 +26041-4;Normephenytoin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normephenytoin [Moles/volume] in Serum or Plasma;Normephenytoin SerPl-sCnc;;ACTIVE;2.00;2.42 +26042-2;Didesmethylcitalopram;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Didesmethylcitalopram [Moles/volume] in Serum or Plasma;Didesmet-citalopram SerPl-sCnc;;ACTIVE;2.00;2.34 +26043-0;HLA-B27;PrThr;Pt;Bld/Tiss;Ord;Probe.amp.tar;HLA;1;HLA-B27 [Presence] by NAA with probe detection;HLA-B27 Ql NAA+probe;;ACTIVE;2.00;2.73 +26044-8;Pepsin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pepsin IgE Ab [Units/volume] in Serum;Pepsin IgE Qn;;ACTIVE;2.00;2.42 +26045-5;Pheneturide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pheneturide [Moles/volume] in Serum or Plasma;Pheneturide SerPl-sCnc;;ACTIVE;2.00;2.34 +26046-3;5-Hydroxypropafenone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;5-Hydroxypropafenone [Moles/volume] in Serum or Plasma;5OH-Propafenone SerPl-sCnc;;ACTIVE;2.00;2.42 +2604-7;Mannitol renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Mannitol renal clearance in 24 hour Urine and Serum or Plasma;Mannitol Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +26047-1;Phytate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phytate [Moles/volume] in Serum or Plasma;Phytate SerPl-sCnc;;ACTIVE;2.00;2.34 +26048-9;Canary serum proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canary serum proteins IgE Ab RAST class [Presence] in Serum;Canary Serum Prot IgE RAST Ql;;ACTIVE;2.00;2.58 +26049-7;Libocedrus decurrens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cedar IgE Ab [Units/volume] in Serum;Cedar IgE Qn;;ACTIVE;2.00;2.73 +26050-5;Libocedrus decurrens Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cedar IgE Ab RAST class [Presence] in Serum;Cedar IgE RAST Ql;;ACTIVE;2.00;2.73 +26051-3;Epithelial cells.extrarenal;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Epithelial cells.extrarenal [#/area] in Urine sediment by Microscopy high power field;Extraren Epi Cells #/area UrnS HPF;;ACTIVE;2.00;2.73 +26052-1;Epithelial cells.renal;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Epithelial cells.renal [#/area] in Urine sediment by Microscopy high power field;Renal Epi Cells #/area UrnS HPF;;ACTIVE;2.00;2.73 +26053-9;N-methylhistamine;SRat;24H;Urine;Qn;;CHEM;1;N-methylhistamine [Moles/time] in 24 hour Urine;Me-histamine 24h Ur-sRate;;ACTIVE;2.00;2.73 +2605-4;Meat fibers;PrThr;Pt;Stool;Ord;Microscopy.light;CHEM;1;Meat fibers [Presence] in Stool by Light microscopy;Meat Fibers Stl Ql Micro;;ACTIVE;1.0;2.73 +26054-7;Mitochondria M2 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Mitochondria M2 Ab [Presence] in Serum;Mitochondria M2 Ab Ser Ql;;ACTIVE;2.00;2.73 +26055-4;Pyridoxine^pre 250 mg pyridoxine PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pyridoxine [Moles/volume] in Serum or Plasma --pre 250 mg pyridoxine PO;Vit B6 pre 250 mg PN PO SerPl-sCnc;;ACTIVE;2.00;2.40 +26056-2;Pyridoxine^post 250 mg pyridoxine PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pyridoxine [Moles/volume] in Serum or Plasma --post 250 mg pyridoxine PO;Vit B6 p 250 mg Vit B6 PO SerPl-sCnc;;ACTIVE;2.00;2.40 +26057-0;Pyridoxine^post pyridoxine PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pyridoxine [Mass/volume] in Serum or Plasma --post pyridoxine PO;Vit B6 p Vit B6 PO SerPl-mCnc;;ACTIVE;2.00;2.34 +26058-8;European tick borne encephalitis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;European tick borne encephalitis virus Ab [Titer] in Serum by Complement fixation;TBEV Ab Titr Ser CF;;ACTIVE;2.00;2.70 +26059-6;European tick borne encephalitis virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;European tick borne encephalitis virus IgG Ab [Units/volume] in Serum by Immunoassay;TBEV IgG Ser IA-aCnc;;ACTIVE;2.00;2.69 +26060-4;European tick borne encephalitis virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;European tick borne encephalitis virus IgM Ab [Units/volume] in Serum by Immunoassay;TBEV IgM Ser IA-aCnc;;ACTIVE;2.00;2.69 +26061-2;European tick borne encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;European tick borne encephalitis virus Ab [Titer] in Serum;TBEV Ab Titr Ser;;ACTIVE;2.00;2.70 +2606-2;Melanin;PrThr;Pt;Urine;Ord;;CHEM;1;Melanin [Presence] in Urine;Melanin Ur Ql;;ACTIVE;1.0;2.73 +26062-0;European tick borne encephalitis virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;European tick borne encephalitis virus IgG Ab [Units/volume] in Serum;TBEV IgG Ser-aCnc;;ACTIVE;2.00;2.69 +26063-8;European tick borne encephalitis virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;European tick borne encephalitis virus IgM Ab [Units/volume] in Serum;TBEV IgM Ser-aCnc;;ACTIVE;2.00;2.69 +26064-6;Views^W contrast IV;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Vein - bilateral Views W contrast IV;RFA Vein-Bl Views W contr IV;;ACTIVE;2.00;2.64 +26065-3;Views^W contrast IV;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Vein - left Views W contrast IV;RFA Vein-L Views W contr IV;;ACTIVE;2.00;2.64 +26066-1;Views^W contrast IV;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Vein - right Views W contrast IV;RFA Vein-R Views W contr IV;;ACTIVE;2.00;2.64 +26067-9;Views^W contrast intra salivary duct;Find;Pt;Head>Salivary gland.bilateral;Doc;RF;RAD;2;RF Salivary gland - bilateral Views W contrast intra salivary duct;RF Saliv gland-Bl Vs W contr intra duct;;ACTIVE;2.00;2.64 +26068-7;Views^W contrast intra salivary duct;Find;Pt;Head>Salivary gland.left;Doc;RF;RAD;2;RF Salivary gland - left Views W contrast intra salivary duct;RF Saliv gland-L Vs W contr intra duct;;ACTIVE;2.00;2.64 +26069-5;Views^W contrast intra salivary duct;Find;Pt;Head>Salivary gland.right;Doc;RF;RAD;2;RF Salivary gland - right Views W contrast intra salivary duct;RF Saliv gland-R Vs W contr intra duct;;ACTIVE;2.00;2.64 +2607-0;Melanin;MCnc;Pt;Urine;Qn;;CHEM;1;Melanin [Mass/volume] in Urine;Melanin Ur-mCnc;;ACTIVE;1.0;2.73 +26070-3;Views^W contrast IS;Find;Pt;Lower extremity.bilateral>Hip;Doc;RF;RAD;2;RF Hip - bilateral Arthrogram;RF Hip-Bl Views W contr IS;;ACTIVE;2.00;2.64 +26071-1;Views^W contrast IS;Find;Pt;Lower extremity.left>Hip;Doc;RF;RAD;2;RF Hip - left Arthrogram;RF Hip-L Views W contr IS;;ACTIVE;2.00;2.64 +26072-9;Views^W contrast IS;Find;Pt;Lower extremity.right>Hip;Doc;RF;RAD;2;RF Hip - right Arthrogram;RF Hip-R Views W contr IS;;ACTIVE;2.00;2.64 +26073-7;Views^W contrast IS;Find;Pt;Lower extremity.bilateral>Knee;Doc;RF;RAD;2;RF Knee - bilateral Arthrogram;RF Knee-Bl Views W contr IS;;ACTIVE;2.00;2.64 +26074-5;Views^W contrast IS;Find;Pt;Lower extremity.left>Knee;Doc;RF;RAD;2;RF Knee - left Arthrogram;RF Knee-L Views W contr IS;;ACTIVE;2.00;2.64 +26075-2;Views^W contrast IS;Find;Pt;Lower extremity.right>Knee;Doc;RF;RAD;2;RF Knee - right Arthrogram;RF Knee-R Views W contr IS;;ACTIVE;2.00;2.64 +26076-0;Views^W contrast IS;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;RF;RAD;2;RF Shoulder - bilateral Arthrogram;RF Shoulder-Bl Views W contr IS;;ACTIVE;2.00;2.64 +26077-8;Views^W contrast IS;Find;Pt;Upper extremity.left>Shoulder;Doc;RF;RAD;2;RF Shoulder - left Arthrogram;RF Should-L Views W contr IS;;ACTIVE;2.00;2.64 +26078-6;Views^W contrast IS;Find;Pt;Upper extremity.right>Shoulder;Doc;RF;RAD;2;RF Shoulder - right Arthrogram;RF Should-R Views W contr IS;;ACTIVE;2.00;2.64 +26079-4;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries.bilateral;Doc;RF.angio;RAD;2;RFA Carotid arteries - bilateral Views W contrast IA;RFA Carotid aa-Bl Views W contr IA;;ACTIVE;2.00;2.64 +26080-2;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries.left;Doc;RF.angio;RAD;2;RFA Carotid arteries - left Views W contrast IA;RFA Carotid aa-L Views W contr IA;;ACTIVE;2.00;2.64 +26081-0;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries.right;Doc;RF.angio;RAD;2;RFA Carotid arteries -right Views W contrast IA;RFA Carotid aa-R Views W contr IA;;ACTIVE;2.00;2.64 +26082-8;Views^W contrast IA;Find;Pt;XXX>Spinal artery.bilateral;Doc;RF.angio;RAD;2;RFA Spinal artery - bilateral Views W contrast IA;RFA Spinal a-Bl Views W contr IA;;ACTIVE;2.00;2.64 +26083-6;Views^W contrast IA;Find;Pt;XXX>Spinal artery.left;Doc;RF.angio;RAD;2;RFA Spinal artery - left Views W contrast IA;RFA Spinal a-L Views W contr IA;;ACTIVE;2.00;2.64 +26084-4;Views^W contrast IA;Find;Pt;XXX>Spinal artery.right;Doc;RF.angio;RAD;2;RFA Spinal artery - right Views W contrast IA;RFA Spinal a-R Views W contr IA;;ACTIVE;2.00;2.64 +26085-1;Views^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Views W standing;XR Knee-Bl Views W Stand;;ACTIVE;2.00;2.64 +26086-9;Views^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Views W standing;XR Knee-L Views W Stand;;ACTIVE;2.00;2.64 +26087-7;Views^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Views W standing;XR Knee-R Views W Stand;;ACTIVE;2.00;2.64 +2608-8;Metanephrines;MCnc;Pt;Urine;Qn;;CHEM;1;Metanephrines [Mass/volume] in Urine;MetanephS Ur-mCnc;;ACTIVE;1.0;2.73 +26088-5;Views^W radionuclide IV;Find;Pt;Lower extremity.bilateral>Knee;Doc;NM;RAD;2;NM Knee - bilateral Views;NM Knee-Bl Views W RNC IV;;ACTIVE;2.00;2.64 +26089-3;Views^W radionuclide IV;Find;Pt;Lower extremity.left>Knee;Doc;NM;RAD;2;NM Knee - left Views;NM Knee-L Views W RNC IV;;ACTIVE;2.00;2.64 +26090-1;Views^W radionuclide IV;Find;Pt;Lower extremity.right>Knee;Doc;NM;RAD;2;NM Knee - right Views;NM Knee-R Views W RNC IV;;ACTIVE;2.00;2.64 +26091-9;Views^W Tc-99m pertechnetate IV;Find;Pt;Pelvis>Scrotum.bilateral+Testicle.bilateral;Doc;NM;RAD;2;NM Scrotum and Testicle - bilateral Views W Tc-99m pertechnetate IV;NM Scrotum+Test-Bl Views W Tc99mP IV;;ACTIVE;2.00;2.64 +26092-7;Views^W Tc-99m pertechnetate IV;Find;Pt;Pelvis>Scrotum.left+Testicle.left;Doc;NM;RAD;2;NM Scrotum and Testicle - left Views W Tc-99m pertechnetate IV;NM Scrotum+Test-L Views W Tc99mP IV;;ACTIVE;2.00;2.64 +26093-5;Views^W Tc-99m pertechnetate IV;Find;Pt;Pelvis>Scrotum.right+Testicle.right;Doc;NM;RAD;2;NM Scrotum and Testicle - right Views W Tc-99m pertechnetate IV;NM Scrotum+Test-R Views W Tc99mP IV;;ACTIVE;2.00;2.64 +26094-3;Views^W standing;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral Views W standing;XR Foot-Bl Views W Stand;;ACTIVE;2.00;2.64 +26095-0;Views^W standing;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left Views W standing;XR Foot-L Views W Stand;;ACTIVE;2.00;2.64 +2609-6;Metanephrines;MRat;24H;Urine;Qn;;CHEM;1;Metanephrines [Mass/time] in 24 hour Urine;MetanephS 24h Ur-mRate;;ACTIVE;1.0;2.73 +26096-8;Views^W standing;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right Views W standing;XR Foot-R Views W Stand;;ACTIVE;2.00;2.64 +26097-6;Views;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral Views;XR Ankle-Bl Views;;ACTIVE;2.00;2.64 +26098-4;Views;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Views;XR Ankle-L Views;;ACTIVE;2.00;2.73 +26099-2;Views;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Views;XR Ankle-R Views;;ACTIVE;2.00;2.73 +26100-8;Views;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral Views;XR Heel-Bl Views;;ACTIVE;2.00;2.64 +26101-6;Views;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Views;XR Heel-L Views;;ACTIVE;2.00;2.64 +26102-4;Views;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Views;XR Heel-R Views;;ACTIVE;2.00;2.64 +26103-2;Views;Find;Pt;Carpal bones.bilateral;Nar;XR;RAD;2;Deprecated Carpal bones - bilateral X-ray;Deprecated Carpal bones-Bl XR;;DEPRECATED;2.00;2.36 +2610-4;Methane;MCnc;Pt;Exhl gas;Qn;;DRUG/TOX;1;Methane [Mass/volume] in Exhaled gas;Methane ExG-mCnc;;ACTIVE;1.0;2.34 +26104-0;Views;Find;Pt;Carpal bones.left;Nar;XR;RAD;2;Deprecated Carpal bones - left X-ray;Deprecated Carpal bones-L XR;;DEPRECATED;2.00;2.34 +26105-7;Views;Find;Pt;Carpal bones.right;Nar;XR;RAD;2;Deprecated Carpal bones - right X-ray;Deprecated Carpal bones-R XR;;DEPRECATED;2.00;2.34 +26106-5;Views;Find;Pt;Chest>Clavicle.bilateral;Doc;XR;RAD;2;XR Clavicle - bilateral Views;XR Clavicle-Bl Views;;ACTIVE;2.00;2.64 +26107-3;Views;Find;Pt;Chest>Clavicle.left;Doc;XR;RAD;2;XR Clavicle - left Views;XR Clavicle-L Views;;ACTIVE;2.00;2.73 +26108-1;Views;Find;Pt;Chest>Clavicle.right;Doc;XR;RAD;2;XR Clavicle - right Views;XR Clavicle-R Views;;ACTIVE;2.00;2.64 +26109-9;Views;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral Views;XR Elbow-Bl Views;;ACTIVE;2.00;2.64 +26110-7;Views;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left Views;XR Elbow-L Views;;ACTIVE;2.00;2.64 +26111-5;Views;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Views;XR Elbow-R Views;;ACTIVE;2.00;2.73 +2611-2;Methcoproporphyrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methcoproporphyrin [Mass/volume] in Serum or Plasma;Methcopro SerPl-mCnc;;ACTIVE;1.0;2.44 +26112-3;Views;Find;Pt;Lower extremity.bilateral;Doc;XR;RAD;2;XR Lower extremity - bilateral Views;XR LE-Bl Views;;ACTIVE;2.00;2.64 +26113-1;Views;Find;Pt;Lower extremity.left;Doc;XR;RAD;2;XR Lower extremity - left Views;XR LE-L Views;;ACTIVE;2.00;2.64 +26114-9;Views;Find;Pt;Lower extremity.right;Doc;XR;RAD;2;XR Lower extremity - right Views;XR LE-R Views;;ACTIVE;2.00;2.64 +26115-6;Views;Find;Pt;Upper extremity.bilateral;Doc;XR;RAD;2;XR Upper extremity - bilateral Views;XR UE-Bl Views;;ACTIVE;2.00;2.64 +26116-4;Views;Find;Pt;Upper extremity.left;Doc;XR;RAD;2;XR Upper extremity - left Views;XR UE-L Views;;ACTIVE;2.00;2.64 +26117-2;Views;Find;Pt;Upper extremity.right;Doc;XR;RAD;2;XR Upper extremity - right Views;XR UE-R Views;;ACTIVE;2.00;2.64 +26118-0;Views;Find;Pt;Lower extremity.bilateral>Femur;Doc;XR;RAD;2;XR Femur - bilateral Views;XR Femur-Bl Views;;ACTIVE;2.00;2.64 +26119-8;Views;Find;Pt;Femur.bilateral;Nar;XR.DEXA;RAD;2;Deprecated Femur - bilateral DEXA Bone density;Deprecated Femur-Bl DEXA;;DEPRECATED;2.00;2.46 +2612-0;Methemalbumin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methemalbumin [Mass/volume] in Serum or Plasma;Methemalb SerPl-mCnc;;ACTIVE;1.0;2.73 +26120-6;Views;Find;Pt;Lower extremity.left>Femur;Doc;XR;RAD;2;XR Femur - left Views;XR Femur-L Views;;ACTIVE;2.00;2.73 +26121-4;Views;Find;Pt;Femur.left;Nar;XR.DEXA;RAD;2;Deprecated Femur- left DEXA Bone density;Deprecated Femur-L DEXA;;DEPRECATED;2.00;2.46 +26122-2;Views;Find;Pt;Lower extremity.right>Femur;Doc;XR;RAD;2;XR Femur - right Views;XR Femur-R Views;;ACTIVE;2.00;2.73 +26123-0;Views;Find;Pt;Femur.right;Nar;XR.DEXA;RAD;2;Deprecated Femur- right DEXA Bone density;Deprecated Femur-R DEXA;;DEPRECATED;2.00;2.46 +26124-8;Views;Find;Pt;Upper extremity.bilateral>Finger;Doc;XR;RAD;2;XR Finger - bilateral Views;XR Finger-Bl Views;;ACTIVE;2.00;2.64 +26125-5;Views;Find;Pt;Upper extremity.left>Finger;Doc;XR;RAD;2;XR Finger - left Views;XR Finger-L Views;;ACTIVE;2.00;2.64 +26126-3;Views;Find;Pt;Upper extremity.right>Finger;Doc;XR;RAD;2;XR Finger - right Views;XR Finger-R Views;;ACTIVE;2.00;2.73 +26127-1;Views;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral Views;XR Foot-Bl Views;;ACTIVE;2.00;2.64 +26128-9;Views;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left Views;XR Foot-L Views;;ACTIVE;2.00;2.73 +26129-7;Views;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right Views;XR Foot-R Views;;ACTIVE;2.00;2.73 +26130-5;Views;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Views;XR Hip-Bl Views;;ACTIVE;2.00;2.64 +26131-3;Views;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Views;XR Hip-L Views;;ACTIVE;2.00;2.64 +26132-1;Views;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Views;XR Hip-R Views;;ACTIVE;2.00;2.64 +26133-9;Views;Find;Pt;Lower extremity.bilateral>Acetabulum;Doc;XR;RAD;2;XR Acetabulum - bilateral Views;XR Acetabulum-Bl Views;;ACTIVE;2.00;2.64 +26134-7;Views;Find;Pt;Lower extremity.left>Acetabulum;Doc;XR;RAD;2;XR Acetabulum - left Views;XR Acetabulum-L Views;;ACTIVE;2.00;2.64 +26135-4;Views;Find;Pt;Lower extremity.right>Acetabulum;Doc;XR;RAD;2;XR Acetabulum - right Views;XR Acetabulum-R Views;;ACTIVE;2.00;2.64 +26136-2;Views;Find;Pt;Upper extremity.bilateral>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - bilateral Views;XR AC joint-Bl Views;;ACTIVE;2.00;2.64 +26137-0;Views;Find;Pt;Upper extremity.left>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - left Views;XR AC joint-L Views;;ACTIVE;2.00;2.64 +2613-8;Methemoglobin;PrThr;Pt;Bld;Ord;;CHEM;1;Methemoglobin [Presence] in Blood;MetHgb Bld Ql;;ACTIVE;1.0;2.73 +26138-8;Views;Find;Pt;Upper extremity.right>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - right Views;XR AC joint-R Views;;ACTIVE;2.00;2.64 +26139-6;Views;Find;Pt;Head>Mastoid.bilateral;Doc;XR;RAD;2;XR Mastoid - bilateral Views;XR Mastoid-Bl Views;;ACTIVE;2.00;2.64 +26140-4;Views;Find;Pt;Head>Mastoid.left;Doc;XR;RAD;2;XR Mastoid - left Views;XR Mastoid-L Views;;ACTIVE;2.00;2.73 +26141-2;Views;Find;Pt;Head>Mastoid.right;Doc;XR;RAD;2;XR Mastoid - right Views;XR Mastoid-R Views;;ACTIVE;2.00;2.64 +26142-0;Views;Find;Pt;Head>Optic foramen.bilateral;Doc;XR;RAD;2;XR Optic foramen - bilateral Views;XR Optic foramen-Bl Views;;ACTIVE;2.00;2.64 +26143-8;Views;Find;Pt;Head>Optic foramen.left;Doc;XR;RAD;2;XR Optic foramen - left Views;XR Optic foramen-L Views;;ACTIVE;2.00;2.64 +26144-6;Views;Find;Pt;Head>Optic foramen.right;Doc;XR;RAD;2;XR Optic foramen - right Views;XR Optic foramen-R Views;;ACTIVE;2.00;2.64 +26145-3;Views;Find;Pt;Radius+Ulna.bilateral;Nar;XR.DEXA;RAD;2;Deprecated Radius & Ulna bilateral DEXA Bone density;Deprecated DEXA;;DEPRECATED;2.00;2.46 +2614-6;Methemoglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Blood;MetHgb MFr Bld;;ACTIVE;1.0;2.73 +26146-1;Views;Find;Pt;Upper extremity.bilateral>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - bilateral Views;XR Radius+Ulna-Bl Views;;ACTIVE;2.00;2.64 +26147-9;Views;Find;Pt;Radius+Ulna.left;Nar;XR.DEXA;RAD;2;Deprecated Radius & Ulna left DEXA Bone density;Deprecated DEXA;;DEPRECATED;2.00;2.46 +26148-7;Views;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left Views;XR Radius+Ulna-L Views;;ACTIVE;2.00;2.73 +26149-5;Views;Find;Pt;Radius+Ulna.right;Nar;XR.DEXA;RAD;2;Deprecated Radius & Ulna right DEXA Bone density views;Deprecated DEXA;;DEPRECATED;2.00;2.46 +26150-3;Views;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right Views;XR Radius+Ulna-R Views;;ACTIVE;2.00;2.73 +26151-1;Views;Find;Pt;Chest>Ribs.bilateral;Doc;XR;RAD;2;XR Ribs - bilateral Views;XR Ribs-Bl Views;;ACTIVE;2.00;2.73 +26152-9;Views;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left Views;XR Ribs-L Views;;ACTIVE;2.00;2.73 +2615-3;Methemoglobin/Hemoglobin.total;MFr;Pt;BldA;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Arterial blood;MetHgb MFr BldA;;ACTIVE;1.0;2.73 +26153-7;Views;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right Views;XR Ribs-R Views;;ACTIVE;2.00;2.73 +26154-5;Views;Find;Pt;Chest>Scapula.bilateral;Doc;XR;RAD;2;XR Scapula - bilateral Views;XR Scapula-Bl Views;;ACTIVE;2.00;2.64 +26155-2;Views;Find;Pt;Chest>Scapula.left;Doc;XR;RAD;2;XR Scapula - left Views;XR Scapula-L Views;;ACTIVE;2.00;2.64 +26156-0;Views;Find;Pt;Chest>Scapula.right;Doc;XR;RAD;2;XR Scapula - right Views;XR Scapula-R Views;;ACTIVE;2.00;2.64 +26157-8;Views;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Views;XR Shoulder-Bl Views;;ACTIVE;2.00;2.64 +26158-6;Views;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Views;XR Should-L Views;;ACTIVE;2.00;2.73 +26159-4;Views;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Views;XR Should-R Views;;ACTIVE;2.00;2.73 +26160-2;Views;Find;Pt;Upper extremity.bilateral>Thumb;Doc;XR;RAD;2;XR Thumb - bilateral Views;XR Thumb-Bl Views;;ACTIVE;2.00;2.64 +2616-1;Methemoglobin/Hemoglobin.total;MFr;Pt;BldC;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Capillary blood;MetHgb MFr BldC;;ACTIVE;1.0;2.73 +26161-0;Views;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left Views;XR Thumb-L Views;;ACTIVE;2.00;2.64 +26162-8;Views;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right Views;XR Thumb-R Views;;ACTIVE;2.00;2.73 +26163-6;Views;Find;Pt;Lower extremity.bilateral>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - bilateral Views;XR Tib+Fib-Bl Views;;ACTIVE;2.00;2.64 +26164-4;Views;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left Views;XR Tib+Fib-L Views;;ACTIVE;2.00;2.73 +26165-1;Views;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right Views;XR Tib+Fib-R Views;;ACTIVE;2.00;2.73 +26166-9;Views;Find;Pt;Lower extremity.bilateral>Toes;Doc;XR;RAD;2;XR Toes - bilateral Views;XR Toes-Bl Views;;ACTIVE;2.00;2.64 +26167-7;Views;Find;Pt;Lower extremity.left>Toes;Doc;XR;RAD;2;XR Toes - left Views;XR Toes-L Views;;ACTIVE;2.00;2.64 +26168-5;Views;Find;Pt;Lower extremity.right>Toes;Doc;XR;RAD;2;XR Toes - right Views;XR Toes-R Views;;ACTIVE;2.00;2.73 +26169-3;Views;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Views;XR Wrist-Bl Views;;ACTIVE;2.00;2.64 +26170-1;Views;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Views;XR Wrist-L Views;;ACTIVE;2.00;2.64 +26171-9;Views;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Views;XR Wrist-R Views;;ACTIVE;2.00;2.73 +26172-7;Views;Find;Pt;Head>Zygomatic arch.bilateral;Doc;XR;RAD;2;XR Zygomatic arch - bilateral Views;XR Zygomatic arch-Bl Views;;ACTIVE;2.00;2.64 +26173-5;Views;Find;Pt;Head>Zygomatic arch.left;Doc;XR;RAD;2;XR Zygomatic arch - left Views;XR Zygomatic arch-L Views;;ACTIVE;2.00;2.64 +26174-3;Views;Find;Pt;Head>Zygomatic arch.right;Doc;XR;RAD;2;XR Zygomatic arch - right Views;XR Zygomatic arch-R Views;;ACTIVE;2.00;2.64 +26175-0;Views screening;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Screening;MG Brst-Bl screening;;ACTIVE;2.00;2.73 +26176-8;Views screening;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Screening;MG Brst-L screening;;ACTIVE;2.00;2.61 +26177-6;Views screening;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Screening;MG Brst-R screening;;ACTIVE;2.00;2.73 +26178-4;View runoff^W contrast IA;Find;Pt;Lower extremity.bilateral>Femoral artery;Doc;RF.angio;RAD;2;RFA Femoral artery - bilateral Runoff W contrast IA;RFA Fem a-Bl Runoff W contr IA;;ACTIVE;2.00;2.61 +2617-9;Methemoglobin/Hemoglobin.total;MFr;Pt;BldV;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Venous blood;MetHgb MFr BldV;;ACTIVE;1.0;2.73 +26179-2;View runoff^W contrast IA;Find;Pt;Lower extremity.left>Femoral artery;Doc;RF.angio;RAD;2;RFA Femoral artery - left Runoff W contrast IA;RFA Fem a-L Runoff W contr IA;;ACTIVE;2.00;2.61 +261-8;Fusidate;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Fusidate [Susceptibility] by Minimum lethal concentration (MLC);Fusidate Islt MLC;;ACTIVE;1.0;2.19 +26180-0;View runoff^W contrast IA;Find;Pt;Lower extremity.right>Femoral artery;Doc;RF.angio;RAD;2;RFA Femoral artery - right Runoff W contrast IA;RFA Fem a-R Runoff W contr IA;;ACTIVE;2.00;2.61 +26181-8;Multisection^W contrast IV;Find;Pt;Chest>Thoracic inlet vessels.bilateral;Doc;MR.angio;RAD;2;MRA Thoracic inlet vessels - bilateral W contrast IV;MRA TI ves-Bl W contr IV;;ACTIVE;2.00;2.61 +26182-6;Multisection^W contrast IV;Find;Pt;Chest>Thoracic inlet vessels.left;Doc;MR.angio;RAD;2;MRA Thoracic inlet vessels - left W contrast IV;MRA TI ves-L W contr IV;;ACTIVE;2.00;2.61 +26183-4;Multisection^W contrast IV;Find;Pt;Chest>Thoracic inlet vessels.right;Doc;MR.angio;RAD;2;MRA Thoracic inlet vessels - right W contrast IV;MRA TI ves-R W contr IV;;ACTIVE;2.00;2.61 +26184-2;Multisection^W contrast IV;Find;Pt;Extremity.bilateral;Doc;CT;RAD;2;CT Extremity - bilateral W contrast IV;CT Extr-Bl W contr IV;;ACTIVE;2.00;2.61 +26185-9;Multisection^W contrast IV;Find;Pt;Extremity.left;Doc;CT;RAD;2;CT Extremity - left W contrast IV;CT Extr-L W contr IV;;ACTIVE;2.00;2.61 +26186-7;Multisection^W contrast IV;Find;Pt;Extremity.right;Doc;CT;RAD;2;CT Extremity - right W contrast IV;CT Extr-R W contr IV;;ACTIVE;2.00;2.61 +2618-7;Methemoglobin/Hemoglobin.total;MFr;Pt;RBC;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Red Blood Cells;MetHgb MFr RBC;;ACTIVE;1.0;2.70 +26187-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Ankle;Doc;MR;RAD;2;MR Ankle - bilateral WO and W contrast IV;MR Ankle-Bl WO+W contr IV;;ACTIVE;2.00;2.61 +26188-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Ankle;Doc;MR;RAD;2;MR Ankle - left WO and W contrast IV;MR Ankle-L WO+W contr IV;;ACTIVE;2.00;2.61 +26189-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Ankle;Doc;MR;RAD;2;MR Ankle - right WO and W contrast IV;MR Ankle-R WO+W contr IV;;ACTIVE;2.00;2.61 +26190-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Brachial plexus.bilateral;Doc;MR;RAD;2;MR Brachial plexus - bilateral WO and W contrast IV;MR Brachial plexus-Bl WO+W contr IV;;ACTIVE;2.00;2.61 +26191-7;Multisection^WO & W contrast IV;Find;Pt;Chest>Brachial plexus.left;Doc;MR;RAD;2;MR Brachial plexus - left WO and W contrast IV;MR Brachial plexus-L WO+W contr IV;;ACTIVE;2.00;2.61 +26192-5;Multisection^WO & W contrast IV;Find;Pt;Chest>Brachial plexus.right;Doc;MR;RAD;2;MR Brachial plexus - right WO and W contrast IV;MR Brachial plexus-R WO+W contr IV;;ACTIVE;2.00;2.61 +26193-3;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral>Elbow;Doc;MR;RAD;2;MR Elbow - bilateral WO and W contrast IV;MR Elbow-Bl WO+W contr IV;;ACTIVE;2.00;2.61 +26194-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Elbow;Doc;MR;RAD;2;MR Elbow - left WO and W contrast IV;MR Elbow-L WO+W contr IV;;ACTIVE;2.00;2.61 +2619-5;Methemoglobin;PrThr;Pt;RBC;Ord;;CHEM;1;Methemoglobin [Presence] in Red Blood Cells;MetHgb RBC Ql;;ACTIVE;1.0;2.56 +26195-8;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Elbow;Doc;MR;RAD;2;MR Elbow - right WO and W contrast IV;MR Elbow-R WO+W contr IV;;ACTIVE;2.00;2.61 +26196-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Thigh;Doc;MR;RAD;2;MR Thigh - bilateral WO and W contrast IV;MR Thigh-Bl WO+W contr IV;;ACTIVE;2.00;2.61 +26197-4;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Thigh;Doc;MR;RAD;2;MR Thigh - left WO and W contrast IV;MR Thigh-L WO+W contr IV;;ACTIVE;2.00;2.61 +26198-2;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Thigh;Doc;MR;RAD;2;MR Thigh - right WO and W contrast IV;MR Thigh-R WO+W contr IV;;ACTIVE;2.00;2.61 +26199-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Knee;Doc;MR;RAD;2;MR Knee - bilateral WO and W contrast IV;MR Knee-Bl WO+W contr IV;;ACTIVE;2.00;2.61 +26200-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Knee;Doc;MR;RAD;2;MR Knee - left WO and W contrast IV;MR Knee-L WO+W contr IV;;ACTIVE;2.00;2.61 +26201-4;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Knee;Doc;MR;RAD;2;MR Knee - right WO and W contrast IV;MR Knee-R WO+W contr IV;;ACTIVE;2.00;2.61 +26202-2;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;MR;RAD;2;MR Shoulder - bilateral WO and W contrast IV;MR Shoulder-Bl WO+W contr IV;;ACTIVE;2.00;2.61 +2620-3;Methionine;PrThr;Pt;Bld;Ord;;CHEM;1;Methionine [Presence] in Blood;Methionine Bld Ql;;ACTIVE;1.0;2.56 +26203-0;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Shoulder;Doc;MR;RAD;2;MR Shoulder - left WO and W contrast IV;MR Should-L WO+W contr IV;;ACTIVE;2.00;2.61 +26204-8;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Shoulder;Doc;MR;RAD;2;MR Shoulder - right WO and W contrast IV;MR Should-R WO+W contr IV;;ACTIVE;2.00;2.61 +26205-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral>Wrist;Doc;MR;RAD;2;MR Wrist - bilateral WO and W contrast IV;MR Wrist-Bl WO+W contr IV;;ACTIVE;2.00;2.61 +26206-3;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Wrist;Doc;MR;RAD;2;MR Wrist - left WO and W contrast IV;MR Wrist-L WO+W contr IV;;ACTIVE;2.00;2.61 +26207-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Wrist;Doc;MR;RAD;2;MR Wrist - right WO and W contrast IV;MR Wrist-R WO+W contr IV;;ACTIVE;2.00;2.61 +26208-9;Multisection;Find;Pt;Lower extremity.bilateral>Ankle;Doc;MR;RAD;2;MR Ankle - bilateral;MR Ankle-Bl;;ACTIVE;2.00;2.61 +26209-7;Multisection;Find;Pt;Lower extremity.left>Ankle;Doc;MR;RAD;2;MR Ankle - left;MR Ankle-L;;ACTIVE;2.00;2.61 +26210-5;Multisection;Find;Pt;Lower extremity.right>Ankle;Doc;MR;RAD;2;MR Ankle - right;MR Ankle-R;;ACTIVE;2.00;2.61 +2621-1;Methionine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Methionine [Presence] in Serum or Plasma;Methionine SerPl Ql;;ACTIVE;1.0;2.73 +26211-3;Multisection;Find;Pt;Chest>Brachial plexus.bilateral;Doc;MR;RAD;2;MR Brachial plexus - bilateral;MR Brachial plexus-Bl;;ACTIVE;2.00;2.61 +26212-1;Multisection;Find;Pt;Chest>Brachial plexus.left;Doc;MR;RAD;2;MR Brachial plexus - left;MR Brachial plexus-L;;ACTIVE;2.00;2.61 +26213-9;Multisection;Find;Pt;Chest>Brachial plexus.right;Doc;MR;RAD;2;MR Brachial plexus - right;MR Brachial plexus-R;;ACTIVE;2.00;2.61 +26214-7;Multisection;Find;Pt;Breast.bilateral;Doc;US;RAD;2;US Breast - bilateral;US Brst-Bl;;ACTIVE;2.00;2.73 +26215-4;Multisection;Find;Pt;Breast.left;Doc;US;RAD;2;US Breast - left;US Brst-L;;ACTIVE;2.00;2.73 +26216-2;Multisection;Find;Pt;Breast.right;Doc;US;RAD;2;US Breast - right;US Brst-R;;ACTIVE;2.00;2.73 +26217-0;Multisection;Find;Pt;Head+Neck>Carotid arteries.bilateral;Doc;US;RAD;2;US Carotid arteries - bilateral;US Carotid aa-Bl;;ACTIVE;2.00;2.73 +26218-8;Multisection;Find;Pt;Head+Neck>Carotid arteries.left;Doc;US;RAD;2;US Carotid arteries - left;US Carotid aa-L;;ACTIVE;2.00;2.61 +26219-6;Multisection;Find;Pt;Head+Neck>Carotid arteries.right;Doc;US;RAD;2;US Carotid arteries -right;US Carotid aa-R;;ACTIVE;2.00;2.61 +26220-4;Multisection;Find;Pt;Upper extremity.bilateral>Elbow;Doc;MR;RAD;2;MR Elbow - bilateral;MR Elbow-Bl;;ACTIVE;2.00;2.61 +26221-2;Multisection;Find;Pt;Upper extremity.left>Elbow;Doc;MR;RAD;2;MR Elbow - left;MR Elbow-L;;ACTIVE;2.00;2.61 +26222-0;Multisection;Find;Pt;Upper extremity.right>Elbow;Doc;MR;RAD;2;MR Elbow - right;MR Elbow-R;;ACTIVE;2.00;2.61 +26223-8;Multisection;Find;Pt;Extremity.bilateral;Doc;US;RAD;2;US Extremity - bilateral;US Extr-Bl;;ACTIVE;2.00;2.61 +26224-6;Multisection;Find;Pt;Extremity.bilateral;Doc;CT;RAD;2;CT Extremity - bilateral;CT Extr-Bl;;ACTIVE;2.00;2.61 +26225-3;Multisection;Find;Pt;Extremity.left;Doc;US;RAD;2;US Extremity - left;US Extr-L;;ACTIVE;2.00;2.73 +26226-1;Multisection;Find;Pt;Extremity.left;Doc;CT;RAD;2;CT Extremity - left;CT Extr-L;;ACTIVE;2.00;2.61 +26227-9;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - bilateral;MR LE joint-Bl;;ACTIVE;2.00;2.65 +26228-7;Multisection;Find;Pt;Lower extremity.left>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - left;MR LE joint-L;;ACTIVE;2.00;2.65 +2622-9;Methionine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methionine [Mass/volume] in Serum or Plasma;Methionine SerPl-mCnc;;ACTIVE;1.0;2.73 +26229-5;Multisection;Find;Pt;Lower extremity.right>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - right;MR LE joint-R;;ACTIVE;2.00;2.65 +26230-3;Multisection;Find;Pt;Extremity.right;Doc;US;RAD;2;US Extremity - right;US Extr-R;;ACTIVE;2.00;2.73 +26231-1;Multisection;Find;Pt;Extremity.right;Doc;CT;RAD;2;CT Extremity - right;CT Extr-R;;ACTIVE;2.00;2.61 +26232-9;Multisection;Find;Pt;Upper extremity.bilateral;Doc;MR;RAD;2;MR Upper extremity - bilateral;MR UE-Bl;;ACTIVE;2.00;2.61 +26233-7;Multisection;Find;Pt;Upper extremity.left;Doc;MR;RAD;2;MR Upper extremity - left;MR UE-L;;ACTIVE;2.00;2.61 +26234-5;Multisection;Find;Pt;Upper extremity.right;Doc;MR;RAD;2;MR Upper extremity - right;MR UE-R;;ACTIVE;2.00;2.61 +26235-2;Multisection;Find;Pt;Lower extremity.bilateral>Thigh;Doc;MR;RAD;2;MR Thigh - bilateral;MR Thigh-Bl;;ACTIVE;2.00;2.61 +26236-0;Multisection;Find;Pt;Lower extremity.left>Thigh;Doc;MR;RAD;2;MR Thigh - left;MR Thigh-L;;ACTIVE;2.00;2.61 +2623-7;Methionine;MCnc;Pt;Urine;Qn;;CHEM;1;Methionine [Mass/volume] in Urine;Methionine Ur-mCnc;;ACTIVE;1.0;2.73 +26237-8;Multisection;Find;Pt;Lower extremity.right>Thigh;Doc;MR;RAD;2;MR Thigh - right;MR Thigh-R;;ACTIVE;2.00;2.61 +26238-6;Multisection;Find;Pt;Upper extremity.bilateral>Finger;Doc;MR;RAD;2;MR Finger - bilateral;MR Finger-Bl;;ACTIVE;2.00;2.61 +26239-4;Multisection;Find;Pt;Upper extremity.left>Finger;Doc;MR;RAD;2;MR Finger - left;MR Finger-L;;ACTIVE;2.00;2.61 +26240-2;Multisection;Find;Pt;Upper extremity.right>Finger;Doc;MR;RAD;2;MR Finger - right;MR Finger-R;;ACTIVE;2.00;2.61 +26241-0;Multisection;Find;Pt;Lower extremity.bilateral>Foot;Doc;MR;RAD;2;MR Foot - bilateral;MR Foot-Bl;;ACTIVE;2.00;2.61 +26242-8;Multisection;Find;Pt;Lower extremity.left>Foot;Doc;MR;RAD;2;MR Foot - left;MR Foot-L;;ACTIVE;2.00;2.61 +26243-6;Multisection;Find;Pt;Lower extremity.right>Foot;Doc;MR;RAD;2;MR Foot - right;MR Foot-R;;ACTIVE;2.00;2.61 +26244-4;Multisection;Find;Pt;Upper extremity.bilateral>Forearm;Doc;MR;RAD;2;MR Forearm - bilateral;MR Forearm-Bl;;ACTIVE;2.00;2.61 +2624-5;Methionine;MRat;24H;Urine;Qn;;CHEM;1;Methionine [Mass/time] in 24 hour Urine;Methionine 24h Ur-mRate;;ACTIVE;1.0;2.73 +26245-1;Multisection;Find;Pt;Upper extremity.left>Forearm;Doc;MR;RAD;2;MR Forearm - left;MR Forearm-L;;ACTIVE;2.00;2.61 +26246-9;Multisection;Find;Pt;Upper extremity.right>Forearm;Doc;MR;RAD;2;MR Forearm - right;MR Forearm-R;;ACTIVE;2.00;2.73 +26247-7;Multisection;Find;Pt;Upper extremity.bilateral>Hand;Doc;MR;RAD;2;MR Hand - bilateral;MR Hand-Bl;;ACTIVE;2.00;2.61 +26248-5;Multisection;Find;Pt;Upper extremity.left>Hand;Doc;MR;RAD;2;MR Hand - left;MR Hand-L;;ACTIVE;2.00;2.61 +26249-3;Multisection;Find;Pt;Upper extremity.right>Hand;Doc;MR;RAD;2;MR Hand - right;MR Hand-R;;ACTIVE;2.00;2.61 +26250-1;Multisection;Find;Pt;Lower extremity.bilateral>Hip;Doc;US;RAD;2;US Hip - bilateral;US Hip-Bl;;ACTIVE;2.00;2.61 +26251-9;Multisection;Find;Pt;Lower extremity.left>Hip;Doc;US;RAD;2;US Hip - left;US Hip-L;;ACTIVE;2.00;2.61 +2625-2;Methionine adenosyltransferase;CCnc;Pt;Ser;Qn;;CHEM;1;Methionine adenosyltransferase [Enzymatic activity/volume] in Serum;MAT Ser-cCnc;;ACTIVE;1.0;2.68 +26252-7;Multisection;Find;Pt;Lower extremity.right>Hip;Doc;US;RAD;2;US Hip - right;US Hip-R;;ACTIVE;2.00;2.61 +26253-5;Multisection;Find;Pt;Head>Internal auditory canal.bilateral;Doc;XR.tomography;RAD;2;XR tomography Internal auditory canal - bilateral;XR tomo IAC-Bl;;ACTIVE;2.00;2.61 +26254-3;Multisection;Find;Pt;Head>Internal auditory canal.left;Doc;XR.tomography;RAD;2;XR tomography Internal auditory canal - left;XR tomo IAC-L;;ACTIVE;2.00;2.61 +26255-0;Multisection;Find;Pt;Head>Internal auditory canal.right;Doc;XR.tomography;RAD;2;XR tomography Internal auditory canal - right;XR tomo IAC-R;;ACTIVE;2.00;2.61 +26256-8;Multisection;Find;Pt;Lower extremity.bilateral>Knee;Doc;MR;RAD;2;MR Knee - bilateral;MR Knee-Bl;;ACTIVE;2.00;2.61 +26257-6;Multisection;Find;Pt;Lower extremity.left>Knee;Doc;MR;RAD;2;MR Knee - left;MR Knee-L;;ACTIVE;2.00;2.61 +26258-4;Multisection;Find;Pt;Lower extremity.right>Knee;Doc;MR;RAD;2;MR Knee - right;MR Knee-R;;ACTIVE;2.00;2.61 +26259-2;Multisection;Find;Pt;Pelvis & Lower extremity.bilateral>Hip;Doc;MR;RAD;2;MR Pelvis and Hip - bilateral;MR Pelvis and Hip-Bl;;ACTIVE;2.00;2.73 +262-6;Fusidate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Fusidate [Susceptibility] by Minimum inhibitory concentration (MIC);Fusidate Islt MIC;;ACTIVE;1.0;2.19 +2626-0;Methoxyacetate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methoxyacetate [Mass/volume] in Serum or Plasma;Methoxyacetate SerPl-mCnc;;ACTIVE;1.0;2.34 +26260-0;Multisection;Find;Pt;Pelvis & Lower extremity.left>Hip;Doc;MR;RAD;2;MR Pelvis and Hip - left;MR Pelvis and Hip-L;;ACTIVE;2.00;2.61 +26261-8;Multisection;Find;Pt;Pelvis & Lower extremity.right>Hip;Doc;MR;RAD;2;MR Pelvis and Hip - right;MR Pelvis and Hip-R;;ACTIVE;2.00;2.61 +26262-6;Multisection;Find;Pt;Lower extremity.bilateral>Popliteal space;Doc;US;RAD;2;US Popliteal space - bilateral;US Popliteal space-Bl;;ACTIVE;2.00;2.61 +26263-4;Multisection;Find;Pt;Lower extremity.left>Popliteal space;Doc;US;RAD;2;US Popliteal space - left;US Popliteal space-L;;ACTIVE;2.00;2.61 +26264-2;Multisection;Find;Pt;Lower extremity.right>Popliteal space;Doc;US;RAD;2;US Popliteal space - right;US Popliteal space-R;;ACTIVE;2.00;2.61 +26265-9;Multisection;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;US;RAD;2;US Shoulder - bilateral;US Shoulder-Bl;;ACTIVE;2.00;2.61 +26266-7;Multisection;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;MR;RAD;2;MR Shoulder - bilateral;MR Shoulder-Bl;;ACTIVE;2.00;2.61 +26267-5;Multisection;Find;Pt;Upper extremity.left>Shoulder;Doc;US;RAD;2;US Shoulder - left;US Should-L;;ACTIVE;2.00;2.61 +26268-3;Multisection;Find;Pt;Upper extremity.left>Shoulder;Doc;MR;RAD;2;MR Shoulder - left;MR Should-L;;ACTIVE;2.00;2.61 +26269-1;Multisection;Find;Pt;Upper extremity.right>Shoulder;Doc;US;RAD;2;US Shoulder - right;US Should-R;;ACTIVE;2.00;2.61 +26270-9;Multisection;Find;Pt;Upper extremity.right>Shoulder;Doc;MR;RAD;2;MR Shoulder - right;MR Should-R;;ACTIVE;2.00;2.61 +26271-7;Multisection;Find;Pt;Pelvis>Scrotum.bilateral+Testicle.bilateral;Doc;US;RAD;2;US Scrotum and Testicle - bilateral;US Scrotum+Test-Bl;;ACTIVE;2.00;2.61 +26272-5;Multisection;Find;Pt;Pelvis>Scrotum.left+Testicle.left;Doc;US;RAD;2;US Scrotum and Testicle - left;US Scrotum+Test-L;;ACTIVE;2.00;2.61 +26273-3;Multisection;Find;Pt;Pelvis>Scrotum.right+Testicle.right;Doc;US;RAD;2;US Scrotum and Testicle - right;US Scrotum+Test-R;;ACTIVE;2.00;2.61 +26274-1;Multisection;Find;Pt;Thigh.bilateral;Nar;MRI;RAD;2;Deprecated Thigh Bilateral MRI Multisection;Deprecated Thigh-Bl MRI;;DEPRECATED;2.00;2.46 +26275-8;Multisection;Find;Pt;Thigh.left;Nar;MRI;RAD;2;Deprecated Thigh Left MRI Multisection;Deprecated Thigh-L MRI;;DEPRECATED;2.00;2.46 +26276-6;Multisection;Find;Pt;Thigh.right;Nar;MRI;RAD;2;Deprecated Thigh Right MRI Multisection;Deprecated Thigh-R MRI;;DEPRECATED;2.00;2.46 +26277-4;Multisection;Find;Pt;Upper extremity.bilateral>Wrist;Doc;MR;RAD;2;MR Wrist - bilateral;MR Wrist-Bl;;ACTIVE;2.00;2.61 +2627-8;Methylenetetrahydrofolate dehydrogenase.NAD;CCnc;Pt;Ser;Qn;;CHEM;1;Methylenetetrahydrofolate dehydrogenase NAD [Enzymatic activity/volume] in Serum;MTD.NAD Ser-cCnc;;ACTIVE;1.0;2.68 +26278-2;Multisection;Find;Pt;Upper extremity.bilateral>Wrist;Doc;US;RAD;2;US Wrist - bilateral;US Wrist-Bl;;ACTIVE;2.00;2.61 +26279-0;Multisection;Find;Pt;Upper extremity.left>Wrist;Doc;MR;RAD;2;MR Wrist - left;MR Wrist-L;;ACTIVE;2.00;2.61 +26280-8;Multisection;Find;Pt;Upper extremity.left>Wrist;Doc;US;RAD;2;US Wrist - left;US Wrist-L;;ACTIVE;2.00;2.61 +26281-6;Multisection;Find;Pt;Upper extremity.right>Wrist;Doc;MR;RAD;2;MR Wrist - right;MR Wrist-R;;ACTIVE;2.00;2.61 +26282-4;Multisection;Find;Pt;Upper extremity.right>Wrist;Doc;US;RAD;2;US Wrist - right;US Wrist-R;;ACTIVE;2.00;2.61 +26283-2;View Merchants;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Merchants;XR Knee-Bl Merchants;;ACTIVE;2.00;2.61 +26284-0;View Merchants;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Merchants;XR Knee-L Merchants;;ACTIVE;2.00;2.61 +26285-7;View Merchants;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Merchants;XR Knee-R Merchants;;ACTIVE;2.00;2.61 +2628-6;Methylenetetrahydrofolate dehydrogenase.NADP;CCnc;Pt;Ser;Qn;;CHEM;1;Methylenetetrahydrofolate dehydrogenase NADP [Enzymatic activity/volume] in Serum;MTD.NADP Ser-cCnc;;ACTIVE;1.0;2.68 +26286-5;Multisection limited;Find;Pt;Breast.bilateral;Doc;US;RAD;2;US Breast - bilateral limited;US Brst-Bl Ltd;;ACTIVE;2.00;2.61 +26287-3;Views limited;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Limited Views;MG Brst-Bl Views Ltd;;ACTIVE;2.00;2.64 +26288-1;Multisection limited;Find;Pt;Breast.left;Doc;US;RAD;2;US Breast - left limited;US Brst-L Ltd;;ACTIVE;2.00;2.61 +26289-9;Views limited;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Limited Views;MG Brst-L Views Ltd;;ACTIVE;2.00;2.64 +26290-7;Multisection limited;Find;Pt;Breast.right;Doc;US;RAD;2;US Breast - right limited;US Brst-R Ltd;;ACTIVE;2.00;2.61 +26291-5;Views limited;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Limited Views;MG Brst-R Views Ltd;;ACTIVE;2.00;2.64 +26292-3;Guidance for percutaneous biopsy;Find;Pt;Breast.bilateral;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for biopsy of Breast - bilateral;MG.stereo Guided Brst-Bl Bx;;ACTIVE;2.00;2.64 +26293-1;Guidance for percutaneous biopsy;Find;Pt;Breast.left;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for biopsy of Breast - left;MG.stereo Guided Brst-L Bx;;ACTIVE;2.00;2.64 +2629-4;Methylmalonate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonate [Mass/volume] in Serum or Plasma;Methylmalonate SerPl-mCnc;;ACTIVE;1.0;2.73 +26294-9;Guidance for percutaneous biopsy;Find;Pt;Breast.right;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for biopsy of Breast - right;MG.stereo Guided Brst-R Bx;;ACTIVE;2.00;2.64 +26295-6;Guidance for reposition of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for reposition of CV catheter in Vein - bilateral-- W contrast IV;RFA Guided Vein-Bl CVC repos--W contr IV;;ACTIVE;2.00;2.64 +26296-4;Guidance for reposition of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Guidance for reposition of CV catheter in Vein - left-- W contrast IV;RFA Guided Vein-L CVC repos--W contr IV;;ACTIVE;2.00;2.64 +26297-2;Guidance for reposition of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Guidance for reposition of CV catheter in Vein - right-- W contrast IV;RFA Guided Vein-R CVC repos--W contr IV;;ACTIVE;2.00;2.64 +26298-0;Guidance for atherectomy^W contrast IV;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Vein - bilateral-- W contrast IV;RFA Guided Vein-Bl Atherect--W contr IV;;ACTIVE;2.00;2.64 +26299-8;Guidance for atherectomy^W contrast IV;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Vein - left-- W contrast IV;RFA Guided Vein-L Atherect--W contr IV;;ACTIVE;2.00;2.64 +26300-4;Guidance for atherectomy^W contrast IV;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Vein - right-- W contrast IV;RFA Guided Vein-R Atherect--W contr IV;;ACTIVE;2.00;2.64 +26301-2;Guidance for placement of stent;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Vein - bilateral;RFA Guided Vein-Bl Stent place;;ACTIVE;2.00;2.64 +2630-2;Methylmalonate;MCnc;Pt;Urine;Qn;;CHEM;1;Methylmalonate [Mass/volume] in Urine;Methylmalonate Ur-mCnc;;ACTIVE;1.0;2.73 +26302-0;Guidance for placement of stent;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Vein - left;RFA Guided Vein-L Stent place;;ACTIVE;2.00;2.64 +26303-8;Guidance for placement of stent;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Vein - right;RFA Guided Vein-R Stent place;;ACTIVE;2.00;2.64 +26304-6;Guidance for placement of peripherally-inserted central venous catheter;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for placement of peripherally-inserted central venous catheter in Vein - bilateral;RFA Guided Vein-Bl PICC place;;ACTIVE;2.00;2.64 +26305-3;Guidance for placement of peripherally-inserted central venous catheter;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Guidance for placement of peripherally-inserted central venous catheter in Vein - left;RFA Guided Vein-L PICC place;;ACTIVE;2.00;2.64 +26306-1;Guidance for placement of peripherally-inserted central venous catheter;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Guidance for placement of peripherally-inserted central venous catheter in Vein - right;RFA Guided Vein-R PICC place;;ACTIVE;2.00;2.64 +26307-9;Guidance for placement of large bore central venous catheter;Find;Pt;XXX>Vein.bilateral;Doc;{Imaging modality};RAD;2;Guidance for placement of large bore CV catheter in Vein - bilateral;Guided Vein-Bl LB CVC place;;ACTIVE;2.00;2.64 +26308-7;Guidance for placement of large bore central venous catheter;Find;Pt;XXX>Vein.left;Doc;{Imaging modality};RAD;2;Guidance for placement of large bore CV catheter in Vein - left;Guided Vein-L LB CVC place;;ACTIVE;2.00;2.64 +26309-5;Guidance for placement of large bore central venous catheter;Find;Pt;XXX>Vein.right;Doc;{Imaging modality};RAD;2;Guidance for placement of large bore CV catheter in Vein - right;Guided Vein-R LB CVC place;;ACTIVE;2.00;2.64 +2631-0;Methylmalonyl CoA mutase;CCnc;Pt;Ser;Qn;;CHEM;1;Methylmalonyl CoA mutase [Enzymatic activity/volume] in Serum;MCM Ser-cCnc;;ACTIVE;1.0;2.68 +26310-3;Guidance for placement of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for placement of CV catheter in Vein - bilateral-- W contrast IV;RFA Guided Vein-Bl CVC place--W contr IV;;ACTIVE;2.00;2.64 +26311-1;Guidance for placement of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Guidance for placement of CV catheter in Vein - left-- W contrast IV;RFA Guided Vein-L CVC place--W contr IV;;ACTIVE;2.00;2.64 +26312-9;Guidance for placement of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Guidance for placement of CV catheter in Vein - right-- W contrast IV;RFA Guided Vein-R CVC place--W contr IV;;ACTIVE;2.00;2.64 +26313-7;Guidance for needle localization;Find;Pt;Breast.bilateral;Doc;US;RAD;2;US Guidance for needle localization of Breast - bilateral;US Guided Brst-Bl Needle loc;;ACTIVE;2.00;2.64 +26314-5;Guidance for needle localization;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for needle localization of Breast - left;US Guided Brst-L Needle loc;;ACTIVE;2.00;2.64 +26315-2;Guidance for needle localization of mass;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Guidance for needle localization of mass of Breast - bilateral;MG Guided Brst-Bl Needle loc mass;;ACTIVE;2.00;2.64 +26316-0;Guidance for needle localization of mass;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for needle localization of mass of Breast - left;MG Guided Brst-L Needle loc mass;;ACTIVE;2.00;2.64 +26317-8;Guidance for needle localization of mass;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for needle localization of mass of Breast - right;MG Guided Brst-R Needle loc mass;;ACTIVE;2.00;2.64 +26318-6;Guidance for needle localization;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for needle localization of Breast - right;US Guided Brst-R Needle loc;;ACTIVE;2.00;2.64 +26319-4;Guidance for injection;Find;Pt;Pelvis>Sacroiliac joint.bilateral;Doc;CT;RAD;2;CT Guidance for injection of Sacroiliac joint - bilateral;CT Guided SIJ-Bl Inj;;ACTIVE;2.00;2.64 +26320-2;Guidance for injection;Find;Pt;Pelvis>Sacroiliac joint.left;Doc;CT;RAD;2;CT Guidance for injection of Sacroiliac joint - left;CT Guided SIJ-L Inj;;ACTIVE;2.00;2.64 +26321-0;Guidance for injection;Find;Pt;Pelvis>Sacroiliac joint.right;Doc;CT;RAD;2;CT Guidance for injection of Sacroiliac joint - right;CT Guided SIJ-R Inj;;ACTIVE;2.00;2.64 +26322-8;Guidance for injection;Find;Pt;XXX>Spine facet joint.bilateral;Doc;RF;RAD;2;RF Guidance for injection of Spine facet joint - bilateral;RF Guided Spine facet joint-Bl Inj;;ACTIVE;2.00;2.64 +26323-6;Guidance for injection;Find;Pt;XXX>Spine facet joint.left;Doc;RF;RAD;2;RF Guidance for injection of Spine facet joint - left;RF Guided Spine facet joint-L Inj;;ACTIVE;2.00;2.64 +26324-4;Guidance for injection;Find;Pt;XXX>Spine facet joint.right;Doc;RF;RAD;2;RF Guidance for injection of Spine facet joint - right;RF Guided Spine facet joint-R Inj;;ACTIVE;2.00;2.64 +26325-1;Guidance for drainage+placement of drainage catheter;Find;Pt;Extremity.bilateral;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Extremity - bilateral;US Guided Extr-Bl Drain+cath place;;ACTIVE;2.00;2.66 +26326-9;Guidance for drainage+placement of drainage catheter;Find;Pt;Extremity.left;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Extremity - left;US Guided Extr-L Drain+cath place;;ACTIVE;2.00;2.66 +26327-7;Guidance for drainage+placement of drainage catheter;Find;Pt;Extremity.right;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Extremity - right;US Guided Extr-R Drain+cath place;;ACTIVE;2.00;2.66 +2632-8;methylTESTOSTERone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methyltestosterone [Presence] in Urine;MeT Ur Ql;;ACTIVE;1.0;2.73 +26328-5;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Kidney.bilateral;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Kidney - bilateral;US Guided Kdny-Bl Drain+cath place;;ACTIVE;2.00;2.66 +26329-3;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Kidney.left;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Kidney - left;US Guided Kidney-L Drain+cath place;;ACTIVE;2.00;2.66 +26330-1;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Kidney.right;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Kidney - right;US Guided Kidney-R Drain+cath place;;ACTIVE;2.00;2.66 +26331-9;Guidance for change of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for change of CV catheter in Vein - bilateral-- W contrast IV;RFA Guided Vein-Bl CVC change--W cont IV;;ACTIVE;2.00;2.64 +26332-7;Guidance for change of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Guidance for change of CV catheter in Vein - left-- W contrast IV;RFA Guided Vein-L CVC change--W contr IV;;ACTIVE;2.00;2.64 +26333-5;Guidance for change of central venous catheter^W contrast IV;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Guidance for change of CV catheter in Vein - right-- W contrast IV;RFA Guided Vein-R CVC change--W contr IV;;ACTIVE;2.00;2.64 +26334-3;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Guidance for percutaneous biopsy.core needle of Breast - bilateral;MG Guided Brst-Bl PC Bx CN;;ACTIVE;2.00;2.64 +26335-0;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for percutaneous biopsy.core needle of Breast - left;MG Guided Brst-L PC Bx CN;;ACTIVE;2.00;2.64 +2633-6;methylTESTOSTERone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyltestosterone [Mass/volume] in Urine;MeT Ur-mCnc;;ACTIVE;1.0;2.42 +26336-8;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for percutaneous biopsy.core needle of Breast - right;MG Guided Brst-R PC Bx CN;;ACTIVE;2.00;2.64 +26337-6;Guidance for percutaneous biopsy;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Guidance for biopsy of Breast - bilateral;MG Guided Brst-Bl Bx;;ACTIVE;2.00;2.64 +26338-4;Guidance for percutaneous biopsy;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for biopsy of Breast - left;MG Guided Brst-L Bx;;ACTIVE;2.00;2.64 +26339-2;Guidance for percutaneous biopsy;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for biopsy of Breast - right;MG Guided Brst-R Bx;;ACTIVE;2.00;2.64 +263-4;Fusidate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Fusidate [Susceptibility] by Disk diffusion (KB);Fusidate Islt KB;;ACTIVE;1.0;2.21 +26340-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.bilateral;Doc;US;RAD;2;US Guidance for biopsy of Kidney - bilateral;US Guided Kdny-Bl Bx;;ACTIVE;2.00;2.64 +26341-8;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.left;Doc;US;RAD;2;US Guidance for biopsy of Kidney - left;US Guided Kidney-L Bx;;ACTIVE;2.00;2.64 +26342-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.right;Doc;US;RAD;2;US Guidance for biopsy of Kidney - right;US Guided Kidney-R Bx;;ACTIVE;2.00;2.64 +26343-4;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Guidance for aspiration of cyst of Breast - bilateral;MG Guided Brst-Bl Cyst asp;;ACTIVE;2.00;2.64 +2634-4;methylTESTOSTERone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Methyltestosterone [Mass/time] in 24 hour Urine;MeT 24h Ur-mRate;;ACTIVE;1.0;2.42 +26344-2;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for aspiration of cyst of Breast - left;MG Guided Brst-L Cyst asp;;ACTIVE;2.00;2.64 +26345-9;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for aspiration of cyst of Breast - right;MG Guided Brst-R Cyst asp;;ACTIVE;2.00;2.64 +26346-7;Views diagnostic;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Diagnostic;MG Brst-Bl Dx;;ACTIVE;2.00;2.61 +26347-5;Views diagnostic;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Diagnostic;MG Brst-L Dx;;ACTIVE;2.00;2.61 +26348-3;Views diagnostic;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Diagnostic;MG Brst-R Dx;;ACTIVE;2.00;2.61 +26349-1;Views limited diagnostic;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Diagnostic Limited Views;MG Brst-Bl Views Dx Ltd;;ACTIVE;2.00;2.64 +26350-9;Views limited diagnostic;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Diagnostic Limited Views;MG Brst-L Views Dx Ltd;;ACTIVE;2.00;2.64 +2635-1;Mianserin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mianserin [Mass/volume] in Serum or Plasma;Mianserin SerPl-mCnc;;ACTIVE;1.0;2.42 +26351-7;Views limited diagnostic;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Diagnostic Limited Views;MG Brst-R Views Dx Ltd;;ACTIVE;2.00;2.64 +26352-5;Views bone age;Find;Pt;Upper extremity.bilateral>Wrist+Hand;Doc;XR;RAD;2;XR Wrist - bilateral and Hand - bilateral Bone age Views;XR Wrist+Hand-Bl Views bone Age;;ACTIVE;2.00;2.64 +26353-3;Views bone age;Find;Pt;Upper extremity.left>Wrist+Hand;Doc;XR;RAD;2;XR Wrist - left and Hand - left Bone age Views;XR Wrist+Hand-L Views bone Age;;ACTIVE;2.00;2.64 +26354-1;Views bone age;Find;Pt;Upper extremity.right>Wrist+Hand;Doc;XR;RAD;2;XR Wrist - right and Hand - right Bone age Views;XR Wrist+Hand-R Views bone Age;;ACTIVE;2.00;2.64 +26355-8;View arthritis;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral Arthritis;XR Hand-Bl Arthritis;;ACTIVE;2.00;2.61 +26356-6;View arthritis;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left Arthritis;XR Hand-L Arthritis;;ACTIVE;2.00;2.61 +26357-4;View arthritis;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right Arthritis;XR Hand-R Arthritis;;ACTIVE;2.00;2.61 +26358-2;View AP^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP W standing;XR Knee-Bl AP W Stand;;ACTIVE;2.00;2.61 +26359-0;View AP^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP W standing;XR Knee-L AP W Stand;;ACTIVE;2.00;2.61 +26360-8;View AP^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP W standing;XR Knee-R AP W Stand;;ACTIVE;2.00;2.61 +26361-6;Views AP + PA^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and PA W standing;XR Knee-Bl AP+PA W Stand;;DISCOURAGED;2.00;2.61 +26362-4;Views AP + PA^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and PA W standing;XR Knee-L AP+PA W Stand;;DISCOURAGED;2.00;2.61 +26363-2;Views AP + PA^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and PA W standing;XR Knee-R AP+PA W Stand;;DISCOURAGED;2.00;2.61 +26364-0;Views AP + lateral^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral W standing;XR Knee-Bl AP+Lat W Stand;;ACTIVE;2.00;2.61 +26365-7;Views AP + lateral^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral W standing;XR Knee-L AP+Lat W Stand;;ACTIVE;2.00;2.61 +26366-5;Views AP + lateral^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and Lateral W standing;XR Knee-R AP+Lat W Stand;;ACTIVE;2.00;2.61 +26367-3;Angioplasty^W contrast IA;Find;Pt;Brachiocephalic artery.bilateral;Nar;XR.fluor.angio;RAD;2;Deprecated Brachiocephalic artery - bilateral Fluoroscopic angiogram Angioplasty W contrast IA;Deprecated BrachCeph a-Bl XRA Angpsty W;;DEPRECATED;2.00;2.34 +26368-1;Angioplasty^W contrast IA;Find;Pt;Brachiocephalic artery.left;Doc;XR.fluor.angio;RAD;2;Deprecated Brachiocephalic artery - left Fluoroscopic angiogram Angioplasty W contrast IA;Deprecated BrachCeph a-L XRA Angpsty W c;;DEPRECATED;2.00;2.58 +2636-9;Mianserin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mianserin [Mass/volume] in Urine;Mianserin Ur-mCnc;;ACTIVE;1.0;2.42 +26369-9;Angioplasty^W contrast IA;Find;Pt;Brachiocephalic artery.right;Doc;XR.fluor.angio;RAD;2;Deprecated Brachiocephalic artery - right Fluoroscopic angiogram Angioplasty W contrast IA;Deprecated BrachCeph a-R XRA Angpsty W c;;DEPRECATED;2.00;2.58 +26370-7;Guidance for angioplasty^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Iliac artery - bilateral-- W contrast IA;RFA Guided Iliac a-Bl Angio--W contr IA;;ACTIVE;2.00;2.64 +26371-5;Guidance for angioplasty^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.left;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Iliac artery - left-- W contrast IA;RFA Guided Iliac a-L Angio--W contr IA;;ACTIVE;2.00;2.64 +26372-3;Guidance for angioplasty^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.right;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Iliac artery - right-- W contrast IA;RFA Guided Iliac a-R Angio--W contr IA;;ACTIVE;2.00;2.64 +26373-1;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity.bilateral>Tibial artery;Doc;RF.angio;RAD;2;Deprecated RFA Guidance for angioplasty of Tibial artery - bilateral-- W contrast IA;Deprecated RFA Tibl a-Bl Angio guide W contr IA;;DEPRECATED;2.00;2.64 +26374-9;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity.left>Tibial artery;Doc;RF.angio;RAD;2;Deprecated RFA Guidance for angioplasty of Tibial artery - left-- W contrast IA;Deprecated RFA Tibl a-L Angio guide W contr IA;;DEPRECATED;2.00;2.64 +26375-6;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity.right>Tibial artery;Doc;RF.angio;RAD;2;Deprecated RFA Guidance for angioplasty of Tibial artery - right-- W contrast IA;Deprecated RFA Tibl a-R Angio guide W contr IA;;DEPRECATED;2.00;2.64 +26376-4;Administration of vasodilator into catheter;Find;Pt;XXX>Vein.bilateral;Doc;;DOC.MISC;2;Administration of vasodilator into catheter Vein - bilateral;VD admin into cath Vein-Bl;;ACTIVE;2.00;2.63 +2637-7;Mucoprotein;MCnc;Pt;Ser;Qn;;CHEM;1;Mucoprotein [Mass/volume] in Serum;Mucoprotein Ser-mCnc;;ACTIVE;1.0;2.42 +26377-2;Administration of vasodilator into catheter;Find;Pt;XXX>Vein.left;Doc;;DOC.MISC;2;Administration of vasodilator into catheter Vein - left;VD admin into cath Vein-L;;ACTIVE;2.00;2.63 +26378-0;Administration of vasodilator into catheter;Find;Pt;XXX>Vein.right;Doc;;DOC.MISC;2;Administration of vasodilator into catheter Vein - right;VD admin into cath Vein-R;;ACTIVE;2.00;2.63 +26379-8;Views 3;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral 3 Views;XR Hand-Bl 3V;;ACTIVE;2.00;2.73 +26380-6;Views 3;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left 3 Views;XR Hand-L 3V;;ACTIVE;2.00;2.73 +26381-4;Views 3;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right 3 Views;XR Hand-R 3V;;ACTIVE;2.00;2.73 +26382-2;Views 3;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral 3 Views;XR Shoulder-Bl 3V;;ACTIVE;2.00;2.61 +26383-0;Views 3;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 3 Views;XR Should-L 3V;;ACTIVE;2.00;2.61 +26384-8;Views 3;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right 3 Views;XR Should-R 3V;;ACTIVE;2.00;2.61 +2638-5;Myelin basic protein;MCnc;Pt;CSF;Qn;;CHEM;1;Myelin basic protein [Mass/volume] in Cerebral spinal fluid;MBP CSF-mCnc;;ACTIVE;1.0;2.73 +26385-5;Views 2;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral 2 Views;XR Ankle-Bl 2V;;ACTIVE;2.00;2.73 +26386-3;Views 2;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left 2 Views;XR Ankle-L 2V;;ACTIVE;2.00;2.73 +26387-1;Views 2;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right 2 Views;XR Ankle-R 2V;;ACTIVE;2.00;2.61 +26388-9;Views 2;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral 2 Views;XR Hand-Bl 2V;;ACTIVE;2.00;2.61 +26389-7;Views 2;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left 2 Views;XR Hand-L 2V;;ACTIVE;2.00;2.73 +26390-5;Views 2;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right 2 Views;XR Hand-R 2V;;ACTIVE;2.00;2.73 +26391-3;Views 2;Find;Pt;Upper extremity.bilateral>Humerus;Doc;XR;RAD;2;XR Humerus - bilateral 2 Views;XR Humerus-Bl 2V;;ACTIVE;2.00;2.61 +26392-1;Views 2;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left 2 Views;XR Humerus-L 2V;;ACTIVE;2.00;2.73 +2639-3;Myoglobin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Myoglobin [Mass/volume] in Serum or Plasma;Myoglobin SerPl-mCnc;;ACTIVE;1.0;2.73 +26393-9;Views 2;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right 2 Views;XR Humerus-R 2V;;ACTIVE;2.00;2.73 +26394-7;Views 2;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 2 Views;XR Knee-Bl 2V;;ACTIVE;2.00;2.61 +26395-4;Views 2;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 2 Views;XR Knee-L 2V;;ACTIVE;2.00;2.73 +26396-2;Views 2;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 Views;XR Knee-R 2V;;ACTIVE;2.00;2.73 +26397-0;Views 2;Find;Pt;Lower extremity.bilateral>Patella;Doc;XR;RAD;2;XR Patella - bilateral 2 Views;XR Patella-Bl 2V;;ACTIVE;2.00;2.61 +26398-8;Views 2;Find;Pt;Lower extremity.left>Patella;Doc;XR;RAD;2;XR Patella - left 2 Views;XR Patella-L 2V;;ACTIVE;2.00;2.61 +26399-6;Views 2;Find;Pt;Lower extremity.right>Patella;Doc;XR;RAD;2;XR Patella - right 2 Views;XR Patella-R 2V;;ACTIVE;2.00;2.61 +26400-2;View;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Single view;XR Hip-Bl 1V;;ACTIVE;2.00;2.64 +2640-1;Myoglobin;PrThr;Pt;Urine;Ord;;CHEM;1;Myoglobin [Presence] in Urine;Myoglobin Ur Ql;;ACTIVE;1.0;2.73 +26401-0;View;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Single view;XR Hip-L 1V;;ACTIVE;2.00;2.64 +26402-8;View;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Single view;XR Hip-R 1V;;ACTIVE;2.00;2.64 +26403-6;Alternaria alternata Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata IgG4 Ab [Units/volume] in Serum;A alternata IgG4 Qn;;ACTIVE;2.00;2.69 +26404-4;Alternaria alternata Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alternaria alternata IgG4 Ab RAST class [Presence] in Serum;A alternata IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26405-1;Aspergillus fumigatus Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus IgG4 Ab [Units/volume] in Serum;A fumigatus IgG4 Qn;;ACTIVE;2.00;2.69 +26406-9;Aspergillus fumigatus Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus IgG4 Ab RAST class [Presence] in Serum;A fumigatus IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26407-7;Apis mellifera Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee IgG4 Ab [Units/volume] in Serum;Honey bee IgG4 Qn;;ACTIVE;2.00;2.69 +26408-5;Apis mellifera Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee IgG4 Ab RAST class [Presence] in Serum;Honey bee IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26409-3;Betula verrucosa Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch IgG4 Ab [Units/volume] in Serum;Silver Birch IgG4 Qn;;ACTIVE;2.00;2.69 +26410-1;Betula verrucosa Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch IgG4 Ab RAST class [Presence] in Serum;Silver Birch IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26411-9;Bran wheat Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat Bran IgG4 Ab [Units/volume] in Serum;Wheat Bran IgG4 Qn;;ACTIVE;2.00;2.69 +26412-7;Bran wheat Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat Bran IgG4 Ab RAST class [Presence] in Serum;Wheat Bran IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26413-5;Candida albicans Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Candida albicans IgG4 Ab [Units/volume] in Serum;C albicans IgG4 Qn;;ACTIVE;2.00;2.68 +26414-3;Candida albicans Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Candida albicans IgG4 Ab RAST class [Presence] in Serum;C albicans IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26415-0;Casein Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Casein IgG4 Ab [Units/volume] in Serum;Casein IgG4 Qn;;ACTIVE;2.00;2.69 +26416-8;Casein Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Casein IgG4 Ab RAST class [Presence] in Serum;Casein IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26417-6;Cladosporium herbarum Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum IgG4 Ab [Units/volume] in Serum;C herbarum IgG4 Qn;;ACTIVE;2.00;2.69 +26418-4;Cladosporium herbarum Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cladosporium herbarum IgG4 Ab RAST class [Presence] in Serum;C herbarum IgG4 RAST Ql;;ACTIVE;2.00;2.58 +2641-9;Myoglobin;MCnc;Pt;Urine;Qn;;CHEM;1;Myoglobin [Mass/volume] in Urine;Myoglobin Ur-mCnc;;ACTIVE;1.0;2.73 +26419-2;Dermatophagoides farinae Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite IgG4 Ab [Units/volume] in Serum;D farinae IgG4 Qn;;ACTIVE;2.00;2.69 +264-2;Fusidate;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Fusidate [Susceptibility] by Serum bactericidal titer;Fusidate Titr SBT;;ACTIVE;1.0;2.32 +26420-0;Dermatophagoides farinae Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;American house dust mite IgG4 Ab RAST class [Presence] in Serum;D farinae IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26421-8;Dermatophagoides pteronyssinus Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite IgG4 Ab [Units/volume] in Serum;D pteronyss IgG4 Qn;;ACTIVE;2.00;2.69 +26422-6;Dermatophagoides pteronyssinus Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European house dust mite IgG4 Ab RAST class [Presence] in Serum;D pteronyss IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26423-4;Egg white Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Egg white IgG4 Ab [Units/volume] in Serum;Egg White IgG4 Qn;;ACTIVE;2.00;2.69 +26424-2;Egg white Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Egg white IgG4 Ab RAST class [Presence] in Serum;Egg White IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26425-9;Lactalbumin alpha Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin alpha IgG4 Ab [Units/volume] in Serum;A-Lactalb IgG4 Qn;;ACTIVE;2.00;2.69 +26426-7;Lactalbumin alpha Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactalbumin alpha IgG4 Ab RAST class [Presence] in Serum;A-Lactalb IgG4 RAST Ql;;ACTIVE;2.00;2.58 +2642-7;Myoglobin;MRat;24H;Urine;Qn;;CHEM;1;Myoglobin [Mass/time] in 24 hour Urine;Myoglobin 24h Ur-mRate;;ACTIVE;1.0;2.42 +26427-5;Lactoglobulin Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactoglobulin IgG4 Ab [Units/volume] in Serum;Lactoglob IgG4 Qn;;ACTIVE;2.00;2.69 +26428-3;Oryza sativa Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rice IgG4 Ab [Units/volume] in Serum;Rice IgG4 Qn;;ACTIVE;2.00;2.69 +26429-1;Oryza sativa Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rice IgG4 Ab RAST class [Presence] in Serum;Rice IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26430-9;Phleum pratense Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy IgG4 Ab [Units/volume] in Serum;Timothy IgG4 Qn;;ACTIVE;2.00;2.69 +26431-7;Phleum pratense Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy IgG4 Ab RAST class [Presence] in Serum;Timothy IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26432-5;Wasp venom Ab.IgG4;ACnc;Pt;Ser/Plas;Qn;;ALLERGY;1;Wasp venom IgG4 Ab [Units/volume] in Serum or Plasma;Wasp Venom IgG4 Qn;;ACTIVE;2.00;2.69 +26433-3;Wasp venom Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wasp venom IgG4 Ab RAST class [Presence] in Serum;Wasp Venom IgG4 RAST Ql;;ACTIVE;2.00;2.58 +26434-1;Lactoglobulin Ab.IgG4.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactoglobulin IgG4 Ab RAST class [Presence] in Serum;Lactoglob IgG4 RAST Ql;;ACTIVE;2.00;2.58 +2643-5;N-acetyl-beta-glucosaminidase;CCnc;Pt;Ser;Qn;;CHEM;1;N-acetyl-beta-glucosaminidase [Enzymatic activity/volume] in Serum;B-NAG Ser-cCnc;;ACTIVE;1.0;2.73 +26435-8;Molecular pathology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Molecular pathology studies (set);;;ACTIVE;2.00;2.00 +26436-6;Laboratory studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Laboratory studies (set);;;ACTIVE;2.00;2.27 +26437-4;Chemistry challenge studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Chemistry challenge studies (set);;;ACTIVE;2.00;2.27 +26438-2;Cytology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Cytology studies (set);;;ACTIVE;2.00;2.00 +26439-0;Surgical pathology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Surgical pathology studies (set);;;ACTIVE;2.00;2.73 +26441-6;Cardiology studies;Cmplx;-;^Patient;Set;;ATTACH.CARD;3;Cardiology studies (set);;;ACTIVE;2.00;2.00 +26442-4;Obstetrical studies;Cmplx;-;^Patient;Set;;ATTACH.OBS;3;Obstetrical studies (set);;;ACTIVE;2.00;2.00 +2644-3;Alpha-N-acetylglucosaminidase;CCnc;Pt;Urine;Qn;;CHEM;1;Alpha-N-acetylglucosaminidase [Enzymatic activity/volume] in Urine;A-NAG Ur-cCnc;;ACTIVE;1.0;2.70 +26443-2;Clinical reports.non lab claims attachment;Cmplx;-;^Patient;Set;;ATTACH;3;Clinical reports.non lab claims attachment;;;ACTIVE;2.00;2.67 +26444-0;Basophils;NCnc;Pt;Bld;Qn;;HEM/BC;1;Basophils [#/volume] in Blood;Basophils # Bld;;ACTIVE;2.00;2.73 +26445-7;Basophils/100 leukocytes;NFr;Pt;XXX;Qn;;HEM/BC;1;Basophils/100 leukocytes in Specimen;Basophils/leuk NFr Spec;;ACTIVE;2.00;2.70 +26446-5;Blasts/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Blasts/100 leukocytes in Blood;Blasts/leuk NFr Bld;;ACTIVE;2.00;2.73 +26447-3;Blasts/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Blasts/100 leukocytes in Cerebral spinal fluid;Blasts/leuk NFr CSF;;ACTIVE;2.00;2.73 +26448-1;Blasts/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Blasts/100 leukocytes in Body fluid;Blasts/leuk NFr Fld;;ACTIVE;2.00;2.73 +26449-9;Eosinophils;NCnc;Pt;Bld;Qn;;HEM/BC;1;Eosinophils [#/volume] in Blood;Eosinophil # Bld;;ACTIVE;2.00;2.73 +2645-0;N-Acetylgalactosamine-4-Sulfatase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/volume] in Amniotic fluid;Arylsulfatase B Amn-cCnc;;ACTIVE;1.0;2.42 +26450-7;Eosinophils/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Blood;Eosinophil/leuk NFr Bld;;ACTIVE;2.00;2.73 +26451-5;Eosinophils/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Cerebral spinal fluid;Eosinophil/leuk NFr CSF;;ACTIVE;2.00;2.73 +26452-3;Eosinophils/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Body fluid;Eosinophil/leuk NFr Fld;;ACTIVE;2.00;2.73 +26453-1;Erythrocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Blood;RBC # Bld;;ACTIVE;2.00;2.73 +26454-9;Erythrocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Cerebral spinal fluid;RBC # CSF;;ACTIVE;2.00;2.73 +26455-6;Erythrocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Body fluid;RBC # Fld;;ACTIVE;2.00;2.73 +26456-4;Erythrocytes;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Pleural fluid;RBC # Plr;;ACTIVE;2.00;2.73 +26457-2;Erythrocytes;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Peritoneal fluid;RBC # Prt;;ACTIVE;2.00;2.73 +26458-0;Erythrocytes;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Synovial fluid;RBC # Snv;;ACTIVE;2.00;2.73 +26459-8;Erythrocytes.nucleated;NCnc;Pt;CSF;Qn;;HEM/BC;1;Nucleated erythrocytes [#/volume] in Cerebral spinal fluid;nRBC # CSF;;ACTIVE;2.00;2.44 +26460-6;Erythrocytes.nucleated;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Nucleated erythrocytes [#/volume] in Body fluid;nRBC # Fld;;ACTIVE;2.00;2.73 +26461-4;Erythrocytes.nucleated/100 erythrocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Nucleated erythrocytes/100 erythrocytes in Blood;nRBC/100 RBC NFr Bld;;DISCOURAGED;2.00;2.73 +26462-2;Large unstained cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Large unstained cells [#/volume] in Blood;LUC # Bld;;ACTIVE;2.00;2.70 +26463-0;Large unstained cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Large unstained cells/100 leukocytes in Blood;LUC/leuk NFr Bld;;ACTIVE;2.00;2.70 +26464-8;Leukocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Blood;WBC # Bld;;ACTIVE;2.00;2.73 +26465-5;Leukocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Leukocytes [#/volume] in Cerebral spinal fluid;WBC # CSF;;ACTIVE;2.00;2.73 +26466-3;Leukocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Body fluid;WBC # Fld;;ACTIVE;2.00;2.73 +26467-1;Leukocytes;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Pleural fluid;WBC # Plr;;ACTIVE;2.00;2.73 +2646-8;N-Acetylgalactosamine-4-Sulfatase;CCnc;Pt;Ser;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/volume] in Serum;Arylsulfatase B Ser-cCnc;;ACTIVE;1.0;2.68 +26468-9;Leukocytes;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Peritoneal fluid;WBC # Prt;;ACTIVE;2.00;2.73 +26469-7;Leukocytes;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Synovial fluid;WBC # Snv;;ACTIVE;2.00;2.73 +26470-5;Leukocytes other;NCnc;Pt;CSF;Qn;;HEM/BC;1;Leukocytes other [#/volume] in Cerebral spinal fluid;WBC Other # CSF;;ACTIVE;2.00;2.44 +26471-3;Leukocytes other/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Blood;WBC Other/leuk NFr Bld;;ACTIVE;2.00;2.73 +26472-1;Leukocytes other/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Cerebral spinal fluid;WBC Other/leuk NFr CSF;;ACTIVE;2.00;2.73 +26473-9;Leukocytes other/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Body fluid;WBC Other/leuk NFr Fld;;ACTIVE;2.00;2.73 +26474-7;Lymphocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes [#/volume] in Blood;Lymphocytes # Bld;;ACTIVE;2.00;2.73 +26475-4;Lymphocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Lymphocytes [#/volume] in Cerebral spinal fluid;Lymphocytes # CSF;;ACTIVE;2.00;2.73 +2647-6;N-Acetylgalactosamine-4-Sulfatase;CCnt;Pt;Tiss;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/mass] in Tissue;Arylsulfatase B Tiss-cCnt;;ACTIVE;1.0;2.42 +26476-2;Lymphocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Lymphocytes [#/volume] in Body fluid;Lymphocytes # Fld;;ACTIVE;2.00;2.73 +26477-0;Lymphocytes.variant;NCnc;Pt;Bld;Qn;;HEM/BC;1;Variant lymphocytes [#/volume] in Blood;Variant Lymphs # Bld;;ACTIVE;2.00;2.73 +26478-8;Lymphocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Blood;Lymphocytes/leuk NFr Bld;;ACTIVE;2.00;2.73 +26479-6;Lymphocytes/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Cerebral spinal fluid;Lymphocytes/leuk NFr CSF;;ACTIVE;2.00;2.73 +26480-4;Lymphocytes/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Pericardial fluid;Lymphocytes/leuk NFr Pcar;;ACTIVE;2.00;2.70 +26481-2;Lymphocytes/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Pleural fluid;Lymphocytes/leuk NFr Plr;;ACTIVE;2.00;2.73 +26482-0;Lymphocytes/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Peritoneal fluid;Lymphocytes/leuk NFr Prt;;ACTIVE;2.00;2.73 +26483-8;Lymphocytes/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Synovial fluid;Lymphocytes/leuk NFr Snv;;ACTIVE;2.00;2.73 +2648-4;N-Acetylgalactosamine-4-Sulfatase;CCnc;Pt;WBC;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/volume] in Leukocytes;Arylsulfatase B WBC-cCnc;;ACTIVE;1.0;2.73 +26484-6;Monocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Monocytes [#/volume] in Blood;Monocytes # Bld;;ACTIVE;2.00;2.73 +26485-3;Monocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Blood;Monocytes/leuk NFr Bld;;ACTIVE;2.00;2.73 +26486-1;Monocytes/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Cerebral spinal fluid;Monocytes/leuk NFr CSF;;ACTIVE;2.00;2.73 +26487-9;Monocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Body fluid;Monocytes/leuk NFr Fld;;ACTIVE;2.00;2.73 +26488-7;Monocytes/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Peritoneal fluid;Monocytes/leuk NFr Prt;;ACTIVE;2.00;2.73 +26489-5;Mononuclear cells;NCnc;Pt;CSF;Qn;;HEM/BC;1;Mononuclear cells [#/volume] in Cerebral spinal fluid;Mononuc Cells # CSF;;ACTIVE;2.00;2.44 +26490-3;Mononuclear cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Mononuclear cells [#/volume] in Body fluid;Mononuc Cells # Fld;;ACTIVE;2.00;2.73 +26491-1;Mononuclear cells;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Mononuclear cells [#/volume] in Synovial fluid;Mononuc Cells # Snv;;ACTIVE;2.00;2.44 +2649-2;N-Acetylgalactosamine-6-Sulfatase;CCnt;Pt;Tiss;Qn;;CHEM;1;N-Acetylgalactosamine-6-Sulfatase [Enzymatic activity/mass] in Tissue;GALNS Tiss-cCnt;;ACTIVE;1.0;2.42 +26492-9;Mononuclear cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Cerebral spinal fluid;Mononuc Cells/leuk NFr CSF;;ACTIVE;2.00;2.73 +26493-7;Mononuclear cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Body fluid;Mononuc Cells/leuk NFr Fld;;ACTIVE;2.00;2.73 +26494-5;Mononuclear cells/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Pleural fluid;Mononuc Cells/leuk NFr Plr;;ACTIVE;2.00;2.70 +26495-2;Mononuclear cells/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Peritoneal fluid;Mononuc Cells/leuk NFr Prt;;ACTIVE;2.00;2.70 +26496-0;Mononuclear cells/100 leukocytes;NFr;Pt;Semen;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Semen;Mononuc Cells/leuk NFr Smn;;ACTIVE;2.00;2.70 +26497-8;Mononuclear cells/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Synovial fluid;Mononuc Cells/leuk NFr Snv;;ACTIVE;2.00;2.73 +26498-6;Myelocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Myelocytes/100 leukocytes in Blood;Myelocytes/leuk NFr Bld;;ACTIVE;2.00;2.73 +26499-4;Neutrophils;NCnc;Pt;Bld;Qn;;HEM/BC;1;Neutrophils [#/volume] in Blood;Neutrophils # Bld;;ACTIVE;2.00;2.73 +26-5;Amphotericin B;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Amphotericin B [Susceptibility] by Serum bactericidal titer;Amphotericin B Titr SBT;;ACTIVE;1.0;2.32 +2650-0;N-Acetylglucosamine-6-Sulfatase;CCnc;Pt;Ser;Qn;;CHEM;1;N-Acetylglucosamine-6-Sulfatase [Enzymatic activity/volume] in Serum;NAG6Sulfatase Ser-cCnc;;ACTIVE;1.0;2.68 +26500-9;Neutrophils;NCnc;Pt;CSF;Qn;;HEM/BC;1;Neutrophils [#/volume] in Cerebral spinal fluid;Neutrophils # CSF;;ACTIVE;2.00;2.44 +26501-7;Neutrophils;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Neutrophils [#/volume] in Pleural fluid;Neutrophils # Plr;;ACTIVE;2.00;2.44 +26502-5;Neutrophils;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Neutrophils [#/volume] in Peritoneal fluid;Neutrophils # Prt;;ACTIVE;2.00;2.73 +26503-3;Neutrophils;NCnc;Pt;Semen;Qn;;FERT;1;Neutrophils [#/volume] in Semen;Neutrophils # Smn;;ACTIVE;2.00;2.42 +26504-1;Neutrophils;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Neutrophils [#/volume] in Synovial fluid;Neutrophils # Snv;;ACTIVE;2.00;2.73 +26505-8;Neutrophils.segmented/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Segmented neutrophils/100 leukocytes in Blood;Neuts Seg/leuk NFr Bld;;ACTIVE;2.00;2.73 +26506-6;Neutrophils.segmented/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Segmented neutrophils/100 leukocytes in Cerebral spinal fluid;Neuts Seg/leuk NFr CSF;;ACTIVE;2.00;2.73 +26507-4;Neutrophils.band form;NCnc;Pt;Bld;Qn;;HEM/BC;1;Band form neutrophils [#/volume] in Blood;Neuts Band # Bld;;ACTIVE;2.00;2.73 +26508-2;Neutrophils.band form/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Band form neutrophils/100 leukocytes in Blood;Neuts Band/leuk NFr Bld;;ACTIVE;2.00;2.73 +26509-0;Neutrophils.band form/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Band form neutrophils/100 leukocytes in Cerebral spinal fluid;Neuts Band/leuk NFr CSF;;ACTIVE;2.00;2.73 +26510-8;Neutrophils.band form/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Band form neutrophils/100 leukocytes in Body fluid;Neuts Band/leuk NFr Fld;;ACTIVE;2.00;2.73 +26511-6;Neutrophils/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Blood;Neutrophils/leuk NFr Bld;;ACTIVE;2.00;2.73 +26512-4;Neutrophils/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Cerebral spinal fluid;Neutrophils/leuk NFr CSF;;ACTIVE;2.00;2.73 +26513-2;Neutrophils/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Body fluid;Neutrophils/leuk NFr Fld;;ACTIVE;2.00;2.73 +26514-0;Neutrophils/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Peritoneal fluid;Neutrophils/leuk NFr Prt;;ACTIVE;2.00;2.70 +26515-7;Platelets;NCnc;Pt;Bld;Qn;;HEM/BC;1;Platelets [#/volume] in Blood;Platelet # Bld;;ACTIVE;2.00;2.73 +26516-5;Platelets;NCnc;Pt;Plas;Qn;;HEM/BC;1;Platelets [#/volume] in Plasma;Platelet # Plas;;ACTIVE;2.00;2.46 +26517-3;Polymorphonuclear cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Cerebral spinal fluid;Polys/leuk NFr CSF;;ACTIVE;2.00;2.73 +2651-8;NADH dehydrogenase;CCnc;Pt;Plas;Qn;;CHEM;1;NADH dehydrogenase [Enzymatic activity/volume] in Plasma;NADH Dehydrog Plas-cCnc;;ACTIVE;1.0;2.68 +26518-1;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Body fluid;Polys/leuk NFr Fld;;ACTIVE;2.00;2.73 +26519-9;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Pleural fluid;Polys/leuk NFr Plr;;ACTIVE;2.00;2.73 +26520-7;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Peritoneal fluid;Polys/leuk NFr Prt;;ACTIVE;2.00;2.73 +26521-5;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Semen;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Semen;Polys/leuk NFr Smn;;ACTIVE;2.00;2.70 +26522-3;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Synovial fluid;Polys/leuk NFr Snv;;ACTIVE;2.00;2.73 +26523-1;Promyelocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Promyelocytes [#/volume] in Blood;Promyelocytes # Bld;;ACTIVE;2.00;2.73 +26524-9;Promyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Promyelocytes/100 leukocytes in Blood;Promyelocytes/leuk NFr Bld;;ACTIVE;2.00;2.73 +26525-6;Cortisol.free^24H post dose corticotropin;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --24 hours post dose corticotropin;Cortis F 24h p ACTH 24h Ur-mCnc;;ACTIVE;2.00;2.34 +2652-6;NADH dehydrogenase;CCnc;Pt;RBC;Qn;;CHEM;1;NADH dehydrogenase [Enzymatic activity/volume] in Red Blood Cells;NADH Dehydrog RBC-cCnc;;ACTIVE;1.0;2.44 +26526-4;Cortisol.free^48H post dose corticotropin;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --48 hours post dose corticotropin;Cortis F 48h p ACTH 24h Ur-mCnc;;ACTIVE;2.00;2.34 +26527-2;Cortisol.free^72H post dose corticotropin;MCnc;24H;Urine;Qn;;CHAL;1;Cortisol Free [Mass/volume] in 24 hour Urine --72 hours post dose corticotropin;Cortis F 72h p ACTH 24h Ur-mCnc;;ACTIVE;2.00;2.34 +26528-0;Cortisol^1H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin;Cortis 1h p ACTH SerPl-mCnc;;ACTIVE;2.00;2.73 +26529-8;Cortisol^24H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --24 hours post dose corticotropin;Cortis 24h p ACTH SerPl-mCnc;;ACTIVE;2.00;2.73 +26530-6;Cortisol^30M post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes post dose corticotropin;Cortis 30M p ACTH SerPl-mCnc;;ACTIVE;2.00;2.73 +26531-4;Cortisol^32H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --32 hours post dose corticotropin;Cortis 32h p ACTH SerPl-mCnc;;ACTIVE;2.00;2.40 +26532-2;Cortisol^48H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --48 hours post dose corticotropin;Cortis 48h p ACTH SerPl-mCnc;;ACTIVE;2.00;2.40 +26533-0;Cortisol^56H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --56 hours post dose corticotropin;Cortis 56h p ACTH SerPl-mCnc;;ACTIVE;2.00;2.40 +2653-4;Cytochrome b5 reductase;MCnc;Pt;RBC;Qn;;CHEM;1;Cytochrome B5 reductase [Mass/volume] in Red Blood Cells;CyB5 Reduct RBC-mCnc;;DISCOURAGED;1.0;2.66 +26534-8;Cortisol^8H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 hours post dose corticotropin;Cortis 8h p ACTH SerPl-mCnc;;ACTIVE;2.00;2.40 +26535-5;Cortisol^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;Cortis 30M p ACTH SerPl-sCnc;;ACTIVE;2.00;2.73 +26536-3;Cortisol^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;Cortis 1h p ACTH SerPl-sCnc;;ACTIVE;2.00;2.73 +26537-1;Glucose^2.5H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --2.5 hours post dose glucose;Glucose 2.5h p Glc Ur Ql Strip;;ACTIVE;2.00;2.56 +26538-9;Glucose^3.5H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --3.5 hours post dose glucose;Glucose 3.5h p Glc Ur Ql Strip;;ACTIVE;2.00;2.56 +26539-7;Glucose^45M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose glucose;Glucose 45M p Glc SerPl-mCnc;;ACTIVE;2.00;2.73 +26540-5;Glucose^3H post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --3 hours post dose glucose;Glucose 3h p Glc Ur-mCnc;;ACTIVE;2.00;2.73 +26541-3;Glucose^4H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 hours post dose glucose;Glucose 4h p Glc SerPl-mCnc;;ACTIVE;2.00;2.73 +2654-2;Neurophysin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Neurophysin [Mass/volume] in Serum or Plasma;Neurophysin SerPl-mCnc;;ACTIVE;1.0;2.42 +26542-1;Glucose^5H post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --5 hours post dose glucose;Glucose 5h p Glc Ur-mCnc;;ACTIVE;2.00;2.34 +26543-9;Glucose^5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post dose glucose;Glucose 5h p Glc SerPl-mCnc;;ACTIVE;2.00;2.73 +26544-7;Glucose^6H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 hours post dose glucose;Glucose 6h p Glc SerPl-mCnc;;ACTIVE;2.00;2.73 +26545-4;Glucose^6H post dose glucose;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --6 hours post dose glucose;Glucose 6h p Glc Ur-mCnc;;ACTIVE;2.00;2.34 +26546-2;Glucose^1H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --1 hour post dose glucose;Glucose 1h p Glc Ur Ql Strip;;ACTIVE;2.00;2.73 +26547-0;Glucose^2H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --2 hours post dose glucose;Glucose 2h p Glc Ur Ql Strip;;ACTIVE;2.00;2.73 +26548-8;Glucose^30M post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --30 minutes post dose glucose;Glucose 30M p Glc Ur Ql Strip;;ACTIVE;2.00;2.73 +26549-6;Glucose^3H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --3 hours post dose glucose;Glucose 3h p Glc Ur Ql Strip;;ACTIVE;2.00;2.73 +26550-4;Glucose^4H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --4 hours post dose glucose;Glucose 4h p Glc Ur Ql Strip;;ACTIVE;2.00;2.73 +26551-2;Glucose^5H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --5 hours post dose glucose;Glucose 5h p Glc Ur Ql Strip;;ACTIVE;2.00;2.56 +26552-0;Glucose^6H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --6 hours post dose glucose;Glucose 6h p Glc Ur Ql Strip;;ACTIVE;2.00;2.56 +26553-8;Glucose^1.5H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --1.5 hours post dose glucose;Glucose 1.5h p Glc Ur Ql Strip;;ACTIVE;2.00;2.56 +26554-6;Glucose^2.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.5 hours post dose glucose;Glucose 2.5h p Glc SerPl-mCnc;;ACTIVE;2.00;2.73 +26555-3;Glucose^3.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3.5 hours post dose glucose;Glucose 3.5h p Glc SerPl-mCnc;;ACTIVE;2.00;2.73 +26556-1;Cells.CD103/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD103 cells/100 cells in Specimen;CD103 Cells NFr Spec;;ACTIVE;2.00;2.73 +26557-9;Cells.CD11b+CD56+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11b+CD56+ cells/100 cells in Specimen;CD11b+CD56+ Cells NFr Spec;;ACTIVE;2.00;2.70 +26558-7;Cells.CD11c+CD25+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11c+CD25+ cells/100 cells in Specimen;CD11c+CD25+ Cells NFr Spec;;ACTIVE;2.00;2.73 +2655-9;Neurotensin;MCnc;Pt;Plas;Qn;;CHEM;1;Neurotensin [Mass/volume] in Plasma;Neurotensin Plas-mCnc;;ACTIVE;1.0;2.73 +26559-5;Cells.CD38+CD56+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD38+CD56+ cells/100 cells in Specimen;CD38+CD56+ Cells NFr Spec;;ACTIVE;2.00;2.70 +26560-3;Cells.CD16/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD16 cells/100 cells in Specimen;CD16 Cells NFr Spec;;ACTIVE;2.00;2.73 +26561-1;Cells.CD16+CD56+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD16+CD56+ cells [#/volume] in Specimen;CD16+CD56+ Cells # Spec;;ACTIVE;2.00;2.73 +26562-9;Cells.CD19+CD38+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+CD38+ cells/100 cells in Specimen;CD19+CD38+ Cells NFr Spec;;ACTIVE;2.00;2.73 +26563-7;Cells.CD1a/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD1a cells/100 cells in Specimen;CD1a Cells NFr Spec;;ACTIVE;2.00;2.73 +26564-5;Cells.CD30;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD30 cells [#/volume] in Specimen;CD30 Cells # Spec;;ACTIVE;2.00;2.70 +26565-2;Cells.CD19+Kappa+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+Kappa+ cells/100 cells in Specimen;CD19+Kappa+ Cells NFr Spec;;ACTIVE;2.00;2.73 +26566-0;Cells.CD19+Lambda+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+Lambda+ cells/100 cells in Specimen;CD19+Lambda+ Cells NFr Spec;;ACTIVE;2.00;2.73 +2656-7;Niacin;MRat;24H;Urine;Qn;;CHEM;1;Niacin [Mass/time] in 24 hour Urine;Niacin 24h Ur-mRate;;ACTIVE;1.0;2.42 +26567-8;Lymphocytes.IgA/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;IgA lymphocytes/100 lymphocytes in Specimen;Lymphs IgA/lymph NFr Spec;;ACTIVE;2.00;2.73 +26568-6;Cells.CD3+HLA-DR+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+HLA-DR+ cells [#/volume] in Blood;CD3+HLA-DR+ Cells # Bld;;ACTIVE;2.00;2.73 +26569-4;Cells.CD4+CD29+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD29+ cells [#/volume] in Blood;CD4+CD29+ Cells # Bld;;ACTIVE;2.00;2.70 +26570-2;Cells.CD4+CD45+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45+ cells [#/volume] in Blood;CD4+CD45+ Cells # Bld;;ACTIVE;2.00;2.73 +26571-0;Cells.CD16;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD16 cells [#/volume] in Blood;CD16 Cells # Bld;;ACTIVE;2.00;2.70 +26572-8;Cells.CD2+CD7+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD2+CD7+ cells/100 cells in Blood;CD2+CD7+ Cells NFr Bld;;ACTIVE;2.00;2.70 +26573-6;Cells.CD4+CD45+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45+ cells/100 cells in Blood;CD4+CD45+ Cells NFr Bld;;ACTIVE;2.00;2.73 +26574-4;1-Methylhistidine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;1-Methylhistidine/Creatinine [Molar ratio] in Urine;1Me-hist/Creat Ur-sRto;;ACTIVE;2.00;2.73 +2657-5;Nitrite;MCnc;Pt;Urine;Qn;;CHEM;1;Nitrite [Mass/volume] in Urine;Nitrite Ur-mCnc;;ACTIVE;1.0;2.73 +26575-1;3-Methylhistidine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methylhistidine/Creatinine [Molar ratio] in Urine;3Me-histidine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26576-9;Anserine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Anserine/Creatinine [Molar ratio] in Urine;Anserine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26577-7;Asparagine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Asparagine/Creatinine [Molar ratio] in Urine;Asparagine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26578-5;Beta alanine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Beta alanine/Creatinine [Molar ratio] in Urine;B-Alanine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26579-3;Beta aminoisobutyrate/Creatinine;SCrto;Pt;Urine;Qn;;CHEM;1;Deprecated Beta aminoisobutyrate/Creatinine [Molecular ratio] in Urine;Deprecated B-AIB/creat Ur-sRto;;DEPRECATED;2.00;2.70 +26580-1;Carnosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Carnosine/Creatinine [Molar ratio] in Urine;Carnosine/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26581-9;Gamma aminobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Gamma aminobutyrate/Creatinine [Molar ratio] in Urine;GABA/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26582-7;Homocysteine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homocysteine/Creatinine [Molar ratio] in Urine;Hcys/Creat Ur-sRto;;ACTIVE;2.00;2.73 +2658-3;Nitrogen;MCnc;Pt;Exhl gas;Qn;;CHEM;1;Nitrogen [Mass/volume] in Exhaled gas;N2 ExG-mCnc;;ACTIVE;1.0;2.34 +26583-5;3-Hydroxy,3-Methylglutarate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;3-Hydroxy,3-Methylglutarate/Creatinine [Molar ratio] in Urine;3OH3Me-glutarate/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26584-3;1-Methylhistidine;SCnc;Pt;CSF;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in Cerebral spinal fluid;1Me-hist CSF-sCnc;;ACTIVE;2.00;2.73 +26585-0;3-Methylhistidine;SCnc;Pt;CSF;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in Cerebral spinal fluid;3Me-histidine CSF-sCnc;;ACTIVE;2.00;2.73 +26586-8;Alpha aminobutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in Cerebral spinal fluid;A-Aminobutyr CSF-sCnc;;ACTIVE;2.00;2.73 +26587-6;Alpha aminoadipate;SCnc;Pt;CSF;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in Cerebral spinal fluid;AAA CSF-sCnc;;ACTIVE;2.00;2.73 +26588-4;Anserine;SCnc;Pt;CSF;Qn;;CHEM;1;Anserine [Moles/volume] in Cerebral spinal fluid;Anserine CSF-sCnc;;ACTIVE;2.00;2.73 +26589-2;Beta alanine;SCnc;Pt;CSF;Qn;;CHEM;1;Beta alanine [Moles/volume] in Cerebral spinal fluid;B-Alanine CSF-sCnc;;ACTIVE;2.00;2.73 +265-9;Ganciclovir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ganciclovir [Susceptibility];Ganciclovir Susc Islt;;ACTIVE;1.0;2.61 +26590-0;Beta aminoisobutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/volume] in Cerebral spinal fluid;B-AIB CSF-sCnc;;ACTIVE;2.00;2.73 +2659-1;Nitrogen;Mass;24H;Stool;Qn;;CHEM;1;Deprecated Nitrogen;Deprecated Nitrogen 24H Stl Qn;;DEPRECATED;1.0;2.36 +26591-8;Carnosine;SCnc;Pt;CSF;Qn;;CHEM;1;Carnosine [Moles/volume] in Cerebral spinal fluid;Carnosine CSF-sCnc;;ACTIVE;2.00;2.73 +26592-6;Cystathionine;SCnc;Pt;CSF;Qn;;CHEM;1;Cystathionine [Moles/volume] in Cerebral spinal fluid;Cystathionin CSF-sCnc;;ACTIVE;2.00;2.73 +26593-4;Ethanolamine;SCnc;Pt;CSF;Qn;;CHEM;1;Ethanolamine [Moles/volume] in Cerebral spinal fluid;Ethanolamine CSF-sCnc;;ACTIVE;2.00;2.73 +26594-2;Gamma aminobutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in Cerebral spinal fluid;GABA CSF-sCnc;;ACTIVE;2.00;2.73 +26595-9;Hydroxylysine;SCnc;Pt;CSF;Qn;;CHEM;1;Hydroxylysine [Moles/volume] in Cerebral spinal fluid;OH-Lysine CSF-sCnc;;ACTIVE;2.00;2.73 +26596-7;Hydroxyproline;SCnc;Pt;CSF;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in Cerebral spinal fluid;OH-Proline CSF-sCnc;;ACTIVE;2.00;2.73 +26597-5;Phosphoethanolamine;SCnc;Pt;CSF;Qn;;CHEM;1;Phosphoethanolamine [Moles/volume] in Cerebral spinal fluid;PETN CSF-sCnc;;ACTIVE;2.00;2.73 +26598-3;Sarcosine;SCnc;Pt;CSF;Qn;;CHEM;1;Sarcosine [Moles/volume] in Cerebral spinal fluid;Sarcosine CSF-sCnc;;ACTIVE;2.00;2.73 +26599-1;Anserine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Anserine [Moles/volume] in Serum or Plasma;Anserine SerPl-sCnc;;ACTIVE;2.00;2.73 +26600-7;Alpha aminoadipate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in Serum or Plasma;AAA SerPl-sCnc;;ACTIVE;2.00;2.73 +26601-5;Alpha aminoadipate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha aminoadipate/Creatinine [Molar ratio] in Urine;AAA/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26602-3;Tryptophan;SCnc;Pt;CSF;Qn;;CHEM;1;Tryptophan [Moles/volume] in Cerebral spinal fluid;Tryptophan CSF-sCnc;;ACTIVE;2.00;2.73 +26603-1;Asparagine;SCnc;Pt;CSF;Qn;;CHEM;1;Asparagine [Moles/volume] in Cerebral spinal fluid;Asparagine CSF-sCnc;;ACTIVE;2.00;2.73 +26604-9;Beta alanine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta alanine [Moles/volume] in Serum or Plasma;B-Alanine SerPl-sCnc;;ACTIVE;2.00;2.73 +26605-6;Beta aminoisobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/volume] in Serum or Plasma;B-AIB SerPl-sCnc;;ACTIVE;2.00;2.73 +26606-4;Carnosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carnosine [Moles/volume] in Serum or Plasma;Carnosine SerPl-sCnc;;ACTIVE;2.00;2.73 +26607-2;Cystathionine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystathionine [Moles/volume] in Serum or Plasma;Cystathionin SerPl-sCnc;;ACTIVE;2.00;2.73 +26608-0;Ethanolamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ethanolamine [Moles/volume] in Serum or Plasma;Ethanolamine SerPl-sCnc;;ACTIVE;2.00;2.73 +2660-9;Nitrogen;MRat;24H;Urine;Qn;;CHEM;1;Nitrogen [Mass/time] in 24 hour Urine;N2 24h Ur-mRate;;ACTIVE;1.0;2.73 +26609-8;Gamma aminobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in Serum or Plasma;GABA SerPl-sCnc;;ACTIVE;2.00;2.73 +26610-6;Hydroxylysine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxylysine [Moles/volume] in Serum or Plasma;OH-Lysine SerPl-sCnc;;ACTIVE;2.00;2.73 +26611-4;Phosphoethanolamine;SRat;24H;Urine;Qn;;CHEM;1;Phosphoethanolamine [Moles/time] in 24 hour Urine;PETN 24h Ur-sRate;;ACTIVE;2.00;2.73 +26612-2;Phosphoethanolamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphoethanolamine [Moles/volume] in Serum or Plasma;PETN SerPl-sCnc;;ACTIVE;2.00;2.73 +26613-0;Sarcosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sarcosine [Moles/volume] in Serum or Plasma;Sarcosine SerPl-sCnc;;ACTIVE;2.00;2.73 +26614-8;Taurine;SCnc;Pt;CSF;Qn;;CHEM;1;Taurine [Moles/volume] in Cerebral spinal fluid;Taurine CSF-sCnc;;ACTIVE;2.00;2.73 +26615-5;Erythrocytes.CD55;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD55 RBC [Presence] in Blood;CD55 RBC Bld Ql;;ACTIVE;2.00;2.73 +26616-3;Erythrocytes.CD59;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD59 RBC [Presence] in Blood;CD59 RBC Bld Ql;;ACTIVE;2.00;2.73 +2661-7;Nitrogen.nonprotein;PrThr;Pt;Bld;Ord;;CHEM;1;Nitrogen.nonprotein [Presence] in Blood;Nitrogen Nonprotein Bld Ql;;ACTIVE;1.0;2.56 +26617-1;Trypanosoma brucei gambiense Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma brucei gambiense Ab [Presence] in Serum;T brucei gamb Ab Ser Ql;;ACTIVE;2.00;2.56 +26618-9;Trypanosoma brucei rhodesiense Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma brucei rhodesiense Ab [Presence] in Serum;T brucei rhodes Ab Ser Ql;;ACTIVE;2.00;2.56 +26619-7;Campylobacter sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Campylobacter sp Ab [Presence] in Serum;Campylobacter Ab Ser Ql;;ACTIVE;2.00;2.56 +26620-5;Hantavirus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hantavirus IgG Ab [Presence] in Serum;Hantavirus IgG Ser Ql;;ACTIVE;2.00;2.73 +26621-3;Legionella sp Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Legionella sp Ag [Presence] in Specimen;Legionella Ag Spec Ql;;ACTIVE;2.00;2.73 +26622-1;Babesia duncani Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia duncani Ab [Presence] in Serum;B duncani Ab Ser Ql;;ACTIVE;2.00;2.56 +26623-9;Chikungunya virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chikungunya virus Ab [Presence] in Serum;CHIKV Ab Ser Ql;;ACTIVE;2.00;2.73 +26624-7;Rickettsia conorii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia conorii Ab [Presence] in Serum;R conorii Ab Ser Ql;;ACTIVE;2.00;2.56 +2662-5;Nitrogen.nonprotein;MCnc;Pt;Bld;Qn;;CHEM;1;Nitrogen.nonprotein [Mass/volume] in Blood;Nitrogen Nonprotein Bld-mCnc;;ACTIVE;1.0;2.42 +26625-4;Coccidioides sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coccidioides sp Ab [Presence] in Serum;Coccidioides Ab Ser Ql;;ACTIVE;2.00;2.56 +26626-2;Chlamydia trachomatis L2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis L2 Ab [Presence] in Serum;C trach L2 Ab Ser Ql;;ACTIVE;2.00;2.56 +26627-0;Legionella polyvalent A Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella polyvalent A Ab [Presence] in Serum;Legionella Polyval A Ab Ser Ql;;ACTIVE;2.00;2.56 +26628-8;Legionella polyvalent B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella polyvalent B Ab [Presence] in Serum;Legionella Polyval B Ab Ser Ql;;ACTIVE;2.00;2.56 +26629-6;Legionella polyvalent C Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella polyvalent C Ab [Presence] in Serum;Legionella Polyval C Ab Ser Ql;;ACTIVE;2.00;2.56 +26630-4;Corynebacterium diphtheriae toxin Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Corynebacterium diphtheriae toxin Ab [Presence] in Serum;C diphtheriae Tox Ab Ser Ql;;ACTIVE;2.00;2.56 +26631-2;Borrelia hermsii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia hermsii Ab [Presence] in Serum;B hermsii Ab Ser Ql;;ACTIVE;2.00;2.56 +26632-0;Legionella dumoffii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella dumoffii Ab [Presence] in Serum;L dumoffii Ab Ser Ql;;ACTIVE;2.00;2.56 +2663-3;Nitrogen.nonprotein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Nitrogen.nonprotein [Mass/volume] in Serum or Plasma;Nitrogen Nonprotein SerPl-mCnc;;ACTIVE;1.0;2.42 +26633-8;Legionella bozemaniae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella bozemaniae Ab [Presence] in Serum;L bozemaniae Ab Ser Ql;;ACTIVE;2.00;2.56 +26634-6;Legionella gormanii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella gormanii Ab [Presence] in Serum;L gormanii Ab Ser Ql;;ACTIVE;2.00;2.56 +26635-3;Legionella micdadei Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella micdadei Ab [Presence] in Serum;L micdadei Ab Ser Ql;;ACTIVE;2.00;2.56 +26636-1;Candida sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Candida sp Ab [Presence] in Serum;Candida Ab Ser Ql;;ACTIVE;2.00;2.73 +26637-9;Leishmania braziliensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania brasilensis Ab [Presence] in Serum;L braziliensis Ab Ser Ql;;ACTIVE;2.00;2.56 +26638-7;Leishmania donovani Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania donovani Ab [Presence] in Serum;L donovani Ab Ser Ql;;ACTIVE;2.00;2.56 +26639-5;Leishmania tropica Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania tropica Ab [Presence] in Serum;L tropica Ab Ser Ql;;ACTIVE;2.00;2.56 +26640-3;Paracoccidioides brasiliensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Paracoccidioides brasiliensis Ab [Presence] in Serum;P brasilien Ab Ser Ql;;ACTIVE;2.00;2.73 +2664-1;Nitrogen;Mass;24H;Stool;Qn;;CHEM;1;Deprecated Nitrogen 24H Stl Qn;Deprecated Nitrogen 24H Stl Qn;;DEPRECATED;1.0;2.36 +26641-1;Histoplasma sp Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Histoplasma capsulatum Ab [Presence] in Serum;Deprecated Histoplasma Ab Ser Ql;;DEPRECATED;2.00;2.36 +26642-9;Jamestown canyon virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Jamestown canyon virus Ab [Presence] in Serum;JCV Ab Ser Ql;;ACTIVE;2.00;2.73 +26643-7;Clostridium tetani toxoid Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Clostridium tetani toxoid Ab [Presence] in Serum;C tetani Toxoid Ab Ser Ql;;ACTIVE;2.00;2.73 +26644-5;Getah virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Getah virus Ab [Presence] in Serum;GETV Ab Ser Ql;;ACTIVE;2.00;2.56 +26645-2;BK virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;BK virus Ab [Presence] in Serum;BKV Ab Ser Ql;;ACTIVE;2.00;2.56 +26646-0;Powassan virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Powassan virus Ab [Presence] in Serum;POWV Ab Ser Ql;;ACTIVE;2.00;2.56 +26647-8;Semliki forest virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Semliki Forest virus Ab [Presence] in Serum;SFV Ab Ser Ql;;ACTIVE;2.00;2.56 +26648-6;Sindbis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Sindbis virus Ab [Presence] in Serum;SINV Ab Ser Ql;;ACTIVE;2.00;2.56 +26649-4;Snowshoe hare virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Snowshoe hare virus Ab [Presence] in Serum;SSHV Ab Ser Ql;;ACTIVE;2.00;2.56 +26650-2;Hantavirus sin nombre Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hantavirus sin nombre IgM Ab [Presence] in Serum;SNV IgM Ser Ql;;ACTIVE;2.00;2.73 +26651-0;Rhizopus arrhizus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rhizopus arrhizus Ab [Presence] in Serum;R arrhizus Ab Ser Ql;;ACTIVE;2.00;2.56 +26652-8;Banzi virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Banzi virus Ab [Presence] in Serum;BANV Ab Ser Ql;;ACTIVE;2.00;2.56 +26653-6;Colorado tick fever virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Colorado tick fever virus Ab [Presence] in Serum;CTFV Ab Ser Ql;;ACTIVE;2.00;2.56 +26654-4;Hantavirus sin nombre Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hantavirus sin nombre IgG Ab [Presence] in Serum;SNV IgG Ser Ql;;ACTIVE;2.00;2.73 +26655-1;Entamoeba sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Entamoeba sp Ab [Presence] in Serum;Entamoeba Ab Ser Ql;;ACTIVE;2.00;2.56 +26656-9;HTLV II Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV II Ab [Presence] in Serum;HTLV II Ab Ser Ql;;ACTIVE;2.00;2.73 +26657-7;Schistosoma haematobium Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Schistosoma haematobium Ab [Presence] in Serum;S haematobium Ab Ser Ql;;ACTIVE;2.00;2.56 +2665-8;Nitrogen;MRat;Pt;Urine;Qn;;CHEM;1;Nitrogen [Mass/time] in Urine;N2 Ur-mRate;;DISCOURAGED;1.0;2.46 +26658-5;Treponema sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Treponema sp Ab [Presence] in Serum;Treponema Ab Ser Ql;;ACTIVE;2.00;2.73 +26659-3;Leptospira autumnalis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Deprecated Leptospira autumnalis Ab [Presence] in Serum;Deprecated L autumnalis Ab Ser Ql;;DEPRECATED;2.00;2.58 +26660-1;Toxocara sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Toxocara sp Ab [Presence] in Serum;Toxocara Ab Ser Ql;;ACTIVE;2.00;2.73 +26661-9;Trichinella sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Trichinella sp Ab [Presence] in Serum;Trichinella Ab Ser Ql;;ACTIVE;2.00;2.73 +26662-7;Bebaru virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bebaru virus Ab [Presence] in Serum;BEBV Ab Ser Ql;;ACTIVE;2.00;2.56 +26663-5;Chlamydia trachomatis D Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis D Ab [Presence] in Serum;C trach D Ab Ser Ql;;ACTIVE;2.00;2.56 +26664-3;Chlamydia trachomatis E Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis E Ab [Presence] in Serum;C trach E Ab Ser Ql;;ACTIVE;2.00;2.56 +26665-0;Chlamydia trachomatis F Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis F Ab [Presence] in Serum;C trach F Ab Ser Ql;;ACTIVE;2.00;2.56 +2666-6;Norepinephrine;MCnc;Pt;Plas;Qn;;CHEM;1;Norepinephrine [Mass/volume] in Plasma;Norepineph Plas-mCnc;;ACTIVE;1.0;2.73 +26666-8;Chlamydia trachomatis H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis H Ab [Presence] in Serum;C trach H Ab Ser Ql;;ACTIVE;2.00;2.56 +26667-6;Chlamydia trachomatis I Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis I Ab [Presence] in Serum;C trach I Ab Ser Ql;;ACTIVE;2.00;2.56 +26668-4;Chlamydia trachomatis L1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis L1 Ab [Presence] in Serum;C trach L1 Ab Ser Ql;;ACTIVE;2.00;2.56 +26669-2;Absidia corymbifera Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Absidia corymbifera Ab [Presence] in Serum;A corymbifera Ab Ser Ql;;ACTIVE;2.00;2.56 +266-7;Gentamicin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Gentamicin [Susceptibility] by Minimum lethal concentration (MLC);Gentamicin Islt MLC;;ACTIVE;1.0;2.73 +26670-0;Rhizomucor pusillus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rhizomucor pusillus Ab [Presence] in Serum;R pusillus Ab Ser Ql;;ACTIVE;2.00;2.56 +26671-8;Ascaris sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ascaris sp Ab [Presence] in Serum;Ascaris Ab Ser Ql;;ACTIVE;2.00;2.56 +26672-6;Ross river virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ross River virus Ab [Presence] in Serum;RRV Ab Ser Ql;;ACTIVE;2.00;2.56 +26673-4;Echinococcus granulosus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echinococcus granulosus Ab [Presence] in Serum;E granulosus Ab Ser Ql;;ACTIVE;2.00;2.56 +2667-4;Norepinephrine;MCnc;Pt;Urine;Qn;;CHEM;1;Norepinephrine [Mass/volume] in Urine;Norepineph Ur-mCnc;;ACTIVE;1.0;2.73 +26674-2;Legionella longbeachae 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella longbeachae 1 Ab [Presence] in Serum;L longbeachae1 Ab Ser Ql;;ACTIVE;2.00;2.56 +26675-9;Legionella longbeachae 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella longbeachae 2 Ab [Presence] in Serum;L longbeachae2 Ab Ser Ql;;ACTIVE;2.00;2.56 +26676-7;Bartonella henselae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella henselae Ab [Presence] in Serum;B henselae Ab Ser Ql;;ACTIVE;2.00;2.56 +26677-5;Bartonella quintana Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella quintana Ab [Presence] in Serum;B quintana Ab Ser Ql;;ACTIVE;2.00;2.56 +26678-3;Bartonella elizabethae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella elizabethae Ab [Presence] in Serum;B elizabethae Ab Ser Ql;;ACTIVE;2.00;2.56 +26679-1;Secobarbital;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Secobarbital [Mass/volume] in Vitreous fluid;Secobarbital Vitf-mCnc;;ACTIVE;2.00;2.70 +26680-9;Aspartate;SCnc;Pt;Urine;Qn;;CHEM;1;Aspartate [Moles/volume] in Urine;Aspartate Ur-sCnc;;ACTIVE;2.00;2.73 +26681-7;Streptococcus pneumoniae 23 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Mass/volume] in Serum;Deprecated S pneum23 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +2668-2;Norepinephrine;MRat;24H;Urine;Qn;;CHEM;1;Norepinephrine [Mass/time] in 24 hour Urine;Norepineph 24h Ur-mRate;;ACTIVE;1.0;2.73 +26682-5;Glycolate;PrThr;Pt;Urine;Ord;;CHEM;1;Glycolate [Presence] in Urine;Glycolate Ur Ql;;ACTIVE;2.00;2.73 +26683-3;Estazolam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Estazolam [Mass/volume] in Vitreous fluid;Estazolam Vitf-mCnc;;ACTIVE;2.00;2.70 +26684-1;Mycoplasma pneumoniae Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma pneumoniae IgA Ab [Presence] in Serum by Immunoassay;M pneumo IgA Ser Ql IA;;ACTIVE;2.00;2.73 +26685-8;3-Hydroxyisovalerate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxyisovalerate [Presence] in Urine;3OH-Isovalerate Ur Ql;;ACTIVE;2.00;2.73 +26686-6;Triazolam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Triazolam [Mass/volume] in Vitreous fluid;Triazolam Vitf-mCnc;;ACTIVE;2.00;2.70 +26687-4;Amobarbital;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Amobarbital [Mass/volume] in Vitreous fluid;Amobarbital Vitf-mCnc;;ACTIVE;2.00;2.70 +26688-2;Mercury/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Mercury/Creatinine [Mass Ratio] in 24 hour Urine;Mercury/Creat 24h Ur;;ACTIVE;2.00;2.73 +26689-0;Butabarbital;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Butabarbital [Mass/volume] in Vitreous fluid;Butabarbital Vitf-mCnc;;ACTIVE;2.00;2.70 +2669-0;Normetanephrine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Normetanephrine [Mass/volume] in Serum or Plasma;Normetanephrine SerPl-mCnc;;ACTIVE;1.0;2.73 +26690-8;Western equine encephalitis virus RNA;PrThr;Pt;CSF;Ord;Probe;MICRO;1;Western equine encephalitis virus RNA [Presence] in Cerebral spinal fluid by Probe;WEEV RNA CSF Ql Probe;;ACTIVE;2.00;2.63 +26691-6;Uroporphyrin 1 isomer;MRat;24H;Stool;Qn;;CHEM;1;Uroporphyrin 1 isomer [Mass/time] in 24 hour Stool;Uropor1 24h Stl-mRate;;ACTIVE;2.00;2.73 +26692-4;Streptococcus pneumoniae 19 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Mass/volume] in Serum;Deprecated S pneum19 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26693-2;Streptococcus pneumoniae 12f Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12f Ab [Mass/volume] in Serum;Deprecated S pneum12f Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26694-0;Clostridioides difficile Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridioides difficile IgM Ab [Units/volume] in Serum;C diff IgM Ser-aCnc;;ACTIVE;2.00;2.69 +26695-7;Glucose^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Glucose sp7 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +26696-5;Morphine.free;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Morphine Free [Mass/mass] in Stool;Morphine Free Stl-mCnt;;ACTIVE;2.00;2.70 +26697-3;Clostridioides difficile Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridioides difficile IgA Ab [Units/volume] in Serum;C diff IgA Ser-aCnc;;ACTIVE;2.00;2.69 +26698-1;Listeria monocytogenes Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes IgG Ab [Units/volume] in Serum;L monocytog IgG Ser-aCnc;;ACTIVE;2.00;2.73 +26699-9;Indicans;ACnc;Pt;Urine;Qn;;CHEM;1;Indicans [Units/volume] in Urine;Indicans Ur-aCnc;;DISCOURAGED;2.00;2.69 +26700-5;Amino beta guanidinopropionate;SRat;24H;Urine;Qn;;CHEM;1;Amino beta guanidinopropionate [Moles/time] in 24 hour Urine;AB-Gp 24h Ur-sRate;;ACTIVE;2.00;2.73 +26701-3;Streptococcus pneumoniae 9 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Mass/volume] in Serum;Deprecated S pneum9 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26702-1;Clostridioides difficile Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridioides difficile IgG Ab [Units/volume] in Serum;C diff IgG Ser-aCnc;;ACTIVE;2.00;2.69 +26703-9;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear IgG Ab [Titer] in Serum by Immunoassay;ENA SM+RNP IgG Titr Ser IA;;ACTIVE;2.00;2.73 +26704-7;Isospora belli;PrThr;Pt;Stool;Ord;IF;MICRO;1;Isospora belli [Presence] in Stool by Immunofluorescence;I belli Stl Ql IF;;ACTIVE;2.00;2.73 +26705-4;Epstein Barr virus nuclear Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus nuclear IgM Ab [Titer] in Serum;EBV NA IgM Titr Ser;;ACTIVE;2.00;2.73 +26706-2;Vanillylmandelate;MCnc;24H;Urine;Qn;;CHEM;1;Vanillylmandelate [Mass/volume] in 24 hour Urine;VMA 24h Ur-mCnc;;ACTIVE;2.00;2.73 +26707-0;Aluminum;MRat;24H;Urine;Qn;;DRUG/TOX;1;Aluminum [Mass/time] in 24 hour Urine;Aluminum 24h Ur-mRate;;ACTIVE;2.00;2.73 +2670-8;Normetanephrine;MCnc;Pt;Urine;Qn;;CHEM;1;Normetanephrine [Mass/volume] in Urine;Normetanephrine Ur-mCnc;;ACTIVE;1.0;2.73 +26708-8;Magnesium;SCnt;Pt;Stool;Qn;;CHEM;1;Magnesium [Moles/mass] in Stool;Magnesium Stl-sCnt;;ACTIVE;2.00;2.70 +26709-6;Xylose^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Xylose sp5 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +26710-4;Leucine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Leucine [Moles/volume] in Amniotic fluid;Leucine Amn-sCnc;;ACTIVE;2.00;2.70 +26711-2;Phendimetrazine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Phendimetrazine [Mass/mass] in Meconium;Phendimetrazine Mec-mCnt;;ACTIVE;2.00;2.70 +26712-0;Phenmetrazine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Phenmetrazine [Mass/mass] in Meconium;Phenmetrazine Mec-mCnt;;ACTIVE;2.00;2.70 +26713-8;Phentermine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Phentermine [Mass/mass] in Meconium;Phentermine Mec-mCnt;;ACTIVE;2.00;2.70 +26714-6;Phenylpropanolamine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Phenylpropanolamine [Mass/mass] in Meconium;PPA Mec-mCnt;;ACTIVE;2.00;2.70 +26715-3;Chlamydia trachomatis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis IgG Ab [Units/volume] in Serum by Immunoassay;C trach IgG Ser IA-aCnc;;ACTIVE;2.00;2.69 +2671-6;Normetanephrine;MRat;24H;Urine;Qn;;CHEM;1;Normetanephrine [Mass/time] in 24 hour Urine;Normetanephrine 24h Ur-mRate;;ACTIVE;1.0;2.73 +26716-1;Chlorphentermine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Chlorphentermine [Mass/mass] in Meconium;Chlorphentermin Mec-mCnt;;ACTIVE;2.00;2.70 +26717-9;Phosphoethanolamine;SCnc;Pt;Bld;Qn;;CHEM;1;Phosphoethanolamine [Moles/volume] in Blood;PETN Bld-sCnc;;ACTIVE;2.00;2.70 +26718-7;HYDROmorphone;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;HYDROmorphone [Mass/mass] in Hair;HYDROmorphone Hair-mCnt;;ACTIVE;2.00;2.40 +26719-5;HYDROcodone;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;HYDROcodone [Mass/mass] in Hair;HYDROcodone Hair-mCnt;;ACTIVE;2.00;2.70 +26720-3;Codeine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Codeine [Mass/mass] in Hair;Codeine Hair-mCnt;;ACTIVE;2.00;2.70 +26721-1;6-Monoacetylmorphine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/mass] in Hair;6MAM Hair-mCnt;;ACTIVE;2.00;2.70 +26722-9;oxyCODONE;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;oxyCODONE [Mass/mass] in Hair;oxyCODONE Hair-mCnt;;ACTIVE;2.00;2.70 +26723-7;Varicella zoster virus Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Varicella zoster virus Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;VZV Ab Titr CSF IF;;ACTIVE;2.00;2.73 +2672-4;Octopamine;SCnc;Pt;Urine;Qn;;CHEM;1;Octopamine [Moles/volume] in Urine;Octopamine Ur-sCnc;;ACTIVE;1.0;2.44 +26724-5;Sarcosine;SCnc;Pt;Urine;Qn;;CHEM;1;Sarcosine [Moles/volume] in Urine;Sarcosine Ur-sCnc;;ACTIVE;2.00;2.70 +26725-2;Alpha aminoadipate;SCnc;Pt;Urine;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in Urine;AAA Ur-sCnc;;ACTIVE;2.00;2.73 +26726-0;Proline;SCnc;Pt;Urine;Qn;;CHEM;1;Proline [Moles/volume] in Urine;Proline Ur-sCnc;;ACTIVE;2.00;2.73 +26727-8;Ephedrine+Pseudoephedrine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Mass/mass] in Meconium;Ephedrin+Pseudo Mec-mCnt;;ACTIVE;2.00;2.70 +26728-6;Cells.CD38;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD38 cells [#/volume] in Blood;CD38 Cells # Bld;;ACTIVE;2.00;2.42 +26729-4;Ovary Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Ovary IgG Ab [Titer] in Serum by Immunofluorescence;Ovary IgG Titr Ser IF;;ACTIVE;2.00;2.70 +26730-2;Isoleucine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Isoleucine [Moles/volume] in Amniotic fluid;Isoleucine Amn-sCnc;;ACTIVE;2.00;2.70 +26731-0;Tetrahydrocannabinol;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/mass] in Stool;THC Stl-mCnt;;ACTIVE;2.00;2.70 +2673-2;Oleate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Oleate (C18:1w9) [Mass/volume] in Serum or Plasma;Oleate SerPl-mCnc;;DISCOURAGED;1.0;2.44 +26732-8;Carboxy tetrahydrocannabinol;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/mass] in Stool;CarboxyTHC Stl-mCnt;;ACTIVE;2.00;2.70 +26733-6;Butabarbital;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Butabarbital [Mass/mass] in Stool;Butabarbital Stl-mCnt;;ACTIVE;2.00;2.70 +26734-4;Methamphetamine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Methamphetamine [Mass/mass] in Stool;Methamphet Stl-mCnt;;ACTIVE;2.00;2.70 +26735-1;Rhodococcus equi Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Rhodococcus equi Ab [Presence] in Serum by Immune diffusion (ID);R equi Ab Ser Ql ID;;ACTIVE;2.00;2.56 +26736-9;Promethazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Promethazine [Presence] in Serum or Plasma;Promethazine SerPl Ql;;ACTIVE;2.00;2.56 +26737-7;Phosphoserine;SCnc;Pt;CSF;Qn;;CHEM;1;Phosphoserine [Moles/volume] in Cerebral spinal fluid;Phosphoserine CSF-sCnc;;ACTIVE;2.00;2.73 +26738-5;Phosphoserine;SCnc;Pt;Urine;Qn;;CHEM;1;Phosphoserine [Moles/volume] in Urine;Phosphoserine Ur-sCnc;;ACTIVE;2.00;2.70 +26739-3;Xylose^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Xylose sp4 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +2674-0;Ornithine;ACnc;Pt;Plas;Ord;;CHEM;1;Deprecated Ornithine [Presence] in Serum or Plasma;Deprecated Ornithine Plas Ql;;DEPRECATED;1.0;2.36 +26740-1;Hydroxyproline;SCnc;Pt;Urine;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in Urine;OH-Proline Ur-sCnc;;ACTIVE;2.00;2.70 +26741-9;Serine;SCnc;Pt;Urine;Qn;;CHEM;1;Serine [Moles/volume] in Urine;Serine Ur-sCnc;;ACTIVE;2.00;2.73 +26742-7;Methylenedioxyamphetamine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Milk;MDA Mlk-mCnc;;ACTIVE;2.00;2.70 +26743-5;Carboxy tetrahydrocannabinol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Serum or Plasma;CarboxyTHC SerPl Ql;;ACTIVE;2.00;2.73 +26744-3;Opiates;MCnt;Pt;Meconium;Qn;Screen;DRUG/TOX;1;Opiates [Mass/mass] in Meconium by Screen method;Opiates Mec Scn-mCnt;;ACTIVE;2.00;2.73 +26745-0;Citrulline;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Citrulline [Moles/volume] in Amniotic fluid;Citrulline Amn-sCnc;;ACTIVE;2.00;2.70 +26746-8;Magnesium;MCnc;Pt;RBC;Qn;;CHEM;1;Magnesium [Mass/volume] in Red Blood Cells;Magnesium RBC-mCnc;;ACTIVE;2.00;2.73 +26747-6;Cannabinoids/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Cannabinoids/Creatinine [Mass Ratio] in Urine;Cannabinoids/Creat Ur;;ACTIVE;2.00;2.73 +26748-4;Osmium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Osmium [Mass/volume] in Blood;Osmium Bld-mCnc;;ACTIVE;2.00;2.70 +26749-2;Urea nitrogen^2nd specimen;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal dialysis fluid --2nd specimen;Urea nit sp2 DiafP-mCnc;;ACTIVE;2.00;2.70 +267-5;Gentamicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Gentamicin [Susceptibility] by Minimum inhibitory concentration (MIC);Gentamicin Islt MIC;;ACTIVE;1.0;2.73 +26750-0;Carnosine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Carnosine [Moles/volume] in Amniotic fluid;Carnosine Amn-sCnc;;ACTIVE;2.00;2.70 +26751-8;Adipate;PrThr;Pt;Urine;Ord;;CHEM;1;Adipate [Presence] in Urine;Adipate Ur Ql;;ACTIVE;2.00;2.73 +26752-6;Creatinine renal clearance;VRat;2H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance in 2 hour Urine and Serum or Plasma;Creat Cl 2h Ur+SerPl-vRate;;ACTIVE;2.00;2.73 +26753-4;Carnitine esters;ACnc;Pt;Urine;Qn;;CHEM;1;Carnitine esters [Units/volume] in Urine;Carn esters Ur-aCnc;;DISCOURAGED;2.00;2.69 +26754-2;Streptococcus pneumoniae Danish serotype 7F Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Mass/volume] in Serum;S pneum Da 7F Ab Ser-mCnc;;ACTIVE;2.00;2.73 +26755-9;Streptococcus pneumoniae Danish serotype 18C Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C Ab [Mass/volume] in Serum;S pneum Da 18C Ab Ser-mCnc;;ACTIVE;2.00;2.73 +26756-7;Isoniazid;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Isoniazid [Units/volume] in Serum or Plasma;Isoniazid SerPl-aCnc;;DISCOURAGED;2.00;2.73 +2675-7;Ornithine;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Ornithine [Mass/volume] in Serum or Plasma;Deprecated Ornithine Plas-mCnc;;DEPRECATED;1.0;2.36 +26757-5;Carnitine.free (C0);ACnc;Pt;Urine;Qn;;CHEM;1;Carnitine free (C0) [Units/volume] in Urine;Carnitine Free Ur-aCnc;;DISCOURAGED;2.00;2.69 +26758-3;Cocaine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Cocaine [Mass/mass] in Stool;Cocaine Stl-mCnt;;ACTIVE;2.00;2.73 +26759-1;Cells.CD4+CD45RA+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45RA+ cells [#/volume] in Blood;CD4+CD45RA+ Cells # Bld;;ACTIVE;2.00;2.73 +26760-9;Cannabinoids;ACnc;Pt;Urine;Qn;;DRUG/TOX;1;Cannabinoids [Units/volume] in Urine;Cannabinoids Ur-aCnc;;DISCOURAGED;2.00;2.73 +26761-7;Sodium renal clearance;VRat;2H;Urine+Ser/Plas;Qn;;CHEM;1;Sodium renal clearance in 2 hour Urine and Serum or Plasma;Sodium Cl 2h Ur+SerPl-vRate;;ACTIVE;2.00;2.70 +26762-5;Chloride;ACnc;Pt;Urine;Qn;;CHEM;1;Chloride [Units/volume] in Urine;Chloride Ur-aCnc;;DISCOURAGED;2.00;2.73 +26763-3;Sodium;MRat;2H;Urine;Qn;;CHEM;1;Sodium [Mass/time] in 2 hour Urine;Sodium 2h Ur-mRate;;ACTIVE;2.00;2.70 +26764-1;Cannabinoids;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Cannabinoids [Presence] in Hair;Cannabinoids Hair Ql;;ACTIVE;2.00;2.56 +2676-5;Organic acids;PrThr;Pt;Urine;Ord;;CHEM;1;Organic acids [Presence] in Urine;Organic Acids Ur Ql;;ACTIVE;1.0;2.73 +26765-8;Antimony;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Antimony [Presence] in Hair;Antimony Hair Ql;;ACTIVE;2.00;2.56 +26766-6;Bacteroides fragilis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Bacteroides fragilis IgG Ab [Units/volume] in Serum;B fragilis IgG Ser-aCnc;;ACTIVE;2.00;2.69 +26767-4;Clostridium perfringens Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium perfringens IgG Ab [Units/volume] in Serum;C perfringens IgG Ser-aCnc;;ACTIVE;2.00;2.69 +26768-2;Clostridium perfringens Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium perfringens IgM Ab [Units/volume] in Serum;C perfringens IgM Ser-aCnc;;ACTIVE;2.00;2.69 +26769-0;Endothelin;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Endothelin [Mass/volume] in Serum or Plasma;Endothelin SerPl-mCnc;;ACTIVE;2.00;2.73 +26770-8;Trichloroacetate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Trichloroacetate/Creatinine [Mass Ratio] in Urine;TCA/Creat Ur;;ACTIVE;2.00;2.73 +26771-6;Ephedrine+Pseudoephedrine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Mass/mass] in Stool;Ephedrin+Pseudo Stl-mCnt;;ACTIVE;2.00;2.70 +26772-4;Mephentermine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Mephentermine [Mass/mass] in Stool;Mephentermine Stl-mCnt;;ACTIVE;2.00;2.70 +2677-3;Organochloride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Organochloride [Mass/volume] in Blood;Organochloride Bld-mCnc;;ACTIVE;1.0;2.42 +26773-2;Benzfetamine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Benzfetamine [Mass/mass] in Stool;Benzfetamine Stl-mCnt;;ACTIVE;2.00;2.70 +26774-0;Flurazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Flurazepam [Mass/mass] in Hair;Flurazepam Hair-mCnt;;ACTIVE;2.00;2.70 +26775-7;Myelin associated glycoprotein Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Myelin associated glycoprotein Ab [Presence] in Serum by Immunoassay;MAG Ab Ser Ql IA;;ACTIVE;2.00;2.73 +26776-5;QUEtiapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;QUEtiapine [Mass/volume] in Serum or Plasma;QUEtiapine SerPl-mCnc;;ACTIVE;2.00;2.73 +26777-3;Glucose^30M post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose lactose PO;Glucose 30M p Lac PO SerPl-mCnc;;ACTIVE;2.00;2.73 +26778-1;Glucose^1H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post dose lactose PO;Glucose 1h p Lac PO SerPl-mCnc;;ACTIVE;2.00;2.73 +26779-9;Glucose^1.5H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose lactose PO;Glucose 1.5h p Lac PO SerPl-mCnc;;ACTIVE;2.00;2.73 +26780-7;Glucose^2H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post dose lactose PO;Glucose 2h p Lac PO SerPl-mCnc;;ACTIVE;2.00;2.73 +2678-1;Ornithine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Ornithine [Presence] in Serum or Plasma;Ornithine SerPl Ql;;ACTIVE;1.0;2.73 +26781-5;Glucose^3H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post dose lactose PO;Glucose 3h p Lac PO SerPl-mCnc;;ACTIVE;2.00;2.73 +26782-3;Glucose^4H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 hours post dose lactose PO;Glucose 4h p Lac PO SerPl-mCnc;;ACTIVE;2.00;2.70 +26783-1;Glucose^5H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post dose lactose PO;Glucose 5h p Lac PO SerPl-mCnc;;ACTIVE;2.00;2.70 +26784-9;diazePAM;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/volume] in Serum or Plasma by Confirmatory method;diazePAM SerPl Cfm-mCnc;;ACTIVE;2.00;2.73 +26785-6;Ephedrine+Pseudoephedrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Mass/volume] in Urine;Ephedrin+Pseudo Ur-mCnc;;ACTIVE;2.00;2.73 +26786-4;Mephentermine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mephentermine [Mass/volume] in Urine;Mephentermine Ur-mCnc;;ACTIVE;2.00;2.70 +26787-2;Anserine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Anserine [Moles/volume] in Amniotic fluid;Anserine Amn-sCnc;;ACTIVE;2.00;2.70 +26788-0;Carnitine;ACnt;Pt;Tiss;Qn;;CHEM;1;Carnitine [Units/mass] in Tissue;Carnitine Tiss-aCnt;;ACTIVE;2.00;2.32 +26789-8;Escherichia coli Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Escherichia coli IgM Ab [Units/volume] in Serum;E coli IgM Ser-aCnc;;ACTIVE;2.00;2.69 +26790-6;chlordiazePOXIDE;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/mass] in Hair;Chlordiazep Hair-mCnt;;ACTIVE;2.00;2.70 +26791-4;Amphetamine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Amphetamine [Mass/mass] in Stool;Amphet Stl-mCnt;;ACTIVE;2.00;2.70 +26792-2;Methylenedioxyamphetamine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/mass] in Stool;MDA Stl-mCnt;;ACTIVE;2.00;2.70 +26793-0;Methylenedioxymethamphetamine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/mass] in Stool;MDMA Stl-mCnt;;ACTIVE;2.00;2.70 +26794-8;Alpha aminobutyrate;PrThr;24H;Urine;Ord;;CHEM;1;Alpha aminobutyrate [Presence] in 24 hour Urine;A-Aminobutyr 24h Ur Ql;;ACTIVE;2.00;2.56 +26795-5;Alanine;PrThr;24H;Urine;Ord;;CHEM;1;Alanine [Presence] in 24 hour Urine;Alanine 24h Ur Ql;;ACTIVE;2.00;2.56 +26796-3;Oxalate;PrThr;Pt;Urine;Ord;;CHEM;1;Oxalate [Presence] in Urine;Oxalate Ur Ql;;ACTIVE;2.00;2.73 +26797-1;Alpha hydroxybutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;Alpha hydroxybutyrate [Presence] in Urine;A-OH-Butyr Ur Ql;;ACTIVE;2.00;2.73 +26798-9;Succinate;PrThr;Pt;Urine;Ord;;CHEM;1;Succinate [Presence] in Urine;Succinate Ur Ql;;ACTIVE;2.00;2.56 +2679-9;Ornithine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ornithine [Mass/volume] in Serum or Plasma;Ornithine SerPl-mCnc;;ACTIVE;1.0;2.73 +26799-7;Fumarate;PrThr;Pt;Urine;Ord;;CHEM;1;Fumarate [Presence] in Urine;Fumarate Ur Ql;;ACTIVE;2.00;2.73 +26800-3;Escherichia coli Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Escherichia coli IgG Ab [Units/volume] in Serum;E coli IgG Ser-aCnc;;ACTIVE;2.00;2.69 +26801-1;Protein;MRat;12H;Urine;Qn;;CHEM;1;Protein [Mass/time] in 12 hour Urine;Prot 12h Ur-mRate;;ACTIVE;2.00;2.73 +26802-9;Midazolam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Midazolam [Mass/mass] in Hair;Midazolam Hair-mCnt;;ACTIVE;2.00;2.70 +26803-7;Ethanolamine;PrThr;24H;Urine;Ord;;CHEM;1;Ethanolamine [Presence] in 24 hour Urine;Ethanolamine 24h Ur Ql;;ACTIVE;2.00;2.56 +26804-5;Gamma aminobutyrate;PrThr;24H;Urine;Ord;;CHEM;1;Gamma aminobutyrate [Presence] in 24 hour Urine;GABA 24h Ur Ql;;ACTIVE;2.00;2.56 +26805-2;Glutamate;PrThr;24H;Urine;Ord;;CHEM;1;Glutamate [Presence] in 24 hour Urine;Glutamate 24h Ur Ql;;ACTIVE;2.00;2.56 +26806-0;Glutamine;PrThr;24H;Urine;Ord;;CHEM;1;Glutamine [Presence] in 24 hour Urine;Glutamine 24h Ur Ql;;ACTIVE;2.00;2.56 +2680-7;Ornithine;MCnc;Pt;Urine;Qn;;CHEM;1;Ornithine [Mass/volume] in Urine;Ornithine Ur-mCnc;;ACTIVE;1.0;2.42 +26807-8;Glycine;PrThr;24H;Urine;Ord;;CHEM;1;Glycine [Presence] in 24 hour Urine;Glycine 24h Ur Ql;;ACTIVE;2.00;2.56 +26808-6;Histidine;PrThr;24H;Urine;Ord;;CHEM;1;Histidine [Presence] in 24 hour Urine;Histidine 24h Ur Ql;;ACTIVE;2.00;2.56 +26809-4;Homocystine;PrThr;24H;Urine;Ord;;CHEM;1;Homocystine [Presence] in 24 hour Urine;(Hcys)2 24h Ur Ql;;ACTIVE;2.00;2.56 +26810-2;Hydroxyproline;PrThr;24H;Urine;Ord;;CHEM;1;Hydroxyproline [Presence] in 24 hour Urine;OH-Proline 24h Ur Ql;;ACTIVE;2.00;2.56 +26811-0;2-Methylcitrate;SCnc;Pt;Urine;Qn;;CHEM;1;2-Methylcitrate [Moles/volume] in Urine;2Me-citrate Ur-sCnc;;ACTIVE;2.00;2.73 +26812-8;Xylose^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Xylose sp3 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +26813-6;Acidity.titratable;SCnc;Pt;Gast fld;Qn;;CHEM;1;Acidity.titratable [Moles/volume] in Gastric fluid;Titratable Acidity Gast-sCnc;;ACTIVE;2.00;2.73 +26814-4;IgG.monoclonal;MCnc;Pt;Ser;Qn;;CHEM;1;IgG.monoclonal [Mass/volume] in Serum;M-IgG Ser-mCnc;;ACTIVE;2.00;2.73 +2681-5;Ornithine;MRat;24H;Urine;Qn;;CHEM;1;Ornithine [Mass/time] in 24 hour Urine;Ornithine 24h Ur-mRate;;ACTIVE;1.0;2.42 +26815-1;Cocaethylene;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Cocaethylene [Mass/mass] in Meconium;Cocaethylene Mec-mCnt;;ACTIVE;2.00;2.73 +26816-9;Nordiazepam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Vitreous fluid;Nordiazepam Vitf-mCnc;;ACTIVE;2.00;2.70 +26817-7;Glucose^11H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --11 hour post XXX challenge;Glucose 11h p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +26818-5;Campylobacter jejuni Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Campylobacter jejuni Ab [Units/volume] in Serum by Immunoassay;C jejuni Ab Ser IA-aCnc;;ACTIVE;2.00;2.73 +26819-3;Alpha aminobutyrate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in Amniotic fluid;A-Aminobutyr Amn-sCnc;;ACTIVE;2.00;2.70 +26820-1;Stachybotrys chartarum Ab.IgA;MCnc;Pt;Ser;Qn;;ALLERGY;1;Stachybotrys chartarum IgA Ab [Mass/volume] in Serum;S chartarum IgA-mCnc;;ACTIVE;2.00;2.73 +26821-9;Lipoprotein.beta;PrThr;Pt;Body fld;Ord;;CHEM;1;Lipoprotein.beta [Presence] in Body fluid;LDL Fld Ql;;ACTIVE;2.00;2.56 +26822-7;Lipoprotein.alpha;PrThr;Pt;Body fld;Ord;;CHEM;1;Lipoprotein.alpha [Presence] in Body fluid;HDL Fld Ql;;ACTIVE;2.00;2.73 +2682-3;Ornithine carbamoyltransferase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Ornithine carbamoyltransferase [Enzymatic activity/volume] in Amniotic fluid;OCT Amn-cCnc;;ACTIVE;1.0;2.68 +26823-5;Lutropin.beta subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin.beta subunit [Mass/volume] in Serum or Plasma;B-LH SerPl-mCnc;;DISCOURAGED;2.00;2.70 +26824-3;Phosphoserine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphoserine [Moles/volume] in Amniotic fluid;Phosphoserine Amn-sCnc;;ACTIVE;2.00;2.70 +26825-0;Eastern equine encephalitis virus RNA;PrThr;Pt;CSF;Ord;Probe;MICRO;1;Eastern equine encephalitis virus RNA [Presence] in Cerebral spinal fluid by Probe;EEEV RNA CSF Ql Probe;;ACTIVE;2.00;2.63 +26826-8;Testosterone;MCnc;24H;Urine;Qn;;CHEM;1;Testosterone [Mass/volume] in 24 hour Urine;Testost 24h Ur-mCnc;;ACTIVE;2.00;2.70 +26827-6;Testosterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Testosterone/Creatinine [Mass Ratio] in 24 hour Urine;Testost/Creat 24h Ur;;ACTIVE;2.00;2.73 +26828-4;Cortisol;ACnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Units/volume] in Saliva (oral fluid);Cortis Sal-aCnc;;DISCOURAGED;2.00;2.69 +26829-2;Phencyclidine;MCnt;Pt;Meconium;Qn;Screen;DRUG/TOX;1;Phencyclidine [Mass/mass] in Meconium by Screen method;PCP Mec Scn-mCnt;;ACTIVE;2.00;2.73 +268-3;Gentamicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Gentamicin [Susceptibility] by Disk diffusion (KB);Gentamicin Islt KB;;ACTIVE;1.0;2.73 +26830-0;Prochlorperazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Prochlorperazine [Presence] in Serum or Plasma;Prochlorperazine SerPl Ql;;ACTIVE;2.00;2.56 +2683-1;Ornithine carbamoyltransferase;CCnc;Pt;Ser;Qn;;CHEM;1;Ornithine carbamoyltransferase [Enzymatic activity/volume] in Serum;OCT Ser-cCnc;;ACTIVE;1.0;2.68 +26831-8;Suberate;PrThr;Pt;Urine;Ord;;CHEM;1;Suberate [Presence] in Urine;Suberate Ur Ql;;ACTIVE;2.00;2.73 +26832-6;Aconitate;PrThr;Pt;Urine;Ord;;CHEM;1;Aconitate [Presence] in Urine;Aconitate Ur Ql;;ACTIVE;2.00;2.56 +26833-4;Hippurate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Hippurate [Presence] in Urine;Hippurate Ur Ql;;ACTIVE;2.00;2.56 +26834-2;Temazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Temazepam [Mass/mass] in Hair;Temazepam Hair-mCnt;;ACTIVE;2.00;2.70 +26835-9;Sebacate;PrThr;Pt;Urine;Ord;;CHEM;1;Sebacate (C8) [Presence] in Urine;Sebacate Ur Ql;;ACTIVE;2.00;2.73 +26836-7;Hydroxyethylflurazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/mass] in Hair;OH-Ethylfluraz Hair-mCnt;;ACTIVE;2.00;2.70 +26837-5;diazePAM;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;diazePAM [Mass/mass] in Hair;diazePAM Hair-mCnt;;ACTIVE;2.00;2.70 +26838-3;LORazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;LORazepam [Mass/mass] in Hair;LORazepam Hair-mCnt;;ACTIVE;2.00;2.70 +26839-1;Oxazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Oxazepam [Mass/mass] in Hair;Oxazepam Hair-mCnt;;ACTIVE;2.00;2.70 +26840-9;Nordiazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Nordiazepam [Mass/mass] in Hair;Nordiazepam Hair-mCnt;;ACTIVE;2.00;2.70 +26841-7;N-desalkylflurazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/mass] in Hair;Desalkylfluraz Hair-mCnt;;ACTIVE;2.00;2.70 +26842-5;Iodine;MCnc;24H;Urine;Qn;;CHEM;1;Iodine [Mass/volume] in 24 hour Urine;Iodine 24h Ur-mCnc;;ACTIVE;2.00;2.73 +26843-3;Cystine;PrThr;24H;Urine;Ord;;CHEM;1;Cystine [Presence] in 24 hour Urine;Cystine 24h Ur Ql;;ACTIVE;2.00;2.73 +26844-1;Methionine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Methionine [Moles/volume] in Amniotic fluid;Methionine Amn-sCnc;;ACTIVE;2.00;2.70 +26845-8;Sialate.lipid bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sialate.lipid bound [Mass/volume] in Serum or Plasma;LASA SerPl-mCnc;;ACTIVE;2.00;2.73 +26846-6;Perphenazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Perphenazine [Presence] in Serum or Plasma;Perphenazine SerPl Ql;;ACTIVE;2.00;2.56 +26847-4;Haloperidol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Haloperidol [Presence] in Serum or Plasma;Haloperidol SerPl Ql;;ACTIVE;2.00;2.73 +26848-2;Interleukin 10;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 10 [Mass/volume] in Serum or Plasma;Il10 SerPl-mCnc;;ACTIVE;2.00;2.73 +2684-9;Alpha-1-Acid glycoprotein;MCnc;Pt;CSF;Qn;;CHEM;1;Alpha-1-acid glycoprotein [Mass/volume] in Cerebral spinal fluid;A1acid Glycoprotein CSF-mCnc;;ACTIVE;1.0;2.42 +26849-0;IgA.secretory;MCnc;Pt;Saliva;Qn;;CHEM;1;IgA.secretory [Mass/volume] in Saliva (oral fluid);SIgA Sal-mCnc;;ACTIVE;2.00;2.73 +26850-8;Oxazepam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Vitreous fluid;Oxazepam Vitf-mCnc;;ACTIVE;2.00;2.70 +26851-6;LORazepam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Vitreous fluid;LORazepam Vitf-mCnc;;ACTIVE;2.00;2.70 +26852-4;Amino beta guanidinopropionate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Amino beta guanidinopropionate [Moles/volume] in Amniotic fluid;AB-Gp Amn-sCnc;;ACTIVE;2.00;2.70 +26853-2;Glucose^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Units/volume] in Serum or Plasma --7th specimen post XXX challenge;Glucose sp7 p chal SerPl-aCnc;;DISCOURAGED;2.00;2.69 +26854-0;Glucose^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Units/volume] in Serum or Plasma --8th specimen post XXX challenge;Glucose sp8 p chal SerPl-aCnc;;DISCOURAGED;2.00;2.69 +26855-7;Parainfluenza virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Parainfluenza virus Ab [Titer] in Serum by Immunofluorescence;HPIV Ab Titr Ser IF;;ACTIVE;2.00;2.70 +2685-6;Alpha-1-Acid glycoprotein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-acid glycoprotein [Mass/volume] in Serum or Plasma;A1acid Glycoprotein SerPl-mCnc;;ACTIVE;1.0;2.73 +26856-5;Cannabinoids;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Cannabinoids [Mass/mass] in Stool;Cannabinoids Stl-mCnt;;ACTIVE;2.00;2.70 +26857-3;Mephentermine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Mephentermine [Mass/mass] in Meconium;Mephentermine Mec-mCnt;;ACTIVE;2.00;2.70 +26858-1;Cells.CD3+CD56+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD56+ cells [#/volume] in Blood;CD3+CD56+ Cells # Bld;;ACTIVE;2.00;2.73 +26859-9;Phencyclidine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Phencyclidine [Mass/mass] in Meconium;PCP Mec-mCnt;;ACTIVE;2.00;2.73 +26860-7;Morphine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Morphine [Mass/mass] in Meconium;Morphine Mec-mCnt;;ACTIVE;2.00;2.73 +26861-5;Gamma aminobutyrate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in Amniotic fluid;GABA Amn-sCnc;;ACTIVE;2.00;2.70 +26862-3;HYDROmorphone;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;HYDROmorphone [Mass/mass] in Meconium;HYDROmorphone Mec-mCnt;;ACTIVE;2.00;2.73 +26863-1;HYDROcodone;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;HYDROcodone [Mass/mass] in Meconium;HYDROcodone Mec-mCnt;;ACTIVE;2.00;2.73 +2686-4;Orotate;MCnc;Pt;Urine;Qn;;CHEM;1;Orotate [Mass/volume] in Urine;Orotate Ur-mCnc;;DISCOURAGED;1.0;2.73 +26864-9;Sporothrix schenckii Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Sporothrix schenckii Ab [Units/volume] in Serum by Latex agglutination;S schenckii Ab Ser LA-aCnc;;ACTIVE;2.00;2.73 +26865-6;Codeine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Codeine [Mass/mass] in Meconium;Codeine Mec-mCnt;;ACTIVE;2.00;2.73 +26866-4;N-desalkylflurazepam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/mass] in Meconium;Desalkylfluraz Mec-mCnt;;ACTIVE;2.00;2.70 +26867-2;fentaNYL;ACnc;24H;Urine;Qn;;DRUG/TOX;1;fentaNYL [Units/volume] in 24 hour Urine;fentaNYL 24h Ur-aCnc;;DISCOURAGED;2.00;2.69 +26868-0;Phenolphthalein;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Phenolphthalein [Presence] in Stool;Phenolphthalein Stl Ql;;ACTIVE;2.00;2.73 +26869-8;oxyCODONE;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;oxyCODONE [Mass/mass] in Meconium;oxyCODONE Mec-mCnt;;ACTIVE;2.00;2.73 +26870-6;Ganglioside GD1b Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1b Ab [Units/volume] in Serum by Immunoassay;GD1b Gangl Ab Ser IA-aCnc;;ACTIVE;2.00;2.73 +26871-4;IgA;MCnc;24H;Urine;Qn;;CHEM;1;IgA [Mass/volume] in 24 hour Urine;IgA 24h Ur-mCnc;;ACTIVE;2.00;2.73 +2687-2;Orotate phosphoribosyltransferase;CCnc;Pt;Ser;Qn;;CHEM;1;Orotate phosphoribosyltransferase [Enzymatic activity/volume] in Serum;OPRT Ser-cCnc;;ACTIVE;1.0;2.68 +26872-2;Orotate;ACnc;Pt;Urine;Qn;;CHEM;1;Orotate [Units/volume] in Urine;Orotate Ur-aCnc;;DISCOURAGED;2.00;2.69 +26873-0;Valine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Valine [Moles/volume] in Amniotic fluid;Valine Amn-sCnc;;ACTIVE;2.00;2.70 +26874-8;Follitropin.beta subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin.beta subunit [Mass/volume] in Serum or Plasma;B-FSH SerPl-mCnc;;DISCOURAGED;2.00;2.73 +26875-5;Streptococcus pneumoniae 4 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Mass/volume] in Serum;Deprecated S pneum4 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26876-3;Streptococcus pneumoniae 1 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Mass/volume] in Serum;Deprecated S pneum 1 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26877-1;Hydroxytriazolam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/mass] in Hair;OH-Triazolam Hair-mCnt;;ACTIVE;2.00;2.70 +26878-9;ALPRAZolam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Vitreous fluid;Alpraz Vitf-mCnc;;ACTIVE;2.00;2.70 +26879-7;Triiodothyronine;MCnc;Pt;Saliva;Qn;;CHEM;1;Triiodothyronine (T3) [Mass/volume] in Saliva (oral fluid);T3 Sal-mCnc;;ACTIVE;2.00;2.73 +2688-0;Orotidine-5'-Phosphate decarboxylase;CCnc;Pt;Ser;Qn;;CHEM;1;Orotidine-5'-Phosphate decarboxylase [Enzymatic activity/volume] in Serum;OMPdecase Ser-cCnc;;ACTIVE;1.0;2.68 +26880-5;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA SM+RNP Ab Ser Ql IA;;ACTIVE;2.00;2.73 +26881-3;Interleukin 6;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 6 [Mass/volume] in Serum or Plasma;Il6 SerPl-mCnc;;ACTIVE;2.00;2.73 +26882-1;Homocystine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Homocystine [Moles/volume] in Amniotic fluid;(Hcys)2 Amn-sCnc;;ACTIVE;2.00;2.70 +26883-9;Amino beta guanidinopropionate;SRat;24H;Urine;Qn;;CHEM;1;Deprecated Amino beta guanidinopropionate [Molecules/time] in 24 hour Urine;Deprecated AB-Gp 24H Ur-sRate;;DEPRECATED;2.00;2.70 +26884-7;Ketones^3H post XXX challenge;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Ketones [Presence] in Urine by Test strip --3 hours post XXX challenge;Ketones 3h p chal Ur Ql Strip;;ACTIVE;2.00;2.56 +26885-4;Ova & parasites identified;Prid;Pt;XXX;Nom;Concentration;MICRO;1;Ova and parasites identified in Specimen by Concentration;O+P Spec Conc;;ACTIVE;2.00;2.73 +26886-2;ALPRAZolam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/mass] in Hair;Alpraz Hair-mCnt;;ACTIVE;2.00;2.70 +26887-0;Alpha hydroxyalprazolam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/mass] in Hair;A-OH Alpraz Hair-mCnt;;ACTIVE;2.00;2.70 +26888-8;Sulfate;SCnc;24H;Urine;Qn;;CHEM;1;Sulfate [Moles/volume] in 24 hour Urine;Sulfate 24h Ur-sCnc;;ACTIVE;2.00;2.73 +26889-6;Sulfate;SRat;24H;Urine;Qn;;CHEM;1;Sulfate [Moles/time] in 24 hour Urine;Sulfate 24h Ur-sRate;;ACTIVE;2.00;2.73 +26890-4;Canine distemper virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Canine distemper virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CDV IgM Titr CSF IF;;ACTIVE;2.00;2.70 +26891-2;Nordiazepam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Nordiazepam [Mass/mass] in Meconium;Nordiazepam Mec-mCnt;;ACTIVE;2.00;2.70 +26892-0;Intrinsic factor blocking Ab.IgG;ACnc;Pt;Ser;Qn;RIA;CHEM;1;Intrinsic factor blocking IgG Ab [Units/volume] in Serum by Radioimmunoassay (RIA);IF Block IgG Ser RIA-aCnc;;ACTIVE;2.00;2.68 +26893-8;Tetrahydrocannabinol;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/mass] in Meconium;THC Mec-mCnt;;ACTIVE;2.00;2.73 +26894-6;Glutamine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Glutamine [Moles/volume] in Amniotic fluid;Glutamine Amn-sCnc;;ACTIVE;2.00;2.70 +26895-3;Amphetamines;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Amphetamines [Mass/mass] in Meconium;Amphetamines Mec-mCnt;;ACTIVE;2.00;2.73 +26896-1;Taurine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurine [Units/volume] in Serum or Plasma;Taurine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +26897-9;Threonine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Threonine [Units/volume] in Serum or Plasma;Threonine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +2689-8;Osmolality;Osmol;Pt;Amnio fld;Qn;;CHEM;1;Osmolality of Amniotic fluid;Osmolality Amn;;ACTIVE;1.0;2.73 +26898-7;Temazepam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Vitreous fluid;Temazepam Vitf-mCnc;;ACTIVE;2.00;2.70 +26899-5;Midazolam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Midazolam [Mass/volume] in Vitreous fluid;Midazolam Vitf-mCnc;;ACTIVE;2.00;2.70 +26900-1;chlordiazePOXIDE;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Vitreous fluid;Chlordiazep Vitf-mCnc;;ACTIVE;2.00;2.70 +26901-9;Flurazepam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Flurazepam [Mass/volume] in Vitreous fluid;Flurazepam Vitf-mCnc;;ACTIVE;2.00;2.70 +26902-7;Doxycycline;ACnc;Pt;XXX;Qn;;DRUG/TOX;1;Doxycycline [Units/volume] in Specimen;Doxycycline Spec-aCnc;;DISCOURAGED;2.00;2.73 +26903-5;Canine distemper virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Canine distemper virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CDV IgG Titr CSF IF;;ACTIVE;2.00;2.70 +26904-3;2-Methylcitrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Methylcitrate [Moles/volume] in Serum or Plasma;2Me-citrate SerPl-sCnc;;ACTIVE;2.00;2.73 +26905-0;PHENobarbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;PHENobarbital [Mass/mass] in Hair;Phenobarb Hair-mCnt;;ACTIVE;2.00;2.40 +2690-6;Osmolality;Osmol;Pt;Plr fld;Qn;;CHEM;1;Osmolality of Pleural fluid;Osmolality Plr;;ACTIVE;1.0;2.30 +26906-8;Mephobarbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Mephobarbital [Mass/mass] in Hair;Mephobarbital Hair-mCnt;;ACTIVE;2.00;2.40 +26907-6;Listeria sp Ab;Titr;Pt;CSF;Qn;;MICRO;1;Listeria sp Ab [Titer] in Cerebral spinal fluid;Listeria Ab Titr CSF;;ACTIVE;2.00;2.73 +26908-4;17-Hydroxyprogesterone;ACnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone [Units/volume] in Urine;17OHP Ur-aCnc;;DISCOURAGED;2.00;2.69 +26909-2;Alpha aminoadipate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in Amniotic fluid;AAA Amn-sCnc;;ACTIVE;2.00;2.70 +269-1;Gentamicin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Gentamicin [Susceptibility] by Serum bactericidal titer;Gentamicin Titr SBT;;ACTIVE;1.0;2.32 +26910-0;Alpha hydroxyalprazolam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/mass] in Meconium;A-OH Alpraz Mec-mCnt;;ACTIVE;2.00;2.70 +26911-8;ALPRAZolam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/mass] in Meconium;Alpraz Mec-mCnt;;ACTIVE;2.00;2.70 +26912-6;Hydroxytriazolam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/mass] in Meconium;OH-Triazolam Mec-mCnt;;ACTIVE;2.00;2.70 +26913-4;Triazolam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Triazolam [Mass/mass] in Meconium;Triazolam Mec-mCnt;;ACTIVE;2.00;2.70 +2691-4;Osmolality;Osmol;Pt;Periton fld;Qn;;CHEM;1;Osmolality of Peritoneal fluid;Osmolality Prt;;ACTIVE;1.0;2.42 +26914-2;Estazolam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Estazolam [Mass/mass] in Meconium;Estazolam Mec-mCnt;;ACTIVE;2.00;2.70 +26915-9;Pyridoxine;PrThr;Pt;Bld;Ord;;CHEM;1;Pyridoxine [Presence] in Blood;Vit B6 Bld Ql;;ACTIVE;2.00;2.73 +26916-7;Cobalamins;PrThr;Pt;Bld;Ord;;CHEM;1;Cobalamin (Vitamin B12) [Presence] in Blood;Vit B12 Bld Ql;;ACTIVE;2.00;2.73 +26917-5;Streptococcus pneumoniae 23 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Mass/volume] in Serum;Deprecated S pneum23 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26918-3;PENTobarbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;PENTobarbital [Mass/mass] in Hair;Pentobarb Hair-mCnt;;ACTIVE;2.00;2.40 +26919-1;Alpha aminobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha aminobutyrate/Creatinine [Molar ratio] in Urine;A-Aminobutyr/Creat Ur-sRto;;ACTIVE;2.00;2.73 +26920-9;Amobarbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Amobarbital [Mass/mass] in Hair;Amobarbital Hair-mCnt;;ACTIVE;2.00;2.40 +26921-7;Cells.CD2+CD26+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD2+CD26+ cells [#/volume] in Blood;CD2+CD26+ Cells # Bld;;ACTIVE;2.00;2.40 +2692-2;Osmolality;Osmol;Pt;Ser/Plas;Qn;;CHEM;1;Osmolality of Serum or Plasma;Osmolality SerPl;;ACTIVE;1.0;2.73 +26922-5;Cells.CD4+CD45RA+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD4+CD45RA+ cells/100 cells in Blood;Deprecated CD4+CD45RA+ Cells Fr Bld;;DEPRECATED;2.00;2.70 +26923-3;Butabarbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Butabarbital [Mass/mass] in Hair;Butabarbital Hair-mCnt;;ACTIVE;2.00;2.70 +26924-1;Cancer Ag 19-9;ACnc;Pt;Body fld;Qn;;CHEM;1;Cancer Ag 19-9 [Units/volume] in Body fluid;Cancer Ag19-9 Fld-aCnc;;ACTIVE;2.00;2.73 +26925-8;Acetophenazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetophenazine [Presence] in Serum or Plasma;Acetophenazine SerPl Ql;;ACTIVE;2.00;2.56 +26926-6;Ganglioside GD1b Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GD1b Ab [Presence] in Serum by Immunoassay;GD1b Gangl Ab Ser Ql IA;;ACTIVE;2.00;2.56 +26927-4;Herpes simplex virus 2 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus 2 IgM Ab [Titer] in Serum by Immunofluorescence;HSV2 IgM Titr Ser IF;;ACTIVE;2.00;2.73 +26928-2;Vasopressin;PrThr;24H;Urine;Ord;;CHEM;1;Vasopressin [Presence] in 24 hour Urine;Vasopressin 24h Ur Ql;;ACTIVE;2.00;2.56 +26929-0;Glycine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Glycine [Moles/volume] in Amniotic fluid;Glycine Amn-sCnc;;ACTIVE;2.00;2.70 +2693-0;Osmolality;Osmol;Pt;Stool;Qn;;CHEM;1;Osmolality of Stool;Osmolality Stl;;ACTIVE;1.0;2.73 +26930-8;Secobarbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Secobarbital [Mass/mass] in Hair;Secobarbital Hair-mCnt;;ACTIVE;2.00;2.40 +26931-6;Complement C4;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4 [Units/volume] in Serum or Plasma;C4 SerPl-aCnc;;ACTIVE;2.00;2.73 +26932-4;Sarcosine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Sarcosine [Moles/volume] in Amniotic fluid;Sarcosine Amn-sCnc;;ACTIVE;2.00;2.70 +26933-2;Oxazepam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Oxazepam [Mass/mass] in Meconium;Oxazepam Mec-mCnt;;ACTIVE;2.00;2.73 +26934-0;LORazepam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;LORazepam [Mass/mass] in Meconium;LORazepam Mec-mCnt;;ACTIVE;2.00;2.70 +26935-7;diazePAM;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;diazePAM [Mass/mass] in Meconium;diazePAM Mec-mCnt;;ACTIVE;2.00;2.70 +26936-5;Hydroxyethylflurazepam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/mass] in Meconium;OH-Ethylfluraz Mec-mCnt;;ACTIVE;2.00;2.70 +26937-3;Temazepam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Temazepam [Mass/mass] in Meconium;Temazepam Mec-mCnt;;ACTIVE;2.00;2.70 +26938-1;chlordiazePOXIDE;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/mass] in Meconium;Chlordiazep Mec-mCnt;;ACTIVE;2.00;2.70 +26939-9;Streptococcus pneumoniae 19 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Mass/volume] in Serum;Deprecated S pneum19 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26940-7;Myelin basic protein;ACnc;Pt;CSF;Qn;;CHEM;1;Myelin basic protein [Units/volume] in Cerebral spinal fluid;MBP CSF-aCnc;;DISCOURAGED;2.00;2.73 +26941-5;Streptococcus pneumoniae 9 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Mass/volume] in Serum;Deprecated S pneum9 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +26942-3;Mumps virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mumps virus Ab [Presence] in Serum by Immunoassay;MuV Ab Ser Ql IA;;ACTIVE;2.00;2.56 +26943-1;11-Ketoandrosterone;MCnc;24H;Urine;Qn;;CHEM;1;11-Ketoandrosterone [Mass/volume] in 24 hour Urine;11Ketoandros 24h Ur-mCnc;;ACTIVE;2.00;2.70 +26944-9;11-Ketoandrosterone;MCnc;Pt;Urine;Qn;;CHEM;1;11-Ketoandrosterone [Mass/volume] in Urine;11Ketoandros Ur-mCnc;;ACTIVE;2.00;2.70 +26945-6;Triazolam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Triazolam [Mass/mass] in Hair;Triazolam Hair-mCnt;;ACTIVE;2.00;2.70 +26946-4;Mycoplasma pneumoniae Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Mycoplasma pneumoniae IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;M pneumo IgM Titr CSF IF;;ACTIVE;2.00;2.70 +26947-2;Mycoplasma pneumoniae Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Mycoplasma pneumoniae IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;M pneumo IgG Titr CSF IF;;ACTIVE;2.00;2.73 +2694-8;Osmolality;Osmol;24H;Urine;Qn;;CHEM;1;Osmolality of 24 hour Urine;Osmolality 24h Ur;;ACTIVE;1.0;2.73 +26948-0;Saccharopolyspora rectivirgula Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Saccharopolyspora rectivirgula IgG Ab [Mass/volume] in Serum;S rectivirgula IgG-mCnc;;ACTIVE;2.00;2.73 +26949-8;Thermoactinomyces sp Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Thermoactinomyces IgG Ab [Mass/volume] in Serum;Thermoactinomyces IgG Ser-mCnc;;ACTIVE;2.00;2.73 +26950-6;11-Hydroxyetiocholanolone;MCnc;Pt;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone [Mass/volume] in Urine;11OH-Etioch Ur-mCnc;;ACTIVE;2.00;2.73 +26951-4;Alternaria alternata Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Alternaria alternata IgG Ab [Mass/volume] in Serum;A alternata IgG Ser-mCnc;;ACTIVE;2.00;2.73 +26952-2;Phoma herbarum Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Phoma herbarum IgG Ab [Mass/volume] in Serum;P herbarum IgG Ser-mCnc;;ACTIVE;2.00;2.73 +26953-0;Dichlorodiphenyltrichloroethane;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Dichlorodiphenyltrichloroethane [Presence] in Serum or Plasma;DDT SerPl Ql;;ACTIVE;2.00;2.68 +26954-8;Aspergillus fumigatus Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Aspergillus fumigatus IgG Ab [Mass/volume] in Serum;A fumigatus IgG Ser-mCnc;;ACTIVE;2.00;2.73 +2695-5;Osmolality;Osmol;Pt;Urine;Qn;;CHEM;1;Osmolality of Urine;Osmolality Ur;;ACTIVE;1.0;2.73 +26955-5;Aureobasidium pullulans Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Aureobasidium pullulans IgG Ab [Mass/volume] in Serum;A pullulans IgG Ser-mCnc;;ACTIVE;2.00;2.73 +26956-3;Cocaine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Cocaine [Mass/mass] in Meconium;Cocaine Mec-mCnt;;ACTIVE;2.00;2.73 +26957-1;Penicillium notatum Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Penicillium notatum IgG Ab [Mass/volume] in Serum;P notatum IgG Ser-mCnc;;ACTIVE;2.00;2.73 +26958-9;IgM;MCnc;24H;Urine;Qn;;CHEM;1;IgM [Mass/volume] in 24 hour Urine;IgM 24h Ur-mCnc;;ACTIVE;2.00;2.73 +26959-7;Amphetamine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Amphetamine [Mass/mass] in Meconium;Amphet Mec-mCnt;;ACTIVE;2.00;2.73 +26960-5;Trypsin;PrThr;Pt;Stool;Ord;;CHEM;1;Trypsin [Presence] in Stool;Trypsin Stl Ql;;ACTIVE;2.00;2.73 +26961-3;Valine;SCnc;Pt;Urine;Qn;;CHEM;1;Valine [Moles/volume] in Urine;Valine Ur-sCnc;;ACTIVE;2.00;2.73 +26962-1;Cystine;SCnc;Pt;Urine;Qn;;CHEM;1;Cystine [Moles/volume] in Urine;Cystine Ur-sCnc;;ACTIVE;2.00;2.73 +2696-3;Osmolality;Osmol;Pt;XXX;Qn;;CHEM;1;Osmolality of Specimen;Osmolality Spec;;ACTIVE;1.0;2.73 +26963-9;Methionine;SCnc;Pt;Urine;Qn;;CHEM;1;Methionine [Moles/volume] in Urine;Methionine Ur-sCnc;;ACTIVE;2.00;2.73 +26964-7;Cystathionine;SCnc;Pt;Urine;Qn;;CHEM;1;Cystathionine [Moles/volume] in Urine;Cystathionin Ur-sCnc;;ACTIVE;2.00;2.73 +26965-4;Isoleucine;SCnc;Pt;Urine;Qn;;CHEM;1;Isoleucine [Moles/volume] in Urine;Isoleucine Ur-sCnc;;ACTIVE;2.00;2.70 +26966-2;Tyrosine;SCnc;Pt;Urine;Qn;;CHEM;1;Tyrosine [Moles/volume] in Urine;Tyrosine Ur-sCnc;;ACTIVE;2.00;2.73 +26967-0;Phenylalanine;SCnc;Pt;Urine;Qn;;CHEM;1;Phenylalanine [Moles/volume] in Urine;Phe Ur-sCnc;;ACTIVE;2.00;2.73 +26968-8;Beta alanine;SCnc;Pt;Urine;Qn;;CHEM;1;Beta alanine [Moles/volume] in Urine;B-Alanine Ur-sCnc;;ACTIVE;2.00;2.73 +26969-6;Parietal cell Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Parietal cell Ab [Presence] in Serum by Immunofluorescence;PCA Ab Ser Ql IF;;ACTIVE;2.00;2.73 +26970-4;Reticulin Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Reticulin IgG Ab [Presence] in Serum by Immunofluorescence;Reticulin IgG Ser Ql IF;;ACTIVE;2.00;2.73 +2697-1;Osteocalcin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Osteocalcin [Mass/volume] in Serum or Plasma;Osteocalcin SerPl-mCnc;;ACTIVE;1.0;2.73 +26971-2;Smooth muscle Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Smooth muscle Ab [Presence] in Serum by Immunofluorescence;Smooth muscle Ab Ser Ql IF;;ACTIVE;2.00;2.73 +26972-0;Herpes virus 7 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 7 IgG Ab [Titer] in Serum by Immunofluorescence;HHV7 IgG Titr Ser IF;;ACTIVE;2.00;2.73 +26973-8;Beta aminoisobutyrate;SCnc;Pt;Urine;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/volume] in Urine;B-AIB Ur-sCnc;;ACTIVE;2.00;2.73 +26974-6;Delta aminolevulinate;MCnc;24H;Urine;Qn;;CHEM;1;Delta aminolevulinate [Mass/volume] in 24 hour Urine;D-ALA 24h Ur-mCnc;;ACTIVE;2.00;2.73 +26975-3;SCL-70 extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA Scl70 Ab Ser IA-aCnc;;ACTIVE;2.00;2.73 +26976-1;Hydroxytriazolam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/mass] in Stool;OH-Triazolam Stl-mCnt;;ACTIVE;2.00;2.70 +26977-9;Coproporphyrin 1;PrThr;Pt;Stool;Ord;;CHEM;1;Coproporphyrin 1 [Presence] in Stool;Copro1 Stl Ql;;ACTIVE;2.00;2.56 +26978-7;Protriptyline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Protriptyline [Mass/volume] in Urine;Protrip Ur-mCnc;;ACTIVE;2.00;2.73 +26979-5;Flurazepam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Flurazepam [Mass/mass] in Meconium;Flurazepam Mec-mCnt;;ACTIVE;2.00;2.70 +26980-3;Coccidioides immitis Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Coccidioides immitis Ab [Titer] in Serum by Immune diffusion (ID);C immitis Ab Titr Ser ID;;ACTIVE;2.00;2.73 +26981-1;Phenylalanine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Phenylalanine [Moles/volume] in Amniotic fluid;Phe Amn-sCnc;;ACTIVE;2.00;2.70 +26982-9;Cells.CD4+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD25+ cells [#/volume] in Blood;CD4+CD25+ Cells # Bld;;ACTIVE;2.00;2.73 +26983-7;Cells.CD4+HLA-DR+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+HLA-DR+ cells [#/volume] in Blood;CD4+HLA-DR+ Cells # Bld;;ACTIVE;2.00;2.42 +26984-5;Helicobacter pylori Ab.IgG;ACnc;Pt;Saliva;Qn;;MICRO;1;Helicobacter pylori IgG Ab [Units/volume] in Saliva (oral fluid);H pylori IgG Sal-aCnc;;ACTIVE;2.00;2.73 +26985-2;Arginine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Arginine [Moles/volume] in Amniotic fluid;Arginine Amn-sCnc;;ACTIVE;2.00;2.70 +26986-0;Trichoderma viride Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Trichoderma viride IgG Ab [Presence] in Serum;T viride IgG Ser Ql;;ACTIVE;2.00;2.56 +26987-8;Pentachlorophenol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Pentachlorophenol/Creatinine [Mass Ratio] in Urine;Pentachlorophen/Creat Ur;;ACTIVE;2.00;2.73 +26988-6;18-Hydroxydeoxycorticosterone;MRat;24H;Urine;Qn;;CHEM;1;18-Hydroxydeoxycorticosterone [Mass/time] in 24 hour Urine;18OH-DOC 24h Ur-mRate;;ACTIVE;2.00;2.42 +2698-9;Osteonectin;MCnc;Pt;Plas;Qn;;CHEM;1;Osteonectin [Mass/volume] in Plasma;Osteonectin Plas-mCnc;;ACTIVE;1.0;2.42 +26989-4;Trypanosoma cruzi Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Trypanosoma cruzi IgM Ab [Presence] in Serum by Immunofluorescence;T cruzi IgM Ser Ql IF;;ACTIVE;2.00;2.73 +26990-2;Phentermine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Phentermine [Mass/volume] in Milk;Phentermine Mlk-mCnc;;ACTIVE;2.00;2.73 +26991-0;Phenylpropanolamine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Phenylpropanolamine [Mass/volume] in Milk;PPA Mlk-mCnc;;ACTIVE;2.00;2.73 +26992-8;Mephentermine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Mephentermine [Mass/volume] in Milk;Mephentermine Mlk-mCnc;;ACTIVE;2.00;2.73 +26993-6;Benzfetamine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Benzfetamine [Mass/volume] in Milk;Benzfetamine Mlk-mCnc;;ACTIVE;2.00;2.70 +26994-4;Phencyclidine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Milk;PCP Mlk-mCnc;;ACTIVE;2.00;2.70 +26995-1;Carboxy tetrahydrocannabinol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Blood;CarboxyTHC Bld-mCnc;;ACTIVE;2.00;2.73 +26996-9;Complement C7;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C7 [Units/volume] in Serum or Plasma;C7 SerPl-aCnc;;ACTIVE;2.00;2.73 +2699-7;Oxalate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Oxalate [Mass/volume] in Serum or Plasma;Oxalate SerPl-mCnc;;ACTIVE;1.0;2.73 +26997-7;Cells.CD3+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD25+ cells [#/volume] in Blood;CD3+CD25+ Cells # Bld;;ACTIVE;2.00;2.73 +26998-5;Thyrotropin;ACnc;Pt;Saliva;Qn;;CHEM;1;Thyrotropin [Units/volume] in Saliva (oral fluid);TSH Sal-aCnc;;ACTIVE;2.00;2.42 +26999-3;Homocystine;SCnc;Pt;Urine;Qn;;CHEM;1;Homocystine [Moles/volume] in Urine;(Hcys)2 Ur-sCnc;;ACTIVE;2.00;2.70 +27000-9;Thyroxine;MCnc;Pt;Saliva;Qn;;CHEM;1;Thyroxine (T4) [Mass/volume] in Saliva (oral fluid);T4 Sal-mCnc;;ACTIVE;2.00;2.73 +27001-7;Diethyl ether;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Diethyl ether [Presence] in Blood;Diethyl Ether Bld Ql;;ACTIVE;2.00;2.56 +27002-5;Secobarbital;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Secobarbital [Mass/mass] in Meconium;Secobarbital Mec-mCnt;;ACTIVE;2.00;2.70 +2700-3;Oxalate;MCnc;Pt;Urine;Qn;;CHEM;1;Oxalate [Mass/volume] in Urine;Oxalate Ur-mCnc;;ACTIVE;1.0;2.73 +27003-3;Mephobarbital;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Mephobarbital [Mass/mass] in Meconium;Mephobarbital Mec-mCnt;;ACTIVE;2.00;2.70 +27004-1;Benzfetamine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Benzfetamine [Mass/mass] in Meconium;Benzfetamine Mec-mCnt;;ACTIVE;2.00;2.70 +27005-8;Xylose^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;Xylose sp9 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27006-6;Xylose^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Xylose sp8 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27007-4;acetoHEXAMIDE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetohexamide [Mass/volume] in Serum or Plasma;acetoHEXAMIDE SerPl-mCnc;;ACTIVE;2.00;2.73 +27008-2;Xylose^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Xylose sp6 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27009-0;Coccidioides sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Coccidioides sp IgG Ab [Units/volume] in Serum;Coccidioides IgG Ser-aCnc;;ACTIVE;2.00;2.73 +27010-8;Mesoporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Mesoporphyrin [Mass/time] in 24 hour Stool;Mesopor 24h Stl-mRate;;ACTIVE;2.00;2.70 +2701-1;Oxalate;MRat;24H;Urine;Qn;;CHEM;1;Oxalate [Mass/time] in 24 hour Urine;Oxalate 24h Ur-mRate;;ACTIVE;1.0;2.73 +27011-6;Cells.CD14;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD14 cells [#/volume] in Blood;CD14 Cells # Bld;;ACTIVE;2.00;2.73 +27012-4;Benzaldehyde;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Benzaldehyde [Presence] in Serum or Plasma;Benzaldehyde SerPl Ql;;ACTIVE;2.00;2.56 +27013-2;Alanine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Alanine [Moles/volume] in Amniotic fluid;Alanine Amn-sCnc;;ACTIVE;2.00;2.70 +27014-0;Inhibin A;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Inhibin A [Presence] in Serum or Plasma;Inhibin A SerPl Ql;;ACTIVE;2.00;2.73 +27015-7;Polychlorinated biphenyl;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Mass/volume] in Body fluid;PCB Fld-mCnc;;ACTIVE;2.00;2.70 +27016-5;Xylose^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Xylose sp7 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27017-3;Allyl alcohol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Allyl alcohol [Presence] in Serum or Plasma;Allyl Alc SerPl Ql;;ACTIVE;2.00;2.56 +27018-1;IgG.monoclonal;PrThr;Pt;Ser;Ord;;CHEM;1;IgG.monoclonal [Presence] in Serum;M-IgG Ser Ql;;ACTIVE;2.00;2.56 +27019-9;IgA.monoclonal;PrThr;Pt;Ser;Ord;;CHEM;1;IgA.monoclonal [Presence] in Serum;M-IgA Ser Ql;;ACTIVE;2.00;2.56 +27020-7;IgM.monoclonal;PrThr;Pt;Ser;Ord;;CHEM;1;IgM.monoclonal [Presence] in Serum;M-IgM Ser Ql;;ACTIVE;2.00;2.56 +27021-5;Neisseria gonorrhoeae Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Neisseria gonorrhoeae Ab [Titer] in Cerebral spinal fluid by Complement fixation;N gonorrhoea Ab Titr CSF CF;;ACTIVE;2.00;2.70 +27022-3;Para aminophenol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Para aminophenol/Creatinine [Mass Ratio] in Urine;p-Aminophenol/Creat Ur;;ACTIVE;2.00;2.70 +27023-1;Cells.CD8+CD11b+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+CD11b+ cells [#/volume] in Blood;CD8+CD11b+ Cells # Bld;;ACTIVE;2.00;2.42 +27024-9;Cannabinoids;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Cannabinoids [Mass/mass] in Meconium;Cannabinoids Mec-mCnt;;ACTIVE;2.00;2.70 +27025-6;glipiZIDE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;glipiZIDE [Mass/volume] in Urine;glipiZIDE Ur-mCnc;;ACTIVE;2.00;2.73 +27026-4;Benzoylecgonine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/mass] in Meconium;BZE Mec-mCnt;;ACTIVE;2.00;2.73 +27027-2;Cystine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Cystine [Moles/volume] in Amniotic fluid;Cystine Amn-sCnc;;ACTIVE;2.00;2.70 +27028-0;Ketones^2H post XXX challenge;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Ketones [Presence] in Urine by Test strip --2 hours post XXX challenge;Ketones 2h p chal Ur Ql Strip;;ACTIVE;2.00;2.56 +2702-9;Oxalate renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Oxalate renal clearance in 24 hour Urine and Serum or Plasma;Oxalate Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +27029-8;Norpropoxyphene;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/mass] in Meconium;Norpropoxyph Mec-mCnt;;ACTIVE;2.00;2.70 +27030-6;Myelin associated glycoprotein Ab.IgM;ACnc;Pt;CSF;Qn;;SERO;1;Myelin associated glycoprotein IgM Ab [Units/volume] in Cerebral spinal fluid;MAG IgM CSF-aCnc;;ACTIVE;2.00;2.69 +27031-4;Oxyphenisatin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxyphenisatin [Mass/volume] in Urine;Oxyphenisatin Ur-mCnc;;ACTIVE;2.00;2.73 +27032-2;Zirconium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zirconium [Mass/volume] in Serum or Plasma;Zirconium SerPl-mCnc;;ACTIVE;2.00;2.73 +27033-0;Proline;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Proline [Moles/volume] in Amniotic fluid;Proline Amn-sCnc;;ACTIVE;2.00;2.70 +27034-8;Drugs identified;Prid;Pt;Hair;Nom;Screen;DRUG/TOX;1;Drugs identified in Hair by Screen method;Drugs Hair Scn;;ACTIVE;2.00;2.73 +27035-5;Dihydrocodeine+Hydrocodeinone;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Dihydrocodeine+Hydrocodeinone [Mass/mass] in Meconium;DHC+Hydrocod Mec-mCnt;;ACTIVE;2.00;2.70 +27036-3;Norchlordiazepoxide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norchlordiazepoxide [Mass/volume] in Urine;Norchlordiazep Ur-mCnc;;ACTIVE;2.00;2.73 +2703-7;Oxygen;PPres;Pt;BldA;Qn;;CHEM;1;Oxygen [Partial pressure] in Arterial blood;pO2 BldA;;ACTIVE;1.0;2.73 +27037-1;Calcium/Creatinine;MRto;2H;Urine;Qn;;CHEM;1;Calcium/Creatinine [Mass Ratio] in 2 hour Urine;Calcium/Creat 2h Ur;;ACTIVE;2.00;2.44 +27038-9;Endomysium Ab.IgA;Titr;Pt;Ser;Qn;IF;SERO;1;Endomysium IgA Ab [Titer] in Serum by Immunofluorescence;Endomysium IgA Titr Ser IF;;ACTIVE;2.00;2.73 +27039-7;Ammonia;MCnc;24H;Urine;Qn;;CHEM;1;Ammonia [Mass/volume] in 24 hour Urine;Ammonia 24h Ur-mCnc;;ACTIVE;2.00;2.73 +27040-5;Ketones^1H post XXX challenge;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Ketones [Presence] in Urine by Test strip --1 hour post XXX challenge;Ketones 1h p chal Ur Ql Strip;;ACTIVE;2.00;2.56 +27041-3;Norpropoxyphene;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/mass] in Stool;Norpropoxyph Stl-mCnt;;ACTIVE;2.00;2.70 +27042-1;Methohexital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methohexital [Mass/volume] in Serum or Plasma;Methohexital SerPl-mCnc;;ACTIVE;2.00;2.70 +27043-9;Glutamine;SCnc;Pt;Urine;Qn;;CHEM;1;Glutamine [Moles/volume] in Urine;Glutamine Ur-sCnc;;ACTIVE;2.00;2.73 +27044-7;1-Methylhistidine;SCnc;Pt;Urine;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in Urine;1Me-hist Ur-sCnc;;ACTIVE;2.00;2.70 +2704-5;Oxygen;PPres;Pt;BldC;Qn;;CHEM;1;Oxygen [Partial pressure] in Capillary blood;pO2 BldC;;ACTIVE;1.0;2.73 +27045-4;Microscopic exam;Imp;Pt;Urine;Nom;Cytology;CYTO;1;Microscopic exam [Interpretation] of Urine by Cytology;Microscopic Ur-Imp;;ACTIVE;2.00;2.73 +27046-2;3-Methylhistidine;SCnc;Pt;Urine;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in Urine;3Me-histidine Ur-sCnc;;ACTIVE;2.00;2.70 +27047-0;Anserine;SCnc;Pt;Urine;Qn;;CHEM;1;Anserine [Moles/volume] in Urine;Anserine Ur-sCnc;;ACTIVE;2.00;2.73 +27048-8;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum;ENA SM+RNP Ab Ser-aCnc;;ACTIVE;2.00;2.73 +27049-6;Secobarbital;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Secobarbital [Mass/volume] in Milk;Secobarbital Mlk-mCnc;;ACTIVE;2.00;2.73 +27050-4;Mephobarbital;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Mephobarbital [Mass/volume] in Milk;Mephobarbital Mlk-mCnc;;ACTIVE;2.00;2.73 +27051-2;PHENobarbital;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;PHENobarbital [Mass/volume] in Milk;Phenobarb Mlk-mCnc;;ACTIVE;2.00;2.73 +2705-2;Oxygen;PPres;Pt;BldV;Qn;;CHEM;1;Oxygen [Partial pressure] in Venous blood;pO2 BldV;;ACTIVE;1.0;2.73 +27052-0;Methadone;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Milk;Methadone Mlk-mCnc;;ACTIVE;2.00;2.70 +27053-8;Morphine;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Morphine [Mass/volume] in Cerebral spinal fluid;Morphine CSF-mCnc;;ACTIVE;2.00;2.70 +27054-6;Morphine.free;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Morphine Free [Mass/volume] in Cerebral spinal fluid;Morphine Free CSF-mCnc;;ACTIVE;2.00;2.70 +27055-3;Catecholamines.free;MRat;24H;Urine;Qn;;CHEM;1;Catecholamines Free [Mass/time] in 24 hour Urine;FCA 24h Ur-mRate;;ACTIVE;2.00;2.73 +27056-1;Citrulline;SCnc;Pt;Urine;Qn;;CHEM;1;Citrulline [Moles/volume] in Urine;Citrulline Ur-sCnc;;ACTIVE;2.00;2.73 +27057-9;Serotonin;MCnc;Pt;Ser;Qn;;CHEM;1;Serotonin [Mass/volume] in Serum;Serotonin Ser-mCnc;;ACTIVE;2.00;2.73 +27058-7;Beta alanine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Beta alanine [Moles/volume] in Amniotic fluid;B-Alanine Amn-sCnc;;ACTIVE;2.00;2.70 +27059-5;traZODone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;traZODone [Mass/volume] in Urine;traZODone Ur-mCnc;;ACTIVE;2.00;2.73 +2706-0;Oxygen;PPres;Pt;Body fld;Qn;;CHEM;1;Oxygen [Partial pressure] in Body fluid;pO2 Fld;;ACTIVE;1.0;2.30 +27060-3;Melatonin;PrThr;Pt;Saliva;Ord;;CHEM;1;Melatonin [Presence] in Saliva (oral fluid);Melatonin Sal Ql;;ACTIVE;2.00;2.56 +27061-1;Butabarbital;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Butabarbital [Mass/mass] in Meconium;Butabarbital Mec-mCnt;;ACTIVE;2.00;2.70 +27062-9;Ketones^1H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --1 hour post XXX challenge;Ketones 1h p chal Ur Ql;;ACTIVE;2.00;2.56 +27063-7;Benzodiazepines;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/mass] in Stool;Benzodiaz Stl-mCnt;;ACTIVE;2.00;2.70 +27064-5;Opiates;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Opiates [Mass/mass] in Stool;Opiates Stl-mCnt;;ACTIVE;2.00;2.70 +27065-2;Ketones^2H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --2 hours post XXX challenge;Ketones 2h p chal Ur Ql;;ACTIVE;2.00;2.56 +27066-0;Ketones^3H post XXX challenge;PrThr;Pt;Urine;Ord;;CHAL;1;Ketones [Presence] in Urine --3 hours post XXX challenge;Ketones 3h p chal Ur Ql;;ACTIVE;2.00;2.56 +27067-8;Propoxyphene;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Propoxyphene [Mass/mass] in Meconium;Propoxyph Mec-mCnt;;ACTIVE;2.00;2.73 +27068-6;Purkinje cells Ab;ACnc;Pt;Ser;Qn;;SERO;1;Purkinje cells Ab [Units/volume] in Serum;Purkinje Cells Ab Ser-aCnc;;ACTIVE;2.00;2.73 +27069-4;Cisapride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cisapride [Mass/volume] in Serum or Plasma;Cisapride SerPl-mCnc;;ACTIVE;2.00;2.70 +27070-2;Loratadine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Loratadine [Mass/volume] in Serum or Plasma;Loratadine SerPl-mCnc;;ACTIVE;2.00;2.70 +27071-0;Cells.CD45;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD45 (Lymphs) cells [#/volume] in Blood;CD45 Cells # Bld;;ACTIVE;2.00;2.73 +27072-8;14-3-3 Ag;ACnc;Pt;CSF;Qn;IA;SERO;1;14-3-3 Ag [Units/volume] in Cerebral spinal fluid by Immunoassay;14-3-3 Ag CSF IA-aCnc;;ACTIVE;2.00;2.69 +27073-6;6-Monoacetylmorphine;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated acetylmorphine [Presence] in Urine;Deprecated 6MAM Ur Ql;;DEPRECATED;2.00;2.40 +27074-4;Methylenedioxyethylamphetamine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Milk;MDEA Mlk-mCnc;;ACTIVE;2.00;2.73 +27075-1;Lycopene;SCnc;Pt;Plas;Qn;;CHEM;1;Lycopene [Moles/volume] in Plasma;Lycopene Plas-sCnc;;ACTIVE;2.00;2.70 +27076-9;Dextromethorphan+Levorphanol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dextromethorphan+Levorphanol [Presence] in Urine;D-methorphan+Levorphanol Ur Ql;;ACTIVE;2.00;2.73 +27077-7;Enterococcus sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Enterococcus sp IgM Ab [Units/volume] in Serum;Enterococ IgM Ser-aCnc;;ACTIVE;2.00;2.69 +2707-8;Oxygen affinity;-;Pt;Bld;Qn;;CHEM;1;Deprecated Oxygen affinity in Blood;Deprecated O2 Afnty Bld;;DEPRECATED;1.0;2.66 +27078-5;Carotene.alpha;SCnc;Pt;Plas;Qn;;CHEM;1;Carotene.alpha [Moles/volume] in Plasma;A-Carotene Plas-sCnc;;ACTIVE;2.00;2.70 +27079-3;Methylenedioxyethylamphetamine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/mass] in Stool;MDEA Stl-mCnt;;ACTIVE;2.00;2.40 +27080-1;Methylenedioxyethylamphetamine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/mass] in Meconium;MDEA Mec-mCnt;;ACTIVE;2.00;2.73 +27081-9;Itraconazole+Hydroxyitraconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Itraconazole+Hydroxyitraconazole [Mass/volume] in Serum or Plasma;Itraconaz+HIT SerPl-mCnc;;ACTIVE;2.00;2.73 +27082-7;Delavirdine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Delavirdine [Mass/volume] in Serum or Plasma;Delavirdine SerPl-mCnc;;ACTIVE;2.00;2.70 +27083-5;Norflunitrazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norflunitrazepam [Mass/volume] in Urine;Norflunitrazepam Ur-mCnc;;ACTIVE;2.00;2.73 +27084-3;7-Aminoflunitrazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;7-Aminoflunitrazepam [Mass/volume] in Urine;7Aminoflunitrazepam Ur-mCnc;;ACTIVE;2.00;2.73 +27085-0;Methylenedioxyethylamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Urine;MDEA Ur-mCnc;;ACTIVE;2.00;2.73 +2708-6;Oxygen saturation;MFr;Pt;BldA;Qn;;CHEM;1;Oxygen saturation in Arterial blood;SaO2 % BldA;;ACTIVE;1.0;2.73 +27086-8;Cannabinoids;PrThr;Pt;Vitr fld;Ord;;DRUG/TOX;1;Cannabinoids [Presence] in Vitreous fluid;Cannabinoids Vitf Ql;;ACTIVE;2.00;2.56 +27087-6;Herpes simplex virus 2 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 2 Ab [Units/volume] in Cerebral spinal fluid;HSV2 Ab CSF-aCnc;;ACTIVE;2.00;2.69 +27088-4;Folate;PrThr;Pt;Bld;Ord;;CHEM;1;Folate [Presence] in Blood;Folate Bld Ql;;ACTIVE;2.00;2.56 +27089-2;Asparagine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Asparagine [Moles/volume] in Amniotic fluid;Asparagine Amn-sCnc;;ACTIVE;2.00;2.70 +270-9;Gramicidin D;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Gramicidin D [Susceptibility] by Minimum lethal concentration (MLC);Gramicidin D Islt MLC;;ACTIVE;1.0;2.19 +27090-0;Entamoeba histolytica Ab.IgA;PrThr;Pt;Saliva;Ord;;MICRO;1;Entamoeba histolytica IgA Ab [Presence] in Saliva (oral fluid);E histolyt IgA Sal Ql;;ACTIVE;2.00;2.56 +27091-8;Calcium;MRat;4H;Urine;Qn;;CHEM;1;Calcium [Mass/time] in 4 hour Urine;Calcium 4h Ur-mRate;;ACTIVE;2.00;2.70 +27092-6;Streptococcus pneumoniae 1 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Mass/volume] in Serum;Deprecated S pneum 1 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27093-4;Leptospira sp Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Leptospira sp IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Leptospira IgG CSF IA-aCnc;;ACTIVE;2.00;2.69 +2709-4;Oxygen saturation;MFr;Pt;BldC;Qn;;HEMODYN.MOLEC;2;Oxygen saturation in Capillary blood;SaO2 % BldC;;ACTIVE;1.0;2.73 +27094-2;Streptococcus pneumoniae 4 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Mass/volume] in Serum;Deprecated S pneum4 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27095-9;Parvovirus B19 Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Titer] in Cerebral spinal fluid;B19V IgG Titr CSF;;ACTIVE;2.00;2.70 +27096-7;Streptococcus pneumoniae 3 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Mass/volume] in Serum;Deprecated S pneum3 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27097-5;2-Methylbutyrylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Methylbutyrylglycine/Creatinine [Mass Ratio] in Urine;2Me-butyrylglycine/Creat Ur;;ACTIVE;2.00;2.73 +27098-3;Methionine;PrThr;24H;Urine;Ord;;CHEM;1;Methionine [Presence] in 24 hour Urine;Methionine 24h Ur Ql;;ACTIVE;2.00;2.56 +27099-1;Riboflavin;PrThr;Pt;Bld;Ord;;CHEM;1;Riboflavin [Presence] in Blood;Vit B2 Bld Ql;;ACTIVE;2.00;2.56 +27100-7;Probenecid;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Probenecid [Mass/volume] in Serum or Plasma;Probenecid SerPl-mCnc;;ACTIVE;2.00;2.70 +27101-5;Phenmetrazine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Phenmetrazine [Mass/volume] in Milk;Phenmetrazine Mlk-mCnc;;ACTIVE;2.00;2.70 +2710-2;Oxygen saturation;MFr;Pt;BldC;Qn;Oximetry;HEMODYN.MOLEC;2;Deprecated Oxygen saturation in Capillary blood by Oximetry;Deprecated SaO2 % BldC Oximetry;;DEPRECATED;1.0;2.70 +27102-3;Phendimetrazine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Phendimetrazine [Mass/volume] in Milk;Phendimetrazine Mlk-mCnc;;ACTIVE;2.00;2.70 +27103-1;Procyclidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Procyclidine [Mass/volume] in Urine;Procyclidine Ur-mCnc;;ACTIVE;2.00;2.70 +27104-9;Glutamate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Glutamate [Moles/volume] in Amniotic fluid;Glutamate Amn-sCnc;;ACTIVE;2.00;2.70 +27105-6;Amphetamines;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Milk;Amphetamines Mlk-mCnc;;ACTIVE;2.00;2.70 +27106-4;Zinc;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Zinc [Presence] in Blood;Zinc Bld Ql;;ACTIVE;2.00;2.73 +27107-2;Lysine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Lysine [Moles/volume] in Amniotic fluid;Lysine Amn-sCnc;;ACTIVE;2.00;2.42 +27108-0;Oleate;PrThr;Pt;Bld;Ord;;CHEM;1;Oleate (C18:1w9) [Presence] in Blood;Oleate Bld Ql;;ACTIVE;2.00;2.56 +27109-8;PARoxetine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;PARoxetine [Presence] in Urine;PARoxetine Ur Ql;;ACTIVE;2.00;2.73 +2711-0;Oxygen saturation;MFr;Pt;BldV;Qn;;HEMODYN.MOLEC;2;Oxygen saturation in Venous blood;SaO2 % BldV;;ACTIVE;1.0;2.73 +27110-6;Androsterone;MCnc;Pt;Urine;Qn;;CHEM;1;Androsterone [Mass/volume] in Urine;Androsterone Ur-mCnc;;ACTIVE;2.00;2.73 +27111-4;Histidine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Histidine [Moles/volume] in Amniotic fluid;Histidine Amn-sCnc;;ACTIVE;2.00;2.70 +27112-2;Microscopic observation;Prid;Pt;Body fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Body fluid by Gram stain;Gram Stn Fld;;ACTIVE;2.00;2.73 +27113-0;Streptococcus pneumoniae 8 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Mass/volume] in Serum;Deprecated S pneum8 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27114-8;Cocaine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cocaine [Mass/mass] in Hair;Cocaine Hair-mCnt;;ACTIVE;2.00;2.73 +27115-5;Parvovirus B19 Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Titer] in Cerebral spinal fluid;B19V IgM Titr CSF;;ACTIVE;2.00;2.70 +27116-3;Methamphetamine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Methamphetamine [Mass/volume] in Milk;Methamphet Mlk-mCnc;;ACTIVE;2.00;2.70 +27117-1;Cadmium;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Cadmium [Mass/mass] in Red Blood Cells;Cadmium RBC-mCnt;;ACTIVE;2.00;2.70 +27118-9;Streptococcus pneumoniae Danish serotype 6B Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Mass/volume] in Serum;S pneum Da 6B IgG Ser-mCnc;;ACTIVE;2.00;2.73 +27119-7;Streptococcus pneumoniae 23 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum23 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27120-5;Streptococcus pneumoniae Danish serotype 7F Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 7F Ab sp2 Ser-mCnc;;ACTIVE;2.00;2.73 +27121-3;Streptococcus pneumoniae Danish serotype 18C Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 18C Ab sp2 Ser-mCnc;;ACTIVE;2.00;2.73 +27122-1;Magnesium;MCnt;Pt;RBC;Qn;;CHEM;1;Magnesium [Mass/mass] in Red Blood Cells;Magnesium RBC-mCnt;;ACTIVE;2.00;2.70 +27123-9;Phosphate;MCnt;Pt;RBC;Qn;;CHEM;1;Phosphate [Mass/mass] in Red Blood Cells;Phosphate RBC-mCnt;;ACTIVE;2.00;2.70 +27124-7;Copper;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Copper [Mass/mass] in Red Blood Cells;Copper RBC-mCnt;;ACTIVE;2.00;2.70 +27125-4;Zinc;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Zinc [Mass/mass] in Red Blood Cells;Zinc RBC-mCnt;;ACTIVE;2.00;2.73 +27126-2;Streptococcus pneumoniae 14 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum14 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27127-0;Arsenic;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Arsenic [Mass/mass] in Red Blood Cells;Arsenic RBC-mCnt;;ACTIVE;2.00;2.70 +2712-8;Oxygen saturation.calc from carbon dioxide.partial pressure;MFr;Pt;Bld;Qn;;CHEM;1;Deprecated Oxygen saturation.calc from carbon dioxide.partial pressure;Deprecated O2 Satn from pCO2 Fr Bld;;DEPRECATED;1.0;2.70 +27128-8;Streptococcus pneumoniae 12 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum12 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27129-6;Lead;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Lead [Mass/mass] in Red Blood Cells;Lead RBC-mCnt;;ACTIVE;2.00;2.73 +27130-4;Mercury;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Mercury [Mass/mass] in Red Blood Cells;Mercury RBC-mCnt;;ACTIVE;2.00;2.70 +27131-2;Phencyclidine;PrThr;Pt;Vitr fld;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Vitreous fluid;PCP Vitf Ql;;ACTIVE;2.00;2.56 +27132-0;Acetoacetate;PrThr;Pt;Urine;Ord;;CHEM;1;Acetoacetate [Presence] in Urine;Acetoacet Ur Ql;;ACTIVE;2.00;2.73 +27133-8;Citrate;PrThr;Pt;Urine;Ord;;CHEM;1;Citrate [Presence] in Urine;Citrate Ur Ql;;ACTIVE;2.00;2.56 +27134-6;Argininosuccinate;PrThr;Pt;Urine;Ord;;CHEM;1;Argininosuccinate [Presence] in Urine;Argininosuccinate Ur Ql;;ACTIVE;2.00;2.56 +27135-3;Tryptophan;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Tryptophan [Moles/volume] in Amniotic fluid;Tryptophan Amn-sCnc;;ACTIVE;2.00;2.70 +2713-6;Oxygen saturation;MFr;Pt;Bld;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation Calculated from oxygen partial pressure in Blood;SaO2 % Bld from pO2;;ACTIVE;1.0;2.73 +27136-1;Opiates;PrThr;Pt;Vitr fld;Ord;;DRUG/TOX;1;Opiates [Presence] in Vitreous fluid;Opiates Vitf Ql;;ACTIVE;2.00;2.73 +27137-9;Antimony;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Antimony [Mass/mass] in Red Blood Cells;Antimony RBC-mCnt;;ACTIVE;2.00;2.70 +27138-7;Streptococcus pneumoniae 23 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum23 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27139-5;Streptococcus pneumoniae 7f Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 51 IgG Ab [Mass/volume] in Serum;Deprecated S pneum7f IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27140-3;Follitropin.alpha subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin.alpha subunit [Mass/volume] in Serum or Plasma;A-FSH SerPl-mCnc;;DISCOURAGED;2.00;2.70 +27141-1;Streptococcus pneumoniae 1 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum 1 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27142-9;Streptococcus pneumoniae 3 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum3 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27143-7;Streptococcus pneumoniae 4 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum4 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +2714-4;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;BldA;Qn;;CHEM;1;Fractional oxyhemoglobin in Arterial blood;OxyHgb MFr BldA;;ACTIVE;1.0;2.73 +27144-5;Streptococcus pneumoniae 8 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum8 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27145-2;Streptococcus pneumoniae 9 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum9 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27146-0;Streptococcus pneumoniae 12 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum12 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27147-8;Streptococcus pneumoniae 19 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum19 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27148-6;Streptococcus pneumoniae 19 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum19 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27149-4;Thiamine;PrThr;Pt;Bld;Ord;;CHEM;1;Thiamine [Presence] in Blood;Vit B1 Bld Ql;;ACTIVE;2.00;2.73 +27150-2;Streptococcus pneumoniae Danish serotype 7F Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F Ab [Mass/volume] in Serum --1st specimen;S pneum Da 7F Ab sp1 Ser-mCnc;;ACTIVE;2.00;2.70 +2715-1;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;BldC;Qn;;CHEM;1;Fractional oxyhemoglobin in Capillary blood;OxyHgb MFr BldC;;ACTIVE;1.0;2.73 +27151-0;Streptococcus pneumoniae Danish serotype 18C Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C Ab [Mass/volume] in Serum --1st specimen;S pneum Da 18C Ab sp1 Ser-mCnc;;ACTIVE;2.00;2.70 +27152-8;Streptococcus pneumoniae 1 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum 1 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27153-6;Streptococcus pneumoniae 3 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum3 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27154-4;Streptococcus pneumoniae 4 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum4 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27155-1;Streptococcus pneumoniae 6 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum6 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27156-9;Streptococcus pneumoniae 8 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum8 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27157-7;Streptococcus pneumoniae 9 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum9 Ab sp2 Ser-mCnc;;DEPRECATED;2.00;2.70 +27158-5;Streptococcus pneumoniae 14 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum14 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +27159-3;Herpes virus 6 Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes virus 6 IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HHV6 IgM Titr CSF IF;;ACTIVE;2.00;2.70 +27160-1;Hydrastine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Hydrastine [Presence] in Serum or Plasma;Hydrastine SerPl Ql;;ACTIVE;2.00;2.73 +27161-9;Interleukin 4;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 4 [Mass/volume] in Serum or Plasma;Il4 SerPl-mCnc;;ACTIVE;2.00;2.73 +27162-7;1-Methylhistidine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in Amniotic fluid;1Me-hist Amn-sCnc;;ACTIVE;2.00;2.70 +27163-5;N-methylacetamide/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;N-methylacetamide/Creatinine [Mass Ratio] in Urine;NMA/Creat Ur;;ACTIVE;2.00;2.73 +27164-3;acetoHEXAMIDE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetohexamide [Mass/volume] in Urine;acetoHEXAMIDE Ur-mCnc;;ACTIVE;2.00;2.73 +27165-0;Hexobarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hexobarbital [Mass/volume] in Urine;Hexobarbital Ur-mCnc;;ACTIVE;2.00;2.70 +27166-8;TOLAZamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;TOLAZamide [Mass/volume] in Urine;TOLAZamide Ur-mCnc;;ACTIVE;2.00;2.73 +27167-6;Chlamydia trachomatis Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydia trachomatis IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C trach IgM Titr CSF IF;;ACTIVE;2.00;2.70 +27168-4;Herpes virus 6 Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes virus 6 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HHV6 IgG Titr CSF IF;;ACTIVE;2.00;2.70 +2716-9;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;BldV;Qn;;CHEM;1;Fractional oxyhemoglobin in Venous blood;OxyHgb MFr BldV;;ACTIVE;1.0;2.73 +27169-2;Butyrate;MCnt;Pt;Stool;Qn;;CHEM;1;Butyrate (C4) [Mass/mass] in Stool;Butyrate Stl-mCnt;;ACTIVE;2.00;2.70 +271-7;Gramicidin D;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Gramicidin D [Susceptibility] by Minimum inhibitory concentration (MIC);Gramicidin D Islt MIC;;ACTIVE;1.0;2.19 +27170-0;TOLBUTamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;TOLBUTamide [Mass/volume] in Urine;TOLBUTamide Ur-mCnc;;ACTIVE;2.00;2.73 +27171-8;Chlorphentermine;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Chlorphentermine [Mass/volume] in Milk;Chlorphentermin Mlk-mCnc;;ACTIVE;2.00;2.73 +27172-6;Calcium;MCnt;24H;Stool;Qn;;CHEM;1;Calcium [Mass/mass] in 24 hour Stool;Calcium 24h Stl-mCnt;;ACTIVE;2.00;2.70 +27173-4;Propylthiouracil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propylthiouracil [Mass/volume] in Urine;Propylthiouracil Ur-mCnc;;ACTIVE;2.00;2.70 +27174-2;Inhibin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin [Units/volume] in Serum or Plasma;Inhibin SerPl-aCnc;;ACTIVE;2.00;2.73 +27175-9;glyBURIDE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;glyBURIDE [Mass/volume] in Urine;glyBURIDE Ur-mCnc;;ACTIVE;2.00;2.73 +27176-7;3-Methylhistidine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in Amniotic fluid;3Me-histidine Amn-sCnc;;ACTIVE;2.00;2.70 +2717-7;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;Plas;Qn;;CHEM;1;Fractional oxyhemoglobin in Plasma;OxyHgb MFr Plas;;ACTIVE;1.0;2.70 +27177-5;Herpes virus 7 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 7 IgM Ab [Titer] in Serum by Immunofluorescence;HHV7 IgM Titr Ser IF;;ACTIVE;2.00;2.73 +27178-3;Phendimetrazine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Phendimetrazine [Mass/volume] in Vitreous fluid;Phendimetrazine Vitf-mCnc;;ACTIVE;2.00;2.70 +27179-1;Threonine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Threonine [Moles/volume] in Amniotic fluid;Threonine Amn-sCnc;;ACTIVE;2.00;2.70 +27180-9;Bisacodyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bisacodyl [Mass/volume] in Urine;Bisacodyl Ur-mCnc;;ACTIVE;2.00;2.73 +27181-7;Hydroxyproline;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in Amniotic fluid;OH-Proline Amn-sCnc;;ACTIVE;2.00;2.70 +27182-5;Calcium;PrThr;Pt;Bld;Ord;;CHEM;1;Calcium [Presence] in Blood;Calcium Bld Ql;;ACTIVE;2.00;2.73 +27183-3;Cardiolipin Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Cardiolipin IgG Ab [Presence] in Serum;Cardiolipin IgG Ser Ql;;ACTIVE;2.00;2.73 +27184-1;Alpha 1 globulin;PrThr;Pt;Urine;Ord;;CHEM;1;Alpha 1 globulin [Presence] in Urine;Alpha1 Glob Ur Ql;;ACTIVE;2.00;2.56 +2718-5;Oxytocin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Oxytocin [Mass/volume] in Serum or Plasma;Oxytocin SerPl-mCnc;;ACTIVE;1.0;2.73 +27185-8;Chlamydia trachomatis Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydia trachomatis IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C trach IgG Titr CSF IF;;ACTIVE;2.00;2.70 +27186-6;Lysozyme;PrThr;Pt;Stool;Ord;;CHEM;1;Lysozyme [Presence] in Stool;Lysozyme Stl Ql;;ACTIVE;2.00;2.56 +27187-4;Methohexital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methohexital [Mass/volume] in Urine;Methohexital Ur-mCnc;;ACTIVE;2.00;2.70 +27188-2;Methylenedioxymethamphetamine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Vitreous fluid;MDMA Vitf-mCnc;;ACTIVE;2.00;2.73 +27189-0;Methylenedioxyamphetamine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Vitreous fluid;MDA Vitf-mCnc;;ACTIVE;2.00;2.73 +27190-8;Propoxyphene;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Propoxyphene [Mass/volume] in Vitreous fluid;Propoxyph Vitf-mCnc;;ACTIVE;2.00;2.73 +27191-6;PHENobarbital;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;PHENobarbital [Mass/volume] in Vitreous fluid;Phenobarb Vitf-mCnc;;ACTIVE;2.00;2.70 +27192-4;diazePAM;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Vitreous fluid;diazePAM Vitf-mCnc;;ACTIVE;2.00;2.70 +2719-3;Palmitate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Palmitate (C16:0) [Mass/volume] in Serum or Plasma;Palmitate SerPl-mCnc;;DISCOURAGED;1.0;2.44 +27193-2;Tetrahydrocannabinol;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Vitreous fluid;THC Vitf-mCnc;;ACTIVE;2.00;2.70 +27194-0;N-desalkylflurazepam;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Vitreous fluid;Desalkylfluraz Vitf-mCnc;;ACTIVE;2.00;2.70 +27195-7;Hydroxylysine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Hydroxylysine [Moles/volume] in Amniotic fluid;OH-Lysine Amn-sCnc;;ACTIVE;2.00;2.70 +27196-5;HYDROmorphone.free;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;HYDROmorphone Free [Mass/volume] in Vitreous fluid;HYDROmorphone Free Vitf-mCnc;;ACTIVE;2.00;2.73 +27197-3;Benzodiazepines;PrThr;Pt;Vitr fld;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Vitreous fluid;Benzodiaz Vitf Ql;;ACTIVE;2.00;2.73 +27198-1;Bilirubin;ACnc;Pt;Amnio fld;Qn;Direct spectrophotometry;CHEM;1;Bilirubin.total [Units/volume] in Amniotic fluid by Spectrophotometry direct;Bilirub Amn Spectrp dir-aCnc;;ACTIVE;2.00;2.73 +27199-9;18-Hydroxycortisol/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;18-Hydroxycortisol/Creatinine [Mass Ratio] in 24 hour Urine;18OH-Cortis/Creat 24h Ur;;ACTIVE;2.00;2.70 +27200-5;Nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Nuclear Ab [Units/volume] in Serum;ANA Ser-aCnc;;ACTIVE;2.00;2.73 +2720-1;Palmitoylphosphatidyl choline;MCnc;Pt;Plas;Qn;;CHEM;1;Palmitoylphosphatidyl choline [Mass/volume] in Plasma;PPC Plas-mCnc;;ACTIVE;1.0;2.34 +27201-3;Zinc/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Zinc/Creatinine [Mass Ratio] in 24 hour Urine;Zinc/Creat 24h Ur;;ACTIVE;2.00;2.73 +27202-1;Halothane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Halothane [Mass/volume] in Blood;Hal Bld-mCnc;;ACTIVE;2.00;2.70 +27203-9;Follitropin;ACnc;24H;Urine;Qn;;CHEM;1;Follitropin [Units/volume] in 24 hour Urine;FSH 24h Ur-aCnc;;ACTIVE;2.00;2.70 +27204-7;Cocaine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Cocaine [Mass/volume] in Vitreous fluid;Cocaine Vitf-mCnc;;ACTIVE;2.00;2.73 +27205-4;Amphetamines;PrThr;Pt;Vitr fld;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Vitreous fluid;Amphetamines Vitf Ql;;ACTIVE;2.00;2.56 +27206-2;Morphine.free;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Morphine Free [Mass/volume] in Vitreous fluid;Morphine Free Vitf-mCnc;;ACTIVE;2.00;2.73 +27207-0;Methadone;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Vitreous fluid;Methadone Vitf-mCnc;;ACTIVE;2.00;2.73 +27208-8;Drugs identified;Prid;Pt;Stool;Nom;Screen;DRUG/TOX;1;Drugs identified in Stool by Screen method;Drugs Stl Scn;;ACTIVE;2.00;2.19 +27209-6;Histoplasma capsulatum yeast phase Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Histoplasma capsulatum yeast phase Ab [Titer] in Cerebral spinal fluid by Complement fixation;H capsul Yst Ab Titr CSF CF;;ACTIVE;2.00;2.73 +27210-4;Magnesium;PrThr;Pt;Bld;Ord;;CHEM;1;Magnesium [Presence] in Blood;Magnesium Bld Ql;;ACTIVE;2.00;2.56 +27211-2;Norpropoxyphene;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/mass] in Hair;Norpropoxyph Hair-mCnt;;ACTIVE;2.00;2.70 +27212-0;DOPamine;MCnc;24H;Urine;Qn;;CHEM;1;DOPamine [Mass/volume] in 24 hour Urine;DOPamine 24h Ur-mCnc;;ACTIVE;2.00;2.73 +27213-8;Carboxy tetrahydrocannabinol;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Vitreous fluid;CarboxyTHC Vitf-mCnc;;ACTIVE;2.00;2.70 +27214-6;Purkinje cells Ab;PrThr;Pt;Ser;Ord;;SERO;1;Purkinje cells Ab [Presence] in Serum;Purkinje Cells Ab Ser Ql;;ACTIVE;2.00;2.73 +27215-3;Mitochondria M2 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Mitochondria M2 IgG Ab [Units/volume] in Serum;Deprecated Mitochondria M2 IgG Ser-aCnc;;DEPRECATED;2.00;2.69 +27216-1;sulfADIAZINE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;sulfADIAZINE [Mass/volume] in Urine;sulfADIAZINE Ur-mCnc;;ACTIVE;2.00;2.70 +27217-9;Beta aminoisobutyrate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/volume] in Amniotic fluid;B-AIB Amn-sCnc;;ACTIVE;2.00;2.70 +27218-7;quiNINE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;quiNINE [Mass/volume] in Urine;quiNINE Ur-mCnc;;ACTIVE;2.00;2.70 +2721-9;Pancreatic polypeptide;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma;Panc Polypept SerPl-mCnc;;ACTIVE;1.0;2.73 +27219-5;Ornithine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Ornithine [Moles/volume] in Amniotic fluid;Ornithine Amn-sCnc;;ACTIVE;2.00;2.70 +27220-3;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Cerebral spinal fluid by Complement fixation;H capsul Myc Ab Titr CSF CF;;ACTIVE;2.00;2.73 +27221-1;Norepinephrine;MCnc;24H;Urine;Qn;;CHEM;1;Norepinephrine [Mass/volume] in 24 hour Urine;Norepineph 24h Ur-mCnc;;ACTIVE;2.00;2.73 +27222-9;Oxalate;MCnc;24H;Urine;Qn;;CHEM;1;Oxalate [Mass/volume] in 24 hour Urine;Oxalate 24h Ur-mCnc;;ACTIVE;2.00;2.73 +27223-7;Serine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Serine [Moles/volume] in Amniotic fluid;Serine Amn-sCnc;;ACTIVE;2.00;2.70 +27224-5;Barbiturates;PrThr;Pt;Vitr fld;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Vitreous fluid;Barbiturates Vitf Ql;;ACTIVE;2.00;2.73 +27225-2;Estriol;MCnc;Pt;Saliva;Qn;;CHEM;1;Estriol (E3) [Mass/volume] in Saliva (oral fluid);Estriol Sal-mCnc;;ACTIVE;2.00;2.73 +27226-0;Cocaethylene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cocaethylene [Mass/volume] in Serum or Plasma;Cocaethylene SerPl-mCnc;;ACTIVE;2.00;2.73 +2722-7;Pantothenate;MCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Pantothenate [Mass/volume] in Serum, Plasma or Blood;Pantothenate SerPlBld-mCnc;;ACTIVE;1.0;2.73 +27227-8;Streptococcus pneumoniae 1 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum 1 IgG Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27228-6;Streptococcus pneumoniae 3 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum3 IgG Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27229-4;Streptococcus pneumoniae 14 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum14 IgG Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27230-2;Streptococcus pneumoniae 19 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum19 IgG Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27231-0;Streptococcus pneumoniae 23 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum23 IgG Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27232-8;Lead;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Milk;Lead Mlk-mCnc;;ACTIVE;2.00;2.70 +27233-6;Lecithin;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Lecithin [Units/volume] in Amniotic fluid;Lecithin Amn-aCnc;;DISCOURAGED;2.00;2.69 +27234-4;Phentermine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Phentermine [Mass/volume] in Vitreous fluid;Phentermine Vitf-mCnc;;ACTIVE;2.00;2.73 +2723-5;Para aminohippurate renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Para aminohippurate renal clearance in 24 hour Urine and Serum or Plasma;PAH Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +27235-1;PHENobarbital;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;PHENobarbital [Mass/mass] in Meconium;Phenobarb Mec-mCnt;;ACTIVE;2.00;2.70 +27236-9;Azatadine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Azatadine [Mass/volume] in Serum or Plasma;Azatadine SerPl-mCnc;;ACTIVE;2.00;2.73 +27237-7;LORazepam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;LORazepam [Mass/mass] in Stool;LORazepam Stl-mCnt;;ACTIVE;2.00;2.70 +27238-5;Oxazepam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Oxazepam [Mass/mass] in Stool;Oxazepam Stl-mCnt;;ACTIVE;2.00;2.70 +27239-3;Nordiazepam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Nordiazepam [Mass/mass] in Stool;Nordiazepam Stl-mCnt;;ACTIVE;2.00;2.70 +27240-1;PHENobarbital;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;PHENobarbital [Mass/mass] in Stool;Phenobarb Stl-mCnt;;ACTIVE;2.00;2.70 +27241-9;Mephobarbital;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Mephobarbital [Mass/mass] in Stool;Mephobarbital Stl-mCnt;;ACTIVE;2.00;2.70 +27242-7;Secobarbital;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Secobarbital [Mass/mass] in Stool;Secobarbital Stl-mCnt;;ACTIVE;2.00;2.70 +2724-3;Para aminohippurate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Para aminohippurate [Mass/volume] in Urine;PAH Ur-mCnc;;ACTIVE;1.0;2.42 +27243-5;PENTobarbital;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;PENTobarbital [Mass/mass] in Stool;Pentobarb Stl-mCnt;;ACTIVE;2.00;2.70 +27244-3;Methylenedioxyamphetamine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/mass] in Meconium;MDA Mec-mCnt;;ACTIVE;2.00;2.73 +27245-0;Amobarbital;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Amobarbital [Mass/mass] in Stool;Amobarbital Stl-mCnt;;ACTIVE;2.00;2.70 +27246-8;Butalbital;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Butalbital [Mass/mass] in Stool;Butalbital Stl-mCnt;;ACTIVE;2.00;2.70 +27247-6;Hydroxyethylflurazepam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/mass] in Stool;OH-Ethylfluraz Stl-mCnt;;ACTIVE;2.00;2.70 +27248-4;Benzoylecgonine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/mass] in Stool;BZE Stl-mCnt;;ACTIVE;2.00;2.70 +27249-2;Temazepam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Temazepam [Mass/mass] in Stool;Temazepam Stl-mCnt;;ACTIVE;2.00;2.70 +272-5;Gramicidin D;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Gramicidin D [Susceptibility] by Disk diffusion (KB);Gramicidin D Islt KB;;ACTIVE;1.0;2.19 +2725-0;Para methylhippurate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Para methylhippurate [Mass/volume] in Urine;p-Methylhippurate Ur-mCnc;;ACTIVE;1.0;2.42 +27250-0;Phenmetrazine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Phenmetrazine [Mass/volume] in Vitreous fluid;Phenmetrazine Vitf-mCnc;;ACTIVE;2.00;2.73 +27251-8;Phenylpropanolamine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Phenylpropanolamine [Mass/volume] in Vitreous fluid;PPA Vitf-mCnc;;ACTIVE;2.00;2.73 +27252-6;Choriogonadotropin.alpha subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.alpha subunit [Mass/volume] in Serum or Plasma;A-HCG SerPl-mCnc;;ACTIVE;2.00;2.70 +27253-4;Chlorphentermine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Chlorphentermine [Mass/volume] in Vitreous fluid;Chlorphentermin Vitf-mCnc;;ACTIVE;2.00;2.70 +27254-2;Amino beta guanidinopropionate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Amino beta guanidinopropionate/Creatinine [Molar ratio] in Urine;AB-Gp/Creat Ur-sRto;;ACTIVE;2.00;2.42 +27255-9;Magnesium;SCnt;24H;Stool;Qn;;CHEM;1;Magnesium [Moles/mass] in 24 hour Stool;Magnesium 24h Stl-sCnt;;ACTIVE;2.00;2.70 +27256-7;Aspartate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Aspartate [Moles/volume] in Amniotic fluid;Aspartate Amn-sCnc;;ACTIVE;2.00;2.70 +27257-5;Sodium;SCnt;24H;Stool;Qn;;CHEM;1;Sodium [Moles/mass] in 24 hour Stool;Sodium 24h Stl-sCnt;;ACTIVE;2.00;2.73 +27258-3;Protein;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Protein [Mass/volume] in Serum or Plasma;Deprecated Prot SerPl-sCnc;;DEPRECATED;2.00;2.70 +27259-1;Estriol.unconjugated;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Estriol (E3).unconjugated [Presence] in Serum or Plasma;u Estriol SerPl Ql;;ACTIVE;2.00;2.73 +27260-9;Schistosoma sp Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Schistosoma sp IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Schistosoma IgG CSF IA-aCnc;;ACTIVE;2.00;2.69 +27261-7;Polio virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Polio virus Ab [Titer] in Serum by Complement fixation;PV Ab Titr Ser CF;;ACTIVE;2.00;2.70 +27262-5;Methaqualone;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Methaqualone [Mass/mass] in Meconium;Methaqualone Mec-mCnt;;ACTIVE;2.00;2.73 +27263-3;Amphetamines;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Vitreous fluid;Amphetamines Vitf-mCnc;;ACTIVE;2.00;2.73 +27264-1;Aluminum;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Cerebral spinal fluid;Aluminum CSF-mCnc;;ACTIVE;2.00;2.70 +27265-8;Giardia sp Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia sp Ag [Presence] in Stool;Giardia Ag Stl Ql;;ACTIVE;2.00;2.73 +27266-6;Histoplasma capsulatum Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Histoplasma capsulatum Ab [Titer] in Serum by Immune diffusion (ID);H capsul Ab Titr Ser ID;;ACTIVE;2.00;2.73 +27267-4;Homovanillate;PrThr;Pt;Urine;Ord;;CHEM;1;Homovanillate [Presence] in Urine;HVA Ur Ql;;ACTIVE;2.00;2.56 +2726-8;Para nitrophenol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Para nitrophenol [Presence] in Urine;p-nitrophenol Ur Ql;;ACTIVE;1.0;2.56 +27268-2;Hydroxydecanedioate;PrThr;Pt;Urine;Ord;;CHEM;1;Hydroxydecanedioate [Presence] in Urine;OH-Decanedioate Ur Ql;;ACTIVE;2.00;2.73 +27269-0;Isocitrate;PrThr;Pt;Urine;Ord;;CHEM;1;Isocitrate [Presence] in Urine;Isocitrate Ur Ql;;ACTIVE;2.00;2.56 +27270-8;4-Hydroxyphenylacetate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;4-Hydroxyphenylacetate [Presence] in Urine;4OH-phenylacetate Ur Ql;;ACTIVE;2.00;2.73 +27271-6;Alpha ketoglutarate;PrThr;Pt;Urine;Ord;;CHEM;1;Alpha ketoglutarate [Presence] in Urine;A-Ketoglut Ur Ql;;ACTIVE;2.00;2.73 +27272-4;3-Hydroxyisobutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxyisobutyrate [Presence] in Urine;3OH-Isobutyrate Ur Ql;;ACTIVE;2.00;2.73 +27273-2;Chlamydia sp Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydia sp Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Chlamydia Ab Titr CSF IF;;ACTIVE;2.00;2.70 +27274-0;Benzfetamine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Deprecated Benzfetamine [Mass/mass] in Meconium;Deprecated Benzfetamine Mec-mCnt;;DEPRECATED;2.00;2.70 +27275-7;diazePAM;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;diazePAM [Mass/mass] in Stool;diazePAM Stl-mCnt;;ACTIVE;2.00;2.70 +2727-6;Para nitrophenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Para nitrophenol [Mass/volume] in Urine;p-nitrophenol Ur-mCnc;;ACTIVE;1.0;2.73 +27276-5;Azatadine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Azatadine [Mass/volume] in Urine;Azatadine Ur-mCnc;;ACTIVE;2.00;2.70 +27277-3;Methamphetamine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Methamphetamine [Mass/volume] in Vitreous fluid;Methamphet Vitf-mCnc;;ACTIVE;2.00;2.73 +27278-1;Phosphoethanolamine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphoethanolamine [Moles/volume] in Amniotic fluid;PETN Amn-sCnc;;ACTIVE;2.00;2.70 +27279-9;Paraoxon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Paraoxon [Mass/volume] in Serum or Plasma;Paraoxon SerPl-mCnc;;ACTIVE;2.00;2.73 +27280-7;Tripelennamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tripelennamine [Mass/volume] in Urine;Tripelennamine Ur-mCnc;;ACTIVE;2.00;2.70 +27281-5;Propoxyphene;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Propoxyphene [Mass/mass] in Stool;Propoxyph Stl-mCnt;;ACTIVE;2.00;2.70 +27282-3;Carbinoxamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carbinoxamine [Mass/volume] in Urine;Carbinoxamine Ur-mCnc;;ACTIVE;2.00;2.70 +27283-1;Methadone;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Methadone [Mass/mass] in Stool;Methadone Stl-mCnt;;ACTIVE;2.00;2.70 +2728-4;Parathion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Parathion [Mass/volume] in Serum or Plasma;Parathion SerPl-mCnc;;ACTIVE;1.0;2.73 +27284-9;Brompheniramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Brompheniramine [Mass/volume] in Urine;Brompheniramine Ur-mCnc;;ACTIVE;2.00;2.70 +27285-6;Estazolam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Estazolam [Mass/mass] in Stool;Estazolam Stl-mCnt;;ACTIVE;2.00;2.70 +27286-4;Triazolam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Triazolam [Mass/mass] in Stool;Triazolam Stl-mCnt;;ACTIVE;2.00;2.70 +27287-2;Flurazepam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Flurazepam [Mass/mass] in Stool;Flurazepam Stl-mCnt;;ACTIVE;2.00;2.70 +27288-0;Midazolam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Midazolam [Mass/mass] in Stool;Midazolam Stl-mCnt;;ACTIVE;2.00;2.70 +27289-8;Methamphetamine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Methamphetamine [Mass/mass] in Meconium;Methamphet Mec-mCnt;;ACTIVE;2.00;2.73 +27290-6;Phenmetrazine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Phenmetrazine [Mass/mass] in Stool;Phenmetrazine Stl-mCnt;;ACTIVE;2.00;2.70 +27291-4;Hydroxylysine;SCnc;Pt;Urine;Qn;;CHEM;1;Hydroxylysine [Moles/volume] in Urine;OH-Lysine Ur-sCnc;;ACTIVE;2.00;2.73 +2729-2;Parathyrin related protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin related protein [Mass/volume] in Serum or Plasma;PTH Related Prot SerPl-mCnc;;ACTIVE;1.0;2.73 +27292-2;Ornithine;SCnc;Pt;Urine;Qn;;CHEM;1;Ornithine [Moles/volume] in Urine;Ornithine Ur-sCnc;;ACTIVE;2.00;2.73 +27293-0;oxyCODONE.free;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;oxyCODONE Free [Mass/mass] in Stool;oxyCODONE Free Stl-mCnt;;ACTIVE;2.00;2.70 +27294-8;Carnosine;SCnc;Pt;Urine;Qn;;CHEM;1;Carnosine [Moles/volume] in Urine;Carnosine Ur-sCnc;;ACTIVE;2.00;2.70 +27295-5;Cocaethylene;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Cocaethylene [Mass/mass] in Stool;Cocaethylene Stl-mCnt;;ACTIVE;2.00;2.70 +27296-3;Arginine;SCnc;Pt;Urine;Qn;;CHEM;1;Arginine [Moles/volume] in Urine;Arginine Ur-sCnc;;ACTIVE;2.00;2.70 +27297-1;Leukocyte esterase;ACnc;Pt;Urine;Qn;;UA;1;Leukocyte esterase [Units/volume] in Urine;Leukocyte esterase Ur-aCnc;;ACTIVE;2.00;2.73 +27298-9;Protein;ACnc;Pt;Urine;Qn;;UA;1;Protein [Units/volume] in Urine;Prot Ur-aCnc;;ACTIVE;2.00;2.73 +27299-7;Methylenedioxyethylamphetamine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Vitreous fluid;MDEA Vitf-mCnc;;ACTIVE;2.00;2.73 +27-3;Ampicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ampicillin [Susceptibility] by Minimum lethal concentration (MLC);Ampicillin Islt MLC;;ACTIVE;1.0;2.19 +2730-0;Parathyrin.C-terminal;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.C-terminal [Mass/volume] in Serum or Plasma;PTH-C SerPl-mCnc;;ACTIVE;1.0;2.73 +27300-3;Mephentermine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Mephentermine [Mass/volume] in Vitreous fluid;Mephentermine Vitf-mCnc;;ACTIVE;2.00;2.70 +27301-1;Glutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutarate [Moles/volume] in Serum or Plasma;Glutarate SerPl-sCnc;;ACTIVE;2.00;2.73 +27302-9;Midazolam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Midazolam [Mass/mass] in Meconium;Midazolam Mec-mCnt;;ACTIVE;2.00;2.70 +27303-7;Phendimetrazine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Phendimetrazine [Mass/mass] in Stool;Phendimetrazine Stl-mCnt;;ACTIVE;2.00;2.70 +27304-5;Lysine;SCnc;Pt;Urine;Qn;;CHEM;1;Lysine [Moles/volume] in Urine;Lysine Ur-sCnc;;ACTIVE;2.00;2.70 +27305-2;Phentermine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Phentermine [Mass/mass] in Stool;Phentermine Stl-mCnt;;ACTIVE;2.00;2.70 +27306-0;Testosterone;PrThr;Pt;Saliva;Ord;;CHEM;1;Testosterone [Presence] in Saliva (oral fluid);Testost Sal Ql;;ACTIVE;2.00;2.56 +27307-8;Chlorphentermine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Chlorphentermine [Mass/mass] in Stool;Chlorphentermin Stl-mCnt;;ACTIVE;2.00;2.70 +27308-6;PENTobarbital;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;PENTobarbital [Mass/mass] in Meconium;Pentobarb Mec-mCnt;;ACTIVE;2.00;2.70 +27309-4;Aspergillus flavus Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Aspergillus flavus Ab [Titer] in Serum by Immune diffusion (ID);A flavus Ab Titr Ser ID;;ACTIVE;2.00;2.73 +27310-2;Taurine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Taurine [Moles/volume] in Amniotic fluid;Taurine Amn-sCnc;;ACTIVE;2.00;2.70 +27311-0;Codeine.free;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Codeine Free [Mass/mass] in Stool;Codeine Free Stl-mCnt;;ACTIVE;2.00;2.70 +27312-8;HYDROcodone.free;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;HYDROcodone Free [Mass/mass] in Stool;HYDROcodone Free Stl-mCnt;;ACTIVE;2.00;2.70 +27313-6;Aspergillus niger Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Aspergillus niger Ab [Titer] in Serum by Immune diffusion (ID);A niger Ab Titr Ser ID;;ACTIVE;2.00;2.73 +27314-4;HYDROmorphone.free;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;HYDROmorphone Free [Mass/mass] in Stool;HYDROmorphone Free Stl-mCnt;;ACTIVE;2.00;2.70 +27315-1;Herpes simplex virus 2 Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 2 IgG Ab [Presence] in Cerebral spinal fluid;HSV2 IgG CSF Ql;;ACTIVE;2.00;2.73 +27316-9;Dioxin;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Dioxin [Presence] in Serum or Plasma;Dioxin SerPl Ql;;ACTIVE;2.00;2.56 +27317-7;Asparagine;SCnc;Pt;Urine;Qn;;CHEM;1;Asparagine [Moles/volume] in Urine;Asparagine Ur-sCnc;;ACTIVE;2.00;2.73 +2731-8;Parathyrin.intact;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.intact [Mass/volume] in Serum or Plasma;PTH-Intact SerPl-mCnc;;ACTIVE;1.0;2.73 +27318-5;Mycoplasma pneumoniae Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;M pneumo Ab Titr CSF IF;;ACTIVE;2.00;2.73 +27319-3;Reducing substances;ACnc;Pt;Stool;Qn;Test strip;CHEM;1;Deprecated Reducing substances [Units/volume] in Stool by Test strip;Deprecated Reducing Subs Stl Strip-aCnc;;DEPRECATED;2.00;2.69 +27320-1;Parietal cell Ab;Titr;Pt;Ser;Qn;;SERO;1;Parietal cell Ab [Titer] in Serum;PCA Ab Titr Ser;;ACTIVE;2.00;2.73 +27321-9;Opiates;MCnc;Pt;Milk;Qn;;DRUG/TOX;1;Opiates [Mass/volume] in Milk;Opiates Mlk-mCnc;;ACTIVE;2.00;2.70 +27322-7;Threonine;SCnc;Pt;Urine;Qn;;CHEM;1;Threonine [Moles/volume] in Urine;Threonine Ur-sCnc;;ACTIVE;2.00;2.73 +27323-5;Leucine;SCnc;Pt;Urine;Qn;;CHEM;1;Leucine [Moles/volume] in Urine;Leucine Ur-sCnc;;ACTIVE;2.00;2.70 +27324-3;Amobarbital;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Amobarbital [Mass/mass] in Meconium;Amobarbital Mec-mCnt;;ACTIVE;2.00;2.70 +27325-0;Glycine;SCnc;Pt;Urine;Qn;;CHEM;1;Glycine [Moles/volume] in Urine;Glycine Ur-sCnc;;ACTIVE;2.00;2.73 +2732-6;Parathyrin.mid molecule;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.mid molecule [Mass/volume] in Serum or Plasma;PTH-M SerPl-mCnc;;ACTIVE;1.0;2.73 +27326-8;Alanine;SCnc;Pt;Urine;Qn;;CHEM;1;Alanine [Moles/volume] in Urine;Alanine Ur-sCnc;;ACTIVE;2.00;2.73 +27327-6;Spermatozoa.motile/100 spermatozoa^12H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --12 hours post ejaculation;Sperm Motile 12h p ejac NFr Smn;;ACTIVE;2.00;2.70 +27328-4;Somatotropin^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;GH sp6 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27329-2;Feline panleukopenia virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Feline panleukopenia virus IgM Ab [Titer] in Serum;FPLV IgM Titr Ser;;ACTIVE;2.00;2.70 +273-3;Gramicidin D;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Gramicidin D [Susceptibility] by Serum bactericidal titer;Gramicidin D Titr SBT;;ACTIVE;1.0;2.32 +27330-0;Insulin^1.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1.5 hours post XXX challenge;Insulin 1.5h p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27331-8;Imipenem;ACnc;Pt;XXX;Qn;;DRUG/TOX;1;Imipenem [Units/volume] in Specimen;Imipenem Spec-aCnc;;DISCOURAGED;2.00;2.69 +27332-6;Feline panleukopenia virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Feline panleukopenia virus IgG Ab [Titer] in Serum;FPLV IgG Titr Ser;;ACTIVE;2.00;2.70 +27333-4;Lysine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Lysine [Units/volume] in Serum or Plasma;Lysine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +2733-4;Parathyrin.N-terminal;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.N-terminal [Mass/volume] in Serum or Plasma;PTH-N SerPl-mCnc;;ACTIVE;1.0;2.73 +27334-2;Tryptophan;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptophan [Units/volume] in Serum or Plasma;Tryptophan SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27335-9;Ornithine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Ornithine [Units/volume] in Serum or Plasma;Ornithine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27336-7;Amino acids;Prid;Pt;Bld;Nom;;CHEM;1;Amino acids [Identifier] in Blood;Amino acids Bld;;ACTIVE;2.00;2.21 +27337-5;Amino beta guanidinopropionate;SCnc;Pt;CSF;Qn;;CHEM;1;Amino beta guanidinopropionate [Moles/volume] in Cerebral spinal fluid;AB-Gp CSF-sCnc;;ACTIVE;2.00;2.70 +27338-3;2,4-Dichlorophenoxyacetate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;2,4-Dichlorophenoxyacetate [Mass/volume] in Serum or Plasma;2,4D SerPl-mCnc;;ACTIVE;2.00;2.73 +27339-1;Nicotinamide;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Nicotinamide [Presence] in Blood;Nicotinamide Bld Ql;;ACTIVE;2.00;2.56 +27340-9;Cholesterol.in HDL;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cholesterol in HDL [Presence] in Serum or Plasma;HDLc SerPl Ql;;ACTIVE;2.00;2.73 +27341-7;Alpha aminobutyrate;SCnc;Pt;Urine;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in Urine;A-Aminobutyr Ur-sCnc;;ACTIVE;2.00;2.73 +2734-2;Pentoses;MRat;24H;Urine;Qn;;CHEM;1;Pentoses [Mass/time] in 24 hour Urine;Pentoses 24h Ur-mRate;;ACTIVE;1.0;2.42 +27342-5;Fasciola hepatica Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Fasciola hepatica Ab [Titer] in Serum by Immunoassay;F hepatica Ab Titr Ser IA;;ACTIVE;2.00;2.70 +27343-3;Molybdenum;MCnt;Pt;RBC;Qn;;DRUG/TOX;1;Molybdenum [Mass/mass] in Red Blood Cells;Molybdenum RBC-mCnt;;ACTIVE;2.00;2.73 +27344-1;Aspartate aminotransferase;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Aspartate aminotransferase [Presence] in Serum or Plasma;AST SerPl Ql;;ACTIVE;2.00;2.73 +27345-8;Hemoglobin A2;PrThr;Pt;Bld;Ord;Electrophoresis;HEM/BC;1;Hemoglobin A2 [Presence] in Blood by Electrophoresis;Hgb A2 Bld Ql Elph;;ACTIVE;2.00;2.73 +27346-6;Benzfetamine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Benzfetamine [Mass/volume] in Vitreous fluid;Benzfetamine Vitf-mCnc;;ACTIVE;2.00;2.42 +27347-4;Methaqualone;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Methaqualone [Mass/volume] in Vitreous fluid;Methaqualone Vitf-mCnc;;ACTIVE;2.00;2.70 +27348-2;DOPamine^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;DOPamine 2h p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27349-0;Cystathionine;PrThr;24H;Urine;Ord;;CHEM;1;Cystathionine [Presence] in 24 hour Urine;Cystathionin 24h Ur Ql;;ACTIVE;2.00;2.56 +27350-8;Cystine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystine [Units/volume] in Serum or Plasma;Cystine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27351-6;Pantothenate;PrThr;Pt;Ser/Plas/Bld;Ord;;CHEM;1;Pantothenate [Presence] in Serum, Plasma or Blood;Pantothenate SerPlBld Ql;;ACTIVE;2.00;2.56 +27352-4;Homocystine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocystine [Units/volume] in Serum or Plasma;(Hcys)2 SerPl-aCnc;;ACTIVE;2.00;2.69 +27353-2;Estimated average glucose;MCnc;Pt;Bld;Qn;Estimated from glycated hemoglobin;CHEM;1;Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin;Est. average glucose Bld gHb Est-mCnc;;ACTIVE;2.00;2.73 +27354-0;Toxoplasma gondii Ab.IgE;PrThr;Pt;Ser;Ord;;MICRO;1;Toxoplasma gondii IgE Ab [Presence] in Serum;T gondii IgE Ser Ql;;ACTIVE;2.00;2.56 +27355-7;Lipoprotein.pre-beta;PrThr;Pt;Plr fld;Ord;;CHEM;1;Lipoprotein.pre-beta [Presence] in Pleural fluid;VLDL Plr Ql;;ACTIVE;2.00;2.56 +27356-5;Phencyclidine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Vitreous fluid;PCP Vitf-mCnc;;ACTIVE;2.00;2.73 +27357-3;HYDROcodone.free;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;HYDROcodone Free [Mass/volume] in Vitreous fluid;HYDROcodone Free Vitf-mCnc;;ACTIVE;2.00;2.73 +27358-1;Benzoylecgonine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Vitreous fluid;BZE Vitf-mCnc;;ACTIVE;2.00;2.73 +2735-9;Pepsinogen;MCnc;Pt;Bld;Qn;;CHEM;1;Pepsinogen [Mass/volume] in Blood;Pepsinogen Bld-mCnc;;ACTIVE;1.0;2.42 +27359-9;Somatotropin^15th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15th specimen post XXX challenge;GH sp15 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27360-7;Myelin basic protein Ab;ACnc;Pt;Ser;Qn;;SERO;1;Myelin basic protein Ab [Units/volume] in Serum;MBP Ab Ser-aCnc;;ACTIVE;2.00;2.73 +27361-5;Tyrosine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Tyrosine [Units/volume] in Serum or Plasma;Tyrosine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27362-3;Phenylalanine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenylalanine [Units/volume] in Serum or Plasma;Phe SerPl-aCnc;;DISCOURAGED;2.00;2.73 +27363-1;DOPamine^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;DOPamine 3h p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27364-9;Aspergillus niger Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;MICRO;1;Aspergillus niger Ab [Presence] in Body fluid by Immune diffusion (ID);A niger Ab Fld Ql ID;;ACTIVE;2.00;2.56 +27365-6;Immunoglobulin light chains.kappa;MCnc;Pt;Urine;Qn;;CHEM;1;Kappa light chains [Mass/volume] in Urine;Kappa LC Ur-mCnc;;ACTIVE;2.00;2.73 +27366-4;Somatotropin^22nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --22nd specimen post XXX challenge;GH sp22 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +2736-7;Pepsinogen I;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pepsinogen I [Mass/volume] in Serum or Plasma;Pepsinogen I SerPl-mCnc;;ACTIVE;1.0;2.73 +27367-2;Manganese/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Manganese/Creatinine [Mass Ratio] in Urine;Manganese/Creat Ur;;ACTIVE;2.00;2.73 +27368-0;Chlamydia trachomatis B Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis B Ab [Titer] in Serum by Immunofluorescence;C trach B Ab Titr Ser IF;;ACTIVE;2.00;2.70 +27369-8;Somatotropin^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;GH 2.5h p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27370-6;Chlamydia trachomatis C Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis C Ab [Titer] in Serum by Immunofluorescence;C trach C Ab Titr Ser IF;;ACTIVE;2.00;2.70 +27371-4;Chlamydia trachomatis G+F+K Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis G+F+K Ab [Titer] in Serum by Immunofluorescence;C trach G+F+K Ab Titr Ser IF;;ACTIVE;2.00;2.70 +27372-2;Insulin^20M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --20 minutes post XXX challenge;Insulin 20M p chal SerPl-aCnc;;ACTIVE;2.00;2.70 +27373-0;Calcium;MCnc;Pt;Dial fld;Qn;;CHEM;1;Calcium [Mass/volume] in Dialysis fluid;Calcium Dial fld-mCnc;;ACTIVE;2.00;2.70 +27374-8;Streptococcus pneumoniae 12 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Mass/volume] in Serum;Deprecated S pneum12 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +2737-5;Pepsinogen I;MCnc;Pt;Urine;Qn;;CHEM;1;Pepsinogen I [Mass/volume] in Urine;Pepsinogen I Ur-mCnc;;ACTIVE;1.0;2.42 +27375-5;Aspergillus fumigatus Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;MICRO;1;Aspergillus fumigatus Ab [Presence] in Body fluid by Immune diffusion (ID);A fumigatus Ab Fld Ql ID;;ACTIVE;2.00;2.56 +27376-3;C peptide;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated C peptide [Mass/volume] in Serum or Plasma;Deprecated C peptide SerPl-mCnc;;DEPRECATED;2.00;2.70 +27377-1;Aspergillus flavus Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;MICRO;1;Aspergillus flavus Ab [Presence] in Body fluid by Immune diffusion (ID);A flavus Ab Fld Ql ID;;ACTIVE;2.00;2.56 +27378-9;pH;LsCnc;24H;Urine;Qn;;CHEM;1;pH of 24 hour Urine;pH 24h Ur;;ACTIVE;2.00;2.73 +27379-7;Insulin^1H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1 hour post XXX challenge;Insulin 1h p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27380-5;DOPamine^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;DOPamine 4h p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27381-3;Alloisoleucine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Alloisoleucine [Units/volume] in Serum or Plasma;Alloisoleucine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27382-1;Porphobilinogen;MCnc;24H;Urine;Qn;;CHEM;1;Porphobilinogen [Mass/volume] in 24 hour Urine;PBG 24h Ur-mCnc;;ACTIVE;2.00;2.73 +2738-3;Pepsinogen II;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pepsinogen II [Mass/volume] in Serum or Plasma;Pepsinogen II SerPl-mCnc;;ACTIVE;1.0;2.73 +27383-9;Feline herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Feline herpesvirus 1 Ab [Presence] in Serum by Immunofluorescence;FeHV1 Ab Ser Ql IF;;ACTIVE;2.00;2.56 +27384-7;Leptospira sp Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Leptospira sp IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Leptospira IgM CSF IA-aCnc;;ACTIVE;2.00;2.69 +27385-4;Somatotropin^18th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --18th specimen post XXX challenge;GH sp18 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27386-2;Blastomyces dermatitidis Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Body fluid by Immune diffusion (ID);B dermat Ab Fld Ql ID;;ACTIVE;2.00;2.56 +27387-0;Streptococcus pneumoniae 14 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Mass/volume] in Serum;Deprecated S pneum14 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27388-8;Streptococcus pneumoniae 26 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 26 IgG Ab [Mass/volume] in Serum;Deprecated S pneum26 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27389-6;Streptococcus pneumoniae 23 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Mass/volume] in Serum;Deprecated S pneum23 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27390-4;Streptococcus pneumoniae 19 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Mass/volume] in Serum;Deprecated S pneum19 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +2739-1;Pepsinogen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pepsinogen [Mass/volume] in Serum or Plasma;Pepsinogen SerPl-mCnc;;ACTIVE;1.0;2.42 +27391-2;Candida sp Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Candida sp IgM Ab [Units/volume] in Serum by Immunoassay;Candida IgM Ser IA-aCnc;;ACTIVE;2.00;2.73 +27392-0;Streptococcus pneumoniae 9 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Mass/volume] in Serum;Deprecated S pneum9 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27393-8;Streptococcus pneumoniae 23f Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23f IgG Ab [Mass/volume] in Serum;Deprecated S pneum23f IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27394-6;Immunoglobulin light chains.lambda;MCnc;Pt;Urine;Qn;;CHEM;1;Lambda light chains [Mass/volume] in Urine;Lambda LC Ur-mCnc;;ACTIVE;2.00;2.73 +27395-3;Streptococcus pneumoniae Danish serotype 18C Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Mass/volume] in Serum;S pneum Da 18C IgG Ser-mCnc;;ACTIVE;2.00;2.73 +27396-1;Hemoglobin.gastrointestinal;MCnt;Pt;Stool;Qn;;CHEM;1;Hemoglobin.gastrointestinal [Mass/mass] in Stool;Hemoccult Stl-mCnt;;ACTIVE;2.00;2.73 +27397-9;Streptococcus pneumoniae 12f Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12f IgG Ab [Mass/volume] in Serum;Deprecated S pneum12f IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27398-7;Streptococcus pneumoniae 9n Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9n IgG Ab [Mass/volume] in Serum;Deprecated S pneum9n IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27399-5;1-Methylhistidine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;1-Methylhistidine [Units/volume] in Serum or Plasma;1Me-hist SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27400-1;Hexacarboxylporphyrin;MCnc;Pt;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/volume] in Urine;Hexa-CP Ur-mCnc;;ACTIVE;2.00;2.73 +27401-9;Hemoglobin.gastrointestinal^6th specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --6th specimen;Hemoccult sp6 Stl Ql;;ACTIVE;2.00;2.73 +27402-7;Norparamethadione;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norparamethadione [Mass/volume] in Urine;NOMO Ur-mCnc;;ACTIVE;2.00;2.70 +27403-5;Gamma glutamyl transferase;CCnc;Pt;Urine;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/volume] in Urine;GGT Ur-cCnc;;ACTIVE;2.00;2.73 +27404-3;Chlamydophila psittaci Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C psittaci IgM Titr CSF IF;;ACTIVE;2.00;2.70 +27405-0;Streptococcus pneumoniae 56 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 56 IgG Ab [Mass/volume] in Serum;Deprecated S pneum56 IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27406-8;Streptococcus pneumoniae 19f Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19f IgG Ab [Mass/volume] in Serum;Deprecated S pneum19f IgG Ser-mCnc;;DEPRECATED;2.00;2.70 +27407-6;Streptococcus pneumoniae 14 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum14 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27408-4;C peptide^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;C peptide 20M p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +2740-9;Pepsins;CCnc;Pt;Gast fld;Qn;;CHEM;1;Pepsins [Enzymatic activity/volume] in Gastric fluid;Pepsins Gast-cCnc;;ACTIVE;1.0;2.68 +27409-2;Methylenedianiline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedianiline [Mass/volume] in Urine;4,4-MDA Ur-mCnc;;ACTIVE;2.00;2.70 +274-1;Hetacillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Hetacillin [Susceptibility] by Minimum lethal concentration (MLC);Hetacillin Islt MLC;;ACTIVE;1.0;2.19 +27410-0;Spermatozoa.motile/100 spermatozoa^24H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --24 hours post ejaculation;Sperm Motile 24h p ejac NFr Smn;;ACTIVE;2.00;2.70 +27411-8;Iron/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Iron/Creatinine [Mass Ratio] in Urine;Iron/Creat Ur;;ACTIVE;2.00;2.70 +27412-6;Ephedrine+Pseudoephedrine;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Mass/volume] in Vitreous fluid;Ephedrin+Pseudo Vitf-mCnc;;ACTIVE;2.00;2.70 +27413-4;Dextromethorphan;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dextromethorphan [Units/volume] in Serum or Plasma;D-methorphan SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27414-2;Fungus identified;Prid;Pt;Stool;Nom;Culture;MICRO;1;Fungus identified in Stool by Culture;Fungus Stl Cult;;ACTIVE;2.00;2.73 +27415-9;Interferon.gamma;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Interferon gamma [Mass/volume] in Serum or Plasma;IGNF SerPl-mCnc;;ACTIVE;2.00;2.73 +27416-7;SCL-70 extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;SCL-70 extractable nuclear Ab [Units/volume] in Serum;ENA Scl70 Ab Ser-aCnc;;ACTIVE;2.00;2.73 +2741-7;Pepsins;CCnc;Pt;Urine;Qn;;CHEM;1;Pepsins [Enzymatic activity/volume] in Urine;Pepsins Ur-cCnc;;ACTIVE;1.0;2.68 +27417-5;Candida sp Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Candida sp IgA Ab [Units/volume] in Serum by Immunoassay;Candida IgA Ser IA-aCnc;;ACTIVE;2.00;2.73 +27418-3;chlordiazePOXIDE;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/mass] in Stool;Chlordiazep Stl-mCnt;;ACTIVE;2.00;2.70 +27419-1;Sodium;SRat;24H;Stool;Qn;;CHEM;1;Sodium [Moles/time] in 24 hour Stool;Sodium 24h Stl-sRate;;ACTIVE;2.00;2.73 +27420-9;Phosphatidylglycerol;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylglycerol [Units/volume] in Amniotic fluid;PG Amn-aCnc;;DISCOURAGED;2.00;2.69 +27421-7;C peptide^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;C peptide 40M p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27422-5;Streptococcus pneumoniae 3 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum3 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27423-3;1,4-Dioxane;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;1,4-Dioxane [Presence] in Serum or Plasma;1,4Dioxane SerPl Ql;;ACTIVE;2.00;2.56 +27424-1;Deoxypyridinoline;SCnc;Pt;Urine;Qn;;CHEM;1;Deoxypyridinoline [Moles/volume] in Urine;DPD Ur-sCnc;;ACTIVE;2.00;2.73 +2742-5;Angiotensin converting enzyme;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma;ACE SerPl-cCnc;;ACTIVE;1.0;2.73 +27425-8;Streptococcus pneumoniae 14 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum14 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27426-6;Trichinella sp Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichinella sp IgM Ab [Units/volume] in Serum by Immunoassay;Trichinella IgM Ser IA-aCnc;;ACTIVE;2.00;2.69 +27427-4;Streptococcus pneumoniae Danish serotype 7F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 7F IgG sp2 Ser IA-mCnc;;ACTIVE;2.00;2.73 +27428-2;Streptococcus pneumoniae 1 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum 1 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27429-0;Streptococcus pneumoniae 19 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum19 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27430-8;Streptococcus pneumoniae 3 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum3 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27431-6;Streptococcus pneumoniae 1 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum 1 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27432-4;Glucose^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Glucose sp8 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +2743-3;pH;LsCnc;Pt;Amnio fld;Qn;;CHEM;1;pH of Amniotic fluid;pH Amn;;ACTIVE;1.0;2.73 +27433-2;Streptococcus pneumoniae Danish serotype 7F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 7F IgG sp1 Ser IA-mCnc;;ACTIVE;2.00;2.73 +27434-0;Streptococcus pneumoniae 23 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum23 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27435-7;Streptococcus pneumoniae 19 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum19 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27436-5;N-desalkylflurazepam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/mass] in Stool;Desalkylfluraz Stl-mCnt;;ACTIVE;2.00;2.70 +27437-3;Streptococcus pneumoniae 23 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum23 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.00;2.70 +27438-1;Protein C Ag/Coagulation factor VII Ag;MRto;Pt;PPP;Qn;IA;COAG;1;Protein C Ag/Coagulation factor VII Ag [Mass Ratio] in Platelet poor plasma by Immunoassay;Prot C Ag/Fact VII Ag PPP IA;;ACTIVE;2.00;2.73 +27439-9;Alpha hydroxyalprazolam;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/mass] in Stool;A-OH Alpraz Stl-mCnt;;ACTIVE;2.00;2.70 +27440-7;Candida sp Ag;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Candida sp Ag [Units/volume] in Serum or Plasma by Immunoassay;Candida Ag SerPl IA-aCnc;;ACTIVE;2.00;2.69 +2744-1;pH;LsCnc;Pt;BldA;Qn;;CHEM;1;pH of Arterial blood;pH BldA;;ACTIVE;1.0;2.73 +27441-5;Potassium;SCnt;24H;Stool;Qn;;CHEM;1;Potassium [Moles/mass] in 24 hour Stool;Potassium 24h Stl-sCnt;;ACTIVE;2.00;2.73 +27442-3;Phenylpropanolamine;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Phenylpropanolamine [Mass/mass] in Stool;PPA Stl-mCnt;;ACTIVE;2.00;2.70 +27443-1;DOPamine^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;DOPamine 1h p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27444-9;Insulin^40M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --40 minutes post XXX challenge;Insulin 40M p chal SerPl-aCnc;;ACTIVE;2.00;2.70 +27445-6;Initial evaluation note;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan Initial evaluation note (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27446-4;Plan of treatment;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27447-2;Progress note+attainment of goals;Find;Pt;Cardiac rehabilitation treatment;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27448-0;Reason to continue;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27449-8;Justification;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27450-6;Psychiatric symptoms;Find;Pt;Cardiac rehabilitation treatment;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27456-3;Author ID;ID;Pt;Cardiac rehabilitation treatment plan;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27457-1;Diagnosis.primary;Cmplx;Pt;Cardiac rehabilitation treatment;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Primary diagnosis Set;;;ACTIVE;2.00;2.40 +2745-8;pH;LsCnc;Pt;BldC;Qn;;CHEM;1;pH of Capillary blood;pH BldC;;ACTIVE;1.0;2.73 +27458-9;Start date;Date;Pt;Hospitalization leading to cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27459-7;End date;Date;Procedure;Hospitalization leading to cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27460-5;Diagnosis.primary;Imp;Pt;Cardiac rehabilitation treatment;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27461-3;Medication name + ID;ID;Pt;Cardiac rehabilitation treatment;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27462-1;Medication XXX;Dosage;Pt;Cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.00;2.66 +27463-9;Medication timing + Quantity;TQ2;Pt;Cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27464-7;Diagnosis.primary;ID;Pt;Cardiac rehabilitation treatment;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27465-4;Diagnosis.addressed by plan;ID;Pt;Cardiac rehabilitation treatment;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.00;2.66 +2746-6;pH;LsCnc;Pt;BldV;Qn;;CHEM;1;pH of Venous blood;pH BldV;;ACTIVE;1.0;2.73 +27466-2;Diagnosis.addressed by plan;Txt;Pt;Cardiac rehabilitation treatment;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.00;2.66 +27468-8;Medication route;Prid;Pt;Cardiac rehabilitation treatment;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27470-4;New &or revised;Type;Pt;Skilled nursing treatment plan;Ord;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, New/revised;Deprecated;;DEPRECATED;2.00;2.66 +27471-2;Date.onset or exacerbation;Date;Pt;Primary Dx for skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.00;2.66 +27472-0;Date.start;TmStp;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, start date;;;DEPRECATED;2.00;2.36 +27473-8;Clinical discipline;Type;Pt;Skilled nursing treatment plan;Nom;;ATTACH.REHAB.NURS;3;Deprecated Clinical discipline - Skilled nursing treatment plan;;;DEPRECATED;2.00;2.40 +2747-4;pH;LsCnc;Pt;CSF;Qn;;CHEM;1;pH of Cerebral spinal fluid;pH CSF;;ACTIVE;1.0;2.73 +27474-6;New &or revised;Type;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, New/revised;Deprecated;;DEPRECATED;2.00;2.66 +27475-3;Date.start;TmStp;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, start date;;;DEPRECATED;2.00;2.36 +27476-1;Clinical discipline;Type;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Clinical discipline - Alcohol-substance abuse rehabilitation treatment plan;;;DEPRECATED;2.00;2.40 +27477-9;Diagnosis.addressed by plan;Imp;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.00;2.66 +27478-7;Author of treatment plan;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Author of treatment plan Set;;;ACTIVE;2.00;2.40 +27479-5;Author name;Pn;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Author name;Deprecated;;DEPRECATED;2.00;2.66 +27480-3;Author profession;Prid;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27481-1;Signature date;TmStp;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.00;2.66 +2748-2;pH;LsCnc;Pt;Body fld;Qn;;CHEM;1;pH of Body fluid;pH Fld;;ACTIVE;1.0;2.73 +27482-9;Visit frequency;TQ2;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27483-7;New &or revised;Type;Pt;Cardiac rehabilitation treatment plan;Ord;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, New/revised;Deprecated;;DEPRECATED;2.00;2.66 +27484-5;Date.onset or exacerbation;Date;Pt;Primary Dx for cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.00;2.66 +27485-2;Date.start;TmStp;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, start date;;;DEPRECATED;2.00;2.36 +27486-0;Visit duration;Time;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.00;2.66 +27487-8;Date range (from_through) described by plan;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.00;2.40 +27488-6;Start date;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Start date;Deprecated;;DEPRECATED;2.00;2.66 +27489-4;Date.end;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, End date;Deprecated;;DEPRECATED;2.00;2.66 +2749-0;pH;LsCnc;Pt;Gast fld;Qn;;CHEM;1;pH of Gastric fluid;pH Gast;;ACTIVE;1.0;2.73 +27490-2;Date range;Cmplx;Enctr;Hospitalization leading to alcohol-substance abuse rehabilitation treatment;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.00;2.40 +27491-0;Continuation status;Type;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Continuation status;Deprecated;;DEPRECATED;2.00;2.66 +27492-8;Date attending MD referred patient for;Date;Pt;Alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.00;2.66 +27493-6;Date attending MD signed;TmStp;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27494-4;Date rehabilitation professional signed;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date rehabilitation professional signed;Deprecated;;DEPRECATED;2.00;2.66 +27495-1;Signature of responsible attending physician on file;Arb;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.00;2.66 +27496-9;Signature of responsible rehabilitation professional on file;Arb;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.00;2.66 +27497-7;Clinical discipline;Type;Pt;Cardiac rehabilitation treatment plan;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Clinical discipline - Cardiac rehabilitation treatment plan;;;DEPRECATED;2.00;2.40 +27498-5;Medication administered;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Medication administered Set;;;ACTIVE;2.00;2.40 +27499-3;Prognosis for rehabilitation;Imp;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.00;2.66 +27500-8;Estimated date of completion;Date;Pt;Alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.00;2.66 +27501-6;Date of last plan of treatment certification;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.00;2.66 +27502-4;Past medical history+Level of function;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27503-2;Initial evaluation note;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan Initial evaluation note (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27504-0;Plan of treatment;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27505-7;Progress note+attainment of goals;Find;Pt;Alcohol-substance abuse rehabilitation treatment;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27506-5;Reason to continue;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27507-3;Justification;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.00;2.66 +2750-8;pH;LsCnc;Pt;Plr fld;Qn;;CHEM;1;pH of Pleural fluid;pH Plr;;ACTIVE;1.0;2.73 +27508-1;Psychiatric symptoms;Find;Pt;Alcohol-substance abuse rehabilitation treatment;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27514-9;Author ID;ID;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27515-6;Diagnosis.primary;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Primary diagnosis Set;;;ACTIVE;2.00;2.40 +2751-6;pH;LsCnc;Pt;Periton fld;Qn;;CHEM;1;pH of Peritoneal fluid;pH Prt;;ACTIVE;1.0;2.73 +27516-4;Start date;Date;Pt;Hospitalization leading to alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27517-2;End date;Date;Procedure;Hospitalization leading to alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27518-0;Diagnosis.addressed by plan;Imp;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.00;2.66 +27519-8;Author of treatment plan;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Author of treatment plan Set;;;ACTIVE;2.00;2.40 +27520-6;Author name;Pn;Pt;Cardiac rehabilitation treatment plan;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Author name;Deprecated;;DEPRECATED;2.00;2.66 +27521-4;Author profession;Prid;Pt;Cardiac rehabilitation treatment plan;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27522-2;Signature date;TmStp;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27523-0;Diagnosis.primary;Imp;Pt;Alcohol-substance abuse rehabilitation treatment;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.00;2.66 +2752-4;pH;LsCnc;Pt;Semen;Qn;;CHEM;1;pH of Semen;pH Smn;;ACTIVE;1.0;2.73 +27524-8;Medication name + ID;ID;Pt;Alcohol-substance abuse rehabilitation treatment;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27525-5;Medication XXX;Dosage;Pt;Alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.00;2.66 +27526-3;Medication timing + Quantity;TQ2;Pt;Alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27527-1;Diagnosis.primary;ID;Pt;Alcohol-substance abuse rehabilitation treatment;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27528-9;Diagnosis.addressed by plan;ID;Pt;Alcohol-substance abuse rehabilitation treatment;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27529-7;Diagnosis.addressed by plan;Txt;Pt;Alcohol-substance abuse rehabilitation treatment;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.00;2.66 +27531-3;Visit frequency;TQ2;Pt;Cardiac rehabilitation treatment plan;Ord;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.00;2.66 +2753-2;pH;LsCnc;Pt;Ser/Plas;Qn;;CHEM;1;pH of Serum or Plasma;pH SerPl;;ACTIVE;1.0;2.73 +27532-1;Visit duration;Time;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.00;2.66 +27533-9;Date range (from_through) described by plan;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.00;2.40 +27534-7;Start date;Date;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Start date;Deprecated;;DEPRECATED;2.00;2.66 +27535-4;Date.end;Date;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, End date;Deprecated;;DEPRECATED;2.00;2.66 +27536-2;Date range;Cmplx;Enctr;Hospitalization leading to cardiac rehabilitation treatment;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.00;2.40 +27537-0;Medication route;Prid;Pt;Alcohol-substance abuse rehabilitation treatment;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27539-6;Continuation status;Type;Pt;Cardiac rehabilitation treatment plan;Ord;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Continuation status;Deprecated;;DEPRECATED;2.00;2.66 +2754-0;pH;LsCnc;Pt;Synv fld;Qn;;CHEM;1;pH of Synovial fluid;pH Snv;;ACTIVE;1.0;2.42 +27540-4;Date attending MD referred patient for;Date;Pt;Cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.00;2.66 +27541-2;Date attending MD signed;TmStp;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27542-0;Date rehabilitation professional signed;Date;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date rehabilitation professional signed;Deprecated;;DEPRECATED;2.00;2.66 +27543-8;Signature of responsible attending physician on file;Arb;Pt;Cardiac rehabilitation treatment plan;Ord;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.00;2.66 +27544-6;Signature of responsible rehabilitation professional on file;Arb;Pt;Cardiac rehabilitation treatment plan;Ord;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.00;2.66 +27545-3;Medication administered;Cmplx;Pt;Cardiac rehabilitation treatment;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Medication administered Set;;;ACTIVE;2.00;2.40 +27546-1;Prognosis for rehabilitation;Imp;Pt;Cardiac rehabilitation treatment plan;Ord;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.00;2.66 +27547-9;Estimated date of completion;Date;Pt;Cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.00;2.66 +27548-7;Date of last plan of treatment certification;Date;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.00;2.66 +27549-5;Past medical history+Level of function;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27550-3;Diagnosis.addressed by plan;Imp;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.00;2.66 +27551-1;Author of treatment plan;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Author of treatment plan Set;;;ACTIVE;2.00;2.40 +27552-9;Author name;Pn;Pt;Skilled nursing treatment plan;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Author name;Deprecated;;DEPRECATED;2.00;2.66 +27553-7;Author profession;Prid;Pt;Skilled nursing treatment plan;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27554-5;Signature date;TmStp;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27555-2;Visit frequency;TQ2;Pt;Skilled nursing treatment plan;Ord;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27556-0;Visit duration;Time;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.00;2.66 +2755-7;pH;LsCnc;Pt;Stool;Qn;;CHEM;1;pH of Stool;pH Stl;;ACTIVE;1.0;2.73 +27557-8;Date range (from_through) described by plan;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.00;2.40 +27558-6;Start date;Date;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Start date;Deprecated;;DEPRECATED;2.00;2.66 +27559-4;Date.end;Date;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, End date;Deprecated;;DEPRECATED;2.00;2.66 +27560-2;Date range;Cmplx;Enctr;Hospitalization leading to skilled nursing treatment;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.00;2.40 +27561-0;Continuation status;Type;Pt;Skilled nursing treatment plan;Ord;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Continuation status;Deprecated;;DEPRECATED;2.00;2.66 +27562-8;Date attending MD referred patient for;Date;Pt;Skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.00;2.66 +27563-6;Date attending MD signed;TmStp;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27564-4;Date rehabilitation professional signed;Date;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date rehabilitation professional signed;Deprecated;;DEPRECATED;2.00;2.66 +2756-5;pH;LsCnc;Pt;Urine;Qn;;CHEM;1;pH of Urine;pH Ur;;ACTIVE;1.0;2.73 +27565-1;Signature of responsible attending physician on file;Arb;Pt;Skilled nursing treatment plan;Ord;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.00;2.66 +27566-9;Signature of responsible rehabilitation professional on file;Arb;Pt;Skilled nursing treatment plan;Ord;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.00;2.66 +27567-7;Medication administered;Cmplx;Pt;Skilled nursing treatment;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Medication administered Set;;;ACTIVE;2.00;2.40 +27568-5;Prognosis for rehabilitation;Imp;Pt;Skilled nursing treatment plan;Ord;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.00;2.66 +27569-3;Estimated date of completion;Date;Pt;Skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.00;2.66 +27570-1;Date of last plan of treatment certification;Date;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.00;2.66 +27571-9;Past medical history+Level of function;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27572-7;Initial evaluation note;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan Initial evaluation note (narrative);Deprecated;;DEPRECATED;2.00;2.66 +2757-3;Phenol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phenol [Mass/volume] in Blood;Phenol Bld-mCnc;;ACTIVE;1.0;2.73 +27573-5;Plan of treatment;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27574-3;Progress note+attainment of goals;Find;Pt;Skilled nursing treatment;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27575-0;Reason to continue;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27576-8;Justification;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27577-6;Psychiatric symptoms;Find;Pt;Skilled nursing treatment;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.00;2.66 +275-8;Hetacillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Hetacillin [Susceptibility] by Minimum inhibitory concentration (MIC);Hetacillin Islt MIC;;ACTIVE;1.0;2.19 +2758-1;Phenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenol [Mass/volume] in Urine;Phenol Ur-mCnc;;ACTIVE;1.0;2.73 +27583-4;Author ID;ID;Pt;Skilled nursing treatment plan;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27584-2;Diagnosis.primary;Cmplx;Pt;Skilled nursing treatment;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Primary diagnosis Set;;;ACTIVE;2.00;2.40 +27585-9;Start date;Date;Pt;Hospitalization leading to skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27586-7;End date;Date;Pt;Hospitalization leading to skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27587-5;Diagnosis.primary;Imp;Pt;Skilled nursing treatment;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27588-3;Medication name + ID;ID;Pt;Skilled nursing treatment;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27589-1;Medication XXX;Dosage;Pt;Skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.00;2.66 +27590-9;Medication timing + Quantity;TQ2;Pt;Skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27591-7;Diagnosis.primary;ID;Pt;Skilled nursing treatment;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27592-5;Diagnosis.addressed by plan;ID;Pt;Skilled nursing treatment;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27593-3;Diagnosis.addressed by plan;Txt;Pt;Skilled nursing treatment;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.00;2.66 +27595-8;Medication route;Prid;Pt;Skilled nursing treatment;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27597-4;New &or revised;Type;Pt;Occupational therapy treatment plan;Ord;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, New/revised;Deprecated;;DEPRECATED;2.00;2.66 +27598-2;Date.onset or exacerbation;Date;Pt;Primary Dx for occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.00;2.66 +2759-9;Phenols;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenols [Mass/volume] in Urine;Phenols Ur-mCnc;;ACTIVE;1.0;2.68 +27599-0;Date.start;Date;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, start date;;;DEPRECATED;2.00;2.50 +27600-6;Clinical discipline;Type;Pt;Occupational therapy treatment plan;Nom;;ATTACH.REHAB.OT;3;Deprecated Clinical discipline - Occupational therapy treatment plan;;;DEPRECATED;2.00;2.40 +27601-4;Diagnosis.addressed by plan;Imp;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.00;2.66 +27602-2;Author of treatment plan;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Author of treatment plan Set;;;ACTIVE;2.00;2.40 +27603-0;Author name;Pn;Pt;Occupational therapy treatment plan;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Author name;Deprecated;;DEPRECATED;2.00;2.66 +27604-8;Author profession;Prid;Pt;Occupational therapy treatment plan;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27605-5;Signature date;TmStp;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27606-3;Visit frequency;TQ2;Pt;Occupational therapy treatment plan;Ord;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.00;2.66 +2760-7;Phenolsulphonphthalein;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenolsulphonphthalein [Mass/volume] in Urine;Phenolsulphonphthalein Ur-mCnc;;ACTIVE;1.0;2.34 +27607-1;Visit duration;Time;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.00;2.66 +27608-9;Date range (from_through) described by plan;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.00;2.40 +27609-7;Start date;Date;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Start date;Deprecated;;DEPRECATED;2.00;2.66 +27610-5;Date.end;Date;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, End date;Deprecated;;DEPRECATED;2.00;2.66 +27611-3;Date range;Cmplx;Enctr;Hospitalization leading to occupational therapy treatment;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.00;2.40 +27612-1;Continuation status;Type;Pt;Occupational therapy treatment plan;Ord;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Continuation status;Deprecated;;DEPRECATED;2.00;2.66 +27613-9;Date attending MD referred patient for;Date;Pt;Occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.00;2.66 +27614-7;Date attending MD signed;TmStp;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +2761-5;Phenylketones;PrThr;Pt;Bld;Ord;;CHEM;1;Phenylketones [Presence] in Blood;Phenylketones Bld Ql;;ACTIVE;1.0;2.73 +27615-4;Date rehabilitation professional signed;Date;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date rehabilitation professional signed;Deprecated;;DEPRECATED;2.00;2.66 +27616-2;Signature of responsible attending physician on file;Arb;Pt;Occupational therapy treatment plan;Ord;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.00;2.66 +27617-0;Signature of responsible rehabilitation professional on file;Arb;Pt;Occupational therapy treatment plan;Ord;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.00;2.66 +27618-8;Medication administered;Cmplx;Pt;Occupational therapy treatment;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Medication administered Set;;;ACTIVE;2.00;2.40 +27619-6;Prognosis for rehabilitation;Imp;Pt;Occupational therapy treatment plan;Ord;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.00;2.66 +27620-4;Estimated date of completion;Date;Pt;Occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.00;2.66 +27621-2;Date of last plan of treatment certification;Date;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.00;2.66 +27622-0;Past medical history+Level of function;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.00;2.66 +2762-3;Phenylalanine;MCnc;Pt;Bld;Qn;;CHEM;1;Phenylalanine [Mass/volume] in Blood;Phe Bld-mCnc;;ACTIVE;1.0;2.73 +27623-8;Assessment.initial;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Initial assessment (narrative);Deprecated;;DEPRECATED;2.00;2.50 +27624-6;Plan of treatment;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27625-3;Progress note+attainment of goals;Find;Pt;Occupational therapy treatment;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27626-1;Reason to continue;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27627-9;Justification;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27628-7;Psychiatric symptoms;Find;Pt;Occupational therapy treatment;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.00;2.66 +2763-1;Phenylalanine;MCnc;Pt;CSF;Qn;;CHEM;1;Phenylalanine [Mass/volume] in Cerebral spinal fluid;Phe CSF-mCnc;;ACTIVE;1.0;2.42 +27634-5;Author ID;ID;Pt;Occupational therapy treatment plan;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27635-2;Diagnosis.primary;Cmplx;Pt;Occupational therapy treatment;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Primary diagnosis Set;;;ACTIVE;2.00;2.40 +27636-0;Start date;Date;Pt;Hospitalization leading to occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27637-8;End date;Date;Pt;Hospitalization leading to occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27638-6;Diagnosis.primary;Imp;Pt;Occupational therapy treatment;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27639-4;Medication name + ID;ID;Pt;Occupational therapy treatment;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27640-2;Medication XXX;Dosage;Pt;Occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.00;2.66 +27641-0;Medication timing + Quantity;TQ2;Pt;Occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27642-8;Diagnosis.primary;ID;Pt;Occupational therapy treatment;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27643-6;Diagnosis.addressed by plan;ID;Pt;Occupational therapy treatment;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27644-4;Diagnosis.addressed by plan;Txt;Pt;Occupational therapy treatment;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.00;2.66 +27646-9;Medication route;Prid;Pt;Occupational therapy treatment;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27648-5;Start date;Date;Pt;Hospitalization leading to physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +2764-9;Phenylalanine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Phenylalanine [Presence] in Serum or Plasma;Phe SerPl Ql;;ACTIVE;1.0;2.73 +27649-3;End date;Date;Pt;Hospitalization leading to physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27650-1;Diagnosis.primary;Imp;Pt;Physical therapy treatment;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27651-9;Medication name + ID;ID;Pt;Physical therapy treatment;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27652-7;Medication XXX;Dosage;Pt;Physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.00;2.66 +27653-5;Medication timing + Quantity;TQ2;Pt;Physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27654-3;Diagnosis.primary;ID;Pt;Physical therapy treatment plan;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27655-0;Diagnosis.addressed by plan;ID;Pt;Physical therapy treatment;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.00;2.66 +2765-6;Phenylalanine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenylalanine [Mass/volume] in Serum or Plasma;Phe SerPl-mCnc;;ACTIVE;1.0;2.73 +27656-8;Diagnosis.addressed by plan;Txt;Pt;Physical therapy treatment;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.00;2.66 +27658-4;Medication route;Prid;Pt;Physical therapy treatment;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.00;2.66 +276-6;Hetacillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Hetacillin [Susceptibility] by Disk diffusion (KB);Hetacillin Islt KB;;ACTIVE;1.0;2.19 +27660-0;New &or revised;Type;Pt;Physical therapy treatment plan;Ord;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, New/revised;Deprecated;;DEPRECATED;2.00;2.66 +27661-8;Date.onset or exacerbation;Date;Pt;Primary Dx for physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.00;2.66 +27662-6;Date.start;Date;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, start date;;;DEPRECATED;2.00;2.50 +27663-4;Clinical discipline;Type;Pt;Physical therapy treatment plan;Nom;;ATTACH.REHAB.PT;3;Deprecated Clinical discipline - Physical therapy treatment plan;;;DEPRECATED;2.00;2.40 +2766-4;Phenylalanine;MCnc;Pt;Urine;Qn;;CHEM;1;Phenylalanine [Mass/volume] in Urine;Phe Ur-mCnc;;ACTIVE;1.0;2.73 +27664-2;Diagnosis.addressed by plan;Imp;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.00;2.66 +27665-9;Author of treatment plan;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Author of treatment plan Set;;;ACTIVE;2.00;2.40 +27666-7;Author name;Pn;Pt;Physical therapy treatment plan;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Author name;Deprecated;;DEPRECATED;2.00;2.66 +27667-5;Author profession;Prid;Pt;Physical therapy treatment plan;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27668-3;Signature date;TmStp;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27669-1;Visit frequency;TQ2;Pt;Physical therapy treatment plan;Ord;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27670-9;Visit duration;Time;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.00;2.66 +27671-7;Date range (from_through) described by plan;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.00;2.40 +2767-2;Phenylalanine;MRat;24H;Urine;Qn;;CHEM;1;Phenylalanine [Mass/time] in 24 hour Urine;Phe 24h Ur-mRate;;ACTIVE;1.0;2.73 +27672-5;Start date;Date;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Start date;Deprecated;;DEPRECATED;2.00;2.66 +27673-3;Date.end;Date;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, End date;Deprecated;;DEPRECATED;2.00;2.66 +27674-1;Date range;Cmplx;Enctr;Hospitalization leading to physical therapy treatment;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.00;2.40 +27675-8;Continuation status;Type;Pt;Physical therapy treatment plan;Ord;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Continuation status;Deprecated;;DEPRECATED;2.00;2.66 +27676-6;Date attending MD referred patient for;Date;Pt;Physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.00;2.66 +27677-4;Date attending MD signed;TmStp;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27678-2;Date rehabilitation professional signed;TmStp;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date rehabilitation professional signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27679-0;Signature of responsible attending physician on file;Arb;Pt;Physical therapy treatment plan;Ord;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.00;2.66 +2768-0;Phenylalanine/Tyrosine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Phenylalanine/Tyrosine [Mass Ratio] in Serum or Plasma;Phe/Tyr SerPl;;ACTIVE;1.0;2.42 +27680-8;Signature of responsible rehabilitation professional on file;Arb;Pt;Physical therapy treatment plan;Ord;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.00;2.66 +27681-6;Medication administered;Cmplx;Pt;Physical therapy treatment;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Medication administered Set;;;ACTIVE;2.00;2.40 +27682-4;Prognosis for rehabilitation;Imp;Pt;Physical therapy treatment plan;Ord;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.00;2.66 +27683-2;Estimated date of completion;Date;Pt;Physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.00;2.66 +27684-0;Date of last plan of treatment certification;Date;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.00;2.66 +27685-7;Past medical history+Level of function;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27686-5;Assessment.initial;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Initial assessment (narrative);Deprecated;;DEPRECATED;2.00;2.50 +27687-3;Plan of treatment;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27688-1;Progress note+attainment of goals;Find;Pt;Physical therapy treatment;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27689-9;Reason to continue;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27690-7;Justification;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27691-5;Psychiatric symptoms;Find;Pt;Physical therapy treatment;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27697-2;Author ID;ID;Pt;Physical therapy treatment plan;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.00;2.66 +2769-8;Phenylketones;PrThr;Pt;Urine;Ord;;CHEM;1;Phenylketones [Presence] in Urine;Phenylketones Ur Ql;;ACTIVE;1.0;2.56 +27698-0;Diagnosis.primary;Cmplx;Pt;Physical therapy treatment;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Primary diagnosis Set;;;ACTIVE;2.00;2.40 +27699-8;New &or revised;Type;Pt;Respiratory therapy treatment plan;Ord;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, New/revised;Deprecated;;DEPRECATED;2.00;2.66 +27700-4;Date.onset or exacerbation;Date;Pt;Primary Dx for respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.00;2.66 +27701-2;Date.start;TmStp;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, start date;;;DEPRECATED;2.00;2.36 +27702-0;Clinical discipline;Type;Pt;Respiratory therapy treatment plan;Nom;;ATTACH.REHAB.RT;3;Deprecated Clinical discipline - Respiratory therapy treatment plan;;;DEPRECATED;2.00;2.40 +27703-8;Diagnosis.addressed by plan;Imp;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.00;2.66 +27704-6;Author of treatment plan;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Author of treatment plan Set;;;ACTIVE;2.00;2.40 +27705-3;Author name;Pn;Pt;Respiratory therapy treatment plan;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Author name;Deprecated;;DEPRECATED;2.00;2.66 +2770-6;Phenylpyruvate;MCnc;Pt;Bld;Qn;;CHEM;1;Phenylpyruvate [Mass/volume] in Blood;Phenylpyruvate Bld-mCnc;;DISCOURAGED;1.0;2.44 +27706-1;Author profession;Prid;Pt;Respiratory therapy treatment plan;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27707-9;Signature date;TmStp;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27708-7;Visit frequency;TQ2;Pt;Respiratory therapy treatment plan;Ord;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27709-5;Visit duration;Time;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.00;2.66 +27710-3;Date range (from_through) described by plan;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.00;2.40 +27711-1;Start date;Date;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Start date;Deprecated;;DEPRECATED;2.00;2.66 +27712-9;Date.end;Date;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, End date;Deprecated;;DEPRECATED;2.00;2.66 +27713-7;Date range;Cmplx;Enctr;Hospitalization leading to respiratory therapy treatment;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.00;2.40 +2771-4;Phenylpyruvate;MCnc;Pt;Plas;Qn;;CHEM;1;Phenylpyruvate [Mass/volume] in Plasma;Phenylpyruvate Plas-mCnc;;DISCOURAGED;1.0;2.44 +27714-5;Continuation status;Type;Pt;Respiratory therapy treatment plan;Ord;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Continuation status;Deprecated;;DEPRECATED;2.00;2.66 +27715-2;Date attending MD referred patient for;Date;Pt;Respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.00;2.66 +27716-0;Date attending MD signed;TmStp;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27717-8;Date rehabilitation professional signed;TmStp;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date rehabilitation professional signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27718-6;Signature of responsible attending physician on file;Arb;Pt;Respiratory therapy treatment plan;Ord;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.00;2.66 +27719-4;Signature of responsible rehabilitation professional on file;Arb;Pt;Respiratory therapy treatment plan;Ord;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.00;2.66 +27720-2;Medication administered;Cmplx;Pt;Respiratory therapy treatment;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Medication administered Set;;;ACTIVE;2.00;2.40 +27721-0;Prognosis for rehabilitation;Imp;Pt;Respiratory therapy treatment plan;Ord;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.00;2.66 +2772-2;Phenylpyruvate;PrThr;Pt;Urine;Ord;;CHEM;1;Phenylpyruvate [Presence] in Urine;Phenylpyruvate Ur Ql;;ACTIVE;1.0;2.73 +27722-8;Estimated date of completion;Date;Pt;Respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.00;2.66 +27723-6;Date of last plan of treatment certification;Date;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.00;2.66 +27724-4;Past medical history+Level of function;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27725-1;Initial evaluation note;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan Initial evaluation note (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27726-9;Plan of treatment;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27727-7;Progress note+attainment of goals;Find;Pt;Respiratory therapy treatment;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27728-5;Reason to continue;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27729-3;Justification;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.00;2.66 +2773-0;Phenylpyruvate;MCnc;Pt;Urine;Qn;;CHEM;1;Phenylpyruvate [Mass/volume] in Urine;Phenylpyruvate Ur-mCnc;;DISCOURAGED;1.0;2.73 +27730-1;Psychiatric symptoms;Find;Pt;Respiratory therapy treatment;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27736-8;Author ID;ID;Pt;Respiratory therapy treatment plan;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27737-6;Diagnosis.primary;Cmplx;Pt;Respiratory therapy treatment;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Primary diagnosis Set;;;ACTIVE;2.00;2.40 +27738-4;Start date;Date;Pt;Hospitalization leading to respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27739-2;End date;Date;Pt;Hospitalization leading to respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +277-4;Hetacillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Hetacillin [Susceptibility] by Serum bactericidal titer;Hetacillin Titr SBT;;ACTIVE;1.0;2.32 +27740-0;Diagnosis.primary;Imp;Pt;Respiratory therapy treatment;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27741-8;Medication name + ID;ID;Pt;Respiratory therapy treatment;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27742-6;Medication XXX;Dosage;Pt;Respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.00;2.66 +27743-4;Medication timing + Quantity;TQ2;Pt;Respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27744-2;Diagnosis.primary;ID;Pt;Respiratory therapy treatment;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27745-9;Diagnosis.addressed by plan;ID;Pt;Respiratory therapy treatment;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27746-7;Diagnosis.addressed by plan;Txt;Pt;Respiratory therapy treatment;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.00;2.66 +2774-8;Phosphate;MCnc;Pt;Bld;Qn;;CHEM;1;Phosphate [Mass/volume] in Blood;Phosphate Bld-mCnc;;ACTIVE;1.0;2.73 +27748-3;Medication route;Prid;Pt;Respiratory therapy treatment;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27750-9;New &or revised;Type;Pt;Medical social services treatment plan;Ord;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, New/revised;Deprecated;;DEPRECATED;2.00;2.66 +27751-7;Date.onset or exacerbation;Date;Pt;Primary Dx for medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.00;2.66 +27752-5;Date.start;TmStp;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, start date;;;DEPRECATED;2.00;2.36 +27753-3;Clinical discipline;Type;Pt;Medical social services treatment plan;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Clinical discipline - Medical social services treatment plan;;;DEPRECATED;2.00;2.40 +27754-1;Diagnosis.addressed by plan;Imp;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.00;2.66 +2775-5;Phosphate;MCnc;Pt;Dial fld;Qn;;CHEM;1;Phosphate [Mass/volume] in Dialysis fluid;Phosphate Dial fld-mCnc;;ACTIVE;1.0;2.70 +27755-8;Author of treatment plan;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Author of treatment plan Set;;;ACTIVE;2.00;2.40 +27756-6;Author name;Pn;Pt;Medical social services treatment plan;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Author name;Deprecated;;DEPRECATED;2.00;2.66 +27757-4;Author profession;Prid;Pt;Medical social services treatment plan;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27758-2;Signature date;TmStp;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27759-0;Visit frequency;TQ2;Pt;Medical social services treatment plan;Ord;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27760-8;Visit duration;Time;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.00;2.66 +27761-6;Date range (from_through) described by plan;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.00;2.40 +27762-4;Start date;Date;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Start date;Deprecated;;DEPRECATED;2.00;2.66 +2776-3;Phosphate renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Phosphate renal clearance in 24 hour Urine and Serum or Plasma;Phosphate Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +27763-2;Date.end;Date;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, End date;Deprecated;;DEPRECATED;2.00;2.66 +27764-0;Date range;Cmplx;Enctr;Hospitalization leading to medical social services treatment;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.00;2.40 +27765-7;Continuation status;Type;Pt;Medical social services treatment plan;Ord;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Continuation status;Deprecated;;DEPRECATED;2.00;2.66 +27766-5;Date attending MD referred patient for;Date;Pt;Medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.00;2.66 +27767-3;Date attending MD signed;TmStp;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27768-1;Date rehabilitation professional signed;TmStp;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date rehabilitation professional signed Date and time;Deprecated;;DEPRECATED;2.00;2.66 +27769-9;Signature of responsible attending physician on file;Arb;Pt;Medical social services treatment plan;Ord;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.00;2.66 +27770-7;Signature of responsible rehabilitation professional on file;Arb;Pt;Medical social services treatment plan;Ord;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.00;2.66 +2777-1;Phosphate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphate [Mass/volume] in Serum or Plasma;Phosphate SerPl-mCnc;;ACTIVE;1.0;2.73 +27771-5;Medication administered;Cmplx;Pt;Medical social services treatment;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Medication administered Set;;;ACTIVE;2.00;2.73 +27772-3;Prognosis for rehabilitation;Imp;Pt;Medical social services treatment plan;Ord;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.00;2.66 +27773-1;Estimated date of completion;Date;Pt;Medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.00;2.66 +27774-9;Date of last plan of treatment certification;Date;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.00;2.66 +27775-6;Past medical history+Level of function;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27776-4;Initial evaluation note;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan Initial evaluation note (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27777-2;Plan of treatment;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27778-0;Progress note+attainment of goals;Find;Pt;Medical social services treatment;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27779-8;Reason to continue;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27780-6;Justification;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27781-4;Psychiatric symptoms;Find;Pt;Medical social services treatment;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27787-1;Author ID;ID;Pt;Medical social services treatment plan;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27788-9;Diagnosis.primary;Cmplx;Pt;Medical social services treatment;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Primary diagnosis Set;;;ACTIVE;2.00;2.40 +2778-9;Phosphate;MCnc;Pt;Urine;Qn;;CHEM;1;Phosphate [Mass/volume] in Urine;Phosphate Ur-mCnc;;ACTIVE;1.0;2.73 +27789-7;Start date;Date;Pt;Hospitalization leading to medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27790-5;End date;Date;Procedure;Hospitalization leading to medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.00;2.66 +27791-3;Diagnosis.primary;Imp;Pt;Medical social services treatment;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.00;2.66 +27792-1;Medication name + ID;ID;Pt;Medical social services treatment;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27793-9;Medication XXX;Dosage;Pt;Medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.00;2.66 +27794-7;Medication timing + Quantity;TQ2;Pt;Medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.00;2.66 +27795-4;Diagnosis.primary;ID;Pt;Medical social services treatment;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27796-2;Diagnosis.addressed by plan;ID;Pt;Medical social services treatment;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.00;2.66 +2779-7;Phosphate;MRat;24H;Urine;Qn;;CHEM;1;Phosphate [Mass/time] in 24 hour Urine;Phosphate 24h Ur-mRate;;ACTIVE;1.0;2.73 +27797-0;Diagnosis.addressed by plan;Txt;Pt;Medical social services treatment;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.00;2.66 +27799-6;Medication route;Prid;Pt;Medical social services treatment;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.00;2.66 +27801-0;Date.onset or exacerbation;Date;Pt;Primary Dx for alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.00;2.66 +2780-5;Phosphate;PrThr;Pt;Urine;Ord;;CHEM;1;Phosphate [Presence] in Urine;Phosphate Ur Ql;;ACTIVE;1.0;2.73 +27810-1;Plasmin inhibitor actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Plasmin inhibitor actual/normal in Platelet poor plasma by Chromogenic method;Plasm Inhib Act/Nor PPP Chro;;ACTIVE;2.00;2.73 +27811-9;Antithrombin actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Antithrombin actual/normal in Platelet poor plasma by Chromogenic method;AT III Act/Nor PPP Chro;;ACTIVE;2.00;2.73 +27812-7;Antithrombin Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Antithrombin Ag actual/normal in Platelet poor plasma by Immunoassay;AT III Ag Act/Nor PPP IA;;ACTIVE;2.00;2.73 +2781-3;Phosphate;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Phosphate [Mass/volume] in Urine;Deprecated Phosphate Ur-mCnc;;DEPRECATED;1.0;2.36 +27813-5;Prothrombin Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Prothrombin Ag actual/normal in Platelet poor plasma by Immunoassay;Prothrom Ag Act/Nor PPP IA;;ACTIVE;2.00;2.73 +27814-3;Coagulation factor VII+Coagulation factor X activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VII+Coagulation factor X actual/normal in Platelet poor plasma by Coagulation assay;Fact VII+Fact X Act/Nor PPP;;ACTIVE;2.00;2.70 +27815-0;Coagulation factor XIII activity actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor XIII activity actual/normal in Platelet poor plasma by Chromogenic method;Fact XIII Act/Nor PPP Chro;;ACTIVE;2.00;2.73 +27816-8;von Willebrand factor Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf) Ag actual/normal in Platelet poor plasma by Immunoassay;vWF Ag Act/Nor PPP IA;;ACTIVE;2.00;2.73 +27817-6;Beta 2 glycoprotein 1 Ab;PrThr;Pt;Ser;Ord;IA;COAG;1;Beta 2 glycoprotein 1 Ab [Presence] in Serum by Immunoassay;B2 Glycoprot1 Ab Ser Ql IA;;ACTIVE;2.00;2.73 +27818-4;Protein C actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Protein C actual/normal in Platelet poor plasma by Chromogenic method;Prot C Act/Nor PPP Chro;;ACTIVE;2.00;2.73 +27819-2;Protein C actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Protein C actual/normal in Platelet poor plasma by Coagulation assay;Prot C Act/Nor PPP;;ACTIVE;2.00;2.73 +278-2;Imipenem;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Imipenem [Susceptibility] by Minimum lethal concentration (MLC);Imipenem Islt MLC;;ACTIVE;1.0;2.19 +27820-0;Protein C Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Protein C Ag actual/normal in Platelet poor plasma by Immunoassay;Prot C Ag Act/Nor PPP IA;;ACTIVE;2.00;2.73 +2782-1;Phosphate;MRat;24H;Urine;Qn;;CHEM;1;Deprecated Phosphate [Mass/time] in 24 hour Urine;Deprecated Phosphate 24H Ur-mRate;;DEPRECATED;1.0;2.36 +27821-8;Protein S.free Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Protein S Free Ag actual/normal in Platelet poor plasma by Immunoassay;Prot S Free Ag Act/Nor PPP IA;;ACTIVE;2.00;2.73 +27822-6;Protein S actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Protein S actual/normal in Platelet poor plasma by Coagulation assay;Prot S Act/Nor PPP;;ACTIVE;2.00;2.73 +27823-4;Protein S Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Protein S Ag actual/normal in Platelet poor plasma by Immunoassay;Prot S Ag Act/Nor PPP IA;;ACTIVE;2.00;2.73 +27824-2;Prothrombin fragment 1+2 Ag;SCnc;Pt;Ser/Plas;Qn;IA;COAG;1;Prothrombin Fragment 1.2 Ag [Moles/volume] in Serum or Plasma by Immunoassay;Pro Frg1+2 Ag SerPl IA-sCnc;;ACTIVE;2.00;2.73 +27825-9;Platelet associated Ab;ACnc;Pt;Bld;Ord;;SERO;1;Deprecated Platelet associated Ab [Presence] in Blood;Deprecated PA Ab Bld Ql;;DEPRECATED;2.00;2.36 +27826-7;Insulin^2H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2 hours post XXX challenge;Insulin 2h p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27827-5;Insulin^30M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --30 minutes post XXX challenge;Insulin 30M p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27828-3;Insulin^3H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3 hours post XXX challenge;Insulin 3h p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27829-1;Somatotropin^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;GH sp8 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27830-9;Insulin^1H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1 hour post 75 g glucose PO;Insulin 1h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.00;2.73 +27831-7;Immune complex;ACnc;Pt;Ser/Plas;Qn;C1q binding assay;SERO;1;Immune complex [Units/volume] in Serum or Plasma by C1q binding assay;IC SerPl C1Q Bind-aCnc;;ACTIVE;2.00;2.73 +27832-5;Insulin^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --4th specimen post XXX challenge;Insulin sp4 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27833-3;Insulin^7H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --7 hours post 75 g glucose PO;Insulin 7h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.00;2.68 +27834-1;Insulin^1.5H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO;Insulin 1.5h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.00;2.73 +27835-8;Somatotropin^11th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --11th specimen post XXX challenge;GH sp11 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27836-6;Somatotropin^12th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --12th specimen post XXX challenge;GH sp12 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27837-4;Somatotropin^13th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --13th specimen post XXX challenge;GH sp13 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27838-2;Somatotropin^14th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --14th specimen post XXX challenge;GH sp14 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +2783-9;Lecithin;MCnc;Pt;Plas;Qn;;CHEM;1;Lecithin [Mass/volume] in Plasma;Lecithin Plas-mCnc;;DISCOURAGED;1.0;2.44 +27839-0;C peptide^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;C peptide 4h p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27840-8;Somatotropin^16th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --16th specimen post XXX challenge;GH sp16 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27841-6;Somatotropin^17th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --17th specimen post XXX challenge;GH sp17 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27842-4;Somatotropin^19th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --19th specimen post XXX challenge;GH sp19 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27843-2;Somatotropin^20th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --20th specimen post XXX challenge;GH sp20 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27844-0;Somatotropin^21st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --21st specimen post XXX challenge;GH sp21 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27845-7;Somatotropin^23rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --23rd specimen post XXX challenge;GH sp23 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27846-5;Somatotropin^24th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --24th specimen post XXX challenge;GH sp24 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +2784-7;Phosphatidylcholine.saturated;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylcholine.saturated [Mass/volume] in Amniotic fluid;PC Satd Amn-mCnc;;ACTIVE;1.0;2.42 +27847-3;Somatotropin^25th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --25th specimen post XXX challenge;GH sp25 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27848-1;Lutropin^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge;LH sp2 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27849-9;Aldosterone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Aldost sp2 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27850-7;Somatotropin^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;GH 10M p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27851-5;Lutropin^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge;LH sp3 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27852-3;Insulin^5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --5 hours post XXX challenge;Insulin 5h p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27853-1;Lutropin^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --4th specimen post XXX challenge;LH sp4 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +2785-4;Phosphatidylglycerol;PrThr;Pt;Amnio fld;Ord;;CHEM;1;Phosphatidylglycerol [Presence] in Amniotic fluid;PG Amn Ql;;ACTIVE;1.0;2.73 +27854-9;Lutropin^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --5th specimen post XXX challenge;LH sp5 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27855-6;Lutropin^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --6th specimen post XXX challenge;LH sp6 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27856-4;Proinsulin^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Proinsulin 2h p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +27857-2;Proinsulin^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;Proinsulin 3h p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +27858-0;Lutropin^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --7th specimen post XXX challenge;LH sp7 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27859-8;Sporothrix schenckii Ab;Titr;Pt;CSF;Qn;;MICRO;1;Sporothrix schenckii Ab [Titer] in Cerebral spinal fluid;S schenckii Ab Titr CSF;;ACTIVE;2.00;2.70 +27860-6;Insulin^2H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2 hours post 75 g glucose PO;Insulin 2h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.00;2.73 +27861-4;Insulin^3H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3 hours post 75 g glucose PO;Insulin 3h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.00;2.73 +2786-2;Phosphatidylglycerol;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylglycerol [Mass/volume] in Amniotic fluid;PG Amn-mCnc;;ACTIVE;1.0;2.73 +27862-2;Insulin^4H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --4 hours post 75 g glucose PO;Insulin 4h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.00;2.73 +27863-0;Insulin^2.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2.5 hours post XXX challenge;Insulin 2.5h p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27864-8;Follitropin^9th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --9th specimen post XXX challenge;FSH sp9 p chal SerPl-aCnc;;ACTIVE;2.00;2.38 +27865-5;Follitropin^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge;FSH sp3 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27866-3;17-Ketogenic steroids;MCnc;24H;Urine;Qn;;CHEM;1;17-Ketogenic steroids [Mass/volume] in 24 hour Urine;17KGS 24h Ur-mCnc;;ACTIVE;2.00;2.73 +27867-1;Insulin^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --7th specimen post XXX challenge;Insulin sp7 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27868-9;Follitropin^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --5th specimen post XXX challenge;FSH sp5 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27869-7;Follitropin^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --8th specimen post XXX challenge;FSH sp8 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +2787-0;Phosphatidylinositol;MCnc;Pt;Ser;Qn;;CHEM;1;Phosphatidylinositol [Mass/volume] in Serum;PI Ser-mCnc;;ACTIVE;1.0;2.73 +27870-5;Follitropin^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --4th specimen post XXX challenge;FSH sp4 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27871-3;Interferon.beta Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Interferon beta IgG Ab [Units/volume] in Serum or Plasma;IFN-B IgG SerPl-aCnc;;ACTIVE;2.00;2.73 +27872-1;Insulin^6H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --6 hours post 75 g glucose PO;Insulin 6h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.00;2.68 +27873-9;Insulin^post CFst;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --fasting;Insulin p fast SerPl-aCnc;;ACTIVE;2.00;2.73 +27874-7;Insulin^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --5th specimen post XXX challenge;Insulin sp5 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27875-4;Insulin^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --6th specimen post XXX challenge;Insulin sp6 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27876-2;Cells.CD14+CD11b+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD14+CD11b+ cells/100 cells in Blood;CD14+CD11b+ Cells NFr Bld;;ACTIVE;2.00;2.70 +27877-0;Cells.CD33+CD11b+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD33+CD11b+ cells/100 cells in Blood;CD33+CD11b+ Cells NFr Bld;;ACTIVE;2.00;2.70 +27878-8;Cells.CD14+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD14+HLA-DR+ cells/100 cells in Blood;CD14+HLA-DR+ Cells NFr Bld;;ACTIVE;2.00;2.70 +27879-6;Cells.CD33+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD33+HLA-DR+ cells/100 cells in Blood;CD33+HLA-DR+ Cells NFr Bld;;ACTIVE;2.00;2.70 +27880-4;Follitropin^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --6th specimen post XXX challenge;FSH sp6 p chal SerPl-aCnc;;ACTIVE;2.00;2.73 +27881-2;Somatotropin^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;GH sp4 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27882-0;Proinsulin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Proinsulin [Moles/volume] in Serum or Plasma;Proinsulin SerPl-sCnc;;ACTIVE;2.00;2.73 +27883-8;Lutropin^15M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --15 minutes post XXX challenge;LH 15M p chal SerPl-aCnc;;ACTIVE;2.00;2.70 +27884-6;Lutropin^40M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --40 minutes post XXX challenge;LH 40M p chal SerPl-aCnc;;ACTIVE;2.00;2.70 +27885-3;Lutropin^1.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1.5 hours post XXX challenge;LH 1.5h p chal SerPl-aCnc;;ACTIVE;2.00;2.70 +27886-1;Follitropin^40M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --40 minutes post XXX challenge;FSH 40M p chal SerPl-aCnc;;ACTIVE;2.00;2.70 +27887-9;Follitropin^15M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --15 minutes post XXX challenge;FSH 15M p chal SerPl-aCnc;;ACTIVE;2.00;2.70 +2788-8;Phosphoenolpyruvate carboxykinase;CCnc;Pt;Ser;Qn;;CHEM;1;Phosphoenolpyruvate carboxykinase [Enzymatic activity/volume] in Serum;PEPCK Ser-cCnc;;ACTIVE;1.0;2.68 +27888-7;Somatotropin^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;GH sp2 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27889-5;Somatotropin^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;GH sp3 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27890-3;Somatotropin^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;GH sp5 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27891-1;Thyroxine^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --baseline;T4 BS SerPl-mCnc;;ACTIVE;2.00;2.70 +27892-9;Butyrylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Butyrylglycine/Creatinine [Mass Ratio] in Urine;Butyrylgly/Creat Ur;;ACTIVE;2.00;2.73 +27893-7;Cells.CD19+CD23+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+CD23+ cells/100 cells in Blood;CD19+CD23+ Cells NFr Bld;;ACTIVE;2.00;2.70 +27894-5;Sulfatide Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Sulfatide IgG Ab [Presence] in Serum by Immunoassay;Sulfatide IgG Ser Ql IA;;ACTIVE;2.00;2.56 +27895-2;Gastroenterology endoscopy studies;Cmplx;-;^Patient;Set;;ATTACH.GI;3;Gastroenterology endoscopy studies (set);;;ACTIVE;2.00;2.00 +2789-6;Phosphoethanolamine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphoethanolamine [Mass/volume] in Serum or Plasma;PETN SerPl-mCnc;;ACTIVE;1.0;2.73 +27896-0;Pulmonary studies;Cmplx;-;^Patient;Set;;ATTACH.RESP;3;Pulmonary studies (set);;;ACTIVE;2.00;2.02 +27897-8;Neuromuscular electrophysiology studies;Cmplx;-;^Patient;Set;;ATTACH;3;Neuromuscular electrophysiology studies (set);;;ACTIVE;2.00;2.00 +27898-6;Pathology studies;Cmplx;-;^Patient;Set;;ATTACH.LAB;3;Pathology studies (set);;;ACTIVE;2.00;2.73 +27899-4;Diagnostic studies.non lab;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Diagnostic studies.non-lab (set);;;ACTIVE;2.00;2.27 +279-0;Imipenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Imipenem [Susceptibility] by Minimum inhibitory concentration (MIC);Imipenem Islt MIC;;ACTIVE;1.0;2.73 +27900-0;Lactobacillus sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Lactobacillus sp IgG Ab [Units/volume] in Serum;Lactobacillus IgG Ser-aCnc;;ACTIVE;2.00;2.69 +27901-8;Lactobacillus sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Lactobacillus sp IgM Ab [Units/volume] in Serum;Lactobacillus IgM Ser-aCnc;;ACTIVE;2.00;2.69 +27902-6;Enterococcus sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Enterococcus sp IgG Ab [Units/volume] in Serum;Enterococ IgG Ser-aCnc;;ACTIVE;2.00;2.69 +27903-4;Coxsackievirus B2 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Coxsackievirus B2 Ab [Presence] in Cerebral spinal fluid;CV B2 Ab CSF Ql;;ACTIVE;2.00;2.56 +2790-4;Phosphoethanolamine;MCnc;Pt;Urine;Qn;;CHEM;1;Phosphoethanolamine [Mass/volume] in Urine;PETN Ur-mCnc;;ACTIVE;1.0;2.73 +27904-2;Histidine;SCnc;Pt;Urine;Qn;;CHEM;1;Histidine [Moles/volume] in Urine;Histidine Ur-sCnc;;ACTIVE;2.00;2.73 +27905-9;Bacteroides fragilis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Bacteroides fragilis IgM Ab [Units/volume] in Serum;B fragilis IgM Ser-aCnc;;ACTIVE;2.00;2.69 +27906-7;Lymphocytes.immature/100 leukocytes;NFr;Pt;Amnio fld;Qn;;HEM/BC;1;Immature lymphocytes/100 leukocytes in Amniotic fluid;Imm Lymphs/leuk NFr Amn;;ACTIVE;2.00;2.70 +27907-5;Cryptosporidium sp;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Cryptosporidium sp [Identifier] in Stool by Organism specific culture;Cryptosp Stl Cult;;ACTIVE;2.00;2.73 +27908-3;Coxsackievirus B1 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Coxsackievirus B1 Ab [Presence] in Cerebral spinal fluid;CV B1 Ab CSF Ql;;ACTIVE;2.00;2.56 +27909-1;Calcium^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Calcium sp1 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27910-9;Calcium^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Calcium sp6 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27911-7;Gamma aminobutyrate;SCnc;Pt;Urine;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in Urine;GABA Ur-sCnc;;ACTIVE;2.00;2.70 +2791-2;Phosphofructokinase;CCnc;Pt;Bld;Qn;;CHEM;1;Phosphofructokinase [Enzymatic activity/volume] in Blood;PFK Bld-cCnc;;ACTIVE;1.0;2.68 +27912-5;Butalbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Butalbital [Mass/mass] in Hair;Butalbital Hair-mCnt;;ACTIVE;2.00;2.70 +27913-3;Calcium^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Calcium sp7 p chal SerPl-mCnc;;ACTIVE;2.00;2.70 +27914-1;Gamma aminoadipate;SRat;24H;Urine;Qn;;CHEM;1;Gamma aminoadipate [Moles/time] in 24 hour Urine;GAA 24h Ur-sRate;;ACTIVE;2.00;2.70 +27915-8;Alpha-1-Antichymotrypsin;ACnc;Pt;Stool;Qn;;CHEM;1;Alpha-1-Antichymotrypsin [Units/volume] in Stool;A1ACT Stl-aCnc;;ACTIVE;2.00;2.73 +27916-6;Calcium^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Calcium sp2 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27917-4;Coxsackievirus B3 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Coxsackievirus B3 Ab [Presence] in Cerebral spinal fluid;CV B3 Ab CSF Ql;;ACTIVE;2.00;2.56 +27918-2;Coxsackievirus B4 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Coxsackievirus B4 Ab [Presence] in Cerebral spinal fluid;CV B4 Ab CSF Ql;;ACTIVE;2.00;2.56 +27919-0;Calcium^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Calcium sp3 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +2792-0;Phosphofructokinase;CCnc;Pt;Ser;Qn;;CHEM;1;Phosphofructokinase [Enzymatic activity/volume] in Serum;PFK Ser-cCnc;;ACTIVE;1.0;2.68 +27920-8;Normeperidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Normeperidine [Presence] in Urine;Normeperidine Ur Ql;;ACTIVE;2.00;2.73 +27921-6;Alpha hydroxyalprazolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Serum or Plasma;A-OH Alpraz SerPl-mCnc;;ACTIVE;2.00;2.73 +27922-4;Echovirus 4 RNA;PrThr;Pt;CSF;Ord;;MICRO;1;Echovirus 4 RNA [Presence] in Cerebral spinal fluid;ECV4 RNA CSF Ql;;ACTIVE;2.00;2.56 +27923-2;Ubiquinone 10;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Coenzyme Q10 [Mass/volume] in Serum or Plasma;Ubiquinone10 SerPl-mCnc;;ACTIVE;2.00;2.73 +27924-0;Ascaris sp Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Ascaris sp Ab [Titer] in Serum by Immunoassay;Ascaris Ab Titr Ser IA;;ACTIVE;2.00;2.73 +27925-7;Hemoglobin.gastrointestinal^7th specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --7th specimen;Hemoccult sp7 Stl Ql;;ACTIVE;2.00;2.73 +27926-5;Hemoglobin.gastrointestinal^8th specimen;PrThr;Pt;Stool;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool --8th specimen;Hemoccult sp8 Stl Ql;;ACTIVE;2.00;2.56 +27927-3;Butalbital;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Butalbital [Mass/volume] in Vitreous fluid;Butalbital Vitf-mCnc;;ACTIVE;2.00;2.70 +27928-1;Echovirus 30 RNA;PrThr;Pt;CSF;Ord;Probe;MICRO;1;Echovirus 30 RNA [Presence] in Cerebral spinal fluid by Probe;ECV30 RNA CSF Ql Probe;;ACTIVE;2.00;2.63 +27929-9;Mandelate;PrThr;Pt;Urine;Ord;;CHEM;1;Mandelate [Presence] in Urine;Mandelate Ur Ql;;ACTIVE;2.00;2.56 +27930-7;Neutrophils/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Bronchial specimen;Neutrophils/leuk NFr Bronch;;ACTIVE;2.00;2.73 +27931-5;Bile acid^2H post meal;SCnc;Pt;Ser;Qn;;CHAL;1;Bile acid [Moles/volume] in Serum --2 hours post meal;Bile Ac 2h p meal Ser-sCnc;;ACTIVE;2.00;2.70 +27932-3;Neutrophils/100 leukocytes;NFr;Pt;Sputum;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Sputum;Neutrophils/leuk NFr Spt;;ACTIVE;2.00;2.73 +27933-1;Calcium^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Calcium sp5 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27934-9;Echovirus 11 RNA;PrThr;Pt;CSF;Ord;Probe;MICRO;1;Echovirus 11 RNA [Presence] in Cerebral spinal fluid by Probe;ECV11 RNA CSF Ql Probe;;ACTIVE;2.00;2.63 +27935-6;Calcium^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Calcium sp4 p chal SerPl-mCnc;;ACTIVE;2.00;2.73 +27936-4;Lymphocytes/100 leukocytes;NFr;Pt;Sputum;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Sputum;Lymphocytes/leuk NFr Spt;;ACTIVE;2.00;2.73 +27937-2;Sporothrix schenckii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Sporothrix schenckii Ab [Titer] in Serum;S schenckii Ab Titr Ser;;ACTIVE;2.00;2.73 +2793-8;Phosphofructokinase.F subunit/Phosphofructokinase.total;CFr;Pt;Platelets;Qn;;CHEM;1;Phosphofructokinase F subunit/Phosphofructokinase.total in Platelets;PFK-F CFr Plts;;ACTIVE;1.0;2.70 +27938-0;Salmonella paratyphi B O Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella paratyphi B O Ab [Titer] in Serum by Agglutination;S paraty B O Ab Titr Ser Aggl;;ACTIVE;2.00;2.70 +27939-8;Collagen crosslinked N-telopeptide;SCnc;Pt;Urine;Qn;;CHEM;1;Collagen crosslinked N-telopeptide [Moles/volume] in Urine;Collagen NTx Ur-sCnc;;ACTIVE;2.00;2.73 +27940-6;Insulin^1.5H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Insulin [Units/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO;Deprecated Insulin 1.5H p 75 g Glc PO Se;;DEPRECATED;2.00;2.40 +27941-4;Lactate;MCnc;Pt;CSF;Qn;;CHEM;1;Lactate [Mass/volume] in Cerebral spinal fluid;Lactate CSF-mCnc;;ACTIVE;2.00;2.73 +27942-2;Follitropin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin [Mass/volume] in Serum or Plasma;FSH SerPl-mCnc;;DISCOURAGED;2.00;2.73 +27943-0;Interferon.omega;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Interferon omega [Mass/volume] in Serum or Plasma;O-IFN SerPl-mCnc;;ACTIVE;2.00;2.70 +27944-8;C peptide;MRat;24H;Urine;Qn;;CHEM;1;C peptide [Mass/time] in 24 hour Urine;C peptide 24h Ur-mRate;;ACTIVE;2.00;2.73 +27945-5;Coxiella burnetii phase 2 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 2 Ab [Titer] in Serum by Immunofluorescence;C burnet Ph2 Ab Titr Ser IF;;ACTIVE;2.00;2.70 +2794-6;Phosphofructokinase.F subunit/Phosphofructokinase.total;CFr;Pt;WBC;Qn;;CHEM;1;Phosphofructokinase F subunit/Phosphofructokinase.total in Leukocytes;PFK-F CFr WBC;;ACTIVE;1.0;2.70 +27946-3;Lactate^1H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Lactate [Mass/volume] in Blood --1 hour post XXX challenge;Lactate 1h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27947-1;Coxsackievirus A7 RNA;ACnc;Pt;CSF;Qn;Probe;MICRO;1;Coxsackievirus A7 RNA [Units/volume] (viral load) in Cerebral spinal fluid by Probe;CV A7 RNA CSF Probe-aCnc;;ACTIVE;2.00;2.69 +27948-9;Herpes simplex virus 1+2 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Units/volume] in Serum by Immunoassay;HSV1+2 IgG Ser IA-aCnc;;ACTIVE;2.00;2.73 +27949-7;Lactate^4H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Lactate [Mass/volume] in Blood --4 hours post XXX challenge;Lactate 4h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27950-5;Saint Louis encephalitis virus RNA;PrThr;Pt;CSF;Ord;Probe;MICRO;1;Saint Louis encephalitis virus RNA [Presence] in Cerebral spinal fluid by Probe;SLEV RNA CSF Ql Probe;;ACTIVE;2.00;2.63 +27951-3;Coxiella burnetii phase 1 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 1 Ab [Titer] in Serum by Immunofluorescence;C burnet Ph1 Ab Titr Ser IF;;ACTIVE;2.00;2.70 +27952-1;Enterovirus RNA;PrThr;Pt;CSF;Ord;Probe;MICRO;1;Enterovirus RNA [Presence] in Cerebral spinal fluid by Probe;EV RNA CSF Ql Probe;;DISCOURAGED;2.00;2.63 +2795-3;Phosphofructokinase.L subunit/Phosphofructokinase.total;CFr;Pt;RBC;Qn;;CHEM;1;Phosphofructokinase L subunit/Phosphofructokinase.total in Red Blood Cells;PFK-L CFr RBC;;ACTIVE;1.0;2.70 +27953-9;Methionine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Methionine [Units/volume] in Serum or Plasma;Methionine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27954-7;Coxsackievirus B6 RNA;ACnc;Pt;CSF;Qn;Probe;MICRO;1;Coxsackievirus B6 RNA [Units/volume] (viral load) in Cerebral spinal fluid by Probe;CV B6 RNA CSF Probe-aCnc;;ACTIVE;2.00;2.69 +27955-4;Lactate^2H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Lactate [Mass/volume] in Blood --2 hours post XXX challenge;Lactate 2h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27956-2;Proinsulin^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Proinsulin 1h p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +27957-0;Pyruvate^4H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --4 hours post XXX challenge;Pyruvate 4h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27958-8;Proinsulin^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Proinsulin 4h p chal SerPl-sCnc;;ACTIVE;2.00;2.70 +27959-6;Pyruvate^baseline;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --baseline;Pyruvate BS Bld-mCnc;;ACTIVE;2.00;2.70 +27960-4;Coxsackievirus B5 RNA;ACnc;Pt;CSF;Qn;Probe;MICRO;1;Coxsackievirus B5 RNA [Units/volume] (viral load) in Cerebral spinal fluid by Probe;CV B5 RNA CSF Probe-aCnc;;ACTIVE;2.00;2.69 +2796-1;Phosphofructokinase.M subunit/Phosphofructokinase.total;CFr;Pt;RBC;Qn;;CHEM;1;Phosphofructokinase M subunit/Phosphofructokinase.total in Red Blood Cells;PFK-M CFr RBC;;ACTIVE;1.0;2.70 +27961-2;Lactate^3H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Lactate [Mass/volume] in Blood --3 hours post XXX challenge;Lactate 3h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27962-0;Butalbital;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Butalbital [Mass/mass] in Meconium;Butalbital Mec-mCnt;;ACTIVE;2.00;2.70 +27963-8;Pyruvate^1H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --1 hour post XXX challenge;Pyruvate 1h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27964-6;Streptococcus pneumoniae 6+26 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6+26 Ab [Mass/volume] in Serum;Deprecated S pneum6+26 Ab Ser-mCnc;;DEPRECATED;2.00;2.70 +27965-3;Babesia microti Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia microti IgM Ab [Presence] in Serum;B microti IgM Ser Ql;;ACTIVE;2.00;2.73 +27966-1;Legionella pneumophila atypical Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila atypical Ab [Titer] in Serum by Immunofluorescence;L pneumo Atyp Ab Titr Ser IF;;ACTIVE;2.00;2.70 +27967-9;Progesterone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --baseline;Progest BS SerPl-mCnc;;ACTIVE;2.00;2.73 +27968-7;Pyruvate^2H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --2 hours post XXX challenge;Pyruvate 2h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27969-5;Coxsackievirus A9 RNA;ACnc;Pt;CSF;Qn;Probe;MICRO;1;Coxsackievirus A9 RNA [Units/volume] (viral load) in Cerebral spinal fluid by Probe;CV A9 RNA CSF Probe-aCnc;;ACTIVE;2.00;2.69 +27970-3;Pyruvate^3H post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --3 hours post XXX challenge;Pyruvate 3h p chal Bld-mCnc;;ACTIVE;2.00;2.70 +27971-1;Catecholamines^4H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --4 hours post XXX challenge;Catechols 4h p chal Plas-mCnc;;ACTIVE;2.00;2.70 +27972-9;Histidine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Histidine [Units/volume] in Serum or Plasma;Histidine SerPl-aCnc;;ACTIVE;2.00;2.69 +27973-7;3-Methylhistidine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methylhistidine [Units/volume] in Serum or Plasma;3Me-histidine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27974-5;Arginine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Arginine [Units/volume] in Serum or Plasma;Arginine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27975-2;Thyrotropin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyrotropin [Mass/volume] in Serum or Plasma;TSH SerPl-mCnc;;DISCOURAGED;2.00;2.73 +27976-0;Lactate^post CFst;MCnc;Pt;Bld;Qn;;CHAL;1;Lactate [Mass/volume] in Blood --fasting;Lactate p fast Bld-mCnc;;ACTIVE;2.00;2.70 +27977-8;Norepinephrine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Norepinephrine/Creatinine [Molar ratio] in 24 hour Urine;Norepineph/Creat 24h Ur-sRto;;ACTIVE;2.00;2.70 +27978-6;Metanephrines/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Metanephrines/Creatinine [Molar ratio] in 24 hour Urine;MetanephS/Creat 24h Ur-sRto;;ACTIVE;2.00;2.70 +2797-9;Phosphoglucomutase;CCnc;Pt;Ser;Qn;;CHEM;1;Phosphoglucomutase [Enzymatic activity/volume] in Serum;Phosphoglucomutase Ser-cCnc;;ACTIVE;1.0;2.68 +27979-4;17-Ketogenic steroids;SRat;24H;Urine;Qn;;CHEM;1;17-Ketogenic steroids [Moles/time] in 24 hour Urine;17KGS 24h Ur-sRate;;ACTIVE;2.00;2.70 +27980-2;Thyroxine binding globulin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine binding globulin [Moles/volume] in Serum or Plasma;T4BG SerPl-sCnc;;ACTIVE;2.00;2.70 +27981-0;2-Hydroxyisobutyrate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;2-Hydroxyisobutyrate [Presence] in Urine;2OH-isobutyrate Ur Ql;;ACTIVE;2.00;2.56 +27982-8;Borrelia burgdorferi 66kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 66kD Ab [Presence] in Serum by Immunoblot;B burgdor66kD Ab Ser Ql IB;;ACTIVE;2.00;2.73 +27983-6;Borrelia burgdorferi 41kD Ab;ACnc;Pt;Ser;Ord;IB;MICRO;1;Deprecated Borrelia burgdorferi 41kD Ab [Presence] in Serum by Immunoblot (IB);Deprecated B burgdor41kD Ab Ser Ql IB;;DEPRECATED;2.00;2.36 +27984-4;SCA8 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA8 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA8 gene CAG Rpt Bld/T Ql;;ACTIVE;2.00;2.73 +27985-1;Borrelia burgdorferi 18kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 18kD Ab [Presence] in Serum by Immunoblot;B burgdor18kD Ab Ser Ql IB;;ACTIVE;2.00;2.73 +27986-9;Borrelia burgdorferi 28kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 28kD Ab [Presence] in Serum by Immunoblot;B burgdor28kD Ab Ser Ql IB;;ACTIVE;2.00;2.58 +2798-7;Phosphoglycerate kinase;CCnc;Pt;Ser;Qn;;CHEM;1;Phosphoglycerate kinase [Enzymatic activity/volume] in Serum;PGK Ser-cCnc;;ACTIVE;1.0;2.68 +27987-7;Thyroxine.free^baseline;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Units/volume] in Serum or Plasma --baseline;T4 Free BS SerPl-aCnc;;ACTIVE;2.00;2.42 +27988-5;Aldosterone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --baseline;Aldost BS SerPl-mCnc;;ACTIVE;2.00;2.73 +27989-3;Thyroxine.free^1H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Units/volume] in Serum or Plasma --1 hour post XXX challenge;T4 Free 1h p chal SerPl-aCnc;;ACTIVE;2.00;2.42 +27990-1;Fibrinogen fragments;MCnc;Pt;PPP;Qn;LA;COAG;1;Fibrinogen fragments [Mass/volume] in Platelet poor plasma by Latex agglutination;Fibrinogen Frg PPP LA-mCnc;;ACTIVE;2.00;2.70 +27991-9;Fibrinogen fragments;MCnc;Pt;Urine;Qn;LA;COAG;1;Fibrinogen fragments [Mass/volume] in Urine by Latex agglutination;Fibrinogen Frg Ur LA-mCnc;;ACTIVE;2.00;2.70 +27992-7;Borrelia burgdorferi 23kD Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor23kD Ab CSF Ql IB;;ACTIVE;2.00;2.58 +27993-5;Sympathomimetics;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sympathomimetics [Mass/volume] in Urine;Sympathomimetics Ur-mCnc;;ACTIVE;2.00;2.70 +27994-3;Ehrlichia chaffeensis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Ehrlichia chaffeensis DNA [Presence] in Blood by NAA with probe detection;E chaffeensis DNA Bld Ql NAA+probe;;ACTIVE;2.00;2.73 +2799-5;Phosphoglyceromutase;CCnc;Pt;Ser;Qn;;CHEM;1;Phosphoglyceromutase [Enzymatic activity/volume] in Serum;Phosphoglyceromutase Ser-cCnc;;ACTIVE;1.0;2.68 +27995-0;Asparagine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Asparagine [Units/volume] in Serum or Plasma;Asparagine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +27996-8;17-Hydroxyprogesterone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --baseline;17OHP BS SerPl-mCnc;;ACTIVE;2.00;2.73 +27997-6;Beta aminoadipate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Beta aminoadipate/Creatinine [Molar ratio] in Urine;BAA/Creat Ur-sRto;;ACTIVE;2.00;2.42 +27998-4;Estrone;MCnc;Pt;Saliva;Qn;;CHEM;1;Estrone (E1) [Mass/volume] in Saliva (oral fluid);Estrone Sal-mCnc;;ACTIVE;2.00;2.73 +27999-2;Toxoplasma gondii DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Amniotic fluid by NAA with probe detection;T gondii DNA Amn Ql NAA+probe;;ACTIVE;2.00;2.73 +28000-8;von Willebrand factor Ag;ACnc;Pt;PPP;Qn;EIA;COAG;1;Deprecated von Willebrand factor (vWf) Ag [Units/volume] in Platelet poor plasma by EIA;Deprecated vWF Ag PPP EIA-aCnc;;DEPRECATED;2.00;2.69 +2800-1;Glucose phosphate isomerase;CCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Glucose phosphate isomerase [Enzymatic activity/volume] in Serum;Deprecated GPI Ser-cCnc;;DEPRECATED;1.0;2.36 +28001-6;Herpes simplex virus 1 Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Herpes simplex virus 1 IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;HSV1 IgG CSF Ql IB;;ACTIVE;2.00;2.58 +28002-4;Borrelia burgdorferi 39kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD Ab [Presence] in Serum by Immunoblot;B burgdor39kD Ab Ser Ql IB;;ACTIVE;2.00;2.73 +28003-2;Sodium/Potassium;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Sodium/Potassium [Molar ratio] in Serum or Plasma;Sodium/Potassium SerPl-sRto;;ACTIVE;2.00;2.42 +28004-0;HIV 1 Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;HIV 1 IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;HIV1 IgG CSF Ql IB;;ACTIVE;2.00;2.58 +28005-7;MTHFR gene.c.677C>T;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MTHFR gene c.677C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal;MTHFR c.677C>T Geno Bld/T;;ACTIVE;2.00;2.73 +28006-5;Hemoglobin F;PrThr;Pt;Vomitus;Ord;;HEM/BC;1;Hemoglobin F [Presence] in Vomitus;Hgb F Vom Ql;;ACTIVE;2.00;2.56 +28007-3;Urobilinogen;ARat;24H;Urine;Qn;;CHEM;1;Urobilinogen [Units] in 24 hour Urine;Urobilinogen 24h Ur;;ACTIVE;2.00;2.70 +28008-1;Cytomegalovirus DNA;PrThr;Pt;Bld;Ord;Probe.amp.sig;MICRO;1;Cytomegalovirus DNA [Presence] in Blood by Probe with signal amplification;CMV DNA Bld Ql Probe+sig amp;;ACTIVE;2.00;2.73 +28009-9;Specimen volume;Vol;Pt;Urine;Qn;;SPEC;1;Volume of Urine;Specimen vol Ur;;ACTIVE;2.00;2.73 +28010-7;Report.total;Find;Pt;Heart;Nar;EKG;ATTACH.CLINRPT;3;EKG Report (narrative);;;ACTIVE;2.00;2.27 +28011-5;Medical records;Find;Pt;Emergency department;Doc;;DOC.MISC;2;Emergency department Medical records;ED Medical records;;ACTIVE;2.00;2.73 +28012-3;Esophagoscopy study;Find;Stdy;Esophagus;Doc;Esophagoscopy;ENDO.GI;2;Esophagoscopy study;Esophagoscopy study;;ACTIVE;2.00;2.72 +28013-1;Study observation;Find;Stdy;Esophagus;Nom;Esophagoscopy;ENDO.GI;2;Esophagoscopy Study observation;Esophagoscopy Study;;ACTIVE;2.00;2.36 +28014-9;Esophagogastroduodenoscopy study;Find;Stdy;Gastrointestinal tract.upper;Doc;EGD;ENDO.GI;2;EGD Study;EGD Study;;ACTIVE;2.00;2.73 +28015-6;Study observation;Find;Stdy;Gastrointestinal tract.upper;Nom;EGD;ENDO.GI;2;EGD Study observation;EGD Study;;ACTIVE;2.00;2.73 +28016-4;ERCP study;Find;Stdy;Liver+Pancreas;Doc;ERCP;ENDO.GI;2;ERCP study;ERCP study;;ACTIVE;2.00;2.72 +28017-2;Study observation;Find;Stdy;Liver+Pancreas;Nom;ERCP;ENDO.GI;2;ERCP Study observation;ERCP Study;;ACTIVE;2.00;2.36 +28018-0;Enteroscopy study;Find;Stdy;Small bowel;Doc;Enteroscopy;ENDO.GI;2;Enteroscopy study;Enteroscopy study;;ACTIVE;2.00;2.72 +2801-9;Phospholipid;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Phospholipid [Mass/volume] in Serum or Plasma;Deprecated Phospholipid SerPl-mCnc;;DEPRECATED;1.0;2.36 +28019-8;Study observation;Find;Stdy;Small bowel;Nom;Enteroscopy;ENDO.GI;2;Enteroscopy Study observation;Enteroscopy Study;;ACTIVE;2.00;2.36 +28020-6;Enteroscopy study through stoma;Find;Stdy;Small bowel;Doc;Enteroscopy.thru stoma;ENDO.GI;2;Enteroscopy study through stoma;Enteroscopy study thru stoma;;ACTIVE;2.00;2.72 +28021-4;Study observation;Find;Stdy;Small bowel;Nom;Enteroscopy.thru stoma;ENDO.GI;2;Enteroscopy through stoma Study observation;Enteroscopy thru stoma Study;;ACTIVE;2.00;2.36 +28022-2;Study observation;Find;Stdy;Lower GI tract;Nar;Colonoscopy;ENDO.GI;2;Colonoscopy Study observation Narrative;Colonoscopy Study;;ACTIVE;2.00;2.70 +28023-0;Study observation;Find;Stdy;Lower GI tract;Nom;Colonoscopy;ENDO.GI;2;Colonoscopy Study observation;Colonoscopy Study;;ACTIVE;2.00;2.70 +28024-8;Study observation;Find;Stdy;Lower GI tract;Nar;Proctosigmoidoscopy.rigid;ENDO.GI;2;Rigid proctosigmoidoscopy Study observation Narrative;PSIG.rigid Study;;ACTIVE;2.00;2.70 +28025-5;Study observation;Find;Stdy;Lower GI tract;Nom;Proctosigmoidoscopy.rigid;ENDO.GI;2;Rigid proctosigmoidoscopy Study observation;PSIG.rigid Study;;ACTIVE;2.00;2.70 +28026-3;Study observation;Find;Stdy;Lower GI tract;Nar;Flexible sigmoidoscopy;ENDO.GI;2;Flexible sigmoidoscopy Study observation Narrative;FSIG Study;;ACTIVE;2.00;2.70 +2802-7;Phosphoserine;MCnc;Pt;Urine;Qn;;CHEM;1;Phosphoserine [Mass/volume] in Urine;Phosphoserine Ur-mCnc;;ACTIVE;1.0;2.73 +28027-1;Study observation;Find;Stdy;Lower GI tract;Nom;Flexible sigmoidoscopy;ENDO.GI;2;Flexible sigmoidoscopy Study observation;FSIG Study;;ACTIVE;2.00;2.70 +28028-9;Anoscopy study;Find;Pt;Anus;Doc;Anoscopy;ENDO.GI;2;Anoscopy study;Anoscopy study;;ACTIVE;2.00;2.72 +28029-7;Study observation;Find;Stdy;Anus;Nom;Anoscopy;ENDO.GI;2;Anoscopy Study observation;Anoscopy Study;;ACTIVE;2.00;2.36 +28032-1;Report.total;Find;Pt;Heart;Doc;Cardiac echo;ATTACH.CLINRPT;3;Deprecated Cardiac echo, study;;;DEPRECATED;2.00;2.46 +28033-9;Colonoscopy study through stoma;Find;Stdy;Colon;Doc;Colonoscopy;ENDO.GI;2;Colonoscopy study through stoma;Colonoscopy study thru stoma;;ACTIVE;2.00;2.72 +28034-7;Study observation;Find;Stdy;Colon;Nom;Colonoscopy.thru stoma;ENDO.GI;2;Colonoscopy.thru stoma Study observation;Colonoscopy.thru Stoma Study;;ACTIVE;2.00;2.36 +2803-5;Phytanate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Phytanate (C16:0(CH3)4) [Mass/volume] in Serum or Plasma;Deprecated Phytanate SerPl-mCnc;;DEPRECATED;1.0;2.36 +28035-4;Escherichia coli shiga-like toxin;ACnc;Pt;XXX;Qn;IA;MICRO;1;Escherichia coli shiga-like toxin [Units/volume] in Specimen by Immunoassay;E coli SXT Spec IA-aCnc;;ACTIVE;2.00;2.69 +28036-2;Borrelia burgdorferi 39kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor39kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28037-0;Borrelia burgdorferi 39kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor39kD IgM CSF Ql IB;;ACTIVE;2.00;2.73 +28038-8;Gamma hydroxybutyrate;MCnc;Pt;Bld;Qn;;CHEM;1;Gamma hydroxybutyrate [Mass/volume] in Blood;G-OH-Butyr Bld-mCnc;;ACTIVE;2.00;2.70 +28039-6;Borrelia burgdorferi 66kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 66kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor66kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28040-4;Borrelia burgdorferi 41kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor41kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28041-2;Gamma hydroxybutyrate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma hydroxybutyrate [Mass/volume] in Serum or Plasma;G-OH-Butyr SerPl-mCnc;;ACTIVE;2.00;2.73 +28042-0;Organophosphate pesticides;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Organophosphate pesticides [Mass/volume] in Urine by Screen method;OP Pesticides Ur Scn-mCnc;;ACTIVE;2.00;2.73 +2804-3;Phytanate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phytanate (C16:0(CH3)4) [Mass/volume] in Serum or Plasma;Phytanate SerPl-mCnc;;DISCOURAGED;1.0;2.73 +28043-8;Borrelia burgdorferi 41kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor41kD IgM CSF Ql IB;;ACTIVE;2.00;2.73 +28044-6;Gamma hydroxybutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Gamma hydroxybutyrate [Mass/volume] in Urine;G-OH-Butyr Ur-mCnc;;ACTIVE;2.00;2.73 +28045-3;Cortisol^1st specimen;PrThr;Pt;Saliva;Ord;;CHEM;1;Cortisol [Presence] in Saliva (oral fluid) --1st specimen;Cortis sp1 Sal Ql;;ACTIVE;2.00;2.56 +28046-1;Cortisol^2nd specimen;PrThr;Pt;Saliva;Ord;;CHEM;1;Cortisol [Presence] in Saliva (oral fluid) --2nd specimen;Cortis sp2 Sal Ql;;ACTIVE;2.00;2.56 +28047-9;Carbamate pesticides;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carbamate pesticides [Mass/volume] in Urine;Carbamate pesticides Ur-mCnc;;ACTIVE;2.00;2.70 +28048-7;Borrelia burgdorferi 58kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 58kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor58kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28049-5;1,2,4-Trichlorobenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,2,4-Trichlorobenzene [Mass/volume] in Serum or Plasma;1,2,4TCB SerPl-mCnc;;ACTIVE;2.00;2.70 +2805-0;Pipecolate;MCnc;Pt;CSF;Qn;;CHEM;1;Pipecolate [Mass/volume] in Cerebral spinal fluid;Pipecolate CSF-mCnc;;DISCOURAGED;1.0;2.44 +28050-3;1,2,3-Trichlorobenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,2,3-Trichlorobenzene [Mass/volume] in Serum or Plasma;1,2,3TCB SerPl-mCnc;;ACTIVE;2.00;2.70 +28051-1;1,3,5-Trichlorobenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,3,5-Trichlorobenzene [Mass/volume] in Serum or Plasma;1,3,5TCB SerPl-mCnc;;ACTIVE;2.00;2.70 +28052-9;HIV 1 Ab.IgG band pattern;Imp;Pt;CSF;Nom;IB;MICRO;1;HIV 1 IgG band pattern [Interpretation] in Cerebral spinal fluid by Immunoblot;HIV1 IgG Patrn CSF IB-Imp;;ACTIVE;2.00;2.73 +28053-7;Borrelia burgdorferi 30kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 30kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor30kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28054-5;Borrelia burgdorferi 93kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 93kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor93kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28055-2;Borrelia burgdorferi 45kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 45kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor45kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28056-0;Borrelia burgdorferi 28kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 28kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor28kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28057-8;Borrelia burgdorferi 23kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor23kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28058-6;Borrelia burgdorferi 21kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 21kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor21kD IgG CSF Ql IB;;ACTIVE;2.00;2.73 +28059-4;7-Aminoclonazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Serum or Plasma;7Aminoclonazepam SerPl-mCnc;;ACTIVE;2.00;2.73 +28060-2;MTHFR gene.c.1298A>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MTHFR gene c.1298A>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;MTHFR c.1298A>C Geno Bld/T;;ACTIVE;2.00;2.73 +28061-0;Naloxone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Naloxone [Mass/volume] in Serum or Plasma;Naloxone SerPl-mCnc;;ACTIVE;2.00;2.73 +28062-8;Borrelia burgdorferi 23kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor23kD IgM CSF Ql IB;;ACTIVE;2.00;2.73 +28063-6;Mercury^2nd specimen;MCnc;Pt;Dentin;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Dentin --2nd specimen;Mercury sp2 Dentin-mCnc;;ACTIVE;2.00;2.70 +28064-4;amLODIPine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;amLODIPine [Mass/volume] in Serum or Plasma;amLODIPine SerPl-mCnc;;ACTIVE;2.00;2.73 +28065-1;Gamma hydroxybutyrate;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Gamma hydroxybutyrate [Mass/volume] in Urine;Deprecated G-OH-Butyr Ur-mCnc;;DEPRECATED;2.00;2.70 +28066-9;Celecoxib;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Celecoxib [Mass/volume] in Serum or Plasma;Celecoxib SerPl-mCnc;;ACTIVE;2.00;2.70 +28067-7;Hemoglobin F;PrThr;Pt;Amnio fld;Ord;;HEM/BC;1;Hemoglobin F [Presence] in Amniotic fluid;Hgb F Amn Ql;;ACTIVE;2.00;2.73 +2806-8;Pipecolate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pipecolate [Mass/volume] in Serum or Plasma;Pipecolate SerPl-mCnc;;DISCOURAGED;1.0;2.73 +28068-5;Beta aminobutyrate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Beta aminobutyrate [Moles/volume] in Amniotic fluid;B-Aminobutyr Amn-sCnc;;ACTIVE;2.00;2.70 +28069-3;Meat fibers;Naric;Pt;Stool;Qn;Microscopy.light;CHEM;1;Meat fibers [#/area] in Stool by Light microscopy;Meat Fibers #/area Stl Micro;;ACTIVE;2.00;2.70 +28070-1;Vegetable fibers;Naric;Pt;Stool;Qn;Microscopy.light;CHEM;1;Vegetable fibers [#/area] in Stool by Light microscopy;Vegetable Fibers #/area Stl Micro;;ACTIVE;2.00;2.70 +28071-9;E selectin;MCnc;Pt;Bld;Qn;;CHEM;1;E selectin [Mass/volume] in Blood;E Selectin Bld-mCnc;;ACTIVE;2.00;2.70 +28072-7;Dihydrocodeine+Hydrocodeinone;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Dihydrocodeine+Hydrocodeinone [Mass/mass] in Stool;DHC+Hydrocod Stl-mCnt;;ACTIVE;2.00;2.70 +28073-5;7-Aminoclonazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Urine;7Aminoclonazepam Ur-mCnc;;ACTIVE;2.00;2.73 +28074-3;Tritium;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tritium [Presence] in Urine;Tritium Ur Ql;;ACTIVE;2.00;2.56 +28075-0;Sildenafil citrate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sildenafil citrate [Mass/volume] in Serum or Plasma;Sildenafil cit SerPl-mCnc;;ACTIVE;2.00;2.70 +2807-6;Pipecolate;MCnc;Pt;Urine;Qn;;CHEM;1;Pipecolate [Mass/volume] in Urine;Pipecolate Ur-mCnc;;DISCOURAGED;1.0;2.44 +28076-8;SUMAtriptan;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;SUMAtriptan [Mass/volume] in Serum or Plasma;SUMAtriptan SerPl-mCnc;;ACTIVE;2.00;2.73 +28077-6;Hexachlorobutadiene;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Hexachlorobutadiene [Presence] in Serum or Plasma;HCBD SerPl Ql;;ACTIVE;2.00;2.56 +28078-4;Bladder tumor Ag;PrThr;Pt;Urine;Ord;IA;SERO;1;Bladder tumor Ag [Presence] in Urine by Immunoassay;Bladder tumor Ag Ur Ql IA;;ACTIVE;2.00;2.73 +28079-2;Activities of daily living alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Activities of daily living alteration [CCC];;;ACTIVE;2.00;2.44 +280-8;Imipenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Imipenem [Susceptibility] by Disk diffusion (KB);Imipenem Islt KB;;ACTIVE;1.0;2.73 +28080-0;Activity alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Activity alteration [CCC];;;ACTIVE;2.00;2.44 +28081-8;Activity intolerance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Activity intolerance [CCC];;;ACTIVE;2.00;2.44 +28082-6;Activity intolerance risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Activity intolerance risk [CCC];;;ACTIVE;2.00;2.44 +28083-4;Acute pain;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Acute pain [CCC];;;ACTIVE;2.00;2.56 +2808-4;Porphobilin;MCnc;Pt;Ser;Qn;;CHEM;1;Porphobilin [Mass/volume] in Serum;Porphobilin Ser-mCnc;;ACTIVE;1.0;2.44 +28084-2;Adjustment impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Adjustment impairment [CCC];;;ACTIVE;2.00;2.44 +28085-9;Airway clearance impairment;Find;Pt;Respiratory system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Airway clearance impairment [CCC];;;ACTIVE;2.00;2.44 +28086-7;Decisional conflict;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Decisional conflict [CCC];;;ACTIVE;2.00;2.44 +28087-5;Defensive coping;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Defensive coping [CCC];;;ACTIVE;2.00;2.44 +28088-3;Denial;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Denial [CCC];;;ACTIVE;2.00;2.44 +28089-1;Diarrhea;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Diarrhea [CCC];;;ACTIVE;2.00;2.44 +28090-9;Disabled family coping;Find;Pt;^Family;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Disabled family coping Family [CCC];;;ACTIVE;2.00;2.44 +28091-7;Disuse syndrome;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Disuse syndrome [CCC];;;ACTIVE;2.00;2.44 +2809-2;Porphobilinogen;PrThr;Pt;Urine;Ord;;CHEM;1;Porphobilinogen [Presence] in Urine;PBG Ur Ql;;ACTIVE;1.0;2.73 +28092-5;Diversional activity deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Diversional activity deficit [CCC];;;ACTIVE;2.00;2.44 +28093-3;Dressing &or grooming deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Dressing/grooming deficit [CCC];;;ACTIVE;2.00;2.56 +28094-1;Dying process;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Dying process [CCC];;;ACTIVE;2.00;2.44 +28095-8;Dysfunctional grieving;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Dysfunctional grieving [CCC];;;ACTIVE;2.00;2.44 +28096-6;Autonomic dysreflexia;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Autonomic dysreflexia [CCC];;;ACTIVE;2.00;2.44 +28097-4;Endocrine alteration;Find;Pt;Endocrine system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Endocrine alteration [CCC];;;ACTIVE;2.00;2.44 +28098-2;Family coping impairment;Find;Pt;^Family;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Family coping impairment Family [CCC];;;ACTIVE;2.00;2.44 +28099-0;Family process alteration;Find;Pt;^Family;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Family process alteration Family [CCC];;;ACTIVE;2.00;2.44 +28-1;Ampicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Ampicillin Islt MIC;;ACTIVE;1.0;2.73 +2810-0;Porphobilinogen;MRat;24H;Urine;Qn;;CHEM;1;Porphobilinogen [Mass/time] in 24 hour Urine;PBG 24h Ur-mRate;;ACTIVE;1.0;2.73 +28100-6;Fatigue;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fatigue [CCC];;;ACTIVE;2.00;2.44 +28101-4;Fear;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fear [CCC];;;ACTIVE;2.00;2.56 +28102-2;Fecal impaction;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fecal impaction [CCC];;;ACTIVE;2.00;2.44 +28103-0;Feeding deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Feeding deficit [CCC];;;ACTIVE;2.00;2.44 +28104-8;Fluid volume alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fluid volume alteration [CCC];;;ACTIVE;2.00;2.44 +28105-5;Fluid volume deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fluid volume deficit [CCC];;;ACTIVE;2.00;2.44 +28106-3;Fluid volume deficit risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fluid volume deficit risk [CCC];;;ACTIVE;2.00;2.44 +28107-1;Fluid volume excess;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fluid volume excess [CCC];;;ACTIVE;2.00;2.44 +28108-9;Fluid volume excess risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fluid volume excess risk [CCC];;;ACTIVE;2.00;2.44 +28109-7;Functional urinary incontinence;Find;Pt;Genitourinary system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Functional urinary incontinence [CCC];;;ACTIVE;2.00;2.44 +28110-5;Gas exchange impairment;Find;Pt;Respiratory system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Gas exchange impairment [CCC];;;ACTIVE;2.00;2.44 +28111-3;Gastrointestinal alteration;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Gastrointestinal alteration [CCC];;;ACTIVE;2.00;2.44 +28112-1;Grieving;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Grieving [CCC];;;ACTIVE;2.00;2.44 +28113-9;Growth and development alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Growth and development alteration [CCC];;;ACTIVE;2.00;2.56 +28114-7;Gustatory alteration;Find;Pt;Mouth;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Gustatory alteration [CCC];;;ACTIVE;2.00;2.56 +28115-4;Health maintenance alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Health maintenance alteration [CCC];;;ACTIVE;2.00;2.56 +28116-2;Health-seeking behavior alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Health-seeking behavior alteration [CCC];;;ACTIVE;2.00;2.44 +28117-0;Home maintenance alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Home maintenance alteration [CCC];;;ACTIVE;2.00;2.44 +2811-8;Porphobilinogen;SCnc;Pt;Urine;Qn;;CHEM;1;Porphobilinogen [Moles/volume] in Urine;PBG Ur-sCnc;;ACTIVE;1.0;2.73 +28118-8;Hopelessness;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Hopelessness [CCC];;;ACTIVE;2.00;2.44 +28119-6;Hypothermia;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Hypothermia [CCC];;;ACTIVE;2.00;2.44 +28120-4;Hyperthermia;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Hyperthermia [CCC];;;ACTIVE;2.00;2.44 +28121-2;Immunologic alteration;Find;Pt;Immune system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Immunologic alteration [CCC];;;ACTIVE;2.00;2.44 +28122-0;Individual coping impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Individual coping impairment [CCC];;;ACTIVE;2.00;2.44 +28123-8;Infection risk;Find;Pt;Immune system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Infection risk [CCC];;;ACTIVE;2.00;2.44 +28124-6;Infection;Find;Pt;Immune system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Infection [CCC];;;ACTIVE;2.00;2.56 +28125-3;Injury risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Injury risk [CCC];;;ACTIVE;2.00;2.44 +2812-6;Porphobilinogen deaminase;CCnc;Pt;RBC;Qn;;CHEM;1;Porphobilinogen deaminase [Enzymatic activity/volume] in Red Blood Cells;PBG Deaminase RBC-cCnc;;ACTIVE;1.0;2.73 +28126-1;Instrumental activity of daily living (IADLS) alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Instrumental activity of daily living (IADLS) alteration [CCC];;;ACTIVE;2.00;2.44 +28127-9;Kinesthetic alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Kinesthetic alteration [CCC];;;ACTIVE;2.00;2.56 +28128-7;Knowledge deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit [CCC];;;ACTIVE;2.00;2.44 +28129-5;Knowledge deficit of diagnostic test;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit of diagnostic test [CCC];;;ACTIVE;2.00;2.44 +28130-3;Knowledge deficit of dietary regimen;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit of dietary regimen [CCC];;;ACTIVE;2.00;2.44 +28131-1;Knowledge deficit of disease process;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit of disease process [CCC];;;ACTIVE;2.00;2.44 +28132-9;Knowledge deficit of fluid volume;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit of fluid volume [CCC];;;ACTIVE;2.00;2.44 +28133-7;Knowledge deficit of medication regimen;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit of medication regimen [CCC];;;ACTIVE;2.00;2.44 +2813-4;Porphobilinogen synthase;CCnc;Pt;RBC;Qn;;CHEM;1;Porphobilinogen synthase [Enzymatic activity/volume] in Red Blood Cells;PBG Synthase RBC-cCnc;;ACTIVE;1.0;2.73 +28134-5;Anticipatory grieving;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Anticipatory grieving [CCC];;;ACTIVE;2.00;2.44 +28135-2;Anxiety;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Anxiety [CCC];;;ACTIVE;2.00;2.44 +28136-0;Aspiration risk;Find;Pt;Respiratory system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Aspiration risk [CCC];;;ACTIVE;2.00;2.44 +28137-8;Auditory alteration;Find;Pt;Ear;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Auditory alteration [CCC];;;ACTIVE;2.00;2.44 +28138-6;Bathing &or hygiene deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Bathing/hygiene deficit [CCC];;;ACTIVE;2.00;2.44 +28139-4;Blood pressure alteration;Find;Pt;Cardiovascular system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Blood pressure alteration [CCC];;;ACTIVE;2.00;2.56 +28140-2;Body image disturbance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Body image disturbance [CCC];;;ACTIVE;2.00;2.56 +28141-0;Body nutrition deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Body nutrition deficit [CCC];;;ACTIVE;2.00;2.44 +2814-2;Porphyrins;MCnc;Pt;RBC;Qn;;CHEM;1;Porphyrins [Mass/volume] in Red Blood Cells;Porphyrins RBC-mCnc;;ACTIVE;1.0;2.73 +28142-8;Body nutrition deficit risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Body nutrition deficit risk [CCC];;;ACTIVE;2.00;2.44 +28143-6;Body nutrition excess;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Body nutrition excess [CCC];;;ACTIVE;2.00;2.44 +28144-4;Body nutrition excess risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Body nutrition excess risk [CCC];;;ACTIVE;2.00;2.44 +28145-1;Bowel elimination alteration;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Bowel elimination alteration [CCC];;;ACTIVE;2.00;2.44 +28146-9;Bowel incontinence;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Bowel incontinence [CCC];;;ACTIVE;2.00;2.44 +28147-7;Breastfeeding impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Breastfeeding impairment [CCC];;;ACTIVE;2.00;2.44 +28148-5;Breathing pattern impairment;Find;Pt;Respiratory system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Breathing pattern impairment [CCC];;;ACTIVE;2.00;2.44 +28149-3;Cardiac output alteration;Find;Pt;Cardiovascular system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Cardiac output alteration [CCC];;;ACTIVE;2.00;2.44 +28150-1;Cardiovascular alteration;Find;Pt;Cardiovascular system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Cardiovascular alteration [CCC];;;ACTIVE;2.00;2.44 +28151-9;Cerebral alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Cerebral alteration [CCC];;;ACTIVE;2.00;2.56 +28152-7;Chronic low self-esteem disturbance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Chronic low self-esteem disturbance [CCC];;;ACTIVE;2.00;2.44 +28153-5;Chronic pain;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Chronic pain [CCC];;;ACTIVE;2.00;2.73 +28154-3;Colonic constipation;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Colonic constipation [CCC];;;DISCOURAGED;2.00;2.56 +28155-0;Comfort alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Comfort alteration [CCC];;;ACTIVE;2.00;2.56 +28156-8;Communication impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Communication impairment [CCC];;;ACTIVE;2.00;2.44 +28157-6;Compromised family coping;Find;Pt;^Family;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Compromised family coping Family [CCC];;;DISCOURAGED;2.00;2.56 +28158-4;May choose to self-deliver at the end;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;May choose to self-deliver at the end [Living with HIV];;;ACTIVE;2.00;2.44 +2815-9;Porphyrins;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Porphyrins [Mass/volume] in Serum or Plasma;Porphyrins SerPl-mCnc;;ACTIVE;1.0;2.73 +28159-2;Meaningful life;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Meaningful life [Living with HIV];;;ACTIVE;2.00;2.44 +281-6;Imipenem;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Imipenem [Susceptibility] by Serum bactericidal titer;Imipenem Titr SBT;;ACTIVE;1.0;2.32 +28160-0;Medications are taking over my life;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Medications are taking over my life [Living with HIV];;;ACTIVE;2.00;2.44 +28161-8;Need help letting go;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Need help letting go [Living with HIV];;;ACTIVE;2.00;2.44 +28162-6;No energy to fight back;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;No energy to fight back [Living with HIV];;;ACTIVE;2.00;2.44 +28163-4;Not enjoying life;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Not enjoying life [Living with HIV];;;ACTIVE;2.00;2.44 +28164-2;Pain is hard to manage;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Pain is hard to manage [Living with HIV];;;ACTIVE;2.00;2.44 +28165-9;So many things yet undone;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;So many things yet undone [Living with HIV];;;ACTIVE;2.00;2.44 +28166-7;Somewhat disconnected;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Somewhat disconnected [Living with HIV];;;ACTIVE;2.00;2.44 +2816-7;Porphyrins;PrThr;Pt;Stool;Ord;;CHEM;1;Porphyrins [Presence] in Stool;Porphyrins Stl Ql;;ACTIVE;1.0;2.73 +28167-5;Stay at home and receive treatment;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Stay at home and receive treatment [Living with HIV];;;ACTIVE;2.00;2.44 +28168-3;Take time for important things;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Take time for important things [Living with HIV];;;ACTIVE;2.00;2.44 +28169-1;Use time wisely;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Use time wisely [Living with HIV];;;ACTIVE;2.00;2.44 +28170-9;Want to die at home;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Want to die at home [Living with HIV];;;ACTIVE;2.00;2.44 +28171-7;Knowledge deficit of safety precautions;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit of safety precautions [CCC];;;ACTIVE;2.00;2.44 +28172-5;Knowledge deficit of therapeutic regimen;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Knowledge deficit of therapeutic regimen [CCC];;;ACTIVE;2.00;2.44 +28173-3;Meaningfulness alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Meaningfulness alteration [CCC];;;ACTIVE;2.00;2.44 +28174-1;Medication risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Medication risk [CCC];;;ACTIVE;2.00;2.44 +2817-5;Porphyrins;MCnc;Pt;Stool;Qn;;CHEM;1;Porphyrins [Mass/volume] in Stool;Porphyrins Stl-mCnc;;ACTIVE;1.0;2.34 +28175-8;Musculoskeletal alteration;Find;Pt;Musculoskeletal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Musculoskeletal alteration [CCC];;;ACTIVE;2.00;2.44 +28176-6;Noncompliance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Noncompliance [CCC];;;ACTIVE;2.00;2.44 +28177-4;Noncompliance with diagnostic test;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Noncompliance with diagnostic test [CCC];;;ACTIVE;2.00;2.44 +28178-2;Noncompliance with dietary regimen;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Noncompliance with dietary regimen [CCC];;;ACTIVE;2.00;2.44 +28179-0;Noncompliance with safety precautions;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Noncompliance with safety precautions [CCC];;;ACTIVE;2.00;2.44 +28180-8;Noncompliance with therapeutic regimen;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Noncompliance with therapeutic regimen [CCC];;;ACTIVE;2.00;2.56 +28181-6;Nutrition alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Nutrition alteration [CCC];;;ACTIVE;2.00;2.44 +28182-4;Olfactory alteration;Find;Pt;Neurologic system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Olfactory alteration [CCC];;;ACTIVE;2.00;2.56 +2818-3;Porphyrins;PrThr;Pt;Urine;Ord;;CHEM;1;Porphyrins [Presence] in Urine;Porphyrins Ur Ql;;ACTIVE;1.0;2.73 +28183-2;Oral mucous membranes impairment;Find;Pt;Mouth & Throat;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Oral mucous membranes impairment [CCC];;;ACTIVE;2.00;2.44 +28184-0;Parental role conflict;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Parental role conflict [CCC];;;ACTIVE;2.00;2.44 +28185-7;Parenting alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Parenting alteration [CCC];;;ACTIVE;2.00;2.44 +28186-5;Perceived constipation;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Perceived constipation [CCC];;;ACTIVE;2.00;2.56 +28187-3;Peripheral alteration;Find;Pt;Skin;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Peripheral alteration [CCC];;;ACTIVE;2.00;2.56 +28188-1;Personal identity disturbance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Personal identity disturbance [CCC];;;ACTIVE;2.00;2.44 +28189-9;Physical mobility impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Physical mobility impairment [CCC];;;ACTIVE;2.00;2.44 +28190-7;Physical regulation alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Physical regulation alteration [CCC];;;ACTIVE;2.00;2.44 +2819-1;Potassium;SCnc;Pt;CSF;Qn;;CHEM;1;Potassium [Moles/volume] in Cerebral spinal fluid;Potassium CSF-sCnc;;ACTIVE;1.0;2.73 +28191-5;Poisoning risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Poisoning risk [CCC];;;ACTIVE;2.00;2.44 +28192-3;Polypharmacy;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Polypharmacy [CCC];;;ACTIVE;2.00;2.44 +28193-1;Post-trauma response;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Post-trauma response [CCC];;;ACTIVE;2.00;2.44 +28194-9;Powerlessness;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Powerlessness [CCC];;;ACTIVE;2.00;2.44 +28195-6;Protection alteration;Find;Pt;Immune system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Protection alteration [CCC];;;DISCOURAGED;2.00;2.56 +28196-4;Rape trauma syndrome;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Rape trauma syndrome [CCC];;;ACTIVE;2.00;2.44 +28197-2;Reflex urinary incontinence;Find;Pt;Genitourinary system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Reflex urinary incontinence [CCC];;;ACTIVE;2.00;2.44 +28198-0;Renal alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Renal alteration [CCC];;;ACTIVE;2.00;2.56 +28199-8;Respiration alteration;Find;Pt;Respiratory system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Respiration alteration [CCC];;;ACTIVE;2.00;2.44 +28200-4;Role performance alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Role performance alteration [CCC];;;ACTIVE;2.00;2.44 +28201-2;Self-care deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Self-care deficit [CCC];;;ACTIVE;2.00;2.44 +28202-0;Self-concept alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Self-concept alteration [CCC];;;ACTIVE;2.00;2.44 +28203-8;Sensory perceptual alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Sensory perceptual alteration [CCC];;;ACTIVE;2.00;2.44 +28204-6;Sexual dysfunction;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Sexual dysfunction [CCC];;;ACTIVE;2.00;2.44 +28205-3;Sexuality patterns alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Sexuality patterns alteration [CCC];;;ACTIVE;2.00;2.44 +28206-1;Situational self-esteem disturbance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Situational self-esteem disturbance [CCC];;;ACTIVE;2.00;2.44 +28207-9;Skin incision;Find;Pt;Skin;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Skin incision [CCC];;;ACTIVE;2.00;2.44 +28208-7;Skin integrity impairment;Find;Pt;Skin;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Skin integrity impairment [CCC];;;ACTIVE;2.00;2.44 +2820-9;Potassium;SCnc;Pt;Dial fld;Qn;;CHEM;1;Potassium [Moles/volume] in Dialysis fluid;Potassium Dial fld-sCnc;;ACTIVE;1.0;2.34 +28209-5;Skin integrity impairment risk;Find;Pt;Skin;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Skin integrity impairment risk [CCC];;;ACTIVE;2.00;2.44 +28210-3;Sleep pattern disturbance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Sleep pattern disturbance [CCC];;;ACTIVE;2.00;2.44 +28211-1;Social interaction alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Social interaction alteration [CCC];;;ACTIVE;2.00;2.44 +28212-9;Social isolation;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Social isolation [CCC];;;ACTIVE;2.00;2.44 +28213-7;Spiritual distress;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Spiritual distress [CCC];;;ACTIVE;2.00;2.44 +28214-5;Spiritual state alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Spiritual state alteration [CCC];;;ACTIVE;2.00;2.44 +28215-2;Stress urinary incontinence;Find;Pt;Genitourinary system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Stress urinary incontinence [CCC];;;ACTIVE;2.00;2.44 +28216-0;Suffocation risk;Find;Pt;Respiratory system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Suffocation risk [CCC];;;ACTIVE;2.00;2.44 +2821-7;Potassium;SCnc;Pt;Body fld;Qn;;CHEM;1;Potassium [Moles/volume] in Body fluid;Potassium Fld-sCnc;;ACTIVE;1.0;2.73 +28217-8;Sanitation.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28218-6;Sanitation.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28219-4;Sanitation.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28220-2;Residence.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28221-0;Residence.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28222-8;Residence.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28223-6;Neighborhood &or workplace safety.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety.behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28224-4;Neighborhood &or workplace safety.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety..knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +2822-5;Potassium;SCnc;Pt;Gast fld;Qn;;CHEM;1;Potassium [Moles/volume] in Gastric fluid;Potassium Gast-sCnc;;ACTIVE;1.0;2.34 +28225-1;Neighborhood &or workplace safety.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety.status Family [OMAHA];;;ACTIVE;2.00;2.44 +28226-9;Swallowing impairment;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Swallowing impairment [CCC];;;ACTIVE;2.00;2.56 +28227-7;Tactile alteration;Find;Pt;Neurologic system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Tactile alteration [CCC];;;ACTIVE;2.00;2.56 +28228-5;Thermoregulation impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Thermoregulation impairment [CCC];;;ACTIVE;2.00;2.44 +28229-3;Thought process alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Thought process alteration [CCC];;;ACTIVE;2.00;2.56 +28230-1;Tissue perfusion alteration;Find;Pt;Cardiovascular system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Tissue perfusion alteration [CCC];;;ACTIVE;2.00;2.44 +28231-9;Toileting deficit;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Toileting deficit [CCC];;;ACTIVE;2.00;2.44 +28232-7;Total urinary incontinence;Find;Pt;Genitourinary system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Total urinary incontinence [CCC];;;DISCOURAGED;2.00;2.56 +2823-3;Potassium;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Potassium [Moles/volume] in Serum or Plasma;Potassium SerPl-sCnc;;ACTIVE;1.0;2.73 +28233-5;Trauma risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Trauma risk [CCC];;;ACTIVE;2.00;2.44 +28234-3;Unilateral neglect;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Unilateral neglect [CCC];;;ACTIVE;2.00;2.44 +28235-0;Constipation;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Constipation [CCC];;;ACTIVE;2.00;2.56 +28236-8;Pain;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Pain [CCC];;;ACTIVE;2.00;2.56 +28237-6;Urge urinary incontinence;Find;Pt;Genitourinary system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Urge urinary incontinence [CCC];;;ACTIVE;2.00;2.44 +28238-4;Urinary elimination alteration;Find;Pt;Genitourinary system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Urinary elimination alteration [CCC];;;ACTIVE;2.00;2.44 +28239-2;Urinary retention;Find;Pt;Genitourinary system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Urinary retention [CCC];;;ACTIVE;2.00;2.44 +282-4;Imipenem+Cilastatin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Deprecated Imipenem+Cilastatin [Susceptibility] by Minimum lethal concentration (MLC);Deprecated Imipenem+Cilastatin Islt MLC;;DEPRECATED;1.0;2.36 +28240-0;Verbal impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Verbal impairment [CCC];;;ACTIVE;2.00;2.44 +2824-1;Potassium;SCnc;Pt;RBC;Qn;;CHEM;1;Potassium [Moles/volume] in Red Blood Cells;Potassium RBC-sCnc;;ACTIVE;1.0;2.73 +28241-8;Violence risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Violence risk [CCC];;;ACTIVE;2.00;2.44 +28242-6;Visual alteration;Find;Pt;Eye;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Visual alteration [CCC];;;ACTIVE;2.00;2.56 +28243-4;Abuse.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28244-2;Abuse.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28245-9;Abuse.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Status [OMAHA];;;ACTIVE;2.00;2.44 +28246-7;Antepartum &or postpartum.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Antepartum/postpartum.behavior [OMAHA];;;ACTIVE;2.00;2.44 +28247-5;Antepartum &or postpartum.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Antepartum/postpartum.status [OMAHA];;;ACTIVE;2.00;2.44 +28248-3;Bowel function.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28249-1;Bowel function.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28250-9;Bowel function.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Status [OMAHA];;;ACTIVE;2.00;2.44 +28251-7;Caretaking &or parenting.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.behavior [OMAHA];;;ACTIVE;2.00;2.44 +28252-5;Caretaking &or parenting.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28253-3;Caretaking &or parenting.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.status [OMAHA];;;ACTIVE;2.00;2.44 +28254-1;Circulation.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28255-8;Circulation.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28256-6;Circulation.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Status [OMAHA];;;ACTIVE;2.00;2.73 +28257-4;Cognition.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Behavior [OMAHA];;;ACTIVE;2.00;2.44 +2825-8;Potassium;SCnc;Pt;Saliva;Qn;;CHEM;1;Potassium [Moles/volume] in Saliva (oral fluid);Potassium Sal-sCnc;;ACTIVE;1.0;2.42 +28258-2;Cognition.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28259-0;Cognition.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Status [OMAHA];;;ACTIVE;2.00;2.44 +28260-8;Communication with community resources.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28261-6;Communication with community resources.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28262-4;Communication with community resources.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Status [OMAHA];;;ACTIVE;2.00;2.44 +28263-2;Consciousness.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28264-0;Consciousness.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28265-7;Consciousness.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Status [OMAHA];;;ACTIVE;2.00;2.44 +2826-6;Potassium;SRat;72H;Stool;Qn;;CHEM;1;Potassium [Moles/time] in 72 hour Stool;Potassium 72h Stl-sRate;;ACTIVE;1.0;2.42 +28266-5;Dentition.behavior;Find;Pt;Mouth & Throat & Teeth;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Dentition.behavior [OMAHA];;;ACTIVE;2.00;2.44 +28267-3;Dentition.knowledge;Find;Pt;Mouth & Throat & Teeth;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Dentition.knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28268-1;Dentition.status;Find;Pt;Mouth & Throat & Teeth;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Dentition.status [OMAHA];;;ACTIVE;2.00;2.44 +28269-9;Digestion-hydration.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28270-7;Digestion-hydration.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28271-5;Digestion-hydration.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Status [OMAHA];;;ACTIVE;2.00;2.44 +28272-3;Mental health.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28273-1;Mental health.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +2827-4;Potassium;SCnc;Pt;Sweat;Qn;;CHEM;1;Potassium [Moles/volume] in Sweat;Potassium Sweat-sCnc;;ACTIVE;1.0;2.34 +28274-9;Mental health.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Status [OMAHA];;;ACTIVE;2.00;2.44 +28275-6;Family planning.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28276-4;Family planning.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28277-2;Family planning.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Status [OMAHA];;;ACTIVE;2.00;2.44 +28278-0;Genito-urinary function.behavior;Find;Pt;Genitourinary system;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Genito-urinary function.behavior [OMAHA];;;ACTIVE;2.00;2.44 +28279-8;Genito-urinary function.knowledge;Find;Pt;Genitourinary system;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Genito-urinary function.knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28280-6;Genito-urinary function.status;Find;Pt;Genitourinary system;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Genito-urinary function.status [OMAHA];;;ACTIVE;2.00;2.44 +28281-4;Grief.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Behavior [OMAHA];;;ACTIVE;2.00;2.44 +2828-2;Potassium;SCnc;Pt;Urine;Qn;;CHEM;1;Potassium [Moles/volume] in Urine;Potassium Ur-sCnc;;ACTIVE;1.0;2.73 +28282-2;Grief.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28283-0;Grief.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Status [OMAHA];;;ACTIVE;2.00;2.44 +28284-8;Growth and development.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28285-5;Growth and development.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28286-3;Growth and development.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Status [OMAHA];;;ACTIVE;2.00;2.44 +28287-1;Health care supervision.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28288-9;Health care supervision.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28289-7;Health care supervision.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Status [OMAHA];;;ACTIVE;2.00;2.44 +2829-0;Potassium;SRat;24H;Urine;Qn;;CHEM;1;Potassium [Moles/time] in 24 hour Urine;Potassium 24h Ur-sRate;;ACTIVE;1.0;2.73 +28290-5;Hearing.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28291-3;Hearing.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28292-1;Hearing.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Status [OMAHA];;;ACTIVE;2.00;2.44 +28293-9;Sexuality.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28294-7;Sexuality.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28295-4;Sexuality.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Status [OMAHA];;;ACTIVE;2.00;2.44 +28296-2;Income.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28297-0;Income.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28298-8;Income.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Status [OMAHA];;;ACTIVE;2.00;2.44 +28299-6;Skin.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28300-2;Skin.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28301-0;Skin.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Status [OMAHA];;;ACTIVE;2.00;2.44 +28302-8;Interpersonal relationship.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28303-6;Interpersonal relationship.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28304-4;Interpersonal relationship.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Status [OMAHA];;;ACTIVE;2.00;2.44 +28305-1;Neglect.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28306-9;Neglect.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28307-7;Neglect.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Status [OMAHA];;;ACTIVE;2.00;2.44 +2830-8;Potassium renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Potassium renal clearance in 24 hour Urine and Serum or Plasma;Potassium Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +28308-5;Neighborhood &or workplace safety.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety.behavior [OMAHA];;;ACTIVE;2.00;2.44 +28309-3;Neighborhood &or workplace safety.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety..knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28310-1;Neighborhood &or workplace safety.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety.status [OMAHA];;;ACTIVE;2.00;2.44 +28311-9;Neuro-musculo-skeletal function.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28312-7;Neuro-musculo-skeletal function.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28313-5;Neuro-musculo-skeletal function.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Status [OMAHA];;;ACTIVE;2.00;2.44 +28314-3;Nutrition.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28315-0;Nutrition.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +2831-6;Pregnancy specific protein 1;MCnc;Pt;Ser;Qn;;CHEM;1;Pregnancy specific protein 1 [Mass/volume] in Serum;Preg Sp Prot1 Ser-mCnc;;ACTIVE;1.0;2.42 +28316-8;Nutrition.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Status [OMAHA];;;ACTIVE;2.00;2.44 +28317-6;Pain.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28318-4;Pain.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28319-2;Pain.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Status [OMAHA];;;ACTIVE;2.00;2.44 +283-2;Imipenem+Cilastatin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Deprecated Imipenem+Cilastatin [Susceptibility] by Minimum inhibitory concentration (MIC);Deprecated Imipenem+Cilastatin Islt MIC;;DEPRECATED;1.0;2.36 +28320-0;Personal care.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28321-8;Personal care.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28322-6;Personal care.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Status [OMAHA];;;ACTIVE;2.00;2.44 +28323-4;Physical activity.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Behavior [OMAHA];;;ACTIVE;2.00;2.44 +2832-4;Pregnanediol;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Pregnanediol [Mass/volume] in Amniotic fluid;Pregnanediol Amn-mCnc;;ACTIVE;1.0;2.42 +28324-2;Physical activity.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28325-9;Physical activity.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Status [OMAHA];;;ACTIVE;2.00;2.44 +28326-7;Medication regimen.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28327-5;Medication regimen.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28328-3;Medication regimen.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Status [OMAHA];;;ACTIVE;2.00;2.44 +28329-1;Residence.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28330-9;Residence.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28331-7;Residence.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Status [OMAHA];;;ACTIVE;2.00;2.44 +2833-2;Pregnanediol;MCnc;Pt;Urine;Qn;;CHEM;1;Pregnanediol [Mass/volume] in Urine;Pregnanediol Ur-mCnc;;ACTIVE;1.0;2.42 +28332-5;Respiration.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28333-3;Respiration.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28334-1;Respiration.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Status [OMAHA];;;ACTIVE;2.00;2.44 +28335-8;Role change.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28336-6;Role change.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28337-4;Role change.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Status [OMAHA];;;ACTIVE;2.00;2.44 +28338-2;Sanitation.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28339-0;Sanitation.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +2834-0;Pregnanediol;MRat;24H;Urine;Qn;;CHEM;1;Pregnanediol [Mass/time] in 24 hour Urine;Pregnanediol 24h Ur-mRate;;ACTIVE;1.0;2.42 +28340-8;Sanitation.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Status [OMAHA];;;ACTIVE;2.00;2.44 +28341-6;Sleep and rest pattern.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28342-4;Sleep and rest pattern.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28343-2;Sleep and rest pattern.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Status [OMAHA];;;ACTIVE;2.00;2.44 +28344-0;Social contact.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28345-7;Social contact.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28346-5;Social contact.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Status [OMAHA];;;ACTIVE;2.00;2.44 +28347-3;Speech and language.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28348-1;Speech and language.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28349-9;Speech and language.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Status [OMAHA];;;ACTIVE;2.00;2.44 +28350-7;Spirituality.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28351-5;Spirituality.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28352-3;Spirituality.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Status [OMAHA];;;ACTIVE;2.00;2.44 +28353-1;Substance use.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28354-9;Substance use.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28355-6;Substance use.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Status [OMAHA];;;ACTIVE;2.00;2.44 +28356-4;Technical procedure.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Technical procedure.behavior [OMAHA];;;ACTIVE;2.00;2.44 +2835-7;Pregnanetriol;MCnc;Pt;Urine;Qn;;CHEM;1;Pregnanetriol [Mass/volume] in Urine;Pregntrl Ur-mCnc;;ACTIVE;1.0;2.73 +28357-2;Technical procedure.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Technical procedure.knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28358-0;Technical procedure.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Technical procedure.status [OMAHA];;;ACTIVE;2.00;2.44 +28359-8;Vision.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Behavior [OMAHA];;;ACTIVE;2.00;2.44 +28360-6;Vision.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28361-4;Vision.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Status [OMAHA];;;ACTIVE;2.00;2.44 +28362-2;Anxiety;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Anxiety [QAM];;;ACTIVE;2.00;2.44 +28363-0;Fear;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Fear [QAM];;;ACTIVE;2.00;2.44 +28364-8;Afraid of pain and suffering;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Afraid of pain and suffering [Living with HIV];;;ACTIVE;2.00;2.44 +2836-5;Pregnanetriol;MRat;24H;Urine;Qn;;CHEM;1;Pregnanetriol [Mass/time] in 24 hour Urine;Pregntrl 24h Ur-mRate;;ACTIVE;1.0;2.73 +28365-5;Afraid to die;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Afraid to die [Living with HIV];;;ACTIVE;2.00;2.44 +28366-3;Comfortable and well cared for;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Comfortable and well cared for [Living with HIV];;;ACTIVE;2.00;2.44 +28367-1;Don't want high technology to keep me alive;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Don't want high technology to keep me alive [Living with HIV];;;ACTIVE;2.00;2.44 +28368-9;Don't have to keep fighting;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Don't have to keep fighting [Living with HIV];;;ACTIVE;2.00;2.44 +28369-7;Embarrassed by the way I look;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Embarrassed by the way I look [Living with HIV];;;ACTIVE;2.00;2.44 +28370-5;Extra effort to do things;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Extra effort to do things [Living with HIV];;;ACTIVE;2.00;2.44 +28371-3;Feel spiritual as I near the end;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Feel spiritual as I near the end [Living with HIV];;;ACTIVE;2.00;2.44 +28372-1;Financial situation is distressing;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Financial situation is distressing [Living with HIV];;;ACTIVE;2.00;2.44 +2837-3;Pregnenolone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pregnenolone [Mass/volume] in Serum or Plasma;Preg SerPl-mCnc;;ACTIVE;1.0;2.73 +28373-9;Frightened over little control;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Frightened over little control [Living with HIV];;;ACTIVE;2.00;2.44 +28374-7;Giving up things;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Giving up things [Living with HIV];;;ACTIVE;2.00;2.44 +28375-4;Anxiety;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Anxiety [HIV-SSC];;;ACTIVE;2.00;2.44 +28376-2;Chills;Find;24H;Immune system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Chills [HIV-SSC];;;ACTIVE;2.00;2.44 +28377-0;Day sweats;Find;24H;Immune system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Day sweats [HIV-SSC];;;ACTIVE;2.00;2.44 +28378-8;Depression;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Depression [HIV-SSC];;;ACTIVE;2.00;2.44 +28379-6;Diarrhea;Find;24H;Gastrointestinal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Diarrhea [HIV-SSC];;;ACTIVE;2.00;2.44 +28380-4;Difficulty concentrating;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Difficulty concentrating [HIV-SSC];;;ACTIVE;2.00;2.44 +2838-1;Progesterone;MCnc;Pt;Saliva;Qn;;CHEM;1;Progesterone [Mass/volume] in Saliva (oral fluid);Progest Sal-mCnc;;ACTIVE;1.0;2.73 +28381-2;Disorientation;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Disorientation [HIV-SSC];;;ACTIVE;2.00;2.44 +28382-0;Dry mouth;Find;24H;Mouth;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Dry mouth [HIV-SSC];;;ACTIVE;2.00;2.44 +28383-8;Fatigue;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Fatigue [HIV-SSC];;;ACTIVE;2.00;2.44 +28384-6;Fear;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Fear [HIV-SSC];;;ACTIVE;2.00;2.44 +28385-3;Fever;Find;24H;Immune system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Fever [HIV-SSC];;;ACTIVE;2.00;2.44 +28386-1;Gas &or bloating;Find;24H;Gastrointestinal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Gas /bloating [HIV-SSC];;;ACTIVE;2.00;2.44 +28387-9;Lack of appetite;Find;24H;Gastrointestinal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Lack of appetite [HIV-SSC];;;ACTIVE;2.00;2.44 +28388-7;Loose stools;Find;24H;Gastrointestinal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Loose stools [HIV-SSC];;;ACTIVE;2.00;2.44 +28389-5;Memory loss;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Memory loss [HIV-SSC];;;ACTIVE;2.00;2.44 +28390-3;Muscle aches;Find;24H;Musculoskeletal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Muscle aches [HIV-SSC];;;ACTIVE;2.00;2.44 +28391-1;Nausea;Find;24H;Gastrointestinal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Nausea [HIV-SSC];;;ACTIVE;2.00;2.44 +28392-9;Night sweats;Find;24H;Immune system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Night sweats [HIV-SSC];;;ACTIVE;2.00;2.44 +28393-7;Painful joints;Find;24H;Musculoskeletal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Painful joints [HIV-SSC];;;ACTIVE;2.00;2.44 +28394-5;Shortness of breath at rest;Find;24H;Respiratory system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Shortness of breath at rest [HIV-SSC];;;ACTIVE;2.00;2.44 +28395-2;Shortness of breath with activity;Find;24H;Respiratory system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Shortness of breath with activity [HIV-SSC];;;ACTIVE;2.00;2.44 +28396-0;Thirsty;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Thirsty [HIV-SSC];;;ACTIVE;2.00;2.44 +28397-8;Vomiting;Find;24H;Gastrointestinal system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Vomiting [HIV-SSC];;;ACTIVE;2.00;2.44 +28398-6;Weakness;Find;24H;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Weakness [HIV-SSC];;;ACTIVE;2.00;2.44 +2839-9;Progesterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Progesterone [Mass/volume] in Serum or Plasma;Progest SerPl-mCnc;;ACTIVE;1.0;2.73 +28399-4;Wheezing;Find;24H;Respiratory system;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Wheezing [HIV-SSC];;;ACTIVE;2.00;2.44 +284-0;Imipenem+Cilastatin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Deprecated Imipenem+Cilastatin [Susceptibility] by Disk diffusion (KB);Deprecated Imipenem+Cilastatin Islt KB;;DEPRECATED;1.0;2.36 +28400-0;I live for today;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;I live for today [Living with HIV];;;ACTIVE;2.00;2.44 +28401-8;Important to be in charge;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Important to be in charge [Living with HIV];;;ACTIVE;2.00;2.44 +28402-6;Important to be surrounded by those I love;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Important to be surrounded by those I love [Living with HIV];;;ACTIVE;2.00;2.44 +28403-4;Independence;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Independence [Living with HIV];;;ACTIVE;2.00;2.44 +28404-2;Live life day to day;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Live life day to day [Living with HIV];;;ACTIVE;2.00;2.44 +28405-9;Losing my looks is devastating;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Losing my looks is devastating [Living with HIV];;;ACTIVE;2.00;2.44 +28406-7;Loss of independence;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Loss of independence [Living with HIV];;;ACTIVE;2.00;2.44 +2840-7;Proinsulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Proinsulin [Mass/volume] in Serum or Plasma;Proinsulin SerPl-mCnc;;ACTIVE;1.0;2.73 +28407-5;Lots of regrets;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Lots of regrets [Living with HIV];;;ACTIVE;2.00;2.44 +28408-3;Toileting;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Toileting [QAM];;;ACTIVE;2.00;2.44 +28409-1;Dressing;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Dressing [QAM];;;ACTIVE;2.00;2.44 +28410-9;Grooming;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Grooming [QAM];;;ACTIVE;2.00;2.44 +28411-7;Personal hygiene;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Personal hygiene [QAM];;;ACTIVE;2.00;2.44 +28412-5;Physical performance;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Physical performance [QAM];;;ACTIVE;2.00;2.44 +28413-3;Ambulation;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Ambulation [QAM];;;ACTIVE;2.00;2.44 +28414-1;Activity;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Activity [QAM];;;ACTIVE;2.00;2.44 +2841-5;Prolactin;MCnc;Pt;Semen;Qn;;CHEM;1;Prolactin [Mass/volume] in Semen;Prolactin Smn-mCnc;;ACTIVE;1.0;2.42 +28415-8;Communication with community resources.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28416-6;Communication with community resources.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28417-4;Communication with community resources.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28418-2;Social contact.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28419-0;Social contact.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28420-8;Social contact.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28421-6;Role change.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28422-4;Role change.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +2842-3;Prolactin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin [Mass/volume] in Serum or Plasma;Prolactin SerPl-mCnc;;ACTIVE;1.0;2.73 +28423-2;Role change.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28424-0;Interpersonal relationship.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28425-7;Interpersonal relationship.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28426-5;Neglect.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28427-3;Spirituality.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28428-1;Spirituality.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28429-9;Spirituality.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28430-7;Grief.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +2843-1;Proline;MCnc;Pt;CSF;Qn;;CHEM;1;Proline [Mass/volume] in Cerebral spinal fluid;Proline CSF-mCnc;;ACTIVE;1.0;2.42 +28431-5;Grief.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28432-3;Grief.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28433-1;Mental health.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28434-9;Mental health.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28435-6;Mental health.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28436-4;Sexuality.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28437-2;Sexuality.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28438-0;Sexuality.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28439-8;Interpersonal relationship.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28440-6;Caretaking &or parenting.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28441-4;Caretaking &or parenting.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28442-2;Caretaking &or parenting.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.status Family [OMAHA];;;ACTIVE;2.00;2.44 +28443-0;Neglect.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28444-8;Neglect.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28445-5;Abuse.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28446-3;Abuse.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28447-1;Abuse.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28448-9;Growth and development.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +2844-9;Proline;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Proline [Presence] in Serum or Plasma;Proline SerPl Ql;;ACTIVE;1.0;2.73 +28449-7;Growth and development.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28450-5;Growth and development.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28451-3;Hearing.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28452-1;Hearing.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28453-9;Vision.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28454-7;Vision.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28455-4;Vision.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Status Family [OMAHA];;;ACTIVE;2.00;2.44 +2845-6;Proline;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Proline [Mass/volume] in Serum or Plasma;Proline SerPl-mCnc;;ACTIVE;1.0;2.73 +28456-2;Speech and language.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28457-0;Speech and language.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28458-8;Speech and language.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28459-6;Dentition.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Dentition.behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28460-4;Dentition.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Dentition.knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28461-2;Dentition.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Dentition.status Family [OMAHA];;;ACTIVE;2.00;2.44 +28462-0;Cognition.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28463-8;Cognition.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +2846-4;Proline;MCnc;Pt;Urine;Qn;;CHEM;1;Proline [Mass/volume] in Urine;Proline Ur-mCnc;;ACTIVE;1.0;2.73 +28464-6;Cognition.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28465-3;Pain.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28466-1;Pain.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28467-9;Pain.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28468-7;Consciousness.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28469-5;Consciousness.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28470-3;Consciousness.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28471-1;Skin.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +2847-2;Proline;MRat;24H;Urine;Qn;;CHEM;1;Proline [Mass/time] in 24 hour Urine;Proline 24h Ur-mRate;;ACTIVE;1.0;2.73 +28472-9;Skin.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28473-7;Skin.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28474-5;Neuro-musculo-skeletal function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28475-2;Neuro-musculo-skeletal function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28476-0;Neuro-musculo-skeletal function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28477-8;Respiration.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28478-6;Respiration.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28479-4;Respiration.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Status Family [OMAHA];;;ACTIVE;2.00;2.44 +2848-0;Proline dipeptidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Proline dipeptidase [Enzymatic activity/mass] in Tissue;Prolidase Tiss-cCnt;;ACTIVE;1.0;2.42 +28480-2;Circulation.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28481-0;Circulation.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28482-8;Circulation.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28483-6;Digestion-hydration.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28484-4;Digestion-hydration.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28485-1;Digestion-hydration.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28486-9;Bowel function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28487-7;Bowel function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28488-5;Bowel function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28489-3;Genito-urinary function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Genito-urinary function.behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28490-1;Genito-urinary function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Genito-urinary function.knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28491-9;Genito-urinary function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Genito-urinary function.status Family [OMAHA];;;ACTIVE;2.00;2.44 +28492-7;Antepartum &or postpartum.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Antepartum/postpartum.behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28493-5;Antepartum &or postpartum.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Antepartum/postpartum.status Family [OMAHA];;;ACTIVE;2.00;2.44 +28494-3;Antepartum &or postpartum.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Antepartum/postpartum.knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28495-0;Nutrition.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28496-8;Nutrition.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28497-6;Nutrition.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Status Family [OMAHA];;;ACTIVE;2.00;2.44 +2849-8;Propionate;MCnc;Pt;Ser;Qn;;CHEM;1;Propionate (C3) [Mass/volume] in Serum;Propionate Ser-mCnc;;DISCOURAGED;1.0;2.44 +28498-4;Sleep and rest pattern.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28499-2;Sleep and rest pattern.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28500-7;Sleep and rest pattern.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28501-5;Physical activity.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28502-3;Physical activity.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28503-1;Physical activity.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28504-9;Personal care.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28505-6;Personal care.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +2850-6;Propionyl CO-A carboxylase;CCnt;Pt;Tiss;Qn;;CHEM;1;Propionyl CoA Carboxylase [Enzymatic activity/mass] in Tissue;PCCA Tiss-cCnt;;ACTIVE;1.0;2.40 +28506-4;Personal care.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28507-2;Substance use.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28508-0;Substance use.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28509-8;Substance use.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28510-6;Family planning.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28511-4;Family planning.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28512-2;Family planning.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28513-0;Health care supervision.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +2851-4;Prostaglandin E;MCnc;Pt;Plas;Qn;;CHEM;1;Prostaglandin E [Mass/volume] in Plasma;Prostaglandin E Plas-mCnc;;ACTIVE;1.0;2.34 +28514-8;Health care supervision.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28515-5;Health care supervision.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28516-3;Medication regimen.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28517-1;Medication regimen.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28518-9;Medication regimen.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28519-7;Technical procedure.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Technical procedure.behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28520-5;Technical procedure.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Technical procedure.knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28521-3;Technical procedure.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Technical procedure.status Family [OMAHA];;;ACTIVE;2.00;2.44 +2852-2;Prostaglandin E1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostaglandin E1 [Mass/volume] in Serum or Plasma;Prostaglandin E1 SerPl-mCnc;;ACTIVE;1.0;2.34 +28522-1;Income.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Status Family [OMAHA];;;ACTIVE;2.00;2.44 +28523-9;Noncompliance with fluid volume;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Noncompliance with fluid volume [CCC];;;ACTIVE;2.00;2.44 +28524-7;Noncompliance with medication regimen;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Noncompliance with medication regimen [CCC];;;ACTIVE;2.00;2.44 +28525-4;Socialization alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Socialization alteration [CCC];;;ACTIVE;2.00;2.44 +28526-2;Skin integrity alteration;Find;Pt;Skin;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Skin integrity alteration [CCC];;;ACTIVE;2.00;2.56 +28527-0;Family embarrassed;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Family embarrassed [Living with HIV];;;ACTIVE;2.00;2.44 +28528-8;No good church experience;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;No good church experience [Living with HIV];;;ACTIVE;2.00;2.44 +28529-6;Strength from family;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Strength from family [Living with HIV];;;ACTIVE;2.00;2.44 +2853-0;Prostaglandin E2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostaglandin E2 [Mass/volume] in Serum or Plasma;Prostaglandin E2 SerPl-mCnc;;ACTIVE;1.0;2.73 +28530-4;Family does what needs done;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;Family does what needs done [Living with HIV];;;ACTIVE;2.00;2.44 +28531-2;My hometown means a lot;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;My hometown means a lot [Living with HIV];;;ACTIVE;2.00;2.44 +28532-0;No purpose in life;Find;Pt;^Patient;Ord;Reported.living-HIV;SURVEY.NURSE.LIV-HIV;4;No purpose in life [Living with HIV];;;ACTIVE;2.00;2.44 +28533-8;Antepartum &or postpartum.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Antepartum/postpartum.knowledge [OMAHA];;;ACTIVE;2.00;2.44 +28534-6;Bathing;Find;Pt;^Patient;Ord;Observed.QAM;SURVEY.NURSE.QAM;4;Bathing [QAM];;;ACTIVE;2.00;2.44 +28535-3;Income.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28536-1;Income.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Behavior Family [OMAHA];;;ACTIVE;2.00;2.44 +28537-9;Hearing.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Knowledge Family [OMAHA];;;ACTIVE;2.00;2.44 +28538-7;Abdominal pain;Find;Pt;^Patient;Ord;Reported.HIV-SSC;SURVEY.NURSE.HIV-SSC;4;Abdominal pain [HIV-SSC];;;ACTIVE;2.00;2.44 +28539-5;Erythrocyte mean corpuscular hemoglobin;EntMass;Pt;RBC;Qn;;HEM/BC;1;MCH [Entitic mass];MCH RBC Qn;;ACTIVE;2.00;2.73 +28540-3;Erythrocyte mean corpuscular hemoglobin concentration;MCnc;Pt;RBC;Qn;;HEM/BC;1;MCHC [Mass/volume];MCHC RBC-mCnc;;ACTIVE;2.00;2.73 +28541-1;Metamyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Metamyelocytes/100 leukocytes in Blood;Metamyelocytes/leuk NFr Bld;;ACTIVE;2.00;2.73 +28542-9;Platelet mean volume;EntVol;Pt;Bld;Qn;;HEM/BC;1;Platelet mean volume [Entitic volume] in Blood;PMV Bld;;ACTIVE;2.00;2.73 +28543-7;Basophils/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Basophils/100 leukocytes in Body fluid;Basophils/leuk NFr Fld;;ACTIVE;2.00;2.73 +28544-5;Mesothelial cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Mesothelial cells/100 leukocytes in Body fluid;Mesothl Cell/leuk NFr Fld;;ACTIVE;2.00;2.73 +28545-2;Mucus;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Mucus [#/area] in Urine sediment by Microscopy low power field;Mucous Threads #/area UrnS LPF;;ACTIVE;2.00;2.73 +28546-0;Neisseria meningitidis serogroup A Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Neisseria meningitidis serogroup A IgG Ab [Mass/volume] in Serum by Immunoassay;N men sg A IgG Ser IA-mCnc;;ACTIVE;2.00;2.73 +28547-8;Neisseria meningitidis serogroup C Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Neisseria meningitidis serogroup C IgG Ab [Mass/volume] in Serum by Immunoassay;N men sg C IgG Ser IA-mCnc;;ACTIVE;2.00;2.73 +2854-8;Prostaglandin F;MCnc;Pt;Plas;Qn;;CHEM;1;Prostaglandin F [Mass/volume] in Plasma;Prostaglandin F Plas-mCnc;;ACTIVE;1.0;2.34 +28548-6;Mycoplasma pneumoniae Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Cerebral spinal fluid by Complement fixation;M pneumo Ab Titr CSF CF;;ACTIVE;2.00;2.70 +28549-4;Yersinia sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Yersinia sp identified in Stool by Organism specific culture;Yersinia Stl Cult;;ACTIVE;2.00;2.73 +28550-2;Cortisol;PrThr;Pt;Urine;Ord;;CHEM;1;Cortisol [Presence] in Urine;Cortis Ur Ql;;ACTIVE;2.00;2.73 +28551-0;Bladder tumor Ag;ACnc;Pt;Urine;Qn;IA;SERO;1;Bladder tumor Ag [Units/volume] in Urine by Immunoassay;Bladder tumor Ag Ur IA-aCnc;;ACTIVE;2.00;2.73 +28552-8;Cladosporium herbarum Ab.IgM;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum IgM Ab [Units/volume] in Serum;C herbarum IgM Qn;;ACTIVE;2.00;2.69 +28553-6;Streptococcus pneumoniae 6+26 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6+26 Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum6+26 Ab sp1 Ser-mCnc;;DEPRECATED;2.00;2.70 +28554-4;Triglyceride;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Triglyceride [Presence] in Serum or Plasma;Trigl SerPl Ql;;ACTIVE;2.00;2.56 +2855-5;Prostaglandin F2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostaglandin F2 [Mass/volume] in Serum or Plasma;Prostaglandin F2 SerPl-mCnc;;ACTIVE;1.0;2.56 +28555-1;Nicotine+Cotinine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Nicotine+Cotinine [Presence] in Urine by Confirmatory method;Nicotine+Cotinine Ur Ql Cfm;;ACTIVE;2.00;2.73 +28556-9;Chlamydia trachomatis D+K Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis D+K IgG Ab [Titer] in Serum by Immunofluorescence;C trach D+K IgG Titr Ser IF;;ACTIVE;2.00;2.70 +28557-7;Chlamydia trachomatis D+K Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis D+K IgA Ab [Titer] in Serum by Immunofluorescence;C trach D+K IgA Titr Ser IF;;ACTIVE;2.00;2.70 +28558-5;Chlamydia trachomatis D+K Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis D+K IgM Ab [Titer] in Serum by Immunofluorescence;C trach D+K IgM Titr Ser IF;;ACTIVE;2.00;2.70 +28559-3;Hemoglobin A2;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin A2 [Presence] in Blood;Hgb A2 Bld Ql;;ACTIVE;2.00;2.73 +28560-1;Neuronal thread protein;MCnc;Pt;CSF;Qn;;SERO;1;Neuronal thread protein [Mass/volume] in Cerebral spinal fluid;Neuronal Thread Prot CSF-mCnc;;ACTIVE;2.00;2.42 +28561-9;Views;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Views;XR Pelvis Views;;ACTIVE;2.00;2.73 +28562-7;Chart section;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Chart section Set;;;ACTIVE;2.00;2.40 +2856-3;Prostaglandin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostaglandin [Mass/volume] in Serum or Plasma;Prostaglandin SerPl-mCnc;;ACTIVE;1.0;2.56 +28563-5;Care provider notes;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Care provider notes Set;;;ACTIVE;2.00;2.67 +28564-3;Views;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Views;XR Skull Views;;ACTIVE;2.00;2.73 +28565-0;Views;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Views;XR Knee Views;;ACTIVE;2.00;2.73 +28566-8;Multisection;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Spine;CT Spine;;DISCOURAGED;2.00;2.61 +28567-6;Views;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus Views;XR Humerus Views;;ACTIVE;2.00;2.73 +28568-4;Note;Find;Pt;Emergency department;Doc;Physician;DOC.ONTOLOGY;2;Physician Emergency department Note;MD ED Note;;ACTIVE;2.00;2.73 +28569-2;Progress note;Find;Pt;{Setting};Doc;Consultant;DOC.ONTOLOGY;2;Consultant Progress note;Consultant Prog note;;ACTIVE;2.00;2.73 +285-7;Imipenem+Cilastatin;Susc;Pt;Isolate+Ser;Ord;SBT;ABXBACT;1;Deprecated Imipenem+Cilastatin [Susceptibility] by Serum bactericidal titer;Deprecated Imipenem+Cilastatin SBT;;DEPRECATED;1.0;2.36 +28570-0;Procedure note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Procedure note;Procedure note;;ACTIVE;2.00;2.58 +2857-1;Prostate specific Ag;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in Serum or Plasma;PSA SerPl-mCnc;;ACTIVE;1.0;2.73 +28571-8;Note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Note;Speech-lang path Note;;ACTIVE;2.00;2.50 +28572-6;Initial evaluation note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Initial evaluation note;Dentistry Initial eval note;;ACTIVE;2.00;2.50 +28573-4;Surgical operation note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician, Operation note;MD Operative note;;ACTIVE;2.00;2.58 +28574-2;Discharge note;Find;Pt;{Setting};Doc;{Role};ATTACH.CLINRPT;3;Deprecated Discharge note;Deprecated Discharge note;;DEPRECATED;2.00;2.63 +28575-9;Progress note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Progress note;Nurse pract Prog note;;ACTIVE;2.00;2.73 +28576-7;Multisection;Find;Pt;XXX>Joint;Doc;MR;RAD;2;MR Joint;MR Joint;;ACTIVE;2.00;2.61 +28577-5;Procedure note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry procedure note;Dentistry Procedure note;;ACTIVE;2.00;2.58 +28578-3;Note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Note;OT Note;;ACTIVE;2.00;2.52 +28579-1;Note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Note;PT Note;;ACTIVE;2.00;2.52 +28580-9;Progress note;Find;Pt;{Setting};Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine Progress note;Chiropractic med Prog note;;ACTIVE;2.00;2.73 +28581-7;Initial evaluation note;Find;Pt;{Setting};Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine Initial evaluation note;Chiropractic med Initial eval note;;ACTIVE;2.00;2.50 +28582-5;Views;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand Views;XR Hand Views;;ACTIVE;2.00;2.64 +28583-3;Surgical operation note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentist Operation note;Dentistry Operative note;;ACTIVE;2.00;2.58 +28584-1;2-Oxoadipate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;2-Oxoadipate/Creatinine [Ratio] in Urine;2-Oxoadipate/Creat Ur-Rto;;ACTIVE;2.00;2.70 +28585-8;4-Hydroxyphenylacetate/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;4-Hydroxyphenylacetate/Creatinine [Ratio] in Urine;4OH-phenylacetate/Creat Ur-Rto;;ACTIVE;2.00;2.70 +28586-6;4-Hydroxyphenyllactate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;4-Hydroxyphenyllactate/Creatinine [Ratio] in Urine;4OH-phenyllactate/Creat Ur-Rto;;ACTIVE;2.00;2.70 +28587-4;Benzoate/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Benzoate/Creatinine [Ratio] in Urine;Benzoate/Creat Ur-Rto;;ACTIVE;2.00;2.70 +28588-2;Beta alanine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Beta alanine/Creatinine [Ratio] in Urine;B-Alanine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +2858-9;Protein.CSF/Protein.serum;RelRto;Pt;Ser+CSF;Qn;;CHEM;1;Protein in CSF/Protein in serum;Prot CSF/SerPl;;ACTIVE;1.0;2.73 +28589-0;Carnitine esters/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Carnitine esters/Creatinine [Ratio] in Urine;Carn esters/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28590-8;Alpha aminobutyrate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Alpha aminobutyrate/Creatinine [Ratio] in Urine;A-Aminobutyr/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28591-6;Amino beta guanidinopropionate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Amino beta guanidinopropionate/Creatinine [Ratio] in Urine;AB-Gp/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28592-4;Beta aminoadipate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Beta aminoadipate/Creatinine [Ratio] in Urine;BAA/Creat Ur-Rto;;ACTIVE;2.00;2.70 +28593-2;Gamma aminobutyrate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Gamma aminobutyrate/Creatinine [Ratio] in Urine;GABA/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28594-0;3-Methylhistidine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;3-Methylhistidine/Creatinine [Ratio] in Urine;3Me-histidine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28595-7;Taurine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Taurine/Creatinine [Ratio] in Urine;Taurine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28596-5;Anserine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Anserine/Creatinine [Ratio] in Urine;Anserine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +2859-7;Protein kinase;CCnc;Pt;Ser;Qn;;CHEM;1;Protein kinase [Enzymatic activity/volume] in Serum;Prot Kinase Ser-cCnc;;ACTIVE;1.0;2.68 +28597-3;Carnosine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Carnosine/Creatinine [Ratio] in Urine;Carnosine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28598-1;Alpha aminoadipate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Alpha aminoadipate/Creatinine [Ratio] in Urine;AAA/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28599-9;Cystathionine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Cystathionine/Creatinine [Ratio] in Urine;Cystathionin/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28600-5;Phosphoserine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Phosphoserine/Creatinine [Ratio] in Urine;Phosphoserine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28601-3;Hydroxyproline/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Hydroxyproline/Creatinine [Ratio] in Urine;OH-Proline/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28602-1;Beta aminoisobutyrate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Beta aminoisobutyrate/Creatinine [Ratio] in Urine;B-AIB/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28603-9;Asparagine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Asparagine/Creatinine [Ratio] in Urine;Asparagine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28604-7;Phosphoethanolamine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Phosphoethanolamine/Creatinine [Ratio] in Urine;PETN/Creat Ur-Rto;;ACTIVE;2.00;2.73 +2860-5;Protein nitrogen;MRat;24H;Urine;Qn;;CHEM;1;Protein nitrogen [Mass/time] in 24 hour Urine;Prot Nitrogen 24h Ur-mRate;;ACTIVE;1.0;2.42 +28605-4;Ethanolamine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Ethanolamine/Creatinine [Ratio] in Urine;Ethanolamine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28606-2;1-Methylhistidine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;1-Methylhistidine/Creatinine [Ratio] in Urine;1Me-hist/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28607-0;Canine parvovirus Ab;PrThr;Pt;Stool;Ord;HAI;MICRO;1;Canine parvovirus Ab [Presence] in Stool by Hemagglutination inhibition;CPV Ab Stl Ql HAI;;ACTIVE;2.00;2.67 +28608-8;Tryptophan/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Tryptophan/Creatinine [Ratio] in Urine;Tryptophan/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28609-6;Alpha aminobutyrate/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Alpha aminobutyrate/Creatinine [Ratio] in 24 hour Urine;A-Aminobutyr/Creat 24h Ur-Rto;;ACTIVE;2.00;2.70 +28610-4;Sarcosine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Sarcosine/Creatinine [Ratio] in Urine;Sarcosine/Creat Ur-Rto;;ACTIVE;2.00;2.73 +28611-2;Amino beta guanidinopropionate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Deprecated Amino beta guanidinopropionate/Creatinine [Ratio] in Urine;Deprecated AB-Gp/creat Ur-Rto;;DEPRECATED;2.00;2.70 +28612-0;Legionella sp Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella sp IgM Ab [Titer] in Serum by Immunofluorescence;Legionella IgM Titr Ser IF;;ACTIVE;2.00;2.70 +2861-3;Albumin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Albumin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;Albumin CSF Elph-mCnc;;ACTIVE;1.0;2.73 +28613-8;Views;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Views;XR Spine Views;;DISCOURAGED;2.00;2.64 +28614-6;Multisection;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;US Liver;US Liver;;ACTIVE;2.00;2.73 +28615-3;Audiology study;Find;-;^Patient;Doc;;DOC.MISC;2;Audiology study;Audiology study;;ACTIVE;2.00;2.67 +28616-1;Transfer summary note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Transfer note;MD Transfer sum note;;ACTIVE;2.00;2.58 +28617-9;Progress note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Progress note;Dentistry Prog note;;ACTIVE;2.00;2.73 +28618-7;Note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Note;Dentistry Note;;ACTIVE;2.00;2.52 +28619-5;Ophthalmology studies;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Ophthalmology/Optometry studies (set);;;ACTIVE;2.00;2.00 +28620-3;Urology studies;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Urology studies (set);;;ACTIVE;2.00;2.27 +2862-1;Albumin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Albumin [Mass/volume] in Serum or Plasma by Electrophoresis;Albumin SerPl Elph-mCnc;;ACTIVE;1.0;2.73 +28621-1;Initial evaluation note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Initial evaluation note;Nurse pract Initial eval note;;ACTIVE;2.00;2.50 +28622-9;Discharge assessment note;Find;Pt;{Setting};Doc;Nursing;ATTACH.CLINRPT;3;Deprecated Nurse Discharge assessment;Deprecated;;DEPRECATED;2.00;2.67 +28623-7;Progress note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Progress note;Nurse Prog note;;ACTIVE;2.00;2.73 +28624-5;Surgical operation note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Operation note;Podiatry Operative note;;ACTIVE;2.00;2.58 +28625-2;Procedure note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry procedure note;Podiatry Procedure note;;ACTIVE;2.00;2.58 +28626-0;History and physical note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician History and physical note;MD H&P note;;ACTIVE;2.00;2.58 +28627-8;Progress note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Progress note;Psychiatric Prog note;;ACTIVE;2.00;2.73 +28628-6;Note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Note;Psychiatric Note;;ACTIVE;2.00;2.52 +28629-4;Perimetry study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Perimetry study;Perimetry study;;ACTIVE;2.00;2.67 +28630-2;Tonometry study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Tonometry study;Tonometry study;;ACTIVE;2.00;2.67 +28631-0;Visual acuity study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Visual acuity study;Visual acuity study;;ACTIVE;2.00;2.67 +28632-8;Heterophoria study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Heterophoria study;Heterophoria study;;ACTIVE;2.00;2.67 +28633-6;Polysomnography study;Find;Pt;^Patient;Doc;Polysomnography;CLIN;2;Polysomnography (sleep) study;Polysomnography study;;ACTIVE;2.00;2.72 +28634-4;Miscellaneous studies;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Miscellaneous studies (set);;;ACTIVE;2.00;2.73 +28635-1;Initial evaluation note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Initial evaluation note;Psychiatric Initial eval note;;ACTIVE;2.00;2.50 +28636-9;Initial evaluation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Initial evaluation note;Initial eval note;;ACTIVE;2.00;2.58 +28637-7;Base deficit;SCnc;Pt;BldCoV;Qn;;CHEM;1;Base deficit in Venous cord blood;Base deficit BldCoV-sCnc;;ACTIVE;2.00;2.73 +28638-5;Base excess;SCnc;Pt;BldCoA;Qn;Calculated;CHEM;1;Base excess in Arterial cord blood by calculation;Base excess BldCoA Calc-sCnc;;ACTIVE;2.00;2.73 +2863-9;Albumin;MCnc;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Albumin [Mass/volume] in Synovial fluid by Electrophoresis;Albumin Snv Elph-mCnc;;ACTIVE;1.0;2.34 +28639-3;Base excess;SCnc;Pt;BldCoV;Qn;Calculated;CHEM;1;Base excess in Venous cord blood by calculation;Base excess BldCoV Calc-sCnc;;ACTIVE;2.00;2.73 +28640-1;Bicarbonate;SCnc;Pt;BldCoA;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Arterial cord blood;HCO3 BldCoA-sCnc;;ACTIVE;2.00;2.73 +28641-9;Bicarbonate;SCnc;Pt;BldCoV;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Venous cord blood;HCO3 BldCoV-sCnc;;ACTIVE;2.00;2.73 +28642-7;Oxygen saturation;MFr;Pt;BldCoA;Qn;;CHEM;1;Oxygen saturation in Arterial cord blood;SaO2 % BldCoA;;ACTIVE;2.00;2.73 +28643-5;Oxygen saturation;MFr;Pt;BldCoV;Qn;;CHEM;1;Oxygen saturation in Venous cord blood;SaO2 % BldCoV;;ACTIVE;2.00;2.73 +28644-3;Carbon dioxide;PPres;Pt;BldCoA;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Arterial cord blood;pCO2 BldCoA;;ACTIVE;2.00;2.73 +28645-0;Carbon dioxide;PPres;Pt;BldCoV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Venous cord blood;pCO2 BldCoV;;ACTIVE;2.00;2.73 +28646-8;pH;LsCnc;Pt;BldCoA;Qn;;CHEM;1;pH of Arterial cord blood;pH BldCoA;;ACTIVE;2.00;2.73 +2864-7;Alpha 1 globulin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;Alpha1 Glob CSF Elph-mCnc;;ACTIVE;1.0;2.73 +28647-6;pH;LsCnc;Pt;BldCoV;Qn;;CHEM;1;pH of Venous cord blood;pH BldCoV;;ACTIVE;2.00;2.73 +28648-4;Oxygen;PPres;Pt;BldCoA;Qn;;CHEM;1;Oxygen [Partial pressure] in Arterial cord blood;pO2 BldCoA;;ACTIVE;2.00;2.73 +28649-2;Oxygen;PPres;Pt;BldCoV;Qn;;CHEM;1;Oxygen [Partial pressure] in Venous cord blood;pO2 BldCoV;;ACTIVE;2.00;2.73 +286-5;Isoniazid;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Isoniazid [Susceptibility] by Minimum lethal concentration (MLC);Isoniazid Islt MLC;;ACTIVE;1.0;2.19 +28650-0;Clinical notes and chart sections;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Clinical notes and chart sections Set;;;ACTIVE;2.00;2.67 +28651-8;Transfer summary note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Transfer note;Nurse Transfer sum note;;ACTIVE;2.00;2.58 +28652-6;Heparinoid;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Heparinoid [Units/volume] in Platelet poor plasma by Chromogenic method;Heparinoid PPP Chro-aCnc;;ACTIVE;2.00;2.68 +28653-4;Note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Note;SW Note;;ACTIVE;2.00;2.73 +2865-4;Alpha 1 globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis;Alpha1 Glob SerPl Elph-mCnc;;ACTIVE;1.0;2.73 +28654-2;Initial evaluation note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending Initial evaluation note;Attend Initial eval note;;ACTIVE;2.00;2.65 +28655-9;Discharge summary note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending Discharge summary;Attend D/C sum;;ACTIVE;2.00;2.73 +28656-7;Progress note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Progress note;SW Prog note;;ACTIVE;2.00;2.73 +28657-5;Coagulation factor X activated actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor X activated actual/normal in Platelet poor plasma by Chromogenic method;Fact Xa Act/Nor PPP Chro;;ACTIVE;2.00;2.73 +28658-3;Plasmin inhibitor actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Plasmin inhibitor actual/normal in Platelet poor plasma by Immunoassay;Plasm Inhib Act/Nor PPP IA;;ACTIVE;2.00;2.58 +28659-1;Prekallikrein actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Prekallikrein (Fletcher Factor) actual/normal in Platelet poor plasma by Chromogenic method;PK Act/Nor PPP Chro;;ACTIVE;2.00;2.73 +28660-9;Plasminogen actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen actual/normal in Platelet poor plasma by Chromogenic method;PLG Act/Nor PPP Chro;;ACTIVE;2.00;2.73 +28661-7;Pupillary distance.binocular;Len;Pt;Eye;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Eye Pupillary distance.binocular Autorefractor.sciascopy;Eye PD binoc Sciascopy;;ACTIVE;2.00;2.70 +2866-2;Alpha 1 globulin;MCnc;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin [Mass/volume] in Synovial fluid by Electrophoresis;Alpha1 Glob Snv Elph-mCnc;;ACTIVE;1.0;2.73 +28662-5;Refraction comment;Imp;Pt;Eye;Nar;Autorefractor.sciascopy;EYE.REFRACTION;2;Eye Refraction comment Autorefractor.sciascopy;Eye Refract comm Sciascopy;;ACTIVE;2.00;2.68 +28663-3;Sphere far;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Sphere far by Phoropter;R eye Sphere far by Phoropter;;ACTIVE;2.00;2.71 +28664-1;Cylinder far;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Cylinder far by Phoropter;R eye Cylinder far by Phoropter;;ACTIVE;2.00;2.71 +28665-8;Axis far;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Axis far by Phoropter;R eye Axis far by Phoropter;;ACTIVE;2.00;2.71 +28666-6;HSA distance;Len;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye HSA distance by Phoropter;R eye HSA distance by Phoropter;;ACTIVE;2.00;2.71 +28667-4;Visual acuity.far;LenRto;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Visual acuity far by Phoropter;R eye Far VA by Phoropter;;ACTIVE;2.00;2.71 +28668-2;Sphere far;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Sphere far by Phoropter;L eye Sphere far by Phoropter;;ACTIVE;2.00;2.71 +28669-0;Cylinder far;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Cylinder far by Phoropter;L eye Cylinder far by Phoropter;;ACTIVE;2.00;2.71 +2867-0;Alpha 2 globulin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;Alpha2 Glob CSF Elph-mCnc;;ACTIVE;1.0;2.73 +28670-8;Corneal indentation depth;Len;Pt;Eye.right;Qn;Tonometry.Goldmann appl;EYE.TONOMETRY;2;Right eye Corneal indentation depth Goldmann appl tonometry;R eye Corn indent depth Goldmann appl;;ACTIVE;2.00;2.70 +28671-6;Corneal indentation depth;Len;Pt;Eye.left;Qn;Tonometry.Goldmann appl;EYE.TONOMETRY;2;Left eye Corneal indentation depth Goldmann appl tonometry;L eye Corn indent depth Goldmann appl;;ACTIVE;2.00;2.70 +28672-4;Tonometry time;TmStp;Pt;Eye;Qn;;EYE.TONOMETRY;2;Eye Tonometry time;Eye Tonometry time;;ACTIVE;2.00;2.68 +28673-2;Tonometry comment;Imp;Pt;Eye;Nar;Tonometry;EYE.TONOMETRY;2;Eye Tonometry comment [Interpretation];Eye Tonometry comment [Imp] Tono;;ACTIVE;2.00;2.68 +28674-0;Corneal indentation depth;Len;Pt;Eye.right;Qn;Tonometry.non contact;EYE.TONOMETRY;2;Right eye Corneal indentation depth Non contact tonometry;R eye Corn indent depth NCT;;ACTIVE;2.00;2.70 +28675-7;Corneal indentation depth;Len;Pt;Eye.left;Qn;Tonometry.non contact;EYE.TONOMETRY;2;Left eye Corneal indentation depth Non contact tonometry;L eye Corn indent depth NCT;;ACTIVE;2.00;2.70 +28676-5;Sphere;InvLen;Pt;Eye.right;Qn;Autorefractor.man;EYE.REFRACTION;2;Right eye Sphere Autorefractor.man;R eye Sphere AR.man;;ACTIVE;2.00;2.70 +28677-3;Cylinder;InvLen;Pt;Eye.right;Qn;Autorefractor.man;EYE.REFRACTION;2;Right eye Cylinder Autorefractor.man;R eye Cylinder AR.man;;ACTIVE;2.00;2.70 +28678-1;Axis;Angle;Pt;Eye.right;Qn;Autorefractor.man;EYE.REFRACTION;2;Right eye Axis Autorefractor.man;R eye Axis AR.man;;ACTIVE;2.00;2.70 +28679-9;Visual acuity;LenRto;Pt;Eye.right;Qn;Autorefractor.man;EYE.REFRACTION;2;Deprecated Visual acuity Right eye Autorefractor.man;Deprecated Vis acuity Eye-R AR.man;;DEPRECATED;2.00;2.63 +28680-7;Sphere;InvLen;Pt;Eye.left;Qn;Autorefractor.man;EYE.REFRACTION;2;Left eye Sphere Autorefractor.man;L eye Sphere AR.man;;ACTIVE;2.00;2.70 +28681-5;Cylinder;InvLen;Pt;Eye.left;Qn;Autorefractor.man;EYE.REFRACTION;2;Left eye Cylinder Autorefractor.man;L eye Cylinder AR.man;;ACTIVE;2.00;2.70 +28682-3;Axis;Angle;Pt;Eye.left;Qn;Autorefractor.man;EYE.REFRACTION;2;Left eye Axis Autorefractor.man;L eye Axis AR.man;;ACTIVE;2.00;2.70 +28683-1;Visual acuity;LenRto;Pt;Eye.left;Qn;Autorefractor.man;EYE.REFRACTION;2;Deprecated Visual acuity Left eye Autorefractor.man;Deprecated Vis acuity Eye-L AR.man;;DEPRECATED;2.00;2.63 +28684-9;Visual acuity.binocular;LenRto;Pt;Eye;Qn;Autorefractor.man;EYE.REFRACTION;2;Deprecated Visual acuity.binocular Eye Autorefractor.man;Deprecated Visual acuity.binoc Eye AR.man;;DEPRECATED;2.00;2.63 +28685-6;Pupillary distance.binocular;Len;Pt;Eye;Qn;Autorefractor.man;EYE.REFRACTION;2;Eye Pupillary distance.binocular Autorefractor.man;Eye PD binoc AR.man;;ACTIVE;2.00;2.70 +28686-4;Refraction comment;Imp;Pt;Eye;Nar;Autorefractor.man;EYE.REFRACTION;2;Eye Refraction comment Autorefractor.man;Eye Refract comm AR.man;;ACTIVE;2.00;2.68 +28687-2;Sphere;InvLen;Pt;Eye.right;Qn;Autorefractor.auto;EYE.REFRACTION;2;Right eye Sphere Autorefractor.auto;R eye Sphere AR.auto;;ACTIVE;2.00;2.70 +2868-8;Alpha 2 globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis;Alpha2 Glob SerPl Elph-mCnc;;ACTIVE;1.0;2.73 +28688-0;Cylinder;InvLen;Pt;Eye.right;Qn;Autorefractor.auto;EYE.REFRACTION;2;Right eye Cylinder Autorefractor.auto;R eye Cylinder AR.auto;;ACTIVE;2.00;2.70 +28689-8;Axis;Angle;Pt;Eye.right;Qn;Autorefractor.auto;EYE.REFRACTION;2;Right eye Axis Autorefractor.auto;R eye Axis AR.auto;;ACTIVE;2.00;2.70 +28690-6;Visual acuity;LenRto;Pt;Eye.right;Qn;Autorefractor.auto;EYE.REFRACTION;2;Deprecated Visual acuity Right eye Autorefractor.auto;Deprecated Vis acuity Eye-R AR.auto;;DEPRECATED;2.00;2.63 +28691-4;Sphere;InvLen;Pt;Eye.left;Qn;Autorefractor.auto;EYE.REFRACTION;2;Left eye Sphere Autorefractor.auto;L eye Sphere AR.auto;;ACTIVE;2.00;2.70 +28692-2;Cylinder;InvLen;Pt;Eye.left;Qn;Autorefractor.auto;EYE.REFRACTION;2;Left eye Cylinder Autorefractor.auto;L eye Cylinder AR.auto;;ACTIVE;2.00;2.70 +28693-0;Axis;Angle;Pt;Eye.left;Qn;Autorefractor.auto;EYE.REFRACTION;2;Left eye Axis Autorefractor.auto;L eye Axis AR.auto;;ACTIVE;2.00;2.70 +28694-8;Visual acuity;LenRto;Pt;Eye.left;Qn;Autorefractor.auto;EYE.REFRACTION;2;Deprecated Visual acuity Left eye Autorefractor.auto;Deprecated Vis acuity Eye-L AR.auto;;DEPRECATED;2.00;2.63 +28695-5;Visual acuity.binocular;LenRto;Pt;Eye;Qn;Autorefractor.auto;EYE.REFRACTION;2;Deprecated Visual acuity.binocular Eye Autorefractor.auto;Deprecated Visual acuity.binoc Eye AR.auto;;DEPRECATED;2.00;2.63 +2869-6;Alpha 2 globulin;MCnc;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin [Mass/volume] in Synovial fluid by Electrophoresis;Alpha2 Glob Snv Elph-mCnc;;ACTIVE;1.0;2.73 +28696-3;Pupillary distance.binocular;Len;Pt;Eye;Qn;Autorefractor.auto;EYE.REFRACTION;2;Eye Pupillary distance.binocular Autorefractor.auto;Eye PD binoc AR.auto;;ACTIVE;2.00;2.70 +28697-1;Refraction comment;Imp;Pt;Eye;Nar;Autorefractor.auto;EYE.REFRACTION;2;Eye Refraction comment Autorefractor.auto;Eye Refract comm AR.auto;;ACTIVE;2.00;2.68 +28698-9;Sphere;InvLen;Pt;Eye.right;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Right eye Sphere Autorefractor.sciascopy;R eye Sphere Sciascopy;;ACTIVE;2.00;2.70 +28699-7;Cylinder;InvLen;Pt;Eye.right;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Right eye Cylinder Autorefractor.sciascopy;R eye Cylinder Sciascopy;;ACTIVE;2.00;2.70 +28700-3;Axis;Angle;Pt;Eye.right;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Right eye Axis Autorefractor.sciascopy;R eye Axis Sciascopy;;ACTIVE;2.00;2.70 +28701-1;Visual acuity;LenRto;Pt;Eye.right;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Deprecated Visual acuity Right eye Autorefractor.sciascopy;Deprecated Vis acuity Eye-R Sciascopy;;DEPRECATED;2.00;2.70 +28702-9;Sphere;InvLen;Pt;Eye.left;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Left eye Sphere Autorefractor.sciascopy;L eye Sphere Sciascopy;;ACTIVE;2.00;2.70 +28703-7;Cylinder;InvLen;Pt;Eye.left;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Left eye Cylinder Autorefractor.sciascopy;L eye Cylinder Sciascopy;;ACTIVE;2.00;2.70 +2870-4;Beta globulin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Beta globulin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;B-Globulin CSF Elph-mCnc;;ACTIVE;1.0;2.73 +28704-5;Axis;Angle;Pt;Eye.left;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Left eye Axis Autorefractor.sciascopy;L eye Axis Sciascopy;;ACTIVE;2.00;2.70 +28705-2;Visual acuity;LenRto;Pt;Eye.left;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Deprecated Visual acuity Left eye Autorefractor.sciascopy;Deprecated Vis acuity Eye-L Sciascopy;;DEPRECATED;2.00;2.63 +28706-0;Visual acuity.binocular;LenRto;Pt;Eye;Qn;Autorefractor.sciascopy;EYE.REFRACTION;2;Deprecated Visual acuity.binocular Eye Autorefractor.sciascopy;Deprecated Visual acuity.binoc Eye Sciascopy;;DEPRECATED;2.00;2.63 +28707-8;Axis far;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Axis far by Phoropter;L eye Axis far by Phoropter;;ACTIVE;2.00;2.71 +28708-6;Prism base direction;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction by Phoropter;L eye Prism base dir by Phoropter;;ACTIVE;2.00;2.71 +28709-4;HSA distance;Len;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye HSA distance by Phoropter;L eye HSA distance by Phoropter;;ACTIVE;2.00;2.71 +28710-2;Visual acuity.far;LenRto;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Visual acuity far by Phoropter;L eye Far VA by Phoropter;;ACTIVE;2.00;2.71 +28711-0;Visual acuity far.binocular;LenRto;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Visual acuity far.binocular by Phoropter;Eye Far VA.binoc by Phoropter;;ACTIVE;2.00;2.73 +2871-2;Beta globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin [Mass/volume] in Serum or Plasma by Electrophoresis;B-Globulin SerPl Elph-mCnc;;ACTIVE;1.0;2.73 +28712-8;Sphere near 1;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Sphere near 1 by Phoropter;R eye Sphere N 1 by Phoropter;;ACTIVE;2.00;2.71 +28713-6;Cylinder near;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Cylinder near by Phoropter;R eye Cylinder near by Phoropter;;ACTIVE;2.00;2.71 +28714-4;Axis near;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Axis near by Phoropter;R eye Axis near by Phoropter;;ACTIVE;2.00;2.71 +28715-1;Sphere near 2;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Sphere near 2 by Phoropter;R eye Sphere N 2 by Phoropter;;ACTIVE;2.00;2.71 +28716-9;Cylinder near 2;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Cylinder near 2 by Phoropter;R eye Cylinder near 2 by Phoropter;;ACTIVE;2.00;2.71 +28717-7;Axis near 2;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Axis near 2 by Phoropter;R eye Axis near 2 by Phoropter;;ACTIVE;2.00;2.71 +28718-5;HSA N;Len;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye HSA N by Phoropter;R eye HSA N by Phoropter;;ACTIVE;2.00;2.71 +28719-3;Visual acuity.near;LenRto;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Visual acuity near by Phoropter;R eye Near VA by Phoropter;;ACTIVE;2.00;2.72 +2872-0;Beta globulin;MCnc;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Beta globulin [Mass/volume] in Synovial fluid by Electrophoresis;B-Globulin Snv Elph-mCnc;;ACTIVE;1.0;2.73 +28720-1;Add 1;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Add 1 by Phoropter;R eye Add 1 by Phoropter;;ACTIVE;2.00;2.71 +28721-9;Add 1.binocular;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Add 1 binocular by Phoropter;Eye Add 1 Binoc by Phoropter;;ACTIVE;2.00;2.71 +28722-7;Add 2;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Add 2 by Phoropter;R eye Add 2 by Phoropter;;ACTIVE;2.00;2.71 +28723-5;Add 2.binocular;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Add 2 binocular by Phoropter;Eye Add 2 Binoc by Phoropter;;ACTIVE;2.00;2.71 +28724-3;Sphere near 1;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Sphere near 1 by Phoropter;L eye Sphere N 1 by Phoropter;;ACTIVE;2.00;2.71 +28725-0;Cylinder near;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Cylinder near by Phoropter;L eye Cylinder near by Phoropter;;ACTIVE;2.00;2.71 +28726-8;Axis near;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Axis near by Phoropter;L eye Axis near by Phoropter;;ACTIVE;2.00;2.71 +28727-6;Sphere near 2;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Sphere near 2 by Phoropter;L eye Sphere N 2 by Phoropter;;ACTIVE;2.00;2.71 +28728-4;Cylinder near 2;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Cylinder near 2 by Phoropter;L eye Cylinder near 2 by Phoropter;;ACTIVE;2.00;2.71 +28729-2;Axis near 2;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Axis near 2 by Phoropter;L eye Axis near 2 by Phoropter;;ACTIVE;2.00;2.71 +287-3;Isoniazid;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Isoniazid [Susceptibility] by Minimum inhibitory concentration (MIC);Isoniazid Islt MIC;;ACTIVE;1.0;2.73 +28730-0;HSA N;Len;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye HSA N by Phoropter;L eye HSA N by Phoropter;;ACTIVE;2.00;2.71 +28731-8;Visual acuity N LI;LenRto;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Visual acuity N LI by Phoropter;Eye Visual acuity N LI by Phoropter;;ACTIVE;2.00;2.71 +28732-6;Add 1;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Add 1 by Phoropter;L eye Add 1 by Phoropter;;ACTIVE;2.00;2.71 +28733-4;Add 2;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Add 2 by Phoropter;L eye Add 2 by Phoropter;;ACTIVE;2.00;2.71 +28734-2;Far vision comment;Imp;Pt;Eye.right;Nar;Phoropter;EYE.REFRACTION;2;Phoropter Right eye Comment far vision [Interpretation];Phoropter R eye Cmnt far vision;;ACTIVE;2.00;2.71 +28735-9;Far vision comment;Imp;Pt;Eye.left;Nar;Phoropter;EYE.REFRACTION;2;Phoropter Left eye Comment far vision [Interpretation];Phoropter L eye Cmnt far vision;;ACTIVE;2.00;2.71 +28736-7;Comment N;Imp;Pt;Eye.left;Nar;Phoropter;EYE.REFRACTION;2;Phoropter Left eye Comment near vision [Interpretation];Phoropter L eye Cmnt near vision;;ACTIVE;2.00;2.71 +28737-5;Visual acuity N.binocular;LenRto;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Visual acuity N.binocular by Phoropter;Eye Visual acuity N.binoc by Phoropter;;ACTIVE;2.00;2.71 +2873-8;Gamma globulin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Gamma globulin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;Gamma glob CSF Elph-mCnc;;ACTIVE;1.0;2.73 +28738-3;Distance signs;Len;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Distance signs by Phoropter;R eye Distance signs by Phoropter;;ACTIVE;2.00;2.71 +28739-1;Distance signs;Len;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Distance signs by Phoropter;L eye Distance signs by Phoropter;;ACTIVE;2.00;2.71 +28740-9;Distance signs.binocular;Len;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Distance signs.binocular by Phoropter;Eye Distance signs.binoc by Phoropter;;ACTIVE;2.00;2.71 +28741-7;Red green balance;Type;Pt;Eye.right;Nom;Phoropter;EYE.REFRACTION;2;Right eye Red green balance by Phoropter;R eye Red green balance by Phoropter;;ACTIVE;2.00;2.71 +28742-5;Red green balance;Type;Pt;Eye.left;Nom;Phoropter;EYE.REFRACTION;2;Left eye Red green balance by Phoropter;L eye Red green balance by Phoropter;;ACTIVE;2.00;2.71 +28743-3;Red green balance.binocular;Type;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Eye Red green balance.binocular by Phoropter;Type of Red green bal.binoc by Phoropter;;ACTIVE;2.00;2.71 +28744-1;Polarization;Prid;Pt;Eye.right;Nom;Phoropter;EYE.REFRACTION;2;Polarization Right eye Phoropter;Polarization Eye-R Phoropter;;ACTIVE;2.00;2.54 +28745-8;Polarization;Prid;Pt;Eye.left;Nom;Phoropter;EYE.REFRACTION;2;Polarization Left eye Phoropter;Polarization Eye-L Phoropter;;ACTIVE;2.00;2.54 +2874-6;Gamma globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis;Gamma glob SerPl Elph-mCnc;;ACTIVE;1.0;2.73 +28746-6;Polarization.binocular;Prid;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Polarization.binocular Eye Phoropter;Polarization.binoc Eye Phoropter;;ACTIVE;2.00;2.27 +28747-4;Vision.binocular;Prid;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Eye Vision.binocular by Phoropter;Eye Vision.binoc by Phoropter;;ACTIVE;2.00;2.71 +28748-2;Accommodation width.absolute;InvLen;Pt;Eye.right;Qn;Hand optometer;EYE.REFRACTION;2;Right eye Accommodation width absolute Hand optometer;R eye Acc width abs Hand Optometer;;ACTIVE;2.00;2.70 +28749-0;Accommodation width.absolute;InvLen;Pt;Eye.left;Qn;Hand optometer;EYE.REFRACTION;2;Left eye Accommodation width absolute Hand optometer;L eye Acc width abs Hand Optometer;;ACTIVE;2.00;2.70 +28750-8;Accommodation width.relative;InvLen;Pt;Eye;Qn;Hand optometer;EYE.REFRACTION;2;Eye Accommodation width relative Hand optometer;Eye Acc width rel Hand Optometer;;ACTIVE;2.00;2.70 +28751-6;Accommodation width.measured 1;Len;Pt;Eye;Qn;Hand optometer;EYE.REFRACTION;2;Eye Accommodation width measured 1 Hand optometer;Eye Acc width meas 1 Hand Optometer;;ACTIVE;2.00;2.70 +28752-4;Accommodation width.measured 2;Len;Pt;Eye;Qn;Hand optometer;EYE.REFRACTION;2;Eye Accommodation width measured 2 Hand optometer;Eye Acc width meas 2 Hand Optometer;;ACTIVE;2.00;2.70 +2875-3;Gamma globulin;MCnc;Pt;Synv fld;Qn;Electrophoresis;CHEM;1;Gamma globulin [Mass/volume] in Synovial fluid by Electrophoresis;Gamma glob Snv Elph-mCnc;;ACTIVE;1.0;2.73 +28753-2;Accommodation width.measured 3;Len;Pt;Eye;Qn;Hand optometer;EYE.REFRACTION;2;Eye Accommodation width measured 3 Hand optometer;Eye Acc width meas 3 Hand Optometer;;ACTIVE;2.00;2.70 +28754-0;Accommodation width.absolute;InvLen;Pt;Eye.right;Qn;Minus glass;EYE.REFRACTION;2;Right eye Accommodation width absolute Minus glass;R eye Acc width abs Minus Glass;;ACTIVE;2.00;2.70 +28755-7;Accommodation width.absolute;InvLen;Pt;Eye.left;Qn;Minus glass;EYE.REFRACTION;2;Left eye Accommodation width absolute Minus glass;L eye Acc width abs Minus Glass;;ACTIVE;2.00;2.70 +28756-5;Accommodation width.relative;InvLen;Pt;Eye;Qn;Minus glass;EYE.REFRACTION;2;Eye Accommodation width relative Minus glass;Eye Acc width rel Minus Glass;;ACTIVE;2.00;2.70 +28757-3;Accommodation width.measured 1;Len;Pt;Eye;Qn;Minus glass;EYE.REFRACTION;2;Eye Accommodation width measured 1 Minus glass;Eye Acc width meas 1 Minus Glass;;ACTIVE;2.00;2.70 +28758-1;Accommodation width.measured 2;Len;Pt;Eye;Qn;Minus glass;EYE.REFRACTION;2;Eye Accommodation width measured 2 Minus glass;Eye Acc width meas 2 Minus Glass;;ACTIVE;2.00;2.70 +28759-9;Accommodation width.measured 3;Len;Pt;Eye;Qn;Minus glass;EYE.REFRACTION;2;Eye Accommodation width measured 3 Minus glass;Eye Acc width meas 3 Minus Glass;;ACTIVE;2.00;2.70 +28760-7;Accommodation width.absolute;InvLen;Pt;Eye.right;Qn;;EYE.REFRACTION;2;Right eye Accommodation width absolute;R eye Acc width abs;;ACTIVE;2.00;2.70 +2876-1;Prealbumin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Prealbumin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;Prealb CSF Elph-mCnc;;ACTIVE;1.0;2.73 +28761-5;Accommodation width.absolute;InvLen;Pt;Eye.left;Qn;;EYE.REFRACTION;2;Left eye Accommodation width absolute;L eye Acc width abs;;ACTIVE;2.00;2.70 +28762-3;Accommodation width.relative;InvLen;Pt;Eye;Qn;;EYE.REFRACTION;2;Eye Accommodation width relative;Eye Acc width rel;;ACTIVE;2.00;2.70 +28763-1;Accommodation width.measured 1;Len;Pt;Eye;Qn;;EYE.REFRACTION;2;Eye Accommodation width measured 1;Eye Acc width meas 1;;ACTIVE;2.00;2.70 +28764-9;Heterophoria;Prid;Pt;Eyes;Nom;Worth test;EYE.HETEROPHORIA;2;Deprecated Worth test for Heterophoria;Deprecated Worth test;;DEPRECATED;2.00;2.72 +28765-6;Heterophoria;Prid;Pt;Eyes;Nom;Schober test;EYE.HETEROPHORIA;2;Schober test for Heterophoria;Schober;;ACTIVE;2.00;2.61 +28766-4;Heterophoria;Prid;Pt;Eyes;Nom;Bagolini test;EYE.HETEROPHORIA;2;Bagolini test for Heterophoria;Bagolini test;;ACTIVE;2.00;2.61 +28767-2;Heterophoria;Prid;Pt;Eyes;Nom;Maddox wing;EYE.HETEROPHORIA;2;Maddox wing for Heterophoria;Maddox wing;;ACTIVE;2.00;2.61 +28768-0;Heterophoria;Prid;Pt;Eyes;Nom;Heterometer test;EYE.HETEROPHORIA;2;Heterometer test for Heterophoria;Heterometer test;;ACTIVE;2.00;2.61 +28769-8;Heterophoria;Prid;Pt;Eyes;Nom;Dark red glass test;EYE.HETEROPHORIA;2;Dark red glass test for Heterophoria;Dark red glass test;;ACTIVE;2.00;2.61 +28770-6;Heterophoria;Prid;Pt;Eyes;Nom;Maddox double prism test;EYE.HETEROPHORIA;2;Maddox double prism test for Heterophoria;Maddox double prism test;;ACTIVE;2.00;2.61 +28771-4;Type;Type;Pt;Corrective lens;Nom;Lensmeter;EYE.GLASSES;2;Corrective lens Type by Lensmeter;Corr lens Type by LM;;ACTIVE;2.00;2.69 +28772-2;Type description;Type;Pt;Corrective lens;Nar;Lensmeter;EYE.GLASSES;2;Corrective lens Type description by Lensmeter;Corr lens Type description by LM;;ACTIVE;2.00;2.69 +28773-0;Since when;TmStp;Pt;Glasses;Qn;;EYE.GLASSES;2;Glasses Since when;Glasses Since when;;ACTIVE;2.00;2.68 +28774-8;Physician code;ID;Pt;Glasses;Nom;;EYE.GLASSES;2;Glasses Physician code;Glasses Physician code;;ACTIVE;2.00;2.68 +28775-5;Physician;ID;Pt;Glasses;Nar;;EYE.GLASSES;2;Glasses Physician [Identifier];Glasses Physician;;ACTIVE;2.00;2.68 +28776-3;Type;Type;Pt;Corrective lens.right;Nom;Lensmeter;EYE.GLASSES;2;Right corrective lens Type by Lensmeter;R corr lens Type by LM;;ACTIVE;2.00;2.69 +28777-1;Type;Type;Pt;Corrective lens.right;Nar;Lensmeter;EYE.GLASSES;2;Right corrective lens Type Narrative by Lensmeter;R corr lens Type by LM;;ACTIVE;2.00;2.69 +28778-9;Type;Type;Pt;Corrective lens.left;Nom;Lensmeter;EYE.GLASSES;2;Left corrective lens Type by Lensmeter;L corr lens Type by LM;;ACTIVE;2.00;2.69 +2877-9;Prealbumin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Prealbumin [Mass/volume] in Serum or Plasma by Electrophoresis;Prealb SerPl Elph-mCnc;;ACTIVE;1.0;2.73 +28779-7;Type;Type;Pt;Corrective lens.left;Nar;Lensmeter;EYE.GLASSES;2;Left corrective lens Type Narrative by Lensmeter;L corr lens Type by LM;;ACTIVE;2.00;2.69 +28780-5;Sphere far;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Sphere far by Lensmeter;R corr lens Sphere far by LM;;ACTIVE;2.00;2.71 +28781-3;Axis far;Angle;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Axis far by Lensmeter;R corr lens Axis far by LM;;ACTIVE;2.00;2.71 +28782-1;Pupillary distance.monocular;Len;Pt;Glasses.lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right glasses lens Pupillary distance.monocular by Lensmeter;R glasses PD monoc by LM;;ACTIVE;2.00;2.71 +28783-9;HSA distance;Len;Pt;Glasses.lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right glasses lens HSA distance by Lensmeter;R glasses HSA distance by LM;;ACTIVE;2.00;2.70 +28784-7;SBM visual acuity far;LenRto;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens SBM visual acuity far by Lensmeter;R corr lens SBM VA far by LM;;ACTIVE;2.00;2.71 +28785-4;SBM sphere far;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens SBM sphere far by Lensmeter;L corr lens SBM sphere far by LM;;ACTIVE;2.00;2.71 +28786-2;Cylinder far;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Cylinder far by Lensmeter;L corr lens Cylinder far by LM;;ACTIVE;2.00;2.71 +2878-7;Protein;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Protein [Mass/volume] in Amniotic fluid;Prot Amn-mCnc;;ACTIVE;1.0;2.40 +28787-0;Axis far;Angle;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Axis far by Lensmeter;L corr lens Axis far by LM;;ACTIVE;2.00;2.71 +28788-8;Prism base direction;Angle;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Prism base direction by Lensmeter;L corr lens Prism base dir by LM;;ACTIVE;2.00;2.71 +28789-6;Pupillary distance.monocular;Len;Pt;Glasses.lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left glasses lens Pupillary distance.monocular by Lensmeter;L glasses PD monoc by LM;;ACTIVE;2.00;2.71 +28790-4;HSA distance;Len;Pt;Glasses.lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left glasses lens HSA distance by Lensmeter;L glasses HSA distance by LM;;ACTIVE;2.00;2.70 +28791-2;Visual acuity.far;LenRto;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Visual acuity far by Lensmeter;L corr lens Far VA by LM;;ACTIVE;2.00;2.71 +28792-0;Pupillary distance.binocular;Len;Pt;Glasses;Qn;Lensmeter;EYE.GLASSES;2;Glasses Pupillary distance.binocular by Lensmeter;Glasses PD binoc by LM;;ACTIVE;2.00;2.70 +28793-8;Sphere near 1;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Sphere near 1 by Lensmeter;R corr lens Sphere N 1 by LM;;ACTIVE;2.00;2.70 +28794-6;Cylinder near;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Cylinder near by Lensmeter;R corr lens Cylinder near by LM;;ACTIVE;2.00;2.71 +2879-5;Protein;PrThr;Pt;CSF;Ord;;CHEM;1;Protein [Presence] in Cerebral spinal fluid;Prot CSF Ql;;ACTIVE;1.0;2.56 +28795-3;Axis near;Angle;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Axis near by Lensmeter;R corr lens Axis near by LM;;ACTIVE;2.00;2.71 +28796-1;Sphere near 2;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Sphere near 2 by Lensmeter;R corr lens Sphere N 2 by LM;;ACTIVE;2.00;2.70 +28797-9;Cylinder near 2;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Cylinder near 2 by Lensmeter;R corr lens Cylinder near 2 by LM;;ACTIVE;2.00;2.71 +28798-7;Axis near 2;Angle;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Axis near 2 by Lensmeter;R corr lens Axis near 2 by LM;;ACTIVE;2.00;2.71 +28799-5;Pupillary distance.monocular near;Len;Pt;Glasses.lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right glasses lens Pupillary distance.monocular near by Lensmeter;R glasses PD monoc near by LM;;ACTIVE;2.00;2.71 +28800-1;HSA N;Len;Pt;Glasses.lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right glasses lens HSA N by Lensmeter;R glasses HSA N by LM;;ACTIVE;2.00;2.70 +28801-9;Visual acuity.near;LenRto;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Visual acuity near by Lensmeter;R corr lens Near VA by LM;;ACTIVE;2.00;2.72 +28802-7;Sphere near 1;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Sphere near 1 by Lensmeter;L corr lens Sphere N 1 by LM;;ACTIVE;2.00;2.70 +2880-3;Protein;MCnc;Pt;CSF;Qn;;CHEM;1;Protein [Mass/volume] in Cerebral spinal fluid;Prot CSF-mCnc;;ACTIVE;1.0;2.73 +28803-5;Cylinder near;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Cylinder near by Lensmeter;L corr lens Cylinder near by LM;;ACTIVE;2.00;2.71 +28804-3;Axis near;Angle;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Axis near by Lensmeter;L corr lens Axis near by LM;;ACTIVE;2.00;2.71 +28805-0;Sphere near 2;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Sphere near 2 by Lensmeter;L corr lens Sphere N 2 by LM;;ACTIVE;2.00;2.70 +28806-8;Cylinder near 2;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Cylinder near 2 by Lensmeter;L corr lens Cylinder near 2 by LM;;ACTIVE;2.00;2.71 +28807-6;Axis near 2;Angle;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Axis near 2 by Lensmeter;L corr lens Axis near 2 by LM;;ACTIVE;2.00;2.71 +28808-4;PO N;Len;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens PO N by Lensmeter;L corr lens PO N by LM;;ACTIVE;2.00;2.70 +28809-2;HSA N;Len;Pt;Glasses.lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left glasses lens HSA N by Lensmeter;L glasses HSA N by LM;;ACTIVE;2.00;2.70 +288-1;Isoniazid;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Isoniazid [Susceptibility] by Disk diffusion (KB);Isoniazid Islt KB;;ACTIVE;1.0;2.19 +28810-0;Add 1;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Add 1 by Lensmeter;R corr lens Add 1 by LM;;ACTIVE;2.00;2.70 +2881-1;Protein;MCnc;Pt;Body fld;Qn;;CHEM;1;Protein [Mass/volume] in Body fluid;Prot Fld-mCnc;;ACTIVE;1.0;2.73 +28811-8;Add 2;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Add 2 by Lensmeter;R corr lens Add 2 by LM;;ACTIVE;2.00;2.70 +28812-6;Add 1;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Add 1 by Lensmeter;L corr lens Add 1 by LM;;ACTIVE;2.00;2.70 +28813-4;Add 2;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Add 2 by Lensmeter;L corr lens Add 2 by LM;;ACTIVE;2.00;2.70 +28814-2;Add 1.binocular;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.GLASSES;2;Corrective lens Add 1 binocular by Lensmeter;Corr lens Add 1 Binoc by LM;;ACTIVE;2.00;2.70 +28815-9;Add 2.binocular;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.GLASSES;2;Corrective lens Add 2 binocular by Lensmeter;Corr lens Add 2 Binoc by LM;;ACTIVE;2.00;2.70 +28816-7;Comment;Imp;Pt;Corrective lens.right;Nom;Lensmeter;EYE.GLASSES;2;Right corrective lens Comment [Interpretation] by Lensmeter;R corr lens Comment [Imp] by LM;;ACTIVE;2.00;2.73 +28817-5;Comment;Imp;Pt;Corrective lens.left;Nom;Lensmeter;EYE.GLASSES;2;Left corrective lens Comment [Interpretation] by Lensmeter;L corr lens Comment [Imp] by LM;;ACTIVE;2.00;2.69 +28818-3;Glasses type;Type;Pt;Glasses prescription;Nom;;EYE.GLASSES;2;prescription Glasses type;presc Glasses type;;ACTIVE;2.00;2.68 +28819-1;Subject to charges;Arb;Pt;Glasses prescription;Ord;;EYE.GLASSES;2;Glasses lens prescription Subject to charges;Glasses Rx Subject to charges;;ACTIVE;2.00;2.68 +28820-9;Private prescription;Arb;Pt;Glasses prescription;Ord;;EYE.GLASSES;2;Glasses lens prescription Private prescription;Glasses Rx Private prescription;;ACTIVE;2.00;2.68 +28821-7;First glasses;Arb;Pt;Glasses prescription;Ord;;EYE.GLASSES;2;prescription First glasses;presc 1st glasses;;ACTIVE;2.00;2.68 +28822-5;Lens type far;Type;Pt;Glasses prescription.lens.right;Nom;;EYE.GLASSES;2;Right glasses lens prescription Lens type far;R glasses Rx Lens type far;;ACTIVE;2.00;2.71 +28823-3;Lens type far;Type;Pt;Glasses prescription.lens.left;Nom;;EYE.GLASSES;2;Left glasses lens prescription Lens type far;L glasses Rx Lens type far;;ACTIVE;2.00;2.71 +28824-1;Lens type N;Type;Pt;Glasses prescription.lens.right;Nom;;EYE.GLASSES;2;Right glasses lens prescription Lens type N;R glasses Rx Lens type N;;ACTIVE;2.00;2.68 +28825-8;Lens type N;Type;Pt;Glasses prescription.lens.left;Nom;;EYE.GLASSES;2;Left glasses lens prescription Lens type N;L glasses Rx Lens type N;;ACTIVE;2.00;2.68 +28826-6;Sphere far;InvLen;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Sphere far;R glasses Rx Sphere far;;ACTIVE;2.00;2.71 +28827-4;Cylinder far;InvLen;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Cylinder far;R glasses Rx Cylinder far;;ACTIVE;2.00;2.71 +28828-2;Axis far;Angle;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Axis far;R glasses Rx Axis far;;ACTIVE;2.00;2.71 +2882-9;Protein;MCnc;Pt;Plr fld;Qn;;CHEM;1;Protein [Mass/volume] in Pleural fluid;Prot Plr-mCnc;;ACTIVE;1.0;2.73 +28829-0;Prism base direction;Angle;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Prism base direction;R glasses Rx Prism base dir;;ACTIVE;2.00;2.71 +28830-8;HSA distance;Len;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription HSA distance;R glasses Rx HSA distance;;ACTIVE;2.00;2.70 +28831-6;Visual acuity.far;LenRto;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Visual acuity far;R glasses Rx Far VA;;ACTIVE;2.00;2.71 +28832-4;Sphere near 1;InvLen;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Sphere near 1;R glasses Rx Sphere N 1;;ACTIVE;2.00;2.70 +28833-2;Cylinder near;InvLen;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Cylinder near;R glasses Rx Cylinder near;;ACTIVE;2.00;2.71 +28834-0;Axis near;Angle;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Axis near;R glasses Rx Axis near;;ACTIVE;2.00;2.71 +28835-7;Sphere near 2;InvLen;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Sphere near 2;R glasses Rx Sphere N 2;;ACTIVE;2.00;2.70 +28836-5;Cylinder near 2;InvLen;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Cylinder near 2;R glasses Rx Cylinder near 2;;ACTIVE;2.00;2.71 +2883-7;Protein;MCnc;Pt;Periton fld;Qn;;CHEM;1;Protein [Mass/volume] in Peritoneal fluid;Prot Prt-mCnc;;ACTIVE;1.0;2.73 +28837-3;Axis near 2;Angle;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Axis near 2;R glasses Rx Axis near 2;;ACTIVE;2.00;2.71 +28838-1;HSA N;Len;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription HSA N;R glasses Rx HSA N;;ACTIVE;2.00;2.70 +28839-9;Visual acuity.near;LenRto;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Visual acuity near;R glasses Rx Near VA;;ACTIVE;2.00;2.72 +28840-7;Pupillary distance.monocular;Len;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Pupillary distance.monocular;R glasses Rx PD monoc;;ACTIVE;2.00;2.71 +28841-5;Pupillary distance.monocular near;Len;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription Pupillary distance.monocular near;R glasses Rx PD monoc near;;ACTIVE;2.00;2.71 +28842-3;Sphere far;InvLen;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Sphere far;L glasses Rx Sphere far;;ACTIVE;2.00;2.71 +28843-1;Cylinder far;InvLen;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Cylinder far;L glasses Rx Cylinder far;;ACTIVE;2.00;2.71 +28844-9;Axis far;Angle;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Axis far;L glasses Rx Axis far;;ACTIVE;2.00;2.71 +2884-5;Protein;MCnc;Pt;Semen;Qn;;CHEM;1;Protein [Mass/volume] in Semen;Prot Smn-mCnc;;ACTIVE;1.0;2.34 +28845-6;Prism base direction;Angle;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Prism base direction;L glasses Rx Prism base dir;;ACTIVE;2.00;2.71 +28846-4;HSA distance;Len;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription HSA distance;L glasses Rx HSA distance;;ACTIVE;2.00;2.70 +28847-2;Visual acuity.far;LenRto;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Visual acuity far;L glasses Rx Far VA;;ACTIVE;2.00;2.71 +28848-0;Distance N.binocular;Len;Pt;Glasses prescription;Qn;;EYE.GLASSES;2;Glasses lens prescription Distance N binocular;Glasses Rx Distance N Binoc;;ACTIVE;2.00;2.70 +28849-8;Sphere near 1;InvLen;Pt;Glasses prescription;Qn;;EYE.GLASSES;2;Glasses lens prescription Sphere near 1;Glasses Rx Sphere N 1;;ACTIVE;2.00;2.70 +28850-6;Cylinder near;InvLen;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Cylinder near;L glasses Rx Cylinder near;;ACTIVE;2.00;2.71 +28851-4;Axis near;Angle;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Axis near;L glasses Rx Axis near;;ACTIVE;2.00;2.71 +2885-2;Protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Protein [Mass/volume] in Serum or Plasma;Prot SerPl-mCnc;;ACTIVE;1.0;2.73 +28852-2;Sphere near 2;InvLen;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Sphere near 2;L glasses Rx Sphere N 2;;ACTIVE;2.00;2.70 +28853-0;Cylinder near 2;InvLen;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Cylinder near 2;L glasses Rx Cylinder near 2;;ACTIVE;2.00;2.71 +28854-8;Axis near 2;Angle;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Axis near 2;L glasses Rx Axis near 2;;ACTIVE;2.00;2.71 +28855-5;HSA N;Len;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription HSA N;L glasses Rx HSA N;;ACTIVE;2.00;2.70 +28856-3;Visual acuity.near;LenRto;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Visual acuity near;L glasses Rx Near VA;;ACTIVE;2.00;2.72 +28857-1;Pupillary distance.monocular;Len;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Pupillary distance.monocular;L glasses Rx PD monoc;;ACTIVE;2.00;2.71 +28858-9;Pupillary distance.binocular;Len;Pt;Glasses prescription;Qn;;EYE.GLASSES;2;Glasses lens prescription Pupillary distance.binocular;Glasses Rx PD binoc;;ACTIVE;2.00;2.70 +28859-7;PO N;Len;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription PO N;L glasses Rx PO N;;ACTIVE;2.00;2.70 +2886-0;Protein;MCnc;Pt;Synv fld;Qn;;CHEM;1;Protein [Mass/volume] in Synovial fluid;Prot Snv-mCnc;;ACTIVE;1.0;2.73 +28860-5;PO N.binocular;Len;Pt;Glasses prescription;Qn;;EYE.GLASSES;2;Glasses lens prescription PO N.binocular;Glasses Rx PO N.binoc;;ACTIVE;2.00;2.70 +28861-3;Correction code;Find;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Correction code;R cont lens Correction code;;ACTIVE;2.00;2.68 +28862-1;Correction text;Find;Pt;Contact lens.right;Nar;;EYE.CONTACT_LENS;2;Right contact lens Correction text;R cont lens Correction text;;ACTIVE;2.00;2.68 +28863-9;Correction code;Find;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Correction code;L cont lens Correction code;;ACTIVE;2.00;2.68 +28864-7;Correction text;Find;Pt;Contact lens.left;Nar;;EYE.CONTACT_LENS;2;Left contact lens Correction text;L cont lens Correction text;;ACTIVE;2.00;2.68 +28865-4;Correction since;TmStp;Pt;Contact lens;Qn;;EYE.CONTACT_LENS;2;Contact lens Correction since;Cont lens Correction since;;ACTIVE;2.00;2.68 +28866-2;Prescription code;Type;Pt;Contact lens;Nom;;EYE.CONTACT_LENS;2;Contact lens Prescription code;Cont lens Rx code;;ACTIVE;2.00;2.68 +28867-0;Prescription text;Prid;Pt;Contact lens;Nar;;EYE.CONTACT_LENS;2;Contact lens Prescription text;Cont lens Rx text;;ACTIVE;2.00;2.68 +28868-8;Dispenser code;Type;Pt;Contact lens;Nom;;EYE.CONTACT_LENS;2;Contact lens Dispenser code;Cont lens Dispenser code;;ACTIVE;2.00;2.68 +28869-6;Dispenser text;Prid;Pt;Contact lens;Nar;;EYE.CONTACT_LENS;2;Contact lens Dispenser text;Cont lens Dispenser text;;ACTIVE;2.00;2.68 +28870-4;Material;Prid;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Material;R cont lens Material;;ACTIVE;2.00;2.68 +28871-2;Type;Type;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Type;R cont lens Type;;ACTIVE;2.00;2.68 +28872-0;Manufacturer code;ID;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Manufacturer code;R cont lens Manufacturer code;;ACTIVE;2.00;2.68 +28873-8;Producer text;Prid;Pt;Contact lens.right;Nar;;EYE.CONTACT_LENS;2;Right contact lens Producer text;R cont lens Producer text;;ACTIVE;2.00;2.68 +28874-6;Color;Type;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Color;R cont lens Color;;ACTIVE;2.00;2.68 +28875-3;Color;Type;Pt;Contact lens.right;Nar;;EYE.CONTACT_LENS;2;Right contact lens Color Narrative;R cont lens Color;;ACTIVE;2.00;2.68 +28876-1;Base curve 1;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Base curve 1;R cont lens Base curve 1;;ACTIVE;2.00;2.70 +28877-9;Base curve 2;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Base curve 2;R cont lens Base curve 2;;ACTIVE;2.00;2.70 +2887-8;Protein;PrThr;Pt;Urine;Ord;;UA;1;Protein [Presence] in Urine;Prot Ur Ql;;ACTIVE;1.0;2.73 +28878-7;Sphere;InvLen;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Sphere;R cont lens Sphere;;ACTIVE;2.00;2.70 +28879-5;Cylinder;InvLen;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Cylinder;R cont lens Cylinder;;ACTIVE;2.00;2.70 +28880-3;Axis;Angle;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Axis;R cont lens Axis;;ACTIVE;2.00;2.70 +28881-1;Axis.DS;Angle;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Axis.DS;R cont lens Axis.DS;;ACTIVE;2.00;2.70 +28882-9;Diameter;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Diameter;R cont lens Diam;;ACTIVE;2.00;2.70 +28883-7;DOZ.inside;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens DOZ.inside;R cont lens DOZ.inside;;ACTIVE;2.00;2.70 +28884-5;DOZ.outside;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens DOZ.outside;R cont lens DOZ.outside;;ACTIVE;2.00;2.70 +28885-2;Bevel width;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Bevel width;R cont lens Bevel width;;ACTIVE;2.00;2.70 +2888-6;Protein;MCnc;Pt;Urine;Qn;;UA;1;Protein [Mass/volume] in Urine;Prot Ur-mCnc;;ACTIVE;1.0;2.73 +28886-0;Bevel radius;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Bevel radius;R cont lens Bevel radius;;ACTIVE;2.00;2.73 +28887-8;Geometry;Prid;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Geometry;R cont lens Geometry;;ACTIVE;2.00;2.68 +28888-6;Torus;Prid;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Torus;R cont lens Torus;;ACTIVE;2.00;2.68 +28889-4;Add;InvLen;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Add;R cont lens Add;;ACTIVE;2.00;2.70 +28890-2;Visual acuity.far;LenRto;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Visual acuity far;R cont lens Far VA;;ACTIVE;2.00;2.71 +28891-0;Visual acuity.near;LenRto;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Visual acuity near;R cont lens Near VA;;ACTIVE;2.00;2.72 +28892-8;Lens fitting;Prid;Pt;Contact lens.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens Lens fitting;R cont lens Lens fitting;;ACTIVE;2.00;2.68 +28893-6;Material;Prid;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Material;L cont lens Material;;ACTIVE;2.00;2.68 +2889-4;Protein;MRat;24H;Urine;Qn;;CHEM;1;Protein [Mass/time] in 24 hour Urine;Prot 24h Ur-mRate;;ACTIVE;1.0;2.73 +28894-4;Type;Type;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Type;L cont lens Type;;ACTIVE;2.00;2.68 +28895-1;Manufacturer code;ID;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Manufacturer code;L cont lens Manufacturer code;;ACTIVE;2.00;2.68 +28896-9;Manufacturer name;ID;Pt;Contact lens.left;Nar;;EYE.CONTACT_LENS;2;Left contact lens Manufacturer name [Identifier];L cont lens Manufacturer name;;ACTIVE;2.00;2.68 +28897-7;Color;Type;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Color;L cont lens Color;;ACTIVE;2.00;2.68 +28898-5;Color;Type;Pt;Contact lens.left;Nar;;EYE.CONTACT_LENS;2;Left contact lens Color Narrative;L cont lens Color;;ACTIVE;2.00;2.68 +28899-3;Base curve 1;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Base curve 1;L cont lens Base curve 1;;ACTIVE;2.00;2.70 +28900-9;Base curve 2;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Base curve 2;L cont lens Base curve 2;;ACTIVE;2.00;2.70 +28901-7;Sphere;InvLen;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Sphere;L cont lens Sphere;;ACTIVE;2.00;2.70 +2890-2;Protein/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Protein/Creatinine [Mass Ratio] in Urine;Prot/Creat Ur;;ACTIVE;1.0;2.73 +28902-5;Cylinder;InvLen;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Cylinder;L cont lens Cylinder;;ACTIVE;2.00;2.73 +28903-3;Axis;Angle;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Axis;L cont lens Axis;;ACTIVE;2.00;2.70 +28904-1;Axis.DS;Angle;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Axis.DS;L cont lens Axis.DS;;ACTIVE;2.00;2.70 +28905-8;Radius;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Radius;L cont lens Radius;;ACTIVE;2.00;2.70 +28906-6;DOZ.inside;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens DOZ.inside;L cont lens DOZ.inside;;ACTIVE;2.00;2.70 +28907-4;DOZ.outside;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens DOZ.outside;L cont lens DOZ.outside;;ACTIVE;2.00;2.70 +28908-2;Bevel width;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Bevel width;L cont lens Bevel width;;ACTIVE;2.00;2.70 +28909-0;Bevel radius;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Bevel radius;L cont lens Bevel radius;;ACTIVE;2.00;2.70 +2891-0;Protoporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Protoporphyrin [Mass/time] in 24 hour Stool;Protopor 24h Stl-mRate;;ACTIVE;1.0;2.73 +28910-8;Lenticulation;Arb;Pt;Contact lens.left;Ord;;EYE.CONTACT_LENS;2;Left contact lens Lenticulation;L cont lens Lenticulation;;ACTIVE;2.00;2.68 +28911-6;Geometry;Prid;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Geometry;L cont lens Geometry;;ACTIVE;2.00;2.68 +28912-4;Torus;Prid;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Torus;L cont lens Torus;;ACTIVE;2.00;2.68 +28913-2;Add;InvLen;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Add;L cont lens Add;;ACTIVE;2.00;2.70 +28914-0;Visual acuity.far;LenRto;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Visual acuity far;L cont lens Far VA;;ACTIVE;2.00;2.71 +28915-7;Visual acuity.near;LenRto;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Visual acuity near;L cont lens Near VA;;ACTIVE;2.00;2.72 +28916-5;Lens fitting;Prid;Pt;Contact lens.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens Lens fitting;L cont lens Lens fitting;;ACTIVE;2.00;2.68 +28917-3;Over refraction sphere;InvLen;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Over refraction sphere;L cont lens OR sphere;;ACTIVE;2.00;2.70 +28918-1;Over refraction cylinder;InvLen;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Over refraction cylinder;L cont lens OR cylinder;;ACTIVE;2.00;2.70 +28919-9;Over refraction axis;Angle;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Over refraction axis;L cont lens OR axis;;ACTIVE;2.00;2.70 +28920-7;Material;Prid;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Material;R cont lens Rx Material;;ACTIVE;2.00;2.68 +28921-5;Type;Type;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Type;R cont lens Rx Type;;ACTIVE;2.00;2.68 +28922-3;Producer code;Type;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Producer code;R cont lens Rx Producer code;;ACTIVE;2.00;2.68 +28923-1;Producer text;Prid;Pt;Contact lens.prescription.right;Nar;;EYE.CONTACT_LENS;2;Right contact lens prescription Producer text;R cont lens Rx Producer text;;ACTIVE;2.00;2.68 +28924-9;Color;Type;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Color;R cont lens Rx Color;;ACTIVE;2.00;2.68 +28925-6;Color;Type;Pt;Contact lens.prescription.right;Nar;;EYE.CONTACT_LENS;2;Right contact lens prescription Color Narrative;R cont lens Rx Color;;ACTIVE;2.00;2.68 +28926-4;Explanation;Imp;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Explanation [Interpretation];R cont lens Rx Explanation [Imp];;ACTIVE;2.00;2.68 +28927-2;Base curve 1;Len;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Base curve 1;R cont lens Rx Base curve 1;;ACTIVE;2.00;2.70 +2892-8;Protoporphyrin.free;MCnc;Pt;Bld;Qn;;CHEM;1;Protoporphyrin Free [Mass/volume] in Blood;FEP Bld-mCnc;;ACTIVE;1.0;2.73 +28928-0;Base curve 2;Len;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Base curve 2;R cont lens Rx Base curve 2;;ACTIVE;2.00;2.70 +28929-8;Sphere;InvLen;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Sphere;R cont lens Rx Sphere;;ACTIVE;2.00;2.70 +28930-6;Cylinder;InvLen;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Cylinder;R cont lens Rx Cylinder;;ACTIVE;2.00;2.70 +28931-4;Axis;Angle;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Axis;R cont lens Rx Axis;;ACTIVE;2.00;2.70 +28932-2;Axis.DS;Angle;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Axis.DS;R cont lens Rx Axis.DS;;ACTIVE;2.00;2.70 +28933-0;Radius;Len;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Radius;R cont lens Rx Radius;;ACTIVE;2.00;2.70 +28934-8;DOZ.inside;Len;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription DOZ.inside;R cont lens Rx DOZ.inside;;ACTIVE;2.00;2.70 +28935-5;DOZ.outside;Len;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription DOZ.outside;R cont lens Rx DOZ.outside;;ACTIVE;2.00;2.70 +2893-6;Protoporphyrin.zinc;PrThr;Pt;Bld;Ord;;CHEM;1;Protoporphyrin.zinc [Presence] in Blood;ZPP Bld Ql;;ACTIVE;1.0;2.73 +28936-3;Bevel width;Len;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Bevel width;R cont lens Rx Bevel width;;ACTIVE;2.00;2.70 +28937-1;Bevel radius;Len;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Bevel radius;R cont lens Rx Bevel radius;;ACTIVE;2.00;2.70 +28938-9;Geometry;Prid;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Geometry;R cont lens Rx Geometry;;ACTIVE;2.00;2.68 +28939-7;Torus;Prid;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Torus;R cont lens Rx Torus;;ACTIVE;2.00;2.68 +28940-5;Add;InvLen;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Add;R cont lens Rx Add;;ACTIVE;2.00;2.70 +28941-3;Visual acuity.far;LenRto;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Visual acuity far;R cont lens Rx Far VA;;ACTIVE;2.00;2.71 +28942-1;Visual acuity.near;LenRto;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Visual acuity near;R cont lens Rx Near VA;;ACTIVE;2.00;2.72 +28943-9;Lens fitting;Prid;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Lens fitting;R cont lens Rx Lens fitting;;ACTIVE;2.00;2.68 +2894-4;Protoporphyrin.zinc;PrThr;Pt;RBC;Ord;;CHEM;1;Protoporphyrin.zinc [Presence] in Red Blood Cells;ZPP RBC Ql;;ACTIVE;1.0;2.56 +28944-7;Over refraction sphere;InvLen;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Over refraction sphere;R cont lens Rx OR sphere;;ACTIVE;2.00;2.70 +28945-4;Over refraction cylinder;InvLen;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Over refraction cylinder;R cont lens Rx OR cylinder;;ACTIVE;2.00;2.70 +28946-2;Over refraction axis;Angle;Pt;Contact lens.prescription.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens prescription Over refraction axis;R cont lens Rx OR axis;;ACTIVE;2.00;2.70 +28947-0;Material;Prid;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Material;L cont lens Rx Material;;ACTIVE;2.00;2.68 +28948-8;Type;Type;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Type;L cont lens Rx Type;;ACTIVE;2.00;2.68 +28949-6;Producer code;Type;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Producer code;L cont lens Rx Producer code;;ACTIVE;2.00;2.68 +28950-4;Producer text;Prid;Pt;Contact lens.prescription.left;Nar;;EYE.CONTACT_LENS;2;Left contact lens prescription Producer text;L cont lens Rx Producer text;;ACTIVE;2.00;2.68 +2895-1;Protoporphyrin.zinc;MCnc;Pt;RBC;Qn;;CHEM;1;Protoporphyrin.zinc [Mass/volume] in Red Blood Cells;ZPP RBC-mCnc;;ACTIVE;1.0;2.73 +28951-2;Color;Type;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Color;L cont lens Rx Color;;ACTIVE;2.00;2.68 +28952-0;Color;Type;Pt;Contact lens.prescription.left;Nar;;EYE.CONTACT_LENS;2;Left contact lens prescription Color Narrative;L cont lens Rx Color;;ACTIVE;2.00;2.68 +28953-8;Explanation;Imp;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Explanation [Interpretation];L cont lens Rx Explanation [Imp];;ACTIVE;2.00;2.68 +28954-6;Base curve 1;Len;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Base curve 1;L cont lens Rx Base curve 1;;ACTIVE;2.00;2.70 +28955-3;Base curve 2;Len;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Base curve 2;L cont lens Rx Base curve 2;;ACTIVE;2.00;2.70 +28956-1;Sphere;InvLen;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Sphere;L cont lens Rx Sphere;;ACTIVE;2.00;2.70 +28957-9;Cylinder;InvLen;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Cylinder;L cont lens Rx Cylinder;;ACTIVE;2.00;2.70 +28958-7;Axis;Angle;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Axis;L cont lens Rx Axis;;ACTIVE;2.00;2.70 +28959-5;Axis.DS;Angle;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Axis.DS;L cont lens Rx Axis.DS;;ACTIVE;2.00;2.70 +28960-3;Radius;Len;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Radius;L cont lens Rx Radius;;ACTIVE;2.00;2.70 +28961-1;DOZ.inside;Len;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription DOZ.inside;L cont lens Rx DOZ.inside;;ACTIVE;2.00;2.70 +28962-9;DOZ.outside;Len;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription DOZ.outside;L cont lens Rx DOZ.outside;;ACTIVE;2.00;2.70 +28963-7;Bevel width;Len;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Bevel width;L cont lens Rx Bevel width;;ACTIVE;2.00;2.70 +28964-5;Bevel radius;Len;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Bevel radius;L cont lens Rx Bevel radius;;ACTIVE;2.00;2.70 +28965-2;Geometry;Prid;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Geometry;L cont lens Rx Geometry;;ACTIVE;2.00;2.68 +28966-0;Torus;Prid;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Torus;L cont lens Rx Torus;;ACTIVE;2.00;2.68 +28967-8;Add;InvLen;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Add;L cont lens Rx Add;;ACTIVE;2.00;2.70 +28968-6;Visual acuity.far;LenRto;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Visual acuity far;L cont lens Rx Far VA;;ACTIVE;2.00;2.71 +2896-9;Protoporphyrin;MCnc;Pt;Bld;Qn;;CHEM;1;Protoporphyrin [Mass/volume] in Blood;Protopor Bld-mCnc;;ACTIVE;1.0;2.73 +28969-4;Visual acuity.near;LenRto;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Visual acuity near;L cont lens Rx Near VA;;ACTIVE;2.00;2.72 +28970-2;Linsensitz;Prid;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Linsensitz;L cont lens Rx Linsensitz;;ACTIVE;2.00;2.68 +28971-0;Over refraction sphere;InvLen;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Over refraction sphere;L cont lens Rx OR sphere;;ACTIVE;2.00;2.70 +28972-8;Over refraction cylinder;InvLen;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Over refraction cylinder;L cont lens Rx OR cylinder;;ACTIVE;2.00;2.70 +28973-6;Over refraction axis;Angle;Pt;Contact lens.prescription.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens prescription Over refraction axis;L cont lens Rx OR axis;;ACTIVE;2.00;2.70 +28974-4;Base curve 1;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Base curve 1 by Keratometry;R cornea Base curve 1 by KM;;ACTIVE;2.00;2.70 +28975-1;Axis;Angle;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Axis by Keratometry;R cornea Axis by KM;;ACTIVE;2.00;2.70 +28976-9;Base curve 2;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Base curve 2 by Keratometry;R cornea Base curve 2 by KM;;ACTIVE;2.00;2.70 +2897-7;Protoporphyrin;PrThr;Pt;RBC;Ord;;CHEM;1;Protoporphyrin [Presence] in Red Blood Cells;Protopor RBC Ql;;ACTIVE;1.0;2.56 +28977-7;Axis 2;Angle;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Axis 2 by Keratometry;R cornea Axis 2 by KM;;ACTIVE;2.00;2.70 +28978-5;Comment;Imp;Pt;Eye.right;Nar;Keratometry;EYE.REFRACTION;2;Right eye Comment [Interpretation] by Keratometry;R eye Comment [Imp] by KM;;ACTIVE;2.00;2.68 +28979-3;Sagittal radius.superior;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Sagittal radius.superior by Keratometry;R cornea Sag rad.sup by KM;;ACTIVE;2.00;2.68 +28980-1;Sagittal radius.inferior;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Sagittal radius.inferior by Keratometry;R cornea Sag rad.inf by KM;;ACTIVE;2.00;2.68 +28981-9;Sagittal radius.temporal;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Sagittal radius.temporal by Keratometry;R cornea Sag rad.temp by KM;;ACTIVE;2.00;2.68 +28982-7;Sagittal radius.nasal;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Sagittal radius.nasal by Keratometry;R cornea Sag rad.nasal by KM;;ACTIVE;2.00;2.68 +28983-5;Longitudinal radius;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Longitudinal radius by Keratometry;R cornea Longit radius by KM;;ACTIVE;2.00;2.68 +28984-3;Base curve 1;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Base curve 1 by Keratometry;L cornea Base curve 1 by KM;;ACTIVE;2.00;2.70 +2898-5;Protoporphyrin;MCnc;Pt;RBC;Qn;;CHEM;1;Protoporphyrin [Mass/volume] in Red Blood Cells;Protopor RBC-mCnc;;ACTIVE;1.0;2.73 +28985-0;Axis;Angle;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Axis by Keratometry;L cornea Axis by KM;;ACTIVE;2.00;2.70 +28986-8;Base curve 2;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Base curve 2 by Keratometry;L cornea Base curve 2 by KM;;ACTIVE;2.00;2.70 +28987-6;Axis 2;Angle;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Axis 2 by Keratometry;L cornea Axis 2 by KM;;ACTIVE;2.00;2.70 +28988-4;Comment;Imp;Pt;Eye.left;Nar;Keratometry;EYE.REFRACTION;2;Left eye Comment [Interpretation] by Keratometry;L eye Comment [Imp] by KM;;ACTIVE;2.00;2.68 +28989-2;Sagittal radius.superior;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Sagittal radius.superior by Keratometry;L cornea Sag rad.sup by KM;;ACTIVE;2.00;2.68 +289-9;Isoniazid;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Isoniazid [Susceptibility] by Serum bactericidal titer;Isoniazid Titr SBT;;ACTIVE;1.0;2.32 +28990-0;Sagittal radius.inferior;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Sagittal radius.inferior by Keratometry;L cornea Sag rad.inf by KM;;ACTIVE;2.00;2.68 +28991-8;Sagittal radius.temporal;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Sagittal radius.temporal by Keratometry;L cornea Sag rad.temp by KM;;ACTIVE;2.00;2.68 +28992-6;Sagittal radius.nasal;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Sagittal radius.nasal by Keratometry;L cornea Sag rad.nasal by KM;;ACTIVE;2.00;2.68 +2899-3;Purine nucleoside phosphorylase;CCnt;Pt;Tiss;Qn;;CHEM;1;Purine nucleoside phosphorylase [Enzymatic activity/mass] in Tissue;PNP Tiss-cCnt;;ACTIVE;1.0;2.42 +28993-4;Longitudinal radius;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Longitudinal radius by Keratometry;L cornea Longit radius by KM;;ACTIVE;2.00;2.68 +28994-2;Refractive power.flat;InvLen;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Flat refractive power by Keratometry;R cornea Power R1 by KM;;ACTIVE;2.00;2.70 +28995-9;Refractive power.steep;InvLen;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Steep refractive power by Keratometry;R cornea Power R2 by KM;;ACTIVE;2.00;2.70 +28996-7;Refractive power.flat;InvLen;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Flat refractive power by Keratometry;L cornea Power R1 by KM;;ACTIVE;2.00;2.70 +28997-5;Refractive power.steep;InvLen;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Steep refractive power by Keratometry;L cornea Power R2 by KM;;ACTIVE;2.00;2.70 +28998-3;Exopthalmia;Len;Pt;Eye.right;Qn;Exopthalmometer.Hertel;EYE.PX;2;Right eye Exopthalmia Exopthalmometer.Hertel;R eye Exopthalmia Hertel;;ACTIVE;2.00;2.68 +28999-1;Exopthalmia;Len;Pt;Eye.left;Qn;Exopthalmometer.Hertel;EYE.PX;2;Left eye Exopthalmia Exopthalmometer.Hertel;L eye Exopthalmia Hertel;;ACTIVE;2.00;2.68 +29000-7;Exopthalmia base;Len;Pt;Eye;Qn;Exopthalmometer.Hertel;EYE.PX;2;Eye Exopthalmia base Exopthalmometer.Hertel;Eye Exopthalmia base Hertel;;ACTIVE;2.00;2.68 +29001-5;Exopthalmia comment;Imp;Pt;Eye.right;Nar;Exopthalmometer.Hertel;EYE.PX;2;Right eye Exopthalmia comment [Interpretation] Exopthalmometer.Hertel;R eye Exopthalmia comment [Imp] Hertel;;ACTIVE;2.00;2.68 +29002-3;Exopthalmia comment;Imp;Pt;Eye.left;Nar;Exopthalmometer.Hertel;EYE.PX;2;Left eye Exopthalmia comment [Interpretation] Exopthalmometer.Hertel;L eye Exopthalmia comment [Imp] Hertel;;ACTIVE;2.00;2.68 +29003-1;Tear secretion 1;Len;Pt;Eye.right;Qn;Schirmer test;EYE.PX;2;Right eye Tear secretion 1 Schirmer test;R eye TS1 Schirmer;;ACTIVE;2.00;2.70 +29004-9;Tear secretion 1;Len;Pt;Eye.left;Qn;Schirmer test;EYE.PX;2;Left eye Tear secretion 1 Schirmer test;L eye TS1 Schirmer;;ACTIVE;2.00;2.70 +29005-6;Tear secretion 2;Len;Pt;Eye.right;Qn;Schirmer test;EYE.PX;2;Right eye Tear secretion 2 Schirmer test;R eye TS2 Schirmer;;ACTIVE;2.00;2.70 +29006-4;Tear secretion 2;Len;Pt;Eye.left;Qn;Schirmer test;EYE.PX;2;Left eye Tear secretion 2 Schirmer test;L eye TS2 Schirmer;;ACTIVE;2.00;2.70 +29007-2;Tear secretion break up;Time;Pt;Eye.right;Qn;Schirmer test;EYE.PX;2;Right eye Tear secretion break up [Time] Schirmer test;R eye TS break up [Time] Schirmer;;ACTIVE;2.00;2.70 +29008-0;Tear secretion break up;Time;Pt;Eye.left;Qn;Schirmer test;EYE.PX;2;Left eye Tear secretion break up [Time] Schirmer test;L eye TS break up [Time] Schirmer;;ACTIVE;2.00;2.70 +2900-9;Pyridoxine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyridoxine [Mass/volume] in Serum or Plasma;Vit B6 SerPl-mCnc;;ACTIVE;1.0;2.73 +29009-8;Tear secretion comment;Imp;Pt;Eye.right;Nar;Schirmer test;EYE.PX;2;Right eye Tear secretion comment [Interpretation] Schirmer test;R eye TS comment [Imp] Schirmer;;ACTIVE;2.00;2.68 +29010-6;Tear secretion comment;Imp;Pt;Eye.left;Nar;Schirmer test;EYE.PX;2;Left eye Tear secretion comment [Interpretation] Schirmer test;L eye TS comment [Imp] Schirmer;;ACTIVE;2.00;2.68 +29011-4;Argon laser coagulation Rx effects;Num;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser coagulation treatment effects;R eye Argon LC effects;;ACTIVE;2.00;2.68 +29012-2;Argon laser coagulation Rx;Time;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser coagulation treatment [Time];R eye Argon LC [Time];;ACTIVE;2.00;2.70 +29013-0;Argon laser coagulation Rx spot size;Len;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser coagulation treatment spot size;R eye Argon LC spot size;;ACTIVE;2.00;2.70 +29014-8;Argon laser coagulation Rx localization;Prid;Pt;Eye.right;Nom;;EYE.RETINAL_RX;2;Right eye Argon laser coagulation treatment localization;R eye Argon LC localization;;ACTIVE;2.00;2.68 +29015-5;Argon laser coagulation Rx comment;Imp;Pt;Eye.right;Nar;;EYE.RETINAL_RX;2;Right eye Argon laser coagulation treatment comment [Interpretation];R eye Argon LC comment [Imp];;ACTIVE;2.00;2.68 +29016-3;Argon laser coagulation Rx effects;Num;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser coagulation treatment effects;L eye Argon LC effects;;ACTIVE;2.00;2.68 +2901-7;Pyridoxine congeners;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyridoxine congeners [Mass/volume] in Serum or Plasma;Vit B6 Congeners SerPl-mCnc;;ACTIVE;1.0;2.40 +29017-1;Argon laser coagulation Rx;Time;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser coagulation treatment [Time];L eye Argon LC [Time];;ACTIVE;2.00;2.70 +29018-9;Argon laser coagulation Rx spot size;Len;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser coagulation treatment spot size;L eye Argon LC spot size;;ACTIVE;2.00;2.70 +29019-7;Argon laser coagulation Rx localization;Prid;Pt;Eye.left;Nom;;EYE.RETINAL_RX;2;Left eye Argon laser coagulation treatment localization;L eye Argon LC localization;;ACTIVE;2.00;2.68 +29020-5;Argon laser coagulation Rx comment;Imp;Pt;Eye.left;Nar;;EYE.RETINAL_RX;2;Left eye Argon laser coagulation treatment comment [Interpretation];L eye Argon LC comment [Imp];;ACTIVE;2.00;2.68 +29021-3;Argon laser trabeculoplasty Rx effects;Num;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser trabeculoplasty treatment effects;R eye Argon LT effects;;ACTIVE;2.00;2.68 +29022-1;Argon laser trabeculoplasty Rx;Time;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser trabeculoplasty treatment [Time];R eye Argon LT [Time];;ACTIVE;2.00;2.70 +29023-9;Argon laser trabeculoplasty Rx spot size;Len;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser trabeculoplasty treatment spot size;R eye Argon LT spot size;;ACTIVE;2.00;2.70 +29024-7;Argon laser trabeculoplasty Rx localization;Prid;Pt;Eye.right;Nom;;EYE.RETINAL_RX;2;Right eye Argon laser trabeculoplasty treatment localization;R eye Argon LT localization;;ACTIVE;2.00;2.68 +2902-5;Pyrimidine-5'-Nucleotidase;PrThr;Pt;Bld;Ord;;CHEM;1;Pyrimidine-5'-Nucleotidase [Presence] in Blood;P5NT Bld Ql;;ACTIVE;1.0;2.73 +29025-4;Argon laser trabeculoplasty Rx comment;Imp;Pt;Eye.right;Nom;;EYE.RETINAL_RX;2;Right eye Argon laser trabeculoplasty treatment comment [Interpretation];R eye Argon LT comment [Imp];;ACTIVE;2.00;2.68 +29026-2;Argon laser trabeculoplasty Rx effects;Num;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser trabeculoplasty treatment effects;L eye Argon LT effects;;ACTIVE;2.00;2.68 +29027-0;Argon laser trabeculoplasty Rx;Time;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser trabeculoplasty treatment [Time];L eye Argon LT [Time];;ACTIVE;2.00;2.68 +29028-8;Argon laser trabeculoplasty Rx spot size;Len;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser trabeculoplasty treatment spot size;L eye Argon LT spot size;;ACTIVE;2.00;2.70 +29029-6;Argon laser trabeculoplasty Rx localization;Prid;Pt;Eye.left;Nom;;EYE.RETINAL_RX;2;Left eye Argon laser trabeculoplasty treatment localization;L eye Argon LT localization;;ACTIVE;2.00;2.68 +29030-4;Argon laser trabeculoplasty Rx comment;Imp;Pt;Eye.left;Nar;;EYE.RETINAL_RX;2;Left eye Argon laser trabeculoplasty treatment comment [Interpretation];L eye Argon LT comment [Imp];;ACTIVE;2.00;2.68 +29031-2;YAG Rx mode;Prid;Pt;Eye.right;Nom;;EYE.RETINAL_RX;2;Right eye YAG mode;R eye YAG mode;;ACTIVE;2.00;2.68 +29032-0;YAG Rx intensity;Enrg;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye YAG intensity;R eye YAG intensity;;ACTIVE;2.00;2.70 +2903-3;Pyrimidine-5'-Nucleotidase;CCnc;Pt;Bld;Qn;;CHEM;1;Pyrimidine-5'-Nucleotidase [Enzymatic activity/volume] in Blood;P5NT Bld-cCnc;;ACTIVE;1.0;2.68 +29033-8;YAG Rx;Num;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye YAG;R eye YAG;;ACTIVE;2.00;2.68 +29034-6;YAG Rx comment;Imp;Pt;Eye.right;Nar;;EYE.RETINAL_RX;2;Right eye YAG comment [Interpretation];R eye YAG comment [Imp];;ACTIVE;2.00;2.68 +29035-3;YAG Rx mode;Prid;Pt;Eye.left;Nom;;EYE.RETINAL_RX;2;Left eye YAG mode;L eye YAG mode;;ACTIVE;2.00;2.68 +29036-1;YAG Rx intensity;Enrg;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye YAG intensity;L eye YAG intensity;;ACTIVE;2.00;2.70 +29037-9;YAG Rx;Num;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye YAG;L eye YAG;;ACTIVE;2.00;2.68 +29038-7;YAG Rx comment;Imp;Pt;Eye.left;Nar;;EYE.RETINAL_RX;2;Left eye YAG comment [Interpretation];L eye YAG comment [Imp];;ACTIVE;2.00;2.68 +29039-5;KW;Angle;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye KW [degrees];R eye KW [degrees];;ACTIVE;2.00;2.70 +29040-3;KW impression code;Imp;Pt;Eye.right;Nom;;EYE.RETINAL_RX;2;Right eye KW impression code;R eye KW impression code;;ACTIVE;2.00;2.68 +2904-1;Pyrophosphate crystals;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Pyrophosphate crystals [#/volume] in Synovial fluid;Pyrophos Cry # Snv;;ACTIVE;1.0;2.44 +29041-1;KW impression comment;Imp;Pt;Eye.right;Nar;;EYE.RETINAL_RX;2;Right eye KW impression comment;R eye KW impression comment;;ACTIVE;2.00;2.68 +29042-9;KW;Angle;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye KW [degrees];L eye KW [degrees];;ACTIVE;2.00;2.70 +29043-7;KW impression code;Imp;Pt;Eye.left;Nom;;EYE.RETINAL_RX;2;Left eye KW impression code;L eye KW impression code;;ACTIVE;2.00;2.68 +29044-5;KW impression comment;Imp;Pt;Eye.left;Nar;;EYE.RETINAL_RX;2;Left eye KW impression comment;L eye KW impression comment;;ACTIVE;2.00;2.68 +29045-2;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.Goldman;EYE.VISUAL_FIELD;2;Perimeter format Goldman;Perimeter format Goldman;;ACTIVE;2.00;2.29 +29046-0;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.Humphrey;EYE.VISUAL_FIELD;2;Perimeter format Humphrey;Perimeter format Humphrey;;ACTIVE;2.00;2.29 +29047-8;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.octupus;EYE.VISUAL_FIELD;2;Perimeter format Octupus;Perimeter format Octupus;;ACTIVE;2.00;2.29 +29048-6;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.Perimat;EYE.VISUAL_FIELD;2;Perimeter format Perimat;Perimeter format Perimat;;ACTIVE;2.00;2.29 +29049-4;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.Peristat;EYE.VISUAL_FIELD;2;Perimeter format Peristat;Perimeter format Peristat;;ACTIVE;2.00;2.29 +29050-2;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.Dicon;EYE.VISUAL_FIELD;2;Perimeter format DICON;Perimeter format DICON;;ACTIVE;2.00;2.29 +29051-0;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.Tuebinger automatic;EYE.VISUAL_FIELD;2;Perimeter format Tuebinger automatic;Perimeter format Tuebinger automatic;;ACTIVE;2.00;2.29 +29052-8;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.TEC;EYE.VISUAL_FIELD;2;Perimeter format TEC;Perimeter format TEC;;ACTIVE;2.00;2.29 +29053-6;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.Kowa;EYE.VISUAL_FIELD;2;Perimeter format Kowa;Perimeter format Kowa;;ACTIVE;2.00;2.29 +29054-4;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.standard;EYE.VISUAL_FIELD;2;Perimeter format Standard;Perimeter format Standard;;ACTIVE;2.00;2.29 +29055-1;Perimeter format;Prid;Pt;Visual sensory;Nom;Perimetry.data interchange;EYE.VISUAL_FIELD;2;Perimeter format Data interchange;Perimeter format Data interchange;;ACTIVE;2.00;2.29 +29056-9;Pressure device type;Type;Pt;*;Nom;Perimetry;EYE.VISUAL_FIELD;2;Pressure device type Perimetry;Pressure device type Perimetry;;ACTIVE;2.00;2.27 +29057-7;Pressure result code;Find;Pt;Eye.right;Nom;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure result code Perimetry;R eye Pressure result code Perimetry;;ACTIVE;2.00;2.68 +2905-8;Pyruvate;MCnc;Pt;Bld;Qn;;CHEM;1;Pyruvate [Mass/volume] in Blood;Pyruvate Bld-mCnc;;ACTIVE;1.0;2.73 +29058-5;Pressure result text;Prid;Pt;Eye.right;Nar;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure result text Perimetry;R eye Pressure result text Perimetry;;ACTIVE;2.00;2.68 +29059-3;GF border code;Find;Pt;Eye.right;Nom;Perimetry;EYE.VISUAL_FIELD;2;Right eye GF border code Perimetry;R eye GF border code Perimetry;;ACTIVE;2.00;2.68 +29060-1;Pressure border text;Prid;Pt;Eye.right;Nar;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure border text Perimetry;R eye Pressure border text Perimetry;;ACTIVE;2.00;2.68 +29061-9;Pressure spot code;Find;Pt;Eye.right;Nom;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure spot code Perimetry;R eye Pressure spot code Perimetry;;ACTIVE;2.00;2.68 +29062-7;Pressure spot text;Prid;Pt;Eye.right;Nar;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure spot text Perimetry;R eye Pressure spot text Perimetry;;ACTIVE;2.00;2.68 +29063-5;Pressure Skotome code;Type;Pt;Eye.right;Nom;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure Skotome code Perimetry;R eye Pressure Skotome code Perimetry;;ACTIVE;2.00;2.68 +29064-3;Pressure Skotome text;Prid;Pt;Eye.right;Nar;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure skotome text Perimetry;R eye Pressure skotome text Perimetry;;ACTIVE;2.00;2.68 +29065-0;Pressure result code;Find;Pt;Eye.left;Nom;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure result code Perimetry;L eye Pressure result code Perimetry;;ACTIVE;2.00;2.68 +2906-6;Pyruvate;MCnc;Pt;BldA;Qn;;CHEM;1;Pyruvate [Mass/volume] in Arterial blood;Pyruvate BldA-mCnc;;ACTIVE;1.0;2.44 +29066-8;Pressure result text;Prid;Pt;Eye.left;Nar;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure result text Perimetry;L eye Pressure result text Perimetry;;ACTIVE;2.00;2.68 +29067-6;Pressure border code;Find;Pt;Eye.left;Nom;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure border code Perimetry;L eye Pressure border code Perimetry;;ACTIVE;2.00;2.68 +29068-4;Pressure border text;Prid;Pt;Eye.left;Nar;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure border text Perimetry;L eye Pressure border text Perimetry;;ACTIVE;2.00;2.68 +29069-2;Pressure spot code;Find;Pt;Eye.left;Nom;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure spot code Perimetry;L eye Pressure spot code Perimetry;;ACTIVE;2.00;2.68 +290-7;Kanamycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Kanamycin [Susceptibility] by Minimum lethal concentration (MLC);Kanamycin Islt MLC;;ACTIVE;1.0;2.19 +29070-0;Pressure spot text;Prid;Pt;Eye.left;Nar;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure spot text Perimetry;L eye Pressure spot text Perimetry;;ACTIVE;2.00;2.68 +29071-8;Pressure Skotome code;Type;Pt;Eye.left;Nom;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure Skotome code Perimetry;L eye Pressure Skotome code Perimetry;;ACTIVE;2.00;2.68 +29072-6;Pressure Skotome text;Prid;Pt;Eye.left;Nar;Perimetry;EYE.VISUAL_FIELD;2;Left eye Pressure skotome text Perimetry;L eye Pressure skotome text Perimetry;;ACTIVE;2.00;2.68 +29073-4;Position;Prid;Pt;Eye.right;Nom;;EYE.PX;2;Right eye Position;R eye Position;;ACTIVE;2.00;2.68 +2907-4;Pyruvate;MCnc;Pt;CSF;Qn;;CHEM;1;Pyruvate [Mass/volume] in Cerebral spinal fluid;Pyruvate CSF-mCnc;;ACTIVE;1.0;2.73 +29074-2;Position;Prid;Pt;Eye.left;Nom;;EYE.PX;2;Left eye Position;L eye Position;;ACTIVE;2.00;2.68 +29075-9;Motility;Prid;Pt;Eye.right;Nom;;EYE.PX;2;Right eye Motility;R eye Motility;;ACTIVE;2.00;2.68 +29076-7;Motility;Prid;Pt;Eye.left;Nom;;EYE.PX;2;Left eye Motility;L eye Motility;;ACTIVE;2.00;2.68 +29077-5;Convergence;Prid;Pt;Eyes;Nom;;EYE.PX;2;Eyes Convergence;Eyes Convergence;;ACTIVE;2.00;2.68 +29078-3;Heterophoria;Prid;Pt;Eyes;Nom;Cover test;EYE.HETEROPHORIA;2;Cover test for Heterophoria;Cover test;;ACTIVE;2.00;2.61 +29079-1;Prism cover;Prid;Pt;Eyes;Nom;;EYE.PX;2;Eyes Prism cover;Eyes Prism cover;;ACTIVE;2.00;2.68 +29080-9;Fusion width;Prid;Pt;Eyes;Nom;;EYE.PX;2;Eyes Fusion width;Eyes Fusion width;;ACTIVE;2.00;2.68 +29081-7;Pupil motoric;Prid;Pt;Eye.right;Nom;;EYE.PX;2;Right eye Pupil motoric;R eye Pupil motoric;;ACTIVE;2.00;2.68 +2908-2;Pyruvate;MCnc;Pt;Urine;Qn;;CHEM;1;Pyruvate [Mass/volume] in Urine;Pyruvate Ur-mCnc;;ACTIVE;1.0;2.73 +29082-5;Pupil motoric;Prid;Pt;Eye.left;Nom;;EYE.PX;2;Left eye Pupil motoric;L eye Pupil motoric;;ACTIVE;2.00;2.68 +29083-3;Binocular status code;Find;Pt;Eyes;Nom;;EYE.PX;2;Eyes Binocular status code;Eyes Binocular status code;;ACTIVE;2.00;2.68 +29084-1;Binocular status text;Prid;Pt;Eyes;Nar;;EYE.PX;2;Eyes Binocular status text;Eyes Binocular status text;;ACTIVE;2.00;2.68 +29085-8;Nystagmus examination;Prid;Pt;Eye.right;Nom;;EYE.PX;2;Right eye Nystagmus examination;R eye Nystagmus exam;;ACTIVE;2.00;2.68 +29086-6;Nystagmus examination;Find;Pt;Eye.right;Nar;;EYE.PX;2;Right eye Nystagmus examination Narrative;R eye Nystagmus exam;;ACTIVE;2.00;2.68 +29087-4;Physical findings;Find;Pt;Eye lid.right;Nar;;EYE.PX;2;Physical findings of Right eye lid Narrative;R eye lid Phys find;;ACTIVE;2.00;2.68 +29088-2;Physical findings;Find;Pt;Eye lid.left;Nar;;EYE.PX;2;Physical findings of Left eye lid Narrative;L eye lid Phys find;;ACTIVE;2.00;2.68 +29089-0;Physical findings;Find;Pt;Lacrimal gland.right;Nar;;EYE.PX;2;Physical findings of Right lacrimal gland Narrative;R lacrimal gland Phys find;;ACTIVE;2.00;2.68 +2909-0;Pyruvate carboxylase;CCnt;Pt;Tiss;Qn;;CHEM;1;Pyruvate carboxylase [Enzymatic activity/mass] in Tissue;Pyruvate Carboxylase Tiss-cCnt;;ACTIVE;1.0;2.40 +29090-8;Physical findings;Find;Pt;Lacrimal gland.left;Nar;;EYE.PX;2;Physical findings of Left lacrimal gland Narrative;L lacrimal gland Phys find;;ACTIVE;2.00;2.68 +29091-6;Physical findings;Find;Pt;Conjunctiva.right;Nar;;EYE.PX;2;Physical findings of Right conjunctiva Narrative;R conjunctiva Phys find;;ACTIVE;2.00;2.68 +29092-4;Physical findings;Find;Pt;Conjunctiva.left;Nar;;EYE.PX;2;Physical findings of Left conjunctiva Narrative;L conjunctiva Phys find;;ACTIVE;2.00;2.68 +29093-2;Physical findings;Find;Pt;Cornea.right;Nar;;EYE.PX;2;Physical findings of Right cornea Narrative;R cornea Phys find;;ACTIVE;2.00;2.68 +29094-0;Physical findings;Find;Pt;Cornea.left;Nar;;EYE.PX;2;Physical findings of Left cornea Narrative;L cornea Phys find;;ACTIVE;2.00;2.73 +29095-7;Physical findings;Find;Pt;Anterior chamber.right;Nar;;EYE.PX;2;Physical findings of Right anterior chamber Narrative;R ant chamber Phys find;;ACTIVE;2.00;2.68 +29096-5;Physical findings;Find;Pt;Anterior chamber.left;Nar;;EYE.PX;2;Physical findings of Left anterior chamber Narrative;L Ant chamber Phys find;;ACTIVE;2.00;2.68 +29097-3;Physical findings;Find;Pt;Iris.right;Nar;;EYE.PX;2;Physical findings of Right iris Narrative;R iris Phys find;;ACTIVE;2.00;2.68 +29098-1;Physical findings;Find;Pt;Iris.left;Nar;;EYE.PX;2;Physical findings of Left iris Narrative;L iris Phys find;;ACTIVE;2.00;2.68 +29099-9;Physical findings;Find;Pt;Optic lens.right;Nar;;EYE.PX;2;Physical findings of Right optic lens Narrative;R optic lens Phys find;;ACTIVE;2.00;2.68 +29100-5;Physical findings;Find;Pt;Optic lens.left;Nar;;EYE.PX;2;Physical findings of Left optic lens Narrative;L optic lens Phys find;;ACTIVE;2.00;2.68 +29101-3;Physical findings;Find;Pt;Ciliary body.right;Nar;;EYE.PX;2;Physical findings of Right ciliary body Narrative;R ciliary body Phys find;;ACTIVE;2.00;2.68 +29102-1;Physical findings;Find;Pt;Ciliary body.left;Nar;;EYE.PX;2;Physical findings of Left ciliary body Narrative;L ciliary body Phys find;;ACTIVE;2.00;2.68 +29103-9;Physical findings;Find;Pt;Vitreous body.right;Nar;;EYE.PX;2;Physical findings of Right vitreous body Narrative;Vitreous body-R Phys find;;ACTIVE;2.00;2.68 +29104-7;Physical findings;Find;Pt;Vitreous body.left;Nar;;EYE.PX;2;Physical findings of Left vitreous body Narrative;Vitreous body-L Phys find;;ACTIVE;2.00;2.68 +29105-4;Physical findings;Find;Pt;Retina.right;Nar;;EYE.PX;2;Physical findings of Right retina Narrative;R ret Phys find;;ACTIVE;2.00;2.68 +29106-2;Physical findings;Find;Pt;Retina.left;Nar;;EYE.PX;2;Physical findings of Left retina Narrative;L ret Phys find;;ACTIVE;2.00;2.68 +29107-0;Physical findings;Find;Pt;Choroidea.right;Nar;;EYE.PX;2;Physical findings of Right choroidea Narrative;R choroidea Phys find;;ACTIVE;2.00;2.68 +2910-8;Pyruvate dehydrogenase.cytochrome;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyruvate dehydrogenase.cytochrome [Enzymatic activity/volume] in Serum or Plasma;PDH Cytochrome SerPl-cCnc;;ACTIVE;1.0;2.68 +29108-8;Physical findings;Find;Pt;Choroidea.left;Nar;;EYE.PX;2;Physical findings of Left choroidea Narrative;L choroidea Phys find;;ACTIVE;2.00;2.68 +29109-6;Multisection;Imp;Pt;Eye.right;Nom;US.2D;EYE.US;2;Eye - right US 2D;Eye-R 2D US;;ACTIVE;2.00;2.29 +29110-4;Multisection;Imp;Pt;Eye.left;Nom;US.2D;EYE.US;2;Eye - left US 2D;Eye-L 2D US;;ACTIVE;2.00;2.29 +29111-2;Photo documentation;Arb;Pt;Eye.right;Ord;;EYE.PX;2;Right eye Photo documentation;R eye Photo doc;;ACTIVE;2.00;2.68 +29112-0;Photo documentation;Arb;Pt;Eye.left;Ord;;EYE.PX;2;Left eye Photo documentation;L eye Photo doc;;ACTIVE;2.00;2.68 +29113-8;Abacavir;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Abacavir [Units/volume] in Serum or Plasma;Abacavir SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29114-6;Amprenavir;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amprenavir [Units/volume] in Serum or Plasma;Amprenavir SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29115-3;Delavirdine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Delavirdine [Units/volume] in Serum or Plasma;Delavirdine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +2911-6;Pyruvate dehydrogenase.lipoamide;CCnt;Pt;Tiss;Qn;;CHEM;1;Pyruvate dehydrogenase.lipoamide [Enzymatic activity/mass] in Tissue;PDH Lipoamide Tiss-cCnt;;ACTIVE;1.0;2.42 +29116-1;Didanosine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Didanosine [Units/volume] in Serum or Plasma;Didanosine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29117-9;Efavirenz;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Efavirenz [Units/volume] in Serum or Plasma;Efavirenz SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29118-7;Indinavir;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Indinavir [Units/volume] in Serum or Plasma;Indinavir SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29119-5;lamiVUDine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;lamiVUDine [Units/volume] in Serum or Plasma;lamiVUDine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29120-3;Nelfinavir;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nelfinavir [Units/volume] in Serum or Plasma;Nelfinavir SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29121-1;Nevirapine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nevirapine [Units/volume] in Serum or Plasma;Nevirapine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29122-9;Ritonavir;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ritonavir [Units/volume] in Serum or Plasma;Ritonavir SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29123-7;Saquinavir;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Saquinavir [Units/volume] in Serum or Plasma;Saquinavir SerPl-aCnc;;DISCOURAGED;2.00;2.69 +2912-4;Pyruvate kinase;CCnc;Pt;RBC;Qn;;CHEM;1;Pyruvate kinase [Enzymatic activity/volume] in Red Blood Cells;PK RBC-cCnc;;ACTIVE;1.0;2.73 +29124-5;Stavudine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Stavudine [Units/volume] in Serum or Plasma;Stavudine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29125-2;Zalcitabine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zalcitabine [Units/volume] in Serum or Plasma;Zalcitabine SerPl-aCnc;;ACTIVE;2.00;2.69 +29126-0;Zidovudine;ACnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zidovudine [Units/volume] in Serum or Plasma;Zidovudine SerPl-aCnc;;DISCOURAGED;2.00;2.69 +29127-8;Corneal indentation depth;Len;Pt;Eye.right;Qn;Tonometry.Schistz;EYE.TONOMETRY;2;Right eye Corneal indentation depth Schistz tonometry;R eye Corn indent depth Schistz;;ACTIVE;2.00;2.70 +29128-6;Corneal indentation depth;Len;Pt;Eye.left;Qn;Tonometry.Schistz;EYE.TONOMETRY;2;Left eye Corneal indentation depth Schistz tonometry;L eye Corn indent depth Schistz;;ACTIVE;2.00;2.70 +29129-4;Weight on cornea;Mass;Pt;Eye.right;Qn;Tonometry.Schistz;EYE.TONOMETRY;2;Right eye Weight on cornea Schistz tonometry;R eye Weight on cornea Schistz;;ACTIVE;2.00;2.70 +29130-2;Weight on cornea;Mass;Pt;Eye.left;Qn;Tonometry.Schistz;EYE.TONOMETRY;2;Left eye Weight on cornea Schistz tonometry;L eye Weight on cornea Schistz;;ACTIVE;2.00;2.70 +29131-0;Accommodation width.measured 2;Len;Pt;Eye;Qn;;EYE.REFRACTION;2;Eye Accommodation width measured 2;Eye Acc width meas 2;;ACTIVE;2.00;2.70 +2913-2;Pyruvate kinase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyruvate kinase [Enzymatic activity/volume] in Serum or Plasma;PK SerPl-cCnc;;ACTIVE;1.0;2.68 +29132-8;Accommodation width.measured 3;Len;Pt;Eye;Qn;;EYE.REFRACTION;2;Eye Accommodation width measured 3;Eye Acc width meas 3;;ACTIVE;2.00;2.70 +29133-6;Heterophoria;Prid;Pt;Eyes;Nom;Maddox Stabchen test;EYE.HETEROPHORIA;2;Maddox Stabchen test for Heterophoria;Maddox Stabchen test;;ACTIVE;2.00;2.61 +29134-4;Cylinder far;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Cylinder far by Lensmeter;R corr lens Cylinder far by LM;;ACTIVE;2.00;2.71 +29135-1;Glasses type;Txt;Pt;Glasses prescription;Nom;;EYE.GLASSES;2;prescription Glasses type [Text];presc Glasses type [Txt];;ACTIVE;2.00;2.68 +29136-9;Argon laser coagulation Rx;EngRat;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser coagulation treatment;L eye Argon LC;;ACTIVE;2.00;2.70 +29137-7;Argon laser trabeculoplasty Rx;EngRat;Pt;Eye.left;Qn;;EYE.RETINAL_RX;2;Left eye Argon laser trabeculoplasty treatment;L eye Argon LT;;ACTIVE;2.00;2.70 +29138-5;Pressure device type;Txt;Pt;*;Nar;Perimetry;EYE.VISUAL_FIELD;2;Pressure device type [Text] Perimetry;Pressure device type [Txt] Perimetry;;ACTIVE;2.00;2.68 +29139-3;Argon laser coagulation Rx;EngRat;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser coagulation treatment;R eye Argon LC;;ACTIVE;2.00;2.70 +2914-0;Pyruvate oxidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyruvate oxidase [Enzymatic activity/volume] in Serum or Plasma;Pyruvate Oxidase SerPl-cCnc;;ACTIVE;1.0;2.68 +29140-1;Argon laser trabeculoplasty Rx;EngRat;Pt;Eye.right;Qn;;EYE.RETINAL_RX;2;Right eye Argon laser trabeculoplasty treatment;R eye Argon LT;;ACTIVE;2.00;2.70 +29141-9;Metanephrine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Metanephrine [Mass/volume] in Serum or Plasma;Metaneph SerPl-mCnc;;ACTIVE;2.03;2.73 +29142-7;Metanephrines;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Metanephrines [Mass/volume] in Serum or Plasma;MetanephS SerPl-mCnc;;ACTIVE;2.03;2.73 +29143-5;1,4-Dimethylbenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,4-Dimethylbenzene [Mass/volume] in Serum or Plasma;1,4DMB SerPl-mCnc;;ACTIVE;2.03;2.73 +29144-3;1,2-Dimethylbenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,2-Dimethylbenzene [Mass/volume] in Serum or Plasma;1,2DMB SerPl-mCnc;;ACTIVE;2.03;2.73 +29145-0;1,3-Dimethylbenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,3-Dimethylbenzene [Mass/volume] in Serum or Plasma;1,3DMB SerPl-mCnc;;ACTIVE;2.03;2.73 +29146-8;Alpha 1 antitrypsin;MCnc;Pt;Body fld;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/volume] in Body fluid;A1AT Fld-mCnc;;ACTIVE;2.03;2.70 +29147-6;carBAMazepine 10,11-Epoxide.bound;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbamazepine 10,11-Epoxide.bound [Mass/volume] in Serum or Plasma;Carbamazepine EP Bnd SerPl-mCnc;;ACTIVE;2.03;2.73 +29148-4;carBAMazepine.bound;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine.bound [Mass/volume] in Serum or Plasma;carBAMazepine Bnd SerPl-mCnc;;ACTIVE;2.03;2.73 +29149-2;Mefloquine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mefloquine [Mass/volume] in Serum or Plasma;Mefloquine SerPl-mCnc;;ACTIVE;2.03;2.70 +291-5;Kanamycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Kanamycin [Susceptibility] by Minimum inhibitory concentration (MIC);Kanamycin Islt MIC;;ACTIVE;1.0;2.19 +29150-0;Mefloquine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mefloquine [Mass/volume] in Urine;Mefloquine Ur-mCnc;;ACTIVE;2.03;2.70 +29151-8;Somatotropin^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;GH 4h p chal SerPl-mCnc;;ACTIVE;2.03;2.73 +29152-6;Somatotropin^5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --5 hours post XXX challenge;GH 5h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +29153-4;Cancer Ag 15-3;ACnc;Pt;Body fld;Qn;;CHEM;1;Cancer Ag 15-3 [Units/volume] in Body fluid;Cancer Ag15-3 Fld-aCnc;;ACTIVE;2.03;2.70 +29154-2;Choriogonadotropin.beta subunit;ACnc;Pt;Body fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Units/volume] in Body fluid;B-HCG Fld-aCnc;;ACTIVE;2.03;2.73 +29155-9;Follitropin/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Follitropin/Creatinine [Ratio] in 24 hour Urine;FSH/Creat 24h Ur-Rto;;ACTIVE;2.03;2.70 +29156-7;Lutropin;ACnc;24H;Urine;Qn;;CHEM;1;Lutropin [Units/volume] in 24 hour Urine;LH 24h Ur-aCnc;;ACTIVE;2.03;2.70 +2915-7;Renin;CCnc;Pt;Plas;Qn;;CHEM;1;Renin [Enzymatic activity/volume] in Plasma;Renin Plas-cCnc;;ACTIVE;1.0;2.73 +29157-5;Lutropin/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Lutropin/Creatinine [Ratio] in 24 hour Urine;LH/Creat 24h Ur-Rto;;ACTIVE;2.03;2.73 +29158-3;Opiates;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Opiates [Mass/mass] in Meconium;Opiates Mec-mCnt;;ACTIVE;2.03;2.73 +29159-1;Methadone;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Methadone [Mass/mass] in Meconium;Methadone Mec-mCnt;;ACTIVE;2.03;2.73 +29160-9;Benzodiazepines;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/mass] in Meconium;Benzodiaz Mec-mCnt;;ACTIVE;2.03;2.73 +29161-7;Barbiturates;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Barbiturates [Mass/mass] in Meconium;Barbiturates Mec-mCnt;;ACTIVE;2.03;2.73 +29162-5;New &or revised;Type;Pt;Speech therapy treatment plan;Ord;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, New/revised;Deprecated;;DEPRECATED;2.03;2.66 +29163-3;Date.onset or exacerbation;Date;Pt;Primary Dx for speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.03;2.66 +29164-1;Date start;Date;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date start;Deprecated;;DEPRECATED;2.03;2.58 +2916-5;Renin renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Renin renal clearance in 24 hour Urine and Serum or Plasma;Renin Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +29165-8;Clinical discipline;Type;Pt;Speech therapy treatment plan;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Clinical discipline - Speech therapy treatment plan;;;DEPRECATED;2.03;2.40 +29166-6;Diagnosis.primary;Imp;Pt;Speech therapy treatment;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Primary diagnosis (narrative);Deprecated;;DEPRECATED;2.03;2.66 +29167-4;Diagnosis.addressed by plan;Imp;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Diagnosis addressed by plan Set;Deprecated;;DEPRECATED;2.03;2.66 +29168-2;Author of treatment plan;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Author of treatment plan Set;;;ACTIVE;2.03;2.40 +29169-0;Visit frequency;TQ2;Pt;Speech therapy treatment plan;Ord;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.03;2.66 +29170-8;Date range (from_through) described by plan;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Date range (from/through) described by plan Set;;;ACTIVE;2.03;2.40 +29171-6;Continuation status;Type;Pt;Speech therapy treatment plan;Ord;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Continuation status;Deprecated;;DEPRECATED;2.03;2.66 +29172-4;Date attending MD referred patient for;Date;Pt;Speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date attending MD referred patient for Date;Deprecated;;DEPRECATED;2.03;2.66 +2917-3;Renin^supine;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --supine;Renin sup Plas-mCnc;;ACTIVE;1.0;2.68 +29173-2;Date attending MD signed;TmStp;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.03;2.66 +29174-0;Signature of responsible attending physician on file;Arb;Pt;Speech therapy treatment plan;Ord;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.03;2.66 +29175-7;Date rehabilitation professional signed;TmStp;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date rehabilitation professional signed Date and time;Deprecated;;DEPRECATED;2.03;2.66 +29176-5;Signature of responsible rehabilitation professional on file;Arb;Pt;Speech therapy treatment plan;Ord;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.03;2.66 +29177-3;Medication administered;Cmplx;Pt;Speech therapy treatment;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Medication administered Set;;;ACTIVE;2.03;2.40 +29178-1;Prognosis for rehabilitation;Imp;Pt;Speech therapy treatment plan;Ord;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.03;2.66 +29179-9;Estimated date of completion;Date;Pt;Speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Estimated date of completion Date;Deprecated;;DEPRECATED;2.03;2.66 +29180-7;Date of last plan of treatment certification;Date;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date of last plan of treatment certification;Deprecated;;DEPRECATED;2.03;2.66 +2918-1;Renin^upright;CCnc;Pt;Plas;Qn;;CHEM;1;Renin [Enzymatic activity/volume] in Plasma --upright;Renin upr Plas-cCnc;;ACTIVE;1.0;2.42 +29181-5;Past medical history+Level of function;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Past medical history and Level of function (narrative);Deprecated;;DEPRECATED;2.03;2.66 +29182-3;Assessment.initial;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Initial assessment (narrative);Deprecated;;DEPRECATED;2.03;2.50 +29183-1;Plan of treatment;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.03;2.66 +29184-9;Progress note+attainment of goals;Find;Pt;Speech therapy treatment;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.03;2.66 +29185-6;Reason to continue;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.03;2.66 +29186-4;Justification;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.03;2.66 +29187-2;Psychiatric symptoms;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Psychiatric symptoms (narrative);Deprecated;;DEPRECATED;2.03;2.66 +29188-0;Author ID;ID;Pt;Speech therapy treatment plan;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.03;2.66 +29189-8;Author name;Pn;Pt;Speech therapy treatment plan;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Author name;Deprecated;;DEPRECATED;2.03;2.66 +29190-6;Author profession;Prid;Pt;Speech therapy treatment plan;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.03;2.66 +29191-4;Date end;Date;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date end;Deprecated;;DEPRECATED;2.03;2.66 +29192-2;Diagnosis.addressed by plan;ID;Pt;Speech therapy treatment;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.03;2.66 +29193-0;Diagnosis.addressed by plan;Txt;Pt;Speech therapy treatment;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Diagnosis addressed by plan (narrative) Text;Deprecated;;DEPRECATED;2.03;2.66 +29194-8;Diagnosis.primary;Cmplx;Pt;Speech therapy treatment;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Primary diagnosis Set;;;ACTIVE;2.03;2.40 +29195-5;Diagnosis.primary;ID;Pt;Speech therapy treatment;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.03;2.66 +29196-3;Medication name + ID;ID;Pt;Speech therapy treatment;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.03;2.66 +29197-1;Medication route;Prid;Pt;Speech therapy treatment;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.03;2.66 +29198-9;Medication timing + Quantity;TQ2;Pt;Speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication timing + Quantity TQ2;Deprecated;;DEPRECATED;2.03;2.66 +2919-9;Reticulin;MCnc;Pt;Ser;Qn;;CHEM;1;Reticulin [Mass/volume] in Serum;Reticulin Ser-mCnc;;DISCOURAGED;1.0;2.44 +29199-7;Medication XXX;Dosage;Pt;Speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.03;2.66 +29200-3;Signature date;TmStp;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Signature date Date and time;Deprecated;;DEPRECATED;2.03;2.66 +29201-1;Start date;Date;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Start date;Deprecated;;DEPRECATED;2.03;2.66 +29202-9;Visit duration;Time;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Visit duration Time;Deprecated;;DEPRECATED;2.03;2.66 +29203-7;Date range;Cmplx;Enctr;Hospitalization leading to speech therapy treatment;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Date range (from/through) of hospitalization leading to treatment Set;;;ACTIVE;2.03;2.40 +29204-5;End date;Date;Pt;Hospitalization leading to speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, End date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.03;2.66 +29205-2;Start date;Date;Pt;Hospitalization leading to speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Start date of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.03;2.66 +29206-0;Rehabilitation.speech therapy service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Speech therapy service attachment;Rehab.speech therapy service Doc;;ACTIVE;2.03;2.73 +2920-7;Retinal;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Retinal [Mass/volume] in Serum or Plasma;Deprecated Retinal SerPl-mCnc;;DEPRECATED;1.0;2.44 +29207-8;Amiodarone;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Amiodarone [Mass/volume] in Body fluid;Amiodarone Fld-mCnc;;ACTIVE;2.03;2.73 +29208-6;Streptolysin O Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Streptolysin O Ab [Units/volume] in Body fluid;ASO Ab Fld-aCnc;;ACTIVE;2.03;2.70 +29209-4;Benzodiazepines;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Body fluid;Benzodiaz Fld-mCnc;;ACTIVE;2.03;2.70 +29210-2;Bilirubin.non-glucuronidated;MCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.indirect [Mass/volume] in Body fluid;Bilirub Indirect Fld-mCnc;;ACTIVE;2.03;2.73 +29211-0;Caffeine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Caffeine [Mass/volume] in Body fluid;Caffeine Fld-mCnc;;ACTIVE;2.03;2.70 +29212-8;carBAMazepine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;carBAMazepine [Mass/volume] in Body fluid;carBAMazepine Fld-mCnc;;ACTIVE;2.03;2.70 +29213-6;Ceruloplasmin;MCnc;Pt;Body fld;Qn;;CHEM;1;Ceruloplasmin [Mass/volume] in Body fluid;Ceruloplasmin Fld-mCnc;;ACTIVE;2.03;2.70 +29214-4;Chloramphenicol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Chloramphenicol [Mass/volume] in Body fluid;Chloramphen Fld-mCnc;;ACTIVE;2.03;2.70 +2921-5;Retinoate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinoate [Mass/volume] in Serum or Plasma;Retinoate SerPl-mCnc;;ACTIVE;1.0;2.42 +29215-1;Digitoxin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Digitoxin [Mass/volume] in Body fluid;Digitoxin Fld-mCnc;;ACTIVE;2.03;2.70 +29216-9;Digoxin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Digoxin [Mass/volume] in Body fluid;Digoxin Fld-mCnc;;ACTIVE;2.03;2.70 +29217-7;Disopyramide;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Disopyramide [Mass/volume] in Body fluid;Disopyramide Fld-mCnc;;ACTIVE;2.03;2.70 +29218-5;Ethosuximide;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Ethosuximide [Mass/volume] in Body fluid;Ethosuximide Fld-mCnc;;ACTIVE;2.03;2.70 +29219-3;FLUoxetine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;FLUoxetine [Mass/volume] in Body fluid;FLUoxetine Fld-mCnc;;ACTIVE;2.03;2.70 +29220-1;Haptoglobin;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Haptoglobin [Mass/volume] in Body fluid;Haptoglob Fld-mCnc;;ACTIVE;2.03;2.70 +29221-9;Mercury;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Body fluid;Mercury Fld-mCnc;;ACTIVE;2.03;2.70 +29222-7;Mexiletine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Mexiletine [Mass/volume] in Body fluid;Mexiletine Fld-mCnc;;ACTIVE;2.03;2.70 +2922-3;Retinol;MCnc;Pt;Bld;Qn;;CHEM;1;Retinol [Mass/volume] in Blood;Vit A Bld-mCnc;;ACTIVE;1.0;2.40 +29223-5;PHENobarbital;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;PHENobarbital [Mass/volume] in Body fluid;Phenobarb Fld-mCnc;;ACTIVE;2.03;2.70 +29224-3;Phenytoin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Phenytoin [Mass/volume] in Body fluid;Phenytoin Fld-mCnc;;ACTIVE;2.03;2.70 +29225-0;Primidone;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Primidone [Mass/volume] in Body fluid;Primidone Fld-mCnc;;ACTIVE;2.03;2.70 +29226-8;quiNIDine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;quiNIDine [Mass/volume] in Body fluid;quiNIDine Fld-mCnc;;ACTIVE;2.03;2.70 +29227-6;Salicylates;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Salicylates [Mass/volume] in Body fluid;Salicylates Fld-mCnc;;ACTIVE;2.03;2.70 +29228-4;Tricyclic antidepressants;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Tricyclic antidepressants [Mass/volume] in Body fluid;Tricyclics Fld-mCnc;;ACTIVE;2.03;2.70 +29229-2;Valproate;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Valproate [Mass/volume] in Body fluid;Valproate Fld-mCnc;;ACTIVE;2.03;2.70 +292-3;Kanamycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Kanamycin [Susceptibility] by Disk diffusion (KB);Kanamycin Islt KB;;ACTIVE;1.0;2.21 +29230-0;Coxsackievirus B1 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B1 Ab [Titer] in Body fluid;CV B1 Ab Titr Fld;;ACTIVE;2.03;2.70 +2923-1;Retinol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinol [Mass/volume] in Serum or Plasma;Vit A SerPl-mCnc;;ACTIVE;1.0;2.73 +29231-8;Coxsackievirus B2 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B2 Ab [Titer] in Body fluid;CV B2 Ab Titr Fld;;ACTIVE;2.03;2.70 +29232-6;Coxsackievirus B3 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B3 Ab [Titer] in Body fluid;CV B3 Ab Titr Fld;;ACTIVE;2.03;2.70 +29233-4;Coxsackievirus B4 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B4 Ab [Titer] in Body fluid;CV B4 Ab Titr Fld;;ACTIVE;2.03;2.70 +29234-2;Coxsackievirus B5 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B5 Ab [Titer] in Body fluid;CV B5 Ab Titr Fld;;ACTIVE;2.03;2.70 +29235-9;Coxsackievirus B6 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B6 Ab [Titer] in Body fluid;CV B6 Ab Titr Fld;;ACTIVE;2.03;2.70 +29236-7;Herpes simplex virus 2 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Herpes simplex virus 2 Ab [Units/volume] in Body fluid;HSV2 Ab Fld-aCnc;;ACTIVE;2.03;2.69 +29237-5;Herpes simplex virus 1 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Herpes simplex virus 1 Ab [Units/volume] in Body fluid;HSV1 Ab Fld-aCnc;;ACTIVE;2.03;2.69 +29238-3;Insulin;ACnc;Pt;Body fld;Qn;;CHEM;1;Insulin [Units/volume] in Body fluid;Insulin Fld-aCnc;;ACTIVE;2.03;2.73 +29239-1;Triiodothyronine.free;MCnc;Pt;Ser/Plas;Qn;Dialysis;CHEM;1;Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma by Dialysis;T3Free SerPl Dialy-mCnc;;ACTIVE;2.03;2.73 +29240-9;Hyaluronate;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Hyaluronate [Mass/volume] in Body fluid;Hyaluronate Fld-mCnc;;ACTIVE;2.03;2.70 +29241-7;Mumps virus Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Mumps virus IgG Ab [Units/volume] in Body fluid;MuV IgG Fld-aCnc;;ACTIVE;2.03;2.69 +29242-5;Measles virus Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Measles virus IgG Ab [Units/volume] in Body fluid;MeV IgG Fld-aCnc;;ACTIVE;2.03;2.69 +29243-3;Thiodiglycolate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiodiglycolate [Mass/volume] in Urine;Thiodiglycolate Ur-mCnc;;ACTIVE;2.03;2.73 +29244-1;Thiodiglycolate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Thiodiglycolate/Creatinine [Mass Ratio] in Urine;Thiodiglycolate/Creat Ur;;ACTIVE;2.03;2.73 +29245-8;Zinc;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Zinc [Mass/mass] in Nail;Zinc Nail-mCnt;;ACTIVE;2.03;2.73 +29246-6;Lactate;MCnc;Pt;Body fld;Qn;;CHEM;1;Lactate [Mass/volume] in Body fluid;Lactate Fld-mCnc;;ACTIVE;2.03;2.73 +29247-4;Sirolimus;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Sirolimus [Mass/volume] in Blood;Sirolimus Bld-mCnc;;ACTIVE;2.03;2.73 +29248-2;Varicella zoster virus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Blood by NAA with probe detection;VZV DNA Bld Ql NAA+probe;;ACTIVE;2.03;2.73 +2924-9;Riboflavin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Riboflavin [Mass/volume] in Serum or Plasma;Vit B2 SerPl-mCnc;;ACTIVE;1.0;2.73 +29249-0;Varicella zoster virus Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Body fluid;VZV IgG Fld-aCnc;;ACTIVE;2.03;2.69 +29250-8;Brucella sp Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Brucella sp Ab [Titer] in Serum --1st specimen;Brucella Ab sp1 Titr Ser;;ACTIVE;2.03;2.70 +29251-6;Brucella sp Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Brucella sp Ab [Titer] in Serum --2nd specimen;Brucella Ab sp2 Titr Ser;;ACTIVE;2.03;2.70 +29252-4;Multisection^WO contrast;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest WO contrast;CT Chest WO contr;;ACTIVE;2.03;2.73 +29253-2;Alpha-1-Fetoprotein^^adjusted;MoM;Pt;Amnio fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] adjusted in Amniotic fluid;AFP adj MoM Amn;;ACTIVE;2.03;2.73 +29254-0;Linezolid;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Linezolid [Susceptibility] by Minimum inhibitory concentration (MIC);Linezolid Islt MIC;;ACTIVE;2.03;2.73 +29255-7;Linezolid;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Linezolid [Susceptibility] by Disk diffusion (KB);Linezolid Islt KB;;ACTIVE;2.03;2.73 +2925-6;Ribonuclease;CCnc;Pt;Ser;Qn;;CHEM;1;Ribonuclease [Enzymatic activity/volume] in Serum;RNase Ser-cCnc;;ACTIVE;1.0;2.68 +29256-5;Fat.microscopic observation;Prid;Pt;Urine sed;Nom;Sudan IV stain;UA;1;Fat.microscopic observation [Identifier] in Urine sediment by Sudan IV stain;Fat UrnS Sudan IV Stn;;ACTIVE;2.03;2.73 +29257-3;Mycoplasma pneumoniae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection;M pneumo DNA Spec Ql NAA+probe;;ACTIVE;2.03;2.73 +29258-1;Linezolid;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Linezolid [Susceptibility];Linezolid Susc Islt;;ACTIVE;2.03;2.73 +29259-9;Monocytes.abnormal/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Monocytes Abnormal/100 leukocytes in Blood by Manual count;Abn Monocytes/leuk NFr Bld Manual;;ACTIVE;2.03;2.73 +29260-7;Monocytes.abnormal;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Monocytes Abnormal [#/volume] in Blood by Manual count;Abn Monocytes # Bld Manual;;ACTIVE;2.03;2.40 +29261-5;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Blood by Manual count;Lymph Abn/leuk NFr Bld Manual;;ACTIVE;2.03;2.73 +29262-3;Lymphocytes.abnormal;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Abnormal lymphocytes [#/volume] in Blood by Manual count;Lymph Abn # Bld Manual;;ACTIVE;2.03;2.73 +29263-1;Fibrin degradation products;PrThr;Pt;Bld;Ord;Aggl;COAG;1;Fibrin degradation products [Presence] in Blood by Agglutination;FDP Bld Ql Aggl;;ACTIVE;2.03;2.73 +2926-4;Ribose;MCnc;Pt;Ser;Qn;;CHEM;1;Ribose [Mass/volume] in Serum;Ribose Ser-mCnc;;ACTIVE;1.0;2.42 +29264-9;Collection time;TmStp;Pt;Bld;Qn;;SPEC;1;Collection time of Blood;Collect Tme Bld;;ACTIVE;2.03;2.73 +29265-6;Calcium^^corrected for albumin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Moles/volume] corrected for albumin in Serum or Plasma;Calcium Album cor SerPl-sCnc;;ACTIVE;2.03;2.73 +29266-4;Coproporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Coproporphyrin [Moles/mass] in Stool;Copro Stl-sCnt;;ACTIVE;2.03;2.73 +29267-2;Protoporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Protoporphyrin [Moles/mass] in Stool;Protopor Stl-sCnt;;ACTIVE;2.03;2.73 +29268-0;Contact lens measurements;Find;Pt;^Patient;Multi;;ATTACH.CLINRPT;3;Contact lens measurements;;;ACTIVE;2.03;2.03 +29269-8;Eye glasses measurements;Find;Pt;^Patient;Multi;;ATTACH.CLINRPT;3;Eye glasses measurements;;;ACTIVE;2.03;2.03 +29270-6;Retinal treatments;Find;Pt;^Patient;Multi;;ATTACH.CLINRPT;3;Retinal treatments;;;ACTIVE;2.03;2.03 +29271-4;Eye physical examination;Find;Pt;^Patient;Multi;;ATTACH.CLINRPT;3;Eye physical examination;;;ACTIVE;2.03;2.03 +2927-2;Ribulose;MCnc;Pt;Ser;Qn;;CHEM;1;Ribulose [Mass/volume] in Serum;Ribulose Ser-mCnc;;DISCOURAGED;1.0;2.44 +29272-2;Eye ultrasound study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Eye ultrasound study;Eye ultrasound study;;ACTIVE;2.03;2.67 +29273-0;Clinical measurements;Cmplx;-;^Patient;Set;;ATTACH.CLINRPT;3;Clinical measurements Set;;;ACTIVE;2.03;2.40 +29274-8;Vital signs measurements;Find;Pt;^Patient;Multi;;ATTACH.CLINRPT;3;Vital signs measurements;;;ACTIVE;2.03;2.34 +29275-5;Body measurements;Find;Pt;^Patient;Multi;;ATTACH.CLINRPT;3;Body measurements;;;ACTIVE;2.03;2.27 +29276-3;Calcium;PrThr;Pt;Urine;Ord;;CHEM;1;Calcium [Presence] in Urine;Calcium Ur Ql;;ACTIVE;2.03;2.73 +29277-1;Carbon disulfide;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Carbon disulfide [Presence] in Blood;Carbon diS Bld Ql;;ACTIVE;2.03;2.56 +29278-9;Codeine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Codeine [Presence] in Meconium;Codeine Mec Ql;;ACTIVE;2.03;2.56 +29279-7;Ethylene glycol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethylene glycol [Presence] in Urine;Ethylene Glycol Ur Ql;;ACTIVE;2.03;2.56 +2928-0;Beta fructofuranosidase;CCnc;Pt;RBC;Qn;;CHEM;1;Deprecated Beta fructofuranosidase [Enzymatic activity/volume] in Red Blood Cells;Deprecated B-Fructofuranosidase RBC-cCnc;;DEPRECATED;1.0;2.36 +29280-5;Fibrin D-dimer;PrThr;Pt;PPP;Ord;LA;COAG;1;Fibrin D-dimer [Presence] in Platelet poor plasma by Latex agglutination;D Dimer PPP Ql LA;;ACTIVE;2.03;2.73 +29281-3;Glutathione reductase;PrThr;Pt;RBC;Ord;;CHEM;1;Glutathione reductase [Presence] in Red Blood Cells;GR RBC Ql;;ACTIVE;2.03;2.56 +29282-1;Glutethimide;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Glutethimide [Presence] in Gastric fluid;Glutethimide Gast Ql;;ACTIVE;2.03;2.56 +29283-9;Hydrogen sulfide;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Hydrogen sulfide [Presence] in Blood;Hydrogen Sulfide Bld Ql;;ACTIVE;2.03;2.56 +29284-7;Leucine;PrThr;Pt;Bld;Ord;;CHEM;1;Leucine [Presence] in Blood;Leucine Bld Ql;;ACTIVE;2.03;2.56 +29285-4;Methadone;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methadone [Presence] in Gastric fluid;Methadone Gast Ql;;ACTIVE;2.03;2.56 +29286-2;Methamphetamine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Methamphetamine [Presence] in Meconium;Methamphet Mec Ql;;ACTIVE;2.03;2.56 +29287-0;Morphine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Morphine [Presence] in Meconium;Morphine Mec Ql;;ACTIVE;2.03;2.56 +29288-8;Orphenadrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Orphenadrine [Presence] in Urine;Orphenadrine Ur Ql;;ACTIVE;2.03;2.73 +29289-6;Phenylethylmalonamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenylethylmalonamide [Presence] in Urine;PEMA Ur Ql;;ACTIVE;2.03;2.73 +29290-4;Carbon disulfide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Carbon disulfide [Mass/volume] in Blood;Carbon diS Bld-mCnc;;ACTIVE;2.03;2.42 +29291-2;Glutethimide;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Glutethimide [Mass/volume] in Gastric fluid;Glutethimide Gast-mCnc;;ACTIVE;2.03;2.42 +29292-0;Hydrogen sulfide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hydrogen sulfide [Mass/volume] in Blood;Hydrogen Sulfide Bld-mCnc;;ACTIVE;2.03;2.42 +29293-8;Leucine;MCnc;Pt;Bld;Qn;;CHEM;1;Leucine [Mass/volume] in Blood;Leucine Bld-mCnc;;ACTIVE;2.03;2.42 +29294-6;Methadone;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Gastric fluid;Methadone Gast-mCnc;;ACTIVE;2.03;2.34 +29295-3;Phenylethylmalonamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenylethylmalonamide [Mass/volume] in Urine;PEMA Ur-mCnc;;ACTIVE;2.03;2.42 +29296-1;Dimethylbenzene;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Dimethylbenzene [Presence] in Blood;DMB Bld Ql;;ACTIVE;2.03;2.56 +29297-9;Color;Type;Pt;XXX;Nom;Visual;H&P.PX;2;Deprecated Color of Unspecified specimen;DeprecatedColor;;DEPRECATED;2.03;2.36 +2929-8;Saccharides;PrThr;Pt;Urine;Ord;;CHEM;1;Saccharides [Presence] in Urine;Saccharides Ur Ql;;ACTIVE;1.0;2.56 +29298-7;Reason for visit;Find;Pt;^Patient;Nom;;H&P.HX;2;Reason for visit;Reason for visit;;ACTIVE;2.03;2.73 +29299-5;Reason for visit;Find;Pt;^Patient;Nar;;H&P.HX;2;Reason for visit Narrative;Reason for visit;;ACTIVE;2.03;2.63 +29300-1;Procedure;Type;Pt;^Patient;Nom;;H&P.PX;2;Procedure type;Procedure type;;ACTIVE;2.03;2.73 +29301-9;Physical findings;Find;Pt;Endocrine system;Nom;Observed;H&P.PX;2;Physical findings of Endocrine system;Phys find Endocrine;;ACTIVE;2.03;2.27 +29302-7;Physical findings;Find;Pt;Integumentary system;Nar;Observed;H&P.PX;2;Physical findings of Integumentary system Narrative;Phys find Integumentary;;ACTIVE;2.03;2.40 +29303-5;Medication administered;Type;Pt;^Patient;Nom;;H&P.PX;2;Medication administered;Medication administered;;ACTIVE;2.03;2.29 +29304-3;Medication dispensed;Type;Pt;^Patient;Nom;;H&P.PX;2;Medication dispensed;Medication dispensed;;ACTIVE;2.03;2.29 +29305-0;Medication prescribed;Type;Pt;^Patient;Nom;;H&P.PX;2;Medication prescribed;Medication prescribed;;ACTIVE;2.03;2.73 +2930-6;Sarcosine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Sarcosine [Presence] in Serum or Plasma;Sarcosine SerPl Ql;;ACTIVE;1.0;2.56 +29306-8;Surgery procedure;Type;Pt;^Patient;Nom;;H&P.PX;2;Surgery procedure;Surgery procedure;;ACTIVE;2.03;2.29 +29307-6;Physical findings;Find;Pt;Endocrine system;Nar;Observed;H&P.PX;2;Physical findings of Endocrine system Narrative;Phys find Endocrine;;ACTIVE;2.03;2.40 +29308-4;Diagnosis;Imp;Pt;^Patient;Nom;;H&P.PX;2;Diagnosis;Dx;;ACTIVE;2.03;2.73 +29309-2;Physical findings;Find;Pt;Integumentary system;Nom;Observed;H&P.PX;2;Physical findings of Integumentary system;Phys find Integumentary;;ACTIVE;2.03;2.27 +293-1;Kanamycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Kanamycin [Susceptibility] by Serum bactericidal titer;Kanamycin Titr SBT;;ACTIVE;1.0;2.32 +29310-0;Treponema pallidum;PrThr;Pt;XXX;Ord;IF;MICRO;1;Treponema pallidum [Presence] in Specimen by Immunofluorescence;T pallidum Spec Ql IF;;ACTIVE;2.03;2.73 +29311-8;Neisseria gonorrhoeae Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Neisseria gonorrhoeae Ag [Presence] in Specimen by Immunofluorescence;N gonorrhoea Ag Spec Ql IF;;DISCOURAGED;2.03;2.69 +2931-4;Sarcosine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sarcosine [Mass/volume] in Serum or Plasma;Sarcosine SerPl-mCnc;;DISCOURAGED;1.0;2.73 +29314-2;Adenovirus Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Adenovirus Ab [Titer] in Body fluid by Complement fixation;HAdV Ab Titr Fld CF;;ACTIVE;2.03;2.30 +29315-9;Isoniazid 0.4 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid 0.4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid 0.4 ug/mL Islt SlowMyco;;ACTIVE;2.03;2.73 +29316-7;Thyrotropin^30M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --30 minutes post XXX challenge;TSH 30M p chal SerPl-aCnc;;ACTIVE;2.03;2.73 +29317-5;Thyrotropin^1H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1 hour post XXX challenge;TSH 1h p chal SerPl-aCnc;;ACTIVE;2.03;2.70 +29318-3;Streptococcus pneumoniae group B Ag;ACnc;Pt;Ser;Ord;LA;MICRO;1;Deprecated Streptococcus pneumoniae group B Ag in serum by latex agglutionation;Deprecated S pneumB Ag Ser Ql LA;;DEPRECATED;2.03;2.40 +29319-1;Streptococcus pneumoniae group B Ag;ACnc;Pt;CSF;Ord;LA;MICRO;1;Deprecated Streptococcus pneumoniae group B Ag by latex agglutionation;Deprecated S pneumB Ag CSF Ql LA;;DEPRECATED;2.03;2.40 +29320-9;Streptococcus pneumoniae group B Ag;ACnc;Pt;Urine;Ord;LA;MICRO;1;Deprecated Streptococcus pneumoniae group B Ag in urine by latex agglutination;Deprecated S pneumB Ag Ur Ql LA;;DEPRECATED;2.03;2.40 +29321-7;Rickettsia typhi Ab.IgG;PrThr;Pt;Body fld;Ord;;MICRO;1;Rickettsia typhi IgG Ab [Presence] in Body fluid;R typhi IgG Fld Ql;;ACTIVE;2.03;2.56 +2932-2;Sarcosine;MCnc;Pt;Urine;Qn;;CHEM;1;Sarcosine [Mass/volume] in Urine;Sarcosine Ur-mCnc;;DISCOURAGED;1.0;2.73 +29322-5;Rickettsia typhi Ab.IgM;PrThr;Pt;Body fld;Ord;;MICRO;1;Rickettsia typhi IgM Ab [Presence] in Body fluid;R typhi IgM Fld Ql;;ACTIVE;2.03;2.56 +29323-3;Cocaine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Cocaine [Mass/volume] in Gastric fluid;Cocaine Gast-mCnc;;ACTIVE;2.03;2.70 +29324-1;Cocaethylene;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Cocaethylene [Mass/volume] in Gastric fluid;Cocaethylene Gast-mCnc;;ACTIVE;2.03;2.70 +29325-8;Cocaethylene;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Cocaethylene [Mass/volume] in Vitreous fluid;Cocaethylene Vitf-mCnc;;ACTIVE;2.03;2.70 +29326-6;Carboxy tetrahydrocannabinol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Gastric fluid;CarboxyTHC Gast-mCnc;;ACTIVE;2.03;2.70 +29327-4;HIV 1 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;HIV 1 Ab [Presence] in Body fluid;HIV1 Ab Fld Ql;;ACTIVE;2.03;2.56 +29328-2;Xylose^2.5H post dose xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --2.5 hours post dose xylose PO;Xylose 2.5h p Xyl PO Bld-mCnc;;ACTIVE;2.03;2.70 +29329-0;Glucose^3.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3.5 hours post XXX challenge;Glucose 3.5h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +2933-0;Secretin;MCnc;Pt;Plas;Qn;;CHEM;1;Secretin [Mass/volume] in Plasma;Secretin Plas-mCnc;;ACTIVE;1.0;2.73 +29330-8;Glucose^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;Glucose 4h p chal SerPl-mCnc;;ACTIVE;2.03;2.73 +29331-6;Glucose^5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post XXX challenge;Glucose 5h p chal SerPl-mCnc;;ACTIVE;2.03;2.73 +29332-4;Glucose^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;Glucose 2.5h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +29333-2;Saccharomonospora viridis Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Saccharomonospora viridis Ab [Presence] in Serum;Deprecated S viridis Ab Ser Ql;;DEPRECATED;2.03;2.36 +29334-0;Aspergillus fumigatus 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus 2 Ab [Presence] in Serum;A fumigatus2 Ab Ser Ql;;ACTIVE;2.03;2.73 +29335-7;Mexiletine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mexiletine [Mass/volume] in Urine;Mexiletine Ur-mCnc;;ACTIVE;2.03;2.70 +29336-5;Mexiletine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Mexiletine [Mass/volume] in Gastric fluid;Mexiletine Gast-mCnc;;ACTIVE;2.03;2.70 +29337-3;Morphine.free;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Morphine Free [Mass/volume] in Gastric fluid;Morphine Free Gast-mCnc;;ACTIVE;2.03;2.70 +29338-1;Flecainide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Flecainide [Mass/volume] in Urine;Flecainide Ur-mCnc;;ACTIVE;2.03;2.70 +29339-9;Flecainide;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Flecainide [Mass/volume] in Gastric fluid;Flecainide Gast-mCnc;;ACTIVE;2.03;2.70 +29340-7;Cells.CD71;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD71 cells [#/volume] in Blood;CD71 Cells # Bld;;ACTIVE;2.03;2.70 +29341-5;Cells.CD11b;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD11b cells [#/volume] in Blood;CD11b Cells # Bld;;ACTIVE;2.03;2.70 +29342-3;Methylmalonate;MRat;24H;Urine;Qn;;CHEM;1;Methylmalonate [Mass/time] in 24 hour Urine;Methylmalonate 24h Ur-mRate;;ACTIVE;2.03;2.70 +29343-1;Rubella virus Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Rubella virus IgG Ab [Units/volume] in Body fluid;RUBV IgG Fld-aCnc;;ACTIVE;2.03;2.70 +29344-9;LORazepam;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Gastric fluid;LORazepam Gast-mCnc;;ACTIVE;2.03;2.70 +29345-6;6-Monoacetylmorphine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/mass] in Meconium;6MAM Mec-mCnt;;ACTIVE;2.03;2.70 +29346-4;Chloramphenicol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chloramphenicol [Mass/volume] in Urine;Chloramphen Ur-mCnc;;ACTIVE;2.03;2.70 +29347-2;Chloramphenicol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Chloramphenicol [Mass/volume] in Gastric fluid;Chloramphen Gast-mCnc;;ACTIVE;2.03;2.70 +2934-8;Serine;MCnc;Pt;CSF;Qn;;CHEM;1;Serine [Mass/volume] in Cerebral spinal fluid;Serine CSF-mCnc;;ACTIVE;1.0;2.42 +29348-0;ALPRAZolam;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Gastric fluid;Alpraz Gast-mCnc;;ACTIVE;2.03;2.70 +29349-8;Potassium^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Potassium [Moles/volume] in Serum or Plasma --post dialysis;Potassium p dialysis SerPl-sCnc;;ACTIVE;2.03;2.73 +29350-6;Cells.CD42;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD42 cells [#/volume] in Blood;CD42 Cells # Bld;;ACTIVE;2.03;2.70 +29351-4;Rheumatoid factor;PrThr;Pt;CSF;Ord;;SERO;1;Rheumatoid factor [Presence] in Cerebral spinal fluid;Rheumatoid fact CSF Ql;;ACTIVE;2.03;2.56 +29352-2;Salicylates;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Salicylates [Mass/volume] in Gastric fluid;Salicylates Gast-mCnc;;ACTIVE;2.03;2.70 +29353-0;17-Ketosteroids.total neutral;MRat;12H;Urine;Qn;;CHEM;1;17-Ketosteroids.total neutral [Mass/time] in 12 hour Urine;17KS Neut 12h Ur-mRate;;ACTIVE;2.03;2.70 +29354-8;Reovirus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Reovirus Ab [Titer] in Cerebral spinal fluid;Reovirus Ab Titr CSF;;ACTIVE;2.03;2.30 +2935-5;Serine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Serine [Presence] in Serum or Plasma;Serine SerPl Ql;;ACTIVE;1.0;2.56 +29355-5;Reovirus Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Reovirus Ab [Titer] in Body fluid by Complement fixation;Reovirus Ab Titr Fld CF;;ACTIVE;2.03;2.30 +29356-3;fentaNYL;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;fentaNYL [Presence] in Serum or Plasma;fentaNYL SerPl Ql;;ACTIVE;2.03;2.73 +29357-1;Cyanide;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Cyanide [Mass/volume] in Gastric fluid;Cyanide Gast-mCnc;;ACTIVE;2.03;2.70 +29358-9;Cortisol^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre XXX challenge;Cortis pre chal SerPl-mCnc;;ACTIVE;2.03;2.73 +29359-7;Parainfluenza virus 2 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Body fluid;HPIV2 Ab Titr Fld;;ACTIVE;2.03;2.30 +29360-5;Streptococcus pneumoniae group B Ag;ACnc;Pt;Urine;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae group B Ag in urine;Deprecated S pneumB Ag Ur Ql;;DEPRECATED;2.03;2.40 +29361-3;Streptococcus pneumoniae group B Ag;ACnc;Pt;CSF;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae group B Ag in CSF;Deprecated S pneumB Ag CSF Ql;;DEPRECATED;2.03;2.40 +29362-1;Streptococcus pneumoniae group B Ag;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Streptococcus pneumoniae group B Ag;Deprecated S pneumB Ag Ser Ql;;DEPRECATED;2.03;2.36 +2936-3;Serine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Serine [Mass/volume] in Serum or Plasma;Serine SerPl-mCnc;;ACTIVE;1.0;2.73 +29363-9;Cortisol^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Cortis 1.5h p chal SerPl-mCnc;;ACTIVE;2.03;2.73 +29364-7;Magnesium;MCnc;Pt;CSF;Qn;;CHEM;1;Magnesium [Mass/volume] in Cerebral spinal fluid;Magnesium CSF-mCnc;;ACTIVE;2.03;2.70 +29365-4;Magnesium;MCnc;Pt;Body fld;Qn;;CHEM;1;Magnesium [Mass/volume] in Body fluid;Magnesium Fld-mCnc;;ACTIVE;2.03;2.73 +29366-2;Parainfluenza virus 1 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Body fluid by Complement fixation;HPIV1 Ab Titr Fld CF;;ACTIVE;2.03;2.30 +29367-0;Parainfluenza virus 2 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Body fluid by Complement fixation;HPIV2 Ab Titr Fld CF;;ACTIVE;2.03;2.30 +29368-8;Parainfluenza virus 3 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Body fluid by Complement fixation;HPIV3 Ab Titr Fld CF;;ACTIVE;2.03;2.30 +29369-6;N-acetylprocainamide/Procainamide;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;N-acetylprocainamide/Procainamide [Mass Ratio] in Serum or Plasma;NAPA/PA SerPl;;ACTIVE;2.03;2.42 +29370-4;cloZAPine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloZAPine [Mass/volume] in Serum or Plasma --trough;cloZAPine Trough SerPl-mCnc;;ACTIVE;2.03;2.70 +2937-1;Serine;MCnc;Pt;Urine;Qn;;CHEM;1;Serine [Mass/volume] in Urine;Serine Ur-mCnc;;ACTIVE;1.0;2.73 +29371-2;cloZAPine^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloZAPine [Mass/volume] in Serum or Plasma --peak;cloZAPine Peak SerPl-mCnc;;ACTIVE;2.03;2.70 +29372-0;Codeine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Codeine [Mass/volume] in Gastric fluid;Codeine Gast-mCnc;;ACTIVE;2.03;2.70 +29373-8;Ethchlorvynol;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Ethchlorvynol [Presence] in Gastric fluid;Ethchlorvynol Gast Ql;;ACTIVE;2.03;2.56 +29374-6;Ribonucleoprotein extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum;ENA RNP Ab Ser-aCnc;;ACTIVE;2.03;2.73 +29375-3;Methanol;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Methanol [Mass/volume] in Unknown substance;Methanol Usub-mCnc;;ACTIVE;2.03;2.70 +29376-1;Narcotics;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Narcotics and opioids [Identifier] in Blood;Narcotics Bld;;ACTIVE;2.03;2.15 +29377-9;Narcotics;Prid;Pt;Gast fld;Nom;;DRUG/TOX;1;Narcotics and opioids [Identifier] in Gastric fluid;Narcotics Gast;;ACTIVE;2.03;2.19 +29378-7;Insulin^4H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --4 hours post XXX challenge;Insulin 4h p chal SerPl-aCnc;;ACTIVE;2.03;2.73 +29379-5;Insulin^6H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --6 hours post XXX challenge;Insulin 6h p chal SerPl-aCnc;;ACTIVE;2.03;2.70 +29380-3;chlordiazePOXIDE;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Gastric fluid;Chlordiazep Gast-mCnc;;ACTIVE;2.03;2.70 +29381-1;Meprobamate;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Meprobamate [Mass/volume] in Gastric fluid;Meprobamate Gast-mCnc;;ACTIVE;2.03;2.70 +29382-9;Warfarin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Warfarin [Mass/volume] in Urine;Warfarin Ur-mCnc;;ACTIVE;2.03;2.73 +29383-7;Warfarin;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Warfarin [Mass/volume] in Gastric fluid;Warfarin Gast-mCnc;;ACTIVE;2.03;2.70 +29384-5;diazePAM;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Gastric fluid;diazePAM Gast-mCnc;;ACTIVE;2.03;2.70 +29385-2;Nordiazepam;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Gastric fluid;Nordiazepam Gast-mCnc;;ACTIVE;2.03;2.70 +29386-0;chlorproMAZINE;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;chlorproMAZINE [Mass/volume] in Gastric fluid;chlorproMAZINE Gast-mCnc;;ACTIVE;2.03;2.70 +29387-8;Norpropoxyphene;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/volume] in Gastric fluid;Norpropoxyph Gast-mCnc;;ACTIVE;2.03;2.70 +29388-6;Methaqualone;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methaqualone [Mass/volume] in Gastric fluid;Methaqualone Gast-mCnc;;ACTIVE;2.03;2.70 +2938-9;Serine;MRat;24H;Urine;Qn;;CHEM;1;Serine [Mass/time] in 24 hour Urine;Serine 24h Ur-mRate;;ACTIVE;1.0;2.73 +29389-4;Acetaminophen;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Acetaminophen [Presence] in Gastric fluid;APAP Gast Ql;;ACTIVE;2.03;2.56 +29390-2;Parathyrin.mid molecule;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.mid molecule [Moles/volume] in Serum or Plasma;PTH-M SerPl-sCnc;;ACTIVE;2.03;2.70 +29391-0;Gastrin^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Gastrin 2h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +29392-8;Gastrin^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Gastrin 1h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +29393-6;Gastrin^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Gastrin 3h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +29394-4;Gastrin^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;Gastrin 2.5h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +29395-1;Gastrin^post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --fasting;Gastrin p fast SerPl-mCnc;;ACTIVE;2.03;2.70 +29396-9;Gastrin^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Gastrin 1.5h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +2939-7;Serotonin;MCnc;Pt;Bld;Qn;;CHEM;1;Serotonin [Mass/volume] in Blood;Serotonin Bld-mCnc;;ACTIVE;1.0;2.73 +29397-7;Gastrin^30M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --30 minutes pre XXX challenge;Gastrin 30M pre chal SerPl-mCnc;;ACTIVE;2.03;2.70 +29398-5;Gastrin^1M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --1 minute pre XXX challenge;Gastrin 1M pre chal SerPl-mCnc;;ACTIVE;2.03;2.73 +29399-3;clonazePAM;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;clonazePAM [Mass/volume] in Gastric fluid;clonazePAM Gast-mCnc;;ACTIVE;2.03;2.70 +29400-9;Meperidine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Meperidine [Mass/volume] in Gastric fluid;Meperidine Gast-mCnc;;ACTIVE;2.03;2.70 +29401-7;Disopyramide;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Disopyramide [Mass/volume] in Gastric fluid;Disopyramide Gast-mCnc;;ACTIVE;2.03;2.70 +29402-5;Trimipramine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Trimipramine [Mass/volume] in Gastric fluid;Trimipramine Gast-mCnc;;ACTIVE;2.03;2.70 +29403-3;Thiothixene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiothixene [Mass/volume] in Urine;Thiothixene Ur-mCnc;;ACTIVE;2.03;2.70 +29404-1;Thiothixene;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Thiothixene [Mass/volume] in Gastric fluid;Thiothixene Gast-mCnc;;ACTIVE;2.03;2.70 +2940-5;Serotonin;MCnc;Pt;Plas;Qn;;CHEM;1;Serotonin [Mass/volume] in Plasma;Serotonin Plas-mCnc;;ACTIVE;1.0;2.73 +29405-8;Maprotiline;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Maprotiline [Mass/volume] in Gastric fluid;Maprotiline Gast-mCnc;;ACTIVE;2.03;2.70 +29406-6;Amitriptyline;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Gastric fluid;Amitrip Gast-mCnc;;ACTIVE;2.03;2.70 +29407-4;Nortriptyline;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Nortriptyline [Mass/volume] in Gastric fluid;Nortrip Gast-mCnc;;ACTIVE;2.03;2.70 +29408-2;Imipramine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Imipramine [Mass/volume] in Gastric fluid;Imipramine Gast-mCnc;;ACTIVE;2.03;2.70 +29409-0;Desipramine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Desipramine [Mass/volume] in Gastric fluid;Desipramine Gast-mCnc;;ACTIVE;2.03;2.70 +29410-8;Doxepin;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Doxepin [Mass/volume] in Gastric fluid;Doxepin Gast-mCnc;;ACTIVE;2.03;2.70 +29411-6;Nordoxepin;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Nordoxepin [Mass/volume] in Gastric fluid;Nordoxepin Gast-mCnc;;ACTIVE;2.03;2.70 +29412-4;Glucose^6H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 hours post XXX challenge;Glucose 6h p chal SerPl-mCnc;;ACTIVE;2.03;2.70 +2941-3;Serotonin;MCnc;Pt;Platelets;Qn;;CHEM;1;Serotonin [Mass/volume] in Platelets;Serotonin Plts-mCnc;;ACTIVE;1.0;2.73 +29413-2;Reovirus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Reovirus Ab [Titer] in Cerebral spinal fluid by Complement fixation;Reovirus Ab Titr CSF CF;;ACTIVE;2.03;2.30 +29414-0;Parainfluenza virus 3 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Body fluid;HPIV3 Ab Titr Fld;;ACTIVE;2.03;2.30 +29415-7;Reovirus Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Reovirus Ab [Titer] in Body fluid;Reovirus Ab Titr Fld;;ACTIVE;2.03;2.30 +29416-5;Adenovirus Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Adenovirus Ab [Titer] in Body fluid;HAdV Ab Titr Fld;;ACTIVE;2.03;2.30 +29417-3;Parainfluenza virus 1 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Body fluid;HPIV1 Ab Titr Fld;;ACTIVE;2.03;2.30 +29418-1;Blood flow velocity.diastole.max;Vel;Pt;Pulmonary vein.right upper;Qn;US.doppler;CARD.US;2;Pulmonary vein - right upper Maximum blood flow velocity during diastole by US.doppler;PV-RU Vmax dias DOP;;ACTIVE;2.03;2.67 +29419-9;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.right upper;Qn;US.doppler;CARD.US;2;Pulmonary vein - right upper Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler;PV-RU Vmax sys/dias DOP;;ACTIVE;2.03;2.69 +29420-7;Blood flow velocity.systole.max;Vel;Pt;Pulmonary vein.right lower;Qn;US.doppler;CARD.US;2;Pulmonary vein - right lower Maximum blood flow velocity during systole by US.doppler;PV-RL Vmax sys DOP;;ACTIVE;2.03;2.67 +2942-1;Sex hormone binding globulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sex hormone binding globulin [Mass/volume] in Serum or Plasma;SHBG SerPl-mCnc;;ACTIVE;1.0;2.73 +29421-5;Blood flow velocity.diastole.max;Vel;Pt;Pulmonary vein.right lower;Qn;US.doppler;CARD.US;2;Pulmonary vein - right lower Maximum blood flow velocity during diastole by US.doppler;PV-RL Vmax dias DOP;;ACTIVE;2.03;2.67 +29422-3;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.right lower;Qn;US.doppler;CARD.US;2;Pulmonary vein - right lower Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler;PV-RL Vmax sys/dias DOP;;ACTIVE;2.03;2.69 +29423-1;Blood flow velocity.systole.max;Vel;Pt;Pulmonary vein.left upper;Qn;US.doppler;CARD.US;2;Pulmonary vein - left upper Maximum blood flow velocity during systole by US.doppler;PV-LU Vmax sys DOP;;ACTIVE;2.03;2.67 +29424-9;Blood flow velocity.diastole.max;Vel;Pt;Pulmonary vein.left upper;Qn;US.doppler;CARD.US;2;Pulmonary vein - left upper Maximum blood flow velocity during diastole by US.doppler;PV-LU Vmax dias DOP;;ACTIVE;2.03;2.67 +29425-6;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.left upper;Qn;US.doppler;CARD.US;2;Pulmonary vein - left upper Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler;PV-LU Vmax sys/dias DOP;;ACTIVE;2.03;2.69 +29426-4;Blood flow velocity.systole.max;Vel;Pt;Pulmonary vein.left lower;Qn;US.doppler;CARD.US;2;Pulmonary vein - left lower Maximum blood flow velocity during systole by US.doppler;PV-LL Vmax sys DOP;;ACTIVE;2.03;2.67 +29427-2;Blood flow velocity.diastole.max;Vel;Pt;Pulmonary vein.left lower;Qn;US.doppler;CARD.US;2;Pulmonary vein - left lower Maximum blood flow velocity during diastole by US.doppler;PV-LL Vmax dias DOP;;ACTIVE;2.03;2.67 +29428-0;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.left lower;Qn;US.doppler;CARD.US;2;Pulmonary vein - left lower Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler;PV-LL Vmax sys/dias DOP;;ACTIVE;2.03;2.69 +29429-8;Diameter^inspiration;Len;Pt;Vena cava.inferior;Qn;US;CARD.US;2;Inferior vena cava Diameter by US --inspiration;IVC Diam insp US;;ACTIVE;2.03;2.48 +29430-6;Thickness.diastole;Len;Pt;Heart.interventricular septum;Qn;US.2D;CARD.US;2;Interventricular septum Thickness during diastole by US 2D;IVS Thickness dia 2D US;;ACTIVE;2.03;2.67 +29431-4;Thickness.diastole;Len;Pt;Heart.interventricular septum;Qn;US.M-mode;CARD.US;2;Interventricular septum Thickness during diastole by US.M-mode;IVS Thickness dia M-mode;;ACTIVE;2.03;2.67 +29432-2;Thickness.systole;Len;Pt;Heart.interventricular septum;Qn;US.2D;CARD.US;2;Interventricular septum Thickness during systole by US 2D;IVS Thickness sys 2D US;;ACTIVE;2.03;2.67 +29433-0;Thickness.systole;Len;Pt;Heart.interventricular septum;Qn;US.M-mode;CARD.US;2;Interventricular septum Thickness during systole by US.M-mode;IVS Thickness sys M-mode;;ACTIVE;2.03;2.67 +29434-8;Fractional shortening.minor axis;LenFr;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Fractional shortening minor axis by US 2D;LV FS 2D US;;ACTIVE;2.03;2.48 +29435-5;Fractional shortening.minor axis;LenFr;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US;2;Left ventricular Fractional shortening minor axis by US.M-mode;LV FS M-mode;;ACTIVE;2.03;2.54 +29436-3;Internal diameter.minor axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Internal diameter minor axis diastole by US;LV Diam dias, short US;;ACTIVE;2.03;2.73 +29437-1;Internal diameter.minor axis.diastole;Len;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US;2;Left ventricular Internal diameter minor axis diastole by US.M-mode;LV Diam dias, short M-mode;;ACTIVE;2.03;2.54 +29438-9;Internal diameter.minor axis.systole;Len;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Internal diameter minor axis systole by US;LV Diam sys, short US;;ACTIVE;2.03;2.73 +2943-9;Sialate;MCnc;Pt;Plas;Qn;;CHEM;1;Sialate [Mass/volume] in Plasma;Sialate Plas-mCnc;;ACTIVE;1.0;2.73 +29439-7;Internal diameter.minor axis.systole;Len;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US;2;Left ventricular Internal diameter minor axis systole by US.M-mode;LV Diam sys, short M-mode;;ACTIVE;2.03;2.54 +29440-5;Thickness.septal wall/Thickness.posterior wall;LenRto;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Thickness septal wall/Thickness posterior wall by US 2D;LV SWT/PWT 2D US;;ACTIVE;2.03;2.48 +29441-3;Thickness.septal wall/Thickness.posterior wall;LenRto;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US;2;Left ventricular Thickness septal wall/Thickness posterior wall by US.M-mode;LV SWT/PWT M-mode;;ACTIVE;2.03;2.54 +29442-1;Thickness.diastole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.2D;CARD.US;2;Left ventricular posterior wall Thickness during diastole by US 2D;LVPW Thickness dia 2D US;;ACTIVE;2.03;2.67 +29443-9;Thickness.diastole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.M-mode;CARD.US;2;Left ventricular posterior wall Thickness during diastole by US.M-mode;LVPW Thickness dia M-mode;;ACTIVE;2.03;2.67 +29444-7;Thickness.systole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.2D;CARD.US;2;Left ventricular posterior wall Thickness during systole by US 2D;LVPW Thickness sys 2D US;;ACTIVE;2.03;2.67 +29445-4;Thickness.systole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.M-mode;CARD.US;2;Left ventricular posterior wall Thickness during systole by US.M-mode;LVPW Thickness sys M-mode;;ACTIVE;2.03;2.67 +29446-2;Thickening.fractional change;LenFr;Pt;Heart.ventricle.left.posterior wall;Qn;US.2D;CARD.US;2;Left ventricular posterior wall Thickening.fractional change by US 2D;LVPW Thick.fract chng 2D US;;ACTIVE;2.03;2.48 +2944-7;Sialate;MCnc;Pt;Urine;Qn;;CHEM;1;Sialate [Mass/volume] in Urine;Sialate Ur-mCnc;;ACTIVE;1.0;2.42 +29447-0;Thickening.fractional change;LenFr;Pt;Heart.ventricle.left.posterior wall;Qn;US.M-mode;CARD.US;2;Left ventricular posterior wall Thickening.fractional change by US.M-mode;LVPW Thick.fract chng M-mode;;ACTIVE;2.03;2.54 +29448-8;Effective regurgitant orifice area;Area;Pt;Mitral valve;Qn;US.doppler+Calculated by PISA method;CARD.US;2;Mitral valve Effective regurgitant orifice area by US.doppler+Calculated by PISA method;MV EROA PISA;;ACTIVE;2.03;2.56 +29449-6;Regurgitant volume;Vol;Pt;Mitral valve;Qn;US.doppler+Calculated by PISA method;CARD.US;2;Mitral valve Regurgitant volume by US.doppler+Calculated by PISA method;MV Reg vol PISA;;ACTIVE;2.03;2.54 +29450-4;Blood flow velocity.systole.max;Vel;Pt;Pulmonary vein;Qn;US.doppler;CARD.US;2;Pulmonary vein Maximum blood flow velocity during systole by US.doppler;Pulm v Vmax sys DOP;;ACTIVE;2.03;2.67 +29451-2;Blood flow velocity.diastole.max;Vel;Pt;Pulmonary vein;Qn;US.doppler;CARD.US;2;Pulmonary vein Maximum blood flow velocity during diastole by US.doppler;Pulm v Vmax dias DOP;;ACTIVE;2.03;2.67 +29452-0;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein;Qn;US.doppler.derived;CARD.US;2;Pulmonary vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived;Pulm v Vmax sys/dias DOP.der;;ACTIVE;2.03;2.69 +29453-8;A wave reversal.max;Vel;Pt;Pulmonary vein;Qn;US.doppler;CARD.US;2;Pulmonary vein Maximum A wave reversal by US.doppler;Pulm v A-wave reversal.max DOP;;ACTIVE;2.03;2.54 +2945-4;Sialidase;CCnc;Pt;Ser;Qn;;CHEM;1;Sialidase [Enzymatic activity/volume] in Serum;Sialidase Ser-cCnc;;ACTIVE;1.0;2.68 +29454-6;Blood flow velocity.systole.max;Vel;Pt;Pulmonary vein.right upper;Qn;US.doppler;CARD.US;2;Pulmonary vein - right upper Maximum blood flow velocity during systole by US.doppler;PV-RU Vmax sys DOP;;ACTIVE;2.03;2.67 +29455-3;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.right upper;Qn;US.doppler.derived;CARD.US;2;Pulmonary vein - right upper Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived;PV-RU Vmax sys/dias DOP.der;;ACTIVE;2.03;2.69 +29456-1;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.right lower;Qn;US.doppler.derived;CARD.US;2;Pulmonary vein - right lower Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived;PV-RL Vmax sys/dias DOP.der;;ACTIVE;2.03;2.69 +29457-9;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.left upper;Qn;US.doppler.derived;CARD.US;2;Pulmonary vein - left upper Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived;PV-LU Vmax sys/dias DOP.der;;ACTIVE;2.03;2.69 +29458-7;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein.left lower;Qn;US.doppler.derived;CARD.US;2;Pulmonary vein - left lower Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived;PV-LL Vmax sys/dias DOP.der;;ACTIVE;2.03;2.69 +29459-5;Diameter^expiration;Len;Pt;Vena cava.inferior;Qn;US;CARD.US;2;Inferior vena cava Diameter by US --expiration;IVC Diam exp US;;ACTIVE;2.03;2.48 +29460-3;Coarctation.flow.max;Vel;Pt;Aorta;Qn;US.doppler;CARD.US;2;Aorta Maximum coarctation flow [Velocity] by US.doppler;Aorta Coarc.flow.max DOP;;ACTIVE;2.03;2.48 +29461-1;Defect.velocity.systole.max;Vel;Pt;Heart.ventricle.septum;Qn;US.doppler;CARD.US;2;Ventricular septal Defect.velocity.systole.maximum by US.doppler;VS Defect.vel.sys.max DOP;;ACTIVE;2.03;2.29 +2946-2;Sialidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Sialidase [Enzymatic activity/mass] in Tissue;Sialidase Tiss-cCnt;;ACTIVE;1.0;2.42 +29462-9;Pulmonic flow/Systemic flow;VRatRto;Pt;Circulatory system.XXX;Qn;US.doppler;CARD.US;2;Pulmonic flow/Systemic flow by US.doppler;Pulmonic/Systemic DOP;;ACTIVE;2.03;2.69 +29463-7;Body weight;Mass;Pt;^Patient;Qn;;BDYWGT.ATOM;2;Body weight;Weight;;ACTIVE;2.03;2.73 +29464-5;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Pulmonary vein;Qn;US.doppler;CARD.US;2;Pulmonary vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler;Pulm v Vmax sys/dias DOP;;ACTIVE;2.03;2.69 +29465-2;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.Teichholz.calculated;CARD.US;2;Left ventricular End-systolic volume by US.Teichholz.calculated;LV ES vol US.Teich;;ACTIVE;2.03;2.67 +29466-0;Superior-Inferior;Len;Pt;Heart.atrium.right;Qn;US.2D.A4C;CARD.US;2;Right atrial Superior-Inferior [Length] by US.2D.A4C;RA Sup-Inf A4C;;ACTIVE;2.03;2.67 +29467-8;Superior-Inferior;Len;Pt;Heart.atrium.left;Qn;US.2D.A4C;CARD.US;2;Left atrial Superior-Inferior [Length] by US.2D.A4C;LA Sup-Inf A4C;;ACTIVE;2.03;2.67 +29468-6;Diameter.anterior-posterior.systole;Len;Pt;Heart.atrium.left;Qn;US.2D;CARD.US;2;Left atrial Diameter anterior-posterior systole by US 2D;LA Diam AP sys 2D US;;ACTIVE;2.03;2.48 +29469-4;Major axis.diameter.anterior-posterior.systole;Len;Pt;Heart.atrium.left;Qn;US.2D;CARD.US;2;Left atrial Major axis diameter anterior-posterior systole by US 2D;LA Major axis diam.AP sys 2D US;;ACTIVE;2.03;2.48 +2947-0;Sodium;SCnc;Pt;Bld;Qn;;CHEM;1;Sodium [Moles/volume] in Blood;Sodium Bld-sCnc;;ACTIVE;1.0;2.73 +29470-2;Blood velocity-time integral;Len;Pt;Mitral valve.annulus;Qn;US.calculated;CARD.US;2;Mitral valve annulus Blood velocity-time integral by US.calculated;MV ann VTI US Calc;;ACTIVE;2.03;2.54 +29471-0;Blood flow velocity.systole.max;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole by US.doppler;Hep v Vmax sys DOP;;ACTIVE;2.03;2.67 +29472-8;Blood flow velocity.diastole.max;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during diastole by US.doppler;Hep v Vmax dias DOP;;ACTIVE;2.03;2.67 +29473-6;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler;Hep v Vmax sys/dias DOP;;ACTIVE;2.03;2.67 +29474-4;A wave reversal.max;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum A wave reversal by US.doppler;Hep v A-wave reversal.max DOP;;ACTIVE;2.03;2.54 +29475-1;Blood flow velocity.systole.max^inspiration;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole by US.doppler --inspiration;Hep v Vmax sys insp DOP;;ACTIVE;2.03;2.67 +29476-9;Blood flow velocity.diastole.max^inspiration;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during diastole by US.doppler --inspiration;Hep v Vmax dias insp DOP;;ACTIVE;2.03;2.67 +29477-7;Blood flow velocity.systole.max/Blood flow velocity.diastole.max^inspiration;VelRto;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler --inspiration;Hep v Vmax sys/dias insp DOP;;ACTIVE;2.03;2.67 +29478-5;A wave reversal.max^inspiration;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum A wave reversal by US.doppler --inspiration;Hep v A-wave reversal.max insp DOP;;ACTIVE;2.03;2.54 +29479-3;Blood flow velocity.systole.max^expiration;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole by US.doppler --expiration;Hep v Vmax sys exp DOP;;ACTIVE;2.03;2.67 +29480-1;Blood flow velocity.diastole.max^expiration;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during diastole by US.doppler --expiration;Hep v Vmax dias exp DOP;;ACTIVE;2.03;2.67 +29481-9;Blood flow velocity.systole.max/Blood flow velocity.diastole.max^expiration;VelRto;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler --expiration;Hep v Vmax sys/dias exp DOP;;ACTIVE;2.03;2.67 +29482-7;A wave reversal.max^expiration;Vel;Pt;Hepatic vein;Qn;US.doppler;CARD.US;2;Hepatic vein Maximum A wave reversal by US.doppler --expiration;Hep v A-wave reversal.max exp DOP;;ACTIVE;2.03;2.54 +29483-5;Blood flow velocity.systole.max/Blood flow velocity.diastole.max;VelRto;Pt;Hepatic vein;Qn;US.doppler.derived;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived;Hep v Vmax sys/dias DOP.der;;ACTIVE;2.03;2.67 +29484-3;Blood flow velocity.systole.max/Blood flow velocity.diastole.max^inspiration;VelRto;Pt;Hepatic vein;Qn;US.doppler.derived;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived --inspiration;Hep v Vmax sys/dias insp DOP.der;;ACTIVE;2.03;2.67 +29485-0;Blood flow velocity.systole.max/Blood flow velocity.diastole.max^expiration;VelRto;Pt;Hepatic vein;Qn;US.doppler.derived;CARD.US;2;Hepatic vein Maximum blood flow velocity during systole/Maximum blood flow velocity during diastole by US.doppler derived --expiration;Hep v Vmax sys/dias exp DOP.der;;ACTIVE;2.03;2.67 +29486-8;Emptying.max;Vel;Pt;Heart.atrium.left.appendage;Qn;US.doppler;CARD.US;2;Left atrial appendage Maximum emptying [Velocity] by US.doppler;LAA Max emptying DOP;;ACTIVE;2.03;2.48 +29487-6;Orifice area;Area;Pt;Aortic valve;Qn;US.2D+Measured by planimetry;CARD.US;2;Aortic valve Orifice area by US.2D+Measured by planimetry;AV Orifice area US.2D.PLN;;ACTIVE;2.03;2.67 +2948-8;Sodium;SCnc;Pt;CSF;Qn;;CHEM;1;Sodium [Moles/volume] in Cerebral spinal fluid;Sodium CSF-sCnc;;ACTIVE;1.0;2.73 +29488-4;LOINC attachment modifier codes;Cmplx;-;^Patient;Set;;PANEL.ATTACH.MOD;3;LOINC attachment modifier codes;;;ACTIVE;2.03;2.56 +29489-2;Time window attachment request modifier codes;Cmplx;-;^Patient;Set;;PANEL.ATTACH.MOD;3;Time window attachment request modifier codes;;;ACTIVE;2.03;2.56 +294-9;Ketoconazole;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ketoconazole [Susceptibility] by Minimum lethal concentration (MLC);Ketoconazole Islt MLC;;ACTIVE;1.0;2.19 +29490-0;Selection item attachment request modifier codes;Cmplx;-;^Patient;Set;;ATTACH.MODIFIER;3;Selection item attachment request modifier codes;;;DISCOURAGED;2.03;2.50 +29491-8;Special attachment request modifier codes;Cmplx;-;^Patient;Set;;ATTACH.MODIFIER;3;Deprecated Special attachment request modifier codes;Deprecated;;DEPRECATED;2.03;2.68 +29492-6;Methicillin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Methicillin [Mass/volume] in Specimen;Methicillin Spec-mCnc;;ACTIVE;2.03;2.70 +29493-4;Colistin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Colistin [Mass/volume] in Specimen;Colistin Spec-mCnc;;ACTIVE;2.03;2.70 +29494-2;Demeclocycline;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Demeclocycline [Mass/volume] in Specimen;Demeclocycline Spec-mCnc;;ACTIVE;2.03;2.70 +29495-9;Herpes virus 6 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Presence] in Specimen by NAA with probe detection;HHV6 DNA Spec Ql NAA+probe;;ACTIVE;2.03;2.73 +2949-6;Sodium;SCnc;Pt;Dial fld;Qn;;CHEM;1;Sodium [Moles/volume] in Dialysis fluid;Sodium Dial fld-sCnc;;ACTIVE;1.0;2.34 +29496-7;Platelet associated Ab.IgA;PrThr;Pt;Bld;Ord;Flow cytometry;SERO;1;Platelet associated IgA Ab [Presence] in Blood by Flow cytometry (FC);PA IgA Bld Ql FC;;ACTIVE;2.03;2.73 +29497-5;Platelet associated Ab.IgG;PrThr;Pt;Bld;Ord;Flow cytometry;SERO;1;Platelet associated IgG Ab [Presence] in Blood by Flow cytometry (FC);PA IgG Bld Ql FC;;ACTIVE;2.03;2.73 +29498-3;Platelet associated Ab.IgM;PrThr;Pt;Bld;Ord;Flow cytometry;SERO;1;Platelet associated IgM Ab [Presence] in Blood by Flow cytometry (FC);PA IgM Bld Ql FC;;ACTIVE;2.03;2.73 +29499-1;Selenium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Selenium [Mass/mass] in Hair;Selenium Hair-mCnt;;ACTIVE;2.03;2.70 +29500-6;2-Hydroxyadipate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyadipate/Creatinine [Molar ratio] in Urine;2OH-adipate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29501-4;2-Hydroxyisobutyrate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;2-Hydroxyisobutyrate/Creatinine [Molar ratio] in Urine;2OH-isobutyrate/Creat Ur-sRto;;ACTIVE;2.03;2.70 +29502-2;2-Hydroxyglutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyglutarate/Creatinine [Molar ratio] in Urine;2OH-gluterate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29503-0;2-Hydroxyisocaproate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyisocaproate/Creatinine [Molar ratio] in Urine;2OH-isocaproate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +2950-4;Sodium;SCnc;Pt;Body fld;Qn;;CHEM;1;Sodium [Moles/volume] in Body fluid;Sodium Fld-sCnc;;ACTIVE;1.0;2.73 +29504-8;2-Hydroxyisovalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyisovalerate/Creatinine [Molar ratio] in Urine;2OH-isovalerate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29505-5;2-Hydroxy-3-Methylvalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxy-3-Methylvalerate/Creatinine [Molar ratio] in Urine;2OH3Me-valerate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29506-3;2-Oxoadipate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Oxoadipate/Creatinine [Molar ratio] in Urine;2-Oxoadipate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29507-1;Alpha ketoglutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha ketoglutarate/Creatinine [Molar ratio] in Urine;A-Ketoglut/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29508-9;3-Hydroxyadipate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyadipate/Creatinine [Molar ratio] in Urine;3OH-Adipate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29509-7;Beta hydroxybutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Beta hydroxybutyrate/Creatinine [Molar ratio] in Urine;B-OH-Butyr/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29510-5;3-Hydroxyglutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyglutarate/Creatinine [Molar ratio] in Urine;3OH-Glutarate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29511-3;3-Hydroxyisobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyisobutyrate/Creatinine [Molar ratio] in Urine;3OH-Isobutyrate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +2951-2;Sodium;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sodium [Moles/volume] in Serum or Plasma;Sodium SerPl-sCnc;;ACTIVE;1.0;2.73 +29512-1;Beta hydroxybutyrate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta hydroxybutyrate [Mass/volume] in Serum or Plasma;B-OH-Butyr SerPl-mCnc;;ACTIVE;2.03;2.73 +29513-9;Cysticercus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Deprecated Taenia solium larva Ab [Units/volume] in Cerebral spinal fluid;Deprecated Cysticercus Ab CSF-aCnc;;DEPRECATED;2.03;2.70 +29514-7;3-Hydroxyisovalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyisovalerate/Creatinine [Molar ratio] in Urine;3OH-Isovalerate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29515-4;3-Hydroxypropionate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxypropionate (3-OH-C3)/Creatinine [Molar ratio] in Urine;3OH-Propionate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29516-2;3-Hydroxyvalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyvalerate/Creatinine [Molar ratio] in Urine;3OH-Valerate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29517-0;Vanillylmandelate/Creatinine;SCrto;Pt;Urine;Qn;;CHEM;1;Deprecated Vanillylmandelate/Creatinine [Molecular ratio] in Urine;Deprecated VMA/creat Ur-sRto;;DEPRECATED;2.03;2.70 +29518-8;3-Methylglutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methylglutarate/Creatinine [Molar ratio] in Urine;3Me-glutarate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29519-6;4-Hydroxyphenylpyruvate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxyphenylpyruvate/Creatinine [Molar ratio] in Urine;4OH-phenylpyruvate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +2952-0;Sodium;Sub;24H;Stool;Qn;;CHEM;1;Sodium [Molar amount] in 24 hour Stool;Sodium 24h sub Stl Qn;;ACTIVE;1.0;2.73 +29520-4;5-Hydroxyindoleacetate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate/Creatinine [Molar ratio] in Urine;5OH-indoleacetate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29521-2;5-Hydroxyhexanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5-Hydroxyhexanoate/Creatinine [Molar ratio] in Urine;5OH-Hexanoate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29522-0;5-Oxoproline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5-Oxoproline/Creatinine [Molar ratio] in Urine;5Oxoproline/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29523-8;2-Ethyl-3-Hydroxypropionate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Ethyl-3-Hydroxypropionate/Creatinine [Molar ratio] in Urine;2Ethyl3OH-Prop/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29524-6;Acetoacetate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Acetoacetate/Creatinine [Molar ratio] in Urine;Acetoacet/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29525-3;Aconitate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Aconitate/Creatinine [Molar ratio] in Urine;Aconitate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29526-1;Azelate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Azelate/Creatinine [Molar ratio] in Urine;Azelate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29527-9;Citrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Citrate/Creatinine [Molar ratio] in Urine;Citrate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29528-7;Hippurate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Hippurate/Creatinine [Molar ratio] in Urine;Hippurate/Creat Ur-sRto;;ACTIVE;2.03;2.73 +29529-5;Acetaminophen;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Acetaminophen [Presence] in Specimen;APAP Spec Ql;;ACTIVE;2.03;2.73 +29530-3;Amphetamines;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Specimen;Amphetamines Spec Ql;;ACTIVE;2.03;2.73 +29531-1;diphenhydrAMINE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;diphenhydrAMINE [Presence] in Specimen;Diphenhy Spec Ql;;ACTIVE;2.03;2.73 +29532-9;Methadone;ACnc;Pt;XXX;Qn;;DRUG/TOX;1;Methadone [Units/volume] in Specimen;Methadone Spec-aCnc;;DISCOURAGED;2.03;2.69 +29533-7;Cryptococcus sp Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Cryptococcus sp Ag [Presence] in Specimen;Cryptoc Ag Spec Ql;;ACTIVE;2.03;2.73 +29534-5;Anguilla anguilla Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Eel IgE Ab RAST class [Presence] in Serum;Eel IgE RAST Ql;;ACTIVE;2.03;2.73 +29535-2;West Nile virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;West Nile virus IgG Ab [Units/volume] in Serum;WNV IgG Ser-aCnc;;ACTIVE;2.03;2.73 +29536-0;West Nile virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;West Nile virus IgM Ab [Units/volume] in Serum;WNV IgM Ser-aCnc;;ACTIVE;2.03;2.73 +29537-8;West Nile virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;West Nile virus IgG Ab [Units/volume] in Cerebral spinal fluid;WNV IgG CSF-aCnc;;ACTIVE;2.03;2.73 +2953-8;Sodium;Sub;72H;Stool;Qn;;CHEM;1;Sodium [Molar amount] in 72 hour Stool;Sodium 72h sub Stl Qn;;ACTIVE;1.0;2.42 +29538-6;West Nile virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;West Nile virus IgM Ab [Units/volume] in Cerebral spinal fluid;WNV IgM CSF-aCnc;;ACTIVE;2.03;2.73 +29539-4;HIV 1 RNA;LnCnc;Pt;Plas;Qn;Probe.amp.sig;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Plasma by Probe with signal amplification;HIV1 RNA Plas Probe+sig amp-Log#;;ACTIVE;2.03;2.73 +29540-2;E-cadherin;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;E-cadherin [Presence] in Tissue by Immune stain;E-Cadherin Tiss Ql ImStn;;ACTIVE;2.03;2.73 +29541-0;HIV 1 RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HIV1 RNA SerPl NAA+probe-Log#;;ACTIVE;2.03;2.73 +29542-8;Beta-N-acetylhexosaminidase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/mass] in Amniotic fluid cells;B-NAH Amnc-cCnt;;ACTIVE;2.03;2.70 +29543-6;Beta-N-acetylhexosaminidase.A/Beta-N-acetylhexosaminidase.total;CFr;Pt;Amnio fld cells;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A/Beta-n-acetylhexosaminidase.total in Amniotic fluid cells;Hexosaminidase A CFr Amnc;;ACTIVE;2.03;2.70 +29544-4;Physical findings;Find;Pt;^Patient;Nom;Observed;H&P.PX;2;Physical findings;Phys find;;ACTIVE;2.03;2.27 +29545-1;Physical findings;Find;Pt;^Patient;Nar;Observed;H&P.PX;2;Physical findings Narrative;Phys find;;ACTIVE;2.03;2.63 +2954-6;Sodium;SCnc;Pt;Sweat;Qn;;CHEM;1;Sodium [Moles/volume] in Sweat;Sodium Sweat-sCnc;;ACTIVE;1.0;2.34 +29546-9;Symptoms & diseases;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of disorders Narrative;Hx of Symp + dis;;ACTIVE;2.03;2.73 +29547-7;Symptoms & diseases;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Symptoms and diseases;Hx of Symp + dis;;ACTIVE;2.03;2.56 +29548-5;Diagnosis;Imp;Pt;^Patient;Nar;;H&P.PX;2;Diagnosis Narrative;Dx;;ACTIVE;2.03;2.73 +29549-3;Medication administered;Type;Pt;^Patient;Nar;;H&P.PX;2;Medication administered Narrative;Medication administered;;ACTIVE;2.03;2.40 +29550-1;Medication dispensed;Type;Pt;^Patient;Nar;;H&P.PX;2;Medication dispensed Narrative;Medication dispensed;;ACTIVE;2.03;2.40 +29551-9;Medication prescribed;Type;Pt;^Patient;Nar;;H&P.PX;2;Medication prescribed Narrative;Medication prescribed;;ACTIVE;2.03;2.73 +29552-7;Color;Type;Pt;XXX;Nar;;H&P.PX;2;Color of Body region Narrative;Color Body reg;;ACTIVE;2.03;2.69 +2955-3;Sodium;SCnc;Pt;Urine;Qn;;CHEM;1;Sodium [Moles/volume] in Urine;Sodium Ur-sCnc;;ACTIVE;1.0;2.73 +29553-5;Age;Time;Pt;^Patient;Qn;Calculated;MISC;1;Age calculated;Age Time Patient Calc;;ACTIVE;2.03;2.73 +29554-3;Procedure;Type;Pt;^Patient;Nar;;H&P.PX;2;Procedure Narrative;Procedure;;ACTIVE;2.03;2.40 +29555-0;Milk production;MRat;24H;^Patient;Qn;;H&P.PX;2;Milk production [Mass/time] 24 hour;Milk production 24h mRate;;ACTIVE;2.03;2.70 +29556-8;Symptoms & diseases;Hx;Pt;Behavior;Nom;;H&P.HX;2;History of Behavior disorders;Hx of Behavior disorders;;ACTIVE;2.03;2.56 +29557-6;Symptoms & diseases;Hx;Pt;Behavior;Nar;;H&P.HX;2;History of Behavior disorders Narrative;Hx of Behavior disorders;;ACTIVE;2.03;2.56 +29558-4;Enterovirus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;EV RNA CSF Ql NAA+probe;;ACTIVE;2.03;2.73 +29559-2;Haemophilus ducreyi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Haemophilus ducreyi DNA [Presence] in Specimen by NAA with probe detection;H ducreyi DNA Spec Ql NAA+probe;;ACTIVE;2.03;2.73 +295-6;Ketoconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ketoconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Ketoconazole Islt MIC;;ACTIVE;1.0;2.73 +29560-0;Anaplasma phagocytophilum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Anaplasma phagocytophilum DNA [Presence] in Specimen by NAA with probe detection;A phagocytoph DNA Spec Ql NAA+probe;;ACTIVE;2.03;2.73 +2956-1;Sodium;SRat;24H;Urine;Qn;;CHEM;1;Sodium [Moles/time] in 24 hour Urine;Sodium 24h Ur-sRate;;ACTIVE;1.0;2.73 +29561-8;Jamestown canyon virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Jamestown canyon virus IgG Ab [Titer] in Serum by Immunofluorescence;JCV IgG Titr Ser IF;;ACTIVE;2.03;2.73 +29562-6;Jamestown canyon virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Jamestown canyon virus neutralizing antibody [Titer] in Serum by Neutralization test;JCV NAb Titr Ser Nt;;ACTIVE;2.03;2.72 +29563-4;La Crosse virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;La Crosse virus neutralizing antibody [Titer] in Serum by Neutralization test;LACV NAb Titr Ser Nt;;ACTIVE;2.03;2.72 +29564-2;Powassan virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Powassan virus IgG Ab [Titer] in Serum by Immunofluorescence;POWV IgG Titr Ser IF;;ACTIVE;2.03;2.30 +29565-9;Powassan virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Powassan virus IgM Ab [Titer] in Serum by Immunofluorescence;POWV IgM Titr Ser IF;;ACTIVE;2.03;2.30 +29566-7;West Nile virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;West Nile virus IgG Ab [Presence] in Serum by Immunoassay;WNV IgG Ser Ql IA;;ACTIVE;2.03;2.73 +29567-5;West Nile virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;West Nile virus IgM Ab [Presence] in Serum by Immunoassay;WNV IgM Ser Ql IA;;ACTIVE;2.03;2.73 +29568-3;West Nile virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;West Nile virus neutralizing antibody [Titer] in Serum by Neutralization test;WNV NAb Titr Ser Nt;;ACTIVE;2.03;2.72 +29569-1;West Nile virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;West Nile virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;WNV IgM CSF Ql IA;;ACTIVE;2.03;2.73 +29570-9;West Nile virus Ab.Neut;Titr;Pt;CSF;Qn;Neut;MICRO;1;West Nile virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test;WNV NAb Titr CSF Nt;;ACTIVE;2.03;2.72 +29571-7;Phenylalanine;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Phenylalanine [Presence] in DBS;Phe DBS Ql;;ACTIVE;2.03;2.73 +29572-5;Phenylalanine;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Phenylalanine [Mass/volume] in DBS;Phe DBS-mCnc;;ACTIVE;2.03;2.73 +29573-3;Phenylalanine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Phenylalanine [Moles/volume] in DBS;Phe DBS-sCnc;;ACTIVE;2.03;2.73 +29574-1;Thyrotropin;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Thyrotropin [Presence] in DBS;TSH DBS Ql;;ACTIVE;2.03;2.73 +29575-8;Thyrotropin;ACnc;Pt;Bld.dot;Qn;;CHEM;1;Thyrotropin [Units/volume] in DBS;TSH DBS-aCnc;;ACTIVE;2.03;2.73 +29576-6;Bacterial susceptibility panel;-;Pt;Isolate;OrdQn;;PANEL.ABXBACT;1;Bacterial susceptibility panel;Bacterial Susc Pnl Islt;;ACTIVE;2.03;2.73 +29577-4;Fungal susceptibility panel;-;Pt;Isolate;OrdQn;;PANEL.ABXBACT;1;Fungal susceptibility panel;Fungal Susc Pnl Islt;;ACTIVE;2.03;2.73 +29578-2;Viral susceptibility panel;-;Pt;Isolate;OrdQn;;PANEL.ABXBACT;1;Viral susceptibility panel;Viral Susc Pnl Islt;;ACTIVE;2.03;2.73 +2957-9;Sodium renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Sodium renal clearance in 24 hour Urine and Serum or Plasma;Sodium Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.73 +29579-0;Mycobacterial susceptibility panel;-;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;PANEL.ABXBACT;1;Mycobacterial susceptibility panel by Method for Slow-growing mycobacteria;Mycobacterial Susc Pnl Islt SlowMyco;;ACTIVE;2.03;2.64 +29580-8;Differential panel;-;Pt;Body fld;-;;PANEL.HEM/BC;1;Differential panel - Body fluid;Diff Pnl Fld;;ACTIVE;2.03;2.73 +29581-6;Differential panel;-;Pt;Periton fld;-;;PANEL.HEM/BC;1;Differential panel - Peritoneal fluid;Diff Pnl Prt;;ACTIVE;2.03;2.42 +29582-4;Differential panel;-;Pt;Synv fld;-;;PANEL.HEM/BC;1;Differential panel - Synovial fluid;Diff Pnl Snv;;ACTIVE;2.03;2.42 +29583-2;Differential panel;-;Pt;Plr fld;-;;PANEL.HEM/BC;1;Differential panel - Pleural fluid;Diff Pnl Plr;;ACTIVE;2.03;2.42 +29584-0;Differential panel;-;Pt;CSF;-;;PANEL.HEM/BC;1;Differential panel - Cerebral spinal fluid;Diff Pnl CSF;;ACTIVE;2.03;2.73 +29585-7;Immunoelectrophoresis panel;-;Pt;Urine;-;;PANEL.CHEM;1;Immunoelectrophoresis panel - Urine;IEP Pnl Ur;;ACTIVE;2.03;2.73 +29586-5;Immunoelectrophoresis panel;-;Pt;Ser;-;;PANEL.CHEM;1;Immunoelectrophoresis panel - Serum;IEP Pnl Ser;;ACTIVE;2.03;2.73 +2958-7;Sodium/Potassium;SRto;Pt;Sweat;Qn;;CHEM;1;Sodium/Potassium [Molar ratio] in Sweat;Sodium/Potassium Sweat-sRto;;ACTIVE;1.0;2.42 +29587-3;Toxicology panel;-;Pt;Bld;-;;PANEL.DRUG/TOX;1;Toxicology panel - Blood;Toxicology Pnl Bld;;ACTIVE;2.03;2.73 +29588-1;Heavy metals panel;-;Pt;Bld;-;;PANEL.DRUG/TOX;1;Heavy metals panel - Blood;Heavy Met Pnl Bld;;ACTIVE;2.03;2.73 +29589-9;Heavy metals panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Heavy metals panel - Urine;Heavy Met Pnl Ur;;ACTIVE;2.03;2.73 +29590-7;Cytomegalovirus DNA;MCnc;Pt;Bld;Qn;Probe;MICRO;1;Cytomegalovirus DNA [Mass/volume] (viral load) in Blood by Probe;CMV DNA Bld Probe-mCnc;;ACTIVE;2.03;2.73 +29591-5;Enterovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Specimen by NAA with probe detection;EV RNA Spec Ql NAA+probe;;ACTIVE;2.03;2.73 +29592-3;Amphetamine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Amphetamine [Mass/volume] in Serum or Plasma by Confirmatory method;Amphet SerPl Cfm-mCnc;;ACTIVE;2.03;2.73 +29593-1;Cells.Ki-67 nuclear Ag/100 cells;NFr;Pt;Tiss;Qn;Immune stain;CELLMARK;1;Cells.Ki-67 nuclear Ag/100 cells in Tissue by Immune stain;Ki-67 nuclear Ag NFr Tiss ImStn;;ACTIVE;2.03;2.73 +29594-9;CD45RO Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD45RO Ag [Presence] in Tissue by Immune stain;CD45RO Ag Tiss Ql ImStn;;ACTIVE;2.03;2.56 +2959-5;Sodium/Potassium;SRto;Pt;Urine;Qn;;CHEM;1;Sodium/Potassium [Molar ratio] in Urine;Sodium/Potassium Ur-sRto;;ACTIVE;1.0;2.42 +29595-6;Alpha-1-Fetoprotein;MoM;Pt;Amnio fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] in Amniotic fluid;AFP MoM Amn;;ACTIVE;2.03;2.73 +29596-4;CD25 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD25 Ag [Presence] in Tissue by Immune stain;CD25 Ag Tiss Ql ImStn;;ACTIVE;2.03;2.73 +29597-2;Mephentermine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Mephentermine [Mass/volume] in Serum or Plasma by Confirmatory method;Mephentermine SerPl Cfm-mCnc;;ACTIVE;2.03;2.70 +29598-0;Methylenedioxyamphetamine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Serum or Plasma by Confirmatory method;MDA SerPl Cfm-mCnc;;ACTIVE;2.03;2.73 +29599-8;Methylenedioxyethylamphetamine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Serum or Plasma by Confirmatory method;MDEA SerPl Cfm-mCnc;;ACTIVE;2.03;2.73 +29600-4;Benzfetamine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Benzfetamine [Mass/volume] in Serum or Plasma by Confirmatory method;Benzfetamine SerPl Cfm-mCnc;;ACTIVE;2.03;2.70 +29601-2;Phenylpropanolamine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Phenylpropanolamine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;PPA SerPlBld Cfm-mCnc;;ACTIVE;2.03;2.73 +29602-0;Chlorphentermine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Chlorphentermine [Mass/volume] in Serum or Plasma by Confirmatory method;Chlorphentermin SerPl Cfm-mCnc;;ACTIVE;2.03;2.70 +2960-3;Somatostatin;PrThr;Pt;Plas;Ord;;CHEM;1;Somatostatin [Presence] in Plasma;Somatostat Plas Ql;;ACTIVE;1.0;2.73 +29603-8;CD5 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD5 Ag [Presence] in Tissue by Immune stain;CD5 Ag Tiss Ql ImStn;;ACTIVE;2.03;2.73 +29604-6;Cytomegalovirus DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Blood by NAA with probe detection;CMV DNA # Bld NAA+probe;;ACTIVE;2.03;2.73 +29605-3;Appearance;Aper;Pt;Synv fld;Nom;;SPEC;1;Appearance of Synovial fluid;Appearance Snv;;ACTIVE;2.03;2.73 +29606-1;Appearance;Aper;Pt;Gast fld;Nom;;SPEC;1;Appearance of Gastric fluid;Appearance Gast;;ACTIVE;2.03;2.73 +29607-9;Tropheryma whipplei DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Tissue by NAA with probe detection;T whipplei DNA Tiss Ql NAA+probe;;ACTIVE;2.03;2.73 +29608-7;Phentermine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Phentermine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Phentermine SerPlBld Cfm-mCnc;;ACTIVE;2.03;2.73 +29609-5;Hepatitis C virus RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.sig;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe with signal amplification;HCV RNA SerPl Probe+sig amp-aCnc;;ACTIVE;2.03;2.73 +29610-3;Hepatitis B virus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Presence] in Serum or Plasma by NAA with probe detection;HBV DNA SerPl Ql NAA+probe;;ACTIVE;2.03;2.73 +2961-1;Somatostatin;MCnc;Pt;Plas;Qn;;CHEM;1;Somatostatin [Mass/volume] in Plasma;Somatostat Plas-mCnc;;ACTIVE;1.0;2.73 +29611-1;Ethchlorvynol;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Ethchlorvynol [Presence] in Specimen;Ethchlorvynol Spec Ql;;ACTIVE;2.03;2.69 +29612-9;Ephedrine+Pseudoephedrine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Mass/volume] in Serum or Plasma by Confirmatory method;Ephedrin+Pseudo SerPl Cfm-mCnc;;ACTIVE;2.03;2.73 +29613-7;Phendimetrazine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Phendimetrazine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Phendimetrazine SerPlBld Cfm-mCnc;;ACTIVE;2.03;2.73 +29614-5;Phenmetrazine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Phenmetrazine [Mass/volume] in Serum or Plasma by Confirmatory method;Phenmetrazine SerPl Cfm-mCnc;;ACTIVE;2.03;2.73 +29615-2;Hepatitis B virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HBV DNA # SerPl NAA+probe;;ACTIVE;2.03;2.73 +29616-0;Stachybotrys chartarum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Stachybotrys chartarum IgE Ab [Units/volume] in Serum;S chartarum IgE Qn;;ACTIVE;2.03;2.73 +29617-8;CD23 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD23 Ag [Presence] in Tissue by Immune stain;CD23 Ag Tiss Ql ImStn;;ACTIVE;2.03;2.73 +29618-6;Stachybotrys chartarum Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Stachybotrys chartarum IgE Ab RAST class [Presence] in Serum;S chartarum IgE RAST Ql;;ACTIVE;2.03;2.73 +29619-4;Methylenedioxymethamphetamine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Serum or Plasma by Confirmatory method;MDMA SerPl Cfm-mCnc;;ACTIVE;2.03;2.73 +29620-2;Zonisamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zonisamide [Mass/volume] in Serum or Plasma;Zonisamide SerPl-mCnc;;ACTIVE;2.03;2.73 +29621-0;3-Hydroxyadipate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxyadipate [Presence] in Urine;3OH-Adipate Ur Ql;;ACTIVE;2.03;2.73 +29622-8;Beta hydroxybutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;Beta hydroxybutyrate [Presence] in Urine;B-OH-Butyr Ur Ql;;ACTIVE;2.03;2.73 +29623-6;3-Hydroxydodecanoate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxydodecanoate (3-OH-C12:0) [Presence] in Urine;3OH-dodecanoate Ur Ql;;ACTIVE;2.03;2.73 +29624-4;3-Hydroxyglutarate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxyglutarate [Presence] in Urine;3OH-Glutarate Ur Ql;;ACTIVE;2.03;2.73 +29625-1;3-Hydroxypropionate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxypropionate (3-OH-C3) [Presence] in Urine;3OH-Propionate Ur Ql;;ACTIVE;2.03;2.73 +29626-9;3-Hydroxysebacate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxysebacate ( 3-OH-C8) [Presence] in Urine;3OHsebacate Ur Ql;;ACTIVE;2.03;2.73 +29627-7;3-Hydroxyvalerate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Hydroxyvalerate [Presence] in Urine;3OH-Valerate Ur Ql;;ACTIVE;2.03;2.73 +29628-5;3-Methylcrotonylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;3-Methylcrotonylglycine [Presence] in Urine;3Me-crotonylglycine Ur Ql;;ACTIVE;2.03;2.73 +2962-9;Somatotropin;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Somatotropin [Mass/volume] in Amniotic fluid;GH Amn-mCnc;;ACTIVE;1.0;2.42 +29629-3;3-Methylglutaconate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Methylglutaconate [Presence] in Urine;3Me-glutaconate Ur Ql;;ACTIVE;2.03;2.73 +29630-1;3-Methylglutarate;PrThr;Pt;Urine;Ord;;CHEM;1;3-Methylglutarate [Presence] in Urine;3Me-glutarate Ur Ql;;ACTIVE;2.03;2.73 +29631-9;N-acetylaspartate;PrThr;Pt;Urine;Ord;;CHEM;1;Deprecated N-acetylaspartate [Presence] in Urine;Deprecated N-Ac-Asp Ur Ql;;DEPRECATED;2.03;2.58 +29632-7;N-acetyltyrosine;PrThr;Pt;Urine;Ord;;CHEM;1;N-acetyltyrosine [Presence] in Urine;NAT Ur Ql;;ACTIVE;2.03;2.73 +29633-5;CD122 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD122 Ag [Presence] in Tissue by Immune stain;CD122 Ag Tiss Ql ImStn;;ACTIVE;2.03;2.56 +29634-3;Terbutaline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Terbutaline [Presence] in Urine;Terbutaline Ur Ql;;ACTIVE;2.03;2.56 +29635-0;Albuterol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Albuterol [Presence] in Urine;Albuterol Ur Ql;;ACTIVE;2.03;2.56 +29636-8;Appearance;Aper;Pt;Stool;Nom;;SPEC;1;Appearance of Stool;Appearance Stl;;ACTIVE;2.03;2.73 +2963-7;Somatotropin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Mass/volume] in Serum or Plasma;GH SerPl-mCnc;;ACTIVE;1.0;2.73 +29637-6;Time last dose;TmStp;Pt;Dose;Qn;;DRUGDOSE;1;Time last dose of Dose;Tme Last Dose;;ACTIVE;2.03;2.73 +29638-4;Specimen weight;Mass;Pt;Tiss;Qn;;SPEC;1;Weight of Tissue;Specimen wt Tiss Qn;;ACTIVE;2.03;2.73 +29639-2;Alkaline phosphatase;CCnt;Pt;Tiss;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/mass] in Tissue;ALP Tiss-cCnt;;ACTIVE;2.03;2.73 +296-4;Ketoconazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ketoconazole [Susceptibility] by Disk diffusion (KB);Ketoconazole Islt KB;;ACTIVE;1.0;2.21 +29640-0;Isomaltase;CCnt;Pt;Tiss;Qn;;CHEM;1;Isomaltase [Enzymatic activity/mass] in Tissue;Isomaltase Tiss-cCnt;;ACTIVE;2.03;2.70 +29641-8;Neutrophil cytoplasmic Ab.atypical;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil Cytoplasmic Ab atypical [Presence] in Serum by Immunofluorescence;Atyp ANCA Ser Ql IF;;ACTIVE;2.03;2.73 +29642-6;Neutrophil cytoplasmic Ab.classic.atypical;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil cytoplasmic Ab.classic.atypical [Presence] in Serum by Immunofluorescence;Atyp c-ANCA Ser Ql IF;;ACTIVE;2.03;2.73 +29643-4;Myeloperoxidase Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Myeloperoxidase Ab [Presence] in Serum by Immunoassay;Myeloperoxidase Ab Ser Ql IA;;ACTIVE;2.03;2.73 +29644-2;Proteinase 3;PrThr;Pt;Ser;Ord;IA;SERO;1;Proteinase 3 [Presence] in Serum by Immunoassay;Proteinase3 Ser Ql IA;;ACTIVE;2.03;2.56 +2964-5;Specific gravity;Rden;Pt;Body fld;Qn;;CHEM;1;Specific gravity of Body fluid;Sp Gr Fld;;ACTIVE;1.0;2.73 +29645-9;Echovirus+Coxsackievirus Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Echovirus+Coxsackievirus IgA Ab [Presence] in Serum by Immunoassay;ECV+CV IgA Ser Ql IA;;ACTIVE;2.03;2.56 +29646-7;Parainfluenza virus 2 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 2 IgM Ab [Presence] in Serum by Immunoassay;HPIV2 IgM Ser Ql IA;;ACTIVE;2.03;2.56 +29647-5;Interferon.beta Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Interferon beta Ab [Presence] in Serum or Plasma;IFN-B Ab SerPl Ql;;ACTIVE;2.03;2.73 +29648-3;Rickettsia australis Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia australis Ab [Titer] in Serum by Immunofluorescence;R australis Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29649-1;Rickettsia australis Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia australis Ab [Presence] in Serum by Immunofluorescence;R australis Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29650-9;Rickettsia honei Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia honei Ab [Titer] in Serum by Immunofluorescence;R honei Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29651-7;Rickettsia honei Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia honei Ab [Presence] in Serum by Immunofluorescence;R honei Ab Ser Ql IF;;ACTIVE;2.03;2.56 +2965-2;Specific gravity;Rden;Pt;Urine;Qn;;CHEM;1;Specific gravity of Urine;Sp Gr Ur;;ACTIVE;1.0;2.73 +29652-5;Dothiepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dothiepin [Mass/volume] in Serum or Plasma;Dothiepin SerPl-mCnc;;ACTIVE;2.03;2.70 +29653-3;Dothiepin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dothiepin [Moles/volume] in Serum or Plasma;Dothiepin SerPl-sCnc;;ACTIVE;2.03;2.70 +29654-1;Temazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Temazepam [Moles/volume] in Serum or Plasma;Temazepam SerPl-sCnc;;ACTIVE;2.03;2.70 +29655-8;Oxazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxazepam [Moles/volume] in Serum or Plasma;Oxazepam SerPl-sCnc;;ACTIVE;2.03;2.70 +29656-6;Sympathomimetics;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Sympathomimetics [Presence] in Urine;Sympathomimetics Ur Ql;;ACTIVE;2.03;2.73 +29657-4;Bordetella pertussis Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bordetella pertussis IgA Ab [Presence] in Serum by Immunoassay;B pert IgA Ser Ql IA;;ACTIVE;2.03;2.73 +29658-2;Bordetella pertussis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bordetella pertussis IgM Ab [Presence] in Serum by Immunoassay;B pert IgM Ser Ql IA;;ACTIVE;2.03;2.73 +29659-0;Bordetella pertussis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bordetella pertussis IgG Ab [Presence] in Serum by Immunoassay;B pert IgG Ser Ql IA;;ACTIVE;2.03;2.73 +2966-0;Specific gravity;Rden;24H;Urine;Qn;;CHEM;1;Specific gravity of 24 hour Urine;Sp Gr 24h Ur;;ACTIVE;1.0;2.73 +29660-8;Parvovirus B19 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parvovirus B19 IgG Ab [Presence] in Serum by Immunoassay;B19V IgG Ser Ql IA;;ACTIVE;2.03;2.73 +29661-6;Dengue virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Dengue virus IgG Ab [Presence] in Serum or Plasma by Immunoassay;DENV IgG SerPl Ql IA;;ACTIVE;2.03;2.73 +29662-4;Varicella zoster virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay;VZV IgM Ser Ql IA;;ACTIVE;2.03;2.73 +29663-2;Dengue virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Dengue virus IgM Ab [Presence] in Serum or Plasma by Immunoassay;DENV IgM SerPl Ql IA;;ACTIVE;2.03;2.66 +29664-0;Chlamydia sp Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydia sp IgA Ab [Presence] in Serum by Immunoassay;Chlamydia IgA Ser Ql IA;;ACTIVE;2.03;2.56 +29665-7;Rickettsia conorii Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia conorii Ab [Titer] in Serum by Immunofluorescence;R conorii Ab Titr Ser IF;;ACTIVE;2.03;2.73 +29666-5;Echovirus+Coxsackievirus Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus+Coxsackievirus IgA Ab [Presence] in Serum;ECV+CV IgA Ser Ql;;ACTIVE;2.03;2.56 +29667-3;Parainfluenza virus 2 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 2 IgM Ab [Presence] in Serum;HPIV2 IgM Ser Ql;;ACTIVE;2.03;2.56 +29668-1;Rickettsia australis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia australis Ab [Titer] in Serum;R australis Ab Titr Ser;;ACTIVE;2.03;2.30 +29669-9;Rickettsia australis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia australis Ab [Presence] in Serum;R australis Ab Ser Ql;;ACTIVE;2.03;2.56 +29670-7;Rickettsia honei Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia honei Ab [Titer] in Serum;R honei Ab Titr Ser;;ACTIVE;2.03;2.30 +29671-5;Rickettsia honei Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia honei Ab [Presence] in Serum;R honei Ab Ser Ql;;ACTIVE;2.03;2.56 +29672-3;Bordetella pertussis Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis IgA Ab [Presence] in Serum;B pert IgA Ser Ql;;ACTIVE;2.03;2.73 +29673-1;Bordetella pertussis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis IgM Ab [Presence] in Serum;B pert IgM Ser Ql;;ACTIVE;2.03;2.73 +29674-9;Bordetella pertussis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis IgG Ab [Presence] in Serum;B pert IgG Ser Ql;;ACTIVE;2.03;2.73 +29675-6;Parvovirus B19 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Parvovirus B19 IgG Ab [Presence] in Serum;B19V IgG Ser Ql;;ACTIVE;2.03;2.73 +29676-4;Dengue virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus IgG Ab [Presence] in Serum;DENV IgG Ser Ql;;ACTIVE;2.03;2.73 +29677-2;Chlamydia sp Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia sp IgA Ab [Presence] in Serum;Chlamydia IgA Ser Ql;;ACTIVE;2.03;2.56 +2967-8;Starch granules;PrThr;Pt;Stool;Ord;Microscopy.light;CHEM;1;Starch granules [Presence] in Stool by Light microscopy;Starch Granules Stl Ql Micro;;ACTIVE;1.0;2.73 +29678-0;Rickettsia conorii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia conorii Ab [Titer] in Serum;R conorii Ab Titr Ser;;ACTIVE;2.03;2.30 +29679-8;Rickettsia sibirica Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia sibirica Ab [Titer] in Serum;R sibirica Ab Titr Ser;;ACTIVE;2.03;2.30 +29680-6;Rickettsia akari Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia akari Ab [Titer] in Serum;R akari Ab Titr Ser;;ACTIVE;2.03;2.30 +29681-4;Rickettsia akari Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia akari Ab [Presence] in Serum;R akari Ab Ser Ql;;ACTIVE;2.03;2.56 +29682-2;Rickettsia prowazekii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia prowazekii Ab [Titer] in Serum;R prowazek Ab Titr Ser;;ACTIVE;2.03;2.30 +29683-0;Rickettsia prowazekii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia prowazekii Ab [Presence] in Serum;R prowazek Ab Ser Ql;;ACTIVE;2.03;2.56 +29684-8;Rickettsia typhi Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi Ab [Titer] in Serum;R typhi Ab Titr Ser;;ACTIVE;2.03;2.30 +29685-5;Rickettsia typhi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia typhi Ab [Presence] in Serum;R typhi Ab Ser Ql;;ACTIVE;2.03;2.73 +2968-6;Starch granules;ACnc;Pt;Stool;Ord;;CHEM;1;Deprecated Starch granules [Presence] in Stool by Light microscopy;Deprecated Starch Granules Stl Ql;;DEPRECATED;1.0;2.36 +29686-3;Orientia tsutsugamushi Gilliam Ab;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Gilliam Ab [Titer] in Serum;O tsut Gill Ab Titr Ser;;ACTIVE;2.03;2.30 +29687-1;Orientia tsutsugamushi Gilliam Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Orientia tsutsugamushi Gilliam Ab [Presence] in Serum;O tsut Gill Ab Ser Ql;;ACTIVE;2.03;2.56 +29688-9;Orientia tsutsugamushi Karp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Karp Ab [Titer] in Serum;O tsut Karp Ab Titr Ser;;ACTIVE;2.03;2.30 +29689-7;Orientia tsutsugamushi Karp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Orientia tsutsugamushi Karp Ab [Presence] in Serum;O tsut Karp Ab Ser Ql;;ACTIVE;2.03;2.56 +29690-5;Orientia tsutsugamushi Kato Ab;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Kato Ab [Titer] in Serum;O tsut Kato Ab Titr Ser;;ACTIVE;2.03;2.30 +29691-3;Orientia tsutsugamushi Kato Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Orientia tsutsugamushi Kato Ab [Presence] in Serum;O tsut Kato Ab Ser Ql;;ACTIVE;2.03;2.56 +29692-1;Orientia tsutsugamushi Litchfield Ab;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Litchfield Ab [Titer] in Serum;O tsut Litch Ab Titr Ser;;ACTIVE;2.03;2.30 +29693-9;Orientia tsutsugamushi Litchfield Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Orientia tsutsugamushi Litchfield Ab [Presence] in Serum;O tsut Litch Ab Ser Ql;;ACTIVE;2.03;2.56 +2969-4;Stercobilin;PrThr;Pt;Stool;Ord;;CHEM;1;Stercobilin [Presence] in Stool;Stercobilin Stl Ql;;ACTIVE;1.0;2.56 +29694-7;Leptospira interrogans serovar Celledoni Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Celledoni Ab [Presence] in Serum;L inter Celled Ab Ser Ql;;ACTIVE;2.03;2.56 +29695-4;Leptospira interrogans serovar Bulgarica Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Bulgarica Ab [Presence] in Serum;L inter Bulgar Ab Ser Ql;;ACTIVE;2.03;2.56 +29696-2;Leptospira interrogans serovar Cynopteri Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Cynopteri Ab [Presence] in Serum;L inter Cynop Ab Ser Ql;;ACTIVE;2.03;2.56 +29697-0;Leptospira interrogans serovar Djasiman Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Djasiman Ab [Presence] in Serum;L inter Djasim Ab Ser Ql;;ACTIVE;2.03;2.56 +29698-8;Leptospira interrogans serovar Javanica Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Javanica Ab [Presence] in Serum;L inter Javani Ab Ser Ql;;ACTIVE;2.03;2.56 +29699-6;Leptospira interrogans serovar Panama Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Panama Ab [Presence] in Serum;L inter Panam Ab Ser Ql;;ACTIVE;2.03;2.56 +29700-2;Leptospira interrogans serovar Shermani Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Shermani Ab [Presence] in Serum;L inter Sherm Ab Ser Ql;;ACTIVE;2.03;2.56 +29701-0;Leptospira interrogans serovar Zanoni Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Zanoni Ab [Presence] in Serum;L inter Zanoni Ab Ser Ql;;ACTIVE;2.03;2.56 +2970-2;Streptomyces proteinase;PrThr;Pt;Ser;Ord;;CHEM;1;Streptomyces proteinase [Presence] in Serum;Streptomyces Proteinase Ser Ql;;ACTIVE;1.0;2.56 +29702-8;Rickettsia conorii Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia conorii Ab [Presence] in Serum by Immunofluorescence;R conorii Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29703-6;Rickettsia sibirica Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia sibirica Ab [Titer] in Serum by Immunofluorescence;R sibirica Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29704-4;Rickettsia sibirica Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia sibirica Ab [Presence] in Serum by Immunofluorescence;R sibirica Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29705-1;Rickettsia rickettsii Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia rickettsii Ab [Titer] in Serum by Immunofluorescence;R rickettsi Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29706-9;Rickettsia rickettsii Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia rickettsii Ab [Presence] in Serum by Immunofluorescence;R rickettsi Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29707-7;Rickettsia akari Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia akari Ab [Titer] in Serum by Immunofluorescence;R akari Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29708-5;Rickettsia akari Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia akari Ab [Presence] in Serum by Immunofluorescence;R akari Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29709-3;Rickettsia prowazekii Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia prowazekii Ab [Titer] in Serum by Immunofluorescence;R prowazek Ab Titr Ser IF;;ACTIVE;2.03;2.30 +2971-0;Substance P;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Substance P [Mass/volume] in Serum or Plasma;Substance P SerPl-mCnc;;ACTIVE;1.0;2.73 +29710-1;Rickettsia prowazekii Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia prowazekii Ab [Presence] in Serum by Immunofluorescence;R prowazek Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29711-9;Rickettsia typhi Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhi Ab [Titer] in Serum by Immunofluorescence;R typhi Ab Titr Ser IF;;ACTIVE;2.03;2.73 +29712-7;Rickettsia typhi Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia typhi Ab [Presence] in Serum by Immunofluorescence;R typhi Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29713-5;Orientia tsutsugamushi Gilliam Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Gilliam Ab [Titer] in Serum by Immunofluorescence;O tsut Gill Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29714-3;Orientia tsutsugamushi Gilliam Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Orientia tsutsugamushi Gilliam Ab [Presence] in Serum by Immunofluorescence;O tsut Gill Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29715-0;Orientia tsutsugamushi Karp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Karp Ab [Titer] in Serum by Immunofluorescence;O tsut Karp Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29716-8;Orientia tsutsugamushi Karp Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Orientia tsutsugamushi Karp Ab [Presence] in Serum by Immunofluorescence;O tsut Karp Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29717-6;Orientia tsutsugamushi Kato Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Kato Ab [Titer] in Serum by Immunofluorescence;O tsut Kato Ab Titr Ser IF;;ACTIVE;2.03;2.30 +29718-4;Orientia tsutsugamushi Kato Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Orientia tsutsugamushi Kato Ab [Presence] in Serum by Immunofluorescence;O tsut Kato Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29719-2;Orientia tsutsugamushi Litchfield Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Litchfield Ab [Titer] in Serum by Immunofluorescence;O tsut Litch Ab Titr Ser IF;;ACTIVE;2.03;2.30 +297-2;Ketoconazole;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ketoconazole [Susceptibility] by Serum bactericidal titer;Ketoconazole Titr SBT;;ACTIVE;1.0;2.32 +29720-0;Orientia tsutsugamushi Litchfield Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Orientia tsutsugamushi Litchfield Ab [Presence] in Serum by Immunofluorescence;O tsut Litch Ab Ser Ql IF;;ACTIVE;2.03;2.56 +29721-8;Influenza virus C Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Influenza virus C Ag [Presence] in Specimen by Immunofluorescence;FLUCV Ag Spec Ql IF;;ACTIVE;2.03;2.69 +29722-6;Chlamydophila pneumoniae Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Chlamydophila pneumoniae Ag [Presence] in Specimen by Immunofluorescence;C pneum Ag Spec Ql IF;;ACTIVE;2.03;2.69 +29723-4;Bordetella parapertussis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bordetella parapertussis DNA [Presence] in Specimen by NAA with probe detection;B parapert DNA Spec Ql NAA+probe;;ACTIVE;2.03;2.73 +29724-2;Leptospira interrogans serovar Celledoni Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Celledoni Ab [Presence] in Serum by Agglutination;L inter Celled Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29725-9;Leptospira interrogans serovar Bulgarica Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Bulgarica Ab [Presence] in Serum by Agglutination;L inter Bulgar Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29726-7;Leptospira interrogans serovar Cynopteri Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Cynopteri Ab [Presence] in Serum by Agglutination;L inter Cynop Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29727-5;Leptospira interrogans serovar Djasiman Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Djasiman Ab [Presence] in Serum by Agglutination;L inter Djasim Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +2972-8;Succinate;MCnc;Pt;Urine;Qn;;CHEM;1;Succinate [Mass/volume] in Urine;Succinate Ur-mCnc;;DISCOURAGED;1.0;2.73 +29728-3;Leptospira interrogans serovar Javanica Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Javanica Ab [Presence] in Serum by Agglutination;L inter Javani Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29729-1;Leptospira interrogans serovar Panama Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Panama Ab [Presence] in Serum by Agglutination;L inter Panam Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29730-9;Leptospira interrogans serovar Shermani Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Shermani Ab [Presence] in Serum by Agglutination;L inter Sherm Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29731-7;Leptospira interrogans serovar Zanoni Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Zanoni Ab [Presence] in Serum by Agglutination;L inter Zanoni Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29732-5;Leptospira interrogans serovar Robinsoni Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Robinsoni Ab [Presence] in Serum by Agglutination;L inter Robins Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29733-3;Leptospira interrogans serovar Kremastos Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Kremastos Ab [Presence] in Serum by Agglutination;L inter Krema Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29734-1;Leptospira interrogans serovar Szwajizak Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Szwajizak Ab [Presence] in Serum by Agglutination;L inter Szwaji Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +29735-8;Leptospira interrogans serovar Medanensis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Leptospira interrogans sv Medanensis Ab [Presence] in Serum by Agglutination;L inter Medane Ab Ser Ql Aggl;;ACTIVE;2.03;2.56 +2973-6;Succinylacetone;MCnc;Pt;Urine;Qn;;CHEM;1;Succinylacetone [Mass/volume] in Urine;Succinylacetone Ur-mCnc;;DISCOURAGED;1.0;2.73 +29736-6;Rickettsia sibirica Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia sibirica Ab [Presence] in Serum;R sibirica Ab Ser Ql;;ACTIVE;2.03;2.56 +29737-4;Rickettsia rickettsii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia rickettsii Ab [Titer] in Serum;R rickettsi Ab Titr Ser;;ACTIVE;2.03;2.30 +29738-2;Leptospira interrogans serovar Robinsoni Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Robinsoni Ab [Presence] in Serum;L inter Robins Ab Ser Ql;;ACTIVE;2.03;2.56 +29739-0;Leptospira interrogans serovar Kremastos Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Kremastos Ab [Presence] in Serum;L inter Krema Ab Ser Ql;;ACTIVE;2.03;2.56 +29740-8;Leptospira interrogans serovar Szwajizak Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Szwajizak Ab [Presence] in Serum;L inter Szwaji Ab Ser Ql;;ACTIVE;2.03;2.56 +29741-6;Leptospira interrogans serovar Medanensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leptospira interrogans sv Medanensis Ab [Presence] in Serum;L inter Medane Ab Ser Ql;;ACTIVE;2.03;2.56 +29742-4;Date last dose;TmStp;Pt;Dose;Qn;;DRUGDOSE;1;Date last dose;Date Last Dose;;ACTIVE;2.03;2.73 +29743-2;Cryofibrinogen;PrThr;Pt;Plas;Ord;3D RT incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 3 day RT incubation;Cryofib Plas Ql 3D RT Inc;;ACTIVE;2.03;2.56 +2974-4;Sucrose;MCnc;Pt;XXX;Qn;;CHEM;1;Sucrose [Mass/volume] in Specimen;Sucrose Spec-mCnc;;ACTIVE;1.0;2.69 +29744-0;Cryofibrinogen;PrThr;Pt;Plas;Ord;3D 37 deg C incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 3 day 37 degree C incubation;Cryofib Plas Ql 3D Inc;;ACTIVE;2.03;2.73 +29745-7;Cryoglobulin;PrThr;Pt;Ser;Ord;3D RT incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 3 day RT incubation;Cryoglob Ser Ql 3D RT Inc;;ACTIVE;2.03;2.56 +29746-5;Cryoglobulin;PrThr;Pt;Ser;Ord;3D 37 deg C incubation;CHEM;1;Cryoglobulin [Presence] in Serum by 3 day 37 degree C incubation;Cryoglob Ser Ql 3D Inc;;ACTIVE;2.03;2.56 +29747-3;Tocopherols;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tocopherols [Moles/volume] in Serum or Plasma;Tocopherols SerPl-sCnc;;ACTIVE;2.03;2.70 +29748-1;Protein;MCnt;Pt;Tiss;Qn;;CHEM;1;Protein [Mass/mass] in Tissue;Prot Tiss-mCnt;;ACTIVE;2.03;2.70 +29749-9;Dialysis records;Find;-;^Patient;Doc;;DOC.MISC;2;Dialysis records;Dialysis records;;ACTIVE;2.03;2.67 +29750-7;Neonatal intensive care records;Find;-;^Patient;Doc;;DOC.MISC;2;Neonatal intensive care records;Neonatal intensive care records;;ACTIVE;2.03;2.67 +2975-1;Sulfate;MCnc;Pt;Urine;Qn;;CHEM;1;Sulfate [Mass/volume] in Urine;Sulfate Ur-mCnc;;ACTIVE;1.0;2.73 +29751-5;Critical care records;Find;-;^Patient;Doc;;DOC.MISC;2;Critical care records;Critical care records;;ACTIVE;2.03;2.67 +29752-3;Perioperative records;Find;-;^Patient;Doc;;DOC.MISC;2;Perioperative records;Perioperative records;;ACTIVE;2.03;2.67 +29753-1;Initial evaluation note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Initial evaluation note;Nurse Initial eval note;;ACTIVE;2.03;2.50 +29754-9;Nystagmogram study;Find;Pt;XXX;Doc;Nystagmogram;DOC.MISC;2;Nystagmogram study;Nystagmogram study;;ACTIVE;2.03;2.72 +29755-6;Nerve conduction study;Find;Pt;^Patient;Doc;Nerve conduction;CLIN;2;Nerve conduction study;Nerve conduction study;;ACTIVE;2.03;2.72 +29756-4;Peritoneoscopy study;Find;Pt;Peritoneal space;Doc;Peritoneoscopy;CLIN;2;Peritoneoscopy study;Peritoneoscopy study;;ACTIVE;2.03;2.72 +29757-2;Colposcopy study;Find;Pt;Cvx/Vag;Doc;Colposcopy;OBGYN;2;Colposcopy study;Colposcopy study;;ACTIVE;2.03;2.72 +29758-0;Nystagmus examination;Prid;Pt;Eye.left;Nom;;EYE.PX;2;Left eye Nystagmus examination;L eye Nystagmus exam;;ACTIVE;2.03;2.68 +29759-8;Nystagmus examination;Find;Pt;Eye.left;Nar;;EYE.PX;2;Left eye Nystagmus examination Narrative;L eye Nystagmus exam;;ACTIVE;2.03;2.68 +29760-6;Bilirubin.glucuronidated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.conjugated [Moles/volume] in Serum or Plasma;Bilirub Conj SerPl-sCnc;;ACTIVE;2.03;2.73 +29761-4;Discharge summary note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Discharge summary;Dentistry D/C sum;;ACTIVE;2.03;2.73 +29762-2;Social history;Find;Pt;^Patient;Nar;;H&P.HX;2;Social history Narrative;Social Hx;;ACTIVE;2.03;2.63 +29763-0;Protoporphyrin.zinc;SRto;Pt;RBC;Qn;;CHEM;1;Protoporphyrin.zinc [Molar ratio] in Red Blood Cells;ZPP RBC-sRto;;ACTIVE;2.03;2.73 +29764-8;Iron;SCnc;Pt;Body fld;Qn;;CHEM;1;Iron [Moles/volume] in Body fluid;Iron Fld-sCnc;;ACTIVE;2.03;2.70 +29765-5;Cholesterol;SCnc;Pt;Body fld;Qn;;CHEM;1;Cholesterol [Moles/volume] in Body fluid;Cholest Fld-sCnc;;ACTIVE;2.03;2.73 +29766-3;Triglyceride;SCnc;Pt;Body fld;Qn;;CHEM;1;Triglyceride [Moles/volume] in Body fluid;Trigl Fld-sCnc;;ACTIVE;2.03;2.73 +29767-1;Bilirubin;SCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Body fluid;Bilirub Fld-sCnc;;ACTIVE;2.03;2.73 +29768-9;Date vaccine information statement published;Date;Pt;^Patient;Qn;;VACCIN;2;Date vaccine information statement published;Date vaccine info published;;ACTIVE;2.03;2.73 +2976-9;Sulfate.inorganic;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sulfate.inorganic [Mass/volume] in Serum or Plasma;Inorg Sulfate SerPl-mCnc;;ACTIVE;1.0;2.44 +29769-7;Date vaccine information statement presented;Date;Pt;^Patient;Qn;;VACCIN;2;Date vaccine information statement presented;Date vaccine info presented;;ACTIVE;2.03;2.73 +29770-5;Karyotype;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Karyotype [Identifier] in Blood or Tissue Nominal;Karyotyp Bld/T;;ACTIVE;2.04;2.73 +29771-3;Hemoglobin.gastrointestinal.lower;PrThr;Pt;Stool;Ord;IA;CHEM;1;Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay;Hemoccult Stl Ql IA;;ACTIVE;2.04;2.73 +29772-1;Coxiella burnetii phase 2 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxiella burnetii phase 2 Ab [Titer] in Serum by Complement fixation;C burnet Ph2 Ab Titr Ser CF;;ACTIVE;2.04;2.30 +29773-9;Coxiella burnetii phase 2 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Presence] in Serum by Immunoassay;C burnet Ph2 IgM Ser Ql IA;;ACTIVE;2.04;2.56 +29774-7;Coxiella burnetii phase 1 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxiella burnetii phase 1 Ab [Titer] in Serum by Complement fixation;C burnet Ph1 Ab Titr Ser CF;;ACTIVE;2.04;2.30 +29775-4;Insulin-like growth factor-I;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor-I [Moles/volume] in Serum or Plasma;IGF-I SerPl-sCnc;;ACTIVE;2.04;2.70 +29776-2;Microscopic observation;Prid;Pt;Bld;Nom;Brilliant cresyl blue;MICRO;1;Microscopic observation [Identifier] in Blood by Brilliant cresyl blue;Brilliant Cresyl Blue Bld;;ACTIVE;2.04;2.73 +2977-7;Sulfite oxidase;CCnc;Pt;Plas;Qn;;CHEM;1;Sulfite oxidase [Enzymatic activity/volume] in Plasma;Sulfite Oxidase Plas-cCnc;;ACTIVE;1.0;2.68 +29777-0;Coxiella burnetii phase 2 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Presence] in Serum by Immunoassay;C burnet Ph2 IgG Ser Ql IA;;ACTIVE;2.04;2.56 +29778-8;West Nile virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;West Nile virus IgM Ab [Presence] in Specimen by Immunoassay;WNV IgM Spec Ql IA;;ACTIVE;2.04;2.73 +29779-6;West Nile virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;West Nile virus neutralizing antibody [Titer] in Specimen by Neutralization test;WNV NAb Titr Spec Nt;;ACTIVE;2.04;2.72 +29780-4;West Nile virus Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;West Nile virus IgM Ab [Presence] in Specimen;WNV IgM Spec Ql;;ACTIVE;2.04;2.73 +29781-2;West Nile virus Ab;Titr;Pt;XXX;Qn;;MICRO;1;West Nile virus Ab [Titer] in Specimen;WNV Ab Titr Spec;;ACTIVE;2.04;2.69 +29782-0;Trivittatus virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Trivittatus virus neutralizing antibody [Titer] in Specimen by Neutralization test;TVTV NAb Titr Spec Nt;;ACTIVE;2.04;2.72 +29783-8;Saint Louis encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Saint Louis encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;SLEV NAb Titr Spec Nt;;ACTIVE;2.04;2.72 +29784-6;Highlands J virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Highlands J virus neutralizing antibody [Titer] in Specimen by Neutralization test;HJV NAb Titr Spec Nt;;ACTIVE;2.04;2.72 +2978-5;Superoxide dismutase;CCnc;Pt;Plas;Qn;;CHEM;1;Superoxide dismutase [Enzymatic activity/volume] in Plasma;SOD Plas-cCnc;;ACTIVE;1.0;2.44 +29785-3;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IF;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Specimen by Immunofluorescence;EEEV IgG Spec Ql IF;;ACTIVE;2.04;2.69 +29786-1;Jamestown canyon virus Ab.IgM;ACnc;Pt;XXX;Qn;IF;MICRO;1;Jamestown canyon virus IgM Ab [Units/volume] in Specimen by Immunofluorescence;JCV IgM Spec IF-aCnc;;ACTIVE;2.04;2.69 +29787-9;Jamestown canyon virus Ab.IgM;PrThr;Pt;XXX;Ord;IF;MICRO;1;Jamestown canyon virus IgM Ab [Presence] in Specimen by Immunofluorescence;JCV IgM Spec Ql IF;;ACTIVE;2.04;2.69 +29788-7;Jamestown canyon virus Ab.IgG;ACnc;Pt;XXX;Qn;IF;MICRO;1;Jamestown canyon virus IgG Ab [Units/volume] in Specimen by Immunofluorescence;JCV IgG Spec IF-aCnc;;ACTIVE;2.04;2.69 +29789-5;La Crosse virus Ab.IgG;PrThr;Pt;XXX;Ord;IF;MICRO;1;La Crosse virus IgG Ab [Presence] in Specimen by Immunofluorescence;LACV IgG Spec Ql IF;;ACTIVE;2.04;2.69 +29790-3;La Crosse virus Ab.IgM;PrThr;Pt;XXX;Ord;IF;MICRO;1;La Crosse virus IgM Ab [Presence] in Specimen by Immunofluorescence;LACV IgM Spec Ql IF;;ACTIVE;2.04;2.69 +29791-1;Powassan virus Ab.IgG;PrThr;Pt;XXX;Ord;IF;MICRO;1;Powassan virus IgG Ab [Presence] in Specimen by Immunofluorescence;POWV IgG Spec Ql IF;;ACTIVE;2.04;2.69 +29792-9;Powassan virus Ab.IgM;PrThr;Pt;XXX;Ord;IF;MICRO;1;Powassan virus IgM Ab [Presence] in Specimen by Immunofluorescence;POWV IgM Spec Ql IF;;ACTIVE;2.04;2.69 +2979-3;Taurine;MCnc;Pt;CSF;Qn;;CHEM;1;Taurine [Mass/volume] in Cerebral spinal fluid;Taurine CSF-mCnc;;ACTIVE;1.0;2.42 +29793-7;Anaplasma phagocytophilum Ab.IgG;PrThr;Pt;XXX;Ord;IB;MICRO;1;Anaplasma phagocytophilum IgG Ab [Presence] in Specimen by Immunoblot;A phagocytoph IgG Spec Ql IB;;ACTIVE;2.04;2.69 +29794-5;Anaplasma phagocytophilum Ab.IgM;PrThr;Pt;XXX;Ord;IB;MICRO;1;Anaplasma phagocytophilum IgM Ab [Presence] in Specimen by Immunoblot;A phagocytoph IgM Spec Ql IB;;ACTIVE;2.04;2.69 +29795-2;Trivittatus virus Ab.Neut;Titr;Pt;CSF;Qn;Neut;MICRO;1;Trivittatus virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test;TVTV NAb Titr CSF Nt;;ACTIVE;2.04;2.72 +29796-0;Saint Louis encephalitis virus Ab.Neut;Titr;Pt;CSF;Qn;Neut;MICRO;1;Saint Louis encephalitis virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test;SLEV NAb Titr CSF Nt;;ACTIVE;2.04;2.72 +29797-8;Highlands J virus Ab.Neut;Titr;Pt;CSF;Qn;Neut;MICRO;1;Highlands J virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test;HJV NAb Titr CSF Nt;;ACTIVE;2.04;2.72 +29798-6;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;CSF;Ord;IF;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;EEEV IgG CSF Ql IF;;ACTIVE;2.04;2.56 +29799-4;Jamestown canyon virus Ab.IgM;ACnc;Pt;CSF;Qn;IF;MICRO;1;Jamestown canyon virus IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;JCV IgM CSF IF-aCnc;;ACTIVE;2.04;2.69 +298-0;Lincomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Lincomycin [Susceptibility] by Minimum lethal concentration (MLC);Lincomycin Islt MLC;;ACTIVE;1.0;2.19 +29800-0;Jamestown canyon virus Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;Jamestown canyon virus IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;JCV IgM CSF Ql IF;;ACTIVE;2.04;2.56 +2980-1;Taurine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Taurine [Presence] in Serum or Plasma;Taurine SerPl Ql;;ACTIVE;1.0;2.73 +29801-8;Jamestown canyon virus Ab.IgG;ACnc;Pt;CSF;Qn;IF;MICRO;1;Jamestown canyon virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;JCV IgG CSF IF-aCnc;;ACTIVE;2.04;2.69 +29802-6;La Crosse virus Ab.IgG;PrThr;Pt;CSF;Ord;IF;MICRO;1;La Crosse virus IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;LACV IgG CSF Ql IF;;ACTIVE;2.04;2.56 +29803-4;La Crosse virus Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;La Crosse virus IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;LACV IgM CSF Ql IF;;ACTIVE;2.04;2.56 +29804-2;Powassan virus Ab.IgG;PrThr;Pt;CSF;Ord;IF;MICRO;1;Powassan virus IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;POWV IgG CSF Ql IF;;ACTIVE;2.04;2.56 +29805-9;Powassan virus Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;Powassan virus IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;POWV IgM CSF Ql IF;;ACTIVE;2.04;2.56 +29806-7;Anaplasma phagocytophilum Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Anaplasma phagocytophilum IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;A phagocytoph IgG CSF Ql IB;;ACTIVE;2.04;2.58 +29807-5;Anaplasma phagocytophilum Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Anaplasma phagocytophilum IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;A phagocytoph IgM CSF Ql IB;;ACTIVE;2.04;2.58 +29808-3;Trivittatus virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Trivittatus virus neutralizing antibody [Titer] in Serum by Neutralization test;TVTV NAb Titr Ser Nt;;ACTIVE;2.04;2.72 +29809-1;Saint Louis encephalitis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Saint Louis encephalitis virus neutralizing antibody [Titer] in Serum by Neutralization test;SLEV NAb Titr Ser Nt;;ACTIVE;2.04;2.72 +29810-9;Highlands J virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Highlands J virus neutralizing antibody [Titer] in Serum by Neutralization test;HJV NAb Titr Ser Nt;;ACTIVE;2.04;2.72 +29811-7;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Serum by Immunofluorescence;EEEV IgG Ser Ql IF;;ACTIVE;2.04;2.56 +29812-5;Jamestown canyon virus Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Jamestown canyon virus IgM Ab [Units/volume] in Serum by Immunofluorescence;JCV IgM Ser IF-aCnc;;ACTIVE;2.04;2.69 +29813-3;Jamestown canyon virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Jamestown canyon virus IgM Ab [Presence] in Serum by Immunofluorescence;JCV IgM Ser Ql IF;;ACTIVE;2.04;2.56 +29814-1;Jamestown canyon virus Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Jamestown canyon virus IgG Ab [Units/volume] in Serum by Immunofluorescence;JCV IgG Ser IF-aCnc;;ACTIVE;2.04;2.69 +29815-8;La Crosse virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;La Crosse virus IgG Ab [Presence] in Serum by Immunofluorescence;LACV IgG Ser Ql IF;;ACTIVE;2.04;2.73 +29816-6;La Crosse virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;La Crosse virus IgM Ab [Presence] in Serum by Immunofluorescence;LACV IgM Ser Ql IF;;ACTIVE;2.04;2.73 +29817-4;Powassan virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Powassan virus IgG Ab [Presence] in Serum by Immunofluorescence;POWV IgG Ser Ql IF;;ACTIVE;2.04;2.56 +29818-2;Powassan virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Powassan virus IgM Ab [Presence] in Serum by Immunofluorescence;POWV IgM Ser Ql IF;;ACTIVE;2.04;2.56 +2981-9;Taurine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurine [Mass/volume] in Serum or Plasma;Taurine SerPl-mCnc;;ACTIVE;1.0;2.73 +29819-0;Anaplasma phagocytophilum Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Anaplasma phagocytophilum IgG Ab [Presence] in Serum by Immunoblot;A phagocytoph IgG Ser Ql IB;;ACTIVE;2.04;2.58 +29820-8;Anaplasma phagocytophilum Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Anaplasma phagocytophilum IgM Ab [Presence] in Serum by Immunoblot;A phagocytoph IgM Ser Ql IB;;ACTIVE;2.04;2.58 +29821-6;Trivittatus virus Ab;Titr;Pt;XXX;Qn;;MICRO;1;Trivittatus virus Ab [Titer] in Specimen;TVTV Ab Titr Spec;;ACTIVE;2.04;2.69 +29822-4;Saint Louis encephalitis virus Ab;Titr;Pt;XXX;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Specimen;SLEV Ab Titr Spec;;ACTIVE;2.04;2.69 +29823-2;Highlands J virus Ab;Titr;Pt;XXX;Qn;;MICRO;1;Highlands J virus Ab [Titer] in Specimen;HJV Ab Titr Spec;;ACTIVE;2.04;2.69 +29824-0;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Specimen;EEEV IgG Spec Ql;;ACTIVE;2.04;2.69 +29825-7;Jamestown canyon virus Ab.IgM;ACnc;Pt;XXX;Qn;;MICRO;1;Jamestown canyon virus IgM Ab [Units/volume] in Specimen;JCV IgM Spec-aCnc;;ACTIVE;2.04;2.69 +29826-5;Jamestown canyon virus Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;Jamestown canyon virus IgM Ab [Presence] in Specimen;JCV IgM Spec Ql;;ACTIVE;2.04;2.69 +2982-7;Taurine;MCnc;Pt;Urine;Qn;;CHEM;1;Taurine [Mass/volume] in Urine;Taurine Ur-mCnc;;ACTIVE;1.0;2.73 +29827-3;Jamestown canyon virus Ab.IgG;ACnc;Pt;XXX;Qn;;MICRO;1;Jamestown canyon virus IgG Ab [Units/volume] in Specimen;JCV IgG Spec-aCnc;;ACTIVE;2.04;2.69 +29828-1;La Crosse virus Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;La Crosse virus IgG Ab [Presence] in Specimen;LACV IgG Spec Ql;;ACTIVE;2.04;2.69 +29829-9;La Crosse virus Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;La Crosse virus IgM Ab [Presence] in Specimen;LACV IgM Spec Ql;;ACTIVE;2.04;2.69 +29830-7;Powassan virus Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;Powassan virus IgG Ab [Presence] in Specimen;POWV IgG Spec Ql;;ACTIVE;2.04;2.69 +29831-5;Powassan virus Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;Powassan virus IgM Ab [Presence] in Specimen;POWV IgM Spec Ql;;ACTIVE;2.04;2.69 +29832-3;Anaplasma phagocytophilum Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;Anaplasma phagocytophilum IgG Ab [Presence] in Specimen;A phagocytoph IgG Spec Ql;;ACTIVE;2.04;2.69 +29833-1;Anaplasma phagocytophilum Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;Anaplasma phagocytophilum IgM Ab [Presence] in Specimen;A phagocytoph IgM Spec Ql;;ACTIVE;2.04;2.69 +29834-9;Trivittatus virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Trivittatus virus Ab [Titer] in Cerebral spinal fluid;TVTV Ab Titr CSF;;ACTIVE;2.04;2.30 +2983-5;Terminal deoxyribonucleotidyl transferase;CCnc;Pt;Plas;Qn;;CHEM;1;Terminal deoxyribonucleotidyl transferase [Enzymatic activity/volume] in Plasma;TdT Plas-cCnc;;ACTIVE;1.0;2.68 +29835-6;Highlands J virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Highlands J virus Ab [Titer] in Cerebral spinal fluid;HJV Ab Titr CSF;;ACTIVE;2.04;2.30 +29836-4;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Cerebral spinal fluid;EEEV IgG CSF Ql;;ACTIVE;2.04;2.73 +29837-2;Jamestown canyon virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Jamestown canyon virus IgM Ab [Units/volume] in Cerebral spinal fluid;JCV IgM CSF-aCnc;;ACTIVE;2.04;2.69 +29838-0;Jamestown canyon virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Jamestown canyon virus IgM Ab [Presence] in Cerebral spinal fluid;JCV IgM CSF Ql;;ACTIVE;2.04;2.56 +29839-8;Jamestown canyon virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Jamestown canyon virus IgG Ab [Units/volume] in Cerebral spinal fluid;JCV IgG CSF-aCnc;;ACTIVE;2.04;2.69 +29840-6;La Crosse virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;La Crosse virus IgG Ab [Presence] in Cerebral spinal fluid;LACV IgG CSF Ql;;ACTIVE;2.04;2.58 +29841-4;La Crosse virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;La Crosse virus IgM Ab [Presence] in Cerebral spinal fluid;LACV IgM CSF Ql;;ACTIVE;2.04;2.58 +29842-2;Powassan virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Powassan virus IgG Ab [Presence] in Cerebral spinal fluid;POWV IgG CSF Ql;;ACTIVE;2.04;2.56 +2984-3;Testosterone;MCnc;Pt;Saliva;Qn;;CHEM;1;Testosterone [Mass/volume] in Saliva (oral fluid);Testost Sal-mCnc;;ACTIVE;1.0;2.73 +29843-0;Powassan virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Powassan virus IgM Ab [Presence] in Cerebral spinal fluid;POWV IgM CSF Ql;;ACTIVE;2.04;2.56 +29844-8;Anaplasma phagocytophilum Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Anaplasma phagocytophilum IgG Ab [Presence] in Cerebral spinal fluid;A phagocytoph IgG CSF Ql;;ACTIVE;2.04;2.56 +29845-5;Anaplasma phagocytophilum Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Anaplasma phagocytophilum IgM Ab [Presence] in Cerebral spinal fluid;A phagocytoph IgM CSF Ql;;ACTIVE;2.04;2.56 +29846-3;Trivittatus virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Trivittatus virus Ab [Titer] in Serum;TVTV Ab Titr Ser;;ACTIVE;2.04;2.30 +29847-1;Highlands J virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Highlands J virus Ab [Titer] in Serum;HJV Ab Titr Ser;;ACTIVE;2.04;2.30 +29848-9;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Serum;EEEV IgG Ser Ql;;ACTIVE;2.04;2.56 +29849-7;Jamestown canyon virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Jamestown canyon virus IgM Ab [Units/volume] in Serum;JCV IgM Ser-aCnc;;ACTIVE;2.04;2.69 +2985-0;Testosterone;MCnc;Pt;Semen;Qn;;CHEM;1;Testosterone [Mass/volume] in Semen;Testost Smn-mCnc;;ACTIVE;1.0;2.34 +29850-5;Jamestown canyon virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Jamestown canyon virus IgM Ab [Presence] in Serum;JCV IgM Ser Ql;;ACTIVE;2.04;2.56 +29851-3;Jamestown canyon virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Jamestown canyon virus IgG Ab [Units/volume] in Serum;JCV IgG Ser-aCnc;;ACTIVE;2.04;2.69 +29852-1;La Crosse virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;La Crosse virus IgG Ab [Presence] in Serum;LACV IgG Ser Ql;;ACTIVE;2.04;2.58 +29853-9;La Crosse virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;La Crosse virus IgM Ab [Presence] in Serum;LACV IgM Ser Ql;;ACTIVE;2.04;2.58 +29854-7;Powassan virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Powassan virus IgG Ab [Presence] in Serum;POWV IgG Ser Ql;;ACTIVE;2.04;2.56 +29855-4;Powassan virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Powassan virus IgM Ab [Presence] in Serum;POWV IgM Ser Ql;;ACTIVE;2.04;2.56 +29856-2;Anaplasma phagocytophilum Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Anaplasma phagocytophilum IgG Ab [Presence] in Serum;A phagocytoph IgG Ser Ql;;ACTIVE;2.04;2.73 +29857-0;Anaplasma phagocytophilum Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Anaplasma phagocytophilum IgM Ab [Presence] in Serum;A phagocytoph IgM Ser Ql;;ACTIVE;2.04;2.56 +29858-8;Alpha hydroxybutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha hydroxybutyrate/Creatinine [Molar ratio] in Urine;A-OH-Butyr/Creat Ur-sRto;;ACTIVE;2.04;2.73 +29859-6;Adipate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adipate/Creatinine [Molar ratio] in Urine;Adipate/Creat Ur-sRto;;ACTIVE;2.04;2.73 +29860-4;Cardiolipin Ab;PrThr;Pt;Ser;Ord;;COAG;1;Cardiolipin Ab [Presence] in Serum;Cardiolipin Ab Ser Ql;;ACTIVE;2.04;2.73 +29861-2;Levisticum officinale Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lovage IgE Ab RAST class [Presence] in Serum;Lovage IgE RAST Ql;;ACTIVE;2.04;2.58 +29862-0;Diospyros kaki Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Persimmon IgE Ab RAST class [Presence] in Serum;Persimmon IgE RAST Ql;;ACTIVE;2.04;2.73 +29863-8;IgD Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgD Ag [Presence] in Tissue by Immune stain;IgD Ag Tiss Ql ImStn;;ACTIVE;2.04;2.73 +29864-6;2-Oxo,3-Methylvalerate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Oxo,3-Methylvalerate [Presence] in Urine;2Oxo3Me-valerate Ur Ql;;ACTIVE;2.04;2.73 +29865-3;2-Oxoisocaproate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Oxoisocaproate [Presence] in Urine;2Oxoisocaproate Ur Ql;;ACTIVE;2.04;2.73 +29866-1;2-Oxoisovalerate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Oxoisovalerate [Presence] in Urine;2Oxoisovalerate Ur Ql;;ACTIVE;2.04;2.73 +29867-9;3-Hydroxy,3-Methylglutarate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;3-Hydroxy,3-Methylglutarate [Presence] in Urine;3OH3Me-glutarate Ur Ql;;ACTIVE;2.04;2.73 +2986-8;Testosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone [Mass/volume] in Serum or Plasma;Testost SerPl-mCnc;;ACTIVE;1.0;2.73 +29868-7;Gamma hydroxybutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;Gamma hydroxybutyrate [Presence] in Urine;G-OH-Butyr Ur Ql;;ACTIVE;2.04;2.73 +29869-5;4-Hydroxycyclohexylacetate;PrThr;Pt;Urine;Ord;;CHEM;1;4-Hydroxycyclohexylacetate [Presence] in Urine;4OH-Cyclohexylacetate Ur Ql;;ACTIVE;2.04;2.73 +29870-3;4-Hydroxyphenyllactate;PrThr;Pt;Urine;Ord;;CHEM;1;4-Hydroxyphenyllactate [Presence] in Urine;4OH-phenyllactate Ur Ql;;ACTIVE;2.04;2.73 +29871-1;4-Hydroxyphenylpyruvate;PrThr;Pt;Urine;Ord;;CHEM;1;4-Hydroxyphenylpyruvate [Presence] in Urine;4OH-phenylpyruvate Ur Ql;;ACTIVE;2.04;2.73 +29872-9;5-Oxoproline;PrThr;Pt;Urine;Ord;;CHEM;1;5-Oxoproline [Presence] in Urine;5Oxoproline Ur Ql;;ACTIVE;2.04;2.73 +29873-7;Isobutyrylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;Isobutyrylglycine [Presence] in Urine;Isobutyrylgly Ur Ql;;ACTIVE;2.04;2.73 +29874-5;Isovalerylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;Isovalerylglycine [Presence] in Urine;Isovalerylgly Ur Ql;;ACTIVE;2.04;2.73 +29875-2;Lactate;PrThr;Pt;Urine;Ord;;CHEM;1;Lactate [Presence] in Urine;Lactate Ur Ql;;ACTIVE;2.04;2.73 +2987-6;Testosterone;PrThr;Pt;Urine;Ord;;CHEM;1;Testosterone [Presence] in Urine;Testost Ur Ql;;ACTIVE;1.0;2.56 +29876-0;2-Methylcitrate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Methylcitrate [Presence] in Urine;2Me-citrate Ur Ql;;ACTIVE;2.04;2.73 +29877-8;Methylmalonate;PrThr;Pt;Urine;Ord;;CHEM;1;Methylmalonate [Presence] in Urine;Methylmalonate Ur Ql;;ACTIVE;2.04;2.73 +29878-6;Argininosuccinate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Argininosuccinate/Creatinine [Molar ratio] in Urine;Argininosuccinate/Creat Ur-sRto;;ACTIVE;2.04;2.50 +29879-4;Dehydroepiandrosterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA)/Creatinine [Mass Ratio] in 24 hour Urine;DHEA/Creat 24h Ur;;ACTIVE;2.04;2.73 +29880-2;2-Hydroxy-3-Methylvalerate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Hydroxy-3-Methylvalerate [Presence] in Urine;2OH3Me-valerate Ur Ql;;ACTIVE;2.04;2.73 +29881-0;2-Hydroxyglutarate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Hydroxyglutarate [Presence] in Urine;2OH-gluterate Ur Ql;;ACTIVE;2.04;2.73 +29882-8;2-Hydroxyisovalerate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Hydroxyisovalerate [Presence] in Urine;2OH-isovalerate Ur Ql;;ACTIVE;2.04;2.73 +29883-6;2-Hydroxyphenylacetate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;2-Hydroxyphenylacetate [Presence] in Urine;2OH-phenylacetate Ur Ql;;ACTIVE;2.04;2.73 +2988-4;Testosterone;MCnc;Pt;Urine;Qn;;CHEM;1;Testosterone [Mass/volume] in Urine;Testost Ur-mCnc;;ACTIVE;1.0;2.73 +29884-4;2-Methylbutyrylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;2-Methylbutyrylglycine [Presence] in Urine;2Me-butyrylglycine Ur Ql;;ACTIVE;2.04;2.73 +29885-1;Actinobacillus sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Actinobacillus sp identified in Specimen by Organism specific culture;Actinobacillus Spec Cult;;ACTIVE;2.04;2.69 +29886-9;Encephalomyocarditis virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Encephalomyocarditis virus neutralizing antibody [Titer] in Serum by Neutralization test;EMCV NAb Titr Ser Nt;;ACTIVE;2.04;2.72 +29887-7;Pasteurella multocida type;Prid;Pt;Isolate;Nom;;MICRO;1;Pasteurella multocida type [Identifier] in Isolate;P multoc Typ Islt;;ACTIVE;2.04;2.19 +29888-5;Pseudorabies virus.G1 gene deletion Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Pseudorabies virus G1 gene deletion Ab [Presence] in Serum by Immunoassay;PRV G1 Ab Ser Ql IA;;ACTIVE;2.04;2.56 +29889-3;Encephalomyocarditis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Encephalomyocarditis virus Ab [Titer] in Serum;EMCV Ab Titr Ser;;ACTIVE;2.04;2.30 +29890-1;Pseudorabies virus.G1 gene deletion Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Pseudorabies virus G1 gene deletion Ab [Presence] in Serum;PRV G1 Ab Ser Ql;;ACTIVE;2.04;2.56 +29891-9;Carbon dioxide^post dose urea;PrThr;Pt;Exhl gas;Ord;;MICRO;1;Helicobacter pylori [Presence] in Stomach by urea breath test;Urea Breath Test Ql;;ACTIVE;2.04;2.73 +2989-2;Testosterone;MRat;24H;Urine;Qn;;CHEM;1;Testosterone [Mass/time] in 24 hour Urine;Testost 24h Ur-mRate;;ACTIVE;1.0;2.73 +29892-7;Carbon dioxide^post dose urea;ACnc;Pt;Exhl gas;Qn;;MICRO;1;Helicobacter pylori [Quantitative] in Stomach by urea breath test;Urea Breath Test-aCnc;;DISCOURAGED;2.04;2.69 +29893-5;HIV 1 Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1 Ab [Presence] in Serum or Plasma by Immunoassay;HIV1 Ab SerPl Ql IA;;ACTIVE;2.04;2.73 +29894-3;Phosphorus;MCnc;24H;Urine;Qn;;CHEM;1;Deprecated Phosphate [Mass/volume] in 24 hour Urine;Deprecated Phosphorus 24H Ur-mCnc;;DEPRECATED;2.04;2.36 +29895-0;Phosphorus;MRat;24H;Urine;Qn;;CHEM;1;Deprecated Phosphorus [Mass/time] in 24 hour Urine;Deprecated Phosphorus 24H Ur-mRate;;DEPRECATED;2.04;2.40 +29896-8;Cryptococcus sp Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Cryptococcus sp Ag [Presence] in Cerebral spinal fluid by Immunoassay;Cryptoc Ag CSF Ql IA;;ACTIVE;2.04;2.73 +29897-6;Styrene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Styrene [Mass/volume] in Urine;Styrene Ur-mCnc;;ACTIVE;2.04;2.73 +29898-4;Borrelia burgdorferi Ab.IgG;PrThr;Pt;XXX;Ord;IB;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Specimen by Immunoblot;B burgdor IgG Spec Ql IB;;ACTIVE;2.04;2.73 +29899-2;Gamma globulin;PrThr;24H;Urine;Ord;;CHEM;1;Gamma globulin [Presence] in 24 hour Urine;Gamma glob 24h Ur Ql;;ACTIVE;2.04;2.73 +29-9;Ampicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ampicillin [Susceptibility] by Disk diffusion (KB);Ampicillin Islt KB;;ACTIVE;1.0;2.73 +2990-0;Testosterone.free+weakly bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone.free+weakly bound [Mass/volume] in Serum or Plasma;Testosterone.free+WB SerPl-mCnc;;ACTIVE;1.0;2.73 +29900-8;Hepatitis B virus DNA;MCnc;Pt;Ser;Qn;Probe.amp.sig;MICRO;1;Hepatitis B virus DNA [Mass/volume] (viral load) in Serum by Probe with signal amplification;HBV DNA Ser Probe+sig amp-mCnc;;ACTIVE;2.04;2.73 +29901-6;HTLV I+II Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;HTLV I+II Ab [Presence] in Serum by Immunoassay;HTLV I+II Ab Ser Ql IA;;ACTIVE;2.04;2.73 +29902-4;Chlorobenzene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorobenzene [Mass/volume] in Urine;Chlorobenz Ur-mCnc;;ACTIVE;2.04;2.34 +29903-2;Cryptococcus sp Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Cryptococcus sp Ag [Presence] in Serum by Immunoassay;Cryptoc Ag Ser Ql IA;;ACTIVE;2.04;2.73 +29904-0;Toxoplasma gondii DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Specimen by NAA with probe detection;T gondii DNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +29905-7;Entamoeba histolytica Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Entamoeba histolytica Ag [Presence] in Stool by Immunoassay;E histolyt Ag Stl Ql IA;;ACTIVE;2.04;2.73 +29906-5;Haemophilus influenzae A DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae A DNA [Presence] in Specimen by NAA with probe detection;Haem influ A DNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +29907-3;Haemophilus influenzae B DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae B DNA [Presence] in Specimen by NAA with probe detection;Haem influ B DNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +29908-1;Parainfluenza virus 1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Specimen by NAA with probe detection;HPIV1 RNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +29909-9;Parainfluenza virus 2 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Specimen by NAA with probe detection;HPIV2 RNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +29910-7;Parainfluenza virus 3 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Specimen by NAA with probe detection;HPIV3 RNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +29911-5;Magnesium;MCnc;Pt;Stool;Qn;;CHEM;1;Magnesium [Mass/volume] in Stool;Magnesium Stl-mCnc;;ACTIVE;2.04;2.73 +29912-3;Magnesium;MRat;Pt;Stool;Qn;;CHEM;1;Magnesium [Mass/time] in Stool;Magnesium Stl-mRate;;ACTIVE;2.04;2.73 +29913-1;Xylose^2H post 5 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --2 hours post 5 g xylose PO;Xylose 2h p 5 g Xyl PO SerPl-mCnc;;ACTIVE;2.04;2.40 +29914-9;Arsenic;MRat;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic [Mass/time] in Urine;Arsenic Ur-mRate;;DISCOURAGED;2.04;2.73 +29915-6;Tellurium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Tellurium [Mass/time] in 24 hour Urine;Tellurium 24h Ur-mRate;;ACTIVE;2.04;2.46 +29916-4;Cobalt;MRat;24H;Urine;Qn;;DRUG/TOX;1;Cobalt [Mass/time] in 24 hour Urine;Cobalt 24h Ur-mRate;;ACTIVE;2.04;2.73 +29917-2;Selenium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Selenium/Creatinine [Mass Ratio] in 24 hour Urine;Selenium/Creat 24h Ur;;ACTIVE;2.04;2.73 +2991-8;Testosterone.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone Free [Mass/volume] in Serum or Plasma;Testost Free SerPl-mCnc;;ACTIVE;1.0;2.73 +29918-0;Bismuth;MRat;24H;Urine;Qn;;DRUG/TOX;1;Bismuth [Mass/time] in 24 hour Urine;Bismuth 24h Ur-mRate;;ACTIVE;2.04;2.40 +29919-8;Chromium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Chromium/Creatinine [Mass Ratio] in 24 hour Urine;Chromium/Creat 24h Ur;;ACTIVE;2.04;2.73 +29920-6;Beryllium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Beryllium/Creatinine [Mass Ratio] in 24 hour Urine;Beryllium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29921-4;Boron;MRat;24H;Urine;Qn;;DRUG/TOX;1;Boron [Mass/time] in 24 hour Urine;Boron 24h Ur-mRate;;ACTIVE;2.04;2.40 +29922-2;Boron/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Boron/Creatinine [Mass Ratio] in 24 hour Urine;Boron/Creat 24h Ur;;ACTIVE;2.04;2.42 +29923-0;Scandium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Scandium [Mass/volume] in 24 hour Urine;Scandium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29924-8;Scandium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Scandium [Mass/time] in 24 hour Urine;Scandium 24h Ur-mRate;;ACTIVE;2.04;2.40 +29925-5;Scandium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Scandium/Creatinine [Mass Ratio] in 24 hour Urine;Scandium/Creat 24h Ur;;ACTIVE;2.04;2.42 +2992-6;Testosterone;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Testosterone [Mass/volume] in Amniotic fluid;Testost Amn-mCnc;;ACTIVE;1.0;2.34 +29926-3;Boron;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Boron [Mass/volume] in 24 hour Urine;Boron 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29927-1;Beryllium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in 24 hour Urine;Beryllium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29928-9;Titanium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Titanium [Mass/volume] in 24 hour Urine;Titanium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29929-7;Titanium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Titanium [Mass/time] in 24 hour Urine;Titanium 24h Ur-mRate;;ACTIVE;2.04;2.40 +29930-5;Titanium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Titanium/Creatinine [Mass Ratio] in 24 hour Urine;Titanium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29931-3;Vanadium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Vanadium [Mass/volume] in 24 hour Urine;Vanadium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29932-1;Vanadium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Vanadium [Mass/time] in 24 hour Urine;Vanadium 24h Ur-mRate;;ACTIVE;2.04;2.40 +29933-9;Vanadium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Vanadium/Creatinine [Mass Ratio] in 24 hour Urine;Vanadium/Creat 24h Ur;;ACTIVE;2.04;2.73 +2993-4;Testosterone;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Testosterone [Mass/volume] in Serum or Plasma;Deprecated Testost Ser-mCnc;;DEPRECATED;1.0;2.36 +29934-7;Cobalt/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Cobalt/Creatinine [Mass Ratio] in 24 hour Urine;Cobalt/Creat 24h Ur;;ACTIVE;2.04;2.73 +29935-4;Manganese/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Manganese/Creatinine [Mass Ratio] in 24 hour Urine;Manganese/Creat 24h Ur;;ACTIVE;2.04;2.73 +29936-2;Nickel;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in 24 hour Urine;Nickel 24h Ur-mCnc;;ACTIVE;2.04;2.73 +29937-0;Aluminum/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Aluminum/Creatinine [Mass Ratio] in 24 hour Urine;Aluminum/Creat 24h Ur;;ACTIVE;2.04;2.73 +29938-8;Thallium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Thallium/Creatinine [Mass Ratio] in 24 hour Urine;Thallium/Creat 24h Ur;;ACTIVE;2.04;2.73 +29939-6;Tellurium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Tellurium/Creatinine [Mass Ratio] in 24 hour Urine;Tellurium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29940-4;Bismuth/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Bismuth/Creatinine [Mass Ratio] in 24 hour Urine;Bismuth/Creat 24h Ur;;ACTIVE;2.04;2.42 +29941-2;Antimony/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Antimony/Creatinine [Mass Ratio] in 24 hour Urine;Antimony/Creat 24h Ur;;ACTIVE;2.04;2.42 +2994-2;Testosterone.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Testosterone Free [Mass/volume] in Serum or Plasma;Deprecated Testost Free SerPl-mCnc;;DEPRECATED;1.0;2.36 +29942-0;Copper/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Copper/Creatinine [Mass Ratio] in 24 hour Urine;Copper/Creat 24h Ur;;ACTIVE;2.04;2.73 +29943-8;Lead/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Lead/Creatinine [Mass Ratio] in 24 hour Urine;Lead/Creat 24h Ur;;ACTIVE;2.04;2.73 +29944-6;Alpha-2-Macroglobulin;MCnc;Pt;XXX;Qn;;CHEM;1;Alpha-2-Macroglobulin [Mass/volume] in Specimen;A2 Macroglob Spec-mCnc;;ACTIVE;2.04;2.73 +29945-3;Alpha 1 globulin;PrThr;24H;Urine;Ord;Electrophoresis;CHEM;1;Alpha 1 globulin [Presence] in 24 hour Urine by Electrophoresis;Alpha1 Glob 24h Ur Ql Elph;;ACTIVE;2.04;2.73 +29946-1;Albumin;PrThr;24H;Urine;Ord;Electrophoresis;CHEM;1;Albumin [Presence] in 24 hour Urine by Electrophoresis;Albumin 24h Ur Ql Elph;;ACTIVE;2.04;2.73 +29947-9;Alpha 2 globulin;PrThr;24H;Urine;Ord;Electrophoresis;CHEM;1;Alpha 2 globulin [Presence] in 24 hour Urine by Electrophoresis;Alpha2 Glob 24h Ur Ql Elph;;ACTIVE;2.04;2.73 +29948-7;Sjogrens syndrome-A extractable nuclear Ab;Titr;Pt;Ser;Qn;Immune diffusion;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Titer] in Serum by Immune diffusion (ID);ENA SS-A Ab Titr Ser ID;;ACTIVE;2.04;2.30 +29949-5;Sjogrens syndrome-B extractable nuclear Ab;Titr;Pt;Ser;Qn;Immune diffusion;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Titer] in Serum by Immune diffusion (ID);ENA SS-B Ab Titr Ser ID;;ACTIVE;2.04;2.30 +29950-3;Nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Nuclear IgG Ab [Presence] in Serum by Immunoassay;Nuclear IgG Ser Ql IA;;ACTIVE;2.04;2.73 +29951-1;Beta globulin;PrThr;24H;Urine;Ord;;CHEM;1;Beta globulin [Presence] in 24 hour Urine;B-Globulin 24h Ur Ql;;ACTIVE;2.04;2.73 +29952-9;Borrelia burgdorferi Ag;MCnc;Pt;Urine;Qn;IA;MICRO;1;Borrelia burgdorferi Ag [Mass/volume] in Urine by Immunoassay;B burgdor Ag Ur IA-mCnc;;ACTIVE;2.04;2.73 +29953-7;Nuclear Ab;Titr;Pt;Ser;Qn;;SERO;1;Nuclear Ab [Titer] in Serum;ANA Titr Ser;;ACTIVE;2.04;2.73 +29954-5;Extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA Ab Ser IA-aCnc;;ACTIVE;2.04;2.68 +29955-2;Legionella pneumophila Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Legionella pneumophila IgG Ab [Units/volume] in Serum by Immunoassay;L pneumo IgG Ser IA-aCnc;;ACTIVE;2.04;2.69 +29956-0;Lysozyme;MCnc;Pt;Body fld;Qn;;CHEM;1;Lysozyme [Mass/volume] in Body fluid;Lysozyme Fld-mCnc;;ACTIVE;2.04;2.73 +29957-8;Herpes simplex virus Ag;PrThr;Pt;Ser;Ord;IB;MICRO;1;Herpes simplex virus Ag [Presence] in Serum by Immunoblot;HSV Ag Ser Ql IB;;ACTIVE;2.04;2.73 +29958-6;Ribonucleoprotein extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ribonucleoprotein extractable nuclear IgG Ab [Units/volume] in Serum by Immunoassay;ENA RNP IgG Ser IA-aCnc;;ACTIVE;2.04;2.73 +2995-9;Tetrahydrocortisol;MRat;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisol [Mass/time] in 24 hour Urine;THF 24h Ur-mRate;;ACTIVE;1.0;2.73 +29959-4;Ganglioside GM1 Ab.IgG;MCnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 IgG Ab [Mass/volume] in Serum by Immunoassay;GM1 Gangl IgG Ser IA-mCnc;;ACTIVE;2.04;2.73 +29960-2;Ganglioside GM1 Ab.IgM;MCnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 IgM Ab [Mass/volume] in Serum by Immunoassay;GM1 Gangl IgM Ser IA-mCnc;;ACTIVE;2.04;2.73 +29961-0;Asialoganglioside GM1 Ab.IgG;MCnc;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgG Ab [Mass/volume] in Serum by Immunoassay;GM1 Asialo IgG Ser IA-mCnc;;ACTIVE;2.04;2.56 +29962-8;Asialoganglioside GM1 Ab.IgM;MCnc;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgM Ab [Mass/volume] in Serum by Immunoassay;GM1 Asialo IgM Ser IA-mCnc;;ACTIVE;2.04;2.56 +29963-6;Parietal cell Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Parietal cell IgG Ab [Presence] in Serum by Immunofluorescence;PCA IgG Ser Ql IF;;ACTIVE;2.04;2.73 +29964-4;Sjogrens syndrome-A extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear IgG Ab [Units/volume] in Serum by Immunoassay;ENA SS-A IgG Ser IA-aCnc;;ACTIVE;2.04;2.73 +29965-1;Sjogrens syndrome-B extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Sjogrens syndrome-B extractable nuclear IgG Ab [Units/volume] in Serum by Immunoassay;ENA SS-B IgG Ser IA-aCnc;;ACTIVE;2.04;2.73 +29966-9;Centromere Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Centromere IgG Ab [Titer] in Serum by Immunofluorescence;Centromere IgG Titr Ser IF;;ACTIVE;2.04;2.73 +2996-7;Tetrahydrodeoxycortisol;MRat;24H;Urine;Qn;;CHEM;1;Tetrahydrodeoxycortisol [Mass/time] in 24 hour Urine;TH-DC 24h Ur-mRate;;ACTIVE;1.0;2.73 +29967-7;Neutrophil cytoplasmic Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Neutrophil cytoplasmic IgG Ab [Titer] in Serum by Immunofluorescence;ANCA IgG Titr Ser IF;;ACTIVE;2.04;2.73 +29968-5;Rubidium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Rubidium [Mass/volume] in 24 hour Urine;Rubidium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29969-3;Rubidium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Rubidium [Mass/time] in 24 hour Urine;Rubidium 24h Ur-mRate;;ACTIVE;2.04;2.40 +29970-1;Rubidium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Rubidium/Creatinine [Mass Ratio] in 24 hour Urine;Rubidium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29971-9;Strontium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Strontium [Mass/volume] in 24 hour Urine;Strontium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29972-7;Strontium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Strontium [Mass/time] in 24 hour Urine;Strontium 24h Ur-mRate;;ACTIVE;2.04;2.40 +29973-5;Strontium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Strontium/Creatinine [Mass Ratio] in 24 hour Urine;Strontium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29974-3;Molybdenum;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Molybdenum [Mass/volume] in 24 hour Urine;Molybdenum 24h Ur-mCnc;;ACTIVE;2.04;2.34 +2997-5;Tetrahydrofolate;MCnc;Pt;Plas;Qn;;CHEM;1;Tetrahydrofolate [Mass/volume] in Plasma;THfolate Plas-mCnc;;ACTIVE;1.0;2.42 +29975-0;Molybdenum;MRat;24H;Urine;Qn;;DRUG/TOX;1;Molybdenum [Mass/time] in 24 hour Urine;Molybdenum 24h Ur-mRate;;ACTIVE;2.04;2.40 +29976-8;Molybdenum/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Molybdenum/Creatinine [Mass Ratio] in 24 hour Urine;Molybdenum/Creat 24h Ur;;ACTIVE;2.04;2.42 +29977-6;Silver;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Silver [Mass/volume] in 24 hour Urine;Silver 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29978-4;Silver/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Silver/Creatinine [Mass Ratio] in 24 hour Urine;Silver/Creat 24h Ur;;ACTIVE;2.04;2.42 +29979-2;Tin;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Tin [Mass/volume] in 24 hour Urine;Tin 24h Ur-mCnc;;ACTIVE;2.04;2.34 +299-8;Lincomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Lincomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Lincomycin Islt MIC;;ACTIVE;1.0;2.19 +29980-0;Tin;MRat;24H;Urine;Qn;;DRUG/TOX;1;Tin [Mass/time] in 24 hour Urine;Tin 24h Ur-mRate;;ACTIVE;2.04;2.40 +29981-8;Tin/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Tin/Creatinine [Mass Ratio] in 24 hour Urine;Tin/Creat 24h Ur;;ACTIVE;2.04;2.42 +29982-6;Cesium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Cesium [Mass/volume] in 24 hour Urine;Cesium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +2998-3;Thiamine;MCnc;Pt;Bld;Qn;;CHEM;1;Thiamine [Mass/volume] in Blood;Vit B1 Bld-mCnc;;ACTIVE;1.0;2.73 +29983-4;Cesium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Cesium [Mass/time] in 24 hour Urine;Cesium 24h Ur-mRate;;ACTIVE;2.04;2.40 +29984-2;Cesium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Cesium/Creatinine [Mass Ratio] in 24 hour Urine;Cesium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29985-9;Barium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Barium [Mass/volume] in 24 hour Urine;Barium 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29986-7;Barium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Barium/Creatinine [Mass Ratio] in 24 hour Urine;Barium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29987-5;Gold;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Gold [Mass/volume] in 24 hour Urine;Gold 24h Ur-mCnc;;ACTIVE;2.04;2.34 +29988-3;Gold/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Gold/Creatinine [Mass Ratio] in 24 hour Urine;Gold/Creat 24h Ur;;ACTIVE;2.04;2.42 +29989-1;Uranium/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Uranium/Creatinine [Mass Ratio] in 24 hour Urine;Uranium/Creat 24h Ur;;ACTIVE;2.04;2.42 +29990-9;Spermatozoa^post vasectomy;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Spermatozoa [Presence] in Semen by Light microscopy --post vasectomy;Sperm p vas Smn Ql Micro;;ACTIVE;2.04;2.73 +2999-1;Thiamine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thiamine [Mass/volume] in Serum or Plasma;Vit B1 SerPl-mCnc;;ACTIVE;1.0;2.73 +29991-7;Fibrin+Fibrinogen fragments;MCnc;Pt;Ser;Qn;LA;COAG;1;Fibrin+Fibrinogen fragments [Mass/volume] in Serum by Latex agglutination;FSP Ser LA-mCnc;;ACTIVE;2.04;2.73 +29992-5;Eosinophils;PrThr;Pt;Nose;Ord;Wright stain;HEM/BC;1;Eosinophils [Presence] in Nose by Wright stain;Eosinophil Nose Ql Wright Stn;;ACTIVE;2.04;2.73 +29993-3;Eosinophils;PrThr;Pt;Sputum;Ord;Wright stain;HEM/BC;1;Eosinophils [Presence] in Sputum by Wright stain;Eosinophil Spt Ql Wright Stn;;ACTIVE;2.04;2.73 +29994-1;Basement membrane Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Basement membrane IgG Ab [Presence] in Serum by Immunofluorescence;BM IgG Ser Ql IF;;ACTIVE;2.04;2.73 +29995-8;Basement membrane Ab.IgA;PrThr;Pt;Ser;Ord;IF;SERO;1;Basement membrane IgA Ab [Presence] in Serum by Immunofluorescence;BM IgA Ser Ql IF;;ACTIVE;2.04;2.73 +29996-6;Histone Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Histone IgG Ab [Units/volume] in Serum by Immunoassay;Histone IgG Ser IA-aCnc;;ACTIVE;2.04;2.73 +29997-4;Basement membrane Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Basement membrane IgG Ab [Units/volume] in Serum by Immunoassay;BM IgG Ser IA-aCnc;;ACTIVE;2.04;2.73 +29998-2;Striated muscle Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Striated muscle IgG Ab [Titer] in Serum by Immunofluorescence;Stria Mus IgG Titr Ser IF;;ACTIVE;2.04;2.73 +29999-0;Xylose;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Xylose [Mass/volume] in Serum or Plasma;Xylose SerPl-mCnc;;ACTIVE;2.04;2.34 +30000-4;Albumin/Creatinine;Ratio;Pt;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin/Creatinine [Ratio] in Urine;Microalbumin/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30001-2;Albumin/Creatinine;Ratio;Pt;Urine;Qn;Detection limit <= 20 mg/L test strip;CHEM;1;Microalbumin/Creatinine [Ratio] in Urine by Test strip;Microalbumin/Creat Ur Test Str-Rto;;ACTIVE;2.04;2.73 +30002-0;Creatinine;SCnc;Pt;Urine;Qn;Test strip;CHEM;1;Creatinine [Moles/volume] in Urine by Test strip;Creat Ur Strip-sCnc;;ACTIVE;2.04;2.70 +30003-8;Albumin;MCnc;24H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/volume] in 24 hour Urine;Microalbumin 24h Ur-mCnc;;ACTIVE;2.04;2.73 +30004-6;Creatinine;MCnc;Pt;Urine;Qn;Test strip;CHEM;1;Creatinine [Mass/volume] in Urine by Test strip;Creat Ur Strip-mCnc;;ACTIVE;2.04;2.73 +30005-3;CYP21A2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CYP21A2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CYP21A2 Mut Anl Bld/T;;ACTIVE;2.04;2.73 +30006-1;Transfuse granulocytes;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse granulocytes [Volume];Trans Granulocytes Vol Patient;;ACTIVE;2.04;2.42 +3000-7;Thiamine pyrophosphate;MCnc;Pt;Ser;Qn;;CHEM;1;Thiamine pyrophosphate [Mass/volume] in Serum;Vit B1 Pyrophoshate Ser-mCnc;;ACTIVE;1.0;2.44 +30007-9;Transfuse cryoprecipitate poor plasma;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse cryoprecipitate poor plasma [Volume];Trans CP Plas Vol Patient;;ACTIVE;2.04;2.42 +30008-7;Blood group antibody screen;Titr;Pt;Ser/Plas;Qn;Albumin technique;BLDBK;1;Blood group antibody screen [Titer] in Serum or Plasma by Albumin technique;Bld gp Ab Scn Titr SerPl Alb Tech;;ACTIVE;2.04;2.30 +30009-5;Fibrin+Fibrinogen fragments;MCnc;Pt;Ser;Qn;;COAG;1;Fibrin+Fibrinogen fragments [Mass/volume] in Serum;FSP Ser-mCnc;;ACTIVE;2.04;2.73 +30010-3;Borrelia burgdorferi 93kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 93kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor93kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30011-1;Borrelia burgdorferi 45kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 45kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor45kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30012-9;Borrelia burgdorferi 28kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 28kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor28kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30013-7;Borrelia burgdorferi 23kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor23kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30014-5;Borrelia burgdorferi 21kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 21kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor21kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +3001-5;Thiocyanate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Thiocyanate [Mass/volume] in Blood;Thiocyanate Bld-mCnc;;ACTIVE;1.0;2.73 +30015-2;Borrelia burgdorferi 41kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor41kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30016-0;Borrelia burgdorferi 66kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 66kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor66kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30017-8;Borrelia burgdorferi 58kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 58kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor58kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30018-6;Borrelia burgdorferi 30kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 30kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor30kD IgG Snv Ql IB;;ACTIVE;2.04;2.73 +30019-4;Borrelia burgdorferi 41kD Ab.IgM;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD IgM Ab [Presence] in Synovial fluid by Immunoblot;B burgdor41kD IgM Snv Ql IB;;ACTIVE;2.04;2.73 +30020-2;Borrelia burgdorferi 39kD Ab.IgM;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD IgM Ab [Presence] in Synovial fluid by Immunoblot;B burgdor39kD IgM Snv Ql IB;;ACTIVE;2.04;2.73 +30021-0;Borrelia burgdorferi 23kD Ab.IgM;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD IgM Ab [Presence] in Synovial fluid by Immunoblot;B burgdor23kD IgM Snv Ql IB;;ACTIVE;2.04;2.73 +30022-8;Botrytis cinerea Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Botrytis cinerea IgG Ab [Units/volume] in Serum;B cinerea IgG Qn;;ACTIVE;2.04;2.68 +3002-3;Thiocyanate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thiocyanate [Mass/volume] in Serum or Plasma;Thiocyanate SerPl-mCnc;;ACTIVE;1.0;2.73 +30023-6;Bacillus subtilis Ab.IgE;ACnc;Pt;Ser;Qn;;MICRO;1;Bacillus subtilis IgE Ab [Units/volume] in Serum;B subtilis IgE Ser-aCnc;;ACTIVE;2.04;2.42 +30024-4;Carbophenothion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbophenothion [Mass/volume] in Serum or Plasma;Carbophenothion SerPl-mCnc;;ACTIVE;2.04;2.73 +30025-1;Coumaphos;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Coumaphos [Mass/volume] in Serum or Plasma;Coumaphos SerPl-mCnc;;ACTIVE;2.04;2.73 +30026-9;Dichlorvos;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dichlorvos [Mass/volume] in Serum or Plasma;Dichlorvos SerPl-mCnc;;ACTIVE;2.04;2.73 +30027-7;Dimethoate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dimethoate [Mass/volume] in Serum or Plasma;Dimethoate SerPl-mCnc;;ACTIVE;2.04;2.73 +30028-5;O-Ethyl O-(p-nitrophenyl) phenylphosphonothionate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;O-Ethyl O-(p-nitrophenyl) phenylphosphonothionate [Mass/volume] in Serum or Plasma;EPN SerPl-mCnc;;ACTIVE;2.04;2.73 +30029-3;Dehydroepiandrosterone;ACnc;Pt;Saliva;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Units/volume] in Saliva (oral fluid);DHEA Sal-aCnc;;DISCOURAGED;2.04;2.73 +30030-1;Iron;MCnc;24H;Urine;Qn;;CHEM;1;Iron [Mass/volume] in 24 hour Urine;Iron 24h Ur-mCnc;;ACTIVE;2.04;2.73 +3003-1;Thiocyanate;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Thiocyanate [Presence] in Serum or Plasma;Thiocyanate SerPl Ql;;ACTIVE;1.0;2.56 +30031-9;(Alternaria alternata+Dermatophagoides farinae) Ab.IgG;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Alternaria alternata+American house dust mite IgG Ab [Presence] in Serum by Multidisk;A alternata+D farinae IgG Ql;;ACTIVE;2.04;2.56 +30032-7;Phoma betae Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phoma betae IgG Ab [Units/volume] in Serum;P betae IgG Qn;;ACTIVE;2.04;2.73 +30033-5;Homocystine^6H post dose methionine;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Homocystine [Moles/volume] in Serum or Plasma --6 hours post dose methionine;Deprecated (Hcys)2 6h p Met SerPl-sCnc;;DEPRECATED;2.04;2.70 +30034-3;Bovine herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Bovine herpesvirus 1 Ab [Presence] in Serum by Complement fixation;BoHV1 Ab Ser Ql CF;;ACTIVE;2.04;2.56 +30035-0;Homocystine^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Homocystine [Moles/volume] in Serum or Plasma --fasting;Deprecated (Hcys)2 p fast SerPl-sCnc;;DEPRECATED;2.04;2.70 +30036-8;Aspergillus fumigatus 2 Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus fumigatus 2 Ab [Presence] in Serum by Immune diffusion (ID);A fumigatus2 Ab Ser Ql ID;;ACTIVE;2.04;2.73 +30037-6;(Alternaria alternata+Dermatophagoides farinae) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Alternaria alternata+American house dust mite IgE Ab [Presence] in Serum by Multidisk;A alternata+D farinae IgE Ql;;ACTIVE;2.04;2.56 +30038-4;Toxoplasma gondii Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;T gondii IgG CSF IA-aCnc;;ACTIVE;2.04;2.73 +30039-2;Anaplasma phagocytophilum DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Anaplasma phagocytophilum DNA [Presence] in Blood by NAA with probe detection;A phagocytoph DNA Bld Ql NAA+probe;;ACTIVE;2.04;2.73 +300-4;Lincomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Lincomycin [Susceptibility] by Disk diffusion (KB);Lincomycin Islt KB;;ACTIVE;1.0;2.19 +30040-0;Dirofilaria immitis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Dirofilaria immitis Ab [Units/volume] in Serum;D immitis Ab Ser-aCnc;;ACTIVE;2.04;2.69 +30041-8;Curcuma longa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Turmeric IgE Ab [Units/volume] in Serum;Turmeric IgE Qn;;ACTIVE;2.04;2.73 +30042-6;Vigabatrin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vigabatrin [Mass/volume] in Serum or Plasma;Vigabatrin SerPl-mCnc;;ACTIVE;2.04;2.73 +30043-4;Rosmarinus officinalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rosemary IgE Ab [Units/volume] in Serum;Rosemary IgE Qn;;ACTIVE;2.04;2.73 +30044-2;Dirofilaria immitis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Dirofilaria immitis Ab [Titer] in Serum;D immitis Ab Titr Ser;;ACTIVE;2.04;2.30 +30045-9;Mycobacterium sp identified;Prid;Pt;Dial fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Dialysis fluid by Organism specific culture;Mycobacterium Dial fld Cult;;ACTIVE;2.04;2.21 +30046-7;Legionella pneumophila Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Legionella pneumophila Ab [Units/volume] in Serum by Immunoassay;L pneumo Ab Ser IA-aCnc;;ACTIVE;2.04;2.73 +30047-5;Histidine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Histidine/Creatinine [Ratio] in Urine;Histidine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30048-3;Lysine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Lysine/Creatinine [Ratio] in Urine;Lysine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +3004-9;Thiocyanate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiocyanate [Mass/volume] in Urine;Thiocyanate Ur-mCnc;;ACTIVE;1.0;2.73 +30049-1;Ornithine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Ornithine/Creatinine [Ratio] in Urine;Ornithine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30050-9;Hydroxylysine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Hydroxylysine/Creatinine [Ratio] in Urine;OH-Lysine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30051-7;Homocystine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Homocystine/Creatinine [Ratio] in Urine;(Hcys)2/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30052-5;Isoleucine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Isoleucine/Creatinine [Ratio] in Urine;Isoleucine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30053-3;Leucine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Leucine/Creatinine [Ratio] in Urine;Leucine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30054-1;Tyrosine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Tyrosine/Creatinine [Ratio] in Urine;Tyrosine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30055-8;Phenylalanine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Phenylalanine/Creatinine [Ratio] in Urine;Phe/Creat Ur-Rto;;ACTIVE;2.04;2.73 +3005-6;Thiosulfate renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Thiosulfate renal clearance in 24 hour Urine and Serum or Plasma;Thiosulfate Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +30056-6;Glutamine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Glutamine/Creatinine [Ratio] in Urine;Glutamine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30057-4;Threonine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Threonine/Creatinine [Ratio] in Urine;Threonine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30058-2;Serine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Serine/Creatinine [Ratio] in Urine;Serine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30059-0;Glutamate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Glutamate/Creatinine [Ratio] in Urine;Glutamate/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30060-8;Amino beta guanidinopropionate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amino beta guanidinopropionate [Moles/volume] in Serum or Plasma;AB-Gp SerPl-sCnc;;ACTIVE;2.04;2.73 +30061-6;Aspartate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Aspartate/Creatinine [Ratio] in Urine;Aspartate/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30062-4;Arginine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Arginine/Creatinine [Ratio] in Urine;Arginine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30063-2;Methionine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Methionine/Creatinine [Ratio] in Urine;Methionine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +3006-4;Threonine;MCnc;Pt;CSF;Qn;;CHEM;1;Threonine [Mass/volume] in Cerebral spinal fluid;Threonine CSF-mCnc;;ACTIVE;1.0;2.42 +30064-0;Valine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Valine/Creatinine [Ratio] in Urine;Valine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30065-7;Cystine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Cystine/Creatinine [Ratio] in Urine;Cystine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30066-5;Glycine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Glycine/Creatinine [Ratio] in Urine;Glycine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30067-3;Proline/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Proline/Creatinine [Ratio] in Urine;Proline/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30068-1;Alanine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Alanine/Creatinine [Ratio] in Urine;Alanine/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30069-9;Tyrosine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Tyrosine [Moles/volume] in Amniotic fluid;Tyrosine Amn-sCnc;;ACTIVE;2.04;2.34 +30070-7;Cystathionine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Cystathionine [Moles/volume] in Amniotic fluid;Cystathionin Amn-sCnc;;ACTIVE;2.04;2.34 +30071-5;Trichoderma viride Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Trichoderma viride IgG Ab [Units/volume] in Serum;T viride IgG Ser-aCnc;;ACTIVE;2.04;2.73 +3007-2;Threonine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Threonine [Presence] in Serum or Plasma;Threonine SerPl Ql;;ACTIVE;1.0;2.73 +30072-3;Cortisone;MCnc;24H;Urine;Qn;HPLC;CHEM;1;Cortisone [Mass/volume] in 24 hour Urine by HPLC;Cortisone 24h Ur HPLC-mCnc;;ACTIVE;2.04;2.73 +30073-1;Voltage-gated calcium channel Ab;PrThr;Pt;Ser;Ord;;SERO;1;Voltage-gated calcium channel Ab [Presence] in Serum;VGCC Ab Ser Ql;;ACTIVE;2.04;2.73 +30074-9;Hemoglobin F;PrThr;Pt;XXX;Ord;;HEM/BC;1;Hemoglobin F [Presence] in Specimen;Hgb F Spec Ql;;ACTIVE;2.04;2.73 +30075-6;Respiratory syncytial virus A RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection;RSV A RNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +30076-4;Respiratory syncytial virus B RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection;RSV B RNA Spec Ql NAA+probe;;ACTIVE;2.04;2.73 +30077-2;Amylase/Creatinine renal clearance;Ratio;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Amylase/Creatinine renal clearance [Ratio] in Urine and Serum or Plasma;Amylase/Cr Cl Ur+SerPl-Rto;;ACTIVE;2.04;2.73 +30078-0;Specimen weight;Mass;Pt;Stool;Qn;;SPEC;1;Weight of Stool;Specimen wt Stl Qn;;ACTIVE;2.04;2.73 +30079-8;Renal tubular casts;Naric;Pt;Urine;Qn;Microscopy.light;UA;1;Renal tubular casts [#/area] in Urine by Light microscopy;Renal Tub Casts #/area Ur Micro;;ACTIVE;2.04;2.73 +3008-0;Threonine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Threonine [Mass/volume] in Serum or Plasma;Threonine SerPl-mCnc;;ACTIVE;1.0;2.73 +30080-6;Cathepsin D;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cathepsin D [Presence] in Tissue by Immune stain;Cathepsin D Tiss Ql ImStn;;ACTIVE;2.04;2.56 +30081-4;IgD;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgD [Presence] in Serum by Immunofixation;IgD Ser Ql IFE;;ACTIVE;2.04;2.73 +30082-2;IgE;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgE [Presence] in Serum by Immunofixation;IgE Ser Ql IFE;;ACTIVE;2.04;2.73 +30083-0;Epstein Barr virus nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum by Immunoassay;EBV NA IgG Ser IA-aCnc;;ACTIVE;2.04;2.73 +30084-8;Lupus erythematosus deoxynucleoproteins Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay;LE DNP IgG Ser IA-aCnc;;ACTIVE;2.04;2.68 +30085-5;Legionella pneumophila Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila IgG Ab [Units/volume] in Serum;L pneumo IgG Ser-aCnc;;ACTIVE;2.04;2.73 +30086-3;Coagulation factor IX inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor IX inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact IX Inhib PPP Ql;;ACTIVE;2.04;2.56 +30087-1;Cow hair+Cow dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow hair+Cow dander IgE Ab [Units/volume] in Serum;Cow Hair+Dander IgE Qn;;ACTIVE;2.04;2.73 +30088-9;Horse hair+Horse dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse hair+Horse dander IgE Ab [Units/volume] in Serum;Horse Hair+Dander IgE Qn;;ACTIVE;2.04;2.73 +30089-7;Transitional cells;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Transitional cells [#/area] in Urine sediment by Microscopy high power field;Trans Cells #/area UrnS HPF;;ACTIVE;2.04;2.73 +30090-5;Burkholderia pseudomallei Ab.IgG;Titr;Pt;XXX;Qn;IF;MICRO;1;Burkholderia pseudomallei IgG Ab [Titer] in Specimen by Immunofluorescence;B pseudomal IgG Titr Spec IF;;ACTIVE;2.04;2.69 +30091-3;Burkholderia pseudomallei Ab.IgM;Titr;Pt;XXX;Qn;IF;MICRO;1;Burkholderia pseudomallei IgM Ab [Titer] in Specimen by Immunofluorescence;B pseudomal IgM Titr Spec IF;;ACTIVE;2.04;2.69 +30092-1;Brucella canis Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Brucella canis IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B canis IgG Titr CSF IF;;ACTIVE;2.04;2.30 +30093-9;Brucella canis Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Brucella canis IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;B canis IgM Titr CSF IF;;ACTIVE;2.04;2.30 +30094-7;Neisseria meningitidis serogroup A Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Specimen by Latex agglutination;N men sg A Ag Spec Ql LA;;ACTIVE;2.04;2.69 +30095-4;Neisseria meningitidis serogroup B Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Specimen by Latex agglutination;N men sg B Ag Spec Ql LA;;ACTIVE;2.04;2.69 +30096-2;Neisseria meningitidis serogroup C Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Specimen by Latex agglutination;N men sg C Ag Spec Ql LA;;ACTIVE;2.04;2.69 +30097-0;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Specimen by Latex agglutination;N men sg W135 Ag Spec Ql LA;;ACTIVE;2.04;2.69 +3009-8;Threonine;MCnc;Pt;Urine;Qn;;CHEM;1;Threonine [Mass/volume] in Urine;Threonine Ur-mCnc;;ACTIVE;1.0;2.73 +30098-8;Neisseria meningitidis serogroup Y Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroup Y Ag [Presence] in Specimen by Latex agglutination;N men sg Y Ag Spec Ql LA;;ACTIVE;2.04;2.69 +30099-6;Neisseria gonorrhoeae;PrThr;Pt;Cnjt;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Conjunctival specimen by Organism specific culture;N gonorrhoea Conjunct Ql Cult;;ACTIVE;2.04;2.73 +30100-2;Yersinia enterocolitica O:3 Ab;Titr;Pt;XXX;Qn;;MICRO;1;Yersinia enterocolitica O:3 Ab [Titer] in Specimen;Y entero O:3 Ab Titr Spec;;ACTIVE;2.04;2.73 +30101-0;Yersinia enterocolitica O:5 Ab;Titr;Pt;XXX;Qn;;MICRO;1;Yersinia enterocolitica O:5 Ab [Titer] in Specimen;Y entero O:5 Ab Titr Spec;;ACTIVE;2.04;2.73 +30102-8;Yersinia enterocolitica O:8 Ab;Titr;Pt;XXX;Qn;;MICRO;1;Yersinia enterocolitica O:8 Ab [Titer] in Specimen;Y entero O:8 Ab Titr Spec;;ACTIVE;2.04;2.73 +30103-6;Yersinia enterocolitica O:9 Ab;Titr;Pt;XXX;Qn;;MICRO;1;Yersinia enterocolitica O:9 Ab [Titer] in Specimen;Y entero O:9 Ab Titr Spec;;ACTIVE;2.04;2.73 +30104-4;Trypanosoma cruzi Ab.IgG;Titr;Pt;XXX;Qn;;MICRO;1;Trypanosoma cruzi IgG Ab [Titer] in Specimen;T cruzi IgG Titr Spec;;ACTIVE;2.04;2.73 +30105-1;Trypanosoma cruzi Ab.IgM;Titr;Pt;XXX;Qn;;MICRO;1;Trypanosoma cruzi IgM Ab [Titer] in Specimen;T cruzi IgM Titr Spec;;ACTIVE;2.04;2.73 +3010-6;Threonine;MRat;24H;Urine;Qn;;CHEM;1;Threonine [Mass/time] in 24 hour Urine;Threonine 24h Ur-mRate;;ACTIVE;1.0;2.73 +30106-9;Acetylcholinesterase;PrThr;Pt;Amnio fld;Ord;;CHEM;1;Acetylcholinesterase [Presence] in Amniotic fluid;AChE Amn Ql;;ACTIVE;2.04;2.73 +30107-7;Ecgonine methyl ester;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ecgonine methyl ester [Mass/volume] in Serum or Plasma;EME SerPl-mCnc;;ACTIVE;2.04;2.73 +30108-5;Ecgonine methyl ester;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Ecgonine methyl ester [Mass/mass] in Meconium;EME Mec-mCnt;;ACTIVE;2.04;2.73 +30109-3;Ecgonine methyl ester;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Ecgonine methyl ester [Mass/volume] in Gastric fluid;EME Gast-mCnc;;ACTIVE;2.04;2.34 +30110-1;Ecgonine methyl ester;MCnc;Pt;Vitr fld;Qn;;DRUG/TOX;1;Ecgonine methyl ester [Mass/volume] in Vitreous fluid;EME Vitf-mCnc;;ACTIVE;2.04;2.34 +30111-9;Thermoactinomyces vulgaris 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Thermoactinomyces vulgaris 2 Ab [Presence] in Serum;T vulgaris2 Ab Ser Ql;;ACTIVE;2.04;2.73 +30112-7;Amphetamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amphetamine [Mass/volume] in Serum or Plasma;Amphet SerPl-mCnc;;ACTIVE;2.04;2.73 +30113-5;Lymphocytes.IgG;NCnc;Pt;WBC;Qn;;CELLMARK;1;IgG lymphocytes [#/volume] in Leukocytes;Lymphs IgG # WBC;;ACTIVE;2.04;2.36 +3011-4;Thromboxane alpha 2;MCnc;Pt;Ser;Qn;;CHEM;1;Thromboxane alpha 2 [Mass/volume] in Serum;TXA2 Ser-mCnc;;ACTIVE;1.0;2.40 +30114-3;Lymphocytes.lambda;NCnc;Pt;Bld;Qn;;CELLMARK;1;Lambda lymphocytes [#/volume] in Blood;Lymphs Lambda # Bld;;ACTIVE;2.04;2.36 +30115-0;Lymphocytes.kappa;NCnc;Pt;Bld;Qn;;CELLMARK;1;Kappa lymphocytes [#/volume] in Blood;Lymphs Kappa # Bld;;ACTIVE;2.04;2.36 +30116-8;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;CSF;Qn;Immunoperoxidase stain;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Cerebral spinal fluid by Immunoperoxidase stain;TdT Cells NFr CSF IP Stn;;ACTIVE;2.04;2.34 +30117-6;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;XXX;Qn;Immunoperoxidase stain;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Specimen by Immunoperoxidase stain;TdT Cells NFr Spec IP Stn;;ACTIVE;2.04;2.69 +30118-4;Lymphocytes.IgA;NCnc;Pt;WBC;Qn;;CELLMARK;1;IgA lymphocytes [#/volume] in Leukocytes;Lymphs IgA # WBC;;ACTIVE;2.04;2.36 +30119-2;Lymphocytes.IgM;NCnc;Pt;WBC;Qn;;CELLMARK;1;IgM lymphocytes [#/volume] in Leukocytes;Lymphs IgM # WBC;;ACTIVE;2.04;2.36 +301-2;Lincomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Lincomycin [Susceptibility] by Serum bactericidal titer;Lincomycin Titr SBT;;ACTIVE;1.0;2.32 +30120-0;Lymphocytes.IgD;NCnc;Pt;WBC;Qn;;CELLMARK;1;IgD lymphocytes [#/volume] in Leukocytes;Lymphs IgD # WBC;;ACTIVE;2.04;2.36 +30121-8;Colony count;NCnc;Pt;Dial fld;Qn;;MICRO;1;Colony count [#/volume] in Dialysis fluid;CC # Dial fld;;ACTIVE;2.04;2.73 +3012-2;Thromboxane beta 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thromboxane beta 2 [Mass/volume] in Serum or Plasma;TXB2 SerPl-mCnc;;ACTIVE;1.0;2.34 +30122-6;Aeromonas sp;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Aeromonas sp [Presence] in Specimen by Organism specific culture;Aeromonas Spec Ql Cult;;ACTIVE;2.04;2.73 +30123-4;Testosterone.bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone.bound [Mass/volume] in Serum or Plasma;Testost Bnd SerPl-mCnc;;ACTIVE;2.04;2.34 +30124-2;Amylase;CRat;1H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/time] in 1 hour Urine;Amylase 1h Ur-cRate;;ACTIVE;2.04;2.40 +30125-9;Gerbil hair Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gerbil hair IgE Ab RAST class [Presence] in Serum;Gerbil Hair IgE RAST Ql;;ACTIVE;2.04;2.58 +30126-7;Platanus acerifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;London Plane IgE Ab RAST class [Presence] in Serum;London Plane IgE RAST Ql;;ACTIVE;2.04;2.73 +30127-5;Gerbil hair Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gerbil hair IgE Ab [Units/volume] in Serum;Gerbil Hair IgE Qn;;ACTIVE;2.04;2.42 +30128-3;Borrelia burgdorferi Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Serum --2nd specimen;B burgdor Ab sp2 Ser-aCnc;;ACTIVE;2.04;2.69 +30129-1;Brucella sp Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella sp Ab [Presence] in Serum --1st specimen;Brucella Ab sp1 Ser Ql;;ACTIVE;2.04;2.56 +3013-0;Thyroglobulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroglobulin [Mass/volume] in Serum or Plasma;Thyroglob SerPl-mCnc;;ACTIVE;1.0;2.73 +30130-9;Brucella sp Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella sp Ab [Presence] in Serum --2nd specimen;Brucella Ab sp2 Ser Ql;;ACTIVE;2.04;2.56 +30131-7;Complement total hemolytic CH50;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement total hemolytic CH50 [Mass/volume] in Serum or Plasma;CH50 SerPl-mCnc;;ACTIVE;2.04;2.73 +30132-5;Coxsackievirus Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus Ab [Presence] in Serum --1st specimen;CV Ab sp1 Ser Ql;;ACTIVE;2.04;2.56 +30133-3;Coxsackievirus Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus Ab [Presence] in Serum --2nd specimen;CV Ab sp2 Ser Ql;;ACTIVE;2.04;2.56 +30134-1;Echovirus Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus Ab [Presence] in Serum --1st specimen;ECV Ab sp1 Ser Ql;;ACTIVE;2.04;2.56 +30135-8;Echovirus Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus Ab [Presence] in Serum --2nd specimen;ECV Ab sp2 Ser Ql;;ACTIVE;2.04;2.56 +30136-6;Epstein Barr virus capsid Ab.IgG^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus capsid IgG Ab [Presence] in Serum --2nd specimen;EBV VCA IgG sp2 Ser Ql;;ACTIVE;2.04;2.56 +30137-4;Epstein Barr virus capsid Ab.IgM^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus capsid IgM Ab [Presence] in Serum --2nd specimen;EBV VCA IgM sp2 Ser Ql;;ACTIVE;2.04;2.56 +30138-2;Epstein Barr virus nuclear Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus nuclear Ab [Presence] in Serum --2nd specimen;EBV NA Ab sp2 Ser Ql;;ACTIVE;2.04;2.56 +30139-0;Hydroxyproline.free;PrThr;24H;Urine;Ord;;CHEM;1;Hydroxyproline Free [Presence] in 24 hour Urine;OH-Proline Free 24h Ur Ql;;ACTIVE;2.04;2.56 +30140-8;IgA;PrThr;24H;Urine;Ord;Immunoelectrophoresis;CHEM;1;IgA [Presence] in 24 hour Urine by Immunoelectrophoresis;IgA 24h Ur Ql IEP;;ACTIVE;2.04;2.56 +30141-6;IgG;PrThr;24H;Urine;Ord;Immunoelectrophoresis;CHEM;1;IgG [Presence] in 24 hour Urine by Immunoelectrophoresis;IgG 24h Ur Ql IEP;;ACTIVE;2.04;2.56 +30142-4;IgM;PrThr;24H;Urine;Ord;Immunoelectrophoresis;CHEM;1;IgM [Presence] in 24 hour Urine by Immunoelectrophoresis;IgM 24h Ur Ql IEP;;ACTIVE;2.04;2.56 +30143-2;Legionella sp Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella sp Ab [Presence] in Serum --1st specimen;Legionella Ab sp1 Ser Ql;;ACTIVE;2.04;2.56 +30144-0;Legionella sp Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella sp Ab [Presence] in Serum --2nd specimen;Legionella Ab sp2 Ser Ql;;ACTIVE;2.04;2.56 +30145-7;Monocytes;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Monocytes [#/volume] in Synovial fluid by Manual count;Monocytes # Snv Manual;;ACTIVE;2.04;2.30 +30146-5;Mumps virus Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Mumps virus Ab [Presence] in Serum --2nd specimen;MuV Ab sp2 Ser Ql;;ACTIVE;2.04;2.56 +30147-3;Respiratory syncytial virus Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Respiratory syncytial virus Ab [Presence] in Serum --1st specimen;RSV Ab sp1 Ser Ql;;ACTIVE;2.04;2.56 +3014-8;Thyroid stimulating immunoglobulins;MCnc;Pt;Ser;Qn;;CHEM;1;Thyroid stimulating immunoglobulins [Mass/volume] in Serum;TSI Ser-mCnc;;DISCOURAGED;1.0;2.73 +30148-1;Respiratory syncytial virus Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Respiratory syncytial virus Ab [Presence] in Serum --2nd specimen;RSV Ab sp2 Ser Ql;;ACTIVE;2.04;2.56 +30149-9;Streptolysin O Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptolysin O Ab [Units/volume] in Serum --1st specimen;ASO Ab sp1 Ser-aCnc;;ACTIVE;2.04;2.34 +30150-7;Streptolysin O Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptolysin O Ab [Units/volume] in Serum --2nd specimen;ASO Ab sp2 Ser-aCnc;;ACTIVE;2.04;2.34 +30151-5;Thyrotropin.long acting;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyrotropin.long acting [Units/volume] in Serum or Plasma;LA TSH SerPl-aCnc;;ACTIVE;2.04;2.70 +30152-3;Mannose-binding protein;MCnc;Pt;Ser;Qn;;CHEM;1;Mannose-binding protein [Mass/volume] in Serum;Mannose-BP Ser-mCnc;;ACTIVE;2.04;2.73 +30153-1;Streptococcus pneumoniae Danish serotype 9V Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Mass/volume] in Serum;S pneum Da 9V IgG Ser-mCnc;;ACTIVE;2.04;2.73 +30154-9;Protein/Creatinine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Protein/Creatinine [Mass Ratio] in Serum or Plasma;Prot/Creat SerPl;;ACTIVE;2.04;2.73 +3015-5;Thyrotropin;ACnc;Pt;Bld;Qn;;CHEM;1;Thyrotropin [Units/volume] in Blood;TSH Bld-aCnc;;ACTIVE;1.0;2.73 +30155-6;Reticulocytes.punctate/100 erythrocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.punctate/100 erythrocytes in Blood;Retics Punctate/100 RBC NFr;;ACTIVE;2.04;2.67 +30156-4;Reticulocytes.aggregate/100 erythrocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.aggregate/100 erythrocytes in Blood;Retics Aggreg/100 RBC NFr;;ACTIVE;2.04;2.73 +30157-2;Heterophils/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Heterophils/100 leukocytes in Blood;Heterophils/leuk NFr Bld;;ACTIVE;2.04;2.67 +30158-0;Toxoplasma gondii;PrThr;Pt;Stool;Ord;;MICRO;1;Toxoplasma gondii [Presence] in Stool;T gondii Stl Ql;;ACTIVE;2.04;2.56 +30159-8;HTLV I+II DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HTLV I+II DNA [Presence] in Blood by NAA with probe detection;HTLV I+II DNA Bld Ql NAA+probe;;ACTIVE;2.04;2.73 +30160-6;Tau protein;MCnc;Pt;CSF;Qn;;CHEM;1;Tau protein [Mass/volume] in Cerebral spinal fluid;Tau Prot CSF-mCnc;;ACTIVE;2.04;2.73 +30161-4;Citrulline/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Citrulline/Creatinine [Ratio] in Urine;Citrulline/Creat Ur-Rto;;ACTIVE;2.04;2.73 +30162-2;Cynara scolymus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Artichoke IgG Ab [Units/volume] in Serum;Artichoke IgG Qn;;ACTIVE;2.04;2.73 +3016-3;Thyrotropin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyrotropin [Units/volume] in Serum or Plasma;TSH SerPl-aCnc;;ACTIVE;1.0;2.73 +30163-0;Agapostemon texanus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sweat Bee IgE Ab [Units/volume] in Serum;Sweat Bee IgE Qn;;ACTIVE;2.04;2.73 +30164-8;(Anacardium occidentale+Carya illinoinensis+Juglans regia) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Nut Allergen Mix (Cashew+Pecan or Hickory nut+English walnut) IgE Ab [Presence] in Serum by Multidisk;Nut Allerg Mix IgE Ql;;ACTIVE;2.04;2.56 +30165-5;Phosphatidylcholine/Albumin;MRto;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylcholine/Albumin [Mass Ratio] in Amniotic fluid;PC/Alb Amn;;ACTIVE;2.04;2.73 +30166-3;Thyroid stimulating immunoglobulins actual/Normal;RelMCnc;Pt;Ser;Qn;;CHEM;1;Thyroid stimulating immunoglobulins actual/normal in Serum;TSI Act/Nor Ser;;ACTIVE;2.04;2.73 +30167-1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Cervix by Probe with signal amplification;HPV I/H Risk 1 DNA Cvx Ql Probe+sig amp;;ACTIVE;2.04;2.73 +30168-9;Juniperus monosperma Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oneseed Juniper IgE Ab [Units/volume] in Serum;Oneseed Juniper IgE Qn;;ACTIVE;2.04;2.73 +30169-7;Chromogranin A;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Chromogranin A [Units/volume] in Serum or Plasma by Immunoassay;CgA SerPl IA-aCnc;;ACTIVE;2.04;2.73 +30170-5;Periplaneta americana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American Cockroach IgE Ab [Units/volume] in Serum;Amer Roach IgE Qn;;ACTIVE;2.04;2.73 +3017-1;Thyrotropin binding inhibitory immunoglobulins;MCnc;Pt;Ser;Qn;;CHEM;1;Thyrotropin binding inhibitory immunoglobulins [Mass/volume] in Serum;TSH BII Ser-mCnc;;DISCOURAGED;1.0;2.73 +30171-3;Cortisol.free/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Cortisol Free/Creatinine [Molar ratio] in 24 hour Urine;Cortis F/Creat 24h Ur-sRto;;ACTIVE;2.04;2.73 +30172-1;Cortisol.free/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Cortisol Free/Creatinine [Molar ratio] in Urine;Cortis F/Creat Ur-sRto;;ACTIVE;2.04;2.73 +30173-9;Cortisol.free;SCnc;Pt;Urine;Qn;;CHEM;1;Cortisol Free [Moles/volume] in Urine;Cortis F Ur-sCnc;;ACTIVE;2.04;2.73 +30174-7;Jamestown canyon virus Ab.IgG;Titr;Pt;XXX;Qn;IF;MICRO;1;Jamestown canyon virus IgG Ab [Titer] in Specimen by Immunofluorescence;JCV IgG Titr Spec IF;;ACTIVE;2.04;2.69 +30175-4;Jamestown canyon virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Jamestown canyon virus neutralizing antibody [Presence] in Specimen by Neutralization test;JCV NAb Spec Ql Nt;;ACTIVE;2.04;2.73 +30176-2;La Crosse virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;La Crosse virus neutralizing antibody [Presence] in Specimen by Neutralization test;LACV NAb Spec Ql Nt;;ACTIVE;2.04;2.72 +30177-0;Powassan virus Ab.IgG;Titr;Pt;XXX;Qn;IF;MICRO;1;Powassan virus IgG Ab [Titer] in Specimen by Immunofluorescence;POWV IgG Titr Spec IF;;ACTIVE;2.04;2.69 +30178-8;West Nile virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;West Nile virus IgG Ab [Presence] in Specimen by Immunoassay;WNV IgG Spec Ql IA;;ACTIVE;2.04;2.73 +30179-6;Powassan virus Ab.IgM;Titr;Pt;XXX;Qn;IF;MICRO;1;Powassan virus IgM Ab [Titer] in Specimen by Immunofluorescence;POWV IgM Titr Spec IF;;ACTIVE;2.04;2.69 +30180-4;Basophils/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Basophils/100 leukocytes in Blood;Basophils/leuk NFr Bld;;ACTIVE;2.04;2.73 +30181-2;Lymphocytes.clefted;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes clefted [#/volume] in Blood by Manual count;Cleft Lymphs # Bld Manual;;ACTIVE;2.04;2.46 +30182-0;(Olea europaea+Salix caprea+Pinus strobus+Eucalyptus spp+Acacia longifolia+Melaleuca leucadendron) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 7 (Olive+Willow+Eastern white pine+Eucalyptus spp+Wattle+Cajeput) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix7 IgE Qn;;ACTIVE;2.04;2.42 +30183-8;(Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Setomelanomma rostrata+Penicillium notatum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Mold Allergen Mix 2 (Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Setomelanomma rostrata+Penicillium notatum) IgE Ab [Units/volume] in Serum by Multidisk;Mold Allerg Mix2 IgE Qn;;ACTIVE;2.04;2.73 +30184-6;(Acer negundo+Betula verrucosa+Quercus alba+Ulmus americana+Juglans californica) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 1 (Boxelder+Silver birch+White oak+White elm+California walnut) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix1 IgE Qn;;ACTIVE;2.04;2.73 +30185-3;(Cat dander+Cow dander+Dog dander+Horse dander) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 1 (Cat dander+Cow dander+Dog dander+Horse dander) IgE Ab [Units/volume] in Serum by Multidisk;Epid Allerg Mix1 IgE Qn;;ACTIVE;2.04;2.73 +30186-1;(Blatella germanica+Dermatophagoides farinae+Dermatophagoides pteronyssinus+House dust Greer) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Dust Allergen Mix A (Cockroach+American house dust mite+European house dust mite+House dust Greer) IgE Ab [Units/volume] in Serum by Multidisk;Dust Allerg Mix A IgE Qn;;ACTIVE;2.04;2.42 +30187-9;(Arachis hypogaea+Cow milk+Egg white+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 5 (Peanut+Cow milk+Egg white+Cod+Soybean+Wheat) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix5 IgE Qn;;ACTIVE;2.04;2.73 +30188-7;(Cynodon dactylon+Lolium perenne+Phleum pratense+Poa pratensis+Sorghum halepense+Paspalum notatum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 2 (Bermuda grass+Perennial rye grass+Timothy+Kentucky blue grass+Johnson grass+Bahia grass) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allerg Mix2 IgE Qn;;ACTIVE;2.04;2.73 +3018-9;Thyrotropin releasing hormone;MCnc;Pt;Plas;Qn;;CHEM;1;Thyrotropin releasing hormone [Mass/volume] in Plasma;Thyrotropin releasing horm Plas-mCnc;;ACTIVE;1.0;2.73 +30189-5;(Dactylis glomerata+Festuca elatior+Lolium perenne+Phleum pratense+Poa pratensis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 1 (Orchard grass+Meadow Fescue+Perennial rye grass+Timothy+Kentucky blue grass) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allerg Mix1 IgE Qn;;ACTIVE;2.04;2.73 +30190-3;3-Hydroxytetradecenoylcarnitine (C14:1-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Moles/volume] in Serum or Plasma;3OH-Tdecenoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30191-1;Acetylcarnitine (C2);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acetylcarnitine (C2) [Moles/volume] in Serum or Plasma;Acetylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30192-9;Acetylcholine receptor modulation Ab/Acetylcholine Ab.total;SFr;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor modulation Ab/Acetylcholine Ab.total in Serum;AChR Mod Ab/AChR Total SFr Ser;;ACTIVE;2.04;2.73 +30193-7;Acylcarnitine/Carnitine.free (C0);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Acylcarnitine/Carnitine.free (C0) [Molar ratio] in Serum or Plasma;Acylcarnitine/C0 SerPl-sRto;;ACTIVE;2.04;2.73 +30194-5;Fatty acids.very long chain.C22:0;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C22:0 (Docosanoate) [Moles/volume] in Serum or Plasma;VLCFA C22:0 SerPl-sCnc;;ACTIVE;2.04;2.73 +30195-2;Fatty acids.very long chain.C24:0;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate) [Moles/volume] in Serum or Plasma;VLCFA C24:0 SerPl-sCnc;;ACTIVE;2.04;2.73 +30196-0;Fatty acids.very long chain.C24:0/C22:0;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate)/C22:0 (Docosanoate) [Molar ratio] in Serum or Plasma;VLCFA C24:0/C22:0 SerPl-sRto;;ACTIVE;2.04;2.73 +3019-7;Thyrotropin.long acting;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Thyrotropin.long acting [Presence] in Serum or Plasma;LA TSH SerPl Ql;;ACTIVE;1.0;2.56 +30197-8;Fatty acids.very long chain.C26:0;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate) [Moles/volume] in Serum or Plasma;VLCFA C26:0 SerPl-sCnc;;ACTIVE;2.04;2.73 +30198-6;Fatty acids.very long chain.C26:0/C22:0;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate)/C22:0 (Docosanoate) [Molar ratio] in Serum or Plasma;VLCFA C26:0/C22:0 SerPl-sRto;;ACTIVE;2.04;2.73 +30199-4;Alpha subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha subunit [Mass/volume] in Serum or Plasma;Alpha subunit SerPl-mCnc;;ACTIVE;2.04;2.73 +302-0;Lomefloxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Lomefloxacin [Susceptibility] by Minimum lethal concentration (MLC);Lomefloxacin Islt MLC;;ACTIVE;1.0;2.19 +30200-0;Asialoganglioside GM1 Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Asialoganglioside GM1 IgM Ab [Presence] in Serum;GM1 Asialo IgM Ser Ql;;ACTIVE;2.04;2.56 +30201-8;B Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;B Ab [Titer] in Serum or Plasma;B Ab Titr SerPl;;ACTIVE;2.04;2.73 +30202-6;Brucella sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella sp Ab [Presence] in Serum;Brucella Ab Ser Ql;;ACTIVE;2.04;2.56 +30203-4;Candida albicans reaction wheal^2D post 0.1 mL Candida albicans ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Candida albicans reaction wheal [Diameter] --2 days post 0.1 mL Candida albicans intradermal;Wheal 2D p .1mL C albicans Diam;;ACTIVE;2.04;2.73 +30204-2;Chlamydia trachomatis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis Ab [Presence] in Serum;C trach Ab Ser Ql;;ACTIVE;2.04;2.56 +3020-5;Thyroxine binding globulin;MCnc;Pt;Bld;Qn;;CHEM;1;Thyroxine binding globulin [Mass/volume] in Blood;T4BG Bld-mCnc;;ACTIVE;1.0;2.73 +30205-9;Chlamydophila pneumoniae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila pneumoniae Ab [Presence] in Serum;C pneum Ab Ser Ql;;ACTIVE;2.04;2.56 +30206-7;Choriogonadotropin.alpha subunit.free;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.alpha subunit free [Units/volume] in Serum or Plasma;A-HCG Free SerPl-aCnc;;ACTIVE;2.04;2.42 +30207-5;Coccidioides immitis Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Coccidioides immitis IgG Ab [Presence] in Cerebral spinal fluid;C immitis IgG CSF Ql;;ACTIVE;2.04;2.56 +30208-3;Coccidioides immitis Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Coccidioides immitis IgM Ab [Presence] in Cerebral spinal fluid;C immitis IgM CSF Ql;;ACTIVE;2.04;2.56 +30209-1;Coccidioides immitis Ab;PrThr;Pt;CSF;Ord;Comp fix;MICRO;1;Coccidioides immitis Ab [Presence] in Cerebral spinal fluid by Complement fixation;C immitis Ab CSF Ql CF;;ACTIVE;2.04;2.56 +30210-9;Coccidioides reaction wheal^2D post 0.1 mL coccidioidin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Coccidioides reaction wheal [Diameter] --2 days post 0.1 mL coccidioidin intradermal;Coccidioides wheal 2D p .1mL CDN Diam;;ACTIVE;2.04;2.30 +30211-7;Collection duration;Time;*;^Specimen;Qn;;SPEC;1;Collection duration of Specimen;Collect duration Time Spec;;ACTIVE;2.04;2.73 +30212-5;Coxiella burnetii Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Coxiella burnetii IgG Ab [Presence] in Serum;C burnet IgG Ser Ql;;ACTIVE;2.04;2.56 +3021-3;Thyroxine binding globulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine binding globulin [Mass/volume] in Serum or Plasma;T4BG SerPl-mCnc;;ACTIVE;1.0;2.73 +30213-3;Coxiella burnetii Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Coxiella burnetii IgM Ab [Presence] in Serum;C burnet IgM Ser Ql;;ACTIVE;2.04;2.56 +30214-1;Coxsackievirus A10 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus A10 Ab [Presence] in Serum;CV A10 Ab Ser Ql;;ACTIVE;2.04;2.56 +30215-8;Coxsackievirus A16 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus A16 Ab [Presence] in Serum;CV A16 Ab Ser Ql;;ACTIVE;2.04;2.56 +30216-6;Coxsackievirus A2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus A2 Ab [Presence] in Serum;CV A2 Ab Ser Ql;;ACTIVE;2.04;2.56 +30217-4;Coxsackievirus A4 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus A4 Ab [Presence] in Serum;CV A4 Ab Ser Ql;;ACTIVE;2.04;2.73 +30218-2;Coxsackievirus A7 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus A7 Ab [Presence] in Serum;CV A7 Ab Ser Ql;;ACTIVE;2.04;2.56 +30219-0;Coxsackievirus A9 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus A9 Ab [Presence] in Serum;CV A9 Ab Ser Ql;;ACTIVE;2.04;2.73 +30220-8;Coxsackievirus B1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus B1 Ab [Presence] in Serum;CV B1 Ab Ser Ql;;ACTIVE;2.04;2.56 +3022-1;Thyroxine free index;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Thyroxine free index in Serum or Plasma;Deprecated FTI SerPl-mCnc;;DEPRECATED;1.0;2.40 +30221-6;Coxsackievirus B2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus B2 Ab [Presence] in Serum;CV B2 Ab Ser Ql;;ACTIVE;2.04;2.56 +30222-4;Coxsackievirus B3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus B3 Ab [Presence] in Serum;CV B3 Ab Ser Ql;;ACTIVE;2.04;2.73 +30223-2;Coxsackievirus B4 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus B4 Ab [Presence] in Serum;CV B4 Ab Ser Ql;;ACTIVE;2.04;2.73 +30224-0;Coxsackievirus B5 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus B5 Ab [Presence] in Serum;CV B5 Ab Ser Ql;;ACTIVE;2.04;2.73 +30225-7;Coxsackievirus B6 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus B6 Ab [Presence] in Serum;CV B6 Ab Ser Ql;;ACTIVE;2.04;2.73 +30226-5;Fibrin+Fibrinogen fragments;MCnc;Pt;PPP;Qn;;COAG;1;Fibrin+Fibrinogen fragments [Mass/volume] in Platelet poor plasma;FSP PPP-mCnc;;ACTIVE;2.04;2.73 +30227-3;Histoplasma capsulatum farciminosum reaction wheal^2D post 0.1 mL histoplasmin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Histoplasma capsulatum farciminosum reaction wheal [Diameter] --2 days post 0.1 mL histoplasmin intradermal;Wheal 2D p .1mL HMIN Diam;;ACTIVE;2.04;2.30 +30228-1;Mumps reaction wheal^2D post 0.1 mL mumps ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Mumps reaction wheal [Diameter] --2 days post 0.1 mL mumps intradermal;Wheal 2D p .1mL Mumps Diam;;ACTIVE;2.04;2.30 +30229-9;Neutrophils.band form;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Band form neutrophils [#/volume] in Blood by Automated count;Neuts Band # Bld Auto;;ACTIVE;2.04;2.73 +30230-7;Neutrophils.segmented/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Segmented neutrophils/100 leukocytes in Body fluid by Manual count;Neuts Seg/leuk NFr Fld Manual;;ACTIVE;2.04;2.73 +30231-5;Rheumatoid factor;ACnc;Pt;Body fld;Qn;;SERO;1;Rheumatoid factor [Units/volume] in Body fluid;Rheumatoid fact Fld-aCnc;;ACTIVE;2.04;2.73 +30232-3;Trichophyton reaction wheal^2D post 0.1ml trichophyton ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Trichophyton reaction wheal [Diameter] --2 days post 0.1ml trichophyton intradermal;Wheal 2D p .1mL Trichophyt Diam;;ACTIVE;2.04;2.26 +30233-1;3-Hydroxydodecanoylcarnitine (C12-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydodecanoylcarnitine (C12-OH) [Moles/volume] in Serum or Plasma;3OH-Dodecanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30234-9;3-Hydroxypalmitoylcarnitine (C16-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in Serum or Plasma;3OH-Palmitoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30235-6;3-Hydroxypalmitoleylcarnitine (C16:1-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in Serum or Plasma;3OH-Palmitoleylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30236-4;3-Hydroxyhexanoylcarnitine (C6-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in Serum or Plasma;3OH-Hexanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30237-2;3-Hydroxylinoleoylcarnitine (C18:2-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in Serum or Plasma;3OH-Linoleoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30238-0;3-Hydroxytetradecanoylcarnitine (C14-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in Serum or Plasma;3OH-Tdecanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +3023-9;Thyroxine uptake;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Thyroxine (T4) uptake [Mass/volume] in Serum or Plasma;Deprecated T4U SerPl-mCnc;;DEPRECATED;1.0;2.48 +30239-8;Aspartate aminotransferase;CCnc;Pt;Ser/Plas;Qn;With P-5'-P;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma by With P-5'-P;AST SerPl w P-5'-P-cCnc;;ACTIVE;2.04;2.73 +30240-6;Fibrin D-dimer;MCnc;Pt;PPP;Qn;;COAG;1;Deprecated Fibrin D-dimer;Deprecated D Dimer PPP-mCnc;;DEPRECATED;2.04;2.70 +30241-4;Lactate;MCnc;Pt;BldV;Qn;;CHEM;1;Lactate [Mass/volume] in Venous blood;Lactate BldV-mCnc;;ACTIVE;2.04;2.73 +30242-2;Lactate;MCnc;Pt;BldA;Qn;;CHEM;1;Lactate [Mass/volume] in Arterial blood;Lactate BldA-mCnc;;ACTIVE;2.04;2.73 +30243-0;Choriogonadotropin.intact;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.intact [Units/volume] in Serum or Plasma;HCG Intact SerPl-aCnc;;ACTIVE;2.04;2.73 +30244-8;Acetylcholinesterase;CCnc;Pt;Bld;Qn;;CHEM;1;Acetylcholinesterase [Enzymatic activity/volume] in Blood;AChE Bld-cCnc;;ACTIVE;2.04;2.15 +30245-5;HIV 1 DNA;ACnc;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Deprecated HIV 1 DNA [Presence] in Serum or Plasma by Probe and target amplification method;Deprecated HIV1 DNA SerPl Ql PCR;;DEPRECATED;2.04;2.52 +30246-3;Cytomegalovirus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Serum or Plasma by NAA with probe detection;CMV DNA SerPl Ql NAA+probe;;ACTIVE;2.04;2.73 +3024-7;Thyroxine.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma;T4 Free SerPl-mCnc;;ACTIVE;1.0;2.73 +30247-1;Cytomegalovirus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;CMV DNA # SerPl NAA+probe;;ACTIVE;2.04;2.73 +30248-9;Transferrin receptor.soluble;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin receptor.soluble [Mass/volume] in Serum or Plasma;sTfR SerPl-mCnc;;ACTIVE;2.04;2.73 +30249-7;Barbiturates;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Barbiturates [Mass/volume] in Serum or Plasma by Screen method;Barbiturates SerPl Scn-mCnc;;ACTIVE;2.04;2.73 +30250-5;Benzodiazepines;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Serum or Plasma by Screen method;Benzodiaz SerPl Scn-mCnc;;ACTIVE;2.04;2.73 +30251-3;Glucose^2.6H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.6 hours post dose glucose;Glucose 2.6h p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +30252-1;Glucose^3.3H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3.3 hours post dose glucose;Glucose 3.3h p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +30253-9;Glucose^3.6H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3.6 hours post dose glucose;Glucose 3.6h p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +3025-4;Thyroxine;MCnc;Pt;Bld;Qn;;CHEM;1;Thyroxine (T4) [Mass/volume] in Blood;T4 Bld-mCnc;;ACTIVE;1.0;2.73 +30254-7;Insulin^15M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --15 minutes post XXX challenge;Insulin 15M p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +30255-4;Insulin^45M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --45 minutes post XXX challenge;Insulin 45M p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +30256-2;Insulin^1.3H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1.3 hours post XXX challenge;Insulin 1.3h p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +30257-0;Insulin^1.6H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1.6 hours post XXX challenge;Insulin 1.6h p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +30258-8;Insulin^2.3H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2.3 hours post XXX challenge;Insulin 2.3h p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +30259-6;Insulin^2.6H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2.6 hours post XXX challenge;Insulin 2.6h p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +30260-4;Insulin^3.3H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3.3 hours post XXX challenge;Insulin 3.3h p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +30261-2;Insulin^3.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3.5 hours post XXX challenge;Insulin 3.5h p chal SerPl-aCnc;;ACTIVE;2.04;2.68 +3026-2;Thyroxine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma;T4 SerPl-mCnc;;ACTIVE;1.0;2.73 +30262-0;Insulin^3.6H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3.6 hours post XXX challenge;Insulin 3.6h p chal SerPl-aCnc;;ACTIVE;2.04;2.73 +30263-8;Glucose^20M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20 minutes post dose glucose;Glucose 20M p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +30264-6;Glucose^40M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --40 minutes post dose glucose;Glucose 40M p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +30265-3;Glucose^1.3H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.3 hours post dose glucose;Glucose 1.3h p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +30266-1;Glucose^1.6H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.6 hours post dose glucose;Glucose 1.6h p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +30267-9;Glucose^2.3H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.3 hours post dose glucose;Glucose 2.3h p Glc SerPl-sCnc;;ACTIVE;2.04;2.34 +30268-7;Zidovudine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Zidovudine [Susceptibility] by Phenotype method;Zidovudine Islt Phenotyp;;ACTIVE;2.04;2.73 +30269-5;lamiVUDine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;lamiVUDine [Susceptibility] by Phenotype method;lamiVUDine Islt Phenotyp;;ACTIVE;2.04;2.19 +3027-0;Thyroxine/Thyroxine binding globulin;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4)/Thyroxine binding globulin [Mass Ratio] in Serum or Plasma;T4/T4BG SerPl;;ACTIVE;1.0;2.73 +30270-3;Didanosine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Didanosine [Susceptibility] by Phenotype method;Didanosine Islt Phenotyp;;ACTIVE;2.04;2.73 +30271-1;Zalcitabine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Zalcitabine [Susceptibility] by Phenotype method;Zalcitabine Islt Phenotyp;;ACTIVE;2.04;2.19 +30272-9;Stavudine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Stavudine [Susceptibility] by Phenotype method;Stavudine Islt Phenotyp;;ACTIVE;2.04;2.73 +30273-7;Abacavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Abacavir [Susceptibility] by Phenotype method;Abacavir Islt Phenotyp;;ACTIVE;2.04;2.73 +30274-5;Adefovir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Adefovir [Susceptibility] by Phenotype method;Adefovir Islt Phenotyp;;ACTIVE;2.04;2.19 +30275-2;Nevirapine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Nevirapine [Susceptibility] by Phenotype method;Nevirapine Islt Phenotyp;;ACTIVE;2.04;2.73 +30276-0;Delavirdine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Delavirdine [Susceptibility] by Phenotype method;Delavirdine Islt Phenotyp;;ACTIVE;2.04;2.19 +30277-8;Efavirenz;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Efavirenz [Susceptibility] by Phenotype method;Efavirenz Islt Phenotyp;;ACTIVE;2.04;2.73 +30278-6;Indinavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Indinavir [Susceptibility] by Phenotype method;Indinavir Islt Phenotyp;;ACTIVE;2.04;2.73 +30279-4;Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Ritonavir [Susceptibility] by Phenotype method;Ritonavir Islt Phenotyp;;ACTIVE;2.04;2.19 +30280-2;Nelfinavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Nelfinavir [Susceptibility] by Phenotype method;Nelfinavir Islt Phenotyp;;ACTIVE;2.04;2.73 +30281-0;Saquinavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Saquinavir [Susceptibility] by Phenotype method;Saquinavir Islt Phenotyp;;ACTIVE;2.04;2.19 +30282-8;Zidovudine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Zidovudine [Susceptibility] by Genotype method;Zidovudine Islt Genotyp;;ACTIVE;2.04;2.73 +30283-6;lamiVUDine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;lamiVUDine [Susceptibility] by Genotype method;lamiVUDine Islt Genotyp;;ACTIVE;2.04;2.73 +30284-4;Didanosine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Didanosine [Susceptibility] by Genotype method;Didanosine Islt Genotyp;;ACTIVE;2.04;2.73 +30285-1;Zalcitabine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Zalcitabine [Susceptibility] by Genotype method;Zalcitabine Islt Genotyp;;ACTIVE;2.04;2.66 +30286-9;Stavudine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Stavudine [Susceptibility] by Genotype method;Stavudine Islt Genotyp;;ACTIVE;2.04;2.73 +30287-7;Abacavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Abacavir [Susceptibility] by Genotype method;Abacavir Islt Genotyp;;ACTIVE;2.04;2.73 +3028-8;Thyroxine/Triiodothyronine uptake index;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4)/Triiodothyronine (T3) uptake index [Mass Ratio] in Serum or Plasma;T4/T3 uptake index SerPl;;DISCOURAGED;1.0;2.73 +30288-5;Adefovir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Adefovir [Susceptibility] by Genotype method;Adefovir Islt Genotyp;;ACTIVE;2.04;2.73 +30289-3;Nevirapine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Nevirapine [Susceptibility] by Genotype method;Nevirapine Islt Genotyp;;ACTIVE;2.04;2.73 +30290-1;Delavirdine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Delavirdine [Susceptibility] by Genotype method;Delavirdine Islt Genotyp;;ACTIVE;2.04;2.66 +30291-9;Efavirenz;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Efavirenz [Susceptibility] by Genotype method;Efavirenz Islt Genotyp;;ACTIVE;2.04;2.73 +30292-7;Indinavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Indinavir [Susceptibility] by Genotype method;Indinavir Islt Genotyp;;ACTIVE;2.04;2.73 +30293-5;Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Ritonavir [Susceptibility] by Genotype method;Ritonavir Islt Genotyp;;ACTIVE;2.04;2.73 +30294-3;Nelfinavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Nelfinavir [Susceptibility] by Genotype method;Nelfinavir Islt Genotyp;;ACTIVE;2.04;2.73 +30295-0;Saquinavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Saquinavir [Susceptibility] by Genotype method;Saquinavir Islt Genotyp;;ACTIVE;2.04;2.73 +3029-6;Transcobalamin I;MCnc;Pt;Ser;Qn;;CHEM;1;Transcobalamin I [Mass/volume] in Serum;Transcobalamin I Ser-mCnc;;DISCOURAGED;1.0;2.44 +30296-8;Amprenavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Amprenavir [Susceptibility] by Phenotype method;Amprenavir Islt Phenotyp;;ACTIVE;2.04;2.19 +30297-6;Amprenavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Amprenavir [Susceptibility] by Genotype method;Amprenavir Islt Genotyp;;ACTIVE;2.04;2.73 +30298-4;lamiVUDine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;lamiVUDine [Susceptibility];lamiVUDine Susc Islt;;ACTIVE;2.04;2.19 +30299-2;Amprenavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amprenavir [Susceptibility];Amprenavir Susc Islt;;ACTIVE;2.04;2.73 +30300-8;Didanosine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Didanosine [Susceptibility];Didanosine Susc Islt;;ACTIVE;2.04;2.19 +30301-6;Zalcitabine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Zalcitabine [Susceptibility];Zalcitabine Susc Islt;;ACTIVE;2.04;2.19 +30302-4;Stavudine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Stavudine [Susceptibility];Stavudine Susc Islt;;ACTIVE;2.04;2.19 +30303-2;Abacavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Abacavir [Susceptibility];Abacavir Susc Islt;;ACTIVE;2.04;2.19 +3030-4;Transcobalamin II;MCnc;Pt;Ser;Qn;;CHEM;1;Transcobalamin II [Mass/volume] in Serum;Transcobalamin II Ser-mCnc;;DISCOURAGED;1.0;2.73 +30304-0;Adefovir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Adefovir [Susceptibility];Adefovir Susc Islt;;ACTIVE;2.04;2.19 +30305-7;Delavirdine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Delavirdine [Susceptibility];Delavirdine Susc Islt;;ACTIVE;2.04;2.19 +30306-5;Efavirenz;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Efavirenz [Susceptibility];Efavirenz Susc Islt;;ACTIVE;2.04;2.19 +30307-3;Indinavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Indinavir [Susceptibility];Indinavir Susc Islt;;ACTIVE;2.04;2.19 +30308-1;Ritonavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ritonavir [Susceptibility];Ritonavir Susc Islt;;ACTIVE;2.04;2.19 +30309-9;Nelfinavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nelfinavir [Susceptibility];Nelfinavir Susc Islt;;ACTIVE;2.04;2.19 +30310-7;Saquinavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Saquinavir [Susceptibility];Saquinavir Susc Islt;;ACTIVE;2.04;2.19 +30311-5;Nevirapine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nevirapine [Susceptibility];Nevirapine Susc Islt;;ACTIVE;2.04;2.19 +3031-2;Transcobalamin III;MCnc;Pt;Ser;Qn;;CHEM;1;Transcobalamin III [Mass/volume] in Serum;Transcobalamin III Ser-mCnc;;DISCOURAGED;1.0;2.44 +30312-3;3-Hydroxyoleoylcarnitine (C18:1-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in Serum or Plasma;3OH-Oleoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30313-1;Hemoglobin;MCnc;Pt;BldA;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Arterial blood;Hgb BldA-mCnc;;ACTIVE;2.04;2.73 +30314-9;A Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;A Ab [Titer] in Serum or Plasma;A Ab Titr SerPl;;ACTIVE;2.04;2.73 +30315-6;Acid alpha glucosidase;CCnt;Pt;Tsmi;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/mass] in Small intestine Tissue;Acid A-Glucosidase TSMI-cCnt;;ACTIVE;2.04;2.73 +30316-4;Alpha subunit.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha subunit free [Mass/volume] in Serum or Plasma;Alpha subunit free SerPl-mCnc;;ACTIVE;2.04;2.73 +30317-2;Base deficit;SCnc;Pt;BldCoA;Qn;;CHEM;1;Base deficit in Arterial cord blood;Base deficit BldCoA-sCnc;;ACTIVE;2.04;2.73 +30318-0;Base deficit;SCnc;Pt;Bld;Qn;;CHEM;1;Base deficit in Blood;Base deficit Bld-sCnc;;ACTIVE;2.04;2.73 +30319-8;Beta galactosidase;CCnt;Pt;Tsmi;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/mass] in Small intestine Tissue;B-Galactosidase TSMI-cCnt;;ACTIVE;2.04;2.73 +3032-0;Transcobalamin;MCnc;Pt;Ser;Qn;;CHEM;1;Transcobalamin [Mass/volume] in Serum;Transcobalamin Ser-mCnc;;DISCOURAGED;1.0;2.44 +30320-6;Cells.CD3+IL2R1+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+IL2R1+ cells [#/volume] in Blood;CD3+IL2R1+ Cells # Bld;;ACTIVE;2.04;2.70 +30321-4;Coagulation surface induced.factor substitution^1H post incubation;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --1 hour post incubation;aPTT 1h p Inc Cont PPP;;ACTIVE;2.04;2.70 +30322-2;Coagulation surface induced.factor substitution^1H post incubation;Time;Pt;PPP;Qn;;COAG;1;aPTT.factor substitution in Platelet poor plasma --1 hour post incubation;aPTT 1h p Inc PPP;;ACTIVE;2.04;2.73 +30323-0;Coagulation surface induced.factor substitution^1H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with normal plasma;aPTT 1h NP PPP;;ACTIVE;2.04;2.73 +30324-8;Cryptococcus sp Ag;PrThr;Pt;Ser;Ord;LA;MICRO;1;Cryptococcus sp Ag [Presence] in Serum by Latex agglutination;Cryptoc Ag Ser Ql LA;;ACTIVE;2.04;2.73 +30325-5;Cytomegalovirus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Cytomegalovirus IgM Ab [Presence] in Serum or Plasma;CMV IgM SerPl Ql;;ACTIVE;2.04;2.73 +30326-3;Cytomegalovirus DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;CMV DNA CSF Ql NAA+probe;;ACTIVE;2.04;2.73 +30327-1;Decanoylcarnitine (C10);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decanoylcarnitine (C10) [Moles/volume] in Serum or Plasma;Decanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30328-9;Decenoylcarnitine (C10:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decenoylcarnitine (C10:1) [Moles/volume] in Serum or Plasma;Decenoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30329-7;Disialylganglioside GD1b Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Deprecated Disialylganglioside GD1b IgG Ab [Titer] in Serum;Deprecated GD1b Disialyl IgG Titr Ser;;DEPRECATED;2.04;2.36 +30330-5;Disialylganglioside GD1b Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Deprecated Disialylganglioside GD1b IgM Ab [Titer] in Serum;Deprecated GD1b Disialyl IgM Titr Ser;;DEPRECATED;2.04;2.36 +30331-3;Dodecanoylcarnitine (C12);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dodecanoylcarnitine (C12) [Moles/volume] in Serum or Plasma;Dodecanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30332-1;Dodecenoylcarnitine (C12:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1) [Moles/volume] in Serum or Plasma;Dodecenoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30333-9;Echovirus 11 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Echovirus 11 Ab [Presence] in Serum by Complement fixation;ECV11 Ab Ser Ql CF;;ACTIVE;2.04;2.56 +30334-7;Echovirus 30 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Echovirus 30 Ab [Presence] in Serum by Complement fixation;ECV30 Ab Ser Ql CF;;ACTIVE;2.04;2.56 +30335-4;Echovirus 4 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Echovirus 4 Ab [Presence] in Serum by Complement fixation;ECV4 Ab Ser Ql CF;;ACTIVE;2.04;2.56 +30336-2;Echovirus 7 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Echovirus 7 Ab [Presence] in Serum by Complement fixation;ECV7 Ab Ser Ql CF;;ACTIVE;2.04;2.56 +30337-0;Echovirus 9 Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Echovirus 9 Ab [Presence] in Serum by Complement fixation;ECV9 Ab Ser Ql CF;;ACTIVE;2.04;2.56 +3033-8;Transcortin;MCnc;Pt;Ser;Qn;;CHEM;1;Transcortin [Mass/volume] in Serum;Transcortin Ser-mCnc;;ACTIVE;1.0;2.73 +30338-8;Anaplasma phagocytophilum Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Anaplasma phagocytophilum Ab [Titer] in Serum by Immunofluorescence;A phagocytoph Ab Titr Ser IF;;ACTIVE;2.04;2.73 +30339-6;Epstein Barr virus capsid Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus capsid IgG Ab [Presence] in Serum;EBV VCA IgG Ser Ql;;ACTIVE;2.04;2.73 +30340-4;Epstein Barr virus capsid Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus capsid IgM Ab [Presence] in Serum;EBV VCA IgM Ser Ql;;ACTIVE;2.04;2.73 +30341-2;Erythrocyte sedimentation rate;Vel;Pt;Bld;Qn;;HEM/BC;1;Erythrocyte sedimentation rate;ESR Bld Qn;;ACTIVE;2.04;2.73 +30342-0;Extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Extractable nuclear Ab [Units/volume] in Serum;ENA Ab Ser-aCnc;;ACTIVE;2.04;2.73 +30343-8;Glomerular basement membrane Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Glomerular basement membrane IgG Ab [Units/volume] in Serum by Immunoassay;GBM IgG Ser IA-aCnc;;ACTIVE;2.04;2.73 +30344-6;Glucose^1H post 1.2 g/kg lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post 1.2 g/kg lactose PO;Glucose 1h p 1.2 g/kg Lac PO SerPl-mCnc;;ACTIVE;2.04;2.70 +30345-3;Glucose^2H post 1.2 g/kg lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post 1.2 g/kg lactose PO;Glucose 2h p 1.2 g/kg Lac PO SerPl-mCnc;;ACTIVE;2.04;2.70 +3034-6;Transferrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin [Mass/volume] in Serum or Plasma;Transferrin SerPl-mCnc;;ACTIVE;1.0;2.73 +30346-1;Glucose^3H post 1.2 g/kg lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post 1.2 g/kg lactose PO;Glucose 3h p 1.2 g/kg Lac PO SerPl-mCnc;;ACTIVE;2.04;2.70 +30347-9;Glutamate decarboxylase 65 Ab;SCnc;Pt;Ser;Qn;;SERO;1;Glutamate decarboxylase 65 Ab [Moles/volume] in Serum;GAD65 Ab Ser-sCnc;;ACTIVE;2.04;2.73 +30348-7;Glutamate;SCnc;Pt;Urine;Qn;;CHEM;1;Glutamate [Moles/volume] in Urine;Glutamate Ur-sCnc;;ACTIVE;2.04;2.73 +30349-5;Glutarylcarnitine (C5-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutarylcarnitine (C5-DC) [Moles/volume] in Serum or Plasma;Glutarylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30350-3;Hemoglobin;MCnc;Pt;BldV;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Venous blood;Hgb BldV-mCnc;;ACTIVE;2.04;2.73 +30351-1;Hemoglobin;MCnc;Pt;BldMV;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Mixed venous blood;Hgb BldMV-mCnc;;ACTIVE;2.04;2.73 +30352-9;Hemoglobin;MCnc;Pt;BldC;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Capillary blood;Hgb BldC-mCnc;;ACTIVE;2.04;2.73 +3035-3;Transferrin;MCnc;Pt;Urine;Qn;;CHEM;1;Transferrin [Mass/volume] in Urine;Transferrin Ur-mCnc;;ACTIVE;1.0;2.73 +30353-7;Hemoglobin;MCnc;Pt;BldCoV;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Venous cord blood;Hgb BldCoV-mCnc;;ACTIVE;2.04;2.73 +30354-5;Hemoglobin;MCnc;Pt;BldCoA;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Arterial cord blood;Hgb BldCoA-mCnc;;ACTIVE;2.04;2.73 +30355-2;Herpes simplex virus 1+2 Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Presence] in Serum by Immunofluorescence;HSV1+2 IgM Ser Ql IF;;ACTIVE;2.04;2.73 +30356-0;Palmitoylcarnitine (C16);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Moles/volume] in Serum or Plasma;Palmitoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30357-8;Palmitoleylcarnitine (C16:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoleylcarnitine (C16:1) [Moles/volume] in Serum or Plasma;Palmitoleylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30358-6;Hexanoylcarnitine (C6);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexanoylcarnitine (C6) [Moles/volume] in Serum or Plasma;Hexanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30359-4;Histone Ab;ACnc;Pt;Ser;Qn;;SERO;1;Histone Ab [Units/volume] in Serum;Histone Ab Ser-aCnc;;ACTIVE;2.04;2.73 +30360-2;Histoplasma capsulatum mycelial phase Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Presence] in Serum by Complement fixation;H capsul Myc Ab Ser Ql CF;;ACTIVE;2.04;2.73 +3036-1;Transketolase;CCnc;Pt;Ser;Qn;;CHEM;1;Transketolase [Enzymatic activity/volume] in Serum;Transketolase Ser-cCnc;;ACTIVE;1.0;2.73 +30361-0;HIV 2 Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 2 Ab [Presence] in Serum or Plasma by Immunoassay;HIV 2 Ab SerPl Ql IA;;ACTIVE;2.04;2.73 +30362-8;Insulin^30M post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --30 minutes post 75 g glucose PO;Insulin 30M p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.04;2.73 +30363-6;Insulin^post 12H CFst;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --12 hours fasting;Insulin p 12h fast SerPl-aCnc;;ACTIVE;2.04;2.73 +30364-4;Lymphocytes;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Lymphocytes [#/volume] in Blood by Flow cytometry (FC);Lymphocytes # Bld FC;;ACTIVE;2.04;2.73 +30365-1;Lymphocytes/100 leukocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Lymphocytes/100 leukocytes in Blood by Flow cytometry (FC);Lymphocytes/leuk NFr Bld FC;;ACTIVE;2.04;2.73 +30366-9;Metamyelocytes/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Metamyelocytes/100 leukocytes in Cerebral spinal fluid;Metamyelocytes/leuk NFr CSF;;ACTIVE;2.04;2.73 +30367-7;Myeloblasts/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Myeloblasts/100 leukocytes in Blood by Automated count;Deprecated Myeloblasts Fr Bld Auto;;DEPRECATED;2.04;2.70 +30368-5;Myelocytes/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Myelocytes/100 leukocytes in Cerebral spinal fluid by Manual count;Myelocytes/leuk NFr CSF Manual;;ACTIVE;2.04;2.73 +30369-3;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;BldCoV;Qn;;CHEM;1;Fractional oxyhemoglobin in Venous cord blood;OxyHgb MFr BldCoV;;ACTIVE;2.04;2.73 +30370-1;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;BldCoA;Qn;;CHEM;1;Fractional oxyhemoglobin in Arterial cord blood;OxyHgb MFr BldCoA;;ACTIVE;2.04;2.73 +30371-9;Promyelocytes/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Promyelocytes/100 leukocytes in Cerebral spinal fluid by Manual count;Promyelocytes/leuk NFr CSF Manual;;ACTIVE;2.04;2.73 +30372-7;Sucrase;CCnt;Pt;Tsmi;Qn;;CHEM;1;Sucrase [Enzymatic activity/mass] in Small intestine Tissue;Sucrase TSMI-cCnt;;ACTIVE;2.04;2.73 +30373-5;Basophils/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Basophils/100 leukocytes in Bronchial specimen;Basophils/leuk NFr Bronch;;ACTIVE;2.04;2.70 +30374-3;Basophils/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Basophils/100 leukocytes in Cerebral spinal fluid;Basophils/leuk NFr CSF;;ACTIVE;2.04;2.73 +30375-0;Basophils/100 leukocytes;NFr;Pt;Sputum;Qn;;HEM/BC;1;Basophils/100 leukocytes in Sputum;Basophils/leuk NFr Spt;;ACTIVE;2.04;2.70 +30376-8;Blasts;NCnc;Pt;Bld;Qn;;HEM/BC;1;Blasts [#/volume] in Blood;Blasts # Bld;;ACTIVE;2.04;2.73 +30377-6;Eosinophils/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Bronchial specimen;Eosinophil/leuk NFr Bronch;;ACTIVE;2.04;2.70 +30378-4;Eosinophils/100 leukocytes;NFr;Pt;Nose;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Nose;Eosinophil/leuk NFr Nose;;ACTIVE;2.04;2.70 +3037-9;Prealbumin;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Prealbumin [Enzymatic activity/volume] in Serum or Plasma;Deprecated Prealb SerPl-cCnc;;DEPRECATED;1.0;2.44 +30379-2;Eosinophils/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Pleural fluid;Eosinophil/leuk NFr Plr;;ACTIVE;2.04;2.70 +303-8;Lomefloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Lomefloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Lomefloxacin Islt MIC;;ACTIVE;1.0;2.73 +30380-0;Eosinophils/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Peritoneal fluid;Eosinophil/leuk NFr Prt;;ACTIVE;2.04;2.73 +30381-8;Eosinophils/100 leukocytes;NFr;Pt;Sputum;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Sputum;Eosinophil/leuk NFr Spt;;ACTIVE;2.04;2.70 +30382-6;Eosinophils/100 leukocytes;NFr;Pt;Stool;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Stool;Eosinophil/leuk NFr Stl;;ACTIVE;2.04;2.70 +30383-4;Epithelial cells;NCnc;Pt;Urine;Qn;;UA;1;Epithelial cells [#/volume] in Urine;Epi Cells # Ur;;ACTIVE;2.04;2.73 +30384-2;Erythrocyte distribution width;EntVol;Pt;RBC;Qn;;HEM/BC;1;Erythrocyte distribution width [Entitic volume];RDW RBC;;ACTIVE;2.04;2.73 +30385-9;Erythrocyte distribution width;Ratio;Pt;RBC;Qn;;HEM/BC;1;Erythrocyte distribution width [Ratio];RDW RBC-Rto;;ACTIVE;2.04;2.73 +30386-7;Erythrocyte mean corpuscular diameter;Len;Pt;RBC;Qn;;HEM/BC;1;Erythrocyte mean corpuscular diameter [Length];MCD RBC;;ACTIVE;2.04;2.44 +3038-7;Trehalase;CCnc;Pt;Urine;Qn;;CHEM;1;Trehalase [Enzymatic activity/volume] in Urine;Trehalase Ur-cCnc;;ACTIVE;1.0;2.68 +30387-5;Erythrocytes;NCnc;Pt;Gast fld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Gastric fluid;RBC # Gast;;ACTIVE;2.04;2.44 +30388-3;Erythrocytes;NCnc;Pt;Pericard fld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Pericardial fluid;RBC # Pcar;;ACTIVE;2.04;2.44 +30389-1;Erythrocytes;NCnc;Pt;Semin plas;Qn;;FERT;1;Erythrocytes [#/volume] in Seminal plasma;RBC # Semin plas;;ACTIVE;2.04;2.42 +30390-9;Erythrocytes;ACnc;Pt;Stool;Qn;;HEM/BC;1;Erythrocytes [Units/volume] in Stool;RBC Stl-aCnc;;DISCOURAGED;2.04;2.69 +30391-7;Erythrocytes;NCnc;Pt;Urine;Qn;;UA;1;Erythrocytes [#/volume] in Urine;RBC # Ur;;ACTIVE;2.04;2.73 +30392-5;Erythrocytes.nucleated;NCnc;Pt;Bld;Qn;;HEM/BC;1;Nucleated erythrocytes [#/volume] in Blood;nRBC # Bld;;ACTIVE;2.04;2.73 +30393-3;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Bld;Qn;;HEM/BC;1;Deprecated Nucleated Erythrocytes/100 leukocytes [Ratio] in Blood;Deprecated nRBC/WBC Bld-Rto;;DEPRECATED;2.04;2.36 +30394-1;Granulocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Granulocytes [#/volume] in Blood;Granulocytes # Bld;;ACTIVE;2.04;2.73 +3039-5;Triacylglycerol lipase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Amniotic fluid;Lipase Amn-cCnc;;ACTIVE;1.0;2.68 +30395-8;Granulocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Granulocytes/100 leukocytes in Blood;Granulocytes/leuk NFr Bld;;ACTIVE;2.04;2.73 +30396-6;Granulocytes/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Granulocytes/100 leukocytes in Bronchial specimen;Granulocytes/leuk NFr Bronch;;ACTIVE;2.04;2.70 +30397-4;Hairy cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Hairy cells [#/volume] in Blood;Hairy Cells # Bld;;ACTIVE;2.04;2.70 +30398-2;Hematocrit;VFr;Pt;CSF;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Cerebral spinal fluid;Hct VFr CSF;;ACTIVE;2.04;2.70 +30399-0;Hemoglobin distribution width;Len;Pt;Bld;Qn;;HEM/BC;1;Deprecated Hemoglobin distribution width [Length] in Blood;Deprecated HDW Bld;;DEPRECATED;2.04;2.44 +30400-6;Hypochromia;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hypochromia [Presence] in Blood;Hypochromia Bld Ql;;ACTIVE;2.04;2.73 +30401-4;Leukocytes;NCnc;Pt;Bronchial;Qn;;HEM/BC;1;Leukocytes [#/volume] in Bronchial specimen;WBC # Bronch;;ACTIVE;2.04;2.19 +30402-2;Leukocytes;NCnc;Pt;Gast fld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Gastric fluid;WBC # Gast;;ACTIVE;2.04;2.44 +3040-3;Triacylglycerol lipase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Serum or Plasma;Lipase SerPl-cCnc;;ACTIVE;1.0;2.73 +30403-0;Leukocytes;NCnc;Pt;Pericard fld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Pericardial fluid;WBC # Pcar;;ACTIVE;2.04;2.44 +30404-8;Leukocytes;NCnc;Pt;Stool;Qn;;HEM/BC;1;Leukocytes [#/volume] in Stool;WBC # Stl;;ACTIVE;2.04;2.73 +30405-5;Leukocytes;NCnc;Pt;Urine;Qn;;UA;1;Leukocytes [#/volume] in Urine;WBC # Ur;;ACTIVE;2.04;2.73 +30406-3;Leukocytes other;NCnc;Pt;Bld;Qn;;HEM/BC;1;Leukocytes other [#/volume] in Blood;WBC Other # Bld;;ACTIVE;2.04;2.73 +30407-1;Leukocytes other/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Pericardial fluid;WBC Other/leuk NFr Pcar;;ACTIVE;2.04;2.70 +30408-9;Leukocytes other/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Pleural fluid;WBC Other/leuk NFr Plr;;ACTIVE;2.04;2.70 +30409-7;Leukocytes other/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Peritoneal fluid;WBC Other/leuk NFr Prt;;ACTIVE;2.04;2.70 +30410-5;Leukocytes other/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Synovial fluid;WBC Other/leuk NFr Snv;;ACTIVE;2.04;2.73 +3041-1;Trichloroacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trichloroacetate [Mass/volume] in Urine;TCA Ur-mCnc;;ACTIVE;1.0;2.73 +30411-3;Leukocytes.left shift;PrThr;Pt;Bld;Ord;;HEM/BC;1;Leukocytes Left Shift [Presence] in Blood;WBC Left Shift Bld Ql;;ACTIVE;2.04;2.73 +30412-1;Lymphocytes.abnormal;NCnc;Pt;Bld;Qn;;HEM/BC;1;Abnormal lymphocytes [#/volume] in Blood;Lymph Abn # Bld;;ACTIVE;2.04;2.73 +30413-9;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Blood;Lymph Abn/leuk NFr Bld;;ACTIVE;2.04;2.73 +30414-7;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Cerebral spinal fluid;Lymph Abn/leuk NFr CSF;;ACTIVE;2.04;2.73 +30415-4;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Synovial fluid;Lymph Abn/leuk NFr Snv;;ACTIVE;2.04;2.73 +30416-2;Lymphocytes.variant/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Cerebral spinal fluid;Variant Lymphs/leuk NFr CSF;;ACTIVE;2.04;2.73 +30417-0;Lymphocytes.variant/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Body fluid;Variant Lymphs/leuk NFr Fld;;ACTIVE;2.04;2.73 +30418-8;Lymphocytes.clefted;NCnc;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes clefted [#/volume] in Blood;Cleft Lymphs # Bld;;ACTIVE;2.04;2.46 +30419-6;Lymphocytes.clefted/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes clefted/100 leukocytes in Blood;Cleft Lymphs/leuk NFr Bld;;ACTIVE;2.04;2.70 +30420-4;Lymphocytes.large granular/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Large granular lymphocytes/100 leukocytes in Blood;Lg Gran Lymphs/leuk NFr Bld;;ACTIVE;2.04;2.70 +30421-2;Lymphocytes/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Bronchial specimen;Lymphocytes/leuk NFr Bronch;;ACTIVE;2.04;2.73 +30422-0;Lymphoma cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Lymphoma cells [#/volume] in Blood;Lymphoma Cells # Bld;;ACTIVE;2.04;2.70 +30423-8;Lymphoma cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Lymphoma cells/100 leukocytes in Blood;Lymphoma Cells/leuk NFr Bld;;ACTIVE;2.04;2.70 +30424-6;Macrocytes;PrThr;Pt;Bld;Ord;;HEM/BC;1;Macrocytes [Presence] in Blood;Macrocytes Bld Ql;;ACTIVE;2.04;2.73 +30425-3;Macrophages/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Macrophages/100 leukocytes in Bronchial specimen;Macrophages/leuk NFr Bronch;;ACTIVE;2.04;2.70 +30426-1;Macrophages/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Macrophages/100 leukocytes in Cerebral spinal fluid;Macrophages/leuk NFr CSF;;ACTIVE;2.04;2.73 +30427-9;Macrophages/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Macrophages/100 leukocytes in Body fluid;Macrophages/leuk NFr Fld;;ACTIVE;2.04;2.73 +30428-7;Erythrocyte mean corpuscular volume;EntVol;Pt;RBC;Qn;;HEM/BC;1;MCV [Entitic volume];MCV RBC;;ACTIVE;2.04;2.73 +3042-9;Chloral hydrate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloral hydrate [Mass/volume] in Serum or Plasma;Chloral Hydrate SerPl-mCnc;;ACTIVE;1.0;2.73 +30429-5;Mesothelial cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Mesothelial cells/100 leukocytes in Cerebral spinal fluid;Mesothl Cell/leuk NFr CSF;;ACTIVE;2.04;2.73 +30430-3;Mesothelial cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Mesothelial cells/100 leukocytes in Pericardial fluid;Mesothl Cell/leuk NFr Pcar;;ACTIVE;2.04;2.70 +30431-1;Mesothelial cells/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Mesothelial cells/100 leukocytes in Pleural fluid;Mesothl Cell/leuk NFr Plr;;ACTIVE;2.04;2.70 +30432-9;Mesothelial cells/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Mesothelial cells/100 leukocytes in Peritoneal fluid;Mesothl Cell/leuk NFr Prt;;ACTIVE;2.04;2.70 +30433-7;Metamyelocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Metamyelocytes [#/volume] in Blood;Metamyelocytes # Bld;;ACTIVE;2.04;2.73 +30434-5;Microcytes;PrThr;Pt;Bld;Ord;;HEM/BC;1;Microcytes [Presence] in Blood;Microcytes Bld Ql;;ACTIVE;2.04;2.73 +30435-2;Monocytes;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Monocytes [#/volume] in Synovial fluid;Monocytes # Snv;;ACTIVE;2.04;2.73 +30436-0;Monocytes+Macrophages/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Cerebral spinal fluid;Monos+Macros/leuk NFr CSF;;ACTIVE;2.04;2.73 +3043-7;Triglyceride;MCnc;Pt;Bld;Qn;;CHEM;1;Triglyceride [Mass/volume] in Blood;Trigl Bld-mCnc;;ACTIVE;1.0;2.73 +30437-8;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Body fluid;Monos+Macros/leuk NFr Fld;;ACTIVE;2.04;2.73 +30438-6;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Synovial fluid;Monos+Macros/leuk NFr Snv;;ACTIVE;2.04;2.73 +30439-4;Monocytes+Macrophages/100 leukocytes;NFr;Pt;XXX;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Specimen;Monos+Macros/leuk NFr Spec;;ACTIVE;2.04;2.70 +30440-2;Monocytes.abnormal;NCnc;Pt;Bld;Qn;;HEM/BC;1;Monocytes Abnormal [#/volume] in Blood;Abn Monocytes # Bld;;ACTIVE;2.04;2.73 +30441-0;Monocytes.abnormal/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Monocytes Abnormal/100 leukocytes in Blood;Abn Monocytes/leuk NFr Bld;;ACTIVE;2.04;2.50 +30442-8;Monocytes/100 leukocytes;NFr;Pt;Urine;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Urine;Monocytes/leuk NFr Ur;;ACTIVE;2.04;2.70 +30443-6;Mononuclear cells/100 leukocytes;NFr;Pt;Gast fld;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Gastric fluid;Mononuc Cells/leuk NFr Gast;;ACTIVE;2.04;2.70 +30444-4;Myeloblasts;NCnc;Pt;Bld;Qn;;HEM/BC;1;Myeloblasts [#/volume] in Blood;Myeloblasts # Bld;;ACTIVE;2.04;2.73 +3044-5;Triglyceride+ester.in HDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride+ester in HDL [Mass/volume] in Serum or Plasma;Trigl+HDL Ester SerPl-mCnc;;ACTIVE;1.0;2.73 +30445-1;Myeloblasts/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Myeloblasts/100 leukocytes in Blood;Myeloblasts/leuk NFr Bld;;ACTIVE;2.04;2.73 +30446-9;Myelocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Myelocytes [#/volume] in Blood;Myelocytes # Bld;;ACTIVE;2.04;2.73 +30447-7;Myelocytes/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Myelocytes/100 leukocytes in Cerebral spinal fluid;Myelocytes/leuk NFr CSF;;ACTIVE;2.04;2.70 +30448-5;Neutrophils;NCnc;Pt;Urine;Qn;;UA;1;Neutrophils [#/volume] in Urine;Neutrophils # Ur;;ACTIVE;2.04;2.73 +30449-3;Neutrophils.hypersegmented;NCnc;Pt;Bld;Qn;;HEM/BC;1;Neutrophils.hypersegmented [#/volume] in Blood;Neuts Hyperseg # Bld;;ACTIVE;2.04;2.73 +30450-1;Neutrophils.hypersegmented/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Neutrophils.hypersegmented/100 leukocytes in Blood;Neuts Hyperseg/leuk NFr Bld;;ACTIVE;2.04;2.73 +30451-9;Neutrophils.segmented;NCnc;Pt;Bld;Qn;;HEM/BC;1;Segmented neutrophils [#/volume] in Blood;Neuts Seg # Bld;;ACTIVE;2.04;2.73 +3045-2;Triglyceride+ester.in IDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride+ester in IDL [Mass/volume] in Serum or Plasma;Trigl+IDL Ester SerPl-mCnc;;ACTIVE;1.0;2.73 +30452-7;Neutrophils.segmented;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Segmented neutrophils [#/volume] in Body fluid;Neuts Seg # Fld;;ACTIVE;2.04;2.73 +30453-5;Neutrophils.segmented/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Segmented neutrophils/100 leukocytes in Body fluid;Neuts Seg/leuk NFr Fld;;ACTIVE;2.04;2.73 +30454-3;Neutrophils/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Pericardial fluid;Neutrophils/leuk NFr Pcar;;ACTIVE;2.04;2.70 +30455-0;Neutrophils/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Pleural fluid;Neutrophils/leuk NFr Plr;;ACTIVE;2.04;2.70 +30456-8;Nonhematic cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Nonhematic cells/100 leukocytes in Cerebral spinal fluid;Nonhematic Cells/leuk NFr CSF;;ACTIVE;2.04;2.70 +30457-6;Nonhematic cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Nonhematic cells/100 leukocytes in Body fluid;Nonhematic Cells/leuk NFr Fld;;ACTIVE;2.04;2.73 +30458-4;Plasma cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Plasma cells [#/volume] in Blood;Plasma Cells # Bld;;ACTIVE;2.04;2.73 +30459-2;Platelet mean diameter;EntLen;Pt;Bld;Qn;;HEM/BC;1;Platelet mean diameter [Entitic length] in Blood;PMD Bld Qn;;ACTIVE;2.04;2.42 +304-6;Lomefloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Lomefloxacin [Susceptibility] by Disk diffusion (KB);Lomefloxacin Islt KB;;ACTIVE;1.0;2.73 +3046-0;Triglyceride+ester.in LDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride+ester in LDL [Mass/volume] in Serum or Plasma;Trigl+LDL Ester SerPl-mCnc;;ACTIVE;1.0;2.73 +30460-0;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Gast fld;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Gastric fluid;Polys/leuk NFr Gast;;ACTIVE;2.04;2.70 +30461-8;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Stool;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Stool;Polys/leuk NFr Stl;;ACTIVE;2.04;2.70 +30462-6;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Urine;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Urine;Polys/leuk NFr Ur;;ACTIVE;2.04;2.70 +30463-4;Promyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Deprecated Promyelocytes/100 leukocytes in Blood;Deprecated Promyelocytes Fr Bld;;DEPRECATED;2.04;2.70 +30464-2;Prolymphocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Prolymphocytes [#/volume] in Blood;Prolymphocytes # Bld;;ACTIVE;2.04;2.73 +30465-9;Prolymphocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Prolymphocytes/100 leukocytes in Blood;Prolymphocytes/leuk NFr Bld;;ACTIVE;2.04;2.73 +30466-7;Promonocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Promonocytes/100 leukocytes in Blood;Promonycytes/leuk NFr Bld;;ACTIVE;2.04;2.73 +30467-5;Promyelocytes/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Promyelocytes/100 leukocytes in Cerebral spinal fluid;Promyelocytes/leuk NFr CSF;;ACTIVE;2.04;2.70 +30468-3;Unidentified cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Unidentified cells/100 leukocytes in Cerebral spinal fluid;Unident Cells/leuk NFr CSF;;ACTIVE;2.04;2.73 +30469-1;Unspecified cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Unspecified cells/100 leukocytes in Body fluid;Unspecified Cells/leuk NFr Fld;;ACTIVE;2.04;2.73 +30470-9;Cardiolipin Ab.IgA;PrThr;Pt;Ser;Ord;;COAG;1;Cardiolipin IgA Ab [Presence] in Serum;Cardiolipin IgA Ser Ql;;ACTIVE;2.04;2.73 +30471-7;levETIRAcetam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;levETIRAcetam [Mass/volume] in Serum or Plasma;levETIRAcetam SerPl-mCnc;;ACTIVE;2.04;2.73 +30472-5;Ethylmalonate;PrThr;Pt;Urine;Ord;;CHEM;1;Ethylmalonate [Presence] in Urine;Ethylmalonate Ur Ql;;ACTIVE;2.04;2.73 +30473-3;Glutaconate;PrThr;Pt;Urine;Ord;;CHEM;1;Glutaconate [Presence] in Urine;Glutaconate Ur Ql;;ACTIVE;2.04;2.73 +30474-1;Glutarate;PrThr;Pt;Urine;Ord;;CHEM;1;Glutarate [Presence] in Urine;Glutarate Ur Ql;;ACTIVE;2.04;2.73 +30475-8;Glycerate;PrThr;Pt;Urine;Ord;;CHEM;1;Glycerate [Presence] in Urine;Glycerate Ur Ql;;ACTIVE;2.04;2.73 +30476-6;Glyoxylate;PrThr;Pt;Urine;Ord;;CHEM;1;Glyoxylate [Presence] in Urine;Glyoxylate Ur Ql;;ACTIVE;2.04;2.73 +30477-4;Hexanoylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;Hexanoylglycine [Presence] in Urine;Hexanoylgly Ur Ql;;ACTIVE;2.04;2.73 +3047-8;Triglyceride+ester.in VLDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride+ester in VLDL [Mass/volume] in Serum or Plasma;Trigl+VLDL Ester SerPl-mCnc;;ACTIVE;1.0;2.73 +30478-2;Malonate;PrThr;Pt;Urine;Ord;;CHEM;1;Malonate [Presence] in Urine;Malonate Ur Ql;;ACTIVE;2.04;2.73 +30479-0;Methylsuccinate;PrThr;Pt;Urine;Ord;;CHEM;1;Methylsuccinate [Presence] in Urine;Me-succinate Ur Ql;;ACTIVE;2.04;2.73 +30480-8;Orotate;PrThr;Pt;Urine;Ord;;CHEM;1;Orotate [Presence] in Urine;Orotate Ur Ql;;ACTIVE;2.04;2.73 +30481-6;Pyruvate;PrThr;Pt;Urine;Ord;;CHEM;1;Pyruvate [Presence] in Urine;Pyruvate Ur Ql;;ACTIVE;2.04;2.73 +30482-4;Suberylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;Suberylglycine [Presence] in Urine;Suberylgly Ur Ql;;ACTIVE;2.04;2.73 +30483-2;Succinylacetone;PrThr;Pt;Urine;Ord;;CHEM;1;Succinylacetone [Presence] in Urine;Succinylacetone Ur Ql;;ACTIVE;2.04;2.73 +30484-0;Tiglylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;Tiglylglycine [Presence] in Urine;Tiglylgly Ur Ql;;ACTIVE;2.04;2.73 +30485-7;Uracil;PrThr;Pt;Urine;Ord;;CHEM;1;Uracil [Presence] in Urine;Uracil Ur Ql;;ACTIVE;2.04;2.73 +3048-6;Triglyceride^post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triglyceride [Mass/volume] in Serum or Plasma --fasting;Trigl p fast SerPl-mCnc;;ACTIVE;1.0;2.73 +30486-5;Catecholamines^baseline;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --baseline;Catechols BS Plas-mCnc;;ACTIVE;2.04;2.73 +30487-3;Catecholamines^1H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Mass/volume] in Plasma --1 hour post XXX challenge;Catechols 1h p chal Plas-mCnc;;ACTIVE;2.04;2.73 +30488-1;Streptococcus pneumoniae 12 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum12 IgG sp1 Ser-mCnc;;DEPRECATED;2.04;2.70 +30489-9;Streptococcus pneumoniae 12 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum12 IgG sp2 Ser-mCnc;;DEPRECATED;2.04;2.70 +30490-7;Streptococcus pneumoniae Danish serotype 18C Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 18C IgG sp1 Ser-mCnc;;ACTIVE;2.04;2.70 +30491-5;Streptococcus pneumoniae Danish serotype 18C Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 18C IgG sp2 Ser-mCnc;;ACTIVE;2.04;2.70 +30492-3;Streptococcus pneumoniae 19 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum19 IgG sp1 Ser-mCnc;;DEPRECATED;2.04;2.70 +30493-1;Streptococcus pneumoniae 19 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum19 IgG sp2 Ser-mCnc;;DEPRECATED;2.04;2.70 +3049-4;Triglyceride;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Triglyceride [Mass/volume] in Serum or Plasma;Deprecated Trigl Plas-mCnc;;DEPRECATED;1.0;2.36 +30494-9;Streptococcus pneumoniae 23 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum23 IgG sp1 Ser-mCnc;;DEPRECATED;2.04;2.70 +30495-6;Streptococcus pneumoniae 23 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum23 IgG sp2 Ser-mCnc;;DEPRECATED;2.04;2.70 +30496-4;Streptococcus pneumoniae 4 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum4 IgG sp1 Ser-mCnc;;DEPRECATED;2.04;2.70 +30497-2;Streptococcus pneumoniae 4 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum4 IgG sp2 Ser-mCnc;;DEPRECATED;2.04;2.70 +30498-0;Streptococcus pneumoniae Danish serotype 6B Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 6B IgG sp1 Ser-mCnc;;ACTIVE;2.04;2.70 +30499-8;Streptococcus pneumoniae Danish serotype 6B Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 6B IgG sp2 Ser-mCnc;;ACTIVE;2.04;2.70 +30500-3;Phosphatidylserine Ab.IgA;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylserine IgA Ab [Presence] in Serum;PS IgA Ser Ql;;ACTIVE;2.04;2.73 +30501-1;Streptococcus pneumoniae Danish serotype 7F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 7F IgG sp1 Ser-mCnc;;ACTIVE;2.04;2.70 +3050-2;Triiodothyronine resin uptake (T3RU);NFr;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine resin uptake (T3RU) in Serum or Plasma;T3RU NFr SerPl;;ACTIVE;1.0;2.73 +30502-9;Streptococcus pneumoniae Danish serotype 7F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 7F IgG sp2 Ser-mCnc;;ACTIVE;2.04;2.70 +30503-7;Streptococcus pneumoniae 8 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum8 IgG sp1 Ser-mCnc;;DEPRECATED;2.04;2.70 +30504-5;Streptococcus pneumoniae 8 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum8 IgG sp2 Ser-mCnc;;DEPRECATED;2.04;2.70 +30505-2;Streptococcus pneumoniae 9 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum9 IgG sp1 Ser-mCnc;;DEPRECATED;2.04;2.70 +30506-0;Streptococcus pneumoniae 9 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum9 IgG sp2 Ser-mCnc;;DEPRECATED;2.04;2.70 +30507-8;Cumene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cumene [Mass/volume] in Urine;Cumene Ur-mCnc;;ACTIVE;2.04;2.70 +30508-6;Etiocholanolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Etiocholanolone/Creatinine [Mass Ratio] in Urine;Etiocholanolone/Creat Ur;;ACTIVE;2.04;2.73 +30509-4;Androsterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Androsterone/Creatinine [Mass Ratio] in Urine;Androsterone/Creat Ur;;ACTIVE;2.04;2.73 +3051-0;Triiodothyronine.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma;T3Free SerPl-mCnc;;ACTIVE;1.0;2.73 +30510-2;Estriol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Estriol (E3)/Creatinine [Mass Ratio] in Urine;Estriol/Creat Ur;;ACTIVE;2.04;2.70 +30511-0;Cortisone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Cortisone/Creatinine [Mass Ratio] in Urine;Cortisone/Creat Ur;;ACTIVE;2.04;2.73 +30512-8;Pregnanetriol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Pregnanetriol/Creatinine [Mass Ratio] in Urine;Pregntrl/Creat Ur;;ACTIVE;2.04;2.73 +30513-6;Pregnanetriolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Pregnanetriolone/Creatinine [Mass Ratio] in Urine;Pregntrlone/Creat Ur;;ACTIVE;2.04;2.70 +30514-4;Tetrahydrocortisone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Tetrahydrocortisone/Creatinine [Mass Ratio] in Urine;THcortisone/Creat Ur;;ACTIVE;2.04;2.70 +30515-1;Tetrahydroaldosterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tetrahydroaldosterone/Creatinine [Mass Ratio] in Urine;THaldost/Creat Ur;;ACTIVE;2.04;2.70 +30516-9;Bromodiphenhydramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromodiphenhydramine [Mass/volume] in Serum or Plasma;Bromodiphenhyd SerPl-mCnc;;ACTIVE;2.04;2.73 +30517-7;Carbinoxamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbinoxamine [Mass/volume] in Serum or Plasma;Carbinoxamine SerPl-mCnc;;ACTIVE;2.04;2.73 +30518-5;Cholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholate [Moles/volume] in Serum or Plasma;Cholate SerPl-sCnc;;ACTIVE;2.04;2.73 +30519-3;Chenodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chenodeoxycholate [Moles/volume] in Serum or Plasma;CDCAe SerPl-sCnc;;ACTIVE;2.04;2.73 +30520-1;Deoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deoxycholate [Moles/volume] in Serum or Plasma;DO-cholate SerPl-sCnc;;ACTIVE;2.04;2.73 +30521-9;Inhibin B;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin B [Units/volume] in Serum or Plasma;Inhibin B SerPl-aCnc;;ACTIVE;2.04;2.73 +30522-7;C reactive protein;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method;CRP SerPl HS-mCnc;;ACTIVE;2.04;2.73 +30523-5;Mycobacterium sp DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Mycobacterium sp DNA [Presence] in Urine by NAA with probe detection;Mycobacterium DNA Ur Ql NAA+probe;;ACTIVE;2.04;2.63 +30524-3;Triglyceride^post 12H CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triglyceride [Moles/volume] in Serum or Plasma --12 hours fasting;Trigl p 12h fast SerPl-sCnc;;ACTIVE;2.04;2.34 +30525-0;Age;Time;Pt;^Patient;Qn;;MISC;1;Age;Age;;ACTIVE;2.04;2.73 +30526-8;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Serum by Immunofluorescence;B burgdor IgM Ser Ql IF;;ACTIVE;2.04;2.73 +30527-6;Calcium;MCnc;Pt;TPN;Qn;;CHEM;1;Calcium [Mass/volume] in Total parental nutrition;Calcium TPN-mCnc;;ACTIVE;2.04;2.73 +3052-8;Triiodothyronine.reverse;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3).reverse [Mass/volume] in Serum or Plasma;T3Reverse SerPl-mCnc;;ACTIVE;1.0;2.73 +30528-4;Heptacarboxylporphyrin;PrThr;Pt;Urine;Ord;;CHEM;1;Heptacarboxylporphyrin [Presence] in Urine;Hepta-CP Ur Ql;;ACTIVE;2.04;2.56 +30529-2;Hexacarboxylporphyrin;PrThr;Pt;Urine;Ord;;CHEM;1;Hexacarboxylporphyrin [Presence] in Urine;Hexa-CP Ur Ql;;ACTIVE;2.04;2.56 +305-3;Lomefloxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Lomefloxacin [Susceptibility] by Serum bactericidal titer;Lomefloxacin Titr SBT;;ACTIVE;1.0;2.32 +30530-0;Intrinsic factor Ab;PrThr;Pt;Ser;Ord;;SERO;1;Intrinsic factor Ab [Presence] in Serum;IF Ab Ser Ql;;ACTIVE;2.04;2.73 +30531-8;Isovalerylcarnitine+Methylbutyrylcarnitine (C5);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5) [Moles/volume] in Serum or Plasma;Isovaleryl+MeButyrylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30532-6;levoFLOXacin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;levoFLOXacin [Mass/volume] in Serum or Plasma --peak;levoFLOXacin Peak SerPl-mCnc;;ACTIVE;2.04;2.70 +30533-4;levoFLOXacin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;levoFLOXacin [Mass/volume] in Serum or Plasma --trough;levoFLOXacin Trough SerPl-mCnc;;ACTIVE;2.04;2.70 +30534-2;Linoleoylcarnitine (C18:2);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Linoleoylcarnitine (C18:2) [Moles/volume] in Serum or Plasma;Linoleoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30535-9;Liver kidney microsomal 1 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Liver kidney microsomal 1 Ab [Presence] in Serum;LKM-1 Ab Ser Ql;;ACTIVE;2.04;2.56 +3053-6;Triiodothyronine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma;T3 SerPl-mCnc;;ACTIVE;1.0;2.73 +30536-7;Magnesium;MCnc;Pt;TPN;Qn;;CHEM;1;Magnesium [Mass/volume] in Total parental nutrition;Magnesium TPN-mCnc;;ACTIVE;2.04;2.70 +30537-5;Myocardium Ab;PrThr;Pt;Ser;Ord;;SERO;1;Myocardium Ab [Presence] in Serum;Myocardium Ab Ser Ql;;ACTIVE;2.04;2.73 +30538-3;Neutrophil cytoplasmic Ab.classic;PrThr;Pt;Ser;Ord;;SERO;1;Neutrophil cytoplasmic Ab.classic [Presence] in Serum;c-ANCA Ser Ql;;ACTIVE;2.04;2.73 +30539-1;Neutrophil cytoplasmic Ab.perinuclear;PrThr;Pt;Ser;Ord;;SERO;1;Neutrophil cytoplasmic Ab.perinuclear [Presence] in Serum;p-ANCA Ser Ql;;ACTIVE;2.04;2.73 +30540-9;Octanoylcarnitine (C8);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octanoylcarnitine (C8) [Moles/volume] in Serum or Plasma;Octanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30541-7;Octenoylcarnitine (C8:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octenoylcarnitine (C8:1) [Moles/volume] in Serum or Plasma;Octenoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30542-5;Oleoylcarnitine (C18:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Oleoylcarnitine (C18:1) [Moles/volume] in Serum or Plasma;Oleoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30543-3;Osmotic fragility^0.75% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.75% sodium chloride;OF .75% NaCl NFr RBC;;ACTIVE;2.04;2.73 +3054-4;Triiodothyronine.true;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3).true [Mass/volume] in Serum or Plasma;T3True SerPl-mCnc;;ACTIVE;1.0;2.73 +30544-1;Phosphate;MCnc;Pt;TPN;Qn;;CHEM;1;Phosphate [Mass/volume] in Total parental nutrition;Phosphate TPN-mCnc;;ACTIVE;2.04;2.70 +30545-8;Platelet Ab;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Platelet Ab [Presence] in Serum;Deprecated Platelet Ab Ser Ql;;DEPRECATED;2.04;2.36 +30546-6;Polio virus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Polio virus 1 Ab [Presence] in Serum;PV1 Ab Ser Ql;;ACTIVE;2.04;2.56 +30547-4;Polio virus 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Polio virus 2 Ab [Presence] in Serum;PV2 Ab Ser Ql;;ACTIVE;2.04;2.56 +30548-2;Polio virus 3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Polio virus 3 Ab [Presence] in Serum;PV3 Ab Ser Ql;;ACTIVE;2.04;2.56 +30549-0;Potassium;SCnc;Pt;TPN;Qn;;CHEM;1;Potassium [Moles/volume] in Total parental nutrition;Potassium TPN-sCnc;;ACTIVE;2.04;2.70 +30550-8;Pristanate/Phytanate;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Pristanate (C15:0(CH3)4)/Phytanate (C16:0(CH3)4) [Molar ratio] in Serum or Plasma;Pristanate/Phytanate SerPl-sRto;;ACTIVE;2.04;2.73 +3055-1;Triiodothyronine/Triiodothyronine uptake index;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3)/Triiodothyronine (T3) uptake index [Ratio] in Serum or Plasma;T3/T3 uptake index SerPl-Rto;;DISCOURAGED;1.0;2.73 +30551-6;Propionylcarnitine (C3);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Propionylcarnitine (C3) [Moles/volume] in Serum or Plasma;Propionylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30552-4;Pyridoxal phosphate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyridoxal phosphate [Mass/volume] in Serum or Plasma;Pyridoxal Phos SerPl-mCnc;;ACTIVE;2.04;2.73 +30553-2;Rabies virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rabies virus Ab [Presence] in Serum;RABV Ab Ser Ql;;ACTIVE;2.04;2.73 +30554-0;HIV reverse transcriptase gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV reverse transcriptase gene mutations detected [Identifier];HIV RT gene Mut Det Islt;;ACTIVE;2.04;2.73 +30555-7;Rickettsia typhus group Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia typhus group IgG Ab [Presence] in Serum;Rick Typhus IgG Ser Ql;;ACTIVE;2.04;2.73 +30556-5;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Titer] in Serum by Immunofluorescence;ENA SM+RNP Ab Titr Ser IF;;ACTIVE;2.04;2.70 +30557-3;Smooth muscle Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Smooth muscle IgG Ab [Presence] in Serum;Smooth muscle IgG Ser Ql;;ACTIVE;2.04;2.73 +30558-1;Sodium;SCnc;Pt;TPN;Qn;;CHEM;1;Sodium [Moles/volume] in Total parental nutrition;Sodium TPN-sCnc;;ACTIVE;2.04;2.70 +30559-9;Spermatozoa Ab;ACnc;Pt;XXX;Qn;;FERT;1;Spermatozoa Ab [Units/volume] in Specimen;Sperm Ab Spec-aCnc;;ACTIVE;2.04;2.69 +30560-7;Stearoylcarnitine (C18);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Stearoylcarnitine (C18) [Moles/volume] in Serum or Plasma;Stearoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30561-5;Streptococcus pneumoniae 6 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 6 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum6 IgG Ser IA-mCnc;;DEPRECATED;2.04;2.70 +30562-3;Surfactant/Albumin;MRto;Pt;Amnio fld;Qn;;CHEM;1;Surfactant/Albumin [Mass Ratio] in Amniotic fluid;Surfactant/Alb Amn;;ACTIVE;2.04;2.73 +30563-1;Taurine;SCnc;Pt;Urine;Qn;;CHEM;1;Taurine [Moles/volume] in Urine;Taurine Ur-sCnc;;ACTIVE;2.04;2.73 +30564-9;Tetradecadienoylcarnitine (C14:2);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2) [Moles/volume] in Serum or Plasma;Tdecadienoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30565-6;Tetradecanoylcarnitine (C14);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecanoylcarnitine (C14) [Moles/volume] in Serum or Plasma;Tdecanoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30566-4;Tetradecenoylcarnitine (C14:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1) [Moles/volume] in Serum or Plasma;Tdecenoylcarn SerPl-sCnc;;ACTIVE;2.04;2.73 +30567-2;Thyroid stimulating immunoglobulins;ACnc;Pt;Ser;Qn;;CHEM;1;Thyroid stimulating immunoglobulins [Units/volume] in Serum;TSI Ser-aCnc;;ACTIVE;2.04;2.73 +30568-0;Toxoplasma gondii Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;T gondii IgG CSF Ql IA;;ACTIVE;2.04;2.73 +3056-9;Trimethylamine;MCnc;Pt;Urine;Qn;;CHEM;1;Trimethylamine [Mass/volume] in Urine;Trimet-amine Ur-mCnc;;ACTIVE;1.0;2.42 +30569-8;Toxoplasma gondii Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Toxoplasma gondii IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;T gondii IgM CSF Ql IA;;ACTIVE;2.04;2.73 +30570-6;Triglyceride;Prctl;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride [Percentile];Trigl Prctl SerPl;;ACTIVE;2.04;2.70 +30571-4;Vanillylmandelate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Vanillylmandelate/Creatinine [Mass Ratio] in 24 hour Urine;VMA/Creat 24h Ur;;ACTIVE;2.04;2.73 +30572-2;Pyridoxal;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyridoxal [Mass/volume] in Serum or Plasma;Pyridoxal SerPl-mCnc;;ACTIVE;2.04;2.73 +30573-0;Date of wound healing;Date;Pt;Wound;Qn;Observed;CLIN;2;Date of wound healing Observed;Date of wound healing Observ;;ACTIVE;2.04;2.50 +30574-8;Acetoacetate+Acetone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acetoacetate+Acetone [Mass/volume] in Serum or Plasma;Acetoacet+Acetone SerPl-mCnc;;ACTIVE;2.04;2.73 +30575-5;Xylose^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --baseline;Xylose BS SerPl-mCnc;;ACTIVE;2.04;2.73 +30576-3;2-Ethyl-3-Hydroxypropionate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Ethyl-3-Hydroxypropionate [Presence] in Urine;2Ethyl3OH-Prop Ur Ql;;ACTIVE;2.04;2.73 +3057-7;Triokinase;CCnc;Pt;Plas;Qn;;CHEM;1;Triokinase [Enzymatic activity/volume] in Plasma;Triokinase Plas-cCnc;;ACTIVE;1.0;2.68 +30577-1;2-Methyl-3-Hydroxybutyrate;PrThr;Pt;Urine;Ord;;CHEM;1;2-methyl-3-hydroxybutyrate (C5-OH) [Presence] in Urine;2Me3OH-butyrate Ur Ql;;ACTIVE;2.04;2.73 +30578-9;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Unspecified body region;CT Guided Absc drain+cath place;;ACTIVE;2.04;2.66 +30579-7;Guidance for injection;Find;Pt;XXX>Spine facet joint;Doc;CT;RAD;2;CT Guidance for injection of Spine facet joint;CT Guided Spine FJ Inj;;ACTIVE;2.04;2.65 +30580-5;Guidance for percutaneous aspiration.fine needle;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Unspecified body region;CT Guided FNA;;ACTIVE;2.04;2.64 +30581-3;Guidance for radiation treatment^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for radiation treatment of Unspecified body region-- W contrast IV;CT Guided RT--W contr IV;;ACTIVE;2.04;2.64 +30582-1;Guidance for radiation treatment^WO contrast;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for radiation treatment of Unspecified body region-- WO contrast;CT Guided RT--WO contr;;ACTIVE;2.04;2.64 +30583-9;Multisection^W contrast IV;Find;Pt;Head>Internal auditory canal;Doc;CT;RAD;2;CT Internal auditory canal W contrast IV;CT IAC W contr IV;;ACTIVE;2.04;2.61 +30584-7;Multisection^WO contrast;Find;Pt;Head>Internal auditory canal;Doc;CT;RAD;2;CT Internal auditory canal WO contrast;CT IAC WO contr;;ACTIVE;2.04;2.61 +3058-5;Triosephosphate isomerase;CCnc;Pt;Ser;Qn;;CHEM;1;Triosephosphate isomerase [Enzymatic activity/volume] in Serum;TPI Ser-cCnc;;ACTIVE;1.0;2.68 +30585-4;Multisection^WO contrast;Find;Pt;Head+Neck>Nasopharynx & Neck;Doc;CT;RAD;2;CT Nasopharynx and Neck WO contrast;CT Nasopharynx+Neck WO contr;;ACTIVE;2.04;2.61 +30586-2;Multisection^WO & W contrast IV;Find;Pt;Neck;Doc;CT;RAD;2;CT Neck WO and W contrast IV;CT Neck WO+W contr IV;;ACTIVE;2.04;2.73 +30587-0;Multisection^WO contrast;Find;Pt;Head>Orbit.bilateral;Doc;CT;RAD;2;CT Orbit - bilateral WO contrast;CT Orbit-Bl WO contr;;ACTIVE;2.04;2.61 +30588-8;Multisection;Find;Pt;Head>Sinuses;Doc;CT;RAD;2;CT Sinuses;CT Sinuses;;ACTIVE;2.04;2.73 +30589-6;Multisection^WO contrast;Find;Pt;Head>Petrous part of temporal bone;Doc;CT;RAD;2;CT Petrous part of temporal bone WO contrast;CT Petr part temp bone WO contr;;ACTIVE;2.04;2.61 +30590-4;Multisection^W contrast IV;Find;Pt;Head>Pituitary+Sella turcica;Doc;CT;RAD;2;CT Pituitary and Sella turcica W contrast IV;CT Pit+Sella turc W contr IV;;ACTIVE;2.04;2.61 +30591-2;Multisection^WO contrast;Find;Pt;Head>Pituitary+Sella turcica;Doc;CT;RAD;2;CT Pituitary and Sella turcica WO contrast;CT Pit+Sella turc WO contr;;ACTIVE;2.04;2.73 +30592-0;Multisection^WO contrast;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine WO contrast;CT C-spine WO contr;;ACTIVE;2.04;2.73 +3059-3;Trypsin;CCnc;Pt;Duod fld;Qn;;CHEM;1;Trypsin [Enzymatic activity/volume] in Duodenal fluid;Trypsin Duod fl-cCnc;;ACTIVE;1.0;2.68 +30593-8;Multisection^WO & W contrast IV;Find;Pt;Head>Head vessels;Doc;CT.angio;RAD;2;CTA Head vessels WO and W contrast IV;CTA Head ves WO+W contr IV;;ACTIVE;2.04;2.61 +30594-6;Multisection^WO & W contrast IV;Find;Pt;Neck>Neck vessels;Doc;CT.angio;RAD;2;CTA Neck vessels WO and W contrast IV;CTA Neck ves WO+W contr IV;;ACTIVE;2.04;2.73 +30595-3;Guidance for percutaneous aspiration.fine needle;Find;Pt;Chest>Lung;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Lung;CT Guided Lung FNA;;ACTIVE;2.04;2.64 +30596-1;Multisection^W contrast IT;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine W contrast IT;CT T-spine W contr IT;;ACTIVE;2.04;2.61 +30597-9;Multisection^WO contrast;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine WO contrast;CT T-spine WO contr;;ACTIVE;2.04;2.73 +30598-7;Multisection^WO & W contrast IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest WO and W contrast IV;CT Chest WO+W contr IV;;ACTIVE;2.04;2.61 +30599-5;Multisection^W contrast;Find;Pt;Abdomen;Doc;CT;RAD;2;Deprecated Abdomen CT W contrast;Deprecated Abd CT W contr;;DEPRECATED;2.04;2.58 +30600-1;Multisection^W positive contrast via enteroclysis tube;Find;Pt;Abdomen>Small bowel;Doc;CT;RAD;2;CT Small bowel W positive contrast via enteroclysis tube;CT SB W pos contr enterocly tube;;ACTIVE;2.04;2.61 +3060-1;Trypsin;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Trypsin [Enzymatic activity/volume] in Serum or Plasma;Trypsin SerPl-cCnc;;ACTIVE;1.0;2.68 +30601-9;Guidance for percutaneous biopsy;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for biopsy of Abdomen;CT Guided Abd Bx;;ACTIVE;2.04;2.64 +30602-7;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Abdomen;CT Guided Abd FNA;;ACTIVE;2.04;2.64 +30603-5;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Liver;CT Guided Liver FNA;;ACTIVE;2.04;2.64 +30604-3;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Guidance for biopsy of Pancreas;CT Guided Pancreas Bx;;ACTIVE;2.04;2.64 +30605-0;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Pancreas;CT Guided Pancreas FNA;;ACTIVE;2.04;2.64 +30606-8;Guidance for percutaneous aspiration.fine needle;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Pelvis;CT Guided Pelvis FNA;;ACTIVE;2.04;2.64 +30607-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.bilateral;Doc;CT;RAD;2;CT Guidance for biopsy of Kidney - bilateral;CT Guided Kdny-Bl Bx;;ACTIVE;2.04;2.64 +30608-4;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Kidney.bilateral;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Kidney - bilateral;CT Guided Kdny-Bl FNA;;ACTIVE;2.04;2.64 +30609-2;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Spleen;Doc;CT;RAD;2;CT Guidance for biopsy of Spleen;CT Guided Spleen Bx;;ACTIVE;2.04;2.64 +306-1;Loracarbef;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Loracarbef [Susceptibility] by Minimum lethal concentration (MLC);Loracarbef Islt MLC;;ACTIVE;1.0;2.19 +30610-0;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Spleen;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Spleen;CT Guided Spleen FNA;;ACTIVE;2.04;2.64 +30611-8;Multisection^WO contrast;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Liver WO contrast;CT Liver WO contr;;ACTIVE;2.04;2.61 +30612-6;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Liver WO and W contrast IV;CT Liver WO+W contr IV;;ACTIVE;2.04;2.61 +30613-4;Multisection^WO contrast;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Pancreas WO contrast;CT Pancreas WO contr;;ACTIVE;2.04;2.61 +30614-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Pancreas WO and W contrast IV;CT Pancreas WO+W contr IV;;ACTIVE;2.04;2.61 +30615-9;Multisection^WO contrast;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis WO contrast;CT Pelvis WO contr;;ACTIVE;2.04;2.73 +30616-7;Multisection^WO & W contrast IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis WO and W contrast IV;CT Pelvis WO+W contr IV;;ACTIVE;2.04;2.61 +30617-5;Multisection^WO contrast;Find;Pt;Kidney.bilateral+Collecting system;Nar;CT;RAD;2;Deprecated Kidney - bilateral and Collecting system CT WO contrast;Deprecated KD-Bl+CS CT WO contr;;DEPRECATED;2.04;2.40 +30618-3;Multisection^W & WO contrast IV;Find;Pt;Kidney.bilateral+Collecting system;Nar;CT;RAD;2;Deprecated Kidney - bilateral and Collecting system CT W and WO contrast IV;Deprecated KD-Bl+CS CT W+WO contr IV;;DEPRECATED;2.04;2.40 +3061-9;Trypsin;CCnc;Pt;Stool;Ord;;CHEM;1;Deprecated Trypsin [Presence] in Stool;Deprecated Trypsin Stl Ql;;DEPRECATED;1.0;2.36 +30619-1;Multisection;Find;Pt;Pelvis>Sacroiliac joint;Doc;CT;RAD;2;CT Sacroiliac Joint;CT SIJ;;ACTIVE;2.04;2.73 +30620-9;Multisection^WO contrast;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine WO contrast;CT L-spine WO contr;;ACTIVE;2.04;2.73 +30621-7;Multisection^WO contrast;Find;Pt;Abdomen>Spleen;Doc;CT;RAD;2;CT Spleen WO contrast;CT Spleen WO contr;;ACTIVE;2.04;2.61 +30622-5;Multisection^W contrast IV;Find;Pt;Abdomen>Spleen;Doc;CT;RAD;2;CT Spleen W contrast IV;CT Spleen W contr IV;;ACTIVE;2.04;2.61 +30623-3;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Pelvis vessels;Doc;CT.angio;RAD;2;CTA Pelvis vessels WO and W contrast IV;CTA Pelvis ves WO+W contr IV;;ACTIVE;2.04;2.61 +30624-1;Multisection^W contrast IV;Find;Pt;Lower extremity;Doc;CT;RAD;2;CT Lower extremity W contrast IV;CT LE W contr IV;;ACTIVE;2.04;2.61 +30625-8;Multisection^WO contrast;Find;Pt;Lower extremity;Doc;CT;RAD;2;CT Lower extremity WO contrast;CT LE WO contr;;ACTIVE;2.04;2.73 +30626-6;Multisection^W contrast IV;Find;Pt;Upper extremity;Doc;CT;RAD;2;CT Upper extremity W contrast IV;CT UE W contr IV;;ACTIVE;2.04;2.61 +3062-7;Trypsin;CRat;24H;Stool;Qn;;CHEM;1;Trypsin [Enzymatic activity/time] in 24 hour Stool;Trypsin 24h Stl-cRate;;ACTIVE;1.0;2.42 +30627-4;Multisection^WO contrast;Find;Pt;Upper extremity;Doc;CT;RAD;2;CT Upper extremity WO contrast;CT UE WO contr;;ACTIVE;2.04;2.61 +30628-2;Guidance for substance removal of foreign body;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for removal of foreign body of Unspecified body region;RF Guided FB rem;;ACTIVE;2.04;2.64 +30629-0;Guidance for procedure;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for procedure of Unspecified body region;RF Guided Procedure;;DISCOURAGED;2.04;2.64 +30630-8;Views^W contrast;Find;Pt;Head+Neck>Cerebral cisterns;Doc;RF.video;RAD;2;RF videography Cerebral cisterns Views W contrast;RF video Cerebral cist Views W contr;;ACTIVE;2.04;2.64 +30631-6;Views;Find;Pt;Chest;Doc;RF;RAD;2;RF Chest Views;RF Chest Views;;ACTIVE;2.04;2.64 +30632-4;Multisection for motion;Find;Pt;Chest>Diaphragm;Doc;RF;RAD;2;RF Diaphragm for motion;RF Diaphragm for motion;;ACTIVE;2.04;2.61 +30633-2;Views^W barium contrast PO;Find;Pt;Chest>Esophagus;Doc;RF;RAD;2;RF Esophagus Views W barium contrast PO;RF Esophagus Views W Ba PO;;ACTIVE;2.04;2.73 +30634-0;Guidance for percutaneous biopsy;Find;Pt;Chest>Lung;Doc;RF;RAD;2;RF Guidance for biopsy of Lung;RF Guided Lung Bx;;ACTIVE;2.04;2.64 +3063-5;Trypsin;CCnc;Pt;Stool;Qn;;CHEM;1;Trypsin [Enzymatic activity/volume] in Stool;Trypsin Stl-cCnc;;ACTIVE;1.0;2.73 +30635-7;View AP && Views^W contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;Deprecated XR and RF Gastrointestinal tract upper AP and Views W contrast PO;Deprecated XR and Flr UGI AP + Views W c;;DEPRECATED;2.04;2.61 +30636-5;Views for reduction^W contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views for reduction W contrast PR;RF Colon Views for reduction W contr PR;;ACTIVE;2.04;2.64 +30637-3;Guidance for placement of tube;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;RF;RAD;2;RF Guidance for placement of tube in Gastrointestinal tract;RF Guided GI tract Tube place;;ACTIVE;2.04;2.64 +30638-1;Guidance for injection;Find;Pt;Lower extremity>Hip;Doc;RF;RAD;2;RF Guidance for injection of Hip;RF Guided Hip Inj;;ACTIVE;2.04;2.64 +30639-9;View^W contrast;Find;Pt;XXX>Vessel;Doc;RF.angio;RAD;2;RFA Vessel Single view W contrast;RFA Ves 1V W contr;;ACTIVE;2.04;2.64 +30640-7;Guidance for angioplasty^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Vein-- W contrast IV;RFA Guided Vein Angio--W contr IV;;ACTIVE;2.04;2.64 +30641-5;Guidance additional for angioplasty^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for Additional angioplasty of Vein-- W contrast IV;RFA Guided Vein Angio addl--W contr IV;;ACTIVE;2.04;2.64 +30642-3;View;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Single view;RF 1V Unsp region;;ACTIVE;2.04;2.64 +3064-3;Trypsin+Trypsinogen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Trypsin+Trypsinogen [Mass/volume] in Serum or Plasma;Trypsin+Trypsinogen SerPl-mCnc;;ACTIVE;1.0;2.73 +30643-1;Guidance for placement of central venous catheter;Find;Pt;XXX>Vein;Doc;US;RAD;2;US Guidance for placement of CV catheter in Vein;US Guided Vein CVC place;;ACTIVE;2.04;2.64 +30644-9;Guidance for placement of tunneled central venous catheter;Find;Pt;XXX>Vein;Doc;US;RAD;2;US Guidance for placement of tunneled CV catheter;US Guided Tun CVC place;;ACTIVE;2.04;2.67 +30645-6;Views^W contrast IV;Find;Pt;Chest>Vena cava.superior;Doc;RF.angio;RAD;2;RFA Superior vena cava Views W contrast IV;RFA SVC Views W contr IV;;ACTIVE;2.04;2.64 +30646-4;Guidance for change of tube^W contrast;Find;Pt;XXX>Sinus tract;Doc;RF;RAD;2;RF Guidance for change of tube in Sinus tract-- W contrast;RF Guided Sinus tr Tube chnge--W contr;;ACTIVE;2.04;2.64 +30647-2;Views^W contrast via T-tube;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;RF;RAD;2;RF Biliary ducts and Gallbladder Views W contrast via T-tube;RF BDs+GB Views W contr via T-tb;;ACTIVE;2.04;2.64 +30648-0;Views for angioplasty^W contrast IA;Find;Pt;XXX>Peripheral artery;Doc;RF.angio;RAD;2;RFA Peripheral artery Views for angioplasty W contrast IA;RFA Periph a Vs angioplasty W contr IA;;ACTIVE;2.04;2.64 +30649-8;Guidance additional for angioplasty^W contrast IA;Find;Pt;XXX>Peripheral artery;Doc;RF.angio;RAD;2;RFA Guidance for Additional angioplasty of Peripheral artery-- W contrast IA;RFA Guided Peri a Angio addl W contr IA;;ACTIVE;2.04;2.64 +3065-0;Trypsinogen;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Trypsinogen [Presence] in Serum or Plasma;Trypsinogen SerPl Ql;;ACTIVE;1.0;2.56 +30650-6;Views for shunt;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views for shunt;RF Views for Shunt;;ACTIVE;2.04;2.64 +30651-4;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for percutaneous biopsy.core needle of Breast;US Guided Brst PC Bx CN;;ACTIVE;2.04;2.64 +30652-2;Guidance for percutaneous biopsy.fine needle;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for fine needle biopsy of Breast;US Guided Brst FN Bx;;ACTIVE;2.04;2.64 +30653-0;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for aspiration of cyst of Breast;US Guided Brst Cyst asp;;ACTIVE;2.04;2.64 +30654-8;Multisection^WO contrast;Find;Pt;Chest>Brachial plexus;Doc;MR;RAD;2;MR Brachial plexus WO contrast;MR Brachial plexus WO contr;;ACTIVE;2.04;2.61 +30655-5;Multisection;Find;Pt;Head+Neck>Cerebral cisterns;Doc;MR;RAD;2;MR Cerebral cisterns;MR Cerebral cist;;ACTIVE;2.04;2.73 +30656-3;Guidance for stereotactic localization^W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Guidance for stereotactic localization of Brain-- W contrast IV;MR Guided Brain Str loc--W contr IV;;ACTIVE;2.04;2.64 +30657-1;Multisection^WO contrast;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain WO contrast;MR Brain WO contr;;ACTIVE;2.04;2.73 +30658-9;Multisection^WO contrast;Find;Pt;Head>Internal auditory canal;Doc;MR;RAD;2;MR Internal auditory canal WO contrast;MR IAC WO contr;;ACTIVE;2.04;2.61 +30659-7;Multisection^WO & W contrast IV;Find;Pt;Head>Internal auditory canal;Doc;MR;RAD;2;MR Internal auditory canal WO and W contrast IV;MR IAC WO+W contr IV;;ACTIVE;2.04;2.61 +30660-5;Multisection^WO contrast;Find;Pt;Neck;Doc;MR;RAD;2;MR Neck WO contrast;MR Neck WO contr;;ACTIVE;2.04;2.61 +30661-3;Multisection^WO contrast;Find;Pt;Head>Orbit.bilateral;Doc;MR;RAD;2;MR Orbit - bilateral WO contrast;MR Orbit-Bl WO contr;;ACTIVE;2.04;2.61 +30662-1;Multisection^WO contrast;Find;Pt;Head>Sinuses;Doc;MR;RAD;2;MR Sinuses WO contrast;MR Sinuses WO contr;;ACTIVE;2.04;2.61 +30663-9;Multisection^WO & W contrast IV;Find;Pt;Head>Sinuses;Doc;MR;RAD;2;MR Sinuses WO and W contrast IV;MR Sinuses WO+W contr IV;;ACTIVE;2.04;2.61 +30664-7;Guidance for radiation treatment^W contrast IV;Find;Pt;XXX;Doc;MR;RAD;2;MR Guidance for radiation treatment of Unspecified body region-- W contrast IV;MR Guided RT--W contr IV;;ACTIVE;2.04;2.64 +30665-4;Guidance for radiation treatment^WO contrast;Find;Pt;XXX;Doc;MR;RAD;2;MR Guidance for radiation treatment of Unspecified body region-- WO contrast;MR Guided RT--WO contr;;ACTIVE;2.04;2.64 +30666-2;Multisection^WO contrast;Find;Pt;Head>Pituitary+Sella turcica;Doc;MR;RAD;2;MR Pituitary and Sella turcica WO contrast;MR Pit+Sella turc WO contr;;ACTIVE;2.04;2.61 +30667-0;Multisection^WO contrast;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine WO contrast;MR C-spine WO contr;;ACTIVE;2.04;2.73 +3066-8;Trypsinogen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Trypsinogen [Mass/volume] in Serum or Plasma;Trypsinogen SerPl-mCnc;;ACTIVE;1.0;2.73 +30668-8;Multisection^WO contrast;Find;Pt;Abdomen;Doc;MR;RAD;2;MR Abdomen WO contrast;MR Abd WO contr;;ACTIVE;2.04;2.73 +30669-6;Multisection^WO contrast;Find;Pt;Abdomen>Liver;Doc;MR;RAD;2;MR Liver WO contrast;MR Liver WO contr;;ACTIVE;2.04;2.61 +30670-4;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Liver;Doc;MR;RAD;2;MR Liver WO and W contrast IV;MR Liver WO+W contr IV;;ACTIVE;2.04;2.73 +30671-2;Multisection^WO contrast;Find;Pt;Pelvis & Lower extremity>Hip;Doc;MR;RAD;2;MR Pelvis and Hip WO contrast;MR Pelvis and Hip WO contr;;ACTIVE;2.04;2.61 +30672-0;Multisection^WO & W contrast IV;Find;Pt;Pelvis & Lower extremity>Hip;Doc;MR;RAD;2;MR Pelvis and Hip WO and W contrast IV;MR Pelvis and Hip WO+W contr IV;;ACTIVE;2.04;2.61 +30673-8;Multisection^WO contrast;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis WO contrast;MR Pelvis WO contr;;ACTIVE;2.04;2.73 +30674-6;Multisection^WO & W contrast IV;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis WO and W contrast IV;MR Pelvis WO+W contr IV;;ACTIVE;2.04;2.73 +30675-3;Multisection;Find;Pt;Pelvis>Prostate;Doc;MR;RAD;2;MR Prostate;MR Prostate;;ACTIVE;2.04;2.61 +3067-6;Trypsinogen I.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Trypsinogen I Free [Mass/volume] in Serum or Plasma;Trypsinogen I Free SerPl-mCnc;;ACTIVE;1.0;2.73 +30676-1;Multisection^WO contrast;Find;Pt;Kidney.bilateral+Collecting system;Nar;MRI;RAD;2;Deprecated Kidney - bilateral and Collecting system MRI WO contrast;Deprecated KD-Bl+CS MRI WO contr;;DEPRECATED;2.04;2.40 +30677-9;Multisection^W & WO contrast IV;Find;Pt;Kidney.bilateral+Collecting system;Nar;MRI;RAD;2;Deprecated Kidney - bilateral and Collecting system MRI W and WO contrast IV;Deprecated KD-Bl+CS MRI W+WO contr IV;;DEPRECATED;2.04;2.40 +30678-7;Multisection^W contrast IV;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine W contrast IV;MR L-spine W contr IV;;ACTIVE;2.04;2.61 +30679-5;Multisection^WO contrast;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine WO contrast;MR L-spine WO contr;;ACTIVE;2.04;2.73 +30680-3;Multisection^WO contrast;Find;Pt;Lower extremity>Ankle;Doc;MR;RAD;2;MR Ankle WO contrast;MR Ankle WO contr;;ACTIVE;2.04;2.61 +30681-1;Multisection^WO contrast;Find;Pt;Lower extremity>Foot;Doc;MR;RAD;2;MR Foot WO contrast;MR Foot WO contr;;ACTIVE;2.04;2.61 +30682-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Foot;Doc;MR;RAD;2;MR Foot WO and W contrast IV;MR Foot WO+W contr IV;;ACTIVE;2.04;2.61 +30683-7;Multisection^WO contrast;Find;Pt;Upper extremity>Forearm;Doc;MR;RAD;2;MR Forearm WO contrast;MR Forearm WO contr;;ACTIVE;2.04;2.61 +3068-4;Tryptophan;MCnc;Pt;CSF;Qn;;CHEM;1;Tryptophan [Mass/volume] in Cerebral spinal fluid;Tryptophan CSF-mCnc;;ACTIVE;1.0;2.42 +30684-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Forearm;Doc;MR;RAD;2;MR Forearm WO and W contrast IV;MR Forearm WO+W contr IV;;ACTIVE;2.04;2.61 +30685-2;Multisection^WO contrast;Find;Pt;Upper extremity>Hand;Doc;MR;RAD;2;MR Hand WO contrast;MR Hand WO contr;;ACTIVE;2.04;2.61 +30686-0;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Hand;Doc;MR;RAD;2;MR Hand WO and W contrast IV;MR Hand WO+W contr IV;;ACTIVE;2.04;2.61 +30687-8;Multisection^WO contrast;Find;Pt;Lower extremity>Hip;Doc;MR;RAD;2;MR Hip WO contrast;MR Hip WO contr;;ACTIVE;2.04;2.61 +30688-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Hip;Doc;MR;RAD;2;MR Hip WO and W contrast IV;MR Hip WO+W contr IV;;ACTIVE;2.04;2.61 +30689-4;Multisection^WO contrast;Find;Pt;Upper extremity>Upper arm;Doc;MR;RAD;2;MR Upper arm WO contrast;MR Upper arm WO contr;;ACTIVE;2.04;2.61 +30690-2;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Upper arm;Doc;MR;RAD;2;MR Upper arm WO and W contrast IV;MR Upper arm WO+W contr IV;;ACTIVE;2.04;2.61 +30691-0;Multisection^WO contrast;Find;Pt;Lower extremity>Knee;Doc;MR;RAD;2;MR Knee WO contrast;MR Knee WO contr;;ACTIVE;2.04;2.61 +3069-2;Tryptophan;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Tryptophan [Presence] in Serum or Plasma;Tryptophan SerPl Ql;;ACTIVE;1.0;2.73 +30692-8;Multisection;Find;Pt;Lower extremity;Doc;MR;RAD;2;MR Lower extremity;MR LE;;ACTIVE;2.04;2.61 +30693-6;Multisection^WO contrast;Find;Pt;Upper extremity>Shoulder;Doc;MR;RAD;2;MR Shoulder WO contrast;MR Should WO contr;;ACTIVE;2.04;2.61 +30694-4;Views+view uptake^W radionuclide IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland and uptake single view;NM Thyroid + Uptake 1 view W RNC IV;;ACTIVE;2.04;2.61 +30695-1;Views^W radionuclide IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views;NM Thyroid Views W RNC IV;;ACTIVE;2.04;2.64 +30696-9;Views^W radionuclide IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;NM;RAD;2;NM Scrotum and testicle Views;NM Scrotum+Test Views W RNC IV;;ACTIVE;2.04;2.64 +30697-7;Views ventilation+perfusion^W radionuclide IH+W radionuclide IV;Find;Pt;Chest>Pulmonary system;Doc;NM;RAD;2;NM Pulmonary system Ventilation and Perfusion;NM Pulm system VP W RNC IH+IV;;ACTIVE;2.04;2.61 +30698-5;Guidance for percutaneous aspiration of cyst;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for aspiration of cyst of Unspecified body region;US Guided Cyst asp;;ACTIVE;2.04;2.64 +30699-3;Guidance for drainage+placement of drainage catheter;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Unspecified body region;US Guided Drain+cath place;;ACTIVE;2.04;2.66 +30-7;Ampicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ampicillin [Susceptibility] by Serum bactericidal titer;Ampicillin Titr SBT;;ACTIVE;1.0;2.32 +3070-0;Tryptophan;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptophan [Mass/volume] in Serum or Plasma;Tryptophan SerPl-mCnc;;ACTIVE;1.0;2.73 +30700-9;Guidance for biopsy.needle;Find;Pt;XXX;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Unspecified body region;Deprecated US XXX Bx needle guide;;DEPRECATED;2.04;2.63 +30701-7;Multisection^during surgery;Find;Pt;XXX;Doc;US;RAD;2;US Unspecified body region during surgery;US in Surg;;ACTIVE;2.04;2.69 +30702-5;Guidance for injection;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;US Guidance for injection of Thyroid gland;US Guided Thyroid Inj;;ACTIVE;2.04;2.64 +30703-3;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Pericardial space;Doc;US;RAD;2;US Guidance for fluid aspiration of Pericardial space;US Guided Pericardial space PC fluid asp;;ACTIVE;2.04;2.64 +30704-1;Multisection limited;Find;Pt;Abdomen;Doc;US;RAD;2;US Abdomen limited;US Abd Ltd;;ACTIVE;2.04;2.73 +30705-8;Multisection;Find;Pt;Pelvis>Uterus+Fallopian tubes;Doc;US;RAD;2;US Uterus and Fallopian tubes;US Uterus+FT;;ACTIVE;2.04;2.61 +30706-6;Multisection^during surgery;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;US Liver during surgery;US Liver in Surg;;ACTIVE;2.04;2.61 +30707-4;Study observation.general.follow-up;Imp;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general.follow-up US;US Fetus Study follow-up [Imp];;ACTIVE;2.04;2.50 +30708-2;Study observation.general.limited;Imp;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general.limited US;US Fetus Study ltd [Imp];;ACTIVE;2.04;2.50 +30709-0;Multisection;Find;Pt;Lower extremity;Doc;US;RAD;2;US Lower extremity;US LE;;ACTIVE;2.04;2.73 +30710-8;Multisection;Find;Pt;Upper extremity;Doc;US;RAD;2;US Upper extremity;US UE;;ACTIVE;2.04;2.73 +30711-6;Multisection^developmental joint assessment;Find;Pt;Lower extremity>Hip;Doc;US;RAD;2;US Hip developmental joint assessment;US Hip Devel joint assess;;ACTIVE;2.04;2.61 +30712-4;Multisection^WO developmental joint assessment;Find;Pt;Lower extremity>Hip;Doc;US;RAD;2;US Hip WO developmental joint assessment;US Hip WO devel joint assess;;ACTIVE;2.04;2.61 +30713-2;Views^W R-bending + W L-bending;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Views W right bending and W left bending;XR Spine Views W R+L-bending;;DISCOURAGED;2.04;2.64 +30714-0;View AP for scoliosis;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP for scoliosis;XR T+L-Spine AP for Scoli;;ACTIVE;2.04;2.64 +30715-7;(Views AP + lateral) for scoliosis;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP and lateral for scoliosis;XR T+L-Spine AP+Lat for Scoli;;ACTIVE;2.04;2.64 +30716-5;Views lateral for scoliosis;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Lateral Views for scoliosis;XR T+L-Spine Lat for Scoli;;ACTIVE;2.04;2.64 +30717-3;Views for scoliosis^W standing;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Views for scoliosis W standing;XR T+L-Spine Views for scoli W Stand;;ACTIVE;2.04;2.64 +3071-8;Tryptophan;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Tryptophan [Mass/volume] in Serum or Plasma;Deprecated Tryptophan Ser-mCnc;;DEPRECATED;1.0;2.36 +30718-1;Views PA & lateral;Find;Pt;Sinuses;Nar;XR.tomo;RAD;2;Deprecated Views PA & lateral;Deprecated Sinuses XR.Tomo PA+Lat;;DEPRECATED;2.04;2.36 +30719-9;Multisection;Find;Pt;Head>Temporomandibular joint;Doc;XR.tomography;RAD;2;XR tomography Temporomandibular joint;XR tomo TMJ;;ACTIVE;2.04;2.61 +30720-7;Views for foreign body;Find;Pt;Head>Orbit.bilateral;Doc;XR;RAD;2;XR Orbit - bilateral Views for foreign body;XR Orbit-Bl Views for FB;;ACTIVE;2.04;2.64 +30721-5;Views PA + lateral;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses PA and Lateral;XR Sinuses PA+Lat;;ACTIVE;2.04;2.61 +30722-3;View;Find;Pt;Head>Skull;Doc;XR.portable;RAD;2;Portable XR Skull Single view;XR port Skull 1V;;ACTIVE;2.04;2.64 +30723-1;Views;Find;Pt;Head>Skull;Doc;XR.portable;RAD;2;Portable XR Skull Views;XR port Skull Views;;ACTIVE;2.04;2.64 +30724-9;View;Find;Pt;Neck>Spine.cervical;Doc;XR.portable;RAD;2;Portable XR Cervical spine Single view;XR port C-spine 1V;;ACTIVE;2.04;2.64 +30725-6;View AP;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP;XR C-spine AP;;ACTIVE;2.04;2.61 +3072-6;Tryptophan;MCnc;Pt;Urine;Qn;;CHEM;1;Tryptophan [Mass/volume] in Urine;Tryptophan Ur-mCnc;;ACTIVE;1.0;2.42 +30726-4;Views AP + lateral;Find;Pt;Neck>Spine.cervical;Doc;XR.portable;RAD;2;Portable XR Cervical spine AP and Lateral;XR port C-spine AP+Lat;;ACTIVE;2.04;2.61 +30727-2;View AP;Find;Pt;Neck>Spine.cervical;Doc;XR.portable;RAD;2;Portable XR Cervical spine AP;XR port C-spine AP;;ACTIVE;2.04;2.61 +30728-0;Views^flexion & extension;Find;Pt;Spine.cervical;Nar;XR;RAD;2;Deprecated Spine Cervical X-ray W flexion & W extension;Deprecated C-spine XR;;DEPRECATED;2.04;2.46 +30729-8;View AP;Find;Pt;Neck>Spine.cervical.odontoid+Spine.cervical.axis;Doc;XR.portable;RAD;2;Portable XR Spine Cervical Odontoid and Cervical axis AP;XR port C-spine.odontoid+axis AP 1V;;ACTIVE;2.04;2.61 +30730-6;Views;Find;Pt;Head>Zygomatic arch.bilateral;Doc;XR.portable;RAD;2;Portable XR Zygomatic arch - bilateral Views;XR port Zygomatic arch-Bl Views;;ACTIVE;2.04;2.64 +30731-4;Views;Find;Pt;Head>Zygomatic arch;Doc;XR.portable;RAD;2;Portable XR Zygomatic arch Views;XR port Zygomatic arch Views;;ACTIVE;2.04;2.64 +30732-2;R & L-oblique views;Find;Pt;Chest;Nar;XR;RAD;2;Deprecated Chest X-ray R-oblique & L-oblique upright;Deprecated Chest XR R & L-oblique;;DEPRECATED;2.04;2.46 +30733-0;Views R-oblique + L-oblique;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Right oblique and Left oblique;XR port Chest R-Obl+L-Obl;;ACTIVE;2.04;2.61 +3073-4;Tryptophan.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptophan Free [Mass/volume] in Serum or Plasma;Tryptophan Free SerPl-mCnc;;ACTIVE;1.0;2.42 +30734-8;View AP lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP lateral-decubitus;XR Chest AP lat decub;;ACTIVE;2.04;2.61 +30735-5;View AP lateral-decubitus;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest AP lateral-decubitus;XR port Chest AP lat decub;;ACTIVE;2.04;2.61 +30736-3;Views^W inspiration + W expiration;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Views W inspiration and expiration;XR Chest Views W insp+exp;;ACTIVE;2.04;2.64 +30737-1;View L-lateral;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Left lateral;XR Chest L-lat;;ACTIVE;2.04;2.73 +30738-9;View L-lateral;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Left lateral;XR port Chest L-lat;;ACTIVE;2.04;2.61 +30739-7;View oblique;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Oblique;XR port Chest Obl;;ACTIVE;2.04;2.64 +30740-5;View oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Oblique;XR Chest Obl;;ACTIVE;2.04;2.64 +30741-3;Views PA + lateral + apical lordotic upright;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and Lordotic upright;XR Chest PA+Lat+Lordotic Upr;;ACTIVE;2.04;2.61 +3074-2;Tumor necrosis factor.alpha;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tumor necrosis factor.alpha [Mass/volume] in Serum or Plasma;A-Tumor Necrosis Fact SerPl-mCnc;;ACTIVE;1.0;2.73 +30742-1;Views PA + lateral + R-oblique + L-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and Right oblique and Left oblique;XR Chest PA+Lat+R-Obl+L-Obl;;ACTIVE;2.04;2.61 +30743-9;Views PA + lateral + R-oblique + L-oblique;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest PA and Lateral and Right oblique and Left oblique;XR port Chest PA+Lat+R-Obl+L-Obl;;ACTIVE;2.04;2.61 +30744-7;Views PA + lateral + oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and Oblique;XR Chest PA+Lat+Obl;;ACTIVE;2.04;2.61 +30745-4;Views;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Views;XR Chest Views;;ACTIVE;2.04;2.64 +30746-2;Views;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest Views;XR port Chest Views;;ACTIVE;2.04;2.64 +30747-0;Views;Find;Pt;Chest>Ribs;Doc;XR.portable;RAD;2;Portable XR Ribs Views;XR port Ribs Views;;ACTIVE;2.04;2.64 +30748-8;View;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Single view;XR Should 1V;;ACTIVE;2.04;2.64 +30749-6;View;Find;Pt;Upper extremity>Shoulder;Doc;XR.portable;RAD;2;Portable XR Shoulder Single view;XR port Should 1V;;ACTIVE;2.04;2.73 +30750-4;Views 5;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder 5 Views;XR Should 5V;;ACTIVE;2.04;2.61 +30751-2;View West Point;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder West Point;XR Should West Point;;ACTIVE;2.04;2.61 +30752-0;View AP;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine AP;XR T-spine AP;;ACTIVE;2.04;2.61 +30753-8;Views AP + lateral;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine AP and Lateral;XR T-spine AP+Lat;;ACTIVE;2.04;2.73 +30754-6;Views AP + lateral;Find;Pt;Chest>Spine.thoracic;Doc;XR.portable;RAD;2;Portable XR Thoracic spine AP and Lateral;XR port T-spine AP+Lat;;ACTIVE;2.04;2.61 +30755-3;View AP;Find;Pt;Chest>Spine.thoracic;Doc;XR.portable;RAD;2;Portable XR Thoracic spine AP;XR port T-spine AP;;ACTIVE;2.04;2.61 +30756-1;View lateral;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Lateral;XR T-spine Lat;;ACTIVE;2.04;2.61 +30757-9;View lateral;Find;Pt;Chest>Spine.thoracic;Doc;XR.portable;RAD;2;Portable XR Thoracic spine Lateral;XR port T-spine Lat;;ACTIVE;2.04;2.61 +30758-7;View oblique;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Oblique;XR T-spine Obl;;ACTIVE;2.04;2.64 +3075-9;Tyramine;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Tyramine [Mass/volume] in Cerebral spinal fluid;Tyramine CSF-mCnc;;ACTIVE;1.0;2.42 +30759-5;View oblique;Find;Pt;Chest>Spine.thoracic;Doc;XR.portable;RAD;2;Portable XR Thoracic spine Oblique;XR port T-spine Obl;;ACTIVE;2.04;2.64 +30760-3;Multisection 3 views^W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR.tomography;RAD;2;XR tomography Kidney - bilateral 3 views W contrast IV;XR tomo Kdny-Bl 3V W contr IV;;ACTIVE;2.04;2.61 +30761-1;Views^W contrast retrograde via urethra;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;Deprecated RF Kidney - bilateral Views W contrast retrograde via urethra;Deprecated RF Kdny-Bl Views W contr RU;;DEPRECATED;2.04;2.64 +30762-9;Multisection;Find;Pt;Abdomen;Doc;XR.tomography;RAD;2;XR tomography Abdomen;XR tomo Abd;;ACTIVE;2.04;2.73 +30763-7;Views AP + lateral crosstable;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen AP and Lateral crosstable;XR port Abd AP+Lat Xtable;;ACTIVE;2.04;2.61 +30764-5;Views;Find;Pt;Lower extremity.bilateral>Acetabulum;Doc;XR.portable;RAD;2;Portable XR Acetabulum - bilateral Views;XR port Acetabulum-Bl Views;;ACTIVE;2.04;2.64 +30765-2;Views;Find;Pt;Lower extremity>Acetabulum;Doc;XR.portable;RAD;2;Portable XR Acetabulum Views;XR port Acetabulum Views;;ACTIVE;2.04;2.64 +30766-0;Views 3;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis 3 Views;XR Pelvis 3V;;ACTIVE;2.04;2.73 +3076-7;Tyramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tyramine [Mass/volume] in Urine;Tyramine Ur-mCnc;;ACTIVE;1.0;2.42 +30767-8;Views;Find;Pt;Pelvis & Lower extremity>Hip;Doc;XR;RAD;2;XR Pelvis and Hip Views;XR Pelvis and Hip Views;;ACTIVE;2.04;2.64 +30768-6;Views;Find;Pt;Pelvis & Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - bilateral Views;XR Pelvis and Hip-Bl Views;;ACTIVE;2.04;2.73 +30769-4;Views max abduction;Find;Pt;Pelvis & Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - bilateral Maximum abduction Views;XR Pelvis and Hip-Bl Views Max abd;;ACTIVE;2.04;2.64 +30770-2;Views AP + lateral frog;Find;Pt;Pelvis & Lower extremity>Hip;Doc;XR;RAD;2;XR Pelvis and Hip AP and Lateral frog;XR Pelvis and Hip AP+Lat frog;;ACTIVE;2.04;2.64 +30771-0;Views inlet + outlet;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Inlet and Outlet;XR Pelvis Inlet+Outlet;;ACTIVE;2.04;2.61 +30772-8;Views;Find;Pt;Pelvis;Doc;XR.portable;RAD;2;Portable XR Pelvis Views;XR port Pelvis Views;;ACTIVE;2.04;2.64 +30773-6;View;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Single view;XR L-spine 1V;;ACTIVE;2.04;2.64 +30774-4;View;Find;Pt;Abdomen>Spine.lumbar;Doc;XR.portable;RAD;2;Portable XR Lumbar spine Single view;XR port L-spine 1V;;ACTIVE;2.04;2.64 +3077-5;Tyrosine;MCnc;Pt;Bld;Qn;;CHEM;1;Tyrosine [Mass/volume] in Blood;Tyrosine Bld-mCnc;;ACTIVE;1.0;2.40 +30775-1;Views 3;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 3 Views;XR L-spine 3V;;ACTIVE;2.04;2.61 +30776-9;Views 3;Find;Pt;Abdomen>Spine.lumbar;Doc;XR.portable;RAD;2;Portable XR Lumbar spine 3 Views;XR port L-spine 3V;;ACTIVE;2.04;2.61 +30777-7;View AP;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP;XR L-spine AP;;ACTIVE;2.04;2.61 +30778-5;View oblique;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Oblique;XR L-spine Obl;;ACTIVE;2.04;2.64 +30779-3;Views AP + lateral;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle AP and Lateral;XR Ankle AP+Lat;;ACTIVE;2.04;2.61 +30780-1;Views;Find;Pt;Upper extremity>Finger.second;Doc;XR;RAD;2;XR Finger second Views;XR Finger.2nd Views;;ACTIVE;2.04;2.73 +30781-9;Views;Find;Pt;Upper extremity>Finger.third;Doc;XR;RAD;2;XR Finger third Views;XR Finger.3rd Views;;ACTIVE;2.04;2.64 +30782-7;Views;Find;Pt;Upper extremity>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth Views;XR Finger.4th Views;;ACTIVE;2.04;2.73 +3078-3;Tyrosine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Tyrosine [Presence] in Serum or Plasma;Tyrosine SerPl Ql;;ACTIVE;1.0;2.73 +30783-5;Views;Find;Pt;Upper extremity>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth Views;XR Finger.5th Views;;ACTIVE;2.04;2.64 +30784-3;Views 2;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot 2 Views;XR Foot 2V;;ACTIVE;2.04;2.61 +30785-0;Views^W forced dorsiflexion;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Views W forced dorsiflexion;XR Foot Views W forced dorsiflex;;ACTIVE;2.04;2.64 +30786-8;View lateral frog;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Lateral frog;XR Hip Lat frog;;ACTIVE;2.04;2.61 +30787-6;View;Find;Pt;XXX>Joint;Doc;XR;RAD;2;XR Joint Single view;XR Joint 1V;;ACTIVE;2.04;2.64 +30788-4;Views 3;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee 3 Views;XR Knee 3V;;ACTIVE;2.04;2.61 +30789-2;Views 4;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee 4 Views;XR Knee 4V;;ACTIVE;2.04;2.61 +307-9;Loracarbef;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Loracarbef [Susceptibility] by Minimum inhibitory concentration (MIC);Loracarbef Islt MIC;;ACTIVE;1.0;2.19 +30790-0;View tunnel;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Tunnel;XR Knee Tunnel;;ACTIVE;2.04;2.61 +3079-1;Tyrosine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tyrosine [Mass/volume] in Serum or Plasma;Tyrosine SerPl-mCnc;;ACTIVE;1.0;2.73 +30791-8;Views;Find;Pt;Lower extremity>Patella;Doc;XR;RAD;2;XR Patella Views;XR Patella Views;;ACTIVE;2.04;2.73 +30792-6;Views;Find;Pt;Lower extremity>Patella;Doc;XR.portable;RAD;2;Portable XR Patella Views;XR port Patella Views;;ACTIVE;2.04;2.64 +30793-4;Views AP + lateral;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist AP and Lateral;XR Wrist AP+Lat;;ACTIVE;2.04;2.61 +30794-2;Multisection;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast;MR Brst;;ACTIVE;2.04;2.73 +30795-9;Multisection;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral;MR Brst-Bl;;ACTIVE;2.04;2.61 +30796-7;Multisection^WO contrast;Find;Pt;Upper extremity>Elbow;Doc;MR;RAD;2;MR Elbow WO contrast;MR Elbow WO contr;;ACTIVE;2.04;2.61 +30797-5;Views 5;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 5 Views;XR L-spine 5V;;ACTIVE;2.04;2.61 +30798-3;Views^W contrast.XXX IV;Find;Pt;Kidney.bilateral+Collecting system;Nar;XR.tomo;RAD;2;Deprecated Kidney Bilateral & Collecting system X-ray tomograph Multisection W contrast IV;Deprecated KD-Bl+CS XR.Tomo;;DEPRECATED;2.04;2.36 +30799-1;Multisection^WO contrast;Find;Pt;Head;Doc;CT;RAD;2;CT Head WO contrast;CT Head WO contr;;ACTIVE;2.04;2.73 +30800-7;Guidance for stereotactic localization^WO contrast;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Guidance for stereotactic localization of Brain-- WO contrast;MR Guided Brain Str loc--WO contr;;ACTIVE;2.04;2.64 +30801-5;Multisection^W contrast IV;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region W contrast IV;CT Maxillofacial W contr IV;;ACTIVE;2.04;2.61 +30802-3;Multisection^WO contrast;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region WO contrast;CT Maxillofacial WO contr;;ACTIVE;2.04;2.73 +30803-1;Multisection^WO & W contrast IV;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region WO and W contrast IV;CT Maxillofacial WO+W contr IV;;ACTIVE;2.04;2.61 +30804-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Chest vessels;Doc;CT.angio;RAD;2;CTA Chest vessels WO and W contrast IV;CTA Chest ves WO+W contr IV;;ACTIVE;2.04;2.73 +30805-6;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Abdominal vessels;Doc;CT.angio;RAD;2;CTA Abdominal vessels WO and W contrast IV;CTA Abd ves WO+W contr IV;;ACTIVE;2.04;2.61 +30806-4;Multisection^W & WO contrast IV;Find;Pt;Aorta+Femoral artery.bilateral;Doc;CT.angio;RAD;2;Deprecated Aorta and Femoral artery - bilateral CT angiogram W and WO contrast IV;Deprecated Aorta+Fem a-Bl CT.Angio W+WO;;DEPRECATED;2.04;2.58 +30807-2;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels WO and W contrast IV;CTA LE ves WO+W contr IV;;ACTIVE;2.04;2.61 +30808-0;Views^W contrast IT;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Cervical and thoracic and lumbar spine Views W contrast IT;RF C+T+L-spine Views W contr IT;;ACTIVE;2.04;2.64 +3080-9;Tyrosine;MCnc;Pt;Urine;Qn;;CHEM;1;Tyrosine [Mass/volume] in Urine;Tyrosine Ur-mCnc;;ACTIVE;1.0;2.73 +30809-8;View^W contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper+Small bowel;Doc;RF;RAD;2;RF Upper gastrointestinal tract and Small bowel Single view W contrast PO;RF UGI+SB 1V W contr PO;;ACTIVE;2.04;2.64 +30810-6;Views^W contrast intra lacrimal duct;Find;Pt;Head>Lacrimal duct;Doc;RF;RAD;2;RF Lacrimal duct Views W contrast intra lacrimal duct;RF Lacrimal duct Views W contr intra LD;;ACTIVE;2.04;2.64 +30811-4;Views^W contrast IT;Find;Pt;Head>Posterior fossa;Doc;RF;RAD;2;RF Posterior fossa Views W contrast IT;RF Post fossa Views W contr IT;;ACTIVE;2.04;2.64 +30812-2;Guidance for injection;Find;Pt;Neck>Spine.cervical facet joint;Doc;RF;RAD;2;RF Guidance for injection of Spine Cervical Facet Joint;RF Guided C-Spine facet joint Inj;;ACTIVE;2.04;2.64 +30813-0;Views^W contrast intrabronchial;Find;Pt;Chest>Lung.bilateral;Doc;XR;RAD;2;XR Lung - bilateral Views W contrast intrabronchial;XR Lung-Bl Views W contr IB;;ACTIVE;2.04;2.64 +30814-8;Guidance for injection;Find;Pt;Chest>Spine.thoracic facet joint;Doc;RF;RAD;2;RF Guidance for injection of Spine Thoracic Facet Joint;RF Guided T-spine facet joint Inj;;ACTIVE;2.04;2.64 +30815-5;Guidance for endoscopy^W contrast retrograde;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts and Pancreatic duct-- W contrast retrograde;RF Guided BD+PD Endo--W contr Retro;;ACTIVE;2.04;2.64 +30816-3;Views^W contrast percutaneous intraperitoneal;Find;Pt;Abdomen>Peritoneum;Doc;RF.angio;RAD;2;RFA Peritoneum Views W contrast percutaneous intraperitoneal;RFA Periton Vs W contr PC intraper;;ACTIVE;2.04;2.64 +3081-7;Tyrosine;MRat;24H;Urine;Qn;;CHEM;1;Tyrosine [Mass/time] in 24 hour Urine;Tyrosine 24h Ur-mRate;;ACTIVE;1.0;2.73 +30817-1;Guidance for injection;Find;Pt;Abdomen>Spine.lumbar facet joint;Doc;RF;RAD;2;RF Guidance for injection of Lumbar Spine Facet Joint;RF Guided L-spine facet joint Inj;;ACTIVE;2.04;2.66 +30818-9;Guidance for placement of catheter^transcervical;Find;Pt;Pelvis>Fallopian tubes;Doc;RF;RAD;2;RF Guidance for placement of catheter in Fallopian tubes-- transcervical;RF Guided FT Cath place--transcervical;;ACTIVE;2.04;2.64 +30819-7;Views^W contrast IV;Find;Pt;XXX>Epidural veins;Doc;RF.angio;RAD;2;RFA Epidural veins Views W contrast IV;RFA Epidural vv Views W contr IV;;ACTIVE;2.04;2.64 +30820-5;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery.external.bilateral;Doc;RF.angio;RAD;2;RFA Carotid artery.external - bilateral Views W contrast IA;RFA Carot a.ext-Bl Views W contr IA;;ACTIVE;2.04;2.64 +30821-3;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery.external;Doc;RF.angio;RAD;2;RFA Carotid artery.external Views W contrast IA;RFA Carot a.ext Views W contr IA;;ACTIVE;2.04;2.64 +30822-1;Views^W contrast IA;Find;Pt;Head>Head artery.bilateral & Neck>Neck artery.bilateral;Doc;RF.angio;RAD;2;RFA Head artery - bilateral and Neck artery - bilateral Views W contrast IA;RFA Head+Neck a-Bl Views W contr IA;;ACTIVE;2.04;2.64 +30823-9;Views^W contrast IA;Find;Pt;Head>Head artery & Neck>Neck artery;Doc;RF.angio;RAD;2;RFA Head artery and Neck artery Views W contrast IA;RFA Head+Neck a Views W contr IA;;ACTIVE;2.04;2.64 +30824-7;Views^W contrast;Find;Pt;Head>Intracranial vessel & Neck>Neck vessel;Doc;RF.angio;RAD;2;RFA Intercranial vessel and Neck Vessel Views W contrast;RFA IC+Neck ves Views W contr;;ACTIVE;2.04;2.64 +3082-5;Tyrosine aminotransferase;MCnc;Pt;Plas;Qn;;CHEM;1;Tyrosine aminotransferase [Mass/volume] in Plasma;TyrAT Plas-mCnc;;DISCOURAGED;1.0;2.44 +30825-4;Views^W contrast IV;Find;Pt;Head>Orbit veins;Doc;RF.angio;RAD;2;RFA Orbit veins Views W contrast IV;RFA Orbit vv Views W contr IV;;ACTIVE;2.04;2.64 +30826-2;Views^W contrast IV;Find;Pt;Sagittal sinus vein+Jugular vein;Doc;XR.fluor.angio;RAD;2;Deprecated Sagittal sinus and Jugular veins Fluoroscopic angiogram W contrast IV;Deprecated SS v+Jugular v XRA W contr IV;;DEPRECATED;2.04;2.58 +30827-0;Views^W contrast IV;Find;Pt;Sagittal sinus vein;Doc;XR.fluor.angio;RAD;2;Deprecated Sagittal sinus vein Fluoroscopic angiogram W contrast IV;Deprecated SS v XRA W contr IV;;DEPRECATED;2.04;2.58 +30828-8;Views^W contrast IA;Find;Pt;Upper extremity>Brachial artery;Doc;RF.angio;RAD;2;RFA Brachial artery Views W contrast IA;RFA Brach a Views W contr IA;;ACTIVE;2.04;2.64 +30829-6;Views^W contrast IA;Find;Pt;Chest>Internal thoracic artery;Doc;RF.angio;RAD;2;RFA Internal thoracic artery Views W contrast IA;RFA IT a Views W contr IA;;ACTIVE;2.04;2.64 +30830-4;Views^W contrast IA;Find;Pt;Chest>Pulmonary arteries.bilateral;Doc;RF.angio;RAD;2;RFA Pulmonary artery - bilateral Views W contrast IA;RFA PA-Bl Views W contr IA;;ACTIVE;2.04;2.64 +30831-2;Views^W contrast IA;Find;Pt;Abdomen>Adrenal artery.bilateral;Doc;RF.angio;RAD;2;RFA Adrenal artery - bilateral Views W contrast IA;RFA Adrenal a-Bl Views W contr IA;;ACTIVE;2.04;2.64 +30832-0;Views^W contrast IA;Find;Pt;Abdomen>Adrenal artery;Doc;RF.angio;RAD;2;RFA Adrenal artery Views W contrast IA;RFA Adrenal a Views W contr IA;;ACTIVE;2.04;2.64 +3083-3;Urate;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Urate [Mass/volume] in Amniotic fluid;Urate Amn-mCnc;;ACTIVE;1.0;2.73 +30833-8;Views^W contrast IA;Find;Pt;Pelvis>Pelvis arteries;Doc;RF.angio;RAD;2;RFA Pelvis arteries Views W contrast IA;RFA Pelvis aa Views W contr IA;;ACTIVE;2.04;2.64 +30834-6;Views^W contrast IA;Find;Pt;Abdomen>Renal artery.bilateral;Doc;RF.angio;RAD;2;RFA Renal artery - bilateral Views W contrast IA;RFA Renal a-Bl Views W contr IA;;ACTIVE;2.04;2.64 +30835-3;View^W contrast.XXX IA;Find;Pt;Artery.renal;Nar;XR.fluor;RAD;2;Deprecated Kidney arteries X-ray fluoroscopy angio W contrast IA;Deprecated Flr;;DEPRECATED;2.04;2.46 +30836-1;Guidance for angioplasty^W contrast IA;Find;Pt;Abdomen>Visceral artery;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Visceral artery-- W contrast IA;RFA Guided Visceral a Angio--W contr IA;;ACTIVE;2.04;2.64 +30837-9;Views^W contrast IA;Find;Pt;Abdomen>Aorta.abdominal;Doc;RF.angio;RAD;2;RFA Abdominal Aorta Views W contrast IA;RFA Abd Aorta Views W contr IA;;ACTIVE;2.04;2.64 +30838-7;Views runoff^W contrast IA;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Lower extremity.bilateral>Femoral artery;Doc;RF.angio;RAD;2;RFA Aorta and Femoral artery - bilateral Runoff W contrast IA;RFA Aorta+Fem a-Bl runoff W contr IA;;ACTIVE;2.04;2.61 +30839-5;Views^W contrast intra lymphatic;Find;Pt;Abdomen>Abdominal lymphatic vessels;Doc;RF.angio;RAD;2;RFA Abdominal lymphatic vessels Views W contrast intra lymphatic;RFA Abd lymph ves Views W contr IL;;ACTIVE;2.04;2.64 +30840-3;Views^W contrast intra lymphatic;Find;Pt;Abdomen>Abdominal lymphatic vessels.bilateral;Doc;RF.angio;RAD;2;RFA Abdominal lymphatic vessels - bilateral Views W contrast intra lymphatic;RFA Abd lymph ves-Bl Views W contr IL;;ACTIVE;2.04;2.64 +3084-1;Urate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urate [Mass/volume] in Serum or Plasma;Urate SerPl-mCnc;;ACTIVE;1.0;2.73 +30841-1;Views^W contrast transhepatic;Find;Pt;Abdomen>Portal vein;Doc;RF.angio;RAD;2;RFA Portal vein Views W contrast transhepatic;RFA Portal v Views W contr TH;;ACTIVE;2.04;2.64 +30842-9;Views for hemodynamics^W contrast transhepatic;Find;Pt;Abdomen>Portal vein;Doc;RF.angio;RAD;2;RFA Portal vein Views for hemodynamics W contrast transhepatic;RFA Portal v Vs hemodynamics W contr TH;;ACTIVE;2.04;2.64 +30843-7;Views^W contrast IV;Find;Pt;Abdomen>Adrenal vein;Doc;RF.angio;RAD;2;RFA Adrenal vein Views W contrast IV;RFA Adrenal v Views W contr IV;;ACTIVE;2.04;2.64 +30844-5;Views^W contrast IV;Find;Pt;Abdomen>Adrenal vein.bilateral;Doc;RF.angio;RAD;2;RFA Adrenal vein - bilateral Views W contrast IV;RFA Adrenal v-Bl Views W contr IV;;ACTIVE;2.04;2.64 +30845-2;Views^W contrast IV;Find;Pt;Abdomen>Vena cava.inferior;Doc;RF.angio;RAD;2;RFA Inferior vena cava Views W contrast IV;RFA IVC Views W contr IV;;ACTIVE;2.04;2.64 +30846-0;Views^W contrast IV;Find;Pt;Abdomen>Renal vein.bilateral;Doc;RF.angio;RAD;2;RFA Renal vein - bilateral Views W contrast IV;RFA Renal v-Bl Views W contr IV;;ACTIVE;2.04;2.64 +30847-8;Views^W contrast IV;Find;Pt;Abdomen>Renal vein;Doc;RF.angio;RAD;2;RFA Renal vein Views W contrast IV;RFA Renal v Views W contr IV;;ACTIVE;2.04;2.64 +30848-6;Views^W contrast IA;Find;Pt;Extremity>Extremity arteries;Doc;RF.angio;RAD;2;RFA Extremity arteries Views W contrast IA;RFA Extr aa Views W contr IA;;ACTIVE;2.04;2.64 +30849-4;Views^W contrast IA;Find;Pt;Extremity.bilateral>Extremity arteries;Doc;RF.angio;RAD;2;RFA Extremity arteries - bilateral Views W contrast IA;RFA Extr aa-Bl Views W contr IA;;ACTIVE;2.04;2.64 +30850-2;Views^W contrast intra lymphatic;Find;Pt;Extremity>Extremity lymphatic vessels;Doc;RF.angio;RAD;2;RFA Extremity lymphatic vessels Views W contrast intra lymphatic;RFA Extremity lymph ves Views W contr IL;;ACTIVE;2.04;2.64 +30851-0;Views^W contrast intra lymphatic;Find;Pt;Extremity.bilateral>Extremity lymphatic vessels;Doc;RF.angio;RAD;2;RFA Extremity lymphatic vessels - bilateral Views W contrast intra lymphatic;RFA Extremity lymph ves-Bl Vs W contr IL;;ACTIVE;2.04;2.64 +30852-8;Views^W contrast IV;Find;Pt;XXX>Peripheral veins.bilateral;Doc;RF.angio;RAD;2;RFA XXX>Peripheral veins - bilateral Views W contrast IV;RFA Peripheral vv-Bl Views W contr IV;;ACTIVE;2.04;2.64 +30853-6;Multisection^W contrast intra duct;Find;Pt;Breast>Breast duct;Doc;US;RAD;2;US Breast duct W contrast intra duct;US Brst duct W contr intra Dct;;ACTIVE;2.04;2.61 +30854-4;Multisection^WO contrast;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Cervical and thoracic and lumbar spine WO contrast;MR C+T+L-spine WO contr;;ACTIVE;2.04;2.61 +30855-1;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Cervical and thoracic and lumbar spine WO and W contrast IV;MR C+T+L-spine WO+W contr IV;;ACTIVE;2.04;2.61 +30856-9;Multisection;Find;Pt;Head>Head vessels;Doc;MR.angio;RAD;2;MRA Head vessels;MRA Head ves;;ACTIVE;2.04;2.61 +30857-7;Multisection;Find;Pt;Head>Nerves.cranial;Doc;MR;RAD;2;MR Nerves cranial;MR Nerves.cranial;;ACTIVE;2.04;2.61 +3085-8;Urate;MCnc;Pt;Synv fld;Qn;;CHEM;1;Urate [Mass/volume] in Synovial fluid;Urate Snv-mCnc;;ACTIVE;1.0;2.73 +30858-5;Multisection;Find;Pt;Head>Head veins;Doc;MR.angio;RAD;2;MRA Head veins;MRA Head vv;;ACTIVE;2.04;2.61 +30859-3;Multisection;Find;Pt;Head+Neck>Carotid vessels & Neck>Neck vessels;Doc;MR.angio;RAD;2;MRA Carotid vessels and Neck vessels;MRA Carotid ves+Neck ves;;ACTIVE;2.04;2.61 +30860-1;Multisection;Find;Pt;Head+Neck>Nasopharynx;Doc;MR;RAD;2;MR Nasopharynx;MR Nasopharynx;;ACTIVE;2.04;2.61 +30861-9;Multisection;Find;Pt;Chest>Aortic arch & Neck>Neck vessels;Doc;MR.angio;RAD;2;MRA Aortic arch and Neck vessels;MRA Ac arch+Neck ves;;ACTIVE;2.04;2.61 +30862-7;Multisection;Find;Pt;Chest>Chest vessels;Doc;MR.angio;RAD;2;MRA Chest vessels;MRA Chest ves;;ACTIVE;2.04;2.73 +30863-5;Multisection;Find;Pt;Aorta+Abdominal arteries;Doc;MRI.angio;RAD;2;Deprecated Abdominal Aorta and Arteries MRI angiogram;Deprecated Aorta+Abd aa MRI.Angio;;DEPRECATED;2.04;2.58 +30864-3;Multisection;Find;Pt;Abdomen>Abdominal veins+Vena cava.inferior;Doc;MR.angio;RAD;2;MRA Abdominal veins and IVC;MRA Abd vv+IVC;;ACTIVE;2.04;2.61 +30865-0;Multisection;Find;Pt;Abdomen>Celiac vessels+Superior mesenteric vessels;Doc;MR.angio;RAD;2;MRA Celiac vessels and Superior mesenteric Vessels;MRA Celiac ves+SM ves;;ACTIVE;2.04;2.61 +3086-6;Urate;MCnc;Pt;Urine;Qn;;CHEM;1;Urate [Mass/volume] in Urine;Urate Ur-mCnc;;ACTIVE;1.0;2.73 +30866-8;Multisection;Find;Pt;Pelvis>Lumbosacral plexus;Doc;MR;RAD;2;MR Lumbosacral plexus;MR Lumbosacral plexus;;ACTIVE;2.04;2.61 +30867-6;Multisection;Find;Pt;Pelvis>Pelvis vessels;Doc;MR.angio;RAD;2;MRA Pelvis vessels;MRA Pelvis ves;;ACTIVE;2.04;2.61 +30868-4;Multisection;Find;Pt;Abdomen>Renal vessels;Doc;MR.angio;RAD;2;MRA Renal vessels;MRA Renal ves;;ACTIVE;2.04;2.61 +30869-2;Multisection^WO contrast;Find;Pt;Lower extremity>Lower leg;Doc;MR;RAD;2;MR Lower leg WO contrast;MR Lower leg WO contr;;ACTIVE;2.04;2.61 +308-7;Loracarbef;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Loracarbef [Susceptibility] by Disk diffusion (KB);Loracarbef Islt KB;;ACTIVE;1.0;2.73 +30870-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Lower leg;Doc;MR;RAD;2;MR Lower leg WO and W contrast IV;MR Lower leg WO+W contr IV;;ACTIVE;2.04;2.61 +30871-8;Multisection;Find;Pt;Lower extremity>Femoral vessels;Doc;MR.angio;RAD;2;MRA Femoral vessels;MRA Fem ves;;ACTIVE;2.04;2.61 +30872-6;Multisection;Find;Pt;Lower extremity>Foot vessels;Doc;MR.angio;RAD;2;MRA Foot vessels;MRA Ft ves;;ACTIVE;2.04;2.61 +30873-4;Multisection;Find;Pt;Upper extremity>Forearm vessels;Doc;MR.angio;RAD;2;MRA Forearm vessels;MRA Forearm ves;;ACTIVE;2.04;2.61 +3087-4;Urate;MRat;24H;Urine;Qn;;CHEM;1;Urate [Mass/time] in 24 hour Urine;Urate 24h Ur-mRate;;ACTIVE;1.0;2.73 +30874-2;Multisection;Find;Pt;Lower extremity>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels;MRA LE ves;;ACTIVE;2.04;2.61 +30875-9;Multisection;Find;Pt;Upper extremity>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity.joint;MR UE joint;;ACTIVE;2.04;2.73 +30876-7;Multisection;Find;Pt;Extremity>Extremity veins;Doc;MR.angio;RAD;2;MRA Extremity veins;MRA Extr vv;;ACTIVE;2.04;2.61 +30877-5;Views^W radionuclide IV;Find;Pt;Abdomen>Kidney+Renal vessels;Doc;NM;RAD;2;NM Kidney+Renal vessels Views;NM Kidney+ves Views W RNC IV;;ACTIVE;2.04;2.64 +30878-3;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for fluid aspiration of Unspecified body region;US Guided PC fluid asp;;ACTIVE;2.04;2.64 +30879-1;Guidance for drainage;Find;Pt;XXX;Nar;US;RAD;2;Deprecated Unspecified system US Guidance for drainage;Deprecated XXX US Drain guid;;DEPRECATED;2.04;2.46 +30880-9;Multisection;Find;Pt;Head>Head vessels & Neck>Neck vessels;Doc;US.doppler;RAD;2;US.doppler Head vessels and Neck vessels;DOP Head+Neck Ves;;ACTIVE;2.04;2.61 +30881-7;Multisection;Find;Pt;Lower extremity>Lower extremity vein;Doc;US.doppler;RAD;2;US.doppler Lower extremity vein;DOP LE v;;ACTIVE;2.04;2.61 +3088-2;Urate renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Urate renal clearance in 24 hour Urine and Serum or Plasma;Urate Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +30882-5;Multisection;Find;Pt;Upper extremity>Upper extremity vein;Doc;US.doppler;RAD;2;US.doppler Upper extremity vein;DOP UE v;;ACTIVE;2.04;2.61 +30883-3;Views;Find;Pt;Pelvis>Coccyx;Doc;XR;RAD;2;XR Coccyx Views;XR Coccyx Views;;ACTIVE;2.04;2.73 +30884-1;Views;Find;Pt;Pelvis>Sacrum;Doc;XR;RAD;2;XR Sacrum Views;XR Sacrum Views;;ACTIVE;2.04;2.64 +30885-8;Views;Find;Pt;Pelvis>Symphysis pubis;Doc;XR;RAD;2;XR Pelvis symphysis pubis Views;XR Pelvis symphysis pubis Views;;ACTIVE;2.04;2.64 +30886-6;Multisection^W contrast.XXX IV;Find;Pt;Vessel.upper extremity;Nar;MRI.angio;RAD;2;Deprecated Upper extremity vessels MRI angio Multisection W contrast IV;Deprecated MRI.Angio;;DEPRECATED;2.04;2.46 +30887-4;Multisection^W contrast IV;Find;Pt;Abdomen>Renal vessels;Doc;MR.angio;RAD;2;MRA Renal vessels W contrast IV;MRA Renal ves W contr IV;;ACTIVE;2.04;2.61 +30888-2;Multisection;Find;Pt;Lower extremity>Tibioperoneal vessels;Doc;MR.angio;RAD;2;MRA Tibioperoneal vessels;MRA Tibioperoneal ves;;ACTIVE;2.04;2.61 +30889-0;Views;Find;Pt;Head>Temporomandibular joint.left;Doc;XR;RAD;2;XR Temporomandibular joint - left Views;XR TMJ-L Views;;ACTIVE;2.04;2.64 +3089-0;Urate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Urate/Creatinine [Mass Ratio] in Urine;Urate/Creat Ur;;ACTIVE;1.0;2.73 +30890-8;Views;Find;Pt;Head>Temporomandibular joint.right;Doc;XR;RAD;2;XR Temporomandibular joint - right Views;XR TMJ-R Views;;ACTIVE;2.04;2.64 +30891-6;Views^W contrast IA;Find;Pt;Cervicocerebral artery;Doc;RF.angio;RAD;2;Deprecated RFA Cervicocerebral artery W contrast IA;Deprecated Cervicocerebral a RFA W contr;;DEPRECATED;2.04;2.61 +30892-4;Guidance for placement of catheter^W contrast retrograde;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for placement of catheter in Biliary ducts and Pancreatic duct-- W contrast retrograde;RF Guided BD+PD Cath place W contr Retro;;ACTIVE;2.04;2.64 +30893-2;Multisection;Find;Pt;Vessels.abdomen;Nar;US.doppler;RAD;2;Deprecated Abdominal vessels US.doppler Multisection;Deprecated US.doppler;;DEPRECATED;2.04;2.46 +30894-0;Aldosterone/Renin;Ratio;Pt;Plas;Qn;;CHEM;1;Aldosterone/Renin [Ratio] in Plasma;Aldost/Renin Plas-Rto;;ACTIVE;2.04;2.73 +30895-7;Renin;ACnc;Pt;Plas;Qn;;CHEM;1;Renin [Units/volume] in Plasma;Renin Plas-aCnc;;ACTIVE;2.04;2.70 +30896-5;Referral lab test identifier;ID;Pt;Referral lab test;Nom;;MISC;1;Referral lab test [Identifier];Ref Lab Test;;ACTIVE;2.04;2.73 +30897-3;Erythrocyte volume;Vol;Pt;^Patient;Qn;Radnuc;CHEM;1;Total Erythrocyte Volume by Scintigraphy;RCV Vol RI;;ACTIVE;2.04;2.56 +30898-1;Plasma volume;Vol;Pt;^Patient;Qn;Radnuc;CHEM;1;Plasma volume by Scintigraphy;Plasma Vol RI;;ACTIVE;2.04;2.56 +30899-9;Blood volume;Vol;Pt;^Patient;Qn;Radnuc;CHEM;1;Blood volume by Scintigraphy;Bld Vol RI;;ACTIVE;2.04;2.44 +30900-5;Cold agglutinin;Titr;Pt;Ser/Plas;Qn;Aggl.adult RBC;SERO;1;Cold agglutinin [Titer] in Serum or Plasma by Adult RBC Agglutination;CA Titr SerPl Adult RBC Aggl;;ACTIVE;2.04;2.73 +30901-3;Cold agglutinin;Titr;Pt;Ser/Plas;Qn;Aggl.cord RBC;SERO;1;Cold agglutinin [Titer] in Serum or Plasma by Cord RBC agglutination;CA Titr SerPl Cord RBC Aggl;;ACTIVE;2.04;2.30 +30902-1;Fibrinogen;MCnc;Pt;PPP;Qn;Heat denaturation;COAG;1;Fibrinogen [Mass/volume] in Platelet poor plasma by Heat denaturation;Fibrinogen PPP Heat Denat-mCnc;;ACTIVE;2.04;2.73 +30903-9;Neutrophil oxidative burst;PrThr;Pt;Bld;Ord;Flow cytometry;HEM/BC;1;Neutrophil oxidative burst [Presence] in Blood by Flow cytometry (FC);Neutrophil OB Bld Ql FC;;ACTIVE;2.04;2.73 +30904-7;Cobalamins^post dose cyanocobalamin;ACnc;24H;Urine;Qn;;CHAL;1;Cobalamin (Vitamin B12) [Units/volume] in 24 hour Urine --post dose cyanocobalamin;Vit B12 p B12 24h Ur-aCnc;;ACTIVE;2.04;2.40 +30905-4;Cobalamins^post dose cyanocobalamin+intrinsic factor/Cobalamins^post cyanocobalamin;Ratio;24H;Urine;Qn;;CHAL;1;Cobalamin (Vitamin B12) [Ratio] in 24 hour Urine --post dose cyanocobalamin+intrinsic factor/post dose cyanocobalamin;Vit B12 p B12+IF/pB12 24H Ur-aCnc;;ACTIVE;2.04;2.32 +30906-2;Cobalamins^post dose cyanocobalamin+intrinsic factor;ACnc;24H;Urine;Qn;;CHAL;1;Cobalamin (Vitamin B12) [Units/volume] in 24 hour Urine --post dose cyanocobalamin+intrinsic factor;Vit B12 p B12+IF 24h Ur-aCnc;;ACTIVE;2.04;2.40 +30907-0;Date of next planned rehabilitation treatment;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Date of next planned rehabilitation treatment Set;;;ACTIVE;2.04;2.40 +3090-8;Urea;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Urea [Mass/volume] in Amniotic fluid;Urea Amn-mCnc;;ACTIVE;1.0;2.42 +30908-8;Next planned treatment start date;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Next planned treatment start date;Deprecated;;DEPRECATED;2.04;2.66 +30909-6;Next planned treatment end date;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Next planned treatment end date;Deprecated;;DEPRECATED;2.04;2.66 +30910-4;Antimicrobials;PrThr;Pt;Urine;Ord;;MICRO;1;Antimicrobials [Presence] in Urine;Antimicrobials Ur Ql;;ACTIVE;2.04;2.56 +30911-2;DNA ploidy;Prid;Pt;XXX;Nom;Flow cytometry;MOLPATH;1;DNA ploidy [Identifier] in Specimen by Flow cytometry (FC) Nominal;DNA Ploidy Spec FC;;ACTIVE;2.04;2.69 +30912-0;DNA index;ACnc;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;DNA index in Specimen by Flow cytometry (FC);DNA Index Spec FC-aCnc;;ACTIVE;2.04;2.73 +30913-8;Cells.S phase/100 cells;NFr;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;S-phase cells/100 cells in Specimen by Flow cytometry (FC);S Phs Cells NFr Spec FC;;ACTIVE;2.04;2.73 +30914-6;Cells.hyperdiploid/100 cells;NFr;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;Hyperdiploid cells/100 cells in Specimen by Flow cytometry (FC);Hyperdiploid Cells NFr Spec FC;;ACTIVE;2.04;2.69 +30915-3;Cells.aneuploid/100 cells;NFr;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;Aneuploid cells/100 cells in Specimen by Flow cytometry (FC);Aneuploid Cells NFr Spec FC;;ACTIVE;2.04;2.69 +3091-6;Urea;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea [Mass/volume] in Serum or Plasma;Urea SerPl-mCnc;;ACTIVE;1.0;2.73 +30916-1;Cells.euploid+Cells.aneuploid/100 cells;NFr;Pt;XXX;Qn;;MOLPATH;1;Euploid+Aneuploid cells/100 cells in Specimen;Euploid+Aneuploid NFr Spec;;ACTIVE;2.04;2.69 +30917-9;DNA ploidy;Imp;Pt;XXX;Nar;Flow cytometry;MOLPATH;1;DNA ploidy [Interpretation] in Specimen by Flow cytometry (FC) Narrative;DNA Ploidy Spec FC-Imp;;ACTIVE;2.04;2.73 +30918-7;Gold;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Gold [Mass/volume] in Urine collected for unspecified duration;Gold ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30919-5;Iron;MCnc;XXX;Urine;Qn;;CHEM;1;Iron [Mass/volume] in Urine collected for unspecified duration;Iron ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30920-3;Copper;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Urine collected for unspecified duration;Copper ?Tm Ur-mCnc;;ACTIVE;2.04;2.73 +30921-1;Mercury;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Urine collected for unspecified duration;Mercury ?Tm Ur-mCnc;;ACTIVE;2.04;2.73 +30922-9;Magnesium;MCnc;XXX;Urine;Qn;;CHEM;1;Magnesium [Mass/volume] in Urine collected for unspecified duration;Magnesium ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30923-7;Chromium;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Urine collected for unspecified duration;Chromium ?Tm Ur-mCnc;;ACTIVE;2.04;2.73 +3092-4;Urea;MCnc;Pt;Urine;Qn;;CHEM;1;Urea [Mass/volume] in Urine;Urea Ur-mCnc;;ACTIVE;1.0;2.73 +30924-5;Arsenic;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Urine collected for unspecified duration;Arsenic ?Tm Ur-mCnc;;ACTIVE;2.04;2.73 +30925-2;Cadmium;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Urine collected for unspecified duration;Cadmium ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30926-0;Aluminum;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Urine collected for unspecified duration;Aluminum ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30927-8;Selenium;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Urine collected for unspecified duration;Selenium ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30928-6;Silver;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Urine collected for unspecified duration;Silver ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30929-4;Thallium;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in Urine collected for unspecified duration;Thallium ?Tm Ur-mCnc;;ACTIVE;2.04;2.73 +30930-2;Zinc;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Urine collected for unspecified duration;Zinc ?Tm Ur-mCnc;;ACTIVE;2.04;2.73 +30931-0;Lead;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Urine collected for unspecified duration;Lead ?Tm Ur-mCnc;;ACTIVE;2.04;2.73 +3093-2;Urea nitrogen;MCnc;Pt;Body fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Body fluid;Urea nit Fld-mCnc;;ACTIVE;1.0;2.73 +30932-8;Manganese;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Urine collected for unspecified duration;Manganese ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30933-6;Nickel;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Urine collected for unspecified duration;Nickel ?Tm Ur-mCnc;;ACTIVE;2.04;2.70 +30934-4;Natriuretic peptide.B;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Natriuretic peptide B [Mass/volume] in Serum or Plasma;BNP SerPl-mCnc;;ACTIVE;2.04;2.73 +30935-1;ST deviation;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST deviation;ST Deviation;;ACTIVE;2.04;2.48 +30936-9;Corynebacterium diphtheriae+Clostridium tetani+Bordetella pertussis dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Corynebacterium diphtheriae+Clostridium tetani+Bordetella pertussis dose count in combination vaccine;DTAP dose count in combo vaccine;;ACTIVE;2.04;2.48 +30937-7;Hepatitis B virus dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Hepatitis B virus dose count in combination vaccine;HBV dose count in combo vaccine;;ACTIVE;2.04;2.48 +30938-5;Haemophilus influenzae B dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Haemophilus influenzae B dose count in combination vaccine;HIB dose count in combo vaccine;;ACTIVE;2.04;2.48 +30939-3;Measles virus dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Measles virus dose count in combination vaccine;MeV dose count in combo vaccine;;ACTIVE;2.04;2.48 +3094-0;Urea nitrogen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Serum or Plasma;BUN SerPl-mCnc;;ACTIVE;1.0;2.73 +30940-1;Measles virus+Mumps virus+Rubella virus dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Measles virus+Mumps virus+Rubella virus dose count in combination vaccine;MMR dose count in combo vaccine;;ACTIVE;2.04;2.48 +30941-9;Mumps virus dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Mumps virus dose count in combination vaccine;MuV dose count in combo vaccine;;ACTIVE;2.04;2.48 +30942-7;Rubella virus dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Rubella virus dose count in combination vaccine;RUBV dose count in combo vaccine;;ACTIVE;2.04;2.48 +30943-5;Varicella zoster virus dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Varicella zoster virus dose count in combination vaccine;VZV dose count in combo vaccine;;ACTIVE;2.04;2.48 +30944-3;Date of vaccination temporary contraindication &or precaution expiration;Date;Pt;^Patient;Qn;;VACCIN;2;Date of vaccination temporary contraindication/precaution expiration;Date vaccine temp contra/precaution exp;;ACTIVE;2.04;2.50 +30945-0;Vaccination contraindication &or precaution;Find;Pt;^Patient;Nom;;VACCIN;2;Vaccination contraindication/precaution;Vaccination contraindication/precaution;;ACTIVE;2.04;2.27 +30946-8;Date.vaccination contraindication &or precaution effective;Date;Pt;^Patient;Qn;;VACCIN;2;Date.vaccination contraindication/precaution effective;Date vaccine contra/precaution effective;;ACTIVE;2.04;2.50 +30947-6;Date form completed;Date;Pt;Form;Qn;;ADMIN;2;Date form completed;Date form completed;;ACTIVE;2.04;2.61 +30948-4;Vaccination adverse event;Find;Pt;^Patient;Nar;;VACCIN;2;Vaccination adverse event Narrative;Vaccination AE;;ACTIVE;2.04;2.40 +30949-2;Vaccination adverse event outcome;Find;Pt;^Patient;Nom;VAERS;VACCIN;2;Vaccination adverse event outcome VAERS;Vaccination AE outcome VAERS;;ACTIVE;2.04;2.42 +309-5;Loracarbef;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Loracarbef [Susceptibility] by Serum bactericidal titer;Loracarbef Titr SBT;;ACTIVE;1.0;2.32 +30950-0;Number of D hospitalized due to vaccination adverse event;Num;Pt;^Patient;Qn;;VACCIN;2;Number of days hospitalized due to vaccination adverse event;# days hospitalized due to vacc AE;;ACTIVE;2.04;2.48 +30951-8;Patient recovered;Find;Pt;^Patient;Ord;VAERS;VACCIN;2;Patient recovered VAERS;Patient recovered VAERS;;ACTIVE;2.04;2.42 +30952-6;Date and time of vaccination;TmStp;Pt;^Patient;Qn;;VACCIN;2;Date and time of vaccination;Date+time of vaccination;;ACTIVE;2.04;2.56 +30953-4;Date and time of onset of vaccination adverse event;TmStp;Pt;^Patient;Qn;;VACCIN;2;Date and time of onset of vaccination adverse event;Date+time onset of vaccine AE;;ACTIVE;2.04;2.27 +30954-2;Relevant diagnostic tests &or laboratory data;Find;Pt;^Patient;Nar;;VACCIN;2;Relevant diagnostic tests/laboratory data Narrative;Relevant Dx tests/lab data;;ACTIVE;2.04;2.63 +30955-9;Vaccines given on same date as vaccine causing adverse event;Cmplx;Pt;Vaccine;Set;;VACCIN;2;Vaccines given on same date as vaccine causing adverse event Set;Vaccines same date as vaccine causing AE;;ACTIVE;2.04;2.27 +30956-7;Type;ID;Pt;Vaccine;Nom;;VACCIN;2;Type [Identifier] Vaccine;Type Vaccine;;ACTIVE;2.04;2.73 +3095-7;Urea nitrogen;MCnc;Pt;Urine;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Urine;UUN Ur-mCnc;;ACTIVE;1.0;2.73 +30957-5;Manufacturer name;ID;Pt;Vaccine;Nom;;VACCIN;2;Manufacturer name [Identifier] Vaccine;Manufacturer name Vaccine;;ACTIVE;2.04;2.27 +30958-3;Route;Prid;Pt;Vaccine.administered;Nom;;VACCIN;2;Route [Identifier] Vaccine administered;Route Vaccine.administered;;ACTIVE;2.04;2.27 +30959-1;Lot number;ID;Pt;Vaccine;Nom;;VACCIN;2;Lot number [Identifier] Vaccine;Lot # Vaccine;;ACTIVE;2.04;2.27 +30960-9;Number of previous doses;Num;Pt;^Patient;Qn;;VACCIN;2;Number of previous doses;# previous doses;;ACTIVE;2.04;2.48 +30961-7;Other vaccines given within 4W prior to vaccination that caused adverse reaction;Cmplx;Pt;^Patient;Set;;VACCIN;2;Other vaccines given within 4 weeks prior to vaccination that caused adverse reaction [Complex] Set;Other vaccines given within 4W;;ACTIVE;2.04;2.40 +30962-5;Vaccinated at;Find;Pt;^Patient;Nom;VAERS;VACCIN;2;Vaccinated at VAERS;Vaccinated at VAERS;;ACTIVE;2.04;2.42 +30963-3;Funds vaccine purchased with;Find;Pt;^Patient;Nom;VAERS;VACCIN;2;Funds vaccine purchased with VAERS;Funds vaccine purchased with VAERS;;ACTIVE;2.04;2.73 +30964-1;Other medications;Find;Pt;^Patient;Nom;;VACCIN;2;Other medications;Other medications;;ACTIVE;2.04;2.27 +3096-5;Urea nitrogen;MRat;24H;Urine;Qn;;CHEM;1;Urea nitrogen [Mass/time] in 24 hour Urine;UUN 24h Ur-mRate;;ACTIVE;1.0;2.73 +30965-8;Illness at time of vaccination;Find;Pt;^Patient;Nom;;VACCIN;2;Illness at time of vaccination;Illness at time of vaccination;;ACTIVE;2.04;2.27 +30966-6;Pre-existing physician-diagnosed allergies, birth defects, medical conditions;Find;Pt;^Patient;Nom;;VACCIN;2;Pre-existing physician-diagnosed allergies, birth defects, medical conditions;Pre-existing conditions;;ACTIVE;2.04;2.27 +30967-4;Adverse event previously reported;Find;Pt;^Patient;Nom;VAERS;VACCIN;2;Adverse event previously reported VAERS;AE previously reported VAERS;;ACTIVE;2.04;2.42 +30968-2;Adverse event following prior vaccination in patient;Cmplx;Pt;^Patient;Set;;VACCIN;2;Adverse event following prior vaccination in patient [Complex] Set;AE p vaccine in patient;;ACTIVE;2.04;2.27 +30969-0;Adverse event following prior vaccination;Cmplx;Pt;^Brother;Set;;VACCIN;2;Adverse event following prior vaccination [Complex] Brother Set;AE p vaccine Brother;;ACTIVE;2.04;2.56 +30970-8;Adverse event following prior vaccination;Cmplx;Pt;^Sister;Set;;VACCIN;2;Adverse event following prior vaccination [Complex] Sister Set;AE p vaccine Sister;;ACTIVE;2.04;2.56 +30971-6;Adverse event;Find;Pt;^Patient;Nom;VAERS;VACCIN;2;Adverse event VAERS;AE VAERS;;ACTIVE;2.04;2.42 +30972-4;Age at onset of adverse event;Time;Pt;^Patient;Qn;;VACCIN;2;Age at onset of adverse event;Age at onset of AE;;ACTIVE;2.04;2.40 +3097-3;Urea nitrogen/Creatinine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma;BUN/Creat SerPl;;ACTIVE;1.0;2.73 +30973-2;Dose number;Num;Pt;^Patient;Qn;;VACCIN;2;Dose number;Dose #;;ACTIVE;2.04;2.27 +30974-0;Number of brothers and sisters;Num;Pt;^Patient;Qn;;VACCIN;2;Number of brothers and sisters;# brothers and sisters;;ACTIVE;2.04;2.48 +30975-7;Creator report number;ID;Pt;Form;Nom;VAERS;VACCIN;2;Creator report number [Identifier] Form VAERS;Creator report # VAERS;;ACTIVE;2.04;2.42 +30976-5;Date received;TmStp;Pt;Form;Qn;;VACCIN;2;Date received Form;Date received;;ACTIVE;2.04;2.73 +30977-3;15 day report;Find;Pt;Form;Ord;VAERS;VACCIN;2;15 day report Form VAERS;15 day report VAERS;;ACTIVE;2.04;2.42 +30978-1;Type;Find;Pt;Form;Nom;VAERS;VACCIN;2;Type Form VAERS;Type VAERS;;ACTIVE;2.04;2.42 +30979-9;Vaccines due next;Cmplx;Pt;^Patient;Set;;VACCIN;2;Vaccines due next [Complex] Set;Vaccines due next;;ACTIVE;2.04;2.27 +30980-7;Date vaccine due;Date;Pt;^Patient;Qn;;VACCIN;2;Date vaccine due;Date vaccine due;;ACTIVE;2.04;2.50 +3098-1;Urea renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Urea renal clearance in 24 hour Urine and Serum or Plasma;Urea Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.73 +30981-5;Earliest date to give;Date;Pt;^Patient;Qn;;VACCIN;2;Earliest date to give;Earliest date to give;;ACTIVE;2.04;2.50 +30982-3;Reason applied by forecast logic to project this vaccine;Find;Pt;^Patient;Nom;;VACCIN;2;Reason applied by forecast logic to project this vaccine;Reason applied to project this vaccine;;ACTIVE;2.04;2.63 +30983-1;Aesculus hippocastanum Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse Chestnut IgE Ab [Presence] in Serum;Horse Chestnut IgE Ql;;ACTIVE;2.04;2.56 +30984-9;Betula verrucosa recombinant (rBet v) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 1 IgE Ab [Units/volume] in Serum;Silver Birch (rBet v) 1 IgE Qn;;ACTIVE;2.04;2.42 +30985-6;Betula verrucosa recombinant (rBet v) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 2 IgE Ab [Units/volume] in Serum;Silver Birch (rBet v) 2 IgE Qn;;ACTIVE;2.04;2.42 +30986-4;Aspergillus fumigatus recombinant (rAsp f) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 1 IgE Ab [Units/volume] in Serum;A fumigatus (rAsp f) 1 IgE Qn;;ACTIVE;2.04;2.42 +30987-2;Chinchilla epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chinchilla epithelium IgE Ab [Units/volume] in Serum;Chinchilla Epith IgE Qn;;ACTIVE;2.04;2.73 +30988-0;Panicum milliaceum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Common Millet IgE Ab [Units/volume] in Serum;Deprecated Common Millet IgE Qn;;DEPRECATED;2.04;2.69 +30989-8;Sardinops melanostictus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sardine (Sardinops melanosticta) IgE Ab [Units/volume] in Serum;Sardine (melanost) IgE Qn;;ACTIVE;2.04;2.73 +30990-6;Aspergillus fumigatus recombinant (rAsp f) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 2 IgE Ab [Units/volume] in Serum;A fumigatus (rAsp f) 2 IgE Qn;;ACTIVE;2.04;2.42 +30991-4;Aspergillus fumigatus recombinant (rAsp f) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 3 IgE Ab [Units/volume] in Serum;A fumigatus (rAsp f) 3 IgE Qn;;ACTIVE;2.04;2.42 +30992-2;Aspergillus fumigatus recombinant (rAsp f) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 4 IgE Ab [Units/volume] in Serum;A fumigatus (rAsp f) 4 IgE Qn;;ACTIVE;2.04;2.42 +30993-0;Aspergillus fumigatus recombinant (rAsp f) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 6 IgE Ab [Units/volume] in Serum;A fumigatus (rAsp f) 6 IgE Qn;;ACTIVE;2.04;2.42 +30994-8;Phleum pratense recombinant (rPhl p) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 1 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 1 IgE Qn;;ACTIVE;2.04;2.42 +30995-5;Phleum pratense recombinant (rPhl p) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 2 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 2 IgE Qn;;ACTIVE;2.04;2.42 +30996-3;Phleum pratense recombinant (rPhl p) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 5 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 5 IgE Qn;;ACTIVE;2.04;2.42 +30997-1;Phleum pratense native (nPhl p) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy native (nPhl p) 4 IgE Ab [Units/volume] in Serum;Timothy native (nPhl p) 4 IgE Qn;;ACTIVE;2.04;2.42 +30998-9;Phleum pratense recombinant (rPhl p) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 6 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 6 IgE Qn;;ACTIVE;2.04;2.42 +3099-9;Uridine diphosphate glucose-4-Epimerase;CCnc;Pt;Plas;Qn;;CHEM;1;Uridine diphosphate glucose-4-Epimerase [Enzymatic activity/volume] in Plasma;UDPG4Epimerase Plas-cCnc;;ACTIVE;1.0;2.68 +30999-7;Phleum pratense recombinant (rPhl p) 7 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 7 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 7 IgE Qn;;ACTIVE;2.04;2.42 +31000-3;Phleum pratense recombinant (rPhl p) 11 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 11 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 11 IgE Qn;;ACTIVE;2.04;2.42 +31001-1;Parietaria judaica Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pellitory (Parietaria judaica) IgE Ab RAST class [Presence] in Serum;Pellitory (judaic) IgE RAST Ql;;ACTIVE;2.04;2.58 +31002-9;Phoenix dactylifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dates IgE Ab [Units/volume] in Serum;Dates IgE Qn;;ACTIVE;2.04;2.73 +31003-7;(Bromus inermis+Cynodon dactylon+Holcus lanatus+Lolium perenne+Paspalum notatum+Sorghum halepense) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 6 (Brome+Bermuda grass+Velvet grass+Perennial rye grass+Bahia grass+Johnson grass) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix 6 IgE Ql;;ACTIVE;2.04;2.56 +31004-5;(Staphylococcus aureus enterotoxin A+Staphylococcus aureus enterotoxin B) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 3 (Staphylococcus aureus enterotoxin A+Staphylococcus aureus enterotoxin B) IgE Ab [Presence] in Serum by Multidisk;Mold Allerg Mix3 IgE Ql;;ACTIVE;2.04;2.56 +3100-5;Uridyl transferase;CCnc;Pt;RBC;Qn;;CHEM;1;Uridyl transferase [Enzymatic activity/volume] in Red Blood Cells;Uridyl Transferase RBC-cCnc;;ACTIVE;1.0;2.73 +31005-2;(Budgerigar feather+Canary feather+Parrot feather+Finch feather) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix B (Budgerigar feather+Canary feather+Parrot feather+Finch feather) IgE Ab [Presence] in Serum by Multidisk;Epid Allerg Mix B IgE Ql;;ACTIVE;2.04;2.56 +31006-0;(Ananas comosus+ Citrus limon+ Fragaria vesca+ Pyrus communis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 16 (Pineapple+Lemon+Strawberry+Pear) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix16 IgE Ql;;ACTIVE;2.04;2.73 +31007-8;(Beef+Chicken meat+Pork+Turkey meat) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 23 (Beef+Chicken meat+Pork+Turkey meat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix23 IgE Ql;;ACTIVE;2.04;2.56 +31008-6;(Actinidia chinensis+Corylus avellana+Musa spp+Pandalus borealis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 24 (Kiwi+Hazelnut+Banana+Shrimp) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix24 IgE Ql;;ACTIVE;2.04;2.56 +31009-4;(Allium cepa+Allium sativum+Sesamum indicum+Yeast) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 25A (Onion+Garlic+Sesame seed+Yeast) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix25A IgE Ql;;ACTIVE;2.04;2.58 +31010-2;(Artemisia dracunculus+Levisticum officinale+Origanum majorana+Thymus vulgaris) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 70 (Tarragon+Lovage+Marjoram+Thyme) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix70 IgE Ql;;ACTIVE;2.04;2.56 +31011-0;Sardinops melanostictus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sardine (Sardinops melanosticta) IgE Ab RAST class [Presence] in Serum;Sardine (melanost) IgE RAST Ql;;ACTIVE;2.04;2.73 +31012-8;Vancomycin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Moles/volume] in Serum or Plasma;Vancomycin SerPl-sCnc;;ACTIVE;2.04;2.73 +3101-3;Uridyl transferase;CCnt;Pt;Tiss;Qn;;CHEM;1;Uridyl transferase [Enzymatic activity/mass] in Tissue;Uridyl Transferase Tiss-cCnt;;ACTIVE;1.0;2.42 +31013-6;Dehydrochlormethyltestosterone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dehydrochlormethyltestosterone [Mass/volume] in Urine;DehydrochlormeT Ur-mCnc;;ACTIVE;2.04;2.70 +31014-4;Corynebacterium diphtheriae Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae Ab [Units/volume] in Serum --2nd specimen;C diphtheriae Ab sp2 Ser-aCnc;;ACTIVE;2.04;2.70 +31015-1;Ethylestrenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethylestrenol [Mass/volume] in Urine;Ethylestrenol Ur-mCnc;;ACTIVE;2.04;2.70 +31016-9;Levoamphetamine/Amphetamines.total;MFr;Pt;Urine;Qn;;DRUG/TOX;1;Levoamphetamine/Amphetamines.total in Urine;L-amphet MFr Ur;;ACTIVE;2.04;2.70 +31017-7;Tissue transglutaminase Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Tissue transglutaminase IgA Ab [Units/volume] in Serum;tTG IgA Ser-aCnc;;ACTIVE;2.04;2.73 +31018-5;Haemophilus influenzae B Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae B IgG Ab [Mass/volume] in Serum --2nd specimen;Haem influ B IgG sp2 Ser-mCnc;;ACTIVE;2.04;2.73 +31019-3;10-Hydroxycarbazepine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;10-Hydroxycarbazepine [Mass/volume] in Serum or Plasma;10OH-Carbazepine SerPl-mCnc;;ACTIVE;2.04;2.73 +31020-1;Dehydroepiandrosterone;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Amniotic fluid;DHEA Amn-mCnc;;ACTIVE;2.04;2.70 +3102-1;Urobilin;MCnc;Pt;Stool;Qn;;CHEM;1;Urobilin [Mass/volume] in Stool;Urobilin Stl-mCnc;;ACTIVE;1.0;2.42 +31021-9;Interferon.beta 1 Ab.Neut;Titr;Pt;Ser/Plas;Qn;Neut;SERO;1;Interferon.beta 1 neutralizing antibody [Titer] in Serum or Plasma by Neutralization test;INF-B1 NAb Titr SerPl Nt;;ACTIVE;2.04;2.72 +31022-7;Filaria identified;Prid;Pt;XXX;Nom;Concentration;MICRO;1;Filaria identified in Specimen by Concentration;Filaria Spec Conc;;ACTIVE;2.04;2.69 +31023-5;Myelin associated glycoprotein Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Myelin associated glycoprotein IgM Ab [Presence] in Serum by Immunoblot;MAG IgM Ser Ql IB;;ACTIVE;2.04;2.73 +31024-3;Voltage-gated calcium channel Ab;SCnc;Pt;Ser;Qn;;SERO;1;Voltage-gated calcium channel Ab [Moles/volume] in Serum;VGCC Ab Ser-sCnc;;ACTIVE;2.04;2.73 +31025-0;Dextroamphetamine/Amphetamines.total;MFr;Pt;Urine;Qn;;DRUG/TOX;1;Dextroamphetamine/Amphetamines.total in Urine;D-amphet MFr Ur;;ACTIVE;2.04;2.70 +31026-8;Dextromethamphetamine/Amphetamines.total;MFr;Pt;Urine;Qn;;DRUG/TOX;1;Dextromethamphetamine/Amphetamines.total in Urine;D-methamphet MFr Ur;;ACTIVE;2.04;2.73 +31027-6;Ritonavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ritonavir [Mass/volume] in Serum or Plasma;Ritonavir SerPl-mCnc;;ACTIVE;2.04;2.73 +31028-4;Amprenavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amprenavir [Mass/volume] in Serum or Plasma;Amprenavir SerPl-mCnc;;ACTIVE;2.04;2.73 +31029-2;Stenbolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Stenbolone [Mass/volume] in Urine;Stenbolone Ur-mCnc;;ACTIVE;2.04;2.70 +310-3;Lymecycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Lymecycline [Susceptibility] by Minimum lethal concentration (MLC);Lymecycline Islt MLC;;ACTIVE;1.0;2.19 +31030-0;Testosterone/Epitestosterone;MRto;Pt;Urine;Qn;;CHEM;1;Testosterone/Epitestosterone [Mass Ratio] in Urine;Testost/Epitestost Ur;;ACTIVE;2.04;2.73 +31031-8;Saccharomyces cerevisiae Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Saccharomyces cerevisiae (Yeast) IgG Ab [Units/volume] in Serum;Deprecated S.cerevisiae IgG Qn;;DEPRECATED;2.04;2.70 +31032-6;Saccharomyces cerevisiae Ab.IgA;ACnc;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast IgA Ab [Units/volume] in Serum;Baker's yeast IgA Qn;;ACTIVE;2.04;2.73 +31033-4;Indinavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Indinavir [Mass/volume] in Serum or Plasma;Indinavir SerPl-mCnc;;ACTIVE;2.04;2.73 +31034-2;Vaccination body site;Anat;Pt;^Patient;Nom;;VACCIN;2;Vaccination body site;Vaccination body site;;ACTIVE;2.04;2.70 +31035-9;Date of other vaccinations given within 4W prior to the date of vaccine causing adverse event;Date;Pt;^Patient;Qn;;VACCIN;2;Date of other vaccinations given within 4 weeks prior to the date of vaccine causing adverse event;Date other vaccines given within 4W;;ACTIVE;2.04;2.50 +31036-7;Gatifloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Gatifloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Gatifloxacin Islt MIC;;ACTIVE;2.05;2.73 +31037-5;Moxifloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Moxifloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Moxifloxacin Islt MIC;;ACTIVE;2.05;2.73 +31038-3;Gatifloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Gatifloxacin [Susceptibility];Gatifloxacin Susc Islt;;ACTIVE;2.05;2.73 +3103-9;Urobilin;PrThr;Pt;Urine;Ord;;CHEM;1;Urobilin [Presence] in Urine;Urobilin Ur Ql;;ACTIVE;1.0;2.56 +31039-1;Moxifloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Moxifloxacin [Susceptibility];Moxifloxacin Susc Islt;;ACTIVE;2.05;2.73 +31040-9;Gatifloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Gatifloxacin [Susceptibility] by Disk diffusion (KB);Gatifloxacin Islt KB;;ACTIVE;2.05;2.19 +31041-7;Moxifloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Moxifloxacin [Susceptibility] by Disk diffusion (KB);Moxifloxacin Islt KB;;ACTIVE;2.05;2.73 +31042-5;Gatifloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Gatifloxacin [Susceptibility] by Gradient strip;Gatifloxacin Islt Grad strip;;ACTIVE;2.05;2.56 +31043-3;Moxifloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Moxifloxacin [Susceptibility] by Gradient strip;Moxifloxacin Islt Grad strip;;ACTIVE;2.05;2.56 +31044-1;Immunization reaction;Find;Pt;^Patient;Nom;;VACCIN;2;Immunization reaction;Immunization reaction;;ACTIVE;2.05;2.52 +31045-8;Creatinine/Urea nitrogen;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine/Urea nitrogen [Mass Ratio] in Serum or Plasma;Creat/Urea nit SerPl;;ACTIVE;2.07;2.73 +31046-6;Rheumatoid factor;PrThr;Pt;Body fld;Ord;;SERO;1;Rheumatoid factor [Presence] in Body fluid;Rheumatoid fact Fld Ql;;ACTIVE;2.07;2.56 +3104-7;Urobilin;MCnc;Pt;Urine;Qn;;CHEM;1;Urobilin [Mass/volume] in Urine;Urobilin Ur-mCnc;;ACTIVE;1.0;2.42 +31047-4;Rubella virus Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Rubella virus IgM Ab [Units/volume] in Body fluid;RUBV IgM Fld-aCnc;;ACTIVE;2.07;2.69 +31048-2;Coccidioides immitis Ab;PrThr;Pt;Body fld;Ord;Comp fix;MICRO;1;Coccidioides immitis Ab [Presence] in Body fluid by Complement fixation;C immitis Ab Fld Ql CF;;ACTIVE;2.07;2.56 +31049-0;Coxsackievirus A7 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus A7 Ab [Titer] in Body fluid by Complement fixation;CV A7 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31050-8;Coxsackievirus A9 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus A9 Ab [Titer] in Body fluid by Complement fixation;CV A9 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31051-6;Coxsackievirus A10 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus A10 Ab [Titer] in Body fluid by Complement fixation;CV A10 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31052-4;Coxsackievirus A16 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus A16 Ab [Titer] in Body fluid by Complement fixation;CV A16 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31053-2;Coxsackievirus B1 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus B1 Ab [Titer] in Body fluid by Complement fixation;CV B1 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +3105-4;Urobilinogen;PrThr;Pt;Stool;Ord;;CHEM;1;Urobilinogen [Presence] in Stool;Urobilinogen Stl Ql;;ACTIVE;1.0;2.56 +31054-0;Coxsackievirus B2 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus B2 Ab [Titer] in Body fluid by Complement fixation;CV B2 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31055-7;Coxsackievirus B3 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus B3 Ab [Titer] in Body fluid by Complement fixation;CV B3 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31056-5;Coxsackievirus B4 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus B4 Ab [Titer] in Body fluid by Complement fixation;CV B4 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31057-3;Coxsackievirus B5 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus B5 Ab [Titer] in Body fluid by Complement fixation;CV B5 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31058-1;Coxsackievirus B6 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coxsackievirus B6 Ab [Titer] in Body fluid by Complement fixation;CV B6 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31059-9;Echovirus 4 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Echovirus 4 Ab [Titer] in Body fluid by Complement fixation;ECV4 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31060-7;Echovirus 9 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Echovirus 9 Ab [Titer] in Body fluid by Complement fixation;ECV9 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31061-5;Echovirus 11 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Echovirus 11 Ab [Titer] in Body fluid by Complement fixation;ECV11 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +3106-2;Urobilinogen;MCnc;Pt;Stool;Qn;;CHEM;1;Urobilinogen [Mass/volume] in Stool;Urobilinogen Stl-mCnc;;ACTIVE;1.0;2.34 +31062-3;Echovirus 30 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Echovirus 30 Ab [Titer] in Body fluid by Complement fixation;ECV30 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31063-1;Polio virus 1 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Polio virus 1 Ab [Titer] in Body fluid by Complement fixation;PV1 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31064-9;Polio virus 2 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Polio virus 2 Ab [Titer] in Body fluid by Complement fixation;PV2 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31065-6;Polio virus 3 Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Polio virus 3 Ab [Titer] in Body fluid by Complement fixation;PV3 Ab Titr Fld CF;;ACTIVE;2.07;2.30 +31066-4;Herpes simplex virus 1 Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Herpes simplex virus 1 IgG Ab [Units/volume] in Body fluid;HSV1 IgG Fld-aCnc;;ACTIVE;2.07;2.69 +31067-2;Herpes simplex virus 2 Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Body fluid;HSV2 IgG Fld-aCnc;;ACTIVE;2.07;2.73 +31068-0;Herpes simplex virus 1 Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Herpes simplex virus 1 IgM Ab [Units/volume] in Body fluid;HSV1 IgM Fld-aCnc;;ACTIVE;2.07;2.69 +31069-8;Herpes simplex virus 2 Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Herpes simplex virus 2 IgM Ab [Titer] in Body fluid by Immunofluorescence;HSV2 IgM Titr Fld IF;;ACTIVE;2.07;2.30 +3107-0;Urobilinogen;MCnc;Pt;Urine;Qn;;CHEM;1;Urobilinogen [Mass/volume] in Urine;Urobilinogen Ur-mCnc;;ACTIVE;1.0;2.73 +31070-6;Histoplasma capsulatum yeast phase Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Histoplasma capsulatum yeast phase Ab [Titer] in Body fluid by Complement fixation;H capsul Yst Ab Titr Fld CF;;ACTIVE;2.07;2.34 +31071-4;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Body fluid by Complement fixation;H capsul Myc Ab Titr Fld CF;;ACTIVE;2.07;2.34 +31072-2;HIV 1 p41 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p41 Ab [Presence] in Serum by Immunoblot;HIV1 p41 Ab Ser Ql IB;;ACTIVE;2.07;2.58 +31073-0;HIV 2 Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;HIV 2 Ab band pattern [Interpretation] in Serum by Immunoblot;HIV 2 Ab Patrn Ser IB-Imp;;ACTIVE;2.07;2.58 +31074-8;Cells.CD30;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD30 cells [#/volume] in Blood;CD30 Cells # Bld;;ACTIVE;2.07;2.70 +31075-5;Legionella pneumophila 1 Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Legionella pneumophila 1 IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;L pneumo1 IgM Titr CSF IF;;ACTIVE;2.07;2.30 +31076-3;Rickettsia typhi Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Body fluid;R typhi IgG Titr Fld;;ACTIVE;2.07;2.30 +31077-1;Rickettsia typhi Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia typhi IgM Ab [Titer] in Body fluid;R typhi IgM Titr Fld;;ACTIVE;2.07;2.30 +31078-9;Casuarina equisetifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Australian pine IgE Ab RAST class [Presence] in Serum;Australian pine IgE RAST Ql;;ACTIVE;2.07;2.73 +31079-7;Gerbil epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Gerbil epithelium IgE Ab RAST class [Presence] in Serum;Gerbil Epith IgE RAST Ql;;ACTIVE;2.07;2.73 +31080-5;Cannabinoids;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Meconium by Screen method;Cannabinoids Mec Ql Scn;;ACTIVE;2.07;2.73 +31081-3;Benzodiazepines;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Benzodiazepines [Presence] in Meconium by Screen method;Benzodiaz Mec Ql Scn;;ACTIVE;2.07;2.73 +31082-1;Ethylene glycol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Ethylene glycol [Mass/volume] in Gastric fluid;Ethylene Glycol Gast-mCnc;;ACTIVE;2.07;2.70 +31083-9;Lead;MRat;8H;Urine;Qn;;DRUG/TOX;1;Lead [Mass/time] in 8 hour Urine;Lead 8h Ur-mRate;;ACTIVE;2.07;2.70 +31084-7;Methadone;MCnc;Pt;Bil fld;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Bile fluid;Methadone Bifl-mCnc;;ACTIVE;2.07;2.70 +31085-4;Methaqualone;MCnc;Pt;Bil fld;Qn;;DRUG/TOX;1;Methaqualone [Mass/volume] in Bile fluid;Methaqualone Bifl-mCnc;;ACTIVE;2.07;2.70 +31086-2;Morphine.free;MCnc;Pt;Bil fld;Qn;;DRUG/TOX;1;Morphine Free [Mass/volume] in Bile fluid;Morphine Free Bifl-mCnc;;ACTIVE;2.07;2.70 +31087-0;Thioridazine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Thioridazine [Mass/volume] in Gastric fluid;Thioridazine Gast-mCnc;;ACTIVE;2.07;2.70 +3108-8;Urobilinogen;MRat;24H;Urine;Qn;;CHEM;1;Urobilinogen [Mass/time] in 24 hour Urine;Urobilinogen 24h Ur-mRate;;ACTIVE;1.0;2.73 +31088-8;Narcotics;Prid;Pt;Bil fld;Nom;;DRUG/TOX;1;Narcotics and opioids [Identifier] in Bile fluid;Narcotics Bifl;;ACTIVE;2.07;2.22 +31089-6;Acetaminophen;PrThr;Pt;Bil fld;Ord;;DRUG/TOX;1;Acetaminophen [Presence] in Bile fluid;APAP Bifl Ql;;ACTIVE;2.07;2.56 +31090-4;Ethchlorvynol;PrThr;Pt;Bil fld;Ord;;DRUG/TOX;1;Ethchlorvynol [Presence] in Bile fluid;Ethchlorvynol Bifl Ql;;ACTIVE;2.07;2.56 +31091-2;Gentamicin^peak post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma --peak post extended interval dosing;Gentamicin Pk EID SerPl-mCnc;;ACTIVE;2.07;2.73 +31092-0;Gentamicin^trough post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma --trough post extended interval dosing;Gentamicin Trough EID SerPl-mCnc;;ACTIVE;2.07;2.73 +31093-8;Gentamicin^random post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma --random post extended interval dosing;Gentamicin Rand EID SerPl-mCnc;;ACTIVE;2.07;2.73 +31094-6;Tobramycin^peak post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma --peak post extended interval dosing;Tobramycin Pk EID SerPl-mCnc;;ACTIVE;2.07;2.73 +31095-3;Tobramycin^trough post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma --trough post extended interval dosing;Tobramycin Trough EID SerPl-mCnc;;ACTIVE;2.07;2.40 +3109-6;Urobilinogen;MRat;2H;Urine;Qn;;CHEM;1;Urobilinogen [Mass/time] in 2 hour Urine;Urobilinogen 2h Ur-mRate;;ACTIVE;1.0;2.42 +31096-1;Tobramycin^random post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma --random post extended interval dosing;Tobramycin Rand EID SerPl-mCnc;;ACTIVE;2.07;2.73 +31097-9;Amikacin^peak post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma --peak post extended interval dosing;Amikacin Pk EID SerPl-mCnc;;ACTIVE;2.07;2.40 +31098-7;Amikacin^trough post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma --trough post extended interval dosing;Amikacin Trough EID SerPl-mCnc;;ACTIVE;2.07;2.40 +31099-5;Amikacin^random post extended interval dosing;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma --random post extended interval dosing;Amikacin Rand EID SerPl-mCnc;;ACTIVE;2.07;2.40 +31100-1;Hematocrit;VFr;Pt;Bld;Qn;Impedance;HEM/BC;1;Hematocrit [Volume Fraction] of Blood by Impedance;Hct VFr Bld Imped;;ACTIVE;2.07;2.73 +31101-9;Creatinine;MRat;24H;Body fld;Qn;;CHEM;1;Creatinine [Mass/time] in 24 hour Body fluid;Creat 24h Fld-mRate;;ACTIVE;2.07;2.73 +31102-7;Protein S actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Protein S actual/normal in Platelet poor plasma by Chromogenic method;Prot S Act/Nor PPP Chro;;ACTIVE;2.07;2.73 +31103-5;Osmotic fragility^0.0% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.0% sodium chloride 24 hour 37 degree C incubation;OF 0% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.70 +3110-4;Uronate;MCnc;Pt;Urine;Qn;;CHEM;1;Uronate [Mass/volume] in Urine;Uronate Ur-mCnc;;ACTIVE;1.0;2.42 +31104-3;Osmotic fragility^0.85% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.85% sodium chloride 24 hour 37 degree C incubation;OF .85% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.73 +31105-0;Osmotic fragility^0.55% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.55% sodium chloride 24 hour 37 degree C incubation;OF .55% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.73 +31106-8;Osmotic fragility^0.50% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.50% sodium chloride 24 hour 37 degree C incubation;OF .50% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.73 +31107-6;Osmotic fragility^0.45% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.45% sodium chloride 24 hour 37 degree C incubation;OF .45% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.73 +31108-4;Osmotic fragility^0.40% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.40% sodium chloride 24 hour 37 degree C incubation;OF .40% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.73 +31109-2;Osmotic fragility^0.35% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.35% sodium chloride 24 hour 37 degree C incubation;OF .35% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.73 +311-1;Lymecycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Lymecycline [Susceptibility] by Minimum inhibitory concentration (MIC);Lymecycline Islt MIC;;ACTIVE;1.0;2.19 +31110-0;Osmotic fragility^0.30% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.30% sodium chloride 24 hour 37 degree C incubation;OF .30% NaCl 24h Inc NFr RBC;;ACTIVE;2.07;2.73 +31111-8;Reticulocytes/100 erythrocytes^^hematocrit adjusted;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocyte production index;Reticulocyte production index;;ACTIVE;2.07;2.73 +3111-2;Uroporphyrin 1 isomer;MCnc;Pt;RBC;Qn;;CHEM;1;Uroporphyrin 1 isomer [Mass/volume] in Red Blood Cells;Uropor1 RBC-mCnc;;ACTIVE;1.0;2.73 +31112-6;Reticulocytes/100 erythrocytes;NFr;Pt;Bld;Qn;Manual;HEM/BC;1;Reticulocytes/100 erythrocytes in Blood by Manual;Retics/100 RBC NFr Manual;;ACTIVE;2.07;2.73 +31113-4;Cells.HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;HLA-DR+ cells/100 cells in Blood;HLA-DR+ Cells NFr Bld;;ACTIVE;2.07;2.73 +31114-2;Cells.aneuploid.population 1/100 cells;NFr;Pt;XXX;Qn;;MOLPATH;1;Aneuploid cell population 1/100 cells in Specimen;Aneuploid cells pop 1 NFr Spec;;ACTIVE;2.07;2.70 +31115-9;Cells.aneuploid.population 2/100 cells;NFr;Pt;XXX;Qn;;MOLPATH;1;Aneuploid cell population 2/100 cells in Specimen;Aneuploid cells pop 2 NFr Spec;;ACTIVE;2.07;2.70 +31116-7;Cells.euploid+Cells.aneuploid.population 1/100 cells;NFr;Pt;XXX;Qn;;MOLPATH;1;Euploid+Aneuploid cells population 1/100 cells in Specimen;Euploid+Aneuploid Pop1 NFr Spec;;ACTIVE;2.07;2.70 +31117-5;Cells.euploid+Cells.aneuploid.population 2/100 cells;NFr;Pt;XXX;Qn;;MOLPATH;1;Euploid+Aneuploid cells population 2/100 cells in Specimen;Euploid+Aneuploid Pop2 NFr Spec;;ACTIVE;2.07;2.70 +31118-3;Cells.G2+M phase/100 cells;NFr;Pt;XXX;Qn;;MOLPATH;1;G2+M phase cells/100 cells in Specimen;G2+M Phs Cells NFr Spec;;ACTIVE;2.07;2.70 +31119-1;Cells.CD227/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD227 cells/100 cells in Blood;CD227 Cells NFr Bld;;ACTIVE;2.07;2.70 +3112-0;Uroporphyrin;PrThr;Pt;Urine;Ord;;CHEM;1;Uroporphyrin [Presence] in Urine;Uropor Ur Ql;;ACTIVE;1.0;2.56 +31120-9;Cells.CD227;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD227 cells [#/volume] in Blood;CD227 Cells # Bld;;ACTIVE;2.07;2.70 +31121-7;Cells.CD235a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD235a cells/100 cells in Blood;Deprecated CD235a Cells Fr Bld;;DEPRECATED;2.07;2.70 +31122-5;Cells.CD235a;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD235a cells [#/volume] in Blood;CD235a Cells # Bld;;ACTIVE;2.07;2.70 +31123-3;Cells.CD25;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD25 cells [#/volume] in Blood;CD25 Cells # Bld;;ACTIVE;2.07;2.73 +31124-1;Cells.CD20+CD25+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20+CD25+ cells/100 cells in Blood;CD20+CD25+ Cells NFr Bld;;ACTIVE;2.07;2.70 +31125-8;Cells.CD20+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD20+CD25+ cells [#/volume] in Blood;CD20+CD25+ Cells # Bld;;ACTIVE;2.07;2.70 +31126-6;Cells.CD20+CD25-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20+CD25- cells/100 cells in Blood;CD20+CD25- Cells NFr Bld;;ACTIVE;2.07;2.70 +31127-4;Cells.CD20+CD25-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD20+CD25- cells [#/volume] in Blood;CD20+CD25- Cells # Bld;;ACTIVE;2.07;2.70 +31128-2;Cells.CD11c-CD20+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11c-CD20+ cells/100 cells in Blood;CD11c-CD20+ Cells NFr Bld;;ACTIVE;2.07;2.70 +31129-0;Cells.CD11c-CD20+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD11c-CD20+ cells [#/volume] in Blood;CD11c-CD20+ Cells # Bld;;ACTIVE;2.07;2.70 +31130-8;Mumps virus soluble Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mumps virus soluble Ab [Titer] in Serum;MuV S Ab Titr Ser;;ACTIVE;2.07;2.30 +31131-6;Mumps virus particle-bound Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mumps virus particle-bound Ab [Titer] in Serum;MuV V Ab Titr Ser;;ACTIVE;2.07;2.52 +31132-4;Mumps virus soluble Ab;Titr;Pt;CSF;Qn;;MICRO;1;Mumps virus soluble Ab [Titer] in Cerebral spinal fluid;MuV S Ab Titr CSF;;ACTIVE;2.07;2.30 +31133-2;Mumps virus particle-bound Ab;Titr;Pt;CSF;Qn;;MICRO;1;Mumps virus particle-bound Ab [Titer] in Cerebral spinal fluid;MuV V Ab Titr CSF;;ACTIVE;2.07;2.52 +31134-0;Nuclear matrix protein 22;ACnc;Pt;Urine;Qn;;SERO;1;Nuclear matrix protein 22 [Units/volume] in Urine;NMP22 Ur-aCnc;;ACTIVE;2.07;2.73 +31135-7;Cocaethylene;MCnc;Pt;Bil fld;Qn;;DRUG/TOX;1;Cocaethylene [Mass/volume] in Bile fluid;Cocaethylene Bifl-mCnc;;ACTIVE;2.07;2.70 +31136-5;Carboxy tetrahydrocannabinol;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/mass] in Meconium;CarboxyTHC Mec-mCnt;;ACTIVE;2.07;2.73 +31137-3;Cocaine;MCnc;Pt;Bil fld;Qn;;DRUG/TOX;1;Cocaine [Mass/volume] in Bile fluid;Cocaine Bifl-mCnc;;ACTIVE;2.07;2.70 +3113-8;Uroporphyrin;MRat;24H;Urine;Qn;;CHEM;1;Uroporphyrin [Mass/time] in 24 hour Urine;Uropor 24h Ur-mRate;;ACTIVE;1.0;2.73 +31138-1;Cefotaxime;Susc;Pt;Isolate.meningitis;OrdQn;MIC;ABXBACT;1;Cefotaxime [Susceptibility] for meningitis by Minimum inhibitory concentration (MIC);Cefotaxime Islt.mening MIC;;ACTIVE;2.07;2.73 +31139-9;Cefotaxime;Susc;Pt;Isolate.meningitis;OrdQn;Gradient strip;ABXBACT;1;Cefotaxime [Susceptibility] for meningitis by Gradient strip;Cefotaxime Islt.mening Grad strip;;ACTIVE;2.07;2.58 +31140-7;cefTRIAXone;Susc;Pt;Isolate.meningitis;OrdQn;MIC;ABXBACT;1;cefTRIAXone [Susceptibility] for meningitis by Minimum inhibitory concentration (MIC);cefTRIAXone Islt.mening MIC;;ACTIVE;2.07;2.73 +31141-5;cefTRIAXone;Susc;Pt;Isolate.meningitis;OrdQn;Gradient strip;ABXBACT;1;cefTRIAXone [Susceptibility] for meningitis by Gradient strip;cefTRIAXone Islt.mening Grad strip;;ACTIVE;2.07;2.73 +31142-3;Cefepime;Susc;Pt;Isolate.meningitis;OrdQn;MIC;ABXBACT;1;Cefepime [Susceptibility] for meningitis by Minimum inhibitory concentration (MIC);Cefepime Islt.mening MIC;;ACTIVE;2.07;2.58 +31143-1;Cefepime;Susc;Pt;Isolate.meningitis;OrdQn;Gradient strip;ABXBACT;1;Cefepime [Susceptibility] for meningitis by Gradient strip;Cefepime Islt.mening Grad strip;;ACTIVE;2.07;2.58 +31144-9;Thyroxine;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Thyroxine (T4) [Mass/volume] in DBS;T4 DBS-mCnc;;ACTIVE;2.07;2.73 +31145-6;Thyroxine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Thyroxine (T4) [Moles/volume] in DBS;T4 DBS-sCnc;;ACTIVE;2.07;2.73 +3114-6;Uroporphyrinogen decarboxylase;CCnc;Pt;Plas;Qn;;CHEM;1;Uroporphyrinogen decarboxylase [Enzymatic activity/volume] in Plasma;URO-D Plas-cCnc;;ACTIVE;1.0;2.68 +31146-4;Reagin Ab;Titr;Pt;CSF;Qn;VDRL;MICRO;1;Reagin Ab [Titer] in Cerebral spinal fluid by VDRL;VDRL CSF-Titr;;ACTIVE;2.07;2.73 +31147-2;Reagin Ab;Titr;Pt;Ser;Qn;RPR;MICRO;1;Reagin Ab [Titer] in Serum by RPR;RPR Ser-Titr;;ACTIVE;2.07;2.73 +31148-0;Heavy metals;Prid;Pt;Tiss;Nom;;DRUG/TOX;1;Heavy metals [Identifier] in Tissue;Heavy Metals Tiss;;ACTIVE;2.07;2.73 +31149-8;P53 protein Ag/100 cells;NFr;Pt;Tiss;Qn;Immune stain;PATH;1;P53 protein Ag/100 cells in Tissue by Immune stain;P53 protein Ag NFr Tiss ImStn;;ACTIVE;2.07;2.70 +31150-6;ERBB2 gene duplication;PrThr;Pt;Tiss;Ord;FISH;MOLPATH;1;ERBB2 gene duplication [Presence] in Tissue by FISH;ERBB2 gene Dp Tiss Ql FISH;;ACTIVE;2.07;2.73 +31151-4;Alpha-2-Microglobulin;MCnc;24H;Urine;Qn;;CHEM;1;Alpha-2-Microglobulin [Mass/volume] in 24 hour Urine;A2 Microglob 24h Ur-mCnc;;ACTIVE;2.07;2.73 +31152-2;Immunoglobulin light chains;PrThr;24H;Urine;Ord;;CHEM;1;Immunoglobulin light chains [Presence] in 24 hour Urine;BJ Protein 24h Ur Ql;;ACTIVE;2.07;2.70 +3115-3;Uroporphyrinogen III synthase;CCnc;Pt;Plas;Qn;;CHEM;1;Uroporphyrinogen III synthase [Enzymatic activity/volume] in Plasma;URO-S Plas-cCnc;;ACTIVE;1.0;2.68 +31153-0;Coccidioides sp Ab;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Coccidioides sp Ab [Presence] in Specimen by Immune diffusion (ID);Coccidioides Ab Spec Ql ID;;ACTIVE;2.07;2.73 +31154-8;Coccidioides sp Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Coccidioides sp IgG Ab [Presence] in Specimen by Immunoassay;Coccidioides IgG Spec Ql IA;;ACTIVE;2.07;2.73 +31155-5;Borrelia burgdorferi Ab;ACnc;Pt;XXX;Qn;IA;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Specimen by Immunoassay;B burgdor Ab Spec IA-aCnc;;ACTIVE;2.07;2.73 +31156-3;Hemoglobin Barts/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin Barts/Hemoglobin.total in Blood;Hgb Barts MFr Bld;;ACTIVE;2.07;2.73 +31157-1;Carboxyhemoglobin;MCnc;Pt;Bld;Qn;;CHEM;1;Carboxyhemoglobin [Mass/volume] in Blood;COHgb Bld-mCnc;;ACTIVE;2.07;2.73 +31158-9;Fibrinogen Ag/Fibrinogen;MRto;Pt;PPP;Qn;;COAG;1;Fibrinogen Ag/Fibrinogen [Mass Ratio] in Platelet poor plasma;Fibrinogen Ag/Func PPP;;ACTIVE;2.07;2.73 +31159-7;Heparin anti Xa;ACnc;Pt;Flu.nonbiological;Qn;;COAG;1;Heparin anti Xa [Units/volume] in Nonbiological fluid;Heparin Anti Xa Fld.NB-aCnc;;ACTIVE;2.07;2.73 +31160-5;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Blood by Manual count;Polys/leuk NFr Bld Manual;;ACTIVE;2.07;2.73 +3116-1;Valine;MCnc;Pt;CSF;Qn;;CHEM;1;Valine [Mass/volume] in Cerebral spinal fluid;Valine CSF-mCnc;;ACTIVE;1.0;2.42 +31161-3;(Chicken feather+Duck feather+Goose feather+Parrot feather) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 73 (Chicken feather+Duck feather+Goose feather+Parrot feather) IgE Ab [Units/volume] in Serum by Multidisk;Epid Allerg Mix73 IgE Qn;;ACTIVE;2.07;2.73 +31162-1;Sulfate-3-Glucuronyl paragloboside Ab;Titr;Pt;Ser;Qn;;SERO;1;Sulfate-3-Glucuronyl paragloboside Ab [Titer] in Serum;SGPG Ab Titr Ser;;ACTIVE;2.07;2.73 +31163-9;Ganglioside GD1b Ab;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GD1b Ab [Titer] in Serum;GD1b Gangl Ab Titr Ser;;ACTIVE;2.07;2.73 +31164-7;Ganglioside GQ1b Ab;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GQ1b Ab [Titer] in Serum;GQ1b Gangl Ab Titr Ser;;ACTIVE;2.07;2.73 +31165-4;Methyl butyl ketone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl butyl ketone [Mass/volume] in Urine;MNBK Ur-mCnc;;ACTIVE;2.07;2.73 +31166-2;Methyl isoamyl ketone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl isoamyl ketone [Mass/volume] in Urine;MIAK Ur-mCnc;;ACTIVE;2.07;2.73 +31167-0;Methyl propyl ketone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl propyl ketone [Mass/volume] in Urine;MPK Ur-mCnc;;ACTIVE;2.07;2.73 +31168-8;Mesityl oxide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mesityl oxide [Mass/volume] in Urine;Mesityl Oxide Ur-mCnc;;ACTIVE;2.07;2.73 +31169-6;Theobromine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theobromine [Mass/volume] in Serum or Plasma;Theobromine SerPl-mCnc;;ACTIVE;2.07;2.73 +31170-4;2,5-Hexanedione;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2,5-Hexanedione [Mass/volume] in Urine;2,5Hexanedione Ur-mCnc;;ACTIVE;2.07;2.70 +31171-2;2,5-Hexanedione/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;2,5-Hexanedione/Creatinine [Mass Ratio] in Urine;2,5Hexanedione/Creat Ur;;ACTIVE;2.07;2.70 +31172-0;Fonofos;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Fonofos [Mass/volume] in Blood;Fonofos Bld-mCnc;;ACTIVE;2.07;2.73 +31173-8;Mevinphos;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Mevinphos [Mass/volume] in Blood;Mevinphos Bld-mCnc;;ACTIVE;2.07;2.73 +31174-6;Terbufos;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Terbufos [Mass/volume] in Blood;Terbufos Bld-mCnc;;ACTIVE;2.07;2.73 +31175-3;Metasystox;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Metasystox [Mass/volume] in Blood;Metasystox Bld-mCnc;;ACTIVE;2.07;2.73 +31176-1;Estradiol;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Estradiol (E2) [Mass/volume] in Amniotic fluid;Estradiol Amn-mCnc;;ACTIVE;2.07;2.70 +31177-9;Estrone;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Estrone (E1) [Mass/volume] in Amniotic fluid;Estrone Amn-mCnc;;ACTIVE;2.07;2.70 +31178-7;Toxoplasma gondii Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Toxoplasma gondii IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;T gondii IgM CSF IA-aCnc;;ACTIVE;2.07;2.73 +3117-9;Valine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Valine [Presence] in Serum or Plasma;Valine SerPl Ql;;ACTIVE;1.0;2.73 +31179-5;Lopinavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lopinavir [Mass/volume] in Serum or Plasma;Lopinavir SerPl-mCnc;;ACTIVE;2.07;2.73 +31180-3;Toxoplasma gondii Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Deprecated Toxoplasma gondii IgM Ab [Units/volume] in Cerebral spinal fluid;Deprecated T gondii IgM CSF-aCnc;;DEPRECATED;2.07;2.70 +31181-1;Toxoplasma gondii Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Toxoplasma gondii IgM Ab [Presence] in Cerebral spinal fluid;T gondii IgM CSF Ql;;ACTIVE;2.07;2.56 +31182-9;7-Aminonitrazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;7-Aminonitrazepam [Mass/volume] in Serum or Plasma;7Aminonitrazepam SerPl-mCnc;;ACTIVE;2.07;2.70 +31183-7;Streptococcus pneumoniae 5 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 5 IgG Ab [Mass/volume] in Serum;Deprecated S pneum5 IgG Ser-mCnc;;DEPRECATED;2.07;2.66 +31184-5;Methyl amyl ketone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl amyl ketone [Mass/volume] in Urine;MAK Ur-mCnc;;ACTIVE;2.07;2.73 +31185-2;Platelet Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Platelet IgA Ab [Presence] in Serum;Platelet IgA Ser Ql;;ACTIVE;2.07;2.73 +31186-0;Platelet Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Platelet IgM Ab [Presence] in Serum;Platelet IgM Ser Ql;;ACTIVE;2.07;2.73 +3118-7;Valine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Valine [Mass/volume] in Serum or Plasma;Valine SerPl-mCnc;;ACTIVE;1.0;2.73 +31187-8;Microscopic observation;Prid;Pt;Lymph node.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Lymph node fine needle aspirate by Cyto stain;Cyto LN FNA;;ACTIVE;2.07;2.19 +31188-6;Microscopic observation;Prid;Pt;Kidney.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Kidney fine needle aspirate by Cyto stain;Cyto Kidney FNA;;ACTIVE;2.07;2.19 +31189-4;Microscopic observation;Prid;Pt;Neck mass.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Neck mass fine needle aspirate by Cyto stain;Cyto Neck Mass FNA;;ACTIVE;2.07;2.73 +31190-2;Microscopic observation;Prid;Pt;Salivary gland.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Salivary gland fine needle aspirate by Cyto stain;Cyto Salivary gland FNA;;ACTIVE;2.07;2.19 +31191-0;Microscopic observation;Prid;Pt;Prostate.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Prostate fine needle aspirate by Cyto stain;Cyto Prostate FNA;;ACTIVE;2.07;2.19 +31192-8;Microscopic observation;Prid;Pt;Liver.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Liver fine needle aspirate by Cyto stain;Cyto Liver FNA;;ACTIVE;2.07;2.19 +31193-6;Microscopic observation;Prid;Pt;Pancreas.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Pancreas fine needle aspirate by Cyto stain;Cyto Panc FNA;;ACTIVE;2.07;2.19 +31194-4;Microscopic observation;Prid;Pt;Submandibular.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Submandibular fine needle aspirate by Cyto stain;Cyto Submandib FNA;;ACTIVE;2.07;2.19 +3119-5;Valine;MCnc;Pt;Urine;Qn;;CHEM;1;Valine [Mass/volume] in Urine;Valine Ur-mCnc;;ACTIVE;1.0;2.73 +31195-1;Microscopic observation;Prid;Pt;Soft tissue.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Soft tissue fine needle aspirate by Cyto stain;Cyto Soft Tiss FNA;;ACTIVE;2.07;2.19 +31196-9;Microscopic observation;Prid;Pt;Abdomen.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Abdomen fine needle aspirate by Cyto stain;Cyto Abdomen FNA;;ACTIVE;2.07;2.19 +31197-7;Microscopic observation;Prid;Pt;Pelvis.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Pelvis fine needle aspirate by Cyto stain;Cyto Pelvis FNA;;ACTIVE;2.07;2.19 +31198-5;Microscopic observation;Prid;Pt;Parotid.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Parotid fine needle aspirate by Cyto stain;Cyto Parotid FNA;;ACTIVE;2.07;2.19 +31199-3;Microscopic observation;Prid;Pt;Lung.FNA;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Lung fine needle aspirate by Cyto stain;Cyto Lung FNA;;ACTIVE;2.07;2.19 +31200-9;Histoplasma capsulatum Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum IgG Ab [Presence] in Serum;H capsul IgG Ser Ql;;ACTIVE;2.07;2.73 +31201-7;HIV 1+2 Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1+2 Ab [Presence] in Serum or Plasma by Immunoassay;HIV1+2 Ab SerPl Ql IA;;ACTIVE;2.07;2.73 +31202-5;Mycoplasma pneumoniae Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum by Immunofluorescence;M pneumo Ab Titr Ser IF;;ACTIVE;2.07;2.16 +3120-3;Valine;MRat;24H;Urine;Qn;;CHEM;1;Valine [Mass/time] in 24 hour Urine;Valine 24h Ur-mRate;;ACTIVE;1.0;2.73 +31203-3;5-Hydroxyindoleacetate;MCnc;24H;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate [Mass/volume] in 24 hour Urine;5OH-indoleacetate 24h Ur-mCnc;;ACTIVE;2.07;2.73 +31204-1;Hepatitis B virus core Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus core IgM Ab [Presence] in Serum;HBV core IgM Ser Ql;;ACTIVE;2.07;2.73 +31205-8;Histology ICD-O-3;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Histology ICD-O-3 Cancer;Histology ICD-O-3 Cancer;;ACTIVE;2.07;2.27 +31206-6;Behavior ICD-O-3;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Behavior ICD-O-3 Cancer;Behavior ICD-O-3 Cancer;;ACTIVE;2.07;2.73 +31207-4;Progesterone receptor;SCnt;Pt;Tiss;Qn;;PATH;1;Progesterone receptor [Moles/mass] in Tissue;PR Tiss-sCnt;;ACTIVE;2.07;2.70 +31208-2;Specimen source;Prid;Pt;XXX;Nom;;SPEC;1;Specimen source identified;Specimen source;;ACTIVE;2.07;2.73 +31209-0;Islet cell 512 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Islet cell 512 Ab [Units/volume] in Serum;Islet Cell512 Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31210-8;Vital status;Type;Pt;^Patient;Nom;NAACCR;TUMRRGT;2;Vital status NAACCR;Vital status;;ACTIVE;2.07;2.48 +3121-1;Vanillylmandelate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vanillylmandelate [Mass/volume] in Serum or Plasma;VMA SerPl-mCnc;;ACTIVE;1.0;2.68 +31211-6;Date of death;TmStp;Pt;^Patient;Qn;;TUMRRGT;2;Date of death;Date of death;;DISCOURAGED;2.07;2.56 +31212-4;Actinobacillus pleuropneumoniae serotype 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinobacillus pleuropneumoniae serotype 1 Ab [Presence] in Serum;A pleuropn 1 Ab Ser Ql;;ACTIVE;2.07;2.61 +31213-2;Actinobacillus pleuropneumoniae serotype 3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinobacillus pleuropneumoniae serotype 3 Ab [Presence] in Serum;A pleuropn 3 Ab Ser Ql;;ACTIVE;2.07;2.61 +31214-0;Actinobacillus pleuropneumoniae serotype 5 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinobacillus pleuropneumoniae serotype 5 Ab [Presence] in Serum;A pleuropn 5 Ab Ser Ql;;ACTIVE;2.07;2.61 +31215-7;Actinobacillus pleuropneumoniae serotype 7 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinobacillus pleuropneumoniae serotype 7 Ab [Presence] in Serum;A pleuropn 7 Ab Ser Ql;;ACTIVE;2.07;2.61 +31216-5;Actinobacillus pleuropneumoniae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Actinobacillus pleuropneumoniae Ab [Units/volume] in Serum;A pleuropn Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31217-3;Adenovirus Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Adenovirus Ab [Units/volume] in Body fluid;HAdV Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31218-1;Afipia felis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Afipia felis IgG Ab [Units/volume] in Serum;A felis IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31219-9;Afipia felis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Afipia felis IgM Ab [Units/volume] in Serum;A felis IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31220-7;African horse sickness virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;African horse sickness virus Ab [Units/volume] in Serum;AHSV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31221-5;Alcelaphine herpesvirus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Alcelaphine herpesvirus 1 Ab [Units/volume] in Serum;AHV1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31222-3;Anaplasma marginale Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Anaplasma marginale Ab [Units/volume] in Serum;A marginale Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31223-1;Arbovirus NOS Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Arbovirus NOS Ab [Units/volume] in Serum;Arbovirus NOS Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31224-9;Ascaris sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Ascaris sp Ab [Units/volume] in Serum;Ascaris Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31225-6;Asialoganglioside GM1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Asialoganglioside GM1 Ab [Units/volume] in Serum;GM1 Asialo Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31226-4;Asialoganglioside GM1 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Asialoganglioside GM1 IgG Ab [Units/volume] in Serum;GM1 Asialo IgG Ser-aCnc;;ACTIVE;2.07;2.68 +31227-2;Asialoganglioside GM1 Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Asialoganglioside GM1 IgM Ab [Units/volume] in Serum;GM1 Asialo IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31228-0;Aspergillus clavatus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus clavatus Ab [Presence] in Serum;A clavatus Ab Ser Ql;;ACTIVE;2.07;2.56 +3122-9;Vanillylmandelate;MRat;24H;Urine;Qn;;CHEM;1;Vanillylmandelate [Mass/time] in 24 hour Urine;VMA 24h Ur-mRate;;ACTIVE;1.0;2.73 +31229-8;Aspergillus flavus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Aspergillus flavus Ab [Presence] in Body fluid;A flavus Ab Fld Ql;;ACTIVE;2.07;2.73 +31230-6;Aspergillus flavus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus flavus Ab [Units/volume] in Serum;A flavus Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31231-4;Aspergillus nidulans Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus nidulans Ab [Presence] in Serum;A nidulans Ab Ser Ql;;ACTIVE;2.07;2.56 +31232-2;Aspergillus niger Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Aspergillus niger Ab [Presence] in Body fluid;A niger Ab Fld Ql;;ACTIVE;2.07;2.56 +31233-0;Aspergillus sp Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Aspergillus sp Ab [Units/volume] in Cerebral spinal fluid;Aspergillus Ab CSF-aCnc;;ACTIVE;2.07;2.73 +31234-8;Aspergillus terreus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus terreus Ab [Presence] in Serum;A terreus Ab Ser Ql;;ACTIVE;2.07;2.56 +31235-5;Aureobasidium pullulans Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aureobasidium pullulans IgG Ab [Units/volume] in Serum;A pullulans IgG Qn;;ACTIVE;2.07;2.69 +31236-3;Infectious bronchitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Ab [Units/volume] in Serum;IBV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3123-7;Vanillylmandelate/Creatine;MRto;Pt;Urine;Qn;;CHEM;1;Vanillylmandelate/Creatine [Mass Ratio] in Urine;VMA/Creatine Ur;;ACTIVE;1.0;2.42 +31237-1;Infectious bronchitis virus Ark-99 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Ark-99 Ab [Units/volume] in Serum;IBV Ark99 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31238-9;Infectious bronchitis virus Conn-42 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Conn-42 Ab [Units/volume] in Serum;IBV Conn42 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31239-7;Infectious bronchitis virus Mass-41 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus Mass-41 Ab [Units/volume] in Serum;IBV Mass41 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31240-5;Avian infectious laryngotracheitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Avian infectious laryngotracheitis virus Ab [Units/volume] in Serum;ILT Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31241-3;Influenza virus A Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Influenza virus A Ab [Units/volume] in Serum;Deprecated FLUAV Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31242-1;Avian paramyxovirus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 1 Ab [Units/volume] in Serum;APMV1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31243-9;Avian paramyxovirus 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 2 Ab [Units/volume] in Serum;APMV2 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31244-7;Babesia microti Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Babesia microti IgG Ab [Units/volume] in Serum;B microti IgG Ser-aCnc;;ACTIVE;2.07;2.73 +3124-5;Vanillylmandelate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Vanillylmandelate/Creatinine [Mass Ratio] in Urine;VMA/Creat Ur;;ACTIVE;1.0;2.73 +31245-4;Babesia microti Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Babesia microti IgM Ab [Units/volume] in Serum;B microti IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31246-2;Babesia sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Babesia sp IgG Ab [Units/volume] in Serum;Babesia IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31247-0;Barmah forest virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Barmah forest virus IgG Ab [Presence] in Serum;BFV IgG Ser Ql;;ACTIVE;2.07;2.56 +31248-8;Barmah forest virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Barmah forest virus IgM Ab [Presence] in Serum;BFV IgM Ser Ql;;ACTIVE;2.07;2.56 +31249-6;Bartonella henselae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bartonella henselae Ab [Units/volume] in Serum;B henselae Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31250-4;Bartonella henselae Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Bartonella henselae IgG Ab [Units/volume] in Cerebral spinal fluid;B henselae IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31251-2;Bartonella henselae Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Bartonella henselae IgM Ab [Units/volume] in Cerebral spinal fluid;B henselae IgM CSF-aCnc;;ACTIVE;2.07;2.69 +3125-2;Vasoactive intestinal peptide;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vasoactive intestinal peptide [Mass/volume] in Serum or Plasma;VIP SerPl-mCnc;;ACTIVE;1.0;2.73 +31252-0;Basement membrane Ab;ACnc;Pt;Ser;Qn;;SERO;1;Basement membrane Ab [Units/volume] in Serum;BM Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31253-8;Basement membrane Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Basement membrane IgA Ab [Presence] in Serum;BM IgA Ser Ql;;ACTIVE;2.07;2.56 +31254-6;Basement membrane Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Basement membrane IgG Ab [Units/volume] in Serum;BM IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31255-3;Basement membrane Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Basement membrane IgG Ab [Presence] in Serum;BM IgG Ser Ql;;ACTIVE;2.07;2.56 +31256-1;Beta 2 glycoprotein 1 Ab;PrThr;Pt;Ser;Ord;;COAG;1;Beta 2 glycoprotein 1 Ab [Presence] in Serum;B2 Glycoprot1 Ab Ser Ql;;ACTIVE;2.07;2.56 +31257-9;Beta tubulin Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Beta tubulin IgG Ab [Units/volume] in Serum;B-Tubulin IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31258-7;Beta tubulin Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Beta tubulin IgM Ab [Units/volume] in Serum;B-Tubulin IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31259-5;Blastomyces dermatitidis Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Body fluid;B dermat Ab Fld Ql;;ACTIVE;2.07;2.56 +3126-0;Vasopressin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vasopressin [Mass/volume] in Serum or Plasma;Vasopressin SerPl-mCnc;;ACTIVE;1.0;2.73 +31260-3;Bluetongue virus 10 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 10 Ab [Units/volume] in Serum;BTV10 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31261-1;Bluetongue virus 11 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 11 Ab [Units/volume] in Serum;BTV11 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31262-9;Bluetongue virus 13 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 13 Ab [Units/volume] in Serum;BTV13 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31263-7;Bluetongue virus 17 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 17 Ab [Units/volume] in Serum;BTV17 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31264-5;Bluetongue virus 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 2 Ab [Units/volume] in Serum;BTV2 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31265-2;Bordetella avium Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella avium Ab [Units/volume] in Serum;B avium Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31266-0;Bordetella pertussis Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Bordetella pertussis Ab [Units/volume] in Specimen;B pert Ab Spec-aCnc;;ACTIVE;2.07;2.69 +31267-8;Bordetella pertussis.secretory Ab.IgA;PrThr;Pt;XXX;Ord;;MICRO;1;Bordetella pertussis secretory IgA Ab [Presence] in Specimen;B pert secr IgA Spec Ql;;ACTIVE;2.07;2.69 +31268-6;Borrelia burgdorferi Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Specimen;B burgdor IgG Spec Ql;;ACTIVE;2.07;2.69 +31269-4;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Body fld;Ord;;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Body fluid;B burgdor IgM Fld Ql;;ACTIVE;2.07;2.56 +31270-2;Bovine diarrhea virus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bovine diarrhea virus 1 Ab [Units/volume] in Serum;BVDV1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31271-0;Bovine diarrhea virus 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bovine diarrhea virus 2 Ab [Units/volume] in Serum;BVDV2 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31272-8;Bovine diarrhea virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bovine diarrhea virus Ab [Units/volume] in Serum;BVDV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31273-6;Bovine herpesvirus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bovine herpesvirus 1 Ab [Units/volume] in Serum;BoHV1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31274-4;Bovine leukemia virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bovine leukemia virus Ab [Units/volume] in Serum;BLV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31275-1;Brush border Ab;PrThr;Pt;Ser;Ord;;SERO;1;Brush border Ab [Presence] in Serum;Brush border Ab Ser Ql;;ACTIVE;2.07;2.56 +31276-9;Burkholderia pseudomallei Ab.IgG;ACnc;Pt;XXX;Qn;;MICRO;1;Burkholderia pseudomallei IgG Ab [Units/volume] in Specimen;B pseudomal IgG Spec-aCnc;;ACTIVE;2.07;2.69 +31277-7;Burkholderia pseudomallei Ab.IgM;ACnc;Pt;XXX;Qn;;MICRO;1;Burkholderia pseudomallei IgM Ab [Units/volume] in Specimen;B pseudomal IgM Spec-aCnc;;ACTIVE;2.07;2.69 +3127-8;Viscosity;Visc;Pt;Body fld;Qn;;SPEC;1;Viscosity of Body fluid;Visc Fld;;ACTIVE;1.0;2.73 +31278-5;Campylobacter fetus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Campylobacter fetus Ab [Units/volume] in Serum;C fetus Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31279-3;Campylobacter jejuni Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Campylobacter jejuni Ab [Units/volume] in Serum;C jejuni Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31280-1;Canary serum proteins Ab;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canary serum proteins Ab [Presence] in Serum;Canary Serum Prot Ab Ql;;ACTIVE;2.07;2.56 +31281-9;Cancer associated retinopathy Ab;PrThr;Pt;Ser;Ord;;SERO;1;Cancer associated retinopathy Ab [Presence] in Serum;CAR Ab Ser Ql;;ACTIVE;2.07;2.56 +31282-7;Canine adenovirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Canine adenovirus 1 Ab [Presence] in Serum;CAdV1 Ab Ser Ql;;ACTIVE;2.07;2.56 +31283-5;Canine coronavirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Canine coronavirus Ab [Presence] in Serum;CCV Ab Ser Ql;;ACTIVE;2.07;2.56 +31284-3;Canine distemper virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Canine distemper virus Ab [Units/volume] in Serum;CDV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31285-0;Canine distemper virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Canine distemper virus Ab [Presence] in Serum;CDV Ab Ser Ql;;ACTIVE;2.07;2.56 +3128-6;Viscosity;Visc;Pt;Ser;Qn;;SPEC;1;Viscosity of Serum;Visc Ser;;ACTIVE;1.0;2.73 +31286-8;Canine parvovirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Canine parvovirus Ab [Units/volume] in Serum;CPV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31287-6;Canine parvovirus Ab;PrThr;Pt;Stool;Ord;;MICRO;1;Canine parvovirus Ab [Presence] in Stool;CPV Ab Stl Ql;;ACTIVE;2.07;2.56 +31288-4;Canine parvovirus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Canine parvovirus IgG Ab [Units/volume] in Serum;CPV IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31289-2;Canine parvovirus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Canine parvovirus IgM Ab [Units/volume] in Serum;CPV IgM Ser-aCnc;;ACTIVE;2.07;2.69 +312-9;Lymecycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Lymecycline [Susceptibility] by Disk diffusion (KB);Lymecycline Islt KB;;ACTIVE;1.0;2.19 +31290-0;Centromere Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Centromere IgG Ab [Units/volume] in Serum;Centromere IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31291-8;Chicken serum Ab;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken serum Ab [Presence] in Serum;Chicken Serum Ab Ql;;ACTIVE;2.07;2.56 +31292-6;Chlamydia sp Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydia sp Ab [Units/volume] in Cerebral spinal fluid;Chlamydia Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31293-4;Chlamydia trachomatis Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis IgA Ab [Units/volume] in Serum;C trach IgA Ser-aCnc;;ACTIVE;2.07;2.69 +3129-4;Menadione;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Menadione [Mass/volume] in Serum or Plasma;Menadione SerPl-mCnc;;ACTIVE;1.0;2.73 +31294-2;Chlamydia trachomatis B Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B IgA Ab [Units/volume] in Serum;C trach B IgA Ser-aCnc;;ACTIVE;2.07;2.69 +31295-9;Chlamydia trachomatis B Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B IgM Ab [Units/volume] in Serum;C trach B IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31296-7;Chlamydia trachomatis D+K Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+K IgA Ab [Units/volume] in Serum;C trach D+K IgA Ser-aCnc;;ACTIVE;2.07;2.69 +31297-5;Chlamydia trachomatis D+K Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+K IgG Ab [Units/volume] in Serum;C trach D+K IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31298-3;Chlamydia trachomatis D+K Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+K IgM Ab [Units/volume] in Serum;C trach D+K IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31299-1;Chlamydophila pneumoniae Ab.IgA;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydophila pneumoniae IgA Ab [Units/volume] in Cerebral spinal fluid;C pneum IgA CSF-aCnc;;ACTIVE;2.07;2.69 +31300-7;Chlamydophila pneumoniae Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum;C pneum IgA Ser-aCnc;;ACTIVE;2.07;2.69 +31301-5;Chlamydophila pneumoniae Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydophila pneumoniae IgG Ab [Units/volume] in Cerebral spinal fluid;C pneum IgG CSF-aCnc;;ACTIVE;2.07;2.69 +3130-2;Vitronectin;MCnc;Pt;Plas;Qn;;CHEM;1;Vitronectin [Mass/volume] in Plasma;Vitronectin Plas-mCnc;;ACTIVE;1.0;2.42 +31302-3;Chlamydophila pneumoniae Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae IgG Ab [Units/volume] in Serum;C pneum IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31303-1;Chlamydophila pneumoniae Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydophila pneumoniae IgM Ab [Units/volume] in Cerebral spinal fluid;C pneum IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31304-9;Chlamydophila pneumoniae Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae IgM Ab [Units/volume] in Serum;C pneum IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31305-6;Chlamydophila psittaci Ab.IgA;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid;C psittaci IgA CSF-aCnc;;ACTIVE;2.07;2.69 +31306-4;Chlamydophila psittaci Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci IgA Ab [Units/volume] in Serum;C psittaci IgA Ser-aCnc;;ACTIVE;2.07;2.69 +31307-2;Chlamydophila psittaci Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid;C psittaci IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31308-0;Clostridioides difficile Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridioides difficile Ab [Units/volume] in Serum;C diff Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31309-8;Coccidioides immitis Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coccidioides immitis Ab [Presence] in Body fluid;C immitis Ab Fld Ql;;ACTIVE;2.07;2.56 +3131-0;Xanthine;MCnc;Pt;Ser;Qn;;CHEM;1;Xanthine [Mass/volume] in Serum;Xanthine Ser-mCnc;;ACTIVE;1.0;2.42 +31310-6;Cockatiel droppings Ab;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cockatiel droppings Ab [Presence] in Serum;Cockatiel Drop Ab Ql;;ACTIVE;2.07;2.56 +31311-4;Coxiella burnetii phase 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 Ab [Units/volume] in Serum;C burnet Ph1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31312-2;Coxiella burnetii phase 1 Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 IgA Ab [Units/volume] in Serum;C burnet Ph1 IgA Ser-aCnc;;ACTIVE;2.07;2.69 +31313-0;Coxiella burnetii phase 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 Ab [Units/volume] in Serum;C burnet Ph2 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31314-8;Coxiella burnetii phase 2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Presence] in Serum;C burnet Ph2 IgG Ser Ql;;ACTIVE;2.07;2.73 +31315-5;Coxiella burnetii phase 2 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Presence] in Serum;C burnet Ph2 IgM Ser Ql;;ACTIVE;2.07;2.73 +31316-3;Coxiella burnetii phase 2 Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 IgA Ab [Units/volume] in Serum;C burnet Ph2 IgA Ser-aCnc;;ACTIVE;2.07;2.69 +31317-1;Coxsackievirus A10 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A10 Ab [Units/volume] in Body fluid;CV A10 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31318-9;Coxsackievirus A16 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A16 Ab [Units/volume] in Body fluid;CV A16 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31319-7;Coxsackievirus A7 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A7 Ab [Units/volume] in Cerebral spinal fluid;CV A7 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31320-5;Coxsackievirus A7 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A7 Ab [Units/volume] in Body fluid;CV A7 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31321-3;Coxsackievirus A9 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A9 Ab [Units/volume] in Cerebral spinal fluid;CV A9 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31322-1;Coxsackievirus A9 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A9 Ab [Units/volume] in Body fluid;CV A9 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31323-9;Coxsackievirus B1 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B1 Ab [Units/volume] in Cerebral spinal fluid;CV B1 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31324-7;Coxsackievirus B1 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B1 Ab [Units/volume] in Body fluid;CV B1 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31325-4;Coxsackievirus B2 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B2 Ab [Units/volume] in Cerebral spinal fluid;CV B2 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31326-2;Coxsackievirus B2 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B2 Ab [Units/volume] in Body fluid;CV B2 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31327-0;Coxsackievirus B3 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B3 Ab [Units/volume] in Cerebral spinal fluid;CV B3 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +3132-8;Xanthine;MCnc;Pt;Urine;Qn;;CHEM;1;Xanthine [Mass/volume] in Urine;Xanthine Ur-mCnc;;ACTIVE;1.0;2.42 +31328-8;Coxsackievirus B3 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B3 Ab [Units/volume] in Body fluid;CV B3 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31329-6;Coxsackievirus B4 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B4 Ab [Units/volume] in Cerebral spinal fluid;CV B4 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31330-4;Coxsackievirus B4 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B4 Ab [Units/volume] in Body fluid;CV B4 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31331-2;Coxsackievirus B5 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B5 Ab [Units/volume] in Cerebral spinal fluid;CV B5 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31332-0;Coxsackievirus B5 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B5 Ab [Units/volume] in Body fluid;CV B5 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31333-8;Coxsackievirus B6 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B6 Ab [Units/volume] in Cerebral spinal fluid;CV B6 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31334-6;Coxsackievirus B6 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus B6 Ab [Units/volume] in Body fluid;CV B6 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31335-3;Cryptococcus sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Cryptococcus sp Ab [Units/volume] in Serum;Cryptoc Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3133-6;Xanthurenate;MCnc;Pt;Urine;Qn;;CHEM;1;Xanthurenate [Mass/volume] in Urine;Xanthuren Ur-mCnc;;ACTIVE;1.0;2.42 +31336-1;Cryptostroma corticale Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Cryptostroma corticale Ab [Presence] in Serum;C corticale Ab Ser Ql;;ACTIVE;2.07;2.56 +31337-9;Cytotoxic percent reactive Ab;PrThr;Pt;Ser;Ord;;HEM/BC;1;Cytotoxic percent reactive Ab [Presence] in Serum;Ctox Pct React Ab Ser Ql;;ACTIVE;2.07;2.56 +31338-7;Dengue virus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Dengue virus 1 Ab [Units/volume] in Serum;DENV1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31339-5;Dengue virus 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Dengue virus 2 Ab [Units/volume] in Serum;DENV2 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31340-3;Dengue virus 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Dengue virus 3 Ab [Units/volume] in Serum;DENV3 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31341-1;Dengue virus 4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Dengue virus 4 Ab [Units/volume] in Serum;DENV4 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31342-9;Dengue virus Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Dengue virus Ab [Units/volume] in Specimen;DENV Ab Spec-aCnc;;ACTIVE;2.07;2.69 +31343-7;Dengue virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Dengue virus Ab [Presence] in Specimen;DENV Ab Spec Ql;;ACTIVE;2.07;2.69 +3134-4;Xylose;MCnc;Pt;Bld;Qn;;CHEM;1;Xylose [Mass/volume] in Blood;Xylose Bld-mCnc;;ACTIVE;1.0;2.73 +31344-5;Ganglioside GD1a Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GD1a Ab [Units/volume] in Serum;GD1a Gangl Ab Ser-aCnc;;ACTIVE;2.07;2.68 +31345-2;Ganglioside GD1b Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GD1b Ab [Units/volume] in Serum;GD1b Gangl Ab Ser-aCnc;;ACTIVE;2.07;2.68 +31346-0;Ganglioside GD1b Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GD1b IgG Ab [Units/volume] in Serum;GD1b Gangl IgG Ser-aCnc;;ACTIVE;2.07;2.68 +31347-8;Ganglioside GD1b Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GD1b IgM Ab [Units/volume] in Serum;GD1b Gangl IgM Ser-aCnc;;ACTIVE;2.07;2.68 +31348-6;DNA double strand Ab;PrThr;Pt;Ser;Ord;;SERO;1;DNA double strand Ab [Presence] in Serum;dsDNA Ab Ser Ql;;ACTIVE;2.07;2.73 +31349-4;Eastern equine encephalomyelitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Eastern equine encephalitis virus Ab [Units/volume] in Serum;Deprecated EEEV Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31350-2;Echovirus 11 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus 11 Ab [Presence] in Serum;ECV11 Ab Ser Ql;;ACTIVE;2.07;2.73 +3135-1;Xylose;MCnc;Pt;Urine;Qn;;CHEM;1;Xylose [Mass/volume] in Urine;Xylose Ur-mCnc;;ACTIVE;1.0;2.73 +31351-0;Echovirus 30 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Echovirus 30 Ab [Units/volume] in Cerebral spinal fluid;ECV30 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31352-8;Echovirus 30 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Echovirus 30 Ab [Units/volume] in Body fluid;ECV30 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31353-6;Echovirus 30 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus 30 Ab [Presence] in Serum;ECV30 Ab Ser Ql;;ACTIVE;2.07;2.73 +31354-4;Echovirus 4 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Echovirus 4 Ab [Units/volume] in Cerebral spinal fluid;ECV4 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31355-1;Echovirus 4 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Echovirus 4 Ab [Units/volume] in Body fluid;ECV4 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31356-9;Echovirus 4 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus 4 Ab [Presence] in Serum;ECV4 Ab Ser Ql;;ACTIVE;2.07;2.56 +31357-7;Echovirus 7 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus 7 Ab [Presence] in Serum;ECV7 Ab Ser Ql;;ACTIVE;2.07;2.73 +31358-5;Echovirus 9 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Echovirus 9 Ab [Units/volume] in Cerebral spinal fluid;ECV9 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31359-3;Echovirus 9 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Echovirus 9 Ab [Units/volume] in Body fluid;ECV9 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31360-1;Echovirus 9 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus 9 Ab [Presence] in Serum;ECV9 Ab Ser Ql;;ACTIVE;2.07;2.73 +31361-9;Ehrlichia canis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Ehrlichia canis Ab [Units/volume] in Serum;E canis Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31362-7;Ehrlichia chaffeensis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Ehrlichia chaffeensis IgM Ab [Units/volume] in Serum;E chaffeensis IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31363-5;Anaplasma phagocytophilum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Anaplasma phagocytophilum Ab [Units/volume] in Serum;A phagocytoph Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31364-3;Encephalomyocarditis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Encephalomyocarditis virus Ab [Units/volume] in Serum;EMCV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31365-0;Endomysium Ab;PrThr;Pt;Ser;Ord;;SERO;1;Endomysium Ab [Presence] in Serum;Endomysium Ab Ser Ql;;ACTIVE;2.07;2.73 +31366-8;Endomysium Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Endomysium IgA Ab [Units/volume] in Serum;Endomysium IgA Ser-aCnc;;ACTIVE;2.07;2.69 +31367-6;Enterovirus NOS Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Enterovirus NOS Ab [Units/volume] in Serum;EV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31368-4;Epidermis Ab;ACnc;Pt;Ser;Qn;;SERO;1;Epidermis Ab [Units/volume] in Serum;Epidis Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3136-9;Xylulose;MCnc;Pt;Ser;Qn;;CHEM;1;Xylulose [Mass/volume] in Serum;Xylulose Ser-mCnc;;ACTIVE;1.0;2.42 +31369-2;Epstein Barr virus capsid Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgA Ab [Units/volume] in Serum;EBV VCA IgA Ser-aCnc;;ACTIVE;2.07;2.73 +313-7;Lymecycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Lymecycline [Susceptibility] by Serum bactericidal titer;Lymecycline Titr SBT;;ACTIVE;1.0;2.32 +31370-0;Epstein Barr virus capsid Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus capsid IgM Ab [Units/volume] in Cerebral spinal fluid;EBV VCA IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31371-8;Epstein Barr virus early Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus early IgG Ab [Units/volume] in Cerebral spinal fluid;EBV EA IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31372-6;Epstein Barr virus nuclear Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus nuclear Ab [Units/volume] in Serum;EBV NA Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31373-4;Epstein Barr virus nuclear Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus nuclear IgG Ab [Units/volume] in Cerebral spinal fluid;EBV NA IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31374-2;Epstein Barr virus nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum;EBV NA IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31375-9;Epstein Barr virus nuclear Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus nuclear IgM Ab [Units/volume] in Serum;EBV NA IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31376-7;Equine arteritis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Equine arteritis virus Ab [Units/volume] in Serum;EAV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3137-7;Body height;Len;Pt;^Patient;Qn;Measured;BDYHGT.ATOM;2;Body height Measured;Body height Measured;;ACTIVE;1.0;2.73 +31377-5;Equine herpesvirus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Equine herpesvirus 1 Ab [Units/volume] in Serum;EHV1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31378-3;Equine herpesvirus 1+4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Equine herpesvirus 1+4 Ab [Units/volume] in Serum;EHV1+4 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31379-1;Equine influenza virus A1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Equine influenza virus A1 Ab [Units/volume] in Serum;EIV A1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31380-9;Equine influenza virus A2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Equine influenza virus A2 Ab [Units/volume] in Serum;EIV A2 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31381-7;Escherichia coli verotoxin 1 Ab;ACnc;Pt;Stool;Qn;;MICRO;1;Escherichia coli verotoxin 1 Ab [Units/volume] in Stool;E coli VTN1 Ab Stl-aCnc;;ACTIVE;2.07;2.69 +31382-5;Escherichia coli verotoxin 2 Ab;ACnc;Pt;Stool;Qn;;MICRO;1;Escherichia coli verotoxin 2 Ab [Units/volume] in Stool;E coli VTN2 Ab Stl-aCnc;;ACTIVE;2.07;2.69 +31383-3;European tick borne encephalitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;European tick borne encephalitis virus Ab [Units/volume] in Serum;TBEV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31384-1;Feline calicivirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline calicivirus Ab [Units/volume] in Serum;FCV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3138-5;Body height;Len;Pt;^Patient;Qn;Stated;BDYHGT.ATOM;2;Body height Stated;Body height Stated;;ACTIVE;1.0;2.73 +31385-8;Feline coronavirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline coronavirus Ab [Units/volume] in Serum;FCoV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31386-6;Feline herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Feline herpesvirus 1 Ab [Presence] in Serum;FeHV1 Ab Ser Ql;;ACTIVE;2.07;2.56 +31387-4;Feline herpesvirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline herpesvirus Ab [Units/volume] in Serum;FeHV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31388-2;Feline immunodeficiency virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline immunodeficiency virus Ab [Units/volume] in Serum;FIV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31389-0;Feline leukemia virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline leukemia virus Ab [Units/volume] in Serum;FeLV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31390-8;Feline panleukopenia virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline panleukopenia virus Ab [Units/volume] in Serum;FPLV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31391-6;Feline panleukopenia virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Feline panleukopenia virus IgG Ab [Units/volume] in Serum;FPLV IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31392-4;Feline panleukopenia virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Feline panleukopenia virus IgM Ab [Units/volume] in Serum;FPLV IgM Ser-aCnc;;ACTIVE;2.07;2.69 +3139-3;Body surface;Area;Pt;^Patient;Qn;Measured;BDYSURF.ATOM;2;Body surface area Measured;BSA Measured;;ACTIVE;1.0;2.73 +31393-2;Feline herpesvirus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline herpesvirus 1 Ab [Units/volume] in Serum;FeHV1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31394-0;Feline syncytial virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Feline syncytial virus Ab [Units/volume] in Serum;FSV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31395-7;Filovirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Filovirus Ab [Units/volume] in Serum;Filovirus Ab Ser-aCnc;;DISCOURAGED;2.07;2.69 +31396-5;Francisella tularensis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Francisella tularensis Ab [Units/volume] in Serum;F tular Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31397-3;Ganglioside GD1a Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GD1a IgG Ab [Units/volume] in Serum;GD1a Gangl IgG Ser-aCnc;;ACTIVE;2.07;2.68 +31398-1;Ganglioside GD1a Ab.IgM;ACnc;Pt;CSF;Qn;;SERO;1;Ganglioside GD1a IgM Ab [Units/volume] in Cerebral spinal fluid;GD1a Gangl IgM CSF-aCnc;;ACTIVE;2.07;2.68 +31399-9;Ganglioside GD1a Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GD1a IgM Ab [Units/volume] in Serum;GD1a Gangl IgM Ser-aCnc;;ACTIVE;2.07;2.68 +31400-5;Ganglioside GD1b Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GD1b Ab [Presence] in Serum;GD1b Gangl Ab Ser Ql;;ACTIVE;2.07;2.56 +3140-1;Body surface;Area;Pt;^Patient;Qn;Derived;BDYSURF.ATOM;2;Body surface area Derived from formula;BSA Derived;;ACTIVE;1.0;2.73 +31401-3;Ganglioside GD1b Ab.IgG;ACnc;Pt;CSF;Qn;;SERO;1;Ganglioside GD1b IgG Ab [Units/volume] in Cerebral spinal fluid;GD1b Gangl IgG CSF-aCnc;;ACTIVE;2.07;2.68 +31402-1;Ganglioside GD1b Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Ganglioside GD1b IgG Ab [Units/volume] in Serum;Deprecated GD1b Gangl IgG Ser-aCnc;;DEPRECATED;2.07;2.69 +31403-9;Ganglioside GD1b Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Ganglioside GD1b IgM Ab [Units/volume] in Serum;Deprecated GD1b Gangl IgM Ser-aCnc;;DEPRECATED;2.07;2.69 +31404-7;Ganglioside GM1b Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GM1b IgG Ab [Units/volume] in Serum;GM1b Gangl IgG Ser-aCnc;;ACTIVE;2.07;2.68 +31405-4;Ganglioside GM1b Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GM1b IgM Ab [Units/volume] in Serum;GM1b Gangl IgM Ser-aCnc;;ACTIVE;2.07;2.68 +31406-2;Glomerular basement membrane Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Glomerular basement membrane IgG Ab [Units/volume] in Serum;GBM IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31407-0;Haemophilus somnus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Haemophilus somnus Ab [Units/volume] in Serum;H somnus Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31408-8;Hantavirus sin nombre Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus sin nombre IgG Ab [Units/volume] in Serum;SNV IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31409-6;Hantavirus sin nombre Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus sin nombre IgM Ab [Units/volume] in Serum;SNV IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31410-4;Herpes simplex virus 1 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1 Ab [Units/volume] in Cerebral spinal fluid;HSV1 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31411-2;Herpes simplex virus 1+2 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Units/volume] in Serum;HSV1+2 IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31412-0;Herpes simplex virus 2 Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Herpes simplex virus 2 IgM Ab [Units/volume] in Body fluid;HSV2 IgM Fld-aCnc;;ACTIVE;2.07;2.69 +31413-8;Herpes simplex virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus Ab [Units/volume] in Cerebral spinal fluid;HSV Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31414-6;Herpes virus 6 Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes virus 6 IgG Ab [Units/volume] in Cerebral spinal fluid;HHV6 IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31415-3;Herpes virus 6 Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes virus 6 IgM Ab [Units/volume] in Cerebral spinal fluid;HHV6 IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31416-1;Herpes virus 7 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes virus 7 IgG Ab [Units/volume] in Serum;HHV7 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31417-9;Herpes virus 7 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes virus 7 IgM Ab [Units/volume] in Serum;HHV7 IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31418-7;Heterophile Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Heterophile Ab [Presence] in Serum;Heteroph Ab Ser Ql;;ACTIVE;2.07;2.73 +3141-9;Body weight;Mass;Pt;^Patient;Qn;Measured;BDYWGT.ATOM;2;Body weight Measured;Weight Measured;;ACTIVE;1.0;2.73 +31419-5;Heterophile Ab;PrThr;Pt;Synv fld;Ord;;MICRO;1;Heterophile Ab [Presence] in Synovial fluid;Heteroph Ab Snv Ql;;ACTIVE;2.07;2.56 +31420-3;Highlands J virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Highlands J virus Ab [Units/volume] in Cerebral spinal fluid;HJV Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31421-1;Highlands J virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Highlands J virus Ab [Units/volume] in Serum;HJV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31422-9;Highlands J virus Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Highlands J virus Ab [Units/volume] in Specimen;HJV Ab Spec-aCnc;;ACTIVE;2.07;2.69 +31423-7;Histone Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Histone IgG Ab [Units/volume] in Serum;Histone IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31424-5;Histone H2a+H2b Ab;PrThr;Pt;Ser;Ord;;SERO;1;Histone H2a+H2b Ab [Presence] in Serum;Histone H2a+H2b Ab Ser Ql;;ACTIVE;2.07;2.56 +31425-2;Histoplasma capsulatum mycelial phase Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Units/volume] in Cerebral spinal fluid;H capsul Myc Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31426-0;Histoplasma capsulatum mycelial phase Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Units/volume] in Body fluid;H capsul Myc Ab Fld-aCnc;;ACTIVE;2.07;2.69 +3142-7;Body weight;Mass;Pt;^Patient;Qn;Stated;BDYWGT.ATOM;2;Body weight Stated;Weight Stated;;ACTIVE;1.0;2.73 +31427-8;Histoplasma capsulatum yeast phase Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Histoplasma capsulatum yeast phase Ab [Units/volume] in Cerebral spinal fluid;H capsul Yst Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31428-6;Histoplasma capsulatum yeast phase Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Histoplasma capsulatum yeast phase Ab [Units/volume] in Body fluid;H capsul Yst Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31429-4;Histoplasma sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Histoplasma capsulatum Ab [Units/volume] in Serum;Deprecated Histoplasma Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31430-2;HIV 1 Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;HIV 1 IgG Ab [Presence] in Cerebral spinal fluid;HIV1 IgG CSF Ql;;ACTIVE;2.07;2.56 +31431-0;HTLV I+II Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II IgG Ab [Presence] in Serum;HTLV I+II IgG Ser Ql;;ACTIVE;2.07;2.73 +31432-8;Human antimouse Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Human antimouse Ab [Units/volume] in Serum;Deprecated Human Antimouse Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31433-6;Anaplasma phagocytophilum Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Anaplasma phagocytophilum IgG Ab [Units/volume] in Serum;Deprecated A phagocytoph IgG Ser-aCnc;;DEPRECATED;2.07;2.69 +31434-4;Anaplasma phagocytophilum Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Anaplasma phagocytophilum IgM Ab [Units/volume] in Serum;Deprecated A phagocytoph IgM Ser-aCnc;;DEPRECATED;2.07;2.69 +3143-5;Donor relation to patient;Type;Pt;^Patient;Nom;;CLIN;2;Donor relation to patient;Donor relation to patient;;ACTIVE;1.0;2.73 +31435-1;Hyaluronidase Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hyaluronidase Ab [Units/volume] in Serum;Hyaluronidase Ab Ser-aCnc;;ACTIVE;2.07;2.68 +31436-9;Infectious bursal disease virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Infectious bursal disease virus Ab [Units/volume] in Serum;IBDV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31437-7;Influenza virus A Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A IgG Ab [Units/volume] in Serum;FLUAV IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31438-5;Influenza virus A Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A IgM Ab [Units/volume] in Serum;FLUAV IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31439-3;Insulin receptor Ab;ACnc;Pt;Ser;Qn;;SERO;1;Insulin receptor Ab [Units/volume] in Serum;Insulin Recep Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31440-1;Intercalated disk Ab;ACnc;Pt;Ser;Qn;;SERO;1;Intercalated disk Ab [Units/volume] in Serum;Intercal Dsk Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31441-9;Intercellular substance Ab;ACnc;Pt;Ser;Qn;;SERO;1;Intercellular substance Ab [Units/volume] in Serum;ICS Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31442-7;Interferon.beta 1 Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Interferon.beta 1 Ab [Units/volume] in Serum or Plasma;INF-B1 Ab SerPl-aCnc;;ACTIVE;2.07;2.69 +3144-3;Menstrual period duration.last;Time;Pt;^Patient;OrdQn;Stated;OBGYN;2;Last menstrual period duration;LMP duration;;ACTIVE;1.0;2.73 +31443-5;Intrinsic factor blocking Ab;ACnc;Pt;Ser;Qn;;CHEM;1;Intrinsic factor blocking Ab [Units/volume] in Serum;IF Block Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31444-3;Intrinsic factor blocking Ab;PrThr;Pt;Ser;Ord;;CHEM;1;Intrinsic factor blocking Ab [Presence] in Serum;IF Block Ab Ser Ql;;ACTIVE;2.07;2.73 +31445-0;Intrinsic factor blocking Ab.IgG;ACnc;Pt;Ser;Qn;;CHEM;1;Intrinsic factor blocking IgG Ab [Units/volume] in Serum;IF Block IgG Ser-aCnc;;ACTIVE;2.07;2.68 +31446-8;Jamestown canyon virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Jamestown canyon virus Ab [Units/volume] in Serum;JCV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31447-6;Jo-1 extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Jo-1 extractable nuclear Ab [Units/volume] in Serum;Deprecated ENA Jo1 Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31448-4;La Crosse virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;La Crosse virus Ab [Units/volume] in Cerebral spinal fluid;LACV Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31449-2;La Crosse virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;La Crosse virus Ab [Presence] in Specimen;LACV Ab Spec Ql;;ACTIVE;2.07;2.69 +314-5;Meclocycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Meclocycline [Susceptibility] by Minimum lethal concentration (MLC);Meclocycline Islt MLC;;ACTIVE;1.0;2.19 +3145-0;Menstrual period start.last;TmStp;Pt;^Patient;Qn;Stated;OBGYN;2;Deprecated Last menstrual period start;Deprecated LMP start;;DEPRECATED;1.0;2.46 +31450-0;La Crosse virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;La Crosse virus IgG Ab [Units/volume] in Cerebral spinal fluid;LACV IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31451-8;La Crosse virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;La Crosse virus IgM Ab [Units/volume] in Cerebral spinal fluid;LACV IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31452-6;Lassa virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Lassa virus IgG Ab [Units/volume] in Serum;LASV IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31453-4;Lassa virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Lassa virus IgM Ab [Units/volume] in Serum;LASV IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31454-2;Legionella pneumophila 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1 Ab [Units/volume] in Serum;L pneumo1 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31455-9;Legionella pneumophila 1 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1 IgG Ab [Units/volume] in Serum;L pneumo1 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31456-7;Legionella pneumophila 1 Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Legionella pneumophila 1 IgM Ab [Units/volume] in Cerebral spinal fluid;L pneumo1 IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31457-5;Legionella pneumophila 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 2 Ab [Units/volume] in Serum;L pneumo2 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31458-3;Legionella pneumophila 2 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 2 IgG Ab [Units/volume] in Serum;L pneumo2 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31459-1;Legionella pneumophila 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 3 Ab [Units/volume] in Serum;L pneumo3 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31460-9;Legionella pneumophila 3 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 3 IgG Ab [Units/volume] in Serum;L pneumo3 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31461-7;Legionella pneumophila 4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 4 Ab [Units/volume] in Serum;L pneumo4 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31462-5;Legionella pneumophila 4 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 4 IgG Ab [Units/volume] in Serum;L pneumo4 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31463-3;Legionella pneumophila 5 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 5 Ab [Units/volume] in Serum;L pneumo5 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31464-1;Legionella pneumophila 5 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 5 IgG Ab [Units/volume] in Serum;L pneumo5 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31465-8;Legionella pneumophila 6 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 6 Ab [Units/volume] in Serum;L pneumo6 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31466-6;Legionella pneumophila 6 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 6 IgG Ab [Units/volume] in Serum;L pneumo6 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31467-4;Legionella pneumophila 6 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 6 IgM Ab [Units/volume] in Serum;L pneumo6 IgM Ser-aCnc;;ACTIVE;2.07;2.69 +3146-8;Menstrual status;Type;Pt;^Patient;Nom;Stated;OBGYN;2;Menstrual status;Menstrual status;;ACTIVE;1.0;2.29 +31468-2;Legionella pneumophila 7 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 7 Ab [Units/volume] in Serum;L pneumo7 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31469-0;Legionella pneumophila 8 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 8 Ab [Units/volume] in Serum;L pneumo8 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31470-8;Legionella pneumophila 9 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 9 Ab [Units/volume] in Serum;L pneumo9 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31471-6;Legionella pneumophila Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila Ab [Units/volume] in Serum;L pneumo Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31472-4;Legionella pneumophila Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila IgM Ab [Units/volume] in Serum;L pneumo IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31473-2;Legionella pneumophila atypical Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila atypical Ab [Units/volume] in Serum;L pneumo Atyp Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31474-0;Legionella sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella sp IgM Ab [Units/volume] in Serum;Legionella IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31475-7;Leishmania donovani Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania donovani Ab [Units/volume] in Serum;L donovani Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3147-6;Oxygen;PPres;Pt;Exhl gas;Qn;;CHEM;1;Oxygen [Partial pressure] in Exhaled gas;pO2 ExG;;ACTIVE;1.0;2.30 +31476-5;Leptospira borgpetersenii serovar Sejroe Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira borgpetersenii sv Sejroe Ab [Units/volume] in Serum;L borgp Sej Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31477-3;Leptospira interrogans serovar Bratislava Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Bratislava Ab [Units/volume] in Serum;L inter Brat Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31478-1;Leptospira interrogans serovar Canicola Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Canicola Ab [Units/volume] in Serum;L inter Canic Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31479-9;Leptospira interrogans serovar Grippotyphosa Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Grippotyphosa Ab [Units/volume] in Serum;L inter Grip Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31480-7;Leptospira interrogans serovar Hardjo Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Hardjo Ab [Units/volume] in Serum;L inter Hard Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31481-5;Leptospira interrogans serovar Icterohaemorrhagiae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Icterohaemorrhagiae Ab [Units/volume] in Serum;L inter Icter Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31482-3;Leptospira interrogans serovar Pomona Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans sv Pomona Ab [Units/volume] in Serum;L inter Pomon Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31483-1;Leptospira sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira sp Ab [Units/volume] in Serum;Leptospira Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3148-4;Oxygen;PPres;Pt;Gas;Qn;;CHEM;1;Oxygen [Partial pressure] in Gas;pO2 Gas;;ACTIVE;1.0;2.30 +31484-9;Leptospira sp Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Leptospira sp IgG Ab [Units/volume] in Cerebral spinal fluid;Leptospira IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31485-6;Leptospira sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira sp IgG Ab [Units/volume] in Serum;Leptospira IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31486-4;Leptospira sp Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Leptospira sp IgM Ab [Units/volume] in Cerebral spinal fluid;Leptospira IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31487-2;Leptospira sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Leptospira sp IgM Ab [Units/volume] in Serum;Leptospira IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31488-0;Listeria sp Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Listeria sp Ab [Units/volume] in Cerebral spinal fluid;Listeria Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31489-8;Lumpy skin disease virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Lumpy skin disease virus Ab [Units/volume] in Serum;LSDV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31490-6;Lupus erythematosus deoxynucleoproteins Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum;LE DNP IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31491-4;Lymphocytic choriomeningitis virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Lymphocytic choriomeningitis virus Ab [Units/volume] in Cerebral spinal fluid;LCMV Ab CSF-aCnc;;ACTIVE;2.07;2.69 +3149-2;Oxygen;PPres;Pt;Inhl gas;Qn;;CHEM;1;Oxygen [Partial pressure] in Inhaled gas;pO2 IhG;;ACTIVE;1.0;2.30 +31492-2;Lymphocytic choriomeningitis virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Units/volume] in Cerebral spinal fluid;LCMV IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31493-0;Lymphocytic choriomeningitis virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Units/volume] in Serum;LCMV IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31494-8;Lymphocytic choriomeningitis virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Units/volume] in Cerebral spinal fluid;LCMV IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31495-5;Lymphocytic choriomeningitis virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Units/volume] in Serum;LCMV IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31496-3;Ganglioside GM1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 Ab [Units/volume] in Serum;GM1 Gangl Ab Ser-aCnc;;ACTIVE;2.07;2.68 +31497-1;Ganglioside GM1 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GM1 Ab [Presence] in Serum;GM1 Gangl Ab Ser Ql;;ACTIVE;2.07;2.56 +31498-9;Ganglioside GM1 Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 IgA Ab [Units/volume] in Serum;GM1 Gangl IgA Ser-aCnc;;ACTIVE;2.07;2.68 +31499-7;Ganglioside GM1 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 IgG Ab [Units/volume] in Serum;GM1 Gangl IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31-5;Ampicillin+Sulbactam;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility] by Minimum lethal concentration (MLC);Ampicillin+Sulbac Islt MLC;;ACTIVE;1.0;2.19 +3150-0;Oxygen/Gas.total;VFr;Pt;Inhl gas;Qn;;CLIN;2;Inhaled oxygen concentration;Inhaled O2 concentration;;ACTIVE;1.0;2.73 +31500-2;Ganglioside GM1 Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 IgG+IgM Ab [Units/volume] in Serum;GM1 Gangl IgG+IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31501-0;Ganglioside GM1 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GM1 IgG+IgM Ab [Presence] in Serum;GM1 Gangl IgG+IgM Ser Ql;;ACTIVE;2.07;2.56 +31502-8;Ganglioside GM1 Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 IgM Ab [Units/volume] in Serum;GM1 Gangl IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31503-6;Mumps virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mumps virus Ab [Presence] in Serum;MuV Ab Ser Ql;;ACTIVE;2.07;2.73 +31504-4;Mumps virus soluble Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Mumps virus soluble Ab [Units/volume] in Cerebral spinal fluid;MuV S Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31505-1;Mumps virus soluble Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus soluble Ab [Units/volume] in Serum;MuV S Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31506-9;Mumps virus particle-bound Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Mumps virus particle-bound Ab [Units/volume] in Cerebral spinal fluid;MuV V Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31507-7;Mumps virus particle-bound Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus particle-bound Ab [Units/volume] in Serum;MuV V Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31508-5;Mycoplasma capricolum subspecies capripneumonia Ab;PrThr;Pt;Bld;Ord;;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Presence] in Blood;M cap caprip Ab Bld Ql;;ACTIVE;2.07;2.56 +31509-3;Mycoplasma capricolum subspecies capripneumonia Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Units/volume] in Serum;M cap caprip Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31510-1;Mycoplasma capricolum subspecies capripneumonia Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma capricolum ss capripneumonia Ab [Presence] in Serum;M cap caprip Ab Ser Ql;;ACTIVE;2.07;2.56 +31511-9;Mycoplasma gallisepticum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma gallisepticum Ab [Units/volume] in Serum;M gallisep Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31512-7;Mycoplasma hominis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma hominis Ab [Units/volume] in Serum;M hominis Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31513-5;Mycoplasma hyopneumoniae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma hyopneumoniae Ab [Presence] in Serum;M hyopneumo Ab Ser Ql;;ACTIVE;2.07;2.56 +31514-3;Mycoplasma mycoides subspecies mycoides large colony Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma mycoides ss mycoides large colony Ab [Presence] in Serum;M myc my lc Ab Ser Ql;;ACTIVE;2.07;2.56 +31515-0;Mycoplasma pneumoniae Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma pneumoniae IgA Ab [Presence] in Serum;M pneumo IgA Ser Ql;;ACTIVE;2.07;2.56 +31516-8;Mycoplasma pneumoniae Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Mycoplasma pneumoniae IgM Ab [Units/volume] in Cerebral spinal fluid;M pneumo IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31517-6;Mycoplasma sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma sp Ab [Units/volume] in Serum;Mycoplasma Ab Ser-aCnc;;ACTIVE;2.07;2.73 +3151-8;Oxygen inhaled;VRat;Pt;Inhl gas;Qn;;CLIN;2;Inhaled oxygen flow rate;Inhaled O2 flow rate;;ACTIVE;1.0;2.73 +31518-4;Mycoplasma synoviae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma synoviae Ab [Units/volume] in Serum;M synoviae Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31519-2;Myelin associated glycoprotein Ab;PrThr;Pt;CSF;Ord;;SERO;1;Myelin associated glycoprotein Ab [Presence] in Cerebral spinal fluid;MAG Ab CSF Ql;;ACTIVE;2.07;2.56 +315-2;Meclocycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Meclocycline [Susceptibility] by Minimum inhibitory concentration (MIC);Meclocycline Islt MIC;;ACTIVE;1.0;2.19 +31520-0;Myelin associated glycoprotein Ab;ACnc;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein Ab [Units/volume] in Serum;MAG Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31521-8;Myelin associated glycoprotein Ab;PrThr;Pt;Ser;Ord;;SERO;1;Myelin associated glycoprotein Ab [Presence] in Serum;MAG Ab Ser Ql;;ACTIVE;2.07;2.56 +31522-6;Myelin associated glycoprotein Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Myelin associated glycoprotein IgM Ab [Presence] in Serum;MAG IgM Ser Ql;;ACTIVE;2.07;2.56 +31523-4;Myxoma virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Myxoma virus Ab [Units/volume] in Serum;MYXV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31524-2;Nairobi sheep disease virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Nairobi sheep disease virus Ab [Units/volume] in Serum;NSDV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31525-9;Neisseria gonorrhoeae Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Neisseria gonorrhoeae Ab [Units/volume] in Cerebral spinal fluid;N gonorrhoea Ab CSF-aCnc;;ACTIVE;2.07;2.69 +3152-6;Oxygen inhaled mechanism;Type;Pt;Dose;Nom;;CLIN;2;Inhaled oxygen mechanism Dose;Inhaled O2 mechanism Dose;;ACTIVE;1.0;2.73 +31526-7;Neisseria meningitidis serogroup A Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup A IgG Ab [Units/volume] in Serum;N men sg A IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31527-5;Neisseria meningitidis serogroup C Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup C IgG Ab [Units/volume] in Serum;N men sg C IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31528-3;Neisseria meningitidis serogroup Y Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Neisseria meningitidis serogroup Y Ab [Units/volume] in Specimen;N men sg Y Ab Spec-aCnc;;ACTIVE;2.07;2.69 +31529-1;Neospora caninum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Neospora caninum Ab [Units/volume] in Serum;N caninum Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31530-9;Neuronal Ab;ACnc;Pt;CSF;Qn;;SERO;1;Neuronal Ab [Units/volume] in Cerebral spinal fluid;Neuronal Ab CSF-aCnc;;ACTIVE;2.07;2.73 +31531-7;Neuronal Ab;PrThr;Pt;CSF;Ord;;SERO;1;Neuronal Ab [Presence] in Cerebral spinal fluid;Neuronal Ab CSF Ql;;ACTIVE;2.07;2.56 +31532-5;Neuronal Ab;ACnc;Pt;Ser;Qn;;SERO;1;Neuronal Ab [Units/volume] in Serum;Neuronal Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31533-3;Neuronal Ab;PrThr;Pt;Ser;Ord;;SERO;1;Neuronal Ab [Presence] in Serum;Neuronal Ab Ser Ql;;ACTIVE;2.07;2.73 +3153-4;Specimen weight;Mass;24H;XXX;Qn;;SPEC;1;Weight of 24 hour Specimen;Wt 24h Spec;;ACTIVE;1.0;2.73 +31534-1;Neuronal Ab.IgG;PrThr;Pt;Body fld;Ord;;SERO;1;Neuronal IgG Ab [Presence] in Body fluid;Neuronal IgG Fld Ql;;ACTIVE;2.07;2.56 +31535-8;Neuronal nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Neuronal nuclear Ab [Units/volume] in Serum;Hu Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31536-6;Neuronal nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Neuronal nuclear IgG Ab [Units/volume] in Serum;Hu IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31537-4;Neuronal nuclear type 1 Ab;ACnc;Pt;CSF;Qn;;SERO;1;Neuronal nuclear type 1 Ab [Units/volume] in Cerebral spinal fluid;Hu1 Ab CSF-aCnc;;ACTIVE;2.07;2.73 +31538-2;Neuronal nuclear type 2 Ab;ACnc;Pt;CSF;Qn;;SERO;1;Neuronal nuclear type 2 Ab [Units/volume] in Cerebral spinal fluid;Hu2 Ab CSF-aCnc;;ACTIVE;2.07;2.73 +31539-0;Neuronal nuclear type 2 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Serum;Hu2 Ab Ser Ql;;ACTIVE;2.07;2.73 +31540-8;Nuclear Ab;ACnc;Pt;Body fld;Qn;;SERO;1;Nuclear Ab [Units/volume] in Body fluid;ANA Fld-aCnc;;ACTIVE;2.07;2.69 +31541-6;Nuclear Ab;ACnc;Pt;Pericard fld;Qn;;SERO;1;Nuclear Ab [Units/volume] in Pericardial fluid;ANA Pcar-aCnc;;ACTIVE;2.07;2.69 +3154-2;Specimen weight;Mass;Pt;XXX;Qn;;SPEC;1;Weight of Specimen;Specimen wt;;ACTIVE;1.0;2.73 +31542-4;Nuclear Ab;ACnc;Pt;Plr fld;Qn;;SERO;1;Nuclear Ab [Units/volume] in Pleural fluid;ANA Plr-aCnc;;ACTIVE;2.07;2.69 +31543-2;Nuclear Ab;ACnc;Pt;Periton fld;Qn;;SERO;1;Nuclear Ab [Units/volume] in Peritoneal fluid;ANA Prt-aCnc;;ACTIVE;2.07;2.69 +31544-0;Nuclear Ab;ACnc;Pt;Synv fld;Qn;;SERO;1;Nuclear Ab [Units/volume] in Synovial fluid;ANA Snv-aCnc;;ACTIVE;2.07;2.69 +31545-7;Nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Nuclear IgG Ab [Presence] in Serum;Nuclear IgG Ser Ql;;ACTIVE;2.07;2.73 +31546-5;Ovary Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ovary IgG Ab [Units/volume] in Serum;Ovary IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31547-3;Pancreatic islet cell Ab;PrThr;Pt;Ser;Ord;;SERO;1;Pancreatic islet cell Ab [Presence] in Serum;Panc Islet Cell Ab Ser Ql;;ACTIVE;2.07;2.73 +31548-1;Parainfluenza virus 1 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Parainfluenza virus 1 Ab [Units/volume] in Body fluid;HPIV1 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31549-9;Parainfluenza virus 1 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1 IgM Ab [Units/volume] in Serum;HPIV1 IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31550-7;Parainfluenza virus 2 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Parainfluenza virus 2 Ab [Units/volume] in Body fluid;HPIV2 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31551-5;Parainfluenza virus 2 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 2 IgM Ab [Units/volume] in Serum;HPIV2 IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31552-3;Parainfluenza virus 3 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Parainfluenza virus 3 Ab [Units/volume] in Body fluid;HPIV3 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31553-1;Parainfluenza virus 3 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 IgG Ab [Units/volume] in Serum;HPIV3 IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31554-9;Parainfluenza virus 3 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 IgM Ab [Units/volume] in Serum;HPIV3 IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31555-6;Parainfluenza virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus Ab [Units/volume] in Serum;HPIV Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31556-4;Parietal cell Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Parietal cell IgG Ab [Presence] in Serum;PCA IgG Ser Ql;;ACTIVE;2.07;2.56 +31557-2;Parvovirus B19 Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Cerebral spinal fluid;B19V IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31558-0;Parvovirus B19 Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Cerebral spinal fluid;B19V IgM CSF-aCnc;;ACTIVE;2.07;2.69 +3155-9;Specimen mass;Mass;Pt;XXX;Qn;;SPEC;1;Deprecated Weight of Unspecified specimen;Deprecated Specimen mass Qn;;DEPRECATED;1.0;2.69 +31559-8;Pasteurella multocida Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Pasteurella multocida Ab [Units/volume] in Serum;P multoc Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31560-6;Peste des petits ruminants virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Peste des petits ruminants virus Ab [Units/volume] in Serum;PPRV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31561-4;Phospholipid Ab.IgA;ACnc;Pt;Ser;Qn;;COAG;1;Phospholipid IgA Ab [Units/volume] in Serum;Phospholipid IgA Ser-aCnc;;ACTIVE;2.07;2.70 +31562-2;PM-SCL extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;PM-SCL extractable nuclear Ab [Units/volume] in Serum;ENA PM/SCL Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31563-0;PM-SCL extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;PM-SCL extractable nuclear Ab [Presence] in Serum;ENA PM/SCL Ab Ser Ql;;ACTIVE;2.07;2.73 +31564-8;Polio virus 1 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Polio virus 1 Ab [Units/volume] in Cerebral spinal fluid;PV1 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31565-5;Polio virus 1 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Polio virus 1 Ab [Units/volume] in Body fluid;PV1 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31566-3;Polio virus 2 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Polio virus 2 Ab [Units/volume] in Cerebral spinal fluid;PV2 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +3156-7;Specimen volume;Vol;Pt;Amnio fld;Qn;;SPEC;1;Volume of Amniotic fluid;Specimen vol Amn;;ACTIVE;1.0;2.73 +31567-1;Polio virus 2 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Polio virus 2 Ab [Units/volume] in Body fluid;PV2 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31568-9;Polio virus 3 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Polio virus 3 Ab [Units/volume] in Cerebral spinal fluid;PV3 Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31569-7;Polio virus 3 Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Polio virus 3 Ab [Units/volume] in Body fluid;PV3 Ab Fld-aCnc;;ACTIVE;2.07;2.69 +31570-5;Porcine influenza virus A Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Porcine influenza virus A Ab [Units/volume] in Serum;Porcine FLUAV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31571-3;Porcine parvovirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Porcine parvovirus Ab [Units/volume] in Serum;PPV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31572-1;Porcine reproductive and respiratory syndrome virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;PRRSV Ab [Units/volume] in Serum;PRRSV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31573-9;Powassan virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Powassan virus IgG Ab [Units/volume] in Serum;POWV IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31574-7;Powassan virus Ab.IgG;ACnc;Pt;XXX;Qn;;MICRO;1;Powassan virus IgG Ab [Units/volume] in Specimen;POWV IgG Spec-aCnc;;ACTIVE;2.07;2.69 +3157-5;Specimen volume;Vol;Pt;Bld;Qn;;SPEC;1;Volume of Blood;Specimen vol Bld;;ACTIVE;1.0;2.73 +31575-4;Powassan virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Powassan virus IgM Ab [Units/volume] in Serum;POWV IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31576-2;Powassan virus Ab.IgM;ACnc;Pt;XXX;Qn;;MICRO;1;Powassan virus IgM Ab [Units/volume] in Specimen;POWV IgM Spec-aCnc;;ACTIVE;2.07;2.69 +31577-0;Pseudorabies virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Pseudorabies virus Ab [Units/volume] in Serum;PRV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31578-8;Pullularia sp Ab;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pullularia sp Ab [Presence] in Serum;Pullaria Ab Ql;;ACTIVE;2.07;2.56 +31579-6;Purkinje cells Ab;ACnc;Pt;CSF;Qn;;SERO;1;Purkinje cells Ab [Units/volume] in Cerebral spinal fluid;Purkinje Cells Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31580-4;Purkinje cells Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Purkinje cells IgG Ab [Units/volume] in Serum;Purkinje Cells IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31581-2;Reovirus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Reovirus Ab [Units/volume] in Cerebral spinal fluid;Reovirus Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31582-0;Reovirus Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Reovirus Ab [Units/volume] in Body fluid;Reovirus Ab Fld-aCnc;;ACTIVE;2.07;2.69 +3158-3;Specimen volume;MRat;24H;Body fld;Qn;;SPEC;1;Volume [Mass/time] of 24 hour Body fluid;Specimen vol 24h Fld-mRate;;ACTIVE;1.0;2.21 +31583-8;Respiratory syncytial virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Respiratory syncytial virus IgG Ab [Units/volume] in Cerebral spinal fluid;RSV IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31584-6;Reticulin Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Reticulin IgG Ab [Units/volume] in Serum;Reticulin IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31585-3;Reticulin Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Reticulin IgG Ab [Presence] in Serum;Reticulin IgG Ser Ql;;ACTIVE;2.07;2.73 +31586-1;Rhodococcus equi Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rhodococcus equi Ab [Units/volume] in Serum;R equi Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31587-9;Rhodococcus equi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rhodococcus equi Ab [Presence] in Serum;R equi Ab Ser Ql;;ACTIVE;2.07;2.56 +31588-7;Ribonucleoprotein extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ribonucleoprotein extractable nuclear IgG Ab [Units/volume] in Serum;ENA RNP IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31589-5;Ribosomal Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ribosomal Ab [Units/volume] in Serum;Ribosomal Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31590-3;Ribosomal Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ribosomal Ab [Presence] in Serum;Ribosomal Ab Ser Ql;;ACTIVE;2.07;2.56 +3159-1;Specimen volume;Vol;Pt;Plas;Qn;;SPEC;1;Volume of Plasma;Specimen vol Plas;;ACTIVE;1.0;2.40 +31591-1;Ribosomal P Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Ribosomal P Ab [Units/volume] in Serum;Deprecated Ribosomal P Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31592-9;Ribosomal P Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ribosomal P Ab [Presence] in Serum;Ribosomal P Ab Ser Ql;;ACTIVE;2.07;2.73 +31593-7;Rickettsia (Proteus OX19) Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia (Proteus OX19) Ab [Units/volume] in Serum;Proteus OX19 Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31594-5;Rickettsia (Proteus OXK) Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia (Proteus OXK) Ab [Units/volume] in Serum;Proteus OXK Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31595-2;Rickettsia akari Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia akari Ab [Units/volume] in Serum;R akari Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31596-0;Rickettsia australis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia australis Ab [Units/volume] in Serum;R australis Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31597-8;Rickettsia conorii Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia conorii Ab [Units/volume] in Serum;R conorii Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31598-6;Rickettsia honei Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia honei Ab [Units/volume] in Serum;R honei Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31599-4;Rickettsia prowazekii Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia prowazekii IgG Ab [Units/volume] in Serum;R prowazek IgG Ser-aCnc;;ACTIVE;2.07;2.69 +316-0;Meclocycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Meclocycline [Susceptibility] by Disk diffusion (KB);Meclocycline Islt KB;;ACTIVE;1.0;2.19 +31600-0;Rickettsia prowazekii Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia prowazekii IgM Ab [Units/volume] in Serum;R prowazek IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31601-8;Rickettsia spotted fever group Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Rickettsia spotted fever group IgM Ab [Units/volume] in Cerebral spinal fluid;Rick SF IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31602-6;Rickettsia typhus group Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Rickettsia typhus group IgM Ab [Units/volume] in Cerebral spinal fluid;Rick Typhus IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31603-4;Rickettsia rickettsii Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia rickettsii Ab [Units/volume] in Serum;R rickettsi Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31604-2;Rickettsia rickettsii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia rickettsii Ab [Presence] in Serum;R rickettsi Ab Ser Ql;;ACTIVE;2.07;2.56 +31605-9;Rickettsia sibirica Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia sibirica Ab [Units/volume] in Serum;R sibirica Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31606-7;Orientia tsutsugamushi Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi IgG Ab [Units/volume] in Serum;O tsut IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31607-5;Orientia tsutsugamushi Gilliam Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Gilliam Ab [Units/volume] in Serum;O tsut Gill Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31608-3;Orientia tsutsugamushi Karp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Karp Ab [Units/volume] in Serum;O tsut Karp Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3160-9;Specimen volume;Vol;Pt;Semen;Qn;;FERT;1;Volume of Semen;Specimen vol Smn;;ACTIVE;1.0;2.73 +31609-1;Orientia tsutsugamushi Kato Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Kato Ab [Units/volume] in Serum;O tsut Kato Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31610-9;Orientia tsutsugamushi Litchfield Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Litchfield Ab [Units/volume] in Serum;O tsut Litch Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31611-7;Rickettsia typhi Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Rickettsia typhi IgM Ab [Units/volume] in Body fluid;R typhi IgM Fld-aCnc;;ACTIVE;2.07;2.69 +31612-5;Rift valley fever virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rift valley fever virus Ab [Units/volume] in Serum;RVFV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31613-3;Rinderpest virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rinderpest virus Ab [Units/volume] in Serum;RPV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31614-1;Ross river virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Ross River virus IgG Ab [Presence] in Serum;RRV IgG Ser Ql;;ACTIVE;2.07;2.56 +31615-8;Ross river virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Ross River virus IgM Ab [Presence] in Serum;RRV IgM Ser Ql;;ACTIVE;2.07;2.73 +31616-6;Rubella virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Rubella virus IgM Ab [Presence] in Serum;RUBV IgM Ser Ql;;ACTIVE;2.07;2.73 +3161-7;Specimen volume;VRat;24H;Sputum;Qn;;SPEC;1;Volume [Flow] of 24 hour Sputum;Specimen vol 24h Spt-vRate;;ACTIVE;1.0;2.42 +31617-4;Saint Louis encephalitis virus Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Units/volume] in Specimen;SLEV Ab Spec-aCnc;;ACTIVE;2.07;2.69 +31618-2;Salmonella paratyphi B H Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi B H Ab [Units/volume] in Serum;S paraty B H Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31619-0;Salmonella paratyphi B O Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi B O Ab [Units/volume] in Serum;S paraty B O Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31620-8;Salmonella pullorum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella pullorum Ab [Units/volume] in Serum;S pullorum Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31621-6;Salmonella typhi H D Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella typhi H D Ab [Units/volume] in Serum;S Typhi H d Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31622-4;Salmonella typhi O D Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella typhi O D Ab [Units/volume] in Serum;S Typhi O D Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31623-2;Salmonella typhimurium Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella typhimurium Ab [Units/volume] in Serum;S Typhimur Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31624-0;Schistosoma sp Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Schistosoma sp IgG Ab [Units/volume] in Cerebral spinal fluid;Schistosoma IgG CSF-aCnc;;ACTIVE;2.07;2.69 +3162-5;Specimen volume;MRat;24H;Stool;Qn;;SPEC;1;Volume [Mass/time] of 24 hour Stool;Specimen vol 24h Stl-mRate;;ACTIVE;1.0;2.21 +31625-7;Sjogrens syndrome-A extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Sjogrens syndrome-A extractable nuclear IgG Ab [Presence] in Serum;ENA SS-A IgG Ser Ql;;ACTIVE;2.07;2.73 +31626-5;Sjogrens syndrome-B extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Sjogrens syndrome-B extractable nuclear IgG Ab [Presence] in Serum;ENA SS-B IgG Ser Ql;;ACTIVE;2.07;2.73 +31627-3;Smith extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Smith extractable nuclear Ab [Presence] in Serum;ENA SM Ab Ser Ql;;ACTIVE;2.07;2.73 +31628-1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Presence] in Serum;ENA SM+RNP Ab Ser Ql;;ACTIVE;2.07;2.73 +31629-9;Smooth muscle Ab;ACnc;Pt;Ser;Qn;;SERO;1;Smooth muscle Ab [Units/volume] in Serum;Smooth muscle Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31630-7;Spermatozoa Ab;PrThr;Pt;Cvm;Ord;;FERT;1;Spermatozoa Ab [Presence] in Cervical mucus;Sperm Ab Cerv mucus Ql;;ACTIVE;2.07;2.56 +31631-5;Spermatozoa Ab;PrThr;Pt;Ser;Ord;;FERT;1;Spermatozoa Ab [Presence] in Serum;Sperm Ab Ser Ql;;ACTIVE;2.07;2.73 +31632-3;Spermatozoa Ab;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Ab [Presence] in Semen;Sperm Ab Smn Ql;;ACTIVE;2.07;2.56 +3163-3;Specimen volume;Vol;72H;Stool;Qn;;SPEC;1;Volume of 72 hour Stool;Specimen vol 72h Stl;;ACTIVE;1.0;2.42 +31633-1;Sporothrix schenckii Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Sporothrix schenckii Ab [Units/volume] in Cerebral spinal fluid;S schenckii Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31634-9;Stachybotrys chartarum Ab.IgA;ACnc;Pt;Ser;Qn;;ALLERGY;1;Stachybotrys chartarum IgA Ab [Units/volume] in Serum;S chartarum IgA Qn;;ACTIVE;2.07;2.73 +31635-6;Streptococcus pneumoniae 1 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum 1 IgG sp1 Ser-aCnc;;DEPRECATED;2.07;2.69 +31636-4;Streptococcus pneumoniae 14 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 Ab [Units/volume] in Serum;Deprecated S pneum14 Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31637-2;Streptococcus pneumoniae 23 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum23 IgG sp1 Ser-aCnc;;DEPRECATED;2.07;2.69 +31638-0;Streptococcus pneumoniae 23 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum23 IgG sp2 Ser-aCnc;;DEPRECATED;2.07;2.69 +31639-8;Streptococcus pneumoniae Danish serotype 6B Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 6B IgG sp2 Ser-aCnc;;ACTIVE;2.07;2.69 +31640-6;Streptococcus pneumoniae 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 Ab [Units/volume] in Serum;Deprecated S pneum3 Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +3164-1;Specimen volume;VRat;24H;Stool;Qn;;SPEC;1;Volume [Flow] of 24 hour Stool;Specimen vol 24h Stl-vRate;;ACTIVE;1.0;2.42 +31641-4;Streptococcus pneumoniae 3 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum3 IgG sp1 Ser-aCnc;;DEPRECATED;2.07;2.69 +31642-2;Streptococcus pneumoniae 3 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum3 IgG sp2 Ser-aCnc;;DEPRECATED;2.07;2.69 +31643-0;Streptococcus pneumoniae 4 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum4 IgG sp1 Ser-aCnc;;DEPRECATED;2.07;2.69 +31644-8;Streptococcus pneumoniae 4 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum4 IgG sp2 Ser-aCnc;;DEPRECATED;2.07;2.69 +31645-5;Streptococcus pneumoniae Danish serotype 7F Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 7F IgG sp1 Ser-aCnc;;ACTIVE;2.07;2.69 +31646-3;Streptococcus pneumoniae Danish serotype 7F Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 7F IgG sp2 Ser-aCnc;;ACTIVE;2.07;2.69 +31647-1;Streptococcus pneumoniae Danish serotype 18C Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 18C IgG sp1 Ser-aCnc;;ACTIVE;2.07;2.69 +31648-9;Streptococcus pneumoniae 6 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6 IgG Ab [Units/volume] in Serum;Deprecated S pneum6 IgG Ser-aCnc;;DEPRECATED;2.07;2.69 +31649-7;Streptococcus pneumoniae 6 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6 Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum6 Ab sp2 Ser-aCnc;;DEPRECATED;2.07;2.69 +31650-5;Streptococcus pneumoniae Danish serotype 9V Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Units/volume] in Serum;S pneum Da 9V IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31651-3;Streptococcus pneumoniae 6a+6b Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6a+6b Ab [Units/volume] in Serum;Deprecated S pneum6a+6b Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31652-1;Streptococcus pneumoniae 6+26 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6+26 Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum6+26 Ab sp1 Ser-aCnc;;DEPRECATED;2.07;2.69 +31653-9;Streptococcus pneumoniae 8 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum8 IgG sp1 Ser-aCnc;;DEPRECATED;2.07;2.69 +31654-7;Streptococcus pneumoniae 8 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum8 IgG sp2 Ser-aCnc;;DEPRECATED;2.07;2.69 +31655-4;Streptococcus pneumoniae 9 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 Ab [Units/volume] in Serum;Deprecated S pneum9 Ab Ser-aCnc;;DEPRECATED;2.07;2.69 +31656-2;Streptococcus pneumoniae 9 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Units/volume] in Serum --1st specimen;Deprecated S pneum9 IgG sp1 Ser-aCnc;;DEPRECATED;2.07;2.69 +31657-0;Streptococcus pneumoniae 9 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Units/volume] in Serum --2nd specimen;Deprecated S pneum9 IgG sp2 Ser-aCnc;;DEPRECATED;2.07;2.69 +3165-8;Specimen volume;VRat;72H;Stool;Qn;;SPEC;1;Volume [Flow] of 72 hour Stool;Specimen vol 72h Stl-vRate;;ACTIVE;1.0;2.42 +31658-8;Streptococcus pyogenes enzyme Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pyogenes enzyme Ab [Units/volume] in Serum;S pyog.enz Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31659-6;Striated muscle Ab;ACnc;Pt;Ser;Qn;;SERO;1;Striated muscle Ab [Units/volume] in Serum;Stria Mus Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31660-4;Striated muscle Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Striated muscle IgG Ab [Units/volume] in Serum;Stria Mus IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31661-2;Sulfate-3-Glucuronyl paragloboside Ab;PrThr;Pt;Ser;Ord;;SERO;1;Sulfate-3-Glucuronyl paragloboside Ab [Presence] in Serum;SGPG Ab Ser Ql;;ACTIVE;2.07;2.56 +31662-0;Sulfate-3-Glucuronyl paragloboside Ab;ACnc;Pt;Ser;Qn;;SERO;1;Sulfate-3-Glucuronyl paragloboside Ab [Units/volume] in Serum;SGPG Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31663-8;Sulfate-3-Glucuronyl paragloboside Ab.IgM;PrThr;Pt;CSF;Ord;;SERO;1;Sulfate-3-Glucuronyl paragloboside IgM Ab [Presence] in Cerebral spinal fluid;SGPG IgM CSF Ql;;ACTIVE;2.07;2.56 +31664-6;Sulfate-3-Glucuronyl paragloboside Ab.IgM;ACnc;Pt;CSF;Qn;;SERO;1;Sulfate-3-Glucuronyl paragloboside IgM Ab [Units/volume] in Cerebral spinal fluid;SGPG IgM CSF-aCnc;;ACTIVE;2.07;2.69 +31665-3;Sulfate-3-Glucuronyl paragloboside Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Sulfate-3-Glucuronyl paragloboside IgM Ab [Presence] in Serum;SGPG IgM Ser Ql;;ACTIVE;2.07;2.73 +3166-6;Specimen volume;VRat;24H;Sweat;Qn;;SPEC;1;Volume [Flow] of 24 hour Sweat;Specimen vol 24h Sweat-vRate;;ACTIVE;1.0;2.42 +31666-1;Sulfate-3-Glucuronyl paragloboside Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Sulfate-3-Glucuronyl paragloboside IgM Ab [Units/volume] in Serum;SGPG IgM Ser-aCnc;;ACTIVE;2.07;2.73 +31667-9;Sulfatide Ab;PrThr;Pt;Ser;Ord;;SERO;1;Sulfatide Ab [Presence] in Serum;Sulfatide Ab Ser Ql;;ACTIVE;2.07;2.73 +31668-7;Sulfatide Ab;ACnc;Pt;Ser;Qn;;SERO;1;Sulfatide Ab [Units/volume] in Serum;Sulfatide Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31669-5;Sulfatide Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Sulfatide IgG Ab [Units/volume] in Serum;Sulfatide IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31670-3;Sulfatide Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Sulfatide IgG Ab [Presence] in Serum;Sulfatide IgG Ser Ql;;ACTIVE;2.07;2.56 +31671-1;Sulfatide Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Sulfatide IgM Ab [Units/volume] in Serum;Sulfatide IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31672-9;Taylorella equigenitalis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Taylorella equigenitalis Ab [Units/volume] in Serum;T equigenit Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31673-7;Teichoate Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Teichoate Ab [Units/volume] in Serum;Teichoate Ab Ser-aCnc;;ACTIVE;2.07;2.73 +3167-4;Specimen volume;Vol;24H;Urine;Qn;;SPEC;1;Volume of 24 hour Urine;Specimen vol 24h Ur;;ACTIVE;1.0;2.73 +31674-5;Ganglioside GQ1b Ab;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GQ1b Ab [Units/volume] in Serum;GQ1b Gangl Ab Ser-aCnc;;ACTIVE;2.07;2.73 +31675-2;Tetrasialylganglioside GQ1b Ab;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Tetrasialylganglioside GQ1b Ab [Presence] in Serum;Deprecated GQ1b Tetra Ab Ser Ql;;DEPRECATED;2.07;2.36 +31676-0;Ganglioside GQ1b Ab.IgG;ACnc;Pt;CSF;Qn;;SERO;1;Ganglioside GQ1b IgG Ab [Units/volume] in Cerebral spinal fluid;GQ1b Gangl IgG CSF-aCnc;;ACTIVE;2.07;2.68 +31677-8;Tetrasialylganglioside GQ1b Ab.IgG;ACnc;Pt;CSF;Ord;;SERO;1;Deprecated Tetrasialylganglioside GQ1b IgG Ab [Presence] in Cerebral spinal fluid;Deprecated GQ1b Tetra IgG CSF Ql;;DEPRECATED;2.07;2.36 +31678-6;Ganglioside GQ1b Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ganglioside GQ1b IgG Ab [Units/volume] in Serum;GQ1b Gangl IgG Ser-aCnc;;ACTIVE;2.07;2.73 +31679-4;Tetrasialylganglioside GQ1b Ab.IgG;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Tetrasialylganglioside GQ1b IgG Ab [Presence] in Serum;Deprecated GQ1b Tetra IgG Ser Ql;;DEPRECATED;2.07;2.36 +31680-2;Theileria annulata Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Theileria annulata Ab [Units/volume] in Serum;T annulata Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31681-0;Theileria mutans Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Theileria mutans Ab [Units/volume] in Serum;T mutans Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3168-2;Specimen volume;VRat;24H;Urine;Qn;;SPEC;1;Volume [Flow] of 24 hour Urine;Specimen vol 24h Ur-vRate;;ACTIVE;1.0;2.73 +31682-8;Theileria parva Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Theileria parva Ab [Units/volume] in Serum;T parva Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31683-6;Thermoactinomyces sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Thermoactinomyces IgG Ab [Units/volume] in Serum;Thermoactinomyces IgG Ser-aCnc;;ACTIVE;2.07;2.69 +31684-4;Toxoplasma gondii Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Deprecated Toxoplasma gondii IgG Ab [Units/volume] in Cerebral spinal fluid;Deprecated T gondii IgG CSF-aCnc;;DEPRECATED;2.07;2.69 +31685-1;Toxoplasma gondii Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Cerebral spinal fluid;T gondii IgG CSF Ql;;ACTIVE;2.07;2.56 +31686-9;Transmissible gastroenteritis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Transmissible gastroenteritis virus Ab [Units/volume] in Serum;TGEV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31687-7;Trichinella sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Trichinella sp IgM Ab [Units/volume] in Serum;Trichinella IgM Ser-aCnc;;ACTIVE;2.07;2.69 +31688-5;Trivittatus virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Trivittatus virus Ab [Units/volume] in Cerebral spinal fluid;TVTV Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31689-3;Trivittatus virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Trivittatus virus Ab [Units/volume] in Serum;TVTV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +3169-0;Specimen volume;Vol;Pt;XXX;Qn;;SPEC;1;Volume of Specimen;Specimen vol;;ACTIVE;1.0;2.73 +31690-1;Trivittatus virus Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Trivittatus virus Ab [Units/volume] in Specimen;TVTV Ab Spec-aCnc;;ACTIVE;2.07;2.69 +31691-9;Trypanosoma cruzi Ab.IgG;ACnc;Pt;XXX;Qn;;MICRO;1;Trypanosoma cruzi IgG Ab [Units/volume] in Specimen;T cruzi IgG Spec-aCnc;;ACTIVE;2.07;2.69 +31692-7;Trypanosoma equiperdum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Trypanosoma equiperdum Ab [Units/volume] in Serum;T equiperdum Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31693-5;Unidentified extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Unidentified extractable nuclear Ab [Presence] in Serum;ENA Unident Ab Ser Ql;;ACTIVE;2.07;2.56 +31694-3;Varicella zoster virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Varicella zoster virus Ab [Units/volume] in Cerebral spinal fluid;VZV Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31695-0;Varicella zoster virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Varicella zoster virus IgM Ab [Units/volume] in Cerebral spinal fluid;VZV IgM CSF-aCnc;;ACTIVE;2.07;2.73 +31696-8;Vesicular stomatitis Indiana virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Vesicular stomatitis Indiana virus Ab [Units/volume] in Serum;VSIV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31697-6;Vesicular stomatitis New Jersey virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Vesicular stomatitis New Jersey virus Ab [Units/volume] in Serum;VSNJV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31698-4;Vibrio cholerae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Vibrio cholerae Ab [Units/volume] in Serum;V cholerae Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31699-2;Rabbit hemorrhagic disease virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rabbit hemorrhagic disease virus Ab [Units/volume] in Serum;RHDV Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31700-8;West Nile virus Ab;ACnc;Pt;XXX;Qn;;MICRO;1;West Nile virus Ab [Units/volume] in Specimen;WNV Ab Spec-aCnc;;ACTIVE;2.07;2.69 +31701-6;West Nile virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;West Nile virus IgG Ab [Presence] in Serum;WNV IgG Ser Ql;;ACTIVE;2.07;2.73 +31702-4;West Nile virus Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;West Nile virus IgG Ab [Presence] in Specimen;WNV IgG Spec Ql;;ACTIVE;2.07;2.73 +31703-2;West Nile virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;West Nile virus IgM Ab [Presence] in Cerebral spinal fluid;WNV IgM CSF Ql;;ACTIVE;2.07;2.73 +31704-0;West Nile virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;West Nile virus IgM Ab [Presence] in Serum;WNV IgM Ser Ql;;ACTIVE;2.07;2.73 +31705-7;Western equine encephalitis virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Western equine encephalitis virus Ab [Units/volume] in Cerebral spinal fluid;WEEV Ab CSF-aCnc;;ACTIVE;2.07;2.69 +31706-5;Western equine encephalitis virus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Western equine encephalitis virus IgG Ab [Units/volume] in Cerebral spinal fluid;WEEV IgG CSF-aCnc;;ACTIVE;2.07;2.69 +31707-3;Yersinia enterocolitica O:5 Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Yersinia enterocolitica O:5 Ab [Units/volume] in Specimen;Y entero O:5 Ab Spec-aCnc;;ACTIVE;2.07;2.69 +3170-8;Specimen volume;VRat;24H;XXX;Qn;;SPEC;1;Volume [Flow] of 24 hour Specimen;Specimen vol 24h Spec-vRate;;ACTIVE;1.0;2.69 +31708-1;Yersinia enterocolitica Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica Ab [Units/volume] in Serum;Y enterocol Ab Ser-aCnc;;ACTIVE;2.07;2.69 +31709-9;Adenovirus 40+41 Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Adenovirus 40+41 Ag [Presence] in Stool;AdV 40+41 Ag Stl Ql;;ACTIVE;2.07;2.73 +31710-7;Adenovirus Ag;PrThr;Pt;Cnjt;Ord;;MICRO;1;Adenovirus Ag [Presence] in Conjunctival specimen;HAdV Ag Conjunct Ql;;ACTIVE;2.07;2.56 +31711-5;Adenovirus Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Adenovirus Ag [Presence] in Stool;HAdV Ag Stl Ql;;ACTIVE;2.07;2.73 +31712-3;Adenovirus Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Adenovirus Ag [Presence] in Throat;HAdV Ag Throat Ql;;ACTIVE;2.07;2.56 +31713-1;Adenovirus Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Adenovirus Ag [Presence] in Urine;HAdV Ag Ur Ql;;ACTIVE;2.07;2.56 +31714-9;Adenovirus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Adenovirus Ag [Presence] in Specimen;HAdV Ag Spec Ql;;ACTIVE;2.07;2.73 +31715-6;African horse sickness virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;African horse sickness virus Ag [Presence] in Specimen;AHSV Ag Spec Ql;;ACTIVE;2.07;2.69 +3171-6;Specimen.dry weight;MRat;72H;Stool;Qn;;SPEC;1;Dry weight [Mass/time] of 72 hour Stool;Dry Spec Wt 72h Stl-mRate;;ACTIVE;1.0;2.73 +31716-4;African swine fever virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;African swine fever virus Ag [Presence] in Specimen;ASFV Ag Spec Ql;;ACTIVE;2.07;2.69 +31717-2;Alcelaphine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Alcelaphine herpesvirus 1 Ag [Presence] in Specimen;AHV1 Ag Spec Ql;;ACTIVE;2.07;2.69 +31718-0;Astrovirus Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Astrovirus Ag [Presence] in Stool;HAstV Ag Stl Ql;;ACTIVE;2.07;2.56 +31719-8;Infectious bronchitis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Infectious bronchitis virus Ag [Presence] in Specimen;IBV Ag Spec Ql;;ACTIVE;2.07;2.69 +31720-6;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;Lung tiss;Ord;;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Lung tissue;ILT Ag Lung tiss Ql;;ACTIVE;2.07;2.56 +31721-4;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;Trac;Ord;;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Trachea;ILT Ag Trachea Ql;;ACTIVE;2.07;2.56 +31722-2;Avian infectious laryngotracheitis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Avian infectious laryngotracheitis virus Ag [Presence] in Specimen;ILT Ag Spec Ql;;ACTIVE;2.07;2.69 +31723-0;Avian leukosis virus Ag;ACnc;Pt;Eggylk;Qn;;MICRO;1;Avian leukosis virus Ag [Units/volume] in Egg yolk;ALV Ag Egg Yolk-aCnc;;ACTIVE;2.07;2.69 +3172-4;Time^post exercise;Time;Pt;^Patient;Qn;;CLIN;2;Time --post exercise;Time p Exc;;ACTIVE;1.0;2.27 +31724-8;Avian leukosis virus Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Avian leukosis virus Ag [Units/volume] in Serum;ALV Ag Ser-aCnc;;ACTIVE;2.07;2.69 +31725-5;Avian paramyxovirus 1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Avian paramyxovirus 1 Ag [Presence] in Specimen;APMV1 Ag Spec Ql;;ACTIVE;2.07;2.69 +31726-3;Bacillus anthracis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bacillus anthracis Ag [Presence] in Specimen;B anthracis Ag Spec Ql;;ACTIVE;2.07;2.69 +31727-1;Bacteroides fragilis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bacteroides fragilis Ag [Presence] in Specimen;B fragilis Ag Spec Ql;;ACTIVE;2.07;2.73 +31728-9;Bacteroides melaninogenicus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bacteroides melaninogenicus Ag [Presence] in Specimen;B melaninogenicus Ag Spec Ql;;ACTIVE;2.07;2.69 +31729-7;Bladder tumor Ag;PrThr;Pt;Urine;Ord;;SERO;1;Bladder tumor Ag [Presence] in Urine;Bladder tumor Ag Ur Ql;;ACTIVE;2.07;2.73 +31730-5;Bladder tumor Ag;ACnc;Pt;Urine;Qn;;SERO;1;Bladder tumor Ag [Units/volume] in Urine;Bladder tumor Ag Ur-aCnc;;ACTIVE;2.07;2.73 +31731-3;Blastomyces dermatitidis Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Blastomyces dermatitidis Ag [Presence] in Serum;B dermat Ag Ser Ql;;ACTIVE;2.07;2.73 +3173-2;Coagulation surface induced;Time;Pt;Bld;Qn;Coag;COAG;1;aPTT in Blood by Coagulation assay;aPTT Bld;;ACTIVE;1.0;2.73 +31732-1;Bluetongue virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bluetongue virus Ag [Presence] in Specimen;BTV Ag Spec Ql;;ACTIVE;2.07;2.69 +31733-9;Border disease virus Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Border disease virus Ag [Presence] in Blood;Border DV Ag Bld Ql;;ACTIVE;2.07;2.56 +31734-7;Border disease virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Border disease virus Ag [Presence] in Specimen;Border DV Ag Spec Ql;;ACTIVE;2.07;2.69 +31735-4;Bordetella bronchiseptica Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bordetella bronchiseptica Ag [Presence] in Specimen;B bronch Ag Spec Ql;;ACTIVE;2.07;2.69 +31736-2;Bordetella parapertussis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bordetella parapertussis Ag [Presence] in Specimen;B parapert Ag Spec Ql;;ACTIVE;2.07;2.69 +31737-0;Bordetella pertussis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bordetella pertussis Ag [Presence] in Specimen;B pert Ag Spec Ql;;ACTIVE;2.07;2.73 +31738-8;Borrelia burgdorferi Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Borrelia burgdorferi Ag [Presence] in Specimen;B burgdor Ag Spec Ql;;ACTIVE;2.07;2.73 +31739-6;Borrelia sp Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Borrelia sp Ag [Presence] in Specimen;Borrelia Ag Spec Ql;;ACTIVE;2.07;2.69 +3174-0;Antithrombin;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Antithrombin [Units/volume] in Platelet poor plasma by Chromogenic method;AT III PPP Chro-aCnc;;ACTIVE;1.0;2.73 +31740-4;Bovine diarrhea virus Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Bovine diarrhea virus Ag [Presence] in Blood;BVDV Ag Bld Ql;;ACTIVE;2.07;2.56 +31741-2;Bovine diarrhea virus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Bovine diarrhea virus Ag [Presence] in Nose;BVDV Ag Nose Ql;;ACTIVE;2.07;2.56 +31742-0;Bovine diarrhea virus Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Bovine diarrhea virus Ag [Presence] in Stool;BVDV Ag Stl Ql;;ACTIVE;2.07;2.56 +31743-8;Bovine diarrhea virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bovine diarrhea virus Ag [Presence] in Specimen;BVDV Ag Spec Ql;;ACTIVE;2.07;2.69 +31744-6;Bovine herpesvirus 1 Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Genital specimen;BoHV1 Ag Genital Ql;;ACTIVE;2.07;2.56 +31745-3;Bovine herpesvirus 1 Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Nose;BoHV1 Ag Nose Ql;;ACTIVE;2.07;2.56 +31746-1;Bovine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Bovine herpesvirus 1 Ag [Presence] in Specimen;BoHV1 Ag Spec Ql;;ACTIVE;2.07;2.69 +31747-9;Bovine herpesvirus 1 Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Bovine herpesvirus 1 Ag [Units/volume] in Specimen;BoHV1 Ag Spec-aCnc;;ACTIVE;2.07;2.69 +31748-7;Bovine herpesvirus 2 Ag;PrThr;Pt;Exudate;Ord;;MICRO;1;Bovine herpesvirus 2 Ag [Presence] in Exudate;BoHV2 Ag Exudate Ql;;ACTIVE;2.07;2.56 +31749-5;Bovine herpesvirus 4 Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Bovine herpesvirus 4 Ag [Presence] in Body fluid;BoHV4 Ag Fld Ql;;ACTIVE;2.07;2.56 +31750-3;Bovine inner ear Ag;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Bovine inner ear Ag [Presence] in Serum or Plasma;Bov Inner Ear Ag SerPl Ql;;ACTIVE;2.07;2.56 +31751-1;Bovine respiratory syncytial virus Ag;PrThr;Pt;Lung;Ord;;MICRO;1;Bovine respiratory syncytial virus Ag [Presence] in Lung;BRSV Ag Lung Ql;;ACTIVE;2.07;2.56 +31752-9;Bovine virus diarrhea virus Ag;ACnc;Pt;Bld;Ord;;MICRO;1;Deprecated Bovine diarrhea virus Ag [Presence] in Blood;Deprecated BVDV Ag Bld Ql;;DEPRECATED;2.07;2.36 +31753-7;Brucella sp Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Brucella sp Ag [Presence] in Vaginal fluid;Brucella Ag Vag Ql;;ACTIVE;2.07;2.56 +31754-5;Brucella sp Ag;PrThr;Pt;Placenta;Ord;;MICRO;1;Brucella sp Ag [Presence] in Placenta;Brucella Ag Placenta Ql;;ACTIVE;2.07;2.63 +31755-2;Campylobacter fetus Ag;PrThr;Pt;Genital fld;Ord;;MICRO;1;Campylobacter fetus Ag [Presence] in Genital fluid;C fetus Ag Genital fl Ql;;ACTIVE;2.07;2.56 +31756-0;Campylobacter fetus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Campylobacter fetus Ag [Presence] in Specimen;C fetus Ag Spec Ql;;ACTIVE;2.07;2.73 +3175-7;Antithrombin Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Antithrombin Ag [Units/volume] in Platelet poor plasma by Immunoassay;AT III Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +31757-8;Canarypox virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Canarypox virus Ag [Presence] in Serum;CNPV Ag Ser Ql;;ACTIVE;2.07;2.56 +31758-6;Candida albicans Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Candida albicans Ag [Presence] in Serum;C albicans Ag Ser Ql;;ACTIVE;2.07;2.56 +31759-4;Candida albicans Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Candida albicans Ag [Units/volume] in Serum;C albicans Ag Ser-aCnc;;ACTIVE;2.07;2.73 +31760-2;Candida sp Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Candida sp Ag [Units/volume] in Serum;Candida Ag Ser-aCnc;;ACTIVE;2.07;2.69 +31761-0;Canine parvovirus Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Canine parvovirus Ag [Presence] in Stool;CPV Ag Stl Ql;;ACTIVE;2.07;2.56 +31762-8;Capripox virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Capripox virus Ag [Presence] in Specimen;Capripox Ag Spec Ql;;ACTIVE;2.07;2.69 +31763-6;Chlamydia sp Ag;PrThr;Pt;Cnjt;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Conjunctival specimen;Chlamydia Ag Conjunct Ql;;ACTIVE;2.07;2.56 +31764-4;Chlamydia sp Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Body fluid;Chlamydia Ag Fld Ql;;ACTIVE;2.07;2.56 +3176-5;Antithrombin;SCnc;Pt;PPP;Qn;Chromo;COAG;1;Antithrombin [Moles/volume] in Platelet poor plasma by Chromogenic method;AT III PPP Chro-sCnc;;ACTIVE;1.0;2.73 +31765-1;Chlamydia sp Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Genital specimen;Chlamydia Ag Genital Ql;;ACTIVE;2.07;2.56 +31766-9;Chlamydia sp Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Stool;Chlamydia Ag Stl Ql;;ACTIVE;2.07;2.56 +31767-7;Chlamydia sp Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Specimen;Chlamydia Ag Spec Ql;;ACTIVE;2.07;2.69 +31768-5;Chlamydia trachomatis Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Blood;C trach Ag Bld Ql;;ACTIVE;2.07;2.56 +31769-3;Chlamydia trachomatis Ag;PrThr;Pt;Cnjt;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Conjunctival specimen;C trach Ag Conjunct Ql;;ACTIVE;2.07;2.56 +31770-1;Chlamydia trachomatis Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Cerebral spinal fluid;C trach Ag CSF Ql;;ACTIVE;2.07;2.56 +31771-9;Chlamydia trachomatis Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Cervix;C trach Ag Cvx Ql;;DISCOURAGED;2.07;2.61 +31772-7;Chlamydia trachomatis Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Vaginal fluid;C trach Ag Vag Ql;;DISCOURAGED;2.07;2.61 +3177-3;Antithrombin Ag;SCnc;Pt;PPP;Qn;IA;COAG;1;Antithrombin Ag [Moles/volume] in Platelet poor plasma by Immunoassay;AT III Ag PPP IA-sCnc;;ACTIVE;1.0;2.73 +31773-5;Chlamydia trachomatis Ag;ACnc;Pt;Penis;Ord;;MICRO;1;Deprecated Chlamydia trachomatis Ag [Presence] in Penis;Deprecated C trach Ag Penis Ql;;DEPRECATED;2.07;2.52 +31774-3;Chlamydia trachomatis Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Stool;C trach Ag Stl Ql;;ACTIVE;2.07;2.56 +31775-0;Chlamydia trachomatis Ag;PrThr;Pt;Urine sed;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Urine sediment;C trach Ag UrnS Ql;;ACTIVE;2.07;2.56 +31776-8;Chlamydia trachomatis Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Urethra;C trach Ag Urth Ql;;DISCOURAGED;2.07;2.61 +31777-6;Chlamydia trachomatis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Specimen;C trach Ag Spec Ql;;ACTIVE;2.07;2.73 +31778-4;Chlamydophila pneumoniae Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Chlamydophila pneumoniae Ag [Presence] in Specimen;C pneum Ag Spec Ql;;ACTIVE;2.07;2.69 +31779-2;Chlamydophila psittaci Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Chlamydophila psittaci Ag [Presence] in Genital specimen;C psittaci Ag Genital Ql;;ACTIVE;2.07;2.56 +317-8;Meclocycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Meclocycline [Susceptibility] by Serum bactericidal titer;Meclocycline Titr SBT;;ACTIVE;1.0;2.32 +31780-0;Chlamydophila psittaci Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Chlamydophila psittaci Ag [Presence] in Specimen;C psittaci Ag Spec Ql;;ACTIVE;2.07;2.69 +3178-1;Bleeding time;Time;Pt;^Patient;Qn;Duke;COAG;1;Bleeding time by Duke method;Bleeding time Patient Duke;;ACTIVE;1.0;2.73 +31781-8;Classical swine fever virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Classical swine fever virus Ag [Presence] in Specimen;CSFV Ag Spec Ql;;ACTIVE;2.07;2.69 +31782-6;Coccidioides immitis Ag;PrThr;Pt;Isolate;Ord;;MICRO;1;Coccidioides immitis Ag [Presence] in Isolate;C immitis Ag Islt Ql;;ACTIVE;2.07;2.56 +31783-4;Coxiella burnetii Ag;PrThr;Pt;Placenta;Ord;;MICRO;1;Coxiella burnetii Ag [Presence] in Placenta;C burnet Ag Placenta Ql;;ACTIVE;2.07;2.63 +31784-2;Coxiella burnetii Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Coxiella burnetii Ag [Presence] in Specimen;C burnet Ag Spec Ql;;ACTIVE;2.07;2.69 +31785-9;Cryptococcus neoformans Ag;ACnc;Pt;CSF;Qn;;MICRO;1;Deprecated Cryptococcus neoformans Ag [Units/volume] in Cerebral spinal fluid;Deprecated C neoform Ag CSF-aCnc;;DEPRECATED;2.07;2.69 +31786-7;Cryptococcus neoformans Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Cryptococcus neoformans Ag [Units/volume] in Serum;Deprecated C neoform Ag Ser-aCnc;;DEPRECATED;2.07;2.69 +31787-5;Cryptococcus neoformans Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Deprecated Cryptococcus neoformans Ag [Units/volume] in Unspecified specimen;Deprecated C neoform Ag XXX-aCnc;;DEPRECATED;2.07;2.69 +31788-3;Cryptococcus sp Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Cryptococcus sp Ag [Presence] in Cerebral spinal fluid;Cryptoc Ag CSF Ql;;ACTIVE;2.07;2.73 +31789-1;Cryptococcus sp Ag;ACnc;Pt;CSF;Qn;;MICRO;1;Cryptococcus sp Ag [Units/volume] in Cerebral spinal fluid;Cryptoc Ag CSF-aCnc;;ACTIVE;2.07;2.73 +31790-9;Cryptococcus sp Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Cryptococcus sp Ag [Presence] in Serum;Cryptoc Ag Ser Ql;;ACTIVE;2.07;2.73 +31791-7;Cryptococcus sp Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Cryptococcus sp Ag [Units/volume] in Serum;Cryptoc Ag Ser-aCnc;;ACTIVE;2.07;2.69 +31792-5;Cryptococcus sp Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Cryptococcus sp Ag [Units/volume] in Specimen;Cryptoc Ag Spec-aCnc;;ACTIVE;2.07;2.69 +31793-3;Cryptosporidium sp Ag;ACnc;Pt;Stool;Qn;;MICRO;1;Cryptosporidium sp Ag [Units/volume] in Stool;Cryptosp Ag Stl-aCnc;;ACTIVE;2.07;2.69 +31794-1;Cryptosporidium sp Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Cryptosporidium sp Ag [Presence] in Specimen;Cryptosp Ag Spec Ql;;ACTIVE;2.07;2.73 +31795-8;Cytomegalovirus Ag;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Cytomegalovirus Ag [Presence] in Serum or Plasma;CMV Ag SerPl Ql;;ACTIVE;2.07;2.64 +31796-6;Cytomegalovirus Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Cytomegalovirus Ag [Presence] in Urine;CMV Ag Ur Ql;;ACTIVE;2.07;2.56 +31797-4;Cytomegalovirus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Cytomegalovirus Ag [Presence] in Specimen;CMV Ag Spec Ql;;ACTIVE;2.07;2.73 +31798-2;Dengue virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Dengue virus Ag [Presence] in Serum;DENV Ag Ser Ql;;ACTIVE;2.07;2.56 +3179-9;Bleeding time;Time;Pt;^Patient;Qn;Ivy;COAG;1;Bleeding time by Ivy method;Bleeding time Patient Ivy;;ACTIVE;1.0;2.73 +31799-0;Dengue virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Dengue virus Ag [Presence] in Specimen;DENV Ag Spec Ql;;ACTIVE;2.07;2.69 +31800-6;Dermatophilus congolensis Ag;PrThr;Pt;Exudate;Ord;;MICRO;1;Dermatophilus congolensis Ag [Presence] in Exudate;D congo Ag Exudate Ql;;ACTIVE;2.07;2.56 +31801-4;Dirofilaria immitis Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Dirofilaria immitis Ag [Presence] in Serum;D immitis Ag Ser Ql;;ACTIVE;2.07;2.56 +31802-2;Duck enteritis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Duck enteritis virus Ag [Presence] in Specimen;DVE Ag Spec Ql;;ACTIVE;2.07;2.69 +31803-0;Duck hepatitis virus 1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Duck hepatitis virus 1 Ag [Presence] in Specimen;DHV1 Ag Spec Ql;;ACTIVE;2.07;2.69 +31804-8;Duck hepatitis virus 2 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Duck hepatitis virus 2 Ag [Presence] in Specimen;DHV2 Ag Spec Ql;;ACTIVE;2.07;2.69 +31805-5;Duck hepatitis virus 3 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Duck hepatitis virus 3 Ag [Presence] in Specimen;DHV3 Ag Spec Ql;;ACTIVE;2.07;2.69 +31806-3;Eastern equine encephalitis virus Ag;PrThr;Pt;Brain;Ord;;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Brain;EEEV Ag Brain Ql;;ACTIVE;2.07;2.56 +3180-7;Cardiolipin Ab;ACnc;Pt;Ser;Qn;IA;COAG;1;Cardiolipin Ab [Units/volume] in Serum by Immunoassay;Cardiolipin Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +31807-1;Eastern equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Serum;EEEV Ag Ser Ql;;ACTIVE;2.07;2.56 +31808-9;Eastern equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Specimen;EEEV Ag Spec Ql;;ACTIVE;2.07;2.69 +31809-7;Echinococcus sp Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Echinococcus sp Ag [Presence] in Stool;Echinococcus Ag Stl Ql;;ACTIVE;2.07;2.56 +31810-5;Entamoeba histolytica Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Entamoeba histolytica Ag [Units/volume] in Serum;E histolyt Ag Ser-aCnc;;ACTIVE;2.07;2.69 +31811-3;Entamoeba histolytica Ag;ACnc;Pt;Stool;Qn;;MICRO;1;Entamoeba histolytica Ag [Units/volume] in Stool;E histolyt Ag Stl-aCnc;;ACTIVE;2.07;2.73 +31812-1;Entamoeba histolytica Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Entamoeba histolytica Ag [Units/volume] in Specimen;E histolyt Ag Spec-aCnc;;ACTIVE;2.07;2.69 +31813-9;Epizootic hemorrhagic disease virus Ag;PrThr;Pt;Lung;Ord;;MICRO;1;Epizootic hemorrhagic disease virus Ag [Presence] in Lung;EHDV Ag Lung Ql;;ACTIVE;2.07;2.56 +31814-7;Equine adenovirus Ag;PrThr;Pt;Lung;Ord;;MICRO;1;Equine adenovirus Ag [Presence] in Lung;EAdV Ag Lung Ql;;ACTIVE;2.07;2.56 +3181-5;Cardiolipin Ab.IgG;ACnc;Pt;Ser;Qn;IA;COAG;1;Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay;Cardiolipin IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +31815-4;Equine arteritis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Equine arteritis virus Ag [Presence] in Specimen;EAV Ag Spec Ql;;ACTIVE;2.07;2.69 +31816-2;Equine herpesvirus 1 Ag;PrThr;Pt;Tracheal swab;Ord;;MICRO;1;Equine herpesvirus 1 Ag [Presence] in Tracheal swab;EHV1 Ag Tracheal Swb Ql;;ACTIVE;2.07;2.56 +31817-0;Equine herpesvirus 1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Equine herpesvirus 1 Ag [Presence] in Specimen;EHV1 Ag Spec Ql;;ACTIVE;2.07;2.69 +31818-8;Equine herpesvirus 1+4 Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Equine herpesvirus 1+4 Ag [Presence] in Body fluid;EHV1+4 Ag Fld Ql;;ACTIVE;2.07;2.56 +31819-6;Equine herpesvirus 4 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Equine herpesvirus 4 Ag [Presence] in Specimen;EHV4 Ag Spec Ql;;ACTIVE;2.07;2.69 +31820-4;Equine infectious anemia virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Equine infectious anemia virus Ag [Presence] in Specimen;EIAV Ag Spec Ql;;ACTIVE;2.07;2.69 +31821-2;Equine influenza virus A1 Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Equine influenza virus A1 Ag [Units/volume] in Specimen;EIV A1 Ag Spec-aCnc;;ACTIVE;2.07;2.69 +31822-0;Equine influenza virus A2 Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Equine influenza virus A2 Ag [Units/volume] in Specimen;EIV A2 Ag Spec-aCnc;;ACTIVE;2.07;2.69 +3182-3;Cardiolipin Ab.IgM;ACnc;Pt;Ser;Qn;IA;COAG;1;Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay;Cardiolipin IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +31823-8;Equine influenza virus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Equine influenza virus Ag [Presence] in Nose;EIV Ag Nose Ql;;ACTIVE;2.07;2.56 +31824-6;Escherichia coli K1 Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Escherichia coli K1 Ag [Presence] in Cerebral spinal fluid;E coli K1 Ag CSF Ql;;ACTIVE;2.07;2.73 +31825-3;Escherichia coli K1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Escherichia coli K1 Ag [Presence] in Specimen;E coli K1 Ag Spec Ql;;ACTIVE;2.07;2.73 +31826-1;Feline infectious peritonitis virus Ag;PrThr;Pt;Tsmi;Ord;;MICRO;1;Feline infectious peritonitis virus Ag [Presence] in Small intestine Tissue;FIPV Ag TSMI Ql;;ACTIVE;2.07;2.56 +31827-9;Foot and mouth disease virus Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Foot and mouth disease virus Ag [Presence] in Throat;FMDV Ag Throat Ql;;ACTIVE;2.07;2.56 +31828-7;Francisella tularensis Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Francisella tularensis Ag [Presence] in Serum;F tular Ag Ser Ql;;ACTIVE;2.07;2.56 +31829-5;Francisella tularensis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Francisella tularensis Ag [Presence] in Specimen;F tular Ag Spec Ql;;ACTIVE;2.07;2.69 +31830-3;Giardia lamblia Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia Ag [Presence] in Stool;G lamblia Ag Stl Ql;;ACTIVE;2.07;2.73 +3183-1;Clotting time;Time;Pt;Bld;Qn;Lee White;COAG;1;Clotting time of Blood by Lee White method;Clotting time Bld Lee White;;ACTIVE;1.0;2.44 +31831-1;Giardia lamblia Ag^2nd specimen;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia Ag [Presence] in Stool --2nd specimen;G lamblia Ag sp2 Stl Ql;;ACTIVE;2.07;2.56 +31832-9;Giardia lamblia Ag^3rd specimen;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia Ag [Presence] in Stool --3rd specimen;G lamblia Ag sp3 Stl Ql;;ACTIVE;2.07;2.56 +31833-7;Haemophilus influenzae A Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Haemophilus influenzae A Ag [Presence] in Specimen;Haem influ A Ag Spec Ql;;ACTIVE;2.07;2.73 +31834-5;Haemophilus influenzae B Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Haemophilus influenzae B Ag [Presence] in Specimen;Haem influ B Ag Spec Ql;;ACTIVE;2.07;2.73 +31835-2;Haemophilus influenzae C Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Haemophilus influenzae C Ag [Presence] in Cerebral spinal fluid;Haem influ C Ag CSF Ql;;ACTIVE;2.07;2.56 +31836-0;Haemophilus influenzae C Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Haemophilus influenzae C Ag [Presence] in Specimen;Haem influ C Ag Spec Ql;;ACTIVE;2.07;2.69 +31837-8;Haemophilus influenzae D Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Haemophilus influenzae D Ag [Presence] in Cerebral spinal fluid;Haem influ D Ag CSF Ql;;ACTIVE;2.07;2.56 +31838-6;Haemophilus influenzae D Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Haemophilus influenzae D Ag [Presence] in Specimen;Haem influ D Ag Spec Ql;;ACTIVE;2.07;2.69 +31839-4;Haemophilus influenzae E Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Haemophilus influenzae E Ag [Presence] in Cerebral spinal fluid;Haem influ E Ag CSF Ql;;ACTIVE;2.07;2.56 +31840-2;Haemophilus influenzae E Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Haemophilus influenzae E Ag [Presence] in Specimen;Haem influ E Ag Spec Ql;;ACTIVE;2.07;2.69 +31841-0;Haemophilus influenzae F Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Haemophilus influenzae F Ag [Presence] in Cerebral spinal fluid;Haem influ F Ag CSF Ql;;ACTIVE;2.07;2.56 +31842-8;Haemophilus influenzae F Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Haemophilus influenzae F Ag [Presence] in Specimen;Haem influ F Ag Spec Ql;;ACTIVE;2.07;2.69 +31843-6;Helicobacter pylori Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Helicobacter pylori Ag [Presence] in Stool;H pylori Ag Stl Ql;;ACTIVE;2.07;2.73 +31844-4;Hepatitis B virus little e Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus e Ag [Presence] in Serum;HBV e Ag Ser Ql;;ACTIVE;2.07;2.73 +31845-1;Hepatitis B virus little e Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus e Ag [Units/volume] in Serum;HBV e Ag Ser-aCnc;;ACTIVE;2.07;2.73 +31846-9;Herpes simplex virus 1 Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Genital specimen;HSV1 Ag Genital Ql;;ACTIVE;2.07;2.56 +31847-7;Herpes simplex virus 1 Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Skin;HSV1 Ag Skin Ql;;ACTIVE;2.07;2.56 +31848-5;Herpes simplex virus 1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Specimen;HSV1 Ag Spec Ql;;ACTIVE;2.07;2.73 +3184-9;Activated clotting time;Time;Pt;Bld;Qn;Coag;COAG;1;Activated clotting time (ACT) of Blood by Coagulation assay;ACT Bld;;ACTIVE;1.0;2.73 +31849-3;Herpes simplex virus 2 Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Genital specimen;HSV2 Ag Genital Ql;;ACTIVE;2.07;2.56 +31850-1;Herpes simplex virus 2 Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Skin;HSV2 Ag Skin Ql;;ACTIVE;2.07;2.56 +31851-9;Herpes simplex virus 2 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Specimen;HSV2 Ag Spec Ql;;ACTIVE;2.07;2.73 +31852-7;Herpes simplex virus Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Genital specimen;HSV Ag Genital Ql;;ACTIVE;2.07;2.56 +31853-5;Herpes simplex virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Serum;HSV Ag Ser Ql;;ACTIVE;2.07;2.56 +31854-3;Herpes simplex virus Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Skin;HSV Ag Skin Ql;;ACTIVE;2.07;2.56 +31855-0;Histoplasma capsulatum Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Serum;H capsul Ag Ser-aCnc;;ACTIVE;2.07;2.73 +3185-6;Coagulation factor IX inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor IX inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact IX Inhib PPP-aCnc;;ACTIVE;1.0;2.73 +31856-8;Histoplasma capsulatum Ag;ACnc;Pt;Urine;Qn;;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Urine;H capsul Ag Ur-aCnc;;ACTIVE;2.07;2.73 +31857-6;Infectious bursal disease virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Infectious bursal disease virus Ag [Presence] in Specimen;IBDV Ag Spec Ql;;ACTIVE;2.07;2.69 +31858-4;Influenza virus A Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Influenza virus A Ag [Presence] in Throat;FLUAV Ag Throat Ql;;ACTIVE;2.07;2.73 +31859-2;Influenza virus A Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Influenza virus A Ag [Presence] in Specimen;FLUAV Ag Spec Ql;;ACTIVE;2.07;2.73 +318-6;Methacycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Methacycline [Susceptibility] by Minimum lethal concentration (MLC);Methacycline Islt MLC;;ACTIVE;1.0;2.19 +31860-0;Influenza virus A+B Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Influenza virus A+B Ag [Presence] in Throat;FLUAV+FLUBV Ag Throat Ql;;ACTIVE;2.07;2.56 +31861-8;Influenza virus A+B+C Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Influenza virus A+B+C Ag [Presence] in Throat;FLUAV+FLUBV+FLUCV Ag Throat Ql;;ACTIVE;2.07;2.56 +31862-6;Influenza virus A+B+C Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Influenza virus A+B+C Ag [Presence] in Specimen;FLUAV+FLUBV+FLUCV Ag Spec Ql;;ACTIVE;2.07;2.73 +31863-4;Influenza virus B Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Influenza virus B Ag [Presence] in Throat;FLUBV Ag Throat Ql;;ACTIVE;2.07;2.73 +3186-4;Coagulation factor IX activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor IX activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact IXa PPP-aCnc;;ACTIVE;1.0;2.73 +31864-2;Influenza virus B Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Influenza virus B Ag [Presence] in Specimen;FLUBV Ag Spec Ql;;ACTIVE;2.07;2.73 +31865-9;Influenza virus C Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Influenza virus C Ag [Presence] in Specimen;FLUCV Ag Spec Ql;;ACTIVE;2.07;2.69 +31866-7;Japanese encephalitis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Japanese encephalitis virus Ag [Presence] in Specimen;JEV Ag Spec Ql;;ACTIVE;2.07;2.69 +31867-5;Lassa virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Lassa virus Ag [Presence] in Serum;LASV Ag Ser Ql;;ACTIVE;2.07;2.56 +31868-3;Legionella pneumophila 1 Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Legionella pneumophila 1 Ag [Presence] in Urine;L pneumo1 Ag Ur Ql;;ACTIVE;2.07;2.73 +31869-1;Legionella pneumophila Ag;PrThr;Pt;Sputum;Ord;;MICRO;1;Legionella pneumophila Ag [Presence] in Sputum;L pneumo Ag Spt Ql;;ACTIVE;2.07;2.56 +31870-9;Legionella pneumophila Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Legionella pneumophila Ag [Presence] in Urine;L pneumo Ag Ur Ql;;ACTIVE;2.07;2.73 +31871-7;Leptospira interrogans Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Leptospira interrogans Ag [Presence] in Specimen;L inter Ag Spec Ql;;ACTIVE;2.07;2.69 +3187-2;Coagulation factor IX activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor IX activity actual/normal in Platelet poor plasma by Coagulation assay;Fact IX Act/Nor PPP;;ACTIVE;1.0;2.73 +31872-5;Leptospira sp Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Leptospira sp Ag [Presence] in Urine;Leptospira Ag Ur Ql;;ACTIVE;2.07;2.56 +31873-3;Mareks disease virus Ag;PrThr;Pt;Feather;Ord;;MICRO;1;Mareks disease virus Ag [Presence] in Feather;GaHV Ag Feather Ql;;ACTIVE;2.07;2.56 +31874-1;Mareks disease virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Mareks disease virus Ag [Presence] in Specimen;GaHV Ag Spec Ql;;ACTIVE;2.07;2.69 +31875-8;Measles virus Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Measles virus Ag [Presence] in Cerebral spinal fluid;MeV Ag CSF Ql;;ACTIVE;2.07;2.56 +31876-6;Measles virus Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Measles virus Ag [Presence] in Cervix;MeV Ag Cvx Ql;;ACTIVE;2.07;2.58 +31877-4;Measles virus Ag;PrThr;Pt;Eye;Ord;;MICRO;1;Measles virus Ag [Presence] in Eye;MeV Ag Eye Ql;;ACTIVE;2.07;2.56 +31878-2;Measles virus Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Measles virus Ag [Presence] in Vaginal fluid;MeV Ag Vag Ql;;ACTIVE;2.07;2.56 +31879-0;Measles virus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Measles virus Ag [Presence] in Nose;MeV Ag Nose Ql;;ACTIVE;2.07;2.56 +3188-0;Coagulation factor IX activity;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor IX activity [Units/volume] in Platelet poor plasma by Chromogenic method;Fact IX PPP Chro-aCnc;;ACTIVE;1.0;2.73 +31880-8;Measles virus Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Measles virus Ag [Presence] in Penis;MeV Ag Penis Ql;;ACTIVE;2.07;2.56 +31881-6;Measles virus Ag;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Measles virus Ag [Presence] in Serum or Plasma;MeV Ag SerPl Ql;;ACTIVE;2.07;2.56 +31882-4;Measles virus Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Measles virus Ag [Presence] in Skin;MeV Ag Skin Ql;;ACTIVE;2.07;2.56 +31883-2;Measles virus Ag;PrThr;Pt;Sputum;Ord;;MICRO;1;Measles virus Ag [Presence] in Sputum;MeV Ag Spt Ql;;ACTIVE;2.07;2.56 +31884-0;Measles virus Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Measles virus Ag [Presence] in Throat;MeV Ag Throat Ql;;ACTIVE;2.07;2.56 +31885-7;Measles virus Ag;PrThr;Pt;Urine sed;Ord;;MICRO;1;Measles virus Ag [Presence] in Urine sediment;MeV Ag UrnS Ql;;ACTIVE;2.07;2.56 +31886-5;Measles virus Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Measles virus Ag [Presence] in Urethra;MeV Ag Urth Ql;;ACTIVE;2.07;2.56 +31887-3;Measles virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Measles virus Ag [Presence] in Specimen;MeV Ag Spec Ql;;ACTIVE;2.07;2.69 +31888-1;Mumps virus Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Mumps virus Ag [Presence] in Cerebral spinal fluid;MuV Ag CSF Ql;;ACTIVE;2.07;2.56 +31889-9;Mumps virus Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Mumps virus Ag [Presence] in Cervix;MuV Ag Cvx Ql;;ACTIVE;2.07;2.58 +31890-7;Mumps virus Ag;PrThr;Pt;Eye;Ord;;MICRO;1;Mumps virus Ag [Presence] in Eye;MuV Ag Eye Ql;;ACTIVE;2.07;2.56 +31891-5;Mumps virus Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Mumps virus Ag [Presence] in Vaginal fluid;MuV Ag Vag Ql;;ACTIVE;2.07;2.56 +31892-3;Mumps virus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Mumps virus Ag [Presence] in Nose;MuV Ag Nose Ql;;ACTIVE;2.07;2.56 +31893-1;Mumps virus Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Mumps virus Ag [Presence] in Penis;MuV Ag Penis Ql;;ACTIVE;2.07;2.56 +31894-9;Mumps virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Mumps virus Ag [Presence] in Serum;MuV Ag Ser Ql;;ACTIVE;2.07;2.56 +31895-6;Mumps virus Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Mumps virus Ag [Presence] in Skin;MuV Ag Skin Ql;;ACTIVE;2.07;2.56 +31896-4;Mumps virus Ag;PrThr;Pt;Sputum;Ord;;MICRO;1;Mumps virus Ag [Presence] in Sputum;MuV Ag Spt Ql;;ACTIVE;2.07;2.56 +31897-2;Mumps virus Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Mumps virus Ag [Presence] in Throat;MuV Ag Throat Ql;;ACTIVE;2.07;2.56 +3189-8;Coagulation factor IX Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor IX Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact IX Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +31898-0;Mumps virus Ag;PrThr;Pt;Urine sed;Ord;;MICRO;1;Mumps virus Ag [Presence] in Urine sediment;MuV Ag UrnS Ql;;ACTIVE;2.07;2.56 +31899-8;Mumps virus Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Mumps virus Ag [Presence] in Urethra;MuV Ag Urth Ql;;ACTIVE;2.07;2.56 +31900-4;Mumps virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Mumps virus Ag [Presence] in Specimen;MuV Ag Spec Ql;;ACTIVE;2.07;2.69 +31901-2;Mycoplasma gallisepticum Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Mycoplasma gallisepticum Ag [Presence] in Specimen;M gallisep Ag Spec Ql;;ACTIVE;2.07;2.69 +31902-0;Mycoplasma mycoides subspecies mycoides small colony Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Mycoplasma mycoides ss mycoides small colony Ag [Presence] in Specimen;M myc my sc Ag Spec Ql;;ACTIVE;2.07;2.69 +31903-8;Myxoma virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Myxoma virus Ag [Presence] in Specimen;MYXV Ag Spec Ql;;ACTIVE;2.07;2.69 +31904-6;Nairobi sheep disease virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Nairobi sheep disease virus Ag [Presence] in Specimen;NSDV Ag Spec Ql;;ACTIVE;2.07;2.69 +31905-3;Neisseria gonorrhoeae Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Neisseria gonorrhoeae Ag [Presence] in Genital specimen;N gonorrhoea Ag Genital Ql;;DISCOURAGED;2.07;2.56 +3190-6;Coagulation factor IX Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor IX Ag actual/normal in Platelet poor plasma by Immunoassay;Fact IX Ag Act/Nor PPP IA;;ACTIVE;1.0;2.73 +31906-1;Neisseria gonorrhoeae Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria gonorrhoeae Ag [Presence] in Specimen;N gonorrhoea Ag Spec Ql;;DISCOURAGED;2.07;2.69 +31907-9;Neisseria meningitidis serogroup A Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Cerebral spinal fluid;N men sg A Ag CSF Ql;;ACTIVE;2.07;2.64 +31908-7;Neisseria meningitidis serogroup A Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Specimen;N men sg A Ag Spec Ql;;ACTIVE;2.07;2.69 +31909-5;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Cerebral spinal fluid;N men sg A+C+W135+Y Ag CSF Ql;;ACTIVE;2.07;2.64 +31910-3;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Specimen;N men sg A+C+W135+Y Ag Spec Ql;;ACTIVE;2.07;2.69 +31911-1;Neisseria meningitidis Ag;ACnc;Pt;CSF;Qn;;MICRO;1;Neisseria meningitidis Ag [Units/volume] in Cerebral spinal fluid;N men Ag CSF-aCnc;;ACTIVE;2.07;2.69 +31912-9;Neisseria meningitidis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis Ag [Presence] in Specimen;N men Ag Spec Ql;;ACTIVE;2.07;2.69 +31913-7;Neisseria meningitidis serogroup B Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Specimen;N men sg B Ag Spec Ql;;ACTIVE;2.07;2.69 +3191-4;Coagulation factor V inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor V inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact V Inhib PPP-aCnc;;ACTIVE;1.0;2.73 +31914-5;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Cerebral spinal fluid;N men sg B+E coli K1 Ag CSF Ql;;ACTIVE;2.07;2.64 +31915-2;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Specimen;N men sg B+E coli K1 Ag Spec Ql;;ACTIVE;2.07;2.69 +31916-0;Neisseria meningitidis serogroup C Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Cerebral spinal fluid;N men sg C Ag CSF Ql;;ACTIVE;2.07;2.64 +31917-8;Neisseria meningitidis serogroup C Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Specimen;N men sg C Ag Spec Ql;;ACTIVE;2.07;2.69 +31918-6;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Cerebral spinal fluid;N men sg W135 Ag CSF Ql;;ACTIVE;2.07;2.64 +31919-4;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Serum or Plasma;N men sg W135 Ag SerPl Ql;;ACTIVE;2.07;2.64 +31920-2;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Specimen;N men sg W135 Ag Spec Ql;;ACTIVE;2.07;2.69 +31921-0;Neisseria meningitidis serogroup Y Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroup Y Ag [Presence] in Specimen;N men sg Y Ag Spec Ql;;ACTIVE;2.07;2.69 +3192-2;Coagulation factor V activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor V activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact Va PPP-aCnc;;ACTIVE;1.0;2.73 +31922-8;Ovine progressive pneumonia virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Ovine progressive pneumonia virus Ag [Presence] in Specimen;OPPV Ag Spec Ql;;ACTIVE;2.07;2.69 +31923-6;Parainfluenza virus 1 Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Throat;HPIV1 Ag Throat Ql;;ACTIVE;2.07;2.56 +31924-4;Parainfluenza virus 1 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Specimen;HPIV1 Ag Spec Ql;;ACTIVE;2.07;2.73 +31925-1;Parainfluenza virus 2 Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Parainfluenza virus 2 Ag [Presence] in Throat;HPIV2 Ag Throat Ql;;ACTIVE;2.07;2.56 +31926-9;Parainfluenza virus 2 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Parainfluenza virus 2 Ag [Presence] in Specimen;HPIV2 Ag Spec Ql;;ACTIVE;2.07;2.73 +31927-7;Parainfluenza virus 3 Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Parainfluenza virus 3 Ag [Presence] in Throat;HPIV3 Ag Throat Ql;;ACTIVE;2.07;2.56 +31928-5;Parainfluenza virus 3 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Parainfluenza virus 3 Ag [Presence] in Specimen;HPIV3 Ag Spec Ql;;ACTIVE;2.07;2.73 +31929-3;Parainfluenza virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Parainfluenza virus Ag [Presence] in Specimen;HPIV Ag Spec Ql;;ACTIVE;2.07;2.69 +3193-0;Coagulation factor V activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor V activity actual/normal in Platelet poor plasma by Coagulation assay;Fact V Act/Nor PPP;;ACTIVE;1.0;2.73 +31930-1;Pasteurella multocida Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Pasteurella multocida Ag [Units/volume] in Specimen;P multoc Ag Spec-aCnc;;ACTIVE;2.07;2.69 +31931-9;Plasmodium vivax Ag;ACnc;Pt;Bld;Qn;;MICRO;1;Plasmodium vivax Ag [Units/volume] in Blood;P vivax Ag Bld-aCnc;;ACTIVE;2.07;2.69 +31932-7;Pneumocystis jiroveci Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Blood;P jiroveci Ag Bld Ql;;ACTIVE;2.07;2.56 +31933-5;Pneumocystis jiroveci Ag;PrThr;Pt;Bronchial;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Bronchial specimen;P jiroveci Ag Bronch Ql;;ACTIVE;2.07;2.56 +31934-3;Pneumocystis jiroveci Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Cerebral spinal fluid;P jiroveci Ag CSF Ql;;ACTIVE;2.07;2.56 +31935-0;Pneumocystis jiroveci Ag;PrThr;Pt;Eye;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Eye;P jiroveci Ag Eye Ql;;ACTIVE;2.07;2.56 +31936-8;Pneumocystis jiroveci Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Nose;P jiroveci Ag Nose Ql;;ACTIVE;2.07;2.56 +31937-6;Pneumocystis jiroveci Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Serum;P jiroveci Ag Ser Ql;;ACTIVE;2.07;2.56 +31938-4;Pneumocystis jiroveci Ag;PrThr;Pt;Semen;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Semen;P jiroveci Ag Smn Ql;;ACTIVE;2.07;2.56 +31939-2;Pneumocystis jiroveci Ag;PrThr;Pt;Sputum;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Sputum;P jiroveci Ag Spt Ql;;ACTIVE;2.07;2.56 +319-4;Methacycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Methacycline [Susceptibility] by Minimum inhibitory concentration (MIC);Methacycline Islt MIC;;ACTIVE;1.0;2.19 +31940-0;Pneumocystis jiroveci Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Stool;P jiroveci Ag Stl Ql;;ACTIVE;2.07;2.56 +31941-8;Pneumocystis jiroveci Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Throat;P jiroveci Ag Throat Ql;;ACTIVE;2.07;2.56 +31942-6;Pneumocystis jiroveci Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Urine;P jiroveci Ag Ur Ql;;ACTIVE;2.07;2.56 +31943-4;Pneumocystis jiroveci Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Specimen;P jiroveci Ag Spec Ql;;ACTIVE;2.07;2.73 +31944-2;Porcine enterovirus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Porcine enterovirus Ag [Presence] in Specimen;PEV Ag Spec Ql;;ACTIVE;2.07;2.69 +31945-9;Pseudorabies virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Pseudorabies virus Ag [Presence] in Specimen;PRV Ag Spec Ql;;ACTIVE;2.07;2.69 +31946-7;Rabies virus Ag;PrThr;Pt;Brain;Ord;;MICRO;1;Rabies virus Ag [Presence] in Brain;RABV Ag Brain Ql;;DISCOURAGED;2.07;2.56 +31947-5;Rabies virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Rabies virus Ag [Presence] in Specimen;RABV Ag Spec Ql;;DISCOURAGED;2.07;2.69 +3194-8;Coagulation factor V Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor V Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact V Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +31948-3;Rabies virus Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Rabies virus Ag [Units/volume] in Specimen;RABV Ag Spec-aCnc;;DISCOURAGED;2.07;2.69 +31949-1;Respiratory syncytial virus Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Respiratory syncytial virus Ag [Presence] in Throat;RSV Ag Throat Ql;;ACTIVE;2.07;2.56 +31950-9;Respiratory syncytial virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Respiratory syncytial virus Ag [Presence] in Specimen;RSV Ag Spec Ql;;ACTIVE;2.07;2.73 +31951-7;Rift valley fever virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Rift valley fever virus Ag [Presence] in Specimen;RVFV Ag Spec Ql;;ACTIVE;2.07;2.69 +31952-5;Rinderpest virus Ag;PrThr;Pt;Exudate;Ord;;MICRO;1;Rinderpest virus Ag [Presence] in Exudate;RPV Ag Exudate Ql;;ACTIVE;2.07;2.56 +31953-3;Rinderpest virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Rinderpest virus Ag [Presence] in Specimen;RPV Ag Spec Ql;;ACTIVE;2.07;2.69 +31954-1;Rinderpest virus Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Rinderpest virus Ag [Units/volume] in Specimen;RPV Ag Spec-aCnc;;ACTIVE;2.07;2.69 +3195-5;Coagulation factor V Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor V Ag actual/normal in Platelet poor plasma by Immunoassay;Fact V Ag Act/Nor PPP IA;;ACTIVE;1.0;2.58 +31955-8;Rubella virus Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Rubella virus Ag [Presence] in Cerebral spinal fluid;RUBV Ag CSF Ql;;ACTIVE;2.07;2.56 +31956-6;Rubella virus Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Rubella virus Ag [Presence] in Cervix;RUBV Ag Cvx Ql;;ACTIVE;2.07;2.58 +31957-4;Rubella virus Ag;PrThr;Pt;Eye;Ord;;MICRO;1;Rubella virus Ag [Presence] in Eye;RUBV Ag Eye Ql;;ACTIVE;2.07;2.56 +31958-2;Rubella virus Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Rubella virus Ag [Presence] in Vaginal fluid;RUBV Ag Vag Ql;;ACTIVE;2.07;2.56 +31959-0;Rubella virus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Rubella virus Ag [Presence] in Nose;RUBV Ag Nose Ql;;ACTIVE;2.07;2.56 +31960-8;Rubella virus Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Rubella virus Ag [Presence] in Penis;RUBV Ag Penis Ql;;ACTIVE;2.07;2.56 +31961-6;Rubella virus Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Rubella virus Ag [Presence] in Skin;RUBV Ag Skin Ql;;ACTIVE;2.07;2.56 +31962-4;Rubella virus Ag;PrThr;Pt;Sputum;Ord;;MICRO;1;Rubella virus Ag [Presence] in Sputum;RUBV Ag Spt Ql;;ACTIVE;2.07;2.56 +3196-3;Coagulation factor VII inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VII inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact VII Inhib PPP-aCnc;;ACTIVE;1.0;2.73 +31963-2;Rubella virus Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Rubella virus Ag [Presence] in Throat;RUBV Ag Throat Ql;;ACTIVE;2.07;2.56 +31964-0;Rubella virus Ag;PrThr;Pt;Urine sed;Ord;;MICRO;1;Rubella virus Ag [Presence] in Urine sediment;RUBV Ag UrnS Ql;;ACTIVE;2.07;2.56 +31965-7;Rubella virus Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Rubella virus Ag [Presence] in Urethra;RUBV Ag Urth Ql;;ACTIVE;2.07;2.56 +31966-5;Rubella virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Rubella virus Ag [Presence] in Specimen;RUBV Ag Spec Ql;;ACTIVE;2.07;2.69 +31967-3;Streptococcus agalactiae Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Streptococcus agalactiae Ag [Presence] in Throat;Gp B Strep Ag Throat Ql;;ACTIVE;2.07;2.73 +31968-1;Streptococcus pneumoniae Ag;PrThr;Pt;Sputum;Ord;;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Sputum;S pneum Ag Spt Ql;;ACTIVE;2.07;2.56 +31969-9;Streptococcus pneumoniae Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Specimen;S pneum Ag Spec Ql;;ACTIVE;2.07;2.73 +31970-7;Streptococcus pyogenes Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcus pyogenes Ag [Presence] in Serum;S pyo Ag Ser Ql;;ACTIVE;2.07;2.56 +3197-1;Coagulation factor VII activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VII activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact VIIa PPP-aCnc;;ACTIVE;1.0;2.73 +31971-5;Streptococcus pyogenes Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Streptococcus pyogenes Ag [Presence] in Specimen;S pyo Ag Spec Ql;;ACTIVE;2.07;2.73 +31972-3;Swine vesicular disease virus Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Swine vesicular disease virus Ag [Presence] in Skin;SVD Ag Skin Ql;;ACTIVE;2.07;2.56 +31973-1;Swine vesicular disease virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Swine vesicular disease virus Ag [Presence] in Specimen;SVD Ag Spec Ql;;ACTIVE;2.07;2.69 +31974-9;Taenia hydatigena Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Taenia hydatigena Ag [Presence] in Stool;T hydatigena Ag Stl Ql;;ACTIVE;2.07;2.56 +31975-6;Taenia sp Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Taenia sp Ag [Presence] in Stool;Taenia Ag Stl Ql;;ACTIVE;2.07;2.56 +31976-4;Taylorella equigenitalis Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Taylorella equigenitalis Ag [Presence] in Specimen;T equigenit Ag Spec Ql;;ACTIVE;2.07;2.69 +31977-2;Transmissible gastroenteritis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Transmissible gastroenteritis virus Ag [Presence] in Specimen;TGEV Ag Spec Ql;;ACTIVE;2.07;2.69 +31978-0;Trichomonas vaginalis Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Trichomonas vaginalis Ag [Presence] in Genital specimen;T vaginalis Ag Genital Ql;;ACTIVE;2.07;2.73 +31979-8;Trypanosoma evansi Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Trypanosoma evansi Ag [Presence] in Blood;T evansi Ag Bld Ql;;ACTIVE;2.07;2.56 +31980-6;Trypanosoma sp Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Trypanosoma sp Ag [Presence] in Blood;Trypanos Ag Bld Ql;;ACTIVE;2.07;2.56 +31981-4;Varicella zoster virus Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Varicella zoster virus Ag [Presence] in Skin;VZV Ag Skin Ql;;ACTIVE;2.07;2.56 +31982-2;Varicella zoster virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Varicella zoster virus Ag [Presence] in Specimen;VZV Ag Spec Ql;;ACTIVE;2.07;2.69 +31983-0;Venezuelan equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Serum;VEEV Ag Ser Ql;;ACTIVE;2.07;2.56 +31984-8;Venezuelan equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Specimen;VEEV Ag Spec Ql;;ACTIVE;2.07;2.69 +31985-5;Vesicular stomatitis virus Ag;PrThr;Pt;Skin;Ord;;MICRO;1;Vesicular stomatitis virus Ag [Presence] in Skin;VSV Ag Skin Ql;;ACTIVE;2.07;2.56 +31986-3;Vesicular stomatitis virus Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Vesicular stomatitis virus Ag [Presence] in Throat;VSV Ag Throat Ql;;ACTIVE;2.07;2.56 +31987-1;Western equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Western equine encephalitis virus Ag [Presence] in Serum;WEEV Ag Ser Ql;;ACTIVE;2.07;2.56 +31988-9;Western equine encephalitis virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Western equine encephalitis virus Ag [Presence] in Specimen;WEEV Ag Spec Ql;;ACTIVE;2.07;2.69 +3198-9;Coagulation factor VII activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay;Fact VII Act/Nor PPP;;ACTIVE;1.0;2.73 +31989-7;14-3-3 Ag;PrThr;Pt;CSF;Ord;;SERO;1;14-3-3 Ag [Presence] in Cerebral spinal fluid;14-3-3 Ag CSF Ql;;ACTIVE;2.07;2.73 +31990-5;14-3-3 Ag;ACnc;Pt;CSF;Qn;;SERO;1;14-3-3 Ag [Units/volume] in Cerebral spinal fluid;14-3-3 Ag CSF-aCnc;;ACTIVE;2.07;2.69 +31991-3;Acylcarnitine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Acylcarnitine [Presence] in Serum or Plasma;Acylcarnitine SerPl Ql;;ACTIVE;2.07;2.63 +31992-1;Aldosterone;MCnc;24H;Urine;Qn;;CHEM;1;Aldosterone [Mass/volume] in 24 hour Urine;Aldost 24h Ur-mCnc;;ACTIVE;2.07;2.73 +31993-9;Alpha-1-Fetoprotein;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alpha-1-Fetoprotein [Presence] in Serum or Plasma;AFP SerPl Ql;;ACTIVE;2.07;2.73 +31994-7;Basophils/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Pericardial fluid by Manual count;Basophils/leuk NFr Pcar Manual;;ACTIVE;2.07;2.50 +31995-4;Basophils/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Pleural fluid by Manual count;Basophils/leuk NFr Plr Manual;;ACTIVE;2.07;2.73 +31996-2;Basophils/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Peritoneal fluid by Manual count;Basophils/leuk NFr Prt Manual;;ACTIVE;2.07;2.73 +3199-7;Coagulation factor VII activity;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor VII activity [Units/volume] in Platelet poor plasma by Chromogenic method;Fact VII PPP Chro-aCnc;;ACTIVE;1.0;2.73 +31997-0;Biotin;PrThr;Pt;Bld;Ord;;CHEM;1;Biotin [Presence] in Blood;Biotin Bld Ql;;ACTIVE;2.07;2.56 +31998-8;Bordetella pertussis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis Ab [Presence] in Serum;B pert Ab Ser Ql;;ACTIVE;2.07;2.73 +31999-6;Broad casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Broad casts [Presence] in Urine sediment by Light microscopy;Broad Casts UrnS Ql Micro;;ACTIVE;2.07;2.73 +32000-2;Catecholamines;MCnc;24H;Urine;Qn;;CHEM;1;Catecholamines [Mass/volume] in 24 hour Urine;Catechols 24h Ur-mCnc;;ACTIVE;2.07;2.73 +32001-0;Chlamydia sp Ag;PrThr;Pt;Vag;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Vaginal fluid by Immunoassay;Chlamydia Ag Vag Ql IA;;ACTIVE;2.07;2.56 +32002-8;Chlamydia sp Ag;ACnc;Pt;Penis;Ord;EIA;MICRO;1;Deprecated Chlamydia sp Ag [Presence] in Penis by Immunoassay;Deprecated Chlamydia Ag Penis Ql EIA;;DEPRECATED;2.07;2.52 +3200-3;Coagulation factor VII activity actual/Normal;SRto;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VII activity actual/normal [Molar ratio] in Platelet poor plasma by Coagulation assay;Fact VII Act/Nor PPP-sRto;;ACTIVE;1.0;2.42 +32003-6;Chlamydia sp Ag;PrThr;Pt;Periton fld;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Peritoneal fluid by Immunoassay;Chlamydia Ag Prt Ql IA;;ACTIVE;2.07;2.56 +32004-4;Chlamydia sp Ag;PrThr;Pt;Urine;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Urine by Immunoassay;Chlamydia Ag Ur Ql IA;;ACTIVE;2.07;2.56 +32005-1;Chlamydia trachomatis B Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis B Ab [Titer] in Serum;C trach B Ab Titr Ser;;ACTIVE;2.07;2.70 +32006-9;Chlamydia trachomatis C Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis C Ab [Titer] in Serum;C trach C Ab Titr Ser;;ACTIVE;2.07;2.70 +32007-7;Chlamydia trachomatis G+F+K Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis G+F+K Ab [Titer] in Serum;C trach G+F+K Ab Titr Ser;;ACTIVE;2.07;2.70 +32008-5;Coproporphyrin/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Coproporphyrin/Creatinine [Molar ratio] in 24 hour Urine;Copro/Creat 24h Ur-sRto;;ACTIVE;2.07;2.42 +32009-3;Cortisol.free/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Cortisol Free/Creatinine [Mass Ratio] in 24 hour Urine;Cortis F/Creat 24h Ur;;ACTIVE;2.07;2.73 +32010-1;Diuretics;Prid;Pt;Ser/Plas;Nom;Screen;DRUG/TOX;1;Diuretics [Identifier] in Serum or Plasma by Screen method;Diuretics SerPl Scn;;ACTIVE;2.07;2.19 +3201-1;Coagulation factor VII Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VII Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact VII Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32011-9;Ehrlichia sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia sp IgG Ab [Titer] in Serum;Ehrlichia IgG Titr Ser;;ACTIVE;2.07;2.70 +32012-7;Ehrlichia sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia sp IgM Ab [Titer] in Serum;Ehrlichia IgM Titr Ser;;ACTIVE;2.07;2.70 +32013-5;Eosinophils/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Pericardial fluid by Manual count;Eosinophil/leuk NFr Pcar Manual;;ACTIVE;2.07;2.73 +32014-3;Eosinophils/100 leukocytes;NFr;Pt;Urine;Qn;Manual count;UA;1;Eosinophils/100 leukocytes in Urine by Manual count;Eosinophil/leuk NFr Ur Manual;;ACTIVE;2.07;2.73 +32015-0;EPINEPHrine;MCnc;24H;Urine;Qn;;CHEM;1;EPINEPHrine [Mass/volume] in 24 hour Urine;Epineph 24h Ur-mCnc;;ACTIVE;2.07;2.73 +32016-8;Glucose;MCnc;Pt;BldC;Qn;;CHEM;1;Glucose [Mass/volume] in Capillary blood;Glucose BldC-mCnc;;ACTIVE;2.07;2.73 +32017-6;Hemoglobin.other/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin.other/Hemoglobin.total in Blood by Electrophoresis;Hgb Other MFr Bld Elph;;ACTIVE;2.07;2.73 +32018-4;Hepatitis A virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis A virus IgG Ab [Presence] in Serum;HAV IgG Ser Ql;;ACTIVE;2.07;2.73 +32019-2;Hepatitis B virus surface Ab;Titr;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus surface Ab [Titer] in Serum;HBV surface Ab Titr Ser;;ACTIVE;2.07;2.73 +320-2;Methacycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Methacycline [Susceptibility] by Disk diffusion (KB);Methacycline Islt KB;;ACTIVE;1.0;2.19 +32020-0;Homocysteine;SCnc;Pt;Urine;Qn;;CHEM;1;Homocysteine [Moles/volume] in Urine;Hcys Ur-sCnc;;ACTIVE;2.07;2.73 +32021-8;HTLV I DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;HTLV I DNA [Presence] in Serum by NAA with probe detection;HTLV I DNA Ser Ql NAA+probe;;ACTIVE;2.07;2.73 +32022-6;Hydroxyproline.free;SCnc;24H;Urine;Qn;;CHEM;1;Hydroxyproline Free [Moles/volume] in 24 hour Urine;OH-Proline Free 24h Ur-sCnc;;ACTIVE;2.07;2.42 +32023-4;Insulin-like growth factor-I;MCnc;Pt;Bld;Qn;;CHEM;1;Insulin-like growth factor-I [Mass/volume] in Blood;IGF-I Bld-mCnc;;ACTIVE;2.07;2.73 +32024-2;Magnesium;MCnc;24H;Urine;Qn;;CHEM;1;Magnesium [Mass/volume] in 24 hour Urine;Magnesium 24h Ur-mCnc;;ACTIVE;2.07;2.73 +32025-9;Malignin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Malignin Ab [Presence] in Serum;Malignin Ab Ser Ql;;ACTIVE;2.07;2.56 +32026-7;Microscopic observation;Prid;Pt;Nose;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Nose by Gram stain;Gram Stn Nose;;ACTIVE;2.07;2.73 +32027-5;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Pericardial fluid by Manual count;Monos+Macros/leuk NFr Pcar Manual;;ACTIVE;2.07;2.73 +32028-3;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Pleural fluid by Manual count;Monos+Macros/leuk NFr Plr Manual;;ACTIVE;2.07;2.73 +3202-9;Coagulation factor VII+Acarboxy Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VII+Acarboxy Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact VII+ACA Ag PPP IA-aCnc;;ACTIVE;1.0;2.69 +32029-1;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Peritoneal fluid by Manual count;Monos+Macros/leuk NFr Prt Manual;;ACTIVE;2.07;2.73 +32030-9;Nitrate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nitrate [Presence] in Urine;Nitrate Ur Ql;;ACTIVE;2.07;2.73 +32031-7;Phosphatidylserine Ab.IgA;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylserine IgA Ab [Units/volume] in Serum by Immunoassay;PS IgA Ser IA-aCnc;;ACTIVE;2.07;2.73 +32032-5;Phosphatidylserine Ab.IgG;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylserine IgG Ab [Units/volume] in Serum by Immunoassay;PS IgG Ser IA-aCnc;;ACTIVE;2.07;2.73 +32033-3;Phosphatidylserine Ab.IgM;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylserine IgM Ab [Units/volume] in Serum by Immunoassay;PS IgM Ser IA-aCnc;;ACTIVE;2.07;2.73 +32034-1;Polymorphonuclear cells;PrThr;Pt;CSF;Ord;Wright stain;HEM/BC;1;Polymorphonuclear cells [Presence] in Cerebral spinal fluid by Wright stain;Polys CSF Ql Wright Stn;;ACTIVE;2.07;2.56 +32035-8;Polymorphonuclear cells;PrThr;Pt;Body fld;Ord;Wright stain;HEM/BC;1;Polymorphonuclear cells [Presence] in Body fluid by Wright stain;Polys Fld Ql Wright Stn;;ACTIVE;2.07;2.56 +32036-6;Polymorphonuclear cells;PrThr;Pt;Pericard fld;Ord;Wright stain;HEM/BC;1;Polymorphonuclear cells [Presence] in Pericardial fluid by Wright stain;Polys Pcar Ql Wright Stn;;ACTIVE;2.07;2.56 +3203-7;Coagulation factor VII+Acarboxy Ag activity actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VII+Acarboxy Ag activity actual/normal in Platelet poor plasma by Immunoassay;Fact VII+ACA Ag Act/Nor PPP IA;;ACTIVE;1.0;2.58 +32037-4;Polymorphonuclear cells;PrThr;Pt;Plr fld;Ord;Wright stain;HEM/BC;1;Polymorphonuclear cells [Presence] in Pleural fluid by Wright stain;Polys Plr Ql Wright Stn;;ACTIVE;2.07;2.56 +32038-2;Polymorphonuclear cells;PrThr;Pt;Periton fld;Ord;Wright stain;HEM/BC;1;Polymorphonuclear cells [Presence] in Peritoneal fluid by Wright stain;Polys Prt Ql Wright Stn;;ACTIVE;2.07;2.56 +32039-0;Polymorphonuclear cells;PrThr;Pt;Synv fld;Ord;Wright stain;HEM/BC;1;Polymorphonuclear cells [Presence] in Synovial fluid by Wright stain;Polys Snv Ql Wright Stn;;ACTIVE;2.07;2.56 +32040-8;Respiratory syncytial virus Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Respiratory syncytial virus Ag [Presence] in Nose by Immunofluorescence;RSV Ag Nose Ql IF;;ACTIVE;2.07;2.73 +32041-6;Sjogrens syndrome-A extractable nuclear Ab+Sjogrens syndrome-B extractable nuclear Ab;ACnc;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-A extractable nuclear Ab+Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum;ENA SS-A+SS-B Ab Ser-aCnc;;ACTIVE;2.07;2.73 +32042-4;Thyroperoxidase Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Thyroperoxidase Ab [Presence] in Serum or Plasma;Thyroperoxidase Ab SerPl Ql;;ACTIVE;2.07;2.73 +32043-2;Uroporphyrin/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Uroporphyrin/Creatinine [Molar ratio] in 24 hour Urine;Uropor/Creat 24h Ur-sRto;;ACTIVE;2.07;2.73 +32044-0;Volatiles;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Volatiles and gases [Identifier] in Serum or Plasma;Volatiles SerPl;;ACTIVE;2.07;2.73 +3204-5;Coagulation factor VIII inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VIII inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact VIII Inhib PPP-aCnc;;ACTIVE;1.0;2.73 +32045-7;Parathyrin.biointact;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.biointact [Mass/volume] in Serum or Plasma;PTH-Biointact SerPl-mCnc;;DISCOURAGED;2.07;2.70 +32046-5;Pregnancy associated plasma protein A;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma;PAPP-A SerPl-aCnc;;ACTIVE;2.07;2.73 +32047-3;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+68+70 DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+68+70 DNA [Presence] in Tissue by Probe;HPV I/H Risk 2 DNA Tiss Ql Probe;;ACTIVE;2.07;2.73 +32048-1;Amitriptyline+Nortriptyline;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Presence] in Specimen;Amitrip+Nor Spec Ql;;ACTIVE;2.07;2.69 +32049-9;Amobarbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Amobarbital [Presence] in Specimen;Amobarbital Spec Ql;;ACTIVE;2.07;2.69 +32050-7;Barbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Barbital [Moles/volume] in Serum or Plasma;Barbital SerPl-sCnc;;ACTIVE;2.07;2.70 +32051-5;Barbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Barbital [Presence] in Specimen;Barbital Spec Ql;;ACTIVE;2.07;2.69 +3205-2;Coagulation factor VIII Ab;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VIII Ab [Units/volume] in Platelet poor plasma by Immunoassay;Fact VIII Ab PPP IA-aCnc;;ACTIVE;1.0;2.69 +32052-3;Benzodiazepines;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzodiazepines [Moles/volume] in Serum or Plasma;Benzodiaz SerPl-sCnc;;ACTIVE;2.07;2.70 +32053-1;Bupivacaine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bupivacaine [Moles/volume] in Serum or Plasma;Bupivacaine SerPl-sCnc;;ACTIVE;2.07;2.70 +32054-9;Butabarbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Butabarbital [Presence] in Specimen;Butabarbital Spec Ql;;ACTIVE;2.07;2.73 +32055-6;Butalbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Butalbital [Moles/volume] in Serum or Plasma;Butalbital SerPl-sCnc;;ACTIVE;2.07;2.70 +32056-4;Butalbital;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Butalbital [Moles/volume] in Urine;Butalbital Ur-sCnc;;ACTIVE;2.07;2.70 +32057-2;Butalbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Butalbital [Presence] in Specimen;Butalbital Spec Ql;;ACTIVE;2.07;2.73 +32058-0;carBAMazepine.free;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine free [Moles/volume] in Serum or Plasma;carBAMazepine free SerPl-sCnc;;ACTIVE;2.07;2.70 +32059-8;chlordiazePOXIDE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Moles/volume] in Serum or Plasma;Chlordiazep SerPl-sCnc;;ACTIVE;2.07;2.70 +3206-0;Coagulation factor VIII inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor VIII inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact VIII Inhib PPP Ql;;ACTIVE;1.0;2.73 +32060-6;Chloroquine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloroquine [Moles/volume] in Serum or Plasma;Chloroquine SerPl-sCnc;;ACTIVE;2.07;2.70 +32061-4;chlorproMAZINE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;chlorproMAZINE [Presence] in Specimen;chlorproMAZINE Spec Ql;;ACTIVE;2.07;2.73 +32062-2;chlorproPAMIDE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlorproPAMIDE [Moles/volume] in Serum or Plasma;chlorproPAMIDE SerPl-sCnc;;ACTIVE;2.07;2.70 +32063-0;Cimetidine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Cimetidine [Presence] in Specimen;Cimetidine Spec Ql;;ACTIVE;2.07;2.69 +32064-8;Clorazepate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clorazepate [Moles/volume] in Serum or Plasma;Clorazepate SerPl-sCnc;;ACTIVE;2.07;2.70 +32065-5;cloZAPine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;cloZAPine [Presence] in Urine;cloZAPine Ur Ql;;ACTIVE;2.07;2.73 +32066-3;cloZAPine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;cloZAPine [Presence] in Specimen;cloZAPine Spec Ql;;ACTIVE;2.07;2.73 +32067-1;Digoxin.free;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digoxin Free [Moles/volume] in Serum or Plasma;Digoxin Free SerPl-sCnc;;ACTIVE;2.07;2.70 +32068-9;diphenhydrAMINE+dimenhyDRINATE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;diphenhydrAMINE+dimenhyDRINATE [Presence] in Specimen;Diphenhyd+Dimenhyd Spec Ql;;ACTIVE;2.07;2.69 +32069-7;Ephedrine+Pseudoephedrine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Presence] in Specimen;Ephedrin+Pseudo Spec Ql;;ACTIVE;2.07;2.69 +32070-5;Ethanol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ethanol [Moles/volume] in Specimen;Ethanol Spec-sCnc;;ACTIVE;2.07;2.73 +32071-3;Ethchlorvynol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethchlorvynol [Moles/volume] in Serum or Plasma;Ethchlorvynol SerPl-sCnc;;ACTIVE;2.07;2.70 +32072-1;FLUoxetine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;FLUoxetine [Presence] in Specimen;FLUoxetine Spec Ql;;ACTIVE;2.07;2.69 +32073-9;fluvoxaMINE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;fluvoxaMINE [Moles/volume] in Serum or Plasma;fluvoxaMINE SerPl-sCnc;;ACTIVE;2.07;2.70 +32074-7;fluvoxaMINE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;fluvoxaMINE [Presence] in Urine;fluvoxaMINE Ur Ql;;ACTIVE;2.07;2.73 +32075-4;fluvoxaMINE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;fluvoxaMINE [Presence] in Specimen;fluvoxaMINE Spec Ql;;ACTIVE;2.07;2.69 +32076-2;Glutethimide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Glutethimide [Moles/volume] in Serum or Plasma;Glutethimide SerPl-sCnc;;ACTIVE;2.07;2.70 +32077-0;Glutethimide;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Glutethimide [Presence] in Specimen;Glutethimide Spec Ql;;ACTIVE;2.07;2.69 +3207-8;Coagulation factor VIII inhibitor;PrThr;Pt;PPP;Ord;Chromo;COAG;1;Coagulation factor VIII inhibitor [Presence] in Platelet poor plasma by Chromogenic method;Fact VIII Inhib PPP Ql Chro;;ACTIVE;1.0;2.67 +32078-8;glyBURIDE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;glyBURIDE [Moles/volume] in Serum or Plasma;glyBURIDE SerPl-sCnc;;ACTIVE;2.07;2.70 +32079-6;Gold;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Gold [Moles/volume] in Urine;Gold Ur-sCnc;;ACTIVE;2.07;2.70 +32080-4;HYDROcodone;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;HYDROcodone [Presence] in Specimen;HYDROcodone Spec Ql;;ACTIVE;2.07;2.73 +32081-2;HYDROmorphone;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;HYDROmorphone [Presence] in Specimen;HYDROmorphone Spec Ql;;ACTIVE;2.07;2.73 +32082-0;Ibuprofen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Moles/volume] in Serum or Plasma;Ibuprofen SerPl-sCnc;;ACTIVE;2.07;2.70 +32083-8;Imipramine+Desipramine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Imipramine+Desipramine [Presence] in Specimen;Imipramine+Desipr Spec Ql;;ACTIVE;2.07;2.69 +32084-6;Isopropanol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Isopropanol [Moles/volume] in Specimen;Isopropanol Spec-sCnc;;ACTIVE;2.07;2.73 +32085-3;Isopropanol;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Isopropanol [Moles/volume] in Urine;Isopropanol Ur-sCnc;;ACTIVE;2.07;2.70 +3208-6;Coagulation factor VIII activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VIII activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact VIIIa PPP-aCnc;;ACTIVE;1.0;2.73 +32086-1;Lidocaine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Lidocaine [Presence] in Specimen;Lidocain Spec Ql;;ACTIVE;2.07;2.69 +32087-9;Loxapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Loxapine [Moles/volume] in Serum or Plasma;Loxapine SerPl-sCnc;;ACTIVE;2.07;2.70 +32088-7;Meperidine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Meperidine [Presence] in Specimen;Meperidine Spec Ql;;ACTIVE;2.07;2.73 +32089-5;Mephobarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mephobarbital [Moles/volume] in Serum or Plasma;Mephobarbital SerPl-sCnc;;ACTIVE;2.07;2.70 +32090-3;Mepivacaine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mepivacaine [Presence] in Urine;Mepivacaine Ur Ql;;ACTIVE;2.07;2.73 +32091-1;Meprobamate;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Meprobamate [Moles/volume] in Specimen;Meprobamate Spec-sCnc;;ACTIVE;2.07;2.70 +32092-9;Meprobamate;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Meprobamate [Presence] in Specimen;Meprobamate Spec Ql;;ACTIVE;2.07;2.69 +32093-7;Methadone;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methadone [Presence] in Specimen;Methadone Spec Ql;;ACTIVE;2.07;2.73 +3209-4;Coagulation factor VIII activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay;Fact VIII Act/Nor PPP;;ACTIVE;1.0;2.73 +32094-5;Methanol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Methanol [Moles/volume] in Specimen;Methanol Spec-sCnc;;ACTIVE;2.07;2.70 +32095-2;Methanol;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methanol [Moles/volume] in Urine;Methanol Ur-sCnc;;ACTIVE;2.07;2.70 +32096-0;Methaqualone;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methaqualone [Presence] in Specimen;Methaqualone Spec Ql;;ACTIVE;2.07;2.69 +32097-8;Methyprylon;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methyprylon [Presence] in Specimen;Methyprylon Spec Ql;;ACTIVE;2.07;2.69 +32098-6;Mexiletine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mexiletine [Moles/volume] in Serum or Plasma;Mexiletine SerPl-sCnc;;ACTIVE;2.07;2.70 +32099-4;6-Monoacetylmorphine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Specimen;6MAM Spec Ql;;ACTIVE;2.07;2.73 +321-0;Methacycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Methacycline [Susceptibility] by Serum bactericidal titer;Methacycline Titr SBT;;ACTIVE;1.0;2.32 +32100-0;Morphine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Morphine [Presence] in Specimen;Morphine Spec Ql;;ACTIVE;2.07;2.73 +32101-8;oxyCODONE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;oxyCODONE [Presence] in Specimen;oxyCODONE Spec Ql;;ACTIVE;2.07;2.73 +3210-2;Coagulation factor VIII activity;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor VIII activity [Units/volume] in Platelet poor plasma by Chromogenic method;Fact VIII PPP Chro-aCnc;;ACTIVE;1.0;2.73 +32102-6;PARoxetine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;PARoxetine [Presence] in Specimen;PARoxetine Spec Ql;;ACTIVE;2.07;2.69 +32103-4;PENTobarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PENTobarbital [Moles/volume] in Serum or Plasma;Pentobarb SerPl-sCnc;;ACTIVE;2.07;2.70 +32104-2;PENTobarbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;PENTobarbital [Presence] in Specimen;Pentobarb Spec Ql;;ACTIVE;2.07;2.69 +32105-9;Perphenazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Perphenazine [Presence] in Urine;Perphenazine Ur Ql;;ACTIVE;2.07;2.73 +32106-7;Perphenazine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Perphenazine [Presence] in Specimen;Perphenazine Spec Ql;;ACTIVE;2.07;2.73 +32107-5;Phencyclidine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Specimen;PCP Spec Ql;;ACTIVE;2.07;2.73 +32108-3;PHENobarbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;PHENobarbital [Presence] in Specimen;Phenobarb Spec Ql;;ACTIVE;2.07;2.73 +32109-1;Phenytoin.free;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin Free [Moles/volume] in Serum or Plasma;Phenytoin Free SerPl-sCnc;;ACTIVE;2.07;2.73 +3211-0;Coagulation factor VIII activity actual/Normal;RelTime;Pt;PPP;Qn;Coag.two stage;COAG;1;Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation.2 stage;Fact VIII Act/Nor PPP 2Stg;;ACTIVE;1.0;2.73 +32110-9;Procyclidine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procyclidine [Moles/volume] in Serum or Plasma;Procyclidine SerPl-sCnc;;ACTIVE;2.07;2.70 +32111-7;Secobarbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Secobarbital [Presence] in Specimen;Secobarbital Spec Ql;;ACTIVE;2.07;2.73 +32112-5;Sertraline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Sertraline [Presence] in Urine;Sertraline Ur Ql;;ACTIVE;2.07;2.73 +32113-3;Sertraline;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Sertraline [Presence] in Specimen;Sertraline Spec Ql;;ACTIVE;2.07;2.69 +32114-1;Thallium;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Thallium [Presence] in Blood;Thallium Bld Ql;;ACTIVE;2.07;2.56 +32115-8;Theophylline^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline [Moles/volume] in Serum or Plasma --peak;Theophylline Peak SerPl-sCnc;;ACTIVE;2.07;2.70 +32116-6;Theophylline^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline [Moles/volume] in Serum or Plasma --trough;Theophylline Trough SerPl-sCnc;;ACTIVE;2.07;2.70 +32117-4;Thiopental;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thiopental [Moles/volume] in Serum or Plasma;Thiopental SerPl-sCnc;;ACTIVE;2.07;2.70 +32118-2;TOLBUTamide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;TOLBUTamide [Moles/volume] in Serum or Plasma;TOLBUTamide SerPl-sCnc;;ACTIVE;2.07;2.70 +32119-0;Valproate.free;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate Free [Moles/volume] in Serum or Plasma;Valproate Free SerPl-sCnc;;ACTIVE;2.07;2.70 +32120-8;Venlafaxine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Venlafaxine [Presence] in Urine;Venlafaxine Ur Ql;;ACTIVE;2.07;2.73 +32121-6;Venlafaxine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Venlafaxine [Presence] in Specimen;Venlafaxine Spec Ql;;ACTIVE;2.07;2.69 +32122-4;Choriogonadotropin.beta subunit.free;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Multiple of the median] in Serum or Plasma;B-HCG Free MoM SerPl;;ACTIVE;2.07;2.40 +32123-2;Pregnancy associated plasma protein A;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Pregnancy associated plasma protein A [Multiple of the median] in Serum or Plasma;PAPP-A MoM SerPl;;ACTIVE;2.07;2.73 +32124-0;Bromazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromazepam [Moles/volume] in Serum or Plasma;Bromazepam SerPl-sCnc;;ACTIVE;2.07;2.70 +32125-7;Propoxyphene;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propoxyphene [Moles/volume] in Serum or Plasma;Propoxyph SerPl-sCnc;;ACTIVE;2.07;2.73 +32126-5;Propylene glycol;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propylene glycol [Moles/volume] in Urine;Prop glycol Ur-sCnc;;ACTIVE;2.07;2.70 +32127-3;raNITIdine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;raNITIdine [Presence] in Specimen;raNITIdine Spec Ql;;ACTIVE;2.07;2.69 +3212-8;Coagulation factor VIII activity.X(little a) activator;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor VIII Activity.Xa activator [Units/volume] in Platelet poor plasma by Chromogenic method;Fact VIII Xa Act PPP Chro-aCnc;;ACTIVE;1.0;2.69 +32128-1;risperiDONE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;risperiDONE [Presence] in Serum or Plasma;risperiDONE SerPl Ql;;ACTIVE;2.07;2.73 +32129-9;risperiDONE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;risperiDONE [Presence] in Urine;risperiDONE Ur Ql;;ACTIVE;2.07;2.73 +32130-7;risperiDONE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;risperiDONE [Presence] in Specimen;risperiDONE Spec Ql;;ACTIVE;2.07;2.69 +32131-5;Hantavirus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hantavirus IgM Ab [Presence] in Serum;Hantavirus IgM Ser Ql;;ACTIVE;2.07;2.73 +32132-3;Lactate;SCnc;Pt;PlasA;Qn;;CHEM;1;Lactate [Moles/volume] in Arterial plasma;Lactate PlasA-sCnc;;ACTIVE;2.07;2.73 +32133-1;Lactate;SCnc;Pt;PlasV;Qn;;CHEM;1;Lactate [Moles/volume] in Plasma venous;Lactate PlasV-sCnc;;ACTIVE;2.07;2.73 +32134-9;Adenovirus+Rotavirus;Prid;Pt;Stool;Nom;;MICRO;1;Adenovirus+Rotavirus [Identifier] in Stool;HAdV+RV Stl;;ACTIVE;2.07;2.19 +32135-6;Alkaline phosphatase.liver;CCnc;Pt;Ser/Plas;Qn;Heat stability;CHEM;1;Alkaline phosphatase.liver [Enzymatic activity/volume] in Serum or Plasma by Heat stability;ALP Liver SerPl HS-cCnc;;ACTIVE;2.07;2.73 +3213-6;Coagulation factor VIII Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VIII Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact VIII Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32136-4;Antidepressants;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Antidepressants [Presence] in Urine;Antidepressants Ur Ql;;ACTIVE;2.07;2.73 +32137-2;Calcium phosphate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium phosphate/Total in Stone;Ca Phos MFr Stone;;ACTIVE;2.07;2.73 +32138-0;Cystine/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Cystine/Total in Stone;Cystine MFr Stone;;ACTIVE;2.07;2.73 +32139-8;Haemophilus influenzae Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Haemophilus influenzae Ag [Presence] in Cerebral spinal fluid;Haem influ Ag CSF Ql;;ACTIVE;2.07;2.56 +32140-6;Hemoglobin F;PrThr;Pt;Bld;Ord;Kleihauer-Betke;HEM/BC;1;Hemoglobin F [Presence] in Blood by Kleihauer-Betke method;Hgb F Bld Ql Kleih Betke;;ACTIVE;2.07;2.73 +32141-4;Herpes simplex virus 1+2 DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HSV1+2 DNA CSF Ql NAA+probe;;ACTIVE;2.07;2.73 +32142-2;Leukocytes;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Leukocytes [Presence] in Synovial fluid by Light microscopy;WBC Snv Ql Micro;;ACTIVE;2.07;2.56 +32143-0;Triple phosphate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Triple phosphate/Total in Stone;Tri-Phos MFr Stone;;ACTIVE;2.07;2.73 +3214-4;Coagulation factor VIII Ag;ACnc;Pt;PPP;Qn;Immunoelectrophoresis;COAG;1;Coagulation factor VIII Ag [Units/volume] in Platelet poor plasma by Immunoelectrophoresis;Fact VIII Ag PPP IEP-aCnc;;ACTIVE;1.0;2.73 +32144-8;Pathologist review;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;Pathologist review of serum or plasma results;Path SerP Rev;;ACTIVE;2.07;2.73 +32145-5;Phosphate crystals.amorphous;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Phosphate crystals amorphous [#/area] in Urine sediment by Microscopy high power field;Amorph Phos Cry #/area UrnS HPF;;ACTIVE;2.07;2.73 +32146-3;Platelets.large;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Platelets Large [Presence] in Blood by Light microscopy;Lg Platelets Bld Ql Smear;;ACTIVE;2.07;2.73 +32147-1;Reducing substances;MCnc;Pt;Urine;Qn;;UA;1;Reducing substances [Mass/volume] in Urine;Reducing Subs Ur-mCnc;;ACTIVE;2.07;2.73 +32148-9;Substance.toxic identified;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Toxic substance identified in Urine;Toxic substance Ur;;ACTIVE;2.07;2.19 +32149-7;Urate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Urate/Total in Stone;Urate MFr Stone;;ACTIVE;2.07;2.73 +32150-5;Urate crystals.amorphous;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Urate crystals amorphous [#/area] in Urine sediment by Microscopy high power field;Amorph Urate Cry #/area UrnS HPF;;ACTIVE;2.07;2.73 +3215-1;Coagulation factor VIII Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VIII Ag [Mass/volume] in Platelet poor plasma by Immunoassay;Fact VIII Ag PPP IA-mCnc;;ACTIVE;1.0;2.58 +32151-3;Microscopic observation;Prid;Pt;Vag;Nom;Cytology.non-gyn;CYTO;1;Microscopic observation [Identifier] in Vaginal fluid by Non-gynecological cytology method;Non-gyn cytology Vag;;ACTIVE;2.07;2.73 +32152-1;17-Hydroxyketosteroids;MRat;24H;Urine;Qn;;CHEM;1;17-Hydroxyketosteroids [Mass/time] in 24 hour Urine;17OHKS 24h Ur-mRate;;ACTIVE;2.07;2.70 +32153-9;Alpha-Phenyl-2-Piperidine acetate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate [Mass/volume] in Serum or Plasma;PPAA SerPl-mCnc;;ACTIVE;2.07;2.73 +32154-7;Basophils+Eosinophils+Monocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Basophils+Eosinophils+Monocytes [#/volume] in Blood by Automated count;Baso+Eos+Monos # Bld Auto;;ACTIVE;2.07;2.73 +32155-4;Basophils+Eosinophils+Monocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Basophils+Eosinophils+Monocytes/100 leukocytes in Blood by Automated count;Baso+Eos+Monos/leuk NFr Bld Auto;;ACTIVE;2.07;2.73 +32156-2;Calcium carbonate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium carbonate/Total in Stone;Ca Carbonate MFr Stone;;ACTIVE;2.07;2.73 +32157-0;Calcium oxalate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium oxalate/Total in Stone;CaOx MFr Stone;;ACTIVE;2.07;2.44 +32158-8;Klebsiella granulomatis;PrThr;Pt;Genital;Ord;Microscopy.light;MICRO;1;Klebsiella granulomatis [Presence] in Genital specimen by Light microscopy;K granulomatis Genital Ql Micro;;ACTIVE;2.07;2.56 +32159-6;Carbonated calcium phosphate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Carbonated calcium phosphate/Total in Stone;Carb Ca Phos MFr Stone;;ACTIVE;2.07;2.44 +32160-4;Carboxyhemoglobin;PrThr;Pt;Bld;Ord;Screen;CHEM;1;Carboxyhemoglobin [Presence] in Blood by Screen method;COHgb Bld Ql Scn;;ACTIVE;2.07;2.73 +32161-2;Catecholamines;PrThr;24H;Urine;Ord;;CHEM;1;Catecholamines [Presence] in 24 hour Urine;Catechols 24h Ur Ql;;ACTIVE;2.07;2.56 +32162-0;Cells;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Cells [#/volume] in Pleural fluid by Manual count;Cells # Plr Manual;;ACTIVE;2.07;2.44 +32163-8;Cells;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Cells [#/volume] in Peritoneal fluid by Manual count;Cells # Prt Manual;;ACTIVE;2.07;2.44 +32164-6;Cells;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Cells [#/volume] in Synovial fluid by Manual count;Cells # Snv Manual;;ACTIVE;2.07;2.73 +32165-3;Cells counted.total;Num;Pt;Pericard fld;Qn;;HEM/BC;1;Cells Counted Total [#] in Pericardial fluid;Total Cells Counted Pcar;;ACTIVE;2.07;2.69 +32166-1;Choriogonadotropin^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma;HCG adj MoM SerPl;;ACTIVE;2.07;2.73 +32167-9;Clarity;Type;Pt;Urine;Nom;;SPEC;1;Clarity of Urine;Clarity Ur;;ACTIVE;2.07;2.73 +32168-7;Color;Type;Pt;CSF.spun;Nom;;SPEC;1;Color of Spun Cerebral spinal fluid;Color spun CSF;;ACTIVE;2.07;2.73 +3216-9;Coagulation factor X inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact X Inhib PPP-aCnc;;ACTIVE;1.0;2.73 +32169-5;Cystine;MCnc;24H;Urine;Qn;;CHEM;1;Cystine [Mass/volume] in 24 hour Urine;Cystine 24h Ur-mCnc;;ACTIVE;2.07;2.73 +32170-3;Cytomegalovirus Ab;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Cytomegalovirus Ab [Titer] in Serum or Plasma by Immunofluorescence;CMV Ab Titr SerPl IF;;ACTIVE;2.07;2.70 +32171-1;Echinococcus sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Echinococcus sp IgG Ab [Presence] in Serum;Echinococcus IgG Ser Ql;;ACTIVE;2.07;2.73 +32172-9;Ehrlichia chaffeensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia chaffeensis Ab [Presence] in Serum;E chaffeensis Ab Ser Ql;;ACTIVE;2.07;2.73 +32173-7;Eosinophils;PrThr;Pt;Bld;Ord;Wright stain;HEM/BC;1;Eosinophils [Presence] in Blood by Wright stain;Eosinophil Bld Ql Wright Stn;;ACTIVE;2.07;2.73 +32174-5;Glucose;PrThr;24H;Urine;Ord;;CHEM;1;Glucose [Presence] in 24 hour Urine;Glucose 24h Ur Ql;;ACTIVE;2.07;2.56 +32175-2;Granular casts.coarse;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Coarse Granular Casts [Presence] in Urine sediment by Light microscopy;Coarse Gran Casts UrnS Ql Micro;;ACTIVE;2.07;2.73 +32176-0;Granular casts.fine;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Fine Granular Casts [Presence] in Urine sediment by Light microscopy;Fine Gran Casts UrnS Ql Micro;;ACTIVE;2.07;2.73 +3217-7;Coagulation factor X activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor X activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact Xa PPP-aCnc;;ACTIVE;1.0;2.73 +32177-8;Granulocytes/100 leukocytes;NFr;Pt;Vag;Qn;;HEM/BC;1;Granulocytes/100 leukocytes in Vaginal fluid;Granulocytes/leuk NFr Vag;;ACTIVE;2.07;2.50 +32178-6;Hepatitis B virus little e Ag;Titr;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus e Ag [Titer] in Serum;HBV e Ag Titr Ser;;ACTIVE;2.07;2.73 +32179-4;Heptacarboxylporphyrin/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin/Creatinine [Molar ratio] in 24 hour Urine;Hepta-CP/Creat 24h Ur-sRto;;ACTIVE;2.07;2.42 +32180-2;Herpes simplex virus 1 Ab;ACnc;Pt;Synv fld;Qn;;MICRO;1;Herpes simplex virus 1 Ab [Units/volume] in Synovial fluid;HSV1 Ab Snv-aCnc;;ACTIVE;2.07;2.69 +32181-0;Herpes simplex virus 2 Ab;ACnc;Pt;Synv fld;Qn;;MICRO;1;Herpes simplex virus 2 Ab [Units/volume] in Synovial fluid;HSV2 Ab Snv-aCnc;;ACTIVE;2.07;2.69 +32182-8;Herpes virus 6 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Herpes virus 6 IgM Ab [Titer] in Serum;HHV6 IgM Titr Ser;;ACTIVE;2.07;2.73 +32183-6;Hydroxyproline.free;SCnc;Pt;Urine;Qn;;CHEM;1;Hydroxyproline Free [Moles/volume] in Urine;OH-Proline Free Ur-sCnc;;ACTIVE;2.07;2.42 +32184-4;Itraconazole^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Itraconazole [Mass/volume] in Serum or Plasma --peak;Itraconaz Peak SerPl-mCnc;;ACTIVE;2.07;2.40 +3218-5;Coagulation factor X activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor X activity actual/normal in Platelet poor plasma by Coagulation assay;Fact X Act/Nor PPP;;ACTIVE;1.0;2.73 +32185-1;Itraconazole^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Itraconazole [Mass/volume] in Serum or Plasma --trough;Itraconaz Trough SerPl-mCnc;;ACTIVE;2.07;2.40 +32186-9;Microscopic observation;Prid;Pt;Penis;Nom;Tzanck smear;MICRO;1;Microscopic observation [Identifier] in Penis by Tzanck smear;Tzanck Smear Penis;;ACTIVE;2.07;2.21 +32187-7;Microscopic observation;Prid;Pt;Skin;Nom;Tzanck smear;MICRO;1;Microscopic observation [Identifier] in Skin by Tzanck smear;Tzanck Smear Skin;;ACTIVE;2.07;2.21 +32188-5;Microscopic observation;Prid;Pt;CSF;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by Acid fast stain;Acid fast Stn CSF;;ACTIVE;2.07;2.73 +32189-3;Microscopic observation;Prid;Pt;Body fld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Body fluid by Acid fast stain;Acid fast Stn Fld;;ACTIVE;2.07;2.73 +32190-1;Microscopic observation;Prid;Pt;CSF;Nom;;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid;CSF Micro;;ACTIVE;2.07;2.73 +32191-9;Monocytes+Macrophages;PrThr;Pt;CSF;Ord;Microscopy.light;HEM/BC;1;Monocytes+Macrophages [Presence] in Cerebral spinal fluid by Light microscopy;Monos+Macros CSF Ql Micro;;ACTIVE;2.07;2.56 +32192-7;Monocytes+Macrophages;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Monocytes+Macrophages [Presence] in Body fluid by Light microscopy;Monos+Macros Fld Ql Micro;;ACTIVE;2.07;2.56 +3219-3;Coagulation factor X activity;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor X activity [Units/volume] in Platelet poor plasma by Chromogenic method;Fact X PPP Chro-aCnc;;ACTIVE;1.0;2.73 +32193-5;Monocytes+Macrophages;PrThr;Pt;Pericard fld;Ord;Microscopy.light;HEM/BC;1;Monocytes+Macrophages [Presence] in Pericardial fluid by Light microscopy;Monos+Macros Pcar Ql Micro;;ACTIVE;2.07;2.56 +32194-3;Monocytes+Macrophages;PrThr;Pt;Plr fld;Ord;Microscopy.light;HEM/BC;1;Monocytes+Macrophages [Presence] in Pleural fluid by Light microscopy;Monos+Macros Plr Ql Micro;;ACTIVE;2.07;2.56 +32195-0;Monocytes+Macrophages;PrThr;Pt;Periton fld;Ord;Microscopy.light;HEM/BC;1;Monocytes+Macrophages [Presence] in Peritoneal fluid by Light microscopy;Monos+Macros Prt Ql Micro;;ACTIVE;2.07;2.56 +32196-8;Monocytes+Macrophages;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Monocytes+Macrophages [Presence] in Synovial fluid by Light microscopy;Monos+Macros Snv Ql Micro;;ACTIVE;2.07;2.56 +32197-6;Myoglobin;MCnc;24H;Urine;Qn;;CHEM;1;Myoglobin [Mass/volume] in 24 hour Urine;Myoglobin 24h Ur-mCnc;;ACTIVE;2.07;2.73 +32198-4;Neisseria gonorrhoeae rRNA;PrThr;Pt;Cvx;Ord;Probe;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Cervix by Probe;N gonorrhoea rRNA Cvx Ql Probe;;DISCOURAGED;2.07;2.73 +32199-2;Neisseria gonorrhoeae rRNA;PrThr;Pt;Urethra;Ord;Probe;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Urethra by Probe;N gonorrhoea rRNA Urth Ql Probe;;DISCOURAGED;2.07;2.63 +32200-8;Neutrophils.segmented/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Segmented neutrophils/100 leukocytes in Blood by Automated count;Neuts Seg/leuk NFr Bld Auto;;ACTIVE;2.07;2.73 +3220-1;Coagulation factor X Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor X Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact X Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32201-6;Unidentified cells;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Unidentified cells [#/volume] in Cerebral spinal fluid by Manual count;Unident Cells # CSF Manual;;ACTIVE;2.07;2.44 +32202-4;Unidentified cells;NCnc;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Unidentified cells [#/volume] in Pericardial fluid by Manual count;Unident Cells # Pcar Manual;;ACTIVE;2.07;2.44 +32203-2;Unidentified cells;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Unidentified cells [#/volume] in Pleural fluid by Manual count;Unident Cells # Plr Manual;;ACTIVE;2.07;2.44 +32204-0;Unidentified cells;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Unidentified cells [#/volume] in Peritoneal fluid by Manual count;Unident Cells # Prt Manual;;ACTIVE;2.07;2.44 +32205-7;Unidentified cells;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Unidentified cells [#/volume] in Synovial fluid by Manual count;Unident Cells # Snv Manual;;ACTIVE;2.07;2.44 +32206-5;Plasmodium sp identified;Prid;Pt;Bld;Nom;Microscopy.light;MICRO;1;Plasmodium sp identified in Blood by Light microscopy;Plasmodium Bld Smear;;ACTIVE;2.07;2.73 +32207-3;Platelet distribution width;EntVol;Pt;Bld;Qn;Automated count;HEM/BC;1;Platelet distribution width [Entitic volume] in Blood by Automated count;PDW Bld Auto;;ACTIVE;2.07;2.73 +32208-1;Platelets.small;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Platelets Small [Presence] in Blood by Light microscopy;Small Platelets Bld Ql Smear;;ACTIVE;2.07;2.73 +32209-9;Protein;PrThr;24H;Urine;Ord;Test strip;UA;1;Protein [Presence] in 24 hour Urine by Test strip;Prot 24h Ur Ql Strip;;ACTIVE;2.07;2.73 +32210-7;Protein pattern;Imp;24H;Urine;Nom;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in 24 hour Urine by Electrophoresis;Prot Pattern 24h Ur Elph-Imp;;ACTIVE;2.07;2.73 +32211-5;Reducing substances;MCnc;Pt;Stool;Qn;;CHEM;1;Reducing substances [Mass/volume] in Stool;Reducing Subs Stl-mCnc;;ACTIVE;2.07;2.73 +32212-3;Salmonella paratyphi A Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi A Ab [Titer] in Serum;S Paraty A Ab Titr Ser;;ACTIVE;2.07;2.16 +32213-1;Salmonella paratyphi B Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi B Ab [Titer] in Serum;S Paraty B Ab Titr Ser;;ACTIVE;2.07;2.16 +32214-9;Thyroid stimulating immunoglobulins;SCnc;Pt;Ser;Qn;;CHEM;1;Thyroid stimulating immunoglobulins [Moles/volume] in Serum;TSI Ser-sCnc;;DISCOURAGED;2.07;2.44 +32215-6;Thyroxine free index;MCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Thyroxine (T4) free index in Serum or Plasma by calculation;FT4I SerPl Calc-mCnc;;ACTIVE;2.07;2.73 +32216-4;Uroporphyrin;MCnc;24H;Urine;Qn;;CHEM;1;Uroporphyrin [Mass/volume] in 24 hour Urine;Uropor 24h Ur-mCnc;;ACTIVE;2.07;2.42 +32217-2;von Willebrand factor multimers;PrThr;Pt;PPP;Ord;;COAG;1;von Willebrand factor (vWf) multimers [Presence] in Platelet poor plasma;vWF multimers PPP Ql;;ACTIVE;2.07;2.73 +32218-0;Cyclic citrullinated peptide Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Cyclic citrullinated peptide Ab [Units/volume] in Serum by Immunoassay;cCP Ab Ser IA-aCnc;;ACTIVE;2.07;2.73 +3221-9;Coagulation factor X Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor X Ag actual/normal in Platelet poor plasma by Immunoassay;Fact X Ag Act/Nor PPP IA;;ACTIVE;1.0;2.73 +32219-8;Soluble liver Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Soluble liver Ab [Units/volume] in Serum by Immunoassay;Soluble liver Ab Ser IA-aCnc;;ACTIVE;2.07;2.73 +32220-6;Liver kidney microsomal 1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Liver kidney microsomal 1 Ab [Units/volume] in Serum;LKM-1 Ab Ser-aCnc;;ACTIVE;2.07;2.73 +32221-4;Alanine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Alanine [Moles/volume] in Vitreous fluid;Alanine Vitf-sCnc;;ACTIVE;2.07;2.70 +32222-2;Alanine;SCnc;Pt;Body fld;Qn;;CHEM;1;Alanine [Moles/volume] in Body fluid;Alanine Fld-sCnc;;ACTIVE;2.07;2.70 +32223-0;Alpha aminobutyrate;SCnc;Pt;Body fld;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in Body fluid;A-Aminobutyr Fld-sCnc;;ACTIVE;2.07;2.70 +32224-8;Alpha aminobutyrate;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in Vitreous fluid;A-Aminobutyr Vitf-sCnc;;ACTIVE;2.07;2.70 +32225-5;Arginine;SCnc;Pt;Body fld;Qn;;CHEM;1;Arginine [Moles/volume] in Body fluid;Arginine Fld-sCnc;;ACTIVE;2.07;2.70 +32226-3;Arginine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Arginine [Moles/volume] in Vitreous fluid;Arginine Vitf-sCnc;;ACTIVE;2.07;2.70 +3222-7;Coagulation factor X+Acarboxy Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor X+Acarboxy Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact X+AAC Ag PPP IA-aCnc;;ACTIVE;1.0;2.69 +32227-1;Argininosuccinate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Argininosuccinate [Moles/volume] in Serum or Plasma;Argininosuccinate SerPl-sCnc;;ACTIVE;2.07;2.73 +32228-9;Argininosuccinate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Argininosuccinate [Moles/volume] in Amniotic fluid;Argininosuccinate Amn-sCnc;;ACTIVE;2.07;2.70 +32229-7;Argininosuccinate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Argininosuccinate/Creatinine [Ratio] in Urine;Argininosuccinate/Creat Ur-Rto;;ACTIVE;2.07;2.73 +32230-5;Asparagine;SCnc;Pt;Body fld;Qn;;CHEM;1;Asparagine [Moles/volume] in Body fluid;Asparagine Fld-sCnc;;ACTIVE;2.07;2.70 +32231-3;Aspartate;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Aspartate [Moles/volume] in Vitreous fluid;Aspartate Vitf-sCnc;;ACTIVE;2.07;2.70 +32232-1;Aspartate;SCnc;Pt;Body fld;Qn;;CHEM;1;Aspartate [Moles/volume] in Body fluid;Aspartate Fld-sCnc;;ACTIVE;2.07;2.70 +32233-9;Carbamoyl phosphate synthetase;CCnt;Pt;Tiss;Qn;;CHEM;1;Carbamoyl phosphate synthetase [Enzymatic activity/mass] in Tissue;CPS Tiss-cCnt;;ACTIVE;2.07;2.70 +32234-7;Citrulline;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Citrulline [Moles/volume] in Vitreous fluid;Citrulline Vitf-sCnc;;ACTIVE;2.07;2.70 +3223-5;Coagulation factor X+Acarboxy Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor X+Acarboxy Ag actual/normal in Platelet poor plasma by Immunoassay;Fact X+AAC Ag Act/Nor PPP IA;;ACTIVE;1.0;2.58 +32235-4;Citrulline;SCnc;Pt;Body fld;Qn;;CHEM;1;Citrulline [Moles/volume] in Body fluid;Citrulline Fld-sCnc;;ACTIVE;2.07;2.70 +32236-2;Cystathionine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Cystathionine [Moles/volume] in Vitreous fluid;Cystathionin Vitf-sCnc;;ACTIVE;2.07;2.70 +32237-0;Cystine;SCnc;Pt;Body fld;Qn;;CHEM;1;Cystine [Moles/volume] in Body fluid;Cystine Fld-sCnc;;ACTIVE;2.07;2.70 +32238-8;Cystine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Cystine [Moles/volume] in Vitreous fluid;Cystine Vitf-sCnc;;ACTIVE;2.07;2.70 +32239-6;Ethanolamine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Ethanolamine [Moles/volume] in Amniotic fluid;Ethanolamine Amn-sCnc;;ACTIVE;2.07;2.70 +32240-4;Fructose;PrThr;Pt;Urine;Ord;;CHEM;1;Fructose [Presence] in Urine;Fructose Ur Ql;;ACTIVE;2.07;2.70 +32241-2;Glutamate;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Glutamate [Moles/volume] in Vitreous fluid;Glutamate Vitf-sCnc;;ACTIVE;2.07;2.70 +32242-0;Glutamine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Glutamine [Moles/volume] in Vitreous fluid;Glutamine Vitf-sCnc;;ACTIVE;2.07;2.70 +3224-3;Coagulation factor XI inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XI inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact XI Inhib PPP-aCnc;;ACTIVE;1.0;2.73 +32243-8;Glutamine;SCnc;Pt;Body fld;Qn;;CHEM;1;Glutamine [Moles/volume] in Body fluid;Glutamine Fld-sCnc;;ACTIVE;2.07;2.70 +32244-6;Glycine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Glycine [Moles/volume] in Vitreous fluid;Glycine Vitf-sCnc;;ACTIVE;2.07;2.70 +32245-3;Glycine;SCnc;Pt;Body fld;Qn;;CHEM;1;Glycine [Moles/volume] in Body fluid;Glycine Fld-sCnc;;ACTIVE;2.07;2.70 +32246-1;Histidine;SCnc;Pt;Body fld;Qn;;CHEM;1;Histidine [Moles/volume] in Body fluid;Histidine Fld-sCnc;;ACTIVE;2.07;2.70 +32247-9;Histidine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Histidine [Moles/volume] in Vitreous fluid;Histidine Vitf-sCnc;;ACTIVE;2.07;2.70 +32248-7;Homocitrulline/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Homocitrulline/Creatinine [Ratio] in Urine;Homocitrulline/Creat Ur-Rto;;ACTIVE;2.07;2.73 +32249-5;Hydroxyproline;SCnc;Pt;Body fld;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in Body fluid;OH-Proline Fld-sCnc;;ACTIVE;2.07;2.70 +3225-0;Coagulation factor XI activated activity;CFr;Pt;PPP;Qn;Coag;COAG;1;Deprecated Coagulation factor XI activated activity;Deprecated Fact Xia Fr PPP;;DEPRECATED;1.0;2.70 +32250-3;Hydroxyproline;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in Vitreous fluid;OH-Proline Vitf-sCnc;;ACTIVE;2.07;2.70 +32251-1;Isoleucine;SCnc;Pt;Body fld;Qn;;CHEM;1;Isoleucine [Moles/volume] in Body fluid;Isoleucine Fld-sCnc;;ACTIVE;2.07;2.70 +32252-9;Isoleucine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Isoleucine [Moles/volume] in Vitreous fluid;Isoleucine Vitf-sCnc;;ACTIVE;2.07;2.70 +32253-7;Leucine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Leucine [Moles/volume] in Vitreous fluid;Leucine Vitf-sCnc;;ACTIVE;2.07;2.70 +32254-5;Leucine;SCnc;Pt;Body fld;Qn;;CHEM;1;Leucine [Moles/volume] in Body fluid;Leucine Fld-sCnc;;ACTIVE;2.07;2.70 +32255-2;Lysine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Lysine [Moles/volume] in Vitreous fluid;Lysine Vitf-sCnc;;ACTIVE;2.07;2.70 +32256-0;Lysine;SCnc;Pt;Body fld;Qn;;CHEM;1;Lysine [Moles/volume] in Body fluid;Lysine Fld-sCnc;;ACTIVE;2.07;2.70 +32257-8;Methionine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Methionine [Moles/volume] in Vitreous fluid;Methionine Vitf-sCnc;;ACTIVE;2.07;2.70 +32258-6;Methionine;SCnc;Pt;Body fld;Qn;;CHEM;1;Methionine [Moles/volume] in Body fluid;Methionine Fld-sCnc;;ACTIVE;2.07;2.70 +32259-4;Methylmalonate;MCnc;Pt;CSF;Qn;;CHEM;1;Methylmalonate [Mass/volume] in Cerebral spinal fluid;Methylmalonate CSF-mCnc;;ACTIVE;2.07;2.70 +32260-2;Ornithine;SCnc;Pt;Body fld;Qn;;CHEM;1;Ornithine [Moles/volume] in Body fluid;Ornithine Fld-sCnc;;ACTIVE;2.07;2.70 +32261-0;Ornithine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Ornithine [Moles/volume] in Vitreous fluid;Ornithine Vitf-sCnc;;ACTIVE;2.07;2.70 +32262-8;Orotate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Orotate/Creatinine [Ratio] in Urine;Orotate/Creat Ur-Rto;;ACTIVE;2.07;2.70 +32263-6;Phenylalanine;SCnc;Pt;Body fld;Qn;;CHEM;1;Phenylalanine [Moles/volume] in Body fluid;Phe Fld-sCnc;;ACTIVE;2.07;2.70 +32264-4;Phenylalanine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Phenylalanine [Moles/volume] in Vitreous fluid;Phe Vitf-sCnc;;ACTIVE;2.07;2.70 +32265-1;Phenylalanine/Tyrosine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Phenylalanine/Tyrosine [Molar ratio] in Serum or Plasma;Phe/Tyr SerPl-sRto;;ACTIVE;2.07;2.70 +32266-9;Proline;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Proline [Moles/volume] in Vitreous fluid;Proline Vitf-sCnc;;ACTIVE;2.07;2.70 +32267-7;Proline;SCnc;Pt;Body fld;Qn;;CHEM;1;Proline [Moles/volume] in Body fluid;Proline Fld-sCnc;;ACTIVE;2.07;2.70 +3226-8;Coagulation factor XI activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XI activity actual/normal in Platelet poor plasma by Coagulation assay;Fact XI Act/Nor PPP;;ACTIVE;1.0;2.73 +32268-5;Ribose;PrThr;Pt;Urine;Ord;;CHEM;1;Ribose [Presence] in Urine;Ribose Ur Ql;;ACTIVE;2.07;2.70 +32269-3;Serine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Serine [Moles/volume] in Vitreous fluid;Serine Vitf-sCnc;;ACTIVE;2.07;2.70 +32270-1;Serine;SCnc;Pt;Body fld;Qn;;CHEM;1;Serine [Moles/volume] in Body fluid;Serine Fld-sCnc;;ACTIVE;2.07;2.70 +32271-9;Taurine;SCnc;Pt;Body fld;Qn;;CHEM;1;Taurine [Moles/volume] in Body fluid;Taurine Fld-sCnc;;ACTIVE;2.07;2.70 +32272-7;Threonine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Threonine [Moles/volume] in Vitreous fluid;Threonine Vitf-sCnc;;ACTIVE;2.07;2.70 +32273-5;Threonine;SCnc;Pt;Body fld;Qn;;CHEM;1;Threonine [Moles/volume] in Body fluid;Threonine Fld-sCnc;;ACTIVE;2.07;2.70 +32274-3;Thiosulfate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Thiosulfate/Creatinine [Ratio] in Urine;Thiosulfate/Creat Ur-Rto;;ACTIVE;2.07;2.73 +32275-0;Tryptophan;SCnc;Pt;Body fld;Qn;;CHEM;1;Tryptophan [Moles/volume] in Body fluid;Tryptophan Fld-sCnc;;ACTIVE;2.07;2.70 +3227-6;Coagulation factor XI activity;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor XI activity [Units/volume] in Platelet poor plasma by Chromogenic method;Fact XI PPP Chro-aCnc;;ACTIVE;1.0;2.73 +32276-8;Tyrosine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Tyrosine [Moles/volume] in Vitreous fluid;Tyrosine Vitf-sCnc;;ACTIVE;2.07;2.70 +32277-6;Tyrosine;SCnc;Pt;Body fld;Qn;;CHEM;1;Tyrosine [Moles/volume] in Body fluid;Tyrosine Fld-sCnc;;ACTIVE;2.07;2.70 +32278-4;Valine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Valine [Moles/volume] in Vitreous fluid;Valine Vitf-sCnc;;ACTIVE;2.07;2.70 +32279-2;Valine;SCnc;Pt;Body fld;Qn;;CHEM;1;Valine [Moles/volume] in Body fluid;Valine Fld-sCnc;;ACTIVE;2.07;2.70 +322-8;Methicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Methicillin [Susceptibility] by Minimum lethal concentration (MLC);Methicillin Islt MLC;;ACTIVE;1.0;2.19 +32280-0;Acylglycines;PrThr;Pt;Urine;Ord;;CHEM;1;Acylglycines [Presence] in Urine;Acylglycines Ur Ql;;ACTIVE;2.07;2.73 +32281-8;Carnitine.free (C0)/Carnitine.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine free (C0)/Carnitine.total in Serum or Plasma;Carnitine Free SFr SerPl;;ACTIVE;2.07;2.73 +32282-6;Succinylpurines;ACnc;Pt;Urine;Ord;;CHEM;1;Deprecated Succinylpurines [Presence] in Urine;Deprecated Succinylpurines Ur Ql;;DEPRECATED;2.07;2.70 +32283-4;Valproate.free/Valproate.total;MFr;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate Free/Valproate.total in Serum or Plasma;Valproate Free MFr SerPl;;ACTIVE;2.07;2.73 +3228-4;Coagulation factor XI Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor XI Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact XI Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32284-2;BK virus DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;BKV DNA SerPl NAA+probe-aCnc;;ACTIVE;2.07;2.74 +32285-9;BK virus DNA;ACnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Units/volume] (viral load) in Urine by NAA with probe detection;BKV DNA Ur NAA+probe-aCnc;;ACTIVE;2.07;2.74 +32286-7;Hepatitis C virus genotype;Prid;Pt;Ser/Plas;Nom;Probe.amp.tar;MICRO;1;Hepatitis C virus genotype [Identifier] in Serum or Plasma by NAA with probe detection;HCV Gentyp SerPl NAA+probe;;ACTIVE;2.07;2.73 +32287-5;Methylmalonate;SCnc;Pt;Urine;Qn;;CHEM;1;Methylmalonate [Moles/volume] in Urine;Methylmalonate Ur-sCnc;;ACTIVE;2.07;2.73 +32288-3;17-Hydroxyprogesterone^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --baseline;17OHP BS SerPl-sCnc;;ACTIVE;2.07;2.70 +32289-1;7-Dehydrocholesterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-Dehydrocholesterol [Moles/volume] in Serum or Plasma;7-DHC SerPl-sCnc;;ACTIVE;2.07;2.70 +32290-9;Acetone;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Acetone [Presence] in Specimen;Acetone Spec Ql;;ACTIVE;2.07;2.69 +32291-7;Acetone;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetone [Moles/volume] in Urine;Acetone Ur-sCnc;;ACTIVE;2.07;2.70 +3229-2;Coagulation factor XI Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor XI Ag actual/normal in Platelet poor plasma by Immunoassay;Fact XI Ag Act/Nor PPP IA;;ACTIVE;1.0;2.58 +32292-5;Acetone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Acetone [Moles/volume] in Specimen;Acetone Spec-sCnc;;ACTIVE;2.07;2.73 +32293-3;Albumin;MCnc;Pt;XXX;Qn;;CHEM;1;Albumin [Mass/volume] in Specimen;Albumin Spec-mCnc;;ACTIVE;2.07;2.73 +32294-1;Albumin/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Albumin/Creatinine [Ratio] in Urine;Albumin/Creat Ur-Rto;;ACTIVE;2.07;2.73 +32295-8;Aluminum;SRat;24H;Urine;Qn;;DRUG/TOX;1;Aluminum [Moles/time] in 24 hour Urine;Aluminum 24h Ur-sRate;;ACTIVE;2.07;2.70 +32296-6;Amino acid pattern;Imp;Pt;Urine;Nom;;CHEM;1;Amino acid pattern [Interpretation] in Urine;Amino acid Pat Ur-Imp;;ACTIVE;2.07;2.73 +32297-4;Amino acids;Imp;Pt;Urine;Nom;;CHEM;1;Deprecated Amino acids [interpretation] in Urine;Deprecated Amino acids Ur-Imp;;DEPRECATED;2.07;2.48 +32298-2;Amylase;CCnc;Pt;XXX;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Specimen;Amylase Spec-cCnc;;ACTIVE;2.07;2.73 +32299-0;Androstenedione^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Moles/volume] in Serum or Plasma --baseline;Androst BS SerPl-sCnc;;ACTIVE;2.07;2.70 +32-3;Ampicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Ampicillin+Sulbac Islt MIC;;ACTIVE;1.0;2.73 +3230-0;Coagulation factor XII inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XII inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact XII Inhib PPP-aCnc;;ACTIVE;1.0;2.73 +32300-6;Base excess;SCnc;Pt;BldCo;Qn;Calculated;CHEM;1;Base excess in Cord blood by calculation;Base excess BldCo Calc-sCnc;;ACTIVE;2.07;2.73 +32301-4;Beta-2-Microglobulin;SCnc;Pt;CSF;Qn;;CHEM;1;Beta-2-Microglobulin [Moles/volume] in Cerebral spinal fluid;B2 Microglob CSF-sCnc;;ACTIVE;2.07;2.70 +32302-2;Beta-2-Microglobulin;SCnc;Pt;Urine;Qn;;CHEM;1;Beta-2-Microglobulin [Moles/volume] in Urine;B2 Microglob Ur-sCnc;;ACTIVE;2.07;2.70 +32303-0;Bilirubin;SCnc;Pt;XXX;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Specimen;Bilirub Spec-sCnc;;ACTIVE;2.07;2.73 +32304-8;Cadmium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Cadmium [Moles/time] in 24 hour Urine;Cadmium 24h Ur-sRate;;ACTIVE;2.07;2.70 +32305-5;Calcium;SCnc;Pt;XXX;Qn;;CHEM;1;Calcium [Moles/volume] in Specimen;Calcium Spec-sCnc;;ACTIVE;2.07;2.73 +32306-3;Carbon dioxide;PPres;Pt;Urine;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Urine;pCO2 Ur;;ACTIVE;2.07;2.73 +32307-1;Chloride;SCnc;Pt;XXX;Qn;;CHEM;1;Chloride [Moles/volume] in Specimen;Chloride Spec-sCnc;;ACTIVE;2.07;2.73 +32308-9;Cholesterol;SCnc;Pt;XXX;Qn;;CHEM;1;Cholesterol [Moles/volume] in Specimen;Cholest Spec-sCnc;;ACTIVE;2.07;2.73 +32309-7;Cholesterol.total/Cholesterol.in HDL;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.total/Cholesterol in HDL [Molar ratio] in Serum or Plasma;Cholest/HDLc SerPl-sRto;;ACTIVE;2.07;2.73 +32310-5;Cortisol;SRat;24H;Urine;Qn;;CHEM;1;Cortisol [Moles/time] in 24 hour Urine;Cortis 24h Ur-sRate;;ACTIVE;2.07;2.70 +32311-3;Cortisol^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Cortis 1h p chal SerPl-sCnc;;ACTIVE;2.07;2.70 +32312-1;Cortisol^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Cortis 2h p chal SerPl-sCnc;;ACTIVE;2.07;2.70 +32313-9;Cortisol^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Cortis 30M p chal SerPl-sCnc;;ACTIVE;2.07;2.70 +32314-7;Cortisol^1.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge;Cortis 1.5h p chal SerPl-sCnc;;ACTIVE;2.07;2.70 +32315-4;Cortisol^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --baseline;Cortis BS SerPl-sCnc;;ACTIVE;2.07;2.73 +32316-2;Follitropin^30M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --30 minutes post XXX challenge;FSH 30M p chal SerPl-aCnc;;ACTIVE;2.07;2.70 +32317-0;Follitropin^baseline;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --baseline;FSH BS SerPl-aCnc;;ACTIVE;2.07;2.73 +3231-8;Coagulation factor XII activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XII activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact XIIa PPP-aCnc;;ACTIVE;1.0;2.73 +32318-8;Glucose;SCnc;Pt;XXX;Qn;;CHEM;1;Glucose [Moles/volume] in Specimen;Glucose Spec-sCnc;;ACTIVE;2.07;2.73 +32319-6;Glucose^30M post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post 75 g glucose PO;Glucose 30M p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.07;2.73 +32320-4;Glucose^3H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post 75 g glucose PO;Glucose 3h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.07;2.70 +32321-2;Glucose^4H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4 hours post 75 g glucose PO;Glucose 4h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.07;2.70 +32322-0;Glucose^5H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5 hours post 75 g glucose PO;Glucose 5h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.07;2.70 +32323-8;Ketones;SCnc;Pt;XXX;Qn;;CHEM;1;Ketones [Moles/volume] in Specimen;Ketones Spec-sCnc;;ACTIVE;2.07;2.73 +32324-6;Lactate dehydrogenase;CCnc;Pt;XXX;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Specimen;LDH Spec-cCnc;;ACTIVE;2.07;2.73 +32325-3;Lead;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Lead [Moles/volume] in Red Blood Cells;Lead RBC-sCnc;;ACTIVE;2.07;2.70 +3232-6;Coagulation factor XII activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XII activity actual/normal in Platelet poor plasma by Coagulation assay;Fact XII Act/Nor PPP;;ACTIVE;1.0;2.73 +32326-1;Lutropin^30M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --30 minutes post XXX challenge;LH 30M p chal SerPl-aCnc;;ACTIVE;2.07;2.73 +32327-9;Lutropin^1H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1 hour post XXX challenge;LH 1h p chal SerPl-aCnc;;ACTIVE;2.07;2.73 +32328-7;Lutropin^baseline;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --baseline;LH BS SerPl-aCnc;;ACTIVE;2.07;2.73 +32329-5;Magnesium;SCnc;Pt;XXX;Qn;;CHEM;1;Magnesium [Moles/volume] in Specimen;Magnesium Spec-sCnc;;ACTIVE;2.07;2.73 +32330-3;Mercury;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Serum or Plasma;Mercury SerPl-sCnc;;ACTIVE;2.07;2.73 +32331-1;Myoglobin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Myoglobin [Presence] in Serum or Plasma;Myoglobin SerPl Ql;;ACTIVE;2.07;2.73 +32332-9;Neopterin/Biopterin;SRto;Pt;Urine;Qn;;CHEM;1;Neopterin/Biopterin [Molar ratio] in Urine;Neopterin/Biopterin Ur-sRto;;ACTIVE;2.07;2.42 +32333-7;Phenylpropanolamine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Phenylpropanolamine [Presence] in Specimen;PPA Spec Ql;;ACTIVE;2.07;2.69 +3233-4;Coagulation factor XII activity;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor XII activity [Units/volume] in Platelet poor plasma by Chromogenic method;Fact XII PPP Chro-aCnc;;ACTIVE;1.0;2.69 +32334-5;Pipecolate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pipecolate [Moles/volume] in Serum or Plasma;Pipecolate SerPl-sCnc;;ACTIVE;2.07;2.73 +32335-2;Pipecolate;SCnc;Pt;Urine;Qn;;CHEM;1;Pipecolate [Moles/volume] in Urine;Pipecolate Ur-sCnc;;ACTIVE;2.07;2.70 +32336-0;Potassium;SCnc;Pt;XXX;Qn;;CHEM;1;Potassium [Moles/volume] in Specimen;Potassium Spec-sCnc;;ACTIVE;2.07;2.73 +32337-8;Protein;MCnc;Pt;XXX;Qn;;CHEM;1;Protein [Mass/volume] in Specimen;Prot Spec-mCnc;;ACTIVE;2.07;2.73 +32338-6;Pyruvate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyruvate [Moles/volume] in Serum or Plasma;Pyruvate SerPl-sCnc;;ACTIVE;2.07;2.73 +32339-4;Serotonin;SRat;24H;Urine;Qn;;CHEM;1;Serotonin [Moles/time] in 24 hour Urine;Serotonin 24h Ur-sRate;;ACTIVE;2.07;2.70 +32340-2;Sodium;SCnc;Pt;XXX;Qn;;CHEM;1;Sodium [Moles/volume] in Specimen;Sodium Spec-sCnc;;ACTIVE;2.07;2.73 +32341-0;Transcobalamin II;SCnc;Pt;Ser;Qn;;CHEM;1;Transcobalamin II [Moles/volume] in Serum;Transcobalamin II Ser-sCnc;;ACTIVE;2.07;2.73 +3234-2;Coagulation factor XII Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor XII Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact XII Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32342-8;Trimethoprim+Sulfamethoxazole;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Trimethoprim+Sulfamethoxazole [Moles/volume] in Serum or Plasma;Deprecated TMP SMX SerPl-sCnc;;DEPRECATED;2.07;2.70 +32343-6;Urate;SCnc;Pt;XXX;Qn;;CHEM;1;Urate [Moles/volume] in Specimen;Urate Spec-sCnc;;ACTIVE;2.07;2.70 +32344-4;Urobilin;PrThr;Pt;Stool;Ord;;CHEM;1;Urobilin [Presence] in Stool;Urobilin Stl Ql;;ACTIVE;2.07;2.56 +32345-1;Uroporphyrin;SCnc;Pt;RBC;Qn;;CHEM;1;Uroporphyrin [Moles/volume] in Red Blood Cells;Uropor RBC-sCnc;;ACTIVE;2.07;2.70 +32346-9;Uroporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Uroporphyrin [Moles/mass] in Stool;Uropor Stl-sCnt;;ACTIVE;2.07;2.70 +32347-7;Xylose;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Xylose [Moles/volume] in Serum or Plasma;Xylose SerPl-sCnc;;ACTIVE;2.07;2.70 +32348-5;Zinc;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Zinc [Moles/volume] in Cerebral spinal fluid;Zinc CSF-sCnc;;ACTIVE;2.07;2.70 +32349-3;Basophils+Eosinophils+Monocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Basophils+Eosinophils+Monocytes [#/volume] in Blood;Baso+Eos+Monos # Bld;;ACTIVE;2.07;2.73 +32350-1;Basophils+Eosinophils+Monocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Basophils+Eosinophils+Monocytes/100 leukocytes in Blood;Baso+Eos+Monos/leuk NFr Bld;;ACTIVE;2.07;2.73 +32351-9;Alkaline phosphatase.heat labile;CCnc;Pt;Ser/Plas;Qn;Heat stability;CHEM;1;Alkaline phosphatase.heat labile [Enzymatic activity/volume] in Serum or Plasma by Heat stability;ALP heat labile SerPl HS-cCnc;;ACTIVE;2.07;2.73 +32352-7;Alkaline phosphatase.heat stable;CCnc;Pt;Ser/Plas;Qn;Heat stability;CHEM;1;Alkaline phosphatase.heat stable [Enzymatic activity/volume] in Serum or Plasma by Heat stability;ALP heat stable SerPl HS-cCnc;;ACTIVE;2.07;2.73 +32353-5;Estriol;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3) [Multiple of the median] in Serum or Plasma;Estriol MoM SerPl;;ACTIVE;2.07;2.73 +32354-3;Hematocrit;VFr;Pt;BldA;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Arterial blood;Hct VFr BldA;;ACTIVE;2.07;2.73 +32355-0;Bacteria identified;Prid;Pt;XXX;Nom;Respiratory culture;MICRO;1;Bacteria identified in Specimen by Respiratory culture;Bacteria Spec Resp Cult;;ACTIVE;2.07;2.73 +32356-8;Yeast;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Yeast [Presence] in Urine sediment by Light microscopy;Yeast UrnS Ql Micro;;ACTIVE;2.07;2.73 +32357-6;Ova+Parasites identified;Prid;Pt;Stool;Nom;;MICRO;1;Deprecated Microscopic observation [Identifier] in Stool by Ova & Parasite Preparation;Deprecated O+P Stl;;DEPRECATED;2.07;2.36 +32358-4;Protein fractions.oligoclonal bands;PrThr;Pt;CSF;Ord;;CHEM;1;Oligoclonal bands [Presence] in Cerebral spinal fluid;Oligoclonal Bands CSF Ql;;ACTIVE;2.07;2.73 +3235-9;Coagulation factor XII Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor XII Ag actual/normal in Platelet poor plasma by Immunoassay;Fact XII Ag Act/Nor PPP IA;;ACTIVE;1.0;2.58 +32359-2;Glucose^10M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10 minutes post dose glucose;Glucose 10M p Glc SerPl-sCnc;;ACTIVE;2.07;2.70 +323-6;Methicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Methicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Methicillin Islt MIC;;ACTIVE;1.0;2.40 +32360-0;Insulin^10M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --10 minutes post XXX challenge;Insulin 10M p chal SerPl-aCnc;;ACTIVE;2.07;2.70 +32361-8;West Nile virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Serum by NAA with probe detection;WNV RNA Ser Ql NAA+probe;;ACTIVE;2.07;2.73 +32362-6;BK virus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;BK virus DNA [Presence] in Serum or Plasma by NAA with probe detection;BKV DNA SerPl Ql NAA+probe;;ACTIVE;2.07;2.73 +32363-4;JC virus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;JC virus DNA [Presence] in Serum or Plasma by NAA with probe detection;JCPyV DNA SerPl Ql NAA+probe;;ACTIVE;2.07;2.73 +32364-2;Herpes virus 8 DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [Presence] in Serum or Plasma by NAA with probe detection;HHV8 DNA SerPl Ql NAA+probe;;ACTIVE;2.07;2.73 +32365-9;Torque teno virus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Torque teno virus DNA [Presence] in Serum or Plasma by NAA with probe detection;TTV DNA SerPl Ql NAA+probe;;ACTIVE;2.07;2.66 +32366-7;Hepatitis B virus genotype;Prid;Pt;Ser/Plas;Nom;Probe.amp.tar;MICRO;1;Hepatitis B virus genotype [Identifier] in Serum or Plasma by NAA with probe detection;HBV Gentyp SerPl NAA+probe;;ACTIVE;2.07;2.73 +3236-7;Coagulation factor XIII inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XIII inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact XIII Inhib PPP-aCnc;;ACTIVE;1.0;2.69 +32367-5;Bacteria identified;Prid;Pt;Isolate;Nom;Aerobic culture;MICRO;1;Bacteria identified in Isolate by Aerobe culture;Bacteria Islt Aerobe Cult;;ACTIVE;2.07;2.73 +32368-3;Ureaplasma sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Ureaplasma sp identified in Specimen by Organism specific culture;Ureaplasma Spec Cult;;ACTIVE;2.07;2.73 +32369-1;Clostridium perfringens enterotoxin;Prid;Pt;XXX;Nom;;MICRO;1;Clostridium perfringens enterotoxin [Identifier] in Specimen;C perfringens Etx Spec;;ACTIVE;2.07;2.69 +32370-9;West Nile virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Tissue by NAA with probe detection;WNV RNA Tiss Ql NAA+probe;;ACTIVE;2.07;2.65 +32371-7;West Nile virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;West Nile virus Ag [Presence] in Tissue by Immune stain;WNV Ag Tiss Ql ImStn;;ACTIVE;2.07;2.65 +32372-5;Fleroxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Fleroxacin [Susceptibility];Fleroxacin Susc Islt;;ACTIVE;2.07;2.19 +32373-3;Arbekacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Arbekacin [Susceptibility];Arbekacin Susc Islt;;ACTIVE;2.07;2.19 +32374-1;Cefotiam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefotiam [Susceptibility];Cefotiam Susc Islt;;ACTIVE;2.07;2.19 +3237-5;Coagulation factor XIII activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XIII activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact XIIIa PPP-aCnc;;ACTIVE;1.0;2.73 +32375-8;Cefmenoxime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefmenoxime [Susceptibility];Cefmenoxime Susc Islt;;ACTIVE;2.07;2.19 +32376-6;Clinafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clinafloxacin [Susceptibility];Clinafloxacin Susc Islt;;ACTIVE;2.07;2.19 +32377-4;Cefetamet;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefetamet [Susceptibility];Cefetamet Susc Islt;;ACTIVE;2.07;2.19 +32378-2;Caspofungin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Caspofungin [Susceptibility];Caspofungin Susc Islt;;ACTIVE;2.07;2.73 +32379-0;Voriconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Voriconazole [Susceptibility];Voriconazole Susc Islt;;ACTIVE;2.07;2.73 +32380-8;Dicloxacillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Deprecated Dicloxacillin [Susceptibility];Deprecated Dicloxacillin Susc Islt;;DEPRECATED;2.07;2.36 +32381-6;Isepamicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Isepamicin [Susceptibility];Isepamicin Susc Islt;;ACTIVE;2.07;2.19 +32382-4;Nitroxoline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Deprecated Nitroxoline [Susceptibility];Deprecated Nitroxoline Susc Islt;;DEPRECATED;2.07;2.36 +3238-3;Coagulation factor XIII Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor XIII Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fact XIII Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32383-2;Pristinamycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pristinamycin [Susceptibility];Pristinamycin Susc Islt;;ACTIVE;2.07;2.19 +32384-0;Thiacetazone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Thiacetazone [Susceptibility];Thiacetazone Susc Islt;;ACTIVE;2.07;2.19 +32385-7;Babinski reflex;Find;Pt;Neurologic system;Nom;Observed;H&P.PX;2;Babinski reflex;Babinski reflex;;ACTIVE;2.07;2.29 +32386-5;Birth injury;Find;Pt;^Newborn;Nom;Stated;NEONAT;2;Newborn Birth injury;NB Birth injury;;ACTIVE;2.07;2.29 +32387-3;Chest tube output.total;VRat;24H;Pleural space.right;Qn;;IO_OUT.TIMED.MOLE;2;Chest tube output 24 hour Pleural space - right;Chest tube output 24h Pl space-R;;ACTIVE;2.07;2.48 +32388-1;Chest tube output.total;VRat;24H;Pleural space.left;Qn;;IO_OUT.TIMED.MOLE;2;Chest tube output 24 hour Pleural space - left;Chest tube output 24h Pl space-L;;ACTIVE;2.07;2.48 +32389-9;Deep tendon reflex;Find;Pt;Achilles;Ord;Observed;H&P.PX;2;Deep tendon reflex of Achilles;DTR Achilles;;ACTIVE;2.07;2.27 +32390-7;Deep tendon reflex;Find;Pt;Biceps;Ord;Observed;H&P.PX;2;Deep tendon reflex of Biceps;DTR Biceps;;ACTIVE;2.07;2.27 +3239-1;Coagulation factor XIII Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor XIII Ag actual/normal in Platelet poor plasma by Immunoassay;Fact XIII Ag Act/Nor PPP IA;;ACTIVE;1.0;2.73 +32391-5;Deep tendon reflex;Find;Pt;Brachioradialis;Ord;Observed;H&P.PX;2;Deep tendon reflex of Brachioradialis;DTR Brachioradialis;;ACTIVE;2.07;2.27 +32392-3;Deep tendon reflex;Find;Pt;Patellar;Ord;Observed;H&P.PX;2;Deep tendon reflex of Patellar;DTR Patellar;;ACTIVE;2.07;2.27 +32393-1;Deep tendon reflex;Find;Pt;Triceps;Ord;Observed;H&P.PX;2;Deep tendon reflex of Triceps;DTR Triceps;;ACTIVE;2.07;2.27 +32394-9;Calorie intake.enteral.total;EngRat;24H;Upper GI tract;Qn;;IO_IN_SALTS+CALS;2;Calorie intake enteral total 24 hour Upper GI tract;Calorie intake enteral 24h Upr GI Tract;;ACTIVE;2.07;2.48 +32395-6;Infant monitor type;Type;Pt;^Patient;Nom;;NEONAT;2;Infant monitor type;Infant monitor type;;ACTIVE;2.07;2.27 +32396-4;Labor duration;Time;Pt;^Patient;Qn;Stated;OBGYN;2;Labor duration;Labor duration;;ACTIVE;2.07;2.48 +32397-2;Liver span below costal margin;Len;Pt;Liver;Qn;Observed;H&P.PX;2;Liver span below costal margin;Liver span below costal margin;;ACTIVE;2.07;2.48 +32398-0;Secondary male genitalia development;Find;Pt;^Patient;Ord;Observed;H&P.PX;2;Secondary male genitalia development;Secondary male genitalia development;;ACTIVE;2.07;2.29 +32399-8;Maternal risk factors;Type;Pt;^Patient;Nom;Stated;OBGYN;2;Maternal risk factors;Maternal risk factors;;ACTIVE;2.07;2.73 +32400-4;Menses finding;Find;Pt;^Patient;Nom;Reported;OBGYN;2;Menses finding;Menses finding;;ACTIVE;2.07;2.29 +32401-2;Color^10M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;10 minute Apgar Color;10M Apgar Color;;ACTIVE;2.07;2.36 +32402-0;Heart rate^10M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;10 minute Apgar Heart rate;10M Apgar Heart rate;;ACTIVE;2.07;2.36 +32403-8;Muscle tone^10M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;10 minute Apgar Muscle tone;10M Apgar Muscle tone;;ACTIVE;2.07;2.36 +32404-6;Reflex irritability^10M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;10 minute Apgar Reflex irritability;10M Apgar Reflex irritability;;ACTIVE;2.07;2.36 +32405-3;Respiratory effort^10M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;10 minute Apgar Respiratory effort;10M Apgar Resp effort;;ACTIVE;2.07;2.36 +32406-1;Color^1M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;1 minute Apgar Color;1M Apgar Color;;ACTIVE;2.07;2.36 +32407-9;Heart rate^1M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;1 minute Apgar Heart rate;1M Apgar Heart rate;;ACTIVE;2.07;2.36 +32408-7;Muscle tone^1M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;1 minute Apgar Muscle tone;1M Apgar Muscle tone;;ACTIVE;2.07;2.36 +3240-9;Coagulation factor XIII coagulum dissolution;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XIII coagulum dissolution [Units/volume] in Platelet poor plasma by Coagulation assay;Fact XIII Clot Dis PPP-aCnc;;ACTIVE;1.0;2.73 +32409-5;Reflex irritability^1M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;1 minute Apgar Reflex irritability;1M Apgar Reflex irritability;;ACTIVE;2.07;2.36 +32410-3;Respiratory effort^1M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;1 minute Apgar Respiratory effort;1M Apgar Resp effort;;ACTIVE;2.07;2.36 +32411-1;Color^5M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;5 minute Apgar Color;5M Apgar Color;;ACTIVE;2.07;2.36 +32412-9;Heart rate^5M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;5 minute Apgar Heart rate;5M Apgar Heart rate;;ACTIVE;2.07;2.36 +32413-7;Muscle tone^5M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;5 minute Apgar Muscle tone;5M Apgar Muscle tone;;ACTIVE;2.07;2.36 +32414-5;Reflex irritability^5M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;5 minute Apgar Reflex irritability;5M Apgar Reflex irritability;;ACTIVE;2.07;2.36 +32415-2;Respiratory effort^5M post birth;Fcn;Pt;^Patient;Ord;Apgar;NEONAT;2;5 minute Apgar Respiratory effort;5M Apgar Resp effort;;ACTIVE;2.07;2.36 +32416-0;Newborn complication;Find;Pt;^Patient;Nom;;NEONAT;2;Newborn complication;NB complication;;ACTIVE;2.07;2.27 +3241-7;Coagulation factor XIII coagulum dissolution at 24H;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor XIII coagulum dissolution at 24 hours [Presence] in Platelet poor plasma by Coagulation assay;Fact XIII Clot Dis 24h PPP Ql;;ACTIVE;1.0;2.73 +32417-8;Newborn intensive care unit admission diagnosis;Find;Pt;^Patient;Nom;;H&P.HX;2;Newborn ICU admission diagnosis;NB ICU admission Dx;;ACTIVE;2.07;2.69 +32418-6;Obstetric trimester;Time;Pt;^Patient;Ord;Stated;H&P.HX;2;Obstetric trimester Stated;OB trimester Stated;;ACTIVE;2.07;2.27 +32419-4;Pain quality;Find;Pt;^Patient;Nom;;H&P.HX;2;Pain quality;Pain quality;;ACTIVE;2.07;2.61 +32420-2;Physical findings;Find;Pt;Adnexa;Nom;Observed;H&P.PX;2;Physical findings of Adnexa;Phys find Adnexa;;ACTIVE;2.07;2.27 +32421-0;Physical findings;Find;Pt;Auditory canal;Nom;Observed;H&P.PX;2;Physical findings of Auditory canal;Phys find Auditory canal;;ACTIVE;2.07;2.27 +32422-8;Physical findings;Find;Pt;Breast;Nom;Observed;H&P.PX;2;Physical findings of Breast;Phys find Brst;;ACTIVE;2.07;2.27 +32423-6;Physical findings;Find;Pt;Cvx;Nom;Observed;H&P.PX;2;Physical findings of Cervix;Phys find Cvx;;ACTIVE;2.07;2.58 +32424-4;Physical findings;Find;Pt;Conjunctiva;Nom;Observed;H&P.PX;2;Physical findings of Conjunctiva;Phys find Conjunctiva;;ACTIVE;2.07;2.27 +3242-5;Coagulation calcium ion induced;Time;Pt;PPP;Qn;Coag;COAG;1;Recalcification time in Platelet poor plasma by Coagulation assay;Recal time PPP;;ACTIVE;1.0;2.44 +32425-1;Physical findings;Find;Pt;Cornea;Nom;Observed;H&P.PX;2;Physical findings of Cornea;Phys find Cornea;;ACTIVE;2.07;2.27 +32426-9;Physical findings;Find;Pt;Nerves.cranial;Nom;Observed;H&P.PX;2;Physical findings of Nerves.cranial;Phys find Nerves.cranial;;ACTIVE;2.07;2.56 +32427-7;Physical findings;Find;Pt;Digits;Nom;Observed;H&P.PX;2;Physical findings of Digits;Phys find Digits;;ACTIVE;2.07;2.27 +32428-5;Physical findings;Find;Pt;Ear.external;Nom;Observed;H&P.PX;2;Physical findings of External Ear;Phys find Ear.Ext;;ACTIVE;2.07;2.27 +32429-3;Physical findings;Find;Pt;Extraocular muscles;Nom;Observed;H&P.PX;2;Physical findings of Extraocular muscles;Phys find Extraocular muscles;;ACTIVE;2.07;2.27 +32430-1;Physical findings;Find;Pt;Extremity;Nom;Observed;H&P.PX;2;Physical findings of Extremity;Phys find Extr;;ACTIVE;2.07;2.27 +32431-9;Physical findings;Find;Pt;Eye lid;Nom;Observed;H&P.PX;2;Physical findings of Eye lid;Phys find Eye lid;;ACTIVE;2.07;2.27 +32432-7;Physical findings;Find;Pt;Face;Nom;Observed;H&P.PX;2;Physical findings of Face;Phys find Face;;ACTIVE;2.07;2.27 +3243-3;Coagulation thrombin induced;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time;Thrombin time;;ACTIVE;1.0;2.73 +32433-5;Physical findings;Find;Pt;Gait;Nom;Observed;H&P.PX;2;Physical findings of Gait;Phys find Gait;;ACTIVE;2.07;2.73 +32434-3;Physical findings;Find;Pt;General appearance;Nom;Observed;H&P.PX;2;General appearance;General appearance;;ACTIVE;2.07;2.29 +32435-0;Symptoms & diseases;Hx;Pt;Hereditary;Nom;;H&P.HX;2;History of Hereditary disorders;Hx of Hereditary disorders;;ACTIVE;2.07;2.73 +32436-8;Physical findings;Find;Pt;Hair;Nom;Observed;H&P.PX;2;Physical findings of Hair;Phys find Hair;;ACTIVE;2.07;2.27 +32437-6;Physical findings;Find;Pt;Hearing;Nom;Observed;H&P.PX;2;Physical findings of Hearing;Phys find Hearing;;ACTIVE;2.07;2.27 +32438-4;Physical findings;Find;Pt;Hemorrhoid;Nom;Observed;H&P.PX;2;Physical findings of Hemorrhoid;Phys find Hemorrhoid;;ACTIVE;2.07;2.27 +32439-2;Physical findings;Find;Pt;Intraoral;Nom;Observed;H&P.PX;2;Physical findings of Intraoral;Phys find Intraoral;;ACTIVE;2.07;2.27 +324-4;Methicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Methicillin [Susceptibility] by Disk diffusion (KB);Methicillin Islt KB;;ACTIVE;1.0;2.19 +32440-0;Physical findings;Find;Pt;Iris;Nom;Observed;H&P.PX;2;Physical findings of Iris;Phys find Iris;;ACTIVE;2.07;2.27 +3244-1;Coagulum lysis;Time;Pt;PPP;Qn;Coag;COAG;1;Clot Lysis [Time] in Platelet poor plasma by Coagulation assay;Clot Lysis PPP;;ACTIVE;1.0;2.73 +32441-8;Physical findings;Find;Pt;Joint;Nom;Observed;H&P.PX;2;Physical findings of Joint;Phys find Joint;;ACTIVE;2.07;2.52 +32442-6;Symptoms & diseases;Hx;Pt;Kidney;Nom;;H&P.HX;2;History of Kidney disorders;Hx of Kidney disorders;;ACTIVE;2.07;2.56 +32443-4;Physical findings;Find;Pt;Lacrimal apparatus;Nom;Observed;H&P.PX;2;Physical findings of Lacrimal apparatus;Phys find Lacrimal apparatus;;ACTIVE;2.07;2.27 +32444-2;Physical findings;Find;Pt;Larynx;Nom;Observed;H&P.PX;2;Physical findings of Larynx;Phys find Larynx;;ACTIVE;2.07;2.27 +32445-9;Physical findings;Find;Pt;Lower leg;Nom;Observed;H&P.PX;2;Physical findings of Lower leg;Phys find Lower leg;;ACTIVE;2.07;2.27 +32446-7;Physical findings;Find;Pt;Lip;Nom;Observed;H&P.PX;2;Physical findings of Lip;Phys find Lip;;ACTIVE;2.07;2.27 +32447-5;Physical findings;Find;Pt;Liver;Nom;;H&P.PX;2;Physical findings of Liver;Phys find Liver;;ACTIVE;2.07;2.27 +32448-3;Physical findings;Find;Pt;Lower extremity;Nom;Observed;H&P.PX;2;Physical findings of Lower extremity;Phys find LE;;ACTIVE;2.07;2.27 +32449-1;Physical findings;Find;Pt;Lung;Nom;;H&P.PX;2;Physical findings of Lung;Phys find Lung;;ACTIVE;2.07;2.27 +32450-9;Physical findings;Find;Pt;Lymph node;Nom;Observed;H&P.PX;2;Physical findings of Lymph node;Phys find LN;;ACTIVE;2.07;2.27 +32451-7;Physical findings;Find;Pt;Macula;Nom;Observed;H&P.PX;2;Physical findings of Macula;Phys find Macula;;ACTIVE;2.07;2.27 +32452-5;Physical findings;Find;Pt;Motor function;Nom;Observed;H&P.PX;2;Physical findings of Motor function;Phys find Motor function;;ACTIVE;2.07;2.27 +32453-3;Physical findings;Find;Pt;Mouth;Nom;Observed;H&P.PX;2;Physical findings of Mouth;Phys find Mouth;;ACTIVE;2.07;2.27 +32454-1;Physical findings;Find;Pt;Mucous membrane;Nom;Observed;H&P.PX;2;Physical findings of Mucous membrane;Phys find Mucous membrane;;ACTIVE;2.07;2.27 +32455-8;Physical findings;Find;Pt;Muscle tone;Nom;Observed;H&P.PX;2;Physical findings of Muscle tone;Phys find Muscle tone;;ACTIVE;2.07;2.27 +32456-6;Physical findings;Find;Pt;Nail;Nom;Observed;H&P.PX;2;Physical findings of Nail;Phys find Nail;;ACTIVE;2.07;2.27 +32457-4;Physical findings;Find;Pt;Nasal septum;Nom;Observed;H&P.PX;2;Physical findings of Nasal septum;Phys find Nasal septum;;ACTIVE;2.07;2.27 +3245-8;Coagulum retraction;Time;Pt;Bld;Qn;Coag;COAG;1;Clot Retraction [Time] in Blood by Coagulation assay;Clot Retract Bld;;ACTIVE;1.0;2.64 +32458-2;Physical findings;Find;Pt;Nostril;Nom;Observed;H&P.PX;2;Physical findings of Nostril;Phys find Nostril;;ACTIVE;2.07;2.27 +32459-0;Physical findings;Find;Pt;Optic lens;Nom;Observed;H&P.PX;2;Physical findings of Optic lens;Phys find Optic lens;;ACTIVE;2.07;2.27 +32460-8;Physical findings;Find;Pt;Palate;Nom;Observed;H&P.PX;2;Physical findings of Palate;Phys find Palate;;ACTIVE;2.07;2.27 +32461-6;Physical findings;Find;Pt;Parametrium;Nom;Observed;H&P.PX;2;Physical findings of Parametrium;Phys find Parametrium;;ACTIVE;2.07;2.27 +32462-4;Physical findings;Find;Pt;Paravertebral muscles;Nom;Observed;H&P.PX;2;Physical findings of Paraverteberal muscles;Phys find Paravertebral muscles;;ACTIVE;2.07;2.27 +32463-2;Physical findings;Find;Pt;Pharynx;Nom;Observed;H&P.PX;2;Physical findings of Pharynx;Phys find Pharynx;;ACTIVE;2.07;2.27 +32464-0;Physical findings;Find;Pt;Pigmentation;Nom;Observed;H&P.PX;2;Physical findings of Pigmentation;Phys find Pigmentation;;ACTIVE;2.07;2.27 +32465-7;Physical findings;Find;Pt;Prostate;Nom;Observed;H&P.PX;2;Physical findings of Prostate;Phys find Prostate;;ACTIVE;2.07;2.27 +3246-6;Fibrin D-dimer;ACnc;Pt;PPP;Qn;IA;COAG;1;Deprecated Fibrin D-dimer [Units/volume] in Platelet poor plasma by Immunoassay;Deprecated D Dimer PPP IA-aCnc;;DEPRECATED;1.0;2.70 +32466-5;Physical findings;Find;Pt;Pupil;Nom;Observed;H&P.PX;2;Physical findings of Pupil;Phys find Pupil;;ACTIVE;2.07;2.27 +32467-3;Physical findings;Find;Pt;Rash;Nom;Observed;H&P.PX;2;Physical findings of Rash;Phys find Rash;;ACTIVE;2.07;2.27 +32468-1;Physical findings;Find;Pt;Retina;Nom;Observed;H&P.PX;2;Physical findings of Retina;Phys find Retina;;ACTIVE;2.07;2.27 +32469-9;Physical findings;Find;Pt;Scalp;Nom;Observed;H&P.PX;2;Physical findings of Scalp;Phys find Scalp;;ACTIVE;2.07;2.27 +32470-7;Physical findings;Find;Pt;Skin.scar;Nom;Observed;H&P.PX;2;Physical findings of Skin scar;Phys find Skin.scar;;ACTIVE;2.07;2.27 +32471-5;Physical findings;Find;Pt;Sclera;Nom;Observed;H&P.PX;2;Physical findings of Sclera;Phys find Sclera;;ACTIVE;2.07;2.27 +32472-3;Symptoms & diseases;Hx;Pt;Seizure activity;Nom;;H&P.HX;2;History of Seizure activity disorders;Hx of Seizure activity disorders;;ACTIVE;2.07;2.56 +32473-1;Physical findings.sensation;Find;Pt;Neurologic system;Nom;Reported;H&P.PX;2;Physical findings sensation;Phys find sensation;;ACTIVE;2.07;2.63 +3247-4;Fibrin D-dimer;MCnc;Pt;PPP;Ord;LA;COAG;1;Deprecated Fibrin D-dimer by agglutination;Deprecated D Dimer PPP Ql LA;;DEPRECATED;1.0;2.40 +32474-9;Physical findings.shoulder shrug;Find;Pt;Shoulder.bilateral;Nom;Observed;H&P.PX;2;Physical findings shoulder shrug;Phys find shoulder shrug;;ACTIVE;2.07;2.27 +32475-6;Physical findings.skin pressure injury;Find;Pt;Skin;Nom;;H&P.PX;2;Physical findings skin pressure injury;Phys find skin ulcer;;ACTIVE;2.07;2.73 +32476-4;Physical findings;Find;Pt;Spine;Nom;Observed;H&P.PX;2;Physical findings of Spine;Phys find Spine;;ACTIVE;2.07;2.27 +32477-2;Physical findings;Find;Pt;Spleen;Nom;;H&P.PX;2;Physical findings of Spleen;Phys find Spleen;;ACTIVE;2.07;2.27 +32478-0;Physical findings;Find;Pt;Teeth and gum;Nom;Observed;H&P.PX;2;Physical findings of Teeth and gum;Phys find Teeth+gum;;ACTIVE;2.07;2.27 +32479-8;Physical findings;Find;Pt;Thyroid;Nom;Observed;H&P.PX;2;Physical findings of Thyroid;Phys find Thyroid;;ACTIVE;2.07;2.27 +32480-6;Physical findings;Find;Pt;Toes;Nom;Observed;H&P.PX;2;Physical findings of Toes;Phys find Toes;;ACTIVE;2.07;2.27 +32481-4;Physical findings;Find;Pt;Toenail;Nom;Observed;H&P.PX;2;Physical findings of Toenail;Phys find Toenail;;ACTIVE;2.07;2.27 +3248-2;Fibrin fragments Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrin fragments Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fibrin Frg Ag PPP IA-aCnc;;ACTIVE;1.0;2.69 +32482-2;Physical findings;Find;Pt;Tonsil;Nom;Observed;H&P.PX;2;Physical findings of Tonsil;Phys find Tonsil;;ACTIVE;2.07;2.27 +32483-0;Physical findings;Find;Pt;Tongue;Nom;Observed;H&P.PX;2;Physical findings of Tongue;Phys find Tongue;;ACTIVE;2.07;2.27 +32484-8;Physical findings;Find;Pt;Tympanic membrane;Nom;Observed;H&P.PX;2;Physical findings of Tympanic membrane;Phys find Tympanic Memb;;ACTIVE;2.07;2.27 +32485-5;Physical findings;Find;Pt;Urinary tract;Nom;;H&P.PX;2;Physical findings of Urinary tract;Phys find Urinary;;ACTIVE;2.07;2.27 +32486-3;Physical findings;Find;Pt;Uterus;Nom;Observed;H&P.PX;2;Physical findings of Uterus;Phys find Uterus;;ACTIVE;2.07;2.27 +32487-1;Physical findings;Find;Pt;Vagina;Nom;Observed;H&P.PX;2;Physical findings of Vagina;Phys find Vagina;;ACTIVE;2.07;2.27 +32488-9;Physical findings;Find;Pt;Vision;Nom;Observed;H&P.PX;2;Physical findings of Vision;Phys find Vision;;ACTIVE;2.07;2.27 +32489-7;Spleen tip distance below costal margin;Len;Pt;Spleen;Qn;;H&P.PX;2;Spleen tip distance below costal margin;Spleen tip distance;;ACTIVE;2.07;2.48 +3249-0;Fibrin fragments;Prid;Pt;PPP;Nom;Immunoelectrophoresis;COAG;1;Fibrin fragments [Identifier] in Platelet poor plasma by Immunoelectrophoresis;Fibrin Frg PPP IEP;;ACTIVE;1.0;2.14 +32490-5;Tocolysis method;Type;Pt;^Patient;Nom;*;IO.TUBE;2;Tocolysis method;Tocolysis method;;ACTIVE;2.07;2.27 +32491-3;Deep tendon reflex;Find;Pt;{Reflex location};Ord;Observed;H&P.PX;2;Deep tendon reflex of {Reflex location};DTR;;ACTIVE;2.07;2.29 +32492-1;Body fluid quality;Type;Pt;Body fld;Nom;;H&P.HX;2;Body fluid quality;Bdy fluid quality;;ACTIVE;2.07;2.73 +32493-9;Cells.CD25/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD25 cells/100 cells in Bone marrow;CD25 Cells NFr Mar;;ACTIVE;2.08;2.70 +32494-7;Cells.CD25/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD25 cells/100 cells in Tissue;CD25 Cells NFr Tiss;;ACTIVE;2.08;2.70 +32495-4;Cells.CD25/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD25 cells/100 cells in Specimen;CD25 Cells NFr Spec;;ACTIVE;2.08;2.73 +32496-2;Cells.CD57/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD57 cells/100 cells in Tissue;CD57 Cells NFr Tiss;;ACTIVE;2.08;2.70 +32497-0;Cells.CD57/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD57 cells/100 cells in Bone marrow;CD57 Cells NFr Mar;;ACTIVE;2.08;2.70 +32498-8;Cells.CD57/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD57 cells/100 cells in Specimen;CD57 Cells NFr Spec;;ACTIVE;2.08;2.73 +32499-6;Cells.CD7-CD13+CD33+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD7-CD13+CD33+ cells/100 cells in Blood;CD7-CD13+CD33+ Cells NFr Bld;;ACTIVE;2.08;2.70 +32500-1;Cells.CD10+CD19+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD10+CD19+ cells/100 cells in Bone marrow;CD10+CD19+ Cells NFr Mar;;ACTIVE;2.08;2.70 +32501-9;Cells.CD10+CD19+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD10+CD19+ cells/100 cells in Tissue;CD10+CD19+ Cells NFr Tiss;;ACTIVE;2.08;2.70 +32502-7;Cells.CD10+CD19+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD10+CD19+ cells/100 cells in Blood;CD10+CD19+ Cells NFr Bld;;ACTIVE;2.08;2.73 +32503-5;Cells.CD13+CD33+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD13+CD33+ cells/100 cells in Blood;CD13+CD33+ Cells NFr Bld;;ACTIVE;2.08;2.70 +32504-3;Cells.CD13+CD33+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD13+CD33+ cells/100 cells in Bone marrow;CD13+CD33+ Cells NFr Mar;;ACTIVE;2.08;2.70 +32505-0;Cells.CD13+CD33+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD13+CD33+ cells/100 cells in Tissue;CD13+CD33+ Cells NFr Tiss;;ACTIVE;2.08;2.70 +32506-8;Cells.CD14/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD14 cells/100 cells in Tissue;CD14 Cells NFr Tiss;;ACTIVE;2.08;2.70 +32507-6;Cells.CD14/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD14 cells/100 cells in Bone marrow;CD14 Cells NFr Mar;;ACTIVE;2.08;2.70 +3250-8;Fibrin monomer;ACnc;Pt;PPP;Qn;LA;COAG;1;Fibrin monomer [Units/volume] in Platelet poor plasma by Latex agglutination;Fibrin Monomer PPP LA-aCnc;;ACTIVE;1.0;2.73 +32508-4;Cells.CD3-CD16+CD56+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells/100 cells in Bone marrow;CD3-CD16+CD56+ Cells NFr Mar;;ACTIVE;2.08;2.70 +32509-2;Cells.CD3-CD16+CD56+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells/100 cells in Tissue;CD3-CD16+CD56+ Cells NFr Tiss;;ACTIVE;2.08;2.70 +325-1;Methicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Methicillin [Susceptibility] by Serum bactericidal titer;Methicillin Titr SBT;;ACTIVE;1.0;2.32 +32510-0;Cells.CD5+CD19+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD5+CD19+ cells/100 cells in Bone marrow;CD5+CD19+ Cells NFr Mar;;ACTIVE;2.08;2.70 +32511-8;Cells.CD5+CD19+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD5+CD19+ cells/100 cells in Tissue;CD5+CD19+ Cells NFr Tiss;;ACTIVE;2.08;2.70 +32512-6;Cells.CD2;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD2 cells [#/volume] in Specimen;CD2 Cells # Spec;;ACTIVE;2.08;2.70 +32513-4;Cells.CD3+CD25+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD3+CD25+ cells [#/volume] in Specimen;CD3+CD25+ Cells # Spec;;ACTIVE;2.08;2.70 +32514-2;Cells.CD3+CD25+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3+CD25+ cells/100 cells in Specimen;CD3+CD25+ Cells NFr Spec;;ACTIVE;2.08;2.70 +32515-9;Cells.CD3+CD4+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells [#/volume] in Specimen;CD3+CD4+ Cells # Spec;;ACTIVE;2.08;2.73 +3251-6;Fibrin+Fibrinogen fragments;ACnc;Pt;PPP;Qn;LA;COAG;1;Fibrin+Fibrinogen fragments [Units/volume] in Platelet poor plasma by Latex agglutination;FSP PPP LA-aCnc;;ACTIVE;1.0;2.73 +32516-7;Cells.CD3+CD4+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 cells in Specimen;CD3+CD4+ Cells NFr Spec;;ACTIVE;2.08;2.73 +32517-5;Cells.CD3+CD8+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells [#/volume] in Specimen;CD3+CD8+ Cells # Spec;;ACTIVE;2.08;2.73 +32518-3;Cells.CD3+CD8+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells/100 cells in Specimen;CD3+CD8+ Cells NFr Spec;;ACTIVE;2.08;2.73 +32519-1;Cells.CD3-CD16+CD56+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells/100 cells in Specimen;CD3-CD16+CD56+ Cells NFr Spec;;ACTIVE;2.08;2.73 +32520-9;Cells.CD7-CD13+CD33+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD7-CD13+CD33+ cells/100 cells in Specimen;CD7-CD13+CD33+ Cells NFr Spec;;ACTIVE;2.08;2.70 +32521-7;Cells.CD10+CD19+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD10+CD19+ cells/100 cells in Specimen;CD10+CD19+ Cells NFr Spec;;ACTIVE;2.08;2.70 +32522-5;Cells.CD13+CD33+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD13+CD33+ cells/100 cells in Specimen;CD13+CD33+ Cells NFr Spec;;ACTIVE;2.08;2.70 +32523-3;Cells.CD5+CD19+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD5+CD19+ cells/100 cells in Specimen;CD5+CD19+ Cells NFr Spec;;ACTIVE;2.08;2.73 +3252-4;Fibrin+Fibrinogen fragments;ACnc;Pt;Ser;Qn;LA;COAG;1;Fibrin+Fibrinogen fragments [Units/volume] in Serum by Latex agglutination;FSP Ser LA-aCnc;;ACTIVE;1.0;2.73 +32524-1;Cells.CD19;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD19 cells [#/volume] in Bone marrow;CD19 Cells # Mar;;ACTIVE;2.08;2.70 +32525-8;Cells.CD19/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19 cells/100 cells in Bone marrow;CD19 Cells NFr Mar;;ACTIVE;2.08;2.70 +32526-6;Cells.CD2;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD2 cells [#/volume] in Bone marrow;CD2 Cells # Mar;;ACTIVE;2.08;2.70 +32527-4;Cells.CD2/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD2 cells/100 cells in Bone marrow;CD2 Cells NFr Mar;;ACTIVE;2.08;2.70 +32528-2;Cells.CD3;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3 cells [#/volume] in Bone marrow;CD3 Cells # Mar;;ACTIVE;2.08;2.70 +32529-0;Cells.CD3/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3 cells/100 cells in Bone marrow;CD3 Cells NFr Mar;;ACTIVE;2.08;2.70 +32530-8;Cells.CD3+CD25+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD25+ cells [#/volume] in Bone marrow;CD3+CD25+ Cells # Mar;;ACTIVE;2.08;2.70 +32531-6;Cells.CD3+CD25+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD25+ cells/100 cells in Bone marrow;CD3+CD25+ Cells NFr Mar;;ACTIVE;2.08;2.70 +3253-2;Fibrin.soluble;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Fibrin.soluble [Units/volume] in Platelet poor plasma by Chromogenic method;Fibrin Sol PPP Chro-aCnc;;ACTIVE;1.0;2.69 +32532-4;Cells.CD3+CD4+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells [#/volume] in Bone marrow;CD3+CD4+ Cells # Mar;;ACTIVE;2.08;2.70 +32533-2;Cells.CD3+CD4+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 cells in Bone marrow;CD3+CD4+ Cells NFr Mar;;ACTIVE;2.08;2.70 +32534-0;Cells.CD3+CD8+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells [#/volume] in Bone marrow;CD3+CD8+ Cells # Mar;;ACTIVE;2.08;2.72 +32535-7;Cells.CD3+CD8+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells/100 cells in Bone marrow;CD3+CD8+ Cells NFr Mar;;ACTIVE;2.08;2.72 +32536-5;Cells.CD3-CD16+CD56+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Bone marrow;CD3-CD16+CD56+ Cells # Mar;;ACTIVE;2.08;2.70 +32537-3;Cells.CD3+CD4+/Cells.CD3+CD8+;NRto;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Bone marrow;CD3+CD4+ Cells/CD3+CD8+ Cells Mar;;ACTIVE;2.08;2.70 +32538-1;17-Hydroxyprogesterone^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;17OHP 2h p chal SerPl-sCnc;;ACTIVE;2.08;2.70 +32539-9;17-Hydroxyprogesterone^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;17OHP 1h p chal SerPl-sCnc;;ACTIVE;2.08;2.70 +3254-0;Fibrin.soluble;ACnc;Pt;Ser;Qn;Coag;COAG;1;Fibrin.soluble [Units/volume] in Serum by Coagulation assay;Fibrin Sol Ser-aCnc;;ACTIVE;1.0;2.69 +32540-7;Glucosylceramidase;CCnt;Pt;WBC;Qn;;CHEM;1;Glucosylceramidase [Enzymatic activity/mass] in Leukocytes;Glucosylceramidase WBC-cCnt;;ACTIVE;2.08;2.73 +32541-5;Calcium;Sub;XXX;Urine;Qn;;CHEM;1;Calcium [Molar amount] in Urine collected for unspecified duration;Calcium ?Tm sub Ur Qn;;ACTIVE;2.08;2.70 +32542-3;Chloride;Sub;XXX;Urine;Qn;;CHEM;1;Chloride [Molar amount] in Urine collected for unspecified duration;Chloride ?Tm sub Ur Qn;;ACTIVE;2.08;2.73 +32543-1;Creatinine;Sub;XXX;Urine;Qn;;CHEM;1;Creatinine [Molar amount] in Urine collected for unspecified duration;Creat ?Tm sub Ur Qn;;ACTIVE;2.08;2.70 +32544-9;Fat intake;SRat;72H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Fat intake 72 hour;Fat intake 72h;;ACTIVE;2.08;2.70 +32545-6;Fat;SRat;72H;Stool;Qn;;CHEM;1;Fat [Moles/time] in 72 hour Stool;Fat 72h Stl-sRate;;ACTIVE;2.08;2.70 +32546-4;Glucose-6-Phosphate dehydrogenase;CCnt;Pt;RBC;Qn;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells;G6PD RBC-cCnt;;ACTIVE;2.08;2.73 +32547-2;Ketones;SCnc;Pt;Ser/Plas;Qn;Test strip;CHEM;1;Ketones [Moles/volume] in Serum or Plasma by Test strip;Ketones SerPl Strip-sCnc;;ACTIVE;2.08;2.70 +32548-0;Nitroprusside reacting substances;PrThr;Pt;Urine;Ord;;CHEM;1;Nitroprusside reacting substances [Presence] in Urine;Nitroprusside Test Ur Ql;;ACTIVE;2.08;2.56 +32549-8;Norepinephrine/Creatinine;SRto;XXX;Urine;Qn;;CHEM;1;Norepinephrine/Creatinine [Molar ratio] in Urine collected for unspecified duration;Norepineph/Creat ?Tm Ur-sRto;;ACTIVE;2.08;2.70 +32550-6;Potassium;Sub;XXX;Urine;Qn;;CHEM;1;Potassium [Molar amount] in Urine collected for unspecified duration;Potassium ?Tm sub Ur Qn;;ACTIVE;2.08;2.70 +32551-4;Protein;Mass;XXX;Urine;Qn;;UA;1;Protein [Mass] in Urine collected for unspecified duration;Prot ?Tm Ur Qn;;ACTIVE;2.08;2.73 +32552-2;Pyruvate kinase;CCnt;Pt;RBC;Qn;;CHEM;1;Pyruvate kinase [Enzymatic activity/mass] in Red Blood Cells;PK RBC-cCnt;;ACTIVE;2.08;2.73 +32553-0;Sodium;Sub;XXX;Urine;Qn;;CHEM;1;Sodium [Molar amount] in Urine collected for unspecified duration;Sodium ?Tm sub Ur Qn;;ACTIVE;2.08;2.70 +32554-8;Thiamine;SCnc;Pt;Bld;Qn;;CHEM;1;Thiamine [Moles/volume] in Blood;Vit B1 Bld-sCnc;;ACTIVE;2.08;2.73 +32555-5;Urate;Sub;XXX;Urine;Qn;;CHEM;1;Urate [Molar amount] in Urine collected for unspecified duration;Urate ?Tm sub Ur Qn;;ACTIVE;2.08;2.70 +32556-3;Urea;Sub;XXX;Urine;Qn;;CHEM;1;Urea [Molar amount] in Urine collected for unspecified duration;Urea ?Tm sub Ur Qn;;ACTIVE;2.08;2.70 +3255-7;Fibrinogen;MCnc;Pt;PPP;Qn;Coag;COAG;1;Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay;Fibrinogen PPP-mCnc;;ACTIVE;1.0;2.73 +32557-1;Candida albicans reaction wheal^1D post 50 ug Candida albicans ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Candida albicans reaction wheal [Diameter] --1 day post 50 ug Candida albicans intradermal;Wheal 1D p 50ug C albicans Diam;;ACTIVE;2.08;2.73 +32558-9;Mumps reaction wheal^1D post 0.1 mL mumps ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Mumps reaction wheal [Diameter] --1 day post 0.1 mL mumps intradermal;Wheal 1D p .1 mL Mumps Diam;;ACTIVE;2.08;2.42 +32559-7;Tau protein;MCnc;Pt;Ser;Qn;;CHEM;1;Tau protein [Mass/volume] in Serum;Tau Prot Ser-mCnc;;ACTIVE;2.08;2.42 +32560-5;Trichophyton reaction wheal^2D post 50 ug trichophyton ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Trichophyton reaction wheal [Diameter] --2 days post 50 ug trichophyton intradermal;Wheal 2D p 50ug Trichophyt Diam;;ACTIVE;2.08;2.42 +32561-3;Tuberculosis reaction wheal^1D post dose mammalian tuberculin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tuberculosis reaction wheal [Diameter] --1 day post dose mammalian tuberculin intradermal;TB Wheal 1D p Mam Tuberc Diam;;ACTIVE;2.08;2.42 +32562-1;Lymphocytes.IgG/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;IgG lymphocytes/100 lymphocytes in Specimen;Lymphs IgG/lymph NFr Spec;;ACTIVE;2.08;2.73 +32563-9;Lymphocytes.IgG/100 lymphocytes;NFr;Pt;CSF;Qn;;CELLMARK;1;IgG lymphocytes/100 lymphocytes in Cerebral spinal fluid;Lymphs IgG/lymph NFr CSF;;ACTIVE;2.08;2.70 +32564-7;Cells.CD3+CD7+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD7+ cells/100 cells in Blood;CD3+CD7+ Cells NFr Bld;;ACTIVE;2.08;2.34 +3256-5;Fibrinogen Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrinogen Ag [Mass/volume] in Platelet poor plasma by Immunoassay;Fibrinogen Ag PPP IA-mCnc;;ACTIVE;1.0;2.73 +32565-4;SCA3 gene.CAG repeats;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRINUC;1;Deprecated MJD gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;Deprecated SCA3 gene.CAG Rpt Bld/T Ql;;DEPRECATED;2.08;2.36 +32566-2;Coxiella burnetii Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxiella burnetii Ab [Titer] in Cerebral spinal fluid;C burnet Ab Titr CSF;;ACTIVE;2.08;2.30 +32567-0;Candida albicans reaction wheal^2D post 50 ug Candida albicans ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Candida albicans reaction wheal [Diameter] --2 days post 50 ug Candida albicans intradermal;Wheal 2D p 50ug C albicans Diam;;ACTIVE;2.08;2.42 +32568-8;Trichophyton reaction wheal^1D post 50 ug trichophyton ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Trichophyton reaction wheal [Diameter] --1 day post 50 ug trichophyton intradermal;Wheal 1D p 50ug Trichophyt Diam;;ACTIVE;2.08;2.42 +32569-6;Corynebacterium diphtheriae Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae Ab [Units/volume] in Serum --1st specimen;C diphtheriae Ab sp1 Ser-aCnc;;ACTIVE;2.08;2.70 +32570-4;Tetrahydroaldosterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Tetrahydroaldosterone/Creatinine [Mass Ratio] in 24 hour Urine;THaldost/Creat 24h Ur;;ACTIVE;2.08;2.73 +32571-2;HIV 1 Ab;PrThr;Pt;Urine;Ord;IB;MICRO;1;HIV 1 Ab [Presence] in Urine by Immunoblot;HIV1 Ab Ur Ql IB;;ACTIVE;2.08;2.73 +32572-0;Tilapia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tilapia IgE Ab [Units/volume] in Serum;Tilapia IgE Qn;;ACTIVE;2.08;2.73 +3257-3;Fibrinogen;MCnc;Pt;PPP;Ord;Turbidimetry;COAG;1;Deprecated Fibrinogen;Deprecated Fibrinogen PPP Ql;;DEPRECATED;1.0;2.36 +32573-8;Tilapia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Tilapia IgE Ab RAST class [Presence] in Serum;Tilapia IgE RAST Ql;;ACTIVE;2.08;2.73 +32574-6;Zaleplon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zaleplon [Mass/volume] in Serum or Plasma;Zaleplon SerPl-mCnc;;ACTIVE;2.08;2.70 +32575-3;Bartonella henselae Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella henselae IgG Ab [Presence] in Serum;B henselae IgG Ser Ql;;ACTIVE;2.08;2.73 +32576-1;Bartonella henselae Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella henselae IgM Ab [Presence] in Serum;B henselae IgM Ser Ql;;ACTIVE;2.08;2.73 +32577-9;Bartonella quintana Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella quintana IgG Ab [Presence] in Serum;B quintana IgG Ser Ql;;ACTIVE;2.08;2.73 +32578-7;Bartonella quintana Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella quintana IgM Ab [Presence] in Serum;B quintana IgM Ser Ql;;ACTIVE;2.08;2.73 +32579-5;Phentermine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phentermine [Mass/volume] in Serum or Plasma;Phentermine SerPl-mCnc;;ACTIVE;2.08;2.73 +32580-3;Chromatin Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Chromatin IgG Ab [Units/volume] in Serum or Plasma;Chromatin IgG SerPl-aCnc;;ACTIVE;2.08;2.73 +3258-1;Fibrinogen Ag;MCnc;Pt;PPP;Qn;Imm;COAG;1;Deprecated Fibrinogen Ag [Mass/volume] in Platelet poor plasma by Immunologic method;Deprecated Fibrinogen Ag PPP Imm-mCnc;;DEPRECATED;1.0;2.36 +32581-1;Epidermal growth factor receptor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Epidermal growth factor receptor Ag [Presence] in Tissue by Immune stain;EGFR Ag Tiss Ql ImStn;;ACTIVE;2.08;2.73 +32582-9;Phenylpropionylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;Phenylpropionylglycine [Presence] in Urine;PPG Ur Ql;;ACTIVE;2.08;2.73 +32583-7;Phenyllactate;PrThr;Pt;Urine;Ord;;CHEM;1;Phenyllactate [Presence] in Urine;Phenyllactate Ur Ql;;ACTIVE;2.08;2.73 +32584-5;Propionylglycine;PrThr;Pt;Urine;Ord;;CHEM;1;Propionylglycine [Presence] in Urine;Propionylgly Ur Ql;;ACTIVE;2.08;2.73 +32585-2;Epstein Barr virus DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Specimen by NAA with probe detection;EBV DNA # Spec NAA+probe;;ACTIVE;2.08;2.73 +32586-0;Follitropin^20M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --20 minutes post XXX challenge;FSH 20M p chal SerPl-aCnc;;ACTIVE;2.08;2.70 +32587-8;Androstenedione^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Androst 2h p chal SerPl-sCnc;;ACTIVE;2.08;2.70 +32588-6;Androstenedione^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Androst 1h p chal SerPl-sCnc;;ACTIVE;2.08;2.70 +32589-4;Gabapentin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Gabapentin [Mass] of Dose;Gabapentin Dose;;ACTIVE;2.08;2.70 +32590-2;Granulocytes units available;Num;Pt;^BPU;Qn;;BLDBK;1;Granulocytes units available [#];Granulocytes Avail BPU;;ACTIVE;2.08;2.70 +32591-0;Heavy metals;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Heavy metals [Presence] in 24 hour Urine;Heavy Metals 24h Ur Ql;;ACTIVE;2.08;2.56 +32592-8;Cryoprecipitate poor plasma units available;Num;Pt;^BPU;Qn;;BLDBK;1;Cryoprecipitate poor plasma units available [#];CP Avail BPU;;ACTIVE;2.08;2.70 +32593-6;Eosinophils/100 leukocytes;NFr;Pt;XXX;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Specimen;Eosinophil/leuk NFr Spec;;ACTIVE;2.08;2.73 +32594-4;Tacrolimus;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tacrolimus [Mass] of Dose;Tacrolimus Dose;;ACTIVE;2.08;2.73 +32595-1;Topiramate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Topiramate [Mass] of Dose;Topiramate Dose;;ACTIVE;2.08;2.73 +32596-9;Trifluoperazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Trifluoperazine [Mass] of Dose;TriFperazine Dose;;ACTIVE;2.08;2.70 +32597-7;Natamycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Natamycin [Susceptibility];Natamycin Susc Islt;;ACTIVE;2.08;2.19 +32598-5;Sertraline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Sertraline [Mass] of Dose;Sertraline Dose;;ACTIVE;2.08;2.70 +3259-9;Fibrinogen fragments Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Fibrinogen fragments Ag [Units/volume] in Platelet poor plasma by Immunoassay;Fibrinogen Frg Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32599-3;Lutropin^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;LH 30M p chal SerPl-mCnc;;DISCOURAGED;2.08;2.70 +32600-9;Felbamate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Felbamate [Mass] of Dose;Felbamate Dose;;ACTIVE;2.08;2.70 +32601-7;Cells.CD59/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD59 cells/100 cells in Specimen;CD59 Cells NFr Spec;;ACTIVE;2.08;2.70 +32602-5;HIV 1+2 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;HIV 1+2 Ab [Presence] in Cerebral spinal fluid;HIV1+2 Ab CSF Ql;;ACTIVE;2.08;2.56 +32603-3;Itraconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Itraconazole [Susceptibility];Itraconaz Susc Islt;;ACTIVE;2.08;2.73 +32604-1;Leptospira sp Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira sp Ab [Titer] in Serum --1st specimen;Leptospira Ab sp1 Titr Ser;;ACTIVE;2.08;2.70 +32605-8;Leptospira sp Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira sp Ab [Titer] in Serum --2nd specimen;Leptospira Ab sp2 Titr Ser;;ACTIVE;2.08;2.70 +32606-6;Lutropin^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;LH 1h p chal SerPl-mCnc;;DISCOURAGED;2.08;2.70 +3260-7;Fibrinopeptide B beta (1-14) Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (1-14) Ag [Mass/volume] in Platelet poor plasma by Immunoassay;FpB Beta1-14 Ag PPP IA-mCnc;;ACTIVE;1.0;2.58 +32607-4;Clorazepate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Clorazepate [Mass] of Dose;Deprecated Clorazepate Dose;;DEPRECATED;2.08;2.69 +32608-2;cloZAPine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cloZAPine [Mass] of Dose;cloZAPine Dose;;ACTIVE;2.08;2.69 +32609-0;Amino acids;SCnc;Pt;Body fld;Qn;;CHEM;1;Amino acids [Moles/volume] in Body fluid;Amino acids Fld-sCnc;;ACTIVE;2.09;2.70 +32610-8;Amino acids;SCnc;Pt;CSF;Qn;;CHEM;1;Amino acids [Moles/volume] in Cerebral spinal fluid;Amino acids CSF-sCnc;;ACTIVE;2.09;2.70 +32611-6;Amino acids;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Amino acids [Moles/volume] in Amniotic fluid;Amino acids Amn-sCnc;;ACTIVE;2.09;2.70 +32612-4;Amino acids;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Amino acids [Moles/volume] in Vitreous fluid;Amino acids Vitf-sCnc;;ACTIVE;2.09;2.70 +32613-2;Carnitine.free (C0)/Carnitine.total;SFr;Pt;Urine;Qn;;CHEM;1;Carnitine free (C0)/Carnitine.total in Urine;Carnitine Free SFr Ur;;ACTIVE;2.09;2.70 +32614-0;Glutamate;SCnc;Pt;Body fld;Qn;;CHEM;1;Glutamate [Moles/volume] in Body fluid;Glutamate Fld-sCnc;;ACTIVE;2.09;2.73 +3261-5;Fibrinopeptide B beta (1-42) Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (1-42) Ag [Mass/volume] in Platelet poor plasma by Immunoassay;FpB Beta1-42 Ag PPP IA-mCnc;;ACTIVE;1.0;2.58 +32615-7;Homocysteine cysteine disulfide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocysteine cysteine disulfide [Moles/volume] in Serum or Plasma;Hycs-Cys diS SerPl-sCnc;;ACTIVE;2.09;2.73 +32616-5;Homocysteine cysteine disulfide/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Homocysteine cysteine disulfide/Creatinine [Ratio] in Urine;Hycs-Cys diS/Creat Ur-Rto;;ACTIVE;2.09;2.73 +32617-3;Ornithine carbamoyltransferase;CCnt;Pt;Tiss;Qn;;CHEM;1;Ornithine carbamoyltransferase [Enzymatic activity/mass] in Tissue;OCT Tiss-cCnt;;ACTIVE;2.09;2.70 +32618-1;3-Methoxytyramine;MRat;24H;Urine;Qn;;CHEM;1;3-Methoxytyramine [Mass/time] in 24 hour Urine;3Me-tyramine 24h Ur-mRate;;ACTIVE;2.09;2.70 +32619-9;Biotinidase;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Biotinidase [Presence] in Serum or Plasma;Biotinidase SerPl Ql;;ACTIVE;2.09;2.56 +32620-7;Corynebacterium diphtheriae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Corynebacterium diphtheriae Ab [Presence] in Serum;C diphtheriae Ab Ser Ql;;ACTIVE;2.09;2.73 +32621-5;HLA-DR;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR [Presence];HLA-DR Ql;;ACTIVE;2.09;2.56 +32622-3;Hyaluronidase Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hyaluronidase Ab [Presence] in Serum;Hyaluronidase Ab Ser Ql;;ACTIVE;2.09;2.56 +3262-3;Fibrinopeptide B beta (15-42) Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (15-42) Ag [Mass/volume] in Platelet poor plasma by Immunoassay;FpB Beta15-42 Ag PPP IA-mCnc;;ACTIVE;1.0;2.58 +32623-1;Platelet mean volume;EntVol;Pt;Bld;Qn;Automated count;HEM/BC;1;Platelet mean volume [Entitic volume] in Blood by Automated count;PMV Bld Auto;;ACTIVE;2.09;2.73 +32624-9;Race;Type;Pt;^Patient;Nom;;CLIN;2;Race;Race;;ACTIVE;2.09;2.73 +32625-6;Spermatozoa Ab.IgA;PrThr;Pt;Ser;Ord;;FERT;1;Spermatozoa IgA Ab [Presence] in Serum;Sperm IgA Ser Ql;;ACTIVE;2.09;2.73 +32626-4;Spermatozoa Ab.IgG;PrThr;Pt;Ser;Ord;;FERT;1;Spermatozoa IgG Ab [Presence] in Serum;Sperm IgG Ser Ql;;ACTIVE;2.09;2.73 +32627-2;Argininosuccinate lyase;CCnt;Pt;RBC;Qn;;CHEM;1;Argininosuccinate lyase [Enzymatic activity/mass] in Red Blood Cells;ASA Lyase RBC-cCnt;;ACTIVE;2.09;2.70 +32628-0;ACADM gene.c.985A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ACADM gene c.985A>G [Presence] in Blood or Tissue by Molecular genetics method;ACADM c.985A>G Bld/T Ql;;ACTIVE;2.09;2.73 +32629-8;Protein.monoclonal/Protein.total;MFr;Pt;XXX;Qn;Immunofixation;CHEM;1;Protein.monoclonal/Protein.total in Specimen by Immunofixation;M Protein MFr Spec IFE;;ACTIVE;2.09;2.70 +32630-6;MSH2 gene+MLH1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MSH2 gene+MLH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MSH2+MLH1 gene Mut Anl Bld/T;;ACTIVE;2.09;2.73 +3263-1;Fibrinopeptide B beta (43-47) Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B beta (43-47) Ag [Mass/volume] in Platelet poor plasma by Immunoassay;FpB Beta43-47 Ag PPP IA-mCnc;;ACTIVE;1.0;2.58 +32631-4;Nitroblue tetrazolium test;PrThr;Pt;Bld;Ord;;HEM/BC;1;Nitroblue Tetrazolium Test (NBT) [Presence] in Blood;NBT Bld Ql;;ACTIVE;2.09;2.56 +32632-2;HEXA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HEXA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HEXA gene Mut Anl Bld/T;;ACTIVE;2.09;2.73 +32633-0;Susceptibility organism^^^4;Prid;Pt;XXX;Nom;;ABXBACT;1;Deprecated Susceptibility organism^^^4;Deprecated Sus XXX org #4;;DEPRECATED;2.09;2.69 +32634-8;Metanephrine.free;MRat;24H;Urine;Qn;;CHEM;1;Metanephrine Free [Mass/time] in 24 hour Urine;Metaneph Free 24h Ur-mRate;;ACTIVE;2.09;2.42 +32635-5;Coagulation factor II inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor II inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;Fact II Inhib PPP-aCnc;;ACTIVE;2.09;2.73 +32636-3;Islet cell 512 Ab;Titr;Pt;Ser;Qn;;SERO;1;Islet cell 512 Ab [Titer] in Serum;Islet Cell512 Ab Titr Ser;;ACTIVE;2.09;2.73 +32637-1;Urease;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue;Urease Tiss Ql;;ACTIVE;2.09;2.73 +32638-9;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;Saline;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by Saline method;Bld gp Ab Scn SerPl Ql Saline;;ACTIVE;2.09;2.56 +32639-7;FANCC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FANCC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FANCC gene Mut Anl Bld/T;;ACTIVE;2.09;2.73 +32640-5;BLM gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BLM gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BLM gene Mut Anl Bld/T;;ACTIVE;2.09;2.73 +32641-3;SMPD1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SMPD1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SMPD1 gene Mut Anl Bld/T;;ACTIVE;2.09;2.73 +32642-1;Dextroamphetamine/Levoamphetamine;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dextroamphetamine/Levoamphetamine [Mass Ratio] in Serum or Plasma;D-amphet/L-amphet SerPl;;ACTIVE;2.09;2.73 +32643-9;Dextromethamphetamine/Levomethamphetamine;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dextromethamphetamine/Levomethamphetamine [Mass Ratio] in Serum or Plasma;D-methamphet/L-methamphet SerPl;;ACTIVE;2.09;2.73 +32644-7;Coxiella burnetii phase 1 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Presence] in Serum;C burnet Ph1 IgG Ser Ql;;ACTIVE;2.09;2.73 +32645-4;Coxiella burnetii phase 1 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Presence] in Serum;C burnet Ph1 IgM Ser Ql;;ACTIVE;2.09;2.73 +32646-2;Nevirapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nevirapine [Mass/volume] in Serum or Plasma;Nevirapine SerPl-mCnc;;ACTIVE;2.09;2.73 +32647-0;Nelfinavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nelfinavir [Mass/volume] in Serum or Plasma;Nelfinavir SerPl-mCnc;;ACTIVE;2.09;2.70 +32648-8;Hydroxyethylflurazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Serum or Plasma;OH-Ethylfluraz SerPl-mCnc;;ACTIVE;2.09;2.73 +3264-9;Fibrinopeptide A Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide A Ag [Mass/volume] in Platelet poor plasma by Immunoassay;FpA Ag PPP IA-mCnc;;ACTIVE;1.0;2.58 +32649-6;Hydroxytriazolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Serum or Plasma;OH-Triazolam SerPl-mCnc;;ACTIVE;2.09;2.73 +32650-4;Norflunitrazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norflunitrazepam [Mass/volume] in Serum or Plasma;Norflunitrazepam SerPl-mCnc;;ACTIVE;2.09;2.73 +32651-2;Ethion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethion [Mass/volume] in Serum or Plasma;Ethion SerPl-mCnc;;ACTIVE;2.09;2.73 +32652-0;Fenthion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fenthion [Mass/volume] in Serum or Plasma;Fenthion SerPl-mCnc;;ACTIVE;2.09;2.73 +32653-8;DYS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DYS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;DYS gene Mut Anl Bld/T;;ACTIVE;2.09;2.73 +32654-6;6-Methylmercaptopurine;EntSub;Pt;RBC;Qn;;DRUG/TOX;1;6-Methylmercaptopurine [Entitic substance] in Red Blood Cells;6MMP EntSub RBC;;ACTIVE;2.09;2.73 +32655-3;Metanephrines/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Metanephrines/Creatinine [Mass Ratio] in 24 hour Urine;MetanephS/Creat 24h Ur;;ACTIVE;2.09;2.73 +3265-6;Fibrinopeptide B Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrinopeptide B Ag [Mass/volume] in Platelet poor plasma by Immunoassay;FpB Ag PPP IA-mCnc;;ACTIVE;1.0;2.58 +32656-1;Aflatoxin Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Aflatoxin IgG Ab [Units/volume] in Serum or Plasma;Aflatoxin IgG SerPl-aCnc;;ACTIVE;2.09;2.73 +32657-9;Aflatoxin Ab.IgA;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Aflatoxin IgA Ab [Units/volume] in Serum or Plasma;Aflatoxin IgA SerPl-aCnc;;ACTIVE;2.09;2.73 +32658-7;Aflatoxin Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Aflatoxin IgM Ab [Units/volume] in Serum or Plasma;Aflatoxin IgM SerPl-aCnc;;ACTIVE;2.09;2.73 +32659-5;Aflatoxin Ab.IgE;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Aflatoxin IgE Ab [Units/volume] in Serum or Plasma;Aflatoxin IgE SerPl-aCnc;;ACTIVE;2.09;2.73 +32660-3;6-Thioguanine;EntSub;Pt;RBC;Qn;;DRUG/TOX;1;6-Thioguanine [Entitic substance] in Red Blood Cells;6-TGN EntSub RBC;;ACTIVE;2.09;2.73 +32661-1;Adrenal Ab;Titr;Pt;Ser;Qn;;SERO;1;Adrenal Ab [Titer] in Serum;Adrenal Ab Titr Ser;;ACTIVE;2.09;2.73 +32662-9;Afipia felis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Afipia felis IgG Ab [Presence] in Serum;A felis IgG Ser Ql;;ACTIVE;2.09;2.56 +32663-7;Afipia felis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Afipia felis IgM Ab [Presence] in Serum;A felis IgM Ser Ql;;ACTIVE;2.09;2.56 +3266-4;Heparin Ab;Threshold;Pt;PPP;Qn;Platelet aggr;COAG;1;Deprecated Heparin Ab [Threshold] in Platelet poor plasma by Platelet aggregation;Deprecated Heparin Ab PPP Qn Pl Agg;;DEPRECATED;1.0;2.65 +32664-5;Ammonia;MCnc;Pt;Bld;Qn;;CHEM;1;Ammonia [Mass/volume] in Blood;Ammonia Bld-mCnc;;ACTIVE;2.09;2.73 +32665-2;Anticonvulsants;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Anticonvulsants [Identifier] in Serum or Plasma;Anticonvulsants SerPl;;ACTIVE;2.09;2.15 +32666-0;Borrelia burgdorferi 25kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 25kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor25kD IgM Ser Ql IB;;ACTIVE;2.09;2.58 +32667-8;Borrelia burgdorferi DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Blood by NAA with probe detection;B burgdor DNA Bld Ql NAA+probe;;ACTIVE;2.09;2.73 +32668-6;Borrelia burgdorferi DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;B burgdor DNA CSF Ql NAA+probe;;ACTIVE;2.09;2.73 +32669-4;Borrelia burgdorferi DNA;PrThr;Pt;Synv fld;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Synovial fluid by NAA with probe detection;B burgdor DNA Snv Ql NAA+probe;;ACTIVE;2.09;2.63 +32670-2;Cells counted.total;Num;Pt;Amnio fld;Qn;;HEM/BC;1;Cells Counted Total [#] in Amniotic fluid;Total Cells Counted Amn;;ACTIVE;2.09;2.69 +32671-0;Chlamydia sp Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Vaginal fluid;Chlamydia Ag Vag Ql;;ACTIVE;2.09;2.56 +3267-2;Heparin Ab;Threshold;Pt;Ser;Qn;Platelet aggr;COAG;1;Deprecated Heparin Ab [Threshold] in Serum by Platelet aggregation;Deprecated Heparin Ab Ser Qn Pl Agg;;DEPRECATED;1.0;2.65 +32672-8;Cold agglutinin;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Cold agglutinin [Presence] in Serum or Plasma;CA SerPl Ql;;ACTIVE;2.09;2.73 +32673-6;Creatine kinase.MB;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.MB [Enzymatic activity/volume] in Serum or Plasma;CK MB SerPl-cCnc;;ACTIVE;2.09;2.73 +32674-4;Cryptococcus sp Ag;Titr;Pt;CSF;Qn;;MICRO;1;Cryptococcus sp Ag [Titer] in Cerebral spinal fluid;Cryptoc Ag Titr CSF;;ACTIVE;2.09;2.73 +32675-1;Cytomegalovirus;PrThr;Pt;Bronchial;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Bronchial specimen by Organism specific culture;CMV Bronch Ql Cult;;ACTIVE;2.09;2.56 +32676-9;Diuretics;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Diuretics [Mass/volume] in Urine;Diuretics Ur-mCnc;;ACTIVE;2.09;2.70 +32677-7;DNA double strand Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;DNA double strand Ab [Units/volume] in Serum by Immunoassay;dsDNA Ab Ser IA-aCnc;;ACTIVE;2.09;2.73 +32678-5;Ehrlichia chaffeensis Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Ehrlichia chaffeensis IgG Ab [Presence] in Cerebral spinal fluid;E chaffeensis IgG CSF Ql;;ACTIVE;2.09;2.56 +32679-3;Ehrlichia chaffeensis Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Ehrlichia chaffeensis IgM Ab [Presence] in Cerebral spinal fluid;E chaffeensis IgM CSF Ql;;ACTIVE;2.09;2.56 +3268-0;Heparin cofactor II Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Heparin cofactor II Ag [Mass/volume] in Platelet poor plasma by Immunoassay;Heparin CF II Ag PPP IA-mCnc;;ACTIVE;1.0;2.73 +32680-1;Granular casts.fine;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Fine Granular Casts [#/area] in Urine sediment by Microscopy low power field;Fine Gran Casts #/area UrnS LPF;;ACTIVE;2.09;2.73 +32681-9;Hemoglobin C/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin C/Hemoglobin.total in Blood by Electrophoresis;Hgb C MFr Bld Elph;;ACTIVE;2.09;2.73 +32682-7;Hemoglobin F/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin F/Hemoglobin.total in Blood by Electrophoresis;Hgb F MFr Bld Elph;;ACTIVE;2.09;2.73 +32683-5;Hemoglobin S/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin S/Hemoglobin.total in Blood by Electrophoresis;Hgb S MFr Bld Elph;;ACTIVE;2.09;2.73 +32684-3;Heparin.low molecular weight;ACnc;Pt;PPP;Qn;;COAG;1;LMW Heparin [Units/volume] in Platelet poor plasma;LMWH PPP-aCnc;;ACTIVE;2.09;2.73 +32685-0;Hepatitis B virus core Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus core IgG Ab [Presence] in Serum;HBV core IgG Ser Ql;;ACTIVE;2.09;2.56 +32686-8;Hepatitis B virus DNA;MCnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus DNA [Mass/volume] in Serum;HBV DNA Ser-mCnc;;ACTIVE;2.09;2.70 +32687-6;Herpes simplex virus 1 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 1 IgM Ab [Presence] in Serum;HSV1 IgM Ser Ql;;ACTIVE;2.09;2.73 +32688-4;Herpes simplex virus 2 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 2 IgM Ab [Presence] in Serum;HSV2 IgM Ser Ql;;ACTIVE;2.09;2.73 +32689-2;Herpes simplex virus identified;Prid;Pt;Eye;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Eye by Organism specific culture;HSV Eye Cult;;ACTIVE;2.09;2.09 +326-9;metroNIDAZOLE;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;metroNIDAZOLE [Susceptibility] by Minimum lethal concentration (MLC);metroNIDAZOLE Islt MLC;;ACTIVE;1.0;2.19 +32690-0;Homocysteine;SRat;24H;Urine;Qn;;CHEM;1;Homocysteine [Moles/time] in 24 hour Urine;Hcys 24h Ur-sRate;;ACTIVE;2.09;2.70 +32691-8;Anaplasma phagocytophilum Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Anaplasma phagocytophilum IgG Ab [Titer] in Serum;A phagocytoph IgG Titr Ser;;ACTIVE;2.09;2.73 +32692-6;Anaplasma phagocytophilum Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Anaplasma phagocytophilum IgM Ab [Titer] in Serum;A phagocytoph IgM Titr Ser;;ACTIVE;2.09;2.73 +32693-4;Lactate;SCnc;Pt;Bld;Qn;;CHEM;1;Lactate [Moles/volume] in Blood;Lactate Bld-sCnc;;ACTIVE;2.09;2.73 +32694-2;Legionella longbeachae 1+2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella longbeachae 1+2 Ab [Titer] in Serum;L longbeachae1+2 Ab Titr Ser;;ACTIVE;2.09;2.70 +32695-9;Legionella pneumophila atypical Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila atypical Ab [Titer] in Serum;L pneumo Atyp Ab Titr Ser;;ACTIVE;2.09;2.70 +32696-7;Legionella pneumophila 1+2+3+4+5+6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1+2+3+4+5+6 Ab [Titer] in Serum;L pneumo pool 1-6 Ab Titr Ser;;ACTIVE;2.09;2.73 +32697-5;Lymphocytes;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Lymphocytes [#/volume] in Synovial fluid by Manual count;Lymphocytes # Snv Manual;;ACTIVE;2.09;2.70 +3269-8;Heparin neutralization;PrThr;Pt;PPP;Ord;;COAG;1;Heparin neutralization [Presence] in Platelet poor plasma;Heparin Nt PPP Ql;;ACTIVE;1.0;2.73 +32698-3;Magnesium.ionized;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Magnesium Ionized [Mass/volume] in Serum or Plasma;Mg Ionized SerPl-mCnc;;ACTIVE;2.09;2.73 +32699-1;Microscopic observation;Prid;Pt;Bld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Blood by Acid fast stain;Acid fast Stn Bld;;ACTIVE;2.09;2.73 +32700-7;Microscopic observation;Prid;Pt;Bld;Nom;Malaria smear;MICRO;1;Microscopic observation [Identifier] in Blood by Malaria smear;Malaria Smear Bld;;ACTIVE;2.09;2.73 +32701-5;Microsporidia identified;Prid;Pt;Stool;Nom;Trichrome modified;MICRO;1;Microsporidia identified in Stool by Trichrome stain modified;Microsporid Stl Mod Tri Stain;;ACTIVE;2.09;2.73 +32702-3;Muscle sarcolemma Ab;PrThr;Pt;Ser;Ord;;SERO;1;Muscle sarcolemma Ab [Presence] in Serum;Mus Sarcolemma Ab Ser Ql;;ACTIVE;2.09;2.56 +32703-1;Cytochrome b5 reductase;CCnt;Pt;RBC;Qn;;CHEM;1;Cytochrome B5 reductase [Enzymatic activity/mass] in Red Blood Cells;CyB5 Reduct RBC-cCnt;;ACTIVE;2.09;2.73 +32704-9;Neisseria gonorrhoeae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Neisseria gonorrhoeae Ab [Presence] in Serum;N gonorrhoea Ab Ser Ql;;DISCOURAGED;2.09;2.56 +32705-6;Neisseria gonorrhoeae DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Vaginal fluid by NAA with probe detection;N gonorrhoea DNA Vag Ql NAA+probe;;ACTIVE;2.09;2.73 +3270-6;Heparin.low molecular weight;ACnc;Pt;PPP;Qn;Coag;COAG;1;LMW Heparin [Units/volume] in Platelet poor plasma by Coagulation assay;LMWH PPP Coag-aCnc;;ACTIVE;1.0;2.73 +32706-4;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Urine;N men sg A+C+W135+Y Ag Ur Ql;;ACTIVE;2.09;2.64 +32707-2;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Urine;N men sg B+E coli K1 Ag Ur Ql;;ACTIVE;2.09;2.64 +32708-0;Neutrophil cytoplasmic Ab.classic;Titr;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic Ab.classic [Titer] in Serum;c-ANCA Titr Ser;;ACTIVE;2.09;2.73 +32709-8;Neutrophils;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Neutrophils [#/volume] in Body fluid;Neutrophils # Fld;;ACTIVE;2.09;2.73 +32710-6;Nitrite;PrThr;Pt;Urine;Ord;;UA;1;Nitrite [Presence] in Urine;Nitrite Ur Ql;;ACTIVE;2.09;2.73 +32711-4;Platelet mean volume;EntVol;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Platelet mean volume [Entitic volume] in Blood by Automated count;Deprecated PMV Bld Qn Auto;;DEPRECATED;2.09;2.70 +32712-2;Platelets.giant/100 leukocytes;Ratio;Pt;Bld;Qn;Manual count;HEM/BC;1;Giant platelets/100 leukocytes [Ratio] in Blood by Manual count;Giant Platelets/leuk Bld Manual-Rto;;ACTIVE;2.09;2.73 +32713-0;Potassium;SCnc;Pt;BldA;Qn;;CHEM;1;Potassium [Moles/volume] in Arterial blood;Potassium BldA-sCnc;;ACTIVE;2.09;2.73 +3271-4;Heparin.low molecular weight;ACnc;Pt;PPP;Qn;Chromo;COAG;1;LMW Heparin [Units/volume] in Platelet poor plasma by Chromogenic method;LMWH PPP Chro-aCnc;;ACTIVE;1.0;2.73 +32714-8;Rickettsia typhus group Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia typhus group IgM Ab [Presence] in Serum;Rick Typhus IgM Ser Ql;;ACTIVE;2.09;2.73 +32715-5;SCL-70 extractable nuclear Ab;Titr;Pt;Ser;Qn;Immune diffusion;SERO;1;SCL-70 extractable nuclear Ab [Titer] in Serum by Immune diffusion (ID);ENA Scl70 Ab Titr Ser ID;;ACTIVE;2.09;2.70 +32716-3;Sjogrens syndrome-A extractable nuclear Ab;Titr;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Titer] in Serum;ENA SS-A Ab Titr Ser;;ACTIVE;2.09;2.70 +32717-1;Sodium;SCnc;Pt;BldA;Qn;;CHEM;1;Sodium [Moles/volume] in Arterial blood;Sodium BldA-sCnc;;ACTIVE;2.09;2.73 +32718-9;Spermatozoa Ab.IgA;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa IgA Ab [Presence] in Semen;Sperm IgA Smn Ql;;ACTIVE;2.09;2.56 +32719-7;Spermatozoa Ab.IgG;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa IgG Ab [Presence] in Semen;Sperm IgG Smn Ql;;ACTIVE;2.09;2.56 +32720-5;Spermatozoa Ab.IgM;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa IgM Ab [Presence] in Semen;Sperm IgM Smn Ql;;ACTIVE;2.09;2.56 +32721-3;Tacrolimus;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Serum or Plasma;Tacrolimus SerPl-mCnc;;ACTIVE;2.09;2.73 +3272-2;Heparin.low molecular weight;MRat;24H;Urine;Qn;;COAG;1;LMW Heparin [Mass/time] in 24 hour Urine;LMWH 24h Ur-mRate;;ACTIVE;1.0;2.19 +32722-1;Triacylglycerol lipase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Peritoneal fluid;Lipase Prt-cCnc;;ACTIVE;2.09;2.73 +32723-9;Trichinella sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichinella sp IgG Ab [Units/volume] in Serum by Immunoassay;Trichinella IgG Ser IA-aCnc;;ACTIVE;2.09;2.73 +32724-7;Trichomonas sp;PrThr;Pt;Urine;Ord;Microscopy.light;MICRO;1;Trichomonas sp [Presence] in Urine by Light microscopy;Trichomonas Ur Ql Micro;;ACTIVE;2.09;2.73 +32725-4;Trypanosoma cruzi Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma cruzi IgG Ab [Presence] in Serum;T cruzi IgG Ser Ql;;ACTIVE;2.09;2.73 +32726-2;Trypanosoma cruzi Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Trypanosoma cruzi IgM Ab [Presence] in Serum;T cruzi IgM Ser Ql;;ACTIVE;2.09;2.73 +32727-0;Urobilinogen;ACnc;Pt;Urine;Qn;;CHEM;1;Urobilinogen [Units/volume] in Urine;Urobilinogen Ur-aCnc;;ACTIVE;2.09;2.73 +32728-8;Beta 1 globulin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Beta 1 globulin/Protein.total in Cerebral spinal fluid by Electrophoresis;Beta1 Glob MFr CSF Elph;;ACTIVE;2.09;2.70 +32729-6;Beta 2 globulin/Protein.total;MFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Beta 2 globulin/Protein.total in Cerebral spinal fluid by Electrophoresis;Beta2 Glob MFr CSF Elph;;ACTIVE;2.09;2.70 +3273-0;Heparin.unfractionated;ACnc;Pt;PPP;Qn;Coag;COAG;1;Heparin unfractionated [Units/volume] in Platelet poor plasma by Coagulation assay;UFH PPP clot-aCnc;;ACTIVE;1.0;2.73 +32730-4;Beta 1 globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis;Beta1 Glob SerPl Elph-mCnc;;ACTIVE;2.09;2.73 +32731-2;Beta 2 globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis;Beta2 Glob SerPl Elph-mCnc;;ACTIVE;2.09;2.73 +32732-0;Beta 1 globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta 1 globulin/Protein.total in Serum or Plasma by Electrophoresis;Beta1 Glob MFr SerPl Elph;;ACTIVE;2.09;2.73 +32733-8;Beta 2 globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta 2 globulin/Protein.total in Serum or Plasma by Electrophoresis;Beta2 Glob MFr SerPl Elph;;ACTIVE;2.09;2.73 +32734-6;Beta 1 globulin;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta 1 globulin [Mass/time] in 24 hour Urine by Electrophoresis;Beta1 Glob 24h Ur Elph-mRate;;ACTIVE;2.09;2.73 +32735-3;Beta 2 globulin;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta 2 globulin [Mass/time] in 24 hour Urine by Electrophoresis;Beta2 Glob 24h Ur Elph-mRate;;ACTIVE;2.09;2.73 +32736-1;Beta 1 globulin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta 1 globulin/Protein.total in Urine by Electrophoresis;Beta1 Glob MFr Ur Elph;;ACTIVE;2.09;2.73 +32737-9;Beta 2 globulin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta 2 globulin/Protein.total in Urine by Electrophoresis;Beta2 Glob MFr Ur Elph;;ACTIVE;2.09;2.73 +32738-7;Beta 1 globulin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta 1 globulin [Mass/volume] in Body fluid by Electrophoresis;Beta1 Glob Fld Elph-mCnc;;ACTIVE;2.09;2.73 +32739-5;Beta 2 globulin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta 2 globulin [Mass/volume] in Body fluid by Electrophoresis;Beta2 Glob Fld Elph-mCnc;;ACTIVE;2.09;2.73 +32740-3;Beta 1 globulin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta 1 globulin/Protein.total in Body fluid by Electrophoresis;Beta1 Glob MFr Fld Elph;;ACTIVE;2.09;2.70 +32741-1;Beta 2 globulin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta 2 globulin/Protein.total in Body fluid by Electrophoresis;Beta2 Glob MFr Fld Elph;;ACTIVE;2.09;2.70 +32742-9;Cells.CD117/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD117 cells/100 cells in Specimen;CD117 Cells NFr Spec;;ACTIVE;2.09;2.73 +32743-7;Cells.CD138/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD138 cells/100 cells in Specimen;CD138 Cells NFr Spec;;ACTIVE;2.09;2.73 +32744-5;Cells.CD55/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD55 cells/100 cells in Specimen;CD55 Cells NFr Spec;;ACTIVE;2.09;2.70 +32745-2;Cells.CD62E/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD62E cells/100 cells in Specimen;CD62E Cells NFr Spec;;ACTIVE;2.09;2.70 +32746-0;Cells.CD62P/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD62P cells/100 cells in Specimen;CD62P Cells NFr Spec;;ACTIVE;2.09;2.70 +32747-8;Cells.CD64/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD64 cells/100 cells in Specimen;CD64 Cells NFr Spec;;ACTIVE;2.09;2.73 +3274-8;Heparin.unfractionated;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Heparin unfractionated [Units/volume] in Platelet poor plasma by Chromogenic method;UFH PPP Chro-aCnc;;ACTIVE;1.0;2.73 +32748-6;Cells.CD90/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD90 cells/100 cells in Specimen;CD90 Cells NFr Spec;;ACTIVE;2.09;2.70 +32749-4;Cells.cyclin D1/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Cyclin D1 cells/100 cells in Specimen;Cyclin D1 Cells NFr Spec;;ACTIVE;2.09;2.70 +32750-2;Cells.CD235a/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD235a cells/100 cells in Specimen;CD235a Cells NFr Spec;;ACTIVE;2.09;2.73 +32751-0;Cells.HLA-DR+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;HLA-DR+ cells/100 cells in Specimen;HLA-DR+ Cells NFr Spec;;ACTIVE;2.09;2.73 +32752-8;Cells.CD3/100 cells;NFr;Pt;Bronchial;Qn;;CELLMARK;1;CD3 cells/100 cells in Bronchial specimen;CD3 Cells NFr Bronch;;ACTIVE;2.09;2.73 +32753-6;Cells.CD4/100 cells;NFr;Pt;Bronchial;Qn;;CELLMARK;1;Deprecated CD4 cells/100 cells in Bronchial specimen;Deprecated CD4 Cells NFr Bronch;;DEPRECATED;2.09;2.70 +32754-4;Cells.CD8/100 cells;NFr;Pt;Bronchial;Qn;;CELLMARK;1;Deprecated CD8 cells/100 cells in Bronchial specimen;Deprecated CD8 Cells NFr Bronch;;DEPRECATED;2.09;2.70 +3275-5;Heparin.unfractionated;MRat;24H;Urine;Qn;;COAG;1;Heparin unfractionated [Mass/time] in 24 hour Urine;UFH 24h Ur-mRate;;ACTIVE;1.0;2.19 +32755-1;Cells.CD19/100 cells;NFr;Pt;Bronchial;Qn;;CELLMARK;1;CD19 cells/100 cells in Bronchial specimen;CD19 Cells NFr Bronch;;ACTIVE;2.09;2.73 +32756-9;Cells.CD3+CD4+/Cells.CD3+CD8+;NRto;Pt;Bronchial;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Bronchial specimen;CD3+CD4+ Cells/CD3+CD8+ Cells Bronch;;ACTIVE;2.09;2.73 +32757-7;Cells.BCL2/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;BCL2 cells/100 cells in Specimen;BCL2 Cells NFr Spec;;ACTIVE;2.09;2.73 +32758-5;Cells.CD11b/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11b cells/100 cells in Specimen;CD11b Cells NFr Spec;;ACTIVE;2.09;2.73 +32759-3;Cells.myeloperoxidase/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Myeloperoxidase cells/100 cells in Specimen;Myeloperoxidase Cells NFr Spec;;ACTIVE;2.09;2.73 +32760-1;Cell type;Type;Pt;XXX;Nom;;CELLMARK;1;Cell type in Specimen;Cell type Spec;;ACTIVE;2.09;2.73 +32761-9;Leukocytes;PrThr;Pt;XXX;Ord;Wet preparation;HEM/BC;1;Leukocytes [Presence] in Specimen by Wet preparation;WBC Spec Ql Wet Prep;;ACTIVE;2.09;2.73 +32762-7;Epithelial cells;PrThr;Pt;XXX;Ord;Wet preparation;HEM/BC;1;Epithelial cells [Presence] in Specimen by Wet preparation;Epi Cells Spec Ql Wet Prep;;ACTIVE;2.09;2.73 +3276-3;Kininogen.high molecular weight;ACnc;Pt;PPP;Qn;Coag;COAG;1;Kininogen HMW [Units/volume] in Platelet poor plasma by Coagulation assay;HMWK PPP-aCnc;;ACTIVE;1.0;2.68 +32763-5;Bacteria;PrThr;Pt;XXX;Ord;Wet preparation;MICRO;1;Bacteria [Presence] in Specimen by Wet preparation;Bacteria Spec Ql Wet Prep;;ACTIVE;2.09;2.73 +32764-3;Clue cells;PrThr;Pt;XXX;Ord;Wet preparation;MICRO;1;Clue cells [Presence] in Specimen by Wet preparation;Clue Cells Spec Ql Wet Prep;;ACTIVE;2.09;2.73 +32765-0;Yeast;PrThr;Pt;XXX;Ord;Wet preparation;MICRO;1;Yeast [Presence] in Specimen by Wet preparation;Yeast Spec Ql Wet Prep;;ACTIVE;2.09;2.73 +32766-8;Trichomonas vaginalis;PrThr;Pt;XXX;Ord;Wet preparation;MICRO;1;Trichomonas vaginalis [Presence] in Specimen by Wet preparation;T vaginalis Spec Ql Wet Prep;;ACTIVE;2.09;2.73 +32767-6;Borrelia burgdorferi 25kD Ab.IgM;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 25kD IgM Ab [Presence] in Serum;Deprecated B burgdor25kD IgM Ser Ql;;DEPRECATED;2.09;2.36 +32768-4;Trichinella sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Trichinella sp IgG Ab [Units/volume] in Serum;Trichinella IgG Ser-aCnc;;ACTIVE;2.09;2.69 +32769-2;Alpha 1 antitrypsin phenotype;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Alpha 1 antitrypsin phenotype [Interpretation] in Serum or Plasma;A1AT Phenotyp SerPl-Imp;;ACTIVE;2.09;2.73 +327-7;metroNIDAZOLE;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;metroNIDAZOLE [Susceptibility] by Minimum inhibitory concentration (MIC);metroNIDAZOLE Islt MIC;;ACTIVE;1.0;2.73 +32770-0;Transfusion band number;ID;Pt;^Patient;Nom;;BLDBK;1;Transfusion band number;Transf Band Num Patient;;ACTIVE;2.09;2.73 +3277-1;Kininogen.high molecular weight;MCnc;Pt;PPP;Qn;IA;COAG;1;Kininogen HMW [Mass/volume] in Platelet poor plasma by Immunoassay;HMWK PPP IA-mCnc;;ACTIVE;1.0;2.58 +32771-8;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldA;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Arterial blood;pCO2 temp adj BldA;;ACTIVE;2.09;2.73 +32772-6;Cells.CD14;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD14 cells [Presence] in Blood;CD14 Cells Bld Ql;;ACTIVE;2.09;2.56 +32773-4;Cells.CD24;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD24 cells [Presence] in Blood;CD24 Cells Bld Ql;;ACTIVE;2.09;2.56 +32774-2;Chlamydia sp DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Genital specimen by NAA with probe detection;Chlamydia DNA Genital Ql NAA+probe;;ACTIVE;2.09;2.73 +32775-9;Clostridium tetani toxoid Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani toxoid Ab [Units/volume] in Serum;C tetani Toxoid Ab Ser-aCnc;;ACTIVE;2.09;2.73 +32776-7;Erythrocytes;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Erythrocytes [Presence] in Urine sediment by Light microscopy;RBC UrnS Ql Micro;;ACTIVE;2.09;2.73 +32777-5;Escherichia coli O157:H7 Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Escherichia coli O157:H7 Ag [Presence] in Stool;E coli O157H7 Ag Stl Ql;;ACTIVE;2.09;2.73 +32778-3;Fibrin strands;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Fibrin strands [Presence] in Blood by Light microscopy;Fibrin strands Bld Ql Smear;;ACTIVE;2.09;2.73 +32779-1;Glucose-6-Phosphatase;CCnc;Pt;RBC;Qn;;CHEM;1;Glucose-6-Phosphatase [Enzymatic activity/volume] in Red Blood Cells;G6Pas RBC-cCnc;;ACTIVE;2.09;2.70 +32780-9;Histoplasma sp Ag;ACnc;Pt;Urine;Qn;;MICRO;1;Deprecated Histoplasma capsulatum Ag [Units/volume] in Urine;Deprecated Histoplasma Ag Ur-aCnc;;DEPRECATED;2.09;2.70 +32781-7;Legionella sp Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Legionella sp Ag [Presence] in Urine;Legionella Ag Ur Ql;;ACTIVE;2.09;2.73 +32782-5;Leukocyte esterase+Nitrite;PrThr;Pt;Urine;Ord;Test strip;UA;1;Leukocyte esterase+Nitrite [Presence] in Urine by Test strip;WBC Est+Nitrite Ur Ql Strip;;ACTIVE;2.09;2.73 +32783-3;Leucine+Isoleucine+Valine;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Leucine+Isoleucine+Valine [Identifier] in Serum or Plasma;Leu+Ile+Val SerPl;;ACTIVE;2.09;2.19 +32784-1;Mean peroxidase activity index;PrThr;Pt;Bld;Ord;;HEM/BC;1;Mean peroxidase activity index [Presence] in Blood;MPXI Bld Ql;;ACTIVE;2.09;2.56 +32785-8;Microscopic observation;Prid;Pt;XXX;Nom;Cytology.non-gyn;CYTO;1;Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method;Non-gyn cytology Spec;;ACTIVE;2.09;2.73 +32786-6;Thyroperoxidase Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Thyroperoxidase Ab [Titer] in Serum or Plasma;Thyroperoxidase Ab Titr SerPl;;ACTIVE;2.09;2.73 +32787-4;Neutrophil cytoplasmic Ab.perinuclear;Titr;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum;p-ANCA Titr Ser;;ACTIVE;2.09;2.73 +32788-2;Polymorphonuclear cells/Monocytes;Ratio;Pt;Bld;Qn;;HEM/BC;1;Polymorphonuclear cells/Monocytes [Ratio] in Blood;Polys/Monocytes Bld-Rto;;ACTIVE;2.09;2.73 +3278-9;Kininogen.high molecular weight actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Kininogen HMW actual/normal in Platelet poor plasma by Immunoassay;HMWK Act/Nor PPP IA;;ACTIVE;1.0;2.73 +32789-0;Viscosity;Visc;Pt;Semen;Ord;;SPEC;1;Viscosity of Semen Qualitative;Visc Smn Ql;;ACTIVE;2.09;2.73 +32790-8;Herpes simplex virus 2 Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 2 IgG Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;HSV2 IgG 1:2 Ser IA-Rto;;ACTIVE;2.09;2.56 +32791-6;Cytomegalovirus Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser/Plas;Qn;IA;MICRO;1;Cytomegalovirus IgG Ab [Ratio] in Serum or Plasma by Immunoassay --1st specimen/2nd specimen;CMV IgG 1:2 SerPl IA-Rto;;ACTIVE;2.09;2.64 +32792-4;Parvovirus B19 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;B19V IgG sp2 Ser IA-aCnc;;ACTIVE;2.09;2.69 +32793-2;Parvovirus B19 Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgG Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;B19V IgG 1:2 Ser IA-Rto;;ACTIVE;2.09;2.56 +32794-0;Parvovirus B19 Ab.IgM^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Serum by Immunoassay --1st specimen;B19V IgM sp1 Ser IA-aCnc;;ACTIVE;2.09;2.69 +32795-7;Parvovirus B19 Ab.IgM^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Serum by Immunoassay --2nd specimen;B19V IgM sp2 Ser IA-aCnc;;ACTIVE;2.09;2.69 +32796-5;Parvovirus B19 Ab.IgM^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgM Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;B19V IgM 1:2 Ser IA-Rto;;ACTIVE;2.09;2.56 +3279-7;Kininogen.low molecular weight;MCnc;Pt;PPP;Qn;IA;COAG;1;Kininogen LMW [Mass/volume] in Platelet poor plasma by Immunoassay;LMWK PPP IA-mCnc;;ACTIVE;1.0;2.58 +32797-3;Drugs identified;Prid;Pt;Meconium;Nom;Screen;DRUG/TOX;1;Drugs identified in Meconium by Screen method;Drugs Mec Scn;;ACTIVE;2.09;2.73 +32798-1;Microscopic observation;Prid;Pt;XXX;Nom;Oil red O stain;PATH;1;Microscopic observation [Identifier] in Specimen by Oil red O stain;ORO Stn Spec;;ACTIVE;2.09;2.69 +32799-9;Glycosaminoglycans/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glycosaminoglycans/Creatinine [Mass Ratio] in Urine;GAG/Creat Ur;;ACTIVE;2.09;2.73 +32800-5;Neisseria meningitidis serogroups C+w135 Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroups C+w135 Ag [Presence] in Specimen by Latex agglutination;N men sg C+W135 Ag Spec Ql LA;;ACTIVE;2.09;2.73 +32801-3;Specimen volume;Vol;Pt;Bronchial;Qn;;SPEC;1;Volume of Bronchial specimen;Specimen vol Bronch;;ACTIVE;2.09;2.73 +32802-1;Color;Type;Pt;Bronchial;Nom;;SPEC;1;Color of Bronchial specimen;Color Bronch;;ACTIVE;2.09;2.73 +32803-9;Appearance;Aper;Pt;Bronchial;Nom;;SPEC;1;Appearance of Bronchial specimen;Appearance Bronch;;ACTIVE;2.09;2.73 +32804-7;Neutrophils/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Bronchial specimen by Manual count;Neutrophils/leuk NFr Bronch Manual;;ACTIVE;2.09;2.73 +3280-5;Kininogen.low molecular weight;MCnc;Pt;Ser;Qn;IA;COAG;1;Kininogen LMW [Mass/volume] in Serum by Immunoassay;LMWK Ser IA-mCnc;;ACTIVE;1.0;2.58 +32805-4;Lymphocytes.variant/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Variant lymphocytes/100 leukocytes in Bronchial specimen by Manual count;Variant Lymphs/leuk NFr Bronch Manual;;ACTIVE;2.09;2.70 +32806-2;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Bronchial specimen by Manual count;Monos+Macros/leuk NFr Bronch Manual;;ACTIVE;2.09;2.73 +32807-0;Mononuclear cells/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Bronchial specimen;Mononuc Cells/leuk NFr Bronch;;ACTIVE;2.09;2.73 +32808-8;Leukocytes other/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Leukocytes other/100 leukocytes in Bronchial specimen;WBC Other/leuk NFr Bronch;;ACTIVE;2.09;2.70 +32809-6;Fungus identified;Prid;Pt;Bronchial;Nom;Fungus stain;MICRO;1;Fungus identified in Bronchial specimen by Fungus stain;Fungus Bronch Fungus Stn;;ACTIVE;2.09;2.73 +32810-4;Bacteria identified;Prid;Pt;Bronchial;Nom;;MICRO;1;Bacteria identified in Bronchial specimen;Bacteria Bronch;;ACTIVE;2.09;2.73 +32811-2;Microscopic observation;Prid;Pt;Bronchial;Nom;Iron hematoxylin stain;MICRO;1;Microscopic observation [Identifier] in Bronchial specimen by Iron hematoxylin stain;IH Stn Bronch;;ACTIVE;2.09;2.73 +32812-0;Microscopic observation;Prid;Pt;Bronchial;Nom;Oil red O stain;PATH;1;Microscopic observation [Identifier] in Bronchial specimen by Oil red O stain;ORO Stn Bronch;;ACTIVE;2.09;2.73 +3281-3;Lupus anticoagulant;Imp;Pt;PPP;Nom;;COAG;1;Lupus anticoagulant [Interpretation] in Platelet poor plasma;LA PPP-Imp;;DISCOURAGED;1.0;2.73 +32813-8;Pathologist interpretation;Imp;Pt;Bronchial;Nom;;PATH;1;Pathologist interpretation of Bronchial specimen tests;Path Interp Bronch-Imp;;ACTIVE;2.09;2.73 +32814-6;Microscopic observation;Prid;Pt;XXX;Nom;Chloracetate esterase stain;PATH;1;Microscopic observation [Identifier] in Specimen by Chloracetate esterase stain;CAE Stn Spec;;ACTIVE;2.09;2.69 +32815-3;Microscopic observation;Prid;Pt;XXX;Nom;Sudan black B stain;PATH;1;Microscopic observation [Identifier] in Specimen by Sudan black B stain;Sudan Black B Stn Spec;;ACTIVE;2.09;2.69 +32816-1;Microscopic observation;Prid;Pt;XXX;Nom;Terminal deoxynucleotidyl transferase stain;PATH;1;Microscopic observation [Identifier] in Specimen by Terminal deoxynucleotidyl transferase stain;TdT Stn Spec;;ACTIVE;2.09;2.73 +32817-9;Microscopic observation;Prid;Pt;XXX;Nom;Myeloperoxidase stain;PATH;1;Microscopic observation [Identifier] in Specimen by Myeloperoxidase stain;Myeloperoxidase Spec;;ACTIVE;2.09;2.73 +32818-7;Microscopic observation;Prid;Pt;XXX;Nom;Acetate esterase stain;PATH;1;Microscopic observation [Identifier] in Specimen by Acetate esterase stain;AE Stn Spec;;ACTIVE;2.09;2.69 +32819-5;Microsporidia identified;Prid;Pt;Stool;Nom;Trichrome stain;MICRO;1;Microsporidia identified in Stool by Trichrome stain;Microsporid Stl Tri Stn;;ACTIVE;2.09;2.73 +32820-3;Glucose^45M post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose lactose PO;Glucose 45M p Lac PO SerPl-mCnc;;ACTIVE;2.09;2.73 +3282-1;Coagulation surface induced.hexagonal phase phospholipid;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT W excess hexagonal phase phospholipid in Platelet poor plasma by Coagulation assay;aPTT Hex PL PPP;;ACTIVE;1.0;2.73 +32821-1;Interpretation;Imp;Pt;Body fld;Nom;Immunofixation;CHEM;1;Immunofixation for Body fluid;Interpretation Fld IFE-Imp;;ACTIVE;2.09;2.54 +32822-9;Epithelial cells.squamous/100 cells;NFr;Pt;Bronchial;Qn;Microscopy.light;HEM/BC;1;Epithelial cells.squamous/100 cells in Bronchial specimen by Light microscopy;Squamous NFr Bronch Micro;;ACTIVE;2.09;2.34 +32823-7;Columnar cells/100 cells;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Columnar cells/100 cells in Bronchial specimen;Columnar Cells NFr Bronch;;ACTIVE;2.09;2.73 +32824-5;Microscopic observation;Prid;Pt;XXX;Nom;Tartrate-resistant acid phosphatase stain;PATH;1;Microscopic observation [Identifier] in Specimen by Tartrate-resistant acid phosphatase stain;TRAP Stn Spec;;ACTIVE;2.09;2.73 +32825-2;Leukocytes;PrThr;Pt;Semen;Ord;;FERT;1;Leukocytes [Presence] in Semen;WBC Smn Ql;;ACTIVE;2.09;2.73 +32826-0;Parvovirus B19 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;B19V IgG sp1 Ser IA-aCnc;;ACTIVE;2.09;2.69 +32827-8;HIV 1 p17+p18 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p17+p18 Ab [Presence] in Serum by Immunoblot;HIV1 p17+p18 Ab Ser Ql IB;;ACTIVE;2.09;2.58 +32828-6;Epstein Barr virus capsid Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;EBV VCA IgG sp1 Ser IA-aCnc;;ACTIVE;2.09;2.69 +32829-4;Epstein Barr virus capsid Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;EBV VCA IgG sp2 Ser IA-aCnc;;ACTIVE;2.09;2.69 +32830-2;Epstein Barr virus capsid Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus capsid IgG Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;EBV VCA IgG 1:2 Ser IA-Rto;;ACTIVE;2.09;2.56 +32831-0;Herpes simplex virus 1 Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 1 IgG Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;HSV1 IgG 1:2 Ser IA-Rto;;ACTIVE;2.09;2.73 +32832-8;Lymphocytes.variant/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Bronchial specimen;Variant Lymphs/leuk NFr Bronch;;ACTIVE;2.09;2.73 +32833-6;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Bronchial specimen;Monos+Macros/leuk NFr Bronch;;ACTIVE;2.09;2.73 +32834-4;Herpes simplex virus 2 Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;HSV2 IgG 1:2 Ser-Rto;;ACTIVE;2.09;2.73 +32835-1;Cytomegalovirus Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgG Ab [Ratio] in Serum or Plasma --1st specimen/2nd specimen;CMV IgG 1:2 SerPl-Rto;;ACTIVE;2.09;2.64 +32836-9;Parvovirus B19 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Serum --1st specimen;B19V IgG sp1 Ser-aCnc;;ACTIVE;2.09;2.69 +32837-7;Parvovirus B19 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Serum --2nd specimen;B19V IgG sp2 Ser-aCnc;;ACTIVE;2.09;2.69 +32838-5;Parvovirus B19 Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;B19V IgG 1:2 Ser-Rto;;ACTIVE;2.09;2.10 +3283-9;Lupus anticoagulant neutralization.high phospholipid;Time;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization high phospholipid [Time] in Platelet poor plasma by Coagulation assay;LA Nt HPL PPP;;DISCOURAGED;1.0;2.73 +32839-3;Parvovirus B19 Ab.IgM^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Serum --2nd specimen;B19V IgM sp2 Ser-aCnc;;ACTIVE;2.09;2.69 +32840-1;Parvovirus B19 Ab.IgM^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Ratio] in Serum --1st specimen/2nd specimen;B19V IgM 1:2 Ser-Rto;;ACTIVE;2.09;2.10 +32841-9;Neisseria meningitidis serogroups C+w135 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroups C+w135 Ag [Presence] in Specimen;N men sg C+W135 Ag Spec Ql;;ACTIVE;2.09;2.73 +32842-7;HIV 1 p17+p18 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 p17+p18 Ab [Presence] in Serum;HIV1 p17+p18 Ab Ser Ql;;ACTIVE;2.09;2.56 +32843-5;Epstein Barr virus capsid Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Serum --1st specimen;EBV VCA IgG sp1 Ser-aCnc;;ACTIVE;2.09;2.69 +32844-3;Epstein Barr virus capsid Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Serum --2nd specimen;EBV VCA IgG sp2 Ser-aCnc;;ACTIVE;2.09;2.69 +32845-0;Epstein Barr virus capsid Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;EBV VCA IgG 1:2 Ser-Rto;;ACTIVE;2.09;2.10 +32846-8;Herpes simplex virus 1 Ab.IgG^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 IgG Ab [Ratio] in Serum --1st specimen/2nd specimen;HSV1 IgG 1:2 Ser-Rto;;ACTIVE;2.09;2.10 +3284-7;Lupus anticoagulant neutralization.platelet;Time;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization platelet [Time] in Platelet poor plasma by Coagulation assay;LA Nt Platelet PPP;;DISCOURAGED;1.0;2.73 +32847-6;Streptococcus pneumoniae 18 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptocuccus pneumoniae 18 IgG Ab [Mass/volume] in Serum;Deprecated S pneum18 IgG Ser-mCnc;;DEPRECATED;2.09;2.70 +32848-4;Neisseria meningitidis serogroups A+Y Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroups A+Y Ag [Presence] in Specimen;N men sg A+Y Ag Spec Ql;;ACTIVE;2.09;2.69 +32849-2;Streptococcus pneumoniae 18 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptocuccus pneumoniae 18 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum18 IgG Ser IA-mCnc;;DEPRECATED;2.09;2.70 +328-5;metroNIDAZOLE;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;metroNIDAZOLE [Susceptibility] by Disk diffusion (KB);metroNIDAZOLE Islt KB;;ACTIVE;1.0;2.21 +32850-0;Streptococcus pneumoniae 5 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 5 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum5 IgG Ser IA-mCnc;;DEPRECATED;2.09;2.70 +32851-8;Neisseria meningitidis serogroups A+Y Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroups A+Y Ag [Presence] in Specimen by Latex agglutination;N men sg A+Y Ag Spec Ql LA;;ACTIVE;2.09;2.73 +32852-6;carBAMazepine.free/carBAMazepine.total;MFr;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine free/carBAMazepine.total in Serum or Plasma;carBAMazepine free MFr SerPl;;ACTIVE;2.09;2.73 +32853-4;Neuronal Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Neuronal Ab [Units/volume] in Serum by Immunoassay;Neuronal Ab Ser IA-aCnc;;ACTIVE;2.09;2.73 +3285-4;Phospholipid Ab;ACnc;Pt;Ser;Qn;IA;COAG;1;Phospholipid Ab [Units/volume] in Serum by Immunoassay;Phospholipid Ab Ser IA-aCnc;;ACTIVE;1.0;2.69 +32854-2;17-Hydroxyprogesterone;PrThr;Pt;Bld.dot;Ord;;CHEM;1;17-Hydroxyprogesterone [Presence] in DBS;17OHP DBS Ql;;ACTIVE;2.09;2.73 +32855-9;Cells.CD62/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD62 cells/100 cells in Specimen;CD62 Cells NFr Spec;;ACTIVE;2.09;2.70 +32856-7;Cells.cytoplasmic CD22/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD22 cells/100 cells in Specimen;cyCD22 Cells NFr Spec;;ACTIVE;2.09;2.70 +32857-5;Cells.cytoplasmic CD3/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD3 cells/100 cells in Specimen;cyCD3 Cells NFr Spec;;ACTIVE;2.09;2.70 +32858-3;Cells.IgG/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;IgG cells/100 cells in Specimen;Cells IgG NFr Spec;;ACTIVE;2.09;2.70 +32859-1;Cells.multiple drug resistance/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Multiple drug resistance cells/100 cells in Specimen;MDR Cells NFr Spec;;ACTIVE;2.09;2.70 +32860-9;Cells.TCR alpha beta/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;TCR alpha beta cells/100 cells in Specimen;TCR A-B Cells NFr Spec;;ACTIVE;2.09;2.73 +32861-7;Cells.TCR gamma delta/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;TCR gamma delta cells/100 cells in Specimen;TCR G-D Cells NFr Spec;;ACTIVE;2.09;2.73 +3286-2;Phospholipid Ab.IgG;ACnc;Pt;Ser;Qn;IA;COAG;1;Phospholipid IgG Ab [Units/volume] in Serum by Immunoassay;Phospholipid IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +32862-5;Osmotic fragility^incubated;Imp;Pt;RBC;Nom;;HEM/BC;1;Osmotic fragility [Interpretation] of Red Blood Cells--Incubated;OF Incubated RBC-Imp;;ACTIVE;2.09;2.73 +32863-3;Osmotic fragility^fresh;Imp;Pt;RBC;Nom;;HEM/BC;1;Osmotic fragility [Interpretation] of Red Blood Cells--fresh;OF Fresh RBC-Imp;;ACTIVE;2.09;2.70 +32864-1;Frankfort horizontal plane to mandibular plane;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Frankfort horizontal plane to mandibular plane [Angle] Skull X-ray measured;FMA Angle Skull XR;;ACTIVE;2.09;2.48 +32865-8;Frankfort horizontal plane to mandibular plane;Angle;Pt;Skull;Qn;CT.measured;DENTAL;2;Frankfort horizontal plane to mandibular plane [Angle] Skull CT measured;FMA Angle Skull CT;;ACTIVE;2.09;2.48 +32866-6;Frankfort horizontal plane to mandibular plane;Angle;Pt;Skull;Qn;Digital model.measured;DENTAL;2;Frankfort horizontal plane to mandibular plane [Angle] Skull Digital model.measured;FMA Angle Skull Digital;;ACTIVE;2.09;2.48 +32867-4;First tooth space boundary;Prid;Pt;{Tooth};Nom;;DENTAL;2;First tooth space boundary [Identifier];1st tooth space boundary;;ACTIVE;2.09;2.27 +32868-2;Second tooth space boundary;Prid;Pt;{Tooth};Nom;;DENTAL;2;Second tooth space boundary [Identifier];2nd tooth space boundary;;ACTIVE;2.09;2.27 +32869-0;Tooth space;Len;Pt;{First tooth space boundary} {second tooth space boundary};Qn;Measured;DENTAL;2;Tooth space {First tooth space boundary} {second tooth space boundary} Measured;Space 1st+2nd tooth bound Measured;;ACTIVE;2.09;2.48 +3287-0;Phospholipid Ab.IgM;ACnc;Pt;Ser;Qn;IA;COAG;1;Phospholipid IgM Ab [Units/volume] in Serum by Immunoassay;Phospholipid IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +32870-8;First facial landmark;Prid;Pt;Head;Nom;;DENTAL;2;First facial landmark [Identifier] Head;1st face landmark Head;;ACTIVE;2.09;2.56 +32871-6;Second facial landmark;Prid;Pt;Head;Nom;;DENTAL;2;Second facial landmark [Identifier] Head;2nd facial landmark Head;;ACTIVE;2.09;2.56 +32872-4;Facial measurement;Len;Pt;{First facial landmark} {second facial landmark};Qn;Measured;DENTAL;2;Facial measurement [Length] {First facial landmark} {second facial landmark} Measured;Face measure 1st+2nd landmark Measured;;ACTIVE;2.09;2.48 +32873-2;Facial measurement method;Type;Pt;Head;Nom;;DENTAL;2;Facial measurement method;Facial measurement method;;ACTIVE;2.09;2.42 +32874-0;Dental treatment anatomical site access;Imp;Pt;Head;Ord;;DENTAL;2;Dental treatment anatomical site access Head;Dent Tx anat site access Head;;ACTIVE;2.09;2.27 +32875-7;Guardian previously informed of patient condition;Find;Pt;^Guardian;Ord;Observed;DENTAL;2;Guardian previously informed of patient condition;Guard prev informed of patient cond;;ACTIVE;2.09;2.56 +32876-5;Guardian informed of patient condition;Find;Pt;^Guardian;Ord;Observed;DENTAL;2;Guardian informed of patient condition Guardian Observed;Guard informed of patient cond;;ACTIVE;2.09;2.56 +32877-3;Guardian previous action taken;Find;Pt;^Guardian;Ord;Observed;DENTAL;2;Guardian previous action taken Guardian Observed;Guard prev action taken;;ACTIVE;2.09;2.56 +32878-1;Guardian current action taken;Find;Pt;^Guardian;Ord;Observed;DENTAL;2;Guardian current action taken Guardian Observed;Guardian current action taken;;ACTIVE;2.09;2.56 +32879-9;Noncompliance with dental treatment;Find;Pt;^Patient;Ord;;DENTAL;2;Noncompliance with dental treatment;Noncompliance W dent Tx;;ACTIVE;2.09;2.27 +32880-7;Dental procedure;Hx;Pt;^Patient;Nom;;DENTAL;2;History of Dental procedure;Hx of Dent procedure;;ACTIVE;2.09;2.56 +32881-5;Dental probing response;Find;Pt;Gingiva;Nom;;DENTAL;2;Dental probing response Gingiva;Dent probing response Gingiva;;ACTIVE;2.09;2.56 +32882-3;Reason for dental evaluation;Find;Pt;^Patient;Nom;;DENTAL;2;Reason for dental evaluation;Reason for dent eval;;ACTIVE;2.09;2.56 +32883-1;Dental arch;Prid;Pt;^Patient;Nom;;DENTAL;2;Dental arch [Identifier];Dent arch;;ACTIVE;2.09;2.56 +32884-9;Identification;Prid;Pt;{Tooth};Nom;;DENTAL;2;Identification {Tooth};ID {Tooth};;ACTIVE;2.09;2.27 +32885-6;Identification;Prid;Pt;{Tooth};Nom;Observed;DENTAL;2;Identification {Tooth} Observed;ID {Tooth} Observ;;ACTIVE;2.09;2.27 +32886-4;Identification;Prid;Pt;{Tooth};Nom;XR;DENTAL;2;Identification {Tooth} XR;ID {Tooth} XR;;ACTIVE;2.09;2.61 +32887-2;Identification;Prid;Pt;{Tooth};Nom;Best estimate;DENTAL;2;Identification {Tooth} Best estimate;ID {Tooth} Best Est;;ACTIVE;2.09;2.27 +3288-8;Prothrombin Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Prothrombin Ag [Units/volume] in Platelet poor plasma by Immunoassay;Prothrom Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +32888-0;Probe site;Prid;Pt;{Tooth}.sulcus;Nom;;DENTAL;2;Probe site {Tooth}.sulcus;Probe site {Tooth}.sulcus;;ACTIVE;2.09;2.56 +32889-8;Surface;Prid;Pt;Tooth;Nom;;DENTAL;2;Surface [Identifier] Tooth;Surface Tooth;;ACTIVE;2.09;2.27 +32890-6;Canal;Prid;Pt;Tooth;Nom;;DENTAL;2;Canal [Identifier] Tooth;Canal Tooth;;ACTIVE;2.09;2.27 +32891-4;Root palpation location;Prid;Pt;Tooth;Nom;;DENTAL;2;Root palpation location [Identifier] Tooth;Root palpation location Tooth;;ACTIVE;2.09;2.27 +32892-2;Side;Prid;Pt;Tooth;Nom;;DENTAL;2;Side [Identifier] Tooth;Side Tooth;;ACTIVE;2.09;2.27 +32893-0;First interdental papilla boundary;Prid;Pt;{Tooth};Nom;;DENTAL;2;First interdental papilla boundary [Identifier] {Tooth};1st interdent papilla boundary {Tooth};;ACTIVE;2.09;2.27 +32894-8;Second interdental papilla boundary;Prid;Pt;{Tooth};Nom;;DENTAL;2;Second interdental papilla boundary [Identifier] {Tooth};2nd interdent papilla boundary {Tooth};;ACTIVE;2.09;2.27 +32895-5;Tooth space available;Len;Pt;{Dental arch};Qn;Measured;DENTAL;2;Tooth space available {Dental arch} Measured;Space avail {Dent arch} Measured;;ACTIVE;2.09;2.48 +3289-6;Prothrombin.activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Prothrombin activity actual/normal in Platelet poor plasma by Coagulation assay;Prothrom Act/Nor PPP;;ACTIVE;1.0;2.73 +32896-3;Width;Len;Pt;{Tooth};Qn;Measured;DENTAL;2;Width {Tooth} Measured;Width {Tooth} Measured;;ACTIVE;2.09;2.48 +32897-1;Height;Len;Pt;{Tooth};Qn;Measured;DENTAL;2;Height {Tooth} Measured;Height {Tooth} Measured;;ACTIVE;2.09;2.48 +32898-9;Tooth space required;Len;Pt;{Dental arch};Qn;Calculated;DENTAL;2;Tooth space required {Dental arch} Calculated;Space required {Dent arch} Calc;;ACTIVE;2.09;2.48 +32899-7;Tooth space required;Len;Pt;{Dental arch};Qn;Estimated;DENTAL;2;Tooth space required {Dental arch} Estimated;Space required {Dent arch} Est;;ACTIVE;2.09;2.48 +32900-3;Tooth space discrepancy;Len;Pt;{Dental arch};Qn;Measured;DENTAL;2;Tooth space discrepancy {Dental arch} Measured;Space discr {Dent arch} Measured;;ACTIVE;2.09;2.48 +32901-1;Tooth space discrepancy;Len;Pt;{Dental arch};Qn;Estimated;DENTAL;2;Tooth space discrepancy {Dental arch} Estimated;Space discr {Dent arch} Est;;ACTIVE;2.09;2.48 +32902-9;Superhelix of ear to side of head distance;Len;Pt;Ear.left+Head;Qn;Measured;DENTAL;2;Superhelix of ear to side of head distance Ear - left and Head Measured;Superhelix distance Ear-L+Head Measured;;ACTIVE;2.09;2.38 +32903-7;Superhelix of ear to side of head distance;Len;Pt;Ear.right+Head;Qn;Measured;DENTAL;2;Superhelix of ear to side of head distance Ear - right and Head Measured;Superhelix distance Ear-R+Head Measured;;ACTIVE;2.09;2.38 +3290-4;2-Oxoisocaproate;MCnc;Pt;Urine;Qn;;CHEM;1;2-Oxoisocaproate [Mass/volume] in Urine;2Oxoisocaproate Ur-mCnc;;DISCOURAGED;1.0;2.73 +32904-5;Midhelix of ear to side of head distance;Len;Pt;Ear.left+Head;Qn;Measured;DENTAL;2;Midhelix of ear to side of head distance Ear - left and Head Measured;Midhelix distance Ear-L+Head Measured;;ACTIVE;2.09;2.48 +32905-2;Midhelix of ear to side of head distance;Len;Pt;Ear.right+Head;Qn;Measured;DENTAL;2;Midhelix of ear to side of head distance Ear - right and Head Measured;Midhelix distance Ear-R+Head Measured;;ACTIVE;2.09;2.48 +32906-0;Cuspid to cuspid distance;Len;Pt;Maxilla;Qn;Measured;DENTAL;2;Cuspid to cuspid distance Maxilla Measured;Cuspid-cuspid dist Maxilla Measured;;ACTIVE;2.09;2.73 +32907-8;Crown length;Len;Pt;{Tooth};Qn;Measured;DENTAL;2;Crown length {Tooth} Measured;Crown length {Tooth} Measured;;ACTIVE;2.09;2.48 +32908-6;Root length;Len;Pt;{Tooth}.{surface};Qn;Measured;DENTAL;2;Root length {Tooth}.{surface} Measured;Root length {Tooth}.{surface} Measured;;ACTIVE;2.09;2.48 +32909-4;Interproximal space height;Len;Pt;{Dental arch};Qn;Measured;DENTAL;2;Interproximal space height {Dental arch} Measured;Interprox space ht {Dent arch} Measured;;ACTIVE;2.09;2.48 +32910-2;Probing depth;Len;Pt;{Tooth}.{probe site};Qn;Measured;DENTAL;2;Probing depth {Tooth}.{probe site} Measured;Probing depth Tooth Measured;;ACTIVE;2.09;2.48 +32911-0;Recession;Len;Pt;{Tooth}.{probe site};Qn;Measured;DENTAL;2;Recession [Length] {Tooth}.{probe site} Measured;Recession Tooth Measured;;ACTIVE;2.09;2.48 +3291-2;2-Pyridone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;2-Pyridone [Mass/volume] in Serum or Plasma;2Pyridone SerPl-mCnc;;ACTIVE;1.0;2.34 +32912-8;Attachment level;Len;Pt;{Tooth}.{probe site};Qn;Calculated;DENTAL;2;Attachment level [Length] {Tooth}.{probe site} Calculated;Att level Tooth Calc;;ACTIVE;2.09;2.48 +32913-6;Mucogingival junction level;Len;Pt;{Tooth}.{probe site};Qn;Measured;DENTAL;2;Mucogingival junction level [Length] {Tooth}.{probe site} Measured;Mg junct lvl Tooth Measured;;ACTIVE;2.09;2.73 +32914-4;Bone attachment level;Len;Pt;{Tooth}.{probe site}.{surface}+Maxilla;Qn;Measured;DENTAL;2;Bone attachment level [Length] {Tooth}.{probe site}.{surface}+Maxilla Measured;Bone AL Max Measured;;ACTIVE;2.09;2.48 +32915-1;Bone attachment level;Len;Pt;{Tooth}.{probe site}.{surface}+Mandible;Qn;Measured;DENTAL;2;Bone attachment level [Length] {Tooth}.{probe site}.{surface}+Mandible Measured;Bone AL Mand Measured;;ACTIVE;2.09;2.48 +32916-9;Horizontal overlap;Len;Pt;Maxilla+Mandible;Qn;Measured;DENTAL;2;Horizontal overlap [Length] Maxilla and Mandible Measured;Horiz overlap Maxi+Mand Measured;;ACTIVE;2.09;2.48 +32917-7;Vertical overlap;Len;Pt;Maxilla+Mandible;Qn;Measured;DENTAL;2;Vertical overlap [Length] Maxilla and Mandible Measured;Vert overlap Maxi+Mand Measured;;ACTIVE;2.09;2.48 +32918-5;Openbite;Len;Pt;Maxilla+Mandible;Qn;Measured;DENTAL;2;Openbite [Length] Maxilla and Mandible Measured;Openbite Maxi+Mand Measured;;ACTIVE;2.09;2.48 +32919-3;Vertical dimension of occlusion;Len;Pt;Maxilla+Mandible;Qn;Measured;DENTAL;2;Vertical dimension of occlusion Maxilla and Mandible Measured;VDO Maxi+Mand Measured;;ACTIVE;2.09;2.48 +3292-0;2-Pyridone/N'-Methylnicotinamide;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;2-Pyridone/N'-methylnicotinamide [Mass Ratio] in Serum or Plasma;2Pyridone/NMN SerPl;;ACTIVE;1.0;2.42 +32920-1;Excursive distance.max;Len;Pt;Mandible;Qn;Measured;DENTAL;2;Excursive distance maximum Mandible Measured;Excursive distance max Mandible Measured;;ACTIVE;2.09;2.48 +32921-9;Centric relation maximum intercuspation anterior shift;Len;Pt;Maxilla+Mandible;Qn;Measured;DENTAL;2;Centric relation maximum intercuspation anterior shift [Length] Maxilla and Mandible Measured;CR MI ant shift Maxi+Mand Measured;;ACTIVE;2.09;2.48 +32922-7;Centric relation maximum intercuspation lateral shift;Len;Pt;Maxilla+Mandible;Qn;Measured;DENTAL;2;Centric relation maximum intercuspation lateral shift [Length] Maxilla and Mandible Measured;CR MI lat shift Maxi+Mand Measured;;ACTIVE;2.09;2.48 +32923-5;Closest speaking space;Len;Pt;Dentition;Qn;Measured;DENTAL;2;Closest speaking space [Length] Dentition Measured;CSS Dentition Measured;;ACTIVE;2.09;2.48 +32924-3;Single tooth area;Prid;Pt;{Tooth};Nom;Best estimate;DENTAL;2;Single tooth area [Identifier] Best estimate;Single tooth area Best Est;;ACTIVE;2.09;2.27 +32925-0;Sella-nasion plane to nasion-B point line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Sella-nasion plane to nasion-B point line [Angle] Skull X-ray measured;SNB Angle Skull XR;;ACTIVE;2.09;2.48 +32926-8;Sella-nasion plane to nasion-B point line;Angle;Pt;Skull;Qn;CT.measured;DENTAL;2;Sella-nasion plane to nasion-B point line [Angle] Skull CT measured;SNB Angle Skull CT;;ACTIVE;2.09;2.48 +32927-6;Sella-nasion plane to nasion-B point line;Angle;Pt;Skull;Qn;Digital model.measured;DENTAL;2;Sella-nasion plane to nasion-B point line [Angle] Skull Digital model.measured;SNB Angle Skull Digital;;ACTIVE;2.09;2.48 +32928-4;A point-nasion line to nasion-B point line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;A point-nasion line to nasion-B point line [Angle] Skull X-ray measured;ANB Angle Skull XR;;ACTIVE;2.09;2.48 +32929-2;A point-nasion line to nasion-B point line;Angle;Pt;Skull;Qn;CT.measured;DENTAL;2;A point-nasion line to nasion-B point line [Angle] Skull CT measured;ANB Angle Skull CT;;ACTIVE;2.09;2.48 +329-3;metroNIDAZOLE;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;metroNIDAZOLE [Susceptibility] by Serum bactericidal titer;metroNIDAZOLE Titr SBT;;ACTIVE;1.0;2.32 +32930-0;A point-nasion line to nasion-B point line;Angle;Pt;Skull;Qn;Digital model.measured;DENTAL;2;A point-nasion line to nasion-B point line [Angle] Skull Digital model.measured;ANB Angle Skull Digital;;ACTIVE;2.09;2.48 +32931-8;Sella-nasion plane to Frankfort horizontal plane;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Sella-nasion plane to Frankfort horizontal plane [Angle] Skull X-ray measured;SN-FH Angle Skull XR;;ACTIVE;2.09;2.48 +32932-6;Sella-nasion plane to Frankfort horizontal plane;Angle;Pt;Skull;Qn;CT.measured;DENTAL;2;Sella-nasion plane to Frankfort horizontal plane [Angle] Skull CT measured;SN-FH Angle Skull CT;;ACTIVE;2.09;2.48 +32933-4;Sella-nasion plane to Frankfort horizontal plane;Angle;Pt;Skull;Qn;Digital model.measured;DENTAL;2;Sella-nasion plane to Frankfort horizontal plane [Angle] Skull Digital model.measured;SN-FH Angle Skull Digital;;ACTIVE;2.09;2.48 +32934-2;Nasion-glabella line to nasion-pronasale line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Nasion-glabella line to nasion-pronasale line [Angle] Skull X-ray measured;Na-Gl to Na-Prn Angle Skull XR;;ACTIVE;2.09;2.48 +32935-9;Nasion-glabella line to nasion-pronasale line;Angle;Pt;Skull;Qn;CT.measured;DENTAL;2;Nasion-glabella line to nasion-pronasale line [Angle] Skull CT measured;Na-Gl to Na-Prn Angle Skull CT;;ACTIVE;2.09;2.48 +32936-7;Nasion-glabella line to nasion-pronasale line;Angle;Pt;Skull;Qn;Digital model.measured;DENTAL;2;Nasion-glabella line to nasion-pronasale line [Angle] Skull Digital model.measured;Na-Gl to Na-Prn Angle Skull Digital;;ACTIVE;2.09;2.48 +32937-5;Frankfort horizontal plane to nasion-pogonion line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Frankfort horizontal plane to nasion-pogonion line [Angle] Skull X-ray measured;FH-NPg Angle Skull XR;;ACTIVE;2.09;2.48 +3293-8;Acebutolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Acebutolol [Presence] in Urine;Acebutolol Ur Ql;;ACTIVE;1.0;2.56 +32938-3;Frankfort horizontal plane to nasion-pogonion line;Angle;Pt;Skull;Qn;CT.measured;DENTAL;2;Frankfort horizontal plane to nasion-pogonion line [Angle] Skull CT measured;FH-NPg Angle Skull CT;;ACTIVE;2.09;2.48 +32939-1;Frankfort horizontal plane to nasion-pogonion line;Angle;Pt;Skull;Qn;Digital model.measured;DENTAL;2;Frankfort horizontal plane to nasion-pogonion line [Angle] Skull Digital model.measured;FH-NPg Angle Skull Digital;;ACTIVE;2.09;2.48 +32940-9;Freeway space;Len;Pt;Dentition;Qn;Measured;DENTAL;2;Freeway space [Length] Dentition Measured;Freeway space Dentition Measured;;ACTIVE;2.09;2.48 +32941-7;Maximum intercuspation left midline discrepancy;Len;Pt;Mandible+Face;Qn;Measured;DENTAL;2;Maximum intercuspation left midline discrepancy [Length] Mandible+Face Measured;MI L-mdl discrepancy Measured;;ACTIVE;2.09;2.73 +32942-5;Maximum intercuspation right midline discrepancy;Len;Pt;Mandible+Face;Qn;Measured;DENTAL;2;Maximum intercuspation right midline discrepancy [Length] Mandible+Face Measured;MI R-mdl discrepancy Measured;;ACTIVE;2.09;2.48 +32943-3;First contact left midline discrepancy;Len;Pt;Mandible+Face;Qn;Measured;DENTAL;2;First contact left midline discrepancy [Length] Mandible+Face Measured;1st contact L-mdl discrepancy Measured;;ACTIVE;2.09;2.48 +32944-1;First contact right midline discrepancy;Len;Pt;Mandible+Face;Qn;Measured;DENTAL;2;First contact right midline discrepancy [Length] Mandible+Face Measured;1st contact R-mdl discrepancy Measured;;ACTIVE;2.09;2.48 +32945-8;Sella-nasion plane to nasion-A point line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Sella-nasion plane to nasion-A point line [Angle] Skull X-ray measured;SNA Angle Skull XR;;ACTIVE;2.09;2.48 +3294-6;Acebutolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acebutolol [Mass/volume] in Urine;Acebutolol Ur-mCnc;;ACTIVE;1.0;2.42 +32946-6;Sella-nasion plane to nasion-A point line;Angle;Pt;Skull;Qn;CT.measured;DENTAL;2;Sella-nasion plane to nasion-A point line [Angle] Skull CT measured;SNA Angle Skull CT;;ACTIVE;2.09;2.48 +32947-4;Sella-nasion plane to nasion-A point line;Angle;Pt;Skull;Qn;Digital model.measured;DENTAL;2;Sella-nasion plane to nasion-A point line [Angle] Skull Digital model.measured;SNA Angle Skull Digital;;ACTIVE;2.09;2.48 +32948-2;Size;Arb;Pt;Ear.right;Ord;Estimated;DENTAL;2;Size Ear - right Estimated;Size Ear-R Est;;ACTIVE;2.09;2.73 +32949-0;Size;Arb;Pt;Ear.left;Ord;Estimated;DENTAL;2;Size Ear - left Estimated;Size Ear-L Est;;ACTIVE;2.09;2.27 +32950-8;Bleeding on probing index;NFr;Pt;Gingiva;Qn;Estimated;DENTAL;2;Bleeding on probing index Gingiva Estimated;BOP index NFr Gingiva Est;;ACTIVE;2.09;2.34 +32951-6;Bleeding on probing index;NFr;Pt;Gingiva;Qn;Calculated;DENTAL;2;Bleeding on probing index Gingiva Calculated;BOP index NFr Gingiva Calc;;ACTIVE;2.09;2.40 +32952-4;Plaque index;NFr;Pt;Dentition;Qn;Estimated;DENTAL;2;Plaque index Dentition Estimated;Plaque index NFr Dentition Est;;ACTIVE;2.09;2.40 +3295-3;Acebutolol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Acebutolol [Mass/time] in 24 hour Urine;Acebutolol 24h Ur-mRate;;ACTIVE;1.0;2.42 +32953-2;Plaque index;NFr;Pt;Dentition;Qn;Calculated;DENTAL;2;Plaque index Dentition Calculated;Plaque index NFr Dentition Calc;;ACTIVE;2.09;2.40 +32954-0;Root development;LenFr;Pt;{Tooth};Qn;Estimated;DENTAL;2;Root development {Tooth} Estimated;Root devel LenFr {Tooth} Est;;ACTIVE;2.09;2.34 +32955-7;Vertical overlap;LenFr;Pt;Maxilla+Mandible;Qn;Estimated;DENTAL;2;Vertical overlap Maxilla and Mandible Estimated;Vert overlap LenFr Maxi+Mand Est;;ACTIVE;2.09;2.48 +32956-5;Alveolar ridge;Shape;Pt;{Dental arch};Nom;;DENTAL;2;Alveolar ridge [Shape] {Dental arch};Alv ridge Shape {Dent arch};;ACTIVE;2.09;2.56 +32957-3;Palate;Shape;Pt;Maxilla;Nom;;DENTAL;2;Palate [Shape] Maxilla;Palate Shape Maxilla;;ACTIVE;2.09;2.56 +32958-1;Crown;Shape;Pt;{Tooth};Nom;;DENTAL;2;Crown [Shape] {Tooth};Crown Shape {Tooth};;ACTIVE;2.09;2.56 +32959-9;Root;Shape;Pt;{Tooth}.{surface};Nom;;DENTAL;2;Root [Shape] {Tooth}.{surface};Root Shape {Tooth}.{surface};;ACTIVE;2.09;2.56 +32960-7;Transverse section;Shape;Pt;{Dental arch};Nom;;DENTAL;2;Transverse section [Shape] {Dental arch};Transverse section Shape {Dent arch};;ACTIVE;2.09;2.56 +3296-1;Acepromazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acepromazine [Mass/volume] in Serum or Plasma;Acepromazine SerPl-mCnc;;ACTIVE;1.0;2.40 +32961-5;Anterior segment;Shape;Pt;{Dental arch};Nom;;DENTAL;2;Anterior segment [Shape] {Dental arch};Ant seg Shape {Dent arch};;ACTIVE;2.09;2.56 +32962-3;Caries risk;Imp;Pt;Dentition;Ord;;DENTAL;2;Caries risk Dentition;Caries risk Dentition;;ACTIVE;2.09;2.56 +32963-1;Peridontal risk;Imp;Pt;Gingiva;Ord;;DENTAL;2;Peridontal risk Gingiva;Peridontal risk Gingiva;;ACTIVE;2.09;2.56 +32964-9;Dental prognosis;Imp;Pt;^Patient;Nom;Best estimate;DENTAL;2;Dental prognosis Best estimate;Dent Px Best Est;;ACTIVE;2.09;2.27 +32965-6;Dental prognosis;Imp;Pt;{Tooth};Nom;Best estimate;DENTAL;2;Dental prognosis {Tooth} Best estimate;Dent Px {Tooth} Best Est;;ACTIVE;2.09;2.27 +32966-4;Dental prognosis;Imp;Pt;{Procedure};Nom;Best estimate;DENTAL;2;Dental prognosis {Procedure} Best estimate;Dent Px {Procedure} Best Est;;ACTIVE;2.09;2.27 +32967-2;Root apex development;Find;Pt;{Tooth}.{surface};Nom;XR;DENTAL;2;Root apex development {Tooth}.{surface} XR;Root apex devel {Tooth}.{surface} XR;;ACTIVE;2.09;2.61 +32968-0;Eruption;Find;Pt;{Tooth};Ord;XR;DENTAL;2;Eruption {Tooth} XR;Eruption {Tooth} XR;;ACTIVE;2.09;2.61 +32969-8;Eruption;Find;Pt;{Dental arch};Ord;XR;DENTAL;2;Eruption {Dental arch} XR;Eruption {Dent arch} XR;;ACTIVE;2.09;2.61 +32970-6;Eruption;Find;Pt;^Patient;Ord;XR;DENTAL;2;Eruption XR;Eruption XR;;ACTIVE;2.09;2.61 +32971-4;Exfoliation;Find;Pt;{Tooth};Ord;XR;DENTAL;2;Exfoliation {Tooth} XR;Exfoliation {Tooth} XR;;ACTIVE;2.09;2.61 +32972-2;Exfoliation;Find;Pt;{Dental arch};Ord;XR;DENTAL;2;Exfoliation {Dental arch} XR;Exfoliation {Dent arch} XR;;ACTIVE;2.09;2.61 +32973-0;Exfoliation;Find;Pt;^Patient;Ord;XR;DENTAL;2;Exfoliation XR;Exfoliation XR;;ACTIVE;2.09;2.61 +32974-8;Size;Arb;Pt;{Dental arch};Nom;;DENTAL;2;Size {Dental arch};Size {Dent arch};;ACTIVE;2.09;2.56 +32975-5;Vertical displacement;Find;Pt;Ear.right;Ord;;DENTAL;2;Vertical displacement Ear - right;Vert displacement Ear-R;;ACTIVE;2.09;2.56 +32976-3;Vertical displacement;Find;Pt;Ear.left;Ord;;DENTAL;2;Vertical displacement Ear - left;Vert displacement Ear-L;;ACTIVE;2.09;2.56 +32977-1;Vertical displacement;Find;Pt;Cheek.right;Ord;;DENTAL;2;Vertical displacement Cheek - right;Vert displacement Cheek-R;;ACTIVE;2.09;2.56 +32978-9;Vertical displacement;Find;Pt;Cheek.left;Ord;;DENTAL;2;Vertical displacement Cheek - left;Vert displacement Cheek-L;;ACTIVE;2.09;2.56 +3297-9;Acetaminophen;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetaminophen [Presence] in Serum or Plasma;APAP SerPl Ql;;ACTIVE;1.0;2.73 +32979-7;Stability;Imp;Pt;{Dental arch}.denture.complete;Ord;Observed;DENTAL;2;Stability {Dental arch}.denture.complete Observed;Stability {Dent arch}.CD Observ;;ACTIVE;2.09;2.27 +32980-5;Stability;Imp;Pt;{Dental arch}.denture.partial;Ord;Observed;DENTAL;2;Stability {Dental arch}.denture.partial Observed;Stability {Dent arch}.PD Observ;;ACTIVE;2.09;2.27 +32981-3;Stability;Imp;Pt;{Dental arch}.denture.complete;Ord;Reported;DENTAL;2;Stability {Dental arch}.denture.complete - Reported;Stability {Dent arch}.CD Reported;;ACTIVE;2.09;2.27 +32982-1;Stability;Imp;Pt;{Dental arch}.denture.partial;Ord;Reported;DENTAL;2;Stability {Dental arch}.denture.partial - Reported;Stability {Dent arch}.PD Reported;;ACTIVE;2.09;2.27 +32983-9;Retention;Imp;Pt;{Dental arch}.denture.complete;Ord;Observed;DENTAL;2;Retention {Dental arch}.denture.complete Observed;Retention {Dent arch}.CD Observ;;ACTIVE;2.09;2.27 +32984-7;Retention;Imp;Pt;{Dental arch}.denture.partial;Ord;Observed;DENTAL;2;Retention {Dental arch}.denture.partial Observed;Retention {Dent arch}.PD Observ;;ACTIVE;2.09;2.27 +32985-4;Retention;Imp;Pt;{Dental arch}.denture.complete;Ord;Reported;DENTAL;2;Retention {Dental arch}.denture.complete - Reported;Retention {Dent arch}.CD Reported;;ACTIVE;2.09;2.27 +32986-2;Retention;Imp;Pt;{Dental arch}.denture.partial;Ord;Reported;DENTAL;2;Retention {Dental arch}.denture.partial - Reported;Retention {Dent arch}.PD Reported;;ACTIVE;2.09;2.27 +3298-7;Acetaminophen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetaminophen [Mass/volume] in Serum or Plasma;APAP SerPl-mCnc;;ACTIVE;1.0;2.73 +32987-0;Support;Imp;Pt;{Dental arch}.denture.complete;Ord;Observed;DENTAL;2;Support {Dental arch}.denture.complete Observed;Support {Dent arch}.CD Observ;;ACTIVE;2.09;2.27 +32988-8;Support;Imp;Pt;{Dental arch}.denture.partial;Ord;Observed;DENTAL;2;Support {Dental arch}.denture.partial Observed;Support {Dent arch}.PD Observ;;ACTIVE;2.09;2.27 +32989-6;Support;Imp;Pt;{Dental arch}.denture.complete;Ord;Reported;DENTAL;2;Support {Dental arch}.denture.complete - Reported;Support {Dent arch}.CD Reported;;ACTIVE;2.09;2.27 +32990-4;Support;Imp;Pt;{Dental arch}.denture.partial;Ord;Reported;DENTAL;2;Support {Dental arch}.denture.partial - Reported;Support {Dent arch}.PD Reported;;ACTIVE;2.09;2.27 +32991-2;Aesthetics;Imp;Pt;{Dental arch}.denture.complete;Ord;Observed;DENTAL;2;Aesthetics {Dental arch}.denture.complete Observed;Aesthetics {Dent arch}.CD Observ;;ACTIVE;2.09;2.27 +32992-0;Aesthetics;Imp;Pt;{Dental arch}.denture.partial;Ord;Observed;DENTAL;2;Aesthetics {Dental arch}.denture.partial Observed;Aesthetics {Dent arch}.PD Observ;;ACTIVE;2.09;2.27 +32993-8;Aesthetics;Imp;Pt;{Dental arch}.denture.complete;Ord;Reported;DENTAL;2;Aesthetics {Dental arch}.denture.complete - Reported;Aesthetics {Dent arch}.CD Reported;;ACTIVE;2.09;2.27 +32994-6;Aesthetics;Imp;Pt;{Dental arch}.denture.partial;Ord;Reported;DENTAL;2;Aesthetics {Dental arch}.denture.partial - Reported;Aesthetics {Dent arch}.PD Reported;;ACTIVE;2.09;2.27 +3299-5;Acetaminophen;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Acetaminophen [Presence] in Urine;APAP Ur Ql;;ACTIVE;1.0;2.73 +32995-3;Lutropin^20M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --20 minutes post XXX challenge;LH 20M p chal SerPl-aCnc;;ACTIVE;2.09;2.70 +32996-1;HER2;MCnc;Pt;Ser;Qn;;PATH;1;HER2 [Mass/volume] in Serum;Her2 Ser-mCnc;;ACTIVE;2.09;2.73 +32997-9;cycloSPORINE^2H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --2 hours post dose;cycloSPORINE 2h p Bld-mCnc;;ACTIVE;2.09;2.73 +32998-7;Tissue transglutaminase Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Tissue transglutaminase IgG Ab [Units/volume] in Serum;tTG IgG Ser-aCnc;;ACTIVE;2.09;2.73 +32999-5;Rickettsia spotted fever group Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia spotted fever group IgG Ab [Presence] in Serum;Rick SF IgG Ser Ql;;ACTIVE;2.09;2.73 +33000-1;Rickettsia spotted fever group Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia spotted fever group IgM Ab [Presence] in Serum;Rick SF IgM Ser Ql;;ACTIVE;2.09;2.73 +3300-1;acetaZOLAMIDE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetazolamide [Mass/volume] in Serum or Plasma;acetaZOLAMIDE SerPl-mCnc;;ACTIVE;1.0;2.73 +33001-9;Rickettsia typhi Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia typhi IgM Ab [Presence] in Serum;R typhi IgM Ser Ql;;ACTIVE;2.09;2.73 +33002-7;Triticum spelta Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spelt IgE Ab [Units/volume] in Serum;Spelt IgE Qn;;ACTIVE;2.09;2.73 +33003-5;Triticum spelta Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spelt IgE Ab RAST class [Presence] in Serum;Spelt IgE RAST Ql;;ACTIVE;2.09;2.73 +33004-3;Kelp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kelp or Seaweed IgE Ab [Units/volume] in Serum;Kelp/Seaweed IgE Qn;;ACTIVE;2.09;2.70 +33005-0;Kelp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Kelp or Seaweed IgE Ab RAST class [Presence] in Serum;Kelp/Seaweed IgE RAST Ql;;ACTIVE;2.09;2.58 +33006-8;Cytomegalovirus DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Specimen by NAA with probe detection;CMV DNA # Spec NAA+probe;;ACTIVE;2.09;2.73 +33007-6;Protoporphyrin.zinc;MCnc;Pt;Bld;Qn;;CHEM;1;Protoporphyrin.zinc [Mass/volume] in Blood;ZPP Bld-mCnc;;ACTIVE;2.09;2.73 +33008-4;Neuronal nuclear type 2 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Serum by Immunoblot;Hu2 Ab Ser Ql IB;;ACTIVE;2.09;2.73 +33009-2;Chylomicrons;PrThr;Pt;Body fld;Ord;;CHEM;1;Chylomicrons [Presence] in Body fluid;Chylo Fld Ql;;ACTIVE;2.09;2.73 +330-1;Mezlocillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Mezlocillin [Susceptibility] by Minimum lethal concentration (MLC);Mezlocillin Islt MLC;;ACTIVE;1.0;2.19 +33010-0;Cheese colby Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Colby Cheese IgE Ab [Units/volume] in Serum;Colby Cheese IgE Qn;;ACTIVE;2.09;2.70 +33011-8;Cheese colby Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Colby Cheese IgE Ab RAST class [Presence] in Serum;Colby Cheese IgE RAST Ql;;ACTIVE;2.09;2.58 +33012-6;Cheese provolone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Provolone Cheese IgE Ab [Units/volume] in Serum;Provolone Cheese IgE Qn;;ACTIVE;2.09;2.70 +33013-4;Cheese provolone Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Provolone Cheese IgE Ab RAST class [Presence] in Serum;Provolone Cheese IgE RAST Ql;;ACTIVE;2.09;2.58 +33014-2;Cheese romano Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Romano Cheese IgE Ab [Units/volume] in Serum;Romano Cheese IgE Qn;;ACTIVE;2.09;2.73 +33015-9;Cheese romano Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Romano Cheese IgE Ab RAST class [Presence] in Serum;Romano Cheese IgE RAST Ql;;ACTIVE;2.09;2.73 +33016-7;Methylenedioxyethylamphetamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Serum or Plasma;MDEA SerPl-mCnc;;ACTIVE;2.09;2.73 +33017-5;Parasites;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Parasites [#/area] in Urine sediment by Microscopy low power field;Parasites #/area UrnS LPF;;ACTIVE;2.09;2.73 +33018-3;Protein.monoclonal;ACnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal [Units/volume] in Serum or Plasma by Electrophoresis;M Protein SerPl Elph-aCnc;;DISCOURAGED;2.09;2.69 +3301-9;acetaZOLAMIDE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Acetazolamide [Presence] in Urine;acetaZOLAMIDE Ur Ql;;ACTIVE;1.0;2.56 +33019-1;Pseudocasts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Pseudocasts [#/area] in Urine sediment by Microscopy low power field;Pseudocasts #/area UrnS LPF;;ACTIVE;2.09;2.70 +33020-9;Triple phosphate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Triple phosphate crystals [#/area] in Urine sediment by Microscopy low power field;Tri-Phos Cry #/area UrnS LPF;;ACTIVE;2.09;2.73 +33021-7;Tyrosine crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Tyrosine crystals [#/area] in Urine sediment by Microscopy low power field;Tyrosine Cry #/area UrnS LPF;;ACTIVE;2.09;2.73 +33022-5;Carbon dioxide;PPres;Pt;BldC;Qn;Transcutaneous CO2 monitor;PULM;2;Carbon dioxide [Partial pressure] in Capillary blood by Transcutaneous CO2 monitor;pCO2 BldC TcCo2;;ACTIVE;2.09;2.73 +33023-3;Cells.CD34/100 cells;NFr;Pt;Bld^BPU;Qn;;CELLMARK;1;CD34 cells/100 cells in Blood from Blood product unit;CD34 Cells NFr Bld BPU;;ACTIVE;2.09;2.73 +33024-1;Glucose^30M post 1.2 g/kg lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post 1.2 g/kg lactose PO;Glucose 30M p 1.2 g/kg Lac PO SerPl-mCnc;;ACTIVE;2.09;2.70 +33025-8;Hemoglobin;MCnc;Pt;BldCoV;Qn;Calculated;HEM/BC;1;Hemoglobin [Mass/volume] in Venous cord blood by calculation;Hgb BldCoV Calc-mCnc;;ACTIVE;2.09;2.70 +33026-6;Hemoglobin;MCnc;Pt;BldCoA;Qn;Calculated;HEM/BC;1;Hemoglobin [Mass/volume] in Arterial cord blood by calculation;Hgb BldCoA Calc-mCnc;;ACTIVE;2.09;2.70 +3302-7;acetaZOLAMIDE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetazolamide [Mass/volume] in Urine;acetaZOLAMIDE Ur-mCnc;;ACTIVE;1.0;2.42 +33027-4;Herpes simplex virus+Varicella zoster virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus+Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection;HSV+VZV DNA Spec Ql NAA+probe;;ACTIVE;2.09;2.73 +33028-2;Leukocytes;NCnc;Pt;Bld^BPU;Qn;;HEM/BC;1;Leukocytes [#/volume] in Blood from Blood product unit;WBC # Bld BPU;;ACTIVE;2.09;2.70 +33029-0;Cells.CD3+TCR/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+TCR cells/100 cells in Blood;CD3+TCR Cells NFr Bld;;ACTIVE;2.09;2.73 +33030-8;Cells.CD34;NCnc;Pt;Bld^BPU;Qn;;CELLMARK;1;CD34 cells [#/volume] in Blood from Blood product unit;CD34 Cells # Bld BPU;;ACTIVE;2.09;2.73 +33031-6;Sodium urate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Sodium urate crystals [#/area] in Urine sediment by Microscopy low power field;Na Urate Cry #/area UrnS LPF;;ACTIVE;2.09;2.73 +33032-4;Spermatozoa.progressive;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Progressive [Presence] in Semen;Sperm Prog Smn Ql;;ACTIVE;2.09;2.73 +33033-2;CD45 positive events;Num;Pt;XXX;Qn;;CELLMARK;1;CD45 positive events [#] in Specimen;CD45 pos events Spec;;ACTIVE;2.09;2.70 +33034-0;CD45 negative events;Num;Pt;XXX;Qn;;CELLMARK;1;CD45 negative events [#] in Specimen;CD45 neg events Spec;;ACTIVE;2.09;2.70 +3303-5;acetaZOLAMIDE;MRat;24H;Urine;Qn;;DRUG/TOX;1;Acetazolamide [Mass/time] in 24 hour Urine;acetaZOLAMIDE 24h Ur-mRate;;ACTIVE;1.0;2.42 +33035-7;Reason for lab test;Find;Pt;Semen;Nom;;FERT;1;Reason for lab test in Semen;Reason for lab test Smn;;ACTIVE;2.09;2.73 +33036-5;Fatty acids.very long chain.C26:1;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:1 (Hexacosenoate) [Moles/volume] in Serum or Plasma;VLCFA C26:1 SerPl-sCnc;;ACTIVE;2.09;2.73 +33037-3;Anion gap;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Anion gap in Serum or Plasma;Anion Gap SerPl-sCnc;;ACTIVE;2.09;2.73 +33038-1;Candida sp identified;Prid;Pt;Vag;Nom;Cyto stain;MICRO;1;Candida sp identified in Vaginal fluid by Cyto stain;Candida Vag Cyto;;ACTIVE;2.09;2.21 +33039-9;Fungus identified;Prid;Pt;Body fld;Nom;Fungus stain;MICRO;1;Fungus identified in Body fluid by Fungus stain;Fungus Fld Fungus Stn;;ACTIVE;2.09;2.26 +33040-7;Hypnotics;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Hypnotics [Presence] in Serum or Plasma by Screen method;Hypnotics SerPl Ql Scn;;ACTIVE;2.09;2.56 +33041-5;Hypnotics;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hypnotics [Presence] in Urine by Screen method;Hypnotics Ur Ql Scn;;ACTIVE;2.09;2.73 +33042-3;Interpretation;Imp;24H;Urine;Nom;Immunofixation;CHEM;1;Immunofixation for 24 hour Urine;Interpretation 24h Ur IFE-Imp;;ACTIVE;2.09;2.73 +3304-3;Acetyldigitoxin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetyldigitoxin [Mass/volume] in Serum or Plasma;Acetyldigitoxin SerPl-mCnc;;ACTIVE;1.0;2.42 +33043-1;Ketones;PrThr;24H;Urine;Ord;;CHEM;1;Ketones [Presence] in 24 hour Urine;Ketones 24h Ur Ql;;ACTIVE;2.09;2.56 +33044-9;Pyknosis;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Pyknosis [Presence] in Blood by Light microscopy;Pyknosis Bld Ql Smear;;ACTIVE;2.09;2.73 +33045-6;Respiratory syncytial virus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Respiratory syncytial virus Ag [Presence] in Nose;RSV Ag Nose Ql;;ACTIVE;2.09;2.73 +33046-4;Tranquilizers;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Tranquilizers [Presence] in Serum or Plasma by Screen method;Tranquilizers SerPl Ql Scn;;ACTIVE;2.09;2.73 +33047-2;Tranquilizers;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Tranquilizers [Presence] in Urine by Screen method;Tranquilizers Ur Ql Scn;;ACTIVE;2.09;2.73 +33048-0;Eosin-5-Maleimide binding;PrThr;Pt;Bld;Ord;Flow cytometry;HEM/BC;1;Eosin-5-Maleimide binding [Presence] in Blood by Flow cytometry (FC);EMA Bind Bld Ql FC;;ACTIVE;2.09;2.73 +33049-8;Hypertonic cryohemolysis;NFr;Pt;RBC;Qn;;HEM/BC;1;Hypertonic cryohemolysis of Red Blood Cells;CHT NFr RBC;;ACTIVE;2.09;2.70 +3305-0;Acetylsalicylate;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetylsalicylate [Presence] in Serum or Plasma;Acetylsalicylate SerPl Ql;;ACTIVE;1.0;2.56 +33050-6;Pseudocholinesterase phenotype;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Pseudocholinesterase phenotype [Identifier] in Serum or Plasma;PChE Phenotyp SerPl;;ACTIVE;2.09;2.73 +33051-4;Erythrocytes;PrThr;Pt;Urine;Ord;;UA;1;Erythrocytes [Presence] in Urine;RBC Ur Ql;;ACTIVE;2.09;2.73 +33052-2;Leukocytes;PrThr;Pt;Urine;Ord;;UA;1;Leukocytes [Presence] in Urine;WBC Ur Ql;;ACTIVE;2.09;2.73 +33053-0;Protoporphyrin;SRto;Pt;RBC;Qn;;CHEM;1;Protoporphyrin [Molar ratio] in Red Blood Cells;Protopor RBC-sRto;;ACTIVE;2.09;2.73 +33054-8;BCL2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BCL2 Ag [Presence] in Tissue by Immune stain;BCL2 Ag Tiss Ql ImStn;;ACTIVE;2.09;2.73 +33055-5;Ki-67 nuclear Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;Ki-67 nuclear Ag [Presence] in Tissue by Immune stain;Ki-67 nuc Ag Tiss Ql ImStn;;ACTIVE;2.09;2.73 +33056-3;Sezary cells;PrThr;Pt;XXX;Ord;Microscopy.light;HEM/BC;1;Sezary cells [Presence] in Specimen by Light microscopy;Sezary Cells Spec Ql Micro;;ACTIVE;2.09;2.73 +33057-1;Heinz bodies/100 erythrocytes;NFr;Pt;Bld;Qn;Microscopy.light;HEM/BC;1;Heinz bodies/100 erythrocytes in Blood by Light microscopy;Heinz Bod/100 RBC NFr Bld Smear;;ACTIVE;2.09;2.73 +33058-9;Ketones;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ketones [Mass/volume] in Serum or Plasma;Ketones SerPl-mCnc;;ACTIVE;2.09;2.73 +33059-7;Fluorescence polarization;PrThr;Pt;Amnio fld;Ord;;CHEM;1;Fluorescence polarization [Presence] in Amniotic fluid;FP Amn Ql;;ACTIVE;2.09;2.70 +33060-5;chlordiazePOXIDE+Metabolites;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlordiazePOXIDE+Metabolites [Mass/volume] in Serum or Plasma;Chlordiazep+Metab SerPl-mCnc;;ACTIVE;2.09;2.73 +33061-3;Homocystine^6H post dose methionine - post CFst;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Homocystine [Molar concentration difference] in Serum or Plasma --6 hours post dose methionine - post CFst;Deprecated (Hcys)2 6h p Met-(Hcys)2 - CF;;DEPRECATED;2.09;2.70 +33062-1;Blood group antigens tested for;Prid;Pt;RBC;Nom;;BLDBK;1;Blood group antigens tested for on Red Blood Cells;Ag Tested RBC;;ACTIVE;2.09;2.73 +33063-9;Alkaline phosphatase isoenzymes;CCnc;Pt;Ser/Plas;Qn;Levamisole inhibition;CHEM;1;Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Levamisole inhibition;ALP Isos SerPl Lev Inh-cCnc;;ACTIVE;2.09;2.68 +33064-7;Chromate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chromate [Mass/volume] in Urine;Chromate Ur-mCnc;;ACTIVE;2.09;2.73 +33065-4;Ectopic pregnancy;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Ectopic pregnancy;Ectopic preg;;ACTIVE;2.09;2.48 +33066-2;Last menstrual period;Date;Pt;^Patient;Qn;Estimated from EDD;OB.US;2;Last menstrual period Estimated from EDD;LMP Est from EDD;;ACTIVE;2.09;2.50 +33067-0;Conception date;Date;Pt;^Patient;Qn;Reported;OB.US;2;Conception date;Conception date;;ACTIVE;2.09;2.50 +3306-8;Acetylsalicylate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetylsalicylate [Mass/volume] in Serum or Plasma;Acetylsalicylate SerPl-mCnc;;ACTIVE;1.0;2.42 +33068-8;Thoracic area;Area;Pt;Thorax^Fetus;Qn;US.measured;OB.US;2;Fetal Thoracic area US;Fet Thoracic area US.meas;;ACTIVE;2.09;2.70 +33069-6;Width.translucency;Len;Pt;Neck.soft tissue^Fetus;Qn;US.measured;OB.US;2;Fetal nuchal translucency measured by US;Fet nuchal translucency US.meas;;ACTIVE;2.09;2.73 +33070-4;Diameter.inner orbital;Len;Pt;Orbit.bilateral^Fetus;Qn;US.measured;OB.US;2;Fetal Orbit - bilateral Diameter.inner orbital US;Fet Orbit-Bl IOD US.meas;;ACTIVE;2.09;2.70 +33071-2;Length from T6 to L3;Len;Pt;Spine^Fetus;Qn;US.measured;OB.US;2;Fetal Spine Length from T6 to L3 US;Fet Spine Length from T6 to L3 US.meas;;ACTIVE;2.09;2.70 +33072-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.ASUM 2000;OB.US;2;Gestational age estimated from Abdominal circumference on US by Australian Society of Ultrasound Medicine 2000 method;GA from AC.ASUM 2000;;ACTIVE;2.09;2.70 +33073-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Hansmann 1985;OB.US;2;Gestational age estimated from Abdominal circumference on US by Hansmann 1985 method;GA from AC.Hansmann85;;ACTIVE;2.09;2.70 +33074-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Lessoway 1998;OB.US;2;Gestational age estimated from Abdominal circumference on US by Lessoway 1998 method;GA from AC.Lessoway98;;ACTIVE;2.09;2.70 +33075-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Merz 1988;OB.US;2;Gestational age estimated from Abdominal circumference on US by Merz 1988 method;GA from AC.Merz 88;;ACTIVE;2.09;2.70 +3307-6;Alfentanil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Alfentanil [Mass/volume] in Serum or Plasma;Alfentanil SerPl-mCnc;;ACTIVE;1.0;2.42 +33076-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Shinozuka 1996;OB.US;2;Gestational age estimated from Abdominal circumference on US by Shinozuka 1996 method;GA from AC.Shinozuka96;;ACTIVE;2.09;2.70 +33077-9;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from APAD.Lessoway 1998;OB.US;2;Gestational age estimated from Anterior-posterior diameter of the abdomen by method of Lessoway 1998 (US);GA from APAD.Lessoway98;;ACTIVE;2.09;2.70 +33078-7;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from AXT.Shinozuka 1996;OB.US;2;Gestational age estimated from AXT by method of Shinozuka 1996 (US);GA from AXT.Shinozuka96;;ACTIVE;2.09;2.70 +33079-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.ASUM 1989;OB.US;2;Gestational age estimated from Biparietal diameter on US by Australian Society of Ultrasound Medicine 1989 method;GA from BPD.ASUM89;;ACTIVE;2.09;2.70 +33080-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Lessoway 1998;OB.US;2;Gestational age estimated from Biparietal diameter on US by Lessoway 1998 method;GA from BPD.Lessoway98;;ACTIVE;2.09;2.70 +33081-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Merz 1988;OB.US;2;Gestational age estimated from Biparietal diameter on US by Merz 1988 method;GA from BPD.Merz88;;ACTIVE;2.09;2.70 +33082-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Osaka 1989;OB.US;2;Gestational age estimated from Biparietal diameter on US by Osaka 1989 method;GA from BPD.Osaka89;;ACTIVE;2.09;2.70 +33083-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Rempen 1991;OB.US;2;Gestational age estimated from Biparietal diameter on US by Rempen 1991 method;GA from BPD.Rempen91;;ACTIVE;2.09;2.70 +3308-4;Alphaprodine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Alphaprodine [Mass/volume] in Serum or Plasma;Alphaprodine SerPl-mCnc;;ACTIVE;1.0;2.42 +33084-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Shinozuka 1996;OB.US;2;Gestational age estimated from Biparietal diameter on US by Shinozuka 1996 method;GA from BPD.Shinozuka96;;ACTIVE;2.09;2.70 +33085-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Tokyo 1986;OB.US;2;Gestational age estimated from Biparietal diameter on US by Tokyo 1986 method;GA from BPD.Tokyo86;;ACTIVE;2.09;2.70 +33086-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from O-I BPD.Chitty 1997;OB.US;2;Gestational age estimated from Outer-Inner Biparietal diameter on US by Chitty 1997 method;GA from O-I BPD.Chitty 1997;;ACTIVE;2.09;2.70 +33087-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from O-O BPD.Chitty 1997;OB.US;2;Gestational age estimated from Outer-Outer Biparietal diameter on US by Chitty 1997 method;GA from O-O BPD.Chitty 1997;;ACTIVE;2.09;2.70 +33088-6;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from clavicle length.Yarkoni 1985;OB.US;2;Gestational age estimated from clavicle length by method of Yarkoni 1985 (US);GA from CL.Yarkoni85;;ACTIVE;2.09;2.70 +33089-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.ASUM 1991;OB.US;2;Gestational age estimated from Crown rump length on US by Australian Society of Ultrasound Medicine 1991 method;GA from CRL.ASUM91;;ACTIVE;2.09;2.70 +33090-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.ASUM 2000;OB.US;2;Gestational age estimated from Crown rump length on US by Australian Society of Ultrasound Medicine 2000 method;GA from CRL.ASUM00;;ACTIVE;2.09;2.70 +33091-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Daya 1993;OB.US;2;Gestational age estimated from Crown rump length on US by Daya 1993 method;GA from CRL.daya93;;ACTIVE;2.09;2.70 +3309-2;Alphaprodine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Alphaprodine [Presence] in Urine;Alphaprodine Ur Ql;;ACTIVE;1.0;2.56 +33092-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Jeanty 1982;OB.US;2;Gestational age estimated from Crown rump length on US by Jeanty 1982 method;GA from CRL.Jeanty82;;ACTIVE;2.09;2.70 +33093-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Osaka 1989;OB.US;2;Gestational age estimated from Crown rump length on US by Osaka 1989 method;GA from CRL.Osaka89;;ACTIVE;2.09;2.70 +33094-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Rempen 1991;OB.US;2;Gestational age estimated from Crown rump length on US by Rempen 1991 method;GA from CRL.Rempen91;;ACTIVE;2.09;2.70 +33095-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Shinozuka 1996;OB.US;2;Gestational age estimated from Crown rump length on US by Shinozuka 1996 method;GA from CRL.Shinozuka96;;ACTIVE;2.09;2.70 +33096-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Tokyo 1986;OB.US;2;Gestational age estimated from Crown rump length on US by Tokyo 1986 method;GA from CRL.Tokyo86;;ACTIVE;2.09;2.70 +33097-7;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from fibula length.Jeanty 1983;OB.US;2;Gestational age estimated from Fibula length by method of Jeanty 1983 (US);GA from Fib Length.Jeanty83;;ACTIVE;2.09;2.70 +33098-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Chitty 1997;OB.US;2;Gestational age estimated from Femur length on US by Chitty 1997 method;GA from FL.Chitty 1997;;ACTIVE;2.09;2.70 +33099-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Jeanty 1982;OB.US;2;Gestational age estimated from Femur length on US by Jeanty 1982 method;GA from FL.Jeanty82;;ACTIVE;2.09;2.70 +33-1;Ampicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility] by Disk diffusion (KB);Ampicillin+Sulbac Islt KB;;ACTIVE;1.0;2.73 +3310-0;Alphaprodine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alphaprodine [Mass/volume] in Urine;Alphaprodine Ur-mCnc;;ACTIVE;1.0;2.42 +33100-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Lessoway 1998;OB.US;2;Gestational age estimated from Femur length on US by Lessoway 1998 method;GA from FL.lessoway98;;ACTIVE;2.09;2.70 +33101-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Osaka 1989;OB.US;2;Gestational age estimated from Femur length on US by Osaka 1989 method;GA from FL.Osaka89;;ACTIVE;2.09;2.70 +33102-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Shinozuka 1996;OB.US;2;Gestational age estimated from Femur length on US by Shinozuka 1996 method;GA from FL.Shinozuka96;;ACTIVE;2.09;2.70 +33103-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Tokyo 1986;OB.US;2;Gestational age estimated from Femur length on US by Tokyo 1986 method;GA from FL.Tokyo86;;ACTIVE;2.09;2.70 +33104-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSD.Daya 1991;OB.US;2;Gestational age estimated from Gestational sac diameter on US by Daya 1991 method;GA from GSD.Daya91;;ACTIVE;2.09;2.70 +33105-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSL.Hansmann 1979;OB.US;2;Gestational age estimated from Gestational sac length on US by Hansmann 1979 method;GA from GSL.Hansmann 1979;;ACTIVE;2.09;2.70 +33106-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSD.Hansmann 1982;OB.US;2;Gestational age estimated from Gestational sac diameter on US by Hansmann 1982 method;GA from GSD.Hansmann82;;ACTIVE;2.09;2.70 +33107-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSL.Nyberg 1992;OB.US;2;Gestational age estimated from Gestational sac length on US by Nyberg 1992 method;GA from GSL.Nyberg 1992;;ACTIVE;2.09;2.70 +33108-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from GSD.Tokyo 1986;OB.US;2;Gestational age estimated from Gestational sac diameter on US by Tokyo 1986 method;GA from GSD.Tokyo86;;ACTIVE;2.09;2.70 +33109-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.ASUM 2000;OB.US;2;Gestational age estimated from Head circumference on US by Australian Society of Ultrasound Medicine 2000 method;GA from HC.ASUM00;;ACTIVE;2.09;2.70 +33110-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC measured.Chitty 1997;OB.US;2;Gestational age estimated from Head circumference measured on US by Chitty 1997 method;GA from HC meas.Chitty97;;ACTIVE;2.09;2.70 +33111-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC derived.Chitty 1997;OB.US;2;Gestational age estimated from Head circumference derived on US by Chitty 1997 method;GA from HC derived.Chitty 1997;;ACTIVE;2.09;2.70 +33112-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Hansmann 1985;OB.US;2;Gestational age estimated from Head circumference on US by Hansmann 1985 method;GA from HC.Hansmann85;;ACTIVE;2.09;2.70 +33113-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Jeanty 1982;OB.US;2;Gestational age estimated from Head circumference on US by Jeanty 1982 method;GA from HC.Jeantyy82;;ACTIVE;2.09;2.70 +33114-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Lessoway 1998;OB.US;2;Gestational age estimated from Head circumference on US by Lessoway 1998 method;GA from HC.Lessoway98;;ACTIVE;2.09;2.70 +33115-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Merz 1988;OB.US;2;Gestational age estimated from Head circumference on US by Merz 1988 method;GA from HC.Merz88;;ACTIVE;2.09;2.70 +33116-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HL.ASUM 2000;OB.US;2;Gestational age estimated from Humerus length on US by Australian Society of Ultrasound Medicine 2000 method;GA from HL.ASUM00;;ACTIVE;2.09;2.70 +33117-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HL.Osaka 1989;OB.US;2;Gestational age estimated from Humerus length on US by Osaka 1989 method;GA from HL.Osaka89;;ACTIVE;2.09;2.70 +3311-8;Alphaprodine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Alphaprodine [Mass/time] in 24 hour Urine;Alphaprodine 24h Ur-mRate;;ACTIVE;1.0;2.42 +33118-1;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from length of vertebra.Tokyo 1986;OB.US;2;Gestational age estimated from length of vertebra by method of Tokyo 1986 (US);GA from LV.Tokyo86;;ACTIVE;2.09;2.70 +33119-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from OFD.ASUM 2000;OB.US;2;Gestational age estimated from Occipital-frontal diameter on US by Australian Society of Ultrasound Medicine 2000 method;GA from OFD.ASUM00;;ACTIVE;2.09;2.70 +33120-7;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from OFD.Hansmann 1986;OB.US;2;Gestational age estimated from Occipital-frontal diameter on US by Hansmann 1986 method;GA from OFD.Hansmann86;;ACTIVE;2.09;2.70 +33121-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from OFD.Lessoway 1998;OB.US;2;Gestational age estimated from Occipital-frontal diameter on US by Lessoway 1998 method;GA from OFD.Lessoway98;;ACTIVE;2.09;2.70 +33122-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from IOD.Mayden 1982;OB.US;2;Gestational age estimated from Inter ocular distance on US by Mayden 1982 method;GA from IOD.Mayden82;;ACTIVE;2.09;2.70 +33123-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from IOD.Trout 1994;OB.US;2;Gestational age estimated from Inter ocular distance on US by Trout 1994 method;GA from IOD.Trout94;;ACTIVE;2.09;2.70 +33124-9;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from OOD.Mayden 1982;OB.US;2;Gestational age estimated from Outer orbital distance on US by Mayden 1982 method;GA from OOD.Mayden82;;ACTIVE;2.09;2.70 +33125-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from OOD.Trout 1994;OB.US;2;Gestational age estimated from Outer orbital distance on US by Trout 1994 method;GA from OOD.Trout94;;ACTIVE;2.09;2.70 +3312-6;ALPRAZolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Serum or Plasma;Alpraz SerPl-mCnc;;ACTIVE;1.0;2.73 +33126-4;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from radius length.Jeanty 1983;OB.US;2;Gestational age estimated from Radius length by method of Jeanty 1983 (US);GA from rad len.Jeanty83;;ACTIVE;2.09;2.70 +33127-2;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from spine length.Tokyo 1989;OB.US;2;Gestational age estimated from Spine length by method of Tokyo 1989 (US);GA from SL.Tokyo89;;ACTIVE;2.09;2.70 +33128-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TAD.Eriksen 1985;OB.US;2;Gestational age estimated from Transverse abdominal diameter on US by Eriksen 1985 method;GA from TAD.Eriksen85;;ACTIVE;2.09;2.70 +33129-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TAD.Hansmann 1979;OB.US;2;Gestational age estimated from Transverse abdominal diameter on US by Hansmann 1979 method;GA from TAD.Hansmann79;;ACTIVE;2.09;2.70 +33130-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TAD.Tokyo 1986;OB.US;2;Gestational age estimated from Transverse abdominal diameter on US by Tokyo 1986 method;GA from TAD.Tokyo86;;ACTIVE;2.09;2.70 +33131-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TC.Chitkara 1987;OB.US;2;Gestational age estimated from Thoracic circumference on US by Chitkara 1987 method;GA from TC.Chitkara87;;ACTIVE;2.09;2.70 +33132-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TCD.Chitty 1994;OB.US;2;Gestational age estimated from Transverse cerebral diameter on US by Chitty 1994 method;GA from TCD.Chitty94;;ACTIVE;2.09;2.70 +33133-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TCD.Goldstein 1987;OB.US;2;Gestational age estimated from Transverse cerebral diameter on US by Goldstein 1987 method;GA from TCD.Goldstein87;;ACTIVE;2.09;2.70 +3313-4;ALPRAZolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Urine;Alpraz Ur-mCnc;;ACTIVE;1.0;2.73 +33134-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TCD.Hill 1990;OB.US;2;Gestational age estimated from Transverse cerebral diameter on US by Hill 1990 method;GA from TCD.Hill90;;ACTIVE;2.09;2.70 +33135-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TC.Nimrod 1986;OB.US;2;Gestational age estimated from Thoracic circumference on US by Nimrod 1986 method;GA from TC.Nimrod86;;ACTIVE;2.09;2.70 +33136-3;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TTD.Hansmann 1985;OB.US;2;Gestational age estimated from Transverse abdominal diameter on US by Hansmann 1985 method;GA from TTD.Hansmann85;;ACTIVE;2.09;2.70 +33137-1;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from TTD.Lessoway 1998;OB.US;2;Gestational age estimated from Transverse abdominal diameter on US by Lessoway 1998 method;GA from TTD.lessoway98;;ACTIVE;2.09;2.70 +33138-9;Gestational age;Time;Pt;^Fetus;Qn;US.estimated from FTA.Osaka 1989;OB.US;2;Gestational age estimated from Fetal trunk area by method of Osaka 1989 (US);GA from FTA.Osaka89;;ACTIVE;2.09;2.70 +33139-7;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from BPD&TTD.Hansmann 1986;OB.US;2;Fetal Body weight estimated from Biparietal diameter and Transverse thoracic diameter on US by Hansmann 1986 method;EFW from BPD&TTD.Hansmann86;;ACTIVE;2.09;2.70 +33140-5;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from BPD&FTA&FL.Osaka 1990;OB.US;2;Fetal Body weight estimated from Biparietal diameter and Fetal trunk area and Femur length on US by Osaka 1990 method;EFW from BPD&FTA&FL.Osaka90;;ACTIVE;2.09;2.70 +33141-3;Body weight;Mass;Pt;^Fetus;Qn;US.estimated from EFW1.Shinozuka 1996;OB.US;2;Fetal weight estimated by method of Shinozuka formula 1 1996 (US);Fet Weight from Shinozuka96 1;;ACTIVE;2.09;2.70 +3314-2;Alprenolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Alprenolol [Mass/volume] in Serum or Plasma;Alprenolol SerPl-mCnc;;ACTIVE;1.0;2.42 +33142-1;Body weight;Mass;Pt;^Fetus;Qn;US.estimated from EFW2.Shinozuka 1996;OB.US;2;Fetal weight estimated by method of Shinozuka formula 2 1996 (US);Fet Weight from Shinozuka96 2;;ACTIVE;2.09;2.70 +33143-9;Body weight;Mass;Pt;^Fetus;Qn;US.estimated from EFW3.Shinozuka 1996;OB.US;2;Fetal weight estimated by method of Shinozuka formula 3 1996 (US);Fet Weight from Shinozuka96 3;;ACTIVE;2.09;2.70 +33144-7;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from Tokyo 1987;OB.US;2;Fetal Body weight estimated on US by Tokyo 1987 method;EFW by Tokyo87;;ACTIVE;2.09;2.70 +33145-4;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.estimated from ASUM 2000;OB.US;2;Fetal Abdomen Circumference estimated from gestational age by method of Australian Society of Ultrasound Medicine 2000 (US);Fet Abd Circum from GA.ASUM00;;ACTIVE;2.09;2.70 +33146-2;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.estimated from Hadlock 1984;OB.US;2;Fetal Abdomen Circumference estimated from gestational age by method of Hadlock 1984 (US);Fet Abd Circum from GA.Hadlock 1984;;ACTIVE;2.09;2.70 +33147-0;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.measured from Chitty 1994;OB.US;2;Fetal Abdomen Circumference measured by method of Chitty 1994 (US);Fet Abd Circum by Chitty94;;ACTIVE;2.09;2.70 +33148-8;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.estimated from Merz 1988;OB.US;2;Fetal Abdomen Circumference estimated from gestational age by method of Merz 1988 (US);Fet Abd Circum from GA.Merz88;;ACTIVE;2.09;2.70 +33149-6;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.estimated from Shinozuka 1996;OB.US;2;Fetal Abdomen Circumference estimated from gestational age by method of Shinozuka 1996 (US);Fet Abd Circum from GA.Shinozuka96;;ACTIVE;2.09;2.70 +33150-4;Diameter product;Len;Pt;Abdomen^Fetus;Qn;US.estimated from Shinozuka 1996;OB.US;2;Fetal Abdomen Diameter product estimated from gestational age by method of Shinozuka 1996 (US);Fet Abd Diam prod from GA.Shinozuka96;;ACTIVE;2.09;2.70 +33151-2;Diameter.biparietal;Len;Pt;Head^Fetus;Qn;US.estimated from ASUM 2000;OB.US;2;Fetal Head Diameter.biparietal estimated from gestational age by method of Australian Society of Ultrasound Medicine 2000 (US);Fet BPD from GA.ASUM00;;ACTIVE;2.09;2.70 +33152-0;Diameter.biparietal outer to outer;Len;Pt;Head^Fetus;Qn;US.estimated from Chitty 1994;OB.US;2;Fetal Head Diameter.biparietal outer to outer estimated from gestational age by method of Chitty 1994 (US);Fet BPD O-O from GA.Chitty94;;ACTIVE;2.09;2.70 +33153-8;Diameter.biparietal;Len;Pt;Head^Fetus;Qn;US.estimated from Jeanty 1982;OB.US;2;Fetal Head Diameter.biparietal estimated from gestational age by method of Jeanty 1982 (US);Fet BPD from GA.Jeanty82;;ACTIVE;2.09;2.70 +33154-6;Diameter.biparietal;Len;Pt;Head^Fetus;Qn;US.estimated from Merz 1988;OB.US;2;Fetal Head Diameter.biparietal estimated from gestational age by method of Merz 1988 (US);Fet BPD from GA.Merz88;;ACTIVE;2.09;2.70 +33155-3;Diameter.biparietal;Len;Pt;Head^Fetus;Qn;US.estimated from Rempen 1991;OB.US;2;Fetal Head Diameter.biparietal estimated from gestational age by method of Rempen 1991 (US);Fet BPD from GA.Rempen91;;ACTIVE;2.09;2.70 +33156-1;Diameter.biparietal;Len;Pt;Head^Fetus;Qn;US.estimated from Shinozuka 1996;OB.US;2;Fetal Head Diameter.biparietal estimated from gestational age by method of Shinozuka 1996 (US);Fet BPD from GA.Shinozuka96;;ACTIVE;2.09;2.70 +33157-9;Diameter.biparietal/Diameter.occipital;LenRto;Pt;Head^Fetus;Qn;US.estimated from Chitty 1994;OB.US;2;Fetal Head Diameter.biparietal/Diameter.occipital estimated from gestational age by method of Chitty 1994 (US);Fet BPD/OFD from GA.Chitty94;;ACTIVE;2.09;2.70 +33158-7;Diameter.biparietal/Diameter.occipital;LenRto;Pt;Head^Fetus;Qn;US.estimated from Hadlock 1981;OB.US;2;Fetal Head Diameter.biparietal/Diameter.occipital estimated from gestational age by method of Hadlock 1981 (US);Fet BPD/OFD from GA.Hadlock 1981;;ACTIVE;2.09;2.70 +3315-9;Alprenolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Alprenolol [Presence] in Urine;Alprenolol Ur Ql;;ACTIVE;1.0;2.56 +33159-5;Length.crown rump;Len;Pt;^Fetus;Qn;US.estimated from ASUM 2000;OB.US;2;Fetal Crown Rump length estimated from gestational age by method of Australian Society of Ultrasound Medicine 2000 (US);Fet CRL from GA.ASUM00;;ACTIVE;2.09;2.70 +33160-3;Length.crown rump;Len;Pt;^Fetus;Qn;US.estimated from Rempen 1991;OB.US;2;Fetal Crown Rump length estimated from gestational age by method of Rempen 1991 (US);Fet CRL from GA.Rempen91;;ACTIVE;2.09;2.70 +33161-1;Length.crown rump;Len;Pt;^Fetus;Qn;US.estimated from Shinozuka 1996;OB.US;2;Fetal Crown Rump length estimated from gestational age by method of Shinozuka 1996 (US);Fet CRL from GA.Shinozuka96;;ACTIVE;2.09;2.70 +33162-9;Body weight;Mass;Pt;^Fetus;Qn;US+Estimated from Hadlock 1991;OB.US;2;Fetal Body weight US+Estimated from Hadlock 1991;EFW from Hadlock 1991;;ACTIVE;2.09;2.70 +33163-7;Body weight;Mass;Pt;^Fetus;Qn;US.estimated from Hansmann 1986;OB.US;2;Fetal weight estimated from gestational age by method of Hansmann 1986 (US);Fet Weight from GA.Hansmann86;;ACTIVE;2.09;2.70 +33164-5;Long axis;Len;Pt;Fibula.diaphysis^Fetus;Qn;US.estimated from Jeanty 1983;OB.US;2;Fetal Fibula diaphysis [Length] estimated from gestational age by method of Jeanty 1983 (US);Fet Fibula Length from GA.Jeanty83;;ACTIVE;2.09;2.70 +33165-2;Long axis;Len;Pt;Femur.diaphysis^Fetus;Qn;US.estimated from ASUM 2000;OB.US;2;Fetal Femur diaphysis [Length] estimated from gestational age by method of Australian Society of Ultrasound Medicine 2000 (US);Fet Femur Length from GA.ASUM00;;ACTIVE;2.09;2.70 +33166-0;Long axis;Len;Pt;Femur.diaphysis^Fetus;Qn;US.estimated from Hadlock 1984;OB.US;2;Fetal Femur diaphysis [Length] estimated from gestational age by method of Hadlock 1984 (US);Fet Femur Length from GA.Hadlock 1984;;ACTIVE;2.09;2.70 +3316-7;Alprenolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alprenolol [Mass/volume] in Urine;Alprenolol Ur-mCnc;;ACTIVE;1.0;2.42 +33167-8;Long axis;Len;Pt;Femur.diaphysis^Fetus;Qn;US.estimated from Chitty 1994;OB.US;2;Fetal Femur diaphysis [Length] estimated from gestational age by method of Chitty 1994 (US);Fet Femur Length from GA.Chitty94;;ACTIVE;2.09;2.70 +33168-6;Long axis;Len;Pt;Femur.diaphysis^Fetus;Qn;US.estimated from Jeanty 1982;OB.US;2;Fetal Femur diaphysis [Length] estimated from gestational age by method of Jeanty 1982 (US);Fet Femur Length from GA.Jeanty82;;ACTIVE;2.09;2.70 +33169-4;Long axis;Len;Pt;Femur.diaphysis^Fetus;Qn;US.estimated from Merz 1988;OB.US;2;Fetal Femur diaphysis [Length] estimated from gestational age by method of Merz 1988 (US);Fet Femur Length from GA.Merz88;;ACTIVE;2.09;2.70 +33170-2;Long axis;Len;Pt;Femur.diaphysis^Fetus;Qn;US.estimated from Shinozuka 1996;OB.US;2;Fetal Femur diaphysis [Length] estimated from gestational age by method of Shinozuka 1996 (US);Fet Femur Length from GA.Shinozuka96;;ACTIVE;2.09;2.70 +33171-0;Diameter;Len;Pt;Gestational sac;Qn;US.estimated from Rempen 1991;OB.US;2;Gestational sac Diameter estimated from gestational age by method of Rempen 1991 (US);GS Diam from GA.Rempen91;;ACTIVE;2.09;2.70 +33172-8;Perimeter;Len;Pt;Head^Fetus;Qn;US.estimated from ASUM 2000;OB.US;2;Fetal Head Circumference estimated from gestational age by method of Australian Society of Ultrasound Medicine 2000 (US);Fet Head Circum from GA.ASUM00;;ACTIVE;2.09;2.70 +33173-6;Perimeter;Len;Pt;Head^Fetus;Qn;US.estimated from Hadlock 1984;OB.US;2;Fetal Head Circumference estimated from gestational age by method of Hadlock 1984 (US);Fet Head Circum from GA.Hadlock 1984;;ACTIVE;2.09;2.70 +33174-4;Perimeter;Len;Pt;Head^Fetus;Qn;US.estimated from Chitty 1994;OB.US;2;Fetal Head Circumference estimated from gestational age by method of Chitty 1994 (US);Fet Head Circum from GA.Chitty94;;ACTIVE;2.09;2.70 +3317-5;Amantadine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amantadine [Mass/volume] in Serum or Plasma;Amantadine SerPl-mCnc;;ACTIVE;1.0;2.73 +33175-1;Perimeter;Len;Pt;Head^Fetus;Qn;US.estimated from Jeanty 1982;OB.US;2;Fetal Head Circumference estimated from gestational age by method of Jeanty 1982 (US);Fet Head Circum from GA.Jeanty82;;ACTIVE;2.09;2.70 +33176-9;Perimeter;Len;Pt;Head^Fetus;Qn;US.estimated from Merz 1988;OB.US;2;Fetal Head Circumference estimated from gestational age by method of Merz 1988 (US);Fet Head Circum from GA.Merz88;;ACTIVE;2.09;2.70 +33177-7;Long axis;Len;Pt;Humerus.diaphysis^Fetus;Qn;US.estimated from ASUM 2000;OB.US;2;Fetal Humerus diaphysis [Length] estimated from gestational age by method of Australian Society of Ultrasound Medicine 2000 (US);Fet Humerus Length from GA.ASUM00;;ACTIVE;2.09;2.70 +33178-5;Occipital frontal diameter;Len;Pt;Head^Fetus;Qn;US.estimated from ASUM 2000;OB.US;2;Occipital frontal diameter estimated from gestational age by method of Australian Society of Ultrasound Medicine 2000 (US);OFD from GA.ASUM00;;ACTIVE;2.09;2.70 +33179-3;Occipital frontal diameter;Len;Pt;Head^Fetus;Qn;US.estimated from Chitty 1994;OB.US;2;Occipital frontal diameter estimated from gestational age by method of Chitty 1994 (US);OFD from GA.Chitty94;;ACTIVE;2.09;2.70 +33180-1;Long axis;Len;Pt;Radius.diaphysis^Fetus;Qn;US.estimated from Jeanty 1983;OB.US;2;Fetal Radius diaphysis [Length] estimated from gestational age by method of Jeanty 1983 (US);Fet Radius Length from GA.Jeanty83;;ACTIVE;2.09;2.70 +33181-9;Diameter.transverse;Len;Pt;Cerebellum^Fetus;Qn;US.estimated from Goldstein 1987;OB.US;2;Fetal Cerebellum Diameter transverse estimated from gestational age by method of Goldstein 1987 (US);Fetal TCD from GA.Goldstein87;;ACTIVE;2.09;2.70 +33182-7;Head circumference/Abdominal circumference;LenRto;Pt;^Fetus;Qn;US.estimated from Campbell 1997;OB.US;2;Deprecated Head circumference/Abdominal circumference estimated from gestational age by method of Campbell 1997 (US);Deprecated HC/AC from GA.Campbell97;;DEPRECATED;2.09;2.54 +3318-3;Amdinocillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amdinocillin [Mass/volume] in Serum or Plasma;Amdinocillin SerPl-mCnc;;ACTIVE;1.0;2.42 +33183-5;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Campbell 1991;OB.US;2;Deprecated Fetal body weight growth percentile estimated from gestational age by method of Campbell 1991 (US);Deprecated FWP from GA.Campbell91;;DEPRECATED;2.09;2.70 +33184-3;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Williams 1982;OB.US;2;Fetal body weight growth percentile estimated from gestational age by method of Williams 1982 (US);FWP from GA.Williams82;;ACTIVE;2.09;2.70 +33185-0;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Alexander 1996;OB.US;2;Fetal body weight growth percentile estimated from gestational age by method of Alexander 1996 (US);FWP from GA.Alexander96;;ACTIVE;2.09;2.70 +33186-8;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Arbuckle 1993 male singleton;OB.US;2;Fetal body weight growth percentile by method of Arbuckle 1993 male singleton (US);FWP by Arbuckle93 Male Singleton;;ACTIVE;2.09;2.70 +33187-6;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Arbuckle 1993 female singleton;OB.US;2;Fetal body weight growth percentile by method of Arbuckle 1993 female singleton (US);FWP by Arbuckle93 Female Singleton;;ACTIVE;2.09;2.70 +33188-4;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Arbuckle 1993 female twins;OB.US;2;Fetal body weight growth percentile by method of Arbuckle 1993 female twins (US);FWP by Arbuckle93 Female Twins;;ACTIVE;2.09;2.70 +33189-2;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Brenner 1976;OB.US;2;Fetal body weight growth percentile estimated from gestational age by method of Brenner 1976 (US);FWP from GA.Brenner 1976;;ACTIVE;2.09;2.70 +331-9;Mezlocillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Mezlocillin [Susceptibility] by Minimum inhibitory concentration (MIC);Mezlocillin Islt MIC;;ACTIVE;1.0;2.73 +33190-0;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Hadlock 1985;OB.US;2;Fetal body weight growth percentile estimated from gestational age by method of Hadlock 1985 (US);FWP from GA.Hadlock85;;ACTIVE;2.09;2.70 +3319-1;Amikacin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma --peak;Amikacin Peak SerPl-mCnc;;ACTIVE;1.0;2.73 +33191-8;Diameter product;Area;Pt;Thorax^Fetus;Qn;US.derived;OB.US;2;Fetal Thorax Diameter product derived by US;Fet Thorax Area Diam prod der US;;ACTIVE;2.09;2.70 +33192-6;Volume;Vol;Pt;Uterus;Qn;US.derived.LWT;OB.US;2;Uterus Volume derived from length, width and thickness (US);Uterus Volume from LWT;;ACTIVE;2.09;2.70 +33193-4;Viable cells/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Viable cells/100 cells in Blood;Viable cells NFr Bld;;ACTIVE;2.09;2.73 +33194-2;Viable cells/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Viable cells/100 cells in Specimen;Viable cells NFr Spec;;ACTIVE;2.09;2.73 +33195-9;Viable cells/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Viable cells/100 cells in Bone marrow;Viable cells NFr Mar;;ACTIVE;2.09;2.70 +33196-7;Width.posterior horn;Len;Pt;Head.lateral cerebral ventricles^Fetus;Qn;US.measured;OB.US;2;Fetal Lateral cerebral ventricles Posterior horn width US;Fet LV PH width US.meas;;ACTIVE;2.09;2.70 +33197-5;Width.anterior horn;Len;Pt;Head.lateral cerebral ventricles^Fetus;Qn;US.measured;OB.US;2;Fetal Lateral cerebral ventricles Anterior horn width US;Fet LV AH width US.meas;;ACTIVE;2.09;2.70 +33198-3;Diameter.biparietal;Len;Pt;Head^Fetus;Qn;US.estimated from Hadlock 1984;OB.US;2;Fetal Head Diameter.biparietal estimated from gestational age by method of Hadlock 1984 (US);Fet BPD from GA.Hadlock 1984;;ACTIVE;2.09;2.70 +33199-1;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US.estimated from Arbuckle 1993 male twins;OB.US;2;Fetal body weight growth percentile by method of Arbuckle 1993 male twins (US);FWP by Arbuckle93 Male Twins;;ACTIVE;2.09;2.70 +33200-7;Amyloid beta 42 peptide;MCnc;Pt;Plas;Qn;;CHEM;1;Amyloid beta 42 peptide [Mass/volume] in Plasma;AL beta42 Plas-mCnc;;ACTIVE;2.09;2.42 +33201-5;Cells.CD11c/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD11c cells/100 cells in Tissue;CD11c Cells NFr Tiss;;ACTIVE;2.09;2.34 +33202-3;Cells.CD11c/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD11c cells/100 cells in Bone marrow;CD11c Cells NFr Mar;;ACTIVE;2.09;2.34 +33203-1;Amyloid beta 42 peptide;MCnc;Pt;CSF;Qn;;CHEM;1;Amyloid beta 42 peptide [Mass/volume] in Cerebral spinal fluid;AL beta42 CSF-mCnc;;ACTIVE;2.09;2.73 +33204-9;Troponin T.cardiac;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Troponin T.cardiac [Presence] in Serum or Plasma;Troponin T SerPl Ql;;ACTIVE;2.09;2.73 +33205-6;Cells.CD235a/100 cells;NFr;Pt;Periton fld;Qn;;CELLMARK;1;CD235a cells/100 cells in Peritoneal fluid;CD235a Cells NFr Prt;;ACTIVE;2.09;2.70 +33206-4;Cells.CD235a/100 cells;NFr;Pt;Plr fld;Qn;;CELLMARK;1;CD235a cells/100 cells in Pleural fluid;CD235a Cells NFr Plr;;ACTIVE;2.09;2.70 +33207-2;Cells.CD235a/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD235a cells/100 cells in Tissue;CD235a Cells NFr Tiss;;ACTIVE;2.09;2.70 +33208-0;Cells.CD235a/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD235a cells/100 cells in Bone marrow;CD235a Cells NFr Mar;;ACTIVE;2.09;2.70 +3320-9;Amikacin^random;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma --random;Amikacin Rand SerPl-mCnc;;DISCOURAGED;1.0;2.73 +33209-8;Cells.CD235a/100 cells;NFr;Pt;Asp;Qn;;CELLMARK;1;CD235a cells/100 cells in Aspirate;CD235a Cells NFr Aspirate;;ACTIVE;2.09;2.70 +33210-6;Transferrin receptor.soluble;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin receptor.soluble [Moles/volume] in Serum or Plasma;sTfR SerPl-sCnc;;ACTIVE;2.09;2.73 +33211-4;Interleukin 8;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 8 [Mass/volume] in Serum or Plasma;Il8 SerPl-mCnc;;ACTIVE;2.09;2.73 +33212-2;N-acetyl-L-aspartate;MCnc;Pt;Body fld;Qn;;CHEM;1;N-acetyl-L-aspartate [Mass/volume] in Body fluid;N-Ac-L-Asp Fld-mCnc;;ACTIVE;2.09;2.70 +33213-0;Glycine plas/Glycine CSF;RelSCnc;Pt;Plas+CSF;Qn;;CHEM;1;Glycine in plasma/Glycine in CSF;Glycine Plas/CSF;;ACTIVE;2.09;2.70 +33214-8;Taurine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Taurine [Moles/volume] in Vitreous fluid;Taurine Vitf-sCnc;;ACTIVE;2.09;2.70 +33215-5;Neutrophils.agranular;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Neutrophils.agranular [Presence] in Blood by Light microscopy;Agran Neuts Bld Ql Smear;;ACTIVE;2.09;2.73 +33216-3;Platelets.agranular;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Platelets agranular [Presence] in Blood by Light microscopy;Agran Platelets Bld Ql Smear;;ACTIVE;2.09;2.73 +3321-7;Amikacin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma --trough;Amikacin Trough SerPl-mCnc;;ACTIVE;1.0;2.73 +33217-1;Spermatozoa.agglutinated;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Agglutinated [Presence] in Semen;Sperm Agglutinated Smn Ql;;ACTIVE;2.09;2.73 +33218-9;Bacteria;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Bacteria [#/area] in Urine sediment by Automated count;Bacteria #/area UrnS Auto;;ACTIVE;2.09;2.73 +33219-7;Epithelial cells.squamous;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Epithelial cells.squamous [#/area] in Urine sediment by Automated count;Squamous #/area UrnS Auto;;ACTIVE;2.09;2.73 +33220-5;Transitional cells;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Transitional cells [#/area] in Urine by Computer assisted method;Trans Cells #/area Ur Comp Assist;;ACTIVE;2.09;2.73 +33221-3;Epithelial cells.renal;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Epithelial cells.renal [#/area] in Urine by Computer assisted method;Renal Epi Cells #/area Ur Comp Assist;;ACTIVE;2.09;2.73 +33222-1;Oval fat bodies (globules);Naric;Pt;Urine sed;Qn;Automated count;UA;1;Oval fat bodies (globules) [#/area] in Urine sediment by Automated count;Oval fat bodies #/area UrnS Auto;;ACTIVE;2.09;2.70 +33223-9;Hyaline casts;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Hyaline casts [#/area] in Urine sediment by Automated count;Hyaline Casts #/area UrnS Auto;;ACTIVE;2.09;2.73 +33224-7;Granular casts.fine;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Fine Granular Casts [#/area] in Urine sediment by Microscopy high power field;Fine Gran Casts #/area UrnS HPF;;ACTIVE;2.09;2.73 +3322-5;aMILoride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;aMILoride [Mass/volume] in Serum or Plasma;aMILoride SerPl-mCnc;;ACTIVE;1.0;2.40 +33225-4;Granular casts.fine;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Fine Granular Casts [#/area] in Urine sediment by Automated count;Fine Gran Casts #/area UrnS Auto;;ACTIVE;2.09;2.73 +33226-2;Granular casts.coarse;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Coarse Granular Casts [#/area] in Urine sediment by Microscopy high power field;Coarse Gran Casts #/area UrnS HPF;;ACTIVE;2.09;2.73 +33227-0;Granular casts.coarse;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Coarse Granular Casts [#/area] in Urine sediment by Automated count;Coarse Gran Casts #/area UrnS Auto;;ACTIVE;2.09;2.73 +33228-8;Leukocyte casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;WBC casts [#/area] in Urine by Computer assisted method;WBC Casts #/area Ur Comp Assist;;ACTIVE;2.09;2.73 +33229-6;Erythrocyte casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;RBC casts [#/area] in Urine by Computer assisted method;RBC Casts #/area Ur Comp Assist;;ACTIVE;2.09;2.73 +33230-4;Waxy casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Waxy casts [#/area] in Urine by Computer assisted method;Waxy Casts #/area Ur Comp Assist;;ACTIVE;2.09;2.73 +33231-2;Fatty casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Fatty casts [#/area] in Urine by Computer assisted method;Fatty Casts #/area Ur Comp Assist;;ACTIVE;2.09;2.73 +33232-0;Spermatozoa;PrThr;Pt;Urine;Ord;Automated;UA;1;Spermatozoa [Presence] in Urine by Automated;Sperm Ur Ql Auto;;ACTIVE;2.09;2.73 +3323-3;aMILoride;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;aMILoride [Presence] in Urine;aMILoride Ur Ql;;ACTIVE;1.0;2.56 +33233-8;Urate crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Urate crystals [Presence] in Urine by Computer assisted method;Urate Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33234-6;Calcium oxalate crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Calcium oxalate crystals [Presence] in Urine by Computer assisted method;CaOx Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33235-3;Calcium phosphate crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Calcium phosphate crystals [Presence] in Urine by Computer assisted method;Ca Phos Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33236-1;Bilirubin crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Bilirubin crystals [Presence] in Urine by Computer assisted method;Bilirub Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.70 +33237-9;Sulfonamide crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Sulfonamide crystals [Presence] in Urine by Computer assisted method;Sulfonamide cry Ur Ql Comp Assist;;ACTIVE;2.09;2.70 +33238-7;Triple phosphate crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Triple phosphate crystals [Presence] in Urine by Computer assisted method;Tri-Phos Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33239-5;Ammonium urate crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Ammonium urate crystals [Presence] in Urine by Computer assisted method;Amm Urate Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33240-3;Cystine crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Cystine crystals [Presence] in Urine by Computer assisted method;Cystine Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +3324-1;aMILoride;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;aMILoride [Mass/volume] in Urine;aMILoride Ur-mCnc;;ACTIVE;1.0;2.42 +33241-1;Calcium carbonate crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Calcium carbonate crystals [Presence] in Urine by Computer assisted method;Ca Carbonate Cry Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33242-9;Fungi.filamentous;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Fungi.filamentous [Presence] in Urine by Computer assisted method;Filament Fungi Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33243-7;Trichomonas vaginalis;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Trichomonas vaginalis [Presence] in Urine by Computer assisted method;T vaginalis Ur Ql Comp Assist;;ACTIVE;2.09;2.73 +33244-5;Guanidinoacetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Guanidinoacetate [Moles/volume] in Serum or Plasma;Guanidinoacetate SerPl-sCnc;;ACTIVE;2.09;2.73 +33245-2;Amylase;CAct;XXX;Urine;Qn;;CHEM;1;Amylase [Catalytic Activity] in Urine collected for unspecified duration;Amylase ?Tm cAct Ur;;ACTIVE;2.09;2.70 +33246-0;Ovary Ab;Titr;Pt;Ser;Qn;;SERO;1;Ovary Ab [Titer] in Serum;Ovary Ab Titr Ser;;ACTIVE;2.09;2.30 +33247-8;Specimen weight;Mass;Pt;Sweat;Qn;;SPEC;1;Weight of Sweat;Specimen wt Sweat Qn;;ACTIVE;2.09;2.73 +33248-6;Diabetes status;Prid;Pt;^Patient;Nom;;MISC;1;Diabetes status [Identifier];Diabetes status Patient;;ACTIVE;2.09;2.73 +33249-4;Hyperchromia;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Hyperchromia [Presence] in Blood by Light microscopy;Hyperchromia Bld Ql Smear;;ACTIVE;2.09;2.73 +33250-2;Cells.CD55;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD55 cells [Presence] in Blood;CD55 Cells Bld Ql;;ACTIVE;2.09;2.73 +33251-0;Monocytes;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Monocytes [#/volume] in Body fluid by Manual count;Monocytes # Fld Manual;;ACTIVE;2.09;2.70 +33252-8;Monocytes;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Monocytes [#/volume] in Cerebral spinal fluid by Manual count;Monocytes # CSF Manual;;ACTIVE;2.09;2.70 +33253-6;Nuclear Ab;Titr;Pt;Ser;Qn;Hep2 substrate;SERO;1;Nuclear Ab [Titer] in Serum by Hep2 substrate;ANA Titr Ser HEp2 subst;;ACTIVE;2.09;2.73 +33254-4;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldA;Qn;;CHEM;1;pH of Arterial blood adjusted to patient's actual temperature;pH temp adj BldA;;ACTIVE;2.09;2.73 +33255-1;Cell fractions;Imp;Pt;Bld;Nom;;HEM/BC;1;Cell Fractions/Differential [Interpretation] in Blood;Cell Fract Bld-Imp;;ACTIVE;2.09;2.73 +33256-9;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Blood by Automated count;WBC nRBC cor # Bld Auto;;ACTIVE;2.09;2.73 +33257-7;Cortisol;MCnc;Pt;CSF;Qn;;CHEM;1;Cortisol [Mass/volume] in Cerebral spinal fluid;Cortis CSF-mCnc;;ACTIVE;2.09;2.70 +3325-8;aMILoride;MRat;24H;Urine;Qn;;DRUG/TOX;1;aMILoride [Mass/time] in 24 hour Urine;aMILoride 24h Ur-mRate;;ACTIVE;1.0;2.42 +33258-5;Thyrotropin^30M post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --30 minutes post dose TRH;TSH 30M p TRH SerPl-aCnc;;ACTIVE;2.09;2.70 +33259-3;Thyrotropin^1H post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1 hour post dose TRH;TSH 1h p TRH SerPl-aCnc;;ACTIVE;2.09;2.70 +33260-1;Thyrotropin^1.5H post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1.5 hours post dose TRH;TSH 1.5h p TRH SerPl-aCnc;;ACTIVE;2.09;2.70 +33261-9;Thyrotropin^2H post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --2 hours post dose TRH;TSH 2h p TRH SerPl-aCnc;;ACTIVE;2.09;2.70 +33262-7;Metamyelocytes/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Metamyelocytes/100 leukocytes in Cerebral spinal fluid by Manual count;Metamyelocytes/leuk NFr CSF Manual;;ACTIVE;2.09;2.70 +33263-5;Metamyelocytes/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Metamyelocytes/100 leukocytes in Body fluid by Manual count;Metamyelocytes/leuk NFr Fld Manual;;ACTIVE;2.09;2.73 +33264-3;Osmol gap;Osmol;Pt;Ser/Plas;Qn;;CHEM;1;Osmol gap of Serum or Plasma;Osmol gap SerPl;;ACTIVE;2.09;2.73 +33265-0;Toxoplasma gondii Ab.IgA;ACnc;Pt;CSF;Qn;;MICRO;1;Toxoplasma gondii IgA Ab [Units/volume] in Cerebral spinal fluid;T gondii IgA CSF-aCnc;;ACTIVE;2.09;2.70 +3326-6;Aminocaproate^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aminocaproate [Mass/volume] in Serum or Plasma --trough;Amicaproate Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +33266-8;Aspergillus sp Ab;Titr;Pt;Urine;Qn;;MICRO;1;Aspergillus sp Ab [Titer] in Urine;Aspergillus Ab Titr Ur;;ACTIVE;2.09;2.70 +33267-6;Aspergillus sp Ab.IgG;PrThr;Pt;Urine;Ord;;MICRO;1;Aspergillus sp IgG Ab [Presence] in Urine;Aspergillus IgG Ur Ql;;ACTIVE;2.09;2.70 +33268-4;Bordetella pertussis.pertussis toxin Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis.pertussis toxin IgG Ab [Mass/volume] in Serum;B pert.PT IgG Ser-mCnc;;ACTIVE;2.09;2.70 +33269-2;Thyrotropin^pre dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --pre dose TRH;TSH pre TRH SerPl-aCnc;;ACTIVE;2.09;2.70 +332-7;Mezlocillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Mezlocillin [Susceptibility] by Disk diffusion (KB);Mezlocillin Islt KB;;ACTIVE;1.0;2.73 +33270-0;Microscopic observation;Prid;Pt;Bld.buffy coat;Nom;Microscopy.light;MICRO;1;Microscopic observation [Identifier] in Buffy Coat by Light microscopy;Micro Buffy Coat;;ACTIVE;2.09;2.73 +33271-8;Microscopic observation;Prid;Pt;Bld;Nom;Malaria thin smear;MICRO;1;Microscopic observation [Identifier] in Blood by Malaria thin smear;Malaria Thin Smear Bld;;ACTIVE;2.09;2.73 +33272-6;Cryoglobulin;ACnc;Pt;Ser;Ord;7D cold incubation;CHEM;1;Deprecated Cryoglobulin [Presence] in Serum by 1 week cold incubation;Deprecated Cryoglob Ser Ql;;DEPRECATED;2.09;2.70 +33273-4;3-Methylglutaconate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methylglutaconate [Moles/volume] in Serum or Plasma;3Me-glutaconate SerPl-sCnc;;ACTIVE;2.09;2.70 +3327-4;Aminopyrine;MCnc;Pt;Exhl gas;Qn;;DRUG/TOX;1;Aminopyrine [Mass/volume] in Exhaled gas;Aminopyrine ExG-mCnc;;ACTIVE;1.0;2.34 +33274-2;5-Methyltetrahydrofolate;PrThr;Pt;CSF;Ord;;CHEM;1;5-Methyltetrahydrofolate [Presence] in Cerebral spinal fluid;5Me-tetrahydrofolate CSF Ql;;ACTIVE;2.09;2.73 +33275-9;7-Dehydrocholesterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-Dehydrocholesterol [Mass/volume] in Serum or Plasma;7-DHC SerPl-mCnc;;ACTIVE;2.09;2.73 +33276-7;Aureobasidium pullulans Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aureobasidium pullulans IgG Ab RAST class [Presence] in Serum;A pullulans IgG RAST Ql;;ACTIVE;2.09;2.58 +33277-5;Acetaminophen+Phenacetin;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Acetaminophen+Phenacetin [Presence] in Urine by Screen method;Acetamin+Phenac Ur Ql Scn;;ACTIVE;2.09;2.73 +33278-3;Acetylcholine receptor blocking Ab;SCnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor blocking Ab [Moles/volume] in Serum;AChR Block Ab Ser-sCnc;;ACTIVE;2.09;2.73 +33279-1;Acetylcholine receptor modulation Ab;SCnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor modulation Ab [Moles/volume] in Serum;AChR Mod Ab Ser-sCnc;;ACTIVE;2.09;2.73 +33280-9;Amphetamine+Methamphetamine;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Amphetamine+Methamphetamine [Mass/volume] in Urine by Screen method;Amphet+Methamphet Ur Scn-mCnc;;ACTIVE;2.09;2.73 +33281-7;Curvularia specifera Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Curvularia specifera IgG Ab RAST class [Presence] in Serum;C specifera IgG RAST Ql;;ACTIVE;2.09;2.73 +3328-2;Aminopyrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aminopyrine [Mass/volume] in Serum or Plasma;Aminopyrine SerPl-mCnc;;ACTIVE;1.0;2.34 +33282-5;Cannabinoids;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Cannabinoids [Mass/mass] in Meconium by Confirmatory method;Cannabinoids Mec Cfm-mCnt;;ACTIVE;2.09;2.73 +33283-3;Ictalurus punctatus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Catfish IgG Ab RAST class [Presence] in Serum;Catfish IgG RAST Ql;;ACTIVE;2.09;2.58 +33284-1;Clinafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Deprecated Clinafloxacin [Susceptibility];Deprecated Clinafloxacin Susc Islt;;DEPRECATED;2.09;2.36 +33285-8;Cytomegalovirus Ab.IgM;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Cytomegalovirus IgM Ab [Units/volume] in Body fluid by Immunoassay;CMV IgM Fld IA-aCnc;;ACTIVE;2.09;2.73 +33286-6;Fusarium moniliforme Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fusarium moniliforme IgG Ab RAST class [Presence] in Serum;F moniliforme IgG RAST Ql;;ACTIVE;2.09;2.58 +33287-4;Glucose-6-Phosphate dehydrogenase;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Presence] in DBS;G6PD DBS Ql;;ACTIVE;2.09;2.73 +33288-2;Galactose 1 phosphate uridyl transferase;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Galactose 1 phosphate uridyl transferase [Presence] in DBS;Gal1PUT DBS Ql;;ACTIVE;2.09;2.73 +33289-0;Helminthosporium sp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Helminthosporium sp IgG Ab RAST class [Presence] in Serum;Helminthosporium IgG RAST Ql;;ACTIVE;2.09;2.58 +3329-0;Aminosalicylate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aminosalicylate [Mass/volume] in Serum or Plasma;Aminosalicylate SerPl-mCnc;;ACTIVE;1.0;2.73 +33290-8;Histamine;SCnc;Pt;Urine;Qn;;CHEM;1;Histamine [Moles/volume] in Urine;Histamine Ur-sCnc;;ACTIVE;2.09;2.73 +33291-6;Herpes simplex virus 1 Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Herpes simplex virus 1 IgG Ab [Presence] in Serum by Immunoblot;HSV1 IgG Ser Ql IB;;ACTIVE;2.09;2.73 +33292-4;Herpes simplex virus 1+2 Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 1+2 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV1+2 Ab Titr CSF IF;;ACTIVE;2.09;2.16 +33293-2;Herpes simplex virus 1+2 Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;HSV1+2 IgG CSF Ql IB;;ACTIVE;2.09;2.58 +33294-0;Herpes simplex virus 1+2 Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;HSV1+2 IgM CSF Ql IF;;ACTIVE;2.09;2.56 +33295-7;JC virus DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;JC virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;JCPyV DNA CSF Ql NAA+probe;;ACTIVE;2.09;2.73 +33296-5;Actinidia chinensis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Kiwifruit IgG Ab RAST class [Presence] in Serum;Kiwifruit IgG RAST Ql;;ACTIVE;2.09;2.58 +33297-3;Mucor racemosus Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mucor racemosus IgG Ab RAST class [Presence] in Serum;M racemosus IgG RAST Ql;;ACTIVE;2.09;2.58 +33298-1;Amdinocillin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Deprecated Amdinocillin [Susceptibility];Deprecated Amdinocillin Susc Islt;;DEPRECATED;2.09;2.36 +33299-9;N-acetyl-L-aspartate;PrThr;Pt;Urine;Ord;;CHEM;1;N-acetyl-L-aspartate [Presence] in Urine;N-Ac-L-Asp Ur Ql;;ACTIVE;2.09;2.73 +33300-5;Naproxen;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Naproxen [Presence] in Urine by Screen method;Naproxen Ur Ql Scn;;ACTIVE;2.09;2.73 +33301-3;Norchlordiazepoxide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norchlordiazepoxide [Presence] in Urine by Screen method;Norchlordiazep Ur Ql Scn;;ACTIVE;2.09;2.56 +33302-1;Phthalic anhydride Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Phthalic anhydride IgG Ab RAST class [Presence] in Serum;PAN IgG RAST Ql;;ACTIVE;2.09;2.58 +33303-9;Phoma betae Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Phoma betae IgG Ab RAST class [Presence] in Serum;P betae IgG RAST Ql;;ACTIVE;2.09;2.73 +33304-7;Penicillium notatum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillium notatum IgG Ab RAST class [Presence] in Serum;P notatum IgG RAST Ql;;ACTIVE;2.09;2.58 +33305-4;Perca spp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Perch IgG Ab RAST class [Presence] in Serum;Perch IgG RAST Ql;;ACTIVE;2.09;2.58 +33306-2;Phosphatidate Ab;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidate Ab [Presence] in Serum;Phosphatidate Ab Ser Ql;;ACTIVE;2.09;2.56 +33307-0;Phosphatidylcholine Ab;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylcholine Ab [Presence] in Serum;PC Ab Ser Ql;;ACTIVE;2.09;2.56 +3330-8;Amiodarone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amiodarone [Mass/volume] in Serum or Plasma;Amiodarone SerPl-mCnc;;ACTIVE;1.0;2.73 +33308-8;Phosphatidylethanolamine Ab;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylethanolamine Ab [Presence] in Serum;PE Ab Ser Ql;;ACTIVE;2.09;2.73 +33309-6;Phosphatidylinositol Ab;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylinositol Ab [Presence] in Serum;PI Ab Ser Ql;;ACTIVE;2.09;2.56 +33310-4;Phosphatidylserine Ab;PrThr;Pt;Ser;Ord;;COAG;1;Phosphatidylserine Ab [Presence] in Serum;PS Ab Ser Ql;;ACTIVE;2.09;2.73 +33311-2;Porphyrins;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Porphyrins [Moles/volume] in Serum or Plasma;Porphyrins SerPl-sCnc;;ACTIVE;2.09;2.73 +33312-0;Rhizopus nigricans Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rhizopus nigricans IgG Ab RAST class [Presence] in Serum;R nigricans IgG RAST Ql;;ACTIVE;2.09;2.58 +33313-8;Rheumatoid factor.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Rheumatoid factor IgA [Units/volume] in Serum;RF IgA Ser-aCnc;;ACTIVE;2.09;2.73 +33314-6;Rheumatoid factor.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Rheumatoid factor IgG [Units/volume] in Serum;RF IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33315-3;Stemphylium botryosum Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Stemphylium botryosum IgG Ab RAST class [Presence] in Serum;S botryosum IgG RAST Ql;;ACTIVE;2.09;2.58 +3331-6;Amiodarone+Desethylamiodarone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amiodarone+Desethylamiodarone [Mass/volume] in Serum or Plasma;Amiodarone+Deseth SerPl-mCnc;;ACTIVE;1.0;2.73 +33316-1;Salmonella paratyphi A O Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi A O Ab [Titer] in Serum;S paraty A O Ab Titr Ser;;ACTIVE;2.09;2.16 +33317-9;Schistosoma sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Schistosoma sp IgG Ab [Presence] in Serum;Schistosoma IgG Ser Ql;;ACTIVE;2.09;2.73 +33318-7;Spermatozoa Ab.IgM;PrThr;Pt;Ser;Ord;;FERT;1;Spermatozoa IgM Ab [Presence] in Serum;Sperm IgM Ser Ql;;ACTIVE;2.09;2.73 +33319-5;Toxoplasma gondii Ab.IgE;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Toxoplasma gondii IgE Ab [Presence] in Serum;Deprecated T gondii IgE Ser Ql;;DEPRECATED;2.09;2.36 +33320-3;Toxoplasma gondii Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Body fluid;T gondii IgG Fld-aCnc;;ACTIVE;2.09;2.73 +33321-1;Toxoplasma gondii Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Toxoplasma gondii IgM Ab [Units/volume] in Body fluid;T gondii IgM Fld-aCnc;;ACTIVE;2.09;2.73 +33322-9;Toxoplasma gondii DNA;ACnc;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Deprecated Toxoplasma gondii DNA [Presence] in Amniotic fluid by Probe & target amplification method;Deprecated T gondii DNA Amn Ql PCR;;DEPRECATED;2.09;2.36 +33323-7;Theophylline;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Theophylline [Presence] in Urine by Screen method;Theophylline Ur Ql Scn;;ACTIVE;2.09;2.73 +3332-4;Amitriptyline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Amitriptyline [Presence] in Serum or Plasma;Amitrip SerPl Ql;;ACTIVE;1.0;2.56 +33324-5;Trichophyton Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichophyton sp IgG Ab RAST class [Presence] in Serum;Trichophyton IgG RAST Ql;;ACTIVE;2.09;2.58 +33325-2;Trypsin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Trypsin [Mass/volume] in Serum or Plasma;Trypsin SerPl-mCnc;;ACTIVE;2.09;2.73 +33326-0;Turbidity;PrThr;Pt;Amnio fld;Ord;;SPEC;1;Turbidity [Presence] of Amniotic fluid Qualitative;Turbidity Amn Ql;;ACTIVE;2.09;2.56 +33327-8;Varicella zoster virus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Varicella zoster virus Ab [Titer] in Cerebral spinal fluid by Complement fixation;VZV Ab Titr CSF CF;;ACTIVE;2.09;2.73 +33328-6;West Nile virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;West Nile virus IgG Ab [Titer] in Cerebral spinal fluid;WNV IgG Titr CSF;;ACTIVE;2.09;2.16 +33329-4;West Nile virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;West Nile virus IgG Ab [Titer] in Serum;WNV IgG Titr Ser;;ACTIVE;2.09;2.73 +33330-2;West Nile virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;West Nile virus IgM Ab [Titer] in Cerebral spinal fluid;WNV IgM Titr CSF;;ACTIVE;2.09;2.16 +33331-0;West Nile virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;West Nile virus IgM Ab [Titer] in Serum;WNV IgM Titr Ser;;ACTIVE;2.09;2.73 +3333-2;Amitriptyline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Serum or Plasma;Amitrip SerPl-mCnc;;ACTIVE;1.0;2.73 +33332-8;Linezolid;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Linezolid [Susceptibility] by Gradient strip;Linezolid Islt Grad strip;;ACTIVE;2.09;2.73 +33333-6;Colistin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Colistin [Susceptibility] by Gradient strip;Colistin Islt Grad strip;;ACTIVE;2.09;2.73 +33334-4;Quinupristin+Dalfopristin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Quinupristin+Dalfopristin [Susceptibility] by Gradient strip;Quinupristin+Dalfoprist Islt Grad strip;;ACTIVE;2.09;2.56 +33335-1;Diphenylmethoxyacetate;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Diphenylmethoxyacetate [Presence] in Urine by Screen method;Diphenylmethoxyac Ur Ql Scn;;ACTIVE;2.09;2.56 +33336-9;Toxoplasma gondii Ab.IgM;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Toxoplasma gondii IgM Ab [Presence] in Serum by Agglutination;T gondii IgM Ser Ql Aggl;;ACTIVE;2.09;2.56 +33337-7;Toxoplasma gondii Ab;ACnc;Pt;Ser;Ord;Aggl;MICRO;1;Deprecated Toxoplasma gondii Ab [Presence] in Serum by Agglutination;Deprecated T gondii Ab Ser Ql Aggl;;DEPRECATED;2.09;2.36 +33338-5;Zolpidem;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Zolpidem [Presence] in Urine;Zolpidem Ur Ql;;ACTIVE;2.09;2.73 +33339-3;Zolpidem;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zolpidem [Mass/volume] in Urine;Zolpidem Ur-mCnc;;ACTIVE;2.09;2.73 +3334-0;Amitriptyline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Amitriptyline [Presence] in Urine;Amitrip Ur Ql;;ACTIVE;1.0;2.73 +33340-1;Zolpidem;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zolpidem [Moles/volume] in Urine;Zolpidem Ur-sCnc;;ACTIVE;2.09;2.70 +33341-9;Granular casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Granular casts [#/area] in Urine by Computer assisted method;Gran Casts #/area Ur Comp Assist;;ACTIVE;2.09;2.73 +33342-7;Epithelial cells;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Epithelial cells [#/area] in Urine sediment by Automated count;Epi Cells #/area UrnS Auto;;ACTIVE;2.09;2.73 +33343-5;Leukotriene E4/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Leukotriene E4/Creatinine [Mass Ratio] in Urine;LTE4/Creat Ur;;ACTIVE;2.09;2.70 +33344-3;Leukotriene E4;MCnc;Pt;Urine;Qn;;CHEM;1;Leukotriene E4 [Mass/volume] in Urine;LTE4 Ur-mCnc;;ACTIVE;2.09;2.70 +33345-0;Histrelin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Histrelin [Mass/volume] in Urine;Histrelin Ur-mCnc;;ACTIVE;2.09;2.70 +33346-8;Cortisol.free;MCnc;24H;Urine;Qn;;CHEM;1;Cortisol Free [Mass/volume] in 24 hour Urine;Cortis F 24h Ur-mCnc;;ACTIVE;2.09;2.73 +33347-6;17-Ketosteroids/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;17-Ketosteroids/Creatinine [Mass Ratio] in Urine;17KS/Creat Ur;;ACTIVE;2.09;2.70 +33348-4;Pemoline;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Pemoline [Mass/volume] in Urine by Screen method;Pemoline Ur Scn-mCnc;;ACTIVE;2.09;2.70 +33349-2;Pemoline;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pemoline [Mass/volume] in Urine by Confirmatory method;Pemoline Ur Cfm-mCnc;;ACTIVE;2.09;2.70 +333-5;Mezlocillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Mezlocillin [Susceptibility] by Serum bactericidal titer;Mezlocillin Titr SBT;;ACTIVE;1.0;2.32 +33350-0;Lysergate diethylamide;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Lysergate diethylamide [Mass/volume] in Urine by Screen method;LSD Ur Scn-mCnc;;ACTIVE;2.09;2.70 +33351-8;11-Dehydro thromboxane beta 2;MCnc;Pt;Urine;Qn;;CHEM;1;11-Dehydro thromboxane beta 2 [Mass/volume] in Urine;11-dehydro TBX2 Ur-mCnc;;ACTIVE;2.09;2.73 +33352-6;Glucose/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glucose/Creatinine [Mass Ratio] in Urine;Glucose/Creat Ur;;ACTIVE;2.09;2.44 +33353-4;Alanine aminopeptidase;CCnc;Pt;Urine;Qn;;CHEM;1;Alanine aminopeptidase [Enzymatic activity/volume] in Urine;AAP Ur-cCnc;;ACTIVE;2.09;2.70 +33354-2;N-acetyl-beta-glucosaminidase;CCnc;Pt;Urine;Qn;;CHEM;1;N-acetyl-beta-glucosaminidase [Enzymatic activity/volume] in Urine;B-NAG Ur-cCnc;;ACTIVE;2.09;2.70 +33355-9;Urea nitrogen;SCnc;24H;Urine;Qn;;CHEM;1;Urea nitrogen [Moles/volume] in 24 hour Urine;UUN 24h Ur-sCnc;;ACTIVE;2.09;2.70 +33356-7;Coagulation tissue factor induced.factor substitution^1H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with normal plasma;PT 1h NP PPP;;ACTIVE;2.09;2.73 +3335-7;Amitriptyline+Nortriptyline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Mass/volume] in Serum or Plasma;Amitrip+Nor SerPl-mCnc;;ACTIVE;1.0;2.73 +33357-5;Coagulation tissue factor induced.factor substitution^1H post incubation;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --1 hour post incubation;PT 1h p Inc PPP;;ACTIVE;2.09;2.73 +33358-3;Protein.monoclonal;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal [Mass/volume] in Serum or Plasma by Electrophoresis;M Protein SerPl Elph-mCnc;;ACTIVE;2.09;2.73 +33359-1;Branched chain keto-acid dehydrogenase complex;Prid;Pt;Bld;Nom;;CHEM;1;Branched chain keto-acid dehydrogenase complex [Identifier] in Blood;BCKAD Bld;;ACTIVE;2.09;2.73 +33360-9;Galactose 1 phosphate;MCnt;Pt;RBC;Qn;;CHEM;1;Galactose 1 phosphate [Mass/mass] in Red Blood Cells;Gal1PO4 RBC-mCnt;;ACTIVE;2.09;2.73 +33361-7;Neutrophils.band form/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Band form neutrophils/100 leukocytes in Synovial fluid;Neuts Band/leuk NFr Snv;;ACTIVE;2.09;2.73 +33362-5;Monocytes/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Pleural fluid;Monocytes/leuk NFr Plr;;ACTIVE;2.09;2.73 +33363-3;Normocytic;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Normocytic [Presence] in Blood by Light microscopy;Normocytic Bld Ql Smear;;ACTIVE;2.09;2.73 +33364-1;Normochromic;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Normochromic [Presence] in Blood by Light microscopy;Normochromic Bld Ql Smear;;ACTIVE;2.09;2.73 +3336-5;Amitriptyline^trough >12h post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Serum or Plasma --trough >12 hours post dose;Amitrip >12h Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +33365-8;Mesothelial cells/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Mesothelial cells/100 leukocytes in Synovial fluid;Mesothl Cell/leuk NFr Snv;;ACTIVE;2.09;2.73 +33366-6;Chloride;SCnc;Pt;Periton fld;Qn;;CHEM;1;Chloride [Moles/volume] in Peritoneal fluid;Chloride Prt-sCnc;;ACTIVE;2.09;2.73 +33367-4;Lactate dehydrogenase;CCnc;Pt;Pericard fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Pericardial fluid;LDH Pcar-cCnc;;DISCOURAGED;2.09;2.70 +33368-2;Amylase;CCnc;Pt;Pericard fld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Pericardial fluid;Amylase Pcar-cCnc;;ACTIVE;2.09;2.73 +33369-0;Lymphocytes.variant/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Peritoneal fluid;Variant Lymphs/leuk NFr Prt;;ACTIVE;2.09;2.70 +33370-8;Lymphocytes.variant/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Pleural fluid;Variant Lymphs/leuk NFr Plr;;ACTIVE;2.09;2.70 +33371-6;Lymphocytes.variant/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Synovial fluid;Variant Lymphs/leuk NFr Snv;;ACTIVE;2.09;2.73 +33372-4;Blasts/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Blasts/100 leukocytes in Peritoneal fluid;Blasts/leuk NFr Prt;;ACTIVE;2.09;2.70 +3337-3;Amobarbital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Amobarbital [Presence] in Serum or Plasma;Amobarbital SerPl Ql;;ACTIVE;1.0;2.73 +33373-2;Blasts/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Blasts/100 leukocytes in Pleural fluid;Blasts/leuk NFr Plr;;ACTIVE;2.09;2.70 +33374-0;Blasts/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Blasts/100 leukocytes in Synovial fluid;Blasts/leuk NFr Snv;;ACTIVE;2.09;2.73 +33375-7;Chylomicrons;PrThr;Pt;Plr fld;Ord;;CHEM;1;Chylomicrons [Presence] in Pleural fluid;Chylo Plr Ql;;ACTIVE;2.09;2.56 +33376-5;Macrophages/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Macrophages/100 leukocytes in Synovial fluid;Macrophages/leuk NFr Snv;;ACTIVE;2.09;2.73 +33377-3;Blastomyces sp Ab;ACnc;Pt;Ser;Ord;Comp fix;MICRO;1;Deprecated Blastomyces dermatitidis Ab [Presence] in Serum by Complement fixation;Deprecated Blastomyces Ab Ser Ql CF;;DEPRECATED;2.09;2.36 +33378-1;Blastomyces sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Deprecated Blastomyces dermatitidis Ab [Titer] in Serum by Complement fixation;Deprecated Blastomyces Ab Titr Ser CF;;DEPRECATED;2.09;2.70 +33379-9;Coccidioides sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Coccidioides sp Ab [Presence] in Serum by Complement fixation;Coccidioides Ab Ser Ql CF;;ACTIVE;2.09;2.73 +33380-7;Coccidioides sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coccidioides sp Ab [Titer] in Serum by Complement fixation;Coccidioides Ab Titr Ser CF;;ACTIVE;2.09;2.73 +3338-1;Amobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amobarbital [Mass/volume] in Serum or Plasma;Amobarbital SerPl-mCnc;;ACTIVE;1.0;2.73 +33381-5;Coccidioides sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coccidioides sp Ab [Units/volume] in Serum;Coccidioides Ab Ser-aCnc;;ACTIVE;2.09;2.69 +33382-3;Respiratory syncytial virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Respiratory syncytial virus Ab [Titer] in Cerebral spinal fluid;RSV Ab Titr CSF;;ACTIVE;2.09;2.70 +33383-1;Influenza virus A Bangkok Ab;Titr;Pt;CSF;Qn;;MICRO;1;Influenza virus A Bangkok Ab [Titer] in Cerebral spinal fluid;FLUAV Bang Ab Titr CSF;;ACTIVE;2.09;2.70 +33384-9;Neutrophils.segmented/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Segmented neutrophils/100 leukocytes in Peritoneal fluid;Neuts Seg/leuk NFr Prt;;ACTIVE;2.09;2.70 +33385-6;Neutrophils.segmented/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Segmented neutrophils/100 leukocytes in Pleural fluid;Neuts Seg/leuk NFr Plr;;ACTIVE;2.09;2.70 +33386-4;Neutrophils.segmented/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Segmented neutrophils/100 leukocytes in Synovial fluid;Neuts Seg/leuk NFr Snv;;ACTIVE;2.09;2.73 +33387-2;Neutrophils.segmented/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Segmented neutrophils/100 leukocytes in Pericardial fluid;Neuts Seg/leuk NFr Pcar;;ACTIVE;2.09;2.70 +33388-0;Neutrophils.band form/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Band form neutrophils/100 leukocytes in Pericardial fluid;Neuts Band/leuk NFr Pcar;;ACTIVE;2.09;2.70 +33389-8;Monocytes/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Pericardial fluid;Monocytes/leuk NFr Pcar;;ACTIVE;2.09;2.70 +33390-6;Respiratory syncytial virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Respiratory syncytial virus Ab [Presence] in Serum;RSV Ab Ser Ql;;ACTIVE;2.09;2.73 +33391-4;Coxsackievirus A8 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A8 Ab [Units/volume] in Serum;CV A8 Ab Ser-aCnc;;ACTIVE;2.09;2.70 +33392-2;Coxsackievirus A8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Coxsackievirus A8 Ab [Presence] in Serum;CV A8 Ab Ser Ql;;ACTIVE;2.09;2.56 +33393-0;Granular casts.coarse;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Coarse Granular Casts [#/area] in Urine sediment by Microscopy low power field;Coarse Gran Casts #/area UrnS LPF;;ACTIVE;2.09;2.73 +33394-8;Myelin associated glycoprotein Ab;Titr;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein Ab [Titer] in Serum;MAG Ab Titr Ser;;ACTIVE;2.09;2.73 +33395-5;Epstein Barr virus capsid Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus capsid Ab [Presence] in Serum;EBV VCA Ab Ser Ql;;ACTIVE;2.09;2.73 +33396-3;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Serum;N men sg A+C+W135+Y Ag Ser Ql;;ACTIVE;2.09;2.64 +33397-1;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;Ser;Ord;LA;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Serum by Latex agglutination;N men sg A+C+W135+Y Ag Ser Ql LA;;ACTIVE;2.09;2.64 +33398-9;Neisseria meningitidis serogroups A+C+w135+Y Ag;PrThr;Pt;Urine;Ord;LA;MICRO;1;Neisseria meningitidis serogroups A+C+w135+Y Ag [Presence] in Urine by Latex agglutination;N men sg A+C+W135+Y Ag Ur Ql LA;;ACTIVE;2.09;2.64 +3339-9;Amobarbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Amobarbital [Presence] in Urine;Amobarbital Ur Ql;;ACTIVE;1.0;2.73 +33399-7;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Serum;N men sg B+E coli K1 Ag Ser Ql;;ACTIVE;2.09;2.73 +33400-3;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;Ser;Ord;LA;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Serum by Latex agglutination;N men sg B+E coli K1 Ag Ser Ql LA;;ACTIVE;2.09;2.64 +33401-1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag;PrThr;Pt;Urine;Ord;LA;MICRO;1;Neisseria meningitidis serogroup B+Escherichia coli K1 Ag [Presence] in Urine by Latex agglutination;N men sg B+E coli K1 Ag Ur Ql LA;;ACTIVE;2.09;2.64 +33402-9;Coccidioides sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coccidioides sp Ab [Titer] in Serum;Coccidioides Ab Titr Ser;;ACTIVE;2.09;2.73 +33403-7;Fatty acids.very long chain.C26:0;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate) [Mass/volume] in Serum or Plasma;VLCFA C26:0 SerPl-mCnc;;ACTIVE;2.09;2.70 +33404-5;Platelet associated Ab.IgG/Platelet associated Ab.IgM;Ratio;Pt;Bld;Qn;;SERO;1;Platelet associated IgG Ab/IgM Ab [Ratio] in Blood;PA IgG/IgM Bld-Rto;;ACTIVE;2.09;2.32 +33405-2;Glucose;MCnc;Pt;Pericard fld;Qn;;CHEM;1;Glucose [Mass/volume] in Pericardial fluid;Glucose Pcar-mCnc;;ACTIVE;2.09;2.73 +33406-0;Candida albicans Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Candida albicans Ab [Units/volume] in Serum by Complement fixation;C albicans Ab Ser CF-aCnc;;ACTIVE;2.09;2.70 +3340-7;Amoxapine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Amoxapine [Presence] in Serum or Plasma;Amoxapine SerPl Ql;;ACTIVE;1.0;2.56 +33407-8;Protein;MCnc;Pt;Pericard fld;Qn;;CHEM;1;Protein [Mass/volume] in Pericardial fluid;Prot Pcar-mCnc;;ACTIVE;2.09;2.73 +33408-6;Complement C2;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C2 [Units/volume] in Serum or Plasma;C2 SerPl-aCnc;;ACTIVE;2.09;2.73 +33409-4;Lymphocytes.variant/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Variant lymphocytes/100 leukocytes in Pericardial fluid;Variant Lymphs/leuk NFr Pcar;;ACTIVE;2.09;2.70 +33410-2;Chlamydia sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Serum by Immunoassay;Chlamydia IgG Ser IA-aCnc;;ACTIVE;2.09;2.73 +33411-0;Hemoglobin.free;PrThr;Pt;Urine;Ord;;HEM/BC;1;Free Hemoglobin [Presence] in Urine;Hgb Free Ur Ql;;ACTIVE;2.09;2.73 +33412-8;Blasts/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Blasts/100 leukocytes in Pericardial fluid;Blasts/leuk NFr Pcar;;ACTIVE;2.09;2.70 +33413-6;Lipoprotein.beta/Lipoprotein.total;MFr;Pt;Plr fld;Qn;;CHEM;1;Lipoprotein.beta/total Lipoprotein in Pleural fluid;LDL MFr Plr;;ACTIVE;2.09;2.70 +33414-4;Lipoprotein.pre-beta/Lipoprotein.total;MFr;Pt;Plr fld;Qn;;CHEM;1;Lipoprotein.pre-beta/total Lipoprotein in Pleural fluid;VLDL MFr Plr;;ACTIVE;2.09;2.70 +3341-5;Amoxapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amoxapine [Mass/volume] in Serum or Plasma;Amoxapine SerPl-mCnc;;ACTIVE;1.0;2.73 +33415-1;IgG;MCnc;Pt;Urine;Qn;;CHEM;1;IgG [Mass/volume] in Urine;IgG Ur-mCnc;;ACTIVE;2.09;2.73 +33416-9;Coccidioides sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coccidioides sp Ab [Presence] in Serum by Immunoassay;Coccidioides Ab Ser Ql IA;;ACTIVE;2.09;2.56 +33417-7;pH;LsCnc;Pt;Pericard fld;Qn;;CHEM;1;pH of Pericardial fluid;pH Pcar;;ACTIVE;2.09;2.73 +33418-5;Neuronal Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Neuronal IgG Ab [Presence] in Serum;Neuronal IgG Ser Ql;;ACTIVE;2.09;2.73 +33419-3;Histoplasma sp Ag;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Histoplasma capsulatum Ag [Presence] in Serum;Deprecated Histoplasma Ag Ser Ql;;DEPRECATED;2.09;2.36 +33420-1;Histoplasma sp Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Histoplasma capsulatum Ag [Units/volume] in Serum;Deprecated Histoplasma Ag Ser-aCnc;;DEPRECATED;2.09;2.69 +33421-9;Alkaline phosphatase.other fractions;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.other fractions [Enzymatic activity/volume] in Serum or Plasma;ALP Other SerPl-cCnc;;ACTIVE;2.09;2.73 +33422-7;Amphiphysin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Amphiphysin Ab [Presence] in Serum;Amphiphysin Ab Ser Ql;;ACTIVE;2.09;2.73 +3342-3;Amoxapine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Amoxapine [Presence] in Urine;Amoxapine Ur Ql;;ACTIVE;1.0;2.73 +33423-5;Amphiphysin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Amphiphysin Ab [Units/volume] in Serum;Amphiphysin Ab Ser-aCnc;;ACTIVE;2.09;2.73 +33424-3;Breath sound qualifier;Type;Pt;Respiratory system;Nom;Auscultation;PULM;2;Breath sound qualifier by Auscultation;Breath sound qualifier Auscultation;;ACTIVE;2.09;2.70 +33425-0;Minute volume setting;VRat;Pt;Ventilator;Qn;;PULM;2;Minute volume setting Ventilator;Minute volume setting Vent;;ACTIVE;2.09;2.73 +33426-8;Inspiratory.pause setting;Time;Pt;Ventilator;Qn;;PULM;2;Inspiratory.pause setting [Time] Ventilator;Inspiratory.pause setting Time Vent;;ACTIVE;2.09;2.70 +33427-6;Inspiratory.pause setting;NFr;Pt;Ventilator;Qn;;PULM;2;Inspiratory.pause setting Ventilator;Inspiratory.pause setting NFr Vent;;ACTIVE;2.09;2.34 +33428-4;Inspiration.duration setting;Time;Pt;Ventilator;Qn;;PULM;2;Inspiration.duration setting [Time] Ventilator;Inspiration.duration setting Time Vent;;ACTIVE;2.09;2.70 +33429-2;Inspiration.duration setting;NFr;Pt;Ventilator;Qn;;PULM;2;Inspiration.duration setting Ventilator;Inspiration.duration setting NFr Vent;;ACTIVE;2.09;2.34 +334-3;Minocycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Minocycline [Susceptibility] by Minimum lethal concentration (MLC);Minocycline Islt MLC;;ACTIVE;1.0;2.19 +33430-0;Breath termination sensitivity setting;NFr;Pt;Ventilator;Qn;;PULM;2;Breath termination sensitivity setting Ventilator;Breath term sens setting NFr Vent;;ACTIVE;2.09;2.34 +3343-1;Amoxapine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amoxapine [Mass/volume] in Urine;Amoxapine Ur-mCnc;;ACTIVE;1.0;2.73 +33431-8;Volume expired max setting;VRat;Pt;Ventilator.alarm;Qn;;PULM;2;Maximum expired volume setting Ventilator alarm;Vol exp max Vent alarm;;ACTIVE;2.09;2.70 +33432-6;Volume expired min setting;VRat;Pt;Ventilator.alarm;Qn;;PULM;2;Minumum expired volume setting Ventilator alarm;Vol exp min Vent alarm;;ACTIVE;2.09;2.70 +33433-4;Pop off setting;Pres;Pt;Ventilator.alarm;Qn;;PULM;2;Pop off setting [Pressure] Ventilator alarm;Pop off setting Vent alarm;;ACTIVE;2.09;2.70 +33434-2;Volume.expired;VRat;Pt;Respiratory system;Qn;;PULM;2;Volume expired (vol/time);Vol exp - rate;;ACTIVE;2.09;2.70 +33435-9;Inspiratory breath^on ventilator;Time;Pt;^Patient;Qn;;PULM;2;Inspiratory breath [Time] --on ventilator;Inspiratory breath on vent Time;;ACTIVE;2.09;2.73 +33436-7;Pressure.drive;Pres;Pt;Ventilator.servo;Qn;;PULM;2;Drive pressure Servo ventilator;Drive Pres Servo vent;;ACTIVE;2.09;2.70 +33437-5;Oxygen;PPres;Pt;BldC;Qn;Transcutaneous O2 monitor;PULM;2;Oxygen [Partial pressure] in Capillary blood by Transcutaneous O2 monitor;pO2 BldC TcO2;;ACTIVE;2.09;2.73 +33438-3;Breaths.mechanical^on ventilator;NRat;Pt;^Patient;Qn;;PULM;2;Breath rate mechanical --on ventilator;Breaths.mechanical on vent;;ACTIVE;2.09;2.73 +33439-1;Class;Type;Pt;Endotracheal suction catheter;Nom;;PULM;2;Type of Endotracheal suction catheter;Endotracheal suction catheter Class;;ACTIVE;2.09;2.70 +33440-9;Airway suction location;Type;Pt;Respiratory system;Nom;;PULM;2;Airway suction location;Airway suction loc;;ACTIVE;2.09;2.70 +33441-7;Diameter;Len;Pt;Suction catheter;Qn;;PULM;2;Diameter Suction catheter;Diam Suction cath;;ACTIVE;2.09;2.70 +33442-5;Lavage amount;Vol;Pt;Intubation tube;Qn;;PULM;2;Lavage amount Intubation tube;Lavage amount Intub tube;;ACTIVE;2.09;2.70 +33443-3;Class;Type;Pt;Intubation tube;Nom;;PULM;2;Type of Intubation tube;Intub tube Class;;ACTIVE;2.09;2.70 +33444-1;Intubation tube depth;Len;Pt;Respiratory system;Qn;;PULM;2;Intubation tube depth Respiratory system;Intubation tube depth Respiratory;;ACTIVE;2.09;2.70 +33445-8;Tube cuff pressure;Pres;Pt;Intubation tube;Qn;;PULM;2;Tube cuff pressure Intubation tube;Tube cuff pressure Intub tube;;ACTIVE;2.09;2.70 +33446-6;Temperature.airway setting;Temp;Pt;Ventilator;Qn;;PULM;2;Airway temperature setting Ventilator;Airway Temp setting Vent;;ACTIVE;2.09;2.70 +33447-4;Temperature.airway;Temp;Pt;Ventilator airway circuit;Qn;;PULM;2;Ventilator airway circuit temperature;Vent airway circuit temp;;ACTIVE;2.09;2.70 +33448-2;Tubing compliance;Compli;Pt;Ventilation tube;Qn;;PULM;2;Tubing compliance Ventilation tube;Tubing compliance Ventilation tube;;ACTIVE;2.09;2.70 +3344-9;Amoxicillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amoxicillin [Mass/volume] in Serum or Plasma;Amoxicillin SerPl-mCnc;;ACTIVE;1.0;2.73 +33449-0;Respiratory therapy goal;Type;Pt;Respiratory therapy;Nom;;PULM;2;Respiratory therapy goal Respiratory therapy;Respiratory therapy goal;;ACTIVE;2.09;2.70 +33450-8;Ventilator adverse event;Find;Pt;^Patient;Nom;;PULM;2;Ventilator adverse event;Vent AE;;ACTIVE;2.09;2.50 +33451-6;Class;Type;Pt;Respiratory analyzer;Nom;;PULM;2;Type of Respiratory analyzer;Resp analyzer Class;;ACTIVE;2.09;2.70 +33452-4;Expiratory gas flow.max;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow Respiratory system airway;PEF Airway;;ACTIVE;2.09;2.73 +33453-2;Expiratory resistance.max;FldResist;Pt;Respiratory system;Qn;;PULM;2;Maximum expiratory resistance Respiratory system;Expiratory resistance.max Respiratory;;ACTIVE;2.09;2.70 +33454-0;Tidal volume.expired/Pressure.peak inspiratory^last 20% of breath on ventilator;Compli;Pt;Respiratory system;Qn;;PULM;2;Tidal volume expired/Peak inspiratory pressure --last 20% of breath on ventilator;VT.exp/PIP last 20% of breath on vent;;ACTIVE;2.09;2.70 +33455-7;Appearance;Aper;Pt;Sputum;Nom;;SPEC;1;Appearance of Sputum;Appearance Spt;;ACTIVE;2.09;2.73 +3345-6;Diethylpropion;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Diethylpropion [Presence] in Urine;Diethylpropion Ur Ql;;ACTIVE;1.0;2.73 +33456-5;Endotracheal tube leak;VFr;Pt;Respiratory system;Qn;;PULM;2;Endotracheal tube leak Respiratory system;Endotracheal tube leak VFr Respiratory;;ACTIVE;2.09;2.34 +33457-3;Compliance of last 20% of breath/Compliance of entire breath;CompliRto;Pt;Respiratory system;Qn;;PULM;2;Compliance of last 20% of breath/Compliance of entire breath;Compl last 20% of breath/Entire breath;;ACTIVE;2.09;2.48 +33458-1;Bilirubin.glucuronidated;MCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.conjugated [Mass/volume] in Body fluid;Bilirub Conj Fld-mCnc;;ACTIVE;2.09;2.70 +33459-9;Toxoplasma gondii Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Toxoplasma gondii IgA Ab [Presence] in Serum;T gondii IgA Ser Ql;;ACTIVE;2.09;2.73 +33460-7;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear IgG Ab [Presence] in Serum;ENA SM+RNP IgG Ser Ql;;ACTIVE;2.09;2.73 +33461-5;Candida albicans Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Candida albicans Ab [Presence] in Cerebral spinal fluid;C albicans Ab CSF Ql;;ACTIVE;2.09;2.70 +33462-3;Hepatitis C virus Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus IgG Ab [Presence] in Serum by Immunoblot;HCV IgG Ser Ql IB;;ACTIVE;2.09;2.70 +33463-1;Hepatitis B virus little e Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis B virus e IgG Ab [Presence] in Serum by Immunoassay;HBV e IgG Ser Ql IA;;ACTIVE;2.09;2.56 +3346-4;Diethylpropion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Diethylpropion [Mass/volume] in Urine;Diethylpropion Ur-mCnc;;ACTIVE;1.0;2.42 +33464-9;Hepatitis D virus Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis D virus Ag [Presence] in Serum;HDV Ag Ser Ql;;ACTIVE;2.09;2.73 +33465-6;Francisella tularensis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Francisella tularensis IgG Ab [Titer] in Serum;F tular IgG Titr Ser;;ACTIVE;2.09;2.73 +33466-4;Francisella tularensis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Francisella tularensis IgM Ab [Titer] in Serum;F tular IgM Titr Ser;;ACTIVE;2.09;2.73 +33467-2;Prealbumin;MCnc;Pt;BldCo;Qn;;CHEM;1;Prealbumin [Mass/volume] in Cord blood;Prealb BldCo-mCnc;;ACTIVE;2.09;2.70 +33468-0;West Nile virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;West Nile virus Ab [Presence] in Specimen;WNV Ab Spec Ql;;ACTIVE;2.09;2.70 +33469-8;Clostridium tetani Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Clostridium tetani IgG Ab [Presence] in Serum;C tetani IgG Ser Ql;;DISCOURAGED;2.09;2.73 +33470-6;Salmonella paratyphi A O Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella paratyphi A O Ab [Titer] in Serum by Agglutination;S paraty A O Ab Titr Ser Aggl;;ACTIVE;2.09;2.30 +33471-4;Hydrogen/Expired gas^post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post XXX challenge;Breath H2 p chal;;ACTIVE;2.09;2.73 +3347-2;Diethylpropion;MRat;24H;Urine;Qn;;DRUG/TOX;1;Diethylpropion [Mass/time] in 24 hour Urine;Diethylpropion 24h Ur-mRate;;ACTIVE;1.0;2.42 +33472-2;Acylcarnitine pattern;Imp;Pt;Urine;Nom;;CHEM;1;Acylcarnitine pattern [Interpretation] in Urine;Acylcarnitine pattern Ur-Imp;;ACTIVE;2.09;2.73 +33473-0;Bile acid pattern;Imp;Pt;Urine;Nom;;CHEM;1;Bile acid pattern [Interpretation] in Urine;Bile Ac Pattern Ur-Imp;;ACTIVE;2.09;2.26 +33474-8;Glycosaminoglycans pattern;Imp;Pt;Urine;Nom;;CHEM;1;Glycosaminoglycans pattern [Interpretation] in Urine;GAG Pattern Ur-Imp;;ACTIVE;2.09;2.26 +33475-5;Organic acids pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Organic acids pattern [Interpretation] in Serum or Plasma;Organic Acids Pattern SerPl-Imp;;ACTIVE;2.09;2.73 +33476-3;Organic acids pattern;Imp;Pt;CSF;Nom;;CHEM;1;Organic acids pattern [Interpretation] in Cerebral spinal fluid;Organic Acids Pattern CSF-Imp;;ACTIVE;2.09;2.26 +33477-1;Organic acids pattern;Imp;Pt;Urine;Nom;;CHEM;1;Organic acids pattern [Interpretation] in Urine;Organic Acids Pattern Ur-Imp;;ACTIVE;2.09;2.73 +33478-9;Fatty acids.very long chain pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Fatty acids.very long chain pattern [Interpretation] in Serum or Plasma;VLCFA Pattern SerPl-Imp;;ACTIVE;2.09;2.73 +33479-7;Epstein Barr virus early restricted Ab;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus early restricted Ab [Titer] in Serum;EBV EA-R Ab Titr Ser;;ACTIVE;2.09;2.70 +3348-0;Amphetamines;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Serum or Plasma;Amphetamines SerPl Ql;;ACTIVE;1.0;2.73 +33480-5;Methane/Expired gas^2H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose lactose PO;Breath methane 2h p Lac PO;;ACTIVE;2.09;2.70 +33481-3;Methane/Expired gas^2.5H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --2.5 hours post dose lactose PO;Breath methane 2.5h p Lac PO;;ACTIVE;2.09;2.70 +33482-1;Methane/Expired gas^3H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --3 hours post dose lactose PO;Breath methane 3h p Lac PO;;ACTIVE;2.09;2.70 +33483-9;Patient symptoms^pre dose lactose PO;Imp;Pt;^Patient;Nom;;CHAL;1;Patient symptoms [Interpretation] --pre dose lactose PO;Symptoms pre Lac PO Patient-Imp;;ACTIVE;2.09;2.12 +33484-7;Patient symptoms^30M post dose lactose PO;Imp;Pt;^Patient;Nom;;CHAL;1;Patient symptoms [Interpretation] --30 minutes post dose lactose PO;Symptoms 30M p Lac PO Patient-Imp;;ACTIVE;2.09;2.12 +33485-4;Patient symptoms^1H post dose lactose PO;Imp;Pt;^Patient;Nom;;CHAL;1;Patient symptoms [Interpretation] --1 hour post dose lactose PO;Symptoms 1h p Lac PO Patient-Imp;;ACTIVE;2.09;2.12 +33486-2;Patient symptoms^1.5H post dose lactose PO;Imp;Pt;^Patient;Nom;;CHAL;1;Patient symptoms [Interpretation] --1.5 hours post dose lactose PO;Symptoms 1.5h p Lac PO Patient-Imp;;ACTIVE;2.09;2.12 +33487-0;Patient symptoms^2H post dose lactose PO;Imp;Pt;^Patient;Nom;;CHAL;1;Patient symptoms [Interpretation] --2 hours post dose lactose PO;Symptoms 2h p Lac PO Patient-Imp;;ACTIVE;2.09;2.12 +33488-8;Patient symptoms^2.5H post dose lactose PO;Imp;Pt;^Patient;Nom;;CHAL;1;Patient symptoms [Interpretation] --2.5 hours post dose lactose PO;Symptoms 2.5h p Lac PO Patient-Imp;;ACTIVE;2.09;2.12 +33489-6;Hydrogen+Methane/Expired gas^3H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen+Methane/Expired gas [Volume Fraction] in Exhaled gas --3 hours post dose lactose PO;Breath H2+methane 3h p Lac PO;;ACTIVE;2.09;2.70 +33490-4;Hydrogen/Expired gas^pre dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --pre dose lactose PO;Breath H2 pre Lac PO;;ACTIVE;2.09;2.70 +33491-2;Hydrogen/Expired gas^30M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose lactose PO;Breath H2 30M p Lac PO;;ACTIVE;2.09;2.70 +33492-0;Hydrogen/Expired gas^1H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose lactose PO;Breath H2 1h p Lac PO;;ACTIVE;2.09;2.70 +33493-8;Hydrogen/Expired gas^1.5H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose lactose PO;Breath H2 1.5h p Lac PO;;ACTIVE;2.09;2.70 +33494-6;Hydrogen/Expired gas^2H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose lactose PO;Breath H2 2h p Lac PO;;ACTIVE;2.09;2.70 +33495-3;Hydrogen/Expired gas^2.5H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.5 hours post dose lactose PO;Breath H2 2.5h p Lac PO;;ACTIVE;2.09;2.70 +33496-1;Hydrogen/Expired gas^3H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3 hours post dose lactose PO;Breath H2 3h p Lac PO;;ACTIVE;2.09;2.70 +33497-9;Methane/Expired gas^pre dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --pre dose lactose PO;Breath methane pre Lac PO;;ACTIVE;2.09;2.70 +3349-8;Amphetamines;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Urine;Amphetamines Ur Ql;;ACTIVE;1.0;2.73 +33498-7;Methane/Expired gas^30M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose lactose PO;Breath methane 30M p Lac PO;;ACTIVE;2.09;2.70 +33499-5;Methane/Expired gas^1H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose lactose PO;Breath methane 1h p Lac PO;;ACTIVE;2.09;2.70 +335-0;Minocycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Minocycline [Susceptibility] by Minimum inhibitory concentration (MIC);Minocycline Islt MIC;;ACTIVE;1.0;2.73 +33500-0;Methane/Expired gas^1.5H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose lactose PO;Breath methane 1.5h p Lac PO;;ACTIVE;2.09;2.70 +33501-8;Hydrogen+Methane/Expired gas^30M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen+Methane/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose lactose PO;Breath H2+methane 30M p Lac PO;;ACTIVE;2.09;2.70 +33502-6;Hydrogen+Methane/Expired gas^1.5H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen+Methane/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose lactose PO;Breath H2+methane 1.5h p Lac PO;;ACTIVE;2.09;2.70 +33503-4;Hydrogen+Methane/Expired gas^2H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen+Methane/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose lactose PO;Breath H2+methane 2h p Lac PO;;ACTIVE;2.09;2.70 +33504-2;Hydrogen+Methane/Expired gas^pre dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen+Methane/Expired gas [Volume Fraction] in Exhaled gas --pre dose lactose PO;Breath H2+methane pre Lac PO;;ACTIVE;2.09;2.70 +33505-9;Hydrogen+Methane/Expired gas^1H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen+Methane/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose lactose PO;Breath H2+methane 1h p Lac PO;;ACTIVE;2.09;2.70 +3350-6;Amphetaminil;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Amphetaminil [Presence] in Urine;Amphetaminil Ur Ql;;ACTIVE;1.0;2.56 +33506-7;Hydrogen+Methane/Expired gas^2.5H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen+Methane/Expired gas [Volume Fraction] in Exhaled gas --2.5 hours post dose lactose PO;Breath H2+methane 2.5h p Lac PO;;ACTIVE;2.09;2.70 +33507-5;Alpha-Phenyl-2-Piperidine acetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate [Mass/volume] in Urine;PPAA Ur-mCnc;;ACTIVE;2.09;2.73 +33508-3;HIV 1 p65+p66 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p65+p66 Ab [Presence] in Serum by Immunoblot;HIV1 p65+p66 Ab Ser Ql IB;;ACTIVE;2.09;2.58 +33509-1;Hemoglobin;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Body fluid;Hgb Fld-mCnc;;ACTIVE;2.09;2.73 +33510-9;Coccidioides immitis Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Coccidioides immitis IgM Ab [Presence] in Specimen by Immunoassay;C immitis IgM Spec Ql IA;;ACTIVE;2.09;2.73 +33511-7;Appearance;Aper;Pt;XXX;Nom;;SPEC;1;Appearance of Specimen;Appearance Spec;;ACTIVE;2.09;2.73 +33512-5;Color;Type;Pt;XXX;Nom;;SPEC;1;Color of Specimen;Color Spec;;ACTIVE;2.09;2.73 +33513-3;Specific gravity;Rden;Pt;XXX;Qn;;CHEM;1;Specific gravity of Specimen;Sp Gr Spec;;ACTIVE;2.09;2.73 +3351-4;Amphetaminil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amphetaminil [Mass/volume] in Urine;Amphetaminil Ur-mCnc;;ACTIVE;1.0;2.34 +33514-1;Specimen volume;Vol;Pt;Sweat;Qn;;SPEC;1;Volume of Sweat;Specimen vol Sweat;;ACTIVE;2.09;2.73 +33515-8;Clarity;Type;Pt;XXX;Nom;;SPEC;1;Clarity of Specimen;Clarity Spec;;ACTIVE;2.09;2.73 +33516-6;Reticulocytes.immature/Reticulocytes.total;NFr;Pt;Bld;Qn;;HEM/BC;1;Immature reticulocytes/Reticulocytes.total in Blood;Imm Retics NFr;;ACTIVE;2.09;2.73 +33517-4;Hemoglobin;PrThr;Pt;Body fld;Ord;;HEM/BC;1;Hemoglobin [Presence] in Body fluid;Hgb Fld Ql;;ACTIVE;2.09;2.73 +33518-2;Platelet aggregation.adenosine diphosphate induced^high dose;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --High dose;PA ADP hi dose PRP;;ACTIVE;2.09;2.73 +33519-0;Platelet aggregation.adenosine diphosphate induced^low dose;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --Low dose;PA ADP lo dose PRP;;ACTIVE;2.09;2.73 +33520-8;Platelet aggregation.collagen induced^high dose;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation collagen induced in Platelet rich plasma --High dose;PA Coll hi dose PRP;;ACTIVE;2.09;2.54 +33521-6;Platelet aggregation.collagen induced^low dose;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation collagen induced in Platelet rich plasma --Low dose;PA Coll lo dose PRP;;ACTIVE;2.09;2.73 +3352-2;Amphetaminil;MRat;24H;Urine;Qn;;DRUG/TOX;1;Amphetaminil [Mass/time] in 24 hour Urine;Amphetaminil 24h Ur-mRate;;ACTIVE;1.0;2.42 +33522-4;Platelet aggregation.ristocetin induced^high dose;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --High dose;PA Rist hi dose PRP;;ACTIVE;2.09;2.73 +33523-2;Platelet aggregation.ristocetin induced^low dose;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --Low dose;PA Rist lo dose PRP;;ACTIVE;2.09;2.73 +33524-0;Coagulum lysis;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Clot Lysis [Time] in Control Platelet poor plasma by Coagulation assay;Clot Lysis Cont PPP;;ACTIVE;2.09;2.70 +33525-7;Coagulation thrombin induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;TT imm NP PPP;;ACTIVE;2.09;2.73 +33526-5;Coagulation reptilase induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Reptilase time.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;Reptilase time imm NP PPP;;ACTIVE;2.09;2.73 +33527-3;Methadone.long acting metabolite;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methadone.long acting metabolite [Mass/volume] in Urine;LA Methadone Metab Ur-mCnc;;ACTIVE;2.09;2.42 +33528-1;Platelet aggregation.adenosine diphosphate induced^high dose;RelACnc;Pt;PRP^Control;Qn;;COAG;1;Platelet aggregation ADP induced in Control Platelet rich plasma --High dose;PA ADP hi dose PRP Cont;;ACTIVE;2.09;2.73 +33529-9;Platelet aggregation.adenosine diphosphate induced^low dose;RelACnc;Pt;PRP^Control;Qn;;COAG;1;Platelet aggregation ADP induced in Control Platelet rich plasma --Low dose;PA ADP lo dose PRP Cont;;ACTIVE;2.09;2.73 +3353-0;Amphotericin B;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Amphotericin B [Mass/volume] in Cerebral spinal fluid;Amphotericin B CSF-mCnc;;ACTIVE;1.0;2.42 +33530-7;Platelet aggregation.EPINEPHrine induced;RelACnc;Pt;PRP^Control;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Control Platelet rich plasma;PA Epineph PRP Cont;;ACTIVE;2.09;2.54 +33531-5;Platelet aggregation.arachidonate induced;RelACnc;Pt;PRP^Control;Qn;;COAG;1;Platelet aggregation arachidonate induced in Control Platelet rich plasma;PA AA PRP Cont;;ACTIVE;2.09;2.73 +33532-3;Platelet aggregation.ristocetin induced^high dose;RelACnc;Pt;PRP^Control;Qn;;COAG;1;Platelet aggregation ristocetin induced in Control Platelet rich plasma --High dose;PA Rist hi dose PRP Cont;;ACTIVE;2.09;2.73 +33533-1;Platelet aggregation.ristocetin induced^low dose;RelACnc;Pt;PRP^Control;Qn;;COAG;1;Platelet aggregation ristocetin induced in Control Platelet rich plasma --Low dose;PA Rist lo dose PRP Cont;;ACTIVE;2.09;2.73 +33534-9;Coccidioides immitis Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;Coccidioides immitis IgM Ab [Presence] in Specimen;C immitis IgM Spec Ql;;ACTIVE;2.09;2.69 +33535-6;Influenza virus A+B Ag;PrThr;Pt;Nph;Ord;;MICRO;1;Influenza virus A+B Ag [Presence] in Nasopharynx;FLUAV+FLUBV Ag Nph Ql;;ACTIVE;2.09;2.73 +33536-4;Allergen.miscellaneous Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Miscellaneous allergen IgE Ab RAST class [Presence] in Serum;Misc Allergen IgE RAST Ql;;ACTIVE;2.09;2.73 +33537-2;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from AC.Jeanty 1982;OB.US;2;Gestational age estimated from Abdominal circumference on US by Jeanty 1982 method;GA from AC.Jeanty82;;ACTIVE;2.09;2.70 +33538-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Hansmann 1986;OB.US;2;Gestational age estimated from Biparietal diameter on US by Hansmann 1986 method;GA from BPD.Hansmann86;;ACTIVE;2.09;2.70 +33539-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BPD.Jeanty 1982;OB.US;2;Gestational age estimated from Biparietal diameter on US by Jeanty 1982 method;GA from BPD.Jeanty82;;ACTIVE;2.09;2.70 +33540-6;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from CRL.Hansmann 1986;OB.US;2;Gestational age estimated from Crown rump length on US by Hansmann 1986 method;GA from CRL.Hansmann86;;ACTIVE;2.09;2.70 +33541-4;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from FL.Hansmann 1986;OB.US;2;Gestational age estimated from Femur length on US by Hansmann 1986 method;GA from FL.Hansmann86;;ACTIVE;2.09;2.70 +33542-2;Gestational age;Time;Pt;^Fetus;Qn;Estimated from FL.Merz 1988;OB.US;2;Gestational age Estimated from FL.Merz 1988;GA Est from FL.Merz.88;;ACTIVE;2.09;2.70 +33543-0;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from HC.Hansmann 1986;OB.US;2;Gestational age estimated from Head circumference on US by Hansmann 1986 method;GA from HC.Hansmann86;;ACTIVE;2.09;2.70 +33544-8;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from OFD.Hansmann 1985;OB.US;2;Gestational age estimated from Occipital-frontal diameter on US by Hansmann 1985 method;GA from OFD.Hansmann85;;ACTIVE;2.09;2.70 +33545-5;Gestational age;Time;Pt;^Fetus;Qn;US+Estimated from BD.Jeanty 1982;OB.US;2;Gestational age estimated from Binocular distance on US by Jeanty 1982 method;GA from BD.Jeanty82;;ACTIVE;2.09;2.70 +33546-3;Perimeter;Len;Pt;Abdomen^Fetus;Qn;US.derived from Chitty 1994;OB.US;2;Fetal Abdomen Circumference derived by method of Chitty 1994 (US);Fet Abd Circum by Chitty94 der;;ACTIVE;2.09;2.70 +33547-1;Creatine kinase.aberrant band/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine Kinase aberrant band/Creatine kinase.total in Serum or Plasma by Electrophoresis;CK-AB CFr SerPl Elph;;ACTIVE;2.09;2.73 +3354-8;Amphotericin B;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amphotericin B [Mass/volume] in Serum or Plasma;Amphotericin B SerPl-mCnc;;ACTIVE;1.0;2.40 +33548-9;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Body fluid by Manual count;Lymph Abn/leuk NFr Fld Manual;;ACTIVE;2.09;2.54 +33549-7;Hantavirus sin nombre Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hantavirus sin nombre Ab [Presence] in Serum;SNV Ab Ser Ql;;ACTIVE;2.09;2.70 +33550-5;Platelet aggregation.ristocetin induced^1500 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --1500 ug/mL;PA Rist 1500 ug/mL PRP;;ACTIVE;2.09;2.70 +33551-3;Platelet aggregation.ristocetin induced^1200 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --1200 ug/mL;PA Rist 1200 ug/mL PRP;;ACTIVE;2.09;2.73 +33552-1;Platelet aggregation.ristocetin induced^900 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --900 ug/mL;PA Rist 900 ug/mL PRP;;ACTIVE;2.09;2.70 +33553-9;Platelet aggregation.ristocetin induced^600 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --600 ug/mL;PA Rist 600 ug/mL PRP;;ACTIVE;2.09;2.73 +33554-7;Platelet aggregation.ristocetin induced^300 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --300 ug/mL;PA Rist 300 ug/mL PRP;;ACTIVE;2.09;2.70 +3355-5;Ampicillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ampicillin [Mass/volume] in Serum or Plasma;Ampicillin SerPl-mCnc;;ACTIVE;1.0;2.73 +33555-4;Inactivated poliovirus vaccine dose count in combination vaccine;Num;Pt;^Patient;Qn;;VACCIN;2;Inactivated poliovirus vaccine dose count in combination vaccine;IPV dose count in combo vaccine;;ACTIVE;2.09;2.48 +33556-2;Diameter.biparietal outer to inner;Len;Pt;Head^Fetus;Qn;US.estimated from Chitty 1994;OB.US;2;Fetal Head Diameter.biparietal outer to inner estimated from gestational age by method of Chitty 1994 (US);Fet BPD O-I from GA.Chitty94;;ACTIVE;2.09;2.70 +33557-0;Completion status;Type;Pt;{Type of task};Ord;Observed;CLIN;2;Completion status Task Observed;Completion status Task Observ;;ACTIVE;2.09;2.34 +33558-8;Creatinine renal clearance;VRat;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance in Urine and Serum or Plasma collected for unspecified duration;Creat Cl ?Tm Ur+SerPl-vRate;;ACTIVE;2.09;2.73 +33559-6;Immunoglobulin light chains.kappa/Immunoglobulin light chains.lambda;MRto;Pt;Urine;Qn;;CHEM;1;Kappa light chains/Lambda light chains [Mass Ratio] in Urine;Kappa LC/Lambda Ur;;ACTIVE;2.09;2.73 +33560-4;Benzodiazepines;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Gastric fluid;Benzodiaz Gast-mCnc;;ACTIVE;2.09;2.70 +33561-2;Cannabinoids;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Cannabinoids [Mass/volume] in Gastric fluid;Cannabinoids Gast-mCnc;;ACTIVE;2.09;2.70 +33562-0;Ampicillin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ampicillin [Mass/volume] in Serum or Plasma --peak;Ampicillin Peak SerPl-mCnc;;ACTIVE;2.09;2.70 +3356-3;Anileridine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Anileridine [Mass/volume] in Serum or Plasma;Anileridine SerPl-mCnc;;ACTIVE;1.0;2.42 +33563-8;Pancreatic islet cell Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Pancreatic islet cell IgG Ab [Units/volume] in Serum;Panc Islet Cell IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33564-6;Smith extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Smith extractable nuclear IgG Ab [Units/volume] in Serum by Immunoassay;ENA SM IgG Ser IA-aCnc;;ACTIVE;2.09;2.73 +33565-3;Smith extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IB;SERO;1;Smith extractable nuclear IgG Ab [Units/volume] in Serum by Immunoblot;ENA SM IgG Ser IB-aCnc;;ACTIVE;2.09;2.69 +33566-1;Sjogrens syndrome-A extractable nuclear Ab;ACnc;Pt;Ser;Qn;IB;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Units/volume] in Serum by Immunoblot;ENA SS-A Ab Ser IB-aCnc;;ACTIVE;2.09;2.69 +33567-9;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear IgG Ab [Units/volume] in Serum by Immunoassay;ENA SM+RNP IgG Ser IA-aCnc;;ACTIVE;2.09;2.73 +33568-7;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IB;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear IgG Ab [Units/volume] in Serum by Immunoblot;ENA SM+RNP IgG Ser IB-aCnc;;ACTIVE;2.09;2.69 +33569-5;Sjogrens syndrome-A extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA SS-A Ab Ser IA-aCnc;;ACTIVE;2.09;2.73 +33570-3;Sjogrens syndrome-B extractable nuclear Ab;ACnc;Pt;Ser;Qn;IB;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum by Immunoblot;ENA SS-B Ab Ser IB-aCnc;;ACTIVE;2.09;2.69 +3357-1;Anileridine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Anileridine [Presence] in Urine;Anileridine Ur Ql;;ACTIVE;1.0;2.73 +33571-1;Jo-1 extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Jo-1 extractable nuclear IgG Ab [Units/volume] in Serum;ENA Jo1 IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33572-9;Aureobasidium pullulans Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Aureobasidium pullulans IgG Ab [Presence] in Serum;A pullulans IgG Ser Ql;;ACTIVE;2.09;2.73 +33573-7;Bactericidal permeability increasing protein Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Bactericidal permeability increasing protein IgG Ab [Units/volume] in Serum by Immunoassay;BPI IgG Ser IA-aCnc;;ACTIVE;2.09;2.70 +33574-5;Chlamydia trachomatis I Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis I IgM Ab [Titer] in Serum by Immunofluorescence;C trach I IgM Titr Ser IF;;ACTIVE;2.09;2.70 +33575-2;Chlamydia trachomatis I Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis I Ab [Titer] in Serum by Immunofluorescence;C trach I Ab Titr Ser IF;;ACTIVE;2.09;2.70 +33576-0;Francisella tularensis Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Francisella tularensis IgA Ab [Titer] in Serum;F tular IgA Titr Ser;;ACTIVE;2.09;2.30 +33577-8;Rheumatoid factor.IgM;Titr;Pt;Ser;Qn;Nephelometry;SERO;1;Rheumatoid factor IgM [Titer] in Serum by Nephelometry;RF IgM Titr Ser Neph;;ACTIVE;2.09;2.70 +33578-6;Dengue virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Dengue virus Ab [Titer] in Serum by Immunofluorescence;DENV Ab Titr Ser IF;;ACTIVE;2.09;2.70 +33579-4;Anaplasma phagocytophilum Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Deprecated Anaplasma phagocytophilum IgM Ab [Titer] in Serum by Immunofluorescence;Deprecated A phagocytoph IgM Titr Ser IF;;DEPRECATED;2.09;2.70 +33580-2;Anaplasma phagocytophilum Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Deprecated Anaplasma phagocytophilum IgG Ab [Titer] in Serum by Immunofluorescence;Deprecated A phagocytoph IgG Titr Ser IF;;DEPRECATED;2.09;2.70 +33581-0;Anaplasma phagocytophilum Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Deprecated Anaplasma phagocytophilum Ab [Titer] in Serum by Immunofluorescence;Deprecated A phagocytoph Ab Titr Ser IF;;DEPRECATED;2.09;2.70 +33582-8;Cells.CD13+CD33+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD13+CD33+ cells [#/volume] in Blood;CD13+CD33+ Cells # Bld;;ACTIVE;2.09;2.40 +33583-6;Sjogrens syndrome-A extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IB;SERO;1;Sjogrens syndrome-A extractable nuclear IgG Ab [Units/volume] in Serum by Immunoblot;ENA SS-A IgG Ser IB-aCnc;;ACTIVE;2.09;2.70 +33584-4;Gastrin^10M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --10 minutes pre XXX challenge;Gastrin 10M pre chal SerPl-mCnc;;ACTIVE;2.09;2.34 +33585-1;Uroporphyrin 3 isomer;MRat;24H;Stool;Qn;;CHEM;1;Uroporphyrin 3 isomer [Mass/time] in 24 hour Stool;Uropor3 24h Stl-mRate;;ACTIVE;2.09;2.73 +33586-9;Cells.CD2+CD7+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD2+CD7+ cells [#/volume] in Blood;CD2+CD7+ Cells # Bld;;ACTIVE;2.09;2.40 +33587-7;Trichinella sp Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Trichinella sp IgA Ab [Units/volume] in Serum;Trichinella IgA Ser-aCnc;;ACTIVE;2.09;2.70 +33588-5;Phosphatidylethanolamine Ab;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylethanolamine Ab [Units/volume] in Serum by Immunoassay;PE Ab Ser IA-aCnc;;ACTIVE;2.09;2.73 +3358-9;Anileridine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Deprecated Anileridine [Molecules/volume] in 24 hour Urine;Deprecated Anileridine 24H Ur-mRate;;DEPRECATED;1.0;2.36 +33589-3;Phosphatidylinositol Ab;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidylinositol Ab [Units/volume] in Serum by Immunoassay;PI Ab Ser IA-aCnc;;ACTIVE;2.09;2.70 +33590-1;Neuronal nuclear Ab.IgG;ACnc;Pt;CSF;Qn;;SERO;1;Neuronal nuclear IgG Ab [Units/volume] in Cerebral spinal fluid;Hu IgG CSF-aCnc;;ACTIVE;2.09;2.69 +33591-9;Neuronal nuclear Ab.IgG;ACnc;Pt;Ser;Qn;Flow cytometry;SERO;1;Neuronal nuclear IgG Ab [Units/volume] in Serum by Flow cytometry (FC);Hu IgG Ser FC-aCnc;;ACTIVE;2.09;2.69 +33592-7;Cells.CD10+HLA-DR+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD10+HLA-DR+ cells [#/volume] in Blood;CD10+HLA-DR+ Cells # Bld;;ACTIVE;2.09;2.40 +33593-5;Hemoglobin G-Coushatta/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin G - Coushatta/Hemoglobin.total in Blood;Hgb G-Coush MFr Bld;;ACTIVE;2.09;2.73 +33594-3;Platelet factor 4;PrThr;Pt;PPP;Ord;;COAG;1;Platelet factor 4 [Presence] in Platelet poor plasma;PF4 PPP Ql;;ACTIVE;2.09;2.73 +33595-0;Cells.CD5+CD20+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD5+CD20+ cells [#/volume] in Blood;CD5+CD20+ Cells # Bld;;ACTIVE;2.09;2.73 +33596-8;Cells.CD10+CD20+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD10+CD20+ cells [#/volume] in Blood;CD10+CD20+ Cells # Bld;;ACTIVE;2.09;2.40 +3359-7;Anileridine;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Anileridine [Moles/volume] in 24 hour Urine;Anileridine 24h Ur-sCnc;;ACTIVE;1.0;2.34 +33597-6;Borrelia burgdorferi 34kD Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Borrelia burgdorferi 34kD IgM Ab [Units/volume] in Serum;Deprecated B burgdor34kD IgM Ser-aCnc;;DEPRECATED;2.09;2.69 +33598-4;Sjogrens syndrome-B extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IB;SERO;1;Sjogrens syndrome-B extractable nuclear IgG Ab [Units/volume] in Serum by Immunoblot;ENA SS-B IgG Ser IB-aCnc;;ACTIVE;2.09;2.69 +33599-2;Amylase;CCnc;XXX;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Urine collected for unspecified duration;Amylase ?Tm Ur-cCnc;;ACTIVE;2.09;2.70 +33600-8;Neuronal nuclear Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear Ab [Units/volume] in Serum by Immunofluorescence;Hu Ab Ser IF-aCnc;;ACTIVE;2.09;2.69 +33601-6;Cells.CD23+CD38+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD23+CD38+ cells [#/volume] in Blood;CD23+CD38+ Cells # Bld;;ACTIVE;2.09;2.30 +33602-4;Myelin associated glycoprotein Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein IgG Ab [Titer] in Serum;MAG IgG Titr Ser;;ACTIVE;2.09;2.73 +33603-2;Bactericidal permeability increasing protein Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Bactericidal permeability increasing protein IgG Ab [Units/volume] in Serum;BPI IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33604-0;Chlamydia trachomatis I Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis I IgM Ab [Titer] in Serum;C trach I IgM Titr Ser;;ACTIVE;2.09;2.70 +3360-5;Atenolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Atenolol [Presence] in Urine;Atenolol Ur Ql;;ACTIVE;1.0;2.73 +33605-7;Chlamydia trachomatis I Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis I Ab [Titer] in Serum;C trach I Ab Titr Ser;;ACTIVE;2.09;2.70 +33606-5;Dengue virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Dengue virus Ab [Titer] in Serum;DENV Ab Titr Ser;;ACTIVE;2.09;2.70 +33607-3;Anaplasma phagocytophilum Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Anaplasma phagocytophilum IgM Ab [Titer] in Serum;Deprecated A phagocytoph IgM Titr Ser;;DEPRECATED;2.09;2.70 +33608-1;Anaplasma phagocytophilum Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Anaplasma phagocytophilum IgG Ab [Titer] in Serum;Deprecated A phagocytoph IgG Titr Ser;;DEPRECATED;2.09;2.70 +33609-9;Anaplasma phagocytophilum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Anaplasma phagocytophilum Ab [Titer] in Serum;A phagocytoph Ab Titr Ser;;ACTIVE;2.09;2.73 +33610-7;Sjogrens syndrome-A extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-A extractable nuclear IgG Ab [Units/volume] in Serum;ENA SS-A IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33611-5;Phosphatidylethanolamine Ab;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine Ab [Units/volume] in Serum;PE Ab Ser-aCnc;;ACTIVE;2.09;2.70 +33612-3;Phosphatidylinositol Ab;ACnc;Pt;Ser;Qn;;COAG;1;Phosphatidylinositol Ab [Units/volume] in Serum;PI Ab Ser-aCnc;;ACTIVE;2.09;2.73 +3361-3;Atenolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Atenolol [Mass/volume] in Urine;Atenolol Ur-mCnc;;ACTIVE;1.0;2.42 +33613-1;Sjogrens syndrome-B extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-B extractable nuclear IgG Ab [Units/volume] in Serum;ENA SS-B IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33614-9;Transferrin.carbohydrate deficient.XXX/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.XXX/Transferrin.total in Serum or Plasma;CDT Other/Tf MFr SerPl;;ACTIVE;2.09;2.70 +33615-6;Neuronal nuclear type 1 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Neuronal nuclear type 1 Ab [Presence] in Serum;Hu1 Ab Ser Ql;;ACTIVE;2.09;2.73 +33616-4;Cytomegalovirus early Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Cytomegalovirus early Ag [Presence] in Urine;CMV EA Ag Ur Ql;;ACTIVE;2.09;2.73 +33617-2;Cells.HLA-DR+;NCnc;Pt;Bld;Qn;;CELLMARK;1;HLA-DR+ cells [#/volume] in Blood;HLA-DR+ Cells # Bld;;ACTIVE;2.09;2.73 +33618-0;Coproporphyrin 3/Coproporphyrin 1;MRto;24H;Stool;Qn;;CHEM;1;Coproporphyrin 3/Coproporphyrin 1 [Mass Ratio] in 24 hour Stool;Copro3/Copro1 24h Stl;;ACTIVE;2.09;2.73 +33619-8;Deuteroporphyrin.semi-proto;MRat;24H;Stool;Qn;;CHEM;1;Deuteroporphyrin.semi-proto [Mass/time] in 24 hour Stool;S P Deuteropor 24h Stl-mRate;;ACTIVE;2.09;2.70 +33620-6;Tricarboxylporphyrin 1;MRat;24H;Stool;Qn;;CHEM;1;Tricarboxylporphyrin 1 [Mass/time] in 24 hour Stool;Tri-CP 24h Stl-mRate;;ACTIVE;2.09;2.70 +3362-1;Atenolol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Atenolol [Mass/time] in 24 hour Urine;Atenolol 24h Ur-mRate;;ACTIVE;1.0;2.44 +33621-4;Tricarboxylporphyrin 3;MRat;24H;Stool;Qn;;CHEM;1;Tricarboxylporphyrin 3 [Mass/time] in 24 hour Stool;Tri-CP3 24h Stl-mRate;;ACTIVE;2.09;2.70 +33622-2;Isotricarboxylporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Isotricarboxylporphyrin [Mass/time] in 24 hour Stool;Isotri-CP 24h Stl-mRate;;ACTIVE;2.09;2.70 +33623-0;Pentacarboxylporphyrin I;MRat;24H;Stool;Qn;;CHEM;1;Pentacarboxylporphyrin I [Mass/time] in 24 hour Stool;Penta-CPI 24h Stl-mRate;;ACTIVE;2.09;2.73 +33624-8;Pentacarboxylporphyrin III;MRat;24H;Stool;Qn;;CHEM;1;Pentacarboxylporphyrin III [Mass/time] in 24 hour Stool;Penta-CP3 24h Stl-mRate;;ACTIVE;2.09;2.73 +33625-5;Isocoproporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Isocoproporphyrin [Mass/time] in 24 hour Stool;Isocopropor 24h Stl-mRate;;ACTIVE;2.09;2.73 +33626-3;Hematoporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Hematoporphyrin [Mass/time] in 24 hour Stool;Hematopor 24h Stl-mRate;;ACTIVE;2.09;2.42 +33627-1;Tenofovir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tenofovir [Susceptibility];Tenofovir Susc Islt;;ACTIVE;2.09;2.19 +33628-9;Cidofovir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cidofovir [Susceptibility];Cidofovir Susc Islt;;ACTIVE;2.09;2.19 +33629-7;Hepatitis B virus sequencing;Prid;Pt;Ser;Nar;Probe.amp.tar;MICRO;1;Hepatitis B virus sequencing [Identifier] in Serum by NAA with probe detection;HBV sequencing Ser NAA+probe;;ACTIVE;2.09;2.73 +33630-5;HIV protease gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV protease gene mutations detected [Identifier];HIV PI gene Mut Det Islt;;ACTIVE;2.09;2.73 +33631-3;Cytomegalovirus UL54 gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;Cytomegalovirus UL54 gene mutations detected [Identifier];CMV UL54 gene Mut Det Islt;;ACTIVE;2.09;2.73 +33632-1;Cytomegalovirus UL54+UL97 gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;Cytomegalovirus UL54+UL97 gene mutations detected [Identifier];CMV UL54+UL97 Gen Mut Det Islt;;ACTIVE;2.09;2.38 +33633-9;Hepatitis B virus precore TAG mutation;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Hepatitis B virus precore TAG [Presence] in Serum by NAA with probe detection;HBV preC TAG Mut Ser Ql NAA+probe;;ACTIVE;2.09;2.73 +33634-7;Mycobacterium tuberculosis rifAMPin resistance gene;Prid;Pt;Sputum;Nom;Probe.amp.tar;ABXBACT;1;Mycobacterium tuberculosis rifAMPin resistance gene [Identifier] in Sputum by NAA with probe detection;MTB RIF res gene Spt NAA+probe;;ACTIVE;2.09;2.73 +33635-4;PM-SCL extractable nuclear Ab;MCnc;Pt;Ser;Qn;Immune diffusion;SERO;1;PM-SCL extractable nuclear Ab [Mass/volume] in Serum by Immune diffusion (ID);ENA PM/SCL Ab Ser ID-mCnc;;ACTIVE;2.09;2.73 +33636-2;IgA.secretory;ACnc;Pt;Saliva;Qn;;CHEM;1;IgA.secretory [Units/volume] in Saliva (oral fluid);SIgA Sal-aCnc;;ACTIVE;2.09;2.70 +33637-0;Phagocytic index;ACnc;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Phagocytic index of Blood by Flow cytometry (FC);PI Bld FC-aCnc;;ACTIVE;2.09;2.70 +33638-8;Lymphocyte proliferation.phytohemagglutinin stimulation;MCnc;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by phytohemagglutinin [Mass/volume] in Blood;LPT PHA Bld-mCnc;;ACTIVE;2.09;2.73 +3363-9;Anthraquinone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Anthraquinone [Mass/volume] in Serum or Plasma;Anthraquinone SerPl-mCnc;;ACTIVE;1.0;2.34 +33639-6;Lymphocyte proliferation.Candida albicans stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by Candida albicans [Units/volume] in Blood;LPT CA Bld-aCnc;;ACTIVE;2.09;2.73 +33640-4;Lymphocyte proliferation.tetanus toxoid stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by tetanus toxoid [Units/volume] in Blood;LPT TT Bld-aCnc;;ACTIVE;2.09;2.73 +33641-2;Lymphocyte proliferation.tuberculin stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by tuberculin [Units/volume] in Blood;LPT Tuberc Bld-aCnc;;ACTIVE;2.09;2.73 +33642-0;Lymphocyte Ab;ACnc;Pt;Ser;Qn;Flow cytometry;SERO;1;Lymphocyte Ab [Units/volume] in Serum by Flow cytometry (FC);Lymphocyte Ab Ser FC-aCnc;;ACTIVE;2.09;2.69 +33643-8;Limulus amebocyte lysate test;ACnc;Pt;Flu.nonbiological;Qn;;MICRO;1;Limulus amebocyte lysate test [Units/volume] in Nonbiological fluid;LAL Test Fld.NB-aCnc;;ACTIVE;2.09;2.68 +33644-6;A1 Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;A1 Ab [Titer] in Serum or Plasma;A1 Ab Titr SerPl;;ACTIVE;2.09;2.73 +33645-3;A2 Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;A2 Ab [Titer] in Serum or Plasma;A2 Ab Titr SerPl;;ACTIVE;2.09;2.73 +33646-1;Methylenedianiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylenedianiline [Mass/volume] in Serum or Plasma;4,4-MDA SerPl-mCnc;;ACTIVE;2.09;2.70 +3364-7;Antipyrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Antipyrine [Mass/volume] in Serum or Plasma;Antipyrine SerPl-mCnc;;ACTIVE;1.0;2.73 +33647-9;Protein.monoclonal/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal/Protein.total in Serum or Plasma by Electrophoresis;M Protein MFr SerPl Elph;;ACTIVE;2.09;2.73 +33648-7;Cryoglobulin.rheumatoid factor;ACnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin Rheumatoid Factor [Units/volume] in Serum;Cryoglob RF Ser-aCnc;;ACTIVE;2.09;2.73 +33649-5;Cryoglobulin.IgG;MCnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin.IgG [Mass/volume] in Serum;Cryoglob IgG Ser-mCnc;;ACTIVE;2.09;2.70 +33650-3;Cryoglobulin.IgA;MCnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin.IgA [Mass/volume] in Serum;Cryoglob IgA Ser-mCnc;;ACTIVE;2.09;2.70 +33651-1;Cryoglobulin.IgM;MCnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin.IgM [Mass/volume] in Serum;Cryoglob IgM Ser-mCnc;;ACTIVE;2.09;2.70 +33652-9;Cells.CD56/Cells.CD38;NRto;Pt;Bld;Qn;;CELLMARK;1;CD56 cells/CD38 Cells [# Ratio] in Blood;CD56 Cells/CD38 Cells Bld;;ACTIVE;2.09;2.70 +33653-7;Beta galactosidase;EntCat;Pt;WBC;Qn;;CHEM;1;Beta galactosidase [Entitic Catalytic Activity] in Leukocytes;B-Galactosidase WBC Qn;;ACTIVE;2.09;2.70 +3365-4;Antipyrine renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Antipyrine renal clearance in 24 hour Urine and Serum or Plasma;Antipyrine Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +33654-5;Insulin-like growth factor binding protein 3^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;IGF BP3 1h p chal SerPl-mCnc;;ACTIVE;2.09;2.70 +33655-2;Beta-N-acetylhexosaminidase;SCnc;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Moles/volume] in Leukocytes;B-NAH WBC-sCnc;;ACTIVE;2.09;2.70 +33656-0;Beta-N-acetylhexosaminidase.B;SCnc;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.B [Moles/volume] in Leukocytes;Hexosaminidase B WBC-sCnc;;ACTIVE;2.09;2.70 +33657-8;Beta-N-acetylhexosaminidase.A;SCnc;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A [Moles/volume] in Leukocytes;Hexosaminidase A WBC-sCnc;;ACTIVE;2.09;2.70 +33658-6;Insulin-like growth factor binding protein 3^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;IGF BP3 2h p chal SerPl-mCnc;;ACTIVE;2.09;2.70 +33659-4;Pipecolate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Pipecolate/Creatinine [Ratio] in Urine;Pipecolate/Creat Ur-Rto;;ACTIVE;2.09;2.70 +33660-2;HIV 1 p24 Ag;PrThr;Pt;Ser/Plas;Ord;Neut;MICRO;1;HIV 1 p24 Ag [Presence] in Serum or Plasma by Neutralization test;HIV1 p24 Ag SerPl Ql Nt;;ACTIVE;2.09;2.70 +33661-0;Glucosylceramidase;EntCat;Pt;WBC;Qn;;CHEM;1;Glucosylceramidase [Entitic Catalytic Activity] in Leukocytes;Glucosylceramidase WBC Qn;;ACTIVE;2.09;2.70 +3366-2;Atenolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Atenolol [Mass/volume] in Serum or Plasma;Atenolol SerPl-mCnc;;ACTIVE;1.0;2.42 +33662-8;Erythrocytes.CD59 deficient/100 Cells.235a;NFr;Pt;Bld;Qn;;CELLMARK;1;Erythrocytes.CD59 deficient/100 erythrocytes in Blood;RBC CD59 deficient NFr;;ACTIVE;2.09;2.73 +33663-6;Cells.CD59 deficient/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD59 deficient cells/100 cells in Blood;CD59 Deficient Cells NFr Bld;;ACTIVE;2.09;2.73 +33664-4;Cells.CD59;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD59 cells [Presence] in Blood;CD59 Cells Bld Ql;;ACTIVE;2.09;2.73 +33665-1;HTLV I+II Ab band pattern;Imp;Pt;Ser;Nom;RIPA;MICRO;1;HTLV I+II Ab band pattern [Interpretation] in Serum by Radioimmunoprecipitation assay (RIPA);HTLV I+II Ab Patrn Ser RIPA-Imp;;ACTIVE;2.09;2.52 +33666-9;Erythrocytes.dysmorphic;NCnc;Pt;Urine;Qn;Microscopy.light;UA;1;Erythrocytes.dysmorphic [#/volume] in Urine by Light microscopy;Dysmorphic RBC # Ur Micro;;ACTIVE;2.09;2.70 +33667-7;Prostate specific Ag.protein bound;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prostate specific Ag.protein bound [Mass/volume] in Serum or Plasma;Complexed PSA SerPl-mCnc;;ACTIVE;2.09;2.73 +33668-5;Erythrocytes;PrThr;Pt;Stool;Ord;;HEM/BC;1;Erythrocytes [Presence] in Stool;RBC Stl Ql;;ACTIVE;2.09;2.56 +33669-3;Trypsin;Titr;Pt;Stool;Qn;;CHEM;1;Trypsin [Titer] in Stool;Trypsin Titr Stl;;ACTIVE;2.09;2.73 +3367-0;Atropine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Atropine [Mass/volume] in Serum or Plasma;Atropine SerPl-mCnc;;ACTIVE;1.0;2.34 +33670-1;Platelet aggregation.collagen induced lag^high dose;Time;Pt;PRP;Qn;;COAG;1;Platelet aggregation collagen induced lag [Time] in Platelet rich plasma --High dose;PA Coll Lag time hi dose PRP;;ACTIVE;2.09;2.44 +33671-9;Platelet aggregation.collagen induced lag^high dose;Time;Pt;PRP^Control;Qn;;COAG;1;Platelet aggregation collagen induced lag [Time] in Control Platelet rich plasma --High dose;PA Coll Lag time hi dose Cont PRP;;ACTIVE;2.09;2.44 +33672-7;Platelet aggregation.ristocetin+Control PPP induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation.ristocetin+Control PPP induced in Platelet rich plasma;PA Rist + Cont PPP PRP;;ACTIVE;2.09;2.54 +33673-5;Coagulation thrombin induced.factor substitution^immediately after addition of protamine sulfate;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of protamine sulfate;TT imm SO4 PPP;;ACTIVE;2.09;2.73 +33674-3;Platelet aggregation.ristocetin+Control PRP induced;RelACnc;Pt;PPP;Qn;;COAG;1;Platelet aggregation.ristocetin+Control PRP induced in Platelet poor plasma;PA Rist + Cont PRP PPP;;ACTIVE;2.09;2.54 +33675-0;Microscopic observation;Prid;Pt;XXX;Nom;Esterase stain.combined;PATH;1;Microscopic observation [Identifier] in Specimen by Esterase stain.combined;CE Stn Spec;;ACTIVE;2.09;2.69 +33676-8;Francisella tularensis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Francisella tularensis [Presence] in Specimen by Organism specific culture;F tular Spec Ql Cult;;ACTIVE;2.09;2.73 +33677-6;Francisella tularensis;PrThr;Pt;Isolate;Ord;Organism specific culture;MICRO;1;Francisella tularensis [Presence] in Isolate by Organism specific culture;F tular Islt Ql Cult;;ACTIVE;2.09;2.65 +33678-4;Francisella tularensis Ag;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Francisella tularensis Ag [Presence] in Isolate by Immunofluorescence;F tular Ag Islt Ql IF;;ACTIVE;2.09;2.65 +33679-2;Francisella tularensis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Francisella tularensis DNA [Presence] in Specimen by NAA with probe detection;F tular DNA Spec Ql NAA+probe;;ACTIVE;2.09;2.73 +336-8;Minocycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Minocycline [Susceptibility] by Disk diffusion (KB);Minocycline Islt KB;;ACTIVE;1.0;2.73 +33680-0;Francisella tularensis DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Francisella tularensis DNA [Presence] in Isolate by NAA with probe detection;F tular DNA Islt Ql NAA+probe;;ACTIVE;2.09;2.65 +33681-8;Francisella tularensis;PrThr;Pt;XXX;Ord;Cell wall fatty acid analysis;MICRO;1;Francisella tularensis [Presence] in Specimen by Cell wall fatty acid analysis;F tular Spec Ql CFA;;ACTIVE;2.09;2.69 +33682-6;Francisella tularensis;PrThr;Pt;Isolate;Ord;Cell wall fatty acid analysis;MICRO;1;Francisella tularensis [Presence] in Isolate by Cell wall fatty acid analysis;F tular Islt Ql CFA;;ACTIVE;2.09;2.65 +33683-4;Francisella tularensis Ab;Titr;Pt;Ser;Qn;Aggl.micro;MICRO;1;Francisella tularensis Ab [Titer] in Serum by Microagglutination;F tular Ab Titr Ser Microaggl;;ACTIVE;2.09;2.30 +33684-2;Francisella tularensis Ab;Titr;Pt;Ser;Qn;Aggl.standard tube;MICRO;1;Francisella tularensis Ab [Titer] in Serum by Tube agglutination;F tular Ab Titr Ser Tube aggl;;ACTIVE;2.09;2.34 +33685-9;Yersinia pestis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Yersinia pestis [Presence] in Specimen by Organism specific culture;Y pestis Spec Ql Cult;;ACTIVE;2.09;2.73 +33686-7;Yersinia pestis;PrThr;Pt;Isolate;Ord;Organism specific culture;MICRO;1;Yersinia pestis [Presence] in Isolate by Organism specific culture;Y pestis Islt Ql Cult;;ACTIVE;2.09;2.65 +33687-5;Yersinia pestis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Yersinia pestis Ag [Presence] in Specimen by Immunofluorescence;Y pestis Ag Spec Ql IF;;ACTIVE;2.09;2.69 +3368-8;Azlocillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Azlocillin [Mass/volume] in Serum or Plasma;Azlocillin SerPl-mCnc;;ACTIVE;1.0;2.34 +33688-3;Yersinia pestis Ag;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Yersinia pestis Ag [Presence] in Isolate by Immunofluorescence;Y pestis Ag Islt Ql IF;;ACTIVE;2.09;2.65 +33689-1;Yersinia pestis Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Yersinia pestis Ab [Presence] in Serum by Hemagglutination inhibition;Y pestis Ab Ser Ql HAI;;ACTIVE;2.09;2.65 +33690-9;Yersinia pestis Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Yersinia pestis Ab [Titer] in Serum by Immunoassay;Y pestis Ab Titr Ser IA;;ACTIVE;2.09;2.56 +33691-7;Yersinia pestis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Yersinia pestis DNA [Presence] in Specimen by NAA with probe detection;Y pestis DNA Spec Ql NAA+probe;;ACTIVE;2.09;2.69 +33692-5;Yersinia pestis DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Yersinia pestis DNA [Presence] in Isolate by NAA with probe detection;Y pestis DNA Islt Ql NAA+probe;;ACTIVE;2.09;2.65 +33693-3;Yersinia pestis;PrThr;Pt;Isolate;Ord;Phage lysis;MICRO;1;Yersinia pestis [Presence] in Isolate by Phage lysis;Y pestis Islt Ql Phage Lys;;ACTIVE;2.09;2.65 +33694-1;Clostridium botulinum;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Clostridium botulinum [Presence] in Specimen by Organism specific culture;C bot Spec Ql Cult;;ACTIVE;2.09;2.69 +33695-8;Clostridium botulinum;PrThr;Pt;Isolate;Ord;Organism specific culture;MICRO;1;Clostridium botulinum [Presence] in Isolate by Organism specific culture;C bot Islt Ql Cult;;ACTIVE;2.09;2.65 +3369-6;Aztreonam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aztreonam [Mass/volume] in Serum or Plasma;Aztreonam SerPl-mCnc;;ACTIVE;1.0;2.42 +33696-6;Clostridium botulinum toxin;PrThr;Pt;XXX;Ord;Mouse bioassay;MICRO;1;Clostridium botulinum toxin [Presence] in Specimen by Mouse bioassay;C bot Tox Spec Ql MA;;ACTIVE;2.09;2.69 +33697-4;Bacillus anthracis Ag;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Bacillus anthracis Ag [Presence] in Isolate by Immunofluorescence;B anthracis Ag Islt Ql IF;;ACTIVE;2.09;2.65 +33698-2;Bacillus anthracis;PrThr;Pt;Isolate;Ord;Phage lysis;MICRO;1;Bacillus anthracis [Presence] in Isolate by Phage lysis;B anthracis Islt Ql Phage Lys;;ACTIVE;2.09;2.65 +33699-0;Microscopic observation;Prid;Pt;XXX;Nom;Malachite green stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Malachite green stain;Mal Green Stn Spec;;ACTIVE;2.09;2.69 +33700-6;Spore identification;Prid;Pt;XXX;Nom;Malachite green stain;MICRO;1;Spore [Identifier] in Specimen by Malachite green stain;Spore ID Spec Mal Green Stn;;ACTIVE;2.09;2.69 +33701-4;Clostridium botulinum toxin A;PrThr;Pt;XXX;Ord;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin A [Presence] in Specimen by Mouse bioassay neutralization;C bot Tox A Spec Ql MA Nt;;ACTIVE;2.09;2.73 +33702-2;Clostridium botulinum toxin E;PrThr;Pt;XXX;Ord;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin E [Presence] in Specimen by Mouse bioassay neutralization;C bot Tox E Spec Ql MA Nt;;ACTIVE;2.09;2.69 +33703-0;Clostridium botulinum toxin F;PrThr;Pt;XXX;Ord;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin F [Presence] in Specimen by Mouse bioassay neutralization;C bot Tox F Spec Ql MA Nt;;ACTIVE;2.09;2.69 +3370-4;Barbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Barbital [Mass/volume] in Serum or Plasma;Barbital SerPl-mCnc;;ACTIVE;1.0;2.73 +33704-8;Clostridium botulinum toxin A+B+E;PrThr;Pt;XXX;Ord;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin A+B+E [Presence] in Specimen by Mouse bioassay neutralization;C bot Tox ABE Spec Ql MA Nt;;ACTIVE;2.09;2.69 +33705-5;Clostridium botulinum toxin B;PrThr;Pt;XXX;Ord;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin B [Presence] in Specimen by Mouse bioassay neutralization;C bot Tox B Spec Ql MA Nt;;ACTIVE;2.09;2.73 +33706-3;Yersinia pestis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia pestis Ab [Presence] in Serum;Y pestis Ab Ser Ql;;ACTIVE;2.09;2.56 +33707-1;Yersinia pestis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia pestis Ab [Titer] in Serum;Y pestis Ab Titr Ser;;ACTIVE;2.09;2.30 +33708-9;Clostridium botulinum toxin;PrThr;Pt;XXX;Ord;;MICRO;1;Clostridium botulinum toxin [Presence] in Specimen;C bot Tox Spec Ql;;ACTIVE;2.09;2.69 +33709-7;Clostridium botulinum toxin A;PrThr;Pt;XXX;Ord;;MICRO;1;Clostridium botulinum toxin A [Presence] in Specimen;C bot Tox A Spec Ql;;ACTIVE;2.09;2.69 +33710-5;Clostridium botulinum toxin E;PrThr;Pt;XXX;Ord;;MICRO;1;Clostridium botulinum toxin E [Presence] in Specimen;C bot Tox E Spec Ql;;ACTIVE;2.09;2.69 +33711-3;Clostridium botulinum toxin F;PrThr;Pt;XXX;Ord;;MICRO;1;Clostridium botulinum toxin F [Presence] in Specimen;C bot Tox F Spec Ql;;ACTIVE;2.09;2.69 +3371-2;Barbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Barbital [Mass/volume] in Urine;Barbital Ur-mCnc;;ACTIVE;1.0;2.34 +33712-1;Clostridium botulinum toxin A+B+E;PrThr;Pt;XXX;Ord;;MICRO;1;Clostridium botulinum toxin A+B+E [Presence] in Specimen;C bot Tox ABE Spec Ql;;ACTIVE;2.09;2.69 +33713-9;Clostridium botulinum toxin B;PrThr;Pt;XXX;Ord;;MICRO;1;Clostridium botulinum toxin B [Presence] in Specimen;C bot Tox B Spec Ql;;ACTIVE;2.09;2.69 +33714-7;Francisella tularensis Ab;PrThr;Pt;XXX;Ord;Aggl.slide;MICRO;1;Francisella tularensis Ab [Presence] in Specimen by Slide agglutination;F tular Ab Spec Ql Slide aggl;;ACTIVE;2.09;2.69 +33715-4;Francisella tularensis Ab;PrThr;Pt;Isolate;Ord;Aggl.slide;MICRO;1;Francisella tularensis Ab [Presence] in Isolate by Slide agglutination;F tular Ab Islt Ql Slide aggl;;ACTIVE;2.09;2.65 +33716-2;Non-gyn cytology study;Find;Pt;^Patient;Doc;Cytology.non-gyn;PATH;1;Non-gynecological cytology study;Non-gynecological cytology study;;ACTIVE;2.09;2.73 +33717-0;Cervical &or Vaginal cytology study;Find;Pt;Cvx/Vag;Doc;;OBGYN;2;Cervical AndOr vaginal cytology study;Cytology Cvx/Vag study;;ACTIVE;2.09;2.73 +33718-8;Cytology report;Find;Pt;Tiss.FNA;Doc;Cyto stain;CYTO;1;Cytology report of Tissue fine needle aspirate Cyto stain;Cytology Tiss FNA Doc Cyto;;ACTIVE;2.09;2.73 +33719-6;Flow cytometry study;Find;Pt;XXX;Doc;Flow cytometry;DOC.MISC;2;Flow cytometry study;Flow cytometry study;;ACTIVE;2.09;2.73 +3372-0;Barbiturate screen absent;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Barbiturate screen absent [Identifier] in Urine;Barbiturate Scn Absent Ur;;ACTIVE;1.0;2.19 +33720-4;Blood bank consult;Find;Pt;^Patient;Doc;;DOC.MISC;2;Blood bank consult;Blood bank consult;;ACTIVE;2.09;2.73 +33721-2;Pathology biopsy report;Find;Pt;Bone mar;Doc;;PATH;1;Bone marrow Pathology biopsy report;Mar Path Bx report;;ACTIVE;2.09;2.73 +33722-0;Collection method;Type;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated CAP cancer protocols Collection method;Deprecated Collection method CAP prot;;DEPRECATED;2.09;2.61 +33723-8;Specimen length;Len;Pt;Specimen;Qn;;PATH.PROTOCOLS.GENER;1;Specimen length;Specimen length;;ACTIVE;2.09;2.70 +33724-6;Collection method;Find;Pt;Specimen;Nar;;PATH.PROTOCOLS.GENER;1;Collection method -;Collection method;;ACTIVE;2.09;2.61 +33725-3;Tumor site;Anat;Pt;Specimen;Nom;;PATH.PROTOCOLS.GENER;1;Tumor site;Tumor site;;ACTIVE;2.09;2.73 +33726-1;Macroscopic tumor configuration;Find;Pt;Specimen;Nom;;PATH.PROTOCOLS.GENER;1;Macroscopic tumor configuration;Macro tumor config;Copyright © 2017 College of American Pathologists Used with permission;ACTIVE;2.09;2.61 +33727-9;Macroscopic tumor configuration;Find;Pt;Specimen;Nar;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated Macroscopic tumor configuration by CAP cancer protocols;Deprecated Macro tumor config CAP prot;;DEPRECATED;2.09;2.61 +33728-7;Size.max.dimension;Len;Pt;Tumor;Qn;;PATH.PROTOCOLS.GENER;1;Size.maximum dimension in Tumor;Size.max.dim Tumor;;ACTIVE;2.09;2.70 +33729-5;Size.additional dimension;Len;Pt;Tumor;Qn;;PATH.PROTOCOLS.GENER;1;Size additional dimension in Tumor;Size addl dim Tumor;;ACTIVE;2.09;2.70 +33730-3;Resection completeness;Find;Pt;Mesorectum;Ord;Macroscopy;PATH.PROTOCOLS.GENER;1;Resection completeness in Mesorectum Qualitative by Macroscopy;Resection completeness Macro;;ACTIVE;2.09;2.61 +33731-1;Histology type;Find;Pt;Cancer specimen;Nar;;PATH.HISTO;1;Histology type in Cancer specimen Narrative;Histology type Ca spec;;ACTIVE;2.09;2.61 +33732-9;Histology grade;Prid;Pt;Cancer specimen;Nom;;PATH.HISTO;1;Histology grade [Identifier] in Cancer specimen;Histology grade Ca spec;;ACTIVE;2.09;2.61 +33733-7;Sites of distant metastasis;Anat;Pt;Specimen;Nar;;PATH.PROTOCOLS.GENER;1;Sites of distant metastasis;Sites of distant mets;;ACTIVE;2.09;2.61 +33734-5;Surgical margin tumor involvement.proximal;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Surgical margin tumor involvement.proximal by CAP cancer protocols;Surg margin tumor invol.prox CAP prot;;ACTIVE;2.09;2.36 +33735-2;Surgical margin tumor involvement.distant;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Surgical margin tumor involvement.distant by CAP cancer protocols;Surg margin tumor invol.distant CAP prot;;ACTIVE;2.09;2.36 +33736-0;Surgical margin tumor involvement.circumferential;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Surgical margin tumor involvement.circumferential by CAP cancer protocols;Surg margin tumor invol.circ CAP prot;;ACTIVE;2.09;2.36 +33737-8;Distance of tumor from closest margin;Len;Pt;Specimen;Qn;;PATH.PROTOCOLS.GENER;1;Distance of tumor from closest margin;Tumor from Closest Margin;;ACTIVE;2.09;2.70 +3373-8;Barbiturate screen absent;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Deprecated Barbiturate screen absent [Identifier] in Urine;Deprecated Barbiturate Scn Absent Ur;;DEPRECATED;1.0;2.36 +33738-6;Closest margin;Type;Pt;Specimen;Nom;;PATH.PROTOCOLS.GENER;1;Closest margin;Closest margin;;ACTIVE;2.09;2.61 +33739-4;Lymphatic.small vessel.invasion;Prid;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Lymphatic.small vessel.invasion [Identifier] in Specimen by CAP cancer protocols;Lymph.small VI Spec CAP prot;;ACTIVE;2.09;2.61 +33740-2;Venous.large vessel.invasion;Prid;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Venous.large vessel.invasion [Identifier] in Specimen by CAP cancer protocols;Venous.large VI Spec CAP prot;;ACTIVE;2.09;2.61 +33741-0;Perineural invasion;Type;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Deprecated Perineural invasion [Type] in Specimen by CAP cancer protocols;Deprecated Perineural invasion Spec CAP prot;;DEPRECATED;2.09;2.66 +33742-8;Tumor border configuration;Type;Pt;Specimen;Nom;;PATH.HISTO;1;Tumor border configuration [Type] in Specimen;Tumor border config Spec;;ACTIVE;2.09;2.61 +33743-6;Intratumoral + Peritumoral lymphocytic response;Type;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated Intratumoral /Peritumoral lymphocytic response by CAP cancer protocols;Deprecated IT/PT lymph response CAP prot;;DEPRECATED;2.09;2.61 +33744-4;Additional pathological findings;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated Additional pathological findings by CAP cancer protocols;Deprecated Add'l path findings CAP prot;;DEPRECATED;2.09;2.61 +33745-1;Polyps;Find;Pt;Specimen;Nar;;PATH;1;Polyps in Specimen Narrative;Polyps Spec;;ACTIVE;2.09;2.71 +3374-6;Barbiturate screen present;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Barbiturate screen present [Identifier] in Urine;Barbiturate Scn Present Ur;;ACTIVE;1.0;2.73 +33746-9;Pathologic findings;Find;Pt;Specimen;Nar;;PATH.PROTOCOLS.GENER;1;Pathologic findings;Path findings;;ACTIVE;2.09;2.61 +33747-7;Number of fragmented pieces;Num;Pt;Specimen;Qn;;PATH.PROTOCOLS.GENER;1;Number of fragmented pieces;# fragmented pieces;;ACTIVE;2.09;2.61 +33748-5;Distance from anal verge;Len;Pt;Specimen;Qn;;PATH.PROTOCOLS.GENER;1;Distance from anal verge;Dist from anal verge;;ACTIVE;2.09;2.70 +33749-3;Distance from anal verge unknown;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated Distance from anal verge unknown by CAP cancer protocols;Deprecated Dist from anal verge unknown CAP prot;;DEPRECATED;2.09;2.66 +33750-1;Margins cannot be assessed;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated Margins cannot be assessed by CAP cancer protocols;Deprecated Margins cannot be assessed CA;;DEPRECATED;2.09;2.61 +33751-9;Surgical margin tumor involvement.lateral;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Surgical margin tumor involvement.lateral in Specimen by CAP cancer protocols;Surg margin tumor invol.lat CAP prot;;ACTIVE;2.09;2.61 +33752-7;Distance of carcinoma from closest lateral margin;Len;Pt;Specimen;Qn;;PATH.HISTO;1;Distance of carcinoma from closest lateral margin [Length] in Specimen;Dist of Ca from closest lat margin CAP;;ACTIVE;2.09;2.70 +3375-3;Barbiturate screen present;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Deprecated Barbiturate screen present [Identifier] in Urine;Deprecated Barbiturate Scn Present Ur;;DEPRECATED;1.0;2.36 +33753-5;Lateral margin location;Find;Pt;Specimen;Nar;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated Lateral margin location by CAP cancer protocols;Deprecated Lat margin location CAP prot;;DEPRECATED;2.09;2.61 +33754-3;Surgical margin tumor involvement.deep;Find;Pt;Specimen;Nar;CAP cancer protocols;PATH.HISTO;1;Surgical margin tumor involvement.deep in Specimen by CAP cancer protocols Narrative;Surg margin tumor invol.deep CAP prot;;ACTIVE;2.09;2.61 +33755-0;Distance of carcinoma from deep margin;Len;Pt;Specimen;Qn;;PATH.HISTO;1;Distance of carcinoma from deep margin [Length] in Specimen;Dist of Ca from deep margin Spec;;ACTIVE;2.09;2.70 +33756-8;Polyp size greatest dimension;Len;Pt;Specimen;Qn;;PATH.PROTOCOLS.GENER;1;Polyp size greatest dimension;Polyp size greatest dim;;ACTIVE;2.09;2.70 +33757-6;Polyp size additional dimensions;Len;Pt;Specimen;Qn;;PATH.PROTOCOLS.GENER;1;Polyp size additional dimensions;Polyp size addl dim;;ACTIVE;2.09;2.70 +33758-4;Polyp stalk length;Prid;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Polyp stalk length by CAP cancer protocols;Polyp stalk length CAP prot;;ACTIVE;2.09;2.61 +33759-2;Extent of invasion deepest;Type;Pt;Specimen;Ord;;PATH.HISTO;1;Deepest extent of invasion [Type] in Specimen;Deepest extent of inv Spec Ql;;ACTIVE;2.09;2.61 +337-6;Minocycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Minocycline [Susceptibility] by Serum bactericidal titer;Minocycline Titr SBT;;ACTIVE;1.0;2.32 +33760-0;Surgical margin tumor involvement.mucosal;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Surgical margin tumor involvement.mucosal in Specimen by CAP cancer protocols;Surg margin tumor invol.mucosal CAP prot;;ACTIVE;2.09;2.61 +3376-1;Barbiturates;PrThr;Pt;Ser/Plas/Bld;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Serum, Plasma or Blood;Barbiturates SerPlBld Ql;;ACTIVE;1.0;2.73 +33761-8;Venous + Lymphatic small vessel invasion;Find;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Venous + Lymphatic small vessel invasion in Specimen by CAP cancer protocols;Venous+Lymph small Vi Spec CAP prot;;ACTIVE;2.09;2.61 +33762-6;Natriuretic peptide.B prohormone N-Terminal;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma;NT-proBNP SerPl-mCnc;;ACTIVE;2.09;2.73 +33763-4;Natriuretic peptide.B prohormone N-Terminal;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Natriuretic peptide.B prohormone N-Terminal [Moles/volume] in Serum or Plasma;NT-proBNP SerPl-sCnc;;ACTIVE;2.09;2.73 +33764-2;Shiga toxin stx gene;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Shiga toxin stx gene [Identifier] in Specimen by NAA with probe detection;Shiga toxin stx gene Spec NAA+probe;;ACTIVE;2.09;2.73 +33765-9;Leukocytes;NCnc;Pt;^BPU.platelet pheresis;Qn;Automated count;BLDBK;1;Leukocytes [#/volume] in Blood Product unit.platelet pheresis by Automated count;WBC # Pheresis BPU Auto;;ACTIVE;2.09;2.72 +33766-7;Radioactivity^pre dose radioactive cyanocobalamin;PrThr;Pt;Urine;Ord;;CHAL;1;Radioactivity [Presence] in Urine --pre dose radioactive cyanocobalamin;Radioactivity pre RA B12 Ur Ql;;ACTIVE;2.09;2.70 +33767-5;Acidity.total;SCnc;Pt;Gast fld;Qn;;CHEM;1;Acidity.total [Moles/volume] in Gastric fluid;Total Acidity Gast-sCnc;;ACTIVE;2.09;2.70 +33768-3;Leukocyte clumps;NCnc;Pt;Urine;Qn;Automated count;UA;1;Leukocyte clumps [#/volume] in Urine by Automated count;WBC clumps # Ur Auto;;ACTIVE;2.09;2.73 +33769-1;Mucin clot^15M post incubation;Aper;Pt;Synv fld;Ord;;HEM/BC;1;Mucin clot [Appearance] in Synovial fluid Qualitative --15 minutes post incubation;Mucin Clot 15M p Inc Snv Ql;;ACTIVE;2.09;2.70 +33770-9;Mucin clot^30M post incubation;Aper;Pt;Synv fld;Ord;;HEM/BC;1;Mucin clot [Appearance] in Synovial fluid Qualitative --30 minutes post incubation;Mucin Clot 30M p Inc Snv Ql;;ACTIVE;2.09;2.70 +33771-7;Pl-12 Ab;PrThr;Pt;Ser;Ord;;SERO;1;PL-12 Ab [Presence] in Serum;PL12 Ab Ser Ql;;ACTIVE;2.09;2.73 +33772-5;Pl-7 Ab;PrThr;Pt;Ser;Ord;;SERO;1;PL-7 Ab [Presence] in Serum;PL7 Ab Ser Ql;;ACTIVE;2.09;2.73 +33773-3;Karyotype;Prid;Pt;Amnio fld;Nom;;MOLPATH;1;Karyotype [Identifier] in Amniotic fluid Nominal;Karyotyp Amn;;ACTIVE;2.09;2.73 +33774-1;Karyotype;Prid;Pt;CVS;Nom;;MOLPATH;1;Karyotype [Identifier] in Chorionic villus sample Nominal;Karyotyp CVS;;ACTIVE;2.09;2.73 +33775-8;Cells.CD41a/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD41a cells/100 cells in Specimen;CD41a Cells NFr Spec;;ACTIVE;2.09;2.70 +33776-6;Cells.CD235a/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated CD235a cells/100 cells in Unspecified specimen;Deprecated CD235a Cells Fr XXX;;DEPRECATED;2.09;2.70 +33777-4;Cells.SmIg/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;SmIg cells/100 cells in Specimen;SmIg Cells NFr Spec;;ACTIVE;2.09;2.70 +33778-2;SmIg Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;SmIg Ag [Presence] in Tissue by Immune stain;SmIg Ag Tiss Ql ImStn;;ACTIVE;2.09;2.56 +3377-9;Barbiturates;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Urine;Barbiturates Ur Ql;;ACTIVE;1.0;2.73 +33779-0;IgG+IgM+IgA heavy chain Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgG+IgM+IgA heavy chain Ag [Presence] in Tissue by Immune stain;Poly-sp Ig Ag Tiss Ql ImStn;;ACTIVE;2.09;2.56 +33780-8;Galactose 1 phosphate uridyl transferase phenotype;Type;Pt;Bld;Nom;;CHEM;1;Galactose 1 phosphate uridyl transferase phenotype [Type] in Blood;Gal1PUT Phenotyp Bld;;ACTIVE;2.09;2.73 +33781-6;Alpha-1-Acid glycoprotein;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-acid glycoprotein [Moles/volume] in Serum or Plasma;A1acid Glycoprotein SerPl-sCnc;;ACTIVE;2.09;2.34 +33782-4;Retinol binding protein;MCnc;Pt;Urine;Qn;;CHEM;1;Retinol binding protein [Mass/volume] in Urine;Retinol Bind Prot Ur-mCnc;;ACTIVE;2.09;2.69 +33783-2;Atrial natriuretic factor;SCnc;Pt;Plas;Qn;;CHEM;1;Atrial natriuretic factor [Moles/volume] in Plasma;ANF Plas-sCnc;;ACTIVE;2.09;2.34 +33784-0;Bacterial casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Bacterial casts [Presence] in Urine sediment by Light microscopy;Bacterial casts UrnS Ql Micro;;ACTIVE;2.09;2.73 +33785-7;Basophils.immature;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Immature basophils [#/volume] in Blood by Manual count;Imm Basophils # Bld Manual;;ACTIVE;2.09;2.54 +33786-5;Basophils.immature/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Immature basophils/100 leukocytes in Blood by Manual count;Imm Basophils/leuk NFr Bld Manual;;ACTIVE;2.09;2.73 +3378-7;Bendroflumethiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Bendroflumethiazide [Presence] in Urine;Bendroflumethiaz Ur Ql;;ACTIVE;1.0;2.73 +33787-3;Calcitonin^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;Calcit sp10 p chal SerPl-mCnc;;ACTIVE;2.09;2.34 +33788-1;Calcitonin^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Calcit sp1 p chal SerPl-mCnc;;ACTIVE;2.09;2.73 +33789-9;Calcium^10th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --10th specimen post XXX challenge;Calcium sp10 p chal Ur-sCnc;;ACTIVE;2.09;2.34 +33790-7;Calcium^1st specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --1st specimen post XXX challenge;Calcium sp1 p chal Ur-sCnc;;ACTIVE;2.09;2.34 +33791-5;Calcium^5th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --5th specimen post XXX challenge;Calcium sp5 p chal Ur-sCnc;;ACTIVE;2.09;2.34 +33792-3;Calcium^6th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --6th specimen post XXX challenge;Calcium sp6 p chal Ur-sCnc;;ACTIVE;2.09;2.34 +33793-1;Calcium^7th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --7th specimen post XXX challenge;Calcium sp7 p chal Ur-sCnc;;ACTIVE;2.09;2.34 +33794-9;Calcium^8th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --8th specimen post XXX challenge;Calcium sp8 p chal Ur-sCnc;;ACTIVE;2.09;2.34 +3379-5;Bendroflumethiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bendroflumethiazide [Mass/volume] in Urine;Bendroflumethiaz Ur-mCnc;;ACTIVE;1.0;2.44 +33795-6;Calcium^9th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Calcium [Moles/volume] in Urine --9th specimen post XXX challenge;Calcium sp9 p chal Ur-sCnc;;ACTIVE;2.09;2.34 +33796-4;Cotinine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cotinine [Moles/volume] in Urine;Cotinine Ur-sCnc;;ACTIVE;2.09;2.34 +33797-2;Creatine;SRat;12H;Urine;Qn;;CHEM;1;Creatine [Moles/time] in 12 hour Urine;Creatine 12h Ur-sRate;;ACTIVE;2.09;2.40 +33798-0;Creatinine;SRat;2H;Urine;Qn;;CHEM;1;Creatinine [Moles/time] in 2 hour Urine;Creat 2h Ur-sRate;;ACTIVE;2.09;2.40 +33799-8;DNA double strand Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;DNA double strand IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;dsDNA IgG SerPl IA-aCnc;;ACTIVE;2.09;2.73 +33800-4;DNA double strand Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;DNA double strand IgG Ab [Units/volume] in Serum;dsDNA IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33801-2;E selectin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;E selectin [Mass/volume] in Serum or Plasma;E Selectin SerPl-mCnc;;ACTIVE;2.09;2.34 +33802-0;Eosinophils.immature;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Immature eosinophils [#/volume] in Blood by Manual count;Imm Eosinophil # Bld Manual;;ACTIVE;2.09;2.54 +3380-3;Bendroflumethiazide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Bendroflumethiazide [Mass/time] in 24 hour Urine;Bendroflumethiaz 24h Ur-mRate;;ACTIVE;1.0;2.44 +33803-8;Eosinophils.immature/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Immature eosinophils/100 leukocytes in Blood by Manual count;Imm Eosinophil/leuk NFr Bld Manual;;ACTIVE;2.09;2.54 +33804-6;Erythrocyte casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;RBC casts [Presence] in Urine sediment by Light microscopy;RBC Casts UrnS Ql Micro;;ACTIVE;2.09;2.73 +33805-3;Fructosamine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fructosamine [Mass/volume] in Serum or Plasma;Fructosamine SerPl-mCnc;;ACTIVE;2.09;2.73 +33806-1;HIV 2 Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 IgG Ab [Presence] in Serum by Immunoblot;HIV 2 IgG Ser Ql IB;;ACTIVE;2.09;2.73 +33807-9;HIV 2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 2 IgG Ab [Presence] in Serum;HIV 2 IgG Ser Ql;;ACTIVE;2.09;2.56 +33808-7;Insulin-like growth factor binding protein 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor binding protein 3 [Moles/volume] in Serum or Plasma;IGF BP3 SerPl-sCnc;;ACTIVE;2.09;2.34 +33809-5;Insulin^10th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --10th specimen post XXX challenge;Insulin sp10 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +33810-3;Insulin^11th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --11th specimen post XXX challenge;Insulin sp11 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +3381-1;Benzfetamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Benzfetamine [Mass/volume] in Blood;Benzfetamine Bld-mCnc;;ACTIVE;1.0;2.73 +33811-1;Insulin^12th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --12th specimen post XXX challenge;Insulin sp12 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +33812-9;Insulin^13th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --13th specimen post XXX challenge;Insulin sp13 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +33813-7;Insulin^14th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --14th specimen post XXX challenge;Insulin sp14 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +33814-5;Insulin^15th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --15th specimen post XXX challenge;Insulin sp15 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +33815-2;Insulin^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1st specimen post XXX challenge;Insulin sp1 p chal SerPl-aCnc;;ACTIVE;2.09;2.73 +33816-0;Insulin^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge;Insulin sp2 p chal SerPl-aCnc;;ACTIVE;2.09;2.73 +33817-8;Insulin^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge;Insulin sp3 p chal SerPl-aCnc;;ACTIVE;2.09;2.73 +33818-6;Insulin^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --8th specimen post XXX challenge;Insulin sp8 p chal SerPl-aCnc;;ACTIVE;2.09;2.73 +33819-4;Insulin^9th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --9th specimen post XXX challenge;Insulin sp9 p chal SerPl-aCnc;;ACTIVE;2.09;2.73 +33820-2;Interferon.alpha;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Interferon alpha [Mass/volume] in Serum or Plasma;IFN-A SerPl-mCnc;;ACTIVE;2.09;2.73 +33821-0;Interleukin 1 alpha;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 1 alpha [Mass/volume] in Serum or Plasma;Il1Alpha SerPl-mCnc;;ACTIVE;2.09;2.34 +33822-8;Interleukin 13;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 13 [Mass/volume] in Serum or Plasma;Il13 SerPl-mCnc;;ACTIVE;2.09;2.73 +33823-6;Interleukin 18;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 18 [Mass/volume] in Serum or Plasma;Il18 SerPl-mCnc;;ACTIVE;2.09;2.34 +33824-4;Iron;SCnc;Pt;Urine;Qn;;CHEM;1;Iron [Moles/volume] in Urine;Iron Ur-sCnc;;ACTIVE;2.09;2.34 +33825-1;Leukocyte casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;WBC casts [Presence] in Urine sediment by Light microscopy;WBC Casts UrnS Ql Micro;;ACTIVE;2.09;2.73 +33826-9;Lutropin^10th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --10th specimen post XXX challenge;LH sp10 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +33827-7;Lutropin^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1st specimen post XXX challenge;LH sp1 p chal SerPl-aCnc;;ACTIVE;2.09;2.73 +33828-5;Lutropin^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --8th specimen post XXX challenge;LH sp8 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +3382-9;Benzfetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Benzfetamine [Presence] in Urine;Benzfetamine Ur Ql;;ACTIVE;1.0;2.56 +33829-3;Lutropin^9th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --9th specimen post XXX challenge;LH sp9 p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +33830-1;Lymphoblasts;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphoblasts [#/volume] in Blood by Manual count;Lymphoblasts # Bld Manual;;ACTIVE;2.09;2.73 +33831-9;Lymphoblasts/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphoblasts/100 leukocytes in Blood by Manual count;Lymphoblasts/leuk NFr Bld Manual;;ACTIVE;2.09;2.73 +33832-7;Lymphocytes.immunoblastic;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes Immunoblastic [#/volume] in Blood by Manual count;Ib Lymphs # Bld Manual;;ACTIVE;2.09;2.40 +33833-5;Lymphocytes.immunoblastic/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes Immunoblastic/100 leukocytes in Blood by Manual count;Ib Lymphs/leuk NFr Bld Manual;;ACTIVE;2.09;2.50 +33834-3;Lymphocytes.plasmacytoid;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes Plasmacytoid [#/volume] in Blood by Manual count;Plasmacoid Lymphs # Bld Manual;;ACTIVE;2.09;2.73 +33835-0;Lymphocytes.plasmacytoid/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes Plasmacytoid/100 leukocytes in Blood by Manual count;Plasmacoid Lymphs/leuk NFr Bld Manual;;ACTIVE;2.09;2.73 +33836-8;Malignant cells;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Malignant cells [#/volume] in Blood by Manual count;Malignant cells # Bld Manual;;ACTIVE;2.09;2.40 +3383-7;Benzfetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzfetamine [Mass/volume] in Urine;Benzfetamine Ur-mCnc;;ACTIVE;1.0;2.42 +33837-6;Malignant cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Malignant cells/100 leukocytes in Blood by Manual count;Malignant cells/leuk NFr Bld Manual;;ACTIVE;2.09;2.50 +33838-4;Mannitol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mannitol [Moles/volume] in Serum or Plasma;Mannitol SerPl-sCnc;;ACTIVE;2.09;2.34 +33839-2;Monoblasts;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Monoblasts [#/volume] in Blood by Manual count;Monoblasts # Bld Manual;;ACTIVE;2.09;2.40 +338-4;Miocamycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Miocamycin [Susceptibility] by Minimum lethal concentration (MLC);Miocamycin Islt MLC;;ACTIVE;1.0;2.19 +33840-0;Monoblasts/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Monoblasts/100 leukocytes in Blood by Manual count;Monoblasts/leuk NFr Bld Manual;;ACTIVE;2.09;2.50 +33841-8;Monocytes.immature;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Immature monocytes [#/volume] in Blood by Manual count;Imm Moncytes # Bld Manual;;ACTIVE;2.09;2.46 +33842-6;Monocytes.immature/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Immature monocytes/100 leukocytes in Blood by Manual count;Imm Moncytes/leuk NFr Bld Manual;;ACTIVE;2.09;2.50 +33843-4;Norepinephrine^standing;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --standing;Norepineph stand Plas-sCnc;;ACTIVE;2.09;2.34 +33844-2;Norepinephrine^supine;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --supine;Norepineph sup Plas-sCnc;;ACTIVE;2.09;2.34 +3384-5;Benzfetamine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Benzfetamine [Mass/time] in 24 hour Urine;Benzfetamine 24h Ur-mRate;;ACTIVE;1.0;2.42 +33845-9;Parathyrin.intact^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;PTH-Intact 1h p chal SerPl-sCnc;;ACTIVE;2.09;2.34 +33846-7;Parathyrin.intact^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;PTH-Intact 2h p chal SerPl-sCnc;;ACTIVE;2.09;2.34 +33847-5;Parathyrin.intact^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;PTH-Intact 30M p chal SerPl-sCnc;;ACTIVE;2.09;2.34 +33848-3;Plasma cell precursor;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Plasma cell precursor [#/volume] in Blood by Manual count;Plasma cell prec # Bld Manual;;ACTIVE;2.09;2.44 +33849-1;Plasma cell precursor/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Plasma cell precursor/100 leukocytes in Blood by Manual count;Plasma cell prec/leuk NFr Bld Manual;;ACTIVE;2.09;2.73 +33850-9;Plasma cells.immature;NCnc;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Plasma cells immature [#/volume] in Bone marrow by Manual count;Imm Plasma Cells # Mar Manual;;ACTIVE;2.09;2.44 +33851-7;Progesterone^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;Progest sp10 p chal SerPl-mCnc;;ACTIVE;2.09;2.34 +3385-2;Benzodiazepines negative;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Benzodiazepines negative [Identifier] in Urine;Benzodiaz Neg Ur;;ACTIVE;1.0;2.19 +33852-5;Progesterone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Progest sp1 p chal SerPl-mCnc;;ACTIVE;2.09;2.73 +33853-3;Progesterone^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;Progest sp1 p chal SerPl-sCnc;;ACTIVE;2.09;2.34 +33854-1;Progesterone^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;Progest sp4 p chal SerPl-sCnc;;ACTIVE;2.09;2.34 +33855-8;Promonocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Promonocytes [#/volume] in Blood by Manual count;Promonycytes # Bld Manual;;ACTIVE;2.09;2.40 +33856-6;Sezary cells;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Sezary cells [#/volume] in Blood by Manual count;Sezary Cells # Bld Manual;;ACTIVE;2.09;2.40 +33857-4;Sezary cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Sezary cells/100 leukocytes in Blood by Manual count;Sezary Cells/leuk NFr Bld Manual;;ACTIVE;2.09;2.54 +33858-2;Somatotropin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Units/volume] in Serum or Plasma;GH SerPl-aCnc;;ACTIVE;2.09;2.73 +33859-0;Somatotropin/Creatinine;Ratio;12H;Urine;Qn;;CHEM;1;Somatotropin/Creatinine [Ratio] in 12 hour Urine;GH/Creat 12h Ur-Rto;;ACTIVE;2.09;2.40 +3386-0;Benzodiazepines negative;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Deprecated Benzodiazepines negative [Identifier] in Urine;Deprecated Benzodiaz Neg Ur;;DEPRECATED;1.0;2.36 +33860-8;Somatotropin/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Somatotropin/Creatinine [Ratio] in 24 hour Urine;GH/Creat 24h Ur-Rto;;ACTIVE;2.09;2.73 +33861-6;Starch granules;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Starch granules [Presence] in Urine sediment by Light microscopy;Starch Granules UrnS Ql Micro;;ACTIVE;2.09;2.73 +33862-4;Waxy casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Waxy casts [Presence] in Urine sediment by Light microscopy;Waxy Casts UrnS Ql Micro;;ACTIVE;2.09;2.73 +33863-2;Cystatin C;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystatin C [Mass/volume] in Serum or Plasma;Cystatin C SerPl-mCnc;;ACTIVE;2.09;2.73 +33864-0;Elastase.leukocyte;MCnc;Pt;Plas;Qn;;CHEM;1;Elastase.leukocyte [Mass/volume] in Plasma;Elastase Leukocyte Plas-mCnc;;ACTIVE;2.09;2.64 +33865-7;Staphylococcus aureus enterotoxin;Prid;Pt;XXX;Nom;;MICRO;1;Staphylococcus aureus enterotoxin [Identifier] in Specimen;S aureus Etx Spec;;ACTIVE;2.09;2.69 +33866-5;HIV 1 Ab;PrThr;Pt;BldC;Ord;IA;MICRO;1;HIV 1 Ab [Presence] in Capillary blood by Immunoassay;HIV1 Ab BldC Ql IA;;ACTIVE;2.09;2.56 +33867-3;Blood velocity/Blood velocity 2;VelRto;Pt;{Circulatory system};Qn;US;GEN.US;2;Blood velocity/Blood velocity 2 by US;Bld vel/Vel 2 US;;ACTIVE;2.09;2.48 +33868-1;Blood flow velocity.max.stenosis.internal carotid artery/Blood flow velocity.max.unobstructed.common carotid artery;VelRto;Pt;{Circulatory system};Qn;US;GEN.US;2;Maximum blood flow velocity ICA at maximum stenosis/Maximum blood flow velocity unobstructed CCA by US;Vmax stenosed ICA/unobstructed CCA US;;ACTIVE;2.09;2.73 +33869-9;Blood flow velocity.max.kidney artery/Blood flow velocity.max.aorta;VelRto;Pt;{Circulatory system};Qn;US;GEN.US;2;Maximum blood flow velocity Kidney artery/Aorta by US;Vmax kidney a/Aorta US;;ACTIVE;2.09;2.67 +33870-7;Bilirubin;PrThr;Pt;XXX;Ord;;CHEM;1;Bilirubin.total [Presence] in Specimen;Bilirub Spec Ql;;ACTIVE;2.09;2.73 +33871-5;Xylose^1H post 5 g xylose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --1 hour post 5 g xylose PO;Xylose 1h p 5 g Xyl PO SerPl-sCnc;;ACTIVE;2.09;2.70 +33872-3;Cystine;SCnt;Pt;WBC;Qn;;CHEM;1;Cystine [Moles/mass] in Leukocytes;Cystine WBC-sCnt;;ACTIVE;2.09;2.70 +33873-1;DOPamine/Creatinine;SRto;XXX;Urine;Qn;;CHEM;1;DOPamine/Creatinine [Molar ratio] in Urine collected for unspecified duration;DOPamine/Creat ?Tm Ur-sRto;;ACTIVE;2.09;2.70 +33874-9;EPINEPHrine/Creatinine;SRto;XXX;Urine;Qn;;CHEM;1;EPINEPHrine/Creatinine [Molar ratio] in Urine collected for unspecified duration;Epineph/Creat ?Tm Ur-sRto;;ACTIVE;2.09;2.70 +33875-6;Oligosaccharides pattern;Imp;Pt;Urine;Nom;;CHEM;1;Oligosaccharides pattern [Interpretation] in Urine;Oligosaccharide Pattern Ur-Imp;;ACTIVE;2.09;2.73 +33876-4;Sulfocysteine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sulfocysteine/Creatinine [Molar ratio] in Urine;Sulfocysteine/Creat Ur-sRto;;ACTIVE;2.09;2.73 +33877-2;Tetrahydrobiopterin/Biopterin;SFr;Pt;Urine;Qn;;CHEM;1;Tetrahydrobiopterin/Biopterin in Urine;Biopterin H4/Biopterin SFr Ur;;ACTIVE;2.09;2.70 +3387-8;Benzodiazepines positive;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Benzodiazepines positive [Identifier] in Urine;Benzodiaz Pos Ur;;ACTIVE;1.0;2.73 +33878-0;Blood flow rate.mean;VRat;Pt;{Circulatory system};Qn;US;GEN.US;2;Mean blood flow rate by US;Vmean US;;ACTIVE;2.09;2.67 +33879-8;Protein.monoclonal;MCnc;Pt;XXX;Qn;Immunofixation;CHEM;1;Protein.monoclonal [Mass/volume] in Specimen by Immunofixation;M Protein Spec IFE-mCnc;;ACTIVE;2.09;2.73 +33880-6;Coagulation tissue factor induced.factor substitution^2H post incubation after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --2H post incubation with normal plasma;PT 2h NP Cont PPP;;ACTIVE;2.09;2.73 +33881-4;Coagulation tissue factor induced.factor substitution^immediately after 1:4 addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --immediately after 1:4 addition of normal plasma;PT imm 1:4 NP Cont PPP;;ACTIVE;2.09;2.70 +33882-2;Collection date;Date;Pt;^Specimen;Qn;;SPEC;1;Collection date of Specimen;Collect Date;;ACTIVE;2.09;2.73 +33883-0;Coagulation tissue factor induced.factor substitution^1H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --1H post incubation with 1:4 normal plasma;PT 1h p 1:4 NP Cont PPP;;ACTIVE;2.09;2.70 +33884-8;Coagulation tissue factor induced.factor substitution^1H post incubation after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --1H post incubation with normal plasma;PT 1h NP Cont PPP;;ACTIVE;2.09;2.73 +33885-5;Coagulation tissue factor induced.factor substitution^2H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with 1:4 normal plasma;PT 2h p 1:4 NP PPP;;ACTIVE;2.09;2.70 +3388-6;Benzodiazepines positive;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Deprecated Benzodiazepines positive [Identifier] in Urine;Deprecated Benzodiaz Pos Ur;;DEPRECATED;1.0;2.36 +33886-3;Coagulation tissue factor induced.factor substitution^2H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --2H post incubation with 1:4 normal plasma;PT 2h p 1:4 NP Cont PPP;;ACTIVE;2.09;2.70 +33887-1;Coagulation tissue factor induced.factor substitution^2H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with normal plasma;PT 2h NP PPP;;ACTIVE;2.09;2.73 +33888-9;Coagulation surface induced.factor substitution^1H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --1H post incubation with 1:4 normal plasma;aPTT 1h p 1:4 NP Cont PPP;;ACTIVE;2.09;2.73 +33889-7;Coagulation surface induced.factor substitution^2H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --2H post incubation with 1:4 normal plasma;aPTT 2h p 1:4 NP Cont PPP;;ACTIVE;2.09;2.70 +33890-5;Coagulation surface induced.factor substitution^2H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with normal plasma;aPTT 2h NP PPP;;ACTIVE;2.09;2.73 +33891-3;Coagulation surface induced.factor substitution^2H post incubation after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --2H post incubation with normal plasma;aPTT 2h NP Cont PPP;;ACTIVE;2.09;2.73 +33892-1;Coagulation surface induced.factor substitution^immediately after 1:4 addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --immediately after 1:4 addition of normal plasma;aPTT imm 1:4 NP Cont PPP;;ACTIVE;2.09;2.73 +33893-9;Karyotype;Prid;Pt;Bone mar;Nom;;MOLPATH;1;Karyotype [Identifier] in Bone marrow Nominal;Karyotyp Mar;;ACTIVE;2.09;2.73 +3389-4;Benzodiazepines;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Serum or Plasma;Benzodiaz SerPl Ql;;ACTIVE;1.0;2.73 +33894-7;Coagulation tissue factor induced.factor substitution^1H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with 1:4 normal plasma;PT 1h p 1:4 NP PPP;;ACTIVE;2.09;2.73 +33895-4;Coagulation tissue factor induced.factor substitution^2H post incubation;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --2 hours post incubation;PT 2h p Inc PPP;;ACTIVE;2.09;2.70 +33896-2;Orientia tsutsugamushi Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Orientia tsutsugamushi IgM Ab [Presence] in Serum or Plasma by Immunoassay;O tsut IgM SerPl Ql IA;;ACTIVE;2.09;2.56 +33897-0;Orientia tsutsugamushi Ab.IgM;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Orientia tsutsugamushi IgM Ab [Presence] in Serum or Plasma;O tsut IgM SerPl Ql;;ACTIVE;2.09;2.56 +33898-8;Bilirubin.glucuronidated+Bilirubin.non-glucuronidated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.conjugated+indirect [Mass/volume] in Serum or Plasma;Bilirub Conj+Unconj SerPl-mCnc;;ACTIVE;2.09;2.73 +33899-6;Bilirubin.glucuronidated+Bilirubin.non-glucuronidated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.conjugated+indirect [Moles/volume] in Serum or Plasma;Bilirub Conj+Unconj SerPl-sCnc;;ACTIVE;2.09;2.70 +33900-2;Fetal cell screen;PrThr;Pt;Bld;Ord;Rosette test;BLDBK;1;Fetal cell screen [Presence] in Blood by Rosette test;Fetal Cell Scn Bld Ql Rosette;;ACTIVE;2.09;2.73 +33901-0;Gestational age;Time;Pt;^Fetus;Qn;Amniocentesis;MISC;1;Gestational age of fetus by Amniocentesis;GA Time Fetus Amniocentesis;;ACTIVE;2.09;2.73 +3390-2;Benzodiazepines;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Urine;Benzodiaz Ur Ql;;ACTIVE;1.0;2.73 +33902-8;Immune complex;MCnc;Pt;Ser/Plas;Qn;Raji cell assay;SERO;1;Deprecated Immune complex [Units/volume] in Serum or Plasma by Raji cell assay;Deprecated IC SerPl Raji Cell-mCnc;;DEPRECATED;2.09;2.70 +33903-6;Ketones;PrThr;Pt;Urine;Ord;;CHEM;1;Ketones [Presence] in Urine;Ketones Ur Ql;;ACTIVE;2.09;2.73 +33904-4;Neisseria gonorrhoeae rRNA;PrThr;Pt;Cnjt;Ord;Probe;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Conjunctival specimen by Probe;N gonorrhoea rRNA Conjunct Ql Probe;;ACTIVE;2.09;2.73 +33905-1;Trichomonas sp;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Trichomonas sp [#/area] in Urine sediment by Microscopy high power field;Trichomonas #/area UrnS HPF;;ACTIVE;2.09;2.73 +33906-9;Prolactin^30M post 200 ug TRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Moles/volume] in Serum or Plasma --30 minutes post 200 ug TRH IV;Prolactin 30M p 200 ug TRH IV SerPl-sCnc;;ACTIVE;2.09;2.70 +33907-7;Prolactin^1H post 200 ug TRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Moles/volume] in Serum or Plasma --1 hour post 200 ug TRH IV;Prolactin 1h p 200 ug TRH IV SerPl-sCnc;;ACTIVE;2.09;2.70 +33908-5;Prolactin^1.5H post 200 ug TRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Moles/volume] in Serum or Plasma --1.5 hours post 200 ug TRH IV;Prolactin 1.5h p 200ug TRH IV SerPl-sCnc;;ACTIVE;2.09;2.70 +33909-3;Prolactin^2H post 200 ug TRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Moles/volume] in Serum or Plasma --2 hours post 200 ug TRH IV;Prolactin 2h p 200 ug TRH IV SerPl-sCnc;;ACTIVE;2.09;2.70 +3391-0;Benzoylecgonine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Benzoylecgonine [Presence] in Serum or Plasma;BZE SerPl Ql;;ACTIVE;1.0;2.73 +33910-1;Rheumatoid factor;PrThr;Pt;Ser;Ord;;SERO;1;Rheumatoid factor [Presence] in Serum;Rheumatoid fact Ser Ql;;ACTIVE;2.09;2.73 +33911-9;Complement C1r actual/Normal;RelMCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1r actual/normal in Serum or Plasma;C1r Act/Nor SerPl;;ACTIVE;2.09;2.73 +33912-7;Complement C1s actual/Normal;RelMCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1s actual/normal in Serum or Plasma;C1s Act/Nor SerPl;;ACTIVE;2.09;2.70 +33913-5;pH;LsCnc;Pt;BldC^Fetus;Qn;;CHEM;1;pH of Capillary blood from Fetus;pH BldC Fetus;;ACTIVE;2.09;2.70 +33914-3;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas;Qn;Creatinine-based formula (MDRD);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum or Plasma by Creatinine-based formula (MDRD);GFR/BSA.pred SerPl MDRD-ArVRat;;DISCOURAGED;2.09;2.73 +33915-0;Anabasine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Anabasine [Mass/volume] in Urine;Anabasine Ur-mCnc;;ACTIVE;2.09;2.73 +33916-8;Trans-3-Hydroxycotinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trans-3-Hydroxycotinine [Mass/volume] in Urine;trans-3-OH-cotinine Ur-mCnc;;ACTIVE;2.09;2.73 +33917-6;Nornicotine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nornicotine [Mass/volume] in Urine;Nornicotine Ur-mCnc;;ACTIVE;2.09;2.73 +33918-4;Acetoacetate;SCnc;Pt;Urine;Qn;;CHEM;1;Acetoacetate [Moles/volume] in Urine;Acetoacet Ur-sCnc;;ACTIVE;2.09;2.73 +33919-2;Ampicillin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ampicillin [Mass/volume] in Serum or Plasma --trough;Ampicillin Trough SerPl-mCnc;;ACTIVE;2.09;2.70 +339-2;Miocamycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Miocamycin [Susceptibility] by Minimum inhibitory concentration (MIC);Miocamycin Islt MIC;;ACTIVE;1.0;2.19 +33920-0;S Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;S Ab [Titer] in Serum or Plasma;S Ab Titr SerPl;;ACTIVE;2.09;2.70 +33921-8;Signal recognition particle Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Signal Recognition Particle (SRP) Ab [Presence] in Serum or Plasma;SRP Ab SerPl Ql;;ACTIVE;2.09;2.73 +33922-6;Wasp venom Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wasp venom IgE Ab RAST class [Presence] in Serum;Wasp Venom IgE RAST Ql;;ACTIVE;2.09;2.70 +33923-4;Hemosiderin;PrThr;Pt;XXX;Ord;;HEM/BC;1;Hemosiderin [Presence] in Specimen;Hemosiderin Spec Ql;;ACTIVE;2.09;2.73 +33924-2;Neuronal nuclear type 3 Ab;Titr;Pt;Ser;Qn;;SERO;1;Neuronal nuclear type 3 Ab [Titer] in Serum;Hu3 Ab Titr Ser;;ACTIVE;2.09;2.73 +33925-9;Purkinje cell cytoplasmic type 2 Ab;Titr;Pt;Ser;Qn;;SERO;1;PCA-2 Ab [Titer] in Serum;PCA-2 Ab Titr Ser;;ACTIVE;2.09;2.73 +33926-7;Purkinje cell cytoplasmic type Tr Ab;Titr;Pt;Ser;Qn;;SERO;1;PCA-Tr Ab [Titer] in Serum;PCA-Tr Ab Titr Ser;;ACTIVE;2.09;2.73 +33927-5;Amphiphysin Ab;Titr;Pt;Ser;Qn;;SERO;1;Amphiphysin Ab [Titer] in Serum;Amphiphysin Ab Titr Ser;;ACTIVE;2.09;2.73 +3392-8;Benzoylecgonine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Serum or Plasma;BZE SerPl-mCnc;;ACTIVE;1.0;2.73 +33928-3;Efavirenz;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Efavirenz [Mass/volume] in Serum or Plasma;Efavirenz SerPl-mCnc;;ACTIVE;2.09;2.70 +33929-1;Tacrolimus^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Serum or Plasma --trough;Tacrolimus Trough SerPl-mCnc;;ACTIVE;2.09;2.40 +33930-9;Coagulation surface induced.hexagonal phase phospholipid;PrThr;Pt;PPP;Ord;;COAG;1;aPTT W excess hexagonal phospholipid (StaClot LA confirm);Confirm aPTT StaClot;;ACTIVE;2.09;2.73 +33931-7;Lymphocyte proliferation.Borrelia burgdorferi stimulation;Ratio;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by Borrelia burgdorferi [Ratio] in Blood;LPT B burgdorf Bld-Rto;;ACTIVE;2.09;2.71 +33932-5;Borrelia burgdorferi Ab;Titr;Pt;CSF;Qn;;MICRO;1;Borrelia burgdorferi Ab [Titer] in Cerebral spinal fluid;B burgdor Ab Titr CSF;;ACTIVE;2.09;2.70 +33933-3;Glutaraldehyde Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Glutaraldehyde IgE Ab [Units/volume] in Serum;Glutaraldehyde IgE Qn;;ACTIVE;2.09;2.70 +33934-1;Methylmethacrylate Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Methylmethacrylate IgE Ab [Presence] in Serum;Methylmethacrylate IgE Ql;;ACTIVE;2.09;2.56 +33935-8;Cyclic citrullinated peptide Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Cyclic citrullinated peptide IgG Ab [Units/volume] in Serum or Plasma;cCP IgG SerPl-aCnc;;ACTIVE;2.09;2.73 +3393-6;Benzoylecgonine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Benzoylecgonine [Presence] in Urine;BZE Ur Ql;;ACTIVE;1.0;2.73 +33936-6;Homocystine.free;SCnc;Pt;Urine;Qn;;CHEM;1;Homocystine Free [Moles/volume] in Urine;Homocystine.free Ur-sCnc;;ACTIVE;2.09;2.70 +33937-4;Homocystine.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocystine Free [Moles/volume] in Serum or Plasma;Homocystine.free SerPl-sCnc;;ACTIVE;2.09;2.70 +33938-2;Interleukin 5;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 5 [Mass/volume] in Serum or Plasma;Il5 SerPl-mCnc;;ACTIVE;2.09;2.73 +33939-0;Interleukin 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 [Mass/volume] in Serum or Plasma;Il2 SerPl-mCnc;;ACTIVE;2.09;2.73 +33940-8;Herpes virus 6 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Presence] in Tissue by NAA with probe detection;HHV6 DNA Tiss Ql NAA+probe;;ACTIVE;2.09;2.70 +33941-6;Herpes virus 6 DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Presence] in Blood by NAA with probe detection;HHV6 DNA Bld Ql NAA+probe;;ACTIVE;2.09;2.70 +33942-4;Herpes virus 6 DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HHV6 DNA CSF Ql NAA+probe;;ACTIVE;2.09;2.73 +33943-2;Chlamydophila pneumoniae+Chlamydophila psittaci DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;C pn+psitt DNA CSF Ql NAA+probe;;ACTIVE;2.09;2.70 +3394-4;Benzoylecgonine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Urine;BZE Ur-mCnc;;ACTIVE;1.0;2.73 +33944-0;Immunoglobulin light chains.lambda.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lambda light chains.free [Mass/volume] in Serum or Plasma;Lambda LC Free SerPl-mCnc;;ACTIVE;2.09;2.73 +33945-7;Brucella abortus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Brucella abortus Ab [Titer] in Cerebral spinal fluid;B abortus Ab Titr CSF;;ACTIVE;2.09;2.70 +33946-5;Ziprasidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ziprasidone [Mass/volume] in Serum or Plasma;Ziprasidone SerPl-mCnc;;ACTIVE;2.09;2.73 +33947-3;Clostridioides difficile toxin Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Clostridioides difficile toxin neutralizing antibody [Titer] in Serum by Neutralization test;C diff Tox NAb Titr Ser Nt;;ACTIVE;2.09;2.73 +33948-1;IgG/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;IgG/Creatinine [Mass Ratio] in Urine;IgG/Creat Ur;;ACTIVE;2.09;2.70 +33949-9;Potassium/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Potassium/Creatinine [Molar ratio] in Urine;Potassium/Creat Ur-sRto;;ACTIVE;2.09;2.73 +33950-7;Magnesium/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Magnesium/Creatinine [Molar ratio] in Urine;Magnesium/Creat Ur-sRto;;ACTIVE;2.09;2.70 +3395-1;Cocaine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Cocaine [Presence] in Serum or Plasma;Cocaine SerPl Ql;;ACTIVE;1.0;2.73 +33951-5;Sodium/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sodium/Creatinine [Molar ratio] in Urine;Sodium/Creat Ur-sRto;;ACTIVE;2.09;2.73 +33952-3;Immune complex.IgM;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Immune complex.IgM [Mass/volume] in Serum or Plasma;IC IgM SerPl-mCnc;;ACTIVE;2.09;2.70 +33953-1;Immune complex.IgA;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Immune complex IgA [Mass/volume] in Serum or Plasma;IC IgA SerPl-mCnc;;ACTIVE;2.09;2.70 +33954-9;Immune complex.IgG;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Immune complex.IgG [Mass/volume] in Serum or Plasma;IC IgG SerPl-mCnc;;ACTIVE;2.09;2.70 +33955-6;cycloSPORINE.monoclonal;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE.monoclonal [Mass/volume] in Blood;cycloSPORINE monocl Bld-mCnc;;ACTIVE;2.09;2.73 +33956-4;cycloSPORINE.polyclonal;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE.polyclonal [Mass/volume] in Blood;cycloSPORINE polycl Bld-mCnc;;ACTIVE;2.09;2.70 +33957-2;Normoblasts/100 blasts;NFr;Pt;Bld;Qn;;HEM/BC;1;Normoblasts/100 blasts in Blood;Normoblasts NFr Bld;;ACTIVE;2.09;2.70 +33958-0;Cholecalciferol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholecalciferol (Vit D3) [Moles/volume] in Serum or Plasma;Vitamin D3 SerPl-sCnc;;ACTIVE;2.09;2.70 +33959-8;Procalcitonin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Procalcitonin [Mass/volume] in Serum or Plasma;Procalcitonin SerPl-mCnc;;ACTIVE;2.09;2.73 +33960-6;Immune complex.IgE;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Immune complex IgE [Units/volume] in Serum or Plasma;IC IgE SerPl-aCnc;;ACTIVE;2.09;2.73 +33961-4;Sulthiame;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulthiame [Mass/volume] in Serum or Plasma;Sulthiame SerPl-mCnc;;ACTIVE;2.09;2.70 +33962-2;Melanoma inhibitory activity protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Melanoma inhibitory activity protein [Mass/volume] in Serum or Plasma;MAI protein SerPl-mCnc;;ACTIVE;2.09;2.70 +33963-0;Granulocytes/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Granulocytes/100 leukocytes in Cerebral spinal fluid;Granulocytes/leuk NFr CSF;;ACTIVE;2.09;2.70 +33964-8;SARS coronavirus Urbani RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus Urbani RNA [Presence] in Specimen by NAA with probe detection;SARS-CoV Urb RNA Spec Ql NAA+probe;;ACTIVE;2.09;2.73 +33965-5;SARS coronavirus Urbani RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus Urbani RNA [Presence] in Stool by NAA with probe detection;SARS-CoV Urb RNA Stl Ql NAA+probe;;ACTIVE;2.09;2.68 +33966-3;SARS coronavirus Urbani RNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus Urbani RNA [Presence] in Nose by NAA with probe detection;SARS-CoV Urb RNA Nose Ql NAA+probe;;ACTIVE;2.09;2.68 +33967-1;SARS coronavirus Urbani RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus Urbani RNA [Presence] in Serum or Plasma by NAA with probe detection;SARS-CoV Urb RNA SerPl Ql NAA+probe;;ACTIVE;2.09;2.68 +33968-9;SARS coronavirus Urbani Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;SARS coronavirus Urbani Ab [Presence] in Serum by Immunoassay;SARS-CoV Urb Ab Ser Ql IA;;ACTIVE;2.09;2.68 +3396-9;Cocaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cocaine [Mass/volume] in Serum or Plasma;Cocaine SerPl-mCnc;;ACTIVE;1.0;2.73 +33969-7;SARS coronavirus Urbani Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;SARS coronavirus Urbani Ab [Units/volume] in Serum by Immunoassay;SARS-CoV Urb Ab Ser IA-aCnc;;ACTIVE;2.09;2.69 +33970-5;SARS coronavirus Urbani Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;SARS coronavirus Urbani Ab [Presence] in Serum by Immunofluorescence;SARS-CoV Urb Ab Ser Ql IF;;ACTIVE;2.09;2.68 +33971-3;SARS coronavirus Urbani Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;SARS coronavirus Urbani Ab [Titer] in Serum by Immunofluorescence;SARS-CoV Urb Ab Titr Ser IF;;ACTIVE;2.09;2.68 +33972-1;SARS coronavirus Urbani Ab;PrThr;Pt;Ser;Ord;;MICRO;1;SARS coronavirus Urbani Ab [Presence] in Serum;SARS-CoV Urb Ab Ser Ql;;ACTIVE;2.09;2.68 +33973-9;SARS coronavirus Urbani Ab;ACnc;Pt;Ser;Qn;;MICRO;1;SARS coronavirus Urbani Ab [Units/volume] in Serum;SARS-CoV Urb Ab Ser-aCnc;;ACTIVE;2.09;2.69 +33974-7;SARS coronavirus Urbani Ab;Titr;Pt;Ser;Qn;;MICRO;1;SARS coronavirus Urbani Ab [Titer] in Serum;SARS-CoV Urb Ab Titr Ser;;ACTIVE;2.09;2.68 +33975-4;SARS coronavirus Urbani RNA;PrThr;Pt;Sputum;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus Urbani RNA [Presence] in Sputum by NAA with probe detection;SARS-CoV Urb RNA Spt Ql NAA+probe;;ACTIVE;2.09;2.68 +33976-2;Plasminogen activator inhibitor 1 Ag;MCnc;Pt;PPP;Qn;EIA;COAG;1;Deprecated Plasminogen activator inhibitor 1 Ag [Mass/volume] in Platelet poor plasma by EIA;Deprecated PAI1 Ag PPP EIA-mCnc;;DEPRECATED;2.09;2.70 +3397-7;Cocaine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cocaine [Presence] in Urine;Cocaine Ur Ql;;ACTIVE;1.0;2.73 +33977-0;F little y super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Fy sup(a) Ab [Titer] in Serum or Plasma;Fy sup(a) Ab Titr SerPl;;ACTIVE;2.09;2.70 +33978-8;BK virus DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;BK virus DNA [Presence] in Urine by NAA with probe detection;BKV DNA Ur Ql NAA+probe;;ACTIVE;2.09;2.73 +33979-6;Voltage-gated calcium channel N type binding Ab;SCnc;Pt;Ser;Qn;;SERO;1;Voltage-gated calcium channel N type binding Ab [Moles/volume] in Serum;VGCC-N Bind Ab Ser-sCnc;;ACTIVE;2.09;2.73 +33980-4;Voltage-gated calcium channel PQ type binding Ab;SCnc;Pt;Ser;Qn;;SERO;1;Voltage-gated calcium channel P/Q type binding Ab [Moles/volume] in Serum;VGCC-P/Q Bind Ab Ser-sCnc;;ACTIVE;2.09;2.73 +33981-2;TBP gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;TBP gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;TBP gene CAG Rpt Bld/T Ql;;ACTIVE;2.09;2.70 +33982-0;Juglans california pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;California Walnut Pollen IgE Ab [Units/volume] in Serum;Calif Walnut Poln IgE Qn;;ACTIVE;2.09;2.73 +33983-8;U1 small nuclear ribonucleoprotein Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;U1 small nuclear ribonucleoprotein IgG Ab [Units/volume] in Serum;U1 snRNP IgG Ser-aCnc;;ACTIVE;2.09;2.73 +33984-6;Coagulation factor X activity actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor X activity actual/normal in Platelet poor plasma by Chromogenic method;Fact X Act/Nor PPP Chro;;ACTIVE;2.09;2.73 +3398-5;Cocaine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cocaine [Mass/volume] in Urine;Cocaine Ur-mCnc;;ACTIVE;1.0;2.73 +33985-3;Bartonella henselae DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Bartonella henselae DNA [Presence] in Tissue by NAA with probe detection;B henselae DNA Tiss Ql NAA+probe;;ACTIVE;2.09;2.70 +33986-1;Bartonella henselae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bartonella henselae DNA [Presence] in Specimen by NAA with probe detection;B henselae DNA Spec Ql NAA+probe;;ACTIVE;2.09;2.73 +33987-9;Heparin cofactor II actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Heparin cofactor II actual/normal in Platelet poor plasma by Chromogenic method;Heparin CF II Act/Nor PPP Chro;;ACTIVE;2.09;2.73 +33988-7;Thymidine phosphorylase;CCnt;Pt;WBC;Qn;;CHEM;1;Thymidine phosphorylase [Enzymatic activity/mass] in Leukocytes;ThdPase WBC-cCnt;;ACTIVE;2.09;2.70 +33989-5;quiNINE induced platelet Ab;PrThr;Pt;Ser;Ord;;SERO;1;quiNINE induced platelet Ab [Presence] in Serum;quiNINE ind plt Ab Ser Ql;;ACTIVE;2.09;2.70 +33990-3;Normoblasts/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Normoblasts/100 leukocytes in Blood;Normoblasts/leuk NFr Bld;;ACTIVE;2.09;2.70 +33991-1;Cells.CD79b/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD79b cells/100 cells in Specimen;CD79b Cells NFr Spec;;ACTIVE;2.09;2.70 +33992-9;Pain trigger point;Anat;Pt;{Primary pain location};Nom;;DENTAL;2;Pain trigger point [Anatomy] {Primary pain location};Pain trigger point {Prim pain loc};;ACTIVE;2.09;2.27 +3399-3;Benzthiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Benzthiazide [Presence] in Urine;Benzthiazide Ur Ql;;ACTIVE;1.0;2.73 +33993-7;Subject tooth;Anat;Pt;*;Nom;;DENTAL;2;Subject tooth [Anatomy];Subject tooth;;ACTIVE;2.09;2.27 +33994-5;Reference tooth;Anat;Pt;*;Nom;;DENTAL;2;Reference tooth [Anatomy];Ref tooth;;ACTIVE;2.09;2.27 +33995-2;Tooth development evaluation;Find;Pt;{Subject tooth}+{Reference tooth};Nom;;DENTAL;2;Tooth development evaluation {Subject tooth}+{Reference tooth};Tooth devel eval Subj+Ref;;ACTIVE;2.09;2.34 +33996-0;Tooth size discrepancy;Len;Pt;Maxilla.cuspid+Mandible.cuspid;Qn;Measured.Bolton analysis;DENTAL;2;Tooth size discrepancy Maxilla.cuspid+Mandible.cuspid Measured Bolton analysis;Size discr Maxi+Mand.cuspid Bolton;;ACTIVE;2.09;2.48 +33997-8;Tooth size discrepancy;Len;Pt;Maxilla.first molar+Mandible.first molar;Qn;Measured.Bolton analysis;DENTAL;2;Tooth size discrepancy Maxilla.first molar+Mandible.first molar Measured Bolton analysis;Size discr Maxi+Mand.1st molar Bolton;;ACTIVE;2.09;2.48 +33998-6;Tooth size discrepancy;Find;Pt;Dentition;Ord;Estimated.Bolton analysis;DENTAL;2;Tooth size discrepancy Dentition Estimated Bolton analysis;Size discr Dentition Bolton est;;ACTIVE;2.09;2.34 +33999-4;Status;Class;Pt;{Diagnosis};Nom;;H&P.HX;2;Diagnosis status;Status {Dx};;ACTIVE;2.09;2.72 +3-4;Almecillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Almecillin [Susceptibility] by Minimum inhibitory concentration (MIC);Almecillin Islt MIC;;ACTIVE;1.0;2.19 +340-0;Miocamycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Miocamycin [Susceptibility] by Disk diffusion (KB);Miocamycin Islt KB;;ACTIVE;1.0;2.19 +34000-0;Treatment urgency;Find;Pt;{Diagnosis};Ord;;DENTAL;2;Treatment urgency {Diagnosis};Tx urgency {Dx};;ACTIVE;2.09;2.56 +34001-8;Etiological factors.dental;Find;Pt;{Diagnosis.dental};Nom;;DENTAL;2;Etiological factors.dental {Diagnosis.dental};Etiol factors.dent {Dx.dent};;ACTIVE;2.09;2.56 +34002-6;Tooth position;Find;Pt;{Tooth};Nom;;DENTAL;2;Tooth position;Tooth position;;ACTIVE;2.09;2.27 +34003-4;Tooth impaction;Find;Pt;{Tooth};Nom;;DENTAL;2;Tooth impaction;Tooth impaction;;ACTIVE;2.09;2.56 +34004-2;Tooth impaction position;Find;Pt;{Tooth};Nom;;DENTAL;2;Tooth impaction position;Tooth impaction position;;ACTIVE;2.09;2.27 +34005-9;Tooth mobility;Find;Pt;{Tooth};Ord;Miller classification;DENTAL;2;Tooth mobility Miller classification;Tooth mobility Miller;;ACTIVE;2.09;2.27 +34006-7;Orthodontic treatment;Class;Pt;{Treatment.dental};Nom;;DENTAL;2;Orthodontic treatment [Class];Orthodontic Tx;;ACTIVE;2.09;2.56 +34007-5;Type of dentition;Find;Pt;Dentition;Nom;;DENTAL;2;Type of dentition Dentition;Type of dentition Dentition;;ACTIVE;2.09;2.56 +34008-3;Status;Class;Pt;{Orthodontic treatment};Nom;;DENTAL;2;Status [Class] {Orthodontic treatment};Status {Ortho Tx};;ACTIVE;2.09;2.56 +3400-9;Benzthiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzthiazide [Mass/volume] in Urine;Benzthiazide Ur-mCnc;;ACTIVE;1.0;2.73 +34009-1;Tooth previously extracted;Find;Pt;{Tooth};Ord;;DENTAL;2;Tooth previously extracted;Tooth previously extracted;;ACTIVE;2.09;2.27 +34010-9;Time since last tooth extraction;Time;Pt;{Tooth};Qn;;DENTAL;2;Time since last tooth extraction;Time since last tooth extraction;;ACTIVE;2.09;2.27 +34011-7;Previous dental surgery;Find;Pt;^Patient;Ord;;DENTAL;2;Previous dental surgery;Prev dent surg;;ACTIVE;2.09;2.27 +34012-5;Previous dental appliance wear;Find;Pt;^Patient;Ord;;DENTAL;2;Previous dental appliance wear;Previ dent appl wear;;ACTIVE;2.09;2.27 +34013-3;Periodontal evaluation;Class;Pt;Gingiva;Ord;PSR scale;DENTAL;2;Periodontal evaluation Gingiva PSR scale;Periodontal eval Gingiva PSR;;ACTIVE;2.09;2.27 +34014-1;Periodontal screening and recording special finding;Find;Pt;Gingiva;Nom;PSR scale;DENTAL;2;Periodontal screening and recording special finding Gingiva PSR scale;Periodont special Gingiva PSR;;ACTIVE;2.09;2.38 +34015-8;Furcation classification;Class;Pt;{Tooth};Ord;Glickman classification;DENTAL;2;Furcation classification {Tooth} Glickman classification;Furc class {Tooth} Glickman;;ACTIVE;2.09;2.27 +34016-6;Dental plaque;Find;Pt;{Probe site};Ord;;DENTAL;2;Dental plaque {Probe site};Dent plaque {Probe site};;ACTIVE;2.09;2.27 +3401-7;Benzthiazide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Benzthiazide [Mass/time] in 24 hour Urine;Benzthiazide 24h Ur-mRate;;ACTIVE;1.0;2.42 +34017-4;Tooth out of bone/Tooth in bone;LenRto;Pt;{Tooth};Qn;Measured;DENTAL;2;Tooth out of bone/Tooth in bone Measured;Tooth out of bone/in bone Measured;;ACTIVE;2.09;2.48 +34018-2;Bone density;Find;Pt;{Dental arch};Ord;Branemark scale;DENTAL;2;Bone density {Dental arch} Branemark scale;BMD {Dent arch} Branemark Scale;;ACTIVE;2.09;2.56 +34019-0;Bone volume;Vol;Pt;{Tooth space};Qn;Measured;DENTAL;2;Bone volume {Tooth space} Measured;Bne volume {Tooth space} Measured;;ACTIVE;2.09;2.48 +34020-8;First bone reference;Anat;Pt;{Dental arch};Nom;;DENTAL;2;First bone reference [Anatomy] {Dental arch};1st bone ref {Dent arch};;ACTIVE;2.09;2.27 +34021-6;Second bone reference;Anat;Pt;{Dental arch};Nom;;DENTAL;2;Second bone reference [Anatomy] {Dental arch};2nd bne ref {Dent arch};;ACTIVE;2.09;2.27 +34022-4;Bone adequate;Find;Pt;{Dental arch};Ord;;DENTAL;2;Bone adequate {Dental arch};Bone adequate {Dent arch};;ACTIVE;2.09;2.27 +34023-2;Bone resorption pattern;Find;Pt;{Dental arch};Nom;Lekholm & Zarb classification;DENTAL;2;Bone resorption pattern {Dental arch} Lekholm and Zarb classification;Bone resorp pattern {Dent arch} LZ;;ACTIVE;2.09;2.38 +34024-0;Reason tooth lost;Find;Pt;{Tooth};Nom;;DENTAL;2;Reason tooth lost;Reason tooth lost;;ACTIVE;2.09;2.56 +3402-5;Bolasterone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Bolasterone [Presence] in Urine;Bolasterone Ur Ql;;ACTIVE;1.0;2.73 +34025-7;Previous dental prosthesis wear;Find;Pt;^Patient;Ord;;DENTAL;2;Previous dental prosthesis wear;Previ dent prosthesis wear;;ACTIVE;2.09;2.27 +34026-5;Dental prosthesis;Type;Pt;*;Nom;;DENTAL;2;Dental prosthesis;Dent prosthesis;;ACTIVE;2.09;2.73 +34027-3;Age;Time;Pt;{Dental prosthesis};Qn;;DENTAL;2;Age {Dental prosthesis};Age {Dent prosth};;ACTIVE;2.09;2.48 +34028-1;Well maintained;Find;Pt;{Dental prosthesis};Ord;;DENTAL;2;Well maintained {Dental prosthesis};Well maintained {Dent prosth};;ACTIVE;2.09;2.34 +34029-9;Prosthesis complaint;Find;Pt;{Dental prosthesis};Ord;Reported;DENTAL;2;Prosthesis complaint {Dental prosthesis} - Reported;Complaint {Dent prosth} Reported;;ACTIVE;2.09;2.34 +34030-7;Reason for prosthesis complaint;Find;Pt;{Dental prosthesis};Nom;Reported;DENTAL;2;Reason for prosthesis complaint {Dental prosthesis} - Reported;Complaint reason {Dent prosth} Reported;;ACTIVE;2.09;2.38 +34031-5;Denture base evaluation;Imp;Pt;{Dental arch};Ord;;DENTAL;2;Denture base evaluation {Dental arch};Dtr base eval {Dent arch};;ACTIVE;2.09;2.56 +34032-3;Denture teeth evaluation;Imp;Pt;{Dental arch};Ord;;DENTAL;2;Denture teeth evaluation {Dental arch};Dtr teeth eval {Dent arch};;ACTIVE;2.09;2.56 +3403-3;Bolasterone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bolasterone [Mass/volume] in Urine;Bolasterone Ur-mCnc;;ACTIVE;1.0;2.42 +34033-1;Denture occlusion;Find;Pt;{Dental prosthesis};Nom;;DENTAL;2;Denture occlusion {Dental prosthesis};Dtr occl {Dent prosth};;ACTIVE;2.09;2.56 +34034-9;Alveolar ridge trauma;Find;Pt;Gingiva;Ord;;DENTAL;2;Alveolar ridge trauma Gingiva;Alv ridge trauma Gingiva;;ACTIVE;2.09;2.27 +34035-6;Alveolar ridge pathology;Find;Pt;Gingiva;Ord;;DENTAL;2;Alveolar ridge pathology Gingiva;Alv ridge path Gingiva;;ACTIVE;2.09;2.27 +34036-4;Keratinized gingiva;Find;Pt;Gingiva;Ord;;DENTAL;2;Keratinized gingiva;Keratinized gingiva;;ACTIVE;2.09;2.56 +34037-2;Size;Arb;Pt;Alveolar ridge;Ord;Estimated;DENTAL;2;Size Alveolar ridge Estimated;Size Alv ridge Est;;ACTIVE;2.09;2.27 +34038-0;Problematic maxillary tuberosity;Find;Pt;Maxilla;Ord;;DENTAL;2;Problematic maxillary tuberosity;Problem max tuberosity;;ACTIVE;2.09;2.29 +34039-8;Edentulous ridge relationship;Find;Pt;Maxilla.left+Mandible.left;Nom;;DENTAL;2;Edentulous ridge relationship Maxilla - left and Mandible - left;Edent ridge rel Maxilla+Mandible-L;;ACTIVE;2.09;2.56 +34040-6;Edentulous ridge relationship;Find;Pt;Maxilla.right+Mandible.right;Nom;;DENTAL;2;Edentulous ridge relationship Maxilla - right and Mandible - right;Edent ridge rel Maxilla+Mandible-R;;ACTIVE;2.09;2.56 +3404-1;Bolasterone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Bolasterone [Mass/time] in 24 hour Urine;Bolasterone 24h Ur-mRate;;ACTIVE;1.0;2.42 +34041-4;Partial edentulism classification;Class;Pt;{Dental arch};Nom;Kennedy classification;DENTAL;2;Partial edentulism {Dental arch} Kennedy classification;Partial edent {Dent arch} Kennedy;;ACTIVE;2.09;2.29 +34042-2;Partially endentulous maxillectomy classification;Class;Pt;Maxilla;Nom;Aramany classification;DENTAL;2;Partially endentulous maxillectomy Aramany classification;Partial endent max Aramany;;ACTIVE;2.09;2.34 +34043-0;Dental examination method;Type;Pt;Dentition;Nom;*;DENTAL;2;Dental examination method Dentition;Dent exam method Dentition;;ACTIVE;2.09;2.27 +34044-8;Magnification instrument;Type;Pt;^Patient;Nom;;DENTAL;2;Magnification instrument;Magnification instrument;;ACTIVE;2.09;2.56 +34045-5;Oral evaluation exam;Type;Pt;^Patient;Nom;;DENTAL;2;Oral evaluation exam;Oral eval exam;;ACTIVE;2.09;2.73 +34046-3;Medical history contribution;Find;Pt;{Chief complaint};Ord;;DENTAL;2;Medical history contribution {Chief complaint};Medical Hx contrib {Chief complaint};;ACTIVE;2.09;2.27 +34047-1;Dental history contribution;Find;Pt;{Chief complaint};Ord;;DENTAL;2;Dental history contribution {Chief complaint};Dent Hx contribution {Chief complaint};;ACTIVE;2.09;2.27 +34048-9;Dental material used &or Proposed;Type;Pt;^Patient;Nom;;DENTAL;2;Dental material used/Proposed;Dent material used/Proposed;;ACTIVE;2.09;2.56 +34049-7;Number of impressions;Num;Pt;Dentition;Qn;;DENTAL;2;Number of impressions Dentition;# impressions Dentition;;ACTIVE;2.09;2.48 +34050-5;Bone height;Len;Pt;{First bone reference}+{Second bone reference};Qn;Measured;DENTAL;2;Bone height {First bone reference}+{Second bone reference} Measured;Bne height 1st+2nd {bne ref} Measured;;ACTIVE;2.09;2.48 +34051-3;Bone width;Len;Pt;{First bone reference}+{Second bone reference};Qn;Measured;DENTAL;2;Bone width {First bone reference}+{Second bone reference} Measured;Bne width 1st+2nd {bne ref} Measured;;ACTIVE;2.09;2.48 +34052-1;Bone length;Len;Pt;{First bone reference}+{Second bone reference};Qn;Measured;DENTAL;2;Bone length {First bone reference}+{Second bone reference} Measured;Bne length 1st+2nd {bne ref} Measured;;ACTIVE;2.09;2.48 +34053-9;Xylose^2H post 5 g xylose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --2 hours post 5 g xylose PO;Xylose 2h p 5 g Xyl PO SerPl-sCnc;;ACTIVE;2.09;2.70 +34054-7;Thyrotropin^pre or post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --pre or post dose TRH;TSH pre/p TRH SerPl-aCnc;;ACTIVE;2.09;2.70 +34055-4;Lutropin^pre or post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --pre or post XXX challenge;LH pre/p chal SerPl-aCnc;;ACTIVE;2.09;2.68 +34056-2;Glucose^pre or post dose arginine;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre or post dose arginine;Glucose pre/p Arg SerPl-sCnc;;ACTIVE;2.09;2.70 +34057-0;Glucose^pre or post dose cloNIDine;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre or post dose cloNIDine;Glucose pre/p CLN SerPl-sCnc;;ACTIVE;2.09;2.70 +3405-8;Bromazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromazepam [Mass/volume] in Serum or Plasma;Bromazepam SerPl-mCnc;;ACTIVE;1.0;2.42 +34058-8;Glucose^pre or post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre or post dose glucagon;Glucose pre/p Gc SerPl-sCnc;;ACTIVE;2.09;2.70 +34059-6;Glucose^pre or post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre or post dose glucose;Glucose pre/p Glc SerPl-sCnc;;ACTIVE;2.09;2.70 +34060-4;Glucose^pre or post dose insulin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre or post dose insulin;Glucose pre/p Ins SerPl-sCnc;;ACTIVE;2.09;2.70 +34061-2;Somatotropin^pre or post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose arginine;GH pre/p Arg SerPl-mCnc;;ACTIVE;2.09;2.70 +34062-0;Somatotropin^pre or post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose cloNIDine;GH pre/p CLN SerPl-mCnc;;ACTIVE;2.09;2.70 +34063-8;Somatotropin^pre or post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose glucagon;GH pre/p Gc SerPl-mCnc;;ACTIVE;2.09;2.70 +34064-6;Somatotropin^pre or post dose insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose insulin;GH pre/p Ins SerPl-mCnc;;ACTIVE;2.09;2.70 +34065-3;Cortisol^pre or post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre or post dose corticotropin;Cortis pre/p ACTH SerPl-sCnc;;ACTIVE;2.09;2.70 +3406-6;Bromazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bromazepam [Mass/volume] in Urine;Bromazepam Ur-mCnc;;ACTIVE;1.0;2.42 +34066-1;Boxed warning section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Boxed warning section;FDA insert Boxed warning;;ACTIVE;2.09;2.34 +34067-9;Indications & usage section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indications and usage section;FDA insert Indications/usage;;ACTIVE;2.09;2.38 +34068-7;Dosage & administration section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Dosage and administration section;FDA insert Dose & admin;;ACTIVE;2.09;2.38 +34069-5;How supplied section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert How supplied section;FDA insert How supplied;;ACTIVE;2.09;2.34 +34070-3;Contraindications section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Contraindications section;FDA insert Contraindications;;ACTIVE;2.09;2.34 +34071-1;Warnings section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Warnings section;FDA insert Warnings;;ACTIVE;2.09;2.34 +34072-9;General precautions section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert General precautions section;FDA insert General precautions;;ACTIVE;2.09;2.34 +34073-7;Drug interactions section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Drug interactions section;FDA insert Drug interactions;;ACTIVE;2.09;2.34 +3407-4;Brompheniramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Brompheniramine [Presence] in Serum or Plasma;Brompheniramine SerPl Ql;;ACTIVE;1.0;2.56 +34074-5;Drug &or laboratory test interactions section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Drug/laboratory test interactions section;FDA insert Drug/lab test interactions;;ACTIVE;2.09;2.34 +34075-2;Laboratory tests section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Laboratory tests section;FDA insert Lab tests;;ACTIVE;2.09;2.34 +34076-0;Information for patients section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Information for patients section;FDA insert Info for patients;;ACTIVE;2.09;2.34 +34077-8;Teratogenic effects section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Teratogenic effects section;FDA insert Teratogenic effects;;ACTIVE;2.09;2.34 +34078-6;Nonteratogenic effects section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Nonteratogenic effects section;FDA insert Nonteratogenic effects;;ACTIVE;2.09;2.34 +34079-4;Labor & delivery section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Labor and delivery section;FDA insert Labor & delivery;;ACTIVE;2.09;2.38 +34080-2;Nursing mothers section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Nursing mothers section;FDA insert Nursing mothers;;ACTIVE;2.09;2.34 +34081-0;Pediatric use section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Pediatric use section;FDA insert Pediatric use;;ACTIVE;2.09;2.34 +3408-2;Brompheniramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Brompheniramine [Presence] in Urine;Brompheniramine Ur Ql;;ACTIVE;1.0;2.73 +34082-8;Geriatric use section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Geriatric use section;FDA insert Geriatric use;;ACTIVE;2.09;2.34 +34083-6;Carcinogenesis & mutagenesis & impairment of fertility section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Carcinogenesis and mutagenesis and impairment of fertility section;FDA insert Carcin/mutagen/imp of fert;;ACTIVE;2.09;2.38 +34084-4;Adverse reactions section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Adverse reactions section;FDA insert Adverse rx;;ACTIVE;2.09;2.34 +34085-1;Controlled substance section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Controlled substance section;FDA insert Controlled substance;;ACTIVE;2.09;2.34 +34086-9;Abuse section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Abuse section;FDA insert Abuse;;ACTIVE;2.09;2.34 +34087-7;Dependence section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Dependence section;FDA insert Dependence;;ACTIVE;2.09;2.34 +34088-5;Overdosage section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Overdosage section;FDA insert Overdosage;;ACTIVE;2.09;2.34 +34089-3;Description section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Description section;FDA insert Description section;;ACTIVE;2.09;2.34 +3409-0;Bumetanide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Bumetanide [Presence] in Urine;Bumetanide Ur Ql;;ACTIVE;1.0;2.73 +34090-1;Clinical pharmacology section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Clinical pharmacology section;FDA insert Clin pharmacology;;ACTIVE;2.09;2.34 +34091-9;Animal pharmacology &or toxicology section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Animal pharmacology/toxicology section;FDA insert Animal pharm/toxicity;;ACTIVE;2.09;2.34 +34092-7;Clinical studies section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Clinical studies section;FDA insert Clin studies;;ACTIVE;2.09;2.34 +34093-5;References section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert References section;FDA insert References;;ACTIVE;2.09;2.34 +34094-3;Admission history and physical note;Find;Pt;Hospital;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Hospital Admission history and physical note;Cardiology Hosp Admit H&P note;;ACTIVE;2.09;2.58 +34095-0;Comprehensive history and physical note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Comprehensive history and physical note;Comp H&P note;;ACTIVE;2.09;2.58 +34096-8;Comprehensive history and physical note;Find;Pt;Nursing facility;Doc;{Role};DOC.ONTOLOGY;2;Nursing facility Comprehensive history and physical note;Nursing facility Comp H&P note;;ACTIVE;2.09;2.58 +34097-6;Conference note;Find;Pt;Nursing facility;Doc;{Role};DOC.ONTOLOGY;2;Nursing facility Conference note;Nursing facility Conf eval note;;ACTIVE;2.09;2.54 +34098-4;Conference note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Conference note;Conf eval note;;ACTIVE;2.09;2.54 +34099-2;Consultation note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Consult note;Cardiology Consult note;;ACTIVE;2.09;2.58 +34100-8;Consultation note;Find;Pt;Intensive care unit;Doc;{Role};DOC.ONTOLOGY;2;Intensive care unit Consult note;ICU Consult note;;ACTIVE;2.09;2.58 +34101-6;Consultation note;Find;Pt;Outpatient;Doc;General medicine;DOC.ONTOLOGY;2;General medicine Outpatient Consult note;General medicine OP Consult note;;ACTIVE;2.09;2.73 +34102-4;Consultation note;Find;Pt;Hospital;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Hospital Consult note;Psychiatric Hosp Consult note;;ACTIVE;2.09;2.58 +34103-2;Consultation note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Consult note;Pulmonary disease Consult note;;ACTIVE;2.09;2.58 +34104-0;Consultation note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Consult note;Hosp Consult note;;ACTIVE;2.09;2.58 +34105-7;Discharge summary note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Discharge summary;Hosp D/C sum;;ACTIVE;2.09;2.73 +34106-5;Discharge summary note;Find;Pt;Hospital;Doc;Physician;DOC.ONTOLOGY;2;Physician Hospital Discharge summary;MD Hosp D/C sum;;ACTIVE;2.09;2.73 +34107-3;Education note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Education note;Pt's home Educ note;;ACTIVE;2.09;2.54 +3410-8;Bumetanide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bumetanide [Mass/volume] in Urine;Bumetanide Ur-mCnc;;ACTIVE;1.0;2.42 +34108-1;Note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Note;OP Note;;ACTIVE;2.09;2.54 +34109-9;Note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Note;Note;;ACTIVE;2.09;2.73 +34110-7;Note;Find;Pt;Outpatient;Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Outpatient Note;Diabetology OP Note;;ACTIVE;2.09;2.50 +34111-5;Note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Note;ED Note;;ACTIVE;2.09;2.54 +34112-3;Note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Note;Hosp Note;;ACTIVE;2.09;2.54 +34113-1;Note;Find;Pt;Nursing facility;Doc;{Role};DOC.ONTOLOGY;2;Nursing facility Note;Nursing facility Note;;ACTIVE;2.09;2.54 +34114-9;Group counseling note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Group counseling note;Hosp Group counseling note;;ACTIVE;2.09;2.54 +34115-6;History and physical note;Find;Pt;Hospital;Doc;Medical student;DOC.ONTOLOGY;2;Medical student Hospital History and physical note;MS Hosp H&P note;;ACTIVE;2.09;2.58 +3411-6;Bumetanide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Bumetanide [Mass/time] in 24 hour Urine;Bumetanide 24h Ur-mRate;;ACTIVE;1.0;2.42 +34116-4;History and physical note;Find;Pt;Nursing facility;Doc;Physician;DOC.ONTOLOGY;2;Physician Nursing facility History and physical note;MD Nursing facility H&P note;;ACTIVE;2.09;2.58 +34117-2;History and physical note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;History and physical note;H&P note;;ACTIVE;2.09;2.63 +34118-0;Initial evaluation note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Initial evaluation note;Pt's home Initial eval note;;ACTIVE;2.09;2.54 +34119-8;Initial evaluation note;Find;Pt;Nursing facility;Doc;{Role};DOC.ONTOLOGY;2;Nursing facility Initial evaluation note;Nursing facility Initial eval note;;ACTIVE;2.09;2.54 +34120-6;Initial evaluation note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Initial evaluation note;OP Initial eval note;;ACTIVE;2.09;2.54 +34121-4;Interventional procedure note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Interventional procedure note;Interv proced note;;ACTIVE;2.09;2.58 +34122-2;Procedure note;Find;Pt;{Setting};Doc;Pathology;DOC.ONTOLOGY;2;Pathology procedure note;Pathology Procedure note;;ACTIVE;2.09;2.73 +34123-0;Preoperative evaluation and management note;Find;Pt;Hospital;Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Hospital Preoperative evaluation and management note;Anesthesiology Hosp Pre-op note;;ACTIVE;2.09;2.52 +3412-4;Bupivacaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bupivacaine [Mass/volume] in Serum or Plasma;Bupivacaine SerPl-mCnc;;ACTIVE;1.0;2.73 +34124-8;Progress note;Find;Pt;Outpatient;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Outpatient Progress note;Cardiology OP Prog note;;ACTIVE;2.09;2.73 +34125-5;Progress note;Find;Pt;Patient's home;Doc;Case manager;DOC.ONTOLOGY;2;Case manager Patient's home Progress note;Case Manager Pt's home Prog note;;ACTIVE;2.09;2.73 +34126-3;Progress note;Find;Pt;Intensive care unit;Doc;{Role};DOC.ONTOLOGY;2;Intensive care unit Progress note;ICU Prog note;;ACTIVE;2.09;2.73 +34127-1;Progress note;Find;Pt;Outpatient;Doc;Dentistry.hygienist;DOC.ONTOLOGY;2;Dentistry Hygienist Outpatient Progress note;Dentistry Hygienist OP Prog note;;ACTIVE;2.09;2.73 +34128-9;Progress note;Find;Pt;Outpatient;Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Outpatient Progress note;Dentistry OP Prog note;;ACTIVE;2.09;2.73 +34129-7;Progress note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Progress note;Pt's home Prog note;;ACTIVE;2.09;2.73 +34130-5;Progress note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Progress note;Hosp Prog note;;ACTIVE;2.09;2.73 +34131-3;Progress note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Progress note;OP Prog note;;ACTIVE;2.09;2.73 +3413-2;Buprenorphine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Buprenorphine [Mass/volume] in Serum or Plasma;Buprenorphine SerPl-mCnc;;ACTIVE;1.0;2.73 +34132-1;Progress note;Find;Pt;Outpatient;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Outpatient Progress note;Pharmacology OP Prog note;;ACTIVE;2.09;2.73 +34133-9;Summary of episode note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Summary of episode note;Summary of episode note;;ACTIVE;2.09;2.70 +34134-7;Supervisory note;Find;Pt;Outpatient;Doc;Attending;DOC.ONTOLOGY;2;Attending Outpatient Supervisory note;Attend OP Supervisory note;;ACTIVE;2.09;2.65 +34135-4;Supervisory note;Find;Pt;Outpatient;Doc;Cardiovascular disease.attending;DOC.ONTOLOGY;2;Cardiology Attending Outpatient Supervisory note;Cardio Attend OP Supervisory note;;ACTIVE;2.09;2.65 +34136-2;Supervisory note;Find;Pt;Outpatient;Doc;Gastroenterology.attending;DOC.ONTOLOGY;2;Gastroenterology Attending Outpatient Supervisory note;Gastroenterology Attend OP Supervis note;;ACTIVE;2.09;2.65 +34137-0;Surgical operation note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Surgical operation note;OP Operative note;;ACTIVE;2.09;2.58 +34138-8;Targeted history and physical note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Targeted history and physical note;Targeted H&P note;;ACTIVE;2.09;2.58 +34139-6;Note;Find;Pt;Telephone encounter;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Telephone encounter Note;Nurse Phone Note;;ACTIVE;2.09;2.58 +3414-0;Buprenorphine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Buprenorphine [Presence] in Urine;Buprenorphine Ur Ql;;ACTIVE;1.0;2.73 +34140-4;Transfer of care referral note;Find;Pt;{Setting};Doc;{Provider};DOC.ONTOLOGY;2;Deprecated Transfer of care referral note;Deprecated Transfer of care ref note;;DEPRECATED;2.09;2.50 +34141-2;Blood flow rate.max;VRat;Pt;{Circulatory system};Qn;US;GEN.US;2;Maximum blood flow rate by US;Vmax US;;ACTIVE;2.10;2.67 +34142-0;Paraneoplastic Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Paraneoplastic Ab [Presence] in Serum by Immunoblot;Paraneoplastic Ab Ser Ql IB;;ACTIVE;2.10;2.73 +34143-8;HLA-DQ locus 2;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DQ locus 2 [Type];HLA-DQ locus 2;;ACTIVE;2.10;2.70 +34144-6;HLA-DR W locus 2;Type;Pt;Bld/Tiss;Nom;;HLA;1;Deprecated HLA-DR w locus 2 [Type];Deprecated HLA-DR w locus 2;;DEPRECATED;2.10;2.70 +34145-3;Human antichimeric Ab;MCnc;Pt;Ser;Qn;;SERO;1;Human antichimeric Ab [Mass/volume] in Serum;HACA Ab Ser-mCnc;;ACTIVE;2.10;2.73 +34146-1;Neopterin;SCnc;Pt;CSF;Qn;;CHEM;1;Neopterin [Moles/volume] in Cerebral spinal fluid;Neopterin CSF-sCnc;;ACTIVE;2.10;2.70 +34147-9;Treponema pallidum Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Treponema pallidum IgG+IgM Ab [Presence] in Serum;T pallidum IgG+IgM Ser Ql;;ACTIVE;2.10;2.73 +34148-7;Borrelia burgdorferi Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi IgG+IgM Ab [Units/volume] in Serum;B burgdor IgG+IgM Ser-aCnc;;ACTIVE;2.10;2.73 +34149-5;N-acetyl-L-aspartate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;N-acetyl-L-aspartate [Moles/volume] in Amniotic fluid;N-Ac-L-Asp Amn-sCnc;;ACTIVE;2.10;2.70 +34150-3;Mycoplasma fermentans DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Mycoplasma fermentans DNA [Presence] in Blood by NAA with probe detection;M fermentans DNA Bld Ql NAA+probe;;ACTIVE;2.10;2.73 +34151-1;Cells.CD10+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD10+CD25+ cells [#/volume] in Blood;CD10+CD25+ Cells # Bld;;ACTIVE;2.10;2.40 +34152-9;Herpes simplex virus 1+2 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Titer] in Serum;HSV1+2 IgM Titr Ser;;ACTIVE;2.10;2.73 +34153-7;Influenza virus A Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Influenza virus A Ab [Units/volume] in Specimen;FLUAV Ab Spec-aCnc;;ACTIVE;2.10;2.73 +34154-5;Influenza virus B Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Influenza virus B Ab [Units/volume] in Specimen;FLUBV Ab Spec-aCnc;;ACTIVE;2.10;2.73 +34155-2;Guanidinoacetate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Guanidinoacetate/Creatinine [Molar ratio] in Urine;Guanidinoacetate/Creat Ur-sRto;;ACTIVE;2.10;2.70 +34156-0;Insulin.bound;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin.bound [Units/volume] in Serum or Plasma;Insulin Bnd SerPl-aCnc;;ACTIVE;2.10;2.70 +3415-7;Buprenorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Buprenorphine [Mass/volume] in Urine;Buprenorphine Ur-mCnc;;ACTIVE;1.0;2.73 +34157-8;little e Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;little e Ab [Titer] in Serum or Plasma;little e Ab Titr SerPl;;ACTIVE;2.10;2.70 +34158-6;Histoplasma capsulatum Ag;ACnc;Pt;CSF;Qn;;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Cerebral spinal fluid;H capsul Ag CSF-aCnc;;ACTIVE;2.10;2.70 +34159-4;Tau protein;PrThr;Pt;Body fld;Ord;;CHEM;1;Tau protein [Presence] in Body fluid;Tau Prot Fld Ql;;ACTIVE;2.10;2.70 +34160-2;Creatine kinase;PrThr;Pt;Body fld;Ord;;CHEM;1;Creatine kinase [Presence] in Body fluid;CK Fld Ql;;ACTIVE;2.10;2.70 +34161-0;Cancer Ag 72-4;ACnc;Pt;Body fld;Qn;;CHEM;1;Cancer Ag 72-4 [Units/volume] in Body fluid;Cancer Ag72-4 Fld-aCnc;;ACTIVE;2.10;2.68 +34162-8;Hepatitis C virus Ab.IgG band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Hepatitis C virus IgG band pattern [Interpretation] in Serum by Immunoblot;HCV IgG Patrn Ser IB-Imp;;ACTIVE;2.10;2.67 +34163-6;Oxygen content;SCnc;Pt;Bld;Qn;;CHEM;1;Oxygen content in Blood;O2 Ct Bld-sCnc;;ACTIVE;2.10;2.73 +34164-4;N-Acetylglucosamine-6-Sulfatase;CCnt;Pt;Tiss;Qn;;CHEM;1;N-Acetylglucosamine-6-Sulfatase [Enzymatic activity/mass] in Tissue;NAG6Sulfatase Tiss-cCnt;;ACTIVE;2.10;2.42 +3416-5;Buprenorphine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Buprenorphine [Mass/time] in 24 hour Urine;Buprenorphine 24h Ur-mRate;;ACTIVE;1.0;2.42 +34165-1;Granulocytes.immature;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Immature granulocytes [Presence] in Blood by Automated count;Imm Granulocytes Bld Ql Auto;;ACTIVE;2.10;2.73 +34166-9;Microscopic observation;Prid;Pt;XXX;Nom;Microscopy.electron;MICRO;1;Microscopic observation [Identifier] in Specimen by Electron microscopy;EM Spec;;ACTIVE;2.10;2.69 +34167-7;Platelets.large;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Platelets Large [Presence] in Blood by Automated count;Lg Platelets Bld Ql Auto;;ACTIVE;2.10;2.73 +34168-5;Sulfocysteine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Sulfocysteine/Creatinine [Ratio] in Urine;Sulfocysteine/Creat Ur-Rto;;ACTIVE;2.10;2.70 +34169-3;Fatty acids.very long chain;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain [Mass/volume] in Serum or Plasma;VLCFA SerPl-mCnc;;ACTIVE;2.10;2.70 +34170-1;Biopterin;SCnc;Pt;Urine;Qn;;CHEM;1;Biopterin [Moles/volume] in Urine;Biopterin Ur-sCnc;;ACTIVE;2.10;2.70 +34171-9;Histoplasma capsulatum Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Specimen;H capsul Ag Spec-aCnc;;ACTIVE;2.10;2.69 +34172-7;Streptococcus pneumoniae Danish serotype 6B Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6B Ab [Mass/volume] in Serum;S pneum Da 6B Ab Ser-mCnc;;ACTIVE;2.10;2.73 +3417-3;Butabarbital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Butabarbital [Presence] in Serum or Plasma;Butabarbital SerPl Ql;;ACTIVE;1.0;2.56 +34173-5;Mixed cellular casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Mixed cellular casts [Presence] in Urine sediment by Light microscopy;Mixed Cell Casts UrnS Ql Micro;;ACTIVE;2.10;2.73 +34174-3;Hemoglobin casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Hemoglobin casts [Presence] in Urine sediment by Light microscopy;Hgb Casts UrnS Ql Micro;;ACTIVE;2.10;2.73 +34175-0;Analgesics;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Analgesics [Identifier] in Serum or Plasma;Analgesics SerPl;;ACTIVE;2.10;2.73 +34176-8;Tricyclic antidepressants;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Specimen;Tricyclics Spec Ql;;ACTIVE;2.10;2.73 +34177-6;Opiates;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Opiates [Presence] in Specimen;Opiates Spec Ql;;ACTIVE;2.10;2.73 +34178-4;Phenothiazines;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Phenothiazines [Presence] in Specimen;Phenothiaz Spec Ql;;ACTIVE;2.10;2.69 +34179-2;Herpes virus 6 Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Herpes virus 6 IgG Ab [Titer] in Serum by Immunoassay;HHV6 IgG Titr Ser IA;;ACTIVE;2.10;2.73 +341-8;Miocamycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Miocamycin [Susceptibility] by Serum bactericidal titer;Miocamycin Titr SBT;;ACTIVE;1.0;2.32 +34180-0;Ethanol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ethanol [Presence] in Urine by Confirmatory method;Ethanol Ur Ql Cfm;;ACTIVE;2.10;2.73 +3418-1;Butabarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Butabarbital [Mass/volume] in Serum or Plasma;Butabarbital SerPl-mCnc;;ACTIVE;1.0;2.73 +34181-8;Methanol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Methanol [Presence] in Urine by Confirmatory method;Methanol Ur Ql Cfm;;ACTIVE;2.10;2.56 +34182-6;Methaqualone metabolite;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Methaqualone metabolite [Presence] in Serum or Plasma by Confirmatory method;Methaqualone Metab SerPl Ql Cfm;;ACTIVE;2.10;2.56 +34183-4;Beta globulin/Protein.total;MFr;24H;Urine;Qn;;CHEM;1;Beta globulin/Protein.total in 24 hour Urine;B-Globulin 24h MFr Ur;;ACTIVE;2.10;2.30 +34184-2;Gamma globulin/Protein.total;MFr;24H;Urine;Qn;;CHEM;1;Gamma globulin/Protein.total in 24 hour Urine;Gamma glob 24h MFr Ur;;ACTIVE;2.10;2.30 +34185-9;methIMAzole;MRat;24H;Urine;Qn;;DRUG/TOX;1;methIMAzole [Mass/time] in 24 hour Urine;methIMAzole 24h Ur-mRate;;ACTIVE;2.10;2.42 +34186-7;Para aminobenzoate;MRat;24H;Urine;Qn;;DRUG/TOX;1;Para aminobenzoate [Mass/time] in 24 hour Urine;pABA 24h Ur-mRate;;ACTIVE;2.10;2.42 +34187-5;DNA double strand Ab;Titr;Pt;Ser;Qn;Crithidia luciliae IF;SERO;1;DNA double strand Ab [Titer] in Serum by Immunofluorescence (IF) Crithidia luciliae;dsDNA Ab Titr Ser CLIF;;ACTIVE;2.10;2.73 +34188-3;Erythrocytes.nucleated;PrThr;Pt;Bld;Ord;;HEM/BC;1;Nucleated erythrocytes [Presence] in Blood;nRBC Bld Ql;;ACTIVE;2.10;2.73 +34189-1;Coagulation surface induced.factor substitution^30M post incubation after addition of normal plasma;Time;Pt;PPP;Qn;;COAG;1;aPTT.factor substitution in Platelet poor plasma --30M post incubation with normal plasma;aPTT 30M NP PPP;;ACTIVE;2.10;2.73 +34190-9;Thermoactinomyces vulgaris Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Thermoactinomyces vulgaris IgG Ab [Mass/volume] in Serum;T vulgaris IgG Ser-mCnc;;ACTIVE;2.10;2.73 +34191-7;Beta glucuronidase;CCnc;Pt;XXX;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/volume] in Specimen;B-Glucuronidase Spec-cCnc;;ACTIVE;2.10;2.70 +34192-5;Beta galactosidase;PrThr;Pt;Amnio fld cells;Ord;;CHEM;1;Beta galactosidase [Presence] in Amniotic fluid cells;B-Galactosidase Amnc Ql;;ACTIVE;2.10;2.70 +34193-3;SMPD1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SMPD1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;SMPD1 gene Mut Tested Bld/T;;ACTIVE;2.10;2.73 +34194-1;Fructose;MCnc;Pt;Body fld;Qn;;CHEM;1;Fructose [Mass/volume] in Body fluid;Fructose Fld-mCnc;;ACTIVE;2.10;2.70 +34195-8;little e Ab;Titr;Pt;Ser;Qn;;BLDBK;1;Deprecated little e Ab [Titer] in Serum or Plasma;Deprecated little e Ab Titr Ser;;DEPRECATED;2.10;2.36 +34196-6;C Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;C Ab [Titer] in Serum or Plasma;C Ab Titr SerPl;;ACTIVE;2.10;2.30 +34197-4;Salicylamide^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylamide [Mass/volume] in Serum or Plasma --trough;Salicylamide Trough SerPl-mCnc;;ACTIVE;2.10;2.40 +34198-2;Salicylamide^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylamide [Mass/volume] in Serum or Plasma --peak;Salicylamide Peak SerPl-mCnc;;ACTIVE;2.10;2.40 +3419-9;Butabarbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Butabarbital [Presence] in Urine;Butabarbital Ur Ql;;ACTIVE;1.0;2.73 +34199-0;Neutrophils.hypersegmented;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Neutrophils.hypersegmented [Presence] in Blood by Automated count;Neuts Hyperseg Bld Ql Auto;;ACTIVE;2.10;2.73 +34200-6;Erythrocytes.nucleated;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Nucleated erythrocytes [Presence] in Blood by Automated count;nRBC Bld Ql Auto;;ACTIVE;2.10;2.73 +34201-4;Cytomegalovirus;PrThr;Pt;Amnio fld;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Amniotic fluid by Organism specific culture;CMV Amn Ql Cult;;ACTIVE;2.10;2.56 +34202-2;Linezolid;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Linezolid [Mass/volume] in Serum or Plasma;Linezolid SerPl-mCnc;;ACTIVE;2.10;2.73 +34203-0;SCA12 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA12 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA12 gene CAG Rpt Bld/T Ql;;ACTIVE;2.10;2.56 +34204-8;11-Deoxycortisol;SCnc;24H;Urine;Qn;;CHEM;1;11-Deoxycortisol [Moles/volume] in 24 hour Urine;11DC 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34205-5;11-Deoxycortisol;SCnc;Pt;Urine;Qn;;CHEM;1;11-Deoxycortisol [Moles/volume] in Urine;11DC Ur-sCnc;;ACTIVE;2.10;2.42 +34206-3;11-Deoxycortisol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;11-Deoxycortisol/Creatinine [Molar ratio] in Urine;11DC/Creat Ur-sRto;;ACTIVE;2.10;2.42 +3420-7;Butalbital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Butalbital [Presence] in Serum or Plasma;Butalbital SerPl Ql;;ACTIVE;1.0;2.73 +34207-1;11-Hydroxyandrosterone;SCnc;24H;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone [Moles/volume] in 24 hour Urine;11OH-Androst 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34208-9;11-Hydroxyandrosterone;SCnc;Pt;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone [Moles/volume] in Urine;11OH-Androst Ur-sCnc;;ACTIVE;2.10;2.42 +34209-7;11-Hydroxyandrosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone/Creatinine [Molar ratio] in Urine;11OH-Androst/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34210-5;11-Hydroxyetiocholanolone;SCnc;24H;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone [Moles/volume] in 24 hour Urine;11OH-Etioch 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34211-3;11-Hydroxyetiocholanolone;SCnc;Pt;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone [Moles/volume] in Urine;11OH-Etioch Ur-sCnc;;ACTIVE;2.10;2.42 +34212-1;11-Hydroxyetiocholanolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone/Creatinine [Molar ratio] in Urine;11OH-Etioch/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34213-9;11-Ketoandrosterone;SCnc;24H;Urine;Qn;;CHEM;1;11-Ketoandrosterone [Moles/volume] in 24 hour Urine;11Ketoandros 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34214-7;11-Ketoandrosterone;SCnc;Pt;Urine;Qn;;CHEM;1;11-Ketoandrosterone [Moles/volume] in Urine;11Ketoandros Ur-sCnc;;ACTIVE;2.10;2.42 +3421-5;Butalbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Butalbital [Presence] in Urine;Butalbital Ur Ql;;ACTIVE;1.0;2.73 +34215-4;11-Ketoandrosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;11-Ketoandrosterone/Creatinine [Molar ratio] in Urine;11Ketoandros/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34216-2;11-Ketoetiocholanolone;SCnc;24H;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone [Moles/volume] in 24 hour Urine;11Ketoetioch 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34217-0;11-Ketoetiocholanolone;SCnc;Pt;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone [Moles/volume] in Urine;11Ketoetioch Ur-sCnc;;ACTIVE;2.10;2.42 +34218-8;17-Hydroxycorticosteroids;SCnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids [Moles/volume] in Urine;17OHCS Ur-sCnc;;ACTIVE;2.10;2.42 +34219-6;17-Hydroxycorticosteroids/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids/Creatinine [Molar ratio] in Urine;17OHCS/Creat Ur-sRto;;ACTIVE;2.10;2.73 +34220-4;17-Hydroxyprogesterone;SCnc;24H;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone [Moles/volume] in 24 hour Urine;17OHP 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34221-2;17-Hydroxyprogesterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone/Creatinine [Molar ratio] in Urine;17OHP/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34222-0;17-Ketosteroids;SCnc;Pt;Urine;Qn;;CHEM;1;17-Ketosteroids [Moles/volume] in Urine;17KS Ur-sCnc;;ACTIVE;2.10;2.42 +3422-3;Caffeine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Caffeine [Mass/volume] in Serum or Plasma;Caffeine SerPl-mCnc;;ACTIVE;1.0;2.73 +34223-8;17-Ketosteroids/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;17-Ketosteroids/Creatinine [Molar ratio] in Urine;17KS/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34224-6;3-Alpha-Androstanediol glucuronide;SCnc;24H;Urine;Qn;;CHEM;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in 24 hour Urine;3A-diol G 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34225-3;3-Alpha-Androstanediol glucuronide;SCnc;Pt;Urine;Qn;;CHEM;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Urine;3A-diol G Ur-sCnc;;ACTIVE;2.10;2.42 +34226-1;3-Alpha-Androstanediol glucuronide/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Alpha-Androstanediol glucuronide/Creatinine [Molar ratio] in Urine;3A-diol G/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34227-9;Acylcarnitine;SRat;24H;Urine;Qn;;CHEM;1;Acylcarnitine [Moles/time] in 24 hour Urine;Acylcarnitine 24h Ur-sRate;;ACTIVE;2.10;2.42 +34228-7;Acylcarnitine;SCnc;24H;Urine;Qn;;CHEM;1;Acylcarnitine [Moles/volume] in 24 hour Urine;Acylcarnitine 24h Ur-sCnc;;ACTIVE;2.10;2.73 +34229-5;Acylcarnitine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Acylcarnitine/Creatinine [Molar ratio] in Urine;Acylcarnitine/Creat Ur-sRto;;ACTIVE;2.10;2.73 +34230-3;Adenosine monophosphate.cyclic;SCnc;24H;Urine;Qn;;CHEM;1;Adenosine monophosphate.cyclic [Moles/volume] in 24 hour Urine;cAMP 24h Ur-sCnc;;ACTIVE;2.10;2.42 +3423-1;Caffeine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Caffeine [Presence] in Urine;Caffeine Ur Ql;;ACTIVE;1.0;2.73 +34231-1;Aldosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Aldosterone/Creatinine [Molar ratio] in Urine;Aldost/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34232-9;Pseudallescheria boydii Ab.IgG;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Pseudallescheria boydii IgG Ab [Presence] in Serum by Immune diffusion (ID);P boydii IgG Ser Ql ID;;ACTIVE;2.10;2.56 +34233-7;Alternaria sp Ab.IgG;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Alternaria sp IgG Ab [Presence] in Serum by Immune diffusion (ID);Alternaria IgG Ql ID;;ACTIVE;2.10;2.56 +34234-5;Ampicillin Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ampicillin IgG Ab [Units/volume] in Serum;Ampicillin IgG Qn;;ACTIVE;2.10;2.69 +34235-2;Amylase/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Amylase/Creatinine [Ratio] in Urine;Amylase/Creat Ur-Rto;;ACTIVE;2.10;2.73 +34236-0;Androstenediol;SCnc;Pt;Urine;Qn;;CHEM;1;Androstenediol [Moles/volume] in Urine;Androstenediol Ur-sCnc;;ACTIVE;2.10;2.42 +34237-8;Androstenediol;SCnc;24H;Urine;Qn;;CHEM;1;Androstenediol [Moles/volume] in 24 hour Urine;Androstenediol 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34238-6;Androstenediol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Androstenediol/Creatinine [Molar ratio] in Urine;Androstenediol/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34239-4;Androstenedione;SCnc;24H;Urine;Qn;;CHEM;1;Androstenedione [Moles/volume] in 24 hour Urine;Androst 24h Ur-sCnc;;ACTIVE;2.10;2.44 +34240-2;Androstenedione/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Androstenedione/Creatinine [Molar ratio] in Urine;Androst/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34241-0;Androsterone;SCnc;24H;Urine;Qn;;CHEM;1;Androsterone [Moles/volume] in 24 hour Urine;Androsterone 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34242-8;Androsterone;SCnc;Pt;Urine;Qn;;CHEM;1;Androsterone [Moles/volume] in Urine;Androsterone Ur-sCnc;;ACTIVE;2.10;2.42 +34243-6;Androsterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Androsterone/Creatinine [Molar ratio] in Urine;Androsterone/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34244-4;Arsenic;SRat;24H;Urine;Qn;;DRUG/TOX;1;Arsenic [Moles/time] in 24 hour Urine;Arsenic 24h Ur-sRate;;ACTIVE;2.10;2.73 +34245-1;Arsenic;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Arsenic [Moles/volume] in 24 hour Urine;Arsenic 24h Ur-sCnc;;ACTIVE;2.10;2.34 +34246-9;Ascorbate;SCnc;24H;Urine;Qn;;CHEM;1;Ascorbate [Moles/volume] in 24 hour Urine;Vit C 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34247-7;Ascorbate;SCnc;Pt;Urine;Qn;;CHEM;1;Ascorbate [Moles/volume] in Urine;Vit C Ur-sCnc;;ACTIVE;2.10;2.42 +34248-5;Ascorbate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Ascorbate/Creatinine [Molar ratio] in Urine;Vit C/Creat Ur-sRto;;ACTIVE;2.10;2.42 +3424-9;Caffeine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Caffeine [Mass/volume] in Urine;Caffeine Ur-mCnc;;ACTIVE;1.0;2.73 +34249-3;Asialoganglioside GM2 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Asialoganglioside GM2 Ab [Units/volume] in Serum;GM2 Asialo Ab Ser-aCnc;;ACTIVE;2.10;2.44 +34250-1;Betula verrucosa recombinant (rBet v) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 4 IgE Ab [Units/volume] in Serum;Silver Birch (rBet v) 4 IgE Qn;;ACTIVE;2.10;2.42 +34251-9;Borrelia garinii Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia garinii IgG Ab [Presence] in Serum by Immunoblot;B garinii IgG Ser Ql IB;;ACTIVE;2.10;2.58 +34252-7;Borrelia garinii Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia garinii IgM Ab [Presence] in Serum by Immunoblot;B garinii IgM Ser Ql IB;;ACTIVE;2.10;2.58 +34253-5;C peptide;SCnc;Pt;Urine;Qn;;CHEM;1;C peptide [Moles/volume] in Urine;C peptide Ur-sCnc;;ACTIVE;2.10;2.42 +34254-3;Cadmium;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Cadmium [Moles/volume] in 24 hour Urine;Cadmium 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34255-0;Cadmium;SRat;Pt;Urine;Qn;;DRUG/TOX;1;Cadmium [Moles/time] in Urine;Cadmium Ur-sRate;;DISCOURAGED;2.10;2.46 +3425-6;Cannabinoids;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Cannabinoids [Presence] in Serum or Plasma;Cannabinoids SerPl Ql;;ACTIVE;1.0;2.73 +34256-8;Cancer Ag 50;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag 50 [Units/volume] in Serum or Plasma;Cancer Ag50 SerPl-aCnc;;ACTIVE;2.10;2.70 +34257-6;Carnitine;SCnc;24H;Urine;Qn;;CHEM;1;Carnitine [Moles/volume] in 24 hour Urine;Carnitine 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34258-4;Carnitine.free (C0);SCnc;24H;Urine;Qn;;CHEM;1;Carnitine free (C0) [Moles/volume] in 24 hour Urine;Carnitine Free 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34259-2;Carnitine.free (C0);SRat;24H;Urine;Qn;;CHEM;1;Carnitine free (C0) [Moles/time] in 24 hour Urine;Carnitine Free 24h Ur-sRate;;ACTIVE;2.10;2.42 +342-6;Moxalactam;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Moxalactam [Susceptibility] by Minimum lethal concentration (MLC);Moxalactam Islt MLC;;ACTIVE;1.0;2.19 +34260-0;Catecholamines;SCnc;24H;Urine;Qn;;CHEM;1;Catecholamines [Moles/volume] in 24 hour Urine;Catechols 24h Ur-sCnc;;ACTIVE;2.10;2.50 +34261-8;Catecholamines;SCnc;Pt;Urine;Qn;;CHEM;1;Catecholamines [Moles/volume] in Urine;Catechols Ur-sCnc;;ACTIVE;2.10;2.73 +34262-6;Catecholamines/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Catecholamines/Creatinine [Molar ratio] in Urine;Catechols/Creat Ur-sRto;;ACTIVE;2.10;2.50 +34263-4;Cefaclor Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cefaclor IgG Ab [Units/volume] in Serum;Cefaclor IgG Qn;;ACTIVE;2.10;2.69 +3426-4;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine;THC Ur Ql;;ACTIVE;1.0;2.73 +34264-2;Chlamydia sp Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia sp IgA Ab [Titer] in Serum by Immunofluorescence;Chlamydia IgA Titr Ser IF;;ACTIVE;2.10;2.30 +34265-9;Chloride/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Chloride/Creatinine [Molar ratio] in Urine;Chloride/Creat Ur-sRto;;ACTIVE;2.10;2.73 +34266-7;Citrate;SCnc;Pt;Urine;Qn;;CHEM;1;Citrate [Moles/volume] in Urine;Citrate Ur-sCnc;;ACTIVE;2.10;2.34 +34267-5;Cladosporium sp Ab.IgG;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Cladosporium sp IgG Ab [Presence] in Serum by Immune diffusion (ID);Cladosporium IgG Ser Ql ID;;ACTIVE;2.10;2.56 +34268-3;Cobalt;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cobalt [Moles/volume] in Urine;Cobalt Ur-sCnc;;ACTIVE;2.10;2.70 +34269-1;Cobalt;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Cobalt [Moles/volume] in 24 hour Urine;Cobalt 24h Ur-sCnc;;ACTIVE;2.10;2.70 +34270-9;Cobalt/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Cobalt/Creatinine [Molar ratio] in Urine;Cobalt/Creat Ur-sRto;;ACTIVE;2.10;2.70 +34271-7;Collagen crosslinked N-telopeptide;MCnc;Pt;Urine;Qn;;CHEM;1;Collagen crosslinked N-telopeptide [Mass/volume] in Urine;Collagen NTx Ur-mCnc;;ACTIVE;2.10;2.73 +3427-2;Cannabinoids;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cannabinoids [Presence] in Urine;Cannabinoids Ur Ql;;ACTIVE;1.0;2.73 +34272-5;Collagen crosslinked N-telopeptide/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Collagen crosslinked N-telopeptide/Creatinine [Ratio] in Urine;Collagen NTx/Creat Ur-Rto;;ACTIVE;2.10;2.73 +34273-3;Copper;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Copper [Moles/volume] in Urine;Copper Ur-sCnc;;ACTIVE;2.10;2.34 +34274-1;Creatine;SCnc;24H;Urine;Qn;;CHEM;1;Creatine [Moles/volume] in 24 hour Urine;Creatine 24h Ur-sCnc;;ACTIVE;2.10;2.73 +34275-8;Creatine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Creatine/Creatinine [Molar ratio] in Urine;Creatine/Creat Ur-sRto;;ACTIVE;2.10;2.73 +34276-6;Cysteate;SCnc;Pt;Urine;Qn;;CHEM;1;Cysteate [Moles/volume] in Urine;Cysteate Ur-sCnc;;ACTIVE;2.10;2.42 +34277-4;Cysteine;SCnc;Pt;Urine;Qn;;CHEM;1;Cysteine [Moles/volume] in Urine;Cysteine Ur-sCnc;;ACTIVE;2.10;2.42 +34278-2;Cystine;SCnc;24H;Urine;Qn;;CHEM;1;Cystine [Moles/volume] in 24 hour Urine;Cystine 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34279-0;Dehydroepiandrosterone;SCnc;Pt;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Moles/volume] in Urine;DHEA Ur-sCnc;;ACTIVE;2.10;2.73 +3428-0;Canrenone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Canrenone [Presence] in Urine;Canrenone Ur Ql;;ACTIVE;1.0;2.56 +34280-8;Dehydroepiandrosterone sulfate;SCnc;Pt;Urine;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Moles/volume] in Urine;DHEA-S Ur-sCnc;;ACTIVE;2.10;2.42 +34281-6;Dehydroepiandrosterone sulfate;SCnc;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Moles/volume] in 24 hour Urine;DHEA-S 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34282-4;Dehydroepiandrosterone sulfate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S)/Creatinine [Molar ratio] in Urine;DHEA-S/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34283-2;Dehydroepiandrosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA)/Creatinine [Molar ratio] in Urine;DHEA/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34284-0;Delta aminolevulinate;SCnc;Pt;Urine;Qn;;CHEM;1;Delta aminolevulinate [Moles/volume] in Urine;D-ALA Ur-sCnc;;ACTIVE;2.10;2.73 +34285-7;Ehrlichia sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Ehrlichia sp Ab [Titer] in Serum by Complement fixation;Ehrlichia Ab Titr Ser CF;;ACTIVE;2.10;2.30 +34286-5;Estradiol;SCnc;Pt;Urine;Qn;;CHEM;1;Estradiol (E2) [Moles/volume] in Urine;Estradiol Ur-sCnc;;ACTIVE;2.10;2.42 +34287-3;Estradiol;SCnc;24H;Urine;Qn;;CHEM;1;Estradiol (E2) [Moles/volume] in 24 hour Urine;Estradiol 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34288-1;Estradiol.unconjugated;SCnc;24H;Urine;Qn;;CHEM;1;Estradiol (E2).unconjugated [Moles/volume] in 24 hour Urine;u Estradiol 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34289-9;Estradiol.unconjugated;SCnc;Pt;Urine;Qn;;CHEM;1;Estradiol (E2).unconjugated [Moles/volume] in Urine;u Estradiol Ur-sCnc;;ACTIVE;2.10;2.42 +34290-7;Estradiol.unconjugated/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Estradiol (E2).unconjugated/Creatinine [Molar ratio] in Urine;u Estradiol/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34291-5;Estradiol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Estradiol (E2)/Creatinine [Molar ratio] in Urine;Estradiol/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34292-3;Estriol;SCnc;24H;Urine;Qn;;CHEM;1;Estriol (E3) [Moles/volume] in 24 hour Urine;Estriol 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34293-1;Estriol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Estriol (E3)/Creatinine [Molar ratio] in Urine;Estriol/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34294-9;Estrogen;SCnc;24H;Urine;Qn;;CHEM;1;Estrogen [Moles/volume] in 24 hour Urine;Estrogen 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34295-6;Estrogen;SCnc;Pt;Urine;Qn;;CHEM;1;Estrogen [Moles/volume] in Urine;Estrogen Ur-sCnc;;ACTIVE;2.10;2.42 +34296-4;Estrogen/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Estrogen/Creatinine [Molar ratio] in Urine;Estrogen/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34297-2;Estrone;SCnc;24H;Urine;Qn;;CHEM;1;Estrone (E1) [Moles/volume] in 24 hour Urine;Estrone 24h Ur-sCnc;;ACTIVE;2.10;2.42 +3429-8;Canrenone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Canrenone [Mass/volume] in Urine;Canrenone Ur-mCnc;;ACTIVE;1.0;2.42 +34298-0;Estrone;SRat;24H;Urine;Qn;;CHEM;1;Estrone (E1) [Moles/time] in 24 hour Urine;Estrone 24h Ur-sRate;;ACTIVE;2.10;2.42 +34299-8;Estrone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Estrone (E1)/Creatinine [Molar ratio] in Urine;Estrone/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34300-4;Ethanolamine;SCnc;Pt;Urine;Qn;;CHEM;1;Ethanolamine [Moles/volume] in Urine;Ethanolamine Ur-sCnc;;ACTIVE;2.10;2.42 +34301-2;Etiocholanolone;SCnc;Pt;Urine;Qn;;CHEM;1;Etiocholanolone [Moles/volume] in Urine;Etiocholanolone Ur-sCnc;;ACTIVE;2.10;2.42 +34302-0;Etiocholanolone;SCnc;24H;Urine;Qn;;CHEM;1;Etiocholanolone [Moles/volume] in 24 hour Urine;Etiocholanolone 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34303-8;Etiocholanolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Etiocholanolone/Creatinine [Molar ratio] in Urine;Etiocholanolone/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34304-6;Fluoride;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fluoride [Moles/volume] in Urine;Fluoride Ur-sCnc;;ACTIVE;2.10;2.42 +34305-3;Flupenthixol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flupenthixol [Mass/volume] in Serum or Plasma;Flupenthixol SerPl-mCnc;;ACTIVE;2.10;2.70 +3430-6;Canrenone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Canrenone [Mass/time] in 24 hour Urine;Canrenone 24h Ur-mRate;;ACTIVE;1.0;2.42 +34306-1;Follitropin;ACnc;24H;Urine;Qn;2nd IRP;CHEM;1;Follitropin [Units/volume] in 24 hour Urine by 2nd IRP;FSH 24h Ur IRP2-aCnc;;ACTIVE;2.10;2.68 +34307-9;Fructose;SCnc;24H;Urine;Qn;;CHEM;1;Fructose [Moles/volume] in 24 hour Urine;Fructose 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34308-7;Fructose;SCnc;Pt;Urine;Qn;;CHEM;1;Fructose [Moles/volume] in Urine;Fructose Ur-sCnc;;ACTIVE;2.10;2.42 +34309-5;Fructose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Fructose/Creatinine [Molar ratio] in Urine;Fructose/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34310-3;Galactose;SCnc;24H;Urine;Qn;;CHEM;1;Galactose [Moles/volume] in 24 hour Urine;Galactose 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34311-1;Galactose;SCnc;Pt;Urine;Qn;;CHEM;1;Galactose [Moles/volume] in Urine;Galactose Ur-sCnc;;ACTIVE;2.10;2.42 +34312-9;Glucose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glucose/Creatinine [Molar ratio] in Urine;Glucose/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34313-7;Heptacarboxylporphyrin;MCnt;Pt;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/mass] in Stool;Hepta-CP Stl-mCnt;;ACTIVE;2.10;2.70 +3431-4;carBAMazepine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;carBAMazepine [Presence] in Serum or Plasma;carBAMazepine SerPl Ql;;ACTIVE;1.0;2.73 +34314-5;Heptacarboxylporphyrin;SCnc;Pt;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin [Moles/volume] in Urine;Hepta-CP Ur-sCnc;;ACTIVE;2.10;2.73 +34315-2;Hexacarboxylporphyrins;MCnt;Pt;Stool;Qn;;CHEM;1;Hexacarboxylporphyrins [Mass/mass] in Stool;Hexa-CPs Stl-mCnt;;ACTIVE;2.10;2.70 +34316-0;Histamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Histamine [Moles/volume] in Serum or Plasma;Histamine SerPl-sCnc;;ACTIVE;2.10;2.73 +34317-8;Histamine;SCnc;24H;Urine;Qn;;CHEM;1;Histamine [Moles/volume] in 24 hour Urine;Histamine 24h Ur-sCnc;;ACTIVE;2.10;2.34 +34318-6;HTLV I+II Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;HTLV I+II Ab [Titer] in Serum by Complement fixation;HTLV I+II Ab Titr Ser CF;;ACTIVE;2.10;2.52 +34319-4;Inhibin B;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin B [Mass/volume] in Serum or Plasma;Inhibin B SerPl-mCnc;;ACTIVE;2.10;2.73 +34320-2;Iodine;SCnc;Pt;Urine;Qn;;CHEM;1;Iodine [Moles/volume] in Urine;Iodine Ur-sCnc;;ACTIVE;2.10;2.42 +34321-0;Iodine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Iodine/Creatinine [Molar ratio] in Urine;Iodine/Creat Ur-sRto;;ACTIVE;2.10;2.42 +3432-2;carBAMazepine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine [Mass/volume] in Serum or Plasma;carBAMazepine SerPl-mCnc;;ACTIVE;1.0;2.73 +34322-8;Iron/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Iron/Creatinine [Molar ratio] in Urine;Iron/Creat Ur-sRto;;ACTIVE;2.10;2.70 +34323-6;Lactate;SCnc;24H;Urine;Qn;;CHEM;1;Lactate [Moles/volume] in 24 hour Urine;Lactate 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34324-4;Lactate;SCnc;Pt;Urine;Qn;;CHEM;1;Lactate [Moles/volume] in Urine;Lactate Ur-sCnc;;ACTIVE;2.10;2.73 +34325-1;Lead;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Lead [Moles/volume] in 24 hour Urine;Lead 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34326-9;Lead/Creatinine;SRat;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Lead/Creatinine [Moles/time] in Urine;Deprecated Lead/Creat Ur-sRate;;DEPRECATED;2.10;2.44 +34327-7;Lead/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Lead/Creatinine [Molar ratio] in Urine;Lead/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34328-5;Levodopa;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Levodopa [Moles/volume] in Serum or Plasma;L-Dopa SerPl-sCnc;;ACTIVE;2.10;2.70 +34329-3;Fat;MCnt;24H;Stool;Qn;;CHEM;1;Fat [Mass/mass] in 24 hour Stool;Fat 24h Stl-mCnt;;ACTIVE;2.10;2.70 +3433-0;carBAMazepine.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine free [Mass/volume] in Serum or Plasma;carBAMazepine free SerPl-mCnc;;ACTIVE;1.0;2.73 +34330-1;Lithium;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Lithium [Moles/volume] in 24 hour Urine;Lithium 24h Ur-sCnc;;ACTIVE;2.10;2.63 +34331-9;Lithium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Lithium/Creatinine [Molar ratio] in Urine;Lithium/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34332-7;Lormetazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lormetazepam [Mass/volume] in Serum or Plasma;Lormetazepam SerPl-mCnc;;ACTIVE;2.10;2.42 +34333-5;Lutropin;ACnc;24H;Urine;Qn;1st IRP;CHEM;1;Lutropin [Units/volume] in 24 hour Urine by 1st IRP;LH 24h Ur IRP1-aCnc;;ACTIVE;2.10;2.44 +34334-3;Lutropin/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Lutropin/Creatinine [Ratio] in Urine;LH/Creat Ur-Rto;;ACTIVE;2.10;2.66 +34335-0;Lysozyme;MCnc;24H;Urine;Qn;;CHEM;1;Lysozyme [Mass/volume] in 24 hour Urine;Lysozyme 24h Ur-mCnc;;ACTIVE;2.10;2.42 +34336-8;Lysozyme/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Lysozyme/Creatinine [Ratio] in Urine;Lysozyme/Creat Ur-Rto;;ACTIVE;2.10;2.21 +34337-6;Mercury;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in 24 hour Urine;Mercury 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34338-4;Mercury;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Urine;Mercury Ur-sCnc;;ACTIVE;2.10;2.42 +34339-2;Metanephrine;SCnc;Pt;Urine;Qn;;CHEM;1;Metanephrine [Moles/volume] in Urine;Metaneph Ur-sCnc;;ACTIVE;2.10;2.73 +343-4;Moxalactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Moxalactam [Susceptibility] by Minimum inhibitory concentration (MIC);Moxalactam Islt MIC;;ACTIVE;1.0;2.19 +34340-0;Methionine sulfoxide;SCnc;Pt;Urine;Qn;;CHEM;1;Methionine sulfoxide [Moles/volume] in Urine;MSO Ur-sCnc;;ACTIVE;2.10;2.42 +34341-8;Mianserin+Normianserin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mianserin+Normianserin [Mass/volume] in Serum or Plasma;Mianserin+Nor SerPl-mCnc;;ACTIVE;2.10;2.42 +34342-6;Niacin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Niacin [Moles/volume] in Serum or Plasma;Niacin SerPl-sCnc;;ACTIVE;2.10;2.70 +34343-4;Nickel;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nickel [Moles/volume] in Urine;Nickel Ur-sCnc;;ACTIVE;2.10;2.34 +34344-2;N-methylhistamine;SCnc;24H;Urine;Qn;;CHEM;1;N-methylhistamine [Moles/volume] in 24 hour Urine;Me-histamine 24h Ur-sCnc;;ACTIVE;2.10;2.44 +34345-9;N-methylhistamine;SCnc;Pt;Urine;Qn;;CHEM;1;N-methylhistamine [Moles/volume] in Urine;Me-histamine Ur-sCnc;;ACTIVE;2.10;2.44 +34346-7;N-methylhistamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N-methylhistamine/Creatinine [Molar ratio] in Urine;Me-histamine/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34347-5;Normetanephrine;SCnc;Pt;Urine;Qn;;CHEM;1;Normetanephrine [Moles/volume] in Urine;Normetanephrine Ur-sCnc;;ACTIVE;2.10;2.42 +3434-8;Carbenicillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbenicillin [Mass/volume] in Serum or Plasma;Carbenicillin SerPl-mCnc;;ACTIVE;1.0;2.42 +34348-3;Normetanephrine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Normetanephrine/Creatinine [Molar ratio] in Urine;Normetanephrine/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34349-1;Oxalate;SCnc;24H;Urine;Qn;;CHEM;1;Oxalate [Moles/volume] in 24 hour Urine;Oxalate 24h Ur-sCnc;;ACTIVE;2.10;2.73 +34350-9;Oxalate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Oxalate/Creatinine [Molar ratio] in Urine;Oxalate/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34351-7;Pentacarboxylporphyrins;MCnt;Pt;Stool;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/mass] in Stool;Penta-CP Stl-mCnt;;ACTIVE;2.10;2.70 +34352-5;Pentacarboxylporphyrins;SCnc;Pt;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins [Moles/volume] in Urine;Penta-CP Ur-sCnc;;ACTIVE;2.10;2.42 +34353-3;Pentacarboxylporphyrins/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins/Creatinine [Molar ratio] in Urine;Penta-CP/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34354-1;Phosphate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phosphate/Creatinine [Molar ratio] in Urine;Phosphate/Creat Ur-sRto;;ACTIVE;2.10;2.42 +3435-5;Carboxy tetrahydrocannabinol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Urine;CarboxyTHC Ur Ql;;ACTIVE;1.0;2.73 +34355-8;Phosphoethanolamine;SCnc;24H;Urine;Qn;;CHEM;1;Phosphoethanolamine [Moles/volume] in 24 hour Urine;PETN 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34356-6;Porphobilinogen;SCnc;24H;Urine;Qn;;CHEM;1;Porphobilinogen [Moles/volume] in 24 hour Urine;PBG 24h Ur-sCnc;;ACTIVE;2.10;2.34 +34357-4;Porphobilinogen/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Porphobilinogen/Creatinine [Molar ratio] in Urine;PBG/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34358-2;Pregnanediol;SCnc;24H;Urine;Qn;;CHEM;1;Pregnanediol [Moles/volume] in 24 hour Urine;Pregnanediol 24h Ur-sCnc;;ACTIVE;2.10;2.42 +34359-0;Pregnanediol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanediol/Creatinine [Molar ratio] in Urine;Pregnanediol/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34360-8;Pregnanetriol;SCnc;24H;Urine;Qn;;CHEM;1;Pregnanetriol [Moles/volume] in 24 hour Urine;Pregntrl 24h Ur-sCnc;;ACTIVE;2.10;2.58 +34361-6;Pregnanetriol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanetriol/Creatinine [Molar ratio] in Urine;Pregntrl/Creat Ur-sRto;;ACTIVE;2.10;2.58 +34362-4;Pregnanetriolone;SCnc;24H;Urine;Qn;;CHEM;1;Pregnanetriolone [Moles/volume] in 24 hour Urine;Pregntrlone 24h Ur-sCnc;;ACTIVE;2.10;2.58 +3436-3;Carboxy tetrahydrocannabinol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Urine;CarboxyTHC Ur-mCnc;;ACTIVE;1.0;2.73 +34363-2;Pregnanetriolone;SCnc;Pt;Urine;Qn;;CHEM;1;Pregnanetriolone [Moles/volume] in Urine;Pregntrlone Ur-sCnc;;ACTIVE;2.10;2.58 +34364-0;Pregnanetriolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanetriolone/Creatinine [Molar ratio] in Urine;Pregntrlone/Creat Ur-sRto;;ACTIVE;2.10;2.58 +34365-7;Primidone+PHENobarbital;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Primidone+PHENobarbital [Moles/volume] in Serum or Plasma;Primidone+Phenobarb SerPl-sCnc;;ACTIVE;2.10;2.70 +34366-5;Protein/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Protein/Creatinine [Ratio] in Urine;Prot/Creat Ur-Rto;;ACTIVE;2.10;2.73 +34367-3;Pyridinoline;SCnc;Pt;Urine;Qn;;CHEM;1;Pyridinoline [Moles/volume] in Urine;PYD Ur-sCnc;;ACTIVE;2.10;2.44 +34368-1;Pyridinoline;SRat;24H;Urine;Qn;;CHEM;1;Pyridinoline [Moles/time] in 24 hour Urine;PYD 24h Ur-sRate;;ACTIVE;2.10;2.73 +34369-9;Salmonella paratyphi C H Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella paratyphi C H Ab [Titer] in Serum by Agglutination;S paraty C H Ab Titr Ser Aggl;;ACTIVE;2.10;2.30 +34370-7;Salmonella paratyphi C O Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella paratyphi C O Ab [Titer] in Serum by Agglutination;S paraty C O Ab Titr Ser Aggl;;ACTIVE;2.10;2.30 +3437-1;Carisoprodol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carisoprodol [Mass/volume] in Serum or Plasma;Carisoprodol SerPl-mCnc;;ACTIVE;1.0;2.73 +34371-5;Salmonella typhi H Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella typhi H Ab [Titer] in Serum by Agglutination;S Typhi H Ab Titr Ser Aggl;;ACTIVE;2.10;2.73 +34372-3;Salmonella typhi O Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella typhi O Ab [Titer] in Serum by Agglutination;S Typhi O Ab Titr Ser Aggl;;ACTIVE;2.10;2.30 +34373-1;Serotonin;SCnc;Pt;Urine;Qn;;CHEM;1;Serotonin [Moles/volume] in Urine;Serotonin Ur-sCnc;;ACTIVE;2.10;2.42 +34374-9;Serotonin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Serotonin/Creatinine [Molar ratio] in Urine;Serotonin/Creat Ur-sRto;;ACTIVE;2.10;2.73 +34375-6;Streptokinase Ab;Titr;Pt;Ser;Qn;;COAG;1;Streptokinase Ab [Titer] in Serum;Streptokinase Ab Titr Ser;;ACTIVE;2.10;2.73 +34376-4;Strongyloides sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Strongyloides sp IgG Ab [Units/volume] in Serum by Immunoassay;Strongyloides IgG Ser IA-aCnc;;ACTIVE;2.10;2.73 +34377-2;Sulthiame;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulthiame [Moles/volume] in Serum or Plasma;Sulthiame SerPl-sCnc;;ACTIVE;2.10;2.70 +34378-0;Teicoplanin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Teicoplanin [Mass/volume] in Serum or Plasma --peak;Teicoplanin Peak SerPl-mCnc;;ACTIVE;2.10;2.42 +34379-8;Teicoplanin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Teicoplanin [Mass/volume] in Serum or Plasma --trough;Teicoplanin Trough SerPl-mCnc;;ACTIVE;2.10;2.42 +34380-6;Testosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Testosterone/Creatinine [Molar ratio] in Urine;Testost/Creat Ur-sRto;;ACTIVE;2.10;2.42 +34381-4;Thioguanine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thioguanine [Mass/volume] in Serum or Plasma;Thioguanine SerPl-mCnc;;ACTIVE;2.10;2.34 +34382-2;Treponema pallidum Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Treponema pallidum Ab [Titer] in Serum by Immunofluorescence;T pallidum Ab Titr Ser IF;;ACTIVE;2.10;2.73 +34383-0;Trypanosoma brucei Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Trypanosoma brucei Ab [Titer] in Serum by Immunofluorescence;T brucei Ab Titr Ser IF;;ACTIVE;2.10;2.30 +34384-8;Tryptophan;SCnc;Pt;Urine;Qn;;CHEM;1;Tryptophan [Moles/volume] in Urine;Tryptophan Ur-sCnc;;ACTIVE;2.10;2.42 +34385-5;Urate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Urate/Creatinine [Molar ratio] in Urine;Urate/Creat Ur-sRto;;ACTIVE;2.10;2.73 +34386-3;Venlafaxine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Venlafaxine [Moles/volume] in Serum or Plasma;Venlafaxine SerPl-sCnc;;ACTIVE;2.10;2.42 +34387-1;Zinc;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zinc [Moles/volume] in Urine;Zinc Ur-sCnc;;ACTIVE;2.10;2.70 +34388-9;Zinc;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Zinc [Moles/volume] in 24 hour Urine;Zinc 24h Ur-sCnc;;ACTIVE;2.10;2.70 +3438-9;Cathine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cathine [Presence] in Urine;Cathine Ur Ql;;ACTIVE;1.0;2.56 +34389-7;Zinc/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Zinc/Creatinine [Molar ratio] in Urine;Zinc/Creat Ur-sRto;;ACTIVE;2.10;2.70 +34390-5;Human OTC drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Human OTC drug label;FDA label Human OTC drug;;ACTIVE;2.10;2.34 +34391-3;Human prescription drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Human prescription drug label;FDA label Human Rx drug;;ACTIVE;2.10;2.34 +34392-1;(Malus sylvestris+Musa spp+Prunus persica+Pyrus communis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 17 (Apple+Banana+Pear+Peach) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix17 IgE Ql;;ACTIVE;2.10;2.73 +34393-9;(Actinidia chinensis+Beef+Pandalus borealis+Sesamum indicum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 28 (Kiwi+Beef+Shrimp+Sesame seed) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix28 IgE Ql;;ACTIVE;2.10;2.56 +34394-7;(Arachis hypogaea+Cow milk+Egg white+Mustard) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 26 (Peanut+Cow milk+Egg white+Mustard) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix26 IgE Ql;;ACTIVE;2.10;2.56 +34395-4;(Corylus avellana+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 27 (Hazelnut+Codfish+Soybean+Wheat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix27 IgE Ql;;ACTIVE;2.10;2.56 +34396-2;11-Ketoetiocholanolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone/Creatinine [Molar ratio] in Urine;11Ketoetioch/Creat Ur-sRto;;ACTIVE;2.10;2.42 +3439-7;Cathine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cathine [Mass/volume] in Urine;Cathine Ur-mCnc;;ACTIVE;1.0;2.73 +34397-0;Amilsulpride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amilsulpride [Mass/volume] in Serum or Plasma;Amilsulpride SerPl-mCnc;;ACTIVE;2.10;2.70 +34398-8;Biotin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Biotin [Moles/volume] in Serum or Plasma;Biotin SerPl-sCnc;;ACTIVE;2.10;2.73 +34399-6;Buccal mucosa Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Buccal mucosa Ab [Titer] in Serum by Immunofluorescence;Buccal mucosa Ab Titr Ser IF;;ACTIVE;2.10;2.30 +34400-2;Colon Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Colon Ab [Titer] in Serum by Immunofluorescence;Colon Ab Titr Ser IF;;ACTIVE;2.10;2.30 +34401-0;Complement C3d;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C3d [Mass/volume] in Serum or Plasma;C3d SerPl-mCnc;;ACTIVE;2.10;2.40 +34402-8;Coproporphyrin/Hemoglobin;MRto;Pt;RBC;Qn;;CHEM;1;Coproporphyrin/Hemoglobin [Mass Ratio] in Red Blood Cells;Copro/Hgb RBC;;ACTIVE;2.10;2.70 +34403-6;Cytomegalovirus Ab avidity;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Cytomegalovirus Ab avidity [Units/volume] in Serum;Deprecated CMV Ab Avidity Ser-aCnc;;DEPRECATED;2.10;2.69 +34404-4;Cytoskeleton Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Cytoskeleton Ab [Titer] in Serum by Immunofluorescence;Cytoskeleton Ab Titr Ser IF;;ACTIVE;2.10;2.30 +3440-5;Cathine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Cathine [Mass/time] in 24 hour Urine;Cathine 24h Ur-mRate;;ACTIVE;1.0;2.42 +34405-1;Escitalopram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Escitalopram [Mass/volume] in Serum or Plasma;Escitalopram SerPl-mCnc;;ACTIVE;2.10;2.73 +34406-9;Exocrine pancreas Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Exocrine pancreas Ab [Titer] in Serum by Immunofluorescence;Exocrine pancreas Ab Titr Ser IF;;ACTIVE;2.10;2.58 +34407-7;Interleukin 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 1 [Mass/volume] in Serum or Plasma;Il1 SerPl-mCnc;;ACTIVE;2.10;2.34 +34408-5;Interleukin 2 receptor.soluble;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 Receptor Soluble [Moles/volume] in Serum or Plasma;Sol Il2 Recep SerPl-sCnc;;DISCOURAGED;2.10;2.44 +34409-3;Keratin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Keratin Ab [Titer] in Serum by Immunofluorescence;Keratin Ab Titr Ser IF;;ACTIVE;2.10;2.30 +34410-1;Saccharopolyspora rectivirgula Ab.IgG;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Saccharopolyspora rectivirgula IgG Ab [Presence] in Serum by Immune diffusion (ID);S rectivirgula IgG Ser Ql ID;;ACTIVE;2.10;2.73 +34411-9;Mitochondria M4 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Mitochondria M4 Ab [Presence] in Serum;Mitochondria M4 Ab Ser Ql;;ACTIVE;2.10;2.56 +34412-7;Mitochondria M9 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Mitochondria M9 Ab [Presence] in Serum;Mitochondria M9 Ab Ser Ql;;ACTIVE;2.10;2.56 +3441-3;Cefamandole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefamandole [Mass/volume] in Serum or Plasma;Cefamandole SerPl-mCnc;;ACTIVE;1.0;2.42 +34413-5;Moclobemide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Moclobemide [Moles/volume] in Serum or Plasma;Moclobemide SerPl-sCnc;;ACTIVE;2.10;2.42 +34414-3;Normianserin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normianserin [Mass/volume] in Serum or Plasma;Normianserin SerPl-mCnc;;ACTIVE;2.10;2.42 +34415-0;Normirtazapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normirtazapine [Mass/volume] in Serum or Plasma;Normirtazapine SerPl-mCnc;;ACTIVE;2.10;2.42 +34416-8;Nucleosome Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Nucleosome Ab [Units/volume] in Serum by Immunoassay;Nucleosome Ab Ser IA-aCnc;;ACTIVE;2.10;2.73 +34417-6;Protoporphyrin.zinc;MCnt;Pt;RBC;Qn;;CHEM;1;Protoporphyrin.zinc [Mass/mass] in Red Blood Cells;ZPP RBC-mCnt;;ACTIVE;2.10;2.70 +34418-4;Protoporphyrin;MCnt;Pt;RBC;Qn;;CHEM;1;Protoporphyrin [Mass/mass] in Red Blood Cells;Protopor RBC-mCnt;;ACTIVE;2.10;2.70 +34419-2;Reticulocytes.mature/Reticulocytes.total;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.mature/Reticulocytes.total in Blood;Mat Retics NFr;;ACTIVE;2.10;2.70 +344-2;Moxalactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Moxalactam [Susceptibility] by Disk diffusion (KB);Moxalactam Islt KB;;ACTIVE;1.0;2.19 +34420-0;Reticulocytes.mid/Reticulocytes.total;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.mid/Reticulocytes.total in Blood;Mid Retics NFr;;ACTIVE;2.10;2.70 +3442-1;ceFAZolin;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated ceFAZolin [Mass/volume] in Serum or Plasma;Deprecated ceFAZolin Ser-mCnc;;DEPRECATED;1.0;2.36 +34421-8;Rubella virus Ab.IgG avidity;Ratio;Pt;Ser;Qn;;MICRO;1;Rubella virus IgG Ab avidity [Ratio] in Serum;RUBV IgG Avidity Ser-Rto;;DISCOURAGED;2.10;2.73 +34422-6;Toxoplasma gondii Ab.IgG avidity;Ratio;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgG Ab avidity [Ratio] in Serum;T gondii IgG Avidity Ser-Rto;;DISCOURAGED;2.10;2.73 +34423-4;Salmonella enteritidis H Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella enteritidis H Ab [Titer] in Serum;S enteritid H Ab Titr Ser;;ACTIVE;2.10;2.30 +34424-2;Salmonella typhimurium H Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella typhimurium H Ab [Titer] in Serum;S Typhimur H Ab Titr Ser;;ACTIVE;2.10;2.30 +34425-9;Betula verrucosa recombinant (rBet v) 1+2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 1 + 2 IgE Ab [Units/volume] in Serum;Silver Birch (rBet v) 1+2 IgE Qn;;ACTIVE;2.10;2.42 +34426-7;cycloSPORINE.monoclonal;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cycloSPORINE.monoclonal [Mass/volume] in Serum or Plasma;cycloSPORINE monocl SerPl-mCnc;;ACTIVE;2.10;2.70 +34427-5;Methadone.R;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methadone.R [Mass/volume] in Serum or Plasma;R-methadone SerPl-mCnc;;ACTIVE;2.10;2.40 +34428-3;Phleum pratense recombinant (rPhl p) 12 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 12 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 12 IgE Qn;;ACTIVE;2.10;2.42 +34429-1;Phleum pratense recombinant (rPhl p) 1+5b Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 1 + 5b IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 1+5b IgE Qn;;ACTIVE;2.10;2.42 +34430-9;Phleum pratense recombinant (rPhl p) 7+12 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 7 + 12 IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 7+12 IgE Qn;;ACTIVE;2.10;2.42 +34431-7;Salmonella enteritidis H Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella enteritidis H Ab [Titer] in Serum by Agglutination;S enteritid H Ab Titr Ser Aggl;;ACTIVE;2.10;2.30 +34432-5;Salmonella typhimurium H Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella typhimurium H Ab [Titer] in Serum by Agglutination;S Typhimur H Ab Titr Ser Aggl;;ACTIVE;2.10;2.30 +34433-3;Bartonella henselae Ab;Titr;Pt;Ser;Qn;Flow cytometry;MICRO;1;Bartonella henselae Ab [Titer] in Serum by Flow cytometry (FC);B henselae Ab Titr Ser FC;;ACTIVE;2.10;2.30 +34434-1;Lutropin/Follitropin;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin/Follitropin [Ratio] in Serum or Plasma;LH/FSH SerPl-Rto;;ACTIVE;2.10;2.73 +34435-8;Protein pattern;Imp;Pt;XXX;Nom;Immunofixation;CHEM;1;Protein Fractions [Interpretation] in Specimen by Immunofixation;Prot Pattern Spec IFE-Imp;;ACTIVE;2.10;2.73 +34436-6;Diethylene glycol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diethylene glycol [Mass/volume] in Serum or Plasma;Diethylene Glycol SerPl-mCnc;;ACTIVE;2.10;2.42 +34437-4;Coxsackievirus B Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B Ab [Titer] in Serum;CV B Ab Titr Ser;;ACTIVE;2.10;2.30 +34438-2;Apolipoprotein E phenotype;Prid;Pt;Bld;Nom;;CHEM;1;Apolipoprotein E phenotype [Identifier] in Blood;Apo E Phenotype Bld;;ACTIVE;2.10;2.71 +3443-9;ceFAZolin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ceFAZolin [Mass/volume] in Serum or Plasma;ceFAZolin SerPl-mCnc;;ACTIVE;1.0;2.42 +34439-0;Natural killer cell function;ACnc;Pt;Bld;Qn;;HEM/BC;1;Natural killer cell function [Units/volume] in Blood;NK Cell Function Bld-aCnc;;ACTIVE;2.10;2.73 +34440-8;Interpretation;Imp;Pt;Urine;Nom;Immunoelectrophoresis;CHEM;1;Immunoelectrophoresis for Urine;Interpretation Ur IEP-Imp;;ACTIVE;2.10;2.73 +34441-6;Spermatozoa;Vel;Pt;Semen;Qn;;FERT;1;Spermatozoa [Velocity] in Semen;Sperm Smn Qn;;ACTIVE;2.10;2.73 +34442-4;Bilirubin.glucuronidated/Bilirubin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.conjugated/Bilirubin.total in Serum or Plasma;Bilirub Conj MFr SerPl;;ACTIVE;2.10;2.73 +34443-2;ZOLMitriptan;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ZOLMitriptan [Mass/volume] in Serum or Plasma;ZOLMitriptan SerPl-mCnc;;ACTIVE;2.10;2.40 +34444-0;Acarboxyprothrombin;MCnc;Pt;Ser/Plas;Qn;;COAG;1;Acarboxyprothrombin [Mass/volume] in Serum or Plasma;Acarboxyprothrombin SerPl-mCnc;;ACTIVE;2.10;2.73 +34445-7;Leukocytes;PrThr;Pt;Body fld;Ord;;HEM/BC;1;Leukocytes [Presence] in Body fluid;WBC Fld Ql;;ACTIVE;2.10;2.73 +34446-5;Erythrocytes;PrThr;Pt;Body fld;Ord;;HEM/BC;1;Erythrocytes [Presence] in Body fluid;RBC Fld Ql;;ACTIVE;2.10;2.73 +3444-7;Cefonicid;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefonicid [Mass/volume] in Serum or Plasma;Cefonocid SerPl-mCnc;;ACTIVE;1.0;2.42 +34447-3;Cache valley virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Cache valley virus RNA [Presence] in Blood by NAA with probe detection;CVV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.63 +34448-1;Cache valley virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Cache valley virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;CVV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.63 +34449-9;Eastern equine encephalitis virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Eastern equine encephalitis virus RNA [Presence] in Blood by NAA with probe detection;EEEV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.63 +34450-7;Eastern equine encephalitis virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Eastern equine encephalitis virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;EEEV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.63 +34451-5;Herpes simplex virus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Blood by NAA with probe detection;HSV DNA Bld Ql NAA+probe;;ACTIVE;2.10;2.63 +34452-3;Jamestown canyon virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Jamestown canyon virus RNA [Presence] in Blood by NAA with probe detection;JCV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.63 +34453-1;Jamestown canyon virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Jamestown canyon virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;JCV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.63 +3445-4;Cefoperazone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefoperazone [Mass/volume] in Serum or Plasma;Cefoperazone SerPl-mCnc;;ACTIVE;1.0;2.40 +34454-9;La Crosse virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;La Crosse virus RNA [Presence] in Blood by NAA with probe detection;LACV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.73 +34455-6;La Crosse virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;La Crosse virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;LACV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.63 +34456-4;Powassan virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Powassan virus RNA [Presence] in Blood by NAA with probe detection;POWV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.63 +34457-2;Powassan virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Powassan virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;POWV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.63 +34458-0;Saint Louis encephalitis virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Saint Louis encephalitis virus RNA [Presence] in Blood by NAA with probe detection;SLEV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.73 +34459-8;Saint Louis encephalitis virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Saint Louis encephalitis virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;SLEV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.63 +34460-6;West Nile virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Blood by NAA with probe detection;WNV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.63 +34461-4;West Nile virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;WNV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.73 +3446-2;Cefotaxime;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefotaxime [Mass/volume] in Serum or Plasma;Cefotaxime SerPl-mCnc;;ACTIVE;1.0;2.42 +34462-2;California serogroup virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;California serogroup RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;CSGV RNA CSF Ql NAA+probe;;ACTIVE;2.10;2.63 +34463-0;California serogroup virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;California serogroup RNA [Presence] in Blood by NAA with probe detection;CSGV RNA Bld Ql NAA+probe;;ACTIVE;2.10;2.63 +34464-8;B Ab;Titr;Pt;Ser/Plas;Qn;Antihuman globulin;BLDBK;1;B Ab [Titer] in Serum or Plasma by Antihuman globulin;B Ab Titr SerPl AHG;;ACTIVE;2.10;2.70 +34465-5;B Ab;Titr;Pt;Ser/Plas;Qn;Immediate spin;BLDBK;1;B Ab [Titer] in Serum or Plasma by Immediate spin;B Ab Titr SerPl Imm Spin;;ACTIVE;2.10;2.70 +34466-3;Carbohydrates;PrThr;Pt;XXX;Ord;;CHEM;1;Carbohydrates [Presence] in Specimen;Carbohydrates Spec Ql;;ACTIVE;2.10;2.69 +34467-1;Cholesterol.in chylomicrons;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.in chylomicrons [Mass/volume] in Serum or Plasma;Cholest in Chylo SerPl-mCnc;;ACTIVE;2.10;2.73 +34468-9;Clostridioides difficile toxin A+B;PrThr;Pt;Stool;Ord;IA;MICRO;1;Clostridioides difficile toxin A+B [Presence] in Stool by Immunoassay;C diff Tox A+B Stl Ql IA;;ACTIVE;2.10;2.73 +34469-7;Leukocytes;PrThr;Pt;Bil fld;Ord;Microscopy.light;HEM/BC;1;Leukocytes [Presence] in Bile fluid by Light microscopy;WBC Bifl Ql Micro;;ACTIVE;2.10;2.73 +3447-0;cefoTEtan;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cefoTEtan [Mass/volume] in Serum or Plasma;cefoTEtan SerPl-mCnc;;ACTIVE;1.0;2.42 +34470-5;Giardia lamblia Ag;PrThr;Pt;Bil fld;Ord;;MICRO;1;Giardia lamblia Ag [Presence] in Bile fluid;G lamblia Ag Bifl Ql;;ACTIVE;2.10;2.73 +34471-3;Calcium bilirubinate crystals;PrThr;Pt;Bil fld;Ord;Microscopy.light;HEM/BC;1;Calcium bilirubinate crystals [Presence] in Bile fluid by Light microscopy;Ca Bilirub Cry Bifl Ql Micro;;ACTIVE;2.10;2.73 +34472-1;Cholesterol crystals;PrThr;Pt;Bil fld;Ord;Microscopy.light;HEM/BC;1;Cholesterol crystals [Presence] in Bile fluid by Light microscopy;Cholest Cry Bifl Ql Micro;;ACTIVE;2.10;2.73 +34473-9;Neutrophils.vacuolated+Segmented;PrThr;Pt;Bld;Ord;;HEM/BC;1;Neutrophils.vacuolated+Segmented [Presence] in Blood;Neut Vac+Seg Bld Ql;;ACTIVE;2.10;2.73 +34474-7;ABO & Rh group;Type;Pt;BldCo;Nom;;BLDBK;1;ABO and Rh group [Type] in Cord blood;ABO + Rh BldCo;;ACTIVE;2.10;2.73 +34475-4;Cells.CD4+CD45RO+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45RO+ cells [#/volume] in Blood;CD4+CD45RO+ Cells # Bld;;ACTIVE;2.10;2.73 +34476-2;Cortisol^1H post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;Cortis 1h p 250 ug ACTH SerPl-mCnc;;ACTIVE;2.10;2.73 +34477-0;Blood group antibodies identified;Prid;Pt;Ser/Plas;Nom;Elution;BLDBK;1;Blood group antibodies identified in Serum or Plasma by Elution;Blood group antibodies SerPl Elution;;ACTIVE;2.10;2.73 +34478-8;Blood group antibodies identified;Prid;Pt;Bld;Nom;Chromo;BLDBK;1;Blood group antibodies identified in Blood by Chromogenic method;Bld gp Ab present Chro;;ACTIVE;2.10;2.52 +34479-6;Blood group antibodies identified;Prid;Pt;Ser/Plas;Nom;Cold absorption;BLDBK;1;Blood group antibodies identified in Serum or Plasma by Cold absorption;Blood group antibodies SerPl Cold Abs;;ACTIVE;2.10;2.52 +34480-4;Blood group antibodies identified;Prid;Pt;Ser/Plas;Nom;Cold incubation;BLDBK;1;Blood group antibodies identified in Serum or Plasma by Cold incubation;Blood group antibodies SerPl Cold;;ACTIVE;2.10;2.73 +34481-2;Blood group antibodies identified;Prid;Pt;Ser/Plas;Nom;Warm incubation;BLDBK;1;Blood group antibodies identified in Serum or Plasma by Warm incubation;Blood group antibodies SerPl Warm;;ACTIVE;2.10;2.73 +34482-0;Blood group antibodies identified;Prid;Pt;Ser/Plas;Nom;Warm absorption;BLDBK;1;Blood group antibodies identified in Serum or Plasma by Warm absorption;Blood group antibodies SerPl Warm Abs;;ACTIVE;2.10;2.52 +34483-8;Medications.report request;Find;Pt;^Patient;Nom;;ATTACH.MEDS;3;Deprecated Medications report request;Deprecated;;DEPRECATED;2.10;2.66 +34484-6;Time administration started;TmStp;Pt;Medication.administered;Qn;;ATTACH.MEDS;3;Administered medication, Time administration started;;;ACTIVE;2.10;2.27 +34485-3;Avian paramyxovirus 1.exotic RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Avian paramyxovirus 1.exotic RNA [Presence] in Specimen by NAA with probe detection;Exotic APMV1 RNA Spec Ql NAA+probe;;ACTIVE;2.10;2.69 +34486-1;Avian paramyxovirus 1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Avian paramyxovirus 1 RNA [Presence] in Specimen by NAA with probe detection;APMV1 RNA Spec Ql NAA+probe;;ACTIVE;2.10;2.69 +34487-9;Influenza virus A RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Specimen by NAA with probe detection;FLUAV RNA Spec Ql NAA+probe;;ACTIVE;2.10;2.73 +3448-8;cefOXitin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cefOXitin [Mass/volume] in Serum or Plasma;cefOXitin SerPl-mCnc;;ACTIVE;1.0;2.42 +34488-7;Avian paramyxovirus 1 subtype;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Avian paramyxovirus 1 subtype [Identifier] in Isolate by NAA with probe detection;APMV1 Subtyp Islt NAA+probe;;ACTIVE;2.10;2.63 +34489-5;TOR1A gene deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;TOR1A gene deletion [Presence] in Blood or Tissue by Molecular genetics method;TOR1A gene Del Bld/T Ql;;ACTIVE;2.10;2.70 +34490-3;MT-TK gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MT-TK gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MT-TK gene Mut Anl Bld/T;;ACTIVE;2.10;2.70 +34491-1;PRF1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PRF1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PRF1 gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34492-9;NOTCH3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NOTCH3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NOTCH3 gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34493-7;PRF1 gene targeted mutation analysis;Find;Pt;Amnio fld;Doc;Molgen;MOLPATH.MUT;1;PRF1 gene targeted mutation analysis in Amniotic fluid by Molecular genetics method;PRF1 gene Mut Anl Amn;;ACTIVE;2.10;2.66 +34494-5;SCA10 gene.ATTCT repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA10 gene ATTCT repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA10 gene ATTCT Rpt Bld/T Ql;;ACTIVE;2.10;2.56 +34495-2;TOR1A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TOR1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TOR1A gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +3449-6;cefTAZidime;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cefTAZidime [Mass/volume] in Serum or Plasma;cefTAZidime SerPl-mCnc;;ACTIVE;1.0;2.42 +34496-0;Chromosome 7 uniparental disomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 7 uniparental disomy [Presence] in Blood or Tissue by Cytogenetics;Chr 7 UpDi Bld/T Ql;;ACTIVE;2.10;2.66 +34497-8;SPINK1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SPINK1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SPINK1 gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34498-6;ACADS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACADS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ACADS gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34499-4;GPC3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GPC3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GPC3 gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34500-9;SHOX gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SHOX gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SHOX gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34501-7;HADHA gene.c.1528G>C;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.MUT;1;HADHA gene c.1528G>C [Identifier] in Blood or Tissue by Molecular genetics method Narrative;HADHA c.1528G>C Bld/T;;ACTIVE;2.10;2.73 +34502-5;VHL gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;VHL gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;VHL gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34503-3;Chromosome 15 uniparental disomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 15 uniparental disomy [Presence] in Blood or Tissue by Cytogenetics;Chr 15 UpDi Bld/T Ql;;ACTIVE;2.10;2.73 +3450-4;Ceftizoxime;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ceftizoxime [Mass/volume] in Serum or Plasma;Ceftizoxime SerPl-mCnc;;ACTIVE;1.0;2.42 +34504-1;GJB6 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GJB6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GJB6 gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34505-8;NPDC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NPDC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NPDC gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34506-6;EGR2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;EGR2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;EGR2 gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34507-4;PRX gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PRX gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PRX gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34508-2;PANK2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PANK2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PANK2 gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34509-0;UGT1A1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;UGT1A1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;UGT1A1 gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34510-8;SDHB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SDHB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SDHB gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34511-6;SDHD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SDHD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SDHD gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +3451-2;cefTRIAXone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cefTRIAXone [Mass/volume] in Serum or Plasma;cefTRIAXone SerPl-mCnc;;ACTIVE;1.0;2.73 +34512-4;NPHS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NPHS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NPHS1 gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34513-2;NPHS1 gene targeted mutation analysis;Find;Pt;Body fld;Doc;Molgen;MOLPATH.MUT;1;NPHS1 gene targeted mutation analysis in Body fluid by Molecular genetics method;NPHS1 gene Mut Anl Fld;;ACTIVE;2.10;2.66 +34514-0;SLC22A18 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC22A18 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC22A18 gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34515-7;GLA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GLA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GLA gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34516-5;SPAST gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SPAST gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SPAST gene Mut Anl Bld/T;;ACTIVE;2.10;2.66 +34517-3;CATCH22 syndrome gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CATCH22 syndrome gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CATCH22 gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34518-1;SMPD1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SMPD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SMPD1 gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +34519-9;HFE gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HFE gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HFE gene Mut Anl Bld/T;;ACTIVE;2.10;2.73 +3452-0;Cefuroxime.parenteral;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefuroxime Parenteral [Mass/volume] in Serum or Plasma;Cefuroxime Parenter SerPl-mCnc;;ACTIVE;1.0;2.42 +34520-7;Carbon dioxide;SCnc;Pt;BldCo;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Cord blood;CO2 BldCo-sCnc;;ACTIVE;2.10;2.73 +34521-5;Carnitine acyltransferase;CCnt;Pt;Tiss;Qn;;CHEM;1;Carnitine acyltransferase [Enzymatic activity/mass] in Tissue;Carnitine AcT Tiss-cCnt;;ACTIVE;2.10;2.42 +34522-3;Phosphorylase kinase;CCnc;Pt;RBC;Qn;;CHEM;1;Phosphorylase kinase [Enzymatic activity/volume] in Red Blood Cells;PhK RBC-cCnc;;ACTIVE;2.10;2.44 +34523-1;Succinate semialdehyde dehydrogenase;CCnt;Pt;WBC;Qn;;CHEM;1;Succinate semialdehyde dehydrogenase [Enzymatic activity/mass] in Leukocytes;SSADH WBC-cCnt;;ACTIVE;2.10;2.70 +34524-9;Neutrophils.band form;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Band form neutrophils [Presence] in Blood by Automated count;Neuts Band Bld Ql Auto;;ACTIVE;2.10;2.73 +34525-6;Erythrocytes.lytic resistant;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Erythrocytes.lytic resistant [Presence] in Blood by Automated count;rstRBC Bld Ql Auto;;ACTIVE;2.10;2.70 +34526-4;Sialooligosaccharides/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Sialooligosaccharides/Creatinine [Ratio] in Urine;Sialooligosacch/Creat Ur-Rto;;ACTIVE;2.10;2.70 +34527-2;Hemogram, Platelets, Differential & Reticulocyte panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Deprecated Hemogram, Platelets, Differential & Reticulocyte panel in Blood;Deprecated CBC,Platelets,Retics+Diff Bld;;DEPRECATED;2.10;2.36 +34528-0;PT panel;-;Pt;PPP;Qn;Coag;PANEL.COAG;1;PT panel - Platelet poor plasma by Coagulation assay;PT Pnl PPP;;ACTIVE;2.10;2.73 +34529-8;PT & aPTT panel;-;Pt;PPP;Qn;Coag;PANEL.COAG;1;PT and aPTT panel - Platelet poor plasma by Coagulation assay;PT + aPTT Pnl PPP;;ACTIVE;2.10;2.73 +34530-6;ABO & Rh group panel;-;Pt;Bld;-;;PANEL.BLDBK;1;ABO and Rh group panel - Blood;ABO + Rh Pnl Bld;;ACTIVE;2.10;2.73 +34531-4;Blood type & Crossmatch panel;-;Pt;Bld;-;;PANEL.BLDBK;1;Blood type and Crossmatch panel - Blood;Type + XM Pnl Bld;;ACTIVE;2.10;2.73 +34532-2;Blood type & Indirect antibody screen panel;-;Pt;Bld;-;;PANEL.BLDBK;1;Blood type and Indirect antibody screen panel - Blood;Type + Ab Scn Pnl Bld;;ACTIVE;2.10;2.73 +34533-0;Odor;Type;Pt;Urine;Nom;;SPEC;1;Odor of Urine;Odor Ur;;ACTIVE;2.10;2.19 +34534-8;12 lead EKG panel;-;Pt;Heart;-;EKG;PANEL.CARDIAC;2;12 lead EKG panel;12 lead EKG Pnl;;ACTIVE;2.10;2.72 +34535-5;Microalbumin/Creatinine ratio panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Microalbumin/Creatinine panel in random Urine;Microalbumin/Creat ratio pnl Ur;;DISCOURAGED;2.10;2.73 +34536-3;Fluid intake & output panel;-;24H;^Patient;-;;PANEL.IO;2;Fluid intake and output panel 24 hour;Fluid IO Pnl 24h;;ACTIVE;2.10;2.38 +34537-1;Fluid intake & output panel;-;8H;^Patient;-;;PANEL.IO;2;Fluid intake and output panel 8 hour;Fluid IO Pnl 8h;;ACTIVE;2.10;2.38 +3453-8;Cephalexin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cephalexin [Mass/volume] in Serum or Plasma;Cephalexin SerPl-mCnc;;ACTIVE;1.0;2.42 +34538-9;Orthostatic blood pressure;PressDiff;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Orthostatic blood pressure;Orthostatic BP;;ACTIVE;2.10;2.73 +34539-7;Protein fractions panel;-;Pt;Urine;Qn;Electrophoresis;PANEL.CHEM;1;Protein electrophoresis panel - Urine;Prot Elph Pnl Ur Elph;;ACTIVE;2.10;2.73 +34540-5;Phenytoin free & total panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Phenytoin free and total panel - Serum or Plasma;Phenytoin Free+Total Pnl SerPl;;ACTIVE;2.10;2.73 +34541-3;ACTH stimulation test using IM corticosteroids;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;ACTH stimulation test using IM corticosteroids in Serum or Plasma;ACTH Stim IM Pnl SerPl;;ACTIVE;2.10;2.73 +34542-1;ACTH stimulation test using IV corticosteroids;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;ACTH stimulation test using IV corticosteroids in Serum or Plasma;ACTH Stim IV Pnl SerPl;;ACTIVE;2.10;2.73 +34543-9;Bilirubin direct & total panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Bilirubin direct and total panel [Mass/volume] - Serum or Plasma;Bilirubin Direct+Tot Pnl SerPl-mCnc;;ACTIVE;2.10;2.73 +34544-7;Complement C3 & C4 panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.HEM/BC;1;Complement C3 and C4 panel [Mass/volume] - Serum or Plasma;Comp C3 + C4 Pnl SerPl-mCnc;;ACTIVE;2.10;2.73 +34545-4;carBAMazepine free & total panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;carBAMazepine free and total panel [Mass/volume] - Serum or Plasma;carBAMazepine free+tot Pnl SerPl-mCnc;;ACTIVE;2.10;2.42 +3454-6;Cephalothin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cephalothin [Mass/volume] in Serum or Plasma;Cephalothin SerPl-mCnc;;ACTIVE;1.0;2.42 +34546-2;Protein & Glucose panel;MCnc;Pt;CSF;Qn;;PANEL.CHEM;1;Protein and Glucose panel [Mass/volume] - Cerebral spinal fluid;Prot + Glucose Pnl CSF-mCnc;;ACTIVE;2.10;2.42 +34547-0;Complement profile panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.HEM/BC;1;Complement profile panel [Mass/volume] - Serum or Plasma;Comp Profile Pnl SerPl-mCnc;;ACTIVE;2.10;2.42 +34548-8;Sodium & Potassium panel;SCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Sodium and Potassium panel [Moles/volume] - Serum or Plasma;Sodium + Potassium Pnl SerPl-sCnc;;ACTIVE;2.10;2.42 +34549-6;Follitropin & Lutropin panel;ACnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Follitropin and Lutropin panel [Units/volume] - Serum or Plasma;FSH + LH Pnl SerPl-aCnc;;ACTIVE;2.10;2.73 +34550-4;Immunoglobulin panel;MCnc;Pt;Ser;Qn;;PANEL.CHEM;1;Immunoglobulin panel [Mass/volume] - Serum;Immunoglobulin Pnl Ser-mCnc;;ACTIVE;2.10;2.73 +34551-2;Catecholamines 3 panel;MCnc;Pt;Plas;Qn;;PANEL.CHEM;1;Catecholamines 3 panel [Mass/volume] - Plasma;Catecholamines 3 Pnl Plas-mCnc;;ACTIVE;2.10;2.73 +34552-0;Cardiac 2D echo panel;-;Pt;Heart;-;;PANEL.CARDIAC;2;Cardiac 2D echo panel;Cardiac 2D echo panel;;ACTIVE;2.10;2.73 +3455-3;Chloramphenicol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloramphenicol [Mass/volume] in Serum or Plasma;Chloramphen SerPl-mCnc;;ACTIVE;1.0;2.73 +34553-8;Orthostatic blood pressure panel;-;Pt;Arterial system;-;;PANEL.BP;2;Orthostatic blood pressure panel;Orthostatic BP Pnl;;ACTIVE;2.10;2.27 +34554-6;Electrolytes 1998 & Venous pH panel;-;Pt;Ser/Plas/BldV;Qn;;PANEL.CHEM;1;Electrolytes 1998 and Venous pH panel - Serum or Plasma + Blood venous;Lytes 1998 + Ven pH Pnl;;ACTIVE;2.10;2.42 +34555-3;Creatinine renal clearance panel;-;24H;Urine+Ser/Plas;Qn;;PANEL.CHEM;1;Creatinine 24H renal clearance panel;Creat 24H Cl Pnl Ur+SerPl;;ACTIVE;2.10;2.73 +34556-1;Cell count panel;-;Pt;Body fld;Qn;;PANEL.HEM/BC;1;Cell count panel - Body fluid;Cell Cnt Pnl Fld;;ACTIVE;2.10;2.73 +34557-9;Cell count & Differential panel;-;Pt;Body fld;Qn;;PANEL.HEM/BC;1;Cell count and Differential panel - Body fluid;Cell Cnt + Diff Pnl Fld;;ACTIVE;2.10;2.73 +34558-7;Cell count panel;-;Pt;Periton fld;Qn;;PANEL.HEM/BC;1;Cell count panel - Peritoneal fluid;Cell Cnt Pnl Prt;;ACTIVE;2.10;2.42 +34559-5;Cell count panel;-;Pt;Synv fld;Qn;;PANEL.HEM/BC;1;Cell count panel - Synovial fluid;Cell Cnt Pnl Snv;;ACTIVE;2.10;2.73 +34560-3;Cell count & Differential panel;-;Pt;Synv fld;Qn;;PANEL.HEM/BC;1;Cell count and Differential panel - Synovial fluid;Cell Cnt + Diff Pnl Snv;;ACTIVE;2.10;2.73 +3456-1;chlordiazePOXIDE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;chlordiazePOXIDE [Presence] in Serum or Plasma;Chlordiazep SerPl Ql;;ACTIVE;1.0;2.73 +34561-1;Cell count panel;-;Pt;Plr fld;Qn;;PANEL.HEM/BC;1;Cell count panel - Pleural fluid;Cell Cnt Pnl Plr;;ACTIVE;2.10;2.42 +34562-9;Cell count & Differential panel;-;Pt;Plr fld;Qn;;PANEL.HEM/BC;1;Cell count and Differential panel - Pleural fluid;Cell Cnt + Diff Pnl Plr;;ACTIVE;2.10;2.73 +34563-7;Cell count panel;-;Pt;CSF;Qn;;PANEL.HEM/BC;1;Cell count panel - Cerebral spinal fluid;Cell Cnt Pnl CSF;;ACTIVE;2.10;2.73 +34564-5;Cell count & Differential panel;-;Pt;CSF;Qn;;PANEL.HEM/BC;1;Cell count and Differential panel - Cerebral spinal fluid;Cell Cnt + Diff Pnl CSF;;ACTIVE;2.10;2.73 +34565-2;Vital signs, weight & height panel;-;Pt;^Patient;-;;PANEL.VITALS;2;Vital signs, weight and height panel;Vital Signs, Weight & Height Pnl;;ACTIVE;2.10;2.38 +34566-0;Vital signs with method details panel;-;Pt;^Patient;-;;PANEL.VITALS;2;Vital signs with method details panel;Vital Signs Pnl;;ACTIVE;2.10;2.40 +34567-8;Cell count & Differential panel;-;Pt;Periton fld;Qn;;PANEL.HEM/BC;1;Cell count and Differential panel - Peritoneal fluid;Cell Cnt + Diff Pnl Prt;;ACTIVE;2.10;2.73 +34568-6;Alkaline phosphatase;PrThr;Pt;Body fld;Ord;;CHEM;1;Alkaline phosphatase [Presence] in Body fluid;ALP Fld Ql;;ACTIVE;2.10;2.73 +34569-4;Coagulation dilute Russell viper venom induced.factor substitution^immediately after 1:2 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:2 addition of normal plasma;dRVVT imm 1:2 NP PPP;;DISCOURAGED;2.10;2.73 +34570-2;Lupus anticoagulant neutralization.high phospholipid.factor substitution^immediately after 1:2 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization high phospholipid.factor substitution [Time] in Platelet poor plasma by Coagulation assay --immediately after 1:2 addition of normal plasma;LA Nt HPL imm 1:2 NP PPP;;DISCOURAGED;2.10;2.70 +34571-0;Coagulation surface induced.lupus sensitive;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive (LA screen);Screen aPTT;;ACTIVE;2.10;2.73 +34572-8;Coagulation surface induced.lupus sensitive;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.lupus sensitive in Control Platelet poor plasma by Coagulation assay;aPTT-LA Cont PPP;;ACTIVE;2.10;2.73 +34573-6;Coagulation surface induced.lupus sensitive.factor substitution^immediately after 1:2 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:2 addition of normal plasma;aPTT-LA imm 1:2 NP PPP;;DISCOURAGED;2.10;2.73 +34574-4;Path report.final diagnosis;Imp;Pt;Specimen;Nom;;TUMRRGT;2;Pathology report final diagnosis;Path report.final Dx Spec;;ACTIVE;2.10;2.73 +34575-1;8-Hydroxyloxapine;PrThr;Pt;Ser/Plas/Bld;Ord;;DRUG/TOX;1;8-Hydroxyloxapine [Presence] in Serum, Plasma or Blood;8OH-Loxapine SerPlBld Ql;;ACTIVE;2.10;2.73 +34576-9;Adenovirus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Adenovirus Ab [Titer] in Cerebral spinal fluid;HAdV Ab Titr CSF;;ACTIVE;2.10;2.70 +34577-7;Apheresis.therapeutic;Imp;Pt;^Patient;Nom;;BLDBK;1;Apheresis.therapeutic [Interpretation];Ther Apheresis Patient-Imp;;ACTIVE;2.10;2.10 +34578-5;Barbiturates;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Meconium by Screen method;Barbiturates Mec Ql Scn;;ACTIVE;2.10;2.73 +3457-9;chlordiazePOXIDE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Serum or Plasma;Chlordiazep SerPl-mCnc;;ACTIVE;1.0;2.73 +34579-3;Basophils;Naric;Pt;Periton fld;Qn;Microscopy.light.HPF;HEM/BC;1;Basophils [#/area] in Peritoneal fluid by Microscopy high power field;Basophils #/area Prt HPF;;ACTIVE;2.10;2.70 +34580-1;Blastomyces dermatitidis Ab;ACnc;Pt;CSF;Ord;;MICRO;1;Deprecated Blastomyces dermatitidis Ab [Presence] in Cerebral spinal fluid;Deprecated B dermat Ab CSF Ql;;DEPRECATED;2.10;2.36 +34581-9;Calcium.ionized;SCnc;Pt;BldA;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Arterial blood;Ca-I BldA-sCnc;;ACTIVE;2.10;2.73 +34582-7;Candida sp Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Candida sp IgA Ab [Presence] in Serum;Candida IgA Ser Ql;;ACTIVE;2.10;2.56 +34583-5;Candida sp Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Candida sp IgG Ab [Presence] in Serum;Candida IgG Ql;;ACTIVE;2.10;2.56 +34584-3;Candida sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Candida sp IgM Ab [Presence] in Serum;Candida IgM Ser Ql;;ACTIVE;2.10;2.73 +34585-0;Inner Ear 68kD Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Inner ear 68kD Ab [Presence] in Serum or Plasma;Inner ear 68kD Ab SerPl Ql;;ACTIVE;2.10;2.73 +34586-8;JC virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;JC virus DNA [Presence] in Tissue by NAA with probe detection;JCPyV DNA Tiss Ql NAA+probe;;ACTIVE;2.10;2.70 +3458-7;chlordiazePOXIDE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;chlordiazePOXIDE [Presence] in Urine;Chlordiazep Ur Ql;;ACTIVE;1.0;2.73 +34587-6;Palmitoyl protein thioesterase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoyl protein thioesterase [Enzymatic activity/volume] in Serum or Plasma;PPT SerPl-cCnc;;ACTIVE;2.10;2.68 +34588-4;Feeding duration;Time;XXX;^Tick;Qn;;MICRO;1;Tick feeding duration;Feeding ?Tm Tick-Time;;ACTIVE;2.10;2.70 +34589-2;von Willebrand factor cleaving protease;PrThr;Pt;PPP;Ord;;COAG;1;von Willebrand factor (vWf) cleaving protease [Presence] in Platelet poor plasma;vWF Cp PPP Ql;;ACTIVE;2.10;2.73 +345-9;Moxalactam;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Moxalactam [Susceptibility] by Serum bactericidal titer;Moxalactam Titr SBT;;ACTIVE;1.0;2.32 +34590-0;von Willebrand factor cleaving protease inhibitor;PrThr;Pt;PPP;Ord;;COAG;1;von Willebrand factor (vWf) cleaving protease inhibitor [Presence] in Platelet poor plasma;vWF Cp Inhib PPP Ql;;ACTIVE;2.10;2.73 +34591-8;HIV 1 Ab;PrThr;Pt;Body fld;Ord;IA;MICRO;1;HIV 1 Ab [Presence] in Body fluid by Immunoassay;HIV1 Ab Fld Ql IA;;ACTIVE;2.11;2.65 +34592-6;HIV 1 Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;HIV 1 Ab [Presence] in Body fluid by Immunoblot;HIV1 Ab Fld Ql IB;;ACTIVE;2.11;2.58 +34593-4;Epstein Barr virus DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;EBV DNA # CSF NAA+probe;;ACTIVE;2.11;2.73 +34594-2;Schistosoma sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Schistosoma sp Ab [Titer] in Serum;Schistosoma Ab Titr Ser;;ACTIVE;2.11;2.30 +3459-5;chlordiazePOXIDE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Urine;Chlordiazep Ur-mCnc;;ACTIVE;1.0;2.73 +34595-9;Collection time;TmStp;Pt;Gast fld;Qn;;SPEC;1;Collection time of Gastric fluid;Collect Tme Gast;;ACTIVE;2.11;2.26 +34596-7;3-O-Methyldopa;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;3-O-Methyldopa [Moles/volume] in Cerebral spinal fluid;3-o-methyldopa CSF-sCnc;;ACTIVE;2.11;2.42 +34597-5;Hepatitis D virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis D virus IgM Ab [Presence] in Serum;HDV IgM Ser Ql;;ACTIVE;2.11;2.73 +34598-3;Sialate;PrThr;Pt;Urine;Ord;;CHEM;1;Sialate [Presence] in Urine;Sialate Ur Ql;;ACTIVE;2.11;2.56 +34599-1;Methotrexate;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Body fluid;MTX Fld-mCnc;;ACTIVE;2.11;2.42 +34600-7;Immunoglobulin heavy chain gene rearrangements;Arb;Pt;CSF;Ord;Molgen;MOLPATH.REARRANGE;1;HC gene rearrangements [Presence] in Cerebral spinal fluid by Molecular genetics method;HC gene Rear CSF Ql;;ACTIVE;2.11;2.73 +34601-5;Drugs identified;Prid;Pt;Body fld;Nom;;DRUG/TOX;1;Drugs identified in Body fluid;Drugs Fld;;ACTIVE;2.11;2.73 +34602-3;E Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;E Ab [Titer] in Serum or Plasma;E Ab Titr SerPl;;ACTIVE;2.11;2.30 +3460-3;Chlormerodrin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chlormerodrin [Presence] in Urine;Chlormerodrin Ur Ql;;ACTIVE;1.0;2.56 +34603-1;I Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;I Ab [Titer] in Serum or Plasma;I Ab Titr SerPl;;ACTIVE;2.11;2.30 +34604-9;M Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;M Ab [Titer] in Serum or Plasma;M Ab Titr SerPl;;ACTIVE;2.11;2.30 +34605-6;Collagen type 2 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Collagen type 2 Ab [Units/volume] in Serum;Collagen2 Ab Ser-aCnc;;ACTIVE;2.11;2.73 +34606-4;Minocycline;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Minocycline [Mass/volume] in Cerebral spinal fluid;Minocycline CSF-mCnc;;ACTIVE;2.11;2.42 +34607-2;Interferon.beta Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Interferon beta Ab [Units/volume] in Serum or Plasma;IFN-B Ab SerPl-aCnc;;ACTIVE;2.11;2.69 +34608-0;Leishmania sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania sp IgG Ab [Titer] in Serum;Leishmania IgG Titr Ser;;ACTIVE;2.11;2.73 +34609-8;Transketolase;CCnt;Pt;Bld;Qn;;CHEM;1;Transketolase [Enzymatic activity/mass] in Blood;Transketolase Bld-cCnt;;ACTIVE;2.11;2.70 +34610-6;N-acetylaspartate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Deprecated N-acetylaspartate/Creatinine [Mass Ratio] in Urine;Deprecated N-Ac-Asp/Creat Ur;;DEPRECATED;2.11;2.70 +3461-1;Chlormerodrin;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Chlormerodrin [Mass/volume] in 24 hour Urine;Chlormerodrin 24h Ur-mCnc;;ACTIVE;1.0;2.42 +34611-4;Prostate specific Ag;MCnc;Pt;Urine;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in Urine;PSA Ur-mCnc;;ACTIVE;2.11;2.42 +34612-2;Iron;MCnc;Pt;Stool;Qn;;CHEM;1;Iron [Mass/volume] in Stool;Iron Stl-mCnc;;ACTIVE;2.11;2.34 +34613-0;Herpes simplex virus 1+2 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Titer] in Serum;HSV1+2 IgG Titr Ser;;ACTIVE;2.11;2.30 +34614-8;Spermatozoa Ab.IgM;ACnc;Pt;Cvm;Qn;;FERT;1;Spermatozoa IgM Ab [Units/volume] in Cervical mucus;Sperm IgM Cerv mucus-aCnc;;ACTIVE;2.11;2.69 +34615-5;Iron.microscopic observation;Prid;Pt;Bld;Nom;Potassium ferrocyanide stain;HEM/BC;1;Iron.microscopic observation [Identifier] in Blood by Potassium ferrocyanide stain;Iron Bld K Ferrocyanide Stn;;ACTIVE;2.11;2.12 +34616-3;Amino acids;Prid;Pt;CSF;Nom;;CHEM;1;Amino acids [Identifier] in Cerebral spinal fluid;Amino acids CSF;;ACTIVE;2.11;2.21 +34617-1;Antibiotic XXX;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Other Antibiotic [Mass/volume] in Specimen;Other Antibiotic Spec-mCnc;;ACTIVE;2.11;2.69 +34618-9;Hemoglobin;PrThr;Pt;XXX;Ord;;HEM/BC;1;Hemoglobin [Presence] in Specimen;Hgb Spec Ql;;ACTIVE;2.11;2.69 +34619-7;Complement C1 esterase inhibitor.functional;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C1 esterase inhibitor.functional [Mass/volume] in Body fluid;C1INH Functional Fld-mCnc;;ACTIVE;2.11;2.44 +34620-5;Camphor;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Camphor [Mass/volume] in Body fluid;Camphor Fld-mCnc;;ACTIVE;2.11;2.42 +34621-3;Liver cytosol Ab;ACnc;Pt;Ser;Qn;;SERO;1;Liver cytosol Ab [Units/volume] in Serum;Liver Cytosol Ab Ser-aCnc;;ACTIVE;2.11;2.73 +34622-1;Cells.CD4+CD25+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD4+CD25+ cells/100 cells in Specimen;CD4+CD25+ Cells NFr Spec;;ACTIVE;2.11;2.73 +34623-9;Colorado tick fever virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Colorado tick fever virus Ab [Titer] in Serum;CTFV Ab Titr Ser;;ACTIVE;2.11;2.30 +34624-7;Cystine.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cystine Free [Moles/volume] in Serum or Plasma;Cystine Free SerPl-sCnc;;ACTIVE;2.11;2.42 +34625-4;Corynebacterium diphtheriae toxin Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae toxin Ab [Units/volume] in Serum;C diphtheriae Tox Ab Ser-aCnc;;ACTIVE;2.11;2.73 +34626-2;2-Methylcitrate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;2-Methylcitrate [Moles/volume] in Amniotic fluid;2Me-citrate Amn-sCnc;;ACTIVE;2.11;2.42 +34627-0;Methylmalonate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Methylmalonate [Moles/volume] in Amniotic fluid;Methylmalonate Amn-sCnc;;ACTIVE;2.11;2.42 +34628-8;Methotrexate;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Cerebral spinal fluid;MTX CSF-sCnc;;ACTIVE;2.11;2.42 +3462-9;Chlormerodrin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlormerodrin [Mass/volume] in Urine;Chlormerodrin Ur-mCnc;;ACTIVE;1.0;2.42 +34629-6;CISplatin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;CISplatin [Mass/volume] in Urine;CISplatin Ur-mCnc;;ACTIVE;2.11;2.34 +34630-4;Substance P;MCnc;Pt;CSF;Qn;;CHEM;1;Substance P [Mass/volume] in Cerebral spinal fluid;Substance P CSF-mCnc;;ACTIVE;2.11;2.42 +34631-2;Cyproheptadine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cyproheptadine [Mass/volume] in Urine;Cyproheptadine Ur-mCnc;;ACTIVE;2.11;2.34 +34632-0;hydrALAZINE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;hydrALAZINE [Mass/volume] in Urine;hydrALAZINE Ur-mCnc;;ACTIVE;2.11;2.42 +34633-8;Hypoglycemics.sulfonyluric;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Hypoglycemics.sulfonyluric [Identifier] in Urine;Sulfonyluric Hypogly Ur;;ACTIVE;2.11;2.19 +34634-6;Cells.CD11+CD18+;NCnc;Pt;WBC;Qn;;CELLMARK;1;CD11+CD18+ cells [#/volume] in Leukocytes;CD11+CD18+ Cells # WBC;;ACTIVE;2.11;2.42 +34635-3;Citalopram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Citalopram [Mass/volume] in Serum or Plasma;Citalopram SerPl-mCnc;;ACTIVE;2.11;2.73 +34636-1;Ciprofloxacin;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Ciprofloxacin [Mass/volume] in Cerebral spinal fluid;Ciprofloxacin CSF-mCnc;;ACTIVE;2.11;2.42 +3463-7;Chloroquine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloroquine [Mass/volume] in Serum or Plasma;Chloroquine SerPl-mCnc;;ACTIVE;1.0;2.42 +34637-9;5-Methyltetrahydrofolate;MCnc;Pt;CSF;Qn;;CHEM;1;5-Methyltetrahydrofolate [Mass/volume] in Cerebral spinal fluid;5Me-tetrahydrofolate CSF-mCnc;;ACTIVE;2.11;2.42 +34638-7;Clarithromycin;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Clarithromycin [Mass/volume] in Cerebral spinal fluid;Clarithro CSF-mCnc;;ACTIVE;2.11;2.42 +34639-5;Epstein Barr virus capsid Ab.IgA;Titr;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus capsid IgA Ab [Titer] in Cerebral spinal fluid;EBV VCA IgA Titr CSF;;ACTIVE;2.11;2.30 +34640-3;Bile acid;MCnc;Pt;Body fld;Qn;;CHEM;1;Bile acid [Mass/volume] in Body fluid;Bile Ac Fld-mCnc;;ACTIVE;2.11;2.70 +34641-1;Protein pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Protein Fractions [Interpretation] in Serum or Plasma;Prot Pattern SerPl-Imp;;ACTIVE;2.11;2.73 +34642-9;Thyroid colloidal Ab;Titr;Pt;Ser;Qn;;SERO;1;Thyroid colloidal Ab [Titer] in Serum;Thyroid Colloidal Ab Titr Ser;;ACTIVE;2.11;2.30 +34643-7;Lopinavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Lopinavir [Susceptibility] by Phenotype method;Lopinavir Islt Phenotyp;;ACTIVE;2.11;2.73 +34644-5;Tenofovir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Tenofovir [Susceptibility] by Phenotype method;Tenofovir Islt Phenotyp;;ACTIVE;2.11;2.73 +3464-5;Chlorothiazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorothiazide [Mass/volume] in Serum or Plasma;Chlorothiazide SerPl-mCnc;;ACTIVE;1.0;2.73 +34645-2;Chlamydophila pneumoniae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection;C pneum DNA Spec Ql NAA+probe;;ACTIVE;2.11;2.73 +34646-0;Sulfatides;PrThr;Pt;Urine;Ord;;CHEM;1;Sulfatides [Presence] in Urine;Sulfatides Ur Ql;;ACTIVE;2.11;2.56 +34647-8;PPT1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PPT1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PPT1 gene Mut Anl Bld/T;;ACTIVE;2.11;2.73 +34648-6;Specimen weight;Mass;XXX;Stool;Qn;;SPEC;1;Weight of unspecified time Stool;Specimen wt ?Tm Stl Qn;;ACTIVE;2.11;2.73 +34649-4;MERRF gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MERRF gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MERRF gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +34650-2;TSC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TSC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TSC gene Mut Anl Bld/T;;ACTIVE;2.11;2.73 +34651-0;CYP21A2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CYP21A2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP21A2 Mut Anl Bld/T;;ACTIVE;2.11;2.73 +3465-2;Chlorpheniramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Chlorpheniramine [Presence] in Serum or Plasma;Chlorphenir SerPl Ql;;ACTIVE;1.0;2.56 +34652-8;Pancreatic islet cell Ab;SCnc;Pt;Ser;Qn;;SERO;1;Pancreatic islet cell Ab [Moles/volume] in Serum;Panc Islet Cell Ab Ser-sCnc;;ACTIVE;2.11;2.34 +34653-6;GJB1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GJB1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GJB1 gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +34654-4;MPZ gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MPZ gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MPZ gene Mut Anl Bld/T;;ACTIVE;2.11;2.73 +34655-1;Herpes simplex virus 1+2 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HSV1+2 DNA # CSF NAA+probe;;ACTIVE;2.11;2.63 +34656-9;KEL gene targeted mutation analysis;Find;Pt;Amnio fld/CVS;Doc;Molgen;MOLPATH.MUT;1;KEL gene targeted mutation analysis in Amniotic fluid or Chorionic villus sample by Molecular genetics method;KEL gene Mut Anl Amn/CVS;;ACTIVE;2.11;2.68 +34657-7;Spermatozoa.immotile;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Immotile [#/volume] in Semen;Sperm Immotile # Smn;;ACTIVE;2.11;2.73 +34658-5;MCOLN1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MCOLN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MCOLN1 gene Mut Anl Bld/T;;ACTIVE;2.11;2.73 +34659-3;ATP7A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ATP7A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ATP7A gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +3466-0;Chlorpheniramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorpheniramine [Mass/volume] in Serum or Plasma;Chlorphenir SerPl-mCnc;;ACTIVE;1.0;2.73 +34660-1;Hemoglobin A2/Hemoglobin.total;MFr;Pt;Bld;Qn;Chromatography.column;HEM/BC;1;Hemoglobin A2/Hemoglobin.total in Blood by Chromatography column;Hgb A2 MFr Bld Column Chrom;;ACTIVE;2.11;2.73 +34661-9;Actin Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Actin IgG Ab [Units/volume] in Serum or Plasma;Actin IgG SerPl-aCnc;;ACTIVE;2.11;2.73 +34662-7;Mephenytoin+Normephenytoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mephenytoin+Normephenytoin [Mass/volume] in Serum or Plasma;Mephenytoin+nor SerPl-mCnc;;ACTIVE;2.11;2.70 +34663-5;Hemoglobin S;PrThr;Pt;Amnio fld;Ord;;HEM/BC;1;Hemoglobin S [Presence] in Amniotic fluid;Hgb S Amn Ql;;ACTIVE;2.11;2.56 +34664-3;Clostridium botulinum toxin A Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Clostridium botulinum toxin A Ab [Presence] in Serum;C bot Tox A Ab Ser Ql;;ACTIVE;2.11;2.70 +34665-0;TORCH panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;TORCH panel - Cerebral spinal fluid;TORCH Pnl CSF;;ACTIVE;2.11;2.42 +34666-8;Carisoprodol+Meprobamate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carisoprodol+Meprobamate [Mass/volume] in Serum or Plasma;Carisoprodol+Meprob SerPl-mCnc;;ACTIVE;2.11;2.73 +34667-6;Heavy metals panel;-;Pt;Hair;-;;PANEL.DRUG/TOX;1;Heavy metals panel - Hair;Heavy Met Pnl Hair;;ACTIVE;2.11;2.42 +34668-4;Prilocaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prilocaine [Mass/volume] in Serum or Plasma;Prilocaine SerPl-mCnc;;ACTIVE;2.11;2.42 +34669-2;Pyrimethamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pyrimethamine [Mass/volume] in Serum or Plasma;Pyrimethamine SerPl-mCnc;;ACTIVE;2.11;2.42 +346-7;Nafcillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Nafcillin [Susceptibility] by Minimum lethal concentration (MLC);Nafcillin Islt MLC;;ACTIVE;1.0;2.19 +34670-0;Choriogonadotropin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin [Mass/volume] in Serum or Plasma;HCG SerPl-mCnc;;ACTIVE;2.11;2.73 +34671-8;8-Dehydrocholesterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;8-Dehydrocholesterol [Mass/volume] in Serum or Plasma;8-DHC SerPl-mCnc;;ACTIVE;2.11;2.44 +34672-6;Immunoelectrophoresis panel;-;24H;Urine;-;;PANEL.CHEM;1;Immunoelectrophoresis panel - 24 hour Urine;IEP Pnl 24h Ur;;ACTIVE;2.11;2.73 +34673-4;Propofol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propofol [Mass/volume] in Serum or Plasma;Propofol SerPl-mCnc;;ACTIVE;2.11;2.42 +34674-2;Tripeptide aminopeptidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tripeptide aminopeptidase [Enzymatic activity/volume] in Serum or Plasma;Tripeptide AP SerPl-cCnc;;ACTIVE;2.11;2.68 +34675-9;Mitochondria DNA targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondria Genes targeted mutation analysis in Blood or Tissue by Molecular genetics method;mtDNA Mut Anl Bld/T;;ACTIVE;2.11;2.66 +34676-7;SMA@ gene mutation analysis;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.MUT;1;Deprecated SMN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Narrative;Deprecated SMA@ gene Mut Anal Bld/T;;DEPRECATED;2.11;2.36 +34677-5;Mitotic spindle apparatus Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Mitotic spindle apparatus Ab [Titer] in Serum or Plasma;Mitotic spindle app Ab Titr SerPl;;ACTIVE;2.11;2.30 +3467-8;Chlorpheniramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chlorpheniramine [Presence] in Urine;Chlorphenir Ur Ql;;ACTIVE;1.0;2.73 +34678-3;MT-RNR1 gene.m.1555A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-RNR1 gene m.1555A>G [Presence] in Blood or Tissue by Molecular genetics method;MT-RNR1 m.1555A>G Bld/T Ql;;ACTIVE;2.11;2.56 +34679-1;PTPN11 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PTPN11 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PTPN11 gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +34680-9;Ceramide trihexoside;PrThr;Pt;Urine;Ord;;CHEM;1;Ceramide trihexoside [Presence] in Urine;Ceramide Trihexoside Ur Ql;;ACTIVE;2.11;2.70 +34681-7;Biopsy;Imp;Pt;Muscle;Nar;;PATH;1;Biopsy [Interpretation] in Muscle Narrative;Biopsy Muscle-Imp;;ACTIVE;2.11;2.73 +34682-5;Coagulation tissue factor induced.factor substitution^immediately after addition of factor V depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor V depleted plasma;PT imm FV DP PPP;;ACTIVE;2.11;2.44 +34683-3;Coagulation surface induced.factor substitution^immediately after addition of factor IX depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor IX depleted plasma;aPTT imm FIX DP PPP;;ACTIVE;2.11;2.52 +34684-1;Coagulation surface induced.factor substitution^immediately after addition of factor XIII depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor XIII depleted plasma;aPTT imm FXIII DP PPP;;ACTIVE;2.11;2.52 +34685-8;Coagulation tissue factor induced.factor substitution^immediately after addition of factor X depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor X depleted plasma;PT imm FX DP PPP;;ACTIVE;2.11;2.44 +3468-6;Chlorphentermine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chlorphentermine [Mass/volume] in Blood;Chlorphentermin Bld-mCnc;;ACTIVE;1.0;2.73 +34686-6;Coagulation tissue factor induced.factor substitution^immediately after addition of factor II depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor II depleted plasma;PT imm FII DP PPP;;ACTIVE;2.11;2.44 +34687-4;Coagulation surface induced.factor substitution^immediately after addition of factor XI depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor XI depleted plasma;aPTT imm FXI DP PPP;;ACTIVE;2.11;2.52 +34688-2;Coagulation surface induced.factor substitution^immediately after addition of factor XII depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor XII depleted plasma;aPTT imm FXII DP PPP;;ACTIVE;2.11;2.52 +34689-0;Sulfatidase;CCnc;Pt;WBC;Qn;;CHEM;1;Sulfatidase [Enzymatic activity/volume] in Leukocytes;Sulfatidase WBC-cCnc;;ACTIVE;2.11;2.15 +34690-8;CV2 Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;CV2 Ab [Presence] in Serum or Plasma;CV2 Ab SerPl Ql;;ACTIVE;2.11;2.73 +34691-6;Erythroamino alcohol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Erythroamino alcohol [Mass/volume] in Serum or Plasma;ErythroaminoAlcohol SerPl-mCnc;;ACTIVE;2.11;2.70 +34692-4;Threoamino alcohol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Threoamino alcohol [Mass/volume] in Serum or Plasma;Threoamino alcohol SerPl-mCnc;;ACTIVE;2.11;2.70 +34693-2;GALOP Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;GALOP Ab [Titer] in Serum or Plasma;GALOP Ab Titr SerPl;;ACTIVE;2.11;2.30 +3469-4;Chlorphentermine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chlorphentermine [Presence] in Urine;Chlorphentermin Ur Ql;;ACTIVE;1.0;2.56 +34694-0;Vascular endothelial growth factor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vascular endothelial growth factor [Mass/volume] in Serum or Plasma;VEGF SerPl-mCnc;;ACTIVE;2.11;2.73 +34695-7;Cholesterol.in VLDL/Triglyceride;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL/Triglyceride [Ratio] in Serum or Plasma;VLDLc/Trigl SerPl-Rto;;ACTIVE;2.11;2.73 +34696-5;Collection method;Type;Pt;Semen;Nom;;SPEC;1;Collection method - Semen;Collection method Smn;;ACTIVE;2.11;2.73 +34697-3;Alpha 1 antitrypsin actual/Normal;RelMCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin actual/normal in Serum or Plasma;A1AT Act/Nor SerPl;;ACTIVE;2.11;2.70 +34698-1;CSTB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CSTB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CSTB gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +34699-9;HIV 2 proviral DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;HIV 2 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection;HIV 2 proviral DNA SerPl Ql NAA+probe;;ACTIVE;2.11;2.73 +34700-5;HIV reverse transcriptase+Protease gene mutations tested for;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV reverse transcriptase+protease gene mutations tested for;HIV RT+PR Mut Tested Islt;;ACTIVE;2.11;2.73 +34701-3;Platelet factor 4 heparin complex induced Ab;PrThr;Pt;Ser;Ord;;SERO;1;Heparin induced platelet Ab [Presence] in Serum;PF4 heparin cmplx Ab Ser Ql;;ACTIVE;2.11;2.73 +3470-2;Chlorphentermine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorphentermine [Mass/volume] in Urine;Chlorphentermin Ur-mCnc;;ACTIVE;1.0;2.42 +34702-1;Mycoplasma sp;PrThr;Pt;XXX;Ord;Hoechst stain;MICRO;1;Mycoplasma sp [Presence] in Specimen by Hoechst stain;Mycoplasma Spec Ql Hoechst Stn;;ACTIVE;2.11;2.69 +34703-9;Hepatitis C virus RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 500 IU/mL;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 500 IU/mL;HCV RNA SerPl NAA DL=500-aCnc;;ACTIVE;2.11;2.70 +34704-7;Hepatitis C virus RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 50 IU/mL;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 50 iU/mL;HCV RNA SerPl NAA DL=50-aCnc;;ACTIVE;2.11;2.73 +34705-4;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;Bld;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood;pCO2 temp adj Bld;;ACTIVE;2.11;2.73 +34706-2;CFTR gene.c.3199del6;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.3199del6 [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.3199del6 Bld/T Ql;;ACTIVE;2.11;2.73 +34707-0;Chlamydophila pneumoniae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Chlamydophila pneumoniae rRNA [Presence] in Specimen by Probe;C pneum rRNA Spec Ql Probe;;ACTIVE;2.11;2.73 +34708-8;Chlamydia sp DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Urine by NAA with probe detection;Chlamydia DNA Ur Ql NAA+probe;;ACTIVE;2.11;2.73 +34709-6;Chlamydia trachomatis Ag;PrThr;Pt;Nph;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Nasopharynx;C trach Ag Nph Ql;;ACTIVE;2.11;2.56 +3471-0;chlorproMAZINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlorproMAZINE [Mass/volume] in Serum or Plasma;chlorproMAZINE SerPl-mCnc;;ACTIVE;1.0;2.73 +34710-4;Chlamydia trachomatis Ag;PrThr;Pt;Anal;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Anal;C trach Ag Anal Ql;;ACTIVE;2.11;2.56 +34711-2;Cholinesterase;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cholinesterase [Presence] in Serum or Plasma;Cholinesterase SerPl Ql;;ACTIVE;2.11;2.56 +34712-0;Clostridioides difficile;PrThr;Pt;Stool;Ord;;MICRO;1;Clostridioides difficile [Presence] in Stool;C diff Stl Ql;;ACTIVE;2.11;2.73 +34713-8;Clostridioides difficile toxin A+B;PrThr;Pt;Stool;Ord;;MICRO;1;Clostridioides difficile toxin A+B [Presence] in Stool;C diff Tox A+B Stl Ql;;ACTIVE;2.11;2.73 +34714-6;Coagulation tissue factor induced.INR;RelTime;Pt;Bld;Qn;Coag;COAG;1;INR in Blood by Coagulation assay;INR Bld;;ACTIVE;2.11;2.73 +34715-3;Cocaine;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Cocaine [Presence] in Hair by Screen method;Cocaine Hair Ql Scn;;ACTIVE;2.11;2.73 +34716-1;Coxiella burnetii phase 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Titer] in Serum by Immunofluorescence;C burnet Ph1 IgG Titr Ser IF;;ACTIVE;2.11;2.73 +34717-9;Coxiella burnetii phase 2 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Titer] in Serum by Immunofluorescence;C burnet Ph2 IgG Titr Ser IF;;ACTIVE;2.11;2.73 +34718-7;CFTR gene targeted mutation analysis;Prid;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;CFTR gene mutations found [Identifier] in Amniotic fluid by Molecular genetics method Nominal;CFTR Mut Anl Amn;;ACTIVE;2.11;2.73 +34719-5;Cytomegalovirus DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Amniotic fluid by NAA with probe detection;CMV DNA Amn Ql NAA+probe;;ACTIVE;2.11;2.73 +34720-3;Cytomegalovirus DNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Units/volume] (viral load) in Specimen by NAA with probe detection;CMV DNA Spec NAA+probe-aCnc;;ACTIVE;2.11;2.73 +34721-1;Dengue virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Dengue virus IgM Ab [Presence] in Cerebral spinal fluid;DENV IgM CSF Ql;;ACTIVE;2.11;2.56 +34722-9;EGR2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;EGR2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;EGR2 gene Mut Anl Bld/T;;ACTIVE;2.11;2.63 +34723-7;Eastern equine encephalitis virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Cerebral spinal fluid;EEEV Ab Titr CSF;;ACTIVE;2.11;2.70 +34724-5;Echovirus 4 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Echovirus 4 Ab [Presence] in Cerebral spinal fluid;ECV4 Ab CSF Ql;;ACTIVE;2.11;2.56 +34725-2;Echovirus 7 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Echovirus 7 Ab [Presence] in Cerebral spinal fluid;ECV7 Ab CSF Ql;;ACTIVE;2.11;2.56 +34726-0;Eosinophils;Naric;Pt;Periton fld;Qn;Microscopy.light.HPF;HEM/BC;1;Eosinophils [#/area] in Peritoneal fluid by Microscopy high power field;Eosinophil #/area Prt HPF;;ACTIVE;2.11;2.40 +34727-8;DMPK gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DMPK gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;DMPK gene Mut Anl Bld/T;;ACTIVE;2.11;2.73 +3472-8;chlorproMAZINE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;chlorproMAZINE [Presence] in Urine;chlorproMAZINE Ur Ql;;ACTIVE;1.0;2.73 +34728-6;Carbon dioxide;SCnc;Pt;Bld;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Blood by calculation;CO2 Bld Calc-sCnc;;ACTIVE;2.11;2.73 +34729-4;CFTR gene.p.Arg117His+5T variant;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene.p.Arg117His+5T variant [Presence] in Blood or Tissue by Molecular genetics method;CFTR p.R117h+5T Var Bld/T Ql;;ACTIVE;2.11;2.73 +34730-2;Chromosome breakage;Imp;Pt;XXX;Nom;;MOLPATH;1;Chromosome breakage [Interpretation] in Specimen;Chrom Break Spec-Imp;;ACTIVE;2.11;2.73 +34731-0;APOE gene allele 1;ID;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APOE gene allele 1 [Identifier] in Blood or Tissue by Molecular genetics method;APOE allele1 Bld/T;;ACTIVE;2.11;2.73 +34732-8;APOE gene allele 2;ID;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APOE gene allele 2 [Identifier] in Blood or Tissue by Molecular genetics method;APOE allele2 Bld/T;;ACTIVE;2.11;2.73 +34733-6;APOE gene allele 3;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated APOE gene allele 3 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Deprecated APOE allele3 Bld/T;;DEPRECATED;2.11;2.50 +34734-4;APOE gene gentoype;Imp;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated APOE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Deprecated APOE Gentyp Bld/T-Imp;;DEPRECATED;2.11;2.36 +34735-1;APOE gene allele 4;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated APOE gene allele 4 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Deprecated APOE allele4 Bld/T;;DEPRECATED;2.11;2.50 +3473-6;chlorproMAZINE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;chlorproMAZINE [Mass/volume] in Urine;chlorproMAZINE Ur-mCnc;;ACTIVE;1.0;2.73 +34736-9;Calcium oxalate index;Ratio;24H;Urine;Qn;;CHEM;1;Calcium oxalate index in 24 hour Urine;CaOx index 24h Ur-Rto;;ACTIVE;2.11;2.73 +34737-7;Nuclear mitotic apparatus Ab;Imp;Pt;Ser/Plas;Nom;;SERO;1;Nuclear mitotic apparatus Ab [Interpretation] in Serum or Plasma;NuMA Ab SerPl-Imp;;ACTIVE;2.11;2.26 +34738-5;K Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;K Ab [Titer] in Serum or Plasma;K Ab Titr SerPl;;ACTIVE;2.11;2.30 +34739-3;NR0B1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NR0B1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NR0B1 gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +34740-1;NEFL gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NEFL gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NEFL gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +34741-9;RHCE gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RHCE gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;RHCE allele Geno Bld/T;;ACTIVE;2.11;2.68 +34742-7;Chromosome breakage;ACnc;Pt;Bld;Qn;Diepoxybutane;MOLPATH;1;Chromosome breakage [Units/volume] in Blood by Diepoxybutane;Chrom Break Bld DEB-aCnc;;ACTIVE;2.11;2.73 +34743-5;Hemoglobin.stable;PrThr;Pt;Bld;Ord;Isopropanol stability;HEM/BC;1;Stable Hemoglobin [Presence] in Blood by Isopropanol stability;Hgb stab Bld Ql IPS;;ACTIVE;2.11;2.70 +3474-4;chlorproPAMIDE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;chlorproPAMIDE [Mass/volume] in Serum or Plasma;chlorproPAMIDE SerPl-mCnc;;ACTIVE;1.0;2.73 +34744-3;Admission evaluation note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Admission evaluation note;Nurse Admit eval note;;ACTIVE;2.11;2.50 +34745-0;Discharge summary note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Discharge summary;Nurse D/C sum;;ACTIVE;2.11;2.73 +34746-8;Note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Note;Nurse Note;;ACTIVE;2.11;2.52 +34747-6;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Preoperative evaluation and management note;Nurse Pre-op note;;ACTIVE;2.11;2.50 +34748-4;Note;Find;Pt;Telephone encounter;Doc;{Role};DOC.ONTOLOGY;2;Telephone encounter Note;Phone Note;;ACTIVE;2.11;2.73 +34749-2;Consultation note;Find;Pt;Outpatient;Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Outpatient Consult note;Anesthesiology OP Consult note;;ACTIVE;2.11;2.58 +347-5;Nafcillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Nafcillin [Susceptibility] by Minimum inhibitory concentration (MIC);Nafcillin Islt MIC;;ACTIVE;1.0;2.19 +34750-0;Note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Note;Anesthesiology Note;;ACTIVE;2.11;2.52 +3475-1;Chlorprothixene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chlorprothixene [Mass/volume] in Blood;Chlorprothixene Bld-mCnc;;ACTIVE;1.0;2.42 +34751-8;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Preoperative evaluation and management note;Anesthesiology Pre-op note;;ACTIVE;2.11;2.52 +34752-6;Note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Note;Cardiology Note;;ACTIVE;2.11;2.52 +34753-4;Note;Find;Pt;Outpatient;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Outpatient Note;Cardiology OP Note;;ACTIVE;2.11;2.50 +34754-2;Note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Note;CCM Note;;ACTIVE;2.11;2.52 +34755-9;Transfer summary note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Transfer summary note;CCM Transfer sum note;;ACTIVE;2.11;2.58 +34756-7;Consultation note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Consult note;Dentistry Consult note;;ACTIVE;2.11;2.58 +34757-5;Evaluation note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Evaluation note;Dentistry Eval note;;ACTIVE;2.11;2.69 +34758-3;Consultation note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Consult note;Dermatology Consult note;;ACTIVE;2.11;2.58 +34759-1;Note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Note;Dermatology Note;;ACTIVE;2.11;2.73 +34760-9;Consultation note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Consult note;Diabetology Consult note;;ACTIVE;2.11;2.58 +34761-7;Consultation note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Consult note;Gastroenterology Consult note;;ACTIVE;2.11;2.58 +34762-5;Note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Note;Gastroenterology Note;;ACTIVE;2.11;2.50 +34763-3;Admission history and physical note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Admission history and physical note;General medicine Admit H&P note;;ACTIVE;2.11;2.58 +34764-1;Consultation note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Consult note;General medicine Consult note;;ACTIVE;2.11;2.58 +34765-8;Note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Note;General medicine Note;;ACTIVE;2.11;2.50 +34766-6;Note;Find;Pt;Outpatient;Doc;General medicine;DOC.ONTOLOGY;2;General medicine Outpatient Note;General medicine OP Note;;ACTIVE;2.11;2.50 +34767-4;Note;Find;Pt;{Setting};Doc;General medicine.medical student;DOC.ONTOLOGY;2;General medicine Medical student Note;Gen med MS Note;;ACTIVE;2.11;2.58 +34768-2;Note;Find;Pt;{Setting};Doc;General medicine.nurse;DOC.ONTOLOGY;2;General medicine Nurse Note;Gen med Nurse Note;;ACTIVE;2.11;2.58 +3476-9;Chlorprothixene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorprothixene [Mass/volume] in Serum or Plasma;Chlorprothixene SerPl-mCnc;;ACTIVE;1.0;2.42 +34769-0;Note;Find;Pt;{Setting};Doc;General medicine.attending;DOC.ONTOLOGY;2;General medicine Attending Note;Gen med Attend Note;;ACTIVE;2.11;2.65 +34770-8;Transfer summary note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Transfer summary note;General medicine Transfer sum note;;ACTIVE;2.11;2.58 +34771-6;Consultation note;Find;Pt;{Setting};Doc;General surgery;DOC.ONTOLOGY;2;Deprecated General surgery Consult note;Deprecated General surgery Consult note;;DEPRECATED;2.11;2.61 +34772-4;Note;Find;Pt;{Setting};Doc;General surgery;DOC.ONTOLOGY;2;Deprecated General surgery Note;Deprecated General surgery Note;;DEPRECATED;2.11;2.50 +34773-2;Note;Find;Pt;{Setting};Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Note;Surg attend Note;;ACTIVE;2.11;2.65 +34774-0;History and physical note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery History and physical note;Surgery H&P note;;ACTIVE;2.11;2.58 +34775-7;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;General surgery;DOC.ONTOLOGY;2;Deprecated General surgery Pre-operative evaluation and management note;Deprecated General surgery Pre-op note;;DEPRECATED;2.11;2.50 +34776-5;Consultation note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Consult note;Geri med Consult note;;ACTIVE;2.11;2.58 +3477-7;Chlorprothixene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorprothixene [Mass/volume] in Urine;Chlorprothixene Ur-mCnc;;ACTIVE;1.0;2.42 +34777-3;Consultation note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Consult note;OBGYN Consult note;;DISCOURAGED;2.11;2.64 +34778-1;Note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Note;OBGYN Note;;DISCOURAGED;2.11;2.64 +34779-9;Consultation note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Consult note;HemOnc Consult note;;ACTIVE;2.11;2.73 +34780-7;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Note;HemOnc Note;;ACTIVE;2.11;2.50 +34781-5;Consultation note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Consult note;Infectious disease Consult note;;ACTIVE;2.11;2.58 +34782-3;Note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Note;Infectious disease Note;;ACTIVE;2.11;2.50 +34783-1;Consultation note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Consult note;Kinesiotherapy Consult note;;ACTIVE;2.11;2.58 +34784-9;Note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Note;Kinesiotherapy Note;;ACTIVE;2.11;2.50 +3478-5;Chlorthalidone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chlorthalidone [Presence] in Urine;Chlorthalidone Ur Ql;;ACTIVE;1.0;2.73 +34785-6;Consultation note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Consult note;Mental health Consult note;;ACTIVE;2.11;2.58 +34786-4;Note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Note;Mental health Note;;ACTIVE;2.11;2.52 +34787-2;Group counseling note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Group counseling note;Mental health Group counseling note;;ACTIVE;2.11;2.50 +34788-0;Consultation note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Consult note;Psychiatric Consult note;;ACTIVE;2.11;2.58 +34789-8;Note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Deprecated Psychiatry Note;Deprecated Psychiatric Note;;DEPRECATED;2.11;2.66 +34790-6;Group counseling note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Group counseling note;Psychiatric Group counseling note;;ACTIVE;2.11;2.50 +34791-4;Consultation note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Consult note;Psych Consult note;;ACTIVE;2.11;2.58 +34792-2;Note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Note;Psych Note;;ACTIVE;2.11;2.73 +3479-3;Chlorthalidone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorthalidone [Mass/volume] in Urine;Chlorthalidone Ur-mCnc;;ACTIVE;1.0;2.73 +34793-0;Group counseling note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Group counseling note;Psych Group counseling note;;ACTIVE;2.11;2.50 +34794-8;Note;Find;Pt;{Setting};Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Note;Interdiscip Note;;ACTIVE;2.11;2.58 +34795-5;Consultation note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Consult note;Nephrology Consult note;;ACTIVE;2.11;2.58 +34796-3;Note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Note;Nephrology Note;;ACTIVE;2.11;2.50 +34797-1;Consultation note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Consult note;Neurology Consult note;;ACTIVE;2.11;2.58 +34798-9;Consultation note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Consult note;Neuro surgery Consult note;;ACTIVE;2.11;2.58 +34799-7;Note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Note;Neuro surgery Note;;ACTIVE;2.11;2.50 +34800-3;Consultation note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Consult note;Nutr+diet Consult note;;ACTIVE;2.11;2.58 +3480-1;Chlorthalidone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Chlorthalidone [Mass/time] in 24 hour Urine;Chlorthalidone 24h Ur-mRate;;ACTIVE;1.0;2.42 +34801-1;Note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Note;Nutr+diet Note;;ACTIVE;2.11;2.58 +34802-9;Note;Find;Pt;{Setting};Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine Note;Occup med Note;;ACTIVE;2.11;2.58 +34803-7;Consultation note;Find;Pt;{Setting};Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine Consult note;Occup med Consult note;;ACTIVE;2.11;2.58 +34804-5;Note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Deprecated Occupational therapy Note;Deprecated OT Note;;DEPRECATED;2.11;2.52 +34805-2;Consultation note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Consult note;Oncology Consult note;;ACTIVE;2.11;2.58 +34806-0;Note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Note;Oncology Note;;ACTIVE;2.11;2.50 +34807-8;Consultation note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Consult note;Ophthalmol Consult note;;ACTIVE;2.11;2.58 +34808-6;Note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Note;Ophthalmol Note;;ACTIVE;2.11;2.50 +34809-4;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Preoperative evaluation and management note;Ophthalmol Pre-op note;;ACTIVE;2.11;2.50 +34810-2;Consultation note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Consult note;Optometry Consult note;;ACTIVE;2.11;2.58 +34811-0;Note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Note;Optometry Note;;ACTIVE;2.11;2.50 +34812-8;Consultation note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Consult note;OMS Consult note;;ACTIVE;2.11;2.58 +34813-6;Note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Note;OMS Note;;ACTIVE;2.11;2.54 +34814-4;Consultation note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Consult note;Orthopaedic surgery Consult note;;ACTIVE;2.11;2.58 +34815-1;Note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Note;Orthopaedic surgery Note;;ACTIVE;2.11;2.50 +34816-9;Consultation note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Consult note;Otolaryngology Consult note;;ACTIVE;2.11;2.58 +34817-7;Note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Note;Otolaryngology Note;;ACTIVE;2.11;2.73 +34818-5;Surgical operation note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Surgical operation note;Otolaryngology Operative note;;ACTIVE;2.11;2.58 +3481-9;Cimetidine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Cimetidine [Presence] in Serum or Plasma;Cimetidine SerPl Ql;;ACTIVE;1.0;2.56 +34819-3;Note;Find;Pt;{Setting};Doc;Pathology;DOC.ONTOLOGY;2;Pathology Note;Pathology Note;;ACTIVE;2.11;2.73 +34820-1;Consultation note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Consult note;Pharmacology Consult note;;ACTIVE;2.11;2.58 +34821-9;Note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Note;Pharmacology Note;;ACTIVE;2.11;2.56 +34822-7;Consultation note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Consult note;PM+R Consult note;;ACTIVE;2.11;2.58 +34823-5;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Note;PM+R Note;;ACTIVE;2.11;2.58 +34824-3;Consultation note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Consult note;PT Consult note;;ACTIVE;2.11;2.58 +34825-0;Evaluation note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Evaluation note;PT Eval note;;ACTIVE;2.11;2.69 +34826-8;Consultation note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Consult note;Plastic surgery Consult note;;ACTIVE;2.11;2.58 +3482-7;Cimetidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cimetidine [Mass/volume] in Serum or Plasma;Cimetidine SerPl-mCnc;;ACTIVE;1.0;2.73 +34827-6;Note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Note;Plastic surgery Note;;ACTIVE;2.11;2.50 +34828-4;Consultation note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Consult note;Podiatry Consult note;;ACTIVE;2.11;2.58 +34829-2;Note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Note;Podiatry Note;;ACTIVE;2.11;2.50 +348-3;Nafcillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Nafcillin [Susceptibility] by Disk diffusion (KB);Nafcillin Islt KB;;ACTIVE;1.0;2.19 +34830-0;Note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Note;Pulmonary disease Note;;ACTIVE;2.11;2.50 +34831-8;Consultation note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Consult note;Radiation Onc Consult note;;ACTIVE;2.11;2.58 +34832-6;Note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Note;Radiation Onc Note;;ACTIVE;2.11;2.58 +34833-4;Consultation note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Consult note;Rec therapy Consult note;;ACTIVE;2.11;2.58 +34834-2;Note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Note;Rec therapy Note;;ACTIVE;2.11;2.50 +3483-5;Cimetidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cimetidine [Presence] in Urine;Cimetidine Ur Ql;;ACTIVE;1.0;2.73 +34835-9;Consultation note;Find;Pt;{Setting};Doc;Rehabilitation;DOC.ONTOLOGY;2;Deprecated Rehabilitation Consult note;Deprecated Rehabilitation Consult note;;DEPRECATED;2.11;2.61 +34836-7;Note;Find;Pt;{Setting};Doc;Rehabilitation;DOC.ONTOLOGY;2;Deprecated Rehabilitation Note;Deprecated Rehabilitation Note;;DEPRECATED;2.11;2.50 +34837-5;Consultation note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Consult note;Resp therapy Consult note;;ACTIVE;2.11;2.58 +34838-3;Note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Note;Resp therapy Note;;ACTIVE;2.11;2.50 +34839-1;Consultation note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Consult note;Rheumatology Consult note;;ACTIVE;2.11;2.58 +34840-9;Note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Note;Rheumatology Note;;ACTIVE;2.11;2.50 +34841-7;Consultation note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Consult note;SW Consult note;;ACTIVE;2.11;2.65 +34842-5;Evaluation note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Evaluation note;SW Eval note;;ACTIVE;2.11;2.69 +3484-3;Ciprofloxacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ciprofloxacin [Mass/volume] in Serum or Plasma;Ciprofloxacin SerPl-mCnc;;ACTIVE;1.0;2.73 +34843-3;Group counseling note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Group counseling note;SW Group counseling note;;ACTIVE;2.11;2.65 +34844-1;Note;Find;Pt;Telephone encounter;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Telephone encounter Note;SW Phone Note;;ACTIVE;2.11;2.65 +34845-8;Consultation note;Find;Pt;{Setting};Doc;Speech-language pathology+Audiology;DOC.ONTOLOGY;2;Speech-language pathology+Audiology Consult note;Speech-lang path+Audiology Consult note;;ACTIVE;2.11;2.58 +34846-6;Note;Find;Pt;{Setting};Doc;Speech-language pathology+Audiology;DOC.ONTOLOGY;2;Speech-language pathology+Audiology Note;Speech-lang path+Audiology Note;;ACTIVE;2.11;2.50 +34847-4;Consultation note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Consult note;Surgery Consult note;;ACTIVE;2.11;2.58 +34848-2;Note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Note;Surgery Note;;ACTIVE;2.11;2.50 +34849-0;Consultation note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Consult note;Cardiothor surg Consult note;;ACTIVE;2.11;2.58 +3485-0;CISplatin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;CISplatin [Mass/volume] in Serum or Plasma;CISplatin SerPl-mCnc;;ACTIVE;1.0;2.34 +34850-8;Note;Find;Pt;Outpatient;Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Outpatient Note;Cardiothor surg OP Note;;ACTIVE;2.11;2.56 +34851-6;Consultation note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Consult note;Urology Consult note;;ACTIVE;2.11;2.58 +34852-4;Note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Note;Urology Note;;ACTIVE;2.11;2.73 +34853-2;Consultation note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Consult note;Vascular surgery Consult note;;ACTIVE;2.11;2.58 +34854-0;Note;Find;Pt;Outpatient;Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Outpatient Note;Vascular surgery OP Note;;ACTIVE;2.11;2.50 +34855-7;Consultation note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Consult note;OT Consult note;;ACTIVE;2.11;2.58 +34856-5;Evaluation and management of anticoagulation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation and management of anticoagulation note;E/M coag note;;ACTIVE;2.11;2.54 +34857-3;Note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Note;Addiction med Note;;ACTIVE;2.11;2.63 +34858-1;Note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Note;Pain medicine Note;;ACTIVE;2.11;2.52 +34859-9;Evaluation and management of hyperlipidemia note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation and management of hyperlipidemia note;E/M hyperlipidemia note;;ACTIVE;2.11;2.58 +34860-7;Evaluation and management of hypertension note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation and management of hypertension note;E/M hyperten note;;ACTIVE;2.11;2.58 +34861-5;Note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Note;Diabetology Note;;ACTIVE;2.11;2.50 +34862-3;Admission evaluation note;Find;Pt;Hospital;Doc;General medicine.attending;DOC.ONTOLOGY;2;General medicine Attending Hospital Admission evaluation note;Gen med Attend Hosp Admit eval note;;ACTIVE;2.11;2.65 +34863-1;Post-operative evaluation and management note;Find;Pt;{Setting};Doc;General surgery;DOC.ONTOLOGY;2;Deprecated General surgery Post-operative evaluation and management note;Deprecated General surgery Post-op E/M n;;DEPRECATED;2.11;2.50 +34864-9;Counseling note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Counseling note;Mental health Counseling note;;ACTIVE;2.11;2.50 +34865-6;Counseling note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Counseling note;Psychiatric Counseling note;;ACTIVE;2.11;2.50 +34866-4;Counseling note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Counseling note;Psych Counseling note;;ACTIVE;2.11;2.50 +34867-2;Postoperative evaluation and management note;Find;Pt;Outpatient;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Outpatient Postoperative evaluation and management note;Ophthalmol OP Post-op E/M note;;ACTIVE;2.11;2.50 +3486-8;Clindamycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clindamycin [Mass/volume] in Serum or Plasma;Clindamycin SerPl-mCnc;;ACTIVE;1.0;2.73 +34868-0;Surgical operation note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Surgical operation note;Orthopaedic surgery Operative note;;ACTIVE;2.11;2.58 +34869-8;Counseling note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Counseling note;Pharmacology Counseling note;;ACTIVE;2.11;2.56 +34870-6;Surgical operation note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Surgical operation note;Plastic surgery Operative note;;ACTIVE;2.11;2.58 +34871-4;Surgical operation note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Deprecated Podiatry operative note;DeprecatedSurgical operation note;;DEPRECATED;2.11;2.58 +34872-2;Counseling note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Counseling note;SW Counseling note;;ACTIVE;2.11;2.65 +34873-0;Admission evaluation note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Admission evaluation note;Surgery Admit eval note;;ACTIVE;2.11;2.50 +34874-8;Surgical operation note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Surgical operation note;Surgery Operative note;;ACTIVE;2.11;2.58 +34875-5;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Postoperative evaluation and management note;Surgery Post-op E/M note;;ACTIVE;2.11;2.50 +3487-6;cloBAZam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloBAZam [Mass/volume] in Serum or Plasma;cloBAZam SerPl-mCnc;;ACTIVE;1.0;2.73 +34876-3;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Preoperative evaluation and management note;Surgery Pre-op note;;ACTIVE;2.11;2.50 +34877-1;Surgical operation note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Surgical operation note;Urology Operative note;;ACTIVE;2.11;2.58 +34878-9;Note;Find;Pt;{Setting};Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Note;Emergency med Note;;ACTIVE;2.11;2.50 +34879-7;Consultation note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Consult note;Endocrinology Consult note;;ACTIVE;2.11;2.58 +34880-5;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Postoperative evaluation and management note;Surgery Nurse Post-op E/M note;;ACTIVE;2.11;2.58 +34881-3;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Preoperative evaluation and management note;Surgery Nurse Pre-op note;;ACTIVE;2.11;2.58 +34882-1;Ethanol;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Saliva (oral fluid);Ethanol Sal-mCnc;;ACTIVE;2.11;2.73 +34883-9;Mycoplasma sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Mycoplasma sp Ag [Presence] in Tissue by Immune stain;Mycoplasma Ag Tiss Ql ImStn;;ACTIVE;2.11;2.56 +3488-4;Clobenzorex;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Clobenzorex [Presence] in Urine;Clobenzorex Ur Ql;;ACTIVE;1.0;2.56 +34884-7;Haemophilus paragallinarum Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Haemophilus paragallinarum Ab [Units/volume] in Serum by Immunoassay;H paragallinar Ab Ser IA-aCnc;;ACTIVE;2.11;2.69 +34885-4;African horse sickness virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;African horse sickness virus Ab [Presence] in Serum by Immunofluorescence;AHSV Ab Ser Ql IF;;ACTIVE;2.11;2.56 +34886-2;Rabbit hemorrhagic disease virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Rabbit hemorrhagic disease virus neutralizing antibody [Titer] in Serum by Neutralization test;RHDV NAb Titr Ser Nt;;ACTIVE;2.11;2.72 +34887-0;Peste des petits ruminants virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Peste des petits ruminants virus Ag [Presence] in Tissue by Immunofluorescence;PPRV Ag Tiss Ql IF;;ACTIVE;2.11;2.56 +34888-8;Aino virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Aino virus neutralizing antibody [Titer] in Serum by Neutralization test;AINOV NAb Titr Ser Nt;;ACTIVE;2.11;2.72 +34889-6;Akabane virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Akabane virus neutralizing antibody [Titer] in Serum by Neutralization test;AKAV NAb Titr Ser Nt;;ACTIVE;2.11;2.72 +34890-4;Coliform bacteria;NCnc;Pt;XXX;Qn;Viability count;MICRO;1;Coliform bacteria [#/volume] in Specimen by Viability count;Coliform # Spec Viab Cnt;;ACTIVE;2.11;2.69 +34891-2;Salmonella enteritidis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Salmonella enteritidis [Presence] in Specimen by Organism specific culture;S Enteritid Spec Ql Cult;;ACTIVE;2.11;2.69 +3489-2;Clobenzorex;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Clobenzorex [Mass/volume] in Urine;Clobenzorex Ur-mCnc;;ACTIVE;1.0;2.42 +34892-0;West Nile virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Specimen by NAA with probe detection;WNV RNA Spec Ql NAA+probe;;ACTIVE;2.11;2.73 +34893-8;Aino virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Aino virus Ab [Titer] in Serum;AINOV Ab Titr Ser;;ACTIVE;2.11;2.30 +34894-6;Akabane virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Akabane virus Ab [Titer] in Serum;AKAV Ab Titr Ser;;ACTIVE;2.11;2.30 +34895-3;Education note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Education note;Educ note;;ACTIVE;2.11;2.73 +34896-1;Interventional procedure note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Interventional procedure note;Cardiology Interv proced note;;ACTIVE;2.11;2.58 +34897-9;Education note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Education note;Diabetology Educ note;;ACTIVE;2.11;2.50 +34898-7;Note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Note;Endocrinology Note;;ACTIVE;2.11;2.50 +34899-5;Interventional procedure note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Interventional procedure note;Gastroenterology Interv proced note;;ACTIVE;2.11;2.58 +34-9;Ampicillin+Sulbactam;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility] by Serum bactericidal titer;Ampicillin+Sulbac Titr SBT;;ACTIVE;1.0;2.32 +3490-0;Clofibrate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clofibrate [Mass/volume] in Serum or Plasma;Clofibrate SerPl-mCnc;;ACTIVE;1.0;2.42 +34900-1;Progress note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Progress note;General medicine Prog note;;ACTIVE;2.11;2.73 +34901-9;Progress note;Find;Pt;Outpatient;Doc;General medicine;DOC.ONTOLOGY;2;General medicine Outpatient Progress note;General medicine OP Prog note;;ACTIVE;2.11;2.73 +34902-7;Education note;Find;Pt;Outpatient;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Outpatient Education note;Geri med OP Educ note;;ACTIVE;2.11;2.50 +34903-5;Note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Deprecated Mental health Note;Deprecated Mental health Note;;DEPRECATED;2.11;2.50 +34904-3;Progress note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Progress note;Mental health Prog note;;ACTIVE;2.11;2.73 +34905-0;Note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Note;Neurology Note;;ACTIVE;2.11;2.50 +34906-8;Note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Note;Pastoral Care Note;;ACTIVE;2.11;2.50 +34907-6;Calcium^^corrected for total protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Mass/volume] corrected for total protein in Serum or Plasma;Calcium TP cor SerPl-mCnc;;ACTIVE;2.11;2.70 +34908-4;Neopterin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Neopterin [Mass/volume] in Serum or Plasma;Neopterin SerPl-mCnc;;ACTIVE;2.11;2.73 +34909-2;Cortisol.free;MCnc;24H;Urine;Qn;HPLC;CHEM;1;Cortisol Free [Mass/volume] in 24 hour Urine by HPLC;Cortis F 24h Ur HPLC-mCnc;;ACTIVE;2.11;2.73 +349-1;Nafcillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Nafcillin [Susceptibility] by Serum bactericidal titer;Nafcillin Titr SBT;;ACTIVE;1.0;2.32 +34910-0;Basophils.immature;NCnc;Pt;Bld;Qn;;HEM/BC;1;Immature basophils [#/volume] in Blood;Imm Basophils # Bld;;ACTIVE;2.11;2.73 +34911-8;Basophils.immature/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Immature basophils/100 leukocytes in Blood;Imm Basophils/leuk NFr Bld;;ACTIVE;2.11;2.54 +34912-6;Eosinophils.immature;NCnc;Pt;Bld;Qn;;HEM/BC;1;Immature eosinophils [#/volume] in Blood;Imm Eosinophil # Bld;;ACTIVE;2.11;2.73 +34913-4;Eosinophils.immature/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Immature eosinophils/100 leukocytes in Blood;Imm Eosinophil/leuk NFr Bld;;ACTIVE;2.11;2.54 +34914-2;Malignant cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Malignant cells [#/volume] in Blood;Malignant cells # Bld;;ACTIVE;2.11;2.40 +34915-9;Malignant cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Malignant cells/100 leukocytes in Blood;Malignant cells/leuk NFr Bld;;ACTIVE;2.11;2.50 +34916-7;Plasma cell precursor;NCnc;Pt;Bld;Qn;;HEM/BC;1;Plasma cell precursor [#/volume] in Blood;Plasma cell prec # Bld;;ACTIVE;2.11;2.30 +34917-5;Plasma cell precursor/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Plasma cell precursor/100 leukocytes in Blood;Plasma cell prec/leuk NFr Bld;;ACTIVE;2.11;2.50 +3491-8;clomiPRAMINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clomiPRAMINE [Mass/volume] in Serum or Plasma;clomiPRAMINE SerPl-mCnc;;ACTIVE;1.0;2.73 +34918-3;Sezary cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Sezary cells [#/volume] in Blood;Sezary Cells # Bld;;ACTIVE;2.11;2.40 +34919-1;Sezary cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Sezary cells/100 leukocytes in Blood;Sezary Cells/leuk NFr Bld;;ACTIVE;2.11;2.70 +34920-9;Lymphocytes.immunoblastic/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes Immunoblastic/100 leukocytes in Blood;Ib Lymphs/leuk NFr Bld;;ACTIVE;2.11;2.70 +34921-7;Lymphocytes.plasmacytoid/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes Plasmacytoid/100 leukocytes in Blood;Plasmacoid Lymphs/leuk NFr Bld;;ACTIVE;2.11;2.70 +34922-5;Lymphoblasts/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Lymphoblasts/100 leukocytes in Blood;Lymphoblasts/leuk NFr Bld;;ACTIVE;2.11;2.70 +34923-3;Monoblasts/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Monoblasts/100 leukocytes in Blood;Monoblasts/leuk NFr Bld;;ACTIVE;2.11;2.73 +34924-1;Monocytes.immature;NCnc;Pt;Bld;Qn;;HEM/BC;1;Immature monocytes [#/volume] in Blood;Imm Moncytes # Bld;;ACTIVE;2.11;2.46 +34925-8;Monocytes.immature/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Immature monocytes/100 leukocytes in Blood;Imm Moncytes/leuk NFr Bld;;ACTIVE;2.11;2.70 +3492-6;clomiPRAMINE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;clomiPRAMINE [Mass/volume] in Urine;clomiPRAMINE Ur-mCnc;;ACTIVE;1.0;2.73 +34926-6;Promonocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Promonocytes [#/volume] in Blood;Promonycytes # Bld;;ACTIVE;2.11;2.73 +34927-4;Urobilinogen;SCnc;Pt;Urine;Qn;;CHEM;1;Urobilinogen [Moles/volume] in Urine;Urobilinogen Ur-sCnc;;ACTIVE;2.11;2.73 +34928-2;Urobilinogen;SCnc;Pt;Urine;Qn;Test strip;UA;1;Urobilinogen [Moles/volume] in Urine by Test strip;Urobilinogen Ur Strip-sCnc;;ACTIVE;2.11;2.73 +34929-0;Cells.CD3+CD4+CD45RO+CD45RA-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD45RO+CD45RA- cells/100 cells in Blood;CD3+4+45RO+45RA- Cells NFr Bld;;ACTIVE;2.11;2.73 +34930-8;Cells.CD3+CD4+CD45RO+CD45RA+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD45RO+CD45RA+ cells/100 cells in Blood;CD3+4+45RO+45RA+ Cells NFr Bld;;ACTIVE;2.11;2.70 +34931-6;Cells.CD3+CD4+CD45RO-CD45RA-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD45RO-CD45RA- cells/100 cells in Blood;CD3+4+45RO-45RA- Cells NFr Bld;;ACTIVE;2.11;2.70 +34932-4;Cells.CD3+CD4+CD45RO-CD45RA+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD45RO-CD45RA+ cells/100 cells in Blood;CD3+4+45RO-45RA+ Cells NFr Bld;;ACTIVE;2.11;2.70 +34933-2;Cells.CD3+CD8+CD45RO+CD45RA-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD45RO+CD45RA- cells/100 cells in Blood;CD3+8+45RO+45RA- Cells NFr Bld;;ACTIVE;2.11;2.73 +3493-4;clomiPRAMINE+Norclomipramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clomiPRAMINE+Norclomipramine [Mass/volume] in Serum or Plasma;clomiPRAMINE+Nor SerPl-mCnc;;ACTIVE;1.0;2.73 +34934-0;Cells.CD3+CD8+CD45RO+CD45RA+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD45RO+CD45RA+ cells/100 cells in Blood;CD3+8+45RO+45RA+ Cells NFr Bld;;ACTIVE;2.11;2.70 +34935-7;Cells.CD3+CD8+CD45RO-CD45RA-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD45RO-CD45RA- cells/100 cells in Blood;CD3+8+45RO-45RA- Cells NFr Bld;;ACTIVE;2.11;2.70 +34936-5;Cells.CD3+CD8+CD45RO-CD45RA+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD45RO-CD45RA+ cells/100 cells in Blood;CD3+8+45RO-45RA+ Cells NFr Bld;;ACTIVE;2.11;2.70 +34937-3;Fibrinopeptide A;MCnc;Pt;PPP;Qn;EIA;COAG;1;Deprecated Fibrinopeptide A Ag [Mass/volume] in Platelet poor plasma by EIA;Deprecated FpA PPP EIA-mCnc;;DEPRECATED;2.11;2.70 +34938-1;Phosphate;SCnc;Pt;Dial fld;Qn;;CHEM;1;Phosphate [Moles/volume] in Dialysis fluid;Phosphate Dial fld-sCnc;;ACTIVE;2.11;2.70 +34939-9;Tumor necrosis factor.alpha;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tumor necrosis factor.alpha [Moles/volume] in Serum or Plasma;A-Tumor Necrosis Fact SerPl-sCnc;;ACTIVE;2.11;2.73 +34940-7;Babesia microti Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Babesia microti IgG and IgM panel - Serum;B microti IgG+IgM Pnl Ser;;ACTIVE;2.11;2.73 +34941-5;Bordetella pertussis Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Bordetella pertussis IgG and IgM panel - Serum;B pert IgG+IgM Pnl Ser;;ACTIVE;2.11;2.73 +3494-2;clonazePAM;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clonazePAM [Mass/volume] in Serum or Plasma;clonazePAM SerPl-mCnc;;ACTIVE;1.0;2.73 +34942-3;Borrelia burgdorferi Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Borrelia burgdorferi IgG and IgM panel - Serum;B burgdor IgG+IgM Pnl Ser;;ACTIVE;2.11;2.73 +34943-1;Borrelia burgdorferi Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Borrelia burgdorferi IgG and IgM panel - Cerebral spinal fluid;B burgdor IgG+IgM Pnl CSF;;ACTIVE;2.11;2.73 +34944-9;Cytomegalovirus Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Cytomegalovirus IgG and IgM panel - Cerebral spinal fluid;CMV IgG+IgM Pnl CSF;;ACTIVE;2.11;2.42 +34945-6;Herpes virus 6 Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Herpes virus 6 IgG and IgM panel - Serum;HHV6 IgG+IgM Pnl Ser;;ACTIVE;2.11;2.73 +34946-4;Herpes virus 6 Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Herpes virus 6 IgG and IgM panel - Cerebral spinal fluid;HHV6 IgG+IgM Pnl CSF;;ACTIVE;2.11;2.42 +34947-2;Herpes virus 7 Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Herpes virus 7 IgG and IgM panel - Serum;HHV7 IgG+IgM Pnl Ser;;ACTIVE;2.11;2.42 +34948-0;Measles virus Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Measles virus IgG and IgM Qn panel - Serum;MeV IgG+IgM Qn Pnl Ser;;ACTIVE;2.11;2.66 +34949-8;Measles virus Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Measles virus IgG and IgM panel - Cerebral spinal fluid;MeV IgG+IgM Pnl CSF;;ACTIVE;2.11;2.42 +34950-6;Parvovirus B19 Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Parvovirus B19 IgG and IgM panel - Serum;B19V IgG+IgM Pnl Ser;;ACTIVE;2.11;2.73 +34951-4;Phosphatidylserine Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.COAG;1;Phosphatidylserine IgG and IgM panel - Serum;PS IgG+IgM Pnl Ser;;ACTIVE;2.11;2.73 +34952-2;Rubella virus Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Rubella virus IgG and IgM panel - Serum;RUBV IgG+IgM Pnl Ser;;ACTIVE;2.11;2.73 +34953-0;Rubella virus Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Rubella virus IgG and IgM panel - Cerebral spinal fluid;RUBV IgG+IgM Pnl CSF;;ACTIVE;2.11;2.42 +34954-8;Treponema pallidum Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Treponema pallidum IgG and IgM panel - Serum;T pallidum IgG+IgM Pnl Ser;;ACTIVE;2.11;2.42 +34955-5;Western equine encephalitis virus Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Western equine encephalitis virus IgG and IgM panel - Cerebral spinal fluid;WEEV IgG+IgM Pnl CSF;;ACTIVE;2.11;2.42 +34956-3;Western equine encephalitis virus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Western equine encephalitis virus IgM Ab [Units/volume] in Cerebral spinal fluid;WEEV IgM CSF-aCnc;;ACTIVE;2.11;2.69 +34957-1;Eosinophils;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Eosinophils [#/volume] in Cerebral spinal fluid by Manual count;Eosinophil # CSF Manual;;ACTIVE;2.11;2.73 +34958-9;Eosinophils;NCnc;Pt;CSF;Qn;;HEM/BC;1;Eosinophils [#/volume] in Cerebral spinal fluid;Eosinophil # CSF;;ACTIVE;2.11;2.73 +3495-9;cloNIDine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloNIDine [Mass/volume] in Serum or Plasma;cloNIDine SerPl-mCnc;;ACTIVE;1.0;2.73 +34959-7;Microscopic observation;Prid;Pt;Bld;Nom;Myeloperoxidase stain;HEM/BC;1;Microscopic observation [Identifier] in Blood by Myeloperoxidase stain;Myeloperoxidase Bld;;ACTIVE;2.11;2.12 +34960-5;HLA Ab;Prid;Pt;Ser/Plas;Nom;;HLA;1;HLA Ab [Identifier] in Serum or Plasma;HLA Ab SerPl;;ACTIVE;2.11;2.73 +34961-3;Rh;Type;Pt;Bld;Nom;Confirm;BLDBK;1;Rh [Type] in Blood by Confirmatory method;Rh Bld Cfm;;ACTIVE;2.11;2.73 +34962-1;Cells.CD3+TCR alpha beta+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+TCR alpha beta+ cells/100 cells in Blood;CD3+TCR A-B+ Cells NFr Bld;;ACTIVE;2.11;2.73 +34963-9;Cells.CD3+TCR alpha beta+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+TCR alpha beta+ cells [#/volume] in Blood;CD3+TCR A-B+ Cells # Bld;;ACTIVE;2.11;2.73 +34964-7;Osmotic fragility;Imp;Pt;RBC;Nom;;HEM/BC;1;Osmotic fragility [Interpretation] of Red Blood Cells;OF RBC-Imp;;ACTIVE;2.11;2.73 +34965-4;Osmotic fragility^0.10% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.10% sodium chloride 24 hour 37 degree C incubation;OF .10% NaCl 24h Inc NFr RBC;;ACTIVE;2.11;2.70 +34966-2;Osmotic fragility^0.10% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.10% sodium chloride;OF .10% NaCl NFr RBC;;ACTIVE;2.11;2.70 +3496-7;Clopenthixol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clopenthixol [Mass/volume] in Serum or Plasma;Clopenthixol SerPl-mCnc;;ACTIVE;1.0;2.42 +34967-0;Osmotic fragility^0.20% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.20% sodium chloride 24 hour 37 degree C incubation;OF .20% NaCl 24h Inc NFr RBC;;ACTIVE;2.11;2.70 +34968-8;Osmotic fragility^0.20% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.20% sodium chloride;OF .20% NaCl NFr RBC;;ACTIVE;2.11;2.70 +34969-6;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;BldMV;Qn;;CHEM;1;Fractional oxyhemoglobin in Mixed venous blood;OxyHgb MFr BldMV;;ACTIVE;2.11;2.73 +34970-4;Date ultrasound;Date;Pt;^Patient;Qn;;MISC;1;Ultrasound date;US Date;;ACTIVE;2.11;2.73 +34971-2;Neutrophil associated Ab;PrThr;Pt;Bld;Ord;;SERO;1;Neutrophil associated Ab [Presence] in Blood;Neut Assoc Ab Bld Ql;;ACTIVE;2.11;2.56 +34972-0;DNA index 3;ACnc;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;DNA index 3 in Specimen by Flow cytometry (FC);DNA Index 3 Spec FC-aCnc;;ACTIVE;2.11;2.69 +34973-8;DNA index 2;ACnc;Pt;Ser/Plas;Qn;Flow cytometry;MOLPATH;1;DNA index 2 in Serum or Plasma by Flow cytometry (FC);DNA Index 2 SerPl FC-aCnc;;ACTIVE;2.11;2.69 +34974-6;DNA index 3;ACnc;Pt;Ser/Plas;Qn;Flow cytometry;MOLPATH;1;DNA index 3 in Serum or Plasma by Flow cytometry (FC);DNA Index 3 SerPl FC-aCnc;;ACTIVE;2.11;2.69 +3497-5;Clopenthixol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Clopenthixol [Mass/volume] in Urine;Clopenthixol Ur-mCnc;;ACTIVE;1.0;2.42 +34975-3;DNA index;ACnc;Pt;Ser/Plas;Qn;Flow cytometry;MOLPATH;1;DNA index in Serum or Plasma by Flow cytometry (FC);DNA Index SerPl FC-aCnc;;ACTIVE;2.11;2.69 +34976-1;DNA index 2;ACnc;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;DNA index 2 in Specimen by Flow cytometry (FC);DNA Index 2 Spec FC-aCnc;;ACTIVE;2.11;2.73 +34977-9;Platelet genotype;Prid;Pt;Bld;Nom;;HEM/BC;1;Platelet genotype [Identifier] in Blood;Platelet Gentyp Bld;;ACTIVE;2.11;2.72 +34978-7;Specimen volume;Vol;Pt;Periton fld;Qn;;SPEC;1;Volume of Peritoneal fluid;Specimen vol Prt;;ACTIVE;2.11;2.73 +34979-5;Specimen volume;Vol;Pt;Plr fld;Qn;;SPEC;1;Volume of Pleural fluid;Specimen vol Plr;;ACTIVE;2.11;2.73 +34980-3;Specimen volume;Vol;Pt;Synv fld;Qn;;SPEC;1;Volume of Synovial fluid;Specimen vol Snv;;ACTIVE;2.11;2.73 +34981-1;Specimen volume;Vol;Pt;Pericard fld;Qn;;SPEC;1;Volume of Pericardial fluid;Specimen vol Pcar;;ACTIVE;2.11;2.42 +34982-9;Unidentified cells/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Unidentified cells/100 leukocytes in Peritoneal fluid;Unident Cells/leuk NFr Prt;;ACTIVE;2.11;2.50 +3498-3;Clorazepate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clorazepate [Mass/volume] in Serum or Plasma;Clorazepate SerPl-mCnc;;ACTIVE;1.0;2.73 +34983-7;Unidentified cells/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Unidentified cells/100 leukocytes in Pleural fluid;Unident Cells/leuk NFr Plr;;ACTIVE;2.11;2.73 +34984-5;Unidentified cells/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Unidentified cells/100 leukocytes in Synovial fluid;Unident Cells/leuk NFr Snv;;ACTIVE;2.11;2.73 +34985-2;Unidentified cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Unidentified cells/100 leukocytes in Body fluid;Unident Cells/leuk NFr Fld;;ACTIVE;2.11;2.73 +34986-0;Unidentified cells;NCnc;Pt;Pericard fld;Qn;;HEM/BC;1;Unidentified cells [#/volume] in Pericardial fluid;Unident Cells # Pcar;;ACTIVE;2.11;2.44 +34987-8;Unidentified cells;NCnc;Pt;CSF;Qn;;HEM/BC;1;Unidentified cells [#/volume] in Cerebral spinal fluid;Unident Cells # CSF;;ACTIVE;2.11;2.73 +34988-6;Unidentified cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Unidentified cells [#/volume] in Body fluid;Unident Cells # Fld;;ACTIVE;2.11;2.73 +34989-4;Unidentified cells;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Unidentified cells [#/volume] in Pleural fluid;Unident Cells # Plr;;ACTIVE;2.11;2.44 +34990-2;Unidentified cells;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Unidentified cells [#/volume] in Peritoneal fluid;Unident Cells # Prt;;ACTIVE;2.11;2.44 +3499-1;Clorprenaline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Clorprenaline [Presence] in Urine;Clorprenaline Ur Ql;;ACTIVE;1.0;2.56 +34991-0;Unidentified cells;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Unidentified cells [#/volume] in Synovial fluid;Unident Cells # Snv;;ACTIVE;2.11;2.73 +34992-8;Smudge cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Smudge cells/100 leukocytes in Blood;Smudge Cells/leuk NFr Bld;;ACTIVE;2.11;2.50 +34993-6;Smudge cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Smudge cells [#/volume] in Blood;Smudge Cells # Bld;;ACTIVE;2.11;2.40 +34994-4;Smear morphology panel;-;Pt;Bld;-;;PANEL.HEM/BC;1;Smear morphology panel - Blood;Smear Morphology Pnl Bld;;DISCOURAGED;2.11;2.42 +34995-1;Promyelocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Promyelocytes [#/volume] in Cerebral spinal fluid;Promyelocytes # CSF;;ACTIVE;2.11;2.44 +34996-9;Promyelocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Promyelocytes [#/volume] in Body fluid;Promyelocytes # Fld;;ACTIVE;2.11;2.73 +34997-7;Promonocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Promonocytes [#/volume] in Body fluid;Promonycytes # Fld;;ACTIVE;2.11;2.44 +34998-5;Prolymphocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Prolymphocytes [#/volume] in Body fluid;Prolymphocytes # Fld;;ACTIVE;2.11;2.44 +34999-3;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Blood;Polys/leuk NFr Bld;;ACTIVE;2.11;2.73 +35000-9;Polymorphonuclear cells;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Polymorphonuclear cells [#/volume] in Pleural fluid;Polys # Plr;;ACTIVE;2.11;2.44 +35001-7;Polymorphonuclear cells;NCnc;Pt;CSF;Qn;;HEM/BC;1;Polymorphonuclear cells [#/volume] in Cerebral spinal fluid;Polys # CSF;;ACTIVE;2.11;2.73 +35002-5;Polymorphonuclear cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Polymorphonuclear cells [#/volume] in Body fluid;Polys # Fld;;ACTIVE;2.11;2.44 +35003-3;Polymorphonuclear cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Polymorphonuclear cells [#/volume] in Blood;Polys # Bld;;ACTIVE;2.11;2.73 +35004-1;Polymorphonuclear cells;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Polymorphonuclear cells [#/volume] in Synovial fluid;Polys # Snv;;ACTIVE;2.11;2.44 +35005-8;Polymorphonuclear cells;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Polymorphonuclear cells [#/volume] in Peritoneal fluid;Polys # Prt;;ACTIVE;2.11;2.44 +3500-6;Clorprenaline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Clorprenaline [Mass/volume] in Urine;Clorprenaline Ur-mCnc;;ACTIVE;1.0;2.42 +35006-6;Plasma cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Plasma cells [#/volume] in Body fluid;Plasma Cells # Fld;;ACTIVE;2.11;2.44 +35007-4;Nonhematic cells;NCnc;Pt;CSF;Qn;;HEM/BC;1;Nonhematic cells [#/volume] in Cerebral spinal fluid;Nonhematic Cells # CSF;;ACTIVE;2.11;2.44 +35008-2;Nonhematic cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Nonhematic cells [#/volume] in Body fluid;Nonhematic Cells # Fld;;ACTIVE;2.11;2.44 +35009-0;Neutrophils.segmented;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Segmented neutrophils [#/volume] in Synovial fluid;Neuts Seg # Snv;;ACTIVE;2.11;2.54 +35010-8;Neutrophils.segmented;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Segmented neutrophils [#/volume] in Peritoneal fluid;Neuts Seg # Prt;;ACTIVE;2.11;2.54 +35011-6;Neutrophils.segmented;NCnc;Pt;CSF;Qn;;HEM/BC;1;Segmented neutrophils [#/volume] in Cerebral spinal fluid;Neuts Seg # CSF;;ACTIVE;2.11;2.73 +35012-4;Neutrophils.segmented;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Segmented neutrophils [#/volume] in Pleural fluid;Neuts Seg # Plr;;ACTIVE;2.11;2.73 +35013-2;Neutrophils.band form;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Band form neutrophils [#/volume] in Synovial fluid;Neuts Band # Snv;;ACTIVE;2.11;2.73 +3501-4;Clorprenaline;MRat;24H;Urine;Qn;;DRUG/TOX;1;Clorprenaline [Mass/time] in 24 hour Urine;Clorprenaline 24h Ur-mRate;;ACTIVE;1.0;2.42 +35014-0;Neutrophils.band form;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Band form neutrophils [#/volume] in Body fluid;Neuts Band # Fld;;ACTIVE;2.11;2.73 +35015-7;Neutrophils.band form;NCnc;Pt;CSF;Qn;;HEM/BC;1;Band form neutrophils [#/volume] in Cerebral spinal fluid;Neuts Band # CSF;;ACTIVE;2.11;2.73 +35016-5;Myelocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Myelocytes [#/volume] in Body fluid;Myelocytes # Fld;;ACTIVE;2.11;2.73 +35017-3;Myelocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Myelocytes [#/volume] in Cerebral spinal fluid;Myelocytes # CSF;;ACTIVE;2.11;2.44 +35018-1;Mononuclear cells;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Mononuclear cells [#/volume] in Pleural fluid;Mononuc Cells # Plr;;ACTIVE;2.11;2.44 +35019-9;Monocytes+Macrophages/100 lymphocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Deprecated Monocytes+Macrophages/100 lymphocytes;Deprecated Monos+Macros Fr Plr;;DEPRECATED;2.11;2.36 +35020-7;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Peritoneal fluid;Monos+Macros/leuk NFr Prt;;ACTIVE;2.11;2.50 +35021-5;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Pleural fluid;Monos+Macros/leuk NFr Plr;;ACTIVE;2.11;2.50 +3502-2;Clostebol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Clostebol [Presence] in Urine;Clostebol Ur Ql;;ACTIVE;1.0;2.73 +35022-3;Monocytes+Macrophages;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Monocytes+Macrophages [#/volume] in Pleural fluid;Monos+Macros # Plr;;ACTIVE;2.11;2.44 +35023-1;Monocytes+Macrophages;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Monocytes+Macrophages [#/volume] in Peritoneal fluid;Monos+Macros # Prt;;ACTIVE;2.11;2.44 +35024-9;Monocytes+Macrophages;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Monocytes+Macrophages [#/volume] in Synovial fluid;Monos+Macros # Snv;;ACTIVE;2.11;2.44 +35025-6;Monocytes+Macrophages;NCnc;Pt;CSF;Qn;;HEM/BC;1;Monocytes+Macrophages [#/volume] in Cerebral spinal fluid;Monos+Macros # CSF;;ACTIVE;2.11;2.73 +35026-4;Monocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Monocytes [#/volume] in Cerebral spinal fluid;Monocytes # CSF;;ACTIVE;2.11;2.73 +35027-2;Monocytes;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Monocytes [#/volume] in Peritoneal fluid;Monocytes # Prt;;ACTIVE;2.11;2.44 +35028-0;Monocytes;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Monocytes [#/volume] in Pleural fluid;Monocytes # Plr;;ACTIVE;2.11;2.44 +35029-8;Monoblasts;NCnc;Pt;Bld;Qn;;HEM/BC;1;Monoblasts [#/volume] in Blood;Monoblasts # Bld;;ACTIVE;2.11;2.40 +3503-0;Clostebol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Clostebol [Mass/volume] in Urine;Clostebol Ur-mCnc;;ACTIVE;1.0;2.42 +35030-6;Metamyelocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Metamyelocytes [#/volume] in Cerebral spinal fluid;Metamyelocytes # CSF;;ACTIVE;2.11;2.44 +35031-4;Metamyelocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Metamyelocytes [#/volume] in Body fluid;Metamyelocytes # Fld;;ACTIVE;2.11;2.73 +35032-2;Mesothelial cells;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Mesothelial cells [#/volume] in Peritoneal fluid;Mesothl Cell # Prt;;ACTIVE;2.11;2.73 +35033-0;Mesothelial cells;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Mesothelial cells [#/volume] in Pleural fluid;Mesothl Cell # Plr;;ACTIVE;2.11;2.44 +35034-8;Mesothelial cells;NCnc;Pt;CSF;Qn;;HEM/BC;1;Mesothelial cells [#/volume] in Cerebral spinal fluid;Mesothl Cell # CSF;;ACTIVE;2.11;2.44 +35035-5;Mesothelial cells;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Mesothelial cells [#/volume] in Synovial fluid;Mesothl Cell # Snv;;ACTIVE;2.11;2.73 +35036-3;Macrophages;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Macrophages [#/volume] in Body fluid;Macrophages # Fld;;ACTIVE;2.11;2.73 +35037-1;Macrophages;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Macrophages [#/volume] in Synovial fluid;Macrophages # Snv;;ACTIVE;2.11;2.73 +35038-9;Macrophages;NCnc;Pt;CSF;Qn;;HEM/BC;1;Macrophages [#/volume] in Cerebral spinal fluid;Macrophages # CSF;;ACTIVE;2.11;2.73 +35039-7;Lymphocytes.plasmacytoid;NCnc;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes Plasmacytoid [#/volume] in Blood;Plasmacoid Lymphs # Bld;;ACTIVE;2.11;2.73 +35040-5;Lymphocytes.immunoblastic;NCnc;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes Immunoblastic [#/volume] in Blood;Ib Lymphs # Bld;;ACTIVE;2.11;2.40 +35041-3;Lymphocytes.variant;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Variant lymphocytes [#/volume] in Peritoneal fluid;Variant Lymphs # Prt;;ACTIVE;2.11;2.54 +35042-1;Lymphocytes.variant;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Variant lymphocytes [#/volume] in Pleural fluid;Variant Lymphs # Plr;;ACTIVE;2.11;2.54 +35043-9;Lymphocytes.variant;NCnc;Pt;CSF;Qn;;HEM/BC;1;Variant lymphocytes [#/volume] in Cerebral spinal fluid;Variant Lymphs # CSF;;ACTIVE;2.11;2.54 +35044-7;Lymphocytes.variant;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Variant lymphocytes [#/volume] in Synovial fluid;Variant Lymphs # Snv;;ACTIVE;2.11;2.73 +35045-4;Lymphocytes.variant;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Variant lymphocytes [#/volume] in Body fluid;Variant Lymphs # Fld;;ACTIVE;2.11;2.54 +35046-2;Lymphocytes.abnormal;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Abnormal lymphocytes [#/volume] in Body fluid;Lymph Abn # Fld;;ACTIVE;2.11;2.54 +35047-0;Lymphocytes.abnormal;NCnc;Pt;CSF;Qn;;HEM/BC;1;Abnormal lymphocytes [#/volume] in Cerebral spinal fluid;Lymph Abn # CSF;;ACTIVE;2.11;2.54 +3504-8;Clostebol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Clostebol [Mass/time] in 24 hour Urine;Clostebol 24h Ur-mRate;;ACTIVE;1.0;2.42 +35048-8;Lymphocytes.abnormal;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Abnormal lymphocytes [#/volume] in Synovial fluid;Lymph Abn # Snv;;ACTIVE;2.11;2.54 +35049-6;Lymphocytes;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Lymphocytes [#/volume] in Synovial fluid;Lymphocytes # Snv;;ACTIVE;2.11;2.73 +35050-4;Lymphoblasts;NCnc;Pt;Bld;Qn;;HEM/BC;1;Lymphoblasts [#/volume] in Blood;Lymphoblasts # Bld;;ACTIVE;2.11;2.73 +35051-2;Leukocytes other;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Leukocytes other [#/volume] in Body fluid;WBC Other # Fld;;ACTIVE;2.11;2.73 +35052-0;Leukocytes other;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Leukocytes other [#/volume] in Pleural fluid;WBC Other # Plr;;ACTIVE;2.11;2.44 +35053-8;Leukocytes other;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Leukocytes other [#/volume] in Synovial fluid;WBC Other # Snv;;ACTIVE;2.11;2.44 +35054-6;Leukocytes other;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Leukocytes other [#/volume] in Peritoneal fluid;WBC Other # Prt;;ACTIVE;2.11;2.44 +3505-5;Codeine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Codeine [Presence] in Serum or Plasma;Codeine SerPl Ql;;ACTIVE;1.0;2.73 +35055-3;Histiocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Histiocytes/100 leukocytes in Body fluid;Histiocytes/leuk NFr Fld;;ACTIVE;2.11;2.73 +35056-1;Histiocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Histiocytes [#/volume] in Cerebral spinal fluid;Histiocytes # CSF;;ACTIVE;2.11;2.73 +35057-9;Histiocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Histiocytes [#/volume] in Body fluid;Histiocytes # Fld;;ACTIVE;2.11;2.73 +35058-7;Hairy cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Hairy cells/100 leukocytes in Blood;Hairy Cells/leuk NFr Bld;;ACTIVE;2.11;2.50 +35059-5;Granulocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Granulocytes [#/volume] in Cerebral spinal fluid;Granulocytes # CSF;;ACTIVE;2.11;2.44 +35060-3;Eosinophils;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Eosinophils [#/volume] in Synovial fluid;Eosinophil # Snv;;ACTIVE;2.11;2.73 +35061-1;Eosinophils;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Eosinophils [#/volume] in Peritoneal fluid;Eosinophil # Prt;;ACTIVE;2.11;2.73 +35062-9;Eosinophils;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Eosinophils [#/volume] in Pleural fluid;Eosinophil # Plr;;ACTIVE;2.11;2.44 +3506-3;Codeine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Codeine [Mass/volume] in Serum or Plasma;Codeine SerPl-mCnc;;ACTIVE;1.0;2.73 +35063-7;Eosinophils;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Eosinophils [#/volume] in Body fluid;Eosinophil # Fld;;ACTIVE;2.11;2.73 +35064-5;Blasts;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Blasts [#/volume] in Synovial fluid;Blasts # Snv;;ACTIVE;2.11;2.44 +35065-2;Blasts;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Blasts [#/volume] in Peritoneal fluid;Blasts # Prt;;ACTIVE;2.11;2.44 +35066-0;Blasts;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Blasts [#/volume] in Pleural fluid;Blasts # Plr;;ACTIVE;2.11;2.44 +35067-8;Blasts;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Blasts [#/volume] in Body fluid;Blasts # Fld;;ACTIVE;2.11;2.73 +35068-6;Blasts;NCnc;Pt;CSF;Qn;;HEM/BC;1;Blasts [#/volume] in Cerebral spinal fluid;Blasts # CSF;;ACTIVE;2.11;2.44 +35069-4;Basophils/100 leukocytes;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Basophils/100 leukocytes in Peritoneal fluid;Basophils/leuk NFr Prt;;ACTIVE;2.11;2.73 +35070-2;Basophils/100 leukocytes;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Basophils/100 leukocytes in Pleural fluid;Basophils/leuk NFr Plr;;ACTIVE;2.11;2.50 +3507-1;Codeine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Codeine [Presence] in Urine;Codeine Ur Ql;;ACTIVE;1.0;2.73 +35071-0;Basophils;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Basophils [#/volume] in Body fluid;Basophils # Fld;;ACTIVE;2.11;2.73 +35072-8;Basophils;NCnc;Pt;CSF;Qn;;HEM/BC;1;Basophils [#/volume] in Cerebral spinal fluid;Basophils # CSF;;ACTIVE;2.11;2.73 +35073-6;Basophils;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Basophils [#/volume] in Peritoneal fluid;Basophils # Prt;;ACTIVE;2.11;2.44 +35074-4;Basophils;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Basophils [#/volume] in Synovial fluid;Basophils # Snv;;ACTIVE;2.11;2.73 +35075-1;Basophils;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Basophils [#/volume] in Pleural fluid;Basophils # Plr;;ACTIVE;2.11;2.44 +35076-9;Monocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Monocytes [#/volume] in Body fluid;Monocytes # Fld;;ACTIVE;2.11;2.73 +35077-7;Lymphocytes.abnormal/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Abnormal lymphocytes/100 leukocytes in Body fluid;Lymph Abn/leuk NFr Fld;;ACTIVE;2.11;2.73 +35078-5;Unspecified cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Unspecified cells [#/volume] in Body fluid;Unspecified Cells # Fld;;ACTIVE;2.11;2.44 +35079-3;Mesothelial cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Mesothelial cells [#/volume] in Body fluid;Mesothl Cell # Fld;;ACTIVE;2.11;2.73 +35080-1;Mononuclear cells;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Mononuclear cells [#/volume] in Peritoneal fluid;Mononuc Cells # Prt;;ACTIVE;2.11;2.44 +35081-9;Lymphocytes+Monocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes+Monocytes [#/volume] in Blood;Lymphs+Monos # Bld;;ACTIVE;2.11;2.40 +35082-7;Lymphocytes.large granular;NCnc;Pt;Bld;Qn;;HEM/BC;1;Large granular lymphocytes [#/volume] in Blood;Lg Gran Lymphs # Bld;;ACTIVE;2.11;2.54 +35083-5;Amino acids panel;SCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Amino acids panel [Moles/volume] - Serum or Plasma;Amino acids Pnl SerPl-sCnc;;ACTIVE;2.11;2.73 +35084-3;Fetal lung maturity;-;Pt;Amnio fld;Qn;;PANEL.CHEM;1;Fetal lung maturity in Amniotic fluid;FLM Amn;;ACTIVE;2.11;2.26 +35085-0;Newborn screening panel;-;Pt;Bld.dot;-;ACMG;PANEL.CHEM;1;Deprecated Newborn screening panel American College of Medical Genetics (ACMG);Deprecated NB Screen Pnl DBS ACMG;;DEPRECATED;2.11;2.68 +35086-8;Second trimester triple maternal screen panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Second trimester triple maternal screen panel - Serum or Plasma;2nd trimester 3 screen Pnl SerPl;;ACTIVE;2.11;2.42 +35087-6;Amino acids panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Amino acids panel - Urine;Amino acids Pnl Ur;;ACTIVE;2.11;2.70 +35088-4;Glasgow coma scale;-;Pt;^Patient;-;;PANEL.FUNCTION;2;Glasgow coma scale;Glasgow coma scale;;ACTIVE;2.11;2.73 +3508-9;Codeine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Codeine [Mass/volume] in Urine;Codeine Ur-mCnc;;ACTIVE;1.0;2.73 +35089-2;History and physical panel;-;Pt;^Patient;-;;PANEL.H&P;2;History and physical panel;History+physical Pnl;;ACTIVE;2.11;2.46 +350-9;Nalidixate;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Nalidixate [Susceptibility] by Minimum lethal concentration (MLC);Nalidixate Islt MLC;;ACTIVE;1.0;2.19 +35090-0;Patient history;-;Pt;^Patient;-;;PANEL.H&P;2;Patient history;Patient Hx;;ACTIVE;2.11;2.73 +35091-8;Patient physical;-;Pt;^Patient;-;;PANEL.H&P;2;Patient physical;Patient physical;;ACTIVE;2.11;2.27 +35092-6;Urology testicular ultrasound;-;Pt;^Patient;-;;PANEL.US.URO;2;Urology testicular ultrasound;Testicular US Pnl;;ACTIVE;2.11;2.27 +35093-4;Urology urinary tract ultrasound;-;Pt;^Patient;-;;PANEL.US.URO;2;Urology urinary tract ultrasound;UT US Pnl;;ACTIVE;2.11;2.27 +35094-2;Blood pressure panel;-;Pt;^Patient;-;;PANEL.BP;2;Blood pressure panel;BP Pnl;;ACTIVE;2.11;2.27 +35095-9;Body temperature panel;-;Pt;^Patient;-;;PANEL.BDYTMP;2;Body temperature panel;Bdy temp Pnl;;ACTIVE;2.11;2.27 +35096-7;OB ultrasound panel;-;Pt;^Patient;-;;PANEL.OB.US;2;OB ultrasound panel;OB US Pnl;;ACTIVE;2.11;2.27 +3509-7;Prochlorperazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prochlorperazine [Mass/volume] in Serum or Plasma;Prochlorperazine SerPl-mCnc;;ACTIVE;1.0;2.73 +35097-5;Lymphocytes;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Lymphocytes [#/volume] in Peritoneal fluid;Lymphocytes # Prt;;ACTIVE;2.11;2.44 +35098-3;Lymphocytes;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Lymphocytes [#/volume] in Pleural fluid;Lymphocytes # Plr;;ACTIVE;2.11;2.44 +35099-1;Monocytes+Macrophages;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Monocytes+Macrophages [#/volume] in Body fluid;Monos+Macros # Fld;;ACTIVE;2.11;2.44 +35100-7;Enterovirus Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Enterovirus IgM Ab [Units/volume] in Cerebral spinal fluid;EV IgM CSF-aCnc;;ACTIVE;2.11;2.69 +35101-5;Intrathecal pressure;Pres;Pt;Intrathecal space;Qn;;MISC;1;Intrathecal pressure;ICP Intrathecal space;;ACTIVE;2.11;2.40 +35102-3;Acenocoumarol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acenocoumarol [Mass/volume] in Serum or Plasma;Acenocoumarol SerPl-mCnc;;ACTIVE;2.11;2.42 +35103-1;Acyclovir^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acyclovir [Mass/volume] in Serum or Plasma --trough;Acyclovir Trough SerPl-mCnc;;ACTIVE;2.11;2.40 +35104-9;Acyclovir^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acyclovir [Mass/volume] in Serum or Plasma --peak;Acyclovir Peak SerPl-mCnc;;ACTIVE;2.11;2.40 +3510-5;Prochlorperazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Prochlorperazine [Presence] in Urine;Prochlorperazine Ur Ql;;ACTIVE;1.0;2.73 +35105-6;Bromperidol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromperidol [Mass/volume] in Serum or Plasma;Bromperidol SerPl-mCnc;;ACTIVE;2.11;2.42 +35106-4;Norcitalopram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norcitalopram [Mass/volume] in Serum or Plasma;Norcitalopram SerPl-mCnc;;ACTIVE;2.11;2.73 +35107-2;Norclobazam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norclobazam [Mass/volume] in Serum or Plasma;Norclobazam SerPl-mCnc;;ACTIVE;2.11;2.73 +35108-0;Normaprotiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normaprotiline [Mass/volume] in Serum or Plasma;Normaprotiline SerPl-mCnc;;ACTIVE;2.11;2.42 +35109-8;Phenprocoumon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenprocoumon [Mass/volume] in Serum or Plasma;Phenprocoumon SerPl-mCnc;;ACTIVE;2.11;2.42 +35110-6;Flecainide^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flecainide [Mass/volume] in Serum or Plasma --trough;Flecainide Trough SerPl-mCnc;;ACTIVE;2.11;2.40 +35111-4;Flecainide^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flecainide [Mass/volume] in Serum or Plasma --peak;Flecainide Peak SerPl-mCnc;;ACTIVE;2.11;2.40 +35112-2;Floxacillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Floxacillin [Mass/volume] in Serum or Plasma;Floxacillin SerPl-mCnc;;ACTIVE;2.11;2.42 +3511-3;Cropropamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cropropamide [Presence] in Urine;Cropropamide Ur Ql;;ACTIVE;1.0;2.56 +35113-0;Nelfinavir M8;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nelfinavir M8 [Mass/volume] in Serum or Plasma;Nelfinavir M8 SerPl-mCnc;;ACTIVE;2.11;2.40 +35114-8;Nordothiepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nordothiepin [Mass/volume] in Serum or Plasma;Nordothiepin SerPl-mCnc;;ACTIVE;2.11;2.42 +35115-5;Pipamperone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pipamperone [Mass/volume] in Serum or Plasma;Pipamperone SerPl-mCnc;;ACTIVE;2.11;2.34 +35116-3;Sulforidazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulforidazine [Mass/volume] in Serum or Plasma;Sulforidazine SerPl-mCnc;;ACTIVE;2.11;2.42 +35117-1;Sulpiride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulpiride [Mass/volume] in Serum or Plasma;Sulpiride SerPl-mCnc;;ACTIVE;2.11;2.42 +35118-9;Acetaldehyde;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetaldehyde [Presence] in Serum or Plasma;Acetaldehyde SerPl Ql;;ACTIVE;2.11;2.56 +35119-7;Chloral hydrate;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Chloral hydrate [Presence] in Serum or Plasma;Chloral Hydrate SerPl Ql;;ACTIVE;2.11;2.56 +35120-5;Dothiepin sulfoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dothiepin sulfoxide [Mass/volume] in Serum or Plasma;Dothiepin sulfoxide SerPl-mCnc;;ACTIVE;2.11;2.40 +3512-1;Cropropamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cropropamide [Mass/volume] in Urine;Cropropamide Ur-mCnc;;ACTIVE;1.0;2.42 +35121-3;E-10-Hydroxynortriptyline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;E-10-Hydroxynortriptyline [Mass/volume] in Serum or Plasma;E-10-OH-NT SerPl-mCnc;;ACTIVE;2.11;2.42 +35122-1;MTM1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MTM1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MTM1 gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +35123-9;Chromosome 14 uniparental disomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 14 uniparental disomy [Presence] in Blood or Tissue by Cytogenetics;Chr 14 UpDi Bld/T Ql;;ACTIVE;2.11;2.73 +35124-7;Dysferlin;PrThr;Pt;WBC;Ord;;CHEM;1;Dysferlin [Presence] in Leukocytes;Dysferlin WBC Ql;;ACTIVE;2.11;2.56 +35125-4;Hemoglobin Lepore/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin Lepore/Hemoglobin.total in Blood;Hgb Lepore MFr Bld;;ACTIVE;2.11;2.73 +35126-2;Hemoglobin O-Arab/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin O - Arab/Hemoglobin.total in Blood;Hgb O-Arab MFr Bld;;ACTIVE;2.11;2.73 +35127-0;Hemoglobin A2.prime/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A2.prime/Hemoglobin.total in Blood;Hgb A2.prime MFr Bld;;ACTIVE;2.11;2.73 +35128-8;Perforin;ACnc;Pt;WBC;Qn;;CHEM;1;Perforin [Units/volume] in Leukocytes;Perforin WBC-aCnc;;ACTIVE;2.11;2.69 +35129-6;Karyotype;Prid;Pt;XXX;Nom;;MOLPATH;1;Karyotype [Identifier] in Specimen Nominal;Karyotyp Spec;;ACTIVE;2.11;2.73 +35130-4;Salicylates;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Salicylates [Presence] in Specimen;Salicylates Spec Ql;;ACTIVE;2.11;2.73 +35131-2;L-dopa decarboxylase;CCnc;Pt;Plas;Qn;;CHEM;1;L-dopa decarboxylase [Enzymatic activity/volume] in Plasma;L-Dopa decase Plas-cCnc;;ACTIVE;2.11;2.68 +35132-0;MELAS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MELAS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MELAS gene Mut Anl Bld/T;;ACTIVE;2.11;2.66 +35133-8;Glutarate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutarate [Mass/volume] in Serum or Plasma;Glutarate SerPl-mCnc;;ACTIVE;2.11;2.70 +35134-6;Thyrotropin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Thyrotropin Ab [Presence] in Serum;TSH Ab Ser Ql;;ACTIVE;2.11;2.73 +35135-3;Adenosine triphosphate/Adenosine diphosphate;MRto;Pt;Bld;Qn;;CHEM;1;Adenosine triphosphate/Adenosine diphosphate [Mass Ratio] in Blood;ATP/ADP Bld;;ACTIVE;2.11;2.44 +35136-1;Patient symptoms^3H post dose lactose PO;Imp;Pt;^Patient;Nom;;CHAL;1;Patient symptoms [Interpretation] --3 hours post dose lactose PO;Symptoms 3h p Lac PO Patient-Imp;;ACTIVE;2.11;2.12 +35137-9;MECP2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MECP2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MECP2 gene Mut Anl Bld/T;;ACTIVE;2.11;2.73 +35138-7;MEFV gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MEFV gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MEFV gene Mut Tested Bld/T;;ACTIVE;2.11;2.13 +3513-9;Cropropamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Cropropamide [Mass/time] in 24 hour Urine;Cropropamide 24h Ur-mRate;;ACTIVE;1.0;2.42 +35139-5;Interferon.beta Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Interferon beta Ab [Titer] in Serum or Plasma;IFN-B Ab Titr SerPl;;ACTIVE;2.11;2.73 +35140-3;Trans-3-Hydroxycotinine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trans-3-Hydroxycotinine [Mass/volume] in Serum or Plasma;trans-3-OH-cotinine SerPl-mCnc;;ACTIVE;2.11;2.73 +35141-1;Purine nucleoside phosphorylase;CCnc;Pt;CSF;Qn;;CHEM;1;Purine nucleoside phosphorylase [Enzymatic activity/volume] in Cerebral spinal fluid;PNP CSF-cCnc;;ACTIVE;2.11;2.68 +35142-9;Amphiphysin Ab;Titr;Pt;CSF;Qn;;SERO;1;Amphiphysin Ab [Titer] in Cerebral spinal fluid;Amphiphysin Ab Titr CSF;;ACTIVE;2.11;2.73 +35143-7;Purkinje cell cytoplasmic type 2 Ab;Titr;Pt;CSF;Qn;;SERO;1;PCA-2 Ab [Titer] in Cerebral spinal fluid;PCA-2 Ab Titr CSF;;ACTIVE;2.11;2.73 +35144-5;Neuronal nuclear type 3 Ab;Titr;Pt;CSF;Qn;;SERO;1;Neuronal nuclear type 3 Ab [Titer] in Cerebral spinal fluid;Hu3 Ab Titr CSF;;ACTIVE;2.11;2.73 +35145-2;Octanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octanoate (C8:0) [Moles/volume] in Serum or Plasma;Octanoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35146-0;Decanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decanoate (C10:0) [Moles/volume] in Serum or Plasma;Decanoate SerPl-sCnc;;ACTIVE;2.11;2.73 +3514-7;Crotetamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Crotethamide [Presence] in Urine;Crotetamide Ur Ql;;ACTIVE;1.0;2.56 +35147-8;Decenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decenoate (C10:1) [Moles/volume] in Serum or Plasma;Decenoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35148-6;Tetradecadienoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecadienoate (C14:2) [Moles/volume] in Serum or Plasma;Tdecadienoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35149-4;Octadecanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octadecanoate (C18:0) [Moles/volume] in Serum or Plasma;Octadecanoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35150-2;Laurate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Laurate (C12:0) [Moles/volume] in Serum or Plasma;Laurate SerPl-sCnc;;ACTIVE;2.11;2.73 +35151-0;Lauroleate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lauroleate (C12:1) [Moles/volume] in Serum or Plasma;Lauroleate SerPl-sCnc;;ACTIVE;2.11;2.73 +35152-8;Fatty acids.very long chain.C26:0;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Fatty acids.very long chain C26:0 (Hexacosanoate) [Molecules/volume] in Serum or Plasma;Deprecated VLCFA C26:0 SerPl-sCnc;;DEPRECATED;2.11;2.36 +35153-6;Fatty acids.very long chain.C26:1;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Fatty acids.very long chain C26:1 (Hexacosenoate) [Molecules/volume] in Serum or Plasma;Deprecated VLCFA C26:1 SerPl-sCnc;;DEPRECATED;2.11;2.36 +3515-4;Crotetamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Crotethamide [Mass/volume] in Urine;Crotetamide Ur-mCnc;;ACTIVE;1.0;2.44 +35154-4;Hexadecadienoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexadecadienoate (C16:2) [Moles/volume] in Serum or Plasma;Hexadecadienoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35155-1;Hexadecenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexadecenoate (C16:1w9) [Moles/volume] in Serum or Plasma;Hexadecenoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35156-9;Fatty acids.very long chain.C24:0;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Fatty acids.very long chain C24:0 (Tetracosanoate) [Molecules/volume] in Serum or Plasma;Deprecated VLCFA C24:0 SerPl-sCnc;;DEPRECATED;2.11;2.36 +35157-7;Myristate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Myristate (C14:0) [Moles/volume] in Serum or Plasma;Myristate SerPl-sCnc;;ACTIVE;2.11;2.73 +35158-5;Myristoleate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Myristoleate (C14:1) [Moles/volume] in Serum or Plasma;Myristoleate SerPl-sCnc;;ACTIVE;2.11;2.73 +35159-3;Fatty acids.very long chain.C22:0;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Fatty acids.very long chain C22:0 (Docosanoate) [Molecules/volume] in Serum or Plasma;Deprecated VLCFA C22:0 SerPl-sCnc;;DEPRECATED;2.11;2.36 +35160-1;Docosenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosenoate (C22:1) [Moles/volume] in Serum or Plasma;Docosenoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35161-9;Palmitate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Palmitate (C16:0) [Moles/volume] in Serum or Plasma;Palmitate SerPl-sCnc;;ACTIVE;2.11;2.73 +3516-2;Crotetamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Crotethamide [Mass/time] in 24 hour Urine;Crotetamide 24h Ur-mRate;;ACTIVE;1.0;2.42 +35162-7;Palmitoleate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoleate (C16:1w7) [Moles/volume] in Serum or Plasma;Palmitoleate SerPl-sCnc;;ACTIVE;2.11;2.73 +35163-5;Gamma linolenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma Linolenate (C18:3w6) [Moles/volume] in Serum or Plasma;G-Linolenate SerPl-sCnc;;ACTIVE;2.11;2.73 +35164-3;Alpha linolenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha linolenate (C18:3w3) [Moles/volume] in Serum or Plasma;A-Linolenate SerPl-sCnc;;ACTIVE;2.11;2.73 +35165-0;Linoleate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Linoleate (C18:2w6) [Moles/volume] in Serum or Plasma;Linoleate SerPl-sCnc;;ACTIVE;2.11;2.73 +35166-8;Oleate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Oleate (C18:1w9) [Moles/volume] in Serum or Plasma;Oleate SerPl-sCnc;;ACTIVE;2.11;2.73 +35167-6;Vaccenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vaccenate (C18:1w7) [Moles/volume] in Serum or Plasma;Vaccenate SerPl-sCnc;;ACTIVE;2.11;2.73 +35168-4;Arachidonate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Arachidonate (C20:4w6) [Moles/volume] in Serum or Plasma;AA SerPl-sCnc;;ACTIVE;2.11;2.73 +35169-2;Arachidate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Arachidate (C20:0) [Moles/volume] in Serum or Plasma;Arachidate SerPl-sCnc;;ACTIVE;2.11;2.73 +351-7;Nalidixate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Nalidixate [Susceptibility] by Minimum inhibitory concentration (MIC);Nalidixate Islt MIC;;ACTIVE;1.0;2.73 +3517-0;Cyclacillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyclacillin [Mass/volume] in Serum or Plasma;Cyclacillin SerPl-mCnc;;ACTIVE;1.0;2.42 +35170-0;Nervonate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Nervonate (C24:1) [Moles/volume] in Serum or Plasma;Nervonate SerPl-sCnc;;ACTIVE;2.11;2.73 +35171-8;Homo-gamma linolenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homo-gamma Linolenate (C20:3w6) [Moles/volume] in Serum or Plasma;Homo-G Linolenate SerPl-sCnc;;ACTIVE;2.11;2.73 +35172-6;Mead acid;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Mead acid (C20:3w9) [Moles/volume] in Serum or Plasma;Mead acid SerPl-sCnc;;ACTIVE;2.11;2.73 +35173-4;Eicosapentaenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Eicosapentaenoate (C20:5w3) [Moles/volume] in Serum or Plasma;EPA SerPl-sCnc;;ACTIVE;2.11;2.73 +35174-2;Docosahexaenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosahexaenoate (C22:6w3) [Moles/volume] in Serum or Plasma;DHA SerPl-sCnc;;ACTIVE;2.11;2.73 +35175-9;Fatty acids.saturated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Saturated fatty acids [Moles/volume] in Serum or Plasma;Sat FA SerPl-sCnc;;ACTIVE;2.11;2.73 +35176-7;Fatty acids.monounsaturated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Monounsaturated fatty acids [Moles/volume] in Serum or Plasma;Monounsat FA SerPl-sCnc;;ACTIVE;2.11;2.73 +35177-5;Fatty acids.polyunsaturated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Polyunsaturated fatty acids [Moles/volume] in Serum or Plasma;Polyunsat FA SerPl-sCnc;;ACTIVE;2.11;2.73 +35178-3;Fatty acids.omega 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Omega 3 fatty acids (w3) [Moles/volume] in Serum or Plasma;w3 FA SerPl-sCnc;;ACTIVE;2.11;2.73 +35179-1;Fatty acids.omega 6;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Omega 6 fatty acids (w6) [Moles/volume] in Serum or Plasma;w6 FA SerPl-sCnc;;ACTIVE;2.11;2.73 +35180-9;Docosapentaenate w3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosapentaenate (C22:5w3) [Moles/volume] in Serum or Plasma;DPA SerPl-sCnc;;ACTIVE;2.11;2.73 +35181-7;Docosapentaenate w6;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosapentaenate (C22:5w6) [Moles/volume] in Serum or Plasma;Docosapentaenate w6 SerPl-sCnc;;ACTIVE;2.11;2.73 +35182-5;Docosatetraenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosatetraenoate (C22:4w6) [Moles/volume] in Serum or Plasma;Docosatetraenoate SerPl-sCnc;;ACTIVE;2.11;2.73 +35183-3;Hemoglobin;MSCnc;Pt;Plas;Qn;;HEM/BC;1;Hemoglobin [Mass or Moles/volume] in Plasma;Hgb Plas-msCnc;;DISCOURAGED;2.11;2.42 +35184-1;Glucose^post CFst;MSCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fasting glucose [Mass or Moles/volume] in Serum or Plasma;Glucose p fast SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35185-8;Aldosterone;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aldosterone [Mass or Moles/volume] in Serum or Plasma;Aldost SerPl-msCnc;;DISCOURAGED;2.11;2.73 +35186-6;Aldosterone;MSCnc;Pt;Urine;Qn;;CHEM;1;Aldosterone [Mass or Moles/volume] in Urine;Aldost Ur-msCnc;;DISCOURAGED;2.11;2.42 +35187-4;Aldosterone^supine;MSCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass or Moles/volume] in Serum or Plasma --supine;Aldost sup SerPl-msCnc;;DISCOURAGED;2.11;2.68 +3518-8;Cyclizine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyclizine [Mass/volume] in Serum or Plasma;Cyclizine SerPl-mCnc;;ACTIVE;1.0;2.42 +35188-2;Aldosterone^upright;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aldosterone [Mass or Moles/volume] in Serum or Plasma --upright;Aldost upr SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35189-0;Androstanolone;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstanolone [Mass or Moles/volume] in Serum or Plasma;Androstanolone SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35190-8;Androstenedione;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstenedione [Mass or Moles/volume] in Serum or Plasma;Androst SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35191-6;Bilirubin.glucuronidated+Bilirubin.albumin bound;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.direct [Mass or Moles/volume] in Serum or Plasma;Bilirub Direct SerPl-msCnc;;DISCOURAGED;2.11;2.73 +35192-4;Bilirubin.non-glucuronidated;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.indirect [Mass or Moles/volume] in Serum or Plasma;Bilirub Indirect SerPl-msCnc;;DISCOURAGED;2.11;2.73 +35193-2;Bilirubin;MSCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.total [Mass or Moles/volume] in Body fluid;Bilirub Fld-msCnc;;DISCOURAGED;2.11;2.42 +35194-0;Bilirubin;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.total [Mass or Moles/volume] in Serum or Plasma;Bilirub SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35195-7;C peptide;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;C peptide [Mass or Moles/volume] in Serum or Plasma;C peptide SerPl-msCnc;;DISCOURAGED;2.11;2.42 +3519-6;cycloSERINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cycloSERINE [Mass/volume] in Serum or Plasma;cycloSERINE SerPl-mCnc;;ACTIVE;1.0;2.73 +35196-5;Calcidiol;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;25-hydroxyvitamin D3 [Mass or Moles/volume] in Serum or Plasma;25(OH)D3 SerPl-msCnc;;DISCOURAGED;2.11;2.68 +35197-3;Cholesterol.in HDL;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL [Mass or Moles/volume] in Serum or Plasma;HDLc SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35198-1;Cholesterol.in LDL;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL [Mass or Moles/volume] in Serum or Plasma;LDLc SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35199-9;Cholesterol.in VLDL;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL [Mass or Moles/volume] in Serum or Plasma;VLDLc SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35200-5;Cholesterol;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol [Mass or Moles/volume] in Serum or Plasma;Cholest SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35201-3;Cobalamins;MSCnc;Pt;Ser;Qn;;CHEM;1;Cobalamin (Vitamin B12) [Mass or Moles/volume] in Serum;Vit B12 Ser-msCnc;;DISCOURAGED;2.11;2.42 +35202-1;Cortisol;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass or Moles/volume] in Serum or Plasma;Cortis SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35203-9;Creatinine;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass or Moles/volume] in Serum or Plasma;Creat SerPl-msCnc;;DISCOURAGED;2.11;2.73 +3520-4;cycloSPORINE;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood;cycloSPORINE Bld-mCnc;;ACTIVE;1.0;2.73 +35204-7;Creatinine;MSCnc;Pt;Urine;Qn;;CHEM;1;Creatinine [Mass or Moles/volume] in Urine;Creat Ur-msCnc;;DISCOURAGED;2.11;2.42 +35205-4;Dehydroepiandrosterone sulfate;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass or Moles/volume] in Serum or Plasma;DHEA-S SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35206-2;Dehydroepiandrosterone;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Mass or Moles/volume] in Serum or Plasma;DHEA SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35207-0;Estradiol;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estradiol (E2) [Mass or Moles/volume] in Serum or Plasma;Estradiol SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35208-8;Estrone;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrone (E1) [Mass or Moles/volume] in Serum or Plasma;Estrone SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35209-6;Ferritin;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ferritin [Mass or Moles/volume] in Serum or Plasma;Ferritin SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35210-4;Folate;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Folate [Mass or Moles/volume] in Serum or Plasma;Folate SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35211-2;Glucose;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass or Moles/volume] in Serum or Plasma;Glucose SerPl-msCnc;;DISCOURAGED;2.11;2.42 +3521-2;cycloSPORINE;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Serum;cycloSPORINE Ser-mCnc;;DISCOURAGED;1.0;2.73 +35212-0;Glucose;MSCnc;Pt;Urine;Qn;;CHEM;1;Glucose [Mass or Moles/volume] in Urine;Glucose Ur-msCnc;;DISCOURAGED;2.11;2.42 +35213-8;Insulin-like growth factor-I;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor-I [Mass or Moles/volume] in Serum or Plasma;IGF-I SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35214-6;Iron;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass or Moles/volume] in Serum or Plasma;Iron SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35215-3;Iron binding capacity;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron binding capacity [Mass or Moles/volume] in Serum or Plasma;TIBC SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35216-1;Iron binding capacity.unsaturated;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron binding capacity.unsaturated [Mass or Moles/volume] in Serum or Plasma;UIBC SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35217-9;Triglyceride;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride [Mass or Moles/volume] in Serum or Plasma;Trigl SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35218-7;Osteocalcin;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Osteocalcin [Mass or Moles/volume] in Serum or Plasma;Osteocalcin SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35219-5;Parathyrin.intact;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.intact [Mass or Moles/volume] in Serum or Plasma;PTH-Intact SerPl-msCnc;;DISCOURAGED;2.11;2.42 +3522-0;cycloSPORINE+Metabolites;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE+Metabolites [Mass/volume] in Blood;cycloSPORINE+Metab Bld-mCnc;;ACTIVE;1.0;2.73 +35220-3;Phosphate;MSCnc;Pt;Dial fld;Qn;;CHEM;1;Phosphate [Mass or Moles/volume] in Dialysis fluid;Phosphate Dial fld-msCnc;;DISCOURAGED;2.11;2.42 +35221-1;Phosphate;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphate [Mass or Moles/volume] in Serum or Plasma;Phosphate SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35222-9;Phosphate;MSCnc;Pt;Urine;Qn;;CHEM;1;Phosphate [Mass or Moles/volume] in Urine;Phosphate Ur-msCnc;;DISCOURAGED;2.11;2.42 +35223-7;Progesterone;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Progesterone [Mass or Moles/volume] in Serum or Plasma;Progest SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35224-5;Testosterone;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone [Mass or Moles/volume] in Serum or Plasma;Testost SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35225-2;Testosterone.free;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone Free [Mass or Moles/volume] in Serum or Plasma;Testost Free SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35226-0;Thyroxine;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4) [Mass or Moles/volume] in Serum or Plasma;T4 SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35227-8;Thyroxine binding globulin;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine binding globulin [Mass or Moles/volume] in Serum or Plasma;T4BG SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35228-6;Thyroxine.free;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyroxine (T4) free [Mass or Moles/volume] in Serum or Plasma;T4 Free SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35229-4;Transferrin;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin [Mass or Moles/volume] in Serum or Plasma;Transferrin SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35230-2;Triiodothyronine.free;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3) Free [Mass or Moles/volume] in Serum or Plasma;T3Free SerPl-msCnc;;DISCOURAGED;2.11;2.73 +35231-0;Triiodothyronine;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3) [Mass or Moles/volume] in Serum or Plasma;T3 SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35232-8;Urate;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urate [Mass or Moles/volume] in Serum or Plasma;Urate SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35233-6;Urate;MSCnc;Pt;Urine;Qn;;CHEM;1;Urate [Mass or Moles/volume] in Urine;Urate Ur-msCnc;;DISCOURAGED;2.11;2.42 +35234-4;Urea nitrogen;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass or Moles/volume] in Serum or Plasma;BUN SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35235-1;Urea nitrogen;MSCnc;Pt;Urine;Qn;;CHEM;1;Urea nitrogen [Mass or Moles/volume] in Urine;UUN Ur-msCnc;;DISCOURAGED;2.11;2.42 +35236-9;Urobilinogen;MSCnc;Pt;Urine;Qn;;CHEM;1;Urobilinogen [Mass or Moles/volume] in Urine;Urobilinogen Ur-msCnc;;DISCOURAGED;2.11;2.42 +35237-7;carBAMazepine;MSCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine [Mass or Moles/volume] in Serum or Plasma;carBAMazepine SerPl-msCnc;;DISCOURAGED;2.11;2.42 +3523-8;cycloSPORINE^12H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --12 hours post dose;cycloSPORINE 12h p Bld-mCnc;;ACTIVE;1.0;2.73 +35238-5;Theophylline;MSCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline [Mass or Moles/volume] in Serum or Plasma;Theophylline SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35239-3;Tobramycin^trough;MSCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass or Moles/volume] in Serum or Plasma --trough;Tobramycin Trough SerPl-msCnc;;DISCOURAGED;2.11;2.73 +35240-1;Ethanol;MSCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethanol [Mass or Moles/volume] in Serum or Plasma;Ethanol SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35241-9;Urea nitrogen;MSCnc;Pt;Dial fld;Qn;;CHEM;1;Urea nitrogen [Mass or Moles/volume] in Dialysis fluid;Urea nit Dial fld-msCnc;;DISCOURAGED;2.11;2.42 +35242-7;Creatinine;MSCnc;Pt;Dial fld;Qn;;CHEM;1;Creatinine [Mass or Moles/volume] in Dialysis fluid;Creat Dial fld-msCnc;;DISCOURAGED;2.11;2.42 +35243-5;Cholesterol.in HDL 3;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 3 [Mass or Moles/volume] in Serum or Plasma;HDL3c SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35244-3;Digoxin;MSCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digoxin [Mass or Moles/volume] in Serum or Plasma;Digoxin SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35245-0;Lactate;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactate [Mass or Moles/volume] in Serum or Plasma;Lactate SerPl-msCnc;;DISCOURAGED;2.11;2.42 +3524-6;cycloSPORINE^12H post dose;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Serum --12 hours post dose;cycloSPORINE 12h p Ser-mCnc;;DISCOURAGED;1.0;2.66 +35246-8;Calcium;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Mass or Moles/volume] in Serum or Plasma;Calcium SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35247-6;Calcium;MSCnc;Pt;Urine;Qn;;CHEM;1;Calcium [Mass or Moles/volume] in Urine;Calcium Ur-msCnc;;DISCOURAGED;2.11;2.42 +35248-4;Calcium;MSCnc;24H;Urine;Qn;;CHEM;1;Calcium [Mass or Moles/volume] in 24 hour Urine;Calcium 24h Ur-msCnc;;DISCOURAGED;2.11;2.42 +35249-2;Magnesium;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Magnesium [Mass or Moles/volume] in Serum or Plasma;Magnesium SerPl-msCnc;;DISCOURAGED;2.11;2.42 +352-5;Nalidixate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Nalidixate [Susceptibility] by Disk diffusion (KB);Nalidixate Islt KB;;ACTIVE;1.0;2.73 +35250-0;Magnesium;MSCnc;Pt;Urine;Qn;;CHEM;1;Magnesium [Mass or Moles/volume] in Urine;Magnesium Ur-msCnc;;DISCOURAGED;2.11;2.42 +35251-8;Creatinine;MSCnc;24H;Urine;Qn;;CHEM;1;Creatinine [Mass or Moles/volume] in 24 hour Urine;Creat 24h Ur-msCnc;;DISCOURAGED;2.11;2.42 +35252-6;Magnesium;MSCnc;24H;Urine;Qn;;CHEM;1;Magnesium [Mass or Moles/volume] in 24 hour Urine;Magnesium 24h Ur-msCnc;;DISCOURAGED;2.11;2.42 +3525-3;cycloSPORINE^24H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --24 hours post dose;cycloSPORINE 24h p Bld-mCnc;;ACTIVE;1.0;2.66 +35253-4;Urate;MSCnc;24H;Urine;Qn;;CHEM;1;Urate [Mass or Moles/volume] in 24 hour Urine;Urate 24h Ur-msCnc;;DISCOURAGED;2.11;2.42 +35254-2;Ammonia;MSCnc;Pt;Plas;Qn;;CHEM;1;Ammonia [Mass or Moles/volume] in Plasma;Ammonia Plas-msCnc;;DISCOURAGED;2.11;2.73 +35255-9;Beta hydroxybutyrate;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta hydroxybutyrate [Mass or Moles/volume] in Serum or Plasma;B-OH-Butyr SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35256-7;Iron;MSCnc;24H;Urine;Qn;;CHEM;1;Iron [Mass or Moles/volume] in 24 hour Urine;Iron 24h Ur-msCnc;;DISCOURAGED;2.11;2.42 +35257-5;Natriuretic peptide.B;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Natriuretic peptide B [Mass or Moles/volume] in Serum or Plasma;BNP SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35258-3;Calcium^^corrected for total protein;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Mass or Moles/volume] corrected for total protein in Serum or Plasma;Calcium TP cor SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35259-1;Neopterin;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Neopterin [Mass or Moles/volume] in Serum or Plasma;Neopterin SerPl-msCnc;;DISCOURAGED;2.11;2.42 +35260-9;Histamine;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Histamine [Mass or Moles/volume] in Serum or Plasma;Histamine SerPl-msCnc;;DISCOURAGED;2.11;2.42 +3526-1;cycloSPORINE^24H post dose;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Serum --24 hours post dose;cycloSPORINE 24h p Ser-mCnc;;DISCOURAGED;1.0;2.66 +35261-7;Cortisol.free;MSCnc;24H;Urine;Qn;HPLC;CHEM;1;Cortisol Free [Mass or Moles/volume] in 24 hour Urine by HPLC;Cortis F 24h Ur HPLC-msCnc;;DISCOURAGED;2.11;2.42 +35262-5;Creatinine;MSRat;24H;Urine;Qn;;CHEM;1;Creatinine [Mass or Moles] in 24 hour Urine;Creat 24h Ur-msRate;;ACTIVE;2.11;2.73 +35263-3;Phosphate;MSRat;24H;Urine;Qn;;CHEM;1;Phosphate [Mass or Moles] in 24 hour Urine;Phosphate 24h Ur-msRate;;ACTIVE;2.11;2.29 +35264-1;Calcium intake;MRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calcium intake 24 hour;Calcium intake 24H-mRate;;ACTIVE;2.11;2.61 +35265-8;Path report.addendum;Find;Pt;Specimen;Nar;;PATH;1;Pathology report addendum in Specimen Narrative;Path Report.addendum Spec;;ACTIVE;2.12;2.73 +35266-6;Gleason score;Score;Pt;Specimen;Ord;;PATH;1;Gleason score in Specimen Qualitative;Gleason Score Spec Ql;;ACTIVE;2.12;2.50 +35267-4;Age at pathology Dx;Time;Pt;^Patient;Qn;;PATH;1;Age at pathology Dx;Age @ Path Dx Time Patient;;ACTIVE;2.12;2.48 +35268-2;Mycobacterium avium subspecies paratuberculosis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Units/volume] in Serum by Immunoassay;M avium paraTB Ab Ser IA-aCnc;;ACTIVE;2.12;2.69 +35269-0;Bartonella henselae Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Bartonella henselae Ab [Presence] in Serum by Immunofluorescence;B henselae Ab Ser Ql IF;;ACTIVE;2.12;2.56 +35270-8;Candida sp Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Candida sp Ab [Presence] in Serum by Immune diffusion (ID);Candida Ab Ser Ql ID;;ACTIVE;2.12;2.73 +35271-6;Candida sp Ag;PrThr;Pt;Ser;Ord;LA;MICRO;1;Candida sp Ag [Presence] in Serum by Latex agglutination;Candida Ag Ser Ql LA;;ACTIVE;2.12;2.73 +35272-4;Centromere Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Centromere IgG Ab [Presence] in Serum;Centromere IgG Ser Ql;;ACTIVE;2.12;2.73 +35273-2;Hepatitis D virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis D virus IgG Ab [Presence] in Serum by Immunoassay;HDV IgG Ser Ql IA;;ACTIVE;2.12;2.56 +35274-0;Histone Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Histone IgG Ab [Presence] in Serum by Immunoassay;Histone IgG Ser Ql IA;;ACTIVE;2.12;2.73 +35275-7;Measles virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Measles virus IgG Ab [Presence] in Serum by Immunoassay;MeV IgG Ser Ql IA;;ACTIVE;2.12;2.73 +35276-5;Measles virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Measles virus IgM Ab [Presence] in Serum by Immunoassay;MeV IgM Ser Ql IA;;ACTIVE;2.12;2.56 +35277-3;Myocardium Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Myocardium IgG Ab [Presence] in Serum;Myocardium IgG Ser Ql;;ACTIVE;2.12;2.73 +35278-1;Neuronal nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Neuronal nuclear Ab [Presence] in Serum by Immunoblot;Hu Ab Ser Ql IB;;ACTIVE;2.12;2.73 +3527-9;Dantron;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dantron [Mass/volume] in Urine;Dantron Ur-mCnc;;ACTIVE;1.0;2.73 +35279-9;Neutrophil cytoplasmic Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil cytoplasmic Ab [Presence] in Serum by Immunofluorescence;ANCA Ab Ser Ql IF;;ACTIVE;2.12;2.73 +35280-7;Tissue transglutaminase Ab.IgA;PrThr;Pt;Ser;Ord;IA;SERO;1;Tissue transglutaminase IgA Ab [Presence] in Serum by Immunoassay;tTG IgA Ser Ql IA;;ACTIVE;2.12;2.73 +35281-5;Toxoplasma gondii Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Serum by Immunofluorescence;T gondii IgG Ser Ql IF;;ACTIVE;2.12;2.56 +35282-3;Toxoplasma gondii Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Toxoplasma gondii IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;T gondii IgM SerPl Ql IF;;ACTIVE;2.12;2.73 +35283-1;Hepatitis D virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis D virus IgG Ab [Presence] in Serum;HDV IgG Ser Ql;;ACTIVE;2.12;2.56 +35284-9;Histone Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Histone IgG Ab [Presence] in Serum;Histone IgG Ser Ql;;ACTIVE;2.12;2.56 +35285-6;Tissue transglutaminase Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Tissue transglutaminase IgA Ab [Presence] in Serum;tTG IgA Ser Ql;;ACTIVE;2.12;2.73 +35286-4;Adverse event following prior vaccination;Cmplx;Pt;Sibling;Set;;VACCIN;2;Adverse event following prior vaccination [Complex] Sibling Set;AE p vaccine Sib;;ACTIVE;2.12;2.27 +3528-7;Tetrahydrocannabinol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Serum or Plasma;THC SerPl-mCnc;;ACTIVE;1.0;2.73 +35287-2;Toxoplasma gondii HS Ab;ACnc;Pt;Ser;Qn;Aggl;MICRO;1;Toxoplasma gondii HS Ab [Units/volume] in Serum by Agglutination;T gondii HS Ab Ser Aggl-aCnc;;ACTIVE;2.13;2.70 +35288-0;MEN1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MEN1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MEN1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35289-8;Peroxide hemolysis;NFr;Pt;RBC;Qn;;HEM/BC;1;Peroxide hemolysis of Red Blood Cells;Peroxide hemolysis NFr RBC;;ACTIVE;2.13;2.70 +35290-6;RPS6KA3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RPS6KA3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;RPS6KA3 gene Mut Anl Bld/T;;ACTIVE;2.13;2.68 +35291-4;UBE3A gene targeted mutation analysis;Prid;Pt;Bld;Nom;Molgen;MOLPATH.MUT;1;UBE3A gene mutations found [Identifier] in Blood by Molecular genetics method Nominal;UBE3A gene Mut Anl Bld;;ACTIVE;2.13;2.63 +35292-2;Chromosome 11 uniparental disomy;Arb;Pt;Bld/Tiss;Ord;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 11 uniparental disomy [Presence] in Blood or Tissue by Cytogenetics;Chr 11 UpDi Bld/T Ql;;ACTIVE;2.13;2.66 +35293-0;TYR gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TYR gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TYR gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +35294-8;PYGM gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PYGM gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PYGM gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +3529-5;Tetrahydrocannabinol;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Tetrahydrocannabinol [Presence] in Urine;Deprecated THC Ur Ql;;DEPRECATED;1.0;2.36 +35295-5;BTK gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BTK gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BTK gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35296-3;PAX3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PAX3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PAX3 gene Mut Anl Bld/T;;ACTIVE;2.13;2.63 +35297-1;LMNA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LMNA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;LMNA gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35298-9;FXN gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FXN gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FXN gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35299-7;PSEN1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PSEN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PSEN1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.63 +35300-3;GJB2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GJB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GJB2 gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35301-1;Transferrin.carbohydrate deficient.asialo;PrThr;Pt;CSF;Ord;;CHEM;1;Transferrin.carbohydrate deficient.asialo [Presence] in Cerebral spinal fluid;CDT Asialo CSF Ql;;ACTIVE;2.13;2.56 +35302-9;HYAL1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HYAL1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HYAL1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.63 +3530-3;Tetrahydrocannabinol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Urine;THC Ur-mCnc;;ACTIVE;1.0;2.73 +35303-7;Glucosylceramidase;CCnt;Pt;XXX;Qn;;CHEM;1;Glucosylceramidase [Enzymatic activity/mass] in Specimen;Glucosylceramidase Spec-cCnt;;ACTIVE;2.13;2.73 +35304-5;CLA2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CLA2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CLA2 gene Mut Anl Bld/T;;ACTIVE;2.13;2.63 +35305-2;Toxoplasma gondii AC Ab;ACnc;Pt;Ser;Qn;Aggl;MICRO;1;Toxoplasma gondii AC Ab [Units/volume] in Serum by Agglutination;T gondii AC Ab Ser Aggl-aCnc;;ACTIVE;2.13;2.70 +35306-0;TTR gene allele 2;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TTR gene allele 2 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TTR allele2 Bld/T;;ACTIVE;2.13;2.73 +35307-8;TTR gene allele 1;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TTR gene allele 1 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TTR allele1 Bld/T;;ACTIVE;2.13;2.73 +35308-6;Trypsin^5th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Trypsin [Enzymatic activity/volume] in Body fluid --5th specimen post Sincalide;Trypsin sp5 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35309-4;Trypsin^4th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Trypsin [Enzymatic activity/volume] in Body fluid --4th specimen post Sincalide;Trypsin sp4 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35310-2;Trypsin^3rd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Trypsin [Enzymatic activity/volume] in Body fluid --3rd specimen post Sincalide;Trypsin sp3 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +3531-1;Desipramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desipramine [Mass/volume] in Serum or Plasma;Desipramine SerPl-mCnc;;ACTIVE;1.0;2.73 +35311-0;Trypsin^2nd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Trypsin [Enzymatic activity/volume] in Body fluid --2nd specimen post Sincalide;Trypsin sp2 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35312-8;Trypsin^1st specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Trypsin [Enzymatic activity/volume] in Body fluid --1st specimen post Sincalide;Trypsin sp1 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35313-6;Triacylglycerol lipase^5th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Lipase [Enzymatic activity/volume] in Body fluid --5th specimen post Sincalide;Lipase sp5 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35314-4;Triacylglycerol lipase^4th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Lipase [Enzymatic activity/volume] in Body fluid --4th specimen post Sincalide;Lipase sp4 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35315-1;Triacylglycerol lipase^3rd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Lipase [Enzymatic activity/volume] in Body fluid --3rd specimen post Sincalide;Lipase sp3 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35316-9;Triacylglycerol lipase^2nd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Lipase [Enzymatic activity/volume] in Body fluid --2nd specimen post Sincalide;Lipase sp2 p sincalide Fld-cCnc;;ACTIVE;2.13;2.73 +35317-7;Thermoactinomyces vulgaris 1 Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Thermoactinomyces vulgaris 1 Ab [Presence] in Serum by Immune diffusion (ID);T vulgaris1 Ab Ser Ql ID;;ACTIVE;2.13;2.73 +35318-5;Laceyella sacchari Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Laceyella sacchari Ab [Presence] in Serum by Immune diffusion (ID);Laceyella sacchari Ab Ser Ql ID;;ACTIVE;2.13;2.74 +35319-3;Protein^5th specimen post dose sincalide;MCnc;Pt;Body fld;Qn;;CHAL;1;Protein [Mass/volume] in Body fluid --5th specimen post Sincalide;Prot sp5 p sincalide Fld-mCnc;;ACTIVE;2.13;2.73 +35320-1;Protein^4th specimen post dose sincalide;MCnc;Pt;Body fld;Qn;;CHAL;1;Protein [Mass/volume] in Body fluid --4th specimen post Sincalide;Prot sp4 p sincalide Fld-mCnc;;ACTIVE;2.13;2.42 +35321-9;Protein^3rd specimen post dose sincalide;MCnc;Pt;Body fld;Qn;;CHAL;1;Protein [Mass/volume] in Body fluid --3rd specimen post Sincalide;Prot sp3 p sincalide Fld-mCnc;;ACTIVE;2.13;2.42 +35322-7;Protein^2nd specimen post dose sincalide;MCnc;Pt;Body fld;Qn;;CHAL;1;Protein [Mass/volume] in Body fluid --2nd specimen post Sincalide;Prot sp2 p sincalide Fld-mCnc;;ACTIVE;2.13;2.42 +35323-5;Protein^1st specimen post dose sincalide;MCnc;Pt;Body fld;Qn;;CHAL;1;Protein [Mass/volume] in Body fluid --1st specimen post Sincalide;Prot sp1 p sincalide Fld-mCnc;;ACTIVE;2.13;2.42 +35324-3;PMP22 gene allele 1;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PMP22 gene allele 1 [Presence] in Blood or Tissue by Molecular genetics method;PMP22 allele1 Bld/T Ql;;ACTIVE;2.13;2.56 +35325-0;PMP22 gene allele 2;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PMP22 gene allele 2 [Presence] in Blood or Tissue by Molecular genetics method;PMP22 allele2 Bld/T Ql;;ACTIVE;2.13;2.56 +35326-8;pH^5th specimen post dose sincalide;LsCnc;Pt;Body fld;Qn;;CHAL;1;pH of Body fluid--5th specimen post Sincalide;pH sp5 p sincalide Fld;;ACTIVE;2.13;2.42 +35327-6;pH^4th specimen post dose sincalide;LsCnc;Pt;Body fld;Qn;;CHAL;1;pH of Body fluid--4th specimen post Sincalide;pH sp4 p sincalide Fld;;ACTIVE;2.13;2.42 +35328-4;pH^3rd specimen post dose sincalide;LsCnc;Pt;Body fld;Qn;;CHAL;1;pH of Body fluid--3rd specimen post Sincalide;pH sp3 p sincalide Fld;;ACTIVE;2.13;2.42 +3532-9;Desipramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Desipramine [Presence] in Serum or Plasma;Desipramine SerPl Ql;;ACTIVE;1.0;2.73 +35329-2;pH^2nd specimen post dose sincalide;LsCnc;Pt;Body fld;Qn;;CHAL;1;pH of Body fluid--2nd specimen post Sincalide;pH sp2 p sincalide Fld;;ACTIVE;2.13;2.42 +353-3;Nalidixate;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Nalidixate [Susceptibility] by Serum bactericidal titer;Nalidixate Titr SBT;;ACTIVE;1.0;2.32 +35330-0;pH^1st specimen post dose sincalide;LsCnc;Pt;Body fld;Qn;;CHAL;1;pH of Body fluid--1st specimen post Sincalide;pH sp1 p sincalide Fld;;ACTIVE;2.13;2.42 +35331-8;OXcarbazepine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OXcarbazepine [Mass/volume] in Serum or Plasma;OXcarbazepine SerPl-mCnc;;ACTIVE;2.13;2.73 +35332-6;Neutrophils.band form/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Band form neutrophils/100 leukocytes in Blood by Automated count;Neuts Band/leuk NFr Bld Auto;;ACTIVE;2.13;2.73 +35333-4;Jo-1 extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA Jo1 Ab Ser IA-aCnc;;ACTIVE;2.13;2.73 +35334-2;Collagen crosslinked N-telopeptide;SCnc;24H;Urine;Qn;;CHEM;1;Collagen crosslinked N-telopeptide [Moles/volume] in 24 hour Urine;Collagen NTx 24h Ur-sCnc;;ACTIVE;2.13;2.73 +35335-9;Chymotrypsin^5th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Chymotrypsin [Enzymatic activity/volume] in Body fluid --5th specimen post Sincalide;Chymotryp sp5 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35336-7;Chymotrypsin^4th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Chymotrypsin [Enzymatic activity/volume] in Body fluid --4th specimen post Sincalide;Chymotryp sp4 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +3533-7;Desipramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Desipramine [Presence] in Urine;Desipramine Ur Ql;;ACTIVE;1.0;2.73 +35337-5;Chymotrypsin^3rd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Chymotrypsin [Enzymatic activity/volume] in Body fluid --3rd specimen post Sincalide;Chymotryp sp3 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35338-3;Chymotrypsin^2nd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Chymotrypsin [Enzymatic activity/volume] in Body fluid --2nd specimen post Sincalide;Chymotryp sp2 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35339-1;Chymotrypsin^1st specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Chymotrypsin [Enzymatic activity/volume] in Body fluid --1st specimen post Sincalide;Chymotryp sp1 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35340-9;ASPA gene.p.Tyr231Ter;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ASPA gene p.Tyr231Ter [Presence] in Blood or Tissue by Molecular genetics method;ASPA p.Y231X Bld/T Ql;;ACTIVE;2.13;2.56 +35341-7;ASPA gene.p.Ala305Glu;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ASPA gene p.Ala305Glu [Presence] in Blood or Tissue by Molecular genetics method;ASPA p.A305E Bld/T Ql;;ACTIVE;2.13;2.56 +35342-5;Amylase^5th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Body fluid --5th specimen post Sincalide;Amylase sp5 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35343-3;Amylase^4th specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Body fluid --4th specimen post Sincalide;Amylase sp4 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35344-1;Amylase^3rd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Body fluid --3rd specimen post Sincalide;Amylase sp3 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +3534-5;Desipramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Desipramine [Mass/volume] in Urine;Desipramine Ur-mCnc;;ACTIVE;1.0;2.73 +35345-8;Amylase^2nd specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Body fluid --2nd specimen post Sincalide;Amylase sp2 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35346-6;Amylase^1st specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Body fluid --1st specimen post Sincalide;Amylase sp1 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35347-4;Microscopic observation;Prid;Pt;XXX;Nom;IF;MICRO;1;Microscopic observation [Identifier] in Specimen by Immunofluorescence;IF Spec;;ACTIVE;2.13;2.73 +35348-2;Corynebacterium diphtheriae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae Ab [Titer] in Serum;C diphtheriae Ab Titr Ser;;ACTIVE;2.13;2.30 +35349-0;Taenia solium larva Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;Taenia solium larva Ab [Presence] in Cerebral spinal fluid by Immunoblot;T sol lar Ab CSF Ql IB;;ACTIVE;2.13;2.58 +35350-8;NAACCR survival to last contact (in months);Time;Pt;^Patient;Qn;;TUMRRGT;2;NAACCR survival to last contact (in months) [Time];NAACCR survi to last contact (in months);;ACTIVE;2.13;2.73 +35351-6;Myotonic dystrophy gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Myotonic dystrophy gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MMD gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +3535-2;Desipramine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desipramine [Mass/volume] in Serum or Plasma --trough;Desipramine Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +35352-4;Mycobacterium tuberculosis genotype;Prid;Pt;Isolate;Nom;;MICRO;1;Mycobacterium tuberculosis genotype [Identifier] in Isolate;M tb Gentyp Islt;;ACTIVE;2.13;2.72 +35353-2;FSHD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FSHD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FSHD gene Mut Anl Bld/T;;ACTIVE;2.13;2.68 +35354-0;COL1A1+COL1A2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COL1A1+COL1A2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;COL1A1+1A2 gene Mut Anl Bld/T;;ACTIVE;2.13;2.63 +35355-7;PABPN1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PABPN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PABPN1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.63 +35356-5;TWIST1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TWIST1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TWIST1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +35357-3;PEO gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PEO gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PEO gene Mut Anl Bld/T;;ACTIVE;2.13;2.63 +35358-1;LHON syndrome gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LHON syndrome gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LHON Syn gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +35359-9;AR gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AR gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;AR gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +3536-0;Norclomipramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norclomipramine [Mass/volume] in Serum or Plasma;Norclomipramine SerPl-mCnc;;ACTIVE;1.0;2.73 +35360-7;Triglyceride.in lipoprotein (little a);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride in Lipoprotein a [Mass/volume] in Serum or Plasma;Lpa Trigl SerPl-mCnc;;ACTIVE;2.13;2.34 +35361-5;Triglyceride.in lipoprotein (little a);PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Triglyceride in Lipoprotein a [Presence] in Serum or Plasma;Lpa Trigl SerPl Ql;;ACTIVE;2.13;2.56 +35362-3;Triglyceride.in chylomicrons;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Triglyceride in Chylomicrons [Presence] in Serum or Plasma;Trig in Chylo SerPl Ql;;ACTIVE;2.13;2.56 +35363-1;Triglyceride.in chylomicrons;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride in Chylomicrons [Mass/volume] in Serum or Plasma;Trig in Chylo SerPl-mCnc;;ACTIVE;2.13;2.73 +35364-9;Triacylglycerol lipase^1st specimen post dose sincalide;CCnc;Pt;Body fld;Qn;;CHAL;1;Lipase [Enzymatic activity/volume] in Body fluid --1st specimen post Sincalide;Lipase sp1 p sincalide Fld-cCnc;;ACTIVE;2.13;2.68 +35365-6;Vitamin D+Metabolites;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vitamin D+Metabolites [Mass/volume] in Serum or Plasma;Vit D+metab SerPl-mCnc;;ACTIVE;2.13;2.73 +35366-4;SCA2 gene allele 2.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA2 gene allele 2 CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA2 allele2 CAG Rpt Bld/T Ql;;ACTIVE;2.13;2.56 +35367-2;SCA2 gene allele 1.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA2 gene allele 1 CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA2 allele1 CAG Rpt Bld/T Ql;;ACTIVE;2.13;2.56 +35368-0;SCA1 gene allele 2.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA1 gene allele 2 CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA1 allele2 CAG Rpt Bld/T Ql;;ACTIVE;2.13;2.56 +35369-8;SCA1 gene allele 1.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA1 gene allele 1 CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA1 allele1 CAG Rpt Bld/T Ql;;ACTIVE;2.13;2.56 +35370-6;GBA gene.g.S84GG;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated GBA gene.g.S84GG [Presence] in Blood or Tissue by Molecular genetics method;Deprecated GBA g.S84GG Bld/T Ql;;DEPRECATED;2.13;2.40 +35371-4;GBA gene.g.N370S;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated GBA gene.g.N370S [Presence] in Blood or Tissue by Molecular genetics method;Deprecated GBA g.N370S Bld/T Ql;;DEPRECATED;2.13;2.40 +35372-2;GBA gene.p.Leu444Pro;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;GBA gene p.Leu444Pro [Presence] in Blood or Tissue by Molecular genetics method;GBA p.L444P Bld/T Ql;;ACTIVE;2.13;2.56 +35373-0;Platelet aggregation.XXX induced;RelACnc;Pt;PRP^Donor;Qn;;COAG;1;Platelet aggregation XXX induced in Platelet rich plasma from Donor;PA XXX PRP Donr;;ACTIVE;2.13;2.54 +35374-8;DMPK gene allele 2.CTG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;DMPK gene allele 2 CTG repeats [Presence] in Blood or Tissue by Molecular genetics method;DMPK allele2 CTG Rpt Bld/T Ql;;ACTIVE;2.13;2.64 +35375-5;DMPK gene allele 1.CTG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;DMPK gene allele 1 CTG repeats [Presence] in Blood or Tissue by Molecular genetics method;DMPK allele1 CTG Rpt Bld/T Ql;;ACTIVE;2.13;2.64 +35376-3;MJD gene allele 2.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;MJD gene allele 2 CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;MJD allele2 CAG Rpt Bld/T Ql;;ACTIVE;2.13;2.56 +35377-1;MJD gene allele 1.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;MJD gene allele 1 CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;MJD allele1 CAG Rpt Bld/T Ql;;ACTIVE;2.13;2.56 +3537-8;Nordiazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Serum or Plasma;Nordiazepam SerPl-mCnc;;ACTIVE;1.0;2.73 +35378-9;HNPCC genes mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HNPCC genes mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HNPCC genes Mut Tested Bld/T;;ACTIVE;2.13;2.54 +35379-7;HNPCC genes targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HNPCC genes mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HNPCC genes Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35380-5;HEXA gene.c.IVS7+1G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HEXA gene c.IVS7+1G>A [Presence] in Blood or Tissue by Molecular genetics method;HEXA c.IVS7+1G>A Bld/T Ql;;ACTIVE;2.13;2.56 +35381-3;HEXA gene.c.IVS12+1G>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HEXA gene c.IVS12+1G>C [Presence] in Blood or Tissue by Molecular genetics method;HEXA .c.IVS12+1G>C Bld/T Ql;;ACTIVE;2.13;2.56 +35382-1;HEXA gene.p.Gly269Ser;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HEXA gene p.Gly269Ser [Presence] in Blood or Tissue by Molecular genetics method;HEXA p.G269S Bld/T Ql;;ACTIVE;2.13;2.56 +35383-9;Galactomannan Ag;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Galactomannan Ag [Units/volume] in Serum or Plasma;Galactomannan Ag SerPl-aCnc;;ACTIVE;2.13;2.73 +35384-7;Estradiol;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method;Estradiol SerPl HS-mCnc;;ACTIVE;2.13;2.73 +35385-4;CV2 Ab.IgG;Titr;Pt;CSF;Qn;;SERO;1;CV2 IgG Ab [Titer] in Cerebral spinal fluid;CV2 IgG Titr CSF;;ACTIVE;2.13;2.73 +3538-6;Dextromethorphan;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Dextromethorphan [Presence] in Serum or Plasma;D-methorphan SerPl Ql;;ACTIVE;1.0;2.56 +35386-2;CV2 Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;CV2 IgG Ab [Titer] in Serum;CV2 IgG Titr Ser;;ACTIVE;2.13;2.73 +35387-0;Cholesterol.in lipoprotein (little a);PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cholesterol. in Lipoprotein (a) [Presence] in Serum or Plasma;Lpa Cholest SerPl Ql;;ACTIVE;2.13;2.73 +35388-8;Cholesterol.in lipoprotein (little a);MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol. in Lipoprotein (a) [Mass/volume] in Serum or Plasma;Lpa Cholest SerPl-mCnc;;ACTIVE;2.13;2.73 +35389-6;Cholesterol.in chylomicrons;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cholesterol.in chylomicrons [Presence] in Serum or Plasma;Cholest in Chylo SerPl Ql;;ACTIVE;2.13;2.56 +35390-4;Vaccinia virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Vaccinia virus DNA [Presence] in Specimen by NAA with probe detection;VACV DNA Spec Ql NAA+probe;;ACTIVE;2.13;2.69 +35391-2;Taenia solium larva Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Taenia solium larva IgG Ab [Units/volume] in Cerebral spinal fluid;T sol lar IgG CSF-aCnc;;ACTIVE;2.13;2.73 +35392-0;Hantavirus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus IgG Ab [Units/volume] in Serum;Hantavirus IgG Ser-aCnc;;ACTIVE;2.13;2.73 +35393-8;Hantavirus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus IgM Ab [Units/volume] in Serum;Hantavirus IgM Ser-aCnc;;ACTIVE;2.13;2.73 +3539-4;Dextromethorphan;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dextromethorphan [Presence] in Urine;D-methorphan Ur Ql;;ACTIVE;1.0;2.73 +35394-6;Legionella pneumophila 1 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 1 IgG Ab [Presence] in Serum;L pneumo1 IgG Ser Ql;;ACTIVE;2.13;2.56 +35395-3;Legionella pneumophila 1 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 1 IgM Ab [Presence] in Serum;L pneumo1 IgM Ser Ql;;ACTIVE;2.13;2.56 +35396-1;Enterovirus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Tissue by NAA with probe detection;EV RNA Tiss Ql NAA+probe;;ACTIVE;2.13;2.63 +35397-9;Epstein Barr virus DNA;PrThr;Pt;Bone mar;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Bone marrow by NAA with probe detection;EBV DNA Mar Ql NAA+probe;;ACTIVE;2.13;2.63 +35398-7;Epstein Barr virus DNA;PrThr;Pt;Mouth;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Mouth by NAA with probe detection;EBV DNA Mouth Ql NAA+probe;;ACTIVE;2.13;2.63 +35399-5;Varicella zoster virus DNA;PrThr;Pt;Eye;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Eye by NAA with probe detection;VZV DNA Eye Ql NAA+probe;;ACTIVE;2.13;2.63 +35400-1;Varicella zoster virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Tissue by NAA with probe detection;VZV DNA Tiss Ql NAA+probe;;ACTIVE;2.13;2.73 +35401-9;Cytomegalovirus DNA;PrThr;Pt;Bronchial;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Bronchial specimen by NAA with probe detection;CMV DNA Bronch Ql NAA+probe;;ACTIVE;2.13;2.63 +3540-2;Dextromoramide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dextromoramide [Presence] in Urine;D-moramide Ur Ql;;ACTIVE;1.0;2.56 +35402-7;Leishmania donovani Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania donovani IgG Ab [Presence] in Serum;L donovani IgG Ser Ql;;ACTIVE;2.13;2.56 +35403-5;Leishmania donovani Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania donovani IgM Ab [Presence] in Serum;L donovani IgM Ser Ql;;ACTIVE;2.13;2.56 +35404-3;Leishmania braziliensis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania brasilensis IgG Ab [Presence] in Serum;L braziliensis IgG Ser Ql;;ACTIVE;2.13;2.56 +35405-0;Leishmania braziliensis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania brasilensis IgM Ab [Presence] in Serum;L braziliensis IgM Ser Ql;;ACTIVE;2.13;2.56 +35406-8;Leishmania mexicana Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania mexicana IgG Ab [Presence] in Serum;L mexicana IgG Ser Ql;;ACTIVE;2.13;2.56 +35407-6;Leishmania mexicana Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania mexicana IgM Ab [Presence] in Serum;L mexicana IgM Ser Ql;;ACTIVE;2.13;2.56 +35408-4;Leishmania tropica Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania tropica IgG Ab [Presence] in Serum;L tropica IgG Ser Ql;;ACTIVE;2.13;2.56 +35409-2;Leishmania tropica Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania tropica IgM Ab [Presence] in Serum;L tropica IgM Ser Ql;;ACTIVE;2.13;2.56 +354-1;Neomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Neomycin [Susceptibility] by Minimum lethal concentration (MLC);Neomycin Islt MLC;;ACTIVE;1.0;2.19 +3541-0;Dextromoramide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dextromoramide [Mass/volume] in Urine;D-moramide Ur-mCnc;;ACTIVE;1.0;2.42 +35410-0;Pressure.continuous positive airway;Pres;Pt;Respiratory system;Qn;;PULM;2;Continuous positive airway pressure Respiratory system;CPAP Respiratory;;ACTIVE;2.13;2.73 +35411-8;Trienoate/Arachidonate;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Trienoate (C20:3w9)/Arachidonate (C20:4w6) [Molar ratio] in Serum or Plasma;Trienoate/AA SerPl-sRto;;ACTIVE;2.13;2.73 +35412-6;Chlamydia sp DNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Nose by NAA with probe detection;Chlamydia DNA Nose Ql NAA+probe;;ACTIVE;2.13;2.63 +35413-4;Coxsackievirus A4+A16 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A4+A16 Ab [Titer] in Serum;CV A4+A16 Ab Titr Ser;;ACTIVE;2.13;2.30 +35414-2;Specific gravity;Rden;Pt;Body fld;Qn;Refractometry;CHEM;1;Specific gravity of Body fluid by Refractometry;Sp Gr Fld Refractometry;;ACTIVE;2.13;2.73 +35415-9;Oxytocin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Oxytocin [Units/volume] in Serum or Plasma;Oxytocin SerPl-aCnc;;ACTIVE;2.13;2.70 +35416-7;Echinococcus granulosus Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Echinococcus granulosus Ab [Presence] in Serum by Immunoblot;E granulosus Ab Ser Ql IB;;ACTIVE;2.13;2.58 +35417-5;Herpes simplex virus identified;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Anal by Organism specific culture;HSV Anal Cult;;ACTIVE;2.13;2.13 +35418-3;Herpes simplex virus identified;Prid;Pt;Bronchial;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Bronchial specimen by Organism specific culture;HSV Bronch Cult;;ACTIVE;2.13;2.19 +35419-1;Herpes simplex virus identified;Prid;Pt;CSF;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Cerebral spinal fluid by Organism specific culture;HSV CSF Cult;;ACTIVE;2.13;2.13 +35420-9;Herpes simplex virus identified;Prid;Pt;Cvx;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Cervix by Organism specific culture;HSV Cvx Cult;;ACTIVE;2.13;2.58 +35421-7;Herpes simplex virus identified;Prid;Pt;Ear;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Ear by Organism specific culture;HSV Ear Cult;;ACTIVE;2.13;2.13 +35422-5;Herpes simplex virus identified;Prid;Pt;Body fld;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Body fluid by Organism specific culture;HSV Fld Cult;;ACTIVE;2.13;2.19 +35423-3;Herpes simplex virus identified;Prid;Pt;Vag;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Vaginal fluid by Organism specific culture;HSV Vag Cult;;ACTIVE;2.13;2.21 +35424-1;Herpes simplex virus identified;Prid;Pt;Penis;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Penis by Organism specific culture;HSV Penis Cult;;ACTIVE;2.13;2.21 +35425-8;Herpes simplex virus identified;Prid;Pt;Placenta;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Placenta by Organism specific culture;HSV Placenta Cult;;ACTIVE;2.13;2.63 +35426-6;Herpes simplex virus identified;Prid;Pt;Plr fld;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Pleural fluid by Organism specific culture;HSV Plr Cult;;ACTIVE;2.13;2.19 +35427-4;Herpes simplex virus identified;Prid;Pt;Periton fld;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Peritoneal fluid by Organism specific culture;HSV Prt Cult;;ACTIVE;2.13;2.19 +3542-8;Propoxyphene;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Propoxyphene [Presence] in Serum or Plasma;Propoxyph SerPl Ql;;ACTIVE;1.0;2.73 +35428-2;Herpes simplex virus identified;Prid;Pt;Synv fld;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Synovial fluid by Organism specific culture;HSV Snv Cult;;ACTIVE;2.13;2.19 +35429-0;Herpes simplex virus identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Stool by Organism specific culture;HSV Stl Cult;;ACTIVE;2.13;2.19 +35430-8;Herpes simplex virus identified;Prid;Pt;Thrt;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Throat by Organism specific culture;HSV Throat Cult;;ACTIVE;2.13;2.17 +35431-6;Herpes simplex virus identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Tissue by Organism specific culture;HSV Tiss Cult;;ACTIVE;2.13;2.22 +35432-4;Herpes simplex virus identified;Prid;Pt;Urine;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Urine by Organism specific culture;HSV Ur Cult;;ACTIVE;2.13;2.19 +35433-2;Herpes simplex virus identified;Prid;Pt;Urethra;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Urethra by Organism specific culture;HSV Urth Cult;;ACTIVE;2.13;2.19 +35434-0;Herpes simplex virus identified;Prid;Pt;Wound;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Wound by Organism specific culture;HSV Wnd Cult;;ACTIVE;2.13;2.19 +35435-7;Histoplasma capsulatum yeast phase Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Histoplasma capsulatum yeast phase Ab [Presence] in Serum by Complement fixation;H capsul Yst Ab Ser Ql CF;;ACTIVE;2.13;2.73 +3543-6;Propoxyphene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propoxyphene [Mass/volume] in Serum or Plasma;Propoxyph SerPl-mCnc;;ACTIVE;1.0;2.73 +35436-5;Spermatozoa^post reanastomosis;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Spermatozoa [Presence] in Semen by Light microscopy --post reanastomosis;Sperm p rev Smn Ql Micro;;ACTIVE;2.13;2.56 +35437-3;HIV 1 Ab;PrThr;Pt;Saliva;Ord;IA;MICRO;1;HIV 1 Ab [Presence] in Saliva (oral fluid) by Immunoassay;HIV1 Ab Sal Ql IA;;ACTIVE;2.13;2.56 +35438-1;HIV 1 Ab;ACnc;Pt;Saliva;Qn;IA;MICRO;1;HIV 1 Ab [Units/volume] in Saliva (oral fluid) by Immunoassay;HIV1 Ab Sal IA-aCnc;;ACTIVE;2.13;2.69 +35439-9;HIV 1 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35440-7;HIV 1 gp160 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 gp160 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 gp160 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35441-5;HIV 1 gp120 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 gp120 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 gp120 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35442-3;HIV 1 p66 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p66 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p66 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35443-1;HIV 1 p65 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p65 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p65 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +3544-4;Propoxyphene;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Propoxyphene [Presence] in Urine;Deprecated Propoxyph Ur Ql;;DEPRECATED;1.0;2.36 +35444-9;HIV 1 p55 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p55 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p55 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35445-6;HIV 1 p51 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p51 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p51 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35446-4;HIV 1 gp41 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 gp41 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 gp41 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35447-2;HIV 1 p31 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p31 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p31 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35448-0;HIV 1 p24 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p24 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p24 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35449-8;HIV 1 p17 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p17 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p17 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +35450-6;HIV 1 p18 Ab;PrThr;Pt;Saliva;Ord;IB;MICRO;1;HIV 1 p18 Ab [Presence] in Saliva (oral fluid) by Immunoblot;HIV1 p18 Ab Sal Ql IB;;ACTIVE;2.13;2.58 +3545-1;Propoxyphene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propoxyphene [Mass/volume] in Urine;Propoxyph Ur-mCnc;;ACTIVE;1.0;2.73 +35451-4;Herpes simplex virus identified;Prid;Pt;Nph;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Nasopharynx by Organism specific culture;HSV Nph Cult;;ACTIVE;2.13;2.29 +35452-2;HIV 1 gp40 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp40 Ab [Presence] in Serum by Immunoblot;HIV1 gp40 Ab Ser Ql IB;;ACTIVE;2.13;2.73 +35453-0;ARSA gene PD allele;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ARSA gene PD allele [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ARSA PD allele Bld/T;;ACTIVE;2.13;2.13 +35454-8;MLL gene rearrangements;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.REARRANGE;1;MLL gene rearrangements in Blood or Tissue by Molecular genetics method;MLL gene Rear Bld/T;;ACTIVE;2.13;2.73 +35455-5;X chromosome inactivation;Prid;Pt;Bld/Tiss;Nar;;MOLPATH;1;X chromosome inactivation [Identifier] in Blood or Tissue Narrative;X Chrom Inactivation Bld/T;;ACTIVE;2.13;2.14 +35456-3;Y chromosome deletion;Prid;Pt;Bld/Tiss;Nom;;MOLPATH.DEL;1;Y chromosome deletion [Identifier] in Blood or Tissue Nominal;Y Chrom Del Bld/T;;ACTIVE;2.13;2.73 +35457-1;Maternal cell contamination;Prid;Pt;Amnio fld;Nom;;MOLPATH;1;Maternal cell contamination [Identifier] in Amniotic fluid Nominal;Maternal Cell Contam Amn;;ACTIVE;2.13;2.73 +35458-9;Ma+Ta Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ma+Ta Ab [Presence] in Serum;Ma+Ta Ab Ser Ql;;ACTIVE;2.13;2.73 +35459-7;T cell crossmatch;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;T cell crossmatch [Interpretation];T Cell XM SerPl-Imp;;ACTIVE;2.13;2.73 +35460-5;Platelet genotype;Prid;Pt;Amnio fld;Nom;;HEM/BC;1;Platelet genotype [Identifier] in Amniotic fluid;Platelet Gentyp Amn;;ACTIVE;2.13;2.72 +35461-3;ELN gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ELN gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ELN gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35462-1;SMN1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SMN1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SMN1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35463-9;Telomere analysis;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Telomere analysis [Identifier] in Blood or Tissue Nominal;Telomere analysis Bld/T;;ACTIVE;2.13;2.13 +35464-7;CMT axonal gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CMT axonal gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CMT2 gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +35465-4;RHD gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RHD gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;RHD allele Geno Bld/T;;ACTIVE;2.13;2.73 +35466-2;AS+PWS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AS+PWS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;AS+PWS gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35467-0;M-chlorophenylpiperazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;M-chlorophenylpiperazine [Presence] in Serum or Plasma;m-CPP SerPl Ql;;ACTIVE;2.13;2.56 +35468-8;Cells.FLAER;PrThr;Pt;Bld;Ord;;CELLMARK;1;FLAER cells [Presence] in Blood;FLAER Cells Bld Ql;;ACTIVE;2.13;2.73 +3546-9;Diamorphine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Diamorphine [Presence] in Urine;DAM Ur Ql;;ACTIVE;1.0;2.56 +35469-6;Transferrin.carbohydrate deficient.disialo/Transferrin.carbohydrate deficient.tetrasialo;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.disialo/Transferrin.carbohydrate deficient.tetrasialo [Mass Ratio] in Serum or Plasma;CDT Disialo/CDT Tetrasialo SerPl;;ACTIVE;2.13;2.73 +35470-4;Mitochondria DNA deletion;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DEL;1;Mitochondria Genes deletion [Identifier] in Blood or Tissue by Molecular genetics method Nominal;mtDNA Del Bld/T;;ACTIVE;2.13;2.16 +35471-2;HLA Ab;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA Ab [Presence];HLA Ab Ql;;ACTIVE;2.13;2.73 +35472-0;HEXA gene.c.1277insTATC;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HEXA gene c.1277insTATC [Presence] in Blood or Tissue by Molecular genetics method;HEXA c.1277insTATC Bld/T Ql;;ACTIVE;2.13;2.56 +35473-8;HEXA gene 7.6kb deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;HEXA gene 7.6kb deletion [Presence] in Blood or Tissue by Molecular genetics method;HEXA 7.6kb Del Bld/T Ql;;ACTIVE;2.13;2.19 +35474-6;Gene XXX targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Gene XXX targeted mutation analysis in Blood or Tissue by Molecular genetics method;Gene XXX Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35475-3;Transferrin.carbohydrate deficient.asialo/Transferrin.carbohydrate deficient.tetrasialo;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.asialo/Transferrin.carbohydrate deficient.tetrasialo [Mass Ratio] in Serum or Plasma;CDT Asialo/CDT Tetrasialo SerPl;;ACTIVE;2.13;2.73 +35476-1;OKT3 blocking Ab;Titr;Pt;Ser/Plas;Qn;Flow cytometry;SERO;1;OKT3 blocking Ab [Titer] in Serum or Plasma by Flow cytometry (FC);OKT3 blocking Ab Titr SerPl FC;;ACTIVE;2.13;2.70 +3547-7;Diamorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Diamorphine [Mass/volume] in Urine;DAM Ur-mCnc;;ACTIVE;1.0;2.73 +35477-9;Ciliated columnar lining cells/100 leukocytes;NRto;Pt;Body fld;Qn;;HEM/BC;1;Ciliated columnar lining cells/100 leukocytes [# Ratio] in Body fluid;Cil columnar lining cells/leuk Fld;;ACTIVE;2.13;2.73 +35478-7;Cytosol aminopeptidase;CRat;24H;Urine;Qn;;CHEM;1;Cytosol aminopeptidase [Enzymatic activity/time] in 24 hour Urine;Cytosol AP 24h Ur-cRate;;ACTIVE;2.13;2.70 +35479-5;Diazinon;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Diazinon [Mass/volume] in Urine;Diazinon Ur-mCnc;;ACTIVE;2.13;2.73 +35480-3;1-Naphthol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;1-Naphthol [Mass/volume] in Urine;1Naphthol Ur-mCnc;;ACTIVE;2.13;2.73 +35481-1;Terbufos;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Terbufos [Mass/volume] in Serum or Plasma;Terbufos SerPl-mCnc;;ACTIVE;2.13;2.73 +35482-9;Para nitrophenol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Para nitrophenol [Mass/volume] in Serum or Plasma;p-nitrophenol SerPl-mCnc;;ACTIVE;2.13;2.73 +35483-7;Mevinphos;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mevinphos [Mass/volume] in Serum or Plasma;Mevinphos SerPl-mCnc;;ACTIVE;2.13;2.73 +35484-5;Methyl parathion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyl parathion [Mass/volume] in Serum or Plasma;Methyl Parathion SerPl-mCnc;;ACTIVE;2.13;2.73 +3548-5;diazePAM;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Serum or Plasma;diazePAM SerPl-mCnc;;ACTIVE;1.0;2.73 +35485-2;Metasystox;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metasystox [Mass/volume] in Serum or Plasma;Metasystox SerPl-mCnc;;ACTIVE;2.13;2.73 +35486-0;Fonofos;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fonofos [Mass/volume] in Serum or Plasma;Fonofos SerPl-mCnc;;ACTIVE;2.13;2.73 +35487-8;Fenchlorphos;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fenchlorphos [Mass/volume] in Serum or Plasma;Fenchlorphos SerPl-mCnc;;ACTIVE;2.13;2.73 +35488-6;Diazinon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diazinon [Mass/volume] in Serum or Plasma;Diazinon SerPl-mCnc;;ACTIVE;2.13;2.73 +35489-4;Chlorpyrifos;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorpyrifos [Mass/volume] in Serum or Plasma;Chlorpyrifos SerPl-mCnc;;ACTIVE;2.13;2.73 +35490-2;Azinphos-methyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Azinphos-methyl [Mass/volume] in Serum or Plasma;Azinphos-Mehyl SerPl-mCnc;;ACTIVE;2.13;2.73 +35491-0;Leptospira sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Leptospira sp DNA [Presence] in Specimen by NAA with probe detection;Leptospira DNA Spec Ql NAA+probe;;ACTIVE;2.13;2.73 +35492-8;Staphylococcus aureus.methicillin resistant DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;ABXBACT;1;Methicillin resistant Staphylococcus aureus (MRSA) DNA [Presence] in Specimen by NAA with probe detection;MRSA DNA Spec Ql NAA+probe;;ACTIVE;2.13;2.73 +3549-3;diazePAM;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;diazePAM [Presence] in Serum or Plasma;diazePAM SerPl Ql;;ACTIVE;1.0;2.73 +35493-6;Ricin;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Ricin [Presence] in Specimen;Ricin Spec Ql;;ACTIVE;2.13;2.69 +35494-4;Succinate dehydrogenase;CCnt;Pt;Tiss;Qn;;CHEM;1;Succinate dehydrogenase [Enzymatic activity/mass] in Tissue;Succinate Dehydrog Tiss-cCnt;;ACTIVE;2.13;2.42 +35495-1;Citrate synthase;CCnt;Pt;Tiss;Qn;;CHEM;1;Citrate synthase [Enzymatic activity/mass] in Tissue;Citrate Synthase Tiss-cCnt;;ACTIVE;2.13;2.42 +35496-9;NADH dehydrogenase;CCnt;Pt;Tiss;Qn;;CHEM;1;NADH dehydrogenase [Enzymatic activity/mass] in Tissue;NADH Dehydrog Tiss-cCnt;;ACTIVE;2.13;2.42 +35497-7;NADH cytochrome C reductase;CCnt;Pt;Tiss;Qn;;CHEM;1;NADH cytochrome C reductase [Enzymatic activity/mass] in Tissue;NADH CyC Reduct Tiss-cCnt;;ACTIVE;2.13;2.42 +35498-5;Succinate cytochrome C reductase;CCnt;Pt;Tiss;Qn;;CHEM;1;Succinate cytochrome C reductase [Enzymatic activity/mass] in Tissue;Succinate CyC Reduct Tiss-cCnt;;ACTIVE;2.13;2.42 +35499-3;Pesticide & Insecticide panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Pesticide and Insecticide panel [Mass/volume] - Serum or Plasma;Pest + Insect Pnl SerPl-mCnc;;ACTIVE;2.13;2.42 +35500-8;Pesticide & Insecticide panel;MCnc;Pt;Urine;Qn;;PANEL.DRUG/TOX;1;Pesticide and Insecticide panel [Mass/volume] - Urine;Pest + Insect Pnl Ur-mCnc;;ACTIVE;2.13;2.42 +3550-1;diazePAM;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;diazePAM [Presence] in Urine;diazePAM Ur Ql;;ACTIVE;1.0;2.73 +35501-6;Pesticide & Insecticide panel;MCnc;Pt;Urine+Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Pesticide and Insecticide panel [Mass/volume] - Urine and Serum or Plasma;Pest + Insect Pnl Ur+SerPl-mCnc;;ACTIVE;2.13;2.42 +35502-4;Mitochondrial myopathy enzyme panel;CCnt;Pt;Tiss;Qn;;PANEL.CHEM;1;Mitochondrial myopathy enzyme panel [Enzymatic activity/mass] - Tissue;Mito Myopathy Enzy Pnl Tiss-cCnt;;ACTIVE;2.13;2.42 +35503-2;Arterial patency^pre arterial puncture;PrThr;Pt;Wrist artery;Ord;;PULM;2;Arterial patency Wrist artery --pre arterial puncture;Arterial patency Wrist a;;ACTIVE;2.13;2.73 +35504-0;Para aminobenzoate^6H post XXX bentiromide PO;MFr;6H;Urine;Qn;;CHAL;1;Para aminobenzoate in 6 hour Urine --6 hours post XXX bentiromide PO;pABA 6h p BT PO 6h MFr Ur;;ACTIVE;2.13;2.30 +35505-7;Lipoprotein.beta.subparticle;Type;Pt;Ser/Plas;Nom;;CHEM;1;Lipoprotein.beta.subparticle [Type] in Serum or Plasma;LDL SerPl;;ACTIVE;2.13;2.73 +35506-5;Chronic lymphocytic leukemia gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Chronic lymphocytic leukemia gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CLL gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35507-3;Amino acids panel;SCnc;Pt;CSF;Qn;;PANEL.CHEM;1;Amino acids panel [Moles/volume] - Cerebral spinal fluid;Amino acids Pnl CSF-sCnc;;ACTIVE;2.13;2.68 +35508-1;Amino acids panel;SCnc;Pt;Amnio fld;Qn;;PANEL.CHEM;1;Amino acids panel [Moles/volume] - Amniotic fluid;Amino acids Pnl Amn-sCnc;;ACTIVE;2.13;2.42 +35509-9;Amino acids panel;SRat;24H;Urine;Qn;;PANEL.CHEM;1;Amino acids panel [Moles/time] - 24 hour Urine;Amino acids Pnl 24h Ur-sRate;;ACTIVE;2.13;2.73 +35510-7;General information section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol General information section;CTP General info;;ACTIVE;2.13;2.27 +35511-5;Background information section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Background information section;CTP Background info;;ACTIVE;2.13;2.27 +35512-3;Trial objectives & purpose section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Trial objectives and purpose section;CTP Trial objectives/purpose;;ACTIVE;2.13;2.38 +35513-1;Trial design section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Trial design section;CTP Trial design;;ACTIVE;2.13;2.27 +35514-9;Subject selection and withdrawal section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Subject selection and withdrawal section;CTP Sub selection/withdrawal;;ACTIVE;2.13;2.73 +35515-6;Subject participation+Epochs section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Subject participation + epochs section;CTP Sub participation/Epochs;;ACTIVE;2.13;2.27 +35516-4;Treatment of subjects+Epochs section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Treatment of subjects + epochs section;CTP Tx of subjects/epochs;;ACTIVE;2.13;2.27 +35517-2;Assessment section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Assessment section;CTP Assessment;;ACTIVE;2.13;2.27 +35518-0;Efficacy assessment section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Efficacy assessment section;CTP Efficacy assessment;;ACTIVE;2.13;2.27 +3551-9;diazePAM;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Urine;diazePAM Ur-mCnc;;ACTIVE;1.0;2.73 +35519-8;Assessment of safety section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Assessment of safety section;CTP Assessment of safety;;ACTIVE;2.13;2.27 +35520-6;Statistics section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Statistics section;CTP Statistics;;ACTIVE;2.13;2.27 +35521-4;Direct access to source data+documents section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Direct access to source data+documents section;CTP Direct access to source data+docs;;ACTIVE;2.13;2.27 +35522-2;Quality control and quality assurance section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Quality control and quality assurance section;CTP QC/QA;;ACTIVE;2.13;2.27 +35523-0;Ethics section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Ethics section;CTP Ethics;;ACTIVE;2.13;2.27 +35524-8;Data handling and record keeping section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Data handling and record keeping section;CTP Data handling & record keeping;;ACTIVE;2.13;2.27 +35525-5;Financing and insurance section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Financing and insurance section;CTP Financing/insurance;;ACTIVE;2.13;2.27 +35526-3;Publication policy section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Publication policy section;CTP Publication policy;;ACTIVE;2.13;2.27 +3552-7;diazePAM^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Serum or Plasma --trough;diazePAM Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +35527-1;Supplements section;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Supplements section;CTP Supplements;;ACTIVE;2.13;2.27 +35528-9;Clinical trial protocol.total;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Clinical trial protocol;CTP Clin trial protocol.total;;ACTIVE;2.13;2.27 +35529-7;Beef Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Beef IgG Ab [Mass/volume] in Serum;Beef IgG-mCnc;;ACTIVE;2.13;2.73 +35530-5;Candida albicans Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Candida albicans IgG Ab [Mass/volume] in Serum;C albicans IgG-mCnc;;ACTIVE;2.13;2.73 +35531-3;Saccharum officinarum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Cane IgG Ab [Mass/volume] in Serum;Sugar Cane IgG-mCnc;;ACTIVE;2.13;2.73 +35532-1;Chicken Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken IgG Ab [Mass/volume] in Serum;Chicken IgG-mCnc;;ACTIVE;2.13;2.73 +35533-9;Coffea spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Coffee IgG Ab [Mass/volume] in Serum;Coffee IgG-mCnc;;ACTIVE;2.13;2.73 +35534-7;Zea mays Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Corn IgG Ab [Mass/volume] in Serum;Corn IgG-mCnc;;ACTIVE;2.13;2.73 +3553-5;Dibenzepin;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dibenzepin [Mass/volume] in Blood;Dibenzepin Bld-mCnc;;ACTIVE;1.0;2.42 +35535-4;Egg white Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Egg white IgG Ab [Mass/volume] in Serum;Egg White IgG-mCnc;;ACTIVE;2.13;2.73 +35536-2;Egg yolk Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Egg yolk IgG Ab [Mass/volume] in Serum;Egg Yolk IgG-mCnc;;ACTIVE;2.13;2.73 +35537-0;Triticum aestivum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Wheat IgG Ab [Mass/volume] in Serum;Wheat IgG-mCnc;;ACTIVE;2.13;2.73 +35538-8;Saccharomyces cerevisiae Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast IgG Ab [Mass/volume] in Serum;Baker's yeast IgG-mCnc;;ACTIVE;2.13;2.73 +35539-6;Cow milk Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cow milk IgG Ab [Mass/volume] in Serum;Cow Milk IgG-mCnc;;ACTIVE;2.13;2.73 +35540-4;Agaricus hortensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mushroom IgG Ab [Mass/volume] in Serum;Mushroom IgG-mCnc;;ACTIVE;2.13;2.73 +35541-2;Allium cepa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Onion IgG Ab [Mass/volume] in Serum;Onion IgG-mCnc;;ACTIVE;2.13;2.73 +35542-0;Arachis hypogaea Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut IgG Ab [Mass/volume] in Serum;Peanut IgG-mCnc;;ACTIVE;2.13;2.73 +3554-3;Dibucaine number;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Dibucaine number [mass/volume] in Serum or Plasma;Deprecated Dibucaine Number Ser-mCnc;;DEPRECATED;1.0;2.40 +35543-8;Pork Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pork IgG Ab [Mass/volume] in Serum;Pork IgG-mCnc;;ACTIVE;2.13;2.73 +35544-6;Solanum tuberosum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Potato IgG Ab [Mass/volume] in Serum;Potato IgG-mCnc;;ACTIVE;2.13;2.73 +35545-3;Oryza sativa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rice IgG Ab [Mass/volume] in Serum;Rice IgG-mCnc;;ACTIVE;2.13;2.73 +35546-1;Glycine max Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Soybean IgG Ab [Mass/volume] in Serum;Soybean IgG-mCnc;;ACTIVE;2.13;2.73 +35547-9;Lycopersicon lycopersicum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tomato IgG Ab [Mass/volume] in Serum;Tomato IgG-mCnc;;ACTIVE;2.13;2.73 +35548-7;Fusarium moniliforme Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium moniliforme IgG Ab [Mass/volume] in Serum;F moniliforme IgG-mCnc;;ACTIVE;2.13;2.73 +35549-5;Mucor racemosus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mucor racemosus IgG Ab [Mass/volume] in Serum;M racemosus IgG-mCnc;;ACTIVE;2.13;2.73 +3555-0;Dichlorphenamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dichlorphenamide [Presence] in Urine;Dichlorphenamide Ur Ql;;ACTIVE;1.0;2.56 +35550-3;Phthalic anhydride Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Phthalic anhydride IgG Ab [Mass/volume] in Serum;PAN IgG-mCnc;;ACTIVE;2.13;2.73 +35551-1;Phoma betae Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Phoma betae IgG Ab [Mass/volume] in Serum;P betae IgG-mCnc;;ACTIVE;2.13;2.73 +35552-9;Rhizopus nigricans Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rhizopus nigricans IgG Ab [Mass/volume] in Serum;R nigricans IgG-mCnc;;ACTIVE;2.13;2.73 +35553-7;Stemphylium botryosum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Stemphylium botryosum IgG Ab [Mass/volume] in Serum;S botryosum IgG-mCnc;;ACTIVE;2.13;2.73 +35554-5;Chocolate Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chocolate IgG Ab [Mass/volume] in Serum;Chocolate IgG-mCnc;;ACTIVE;2.13;2.73 +35555-2;Setomelanomma rostrata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Setomelanomma rostrata IgG Ab [Mass/volume] in Serum;S rostrata IgG-mCnc;;ACTIVE;2.13;2.73 +35556-0;Trichophyton rubrum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Trichophyton rubrum IgG Ab [Mass/volume] in Serum;T rubrum IgG-mCnc;;ACTIVE;2.13;2.73 +35557-8;Cladosporium cladosporioides Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium cladosporioides IgG Ab [Mass/volume] in Serum;C cladosporioides IgG-mCnc;;ACTIVE;2.13;2.70 +35558-6;Cholinesterase panel;CCnc;Pt;Bld;Qn;;PANEL.CHEM;1;Cholinesterase panel [Enzymatic activity/volume] - Blood;Cholinesterase Pnl Bld-cCnc;;ACTIVE;2.13;2.73 +35559-4;Protein.monoclonal band 2;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis;M Protein 2 SerPl Elph-mCnc;;ACTIVE;2.13;2.73 +35560-2;Protein.monoclonal;MCnc;Pt;Urine;Qn;;CHEM;1;Protein.monoclonal [Mass/volume] in Urine;M Protein Ur-mCnc;;ACTIVE;2.13;2.73 +35561-0;Protein.monoclonal band 2;MCnc;Pt;Urine;Qn;;CHEM;1;Protein.monoclonal band 2 [Mass/volume] in Urine;M Protein 2 Ur-mCnc;;ACTIVE;2.13;2.73 +35562-8;Bile acid^post CFst;SCnc;Pt;Ser;Qn;;CHAL;1;Bile acid [Moles/volume] in Serum --fasting;Bile Ac p fast Ser-sCnc;;ACTIVE;2.13;2.73 +35563-6;Rickettsia rickettsii Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Rickettsia rickettsii IgG and IgM panel - Serum;R rickettsi IgG+IgM Pnl Ser;;ACTIVE;2.13;2.73 +35564-4;HIV 1 p31+p32 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p31+p32 Ab [Presence] in Serum by Immunoblot;HIV 1 p31+p32 Ab Ser Ql IB;;ACTIVE;2.13;2.58 +35565-1;HIV 1 p40 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p40 Ab [Presence] in Serum by Immunoblot;HIV 1 p40 Ab Ser Ql IB;;ACTIVE;2.13;2.73 +35566-9;Parathyrin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin [Mass/volume] in Serum or Plasma --baseline;PTH BS SerPl-mCnc;;ACTIVE;2.13;2.73 +35567-7;Parathyrin^10M post excision;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin [Mass/volume] in Serum or Plasma --10 minutes post excision;PTH 10m p Excision SerPl-mCnc;;ACTIVE;2.13;2.70 +3556-8;Dichlorphenamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dichlorphenamide [Mass/volume] in Urine;Dichlorphenamide Ur-mCnc;;ACTIVE;1.0;2.42 +35568-5;Protein fractions.oligoclonal bands;Num;Pt;CSF;Qn;Electrophoresis;CHEM;1;Oligoclonal bands [#] in Cerebral spinal fluid by Electrophoresis;Oligoclonal Bands CSF Elph;;ACTIVE;2.13;2.69 +35569-3;Protein fractions.oligoclonal bands;Num;Pt;Ser/Plas;Qn;;CHEM;1;Oligoclonal bands [#] in Serum or Plasma;Oligoclonal Bands SerPl;;ACTIVE;2.13;2.73 +35570-1;Renin;MCnc;Pt;Plas;Qn;;CHEM;1;Renin [Mass/volume] in Plasma;Renin Plas-mCnc;;ACTIVE;2.13;2.73 +35571-9;Tyrosine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Tyrosine [Moles/volume] in DBS;Tyrosine DBS-sCnc;;ACTIVE;2.13;2.73 +35572-7;Phenylalanine/Tyrosine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Phenylalanine/Tyrosine [Molar ratio] in DBS;Phe/Tyr DBS-sRto;;ACTIVE;2.13;2.73 +35573-5;Procollagen+Collagen;Prid;Pt;Fibroblasts;Nom;Electrophoresis;CHEM;1;Procollagen+Collagen [Identifier] in Fibroblast by Electrophoresis;Procollagen+Collagen Fib Elph;;ACTIVE;2.13;2.21 +35574-3;Fatty acid oxidation;Prid;Pt;Fibroblasts;Nom;;CHEM;1;Fatty acid oxidation [Identifier] in Fibroblast;FA Oxidation Fib;;ACTIVE;2.13;2.54 +35575-0;Pigeon antibody panel;-;Pt;Ser;-;;PANEL.ALLERGY;1;Pigeon antibody panel - Serum;Pigeon Ab Pnl Ser;;ACTIVE;2.13;2.42 +3557-6;Dichlorphenamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Dichlorphenamide [Mass/time] in 24 hour Urine;Dichlorphenamide 24h Ur-mRate;;ACTIVE;1.0;2.42 +35576-8;Hydrocarbon and oxygenated volatiles panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Hydrocarbon and Oxygenated Volatiles panel - Serum or Plasma;Hydrocarb & Oxy Vol Pnl SerPl;;ACTIVE;2.13;2.42 +35577-6;Hypersensitivity pneumonitis panel;-;Pt;Ser;-;;PANEL.ALLERGY;1;Hypersensitivity pneumonitis panel - Serum;HP Pnl Ser;;ACTIVE;2.13;2.73 +35578-4;1,2-Glyceryl dinitrate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,2-Glyceryl dinitrate [Mass/volume] in Blood;1,2-GDN Bld-mCnc;;ACTIVE;2.13;2.70 +35579-2;Tetrahydrofuran;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tetrahydrofuran [Mass/volume] in Urine;Tetrahydrofuran Ur-mCnc;;ACTIVE;2.13;2.70 +355-8;Neomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Neomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Neomycin Islt MIC;;ACTIVE;1.0;2.19 +35580-0;N-methyl valine;MCnc;Pt;Bld;Qn;;CHEM;1;N-methyl valine [Mass/volume] in Blood;N-Methyl valine Bld-mCnc;;ACTIVE;2.13;2.70 +35581-8;Hydroxyethyl valine;MCnc;Pt;Bld;Qn;;CHEM;1;Hydroxyethyl valine [Mass/volume] in Blood;OH-Ethyl valine Bld-mCnc;;ACTIVE;2.13;2.70 +35582-6;Hydrazine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hydrazine [Mass/volume] in Blood;Hydrazine Bld-mCnc;;ACTIVE;2.13;2.70 +35583-4;Hydrazine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Hydrazine/Creatinine [Mass Ratio] in Urine;Hydrazine/Creat Ur;;ACTIVE;2.13;2.42 +3558-4;Dicoumarol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dicoumarol [Mass/volume] in Serum or Plasma;Dicoumarol SerPl-mCnc;;ACTIVE;1.0;2.34 +35584-2;Aniline;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Aniline [Mass/volume] in Blood;Aniline Bld-mCnc;;ACTIVE;2.13;2.70 +35585-9;2-Butoxyacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2-Butoxyacetate [Mass/volume] in Urine;2-Butoxyacetate Ur-mCnc;;ACTIVE;2.13;2.70 +35586-7;4-Tert-Butylphenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;4-Tert-Butylphenol [Mass/volume] in Urine;4-tert-butylphenol Ur-mCnc;;ACTIVE;2.13;2.73 +35587-5;2-Ethoxyacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2-Ethoxyacetate [Mass/volume] in Urine;2-ethoxyacetate Ur-mCnc;;ACTIVE;2.13;2.70 +35588-3;Ethylene glycol dinitrate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethylene glycol dinitrate [Mass/volume] in Blood;EGDN Bld-mCnc;;ACTIVE;2.13;2.73 +35589-1;Furoate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Furoate/Creatinine [Mass Ratio] in Urine;Furoate/Creat Ur;;ACTIVE;2.13;2.42 +35590-9;Aniline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aniline [Mass/volume] in Urine;Aniline Ur-mCnc;;ACTIVE;2.13;2.70 +35591-7;Creatinine renal clearance.predicted;VRat;Pt;Ser/Plas;Qn;Cockcroft-Gault formula;CHEM;1;Creatinine renal clearance predicted by Cockcroft-Gault formula;Creat Cl predicted SerPl C-G-vRate;;ACTIVE;2.13;2.73 +3559-2;Digitoxin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digitoxin [Mass/volume] in Serum or Plasma;Digitoxin SerPl-mCnc;;ACTIVE;1.0;2.73 +35592-5;Creatinine renal clearance/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas;Qn;Cockcroft-Gault formula, BSA formula;CHEM;1;Creatinine renal clearance/1.73 sq M.predicted by Cockcroft-Gault formula, BSA formula;Creat Cl/BSA.pred SerPl C-G-ArVRat;;ACTIVE;2.13;2.73 +35593-3;Creatinine renal clearance/1.73 sq M;ArVRat;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance/1.73 sq M in Urine and Serum or Plasma collected for unspecified duration;Creat Cl/1.73 sq M ?Tm Ur+SerPl-ArVRat;;ACTIVE;2.13;2.73 +35594-1;Creatinine renal clearance/1.73 sq M;ArVRat;2H;Urine+Ser/Plas;Qn;;CHEM;1;Creatinine renal clearance/1.73 sq M in 2 hour Urine and Serum or Plasma;Creat Cl/1.73 sq M 2h Ur+SerPl-ArVRat;;ACTIVE;2.13;2.66 +35595-8;Acetaminophen;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Acetaminophen [Mass/volume] in Serum or Plasma by Screen method;APAP SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35596-6;Theophylline;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Theophylline [Mass/volume] in Serum or Plasma by Screen method;Theophylline SerPl Scn-mCnc;;ACTIVE;2.13;2.42 +35597-4;Salicylates;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Salicylates [Mass/volume] in Serum or Plasma by Screen method;Salicylates SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35598-2;Butalbital;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Butalbital [Mass/volume] in Serum or Plasma by Screen method;Butalbital SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35599-0;carBAMazepine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;carBAMazepine [Mass/volume] in Serum or Plasma by Screen method;carBAMazepine SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35-6;Azithromycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Azithromycin [Susceptibility] by Minimum lethal concentration (MLC);Azithromycin Islt MLC;;ACTIVE;1.0;2.19 +3560-0;Digitoxin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Digitoxin [Mass/volume] in Urine;Digitoxin Ur-mCnc;;ACTIVE;1.0;2.42 +35600-6;chlordiazePOXIDE;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Serum or Plasma by Screen method;Chlordiazep SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35601-4;chlorproMAZINE;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;chlorproMAZINE [Mass/volume] in Serum or Plasma by Screen method;chlorproMAZINE SerPl Scn-mCnc;;ACTIVE;2.13;2.42 +35602-2;clomiPRAMINE;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;clomiPRAMINE [Mass/volume] in Serum or Plasma by Screen method;clomiPRAMINE SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35603-0;clonazePAM;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;clonazePAM [Mass/volume] in Serum or Plasma by Screen method;clonazePAM SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35604-8;Cyclobenzaprine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Cyclobenzaprine [Mass/volume] in Serum or Plasma by Screen method;Cyclobenzaprine SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35605-5;N-desalkylflurazepam;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Serum or Plasma by Screen method;Desalkylfluraz SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35606-3;Desipramine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Desipramine [Mass/volume] in Serum or Plasma by Screen method;Desipramine SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35607-1;diazePAM;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;diazePAM [Mass/volume] in Serum or Plasma by Screen method;diazePAM SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35608-9;diphenhydrAMINE;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;diphenhydrAMINE [Mass/volume] in Serum or Plasma by Screen method;Diphenhy SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35609-7;Doxepin;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Doxepin [Mass/volume] in Serum or Plasma by Screen method;Doxepin SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35610-5;FLUoxetine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;FLUoxetine [Mass/volume] in Serum or Plasma by Screen method;FLUoxetine SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35611-3;Flurazepam;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Flurazepam [Mass/volume] in Serum or Plasma by Screen method;Flurazepam SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35612-1;fluvoxaMINE;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;fluvoxaMINE [Mass/volume] in Serum or Plasma by Screen method;fluvoxaMINE SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35613-9;Glutethimide;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Glutethimide [Mass/volume] in Serum or Plasma by Screen method;Glutethimide SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35614-7;Ibuprofen;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma by Screen method;Ibuprofen SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35615-4;Lidocaine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Lidocaine [Mass/volume] in Serum or Plasma by Screen method;Lidocain SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35616-2;LORazepam;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;LORazepam [Mass/volume] in Serum or Plasma by Screen method;LORazepam SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35617-0;Meperidine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Meperidine [Mass/volume] in Serum or Plasma by Screen method;Meperidine SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +3561-8;Digitoxin>6H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digitoxin>6h post dose [Mass/volume] in Serum or Plasma;Digitoxin >6H SerPl-mCnc;;ACTIVE;1.0;2.40 +35618-8;Methadone;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Methadone [Mass/volume] in Serum or Plasma by Screen method;Methadone SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35619-6;Methaqualone;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Methaqualone [Mass/volume] in Serum or Plasma by Screen method;Methaqualone SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35620-4;Metoprolol;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Metoprolol [Presence] in Serum or Plasma by Screen method;Metoprolol SerPl Ql Scn;;ACTIVE;2.13;2.73 +35621-2;Norclomipramine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Norclomipramine [Mass/volume] in Serum or Plasma by Screen method;Norclomipramine SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35622-0;Nordiazepam;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Nordiazepam [Mass/volume] in Serum or Plasma by Screen method;Nordiazepam SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35623-8;Nordoxepin;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Nordoxepin [Mass/volume] in Serum or Plasma by Screen method;Nordoxepin SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35624-6;Norfluoxetine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Norfluoxetine [Mass/volume] in Serum or Plasma by Screen method;Norfluoxetine SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35625-3;Normeperidine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Normeperidine [Mass/volume] in Serum or Plasma by Screen method;Normeperidine SerPl Scn-mCnc;;ACTIVE;2.13;2.42 +3562-6;Digoxin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digoxin Free [Mass/volume] in Serum or Plasma;Digoxin Free SerPl-mCnc;;ACTIVE;1.0;2.73 +35626-1;Norpropoxyphene;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Norpropoxyphene [Mass/volume] in Serum or Plasma by Screen method;Norpropoxyph SerPl Scn-mCnc;;ACTIVE;2.13;2.42 +35627-9;Nortriptyline;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Nortriptyline [Mass/volume] in Serum or Plasma by Screen method;Nortrip SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35628-7;Norverapamil;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Norverapamil [Presence] in Serum or Plasma by Screen method;Norverapamil SerPl Ql Scn;;ACTIVE;2.13;2.56 +35629-5;Oxazepam;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Oxazepam [Mass/volume] in Serum or Plasma by Screen method;Oxazepam SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35630-3;PENTobarbital;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;PENTobarbital [Mass/volume] in Serum or Plasma by Screen method;Pentobarb SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35631-1;PHENobarbital;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;PHENobarbital [Mass/volume] in Serum or Plasma by Screen method;Phenobarb SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35632-9;Phenytoin;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Phenytoin [Mass/volume] in Serum or Plasma by Screen method;Phenytoin SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35633-7;Propranolol;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Propranolol [Mass/volume] in Serum or Plasma by Screen method;Propranolol SerPl Scn-mCnc;;ACTIVE;2.13;2.42 +3563-4;Digoxin>12H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Digoxin>12 hours post dose [Mass/volume] in Serum or Plasma;Digoxin>12h p dose SerPl-mCnc;;ACTIVE;1.0;2.73 +35634-5;Secobarbital;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Secobarbital [Mass/volume] in Serum or Plasma by Screen method;Secobarbital SerPl Scn-mCnc;;ACTIVE;2.13;2.40 +35635-2;traZODone;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;traZODone [Mass/volume] in Serum or Plasma by Screen method;traZODone SerPl Scn-mCnc;;ACTIVE;2.13;2.42 +35636-0;Amitriptyline;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Amitriptyline [Mass/volume] in Serum or Plasma by Screen method;Amitrip SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35637-8;4-Hydroxyglutethimide;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;4-Hydroxyglutethimide [Mass/volume] in Serum or Plasma by Screen method;4OH-glutethimide SerPl Scn-mCnc;;ACTIVE;2.13;2.42 +35638-6;Borrelia burgdorferi DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Tissue by NAA with probe detection;B burgdor DNA Tiss Ql NAA+probe;;ACTIVE;2.13;2.63 +35639-4;Chlamydophila pneumoniae+Chlamydophila psittaci DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Tissue by NAA with probe detection;C pn+psitt DNA Tiss Ql NAA+probe;;ACTIVE;2.13;2.63 +35640-2;Cells.CD5/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD5 cells/100 cells in Bone marrow;CD5 Cells NFr Mar;;ACTIVE;2.13;2.34 +35641-0;Cells.CD7/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD7 cells/100 cells in Bone marrow;CD7 Cells NFr Mar;;ACTIVE;2.13;2.34 +3564-2;Dimetamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dimetamphetamine [Presence] in Urine;Dimetamphet Ur Ql;;ACTIVE;1.0;2.56 +35642-8;Cotinine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cotinine [Presence] in Urine by Confirmatory method;Cotinine Ur Ql Cfm;;ACTIVE;2.13;2.73 +35643-6;Collagen type 2 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Collagen type 2 Ab [Presence] in Serum by Immunoassay;Collagen2 Ab Ser Ql IA;;ACTIVE;2.13;2.56 +35644-4;Metanephrine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Metanephrine/Creatinine [Mass Ratio] in 24 hour Urine;Metaneph/Creat 24h Ur;;ACTIVE;2.13;2.73 +35645-1;NSD1 gene deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;NSD1 gene deletion [Presence] in Blood or Tissue by Molecular genetics method;NSD1 gene Del Bld/T Ql;;ACTIVE;2.13;2.15 +35646-9;Deoxypyridinoline/Creatinine;SRto;XXX;Urine;Qn;;CHEM;1;Deoxypyridinoline/Creatinine [Molar ratio] in Urine collected for unspecified duration;DPD/Creat ?Tm Ur-sRto;;ACTIVE;2.13;2.52 +35647-7;Pyridinoline+Deoxypyridinoline/Creatinine;SRto;XXX;Urine;Qn;;CHEM;1;Pyridinoline+Deoxypyridinoline/Creatinine [Molar ratio] in Urine collected for unspecified duration;PYD+DPD/Creat ?Tm Ur-sRto;;ACTIVE;2.13;2.52 +35648-5;C reactive protein;Quintile;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;C reactive protein [Quintile] in Serum or Plasma by High sensitivity method;CRP Quint SerPl Qn HS;;ACTIVE;2.13;2.73 +35649-3;Propoxyphene;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Propoxyphene [Mass/volume] in Serum or Plasma by Screen method;Propoxyph SerPl Scn-mCnc;;ACTIVE;2.13;2.73 +35650-1;Lymphocytic choriomeningitis virus Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Lymphocytic choriomeningitis virus IgG and IgM panel - Cerebral spinal fluid;LCMV IgG+IgM Pnl CSF;;ACTIVE;2.13;2.42 +35651-9;Synovial lining cells/100 cells;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Synovial lining cells/100 cells in Synovial fluid;Synoviocytes NFr Snv;;ACTIVE;2.13;2.73 +35652-7;Epithelial cells/100 cells;NFr;Pt;Body fld;Qn;;HEM/BC;1;Epithelial cells/100 cells in Body fluid;Epi Cells NFr Fld;;ACTIVE;2.13;2.73 +35653-5;Cells.CD158;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD158 cells [#/volume] in Blood;CD158 Cells # Bld;;ACTIVE;2.13;2.40 +35654-3;Creatinine/body weight;RelMRat;24H;Urine;Qn;;CHEM;1;Creatinine/Body weight [Mass/kg/time] in 24 hour Urine;Creat/BW 24h Ur-RelMRat;;ACTIVE;2.13;2.73 +35655-0;Butyrylcarnitine (C4);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Butyrylcarnitine (C4) [Moles/volume] in Serum or Plasma;Butyrylcarn SerPl-sCnc;;ACTIVE;2.13;2.73 +35656-8;3-Hydroxystearoylcarnitine (C18-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in Serum or Plasma;3OH-stearoylcarn SerPl-sCnc;;ACTIVE;2.13;2.73 +35657-6;Urea nitrogen/body weight;RelMRat;24H;Urine;Qn;;CHEM;1;Urea nitrogen/Body weight [Mass/kg/time] in 24 hour Urine;UUN/BW 24h Ur-RelMRat;;ACTIVE;2.13;2.70 +35658-4;Tumor survival (in months);Time;Pt;^Patient;Qn;;TUMRRGT;2;Tumor survival (in months) [Time];Tumor survival (in months) Time;;ACTIVE;2.13;2.54 +3565-9;Dimetamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dimetamphetamine [Mass/volume] in Urine;Dimetamphet Ur-mCnc;;ACTIVE;1.0;2.42 +35659-2;Age at specimen collection;Time;Pt;^Patient;Qn;;TUMRRGT;2;Age at specimen collection;Age at specimen collection;;ACTIVE;2.13;2.73 +356-6;Neomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Neomycin [Susceptibility] by Disk diffusion (KB);Neomycin Islt KB;;ACTIVE;1.0;2.73 +35660-0;Path report.final diagnosis section - text;Imp;Pt;Specimen;Nom;;TUMRRGT;2;Deprecated Pathology report final diagnosis section - text;Deprecated Path report.final Dx section;;DEPRECATED;2.13;2.36 +35661-8;JC virus DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;JC virus DNA [Presence] in Urine by NAA with probe detection;JCPyV DNA Ur Ql NAA+probe;;ACTIVE;2.13;2.73 +35662-6;Glucose;MCnc;XXX;Urine;Qn;;CHEM;1;Glucose [Mass/volume] in Urine collected for unspecified duration;Glucose ?Tm Ur-mCnc;;ACTIVE;2.13;2.70 +35663-4;Protein;MCnc;XXX;Urine;Qn;;UA;1;Protein [Mass/volume] in Urine collected for unspecified duration;Prot ?Tm Ur-mCnc;;ACTIVE;2.13;2.73 +35664-2;Ethanol;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Urine collected for unspecified duration;Ethanol ?Tm Ur-mCnc;;ACTIVE;2.13;2.70 +35665-9;Acetone;MCnc;XXX;Urine;Qn;;DRUG/TOX;1;Acetone [Mass/volume] in Urine collected for unspecified duration;Acetone ?Tm Ur-mCnc;;ACTIVE;2.13;2.52 +35666-7;Lymphocytic choriomeningitis virus Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Lymphocytic choriomeningitis virus IgG and IgM panel - Serum;LCMV IgG+IgM Pnl Ser;;ACTIVE;2.13;2.42 +3566-7;Dimetamphetamine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Dimetamphetamine [Mass/time] in 24 hour Urine;Dimetamphet 24h Ur-mRate;;ACTIVE;1.0;2.42 +35667-5;Atomoxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Atomoxetine [Mass/volume] in Serum or Plasma;Atomoxetine SerPl-mCnc;;ACTIVE;2.13;2.73 +35668-3;Gentamicin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma;Gentamicin SerPl-mCnc;;ACTIVE;2.13;2.73 +35669-1;Amikacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma;Amikacin SerPl-mCnc;;ACTIVE;2.13;2.73 +35670-9;Tobramycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma;Tobramycin SerPl-mCnc;;ACTIVE;2.13;2.73 +35671-7;Galactomannan Ag;ACnc;Pt;XXX;Qn;;MICRO;1;Galactomannan Ag [Units/volume] in Specimen;Galactomannan Ag Spec-aCnc;;ACTIVE;2.13;2.73 +35672-5;Bilirubin.glucuronidated+Bilirubin.albumin bound/Bilirubin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Bilirubin.direct/Bilirubin.total in Serum or Plasma;Bilirub Direct MFr SerPl;;ACTIVE;2.13;2.34 +35673-3;Phosphate;MCnc;XXX;Urine;Qn;;CHEM;1;Phosphate [Mass/volume] in Urine collected for unspecified duration;Phosphate ?Tm Ur-mCnc;;ACTIVE;2.13;2.73 +35674-1;Creatinine;MCnc;XXX;Urine;Qn;;CHEM;1;Creatinine [Mass/volume] in Urine collected for unspecified duration;Creat ?Tm Ur-mCnc;;ACTIVE;2.13;2.73 +3567-5;Dimethyltryptamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dimethyltryptamine [Mass/volume] in Serum or Plasma;Dimet-tryptamine SerPl-mCnc;;ACTIVE;1.0;2.42 +35675-8;Calcium;MCnc;XXX;Urine;Qn;;CHEM;1;Calcium [Mass/volume] in Urine collected for unspecified duration;Calcium ?Tm Ur-mCnc;;ACTIVE;2.13;2.73 +35676-6;Chloride;SCnc;XXX;Urine;Qn;;CHEM;1;Chloride [Moles/volume] in Urine collected for unspecified duration;Chloride ?Tm Ur-sCnc;;ACTIVE;2.13;2.73 +35677-4;Potassium;SCnc;XXX;Urine;Qn;;CHEM;1;Potassium [Moles/volume] in Urine collected for unspecified duration;Potassium ?Tm Ur-sCnc;;ACTIVE;2.13;2.73 +35678-2;Sodium;SCnc;XXX;Urine;Qn;;CHEM;1;Sodium [Moles/volume] in Urine collected for unspecified duration;Sodium ?Tm Ur-sCnc;;ACTIVE;2.13;2.73 +35679-0;Varicella zoster virus Ab.IgG & IgM panel;-;Pt;CSF;Qn;;PANEL.MICRO;1;Varicella zoster virus IgG and IgM panel - Cerebral spinal fluid;VZV IgG+IgM Pnl CSF;;ACTIVE;2.13;2.42 +35680-8;Hepatitis E virus Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis E virus Ab panel - Serum;HEV Ab Pnl Ser;;ACTIVE;2.13;2.68 +35681-6;Tissue transglutaminase Ab panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Tissue transglutaminase Ab panel - Serum;tTG Ab Pnl Ser;;ACTIVE;2.13;2.73 +35682-4;Trypanosoma cruzi Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Trypanosoma cruzi IgG and IgM panel - Serum;T cruzi IgG+IgM Pnl Ser;;ACTIVE;2.13;2.42 +3568-3;Dimethyltryptamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dimethyltryptamine [Mass/volume] in Urine;Dimet-tryptamine Ur-mCnc;;ACTIVE;1.0;2.42 +35683-2;Burkholderia pseudomallei Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Burkholderia pseudomallei IgG and IgM panel - Serum;B pseudomal IgG+IgM Pnl Ser;;ACTIVE;2.13;2.42 +35684-0;Colorado tick fever virus Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Colorado tick fever virus IgG and IgM panel - Serum;CTFV IgG+IgM Pnl Ser;;ACTIVE;2.13;2.42 +35685-7;Carbon dioxide;SCnc;XXX;Urine;Qn;;CHEM;1;Carbon dioxide [Moles/volume] in Urine collected for unspecified duration;CO2 ?Tm Ur-sCnc;;ACTIVE;2.13;2.70 +35686-5;GBA gene.c.1226A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;GBA gene c.1226A>G [Presence] in Blood or Tissue by Molecular genetics method;GBA c.1226A>G Bld/T Ql;;ACTIVE;2.13;2.56 +35687-3;GBA gene.c.1297G>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;GBA gene c.1297G>T [Presence] in Blood or Tissue by Molecular genetics method;GBA c.1297G>T Bld/T Ql;;ACTIVE;2.13;2.56 +35688-1;GBA gene.c.1448T>G & 1448T>C;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;GBA gene c.1448T>G and 1448T>C [Presence] in Blood or Tissue by Molecular genetics method;GBA c.1448T>G & 1448T>C Bld/T Ql;;ACTIVE;2.13;2.40 +35689-9;GBA gene.c.84insG;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;GBA gene c.84insG [Presence] in Blood or Tissue by Molecular genetics method;GBA c.84insG Bld/T Ql;;ACTIVE;2.13;2.56 +35690-7;GBA gene.c.IVS2(+1)G>A & IVS2(+1)G>T;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;GBA gene c.IVS2(+1)G>A and IVS2(+1)G>T [Presence] in Blood or Tissue by Molecular genetics method;GBA c.IVS2+1G>A/T Bld/T Ql;;ACTIVE;2.13;2.40 +3569-1;diphenhydrAMINE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;diphenhydrAMINE [Presence] in Serum or Plasma;Diphenhy SerPl Ql;;ACTIVE;1.0;2.56 +35691-5;XXX microorganism DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;XXX microorganism DNA [Presence] in Specimen by NAA with probe detection;Other microorg DNA Spec Ql NAA+probe;;ACTIVE;2.13;2.73 +35692-3;Cells.G0+G1 phase/100 cells;NFr;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;G0+G1 phase cells/100 cells in Specimen by Flow cytometry (FC);G0+G1 Phs Cells NFr Spec FC;;ACTIVE;2.13;2.69 +35693-1;GBA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GBA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GBA gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +35694-9;California encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;California encephalitis virus IgG Ab [Titer] in Serum;CEV IgG Titr Ser;;ACTIVE;2.13;2.68 +35695-6;California encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;California encephalitis virus IgM Ab [Titer] in Serum;CEV IgM Titr Ser;;ACTIVE;2.13;2.68 +35696-4;California encephalitis virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;California encephalitis virus Ab [Titer] in Cerebral spinal fluid;CEV Ab Titr CSF;;ACTIVE;2.13;2.68 +35697-2;La Crosse virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;La Crosse virus Ab [Titer] in Serum by Complement fixation;LACV Ab Titr Ser CF;;ACTIVE;2.13;2.58 +35698-0;metFORMIN;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;metFORMIN [Mass/volume] in Serum or Plasma;metFORMIN SerPl-mCnc;;ACTIVE;2.13;2.73 +35699-8;Anti-hyperglycemics;Prid;Pt;Ser/Plas;Nom;Screen;DRUG/TOX;1;Anti-hyperglycemics [Identifier] in Serum or Plasma by Screen method;Anti-hyperglycemics SerPl Scn;;ACTIVE;2.13;2.15 +35700-4;Acetaminophen;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Acetaminophen [Mass/volume] in Gastric fluid;APAP Gast-mCnc;;ACTIVE;2.13;2.44 +35701-2;Acetylcholinesterase;CCnc;Pt;XXX;Qn;;CHEM;1;Acetylcholinesterase [Enzymatic activity/volume] in Specimen;AChE Spec-cCnc;;ACTIVE;2.13;2.69 +35702-0;Acid hemolysis;NFr;Pt;Bld;Qn;;HEM/BC;1;Acid hemolysis fraction in Blood;Acid hemolysis NFr Bld;;ACTIVE;2.13;2.34 +35703-8;Adenosine deaminase;CCnc;Pt;CSF;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Cerebral spinal fluid;Adenosine deaminase CSF-cCnc;;ACTIVE;2.13;2.73 +35704-6;Adenosine deaminase;CCnc;Pt;Plr fld;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Pleural fluid;Adenosine deaminase Plr-cCnc;;ACTIVE;2.13;2.73 +35705-3;Adenovirus Ag;PrThr;Pt;Nph;Ord;;MICRO;1;Adenovirus Ag [Presence] in Nasopharynx;HAdV Ag Nph Ql;;ACTIVE;2.13;2.56 +35706-1;Albumin/Protein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Albumin/Protein.total in Serum or Plasma;Albumin MFr SerPl;;ACTIVE;2.13;2.73 +35707-9;Alkaline phosphatase.macrohepatic/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.macrohepatic/Alkaline phosphatase.total in Serum or Plasma;ALP Macrohepatic CFr SerPl;;ACTIVE;2.13;2.73 +35708-7;Alpha 1 globulin;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin [Mass/volume] in 24 hour Urine by Electrophoresis;Alpha1 Glob 24h Ur Elph-mCnc;;ACTIVE;2.13;2.73 +3570-9;diphenhydrAMINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;diphenhydrAMINE [Mass/volume] in Serum or Plasma;Diphenhy SerPl-mCnc;;ACTIVE;1.0;2.73 +35709-5;La Crosse virus Ab;Titr;Pt;Body fld;Qn;;MICRO;1;La Crosse virus Ab [Titer] in Body fluid;LACV Ab Titr Fld;;ACTIVE;2.13;2.58 +35710-3;Chlamydia sp DNA;PrThr;Pt;Cnjt;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Conjunctival specimen by NAA with probe detection;Chlamydia DNA Conjunct Ql NAA+probe;;ACTIVE;2.13;2.73 +35711-1;Chlamydia sp DNA;PrThr;Pt;Anal;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Anal by NAA with probe detection;Chlamydia DNA Anal Ql NAA+probe;;ACTIVE;2.13;2.63 +35712-9;Chlamydia sp rRNA;PrThr;Pt;Cnjt;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Conjunctival specimen by Probe;Chlamydia rRNA Conjunct Ql Probe;;ACTIVE;2.13;2.63 +35713-7;Chlamydia sp DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Cervix by NAA with probe detection;Chlamydia DNA Cvx Ql NAA+probe;;ACTIVE;2.13;2.73 +35714-5;Chlamydia sp rRNA;PrThr;Pt;Cvx;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Cervix by Probe;Chlamydia rRNA Cvx Ql Probe;;ACTIVE;2.13;2.63 +35715-2;Chlamydia sp rRNA;PrThr;Pt;Genital;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Genital specimen by Probe;Chlamydia rRNA Genital Ql Probe;;ACTIVE;2.13;2.73 +35716-0;Chlamydia sp DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Vaginal fluid by NAA with probe detection;Chlamydia DNA Vag Ql NAA+probe;;ACTIVE;2.13;2.73 +3571-7;diphenhydrAMINE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;diphenhydrAMINE [Presence] in Urine;Diphenhy Ur Ql;;ACTIVE;1.0;2.73 +35717-8;Chlamydia sp rRNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Vaginal fluid by Probe;Chlamydia rRNA Vag Ql Probe;;ACTIVE;2.13;2.63 +35718-6;Chlamydia sp rRNA;PrThr;Pt;Nose;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Nose by Probe;Chlamydia rRNA Nose Ql Probe;;ACTIVE;2.13;2.63 +35719-4;Chlamydia sp DNA;ACnc;Pt;Penis;Ord;Probe.amp.tar;MICRO;1;Deprecated Chlamydia sp DNA [Presence] in Penis by Probe and target amplification method;Deprecated Chlamydia DNA Penis Ql PCR;;DEPRECATED;2.13;2.52 +35720-2;Chlamydia sp rRNA;ACnc;Pt;Penis;Ord;Probe;MICRO;1;Deprecated Chlamydia sp rRNA [Presence] in Penis by DNA probe;Deprecated Chlamydia rRNA Penis Ql Prb;;DEPRECATED;2.13;2.52 +35721-0;Chlamydia sp rRNA;PrThr;Pt;Anal;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Anal by Probe;Chlamydia rRNA Anal Ql Probe;;ACTIVE;2.13;2.63 +35722-8;Chlamydia sp DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Serum by NAA with probe detection;Chlamydia DNA Ser Ql NAA+probe;;ACTIVE;2.13;2.73 +35723-6;Chlamydia sp rRNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Serum by Probe;Chlamydia rRNA Ser Ql Probe;;ACTIVE;2.13;2.73 +35724-4;Chlamydia sp DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Throat by NAA with probe detection;Chlamydia DNA Throat Ql NAA+probe;;ACTIVE;2.13;2.63 +3572-5;diphenhydrAMINE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;diphenhydrAMINE [Mass/volume] in Urine;Diphenhy Ur-mCnc;;ACTIVE;1.0;2.73 +35725-1;Chlamydia sp rRNA;PrThr;Pt;Thrt;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Throat by Probe;Chlamydia rRNA Throat Ql Probe;;ACTIVE;2.13;2.63 +35726-9;Chlamydia sp rRNA;PrThr;Pt;Urine;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Urine by Probe;Chlamydia rRNA Ur Ql Probe;;ACTIVE;2.13;2.73 +35727-7;Chlamydia sp DNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Urethra by NAA with probe detection;Chlamydia DNA Urth Ql NAA+probe;;ACTIVE;2.13;2.63 +35728-5;Chlamydia sp rRNA;PrThr;Pt;Urethra;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Urethra by Probe;Chlamydia rRNA Urth Ql Probe;;ACTIVE;2.13;2.63 +35729-3;Chlamydia sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chlamydia sp DNA [Presence] in Specimen by NAA with probe detection;Chlamydia DNA Spec Ql NAA+probe;;ACTIVE;2.13;2.73 +35730-1;Chlamydia sp rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Specimen by Probe;Chlamydia rRNA Spec Ql Probe;;ACTIVE;2.13;2.73 +35731-9;Corylus avellana Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hazelnut IgG Ab RAST class [Presence] in Serum;Hazelnut IgG RAST Ql;;ACTIVE;2.13;2.58 +35732-7;Histoplasma capsulatum H Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum H Ab [Presence] in Serum by Immune diffusion (ID);H capsul H Ab Ser Ql ID;;ACTIVE;2.13;2.73 +3573-3;Dipipanone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dipipanone [Presence] in Urine;Dipipanone Ur Ql;;ACTIVE;1.0;2.56 +35733-5;Histoplasma capsulatum M Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum M Ab [Presence] in Serum by Immune diffusion (ID);H capsul M Ab Ser Ql ID;;ACTIVE;2.13;2.56 +35734-3;Histoplasma capsulatum Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Histoplasma capsulatum Ag [Presence] in Urine;H capsul Ag Ur Ql;;ACTIVE;2.13;2.73 +35735-0;Neisseria gonorrhoeae DNA;PrThr;Pt;Cnjt;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Conjunctival specimen by NAA with probe detection;N gonorrhoea DNA Conjunct Ql NAA+probe;;ACTIVE;2.13;2.73 +35736-8;Chlamydia sp rRNA;PrThr;Pt;Nph;Ord;Probe;MICRO;1;Chlamydia sp rRNA [Presence] in Nasopharynx by Probe;Chlamydia rRNA Nph Ql Probe;;ACTIVE;2.13;2.63 +35737-6;Microscopic observation;Prid;Pt;Amnio fld;Nom;Nile blue prusside;PATH;1;Microscopic observation [Identifier] in Amniotic fluid by Nile blue prusside;Nile Blue Prusside Amn;;ACTIVE;2.13;2.19 +35738-4;Inhibin A;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin A [Multiple of the median] in Serum or Plasma;Inhibin A MoM SerPl;;ACTIVE;2.13;2.73 +35739-2;Brucella sp Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Brucella sp IgG and IgM panel - Serum;Brucella IgG+IgM Pnl Ser;;ACTIVE;2.13;2.73 +357-4;Neomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Neomycin [Susceptibility] by Serum bactericidal titer;Neomycin Titr SBT;;ACTIVE;1.0;2.32 +35740-0;Rickettsia sp Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Rickettsia sp IgG and IgM panel - Serum;Rickettsia IgG+IgM Pnl Ser;;ACTIVE;2.13;2.42 +3574-1;Dipipanone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dipipanone [Mass/volume] in Urine;Dipipanone Ur-mCnc;;ACTIVE;1.0;2.73 +35741-8;Prostate specific Ag;MCnc;Pt;Ser/Plas;Qn;Detection limit <= 0.01 ng/mL;CHEM;1;Prostate specific Ag [Mass/volume] in Serum or Plasma by Detection limit <= 0.01 ng/mL;PSA SerPl DL<=0.01 ng/mL-mCnc;;ACTIVE;2.13;2.73 +35742-6;SH2D1A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SH2D1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SH2D1A gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +35743-4;Eastern equine encephalitis virus Ab.IgG & IgM panel;-;Pt;XXX;Qn;;PANEL.MICRO;1;Eastern equine encephalitis virus IgG and IgM panel - Specimen;EEEV IgG+IgM Pnl Spec;;ACTIVE;2.13;2.69 +35744-2;TP73L gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TP73L gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TP73L gene Mut Anl Bld/T;;ACTIVE;2.13;2.68 +35745-9;Fat/Solids.total;MRto;Pt;Stool;Qn;;CHEM;1;Fat/Total solids [Mass Ratio] in Stool;Fat/total solids Stl;;ACTIVE;2.13;2.73 +35746-7;Hyperchromia;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Hyperchromia [Presence] in Blood by Automated count;Hyperchromia Bld Ql Auto;;ACTIVE;2.13;2.56 +35747-5;Hydrogen ion;SCnc;Pt;BldA;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Arterial blood;H ion BldA-sCnc;;ACTIVE;2.13;2.34 +35748-3;Hydrogen ion^^adjusted to patient's actual temperature;SCnc;Pt;BldA;Qn;;CHEM;1;Hydrogen ion [Moles/volume] adjusted to patient's actual temperature in Arterial blood;H ion temp adj BldA-sCnc;;ACTIVE;2.13;2.54 +35749-1;DMPK phenotype;Type;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DMPK phenotype [Type] in Blood or Tissue by Molecular genetics method;DMPK Phenotype Bld/T;;ACTIVE;2.13;2.71 +35750-9;DMPK gene allele 2.CTG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;DMPK gene allele 2 CTG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;DMPK allele2 CTG Rpt EntNum Bld/T;;ACTIVE;2.13;2.52 +35751-7;DMPK gene allele 1.CTG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;DMPK gene allele 1 CTG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;DMPK allele1 CTG Rpt EntNum Bld/T;;ACTIVE;2.13;2.52 +35752-5;Escherichia coli O157:H7 Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Escherichia coli O157:H7 IgG and IgM panel - Serum;E coli O157H7 IgG+IgM Pnl Ser;;ACTIVE;2.13;2.42 +35753-3;Mitochondrial myopathy gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondrial myopathy gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MM gene Mut Anl Bld/T;;ACTIVE;2.13;2.66 +35754-1;Avilamycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Avilamycin [Susceptibility] by Disk diffusion (KB);Avilamycin Islt KB;;ACTIVE;2.13;2.19 +35755-8;Avilamycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Avilamycin [Susceptibility] by Minimum inhibitory concentration (MIC);Avilamycin Islt MIC;;ACTIVE;2.13;2.19 +35756-6;Avilamycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Avilamycin [Susceptibility];Avilamycin Susc Islt;;ACTIVE;2.13;2.19 +35757-4;Cefdinir;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefdinir [Susceptibility] by Gradient strip;Cefdinir Islt Grad strip;;ACTIVE;2.13;2.56 +3575-8;Dipipanone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Dipipanone [Mass/time] in 24 hour Urine;Dipipanone 24h Ur-mRate;;ACTIVE;1.0;2.19 +35758-2;Cefdinir;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefdinir [Susceptibility] by Disk diffusion (KB);Cefdinir Islt KB;;ACTIVE;2.13;2.19 +35759-0;Cefditoren;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefditoren [Susceptibility] by Disk diffusion (KB);Cefditoren Islt KB;;ACTIVE;2.13;2.19 +35760-8;Cefditoren;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefditoren [Susceptibility] by Gradient strip;Cefditoren Islt Grad strip;;ACTIVE;2.13;2.56 +35761-6;Cefditoren;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefditoren [Susceptibility] by Minimum inhibitory concentration (MIC);Cefditoren Islt MIC;;ACTIVE;2.13;2.19 +35762-4;Cefditoren;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefditoren [Susceptibility];Cefditoren Susc Islt;;ACTIVE;2.13;2.19 +35763-2;Cefepime+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefepime+Clavulanate [Susceptibility] by Gradient strip;Cefepime+Clav Islt Grad strip;;ACTIVE;2.13;2.56 +35764-0;Cefetamet;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefetamet [Susceptibility] by Disk diffusion (KB);Cefetamet Islt KB;;ACTIVE;2.13;2.19 +35765-7;Cefetamet;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefetamet [Susceptibility] by Minimum inhibitory concentration (MIC);Cefetamet Islt MIC;;ACTIVE;2.13;2.19 +3576-6;Disopyramide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Disopyramide [Mass/volume] in Serum or Plasma;Disopyramide SerPl-mCnc;;ACTIVE;1.0;2.73 +35766-5;Cefixime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefixime [Susceptibility] by Gradient strip;Cefixime Islt Grad strip;;ACTIVE;2.13;2.56 +35767-3;Cefoperazone;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefoperazone [Susceptibility] by Gradient strip;Cefoperazone Islt Grad strip;;ACTIVE;2.13;2.56 +35768-1;Cefoperazone+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefoperazone+Sulbactam [Susceptibility] by Gradient strip;Cefoperazone+Sulbac Islt Grad strip;;ACTIVE;2.13;2.56 +35769-9;Cefotaxime+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefotaxime+Clavulanate [Susceptibility] by Disk diffusion (KB);Cefotaxime+Clav Islt KB;;ACTIVE;2.13;2.19 +35770-7;Cefotaxime+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefotaxime+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);Cefotaxime+Clav Islt MIC;;ACTIVE;2.13;2.19 +35771-5;Cefotaxime+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefotaxime+Clavulanate [Susceptibility];Cefotaxime+Clav Susc Islt;;ACTIVE;2.13;2.19 +35772-3;Cefotiam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefotiam [Susceptibility] by Disk diffusion (KB);Cefotiam Islt KB;;ACTIVE;2.13;2.19 +35773-1;Cefotiam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefotiam [Susceptibility] by Minimum inhibitory concentration (MIC);Cefotiam Islt MIC;;ACTIVE;2.13;2.19 +3577-4;Disulfiram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Disulfiram [Mass/volume] in Serum or Plasma;Disulfiram SerPl-mCnc;;ACTIVE;1.0;2.42 +35774-9;cefTAZidime+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefTAZidime+Clavulanate [Susceptibility] by Disk diffusion (KB);cefTAZidime+Clav Islt KB;;ACTIVE;2.13;2.19 +35775-6;cefTAZidime+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefTAZidime+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);cefTAZidime+Clav Islt MIC;;ACTIVE;2.13;2.19 +35776-4;cefTAZidime+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefTAZidime+Clavulanate [Susceptibility];cefTAZidime+Clav Susc Islt;;ACTIVE;2.13;2.19 +35777-2;Ceftibuten;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceftibuten [Susceptibility] by Disk diffusion (KB);Ceftibuten Islt KB;;ACTIVE;2.13;2.19 +35778-0;Ceftibuten;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceftibuten [Susceptibility] by Minimum inhibitory concentration (MIC);Ceftibuten Islt MIC;;ACTIVE;2.13;2.19 +35779-8;Ceftibuten;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceftibuten [Susceptibility];Ceftibuten Susc Islt;;ACTIVE;2.13;2.19 +35780-6;Ceftiofur;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceftiofur [Susceptibility] by Disk diffusion (KB);Ceftiofur Islt KB;;ACTIVE;2.13;2.19 +35781-4;Ceftiofur;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceftiofur [Susceptibility] by Minimum inhibitory concentration (MIC);Ceftiofur Islt MIC;;ACTIVE;2.13;2.19 +3578-2;Doxepin;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Doxepin [Presence] in Serum or Plasma;Doxepin SerPl Ql;;ACTIVE;1.0;2.73 +35782-2;Cefuroxime.oral;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefuroxime Oral [Susceptibility] by Disk diffusion (KB);Cefuroxime Oral Islt KB;;ACTIVE;2.13;2.73 +35783-0;Cefuroxime.oral;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefuroxime Oral [Susceptibility];Cefuroxime Oral Susc Islt;;ACTIVE;2.13;2.73 +35784-8;Cephalexin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cephalexin [Susceptibility] by Gradient strip;Cephalexin Islt Grad strip;;ACTIVE;2.13;2.56 +35785-5;Clinafloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clinafloxacin [Susceptibility] by Disk diffusion (KB);Clinafloxacin Islt KB;;ACTIVE;2.13;2.19 +35786-3;Clinafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clinafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Clinafloxacin Islt MIC;;ACTIVE;2.13;2.19 +35787-1;DAPTOmycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;DAPTOmycin [Susceptibility] by Disk diffusion (KB);DAPTOmycin Islt KB;;ACTIVE;2.13;2.19 +35788-9;DAPTOmycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;DAPTOmycin [Susceptibility] by Minimum inhibitory concentration (MIC);DAPTOmycin Islt MIC;;ACTIVE;2.13;2.73 +35789-7;DAPTOmycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;DAPTOmycin [Susceptibility];DAPTOmycin Susc Islt;;ACTIVE;2.13;2.73 +3579-0;Doxepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxepin [Mass/volume] in Serum or Plasma;Doxepin SerPl-mCnc;;ACTIVE;1.0;2.73 +35790-5;Difloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Difloxacin [Susceptibility] by Disk diffusion (KB);Difloxacin Islt KB;;ACTIVE;2.13;2.19 +35791-3;Difloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Difloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Difloxacin Islt MIC;;ACTIVE;2.13;2.19 +35792-1;Difloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Difloxacin [Susceptibility];Difloxacin Susc Islt;;ACTIVE;2.13;2.19 +35793-9;Dirithromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Dirithromycin [Susceptibility] by Disk diffusion (KB);Dirithromycin Islt KB;;ACTIVE;2.13;2.19 +35794-7;Dirithromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Dirithromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Dirithromycin Islt MIC;;ACTIVE;2.13;2.19 +35795-4;Dirithromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Dirithromycin [Susceptibility];Dirithromycin Susc Islt;;ACTIVE;2.13;2.19 +35796-2;Enrofloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Enrofloxacin [Susceptibility] by Gradient strip;Enrofloxacin Islt Grad strip;;ACTIVE;2.13;2.56 +35797-0;Enrofloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Enrofloxacin [Susceptibility] by Disk diffusion (KB);Enrofloxacin Islt KB;;ACTIVE;2.13;2.19 +35798-8;Enrofloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Enrofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Enrofloxacin Islt MIC;;ACTIVE;2.13;2.19 +35799-6;Ertapenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ertapenem [Susceptibility] by Disk diffusion (KB);Ertapenem Islt KB;;ACTIVE;2.13;2.73 +35800-2;Ertapenem;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ertapenem [Susceptibility] by Gradient strip;Ertapenem Islt Grad strip;;ACTIVE;2.13;2.56 +35801-0;Ertapenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ertapenem [Susceptibility] by Minimum inhibitory concentration (MIC);Ertapenem Islt MIC;;ACTIVE;2.13;2.73 +35802-8;Ertapenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ertapenem [Susceptibility];Ertapenem Susc Islt;;ACTIVE;2.13;2.73 +35803-6;Bambermycins;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Bambermycins [Susceptibility] by Disk diffusion (KB);Bambermycins Islt KB;;ACTIVE;2.13;2.19 +35804-4;Bambermycins;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Bambermycins [Susceptibility] by Minimum inhibitory concentration (MIC);Bambermycins Islt MIC;;ACTIVE;2.13;2.19 +35805-1;Bambermycins;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Bambermycins [Susceptibility];Bambermycins Susc Islt;;ACTIVE;2.13;2.19 +35806-9;Fleroxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Fleroxacin [Susceptibility] by Disk diffusion (KB);Fleroxacin Islt KB;;ACTIVE;2.13;2.19 +35807-7;Florfenicol;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Florfenicol [Susceptibility] by Disk diffusion (KB);Florfenicol Islt KB;;ACTIVE;2.13;2.19 +3580-8;Doxepin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Doxepin [Presence] in Urine;Doxepin Ur Ql;;ACTIVE;1.0;2.73 +35808-5;Florfenicol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Florfenicol [Susceptibility] by Minimum inhibitory concentration (MIC);Florfenicol Islt MIC;;ACTIVE;2.13;2.19 +35809-3;Fosfomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Fosfomycin [Susceptibility] by Gradient strip;Fosfomycin Islt Grad strip;;ACTIVE;2.13;2.73 +35810-1;Fosfomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Fosfomycin [Susceptibility] by Disk diffusion (KB);Fosfomycin Islt KB;;ACTIVE;2.13;2.73 +35811-9;Garenoxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Garenoxacin [Susceptibility] by Disk diffusion (KB);Garenoxacin Islt KB;;ACTIVE;2.13;2.19 +35812-7;Garenoxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Garenoxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Garenoxacin Islt MIC;;ACTIVE;2.13;2.19 +35813-5;Garenoxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Garenoxacin [Susceptibility];Garenoxacin Susc Islt;;ACTIVE;2.13;2.19 +35814-3;Gemifloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Gemifloxacin [Susceptibility] by Disk diffusion (KB);Gemifloxacin Islt KB;;ACTIVE;2.13;2.19 +35815-0;Gemifloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Gemifloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Gemifloxacin Islt MIC;;ACTIVE;2.13;2.19 +3581-6;Doxepin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Doxepin [Mass/volume] in Urine;Doxepin Ur-mCnc;;ACTIVE;1.0;2.73 +35816-8;Gemifloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Gemifloxacin [Susceptibility];Gemifloxacin Susc Islt;;ACTIVE;2.13;2.19 +35817-6;Gentamicin.high potency;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Gentamicin.high potency [Susceptibility] by Gradient strip;Gentamicin Synergy Islt Grad strip;;ACTIVE;2.13;2.56 +35818-4;Grepafloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Grepafloxacin [Susceptibility] by Disk diffusion (KB);Grepafloxacin Islt KB;;ACTIVE;2.13;2.19 +35819-2;Imipenem+EDTA;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Imipenem+EDTA [Susceptibility] by Gradient strip;Imipenem+EDTA Islt Grad strip;;ACTIVE;2.13;2.56 +358-2;Netilmicin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Netilmicin [Susceptibility] by Minimum lethal concentration (MLC);Netilmicin Islt MLC;;ACTIVE;1.0;2.19 +35820-0;Isepamicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Isepamicin [Susceptibility] by Disk diffusion (KB);Isepamicin Islt KB;;ACTIVE;2.13;2.19 +35821-8;Isepamicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Isepamicin [Susceptibility] by Minimum inhibitory concentration (MIC);Isepamicin Islt MIC;;ACTIVE;2.13;2.19 +35822-6;Mupirocin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Mupirocin [Susceptibility] by Disk diffusion (KB);Mupirocin Islt KB;;ACTIVE;2.13;2.19 +35823-4;Mupirocin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Mupirocin [Susceptibility] by Minimum inhibitory concentration (MIC);Mupirocin Islt MIC;;ACTIVE;2.13;2.19 +3582-4;Doxepin+Nordoxepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxepin+Nordoxepin [Mass/volume] in Serum or Plasma;Doxepin+Nor SerPl-mCnc;;ACTIVE;1.0;2.73 +35824-2;Nystatin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Nystatin [Susceptibility] by Disk diffusion (KB);Nystatin Islt KB;;ACTIVE;2.13;2.19 +35825-9;Orbifloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Orbifloxacin [Susceptibility] by Disk diffusion (KB);Orbifloxacin Islt KB;;ACTIVE;2.13;2.19 +35826-7;Orbifloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Orbifloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Orbifloxacin Islt MIC;;ACTIVE;2.13;2.19 +35827-5;Orbifloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Orbifloxacin [Susceptibility];Orbifloxacin Susc Islt;;ACTIVE;2.13;2.19 +35828-3;Pefloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Pefloxacin [Susceptibility] by Disk diffusion (KB);Pefloxacin Islt KB;;ACTIVE;2.13;2.19 +35829-1;Pirlimycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Pirlimycin [Susceptibility] by Disk diffusion (KB);Pirlimycin Islt KB;;ACTIVE;2.13;2.19 +35830-9;Pirlimycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Pirlimycin [Susceptibility] by Minimum inhibitory concentration (MIC);Pirlimycin Islt MIC;;ACTIVE;2.13;2.19 +35831-7;Pirlimycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pirlimycin [Susceptibility];Pirlimycin Susc Islt;;ACTIVE;2.13;2.19 +3583-2;Doxepin+Metabolites;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxepin+Metabolites [Mass/volume] in Serum or Plasma;Doxepin+Metab SerPl-mCnc;;ACTIVE;1.0;2.40 +35832-5;Polymyxin B;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Polymyxin B [Susceptibility] by Gradient strip;Polymyxin B Islt Grad strip;;ACTIVE;2.13;2.56 +35833-3;Pristinamycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Pristinamycin [Susceptibility] by Disk diffusion (KB);Pristinamycin Islt KB;;ACTIVE;2.13;2.19 +35834-1;Pristinamycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Pristinamycin [Susceptibility] by Minimum inhibitory concentration (MIC);Pristinamycin Islt MIC;;ACTIVE;2.13;2.19 +35835-8;Quinupristin+Dalfopristin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Quinupristin+Dalfopristin [Susceptibility] by Disk diffusion (KB);Quinupristin+Dalfoprist Islt KB;;ACTIVE;2.13;2.19 +35836-6;Salinomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Salinomycin [Susceptibility] by Disk diffusion (KB);Salinomycin Islt KB;;ACTIVE;2.13;2.19 +35837-4;Salinomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Salinomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Salinomycin Islt MIC;;ACTIVE;2.13;2.19 +35838-2;Salinomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Salinomycin [Susceptibility];Salinomycin Susc Islt;;ACTIVE;2.13;2.19 +35839-0;Sparfloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Sparfloxacin [Susceptibility] by Disk diffusion (KB);Sparfloxacin Islt KB;;ACTIVE;2.13;2.19 +3584-0;Doxepin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxepin [Mass/volume] in Serum or Plasma --trough;Doxepin Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +35840-8;Spectinomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Spectinomycin [Susceptibility] by Gradient strip;Spectinomycin Islt Grad strip;;ACTIVE;2.13;2.56 +35841-6;Streptomycin.high potency;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Streptomycin.high potency [Susceptibility] by Gradient strip;Streptomycin High Pot Islt Grad strip;;ACTIVE;2.13;2.56 +35842-4;Sulfonamide;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Sulfonamide [Susceptibility] by Gradient strip;Sulfonamide Islt Grad strip;;ACTIVE;2.13;2.56 +35843-2;Telithromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Telithromycin [Susceptibility] by Disk diffusion (KB);Telithromycin Islt KB;;ACTIVE;2.13;2.19 +35844-0;Telithromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Telithromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Telithromycin Islt MIC;;ACTIVE;2.13;2.19 +35845-7;Telithromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Telithromycin [Susceptibility];Telithromycin Susc Islt;;ACTIVE;2.13;2.19 +35846-5;Tiamulin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tiamulin [Susceptibility] by Disk diffusion (KB);Tiamulin Islt KB;;ACTIVE;2.13;2.19 +35847-3;Tiamulin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tiamulin [Susceptibility] by Minimum inhibitory concentration (MIC);Tiamulin Islt MIC;;ACTIVE;2.13;2.19 +35848-1;Tiamulin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tiamulin [Susceptibility];Tiamulin Susc Islt;;ACTIVE;2.13;2.19 +35849-9;Tilmicosin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tilmicosin [Susceptibility] by Disk diffusion (KB);Tilmicosin Islt KB;;ACTIVE;2.13;2.19 +35850-7;Tilmicosin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tilmicosin [Susceptibility] by Minimum inhibitory concentration (MIC);Tilmicosin Islt MIC;;ACTIVE;2.13;2.19 +35851-5;Tilmicosin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tilmicosin [Susceptibility];Tilmicosin Susc Islt;;ACTIVE;2.13;2.19 +35852-3;Trospectinomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Trospectinomycin [Susceptibility] by Disk diffusion (KB);Trospectinomycin Islt KB;;ACTIVE;2.13;2.19 +35853-1;Trospectinomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Trospectinomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Trospectinomycin Islt MIC;;ACTIVE;2.13;2.19 +35854-9;Trospectinomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Trospectinomycin [Susceptibility];Trospectinomycin Susc Islt;;ACTIVE;2.13;2.19 +35855-6;Trovafloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Trovafloxacin [Susceptibility] by Disk diffusion (KB);Trovafloxacin Islt KB;;ACTIVE;2.13;2.19 +35856-4;Tylosin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tylosin [Susceptibility] by Disk diffusion (KB);Tylosin Islt KB;;ACTIVE;2.13;2.19 +3585-7;Doxylamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Doxylamine [Presence] in Serum or Plasma;Doxylamine SerPl Ql;;ACTIVE;1.0;2.56 +35857-2;Tylosin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tylosin [Susceptibility] by Minimum inhibitory concentration (MIC);Tylosin Islt MIC;;ACTIVE;2.13;2.19 +35858-0;Tylosin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tylosin [Susceptibility];Tylosin Susc Islt;;ACTIVE;2.13;2.19 +35859-8;Virginiamycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Virginiamycin [Susceptibility] by Disk diffusion (KB);Virginiamycin Islt KB;;ACTIVE;2.13;2.19 +35860-6;Virginiamycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Virginiamycin [Susceptibility] by Minimum inhibitory concentration (MIC);Virginiamycin Islt MIC;;ACTIVE;2.13;2.19 +35861-4;Virginiamycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Virginiamycin [Susceptibility];Virginiamycin Susc Islt;;ACTIVE;2.13;2.19 +35862-2;Voriconazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Voriconazole [Susceptibility] by Gradient strip;Voriconazole Islt Grad strip;;ACTIVE;2.13;2.56 +35863-0;Voriconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Voriconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Voriconazole Islt MIC;;ACTIVE;2.13;2.73 +35864-8;Chronic lymphocytic leukemia gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Chronic lymphocytic leukemia gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CLL gene Mut Tested Bld/T;;ACTIVE;2.13;2.56 +3586-5;Doxylamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Doxylamine [Presence] in Urine;Doxylamine Ur Ql;;ACTIVE;1.0;2.73 +35865-5;Lipoprotein.intermediate density;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lipoprotein.intermediate density [Presence] in Serum or Plasma;IDL SerPl Ql;;ACTIVE;2.13;2.56 +35866-3;Organic acids panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Organic acids panel - Serum or Plasma;Organic Acids Pnl SerPl;;ACTIVE;2.13;2.42 +35867-1;Acetoacetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acetoacetate [Moles/volume] in Serum or Plasma;Acetoacet SerPl-sCnc;;ACTIVE;2.13;2.73 +35868-9;2-Oxoisovalerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Oxoisovalerate [Moles/volume] in Serum or Plasma;2Oxoisovalerate SerPl-sCnc;;ACTIVE;2.13;2.73 +35869-7;2-Oxo,3-Methylvalerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Oxo,3-Methylvalerate [Moles/volume] in Serum or Plasma;2Oxo3Me-valerate SerPl-sCnc;;ACTIVE;2.13;2.73 +35870-5;2-Oxoisocaproate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Oxoisocaproate [Moles/volume] in Serum or Plasma;2Oxoisocaproate SerPl-sCnc;;ACTIVE;2.13;2.73 +35871-3;Succinate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Succinate [Moles/volume] in Serum or Plasma;Succinate SerPl-sCnc;;ACTIVE;2.13;2.73 +35872-1;Penicillin+Novobiocin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Penicillin+Novobiocin [Susceptibility] by Disk diffusion (KB);Penicillin+Novobiocin Islt KB;;ACTIVE;2.13;2.19 +3587-3;Dyphylline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dyphylline [Mass/volume] in Serum or Plasma;Dyphylline SerPl-mCnc;;ACTIVE;1.0;2.73 +35873-9;Penicillin+Novobiocin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Penicillin+Novobiocin [Susceptibility] by Minimum inhibitory concentration (MIC);Penicillin+Novobiocin Islt MIC;;ACTIVE;2.13;2.19 +35874-7;Penicillin+Novobiocin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Penicillin+Novobiocin [Susceptibility];Penicillin+Novobiocin Susc Islt;;ACTIVE;2.13;2.19 +35875-4;Herpes simplex virus 1+2 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1+2 Ab [Units/volume] in Cerebral spinal fluid;HSV1+2 Ab CSF-aCnc;;ACTIVE;2.13;2.69 +35876-2;Rickettsia sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia sp IgM Ab [Units/volume] in Serum;Rickettsia IgM Ser-aCnc;;ACTIVE;2.13;2.73 +35877-0;Rickettsia sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia sp IgG Ab [Units/volume] in Serum;Rickettsia IgG Ser-aCnc;;ACTIVE;2.13;2.69 +35878-8;Escherichia coli O157:H7 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Escherichia coli O157:H7 IgM Ab [Units/volume] in Serum;E coli O157H7 IgM Ser-aCnc;;ACTIVE;2.13;2.69 +35879-6;Escherichia coli O157:H7 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Escherichia coli O157:H7 IgG Ab [Units/volume] in Serum;E coli O157H7 IgG Ser-aCnc;;ACTIVE;2.13;2.69 +35880-4;Tissue transglutaminase Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Tissue transglutaminase IgM Ab [Units/volume] in Serum;tTG IgM Ser-aCnc;;ACTIVE;2.13;2.73 +3588-1;Emetine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Emetine [Presence] in Urine;Emetine Ur Ql;;ACTIVE;1.0;2.56 +35881-2;Guidance for angioplasty^W contrast IA;Find;Pt;Extremity>Extremity artery;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Extremity artery-- W contrast IA;RFA Guided Extr a Angio--W contr IA;;ACTIVE;2.14;2.64 +35882-0;Guidance for angioplasty^W contrast IV;Find;Pt;Abdomen>Vena cava.inferior;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Inferior vena cava-- W contrast IV;RFA Guided IVC Angio--W contr IV;;ACTIVE;2.14;2.64 +35883-8;Guidance for atherectomy^W contrast IA;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Thoracic and abdominal aorta-- W contrast IA;RFA Guided TA + AA Atherect--W contr IA;;ACTIVE;2.14;2.64 +35884-6;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Abdomen;CT Guided Abd Absc drain+cath place;;ACTIVE;2.14;2.66 +35885-3;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of drainage catheter of Unspecified body region;RF Guided Absc drain+cath place;;ACTIVE;2.14;2.66 +35886-1;Guidance for percutaneous aspiration of fluid;Find;Pt;Breast;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Breast;CT Guided Brst PC fluid asp;;ACTIVE;2.14;2.64 +35887-9;Guidance for percutaneous aspiration of cyst;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Unspecified body region;CT Guided Cyst asp;;ACTIVE;2.14;2.64 +35888-7;Guidance for percutaneous aspiration of fluid;Find;Pt;Lower extremity>Hip;Doc;RF;RAD;2;RF Guidance for arthrocentesis of Hip;RF Guided Hip Arthrocentesis;;ACTIVE;2.14;2.66 +35889-5;Guidance for bronchoscopy;Find;Pt;Chest;Doc;RF;RAD;2;RF Guidance for bronchoscopy of Chest;RF Guided Chest Bronch;;ACTIVE;2.14;2.64 +35890-3;Guidance for percutaneous biopsy;Find;Pt;Abdomen;Doc;RF;RAD;2;RF Guidance for biopsy of Abdomen;RF Guided Abd Bx;;ACTIVE;2.14;2.64 +35891-1;Guidance for percutaneous biopsy;Find;Pt;XXX>Bone;Doc;CT;RAD;2;CT guidance for percutaneous biopsy of Bone;CT Bone PC Bx;;ACTIVE;2.14;2.63 +35892-9;Guidance for percutaneous biopsy;Find;Pt;Head;Doc;CT;RAD;2;CT Guidance for biopsy of Head;CT Guided Head Bx;;ACTIVE;2.14;2.64 +35893-7;Guidance for percutaneous biopsy;Find;Pt;Breast;Doc;CT;RAD;2;CT Guidance for biopsy of Breast;CT Guided Brst Bx;;ACTIVE;2.14;2.64 +35894-5;Guidance for percutaneous biopsy;Find;Pt;Chest;Doc;RF;RAD;2;RF Guidance for biopsy of Chest;RF Guided Chest Bx;;ACTIVE;2.14;2.64 +35895-2;Guidance for percutaneous biopsy;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for biopsy of Chest;CT Guided Chest Bx;;ACTIVE;2.14;2.64 +35896-0;Guidance for percutaneous biopsy;Find;Pt;Lower extremity;Doc;CT;RAD;2;CT Guidance for biopsy of Lower extremity;CT Guided LE Bx;;ACTIVE;2.14;2.64 +35897-8;Guidance for percutaneous biopsy;Find;Pt;Upper extremity;Doc;CT;RAD;2;CT Guidance for biopsy of Upper extremity;CT Guided UE Bx;;ACTIVE;2.14;2.64 +35898-6;Guidance for percutaneous biopsy;Find;Pt;Head>Salivary gland;Doc;CT;RAD;2;CT Guidance for biopsy of Salivary gland;CT Guided Salivary gland Bx;;ACTIVE;2.14;2.64 +3589-9;Encainide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Encainide [Mass/volume] in Serum or Plasma;Encainide SerPl-mCnc;;ACTIVE;1.0;2.42 +35899-4;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney;Doc;RF;RAD;2;RF Guidance for biopsy of Kidney;RF Guided Kidney Bx;;ACTIVE;2.14;2.64 +359-0;Netilmicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Netilmicin [Susceptibility] by Minimum inhibitory concentration (MIC);Netilmicin Islt MIC;;ACTIVE;1.0;2.73 +35900-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;RF Guidance for percutaneous biopsy of Liver;RF Guided Liver Bx;;ACTIVE;2.14;2.64 +35901-8;Guidance for percutaneous biopsy;Find;Pt;XXX>Lymph node;Doc;CT;RAD;2;CT Guidance for biopsy of Lymph node;CT Guided LN Bx;;ACTIVE;2.14;2.64 +35902-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Pancreas;Doc;RF;RAD;2;RF Guidance for biopsy of Pancreas;RF Guided Pancreas Bx;;ACTIVE;2.14;2.64 +35903-4;Guidance for biopsy;Find;Pt;Pelvis>Prostate;Doc;CT;RAD;2;CT Guidance for biopsy of Prostate;CT Guided Prostate Bx;;ACTIVE;2.14;2.64 +35904-2;Guidance for percutaneous biopsy;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Guidance for biopsy of Cervical spine;CT Guided C-spine Bx;;ACTIVE;2.14;2.64 +35905-9;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Guidance for biopsy of Lumbar spine;CT Guided L-spine Bx;;ACTIVE;2.14;2.64 +35906-7;Guidance for percutaneous biopsy;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Guidance for biopsy of Thoracic spine;CT Guided T-spine Bx;;ACTIVE;2.14;2.64 +3590-7;Enoxacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Enoxacin [Mass/volume] in Serum or Plasma;Enoxacin SerPl-mCnc;;ACTIVE;1.0;2.42 +35907-5;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Spleen;Doc;RF;RAD;2;RF Guidance for biopsy of Spleen;RF Guided Spleen Bx;;ACTIVE;2.14;2.64 +35908-3;Guidance for percutaneous biopsy;Find;Pt;Neck>Thyroid gland;Doc;CT;RAD;2;CT Guidance for biopsy of Thyroid gland;CT Guided Thyroid Bx;;ACTIVE;2.14;2.64 +35909-1;Guidance for percutaneous biopsy^W contrast IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for biopsy of Chest-- W contrast IV;CT Guided Chest Bx--W contr IV;;ACTIVE;2.14;2.64 +35910-9;Guidance for percutaneous biopsy^WO & W contrast IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for biopsy of Chest-- WO and W contrast IV;CT Guided Chest Bx--WO+W contr IV;;ACTIVE;2.14;2.64 +35911-7;Guidance for percutaneous biopsy^WO contrast;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for biopsy of Chest-- WO contrast;CT Guided Chest Bx--WO contr;;ACTIVE;2.14;2.64 +35912-5;Guidance for placement of catheter;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for placement of catheter in Unspecified body region;RF Guided Cath place;;ACTIVE;2.14;2.64 +35913-3;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Abdomen;CT Guided Abd Drain+cath place;;ACTIVE;2.14;2.66 +35914-1;Guidance for drainage+placement of drainage catheter;Find;Pt;Pelvis>Anus;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Anus;CT Guided Anus Drain+cath place;;ACTIVE;2.14;2.66 +3591-5;ePHEDrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ePHEDrine [Mass/volume] in Serum or Plasma;Ephedrin SerPl-mCnc;;ACTIVE;1.0;2.73 +35915-8;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen+Pelvis>Appendix;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Appendix;CT Guided Appendix Drain+cath place;;ACTIVE;2.14;2.66 +35916-6;Guidance for drainage+placement of drainage catheter;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Chest;CT Guided Chest Drain+cath place;;ACTIVE;2.14;2.66 +35917-4;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Gallbladder;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Gallbladder;CT Guided GB Drain+cath place;;ACTIVE;2.14;2.66 +35918-2;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Kidney;CT Guided Kidney Drain+cath place;;ACTIVE;2.14;2.66 +35919-0;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Liver;CT Guided Liver Drain+cath place;;ACTIVE;2.14;2.66 +35920-8;Guidance for drainage;Find;Pt;XXX>Lymph node;Doc;CT;RAD;2;CT Guidance for drainage of Lymph node;CT Guided LN Drainage;;ACTIVE;2.14;2.64 +35921-6;Guidance for drainage+placement of drainage catheter;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Pelvis;CT Guided Pelvis Drain+cath place;;ACTIVE;2.14;2.66 +35922-4;Guidance for drainage+placement of drainage catheter;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Unspecified body region;CT Guided Drain+cath place;;ACTIVE;2.14;2.66 +3592-3;ePHEDrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;ePHEDrine [Presence] in Urine;Ephedrin Ur Ql;;ACTIVE;1.0;2.73 +35923-2;Guidance for drainage+placement of drainage catheter^W contrast IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Chest-- W contrast IV;CT Guide Chst Drn+cath plc--W contr IV;;ACTIVE;2.14;2.66 +35924-0;Guidance for drainage+placement of drainage catheter^WO contrast;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Chest-- WO contrast;CT Guide Chest Drn+cath place--WO contr;;ACTIVE;2.14;2.66 +35925-7;Guidance for endoscopy;Find;Pt;Abdomen>Stomach;Doc;RF;RAD;2;RF Guidance for endoscopy of Stomach;RF Guided Stom Endo;;ACTIVE;2.14;2.64 +35926-5;Guidance for gastrostomy;Find;Pt;Abdomen>Stomach;Doc;RF;RAD;2;RF Guidance for gastrostomy of Stomach;RF Guided Stom Gastrostomy;;ACTIVE;2.14;2.64 +35927-3;Guidance for injection;Find;Pt;Pelvis>Sacroiliac joint;Doc;RF;RAD;2;RF Guidance for injection of Sacroiliac Joint;RF Guided SIJ Inj;;ACTIVE;2.14;2.64 +35928-1;Guidance for localization;Find;Pt;Breast.left;Doc;CT;RAD;2;CT Guidance for localization of Breast - left;CT Guided Brst-L Loc;;ACTIVE;2.14;2.64 +35929-9;Guidance for localization;Find;Pt;Breast.right;Doc;CT;RAD;2;CT Guidance for localization of Breast - right;CT Guided Brst-R Loc;;ACTIVE;2.14;2.64 +35930-7;Guidance for nerve block;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for nerve block of Abdomen;CT Guided Abd Nerve block;;ACTIVE;2.14;2.64 +3593-1;ePHEDrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;ePHEDrine [Mass/volume] in Urine;Ephedrin Ur-mCnc;;ACTIVE;1.0;2.73 +35931-5;Guidance for nerve block;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for nerve block of Pelvis;CT Guided Pelvis Nerve block;;ACTIVE;2.14;2.64 +35932-3;Guidance for nerve block;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Guidance for nerve block of Lumbar spine;CT Guided L-spine Nerve block;;ACTIVE;2.14;2.64 +35933-1;Guidance for percutaneous vertebroplasty;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Guidance for percutaneous vertebroplasty of Spine;CT Guided Spine PC Vertebroplasty;;DISCOURAGED;2.14;2.64 +35934-9;Guidance for percutaneous vertebroplasty;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Guidance for percutaneous vertebroplasty of Lumbar spine;CT Guided L-spine PC Vertebroplasty;;ACTIVE;2.14;2.64 +35935-6;Guidance for percutaneous vertebroplasty;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Guidance for percutaneous vertebroplasty of Thoracic spine;CT Guided T-spine PC Vertebroplasty;;ACTIVE;2.14;2.64 +35936-4;Guidance for percutaneous vertebroplasty;Find;Pt;XXX>Spine;Doc;RF;RAD;2;RF Guidance for percutaneous vertebroplasty of Spine;RF Guided Spine PC Vertebroplasty;;DISCOURAGED;2.14;2.64 +35937-2;Guidance for placement of radiation therapy fields;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for placement of radiation therapy fields in Unspecified body region;CT Guided RT fields place;;ACTIVE;2.14;2.64 +35938-0;Guidance for placement of tube;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for placement of tube in Chest;CT Guided Chest Tube place;;ACTIVE;2.14;2.64 +35939-8;Multisection;Find;Pt;Lower extremity>Ankle;Doc;XR.tomography;RAD;2;XR tomography Ankle;XR tomo Ankle;;ACTIVE;2.14;2.61 +35940-6;Multisection;Find;Pt;Lower extremity>Ankle;Doc;CT;RAD;2;CT Ankle;CT Ankle;;ACTIVE;2.14;2.73 +35941-4;Multisection;Find;Pt;Lower extremity.bilateral>Ankle;Doc;CT;RAD;2;CT Ankle - bilateral;CT Ankle-Bl;;ACTIVE;2.14;2.61 +35942-2;Multisection;Find;Pt;Lower extremity.left>Ankle;Doc;CT;RAD;2;CT Ankle - left;CT Ankle-L;;ACTIVE;2.14;2.61 +35943-0;Multisection;Find;Pt;Lower extremity.left>Ankle;Doc;XR.tomography;RAD;2;XR tomography Ankle - left;XR tomo Ankle-L;;ACTIVE;2.14;2.61 +35944-8;Multisection;Find;Pt;Lower extremity.right>Ankle;Doc;CT;RAD;2;CT Ankle - right;CT Ankle-R;;ACTIVE;2.14;2.61 +35945-5;Multisection;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Thoracic and abdominal aorta;CT TA + AA;;ACTIVE;2.14;2.61 +35946-3;Multisection;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;MR.angio;RAD;2;MRA Thoracic and abdominal aorta;MRA TA + AA;;ACTIVE;2.14;2.61 +35947-1;Multisection;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;MR;RAD;2;MR Thoracic and abdominal aorta;MR TA + AA;;ACTIVE;2.14;2.61 +35948-9;Multisection;Find;Pt;Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Abdominal Aorta;CT Abd Aorta;;ACTIVE;2.14;2.61 +3594-9;Ephedrine+Pseudoephedrine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Presence] in Serum or Plasma;Ephedrin+Pseudo SerPl Ql;;ACTIVE;1.0;2.56 +35949-7;Multisection;Find;Pt;Abdomen>Aorta.abdominal;Doc;MR;RAD;2;MR Abdominal Aorta;MR Abd Aorta;;ACTIVE;2.14;2.61 +35950-5;Multisection;Find;Pt;Chest>Aorta.thoracic;Doc;MR;RAD;2;MR Thoracic Aorta;MR TA;;ACTIVE;2.14;2.61 +35951-3;Multisection;Find;Pt;Chest>Aortic arch;Doc;MR.angio;RAD;2;MRA Aortic arch;MRA Ao arch;;ACTIVE;2.14;2.61 +35952-1;Multisection;Find;Pt;Abdomen+Pelvis>Appendix;Doc;CT;RAD;2;CT Appendix;CT Appendix;;ACTIVE;2.14;2.61 +35953-9;Multisection;Find;Pt;Head>Face;Doc;MR;RAD;2;MR Face;MR Face;;ACTIVE;2.14;2.61 +35954-7;Multisection;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Breast - left;MR Brst-L;;ACTIVE;2.14;2.61 +35955-4;Multisection;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Breast - right;MR Brst-R;;ACTIVE;2.14;2.61 +3595-6;Ephedrine+Pseudoephedrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Mass/volume] in Serum or Plasma;Ephedrin+Pseudo SerPl-mCnc;;ACTIVE;1.0;2.73 +35956-2;Multisection;Find;Pt;Head>Internal auditory canal;Doc;MR;RAD;2;MR Internal auditory canal;MR IAC;;ACTIVE;2.14;2.61 +35957-0;Multisection;Find;Pt;Head>Internal auditory canal.left;Doc;CT;RAD;2;CT Internal auditory canal - left;CT IAC-L;;ACTIVE;2.14;2.61 +35958-8;Multisection;Find;Pt;Head>Internal auditory canal;Doc;CT;RAD;2;CT Internal auditory canal;CT IAC;;ACTIVE;2.14;2.73 +35959-6;Multisection;Find;Pt;Chest>Clavicle;Doc;XR.tomography;RAD;2;XR tomography Clavicle;XR tomo Clavicle;;ACTIVE;2.14;2.61 +35960-4;Multisection;Find;Pt;Chest>Clavicle;Doc;CT;RAD;2;CT Clavicle;CT Clavicle;;ACTIVE;2.14;2.73 +35961-2;Multisection;Find;Pt;Chest>Clavicle;Doc;MR;RAD;2;MR Clavicle;MR Clavicle;;ACTIVE;2.14;2.61 +35962-0;Multisection;Find;Pt;Upper extremity>Elbow;Doc;CT;RAD;2;CT Elbow;CT Elbow;;ACTIVE;2.14;2.73 +35963-8;Multisection;Find;Pt;Upper extremity>Elbow;Doc;XR.tomography;RAD;2;XR tomography Elbow;XR tomo Elbow;;ACTIVE;2.14;2.61 +3596-4;Ephedrine+Pseudoephedrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Presence] in Urine;Ephedrin+Pseudo Ur Ql;;ACTIVE;1.0;2.73 +35964-6;Multisection;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR.tomography;RAD;2;XR tomography Elbow - bilateral;XR tomo Elbow-Bl;;ACTIVE;2.14;2.61 +35965-3;Multisection;Find;Pt;Upper extremity.bilateral>Elbow;Doc;CT;RAD;2;CT Elbow - bilateral;CT Elbow-Bl;;ACTIVE;2.14;2.61 +35966-1;Multisection;Find;Pt;Upper extremity.left>Elbow;Doc;CT;RAD;2;CT Elbow - left;CT Elbow-L;;ACTIVE;2.14;2.61 +35967-9;Multisection;Find;Pt;Upper extremity.left>Elbow;Doc;XR.tomography;RAD;2;XR tomography Elbow - left;XR tomo Elbow-L;;ACTIVE;2.14;2.61 +35968-7;Multisection;Find;Pt;Upper extremity.right>Elbow;Doc;CT;RAD;2;CT Elbow - right;CT Elbow-R;;ACTIVE;2.14;2.61 +35969-5;Multisection;Find;Pt;Chest>Esophagus;Doc;CT;RAD;2;CT Esophagus;CT Esophagus;;ACTIVE;2.14;2.73 +35970-3;Multisection;Find;Pt;Extremity;Doc;XR.tomography;RAD;2;XR tomography Extremity;XR tomo Extr;;ACTIVE;2.14;2.61 +35971-1;Multisection;Find;Pt;Lower extremity;Doc;CT;RAD;2;CT Lower extremity;CT LE;;ACTIVE;2.14;2.73 +3597-2;Erythromycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Erythromycin [Mass/volume] in Serum or Plasma;Erythromycin SerPl-mCnc;;ACTIVE;1.0;2.73 +35972-9;Multisection;Find;Pt;Lower extremity;Doc;XR.tomography;RAD;2;XR tomography Lower extremity;XR tomo LE;;ACTIVE;2.14;2.61 +35973-7;Multisection;Find;Pt;Lower extremity.bilateral;Doc;CT;RAD;2;CT Lower extremity - bilateral;CT LE-Bl;;ACTIVE;2.14;2.61 +35974-5;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - bilateral;MRA LE ves-Bl;;ACTIVE;2.14;2.61 +35975-2;Multisection;Find;Pt;Lower extremity.bilateral;Doc;MR;RAD;2;MR Lower extremity - bilateral;MR LE-Bl;;ACTIVE;2.14;2.61 +35976-0;Multisection;Find;Pt;Lower extremity.left;Doc;CT;RAD;2;CT Lower extremity - left;CT LE-L;;ACTIVE;2.14;2.61 +35977-8;Multisection;Find;Pt;Lower extremity.left;Doc;XR.tomography;RAD;2;XR tomography Lower extremity - left;XR tomo LE-L;;ACTIVE;2.14;2.61 +35978-6;Multisection;Find;Pt;Lower extremity.left;Doc;MR;RAD;2;MR Lower extremity - left;MR LE-L;;ACTIVE;2.14;2.61 +35979-4;Multisection;Find;Pt;Lower extremity.right;Doc;CT;RAD;2;CT Lower extremity - right;CT LE-R;;ACTIVE;2.14;2.73 +3598-0;Estazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Estazolam [Mass/volume] in Urine;Estazolam Ur-mCnc;;ACTIVE;1.0;2.73 +35980-2;Multisection;Find;Pt;Lower extremity.right;Doc;MR;RAD;2;MR Lower extremity - right;MR LE-R;;ACTIVE;2.14;2.61 +35981-0;Multisection;Find;Pt;Upper extremity;Doc;CT;RAD;2;CT Upper extremity;CT UE;;ACTIVE;2.14;2.73 +35982-8;Multisection;Find;Pt;Upper extremity.left;Doc;CT;RAD;2;CT Upper extremity - left;CT UE-L;;ACTIVE;2.14;2.61 +35983-6;Multisection;Find;Pt;Upper extremity.right;Doc;CT;RAD;2;CT Upper extremity - right;CT UE-R;;ACTIVE;2.14;2.61 +35984-4;Multisection;Find;Pt;Lower extremity>Thigh;Doc;CT;RAD;2;CT Thigh;CT Thigh;;ACTIVE;2.14;2.73 +35985-1;Multisection;Find;Pt;Lower extremity>Femur;Doc;XR.tomography;RAD;2;XR tomography Femur;XR tomo Femur;;ACTIVE;2.14;2.61 +35986-9;Multisection;Find;Pt;Lower extremity.bilateral>Femur;Doc;XR.tomography;RAD;2;XR tomography Femur - bilateral;XR tomo Femur-Bl;;ACTIVE;2.14;2.61 +35987-7;Multisection;Find;Pt;Lower extremity.left>Thigh;Doc;CT;RAD;2;CT Thigh - left;CT Thigh-L;;ACTIVE;2.14;2.61 +35988-5;Multisection;Find;Pt;Lower extremity.left>Femur;Doc;XR.tomography;RAD;2;XR tomography Femur - left;XR tomo Femur-L;;ACTIVE;2.14;2.61 +35989-3;Multisection;Find;Pt;Lower extremity.right>Thigh;Doc;CT;RAD;2;CT Thigh - right;CT Thigh-R;;ACTIVE;2.14;2.61 +35990-1;Multisection;Find;Pt;^Fetus;Doc;MR;RAD;2;MR Fetal;MR Fet;;ACTIVE;2.14;2.61 +35991-9;Multisection;Find;Pt;Lower extremity>Foot;Doc;CT;RAD;2;CT Foot;CT Foot;;ACTIVE;2.14;2.73 +35992-7;Multisection;Find;Pt;Lower extremity>Foot;Doc;XR.tomography;RAD;2;XR tomography Foot;XR tomo Foot;;ACTIVE;2.14;2.61 +35993-5;Multisection;Find;Pt;Lower extremity.bilateral>Foot;Doc;CT;RAD;2;CT Foot - bilateral;CT Foot-Bl;;ACTIVE;2.14;2.61 +35994-3;Multisection;Find;Pt;Lower extremity.left>Foot;Doc;CT;RAD;2;CT Foot - left;CT Foot-L;;ACTIVE;2.14;2.73 +35995-0;Multisection;Find;Pt;Lower extremity.left>Foot;Doc;XR.tomography;RAD;2;XR tomography Foot - left;XR tomo Foot-L;;ACTIVE;2.14;2.61 +35996-8;Multisection;Find;Pt;Lower extremity.right>Foot;Doc;CT;RAD;2;CT Foot - right;CT Foot-R;;ACTIVE;2.14;2.73 +35997-6;Multisection;Find;Pt;Upper extremity>Forearm;Doc;CT;RAD;2;CT Forearm;CT Forearm;;ACTIVE;2.14;2.61 +3599-8;Etafedrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Etafedrine [Presence] in Urine;Etafedrine Ur Ql;;ACTIVE;1.0;2.56 +35998-4;Multisection;Find;Pt;Upper extremity.bilateral>Forearm;Doc;CT;RAD;2;CT Forearm - bilateral;CT Forearm-Bl;;ACTIVE;2.14;2.61 +35999-2;Multisection;Find;Pt;Upper extremity.left>Forearm;Doc;CT;RAD;2;CT Forearm - left;CT Forearm-L;;ACTIVE;2.14;2.61 +36000-8;Multisection;Find;Pt;Upper extremity.right>Forearm;Doc;CT;RAD;2;CT Forearm - right;CT Forearm-R;;ACTIVE;2.14;2.61 +36001-6;Multisection;Find;Pt;Abdomen>Gallbladder;Doc;XR.tomography;RAD;2;XR tomography Gallbladder;XR tomo GB;;ACTIVE;2.14;2.61 +36002-4;Multisection;Find;Pt;Upper extremity>Hand;Doc;CT;RAD;2;CT Hand;CT Hand;;ACTIVE;2.14;2.73 +36003-2;Multisection;Find;Pt;Upper extremity>Hand;Doc;XR.tomography;RAD;2;XR tomography Hand;XR tomo Hand;;ACTIVE;2.14;2.73 +3600-4;Etafedrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Etafedrine [Mass/volume] in Urine;Etafedrine Ur-mCnc;;ACTIVE;1.0;2.42 +36004-0;Multisection;Find;Pt;Upper extremity.bilateral>Hand;Doc;CT;RAD;2;CT Hand - bilateral;CT Hand-Bl;;ACTIVE;2.14;2.61 +36005-7;Multisection;Find;Pt;Upper extremity.left>Hand;Doc;CT;RAD;2;CT Hand - left;CT Hand-L;;ACTIVE;2.14;2.61 +36006-5;Multisection;Find;Pt;Upper extremity.left>Hand;Doc;XR.tomography;RAD;2;XR tomography Hand - left;XR tomo Hand-L;;ACTIVE;2.14;2.61 +36007-3;Multisection;Find;Pt;Upper extremity.right>Hand;Doc;CT;RAD;2;CT Hand - right;CT Hand-R;;ACTIVE;2.14;2.61 +36008-1;Multisection;Find;Pt;Upper extremity>Wrist+Hand;Doc;MR;RAD;2;MR Wrist and Hand;MR Wrist+Hand;;ACTIVE;2.14;2.61 +36009-9;Multisection;Find;Pt;Chest>Heart;Doc;MR.angio;RAD;2;MRA Heart;MRA Hrt;;ACTIVE;2.14;2.61 +36010-7;Multisection;Find;Pt;Calcaneus;Doc;CT;RAD;2;Deprecated Calcaneus CT;Deprecated Heel CT;;DEPRECATED;2.14;2.58 +36011-5;Multisection;Find;Pt;Lower extremity>Calcaneus;Doc;XR.tomography;RAD;2;XR tomography Calcaneus;XR tomo Heel;;ACTIVE;2.14;2.61 +3601-2;Etafedrine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Etafedrine [Mass/time] in 24 hour Urine;Etafedrine 24h Ur-mRate;;ACTIVE;1.0;2.42 +36012-3;Multisection;Find;Pt;Lower extremity>Hip;Doc;XR.tomography;RAD;2;XR tomography Hip;XR tomo Hip;;ACTIVE;2.14;2.61 +36013-1;Multisection;Find;Pt;Lower extremity>Hip;Doc;MR;RAD;2;MR Hip;MR Hip;;ACTIVE;2.14;2.61 +36014-9;Multisection;Find;Pt;Lower extremity>Hip;Doc;CT;RAD;2;CT Hip;CT Hip;;ACTIVE;2.14;2.73 +36015-6;Multisection;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR.tomography;RAD;2;XR tomography Hip - bilateral;XR tomo Hip-Bl;;ACTIVE;2.14;2.61 +36016-4;Multisection;Find;Pt;Lower extremity.bilateral>Hip;Doc;CT;RAD;2;CT Hip - bilateral;CT Hip-Bl;;ACTIVE;2.14;2.61 +36017-2;Multisection;Find;Pt;Lower extremity.bilateral>Hip;Doc;MR;RAD;2;MR Hip - bilateral;MR Hip-Bl;;ACTIVE;2.14;2.61 +36018-0;Multisection;Find;Pt;Lower extremity.left>Hip;Doc;CT;RAD;2;CT Hip - left;CT Hip-L;;ACTIVE;2.14;2.61 +36019-8;Multisection;Find;Pt;Lower extremity.left>Hip;Doc;XR.tomography;RAD;2;XR tomography Hip - left;XR tomo Hip-L;;ACTIVE;2.14;2.61 +3602-0;Etamivan;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Etamivan [Presence] in Urine;Etamivan Ur Ql;;ACTIVE;1.0;2.56 +36020-6;Multisection;Find;Pt;Lower extremity.left>Hip;Doc;MR;RAD;2;MR Hip - left;MR Hip-L;;ACTIVE;2.14;2.61 +36021-4;Multisection;Find;Pt;Lower extremity.right>Hip;Doc;CT;RAD;2;CT Hip - right;CT Hip-R;;ACTIVE;2.14;2.61 +36022-2;Multisection;Find;Pt;Lower extremity.right>Hip;Doc;MR;RAD;2;MR Hip - right;MR Hip-R;;ACTIVE;2.14;2.61 +36023-0;Multisection;Find;Pt;Upper extremity>Upper arm;Doc;CT;RAD;2;CT Upper arm;CT Upper arm;;ACTIVE;2.14;2.61 +36024-8;Multisection;Find;Pt;Upper extremity>Humerus;Doc;XR.tomography;RAD;2;XR tomography Humerus;XR tomo Humerus;;ACTIVE;2.14;2.61 +36025-5;Multisection;Find;Pt;Upper extremity>Upper arm;Doc;MR;RAD;2;MR Upper arm;MR Upper arm;;ACTIVE;2.14;2.61 +36026-3;Multisection;Find;Pt;Upper extremity.bilateral>Upper arm;Doc;CT;RAD;2;CT Upper arm - bilateral;CT Upper arm-Bl;;ACTIVE;2.14;2.61 +36027-1;Multisection;Find;Pt;Upper extremity.left>Upper arm;Doc;CT;RAD;2;CT Upper arm - left;CT Upper arm-L;;ACTIVE;2.14;2.73 +36028-9;Multisection;Find;Pt;Upper extremity.left>Upper arm;Doc;MR;RAD;2;MR Upper arm - left;MR Upper arm-L;;ACTIVE;2.14;2.61 +36029-7;Multisection;Find;Pt;Upper extremity.right>Upper arm;Doc;CT;RAD;2;CT Upper arm - right;CT Upper arm-R;;ACTIVE;2.14;2.73 +36030-5;Multisection;Find;Pt;Upper extremity.right>Upper arm;Doc;MR;RAD;2;MR Upper arm - right;MR Upper arm-R;;ACTIVE;2.14;2.61 +36031-3;Multisection;Find;Pt;Pelvis>Sacroiliac joint;Doc;MR;RAD;2;MR Sacroiliac Joint;MR SIJ;;ACTIVE;2.14;2.61 +36032-1;Multisection;Find;Pt;Abdomen>Kidney;Doc;XR.tomography;RAD;2;XR tomography Kidney;XR tomo Kidney;;ACTIVE;2.14;2.61 +36033-9;Multisection;Find;Pt;Abdomen>Kidney;Doc;MR;RAD;2;MR Kidney;MR Kidney;;ACTIVE;2.14;2.61 +36034-7;Multisection;Find;Pt;Abdomen>Kidney.bilateral;Doc;MR;RAD;2;MR Kidney - bilateral;MR Kdny-Bl;;ACTIVE;2.14;2.61 +36035-4;Multisection;Find;Pt;Abdomen>Kidney.left;Doc;MR;RAD;2;MR Kidney - left;MR Kidney-L;;ACTIVE;2.14;2.61 +36036-2;Multisection;Find;Pt;Abdomen>Kidney.right;Doc;MR;RAD;2;MR Kidney - right;MR Kidney-R;;ACTIVE;2.14;2.61 +36037-0;Multisection;Find;Pt;Lower extremity>Knee;Doc;CT;RAD;2;CT Knee;CT Knee;;ACTIVE;2.14;2.73 +3603-8;Etamivan;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Etamivan [Mass/volume] in Urine;Etamivan Ur-mCnc;;ACTIVE;1.0;2.42 +36038-8;Multisection;Find;Pt;Lower extremity>Knee;Doc;XR.tomography;RAD;2;XR tomography Knee;XR tomo Knee;;ACTIVE;2.14;2.61 +36039-6;Multisection;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR.tomography;RAD;2;XR tomography Knee - bilateral;XR tomo Knee-Bl;;ACTIVE;2.14;2.61 +36040-4;Multisection;Find;Pt;Lower extremity.bilateral>Knee;Doc;CT;RAD;2;CT Knee - bilateral;CT Knee-Bl;;ACTIVE;2.14;2.61 +36041-2;Multisection;Find;Pt;Lower extremity.left>Knee;Doc;CT;RAD;2;CT Knee - left;CT Knee-L;;ACTIVE;2.14;2.73 +36042-0;Multisection;Find;Pt;Lower extremity.left>Knee;Doc;XR.tomography;RAD;2;XR tomography Knee - left;XR tomo Knee-L;;ACTIVE;2.14;2.61 +36043-8;Multisection;Find;Pt;Lower extremity.right>Knee;Doc;CT;RAD;2;CT Knee - right;CT Knee-R;;ACTIVE;2.14;2.61 +36044-6;Multisection;Find;Pt;Head+Neck>Larynx;Doc;XR.tomography;RAD;2;XR tomography Larynx;XR tomo Larynx;;ACTIVE;2.14;2.61 +36045-3;Multisection;Find;Pt;Head+Neck>Larynx;Doc;MR;RAD;2;MR Larynx;MR Larynx;;ACTIVE;2.14;2.61 +3604-6;Etamivan;MRat;24H;Urine;Qn;;DRUG/TOX;1;Etamivan [Mass/time] in 24 hour Urine;Etamivan 24h Ur-mRate;;ACTIVE;1.0;2.42 +36046-1;Multisection;Find;Pt;Abdomen>Liver;Doc;MR;RAD;2;MR Liver;MR Liver;;ACTIVE;2.14;2.61 +36047-9;Multisection;Find;Pt;Head>Mandible;Doc;CT;RAD;2;CT Mandible;CT Mandible;;ACTIVE;2.14;2.73 +36048-7;Multisection;Find;Pt;Head>Mandible;Doc;XR.tomography;RAD;2;XR tomography Mandible;XR tomo Mandible;;ACTIVE;2.14;2.61 +36049-5;Multisection;Find;Pt;Head>Maxilla+Mandible;Doc;CT;RAD;2;CT Maxilla and Mandible;CT Max+Mand;;ACTIVE;2.14;2.61 +36050-3;Multisection;Find;Pt;Head>Maxilla;Doc;CT;RAD;2;CT Maxilla;CT Maxilla;;ACTIVE;2.14;2.73 +36051-1;Multisection;Find;Pt;Neck;Doc;CT;RAD;2;CT Neck;CT Neck;;ACTIVE;2.14;2.73 +36052-9;Multisection;Find;Pt;Abdomen>Pancreas;Doc;MR;RAD;2;MR Pancreas;MR Pancreas;;ACTIVE;2.14;2.61 +3605-3;Ethacrynate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethacrynate [Presence] in Urine;Ethacrynate Ur Ql;;ACTIVE;1.0;2.73 +36053-7;Multisection;Find;Pt;Neck>Parathyroid gland;Doc;MR;RAD;2;MR Parathyroid gland;MR Parathyroid gland;;ACTIVE;2.14;2.61 +36054-5;Multisection;Find;Pt;Chest>Brachial plexus;Doc;CT;RAD;2;CT Brachial plexus;CT Brachial plexus;;ACTIVE;2.14;2.61 +36055-2;Multisection;Find;Pt;Head>Posterior fossa;Doc;CT;RAD;2;CT Posterior fossa;CT Post fossa;;ACTIVE;2.14;2.61 +36056-0;Multisection;Find;Pt;Head>Posterior fossa;Doc;MR;RAD;2;MR Posterior fossa;MR Post fossa;;ACTIVE;2.14;2.61 +36057-8;Multisection;Find;Pt;Pelvis>Prostate;Doc;CT;RAD;2;CT Prostate;CT Prostate;;ACTIVE;2.14;2.61 +36058-6;Multisection;Find;Pt;Pelvis>Sacrum;Doc;CT;RAD;2;CT Sacrum;CT Sacrum;;ACTIVE;2.14;2.61 +36059-4;Multisection;Find;Pt;Pelvis>Sacrum;Doc;MR;RAD;2;MR Sacrum;MR Sacrum;;ACTIVE;2.14;2.61 +36060-2;Multisection;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;MR;RAD;2;MR Sacrum and Coccyx;MR Sacrum+Coccyx;;ACTIVE;2.14;2.61 +3606-1;Ethacrynate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethacrynate [Mass/volume] in Urine;Ethacrynate Ur-mCnc;;ACTIVE;1.0;2.34 +36061-0;Multisection;Find;Pt;Chest>Scapula;Doc;MR;RAD;2;MR Scapula;MR Scapula;;ACTIVE;2.14;2.61 +36062-8;Multisection;Find;Pt;Upper extremity>Shoulder;Doc;CT;RAD;2;CT Shoulder;CT Should;;ACTIVE;2.14;2.73 +36063-6;Multisection;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;CT;RAD;2;CT Shoulder - bilateral;CT Shoulder-Bl;;ACTIVE;2.14;2.61 +36064-4;Multisection;Find;Pt;Upper extremity.left>Shoulder;Doc;CT;RAD;2;CT Shoulder - left;CT Should-L;;ACTIVE;2.14;2.61 +36065-1;Multisection;Find;Pt;Upper extremity.left>Shoulder;Doc;XR.tomography;RAD;2;XR tomography Shoulder - left;XR tomo Should-L;;ACTIVE;2.14;2.61 +36066-9;Multisection;Find;Pt;Upper extremity.right>Shoulder;Doc;CT;RAD;2;CT Shoulder - right;CT Should-R;;ACTIVE;2.14;2.73 +36067-7;Multisection;Find;Pt;XXX>Spine;Doc;MR;RAD;2;MR Spine;MR Spine;;DISCOURAGED;2.14;2.61 +36068-5;Multisection;Find;Pt;Neck>Spine.cervical;Doc;XR.tomography;RAD;2;XR tomography Cervical spine;XR tomo C-spine;;ACTIVE;2.14;2.61 +36069-3;Multisection;Find;Pt;Abdomen>Spine.lumbar;Doc;XR.tomography;RAD;2;XR tomography Lumbar spine;XR tomo L-spine;;ACTIVE;2.14;2.61 +36070-1;Multisection;Find;Pt;Abdomen>Spleen;Doc;MR;RAD;2;MR Spleen;MR Spleen;;ACTIVE;2.14;2.61 +36071-9;Multisection;Find;Pt;Chest>Sternum;Doc;CT;RAD;2;CT Sternum;CT Sternum;;ACTIVE;2.14;2.61 +36072-7;Multisection;Find;Pt;Chest>Sternum;Doc;MR;RAD;2;MR Sternum;MR Sternum;;ACTIVE;2.14;2.61 +36073-5;Multisection;Find;Pt;Pelvis>Scrotum+Testicle;Doc;MR;RAD;2;MR Scrotum and testicle;MR Scrotum+Test;;ACTIVE;2.14;2.61 +36074-3;Multisection;Find;Pt;Lower extremity>Lower leg;Doc;CT;RAD;2;CT Lower leg;CT Lower leg;;ACTIVE;2.14;2.61 +36075-0;Multisection;Find;Pt;Lower extremity.left>Lower leg;Doc;MR;RAD;2;MR Lower leg - left;MR Lower leg-L;;ACTIVE;2.14;2.61 +36076-8;Multisection;Find;Pt;Lower extremity.right>Lower leg;Doc;MR;RAD;2;MR Lower leg - right;MR Lower leg-R;;ACTIVE;2.14;2.61 +36077-6;Multisection;Find;Pt;Abdomen>Portal vein;Doc;MR.angio;RAD;2;MRA Portal vein;MRA Portal v;;ACTIVE;2.14;2.61 +36078-4;Multisection;Find;Pt;Abdomen>Renal vein;Doc;MR.angio;RAD;2;MRA Renal vein;MRA Renal v;;ACTIVE;2.14;2.61 +3607-9;Ethambutol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethambutol [Mass/volume] in Serum or Plasma;Ethambutol SerPl-mCnc;;ACTIVE;1.0;2.73 +36079-2;Multisection;Find;Pt;Lower extremity>Lower extremity veins;Doc;MR.angio;RAD;2;MRA Lower extremity veins;MRA LE vv;;ACTIVE;2.14;2.61 +360-8;Netilmicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Netilmicin [Susceptibility] by Disk diffusion (KB);Netilmicin Islt KB;;ACTIVE;1.0;2.19 +36080-0;Multisection;Find;Pt;Upper extremity>Upper extremity veins;Doc;MR.angio;RAD;2;MRA Upper extremity veins;MRA UE vv;;ACTIVE;2.14;2.61 +36081-8;Multisection;Find;Pt;Chest+Abdomen>Vena cava.superior &or Vena cava.inferior;Doc;MR.angio;RAD;2;MRA Vena cava;MRA Vena cava;;ACTIVE;2.14;2.61 +36082-6;Multisection;Find;Pt;Abdomen>Vena cava.inferior;Doc;MR.angio;RAD;2;MRA Inferior vena cava;MRA IVC;;ACTIVE;2.14;2.61 +36083-4;Multisection;Find;Pt;Abdomen>Vena cava.inferior;Doc;MR;RAD;2;MR Inferior vena cava;MR IVC;;ACTIVE;2.14;2.61 +36084-2;Multisection;Find;Pt;Upper extremity>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels;MRA UE ves;;ACTIVE;2.14;2.61 +36085-9;Multisection;Find;Pt;Neck>Neck vessels;Doc;MR.angio;RAD;2;MRA Neck vessels;MRA Neck ves;;ACTIVE;2.14;2.73 +36086-7;Multisection limited;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen limited;CT Abd Ltd;;ACTIVE;2.14;2.61 +3608-7;Ethchlorvynol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethchlorvynol [Mass/volume] in Blood;Ethchlorvynol Bld-mCnc;;ACTIVE;1.0;2.40 +36087-5;Multisection limited;Find;Pt;Head;Doc;CT;RAD;2;CT Head limited;CT Head Ltd;;ACTIVE;2.14;2.61 +36088-3;Multisection limited;Find;Pt;Head>Internal auditory canal;Doc;MR;RAD;2;MR Internal auditory canal limited;MR IAC Ltd;;ACTIVE;2.14;2.61 +36089-1;Multisection limited;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest limited;CT Chest Ltd;;ACTIVE;2.14;2.61 +36090-9;Multisection limited;Find;Pt;Extremity;Doc;CT;RAD;2;CT Extremity limited;CT Extr Ltd;;ACTIVE;2.14;2.61 +36091-7;Multisection limited;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart limited;MR Hrt Ltd;;ACTIVE;2.14;2.61 +36092-5;Multisection limited;Find;Pt;Lower extremity>Hip;Doc;CT;RAD;2;CT Hip limited;CT Hip Ltd;;ACTIVE;2.14;2.61 +36093-3;Multisection limited;Find;Pt;Lower extremity>Lower extremity joint;Doc;MR;RAD;2;MR Lower Extremity Joint limited;MR LE joint Ltd;;ACTIVE;2.14;2.65 +36094-1;Multisection limited;Find;Pt;Upper extremity>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity.joint limited;MR UE joint Ltd;;ACTIVE;2.14;2.61 +3609-5;Ethchlorvynol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ethchlorvynol [Presence] in Serum or Plasma;Ethchlorvynol SerPl Ql;;ACTIVE;1.0;2.73 +36095-8;Multisection limited^W contrast IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen limited W contrast IV;CT Abd Ltd W contr IV;;ACTIVE;2.14;2.61 +36096-6;Multisection limited^W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain limited W contrast IV;MR Brain Ltd W contr IV;;ACTIVE;2.14;2.61 +36097-4;Multisection limited^W contrast IV;Find;Pt;Upper extremity;Doc;CT;RAD;2;CT Upper extremity limited W contrast IV;CT UE Ltd W contr IV;;ACTIVE;2.14;2.61 +36098-2;Multisection limited^W contrast IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis limited W contrast IV;CT Pelvis Ltd W contr IV;;ACTIVE;2.14;2.61 +36099-0;Multisection limited^W contrast IV;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine limited W contrast IV;CT C-spine Ltd W contr IV;;ACTIVE;2.14;2.61 +36100-6;Multisection limited^W contrast IV;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine limited W contrast IV;MR L-spine Ltd W contr IV;;ACTIVE;2.14;2.61 +36101-4;Multisection limited^W contrast IV;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine limited W contrast IV;MR T-spine Ltd W contr IV;;ACTIVE;2.14;2.61 +36102-2;Multisection limited^WO & W contrast IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen limited WO and W contrast IV;CT Abd Ltd WO+W contr IV;;ACTIVE;2.14;2.61 +3610-3;Ethchlorvynol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethchlorvynol [Mass/volume] in Serum or Plasma;Ethchlorvynol SerPl-mCnc;;ACTIVE;1.0;2.73 +36103-0;Multisection limited^WO contrast;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen limited WO contrast;CT Abd Ltd WO contr;;ACTIVE;2.14;2.61 +36104-8;Multisection limited^WO contrast;Find;Pt;Head;Doc;CT;RAD;2;CT Head limited WO contrast;CT Head Ltd WO contr;;ACTIVE;2.14;2.61 +36105-5;Multisection limited^WO contrast;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain limited WO contrast;MR Brain Ltd WO contr;;ACTIVE;2.14;2.61 +36106-3;Multisection limited^WO contrast;Find;Pt;Lower extremity;Doc;CT;RAD;2;CT Lower extremity limited WO contrast;CT LE Ltd WO contr;;ACTIVE;2.14;2.61 +36107-1;Multisection limited^WO contrast;Find;Pt;Lower extremity.left>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - left limited WO contrast;MR LE joint-L Ltd WO contr;;ACTIVE;2.14;2.65 +36108-9;Multisection limited^WO contrast;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis limited WO contrast;CT Pelvis Ltd WO contr;;ACTIVE;2.14;2.61 +36109-7;Multisection limited^WO contrast;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine limited WO contrast;CT C-spine Ltd WO contr;;ACTIVE;2.14;2.61 +36110-5;Multisection limited^WO contrast;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine limited WO contrast;CT L-spine Ltd WO contr;;ACTIVE;2.14;2.61 +3611-1;Ethchlorvynol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethchlorvynol [Presence] in Urine;Ethchlorvynol Ur Ql;;ACTIVE;1.0;2.73 +36111-3;Multisection limited^WO contrast;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine limited WO contrast;MR L-spine Ltd WO contr;;ACTIVE;2.14;2.61 +36112-1;Multisection limited^WO contrast;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine limited WO contrast;MR T-spine Ltd WO contr;;ACTIVE;2.14;2.61 +36113-9;Multisection^W contrast IV;Find;Pt;Abdomen>Kidney;Doc;MR;RAD;2;MR Kidney W contrast IV;MR Kidney W contr IV;;ACTIVE;2.14;2.61 +36114-7;Multisection dynamic^W contrast IV;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral dynamic W contrast IV;MR Brst-Bl Dyn W contr IV;;ACTIVE;2.14;2.61 +36115-4;Multisection^W contrast IS;Find;Pt;Lower extremity>Ankle;Doc;MR;RAD;2;MR Ankle Arthrogram;MR Ankle W contr IS;;ACTIVE;2.14;2.61 +36116-2;Multisection^W contrast IS;Find;Pt;Lower extremity.left>Ankle;Doc;MR;RAD;2;MR Ankle - left Arthrogram;MR Ankle-L W contr IS;;ACTIVE;2.14;2.61 +36117-0;Multisection^W contrast IS;Find;Pt;Lower extremity.right>Ankle;Doc;MR;RAD;2;MR Ankle - right Arthrogram;MR Ankle-R W contr IS;;ACTIVE;2.14;2.61 +36118-8;Multisection^W contrast IS;Find;Pt;Upper extremity.left>Elbow;Doc;MR;RAD;2;MR Elbow - left Arthrogram;MR Elbow-L W contr IS;;ACTIVE;2.14;2.61 +36119-6;Multisection^W contrast IS;Find;Pt;Upper extremity.right>Elbow;Doc;MR;RAD;2;MR Elbow - right Arthrogram;MR Elbow-R W contr IS;;ACTIVE;2.14;2.61 +36120-4;Multisection^W contrast IS;Find;Pt;Lower extremity>Hip;Doc;MR;RAD;2;MR Hip Arthrogram;MR Hip W contr IS;;ACTIVE;2.14;2.61 +36121-2;Multisection^W contrast IS;Find;Pt;Lower extremity.left>Hip;Doc;MR;RAD;2;MR Hip - left Arthrogram;MR Hip-L W contr IS;;ACTIVE;2.14;2.61 +36122-0;Multisection^W contrast IS;Find;Pt;Lower extremity.right>Hip;Doc;MR;RAD;2;MR Hip - right Arthrogram;MR Hip-R W contr IS;;ACTIVE;2.14;2.61 +36123-8;Multisection^W contrast IS;Find;Pt;Pelvis>Sacroiliac joint;Doc;CT;RAD;2;CT Sacroiliac Joint Arthrogram;CT SIJ W contr IS;;ACTIVE;2.14;2.61 +36124-6;Multisection^W contrast IS;Find;Pt;Lower extremity>Knee;Doc;CT;RAD;2;CT Knee Arthrogram;CT Knee W contr IS;;ACTIVE;2.14;2.61 +36125-3;Multisection^W contrast IS;Find;Pt;Lower extremity>Knee;Doc;MR;RAD;2;MR Knee Arthrogram;MR Knee W contr IS;;ACTIVE;2.14;2.61 +36126-1;Multisection^W contrast IS;Find;Pt;Lower extremity.left>Knee;Doc;MR;RAD;2;MR Knee - left Arthrogram;MR Knee-L W contr IS;;ACTIVE;2.14;2.61 +36127-9;Multisection^W contrast IS;Find;Pt;Lower extremity.right>Knee;Doc;MR;RAD;2;MR Knee - right Arthrogram;MR Knee-R W contr IS;;ACTIVE;2.14;2.61 +36128-7;Multisection^W contrast IS;Find;Pt;Upper extremity>Shoulder;Doc;CT;RAD;2;CT Shoulder Arthrogram;CT Should W contr IS;;ACTIVE;2.14;2.73 +3612-9;Ethchlorvynol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethchlorvynol [Mass/volume] in Urine;Ethchlorvynol Ur-mCnc;;ACTIVE;1.0;2.42 +36129-5;Multisection^W contrast IS;Find;Pt;Upper extremity>Shoulder;Doc;MR;RAD;2;MR Shoulder Arthrogram;MR Should W contr IS;;ACTIVE;2.14;2.61 +36130-3;Multisection^W contrast IS;Find;Pt;Upper extremity.left>Shoulder;Doc;MR;RAD;2;MR Shoulder - left Arthrogram;MR Should-L W contr IS;;ACTIVE;2.14;2.61 +36131-1;Multisection^W contrast IS;Find;Pt;Upper extremity.right>Shoulder;Doc;CT;RAD;2;CT Shoulder - right Arthrogram;CT Should-R W contr IS;;ACTIVE;2.14;2.61 +36132-9;Multisection^W contrast IS;Find;Pt;Upper extremity.right>Shoulder;Doc;MR;RAD;2;MR Shoulder - right Arthrogram;MR Should-R W contr IS;;ACTIVE;2.14;2.61 +36133-7;Multisection^W contrast IT;Find;Pt;Head.cistern;Nar;CT;RAD;2;Deprecated Head Cistern CT Multisection W contrast IT;Deprecated Head.cistern CT W contr IT;;DEPRECATED;2.14;2.36 +36134-5;Multisection^W contrast IV;Find;Pt;Abdomen;Doc;MR;RAD;2;MR Abdomen W contrast IV;MR Abd W contr IV;;ACTIVE;2.14;2.61 +36135-2;Multisection^W contrast IV;Find;Pt;Lower extremity>Ankle;Doc;CT;RAD;2;CT Ankle W contrast IV;CT Ankle W contr IV;;ACTIVE;2.14;2.61 +36136-0;Multisection^W contrast IV;Find;Pt;Lower extremity>Ankle;Doc;MR;RAD;2;MR Ankle W contrast IV;MR Ankle W contr IV;;ACTIVE;2.14;2.61 +3613-7;Ethoheptazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethoheptazine [Presence] in Urine;Ethoheptazine Ur Ql;;ACTIVE;1.0;2.56 +36137-8;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Ankle;Doc;CT;RAD;2;CT Ankle - left W contrast IV;CT Ankle-L W contr IV;;ACTIVE;2.14;2.61 +36138-6;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Ankle;Doc;MR;RAD;2;MR Ankle - left W contrast IV;MR Ankle-L W contr IV;;ACTIVE;2.14;2.61 +36139-4;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Ankle;Doc;CT;RAD;2;CT Ankle - right W contrast IV;CT Ankle-R W contr IV;;ACTIVE;2.14;2.61 +36140-2;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Ankle;Doc;MR;RAD;2;MR Ankle - right W contrast IV;MR Ankle-R W contr IV;;ACTIVE;2.14;2.61 +36141-0;Multisection^W contrast IV;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;CT.angio;RAD;2;CTA Thoracic and abdominal aorta W contrast IV;CTA TA + AA W contr IV;;ACTIVE;2.14;2.61 +36142-8;Multisection^W contrast IV;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Thoracic and abdominal aorta W contrast IV;CT TA + AA W contr IV;;ACTIVE;2.14;2.61 +36143-6;Multisection^W contrast IV;Find;Pt;Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Abdominal Aorta W contrast IV;CT Abd Aorta W contr IV;;ACTIVE;2.14;2.61 +36144-4;Multisection^W contrast IV;Find;Pt;Chest>Aortic arch;Doc;CT.angio;RAD;2;CTA Aortic arch W contrast IV;CTA Ao arch W contr IV;;ACTIVE;2.14;2.61 +3614-5;Ethoheptazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethoheptazine [Mass/volume] in Urine;Ethoheptazine Ur-mCnc;;ACTIVE;1.0;2.34 +36145-1;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis>Appendix;Doc;CT;RAD;2;CT Appendix W contrast IV;CT Appendix W contr IV;;ACTIVE;2.14;2.61 +36146-9;Multisection^W contrast IV;Find;Pt;Head+Neck>Carotid artery;Doc;CT.angio;RAD;2;CTA Carotid artery W contrast IV;CTA Carotid a W contr IV;;ACTIVE;2.14;2.61 +36147-7;Multisection^W contrast IV;Find;Pt;Chest>Pulmonary arteries;Doc;CT.angio;RAD;2;CTA Pulmonary arteries W contrast IV;CTA PA W contr IV;;ACTIVE;2.14;2.61 +36148-5;Multisection^W contrast IV;Find;Pt;Head>Face;Doc;MR;RAD;2;MR Face W contrast IV;MR Face W contr IV;;ACTIVE;2.14;2.61 +36149-3;Multisection^W contrast IV;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast W contrast IV;MR Brst W contr IV;;ACTIVE;2.14;2.61 +36150-1;Multisection^W contrast IV;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral W contrast IV;MR Brst-Bl W contr IV;;ACTIVE;2.14;2.61 +36151-9;Multisection^W contrast IV;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Breast - left W contrast IV;MR Brst-L W contr IV;;ACTIVE;2.14;2.61 +3615-2;Ethoheptazine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Ethoheptazine [Mass/time] in 24 hour Urine;Ethoheptazine 24h Ur-mRate;;ACTIVE;1.0;2.19 +36152-7;Multisection^W contrast IV;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Breast - right W contrast IV;MR Brst-R W contr IV;;ACTIVE;2.14;2.61 +36153-5;Multisection^W contrast IV;Find;Pt;Calcaneus.left;Doc;CT;RAD;2;Deprecated Calcaneus - left CT W contrast IV;Deprecated Heel-L CT W contr IV;;DEPRECATED;2.14;2.58 +36154-3;Multisection^W contrast IV;Find;Pt;Calcaneus.right;Doc;CT;RAD;2;Deprecated Calcaneus - right CT W contrast IV;Deprecated Heel-R CT W contr IV;;DEPRECATED;2.14;2.58 +36155-0;Multisection^W contrast IV;Find;Pt;Head>Internal auditory canal;Doc;MR;RAD;2;MR Internal auditory canal W contrast IV;MR IAC W contr IV;;ACTIVE;2.14;2.61 +36156-8;Multisection^W contrast IV;Find;Pt;Chest;Doc;MR;RAD;2;MR Chest W contrast IV;MR Chest W contr IV;;ACTIVE;2.14;2.61 +36157-6;Multisection^W contrast IV;Find;Pt;Upper extremity>Elbow;Doc;CT;RAD;2;CT Elbow W contrast IV;CT Elbow W contr IV;;ACTIVE;2.14;2.61 +36158-4;Multisection^W contrast IV;Find;Pt;Upper extremity>Elbow;Doc;MR;RAD;2;MR Elbow W contrast IV;MR Elbow W contr IV;;ACTIVE;2.14;2.61 +36159-2;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Elbow;Doc;CT;RAD;2;CT Elbow - left W contrast IV;CT Elbow-L W contr IV;;ACTIVE;2.14;2.61 +361-6;Netilmicin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Netilmicin [Susceptibility] by Serum bactericidal titer;Netilmicin Titr SBT;;ACTIVE;1.0;2.32 +3616-0;Ethosuximide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethosuximide [Mass/volume] in Serum or Plasma;Ethosuximide SerPl-mCnc;;ACTIVE;1.0;2.73 +36160-0;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Elbow;Doc;MR;RAD;2;MR Elbow - left W contrast IV;MR Elbow-L W contr IV;;ACTIVE;2.14;2.61 +36161-8;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Elbow;Doc;CT;RAD;2;CT Elbow - right W contrast IV;CT Elbow-R W contr IV;;ACTIVE;2.14;2.61 +36162-6;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Elbow;Doc;MR;RAD;2;MR Elbow - right W contrast IV;MR Elbow-R W contr IV;;ACTIVE;2.14;2.61 +36163-4;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral;Doc;MR;RAD;2;MR Lower extremity - bilateral W contrast IV;MR LE-Bl W contr IV;;ACTIVE;2.14;2.61 +36164-2;Multisection^W contrast IV;Find;Pt;Lower extremity.left;Doc;CT;RAD;2;CT Lower extremity - left W contrast IV;CT LE-L W contr IV;;ACTIVE;2.14;2.61 +36165-9;Multisection^W contrast IV;Find;Pt;Lower extremity.left;Doc;MR;RAD;2;MR Lower extremity - left W contrast IV;MR LE-L W contr IV;;ACTIVE;2.14;2.61 +36166-7;Multisection^W contrast IV;Find;Pt;Lower extremity.right;Doc;CT;RAD;2;CT Lower extremity - right W contrast IV;CT LE-R W contr IV;;ACTIVE;2.14;2.61 +36167-5;Multisection^W contrast IV;Find;Pt;Lower extremity.right;Doc;MR;RAD;2;MR Lower extremity - right W contrast IV;MR LE-R W contr IV;;ACTIVE;2.14;2.61 +36168-3;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral;Doc;CT;RAD;2;CT Upper extremity - bilateral W contrast IV;CT UE-Bl W contr IV;;ACTIVE;2.14;2.61 +36169-1;Multisection^W contrast IV;Find;Pt;Upper extremity.left;Doc;CT;RAD;2;CT Upper extremity - left W contrast IV;CT UE-L W contr IV;;ACTIVE;2.14;2.61 +36170-9;Multisection^W contrast IV;Find;Pt;Upper extremity.right;Doc;CT;RAD;2;CT Upper extremity - right W contrast IV;CT UE-R W contr IV;;ACTIVE;2.14;2.61 +36171-7;Multisection^W contrast IV;Find;Pt;Upper extremity.right;Doc;MR;RAD;2;MR Upper extremity - right W contrast IV;MR UE-R W contr IV;;ACTIVE;2.14;2.61 +36172-5;Multisection^W contrast IV;Find;Pt;Lower extremity>Thigh;Doc;CT;RAD;2;CT Thigh W contrast IV;CT Thigh W contr IV;;ACTIVE;2.14;2.61 +36173-3;Multisection^W contrast IV;Find;Pt;Lower extremity>Thigh;Doc;MR;RAD;2;MR Thigh W contrast IV;MR Thigh W contr IV;;ACTIVE;2.14;2.61 +36174-1;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Thigh;Doc;CT;RAD;2;CT Thigh - left W contrast IV;CT Thigh-L W contr IV;;ACTIVE;2.14;2.61 +36175-8;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Thigh;Doc;MR;RAD;2;MR Thigh - left W contrast IV;MR Thigh-L W contr IV;;ACTIVE;2.14;2.61 +36176-6;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Thigh;Doc;CT;RAD;2;CT Thigh - right W contrast IV;CT Thigh-R W contr IV;;ACTIVE;2.14;2.61 +36177-4;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Thigh;Doc;MR;RAD;2;MR Thigh - right W contrast IV;MR Thigh-R W contr IV;;ACTIVE;2.14;2.61 +3617-8;Ethotoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethotoin [Mass/volume] in Serum or Plasma;Ethotoin SerPl-mCnc;;ACTIVE;1.0;2.73 +36178-2;Multisection^W contrast IV;Find;Pt;Lower extremity>Foot;Doc;CT;RAD;2;CT Foot W contrast IV;CT Foot W contr IV;;ACTIVE;2.14;2.61 +36179-0;Multisection^W contrast IV;Find;Pt;Lower extremity>Foot;Doc;MR;RAD;2;MR Foot W contrast IV;MR Foot W contr IV;;ACTIVE;2.14;2.61 +36180-8;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Foot;Doc;MR;RAD;2;MR Foot - bilateral W contrast IV;MR Foot-Bl W contr IV;;ACTIVE;2.14;2.61 +36181-6;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Foot;Doc;CT;RAD;2;CT Foot - left W contrast IV;CT Foot-L W contr IV;;ACTIVE;2.14;2.61 +36182-4;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Foot;Doc;MR;RAD;2;MR Foot - left W contrast IV;MR Foot-L W contr IV;;ACTIVE;2.14;2.61 +36183-2;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Foot;Doc;CT;RAD;2;CT Foot - right W contrast IV;CT Foot-R W contr IV;;ACTIVE;2.14;2.61 +36184-0;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Foot;Doc;MR;RAD;2;MR Foot - right W contrast IV;MR Foot-R W contr IV;;ACTIVE;2.14;2.61 +36185-7;Multisection^W contrast IV;Find;Pt;Upper extremity>Forearm;Doc;CT;RAD;2;CT Forearm W contrast IV;CT Forearm W contr IV;;ACTIVE;2.14;2.61 +3618-6;Ethylmorphine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethylmorphine [Presence] in Urine;EMP Ur Ql;;ACTIVE;1.0;2.73 +36186-5;Multisection^W contrast IV;Find;Pt;Upper extremity>Forearm;Doc;MR;RAD;2;MR Forearm W contrast IV;MR Forearm W contr IV;;ACTIVE;2.14;2.61 +36187-3;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Forearm;Doc;CT;RAD;2;CT Forearm - left W contrast IV;CT Forearm-L W contr IV;;ACTIVE;2.14;2.61 +36188-1;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Forearm;Doc;MR;RAD;2;MR Forearm - left W contrast IV;MR Forearm-L W contr IV;;ACTIVE;2.14;2.61 +36189-9;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Forearm;Doc;CT;RAD;2;CT Forearm - right W contrast IV;CT Forearm-R W contr IV;;ACTIVE;2.14;2.61 +36190-7;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Forearm;Doc;MR;RAD;2;MR Forearm - right W contrast IV;MR Forearm-R W contr IV;;ACTIVE;2.14;2.61 +36191-5;Multisection^W contrast IV;Find;Pt;Upper extremity>Hand;Doc;CT;RAD;2;CT Hand W contrast IV;CT Hand W contr IV;;ACTIVE;2.14;2.61 +36192-3;Multisection^W contrast IV;Find;Pt;Upper extremity>Hand;Doc;MR;RAD;2;MR Hand W contrast IV;MR Hand W contr IV;;ACTIVE;2.14;2.61 +36193-1;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Hand;Doc;CT;RAD;2;CT Hand - left W contrast IV;CT Hand-L W contr IV;;ACTIVE;2.14;2.61 +3619-4;Ethylmorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethylmorphine [Mass/volume] in Urine;EMP Ur-mCnc;;ACTIVE;1.0;2.42 +36194-9;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Hand;Doc;MR;RAD;2;MR Hand - left W contrast IV;MR Hand-L W contr IV;;ACTIVE;2.14;2.61 +36195-6;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Hand;Doc;CT;RAD;2;CT Hand - right W contrast IV;CT Hand-R W contr IV;;ACTIVE;2.14;2.61 +36196-4;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Hand;Doc;MR;RAD;2;MR Hand - right W contrast IV;MR Hand-R W contr IV;;ACTIVE;2.14;2.61 +36197-2;Multisection^W contrast IV;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart W contrast IV;MR Hrt W contr IV;;ACTIVE;2.14;2.61 +36198-0;Multisection^W contrast IV;Find;Pt;Calcaneus;Doc;CT;RAD;2;Deprecated Calcaneus CT W contrast IV;Deprecated Heel CT W contr IV;;DEPRECATED;2.14;2.58 +36199-8;Multisection^W contrast IV;Find;Pt;Lower extremity>Hip;Doc;MR;RAD;2;MR Hip W contrast IV;MR Hip W contr IV;;ACTIVE;2.14;2.61 +36200-4;Multisection^W contrast IV;Find;Pt;Lower extremity>Hip;Doc;CT;RAD;2;CT Hip W contrast IV;CT Hip W contr IV;;ACTIVE;2.14;2.61 +36201-2;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Hip;Doc;CT;RAD;2;CT Hip - bilateral W contrast IV;CT Hip-Bl W contr IV;;ACTIVE;2.14;2.61 +3620-2;N-ethylnicotinamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;N-ethylnicotinamide [Mass/volume] in Urine;NEN Ur-mCnc;;ACTIVE;1.0;2.42 +36202-0;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Hip;Doc;MR;RAD;2;MR Hip - bilateral W contrast IV;MR Hip-Bl W contr IV;;ACTIVE;2.14;2.61 +36203-8;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Hip;Doc;CT;RAD;2;CT Hip - left W contrast IV;CT Hip-L W contr IV;;ACTIVE;2.14;2.61 +36204-6;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Hip;Doc;MR;RAD;2;MR Hip - left W contrast IV;MR Hip-L W contr IV;;ACTIVE;2.14;2.61 +36205-3;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Hip;Doc;CT;RAD;2;CT Hip - right W contrast IV;CT Hip-R W contr IV;;ACTIVE;2.14;2.61 +36206-1;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Hip;Doc;MR;RAD;2;MR Hip - right W contrast IV;MR Hip-R W contr IV;;ACTIVE;2.14;2.61 +36207-9;Multisection^W contrast IV;Find;Pt;Upper extremity>Upper arm;Doc;CT;RAD;2;CT Upper arm W contrast IV;CT Upper arm W contr IV;;ACTIVE;2.14;2.61 +36208-7;Multisection^W contrast IV;Find;Pt;Upper extremity>Upper arm;Doc;MR;RAD;2;MR Upper arm W contrast IV;MR Upper arm W contr IV;;ACTIVE;2.14;2.61 +36209-5;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Upper arm;Doc;CT;RAD;2;CT Upper arm - left W contrast IV;CT Upper arm-L W contr IV;;ACTIVE;2.14;2.61 +3621-0;Etilefrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Etilefrine [Presence] in Urine;Etilefrine Ur Ql;;ACTIVE;1.0;2.56 +36210-3;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Upper arm;Doc;MR;RAD;2;MR Upper arm - left W contrast IV;MR Upper arm-L W contr IV;;ACTIVE;2.14;2.61 +36211-1;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Upper arm;Doc;CT;RAD;2;CT Upper arm - right W contrast IV;CT Upper arm-R W contr IV;;ACTIVE;2.14;2.61 +36212-9;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Upper arm;Doc;MR;RAD;2;MR Upper arm - right W contrast IV;MR Upper arm-R W contr IV;;ACTIVE;2.14;2.61 +36213-7;Multisection^W contrast IV;Find;Pt;Lower extremity>Lower extremity joint;Doc;MR;RAD;2;MR Lower Extremity Joint W contrast IV;MR LE joint W contr IV;;ACTIVE;2.14;2.65 +36214-5;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - left W contrast IV;MR LE joint-L W contr IV;;ACTIVE;2.14;2.65 +36215-2;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - right W contrast IV;MR LE joint-R W contr IV;;ACTIVE;2.14;2.65 +36216-0;Multisection^W contrast IV;Find;Pt;Upper extremity>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity.joint W contrast IV;MR UE joint W contr IV;;ACTIVE;2.14;2.61 +36217-8;Multisection^W contrast IV;Find;Pt;Pelvis>Sacroiliac joint;Doc;CT;RAD;2;CT Sacroiliac Joint W contrast IV;CT SIJ W contr IV;;ACTIVE;2.14;2.61 +36218-6;Multisection^W contrast IV;Find;Pt;Pelvis>Sacroiliac joint;Doc;MR;RAD;2;MR Sacroiliac Joint W contrast IV;MR SIJ W contr IV;;ACTIVE;2.14;2.61 +36219-4;Multisection^W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;MR;RAD;2;MR Kidney - bilateral W contrast IV;MR Kdny-Bl W contr IV;;ACTIVE;2.14;2.61 +36220-2;Multisection^W contrast IV;Find;Pt;Abdomen>Kidney.left;Doc;MR;RAD;2;MR Kidney - left W contrast IV;MR Kidney-L W contr IV;;ACTIVE;2.14;2.61 +36221-0;Multisection^W contrast IV;Find;Pt;Abdomen>Kidney.right;Doc;MR;RAD;2;MR Kidney - right W contrast IV;MR Kidney-R W contr IV;;ACTIVE;2.14;2.61 +36222-8;Multisection^W contrast IV;Find;Pt;Lower extremity>Knee;Doc;CT;RAD;2;CT Knee W contrast IV;CT Knee W contr IV;;ACTIVE;2.14;2.61 +36223-6;Multisection^W contrast IV;Find;Pt;Lower extremity>Knee;Doc;MR;RAD;2;MR Knee W contrast IV;MR Knee W contr IV;;ACTIVE;2.14;2.61 +36224-4;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Knee;Doc;MR;RAD;2;MR Knee - bilateral W contrast IV;MR Knee-Bl W contr IV;;ACTIVE;2.14;2.61 +36225-1;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Knee;Doc;CT;RAD;2;CT Knee - left W contrast IV;CT Knee-L W contr IV;;ACTIVE;2.14;2.61 +36226-9;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Knee;Doc;MR;RAD;2;MR Knee - left W contrast IV;MR Knee-L W contr IV;;ACTIVE;2.14;2.61 +36227-7;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Knee;Doc;CT;RAD;2;CT Knee - right W contrast IV;CT Knee-R W contr IV;;ACTIVE;2.14;2.61 +3622-8;Etilefrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Etilefrine [Mass/volume] in Urine;Etilefrine Ur-mCnc;;ACTIVE;1.0;2.42 +36228-5;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Knee;Doc;MR;RAD;2;MR Knee - right W contrast IV;MR Knee-R W contr IV;;ACTIVE;2.14;2.61 +36229-3;Multisection^W contrast IV;Find;Pt;Head+Neck>Larynx;Doc;CT;RAD;2;CT Larynx W contrast IV;CT Larynx W contr IV;;ACTIVE;2.14;2.61 +36230-1;Multisection^W contrast IV;Find;Pt;Head+Neck>Larynx;Doc;MR;RAD;2;MR Larynx W contrast IV;MR Larynx W contr IV;;ACTIVE;2.14;2.61 +36231-9;Multisection^W contrast IV;Find;Pt;Abdomen>Liver;Doc;MR;RAD;2;MR Liver W contrast IV;MR Liver W contr IV;;ACTIVE;2.14;2.61 +36232-7;Multisection^W contrast IV;Find;Pt;Head>Mandible;Doc;CT;RAD;2;CT Mandible W contrast IV;CT Mandible W contr IV;;ACTIVE;2.14;2.61 +36233-5;Multisection^W contrast IV;Find;Pt;Head+Neck>Nasopharynx;Doc;MR;RAD;2;MR Nasopharynx W contrast IV;MR Nasopharynx W contr IV;;ACTIVE;2.14;2.61 +36234-3;Multisection^W contrast IV;Find;Pt;Neck>Neck vessels;Doc;CT.angio;RAD;2;CTA Neck vessels W contrast IV;CTA Neck ves W contr IV;;ACTIVE;2.14;2.61 +36235-0;Multisection^W contrast IV;Find;Pt;Neck;Doc;CT;RAD;2;CT Neck W contrast IV;CT Neck W contr IV;;ACTIVE;2.14;2.73 +3623-6;Etilefrine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Etilefrine [Mass/time] in 24 hour Urine;Etilefrine 24h Ur-mRate;;ACTIVE;1.0;2.42 +36236-8;Multisection^W contrast IV;Find;Pt;Abdomen>Pancreas;Doc;MR;RAD;2;MR Pancreas W contrast IV;MR Pancreas W contr IV;;ACTIVE;2.14;2.61 +36237-6;Multisection^W contrast IV;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis W contrast IV;MR Pelvis W contr IV;;ACTIVE;2.14;2.61 +36238-4;Multisection^W contrast IV;Find;Pt;Head>Pituitary+Sella turcica;Doc;MR;RAD;2;MR Pituitary and Sella turcica W contrast IV;MR Pit+Sella turc W contr IV;;ACTIVE;2.14;2.61 +36239-2;Multisection^W contrast IV;Find;Pt;Chest>Brachial plexus;Doc;MR;RAD;2;MR Brachial plexus W contrast IV;MR Brachial plexus W contr IV;;ACTIVE;2.14;2.61 +362-4;Nitrofurantoin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Nitrofurantoin [Susceptibility] by Minimum lethal concentration (MLC);Nitrofurantoin Islt MLC;;ACTIVE;1.0;2.19 +36240-0;Multisection^W contrast IV;Find;Pt;Chest>Brachial plexus.left;Doc;MR;RAD;2;MR Brachial plexus - left W contrast IV;MR Brachial plexus-L W contr IV;;ACTIVE;2.14;2.61 +36241-8;Multisection^W contrast IV;Find;Pt;Chest>Brachial plexus.right;Doc;MR;RAD;2;MR Brachial plexus - right W contrast IV;MR Brachial plexus-R W contr IV;;ACTIVE;2.14;2.61 +36242-6;Multisection^W contrast IV;Find;Pt;Head>Posterior fossa;Doc;CT;RAD;2;CT Posterior fossa W contrast IV;CT Post fossa W contr IV;;ACTIVE;2.14;2.61 +36243-4;Multisection^W contrast IV;Find;Pt;Head>Posterior fossa;Doc;MR;RAD;2;MR Posterior fossa W contrast IV;MR Post fossa W contr IV;;ACTIVE;2.14;2.61 +3624-4;Fencamfamin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Fencamfamin [Presence] in Urine;Fencamfamin Ur Ql;;ACTIVE;1.0;2.56 +36244-2;Multisection^W contrast IV;Find;Pt;Pelvis>Prostate;Doc;MR;RAD;2;MR Prostate W contrast IV;MR Prostate W contr IV;;ACTIVE;2.14;2.61 +36245-9;Multisection^W contrast IV;Find;Pt;Pelvis>Sacrum;Doc;CT;RAD;2;CT Sacrum W contrast IV;CT Sacrum W contr IV;;ACTIVE;2.14;2.61 +36246-7;Multisection^W contrast IV;Find;Pt;Pelvis>Sacrum;Doc;MR;RAD;2;MR Sacrum W contrast IV;MR Sacrum W contr IV;;ACTIVE;2.14;2.61 +36247-5;Multisection^W contrast IV;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;MR;RAD;2;MR Sacrum and Coccyx W contrast IV;MR Sacrum+Coccyx W contr IV;;ACTIVE;2.14;2.61 +36248-3;Multisection^W contrast IV;Find;Pt;Chest>Scapula.left;Doc;MR;RAD;2;MR Scapula - left W contrast IV;MR Scapula-L W contr IV;;ACTIVE;2.14;2.61 +36249-1;Multisection^W contrast IV;Find;Pt;Chest>Scapula.right;Doc;MR;RAD;2;MR Scapula - right W contrast IV;MR Scapula-R W contr IV;;ACTIVE;2.14;2.61 +36250-9;Multisection^W contrast IV;Find;Pt;Upper extremity>Shoulder;Doc;CT;RAD;2;CT Shoulder W contrast IV;CT Should W contr IV;;ACTIVE;2.14;2.61 +3625-1;Fencamfamin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fencamfamin [Mass/volume] in Urine;Fencamfamin Ur-mCnc;;ACTIVE;1.0;2.34 +36251-7;Multisection^W contrast IV;Find;Pt;Upper extremity>Shoulder;Doc;MR;RAD;2;MR Shoulder W contrast IV;MR Should W contr IV;;ACTIVE;2.14;2.61 +36252-5;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Shoulder;Doc;CT;RAD;2;CT Shoulder - left W contrast IV;CT Should-L W contr IV;;ACTIVE;2.14;2.61 +36253-3;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Shoulder;Doc;CT;RAD;2;CT Shoulder - right W contrast IV;CT Should-R W contr IV;;ACTIVE;2.14;2.61 +36254-1;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Shoulder;Doc;MR;RAD;2;MR Shoulder - right W contrast IV;MR Should-R W contr IV;;ACTIVE;2.14;2.61 +36255-8;Multisection^W contrast IV;Find;Pt;Head>Sinuses;Doc;CT;RAD;2;CT Sinuses W contrast IV;CT Sinuses W contr IV;;ACTIVE;2.14;2.61 +36256-6;Multisection^W contrast IV;Find;Pt;XXX>Spine;Doc;MR;RAD;2;MR Spine W contrast IV;MR Spine W contr IV;;DISCOURAGED;2.14;2.61 +36257-4;Multisection^W contrast IV;Find;Pt;Chest>Sternum;Doc;CT;RAD;2;CT Sternum W contrast IV;CT Sternum W contr IV;;ACTIVE;2.14;2.61 +36258-2;Multisection^W contrast IV;Find;Pt;Lower extremity>Lower leg;Doc;CT;RAD;2;CT Lower leg W contrast IV;CT Lower leg W contr IV;;ACTIVE;2.14;2.61 +36259-0;Multisection^W contrast IV;Find;Pt;Lower extremity>Lower leg;Doc;MR;RAD;2;MR Lower leg W contrast IV;MR Lower leg W contr IV;;ACTIVE;2.14;2.61 +36260-8;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Lower leg;Doc;CT;RAD;2;CT Lower leg - left W contrast IV;CT Lower leg-L W contr IV;;ACTIVE;2.14;2.61 +36261-6;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Lower leg;Doc;MR;RAD;2;MR Lower leg - left W contrast IV;MR Lower leg-L W contr IV;;ACTIVE;2.14;2.61 +36262-4;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Lower leg;Doc;CT;RAD;2;CT Lower leg - right W contrast IV;CT Lower leg-R W contr IV;;ACTIVE;2.14;2.61 +36263-2;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Lower leg;Doc;MR;RAD;2;MR Lower leg - right W contrast IV;MR Lower leg-R W contr IV;;ACTIVE;2.14;2.61 +36264-0;Multisection^W contrast IV;Find;Pt;Pelvis>Uterus;Doc;CT;RAD;2;CT Uterus W contrast IV;CT Uterus W contr IV;;ACTIVE;2.14;2.61 +36265-7;Multisection^W contrast IV;Find;Pt;Pelvis>Uterus;Doc;MR;RAD;2;MR Uterus W contrast IV;MR Uterus W contr IV;;ACTIVE;2.14;2.61 +36266-5;Multisection^W contrast IV;Find;Pt;Chest>Chest vessels;Doc;CT.angio;RAD;2;CTA Chest vessels W contrast IV;CTA Chest ves W contr IV;;ACTIVE;2.14;2.61 +36267-3;Multisection^WO & W contrast IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen WO and W contrast IV;CT Abd WO+W contr IV;;ACTIVE;2.14;2.61 +36268-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Ankle;Doc;CT;RAD;2;CT Ankle WO and W contrast IV;CT Ankle WO+W contr IV;;ACTIVE;2.14;2.61 +3626-9;Fencamfamin;MRat;24H;Urine;Qn;;DRUG/TOX;1;Fencamfamin [Mass/time] in 24 hour Urine;Fencamfamin 24h Ur-mRate;;ACTIVE;1.0;2.19 +36269-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Ankle;Doc;CT;RAD;2;CT Ankle - left WO and W contrast IV;CT Ankle-L WO+W contr IV;;ACTIVE;2.14;2.61 +36270-7;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Ankle;Doc;CT;RAD;2;CT Ankle - right WO and W contrast IV;CT Ankle-R WO+W contr IV;;ACTIVE;2.14;2.61 +36271-5;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Abdominal Aorta WO and W contrast IV;CT Abd Aorta WO+W contr IV;;ACTIVE;2.14;2.61 +36272-3;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Aorta.abdominal;Doc;MR.angio;RAD;2;MRA Abdominal Aorta WO and W contrast IV;MRA Abd Aorta WO+W contr IV;;ACTIVE;2.14;2.61 +36273-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Aorta.abdominal;Doc;MR;RAD;2;MR Abdominal Aorta WO and W contrast IV;MR Abd Aorta WO+W contr IV;;ACTIVE;2.14;2.61 +36274-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Aorta.thoracic;Doc;MR.angio;RAD;2;MRA Thoracic Aorta WO and W contrast IV;MRA TA WO+W contr IV;;ACTIVE;2.14;2.61 +36275-6;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Renal artery;Doc;MR.angio;RAD;2;MRA Renal artery WO and W contrast IV;MRA Renal a WO+W contr IV;;ACTIVE;2.14;2.61 +36276-4;Multisection^WO & W contrast IV;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast WO and W contrast IV;MR Brst WO+W contr IV;;ACTIVE;2.14;2.61 +3627-7;Fenetylline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Fenetylline [Presence] in Urine;Fenetylline Ur Ql;;ACTIVE;1.0;2.56 +36277-2;Multisection^WO & W contrast IV;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral WO and W contrast IV;MR Brst-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +36278-0;Multisection^WO & W contrast IV;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Breast - left WO and W contrast IV;MR Brst-L WO+W contr IV;;ACTIVE;2.14;2.61 +36279-8;Multisection^WO & W contrast IV;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Breast - right WO and W contrast IV;MR Brst-R WO+W contr IV;;ACTIVE;2.14;2.61 +36280-6;Multisection^WO & W contrast IV;Find;Pt;Calcaneus.left;Doc;CT;RAD;2;Deprecated Calcaneus - left CT WO and W contrast IV;Deprecated Heel-L CT WO+W contr IV;;DEPRECATED;2.14;2.58 +36281-4;Multisection^WO & W contrast IV;Find;Pt;Calcaneus.right;Doc;CT;RAD;2;Deprecated Calcaneus - right CT WO and W contrast IV;Deprecated Heel-R CT WO+W contr IV;;DEPRECATED;2.14;2.58 +36282-2;Multisection^WO & W contrast IV;Find;Pt;Head>Internal auditory canal;Doc;CT;RAD;2;CT Internal auditory canal WO and W contrast IV;CT IAC WO+W contr IV;;ACTIVE;2.14;2.61 +36283-0;Multisection^WO & W contrast IV;Find;Pt;Chest;Doc;MR;RAD;2;MR Chest WO and W contrast IV;MR Chest WO+W contr IV;;ACTIVE;2.14;2.61 +36284-8;Multisection^WO & W contrast IV;Find;Pt;Chest+Abdomen;Doc;MR;RAD;2;MR Chest and Abdomen WO and W contrast IV;MR Chest+Abd WO+W contr IV;;ACTIVE;2.14;2.61 +3628-5;Fenetylline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fenetylline [Mass/volume] in Urine;Fenetylline Ur-mCnc;;ACTIVE;1.0;2.34 +36285-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Elbow;Doc;CT;RAD;2;CT Elbow WO and W contrast IV;CT Elbow WO+W contr IV;;ACTIVE;2.14;2.61 +36286-3;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Elbow;Doc;CT;RAD;2;CT Elbow - left WO and W contrast IV;CT Elbow-L WO+W contr IV;;ACTIVE;2.14;2.61 +36287-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Elbow;Doc;CT;RAD;2;CT Elbow - right WO and W contrast IV;CT Elbow-R WO+W contr IV;;ACTIVE;2.14;2.61 +36288-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity;Doc;CT;RAD;2;CT Lower extremity WO and W contrast IV;CT LE WO+W contr IV;;ACTIVE;2.14;2.61 +36289-7;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral;Doc;MR;RAD;2;MR Lower extremity - bilateral WO and W contrast IV;MR LE-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +36290-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left;Doc;CT;RAD;2;CT Lower extremity - left WO and W contrast IV;CT LE-L WO+W contr IV;;ACTIVE;2.14;2.61 +36291-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left;Doc;MR;RAD;2;MR Lower extremity - left WO and W contrast IV;MR LE-L WO+W contr IV;;ACTIVE;2.14;2.61 +36292-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right;Doc;CT;RAD;2;CT Lower extremity - right WO and W contrast IV;CT LE-R WO+W contr IV;;ACTIVE;2.14;2.61 +3629-3;Fenetylline;MRat;24H;Urine;Qn;;DRUG/TOX;1;Fenetylline [Mass/time] in 24 hour Urine;Fenetylline 24h Ur-mRate;;ACTIVE;1.0;2.19 +36293-9;Views 3;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen 3 Views;XR Abd 3V;;ACTIVE;2.14;2.61 +36294-7;Views 3;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle 3 Views;XR Ankle 3V;;ACTIVE;2.14;2.61 +36295-4;Views 3;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral 3 Views;XR Ankle-Bl 3V;;ACTIVE;2.14;2.61 +36296-2;Views 3;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left 3 Views;XR Ankle-L 3V;;ACTIVE;2.14;2.61 +36297-0;Views 3;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones 3 Views;XR Face 3V;;ACTIVE;2.14;2.61 +36298-8;Views 3;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest 3 Views;XR Chest 3V;;ACTIVE;2.14;2.61 +36299-6;Views 3;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow 3 Views;XR Elbow 3V;;ACTIVE;2.14;2.61 +36300-2;Views 3;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral 3 Views;XR Elbow-Bl 3V;;ACTIVE;2.14;2.61 +3630-1;Fenfluramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fenfluramine [Mass/volume] in Serum or Plasma;Fenfluramine SerPl-mCnc;;ACTIVE;1.0;2.42 +36301-0;Views 3;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left 3 Views;XR Elbow-L 3V;;ACTIVE;2.14;2.73 +36302-8;Views 3;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur 3 Views;XR Femur 3V;;ACTIVE;2.14;2.61 +36303-6;Views 3;Find;Pt;Upper extremity>Finger;Doc;XR;RAD;2;XR Finger 3 Views;XR Finger 3V;;ACTIVE;2.14;2.61 +36304-4;Views 3;Find;Pt;Upper extremity.left>Finger;Doc;XR;RAD;2;XR Finger - left 3 Views;XR Finger-L 3V;;ACTIVE;2.14;2.61 +36305-1;Views 3;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot 3 Views;XR Foot 3V;;ACTIVE;2.14;2.61 +36306-9;Views 3;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral 3 Views;XR Foot-Bl 3V;;ACTIVE;2.14;2.61 +36307-7;Views 3;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left 3 Views;XR Foot-L 3V;;ACTIVE;2.14;2.73 +36308-5;Views 3;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral 3 Views;XR Hip-Bl 3V;;ACTIVE;2.14;2.61 +36309-3;Views 3;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left 3 Views;XR Hip-L 3V;;ACTIVE;2.14;2.61 +36310-1;Views 3;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 3 Views;XR Knee-Bl 3V;;ACTIVE;2.14;2.61 +36311-9;Views 3;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 3 Views;XR Knee-L 3V;;ACTIVE;2.14;2.61 +36312-7;Views 3;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible 3 Views;XR Mandible 3V;;ACTIVE;2.14;2.61 +36313-5;Views 3;Find;Pt;Chest>Ribs.bilateral;Doc;XR;RAD;2;XR Ribs - bilateral 3 Views;XR Ribs-Bl 3V;;ACTIVE;2.14;2.61 +36314-3;Views 3;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left 3 Views;XR Ribs-L 3V;;ACTIVE;2.14;2.61 +36315-0;Views 3;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left 3 Views;XR Thumb-L 3V;;ACTIVE;2.14;2.61 +36316-8;Views 3;Find;Pt;Lower extremity.left>Toes;Doc;XR;RAD;2;XR Toes - left 3 Views;XR Toes-L 3V;;ACTIVE;2.14;2.61 +36317-6;Views 4;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle 4 Views;XR Ankle 4V;;ACTIVE;2.14;2.61 +36318-4;Views 4;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones 4 Views;XR Face 4V;;ACTIVE;2.14;2.61 +3631-9;Fenfluramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fenfluramine [Mass/volume] in Urine;Fenfluramine Ur-mCnc;;ACTIVE;1.0;2.42 +36319-2;Views 4;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast 4 Views;MG Brst 4V;;ACTIVE;2.14;2.61 +363-2;Nitrofurantoin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Nitrofurantoin [Susceptibility] by Minimum inhibitory concentration (MIC);Nitrofurantoin Islt MIC;;ACTIVE;1.0;2.73 +36320-0;Views 4;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest 4 Views;XR Chest 4V;;ACTIVE;2.14;2.61 +36321-8;Views 4 && Views;Find;Pt;Chest;Doc;XR && RF;RAD;2;XR and RF Chest 4 Views and Views;XR and Flr Chest 4V + Views;;ACTIVE;2.14;2.61 +36322-6;Views 4;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral 4 Views;XR Elbow-Bl 4V;;ACTIVE;2.14;2.61 +36323-4;Views 4;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left 4 Views;XR Elbow-L 4V;;ACTIVE;2.14;2.61 +36324-2;Views 4;Find;Pt;Lower extremity.left>Femur;Doc;XR;RAD;2;XR Femur - left 4 Views;XR Femur-L 4V;;ACTIVE;2.14;2.61 +36325-9;Views 4;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 4 Views;XR Knee-Bl 4V;;ACTIVE;2.14;2.61 +36326-7;Views 4;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 4 Views;XR Knee-L 4V;;ACTIVE;2.14;2.61 +3632-7;Fenoprofen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fenoprofen [Mass/volume] in Serum or Plasma;Fenoprofen SerPl-mCnc;;ACTIVE;1.0;2.73 +36327-5;Views 4;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible 4 Views;XR Mandible 4V;;ACTIVE;2.14;2.61 +36328-3;Views 4;Find;Pt;Chest>Ribs.bilateral;Doc;XR;RAD;2;XR Ribs - bilateral 4 Views;XR Ribs-Bl 4V;;ACTIVE;2.14;2.61 +36329-1;Views 4;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral 4 Views;XR Shoulder-Bl 4V;;ACTIVE;2.14;2.61 +36330-9;Views 4;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 4 Views;XR Should-L 4V;;ACTIVE;2.14;2.61 +36331-7;Views 4;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 4 Views;XR C-spine 4V;;ACTIVE;2.14;2.61 +36332-5;Views 4;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 4 Views;XR L-spine 4V;;ACTIVE;2.14;2.61 +36333-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right;Doc;MR;RAD;2;MR Lower extremity - right WO and W contrast IV;MR LE-R WO+W contr IV;;ACTIVE;2.14;2.61 +36334-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity;Doc;CT;RAD;2;CT Upper extremity WO and W contrast IV;CT UE WO+W contr IV;;ACTIVE;2.14;2.73 +3633-5;Fenproporex;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Fenproporex [Presence] in Urine;Fenproporex Ur Ql;;ACTIVE;1.0;2.56 +36335-8;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left;Doc;CT;RAD;2;CT Upper extremity - left WO and W contrast IV;CT UE-L WO+W contr IV;;ACTIVE;2.14;2.61 +36336-6;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right;Doc;CT;RAD;2;CT Upper extremity - right WO and W contrast IV;CT UE-R WO+W contr IV;;ACTIVE;2.14;2.61 +36337-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right;Doc;MR;RAD;2;MR Upper extremity - right WO and W contrast IV;MR UE-R WO+W contr IV;;ACTIVE;2.14;2.61 +36338-2;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Thigh;Doc;CT;RAD;2;CT Thigh WO and W contrast IV;CT Thigh WO+W contr IV;;ACTIVE;2.14;2.61 +36339-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Thigh;Doc;CT;RAD;2;CT Thigh - left WO and W contrast IV;CT Thigh-L WO+W contr IV;;ACTIVE;2.14;2.61 +36340-8;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Thigh;Doc;CT;RAD;2;CT Thigh - right WO and W contrast IV;CT Thigh-R WO+W contr IV;;ACTIVE;2.14;2.61 +36341-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Foot;Doc;CT;RAD;2;CT Foot WO and W contrast IV;CT Foot WO+W contr IV;;ACTIVE;2.14;2.61 +36342-4;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Foot;Doc;MR;RAD;2;MR Foot - bilateral WO and W contrast IV;MR Foot-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +3634-3;Fenproporex;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fenproporex [Mass/volume] in Urine;Fenproporex Ur-mCnc;;ACTIVE;1.0;2.42 +36343-2;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Foot;Doc;CT;RAD;2;CT Foot - left WO and W contrast IV;CT Foot-L WO+W contr IV;;ACTIVE;2.14;2.61 +36344-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Foot;Doc;MR;RAD;2;MR Foot - left WO and W contrast IV;MR Foot-L WO+W contr IV;;ACTIVE;2.14;2.61 +36345-7;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Foot;Doc;CT;RAD;2;CT Foot - right WO and W contrast IV;CT Foot-R WO+W contr IV;;ACTIVE;2.14;2.61 +36346-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Foot;Doc;MR;RAD;2;MR Foot - right WO and W contrast IV;MR Foot-R WO+W contr IV;;ACTIVE;2.14;2.61 +36347-3;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Forearm;Doc;CT;RAD;2;CT Forearm WO and W contrast IV;CT Forearm WO+W contr IV;;ACTIVE;2.14;2.61 +36348-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Forearm;Doc;CT;RAD;2;CT Forearm - left WO and W contrast IV;CT Forearm-L WO+W contr IV;;ACTIVE;2.14;2.61 +36349-9;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Forearm;Doc;MR;RAD;2;MR Forearm - left WO and W contrast IV;MR Forearm-L WO+W contr IV;;ACTIVE;2.14;2.61 +3635-0;Fenproporex;MRat;24H;Urine;Qn;;DRUG/TOX;1;Fenproporex [Mass/time] in 24 hour Urine;Fenproporex 24h Ur-mRate;;ACTIVE;1.0;2.42 +36350-7;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Forearm;Doc;CT;RAD;2;CT Forearm - right WO and W contrast IV;CT Forearm-R WO+W contr IV;;ACTIVE;2.14;2.61 +36351-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Forearm;Doc;MR;RAD;2;MR Forearm - right WO and W contrast IV;MR Forearm-R WO+W contr IV;;ACTIVE;2.14;2.61 +36352-3;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Hand;Doc;CT;RAD;2;CT Hand WO and W contrast IV;CT Hand WO+W contr IV;;ACTIVE;2.14;2.61 +36353-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Hand;Doc;CT;RAD;2;CT Hand - left WO and W contrast IV;CT Hand-L WO+W contr IV;;ACTIVE;2.14;2.61 +36354-9;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Hand;Doc;MR;RAD;2;MR Hand - left WO and W contrast IV;MR Hand-L WO+W contr IV;;ACTIVE;2.14;2.61 +36355-6;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Hand;Doc;CT;RAD;2;CT Hand - right WO and W contrast IV;CT Hand-R WO+W contr IV;;ACTIVE;2.14;2.61 +36356-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Hand;Doc;MR;RAD;2;MR Hand - right WO and W contrast IV;MR Hand-R WO+W contr IV;;ACTIVE;2.14;2.61 +36357-2;Multisection^WO & W contrast IV;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart WO and W contrast IV;MR Hrt WO+W contr IV;;ACTIVE;2.14;2.73 +36358-0;Multisection^WO & W contrast IV;Find;Pt;Calcaneus;Doc;CT;RAD;2;Deprecated Calcaneus CT WO and W contrast IV;Deprecated Heel CT WO+W contr IV;;DEPRECATED;2.14;2.58 +36359-8;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Hip;Doc;CT;RAD;2;CT Hip WO and W contrast IV;CT Hip WO+W contr IV;;ACTIVE;2.14;2.61 +36360-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Hip;Doc;CT;RAD;2;CT Hip - bilateral WO and W contrast IV;CT Hip-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +36361-4;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Hip;Doc;MR;RAD;2;MR Hip - bilateral WO and W contrast IV;MR Hip-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +36362-2;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Hip;Doc;CT;RAD;2;CT Hip - left WO and W contrast IV;CT Hip-L WO+W contr IV;;ACTIVE;2.14;2.61 +36363-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Hip;Doc;MR;RAD;2;MR Hip - left WO and W contrast IV;MR Hip-L WO+W contr IV;;ACTIVE;2.14;2.61 +36364-8;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Hip;Doc;CT;RAD;2;CT Hip - right WO and W contrast IV;CT Hip-R WO+W contr IV;;ACTIVE;2.14;2.61 +36365-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Hip;Doc;MR;RAD;2;MR Hip - right WO and W contrast IV;MR Hip-R WO+W contr IV;;ACTIVE;2.14;2.61 +36366-3;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Upper arm;Doc;CT;RAD;2;CT Upper arm WO and W contrast IV;CT Upper arm WO+W contr IV;;ACTIVE;2.14;2.61 +36367-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Upper arm;Doc;CT;RAD;2;CT Upper arm - left WO and W contrast IV;CT Upper arm-L WO+W contr IV;;ACTIVE;2.14;2.61 +3636-8;fentaNYL;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;fentaNYL [Mass/volume] in Serum or Plasma;fentaNYL SerPl-mCnc;;ACTIVE;1.0;2.73 +36368-9;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Upper arm;Doc;MR;RAD;2;MR Upper arm - left WO and W contrast IV;MR Upper arm-L WO+W contr IV;;ACTIVE;2.14;2.61 +36369-7;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Upper arm;Doc;CT;RAD;2;CT Upper arm - right WO and W contrast IV;CT Upper arm-R WO+W contr IV;;ACTIVE;2.14;2.61 +36370-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Upper arm;Doc;MR;RAD;2;MR Upper arm - right WO and W contrast IV;MR Upper arm-R WO+W contr IV;;ACTIVE;2.14;2.61 +36371-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Lower extremity joint;Doc;MR;RAD;2;MR Lower Extremity Joint WO and W contrast IV;MR LE joint WO+W contr IV;;ACTIVE;2.14;2.65 +36372-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - left WO and W contrast IV;MR LE joint-L WO+W contr IV;;ACTIVE;2.14;2.65 +36373-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - right WO and W contrast IV;MR LE joint-R WO+W contr IV;;ACTIVE;2.14;2.65 +36374-7;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity.joint WO and W contrast IV;MR UE joint WO+W contr IV;;ACTIVE;2.14;2.61 +36375-4;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Sacroiliac joint;Doc;CT;RAD;2;CT Sacroiliac Joint WO and W contrast IV;CT SIJ WO+W contr IV;;ACTIVE;2.14;2.61 +3637-6;fentaNYL;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;fentaNYL [Mass/volume] in Urine;fentaNYL Ur-mCnc;;ACTIVE;1.0;2.73 +36376-2;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Sacroiliac joint;Doc;MR;RAD;2;MR Sacroiliac Joint WO and W contrast IV;MR SIJ WO+W contr IV;;ACTIVE;2.14;2.61 +36377-0;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;CT;RAD;2;CT Kidney - bilateral WO and W contrast IV;CT Kdny-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +36378-8;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;MR;RAD;2;MR Kidney - bilateral WO and W contrast IV;MR Kdny-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +36379-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Knee;Doc;CT;RAD;2;CT Knee WO and W contrast IV;CT Knee WO+W contr IV;;ACTIVE;2.14;2.61 +36380-4;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Knee;Doc;CT;RAD;2;CT Knee - left WO and W contrast IV;CT Knee-L WO+W contr IV;;ACTIVE;2.14;2.61 +36381-2;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Knee;Doc;CT;RAD;2;CT Knee - right WO and W contrast IV;CT Knee-R WO+W contr IV;;ACTIVE;2.14;2.61 +36382-0;Multisection^WO & W contrast IV;Find;Pt;Head+Neck>Larynx;Doc;MR;RAD;2;MR Larynx WO and W contrast IV;MR Larynx WO+W contr IV;;ACTIVE;2.14;2.61 +36383-8;Multisection^WO & W contrast IV;Find;Pt;Head>Mandible;Doc;CT;RAD;2;CT Mandible WO and W contrast IV;CT Mandible WO+W contr IV;;ACTIVE;2.14;2.61 +3638-4;Flecainide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flecainide [Mass/volume] in Serum or Plasma;Flecainide SerPl-mCnc;;ACTIVE;1.0;2.73 +36384-6;Multisection^WO & W contrast IV;Find;Pt;Head+Neck>Nasopharynx;Doc;MR;RAD;2;MR Nasopharynx WO and W contrast IV;MR Nasopharynx WO+W contr IV;;ACTIVE;2.14;2.61 +36385-3;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Pancreas;Doc;MR;RAD;2;MR Pancreas WO and W contrast IV;MR Pancreas WO+W contr IV;;ACTIVE;2.14;2.61 +36387-9;Multisection^WO & W contrast IV;Find;Pt;Head>Posterior fossa;Doc;CT;RAD;2;CT Posterior fossa WO and W contrast IV;CT Post fossa WO+W contr IV;;ACTIVE;2.14;2.61 +36388-7;Multisection^WO & W contrast IV;Find;Pt;Head>Posterior fossa;Doc;MR;RAD;2;MR Posterior fossa WO and W contrast IV;MR Post fossa WO+W contr IV;;ACTIVE;2.14;2.61 +36389-5;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Prostate;Doc;MR;RAD;2;MR Prostate WO and W contrast IV;MR Prostate WO+W contr IV;;ACTIVE;2.14;2.61 +36390-3;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Sacrum;Doc;CT;RAD;2;CT Sacrum WO and W contrast IV;CT Sacrum WO+W contr IV;;ACTIVE;2.14;2.61 +36391-1;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Sacrum;Doc;MR;RAD;2;MR Sacrum WO and W contrast IV;MR Sacrum WO+W contr IV;;ACTIVE;2.14;2.61 +3639-2;5-Fluorocytosine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;5-Fluorocytosine [Mass/volume] in Serum or Plasma;5-fluorocytosine SerPl-mCnc;;ACTIVE;1.0;2.73 +36392-9;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;MR;RAD;2;MR Sacrum and Coccyx WO and W contrast IV;MR Sacrum+Coccyx WO+W contr IV;;ACTIVE;2.14;2.61 +36393-7;Multisection^WO & W contrast IV;Find;Pt;Chest>Scapula.left;Doc;MR;RAD;2;MR Scapula - left WO and W contrast IV;MR Scapula-L WO+W contr IV;;ACTIVE;2.14;2.61 +36394-5;Multisection^WO & W contrast IV;Find;Pt;Chest>Scapula.right;Doc;MR;RAD;2;MR Scapula - right WO and W contrast IV;MR Scapula-R WO+W contr IV;;ACTIVE;2.14;2.61 +36395-2;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Shoulder;Doc;CT;RAD;2;CT Shoulder WO and W contrast IV;CT Should WO+W contr IV;;ACTIVE;2.14;2.61 +36396-0;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Shoulder;Doc;CT;RAD;2;CT Shoulder - left WO and W contrast IV;CT Should-L WO+W contr IV;;ACTIVE;2.14;2.61 +36397-8;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Shoulder;Doc;CT;RAD;2;CT Shoulder - right WO and W contrast IV;CT Should-R WO+W contr IV;;ACTIVE;2.14;2.61 +36398-6;Multisection^WO & W contrast IV;Find;Pt;Head>Sinuses;Doc;CT;RAD;2;CT Sinuses WO and W contrast IV;CT Sinuses WO+W contr IV;;ACTIVE;2.14;2.61 +36399-4;Multisection^WO & W contrast IV;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Spine WO and W contrast IV;CT Spine WO+W contr IV;;DISCOURAGED;2.14;2.61 +36-4;Azithromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Azithromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Azithromycin Islt MIC;;ACTIVE;1.0;2.73 +364-0;Nitrofurantoin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Nitrofurantoin [Susceptibility] by Disk diffusion (KB);Nitrofurantoin Islt KB;;ACTIVE;1.0;2.73 +3640-0;Flunitrazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Flunitrazepam [Mass/volume] in Blood;Flunitrazepam Bld-mCnc;;ACTIVE;1.0;2.73 +36400-0;Multisection^WO & W contrast IV;Find;Pt;XXX>Spine;Doc;MR;RAD;2;MR Spine WO and W contrast IV;MR Spine WO+W contr IV;;DISCOURAGED;2.14;2.61 +36401-8;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine WO and W contrast IV;CT C-spine WO+W contr IV;;ACTIVE;2.14;2.61 +36402-6;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine WO and W contrast IV;CT L-spine WO+W contr IV;;ACTIVE;2.14;2.61 +36403-4;Multisection^WO & W contrast IV;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine WO and W contrast IV;CT T-spine WO+W contr IV;;ACTIVE;2.14;2.61 +36404-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Spleen;Doc;MR;RAD;2;MR Spleen WO and W contrast IV;MR Spleen WO+W contr IV;;ACTIVE;2.14;2.61 +36405-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Sternum;Doc;CT;RAD;2;CT Sternum WO and W contrast IV;CT Sternum WO+W contr IV;;ACTIVE;2.14;2.61 +36406-7;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;MR;RAD;2;MR Scrotum and testicle WO and W contrast IV;MR Scrotum+Test WO+W contr IV;;ACTIVE;2.14;2.61 +36407-5;Multisection^WO & W contrast IV;Find;Pt;Neck>Thyroid gland;Doc;MR;RAD;2;MR Thyroid gland WO and W contrast IV;MR Thyroid WO+W contr IV;;ACTIVE;2.14;2.61 +36408-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Lower leg;Doc;CT;RAD;2;CT Lower leg WO and W contrast IV;CT Lower leg WO+W contr IV;;ACTIVE;2.14;2.61 +36409-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Lower leg;Doc;CT;RAD;2;CT Lower leg - left WO and W contrast IV;CT Lower leg-L WO+W contr IV;;ACTIVE;2.14;2.61 +36410-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Lower leg;Doc;MR;RAD;2;MR Lower leg - left WO and W contrast IV;MR Lower leg-L WO+W contr IV;;ACTIVE;2.14;2.61 +36411-7;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Lower leg;Doc;CT;RAD;2;CT Lower leg - right WO and W contrast IV;CT Lower leg-R WO+W contr IV;;ACTIVE;2.14;2.61 +36412-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Lower leg;Doc;MR;RAD;2;MR Lower leg - right WO and W contrast IV;MR Lower leg-R WO+W contr IV;;ACTIVE;2.14;2.61 +36413-3;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Uterus;Doc;MR;RAD;2;MR Uterus WO and W contrast IV;MR Uterus WO+W contr IV;;ACTIVE;2.14;2.61 +36414-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Portal vein;Doc;MR.angio;RAD;2;MRA Portal vein WO and W contrast IV;MRA Portal v WO+W contr IV;;ACTIVE;2.14;2.61 +36415-8;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Renal vein;Doc;MR.angio;RAD;2;MRA Renal vein WO and W contrast IV;MRA Renal v WO+W contr IV;;ACTIVE;2.14;2.61 +36416-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Lower extremity veins;Doc;MR.angio;RAD;2;MRA Lower extremity veins WO and W contrast IV;MRA LE vv WO+W contr IV;;ACTIVE;2.14;2.61 +36417-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Upper extremity veins;Doc;MR.angio;RAD;2;MRA Upper extremity veins WO and W contrast IV;MRA UE vv WO+W contr IV;;ACTIVE;2.14;2.61 +3641-8;Flunitrazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Flunitrazepam [Mass/volume] in Urine;Flunitrazepam Ur-mCnc;;ACTIVE;1.0;2.73 +36418-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Vena cava.inferior;Doc;MR;RAD;2;MR Inferior vena cava WO and W contrast IV;MR IVC WO+W contr IV;;ACTIVE;2.14;2.61 +36419-0;Multisection^WO & W contrast IV;Find;Pt;Chest>Vena cava.superior;Doc;MR;RAD;2;MR Superior vena cava WO and W contrast IV;MR SVC WO+W contr IV;;ACTIVE;2.14;2.61 +36420-8;Multisection^WO & W contrast IV;Find;Pt;Chest>Chest vessels;Doc;MR.angio;RAD;2;MRA Chest vessels WO and W contrast IV;MRA Chest ves WO+W contr IV;;ACTIVE;2.14;2.61 +36421-6;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels WO and W contrast IV;CTA UE ves WO+W contr IV;;ACTIVE;2.14;2.61 +36422-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels WO and W contrast IV;MRA UE ves WO+W contr IV;;ACTIVE;2.14;2.61 +36423-2;Multisection^WO & W contrast IV;Find;Pt;Neck>Neck vessels;Doc;MR.angio;RAD;2;MRA Neck vessels WO and W contrast IV;MRA Neck ves WO+W contr IV;;ACTIVE;2.14;2.61 +36424-0;Multisection^WO contrast;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen WO contrast;CT Abd WO contr;;ACTIVE;2.14;2.73 +36425-7;Multisection^WO contrast;Find;Pt;Lower extremity>Ankle;Doc;CT;RAD;2;CT Ankle WO contrast;CT Ankle WO contr;;ACTIVE;2.14;2.61 +3642-6;Fluorouracil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fluorouracil [Mass/volume] in Serum or Plasma;Fluorouracil SerPl-mCnc;;ACTIVE;1.0;2.42 +36426-5;Multisection^WO contrast;Find;Pt;Lower extremity.left>Ankle;Doc;CT;RAD;2;CT Ankle - left WO contrast;CT Ankle-L WO contr;;ACTIVE;2.14;2.61 +36427-3;Multisection^WO contrast;Find;Pt;Lower extremity.left>Ankle;Doc;MR;RAD;2;MR Ankle - left WO contrast;MR Ankle-L WO contr;;ACTIVE;2.14;2.73 +36428-1;Multisection^WO contrast;Find;Pt;Lower extremity.right>Ankle;Doc;CT;RAD;2;CT Ankle - right WO contrast;CT Ankle-R WO contr;;ACTIVE;2.14;2.61 +36429-9;Multisection^WO contrast;Find;Pt;Lower extremity.right>Ankle;Doc;MR;RAD;2;MR Ankle - right WO contrast;MR Ankle-R WO contr;;ACTIVE;2.14;2.61 +36430-7;Multisection^WO contrast;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Thoracic and abdominal aorta WO contrast;CT TA + AA WO contr;;ACTIVE;2.14;2.61 +36431-5;Multisection^WO contrast;Find;Pt;Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Abdominal Aorta WO contrast;CT Abd Aorta WO contr;;ACTIVE;2.14;2.61 +36432-3;Multisection^WO contrast;Find;Pt;Abdomen>Aorta.abdominal;Doc;MR.angio;RAD;2;MRA Abdominal Aorta WO contrast;MRA Abd Aorta WO contr;;ACTIVE;2.14;2.61 +36433-1;Multisection^WO contrast;Find;Pt;Chest>Aorta.thoracic;Doc;MR.angio;RAD;2;MRA Thoracic Aorta WO contrast;MRA TA WO contr;;ACTIVE;2.14;2.61 +3643-4;FLUoxetine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;FLUoxetine [Presence] in Serum or Plasma;FLUoxetine SerPl Ql;;ACTIVE;1.0;2.73 +36434-9;Multisection^WO contrast;Find;Pt;Abdomen+Pelvis>Appendix;Doc;CT;RAD;2;CT Appendix WO contrast;CT Appendix WO contr;;ACTIVE;2.14;2.61 +36435-6;Multisection^WO contrast;Find;Pt;Head>Face;Doc;MR;RAD;2;MR Face WO contrast;MR Face WO contr;;ACTIVE;2.14;2.61 +36436-4;Multisection^WO contrast;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast WO contrast;MR Brst WO contr;;ACTIVE;2.14;2.61 +36437-2;Multisection^WO contrast;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral WO contrast;MR Brst-Bl WO contr;;ACTIVE;2.14;2.61 +36438-0;Multisection^WO contrast;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Breast - left WO contrast;MR Brst-L WO contr;;ACTIVE;2.14;2.61 +36439-8;Multisection^WO contrast;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Breast - right WO contrast;MR Brst-R WO contr;;ACTIVE;2.14;2.61 +36440-6;Multisection^WO contrast;Find;Pt;Calcaneus.left;Doc;CT;RAD;2;Deprecated Calcaneus - left CT WO contrast;Deprecated Heel-L CT WO contr;;DEPRECATED;2.14;2.58 +36441-4;Multisection^WO contrast;Find;Pt;Calcaneus.right;Doc;CT;RAD;2;Deprecated Calcaneus - right CT WO contrast;Deprecated Heel-R CT WO contr;;DEPRECATED;2.14;2.58 +3644-2;FLUoxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;FLUoxetine [Mass/volume] in Serum or Plasma;FLUoxetine SerPl-mCnc;;ACTIVE;1.0;2.73 +36442-2;Multisection^WO contrast;Find;Pt;Chest;Doc;MR;RAD;2;MR Chest WO contrast;MR Chest WO contr;;ACTIVE;2.14;2.61 +36443-0;Multisection^WO contrast;Find;Pt;Upper extremity>Elbow;Doc;CT;RAD;2;CT Elbow WO contrast;CT Elbow WO contr;;ACTIVE;2.14;2.61 +36444-8;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Elbow;Doc;CT;RAD;2;CT Elbow - bilateral WO contrast;CT Elbow-Bl WO contr;;ACTIVE;2.14;2.61 +36445-5;Multisection^WO contrast;Find;Pt;Upper extremity.left>Elbow;Doc;CT;RAD;2;CT Elbow - left WO contrast;CT Elbow-L WO contr;;ACTIVE;2.14;2.61 +36446-3;Multisection^WO contrast;Find;Pt;Upper extremity.left>Elbow;Doc;MR;RAD;2;MR Elbow - left WO contrast;MR Elbow-L WO contr;;ACTIVE;2.14;2.61 +36447-1;Multisection^WO contrast;Find;Pt;Upper extremity.right>Elbow;Doc;CT;RAD;2;CT Elbow - right WO contrast;CT Elbow-R WO contr;;ACTIVE;2.14;2.61 +36448-9;Multisection^WO contrast;Find;Pt;Upper extremity.right>Elbow;Doc;MR;RAD;2;MR Elbow - right WO contrast;MR Elbow-R WO contr;;ACTIVE;2.14;2.61 +36449-7;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral;Doc;CT;RAD;2;CT Lower extremity - bilateral WO contrast;CT LE-Bl WO contr;;ACTIVE;2.14;2.61 +36450-5;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - bilateral WO contrast;MRA LE ves-Bl WO contr;;ACTIVE;2.14;2.61 +36451-3;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral;Doc;MR;RAD;2;MR Lower extremity - bilateral WO contrast;MR LE-Bl WO contr;;ACTIVE;2.14;2.61 +36452-1;Multisection^WO contrast;Find;Pt;Lower extremity.left;Doc;CT;RAD;2;CT Lower extremity - left WO contrast;CT LE-L WO contr;;ACTIVE;2.14;2.61 +36453-9;Multisection^WO contrast;Find;Pt;Lower extremity.left;Doc;MR;RAD;2;MR Lower extremity - left WO contrast;MR LE-L WO contr;;ACTIVE;2.14;2.61 +36454-7;Multisection^WO contrast;Find;Pt;Lower extremity.right;Doc;CT;RAD;2;CT Lower extremity - right WO contrast;CT LE-R WO contr;;ACTIVE;2.14;2.61 +36455-4;Multisection^WO contrast;Find;Pt;Lower extremity.right;Doc;MR;RAD;2;MR Lower extremity - right WO contrast;MR LE-R WO contr;;ACTIVE;2.14;2.61 +36456-2;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral;Doc;CT;RAD;2;CT Upper extremity - bilateral WO contrast;CT UE-Bl WO contr;;ACTIVE;2.14;2.61 +36457-0;Multisection^WO contrast;Find;Pt;Upper extremity.left;Doc;CT;RAD;2;CT Upper extremity - left WO contrast;CT UE-L WO contr;;ACTIVE;2.14;2.61 +36458-8;Multisection^WO contrast;Find;Pt;Upper extremity.right;Doc;CT;RAD;2;CT Upper extremity - right WO contrast;CT UE-R WO contr;;ACTIVE;2.14;2.61 +3645-9;FLUoxetine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;FLUoxetine [Presence] in Urine;FLUoxetine Ur Ql;;ACTIVE;1.0;2.73 +36459-6;Multisection^WO contrast;Find;Pt;Upper extremity.right;Doc;MR;RAD;2;MR Upper extremity - right WO contrast;MR UE-R WO contr;;ACTIVE;2.14;2.61 +36460-4;Multisection^WO contrast;Find;Pt;Lower extremity>Thigh;Doc;CT;RAD;2;CT Thigh WO contrast;CT Thigh WO contr;;ACTIVE;2.14;2.61 +36461-2;Multisection^WO contrast;Find;Pt;Lower extremity>Thigh;Doc;MR;RAD;2;MR Thigh WO contrast;MR Thigh WO contr;;ACTIVE;2.14;2.61 +36462-0;Multisection^WO contrast;Find;Pt;Lower extremity.left>Thigh;Doc;CT;RAD;2;CT Thigh - left WO contrast;CT Thigh-L WO contr;;ACTIVE;2.14;2.61 +36463-8;Multisection^WO contrast;Find;Pt;Lower extremity.left>Thigh;Doc;MR;RAD;2;MR Thigh - left WO contrast;MR Thigh-L WO contr;;ACTIVE;2.14;2.61 +36464-6;Multisection^WO contrast;Find;Pt;Lower extremity.right>Thigh;Doc;CT;RAD;2;CT Thigh - right WO contrast;CT Thigh-R WO contr;;ACTIVE;2.14;2.61 +36465-3;Multisection^WO contrast;Find;Pt;Lower extremity.right>Thigh;Doc;MR;RAD;2;MR Thigh - right WO contrast;MR Thigh-R WO contr;;ACTIVE;2.14;2.61 +36466-1;Multisection^WO contrast;Find;Pt;Lower extremity>Foot;Doc;CT;RAD;2;CT Foot WO contrast;CT Foot WO contr;;ACTIVE;2.14;2.61 +3646-7;Fluoxymesterone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Fluoxymesterone [Presence] in Urine;Fluoxymesterone Ur Ql;;ACTIVE;1.0;2.73 +36467-9;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Foot;Doc;MR;RAD;2;MR Foot - bilateral WO contrast;MR Foot-Bl WO contr;;ACTIVE;2.14;2.61 +36468-7;Multisection^WO contrast;Find;Pt;Lower extremity.left>Foot;Doc;CT;RAD;2;CT Foot - left WO contrast;CT Foot-L WO contr;;ACTIVE;2.14;2.61 +36469-5;Multisection^WO contrast;Find;Pt;Lower extremity.left>Foot;Doc;MR;RAD;2;MR Foot - left WO contrast;MR Foot-L WO contr;;ACTIVE;2.14;2.73 +36470-3;Multisection^WO contrast;Find;Pt;Lower extremity.right>Foot;Doc;CT;RAD;2;CT Foot - right WO contrast;CT Foot-R WO contr;;ACTIVE;2.14;2.61 +36471-1;Multisection^WO contrast;Find;Pt;Lower extremity.right>Foot;Doc;MR;RAD;2;MR Foot - right WO contrast;MR Foot-R WO contr;;ACTIVE;2.14;2.73 +36472-9;Multisection^WO contrast;Find;Pt;Upper extremity>Forearm;Doc;CT;RAD;2;CT Forearm WO contrast;CT Forearm WO contr;;ACTIVE;2.14;2.61 +36473-7;Multisection^WO contrast;Find;Pt;Upper extremity.left>Forearm;Doc;CT;RAD;2;CT Forearm - left WO contrast;CT Forearm-L WO contr;;ACTIVE;2.14;2.61 +36474-5;Multisection^WO contrast;Find;Pt;Upper extremity.left>Forearm;Doc;MR;RAD;2;MR Forearm - left WO contrast;MR Forearm-L WO contr;;ACTIVE;2.14;2.61 +3647-5;Fluoxymesterone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fluoxymesterone [Mass/volume] in Urine;Fluoxymesterone Ur-mCnc;;ACTIVE;1.0;2.34 +36475-2;Multisection^WO contrast;Find;Pt;Upper extremity.right>Forearm;Doc;CT;RAD;2;CT Forearm - right WO contrast;CT Forearm-R WO contr;;ACTIVE;2.14;2.61 +36476-0;Multisection^WO contrast;Find;Pt;Upper extremity.right>Forearm;Doc;MR;RAD;2;MR Forearm - right WO contrast;MR Forearm-R WO contr;;ACTIVE;2.14;2.61 +36477-8;Multisection^WO contrast;Find;Pt;Upper extremity>Hand;Doc;CT;RAD;2;CT Hand WO contrast;CT Hand WO contr;;ACTIVE;2.14;2.61 +36478-6;Multisection^WO contrast;Find;Pt;Upper extremity.left>Hand;Doc;CT;RAD;2;CT Hand - left WO contrast;CT Hand-L WO contr;;ACTIVE;2.14;2.61 +36479-4;Multisection^WO contrast;Find;Pt;Upper extremity.left>Hand;Doc;MR;RAD;2;MR Hand - left WO contrast;MR Hand-L WO contr;;ACTIVE;2.14;2.61 +36480-2;Multisection^WO contrast;Find;Pt;Upper extremity.right>Hand;Doc;CT;RAD;2;CT Hand - right WO contrast;CT Hand-R WO contr;;ACTIVE;2.14;2.61 +36481-0;Multisection^WO contrast;Find;Pt;Upper extremity.right>Hand;Doc;MR;RAD;2;MR Hand - right WO contrast;MR Hand-R WO contr;;ACTIVE;2.14;2.61 +36482-8;Multisection^WO contrast;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart WO contrast;MR Hrt WO contr;;ACTIVE;2.14;2.61 +3648-3;Fluoxymesterone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Fluoxymesterone [Mass/time] in 24 hour Urine;Fluoxymesterone 24h Ur-mRate;;ACTIVE;1.0;2.19 +36483-6;Multisection^WO contrast;Find;Pt;Calcaneus;Doc;CT;RAD;2;Deprecated Calcaneus CT WO contrast;Deprecated Heel CT WO contr;;DEPRECATED;2.14;2.58 +36484-4;Multisection^WO contrast;Find;Pt;Lower extremity>Hip;Doc;CT;RAD;2;CT Hip WO contrast;CT Hip WO contr;;ACTIVE;2.14;2.61 +36485-1;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Hip;Doc;CT;RAD;2;CT Hip - bilateral WO contrast;CT Hip-Bl WO contr;;ACTIVE;2.14;2.61 +36486-9;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Hip;Doc;MR;RAD;2;MR Hip - bilateral WO contrast;MR Hip-Bl WO contr;;ACTIVE;2.14;2.61 +36487-7;Multisection^WO contrast;Find;Pt;Lower extremity.left>Hip;Doc;CT;RAD;2;CT Hip - left WO contrast;CT Hip-L WO contr;;ACTIVE;2.14;2.61 +36488-5;Multisection^WO contrast;Find;Pt;Lower extremity.left>Hip;Doc;MR;RAD;2;MR Hip - left WO contrast;MR Hip-L WO contr;;ACTIVE;2.14;2.73 +36489-3;Multisection^WO contrast;Find;Pt;Lower extremity.right>Hip;Doc;CT;RAD;2;CT Hip - right WO contrast;CT Hip-R WO contr;;ACTIVE;2.14;2.61 +36490-1;Multisection^WO contrast;Find;Pt;Lower extremity.right>Hip;Doc;MR;RAD;2;MR Hip - right WO contrast;MR Hip-R WO contr;;ACTIVE;2.14;2.61 +3649-1;Flupenthixol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Flupenthixol [Mass/volume] in Urine;Flupenthixol Ur-mCnc;;ACTIVE;1.0;2.42 +36491-9;Multisection^WO contrast;Find;Pt;Upper extremity>Upper arm;Doc;CT;RAD;2;CT Upper arm WO contrast;CT Upper arm WO contr;;ACTIVE;2.14;2.61 +36492-7;Multisection^WO contrast;Find;Pt;Upper extremity.left>Upper arm;Doc;CT;RAD;2;CT Upper arm - left WO contrast;CT Upper arm-L WO contr;;ACTIVE;2.14;2.61 +36493-5;Multisection^WO contrast;Find;Pt;Upper extremity.left>Upper arm;Doc;MR;RAD;2;MR Upper arm - left WO contrast;MR Upper arm-L WO contr;;ACTIVE;2.14;2.61 +36494-3;Multisection^WO contrast;Find;Pt;Upper extremity.right>Upper arm;Doc;CT;RAD;2;CT Upper arm - right WO contrast;CT Upper arm-R WO contr;;ACTIVE;2.14;2.61 +36495-0;Multisection^WO contrast;Find;Pt;Upper extremity.right>Upper arm;Doc;MR;RAD;2;MR Upper arm - right WO contrast;MR Upper arm-R WO contr;;ACTIVE;2.14;2.61 +36496-8;Multisection^WO contrast;Find;Pt;Upper extremity>Acromioclavicular joint;Doc;MR;RAD;2;MR Acromioclavicular Joint WO contrast;MR AC joint WO contr;;ACTIVE;2.14;2.61 +36497-6;Multisection^WO contrast;Find;Pt;Lower extremity>Lower extremity joint;Doc;MR;RAD;2;MR Lower Extremity Joint WO contrast;MR LE joint WO contr;;ACTIVE;2.14;2.65 +36498-4;Multisection^WO contrast;Find;Pt;Lower extremity.left>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - left WO contrast;MR LE joint-L WO contr;;ACTIVE;2.14;2.65 +36499-2;Multisection^WO contrast;Find;Pt;Lower extremity.right>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - right WO contrast;MR LE joint-R WO contr;;ACTIVE;2.14;2.65 +36500-7;Multisection^WO contrast;Find;Pt;Upper extremity>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity.joint WO contrast;MR UE joint WO contr;;ACTIVE;2.14;2.61 +36501-5;Multisection^WO contrast;Find;Pt;Pelvis>Sacroiliac joint;Doc;CT;RAD;2;CT Sacroiliac Joint WO contrast;CT SIJ WO contr;;ACTIVE;2.14;2.61 +36502-3;Multisection^WO contrast;Find;Pt;Pelvis>Sacroiliac joint;Doc;MR;RAD;2;MR Sacroiliac Joint WO contrast;MR SIJ WO contr;;ACTIVE;2.14;2.61 +36503-1;Multisection^WO contrast;Find;Pt;Abdomen>Kidney.bilateral;Doc;CT;RAD;2;CT Kidney - bilateral WO contrast;CT Kdny-Bl WO contr;;ACTIVE;2.14;2.61 +36504-9;Multisection^WO contrast;Find;Pt;Abdomen>Kidney.bilateral;Doc;MR;RAD;2;MR Kidney - bilateral WO contrast;MR Kdny-Bl WO contr;;ACTIVE;2.14;2.61 +36505-6;Multisection^WO contrast;Find;Pt;Lower extremity>Knee;Doc;CT;RAD;2;CT Knee WO contrast;CT Knee WO contr;;ACTIVE;2.14;2.61 +36506-4;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Knee;Doc;MR;RAD;2;MR Knee - bilateral WO contrast;MR Knee-Bl WO contr;;ACTIVE;2.14;2.61 +36507-2;Multisection^WO contrast;Find;Pt;Lower extremity.left>Knee;Doc;CT;RAD;2;CT Knee - left WO contrast;CT Knee-L WO contr;;ACTIVE;2.14;2.61 +36508-0;Multisection^WO contrast;Find;Pt;Lower extremity.left>Knee;Doc;MR;RAD;2;MR Knee - left WO contrast;MR Knee-L WO contr;;ACTIVE;2.14;2.73 +3650-9;fluPHENAZine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;fluPHENAZine [Mass/volume] in Serum or Plasma;fluPHENAZine SerPl-mCnc;;ACTIVE;1.0;2.73 +36509-8;Multisection^WO contrast;Find;Pt;Lower extremity.right>Knee;Doc;CT;RAD;2;CT Knee - right WO contrast;CT Knee-R WO contr;;ACTIVE;2.14;2.61 +36510-6;Multisection^WO contrast;Find;Pt;Lower extremity.right>Knee;Doc;MR;RAD;2;MR Knee - right WO contrast;MR Knee-R WO contr;;ACTIVE;2.14;2.73 +36511-4;Multisection^WO contrast;Find;Pt;Head+Neck>Larynx;Doc;CT;RAD;2;CT Larynx WO contrast;CT Larynx WO contr;;ACTIVE;2.14;2.61 +36512-2;Multisection^WO contrast;Find;Pt;Head>Mandible;Doc;CT;RAD;2;CT Mandible WO contrast;CT Mandible WO contr;;ACTIVE;2.14;2.61 +36513-0;Multisection^WO contrast;Find;Pt;Head+Neck>Nasopharynx;Doc;MR;RAD;2;MR Nasopharynx WO contrast;MR Nasopharynx WO contr;;ACTIVE;2.14;2.61 +36514-8;Multisection^WO contrast;Find;Pt;Neck;Doc;CT;RAD;2;CT Neck WO contrast;CT Neck WO contr;;ACTIVE;2.14;2.73 +36515-5;Multisection^WO contrast;Find;Pt;Abdomen>Pancreas;Doc;MR;RAD;2;MR Pancreas WO contrast;MR Pancreas WO contr;;ACTIVE;2.14;2.61 +36516-3;Multisection^WO contrast;Find;Pt;Chest>Brachial plexus.right;Doc;MR;RAD;2;MR Brachial plexus - right WO contrast;MR Brachial plexus-R WO contr;;ACTIVE;2.14;2.61 +3651-7;fluPHENAZine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;fluPHENAZine [Mass/volume] in Urine;fluPHENAZine Ur-mCnc;;ACTIVE;1.0;2.73 +36517-1;Multisection^WO contrast;Find;Pt;Head>Posterior fossa;Doc;CT;RAD;2;CT Posterior fossa WO contrast;CT Post fossa WO contr;;ACTIVE;2.14;2.61 +36518-9;Multisection^WO contrast;Find;Pt;Head>Posterior fossa;Doc;MR;RAD;2;MR Posterior fossa WO contrast;MR Post fossa WO contr;;ACTIVE;2.14;2.61 +36519-7;Multisection^WO contrast;Find;Pt;Pelvis>Prostate;Doc;MR;RAD;2;MR Prostate WO contrast;MR Prostate WO contr;;ACTIVE;2.14;2.61 +36520-5;Multisection^WO contrast;Find;Pt;Pelvis>Sacrum;Doc;CT;RAD;2;CT Sacrum WO contrast;CT Sacrum WO contr;;ACTIVE;2.14;2.61 +36521-3;Multisection^WO contrast;Find;Pt;Pelvis>Sacrum;Doc;MR;RAD;2;MR Sacrum WO contrast;MR Sacrum WO contr;;ACTIVE;2.14;2.61 +36522-1;Multisection^WO contrast;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;MR;RAD;2;MR Sacrum and Coccyx WO contrast;MR Sacrum+Coccyx WO contr;;ACTIVE;2.14;2.61 +36523-9;Multisection^WO contrast;Find;Pt;Chest>Scapula.left;Doc;MR;RAD;2;MR Scapula - left WO contrast;MR Scapula-L WO contr;;ACTIVE;2.14;2.61 +36524-7;Multisection^WO contrast;Find;Pt;Upper extremity>Shoulder;Doc;CT;RAD;2;CT Shoulder WO contrast;CT Should WO contr;;ACTIVE;2.14;2.61 +3652-5;Flurazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Flurazepam [Presence] in Serum or Plasma;Flurazepam SerPl Ql;;ACTIVE;1.0;2.73 +36525-4;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;MR;RAD;2;MR Shoulder - bilateral WO contrast;MR Shoulder-Bl WO contr;;ACTIVE;2.14;2.61 +36526-2;Multisection^WO contrast;Find;Pt;Upper extremity.left>Shoulder;Doc;CT;RAD;2;CT Shoulder - left WO contrast;CT Should-L WO contr;;ACTIVE;2.14;2.61 +36527-0;Multisection^WO contrast;Find;Pt;Upper extremity.right>Shoulder;Doc;CT;RAD;2;CT Shoulder - right WO contrast;CT Should-R WO contr;;ACTIVE;2.14;2.61 +36528-8;Multisection^WO contrast;Find;Pt;Upper extremity.right>Shoulder;Doc;MR;RAD;2;MR Shoulder - right WO contrast;MR Should-R WO contr;;ACTIVE;2.14;2.73 +36529-6;Multisection^WO contrast;Find;Pt;Head>Sinuses;Doc;CT;RAD;2;CT Sinuses WO contrast;CT Sinuses WO contr;;ACTIVE;2.14;2.61 +36530-4;Multisection^WO contrast;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Spine WO contrast;CT Spine WO contr;;DISCOURAGED;2.14;2.61 +36531-2;Multisection^WO contrast;Find;Pt;XXX>Spine;Doc;MR;RAD;2;MR Spine WO contrast;MR Spine WO contr;;DISCOURAGED;2.14;2.61 +36532-0;Multisection^WO contrast;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine WO contrast;MR T-spine WO contr;;ACTIVE;2.14;2.61 +3653-3;Flurazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flurazepam [Mass/volume] in Serum or Plasma;Flurazepam SerPl-mCnc;;ACTIVE;1.0;2.73 +36533-8;Multisection^WO contrast;Find;Pt;Abdomen>Spleen;Doc;MR;RAD;2;MR Spleen WO contrast;MR Spleen WO contr;;ACTIVE;2.14;2.61 +36534-6;Multisection^WO contrast;Find;Pt;Chest>Sternum;Doc;CT;RAD;2;CT Sternum WO contrast;CT Sternum WO contr;;ACTIVE;2.14;2.61 +36535-3;Multisection^WO contrast;Find;Pt;Pelvis>Scrotum+Testicle;Doc;MR;RAD;2;MR Scrotum and testicle WO contrast;MR Scrotum+Test WO contr;;ACTIVE;2.14;2.61 +36536-1;Multisection^WO contrast;Find;Pt;Neck>Thyroid gland;Doc;MR;RAD;2;MR Thyroid gland WO contrast;MR Thyroid WO contr;;ACTIVE;2.14;2.61 +36537-9;Multisection^WO contrast;Find;Pt;Lower extremity>Lower leg;Doc;CT;RAD;2;CT Lower leg WO contrast;CT Lower leg WO contr;;ACTIVE;2.14;2.61 +36538-7;Multisection^WO contrast;Find;Pt;Lower extremity.left>Lower leg;Doc;CT;RAD;2;CT Lower leg - left WO contrast;CT Lower leg-L WO contr;;ACTIVE;2.14;2.61 +36539-5;Multisection^WO contrast;Find;Pt;Lower extremity.left>Lower leg;Doc;MR;RAD;2;MR Lower leg - left WO contrast;MR Lower leg-L WO contr;;ACTIVE;2.14;2.61 +36540-3;Multisection^WO contrast;Find;Pt;Lower extremity.right>Lower leg;Doc;CT;RAD;2;CT Lower leg - right WO contrast;CT Lower leg-R WO contr;;ACTIVE;2.14;2.61 +3654-1;Flurazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Flurazepam [Presence] in Urine;Flurazepam Ur Ql;;ACTIVE;1.0;2.73 +36541-1;Multisection^WO contrast;Find;Pt;Lower extremity.right>Lower leg;Doc;MR;RAD;2;MR Lower leg - right WO contrast;MR Lower leg-R WO contr;;ACTIVE;2.14;2.61 +36542-9;Multisection^WO contrast;Find;Pt;Pelvis>Uterus;Doc;MR;RAD;2;MR Uterus WO contrast;MR Uterus WO contr;;ACTIVE;2.14;2.61 +36543-7;Multisection^WO contrast;Find;Pt;Abdomen>Portal vein;Doc;MR.angio;RAD;2;MRA Portal vein WO contrast;MRA Portal v WO contr;;ACTIVE;2.14;2.61 +36544-5;Multisection^WO contrast;Find;Pt;Abdomen>Renal vein;Doc;MR.angio;RAD;2;MRA Renal vein WO contrast;MRA Renal v WO contr;;ACTIVE;2.14;2.61 +36545-2;Multisection^WO contrast;Find;Pt;Abdomen>Vena cava.inferior;Doc;MR;RAD;2;MR Inferior vena cava WO contrast;MR IVC WO contr;;ACTIVE;2.14;2.61 +36546-0;Multisection^WO contrast;Find;Pt;Chest>Vena cava.superior;Doc;MR;RAD;2;MR Superior vena cava WO contrast;MR SVC WO contr;;ACTIVE;2.14;2.61 +36547-8;Multisection^WO contrast;Find;Pt;Chest>Chest vessels;Doc;MR.angio;RAD;2;MRA Chest vessels WO contrast;MRA Chest ves WO contr;;ACTIVE;2.14;2.61 +36548-6;Multisection^WO contrast;Find;Pt;Upper extremity>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels WO contrast;MRA UE ves WO contr;;ACTIVE;2.14;2.61 +36549-4;Multisection^WO contrast;Find;Pt;Neck>Neck vessels;Doc;MR.angio;RAD;2;MRA Neck vessels WO contrast;MRA Neck ves WO contr;;ACTIVE;2.14;2.61 +36550-2;View;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Single view;XR Abd 1V;;ACTIVE;2.14;2.64 +36551-0;View;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle Single view;XR Ankle 1V;;ACTIVE;2.14;2.64 +36554-4;View;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Single view;XR Chest 1V;;ACTIVE;2.14;2.64 +36555-1;View;Find;Pt;Chest>Clavicle;Doc;XR;RAD;2;XR Clavicle Single view;XR Clavicle 1V;;ACTIVE;2.14;2.64 +36556-9;View;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow Single view;XR Elbow 1V;;ACTIVE;2.14;2.64 +36557-7;View;Find;Pt;Lower extremity.bilateral;Doc;XR;RAD;2;XR Lower extremity - bilateral Single view;XR LE-Bl 1V;;ACTIVE;2.14;2.64 +3655-8;Flurazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Flurazepam [Mass/volume] in Urine;Flurazepam Ur-mCnc;;ACTIVE;1.0;2.73 +36558-5;View;Find;Pt;Lower extremity.left;Doc;XR;RAD;2;XR Lower extremity - left Single view;XR LE-L 1V;;ACTIVE;2.14;2.64 +36559-3;View;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur Single view;XR Femur 1V;;ACTIVE;2.14;2.64 +36560-1;View;Find;Pt;Lower extremity.left>Femur;Doc;XR;RAD;2;XR Femur - left Single view;XR Femur-L 1V;;ACTIVE;2.14;2.64 +36561-9;View;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Single view;XR Foot 1V;;ACTIVE;2.14;2.64 +36563-5;View;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand Single view;XR Hand 1V;;ACTIVE;2.14;2.64 +36564-3;View;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus Single view;XR Heel 1V;;ACTIVE;2.14;2.64 +36565-0;View;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus Single view;XR Humerus 1V;;ACTIVE;2.14;2.64 +3656-6;Furfenorex;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Furfenorex [Presence] in Urine;Furfenorex Ur Ql;;ACTIVE;1.0;2.56 +36566-8;View;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Single view;XR Knee-Bl 1V;;ACTIVE;2.14;2.64 +36567-6;View;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Single view;XR Knee-L 1V;;ACTIVE;2.14;2.64 +36568-4;View;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Single view;XR Shoulder-Bl 1V;;ACTIVE;2.14;2.64 +36569-2;View;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Single view;XR Should-L 1V;;ACTIVE;2.14;2.64 +365-7;Nitrofurantoin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Nitrofurantoin [Susceptibility] by Serum bactericidal titer;Nitrofurantoin Titr SBT;;ACTIVE;1.0;2.32 +36570-0;View;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Single view;XR Wrist-L 1V;;ACTIVE;2.14;2.64 +36571-8;View AP;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle AP;XR Ankle AP;;ACTIVE;2.14;2.61 +36572-6;View AP;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP;XR Chest AP;;ACTIVE;2.14;2.61 +36573-4;View AP;Find;Pt;Chest>Clavicle;Doc;XR;RAD;2;XR Clavicle AP;XR Clavicle AP;;ACTIVE;2.14;2.61 +3657-4;Furfenorex;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Furfenorex [Mass/volume] in Urine;Furfenorex Ur-mCnc;;ACTIVE;1.0;2.34 +36574-2;View AP;Find;Pt;Lower extremity;Doc;XR;RAD;2;XR Lower extremity AP;XR LE AP;;ACTIVE;2.14;2.61 +36575-9;View AP;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur AP;XR Femur AP;;ACTIVE;2.14;2.61 +36576-7;View AP;Find;Pt;Upper extremity>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth AP;XR Finger.5th AP;;ACTIVE;2.14;2.61 +36577-5;View AP;Find;Pt;Upper extremity>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth AP;XR Finger.4th AP;;ACTIVE;2.14;2.61 +36578-3;View AP;Find;Pt;Upper extremity>Finger.third;Doc;XR;RAD;2;XR Finger third AP;XR Finger.3rd AP;;ACTIVE;2.14;2.61 +36579-1;View AP;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot AP;XR Foot AP;;ACTIVE;2.14;2.61 +36580-9;View AP;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral AP;XR Foot-Bl AP;;ACTIVE;2.14;2.61 +36581-7;View AP;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip AP;XR Hip AP;;ACTIVE;2.14;2.61 +3658-2;Furfenorex;MRat;24H;Urine;Qn;;DRUG/TOX;1;Furfenorex [Mass/time] in 24 hour Urine;Furfenorex 24h Ur-mRate;;ACTIVE;1.0;2.19 +36582-5;View AP;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left AP;XR Hip-L AP;;ACTIVE;2.14;2.61 +36583-3;View AP;Find;Pt;Upper extremity.left>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - left AP;XR AC joint-L AP;;ACTIVE;2.14;2.61 +36584-1;View AP;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP;XR Knee AP;;ACTIVE;2.14;2.61 +36585-8;View AP;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP;XR Knee-Bl AP;;ACTIVE;2.14;2.61 +36586-6;View AP;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP;XR Shoulder-Bl AP;;ACTIVE;2.14;2.61 +36587-4;View AP;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP;XR Should-L AP;;ACTIVE;2.14;2.61 +36588-2;View AP;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen AP;XR port Abd AP;;ACTIVE;2.14;2.61 +36589-0;View AP;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest AP single view;XR port Chest AP 1 view;;ACTIVE;2.14;2.61 +3659-0;Furosemide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Furosemide [Mass/volume] in Serum or Plasma;Furosemide SerPl-mCnc;;ACTIVE;1.0;2.73 +36590-8;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral;XR Knee-Bl AP+Lat;;ACTIVE;2.14;2.61 +36591-6;View lateral;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Lateral;XR Abd Lat;;ACTIVE;2.14;2.61 +36592-4;View lateral;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle Lateral;XR Ankle Lat;;ACTIVE;2.14;2.61 +36593-2;View lateral;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur Lateral;XR Femur Lat;;ACTIVE;2.14;2.61 +36594-0;View lateral;Find;Pt;Upper extremity>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth Lateral;XR Finger.5th Lat;;ACTIVE;2.14;2.61 +36595-7;View lateral;Find;Pt;Upper extremity>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth Lateral;XR Finger.4th Lat;;ACTIVE;2.14;2.61 +36596-5;View lateral;Find;Pt;Upper extremity>Finger.second;Doc;XR;RAD;2;XR Finger second Lateral;XR Finger.2nd Lat;;ACTIVE;2.14;2.61 +36597-3;View lateral;Find;Pt;Upper extremity>Finger.third;Doc;XR;RAD;2;XR Finger third Lateral;XR Finger.3rd Lat;;ACTIVE;2.14;2.61 +36598-1;View lateral;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left Lateral;XR Foot-L Lat;;ACTIVE;2.14;2.73 +36599-9;View lateral;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand Lateral;XR Hand Lat;;ACTIVE;2.14;2.61 +36600-5;View lateral;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral Lateral;XR Hand-Bl Lat;;ACTIVE;2.14;2.61 +36601-3;View lateral;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left Lateral;XR Hand-L Lat;;ACTIVE;2.14;2.61 +36602-1;View lateral;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Lateral;XR Hip Lat;;ACTIVE;2.14;2.61 +36603-9;View lateral;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Lateral;XR Hip-L Lat;;ACTIVE;2.14;2.61 +36604-7;View lateral;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Lateral;XR Knee Lat;;ACTIVE;2.14;2.73 +36605-4;View lateral;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Lateral;XR Knee-Bl Lat;;ACTIVE;2.14;2.61 +36606-2;View lateral;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Lateral;XR Knee-L Lat;;ACTIVE;2.14;2.61 +36607-0;View oblique;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Oblique;XR Abd Obl;;ACTIVE;2.14;2.64 +3660-8;Furosemide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Furosemide [Presence] in Urine;Furosemide Ur Ql;;ACTIVE;1.0;2.73 +36608-8;Views oblique;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow Oblique Views;XR Elbow Views Obl;;ACTIVE;2.14;2.64 +36609-6;View oblique;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur Oblique;XR Femur Obl;;ACTIVE;2.14;2.64 +36610-4;View oblique;Find;Pt;Upper extremity>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth Oblique;XR Finger.5th Obl;;ACTIVE;2.14;2.64 +36611-2;View oblique;Find;Pt;Upper extremity>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth Oblique;XR Finger.4th Obl;;ACTIVE;2.14;2.64 +36612-0;View oblique;Find;Pt;Upper extremity>Finger.second;Doc;XR;RAD;2;XR Finger second Oblique;XR Finger.2nd Obl;;ACTIVE;2.14;2.64 +36613-8;View oblique;Find;Pt;Upper extremity>Finger.third;Doc;XR;RAD;2;XR Finger third Oblique;XR Finger.3rd Obl;;ACTIVE;2.14;2.64 +36614-6;View oblique;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Oblique;XR Foot Obl;;ACTIVE;2.14;2.64 +36615-3;View oblique;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left Oblique;XR Foot-L Obl;;ACTIVE;2.14;2.64 +3661-6;Furosemide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Furosemide [Mass/volume] in Urine;Furosemide Ur-mCnc;;ACTIVE;1.0;2.73 +36616-1;View oblique;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand Oblique;XR Hand Obl;;ACTIVE;2.14;2.64 +36617-9;View oblique;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Oblique;XR Hip Obl;;ACTIVE;2.14;2.64 +36618-7;View oblique;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Oblique;XR Hip-Bl Obl;;ACTIVE;2.14;2.64 +36619-5;Views oblique;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Oblique Views;XR Knee Views Obl;;ACTIVE;2.14;2.64 +36620-3;View L-anterior oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Left anterior oblique;XR Chest L-ant obl;;ACTIVE;2.14;2.61 +36621-1;View PA;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand PA;XR Hand PA;;ACTIVE;2.14;2.61 +36622-9;View PA;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral PA;XR Hand-Bl PA;;ACTIVE;2.14;2.61 +36623-7;View PA;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left PA;XR Hand-L PA;;ACTIVE;2.14;2.73 +3662-4;Furosemide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Furosemide [Mass/time] in 24 hour Urine;Furosemide 24h Ur-mRate;;ACTIVE;1.0;2.42 +36624-5;View PA;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral PA;XR Wrist-Bl PA;;ACTIVE;2.14;2.61 +36625-2;Views;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Views;MG Brst Views;;ACTIVE;2.14;2.73 +36626-0;Views;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Views;MG Brst-Bl Views;;ACTIVE;2.14;2.73 +36627-8;Views;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Views;MG Brst-L Views;;ACTIVE;2.14;2.64 +36628-6;Views;Find;Pt;Head>Internal auditory canal;Doc;XR;RAD;2;XR Internal auditory canal Views;XR IAC Views;;ACTIVE;2.14;2.64 +36629-4;Views;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral Views;XR Hand-Bl Views;;ACTIVE;2.14;2.64 +36630-2;Views;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left Views;XR Hand-L Views;;ACTIVE;2.14;2.64 +36631-0;Views;Find;Pt;Pelvis & Lower extremity.left>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - left Views;XR Pelvis and Hip-L Views;;ACTIVE;2.14;2.64 +3663-2;Gentamicin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma --peak;Gentamicin Peak SerPl-mCnc;;ACTIVE;1.0;2.73 +36632-8;Views;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left Views;XR Humerus-L Views;;ACTIVE;2.14;2.73 +36633-6;Views;Find;Pt;Pelvis>Sacroiliac joint.bilateral;Doc;XR;RAD;2;XR Sacroiliac joint - bilateral Views;XR SIJ-Bl Views;;ACTIVE;2.14;2.64 +36634-4;Views;Find;Pt;Pelvis>Sacroiliac joint.left;Doc;XR;RAD;2;XR Sacroiliac joint - left Views;XR SIJ-L Views;;ACTIVE;2.14;2.64 +36635-1;Views;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Views;XR Knee-Bl Views;;ACTIVE;2.14;2.64 +36636-9;Views;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Views;XR Knee-L Views;;ACTIVE;2.14;2.64 +36637-7;Views;Find;Pt;Head>Maxilla;Doc;XR;RAD;2;XR Maxilla Views;XR Maxilla Views;;ACTIVE;2.14;2.64 +36638-5;Views;Find;Pt;Lower extremity.bilateral>Patella;Doc;XR;RAD;2;XR Patella - bilateral Views;XR Patella-Bl Views;;ACTIVE;2.14;2.64 +36639-3;Views;Find;Pt;Lower extremity.left>Patella;Doc;XR;RAD;2;XR Patella - left Views;XR Patella-L Views;;ACTIVE;2.14;2.64 +3664-0;Gentamicin^random;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma --random;Gentamicin Rand SerPl-mCnc;;DISCOURAGED;1.0;2.73 +36640-1;Views;Find;Pt;Neck>Spine.cervical;Doc;RF;RAD;2;RF Cervical spine Views;RF C-spine Views;;ACTIVE;2.14;2.64 +36641-9;Views 2;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen 2 Views;XR Abd 2V;;ACTIVE;2.14;2.61 +36642-7;Views 2;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left 2 Views;MG Brst-L 2V;;ACTIVE;2.14;2.61 +36643-5;Views 2;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest 2 Views;XR Chest 2V;;ACTIVE;2.14;2.61 +36644-3;Views 2 && Views;Find;Pt;Chest;Doc;XR && RF;RAD;2;XR and RF Chest 2 Views and Views;XR and Flr Chest 2V + Views;;ACTIVE;2.14;2.61 +36645-0;Views 2;Find;Pt;Chest>Clavicle;Doc;XR;RAD;2;XR Clavicle 2 Views;XR Clavicle 2V;;ACTIVE;2.14;2.61 +36646-8;Views 2;Find;Pt;Chest>Clavicle.left;Doc;XR;RAD;2;XR Clavicle - left 2 Views;XR Clavicle-L 2V;;ACTIVE;2.14;2.61 +36647-6;Views 2;Find;Pt;Pelvis>Coccyx;Doc;XR;RAD;2;XR Coccyx 2 Views;XR Coccyx 2V;;ACTIVE;2.14;2.61 +36648-4;Views 2;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow 2 Views;XR Elbow 2V;;ACTIVE;2.14;2.61 +36649-2;Views 2;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral 2 Views;XR Elbow-Bl 2V;;ACTIVE;2.14;2.61 +366-5;Norfloxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Norfloxacin [Susceptibility] by Minimum lethal concentration (MLC);Norfloxacin Islt MLC;;ACTIVE;1.0;2.73 +36650-0;Views 2;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left 2 Views;XR Elbow-L 2V;;ACTIVE;2.14;2.61 +36651-8;Views 2;Find;Pt;Lower extremity;Doc;XR;RAD;2;XR Lower extremity 2 Views;XR LE 2V;;ACTIVE;2.14;2.61 +36652-6;Views 2;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur 2 Views;XR Femur 2V;;ACTIVE;2.14;2.61 +36653-4;Views 2;Find;Pt;Lower extremity.bilateral>Femur;Doc;XR;RAD;2;XR Femur - bilateral 2 Views;XR Femur-Bl 2V;;ACTIVE;2.14;2.61 +36654-2;Views 2;Find;Pt;Lower extremity.left>Femur;Doc;XR;RAD;2;XR Femur - left 2 Views;XR Femur-L 2V;;ACTIVE;2.14;2.61 +36655-9;Views 2;Find;Pt;Upper extremity>Finger;Doc;XR;RAD;2;XR Finger 2 Views;XR Finger 2V;;ACTIVE;2.14;2.61 +36656-7;Views 2;Find;Pt;Upper extremity.left>Finger;Doc;XR;RAD;2;XR Finger - left 2 Views;XR Finger-L 2V;;ACTIVE;2.14;2.61 +3665-7;Gentamicin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma --trough;Gentamicin Trough SerPl-mCnc;;ACTIVE;1.0;2.73 +36657-5;Views 2;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral 2 Views;XR Foot-Bl 2V;;ACTIVE;2.14;2.61 +36658-3;Views 2;Find;Pt;Upper extremity>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna 2 Views;XR Radius+Ulna 2V;;ACTIVE;2.14;2.61 +36659-1;Views 2;Find;Pt;Upper extremity.bilateral>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - bilateral 2 Views;XR Radius+Ulna-Bl 2V;;ACTIVE;2.14;2.61 +36660-9;Views 2;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left 2 Views;XR Radius+Ulna-L 2V;;ACTIVE;2.14;2.61 +36661-7;Views 2;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus 2 Views;XR Heel 2V;;ACTIVE;2.14;2.61 +36662-5;Views 2;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left 2 Views;XR Heel-L 2V;;ACTIVE;2.14;2.61 +36663-3;Views 2;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip 2 Views;XR Hip 2V;;ACTIVE;2.14;2.61 +36664-1;Views 2;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left 2 Views;XR Hip-L 2V;;ACTIVE;2.14;2.73 +3666-5;Glutethimide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Glutethimide [Mass/volume] in Serum or Plasma;Glutethimide SerPl-mCnc;;ACTIVE;1.0;2.73 +36665-8;Views 2;Find;Pt;Upper extremity.left>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - left 2 Views;XR AC joint-L 2V;;ACTIVE;2.14;2.61 +36666-6;Views 2;Find;Pt;Chest>Scapula.left;Doc;XR;RAD;2;XR Scapula - left 2 Views;XR Scapula-L 2V;;ACTIVE;2.14;2.61 +36667-4;Views 2;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral 2 Views;XR Shoulder-Bl 2V;;ACTIVE;2.14;2.61 +36668-2;Views 2;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 2 Views;XR Should-L 2V;;ACTIVE;2.14;2.73 +36669-0;Views 2;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 2 Views;XR C-spine 2V;;ACTIVE;2.14;2.61 +36670-8;Views 2;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 2 Views;XR L-spine 2V;;ACTIVE;2.14;2.61 +36671-6;Views 2;Find;Pt;Lower extremity.bilateral>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - bilateral 2 Views;XR Tib+Fib-Bl 2V;;ACTIVE;2.14;2.64 +36672-4;Views 2;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left 2 Views;XR Tib+Fib-L 2V;;ACTIVE;2.14;2.64 +3667-3;Glutethimide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Glutethimide [Presence] in Urine;Glutethimide Ur Ql;;ACTIVE;1.0;2.73 +36673-2;Views 2;Find;Pt;Lower extremity.left>Toes;Doc;XR;RAD;2;XR Toes - left 2 Views;XR Toes-L 2V;;ACTIVE;2.14;2.61 +36674-0;Views 2;Find;Pt;Abdomen>Spine.lumbar;Doc;XR.portable;RAD;2;Portable XR Lumbar spine 2 Views;XR port L-spine 2V;;ACTIVE;2.14;2.61 +36675-7;Views 5;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones 5 Views;XR Face 5V;;ACTIVE;2.14;2.61 +36676-5;Views 5;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 5 Views;XR Knee-L 5V;;ACTIVE;2.14;2.61 +36677-3;Views 5;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 5 Views;XR Should-L 5V;;ACTIVE;2.14;2.61 +36678-1;Views 6;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 6 Views;XR Knee-Bl 6V;;ACTIVE;2.14;2.61 +36679-9;Views 6;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 6 Views;XR Should-L 6V;;ACTIVE;2.14;2.61 +36680-7;Views 7;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 7 Views;XR C-spine 7V;;ACTIVE;2.14;2.61 +3668-1;Glutethimide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Glutethimide [Mass/volume] in Urine;Glutethimide Ur-mCnc;;ACTIVE;1.0;2.42 +36681-5;Views 7;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 7 Views;XR L-spine 7V;;ACTIVE;2.14;2.61 +36682-3;Views 8;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 8 Views;XR Knee-Bl 8V;;ACTIVE;2.14;2.61 +36683-1;Views 8;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 8 Views;XR Wrist-L 8V;;ACTIVE;2.14;2.61 +36684-9;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral AP and Lateral;XR Ankle-Bl AP+Lat;;ACTIVE;2.14;2.61 +36685-6;Views AP + lateral;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left AP and Lateral;XR Ankle-L AP+Lat;;ACTIVE;2.14;2.61 +36686-4;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral AP and Lateral;XR Heel-Bl AP+Lat;;ACTIVE;2.14;2.61 +36687-2;Views AP + lateral;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP and Lateral;XR Chest AP+Lat;;ACTIVE;2.14;2.61 +36688-0;Views AP + lateral;Find;Pt;Pelvis>Coccyx;Doc;XR;RAD;2;XR Coccyx AP and Lateral;XR Coccyx AP+Lat;;ACTIVE;2.14;2.61 +36689-8;Views AP + lateral;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow AP and Lateral;XR Elbow AP+Lat;;ACTIVE;2.14;2.61 +36690-6;Views AP + lateral;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral AP and Lateral;XR Elbow-Bl AP+Lat;;ACTIVE;2.14;2.61 +36691-4;Views AP + lateral;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left AP and Lateral;XR Elbow-L AP+Lat;;ACTIVE;2.14;2.73 +36692-2;Views AP + lateral;Find;Pt;Lower extremity;Doc;XR;RAD;2;XR Lower extremity AP and Lateral;XR LE AP+Lat;;ACTIVE;2.14;2.61 +36693-0;Views AP + lateral;Find;Pt;Lower extremity>Femur;Doc;XR;RAD;2;XR Femur AP and Lateral;XR Femur AP+Lat;;ACTIVE;2.14;2.61 +36694-8;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Femur;Doc;XR;RAD;2;XR Femur - bilateral AP and Lateral;XR Femur-Bl AP+Lat;;ACTIVE;2.14;2.61 +36695-5;Views AP + lateral;Find;Pt;Lower extremity.left>Femur;Doc;XR;RAD;2;XR Femur - left AP and Lateral;XR Femur-L AP+Lat;;ACTIVE;2.14;2.61 +36696-3;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral AP and Lateral;XR Foot-Bl AP+Lat;;ACTIVE;2.14;2.61 +36697-1;Views AP + lateral;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left AP and Lateral;XR Foot-L AP+Lat;;ACTIVE;2.14;2.61 +36698-9;Views AP + lateral;Find;Pt;Upper extremity>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna AP and Lateral;XR Radius+Ulna AP+Lat;;ACTIVE;2.14;2.61 +3669-9;Haloperidol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Haloperidol [Mass/volume] in Serum or Plasma;Haloperidol SerPl-mCnc;;ACTIVE;1.0;2.73 +36699-7;Views AP + lateral;Find;Pt;Upper extremity.bilateral>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - bilateral AP and Lateral;XR Radius+Ulna-Bl AP+Lat;;ACTIVE;2.14;2.61 +36700-3;Views AP + lateral;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left AP and Lateral;XR Radius+Ulna-L AP+Lat;;ACTIVE;2.14;2.61 +36701-1;Views AP + lateral;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left AP and Lateral;XR Heel-L AP+Lat;;ACTIVE;2.14;2.61 +36702-9;Views AP + lateral;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip AP and Lateral;XR Hip AP+Lat;;ACTIVE;2.14;2.61 +36703-7;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral AP and Lateral;XR Hip-Bl AP+Lat;;ACTIVE;2.14;2.61 +36704-5;Views AP + lateral;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left AP and Lateral;XR Hip-L AP+Lat;;ACTIVE;2.14;2.61 +36705-2;Views AP + lateral;Find;Pt;Pelvis & Lower extremity>Hip;Doc;XR;RAD;2;XR Pelvis and Hip AP and Lateral;XR Pelvis and Hip AP+Lat;;ACTIVE;2.14;2.61 +36706-0;Views AP + lateral;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus AP and Lateral;XR Humerus AP+Lat;;ACTIVE;2.14;2.61 +3670-7;Haloperidol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Haloperidol [Presence] in Urine;Haloperidol Ur Ql;;ACTIVE;1.0;2.73 +36707-8;Views AP + lateral;Find;Pt;Upper extremity.bilateral>Humerus;Doc;XR;RAD;2;XR Humerus - bilateral AP and Lateral;XR Humerus-Bl AP+Lat;;ACTIVE;2.14;2.61 +36708-6;Views AP + lateral;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left AP and Lateral;XR Humerus-L AP+Lat;;ACTIVE;2.14;2.61 +36709-4;Views AP + lateral;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral;XR Knee AP+Lat;;ACTIVE;2.14;2.61 +36710-2;Views AP + lateral;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral;XR Knee-L AP+Lat;;ACTIVE;2.14;2.61 +36711-0;Views AP + lateral;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible AP and Lateral;XR Mandible AP+Lat;;ACTIVE;2.14;2.61 +36712-8;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Patella;Doc;XR;RAD;2;XR Patella - bilateral AP and Lateral;XR Patella-Bl AP+Lat;;ACTIVE;2.14;2.61 +36713-6;Views AP + lateral;Find;Pt;Lower extremity.left>Patella;Doc;XR;RAD;2;XR Patella - left AP and Lateral;XR Patella-L AP+Lat;;ACTIVE;2.14;2.61 +36714-4;Views AP + lateral;Find;Pt;Chest>Scapula.bilateral;Doc;XR;RAD;2;XR Scapula - bilateral AP and Lateral;XR Scapula-Bl AP+Lat;;ACTIVE;2.14;2.61 +3671-5;Haloperidol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Haloperidol [Mass/volume] in Urine;Haloperidol Ur-mCnc;;ACTIVE;1.0;2.42 +36715-1;Views AP + lateral;Find;Pt;Chest>Scapula.left;Doc;XR;RAD;2;XR Scapula - left AP and Lateral;XR Scapula-L AP+Lat;;ACTIVE;2.14;2.61 +36716-9;Views AP + lateral;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP and Lateral;XR Shoulder-Bl AP+Lat;;ACTIVE;2.14;2.61 +36717-7;Views AP + lateral;Find;Pt;Lower extremity.bilateral>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - bilateral AP and Lateral;XR Tib+Fib-Bl AP+Lat;;ACTIVE;2.14;2.64 +36718-5;Views AP + lateral;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left AP and Lateral;XR Tib+Fib-L AP+Lat;;ACTIVE;2.14;2.64 +36719-3;Views AP + lateral;Find;Pt;Lower extremity.left>Toes;Doc;XR;RAD;2;XR Toes - left AP and Lateral;XR Toes-L AP+Lat;;ACTIVE;2.14;2.61 +36720-1;Views AP + lateral + oblique;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral AP and Lateral and oblique;XR Ankle-Bl AP+Lat+Obl;;ACTIVE;2.14;2.61 +36721-9;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left AP and Lateral and oblique;XR Ankle-L AP+Lat+Obl;;ACTIVE;2.14;2.61 +36722-7;Views AP + lateral + oblique;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow AP and Lateral and oblique;XR Elbow AP+Lat+Obl;;ACTIVE;2.14;2.61 +3672-3;Heptaminol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Heptaminol [Presence] in Urine;Heptaminol Ur Ql;;ACTIVE;1.0;2.56 +36723-5;Views AP + lateral + oblique;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral AP and Lateral and oblique;XR Elbow-Bl AP+Lat+Obl;;ACTIVE;2.14;2.61 +36724-3;Views AP + lateral + oblique;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left AP and Lateral and oblique;XR Elbow-L AP+Lat+Obl;;ACTIVE;2.14;2.61 +36725-0;Views AP + lateral + oblique;Find;Pt;Upper extremity>Finger;Doc;XR;RAD;2;XR Finger AP and Lateral and oblique;XR Finger AP+Lat+Obl;;ACTIVE;2.14;2.61 +36726-8;Views AP + lateral + oblique;Find;Pt;Upper extremity.bilateral>Finger;Doc;XR;RAD;2;XR Finger - bilateral AP and Lateral and oblique;XR Finger-Bl AP+Lat+Obl;;ACTIVE;2.14;2.61 +36727-6;Views AP + lateral + oblique;Find;Pt;Upper extremity.left>Finger;Doc;XR;RAD;2;XR Finger - left AP and Lateral and oblique;XR Finger-L AP+Lat+Obl;;ACTIVE;2.14;2.61 +36728-4;Views AP + lateral + oblique;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot AP and Lateral and oblique;XR Foot AP+Lat+Obl;;ACTIVE;2.14;2.61 +36729-2;Views AP + lateral + oblique;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral AP and Lateral and oblique;XR Foot-Bl AP+Lat+Obl;;ACTIVE;2.14;2.61 +367-3;Norfloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Norfloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Norfloxacin Islt MIC;;ACTIVE;1.0;2.73 +36730-0;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left AP and Lateral and oblique;XR Foot-L AP+Lat+Obl;;ACTIVE;2.14;2.61 +3673-1;Heptaminol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Heptaminol [Mass/volume] in Urine;Heptaminol Ur-mCnc;;ACTIVE;1.0;2.42 +36731-8;Views AP + lateral + oblique;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus AP and Lateral and oblique;XR Heel AP+Lat+Obl;;ACTIVE;2.14;2.61 +36732-6;Views AP + lateral + oblique;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral and oblique;XR Knee-Bl AP+Lat+Obl;;ACTIVE;2.14;2.61 +36733-4;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral and oblique;XR Knee-L AP+Lat+Obl;;ACTIVE;2.14;2.61 +36734-2;Views AP + lateral + oblique;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Lateral and oblique;XR C-spine AP+Lat+Obl;;ACTIVE;2.14;2.61 +36735-9;Views AP + lateral + oblique;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP and Lateral and oblique;XR L-spine AP+Lat+Obl;;ACTIVE;2.14;2.61 +36736-7;Views AP + lateral + oblique;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left AP and Lateral and oblique;XR Thumb-L AP+Lat+Obl;;ACTIVE;2.14;2.61 +36737-5;Views limited;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones Limited Views;XR Face Views Ltd;;ACTIVE;2.14;2.64 +36738-3;Views limited;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible Limited Views;XR Mandible Views Ltd;;ACTIVE;2.14;2.64 +36739-1;Views limited;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Limited Views;XR Wrist-Bl Views Ltd;;ACTIVE;2.14;2.64 +36740-9;Views oblique;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral Oblique Views;XR Elbow-Bl Views Obl;;ACTIVE;2.14;2.64 +36741-7;Views oblique;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left Oblique Views;XR Elbow-L Views Obl;;ACTIVE;2.14;2.64 +36742-5;Views oblique;Find;Pt;Upper extremity.bilateral>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - bilateral Oblique Views;XR Radius+Ulna-Bl Views Obl;;ACTIVE;2.14;2.64 +36743-3;Views oblique;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left Oblique Views;XR Radius+Ulna-L Views Obl;;ACTIVE;2.14;2.64 +36744-1;Views oblique;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left Oblique Views;XR Humerus-L Views Obl;;ACTIVE;2.14;2.64 +36745-8;Views oblique;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Oblique Views;XR Knee-Bl Views Obl;;ACTIVE;2.14;2.64 +36746-6;Views oblique;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Oblique Views;XR Knee-L Views Obl;;ACTIVE;2.14;2.64 +36747-4;Views oblique;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible Oblique Views;XR Mandible Views Obl;;ACTIVE;2.14;2.64 +36748-2;Views oblique;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Oblique Views;XR C-spine Views Obl;;ACTIVE;2.14;2.64 +3674-9;Heptaminol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Heptaminol [Mass/time] in 24 hour Urine;Heptaminol 24h Ur-mRate;;ACTIVE;1.0;2.42 +36749-0;Views oblique;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left Oblique Views;XR Tib+Fib-L Views Obl;;ACTIVE;2.14;2.64 +36750-8;Views PA + AP lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and AP lateral-decubitus;XR Chest PA+AP Lat-Decub;;ACTIVE;2.14;2.61 +36751-6;Views PA + lateral && Views;Find;Pt;Chest;Doc;XR && RF;RAD;2;XR and RF Chest PA and Lateral and Views;XR and Flr Chest PA+Lat + Views;;ACTIVE;2.14;2.61 +36752-4;Views PA + lateral;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral PA and Lateral;XR Hand-Bl PA+Lat;;ACTIVE;2.14;2.61 +36753-2;Views PA + lateral;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left PA and Lateral;XR Hand-L PA+Lat;;ACTIVE;2.14;2.61 +36754-0;Views PA + lateral;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible PA and Lateral;XR Mandible PA+Lat;;ACTIVE;2.14;2.61 +36755-7;Views PA + lateral + oblique;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand PA and Lateral and Oblique;XR Hand PA+Lat+Obl;;ACTIVE;2.14;2.61 +3675-6;hydroCHLOROthiazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;hydroCHLOROthiazide [Mass/volume] in Serum or Plasma;HTCZ SerPl-mCnc;;ACTIVE;1.0;2.73 +36756-5;Views PA + lateral + oblique;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral PA and Lateral and Oblique;XR Hand-Bl PA+Lat+Obl;;ACTIVE;2.14;2.61 +36757-3;Views PA + lateral + oblique;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left PA and Lateral and Oblique;XR Hand-L PA+Lat+Obl;;ACTIVE;2.14;2.61 +36758-1;Views PA + lateral + oblique + apical lordotic;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and Oblique and Apical lordotic;XR Chest PA+Lat+Obl+Apical lordot;;ACTIVE;2.14;2.61 +36759-9;Views PA + apical lordotic;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Apical lordotic;XR Chest PA+Apical lord;;ACTIVE;2.14;2.61 +36760-7;Guidance for angioplasty^W contrast;Find;Pt;XXX>AV shunt;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of AV shunt-- W contrast;RFA Guided AV shunt Angio--W contr;;ACTIVE;2.14;2.64 +36761-5;Guidance for balloon dilatation^W contrast;Find;Pt;Abdomen>Biliary ducts;Doc;RF;RAD;2;RF Guidance for balloon dilatation of Biliary ducts-- W contrast;RF Guided BDs Balloon dilat--W contr;;ACTIVE;2.14;2.64 +36762-3;Guidance for angioplasty^W contrast;Find;Pt;Extremity>Extremity vessel;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Extremity vessel-- W contrast;RFA Guided Extremity ves Angio--W contr;;ACTIVE;2.14;2.64 +36763-1;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity>Femoral artery+Popliteal artery;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Femoral artery and Popliteal artery-- W contrast IA;RFA Guided Fem a+Pop a Angio--W contr IA;;ACTIVE;2.14;2.64 +3676-4;hydroCHLOROthiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;hydroCHLOROthiazide [Presence] in Urine;HTCZ Ur Ql;;ACTIVE;1.0;2.73 +36764-9;Guidance for atherectomy^W contrast;Find;Pt;Lower extremity>Femoral vessel+Popliteal artery;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Femoral vessel and Popliteal artery-- W contrast;RFA Guided Fem ves+Pop a Ather W contr;;ACTIVE;2.14;2.64 +36765-6;Guidance for atherectomy^W contrast;Find;Pt;XXX>Vessel;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Vessel-- W contrast;RFA Guided Ves Atherect--W contr;;ACTIVE;2.14;2.64 +36766-4;Guidance for atherectomy^W contrast IA;Find;Pt;Chest>Coronary arteries;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Coronary arteries-- W contrast IA;RFA Guided CA Atherect--W contr IA;;ACTIVE;2.14;2.64 +36767-2;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Adrenal gland;Doc;CT;RAD;2;CT Guidance for biopsy of Adrenal gland;CT Guided Adrenal Bx;;ACTIVE;2.14;2.64 +36768-0;Guidance for percutaneous biopsy;Find;Pt;XXX>Muscle;Doc;CT;RAD;2;CT Guidance for percutaneous biopsy of Muscle;CT Guided Muscle Bx;;ACTIVE;2.14;2.64 +36769-8;Guidance for exchange of nephrostomy tube;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for exchange of nephrostomy tube of Kidney;CT Guided Kidney NT exchange;;ACTIVE;2.14;2.64 +36770-6;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Biliary ducts and Gallbladder;CT Guided BDs+GB Drain+cath place;;ACTIVE;2.14;2.66 +36771-4;Guidance for injection;Find;Pt;XXX>Joint;Doc;RF;RAD;2;RF Guidance for injection of Joint;RF Guided Joint Inj;;ACTIVE;2.14;2.64 +3677-2;hydroCHLOROthiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;hydroCHLOROthiazide [Mass/volume] in Urine;HTCZ Ur-mCnc;;ACTIVE;1.0;2.73 +36772-2;Guidance for placement of nephrostomy tube;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for placement of nephrostomy tube in Kidney;CT Guided Kidney NT place;;ACTIVE;2.14;2.64 +36773-0;Multisection;Find;Pt;Head>Temporal bone;Doc;CT;RAD;2;CT Temporal bone;CT Temporal bone;;ACTIVE;2.14;2.73 +36774-8;Multisection;Find;Pt;Upper extremity.left>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - left;MR UE joint-L;;ACTIVE;2.14;2.61 +36775-5;Multisection;Find;Pt;Upper extremity.right>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - right;MR UE joint-R;;ACTIVE;2.14;2.61 +36776-3;Multisection;Find;Pt;Head>Mastoid;Doc;XR.tomography;RAD;2;XR tomography Mastoid;XR tomo Mastoid;;ACTIVE;2.14;2.61 +36777-1;Multisection;Find;Pt;Head>Orbit;Doc;MR;RAD;2;MR Orbit;MR Orbit;;ACTIVE;2.14;2.61 +36778-9;Multisection;Find;Pt;Head>Orbit.right;Doc;MR;RAD;2;MR Orbit - right;MR Orbit-R;;ACTIVE;2.14;2.61 +36779-7;Multisection;Find;Pt;Pelvis>Ovary;Doc;MR;RAD;2;MR Ovary;MR Ovary;;ACTIVE;2.14;2.61 +3678-0;hydroCHLOROthiazide;MRat;24H;Urine;Qn;;DRUG/TOX;1;hydroCHLOROthiazide [Mass/time] in 24 hour Urine;HTCZ 24h Ur-mRate;;ACTIVE;1.0;2.44 +36780-5;Multisection;Find;Pt;Lower extremity>Toe;Doc;MR;RAD;2;MR Toe;MR Toe;;ACTIVE;2.14;2.61 +36781-3;Multisection;Find;Pt;Abdomen>Abdominal veins;Doc;MR.angio;RAD;2;MRA Abdominal veins;MRA Abd vv;;ACTIVE;2.14;2.61 +36782-1;Multisection;Find;Pt;Chest>Subclavian artery;Doc;MR.angio;RAD;2;MRA Subclavian artery;MRA Subclavian a;;ACTIVE;2.14;2.61 +36783-9;Multisection;Find;Pt;XXX>Veins;Doc;MR.angio;RAD;2;MRA Veins;MRA Veins;;ACTIVE;2.14;2.61 +36784-7;Multisection;Find;Pt;Lower extremity.left>Lower extremity veins;Doc;MR.angio;RAD;2;MRA Lower extremity veins - left;MRA LE vv-L;;ACTIVE;2.14;2.61 +36785-4;Multisection;Find;Pt;Lower extremity.right>Lower extremity veins;Doc;MR.angio;RAD;2;MRA Lower extremity veins - right;MRA LE vv-R;;ACTIVE;2.14;2.61 +36786-2;Multisection;Find;Pt;Upper extremity.left>Upper extremity veins;Doc;MR.angio;RAD;2;MRA Upper extremity veins - left;MRA UE vv-L;;ACTIVE;2.14;2.61 +36787-0;Multisection;Find;Pt;Upper extremity.right>Upper extremity veins;Doc;MR.angio;RAD;2;MRA Upper extremity veins - right;MRA UE vv-R;;ACTIVE;2.14;2.61 +36788-8;Multisection;Find;Pt;Neck>Neck veins;Doc;MR.angio;RAD;2;MRA Neck veins;MRA Neck vv;;ACTIVE;2.14;2.61 +36789-6;Multisection;Find;Pt;Pelvis>Pelvis veins;Doc;MR.angio;RAD;2;MRA Pelvis veins;MRA Pelvis vv;;ACTIVE;2.14;2.61 +36790-4;Multisection;Find;Pt;Abdomen>Vena cava.inferior & Pelvis+Lower extremity.bilateral>Tributaries;Doc;MR.angio;RAD;2;MRA Inferior vena cava + tributaries;MRA IVC+tributaries;;ACTIVE;2.14;2.61 +36791-2;Multisection;Find;Pt;Abdomen>Abdominal vessels;Doc;MR.angio;RAD;2;MRA Abdominal vessels;MRA Abd ves;;ACTIVE;2.14;2.61 +36792-0;Multisection;Find;Pt;Abdomen>Adrenal vessels;Doc;MR.angio;RAD;2;MRA Adrenal vessels;MRA Adrenal ves;;ACTIVE;2.14;2.61 +36793-8;Multisection;Find;Pt;Carotid vessel;Doc;MR.angio;RAD;2;Deprecated Carotid vessel MR angiogram;Deprecated Carot ves MR.angio;;DEPRECATED;2.14;2.58 +36794-6;Multisection;Find;Pt;Extremity>Extremity vessels;Doc;MR.angio;RAD;2;MRA Extremity vessels;MRA Extremity ves;;ACTIVE;2.14;2.61 +36795-3;Multisection;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - left;MRA LE ves-L;;ACTIVE;2.14;2.61 +36796-1;Multisection;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - right;MRA LE ves-R;;ACTIVE;2.14;2.61 +36797-9;Multisection;Find;Pt;Upper extremity.left>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels - left;MRA UE ves-L;;ACTIVE;2.14;2.61 +3679-8;HYDROcodone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;HYDROcodone [Presence] in Serum or Plasma;HYDROcodone SerPl Ql;;ACTIVE;1.0;2.73 +36798-7;Multisection;Find;Pt;Upper extremity.right>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels - right;MRA UE ves-R;;ACTIVE;2.14;2.61 +36799-5;Multisection;Find;Pt;Lower extremity>Knee vessels;Doc;MR.angio;RAD;2;MRA Knee vessels;MRA Knee ves;;ACTIVE;2.14;2.61 +36800-1;Multisection;Find;Pt;Lower extremity.left>Knee vessels;Doc;MR.angio;RAD;2;MRA Knee vessels - left;MRA Knee ves-L;;ACTIVE;2.14;2.61 +36801-9;Multisection;Find;Pt;Lower extremity.right>Knee vessels;Doc;MR.angio;RAD;2;MRA Knee vessels - right;MRA Knee ves-R;;ACTIVE;2.14;2.61 +36802-7;Multisection;Find;Pt;Head>Orbit vessels;Doc;MR.angio;RAD;2;MRA Orbit vessels;MRA Orbit ves;;ACTIVE;2.14;2.61 +36803-5;Multisection;Find;Pt;Chest>Pulmonary vessels;Doc;MR.angio;RAD;2;MRA Pulmonary vessels;MRA Pulmonary ves;;ACTIVE;2.14;2.61 +36804-3;Multisection;Find;Pt;Abdomen>Renal vessels.bilateral;Doc;MR.angio;RAD;2;MRA Renal vessels - bilateral;MRA Renal ves-Bl;;ACTIVE;2.14;2.61 +36805-0;Multisection;Find;Pt;Upper extremity>Shoulder vessels;Doc;MR.angio;RAD;2;MRA Shoulder vessels;MRA Should ves;;ACTIVE;2.14;2.61 +3680-6;HYDROcodone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;HYDROcodone [Mass/volume] in Serum or Plasma;HYDROcodone SerPl-mCnc;;ACTIVE;1.0;2.73 +36806-8;Multisection;Find;Pt;Upper extremity.left>Shoulder vessels;Doc;MR.angio;RAD;2;MRA Shoulder vessels - left;MRA Should ves-L;;ACTIVE;2.14;2.61 +36807-6;Multisection;Find;Pt;Upper extremity.right>Shoulder vessels;Doc;MR.angio;RAD;2;MRA Shoulder vessels - right;MRA Should ves-R;;ACTIVE;2.14;2.61 +36808-4;Multisection limited;Find;Pt;Head>Head vessels;Doc;MR.angio;RAD;2;MRA Head vessels limited;MRA Head ves Ltd;;ACTIVE;2.14;2.61 +36809-2;Multisection^W contrast IA;Find;Pt;Abdomen>Hepatic artery;Doc;CT.angio;RAD;2;CTA Hepatic artery W contrast IA;CTA Hep a W contr IA;;ACTIVE;2.14;2.61 +368-1;Norfloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Norfloxacin [Susceptibility] by Disk diffusion (KB);Norfloxacin Islt KB;;ACTIVE;1.0;2.73 +36810-0;Multisection^W contrast IS;Find;Pt;Upper joint;Doc;CT;RAD;2;Deprecated Upper Joint CT W contrast IS;Deprecated Upper joint CT W contr IS;;DEPRECATED;2.14;2.58 +36811-8;Multisection^W contrast IS;Find;Pt;XXX>Joint;Doc;CT;RAD;2;CT Joint Arthrogram;CT Joint W contr IS;;ACTIVE;2.14;2.61 +36812-6;Multisection^W contrast IS;Find;Pt;XXX>Joint;Doc;MR;RAD;2;MR Joint Arthrogram;MR Joint W contr IS;;ACTIVE;2.14;2.61 +36813-4;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen and Pelvis W contrast IV;CT Abd+Pelvis W contr IV;;ACTIVE;2.14;2.73 +3681-4;HYDROcodone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;HYDROcodone [Mass/volume] in Urine;HYDROcodone Ur-mCnc;;ACTIVE;1.0;2.73 +36814-2;Multisection^W contrast IV;Find;Pt;Head>Head arteries;Doc;CT.angio;RAD;2;CTA Head Arteries W contrast IV;CTA Head Arteries W contr IV;;ACTIVE;2.14;2.61 +36815-9;Multisection^W contrast IV;Find;Pt;Head>Temporal bone;Doc;CT;RAD;2;CT Temporal bone W contrast IV;CT Temporal bone W contr IV;;ACTIVE;2.14;2.61 +36816-7;Multisection^W contrast IV;Find;Pt;Head>Temporal bone.right;Doc;CT;RAD;2;CT Temporal bone - right W contrast IV;CT Temporal bone-R W contr IV;;ACTIVE;2.14;2.61 +36817-5;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - bilateral W contrast IV;MR UE joint-Bl W contr IV;;ACTIVE;2.14;2.61 +36818-3;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - left W contrast IV;MR UE joint-L W contr IV;;ACTIVE;2.14;2.61 +36819-1;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - right W contrast IV;MR UE joint-R W contr IV;;ACTIVE;2.14;2.61 +36820-9;Multisection^W contrast IV;Find;Pt;Head>Orbit;Doc;MR;RAD;2;MR Orbit W contrast IV;MR Orbit W contr IV;;ACTIVE;2.14;2.61 +36821-7;Multisection^W contrast IV;Find;Pt;Head>Orbit.left;Doc;MR;RAD;2;MR Orbit - left W contrast IV;MR Orbit-L W contr IV;;ACTIVE;2.14;2.61 +3682-2;HYDROmorphone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;HYDROmorphone [Presence] in Serum or Plasma;HYDROmorphone SerPl Ql;;ACTIVE;1.0;2.73 +36822-5;Multisection^W contrast IV;Find;Pt;Head>Orbit.right;Doc;MR;RAD;2;MR Orbit - right W contrast IV;MR Orbit-R W contr IV;;ACTIVE;2.14;2.61 +36823-3;Multisection^W contrast IV;Find;Pt;Pelvis>Ovary;Doc;MR;RAD;2;MR Ovary W contrast IV;MR Ovary W contr IV;;ACTIVE;2.14;2.61 +36824-1;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Lower extremity veins - left W contrast IV;CTA LE vv-L W contr IV;;ACTIVE;2.14;2.63 +36825-8;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Lower extremity veins - right W contrast IV;CTA LE vv-R W contr IV;;ACTIVE;2.14;2.63 +36826-6;Multisection^W contrast IV;Find;Pt;Head>Head veins;Doc;MR.angio;RAD;2;MRA Head veins W contrast IV;MRA Head vv W contr IV;;ACTIVE;2.14;2.61 +36827-4;Multisection^W contrast IV;Find;Pt;Neck>Neck veins;Doc;MR.angio;RAD;2;MRA Neck veins W contrast IV;MRA Neck vv W contr IV;;ACTIVE;2.14;2.61 +36828-2;Multisection^W contrast IV;Find;Pt;Abdomen>Abdominal vessels;Doc;CT.angio;RAD;2;CTA Abdominal vessels W contrast IV;CTA Abd ves W contr IV;;ACTIVE;2.14;2.61 +36829-0;Multisection^W contrast IV;Find;Pt;Carotid vessel;Doc;MR.angio;RAD;2;Deprecated Carotid vessel MR angiogram W contrast IV;Deprecated Carot ves MR.angio W contr IV;;DEPRECATED;2.14;2.58 +3683-0;HYDROmorphone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;HYDROmorphone [Mass/volume] in Serum or Plasma;HYDROmorphone SerPl-mCnc;;ACTIVE;1.0;2.73 +36830-8;Multisection^W contrast IV;Find;Pt;Head>Head vessels;Doc;CT.angio;RAD;2;CTA Head vessels W contrast IV;CTA Head ves W contr IV;;ACTIVE;2.14;2.61 +36831-6;Multisection^W contrast IV;Find;Pt;Lower extremity>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels W contrast IV;CTA LE ves W contr IV;;ACTIVE;2.14;2.61 +36832-4;Multisection^W contrast IV;Find;Pt;Head>Orbit vessels;Doc;MR.angio;RAD;2;MRA Orbit vessels W contrast IV;MRA Orbit ves W contr IV;;ACTIVE;2.14;2.61 +36833-2;Multisection^W contrast IV;Find;Pt;Abdomen>Renal vessels;Doc;CT.angio;RAD;2;CTA Renal vessels W contrast IV;CTA Renal ves W contr IV;;ACTIVE;2.14;2.61 +36834-0;Multisection^W contrast IV;Find;Pt;XXX>Vessel;Doc;CT.angio;RAD;2;CTA Vessel W contrast IV;CTA Ves W contr IV;;ACTIVE;2.14;2.61 +36835-7;Multisection^WO & W contrast IV;Find;Pt;Head>Petrous part of temporal bone;Doc;CT;RAD;2;CT Petrous part of temporal bone WO and W contrast IV;CT Petr part temp bone WO+W contr IV;;ACTIVE;2.14;2.61 +36836-5;Multisection^W & WO contrast IV;Find;Pt;Temporal bone;Nar;MRI;RAD;2;Deprecated Temporal bones MRI W & WO contrast IV;Deprecated Temporal bones MRI W+WO contr;;DEPRECATED;2.14;2.38 +36837-3;Multisection^WO & W contrast IV;Find;Pt;Head>Temporal bone;Doc;CT;RAD;2;CT Temporal bone WO and W contrast IV;CT Temporal bone WO+W contr IV;;ACTIVE;2.14;2.61 +36838-1;Views 3;Find;Pt;Head>Mastoid;Doc;XR;RAD;2;XR Mastoid 3 Views;XR Mastoid 3V;;ACTIVE;2.14;2.61 +36839-9;Views 4;Find;Pt;Head>Mastoid;Doc;XR;RAD;2;XR Mastoid 4 Views;XR Mastoid 4V;;ACTIVE;2.14;2.61 +36840-7;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - left WO and W contrast IV;MR UE joint-L WO+W contr IV;;ACTIVE;2.14;2.61 +36841-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - right WO and W contrast IV;MR UE joint-R WO+W contr IV;;ACTIVE;2.14;2.61 +36842-3;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit;Doc;MR;RAD;2;MR Orbit WO and W contrast IV;MR Orbit WO+W contr IV;;ACTIVE;2.14;2.61 +36843-1;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit.left;Doc;MR;RAD;2;MR Orbit - left WO and W contrast IV;MR Orbit-L WO+W contr IV;;ACTIVE;2.14;2.61 +36844-9;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit.right;Doc;MR;RAD;2;MR Orbit - right WO and W contrast IV;MR Orbit-R WO+W contr IV;;ACTIVE;2.14;2.61 +36845-6;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Ovary;Doc;MR;RAD;2;MR Ovary WO and W contrast IV;MR Ovary WO+W contr IV;;ACTIVE;2.14;2.61 +36846-4;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Abdominal veins;Doc;MR.angio;RAD;2;MRA Abdominal veins WO and W contrast IV;MRA Abd vv WO+W contr IV;;ACTIVE;2.14;2.61 +36847-2;Multisection^WO & W contrast IV;Find;Pt;Head>Head veins;Doc;MR.angio;RAD;2;MRA Head veins WO and W contrast IV;MRA Head vv WO+W contr IV;;ACTIVE;2.14;2.61 +3684-8;Hydroxychloroquine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxychloroquine [Mass/volume] in Serum or Plasma;OH-Chloroquine SerPl-mCnc;;ACTIVE;1.0;2.73 +36848-0;Multisection^WO & W contrast IV;Find;Pt;Chest>Chest veins;Doc;MR.angio;RAD;2;MRA Chest veins WO and W contrast IV;MRA Chest vv WO+W contr IV;;ACTIVE;2.14;2.61 +36849-8;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Lower extremity veins;Doc;MR.angio;RAD;2;MRA Lower extremity veins - left WO and W contrast IV;MRA LE vv-L WO+W contr IV;;ACTIVE;2.14;2.61 +36850-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Lower extremity veins;Doc;MR.angio;RAD;2;MRA Lower extremity veins - right WO and W contrast IV;MRA LE vv-R WO+W contr IV;;ACTIVE;2.14;2.61 +36851-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Upper extremity veins;Doc;MR.angio;RAD;2;MRA Upper extremity veins - left WO and W contrast IV;MRA UE vv-L WO+W contr IV;;ACTIVE;2.14;2.61 +36852-2;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Upper extremity veins;Doc;MR.angio;RAD;2;MRA Upper extremity veins - right WO and W contrast IV;MRA UE vv-R WO+W contr IV;;ACTIVE;2.14;2.61 +36853-0;Multisection^WO & W contrast IV;Find;Pt;Neck>Neck veins;Doc;MR.angio;RAD;2;MRA Neck veins WO and W contrast IV;MRA Neck vv WO+W contr IV;;ACTIVE;2.14;2.61 +36854-8;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Pelvis veins;Doc;MR.angio;RAD;2;MRA Pelvis veins WO and W contrast IV;MRA Pelvis vv WO+W contr IV;;ACTIVE;2.14;2.61 +3685-5;Hydroxymethoxyphenamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hydroxymethoxyphenamine [Mass/volume] in Urine;OH-Methoxyphenamine Ur-mCnc;;ACTIVE;1.0;2.34 +36855-5;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Abdominal vessels;Doc;MR.angio;RAD;2;MRA Abdominal vessels WO and W contrast IV;MRA Abd ves WO+W contr IV;;ACTIVE;2.14;2.61 +36856-3;Multisection^WO & W contrast IV;Find;Pt;Carotid vessel;Doc;MR.angio;RAD;2;Deprecated Carotid vessel MR angiogram WO and W contrast IV;Deprecated Carot ves MR.angio WO+W contr;;DEPRECATED;2.14;2.58 +36857-1;Multisection^WO & W contrast IV;Find;Pt;Head>Head vessels;Doc;MR.angio;RAD;2;MRA Head vessels WO and W contrast IV;MRA Head ves WO+W contr IV;;ACTIVE;2.14;2.61 +36858-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - left WO and W contrast IV;MRA LE ves-L WO+W contr IV;;ACTIVE;2.14;2.61 +36859-7;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - right WO and W contrast IV;MRA LE ves-R WO+W contr IV;;ACTIVE;2.14;2.61 +36860-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels - left WO and W contrast IV;MRA UE ves-L WO+W contr IV;;ACTIVE;2.14;2.61 +36861-3;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Upper extremity vessels;Doc;MR.angio;RAD;2;MRA Upper extremity vessels - right WO and W contrast IV;MRA UE ves-R WO+W contr IV;;ACTIVE;2.14;2.61 +36862-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Knee vessels;Doc;MR.angio;RAD;2;MRA Knee vessels - right WO and W contrast IV;MRA Knee ves-R WO+W contr IV;;ACTIVE;2.14;2.61 +3686-3;hydrOXYzine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;hydrOXYzine [Mass/volume] in Serum or Plasma;hydrOXYzine SerPl-mCnc;;ACTIVE;1.0;2.73 +36863-9;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Pelvis vessels;Doc;MR.angio;RAD;2;MRA Pelvis vessels WO and W contrast IV;MRA Pelvis ves WO+W contr IV;;ACTIVE;2.14;2.61 +36864-7;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Shoulder vessels;Doc;MR.angio;RAD;2;MRA Shoulder vessels - left WO and W contrast IV;MRA Should ves-L WO+W contr IV;;ACTIVE;2.14;2.61 +36865-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Shoulder vessels;Doc;MR.angio;RAD;2;MRA Shoulder vessels - right WO and W contrast IV;MRA Should ves-R WO+W contr IV;;ACTIVE;2.14;2.61 +36866-2;Multisection^WO contrast;Find;Pt;Head>Temporal bone;Doc;CT;RAD;2;CT Temporal bone WO contrast;CT Temporal bone WO contr;;ACTIVE;2.14;2.61 +36867-0;Multisection^WO contrast;Find;Pt;Head>Temporal bone.left;Doc;CT;RAD;2;CT Temporal bone - left WO contrast;CT Temporal bone-L WO contr;;ACTIVE;2.14;2.61 +36868-8;Multisection^WO contrast;Find;Pt;Head>Temporal bone.right;Doc;CT;RAD;2;CT Temporal bone - right WO contrast;CT Temporal bone-R WO contr;;ACTIVE;2.14;2.61 +36869-6;Multisection^WO contrast;Find;Pt;Upper extremity.left>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - left WO contrast;MR UE joint-L WO contr;;ACTIVE;2.14;2.73 +36870-4;Multisection^WO contrast;Find;Pt;Upper extremity.right>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity joint - right WO contrast;MR UE joint-R WO contr;;ACTIVE;2.14;2.73 +3687-1;Ibuprofen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma;Ibuprofen SerPl-mCnc;;ACTIVE;1.0;2.73 +36871-2;Multisection^WO contrast;Find;Pt;XXX>Joint;Doc;MR;RAD;2;MR Joint WO contrast;MR Joint WO contr;;ACTIVE;2.14;2.61 +36872-0;Multisection^WO contrast;Find;Pt;Head>Orbit;Doc;MR;RAD;2;MR Orbit WO contrast;MR Orbit WO contr;;ACTIVE;2.14;2.61 +36873-8;Multisection^WO contrast;Find;Pt;Head>Orbit.left;Doc;MR;RAD;2;MR Orbit - left WO contrast;MR Orbit-L WO contr;;ACTIVE;2.14;2.61 +36874-6;Multisection^WO contrast;Find;Pt;Head>Orbit.right;Doc;MR;RAD;2;MR Orbit - right WO contrast;MR Orbit-R WO contr;;ACTIVE;2.14;2.61 +36875-3;Multisection^WO contrast;Find;Pt;Pelvis>Ovary;Doc;MR;RAD;2;MR Ovary WO contrast;MR Ovary WO contr;;ACTIVE;2.14;2.61 +36876-1;Multisection^WO contrast;Find;Pt;Head>Head veins;Doc;MR.angio;RAD;2;MRA Head veins WO contrast;MRA Head vv WO contr;;ACTIVE;2.14;2.61 +36877-9;Multisection^WO contrast;Find;Pt;Neck>Neck veins;Doc;MR.angio;RAD;2;MRA Neck veins WO contrast;MRA Neck vv WO contr;;ACTIVE;2.14;2.61 +36878-7;Multisection^WO contrast;Find;Pt;Abdomen>Abdominal vessels;Doc;MR.angio;RAD;2;MRA Abdominal vessels WO contrast;MRA Abd ves WO contr;;ACTIVE;2.14;2.61 +36879-5;Multisection^WO contrast;Find;Pt;Lower extremity>Ankle vessels;Doc;MR.angio;RAD;2;MRA Ankle vessels WO contrast;MRA Ankle ves WO contr;;ACTIVE;2.14;2.61 +36880-3;Multisection^WO contrast;Find;Pt;Carotid vessel;Doc;MR.angio;RAD;2;Deprecated Carotid vessel MR angiogram WO contrast;Deprecated Carot ves MR.angio WO contr;;DEPRECATED;2.14;2.58 +36881-1;Multisection^WO contrast;Find;Pt;Head>Head vessels;Doc;MR.angio;RAD;2;MRA Head vessels WO contrast;MRA Head ves WO contr;;ACTIVE;2.14;2.61 +36882-9;Multisection^WO contrast;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - left WO contrast;MRA LE ves-L WO contr;;ACTIVE;2.14;2.61 +36883-7;Multisection^WO contrast;Find;Pt;Pelvis>Pelvis vessels;Doc;MR.angio;RAD;2;MRA Pelvis vessels WO contrast;MRA Pelvis ves WO contr;;ACTIVE;2.14;2.61 +36886-0;Views;Find;Pt;Head>Orbit;Doc;XR;RAD;2;XR Orbit Views;XR Orbit Views;;ACTIVE;2.14;2.64 +36887-8;Views;Find;Pt;Head>Orbit.left;Doc;XR;RAD;2;XR Orbit - left Views;XR Orbit-L Views;;ACTIVE;2.14;2.64 +3688-9;Imipenem+Cilastatin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Imipenem+Cilastatin [Mass/volume] in Serum or Plasma;Deprecated IMP+CS SerPl-mCnc;;DEPRECATED;1.0;2.65 +36890-2;Views 5;Find;Pt;Head>Mastoid;Doc;XR;RAD;2;XR Mastoid 5 Views;XR Mastoid 5V;;ACTIVE;2.14;2.61 +36893-6;Views limited;Find;Pt;Head>Mastoid;Doc;XR;RAD;2;XR Mastoid Limited Views;XR Mastoid Views Ltd;;ACTIVE;2.14;2.64 +36894-4;Views oblique;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula Oblique Views;XR Tib+Fib Views Obl;;ACTIVE;2.14;2.64 +36895-1;Arbovirus Ab;Prid;Pt;XXX;Nom;IF;MICRO;1;Arbovirus Ab [Identifier] in Specimen by Immunofluorescence;Arbovirus Ab Spec IF;;ACTIVE;2.13;2.69 +36896-9;West Nile virus polyvalent E Ab;PrThr;Pt;XXX;Ord;IA;MICRO;1;West Nile virus polyvalent E Ab [Presence] in Specimen by Immunoassay;WNV Polyval E Ab Spec Ql IA;;ACTIVE;2.13;2.69 +3689-7;Imipramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Imipramine [Presence] in Serum or Plasma;Imipramine SerPl Ql;;ACTIVE;1.0;2.56 +36897-7;West Nile virus Ab;PrThr;Pt;XXX;Ord;IA;MICRO;1;West Nile virus Ab [Presence] in Specimen by Immunoassay;WNV Ab Spec Ql IA;;ACTIVE;2.13;2.69 +36898-5;West Nile virus NS5 Ab;PrThr;Pt;XXX;Ord;IA;MICRO;1;West Nile virus NS5 Ab [Presence] in Specimen by Immunoassay;WNV NS5 Ab Spec Ql IA;;ACTIVE;2.13;2.69 +36899-3;Arbovirus Ab;Prid;Pt;XXX;Nom;;MICRO;1;Arbovirus Ab [Identifier] in Specimen;Arbovirus Ab Spec;;ACTIVE;2.13;2.69 +36900-9;West Nile virus polyvalent E Ab;PrThr;Pt;XXX;Ord;;MICRO;1;West Nile virus polyvalent E Ab [Presence] in Specimen;WNV Polyval E Ab Spec Ql;;ACTIVE;2.13;2.69 +36901-7;West Nile virus NS5 Ab;PrThr;Pt;XXX;Ord;;MICRO;1;West Nile virus NS5 Ab [Presence] in Specimen;WNV NS5 Ab Spec Ql;;ACTIVE;2.13;2.69 +36902-5;Chlamydia trachomatis+Neisseria gonorrhoeae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection;C trach+GC DNA Spec Ql NAA+probe;;ACTIVE;2.13;2.73 +36903-3;Chlamydia trachomatis & Neisseria gonorrhoeae DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae DNA [Identifier] in Specimen by NAA with probe detection;C trach+GC DNA Spec NAA+probe;;ACTIVE;2.13;2.73 +36904-1;Inhibin A^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin A [Multiple of the median] adjusted in Serum or Plasma;Inhibin A adj MoM SerPl;;ACTIVE;2.13;2.73 +3690-5;Imipramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imipramine [Mass/volume] in Serum or Plasma;Imipramine SerPl-mCnc;;ACTIVE;1.0;2.73 +36905-8;Inhibin A^^unadjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Inhibin A [Multiple of the median] unadjusted in Serum or Plasma;Inhibin A unadj MoM SerPl;;DISCOURAGED;2.13;2.42 +36906-6;Complement C1 esterase inhibitor;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C1 esterase inhibitor [Mass/volume] in Body fluid;C1INH Fld-mCnc;;ACTIVE;2.13;2.70 +36907-4;Chromosome 8 trisomy;Prctl;Pt;Bld/Tiss;Qn;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 8 trisomy [Percentile] by Cytogenetics;Chr 8 Ts Prctl Bld/T;;ACTIVE;2.13;2.73 +36908-2;Gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;Gene Mut Tested Bld/T;;ACTIVE;2.13;2.73 +36909-0;Cells.G0+G1 phase/100 cells;NFr;Pt;Bld;Qn;;MOLPATH;1;G0+G1 phase cells/100 cells in Blood;G0+G1 Phs Cells NFr Bld;;ACTIVE;2.13;2.34 +36910-8;Cells.S phase/100 cells;NFr;Pt;Bld;Qn;;MOLPATH;1;S-phase cells/100 cells in Blood;S Phs Cells NFr Bld;;ACTIVE;2.13;2.34 +36911-6;Spinocerebellar ataxia gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SCA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SCA gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +36912-4;CATCH22 syndrome gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CATCH22 syndrome gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CATCH22 gene Mut Tested Bld/T;;ACTIVE;2.13;2.14 +3691-3;Imipramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Imipramine [Presence] in Urine;Imipramine Ur Ql;;ACTIVE;1.0;2.73 +36913-2;FMR1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FMR1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FMR1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +36914-0;FMR1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FMR1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;FMR1 gene Mut Tested Bld/T;;ACTIVE;2.13;2.13 +36915-7;AS+PWS gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;AS+PWS gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;AS+PWS gene Mut Tested Bld/T;;ACTIVE;2.13;2.13 +36916-5;Immunoglobulin light chains.kappa.free;MCnc;Pt;Ser;Qn;;CHEM;1;Kappa light chains.free [Mass/volume] in Serum;Kappa LC Free Ser-mCnc;;ACTIVE;2.13;2.73 +36917-3;Chromosome uniparental disomy;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.TRISOMY;1;Chromosome uniparental disomy [Identifier] in Blood or Tissue by Molecular genetics method Narrative;Chr UpDi Bld/T;;ACTIVE;2.13;2.73 +36918-1;ALDOB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ALDOB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ALDOB gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +36919-9;ELN gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ELN gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;ELN gene Mut Tested Bld/T;;ACTIVE;2.13;2.15 +36920-7;PROP1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PROP1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PROP1 gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +3692-1;Imipramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Imipramine [Mass/volume] in Urine;Imipramine Ur-mCnc;;ACTIVE;1.0;2.73 +36921-5;Herpes simplex virus 1+2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Presence] in Serum;HSV1+2 IgG Ser Ql;;ACTIVE;2.13;2.73 +36922-3;TPMT gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;TPMT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TPMT gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +36923-1;Epstein Barr virus DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Blood by NAA with probe detection;EBV DNA # Bld NAA+probe;;ACTIVE;2.13;2.73 +36924-9;14-3-3 Ag;MCnc;Pt;CSF;Qn;;SERO;1;14-3-3 Ag [Mass/volume] in Cerebral spinal fluid;14-3-3 Ag CSF-mCnc;;ACTIVE;2.13;2.73 +36925-6;MEFV gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MEFV gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MEFV gene Mut Anl Bld/T;;ACTIVE;2.13;2.73 +36926-4;Guidance for aspiration+placement of drainage tube;Find;Pt;Abdomen;Doc;CT;RAD;2;Deprecated CT Guidance for aspiration and placement of drainage tube of Abdomen;Deprecated CT Guided Abd Asp+Drain tube place;;DEPRECATED;2.14;2.66 +36927-2;Guidance for percutaneous biopsy;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Guidance for biopsy of Maxillofacial region;CT Guided Maxillofacial Bx;;ACTIVE;2.14;2.64 +36928-0;Guidance for stereotactic biopsy;Find;Pt;Head;Doc;CT;RAD;2;CT Guidance for stereotactic biopsy of Head;CT Guided Head Str Bx;;ACTIVE;2.14;2.64 +36929-8;Guidance for stereotactic biopsy^WO contrast;Find;Pt;Head;Doc;CT;RAD;2;CT Guidance for stereotactic biopsy of Head-- WO contrast;CT Guided Head Str Bx--WO contr;;ACTIVE;2.14;2.64 +36930-6;Multisection;Find;Pt;Abdomen>Adrenal gland;Doc;CT;RAD;2;CT Adrenal gland;CT Adrenal;;ACTIVE;2.14;2.73 +36931-4;Multisection;Find;Pt;Abdomen>Adrenal gland;Doc;MR;RAD;2;MR Adrenal gland;MR Adrenal;;ACTIVE;2.14;2.61 +36932-2;Multisection;Find;Pt;Head>Pituitary+Sella turcica;Doc;CT;RAD;2;CT Pituitary and Sella turcica;CT Pit+Sella turc;;ACTIVE;2.14;2.61 +36933-0;Multisection;Find;Pt;Head>Salivary gland;Doc;MR;RAD;2;MR Salivary gland;MR Salivary gland;;ACTIVE;2.14;2.61 +36934-8;Multisection for calcium score;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart for calcium scoring;CT Hrt for Calcium Score;;DISCOURAGED;2.14;2.61 +36935-5;Multisection for calcium score^W contrast IV;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart for calcium scoring W contrast IV;CT Hrt for Calcium Score W contr IV;;DISCOURAGED;2.14;2.61 +36936-3;Guidance for stereotactic biopsy;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Guidance for stereotactic biopsy of Brain;MR Guided Brain Str Bx;;ACTIVE;2.14;2.64 +36937-1;Multisection limited;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region limited;CT Maxillofacial Ltd;;ACTIVE;2.14;2.61 +36938-9;Multisection limited^WO contrast;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region limited WO contrast;CT Maxillofacial Ltd WO contr;;ACTIVE;2.14;2.61 +3693-9;Imipramine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imipramine [Mass/volume] in Serum or Plasma --trough;Imipramine Trough SerPl-mCnc;;ACTIVE;1.0;2.42 +36939-7;Multisection stereotactic;Find;Pt;Spine;Doc;CT;RAD;2;Deprecated Spine CT stereotactic;Deprecated Spine CT Stereo;;DEPRECATED;2.14;2.58 +36940-5;Multisection stereotactic;Find;Pt;XXX;Doc;CT;RAD;2;Deprecated Unspecified body region CT stereotactic;Deprecated XXX CT Stereo;;DEPRECATED;2.14;2.58 +36941-3;Multisection^W contrast intra salivary duct;Find;Pt;Head>Salivary gland;Doc;CT;RAD;2;CT Salivary gland W contrast intra salivary duct;CT Salivary gland W contr intra SD;;ACTIVE;2.14;2.61 +36942-1;Multisection^W contrast IV;Find;Pt;Chest+Abdomen;Doc;MR;RAD;2;MR Chest and Abdomen W contrast IV;MR Chest+Abd W contr IV;;ACTIVE;2.14;2.61 +36943-9;Multisection^W contrast IV;Find;Pt;Abdomen>Adrenal gland;Doc;CT;RAD;2;CT Adrenal gland W contrast IV;CT Adrenal W contr IV;;ACTIVE;2.14;2.61 +36944-7;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;MR;RAD;2;MR Biliary ducts and Pancreatic duct WO and W contrast IV;MR BD+PD WO+W contr IV;;ACTIVE;2.14;2.61 +36945-4;Views 2^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 2 Views W standing;XR Knee-Bl 2V W Stand;;ACTIVE;2.14;2.61 +36946-2;Views 2^W standing;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 2 Views W standing;XR L-spine 2V W Stand;;ACTIVE;2.14;2.61 +3694-7;Indomethacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Indomethacin [Mass/volume] in Serum or Plasma;Indomethacin SerPl-mCnc;;ACTIVE;1.0;2.73 +36947-0;Views 3^W standing;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral 3 Views W standing;XR Foot-Bl 3V W Stand;;ACTIVE;2.14;2.61 +36948-8;Views 3^W standing;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left 3 Views W standing;XR Foot-L 3V W Stand;;ACTIVE;2.14;2.61 +36949-6;Views 3^W standing;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 3 Views W standing;XR L-spine 3V W Stand;;ACTIVE;2.14;2.61 +36950-4;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Adrenal gland;Doc;CT;RAD;2;CT Adrenal gland WO and W contrast IV;CT Adrenal WO+W contr IV;;ACTIVE;2.14;2.61 +36951-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Adrenal gland;Doc;MR;RAD;2;MR Adrenal gland WO and W contrast IV;MR Adrenal WO+W contr IV;;ACTIVE;2.14;2.61 +36952-0;Multisection^WO contrast;Find;Pt;Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen and Pelvis WO contrast;CT Abd+Pelvis WO contr;;ACTIVE;2.14;2.73 +36953-8;Multisection^WO contrast;Find;Pt;Abdomen>Adrenal gland;Doc;CT;RAD;2;CT Adrenal gland WO contrast;CT Adrenal WO contr;;ACTIVE;2.14;2.61 +3695-4;Insulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin [Mass/volume] in Serum or Plasma;Insulin SerPl-mCnc;;ACTIVE;1.0;2.73 +36954-6;Multisection^WO contrast;Find;Pt;Abdomen>Adrenal gland;Doc;MR;RAD;2;MR Adrenal gland WO contrast;MR Adrenal WO contr;;ACTIVE;2.14;2.61 +36955-3;Multisection^WO contrast;Find;Pt;Neck>Thyroid gland;Doc;CT;RAD;2;CT Thyroid gland WO contrast;CT Thyroid WO contr;;ACTIVE;2.14;2.61 +36956-1;Multisection^WO contrast;Find;Pt;Head>Orbit+Face;Doc;MR;RAD;2;MR Orbit and Face WO contrast;MR Orbit+Face WO contr;;ACTIVE;2.14;2.61 +36957-9;Multisection & 3D reconstruction;Find;Pt;Maxillofacial region;Doc;CT;RAD;2;Deprecated Maxillofacial region CT and 3D reconstruction;Deprecated Maxillofacial CT +3DR;;DEPRECATED;2.14;2.58 +36958-7;View AP;Find;Pt;Chest>Ribs.bilateral;Doc;XR;RAD;2;XR Ribs - bilateral AP;XR Ribs-Bl AP;;ACTIVE;2.14;2.61 +36959-5;View AP;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left AP;XR Ribs-L AP;;ACTIVE;2.14;2.61 +36960-3;View AP upright;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest AP upright;XR port Chest AP upr;;ACTIVE;2.14;2.61 +36961-1;Views AP + West Point + outlet;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and West Point and Outlet;XR Should-L AP+West Point+Outlet;;ACTIVE;2.14;2.61 +3696-2;Insulin renal clearance;VRat;24H;Urine;Qn;;CHEM;1;Deprecated Inulin renal clearance in 24 hour;Deprecated Insulin Cl 24H Ur-vRate;;DEPRECATED;1.0;2.36 +36962-9;View axillary;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Axillary;MG Brst Ax;;ACTIVE;2.14;2.61 +36963-7;View axillary;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Axillary;XR Shoulder-Bl Ax;;ACTIVE;2.14;2.61 +36964-5;View axillary;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Axillary;XR Should-L Ax;;ACTIVE;2.14;2.61 +36965-2;View Ball Catcher;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand Ball Catcher;XR Hand Ball Catcher;;ACTIVE;2.14;2.61 +36966-0;View Brewerton;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral Brewerton;XR Hand-Bl Brewerton;;ACTIVE;2.14;2.61 +36967-8;View Brewerton;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left Brewerton;XR Hand-L Brewerton;;ACTIVE;2.14;2.61 +36968-6;View^W clenched fist;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Single view W clenched fist;XR Wrist-Bl 1V W clenched fist;;ACTIVE;2.14;2.64 +36969-4;View decubitus;Find;Pt;Abdomen;Nar;XR;RAD;2;Deprecated View decubitus;Deprecated Abd XR decubitus;;DEPRECATED;2.14;2.36 +3697-0;Isoniazid;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Isoniazid [Mass/volume] in Serum or Plasma;Isoniazid SerPl-mCnc;;ACTIVE;1.0;2.73 +36970-2;View decubitus portable;Find;Pt;Abdomen;Nar;XR;RAD;2;Deprecated View decubitus portable;Deprecated Abd XR Decub Port;;DEPRECATED;2.14;2.36 +36971-0;View lateral^W extension;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Lateral W extension;XR Wrist-L Lat W Ext;;ACTIVE;2.14;2.61 +36972-8;View lateral^W flexion;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Lateral W flexion;XR Wrist-L Lat W Flx;;ACTIVE;2.14;2.61 +36973-6;View Friedman;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Friedman;XR Hip Friedman;;ACTIVE;2.14;2.61 +36974-4;View Garth;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Garth;XR Should-L Garth;;ACTIVE;2.14;2.61 +36975-1;View Harris;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral Harris;XR Heel-Bl Harris;;ACTIVE;2.14;2.61 +36976-9;View Harris;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Harris;XR Foot Harris;;ACTIVE;2.14;2.61 +36977-7;View Harris;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Harris;XR Heel-L Harris;;ACTIVE;2.14;2.61 +36978-5;View Holmblad;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Holmblad;XR Knee Holmblad;;ACTIVE;2.14;2.61 +36979-3;View Jones;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow Jones;XR Elbow Jones;;ACTIVE;2.14;2.61 +36980-1;View Jones;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left Jones;XR Elbow-L Jones;;ACTIVE;2.14;2.61 +36981-9;View Judet;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Judet;XR Hip Judet;;ACTIVE;2.14;2.61 +36982-7;View Judet;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Judet;XR Hip-Bl Judet;;ACTIVE;2.14;2.61 +36983-5;View Judet;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Judet;XR Hip-L Judet;;ACTIVE;2.14;2.61 +36984-3;View lateral crosstable;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Lateral crosstable;XR Abd Lat Xtable;;ACTIVE;2.14;2.61 +36985-0;View lateral crosstable;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Lateral crosstable;XR Hip Lat Xtable;;ACTIVE;2.14;2.61 +36986-8;View lateral crosstable;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Lateral crosstable;XR Hip-Bl Lat Xtable;;ACTIVE;2.14;2.61 +36987-6;View lateral crosstable;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Lateral crosstable;XR Hip-L Lat Xtable;;ACTIVE;2.14;2.61 +3698-8;Kanamycin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Kanamycin [Mass/volume] in Serum or Plasma --peak;Kanamycin Peak SerPl-mCnc;;ACTIVE;1.0;2.40 +36988-4;View lateral crosstable;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Lateral crosstable;XR Knee Lat Xtable;;ACTIVE;2.14;2.61 +36989-2;View lateral crosstable;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Lateral crosstable;XR C-spine Lat Xtable;;ACTIVE;2.14;2.61 +369-9;Norfloxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Norfloxacin [Susceptibility] by Serum bactericidal titer;Norfloxacin Titr SBT;;ACTIVE;1.0;2.32 +36990-0;View lateral crosstable;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Lateral crosstable;XR L-spine Lat Xtable;;ACTIVE;2.14;2.61 +36991-8;View lateral crosstable;Find;Pt;Neck>Spine.cervical;Doc;XR.portable;RAD;2;Portable XR Cervical spine Lateral crosstable;XR port C-spine Lat Xtable;;ACTIVE;2.14;2.61 +36992-6;View lateral crosstable;Find;Pt;Abdomen>Spine.lumbar;Doc;XR.portable;RAD;2;Portable XR Lumbar spine Lateral crosstable;XR port L-spine Lat Xtable;;ACTIVE;2.14;2.61 +36993-4;View lateral frog;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Lateral frog;XR Hip-Bl Lat frog;;ACTIVE;2.14;2.61 +36994-2;View lateral frog;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Lateral frog;XR Hip-L Lat frog;;ACTIVE;2.14;2.61 +36995-9;View L-lateral;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Left lateral;XR Abd L-lat;;ACTIVE;2.14;2.61 +3699-6;Kanamycin^random;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Kanamycin [Mass/volume] in Serum or Plasma --random;Kanamycin Rand SerPl-mCnc;;DISCOURAGED;1.0;2.40 +36996-7;View R-lateral;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Right lateral;XR Abd R-lat;;ACTIVE;2.14;2.61 +36997-5;View lateral^W extension;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Lateral W extension;XR C-spine Lat W Ext;;ACTIVE;2.14;2.61 +36998-3;View lateral^W flexion;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Lateral W flexion;XR C-spine Lat W Flx;;ACTIVE;2.14;2.73 +36999-1;View lateral^W extension;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Lateral W extension;XR Knee-Bl Lat W Ext;;ACTIVE;2.14;2.64 +37000-7;View lateral^W extension;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Lateral W extension;XR Knee-L Lat W Ext;;ACTIVE;2.14;2.64 +37001-5;View lateral^W standing;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Lateral W standing;XR Foot Lat W Stand;;ACTIVE;2.14;2.61 +3700-2;Kanamycin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Kanamycin [Mass/volume] in Serum or Plasma --trough;Kanamycin Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +37002-3;View lateral^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Lateral W standing;XR Knee-L Lat W Stand;;ACTIVE;2.14;2.61 +37003-1;View lateral^W standing;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Lateral W standing;XR L-spine Lat W Stand;;ACTIVE;2.14;2.61 +37004-9;View Laurin;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Laurin;XR Knee Laurin;;ACTIVE;2.14;2.61 +37005-6;View magnification;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Magnification;MG Brst-L Mag;;ACTIVE;2.14;2.61 +37006-4;View MLO;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral MLO;MG Brst-Bl MLO;;ACTIVE;2.14;2.61 +37007-2;View Mortise;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle Mortise;XR Ankle Mortise;;ACTIVE;2.14;2.61 +37008-0;View L-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Left oblique;XR Chest L-obl;;ACTIVE;2.14;2.61 +37009-8;View L-oblique;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Left oblique;XR L-spine L-obl;;ACTIVE;2.14;2.61 +3701-0;Ketamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ketamine [Mass/volume] in Serum or Plasma;Ketamine SerPl-mCnc;;ACTIVE;1.0;2.73 +37010-6;View R-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Right oblique;XR Chest R-obl;;ACTIVE;2.14;2.61 +37011-4;View R-oblique;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Right oblique;XR L-spine R-obl;;ACTIVE;2.14;2.61 +37012-2;View outlet;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Outlet;XR Shoulder-Bl Outlet;;ACTIVE;2.14;2.61 +37013-0;View outlet;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Outlet;XR Should-L Outlet;;ACTIVE;2.14;2.61 +37014-8;View PA^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left PA W standing;XR Knee-L PA W Stand;;ACTIVE;2.14;2.61 +37015-5;View PA prone;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen PA prone;XR Abd PA prone;;ACTIVE;2.14;2.61 +37016-3;Views rolled;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Rolled Views;MG Brst-Bl Views rolled;;ACTIVE;2.14;2.64 +37017-1;Views rolled;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Rolled Views;MG Brst-L Views rolled;;ACTIVE;2.14;2.64 +37018-9;View Rosenberg^W standing;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Rosenberg W standing;XR Knee Rosenberg W Stand;;ACTIVE;2.14;2.61 +37019-7;View Rosenberg^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Rosenberg W standing;XR Knee-L Rosenberg W Stand;;ACTIVE;2.14;2.61 +37020-5;View Rosenberg^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Rosenberg W standing;XR Knee-Bl Rosenberg W Stand;;ACTIVE;2.14;2.61 +37021-3;Views ski jump;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral Ski jump Views;XR Heel-Bl Views Ski Jump;;ACTIVE;2.14;2.64 +37022-1;Views ski jump;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus Ski jump Views;XR Heel Views Ski Jump;;ACTIVE;2.14;2.64 +37023-9;Views ski jump;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Ski jump Views;XR Heel-L Views Ski Jump;;ACTIVE;2.14;2.64 +37024-7;View Stryker Notch;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Stryker Notch;XR Shoulder-Bl Stryker Notch;;ACTIVE;2.14;2.61 +37025-4;View Stryker Notch;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Stryker Notch;XR Should-L Stryker Notch;;ACTIVE;2.14;2.61 +37026-2;View submentovertex;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Submentovertex;XR Skull SMV;;ACTIVE;2.14;2.61 +37027-0;View Sunrise;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Sunrise;XR Knee-Bl Sunrise;;ACTIVE;2.14;2.61 +3702-8;Ketobemidone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ketobemidone [Presence] in Urine;Ketobemidone Ur Ql;;ACTIVE;1.0;2.56 +37028-8;View tangential;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Tangential;MG Brst Tangential;;ACTIVE;2.14;2.61 +37029-6;View tangential;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Tangential;MG Brst-Bl Tangential;;ACTIVE;2.14;2.61 +37030-4;View tangential;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Tangential;MG Brst-L Tangential;;ACTIVE;2.14;2.61 +37031-2;View transthoracic;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus Transthoracic;XR Humerus Transthoracic;;ACTIVE;2.14;2.61 +37032-0;View transthoracic;Find;Pt;Upper extremity.bilateral>Humerus;Doc;XR;RAD;2;XR Humerus - bilateral Transthoracic;XR Humerus-Bl Transthoracic;;ACTIVE;2.14;2.61 +37033-8;View transthoracic;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left Transthoracic;XR Humerus-L Transthoracic;;ACTIVE;2.14;2.61 +37034-6;View transthoracic;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Transthoracic;XR Should-L Transthoracic;;ACTIVE;2.14;2.61 +37035-3;View Grashey;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Grashey;XR Shoulder-Bl Grashey;;ACTIVE;2.14;2.61 +3703-6;Ketobemidone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ketobemidone [Mass/volume] in Urine;Ketobemidone Ur-mCnc;;ACTIVE;1.0;2.42 +37037-9;View true lateral;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast True lateral;MG Brst True lat;;ACTIVE;2.14;2.61 +37038-7;View true lateral;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral True lateral;MG Brst-Bl True lat;;ACTIVE;2.14;2.61 +37039-5;View true lateral;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip True lateral;XR Hip True lat;;ACTIVE;2.14;2.61 +37040-3;View true lateral;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left True lateral;XR Hip-L True lat;;ACTIVE;2.14;2.61 +37041-1;View tunnel;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Tunnel;XR Knee-Bl Tunnel;;ACTIVE;2.14;2.61 +37042-9;View tunnel;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Tunnel;XR Knee-L Tunnel;;ACTIVE;2.14;2.61 +37043-7;View tunnel^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Tunnel W standing;XR Knee-L Tunnel W Stand;;ACTIVE;2.14;2.61 +3704-4;Labetalol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Labetalol [Mass/volume] in Serum or Plasma;Labetalol SerPl-mCnc;;ACTIVE;1.0;2.42 +37044-5;View ulnar deviation;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Ulnar deviation;XR Wrist-L Ulnar deviation;;ACTIVE;2.14;2.61 +37045-2;View ulnar deviation;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Ulnar deviation;XR Wrist-Bl Ulnar deviation;;ACTIVE;2.14;2.64 +37046-0;View upright;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Upright;XR Abd Upr;;ACTIVE;2.14;2.73 +37047-8;View Velpeau axillary;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Velpeau axillary;XR Shoulder-Bl Velpeau ax;;ACTIVE;2.14;2.61 +37048-6;View Velpeau axillary;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Velpeau axillary;XR Should-L Velpeau ax;;ACTIVE;2.14;2.61 +37049-4;View Von Rosen;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Von Rosen;XR Hip Von Rosen;;ACTIVE;2.14;2.61 +37050-2;View West Point;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral West Point;XR Shoulder-Bl West Point;;ACTIVE;2.14;2.61 +3705-1;Labetalol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Labetalol [Presence] in Urine;Labetalol Ur Ql;;ACTIVE;1.0;2.56 +37051-0;View West Point;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left West Point;XR Should-L West Point;;ACTIVE;2.14;2.61 +37052-8;View XCCL;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral XCCL;MG Brst-Bl XCCL;;ACTIVE;2.14;2.61 +37053-6;View XCCL;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left XCCL;MG Brst-L XCCL;;ACTIVE;2.14;2.61 +37054-4;View Y;Find;Pt;Chest>Scapula.left;Doc;XR;RAD;2;XR Scapula - left Y;XR Scapula-L Y;;ACTIVE;2.14;2.61 +37055-1;View Y;Find;Pt;Chest>Scapula.bilateral;Doc;XR;RAD;2;XR Scapula - bilateral Y;XR Scapula-Bl Y;;ACTIVE;2.14;2.61 +37056-9;View Zanca;Find;Pt;Upper extremity.bilateral>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - bilateral Zanca;XR AC joint-Bl Zanca;;ACTIVE;2.14;2.61 +37057-7;View Zanca;Find;Pt;Upper extremity.left>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - left Zanca;XR AC joint-L Zanca;;ACTIVE;2.14;2.61 +37058-5;View^W standing;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral Single view W standing;XR Heel-Bl 1V W Stand;;ACTIVE;2.14;2.64 +37059-3;View^W standing;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Single view W standing;XR Hip-Bl 1V W Stand;;ACTIVE;2.14;2.64 +37060-1;Views;Find;Pt;^Fetus;Doc;XR;RAD;2;XR Fetal Views;XR Fetal Views;;ACTIVE;2.14;2.64 +37062-7;Views;Find;Pt;Upper extremity.bilateral>Humerus;Doc;XR;RAD;2;XR Humerus - bilateral Views;XR Humerus-Bl Views;;ACTIVE;2.14;2.64 +37063-5;Views of foreign body;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views for foreign body;RF Views for FB;;ACTIVE;2.14;2.64 +37064-3;Views 2;Find;Pt;Lower extremity.left>Acetabulum;Doc;XR;RAD;2;XR Acetabulum - left 2 Views;XR Acetabulum-L 2V;;ACTIVE;2.14;2.61 +37066-8;Views 2;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left 2 Views;XR Ribs-L 2V;;ACTIVE;2.14;2.61 +37067-6;Views 2^W nipple markers;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest 2 Views W nipple markers;XR Chest 2V W nipple markers;;ACTIVE;2.14;2.61 +37068-4;Views 2^W standing;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral 2 Views W standing;XR Foot-Bl 2V W Stand;;ACTIVE;2.14;2.61 +3706-9;Labetalol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Labetalol [Mass/volume] in Urine;Labetalol Ur-mCnc;;ACTIVE;1.0;2.42 +37069-2;Views 2^W standing;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left 2 Views W standing;XR Foot-L 2V W Stand;;ACTIVE;2.14;2.61 +370-7;Novobiocin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Novobiocin [Susceptibility] by Minimum lethal concentration (MLC);Novobiocin Islt MLC;;ACTIVE;1.0;2.19 +37070-0;Views 4;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral 4 Views;XR Wrist-Bl 4V;;ACTIVE;2.14;2.61 +37071-8;Views 4;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 4 Views;XR Wrist-L 4V;;ACTIVE;2.14;2.61 +37072-6;Views 5;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 5 Views;XR Wrist-L 5V;;ACTIVE;2.14;2.61 +37073-4;Views 5^W standing;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 5 Views W standing;XR L-spine 5V W Stand;;ACTIVE;2.14;2.61 +37074-2;Views 6;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 6 Views;XR Wrist-L 6V;;ACTIVE;2.14;2.61 +37075-9;Views AP;Find;Pt;Lower extremity>Hip;Doc;XR.portable;RAD;2;Portable XR Hip Views AP;XR port Hip Views AP;;ACTIVE;2.14;2.64 +37076-7;Views supine + lateral-decubitus;Find;Pt;Abdomen;Doc;XR.portable;RAD;2;Portable XR Abdomen Supine and Lateral-decubitus;XR port Abd sup+Lat Decub;;ACTIVE;2.14;2.61 +3707-7;Labetalol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Labetalol [Mass/time] in 24 hour Urine;Labetalol 24h Ur-mRate;;ACTIVE;1.0;2.42 +37077-5;Views AP + lateral crosstable;Find;Pt;Lower extremity>Hip;Doc;XR.portable;RAD;2;Portable XR Hip AP and Lateral crosstable;XR port Hip AP+Lat Xtable;;ACTIVE;2.14;2.61 +37078-3;Views AP + lateral;Find;Pt;Abdomen>Spine.lumbar;Doc;XR.portable;RAD;2;Portable XR Lumbar spine AP and Lateral;XR port L-spine AP+Lat;;ACTIVE;2.14;2.61 +37079-1;Views AP + lateral + odontoid;Find;Pt;Neck>Spine.cervical;Doc;XR.portable;RAD;2;Portable XR Cervical spine AP and Lateral and Odontoid;XR port C-spine AP+Lat+Odont;;ACTIVE;2.14;2.61 +37080-9;Views AP + axillary;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP and Axillary;XR Shoulder-Bl AP+Ax;;ACTIVE;2.14;2.61 +37081-7;Views AP + axillary + outlet;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP and Axillary and Outlet;XR Shoulder-Bl AP+Ax+Outlet;;ACTIVE;2.14;2.61 +37082-5;Views AP + axillary + outlet;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and Axillary and Outlet;XR Should-L AP+Ax+Outlet;;ACTIVE;2.14;2.61 +37083-3;Views AP + axillary + outlet + Zanca;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and Axillary and Outlet and Zanca;XR Should-L AP+Ax+Outlet+Zanca;;ACTIVE;2.14;2.61 +37084-1;Views AP + axillary + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and Axillary and Y;XR Should-L AP+Ax+Y;;ACTIVE;2.14;2.61 +3708-5;Methotrimeprazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methotrimeprazine [Mass/volume] in Urine;Methotrimeprazine Ur-mCnc;;ACTIVE;1.0;2.52 +37085-8;Views supine + lateral-decubitus;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Supine and Lateral-decubitus;XR Abd sup+Lat Decub;;ACTIVE;2.14;2.61 +37086-6;Views AP + lateral crosstable;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip AP and Lateral crosstable;XR Hip AP+Lat Xtable;;ACTIVE;2.14;2.61 +37087-4;Views AP + lateral crosstable;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left AP and Lateral crosstable;XR Hip-L AP+Lat Xtable;;ACTIVE;2.14;2.61 +37088-2;Views AP + lateral crosstable;Find;Pt;Pelvis & Lower extremity.left>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - left AP and Lateral crosstable;XR Pelvis and Hip-L AP+Lat Xtable;;ACTIVE;2.14;2.61 +37089-0;Views AP + lateral crosstable;Find;Pt;Pelvis & Lower extremity>Hip;Doc;XR;RAD;2;XR Pelvis and Hip AP and Lateral crosstable;XR Pelvis and Hip AP+Lat Xtable;;ACTIVE;2.14;2.61 +37090-8;Views AP + lateral crosstable;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral crosstable;XR Knee AP+Lat Xtable;;ACTIVE;2.14;2.61 +37091-6;Views AP + lateral frog;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip AP and Lateral frog;XR Hip AP+Lat frog;;ACTIVE;2.14;2.64 +37092-4;Views AP + lateral frog;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral AP and Lateral frog;XR Hip-Bl AP+Lat frog;;ACTIVE;2.14;2.64 +3709-3;Levomepromazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Levomepromazine [Mass/volume] in Urine;Deprecated L-Mepromazine Ur-mCnc;;DEPRECATED;1.0;2.36 +37093-2;Views AP + lateral frog;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left AP and Lateral frog;XR Hip-L AP+Lat frog;;ACTIVE;2.14;2.64 +37094-0;Views AP + lateral frog;Find;Pt;Pelvis & Lower extremity.left>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - left AP and Lateral frog;XR Pelvis and Hip-L AP+Lat frog;;ACTIVE;2.14;2.64 +37095-7;Views AP + lateral + Mortise;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle AP and Lateral and Mortise;XR Ankle AP+Lat+Mortise;;ACTIVE;2.14;2.61 +37096-5;Views AP + lateral + Mortise;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral AP and Lateral and Mortise;XR Ankle-Bl AP+Lat+Mortise;;ACTIVE;2.14;2.61 +37097-3;Views AP + lateral + Mortise;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left AP and Lateral and Mortise;XR Ankle-L AP+Lat+Mortise;;ACTIVE;2.14;2.61 +37098-1;(Views AP + oblique) + (View lateral^W flexion + W extension);Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Oblique and (Lateral W flexion and W extension);XR C-spine AP+obl+lat W FE;;ACTIVE;2.14;2.61 +37099-9;Views AP + lateral + oblique + odontoid;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Lateral and Oblique and Odontoid;XR C-spine AP+Lat+Obl+Odont;;ACTIVE;2.14;2.61 +37100-5;(Views AP + oblique + odontoid) + (View lateral^W flexion + W extension);Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Oblique and Odontoid and (Lateral W flexion and W extension);XR C-spine AP+obl+odont+lat W FE;;ACTIVE;2.14;2.61 +3710-1;Levorphanol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Levorphanol [Mass/volume] in Serum or Plasma;Levorphanol SerPl-mCnc;;ACTIVE;1.0;2.73 +37101-3;Views AP + lateral + oblique + spot;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP and Lateral and Oblique and Spot;XR L-spine AP+Lat+Obl+Spot;;ACTIVE;2.14;2.61 +37102-1;Views AP + lateral + oblique + Sunrise;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral and Oblique and Sunrise;XR Knee-Bl AP+Lat+Obl+Sunrise;;ACTIVE;2.14;2.61 +37103-9;Views AP + lateral + odontoid;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Lateral and Odontoid;XR C-spine AP+Lat+Odont;;ACTIVE;2.14;2.61 +37104-7;(Views AP + odontoid) + (View lateral^W flexion + W extension);Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Odontoid and (Lateral W flexion and W extension);XR C-spine AP+odont+lat W FE;;ACTIVE;2.14;2.61 +37105-4;Views AP + lateral + spot;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP and Lateral and Spot;XR L-spine AP+Lat+Spot;;ACTIVE;2.14;2.61 +37106-2;Views AP + lateral + Sunrise;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral and Sunrise;XR Knee AP+Lat+Sunrise;;ACTIVE;2.14;2.61 +37107-0;Views AP + lateral + Sunrise;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral and Sunrise;XR Knee-Bl AP+Lat+Sunrise;;ACTIVE;2.14;2.61 +37108-8;Views AP + lateral + Sunrise;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral and Sunrise;XR Knee-L AP+Lat+Sunrise;;ACTIVE;2.14;2.61 +37109-6;Views AP + lateral + Sunrise;Find;Pt;Lower extremity.bilateral>Patella;Doc;XR;RAD;2;XR Patella - bilateral AP and Lateral and Sunrise;XR Patella-Bl AP+Lat+Sunrise;;ACTIVE;2.14;2.61 +37110-4;Views AP + lateral + Sunrise;Find;Pt;Lower extremity.left>Patella;Doc;XR;RAD;2;XR Patella - left AP and Lateral and Sunrise;XR Patella-L AP+Lat+Sunrise;;ACTIVE;2.14;2.61 +37111-2;Views AP + lateral + Sunrise + tunnel;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral and Sunrise and tunnel;XR Knee AP+Lat+Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37112-0;Views AP + lateral + tunnel;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral and Tunnel;XR Knee AP+Lat+Tunnel;;ACTIVE;2.14;2.61 +37113-8;Views AP + lateral + tunnel;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral and Tunnel;XR Knee-Bl AP+Lat+Tunnel;;ACTIVE;2.14;2.61 +37114-6;Views AP + lateral + tunnel;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral and Tunnel;XR Knee-L AP+Lat+Tunnel;;ACTIVE;2.14;2.61 +37115-3;Views AP + lateral + oblique + tunnel;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral and Oblique and Tunnel;XR Knee AP+Lat+Obl+Tunnel;;ACTIVE;2.14;2.61 +37116-1;Views AP + lateral + Sunrise + tunnel;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral and Sunrise and tunnel;XR Knee-Bl AP+Lat+Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37117-9;Views AP + lateral + Sunrise + tunnel;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral and Sunrise and tunnel;XR Knee-L AP+Lat+Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37118-7;Views AP + lateral + oblique + Sunrise + tunnel;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral and Oblique and Sunrise and Tunnel;XR Knee-Bl AP+Lat+Obl+Sunrise+Tunnel;;ACTIVE;2.14;2.61 +3711-9;Levorphanol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Levorphanol [Presence] in Urine;Levorphanol Ur Ql;;ACTIVE;1.0;2.73 +37119-5;Views AP + oblique;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP and Oblique;XR Abd AP+Obl;;ACTIVE;2.14;2.61 +37120-3;Views AP + odontoid + lateral crosstable;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Odontoid and Lateral crosstable;XR C-spine AP+Odont+Lat Xtable;;ACTIVE;2.14;2.61 +37121-1;Views AP + Serendipity;Find;Pt;Chest>Clavicle.left;Doc;XR;RAD;2;XR Clavicle - left AP and Serendipity;XR Clavicle-L AP+Serendipity;;ACTIVE;2.14;2.61 +37122-9;Views AP + Stryker Notch;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and Stryker Notch;XR Should-L AP+Stryker Notch;;ACTIVE;2.14;2.61 +37123-7;Views AP + West Point;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and West Point;XR Should-L AP+West Point;;ACTIVE;2.14;2.61 +37124-5;Views AP + Y;Find;Pt;Chest>Scapula.left;Doc;XR;RAD;2;XR Scapula - left AP and Y;XR Scapula-L AP+Y;;ACTIVE;2.14;2.61 +37125-2;Views AP + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and Y;XR Should-L AP+Y;;ACTIVE;2.14;2.61 +37126-0;Views AP + axillary + Y;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP and Axillary and Y;XR Shoulder-Bl AP+Ax+Y;;ACTIVE;2.14;2.61 +3712-7;Levorphanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Levorphanol [Mass/volume] in Urine;Levorphanol Ur-mCnc;;ACTIVE;1.0;2.42 +37127-8;Views axillary + Y;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Axillary and Y;XR Shoulder-Bl Ax+Y;;ACTIVE;2.14;2.61 +37128-6;Views axillary + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Axillary and Y;XR Should-L Ax+Y;;ACTIVE;2.14;2.61 +37129-4;Views AP & axillary & Y;Find;Pt;Shoulder.left;Nar;XR;RAD;2;Deprecated Shoulder Left X-ray AP & axillary & Y;Deprecated Should-L XR AP+Ax+Y;;DEPRECATED;2.14;2.46 +37131-0;Views R-lateral + L-lateral;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Right lateral and Left lateral;XR Abd R-Lat+L-Lat;;ACTIVE;2.14;2.61 +37132-8;Views lateral^W flexion + W extension;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Lateral Views W flexion and W extension;XR L-spine Views Lat W FE;;ACTIVE;2.14;2.64 +37133-6;Views lateral^W flexion + W extension;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Lateral Views W flexion and W extension;XR C-spine Views Lat W FE;;ACTIVE;2.14;2.64 +37134-4;Views lateral + Mortise;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral Lateral and Mortise;XR Ankle-Bl Lat+Mortise;;ACTIVE;2.14;2.61 +3713-5;Levorphanol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Levorphanol [Mass/time] in 24 hour Urine;Levorphanol 24h Ur-mRate;;ACTIVE;1.0;2.42 +37135-1;Views lateral + Mortise;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Lateral and Mortise;XR Ankle-L Lat+Mortise;;ACTIVE;2.14;2.61 +37136-9;Views lateral + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Lateral and Y;XR Should-L Lat+Y;;ACTIVE;2.14;2.61 +37137-7;Views limited^W contrast IV;Find;Pt;Abdomen>Kidney;Doc;XR;RAD;2;XR Kidney Limited Views W contrast IV;XR Kidney Views Ltd W contr IV;;ACTIVE;2.14;2.64 +37138-5;Views R-oblique + L-oblique;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Right oblique and Left oblique;XR Abd R-Obl+L-Obl;;ACTIVE;2.14;2.61 +37139-3;(View oblique) + (View lateral^W flexion + W extension);Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Oblique and (Lateral W flexion and W extension);XR C-spine Obl+lat W FE;;ACTIVE;2.14;2.61 +37140-1;Views outlet + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Outlet and Y;XR Should-L Outlet+Y;;ACTIVE;2.14;2.61 +37141-9;Views PA + R-lateral;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Right lateral;XR Chest PA+R-Lat;;ACTIVE;2.14;2.61 +37142-7;Views PA + lateral + Ball Catcher;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral PA and Lateral and Ball Catcher;XR Hand-Bl PA+Lat+Ball Catcher;;ACTIVE;2.14;2.61 +3714-3;Lidocaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lidocaine [Mass/volume] in Serum or Plasma;Lidocain SerPl-mCnc;;ACTIVE;1.0;2.73 +37143-5;Views PA + lateral + AP lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and AP lateral-decubitus;XR Chest PA+Lat+AP Lat-Decub;;ACTIVE;2.14;2.61 +37144-3;Views PA + lateral + AP L-lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and AP left lateral-decubitus;XR Chest PA+Lat+AP l-Lat-Decub;;ACTIVE;2.14;2.61 +37145-0;Views PA + lateral + AP R-lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and AP right lateral-decubitus;XR Chest PA+Lat+AP R-Lat-Decub;;ACTIVE;2.14;2.61 +37146-8;Views PA + lateral + L-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and Left oblique;XR Chest PA+Lat+L-Obl;;ACTIVE;2.14;2.61 +37147-6;Views PA + lateral + R-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral and Right oblique;XR Chest PA+Lat+R-Obl;;ACTIVE;2.14;2.61 +37148-4;Views PA + lateral + oblique + Towne;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible PA and Lateral and Oblique and Towne;XR Mandible PA+Lat+Obl+Towne;;ACTIVE;2.14;2.61 +37149-2;Views PA + lateral + Sunrise;Find;Pt;Lower extremity.left>Patella;Doc;XR;RAD;2;XR Patella - left PA and Lateral and Sunrise;XR Patella-L PA+Lat+Sunrise;;ACTIVE;2.14;2.61 +371-5;Novobiocin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Novobiocin [Susceptibility] by Minimum inhibitory concentration (MIC);Novobiocin Islt MIC;;ACTIVE;1.0;2.19 +3715-0;Lidocaine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Lidocaine [Presence] in Serum or Plasma;Lidocain SerPl Ql;;ACTIVE;1.0;2.56 +37150-0;Views PA + R-oblique + L-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Right oblique and Left oblique;XR Chest PA+R-Obl+L-Obl;;ACTIVE;2.14;2.61 +37151-8;Views;Find;Pt;XXX;Doc;RF.portable;RAD;2;Portable RF Unspecified body region Views;RF port Views;;ACTIVE;2.14;2.64 +37152-6;Views outlet + Y;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Outlet and Y;XR Shoulder-Bl Outlet+Y;;ACTIVE;2.14;2.61 +37153-4;Views Stenver + Arcelin;Find;Pt;Head>Mastoid;Doc;XR;RAD;2;XR Mastoid Stenver and Arcelin;XR Mastoid Stenver+Arcelin;;ACTIVE;2.14;2.61 +37154-2;Views oblique + Sunrise;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Oblique and Sunrise;XR Knee Obl+Sunrise;;ACTIVE;2.14;2.61 +37155-9;Views oblique + Sunrise + tunnel;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Oblique and Sunrise and Tunnel;XR Knee Obl+Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37156-7;Views Sunrise + tunnel;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Sunrise and Tunnel;XR Knee-L Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37157-5;Views Grashey + outlet;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey and Outlet;XR Should-L Grashey+Outlet;;ACTIVE;2.14;2.61 +37158-3;Views Grashey + axillary + outlet;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey and Axillary and Outlet;XR Should-L Grashey+Ax+Outlet;;ACTIVE;2.14;2.61 +37159-1;Views tarsal;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;Deprecated XR Foot - left Tarsal Views;Deprecated XR Foot-L Views tarsal;;DEPRECATED;2.14;2.64 +37160-9;Views Grashey + axillary;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey and Axillary;XR Should-L Grashey+Ax;;ACTIVE;2.14;2.61 +37161-7;Views Grashey + axillary + outlet + Zanca;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Grashey and Axillary and Outlet and Zanca;XR Shoulder-Bl Grashey+Ax+Outlet+Zanca;;ACTIVE;2.14;2.61 +37162-5;Views Grashey + outlet + Serendipity;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey and Outlet and Serendipity;XR Should-L Grashey+Outlet+Serend;;ACTIVE;2.14;2.61 +37163-3;Views Sunrise + tunnel;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Sunrise and Tunnel;XR Knee-Bl Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37164-1;Views lateral + Caldwell + Waters;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones Lateral and Caldwell and Waters;XR Face Lat+Caldwell+Waters;;ACTIVE;2.14;2.61 +37165-8;Views lateral + Caldwell + Waters + submentovertex;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones Lateral and Caldwell and Waters and Submentovertex;XR Face Lat+Caldwell+Waters+SMV;;ACTIVE;2.14;2.61 +37166-6;Views lateral + Caldwell + Waters + submentovertex + Towne;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones Lateral and Caldwell and Waters and Submentovertex and Towne;XR Face Lat+Caldwell+Waters+SMV+Towne;;ACTIVE;2.14;2.61 +37167-4;Views Grashey + West Point;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey and West Point;XR Should-L Grashey+West Point;;ACTIVE;2.14;2.61 +3716-8;Lidocaine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Lidocaine [Presence] in Urine;Lidocain Ur Ql;;ACTIVE;1.0;2.73 +37168-2;Views;Find;Pt;Lower extremity>Hip;Doc;XR.portable;RAD;2;Portable XR Hip Views;XR port Hip Views;;ACTIVE;2.14;2.64 +37169-0;Views;Find;Pt;Lower extremity.left>Hip;Doc;XR.portable;RAD;2;Portable XR Hip - left Views;XR port Hip-L Views;;ACTIVE;2.14;2.64 +37170-8;Views;Find;Pt;Upper extremity>Humerus;Doc;XR.portable;RAD;2;Portable XR Humerus Views;XR port Humerus Views;;ACTIVE;2.14;2.64 +37171-6;Views;Find;Pt;Neck>Spine.cervical;Doc;XR.portable;RAD;2;Portable XR Cervical spine Views;XR port C-spine Views;;ACTIVE;2.14;2.64 +37172-4;Views;Find;Pt;Abdomen>Spine.lumbar;Doc;XR.portable;RAD;2;Portable XR Lumbar spine Views;XR port L-spine Views;;ACTIVE;2.14;2.64 +37173-2;Views^W contrast IA;Find;Pt;Head>Cerebral artery;Doc;RF.angio;RAD;2;RFA Cerebral artery Views W contrast IA;RFA Cerebral a Views W contr IA;;ACTIVE;2.14;2.64 +37174-0;Views^W contrast IA;Find;Pt;Chest>Coronary arteries;Doc;RF.angio;RAD;2;RFA Coronary arteries Views W contrast IA;RFA CA Views W contr IA;;ACTIVE;2.14;2.64 +37175-7;Views^W contrast IA;Find;Pt;Lower extremity>Femoral artery;Doc;RF.angio;RAD;2;RFA Femoral artery Views W contrast IA;RFA Fem a Views W contr IA;;ACTIVE;2.14;2.64 +3717-6;Lidocaine^>45m post bolus dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lidocaine [Mass/volume] in Serum or Plasma -->45 minutes post bolus dose;Lidocain >45M p bol SerPl-mCnc;;ACTIVE;1.0;2.40 +37176-5;Views^W contrast IA;Find;Pt;Lower extremity>Femoral artery+Popliteal artery;Doc;RF.angio;RAD;2;RFA Femoral artery and Popliteal artery Views W contrast IA;RFA Fem a+Pop a Views W contr IA;;ACTIVE;2.14;2.64 +37177-3;Views^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.bilateral;Doc;RF.angio;RAD;2;RFA Iliac artery - bilateral Views W contrast IA;RFA Iliac a-Bl Views W contr IA;;ACTIVE;2.14;2.64 +37178-1;Views^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.left;Doc;RF.angio;RAD;2;RFA Iliac artery - left Views W contrast IA;RFA Iliac a-L Views W contr IA;;ACTIVE;2.14;2.64 +37179-9;Views^W contrast IA;Find;Pt;Abdomen>Inferior mesenteric artery;Doc;RF.angio;RAD;2;RFA Inferior mesenteric artery Views W contrast IA;RFA IM a Views W contr IA;;ACTIVE;2.14;2.64 +37180-7;Views^W contrast IA;Find;Pt;Abdomen>Superior mesenteric artery;Doc;RF.angio;RAD;2;RFA Superior mesenteric artery Views W contrast IA;RFA SM a Views W contr IA;;ACTIVE;2.14;2.64 +37181-5;Views^W contrast IA;Find;Pt;Lower extremity.left>Popliteal artery;Doc;RF.angio;RAD;2;RFA Popliteal artery - left Views W contrast IA;RFA Pop a-L Views W contr IA;;ACTIVE;2.14;2.64 +37182-3;Views^W contrast IA;Find;Pt;Chest>Pulmonary arteries.left;Doc;RF.angio;RAD;2;RFA Pulmonary arteries - left Views W contrast IA;RFA PA-L Views W contr IA;;ACTIVE;2.14;2.64 +37183-1;Views^W contrast IS;Find;Pt;Lower extremity>Ankle;Doc;RF;RAD;2;RF Ankle Arthrogram;RF Ankle Views W contr IS;;ACTIVE;2.14;2.64 +3718-4;Lithium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Lithium [Mass/mass] in Hair;Lithium Hair-mCnt;;ACTIVE;1.0;2.42 +37184-9;Views^W contrast IS;Find;Pt;Lower extremity.bilateral>Ankle;Doc;RF;RAD;2;RF Ankle - bilateral Arthrogram;RF Ankle-Bl Views W contr IS;;ACTIVE;2.14;2.64 +37185-6;Views^W contrast IS;Find;Pt;Lower extremity.left>Ankle;Doc;RF;RAD;2;RF Ankle - left Arthrogram;RF Ankle-L Views W contr IS;;ACTIVE;2.14;2.64 +37186-4;Views^W contrast IS;Find;Pt;Upper extremity>Elbow;Doc;RF;RAD;2;RF Elbow Arthrogram;RF Elbow Views W contr IS;;ACTIVE;2.14;2.64 +37187-2;Views^W contrast IS;Find;Pt;Upper extremity.bilateral>Elbow;Doc;RF;RAD;2;RF Elbow - bilateral Arthrogram;RF Elbow-Bl Views W contr IS;;ACTIVE;2.14;2.64 +37188-0;Views^W contrast IS;Find;Pt;Upper extremity.left>Elbow;Doc;RF;RAD;2;RF Elbow - left Arthrogram;RF Elbow-L Views W contr IS;;ACTIVE;2.14;2.64 +37189-8;Views^W contrast IS;Find;Pt;Pelvis>Sacroiliac joint.bilateral;Doc;RF;RAD;2;RF Sacroiliac joint - bilateral Arthrogram;RF SIJ-Bl Views W contr IS;;ACTIVE;2.14;2.64 +37190-6;Views^W contrast IS;Find;Pt;Pelvis>Sacroiliac joint.left;Doc;RF;RAD;2;RF Sacroiliac joint - left Arthrogram;RF SIJ-L Views W contr IS;;ACTIVE;2.14;2.64 +37191-4;Views^W contrast IS;Find;Pt;XXX>Joint;Doc;RF;RAD;2;RF Joint Arthrogram;RF Joint Views W contr IS;;ACTIVE;2.14;2.64 +3719-2;Lithium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lithium [Mass/volume] in Serum or Plasma;Lithium SerPl-mCnc;;ACTIVE;1.0;2.73 +37192-2;Views^W contrast intradisc;Find;Pt;Neck>Spine.cervical;Doc;RF;RAD;2;RF Cervical spine Views W contrast intradisc;RF C-spine Views W contr ID;;ACTIVE;2.14;2.64 +37193-0;Views^W contrast intradisc;Find;Pt;Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Lumbar spine Views W contrast intradisc;RF L-spine Views W contr ID;;ACTIVE;2.14;2.64 +37195-5;Views^W contrast IV;Find;Pt;Head>Cerebral vein;Doc;RF.angio;RAD;2;RFA Cerebral vein Views W contrast IV;RFA Cerebral v Views W contr IV;;ACTIVE;2.14;2.64 +37196-3;Views^W contrast IV;Find;Pt;Lower extremity.left>Lower extremity veins;Doc;RF.angio;RAD;2;RFA Lower extremity veins - left Views W contrast IV;RFA LE vv-L Views W contr IV;;ACTIVE;2.14;2.64 +37197-1;Views^W contrast IV;Find;Pt;Head+Neck>Jugular vein;Doc;RF.angio;RAD;2;Deprecated RFA Jugular vein W contrast IV;Deprecated RFA Jugular v W contr IV;;DEPRECATED;2.14;2.64 +37198-9;Views^W contrast PO;Find;Pt;Chest>Esophagus;Doc;XR;RAD;2;XR Esophagus Views W contrast PO;XR Esophagus Views W contr PO;;ACTIVE;2.14;2.64 +37199-7;Views^W contrast PO;Find;Pt;Chest;Doc;RF;RAD;2;RF Chest Views W contrast PO;RF Chest Views W contr PO;;ACTIVE;2.14;2.64 +37-2;Azithromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Azithromycin [Susceptibility] by Disk diffusion (KB);Azithromycin Islt KB;;ACTIVE;1.0;2.73 +3720-0;Lithium;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Lithium [Presence] in Serum or Plasma;Lithium SerPl Ql;;ACTIVE;1.0;2.73 +37200-3;Views^W contrast PO;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Views W contrast PO;XR Chest Views W contr PO;;ACTIVE;2.14;2.64 +37201-1;Views^W standing;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle Views W standing;XR Ankle Views W Stand;;ACTIVE;2.14;2.64 +37202-9;Views^W standing;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral Views W standing;XR Ankle-Bl Views W Stand;;ACTIVE;2.14;2.64 +37203-7;Views^W standing;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Views W standing;XR Ankle-L Views W Stand;;ACTIVE;2.14;2.64 +37204-5;Views^W standing;Find;Pt;Lower extremity;Doc;XR;RAD;2;XR Lower extremity Views W standing;XR LE Views W Stand;;ACTIVE;2.14;2.64 +37205-2;Views^W standing;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus Views W standing;XR Heel Views W Stand;;ACTIVE;2.14;2.64 +37206-0;Views^W standing;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Views W standing;XR Heel-L Views W Stand;;ACTIVE;2.14;2.64 +37207-8;View^W standing;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Single view W standing;XR Hip-L 1V W Stand;;ACTIVE;2.14;2.64 +37208-6;Views^W standing;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views W standing;XR L-spine Views W Stand;;ACTIVE;2.14;2.64 +37209-4;Views^W standing;Find;Pt;Lower extremity.left>Toes;Doc;XR;RAD;2;XR Toes - left Views W standing;XR Toes-L Views W Stand;;ACTIVE;2.14;2.64 +37210-2;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Abdomen;CT Guided Abd Cyst asp;;ACTIVE;2.14;2.64 +37211-0;Guidance for percutaneous biopsy;Find;Pt;XXX>Bone marrow;Doc;CT;RAD;2;CT Guidance for biopsy of Bone marrow;CT Guided Bone mar Bx;;ACTIVE;2.14;2.64 +37212-8;Guidance for percutaneous biopsy;Find;Pt;Pelvis>Epididymis;Doc;CT;RAD;2;CT Guidance for biopsy of Epididymis;CT Guided Epid Bx;;ACTIVE;2.14;2.64 +37213-6;Guidance for percutaneous biopsy;Find;Pt;Chest>Mediastinum;Doc;CT;RAD;2;CT Guidance for biopsy of Mediastinum;CT Guided Mediastinum Bx;;ACTIVE;2.14;2.64 +37214-4;Guidance for superficial biopsy;Find;Pt;XXX>Tissue;Doc;CT;RAD;2;CT Guidance for superficial biopsy of Tissue;CT Guided Tiss Super Bx;;ACTIVE;2.14;2.64 +37215-1;Multisection^W contrast IV;Find;Pt;Head>Brain & Head+Neck>Larynx;Doc;MR;RAD;2;MR Brain and Larynx W contrast IV;MR Brain+Larynx W contr IV;;ACTIVE;2.14;2.61 +37216-9;Multisection;Find;Pt;Aorta.endograft;Doc;CT;RAD;2;Deprecated Aorta.endograft CT;Deprecated Aorta.endograft CT;;DEPRECATED;2.14;2.58 +37217-7;Multisection;Find;Pt;Head>Brain stem+Nerves.cranial;Doc;MR;RAD;2;MR Brain stem and Cranial nerves;MR Brain stem+Cranial nerves;;ACTIVE;2.14;2.61 +3721-8;Lithium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lithium [Mass/volume] in Urine;Lithium Ur-mCnc;;ACTIVE;1.0;2.73 +37218-5;Multisection;Find;Pt;Head>Brain.temporal;Doc;MR;RAD;2;MR Brain.temporal;MR Brain.temporal;;ACTIVE;2.14;2.61 +37219-3;Multisection;Find;Pt;Abdomen>Biliary ducts;Doc;MR;RAD;2;MR Biliary ducts;MR BDs;;ACTIVE;2.14;2.61 +37220-1;Multisection;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;MR;RAD;2;MR Biliary ducts and Pancreatic duct;MR BD+PD;;ACTIVE;2.14;2.61 +37221-9;Multisection for fistula;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region for fistula;CT for fistula;;ACTIVE;2.14;2.64 +37222-7;Multisection;Find;Pt;Lower extremity>Ankle+Foot;Doc;MR;RAD;2;MR Ankle and Foot;MR Ankle+Ft;;ACTIVE;2.14;2.61 +37223-5;Multisection;Find;Pt;Neck>Parotid gland;Doc;CT;RAD;2;CT Parotid gland;CT Parotid gland;;ACTIVE;2.14;2.61 +37224-3;Multisection;Find;Pt;Neck>Parotid gland;Doc;MR;RAD;2;MR Parotid gland;MR Parotid gland;;ACTIVE;2.14;2.61 +37225-0;Multisection;Find;Pt;Chest>Sternoclavicular joint;Doc;CT;RAD;2;CT Sternoclavicular Joint;CT SC joint;;ACTIVE;2.14;2.61 +3722-6;Lithium renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Lithium renal clearance in 24 hour Urine and Serum or Plasma;Lithium Cl 24h Ur+SerPl-vRate;;ACTIVE;1.0;2.66 +37226-8;Multisection;Find;Pt;Head>Temporomandibular joint;Doc;CT;RAD;2;CT Temporomandibular joint;CT TMJ;;ACTIVE;2.14;2.61 +37227-6;Multisection;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;XR.tomography;RAD;2;XR tomography Temporomandibular joint - bilateral;XR tomo TMJ-Bl;;ACTIVE;2.14;2.61 +37228-4;Multisection;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;MR;RAD;2;MR Temporomandibular joint - bilateral;MR TMJ-Bl;;ACTIVE;2.14;2.61 +37229-2;Multisection;Find;Pt;Head>Temporomandibular joint.left;Doc;XR.tomography;RAD;2;XR tomography Temporomandibular joint - left;XR tomo TMJ-L;;ACTIVE;2.14;2.61 +372-3;Novobiocin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Novobiocin [Susceptibility] by Disk diffusion (KB);Novobiocin Islt KB;;ACTIVE;1.0;2.19 +37230-0;Multisection;Find;Pt;Head>Temporomandibular joint.left;Doc;MR;RAD;2;MR Temporomandibular joint - left;MR TMJ-L;;ACTIVE;2.14;2.61 +37231-8;Multisection;Find;Pt;Head>Temporomandibular joint.right;Doc;MR;RAD;2;MR Temporomandibular joint - right;MR TMJ-R;;ACTIVE;2.14;2.61 +37232-6;Multisection;Find;Pt;Abdomen+Pelvis>Spine.lumbosacral junction;Doc;CT;RAD;2;CT Spine lumbosacral junction;CT LSJ;;ACTIVE;2.14;2.61 +37233-4;Multisection;Find;Pt;Chest>Mediastinum;Doc;XR.tomography;RAD;2;XR tomography Mediastinum;XR tomo Mediastinum;;ACTIVE;2.14;2.61 +3723-4;Lithium^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lithium [Mass/volume] in Serum or Plasma --trough;Lithium Trough SerPl-mCnc;;ACTIVE;1.0;2.42 +37234-2;Multisection;Find;Pt;Chest>Mediastinum;Doc;MR;RAD;2;MR Mediastinum;MR Mediastinum;;ACTIVE;2.14;2.61 +37235-9;Multisection;Find;Pt;Head+Neck>Circle of Willis;Doc;MR.angio;RAD;2;MRA Circle of Willis;MRA Circle of Willis;;ACTIVE;2.14;2.61 +37236-7;Multisection;Find;Pt;Great vessel;Doc;MR;RAD;2;Deprecated Great vessel MR;Deprecated Great ves MR;;DEPRECATED;2.14;2.58 +37237-5;Multisection^W contrast intra sinus tract;Find;Pt;XXX>Sinus tract;Doc;CT;RAD;2;CT Sinus tract W contrast intra sinus tract;CT Sinus tr W contr intra ST;;ACTIVE;2.14;2.61 +37238-3;Multisection^W contrast IS;Find;Pt;Lower extremity>Lower extremity joint;Doc;CT;RAD;2;CT Lower Extremity Joint Arthrogram;CT LE joint W contr IS;;ACTIVE;2.14;2.65 +37239-1;Multisection^W contrast IV;Find;Pt;Head>Brain+Internal auditory canal;Doc;MR;RAD;2;MR Brain and Internal auditory canal W contrast IV;MR Brain+IAC W contr IV;;ACTIVE;2.14;2.61 +37240-9;Multisection^W contrast IV;Find;Pt;Neck>Parotid gland;Doc;CT;RAD;2;CT Parotid gland W contrast IV;CT Parotid gland W contr IV;;ACTIVE;2.14;2.61 +37241-7;Multisection^W contrast IV;Find;Pt;Neck>Parotid gland;Doc;MR;RAD;2;MR Parotid gland W contrast IV;MR Parotid gland W contr IV;;ACTIVE;2.14;2.61 +3724-2;LORazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Serum or Plasma;LORazepam SerPl-mCnc;;ACTIVE;1.0;2.73 +37242-5;Multisection^W contrast IV;Find;Pt;Chest>Sternoclavicular joint;Doc;CT;RAD;2;CT Sternoclavicular Joint W contrast IV;CT SC joint W contr IV;;ACTIVE;2.14;2.61 +37243-3;Multisection^W contrast IV;Find;Pt;Head>Temporomandibular joint;Doc;CT;RAD;2;CT Temporomandibular joint W contrast IV;CT TMJ W contr IV;;ACTIVE;2.14;2.61 +37244-1;Multisection^W contrast IV;Find;Pt;Head>Temporomandibular joint;Doc;MR;RAD;2;MR Temporomandibular joint W contrast IV;MR TMJ W contr IV;;ACTIVE;2.14;2.61 +37245-8;Multisection^W contrast IV;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;MR;RAD;2;MR Temporomandibular joint - bilateral W contrast IV;MR TMJ-Bl W contr IV;;ACTIVE;2.14;2.61 +37246-6;Multisection^W contrast IV;Find;Pt;Head>Temporomandibular joint.left;Doc;CT;RAD;2;CT Temporomandibular joint - left W contrast IV;CT TMJ-L W contr IV;;ACTIVE;2.14;2.61 +37247-4;Multisection^W contrast IV;Find;Pt;Head>Temporomandibular joint.left;Doc;MR;RAD;2;MR Temporomandibular joint - left W contrast IV;MR TMJ-L W contr IV;;ACTIVE;2.14;2.61 +37248-2;Multisection^W contrast IV;Find;Pt;Head>Temporomandibular joint.right;Doc;CT;RAD;2;CT Temporomandibular joint - right W contrast IV;CT TMJ-R W contr IV;;ACTIVE;2.14;2.61 +37249-0;Multisection^W contrast IV;Find;Pt;Head>Temporomandibular joint.right;Doc;MR;RAD;2;MR Temporomandibular joint - right W contrast IV;MR TMJ-R W contr IV;;ACTIVE;2.14;2.61 +37253-2;Multisection^W contrast IV;Find;Pt;XXX>Soft tissue;Doc;MR;RAD;2;MR Soft tissue W contrast IV;MR Soft tiss W contr IV;;ACTIVE;2.14;2.61 +37254-0;Multisection^W contrast IV;Find;Pt;Head+Neck>Circle of Willis;Doc;MR.angio;RAD;2;MRA Circle of Willis W contrast IV;MRA Circle of Willis W contr IV;;ACTIVE;2.14;2.61 +37256-5;Views 3;Find;Pt;Abdomen>Spine.lumbar & Pelvis;Doc;XR;RAD;2;XR Pelvis and Spine Lumbar 3 Views;XR Pelvis+L-spine 3V;;ACTIVE;2.14;2.61 +37257-3;Views 3;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Spine Lumbar and Sacroiliac Joint 3 Views;XR L-spine+SIJ 3V;;ACTIVE;2.14;2.61 +3725-9;LORazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Urine;LORazepam Ur-mCnc;;ACTIVE;1.0;2.73 +37259-9;Views 3;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum 3 Views;XR L-spine+Sacrum 3V;;ACTIVE;2.14;2.61 +37260-7;Views 3;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum and Coccyx 3 Views;XR L-spine+Sacrum+Coccyx 3V;;ACTIVE;2.14;2.61 +37261-5;Views 3;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum+Sacroiliac joint+Coccyx;Doc;XR;RAD;2;XR Lumbar spine and Sacrum and SI joint and Coccyx 3 Views;XR L-spine+Sacrum+SIJ+Coccyx 3V;;ACTIVE;2.14;2.61 +37265-6;Multisection^WO & W contrast IV;Find;Pt;Neck>Parotid gland;Doc;MR;RAD;2;MR Parotid gland WO and W contrast IV;MR Parotid gland WO+W contr IV;;ACTIVE;2.14;2.61 +37266-4;Multisection^WO & W contrast IV;Find;Pt;Chest>Sternoclavicular joint;Doc;CT;RAD;2;CT Sternoclavicular Joint WO and W contrast IV;CT SC joint WO+W contr IV;;ACTIVE;2.14;2.61 +3726-7;Lormetazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lormetazepam [Mass/volume] in Urine;Lormetazepam Ur-mCnc;;ACTIVE;1.0;2.42 +37267-2;Multisection^WO & W contrast IV;Find;Pt;Head>Temporomandibular joint;Doc;CT;RAD;2;CT Temporomandibular joint WO and W contrast IV;CT TMJ WO+W contr IV;;ACTIVE;2.14;2.61 +37268-0;Multisection^WO & W contrast IV;Find;Pt;Head>Temporomandibular joint;Doc;MR;RAD;2;MR Temporomandibular joint WO and W contrast IV;MR TMJ WO+W contr IV;;ACTIVE;2.14;2.61 +37269-8;Multisection^WO & W contrast IV;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;MR;RAD;2;MR Temporomandibular joint - bilateral WO and W contrast IV;MR TMJ-Bl WO+W contr IV;;ACTIVE;2.14;2.61 +37270-6;Multisection^WO & W contrast IV;Find;Pt;Head>Temporomandibular joint.left;Doc;MR;RAD;2;MR Temporomandibular joint - left WO and W contrast IV;MR TMJ-L WO+W contr IV;;ACTIVE;2.14;2.61 +37271-4;Multisection^WO & W contrast IV;Find;Pt;Head>Temporomandibular joint.right;Doc;MR;RAD;2;MR Temporomandibular joint - right WO and W contrast IV;MR TMJ-R WO+W contr IV;;ACTIVE;2.14;2.61 +37272-2;Multisection^WO & W contrast IV;Find;Pt;Chest>Mediastinum;Doc;MR;RAD;2;MR Mediastinum WO and W contrast IV;MR Mediastinum WO+W contr IV;;ACTIVE;2.14;2.61 +3727-5;Loxapine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Loxapine [Presence] in Serum or Plasma;Loxapine SerPl Ql;;ACTIVE;1.0;2.73 +37277-1;Multisection^WO & W contrast IV;Find;Pt;XXX>Spinal veins;Doc;MR.angio;RAD;2;MRA Spinal veins WO and W contrast IV;MRA Spinal vv WO+W contr IV;;ACTIVE;2.14;2.61 +37278-9;Multisection^WO contrast;Find;Pt;Head>Brain+Internal auditory canal;Doc;MR;RAD;2;MR Brain and Internal auditory canal WO contrast;MR Brain+IAC WO contr;;ACTIVE;2.14;2.61 +37279-7;Multisection^WO contrast;Find;Pt;Head>Brain & Head+Neck>Larynx;Doc;MR;RAD;2;MR Brain and Larynx WO contrast;MR Brain+Larynx WO contr;;ACTIVE;2.14;2.61 +37280-5;Multisection^WO contrast;Find;Pt;Neck>Parotid gland;Doc;CT;RAD;2;CT Parotid gland WO contrast;CT Parotid gland WO contr;;ACTIVE;2.14;2.61 +37281-3;Multisection^WO contrast;Find;Pt;Neck>Parotid gland;Doc;MR;RAD;2;MR Parotid gland WO contrast;MR Parotid gland WO contr;;ACTIVE;2.14;2.61 +37282-1;Multisection^WO contrast;Find;Pt;Chest>Sternoclavicular joint;Doc;CT;RAD;2;CT Sternoclavicular Joint WO contrast;CT SC joint WO contr;;ACTIVE;2.14;2.61 +3728-3;Loxapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Loxapine [Mass/volume] in Serum or Plasma;Loxapine SerPl-mCnc;;ACTIVE;1.0;2.73 +37283-9;Multisection^WO contrast;Find;Pt;Head>Temporomandibular joint;Doc;CT;RAD;2;CT Temporomandibular joint WO contrast;CT TMJ WO contr;;ACTIVE;2.14;2.61 +37284-7;Multisection^WO contrast;Find;Pt;Head>Temporomandibular joint;Doc;MR;RAD;2;MR Temporomandibular joint WO contrast;MR TMJ WO contr;;ACTIVE;2.14;2.61 +37285-4;Multisection^WO contrast;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;MR;RAD;2;MR Temporomandibular joint - bilateral WO contrast;MR TMJ-Bl WO contr;;ACTIVE;2.14;2.61 +37286-2;Multisection^WO contrast;Find;Pt;Head>Temporomandibular joint.left;Doc;MR;RAD;2;MR Temporomandibular joint - left WO contrast;MR TMJ-L WO contr;;ACTIVE;2.14;2.61 +37287-0;Multisection^WO contrast;Find;Pt;Head>Temporomandibular joint.right;Doc;MR;RAD;2;MR Temporomandibular joint - right WO contrast;MR TMJ-R WO contr;;ACTIVE;2.14;2.61 +37288-8;Multisection^WO contrast;Find;Pt;Abdomen+Pelvis>Spine.lumbosacral junction;Doc;CT;RAD;2;CT Spine lumbosacral junction WO contrast;CT LSJ WO contr;;ACTIVE;2.14;2.61 +3729-1;Loxapine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Loxapine [Presence] in Urine;Loxapine Ur Ql;;ACTIVE;1.0;2.73 +37293-8;Multisection^WO contrast;Find;Pt;XXX>Soft tissue;Doc;MR;RAD;2;MR Soft tissue WO contrast;MR Soft tiss WO contr;;ACTIVE;2.14;2.61 +37294-6;Multisection & 3D reconstruction;Find;Pt;Head;Doc;CT;RAD;2;Deprecated Head CT and 3D reconstruction;Deprecated Head CT +3DR;;DEPRECATED;2.14;2.58 +37295-3;Multisection anteversion measurement;Find;Pt;Femur+Hip;Doc;CT;RAD;2;Deprecated Femur and Hip CT anteversion measurement;Deprecated Femur+Hip CT Anteversion Meas;;DEPRECATED;2.14;2.58 +37297-9;View for fetal age;Find;Pt;Abdomen+^Fetus;Doc;XR;RAD;2;XR Abdomen and Fetal Single view for fetal age;XR Abdomen+ Fet 1V for FTA;;ACTIVE;2.14;2.64 +37298-7;View Serendipity;Find;Pt;Chest>Sternoclavicular joint.bilateral;Doc;XR;RAD;2;XR Sternoclavicular joint - bilateral Serendipity;XR SC joint-Bl Serendipity;;ACTIVE;2.14;2.61 +37299-5;View Serendipity;Find;Pt;Chest>Sternoclavicular joint.left;Doc;XR;RAD;2;XR Sternoclavicular joint - left Serendipity;XR SC joint-L Serendipity;;ACTIVE;2.14;2.61 +37300-1;View true AP;Find;Pt;Abdomen+Pelvis>Spine.lumbosacral junction;Doc;XR;RAD;2;XR Spine lumbosacral junction True AP;XR LSJ True AP;;ACTIVE;2.14;2.61 +37302-7;Views scaphoid;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Scaphoid Views;XR Wrist-L Views scaphoid;;ACTIVE;2.14;2.64 +37303-5;Views;Find;Pt;Head>Facial bones+Zygomatic arch;Doc;XR;RAD;2;XR Facial bones and Zygomatic arch Views;XR Face+Zygomatic Arch Views;;ACTIVE;2.14;2.64 +37304-3;Views scaphoid;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Scaphoid Views;XR Wrist-Bl Views scaphoid;;ACTIVE;2.14;2.64 +3730-9;Lysergate diethylamide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Lysergate diethylamide [Presence] in Serum or Plasma;LSD SerPl Ql;;ACTIVE;1.0;2.73 +373-1;Novobiocin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Novobiocin [Susceptibility] by Serum bactericidal titer;Novobiocin Titr SBT;;ACTIVE;1.0;2.32 +3731-7;Lysergate diethylamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lysergate diethylamide [Mass/volume] in Serum or Plasma;LSD SerPl-mCnc;;ACTIVE;1.0;2.73 +37319-1;Views;Find;Pt;Upper extremity>Humerus.bicipital groove;Doc;XR;RAD;2;XR Humerus bicipital groove Views;XR Humerus bicipital groove Views;;ACTIVE;2.14;2.64 +37320-9;Views;Find;Pt;Upper extremity.left>Humerus.bicipital groove;Doc;XR;RAD;2;XR Humerus bicipital groove - left Views;XR Humerus bicipital groove-L Views;;ACTIVE;2.14;2.64 +37321-7;Views;Find;Pt;Upper extremity.bilateral>Humerus.bicipital groove;Doc;XR;RAD;2;XR Humerus bicipital groove - bilateral Views;XR Humerus bicipital groove-Bl Views;;ACTIVE;2.14;2.64 +37323-3;Views;Find;Pt;Chest>Sternoclavicular joint.bilateral;Doc;XR;RAD;2;XR Sternoclavicular joint - bilateral Views;XR SC joint-Bl Views;;ACTIVE;2.14;2.64 +37324-1;Views;Find;Pt;Chest>Sternoclavicular joint.left;Doc;XR;RAD;2;XR Sternoclavicular joint - left Views;XR SC joint-L Views;;ACTIVE;2.14;2.64 +3732-5;Lysergate diethylamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Lysergate diethylamide [Presence] in Urine;LSD Ur Ql;;ACTIVE;1.0;2.73 +37325-8;Views;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;XR;RAD;2;XR Temporomandibular joint - bilateral Views;XR TMJ-Bl Views;;ACTIVE;2.14;2.64 +37332-4;Views;Find;Pt;Upper extremity.left>Olecranon;Doc;XR;RAD;2;XR Olecranon - left Views;XR Olecranon-L Views;;ACTIVE;2.14;2.64 +3733-3;Lysergate diethylamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Lysergate diethylamide [Mass/volume] in Urine;Deprecated LSD Ur-mCnc;;DEPRECATED;1.0;2.36 +37338-1;Views;Find;Pt;Head>Skull+Facial bones+Mandible;Doc;XR;RAD;2;XR Skull and Facial bones and Mandible Views;XR Skull+Face+Mandible Views;;ACTIVE;2.14;2.64 +37340-7;Views;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum Views;XR L-spine+Sacrum Views;;ACTIVE;2.14;2.64 +3734-1;Maprotiline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Maprotiline [Presence] in Serum or Plasma;Maprotiline SerPl Ql;;ACTIVE;1.0;2.56 +37341-5;Views;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum and Coccyx Views;XR L-spine+Sacrum+Coccyx Views;;ACTIVE;2.14;2.64 +37342-3;Views;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum+Sacroiliac joint+Coccyx;Doc;XR;RAD;2;XR Lumbar spine and Sacrum and SI joint and Coccyx Views;XR L-spine+Sacrum+SIJ+Coccyx Views;;ACTIVE;2.14;2.64 +37348-0;Views 2;Find;Pt;Lower extremity.bilateral>Toes;Doc;XR;RAD;2;XR Toes - bilateral 2 Views;XR Toes-Bl 2V;;ACTIVE;2.14;2.61 +37350-6;Views 5;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;XR;RAD;2;XR Temporomandibular joint - bilateral 5 Views;XR TMJ-Bl 5V;;ACTIVE;2.14;2.61 +37351-4;Views 5;Find;Pt;Abdomen>Spine.lumbar & Pelvis;Doc;XR;RAD;2;XR Pelvis and Spine Lumbar 5 Views;XR Pelvis+L-spine 5V;;ACTIVE;2.14;2.61 +37353-0;Views 5;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Spine Lumbar and Sacroiliac Joint 5 Views;XR L-spine+SIJ 5V;;ACTIVE;2.14;2.61 +37355-5;Views 5;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum 5 Views;XR L-spine+Sacrum 5V;;ACTIVE;2.14;2.61 +37356-3;Views 5;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum and Coccyx 5 Views;XR L-spine+Sacrum+Coccyx 5V;;ACTIVE;2.14;2.61 +37357-1;Views 5;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum+Sacroiliac joint+Coccyx;Doc;XR;RAD;2;XR Lumbar spine and Sacrum and SI joint and Coccyx 5 Views;XR L-spine+Sacrum+SIJ+Coccyx 5V;;ACTIVE;2.14;2.61 +3735-8;Maprotiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Maprotiline [Mass/volume] in Serum or Plasma;Maprotiline SerPl-mCnc;;ACTIVE;1.0;2.73 +37361-3;Views AP + lateral;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;XR;RAD;2;XR Cervical and thoracic spine AP and Lateral;XR C+T-spine AP+Lat;;ACTIVE;2.14;2.61 +37362-1;Views bone age;Find;Pt;XXX>Bones;Doc;XR;RAD;2;XR Bones Bone age Views;XR Bones Views bone Age;;ACTIVE;2.14;2.64 +37363-9;Views runoff^W contrast IA;Find;Pt;Aorta+Femoral artery;Nar;XR.fluor.angio;RAD;2;Deprecated Aorta and Femoral artery Narrative Fluoroscopic angiogram runoff W contrast IA;Deprecated;;DEPRECATED;2.14;2.42 +37364-7;Views runoff^W contrast IA;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Lower extremity.left>Femoral artery;Doc;RF.angio;RAD;2;RFA Aorta and Femoral artery - left Runoff W contrast IA;RFA Aorta+Fem a-L runoff W contr IA;;ACTIVE;2.14;2.61 +37365-4;Views survey for metastasis;Find;Pt;XXX>Bones;Doc;XR;RAD;2;XR Bones Survey Views for metastasis;XR Bones Survey for metastasis;;ACTIVE;2.14;2.64 +3736-6;Maprotiline;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Maprotiline [Mass/volume] in Serum or Plasma;Deprecated Maprotiline Ser-mCnc;;DEPRECATED;1.0;2.36 +37366-2;Views^W contrast IA;Find;Pt;Aorta+Abdominal arteries;Doc;RF.angio;RAD;2;Deprecated RFA Abdominal Aorta and Arteries W contrast IA;Deprecated Aorta+Abd aa RFA W contr IA;;DEPRECATED;2.14;2.61 +3737-4;Maprotiline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Maprotiline [Presence] in Urine;Maprotiline Ur Ql;;ACTIVE;1.0;2.73 +37379-5;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Upper extremity>Upper extremity artery;Doc;RF.angio;RAD;2;RFA Aortic arch and Upper Extremity artery Views W contrast IA;RFA Ac arch+UE a Views W contr IA;;ACTIVE;2.14;2.64 +37380-3;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Upper extremity>Brachial artery;Doc;RF.angio;RAD;2;RFA Aortic arch and Brachial artery Views W contrast IA;RFA Ac arch+Brach a Views W contr IA;;ACTIVE;2.14;2.64 +37381-1;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery;Doc;RF.angio;RAD;2;RFA Carotid artery Views W contrast IA;RFA Carotid a Views W contr IA;;ACTIVE;2.14;2.64 +3738-2;Maprotiline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Maprotiline [Mass/volume] in Urine;Maprotiline Ur-mCnc;;ACTIVE;1.0;2.73 +37382-9;Views^W contrast IA;Find;Pt;Chest>Aortic arch+Subclavian artery;Doc;RF.angio;RAD;2;RFA Aortic arch and Subclavian artery Views W contrast IA;RFA Ao arch+Subcl a Views W contr IA;;DISCOURAGED;2.14;2.64 +37383-7;Views^W contrast IA;Find;Pt;Chest>Aortic arch+Subclavian artery.left;Doc;RF.angio;RAD;2;RFA Aortic arch and Subclavian artery - left Views W contrast IA;RFA Ao arch+Subcl a-L Views W contr IA;;DISCOURAGED;2.14;2.64 +37384-5;Views^W contrast IA;Find;Pt;Head+Neck>Vertebral artery;Doc;RF.angio;RAD;2;RFA Vertebral artery Views W contrast IA;RFA VA Views W contr IA;;ACTIVE;2.14;2.64 +37385-2;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Head+Neck>Vertebral artery.left;Doc;RF.angio;RAD;2;RFA Aortic arch and Vertebral artery - left Views W contrast IA;RFA Ao arch+Vert a-L Views W contr IA;;DISCOURAGED;2.14;2.64 +37386-0;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Head+Neck>Vertebral artery.right;Doc;RF.angio;RAD;2;RFA Aortic arch and Vertebral artery - right Views W contrast IA;RFA Ao arch+Vert a-R Views W contr IA;;DISCOURAGED;2.14;2.64 +37387-8;Views^W contrast IA;Find;Pt;Abdomen>Adrenal artery.left;Doc;RF.angio;RAD;2;RFA Adrenal artery - left Views W contrast IA;RFA Adrenal a-L Views W contr IA;;ACTIVE;2.14;2.64 +37388-6;Views^W contrast IA;Find;Pt;Upper extremity.bilateral>Brachial artery;Doc;RF.angio;RAD;2;RFA Brachial artery - bilateral Views W contrast IA;RFA Brachial a-Bl Views W contr IA;;ACTIVE;2.14;2.64 +37389-4;Views^W contrast IA;Find;Pt;Chest>Bronchial artery;Doc;RF.angio;RAD;2;RFA Bronchial artery Views W contrast IA;RFA Bronchial a Views W contr IA;;ACTIVE;2.14;2.64 +3739-0;Medazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Medazepam [Mass/volume] in Blood;Medazepam Bld-mCnc;;ACTIVE;1.0;2.42 +37390-2;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery.external.left;Doc;RF.angio;RAD;2;RFA Carotid artery.external - left Views W contrast IA;RFA Carot a.ext-L Views W contr IA;;ACTIVE;2.14;2.64 +37391-0;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries+Vertebral artery;Doc;RF.angio;RAD;2;RFA Carotid arteries and Vertebral artery Views W contrast IA;RFA Carot aa+VA Views W contr IA;;ACTIVE;2.14;2.64 +37392-8;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries.bilateral+Vertebral artery.bilateral;Doc;RF.angio;RAD;2;RFA Carotid arteries and Vertebral artery - bilateral Views W contrast IA;RFA Carot aa+VA-Bl Views W contr IA;;ACTIVE;2.14;2.64 +37393-6;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries.left+Vertebral artery.left;Doc;RF.angio;RAD;2;RFA Carotid arteries and Vertebral artery - left Views W contrast IA;RFA Carot aa+VA-L Views W contr IA;;ACTIVE;2.14;2.64 +37394-4;Views^W contrast IA;Find;Pt;Abdomen>Celiac artery+Superior mesenteric artery+Inferior mesenteric artery;Doc;RF.angio;RAD;2;RFA Celiac artery and Superior mesenteric artery and Inferior mesenteric artery Views W contrast IA;RFA Celiac a+IM-a+SM a Views W contr IA;;ACTIVE;2.14;2.64 +37395-1;Views^W contrast IA;Find;Pt;Extremity.left>Extremity arteries;Doc;RF.angio;RAD;2;RFA Extremity arteries - left Views W contrast IA;RFA Extr aa-L Views W contr IA;;ACTIVE;2.14;2.64 +37396-9;Views^W contrast IA;Find;Pt;Upper extremity.bilateral>Upper extremity arteries;Doc;RF.angio;RAD;2;RFA Upper extremity arteries - bilateral Views W contrast IA;RFA UE aa-Bl Views W contr IA;;ACTIVE;2.14;2.64 +37397-7;Views^W contrast IA;Find;Pt;Abdomen>Gastric artery;Doc;RF.angio;RAD;2;RFA Gastric artery Views W contrast IA;RFA Gastric a Views W contr IA;;ACTIVE;2.14;2.64 +37398-5;Views^W contrast IA;Find;Pt;Abdomen>Gastric artery.left;Doc;RF.angio;RAD;2;RFA Gastric artery - left Views W contrast IA;RFA Gastric a-L Views W contr IA;;ACTIVE;2.14;2.64 +37399-3;Views^W contrast IA;Find;Pt;Abdomen>Gastroduodenal artery;Doc;RF.angio;RAD;2;RFA Gastroduodenal artery Views W contrast IA;RFA Gastroduodenal a Views W contr IA;;ACTIVE;2.14;2.64 +37401-7;Views^W contrast IA;Find;Pt;Head>Internal maxillary artery;Doc;RF.angio;RAD;2;RFA Internal maxillary artery Views W contrast IA;RFA Int max a Views W contr IA;;ACTIVE;2.14;2.64 +37402-5;Views^W contrast IA;Find;Pt;Abdomen>Superior mesenteric artery+Inferior mesenteric artery;Doc;RF.angio;RAD;2;RFA Superior mesenteric artery and Inferior mesenteric artery Views W contrast IA;RFA SM a+IM a Views W contr IA;;ACTIVE;2.14;2.64 +37403-3;Views^W contrast IA;Find;Pt;Abdomen>Celiac artery+Gastric artery.left+Superior mesenteric artery;Doc;RF.angio;RAD;2;RFA Celiac artery and Gastric artery - left and Superior mesenteric artery Views W contrast IA;RFA Cel a+Gastr a-L+SM a Vs W contr IA;;ACTIVE;2.14;2.64 +37404-1;Views^W contrast IA;Find;Pt;Pelvis>Internal pudendal artery;Doc;RF.angio;RAD;2;RFA Internal pudendal artery Views W contrast IA;RFA IPA Views W contr IA;;ACTIVE;2.14;2.64 +37405-8;Views^W contrast IA;Find;Pt;Chest>Subclavian artery.bilateral;Doc;RF.angio;RAD;2;RFA Subclavian artery - bilateral Views W contrast IA;RFA Subclavian a-Bl Views W contr IA;;ACTIVE;2.14;2.64 +37406-6;Views^W contrast IA;Find;Pt;Chest>Subclavian artery.left;Doc;RF.angio;RAD;2;RFA Subclavian artery - left Views W contrast IA;RFA Subclavian a-L Views W contr IA;;ACTIVE;2.14;2.64 +37407-4;Views^W contrast IA;Find;Pt;Head+Neck>Vertebral artery.bilateral;Doc;RF.angio;RAD;2;RFA Vertebral artery - bilateral Views W contrast IA;RFA VA-Bl Views W contr IA;;ACTIVE;2.14;2.64 +3740-8;Medazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Medazepam [Mass/volume] in Urine;Medazepam Ur-mCnc;;ACTIVE;1.0;2.42 +37409-0;Views^W contrast IS;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;RF;RAD;2;RF Temporomandibular joint - bilateral Arthrogram;RF TMJ-Bl Views W contr IS;;ACTIVE;2.14;2.64 +37410-8;Views^W contrast IS;Find;Pt;Head>Temporomandibular joint.left;Doc;RF;RAD;2;RF Temporomandibular joint - left Arthrogram;RF TMJ-L Views W contr IS;;ACTIVE;2.14;2.64 +37411-6;Views^W contrast IV;Find;Pt;Chest+Abdomen>Azygos vein;Doc;RF.angio;RAD;2;RFA Azygos vein Views W contrast IV;RFA Azygos v Views W contr IV;;ACTIVE;2.14;2.64 +37412-4;Views^W contrast IV;Find;Pt;Extremity.bilateral>Extremity veins;Doc;RF.angio;RAD;2;RFA Extremity veins - bilateral Views W contrast IV;RFA Extr vv-Bl Views W contr IV;;ACTIVE;2.14;2.64 +37413-2;Views^W contrast IV;Find;Pt;Extremity.left>Extremity veins;Doc;RF.angio;RAD;2;RFA Extremity veins - left Views W contrast IV;RFA Extr vv-L Views W contr IV;;ACTIVE;2.14;2.64 +37414-0;Views^W contrast IV;Find;Pt;Lower extremity.bilateral>Lower extremity veins;Doc;RF.angio;RAD;2;RFA Lower extremity veins - bilateral Views W contrast IV;RFA LE vv-Bl Views W contr IV;;ACTIVE;2.14;2.64 +37415-7;Views^W contrast IV;Find;Pt;Upper extremity.bilateral>Upper extremity veins;Doc;RF.angio;RAD;2;RFA Upper extremity veins - bilateral Views W contrast IV;RFA UE vv-Bl Views W contr IV;;ACTIVE;2.14;2.64 +3741-6;Mefenorex;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mefenorex [Presence] in Urine;Mefenorex Ur Ql;;ACTIVE;1.0;2.56 +37416-5;Views^W contrast IV;Find;Pt;Lower extremity>Femoral vein;Doc;RF.angio;RAD;2;RFA Femoral vein Views W contrast IV;RFA Fem v Views W contr IV;;ACTIVE;2.14;2.64 +37419-9;Views^W contrast IV;Find;Pt;XXX>Intraosseous veins;Doc;RF.angio;RAD;2;RFA Intraosseous veins Views W contrast IV;RFA Intraosseous vv Views W contr IV;;ACTIVE;2.14;2.64 +37420-7;Views^W contrast IV;Find;Pt;Head+Neck>Jugular vein.left;Doc;RF.angio;RAD;2;Deprecated RFA Jugular vein - left W contrast IV;Deprecated RFA Jugular v-L W contr IV;;DEPRECATED;2.14;2.64 +37421-5;Views^W contrast IV;Find;Pt;Abdomen>Inferior mesenteric vein;Doc;RF.angio;RAD;2;RFA Inferior mesenteric vein Views W contrast IV;RFA IM v Views W contr IV;;ACTIVE;2.14;2.64 +37422-3;Views^W contrast IV;Find;Pt;Head>Orbit veins.left;Doc;RF.angio;RAD;2;RFA Orbit veins - left Views W contrast IV;RFA Orbit vv-L Views W contr IV;;ACTIVE;2.14;2.64 +37423-1;Views^W contrast IV;Find;Pt;Abdomen>Renal vein.left;Doc;RF.angio;RAD;2;RFA Renal vein - left Views W contrast IV;RFA Renal v-L Views W contr IV;;ACTIVE;2.14;2.64 +3742-4;Mefenorex;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mefenorex [Mass/volume] in Urine;Mefenorex Ur-mCnc;;ACTIVE;1.0;2.34 +37424-9;Perchlorate;MCnc;Pt;XXX;Qn;HPLC;DRUG/TOX;1;Perchlorate [Mass/volume] in Specimen by HPLC;Perchlorate Spec HPLC-mCnc;;ACTIVE;2.13;2.70 +37425-6;Prion protein.abnormal;PrThr;Pt;Brain;Ord;IA;MICRO;1;Abnormal Prion Protein [Presence] in Brain by Immunoassay;Abn Prion Prot Brain Ql IA;;ACTIVE;2.13;2.56 +37426-4;Guidance for angioplasty^W contrast IV;Find;Pt;Lower extremity>Lower extremity vein;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Lower extremity vein-- W contrast IV;RFA Guided LE v Angio--W contr IV;;ACTIVE;2.14;2.64 +37427-2;Guidance for injection;Find;Pt;XXX>Spine;Doc;RF;RAD;2;RF Guidance for injection of Spine;RF Guided Spine Inj;;DISCOURAGED;2.14;2.64 +37428-0;Multisection;Find;Pt;Upper extremity>Wrist;Doc;CT;RAD;2;CT Wrist;CT Wrist;;ACTIVE;2.14;2.73 +37429-8;Multisection;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR.tomography;RAD;2;XR tomography Wrist - bilateral;XR tomo Wrist-Bl;;ACTIVE;2.14;2.61 +37430-6;Multisection;Find;Pt;Upper extremity.bilateral>Wrist;Doc;CT;RAD;2;CT Wrist - bilateral;CT Wrist-Bl;;ACTIVE;2.14;2.61 +37431-4;Multisection;Find;Pt;Upper extremity.left>Wrist;Doc;CT;RAD;2;CT Wrist - left;CT Wrist-L;;ACTIVE;2.14;2.61 +3743-2;Mefenorex;MRat;24H;Urine;Qn;;DRUG/TOX;1;Mefenorex [Mass/time] in 24 hour Urine;Mefenorex 24h Ur-mRate;;ACTIVE;1.0;2.19 +37432-2;Multisection;Find;Pt;Upper extremity.left>Wrist;Doc;XR.tomography;RAD;2;XR tomography Wrist - left;XR tomo Wrist-L;;ACTIVE;2.14;2.61 +37433-0;Multisection;Find;Pt;Upper extremity.right>Wrist;Doc;CT;RAD;2;CT Wrist - right;CT Wrist-R;;ACTIVE;2.14;2.61 +37434-8;Multisection cine for function;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart cine for function;MR Hrt Cine for Function;;ACTIVE;2.14;2.61 +37435-5;Multisection cine;Find;Pt;Head>Temporomandibular joint;Doc;MR;RAD;2;MR Temporomandibular joint cine;MR TMJ Cine;;ACTIVE;2.14;2.61 +37436-3;Multisection diffusion weighted;Find;Pt;Head>Brain;Doc;MR;RAD;2;Deprecated Brain MR diffusion weighted;Deprecated Brain MR Diff Wt;;DEPRECATED;2.14;2.58 +37437-1;Multisection dynamic^W contrast IV;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast dynamic W contrast IV;MR Brst Dyn W contr IV;;ACTIVE;2.14;2.61 +37438-9;Multisection dynamic^W contrast IV;Find;Pt;Head>Pituitary+Sella turcica;Doc;CT;RAD;2;Deprecated Pituitary and Sella turcica CT dynamic W contrast IV;Deprecated Pituitary+ST CT Dyn W contr I;;DEPRECATED;2.14;2.58 +37439-7;Multisection;Find;Pt;Chest>Lung parenchyma;Doc;CT;RAD;2;CT Lung parenchyma;CT Lung parenchyma;;ACTIVE;2.14;2.73 +3744-0;Meperidine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Meperidine [Presence] in Serum or Plasma;Meperidine SerPl Ql;;ACTIVE;1.0;2.73 +37440-5;Multisection^W contrast IV;Find;Pt;Chest>Lung parenchyma;Doc;CT;RAD;2;CT Lung parenchyma W contrast IV;CT Lung parenchyma W contr IV;;ACTIVE;2.14;2.61 +37441-3;Multisection^WO contrast;Find;Pt;Chest>Lung parenchyma;Doc;CT;RAD;2;CT Lung parenchyma WO contrast;CT Lung parenchyma WO contr;;ACTIVE;2.14;2.61 +37442-1;Multisection;Find;Pt;Head>Brain;Doc;MR.spectroscopy;RAD;2;MR spectroscopy Brain;MRS Brain;;ACTIVE;2.14;2.61 +37443-9;Multisection;Find;Pt;XXX;Doc;MR.spectroscopy;RAD;2;MR spectroscopy Unspecified body region;MRS Unsp region;;ACTIVE;2.14;2.64 +37444-7;Multisection^W contrast IS;Find;Pt;Upper extremity>Wrist;Doc;MR;RAD;2;MR Wrist Arthrogram;MR Wrist W contr IS;;ACTIVE;2.14;2.61 +37445-4;Multisection^W contrast IS;Find;Pt;Upper extremity.left>Wrist;Doc;MR;RAD;2;MR Wrist - left Arthrogram;MR Wrist-L W contr IS;;ACTIVE;2.14;2.61 +37446-2;Multisection^W contrast IS;Find;Pt;Upper extremity.right>Wrist;Doc;MR;RAD;2;MR Wrist - right Arthrogram;MR Wrist-R W contr IS;;ACTIVE;2.14;2.61 +37447-0;Multisection^W contrast IV;Find;Pt;Upper extremity>Wrist;Doc;CT;RAD;2;CT Wrist W contrast IV;CT Wrist W contr IV;;ACTIVE;2.14;2.61 +37448-8;Multisection^W contrast IV;Find;Pt;Upper extremity>Wrist;Doc;MR;RAD;2;MR Wrist W contrast IV;MR Wrist W contr IV;;ACTIVE;2.14;2.61 +37449-6;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Wrist;Doc;MR;RAD;2;MR Wrist - bilateral W contrast IV;MR Wrist-Bl W contr IV;;ACTIVE;2.14;2.61 +37450-4;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Wrist;Doc;CT;RAD;2;CT Wrist - left W contrast IV;CT Wrist-L W contr IV;;ACTIVE;2.14;2.61 +37451-2;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Wrist;Doc;MR;RAD;2;MR Wrist - left W contrast IV;MR Wrist-L W contr IV;;ACTIVE;2.14;2.61 +37452-0;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Wrist;Doc;CT;RAD;2;CT Wrist - right W contrast IV;CT Wrist-R W contr IV;;ACTIVE;2.14;2.61 +37453-8;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Wrist;Doc;MR;RAD;2;MR Wrist - right W contrast IV;MR Wrist-R W contr IV;;ACTIVE;2.14;2.61 +37454-6;Views 3;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral 3 Views;XR Wrist-Bl 3V;;ACTIVE;2.14;2.61 +37455-3;Views 3;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 3 Views;XR Wrist-L 3V;;ACTIVE;2.14;2.73 +3745-7;Meperidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meperidine [Mass/volume] in Serum or Plasma;Meperidine SerPl-mCnc;;ACTIVE;1.0;2.73 +37457-9;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Wrist;Doc;CT;RAD;2;CT Wrist WO and W contrast IV;CT Wrist WO+W contr IV;;ACTIVE;2.14;2.61 +37458-7;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Wrist;Doc;CT;RAD;2;CT Wrist - left WO and W contrast IV;CT Wrist-L WO+W contr IV;;ACTIVE;2.14;2.61 +37459-5;Multisection^WO contrast;Find;Pt;Upper extremity>Wrist;Doc;CT;RAD;2;CT Wrist WO contrast;CT Wrist WO contr;;ACTIVE;2.14;2.61 +37460-3;Multisection^WO contrast;Find;Pt;Upper extremity>Wrist;Doc;MR;RAD;2;MR Wrist WO contrast;MR Wrist WO contr;;ACTIVE;2.14;2.61 +37461-1;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Wrist;Doc;CT;RAD;2;CT Wrist - bilateral WO contrast;CT Wrist-Bl WO contr;;ACTIVE;2.14;2.61 +37462-9;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Wrist;Doc;MR;RAD;2;MR Wrist - bilateral WO contrast;MR Wrist-Bl WO contr;;ACTIVE;2.14;2.61 +37463-7;Multisection^WO contrast;Find;Pt;Upper extremity.left>Wrist;Doc;CT;RAD;2;CT Wrist - left WO contrast;CT Wrist-L WO contr;;ACTIVE;2.14;2.61 +37464-5;Multisection^WO contrast;Find;Pt;Upper extremity.left>Wrist;Doc;MR;RAD;2;MR Wrist - left WO contrast;MR Wrist-L WO contr;;ACTIVE;2.14;2.61 +3746-5;Meperidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Meperidine [Presence] in Urine;Meperidine Ur Ql;;ACTIVE;1.0;2.73 +37465-2;Multisection^WO contrast;Find;Pt;Upper extremity.right>Wrist;Doc;CT;RAD;2;CT Wrist - right WO contrast;CT Wrist-R WO contr;;ACTIVE;2.14;2.61 +37466-0;Multisection^WO contrast;Find;Pt;Upper extremity.right>Wrist;Doc;MR;RAD;2;MR Wrist - right WO contrast;MR Wrist-R WO contr;;ACTIVE;2.14;2.61 +37467-8;View 10 degree cephalic angle;Find;Pt;Upper extremity>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular Joint 10 degree cephalic angle;XR AC joint 10 deg ceph angle;;ACTIVE;2.14;2.61 +37468-6;View 30 degree caudal angle;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral 30 degree caudal angle;XR Shoulder-Bl 30 deg cau angle;;ACTIVE;2.14;2.61 +37469-4;View 45 degree cephalic angle;Find;Pt;Chest>Clavicle.bilateral;Doc;XR;RAD;2;XR Clavicle - bilateral 45 degree cephalic angle;XR Clavicle-Bl 45 deg ceph angle;;ACTIVE;2.14;2.61 +37470-2;View 45 degree cephalic angle;Find;Pt;Chest>Clavicle.left;Doc;XR;RAD;2;XR Clavicle - left 45 degree cephalic angle;XR Clavicle-L 45 deg ceph angle;;ACTIVE;2.14;2.61 +37471-0;View Bora;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral Bora;XR Hand-Bl Bora;;ACTIVE;2.14;2.61 +37472-8;View Bora;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left Bora;XR Hand-L Bora;;ACTIVE;2.14;2.61 +3747-3;Meperidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Meperidine [Mass/volume] in Urine;Meperidine Ur-mCnc;;ACTIVE;1.0;2.73 +37473-6;View Grashey;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey;XR Should-L Grashey;;ACTIVE;2.14;2.61 +37474-4;Views lateral^W manual stress;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Lateral Views W manual stress;XR Ankle-L Views Lat W man stress;;ACTIVE;2.14;2.71 +37475-1;View Mortise^W manual stress;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Mortise W manual stress;XR Ankle-L Mortise W man stress;;ACTIVE;2.14;2.71 +37476-9;View PA 45 degree flexion;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee PA 45 degree flexion;XR Knee PA 45 deg flex;;ACTIVE;2.14;2.61 +37477-7;View PA 45 degree flexion^W standing;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee PA 45 degree flexion W standing;XR Knee PA 45 deg flex W Stand;;ACTIVE;2.14;2.61 +3748-1;Meperidine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Meperidine [Mass/time] in 24 hour Urine;Meperidine 24h Ur-mRate;;ACTIVE;1.0;2.42 +37481-9;Views;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;XR;RAD;2;XR Cervical and thoracic spine Views;XR C+T-spine Views;;ACTIVE;2.14;2.64 +37482-7;Views 2;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral 2 Views;XR Wrist-Bl 2V;;ACTIVE;2.14;2.61 +37483-5;Views 2;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 2 Views;XR Wrist-L 2V;;ACTIVE;2.14;2.61 +37484-3;Views AP^W manual stress;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Views AP W manual stress;XR Knee-L Views AP W man stress;;ACTIVE;2.14;2.71 +37485-0;Views AP + transthoracic;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus AP and Transthoracic;XR Humerus AP+Transthoracic;;ACTIVE;2.14;2.61 +37486-8;Views Broden^W manual stress;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle Broden Views W manual stress;XR Ankle Views Broden W man stress;;ACTIVE;2.14;2.71 +37487-6;Views^W contrast IA;Find;Pt;Lower extremity>Lower extremity arteries;Doc;RF.angio;RAD;2;RFA Lower extremity arteries Views W contrast IA;RFA LE aa Views W contr IA;;ACTIVE;2.14;2.64 +37488-4;Views^W contrast IA;Find;Pt;Upper extremity.left>Upper extremity arteries;Doc;RF.angio;RAD;2;RFA Upper extremity arteries - left Views W contrast IA;RFA UE aa-L Views W contr IA;;ACTIVE;2.14;2.64 +37489-2;Views^W contrast IA;Find;Pt;Lower extremity>Tibioperoneal arteries;Doc;RF.angio;RAD;2;RFA Tibioperoneal arteries Views W contrast IA;RFA Tibioper aa Views W contr IA;;ACTIVE;2.14;2.64 +374-9;Ofloxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ofloxacin [Susceptibility] by Minimum lethal concentration (MLC);Ofloxacin Islt MLC;;ACTIVE;1.0;2.19 +37490-0;Views^W contrast IA;Find;Pt;Head+Neck>Vertebral artery.left;Doc;RF.angio;RAD;2;RFA Vertebral artery - left Views W contrast IA;RFA VA-L Views W contr IA;;ACTIVE;2.14;2.64 +37491-8;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Pleural space;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Pleural space;CT Guided Pl space PC fluid asp;;ACTIVE;2.14;2.64 +37492-6;Guidance for percutaneous biopsy;Find;Pt;Chest>Pleura;Doc;CT;RAD;2;CT Guidance for biopsy of Chest Pleura;CT Guided Chest Pleura Bx;;ACTIVE;2.14;2.64 +37493-4;Guidance for injection;Find;Pt;Neck>Spine.cervical intervertebral disc;Doc;CT;RAD;2;CT Guidance for injection of Cervical spine Intervertebral disc;CT Guided C-spine interv disc Inj;;ACTIVE;2.14;2.64 +37494-2;Guidance for injection;Find;Pt;XXX>Tendon;Doc;RF;RAD;2;RF Guidance for injection of Tendon;RF Guided Tendon Inj;;ACTIVE;2.14;2.64 +37495-9;Multisection;Find;Pt;Head>Skull.base;Doc;CT;RAD;2;CT Skull base;CT Skull.base;;ACTIVE;2.14;2.61 +37496-7;Multisection^W contrast intradisc;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine W contrast intradisc;CT C-spine W contr ID;;ACTIVE;2.14;2.61 +37497-5;Multisection;Find;Pt;XXX>Spine vessels;Doc;MR.angio;RAD;2;MRA Spine vessels;MRA Spine ves;;ACTIVE;2.14;2.61 +37498-3;Multisection^W contrast IV;Find;Pt;Head>Head vessels & Neck>Neck vessels;Doc;CT.angio;RAD;2;CTA Head vessels and Neck vessels W contrast IV;CTA Head+Neck Ves W contr IV;;ACTIVE;2.14;2.61 +3749-9;Mephenytoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mephenytoin [Mass/volume] in Serum or Plasma;Mephenytoin SerPl-mCnc;;ACTIVE;1.0;2.73 +37499-1;Multisection^W contrast IV;Find;Pt;Aortic stent;Doc;CT.angio;RAD;2;Deprecated Aortic stent CT angiogram W contrast IV;Deprecated Ac stent CT.Angio W contr IV;;DEPRECATED;2.14;2.58 +37500-6;Multisection^W contrast IV;Find;Pt;XXX>Spine vessels;Doc;MR.angio;RAD;2;MRA Spine vessels W contrast IV;MRA Spine ves W contr IV;;ACTIVE;2.14;2.61 +37501-4;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical vessels;Doc;MR.angio;RAD;2;MRA Cervical spine vessels W contrast IV;MRA C-spine ves W contr IV;;ACTIVE;2.14;2.61 +37502-2;Multisection^W contrast IV;Find;Pt;Abdomen>Spine.lumbar vessels;Doc;MR.angio;RAD;2;MRA Lumbar spine vessels W contrast IV;MRA L-spine ves W contr IV;;ACTIVE;2.14;2.61 +37503-0;Multisection^W contrast IV;Find;Pt;Chest>Spine.thoracic vessels;Doc;MR.angio;RAD;2;MRA Thoracic spine vessels W contrast IV;MRA T-spine ves W contr IV;;ACTIVE;2.14;2.61 +37505-5;Multisection^WO & W contrast IV;Find;Pt;XXX>Spine vessels;Doc;MR.angio;RAD;2;MRA Spine vessels WO and W contrast IV;MRA Spine ves WO+W contr IV;;ACTIVE;2.14;2.61 +37506-3;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical vessels;Doc;MR.angio;RAD;2;MRA Cervical spine vessels WO and W contrast IV;MRA C-spine ves WO+W contr IV;;ACTIVE;2.14;2.61 +3750-7;Mephobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mephobarbital [Mass/volume] in Serum or Plasma;Mephobarbital SerPl-mCnc;;ACTIVE;1.0;2.73 +37507-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Spine.lumbar vessels;Doc;MR.angio;RAD;2;MRA Lumbar spine vessels WO and W contrast IV;MRA L-spine ves WO+W contr IV;;ACTIVE;2.14;2.61 +37508-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Spine.thoracic vessels;Doc;MR.angio;RAD;2;MRA Thoracic spine vessels WO and W contrast IV;MRA T-spine ves WO+W contr IV;;ACTIVE;2.14;2.61 +37509-7;Multisection^W contrast intradisc;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine W contrast intradisc;CT L-spine W contr ID;;ACTIVE;2.14;2.61 +37510-5;Multisection^WO contrast;Find;Pt;XXX>Spine vessels;Doc;MR.angio;RAD;2;MRA Spine vessels WO contrast;MRA Spine ves WO contr;;ACTIVE;2.14;2.61 +37511-3;Multisection^WO contrast;Find;Pt;Neck>Spine.cervical vessels;Doc;MR.angio;RAD;2;MRA Cervical spine vessels WO contrast;MRA C-spine ves WO contr;;ACTIVE;2.14;2.61 +37512-1;Multisection^WO contrast;Find;Pt;Chest>Spine.thoracic vessels;Doc;MR.angio;RAD;2;MRA Thoracic spine vessels WO contrast;MRA T-spine ves WO contr;;ACTIVE;2.14;2.61 +37513-9;View 10 degree caudal angle;Find;Pt;Lower extremity.bilateral>Tibia;Doc;XR;RAD;2;XR Tibia - bilateral 10 degree caudal angle;XR Tib-Bl 10 deg cau angle;;ACTIVE;2.14;2.61 +37514-7;View 10 degree caudal angle;Find;Pt;Lower extremity.left>Tibia;Doc;XR;RAD;2;XR Tibia - left 10 degree caudal angle;XR Tib-L 10 deg cau angle;;ACTIVE;2.14;2.61 +3751-5;Mephobarbital;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Mephobarbital [Mass/volume] in Serum or Plasma;Deprecated Mephobarbital Ser-mCnc;;DEPRECATED;1.0;2.36 +37515-4;View lateral spot;Find;Pt;Abdomen+Pelvis>Spine.lumbosacral junction;Doc;XR;RAD;2;XR Spine lumbosacral junction Lateral spot;XR LSJ Lat spot;;ACTIVE;2.14;2.61 +37516-2;View lateral spot^W standing;Find;Pt;Abdomen+Pelvis>Spine.lumbosacral junction;Doc;XR;RAD;2;XR Spine lumbosacral junction Lateral spot W standing;XR LSJ Lat spot W Stand;;ACTIVE;2.14;2.61 +37517-0;Views;Find;Pt;Upper extremity.bilateral>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - bilateral Views;XR Finger.5th-Bl Views;;ACTIVE;2.14;2.64 +37518-8;Views;Find;Pt;Upper extremity.left>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - left Views;XR Finger.5th-L Views;;ACTIVE;2.14;2.64 +37519-6;Views;Find;Pt;Upper extremity.bilateral>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - bilateral Views;XR Finger.4th-Bl Views;;ACTIVE;2.14;2.64 +37520-4;Views;Find;Pt;Upper extremity.left>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - left Views;XR Finger.4th-L Views;;ACTIVE;2.14;2.73 +37521-2;Views;Find;Pt;Upper extremity.bilateral>Finger.second;Doc;XR;RAD;2;XR Finger second - bilateral Views;XR Finger.2nd-Bl Views;;ACTIVE;2.14;2.64 +37522-0;Views;Find;Pt;Upper extremity.left>Finger.second;Doc;XR;RAD;2;XR Finger second - left Views;XR Finger.2nd-L Views;;ACTIVE;2.14;2.73 +3752-3;Meprobamate;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Meprobamate [Presence] in Serum or Plasma;Meprobamate SerPl Ql;;ACTIVE;1.0;2.73 +37523-8;Views;Find;Pt;Upper extremity.bilateral>Finger.third;Doc;XR;RAD;2;XR Finger third - bilateral Views;XR Finger.3rd-Bl Views;;ACTIVE;2.14;2.64 +37524-6;Views;Find;Pt;Upper extremity.left>Finger.third;Doc;XR;RAD;2;XR Finger third - left Views;XR Finger.3rd-L Views;;ACTIVE;2.14;2.73 +37530-3;Views;Find;Pt;Lower extremity.left>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - left Views;XR Toe 5th-L Views;;ACTIVE;2.14;2.73 +3753-1;Meprobamate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meprobamate [Mass/volume] in Serum or Plasma;Meprobamate SerPl-mCnc;;ACTIVE;1.0;2.73 +37531-1;Views;Find;Pt;Lower extremity.left>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - left Views;XR Toe 4th-L Views;;ACTIVE;2.14;2.64 +37532-9;Views;Find;Pt;Lower extremity.bilateral>Great toe;Doc;XR;RAD;2;XR Great toe - bilateral Views;XR Great toe-Bl Views;;ACTIVE;2.14;2.64 +37533-7;Views;Find;Pt;Lower extremity.left>Great toe;Doc;XR;RAD;2;XR Great toe - left Views;XR Great toe-L Views;;ACTIVE;2.14;2.73 +37534-5;Views;Find;Pt;Lower extremity.left>Toe.second;Doc;XR;RAD;2;XR Toe second - left Views;XR Toe 2nd-L Views;;ACTIVE;2.14;2.64 +37535-2;Views;Find;Pt;Lower extremity.left>Toe.third;Doc;XR;RAD;2;XR Toe third - left Views;XR Toe 3rd-L Views;;ACTIVE;2.14;2.64 +37538-6;Views Grashey + axillary + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey and Axillary and Y;XR Should-L Grashey+Ax+Y;;ACTIVE;2.14;2.61 +37539-4;Views grid;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Grid Views;MG Brst Views Grid;;ACTIVE;2.14;2.64 +37540-2;Views Holmblad^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Holmblad Views W standing;XR Knee-Bl Views Holmblad W Stand;;ACTIVE;2.14;2.64 +37541-0;Views Law + Mayer + Stenver + Towne;Find;Pt;Head>Mastoid.bilateral;Doc;XR;RAD;2;XR Mastoid - bilateral Law and Mayer and Stenver and Towne;XR Mastoid-Bl Law+Mayer+Stenver+Towne;;ACTIVE;2.14;2.64 +37542-8;Views magnification;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Magnification Views;MG Brst Views Mag;;ACTIVE;2.14;2.64 +37543-6;Views magnification;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Magnification Views;MG Brst-Bl Views Mag;;ACTIVE;2.14;2.64 +37544-4;Views oblique;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Oblique Views;XR Wrist-Bl Views Obl;;ACTIVE;2.14;2.64 +37545-1;View oblique crosstable;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Oblique crosstable;XR Hip-L Obl Xtable;;ACTIVE;2.14;2.61 +37546-9;Views open mouth + closed mouth;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;XR;RAD;2;XR Temporomandibular joint - bilateral Open and Closed mouth;XR TMJ-Bl Open+Closed Mouth;;ACTIVE;2.14;2.61 +37547-7;Views PA + lateral;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral PA and Lateral;XR Wrist-Bl PA+Lat;;ACTIVE;2.14;2.61 +37548-5;Views PA + lateral;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left PA and Lateral;XR Wrist-L PA+Lat;;ACTIVE;2.14;2.61 +3754-9;Meprobamate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Meprobamate [Presence] in Urine;Meprobamate Ur Ql;;ACTIVE;1.0;2.73 +37549-3;Views PA + lateral + oblique;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral PA and Lateral and Oblique;XR Wrist-Bl PA+Lat+Obl;;ACTIVE;2.14;2.61 +37550-1;Views PA + lateral + oblique;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left PA and Lateral and Oblique;XR Wrist-L PA+Lat+Obl;;ACTIVE;2.14;2.61 +37551-9;Views spot;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Spot Views;MG Brst Views spot;;ACTIVE;2.14;2.64 +37552-7;Views spot;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Spot Views;MG Brst-Bl Views spot;;ACTIVE;2.14;2.64 +37553-5;Views spot^compression;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Spot Views compression;MG Brst-L Views spot Compression;;ACTIVE;2.14;2.64 +37554-3;Views magnification+spot;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Magnification and Spot;MG Brst-Bl Mag+Spot;;ACTIVE;2.14;2.61 +37555-0;Views ulnar deviation + radial deviation;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Ulnar deviation and Radial deviation;XR Wrist-L Ulnar+Radial Deviation;;ACTIVE;2.14;2.61 +3755-6;Meprobamate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Meprobamate [Mass/volume] in Urine;Meprobamate Ur-mCnc;;ACTIVE;1.0;2.73 +37556-8;Views^W manual stress;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle Views W manual stress;XR Ankle Views W man stress;;ACTIVE;2.14;2.73 +37557-6;Views^W manual stress;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral Views W manual stress;XR Ankle-Bl Views W man stress;;ACTIVE;2.14;2.71 +37558-4;Views^W manual stress;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Views W manual stress;XR Ankle-L Views W man stress;;ACTIVE;2.14;2.71 +37559-2;Views^W manual stress;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left Views W manual stress;XR Foot-L Views W man stress;;ACTIVE;2.14;2.71 +375-6;Ofloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Ofloxacin Islt MIC;;ACTIVE;1.0;2.73 +37560-0;Views^W manual stress;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Views W manual stress;XR Knee Views W man stress;;ACTIVE;2.14;2.71 +37561-8;Views^W manual stress;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Views W manual stress;XR Knee-Bl Views W man stress;;ACTIVE;2.14;2.71 +37562-6;Views^W manual stress;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Views W manual stress;XR Knee-L Views W man stress;;ACTIVE;2.14;2.71 +37563-4;Views^W manual stress;Find;Pt;Upper extremity.bilateral>Thumb;Doc;XR;RAD;2;XR Thumb - bilateral Views W manual stress;XR Thumb-Bl Views W man stress;;ACTIVE;2.14;2.71 +3756-4;Mersalyl;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mersalyl [Presence] in Urine;Mersalyl Ur Ql;;ACTIVE;1.0;2.56 +37564-2;Views^W manual stress;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left Views W manual stress;XR Thumb-L Views W man stress;;ACTIVE;2.14;2.71 +37565-9;Views^W barium contrast via fistula;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views W barium contrast via fistula;RF Views W Ba via Fistula;;ACTIVE;2.14;2.64 +37566-7;Views^W contrast via catheter;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views W contrast via catheter;RF Views W contr via cath;;ACTIVE;2.14;2.64 +37567-5;Views^W contrast via colostomy;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views W contrast via colostomy;RF Colon Views W contr via Colostomy;;ACTIVE;2.14;2.64 +37568-3;Views^W contrast via fistula;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views W contrast via fistula;RF Views W contr via Fistula;;ACTIVE;2.14;2.64 +37569-1;Views^W contrast via suprapubic tube;Find;Pt;Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Urinary bladder Views W contrast via suprapubic tube;RF Bladder Views W contr via SP tb;;ACTIVE;2.14;2.64 +37570-9;Views^W contrast IS;Find;Pt;Upper extremity.bilateral>Wrist;Doc;RF;RAD;2;RF Wrist - bilateral Arthrogram;RF Wrist-Bl Views W contr IS;;ACTIVE;2.14;2.64 +37571-7;Views^W contrast IS;Find;Pt;Upper extremity.left>Wrist;Doc;RF;RAD;2;RF Wrist - left Arthrogram;RF Wrist-L Views W contr IS;;ACTIVE;2.14;2.64 +3757-2;Mersalyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mersalyl [Mass/volume] in Urine;Mersalyl Ur-mCnc;;ACTIVE;1.0;2.34 +37572-5;Views^W contrast IT;Find;Pt;XXX>Spine;Doc;RF;RAD;2;RF Spine Views W contrast IT;RF Spine Views W contr IT;;DISCOURAGED;2.14;2.64 +37573-3;Views^W contrast IV;Find;Pt;Upper extremity arteries.left;Nar;XR.fluor.angio;RAD;2;Deprecated Upper extremity arteries - left Fluoroscopic angiogram W contrast;Deprecated UE aa-L XRA W contr IV;;DEPRECATED;2.14;2.34 +37574-1;Views^W contrast IV;Find;Pt;Lower extremity>Lower extremity vessels;Doc;RF.angio;RAD;2;RFA Lower extremity vessels Views W contrast IV;RFA LE ves Views W contr IV;;ACTIVE;2.14;2.64 +37575-8;Views^post fatty meal+W contrast PO;Find;Pt;Abdomen>Gallbladder;Doc;XR;RAD;2;XR Gallbladder Views W contrast and fatty meal PO;XR GB Views W contr+Fatty Meal PO;;ACTIVE;2.14;2.64 +37576-6;Views^W gastrografin via fistula;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views W gastrografin via fistula;RF Views W Gastrografin via Fistula;;ACTIVE;2.14;2.64 +37577-4;Views^W weight;Find;Pt;Upper extremity>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular Joint Views W weight;XR AC joint Views W Wt;;ACTIVE;2.14;2.64 +37578-2;Views^W weight;Find;Pt;Upper extremity.bilateral>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - bilateral Views W weight;XR AC joint-Bl Views W Wt;;ACTIVE;2.14;2.64 +37579-0;Views^WO & W weight;Find;Pt;Upper extremity>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular Joint Views WO and W weight;XR AC joint Views WO+W Wt;;ACTIVE;2.14;2.64 +3758-0;Mersalyl;MRat;24H;Urine;Qn;;DRUG/TOX;1;Mersalyl [Mass/time] in 24 hour Urine;Mersalyl 24h Ur-mRate;;ACTIVE;1.0;2.19 +37580-8;Views^WO & W weight;Find;Pt;Upper extremity.bilateral>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - bilateral Views WO and W weight;XR AC joint-Bl Views WO+W Wt;;ACTIVE;2.14;2.64 +37581-6;Views^WO & W weight;Find;Pt;Upper extremity.left>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - left Views WO and W weight;XR AC joint-L Views WO+W Wt;;ACTIVE;2.14;2.64 +37582-4;Views^WO weight;Find;Pt;Upper extremity>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular Joint Views WO weight;XR AC joint Views WO Wt;;ACTIVE;2.14;2.64 +37583-2;Views + lateral frog;Find;Pt;Pelvis & Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - bilateral Views and Lateral frog;XR Pelvis and Hip-Bl Views+Lat Frog;;ACTIVE;2.14;2.64 +37584-0;Views^W standing;Find;Pt;Lower extremity.left>Great toe;Doc;XR;RAD;2;XR Great toe - left Views W standing;XR Great toe-L Views W Stand;;ACTIVE;2.14;2.64 +37585-7;Views^W contrast;Find;Pt;Abdomen>Jejunum;Doc;RF;RAD;2;RF Jejunum Views W contrast;RF Jejunum Views W contr;;ACTIVE;2.14;2.64 +37586-5;Views^W contrast intra corpus cavernosum;Find;Pt;Pelvis>Penis;Doc;RF;RAD;2;RF Penis Views W contrast intra corpus cavernosum;RF Penis Views W contr intra CC;;ACTIVE;2.14;2.64 +37587-3;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Head+Neck>Carotid artery.bilateral+Vertebral artery.bilateral;Doc;RF.angio;RAD;2;RFA Aortic arch and Carotid artery - bilateral and Vertebral artery - bilateral Views W contrast IA;RFA Ao arch+Carot+Vert a-Bl Vs W contr IA;;ACTIVE;2.14;2.64 +37588-1;Views^W contrast IA;Find;Pt;Neck>Carotid artery.common.bilateral;Doc;RF.angio;RAD;2;RFA Common carotid artery - bilateral Views W contrast IA;RFA Ao arch+Com carot a-Bl Vs W contr IA;;ACTIVE;2.14;2.64 +37589-9;Views^W contrast IA;Find;Pt;Neck>Carotid artery.common.left;Doc;RF.angio;RAD;2;RFA Common carotid artery - left Views W contrast IA;RFA Ao arch+Com carot a-L Vs W contr IA;;ACTIVE;2.14;2.64 +37590-7;Views^W contrast IA;Find;Pt;Neck>Carotid artery.common.right;Doc;RF.angio;RAD;2;RFA Common carotid artery - right Views W contrast IA;RFA Ao arch+Com carot a-R Vs W contr IA;;ACTIVE;2.14;2.64 +37591-5;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Head+Neck>Carotid artery.external.bilateral;Doc;RF.angio;RAD;2;RFA Aortic arch and External carotid artery - bilateral Views W contrast IA;RFA Ao arch+Ext carot a-Bl Vs W contr IA;;DISCOURAGED;2.14;2.64 +37592-3;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Head+Neck>Carotid artery.external.left;Doc;RF.angio;RAD;2;RFA Aortic arch and External carotid artery - left Views W contrast IA;RFA Ao arch+Ext carot a-L Vs W contr IA;;DISCOURAGED;2.14;2.64 +37593-1;Views^W contrast IA;Find;Pt;Chest>Aortic arch & Head+Neck>Carotid artery.external.right;Doc;RF.angio;RAD;2;RFA Aortic arch and External carotid artery - right Views W contrast IA;RFA Ao arch+Ext carot a-R Vs W contr IA;;DISCOURAGED;2.14;2.64 +37594-9;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery+Vertebral artery;Doc;RF.angio;RAD;2;RFA Carotid artery and Vertebral artery Views W contrast IA;RFA Ao arch+Carot a+Vert a Vs W contr IA;;ACTIVE;2.14;2.64 +37595-6;Views for graft^W contrast IA;Find;Pt;Chest>Coronary arteries;Doc;RF.angio;RAD;2;RFA Coronary arteries Views for graft W contrast IA;RFA CA Views for graft W contr IA;;ACTIVE;2.14;2.64 +37596-4;Views^W contrast intra lymphatic;Find;Pt;Abdomen>Abdominal lymphatic vessels.left & Pelvis>Pelvic lymphatic vessels.left;Doc;RF.angio;RAD;2;RFA Abdominal and pelvic lymphatic vessels - left Views W contrast intra lymphatic;RFA Abd+Pelvic lymph ves-L Vs W contr IL;;ACTIVE;2.14;2.64 +37597-2;Views^W contrast intra lymphatic;Find;Pt;Abdomen>Abdominal lymphatic vessels & Pelvis>Pelvic lymphatic vessels;Doc;RF.angio;RAD;2;RFA Abdominal and pelvic lymphatic vessels Views W contrast intra lymphatic;RFA Abd+Pelvic lymph ves Vs W contr IL;;ACTIVE;2.14;2.64 +3759-8;Mesantoin;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Mephenytoin [Mass/volume] in Serum or Plasma;Deprecated Mesantoin Ser-mCnc;;DEPRECATED;1.0;2.36 +37598-0;Views^W contrast intra lymphatic;Find;Pt;Abdomen>Abdominal lymphatic vessels.bilateral & Pelvis>Pelvic lymphatic vessels.bilateral;Doc;RF.angio;RAD;2;RFA Abdominal and pelvic lymphatic vessels - bilateral Views W contrast intra lymphatic;RFA Abd+Pelv lymph ves-Bl Vs W contr IL;;ACTIVE;2.14;2.64 +37599-8;Views^W contrast intra lymphatic;Find;Pt;Extremity.left>Extremity lymphatic vessels;Doc;RF.angio;RAD;2;RFA Extremity lymphatic vessels - left Views W contrast intra lymphatic;RFA Extremity lymph ves-L Vs W contr IL;;ACTIVE;2.14;2.64 +37600-4;Views^W contrast intra lymphatic;Find;Pt;XXX>Lymphatic vessels.left;Doc;RF.angio;RAD;2;RFA Lymphatic vessels - left Views W contrast intra lymphatic;RFA Lymph ves-L Views W contr IL;;ACTIVE;2.14;2.64 +37601-2;Views^W contrast intra lymphatic;Find;Pt;Pelvis>Pelvic lymphatic vessels.bilateral;Doc;RF.angio;RAD;2;RFA Pelvic lymphatic vessels - bilateral Views W contrast intra lymphatic;RFA Pelvic lymph ves-Bl Views W contr IL;;ACTIVE;2.14;2.64 +37602-0;Views^W contrast IV;Find;Pt;Abdomen>Adrenal vein.left;Doc;RF.angio;RAD;2;RFA Adrenal vein - left Views W contrast IV;RFA Adrenal v-L Views W contr IV;;ACTIVE;2.14;2.64 +37603-8;Views lateral & PA chest;Find;Pt;Ribs.left+Chest;Doc;XR;RAD;2;Deprecated Ribs - left and Chest X-ray lateral and PA;Deprecated Ribs-L + Chest XR Lat+PA;;DEPRECATED;2.14;2.58 +37604-6;Views 3;Find;Pt;Head>Nasal bones;Doc;XR;RAD;2;XR Nasal bones 3 Views;XR Nasal bones 3V;;ACTIVE;2.14;2.61 +37605-3;Views lateral + Waters;Find;Pt;Head>Nasal bones;Doc;XR;RAD;2;XR Nasal bones Lateral and Waters;XR Nasal bones Lat+Waters;;ACTIVE;2.14;2.61 +3760-6;Mesoridazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mesoridazine [Mass/volume] in Serum or Plasma;Mesoridazine SerPl-mCnc;;ACTIVE;1.0;2.73 +37606-1;Multisection;Find;Pt;Head>Nasal bones;Doc;XR.tomography;RAD;2;XR tomography Nasal bones;XR tomo Nasal bones;;ACTIVE;2.14;2.61 +37607-9;Views^W contrast IV;Find;Pt;Abdomen>Kidney;Doc;XR;RAD;2;XR Kidney Views W contrast IV;XR Kidney Views W contr IV;;ACTIVE;2.14;2.64 +37608-7;Guidance for localization of foreign body;Find;Pt;Head>Eye;Doc;US;RAD;2;US Guidance for localization of foreign body of Eye;US Guided Eye FB loc;;ACTIVE;2.14;2.64 +37609-5;Views 4;Find;Pt;Head>Optic foramen;Doc;XR;RAD;2;XR Optic foramen 4 Views;XR Optic foramen 4V;;ACTIVE;2.14;2.61 +37611-1;Multisection;Find;Pt;Head>Orbit.bilateral;Doc;XR.tomography;RAD;2;XR tomography Orbit - bilateral;XR tomo Orbit-Bl;;ACTIVE;2.14;2.73 +37612-9;Views 4;Find;Pt;Head>Orbit.bilateral;Doc;XR;RAD;2;XR Orbit - bilateral 4 Views;XR Orbit-Bl 4V;;ACTIVE;2.14;2.61 +37613-7;View Waters;Find;Pt;Head>Orbit.bilateral;Doc;XR;RAD;2;XR Orbit - bilateral Waters;XR Orbit-Bl Waters;;ACTIVE;2.14;2.61 +3761-4;Mesterolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mesterolone [Presence] in Urine;Mesterolone Ur Ql;;ACTIVE;1.0;2.73 +37614-5;View;Find;Pt;Lower extremity>Patella;Doc;XR;RAD;2;XR Patella Single view;XR Patella 1V;;ACTIVE;2.14;2.64 +37615-2;Views^W contrast;Find;Pt;Pelvis>Pelvis vessels;Doc;RF.angio;RAD;2;RFA Pelvis vessels Views W contrast;RFA Pelvis ves Views W contr;;ACTIVE;2.14;2.64 +37616-0;View;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Single view;XR Pelvis 1V;;ACTIVE;2.14;2.64 +37617-8;Views 2;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis 2 Views;XR Pelvis 2V;;ACTIVE;2.14;2.61 +37618-6;Views AP + inlet;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP and Inlet;XR Pelvis AP+Inlet;;ACTIVE;2.14;2.61 +37619-4;Views AP + Judet;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP and Judet;XR Pelvis AP+Judet;;ACTIVE;2.14;2.61 +37620-2;Views AP + lateral;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP and Lateral;XR Pelvis AP+Lat;;ACTIVE;2.14;2.61 +37621-0;Views AP + oblique;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP and Oblique;XR Pelvis AP+Obl;;ACTIVE;2.14;2.61 +3762-2;Mesterolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mesterolone [Mass/volume] in Urine;Mesterolone Ur-mCnc;;ACTIVE;1.0;2.42 +37622-8;View AP;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP;XR Pelvis AP;;ACTIVE;2.14;2.61 +37623-6;Views AP + inlet + outlet;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP and Inlet and Outlet;XR Pelvis AP+Inlet+Outlet;;ACTIVE;2.14;2.61 +37624-4;Views AP + lateral + oblique;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP and Lateral and oblique;XR Pelvis AP+Lat+Obl;;ACTIVE;2.14;2.61 +37625-1;View Ferguson;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Ferguson;XR Pelvis Ferguson;;ACTIVE;2.14;2.61 +37626-9;View lateral frog;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Lateral frog;XR Pelvis Lat frog;;ACTIVE;2.14;2.61 +37627-7;Views inlet + outlet + oblique;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Inlet and Outlet and Oblique;XR Pelvis Inlet+Outlet+Obl;;ACTIVE;2.14;2.61 +37628-5;View inlet;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Inlet;XR Pelvis Inlet;;ACTIVE;2.14;2.61 +37629-3;View lateral;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Lateral;XR Pelvis Lat;;ACTIVE;2.14;2.61 +3763-0;Mesterolone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Mesterolone [Mass/time] in 24 hour Urine;Mesterolone 24h Ur-mRate;;ACTIVE;1.0;2.42 +37630-1;Views oblique;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Oblique Views;XR Pelvis Views Obl;;ACTIVE;2.14;2.64 +37631-9;View outlet;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Outlet;XR Pelvis Outlet;;ACTIVE;2.14;2.61 +37632-7;Multisection;Find;Pt;Pelvis;Doc;XR.tomography;RAD;2;XR tomography Pelvis;XR tomo Pelvis;;ACTIVE;2.14;2.61 +37633-5;View^W standing;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Single view W standing;XR Pelvis 1V W Stand;;ACTIVE;2.14;2.64 +37634-3;View AP 20 degree cephalic angle;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP 20 degree cephalic angle;XR Pelvis AP 20 deg ceph angle;;ACTIVE;2.14;2.61 +37635-0;Views 3;Find;Pt;Lower extremity>Acetabulum;Doc;XR;RAD;2;XR Acetabulum 3 Views;XR Acetabulum 3V;;ACTIVE;2.14;2.61 +37636-8;Views;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Views;XR Abd Views;;ACTIVE;2.14;2.64 +37637-6;Views;Find;Pt;Extremity;Doc;XR;RAD;2;XR Extremity Views;XR Extr Views;;ACTIVE;2.14;2.64 +37639-2;Views;Find;Pt;Neck;Doc;XR;RAD;2;XR Neck Views;XR Neck Views;;ACTIVE;2.14;2.64 +376-4;Ofloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ofloxacin [Susceptibility] by Disk diffusion (KB);Ofloxacin Islt KB;;ACTIVE;1.0;2.73 +37640-0;Views^W contrast;Find;Pt;Abdomen>Renal vessels;Doc;RF.angio;RAD;2;RFA Renal vessels Views W contrast;RFA Renal ves Views W contr;;ACTIVE;2.14;2.64 +37641-8;Views^W contrast IS;Find;Pt;Upper extremity.right>Wrist;Doc;RF;RAD;2;RF Wrist - right Arthrogram;RF Wrist-R Views W contr IS;;ACTIVE;2.14;2.64 +37642-6;Views limited;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Limited Views;XR Wrist-R Views Ltd;;ACTIVE;2.14;2.64 +37643-4;Views oblique;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Oblique Views;XR Wrist-R Views Obl;;ACTIVE;2.14;2.64 +37644-2;Multisection;Find;Pt;Upper extremity.right>Wrist;Doc;XR.tomography;RAD;2;XR tomography Wrist - right;XR tomo Wrist-R;;ACTIVE;2.14;2.61 +37645-9;View ulnar deviation;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Ulnar deviation;XR Wrist-R Ulnar deviation;;ACTIVE;2.14;2.61 +37646-7;Views limited;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint Limited Views;XR SIJ Views Ltd;;ACTIVE;2.14;2.64 +37647-5;Views^W contrast IS;Find;Pt;Pelvis>Sacroiliac joint;Doc;RF;RAD;2;RF Sacroiliac Joint Arthrogram;RF SIJ Views W contr IS;;ACTIVE;2.14;2.64 +3764-8;Metandienone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Metandienone [Presence] in Urine;Metandienone Ur Ql;;ACTIVE;1.0;2.73 +37648-3;Views 3;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint 3 Views;XR SIJ 3V;;ACTIVE;2.14;2.61 +37649-1;Views AP + oblique;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint AP and Oblique;XR SIJ AP+Obl;;ACTIVE;2.14;2.61 +37650-9;View Ferguson;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint Ferguson;XR SIJ Ferguson;;ACTIVE;2.14;2.61 +37651-7;Views 2;Find;Pt;Pelvis>Sacrum;Doc;XR;RAD;2;XR Sacrum 2 Views;XR Sacrum 2V;;ACTIVE;2.14;2.61 +37652-5;Views AP + lateral;Find;Pt;Pelvis>Sacrum;Doc;XR;RAD;2;XR Sacrum AP and Lateral;XR Sacrum AP+Lat;;ACTIVE;2.14;2.61 +37653-3;Multisection;Find;Pt;Pelvis>Sacrum;Doc;XR.tomography;RAD;2;XR tomography Sacrum;XR tomo Sacrum;;ACTIVE;2.14;2.61 +37654-1;View;Find;Pt;Chest>Scapula;Doc;XR;RAD;2;XR Scapula Single view;XR Scapula 1V;;ACTIVE;2.14;2.64 +3765-5;Metandienone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Metandienone [Mass/volume] in Urine;Metandienone Ur-mCnc;;ACTIVE;1.0;2.34 +37655-8;Views 2;Find;Pt;Chest>Scapula;Doc;XR;RAD;2;XR Scapula 2 Views;XR Scapula 2V;;ACTIVE;2.14;2.61 +37656-6;View Y;Find;Pt;Chest>Scapula;Doc;XR;RAD;2;XR Scapula Y;XR Scapula Y;;ACTIVE;2.14;2.61 +37658-2;Views 2 for scoliosis;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine 2 Views for scoliosis;XR T+L-Spine 2V for scoli;;ACTIVE;2.14;2.73 +37659-0;View AP for scoliosis^W standing;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP for scoliosis W standing;XR T+L-Spine AP for Scoli W Stand;;ACTIVE;2.14;2.64 +37660-8;View lateral for scoliosis^W standing;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Lateral for scoliosis W standing;XR T+L-Spine Lat for Scoli W Stand;;ACTIVE;2.14;2.64 +37661-6;Views 2;Find;Pt;Upper extremity.right>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - right 2 Views;XR AC joint-R 2V;;ACTIVE;2.14;2.61 +37662-4;View AP;Find;Pt;Upper extremity.right>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - right AP;XR AC joint-R AP;;ACTIVE;2.14;2.61 +3766-3;Metandienone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Metandienone [Mass/time] in 24 hour Urine;Metandienone 24h Ur-mRate;;ACTIVE;1.0;2.19 +37663-2;Views^WO & W weight;Find;Pt;Upper extremity.right>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - right Views WO and W weight;XR AC joint-R Views WO+W Wt;;ACTIVE;2.14;2.64 +37664-0;Views 2;Find;Pt;Lower extremity.right>Acetabulum;Doc;XR;RAD;2;XR Acetabulum - right 2 Views;XR Acetabulum-R 2V;;ACTIVE;2.14;2.61 +37665-7;Views 3;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right 3 Views;XR Ankle-R 3V;;ACTIVE;2.14;2.61 +37666-5;Views AP + lateral + Mortise;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right AP and Lateral and Mortise;XR Ankle-R AP+Lat+Mortise;;ACTIVE;2.14;2.61 +37667-3;Views AP + lateral;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right AP and Lateral;XR Ankle-R AP+Lat;;ACTIVE;2.14;2.61 +37668-1;Views AP + lateral + oblique;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right AP and Lateral and oblique;XR Ankle-R AP+Lat+Obl;;ACTIVE;2.14;2.61 +37669-9;Views lateral^W manual stress;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Lateral Views W manual stress;XR Ankle-R Views Lat W man stress;;ACTIVE;2.14;2.71 +37670-7;Views lateral + Mortise;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Lateral and Mortise;XR Ankle-R Lat+Mortise;;ACTIVE;2.14;2.61 +3767-1;Metaraminol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Metaraminol [Mass/volume] in Urine;Metaraminol Ur-mCnc;;ACTIVE;1.0;2.42 +37671-5;View Mortise^W manual stress;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Mortise W manual stress;XR Ankle-R Mortise W man stress;;ACTIVE;2.14;2.71 +37672-3;Views 2^W manual stress;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right 2 Views W manual stress;XR Ankle-R 2V W man stress;;ACTIVE;2.14;2.71 +37673-1;Views^W manual stress;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Views W manual stress;XR Ankle-R Views W man stress;;ACTIVE;2.14;2.71 +37674-9;Multisection;Find;Pt;Lower extremity.right>Ankle;Doc;XR.tomography;RAD;2;XR tomography Ankle - right;XR tomo Ankle-R;;ACTIVE;2.14;2.61 +37675-6;Views 2^W standing;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right 2 Views W standing;XR Ankle-R 2V W Stand;;ACTIVE;2.14;2.61 +37676-4;Views^W standing;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Views W standing;XR Ankle-R Views W Stand;;ACTIVE;2.14;2.64 +37677-2;View carpal tunnel;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Carpal tunnel;XR Wrist-R Carpal tunnel;;ACTIVE;2.14;2.64 +37678-0;Views 2 carpal tunnel;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 2 Carpal tunnel Views;XR Wrist-R 2V Carpal tunnel;;ACTIVE;2.14;2.64 +37679-8;Views 2;Find;Pt;Chest>Clavicle.right;Doc;XR;RAD;2;XR Clavicle - right 2 Views;XR Clavicle-R 2V;;ACTIVE;2.14;2.61 +37680-6;Views AP + Serendipity;Find;Pt;Chest>Clavicle.right;Doc;XR;RAD;2;XR Clavicle - right AP and Serendipity;XR Clavicle-R AP+Serendipity;;ACTIVE;2.14;2.61 +37681-4;Views 2;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right 2 Views;XR Elbow-R 2V;;ACTIVE;2.14;2.61 +37682-2;Views 3;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right 3 Views;XR Elbow-R 3V;;ACTIVE;2.14;2.73 +37683-0;Views 4;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right 4 Views;XR Elbow-R 4V;;ACTIVE;2.14;2.61 +37684-8;Views AP + lateral;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right AP and Lateral;XR Elbow-R AP+Lat;;ACTIVE;2.14;2.73 +37685-5;Views AP + lateral + oblique;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right AP and Lateral and oblique;XR Elbow-R AP+Lat+Obl;;ACTIVE;2.14;2.61 +37686-3;Views 2 oblique;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right 2 Oblique Views;XR Elbow-R 2V Obl;;ACTIVE;2.14;2.64 +37687-1;Views oblique;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Oblique Views;XR Elbow-R Views Obl;;ACTIVE;2.14;2.64 +37688-9;Multisection;Find;Pt;Upper extremity.right>Elbow;Doc;XR.tomography;RAD;2;XR tomography Elbow - right;XR tomo Elbow-R;;ACTIVE;2.14;2.61 +3768-9;Metenolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Metenolone [Presence] in Urine;Metenolone Ur Ql;;ACTIVE;1.0;2.73 +37689-7;View;Find;Pt;Lower extremity.right>Femur;Doc;XR;RAD;2;XR Femur - right Single view;XR Femur-R 1V;;ACTIVE;2.14;2.64 +37690-5;Views 2;Find;Pt;Lower extremity.right>Femur;Doc;XR;RAD;2;XR Femur - right 2 Views;XR Femur-R 2V;;ACTIVE;2.14;2.61 +37691-3;Views 4;Find;Pt;Lower extremity.right>Femur;Doc;XR;RAD;2;XR Femur - right 4 Views;XR Femur-R 4V;;ACTIVE;2.14;2.61 +37692-1;Views AP + lateral;Find;Pt;Lower extremity.right>Femur;Doc;XR;RAD;2;XR Femur - right AP and Lateral;XR Femur-R AP+Lat;;ACTIVE;2.14;2.61 +37693-9;Views^W standing;Find;Pt;Lower extremity.right>Femur;Doc;XR;RAD;2;XR Femur - right Views W standing;XR Femur-R Views W Stand;;ACTIVE;2.14;2.64 +37694-7;Views 2;Find;Pt;Upper extremity.right>Finger;Doc;XR;RAD;2;XR Finger - right 2 Views;XR Finger-R 2V;;ACTIVE;2.14;2.61 +37695-4;Views 3;Find;Pt;Upper extremity.right>Finger;Doc;XR;RAD;2;XR Finger - right 3 Views;XR Finger-R 3V;;ACTIVE;2.14;2.61 +37696-2;Views AP + lateral + oblique;Find;Pt;Upper extremity.right>Finger;Doc;XR;RAD;2;XR Finger - right AP and Lateral and oblique;XR Finger-R AP+Lat+Obl;;ACTIVE;2.14;2.61 +3769-7;Metenolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Metenolone [Mass/volume] in Urine;Metenolone Ur-mCnc;;ACTIVE;1.0;2.34 +37697-0;Views 2;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right 2 Views;XR Foot-R 2V;;ACTIVE;2.14;2.73 +37698-8;Views 2^W standing;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right 2 Views W standing;XR Foot-R 2V W Stand;;ACTIVE;2.14;2.61 +37699-6;Views 3;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right 3 Views;XR Foot-R 3V;;ACTIVE;2.14;2.73 +37700-2;Views 3^W standing;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right 3 Views W standing;XR Foot-R 3V W Stand;;ACTIVE;2.14;2.61 +37701-0;Views AP + lateral;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right AP and Lateral;XR Foot-R AP+Lat;;ACTIVE;2.14;2.61 +37702-8;Views AP + lateral + oblique;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right AP and Lateral and oblique;XR Foot-R AP+Lat+Obl;;ACTIVE;2.14;2.61 +37703-6;View lateral;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right Lateral;XR Foot-R Lat;;ACTIVE;2.14;2.61 +37704-4;View oblique;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right Oblique;XR Foot-R Obl;;ACTIVE;2.14;2.64 +3770-5;Metenolone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Metenolone [Mass/time] in 24 hour Urine;Metenolone 24h Ur-mRate;;ACTIVE;1.0;2.19 +37705-1;Views^W manual stress;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right Views W manual stress;XR Foot-R Views W man stress;;ACTIVE;2.14;2.71 +37706-9;Multisection;Find;Pt;Lower extremity.right>Foot;Doc;XR.tomography;RAD;2;XR tomography Foot - right;XR tomo Foot-R;;ACTIVE;2.14;2.61 +37707-7;Views 2;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right 2 Views;XR Radius+Ulna-R 2V;;ACTIVE;2.14;2.61 +37708-5;Views AP + lateral;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right AP and Lateral;XR Radius+Ulna-R AP+Lat;;ACTIVE;2.14;2.61 +37709-3;Views oblique;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right Oblique Views;XR Radius+Ulna-R Views Obl;;ACTIVE;2.14;2.64 +37710-1;Views AP + lateral;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right AP and Lateral;XR Hand-R AP+Lat;;ACTIVE;2.14;2.61 +37711-9;Views AP + lateral + oblique;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right AP and Lateral and oblique;XR Hand-R AP+Lat+Obl;;ACTIVE;2.14;2.61 +37712-7;View lateral;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right Lateral;XR Hand-R Lat;;ACTIVE;2.14;2.61 +3771-3;Methadone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methadone [Presence] in Serum or Plasma;Methadone SerPl Ql;;ACTIVE;1.0;2.73 +37713-5;Views PA + lateral;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right PA and Lateral;XR Hand-R PA+Lat;;ACTIVE;2.14;2.61 +37714-3;View PA;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right PA;XR Hand-R PA;;ACTIVE;2.14;2.73 +37715-0;Views PA + lateral + oblique;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right PA and Lateral and Oblique;XR Hand-R PA+Lat+Obl;;ACTIVE;2.14;2.61 +37716-8;Views;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right Views;XR Hand-R Views;;ACTIVE;2.14;2.64 +37717-6;Multisection;Find;Pt;Upper extremity.right>Hand;Doc;XR.tomography;RAD;2;XR tomography Hand - right;XR tomo Hand-R;;ACTIVE;2.14;2.61 +37718-4;Views 2;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right 2 Views;XR Heel-R 2V;;ACTIVE;2.14;2.61 +37719-2;Views AP + lateral;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right AP and Lateral;XR Heel-R AP+Lat;;ACTIVE;2.14;2.61 +377-2;Ofloxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ofloxacin [Susceptibility] by Serum bactericidal titer;Ofloxacin Titr SBT;;ACTIVE;1.0;2.32 +37720-0;Views^W standing;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Views W standing;XR Heel-R Views W Stand;;ACTIVE;2.14;2.64 +3772-1;Methadone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Serum or Plasma;Methadone SerPl-mCnc;;ACTIVE;1.0;2.73 +37721-8;Views 2;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right 2 Views;XR Hip-R 2V;;ACTIVE;2.14;2.73 +37722-6;Views 3;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right 3 Views;XR Hip-R 3V;;ACTIVE;2.14;2.61 +37723-4;Views AP + lateral crosstable;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right AP and Lateral crosstable;XR Hip-R AP+Lat Xtable;;ACTIVE;2.14;2.61 +37724-2;Views AP + lateral frog;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right AP and Lateral frog;XR Hip-R AP+Lat frog;;ACTIVE;2.14;2.64 +37725-9;Views AP + lateral;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right AP and Lateral;XR Hip-R AP+Lat;;ACTIVE;2.14;2.61 +37726-7;View AP;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right AP;XR Hip-R AP;;ACTIVE;2.14;2.73 +37727-5;View lateral crosstable;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Lateral crosstable;XR Hip-R Lat Xtable;;ACTIVE;2.14;2.61 +37728-3;View oblique crosstable;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Oblique crosstable;XR Hip-R Obl Xtable;;ACTIVE;2.14;2.61 +37729-1;View lateral frog;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Lateral frog;XR Hip-R Lat frog;;ACTIVE;2.14;2.61 +37730-9;View lateral;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Lateral;XR Hip-R Lat;;ACTIVE;2.14;2.61 +37731-7;View^W standing;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Single view W standing;XR Hip-R 1V W Stand;;ACTIVE;2.14;2.64 +37732-5;View Judet;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Judet;XR Hip-R Judet;;ACTIVE;2.14;2.61 +37733-3;View AP^W standing;Find;Pt;Lower extremity.right;Doc;XR;RAD;2;XR Lower extremity - right AP W standing;XR LE-R AP W Stand;;ACTIVE;2.14;2.61 +37734-1;View^W standing;Find;Pt;Lower extremity.right;Doc;XR;RAD;2;XR Lower extremity - right Single view W standing;XR LE-R 1V W Stand;;ACTIVE;2.14;2.64 +37735-8;Multisection;Find;Pt;Lower extremity.right>Hip;Doc;XR.tomography;RAD;2;XR tomography Hip - right;XR tomo Hip-R;;ACTIVE;2.14;2.61 +37736-6;Views AP + lateral;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right AP and Lateral;XR Humerus-R AP+Lat;;ACTIVE;2.14;2.61 +37737-4;Views oblique;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right Oblique Views;XR Humerus-R Views Obl;;ACTIVE;2.14;2.64 +37738-2;Views;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right Views;XR Humerus-R Views;;ACTIVE;2.14;2.73 +3773-9;Methadone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methadone [Presence] in Urine;Methadone Ur Ql;;ACTIVE;1.0;2.73 +37739-0;Views^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.right;Doc;RF.angio;RAD;2;RFA Iliac artery - right Views W contrast IA;RFA Iliac a-R Views W contr IA;;ACTIVE;2.14;2.64 +37740-8;Views AP + lateral + Sunrise + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and Lateral and Sunrise and tunnel;XR Knee-R AP+Lat+Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37741-6;View;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Single view;XR Knee-R 1V;;ACTIVE;2.14;2.64 +37742-4;Views 3;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 3 Views;XR Knee-R 3V;;ACTIVE;2.14;2.61 +37743-2;Views 4;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 4 Views;XR Knee-R 4V;;ACTIVE;2.14;2.61 +37744-0;Views 5;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 5 Views;XR Knee-R 5V;;ACTIVE;2.14;2.61 +37745-7;Views AP + lateral;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and Lateral;XR Knee-R AP+Lat;;ACTIVE;2.14;2.61 +37746-5;Views AP^W manual stress;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Views AP W manual stress;XR Knee-R Views AP W man stress;;ACTIVE;2.14;2.71 +3774-7;Methadone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Urine;Methadone Ur-mCnc;;ACTIVE;1.0;2.73 +37747-3;Views AP + lateral + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and Lateral and Tunnel;XR Knee-R AP+Lat+Tunnel;;ACTIVE;2.14;2.61 +37748-1;Views AP + lateral + oblique;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and Lateral and oblique;XR Knee-R AP+Lat+Obl;;ACTIVE;2.14;2.61 +37749-9;Views AP + lateral + Sunrise;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and Lateral and Sunrise;XR Knee-R AP+Lat+Sunrise;;ACTIVE;2.14;2.61 +37750-7;View lateral^W extension;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Lateral W extension;XR Knee-R Lat W Ext;;ACTIVE;2.14;2.64 +37751-5;View lateral;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Lateral;XR Knee-R Lat;;ACTIVE;2.14;2.61 +37752-3;View Rosenberg^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Rosenberg W standing;XR Knee-R Rosenberg W Stand;;ACTIVE;2.14;2.61 +37753-1;Views^W manual stress;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Views W manual stress;XR Knee-R Views W man stress;;ACTIVE;2.14;2.71 +3775-4;Methadone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Methadone [Mass/time] in 24 hour Urine;Methadone 24h Ur-mRate;;ACTIVE;1.0;2.42 +37754-9;View lateral^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Lateral W standing;XR Knee-R Lat W Stand;;ACTIVE;2.14;2.61 +37755-6;View PA^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right PA W standing;XR Knee-R PA W Stand;;ACTIVE;2.14;2.61 +37756-4;View tunnel^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Tunnel W standing;XR Knee-R Tunnel W Stand;;ACTIVE;2.14;2.61 +37757-2;Views oblique;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Oblique Views;XR Knee-R Views Obl;;ACTIVE;2.14;2.64 +37758-0;Views;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Views;XR Knee-R Views;;ACTIVE;2.14;2.64 +37759-8;Views Sunrise + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Sunrise and Tunnel;XR Knee-R Sunrise+Tunnel;;ACTIVE;2.14;2.61 +37760-6;Multisection;Find;Pt;Lower extremity.right>Knee;Doc;XR.tomography;RAD;2;XR tomography Knee - right;XR tomo Knee-R;;ACTIVE;2.14;2.61 +37761-4;View tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Tunnel;XR Knee-R Tunnel;;ACTIVE;2.14;2.61 +3776-2;Methamphetamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methamphetamine [Mass/volume] in Blood;Methamphet Bld-mCnc;;ACTIVE;1.0;2.73 +37762-2;Views 2^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 Views W standing;XR Knee-R 2V W Stand;;ACTIVE;2.14;2.61 +37763-0;Views 4^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 4 Views W standing;XR Knee-R 4V W Stand;;ACTIVE;2.14;2.61 +37764-8;View;Find;Pt;Lower extremity.right;Doc;XR;RAD;2;XR Lower extremity - right Single view;XR LE-R 1V;;ACTIVE;2.14;2.64 +37765-5;Views^W contrast;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;RF.angio;RAD;2;RFA Lower extremity vessels - right Views W contrast;RFA LE ves-R Views W contr;;ACTIVE;2.14;2.64 +37766-3;Multisection;Find;Pt;Lower extremity.right;Doc;XR.tomography;RAD;2;XR tomography Lower extremity - right;XR tomo LE-R;;ACTIVE;2.14;2.61 +37767-1;Views^W contrast IV;Find;Pt;Lower extremity.right>Lower extremity veins;Doc;RF.angio;RAD;2;RFA Lower extremity veins - right Views W contrast IV;RFA LE vv-R Views W contr IV;;ACTIVE;2.14;2.64 +37768-9;Views 2;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right 2 Views;MG Brst-R 2V;;ACTIVE;2.14;2.61 +37769-7;Views magnification+spot;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Magnification and Spot;MG Brst-R Mag+Spot;;ACTIVE;2.14;2.61 +3777-0;Methamphetamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methamphetamine [Presence] in Serum or Plasma;Methamphet SerPl Ql;;ACTIVE;1.0;2.73 +37770-5;View tangential;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Tangential;MG Brst-R Tangential;;ACTIVE;2.14;2.61 +37771-3;View true lateral;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right True lateral;MG Brst-R True lat;;ACTIVE;2.14;2.61 +37772-1;View XCCL;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right XCCL;MG Brst-R XCCL;;ACTIVE;2.14;2.61 +37773-9;View magnification;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Magnification;MG Brst-R Mag;;ACTIVE;2.14;2.61 +37774-7;Views;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Views;MG Brst-R Views;;ACTIVE;2.14;2.64 +37775-4;Views rolled;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Rolled Views;MG Brst-R Views rolled;;ACTIVE;2.14;2.64 +37776-2;Views AP + lateral;Find;Pt;Lower extremity.right>Patella;Doc;XR;RAD;2;XR Patella - right AP and Lateral;XR Patella-R AP+Lat;;ACTIVE;2.14;2.61 +37777-0;Views;Find;Pt;Lower extremity.right>Patella;Doc;XR;RAD;2;XR Patella - right Views;XR Patella-R Views;;ACTIVE;2.14;2.64 +37778-8;Views^W contrast IA;Find;Pt;Lower extremity.right>Popliteal artery;Doc;RF.angio;RAD;2;RFA Popliteal artery - right Views W contrast IA;RFA Pop a-R Views W contr IA;;ACTIVE;2.14;2.64 +37779-6;Views^W contrast IA;Find;Pt;Chest>Pulmonary arteries.right;Doc;RF.angio;RAD;2;RFA Right pulmonary arteries Views W contrast IA;RFA PA-R Views W contr IA;;ACTIVE;2.14;2.64 +37780-4;Views 2;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right 2 Views;XR Ribs-R 2V;;ACTIVE;2.14;2.61 +37781-2;Views 3;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right 3 Views;XR Ribs-R 3V;;ACTIVE;2.14;2.61 +37782-0;Views anterior + lateral;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right Anterior and Lateral;XR Ribs-R Ant+Lat;;ACTIVE;2.14;2.61 +37783-8;View AP;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right AP;XR Ribs-R AP;;ACTIVE;2.14;2.61 +37784-6;View lateral;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right Lateral;XR Ribs-R Lat;;ACTIVE;2.14;2.61 +37785-3;Views^W contrast IS;Find;Pt;Pelvis>Sacroiliac joint.right;Doc;RF;RAD;2;RF Sacroiliac joint - right Arthrogram;RF SIJ-R Views W contr IS;;ACTIVE;2.14;2.64 +37786-1;Views;Find;Pt;Pelvis>Sacroiliac joint.right;Doc;XR;RAD;2;XR Sacroiliac joint - right Views;XR SIJ-R Views;;ACTIVE;2.14;2.64 +37787-9;Views 2;Find;Pt;Chest>Scapula.right;Doc;XR;RAD;2;XR Scapula - right 2 Views;XR Scapula-R 2V;;ACTIVE;2.14;2.61 +3778-8;Methamphetamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methamphetamine [Mass/volume] in Serum or Plasma;Methamphet SerPl-mCnc;;ACTIVE;1.0;2.73 +37788-7;Views AP + lateral;Find;Pt;Chest>Scapula.right;Doc;XR;RAD;2;XR Scapula - right AP and Lateral;XR Scapula-R AP+Lat;;ACTIVE;2.14;2.61 +37789-5;Views AP + Y;Find;Pt;Chest>Scapula.right;Doc;XR;RAD;2;XR Scapula - right AP and Y;XR Scapula-R AP+Y;;ACTIVE;2.14;2.61 +37790-3;View Y;Find;Pt;Chest>Scapula.right;Doc;XR;RAD;2;XR Scapula - right Y;XR Scapula-R Y;;ACTIVE;2.14;2.61 +37791-1;View Stryker Notch;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Stryker Notch;XR Should-R Stryker Notch;;ACTIVE;2.14;2.61 +37792-9;View;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Single view;XR Should-R 1V;;ACTIVE;2.14;2.64 +37793-7;Views 2;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right 2 Views;XR Should-R 2V;;ACTIVE;2.14;2.73 +37794-5;Views 4;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right 4 Views;XR Should-R 4V;;ACTIVE;2.14;2.61 +37795-2;Views 5;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right 5 Views;XR Should-R 5V;;ACTIVE;2.14;2.61 +3779-6;Methamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methamphetamine [Presence] in Urine;Methamphet Ur Ql;;ACTIVE;1.0;2.73 +37796-0;Views 6;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right 6 Views;XR Should-R 6V;;ACTIVE;2.14;2.61 +37797-8;Views AP + Stryker Notch;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and Stryker Notch;XR Should-R AP+Stryker Notch;;ACTIVE;2.14;2.61 +37798-6;View AP;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP;XR Should-R AP;;ACTIVE;2.14;2.61 +37799-4;Views AP + West Point + outlet;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and West Point and Outlet;XR Should-R AP+West Point+Outlet;;ACTIVE;2.14;2.61 +378-0;Oleandomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Oleandomycin [Susceptibility] by Minimum lethal concentration (MLC);Oleandomycin Islt MLC;;ACTIVE;1.0;2.19 +37800-0;View axillary;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Axillary;XR Should-R Ax;;ACTIVE;2.14;2.61 +37801-8;View Garth;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Garth;XR Should-R Garth;;ACTIVE;2.14;2.61 +37802-6;View outlet;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Outlet;XR Should-R Outlet;;ACTIVE;2.14;2.61 +37803-4;Views lateral + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Lateral and Y;XR Should-R Lat+Y;;ACTIVE;2.14;2.61 +3780-4;Methamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methamphetamine [Mass/volume] in Urine;Methamphet Ur-mCnc;;ACTIVE;1.0;2.73 +37804-2;Views outlet + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Outlet and Y;XR Should-R Outlet+Y;;ACTIVE;2.14;2.61 +37805-9;View Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Y;XR Should-R Y;;ACTIVE;2.14;2.61 +37806-7;Views Grashey + axillary + outlet;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey and Axillary and Outlet;XR Should-R Grashey+Ax+Outlet;;ACTIVE;2.14;2.61 +37807-5;Views axillary + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Axillary and Y;XR Should-R Ax+Y;;ACTIVE;2.14;2.61 +37808-3;View Serendipity;Find;Pt;Chest>Sternoclavicular joint.right;Doc;XR;RAD;2;XR Sternoclavicular joint - right Serendipity;XR SC joint-R Serendipity;;ACTIVE;2.14;2.61 +37809-1;View West Point;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right West Point;XR Should-R West Point;;ACTIVE;2.14;2.61 +37810-9;View Zanca;Find;Pt;Upper extremity.right>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - right Zanca;XR AC joint-R Zanca;;ACTIVE;2.14;2.61 +37811-7;Multisection;Find;Pt;Upper extremity.right>Shoulder;Doc;XR.tomography;RAD;2;XR tomography Shoulder - right;XR tomo Should-R;;ACTIVE;2.14;2.61 +3781-2;Methapyrilene;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methapyrilene [Presence] in Serum or Plasma;Methapyrilene SerPl Ql;;ACTIVE;1.0;2.56 +37812-5;Views 3;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right 3 Views;XR Thumb-R 3V;;ACTIVE;2.14;2.61 +37813-3;Views AP + lateral + oblique;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right AP and Lateral and oblique;XR Thumb-R AP+Lat+Obl;;ACTIVE;2.14;2.61 +37814-1;Views^W manual stress;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right Views W manual stress;XR Thumb-R Views W man stress;;ACTIVE;2.14;2.71 +37815-8;Views 2;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right 2 Views;XR Tib+Fib-R 2V;;ACTIVE;2.14;2.64 +37816-6;Views AP + lateral;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right AP and Lateral;XR Tib+Fib-R AP+Lat;;ACTIVE;2.14;2.73 +37817-4;Views oblique;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right Oblique Views;XR Tib+Fib-R Views Obl;;ACTIVE;2.14;2.64 +37818-2;Views^W contrast IS;Find;Pt;Head>Temporomandibular joint.right;Doc;RF;RAD;2;RF Temporomandibular joint - right Arthrogram;RF TMJ-R Views W contr IS;;ACTIVE;2.14;2.64 +37819-0;Multisection;Find;Pt;Head>Temporomandibular joint.right;Doc;XR.tomography;RAD;2;XR tomography Temporomandibular joint - right;XR tomo TMJ-R;;ACTIVE;2.14;2.61 +3782-0;Methapyrilene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methapyrilene [Mass/volume] in Serum or Plasma;Methapyrilene SerPl-mCnc;;ACTIVE;1.0;2.73 +37820-8;Views 3;Find;Pt;Lower extremity.right>Toes;Doc;XR;RAD;2;XR Toes - right 3 Views;XR Toes-R 3V;;ACTIVE;2.14;2.61 +37821-6;Views 2;Find;Pt;Lower extremity.right>Toes;Doc;XR;RAD;2;XR Toes - right 2 Views;XR Toes-R 2V;;ACTIVE;2.14;2.61 +37822-4;Views AP + lateral;Find;Pt;Lower extremity.right>Toes;Doc;XR;RAD;2;XR Toes - right AP and Lateral;XR Toes-R AP+Lat;;ACTIVE;2.14;2.61 +37823-2;Views^W standing;Find;Pt;Lower extremity.right>Toes;Doc;XR;RAD;2;XR Toes - right Views W standing;XR Toes-R Views W Stand;;ACTIVE;2.14;2.64 +37824-0;Views^W contrast IV;Find;Pt;Upper extremity.right>Upper extremity veins;Doc;RF.angio;RAD;2;RFA Upper extremity veins - right Views W contrast IV;RFA UE vv-R Views W contr IV;;ACTIVE;2.14;2.64 +37825-7;View;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Single view;XR Wrist-R 1V;;ACTIVE;2.14;2.64 +37826-5;Views 2;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 2 Views;XR Wrist-R 2V;;ACTIVE;2.14;2.61 +37827-3;Views 3;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 3 Views;XR Wrist-R 3V;;ACTIVE;2.14;2.73 +37828-1;Views 4;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 4 Views;XR Wrist-R 4V;;ACTIVE;2.14;2.61 +37829-9;Views 5;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 5 Views;XR Wrist-R 5V;;ACTIVE;2.14;2.61 +37830-7;Views 6;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 6 Views;XR Wrist-R 6V;;ACTIVE;2.14;2.61 +37831-5;Views 8;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 8 Views;XR Wrist-R 8V;;ACTIVE;2.14;2.61 +37832-3;Views AP + lateral;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right AP and Lateral;XR Wrist-R AP+Lat;;ACTIVE;2.14;2.61 +37833-1;View lateral^W extension;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Lateral W extension;XR Wrist-R Lat W Ext;;ACTIVE;2.14;2.61 +37834-9;View lateral^W flexion;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Lateral W flexion;XR Wrist-R Lat W Flx;;ACTIVE;2.14;2.61 +37835-6;Views PA + lateral;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right PA and Lateral;XR Wrist-R PA+Lat;;ACTIVE;2.14;2.61 +37836-4;Views PA + lateral + oblique;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right PA and Lateral and Oblique;XR Wrist-R PA+Lat+Obl;;ACTIVE;2.14;2.61 +37837-2;Views 3;Find;Pt;Wrist.right;Nar;XR;RAD;2;Deprecated Wrist Right X-ray 3 views;Deprecated Wrist-R XR 3V;;DEPRECATED;2.14;2.46 +3783-8;Methapyrilene;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methapyrilene [Presence] in Urine;Methapyrilene Ur Ql;;ACTIVE;1.0;2.73 +37838-0;Views 4;Find;Pt;Wrist.right;Nar;XR;RAD;2;Deprecated Wrist Right X-ray 4 views;Deprecated Wrist-R XR 4V;;DEPRECATED;2.14;2.46 +37839-8;Views AP + lateral + axillary;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP and Lateral and Axillary;XR Should AP+Lat+Ax;;ACTIVE;2.14;2.61 +37840-6;Views 2;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder 2 Views;XR Should 2V;;ACTIVE;2.14;2.61 +37841-4;Views AP + lateral;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP and Lateral;XR Should AP+Lat;;ACTIVE;2.14;2.61 +37842-2;View AP;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP;XR Should AP;;ACTIVE;2.14;2.61 +37843-0;View Garth;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Garth;XR Should Garth;;ACTIVE;2.14;2.61 +37844-8;View Grashey;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Grashey;XR Should Grashey;;ACTIVE;2.14;2.61 +37845-5;View outlet;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Outlet;XR Should Outlet;;ACTIVE;2.14;2.61 +3784-6;Methaqualone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methaqualone [Presence] in Serum or Plasma;Methaqualone SerPl Ql;;ACTIVE;1.0;2.73 +37846-3;View Serendipity;Find;Pt;Chest>Sternoclavicular joint;Doc;XR;RAD;2;XR Sternoclavicular Joint Serendipity;XR SC joint Serendipity;;ACTIVE;2.14;2.61 +37847-1;View Y;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Y;XR Should Y;;ACTIVE;2.14;2.61 +37848-9;View Zanca;Find;Pt;Upper extremity>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular Joint Zanca;XR AC joint Zanca;;ACTIVE;2.14;2.61 +37849-7;View axillary;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Axillary;XR Should Ax;;ACTIVE;2.14;2.61 +37850-5;Multisection;Find;Pt;Upper extremity>Shoulder;Doc;XR.tomography;RAD;2;XR tomography Shoulder;XR tomo Should;;ACTIVE;2.14;2.61 +37851-3;View;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Single view;XR Sinuses 1V;;ACTIVE;2.14;2.64 +37852-1;Views Caldwell + Waters;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Caldwell and Waters;XR Sinuses Caldwell+Waters;;ACTIVE;2.14;2.61 +3785-3;Methaqualone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methaqualone [Mass/volume] in Serum or Plasma;Methaqualone SerPl-mCnc;;ACTIVE;1.0;2.73 +37853-9;Views 2;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses 2 Views;XR Sinuses 2V;;ACTIVE;2.14;2.61 +37854-7;Views 3;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses 3 Views;XR Sinuses 3V;;ACTIVE;2.14;2.61 +37855-4;Views 4;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses 4 Views;XR Sinuses 4V;;ACTIVE;2.14;2.61 +37856-2;Views 5;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses 5 Views;XR Sinuses 5V;;ACTIVE;2.14;2.61 +37857-0;View Caldwell;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Caldwell;XR Sinuses Caldwell;;ACTIVE;2.14;2.61 +37858-8;View lateral;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Lateral;XR Sinuses Lat;;ACTIVE;2.14;2.61 +37859-6;Views PA + lateral + Waters;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses PA and Lateral and Waters;XR Sinuses PA+Lat+Waters;;ACTIVE;2.14;2.61 +37860-4;Views PA + lateral + Caldwell + Waters;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses PA and Lateral and Caldwell and Waters;XR Sinuses PA+Lat+Caldwell+Waters;;ACTIVE;2.14;2.61 +3786-1;Methaqualone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methaqualone [Presence] in Urine;Methaqualone Ur Ql;;ACTIVE;1.0;2.73 +37861-2;View submentovertex;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Submentovertex;XR Sinuses SMV;;ACTIVE;2.14;2.61 +37862-0;Views lateral + Waters;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Lateral and Waters;XR Sinuses Lat+Waters;;ACTIVE;2.14;2.61 +37863-8;View Waters;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Waters;XR Sinuses Waters;;ACTIVE;2.14;2.61 +37864-6;Views lateral + Caldwell + Waters;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Lateral and Caldwell and Waters;XR Sinuses Lat+Caldwell+Waters;;ACTIVE;2.14;2.61 +37865-3;View 1 limited;Find;Pt;Sinuses;Nar;XR;RAD;2;Deprecated Sinuses X-ray View;Deprecated Sinuses XR 1V Ltd;;DEPRECATED;2.14;2.36 +37866-1;Multisection;Find;Pt;Head>Sinuses;Doc;XR.tomography;RAD;2;XR tomography Sinuses;XR tomo Sinuses;;ACTIVE;2.14;2.61 +37867-9;Views 2;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull 2 Views;XR Skull 2V;;ACTIVE;2.14;2.61 +37868-7;Views 4;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull 4 Views;XR Skull 4V;;ACTIVE;2.14;2.61 +37869-5;Views lateral + Towne;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Lateral and Towne;XR Skull Lat+Towne;;ACTIVE;2.14;2.61 +37870-3;View Towne;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Towne;XR Skull Towne;;ACTIVE;2.14;2.61 +37871-1;Views lateral + Caldwell + Waters + Towne;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Lateral and Caldwell and Waters and Towne;XR Skull Lat+Caldwell+Waters+Towne;;ACTIVE;2.14;2.61 +37872-9;View lateral crosstable;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Lateral crosstable;XR Skull Lat Xtable;;ACTIVE;2.14;2.61 +37873-7;View 1 limited;Find;Pt;Skull;Nar;XR;RAD;2;Deprecated Skull X-ray View;Deprecated Skull XR 1V Ltd;;DEPRECATED;2.14;2.36 +37874-5;Multisection;Find;Pt;Head>Skull;Doc;XR.tomography;RAD;2;XR tomography Skull;XR tomo Skull;;ACTIVE;2.14;2.61 +37875-2;View;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Single view;XR Spine 1V;;DISCOURAGED;2.14;2.64 +37876-0;Views 4;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine 4 Views;XR Spine 4V;;DISCOURAGED;2.14;2.61 +37877-8;View AP;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine AP;XR Spine AP;;DISCOURAGED;2.14;2.61 +37878-6;View lateral crosstable;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Lateral crosstable;XR Spine Lat Xtable;;DISCOURAGED;2.14;2.61 +3787-9;Methaqualone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methaqualone [Mass/volume] in Urine;Methaqualone Ur-mCnc;;ACTIVE;1.0;2.73 +37879-4;Views 2;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine 2 Views;XR Spine 2V;;DISCOURAGED;2.14;2.61 +37880-2;View AP;Find;Pt;Chest>Sternoclavicular joint;Doc;XR;RAD;2;XR Sternoclavicular Joint AP;XR SC joint AP;;ACTIVE;2.14;2.61 +37881-0;Views 3;Find;Pt;Chest>Sternoclavicular joint;Doc;XR;RAD;2;XR Sternoclavicular Joint 3 Views;XR SC joint 3V;;ACTIVE;2.14;2.61 +37882-8;Views 4;Find;Pt;Chest>Sternoclavicular joint;Doc;XR;RAD;2;XR Sternoclavicular Joint 4 Views;XR SC joint 4V;;ACTIVE;2.14;2.61 +37883-6;Views 2;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum 2 Views;XR Sternum 2V;;ACTIVE;2.14;2.61 +37884-4;Views PA + lateral + oblique;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum PA and Lateral and Oblique;XR Sternum PA+Lat+Obl;;ACTIVE;2.14;2.61 +37885-1;Multisection;Find;Pt;Chest>Sternum;Doc;XR.tomography;RAD;2;XR tomography Sternum;XR tomo Sternum;;ACTIVE;2.14;2.61 +37886-9;Views^W contrast IA;Find;Pt;Chest>Subclavian artery;Doc;RF.angio;RAD;2;RFA Subclavian artery Views W contrast IA;RFA Subclavian a Views W contr IA;;ACTIVE;2.14;2.64 +3788-7;Methicillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methicillin [Mass/volume] in Serum or Plasma;Methicillin SerPl-mCnc;;ACTIVE;1.0;2.42 +37887-7;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Pleural space;Doc;RF;RAD;2;RF Guidance for fluid aspiration of Pleural space;RF Guided Pl space PC fluid asp;;ACTIVE;2.14;2.64 +37888-5;Views 3;Find;Pt;Upper extremity>Thumb;Doc;XR;RAD;2;XR Thumb 3 Views;XR Thumb 3V;;ACTIVE;2.14;2.61 +37889-3;Views AP + lateral;Find;Pt;Upper extremity>Thumb;Doc;XR;RAD;2;XR Thumb AP and Lateral;XR Thumb AP+Lat;;ACTIVE;2.14;2.61 +37890-1;View AP;Find;Pt;Upper extremity>Thumb;Doc;XR;RAD;2;XR Thumb AP;XR Thumb AP;;ACTIVE;2.14;2.61 +37891-9;View lateral;Find;Pt;Upper extremity>Thumb;Doc;XR;RAD;2;XR Thumb Lateral;XR Thumb Lat;;ACTIVE;2.14;2.61 +37892-7;View oblique;Find;Pt;Upper extremity>Thumb;Doc;XR;RAD;2;XR Thumb Oblique;XR Thumb Obl;;ACTIVE;2.14;2.64 +37893-5;View lateral;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula Lateral;XR Tib+Fib Lat;;ACTIVE;2.14;2.61 +37894-3;View;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula Single view;XR Tib+Fib 1V;;ACTIVE;2.14;2.64 +3789-5;Methocarbamol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methocarbamol [Presence] in Serum or Plasma;Methocarbamol SerPl Ql;;ACTIVE;1.0;2.56 +37895-0;Views 2;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula 2 Views;XR Tib+Fib 2V;;ACTIVE;2.14;2.61 +37896-8;Views AP + lateral;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula AP and Lateral;XR Tib+Fib AP+Lat;;ACTIVE;2.14;2.61 +37897-6;View AP;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula AP;XR Tib+Fib AP;;ACTIVE;2.14;2.61 +37898-4;Multisection;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR.tomography;RAD;2;XR tomography Tibia and Fibula;XR tomo Tib+Fib;;ACTIVE;2.14;2.61 +37899-2;Views^W standing;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula Views W standing;XR Tib+Fib Views W Stand;;ACTIVE;2.14;2.64 +37900-8;Views^W contrast IA;Find;Pt;Lower extremity>Tibial artery;Doc;RF.angio;RAD;2;Deprecated RFA Tibial artery W contrast IA;Deprecated RFA Tibl a W contr IA;;DEPRECATED;2.14;2.64 +37901-6;Views^W contrast IS;Find;Pt;Head>Temporomandibular joint;Doc;RF;RAD;2;RF Temporomandibular joint Arthrogram;RF TMJ Views W contr IS;;ACTIVE;2.14;2.64 +37902-4;Views 2;Find;Pt;Lower extremity>Toes;Doc;XR;RAD;2;XR Toes 2 Views;XR Toes 2V;;ACTIVE;2.14;2.61 +3790-3;Methocarbamol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methocarbamol [Mass/volume] in Serum or Plasma;Methocarbamol SerPl-mCnc;;ACTIVE;1.0;2.73 +37903-2;View lateral crosstable;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Lateral crosstable;XR T-spine Lat Xtable;;ACTIVE;2.14;2.61 +37904-0;View;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Single view;XR T-spine 1V;;ACTIVE;2.14;2.64 +37905-7;Views 2;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 2 Views;XR T-spine 2V;;ACTIVE;2.14;2.61 +37906-5;Views 3;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 3 Views;XR T-spine 3V;;ACTIVE;2.14;2.61 +37907-3;Views 4;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 4 Views;XR T-spine 4V;;ACTIVE;2.14;2.61 +37908-1;Views AP + lateral + oblique;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine AP and Lateral and oblique;XR T-spine AP+Lat+Obl;;ACTIVE;2.14;2.61 +37909-9;View lateral^W hyperextension;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Lateral W hyperextension;XR T-spine Lat W hyperext;;ACTIVE;2.14;2.64 +37910-7;View lateral^W standing;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Lateral W standing;XR T-spine Lat W Stand;;ACTIVE;2.14;2.61 +3791-1;Methocarbamol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methocarbamol [Presence] in Urine;Methocarbamol Ur Ql;;ACTIVE;1.0;2.73 +37911-5;Multisection;Find;Pt;Chest>Spine.thoracic;Doc;XR.tomography;RAD;2;XR tomography Thoracic spine;XR tomo T-spine;;ACTIVE;2.14;2.61 +37912-3;Guidance for percutaneous biopsy;Find;Pt;Breast.bilateral;Doc;US;RAD;2;US Guidance for biopsy of Breast - bilateral;US Guided Brst-Bl Bx;;ACTIVE;2.14;2.64 +37913-1;Guidance for percutaneous biopsy;Find;Pt;Abdomen;Doc;US;RAD;2;US Guidance for biopsy of Abdomen;US Guided Abd Bx;;ACTIVE;2.14;2.64 +37914-9;Guidance for percutaneous biopsy;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for biopsy of Breast;US Guided Brst Bx;;ACTIVE;2.14;2.64 +37915-6;Guidance for percutaneous biopsy;Find;Pt;Chest;Doc;US;RAD;2;US Guidance for biopsy of Chest;US Guided Chest Bx;;ACTIVE;2.14;2.64 +37916-4;Guidance for biopsy.needle;Find;Pt;XXX>Lymph node;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Lymph node;Deprecated US LN Bx needle guide;;DEPRECATED;2.14;2.63 +37917-2;Guidance for percutaneous biopsy;Find;Pt;XXX>Muscle;Doc;US;RAD;2;US Guidance for percutaneous biopsy of Muscle;US Guided Muscle Bx;;ACTIVE;2.14;2.64 +37918-0;Guidance for percutaneous biopsy;Find;Pt;Neck;Doc;US;RAD;2;US Guidance for biopsy of Neck;US Guided Neck Bx;;ACTIVE;2.14;2.64 +37919-8;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Pancreas;Doc;US;RAD;2;US Guidance for biopsy of Pancreas;US Guided Pancreas Bx;;ACTIVE;2.14;2.64 +37920-6;Guidance for percutaneous biopsy;Find;Pt;Head>Salivary gland;Doc;US;RAD;2;US Guidance for biopsy of Salivary gland;US Guided Salivary gland Bx;;ACTIVE;2.14;2.64 +37921-4;Guidance for needle localization;Find;Pt;Chest;Doc;US;RAD;2;US Guidance for needle localization of Chest;US Guided Chest Needle loc;;ACTIVE;2.14;2.64 +37922-2;Views 2;Find;Pt;Upper extremity;Doc;XR;RAD;2;XR Upper extremity 2 Views;XR UE 2V;;ACTIVE;2.14;2.61 +37923-0;Multisection;Find;Pt;Upper extremity;Doc;XR.tomography;RAD;2;XR tomography Upper extremity;XR tomo UE;;ACTIVE;2.14;2.61 +37924-8;View;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Single view;XR Wrist 1V;;ACTIVE;2.14;2.64 +37925-5;Views 2;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist 2 Views;XR Wrist 2V;;ACTIVE;2.14;2.61 +37926-3;Views 3;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist 3 Views;XR Wrist 3V;;ACTIVE;2.14;2.61 +37927-1;Views AP + lateral + oblique;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist AP and Lateral and oblique;XR Wrist AP+Lat+Obl;;ACTIVE;2.14;2.61 +37928-9;View Brewerton;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Brewerton;XR Wrist Brewerton;;ACTIVE;2.14;2.61 +3792-9;Methotrexate;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Cerebral spinal fluid;MTX CSF-mCnc;;ACTIVE;1.0;2.42 +37929-7;Views lateral^W flexion + W extension;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Lateral Views W flexion and W extension;XR Wrist Views Lat W FE;;ACTIVE;2.14;2.64 +37930-5;View lateral;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Lateral;XR Wrist Lat;;ACTIVE;2.14;2.61 +37931-3;View PA;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist PA;XR Wrist PA;;ACTIVE;2.14;2.61 +37932-1;Multisection;Find;Pt;Upper extremity>Wrist;Doc;XR.tomography;RAD;2;XR tomography Wrist;XR tomo Wrist;;ACTIVE;2.14;2.61 +37933-9;Views 3;Find;Pt;Head>Zygomatic arch;Doc;XR;RAD;2;XR Zygomatic arch 3 Views;XR Zygomatic arch 3V;;ACTIVE;2.14;2.61 +37934-7;Views 4;Find;Pt;Head>Zygomatic arch;Doc;XR;RAD;2;XR Zygomatic arch 4 Views;XR Zygomatic arch 4V;;ACTIVE;2.14;2.61 +37935-4;Views^W contrast IA;Find;Pt;Pelvis>Pelvis arteries & Lower extremity.bilateral>Lower extremity arteries;Doc;RF.angio;RAD;2;RFA Pelvis arteries and Lower extremity arteries - bilateral Views W contrast IA;RFA Pelvis aa+LE aa-Bl Views W contr IA;;ACTIVE;2.14;2.64 +37936-2;Views^W contrast;Find;Pt;XXX>Peripheral vessels;Doc;RF.angio;RAD;2;RFA Peripheral vessels Views W contrast;RFA Periph ves Views W contr;;ACTIVE;2.14;2.64 +3793-7;Methotrexate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Serum or Plasma;MTX SerPl-mCnc;;ACTIVE;1.0;2.73 +37937-0;Views;Find;Pt;Chest>Ribs.anterior;Doc;XR;RAD;2;XR Ribs anterior Views;XR Ribs Ant Views;;ACTIVE;2.14;2.73 +37938-8;Views;Find;Pt;Chest>Ribs.posterior;Doc;XR;RAD;2;XR Ribs posterior Views;XR Ribs post Views;;ACTIVE;2.14;2.64 +37939-6;Views^W contrast IA;Find;Pt;Abdomen>Adrenal artery.right;Doc;RF.angio;RAD;2;RFA Adrenal artery - right Views W contrast IA;RFA Adrenal a-R Views W contr IA;;ACTIVE;2.14;2.64 +37940-4;Views^W contrast IV;Find;Pt;Abdomen>Adrenal vein.right;Doc;RF.angio;RAD;2;RFA Adrenal vein - right Views W contrast IV;RFA Adrenal v-R Views W contr IV;;ACTIVE;2.14;2.64 +37941-2;Views^W contrast IA;Find;Pt;Lower extremity.right>Ankle arteries;Doc;RF.angio;RAD;2;RFA Ankle arteries - right Views W contrast IA;RFA Ankle aa-R Views W contr IA;;ACTIVE;2.14;2.64 +37942-0;Views^W contrast IS;Find;Pt;Lower extremity.right>Ankle;Doc;RF;RAD;2;RF Ankle - right Arthrogram;RF Ankle-R Views W contr IS;;ACTIVE;2.14;2.64 +37943-8;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries.right+Vertebral artery.right;Doc;RF.angio;RAD;2;RFA Carotid arteries and Vertebral artery - right Views W contrast IA;RFA Carot aa+VA-R Views W contr IA;;ACTIVE;2.14;2.64 +37944-6;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery & Head>Cerebral artery.right;Doc;RF.angio;RAD;2;RFA Carotid artery and Cerebral artery - right Views W contrast IA;RFA Carot a+Cerebral a-R Vs W contr IA;;ACTIVE;2.14;2.64 +3794-5;Methotrexate^1-2w post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Serum or Plasma --1-2 weeks post dose;MTX 1-2W p SerPl-mCnc;;ACTIVE;1.0;2.34 +37945-3;Views^W contrast IA;Find;Pt;Neck>Carotid artery.cervical.right;Doc;RF.angio;RAD;2;RFA Carotid artery.cervical - right Views W contrast IA;RFA Carot a.cervical-R Views W contr IA;;ACTIVE;2.14;2.64 +37947-9;Views^W contrast IS;Find;Pt;Upper extremity.right>Elbow;Doc;RF;RAD;2;RF Elbow - right Arthrogram;RF Elbow-R Views W contr IS;;ACTIVE;2.14;2.64 +37948-7;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery.external.right;Doc;RF.angio;RAD;2;RFA Carotid artery.external - right Views W contrast IA;RFA Carot a.ext-R Views W contr IA;;ACTIVE;2.14;2.64 +37949-5;Views^W contrast IA;Find;Pt;Extremity.right>Extremity arteries;Doc;RF.angio;RAD;2;RFA Extremity arteries - right Views W contrast IA;RFA Extr aa-R Views W contr IA;;ACTIVE;2.14;2.64 +37950-3;Views^W contrast IV;Find;Pt;Extremity.right>Extremity veins;Doc;RF.angio;RAD;2;RFA Extremity veins - right Views W contrast IV;RFA Extr vv-R Views W contr IV;;ACTIVE;2.14;2.64 +3795-2;Methotrexate^24H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Serum or Plasma --24 hours post dose;MTX 24h p SerPl-mCnc;;ACTIVE;1.0;2.34 +37952-9;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery.internal.right;Doc;RF.angio;RAD;2;RFA Carotid artery.internal - right Views W contrast IA;RFA Carot a.int-R Views W contr IA;;ACTIVE;2.14;2.64 +37953-7;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery & Head>Cerebral artery internal.right;Doc;RF.angio;RAD;2;RFA Carotid artery and Cerebral artery internal - right Views W contrast IA;RFA Carot a+Cereb a.int-R Vs W contr IA;;ACTIVE;2.14;2.64 +37954-5;Views^W contrast IV;Find;Pt;Head+Neck>Jugular vein.right;Doc;RF.angio;RAD;2;Deprecated RFA Jugular vein - right W contrast IV;Deprecated RFA Jugular v-R W contr IV;;DEPRECATED;2.14;2.64 +37958-6;Views^W contrast IV;Find;Pt;Head>Orbit veins.right;Doc;RF.angio;RAD;2;RFA Orbit veins - right Views W contrast IV;RFA Orbit vv-R Views W contr IV;;ACTIVE;2.14;2.64 +37959-4;Views^W contrast IV;Find;Pt;Abdomen>Renal vein.right;Doc;RF.angio;RAD;2;RFA Renal vein - right Views W contrast IV;RFA Renal v-R Views W contr IV;;ACTIVE;2.14;2.64 +3796-0;Methotrexate^48H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Serum or Plasma --48 hours post dose;MTX 48h p SerPl-mCnc;;ACTIVE;1.0;2.34 +37960-2;Views;Find;Pt;Chest>Ribs.lower.right;Doc;XR;RAD;2;XR Ribs lower - right Views;XR Ribs.lower-R Views;;ACTIVE;2.14;2.64 +37961-0;Views;Find;Pt;Chest>Ribs.upper.right;Doc;XR;RAD;2;XR Ribs upper - right Views;XR Ribs upper-R Views;;ACTIVE;2.14;2.64 +37962-8;Views;Find;Pt;Chest>Ribs.anterior.right+Ribs.posterior.right;Doc;XR;RAD;2;XR Ribs anterior and posterior - right Views;XR Ribs Ant+Post-R Views;;ACTIVE;2.14;2.64 +37963-6;Views;Find;Pt;Chest>Ribs.anterior.right;Doc;XR;RAD;2;XR Ribs anterior - right Views;XR Ribs Ant-R Views;;ACTIVE;2.14;2.64 +37964-4;Views;Find;Pt;Chest>Ribs.posterior.right;Doc;XR;RAD;2;XR Ribs posterior - right Views;XR Ribs post-R Views;;ACTIVE;2.14;2.73 +37965-1;Views;Find;Pt;Chest>Sternoclavicular joint.right;Doc;XR;RAD;2;XR Sternoclavicular joint - right Views;XR SC joint-R Views;;ACTIVE;2.14;2.64 +37966-9;Views^W contrast IA;Find;Pt;Chest>Subclavian artery.right;Doc;RF.angio;RAD;2;RFA Subclavian artery - right Views W contrast IA;RFA Subclavian a-R Views W contr IA;;ACTIVE;2.14;2.64 +37967-7;Views^W contrast IA;Find;Pt;Upper extremity.right>Upper extremity arteries;Doc;RF.angio;RAD;2;RFA Upper extremity arteries - right Views W contrast IA;RFA UE aa-R Views W contr IA;;ACTIVE;2.14;2.64 +37968-5;Views^W contrast IA;Find;Pt;Head+Neck>Vertebral artery.right;Doc;RF.angio;RAD;2;RFA Vertebral artery - right Views W contrast IA;RFA VA-R Views W contr IA;;ACTIVE;2.14;2.64 +37969-3;Views^W contrast IV;Find;Pt;Head>Sinus vein;Doc;RF.angio;RAD;2;RFA Sinus vein Views W contrast IV;RFA Sinus v Views W contr IV;;ACTIVE;2.14;2.64 +37970-1;Views^W contrast IV;Find;Pt;Abdomen>Splenic vein;Doc;RF.angio;RAD;2;RFA Splenic vein Views W contrast IV;RFA Splenic v Views W contr IV;;ACTIVE;2.14;2.64 +37971-9;Views^W contrast IV;Find;Pt;Chest>Subclavian vein;Doc;RF.angio;RAD;2;RFA Subclavian vein Views W contrast IV;RFA Subclavian v Views W contr IV;;ACTIVE;2.14;2.64 +37972-7;Views^W contrast IV;Find;Pt;Abdomen>Superior mesenteric vein;Doc;RF.angio;RAD;2;RFA Superior mesenteric vein Views W contrast IV;RFA SM v Views W contr IV;;ACTIVE;2.14;2.64 +37973-5;Views^W contrast;Find;Pt;Pelvis>Testicular vessels;Doc;RF;RAD;2;RF Testicular vessels Views W contrast;RF Testicle ves Views W contr;;ACTIVE;2.14;2.64 +37974-3;Views AP + lateral;Find;Pt;Chest+Abdomen>Spine.thoracolumbar junction;Doc;XR;RAD;2;XR Spine thoracolumbar junction AP and Lateral;XR TLJ AP+Lat;;ACTIVE;2.14;2.61 +37975-0;Views;Find;Pt;Chest+Abdomen>Spine.thoracolumbar junction;Doc;XR;RAD;2;XR Spine thoracolumbar junction Views;XR TLJ Views;;ACTIVE;2.14;2.64 +37976-8;Views^W contrast;Find;Pt;Upper extremity>Upper extremity vessels;Doc;RF.angio;RAD;2;RFA Upper extremity vessels Views W contrast;RFA UE ves Views W contr;;ACTIVE;2.14;2.64 +37977-6;Views^W contrast IA;Find;Pt;Upper extremity>Upper extremity arteries;Doc;RF.angio;RAD;2;RFA Upper extremity arteries Views W contrast IA;RFA UE aa Views W contr IA;;ACTIVE;2.14;2.64 +3797-8;Methotrexate^72H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Mass/volume] in Serum or Plasma --72 hours post dose;MTX 72h p SerPl-mCnc;;ACTIVE;1.0;2.34 +37979-2;Views^W contrast IA;Find;Pt;Pelvis>Uterine artery;Doc;RF.angio;RAD;2;RFA Uterine artery Views W contrast IA;RFA Uterine a Views W contr IA;;ACTIVE;2.14;2.64 +379-8;Oleandomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Oleandomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Oleandomycin Islt MIC;;ACTIVE;1.0;2.19 +37980-0;Views^W contrast;Find;Pt;XXX>Vertebral vessels;Doc;RF.angio;RAD;2;RFA Vertebral vessels Views W contrast;RFA Vertebral ves Views W contr;;ACTIVE;2.14;2.64 +37981-8;Views^W contrast;Find;Pt;XXX>Visceral vessels;Doc;RF.angio;RAD;2;RFA Visceral vessels Views W contrast;RFA Visceral ves Views W contr;;ACTIVE;2.14;2.64 +37982-6;Avian paramyxovirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Avian paramyxovirus [Presence] in Specimen by Organism specific culture;APMV Spec Ql Cult;;ACTIVE;2.13;2.69 +37983-4;Eastern equine encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Eastern equine encephalitis virus RNA [Presence] in Specimen by Probe;EEEV RNA Spec Ql Probe;;ACTIVE;2.13;2.69 +37984-2;Saint Louis encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Saint Louis encephalitis virus RNA [Presence] in Specimen by Probe;SLEV RNA Spec Ql Probe;;ACTIVE;2.13;2.73 +37985-9;West Nile virus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;West Nile virus RNA [Presence] in Specimen by Probe;WNV RNA Spec Ql Probe;;ACTIVE;2.13;2.69 +3798-6;Methoxyphenamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methoxyphenamine [Presence] in Urine;Methoxyphenamine Ur Ql;;ACTIVE;1.0;2.56 +37986-7;California serogroup virus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;California serogroup RNA [Presence] in Specimen by Probe;CSGV RNA Spec Ql Probe;;ACTIVE;2.13;2.69 +37987-5;(Blatella germanica+Dermatophagoides farinae+Dermatophagoides pteronyssinus+House dust Hollister Stier) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Dust Allergen Mix 2 (Cockroach+American house dust mite+European house dust mite+House dust Hollister Stier) IgE Ab [Units/volume] in Serum by Multidisk;Dust Allerg Mix2 IgE Qn;;ACTIVE;2.13;2.73 +37988-3;(Aspergillus fumigatus+Blatella germanica+Cat dander+Dermatophagoides pteronyssinus) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Regional Allergy Mix 5 (Aspergillus fumigatus+Cockroach+Cat dander+European house dust mite) IgE Ab [Units/volume] in Serum by Multidisk;Region Allerg Mix5 IgE Qn;;ACTIVE;2.13;2.70 +37989-1;(Artemisia vulgaris+Betula verrucosa+Cat dander+Cladosporium herbarum+Dermatophagoides pteronyssinus+Dog dander+Phleum pratense+Secale cereale) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Inhalant Allergen Mix 8 (Mugwort+Common silver birch+Cat dander+C herbarum+Dermatophagoides pteronyssinus+Dog dander+Timothy grass+Rye) IgE Ab [Presence] in Serum by Multidisk;Inhalant Allerg Mix 8 IgE Ql;;ACTIVE;2.13;2.56 +37990-9;Corticotropin releasing hormone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Corticotropin releasing hormone [Moles/volume] in Serum or Plasma;ACTH RH SerPl-sCnc;;ACTIVE;2.13;2.70 +37991-7;Neutrophil cytoplasmic Ab.perinuclear;ACnc;Pt;Ser;Qn;IA;SERO;1;Neutrophil cytoplasmic Ab.perinuclear [Units/volume] in Serum by Immunoassay;p-ANCA Ser IA-aCnc;;ACTIVE;2.13;2.73 +37992-5;Neutrophil cytoplasmic Ab.classic;ACnc;Pt;Ser;Qn;IA;SERO;1;Neutrophil cytoplasmic Ab.classic [Units/volume] in Serum by Immunoassay;c-ANCA Ser IA-aCnc;;ACTIVE;2.13;2.70 +37993-3;DNA double strand Ab;MCnc;Pt;Ser;Qn;RIA;SERO;1;DNA double strand Ab [Mass/volume] in Serum by Radioimmunoassay (RIA);dsDNA Ab Ser RIA-mCnc;;ACTIVE;2.13;2.73 +3799-4;Methoxyphenamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methoxyphenamine [Mass/volume] in Urine;Methoxyphenamine Ur-mCnc;;ACTIVE;1.0;2.34 +37994-1;Multisection^WO contrast;Find;Pt;Abdomen>Spine.lumbar vessels;Doc;MR.angio;RAD;2;MRA Lumbar spine vessels WO contrast;MRA L-spine ves WO contr;;ACTIVE;2.14;2.61 +37995-8;Views Broden;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral Broden Views;XR Heel-Bl Views Broden;;ACTIVE;2.14;2.64 +37996-6;Views Broden;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus Broden Views;XR Heel Views Broden;;ACTIVE;2.14;2.64 +37997-4;Views Broden;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Broden Views;XR Heel-L Views Broden;;ACTIVE;2.14;2.64 +37998-2;View radial head capitellar;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow Radial head capitellar;XR Elbow Radial head capitellar;;ACTIVE;2.14;2.61 +37999-0;View radial head capitellar;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral Radial head capitellar;XR Elbow-Bl Radial head capitellar;;ACTIVE;2.14;2.61 +38-0;Azithromycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Azithromycin [Susceptibility] by Serum bactericidal titer;Azithromycin Titr SBT;;ACTIVE;1.0;2.32 +3800-0;Methoxyphenamine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Methoxyphenamine [Mass/time] in 24 hour Urine;Methoxyphenamine 24h Ur-mRate;;ACTIVE;1.0;2.19 +38000-6;View radial head capitellar;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left Radial head capitellar;XR Elbow-L Radial head capitellar;;ACTIVE;2.14;2.61 +38001-4;View^W expiration;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Single view W expiration;XR Chest 1V W Exp;;ACTIVE;2.14;2.64 +38002-2;View^W inspiration;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Single view W inspiration;XR Chest 1V W Insp;;ACTIVE;2.14;2.64 +38003-0;Views AP^W standing;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left Views AP W standing;XR Foot-L Views AP W Stand;;ACTIVE;2.14;2.64 +38004-8;Views Grashey^WO & W weight;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey Views WO and W weight;XR Should-L Views Grashey WO+W Wt;;ACTIVE;2.14;2.64 +38006-3;View radial head capitellar;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Radial head capitellar;XR Elbow-R Radial head capitellar;;ACTIVE;2.14;2.61 +38007-1;View transthoracic;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right Transthoracic;XR Humerus-R Transthoracic;;ACTIVE;2.14;2.61 +38008-9;Views;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Cervical and thoracic and lumbar spine Views;XR C+T+L-spine Views;;ACTIVE;2.14;2.64 +38009-7;Views AP + lateral + Swimmers;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine AP and Lateral and Swimmers;XR T-spine AP+Lat+Swimmers;;ACTIVE;2.14;2.61 +38010-5;Views lateral^W flexion + W extension;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Lateral Views W flexion and W extension;XR T-spine Views Lat W FE;;ACTIVE;2.14;2.64 +38011-3;Multisection limited;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;US;RAD;2;US Thoracic and abdominal aorta limited;US TA + AA Ltd;;ACTIVE;2.14;2.61 +38012-1;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast.bilateral;Doc;US;RAD;2;US Guidance for aspiration of cyst of Breast - bilateral;US Guided Brst-Bl Cyst asp;;ACTIVE;2.14;2.64 +38013-9;Multisection;Find;Pt;Lower extremity.bilateral;Doc;US;RAD;2;US Lower extremity - bilateral;US LE-Bl;;ACTIVE;2.14;2.61 +38014-7;Multisection;Find;Pt;Upper extremity.bilateral>Upper extremity artery;Doc;US;RAD;2;US Upper extremity artery - bilateral;US UE a-Bl;;ACTIVE;2.14;2.61 +38015-4;Multisection limited;Find;Pt;Head+Neck>Carotid arteries;Doc;US;RAD;2;US Carotid arteries limited;US Carotid aa Ltd;;ACTIVE;2.14;2.61 +38016-2;Multisection;Find;Pt;Chest>Chest wall;Doc;US;RAD;2;US Chest wall;US Chest wall;;ACTIVE;2.14;2.73 +38017-0;Guidance for aspiration.fine needle;Find;Pt;Pelvis>Prostate;Doc;US;RAD;2;US Guidance for FNA of Prostate;US Guided Prostate FNA;;ACTIVE;2.14;2.64 +3801-8;Methsuximide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methsuximide [Mass/volume] in Serum or Plasma;Methsuximide SerPl-mCnc;;ACTIVE;1.0;2.73 +38018-8;Guidance for percutaneous aspiration.fine needle;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for fine needle aspiration of Unspecified body region;US Guided FNA;;ACTIVE;2.14;2.64 +38019-6;Guidance for percutaneous aspiration.fine needle;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;US Guidance for fine needle aspiration of Thyroid gland;US Guided Thyroid FNA;;ACTIVE;2.14;2.64 +38020-4;Multisection limited;Find;Pt;Abdomen>Gallbladder;Doc;US;RAD;2;US Gallbladder limited;US GB Ltd;;ACTIVE;2.14;2.61 +38021-2;Multisection;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;US;RAD;2;US Biliary ducts and Gallbladder;US BDs+GB;;ACTIVE;2.14;2.61 +38022-0;Multisection^W cholecystokinin;Find;Pt;Abdomen>Gallbladder;Doc;US;RAD;2;US Gallbladder W cholecystokinin;US GB W CCK;;ACTIVE;2.14;2.61 +38023-8;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for percutaneous biopsy.core needle of Breast - left;US Guided Brst-L PC Bx CN;;ACTIVE;2.14;2.64 +38024-6;Guidance for biopsy.core needle;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for core needle biopsy of Unspecified body region;US Guided CN Bx;;ACTIVE;2.14;2.64 +38025-3;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for percutaneous biopsy.core needle of Breast - right;US Guided Brst-R PC Bx CN;;ACTIVE;2.14;2.64 +3802-6;Methyldopa;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyldopa [Mass/volume] in Serum or Plasma;Methyldopa SerPl-mCnc;;ACTIVE;1.0;2.42 +38026-1;Guidance for percutaneous aspiration.fine needle;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for fine needle aspiration of Breast - left;US Guided Brst-L FNA;;ACTIVE;2.14;2.73 +38027-9;Guidance for biopsy.needle;Find;Pt;Abdomen>Kidney.bilateral;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Kidney - bilateral;Deprecated US Kdny-Bl Bx needle guide;;DEPRECATED;2.14;2.63 +38028-7;Guidance for biopsy.needle;Find;Pt;Breast;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Breast;Deprecated US Brst Bx needle guide;;DEPRECATED;2.14;2.63 +38029-5;Guidance for biopsy.needle;Find;Pt;Chest;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Chest;Deprecated US Chest Bx needle guide;;DEPRECATED;2.14;2.63 +38030-3;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Spleen;Doc;US;RAD;2;US Guidance for biopsy of Spleen;US Guided Spleen Bx;;ACTIVE;2.14;2.64 +38031-1;Guidance for biopsy.needle;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Thyroid gland;Deprecated US Thyroid Bx needle guide;;DEPRECATED;2.14;2.63 +38032-9;Guidance for needle localization;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for needle localization of Unspecified body region;US Guided Needle loc;;ACTIVE;2.14;2.64 +38033-7;Guidance for percutaneous aspiration.fine needle;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for fine needle aspiration of Breast - right;US Guided Brst-R FNA;;ACTIVE;2.14;2.73 +3803-4;MethylePHEDrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;MethylePHEDrine [Presence] in Urine;Me-ePHEDrine Ur Ql;;ACTIVE;1.0;2.73 +38034-5;Multisection limited;Find;Pt;Head;Doc;US;RAD;2;US Head limited;US Head Ltd;;ACTIVE;2.14;2.61 +38035-2;Multisection limited;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Kidney limited;US Kidney Ltd;;ACTIVE;2.14;2.61 +38036-0;Multisection;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Kidney;US Kidney;;ACTIVE;2.14;2.73 +38037-8;Multisection;Find;Pt;Lower extremity.left>Femur;Doc;US;RAD;2;US Femur - left;US Femur-L;;ACTIVE;2.14;2.61 +38038-6;Multisection;Find;Pt;Abdomen>Kidney.left;Doc;US;RAD;2;US Kidney - left;US Kidney-L;;ACTIVE;2.14;2.73 +38039-4;Multisection limited;Find;Pt;Lower extremity.left;Doc;US;RAD;2;US Lower extremity - left limited;US LE-L Ltd;;ACTIVE;2.14;2.61 +38040-2;Multisection;Find;Pt;Lower extremity.left;Doc;US;RAD;2;US Lower extremity - left;US LE-L;;ACTIVE;2.14;2.61 +38041-0;Multisection;Find;Pt;Upper extremity.left;Doc;US;RAD;2;US Upper extremity - left;US UE-L;;ACTIVE;2.14;2.61 +3804-2;MethylePHEDrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;MethylePHEDrine [Mass/volume] in Urine;Me-ePHEDrine Ur-mCnc;;ACTIVE;1.0;2.73 +38042-8;Multisection limited;Find;Pt;Lower extremity>Lower extremity artery;Doc;US.doppler;RAD;2;US.doppler Lower extremity artery limited;DOP LE a Ltd;;ACTIVE;2.14;2.61 +38043-6;Multisection;Find;Pt;Head>Mastoid;Doc;US;RAD;2;US Mastoid;US Mastoid;;ACTIVE;2.14;2.61 +38044-4;Multisection;Find;Pt;Chest>Mediastinum;Doc;US;RAD;2;US Mediastinum;US Mediastinum;;ACTIVE;2.14;2.61 +38045-1;Multisection;Find;Pt;Neck>Parathyroid gland;Doc;US;RAD;2;US Parathyroid gland;US Parathyroid gland;;ACTIVE;2.14;2.61 +38046-9;Multisection limited;Find;Pt;Pelvis;Doc;US;RAD;2;US Pelvis limited;US Pelvis Ltd;;ACTIVE;2.14;2.73 +38047-7;Multisection limited;Find;Pt;Abdomen>Retroperitoneum;Doc;US;RAD;2;US Retroperitoneum limited;US Retroperitoneum Ltd;;ACTIVE;2.14;2.73 +38048-5;Multisection;Find;Pt;Lower extremity.right>Femur;Doc;US;RAD;2;US Femur - right;US Femur-R;;ACTIVE;2.14;2.61 +38049-3;Multisection;Find;Pt;Abdomen>Kidney.right;Doc;US;RAD;2;US Kidney - right;US Kidney-R;;ACTIVE;2.14;2.61 +38050-1;Multisection limited;Find;Pt;Lower extremity.right;Doc;US;RAD;2;US Lower extremity - right limited;US LE-R Ltd;;ACTIVE;2.14;2.61 +38051-9;Multisection;Find;Pt;Lower extremity.right;Doc;US;RAD;2;US Lower extremity - right;US LE-R;;ACTIVE;2.14;2.61 +38052-7;Multisection;Find;Pt;Upper extremity.right;Doc;US;RAD;2;US Upper extremity - right;US UE-R;;ACTIVE;2.14;2.61 +38053-5;Multisection;Find;Pt;Pelvis>Sacrum;Doc;US;RAD;2;US Sacrum;US Sacrum;;ACTIVE;2.14;2.61 +38054-3;Multisection;Find;Pt;Abdomen>Visceral artery;Doc;US;RAD;2;US Visceral artery;US Visceral a;;ACTIVE;2.14;2.61 +38055-0;Multisection^W contrast;Find;Pt;XXX;Doc;US;RAD;2;Deprecated Unspecified body region US W contrast;Deprecated XXX US W contr;;DEPRECATED;2.14;2.58 +38056-8;SPL supplemental patient material;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Structured product laballing supplemental patient material;FDA insert SPL suppl patient material;;ACTIVE;2.13;2.34 +38057-6;Multisection for implant;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Breast - left for implant;MR Brst-L for Implant;;ACTIVE;2.14;2.61 +38058-4;Multisection for implant;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Breast - right for implant;MR Brst-R for Implant;;ACTIVE;2.14;2.61 +3805-9;MethylePHEDrine;MRat;24H;Urine;Qn;;DRUG/TOX;1;MethylePHEDrine [Mass/time] in 24 hour Urine;Me-ePHEDrine 24h Ur-mRate;;ACTIVE;1.0;2.42 +38059-2;Multisection;Find;Pt;Talus;Doc;CT;RAD;2;Deprecated Talus CT;Deprecated Talus CT;;DEPRECATED;2.14;2.58 +380-6;Oleandomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Oleandomycin [Susceptibility] by Disk diffusion (KB);Oleandomycin Islt KB;;ACTIVE;1.0;2.19 +38060-0;Multisection sagittal;Find;Pt;Spine.lumbosacral+Cervical+Thoracic;Doc;MRI;RAD;2;Deprecated Spine.lumbosacral+Cervical+Thoracic MRI sagittal;Deprecated Lumbrosac+C+T-spine MRI Sagit;;DEPRECATED;2.13;2.58 +38061-8;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;MR;RAD;2;MR Spine Cervical and Spine Thoracic and Spine Lumbar and Sacrum W contrast IV;MR C+T+L+Sacrum W contr IV;;ACTIVE;2.14;2.61 +38062-6;Multisection for implant^WO & W contrast IV;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Breast - right for implant WO and W contrast IV;MR Brst-R for Implant WO+W contr IV;;ACTIVE;2.14;2.61 +38064-2;Multisection for implant^WO contrast;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Breast - left for implant WO contrast;MR Brst-L for Implant WO contr;;ACTIVE;2.14;2.61 +38065-9;View^during surgery;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Single view during surgery;XR Hip-L 1V in Surg;;ACTIVE;2.14;2.64 +38066-7;View lateral^during surgery;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Lateral during surgery;XR Hip-L Lat in Surg;;ACTIVE;2.14;2.61 +3806-7;Methylphenidate;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methylphenidate [Presence] in Serum or Plasma;Me-phenidate SerPl Ql;;ACTIVE;1.0;2.73 +38067-5;View nipple profile;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;Deprecated Breast - bilateral Mammogram nipple profile;Deprecated Brst-Bl Nipple Profile;;DEPRECATED;2.13;2.61 +38068-3;View R-anterior oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Right anterior oblique;XR Chest R-ant obl;;ACTIVE;2.14;2.61 +38069-1;View L-posterior oblique;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Left posterior oblique;XR Abd L-post obl;;ACTIVE;2.13;2.61 +38070-9;Views for implant;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Views for implant;MG Brst Views for implant;;ACTIVE;2.14;2.64 +38071-7;Views for implant;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Views for implant;MG Brst-Bl Views for implant;;ACTIVE;2.14;2.64 +38072-5;Views for implant;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Views for implant;MG Brst-L Views for implant;;ACTIVE;2.14;2.64 +38073-3;Views;Find;Pt;Chest>Ribs.anterior.bilateral;Doc;XR;RAD;2;XR Ribs anterior - bilateral Views;XR Ribs Ant-Bl Views;;ACTIVE;2.14;2.64 +38074-1;Views;Find;Pt;Chest>Ribs.anterior.left;Doc;XR;RAD;2;XR Ribs anterior - left Views;XR Ribs Ant-L Views;;ACTIVE;2.14;2.64 +3807-5;Methylphenidate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylphenidate [Mass/volume] in Serum or Plasma;Me-phenidate SerPl-mCnc;;ACTIVE;1.0;2.73 +38079-0;Views;Find;Pt;^Breast specimen.bilateral;Doc;MG;RAD;2;MG Breast specimen - bilateral Views;MG Brst spec-Bl Views;;ACTIVE;2.14;2.64 +38080-8;Views;Find;Pt;^Breast specimen.left;Doc;MG;RAD;2;MG Breast specimen - left Views;MG Brst spec-L Views;;ACTIVE;2.14;2.64 +38082-4;Views AP + transthoracic;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and Transthoracic;XR Should-L AP+Transthoracic;;ACTIVE;2.14;2.61 +3808-3;Methylphenidate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methylphenidate [Presence] in Urine;Me-phenidate Ur Ql;;ACTIVE;1.0;2.73 +38083-2;Views AP + lateral + oblique + odontoid + swimmers;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine AP and Lateral and Oblique and Odontoid and Swimmers;XR C-spine AP+Lat+Obl+Odont+Swimmers;;ACTIVE;2.14;2.61 +38084-0;Views AP + L-posterior oblique;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP and Left posterior oblique;XR Abd AP+L-Post Obl;;ACTIVE;2.13;2.61 +38085-7;Views magnification & spot^compression;Find;Pt;Breast.left;Nar;Mam;RAD;2;Deprecated Breast - left Mammogram magnification & spot compression;Deprecated Brst-L Mam Mag+Spot Compressi;;DEPRECATED;2.14;2.34 +38086-5;Views Merchants 30 degrees + Merchants 45 degrees + Merchants 60 degrees;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Merchants 30 and 45 and 60 degrees;XR Knee Merchants 30+45+60 Deg;;ACTIVE;2.14;2.61 +38087-3;Views Sunrise 20 degrees + Sunrise 40 degrees + Sunrise 60 degrees;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Sunrise 20 and 40 and 60 degrees;XR Knee-L Sunrise 20+40+60 deg;;ACTIVE;2.13;2.61 +38088-1;Views Sunrise 20 degrees + Sunrise 40 degrees + Sunrise 60 degrees;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Sunrise 20 and 40 and 60 degrees;XR Knee-Bl Sunrise 20+40+60 deg;;ACTIVE;2.13;2.61 +38089-9;Views survey limited for metastasis;Find;Pt;XXX>Bones;Doc;XR;RAD;2;XR Bones Limited Survey Views for metastasis;XR Bones Survey for metastasis Ltd;;ACTIVE;2.14;2.64 +38090-7;Views air gap;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Air gap Views;MG Brst-Bl Views air gap;;ACTIVE;2.13;2.64 +3809-1;Methylphenidate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylphenidate [Mass/volume] in Urine;Me-phenidate Ur-mCnc;;ACTIVE;1.0;2.73 +38091-5;Views air gap;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Air gap Views;MG Brst-L Views air gap;;ACTIVE;2.13;2.64 +38092-3;Views^W chain intra bladder+W contrast intra bladder;Find;Pt;Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Urinary bladder Views W chain and contrast intra bladder;RF Bladder Views W Chain+contr IB;;ACTIVE;2.14;2.64 +38093-1;Views^W nipple markers;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Views W nipple markers;XR Chest Views W nipple markers;;ACTIVE;2.14;2.64 +38094-9;Views^W contrast;Find;Pt;XXX>Spinal cavity;Doc;RF;RAD;2;RF Spinal cavity Views W contrast;RF Spinal cavity Views W contr;;ACTIVE;2.14;2.64 +38095-6;Views^W contrast intra duct;Find;Pt;Breast>Breast duct.bilateral;Doc;MG;RAD;2;MG Breast duct - bilateral Views W contrast intra duct;MG Brst duct-Bl Views W contr intra Dct;;ACTIVE;2.14;2.64 +38096-4;Views^W contrast intra duct;Find;Pt;Breast>Breast duct.left;Doc;MG;RAD;2;MG Breast duct - left Views W contrast intra duct;MG Brst duct-L Views W contr intra Dct;;ACTIVE;2.14;2.64 +38097-2;Views^W contrast intra salivary duct;Find;Pt;Neck>Parotid gland.left;Doc;RF;RAD;2;RF Parotid gland - left Views W contrast intra salivary duct;RF Parotid gland-L Vs W contr intra SD;;ACTIVE;2.14;2.64 +38098-0;Views^W contrast intra lacrimal duct;Find;Pt;Head>Lacrimal duct.bilateral;Doc;RF;RAD;2;RF Lacrimal duct - bilateral Views W contrast intra lacrimal duct;RF Lacrimal duct-Bl Vs W contr intra LD;;ACTIVE;2.14;2.64 +38099-8;Views^W contrast intra lacrimal duct;Find;Pt;Head>Lacrimal duct.left;Doc;RF;RAD;2;RF Lacrimal duct - left Views W contrast intra lacrimal duct;RF Lacrimal duct-L Vs W contr intra LD;;ACTIVE;2.14;2.64 +38100-4;Views^W contrast antegrade;Find;Pt;Pelvis>Urinary bladder+Urethra;Doc;RF;RAD;2;RF Urinary bladder and Urethra Views W contrast antegrade;RF Bladder+Urethra Views W contr Ante;;ACTIVE;2.14;2.64 +38101-2;Views^W contrast antegrade;Find;Pt;Abdomen>Kidney;Doc;XR;RAD;2;XR Kidney Views W contrast antegrade;XR Kidney Views W contr Ante;;ACTIVE;2.14;2.64 +38102-0;Views^W contrast antegrade via pyelostomy;Find;Pt;Abdomen>Kidney;Doc;XR;RAD;2;XR Kidney Views W contrast antegrade via pyelostomy;XR Kidney Vs W contr Ante via Pyelostomy;;ACTIVE;2.14;2.64 +38103-8;Views^W contrast IT;Find;Pt;Neck>Spine.cervical & Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Spine Cervical and Spine Lumbar Views W contrast IT;RF C-spine+L-spine Views W contr IT;;ACTIVE;2.14;2.64 +38104-6;Views^W contrast IT;Find;Pt;XXX>Spine epidural space;Doc;RF;RAD;2;RF Spine epidural space Views W contrast IT;RF Epidural space Views W contr IT;;ACTIVE;2.14;2.64 +38105-3;Views^W contrast retrograde;Find;Pt;Abdomen>Kidney;Doc;XR;RAD;2;XR Kidney Views W contrast retrograde;XR Kidney Views W contr Retro;;ACTIVE;2.14;2.73 +38107-9;Views scaphoid;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Scaphoid Views;XR Wrist Views scaphoid;;ACTIVE;2.14;2.64 +38108-7;Views 2 oblique;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 Oblique Views;XR Knee-R 2V Obl;;ACTIVE;2.14;2.64 +3810-9;Methylphenidate;MRat;24H;Urine;Qn;;DRUG/TOX;1;Methylphenidate [Mass/time] in 24 hour Urine;Me-phenidate 24h Ur-mRate;;ACTIVE;1.0;2.42 +38112-9;Views^W contrast via nephrostomy tube;Find;Pt;Abdomen>Kidney.right;Doc;RF;RAD;2;RF Kidney - right Views W contrast via nephrostomy tube;RF Kidney-R Views W contr via NT;;ACTIVE;2.14;2.64 +38113-7;Views^W contrast retrograde via urethra;Find;Pt;Abdomen>Kidney.right;Doc;RF;RAD;2;Deprecated RF Kidney - right Views W contrast retrograde via urethra;Deprecated RF Kidney-R Views W contr RU;;DEPRECATED;2.14;2.64 +38114-5;Views 2 oblique;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right 2 Oblique Views;XR Tib+Fib-R 2V Obl;;ACTIVE;2.14;2.64 +38115-2;Views scaphoid;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Scaphoid Views;XR Wrist-R Views scaphoid;;ACTIVE;2.14;2.64 +38116-0;Views^W contrast intra salivary duct;Find;Pt;Neck>Parotid gland;Doc;RF;RAD;2;RF Parotid gland Views W contrast intra salivary duct;RF Parotid gland Views W contr intra SD;;ACTIVE;2.14;2.64 +3811-7;Methyprylon;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methyprylon [Presence] in Serum or Plasma;Methyprylon SerPl Ql;;ACTIVE;1.0;2.56 +38117-8;View Waters upright;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Waters upright;XR Sinuses Waters upr;;ACTIVE;2.14;2.61 +38118-6;Views 2 lateral;Find;Pt;Neck;Doc;XR;RAD;2;XR Neck 2 Lateral Views;XR Neck 2V Lat;;ACTIVE;2.14;2.64 +38119-4;Views^W contrast IA;Find;Pt;Chest>Thoracic artery;Doc;RF.angio;RAD;2;RFA Thoracic artery Views W contrast IA;RFA Thoracic a Views W contr IA;;ACTIVE;2.14;2.64 +38120-2;Views limited^W contrast IT;Find;Pt;Chest>Spine.thoracic;Doc;RF;RAD;2;RF Thoracic spine Limited Views W contrast IT;RF T-spine Views Ltd W contr IT;;ACTIVE;2.14;2.64 +38121-0;View;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Single view;XR T+L-Spine 1V;;ACTIVE;2.14;2.64 +38123-6;Views AP + lateral;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP and Lateral;XR T+L-Spine AP+Lat;;ACTIVE;2.14;2.61 +38124-4;Views^W standing;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Views W standing;XR T+L-Spine Views W Stand;;ACTIVE;2.14;2.64 +3812-5;Methyprylon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyprylon [Mass/volume] in Serum or Plasma;Methyprylon SerPl-mCnc;;ACTIVE;1.0;2.73 +38125-1;Views limited^W contrast IT;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Cervical and thoracic and lumbar spine Limited Views W contrast IT;RF C+T+L-spine Views Ltd W contr IT;;ACTIVE;2.14;2.64 +38126-9;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for aspiration of cyst of Kidney;US Guided Kidney Cyst asp;;ACTIVE;2.14;2.64 +38127-7;Guidance for aspiration of CSF;Find;Pt;XXX>Spine;Doc;US;RAD;2;US Guidance for aspiration of CSF of Spine;US Guided Spine CSF asp;;DISCOURAGED;2.14;2.64 +38128-5;Multisection;Find;Pt;Lower extremity.bilateral>Femoral vessels;Doc;US;RAD;2;US Femoral vessels - bilateral;US Fem ves-Bl;;ACTIVE;2.14;2.61 +38129-3;Multisection;Find;Pt;Abdomen+Pelvis>Iliac vessels.bilateral;Doc;US;RAD;2;US Iliac vessels - bilateral;US Iliac ves-Bl;;ACTIVE;2.14;2.61 +38130-1;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity artery;Doc;US;RAD;2;US Lower extremity artery - bilateral;US LE a-Bl;;ACTIVE;2.14;2.73 +38131-9;Multisection;Find;Pt;Chest>Subclavian vessels.bilateral;Doc;US;RAD;2;US Subclavian vessels - bilateral;US Subclavian ves-Bl;;ACTIVE;2.14;2.61 +38132-7;Guidance for percutaneous biopsy;Find;Pt;Pelvis>Scrotum+Testicle;Doc;US;RAD;2;US Guidance for biopsy of Scrotum and testicle;US Guided Scrotum+Test Bx;;ACTIVE;2.14;2.64 +3813-3;Methyprylon;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methyprylon [Presence] in Urine;Methyprylon Ur Ql;;ACTIVE;1.0;2.56 +38133-5;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Pancreas;Doc;US;RAD;2;US Guidance for aspiration of cyst of Pancreas;US Guided Pancreas Cyst asp;;ACTIVE;2.14;2.64 +38134-3;Multisection;Find;Pt;Lower extremity>Femoral vessels;Doc;US;RAD;2;US Femoral vessels;US Fem ves;;ACTIVE;2.14;2.61 +38135-0;Guidance for deep aspiration.fine needle;Find;Pt;XXX>Tissue;Doc;US;RAD;2;US Guidance for deep aspiration.fine needle of Tissue;US Guided Tiss Deep FNA;;ACTIVE;2.14;2.64 +38136-8;Guidance for superficial aspiration.fine needle;Find;Pt;XXX>Tissue;Doc;US;RAD;2;US Guidance for superficial aspiration.fine needle of Tissue;US Guided Tiss Sup FNA;;ACTIVE;2.14;2.64 +38137-6;Multisection;Find;Pt;Abdomen+Pelvis>Iliac vessels.left;Doc;US;RAD;2;US Iliac vessels - left;US Iliac ves-L;;ACTIVE;2.14;2.61 +38138-4;Multisection;Find;Pt;Neck>Parotid gland;Doc;US;RAD;2;US Parotid gland;US Parotid gland;;ACTIVE;2.14;2.73 +38139-2;Multisection;Find;Pt;Pelvis>Penis vessels;Doc;US;RAD;2;US Penis vessels;US Penis ves;;ACTIVE;2.14;2.61 +381-4;Oleandomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Oleandomycin [Susceptibility] by Serum bactericidal titer;Oleandomycin Titr SBT;;ACTIVE;1.0;2.32 +38140-0;Multisection;Find;Pt;Pelvis>Penis;Doc;US;RAD;2;US Penis;US Penis;;ACTIVE;2.14;2.61 +3814-1;Methyprylon;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyprylon [Mass/volume] in Urine;Methyprylon Ur-mCnc;;ACTIVE;1.0;2.42 +38141-8;Multisection;Find;Pt;Abdomen+Pelvis>Iliac vessels.right;Doc;US;RAD;2;US Iliac vessels - right;US Iliac ves-R;;ACTIVE;2.14;2.61 +38142-6;Guidance for drainage+placement of drainage catheter;Find;Pt;Chest;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Chest;US Guided Chest Drain+cath place;;ACTIVE;2.14;2.66 +38143-4;Multisection limited;Find;Pt;Upper extremity>Upper extremity artery;Doc;US.doppler;RAD;2;US.doppler Upper extremity artery limited;DOP UE a Ltd;;ACTIVE;2.14;2.61 +38144-2;Views;Find;Pt;Upper extremity.right>Finger.second;Doc;XR;RAD;2;XR Finger second - right Views;XR Finger.2nd-R Views;;ACTIVE;2.14;2.73 +38145-9;Views;Find;Pt;Upper extremity.right>Finger.third;Doc;XR;RAD;2;XR Finger third - right Views;XR Finger.3rd-R Views;;ACTIVE;2.14;2.73 +38146-7;Views;Find;Pt;Upper extremity.right>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - right Views;XR Finger.4th-R Views;;ACTIVE;2.14;2.73 +38147-5;Views;Find;Pt;Upper extremity.right>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - right Views;XR Finger.5th-R Views;;ACTIVE;2.14;2.73 +38148-3;Views;Find;Pt;Lower extremity.right>Toe.second;Doc;XR;RAD;2;XR Toe second - right Views;XR Toe 2nd-R Views;;ACTIVE;2.14;2.64 +38149-1;Views;Find;Pt;Lower extremity.right>Toe.third;Doc;XR;RAD;2;XR Toe third - right Views;XR Toe 3rd-R Views;;ACTIVE;2.14;2.73 +38150-9;Views;Find;Pt;Lower extremity.right>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - right Views;XR Toe 4th-R Views;;ACTIVE;2.14;2.73 +38151-7;Views;Find;Pt;Lower extremity.right>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - right Views;XR Toe 5th-R Views;;ACTIVE;2.14;2.73 +38152-5;Views;Find;Pt;Lower extremity.right>Great toe;Doc;XR;RAD;2;XR Great toe - right Views;XR Great toe-R Views;;ACTIVE;2.14;2.73 +38153-3;Views^W contrast intra salivary duct;Find;Pt;Head>Submandibular gland;Doc;RF;RAD;2;RF Submandibular gland Views W contrast intra salivary duct;RF Submandib gland Vs W contr intra SD;;ACTIVE;2.14;2.64 +38154-1;Guidance for superficial biopsy;Find;Pt;XXX>Bone;Doc;RF;RAD;2;RF Guidance for superficial biopsy of Bone;RF Guided Bone Super Bx;;ACTIVE;2.14;2.64 +38155-8;Views 4;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist 4 Views;XR Wrist 4V;;ACTIVE;2.14;2.61 +38156-6;Views 6;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist 6 Views;XR Wrist 6V;;ACTIVE;2.14;2.61 +38157-4;Parathyrin.intact^5M post excision;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --5 minutes post excision;PTH-Intact 5m p Excision SerPl-mCnc;;ACTIVE;2.13;2.73 +3815-8;Metoprolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metoprolol [Mass/volume] in Serum or Plasma;Metoprolol SerPl-mCnc;;ACTIVE;1.0;2.73 +38158-2;Parathyrin.intact^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --baseline;PTH-Intact BS SerPl-mCnc;;ACTIVE;2.13;2.73 +38159-0;levETIRAcetam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;levETIRAcetam [Mass/volume] in Urine;levETIRAcetam Ur-mCnc;;ACTIVE;2.13;2.34 +38160-8;Porphyrins/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Porphyrins/Creatinine [Mass Ratio] in Urine;Porphyrins/Creat Ur;;ACTIVE;2.13;2.73 +38161-6;Pentacarboxylporphyrins/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins/Creatinine [Mass Ratio] in Urine;Penta-CP/Creat Ur;;ACTIVE;2.13;2.73 +38162-4;Coproporphyrin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Coproporphyrin/Creatinine [Mass Ratio] in Urine;Copro/Creat Ur;;ACTIVE;2.13;2.73 +38163-2;Heptacarboxylporphyrin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin/Creatinine [Mass Ratio] in Urine;Hepta-CP/Creat Ur;;ACTIVE;2.13;2.73 +38164-0;Hexacarboxylporphyrin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin/Creatinine [Mass Ratio] in Urine;Hexa-CP/Creat Ur;;ACTIVE;2.13;2.73 +38165-7;Uroporphyrin/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Uroporphyrin/Creatinine [Mass Ratio] in 24 hour Urine;Uropor/Creat 24h Ur;;ACTIVE;2.13;2.70 +3816-6;Metoprolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Metoprolol [Presence] in Urine;Metoprolol Ur Ql;;ACTIVE;1.0;2.73 +38166-5;West Nile virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;West Nile virus IgM Ab [Units/volume] in Serum by Immunoassay;WNV IgM Ser IA-aCnc;;ACTIVE;2.13;2.73 +38167-3;Major crossmatch;Imp;Pt;Ser/Plas;Nom;PEG;BLDBK;1;Major crossmatch [Interpretation] by Polyethylene glycol (PEG) method;Maj XM SerPl PEG-Imp;;ACTIVE;2.13;2.21 +38168-1;Major crossmatch;Imp;Pt;Ser/Plas;Nom;LISS;BLDBK;1;Major crossmatch [Interpretation] by Low ionic strength saline (LISS);Maj XM SerPl LISS-Imp;;ACTIVE;2.13;2.73 +38169-9;Immunoglobulin light chains.lambda.free;MRat;24H;Urine;Qn;;CHEM;1;Lambda light chains.free [Mass/time] in 24 hour Urine;Lambda LC Free 24h Ur-mRate;;ACTIVE;2.13;2.73 +38170-7;Cells.CD18/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD18 cells/100 cells in Specimen;CD18 Cells NFr Spec;;ACTIVE;2.13;2.73 +38171-5;Cells.CD3-CD19+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3-CD19+ cells/100 cells in Specimen;CD3-CD19+ Cells NFr Spec;;ACTIVE;2.13;2.73 +38172-3;Organic acids;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Organic acids [Moles/volume] in Serum or Plasma;Organic Acids SerPl-sCnc;;ACTIVE;2.13;2.73 +38173-1;Borrelia burgdorferi C6 Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi C6 Ab [Units/volume] in Serum by Immunoassay;B burgdor C6 Ab Ser IA-aCnc;;ACTIVE;2.13;2.73 +3817-4;Metoprolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Metoprolol [Mass/volume] in Urine;Metoprolol Ur-mCnc;;ACTIVE;1.0;2.73 +38174-9;Borrelia burgdorferi C6 Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Borrelia burgdorferi C6 Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B burgdor C6 Ab CSF IA-aCnc;;ACTIVE;2.13;2.70 +38175-6;Heptacarboxylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Heptacarboxylate/Creatinine [Molar ratio] in Urine;Heptacarboxylate/Creat Ur-sRto;;ACTIVE;2.13;2.73 +38176-4;Immunoglobulin light chains.kappa.free;MCnc;Pt;Urine;Qn;;CHEM;1;Kappa light chains.free [Mass/volume] in Urine;Kappa LC Free Ur-mCnc;;ACTIVE;2.13;2.73 +38177-2;Immunoglobulin light chains.kappa.free;MRat;24H;Urine;Qn;;CHEM;1;Kappa light chains.free [Mass/time] in 24 hour Urine;Kappa LC Free 24h Ur-mRate;;ACTIVE;2.13;2.73 +38178-0;Immunoglobulin light chains.lambda.free;MCnc;Pt;Urine;Qn;;CHEM;1;Lambda light chains.free [Mass/volume] in Urine;Lambda LC Free Ur-mCnc;;ACTIVE;2.13;2.73 +38179-8;Peripheral neuropathy gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Peripheral neuropathy gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PNP gene Mut Anl Bld/T;;ACTIVE;2.13;2.68 +38180-6;Hepatitis C virus RNA;LaCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [log units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HCV RNA SerPl NAA+probe-Log IU;;ACTIVE;2.13;2.73 +38181-4;Diameter.lateral;Len;Pt;Chest;Qn;XR;RAD;2;XR Chest Diameter.lateral;XR Chest Diam Lat;;ACTIVE;2.14;2.61 +3818-2;Metoprolol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Metoprolol [Mass/time] in 24 hour Urine;Metoprolol 24h Ur-mRate;;ACTIVE;1.0;2.42 +38182-2;Parainfluenza virus 1 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1 IgG Ab [Units/volume] in Serum;HPIV1 IgG Ser-aCnc;;ACTIVE;2.13;2.70 +38183-0;Parainfluenza virus 2 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 2 IgG Ab [Units/volume] in Serum;HPIV2 IgG Ser-aCnc;;ACTIVE;2.13;2.70 +38184-8;Basophils/100 leukocytes;NFr;Pt;Amnio fld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Amniotic fluid by Manual count;Basophils/leuk NFr Amn Manual;;ACTIVE;2.13;2.50 +38185-5;Beta galactosidase;PrThr;Pt;Bld;Ord;;CHEM;1;Beta galactosidase [Presence] in Blood;B-Galactosidase Bld Ql;;ACTIVE;2.13;2.56 +38186-3;Beta globulin;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin [Mass/volume] in 24 hour Urine by Electrophoresis;B-Globulin 24h Ur Elph-mCnc;;ACTIVE;2.13;2.73 +38187-1;Bile acid.dihydroxy;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bile acid.dihydroxy [Moles/volume] in Serum or Plasma;Di-OH Bile Ac SerPl-sCnc;;ACTIVE;2.13;2.67 +38188-9;Bile acid.trihydroxy;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Bile acid.trihydroxy [Moles/volume] in Serum or Plasma;Tri-OH Bile Ac SerPl-sCnc;;ACTIVE;2.13;2.66 +38189-7;Alpha 2 globulin;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin [Mass/volume] in 24 hour Urine by Electrophoresis;Alpha2 Glob 24h Ur Elph-mCnc;;ACTIVE;2.13;2.73 +3819-0;Mexiletine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mexiletine [Mass/volume] in Serum or Plasma;Mexiletine SerPl-mCnc;;ACTIVE;1.0;2.73 +38190-5;Alpha 2 globulin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin [Mass/volume] in Urine by Electrophoresis;Alpha2 Glob Ur Elph-mCnc;;ACTIVE;2.13;2.73 +38191-3;Ammonium urate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Ammonium urate/Total in Stone;Amm Urate MFr Stone;;ACTIVE;2.13;2.73 +38192-1;Amylase;CCnc;2H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in 2 hour Urine;Amylase 2h Ur-cCnc;;ACTIVE;2.13;2.73 +38193-9;Amylase;CRat;XXX;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/time] in Urine collected for unspecified duration;Amylase ?Tm Ur-cRate;;ACTIVE;2.13;2.73 +38194-7;Antidepressants;Prid;Pt;Gast fld;Nom;;DRUG/TOX;1;Antidepressants [Identifier] in Gastric fluid;Antidepressants Gast;;ACTIVE;2.13;2.19 +38195-4;Antihistamines;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Antihistamines [Presence] in Gastric fluid;Antihistamines Gast Ql;;ACTIVE;2.13;2.56 +38196-2;Appearance;Aper;Pt;Bld;Nom;;SPEC;1;Appearance of Blood;Appearance Bld;;ACTIVE;2.13;2.73 +38197-0;Bordetella parapertussis Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Bordetella parapertussis Ag [Presence] in Nasopharynx by Immunofluorescence;B parapert Ag Nph Ql IF;;ACTIVE;2.13;2.73 +38198-8;Bordetella pertussis Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Bordetella pertussis Ag [Presence] in Nasopharynx by Immunofluorescence;B pert Ag Nph Ql IF;;ACTIVE;2.13;2.73 +38199-6;Pressure.positive end expiratory.intrinsic;Pres;Pt;Respiratory system;Qn;;PULM;2;Intrinsic PEEP Respiratory system;Intrinsic PEEP Respiratory;;ACTIVE;2.13;2.73 +38200-2;Specimen volume;Vol;Pt;Sputum;Qn;;SPEC;1;Volume of Sputum;Specimen vol Spt;;ACTIVE;2.13;2.70 +38201-0;Pain onset;TmStp;Pt;^Patient;Qn;Reported;H&P.HX;2;Pain onset [Date and time] - Reported;Pain onset Reported;;ACTIVE;2.13;2.27 +38202-8;Pain onset.hours ago;Time;Pt;^Patient;Qn;Reported;H&P.HX;2;Pain onset.hours ago - Reported;Pain onset.hours ago;;ACTIVE;2.13;2.48 +38203-6;Speed of pain onset;Find;Pt;^Patient;Ord;Reported;H&P.HX;2;Speed of pain onset - Reported;Speed of pain onset Reported;;ACTIVE;2.13;2.27 +38204-4;Pain primary location;Anat;Pt;*;Nom;Reported;H&P.HX;2;Pain primary location - Reported;Pain primary location Reported;;ACTIVE;2.13;2.73 +38205-1;Pain radiation;Find;Pt;*;Nom;;H&P.HX;2;Pain radiation;Pain radiation;;ACTIVE;2.13;2.27 +38206-9;Pain temporal pattern;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Pain temporal pattern - Reported;Pain temporal pattern Reported;;ACTIVE;2.13;2.27 +38207-7;Pain duration;Time;Pt;^Patient;Qn;Reported;H&P.HX;2;Pain duration - Reported;Pain duration Reported;;ACTIVE;2.13;2.73 +3820-8;Mezlocillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mezlocillin [Mass/volume] in Serum or Plasma;Mezlocillin SerPl-mCnc;;ACTIVE;1.0;2.42 +38208-5;Pain severity;Find;Pt;^Patient;Ord;Reported;H&P.HX;2;Pain severity - Reported;Pain severity Reported;;ACTIVE;2.13;2.73 +38209-3;Pain exacerbating factors;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Pain exacerbating factors - Reported;Pain exacerbating factors Reported;;ACTIVE;2.13;2.27 +38210-1;Pain alleviating factors;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Pain alleviating factors - Reported;Pain alleviating factors Reported;;ACTIVE;2.13;2.27 +38211-9;Pain initiating event;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Pain initiating event Narrative - Reported;Pain initiating event Reported;;ACTIVE;2.13;2.40 +38212-7;Pain assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Pain assessment panel;Pain Assessment Pnl;;ACTIVE;2.13;2.69 +38213-5;FLACC pain assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;FLACC pain assessment panel;FLACC Pain Assessment Pnl;Copyright © 2019 The Regents of the University of Michigan Users must obtain a license to use the FLACC and rFLACC instruments. The license can be obtained from the University of Michigan Office of Technology Transfer at https://umich.flintbox.com/?embed=true#technologies/45bdf7ff-2a1c-4d5f-89e5- a0f94ce42a35;ACTIVE;2.13;2.72 +38214-3;Pain severity;Score;Pt;^Patient;Qn;Reported.visual analog score;H&P.HX;2;Pain severity [Score] Visual analog score;Pain severity Score VAS;;ACTIVE;2.13;2.73 +38215-0;Pain severity.total;Score;Pt;^Patient;Qn;Observed.FLACC;H&P.HX;2;Pain severity total [Score] FLACC;Pain severity total Score FLACC;Copyright © 2019 The Regents of the University of Michigan Users must obtain a license to use the FLACC and rFLACC instruments. The license can be obtained from the University of Michigan Office of Technology Transfer at https://umich.flintbox.com/?embed=true#technologies/45bdf7ff-2a1c-4d5f-89e5- a0f94ce42a35;ACTIVE;2.13;2.69 +3821-6;Midazolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Midazolam [Mass/volume] in Serum or Plasma;Midazolam SerPl-mCnc;;ACTIVE;1.0;2.73 +38216-8;Pain severity.face;Find;Pt;^Patient;Ord;Observed.FLACC;H&P.HX;2;Pain severity Face FLACC;Pain severity Face FLACC;Copyright © 2019 The Regents of the University of Michigan Users must obtain a license to use the FLACC and rFLACC instruments. The license can be obtained from the University of Michigan Office of Technology Transfer at https://umich.flintbox.com/?embed=true#technologies/45bdf7ff-2a1c-4d5f-89e5- a0f94ce42a35;ACTIVE;2.13;2.73 +38217-6;Pain severity.legs;Find;Pt;^Patient;Ord;Observed.FLACC;H&P.HX;2;Pain severity Legs FLACC;Pain severity Legs FLACC;Copyright © 2019 The Regents of the University of Michigan Users must obtain a license to use the FLACC and rFLACC instruments. The license can be obtained from the University of Michigan Office of Technology Transfer at https://umich.flintbox.com/?embed=true#technologies/45bdf7ff-2a1c-4d5f-89e5- a0f94ce42a35;ACTIVE;2.13;2.73 +38218-4;Pain severity.activity;Find;Pt;^Patient;Ord;Observed.FLACC;H&P.HX;2;Pain severity Activity FLACC;Pain severity Activity FLACC;Copyright © 2019 The Regents of the University of Michigan Users must obtain a license to use the FLACC and rFLACC instruments. The license can be obtained from the University of Michigan Office of Technology Transfer at https://umich.flintbox.com/?embed=true#technologies/45bdf7ff-2a1c-4d5f-89e5- a0f94ce42a35;ACTIVE;2.13;2.69 +38219-2;Pain severity.cry;Find;Pt;^Patient;Ord;Observed.FLACC;H&P.HX;2;Pain severity Cry FLACC;Pain severity Cry FLACC;Copyright © 2019 The Regents of the University of Michigan Users must obtain a license to use the FLACC and rFLACC instruments. The license can be obtained from the University of Michigan Office of Technology Transfer at https://umich.flintbox.com/?embed=true#technologies/45bdf7ff-2a1c-4d5f-89e5- a0f94ce42a35;ACTIVE;2.13;2.69 +382-2;Oxacillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Oxacillin [Susceptibility] by Minimum lethal concentration (MLC);Oxacillin Islt MLC;;ACTIVE;1.0;2.19 +38220-0;Pain severity.consolability;Find;Pt;^Patient;Ord;Observed.FLACC;H&P.HX;2;Pain severity Consolability FLACC;Pain severity Consolability FLACC;Copyright © 2019 The Regents of the University of Michigan Users must obtain a license to use the FLACC and rFLACC instruments. The license can be obtained from the University of Michigan Office of Technology Transfer at https://umich.flintbox.com/?embed=true#technologies/45bdf7ff-2a1c-4d5f-89e5- a0f94ce42a35;ACTIVE;2.13;2.69 +38221-8;Pain severity;Find;Pt;^Patient;Ord;Reported.Wong-Baker FACES pain rating scale;H&P.HX;2;Pain severity Wong-Baker FACES pain rating scale;Pain severity Wong-Baker FACES Scale;;ACTIVE;2.13;2.27 +38222-6;Sensory perception;Find;Pt;Skin;Ord;Observed.Braden scale;H&P.HX;2;Sensory perception Braden scale;Sensory perception Braden Scale;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.50 +38223-4;Physical activity;Find;Pt;^Patient;Ord;Observed.Braden scale;H&P.HX;2;Physical activity Braden scale;Physical Activity Braden Scale;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.50 +3822-4;Minocycline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Minocycline [Mass/volume] in Serum or Plasma;Minocycline SerPl-mCnc;;ACTIVE;1.0;2.73 +38224-2;Physical mobility;Find;Pt;^Patient;Ord;Observed.Braden scale;H&P.HX;2;Physical mobility Braden scale;Physical mobility Braden Scale;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.50 +38225-9;Nutrition intake pattern;Find;Pt;^Patient;Ord;Observed.Braden scale;H&P.HX;2;Nutrition intake pattern Braden scale;Nutrition Intake Pattern Braden Scale;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.50 +38226-7;Friction & shear;Find;Pt;Skin;Ord;Observed.Braden scale;H&P.HX;2;Friction and shear Braden scale;Friction+Shear Braden Scale;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.50 +38227-5;Braden scale score.total;Score;Pt;^Patient;Qn;Observed.Braden scale;H&P.HX;2;Braden scale total score;Braden Scale Total Score;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.73 +38228-3;Braden scale skin assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Braden scale skin assessment panel;Braden Scale Skin Assess Pnl;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.50 +38229-1;Moisture exposure;Find;Pt;Skin;Ord;Observed.Braden scale;H&P.HX;2;Moisture exposure Braden scale;Moisture exposure Braden Scale;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.13;2.50 +38230-9;Calcium.ionized;MCnc;Pt;Bld;Qn;;CHEM;1;Calcium.ionized [Mass/volume] in Blood;Ca-I Bld-mCnc;;ACTIVE;2.13;2.73 +38231-7;Cells.CD11b+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11b+HLA-DR+ cells/100 cells in Blood;CD11b+HLA-DR+ Cells NFr Bld;;ACTIVE;2.13;2.70 +3823-2;Morazone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Morazone [Presence] in Urine;Morazone Ur Ql;;ACTIVE;1.0;2.56 +38232-5;Cells.CD13+CD16+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD13+CD16+ cells/100 cells in Blood;CD13+CD16+ Cells NFr Bld;;ACTIVE;2.13;2.70 +38233-3;Cells.CD3+CD62L+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD62L+ cells [#/volume] in Blood;CD3+CD62L+ Cells # Bld;;ACTIVE;2.13;2.70 +38234-1;Cells.CD3+CD62L+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD62L+ cells/100 cells in Blood;CD3+CD62L+ Cells NFr Bld;;ACTIVE;2.13;2.70 +38235-8;Cells.CD3+TCR gamma delta+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+TCR gamma delta+ cells [#/volume] in Blood;CD3+TCR G-D+ Cells # Bld;;ACTIVE;2.13;2.70 +38236-6;Cells.CD3+TCR gamma delta+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3+TCR gamma delta+ cells/100 cells in Specimen;CD3+TCR G-D+ Cells NFr Spec;;ACTIVE;2.13;2.70 +38237-4;Cells.CD4+CD28+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD28+ cells [#/volume] in Blood;CD4+CD28+ Cells # Bld;;ACTIVE;2.13;2.70 +38238-2;Cells.CD4+CD28+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD28+ cells/100 cells in Blood;CD4+CD28+ Cells NFr Bld;;ACTIVE;2.13;2.70 +38239-0;Cells.CD4+CD95+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD95+ cells [#/volume] in Blood;CD4+CD95+ Cells # Bld;;ACTIVE;2.13;2.70 +3824-0;Morazone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Morazone [Mass/volume] in Urine;Morazone Ur-mCnc;;ACTIVE;1.0;2.42 +38240-8;Cells.CD4+CD95+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD95+ cells/100 cells in Blood;CD4+CD95+ Cells NFr Bld;;ACTIVE;2.13;2.70 +38241-6;Cells.CD8+CD95+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+CD95+ cells [#/volume] in Blood;CD8+CD95+ Cells # Bld;;ACTIVE;2.13;2.70 +38242-4;Cells.CD8+CD95+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD95+ cells/100 cells in Blood;CD8+CD95+ Cells NFr Bld;;ACTIVE;2.13;2.70 +38243-2;Brucella abortus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella abortus IgG Ab [Presence] in Serum;B abortus IgG Ser Ql;;ACTIVE;2.13;2.73 +38244-0;Brucella abortus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella abortus IgM Ab [Presence] in Serum;B abortus IgM Ser Ql;;ACTIVE;2.13;2.56 +38245-7;Brucella canis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella canis IgG Ab [Presence] in Serum;B canis IgG Ser Ql;;ACTIVE;2.13;2.56 +38246-5;Brucella canis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Brucella canis IgM Ab [Presence] in Serum;B canis IgM Ser Ql;;ACTIVE;2.13;2.56 +38247-3;Brucella sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Brucella sp IgG Ab [Titer] in Serum;Brucella IgG Titr Ser;;ACTIVE;2.13;2.73 +38248-1;Brucella sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Brucella sp IgM Ab [Titer] in Serum;Brucella IgM Titr Ser;;ACTIVE;2.13;2.73 +38249-9;C peptide^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;C peptide 15M p chal SerPl-mCnc;;ACTIVE;2.13;2.34 +38250-7;Calcium;MCnc;Pt;XXX;Qn;;CHEM;1;Calcium [Mass/volume] in Specimen;Calcium Spec-mCnc;;ACTIVE;2.13;2.73 +38251-5;Calcium oxalate;MRat;24H;Urine;Qn;;CHEM;1;Calcium oxalate [Mass/time] in 24 hour Urine;CaOx 24h Ur-mRate;;ACTIVE;2.13;2.73 +38252-3;Calcium oxalate monohydrate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium oxalate monohydrate/Total in Stone;COM MFr Stone;;ACTIVE;2.13;2.73 +38253-1;Carbon dioxide;SCnc;Pt;XXX;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Specimen;CO2 Spec-sCnc;;ACTIVE;2.13;2.73 +38254-9;Carbonated calcium phosphate;PrThr;Pt;Calculus;Ord;;CHEM;1;Carbonated calcium phosphate [Presence] in Stone;Carb Ca Phos Stone Ql;;ACTIVE;2.13;2.56 +38255-6;Cat dander Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cat dander IgE Ab/IgE total in Serum;Cat Dander IgE/IgE total %;;ACTIVE;2.13;2.73 +38256-4;Cells counted.total;Num;Pt;Body fld;Qn;;HEM/BC;1;Cells Counted Total [#] in Body fluid;Total Cells Counted Fld;;ACTIVE;2.13;2.73 +3825-7;Morazone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Morazone [Mass/time] in 24 hour Urine;Morazone 24h Ur-mRate;;ACTIVE;1.0;2.42 +38257-2;Cells counted.total;Num;Pt;Bone mar;Qn;;HEM/BC;1;Cells Counted Total [#] in Bone marrow;Total Cells Counted Mar;;ACTIVE;2.13;2.69 +38258-0;Cells counted.total;Num;Pt;Plr fld;Qn;;HEM/BC;1;Cells Counted Total [#] in Pleural fluid;Total Cells Counted Plr;;ACTIVE;2.13;2.73 +38259-8;Cells counted.total;Num;Pt;Periton fld;Qn;;HEM/BC;1;Cells Counted Total [#] in Peritoneal fluid;Total Cells Counted Prt;;ACTIVE;2.13;2.73 +38260-6;Cells counted.total;Num;Pt;Synv fld;Qn;;HEM/BC;1;Cells Counted Total [#] in Synovial fluid;Total Cells Counted Snv;;ACTIVE;2.13;2.73 +38261-4;Views for bone density;ArMass;Pt;Lower extremity>Hip;Qn;DXA;RAD;2;DXA Hip [Mass/Area] Bone density;DXA Hip ArMass BMD;;ACTIVE;2.14;2.70 +38262-2;Views for bone density;ArMass;Pt;Lower extremity>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus [Mass/Area] Bone density;DXA Heel ArMass BMD;;ACTIVE;2.14;2.70 +38263-0;Views for bone density;Tscore;Pt;Lower extremity>Femur;Qn;DXA;RAD;2;DXA Femur [T-score] Bone density;DXA Femur T-score BMD;;ACTIVE;2.14;2.64 +38264-8;Views for bone density;Tscore;Pt;Lower extremity>Hip;Qn;DXA;RAD;2;DXA Hip [T-score] Bone density;DXA Hip T-score BMD;;ACTIVE;2.14;2.73 +3826-5;Morphine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Morphine [Presence] in Serum or Plasma;Morphine SerPl Ql;;ACTIVE;1.0;2.73 +38265-5;Views for bone density;Tscore;Pt;Upper extremity>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna [T-score] Bone density;DXA Radius+Ulna T-score BMD;;ACTIVE;2.14;2.64 +38266-3;Views for bone density;Tscore;Pt;Lower extremity>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus [T-score] Bone density;DXA Heel T-score BMD;;ACTIVE;2.14;2.68 +38267-1;Views for bone density;Tscore;Pt;Abdomen>Spine.lumbar;Qn;DXA;RAD;2;DXA Lumbar spine [T-score] Bone density;DXA L-spine T-score BMD;;ACTIVE;2.14;2.73 +38268-9;Views for bone density;Find;Pt;Whole body>Skeletal system;Doc;DXA;RAD;2;DXA Skeletal system Views for bone density;DXA Skeletal Sys Views for BMD;;ACTIVE;2.14;2.73 +38269-7;Study report;Find;Pt;Whole body>Skeletal system;Doc;DXA;PANEL.RAD;2;Study report Skeletal system DXA;Study report Skeletal DXA;;ACTIVE;2.14;2.72 +38270-5;Influenza virus A H7 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H7 RNA [Presence] in Specimen by NAA with probe detection;FLUAV H7 RNA Spec Ql NAA+probe;;ACTIVE;2.13;2.69 +38271-3;Influenza virus A H6 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H6 RNA [Presence] in Specimen by NAA with probe detection;FLUAV H6 RNA Spec Ql NAA+probe;;ACTIVE;2.13;2.69 +38272-1;Influenza virus A H5 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H5 RNA [Presence] in Specimen by NAA with probe detection;FLUAV H5 RNA Spec Ql NAA+probe;;ACTIVE;2.13;2.73 +3827-3;Morphine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Morphine [Mass/volume] in Serum or Plasma;Morphine SerPl-mCnc;;ACTIVE;1.0;2.73 +38273-9;Influenza virus A Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A Ab [Units/volume] in Serum by Immunoassay;FLUAV Ab Ser IA-aCnc;;ACTIVE;2.13;2.69 +38274-7;Columbid circovirus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Columbid circovirus DNA [Presence] in Specimen by NAA with probe detection;CoCV DNA Spec Ql NAA+probe;;ACTIVE;2.13;2.69 +38275-4;Transmissible spongiform encephalopathy;PrThr;Pt;Brain;Ord;Microscopy.light;MICRO;1;Transmissible spongiform encephalopathy [Presence] in Brain by Light microscopy;TSE Brain Ql Micro;;ACTIVE;2.13;2.56 +38276-2;Coagulation surface induced^1H post incubation;Time;Pt;PPP^Pool;Qn;Coag;COAG;1;aPTT in Pooled Platelet poor plasma by Coagulation assay --1 hour post incubation;aPTT 1h p Inc Pool PPP;;ACTIVE;2.13;2.73 +38277-0;Lymphocyte proliferation. 0.5 ug/mL Candida albicans stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 0.5 ug/mL Candida albicans [Units/volume] in Blood;LPT 0.5 ug/mL CA Bld-aCnc;;ACTIVE;2.13;2.69 +38278-8;Lymphocyte proliferation. 1.0 ug/mL Candida albicans stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 1.0 ug/mL Candida albicans [Units/volume] in Blood;LPT 1.0 ug/mL CA Bld-aCnc;;ACTIVE;2.13;2.69 +38279-6;Lymphocyte proliferation. 2.5 ug/mL Candida albicans stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 2.5 ug/mL Candida albicans [Units/volume] in Blood;LPT 2.5 ug/mL CA Bld-aCnc;;ACTIVE;2.13;2.69 +38280-4;Lymphocyte proliferation. 5.0 ug/mL Candida albicans stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 5.0 ug/mL Candida albicans [Units/volume] in Blood;LPT 5.0 ug/mL CA Bld-aCnc;;ACTIVE;2.13;2.69 +3828-1;Morphine.free;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Morphine Free [Presence] in Urine;Morphine Free Ur Ql;;ACTIVE;1.0;2.56 +38281-2;Lymphocyte proliferation. 2.41 ug/mL tetanus toxoid stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 2.41 ug/mL tetanus toxoid [Units/volume] in Blood;LPT 2.41 ug/mL TT Bld-aCnc;;ACTIVE;2.13;2.69 +38282-0;Lymphocyte proliferation. 4.83 ug/mL tetanus toxoid stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 4.83 ug/mL tetanus toxoid [Units/volume] in Blood;LPT 4.83 ug/mL TT Bld-aCnc;;ACTIVE;2.13;2.69 +38283-8;Lymphocyte proliferation. 9.67 ug/mL tetanus toxoid stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 9.67 ug/mL tetanus toxoid [Units/volume] in Blood;LPT 9.67 ug/mL TT Bld-aCnc;;ACTIVE;2.13;2.69 +38284-6;Lymphocyte proliferation. 19.3 ug/mL tetanus toxoid stimulation;ACnc;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by 19.3 ug/mL tetanus toxoid [Units/volume] in Blood;LPT 19.3 ug/mL TT Bld-aCnc;;ACTIVE;2.13;2.69 +38285-3;Erythrocytes;PrThr;Pt;Duod fld;Ord;;HEM/BC;1;Erythrocytes [Presence] in Duodenal fluid;RBC Duod fl Ql;;ACTIVE;2.13;2.56 +38286-1;2,4-Dichlorophenoxyacetate;MCnc;Pt;Water;Qn;;DRUG/TOX;1;2,4-Dichlorophenoxyacetate [Mass/volume] in Water;2,4D Wat-mCnc;;ACTIVE;2.13;2.34 +38287-9;2,2-Dichloropropionate;MCnc;Pt;Water;Qn;;DRUG/TOX;1;2,2-Dichloropropionate [Mass/volume] in Water;2,2-DPA Wat-mCnc;;ACTIVE;2.13;2.34 +38288-7;1,2-Dibromo-3-Chloropropane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,2-Dibromo-3-Chloropropane [Mass/volume] in Water;DBCP Wat-mCnc;;ACTIVE;2.13;2.34 +38289-5;1,2-Dichlorobenzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,2-Dichlorobenzene [Mass/volume] in Water;1,2DCB Wat-mCnc;;ACTIVE;2.13;2.34 +38290-3;1,4-Dichlorobenzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,4-Dichlorobenzene [Mass/volume] in Water;1,4DCB Wat-mCnc;;ACTIVE;2.13;2.34 +38291-1;1,2-Dichloroethane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,2-Dichloroethane [Mass/volume] in Water;1,2DCA Wat-mCnc;;ACTIVE;2.13;2.34 +38292-9;1,1-Dichloroethylene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,1-Dichloroethylene [Mass/volume] in Water;1,1-DCE Wat-mCnc;;ACTIVE;2.13;2.34 +38293-7;cis-1,2-Dichloroethylene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;cis-1,2-Dichloroethylene [Mass/volume] in Water;cis-1,2-DCE Wat-mCnc;;ACTIVE;2.13;2.34 +38294-5;Trans-1,2-Dichloroethylene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Trans-1,2-Dichloroethylene [Mass/volume] in Water;trans-1,2-DCE Wat-mCnc;;ACTIVE;2.13;2.34 +38295-2;Methylene chloride;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Methylene chloride [Mass/volume] in Water;DCM Wat-mCnc;;ACTIVE;2.13;2.34 +38296-0;1,2-Dichloropropane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,2-Dichloropropane [Mass/volume] in Water;1,2DCP Wat-mCnc;;ACTIVE;2.13;2.34 +38297-8;Di(2-Ethylhexyl) phthalate;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Di(2-Ethylhexyl) phthalate [Mass/volume] in Water;DEHP Wat-mCnc;;ACTIVE;2.13;2.34 +38298-6;Dinoseb;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Dinoseb [Mass/volume] in Water;Dinoseb Wat-mCnc;;ACTIVE;2.13;2.34 +3829-9;Morphine.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Morphine Free [Mass/volume] in Urine;Morphine Free Ur-mCnc;;ACTIVE;1.0;2.73 +38299-4;Dioxin;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Dioxin [Mass/volume] in Water;Dioxin Wat-mCnc;;ACTIVE;2.13;2.34 +383-0;Oxacillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Oxacillin [Susceptibility] by Minimum inhibitory concentration (MIC);Oxacillin Islt MIC;;ACTIVE;1.0;2.73 +38300-0;Diquat;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Diquat [Mass/volume] in Water;Diquat Wat-mCnc;;ACTIVE;2.13;2.34 +38301-8;Endothall;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Endothall [Mass/volume] in Water;Endothall Wat-mCnc;;ACTIVE;2.13;2.34 +38302-6;Endrin;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Endrin [Mass/volume] in Water;Endrin Wat-mCnc;;ACTIVE;2.13;2.34 +38303-4;Epichlorohydrin;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Epichlorohydrin [Mass/volume] in Water;Epichlorohydrin Wat-mCnc;;ACTIVE;2.13;2.34 +38304-2;Ethylene dibromide;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Ethylene dibromide [Mass/volume] in Water;EDB Wat-mCnc;;ACTIVE;2.13;2.34 +38305-9;Glyphosate;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Glyphosate [Mass/volume] in Water;Glyphosate Wat-mCnc;;ACTIVE;2.13;2.34 +38306-7;Heptachlor;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Heptachlor [Mass/volume] in Water;Heptachlor Wat-mCnc;;ACTIVE;2.13;2.34 +3830-7;Morphine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Morphine [Presence] in Urine;Morphine Ur Ql;;ACTIVE;1.0;2.73 +38307-5;Heptachlorepoxide;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Heptachlorepoxide [Mass/volume] in Water;Heptachlorepoxide Wat-mCnc;;ACTIVE;2.13;2.34 +38308-3;Antimony;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Antimony [Mass/volume] in Water;Antimony Wat-mCnc;;ACTIVE;2.13;2.34 +38309-1;Asbestos;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Asbestos [Mass/volume] in Water;Asbestos Wat-mCnc;;ACTIVE;2.13;2.34 +38310-9;Beryllium;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in Water;Beryllium Wat-mCnc;;ACTIVE;2.13;2.34 +38311-7;Thallium;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in Water;Thallium Wat-mCnc;;ACTIVE;2.13;2.34 +38312-5;Tetrachloroethylene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Tetrachloroethylene [Mass/volume] in Water;TTCE Wat-mCnc;;ACTIVE;2.13;2.34 +38313-3;Toluene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Toluene [Mass/volume] in Water;Toluene Wat-mCnc;;ACTIVE;2.13;2.34 +38314-1;Cyclohexanone;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Cyclohexanone [Mass/volume] in Water;Cyclohexanone Wat-mCnc;;ACTIVE;2.13;2.34 +3831-5;Morphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Morphine [Mass/volume] in Urine;Morphine Ur-mCnc;;ACTIVE;1.0;2.73 +38315-8;Dichlorobenzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Dichlorobenzene [Mass/volume] in Water;DCB Wat-mCnc;;ACTIVE;2.13;2.34 +38316-6;Dichloroethane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Dichloroethane [Mass/volume] in Water;DCA Wat-mCnc;;ACTIVE;2.13;2.34 +38317-4;Hexane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Hexane [Mass/volume] in Water;Hexane Wat-mCnc;;ACTIVE;2.13;2.34 +38318-2;Acrylamide;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Acrylamide [Mass/volume] in Water;Acrylamide Wat-mCnc;;ACTIVE;2.13;2.34 +38319-0;Alachlor;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Alachlor [Mass/volume] in Water;Alachlor Wat-mCnc;;ACTIVE;2.13;2.34 +38320-8;Benzo alpha pyrene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Benzo alpha pyrene [Mass/volume] in Water;BaP Wat-mCnc;;ACTIVE;2.13;2.34 +38321-6;Carbofuran;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Carbofuran [Mass/volume] in Water;Carbofuran Wat-mCnc;;ACTIVE;2.13;2.34 +38322-4;Carbon tetrachloride;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Carbon tetrachloride [Mass/volume] in Water;Carbon Tet Wat-mCnc;;ACTIVE;2.13;2.34 +3832-3;Morphine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Morphine [Mass/time] in 24 hour Urine;Morphine 24h Ur-mRate;;ACTIVE;1.0;2.42 +38323-2;Lindane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Lindane [Mass/volume] in Water;Lindane Wat-mCnc;;ACTIVE;2.13;2.34 +38324-0;Methoxychlor;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Methoxychlor [Mass/volume] in Water;Methoxychlor Wat-mCnc;;ACTIVE;2.13;2.34 +38325-7;Oxamyl;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Oxamyl [Mass/volume] in Water;Oxamyl Wat-mCnc;;ACTIVE;2.13;2.34 +38326-5;Pentachlorophenol;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Pentachlorophenol [Mass/volume] in Water;Pentachlorophen Wat-mCnc;;ACTIVE;2.13;2.34 +38327-3;Picloram;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Picloram [Mass/volume] in Water;Picloram Wat-mCnc;;ACTIVE;2.13;2.34 +38328-1;Simazine;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Simazine [Mass/volume] in Water;Simazine Wat-mCnc;;ACTIVE;2.13;2.34 +38329-9;Styrene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Styrene [Mass/volume] in Water;Styrene Wat-mCnc;;ACTIVE;2.13;2.34 +38330-7;Toxaphene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Toxaphene [Mass/volume] in Water;Toxaphene Wat-mCnc;;ACTIVE;2.13;2.34 +3833-1;Moxalactam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Moxalactam [Mass/volume] in Serum or Plasma;Moxalactam SerPl-mCnc;;ACTIVE;1.0;2.40 +38331-5;2,4,5-Trichlorophenoxyacetate;MCnc;Pt;Water;Qn;;DRUG/TOX;1;2,4,5-Trichlorophenoxyacetate [Mass/volume] in Water;2,4,5T Wat-mCnc;;ACTIVE;2.13;2.34 +38332-3;1,2,4-Trichlorobenzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,2,4-Trichlorobenzene [Mass/volume] in Water;1,2,4TCB Wat-mCnc;;ACTIVE;2.13;2.34 +38333-1;Trichloroethane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Trichloroethane [Mass/volume] in Water;TCE Wat-mCnc;;ACTIVE;2.13;2.34 +38334-9;1,1,2-Trichloroethane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;1,1,2-Trichloroethane [Mass/volume] in Water;1,1,2TCE Wat-mCnc;;ACTIVE;2.13;2.34 +38335-6;Vinyl chloride;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Vinyl chloride [Mass/volume] in Water;Vinyl Chloride Wat-mCnc;;ACTIVE;2.13;2.34 +38336-4;Ethyl benzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Ethyl benzene [Mass/volume] in Water;Ethyl Benzene Wat-mCnc;;ACTIVE;2.13;2.34 +38337-2;Hexachlorocyclopentadiene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Hexachlorocyclopentadiene [Mass/volume] in Water;HEX Wat-mCnc;;ACTIVE;2.13;2.34 +38338-0;Cyanide;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Cyanide [Mass/volume] in Water;Cyanide Wat-mCnc;;ACTIVE;2.13;2.34 +38339-8;Benzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Benzene [Mass/volume] in Water;Benzene Wat-mCnc;;ACTIVE;2.13;2.34 +38340-6;Dichlorodiphenyltrichloroethane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Deprecated Dichlorodiphenyltrichloroethane;Deprecated DDT Wat-mCnc;;DEPRECATED;2.13;2.36 +38341-4;Chlordane;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Chlordane [Mass/volume] in Water;Chlordane Wat-mCnc;;ACTIVE;2.13;2.34 +38342-2;Hexachlorobenzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Hexachlorobenzene [Mass/volume] in Water;HCB Wat-mCnc;;ACTIVE;2.13;2.34 +38343-0;Chlorobenzene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Chlorobenzene [Mass/volume] in Water;Chlorobenz Wat-mCnc;;ACTIVE;2.13;2.34 +38344-8;Trichloroethylene;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Trichloroethylene [Mass/volume] in Water;TCY Wat-mCnc;;ACTIVE;2.13;2.34 +38345-5;Sporothrix schenckii Ab;Titr;Pt;CSF;Qn;LA;MICRO;1;Sporothrix schenckii Ab [Titer] in Cerebral spinal fluid by Latex agglutination;S schenckii Ab Titr CSF LA;;ACTIVE;2.13;2.30 +38346-3;Sporothrix schenckii Ab;Titr;Pt;CSF;Qn;;MICRO;1;Deprecated Sporothrix schenckii Ab [Titer] in Cerebral spinal fluid;Deprecated S schenckii Ab Titr CSF;;DEPRECATED;2.13;2.36 +38347-1;XXX microorganism DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;XXX microorganism DNA [Identifier] in Specimen by NAA with probe detection;Other microorg DNA Spec NAA+probe;;ACTIVE;2.14;2.73 +38348-9;Herpes virus 6 DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Identifier] in Specimen by NAA with probe detection;HHV6 DNA Spec NAA+probe;;ACTIVE;2.14;2.73 +3834-9;N-acetylprocainamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;N-acetylprocainamide [Mass/volume] in Serum or Plasma;NAPA SerPl-mCnc;;ACTIVE;1.0;2.73 +38349-7;Herpes virus 6 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HHV6 DNA # Spec NAA+probe;;ACTIVE;2.14;2.73 +38350-5;Herpes virus 6 DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HHV6 DNA Spec NAA+probe-Log#;;ACTIVE;2.14;2.73 +38351-3;Herpes virus 6 DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Herpes virus 6 DNA panel - Specimen by NAA with probe detection;HHV6 DNA Pnl Spec NAA+probe;;ACTIVE;2.14;2.69 +38352-1;Interleukin 2 receptor;ACnc;Pt;XXX;Qn;;CHEM;1;Interleukin 2 receptor [Units/volume] in Specimen;Il2Recep Spec-aCnc;;ACTIVE;2.14;2.73 +38353-9;Streptococcus sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Streptococcus sp identified in Specimen by Organism specific culture;Streptococcus Spec Cult;;ACTIVE;2.14;2.73 +38354-7;Bartonella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Bartonella sp identified in Specimen by Organism specific culture;Bartonella Spec Cult;;ACTIVE;2.14;2.69 +38355-4;Chitotriosidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chitotriosidase [Enzymatic activity/volume] in Serum or Plasma;Chitotriosidase SerPl-cCnc;;ACTIVE;2.14;2.73 +3835-6;N-ethylnicotinamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated N-ethylnicotinamide [Mass/volume] in Urine;Deprecated NEN Ur-mCnc;;DEPRECATED;1.0;2.36 +38356-2;Thyroxine Ab;PrThr;Pt;Ser;Ord;;SERO;1;Thyroxine (T4) Ab [Presence] in Serum;T4 Ab Ser Ql;;ACTIVE;2.14;2.73 +38357-0;B cell crossmatch;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;B cell crossmatch [Interpretation];B Cell XM SerPl-Imp;;ACTIVE;2.14;2.73 +38358-8;A Ab;Titr;Pt;Ser/Plas;Qn;Antihuman globulin;BLDBK;1;A Ab [Titer] in Serum or Plasma by Antihuman globulin;A Ab Titr SerPl AHG;;ACTIVE;2.14;2.73 +38359-6;A Ab;Titr;Pt;Ser/Plas;Qn;Immediate spin;BLDBK;1;A Ab [Titer] in Serum or Plasma by Immediate spin;A Ab Titr SerPl Imm Spin;;ACTIVE;2.14;2.30 +38360-4;Isobutyrylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Isobutyrylglycine/Creatinine [Mass Ratio] in Urine;Isobutyrylgly/Creat Ur;;ACTIVE;2.14;2.73 +38361-2;(Chicken feather+Duck feather+Goose feather+Turkey feather) Ab.IgG;MCnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 71 (Chicken feather+Duck feather+Goose feather+Turkey feather) IgG Ab [Mass/volume] in Serum by Multidisk;Epid Allerg Mix71 IgG-mCnc;;ACTIVE;2.14;2.73 +38362-0;Muscle specific receptor tyrosine kinase Ab;PrThr;Pt;Ser;Ord;;SERO;1;Muscle specific receptor tyrosine kinase Ab [Presence] in Serum;MuSK Ab Ser Ql;;ACTIVE;2.14;2.73 +38363-8;Cefepime;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefepime [Mass/volume] in Serum or Plasma;Cefepime SerPl-mCnc;;ACTIVE;2.14;2.34 +3836-4;Nadolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nadolol [Presence] in Urine;Nadolol Ur Ql;;ACTIVE;1.0;2.56 +38364-6;Haloperidol.reduced;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Haloperidol reduced [Mass/volume] in Serum or Plasma;Reduced Haloperidol SerPl-mCnc;;ACTIVE;2.14;2.73 +38365-3;Hexadecadienoate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Hexadecadienoate (C16:2)/Creatinine [Mass Ratio] in Urine;Hexadecadienoate/Creat Ur;;ACTIVE;2.14;2.73 +38366-1;Hypoxanthine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hypoxanthine/Creatinine [Molar ratio] in Urine;Hypoxanthine/Creat Ur-sRto;;ACTIVE;2.14;2.73 +38367-9;N-octanoylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;N-octanoylglycine/Creatinine [Mass Ratio] in Urine;n-octanoylgly/Creat Ur;;ACTIVE;2.14;2.73 +38368-7;Pigeon droppings Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon droppings IgG Ab [Mass/volume] in Serum;Pigeon Drop IgG-mCnc;;ACTIVE;2.14;2.73 +38369-5;U1 small nuclear ribonucleoprotein Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;U1 small nuclear ribonucleoprotein IgG Ab [Presence] in Serum;U1 snRNP IgG Ser Ql;;ACTIVE;2.14;2.73 +38370-3;Voriconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Voriconazole [Mass/volume] in Serum or Plasma;Voriconazole SerPl-mCnc;;ACTIVE;2.14;2.73 +38371-1;Xanthine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Xanthine/Creatinine [Molar ratio] in Urine;Xanthine/Creat Ur-sRto;;ACTIVE;2.14;2.73 +3837-2;Nadolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nadolol [Mass/volume] in Urine;Nadolol Ur-mCnc;;ACTIVE;1.0;2.42 +38372-9;Human papilloma virus 6+11+16+18+31+33+35+39+42+43+44+45+51+52+56+58+59+68 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 6+11+16+18+31+33+35+39+42+43+44+45+51+52+56+58+59+68 DNA [Presence] in Cervix by Probe with signal amplification;HPV DNA Cvx Ql Probe+sig amp;;ACTIVE;2.14;2.73 +38373-7;Buprenorphine+Norbuprenorphine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Buprenorphine+Norbuprenorphine [Presence] in Urine;Buprenorphine+Nor Ur Ql;;ACTIVE;2.14;2.73 +38374-5;Tenofovir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tenofovir [Mass/volume] in Serum or Plasma;Tenofovir SerPl-mCnc;;ACTIVE;2.14;2.34 +38375-2;Adenovirus DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HAdV DNA CSF Ql NAA+probe;;ACTIVE;2.14;2.63 +38376-0;Cryptococcus sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Cryptococcus sp identified in Specimen by Organism specific culture;Cryptoc Spec Cult;;ACTIVE;2.14;2.69 +38377-8;Cryptococcus neoformans;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Cryptococcus neoformans [Presence] in Specimen by Organism specific culture;C neoform Spec Ql Cult;;ACTIVE;2.14;2.69 +38378-6;Mycobacterium tuberculosis complex rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Mycobacterium tuberculosis complex rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated M TB Cmplx rRNA XXX Ql Prb;;DEPRECATED;2.14;2.69 +38379-4;Mycobacterium tuberculosis complex DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis complex DNA [Presence] in Specimen by NAA with probe detection;M TB Cmplx DNA Spec Ql NAA+probe;;ACTIVE;2.14;2.73 +3838-0;Nadolol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Nadolol [Mass/time] in 24 hour Urine;Nadolol 24h Ur-mRate;;ACTIVE;1.0;2.42 +38380-2;HFE gene.p.Ser65Cys;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HFE gene.p.Ser65Cys [Presence] in Blood or Tissue by Molecular genetics method;HFE p.S65C Bld/T Ql;;ACTIVE;2.14;2.73 +38381-0;Influenza virus A cDNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A cDNA [Presence] in Specimen by NAA with probe detection;FLUAV cDNA Spec Ql NAA+probe;;ACTIVE;2.14;2.73 +38382-8;Influenza virus B;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Influenza virus B [Presence] in Specimen by Organism specific culture;FLUBV Spec Ql Cult;;ACTIVE;2.14;2.73 +38383-6;Enterococcus sp rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Enterococcus sp rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated Enterococcus rRNA XXX Ql Prb;;DEPRECATED;2.14;2.69 +38384-4;Cocaine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Cocaine [Presence] in Gastric fluid;Cocaine Gast Ql;;ACTIVE;2.14;2.56 +38385-1;Coccidioides immitis Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Coccidioides immitis Ag [Presence] in Cerebral spinal fluid;C immitis Ag CSF Ql;;ACTIVE;2.14;2.56 +38386-9;Color;Type;Pt;Amnio fld;Nom;;SPEC;1;Color of Amniotic fluid;Color Amn;;ACTIVE;2.14;2.73 +38387-7;C3 nephritic factor;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;C3 nephritic factor [Presence] in Serum or Plasma;C3 NeF SerPl Ql;;ACTIVE;2.14;2.73 +38388-5;Complement C3;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Complement C3 [Presence] in Serum or Plasma;C3 SerPl Ql;;ACTIVE;2.14;2.73 +38389-3;Coxiella burnetii phase 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 Ab [Titer] in Serum;C burnet Ph2 Ab Titr Ser;;ACTIVE;2.14;2.30 +38390-1;Cryptococcus neoformans Ag;ACnc;Pt;CSF;Ord;;MICRO;1;Deprecated Cryptococcus neoformans Ag [Presence] in Cerebral spinal fluid;Deprecated C neoform Ag CSF Ql;;DEPRECATED;2.14;2.50 +38391-9;Cryptococcus neoformans Ag;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Cryptococcus neoformans Ag [Presence] in Serum;Deprecated C neoform Ag Ser Ql;;DEPRECATED;2.14;2.40 +38392-7;Legionella sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella sp Ab [Presence] in Serum;Legionella Ab Ser Ql;;ACTIVE;2.14;2.56 +38393-5;Legionella sp identified;Prid;Pt;Plr fld;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Pleural fluid by Organism specific culture;Legionella Plr Cult;;ACTIVE;2.14;2.19 +38394-3;Legionella sp identified;Prid;Pt;Urine;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Urine by Organism specific culture;Legionella Ur Cult;;ACTIVE;2.14;2.19 +38395-0;Parainfluenza virus 1 Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Nasopharynx by Immunofluorescence;HPIV1 Ag Nph Ql IF;;ACTIVE;2.14;2.56 +38396-8;Parainfluenza virus 1 Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Nose by Immunofluorescence;HPIV1 Ag Nose Ql IF;;ACTIVE;2.14;2.56 +38397-6;Crystals;Prid;Pt;Amnio fld;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Amniotic fluid by Light microscopy;Crystals Amn Micro;;ACTIVE;2.14;2.73 +3839-8;Nalbuphine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nalbuphine [Presence] in Urine;Nalbuphine Ur Ql;;ACTIVE;1.0;2.73 +38398-4;Crystals;Prid;Pt;Pericard fld;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Pericardial fluid by Light microscopy;Crystals Pcar Micro;;ACTIVE;2.14;2.26 +38399-2;Crystals;Prid;Pt;Periton fld;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Peritoneal fluid by Light microscopy;Crystals Prt Micro;;ACTIVE;2.14;2.26 +38400-8;Parainfluenza virus 1+2+3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 1+2+3 Ab [Presence] in Serum;HPIV1+2+3 Ab Ser Ql;;ACTIVE;2.14;2.56 +38401-6;Protozoa identified;Prid;Pt;XXX;Nom;;MICRO;1;Protozoa identified in Specimen;Protozoa Spec;;ACTIVE;2.14;2.69 +38402-4;Parasite identified;Prid;Pt;Tiss;Nom;;MICRO;1;Parasite identified in Tissue;Parasite Tiss;;ACTIVE;2.14;2.22 +38403-2;Cyclospora sp Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Cyclospora sp Ag [Presence] in Stool by Immunoassay;Cyclospora Ag Stl Ql IA;;ACTIVE;2.14;2.56 +38404-0;CFTR gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CFTR gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CFTR Mut Anl Bld/T;;ACTIVE;2.14;2.73 +38405-7;MT-ATP6 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MT-ATP6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MT-ATP6 gene Mut Anl Bld/T;;ACTIVE;2.14;2.66 +3840-6;Nalbuphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nalbuphine [Mass/volume] in Urine;Nalbuphine Ur-mCnc;;ACTIVE;1.0;2.73 +38406-5;PABPN1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PABPN1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PABPN1 gene Mut Anl Bld/T;;ACTIVE;2.14;2.66 +38407-3;PAX3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PAX3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PAX3 gene Mut Anl Bld/T;;ACTIVE;2.14;2.66 +38408-1;PEO gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PEO gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PEO gene Mut Anl Bld/T;;ACTIVE;2.14;2.66 +38409-9;SERPINA1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SERPINA1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SERPINA1 gene Mut Anl Bld/T;;ACTIVE;2.14;2.73 +38410-7;Basement membrane zone Ab;Titr;Pt;Ser;Qn;;SERO;1;Basement membrane zone Ab [Titer] in Serum;BMZ Ab Titr Ser;;ACTIVE;2.14;2.30 +38411-5;TOR1A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TOR1A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TOR1A gene Mut Anl Bld/T;;ACTIVE;2.14;2.63 +38412-3;FGFR2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FGFR2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FGFR2 gene Mut Anl Bld/T;;ACTIVE;2.14;2.73 +38413-1;FGFR3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FGFR3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FGFR3 gene Mut Anl Bld/T;;ACTIVE;2.14;2.73 +3841-4;Nalbuphine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Nalbuphine [Mass/time] in 24 hour Urine;Nalbuphine 24h Ur-mRate;;ACTIVE;1.0;2.42 +38414-9;Iron;SCnt;Pt;Tiss;Qn;;CHEM;1;Iron [Moles/mass] in Tissue;Iron Tiss-sCnt;;ACTIVE;2.14;2.73 +38415-6;MTHFR gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MTHFR gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MTHFR gene Mut Anl Bld/T;;ACTIVE;2.14;2.73 +38416-4;Parasite identified;Prid;Pt;Body fld;Nom;Inspection;MICRO;1;Parasite identified in Body fluid by Inspection;Parasite Fld Inspect;;ACTIVE;2.14;2.19 +38417-2;Trans-cinnamoylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Trans-cinnamoylglycine/Creatinine [Mass Ratio] in Urine;tr-Cinnamoylgly/Creat Ur;;ACTIVE;2.14;2.73 +38418-0;Pigeon droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon droppings IgG Ab [Presence] in Serum;Pigeon Drop IgG Ql;;ACTIVE;2.14;2.70 +38419-8;Cells.CD21/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD21 cells/100 cells in Specimen;CD21 Cells NFr Spec;;ACTIVE;2.14;2.73 +38420-6;Soluble liver Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Soluble liver IgG Ab [Units/volume] in Serum by Immunoassay;Soluble liver IgG Ser IA-aCnc;;ACTIVE;2.14;2.73 +38421-4;C peptide^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;C peptide 30M p chal SerPl-sCnc;;ACTIVE;2.14;2.70 +3842-2;Nalorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nalorphine [Mass/volume] in Urine;Nalorphine Ur-mCnc;;ACTIVE;1.0;2.42 +38422-2;C peptide^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;C peptide 1h p chal SerPl-sCnc;;ACTIVE;2.14;2.70 +38423-0;C peptide^1.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge;C peptide 1.5h p chal SerPl-sCnc;;ACTIVE;2.14;2.70 +38424-8;C peptide^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;C peptide 2h p chal SerPl-sCnc;;ACTIVE;2.14;2.70 +38425-5;C peptide^2.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge;C peptide 2.5h p chal SerPl-sCnc;;ACTIVE;2.14;2.70 +38426-3;C peptide^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;C peptide 3h p chal SerPl-sCnc;;ACTIVE;2.14;2.70 +38427-1;Thiocyanate;MRat;24H;Urine;Qn;;DRUG/TOX;1;Thiocyanate [Mass/time] in 24 hour Urine;Thiocyanate 24h Ur-mRate;;ACTIVE;2.14;2.70 +38428-9;Ibuprofen^pre dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma --pre dose;Ibuprofen Pre Dose SerPl-mCnc;;ACTIVE;2.14;2.70 +38429-7;Ibuprofen^30M post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma --30 minutes post dose;Ibuprofen 30M p SerPl-mCnc;;ACTIVE;2.14;2.70 +3843-0;Nandrolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nandrolone [Presence] in Urine;Nandrolone Ur Ql;;ACTIVE;1.0;2.73 +38430-5;Ibuprofen^1H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma --1 hour post dose;Ibuprofen 1h p SerPl-mCnc;;ACTIVE;2.14;2.70 +38431-3;Ibuprofen^1.5H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma --1.5 hours post dose;Ibuprofen 1.5h p SerPl-mCnc;;ACTIVE;2.14;2.70 +38432-1;Ibuprofen^2H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma --2 hours post dose;Ibuprofen 2h p SerPl-mCnc;;ACTIVE;2.14;2.70 +38433-9;Ibuprofen^2.5H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma --2.5 hours post dose;Ibuprofen 2.5h p SerPl-mCnc;;ACTIVE;2.14;2.70 +38434-7;Ibuprofen^3H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Serum or Plasma --3 hours post dose;Ibuprofen 3h p SerPl-mCnc;;ACTIVE;2.14;2.70 +38435-4;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Specimen;TdT Cells NFr Spec;;ACTIVE;2.14;2.73 +38436-2;Colony count;NCnt;Pt;XXX;Qn;VC;MICRO;1;Colony count [#/mass] in Specimen by Visual count;CC Spec #/mass VC;;ACTIVE;2.14;2.69 +38437-0;Anacardium occidentale Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cashew nut IgE Ab/IgE total in Serum;Cashew nut IgE/IgE total %;;ACTIVE;2.14;2.70 +38438-8;Aspergillus fumigatus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus IgE Ab/IgE total in Serum;A fumigatus IgE/IgE total %;;ACTIVE;2.14;2.73 +38439-6;Barbiturates;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Barbiturates [Presence] in Meconium by Confirmatory method;Barbiturates Mec Ql Cfm;;ACTIVE;2.14;2.56 +38440-4;Basement membrane zone Ab;PrThr;Pt;Ser;Ord;;SERO;1;Basement membrane zone Ab [Presence] in Serum;BMZ Ab Ser Ql;;ACTIVE;2.14;2.56 +38441-2;Benzodiazepines;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Benzodiazepines [Presence] in Meconium by Confirmatory method;Benzodiaz Mec Ql Cfm;;ACTIVE;2.14;2.56 +38442-0;Bilirubin crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Bilirubin crystals [#/area] in Urine sediment by Microscopy low power field;Bilirub Cry #/area UrnS LPF;;ACTIVE;2.14;2.70 +38443-8;Blastomyces dermatitidis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Blastomyces dermatitidis IgM Ab [Presence] in Serum by Immunoassay;B dermat IgM Ser Ql IA;;ACTIVE;2.14;2.56 +38444-6;Bromide;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Bromide [Presence] in 24 hour Urine;Bromide 24h Ur Ql;;ACTIVE;2.14;2.56 +38445-3;Calprotectin;MCnt;Pt;Stool;Qn;;CHEM;1;Calprotectin [Mass/mass] in Stool;Calprotectin Stl-mCnt;;ACTIVE;2.14;2.73 +38446-1;Catecholamines;MRat;72H;Urine;Qn;;CHEM;1;Catecholamines [Mass/time] in 72 hour Urine;Catechols 72h Ur-mRate;;ACTIVE;2.14;2.50 +38447-9;CFTR gene.c.711+1G>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.711+1G>T [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.711+1G>T Bld/T Ql;;ACTIVE;2.14;2.56 +3844-8;Nandrolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nandrolone [Mass/volume] in Urine;Nandrolone Ur-mCnc;;ACTIVE;1.0;2.42 +38448-7;CFTR gene.p.Ala455Glu;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene p.Ala455Glu [Presence] in Blood or Tissue by Molecular genetics method;CFTR p.A455E Bld/T Ql;;ACTIVE;2.14;2.56 +38449-5;CFTR gene.c.1078delT;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.1078delT [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.1078delT Bld/T Ql;;ACTIVE;2.14;2.56 +38450-3;CFTR gene.c.2184delA;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.2184delA [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.2184delA Bld/T Ql;;ACTIVE;2.14;2.56 +38451-1;CFTR gene.c.2789+5G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.2789+5G>A [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.2789+5G>A Bld/T Ql;;ACTIVE;2.14;2.56 +38452-9;CFTR gene.c.3120+1G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.3120+1G>A [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.3120+1G>A Bld/T Ql;;ACTIVE;2.14;2.56 +38453-7;CFTR gene.c.3659delC;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.3659delC [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.3659delC Bld/T Ql;;ACTIVE;2.14;2.56 +38454-5;CFTR gene.p.Gly85Glu;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene p.Gly85Glu [Presence] in Blood or Tissue by Molecular genetics method;CFTR p.G85E Bld/T Ql;;ACTIVE;2.14;2.56 +3845-5;Nandrolone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Nandrolone [Mass/time] in 24 hour Urine;Nandrolone 24h Ur-mRate;;ACTIVE;1.0;2.42 +38455-2;CFTR gene.c.621+1G>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.621+1G>T [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.621+1G>T Bld/T Ql;;ACTIVE;2.14;2.56 +38456-0;CFTR gene.c.3849+10kbC>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.3849+10kbC>T [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.3849+10kbC>T Bld/T Ql;;ACTIVE;2.14;2.56 +38457-8;Immune complex.C3d+IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Immune complex.C3d+IgG [Units/volume] in Serum or Plasma;IC C3d+IigG SerPl-aCnc;;ACTIVE;2.14;2.69 +38458-6;Crystals;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Crystals [Presence] in Synovial fluid by Light microscopy;Crystals Snv Ql Micro;;ACTIVE;2.14;2.73 +38459-4;Crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Crystals [#/area] in Urine sediment by Microscopy high power field;Crystals #/area UrnS HPF;;ACTIVE;2.14;2.73 +38460-2;Legionella sp Ag;PrThr;Pt;Bronchial;Ord;IF;MICRO;1;Legionella sp Ag [Presence] in Bronchial specimen by Immunofluorescence;Legionella Ag Bronch Ql IF;;ACTIVE;2.14;2.56 +38461-0;Legionella sp Ag;PrThr;Pt;Plr fld;Ord;IF;MICRO;1;Legionella sp Ag [Presence] in Pleural fluid by Immunofluorescence;Legionella Ag Plr Ql IF;;ACTIVE;2.14;2.56 +38462-8;Legionella sp Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Legionella sp Ag [Presence] in Sputum by Immunofluorescence;Legionella Ag Spt Ql IF;;ACTIVE;2.14;2.56 +3846-3;Naproxen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Naproxen [Mass/volume] in Serum or Plasma;Naproxen SerPl-mCnc;;ACTIVE;1.0;2.73 +38463-6;Legionella sp Ag;PrThr;Pt;Urine;Ord;IF;MICRO;1;Legionella sp Ag [Presence] in Urine by Immunofluorescence;Legionella Ag Ur Ql IF;;ACTIVE;2.14;2.56 +38464-4;Juniperus sabinoides Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Mountain Juniper IgE Ab/IgE total in Serum;Mt Juniper IgE/IgE total %;;ACTIVE;2.14;2.70 +38465-1;Chicken Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Chicken IgE Ab/IgE total in Serum;Chicken IgE/IgE total %;;ACTIVE;2.14;2.70 +38466-9;Chicken serum proteins Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken serum proteins IgG Ab [Presence] in Serum;Chicken Serum Prot IgG Ql;;ACTIVE;2.14;2.56 +38467-7;Chlamydia sp Ab.IgG;PrThr;Pt;Body fld;Ord;;MICRO;1;Chlamydia sp IgG Ab [Presence] in Body fluid;Chlamydia IgG Fld Ql;;ACTIVE;2.14;2.56 +38468-5;Chlamydia sp Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Chlamydia sp Ab [Presence] in Cerebral spinal fluid;Chlamydia Ab CSF Ql;;ACTIVE;2.14;2.56 +38469-3;Chlamydia trachomatis rRNA;PrThr;Pt;Bld;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Blood by Probe;C trach rRNA Bld Ql Probe;;ACTIVE;2.14;2.63 +38470-1;chlorproPAMIDE;MCnc;24H;Urine;Qn;;DRUG/TOX;1;chlorproPAMIDE [Mass/volume] in 24 hour Urine;chlorproPAMIDE 24h Ur-mCnc;;ACTIVE;2.14;2.42 +3847-1;Neopterin;MCnc;Pt;Urine;Qn;;CHEM;1;Neopterin [Mass/volume] in Urine;Neopterin Ur-mCnc;;ACTIVE;1.0;2.73 +38471-9;Karyotype;Prid;Pt;Urine;Nom;;MOLPATH;1;Karyotype [Identifier] in Urine Nominal;Karyotyp Ur;;ACTIVE;2.14;2.19 +38472-7;17-Hydroxycorticosteroids/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids/Creatinine [Mass Ratio] in Urine;17OHCS/Creat Ur;;ACTIVE;2.14;2.73 +38473-5;17-Hydroxyprogesterone;MCnc;Pt;Bld.dot;Qn;;CHEM;1;17-Hydroxyprogesterone [Mass/volume] in DBS;17OHP DBS-mCnc;;ACTIVE;2.14;2.73 +38474-3;Acylcarnitine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Acylcarnitine [Moles/volume] in DBS;Acylcarnitine DBS-sCnc;;ACTIVE;2.14;2.70 +38475-0;Acid alpha glucosidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/volume] in Serum or Plasma;Acid A-Glucosidase SerPl-cCnc;;ACTIVE;2.14;2.70 +38476-8;Mullerian inhibiting substance;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Mullerian inhibiting substance [Mass/volume] in Serum or Plasma;MIS SerPl-mCnc;;ACTIVE;2.14;2.73 +38477-6;Glucosylceramidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucosylceramidase [Enzymatic activity/volume] in Serum or Plasma;Glucosylceramidase SerPl-cCnc;;ACTIVE;2.14;2.70 +38478-4;Biotinidase;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Biotinidase [Presence] in DBS;Biotinidase DBS Ql;;ACTIVE;2.14;2.73 +38479-2;Branched chain keto-acid dehydrogenase complex;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Branched chain keto-acid dehydrogenase complex [Presence] in DBS;BCKAD DBS Ql;;ACTIVE;2.14;2.73 +384-8;Oxacillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Oxacillin [Susceptibility] by Disk diffusion (KB);Oxacillin Islt KB;;ACTIVE;1.0;2.73 +38480-0;Carnitine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Carnitine [Moles/volume] in DBS;Carnitine DBS-sCnc;;ACTIVE;2.14;2.70 +38481-8;Carnitine.free (C0);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Carnitine free (C0) [Moles/volume] in DBS;Carnitine Free DBS-sCnc;;ACTIVE;2.14;2.73 +38482-6;Creatine kinase.MB;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Creatine kinase.MB [Presence] in Serum or Plasma;CK MB SerPl Ql;;ACTIVE;2.14;2.73 +38483-4;Creatinine;MCnc;Pt;Bld;Qn;;CHEM;1;Creatinine [Mass/volume] in Blood;Creat Bld-mCnc;;ACTIVE;2.14;2.73 +38484-2;Cysteine;MRat;24H;Urine;Qn;;CHEM;1;Cysteine [Mass/time] in 24 hour Urine;Cysteine 24h Ur-mRate;;ACTIVE;2.14;2.70 +38485-9;Galactose 1 phosphate;SCnt;Pt;RBC;Qn;;CHEM;1;Galactose 1 phosphate [Moles/mass] in Red Blood Cells;Gal1PO4 RBC-sCnt;;ACTIVE;2.14;2.73 +38486-7;Homocystine;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Homocystine [Presence] in DBS;(Hcys)2 DBS Ql;;ACTIVE;2.14;2.73 +38487-5;IgA;ACnc;Pt;Ser;Qn;;CHEM;1;IgA [Units/volume] in Serum;IgA Ser-aCnc;;ACTIVE;2.14;2.73 +38488-3;IgG;ACnc;Pt;Ser;Qn;;CHEM;1;IgG [Units/volume] in Serum;IgG Ser-aCnc;;ACTIVE;2.14;2.73 +3848-9;Netilmicin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Netilmicin [Mass/volume] in Serum or Plasma --peak;Netilmicin Peak SerPl-mCnc;;ACTIVE;1.0;2.34 +38489-1;Insulin bovine Ab;Titr;Pt;Ser;Qn;;SERO;1;Insulin bovine Ab [Titer] in Serum;Insulin Bovine Ab Titr Ser;;ACTIVE;2.14;2.15 +38490-9;Insulin porcine Ab;Titr;Pt;Ser;Qn;;SERO;1;Insulin porcine Ab [Titer] in Serum;Insulin Porcine Ab Titr Ser;;ACTIVE;2.14;2.15 +38491-7;Insulin-like growth factor binding protein 3.acid labile;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor binding protein 3.acid labile [Mass/volume] in Serum or Plasma;IGF BP3 AL SerPl-mCnc;;ACTIVE;2.14;2.73 +38492-5;Insulin-like growth factor-I;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor-I [Units/volume] in Serum or Plasma;IGF-I SerPl-aCnc;;ACTIVE;2.14;2.73 +38493-3;Ketones;Titr;Pt;Ser/Plas;Qn;;CHEM;1;Ketones [Titer] in Serum or Plasma;Ketones Titr SerPl;;ACTIVE;2.14;2.73 +38494-1;Metanephrine.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Metanephrine Free [Mass/volume] in Serum or Plasma;Metaneph Free SerPl-mCnc;;ACTIVE;2.14;2.73 +38495-8;Phenylalanine+Tyrosine;PrThr;Pt;Urine;Ord;;CHEM;1;Phenylalanine+Tyrosine [Presence] in Urine;Phe+Tyr Ur Ql;;ACTIVE;2.14;2.56 +38496-6;Retinyl palmitate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Retinyl palmitate [Mass/volume] in Serum or Plasma;Retinyl Palmitate SerPl-mCnc;;ACTIVE;2.14;2.73 +3849-7;Netilmicin^random;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Netilmicin [Mass/volume] in Serum or Plasma --random;Netilmicin Rand SerPl-mCnc;;DISCOURAGED;1.0;2.40 +38497-4;Spermatozoa.amorphous head;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Amorphous Head [Presence] in Semen;Sperm Amorphous Head Smn Ql;;ACTIVE;2.14;2.56 +38498-2;Spermatozoa.nonviable/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Nonviable/100 spermatozoa in Semen;Sperm Nonvialbe NFr Smn;;ACTIVE;2.14;2.73 +38499-0;Spermatozoa.progressive^4H post ejaculation;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Progressive [Presence] in Semen --4 hours post ejaculation;Sperm Prog 4h p ejac Smn Ql;;ACTIVE;2.14;2.73 +38500-5;Spermatozoa.progressive.grade 1/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 1/100 spermatozoa in Semen;Sperm Prog 1 NFr Smn;;ACTIVE;2.14;2.73 +38501-3;Spermatozoa.progressive.grade 2/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 2/100 spermatozoa in Semen;Sperm Prog 2 NFr Smn;;ACTIVE;2.14;2.34 +38502-1;Spermatozoa.progressive.grade 4/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 4/100 spermatozoa in Semen;Sperm Prog 4 NFr Smn;;ACTIVE;2.14;2.34 +38503-9;Spermatozoa.progressive.grade 3/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 3/100 spermatozoa in Semen;Sperm Prog 3 NFr Smn;;ACTIVE;2.14;2.34 +38504-7;Thyroglobulin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Thyroglobulin Ab [Titer] in Serum by Immunofluorescence;Thyroglob Ab Titr Ser IF;;ACTIVE;2.14;2.73 +3850-5;Netilmicin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Netilmicin [Mass/volume] in Serum or Plasma --trough;Netilmicin Trough SerPl-mCnc;;ACTIVE;1.0;2.34 +38505-4;Thyroglobulin recovery;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Thyroglobulin recovery in Serum or Plasma;Thyroglob Recovery MFr SerPl;;ACTIVE;2.14;2.73 +38506-2;Thyroxine;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Thyroxine (T4) [Presence] in DBS;T4 DBS Ql;;ACTIVE;2.14;2.73 +38507-0;Urobilinogen;ACnt;Pt;Stool;Qn;;CHEM;1;Urobilinogen [Units/mass] in Stool;Urobilinogen Stl-aCnt;;ACTIVE;2.14;2.70 +38508-8;Uroporphyrin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Uroporphyrin/Creatinine [Mass Ratio] in Urine;Uropor/Creat Ur;;ACTIVE;2.14;2.73 +38509-6;Viscosity^30M post collection;Visc;Pt;Semen;Ord;;SPEC;1;Viscosity of Semen Qualitative--30 minutes post collection;Visc 30M p coll Smn Ql;;ACTIVE;2.14;2.58 +38510-4;Cells.CD11b+CD11c+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11b+CD11c+ cells/100 cells in Specimen;CD11b+CD11c+ Cells NFr Spec;;ACTIVE;2.14;2.69 +38511-2;Cells.CD19+CD33+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+CD33+ cells/100 cells in Blood;CD19+CD33+ Cells NFr Bld;;ACTIVE;2.14;2.34 +38512-0;Cells.CD2+CD3+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD2+CD3+ cells/100 cells in Specimen;CD2+CD3+ Cells NFr Spec;;ACTIVE;2.14;2.69 +3851-3;Nicomorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nicomorphine [Mass/volume] in Urine;NMP Ur-mCnc;;ACTIVE;1.0;2.42 +38513-8;Cells.CD2+CD3+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD2+CD3+ cells [#/volume] in Specimen;CD2+CD3+ Cells # Spec;;ACTIVE;2.14;2.69 +38514-6;Cells.CD33+CD34+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD33+CD34+ cells/100 cells in Blood;CD33+CD34+ Cells NFr Bld;;ACTIVE;2.14;2.73 +38515-3;Cells.cytoplasmic Ig mu;NCnc;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic Ig mu cells [#/volume] in Blood;CyIg mu Cells # Bld;;ACTIVE;2.14;2.42 +38516-1;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;XXX;Qn;IA;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Specimen by Immunoassay;TdT Cells NFr Spec IA;;ACTIVE;2.14;2.69 +38517-9;Coagulation surface induced.factor substitution^2H post incubation;Time;Pt;PPP;Qn;;COAG;1;aPTT.factor substitution in Platelet poor plasma --2 hours post incubation;aPTT 2h p Inc PPP;;ACTIVE;2.14;2.73 +38518-7;Granulocytes.immature/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Immature granulocytes/100 leukocytes in Blood;Imm Granulocytes/leuk NFr Bld;;ACTIVE;2.14;2.73 +38519-5;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Prussian blue stain;HEM/BC;1;Microscopic observation [Identifier] in Blood or Marrow by Prussian blue stain;Prus Bl St Bld/Mar;;ACTIVE;2.14;2.72 +38520-3;Capillary fragility;PrThr;Pt;^Patient;Ord;;COAG;1;Capillary fragility [Presence];Capillary Fragility Patient Ql;;ACTIVE;2.14;2.56 +3852-1;Nicotinamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nicotinamide [Mass/volume] in Urine;Nicotinamide Ur-mCnc;;ACTIVE;1.0;2.73 +38521-1;Coagulation factor VIII Ag actual/Normal;RelMCnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VIII Ag actual/normal in Platelet poor plasma by Immunoassay;Fact VIII Ag Act/Nor PPP IA;;ACTIVE;2.14;2.73 +38522-9;Complement C4b binding protein actual/Normal;RelMCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4b binding protein actual/normal in Serum or Plasma;C4b BP Act/Nor SerPl;;ACTIVE;2.14;2.73 +38523-7;Fibrinopeptide A;MCnc;Pt;Urine;Qn;;COAG;1;Fibrinopeptide A [Mass/volume] in Urine;FpA Ur-mCnc;;ACTIVE;2.14;2.70 +38524-5;Hemoglobin F/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin F/Hemoglobin.total in Blood by Electrophoresis alkaline (pH 8.9);Hgb F MFr Bld Elph Alk;;ACTIVE;2.14;2.73 +38525-2;Protein fractions.oligoclonal bands;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Oligoclonal bands [Mass/volume] in Urine by Electrophoresis;Oligoclonal Bands Ur Elph-mCnc;;ACTIVE;2.14;2.70 +38526-0;Number of specimens tested;Num;Stdy;Stool;Qn;;SPEC;1;Number of specimens tested of Stool;# Spec Tst Stl;;ACTIVE;2.14;2.73 +38527-8;Number of specimens received;Num;Stdy;Stool;Qn;;SPEC;1;Number of specimens received of Stool;# Spec Recd Stl;;ACTIVE;2.14;2.73 +38528-6;Protein.abnormal band;MRat;24H;Urine;Qn;;CHEM;1;Protein.abnormal band [Mass/time] in 24 hour Urine;Abn Prot 24h Ur-mRate;;ACTIVE;2.14;2.73 +38529-4;CMTX2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CMTX2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CMTX2 gene Mut Anl Bld/T;;ACTIVE;2.14;2.63 +38530-2;BRCA2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BRCA2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BRCA2 gene Mut Anl Bld/T;;ACTIVE;2.14;2.73 +38531-0;BRCA2 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BRCA2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;BRCA2 gene Mut Tested Bld/T;;ACTIVE;2.14;2.52 +38532-8;SPG3A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SPG3A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SPG3A gene Mut Anl Bld/T;;ACTIVE;2.14;2.63 +38533-6;TCOF1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TCOF1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TCOF1 gene Mut Anl Bld/T;;ACTIVE;2.14;2.63 +38534-4;COL5A1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;COL5A1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;COL5A1 gene Mut Anl Bld/T;;ACTIVE;2.14;2.66 +38535-1;LAMA2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LAMA2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LAMA2 gene Mut Anl Bld/T;;ACTIVE;2.14;2.66 +38536-9;MLH1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MLH1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MLH1 gene Mut Anl Bld/T;;ACTIVE;2.14;2.73 +38537-7;ARX gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ARX gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ARX gene Mut Anl Bld/T;;ACTIVE;2.14;2.63 +38538-5;Fatty acids.very long chain.C26:1/C22:0;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:1 (Hexacosenoate)/C22:0 (Docosanoate) [Mass Ratio] in Serum or Plasma;VLCFA C26:1/C22:0 SerPl;;ACTIVE;2.14;2.42 +3853-9;Nicotine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nicotine [Mass/volume] in Serum or Plasma;Nicotine SerPl-mCnc;;ACTIVE;1.0;2.73 +38539-3;Spermatozoa.motile/100 spermatozoa^post washing;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --post washing;Sperm Motile p Wash NFr Smn;;ACTIVE;2.14;2.70 +38540-1;Spermatozoa.motile/100 spermatozoa^pre washing;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen --pre washing;Sperm Motile Pre Wash NFr Smn;;ACTIVE;2.14;2.73 +38541-9;Spermatozoa.motile^pre washing;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Motile [Presence] in Semen --pre washing;Sperm Motile Pre Wash Smn Ql;;ACTIVE;2.14;2.73 +38542-7;Repaglinide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Repaglinide [Mass/volume] in Serum or Plasma;Repaglinide SerPl-mCnc;;ACTIVE;2.14;2.73 +38543-5;Spermatozoa^post washing;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa [#/volume] in Semen --post washing;Sperm p Wash # Smn;;ACTIVE;2.14;2.70 +38544-3;Spermatozoa^pre washing;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa [#/volume] in Semen --pre washing;Sperm Pre Wash # Smn;;ACTIVE;2.14;2.73 +38545-0;Methylmercury;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Methylmercury [Mass/mass] in Tissue;Methylmercury Tiss-mCnt;;ACTIVE;2.14;2.30 +38546-8;HLA-B locus;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-B locus [Type];HLA-B locus;;ACTIVE;2.14;2.73 +3854-7;Nicotine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nicotine [Mass/volume] in Urine;Nicotine Ur-mCnc;;ACTIVE;1.0;2.73 +38547-6;HLA-C locus;Type;Pt;Bld/Tiss;Nom;;HLA;1;Deprecated HLA-C locus [Type];Deprecated HLA-C locus;;DEPRECATED;2.14;2.54 +38548-4;HLA-A locus;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-A locus [Type];HLA-A locus;;ACTIVE;2.14;2.73 +38549-2;HLA-B W locus;Type;Pt;Bld/Tiss;Nom;;HLA;1;Deprecated HLA-Bw locus [Type];Deprecated HLA-Bw locus;;DEPRECATED;2.14;2.69 +385-5;Oxacillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Oxacillin [Susceptibility] by Serum bactericidal titer;Oxacillin Titr SBT;;ACTIVE;1.0;2.32 +38550-0;MSH2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MSH2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MSH2 gene Mut Anl Bld/T;;ACTIVE;2.14;2.73 +38551-8;Cortisol^pre or post dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre or post dose dexamethasone;Cortis pre/p Dex SerPl-mCnc;;ACTIVE;2.14;2.73 +38552-6;Acylcarnitine.short chain;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acylcarnitine short chain [Moles/volume] in Serum or Plasma;Acylcarnitine SC SerPl-sCnc;;ACTIVE;2.14;2.70 +38553-4;Narcolepsy associated Ag;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Narcolepsy associated Ag [Presence] in Serum or Plasma;Narcolepsy Assoc Ag SerPl Ql;;ACTIVE;2.14;2.73 +3855-4;Nikethamide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nikethamide [Presence] in Urine;Nikethamide Ur Ql;;ACTIVE;1.0;2.56 +38554-2;Spermatozoa.head.motile with IgA/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.head Motile w IgA/100 spermatozoa in Semen by Immunobead;Sperm.head w IgA NFr Smn IBT;;ACTIVE;2.14;2.70 +38555-9;Spermatozoa.head.motile with IgG/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.head Motile w IgG/100 spermatozoa in Semen by Immunobead;Sperm.head w IgG NFr Smn IBT;;ACTIVE;2.14;2.70 +38556-7;Spermatozoa.head.motile with IgM/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.head Motile w IgM/100 spermatozoa in Semen by Immunobead;Sperm.head w IgM NFr Smn IBT;;ACTIVE;2.14;2.70 +38557-5;Spermatozoa.midpiece.motile with IgA/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.midpiece Motile w IgA/100 spermatozoa in Semen by Immunobead;Sperm.midpiece w IgA NFr Smn IBT;;ACTIVE;2.14;2.70 +38558-3;Spermatozoa.midpiece.motile with IgG/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.midpiece Motile w IgG/100 spermatozoa in Semen by Immunobead;Sperm.midpiece w IgG NFr Smn IBT;;ACTIVE;2.14;2.70 +38559-1;Spermatozoa.midpiece.motile with IgM/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.midpiece Motile w IgM/100 spermatozoa in Semen by Immunobead;Sperm.midpiece w IgM NFr Smn IBT;;ACTIVE;2.14;2.70 +38560-9;Spermatozoa.tail.motile with IgA/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.tail Motile w IgA/100 spermatozoa in Semen by Immunobead;Sperm.tail w IgA NFr Smn IBT;;ACTIVE;2.14;2.70 +38561-7;Spermatozoa.tail.motile with IgG/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.tail Motile w IgG/100 spermatozoa in Semen by Immunobead;Sperm.tail w IgG NFr Smn IBT;;ACTIVE;2.14;2.70 +3856-2;Nikethamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nikethamide [Mass/volume] in Urine;Nikethamide Ur-mCnc;;ACTIVE;1.0;2.42 +38562-5;Spermatozoa.tail.motile with IgM/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.tail Motile w IgM/100 spermatozoa in Semen by Immunobead;Sperm.tail w IgM NFr Smn IBT;;ACTIVE;2.14;2.70 +38563-3;Spermatozoa.tail tip.motile with IgA/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.tail tip Motile w IgA/100 spermatozoa in Semen by Immunobead;Sperm.tail tip w IgA NFr Smn IBT;;ACTIVE;2.14;2.70 +38564-1;Spermatozoa.tail tip.motile with IgG/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.tail tip Motile w IgG/100 spermatozoa in Semen by Immunobead;Sperm.tail tip w IgG NFr Smn IBT;;ACTIVE;2.14;2.70 +38565-8;Spermatozoa.tail tip.motile with IgM/100 spermatozoa;NFr;Pt;Semen;Qn;Immunobead;FERT;1;Spermatozoa.tail Tip Motile w IgM/100 spermatozoa in Semen by Immunobead;Sperm.tail tip w IgM NFr Smn IBT;;ACTIVE;2.14;2.70 +38566-6;Spermatozoa.motile^post washing;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Motile [Presence] in Semen --post washing;Sperm Motile p Wash Smn Ql;;ACTIVE;2.14;2.73 +38567-4;Aniline;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Aniline [Mass/volume] in Air;Aniline Air-mCnc;;ACTIVE;2.14;2.34 +38568-2;Asbestos;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Asbestos [Mass/volume] in Air;Asbestos Air-mCnc;;ACTIVE;2.14;2.34 +38569-0;Arsenic;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Air;Arsenic Air-mCnc;;ACTIVE;2.14;2.34 +3857-0;Nikethamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;Nikethamide [Mass/time] in 24 hour Urine;Nikethamide 24h Ur-mRate;;ACTIVE;1.0;2.42 +38570-8;Azinphos-methyl;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Azinphos-methyl [Mass/volume] in Air;Azinphos-Mehyl Air-mCnc;;ACTIVE;2.14;2.34 +38571-6;Barium;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Barium [Mass/volume] in Air;Barium Air-mCnc;;ACTIVE;2.14;2.34 +38572-4;Benzidine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Benzidine [Mass/volume] in Air;Benzidine Air-mCnc;;ACTIVE;2.14;2.34 +38573-2;Acrylamide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acrylamide [Mass/volume] in Air;Acrylamide Air-mCnc;;ACTIVE;2.14;2.34 +38574-0;Beryllium;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in Air;Beryllium Air-mCnc;;ACTIVE;2.14;2.34 +38575-7;Bromoform;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Bromoform [Mass/volume] in Air;Bromoform Air-mCnc;;ACTIVE;2.14;2.34 +38576-5;Butane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Butane [Mass/volume] in Air;Butane Air-mCnc;;ACTIVE;2.14;2.34 +38577-3;Carbon disulfide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Carbon disulfide [Mass/volume] in Air;Carbon diS Air-mCnc;;ACTIVE;2.14;2.34 +38578-1;Carbon tetrachloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Carbon tetrachloride [Mass/volume] in Air;Carbon Tet Air-mCnc;;ACTIVE;2.14;2.34 +38579-9;Chlordane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chlordane [Mass/volume] in Air;Chlordane Air-mCnc;;ACTIVE;2.14;2.34 +38580-7;Cresols;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Cresols [Mass/volume] in Air;Cresols Air-mCnc;;ACTIVE;2.14;2.34 +38581-5;Cumene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Cumene [Mass/volume] in Air;Cumene Air-mCnc;;ACTIVE;2.14;2.34 +38582-3;2,4-Dichlorophenoxyacetate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2,4-Dichlorophenoxyacetate [Mass/volume] in Air;2,4D Air-mCnc;;ACTIVE;2.14;2.34 +38583-1;1,2-Dibromo-3-Chloropropane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,2-Dibromo-3-Chloropropane [Mass/volume] in Air;DBCP Air-mCnc;;ACTIVE;2.14;2.34 +38584-9;Acetaldehyde;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acetaldehyde [Mass/volume] in Air;Acetaldehyde Air-mCnc;;ACTIVE;2.14;2.70 +38585-6;Acetone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acetone [Mass/volume] in Air;Acetone Air-mCnc;;ACTIVE;2.14;2.34 +38586-4;Acetonitrile;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acetonitrile [Mass/volume] in Air;Acetonitrile Air-mCnc;;ACTIVE;2.14;2.34 +38587-2;Acrylaldehyde;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acrylaldehyde [Mass/volume] in Air;Acrylaldehyde Air-mCnc;;ACTIVE;2.14;2.34 +3858-8;Nitrazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitrazepam [Mass/volume] in Serum or Plasma;Nitrazepam SerPl-mCnc;;ACTIVE;1.0;2.73 +38588-0;Acrylonitrile;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acrylonitrile [Mass/volume] in Air;Acrylonitrile Air-mCnc;;ACTIVE;2.14;2.34 +38589-8;Ammonia;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ammonia [Mass/volume] in Air;Ammonia Air-mCnc;;ACTIVE;2.14;2.34 +38590-6;1,4-Dichlorobenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,4-Dichlorobenzene [Mass/volume] in Air;1,4DCB Air-mCnc;;ACTIVE;2.14;2.34 +38591-4;Dichlorvos;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dichlorvos [Mass/volume] in Air;Dichlorvos Air-mCnc;;ACTIVE;2.14;2.34 +38592-2;Dimethylformamide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dimethylformamide [Mass/volume] in Air;DMF Air-mCnc;;ACTIVE;2.14;2.34 +38593-0;1,4-Dioxane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,4-Dioxane [Mass/volume] in Air;1,4Dioxane Air-mCnc;;ACTIVE;2.14;2.34 +38594-8;Epichlorohydrin;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Epichlorohydrin [Mass/volume] in Air;Epichlorohydrin Air-mCnc;;ACTIVE;2.14;2.34 +38595-5;Ethylene dibromide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ethylene dibromide [Mass/volume] in Air;EDB Air-mCnc;;ACTIVE;2.14;2.34 +3859-6;Nitrazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nitrazepam [Mass/volume] in Urine;Nitrazepam Ur-mCnc;;ACTIVE;1.0;2.42 +38596-3;Ethylene glycol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ethylene glycol [Mass/volume] in Air;Ethylene Glycol Air-mCnc;;ACTIVE;2.14;2.34 +38597-1;Heptachlor;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Heptachlor [Mass/volume] in Air;Heptachlor Air-mCnc;;ACTIVE;2.14;2.34 +38598-9;Hexachlorobenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hexachlorobenzene [Mass/volume] in Air;HCB Air-mCnc;;ACTIVE;2.14;2.34 +38599-7;Hexachlorobutadiene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hexachlorobutadiene [Mass/volume] in Air;HCBD Air-mCnc;;ACTIVE;2.14;2.34 +38600-3;Hexachloroethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hexachloroethane [Mass/volume] in Air;HCE Air-mCnc;;ACTIVE;2.14;2.34 +38601-1;Hexane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hexane [Mass/volume] in Air;Hexane Air-mCnc;;ACTIVE;2.14;2.34 +38602-9;Hydrazine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hydrazine [Mass/volume] in Air;Hydrazine Air-mCnc;;ACTIVE;2.14;2.34 +38603-7;Hydrogen sulfide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hydrogen sulfide [Mass/volume] in Air;Hydrogen Sulfide Air-mCnc;;ACTIVE;2.14;2.34 +3860-4;Nitrofurantoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitrofurantoin [Mass/volume] in Serum or Plasma;Nitrofurantoin SerPl-mCnc;;ACTIVE;1.0;2.73 +38604-5;Hydroquinone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hydroquinone [Mass/volume] in Air;Hydroquinone Air-mCnc;;ACTIVE;2.14;2.34 +38605-2;Lindane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Lindane [Mass/volume] in Air;Lindane Air-mCnc;;ACTIVE;2.14;2.34 +38606-0;Maleic anhydride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Maleic anhydride [Mass/volume] in Air;Maleic Anhydride Air-mCnc;;ACTIVE;2.14;2.34 +38607-8;Methoxychlor;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methoxychlor [Mass/volume] in Air;Methoxychlor Air-mCnc;;ACTIVE;2.14;2.34 +38608-6;Methyl bromide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methyl bromide [Mass/volume] in Air;Me- Bromide Air-mCnc;;ACTIVE;2.14;2.34 +38609-4;Methyl tert-butyl ether;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methyl tert-butyl ether [Mass/volume] in Air;MTBE Air-mCnc;;ACTIVE;2.14;2.34 +38610-2;Methylene chloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methylene chloride [Mass/volume] in Air;DCM Air-mCnc;;ACTIVE;2.14;2.34 +38611-0;Methyl isobutyl ketone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methyl isobutyl ketone [Mass/volume] in Air;MIBK Air-mCnc;;ACTIVE;2.14;2.34 +3861-2;Nordiazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nordiazepam [Presence] in Urine;Nordiazepam Ur Ql;;ACTIVE;1.0;2.73 +38612-8;Naphthalene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Naphthalene [Mass/volume] in Air;Naphthalene Air-mCnc;;ACTIVE;2.14;2.34 +38613-6;Parathion;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Parathion [Mass/volume] in Air;Parathion Air-mCnc;;ACTIVE;2.14;2.34 +38614-4;Pentachlorophenol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Pentachlorophenol [Mass/volume] in Air;Pentachlorophen Air-mCnc;;ACTIVE;2.14;2.34 +38615-1;Phenol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Phenol [Mass/volume] in Air;Phenol Air-mCnc;;ACTIVE;2.14;2.34 +38616-9;Propoxur;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Propoxur [Mass/volume] in Air;Propoxur Air-mCnc;;ACTIVE;2.14;2.34 +38617-7;1,2-Dichloropropane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,2-Dichloropropane [Mass/volume] in Air;1,2DCP Air-mCnc;;ACTIVE;2.14;2.34 +38618-5;Styrene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Styrene [Mass/volume] in Air;Styrene Air-mCnc;;ACTIVE;2.14;2.34 +38619-3;Dioxin;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dioxin [Mass/volume] in Air;Dioxin Air-mCnc;;ACTIVE;2.14;2.34 +3862-0;Nordoxepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nordoxepin [Mass/volume] in Serum or Plasma;Nordoxepin SerPl-mCnc;;ACTIVE;1.0;2.73 +38620-1;Tetrachloroethylene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Tetrachloroethylene [Mass/volume] in Air;TTCE Air-mCnc;;ACTIVE;2.14;2.34 +38621-9;Toluene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Toluene [Mass/volume] in Air;Toluene Air-mCnc;;ACTIVE;2.14;2.34 +38622-7;Toxaphene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Toxaphene [Mass/volume] in Air;Toxaphene Air-mCnc;;ACTIVE;2.14;2.34 +38623-5;1,2,4-Trichlorobenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,2,4-Trichlorobenzene [Mass/volume] in Air;1,2,4TCB Air-mCnc;;ACTIVE;2.14;2.34 +38624-3;1,1,2-Trichloroethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,1,2-Trichloroethane [Mass/volume] in Air;1,1,2TCE Air-mCnc;;ACTIVE;2.14;2.34 +38625-0;Trichloroethylene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Trichloroethylene [Mass/volume] in Air;TCY Air-mCnc;;ACTIVE;2.14;2.34 +38626-8;Vinyl chloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Vinyl chloride [Mass/volume] in Air;Vinyl Chloride Air-mCnc;;ACTIVE;2.14;2.34 +38627-6;Benzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Benzene [Mass/volume] in Air;Benzene Air-mCnc;;ACTIVE;2.14;2.34 +38628-4;Benzo alpha pyrene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Benzo alpha pyrene [Mass/volume] in Air;BaP Air-mCnc;;ACTIVE;2.14;2.34 +38629-2;Acetamide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acetamide [Mass/volume] in Air;Acetamide Air-mCnc;;ACTIVE;2.14;2.34 +386-3;Oxytetracycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Oxytetracycline [Susceptibility] by Minimum lethal concentration (MLC);Oxytetracycline Islt MLC;;ACTIVE;1.0;2.19 +38630-0;Acrylate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acrylate [Mass/volume] in Air;Acrylate Air-mCnc;;ACTIVE;2.14;2.34 +38631-8;Allyl chloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Allyl chloride [Mass/volume] in Air;Allyl chloride Air-mCnc;;ACTIVE;2.14;2.34 +38632-6;4-Biphenylamine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;4-Biphenylamine [Mass/volume] in Air;4-biphenylamine Air-mCnc;;ACTIVE;2.14;2.34 +38633-4;Benzotrichloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Benzotrichloride [Mass/volume] in Air;Benzotrichloride Air-mCnc;;ACTIVE;2.14;2.34 +38634-2;Benzyl chloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Benzyl chloride [Mass/volume] in Air;Benzyl chloride Air-mCnc;;ACTIVE;2.14;2.34 +38635-9;Biphenyl;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Biphenyl [Mass/volume] in Air;Biphenyl Air-mCnc;;ACTIVE;2.14;2.34 +38636-7;Di(2-Ethylhexyl) phthalate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Di(2-Ethylhexyl) phthalate [Mass/volume] in Air;DEHP Air-mCnc;;ACTIVE;2.14;2.34 +38637-5;Bis(chloromethyl)ether;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Bis(Chloromethyl) Ether [Mass/volume] in Air;BCME Air-mCnc;;ACTIVE;2.14;2.34 +3863-8;Norethandrolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norethandrolone [Presence] in Urine;Norethandrolone Ur Ql;;ACTIVE;1.0;2.73 +38638-3;Boron oxide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Boron oxide [Mass/volume] in Air;Boron oxide Air-mCnc;;ACTIVE;2.14;2.34 +38639-1;Boron trifluoride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Boron trifluoride [Mass/volume] in Air;Boron trifluoride Air-mCnc;;ACTIVE;2.14;2.34 +38640-9;Bromine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Bromine [Mass/volume] in Air;Bromine Air-mCnc;;ACTIVE;2.14;2.34 +38641-7;Ethyl bromide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ethyl bromide [Mass/volume] in Air;Ethyl bromide Air-mCnc;;ACTIVE;2.14;2.34 +38642-5;1,3-Butadiene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,3-Butadiene [Mass/volume] in Air;1,3-butadiene Air-mCnc;;ACTIVE;2.14;2.34 +38643-3;Calcium cyanamide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Calcium cyanamide [Mass/volume] in Air;Calcium cyanamide Air-mCnc;;ACTIVE;2.14;2.34 +38644-1;Caprolactam;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Caprolactam [Mass/volume] in Air;Caprolactam Air-mCnc;;ACTIVE;2.14;2.34 +38645-8;Captan;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Captan [Mass/volume] in Air;Captan Air-mCnc;;ACTIVE;2.14;2.34 +3864-6;Norethandrolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norethandrolone [Mass/volume] in Urine;Norethandrolone Ur-mCnc;;ACTIVE;1.0;2.42 +38646-6;Catechol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Catechol [Mass/volume] in Air;Catechol Air-mCnc;;ACTIVE;2.14;2.34 +38647-4;Chlorine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chlorine [Mass/volume] in Air;Chlorine Air-mCnc;;ACTIVE;2.14;2.34 +38648-2;Chlorobenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chlorobenzene [Mass/volume] in Air;Chlorobenz Air-mCnc;;ACTIVE;2.14;2.34 +38649-0;Chloroform;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chloroform [Mass/volume] in Air;Chloroform Air-mCnc;;ACTIVE;2.14;2.34 +38650-8;Chloromethyl methyl ether;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chloromethyl methyl ether [Mass/volume] in Air;CMME Air-mCnc;;ACTIVE;2.14;2.34 +38651-6;2-Chloro-1,3-Butadiene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2-Chloro-1,3-Butadiene [Mass/volume] in Air;2-CBD Air-mCnc;;ACTIVE;2.14;2.34 +38652-4;Carbonyl sulfide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Carbonyl sulfide [Mass/volume] in Air;Carbonyl sulfide Air-mCnc;;ACTIVE;2.14;2.34 +3865-3;Norethandrolone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Norethandrolone [Mass/time] in 24 hour Urine;Norethandrolone 24h Ur-mRate;;ACTIVE;1.0;2.42 +38653-2;Amiben;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Amiben [Mass/volume] in Air;Amiben Air-mCnc;;ACTIVE;2.14;2.34 +38654-0;Chloroacetate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chloroacetate [Mass/volume] in Air;Chloroacetate Air-mCnc;;ACTIVE;2.14;2.34 +38655-7;2-Chloroacetophenone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2-Chloroacetophenone [Mass/volume] in Air;2-CAP Air-mCnc;;ACTIVE;2.14;2.34 +38656-5;Chlorobenzilate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chlorobenzilate [Mass/volume] in Air;Chlorobenzilate Air-mCnc;;ACTIVE;2.14;2.34 +38657-3;Diazomethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Diazomethane [Mass/volume] in Air;Diazomethane Air-mCnc;;ACTIVE;2.14;2.34 +38658-1;Acetate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acetate [Mass/volume] in Air;Acetate Air-mCnc;;ACTIVE;2.14;2.70 +38659-9;Acetophenone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acetophenone [Mass/volume] in Air;Acetophenone Air-mCnc;;ACTIVE;2.14;2.34 +38660-7;Acetylene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Acetylene [Mass/volume] in Air;Acetylene Air-mCnc;;ACTIVE;2.14;2.34 +3866-1;Norfenefrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norfenefrine [Mass/volume] in Urine;Norfenefrine Ur-mCnc;;ACTIVE;1.0;2.42 +38661-5;Aldrin;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Aldrin [Mass/volume] in Air;Aldrin Air-mCnc;;ACTIVE;2.14;2.34 +38662-3;Aluminum oxide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Aluminum oxide [Mass/volume] in Air;Aluminum oxide Air-mCnc;;ACTIVE;2.14;2.34 +38663-1;Dichlorobenzidine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dichlorobenzidine [Mass/volume] in Air;Dichlorobenzidine Air-mCnc;;ACTIVE;2.14;2.34 +38664-9;Bis(2-Chloroethyl) ether;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Bis(2-Chloroethyl) ether [Mass/volume] in Air;BCEE Air-mCnc;;ACTIVE;2.14;2.34 +38665-6;Diethanolamine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Diethanolamine [Mass/volume] in Air;Diethanolamine Air-mCnc;;ACTIVE;2.14;2.34 +38666-4;Diethylsulfate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Diethylsulfate [Mass/volume] in Air;Diethylsulfate Air-mCnc;;ACTIVE;2.14;2.34 +38667-2;3,3'-Dimethoxybenzidine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;3,3'-Dimethoxybenzidine [Mass/volume] in Air;3,3'-DMOB Air-mCnc;;ACTIVE;2.14;2.34 +38668-0;Dimethylaniline;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dimethylaniline [Mass/volume] in Air;Dimethylaniline Air-mCnc;;ACTIVE;2.14;2.34 +38669-8;Dichlorodiphenyldichloroethylene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dichlorodiphenyldichloroethylene [Mass/volume] in Air;DDE Air-mCnc;;ACTIVE;2.14;2.34 +38670-6;Orthocresol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Orthocresol [Mass/volume] in Air;Orthocresol Air-mCnc;;ACTIVE;2.14;2.34 +38671-4;M-cresol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;M-cresol [Mass/volume] in Air;m-Cresol Air-mCnc;;ACTIVE;2.14;2.34 +38672-2;P-cresol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;P-cresol [Mass/volume] in Air;p-Cresol Air-mCnc;;ACTIVE;2.14;2.34 +38673-0;Dimethylphthalate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dimethylphthalate [Mass/volume] in Air;Dimethylphthalate Air-mCnc;;ACTIVE;2.14;2.34 +38674-8;Spermatozoa.head Ab.IgA/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Head IgA Ab/100 spermatozoa in Specimen by Immunobead;Sperm Head IgA NFr Spec IBT;;ACTIVE;2.14;2.73 +38675-5;Spermatozoa.midpiece Ab.IgA/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Midpiece IgA Ab/100 spermatozoa in Specimen by Immunobead;Sperm Midpiece IgA NFr Spec IBT;;ACTIVE;2.14;2.73 +38676-3;Spermatozoa.tail tip Ab.IgA/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Tail Tip IgA Ab/100 spermatozoa in Specimen by Immunobead;Sperm Tail Tip IgA NFr Spec IBT;;ACTIVE;2.14;2.73 +38677-1;Spermatozoa.tail Ab.IgA/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Tail IgA Ab/100 spermatozoa in Specimen by Immunobead;Sperm Tail IgA NFr Spec IBT;;ACTIVE;2.14;2.73 +38678-9;Spermatozoa.head Ab.IgG/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Head IgG Ab/100 spermatozoa in Specimen by Immunobead;Sperm Head IgG NFr Spec IBT;;ACTIVE;2.14;2.73 +3867-9;Norfloxacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norfloxacin [Mass/volume] in Serum or Plasma;Norfloxacin SerPl-mCnc;;ACTIVE;1.0;2.42 +38679-7;Spermatozoa.midpiece Ab.IgG/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Midpiece IgG Ab/100 spermatozoa in Specimen by Immunobead;Sperm Midpiece IgG NFr Spec IBT;;ACTIVE;2.14;2.73 +38680-5;Spermatozoa.tail tip Ab.IgG/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Tail Tip IgG Ab/100 spermatozoa in Specimen by Immunobead;Sperm Tail Tip IgG NFr Spec IBT;;ACTIVE;2.14;2.73 +38681-3;Spermatozoa.tail Ab.IgG/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Tail IgG Ab/100 spermatozoa in Specimen by Immunobead;Sperm Tail IgG NFr Spec IBT;;ACTIVE;2.14;2.73 +38682-1;Spermatozoa.head Ab.IgM/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Head IgM Ab/100 spermatozoa in Specimen by Immunobead;Sperm Head IgM NFr Spec IBT;;ACTIVE;2.14;2.70 +38683-9;Spermatozoa.midpiece Ab.IgM/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Midpiece IgM Ab/100 spermatozoa in Specimen by Immunobead;Sperm Midpiece IgM NFr Spec IBT;;ACTIVE;2.14;2.70 +38684-7;Spermatozoa.tail tip Ab.IgM/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Tail Tip IgM Ab/100 spermatozoa in Specimen by Immunobead;Sperm Tail Tip IgM NFr Spec IBT;;ACTIVE;2.14;2.70 +38685-4;Spermatozoa.tail Ab.IgM/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Sperm Tail IgM Ab/100 spermatozoa in Specimen by Immunobead;Sperm Tail IgM NFr Spec IBT;;ACTIVE;2.14;2.70 +38686-2;Spermatozoa Ab.IgA+IgG/100 spermatozoa;NFr;Pt;XXX;Qn;Immunobead;FERT;1;Spermatozoa IgA+IgG Ab/100 spermatozoa in Specimen by Immunobead;Sperm IgA+IgG NFr Spec IBT;;ACTIVE;2.14;2.70 +3868-7;Norfluoxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norfluoxetine [Mass/volume] in Serum or Plasma;Norfluoxetine SerPl-mCnc;;ACTIVE;1.0;2.73 +38687-0;2-Acetylaminofluorene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2-Acetylaminofluorene [Mass/volume] in Air;2-AAF Air-mCnc;;ACTIVE;2.14;2.34 +38688-8;1,1-Dimethylhydrazine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,1-Dimethylhydrazine [Mass/volume] in Air;DMH Air-mCnc;;ACTIVE;2.14;2.34 +38689-6;Dimethyl sulfate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dimethyl sulfate [Mass/volume] in Air;Dimethyl sulfate Air-mCnc;;ACTIVE;2.14;2.34 +38690-4;4,6-Dinitro-O-Cresol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;4,6-Dinitro-O-Cresol [Mass/volume] in Air;4,6-dinitro-o-cresol Air-mCnc;;ACTIVE;2.14;2.34 +38691-2;1,2-Diphenylhydrazine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,2-Diphenylhydrazine [Mass/volume] in Air;DPH Air-mCnc;;ACTIVE;2.14;2.34 +38692-0;1-Butene oxide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1-Butene oxide [Mass/volume] in Air;1-butene oxide Air-mCnc;;ACTIVE;2.14;2.34 +38693-8;Ethyl acrylate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ethyl acrylate [Mass/volume] in Air;Ethyl acrylate Air-mCnc;;ACTIVE;2.14;2.34 +38694-6;Chloroethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chloroethane [Mass/volume] in Air;Chloroethane Air-mCnc;;ACTIVE;2.14;2.34 +3869-5;Normeperidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Normeperidine [Mass/volume] in Urine;Normeperidine Ur-mCnc;;ACTIVE;1.0;2.73 +38695-3;1,2-Dichloroethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,2-Dichloroethane [Mass/volume] in Air;1,2DCA Air-mCnc;;ACTIVE;2.14;2.34 +38696-1;Ethylene oxide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ethylene oxide [Mass/volume] in Air;Ethylene Oxide Air-mCnc;;ACTIVE;2.14;2.34 +38697-9;Ethylene thiourea;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ethylene thiourea [Mass/volume] in Air;Ethylene thiourea Air-mCnc;;ACTIVE;2.14;2.34 +38698-7;Ethyleneimine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Ethyleneimine [Mass/volume] in Air;Ethyleneimine Air-mCnc;;ACTIVE;2.14;2.34 +38699-5;1,1-Dichloroethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,1-Dichloroethane [Mass/volume] in Air;1,1-DCA Air-mCnc;;ACTIVE;2.14;2.34 +38700-1;Formaldehyde;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Formaldehyde [Mass/volume] in Air;Formaldehyde Air-mCnc;;ACTIVE;2.14;2.34 +38701-9;Hexachlorocyclopentadiene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hexachlorocyclopentadiene [Mass/volume] in Air;HEX Air-mCnc;;ACTIVE;2.14;2.34 +38702-7;Hexamethylene diisocyanate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hexamethylene diisocyanate [Mass/volume] in Air;HMDI Air-mCnc;;ACTIVE;2.14;2.34 +3870-3;Norpropoxyphene;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Norpropoxyphene [Presence] in Serum or Plasma;Norpropoxyph SerPl Ql;;ACTIVE;1.0;2.56 +38703-5;Hexamethylphosphoramide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hexamethylphosphoramide [Mass/volume] in Air;HMPA Air-mCnc;;ACTIVE;2.14;2.34 +38704-3;Isophorone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Isophorone [Mass/volume] in Air;Isophorone Air-mCnc;;ACTIVE;2.14;2.34 +38705-0;Methanol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methanol [Mass/volume] in Air;Methanol Air-mCnc;;ACTIVE;2.14;2.34 +38706-8;Chloromethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chloromethane [Mass/volume] in Air;Chloromethane Air-mCnc;;ACTIVE;2.14;2.34 +38707-6;Trichloroethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Trichloroethane [Mass/volume] in Air;TCE Air-mCnc;;ACTIVE;2.14;2.34 +38708-4;Methyl hydrazine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methyl hydrazine [Mass/volume] in Air;Methyl hydrazine Air-mCnc;;ACTIVE;2.14;2.34 +38709-2;Methyl iodide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methyl iodide [Mass/volume] in Air;Methyl iodide Air-mCnc;;ACTIVE;2.14;2.34 +387-1;Oxytetracycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Oxytetracycline [Susceptibility] by Minimum inhibitory concentration (MIC);Oxytetracycline Islt MIC;;ACTIVE;1.0;2.19 +38710-0;Nitrobenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Nitrobenzene [Mass/volume] in Air;Nitrobenzene Air-mCnc;;ACTIVE;2.14;2.34 +3871-1;Norpropoxyphene;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norpropoxyphene [Presence] in Urine;Norpropoxyph Ur Ql;;ACTIVE;1.0;2.73 +38711-8;2-Nitropropane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2-Nitropropane [Mass/volume] in Air;2-nitropropane Air-mCnc;;ACTIVE;2.14;2.34 +38712-6;N-nitrosodimethylamine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;N-nitrosodimethylamine [Mass/volume] in Air;NDMA Air-mCnc;;ACTIVE;2.14;2.34 +38713-4;N-nitrosomorpholine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;N-nitrosomorpholine [Mass/volume] in Air;NMOR Air-mCnc;;ACTIVE;2.14;2.34 +38714-2;Pentachloronitrobenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Pentachloronitrobenzene [Mass/volume] in Air;PCNB Air-mCnc;;ACTIVE;2.14;2.34 +38715-9;Phosgene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Phosgene [Mass/volume] in Air;Phosgene Air-mCnc;;ACTIVE;2.14;2.34 +38716-7;Phosphine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Phosphine [Mass/volume] in Air;Phosphine Air-mCnc;;ACTIVE;2.14;2.34 +38717-5;Phosphate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Phosphate [Mass/volume] in Air;Phosphate Air-mCnc;;ACTIVE;2.14;2.34 +38718-3;Phthalic anhydride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Phthalic anhydride [Mass/volume] in Air;PAN Air-mCnc;;ACTIVE;2.14;2.34 +38719-1;1,3-Propane sultone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,3-Propane sultone [Mass/volume] in Air;1,3-PS Air-mCnc;;ACTIVE;2.14;2.34 +38720-9;Beta-propiolactone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Beta-propiolactone [Mass/volume] in Air;B-propiolactone Air-mCnc;;ACTIVE;2.14;2.34 +38721-7;Propionaldehyde;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Propionaldehyde [Mass/volume] in Air;Propionaldehyde Air-mCnc;;ACTIVE;2.14;2.34 +38722-5;Propyleneimine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Propyleneimine [Mass/volume] in Air;Propyleneimine Air-mCnc;;ACTIVE;2.14;2.34 +38723-3;1,4-Benzoquinone;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,4-Benzoquinone [Mass/volume] in Air;1,4-BQ Air-mCnc;;ACTIVE;2.14;2.34 +38724-1;Quinoline;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Quinoline [Mass/volume] in Air;Quinoline Air-mCnc;;ACTIVE;2.14;2.34 +38725-8;Styrene-7,8-Oxide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Styrene-7,8-Oxide [Mass/volume] in Air;Styrene-7,8-oxide Air-mCnc;;ACTIVE;2.14;2.34 +38726-6;Titanium tetrachloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Titanium tetrachloride [Mass/volume] in Air;TiCl4 Air-mCnc;;ACTIVE;2.14;2.34 +38727-4;2,4 toluenediamine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2,4 toluenediamine [Mass/volume] in Air;2,4Toluenediam Air-mCnc;;ACTIVE;2.14;2.34 +38728-2;2-Aminotoluene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2-Aminotoluene [Mass/volume] in Air;2-aminotoluene Air-mCnc;;ACTIVE;2.14;2.34 +3872-9;Nortriptyline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortriptyline [Mass/volume] in Serum or Plasma;Nortrip SerPl-mCnc;;ACTIVE;1.0;2.73 +38729-0;2,4,5-Trichlorophenol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2,4,5-Trichlorophenol [Mass/volume] in Air;2,4,5-TCP Air-mCnc;;ACTIVE;2.14;2.34 +38730-8;2,4,6-Trichlorophenol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2,4,6-Trichlorophenol [Mass/volume] in Air;2,4,6-TCP Air-mCnc;;ACTIVE;2.14;2.34 +38731-6;Triethylamine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Triethylamine [Mass/volume] in Air;Triethylamine Air-mCnc;;ACTIVE;2.14;2.34 +38732-4;Trifluralin;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Trifluralin [Mass/volume] in Air;Trifluralin Air-mCnc;;ACTIVE;2.14;2.34 +38733-2;Vinyl acetate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Vinyl acetate [Mass/volume] in Air;Vinyl acetate Air-mCnc;;ACTIVE;2.14;2.34 +38734-0;Vinyl bromide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Vinyl bromide [Mass/volume] in Air;Vinyl bromide Air-mCnc;;ACTIVE;2.14;2.34 +38735-7;1,1-Dichloroethylene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,1-Dichloroethylene [Mass/volume] in Air;1,1-DCE Air-mCnc;;ACTIVE;2.14;2.34 +38736-5;Animal hair+Epithelium;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Animal hair+Epithelium [Mass/volume] in Air;Animal hair+epith Air-mCnc;;ACTIVE;2.14;2.34 +3873-7;Nortriptyline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Nortriptyline [Presence] in Serum or Plasma;Nortrip SerPl Ql;;ACTIVE;1.0;2.73 +38737-3;O-anisidine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;O-anisidine [Mass/volume] in Air;o-anisidine Air-mCnc;;ACTIVE;2.14;2.34 +38738-1;Carbaryl;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Carbaryl [Mass/volume] in Air;Carbaryl Air-mCnc;;ACTIVE;2.14;2.34 +38739-9;1,3-Dichloropropene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,3-Dichloropropene [Mass/volume] in Air;DCP Air-mCnc;;ACTIVE;2.14;2.34 +38740-7;Dimethylcarbamoyl chloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dimethylcarbamoyl chloride [Mass/volume] in Air;DDC Air-mCnc;;ACTIVE;2.14;2.34 +38741-5;2,4-Dinitrophenol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2,4-Dinitrophenol [Mass/volume] in Air;2,4-DNP Air-mCnc;;ACTIVE;2.14;2.34 +38742-3;2,4-Dinitrotoluene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2,4-Dinitrotoluene [Mass/volume] in Air;2,4-DNT Air-mCnc;;ACTIVE;2.14;2.34 +38743-1;Hydrogen chloride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hydrogen chloride [Mass/volume] in Air;Hydrogen chloride Air-mCnc;;ACTIVE;2.14;2.34 +38744-9;Hydrogen fluoride;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Hydrogen fluoride [Mass/volume] in Air;Hydrogen fluoride Air-mCnc;;ACTIVE;2.14;2.34 +3874-5;Nortriptyline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nortriptyline [Presence] in Urine;Nortrip Ur Ql;;ACTIVE;1.0;2.73 +38745-6;Diphenylmethane diisocyanate (MDI);MCnc;Pt;Air;Qn;;DRUG/TOX;1;Isocyanate MDI [Mass/volume] in Air;Isocyanate MDI Air-mCnc;;ACTIVE;2.14;2.34 +38746-4;4,4'-Methylene bis(2-Chloroaniline);MCnc;Pt;Air;Qn;;DRUG/TOX;1;4,4'-Methylene bis(2-Chloroaniline) [Mass/volume] in Air;4,4'-MBOCA Air-mCnc;;ACTIVE;2.14;2.34 +38747-2;Methyl isocyanate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methyl isocyanate [Mass/volume] in Air;Methyl isocyanate Air-mCnc;;ACTIVE;2.14;2.34 +38748-0;Methylenedianiline;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Methylenedianiline [Mass/volume] in Air;4,4-MDA Air-mCnc;;ACTIVE;2.14;2.34 +38749-8;P-nitrobiphenyl;MCnc;Pt;Air;Qn;;DRUG/TOX;1;P-nitrobiphenyl [Mass/volume] in Air;P-nitrobiphenyl Air-mCnc;;ACTIVE;2.14;2.34 +38750-6;Para nitrophenol;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Para nitrophenol [Mass/volume] in Air;p-nitrophenol Air-mCnc;;ACTIVE;2.14;2.34 +38751-4;1,4-Benzenediamine;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,4-Benzenediamine [Mass/volume] in Air;PPD Air-mCnc;;ACTIVE;2.14;2.34 +3875-2;Nortriptyline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nortriptyline [Mass/volume] in Urine;Nortrip Ur-mCnc;;ACTIVE;1.0;2.73 +38752-2;Polychlorinated biphenyl;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Mass/volume] in Air;PCB Air-mCnc;;ACTIVE;2.14;2.46 +38753-0;Tetrachloroethane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Tetrachloroethane [Mass/volume] in Air;Tetrachloroethane Air-mCnc;;ACTIVE;2.14;2.34 +38754-8;2,4-Toluene diisocyanate;MCnc;Pt;Air;Qn;;DRUG/TOX;1;2,4-Toluene diisocyanate [Mass/volume] in Air;2,4-TDI Air-mCnc;;ACTIVE;2.14;2.34 +38755-5;Dimethylbenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dimethylbenzene [Mass/volume] in Air;DMB Air-mCnc;;ACTIVE;2.14;2.34 +38756-3;1,2-Dimethylbenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,2-Dimethylbenzene [Mass/volume] in Air;1,2DMB Air-mCnc;;ACTIVE;2.14;2.34 +38757-1;1,3-Dimethylbenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,3-Dimethylbenzene [Mass/volume] in Air;1,3DMB Air-mCnc;;ACTIVE;2.14;2.34 +38758-9;1,4-Dimethylbenzene;MCnc;Pt;Air;Qn;;DRUG/TOX;1;1,4-Dimethylbenzene [Mass/volume] in Air;1,4DMB Air-mCnc;;ACTIVE;2.14;2.34 +38759-7;Aluminum;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Air;Aluminum Air-mCnc;;ACTIVE;2.14;2.34 +3876-0;Nortriptyline^trough >12h post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortriptyline [Mass/volume] in Serum or Plasma --trough >12 hours post dose;Nortrip >12h Trough SerPl-mCnc;;ACTIVE;1.0;2.42 +38760-5;Dibenzofuran;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Dibenzofuran [Mass/volume] in Air;Dibenzofuran Air-mCnc;;ACTIVE;2.14;2.34 +38761-3;Asphalt;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Asphalt [Mass/volume] in Air;Asphalt Air-mCnc;;ACTIVE;2.14;2.34 +38762-1;Isooctane;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Iso-octane [Mass/volume] in Air;Iso-octane Air-mCnc;;ACTIVE;2.14;2.34 +38763-9;Eastern equine encephalitis virus Ab.IgM;ACnc;Pt;XXX;Qn;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Units/volume] in Specimen;EEEV IgM Spec-aCnc;;ACTIVE;2.14;2.69 +38764-7;Eastern equine encephalitis virus Ab.IgG;ACnc;Pt;XXX;Qn;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Units/volume] in Specimen;EEEV IgG Spec-aCnc;;ACTIVE;2.14;2.69 +38765-4;Guidance for biopsy of transplanted liver;Find;Pt;Abdomen;Doc;US;RAD;2;US Guidance for biopsy of transplanted liver;US Guided Bx of liver transplant;;ACTIVE;2.14;2.64 +38766-2;Guidance for biopsy of transplanted kidney;Find;Pt;Pelvis;Doc;US;RAD;2;US Guidance for biopsy of transplanted kidney;US Guided Bx of kidney transplant;;ACTIVE;2.14;2.64 +38767-0;Multisection;Find;Pt;Head>Internal auditory canal.right;Doc;CT;RAD;2;CT Internal auditory canal - right;CT IAC-R;;ACTIVE;2.14;2.61 +38768-8;Multisection;Find;Pt;Lower extremity.right>Femur;Doc;XR.tomography;RAD;2;XR tomography Femur - right;XR tomo Femur-R;;ACTIVE;2.14;2.61 +38769-6;Multisection limited^WO contrast;Find;Pt;Lower extremity.right>Lower extremity joint;Doc;MR;RAD;2;MR Lower extremity joint - right limited WO contrast;MR LE joint-R Ltd WO contr;;ACTIVE;2.14;2.65 +38770-4;Multisection^WO contrast;Find;Pt;Chest>Scapula.right;Doc;MR;RAD;2;MR Scapula - right WO contrast;MR Scapula-R WO contr;;ACTIVE;2.14;2.61 +38771-2;Views;Find;Pt;Pelvis & Lower extremity.right>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - right Views;XR Pelvis and Hip-R Views;;ACTIVE;2.14;2.64 +38772-0;View true lateral;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right True lateral;XR Hip-R True lat;;ACTIVE;2.14;2.61 +38773-8;Multisection^WO contrast;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - right WO contrast;MRA LE ves-R WO contr;;ACTIVE;2.14;2.61 +38774-6;Views;Find;Pt;Head>Orbit.right;Doc;XR;RAD;2;XR Orbit - right Views;XR Orbit-R Views;;ACTIVE;2.14;2.64 +38775-3;View Brewerton;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right Brewerton;XR Hand-R Brewerton;;ACTIVE;2.14;2.61 +38776-1;View Harris;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Harris;XR Heel-R Harris;;ACTIVE;2.14;2.61 +38777-9;View Jones;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Jones;XR Elbow-R Jones;;ACTIVE;2.14;2.61 +3877-8;Ofloxacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ofloxacin [Mass/volume] in Serum or Plasma;Ofloxacin SerPl-mCnc;;ACTIVE;1.0;2.42 +38778-7;Views ski jump;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Ski jump Views;XR Heel-R Views Ski Jump;;ACTIVE;2.14;2.64 +38779-5;View transthoracic;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Transthoracic;XR Should-R Transthoracic;;ACTIVE;2.14;2.61 +38780-3;View Velpeau axillary;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Velpeau axillary;XR Should-R Velpeau ax;;ACTIVE;2.14;2.61 +38781-1;Views AP + axillary + outlet;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and Axillary and Outlet;XR Should-R AP+Ax+Outlet;;ACTIVE;2.14;2.61 +38782-9;Views AP + axillary + outlet + Zanca;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and Axillary and Outlet and Zanca;XR Should-R AP+Ax+Outlet+Zanca;;ACTIVE;2.14;2.61 +38783-7;Views AP + axillary + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and Axillary and Y;XR Should-R AP+Ax+Y;;ACTIVE;2.14;2.61 +38784-5;Views AP + lateral crosstable;Find;Pt;Pelvis & Lower extremity.right>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - right AP and Lateral crosstable;XR Pelvis and Hip-R AP+Lat Xtable;;ACTIVE;2.14;2.61 +38785-2;Views AP + lateral frog;Find;Pt;Pelvis & Lower extremity.right>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - right AP and Lateral frog;XR Pelvis and Hip-R AP+Lat frog;;ACTIVE;2.14;2.64 +3878-6;Opiates;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Opiates [Presence] in Serum or Plasma;Opiates SerPl Ql;;ACTIVE;1.0;2.73 +38786-0;Views AP + lateral + Sunrise;Find;Pt;Lower extremity.right>Patella;Doc;XR;RAD;2;XR Patella - right AP and Lateral and Sunrise;XR Patella-R AP+Lat+Sunrise;;ACTIVE;2.14;2.61 +38787-8;Views AP + West Point;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and West Point;XR Should-R AP+West Point;;ACTIVE;2.14;2.61 +38788-6;Views AP + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and Y;XR Should-R AP+Y;;ACTIVE;2.14;2.61 +38789-4;Views Grashey + axillary + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey and Axillary and Y;XR Should-R Grashey+Ax+Y;;ACTIVE;2.14;2.61 +38790-2;Views PA + lateral + Sunrise;Find;Pt;Lower extremity.right>Patella;Doc;XR;RAD;2;XR Patella - right PA and Lateral and Sunrise;XR Patella-R PA+Lat+Sunrise;;ACTIVE;2.14;2.61 +38791-0;Views Grashey + outlet;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey and Outlet;XR Should-R Grashey+Outlet;;ACTIVE;2.14;2.61 +38792-8;Views tarsal;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;Deprecated XR Foot - right Tarsal Views;Deprecated XR Foot-R Views tarsal;;DEPRECATED;2.14;2.64 +38793-6;Views Grashey + axillary;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey and Axillary;XR Should-R Grashey+Ax;;ACTIVE;2.14;2.61 +3879-4;Opiates;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Opiates [Presence] in Urine;Opiates Ur Ql;;ACTIVE;1.0;2.73 +38794-4;Views Grashey + outlet + Serendipity;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey and Outlet and Serendipity;XR Should-R Grashey+Outlet+Serend;;ACTIVE;2.14;2.61 +38795-1;Views Grashey + West Point;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey and West Point;XR Should-R Grashey+West Point;;ACTIVE;2.14;2.61 +38796-9;Views;Find;Pt;Lower extremity.right>Hip;Doc;XR.portable;RAD;2;Portable XR Hip - right Views;XR port Hip-R Views;;ACTIVE;2.14;2.64 +38797-7;Views;Find;Pt;Upper extremity.right>Humerus.bicipital groove;Doc;XR;RAD;2;XR Humerus bicipital groove - right Views;XR Humerus bicipital groove-R Views;;ACTIVE;2.14;2.64 +38798-5;Views;Find;Pt;Upper extremity.right>Olecranon;Doc;XR;RAD;2;XR Olecranon - right Views;XR Olecranon-R Views;;ACTIVE;2.14;2.64 +38799-3;Views runoff^W contrast IA;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Lower extremity.right>Femoral artery;Doc;RF.angio;RAD;2;RFA Aorta and Femoral artery - right Runoff W contrast IA;RFA Aorta+Fem a-R runoff W contr IA;;ACTIVE;2.14;2.61 +38800-9;Views^W contrast IA;Find;Pt;Chest>Aortic arch+Subclavian artery.right;Doc;RF.angio;RAD;2;RFA Aortic arch and Subclavian artery - right Views W contrast IA;RFA Ao arch+Subcl a-R Views W contr IA;;DISCOURAGED;2.14;2.64 +38801-7;Views^W contrast IA;Find;Pt;Abdomen>Gastric artery.right;Doc;RF.angio;RAD;2;RFA Gastric artery right Views W contrast IA;RFA Gastric a-R Views W contr IA;;ACTIVE;2.14;2.64 +3880-2;Orphenadrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Orphenadrine [Mass/volume] in Serum or Plasma;Orphenadrine SerPl-mCnc;;ACTIVE;1.0;2.73 +38802-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Wrist;Doc;CT;RAD;2;CT Wrist - right WO and W contrast IV;CT Wrist-R WO+W contr IV;;ACTIVE;2.14;2.61 +38803-3;View 45 degree cephalic angle;Find;Pt;Chest>Clavicle.right;Doc;XR;RAD;2;XR Clavicle - right 45 degree cephalic angle;XR Clavicle-R 45 deg ceph angle;;ACTIVE;2.14;2.61 +38804-1;View Bora;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right Bora;XR Hand-R Bora;;ACTIVE;2.14;2.61 +38805-8;View Grashey;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey;XR Should-R Grashey;;ACTIVE;2.14;2.61 +38806-6;View 10 degree caudal angle;Find;Pt;Lower extremity.right>Tibia;Doc;XR;RAD;2;XR Tibia - right 10 degree caudal angle;XR Tib-R 10 deg cau angle;;ACTIVE;2.14;2.61 +38807-4;Views spot;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Spot Views;MG Brst-R Views spot;;ACTIVE;2.14;2.64 +38808-2;Views ulnar deviation + radial deviation;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Ulnar deviation and Radial deviation;XR Wrist-R Ulnar+Radial Deviation;;ACTIVE;2.14;2.61 +38809-0;Views^W contrast IA;Find;Pt;Upper extremity arteries.right;Nar;XR.fluor.angio;RAD;2;Deprecated Upper extremity arteries Right X-ray fluoroscopy angio W contrast IA;Deprecated UE aa-R XRA W contr IA;;DEPRECATED;2.14;2.36 +3881-0;Ouabain;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ouabain [Mass/volume] in Serum or Plasma;Ouabain SerPl-mCnc;;ACTIVE;1.0;2.34 +38810-8;Views^W standing;Find;Pt;Lower extremity.right>Great toe;Doc;XR;RAD;2;XR Great toe - right Views W standing;XR Great toe-R Views W Stand;;ACTIVE;2.14;2.64 +38811-6;Views^W contrast intra lymphatic;Find;Pt;Abdomen>Abdominal lymphatic vessels.right & Pelvis>Pelvic lymphatic vessels.right;Doc;RF.angio;RAD;2;RFA Abdominal and pelvic lymphatic vessels - right Views W contrast intra lymphatic;RFA Abd+Pelvic lymph ves-R Vs W contr IL;;ACTIVE;2.14;2.64 +38812-4;Views^W contrast intra lymphatic;Find;Pt;Extremity.right>Extremity lymphatic vessels;Doc;RF.angio;RAD;2;RFA Extremity lymphatic vessels - right Views W contrast intra lymphatic;RFA Extremity lymph ves-R Vs W contr IL;;ACTIVE;2.14;2.64 +38813-2;Views^W contrast intra lymphatic;Find;Pt;XXX>Lymphatic vessels.right;Doc;RF.angio;RAD;2;RFA Lymphatic vessels - right Views W contrast intra lymphatic;RFA Lymph ves-R Views W contr IL;;ACTIVE;2.14;2.64 +38814-0;Views Broden;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Broden Views;XR Heel-R Views Broden;;ACTIVE;2.14;2.64 +38815-7;Views AP^W standing;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right Views AP W standing;XR Foot-R Views AP W Stand;;ACTIVE;2.14;2.64 +38816-5;Views Grashey^WO & W weight;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey Views WO and W weight;XR Should-R Views Grashey WO+W Wt;;ACTIVE;2.14;2.64 +38817-3;Multisection for implant^WO contrast;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Breast - right for implant WO contrast;MR Brst-R for Implant WO contr;;ACTIVE;2.14;2.61 +38818-1;View^during surgery;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Single view during surgery;XR Hip-R 1V in Surg;;ACTIVE;2.14;2.64 +38819-9;View lateral^during surgery;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Lateral during surgery;XR Hip-R Lat in Surg;;ACTIVE;2.14;2.61 +38820-7;Views for implant;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Views for implant;MG Brst-R Views for implant;;ACTIVE;2.14;2.64 +38821-5;Views;Find;Pt;^Breast specimen.right;Doc;MG;RAD;2;MG Breast specimen - right Views;MG Brst spec-R Views;;ACTIVE;2.14;2.64 +38822-3;Views AP + transthoracic;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and Transthoracic;XR Should-R AP+Transthoracic;;ACTIVE;2.14;2.61 +38823-1;Views magnification & spot^compression;Find;Pt;Breast.right;Nar;Mam;RAD;2;Deprecated Breast - right Mammogram magnification & spot compression;Deprecated Brst-R Mam Mag+Spot Compressi;;DEPRECATED;2.14;2.34 +38824-9;Views Sunrise 20 degrees + Sunrise 40 degrees + Sunrise 60 degrees;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Sunrise 20 and 40 and 60 degrees;XR Knee-R Sunrise 20+40+60 deg;;ACTIVE;2.14;2.61 +38825-6;Views^W contrast intra duct;Find;Pt;Breast>Breast duct.right;Doc;MG;RAD;2;MG Breast duct - right Views W contrast intra duct;MG Brst duct-R Views W contr intra Dct;;ACTIVE;2.14;2.64 +38826-4;Views^W contrast intra salivary duct;Find;Pt;Neck>Parotid gland.right;Doc;RF;RAD;2;RF Parotid gland - right Views W contrast intra salivary duct;RF Parotid gland-R Vs W contr intra SD;;ACTIVE;2.14;2.64 +38827-2;Views^W contrast intra lacrimal duct;Find;Pt;Head>Lacrimal duct.right;Doc;RF;RAD;2;RF Lacrimal duct - right Views W contrast intra lacrimal duct;RF Lacrimal Duct-R Vs W contr intra LD;;ACTIVE;2.14;2.64 +3882-8;Oxacillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxacillin [Mass/volume] in Serum or Plasma;Oxacillin SerPl-mCnc;;ACTIVE;1.0;2.42 +38828-0;Multisection^W contrast IS;Find;Pt;Upper extremity.left>Shoulder;Doc;CT;RAD;2;CT Shoulder - left Arthrogram;CT Should-L W contr IS;;ACTIVE;2.14;2.61 +38829-8;Multisection^W contrast IV;Find;Pt;Upper extremity.left;Doc;MR;RAD;2;MR Upper extremity - left W contrast IV;MR UE-L W contr IV;;ACTIVE;2.14;2.61 +38830-6;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Shoulder;Doc;MR;RAD;2;MR Shoulder - left W contrast IV;MR Should-L W contr IV;;ACTIVE;2.14;2.61 +38831-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left;Doc;MR;RAD;2;MR Upper extremity - left WO and W contrast IV;MR UE-L WO+W contr IV;;ACTIVE;2.14;2.61 +38832-2;Multisection^WO contrast;Find;Pt;Upper extremity.left;Doc;MR;RAD;2;MR Upper extremity - left WO contrast;MR UE-L WO contr;;ACTIVE;2.14;2.61 +38833-0;Multisection^WO contrast;Find;Pt;Chest>Brachial plexus.left;Doc;MR;RAD;2;MR Brachial plexus - left WO contrast;MR Brachial plexus-L WO contr;;ACTIVE;2.14;2.61 +38834-8;Multisection^WO contrast;Find;Pt;Upper extremity.left>Shoulder;Doc;MR;RAD;2;MR Shoulder - left WO contrast;MR Should-L WO contr;;ACTIVE;2.14;2.73 +38835-5;Multisection^W contrast IV;Find;Pt;Head>Temporal bone.left;Doc;CT;RAD;2;CT Temporal bone - left W contrast IV;CT Temporal bone-L W contr IV;;ACTIVE;2.14;2.61 +3883-6;Oxandrolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Oxandrolone [Presence] in Urine;Oxandrolone Ur Ql;;ACTIVE;1.0;2.73 +38836-3;Multisection;Find;Pt;Head>Orbit.left;Doc;MR;RAD;2;MR Orbit - left;MR Orbit-L;;ACTIVE;2.14;2.61 +38837-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Knee vessels;Doc;MR.angio;RAD;2;MRA Knee vessels - left WO and W contrast IV;MRA Knee ves-L WO+W contr IV;;ACTIVE;2.14;2.61 +38838-9;Views limited;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Limited Views;XR Wrist-L Views Ltd;;ACTIVE;2.14;2.64 +38839-7;Views oblique;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Oblique Views;XR Wrist-L Views Obl;;ACTIVE;2.14;2.64 +38840-5;Views 2^W manual stress;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left 2 Views W manual stress;XR Ankle-L 2V W man stress;;ACTIVE;2.14;2.71 +38841-3;Views 2^W standing;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left 2 Views W standing;XR Ankle-L 2V W Stand;;ACTIVE;2.14;2.61 +38842-1;View carpal tunnel;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Carpal tunnel;XR Wrist-L Carpal tunnel;;ACTIVE;2.14;2.64 +38843-9;Views 2 carpal tunnel;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 2 Carpal tunnel Views;XR Wrist-L 2V Carpal tunnel;;ACTIVE;2.14;2.64 +3884-4;Oxandrolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxandrolone [Mass/volume] in Urine;Oxandrolone Ur-mCnc;;ACTIVE;1.0;2.34 +38844-7;Views 2 oblique;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left 2 Oblique Views;XR Elbow-L 2V Obl;;ACTIVE;2.14;2.64 +38845-4;Views^W standing;Find;Pt;Lower extremity.left>Femur;Doc;XR;RAD;2;XR Femur - left Views W standing;XR Femur-L Views W Stand;;ACTIVE;2.14;2.64 +38846-2;Views 2;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left 2 Views;XR Foot-L 2V;;ACTIVE;2.14;2.73 +38847-0;Views AP + lateral;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left AP and Lateral;XR Hand-L AP+Lat;;ACTIVE;2.14;2.61 +38848-8;Views AP + lateral + oblique;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left AP and Lateral and oblique;XR Hand-L AP+Lat+Obl;;ACTIVE;2.14;2.61 +38849-6;View AP^W standing;Find;Pt;Lower extremity.left;Doc;XR;RAD;2;XR Lower extremity - left AP W standing;XR LE-L AP W Stand;;ACTIVE;2.14;2.61 +38850-4;View^W standing;Find;Pt;Lower extremity.left;Doc;XR;RAD;2;XR Lower extremity - left Single view W standing;XR LE-L 1V W Stand;;ACTIVE;2.14;2.64 +3885-1;Oxandrolone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Oxandrolone [Mass/time] in 24 hour Urine;Oxandrolone 24h Ur-mRate;;ACTIVE;1.0;2.19 +38851-2;Views 2^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 2 Views W standing;XR Knee-L 2V W Stand;;ACTIVE;2.14;2.61 +38852-0;Views 4^W standing;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 4 Views W standing;XR Knee-L 4V W Stand;;ACTIVE;2.14;2.61 +38853-8;Views^W contrast;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;RF.angio;RAD;2;RFA Lower extremity vessels - left Views W contrast;RFA LE ves-L Views W contr;;ACTIVE;2.14;2.64 +38854-6;Views magnification+spot;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Magnification and Spot;MG Brst-L Mag+Spot;;ACTIVE;2.14;2.61 +38855-3;View true lateral;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left True lateral;MG Brst-L True lat;;ACTIVE;2.14;2.61 +38856-1;Views anterior + lateral;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left Anterior and Lateral;XR Ribs-L Ant+Lat;;ACTIVE;2.14;2.61 +38857-9;View lateral;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left Lateral;XR Ribs-L Lat;;ACTIVE;2.14;2.61 +38858-7;View Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Y;XR Should-L Y;;ACTIVE;2.14;2.61 +38859-5;Views^W contrast IV;Find;Pt;Upper extremity.left>Upper extremity veins;Doc;RF.angio;RAD;2;RFA Upper extremity veins - left Views W contrast IV;RFA UE vv-L Views W contr IV;;ACTIVE;2.14;2.64 +38860-3;Views AP + lateral;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left AP and Lateral;XR Wrist-L AP+Lat;;ACTIVE;2.14;2.61 +38861-1;Views^W contrast IA;Find;Pt;Lower extremity.left>Ankle arteries;Doc;RF.angio;RAD;2;RFA Ankle arteries - left Views W contrast IA;RFA Ankle aa-L Views W contr IA;;ACTIVE;2.14;2.64 +38862-9;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery & Head>Cerebral artery.left;Doc;RF.angio;RAD;2;RFA Carotid artery and Cerebral artery - left Views W contrast IA;RFA Carot a+Cerebral a-L Vs W contr IA;;ACTIVE;2.14;2.64 +38863-7;Views^W contrast IA;Find;Pt;Neck>Carotid artery.cervical.left;Doc;RF.angio;RAD;2;RFA Carotid artery.cervical - left Views W contrast IA;RFA Carot a cervical-L Views W contr IA;;ACTIVE;2.14;2.64 +38864-5;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery.internal.left;Doc;RF.angio;RAD;2;RFA Carotid artery.internal - left Views W contrast IA;RFA Carot a.int-L Views W contr IA;;ACTIVE;2.14;2.64 +38865-2;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery & Head>Cerebral artery internal.left;Doc;RF.angio;RAD;2;RFA Carotid artery and Cerebral artery internal - left Views W contrast IA;RFA Carot a+Cereb a.ext-L Vs W contr IA;;ACTIVE;2.14;2.64 +38866-0;Views;Find;Pt;Chest>Ribs.lower.left;Doc;XR;RAD;2;XR Ribs lower - left Views;XR Ribs lower-L Views;;ACTIVE;2.14;2.64 +38867-8;Views;Find;Pt;Chest>Ribs.upper.left;Doc;XR;RAD;2;XR Ribs upper - left Views;XR Ribs upper-L Views;;ACTIVE;2.14;2.64 +38868-6;Views;Find;Pt;Chest>Ribs.anterior.left+Ribs.posterior.left;Doc;XR;RAD;2;XR Ribs anterior and posterior - left Views;XR Ribs Ant+Post-L Views;;ACTIVE;2.14;2.64 +3886-9;Oxazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Serum or Plasma;Oxazepam SerPl-mCnc;;ACTIVE;1.0;2.73 +38869-4;Views;Find;Pt;Chest>Ribs.posterior.left;Doc;XR;RAD;2;XR Ribs posterior - left Views;XR Ribs post-L Views;;ACTIVE;2.14;2.73 +38870-2;Multisection for implant^WO & W contrast IV;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Breast - left for implant WO and W contrast IV;MR Brst-L for Implant WO+W contr IV;;ACTIVE;2.14;2.61 +38871-0;Views 2 oblique;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 2 Oblique Views;XR Knee-L 2V Obl;;ACTIVE;2.14;2.64 +38872-8;Views^W contrast via nephrostomy tube;Find;Pt;Abdomen>Kidney.left;Doc;RF;RAD;2;RF Kidney - left Views W contrast via nephrostomy tube;RF Kidney-L Views W contr via NT;;ACTIVE;2.14;2.64 +38873-6;Views^W contrast retrograde via urethra;Find;Pt;Abdomen>Kidney.left;Doc;RF;RAD;2;Deprecated RF Kidney - left Views W contrast retrograde via urethra;Deprecated RF Kidney-L Views W contr RU;;DEPRECATED;2.14;2.64 +38874-4;Views 2 oblique;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left 2 Oblique Views;XR Tib+Fib-L 2V Obl;;ACTIVE;2.14;2.64 +38875-1;Coagulation tissue factor induced.INR;RelTime;Pt;PPP/Bld;Qn;Coag;COAG;1;INR in Platelet poor plasma or blood by Coagulation assay;INR PPP/Bld;;ACTIVE;2.15;2.73 +38876-9;Respiratory contraindications to elevating head of bed greater than 30 degrees;Find;Pt;^Patient;Nom;;RESP.ATOM;2;Respiratory contraindications to elevating head of bed greater than 30 degrees;Resp contra to elev head of bed >30 deg;;ACTIVE;2.15;2.27 +3887-7;Oxazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Urine;Oxazepam Ur-mCnc;;ACTIVE;1.0;2.73 +38877-7;Oral care given;Type;Pt;^Patient;Nom;;RESP.ATOM;2;Oral care given;Oral care Gvn;;ACTIVE;2.15;2.27 +38878-5;Ventilator mode change reason;Find;Pt;^Patient;Nom;;RESP.ATOM;2;Ventilator mode change reason;Vent mode change reason;;ACTIVE;2.15;2.27 +38879-3;Ventilator disconnect reason;Type;Pt;^Patient;Nom;;RESP.ATOM;2;Ventilator disconnect reason;Vent disconnect reason;;ACTIVE;2.15;2.27 +38880-1;Ventilator alarm reason;Find;Pt;^Patient;Nom;;RESP.ATOM;2;Ventilator alarm reason;Vent alarm reason;;ACTIVE;2.15;2.27 +38881-9;Emotional stability behavior^pre {event};Find;Pt;^Patient;Nom;;RESP.ATOM;2;Emotional stability behavior --pre event;Emot stability behav Pre {event};;ACTIVE;2.15;2.27 +38882-7;Emotional stability behavior^post {event};Find;Pt;^Patient;Nom;;RESP.ATOM;2;Emotional stability behavior --post event;Emot stability behav Post {event};;ACTIVE;2.15;2.27 +38883-5;Reintubated urgency;Type;Pt;^Patient;Ord;;RESP.ATOM;2;Reintubated urgency;Reintubated urgency;;ACTIVE;2.15;2.27 +38884-3;Vendor serial number;ID;Pt;Ventilator;Nom;;DEVICES;2;Ventilator Vendor serial number;Vent Serial #;;ACTIVE;2.15;2.66 +3888-5;Oxedrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxedrine [Mass/volume] in Urine;Oxedrine Ur-mCnc;;ACTIVE;1.0;2.34 +38885-0;Extubation urgency;Type;Pt;^Patient;Ord;;RESP.ATOM;2;Extubation urgency;Extubation Urgency;;ACTIVE;2.15;2.27 +38886-8;Endotracheal tube secure method;Type;Pt;Tube;Nom;;RESP.ATOM;2;Endotracheal tube secure method;Endotracheal tube secure method;;ACTIVE;2.15;2.29 +38887-6;Person present^at time of {event};Type;Pt;{Event};Nom;;RESP.ATOM;2;Person present --at time of event;Person Present at time of event;;ACTIVE;2.15;2.29 +38888-4;Status of nursing unit activity level;Find;Pt;{Nursing unit};Nom;;RESP.ATOM;2;Status of nursing unit activity level;Status of nursing unit activity level;;ACTIVE;2.15;2.27 +38889-2;Personnel notified of {event};Type;Pt;{Event};Nom;;RESP.ATOM;2;Personnel notified of {event};Personnel Notified of {event};;ACTIVE;2.15;2.73 +388-9;Oxytetracycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Oxytetracycline [Susceptibility] by Disk diffusion (KB);Oxytetracycline Islt KB;;ACTIVE;1.0;2.19 +38890-0;Vaccine component type;ID;Pt;Vaccine;Nom;;VACCIN;2;Vaccine component type [Identifier];Vaccine Component Type;;ACTIVE;2.15;2.27 +38891-8;ABCC8 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ABCC8 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ABCC8 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +38892-6;Anisocytosis;PrThr;Pt;Bld;Ord;;HEM/BC;1;Anisocytosis [Presence] in Blood;Anisocytosis Bld Ql;;ACTIVE;2.15;2.73 +3889-3;Oxprenolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxprenolol [Mass/volume] in Serum or Plasma;Oxprenolol SerPl-mCnc;;ACTIVE;1.0;2.42 +38893-4;ARIPiprazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ARIPiprazole [Mass/volume] in Serum or Plasma;ARIPiprazole SerPl-mCnc;;ACTIVE;2.15;2.73 +38894-2;Cells.CD158;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD158 cells [#/volume] in Specimen;CD158 Cells # Spec;;ACTIVE;2.15;2.69 +38895-9;ELA2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ELA2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ELA2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38896-7;F9 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F9 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;F9 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38897-5;Fibers;PrThr;Pt;Stool;Ord;Microscopy.light;CHEM;1;Fibers [Presence] in Stool by Light microscopy;Fibers Stl Ql Micro;;ACTIVE;2.15;2.56 +38898-3;Fibrin D-dimer;Titr;Pt;PPP;Qn;;COAG;1;Fibrin D-dimer [Titer] in Platelet poor plasma;D Dimer Titr PPP;;ACTIVE;2.15;2.30 +38899-1;fluPHENAZine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;fluPHENAZine [Presence] in Serum or Plasma;fluPHENAZine SerPl Ql;;ACTIVE;2.15;2.73 +38900-7;HEXA gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HEXA gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HEXA gene Mut Tested Bld/T;;ACTIVE;2.15;2.73 +3890-1;Oxprenolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Oxprenolol [Presence] in Urine;Oxprenolol Ur Ql;;ACTIVE;1.0;2.56 +38901-5;Leflunomide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Leflunomide [Mass/volume] in Serum or Plasma;Leflunomide SerPl-mCnc;;ACTIVE;2.15;2.73 +38902-3;LITAF gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LITAF gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LITAF gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +38903-1;Lymphocytes;PrThr;Pt;Stool;Ord;Microscopy.light;HEM/BC;1;Lymphocytes [Presence] in Stool by Light microscopy;Lymphocytes Stl Ql Micro;;ACTIVE;2.15;2.56 +38904-9;MFN2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MFN2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MFN2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +38905-6;MLL gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MLL gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MLL gene Mut Tested Bld/T;;ACTIVE;2.15;2.15 +38906-4;MSH6 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MSH6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MSH6 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +38907-2;NIPA1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NIPA1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NIPA1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38908-0;Poikilocytosis;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Poikilocytosis [Presence] in Blood by Automated count;Poikilocytosis Bld Ql Auto;;ACTIVE;2.15;2.73 +38909-8;PTCH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PTCH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PTCH gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +38910-6;Schistocytes;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Schistocytes [Presence] in Blood by Automated count;Schistocytes Bld Ql Auto;;ACTIVE;2.15;2.73 +38911-4;SDHC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SDHC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SDHC gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +38912-2;Succinylacetone;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Succinylacetone [Moles/volume] in Amniotic fluid;Succinylacetone Amn-sCnc;;ACTIVE;2.15;2.34 +38913-0;TBX5 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TBX5 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TBX5 gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +38914-8;RS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;RS1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +38915-5;Zinc finger protein of the cerebellum 4 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Zinc finger protein of the cerebellum 4 Ab [Presence] in Serum;Zic4 Ab Ser Ql;;ACTIVE;2.15;2.56 +38916-3;Calicivirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Calicivirus RNA [Presence] in Specimen by NAA with probe detection;Calicivirus RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.69 +38917-1;Human metapneumovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection;hMPV RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +38918-9;ABCC8 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ABCC8 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ABCC8 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +3891-9;Oxprenolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxprenolol [Mass/volume] in Urine;Oxprenolol Ur-mCnc;;ACTIVE;1.0;2.42 +38919-7;LITAF gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LITAF gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;LITAF gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38920-5;MFN2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MFN2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MFN2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38921-3;MSH6 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MSH6 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MSH6 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +38922-1;PTCH gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PTCH gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PTCH gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38923-9;SDHC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SDHC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SDHC gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38924-7;TBX5 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TBX5 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TBX5 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38925-4;RS1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RS1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;RS1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38926-2;Macroprolactin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Macroprolactin [Mass/volume] in Serum or Plasma;Macroprolactin SerPl-mCnc;;ACTIVE;2.15;2.73 +3892-7;Oxprenolol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Oxprenolol [Mass/time] in 24 hour Urine;Oxprenolol 24h Ur-mRate;;ACTIVE;1.0;2.42 +38927-0;TRPS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TRPS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TRPS1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +38928-8;FAH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FAH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FAH gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +38929-6;FAH gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FAH gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FAH gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38930-4;EXT1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;EXT1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;EXT1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38931-2;TRPS1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TRPS1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TRPS1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +38932-0;VA C&P exam.acromegaly note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination acromegaly;VA C&P exam acromegaly;;ACTIVE;2.15;2.67 +38933-8;VA C&P exam.aid and attendance &or housebound note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination aid and attendance/housebound;VA C&P exam aid+attendance/housebound;;ACTIVE;2.15;2.67 +38934-6;VA C&P exam.arrhythmias note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination arrhythmias;VA C&P exam arrhythmias;;ACTIVE;2.15;2.67 +3893-5;oxyCODONE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;oxyCODONE [Mass/volume] in Serum or Plasma;oxyCODONE SerPl-mCnc;;ACTIVE;1.0;2.73 +38935-3;VA C&P exam.miscellaneous arteries &or veins note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination miscellaneous arteries/veins;VA C&P exam misc arteries/veins;;ACTIVE;2.15;2.67 +38936-1;VA C&P exam.audio note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination audio;VA C&P exam audio;;ACTIVE;2.15;2.67 +38937-9;VA C&P exam.bones fractures &or bone disease note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination bones fractures/bone disease;VA C&P exam bones fractures/bone disease;;ACTIVE;2.15;2.67 +38938-7;VA C&P exam.brain &or spinal cord note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination brain/spinal cord;VA C&P exam brain/spinal cord;;ACTIVE;2.15;2.67 +38939-5;VA C&P exam.chronic fatigue syndrome note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination chronic fatigue syndrome;VA C&P exam chronic fatigue syndrome;;ACTIVE;2.15;2.67 +38940-3;VA C&P exam.cold injury protocol note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination cold injury protocol;VA C&P exam cold injury protocol;;ACTIVE;2.15;2.67 +38941-1;VA C&P exam.cranial nerves note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination cranial nerves;VA C&P exam cranial nerves;;ACTIVE;2.15;2.67 +38942-9;VA C&P exam.Cushings syndrome note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination Cushings syndrome;VA C&P exam Cushings syndrome;;ACTIVE;2.15;2.67 +3894-3;Oxymesterone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Oxymesterone [Presence] in Urine;Oxymesterone Ur Ql;;ACTIVE;1.0;2.73 +38943-7;VA C&P exam.dental &or oral note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination dental/oral;VA C&P exam dent/oral;;ACTIVE;2.15;2.67 +38944-5;VA C&P exam.diabetes mellitus note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination diabetes mellitus;VA C&P exam diabetes mellitus;;ACTIVE;2.15;2.67 +38945-2;VA C&P exam.miscellaneous digestive conditions note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination miscellaneous digestive conditions;VA C&P exam misc digestive conditions;;ACTIVE;2.15;2.67 +38946-0;VA C&P exam.ear disease note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination ear disease;VA C&P exam ear disease;;ACTIVE;2.15;2.67 +38947-8;VA C&P exam.mental health eating disorders note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination mental health eating disorders;VA C&P exam MH-ED;;ACTIVE;2.15;2.67 +38948-6;VA C&P exam.miscellaneous endocrine diseases note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination miscellaneous endocrine diseases;VA C&P exam misc endocrine diseases;;ACTIVE;2.15;2.67 +38949-4;VA C&P exam.epilepsy &or narcolepsy note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination epilepsy/narcolepsy;VA C&P exam epilepsy/narcolepsy;;ACTIVE;2.15;2.67 +3895-0;Oxymesterone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxymesterone [Mass/volume] in Urine;Oxymesterone Ur-mCnc;;ACTIVE;1.0;2.34 +38950-2;VA C&P exam.esophagus &or hiatal hernia note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination esophagus/hiatal hernia;VA C&P exam esophagus/hiatal hernia;;ACTIVE;2.15;2.67 +38951-0;VA C&P exam.eye note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination eye;VA C&P exam eye;;ACTIVE;2.15;2.67 +38952-8;VA C&P exam.feet note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination feet;VA C&P exam feet;;ACTIVE;2.15;2.67 +38953-6;VA C&P exam.fibromyalgia note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination fibromyalgia;VA C&P exam fibromyalgia;;ACTIVE;2.15;2.67 +38954-4;VA C&P exam.general medical note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination general medical;VA C&P exam general medical;;ACTIVE;2.15;2.67 +38955-1;VA C&P exam.genitourinary note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination genitourinary;VA C&P exam genitourinary;;ACTIVE;2.15;2.67 +38956-9;VA C&P exam.disability in gulf war veterans note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination disability in gulf war veterans;VA C&P exam disability in gulf war vet;;ACTIVE;2.15;2.67 +38957-7;VA C&P exam.gynecological conditions &or disorders of the breast note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination gynecological conditions/disorders of the breast;VA C&P exam gyn/disorders of breast;;ACTIVE;2.15;2.67 +38958-5;VA C&P exam.hand &or thumb &or fingers note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination hand/thumb/fingers;VA C&P exam hand/thumb/fingers;;ACTIVE;2.15;2.67 +38959-3;VA C&P exam.heart note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination heart;VA C&P exam heart;;ACTIVE;2.15;2.67 +38960-1;VA C&P exam.hemic disorders note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination hemic disorders;VA C&P exam hemic disorders;;ACTIVE;2.15;2.67 +38961-9;VA C&P exam.HIV-related illness note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination HIV-related illness;VA C&P exam HIV-related illness;;ACTIVE;2.15;2.67 +38962-7;VA C&P exam.hypertension note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination hypertension;VA C&P exam hypertension;;ACTIVE;2.15;2.67 +38963-5;VA C&P exam.infectious &or immune &or nutritional disabilities note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination infectious/immune/nutritional disabilities;VA C&P exam inf/immune/nut disabilities;;ACTIVE;2.15;2.67 +38964-3;VA C&P exam.initial evaluation post-traumatic stress disorder note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination initial evaluation post-traumatic stress disorder;VA C&P exam initial eval PTSD;;ACTIVE;2.15;2.67 +38965-0;VA C&P exam.large &or small intestines note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination large/small intestines;VA C&P exam large/small intestines;;ACTIVE;2.15;2.67 +38966-8;VA C&P exam.extremity joints note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination extremity joints;VA C&P exam extremity joints;;ACTIVE;2.15;2.67 +38967-6;VA C&P exam.liver &or gall bladder &or pancreas note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination liver/gall bladder/pancreas;VA C&P exam liver/gall bladder/pancreas;;ACTIVE;2.15;2.67 +3896-8;Oxymesterone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Oxymesterone [Mass/time] in 24 hour Urine;Oxymesterone 24h Ur-mRate;;ACTIVE;1.0;2.19 +38968-4;VA C&P exam.lymphatic disorders note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination lymphatic disorders;VA C&P exam lymphatic disorders;;ACTIVE;2.15;2.67 +38969-2;VA C&P exam.general mental disorders note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination general mental disorders;VA C&P exam general mental disorders;;ACTIVE;2.15;2.67 +389-7;Oxytetracycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Oxytetracycline [Susceptibility] by Serum bactericidal titer;Oxytetracycline Titr SBT;;ACTIVE;1.0;2.32 +38970-0;VA C&P exam.mouth &or lips &or tongue note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination mouth/lips/tongue;VA C&P exam mouth/lips/tongue;;ACTIVE;2.15;2.67 +38971-8;VA C&P exam.muscles note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination muscles;VA C&P exam muscles;;ACTIVE;2.15;2.67 +38972-6;VA C&P exam.miscellaneous neurological disorders note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination miscellaneous neurological disorders;VA C&P exam misc neurological disorders;;ACTIVE;2.15;2.67 +38973-4;VA C&P exam.nose &or sinus &or larynx &or pharynx note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination nose/sinus/larynx/pharynx;VA C&P exam nose/sinus/larynx/pharynx;;ACTIVE;2.15;2.67 +38974-2;VA C&P exam.peripheral nerves note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination peripheral nerves;VA C&P exam peripheral nerves;;ACTIVE;2.15;2.67 +38975-9;VA C&P exam.prisoner of war protocol note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination prisoner of war protocol;VA C&P exam prisoner of war protocol;;ACTIVE;2.15;2.67 +3897-6;Oxymetholone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Oxymetholone [Presence] in Urine;Oxymetholone Ur Ql;;ACTIVE;1.0;2.73 +38976-7;VA C&P exam.pulmonary tuberculosis &or mycobacterial diseases note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination pulmonary tuberculosis/mycobacterial diseases;VA C&P exam pulm TB/mycobact diseases;;ACTIVE;2.15;2.67 +38977-5;VA C&P exam.rectum &or anus note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination rectum/anus;VA C&P exam rectum/anus;;ACTIVE;2.15;2.67 +38978-3;VA C&P exam.residuals of amputations note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination residuals of amputations;VA C&P exam residuals of amputations;;ACTIVE;2.15;2.67 +38979-1;VA C&P exam.obstructive &or restrictive &or interstitial respiratory diseases note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination obstructive/restrictive/interstitial respiratory diseases;VA C&P exam obst/rest/IRD;;ACTIVE;2.15;2.67 +38980-9;VA C&P exam.miscellaneous respiratory diseases note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination miscellaneous respiratory diseases;VA C&P exam misc respiratory diseases;;ACTIVE;2.15;2.67 +38981-7;VA C&P exam.review evaluation post-traumatic stress disorder note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination review evaluation post-traumatic stress disorder;VA C&P exam review eval PTSD;;ACTIVE;2.15;2.67 +38982-5;VA C&P exam.scars note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination scars;VA C&P exam scars;;ACTIVE;2.15;2.67 +38983-3;VA C&P exam.sense of smell &or taste note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination sense of smell/taste;VA C&P exam sense of smell/taste;;ACTIVE;2.15;2.67 +3898-4;Oxymetholone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxymetholone [Mass/volume] in Urine;Oxymetholone Ur-mCnc;;ACTIVE;1.0;2.34 +38984-1;VA C&P exam.skin diseases other than scars note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination skin diseases other than scars;VA C&P exam skn dis other than scars;;ACTIVE;2.15;2.67 +38985-8;VA C&P exam.social &or industrial survey note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination social/industrial survey;VA C&P exam social/industrial survey;;ACTIVE;2.15;2.67 +38986-6;VA C&P exam.spine note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination spine;VA C&P exam spine;;ACTIVE;2.15;2.67 +38987-4;VA C&P exam.stomach &or duodenum &or peritoneal adhesions note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination stomach/duodenum/peritoneal adhesions;VA C&P exam stom/duod/perit adhesions;;ACTIVE;2.15;2.67 +38988-2;VA C&P exam.thyroid &or parathyroid diseases note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) examination thyroid/parathyroid diseases;VA C&P exam thyroid/parathyroid diseases;;ACTIVE;2.15;2.67 +38989-0;Clostridium botulinum toxin A+B+E+F+G;PrThr;Pt;XXX;Ord;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin A+B+E+F+G [Presence] in Specimen by Mouse bioassay neutralization;C bot Tox ABEFG Spec Ql MA Nt;;ACTIVE;2.15;2.69 +38990-8;Escherichia coli O157:H7 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Escherichia coli O157:H7 DNA [Presence] in Specimen by NAA with probe detection;E coli O157H7 DNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +38991-6;Amylase;CCnc;12H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in 12 hour Urine;Amylase 12h Ur-cCnc;;ACTIVE;2.15;2.70 +3899-2;Oxymetholone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Oxymetholone [Mass/time] in 24 hour Urine;Oxymetholone 24h Ur-mRate;;ACTIVE;1.0;2.19 +38992-4;Amylase;ACnc;24H;Urine;Qn;;CHEM;1;Amylase [Units/volume] in 24 hour Urine;Amylase 24h Ur-aCnc;;ACTIVE;2.15;2.73 +38993-2;Calcium oxalate dihydrate crystals;PrThr;Pt;Urine sed;Ord;;UA;1;Calcium oxalate dihydrate crystals [Presence] in Urine sediment;COD Cry UrnS Ql;;ACTIVE;2.15;2.73 +38994-0;Histiocytes;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Histiocytes [Presence] in Urine sediment by Light microscopy;Histiocytes UrnS Ql Micro;;ACTIVE;2.15;2.56 +38995-7;Mixed cellular casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Mixed cellular casts [#/area] in Urine sediment by Microscopy low power field;Mixed Cell Casts #/area UrnS LPF;;ACTIVE;2.15;2.73 +38996-5;Neutrophils;PrThr;Pt;Urine;Ord;Microscopy.light;UA;1;Neutrophils [Presence] in Urine by Light microscopy;Neutrophils Ur Ql Micro;;ACTIVE;2.15;2.73 +38997-3;West Nile virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;West Nile virus IgG Ab [Units/volume] in Serum by Immunoassay;WNV IgG Ser IA-aCnc;;ACTIVE;2.15;2.73 +38998-1;HIV 1+Hepatitis C virus RNA;PrThr;Pt;Ser/Plas^BPU;Ord;Probe.amp.tar;MICRO;1;HIV 1+Hepatitis C virus RNA [Presence] in Serum or Plasma from Blood product unit by NAA with probe detection;HIV 1+HCV RNA SerPl BPU Ql NAA+probe;;ACTIVE;2.15;2.73 +38999-9;Hospital discharge DRG;Imp;Pt;^Patient;Nom;;H&P.HX;2;Hospital discharge DRG [Interpretation];Hospital Discharge DRG Imp;;ACTIVE;2.15;2.50 +39000-5;3-Hydroxybutyrylcarnitine (C4-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in Serum or Plasma;3OH-Butyrcarn SerPl-sCnc;;ACTIVE;2.15;2.73 +39001-3;3-Hydroxyisovalerylcarnitine (C5-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in Serum or Plasma;3OH-Isovalerylcarn SerPl-sCnc;;ACTIVE;2.15;2.73 +39002-1;Adipoylcarnitine (C6-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adipoylcarnitine (C6-DC) [Moles/volume] in Serum or Plasma;Adipoylcarn SerPl-sCnc;;ACTIVE;2.15;2.73 +39003-9;Cytomegalovirus DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;CMV DNA # CSF NAA+probe;;ACTIVE;2.15;2.73 +39004-7;Epidermal growth factor receptor Ag;PrThr;Pt;Tiss;Ord;;PATH;1;Epidermal growth factor receptor Ag [Presence] in Tissue;EGFR Ag Tiss Ql;;ACTIVE;2.15;2.73 +39005-4;Hepatitis B virus core Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis B virus core Ab [Presence] in Body fluid;HBV core Ab Fld Ql;;ACTIVE;2.15;2.73 +39006-2;Hepatitis B virus little e Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis B virus e Ab [Presence] in Body fluid;HBV e Ab Fld Ql;;ACTIVE;2.15;2.56 +39007-0;Hepatitis B virus little e Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Hepatitis B virus e Ag [Presence] in Specimen;HBV e Ag Spec Ql;;ACTIVE;2.15;2.73 +3900-8;Oxyphenbutazone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxyphenbutazone [Mass/volume] in Serum or Plasma;Oxyphenbutazone SerPl-mCnc;;ACTIVE;1.0;2.73 +39008-8;Hepatitis C virus Ab;PrThr;Pt;Body fld;Ord;IB;MICRO;1;Hepatitis C virus Ab [Presence] in Body fluid by Immunoblot;HCV Ab Fld Ql IB;;ACTIVE;2.15;2.73 +39009-6;Isovalerylcarnitine (C5);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isovalerylcarnitine (C5) [Moles/volume] in Serum or Plasma;Isovalerylcarn SerPl-sCnc;;ACTIVE;2.15;2.73 +39010-4;Methylmalonylcarnitine (C4-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC) [Moles/volume] in Serum or Plasma;Me-malonylcarn SerPl-sCnc;;ACTIVE;2.15;2.73 +39011-2;Mumps virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Mumps virus IgG Ab [Presence] in Cerebral spinal fluid;MuV IgG CSF Ql;;ACTIVE;2.15;2.56 +39012-0;Mycoplasma pneumoniae Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Mycoplasma pneumoniae Ab [Presence] in Body fluid;M pneumo Ab Fld Ql;;ACTIVE;2.15;2.56 +39013-8;Rubella virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Rubella virus IgG Ab [Presence] in Cerebral spinal fluid;RUBV IgG CSF Ql;;ACTIVE;2.15;2.56 +39014-6;Suberylcarnitine (C8-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Suberylcarnitine (C8-DC) [Moles/volume] in Serum or Plasma;Suberylcarn SerPl-sCnc;;ACTIVE;2.15;2.73 +39015-3;Treponema pallidum Ab;ACnc;Pt;Body fld;Qn;HA;MICRO;1;Treponema pallidum Ab [Units/volume] in Body fluid by Hemagglutination;T pallidum Ab Fld HA-aCnc;;ACTIVE;2.15;2.69 +3901-6;Para hydroxyamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Para hydroxyamphetamine [Presence] in Urine;P-OH-Amphet Ur Ql;;ACTIVE;1.0;2.56 +39016-1;Age at death;Time;Pt;^Patient;Qn;;MISC;1;Age at death;Age @ Death Time Patient;;ACTIVE;2.15;2.40 +39017-9;Mycobacterium tuberculosis tuberculin stimulated gamma interferon/Mitogen stimulated gamma interferon;RelACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis tuberculin stimulated gamma interferon/Mitogen stimulated gamma interferon in Blood;M TB tuberc IFN-g/Mitogen IGNF Bld;;ACTIVE;2.15;2.73 +39018-7;Coliform bacteria;NCnt;Pt;XXX;Qn;Viability count;MICRO;1;Coliform bacteria [#/mass] in Specimen by Viability count;Coliform Spec Viab Cnt;;ACTIVE;2.15;2.69 +39019-5;Escherichia coli O157:H7 Ag;PrThr;Pt;Mlk.raw;Ord;IA;MICRO;1;Escherichia coli O157:H7 Ag [Presence] in Raw milk by Immunoassay;E coli O157H7 Ag RawMilk Ql IA;;ACTIVE;2.15;2.65 +39020-3;Prion protein.abnormal;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Abnormal Prion Protein [Presence] in Tissue by Immune stain;Abn Prion Prot Tiss Ql ImStn;;ACTIVE;2.15;2.56 +39021-1;Prion protein.abnormal;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Abnormal Prion Protein [Presence] in Tissue by Immunoassay;Abn Prion Prot Tiss Ql IA;;ACTIVE;2.15;2.56 +39022-9;Sarcocystis neurona Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Sarcocystis neurona Ab [Presence] in Serum by Immunofluorescence;S neurona Ab Ser Ql IF;;ACTIVE;2.15;2.56 +39023-7;Vesicular stomatitis Indiana virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Vesicular stomatitis Indiana virus RNA [Presence] in Specimen by NAA with probe detection;VSIV RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.69 +3902-4;Para hydroxyamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Para hydroxyamphetamine [Mass/volume] in Urine;P-OH-Amphet Ur-mCnc;;ACTIVE;1.0;2.42 +39024-5;Vesicular stomatitis New Jersey virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Vesicular stomatitis New Jersey virus RNA [Presence] in Specimen by NAA with probe detection;VSNJV RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.69 +39025-2;Influenza virus A hemagglutinin cDNA;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Influenza virus A hemagglutinin cDNA [Identifier] in Specimen by Sequencing;FLUAV HA cDNA Spec Seq;;ACTIVE;2.15;2.69 +39026-0;Guidance for needle localization;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for needle localization of Unspecified body region;CT Guided Needle loc;;ACTIVE;2.15;2.64 +39027-8;Guidance for needle localization;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for needle localization of Unspecified body region;RF Guided Needle loc;;ACTIVE;2.15;2.64 +39028-6;Guidance for needle localization;Find;Pt;XXX;Doc;MR;RAD;2;MR Guidance for needle localization of Unspecified body region;MR Guided Needle loc;;ACTIVE;2.15;2.64 +39029-4;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit+Face;Doc;MR;RAD;2;MR Orbit and Face WO and W contrast IV;MR Orbit+Face WO+W contr IV;;ACTIVE;2.15;2.61 +39030-2;Multisection;Find;Pt;XXX>Vein.bilateral;Doc;US;RAD;2;US Vein - bilateral;US Vein-Bl;;ACTIVE;2.15;2.61 +39031-0;Multisection;Find;Pt;Extremity.bilateral>Extremity artery;Doc;US.doppler;RAD;2;US.doppler Extremity artery - bilateral;DOP Extr a-Bl;;ACTIVE;2.15;2.61 +3903-2;Para hydroxyamphetamine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Para hydroxyamphetamine [Mass/time] in 24 hour Urine;P-OH-Amphet 24h Ur-mRate;;ACTIVE;1.0;2.42 +39032-8;Multisection for transplanted kidney;Find;Pt;Pelvis;Doc;US;RAD;2;US for transplanted kidney;US for transplanted kidney;;ACTIVE;2.15;2.73 +39033-6;Multisection^WO contrast;Find;Pt;Upper extremity;Doc;MR;RAD;2;MR Upper extremity WO contrast;MR UE WO contr;;ACTIVE;2.15;2.61 +39034-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity;Doc;MR;RAD;2;MR Upper extremity WO and W contrast IV;MR UE WO+W contr IV;;ACTIVE;2.15;2.61 +39035-1;Multisection;Find;Pt;XXX;Nar;US;RAD;2;Deprecated Unspecified system US Multisection;Deprecated XXX US;;DEPRECATED;2.15;2.36 +39036-9;Multisection;Find;Pt;XXX>Vein;Doc;US;RAD;2;US Vein;US Vein;;ACTIVE;2.15;2.73 +39037-7;Multisection^W contrast IV;Find;Pt;Upper extremity;Doc;MR;RAD;2;MR Upper extremity W contrast IV;MR UE W contr IV;;ACTIVE;2.15;2.61 +39038-5;Multisection^W contrast IV;Find;Pt;Head>Orbit+Face;Doc;MR;RAD;2;MR Orbit and Face W contrast IV;MR Orbit+Face W contr IV;;ACTIVE;2.15;2.61 +39039-3;Multisection;Find;Pt;Chest>Brachiocephalic artery;Doc;US.doppler;RAD;2;US.doppler Brachiocephalic artery;DOP BrachCeph a;;ACTIVE;2.15;2.61 +3904-0;Paraldehyde;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Paraldehyde [Mass/volume] in Blood;Paraldehyde Bld-mCnc;;ACTIVE;1.0;2.73 +39040-1;Multisection;Find;Pt;XXX>AV fistula;Doc;US;RAD;2;US AV fistula;US AVF;;ACTIVE;2.15;2.61 +39041-9;Multisection^W contrast intrauterine;Find;Pt;Uterus+Fallopian tubes;Nar;US;RAD;2;Deprecated Uterus & Fallopian tubes US W contrast intrauterine;Deprecated Uterus+FT US W contr IU;;DEPRECATED;2.15;2.34 +39042-7;Multisection;Find;Pt;Extremity>Extremity artery;Doc;US.doppler;RAD;2;US.doppler Extremity artery;DOP Extr a;;ACTIVE;2.15;2.61 +39043-5;Multisection & 3D reconstruction;Find;Pt;XXX;Doc;MRI;RAD;2;Deprecated Unspecified body region MRI and 3D reconstruction;Deprecated XXX MRI +3DR;;DEPRECATED;2.15;2.58 +39044-3;Multisection limited;Find;Pt;Head>Head vessels;Doc;US.doppler;RAD;2;US.doppler Head vessels limited;DOP Head ves Ltd;;ACTIVE;2.15;2.61 +39045-0;Multisection limited;Find;Pt;XXX>Vein;Doc;US;RAD;2;US Vein limited;US Vein Ltd;;ACTIVE;2.15;2.61 +39046-8;Multisection limited for pelvimetry^WO contrast;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis limited for pelvimetry WO contrast;CT Pelvis Pelvimetry Ltd WO contr;;ACTIVE;2.15;2.64 +39047-6;View^during surgery;Find;Pt;Lower extremity>Hip;Doc;RF;RAD;2;RF Hip Single view during surgery;RF Hip 1V in Surg;;ACTIVE;2.15;2.64 +39048-4;View AP;Find;Pt;Chest>Scapula;Doc;XR;RAD;2;XR Scapula AP;XR Scapula AP;;ACTIVE;2.15;2.61 +39049-2;View AP;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP;XR T+L-Spine AP;;ACTIVE;2.15;2.61 +390-5;Pefloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Pefloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Pefloxacin Islt MIC;;ACTIVE;1.0;2.19 +39050-0;View AP;Find;Pt;Chest>Ribs;Doc;XR;RAD;2;XR Ribs AP;XR Ribs AP;;ACTIVE;2.15;2.73 +39051-8;View lateral;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Lateral;XR Chest Lat;;ACTIVE;2.15;2.61 +39052-6;View lateral;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Lateral;XR Spine Lat;;DISCOURAGED;2.15;2.61 +39053-4;View lateral;Find;Pt;Chest>Ribs;Doc;XR;RAD;2;XR Ribs Lateral;XR Ribs Lat;;ACTIVE;2.15;2.61 +39054-2;Views^W contrast intra duct;Find;Pt;Breast>Breast duct;Doc;MG;RAD;2;MG Breast duct Views W contrast intra duct;MG Brst duct Views W contr intra Dct;;ACTIVE;2.15;2.64 +39055-9;Views^W contrast IV;Find;Pt;Extremity>Extremity veins;Doc;RF.angio;RAD;2;RFA Extremity veins Views W contrast IV;RFA Extr vv Views W contr IV;;ACTIVE;2.15;2.64 +39056-7;Views^W manual stress;Find;Pt;XXX;Doc;XR;RAD;2;XR Unspecified body region Views W manual stress;XR Views W man stress;;ACTIVE;2.15;2.71 +3905-7;Paraldehyde;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Paraldehyde [Mass/volume] in Serum or Plasma;Paraldehyde SerPl-mCnc;;ACTIVE;1.0;2.73 +39057-5;Views^W contrast IA;Find;Pt;Chest>Pulmonary arteries;Doc;RF.angio;RAD;2;RFA Pulmonary arteries Views W contrast IA;RFA PA Views W contr IA;;ACTIVE;2.15;2.64 +39058-3;Views;Find;Pt;Head>Salivary gland;Doc;XR;RAD;2;XR Salivary gland Views;XR Salivary gland Views;;ACTIVE;2.15;2.64 +39059-1;View && Views^W air contrast PR+W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;Deprecated XR and RF Gastrointestinal tract upper View and Views W air contrast PR and W barium contrast PO;Deprecated AXR and UGI RF Views W Air PR;;DEPRECATED;2.15;2.61 +39060-9;Views 2;Find;Pt;Chest>Ribs;Doc;XR;RAD;2;XR Ribs 2 Views;XR Ribs 2V;;ACTIVE;2.15;2.61 +39061-7;Views 3;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Sacrum and Coccyx 3 Views;XR Sacrum+Coccyx 3V;;ACTIVE;2.15;2.61 +39062-5;Views 3;Find;Pt;Chest>Ribs;Doc;XR;RAD;2;XR Ribs 3 Views;XR Ribs 3V;;ACTIVE;2.15;2.61 +39063-3;Views 5^W flexion + W extension;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 5 Views W flexion and W extension;XR L-spine 5V W FE;;ACTIVE;2.15;2.61 +39064-1;Views anterior + lateral;Find;Pt;Chest>Ribs;Doc;XR;RAD;2;XR Ribs Anterior and Lateral;XR Ribs Ant+Lat;;ACTIVE;2.15;2.61 +3906-5;Pefloxacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pefloxacin [Mass/volume] in Serum or Plasma;Pefloxacin SerPl-mCnc;;ACTIVE;1.0;2.42 +39065-8;Views AP + inlet + outlet + oblique;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP and Inlet and Outlet and Oblique;XR Pelvis AP+Inlet+Outlet+Obl;;ACTIVE;2.15;2.61 +39066-6;Views AP + lateral && Views;Find;Pt;Chest;Doc;XR && RF;RAD;2;XR and RF Chest AP and Lateral and Views;XR and Flr Chest AP+lat + Views;;ACTIVE;2.15;2.61 +39067-4;Views AP + lateral;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Cervical and thoracic and lumbar spine AP and Lateral;XR C+T+L-spine AP+Lat;;ACTIVE;2.15;2.61 +39068-2;Views AP + lateral^W standing;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot AP and Lateral W standing;XR Foot AP+Lat W Stand;;ACTIVE;2.15;2.61 +39069-0;Views AP + lateral;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot AP and Lateral;XR Foot AP+Lat;;ACTIVE;2.15;2.61 +39070-8;Views AP + lateral + apical lordotic;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP and Lateral and Apical lordotic;XR Chest AP+Lat+Apical lord;;DISCOURAGED;2.15;2.61 +39071-6;Views AP + lateral + Merchants;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral and Merchants;XR Knee AP+Lat+Merchants;;ACTIVE;2.15;2.61 +39072-4;Views AP + lateral + oblique;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle AP and Lateral and oblique;XR Ankle AP+Lat+Obl;;ACTIVE;2.15;2.61 +3907-3;Pemoline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pemoline [Mass/volume] in Serum or Plasma;Pemoline SerPl-mCnc;;ACTIVE;1.0;2.73 +39073-2;Views AP + lateral + R-oblique + L-oblique;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee AP and Lateral and Right oblique and Left oblique;XR Knee AP+Lat+R-Obl+L-Obl;;ACTIVE;2.15;2.61 +39074-0;Views AP + lateral + R-oblique + L-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP and Lateral and Right oblique and Left oblique;XR Chest AP+Lat+R-Obl+L-Obl;;ACTIVE;2.15;2.61 +39075-7;Views AP + oblique;Find;Pt;Lower extremity>Toes;Doc;XR;RAD;2;XR Toes AP and Oblique;XR Toes AP+Obl;;ACTIVE;2.15;2.61 +39076-5;Views AP + oblique;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot AP and Oblique;XR Foot AP+Obl;;ACTIVE;2.15;2.61 +39077-3;Views AP + transthoracic;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP and Transthoracic;XR Should AP+Transthoracic;;ACTIVE;2.15;2.61 +39078-1;Views PA + lateral + oblique;Find;Pt;Upper extremity>Finger;Doc;XR;RAD;2;XR Finger PA and Lateral and Oblique;XR Finger PA+Lat+Obl;;ACTIVE;2.15;2.61 +39079-9;Views PA + oblique;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand PA and Oblique;XR Hand PA+Obl;;ACTIVE;2.15;2.61 +39080-7;EPM2A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;EPM2A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;EPM2A gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +3908-1;Pemoline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pemoline [Presence] in Urine;Pemoline Ur Ql;;ACTIVE;1.0;2.56 +39081-5;Gadus morhua Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Codfish IgE Ab/IgE total in Serum;Codfish IgE/IgE total %;;ACTIVE;2.15;2.70 +39082-3;Gentamicin^peak;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Cerebral spinal fluid --peak;Gentamicin Peak CSF-mCnc;;ACTIVE;2.15;2.70 +39083-1;Herpes virus 8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes virus 8 Ab [Presence] in Serum;HHV8 Ab Ser Ql;;ACTIVE;2.15;2.73 +39084-9;Iva ciliata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Rough Marsh Elder IgE Ab/IgE total in Serum;Marsh Elder IgE/IgE total %;;ACTIVE;2.15;2.72 +39085-6;Juglans california pollen Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;California Walnut Pollen IgE Ab/IgE total in Serum;Calif Walnut Poln IgE/IgE total %;;ACTIVE;2.15;2.70 +39086-4;Microscopic observation;Prid;Pt;Vag;Nom;Cyto stain.thin prep;CYTO;1;Microscopic observation [Identifier] in Vaginal fluid by Cyto stain.thin prep;Thin Prep Vag;;ACTIVE;2.15;2.21 +39087-2;Myelin associated glycoprotein Ab.IgM;Titr;Pt;Ser;Qn;IA;SERO;1;Myelin associated glycoprotein IgM Ab [Titer] in Serum by Immunoassay;MAG IgM Titr Ser IA;;ACTIVE;2.15;2.73 +39088-0;Pecten spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Scallop IgE Ab/IgE total in Serum;Scallop IgE/IgE total %;;ACTIVE;2.15;2.70 +39089-8;PLP1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PLP1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PLP1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +39090-6;Ruditapes spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Clam IgE Ab/IgE total in Serum;Clam IgE/IgE total %;;ACTIVE;2.15;2.70 +39091-4;Sorghum halepense Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Johnson grass IgE Ab/IgE total in Serum;Johnson grass IgE/IgE total %;;ACTIVE;2.15;2.70 +39092-2;Vancomycin^peak;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Cerebral spinal fluid --peak;Vancomycin Peak CSF-mCnc;;ACTIVE;2.15;2.70 +39093-0;Views^W contrast IV;Find;Pt;Abdomen>Hepatic veins;Doc;RF.angio;RAD;2;RFA Hepatic veins Views W contrast IV;RFA Hep vv Views W contr IV;;ACTIVE;2.15;2.64 +39094-8;Views^W contrast IA;Find;Pt;Neck>Carotid artery.cervical;Doc;RF.angio;RAD;2;RFA Carotid artery.cervical Views W contrast IA;RFA Carot a.cervical Views W contr IA;;ACTIVE;2.15;2.64 +39095-5;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery & Head>Cerebral artery;Doc;RF.angio;RAD;2;RFA Carotid artery and Cerebral artery Views W contrast IA;RFA Carot a+Cerebral a Vs W contr IA;;ACTIVE;2.15;2.64 +39096-3;Views for hemodynamics^W contrast IV;Find;Pt;Abdomen>Hepatic veins;Doc;RF.angio;RAD;2;RFA Hepatic veins Views for hemodynamics W contrast IV;RFA Hep vv Vs hemodynamics W contr IV;;ACTIVE;2.15;2.64 +39097-1;Views^W contrast IA;Find;Pt;Head+Neck>Carotid artery.bilateral & Head>Cerebral artery.bilateral;Doc;RF.angio;RAD;2;RFA Carotid artery - bilateral and Cerebral artery - bilateral Views W contrast IA;RFA Carot a-Bl+Cereb a-Bl Vs W contr IA;;ACTIVE;2.15;2.64 +39098-9;Views^W contrast IA;Find;Pt;Neck>Carotid artery.cervical.bilateral;Doc;RF.angio;RAD;2;RFA Carotid artery.cervical.bilateral Views W contrast IA;RFA Carot a cervical-Bl Views W contr IA;;ACTIVE;2.15;2.64 +3909-9;Pemoline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pemoline [Mass/volume] in Urine;Pemoline Ur-mCnc;;ACTIVE;1.0;2.42 +39099-7;Views 4 && view PA;Find;Pt;Chest>Ribs.bilateral && Chest;Doc;XR;RAD;2;XR Ribs - bilateral 4 Views and Chest PA;XR Ribs-Bl 4V + Chest PA;;ACTIVE;2.15;2.64 +39100-3;Views lateral & PA chest;Find;Pt;Ribs.right+Chest;Doc;XR;RAD;2;Deprecated Ribs - right and Chest X-ray lateral and PA;Deprecated Ribs-R + Chest XR Lat+PA;;DEPRECATED;2.15;2.58 +39101-1;Views lateral & PA chest;Find;Pt;Ribs+Chest;Doc;XR;RAD;2;Deprecated Ribs and Chest X-ray lateral and PA;Deprecated Ribs + Chest XR Lat+PA;;DEPRECATED;2.15;2.58 +39102-9;Influenza virus A hemagglutinin cDNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Influenza virus A hemagglutinin cDNA [Identifier] in Specimen by NAA with probe detection;FLUAV HA cDNA Spec NAA+probe;;ACTIVE;2.15;2.69 +39103-7;Influenza virus A neuraminidase cDNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Influenza virus A neuraminidase cDNA [Identifier] in Specimen by NAA with probe detection;FLUAV NA cDNA Spec NAA+probe;;ACTIVE;2.15;2.69 +39104-5;Appearance;Aper;Pt;Skin;Nar;;H&P.HX;2;Appearance of Skin Narrative;Appearance Skin;;ACTIVE;2.15;2.27 +39105-2;Appearance;Aper;Pt;Skin;Nom;;H&P.HX;2;Appearance of Skin;Appearance Skin;;ACTIVE;2.15;2.27 +39106-0;Temperature;Find;Pt;Skin;Nom;;H&P.HX;2;Temperature of Skin;Temp Skin;;ACTIVE;2.15;2.73 +3910-7;Pemoline;MRat;24H;Urine;Qn;;DRUG/TOX;1;Pemoline [Mass/time] in 24 hour Urine;Pemoline 24h Ur-mRate;;ACTIVE;1.0;2.42 +39107-8;Color;Type;Pt;Skin;Nom;;H&P.HX;2;Color of Skin;Color Skin;;ACTIVE;2.15;2.73 +39108-6;Body hair distribution;Imp;Pt;^Patient;Nom;;H&P.HX;2;Body hair distribution [Interpretation];Body hair distribution Imp;;ACTIVE;2.15;2.50 +39109-4;Turgor;Imp;Pt;Skin;Nom;;H&P.HX;2;Turgor [Interpretation] of Skin;Turgor Imp Skin;;ACTIVE;2.15;2.50 +39110-2;Protection;Type;Pt;Skin;Nom;;H&P.HX;2;Protection of Skin;Protection Skin;;ACTIVE;2.15;2.44 +39111-0;Body site;Anat;Pt;^Patient;Nom;;H&P.HX;2;Body site;Bdy site;;ACTIVE;2.15;2.73 +39112-8;Body location qualifier;Find;Pt;^Patient;Nom;;H&P.HX;2;Body location qualifier;Bdy location qualifier;;ACTIVE;2.15;2.27 +39113-6;Nail angle;Angle;Pt;Nail;Qn;Estimated;H&P.HX;2;Nail angle Estimated;Nail Angle Est;;ACTIVE;2.15;2.48 +39114-4;Depth;Find;Pt;Wound;Nom;;H&P.HX;2;Depth of Wound - nominal;Dpth Find Wnd;;ACTIVE;2.15;2.32 +3911-5;Penicillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Penicillin [Mass/volume] in Serum or Plasma;Penicillin SerPl-mCnc;;ACTIVE;1.0;2.73 +39115-1;Drainage description;Aper;Pt;Wound;Nar;;H&P.HX;2;Drainage description of Wound Narrative;Drainage Desc Wnd;;ACTIVE;2.15;2.27 +39116-9;Drainage amount;Find;Pt;Wound;Ord;;H&P.HX;2;Drainage amount of Wound;Drainage Amt Wnd;;ACTIVE;2.15;2.42 +39117-7;Saturated 2x2 gauze dressings;Num;Pt;Wound;Qn;;H&P.HX;2;Saturated 2x2 gauze dressings [#] of Wound;Sat 2x2 gauze dressings Wnd;;ACTIVE;2.15;2.48 +39118-5;Saturated 4x4 gauze dressings;Num;Pt;Wound;Qn;;H&P.HX;2;Saturated 4x4 gauze dressings [#] of Wound;Sat 4x4 gauze dressings Wnd;;ACTIVE;2.15;2.48 +39119-3;Saturated 4x8 gauze dressings;Num;Pt;Wound;Qn;;H&P.HX;2;Saturated 4x8 gauze dressings [#] of Wound;Sat 4x8 gauze dressings Wnd;;ACTIVE;2.15;2.48 +39120-1;Saturated abdominal dressings;Num;Pt;Wound;Qn;;H&P.HX;2;Saturated abdominal dressings [#] of Wound;Sat abd dressing Wnd;;ACTIVE;2.15;2.48 +39121-9;Dressing;Type;Pt;Wound;Nom;;H&P.HX;2;Dressing for Wound;Dressing Wnd;;ACTIVE;2.15;2.42 +39122-7;Fluid output.wound drain;Vol;Pt;Wound;Qn;Estimated;H&P.HX;2;Fluid output wound drain Estimated;Fluid output wound drain Est;;ACTIVE;2.15;2.54 +3912-3;Penicillin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Penicillin [Mass/volume] in Urine;Penicillin Ur-mCnc;;ACTIVE;1.0;2.42 +39123-5;Wound status;Find;Pt;Wound;Nom;;H&P.HX;2;Wound status;Wound status;;ACTIVE;2.15;2.73 +39124-3;Clinical trend;Find;Pt;Wound;Nom;Observed;H&P.HX;2;Clinical trend of Wound Observed;Clinical trend Wnd Observ;;ACTIVE;2.15;2.27 +39125-0;Width;Len;Pt;Wound;Qn;;H&P.HX;2;Width of Wound;Width Wnd;;ACTIVE;2.15;2.30 +39126-8;Length;Len;Pt;Wound;Qn;;H&P.HX;2;Length of Wound;Length Wnd;;ACTIVE;2.15;2.30 +39127-6;Depth;Len;Pt;Wound;Qn;;H&P.HX;2;Depth of Wound;Dpth Wnd;;ACTIVE;2.15;2.30 +39128-4;Wound irrigation &or cleaning fluid;Type;Pt;Flu.nonbiological;Nom;;H&P.HX;2;Wound irrigation/Cleaning fluid;Wound irrigation/Cleaning fluid;;ACTIVE;2.15;2.29 +39129-2;Moisture;Type;Pt;Skin;Nom;;H&P.HX;2;Moisture of Skin;Moisture Skin;;ACTIVE;2.15;2.29 +391-3;Penicillin G;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Penicillin G [Susceptibility] by Minimum lethal concentration (MLC);Penicillin G Islt MLC;;ACTIVE;1.0;2.19 +39130-0;Firmness;Find;Pt;Nail bed;Nom;;H&P.HX;2;Firmness of Nail bed;Firmness Nail Bed;;ACTIVE;2.15;2.27 +3913-1;Penicillin G;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Penicillin G [Mass/volume] in Serum or Plasma;Penicillin G SerPl-mCnc;;ACTIVE;1.0;2.42 +39131-8;Color;Type;Pt;Nail bed;Nom;;H&P.HX;2;Color of Nail bed;Color Nail Bed;;ACTIVE;2.15;2.27 +39132-6;Color;Type;Pt;Wound.base;Nom;;H&P.HX;2;Color of Wound base;Color Wnd base;;ACTIVE;2.15;2.27 +39133-4;Color;Type;Pt;Wound.edge;Nom;;H&P.HX;2;Color of Wound edge;Color Wnd edge;;ACTIVE;2.15;2.27 +39134-2;Color;Type;Pt;Periwound;Nom;;H&P.HX;2;Color of Periwound;Color Periwnd;;ACTIVE;2.15;2.42 +39135-9;Wound assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Wound assessment panel;Wound Assessment Pnl;;ACTIVE;2.15;2.68 +39136-7;Skin assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Deprecated Skin assessment panel;Deprecated Skin Assessment Pnl;;DEPRECATED;2.15;2.42 +39137-5;Oral assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Oral assessment panel;Oral Assessment Pnl;;ACTIVE;2.15;2.27 +39138-3;Guidance for vascular access;Find;Pt;XXX>Vessel;Doc;RF.angio;RAD;2;RFA Guidance for vascular access of Vessel;RFA Guided Ves VA;;ACTIVE;2.15;2.64 +39139-1;Guidance for vascular access;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for vascular access of Unspecified body region;US Guided VA;;ACTIVE;2.15;2.64 +39140-9;Multisection cine for blood flow velocity mapping;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart cine for blood flow velocity mapping;MR Hrt Cine for Flow VM;;ACTIVE;2.15;2.61 +39141-7;Multisection;Find;Pt;XXX>Bone marrow;Doc;MR;RAD;2;MR Bone marrow;MR Bone mar;;ACTIVE;2.15;2.61 +39142-5;Multisection^W contrast IV;Find;Pt;Head;Doc;CT.perfusion;RAD;2;CT perfusion Head W contrast IV;CT.perfusion Head W contr IV;;ACTIVE;2.15;2.61 +39143-3;View^W contrast retrograde PR;Find;Pt;Gastrointestine.upper;Nar;XR.fluor;RAD;2;Deprecated Gastrointestine upper Fluoroscopy W contrast retrograde PR;Deprecated UGI Flr W contr retro PR;;DEPRECATED;2.15;2.34 +39144-1;View^W air contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Gastrointestinal tract upper Single view W air contrast PO;RF UGI 1V W Air contr PO;;ACTIVE;2.15;2.64 +39145-8;Views^W contrast intra multiple ducts;Find;Pt;Breast>Breast duct.left;Doc;MG;RAD;2;MG Breast duct - left Views W contrast intra multiple ducts;MG Brst duct-L Views W contr intra Dcts;;ACTIVE;2.15;2.64 +39146-6;Views^W contrast intra multiple ducts;Find;Pt;Breast>Breast duct.bilateral;Doc;MG;RAD;2;MG Breast duct - bilateral Views W contrast intra multiple ducts;MG Brst duct-Bl Views W contr intra Dcts;;ACTIVE;2.15;2.64 +39147-4;Views^W contrast intra multiple ducts;Find;Pt;Breast>Breast duct.right;Doc;MG;RAD;2;MG Breast duct - right Views W contrast intra multiple ducts;MG Brst duct-R Views W contr intra Dcts;;ACTIVE;2.15;2.64 +39148-2;Views^W contrast intra multiple ducts;Find;Pt;Breast>Breast duct;Doc;MG;RAD;2;MG Breast duct Views W contrast intra multiple ducts;MG Brst duct Views W contr intra Dcts;;ACTIVE;2.15;2.64 +3914-9;Penicillin V;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Penicillin V [Mass/volume] in Serum or Plasma;Penicillin V SerPl-mCnc;;ACTIVE;1.0;2.42 +39149-0;View for foreign body;Find;Pt;Whole body>Gastrointestinal tract+Pulmonary system;Doc;XR;RAD;2;XR Gastrointestinal tract and Pulmonary system Single view for foreign body;XR GI+Pulm 1V for FB;;ACTIVE;2.15;2.64 +39150-8;Views^post localization;Find;Pt;Breast;Doc;MG.FFD;RAD;2;FFD mammogram Breast Views Post Localization;FFDM Brst Views p local;;DISCOURAGED;2.15;2.64 +39151-6;Views^W contrast intra vas deferens;Find;Pt;Pelvis>Vas deferens;Doc;RF;RAD;2;RF Vas deferens Views W contrast intra vas deferens;RF Vas deferens Views W contr intra VD;;ACTIVE;2.15;2.64 +39152-4;Views diagnostic;Find;Pt;Breast;Doc;MG.FFD;RAD;2;FFD mammogram Breast Diagnostic;FFDM Brst Dx;;DISCOURAGED;2.15;2.61 +39153-2;Views screening;Find;Pt;Breast;Doc;MG.FFD;RAD;2;FFD mammogram Breast Screening;FFDM Brst screening;;DISCOURAGED;2.15;2.61 +39154-0;Views diagnostic;Find;Pt;Breast.bilateral;Doc;MG.FFD;RAD;2;FFD mammogram Breast - bilateral Diagnostic;FFDM Brst-Bl Dx;;DISCOURAGED;2.15;2.61 +39155-7;Family history or condition or disease and action;Arb;Pt;^Family;Ord;CPHS;ATTACH.CPHS;3;Family history or condition or disease and action Family CPHS;;;ACTIVE;2.15;2.56 +3915-6;Pentazocine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Pentazocine [Presence] in Serum or Plasma;Pentazocine SerPl Ql;;ACTIVE;1.0;2.56 +39156-5;Body mass index;Ratio;Pt;^Patient;Qn;;BDYWGT.ATOM;2;Body mass index (BMI) [Ratio];BMI;;ACTIVE;2.15;2.73 +39157-3;Screen type indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Screen type indicator CPHS;;;ACTIVE;2.15;2.27 +39158-1;Screening on schedule to patient age;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Screening on schedule to patient age CPHS;;;ACTIVE;2.15;2.27 +39159-9;Screening extent;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Screening extent CPHS;;;ACTIVE;2.15;2.27 +39160-7;Visit was for recheck;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Visit was for recheck CPHS;;;ACTIVE;2.15;2.27 +39161-5;Date next screen visit;Date;Pt;^Patient;Qn;CPHS;ATTACH.CPHS;3;Date next screen visit CPHS;;;ACTIVE;2.15;2.50 +39162-3;Chronic illness indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Chronic illness indicator CPHS;;;ACTIVE;2.15;2.27 +39163-1;History and physical results indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;History and physical results indicator CPHS;;;ACTIVE;2.15;2.27 +3916-4;Pentazocine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pentazocine [Mass/volume] in Serum or Plasma;Pentazocine SerPl-mCnc;;ACTIVE;1.0;2.73 +39164-9;History and physical follow-up status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;History and physical follow-up status CPHS;;;ACTIVE;2.15;2.27 +39165-6;History and physical finding recency;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;History and physical finding recency CPHS;;;ACTIVE;2.15;2.27 +39166-4;Behavioral &or mental health screen assessment;Cmplx;Pt;Behavior;Set;CPHS;ATTACH.CPHS;3;Behavioral/mental health screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39167-2;Behavioral &or mental health screen results indicator;Type;Pt;Behavior;Nom;CPHS;ATTACH.CPHS;3;Behavioral/mental health screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39168-0;Behavioral &or mental health screen follow-up status;Type;Pt;Behavior;Nom;CPHS;ATTACH.CPHS;3;Behavioral/mental health screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39169-8;Behavioral &or mental health screen finding recency;Type;Pt;Behavior;Nom;CPHS;ATTACH.CPHS;3;Behavioral/mental health screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39170-6;Cardiac screen results indicator;Type;Pt;Cardiovascular system;Nom;CPHS;ATTACH.CPHS;3;Cardiac screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39171-4;Cardiac screen follow-up status;Type;Pt;Cardiovascular system;Nom;CPHS;ATTACH.CPHS;3;Cardiac screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +3917-2;Pentazocine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pentazocine [Presence] in Urine;Pentazocine Ur Ql;;ACTIVE;1.0;2.73 +39172-2;Cardiac screen finding recency;Type;Pt;Cardiovascular system;Nom;CPHS;ATTACH.CPHS;3;Cardiac screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39173-0;Dental screen assessment;Cmplx;Pt;Dentition;Set;CPHS;ATTACH.CPHS;3;Dental screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39174-8;Dental screen results indicator;Type;Pt;Dentition;Nom;CPHS;ATTACH.CPHS;3;Dental screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39175-5;Dental screen follow-up status;Type;Pt;Dentition;Nom;CPHS;ATTACH.CPHS;3;Dental screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39176-3;Dental screen finding recency;Type;Pt;Dentition;Nom;CPHS;ATTACH.CPHS;3;Dental screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39177-1;Endocrine screen assessment;Cmplx;Pt;Endocrine system;Set;CPHS;ATTACH.CPHS;3;Endocrine screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39178-9;Endocrine screen results indicator;Type;Pt;Endocrine system;Nom;CPHS;ATTACH.CPHS;3;Endocrine screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39179-7;Endocrine screen follow-up status;Type;Pt;Endocrine system;Nom;CPHS;ATTACH.CPHS;3;Endocrine screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +3918-0;Pentazocine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pentazocine [Mass/volume] in Urine;Pentazocine Ur-mCnc;;ACTIVE;1.0;2.73 +39180-5;Endocrine screen finding recency;Type;Pt;Endocrine system;Nom;CPHS;ATTACH.CPHS;3;Endocrine screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39181-3;Genitourinary screen assessment;Cmplx;Pt;Genitourinary systems;Set;CPHS;ATTACH.CPHS;3;Genitourinary screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39182-1;Genitourinary screen results indicator;Type;Pt;Genitourinary systems;Nom;CPHS;ATTACH.CPHS;3;Genitourinary screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39183-9;Genitourinary screen follow-up status;Type;Pt;Genitourinary systems;Nom;CPHS;ATTACH.CPHS;3;Genitourinary screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39184-7;Genitourinary screen finding recency;Type;Pt;Genitourinary systems;Nom;CPHS;ATTACH.CPHS;3;Genitourinary screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39185-4;Growth and development (includes speech) screen assessment;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Growth and development (includes speech) screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39186-2;Growth and development (includes speech) screen results indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Growth and development (includes speech) screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39187-0;Growth and development (includes speech) screen follow-up status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Growth and development (includes speech) screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39188-8;Growth and development (includes speech) screen finding recency;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Growth and development (includes speech) screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39189-6;Hearing screen assessment;Cmplx;Pt;Ear;Set;CPHS;ATTACH.CPHS;3;Hearing screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39190-4;Hearing screen results indicator;Type;Pt;Ear;Nom;CPHS;ATTACH.CPHS;3;Hearing screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39191-2;Hearing screen follow-up status;Type;Pt;Ear;Nom;CPHS;ATTACH.CPHS;3;Hearing screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39192-0;Hearing screen finding recency;Type;Pt;Ear;Nom;CPHS;ATTACH.CPHS;3;Hearing screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39193-8;Lead (exposure to) screen assessment;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Lead (exposure to) screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39194-6;Lead (exposure to) screen results indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Lead (exposure to) screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39195-3;Lead (exposure to) screen follow-up status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Lead (exposure to) screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39196-1;Lead (exposure to) screen finding recency;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Lead (exposure to) screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39197-9;Neurologic screen results indicator;Type;Pt;Neurologic system;Nom;CPHS;ATTACH.CPHS;3;Neurologic screen results indicator CPHS;;;ACTIVE;2.15;2.27 +3919-8;Pentazocine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Pentazocine [Mass/time] in 24 hour Urine;Pentazocine 24h Ur-mRate;;ACTIVE;1.0;2.42 +39198-7;Neurologic screen follow-up status;Type;Pt;Neurologic system;Nom;CPHS;ATTACH.CPHS;3;Neurologic screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39199-5;Neurologic screen finding recency;Type;Pt;Neurologic system;Nom;CPHS;ATTACH.CPHS;3;Neurologic screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39200-1;Nutrition screen assessment;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Nutrition screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39201-9;Nutrition screen results indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Nutrition screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39202-7;Nutrition screen follow-up status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Nutrition screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39203-5;Nutrition screen finding recency;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Nutrition screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39204-3;Orthopedic screen assessment;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Orthopedic screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39205-0;Orthopedic screen results indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Orthopedic screen results indicator CPHS;;;ACTIVE;2.15;2.27 +3920-6;Pentetrazol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pentetrazol [Presence] in Urine;Pentetrazol Ur Ql;;ACTIVE;1.0;2.56 +39206-8;Orthopedic screen follow-up status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Orthopedic screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39207-6;Orthopedic screen finding recency;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Orthopedic screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39208-4;Tuberculosis exposure screen assessment;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Tuberculosis exposure screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39209-2;Tuberculosis exposure screen results indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Tuberculosis exposure screen results indicator CPHS;;;ACTIVE;2.15;2.27 +392-1;Penicillin G;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Penicillin G [Susceptibility] by Minimum inhibitory concentration (MIC);Penicillin G Islt MIC;;ACTIVE;1.0;2.73 +39210-0;Tuberculosis exposure screen follow-up status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Tuberculosis exposure screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39211-8;Tuberculosis exposure screen finding recency;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Tuberculosis exposure screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39212-6;Vision screen assessment;Cmplx;Pt;Eye;Set;CPHS;ATTACH.CPHS;3;Vision screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39213-4;Vision screen results indicator;Type;Pt;Eye;Nom;CPHS;ATTACH.CPHS;3;Vision screen results indicator CPHS;;;ACTIVE;2.15;2.27 +3921-4;Pentetrazol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pentetrazol [Mass/volume] in Urine;Pentetrazol Ur-mCnc;;ACTIVE;1.0;2.42 +39214-2;Vision screen follow-up status;Type;Pt;Eye;Nom;CPHS;ATTACH.CPHS;3;Vision screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39215-9;Vision screen finding recency;Type;Pt;Eye;Nom;CPHS;ATTACH.CPHS;3;Vision screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39216-7;Other screen assessment;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Other screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39217-5;Other screen name;Txt;Pt;^Patient;Nar;CPHS;ATTACH.CPHS;3;Other screen name CPHS;;;ACTIVE;2.15;2.27 +39218-3;Other screen results indicator;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Other screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39219-1;Other screen follow-up status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Other screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39220-9;Other screen finding recency;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Other screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39221-7;Diagnosis recommendations;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Diagnosis recommendations Set CPHS;;;ACTIVE;2.15;2.73 +3922-2;Pentetrazol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Pentetrazol [Mass/time] in 24 hour Urine;Pentetrazol 24h Ur-mRate;;ACTIVE;1.0;2.42 +39222-5;Diagnosis recommendations, ICD9-CM;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Diagnosis recommendations, ICD9-CM CPHS;;;ACTIVE;2.15;2.27 +39223-3;Diagnosis recommendations, description;Txt;Pt;^Patient;Nar;CPHS;ATTACH.CPHS;3;Diagnosis recommendations, description (narrative) CPHS;;;ACTIVE;2.15;2.27 +39224-1;Chlamydia screen test status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Chlamydia screen test status CPHS;;;ACTIVE;2.15;2.27 +39225-8;Gonorrhea screen test status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Gonorrhea screen test status CPHS;;;ACTIVE;2.15;2.27 +39226-6;Hemoglobin test status;Type;Pt;Bld;Nom;CPHS;ATTACH.CPHS;3;Hemoglobin test status CPHS;;;ACTIVE;2.15;2.27 +39227-4;Hematocrit test status;Type;Pt;Bld;Nom;CPHS;ATTACH.CPHS;3;Hematocrit test status CPHS;;;ACTIVE;2.15;2.27 +39228-2;Lead screen test status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Lead screen test status CPHS;;;ACTIVE;2.15;2.27 +39229-0;Lipid screen test status;Type;Pt;Ser/Plas;Nom;CPHS;ATTACH.CPHS;3;Lipid screen test status CPHS;;;ACTIVE;2.15;2.27 +3923-0;PENTobarbital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;PENTobarbital [Presence] in Serum or Plasma;Pentobarb SerPl Ql;;ACTIVE;1.0;2.73 +39230-8;Sickle cell screen test status;Type;Pt;Bld;Nom;CPHS;ATTACH.CPHS;3;Sickle cell screen test status CPHS;;;ACTIVE;2.15;2.73 +39231-6;Syphilis screen test status;Type;Pt;Ser;Nom;CPHS;ATTACH.CPHS;3;Syphilis screen test status CPHS;;;ACTIVE;2.15;2.73 +39232-4;Screen test, other;Cmplx;Pt;XXX;Set;CPHS;ATTACH.CPHS;3;Screen test, other Set CPHS;;;ACTIVE;2.15;2.40 +39233-2;Screen test, other name;Txt;Pt;XXX;Nar;CPHS;ATTACH.CPHS;3;Screen test, other name CPHS;;;ACTIVE;2.15;2.27 +39234-0;Screen test, other status;Type;Pt;XXX;Nom;CPHS;ATTACH.CPHS;3;Screen test, other status CPHS;;;ACTIVE;2.15;2.27 +39235-7;Immunization data;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Immunization data Set CPHS;;;ACTIVE;2.15;2.40 +39236-5;Vaccine code (CPT);Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Vaccine code (CPT) CPHS;;;ACTIVE;2.15;2.27 +39237-3;Immunization status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Immunization status CPHS;;;ACTIVE;2.15;2.27 +39238-1;Anticipatory guidance indicator;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Anticipatory guidance indicator CPHS;;;ACTIVE;2.15;2.27 +39239-9;Anticipatory guidance or health education type;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Anticipatory guidance or health education type CPHS;;;ACTIVE;2.15;2.27 +39240-7;Tobacco use status;Find;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Tobacco use status CPHS;;;ACTIVE;2.15;2.58 +39241-5;Tobacco use counselled;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Tobacco use counselled CPHS;;;ACTIVE;2.15;2.27 +39242-3;Tobacco prevention referred;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Tobacco prevention referred CPHS;;;ACTIVE;2.15;2.58 +39243-1;Second hand smoke exposure;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Second hand smoke exposure CPHS;;;ACTIVE;2.15;2.27 +39244-9;Patient drug or alcohol use;Find;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Patient drug or alcohol use CPHS;;;ACTIVE;2.15;2.46 +39245-6;Drug or alcohol abuse counselled;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Drug or alcohol abuse counselled CPHS;;;ACTIVE;2.15;2.27 +39246-4;Risk assessment provided;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Risk assessment provided CPHS;;;ACTIVE;2.15;2.27 +39247-2;Prenatal assessment provided;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Prenatal assessment provided CPHS;;;ACTIVE;2.15;2.27 +3924-8;PENTobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PENTobarbital [Mass/volume] in Serum or Plasma;Pentobarb SerPl-mCnc;;ACTIVE;1.0;2.73 +39248-0;Prenatal interview w infants primary care provider indicator;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Prenatal interview with infants primary care provider indicator CPHS;;;ACTIVE;2.15;2.46 +39249-8;Program participation;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Program participation Set CPHS;;;ACTIVE;2.15;2.40 +39250-6;Program participation, name;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Program participation, name CPHS;;;ACTIVE;2.15;2.27 +39251-4;Other program participation name;Txt;Pt;^Patient;Nar;CPHS;ATTACH.CPHS;3;Other program participation name CPHS;;;ACTIVE;2.15;2.27 +39252-2;Foster care indicator;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Foster care indicator CPHS;;;ACTIVE;2.15;2.27 +39253-0;Primary care practitioner (PCP) indicator;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Primary care practitioner (PCP) indicator CPHS;;;ACTIVE;2.15;2.29 +39254-8;Primary care practitioner (PCP) perform screen indicator;Arb;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Primary care practitioner (PCP) perform screen indicator CPHS;;;ACTIVE;2.15;2.29 +3925-5;PENTobarbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;PENTobarbital [Presence] in Urine;Pentobarb Ur Ql;;ACTIVE;1.0;2.73 +39255-5;Date previous screen visit;Date;Pt;^Patient;Qn;CPHS;ATTACH.CPHS;3;Date previous screen visit CPHS;;;ACTIVE;2.15;2.50 +39256-3;History and physical screen assessment;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;History and physical screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39257-1;Cardiac screen assessment;Cmplx;Pt;Cardiovascular system;Set;CPHS;ATTACH.CPHS;3;Cardiac screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39258-9;ENT screen assessment;Cmplx;Pt;ENT;Set;CPHS;ATTACH.CPHS;3;ENT screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +39259-7;ENT screen results indicator;Type;Pt;ENT;Nom;CPHS;ATTACH.CPHS;3;ENT screen results indicator CPHS;;;ACTIVE;2.15;2.27 +39260-5;ENT screen follow-up status;Type;Pt;ENT;Nom;CPHS;ATTACH.CPHS;3;ENT screen follow-up status CPHS;;;ACTIVE;2.15;2.27 +39261-3;ENT screen finding recency;Type;Pt;ENT;Nom;CPHS;ATTACH.CPHS;3;ENT screen finding recency CPHS;;;ACTIVE;2.15;2.27 +39262-1;Neurologic screen assessment;Cmplx;Pt;Neurologic system;Set;CPHS;ATTACH.CPHS;3;Neurologic screen assessment Set CPHS;;;ACTIVE;2.15;2.40 +3926-3;PENTobarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;PENTobarbital [Mass/volume] in Urine;Pentobarb Ur-mCnc;;ACTIVE;1.0;2.73 +39263-9;Tuberculin screen test status;Type;Pt;^Patient;Nom;CPHS;ATTACH.CPHS;3;Tuberculin screen test status CPHS;;;ACTIVE;2.15;2.73 +39264-7;Urinalysis dipstick test status;Type;Pt;Urine;Nom;CPHS;ATTACH.CPHS;3;Urinalysis dipstick test status CPHS;;;ACTIVE;2.15;2.27 +39265-4;Urinalysis complete status;Type;Pt;Urine;Nom;CPHS;ATTACH.CPHS;3;Urinalysis complete status CPHS;;;ACTIVE;2.15;2.27 +39266-2;Follow-up (referred to) provider &or specialist;Cmplx;Pt;Clinical referral;Set;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist Set CPHS;;;ACTIVE;2.15;2.40 +39267-0;Reason for follow-up (referred to) provider &or specialist;Find;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Reason for follow-up (referred to) provider /specialist CPHS;;;ACTIVE;2.15;2.27 +39268-8;Follow-up (referred to) provider &or specialist, name;Pn;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, name CPHS;;;ACTIVE;2.15;2.27 +39269-6;Follow-up (referred to) provider &or specialist, provider type;Type;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, provider type CPHS;;;ACTIVE;2.15;2.27 +39270-4;Follow-up (referred to) provider &or specialist, address;Addr;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, address CPHS;;;ACTIVE;2.15;2.27 +3927-1;Perphenazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Perphenazine [Mass/volume] in Serum or Plasma;Perphenazine SerPl-mCnc;;ACTIVE;1.0;2.73 +39271-2;Follow-up (referred to) provider &or specialist, phone;Tele;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, phone CPHS;;;ACTIVE;2.15;2.27 +39272-0;Follow-up (referred to) provider &or specialist, network location indicator;Type;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, network location indicator CPHS;;;ACTIVE;2.15;2.27 +39273-8;Follow-up (referred to) program;Cmplx;Pt;Program referral;Set;CPHS;ATTACH.CPHS;3;Follow-up (referred to) program Set CPHS;Follow-up (referred to) program CPHS;;ACTIVE;2.15;2.40 +39274-6;Reason for follow-up (referred to) program;Find;Pt;Program referral;Nar;CPHS;ATTACH.CPHS;3;Reason for follow-up (referred to) program (narrative) CPHS;Reason for follow-up program CPHS;;ACTIVE;2.15;2.38 +39275-3;Follow-up (referred to) program, name;Txt;Pt;Program referral;Nar;CPHS;ATTACH.CPHS;3;Follow-up (referred to) program, name CPHS;;;ACTIVE;2.15;2.46 +39276-1;Follow-up (referred to) program, address;Addr;Pt;Program referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) program, address CPHS;;;ACTIVE;2.15;2.46 +39277-9;Follow-up (referred to) program, phone;Tele;Pt;Program referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) program, phone CPHS;;;ACTIVE;2.15;2.46 +39278-7;Tobacco use counselled;Arb;Pt;^Family member-caregiver;Ord;CPHS;ATTACH.CPHS;3;Tobacco use counselled Family member/caregiver CPHS;;;ACTIVE;2.15;2.27 +39279-5;Tobacco prevention referred;Arb;Pt;^Family member-caregiver;Ord;CPHS;ATTACH.CPHS;3;Tobacco prevention referred Family member/caregiver CPHS;;;ACTIVE;2.15;2.58 +39280-3;Responsible party;Cmplx;Pt;Responsible party;Set;CPHS;ATTACH.CPHS;3;Responsible party Set CPHS;;;ACTIVE;2.15;2.40 +39281-1;Responsible party, name;Pn;Pt;Responsible party;Nom;CPHS;ATTACH.CPHS;3;Responsible party, name CPHS;;;ACTIVE;2.15;2.27 +39282-9;Responsible party, home phone number;Tele;Pt;Responsible party;Nom;CPHS;ATTACH.CPHS;3;Responsible party, home phone number CPHS;;;ACTIVE;2.15;2.27 +39283-7;Responsible party, work number;Tele;Pt;Responsible party;Nom;CPHS;ATTACH.CPHS;3;Responsible party, work number CPHS;;;ACTIVE;2.15;2.27 +39284-5;Patient escort information panel;-;Pt;^Escort;-;;PANEL.ADMIN;2;Patient escort information panel;Patient escort info Pnl;;ACTIVE;2.15;2.67 +39285-2;Name;Pn;Pt;^Escort;Nom;;ADMIN;2;Escort Name;Escort Name;;ACTIVE;2.15;2.67 +39286-0;Relationship to patient;Type;Pt;^Escort;Nom;;ADMIN;2;Escort Relationship to patient;Escort Relationship to pt;;ACTIVE;2.15;2.67 +39287-8;Patient escort, other escort relationship;Txt;Pt;Escort;Nar;CPHS;ATTACH.CPHS;3;Deprecated Patient escort, other escort relationship (narrative) CPHS;Deprecated;;DEPRECATED;2.15;2.67 +39288-6;Pre-paid health plan indicator;Type;Pt;^Patient;Ord;CPHS;ATTACH.CPHS;3;Pre-paid health plan indicator CPHS;;;ACTIVE;2.15;2.27 +3928-9;Perphenazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Perphenazine [Mass/volume] in Urine;Perphenazine Ur-mCnc;;ACTIVE;1.0;2.73 +39289-4;Follow-up (referred to) provider &or specialist, appointment date;Date;Pt;Clinical referral;Qn;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, appointment date CPHS;;;ACTIVE;2.15;2.50 +39290-2;Follow-up (referred to) program, appointment date;Date;Pt;Program referral;Qn;CPHS;ATTACH.CPHS;3;Follow-up (referred to) program, appointment date CPHS;;;ACTIVE;2.15;2.50 +39291-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity;Doc;MR;RAD;2;MR Lower extremity WO and W contrast IV;MR LE WO+W contr IV;;ACTIVE;2.15;2.61 +39292-8;Multisection^WO contrast;Find;Pt;Lower extremity;Doc;MR;RAD;2;MR Lower extremity WO contrast;MR LE WO contr;;ACTIVE;2.15;2.61 +39293-6;Multisection^W contrast IV;Find;Pt;Lower extremity;Doc;MR;RAD;2;MR Lower extremity W contrast IV;MR LE W contr IV;;ACTIVE;2.15;2.61 +39294-4;Children's preventive health services attachment;Cmplx;Pt;^Patient;Set;;ATTACH.CPHS;3;Children's preventive health services attachment Set;;;ACTIVE;2.15;2.67 +39295-1;Influenza virus A Ab;PrThr;Pt;Eggylk;Ord;Immune diffusion;MICRO;1;Influenza virus A Ab [Presence] in Egg yolk by Immune diffusion (ID);FLUAV Ab Egg Yolk Ql ID;;ACTIVE;2.15;2.56 +39296-9;Influenza virus A H1 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H1 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H1 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +3929-7;Phenacetin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenacetin [Mass/volume] in Serum or Plasma;Phenac SerPl-mCnc;;ACTIVE;1.0;2.42 +39297-7;Influenza virus A H10 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H10 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H10 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39298-5;Influenza virus A H11 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H11 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H11 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39299-3;Influenza virus A H12 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H12 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H12 Ab Titr Ser HAI;;ACTIVE;2.15;2.56 +39300-9;Influenza virus A H13 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H13 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H13 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39301-7;Influenza virus A H14 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H14 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H14 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39302-5;Influenza virus A H15 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H15 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H15 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39303-3;Influenza virus A H2 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H2 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H2 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39304-1;Influenza virus A H3 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H3 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H3 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +3930-5;Phenacetin;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Phenacetin [Mass/volume] in Serum or Plasma;Deprecated Phenac Ser-mCnc;;DEPRECATED;1.0;2.36 +39305-8;Influenza virus A H4 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H4 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H4 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39306-6;Influenza virus A H5 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H5 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H5 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39307-4;Influenza virus A H6 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H6 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H6 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39308-2;Influenza virus A H7 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H7 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H7 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39309-0;Influenza virus A H8 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H8 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H8 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39310-8;Influenza virus A H9 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H9 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H9 Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +39311-6;Influenza virus A N1 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N1 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N1 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39312-4;Influenza virus A N2 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N2 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N2 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +3931-3;Phenazocine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenazocine [Presence] in Urine;Phenazocine Ur Ql;;ACTIVE;1.0;2.56 +39313-2;Influenza virus A N3 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N3 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N3 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39314-0;Influenza virus A N4 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N4 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N4 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39315-7;Influenza virus A N5 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N5 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N5 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39316-5;Influenza virus A N6 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N6 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N6 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39317-3;Influenza virus A N7 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N7 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N7 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39318-1;Influenza virus A N8 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N8 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N8 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39319-9;Influenza virus A N9 Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Influenza virus A N9 neutralizing antibody [Presence] in Serum by Neutralization test;FLUAV N9 NAb Ser Ql Nt;;ACTIVE;2.15;2.72 +39320-7;Prion protein.abnormal;PrThr;Pt;Tiss;Ord;IB;MICRO;1;Abnormal Prion Protein [Presence] in Tissue by Immunoblot;Abn Prion Prot Tiss Ql IB;;ACTIVE;2.15;2.65 +3932-1;Phenazocine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenazocine [Mass/volume] in Urine;Phenazocine Ur-mCnc;;ACTIVE;1.0;2.42 +39321-5;Views AP internal rotation + AP external rotation + axillary;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP internal rotation and AP external rotation and Axillary;XR Should AP IR+AP ER+Ax;;ACTIVE;2.15;2.61 +39322-3;Multisection^W contrast intradisc;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Spine W contrast intradisc;CT Spine W contr ID;;DISCOURAGED;2.15;2.61 +39323-1;View R-posterior oblique;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Right posterior oblique;XR Abd R-post obl;;ACTIVE;2.15;2.61 +39324-9;View PA^W clenched fist;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left PA W clenched fist;XR Wrist-L PA W clenched fist;;ACTIVE;2.15;2.61 +39325-6;View AP internal rotation + Grashey + axillary + outlet;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP internal rotation and Grashey and Axillary and Outlet;XR Should-L AP IR+Grashey+Ax+Outlet;;ACTIVE;2.15;2.61 +39326-4;Views;Find;Pt;Chest>Ribs.left & Chest;Doc;XR;RAD;2;XR Ribs - left and Chest Views;XR Ribs-L + Chest Views;;ACTIVE;2.15;2.73 +39327-2;Views for fetal age;Find;Pt;Abdomen+^Fetus;Doc;XR;RAD;2;XR Abdomen and Fetal Views for fetal age;XR Abdomen+ Fet Views for FTA;;ACTIVE;2.15;2.64 +39328-0;Views AP internal rotation + AP external rotation;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP internal rotation and AP external rotation;XR Should-L AP IR+AP ER;;ACTIVE;2.15;2.61 +39329-8;Views AP internal rotation + AP external rotation;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP internal rotation and AP external rotation;XR Shoulder-Bl AP IR+AP ER;;ACTIVE;2.15;2.61 +39330-6;Views AP + lateral^W standing;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral AP and Lateral W standing;XR Ankle-Bl AP+Lat W Stand;;ACTIVE;2.15;2.61 +39331-4;Views AP + lateral^W standing;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral AP and Lateral W standing;XR Foot-Bl AP+Lat W Stand;;ACTIVE;2.15;2.61 +39332-2;Views AP + lateral^W standing;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left AP and Lateral W standing;XR Foot-L AP+Lat W Stand;;ACTIVE;2.15;2.61 +39333-0;Views AP + lateral^W standing;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP and Lateral W standing;XR L-spine AP+Lat W Stand;;ACTIVE;2.15;2.61 +39334-8;Views AP + lateral + oblique^W standing;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left AP and Lateral and oblique W standing;XR Foot-L AP+Lat+Obl W Stand;;ACTIVE;2.15;2.61 +39335-5;Views AP internal rotation + AP external rotation + axillary;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP internal rotation and AP external rotation and Axillary;XR Should-L AP IR+AP ER+Ax;;ACTIVE;2.15;2.61 +39336-3;Views AP internal rotation + AP external rotation + axillary;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP internal rotation and AP external rotation and Axillary;XR Shoulder-Bl AP IR+AP ER+Ax;;ACTIVE;2.15;2.61 +39337-1;Views AP internal rotation + AP external rotation + axillary + outlet;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP internal rotation and AP external rotation and Axillary and Outlet;XR Shoulder-Bl AP IR+AP ER+Ax+Outlet;;ACTIVE;2.15;2.61 +39338-9;Views AP internal rotation + AP external rotation + axillary + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP internal rotation and AP external rotation and Axillary and Y;XR Should-L AP IR+AP ER+Ax+Y;;ACTIVE;2.15;2.61 +3933-9;Phenazocine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Phenazocine [Mass/time] in 24 hour Urine;Phenazocine 24h Ur-mRate;;ACTIVE;1.0;2.42 +39339-7;Views AP + axillary + outlet + 30 degree caudal angle;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP and Axillary and Outlet and 30 degree caudal angle;XR Shoulder-Bl AP+Ax+Outlet+30 Deg Cau;;ACTIVE;2.15;2.61 +39340-5;Views lateral^W standing + W flexion + W extension;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Lateral Views W standing and W flexion and W extension;XR L-spine Views Lat W stand+W flx+W ext;;ACTIVE;2.15;2.64 +39341-3;Views lateral + PA^W inspiration + W expiration;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Lateral and PA W inspiration and expiration;XR Chest Lat+PA W insp+exp;;ACTIVE;2.15;2.61 +39342-1;Views PA & oblique^W nipple markers;Find;Pt;Chest;Nar;XR;RAD;2;Deprecated Chest X-ray PA & oblique W nipple markers;Deprecated Chest XR PA+Obl W nipple mark;;DEPRECATED;2.15;2.34 +39343-9;Views AP internal rotation + AP external rotation + Y;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP internal rotation and AP external rotation and Y;XR Shoulder-Bl AP IR+AP ER+Y;;ACTIVE;2.15;2.61 +39344-7;Views AP internal rotation + AP external rotation + axillary + Y;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP internal rotation and AP external rotation and Axillary and Y;XR Shoulder-Bl AP IR+AP ER+Ax+Y;;ACTIVE;2.15;2.61 +39345-4;(View Sunrise) + (View tunnel^W standing);Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Sunrise and (Tunnel W standing);XR Knee-L Sunrise+tunnel Stand;;ACTIVE;2.15;2.61 +39346-2;View AP internal rotation + West Point;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP internal rotation and West Point;XR Shoulder-Bl AP IR+West Point;;ACTIVE;2.15;2.61 +3934-7;Phencyclidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Serum or Plasma;PCP SerPl-mCnc;;ACTIVE;1.0;2.73 +39347-0;View AP internal rotation + West Point;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP internal rotation and West Point;XR Should-L AP IR+West Point;;ACTIVE;2.15;2.61 +39348-8;Views AP internal rotation + AP external rotation + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP internal rotation and AP external rotation and Y;XR Should-L AP IR+AP ER+Y;;ACTIVE;2.15;2.61 +39349-6;Views^W contrast retrograde;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Kidney - bilateral Views W contrast retrograde;RF Kdny-Bl Views W contr Retro;;ACTIVE;2.15;2.64 +39350-4;Views Grashey + outlet + Serendipity;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral Grashey and Outlet and Serendipity;XR Shoulder-Bl Grashey+Outlet+Serend;;ACTIVE;2.15;2.61 +39351-2;Views;Find;Pt;Chest>Ribs.upper.anterior.left+Ribs.upper.posterior.left;Doc;XR;RAD;2;XR Ribs upper anterior and posterior - left Views;XR Ribs upper ant+post-L Views;;ACTIVE;2.15;2.64 +39352-0;Views;Find;Pt;Chest>Ribs.posterior.bilateral;Doc;XR;RAD;2;XR Ribs posterior - bilateral Views;XR Ribs post-Bl Views;;ACTIVE;2.15;2.64 +39353-8;Views;Find;Pt;Chest>Ribs.upper.posterior.left;Doc;XR;RAD;2;XR Ribs upper posterior - left Views;XR Ribs upper post-L Views;;ACTIVE;2.15;2.64 +3935-4;Phencyclidine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Serum or Plasma;PCP SerPl Ql;;ACTIVE;1.0;2.73 +39354-6;Cholinesterase^dibucaine/Cholinesterase;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase in Serum or Plasma --dibucaine/Cholinesterase;Cholinesterase dibucaine/CHe CFr SerPl;;ACTIVE;2.15;2.73 +39355-3;Cholinesterase.fluoride inhibited/Cholinesterase;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.fluoride inhibited/Cholinesterase in Serum or Plasma;Fluoride Inhib/CHe CFr SerPl;;ACTIVE;2.15;2.70 +39356-1;Cholinesterase.scoline inhibited/Cholinesterase;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.scoline inhibited/Cholinesterase in Serum or Plasma;Scoline Inhib/CHe CFr SerPl;;ACTIVE;2.15;2.70 +39357-9;Cholinesterase.chloride inhibited/Cholinesterase;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.chloride inhibited/Cholinesterase in Serum or Plasma;Chloride Inhib/CHe CFr SerPl;;ACTIVE;2.15;2.70 +39358-7;Cholinesterase.RO 020683 inhibited/Cholinesterase;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.RO 020683 inhibited/Cholinesterase in Serum or Plasma;RO 020683 Inhib/CHe CFr SerPl;;ACTIVE;2.15;2.70 +39359-5;Multisection^WO contrast;Find;Pt;Abdomen>Kidney.bilateral;Doc;XR.tomography;RAD;2;XR tomography Kidney - bilateral WO contrast;XR tomo Kdny-Bl WO contr;;ACTIVE;2.15;2.61 +39360-3;Views + inlet + outlet;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Views and Inlet and Outlet;XR Pelvis Views+Inlet+Outlet;;ACTIVE;2.15;2.64 +39361-1;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of drainage catheter of Liver;RF Guided Liver Absc drain+cath place;;ACTIVE;2.15;2.66 +3936-2;Phencyclidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Urine;PCP Ur Ql;;ACTIVE;1.0;2.73 +39362-9;Guidance for placement of tube;Find;Pt;Chest;Doc;RF;RAD;2;RF Guidance for placement of tube in Chest;RF Guided Chest Tube place;;ACTIVE;2.15;2.64 +39363-7;Views^W contrast retrograde;Find;Pt;XXX>AV fistula;Doc;RF.angio;RAD;2;RFA AV fistula Views W contrast retrograde;RFA AVF Views W contr Retro;;ACTIVE;2.15;2.64 +39364-5;Views 3 + radial deviation;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 3 Views and Radial deviation;XR Wrist-R 3V+Radial deviation;;ACTIVE;2.15;2.61 +39365-2;Views 3 + ulnar deviation;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 3 Views and Ulnar deviation;XR Wrist-R 3V+Ulnar deviation;;ACTIVE;2.15;2.61 +39366-0;Views lateral + outlet;Find;Pt;Chest>Scapula;Doc;XR;RAD;2;XR Scapula Lateral and outlet;XR Scapula Lat+Outlet;;ACTIVE;2.15;2.61 +39367-8;(Views AP + lateral) for scoliosis^W standing;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP and lateral for scoliosis W standing;XR T+L-Spine AP+Lat for Scoli W Stand;;ACTIVE;2.15;2.64 +39368-6;Views AP + lateral^W standing;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right AP and Lateral W standing;XR Ankle-R AP+Lat W Stand;;ACTIVE;2.15;2.61 +39369-4;(Views AP + lateral + oblique) + (view^W manual stress);Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right AP and Lateral and Oblique and (View W manual stress);XR Ankle-R AP+Lat+Obl+1V W Stress;;ACTIVE;2.15;2.61 +3937-0;Phencyclidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Urine;PCP Ur-mCnc;;ACTIVE;1.0;2.73 +39370-2;(Views) + (view^W manual stress);Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Views and (View W manual stress);XR Ankle-R Views+1V W Stress;;ACTIVE;2.15;2.61 +39371-0;Views AP + lateral + oblique^W standing;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right AP and Lateral and oblique W standing;XR Ankle-R AP+Lat+Obl W Stand;;ACTIVE;2.15;2.61 +39372-8;Views + Mortise;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Views and Mortise;XR Ankle-R Views+Mortise;;ACTIVE;2.15;2.64 +39373-6;Views + oblique;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Views and Oblique;XR Elbow-R Views+Obl;;ACTIVE;2.15;2.64 +39374-4;Views AP + lateral^W standing;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right AP and Lateral W standing;XR Foot-R AP+Lat W Stand;;ACTIVE;2.15;2.61 +39375-1;Views AP + lateral + oblique^W standing;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right AP and Lateral and oblique W standing;XR Foot-R AP+Lat+Obl W Stand;;ACTIVE;2.15;2.61 +39376-9;Views + oblique;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right Views and Oblique;XR Radius+Ulna-R Views+Obl;;ACTIVE;2.15;2.64 +39377-7;Views + lateral crosstable;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Views and Lateral crosstable;XR Hip-R Views+Lat Xtable;;ACTIVE;2.15;2.64 +39378-5;Views 2 + oblique;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 Views and Oblique;XR Knee-R 2V+Obl;;ACTIVE;2.15;2.61 +39379-3;Views 2 + Sunrise;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 Views and Sunrise;XR Knee-R 2V+Sunrise;;ACTIVE;2.15;2.61 +39380-1;Views 2 + Sunrise + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 Views and Sunrise and Tunnel;XR Knee-R 2V+Sunrise+Tunnel;;ACTIVE;2.15;2.61 +39381-9;Views 2 + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 Views and Tunnel;XR Knee-R 2V+Tunnel;;ACTIVE;2.15;2.61 +39382-7;(Views 2) + (view tunnel^W standing);Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 views and (Tunnel W standing);XR Knee-R 2V + tunnel Stand;;ACTIVE;2.15;2.61 +39383-5;Views 3 + Sunrise;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 3 Views and Sunrise;XR Knee-R 3V+Sunrise;;ACTIVE;2.15;2.61 +39384-3;(Views 4) + (view AP^W standing);Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 4 views and (AP W standing);XR Knee-R 4V+AP Stand;;ACTIVE;2.15;2.61 +39385-0;Views 4 + oblique;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 4 Views and Oblique;XR Knee-R 4V+Obl;;ACTIVE;2.15;2.61 +39386-8;Views 4 + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 4 views and Tunnel;XR Knee-R 4V+Tunnel;;ACTIVE;2.15;2.61 +39387-6;Views 4 + Sunrise + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 4 Views and Sunrise and Tunnel;XR Knee-R 4V+Sunrise+Tunnel;;ACTIVE;2.15;2.61 +3938-8;Phendimetrazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phendimetrazine [Mass/volume] in Serum or Plasma;Phendimetrazine SerPl-mCnc;;ACTIVE;1.0;2.73 +39388-4;Views AP + lateral + R-oblique + L-oblique;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP and Lateral and Right oblique and Left oblique;XR Knee-R AP+Lat+R-Obl+L-Obl;;ACTIVE;2.15;2.61 +39389-2;Views + tunnel;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Views and Tunnel;XR Knee-R Views+Tunnel;;ACTIVE;2.15;2.64 +393-9;Penicillin G;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Penicillin G [Susceptibility] by Disk diffusion (KB);Penicillin G Islt KB;;ACTIVE;1.0;2.73 +39390-0;Views + oblique;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Views and Oblique;XR Knee-R Views+Obl;;ACTIVE;2.15;2.64 +39391-8;Views + Sunrise;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Views and Sunrise;XR Knee-R Views+Sunrise;;ACTIVE;2.15;2.64 +39392-6;Views internal rotation + external rotation + axillary;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Internal rotation and External rotation and Axillary;XR Should-R V IR+ER+Ax;;ACTIVE;2.15;2.61 +39393-4;Views 3 + axillary;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right 3 Views and Axillary;XR Should-R 3V+Ax;;ACTIVE;2.15;2.61 +39394-2;Views 3 + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right 3 Views and Y;XR Should-R 3V+Y;;ACTIVE;2.15;2.61 +39395-9;Views AP internal rotation + AP external rotation;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP internal rotation and AP external rotation;XR Should-R AP IR+AP ER;;ACTIVE;2.15;2.61 +3939-6;Phendimetrazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phendimetrazine [Presence] in Urine;Phendimetrazine Ur Ql;;ACTIVE;1.0;2.56 +39396-7;View AP internal rotation + West Point;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP internal rotation and West Point;XR Should-R AP IR+West Point;;ACTIVE;2.15;2.61 +39397-5;Views AP internal rotation + AP external rotation + West Point;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP internal rotation and AP external rotation and West Point;XR Should-R AP IR+AP ER+West Point;;ACTIVE;2.15;2.61 +39398-3;Views + oblique;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right Views and Oblique;XR Tib+Fib-R Views+Obl;;ACTIVE;2.15;2.64 +39399-1;Views 3 + carpal tunnel;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right 3 Views and Carpal tunnel;XR Wrist-R 3V+Carpal tunnel;;ACTIVE;2.15;2.61 +39400-7;Views + carpal tunnel;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Views and Carpal tunnel;XR Wrist-R Views+Carpal tunnel;;ACTIVE;2.15;2.64 +39401-5;Views AP + Grashey + axillary;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP and Grashey and Axillary;XR Should AP+Grashey+Ax;;ACTIVE;2.15;2.61 +39402-3;Views AP internal rotation + AP external rotation;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP internal rotation and AP external rotation;XR Should AP IR+AP ER;;ACTIVE;2.15;2.61 +39403-1;Views axillary + transcapular;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Axillary and Transcapular;XR Should Ax+Transcapular;;ACTIVE;2.15;2.61 +3940-4;Phendimetrazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phendimetrazine [Mass/volume] in Urine;Phendimetrazine Ur-mCnc;;ACTIVE;1.0;2.73 +39404-9;Views 3 + submentovertex;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses 3 Views and Submentovertex;XR Sinuses 3V+SMV;;ACTIVE;2.15;2.61 +39405-6;Views lateral + R-oblique + L-oblique;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum Lateral and right oblique and left oblique;XR Sternum Lat+R-Obl+L-Obl;;ACTIVE;2.15;2.61 +39406-4;Views lateral + R-anterior oblique;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum Lateral and right anterior oblique;XR Sternum Lat+R-ant Obl;;ACTIVE;2.15;2.61 +39407-2;Views 5 + oblique;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 5 Views and Oblique;XR T-spine 5V+Obl;;ACTIVE;2.15;2.61 +39408-0;Multisection AP;Find;Pt;Chest>Spine.thoracic;Doc;XR.tomography;RAD;2;XR tomography Thoracic spine AP;XR tomo T-spine AP;;ACTIVE;2.15;2.61 +39409-8;Multisection lateral;Find;Pt;Chest>Spine.thoracic;Doc;XR.tomography;RAD;2;XR tomography Thoracic spine lateral;XR tomo T-spine Lat;;ACTIVE;2.15;2.61 +39410-6;View AP^W L-bending;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine AP W left bending;XR T-spine AP W L-bending;;ACTIVE;2.15;2.61 +39411-4;View AP^W R-bending;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine AP W right bending;XR T-spine AP W R-bending;;ACTIVE;2.15;2.61 +3941-2;Phendimetrazine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Phendimetrazine [Mass/time] in 24 hour Urine;Phendimetrazine 24h Ur-mRate;;ACTIVE;1.0;2.42 +39412-2;Views + Swimmers;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Views and Swimmers;XR T-spine Views+Swimmers;;ACTIVE;2.15;2.64 +39413-0;Views 4 + oblique;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 4 Views and Oblique;XR T-spine 4V+Obl;;ACTIVE;2.15;2.61 +39414-8;Views + oblique;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Views and Oblique;XR T-spine Views+Obl;;ACTIVE;2.15;2.64 +39415-5;Multisection;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;US;RAD;2;US Gastrointestinal tract;US GI tract;;ACTIVE;2.15;2.61 +39416-3;Multisection;Find;Pt;Abdomen+Pelvis>Genitourinary tract;Doc;US;RAD;2;US Genitourinary tract;US GU tract;;ACTIVE;2.15;2.61 +39417-1;Multisection;Find;Pt;Kidney.bilateral+Collecting system;Nar;US;RAD;2;Deprecated Kidney Bilateral & Collecting system US Multisection;Deprecated KD-Bl+CS US;;DEPRECATED;2.15;2.40 +39418-9;Multisection;Find;Pt;Extremity.bilateral>Extremity vein;Doc;US.doppler;RAD;2;US.doppler Extremity vein - bilateral;DOP Extr v-Bl;;ACTIVE;2.15;2.73 +39419-7;Multisection;Find;Pt;Abdomen>Renal vessels.bilateral;Doc;US.doppler;RAD;2;US.doppler Renal vessels - bilateral;DOP Renal ves-Bl;;ACTIVE;2.15;2.61 +3942-0;Pheniramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pheniramine [Mass/volume] in Serum or Plasma;Pheniramine SerPl-mCnc;;ACTIVE;1.0;2.73 +39420-5;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity vein;Doc;US.doppler;RAD;2;US.doppler Lower extremity vein - bilateral;DOP LE v-Bl;;ACTIVE;2.15;2.73 +39421-3;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity artery;Doc;US.doppler;RAD;2;US.doppler Lower extremity artery - bilateral;DOP LE a-Bl;;ACTIVE;2.15;2.61 +39422-1;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity vessels;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessels - bilateral;DOP LE ves-Bl;;ACTIVE;2.15;2.61 +39423-9;Multisection;Find;Pt;Upper extremity.bilateral>Upper extremity artery;Doc;US.doppler;RAD;2;US.doppler Upper extremity artery - bilateral;DOP UE a-Bl;;ACTIVE;2.15;2.61 +39424-7;Multisection limited;Find;Pt;Extremity>Extremity vessels;Doc;US.doppler;RAD;2;US.doppler Extremity vessels limited;DOP Extremity ves Ltd;;ACTIVE;2.15;2.61 +39425-4;Multisection;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;US.doppler;RAD;2;US.doppler Iliac artery;DOP Iliac a;;ACTIVE;2.15;2.73 +39426-2;Multisection;Find;Pt;Abdomen>Renal vessels;Doc;US.doppler;RAD;2;US.doppler Renal vessels;DOP Renal ves;;ACTIVE;2.15;2.61 +39427-0;Multisection;Find;Pt;Head+Neck>Carotid arteries.left;Doc;US.doppler;RAD;2;US.doppler Carotid arteries - left;DOP Carotid aa-L;;ACTIVE;2.15;2.61 +39428-8;Multisection;Find;Pt;Extremity.left>Extremity artery;Doc;US.doppler;RAD;2;US.doppler Extremity artery - left;DOP Extr a-L;;ACTIVE;2.15;2.61 +39429-6;Multisection;Find;Pt;Extremity.left>Extremity vein;Doc;US.doppler;RAD;2;US.doppler Extremity vein - left;DOP Extr v-L;;ACTIVE;2.15;2.61 +39430-4;Multisection limited;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessels - left limited;DOP LE ves-L Ltd;;ACTIVE;2.15;2.61 +39431-2;Multisection;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessels - left;DOP LE ves-L;;ACTIVE;2.15;2.61 +39432-0;Multisection;Find;Pt;Lower extremity.left>Lower extremity vein;Doc;US.doppler;RAD;2;US.doppler Lower extremity vein - left;DOP LE v-L;;ACTIVE;2.15;2.73 +39433-8;Multisection;Find;Pt;Upper extremity.left>Upper extremity vessels;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessels - left;DOP UE ves-L;;ACTIVE;2.15;2.61 +39434-6;Multisection;Find;Pt;Lower extremity>Lower extremity artery;Doc;US.doppler;RAD;2;US.doppler Lower extremity artery;DOP LE a;;ACTIVE;2.15;2.61 +39435-3;Multisection;Find;Pt;Abdomen>Renal artery;Doc;US.doppler;RAD;2;US.doppler Renal artery;DOP Renal a;;ACTIVE;2.15;2.73 +39436-1;Multisection limited;Find;Pt;Abdomen>Renal vessels;Doc;US.doppler;RAD;2;US.doppler Renal vessels limited;DOP Renal ves Ltd;;ACTIVE;2.15;2.61 +39437-9;Multisection;Find;Pt;Head+Neck>Carotid arteries.right;Doc;US.doppler;RAD;2;US.doppler Carotid arteries -right;DOP Carotid aa-R;;ACTIVE;2.15;2.61 +3943-8;Phenmetrazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenmetrazine [Mass/volume] in Serum or Plasma;Phenmetrazine SerPl-mCnc;;ACTIVE;1.0;2.73 +39438-7;Multisection;Find;Pt;Carotid artery.right;Nar;US.doppler;RAD;2;Deprecated Carotid artery Right US.doppler Multisection;Deprecated Carot a-R US.doppler;;DEPRECATED;2.15;2.46 +39439-5;Multisection;Find;Pt;Extremity.right>Extremity artery;Doc;US.doppler;RAD;2;US.doppler Extremity artery - right;DOP Extr a-R;;ACTIVE;2.15;2.61 +39440-3;Multisection;Find;Pt;Extremity.right>Extremity vein;Doc;US.doppler;RAD;2;US.doppler Extremity vein - right;DOP Extr v-R;;ACTIVE;2.15;2.73 +39441-1;Multisection limited;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessels - right limited;DOP LE ves-R Ltd;;ACTIVE;2.15;2.61 +39442-9;Multisection;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessels - right;DOP LE ves-R;;ACTIVE;2.15;2.61 +39443-7;Multisection;Find;Pt;Lower extremity.right>Lower extremity vein;Doc;US.doppler;RAD;2;US.doppler Lower extremity vein - right;DOP LE v-R;;ACTIVE;2.15;2.73 +39444-5;Multisection;Find;Pt;Upper extremity.right>Upper extremity vessels;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessels - right;DOP UE ves-R;;ACTIVE;2.15;2.61 +39445-2;Multisection;Find;Pt;XXX>Vessels;Doc;US.doppler;RAD;2;US.doppler Vessels;DOP Vesl;;ACTIVE;2.15;2.61 +3944-6;Phenmetrazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenmetrazine [Presence] in Urine;Phenmetrazine Ur Ql;;ACTIVE;1.0;2.73 +39446-0;Multisection;Find;Pt;Pelvis>Testicular vessels;Doc;US.doppler;RAD;2;US.doppler Testicular vessels;DOP Testicle ves;;ACTIVE;2.15;2.61 +39447-8;Multisection;Find;Pt;Upper extremity>Upper extremity artery;Doc;US.doppler;RAD;2;US.doppler Upper extremity artery;DOP UE a;;ACTIVE;2.15;2.61 +39448-6;Multisection;Find;Pt;Upper extremity>Upper extremity vessels;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessels;DOP UE ves;;ACTIVE;2.15;2.61 +39449-4;Multisection;Find;Pt;Extremity>Extremity vein;Doc;US.doppler;RAD;2;US.doppler Extremity vein;DOP Extr v;;ACTIVE;2.15;2.61 +39450-2;Multisection^W contrast PO;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;US;RAD;2;US Gastrointestinal tract W contrast PO;US GI tract W contr PO;;ACTIVE;2.15;2.61 +39451-0;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for drainage of abscess and placement of drainage catheter of Unspecified body region;US Guided Absc drain+cath place;;ACTIVE;2.15;2.66 +39452-8;Guidance for percutaneous aspiration of fluid;Find;Pt;Pelvis>Ovary;Doc;US;RAD;2;US Guidance for fluid aspiration of Ovary;US Guided Ovary PC fluid asp;;ACTIVE;2.15;2.64 +3945-3;Phenmetrazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenmetrazine [Mass/volume] in Urine;Phenmetrazine Ur-mCnc;;ACTIVE;1.0;2.73 +39453-6;Multisection;Find;Pt;XXX>Tendon;Doc;US;RAD;2;US Tendon;US Tendon;;ACTIVE;2.15;2.61 +39454-4;Multisection for transplanted liver;Find;Pt;Abdomen;Doc;US;RAD;2;US for transplanted liver;US for transplanted liver;;ACTIVE;2.15;2.58 +39455-1;9-Hydroxyrisperidone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;9-Hydroxyrisperidone [Moles/volume] in Serum or Plasma;9OH-risperidone SerPl-sCnc;;ACTIVE;2.15;2.70 +39456-9;Acetaminophen;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetaminophen [Moles/volume] in Urine;APAP Ur-sCnc;;ACTIVE;2.15;2.70 +39457-7;Beta aminobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta aminobutyrate [Moles/volume] in Serum or Plasma;B-Aminobutyr SerPl-sCnc;;ACTIVE;2.15;2.70 +39458-5;Beta-2-Microglobulin;SCnc;Pt;Body fld;Qn;;CHEM;1;Beta-2-Microglobulin [Moles/volume] in Body fluid;B2 Microglob Fld-sCnc;;ACTIVE;2.15;2.70 +39459-3;Bicarbonate^^standard;SCnc;Pt;BldCoV;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Venous cord blood;HCO3 std BldCoV-sCnc;;ACTIVE;2.15;2.70 +39460-1;Bicarbonate^^standard;SCnc;Pt;BldCoA;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Arterial cord blood;HCO3 std BldCoA-sCnc;;ACTIVE;2.15;2.70 +3946-1;Phenmetrazine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Phenmetrazine [Mass/time] in 24 hour Urine;Phenmetrazine 24h Ur-mRate;;ACTIVE;1.0;2.42 +39461-9;Bilirubin;SCnc;Pt;Periton fld;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Peritoneal fluid;Bilirub Prt-sCnc;;ACTIVE;2.15;2.70 +39462-7;Bilirubin.glucuronidated;SCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.conjugated [Moles/volume] in Body fluid;Bilirub Conj Fld-sCnc;;ACTIVE;2.15;2.70 +39463-5;Bilirubin.non-glucuronidated;SCnc;Pt;Body fld;Qn;;CHEM;1;Bilirubin.indirect [Moles/volume] in Body fluid;Bilirub Indirect Fld-sCnc;;ACTIVE;2.15;2.70 +39464-3;Carbon dioxide;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Peritoneal dialysis fluid;CO2 DiafP-sCnc;;ACTIVE;2.15;2.70 +39465-0;Carbon dioxide;SCnc;Pt;BldCoV;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Venous cord blood;CO2 BldCoV-sCnc;;ACTIVE;2.15;2.73 +39466-8;Carbon dioxide;SCnc;Pt;BldCoA;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Arterial cord blood;CO2 BldCoA-sCnc;;ACTIVE;2.15;2.73 +39467-6;Chloride;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Chloride [Moles/volume] in Peritoneal dialysis fluid;Chloride DiafP-sCnc;;ACTIVE;2.15;2.70 +39468-4;Cholesterol;SCnc;Pt;Plr fld;Qn;;CHEM;1;Cholesterol [Moles/volume] in Pleural fluid;Cholest Plr-sCnc;;ACTIVE;2.15;2.70 +39469-2;Cholesterol.in LDL;SCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Cholesterol in LDL [Moles/volume] in Serum or Plasma by calculation;LDLc SerPl Calc-sCnc;;ACTIVE;2.15;2.73 +394-7;Penicillin G;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Penicillin G [Susceptibility] by Serum bactericidal titer;Penicillin G Titr SBT;;ACTIVE;1.0;2.32 +39470-0;Prochlorperazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prochlorperazine [Moles/volume] in Serum or Plasma;Prochlorperazine SerPl-sCnc;;ACTIVE;2.15;2.70 +39471-8;Creatinine;SCnc;24H;Dial fld prt;Qn;;CHEM;1;Creatinine [Moles/volume] in 24 hour Peritoneal dialysis fluid;Creat 24h DiafP-sCnc;;ACTIVE;2.15;2.70 +39472-6;Creatinine;SCnc;24H;Dial fld;Qn;;CHEM;1;Creatinine [Moles/volume] in 24 hour Dialysis fluid;Creat 24h Dial fld-sCnc;;ACTIVE;2.15;2.70 +39473-4;Creatinine;SCnc;72H;Urine;Qn;;CHEM;1;Creatinine [Moles/volume] in 72 hour Urine;Creat 72h Ur-sCnc;;ACTIVE;2.15;2.70 +39474-2;Creatinine;SCnc;Pt;Periton fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Peritoneal fluid;Creat Prt-sCnc;;ACTIVE;2.15;2.70 +39475-9;dimenhyDRINATE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;dimenhyDRINATE [Moles/volume] in Serum or Plasma;dimenhyDRINATE SerPl-sCnc;;ACTIVE;2.15;2.70 +39476-7;diphenhydrAMINE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;diphenhydrAMINE [Moles/volume] in Serum or Plasma;Diphenhy SerPl-sCnc;;ACTIVE;2.15;2.70 +39477-5;fluPHENAZine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;fluPHENAZine [Moles/volume] in Serum or Plasma;fluPHENAZine SerPl-sCnc;;ACTIVE;2.15;2.70 +39478-3;Glucose;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Glucose [Moles/volume] in Vitreous fluid;Glucose Vitf-sCnc;;ACTIVE;2.15;2.70 +3947-9;PHENobarbital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;PHENobarbital [Presence] in Serum or Plasma;Phenobarb SerPl Ql;;ACTIVE;1.0;2.73 +39479-1;Glucose;SCnc;Pt;Pericard fld;Qn;;CHEM;1;Glucose [Moles/volume] in Pericardial fluid;Glucose Pcar-sCnc;;ACTIVE;2.15;2.70 +39480-9;Glucose;SCnc;Pt;BldV;Qn;;CHEM;1;Glucose [Moles/volume] in Venous blood;Glucose BldV-sCnc;;ACTIVE;2.15;2.73 +39481-7;Glucose;SCnc;Pt;BldA;Qn;;CHEM;1;Glucose [Moles/volume] in Arterial blood;Glucose BldA-sCnc;;ACTIVE;2.15;2.73 +39482-5;Trimeprazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimeprazine [Moles/volume] in Serum or Plasma;Trimeprazine SerPl-sCnc;;ACTIVE;2.15;2.70 +39483-3;Normethsuximide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normethsuximide [Moles/volume] in Serum or Plasma;Normethsuximide SerPl-sCnc;;ACTIVE;2.15;2.70 +39484-1;OLANZapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OLANZapine [Moles/volume] in Serum or Plasma;OLANZapine SerPl-sCnc;;ACTIVE;2.15;2.70 +39485-8;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldC;Qn;;CHEM;1;pH of Capillary blood adjusted to patient's actual temperature;pH temp adj BldC;;ACTIVE;2.15;2.73 +39486-6;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldV;Qn;;CHEM;1;pH of Venous blood adjusted to patient's actual temperature;pH temp adj BldV;;ACTIVE;2.15;2.73 +3948-7;PHENobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PHENobarbital [Mass/volume] in Serum or Plasma;Phenobarb SerPl-mCnc;;ACTIVE;1.0;2.73 +39487-4;PHENobarbital;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;PHENobarbital [Moles/volume] in Urine;Phenobarb Ur-sCnc;;ACTIVE;2.15;2.70 +39488-2;Phensuximide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phensuximide [Moles/volume] in Serum or Plasma;Phensuximide SerPl-sCnc;;ACTIVE;2.15;2.70 +39489-0;Views;Find;Pt;Chest>Ribs.lower.posterior;Doc;XR;RAD;2;XR Ribs lower posterior Views;XR Ribs lower post Views;;ACTIVE;2.15;2.64 +39490-8;Views for leg length;Find;Pt;Lower extremity.right>Femur+Tibia;Doc;XR;RAD;2;XR Femur and Tibia - right Views for leg length;XR Femur+Tib-R Views for leg length;;ACTIVE;2.15;2.64 +39491-6;Views;Find;Pt;Chest>Ribs.upper.anterior.right+Ribs.upper.posterior.right;Doc;XR;RAD;2;XR Ribs upper anterior and posterior - right Views;XR Ribs upper ant+post-R Views;;ACTIVE;2.15;2.64 +39492-4;Views;Find;Pt;Chest>Ribs.upper.posterior.right;Doc;XR;RAD;2;XR Ribs upper posterior - right Views;XR Ribs upper post-R Views;;ACTIVE;2.15;2.64 +39493-2;Views;Find;Pt;Chest>Ribs.lower.posterior.right;Doc;XR;RAD;2;XR Ribs lower posterior - right Views;XR Ribs lower post-R Views;;ACTIVE;2.15;2.64 +39494-0;Multisection;Find;Pt;Abdomen>Abdominal wall;Doc;US;RAD;2;US Abdominal wall;US Abd wall;;ACTIVE;2.15;2.73 +3949-5;PHENobarbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;PHENobarbital [Presence] in Urine;Phenobarb Ur Ql;;ACTIVE;1.0;2.73 +39495-7;Multisection;Find;Pt;Extremity.bilateral>Extremity vessels;Doc;US.doppler;RAD;2;US.doppler Extremity vessels - bilateral;DOP Extremity ves-Bl;;ACTIVE;2.15;2.61 +39496-5;Multisection;Find;Pt;Upper extremity.bilateral>Upper extremity vein;Doc;US.doppler;RAD;2;US.doppler Upper extremity vein - bilateral;DOP UE v-Bl;;ACTIVE;2.15;2.61 +39497-3;Multisection;Find;Pt;Abdomen+Pelvis>Iliac vessels;Doc;US.doppler;RAD;2;US.doppler Iliac vessels;DOP Iliac ves;;ACTIVE;2.15;2.61 +39498-1;Multisection;Find;Pt;Lower extremity.left>Femoral vessels;Doc;US.doppler;RAD;2;US.doppler Femoral vessels - left;DOP Fem ves-L;;ACTIVE;2.15;2.61 +39499-9;Multisection;Find;Pt;Lower extremity.left>Lower extremity artery;Doc;US.doppler;RAD;2;US.doppler Lower extremity artery - left;DOP LE a-L;;ACTIVE;2.15;2.61 +39500-4;Multisection;Find;Pt;Upper extremity.left>Upper extremity artery;Doc;US.doppler;RAD;2;US.doppler Upper extremity artery - left;DOP UE a-L;;ACTIVE;2.15;2.61 +39501-2;Multisection;Find;Pt;Upper extremity.left>Upper extremity vein;Doc;US.doppler;RAD;2;US.doppler Upper extremity vein - left;DOP UE v-L;;ACTIVE;2.15;2.61 +39502-0;Multisection;Find;Pt;Pelvis>Ovarian vessels;Doc;US.doppler;RAD;2;US.doppler Ovarian vessels;DOP Ovarian ves;;ACTIVE;2.15;2.61 +3950-3;PHENobarbital;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;PHENobarbital [Mass/volume] in Urine;Phenobarb Ur-mCnc;;ACTIVE;1.0;2.73 +39503-8;Multisection;Find;Pt;Extremity.right>Extremity vessels;Doc;US.doppler;RAD;2;US.doppler Extremity vessels - right;DOP Extremity ves-R;;ACTIVE;2.15;2.61 +39504-6;Multisection;Find;Pt;Lower extremity.right>Femoral vessels;Doc;US.doppler;RAD;2;US.doppler Femoral vessels - right;DOP Fem ves-R;;ACTIVE;2.15;2.61 +39505-3;Multisection;Find;Pt;Lower extremity.right>Lower extremity artery;Doc;US.doppler;RAD;2;US.doppler Lower extremity artery - right;DOP LE a-R;;ACTIVE;2.15;2.73 +39506-1;Multisection;Find;Pt;Upper extremity.right>Upper extremity artery;Doc;US.doppler;RAD;2;US.doppler Upper extremity artery - right;DOP UE a-R;;ACTIVE;2.15;2.61 +39507-9;Multisection;Find;Pt;Upper extremity.right>Upper extremity vein;Doc;US.doppler;RAD;2;US.doppler Upper extremity vein - right;DOP UE v-R;;ACTIVE;2.15;2.73 +39508-7;Multisection;Find;Pt;Umbilical vessels^Fetus;Doc;US.doppler;RAD;2;US.doppler Umbilical vessels Fetal;DOP Umb ves Fet;;ACTIVE;2.15;2.61 +39509-5;Multisection for transplanted pancreas;Find;Pt;Abdomen;Doc;US;RAD;2;US for transplanted pancreas;US for transplanted pancreas;;ACTIVE;2.15;2.58 +39510-3;Views^W contrast intra lymphatic;Find;Pt;Pelvis>Pelvic lymphatic vessels;Doc;RF.angio;RAD;2;RFA Pelvic lymphatic vessels Views W contrast intra lymphatic;RFA Pelvic lymph ves Views W contr IL;;ACTIVE;2.15;2.64 +3951-1;PHENobarbital.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PHENobarbital Free [Mass/volume] in Serum or Plasma;PHENobarb Free SerPl-mCnc;;ACTIVE;1.0;2.73 +39511-1;Views + oblique;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis Views and Oblique;XR Pelvis Views+Obl;;ACTIVE;2.15;2.64 +39512-9;Views AP + Danelius Miller;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right AP and Danelius Miller;XR Hip-R AP+Danelius Miller;;ACTIVE;2.15;2.61 +39513-7;Views + Danelius Miller;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Views and Danelius Miller;XR Hip-R Views+Danelius Miller;;ACTIVE;2.15;2.64 +39514-5;View Danelius Miller;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Danelius Miller;XR Hip-R Danelius Miller;;ACTIVE;2.15;2.61 +39515-2;Views lateral^W flexion + W extension;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Lateral Views W flexion and W extension;XR Wrist-R Views Lat W FE;;ACTIVE;2.15;2.64 +39516-0;View Stryker Notch;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Stryker Notch;XR Should Stryker Notch;;ACTIVE;2.15;2.61 +39517-8;Views Stryker Notch + West Point;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Stryker Notch and West Point;XR Should Stryker Notch+ West Point;;ACTIVE;2.15;2.61 +39518-6;Views survey limited;Find;Pt;XXX>Bones.long;Doc;XR;RAD;2;XR Long bones Limited Survey Views;XR Bones.long Survey Ltd;;ACTIVE;2.15;2.64 +39519-4;Views PA + R-lateral + L-lateral;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull PA and Right lateral and Left lateral;XR Skull PA+R-Lat+L-Lat;;ACTIVE;2.15;2.61 +39520-2;Views PA + R-lateral + L-lateral + Towne;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull PA and Right lateral and Left lateral and Towne;XR Skull PA+R-Lat+L-Lat+Towne;;ACTIVE;2.15;2.61 +39521-0;Views PA + R-lateral + L-lateral + Caldwell + Towne;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull PA and Right lateral and Left lateral and Caldwell and Towne;XR Skull PA+R-Lat+L-Lat+Caldwell+Towne;;ACTIVE;2.15;2.61 +39522-8;Guidance for percutaneous biopsy;Find;Pt;XXX>Lymph node;Doc;US;RAD;2;US guidance for percutaneous biopsy of Lymph node;US LN PC Bx;;ACTIVE;2.15;2.73 +39523-6;Multisection;Find;Pt;XXX>Artery;Doc;US.doppler;RAD;2;US.doppler Artery;DOP Artery;;ACTIVE;2.15;2.73 +39524-4;Multisection limited;Find;Pt;XXX>Vein;Doc;US.doppler;RAD;2;US.doppler Vein limited;DOP Vein Ltd;;ACTIVE;2.15;2.61 +39525-1;Multisection;Find;Pt;XXX>Vein;Doc;US.doppler;RAD;2;US.doppler Vein;DOP Vein;;ACTIVE;2.15;2.73 +39526-9;Multisection limited;Find;Pt;Extremity;Doc;US;RAD;2;US Extremity limited;US Extr Ltd;;ACTIVE;2.15;2.61 +39527-7;Multisection for foreign body;Find;Pt;XXX;Doc;US;RAD;2;US Unspecified body region for foreign body;US for FB;;ACTIVE;2.15;2.64 +39528-5;Adenovirus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Specimen by NAA with probe detection;HAdV DNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +3952-9;Phenothiazines;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Phenothiazines [Presence] in Serum or Plasma;Phenothiaz SerPl Ql;;ACTIVE;1.0;2.56 +39529-3;Acetone;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Acetone [Presence] in Blood;Acetone Bld Ql;;ACTIVE;2.15;2.73 +39530-1;Isopropanol;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Isopropanol [Presence] in Blood;Isopropanol Bld Ql;;ACTIVE;2.15;2.56 +39531-9;Acetaldehyde;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Acetaldehyde [Presence] in Blood;Acetaldehyde Bld Ql;;ACTIVE;2.15;2.56 +39532-7;Inhibin B;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Inhibin B [Presence] in Serum or Plasma;Inhibin B SerPl Ql;;ACTIVE;2.15;2.73 +39533-5;Deoxyhemoglobin;MCnc;Pt;Bld;Qn;;HEM/BC;1;Deoxyhemoglobin [Mass/volume] in Blood;DO-Hgb Bld-mCnc;;ACTIVE;2.15;2.73 +39534-3;Cryptosporidium sp Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Cryptosporidium sp Ag [Presence] in Stool by Immunofluorescence;Cryptosp Ag Stl Ql IF;;ACTIVE;2.15;2.73 +39535-0;Hepatitis B virus surface Ab;PrThr;Pt;Ser;Ord;RIA;MICRO;1;Hepatitis B virus surface Ab [Presence] in Serum by Radioimmunoassay (RIA);HBV surface Ab Ser Ql RIA;;ACTIVE;2.15;2.56 +39536-8;Influenza virus A Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus A Ab [Units/volume] in Serum by Complement fixation;FLUAV Ab Ser CF-aCnc;;ACTIVE;2.15;2.69 +3953-7;Phenothiazines;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenothiazines [Presence] in Urine;Phenothiaz Ur Ql;;ACTIVE;1.0;2.73 +39537-6;Influenza virus B Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus B Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUBV Ab Ser HAI-aCnc;;ACTIVE;2.15;2.69 +39538-4;Finch droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Finch droppings IgG Ab [Presence] in Serum;Finch Drop IgG Ql;;ACTIVE;2.15;2.56 +39539-2;Cockatiel droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cockatiel droppings IgG Ab [Presence] in Serum;Cockatiel Drop IgG Ql;;ACTIVE;2.15;2.56 +395-4;Penicillin V;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Penicillin V [Susceptibility] by Minimum lethal concentration (MLC);Penicillin V Islt MLC;;ACTIVE;1.0;2.73 +39540-0;Uranium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Uranium/Creatinine [Mass Ratio] in Urine;Uranium/Creat Ur;;ACTIVE;2.15;2.42 +39541-8;Legionella sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Legionella sp Ag [Presence] in Specimen by Immunofluorescence;Legionella Ag Spec Ql IF;;ACTIVE;2.15;2.73 +39542-6;Prunus dulcis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Almond IgE Ab/IgE total in Serum;Almond IgE/IgE total %;;ACTIVE;2.15;2.65 +39543-4;Corylus avellana Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Hazelnut IgE Ab/IgE total in Serum;Hazelnut IgE/IgE total %;;ACTIVE;2.15;2.73 +39544-2;Dolichovespula arenaria Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Yellow Hornet IgE Ab/IgE total in Serum;Yellow Hornet IgE/IgE total %;;ACTIVE;2.15;2.70 +3954-5;Phenothiazines;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenothiazines [Mass/volume] in Urine;Phenothiaz Ur-mCnc;;ACTIVE;1.0;2.73 +39545-9;Cancer pagurus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Crab IgE Ab/IgE total in Serum;Crab IgE/IgE total %;;ACTIVE;2.15;2.70 +39546-7;Homarus gammarus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lobster IgE Ab/IgE total in Serum;Lobster IgE/IgE total %;;ACTIVE;2.15;2.70 +39547-5;Thunnus albacares Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Tuna IgE Ab/IgE total in Serum;Tuna IgE/IgE total %;;ACTIVE;2.15;2.70 +39548-3;Salmo salar Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Salmon IgE Ab/IgE total in Serum;Salmon IgE/IgE total %;;ACTIVE;2.15;2.70 +39549-1;Helix aspersa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Escargot IgE Ab/IgE total in Serum;Escargot IgE/IgE total %;;ACTIVE;2.15;2.70 +39550-9;Horse dander Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Horse dander IgE Ab/IgE total in Serum;Horse Dander IgE/IgE total %;;ACTIVE;2.15;2.70 +39551-7;Cow dander Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cow dander IgE Ab/IgE total in Serum;Cow Dander IgE/IgE total %;;ACTIVE;2.15;2.70 +3955-2;Phensuximide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phensuximide [Mass/volume] in Serum or Plasma;Phensuximide SerPl-mCnc;;ACTIVE;1.0;2.73 +39552-5;Lamb Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lamb IgE Ab/IgE total in Serum;Lamb IgE/IgE total %;;ACTIVE;2.15;2.70 +39553-3;Penicillin V Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Penicillin V IgE Ab/IgE total in Serum;Penicillin V IgE/IgE total %;;ACTIVE;2.15;2.70 +39554-1;Endomysium Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Endomysium IgG Ab [Presence] in Serum;Endomysium IgG Ser Ql;;ACTIVE;2.15;2.73 +39555-8;West Nile virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;West Nile virus Ab [Units/volume] in Serum;WNV Ab Ser-aCnc;;ACTIVE;2.15;2.69 +39556-6;Coagulation factor X inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor X inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact X Inhib PPP Ql;;ACTIVE;2.15;2.56 +39557-4;Neisseria gonorrhoeae rRNA;ACnc;Pt;Cvx;Ord;Probe;MICRO;1;Deprecated Neisseria gonorrhoeae rRNA [Presence] in Cervix by DNA probe;Deprecated N gonorrhoea rRNA Cervix Ql P;;DEPRECATED;2.15;2.36 +39558-2;West Nile virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;West Nile virus Ab [Presence] in Cerebral spinal fluid;WNV Ab CSF Ql;;ACTIVE;2.15;2.73 +39559-0;Legionella sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella sp IgM Ab [Titer] in Serum;Legionella IgM Titr Ser;;ACTIVE;2.15;2.30 +3956-0;Phentermine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phentermine [Mass/volume] in Blood;Phentermine Bld-mCnc;;ACTIVE;1.0;2.73 +39560-8;Sulfate.inorganic;SRat;24H;Ser/Plas;Qn;;CHEM;1;Deprecated Sulfate.inorganic [Moles/time] in 24 hour Serum or Plasma;Deprecated Inorg Sulfate 24H SerPl-sRate;;DEPRECATED;2.15;2.70 +39561-6;Glucose^1st specimen post dose lactose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1st specimen post dose lactose;Glucose sp1 p Lac SerPl-mCnc;;ACTIVE;2.15;2.73 +39562-4;Glucose^2nd specimen post dose lactose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2nd specimen post dose lactose;Glucose sp2 p Lac SerPl-mCnc;;ACTIVE;2.15;2.73 +39563-2;Glucose^3rd specimen post dose lactose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3rd specimen post dose lactose;Glucose sp3 p Lac SerPl-mCnc;;ACTIVE;2.15;2.73 +39564-0;Corticotropin^1st specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1st specimen post XXX challenge;ACTH sp1 p chal Plas-mCnc;;ACTIVE;2.15;2.73 +39565-7;Complement C4d;MCnc;Pt;Plas;Qn;IA;HEM/BC;1;Complement C4d [Mass/volume] in Plasma by Immunoassay;C4d Plas IA-mCnc;;ACTIVE;2.15;2.56 +39566-5;Pregnanetriol/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Pregnanetriol/Creatinine [Mass Ratio] in 24 hour Urine;Pregntrl/Creat 24h Ur;;ACTIVE;2.15;2.73 +39567-3;TOLAZamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;TOLAZamide [Mass/volume] in 24 hour Urine;TOLAZamide 24h Ur-mCnc;;ACTIVE;2.15;2.42 +39568-1;TOLBUTamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;TOLBUTamide [Mass/volume] in 24 hour Urine;TOLBUTamide 24h Ur-mCnc;;ACTIVE;2.15;2.42 +39569-9;Trichoderma viride Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Trichoderma viride Ab [Mass/volume] in Serum;T viride Ab Ser-mCnc;;ACTIVE;2.15;2.73 +39570-7;Alternaria sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria sp IgG Ab [Mass/volume] in Serum;Alternaria IgG-mCnc;;ACTIVE;2.15;2.40 +39571-5;Herpes simplex virus 1+2 Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Titer] in Cerebral spinal fluid;HSV1+2 IgM Titr CSF;;ACTIVE;2.15;2.30 +39572-3;West Nile virus Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;West Nile virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;WNV IgG CSF IA-aCnc;;ACTIVE;2.15;2.73 +39573-1;West Nile virus Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;West Nile virus IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;WNV IgM CSF IA-aCnc;;ACTIVE;2.15;2.73 +39574-9;Hexacarboxylporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/time] in 24 hour Stool;Hexa-CP 24h Stl-mRate;;ACTIVE;2.15;2.42 +39575-6;Fungus.microscopic observation;Prid;Pt;XXX;Nom;Periodic acid-Schiff stain;PATH;1;Fungus.microscopic observation [Identifier] in Specimen by Periodic acid-Schiff stain;Fungus Spec PAS Stn;;ACTIVE;2.15;2.73 +39576-4;Sulfate;MRat;24H;Urine;Qn;;CHEM;1;Sulfate [Mass/time] in 24 hour Urine;Sulfate 24h Ur-mRate;;ACTIVE;2.15;2.44 +39577-2;Leishmania sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania sp IgM Ab [Titer] in Serum;Leishmania IgM Titr Ser;;ACTIVE;2.15;2.30 +3957-8;Phentermine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phentermine [Presence] in Urine;Phentermine Ur Ql;;ACTIVE;1.0;2.73 +39578-0;Alternaria alternata Ab;MCnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata Ab [Mass/volume] in Serum;A alternata Ab-mCnc;;ACTIVE;2.15;2.70 +39579-8;Penicillium notatum Ab;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium notatum Ab [Mass/volume] in Serum;P notatum Ab-mCnc;;ACTIVE;2.15;2.40 +39580-6;Phoma herbarum Ab;MCnc;Pt;Ser;Qn;;ALLERGY;1;Phoma herbarum Ab [Mass/volume] in Serum;P herbarum Ab-mCnc;;ACTIVE;2.15;2.70 +39581-4;Rubella virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Rubella virus Ab [Presence] in Cerebral spinal fluid;RUBV Ab CSF Ql;;ACTIVE;2.15;2.56 +39582-2;Amino beta guanidinopropionate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Amino beta guanidinopropionate/Creatinine [Molar ratio] in 24 hour Urine;AB-Gp/Creat 24h Ur-sRto;;ACTIVE;2.15;2.70 +39583-0;Mercury;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Mercury [Presence] in Hair;Mercury Hair Ql;;ACTIVE;2.15;2.56 +39584-8;Mercury;PrThr;Pt;Nail;Ord;;DRUG/TOX;1;Mercury [Presence] in Nail;Mercury Nail Ql;;ACTIVE;2.15;2.56 +39585-5;Tritium;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Tritium [Presence] in 24 hour Urine;Tritium 24h Ur Ql;;ACTIVE;2.15;2.56 +3958-6;Phentermine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phentermine [Mass/volume] in Urine;Phentermine Ur-mCnc;;ACTIVE;1.0;2.73 +39586-3;Disialylganglioside GD1b Ab;Titr;Pt;Ser;Qn;;SERO;1;Deprecated Disialylganglioside GD1b Ab [Titer] in Serum;Deprecated GD1b Disialyl Ab Titr Ser;;DEPRECATED;2.15;2.36 +39587-1;Neutrophil Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Neutrophil Ab [Presence] in Serum by Immunoassay;Neutrophil Ab Ser Ql IA;;ACTIVE;2.15;2.56 +39588-9;Histoplasma capsulatum Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Histoplasma capsulatum IgG Ab [Presence] in Serum by Immunoassay;H capsul IgG Ser Ql IA;;ACTIVE;2.15;2.56 +39589-7;HTLV I p19 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HTLV I p19 Ab [Units/volume] in Serum;HTLV I p19 Ab Ser-aCnc;;ACTIVE;2.15;2.69 +39590-5;HTLV I+II p19 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;HTLV I+II p19 Ab [Units/volume] in Serum;HTLV I+II p19 Ab Ser-aCnc;;ACTIVE;2.15;2.69 +39591-3;PARoxetine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;PARoxetine [Mass/volume] in Urine;PARoxetine Ur-mCnc;;ACTIVE;2.15;2.73 +39592-1;Bertholletia excelsa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Brazil Nut IgE Ab/IgE total in Serum;Brazil Nut IgE/IgE total %;;ACTIVE;2.15;2.65 +39593-9;Cocos nucifera Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Coconut IgE Ab/IgE total in Serum;Coconut IgE/IgE total %;;ACTIVE;2.15;2.65 +3959-4;Phentermine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Phentermine [Mass/time] in 24 hour Urine;Phentermine 24h Ur-mRate;;ACTIVE;1.0;2.42 +39594-7;Carya illinoinensis nut Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Nut IgE Ab/IgE total in Serum;Pecan/Hick Nut IgE/IgE total %;;ACTIVE;2.15;2.70 +39595-4;Hippoglossus hippoglossus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Halibut IgE Ab/IgE total in Serum;Halibut IgE/IgE total %;;ACTIVE;2.15;2.70 +39596-2;Mytilus edulis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Blue mussel IgE Ab/IgE total in Serum;Blue mussel IgE/IgE total %;;ACTIVE;2.15;2.70 +39597-0;Cucurbita pepo Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pumpkin IgE Ab/IgE total in Serum;Pumpkin IgE/IgE total %;;ACTIVE;2.15;2.70 +39598-8;Curvularia lunata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Curvularia lunata IgE Ab/IgE total in Serum;C lunata IgE/IgE total %;;ACTIVE;2.15;2.73 +39599-6;Epicoccum purpurascens Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Epicoccum purpurascens IgE Ab/IgE total in Serum;E purpurascens IgE/IgE total %;;ACTIVE;2.15;2.65 +39600-2;Fusarium moniliforme Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Fusarium moniliforme IgE Ab/IgE total in Serum;F moniliforme IgE/IgE total %;;ACTIVE;2.15;2.73 +39601-0;Stemphylium botryosum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Stemphylium botryosum IgE Ab/IgE total in Serum;S botryosum IgE/IgE total %;;ACTIVE;2.15;2.73 +3960-2;Phenylbutazone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenylbutazone [Mass/volume] in Serum or Plasma;Phenylbutazone SerPl-mCnc;;ACTIVE;1.0;2.73 +39602-8;Hamster epithelium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Hamster epithelium IgE Ab/IgE total in Serum;Hmtr Epith IgE/IgE total %;;ACTIVE;2.15;2.70 +39603-6;Guinea pig epithelium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Guinea pig epithelium IgE Ab/IgE total in Serum;Guinea Pig Epith IgE/IgE total %;;ACTIVE;2.15;2.70 +39604-4;Artemisia vulgaris Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Mugwort IgE Ab/IgE total in Serum;Mugwort IgE/IgE total %;;ACTIVE;2.15;2.70 +39605-1;Goose feather Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Goose feather IgE Ab/IgE total in Serum;Goose Feather IgE/IgE total %;;ACTIVE;2.15;2.73 +39606-9;Rabbit epithelium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Rabbit epithelium IgE Ab/IgE total in Serum;Rabbit Epith IgE/IgE total %;;ACTIVE;2.15;2.73 +39607-7;Spermatozoa.motile;Naric;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Spermatozoa Motile [#/area] in Semen by Microscopy high power field;Sperm Motile #/area Smn HPF;;ACTIVE;2.15;2.73 +39608-5;Spermatozoa.immotile;Naric;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Spermatozoa Immotile [#/area] in Semen by Microscopy high power field;Sperm Immotile #/area Smn HPF;;ACTIVE;2.15;2.73 +39609-3;Vaccinium myrtillus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Blueberry IgE Ab/IgE total in Serum;Blueberry IgE/IgE total %;;ACTIVE;2.15;2.73 +3961-0;Phenylbutazone;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Phenylbutazone [Mass/volume] in Serum or Plasma;Deprecated Phenylbutazone Ser-mCnc;;DEPRECATED;1.0;2.36 +39610-1;Neisseria meningitidis serogroup w135 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup w135 Ab [Mass/volume] in Serum;N men sg W135 Ab Ser-mCnc;;ACTIVE;2.15;2.73 +39611-9;Silicone Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Silicone IgG Ab [Units/volume] in Serum by Immunoassay;Silicone IgG Ser IA-aCnc;;ACTIVE;2.15;2.69 +39612-7;Silicone Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Silicone IgA Ab [Units/volume] in Serum by Immunoassay;Silicone IgA Ser IA-aCnc;;ACTIVE;2.15;2.69 +39613-5;Silicone Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Silicone IgM Ab [Units/volume] in Serum by Immunoassay;Silicone IgM Ser IA-aCnc;;ACTIVE;2.15;2.69 +39614-3;Silicone Ab.IgE;ACnc;Pt;Ser;Qn;IA;SERO;1;Silicone IgE Ab [Units/volume] in Serum by Immunoassay;Silicone IgE Ser IA-aCnc;;ACTIVE;2.15;2.56 +39615-0;Benzoylcarnitine (BzCn);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Benzoylcarnitine (BzCn) [Moles/volume] in Serum or Plasma;Benzoylcarn SerPl-sCnc;;ACTIVE;2.15;2.73 +39616-8;Palmitoylcarnitine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Palmitoylcarnitine (C16) [Molecules/volume] in Serum or Plasma;Deprecated Palmitoylcarn SerPl-sCnc;;DEPRECATED;2.15;2.70 +39617-6;3-Hydroxypalmitoylcarnitine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated 3-Hydroxypalmitoylcarnitine (C16-OH) [Molecules/volume] in Serum or Plasma;Deprecated 3OH-Palmitoylcarn SerPl-sCnc;;DEPRECATED;2.15;2.70 +39618-4;Neisseria meningitidis serogroup Y Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup Y Ab [Mass/volume] in Serum;N men sg Y Ab Ser-mCnc;;ACTIVE;2.15;2.73 +39619-2;Views^W radionuclide IV;Find;Pt;Chest>Pulmonary system;Doc;NM;RAD;2;NM Pulmonary system Views;NM Pulm system Views W RNC IV;;ACTIVE;2.15;2.64 +396-2;Penicillin V;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Penicillin V [Susceptibility] by Minimum inhibitory concentration (MIC);Penicillin V Islt MIC;;ACTIVE;1.0;2.73 +39620-0;Guidance limited for localization of abscess^W radionuclide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Guidance for abscess localization limited of Unspecified body region;NM Guided Abscess loc Ltd--W RNC IV;;ACTIVE;2.15;2.64 +39621-8;Guidance for localization of abscess^W radionuclide IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Guidance for abscess localization of Unspecified body region;SPECT Guided Absc loc--W RNC IV;;ACTIVE;2.15;2.64 +39622-6;Guidance for localization of abscess^W radionuclide IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Guidance for abscess localization of Whole body;SPECT Guided WB Absc loc--W RNC IV;;ACTIVE;2.15;2.64 +39623-4;Guidance for localization of abscess^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Guidance for abscess localization of Whole body;NM Guided Whole body Absc loc--W RNC IV;;ACTIVE;2.15;2.64 +39624-2;Views^W I-131 NP59 IV;Find;Pt;Abdomen>Adrenal gland;Doc;NM;RAD;2;NM Adrenal gland Views W I-131 NP59 IV;NM Adrenal Views W I-131 NP59 IV;;ACTIVE;2.15;2.64 +39625-9;Views^W Tc-99m DTPA IA;Find;Pt;XXX>Artery;Doc;NM;RAD;2;NM Artery Views W Tc-99m DTPA IA;NM Artery Views W Tc99mDTPA IA;;ACTIVE;2.15;2.64 +39626-7;Views^W radionuclide IV;Find;Pt;XXX>Vein.bilateral;Doc;NM;RAD;2;NM Vein - bilateral Views;NM Vein-Bl Views W RNC IV;;ACTIVE;2.15;2.64 +39627-5;Views limited^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Limited Views;NM Bone Views Ltd W RNC IV;;ACTIVE;2.15;2.64 +3962-8;Phenylephrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenylephrine [Mass/volume] in Urine;Phenylephrine Ur-mCnc;;ACTIVE;1.0;2.42 +39628-3;Multisection for Meckel's diverticulum^W radionuclide IV;Find;Pt;Abdomen>Small bowel;Doc;NM.SPECT;RAD;2;SPECT Small bowel for Meckel's diverticulum;SPECT Small bowel Meckel's div W RNC IV;;ACTIVE;2.15;2.61 +39629-1;Views for Meckel's diverticulum^W radionuclide IV;Find;Pt;Abdomen>Small bowel;Doc;NM;RAD;2;NM Small bowel Views for Meckel's diverticulum;NM SB Views for Meckel's div W RNC IV;;ACTIVE;2.15;2.64 +39630-9;Views^W Tc-99m HMPAO IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views W Tc-99m HMPAO IV;NM Brain Views W Tc99mHMPAO IV;;ACTIVE;2.15;2.64 +39631-7;Multisection^W Tc-99m HMPAO IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W Tc-99m HMPAO IV;SPECT Brain W Tc99mHMPAO IV;;ACTIVE;2.15;2.61 +39632-5;Multisection^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain;SPECT Brain W RNC IV;;ACTIVE;2.15;2.61 +39633-3;Views static^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;Deprecated NM Brain Static Views;Deprecated NM Brain Static W RNC IV;;DEPRECATED;2.15;2.64 +39634-1;Views limited^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Limited Views;NM Brain Views Ltd W RNC IV;;ACTIVE;2.15;2.64 +39635-8;Views^W Tl-201 IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views W Tl-201 IV;NM Brain Views W Tl-201 IV;;ACTIVE;2.15;2.64 +3963-6;Phenylpropanolamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Phenylpropanolamine [Presence] in Serum or Plasma;PPA SerPl Ql;;ACTIVE;1.0;2.56 +39636-6;Views for blood flow^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views for blood flow;NM Brain Vs bld flow W RNC IV;;ACTIVE;2.15;2.64 +39637-4;Multisection for blood flow^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain for blood flow;SPECT Brain bld flow W RNC IV;;ACTIVE;2.15;2.61 +39638-2;Multisection^W I-123 IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W I-123 IV;SPECT Brain W I-123 IV;;ACTIVE;2.15;2.61 +39639-0;Multisection^W Tl-201 IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W Tl-201 IV;SPECT Brain W Tl-201 IV;;ACTIVE;2.15;2.61 +39640-8;Multisection^W Tc-99m DTPA IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W Tc-99m DTPA IV;SPECT Brain W Tc99mDTPA IV;;ACTIVE;2.15;2.61 +39641-6;Multisection^W Tc-99m glucoheptonate IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W Tc-99m glucoheptonate IV;SPECT Brain W Tc99mGHA IV;;ACTIVE;2.15;2.61 +39642-4;Views^W Tc-99m glucoheptonate IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views W Tc-99m glucoheptonate IV;NM Brain Views W Tc99mGHA IV;;ACTIVE;2.15;2.64 +39643-2;Views^W radionuclide IV;Find;Pt;Head>Brain veins;Doc;NM;RAD;2;NM Brain veins Views;NM Brain vv Views W RNC IV;;ACTIVE;2.15;2.64 +3964-4;Phenylpropanolamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenylpropanolamine [Mass/volume] in Serum or Plasma;PPA SerPl-mCnc;;ACTIVE;1.0;2.73 +39644-0;Multisection^W radionuclide IV;Find;Pt;Breast;Doc;NM.SPECT;RAD;2;SPECT Breast;SPECT Brst W RNC IV;;ACTIVE;2.15;2.61 +39645-7;Views limited^W radionuclide IV;Find;Pt;Breast;Doc;NM;RAD;2;NM Breast Limited Views;NM Brst Views Ltd W RNC IV;;ACTIVE;2.15;2.64 +39646-5;Views^W radionuclide IV;Find;Pt;Breast;Doc;NM;RAD;2;NM Breast Views;NM Brst Views W RNC IV;;ACTIVE;2.15;2.64 +39647-3;Multisection^W Tc-99m Tetrofosmin IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart W Tc-99m Tetrofosmin IV;SPECT Hrt W Tc99mTF IV;;ACTIVE;2.15;2.61 +39648-1;Multisection^W dipyridamole IV+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart W dipyridamole IV;SPECT Hrt W DPY+RNC IV;;ACTIVE;2.15;2.64 +39649-9;Multisection^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart;SPECT Hrt W RNC IV;;ACTIVE;2.15;2.73 +39650-7;Views^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views;NM Hrt Views W RNC IV;;ACTIVE;2.15;2.64 +3965-1;Phenylpropanolamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Phenylpropanolamine [Presence] in Urine;PPA Ur Ql;;ACTIVE;1.0;2.73 +39651-5;Views^W adenosine+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W adenosine and W Tl-201 IV;NM Hrt Views W ADE+Tl-201 IV;;ACTIVE;2.15;2.64 +39652-3;Views^W DOBUTamine+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W dobutamine and W Tl-201 IV;NM Hrt Views W DBM+Tl-201 IV;;ACTIVE;2.15;2.64 +39653-1;Views for infarct^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for infarct;NM Hrt Vs infarct W RNC IV;;ACTIVE;2.15;2.64 +39654-9;Multisection for infarct^W Tc-99m PYP IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart for infarct W Tc-99m PYP IV;SPECT Hrt for Infarct W Tc99mPyp IV;;ACTIVE;2.15;2.61 +39655-6;Multisection for infarct^W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart for infarct W Tc-99m Sestamibi IV;SPECT Hrt for Infarct W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39656-4;Multisection for infarct^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart for infarct;SPECT Hrt for Infarct W RNC IV;;ACTIVE;2.15;2.61 +39657-2;Views for infarct^W Tc-99m PYP IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for infarct W Tc-99m PYP IV;NM Hrt Vs infarct W Tc99mPyp IV;;ACTIVE;2.15;2.64 +39658-0;Multisection^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart at rest and W radionuclide IV;SPECT Hrt Rest+W RNC IV;;ACTIVE;2.15;2.61 +39659-8;Views^at rest & W 201 TI IV;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scintigraphy at rest & W Tl-201 IV;Deprecated Hrt RI;;DEPRECATED;2.15;2.36 +39660-6;Views^at rest+W dipyridamole IV+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views at rest and W dipyridamole and W radionuclide IV;NM Hrt Views Rest+W DPY+RNC IV;;ACTIVE;2.15;2.64 +39661-4;Views^at rest+W DOBUTamine+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views at rest and W dobutamine and W radionuclide IV;NM Hrt Views Rest+W DBM+RNC IV;;ACTIVE;2.15;2.64 +39662-2;Multisection^at rest+W stress+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart at rest and W stress and W Tc-99m Sestamibi IV;SPECT Hrt Rest+stress+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39663-0;Views^at rest+W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views at rest and W stress and W radionuclide IV;NM Hrt Views Rest+stress+W RNC IV;;ACTIVE;2.15;2.64 +39664-8;Views for shunt detection^W Tc-99m MAA IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for shunt detection W Tc-99m MAA IV;NM Hrt Vs for shunt det W Tc99mMAA IV;;ACTIVE;2.15;2.64 +39665-5;Views for shunt detection^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for shunt detection;NM Hrt Vs for shunt det W RNC IV;;ACTIVE;2.15;2.64 +39666-3;Views^W stress+W 201 TH IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W stress and W 201 Th IV;NM Hrt Views W Stress+W 201 TH IV;;ACTIVE;2.15;2.64 +39667-1;Views^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W stress and W radionuclide IV;NM Hrt Views W Stress+W RNC IV;;ACTIVE;2.15;2.64 +39668-9;Multisection^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart W stress and W radionuclide IV;SPECT Hrt W Stress+W RNC IV;;ACTIVE;2.15;2.61 +3966-9;Phenylpropanolamine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Phenylpropanolamine [Mass/time] in 24 hour Urine;PPA 24h Ur-mRate;;ACTIVE;1.0;2.42 +39669-7;Views^W Tc-99m Arcitumomab IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W Tc-99m Arcitumomab IV;NM Whole body Views W Tc99mCEA IV;;ACTIVE;2.15;2.64 +39670-5;Views^W radionuclide intra lacrimal duct;Find;Pt;Head>Lacrimal duct;Doc;NM;RAD;2;NM Lacrimal duct Views W radionuclide intra lacrimal duct;NM Lacrimal duct Views W RNC intra LD;;ACTIVE;2.15;2.64 +39671-3;Views^W radionuclide PO;Find;Pt;Pelvis>Rectum;Doc;NM;RAD;2;NM Rectum Views W radionuclide PO;NM Rectum Views W RNC PO;;ACTIVE;2.15;2.64 +39672-1;Views for motility^W radionuclide PO;Find;Pt;Chest>Esophagus;Doc;NM;RAD;2;NM Esophagus Views for motility W radionuclide PO;NM Esophagus Views for motility W RNC PO;;ACTIVE;2.15;2.64 +39673-9;Views for reflux^W radionuclide PO;Find;Pt;Chest>Esophagus;Doc;NM;RAD;2;NM Esophagus Views for reflux W radionuclide PO;NM Esophagus Views for reflux W RNC PO;;ACTIVE;2.15;2.64 +39674-7;Views^W Tc-99m DISIDA IV;Find;Pt;Abdomen>Gallbladder;Doc;NM;RAD;2;NM Gallbladder Views W Tc-99m DISIDA IV;NM GB Views W Tc99mDISIDA IV;;ACTIVE;2.15;2.64 +39675-4;Multisection for infection^W Ga-67 IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body for infection W Ga-67 IV;SPECT Whole body for Inf W Ga-67 IV;;ACTIVE;2.15;2.64 +39676-2;Views static for infection^W Ga-67 IV;Find;Pt;^Patient;Doc;NM;RAD;2;Deprecated NM Static Views for infection W Ga-67 IV;Deprecated NM Static for Inf W Ga-67 IV;;DEPRECATED;2.15;2.64 +3967-7;Phenytoin;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Phenytoin [Presence] in Serum or Plasma;Phenytoin SerPl Ql;;ACTIVE;1.0;2.73 +39677-0;Views for infection^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for infection W Ga-67 IV;NM Views for infect W Ga-67 IV;;ACTIVE;2.15;2.64 +39678-8;Multisection for tumor^W Ga-67 IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body for tumor W Ga-67 IV;SPECT Whole body for Tumor W Ga-67 IV;;ACTIVE;2.15;2.64 +39679-6;Views for tumor^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for tumor W Ga-67 IV;NM Views for tumor W Ga-67 IV;;ACTIVE;2.15;2.64 +39680-4;Multisection^W Ga-67 IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body W Ga-67 IV;SPECT Whole body W Ga-67 IV;;ACTIVE;2.15;2.61 +39681-2;Multisection limited^W Ga-67 IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Unspecified body region limited W Ga-67 IV;SPECT Ltd W Ga-67 IV;;ACTIVE;2.15;2.64 +39682-0;Multisection^W Ga-67 IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Unspecified body region W Ga-67 IV;SPECT W Ga-67 IV;;ACTIVE;2.15;2.64 +39683-8;Views^W Ga-67 IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W Ga-67 IV;NM Whole body Views W Ga-67 IV;;ACTIVE;2.15;2.64 +39684-6;Multisection for abscess^W Ga-67 IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Unspecified body region for abscess W Ga-67 IV;SPECT for Abscess W Ga-67 IV;;ACTIVE;2.15;2.64 +3968-5;Phenytoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin [Mass/volume] in Serum or Plasma;Phenytoin SerPl-mCnc;;ACTIVE;1.0;2.73 +39685-3;Views for abscess^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for abscess W Ga-67 IV;NM Views for Abscess W Ga-67 IV;;ACTIVE;2.15;2.64 +39686-1;Views for lymphoma^W Ga-67 IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for lymphoma W Ga-67 IV;NM WB Views for lymphoma W Ga-67 IV;;ACTIVE;2.15;2.64 +39687-9;Views limited^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Limited Views W Ga-67 IV;NM Views Ltd W Ga-67 IV;;ACTIVE;2.15;2.64 +39688-7;Views^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views W Ga-67 IV;NM Views W Ga-67 IV;;ACTIVE;2.15;2.64 +39689-5;Views^W Tc-99m SC IV;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;NM;RAD;2;NM Gastrointestinal tract Views W Tc-99m SC IV;NM GI tract Views W Tc99mSC IV;;ACTIVE;2.15;2.64 +39690-3;Views^W Tc-99m tagged RBC IV;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views W Tc-99m tagged RBC IV;NM Liver Views W Tc99m RBC IV;;ACTIVE;2.15;2.64 +39691-1;Multisection^W Tc-99m tagged RBC IV;Find;Pt;Abdomen>Liver;Doc;NM.SPECT;RAD;2;SPECT Liver W Tc-99m tagged RBC IV;SPECT Liver W Tc99m RBC IV;;ACTIVE;2.15;2.63 +39692-9;Multisection^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM.SPECT;RAD;2;SPECT Liver;SPECT Liver W RNC IV;;ACTIVE;2.15;2.73 +3969-3;Phenytoin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin Free [Mass/volume] in Serum or Plasma;Phenytoin Free SerPl-mCnc;;ACTIVE;1.0;2.73 +39693-7;Views^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views;NM Liver Views W RNC IV;;ACTIVE;2.15;2.64 +39694-5;Views for transplanted liver^W radionuclide IV;Find;Pt;Abdomen;Doc;NM;RAD;2;NM Views for transplanted liver;NM Views for trans liver W RNC IV;;ACTIVE;2.15;2.64 +39695-2;Views limited^W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Limited Views;NM Lung Views Ltd W RNC IV;;ACTIVE;2.15;2.64 +39696-0;Views^W depreotide+W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Views W depreotide IV;NM Lung Views W Depreotide+RNC IV;;ACTIVE;2.15;2.64 +39697-8;Views perfusion^W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Perfusion;NM Lung PF W RNC IV;;ACTIVE;2.15;2.61 +39698-6;Views^W I-131 MIBG IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W I-131 MIBG IV;NM Whole body Views W I-131 mIBG IV;;ACTIVE;2.15;2.64 +39699-4;Views perfusion^at rest+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W Tc-99m Sestamibi IV;NM Hrt PF Rest+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +397-0;Penicillin V;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Penicillin V [Susceptibility] by Disk diffusion (KB);Penicillin V Islt KB;;ACTIVE;1.0;2.21 +39700-0;Multisection perfusion^W adenosine+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion W adenosine and W radionuclide IV;SPECT Hrt PF W ADE+RNC IV;;ACTIVE;2.15;2.61 +3970-1;Pholedrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pholedrine [Mass/volume] in Urine;Pholedrine Ur-mCnc;;ACTIVE;1.0;2.42 +39701-8;Views perfusion^W adenosine+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W adenosine and W radionuclide IV;NM Hrt PF W ADE+RNC IV;;ACTIVE;2.15;2.61 +39702-6;Views perfusion^W DOBUTamine+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W dobutamine and W Tc-99m Sestamibi IV;NM Hrt PF W DBM+Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39703-4;Views perfusion^W DOBUTamine+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W dobutamine IV;NM Hrt PF W DBM+RNC IV;;ACTIVE;2.15;2.61 +39704-2;Views perfusion^W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W Tc-99m Sestamibi IV;NM Hrt PF W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39705-9;Views perfusion^W dipyridamole IV+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W dipyridamole and W Tc-99m Sestamibi IV;NM Hrt PF W DIPY+Tc99mMIBI IV;;ACTIVE;2.15;2.64 +39706-7;Views perfusion^W dipyridamole & W 99m Tc mibi IV;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scintigraphy perfusion W dipyridamole & W Tc-99m Sestamibi IV;Deprecated Hrt RI PF;;DEPRECATED;2.15;2.36 +39707-5;Views perfusion^W dipyridamole IV+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W dipyridamole and W Tl-201 IV;NM Hrt PF W DPY+Tl-201 IV;;ACTIVE;2.15;2.64 +39708-3;Views perfusion^W dipyridamole IV+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W dipyridamole IV;NM Hrt PF W DPY+RNC IV;;ACTIVE;2.15;2.64 +39709-1;Views perfusion^W dipyridamole IV+W Tc-99m IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W dipyridamole and W Tc-99m IV;NM Hrt PF W DIPY+Tc99mIV;;ACTIVE;2.15;2.64 +39710-9;Multisection perfusion^W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion W Tc-99m Sestamibi IV;SPECT Hrt PF W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39711-7;Multisection perfusion^W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion W Tl-201 IV;SPECT Hrt PF W Tl-201 IV;;ACTIVE;2.15;2.61 +39712-5;Multisection perfusion^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion;SPECT Hrt PF W RNC IV;;ACTIVE;2.15;2.61 +39713-3;Views perfusion^W Tl-201 IV+W Tc-99m Tetrofosmin IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W Tl-201 IV and W Tc-99m Tetrofosmin IV;NM Hrt PF W Tl-201 IV+Tc99mTF IV;;ACTIVE;2.15;2.61 +39714-1;Views perfusion^W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W Tl-201 IV;NM Hrt PF W Tl-201 IV;;ACTIVE;2.15;2.61 +39715-8;Views perfusion^W stress+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W stress and W Tl-201 IV;NM Hrt PF W Stress+W Tl-201 IV;;ACTIVE;2.15;2.61 +39716-6;Views perfusion^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion;NM Hrt PF W RNC IV;;ACTIVE;2.15;2.61 +39717-4;Views perfusion^at rest & W 99m Tc mibi IV;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scintigraphy perfusion at rest & W Tc-99m Sestamibi IV;Deprecated Hrt RI PF;;DEPRECATED;2.15;2.36 +39718-2;Multisection perfusion^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion at rest and W radionuclide IV;SPECT Hrt PF Rest+W RNC IV;;ACTIVE;2.15;2.61 +3971-9;Pindolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pindolol [Mass/volume] in Serum or Plasma;Pindolol SerPl-mCnc;;ACTIVE;1.0;2.42 +39719-0;Views perfusion^at rest+W adenosine+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W adenosine and W radionuclide IV;NM Hrt PF Rest+W ADE+RNC IV;;ACTIVE;2.15;2.61 +39720-8;Views perfusion^at rest+W dipyridamole IV+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W dipyridamole and W Tc-99m Sestamibi IV;NM Hrt PF Rest+W DPY+Tc99mMIBI IV;;ACTIVE;2.15;2.64 +39721-6;Views perfusion^at rest & W stress & W 99m Tc Sestamibi IV;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scintigraphy perfusion at rest & W stress & W Tc-99m Sestamibi IV;Deprecated Hrt RI PF;;DEPRECATED;2.15;2.36 +39722-4;Views perfusion^at rest+W dipyridamole IV+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W dipyridamole and W radionuclide IV;NM Hrt PF Rest+W DPY+RNC IV;;ACTIVE;2.15;2.64 +39723-2;Multisection perfusion^at rest+W stress+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion at rest and W stress and W Tl-201 IV;SPECT Hrt PF Rest+stress+W Tl201 IV;;ACTIVE;2.15;2.61 +39724-0;Multisection perfusion^at rest+W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion at rest and W stress and W radionuclide IV;SPECT Hrt PF Rest+stress+W RNC IV;;ACTIVE;2.15;2.61 +39725-7;Multisection perfusion^at rest+W adenosine+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion at rest and W adenosine and W Tl-201 IV;SPECT Hrt PF Rest+W ADE+Tl201 IV;;ACTIVE;2.15;2.61 +39726-5;Views perfusion^at rest+W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W stress and W radionuclide IV;NM Hrt PF Rest+stress+W RNC IV;;ACTIVE;2.15;2.61 +3972-7;Piperacillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Piperacillin [Mass/volume] in Serum or Plasma;Piperacillin SerPl-mCnc;;ACTIVE;1.0;2.40 +39727-3;Views perfusion^at rest+W stress+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W stress and W Tc-99m Sestamibi IV;NM Hrt PF Rest+stress+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39728-1;Views perfusion^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W radionuclide IV;NM Hrt PF Rest+W RNC IV;;ACTIVE;2.15;2.61 +39729-9;Multisection perfusion^at rest+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion at rest and W Tl-201 IV;SPECT Hrt PF Rest+W Tl201 IV;;ACTIVE;2.15;2.61 +39730-7;Views perfusion^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W stress and W radionuclide IV;NM Hrt PF W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39731-5;Views perfusion^W adenosine+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W adenosine and W Tc-99m Sestamibi IV;NM Hrt PF W ADE+Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39732-3;Views perfusion^W stress+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W stress and W Tc-99m Sestamibi IV;NM Hrt PF W Stress+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39733-1;Views perfusion^W DOBUTamine+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W dobutamine and W Tl-201 IV;NM Hrt PF W DBM+Tl-201 IV;;ACTIVE;2.15;2.61 +39734-9;Multisection perfusion^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion W stress and W radionuclide IV;SPECT Hrt PF W Stress+W RNC IV;;ACTIVE;2.15;2.61 +3973-5;Pipradrol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pipradrol [Presence] in Urine;Pipradrol Ur Ql;;ACTIVE;1.0;2.56 +39735-6;Views perfusion^W adenosine+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W adenosine and W Tl-201 IV;NM Hrt PF W ADE+Tl-201 IV;;ACTIVE;2.15;2.61 +39736-4;Multisection perfusion^W stress+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion W stress and W Tc-99m Sestamibi IV;SPECT Hrt PF W Stress+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39737-2;Views^W radionuclide IV;Find;Pt;Neck;Doc;NM;RAD;2;NM Neck Views;NM Neck Views W RNC IV;;ACTIVE;2.15;2.64 +39738-0;Views^W In-111 Satumomab IV;Find;Pt;Abdomen;Doc;NM;RAD;2;NM Abdomen Views W In-111 Satumomab IV;NM Abd Views W In-111 Satmb IV;;ACTIVE;2.15;2.64 +39739-8;Views^W radionuclide IV;Find;Pt;Abdomen>Pancreas;Doc;NM;RAD;2;NM Pancreas Views;NM Pancreas Views W RNC IV;;ACTIVE;2.15;2.64 +39740-6;Multisection^W radionuclide IV;Find;Pt;Neck>Parathyroid gland;Doc;NM.SPECT;RAD;2;SPECT Parathyroid gland;SPECT Parathyroid gland W RNC IV;;ACTIVE;2.15;2.61 +39741-4;Views delayed^W radionuclide IV;Find;Pt;Neck>Parathyroid gland;Doc;NM;RAD;2;NM Parathyroid gland Delayed Views;NM Parathyroid gland delayed W RNC IV;;ACTIVE;2.15;2.64 +39742-2;Views^W radionuclide IV;Find;Pt;Neck>Parathyroid gland;Doc;NM;RAD;2;NM Parathyroid gland Views;NM Parathyroid gland Views W RNC IV;;ACTIVE;2.15;2.64 +3974-3;Pipradrol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pipradrol [Mass/volume] in Urine;Pipradrol Ur-mCnc;;ACTIVE;1.0;2.42 +39743-0;Multisection^W Tc-99m capromab pendatide IV;Find;Pt;Pelvis>Prostate;Doc;NM.SPECT;RAD;2;SPECT Prostate W Tc-99m capromab pendatide IV;SPECT Prostate W Tc99mPMSA IV;;ACTIVE;2.15;2.61 +39744-8;Views^W Tc-99m capromab pendatide IV;Find;Pt;Pelvis>Prostate;Doc;NM;RAD;2;NM Prostate Views W Tc-99m capromab pendatide IV;NM Prostate Views W Tc99mPMSA IV;;ACTIVE;2.15;2.64 +39745-5;Views^W Tc-99m DTPA IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views W Tc-99m DTPA IV;NM Kidney Views W Tc99mDTPA IV;;ACTIVE;2.15;2.64 +39746-3;Views^W Tc-99m Mertiatide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views W Tc-99m Mertiatide IV;NM Kidney Views W Tc99mMAG3 IV;;ACTIVE;2.15;2.64 +39747-1;Views^W radionuclide IV;Find;Pt;Head>Salivary gland;Doc;NM;RAD;2;NM Salivary gland Views;NM Salivary gland Views W RNC IV;;ACTIVE;2.15;2.64 +39748-9;Multisection for tumor^W Tc-99m Sestamibi IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body for tumor W Tc-99m Sestamibi IV;SPECT WB for Tumor W Tc99mMIBI IV;;ACTIVE;2.15;2.64 +39749-7;Views for tumor^W Tc-99m Sestamibi IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for tumor W Tc-99m Sestamibi IV;NM Whole body Vs tumor W Tc99mMIBI IV;;ACTIVE;2.15;2.64 +3975-0;Pipradrol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Pipradrol [Mass/time] in 24 hour Urine;Pipradrol 24h Ur-mRate;;ACTIVE;1.0;2.42 +39750-5;Views for tumor^W Tc-99m Sestamibi IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for tumor W Tc-99m Sestamibi IV;NM Views for tumor W Tc99mMIBI IV;;ACTIVE;2.15;2.64 +39751-3;Views^W radionuclide IV;Find;Pt;Abdomen>Spleen;Doc;NM;RAD;2;NM Spleen Views;NM Spleen Views W RNC IV;;ACTIVE;2.15;2.64 +39752-1;Views^W radionuclide tagged heat damaged RBC IV;Find;Pt;Abdomen>Spleen;Doc;NM;RAD;2;NM Spleen Views W radionuclide tagged heat damaged RBC IV;NM Spleen Vs W RNC Heat Damaged RBC IV;;ACTIVE;2.15;2.64 +39753-9;Views^W Tc-99m DTPA IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;NM;RAD;2;NM Scrotum and testicle Views W Tc-99m DTPA IV;NM Scrotum+Test Views W Tc99mDTPA IV;;ACTIVE;2.15;2.64 +39754-7;Views limited^W I-131 IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Limited Views W I-131 IV;NM Thyroid Views Ltd W I-131 IV;;ACTIVE;2.15;2.64 +39755-4;Multisection^W I-131 IV;Find;Pt;Neck>Thyroid gland;Doc;NM.SPECT;RAD;2;SPECT Thyroid gland W I-131 IV;SPECT Thyroid W I-131 IV;;ACTIVE;2.15;2.61 +39756-2;Views^W Tc-99m Sestamibi IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views W Tc-99m Sestamibi IV;NM Thyroid Views W Tc99mMIBI IV;;ACTIVE;2.15;2.64 +39757-0;Views^W Tc-99m IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views W Tc-99m IV;NM Thyroid Views W Tc99mIV;;ACTIVE;2.15;2.64 +39758-8;Guidance for localization of tumor^W radionuclide IV;Find;Pt;Breast;Doc;NM;RAD;2;NM Guidance for localization of tumor of Breast;NM Guided Brst Tum loc--W RNC IV;;ACTIVE;2.15;2.64 +39759-6;Guidance limited for localization of tumor^W radionuclide IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Guidance limited for localization of tumor;SPECT Guided Tum loc Ltd--W RNC IV;;ACTIVE;2.15;2.64 +39760-4;Guidance limited for localization of tumor^W radionuclide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Guidance limited for localization of tumor;NM Guided Tum loc Ltd--W RNC IV;;ACTIVE;2.15;2.64 +39761-2;Guidance limited for localization of tumor^W Tc-99m Sestamibi IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Guidance limited for localization of tumor-- W Tc-99m Sestamibi IV;NM Guide Tum loc Ltd--W Tc99mMIBI IV;;ACTIVE;2.15;2.64 +39762-0;Guidance for localization of tumor^W radionuclide IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Guidance for localization of tumor of Whole body;SPECT Guided WB Tum loc--W RNC IV;;ACTIVE;2.15;2.64 +39763-8;Guidance for localization of tumor^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Guidance for localization of tumor of Whole body;NM Guided Whole body Tum loc--W RNC IV;;ACTIVE;2.15;2.64 +39764-6;Views^W Tc-99m SC IV;Find;Pt;XXX>Vein;Doc;NM;RAD;2;NM Vein Views W Tc-99m SC IV;NM Vein Views W Tc99mSC IV;;ACTIVE;2.15;2.64 +39765-3;Views^W Tc-99m DTPA IV;Find;Pt;XXX>Vein;Doc;NM;RAD;2;NM Vein Views W Tc-99m DTPA IV;NM Vein Views W Tc99mDTPA IV;;ACTIVE;2.15;2.64 +39766-1;Views^W Tc-99m HDP IV;Find;Pt;XXX>Vein;Doc;NM;RAD;2;NM Vein Views W Tc-99m HDP IV;NM Vein Views W Tc99mHDP IV;;ACTIVE;2.15;2.64 +39767-9;Views for gastric emptying liquid phase^W radionuclide PO;Find;Pt;Abdomen>Stomach;Doc;NM;RAD;2;NM Stomach Views for gastric emptying liquid phase W radionuclide PO;NM Stom Views for LPGE W RNC PO;;ACTIVE;2.15;2.64 +3976-8;Practolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Practolol [Mass/volume] in Urine;Practolol Ur-mCnc;;ACTIVE;1.0;2.42 +39768-7;Views for gastric emptying ^W Tc-99m SC PO;Find;Pt;Abdomen>Stomach;Doc;NM;RAD;2;NM Stomach Views for gastric emptying W Tc-99m SC PO;NM Stom Views for GE W Tc99mSC PO;;ACTIVE;2.15;2.64 +39769-5;Views for gastric emptying^W radionuclide PO;Find;Pt;Abdomen>Stomach;Doc;NM;RAD;2;NM Stomach Views for gastric emptying W radionuclide PO;NM Stom Views for GE W RNC PO;;ACTIVE;2.15;2.73 +39770-3;Multisection^W radionuclide IV;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;NM.SPECT;RAD;2;SPECT Gastrointestinal tract;SPECT GI tract W RNC IV;;ACTIVE;2.15;2.61 +39771-1;Porphyrins;SCnc;Pt;Urine;Qn;;CHEM;1;Porphyrins [Moles/volume] in Urine;Porphyrins Ur-sCnc;;ACTIVE;2.15;2.70 +39772-9;Sulfamethoxazole;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfamethoxazole [Moles/volume] in Serum or Plasma;Sulfamethoxazole SerPl-sCnc;;ACTIVE;2.15;2.70 +39773-7;Beta-2-Microglobulin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Beta-2-Microglobulin/Creatinine [Molar ratio] in Urine;B2 Microglob/Creat Ur-sRto;;ACTIVE;2.15;2.70 +39774-5;Porphyrins;SCnt;Pt;Stool;Qn;;CHEM;1;Porphyrins [Moles/mass] in Stool;Porphyrins Stl-sCnt;;ACTIVE;2.15;2.73 +39775-2;Protoporphyrin.free;SCnc;Pt;RBC;Qn;;CHEM;1;Protoporphyrin Free [Moles/volume] in Red Blood Cells;FEP RBC-sCnc;;ACTIVE;2.15;2.73 +3977-6;Prazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prazepam [Mass/volume] in Serum or Plasma;Prazepam SerPl-mCnc;;ACTIVE;1.0;2.73 +39776-0;Urea^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea [Moles/volume] in Serum or Plasma --post dialysis;Urea p dialysis SerPl-sCnc;;ACTIVE;2.15;2.70 +39777-8;Urea^pre dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea [Moles/volume] in Serum or Plasma --pre dialysis;Urea pre dial SerPl-sCnc;;ACTIVE;2.15;2.70 +39778-6;Iron/Iron binding capacity.total;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Iron/Iron binding capacity.total [Molar ratio] in Serum or Plasma;Iron/TIBC SerPl-sRto;;DISCOURAGED;2.15;2.73 +39779-4;Urea;SCnc;24H;Dial fld;Qn;;CHEM;1;Urea [Moles/volume] in 24 hour Dialysis fluid;Urea 24h Dial fld-sCnc;;ACTIVE;2.15;2.70 +39780-2;Urea;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea [Moles/volume] in Peritoneal dialysis fluid;Urea DiafP-sCnc;;ACTIVE;2.15;2.70 +39781-0;Urea;SCnc;Pt;Periton fld;Qn;;CHEM;1;Urea [Moles/volume] in Peritoneal fluid;Urea Prt-sCnc;;ACTIVE;2.15;2.70 +39782-8;Delta aminolevulinate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Delta aminolevulinate/Creatinine [Molar ratio] in Urine;D-ALA/Creat Ur-sRto;;ACTIVE;2.15;2.70 +39783-6;Urea/Creatinine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Urea/Creatinine [Molar ratio] in Serum or Plasma;Urea/Creat SerPl-sRto;;ACTIVE;2.15;2.73 +3978-4;Primidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Primidone [Mass/volume] in Serum or Plasma;Primidone SerPl-mCnc;;ACTIVE;1.0;2.73 +39784-4;Porphyrins;SCnc;Pt;RBC;Qn;;CHEM;1;Porphyrins [Moles/volume] in Red Blood Cells;Porphyrins RBC-sCnc;;ACTIVE;2.15;2.70 +39785-1;Potassium;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Potassium [Moles/volume] in Peritoneal dialysis fluid;Potassium DiafP-sCnc;;ACTIVE;2.15;2.70 +39786-9;Pyridoxine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyridoxine [Moles/volume] in Serum or Plasma;Vit B6 SerPl-sCnc;;ACTIVE;2.15;2.73 +39787-7;Sodium;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Sodium [Moles/volume] in Peritoneal dialysis fluid;Sodium DiafP-sCnc;;ACTIVE;2.15;2.70 +39788-5;Urate;SCnc;Pt;Synv fld;Qn;;CHEM;1;Urate [Moles/volume] in Synovial fluid;Urate Snv-sCnc;;ACTIVE;2.15;2.73 +39789-3;Potassium;SCnc;Pt;BldV;Qn;;CHEM;1;Potassium [Moles/volume] in Venous blood;Potassium BldV-sCnc;;ACTIVE;2.15;2.73 +39790-1;Potassium;SCnc;Pt;BldC;Qn;;CHEM;1;Potassium [Moles/volume] in Capillary blood;Potassium BldC-sCnc;;ACTIVE;2.15;2.73 +39791-9;Sodium;SCnc;Pt;BldV;Qn;;CHEM;1;Sodium [Moles/volume] in Venous blood;Sodium BldV-sCnc;;ACTIVE;2.15;2.73 +3979-2;Probenecid;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Probenecid [Presence] in Urine;Probenecid Ur Ql;;ACTIVE;1.0;2.73 +39792-7;Sodium;SCnc;Pt;BldC;Qn;;CHEM;1;Sodium [Moles/volume] in Capillary blood;Sodium BldC-sCnc;;ACTIVE;2.15;2.73 +39793-5;Coproporphyrin 3/Coproporphyrin 1;SRto;24H;Urine;Qn;;CHEM;1;Coproporphyrin 3/Coproporphyrin 1 [Molar ratio] in 24 hour Urine;Copro3/Copro1 24h Ur-sRto;;ACTIVE;2.15;2.70 +39794-3;Tocainide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tocainide [Moles/volume] in Serum or Plasma;Tocainide SerPl-sCnc;;ACTIVE;2.15;2.70 +39795-0;Trifluoperazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trifluoperazine [Moles/volume] in Serum or Plasma;TriFperazine SerPl-sCnc;;ACTIVE;2.15;2.70 +39796-8;Vancomycin^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Moles/volume] in Serum or Plasma --peak;Vancomycin Peak SerPl-sCnc;;ACTIVE;2.15;2.73 +39797-6;Vancomycin^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Moles/volume] in Serum or Plasma --trough;Vancomycin Trough SerPl-sCnc;;ACTIVE;2.15;2.73 +39798-4;Warfarin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Warfarin [Moles/volume] in Serum or Plasma;Warfarin SerPl-sCnc;;ACTIVE;2.15;2.70 +39799-2;risperiDONE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;risperiDONE [Moles/volume] in Serum or Plasma;risperiDONE SerPl-sCnc;;ACTIVE;2.15;2.70 +39-8;Azlocillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Azlocillin [Susceptibility] by Minimum lethal concentration (MLC);Azlocillin Islt MLC;;ACTIVE;1.0;2.19 +3980-0;Probenecid;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Probenecid [Mass/volume] in Urine;Probenecid Ur-mCnc;;ACTIVE;1.0;2.42 +39800-8;Risperidone+9-Hydroxyrisperidone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;risperiDONE+9-Hydroxyrisperidone [Moles/volume] in Serum or Plasma;risperiDONE+9OH-Ris SerPl-sCnc;;ACTIVE;2.15;2.70 +39801-6;Triglyceride;SCnc;Pt;Plr fld;Qn;;CHEM;1;Triglyceride [Moles/volume] in Pleural fluid;Trigl Plr-sCnc;;ACTIVE;2.15;2.70 +39802-4;Creatinine dial fld/Creatinine ser_plas;RelRto;Pt;Dial fld+Ser/Plas;Qn;;CHEM;1;Creatinine in dialysis fluid/Creatinine in serum or plasma;Creat diaf/SerPl;;ACTIVE;2.15;2.70 +39803-2;inFLIXimab;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;inFLIXimab [Mass/volume] in Serum or Plasma;inFLIXimab SerPl-mCnc;;ACTIVE;2.15;2.73 +39804-0;Lipoprotein associated phospholipase A2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein associated phospholipase A2 [Mass/volume] in Serum or Plasma;Lp-PLA2 SerPl-mCnc;;ACTIVE;2.15;2.73 +39805-7;Rabbit hair Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit hair IgE Ab [Units/volume] in Serum;Rabbit Hair IgE Qn;;ACTIVE;2.15;2.73 +39806-5;Stage.summary at Dx 2000 revised;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Summary stage at Dx 2000 revised Cancer;SS at Dx 2000 revised Cancer;;ACTIVE;2.15;2.32 +39807-3;Surgery site.98-02;Anat;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery site.98-02 Cancer;Surgery site.98-02 Cancer;;ACTIVE;2.15;2.27 +39808-1;Date 1st most definitive surgery Rx for;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st most definitive surgery treatment for Cancer;Date 1st most defn srg Cancer;;ACTIVE;2.15;2.32 +39809-9;Date 1st systemic treatment;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date 1st systemic treatment Cancer;Date 1st systemic Cancer;;ACTIVE;2.15;2.27 +39810-7;RuralUrban continuum 1993;Arb;Pt;^Patient;Ord;;TUMRRGT;2;RuralUrban continuum 1993;RuralUrban continuum 1993;;ACTIVE;2.15;2.27 +39811-5;Multisection for abscess^W radionuclide IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Unspecified body region for abscess;SPECT for Abscess W RNC IV;;ACTIVE;2.15;2.64 +39812-3;Views^W Tc-99m HMPAO IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Views W Tc-99m HMPAO IV;NM Bone Views W Tc99mHMPAO IV;;ACTIVE;2.15;2.64 +39813-1;Multisection limited^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM.SPECT;RAD;2;SPECT Bone limited;SPECT Bone Ltd W RNC IV;;ACTIVE;2.15;2.61 +39814-9;Views static limited ^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;Deprecated NM Bone Limited Static Views;Deprecated NM Bone Static Ltd W RNC IV;;DEPRECATED;2.15;2.64 +39815-6;Views static^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;Deprecated NM Bone Static Views;Deprecated NM Bone Static W RNC IV;;DEPRECATED;2.15;2.64 +39816-4;Multisection^W radionuclide IV;Find;Pt;Whole body>Bone;Doc;NM.SPECT;RAD;2;SPECT Whole body Bone;SPECT WB Bone W RNC IV;;ACTIVE;2.15;2.61 +39817-2;Views static^W radionuclide IV;Find;Pt;Whole body>Bone;Doc;NM;RAD;2;Deprecated NM Whole body Bone Static Views;Deprecated NM WB Bone Static W RNC IV;;DEPRECATED;2.15;2.64 +3981-8;Probenecid;MRat;24H;Urine;Qn;;DRUG/TOX;1;Probenecid [Mass/time] in 24 hour Urine;Probenecid 24h Ur-mRate;;ACTIVE;1.0;2.42 +39818-0;Views^W radionuclide IV;Find;Pt;Whole body>Bone;Doc;NM;RAD;2;NM Whole body Bone Views;NM WB Bone Views W RNC IV;;ACTIVE;2.15;2.64 +39819-8;Views delayed^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Delayed Views;NM Bone delayed W RNC IV;;ACTIVE;2.15;2.64 +39820-6;Views^W Sm-153 IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Views W Sm-153 IV;NM Bone Views W Sm-153 IV;;ACTIVE;2.15;2.64 +39821-4;Multisection limited^W radionuclide IV;Find;Pt;XXX>Bone marrow;Doc;NM.SPECT;RAD;2;SPECT Bone marrow limited;SPECT Bone mar Ltd W RNC IV;;ACTIVE;2.15;2.61 +39822-2;Views limited^W radionuclide IV;Find;Pt;XXX>Bone marrow;Doc;NM;RAD;2;NM Bone marrow Limited Views;NM Bone mar Views Ltd W RNC IV;;ACTIVE;2.15;2.64 +39823-0;Multisection^W radionuclide IV;Find;Pt;XXX>Bone marrow;Doc;NM.SPECT;RAD;2;SPECT Bone marrow;SPECT Bone mar W RNC IV;;ACTIVE;2.15;2.61 +39824-8;Views^W radionuclide IV;Find;Pt;XXX>Bone marrow;Doc;NM;RAD;2;NM Bone marrow Views;NM Bone mar Views W RNC IV;;ACTIVE;2.15;2.64 +39825-5;Multisection^W radionuclide IV;Find;Pt;Whole body>Bone marrow;Doc;NM.SPECT;RAD;2;SPECT Whole body Bone marrow;SPECT WB Bone mar W RNC IV;;ACTIVE;2.15;2.61 +3982-6;Procainamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procainamide [Mass/volume] in Serum or Plasma;Procainamide SerPl-mCnc;;ACTIVE;1.0;2.73 +39826-3;Views^W radionuclide IV;Find;Pt;Whole body>Bone marrow;Doc;NM;RAD;2;NM Whole body Bone marrow Views;NM WB Bone mar Views W RNC IV;;ACTIVE;2.15;2.64 +39827-1;Views for endocrine tumor^W I-131 MIBG IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for endocrine tumor W I-131 MIBG IV;NM WB Vs Endo tum W I-131 MIBG IV;;ACTIVE;2.15;2.64 +39828-9;Views for endocrine tumor^W In-111 pentetreotide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for endocrine tumor W In-111 pentetreotide IV;NM Whole body Vs Endo tum W In-111-P IV;;ACTIVE;2.15;2.64 +39829-7;Views for tumor^W Ga-67 IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for tumor W Ga-67 IV;NM Whole body Views for tumor W Ga-67 IV;;ACTIVE;2.15;2.64 +39830-5;Views for infection^W Ga-67 IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for infection W Ga-67 IV;NM Whole body Vs for infect W Ga-67 IV;;ACTIVE;2.15;2.64 +39831-3;Views limited for tumor^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Limited Views for tumor W Ga-67 IV;NM Vs for tumor Ltd W Ga-67 IV;;ACTIVE;2.15;2.64 +39832-1;Views static^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;Deprecated NM Liver Static Views;Deprecated NM Liver Static W RNC IV;;DEPRECATED;2.15;2.64 +39833-9;Views perfusion^W radionuclide gaseous IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;Deprecated Lung NM perfusion W radionuclide gaseous IH;Deprecated Lung NM PF W RNC Gas IH;;DEPRECATED;2.15;2.58 +3983-4;Procainamide+N-acetylprocainamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procainamide+N-acetylprocainamide [Mass/volume] in Serum or Plasma;Procainamide+NAPA SerPl-mCnc;;ACTIVE;1.0;2.73 +39834-7;Views ventilation^W Tc-99m DTPA aerosol IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Ventilation W Tc-99m DTPA aerosol IH;NM Lung V W Tc99mDTPA AeroIH;;ACTIVE;2.15;2.73 +39835-4;Views ventilation^W radionuclide aerosol IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;Deprecated Lung NM ventilation W radionuclide aerosol IH;Deprecated Lung NM V W RNC Aero IH;;DEPRECATED;2.15;2.58 +39836-2;Views ventilation^W radionuclide gaseous IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;Deprecated Lung NM ventilation W radionuclide gaseous IH;Deprecated Lung NM V W RNC Gas IH;;DEPRECATED;2.15;2.58 +39837-0;Views ventilation^W radionuclide IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Ventilation;NM Lung V W RNC IH;;ACTIVE;2.15;2.61 +39838-8;Multisection ventilation+perfusion^W radionuclide IH+W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM.SPECT;RAD;2;SPECT Lung ventilation and perfusion;SPECT Lung VP W RNC IH+IV;;ACTIVE;2.15;2.61 +39839-6;Multisection^W I-131 MIBG IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body W I-131 MIBG IV;SPECT Whole body W I-131 mIBG IV;;ACTIVE;2.15;2.64 +39840-4;Views delayed^W I-131 MIBG IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Delayed Views W I-131 MIBG IV;NM Whole body delayed W I-131 mIBG IV;;ACTIVE;2.15;2.64 +39841-2;Views^W I-131 MIBG IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views W I-131 MIBG IV;NM Views W I-131 mIBG IV;;ACTIVE;2.15;2.64 +3984-2;Prolintane;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Prolintane [Presence] in Urine;Prolintane Ur Ql;;ACTIVE;1.0;2.56 +39842-0;Views delayed^W In-111 Satumomab IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Delayed Views W In-111 Satumomab IV;NM Whole body delayed W In-111 Satmb IV;;ACTIVE;2.15;2.64 +39843-8;Views limited^W In-111 Satumomab IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Limited Views W In-111 Satumomab IV;NM Views Ltd W In-111 Satmb IV;;ACTIVE;2.15;2.64 +39844-6;Multisection^W In-111 Satumomab IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body W In-111 Satumomab IV;SPECT Whole body W In-111 Satmb IV;;ACTIVE;2.15;2.64 +39845-3;Views^W In-111 Satumomab IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W In-111 Satumomab IV;NM Whole body Views W In-111 Satmb IV;;ACTIVE;2.15;2.64 +39846-1;Views^W In-111 Satumomab IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views W In-111 Satumomab IV;NM Views W In-111 Satmb IV;;ACTIVE;2.15;2.64 +39847-9;Views for blood flow^W radionuclide IV;Find;Pt;Neck>Parotid gland;Doc;NM;RAD;2;NM Parotid gland Views for blood flow;NM Parotid gland Vs bld flow W RNC IV;;ACTIVE;2.15;2.64 +39848-7;Views for shunt patency^W In-111 IT;Find;Pt;Head+Neck+Chest+Abdomen+Pelvis;Doc;NM;RAD;2;NM Head to Pelvis Views for shunt patency W In-111 IT;NM Head Pelvis Vs shunt pat W In-111 IT;;ACTIVE;2.15;2.64 +39849-5;Views for shunt patency^W radionuclide IT;Find;Pt;Head+Neck+Chest+Abdomen+Pelvis;Doc;NM;RAD;2;NM Head to Pelvis Views for shunt patency W radionuclide IT;NM Head Pelvis Vs shunt pat W contr IT;;ACTIVE;2.15;2.64 +39850-3;Views^W I-131 IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;NM;RAD;2;NM Kidney - bilateral Views W I-131 IV;NM Kdny-Bl Views W I-131 IV;;ACTIVE;2.15;2.64 +39851-1;Multisection^W Tc-99m Mertiatide IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;NM.SPECT;RAD;2;SPECT Kidney - bilateral W Tc-99m Mertiatide IV;SPECT Kdny-Bl W Tc99mMAG3 IV;;ACTIVE;2.15;2.61 +39852-9;Multisection^W radionuclide IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;NM.SPECT;RAD;2;SPECT Kidney - bilateral;SPECT Kdny-Bl W RNC IV;;ACTIVE;2.15;2.61 +39853-7;Views static^W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;Deprecated NM Kidney Static Views;Deprecated NM Kidney Static W RNC IV;;DEPRECATED;2.15;2.64 +39854-5;Views static^W Tc-99m DMSA IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;Deprecated NM Kidney Static Views W Tc-99m DMSA IV;Deprecated NM Kidney Static W Tc99mDMCA IV;;DEPRECATED;2.15;2.64 +39855-2;Views static^W radionuclide IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;NM;RAD;2;Deprecated NM Scrotum and testicle Static Views;Deprecated NM Scrotum+Test Static W RNC IV;;DEPRECATED;2.15;2.64 +39856-0;Views for blood flow^W radionuclide IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views for blood flow;NM Thyroid Vs bld flow W RNC IV;;ACTIVE;2.15;2.64 +39857-8;Views^W I-131 MIBG IV;Find;Pt;Abdomen>Adrenal gland;Doc;NM;RAD;2;NM Adrenal gland Views W I-131 MIBG IV;NM Adrenal Views W I-131 mIBG IV;;ACTIVE;2.15;2.64 +39858-6;Views for blood flow^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Views for blood flow;NM Bone Vs bld flow W RNC IV;;ACTIVE;2.15;2.64 +3985-9;Prolintane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Prolintane [Mass/volume] in Urine;Prolintane Ur-mCnc;;ACTIVE;1.0;2.42 +39859-4;Views delayed^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Delayed Views;NM Brain delayed W RNC IV;;ACTIVE;2.15;2.64 +39860-2;Views blood pool^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Blood pool W stress and W radionuclide IV;NM Hrt BP W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39861-0;Views blood pool^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Blood pool;NM Hrt BP W RNC IV;;ACTIVE;2.15;2.61 +39862-8;Multisection blood pool^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart blood pool at rest and W radionuclide IV;SPECT Hrt BP Rest+W RNC IV;;ACTIVE;2.15;2.61 +39863-6;Views first pass^at rest+W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass at rest and W stress and W radionuclide IV;NM Hrt FP Rest+stress+W RNC IV;;ACTIVE;2.15;2.61 +39864-4;Views first pass^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass;NM Hrt FP W RNC IV;;ACTIVE;2.15;2.61 +39865-1;Views first pass^W radionuclide IV;Find;Pt;Chest>Heart.ventricle.left;Doc;NM;RAD;2;NM Left ventricle First pass;NM LV FP W RNC IV;;ACTIVE;2.15;2.61 +39866-9;Views first pass^at rest+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass at rest and W Tc-99m Sestamibi IV;NM Hrt FP Rest+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +3986-7;Prolintane;MRat;24H;Urine;Qn;;DRUG/TOX;1;Prolintane [Mass/time] in 24 hour Urine;Prolintane 24h Ur-mRate;;ACTIVE;1.0;2.42 +39867-7;Views first pass^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass at rest and W radionuclide IV;NM Hrt FP Rest+W RNC IV;;ACTIVE;2.15;2.61 +39868-5;Views first pass^W stress+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass W stress and W Tc-99m Sestamibi IV;NM Hrt FP W Stress+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39869-3;Views first pass^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass W stress and W radionuclide IV;NM Hrt FP W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39870-1;Views for blood flow^W Tc-99m pertechnetate IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for blood flow W Tc-99m pertechnetate IV;NM Hrt Vs bld flow W Tc99mP IV;;ACTIVE;2.15;2.64 +39871-9;Views for blood flow^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for blood flow;NM Hrt Vs bld flow W RNC IV;;ACTIVE;2.15;2.64 +39872-7;Multisection wall motion^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart wall motion;SPECT Hrt WM W RNC IV;;ACTIVE;2.15;2.73 +39873-5;Views wall motion^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Wall motion;NM Hrt WM W RNC IV;;ACTIVE;2.15;2.61 +39874-3;Views delayed^W radionuclide IT;Find;Pt;Head+Neck>Cerebral cisterns;Doc;NM;RAD;2;NM Cerebral cisterns Delayed Views W radionuclide IT;NM Cerebral cist delayed W RNC IT;;ACTIVE;2.15;2.64 +3987-5;Promazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Promazine [Mass/volume] in Urine;Promazine Ur-mCnc;;ACTIVE;1.0;2.73 +39875-0;Views delayed^W Ga-67 IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Delayed Views W Ga-67 IV;NM Whole body delayed W Ga-67 IV;;ACTIVE;2.15;2.64 +39876-8;Multisection^W radionuclide IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM.SPECT;RAD;2;SPECT Liver and Spleen;SPECT Liver+Spleen W RNC IV;;ACTIVE;2.15;2.61 +39877-6;Views^W radionuclide IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM;RAD;2;NM Liver and Spleen Views;NM Liver+Spleen Views W RNC IV;;ACTIVE;2.15;2.64 +39878-4;Views static^W radionuclide IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM;RAD;2;Deprecated NM Liver and Spleen Static Views;Deprecated NM Liver+Spleen Static W RNC IV;;DEPRECATED;2.15;2.64 +39879-2;Multisection^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM.SPECT;RAD;2;SPECT Bone;SPECT Bone W RNC IV;;ACTIVE;2.15;2.61 +398-8;Penicillin V;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Penicillin V [Susceptibility] by Serum bactericidal titer;Penicillin V Titr SBT;;ACTIVE;1.0;2.32 +39880-0;Views 2 phase^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone 2 Phase Views;NM Bone 2 Phase W RNC IV;;ACTIVE;2.15;2.64 +39881-8;Multisection 3 phase^W radionuclide IV;Find;Pt;Whole body>Bone;Doc;NM.SPECT;RAD;2;SPECT Whole body Bone 3 phase;SPECT WB Bone 3 Phase W RNC IV;;ACTIVE;2.15;2.61 +39882-6;Views 3 phase^W radionuclide IV;Find;Pt;Whole body>Bone;Doc;NM;RAD;2;NM Whole body Bone 3 Phase Views;NM WB Bone 3 Phase W RNC IV;;ACTIVE;2.15;2.64 +3988-3;Promethazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Promethazine [Mass/volume] in Serum or Plasma;Promethazine SerPl-mCnc;;ACTIVE;1.0;2.73 +39883-4;Views 3 phase^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone 3 Phase Views;NM Bone 3 Phase W RNC IV;;ACTIVE;2.15;2.64 +39884-2;Views blood pool^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Blood pool;NM Bone BP W RNC IV;;ACTIVE;2.15;2.61 +39885-9;Views first pass+ventricular volume^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Ventricular volume;NM Hrt FP+VV W RNC IV;;ACTIVE;2.15;2.61 +39886-7;Views first pass+wall motion^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Wall motion at rest and W radionuclide IV;NM Hrt FP+WM Rest+W RNC IV;;ACTIVE;2.15;2.61 +39887-5;Views first pass+ejection fraction^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Ejection fraction at rest and W radionuclide IV;NM Hrt FP+EF Rest+W RNC IV;;ACTIVE;2.15;2.61 +39888-3;Views first pass+wall motion^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Wall motion W stress and W radionuclide IV;NM Hrt FP+WM W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39889-1;Views first pass+ejection fraction^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Ejection fraction;NM Hrt FP+EF W RNC IV;;ACTIVE;2.15;2.61 +39890-9;Views first pass+wall motion^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Wall motion;NM Hrt FP+WM W RNC IV;;ACTIVE;2.15;2.61 +3989-1;Promethazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Promethazine [Mass/volume] in Urine;Promethazine Ur-mCnc;;ACTIVE;1.0;2.73 +39891-7;Views for infarct+first pass^W Tc-99m PYP IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for infarct and first pass W Tc-99m PYP IV;NM Hrt Vs infarct+FP W Tc99mPyp IV;;ACTIVE;2.15;2.64 +39892-5;Views for infarct+first pass^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for infarct and first pass;NM Hrt Vs infarct+FP W RNC IV;;ACTIVE;2.15;2.64 +39893-3;Views for blood flow+shunt detection^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views for blood flow and shunt detection;NM Hrt Views for Flow+Shunt Det W RNC IV;;ACTIVE;2.15;2.64 +39894-1;Views static for shunt detection^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;Deprecated NM Heart Static Views for shunt detection;Deprecated NM Hrt Static for Shunt Det W RNC IV;;DEPRECATED;2.15;2.64 +39895-8;Views for ejection fraction^W Tc-99m DISIDA IV;Find;Pt;Abdomen>Gallbladder;Doc;NM;RAD;2;NM Gallbladder Views for ejection fraction W Tc-99m DISIDA IV;NM GB Views for EF W Tc99mDISIDA IV;;ACTIVE;2.15;2.64 +39896-6;Views static for tumor^W Ga-67 IV;Find;Pt;^Patient;Doc;NM;RAD;2;Deprecated NM Static Views for tumor W Ga-67 IV;Deprecated NM Static for Tumor W Ga-67 IV;;DEPRECATED;2.15;2.64 +39897-4;Views^W radionuclide IV;Find;Pt;Chest>Lung & Abdomen>Liver;Doc;NM;RAD;2;NM Lung and Liver Views;NM Lung+Liver Views W RNC IV;;ACTIVE;2.15;2.64 +39898-2;Multisection ventilation^W radionuclide aerosol IH;Find;Pt;Chest>Lung;Doc;NM.SPECT;RAD;2;SPECT Lung ventilation;SPECT Lung V W RNC Aero IH;;ACTIVE;2.15;2.61 +39899-0;Views for blood flow^W radionuclide IV;Find;Pt;Head>Salivary gland;Doc;NM;RAD;2;NM Salivary gland Views for blood flow;NM Salivary gland Vs bld flow W RNC IV;;ACTIVE;2.15;2.64 +39900-6;Views static^W radionuclide IV;Find;Pt;Head>Salivary gland;Doc;NM;RAD;2;Deprecated NM Salivary gland Static Views;Deprecated NM Salivary gland Static W RNC IV;;DEPRECATED;2.15;2.64 +39901-4;Views 3 phase multiple areas ^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone 3 Phase Views multiple areas;NM Bone 3 Phase Mult areas W RNC IV;;ACTIVE;2.15;2.64 +39902-2;Views 3 phase single area ^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone 3 Phase Views single area;NM Bone 3 Phase Single W RNC IV;;ACTIVE;2.15;2.64 +39903-0;Views static multiple areas^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;Deprecated NM Bone Multiple areas Static Views;Deprecated NM Bone Static Mult areas W RNC IV;;DEPRECATED;2.15;2.64 +39904-8;Views multiple areas^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Multiple area Views;NM Bone Vs Mult areas W RNC IV;;ACTIVE;2.15;2.64 +39905-5;Multisection multiple areas^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM.SPECT;RAD;2;SPECT Bone multiple areas;SPECT Bone Mult areas W RNC IV;;ACTIVE;2.15;2.64 +39906-3;Multisection multiple areas^W radionuclide IV;Find;Pt;XXX>Bone marrow;Doc;NM.SPECT;RAD;2;SPECT Bone marrow multiple areas;SPECT Bone mar Mult areas W RNC IV;;ACTIVE;2.15;2.64 +39907-1;Views multiple areas^W radionuclide IV;Find;Pt;XXX>Bone marrow;Doc;NM;RAD;2;NM Bone marrow Multiple area Views;NM Bone mar Vs Mult areas W RNC IV;;ACTIVE;2.15;2.64 +39908-9;Views first pass+wall motion+ventricular volume^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Wall motion and Ventricular volume W stress and W radionuclide IV;NM Hrt FP+WM+VV W Stress+W RNC IV;;ACTIVE;2.15;2.61 +3990-9;Propranolol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Propranolol [Mass/time] in 24 hour Urine;Propranolol 24h Ur-mRate;;ACTIVE;1.0;2.42 +39909-7;Views first pass+wall motion+ventricular volume+ejection fraction^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Wall motion and Ventricular volume and Ejection fraction W stress and W radionuclide IV;NM Hrt FP+WM+VV+EF W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39910-5;Views first pass+wall motion+ejection fraction^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Wall motion and Ejection fraction;NM Hrt FP+WM+EF W RNC IV;;ACTIVE;2.15;2.61 +39911-3;View first pass & wall motion & ejection fraction^W radionuclide IV;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scan first pass & wall motion & ejection fraction single view;Deprecated Hrt RI FP+WM+EF V1 W RNC IV;;DEPRECATED;2.15;2.36 +39912-1;Views first pass+wall motion+ventricular volume+ejection fraction^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Wall motion and Ventricular volume and Ejection fraction;NM Hrt FP+WM+VV+EF W RNC IV;;ACTIVE;2.15;2.61 +39913-9;Multisection gated+ejection fraction^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart gated and ejection fraction;SPECT Hrt Gated+EF W RNC IV;;ACTIVE;2.15;2.61 +39914-7;Views gated^W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated W Tc-99m Sestamibi IV;NM Hrt Gated W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39915-4;Views gated^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated;NM Hrt Gated W RNC IV;;ACTIVE;2.15;2.61 +39916-2;Multisection gated^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart gated;SPECT Hrt Gated W RNC IV;;ACTIVE;2.15;2.61 +3991-7;Propranolol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Propranolol [Presence] in Serum or Plasma;Propranolol SerPl Ql;;ACTIVE;1.0;2.73 +39917-0;Views gated+ejection fraction^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Ejection fraction;NM Hrt Gated+EF W RNC IV;;ACTIVE;2.15;2.61 +39918-8;Multisection gated+wall motion^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart gated and wall motion;SPECT Hrt Gated+WM W RNC IV;;ACTIVE;2.15;2.61 +39919-6;Views gated+first pass^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and First pass;NM Hrt Gated+FP W RNC IV;;ACTIVE;2.15;2.61 +39920-4;Views gated^at rest+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated at rest and W Tc-99m Sestamibi IV;NM Hrt Gated Rest+W Tc99mMIBI IV;;ACTIVE;2.15;2.61 +39921-2;Views gated^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated at rest and W radionuclide IV;NM Hrt Gated Rest+W RNC IV;;ACTIVE;2.15;2.61 +39922-0;Views gated^at rest+W Tc-99m pertechnetate IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated at rest and W Tc-99m pertechnetate IV;NM Hrt Gated Rest+W Tc-99mP IV;;ACTIVE;2.15;2.61 +39923-8;Views gated+ejection fraction^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Ejection fraction at rest and W radionuclide IV;NM Hrt Gated+EF Rest+W RNC IV;;ACTIVE;2.15;2.61 +39924-6;Views gated^at rest+W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated at rest and W stress and W radionuclide IV;NM Hrt Gated Rest+stress+W RNC IV;;ACTIVE;2.15;2.61 +3992-5;Propranolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propranolol [Mass/volume] in Serum or Plasma;Propranolol SerPl-mCnc;;ACTIVE;1.0;2.73 +39925-3;Views gated+wall motion+ejection fraction^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Wall motion and Ejection fraction at rest and W radionuclide IV;NM Hrt Gated+WM+EF Rest+W RNC IV;;ACTIVE;2.15;2.61 +39926-1;View gated^W stress & W radionuclide IV;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scintigraphy gated W stress & W radionuclide IV;Deprecated Hrt RI Gated V1 W Stress+W RN;;DEPRECATED;2.15;2.36 +39927-9;Views gated^W stress+W Tc-99m pertechnetate IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated W stress and W Tc-99m pertechnetate IV;NM Hrt Gated W Stress+W Tc99mP IV;;ACTIVE;2.15;2.61 +39928-7;Views gated^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated W stress and W radionuclide IV;NM Hrt Gated W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39929-5;Views gated+wall motion^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Wall motion W stress and W radionuclide IV;NM Hrt Gated+WM W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39930-3;Multisection gated^W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart gated W stress and W radionuclide IV;SPECT Hrt Gated W Stress+W RNC IV;;ACTIVE;2.15;2.61 +39931-1;Views gated+wall motion+ejection fraction^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Wall motion and Ejection fraction;NM Hrt Gated+WM+EF W RNC IV;;ACTIVE;2.15;2.61 +39932-9;Views wall motion+ejection fraction^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Wall motion and Ejection fraction;NM Hrt WM+EF W RNC IV;;ACTIVE;2.15;2.61 +3993-3;Propranolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Propranolol [Presence] in Urine;Propranolol Ur Ql;;ACTIVE;1.0;2.73 +39933-7;Views for infection multiple areas^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for infection multiple areas W Ga-67 IV;NM Vs for infect Mult areas W Ga-67 IV;;ACTIVE;2.15;2.64 +39934-5;Views for tumor multiple areas^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for tumor multiple areas W Ga-67 IV;NM Vs for tumor Mult areas W Ga-67 IV;;ACTIVE;2.15;2.64 +39935-2;Views multiple areas^W Ga-67 IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Multiple area Views W Ga-67 IV;NM Vs Mult areas W Ga-67 IV;;ACTIVE;2.15;2.64 +39936-0;Views limited^W radionuclide IV;Find;Pt;XXX>Joint;Doc;NM;RAD;2;NM Joint Limited Views;NM Joint Views Ltd W RNC IV;;ACTIVE;2.15;2.64 +39937-8;Views multiple areas^W radionuclide XXX;Find;Pt;XXX>Joint;Doc;NM;RAD;2;NM Joint Multiple area Views W radionuclide XXX;NM Joint Vs Mult areas W RNC XXX;;ACTIVE;2.15;2.64 +39938-6;Multisection^W radionuclide IV;Find;Pt;XXX>Joint;Doc;NM.SPECT;RAD;2;SPECT Joint;SPECT Joint W RNC IV;;ACTIVE;2.15;2.61 +39939-4;Views^W radionuclide IV;Find;Pt;XXX>Joint;Doc;NM;RAD;2;NM Joint Views;NM Joint Views W RNC IV;;ACTIVE;2.15;2.64 +39940-2;Views for clearance^W Tc-99m DTPA aerosol IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Clearance W Tc-99m DTPA aerosol IH;NM Lung Clear W Tc99mDTPA AeroIH;;ACTIVE;2.15;2.61 +3994-1;Propranolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propranolol [Mass/volume] in Urine;Propranolol Ur-mCnc;;ACTIVE;1.0;2.42 +39941-0;Views perfusion^W particulate radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;Deprecated Lung NM perfusion W particulate radionuclide IV;Deprecated Lung NM PF W Particulate RNC;;DEPRECATED;2.15;2.58 +39942-8;Views ventilation+perfusion^W radionuclide IH+W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Ventilation and Perfusion;NM Lung VP W RNC IH+IV;;ACTIVE;2.15;2.61 +39943-6;Views ventilation & perfusion^W radionuclide IH & W particulate radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;Deprecated Lung NM ventilation and perfusion W radionuclide IH and W particulate radionuclide IV;Deprecated Lung NM VP W RNC IH+Particula;;DEPRECATED;2.15;2.58 +39944-4;Views ventilation+equilibrium+washout^W radionuclide IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Ventilation and Equilibrium and Washout;NM Lung V+EQ+WO W RNC IH;;ACTIVE;2.15;2.61 +39945-1;Views ventilation^W radionuclide gaseous IH single breath;Find;Pt;Chest>Lung;Doc;NM;RAD;2;Deprecated Lung NM ventilation W radionuclide gaseous IH single breath;Deprecated Lung NM V W RNC Gas IH SB;;DEPRECATED;2.15;2.58 +39946-9;Views ventilation+perfusion+differential^W radionuclide IH+W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Ventilation and Perfusion and Differential;NM Lung VP+Diff W RNC IH+IV;;ACTIVE;2.15;2.61 +39947-7;Views ventilation+equilibrium^W radionuclide IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Ventilation and Equilibrium;NM Lung V+EQ W RNC IH;;ACTIVE;2.15;2.61 +39948-5;Views ventilation & equilibrium & washout^W radionuclide IH single breath;Find;Pt;Chest>Lung;Doc;NM;RAD;2;Deprecated Lung NM ventilation and equilibrium and washout W radionuclide IH single breath;Deprecated Lung NM V+EQ+WO W RNC IH SB;;DEPRECATED;2.15;2.58 +39949-3;Views multiple areas^W In-111 Satumomab IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Multiple area Views W In-111 Satumomab IV;NM Vs Mult areas W In-111 Satmb IV;;ACTIVE;2.15;2.64 +39950-1;Views multiple areas^W Tc-99m capromab pendatide IV;Find;Pt;Pelvis>Prostate;Doc;NM;RAD;2;NM Prostate Multiple area Views W Tc-99m capromab pendatide IV;NM Prostate Vs Mult areas W Tc99mPMSA IV;;ACTIVE;2.15;2.64 +39951-9;Views for tumor multiple areas^W Tc-99m Sestamibi IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for tumor multiple areas W Tc-99m Sestamibi IV;NM Vs Mult area for tumor W Tc99mMIBI IV;;ACTIVE;2.15;2.64 +39952-7;Views for blood flow+function^W radionuclide IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;NM;RAD;2;NM Scrotum and testicle Views for blood flow and function;NM Scrotum+Test Vs bld flow+fn W RNC IV;;ACTIVE;2.15;2.64 +39953-5;Guidance for localization of tumor multiple areas^W radionuclide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Guidance for localization of tumor multiple areas of Unspecified body region;NM Guided Tum loc Mult areas--W RNC IV;;ACTIVE;2.15;2.64 +39954-3;Views for thrombosis^W radionuclide IV;Find;Pt;XXX>Vein;Doc;NM;RAD;2;NM Vein Views for thrombosis;NM Vein Vs for thrombosis W RNC IV;;ACTIVE;2.15;2.64 +39955-0;Creatinine^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --pre XXX challenge;Creat pre chal SerPl-mCnc;;ACTIVE;2.15;2.73 +39956-8;Creatinine^1.5H pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --1.5 hours pre XXX challenge;Creat 1.5h pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39957-6;Creatinine^1H pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --1 hour pre XXX challenge;Creat 1h pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +3995-8;Propylhexedrine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Propylhexedrine [Mass/volume] in Blood;Propylhexedrine Bld-mCnc;;ACTIVE;1.0;2.42 +39958-4;Creatinine^45M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --45 minutes pre XXX challenge;Creat 45M pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39959-2;Creatinine^30M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --30 minutes pre XXX challenge;Creat 30M pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +399-6;Phenethicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Phenethicillin [Susceptibility] by Minimum lethal concentration (MLC);Phenethicillin Islt MLC;;ACTIVE;1.0;2.19 +39960-0;Creatinine^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Creat 45M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39961-8;Creatinine^3.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --3.5 hours post XXX challenge;Creat 3.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39962-6;Creatinine^3.75H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --3.75 hours post XXX challenge;Creat 3.75h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39963-4;Creatinine^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;Creat 4h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39964-2;Creatinine^4.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --4.5 hours post XXX challenge;Creat 4.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39965-9;Creatinine^5.25H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --5.25 hours post XXX challenge;Creat 5.25h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +3996-6;Propylhexedrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Propylhexedrine [Presence] in Urine;Propylhexedrine Ur Ql;;ACTIVE;1.0;2.56 +39966-7;Creatinine^5.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --5.5 hours post XXX challenge;Creat 5.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39967-5;Creatinine^6.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --6.5 hours post XXX challenge;Creat 6.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39968-3;Creatinine^8H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --8 hours post XXX challenge;Creat 8h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39969-1;Creatinine^9H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --9 hours post XXX challenge;Creat 9h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39970-9;Creatinine^10H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --10 hours post XXX challenge;Creat 10h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39971-7;Creatinine^12H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --12 hours post XXX challenge;Creat 12h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39972-5;Creatinine^16H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --16 hours post XXX challenge;Creat 16h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39973-3;Creatinine^18H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --18 hours post XXX challenge;Creat 18h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +3997-4;Propylhexedrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propylhexedrine [Mass/volume] in Urine;Propylhexedrine Ur-mCnc;;ACTIVE;1.0;2.42 +39974-1;Creatinine^2D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --2 days post XXX challenge;Creat 2D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39975-8;Creatinine^4D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --4 days post XXX challenge;Creat 4D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39976-6;Creatinine^7D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --7 days post XXX challenge;Creat 7D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +39977-4;Creatinine^pre XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --pre XXX challenge;Creat pre chal Ur-mCnc;;ACTIVE;2.15;2.70 +39978-2;Creatinine^2.25H pre XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --2.25 hours pre XXX challenge;Creat 2.25h pre chal Ur-mCnc;;ACTIVE;2.15;2.70 +39979-0;Creatinine^1.5H pre XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --1.5 hours pre XXX challenge;Creat 1.5h pre chal Ur-mCnc;;ACTIVE;2.15;2.70 +39980-8;Creatinine^1H pre XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --1 hour pre XXX challenge;Creat 1h pre chal Ur-mCnc;;ACTIVE;2.15;2.70 +39981-6;Creatinine^30M pre XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --30 minutes pre XXX challenge;Creat 30M pre chal Ur-mCnc;;ACTIVE;2.15;2.70 +3998-2;Propylhexedrine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Propylhexedrine [Mass/time] in 24 hour Urine;Propylhexedrine 24h Ur-mRate;;ACTIVE;1.0;2.42 +39982-4;Creatinine^baseline;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --baseline;Creat BS Ur-mCnc;;ACTIVE;2.15;2.73 +39983-2;Creatinine^30M post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --30 minutes post XXX challenge;Creat 30M p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39984-0;Creatinine^1H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --1 hour post XXX challenge;Creat 1h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39985-7;Creatinine^1.5H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --1.5 hours post XXX challenge;Creat 1.5h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39986-5;Creatinine^2H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --2 hours post XXX challenge;Creat 2h p chal Ur-mCnc;;ACTIVE;2.15;2.73 +39987-3;Creatinine^2.5H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --2.5 hours post XXX challenge;Creat 2.5h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39988-1;Creatinine^3H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --3 hours post XXX challenge;Creat 3h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39989-9;Creatinine^3.5H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --3.5 hours post XXX challenge;Creat 3.5h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +3999-0;Protriptyline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Protriptyline [Mass/volume] in Serum or Plasma;Protrip SerPl-mCnc;;ACTIVE;1.0;2.73 +39990-7;Creatinine^4H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --4 hours post XXX challenge;Creat 4h p chal Ur-mCnc;;ACTIVE;2.15;2.73 +39991-5;Creatinine^4.5H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --4.5 hours post XXX challenge;Creat 4.5h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39992-3;Creatinine^5H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --5 hours post XXX challenge;Creat 5h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39993-1;Creatinine^5.5H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --5.5 hours post XXX challenge;Creat 5.5h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39994-9;Creatinine^6H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --6 hours post XXX challenge;Creat 6h p chal Ur-mCnc;;ACTIVE;2.15;2.73 +39995-6;Creatinine^8H post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --8 hours post XXX challenge;Creat 8h p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39996-4;Creatinine^1D post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --1 day post XXX challenge;Creat 1D p chal Ur-mCnc;;ACTIVE;2.15;2.70 +39997-2;Glucose^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre XXX challenge;Glucose pre chal SerPl-mCnc;;ACTIVE;2.15;2.73 +39998-0;Glucose^30M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes pre XXX challenge;Glucose 30M pre chal SerPl-mCnc;;ACTIVE;2.15;2.73 +39999-8;Glucose^15M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 minutes pre XXX challenge;Glucose 15M pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40000-2;Glucose^5M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 minutes pre XXX challenge;Glucose 5M pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40001-0;Glucose^5M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 minutes post XXX challenge;Glucose 5M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40002-8;Glucose^80M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --80 minutes post XXX challenge;Glucose 80M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40003-6;Glucose^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Glucose 1.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.73 +40004-4;Glucose^100M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --100 minutes post XXX challenge;Glucose 100M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40005-1;Glucose^110M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --110 minutes post XXX challenge;Glucose 110m p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4000-6;Protriptyline;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Protriptyline [Presence] in Serum or Plasma;Protrip SerPl Ql;;ACTIVE;1.0;2.73 +40006-9;Glucose^8.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --8.5 hours post XXX challenge;Glucose 8.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40007-7;Glucose^9.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --9.5 hours post XXX challenge;Glucose 9.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40008-5;Glucose^11.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --11.5 hours post XXX challenge;Glucose 11.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40009-3;Glucose^12.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12.5 hours post XXX challenge;Glucose 12.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40010-1;Glucose^13H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --13 hours post XXX challenge;Glucose 13h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40011-9;Glucose^13.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --13.5 hours post XXX challenge;Glucose 13.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40012-7;Glucose^14H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --14 hours post XXX challenge;Glucose 14h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40013-5;Glucose^15.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15.5 hours post XXX challenge;Glucose 15.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4001-4;Protriptyline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Protriptyline [Presence] in Urine;Protrip Ur Ql;;ACTIVE;1.0;2.73 +40014-3;Glucose^16H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --16 hours post XXX challenge;Glucose 16h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40015-0;Glucose^17.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --17.5 hours post XXX challenge;Glucose 17.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40016-8;Glucose^18H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --18 hours post XXX challenge;Glucose 18h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40017-6;Glucose^18.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --18.5 hours post XXX challenge;Glucose 18.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40018-4;Glucose^19.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --19.5 hours post XXX challenge;Glucose 19.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40019-2;Glucose^20H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20 hours post XXX challenge;Glucose 20H p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +400-2;Phenethicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Phenethicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Phenethicillin Islt MIC;;ACTIVE;1.0;2.19 +40020-0;Glucose^20.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20.5 hours post XXX challenge;Glucose 20.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40021-8;Glucose^21.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --21.5 hours post XXX challenge;Glucose 21.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4002-2;Protriptyline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Protriptyline [Mass/volume] in Serum or Plasma --trough;Protrip Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +40022-6;Glucose^22H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --22 hours post XXX challenge;Glucose 22h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40023-4;Glucose^23.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --23.5 hours post XXX challenge;Glucose 23.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40024-2;Glucose^1D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 day post XXX challenge;Glucose 1D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40025-9;Glucose^3M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 minutes post XXX challenge;Glucose 3M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40026-7;Glucose^ 6M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 minutes post XXX challenge;Glucose 6M p chal SerPl-mCnc;;ACTIVE;2.15;2.73 +40027-5;Glucose^9M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --9 minutes post XXX challenge;Glucose 9M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40028-3;Glucose^12M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12 minutes post XXX challenge;Glucose 12M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40029-1;Glucose^14M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --14 minutes post XXX challenge;Glucose 14m p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4003-0;Pseudoephedrine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pseudoephedrine [Presence] in Urine;Pseudoephedrine Ur Ql;;ACTIVE;1.0;2.56 +40030-9;Glucose^16M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --16 minutes post XXX challenge;Glucose 16m p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40031-7;Glucose^19M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --19 minutes post XXX challenge;Glucose 19M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40032-5;Glucose^22M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --22 minutes post XXX challenge;Glucose 22M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40033-3;Glucose^25M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --25 minutes post XXX challenge;Glucose 25M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40034-1;Glucose^27M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --27 minutes post XXX challenge;Glucose 27M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40035-8;Glucose^4.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4.5 hours post XXX challenge;Glucose 4.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40036-6;Glucose^5.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5.5 hours post XXX challenge;Glucose 5.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40037-4;Glucose^25H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --25 hours post XXX challenge;Glucose 25h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40038-2;Glucose^26H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --26 hours post XXX challenge;Glucose 26h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40039-0;Glucose^27H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --27 hours post XXX challenge;Glucose 27h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40040-8;Glucose^28H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --28 hours post XXX challenge;Glucose 28h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40041-6;Glucose^29H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --29 hours post XXX challenge;Glucose 29h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40042-4;Glucose^30H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 hours post XXX challenge;Glucose 30H p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40043-2;Glucose^31H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --31 hour post XXX challenge;Glucose 31h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40044-0;Glucose^36H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --36 hours post XXX challenge;Glucose 36h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40045-7;Glucose^2D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 days post XXX challenge;Glucose 2D p chal SerPl-mCnc;;ACTIVE;2.15;2.73 +40046-5;Albumin^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --pre XXX challenge;Albumin pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40047-3;Albumin^45M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --45 minutes pre XXX challenge;Albumin 45M pre chal SerPl-mCnc;;ACTIVE;2.15;2.73 +4004-8;Pseudoephedrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pseudoephedrine [Mass/volume] in Urine;Pseudoephedrine Ur-mCnc;;ACTIVE;1.0;2.73 +40048-1;Albumin^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Albumin 30M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40049-9;Albumin^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Albumin 45M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40050-7;Albumin^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Albumin 1h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40051-5;Albumin^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Albumin 1.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40052-3;Albumin^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Albumin 2h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40053-1;Albumin^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Albumin 3h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40054-9;Albumin^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;Albumin 4h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4005-5;Pseudoephedrine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Pseudoephedrine [Mass/time] in 24 hour Urine;Pseudoephedrine 24h Ur-mRate;;ACTIVE;1.0;2.42 +40055-6;Albumin^5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --5 hours post XXX challenge;Albumin 5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40056-4;Albumin^6H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --6 hours post XXX challenge;Albumin 6h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40057-2;Albumin^6.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --6.5 hours post XXX challenge;Albumin 6.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40058-0;Albumin^8H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --8 hours post XXX challenge;Albumin 8h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40059-8;Albumin^12H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --12 hours post XXX challenge;Albumin 12h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40060-6;Albumin^1D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --1 day post XXX challenge;Albumin 1D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40061-4;Albumin^2D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --2 days post XXX challenge;Albumin 2D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40062-2;Albumin^3D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --3 days post XXX challenge;Albumin 3D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4006-3;Pyrilamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pyrilamine [Mass/volume] in Blood;Pyrilamine Bld-mCnc;;ACTIVE;1.0;2.42 +40063-0;Albumin^4D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Albumin [Mass/volume] in Serum or Plasma --4 days post XXX challenge;Albumin 4D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40064-8;Calcium^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --pre XXX challenge;Calcium pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40065-5;Calcium^45M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --45 minutes pre XXX challenge;Calcium 45M pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40066-3;Calcium^15M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --15 minutes pre XXX challenge;Calcium 15M pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40067-1;Calcium^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --baseline;Calcium BS SerPl-mCnc;;ACTIVE;2.15;2.70 +40068-9;Calcium^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Calcium 45M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40069-7;Calcium^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Calcium 1.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40070-5;Calcium^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;Calcium 2.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4007-1;Pyrilamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Pyrilamine [Presence] in Serum or Plasma;Pyrilamine SerPl Ql;;ACTIVE;1.0;2.56 +40071-3;Calcium^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Calcium 3h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40072-1;Calcium^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;Calcium 4h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40073-9;Calcium^5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --5 hours post XXX challenge;Calcium 5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40074-7;Calcium^6H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --6 hours post XXX challenge;Calcium 6h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40075-4;Calcium^6.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --6.5 hours post XXX challenge;Calcium 6.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40076-2;Calcium^7.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --7.5 hours post XXX challenge;Calcium 7.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40077-0;Calcium^8H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --8 hours post XXX challenge;Calcium 8h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40078-8;Calcium^12H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --12 hours post XXX challenge;Calcium 12h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40079-6;Calcium^13H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --13 hours post XXX challenge;Calcium 13h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40080-4;Calcium^14H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --14 hours post XXX challenge;Calcium 14h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40081-2;Calcium^16H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --16 hours post XXX challenge;Calcium 16h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40082-0;Calcium^20H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --20 hours post XXX challenge;Calcium 20H p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40083-8;Calcium^1D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --1 day post XXX challenge;Calcium 1D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40084-6;Calcium^36H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --36 hours post XXX challenge;Calcium 36h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40085-3;Calcium^2D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --2 days post XXX challenge;Calcium 2D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40086-1;Calcium^3D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Mass/volume] in Serum or Plasma --3 days post XXX challenge;Calcium 3D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40087-9;Coagulation tissue factor induced^2H pre XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --2 hours pre XXX challenge;PT 2h pre chal PPP;;ACTIVE;2.15;2.70 +40088-7;Coagulation tissue factor induced^baseline;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --baseline;PT BS PPP;;ACTIVE;2.15;2.73 +4008-9;Pyrilamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pyrilamine [Mass/volume] in Serum or Plasma;Pyrilamine SerPl-mCnc;;ACTIVE;1.0;2.73 +40089-5;Coagulation tissue factor induced^30M post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --30 minutes post XXX challenge;PT 30M p chal PPP;;ACTIVE;2.15;2.73 +40090-3;Coagulation tissue factor induced^1H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --1 hour post XXX challenge;PT 1h p chal PPP;;ACTIVE;2.15;2.70 +40091-1;Coagulation tissue factor induced^1.5H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --1.5 hours post XXX challenge;PT 1.5h p chal PPP;;ACTIVE;2.15;2.70 +40092-9;Coagulation tissue factor induced^2H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --2 hours post XXX challenge;PT 2h p chal PPP;;ACTIVE;2.15;2.70 +40093-7;Coagulation tissue factor induced^3H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --3 hours post XXX challenge;PT 3h p chal PPP;;ACTIVE;2.15;2.70 +40094-5;Coagulation tissue factor induced^4H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --4 hours post XXX challenge;PT 4h p chal PPP;;ACTIVE;2.15;2.70 +40095-2;Coagulation tissue factor induced^6H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --6 hours post XXX challenge;PT 6h p chal PPP;;ACTIVE;2.15;2.70 +40096-0;Coagulation tissue factor induced^8H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --8 hours post XXX challenge;PT 8h p chal PPP;;ACTIVE;2.15;2.70 +4009-7;Pyrilamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pyrilamine [Presence] in Urine;Pyrilamine Ur Ql;;ACTIVE;1.0;2.73 +40097-8;Coagulation tissue factor induced^12H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --12 hours post XXX challenge;PT 12h p chal PPP;;ACTIVE;2.15;2.70 +40098-6;Coagulation tissue factor induced^1D post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --1 day post XXX challenge;PT 1D p chal PPP;;ACTIVE;2.15;2.70 +40099-4;Coagulation surface induced^2H pre XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --2 hours pre XXX challenge;aPTT 2h pre chal PPP;;ACTIVE;2.15;2.70 +401-0;Phenethicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Phenethicillin [Susceptibility] by Disk diffusion (KB);Phenethicillin Islt KB;;ACTIVE;1.0;2.19 +40100-0;Coagulation surface induced^baseline;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --baseline;aPTT BS PPP;;ACTIVE;2.15;2.73 +40101-8;Coagulation surface induced^30M post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --30 minutes post XXX challenge;aPTT 30M p chal PPP;;ACTIVE;2.15;2.70 +40102-6;Coagulation surface induced^1H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --1 hour post XXX challenge;aPTT 1h p chal PPP;;ACTIVE;2.15;2.70 +40103-4;Coagulation surface induced^1.5H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --1.5 hours post XXX challenge;aPTT 1.5h p chal PPP;;ACTIVE;2.15;2.70 +40104-2;Coagulation surface induced^2H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --2 hours post XXX challenge;aPTT 2h p chal PPP;;ACTIVE;2.15;2.70 +4010-5;Pyrilamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pyrilamine [Mass/volume] in Urine;Pyrilamine Ur-mCnc;;ACTIVE;1.0;2.73 +40105-9;Coagulation surface induced^3H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --3 hours post XXX challenge;aPTT 3h p chal PPP;;ACTIVE;2.15;2.70 +40106-7;Coagulation surface induced^4H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --4 hours post XXX challenge;aPTT 4h p chal PPP;;ACTIVE;2.15;2.70 +40107-5;Coagulation surface induced^6H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --6 hours post XXX challenge;aPTT 6h p chal PPP;;ACTIVE;2.15;2.70 +40108-3;Coagulation surface induced^8H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --8 hours post XXX challenge;aPTT 8h p chal PPP;;ACTIVE;2.15;2.70 +40109-1;Coagulation surface induced^12H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --12 hours post XXX challenge;aPTT 12h p chal PPP;;ACTIVE;2.15;2.70 +40110-9;Coagulation surface induced^1D post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --1 day post XXX challenge;aPTT 1D p chal PPP;;ACTIVE;2.15;2.70 +40111-7;Coagulation surface induced^18H post XXX challenge;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --18 hours post XXX challenge;aPTT 18h p chal PPP;;ACTIVE;2.15;2.70 +40112-5;Creatinine^pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --pre XXX challenge;Creat pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4011-3;Pyrovalerone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pyrovalerone [Presence] in Urine;Pyrovalerone Ur Ql;;ACTIVE;1.0;2.56 +40113-3;Creatinine^1.5H pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --1.5 hours pre XXX challenge;Creat 1.5h pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40114-1;Creatinine^1H pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --1 hour pre XXX challenge;Creat 1h pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40115-8;Creatinine^45M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --45 minutes pre XXX challenge;Creat 45M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40116-6;Creatinine^30M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --30 minutes pre XXX challenge;Creat 30M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40117-4;Creatinine^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;Creat 45M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40118-2;Creatinine^3.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --3.5 hours post XXX challenge;Creat 3.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.73 +40119-0;Creatinine^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Creat 4h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40120-8;Creatinine^8H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --8 hours post XXX challenge;Creat 8h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4012-1;Pyrovalerone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pyrovalerone [Mass/volume] in Urine;Pyrovalerone Ur-mCnc;;ACTIVE;1.0;2.42 +40121-6;Creatinine^9H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --9 hours post XXX challenge;Creat 9h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40122-4;Creatinine^10H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --10 hours post XXX challenge;Creat 10h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40123-2;Creatinine^12H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --12 hours post XXX challenge;Creat 12h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40124-0;Creatinine^16H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --16 hours post XXX challenge;Creat 16h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40125-7;Creatinine^18H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --18 hours post XXX challenge;Creat 18h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40126-5;Creatinine^2D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --2 days post XXX challenge;Creat 2D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40127-3;Creatinine^4D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --4 days post XXX challenge;Creat 4D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40128-1;Creatinine^7D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --7 days post XXX challenge;Creat 7D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40129-9;Creatinine^pre XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --pre XXX challenge;Creat pre chal Ur-sCnc;;ACTIVE;2.15;2.70 +40130-7;Creatinine^1.5H pre XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --1.5 hours pre XXX challenge;Creat 1.5h pre chal Ur-sCnc;;ACTIVE;2.15;2.70 +40131-5;Creatinine^1H pre XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --1 hour pre XXX challenge;Creat 1h pre chal Ur-sCnc;;ACTIVE;2.15;2.70 +40132-3;Creatinine^30M pre XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --30 minutes pre XXX challenge;Creat 30M pre chal Ur-sCnc;;ACTIVE;2.15;2.70 +40133-1;Creatinine^baseline;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --baseline;Creat BS Ur-sCnc;;ACTIVE;2.15;2.70 +40134-9;Creatinine^30M post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --30 minutes post XXX challenge;Creat 30M p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40135-6;Creatinine^1H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --1 hour post XXX challenge;Creat 1h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40136-4;Creatinine^1.5H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --1.5 hours post XXX challenge;Creat 1.5h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40137-2;Creatinine^2H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --2 hours post XXX challenge;Creat 2h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40138-0;Creatinine^2.5H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --2.5 hours post XXX challenge;Creat 2.5h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +4013-9;Pyrovalerone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Pyrovalerone [Mass/time] in 24 hour Urine;Pyrovalerone 24h Ur-mRate;;ACTIVE;1.0;2.42 +40139-8;Creatinine^3H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --3 hours post XXX challenge;Creat 3h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40140-6;Creatinine^3.5H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --3.5 hours post XXX challenge;Creat 3.5h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40141-4;Creatinine^4H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --4 hours post XXX challenge;Creat 4h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40142-2;Creatinine^4.5H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --4.5 hours post XXX challenge;Creat 4.5h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40143-0;Creatinine^5H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --5 hours post XXX challenge;Creat 5h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40144-8;Creatinine^5.5H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --5.5 hours post XXX challenge;Creat 5.5h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40145-5;Creatinine^6H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --6 hours post XXX challenge;Creat 6h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40146-3;Creatinine^8H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --8 hours post XXX challenge;Creat 8h p chal Ur-sCnc;;ACTIVE;2.15;2.70 +4014-7;quiNIDine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;quiNIDine [Mass/volume] in Blood;quiNIDine Bld-mCnc;;ACTIVE;1.0;2.40 +40147-1;Creatinine^1D post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Moles/volume] in Urine --1 day post XXX challenge;Creat 1D p chal Ur-sCnc;;ACTIVE;2.15;2.70 +40148-9;Glucose^pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre XXX challenge;Glucose pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40149-7;Glucose^30M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes pre XXX challenge;Glucose 30M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40150-5;Glucose^15M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes pre XXX challenge;Glucose 15M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40151-3;Glucose^10M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10 minutes pre XXX challenge;Glucose 10M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40152-1;Glucose^5M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5 minutes pre XXX challenge;Glucose 5M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40153-9;Glucose^5M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge;Glucose 5M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4015-4;quiNIDine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;quiNIDine [Presence] in Urine;quiNIDine Ur Ql;;ACTIVE;1.0;2.73 +40154-7;Glucose^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;Glucose 10M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40155-4;Glucose^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;Glucose 15M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40156-2;Glucose^20M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge;Glucose 20M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40157-0;Glucose^40M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --40 minutes post XXX challenge;Glucose 40M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40158-8;Glucose^50M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --50 minutes post XXX challenge;Glucose 50M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40159-6;Glucose^70M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --70 minutes post XXX challenge;Glucose 70M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40160-4;Glucose^75M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --75 minutes post XXX challenge;Glucose 75M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40161-2;Glucose^2.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge;Glucose 2.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4016-2;quiNIDine+Quinine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;quiNIDine+Quinine [Presence] in Serum or Plasma;quiNIDine+Quinine SerPl Ql;;ACTIVE;1.0;2.56 +40162-0;Glucose^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;Glucose 3h p chal SerPl-sCnc;;ACTIVE;2.15;2.73 +40163-8;Glucose^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Glucose 4h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40164-6;Glucose^5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5 hours post XXX challenge;Glucose 5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40165-3;Glucose^6H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --6 hours post XXX challenge;Glucose 6h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40166-1;Glucose^6.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --6.5 hours post XXX challenge;Glucose 6.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40167-9;Glucose^7H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --7 hours post XXX challenge;Glucose 7h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40168-7;Glucose^7.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --7.5 hours post XXX challenge;Glucose 7.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40169-5;Glucose^8H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8 hours post XXX challenge;Glucose 8h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4017-0;quiNIDine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNIDine [Mass/volume] in Serum or Plasma --trough;quiNIDine Trough SerPl-mCnc;;ACTIVE;1.0;2.40 +40170-3;Glucose^8.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8.5 hours post XXX challenge;Glucose 8.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40171-1;Glucose^9H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --9 hours post XXX challenge;Glucose 9h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40172-9;Glucose^9.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --9.5 hours post XXX challenge;Glucose 9.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40173-7;Glucose^10H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10 hours post XXX challenge;Glucose 10h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40174-5;Glucose^10.75H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10.75 hours post XXX challenge;Glucose 10.75h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40175-2;Glucose^11.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --11.5 hours post XXX challenge;Glucose 11.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40176-0;Glucose^12H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --12 hours post XXX challenge;Glucose 12h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40177-8;Glucose^12.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --12.5 hours post XXX challenge;Glucose 12.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40178-6;Glucose^13H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --13 hours post XXX challenge;Glucose 13h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40179-4;Glucose^13.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --13.5 hours post XXX challenge;Glucose 13.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40180-2;Glucose^14H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --14 hours post XXX challenge;Glucose 14h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40181-0;Glucose^15.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15.5 hours post XXX challenge;Glucose 15.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40182-8;Glucose^16H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --16 hours post XXX challenge;Glucose 16h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40183-6;Glucose^17.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --17.5 hours post XXX challenge;Glucose 17.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40184-4;Glucose^18H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --18 hours post XXX challenge;Glucose 18h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40185-1;Glucose^18.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --18.5 hours post XXX challenge;Glucose 18.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40186-9;Glucose^19.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --19.5 hours post XXX challenge;Glucose 19.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40187-7;Glucose^20H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20 hours post XXX challenge;Glucose 20H p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4018-8;quiNINE;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;quiNINE [Mass/volume] in Blood;quiNINE Bld-mCnc;;ACTIVE;1.0;2.40 +40188-5;Glucose^20.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20.5 hours post XXX challenge;Glucose 20.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40189-3;Glucose^21.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --21.5 hours post XXX challenge;Glucose 21.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40190-1;Glucose^22H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --22 hours post XXX challenge;Glucose 22h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40191-9;Glucose^23.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --23.5 hours post XXX challenge;Glucose 23.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40192-7;Glucose^1D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 day post XXX challenge;Glucose 1D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40193-5;Glucose^pre-meal;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre-meal;Glucose pre-meal SerPl-sCnc;;ACTIVE;2.15;2.70 +40194-3;Glucose^20M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20 minutes pre XXX challenge;Glucose 20M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40195-0;Glucose^13M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --13 minutes pre XXX challenge;Glucose 13m pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4019-6;quiNINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNINE [Mass/volume] in Serum or Plasma;quiNINE SerPl-mCnc;;ACTIVE;1.0;2.73 +40196-8;Glucose^8M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8 minutes pre XXX challenge;Glucose 8M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40197-6;Glucose^3M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 minutes pre XXX challenge;Glucose 3M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40198-4;Glucose^2M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 minutes post XXX challenge;Glucose 2M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40199-2;Glucose^3M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 minutes post XXX challenge;Glucose 3M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40200-8;Glucose^4M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4 minutes post XXX challenge;Glucose 4M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40201-6;Glucose^6M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --6 minutes post XXX challenge;Glucose 6M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40202-4;Glucose^8M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8 minutes post XXX challenge;Glucose 8M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40203-2;Glucose^9M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --9 minutes post XXX challenge;Glucose 9M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4020-4;quiNINE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;quiNINE [Presence] in Urine;quiNINE Ur Ql;;ACTIVE;1.0;2.73 +40204-0;Glucose^12M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --12 minutes post XXX challenge;Glucose 12M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40205-7;Glucose^14M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --14 minutes post XXX challenge;Glucose 14m p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40206-5;Glucose^16M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --16 minutes post XXX challenge;Glucose 16m p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40207-3;Glucose^19M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --19 minutes post XXX challenge;Glucose 19M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40208-1;Glucose^22M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --22 minutes post XXX challenge;Glucose 22M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40209-9;Glucose^25M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --25 minutes post XXX challenge;Glucose 25M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40210-7;Glucose^27M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --27 minutes post XXX challenge;Glucose 27M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40211-5;Glucose^3.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3.5 hours post XXX challenge;Glucose 3.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4021-2;rifAMPin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;rifAMPin [Mass/volume] in Serum or Plasma;rifAMPin SerPl-mCnc;;ACTIVE;1.0;2.73 +40212-3;Glucose^4.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4.5 hours post XXX challenge;Glucose 4.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40213-1;Glucose^5.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5.5 hours post XXX challenge;Glucose 5.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40214-9;Glucose^25H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --25 hours post XXX challenge;Glucose 25h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40215-6;Glucose^26H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --26 hours post XXX challenge;Glucose 26h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40216-4;Glucose^27H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --27 hours post XXX challenge;Glucose 27h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40217-2;Glucose^28H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --28 hours post XXX challenge;Glucose 28h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40218-0;Glucose^29H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --29 hours post XXX challenge;Glucose 29h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40219-8;Glucose^30H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 hours post XXX challenge;Glucose 30H p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4022-0;Salicylamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylamide [Mass/volume] in Serum or Plasma;Salicylamide SerPl-mCnc;;ACTIVE;1.0;2.34 +40220-6;Glucose^31H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --31 hour post XXX challenge;Glucose 31h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40221-4;Glucose^36H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --36 hours post XXX challenge;Glucose 36h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40222-2;Glucose^2D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 days post XXX challenge;Glucose 2D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40223-0;Calcium^pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --pre XXX challenge;Calcium pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40224-8;Calcium^45M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --45 minutes pre XXX challenge;Calcium 45M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40225-5;Calcium^15M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --15 minutes pre XXX challenge;Calcium 15M pre chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40226-3;Calcium^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --baseline;Calcium BS SerPl-sCnc;;ACTIVE;2.15;2.70 +40227-1;Calcium^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Calcium 30M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40228-9;Calcium^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;Calcium 45M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40229-7;Calcium^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Calcium 1h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40230-5;Calcium^1.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge;Calcium 1.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40231-3;Calcium^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Calcium 2h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40232-1;Calcium^2.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge;Calcium 2.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40233-9;Calcium^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;Calcium 3h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40234-7;Calcium^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Calcium 4h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40235-4;Calcium^5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --5 hours post XXX challenge;Calcium 5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40236-2;Calcium^6.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --6.5 hours post XXX challenge;Calcium 6.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40237-0;Calcium^7.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --7.5 hours post XXX challenge;Calcium 7.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4023-8;Salicylates;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Salicylates [Presence] in Serum or Plasma;Salicylates SerPl Ql;;ACTIVE;1.0;2.73 +40238-8;Calcium^8H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --8 hours post XXX challenge;Calcium 8h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40239-6;Calcium^12H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --12 hours post XXX challenge;Calcium 12h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40240-4;Calcium^13H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --13 hours post XXX challenge;Calcium 13h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40241-2;Calcium^14H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --14 hours post XXX challenge;Calcium 14h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40242-0;Calcium^16H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --16 hours post XXX challenge;Calcium 16h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40243-8;Calcium^20H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --20 hours post XXX challenge;Calcium 20H p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40244-6;Calcium^1D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --1 day post XXX challenge;Calcium 1D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40245-3;Calcium^36H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --36 hours post XXX challenge;Calcium 36h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +4024-6;Salicylates;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylates [Mass/volume] in Serum or Plasma;Salicylates SerPl-mCnc;;ACTIVE;1.0;2.73 +40246-1;Calcium^2D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --2 days post XXX challenge;Calcium 2D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40247-9;Calcium^3D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcium [Moles/volume] in Serum or Plasma --3 days post XXX challenge;Calcium 3D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40248-7;Creatinine^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --baseline;Creat BS SerPl-mCnc;;ACTIVE;2.15;2.73 +40249-5;Creatinine^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Creat 30M p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40250-3;Creatinine^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Creat 1h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40251-1;Creatinine^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Creat 1.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40252-9;Creatinine^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Creat 2h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4025-3;Salicylates;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Salicylates [Presence] in Urine;Salicylates Ur Ql;;ACTIVE;1.0;2.73 +40253-7;Creatinine^2.25H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --2.25 hours post XXX challenge;Creat 2.25h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40254-5;Creatinine^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;Creat 2.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40255-2;Creatinine^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Creat 3h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40256-0;Creatinine^5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --5 hours post XXX challenge;Creat 5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40257-8;Creatinine^6H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --6 hours post XXX challenge;Creat 6h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40258-6;Creatinine^1D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --1 day post XXX challenge;Creat 1D p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40259-4;Glucose^10.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10.5 hours post XXX challenge;Glucose 10.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40260-2;Glucose^10.75H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10.75 hours post XXX challenge;Glucose 10.75h p chal SerPl-mCnc;;ACTIVE;2.15;2.70 +4026-1;Salicylates;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Salicylates [Mass/volume] in Urine;Salicylates Ur-mCnc;;ACTIVE;1.0;2.73 +40261-0;Glucose^13M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --13 minutes pre XXX challenge;Glucose 13m pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40262-8;Glucose^3M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 minutes pre XXX challenge;Glucose 3M pre chal SerPl-mCnc;;ACTIVE;2.15;2.70 +40263-6;Glucose^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Glucose 30M p chal SerPl-mCnc;;ACTIVE;2.15;2.73 +40264-4;Creatinine^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --baseline;Creat BS SerPl-sCnc;;ACTIVE;2.15;2.70 +40265-1;Creatinine^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Creat 30M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40266-9;Creatinine^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Creat 1h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40267-7;Creatinine^1.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge;Creat 1.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40268-5;Creatinine^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Creat 2h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40269-3;Creatinine^2.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge;Creat 2.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40270-1;Creatinine^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;Creat 3h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40271-9;Creatinine^5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --5 hours post XXX challenge;Creat 5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40272-7;Creatinine^6H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --6 hours post XXX challenge;Creat 6h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40273-5;Creatinine^1D post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --1 day post XXX challenge;Creat 1D p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40274-3;Cortisol^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;Cortis 15M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40275-0;Cortisol^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;Cortis 45M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40276-8;Glucose^30M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose lactose PO;Glucose 30M p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +40277-6;Glucose^1H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post dose lactose PO;Glucose 1h p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +40278-4;Glucose^1.5H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose lactose PO;Glucose 1.5h p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +4027-9;Secobarbital;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Secobarbital [Presence] in Serum or Plasma;Secobarbital SerPl Ql;;ACTIVE;1.0;2.73 +40279-2;Glucose^2H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post dose lactose PO;Glucose 2h p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +402-8;Phenethicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Phenethicillin [Susceptibility] by Serum bactericidal titer;Phenethicillin Titr SBT;;ACTIVE;1.0;2.32 +40280-0;Glucose^3H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post dose lactose PO;Glucose 3h p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +40281-8;Lactose^30M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Moles/volume] in Serum or Plasma --30 minutes post dose lactose PO;Lactose 30M p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +40282-6;Lactose^1H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Moles/volume] in Serum or Plasma --1 hour post dose lactose PO;Lactose 1h p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +40283-4;Lactose^1.5H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Moles/volume] in Serum or Plasma --1.5 hours post dose lactose PO;Lactose 1.5h p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +40284-2;Lactose^2H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Moles/volume] in Serum or Plasma --2 hours post dose lactose PO;Lactose 2h p Lac PO SerPl-sCnc;;ACTIVE;2.15;2.70 +40285-9;Glucose^75M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --75 minutes post dose glucose;Glucose 75M p Glc SerPl-sCnc;;ACTIVE;2.15;2.70 +40286-7;Glucose^105M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --105 minutes post dose glucose;Glucose 105M p Glc SerPl-sCnc;;ACTIVE;2.15;2.70 +4028-7;Secobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Secobarbital [Mass/volume] in Serum or Plasma;Secobarbital SerPl-mCnc;;ACTIVE;1.0;2.73 +40287-5;Glucose^1H post meal;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post meal;Glucose 1h p meal SerPl-sCnc;;ACTIVE;2.15;2.73 +40288-3;Insulin^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Insulin 30M p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40289-1;Insulin^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Insulin 1h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40290-9;Insulin^1.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge;Insulin 1.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40291-7;Insulin^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Insulin 2h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40292-5;Insulin^2.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge;Insulin 2.5h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40293-3;Insulin^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;Insulin 3h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40294-1;Insulin^pre or post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --pre or post dose glucose;Insulin pre/p Glc SerPl-sCnc;;ACTIVE;2.15;2.70 +4029-5;Secobarbital;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Secobarbital [Presence] in Urine;Secobarbital Ur Ql;;ACTIVE;1.0;2.73 +40295-8;Triiodothyronine.free^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;T3Free 2h p chal SerPl-sCnc;;ACTIVE;2.15;2.70 +40296-6;Xylose^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Moles/volume] in Serum or Plasma --fasting;Xylose p fast SerPl-sCnc;;ACTIVE;2.15;2.70 +40297-4;Somatotropin^3.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3.5 hours post XXX challenge;GH 3.5h p chal SerPl-mCnc;;ACTIVE;2.15;2.73 +40298-2;Somatotropin^pre dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre dose cloNIDine;GH pre CLN SerPl-mCnc;;ACTIVE;2.15;2.70 +40299-0;Somatotropin^1H post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose cloNIDine;GH 1h p CLN SerPl-mCnc;;ACTIVE;2.15;2.73 +40300-6;Somatotropin^1.5H post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose cloNIDine;GH 1.5h p CLN SerPl-mCnc;;ACTIVE;2.15;2.73 +40301-4;Somatotropin^2H post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose cloNIDine;GH 2h p CLN SerPl-mCnc;;ACTIVE;2.15;2.73 +40302-2;Somatotropin^pre dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre dose arginine;GH pre Arg SerPl-mCnc;;ACTIVE;2.15;2.70 +4030-3;Sotalol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Sotalol [Presence] in Urine;Sotalol Ur Ql;;ACTIVE;1.0;2.56 +40303-0;Somatotropin^1H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose arginine;GH 1h p Arg SerPl-mCnc;;ACTIVE;2.15;2.73 +40304-8;Somatotropin^1.5H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose arginine;GH 1.5h p Arg SerPl-mCnc;;ACTIVE;2.15;2.73 +40305-5;Somatotropin^2H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose arginine;GH 2h p Arg SerPl-mCnc;;ACTIVE;2.15;2.73 +40306-3;Somatotropin^3H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3 hours post dose arginine;GH 3h p Arg SerPl-mCnc;;ACTIVE;2.15;2.70 +40307-1;Somatotropin^3.5H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3.5 hours post dose arginine;GH 3.5h p Arg SerPl-mCnc;;ACTIVE;2.15;2.70 +40308-9;Somatotropin^4H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --4 hours post dose arginine;GH 4h p Arg SerPl-mCnc;;ACTIVE;2.15;2.70 +40309-7;Somatotropin^pre or post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose glucose;GH pre/p Glc SerPl-mCnc;;ACTIVE;2.15;2.70 +40310-5;Cortisol^pre dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre dose triple bolus;Cortis pre Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +4031-1;Sotalol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sotalol [Mass/volume] in Urine;Sotalol Ur-mCnc;;ACTIVE;1.0;2.42 +40311-3;Cortisol^15M post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --15 minutes post dose triple bolus;Cortis 15M p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40312-1;Cortisol^30M post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --30 minutes post dose triple bolus;Cortis 30M p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40313-9;Cortisol^45M post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --45 minutes post dose triple bolus;Cortis 45M p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40314-7;Cortisol^1H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1 hour post dose triple bolus;Cortis 1h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40315-4;Cortisol^1.5H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1.5 hours post dose triple bolus;Cortis 1.5h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40316-2;Cortisol^2H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --2 hours post dose triple bolus;Cortis 2h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40317-0;Cortisol^3H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --3 hours post dose triple bolus;Cortis 3h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40318-8;Glucose^pre dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre dose triple bolus;Glucose pre Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40319-6;Glucose^15M post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose triple bolus;Glucose 15M p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40320-4;Glucose^30M post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose triple bolus;Glucose 30M p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40321-2;Glucose^45M post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose triple bolus;Glucose 45M p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40322-0;Glucose^1H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post dose triple bolus;Glucose 1h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40323-8;Glucose^2H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post dose triple bolus;Glucose 2h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40324-6;Glucose^3H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post dose triple bolus;Glucose 3h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40325-3;Testosterone^pre dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Moles/volume] in Serum or Plasma --pre dose triple bolus;Testost pre Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40326-1;Testosterone^3H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Moles/volume] in Serum or Plasma --3 hours post dose triple bolus;Testost 3h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40327-9;Triiodothyronine.free^pre dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --pre dose triple bolus;T3Free pre Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +40328-7;Triiodothyronine.free^2H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --2 hours post dose triple bolus;T3Free 2h p Triple Bolus SerPl-sCnc;;ACTIVE;2.15;2.70 +4032-9;Sotalol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Sotalol [Mass/time] in 24 hour Urine;Sotalol 24h Ur-mRate;;ACTIVE;1.0;2.42 +40329-5;Prolactin^pre dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --pre dose triple bolus;Prolactin pre Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40330-3;Prolactin^15M post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --15 minutes post dose triple bolus;Prolactin 15M p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40331-1;Prolactin^20M post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --20 minutes post dose triple bolus;Prolactin 20M p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40332-9;Prolactin^30M post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --30 minutes post dose triple bolus;Prolactin 30M p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40333-7;Prolactin^1H post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1 hour post dose triple bolus;Prolactin 1h p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40334-5;Somatotropin^pre dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre dose triple bolus;GH pre Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40335-2;Somatotropin^15M post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15 minutes post dose triple bolus;GH 15M p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40336-0;Somatotropin^30M post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose triple bolus;GH 30M p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +4033-7;Spironolactone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Spironolactone [Mass/volume] in Urine;Deprecated Spironolactone Ur-mCnc;;DEPRECATED;1.0;2.36 +40337-8;Somatotropin^45M post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --45 minutes post dose triple bolus;GH 45M p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40338-6;Somatotropin^1H post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose triple bolus;GH 1h p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40339-4;Somatotropin^2H post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose triple bolus;GH 2h p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40340-2;Somatotropin^3H post dose triple bolus;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3 hours post dose triple bolus;GH 3h p Triple Bolus SerPl-mCnc;;ACTIVE;2.15;2.70 +40341-0;MT-ATP6 gene.m.8993T>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ATP6 gene m.8993T>G [Presence] in Blood or Tissue by Molecular genetics method;MT-ATP6 m.8993T>G Bld/T Ql;;ACTIVE;2.15;2.56 +40342-8;MT-TL1 gene.m.3271T>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TL1 gene m.3271T>C [Presence] in Blood or Tissue by Molecular genetics method;MT-TL1 m.3271T>C Bld/T Ql;;ACTIVE;2.15;2.56 +40343-6;MT-TK gene.m.8296A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TK gene m.8296A>G [Presence] in Blood or Tissue by Molecular genetics method;MT-TK m.8296A>G Bld/T Ql;;ACTIVE;2.15;2.56 +40344-4;Mttl1 gene.c.A3243G;Arb;Pt;Bld/Tiss;Ord;;MOLPATH.MUT;1;Deprecated MTTL1 gene c.A3243G [Presence] in Blood or Tissue by Molecular genetics method;Deprecated MTTL1 c.A3243G Bld/T Ql;;DEPRECATED;2.15;2.36 +4034-5;Spironolactone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Spironolactone [Mass/volume] in Urine;Spironolactone Ur-mCnc;;ACTIVE;1.0;2.34 +40345-1;MT-TK gene.m.8356T>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TK gene m.8356T>C [Presence] in Blood or Tissue by Molecular genetics method;MT-TK m.8356T>C Bld/T Ql;;ACTIVE;2.15;2.56 +40346-9;MT-CO1 gene.m.7445A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-CO1 gene m.7445A>G [Presence] in Blood or Tissue by Molecular genetics method;MT-CO1 m.7445A>G Bld/T Ql;;ACTIVE;2.15;2.56 +40347-7;MT-TL1 gene.m.3256C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TL1 gene m.3256C>T [Presence] in Blood or Tissue by Molecular genetics method;MT-TL1 m.3256C>T Bld/T Ql;;ACTIVE;2.15;2.56 +40348-5;MT-TL1 gene.m.3252T>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TL1 gene m.3252T>C [Presence] in Blood or Tissue by Molecular genetics method;MT-TL1 m.3252T>C Bld/T Ql;;ACTIVE;2.15;2.56 +40349-3;MT-TK gene.m.8363G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TK gene m.8363G>A [Presence] in Blood or Tissue by Molecular genetics method;MT-TK m.8363G>A Bld/T Ql;;ACTIVE;2.15;2.56 +40350-1;MT-TL1 gene.m.3291T>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-TL1 gene m.3291T>C [Presence] in Blood or Tissue by Molecular genetics method;MT-TL1 m.3291T>C Bld/T Ql;;ACTIVE;2.15;2.56 +40351-9;MT-ND4 gene.m.11778G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND4 gene m.11778G>A [Presence] in Blood or Tissue by Molecular genetics method;MT-ND4 m.11778G>A Bld/T Ql;;ACTIVE;2.15;2.73 +4035-2;Spironolactone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Spironolactone [Mass/time] in 24 hour Urine;Spironolactone 24h Ur-mRate;;ACTIVE;1.0;2.19 +40352-7;MT-ND5 gene.m.13513G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND5 gene m.13513G>A [Presence] in Blood or Tissue by Molecular genetics method;MT-ND5 m.13513G>A Bld/T Ql;;ACTIVE;2.15;2.56 +40353-5;MT-ND6 gene.m.14484T>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND6 gene m.14484T>C [Presence] in Blood or Tissue by Molecular genetics method;MT-ND6 m.14484T>C Bld/T Ql;;ACTIVE;2.15;2.56 +40354-3;MT-ND1 gene.m.3460G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND1 gene m.3460G>A [Presence] in Blood or Tissue by Molecular genetics method;MT-ND1 m.3460G>A Bld/T Ql;;ACTIVE;2.15;2.56 +40355-0;Cotinine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Cotinine [Presence] in Hair;Cotinine Hair Ql;;ACTIVE;2.15;2.56 +40356-8;Creatinine;SRat;24H;Dial fld;Qn;;CHEM;1;Creatinine [Moles/time] in 24 hour Dialysis fluid;Creat 24h Dial fld-sRate;;ACTIVE;2.15;2.70 +40357-6;Creatinine;SRat;24H;Body fld;Qn;;CHEM;1;Creatinine [Moles/time] in 24 hour Body fluid;Creat 24h Fld-sRate;;ACTIVE;2.15;2.70 +40358-4;Desipramine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Desipramine [Presence] in Gastric fluid;Desipramine Gast Ql;;ACTIVE;2.15;2.56 +40359-2;Dextromethorphan;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Dextromethorphan [Presence] in Specimen;D-methorphan Spec Ql;;ACTIVE;2.15;2.73 +403-6;Pipemidate;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Pipemidate [Susceptibility] by Minimum lethal concentration (MLC);Pipemidate Islt MLC;;ACTIVE;1.0;2.19 +4036-0;Stanozolol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Stanozolol [Presence] in Urine;Stanozolol Ur Ql;;ACTIVE;1.0;2.73 +40360-0;Follitropin^15M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --15 minutes post dose triple bolus;FSH 15M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40361-8;Follitropin^1H post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1 hour post dose triple bolus;FSH 1h p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40362-6;Follitropin^20M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --20 minutes post dose triple bolus;FSH 20M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40363-4;Follitropin^2H post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --2 hours post dose triple bolus;FSH 2h p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40364-2;Follitropin^30M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --30 minutes post dose triple bolus;FSH 30M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40365-9;Follitropin^pre dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --pre dose triple bolus;FSH pre Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40366-7;Glucose;SRat;24H;Body fld;Qn;;CHEM;1;Glucose [Moles/time] in 24 hour Body fluid;Glucose 24h Fld-sRate;;ACTIVE;2.15;2.70 +40367-5;Heptacarboxylate;SRat;24H;Urine;Qn;;CHEM;1;Heptacarboxylate [Moles/time] in 24 hour Urine;Heptacarboxylate 24h Ur-sRate;;ACTIVE;2.15;2.70 +40368-3;Hexacarboxylate;SRat;24H;Urine;Qn;;CHEM;1;Hexacarboxylate [Moles/time] in 24 hour Urine;Hexacarboxylate 24h Ur-sRate;;ACTIVE;2.15;2.70 +40369-1;HYDROmorphone;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;HYDROmorphone [Presence] in Gastric fluid;HYDROmorphone Gast Ql;;ACTIVE;2.15;2.56 +40370-9;Imipramine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Imipramine [Presence] in Gastric fluid;Imipramine Gast Ql;;ACTIVE;2.15;2.56 +40371-7;Isoniazid;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Isoniazid [Presence] in Urine;Isoniazid Ur Ql;;ACTIVE;2.15;2.56 +40372-5;Isopropanol;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Isopropanol [Presence] in Gastric fluid;Isopropanol Gast Ql;;ACTIVE;2.15;2.56 +40373-3;Lutropin^15M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --15 minutes post dose triple bolus;LH 15M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40374-1;Lutropin^1H post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1 hour post dose triple bolus;LH 1h p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40375-8;Lutropin^20M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --20 minutes post dose triple bolus;LH 20M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40376-6;Lutropin^2H post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --2 hours post dose triple bolus;LH 2h p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40377-4;Lutropin^30M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --30 minutes post dose triple bolus;LH 30M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +4037-8;Stanozolol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Stanozolol [Mass/volume] in Urine;Stanozolol Ur-mCnc;;ACTIVE;1.0;2.42 +40378-2;Lutropin^pre dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --pre dose triple bolus;LH pre Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40379-0;Maprotiline;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Maprotiline [Presence] in Gastric fluid;Maprotiline Gast Ql;;ACTIVE;2.15;2.56 +40380-8;Meprobamate;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Meprobamate [Presence] in Gastric fluid;Meprobamate Gast Ql;;ACTIVE;2.15;2.56 +40381-6;Methamphetamine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methamphetamine [Presence] in Specimen;Methamphet Spec Ql;;ACTIVE;2.15;2.73 +40382-4;Methaqualone;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methaqualone [Presence] in Gastric fluid;Methaqualone Gast Ql;;ACTIVE;2.15;2.56 +40383-2;Methyprylon;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methyprylon [Presence] in Gastric fluid;Methyprylon Gast Ql;;ACTIVE;2.15;2.56 +40384-0;Morphine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Morphine [Presence] in Hair;Morphine Hair Ql;;ACTIVE;2.15;2.56 +40385-7;Nicotine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Nicotine [Presence] in Meconium;Nicotine Mec Ql;;ACTIVE;2.15;2.56 +4038-6;Stanozolol;MRat;24H;Urine;Qn;;DRUG/TOX;1;Stanozolol [Mass/time] in 24 hour Urine;Stanozolol 24h Ur-mRate;;ACTIVE;1.0;2.42 +40386-5;Nicotine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Nicotine [Presence] in Hair;Nicotine Hair Ql;;ACTIVE;2.15;2.56 +40387-3;Nicotine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Nicotine [Presence] in Gastric fluid;Nicotine Gast Ql;;ACTIVE;2.15;2.56 +40388-1;Nitrogen;SRat;24H;Urine;Qn;;CHEM;1;Nitrogen [Moles/time] in 24 hour Urine;N2 24h Ur-sRate;;ACTIVE;2.15;2.70 +40389-9;Nortriptyline;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Nortriptyline [Presence] in Gastric fluid;Nortrip Gast Ql;;ACTIVE;2.15;2.56 +40390-7;OLANZapine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;OLANZapine [Presence] in Urine;OLANZapine Ur Ql;;ACTIVE;2.15;2.73 +40391-5;Para aminobenzoate.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Para aminobenzoate free [Mass/volume] in Serum or Plasma;pABA Free SerPl-mCnc;;ACTIVE;2.15;2.70 +40392-3;Pentacarboxylate;SRat;24H;Urine;Qn;;CHEM;1;Pentacarboxylate [Moles/time] in 24 hour Urine;Pentacarboxylate 24h Ur-sRate;;ACTIVE;2.15;2.70 +40393-1;Pentazocine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Pentazocine [Presence] in Gastric fluid;Pentazocine Gast Ql;;ACTIVE;2.15;2.56 +4039-4;Streptomycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Streptomycin [Mass/volume] in Serum or Plasma;Streptomycin SerPl-mCnc;;ACTIVE;1.0;2.73 +40394-9;Phencyclidine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Hair;PCP Hair Ql;;ACTIVE;2.15;2.56 +40395-6;Phentermine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Phentermine [Presence] in Gastric fluid;Phentermine Gast Ql;;ACTIVE;2.15;2.56 +40396-4;Porphyrins;SRat;24H;Urine;Qn;;CHEM;1;Porphyrins [Moles/time] in 24 hour Urine;Porphyrins 24h Ur-sRate;;ACTIVE;2.15;2.73 +40397-2;Thyrotropin^15M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --15 minutes post dose triple bolus;TSH 15M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40398-0;Thyrotropin^1H post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1 hour post dose triple bolus;TSH 1h p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40399-8;Thyrotropin^20M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --20 minutes post dose triple bolus;TSH 20M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40400-4;Thyrotropin^30M post dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --30 minutes post dose triple bolus;TSH 30M p Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +40401-2;Thyrotropin^pre dose triple bolus;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --pre dose triple bolus;TSH pre Triple Bolus SerPl-aCnc;;ACTIVE;2.15;2.70 +4040-2;Sulfonamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfonamide [Mass/volume] in Serum or Plasma;Sulfonamide SerPl-mCnc;;ACTIVE;1.0;2.73 +40402-0;traZODone;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;traZODone [Presence] in Gastric fluid;traZODone Gast Ql;;ACTIVE;2.15;2.56 +40403-8;Trimipramine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Trimipramine [Presence] in Gastric fluid;Trimipramine Gast Ql;;ACTIVE;2.15;2.56 +40404-6;Tripelennamine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Tripelennamine [Presence] in Gastric fluid;Tripelennamine Gast Ql;;ACTIVE;2.15;2.56 +40405-3;Urea;SRat;24H;Dial fld;Qn;;CHEM;1;Urea [Moles/time] in 24 hour Dialysis fluid;Urea 24h Dial fld-sRate;;ACTIVE;2.15;2.70 +40406-1;Urea;SRat;24H;Body fld;Qn;;CHEM;1;Urea [Moles/time] in 24 hour Body fluid;Urea 24h Fld-sRate;;ACTIVE;2.15;2.70 +40407-9;Uroporphyrin 1 isomer;SRat;24H;Urine;Qn;;CHEM;1;Uroporphyrin 1 isomer [Moles/time] in 24 hour Urine;Uropor1 24h Ur-sRate;;ACTIVE;2.15;2.70 +40408-7;Uroporphyrin 3 isomer;SRat;24H;Urine;Qn;;CHEM;1;Uroporphyrin 3 isomer [Moles/time] in 24 hour Urine;Uropor3 24h Ur-sRate;;ACTIVE;2.15;2.70 +40409-5;3-Methoxytyramine;SRat;24H;Urine;Qn;;CHEM;1;3-Methoxytyramine [Moles/time] in 24 hour Urine;3Me-tyramine 24h Ur-sRate;;ACTIVE;2.15;2.70 +4041-0;Sulfonamide;PrThr;Pt;Ser/Bld;Ord;;DRUG/TOX;1;Sulfonamide [Presence] in Serum or Blood;Sulfonamide SerBld Ql;;ACTIVE;1.0;2.73 +40410-3;Alkaline phosphatase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Peritoneal fluid;ALP Prt-cCnc;;ACTIVE;2.15;2.73 +40411-1;Amitriptyline;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Amitriptyline [Presence] in Gastric fluid;Amitrip Gast Ql;;ACTIVE;2.15;2.56 +40412-9;Barbiturates;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Meconium;Barbiturates Mec Ql;;ACTIVE;2.15;2.73 +40413-7;Barbiturates;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Barbiturates [Presence] in Hair;Barbiturates Hair Ql;;ACTIVE;2.15;2.56 +40414-5;Benzodiazepines;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Meconium;Benzodiaz Mec Ql;;ACTIVE;2.15;2.73 +40415-2;Benzodiazepines;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Hair;Benzodiaz Hair Ql;;ACTIVE;2.15;2.56 +40416-0;Caffeine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Caffeine [Presence] in Gastric fluid;Caffeine Gast Ql;;ACTIVE;2.15;2.56 +40417-8;Chromium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Chromium [Moles/time] in 24 hour Urine;Chromium 24h Ur-sRate;;ACTIVE;2.15;2.70 +40418-6;Cotinine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Cotinine [Presence] in Meconium;Cotinine Mec Ql;;ACTIVE;2.15;2.56 +40419-4;Amphetamine+Methamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Amphetamine+Methamphetamine [Presence] in Urine;Amphet+Methamphet Ur Ql;;ACTIVE;2.15;2.73 +40420-2;Amphetamine+Methamphetamine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Amphetamine+Methamphetamine [Presence] in Specimen;Amphet+Methamphet Spec Ql;;ACTIVE;2.15;2.73 +40421-0;Amphetamine+Methamphetamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Amphetamine+Methamphetamine [Presence] in Serum or Plasma;Amphet+Methamphet SerPl Ql;;ACTIVE;2.15;2.73 +40422-8;Methotrimeprazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methotrimeprazine [Presence] in Urine;Methotrimeprazine Ur Ql;;ACTIVE;2.15;2.56 +40423-6;Methotrimeprazine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methotrimeprazine [Presence] in Specimen;Methotrimeprazine Spec Ql;;ACTIVE;2.15;2.69 +40424-4;Methotrimeprazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methotrimeprazine [Presence] in Serum or Plasma;Methotrimeprazine SerPl Ql;;ACTIVE;2.15;2.56 +40425-1;CYP2D6 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP2D6 allele Geno Bld/T;;ACTIVE;2.15;2.73 +40426-9;FGD1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FGD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FGD1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40427-7;FGF23 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FGF23 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FGF23 gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +4042-8;Sulfonamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sulfonamide [Mass/volume] in Urine;Sulfonamide Ur-mCnc;;ACTIVE;1.0;2.42 +40428-5;NIPBL gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NIPBL gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NIPBL gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40429-3;NOD2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NOD2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NOD2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.68 +40430-1;TH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TH gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40431-9;Osmotic fragility^fresh;Imp;Pt;RBC^Control;Nom;;HEM/BC;1;Osmotic fragility [Interpretation] of Red Blood Cells from Control--fresh;OF Fresh RBC Cont-Imp;;ACTIVE;2.15;2.73 +40432-7;Osmotic fragility^incubated;Imp;Pt;RBC^Control;Nom;;HEM/BC;1;Osmotic fragility [Interpretation] of Red Blood Cells from Control--Incubated;OF Incubated RBC Cont-Imp;;ACTIVE;2.15;2.15 +40433-5;Sucrose hemolysis;NFr;Pt;RBC^Control;Qn;;HEM/BC;1;Sucrose hemolysis of Red Blood Cells from Control;Sucrose Hemolysis NFr Cont RBC;;ACTIVE;2.15;2.38 +40434-3;APTX gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;APTX gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;APTX gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40435-0;Fungus identified;Prid;Pt;Urine;Nom;Culture;MICRO;1;Fungus identified in Urine by Culture;Fungus Ur Cult;;ACTIVE;2.15;2.73 +4043-6;Teicoplanin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Teicoplanin [Mass/volume] in Serum or Plasma;Teicoplanin SerPl-mCnc;;ACTIVE;1.0;2.42 +40436-8;Parainfluenza virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Parainfluenza virus identified in Specimen by Organism specific culture;HPIV Spec Cult;;ACTIVE;2.15;2.73 +40437-6;HIV 1 p24 Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1 p24 Ab [Presence] in Serum or Plasma by Immunoassay;HIV1 p24 Ab SerPl Ql IA;;ACTIVE;2.15;2.56 +40438-4;HIV 1 gp41 Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1 gp41 Ab [Presence] in Serum or Plasma by Immunoassay;HIV1 gp41 Ab SerPl Ql IA;;ACTIVE;2.15;2.56 +40439-2;HIV 1 gp120+gp160 Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1 gp120+gp160 Ab [Presence] in Serum or Plasma by Immunoassay;HIV1 gp120+gp160 Ab SerPl Ql IA;;ACTIVE;2.15;2.56 +404-4;Pipemidate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Pipemidate [Susceptibility] by Minimum inhibitory concentration (MIC);Pipemidate Islt MIC;;ACTIVE;1.0;2.19 +40440-0;XXX microorganism serotype;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;XXX microorganism serotype [Identifier] in Isolate by Agglutination;Other microorg Sertyp Islt Aggl;;ACTIVE;2.15;2.73 +40441-8;Breaths^post exercise;NRat;Pt;Respiratory system;Qn;;PULM;2;Respiratory rate --post exercise;Resp rate p Exc;;ACTIVE;2.15;2.73 +40442-6;Heart rate^post exercise;NRat;Pt;XXX;Qn;;HRTRATE.MOLEC;2;Heart rate --post exercise;Heart rate p Exc;;ACTIVE;2.15;2.73 +40443-4;Heart rate^resting;NRat;Pt;XXX;Qn;;HRTRATE.MOLEC;2;Heart rate --resting;Heart rate Resting;;ACTIVE;2.15;2.42 +4044-4;Tetracaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tetracaine [Mass/volume] in Serum or Plasma;Tetracaine SerPl-mCnc;;ACTIVE;1.0;2.42 +40444-2;Cytomegalovirus gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;CMV gene mutations detected [Identifier];CMV gene Mut Det Islt;;ACTIVE;2.15;2.73 +40445-9;Gas delivery source^resting;Type;Pt;Respiratory system;Nom;;PULM;2;Gas delivery source Respiratory system --resting;Gas deliv source Resting Respiratory;;ACTIVE;2.15;2.29 +40446-7;Gas delivery source^post exercise;Type;Pt;Respiratory system;Nom;;CLIN;2;Gas delivery source Respiratory system --post exercise;Gas deliv source p Exc Respiratory;;ACTIVE;2.15;2.29 +40447-5;Gas flow.oxygen^resting;VRat;Pt;Oxygen delivery system;Qn;;PULM;2;Oxygen gas flow Oxygen delivery system --resting;Gas flow.O2 Resting O2 delivery sys;;ACTIVE;2.15;2.40 +40448-3;Gas flow.oxygen^post exercise;VRat;Pt;Oxygen delivery system;Qn;;PULM;2;Oxygen gas flow Oxygen delivery system --post exercise;Gas flow.O2 p Exc O2 delivery sys;;ACTIVE;2.15;2.40 +40449-1;Oxygen saturation^resting;MFr;Pt;BldC;Qn;Oximetry;HEMODYN.MOLEC;2;Deprecated Oxygen saturation in Capillary blood by Oximetry --resting;Deprecated SaO2% Resting BldC Oximetry;;DEPRECATED;2.15;2.36 +40450-9;Oxygen saturation^post exercise;MFr;Pt;BldC;Qn;Oximetry;HEMODYN.MOLEC;2;Deprecated Oxygen saturation in Capillary blood by Oximetry --post exercise;Deprecated SaO2% p Exc BldC Oximetry;;DEPRECATED;2.15;2.36 +4045-1;Tetracycline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tetracycline [Mass/volume] in Serum or Plasma;Tetracycline SerPl-mCnc;;ACTIVE;1.0;2.73 +40451-7;Lead;PrThr;Pt;Stool;Ord;;DRUG/TOX;1;Lead [Presence] in Stool;Lead Stl Ql;;ACTIVE;2.15;2.56 +40452-5;Sialate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Sialate/Creatinine [Ratio] in Urine;Sialate/Creat Ur-Rto;;ACTIVE;2.15;2.70 +40453-3;Sialooligosaccharides;PrThr;Pt;Urine;Ord;;CHEM;1;Sialooligosaccharides [Presence] in Urine;Sialooligosacch Ur Ql;;ACTIVE;2.15;2.56 +40454-1;Coagulum lysis;PrThr;Pt;PPP;Ord;Coag;COAG;1;Clot Lysis [Presence] in Platelet poor plasma by Coagulation assay;Clot Lysis PPP Ql;;ACTIVE;2.15;2.73 +40455-8;Ceruloplasmin actual/Normal;RelMCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ceruloplasmin actual/normal in Serum or Plasma;Ceruloplasmin Act/Nor SerPl;;ACTIVE;2.15;2.70 +40456-6;Beta 2 glycoprotein 1 Ab;ACnc;Pt;Ser;Qn;;COAG;1;Beta 2 glycoprotein 1 Ab [Units/volume] in Serum;B2 Glycoprot1 Ab Ser-aCnc;;ACTIVE;2.15;2.73 +40457-4;Prothrombin Ab;ACnc;Pt;Ser/Plas;Qn;;COAG;1;Prothrombin Ab [Units/volume] in Serum or Plasma;Prothrom Ab SerPl-aCnc;;ACTIVE;2.15;2.73 +40458-2;Coagulation tissue factor induced.factor substitution^immediately after addition of factor VIII depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor VIII depleted plasma;PT imm FVIII DP PPP;;ACTIVE;2.15;2.44 +40459-0;Hepatitis B virus DNA;LnCnc;Pt;Ser;Qn;Probe.amp.sig;MICRO;1;Hepatitis B virus DNA [Log #/volume] (viral load) in Serum by Probe with signal amplification;HBV DNA Ser Probe+sig amp-Log#;;ACTIVE;2.15;2.73 +40460-8;Phenytoin.bound;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin.bound [Mass/volume] in Serum or Plasma;Bnd Phenytoin SerPl-mCnc;;ACTIVE;2.15;2.73 +40461-6;GJB1 gene allele 1;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GJB1 gene allele 1 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GJB1 allele 1 Bld/T;;ACTIVE;2.15;2.15 +40462-4;GJB1 gene allele 2;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GJB1 gene allele 2 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GJB1 allele 2 Bld/T;;ACTIVE;2.15;2.15 +40463-2;TNFRSF1A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TNFRSF1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TNFRSF1A gene Mut Anl Bld/T;;ACTIVE;2.15;2.68 +40464-0;Drugs identified;Prid;Pt;Urine;Nom;Confirm;DRUG/TOX;1;Drugs identified in Urine by Confirmatory method;Drugs Ur Cfm;;ACTIVE;2.15;2.73 +40465-7;Glimepiride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Glimepride [Mass/volume] in Serum or Plasma;Glimepiride SerPl-mCnc;;ACTIVE;2.15;2.73 +40466-5;Herpes simplex virus 1 Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Herpes simplex virus 1 IgM Ab [Presence] in Serum by Immunofluorescence;HSV1 IgM Ser Ql IF;;ACTIVE;2.15;2.73 +40467-3;U1 small nuclear ribonucleoprotein Ab.IgG;ACnc;Pt;Ser;Qn;IB;SERO;1;U1 small nuclear ribonucleoprotein IgG Ab [Units/volume] in Serum by Immunoblot;U1 snRNP IgG Ser IB-aCnc;;ACTIVE;2.15;2.69 +40468-1;SLC26A4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC26A4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC26A4 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +4046-9;Tetrahydrocortisone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tetrahydrocortisone [Mass/volume] in Urine;THcortisone Ur-mCnc;;ACTIVE;1.0;2.42 +40469-9;Hydroflumethiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Hydroflumethiazide [Presence] in Urine;Hydroflumethiazide Ur Ql;;ACTIVE;2.15;2.73 +40470-7;Lymphocytes;Naric;Pt;Semen;Qn;Microscopy.light.HPF;HEM/BC;1;Lymphocytes [#/area] in Semen by Microscopy high power field;Lymphocytes #/area Smn HPF;;ACTIVE;2.15;2.70 +40471-5;FBN1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FBN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FBN1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +40472-3;Tetradecadienoate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tetradecadienoate (C14:2)/Creatinine [Mass Ratio] in Urine;Tdecadienoate/Creat Ur;;ACTIVE;2.15;2.70 +40473-1;Thermoactinomyces vulgaris 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Thermoactinomyces vulgaris 1 Ab [Presence] in Serum;T vulgaris1 Ab Ser Ql;;ACTIVE;2.15;2.73 +40474-9;Volatiles;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Volatiles and gases [Identifier] in Specimen;Volatiles Spec;;ACTIVE;2.15;2.69 +40475-6;WFS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;WFS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;WFS1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40476-4;PARK2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PARK2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PARK2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.68 +4047-7;Theophylline;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Blood;Theophylline Bld-mCnc;;ACTIVE;1.0;2.40 +40477-2;L1CAM gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;L1CAM gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;L1CAM gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +40478-0;MAPT gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MAPT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MAPT gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40479-8;Virus identified;Prid;Pt;Body fld;Nom;Culture;MICRO;1;Virus identified in Body fluid by Culture;Virus Fld Cult;;ACTIVE;2.15;2.19 +40480-6;Virus identified;Prid;Pt;Genital;Nom;Culture;MICRO;1;Virus identified in Genital specimen by Culture;Virus Genital Cult;;ACTIVE;2.15;2.73 +40481-4;Methylenedioxymethamphetamine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Specimen;MDMA Spec Ql;;ACTIVE;2.15;2.73 +40482-2;Crystals.unidentified;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Unidentified crystals [#/area] in Urine sediment by Microscopy low power field;Unident Crys #/area UrnS LPF;;ACTIVE;2.15;2.70 +40483-0;Phosphate crystals.amorphous;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Phosphate crystals amorphous [#/area] in Urine sediment by Microscopy low power field;Amorph Phos Cry #/area UrnS LPF;;ACTIVE;2.15;2.70 +40484-8;Urate crystals.amorphous;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Urate crystals amorphous [#/area] in Urine sediment by Microscopy low power field;Amorph Urate Cry #/area UrnS LPF;;ACTIVE;2.15;2.73 +4048-5;Theophylline;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Saliva (oral fluid);Theophylline Sal-mCnc;;ACTIVE;1.0;2.42 +40485-5;Urate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Urate crystals [#/area] in Urine sediment by Microscopy low power field;Urate Cry #/area UrnS LPF;;ACTIVE;2.15;2.73 +40486-3;Protein/Creatinine;Ratio;24H;Urine;Qn;;UA;1;Protein/Creatinine [Ratio] in 24 hour Urine;Prot/Creat 24h Ur-Rto;;ACTIVE;2.15;2.73 +40487-1;Urea/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Urea/Creatinine [Ratio] in Urine;Urea/Creat Ur-Rto;;ACTIVE;2.15;2.70 +40488-9;Glucose/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Glucose/Creatinine [Ratio] in Urine;Glucose/Creat Ur-Rto;;ACTIVE;2.15;2.70 +40489-7;Histiocytes/100 cells;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Histiocytes/100 cells in Synovial fluid by Manual count;Histiocytes NFr Snv Manual;;ACTIVE;2.15;2.73 +40490-5;Macrophages/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Synovial fluid by Manual count;Macrophages/leuk NFr Snv Manual;;ACTIVE;2.15;2.73 +40491-3;Neutrophils/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Synovial fluid by Manual count;Neutrophils/leuk NFr Snv Manual;;ACTIVE;2.15;2.73 +40492-1;Plasma cells/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Plasma cells/100 leukocytes in Synovial fluid by Manual count;Plasma Cells/leuk NFr Snv Manual;;ACTIVE;2.15;2.73 +4049-3;Theophylline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Serum or Plasma;Theophylline SerPl-mCnc;;ACTIVE;1.0;2.73 +40493-9;Methylenedioxymethamphetamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Serum or Plasma;MDMA SerPl Ql;;ACTIVE;2.15;2.73 +40494-7;Yersinia pseudotuberculosis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Yersinia pseudotuberculosis Ab [Titer] in Serum by Agglutination;Y pseudoTB Ab Titr Ser Aggl;;ACTIVE;2.15;2.30 +40495-4;Yersinia pseudotuberculosis 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia pseudotuberculosis 3 Ab [Titer] in Serum;Y pseudoTB 3 Ab Titr Ser;;ACTIVE;2.15;2.30 +40496-2;Yersinia pseudotuberculosis 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia pseudotuberculosis 2 Ab [Titer] in Serum;Y pseudoTB 2 Ab Titr Ser;;ACTIVE;2.15;2.30 +40497-0;Yersinia pseudotuberculosis 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia pseudotuberculosis 1 Ab [Titer] in Serum;Y pseudoTB 1 Ab Titr Ser;;ACTIVE;2.15;2.30 +40498-8;Yersinia enterocolitica Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Yersinia enterocolitica Ab [Titer] in Serum by Agglutination;Y enterocol Ab Titr Ser Aggl;;ACTIVE;2.15;2.30 +40499-6;Lymphocytic choriomeningitis virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Titer] in Serum by Immunoassay;LCMV IgM Titr Ser IA;;ACTIVE;2.15;2.56 +40500-1;Lymphocytic choriomeningitis virus Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Titer] in Serum by Immunoassay;LCMV IgG Titr Ser IA;;ACTIVE;2.15;2.56 +4050-1;Thiopental;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thiopental [Mass/volume] in Serum or Plasma;Thiopental SerPl-mCnc;;ACTIVE;1.0;2.73 +40501-9;Candida sp Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Candida sp Ab [Titer] in Serum by Latex agglutination;Candida Ab Titr Ser LA;;ACTIVE;2.15;2.30 +40502-7;Saint Louis encephalitis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum by Complement fixation;SLEV Ab Titr Ser CF;;ACTIVE;2.15;2.30 +40503-5;Sindbis virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Sindbis virus Ab [Titer] in Serum by Hemagglutination inhibition;SINV Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +40504-3;Powassan virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Powassan virus Ab [Titer] in Serum by Complement fixation;POWV Ab Titr Ser CF;;ACTIVE;2.15;2.30 +40505-0;Chikungunya virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Chikungunya virus Ab [Titer] in Serum by Hemagglutination inhibition;CHIKV Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +40506-8;Jamestown canyon virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Jamestown canyon virus Ab [Titer] in Serum by Immunofluorescence;JCV Ab Titr Ser IF;;ACTIVE;2.15;2.30 +40507-6;Jamestown canyon virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Jamestown canyon virus Ab [Titer] in Serum by Hemagglutination inhibition;JCV Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +40508-4;Jamestown canyon virus Ab.IgM;Titr;Pt;Ser;Qn;Neut;MICRO;1;Jamestown canyon virus IgM Ab [Titer] in Serum by Neutralization test;JCV IgM Titr Ser Nt;;ACTIVE;2.15;2.30 +40509-2;Snowshoe hare virus Ab.IgM;Titr;Pt;Ser;Qn;Neut;MICRO;1;Snowshoe hare virus IgM Ab [Titer] in Serum by Neutralization test;SSHV IgM Titr Ser Nt;;ACTIVE;2.15;2.30 +405-1;Pipemidate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Pipemidate [Susceptibility] by Disk diffusion (KB);Pipemidate Islt KB;;ACTIVE;1.0;2.21 +40510-0;Snowshoe hare virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Snowshoe hare virus Ab [Titer] in Serum by Immunofluorescence;SSHV Ab Titr Ser IF;;ACTIVE;2.15;2.30 +40511-8;Snowshoe hare virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Snowshoe hare virus Ab [Titer] in Serum by Hemagglutination inhibition;SSHV Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +40512-6;Semliki forest virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Semliki Forest virus Ab [Titer] in Serum by Hemagglutination inhibition;SFV Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +40513-4;Powassan virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Powassan virus Ab [Titer] in Serum by Hemagglutination inhibition;POWV Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +40514-2;Saint Louis encephalitis virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum by Hemagglutination inhibition;SLEV Ab Titr Ser HAI;;ACTIVE;2.15;2.32 +40515-9;Dengue virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Dengue virus Ab [Titer] in Serum by Complement fixation;DENV Ab Titr Ser CF;;ACTIVE;2.15;2.30 +40516-7;Histiocytes/100 cells;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Histiocytes/100 cells in Peritoneal fluid by Manual count;Histiocytes NFr Prt Manual;;ACTIVE;2.15;2.70 +40517-5;Macrophages/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Peritoneal fluid by Manual count;Macrophages/leuk NFr Prt Manual;;ACTIVE;2.15;2.70 +40518-3;Plasma cells/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Plasma cells/100 leukocytes in Peritoneal fluid by Manual count;Plasma Cells/leuk NFr Prt Manual;;ACTIVE;2.15;2.70 +4051-9;Thioridazine;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Thioridazine [Mass/volume] in Serum or Plasma;Deprecated Thioridazine Ser-mCnc;;DEPRECATED;1.0;2.36 +40519-1;Histiocytes/100 cells;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Histiocytes/100 cells in Pleural fluid by Manual count;Histiocytes NFr Plr Manual;;ACTIVE;2.15;2.70 +40520-9;Macrophages/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Pleural fluid by Manual count;Macrophages/leuk NFr Plr Manual;;ACTIVE;2.15;2.70 +40521-7;Monocytes/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Pleural fluid by Manual count;Monocytes/leuk NFr Plr Manual;;ACTIVE;2.15;2.73 +40522-5;Plasma cells/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Plasma cells/100 leukocytes in Pleural fluid by Manual count;Plasma Cells/leuk NFr Plr Manual;;ACTIVE;2.15;2.70 +40523-3;Histiocytes/100 cells;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Histiocytes/100 cells in Pericardial fluid by Manual count;Histiocytes NFr Pcar Manual;;ACTIVE;2.15;2.70 +40524-1;Macrophages/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Pericardial fluid by Manual count;Macrophages/leuk NFr Pcar Manual;;ACTIVE;2.15;2.70 +40525-8;Monocytes/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Pericardial fluid by Manual count;Monocytes/leuk NFr Pcar Manual;;ACTIVE;2.15;2.73 +40526-6;Plasma cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Plasma cells/100 leukocytes in Pericardial fluid by Manual count;Plasma Cells/leuk NFr Pcar Manual;;ACTIVE;2.15;2.70 +4052-7;Thioridazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thioridazine [Mass/volume] in Serum or Plasma;Thioridazine SerPl-mCnc;;ACTIVE;1.0;2.73 +40527-4;Cocaine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Cocaine [Presence] in Meconium;Cocaine Mec Ql;;ACTIVE;2.15;2.73 +40528-2;Opiates;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Opiates [Presence] in Hair;Opiates Hair Ql;;ACTIVE;2.15;2.73 +40529-0;Amphetamines;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Hair;Amphetamines Hair Ql;;ACTIVE;2.15;2.56 +40530-8;Ethanol;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Ethanol [Presence] in Gastric fluid;Ethanol Gast Ql;;ACTIVE;2.15;2.73 +40531-6;Methylenedioxyamphetamine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Gastric fluid;MDA Gast Ql;;ACTIVE;2.15;2.56 +40532-4;Methanol;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methanol [Presence] in Gastric fluid;Methanol Gast Ql;;ACTIVE;2.15;2.56 +40533-2;Leukocytes;NCnc;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Peritoneal dialysis fluid by Manual count;WBC # DiafP Manual;;ACTIVE;2.15;2.70 +40534-0;Erythrocytes;NCnc;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Peritoneal dialysis fluid by Manual count;RBC # DiafP Manual;;ACTIVE;2.15;2.70 +4053-5;Thioridazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thioridazine [Mass/volume] in Urine;Thioridazine Ur-mCnc;;ACTIVE;1.0;2.73 +40535-7;Leukocytes other/100 leukocytes;NFr;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Peritoneal dialysis fluid by Manual count;WBC Other/leuk NFr DiafP Manual;;ACTIVE;2.15;2.70 +40536-5;Neutrophils/100 leukocytes;NFr;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Peritoneal dialysis fluid by Manual count;Neutrophils/leuk NFr DiafP Manual;;ACTIVE;2.15;2.70 +40537-3;Monocytes/100 leukocytes;NFr;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Peritoneal dialysis fluid by Manual count;Monocytes/leuk NFr DiafP Manual;;ACTIVE;2.15;2.70 +40538-1;Lymphocytes/100 leukocytes;NFr;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Peritoneal dialysis fluid by Manual count;Lymphocytes/leuk NFr DiafP Manual;;ACTIVE;2.15;2.70 +40539-9;Eosinophils/100 leukocytes;NFr;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Peritoneal dialysis fluid by Manual count;Eosinophil/leuk NFr DiafP Manual;;ACTIVE;2.15;2.70 +40540-7;Basophils/100 leukocytes;NFr;Pt;Dial fld prt;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Peritoneal dialysis fluid by Manual count;Basophils/leuk NFr DiafP Manual;;ACTIVE;2.15;2.70 +40541-5;Plasma cells/100 leukocytes;NFr;Pt;CSF;Qn;Microscopy;HEM/BC;1;Plasma cells/100 leukocytes in Cerebral spinal fluid by Microscopy;Plasma Cells/leuk NFr CSF Micro;;ACTIVE;2.15;2.70 +40542-3;Rubella virus Ab;Titr;Pt;CSF;Qn;LA;MICRO;1;Rubella virus Ab [Titer] in Cerebral spinal fluid by Latex agglutination;RUBV Ab Titr CSF LA;;ACTIVE;2.15;2.30 +4054-3;Ticarcillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ticarcillin [Mass/volume] in Serum or Plasma;Ticarcillin SerPl-mCnc;;ACTIVE;1.0;2.42 +40543-1;Leukocytes other/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Bronchial specimen by Manual count;WBC Other/leuk NFr Bronch Manual;;ACTIVE;2.15;2.70 +40544-9;Monocytes/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Bronchial specimen by Manual count;Monocytes/leuk NFr Bronch Manual;;ACTIVE;2.15;2.70 +40545-6;Hemoglobin C;PrThr;Pt;Bld;Ord;Electrophoresis;HEM/BC;1;Hemoglobin C [Presence] in Blood by Electrophoresis;Hgb C Bld Ql Elph;;ACTIVE;2.15;2.73 +40546-4;Hemoglobin E;PrThr;Pt;Bld;Ord;Electrophoresis;HEM/BC;1;Hemoglobin E [Presence] in Blood by Electrophoresis;Hgb E Bld Ql Elph;;ACTIVE;2.15;2.73 +40547-2;Hemoglobin H;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin H [Presence] in Blood;Hgb H Bld Ql;;ACTIVE;2.15;2.56 +40548-0;Mononuclear cells.atypical;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Mononuclear cells atypical [#/volume] in Blood by Manual count;Atypical Mononuc # Bld Manual;;ACTIVE;2.15;2.73 +40549-8;Hemoglobin F;MCnc;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin F [Mass/volume] in Blood by Electrophoresis;Hgb F Bld Elph-mCnc;;ACTIVE;2.15;2.73 +4055-0;Ticarcillin+Clavulanate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Ticarcillin+Clavulanate [Mass/volume] in Serum or Plasma;Deprecated Ticarcillin+Clav SerPl-mCnc;;DEPRECATED;1.0;2.65 +40550-6;Hemoglobin H;MCnc;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin H [Mass/volume] in Blood by Electrophoresis;Hgb H Bld Elph-mCnc;;ACTIVE;2.15;2.70 +40551-4;CD10 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD10 Ag [Presence] in Tissue by Immune stain;CD10 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40552-2;CD117 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD117 Ag [Presence] in Tissue by Immune stain;CD117 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40553-0;CD19 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD19 Ag [Presence] in Tissue by Immune stain;CD19 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.56 +40554-8;CD45 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD45 Ag [Presence] in Tissue by Immune stain;CD45 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40555-5;CD66e Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD66e Ag [Presence] in Tissue by Immune stain;CD66e Ag Tiss Ql ImStn;;ACTIVE;2.15;2.56 +40556-3;Estrogen receptor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Estrogen receptor Ag [Presence] in Tissue by Immune stain;ER Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40557-1;Progesterone receptor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Progesterone receptor Ag [Presence] in Tissue by Immune stain;PR Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40558-9;Cytokeratin 20 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytokeratin 20 Ag [Presence] in Tissue by Immune stain;CK 20 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40559-7;Cytokeratin 7 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytokeratin 7 Ag [Presence] in Tissue by Immune stain;CK 7 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40560-5;Cytokeratin AE1+AE3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytokeratin AE1/AE3 Ag [Presence] in Tissue by Immune stain;CK AE1/AE3 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40561-3;Cytokeratin Cam5.2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytokeratin Cam5.2 Ag [Presence] in Tissue by Immune stain;CK Cam5.2 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40562-1;Actin.muscle specific Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Actin muscle specific Ag [Presence] in Tissue by Immune stain;MuSA Ag Tiss Ql ImStn;;ACTIVE;2.15;2.56 +40563-9;Actin.smooth muscle Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Actin smooth muscle Ag [Presence] in Tissue by Immune stain;SMA Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40564-7;Thyroid transcription factor 1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Thyroid transcription factor 1 Ag [Presence] in Tissue by Immune stain;TTF1 Ag Tiss Ql ImStn;;ACTIVE;2.15;2.73 +40565-4;Promyelocytes;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Promyelocytes [#/volume] in Body fluid by Manual count;Promyelocytes # Fld Manual;;ACTIVE;2.15;2.70 +40566-2;Neutrophils;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Body fluid by Manual count;Neutrophils # Fld Manual;;ACTIVE;2.15;2.70 +40567-0;Myelocytes;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Myelocytes [#/volume] in Body fluid by Manual count;Myelocytes # Fld Manual;;ACTIVE;2.15;2.70 +4056-8;Timolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Timolol [Mass/volume] in Serum or Plasma;Timolol SerPl-mCnc;;ACTIVE;1.0;2.42 +40568-8;Metamyelocytes;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Metamyelocytes [#/volume] in Body fluid by Manual count;Metamyelocytes # Fld Manual;;ACTIVE;2.15;2.70 +40569-6;Eosinophils;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Eosinophils [#/volume] in Body fluid by Manual count;Eosinophil # Fld Manual;;ACTIVE;2.15;2.73 +40570-4;Blasts;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Blasts [#/volume] in Body fluid by Manual count;Blasts # Fld Manual;;ACTIVE;2.15;2.70 +40571-2;Basophils;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Basophils [#/volume] in Body fluid by Manual count;Basophils # Fld Manual;;ACTIVE;2.15;2.73 +40572-0;Neutrophils.band form;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Band form neutrophils [#/volume] in Body fluid by Manual count;Neuts Band # Fld Manual;;ACTIVE;2.15;2.70 +40573-8;Lymphocytes.variant;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Variant lymphocytes [#/volume] in Body fluid by Manual count;Variant Lymphs # Fld Manual;;ACTIVE;2.15;2.73 +40574-6;Platelets;NCnc;Pt;Body fld;Qn;Automated count;HEM/BC;1;Platelets [#/volume] in Body fluid by Automated count;Platelet # Fld Auto;;ACTIVE;2.15;2.73 +40575-3;Yersinia enterocolitica O:5,27 Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Yersinia enterocolitica O:5,27 Ab [Titer] in Serum by Agglutination;Y entero O:5,27 Ab Titr Ser Aggl;;ACTIVE;2.15;2.61 +4057-6;Tobramycin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma --peak;Tobramycin Peak SerPl-mCnc;;ACTIVE;1.0;2.73 +40576-1;Yersinia enterocolitica O:8 Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Yersinia enterocolitica O:8 Ab [Titer] in Serum by Agglutination;Y entero O:8 Ab Titr Ser Aggl;;ACTIVE;2.15;2.61 +40577-9;Yersinia enterocolitica O:3 Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Yersinia enterocolitica O:3 Ab [Titer] in Serum by Agglutination;Y entero O:3 Ab Titr Ser Aggl;;ACTIVE;2.15;2.61 +40578-7;Cryoglobulin.IgM;MCnc;Pt;Ser;Qn;Cold incubation;SERO;1;Cryoglobulin.IgM [Mass/volume] in Serum by Cold incubation;Cryoglob IgM Ser Cold-mCnc;;ACTIVE;2.15;2.70 +40579-5;Cryoglobulin.IgG;MCnc;Pt;Ser;Qn;Cold incubation;SERO;1;Cryoglobulin.IgG [Mass/volume] in Serum by Cold incubation;Cryoglob IgG Ser Cold-mCnc;;ACTIVE;2.15;2.70 +40580-3;Cryoglobulin.IgA;MCnc;Pt;Ser;Qn;Cold incubation;SERO;1;Cryoglobulin.IgA [Mass/volume] in Serum by Cold incubation;Cryoglob IgA Ser Cold-mCnc;;ACTIVE;2.15;2.70 +40581-1;Cryoglobulin.IgM;MCnc;Pt;Ser;Qn;37 deg C incubation;SERO;1;Cryoglobulin.IgM [Mass/volume] in Serum by 37 degree C incubation;Cryoglob IgM Ser Inc-mCnc;;ACTIVE;2.15;2.70 +40582-9;Cryoglobulin.IgG;MCnc;Pt;Ser;Qn;37 deg C incubation;SERO;1;Cryoglobulin.IgG [Mass/volume] in Serum by 37 degree C incubation;Cryoglob IgG Ser Inc-mCnc;;ACTIVE;2.15;2.70 +40583-7;Invasive trophoblast Ag;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Invasive trophoblast Ag [Mass/volume] in Serum or Plasma;ITA SerPl-mCnc;;ACTIVE;2.15;2.73 +4058-4;Tobramycin^random;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma --random;Tobramycin Rand SerPl-mCnc;;DISCOURAGED;1.0;2.73 +40584-5;Arbovirus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Arbovirus IgM Ab [Presence] in Serum;Arbovirus IgM Ser Ql;;ACTIVE;2.15;2.56 +40585-2;Drugs identified;Prid;Pt;XXX;Nom;Confirm;DRUG/TOX;1;Drugs identified in Specimen by Confirmatory method;Drugs Spec Cfm;;ACTIVE;2.15;2.73 +40586-0;Heart beat^pre exercise;NRat;Pt;XXX;Qn;Oximetry;HRTRATE.MOLEC;2;Deprecated Heart beat^pre exercise: NRat: Pt: XXX: Qn: Oximetry;DeprecatedHeart beat^pre exercise;;DEPRECATED;2.15;2.36 +40587-8;Heart rate^post exercise;NRat;Pt;XXX;Qn;Oximetry;HRTRATE.MOLEC;2;Deprecated Heart rate by Oximetry --post exercise;Deprecated Heart rate p Exc Oximetry;;DEPRECATED;2.15;2.54 +40588-6;Inulin;MCnc;Pt;Ser^Control;Qn;;DRUG/TOX;1;Inulin [Mass/volume] in Control Serum;Inulin Ser Cont-mCnc;;ACTIVE;2.15;2.38 +40589-4;Oxygen^post exercise;PPres;Pt;Bld;Qn;Oximetry;PULM;2;Deprecated Oxygen [Partial pressure] by Oximetry --post exercise;Deprecated pO2 p Exc Oximetry;;DEPRECATED;2.15;2.36 +40590-2;Oxygen saturation^pre exercise;MFr;Pt;BldA;Qn;Oximetry;HEMODYN.MOLEC;2;Deprecated Oxygen saturation^pre exercise: SFr: Pt: BldA: Qn: Oximetry;DeprecatedOxygen saturation^pre exercise;;DEPRECATED;2.15;2.46 +40591-0;Oxyhemoglobin/Hemoglobin.total^post exercise;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --post exercise;Deprecated OxyHgb p Exc % PulseOx;;DEPRECATED;2.15;2.32 +4059-2;Tobramycin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma --trough;Tobramycin Trough SerPl-mCnc;;ACTIVE;1.0;2.73 +40592-8;Oxyhemoglobin/Hemoglobin.total^resting;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Deprecated Fractional oxyhemoglobin by Pulse oximetry --resting;Deprecated OxyHgb Resting % PulseOx;;DEPRECATED;2.15;2.32 +40593-6;Platelet aggregation.EPINEPHrine induced^50 umol/L;ACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced [Units/volume] in Platelet rich plasma --50 umol/L;PA Epineph 50 umol/L PRP-aCnc;;ACTIVE;2.15;2.73 +40594-4;Platelet aggregation.EPINEPHrine induced^100 umol/L;ACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced [Units/volume] in Platelet rich plasma --100 umol/L;PA Epineph 100 umol/L PRP-aCnc;;ACTIVE;2.15;2.73 +40595-1;Prothrombin Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;COAG;1;Prothrombin IgG Ab [Units/volume] in Serum or Plasma;Prothrom IgG SerPl-aCnc;;ACTIVE;2.15;2.73 +40596-9;Prothrombin Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;COAG;1;Prothrombin IgM Ab [Units/volume] in Serum or Plasma;Prothrom IgM SerPl-aCnc;;ACTIVE;2.15;2.73 +40597-7;7-Dehydrocholesterol;PrThr;Pt;Amnio fld;Ord;;CHEM;1;7-Dehydrocholesterol [Presence] in Amniotic fluid;7-DHC Amn Ql;;ACTIVE;2.15;2.56 +40598-5;Acetone;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Acetone [Presence] in Gastric fluid;Acetone Gast Ql;;ACTIVE;2.15;2.56 +40599-3;Albumin;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Albumin [Mass/volume] in Peritoneal dialysis fluid;Albumin DiafP-mCnc;;ACTIVE;2.15;2.70 +40-6;Azlocillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Azlocillin [Susceptibility] by Minimum inhibitory concentration (MIC);Azlocillin Islt MIC;;ACTIVE;1.0;2.19 +4060-0;Tocainide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tocainide [Mass/volume] in Serum or Plasma;Tocainide SerPl-mCnc;;ACTIVE;1.0;2.73 +40600-9;Alpha-1-Acid glycoprotein;PrThr;Pt;Urine;Ord;Immunoelectrophoresis;CHEM;1;Alpha-1-acid glycoprotein [Presence] in Urine by Immunoelectrophoresis;A1acid Glycoprotein Ur Ql IEP;;ACTIVE;2.15;2.56 +40601-7;Alpha-1-Acid glycoprotein;PrThr;Pt;Ser/Plas;Ord;Immunoelectrophoresis;CHEM;1;Alpha-1-acid glycoprotein [Presence] in Serum or Plasma by Immunoelectrophoresis;A1acid Glycoprotein SerPl Ql IEP;;ACTIVE;2.15;2.56 +40602-5;Alpha 1 antitrypsin;PrThr;Pt;Urine;Ord;Immunoelectrophoresis;CHEM;1;Alpha 1 antitrypsin [Presence] in Urine by Immunoelectrophoresis;A1AT Ur Ql IEP;;ACTIVE;2.15;2.56 +40603-3;Alpha 1 antitrypsin;PrThr;Pt;Ser/Plas;Ord;Immunoelectrophoresis;CHEM;1;Alpha 1 antitrypsin [Presence] in Serum or Plasma by Immunoelectrophoresis;A1AT SerPl Ql IEP;;ACTIVE;2.15;2.56 +40604-1;Alpha-2-Macroglobulin;PrThr;Pt;Urine;Ord;Immunoelectrophoresis;CHEM;1;Alpha-2-Macroglobulin [Presence] in Urine by Immunoelectrophoresis;A2 Macroglob Ur Ql IEP;;ACTIVE;2.15;2.56 +40605-8;Alpha-2-Macroglobulin;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;Alpha-2-Macroglobulin [Presence] in Serum by Immunoelectrophoresis;A2 Macroglob Ser Ql IEP;;ACTIVE;2.15;2.73 +40606-6;Appearance;Aper;Pt;Dial fld prt;Nom;;SPEC;1;Appearance of Peritoneal dialysis fluid;Appearance DiafP;;ACTIVE;2.15;2.21 +40607-4;Ascaris lumbricoides Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Ascaris lumbricoides IgG Ab [Units/volume] in Serum by Immunoassay;A lumbric IgG Ser IA-aCnc;;ACTIVE;2.15;2.73 +40608-2;Ascaris lumbricoides Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Ascaris lumbricoides IgM Ab [Units/volume] in Serum by Immunoassay;A lumbric IgM Ser IA-aCnc;;ACTIVE;2.15;2.69 +40609-0;Benzoylecgonine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Benzoylecgonine [Presence] in Specimen;BZE Spec Ql;;ACTIVE;2.15;2.73 +40610-8;Beta-2 transferrin;PrThr;Pt;CSF;Ord;;CHEM;1;Beta-2 transferrin [Presence] in Cerebral spinal fluid;B2 Transferrin CSF Ql;;ACTIVE;2.15;2.56 +40611-6;Blasts;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Blasts [#/volume] in Blood by Automated count;Deprecated Blasts # Bld Auto;;DEPRECATED;2.15;2.70 +40612-4;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Serum or Plasma by Immunoassay;B burgdor IgM SerPl Ql IA;;ACTIVE;2.15;2.73 +40613-2;Brucella sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Brucella sp Ab [Presence] in Serum by Complement fixation;Brucella Ab Ser Ql CF;;ACTIVE;2.15;2.56 +40614-0;Brucella sp Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Brucella sp Ab [Presence] in Serum by Agglutination;Brucella Ab Ser Ql Aggl;;ACTIVE;2.15;2.73 +40615-7;Calcium oxalate crystals;ACnc;Pt;Urine sed;Ord;Microscopy.light.LPF;UA;1;Deprecated Calcium oxalate crystals [Presence] in Urine sediment by Microscopy low power field;Deprecated CaOx Cry UrnS Ql LPF;;DEPRECATED;2.15;2.36 +40616-5;Campylobacter sp Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Campylobacter sp IgA Ab [Presence] in Serum by Immunoassay;Campylobacter IgA Ser Ql IA;;ACTIVE;2.15;2.56 +40617-3;Campylobacter sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Campylobacter sp IgG Ab [Presence] in Serum by Immunoassay;Campylobacter IgG Ser Ql IA;;ACTIVE;2.15;2.56 +4061-8;TOLBUTamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;TOLBUTamide [Mass/volume] in Serum or Plasma;TOLBUTamide SerPl-mCnc;;ACTIVE;1.0;2.73 +40618-1;Cancer Ag 125;ACnc;Pt;Periton fld;Qn;;CHEM;1;Cancer Ag 125 [Units/volume] in Peritoneal fluid;Cancer Ag125 Prt-aCnc;;ACTIVE;2.15;2.70 +40619-9;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Venous blood;pCO2 temp adj BldV;;ACTIVE;2.15;2.73 +40620-7;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldC;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Capillary blood;pCO2 temp adj BldC;;ACTIVE;2.15;2.70 +40621-5;Carcinoembryonic Ag;MCnc;Pt;Pericard fld;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Pericardial fluid;CEA Pcar-mCnc;;ACTIVE;2.15;2.73 +40622-3;Carcinoembryonic Ag;MCnc;Pt;Periton fld;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Peritoneal fluid;CEA Prt-mCnc;;ACTIVE;2.15;2.73 +40623-1;Cells.CD3+CD4+/100 cells;NFr;Pt;Bronchial;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 cells in Bronchial specimen;CD3+CD4+ Cells NFr Bronch;;ACTIVE;2.15;2.73 +40624-9;Cells.CD3+CD8+/100 cells;NFr;Pt;Bronchial;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells/100 cells in Bronchial specimen;CD3+CD8+ Cells NFr Bronch;;ACTIVE;2.15;2.73 +40625-6;Cocaine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Cocaine [Presence] in Specimen;Cocaine Spec Ql;;ACTIVE;2.15;2.73 +4062-6;Tranylcypromine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tranylcypromine [Mass/volume] in Urine;Tranylcypromine Ur-mCnc;;ACTIVE;1.0;2.73 +40626-4;Codeine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Codeine [Presence] in Specimen;Codeine Spec Ql;;ACTIVE;2.15;2.73 +40627-2;Coproporphyrin;MCnt;Pt;Stool;Qn;;CHEM;1;Coproporphyrin [Mass/mass] in Stool;Copro Stl-mCnt;;ACTIVE;2.15;2.70 +40628-0;Cryoglobulin.IgA;MCnc;Pt;Ser;Qn;37 deg C incubation;SERO;1;Cryoglobulin.IgA [Mass/volume] in Serum by 37 degree C incubation;Cryoglob IgA Ser Inc-mCnc;;ACTIVE;2.15;2.70 +40629-8;Doxepin;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Doxepin [Presence] in Specimen;Doxepin Spec Ql;;ACTIVE;2.15;2.69 +40630-6;Erythrocytes.nucleated;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Nucleated erythrocytes [Presence] in Blood by Light microscopy;nRBC Bld Ql Smear;;ACTIVE;2.15;2.73 +40631-4;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;CSF;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Cerebral spinal fluid by Manual count;nRBC/100 WBC CSF Manual-Rto;;ACTIVE;2.15;2.73 +40632-2;Gamma globulin/Beta globulin;MRto;Pt;CSF;Qn;Electrophoresis;CHEM;1;Gamma globulin/Beta globulin [Mass Ratio] in Cerebral spinal fluid by Electrophoresis;Gamma glob/Beta glob CSF Elph;;ACTIVE;2.15;2.42 +40633-0;Hemopexin;PrThr;Pt;Ser;Ord;;CHEM;1;Hemopexin [Presence] in Serum;Hemopexin Ser Ql;;ACTIVE;2.15;2.56 +4063-4;traZODone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;traZODone [Presence] in Serum or Plasma;traZODone SerPl Ql;;ACTIVE;1.0;2.56 +40634-8;HYDROcodone;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;HYDROcodone [Presence] in Gastric fluid;HYDROcodone Gast Ql;;ACTIVE;2.15;2.56 +40635-5;Immunoglobulin light chains.kappa;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;Kappa light chains [Presence] in Serum by Immunofixation;Kappa LC Ser Ql IFE;;ACTIVE;2.15;2.73 +40636-3;Immunoglobulin light chains.kappa;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;Kappa light chains [Presence] in Urine by Immunofixation;Kappa LC Ur Ql IFE;;ACTIVE;2.15;2.73 +40637-1;Immunoglobulin light chains.kappa.free;PrThr;Pt;Urine;Ord;;CHEM;1;Kappa light chains.free [Presence] in Urine;Kappa LC Free Ur Ql;;ACTIVE;2.15;2.73 +40638-9;Immunoglobulin light chains.lambda;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;Lambda light chains [Presence] in Urine by Immunofixation;Lambda LC Ur Ql IFE;;ACTIVE;2.15;2.73 +40639-7;Immunoglobulin light chains.lambda;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;Lambda light chains [Presence] in Serum by Immunofixation;Lambda LC Ser Ql IFE;;ACTIVE;2.15;2.73 +40640-5;Immunoglobulin light chains.lambda.free;PrThr;Pt;Urine;Ord;;CHEM;1;Lambda light chains.free [Presence] in Urine;Lambda LC Free Ur Ql;;ACTIVE;2.15;2.73 +40641-3;Ketones;PrThr;Pt;Vitr fld;Ord;;CHEM;1;Ketones [Presence] in Vitreous fluid;Ketones Vitf Ql;;ACTIVE;2.15;2.56 +4064-2;traZODone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;traZODone [Mass/volume] in Serum or Plasma;traZODone SerPl-mCnc;;ACTIVE;1.0;2.73 +40642-1;Leptospira autumnalis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Deprecated Leptospira autumnalis Ab [Titer] in Serum by Agglutination;Deprecated L autumnalis Ab Titr Ser Aggl;;DEPRECATED;2.15;2.58 +40643-9;Leptospira borgpetersenii serovar Ballum Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira borgpetersenii sv Ballum Ab [Titer] in Serum by Agglutination;L borgp Ball Ab Titr Ser Aggl;;ACTIVE;2.15;2.30 +40644-7;Leptospira borgpetersenii serovar Sejroe Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira borgpetersenii sv Sejroe Ab [Titer] in Serum by Agglutination;L borgp Sej Ab Titr Ser Aggl;;ACTIVE;2.15;2.30 +40645-4;Leptospira borgpetersenii serovar Tarrasovi Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira borgpetersenii sv Tarrasovi Ab [Titer] in Serum by Agglutination;L borgp Tarra Ab Titr Ser Aggl;;ACTIVE;2.15;2.30 +40646-2;Leukocytes other/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Leukocytes other/100 leukocytes in Blood by Automated count;WBC Other/leuk NFr Bld Auto;;ACTIVE;2.15;2.73 +40647-0;Lupus anticoagulant neutralization.platelet;PrThr;Pt;PPP;Ord;Coag;COAG;1;Lupus anticoagulant neutralization platelet [Presence] in Platelet poor plasma by Coagulation assay;LA Nt Platelet PPP Ql;;DISCOURAGED;2.15;2.56 +40648-8;Measles virus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Measles virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;MeV IgG CSF Ql IA;;ACTIVE;2.15;2.56 +40649-6;Measles virus Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Measles virus IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;MeV IgM CSF IA-aCnc;;ACTIVE;2.15;2.69 +40650-4;Mesothelial cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Blood by Manual count;Mesothl Cell/leuk NFr Bld Manual;;ACTIVE;2.15;2.70 +40651-2;Metamyelocytes;PrThr;Pt;Bld;Ord;;HEM/BC;1;Metamyelocytes [Presence] in Blood;Metamyelocytes Bld Ql;;ACTIVE;2.15;2.73 +40652-0;Methamphetamine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Methamphetamine [Presence] in Hair;Methamphet Hair Ql;;ACTIVE;2.15;2.56 +40653-8;Myelocytes/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Myelocytes/100 leukocytes in Body fluid by Manual count;Myelocytes/leuk NFr Fld Manual;;ACTIVE;2.15;2.73 +40654-6;Neutrophils.hypogranulated;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Neutrophils.hypogranulated [Presence] in Blood by Light microscopy;Hypogran Neuts Bld Ql Smear;;ACTIVE;2.15;2.73 +40655-3;Nuclear Ab;Titr;Pt;Ser;Qn;IA;SERO;1;Nuclear Ab [Titer] in Serum by Immunoassay;ANA Titr Ser IA;;ACTIVE;2.15;2.73 +40656-1;Parasite identified;Prid;Pt;Bld;Nom;Thick film;MICRO;1;Parasite identified in Blood by Thick film;Parasite Bld Thick Film;;ACTIVE;2.15;2.73 +40657-9;Parvovirus B19 Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Parvovirus B19 IgG Ab [Presence] in Serum by Immunofluorescence;B19V IgG Ser Ql IF;;ACTIVE;2.15;2.56 +40658-7;Parvovirus B19 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parvovirus B19 IgM Ab [Presence] in Serum by Immunoassay;B19V IgM Ser Ql IA;;ACTIVE;2.15;2.73 +4065-9;traZODone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;traZODone [Presence] in Urine;traZODone Ur Ql;;ACTIVE;1.0;2.73 +40659-5;Parvovirus B19 Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Parvovirus B19 IgM Ab [Presence] in Serum by Immunofluorescence;B19V IgM Ser Ql IF;;ACTIVE;2.15;2.56 +40660-3;Promyelocytes/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Promyelocytes/100 leukocytes in Body fluid by Manual count;Promyelocytes/leuk NFr Fld Manual;;ACTIVE;2.15;2.73 +40661-1;Protein.monoclonal;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal [Mass/volume] in Urine by Electrophoresis;M Protein Ur Elph-mCnc;;ACTIVE;2.15;2.73 +40662-9;Protein^resting;MRat;12H;Urine;Qn;;CHEM;1;Protein [Mass/time] in 12 hour Urine --resting;Prot Resting 12h Ur-mRate;;ACTIVE;2.15;2.70 +40663-7;Protein^upright;MRat;12H;Urine;Qn;;CHEM;1;Protein [Mass/time] in 12 hour Urine --upright;Prot upr 12h Ur-mRate;;ACTIVE;2.15;2.70 +40664-5;Pyrophosphate crystals;PrThr;Pt;Body fld;Ord;;HEM/BC;1;Pyrophosphate crystals [Presence] in Body fluid;Pyrophos Cry Fld Ql;;ACTIVE;2.15;2.73 +40665-2;Reticulocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Reticulocytes [#/volume] in Blood by Manual count;Retics # Manual;;ACTIVE;2.15;2.73 +40666-0;Rubella virus Ab;PrThr;Pt;CSF;Ord;LA;MICRO;1;Rubella virus Ab [Presence] in Cerebral spinal fluid by Latex agglutination;RUBV Ab CSF Ql LA;;ACTIVE;2.15;2.56 +4066-7;Triamterene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Triamterene [Mass/volume] in Urine;Triamterene Ur-mCnc;;ACTIVE;1.0;2.73 +40667-8;Rubella virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Rubella virus IgG Ab [Presence] in Serum or Plasma by Immunoassay;RUBV IgG SerPl Ql IA;;ACTIVE;2.15;2.73 +40668-6;Rubella virus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Rubella virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;RUBV IgG CSF Ql IA;;ACTIVE;2.15;2.56 +40669-4;Rubella virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Rubella virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;RUBV IgM CSF Ql IA;;ACTIVE;2.15;2.56 +40670-2;Smudge cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Smudge cells/100 leukocytes in Body fluid by Manual count;Smudge Cells/leuk NFr Fld Manual;;ACTIVE;2.15;2.70 +40671-0;Specimen volume;Vol;72H;Urine;Qn;;SPEC;1;Volume of 72 hour Urine;Specimen vol 72h Ur;;ACTIVE;2.15;2.70 +40672-8;Sucrose;PrThr;Pt;Stool;Ord;;CHEM;1;Sucrose [Presence] in Stool;Sucrose Stl Ql;;ACTIVE;2.15;2.56 +40673-6;Thyrotropin binding inhibitory immunoglobulins;ACnc;Pt;Ser;Qn;;CHEM;1;Thyrotropin binding inhibitory immunoglobulins [Units/volume] in Serum;TSH BII Ser-aCnc;;ACTIVE;2.15;2.73 +40674-4;Toxocara canis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toxocara canis IgG Ab [Presence] in Serum by Immunoassay;T canis IgG Ser Ql IA;;ACTIVE;2.15;2.73 +4067-5;Triamterene;MRat;24H;Urine;Qn;;DRUG/TOX;1;Triamterene [Mass/time] in 24 hour Urine;Triamterene 24h Ur-mRate;;ACTIVE;1.0;2.42 +40675-1;Toxocara canis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toxocara canis IgM Ab [Presence] in Serum by Immunoassay;T canis IgM Ser Ql IA;;ACTIVE;2.15;2.56 +40676-9;Toxoplasma gondii Ab;ACnc;Pt;Ser;Ord;LA;MICRO;1;Deprecated Toxoplasma gondii Ab [Presence] in Serum by Latex agglutination;Deprecated T gondii Ab Ser Ql LA;;DEPRECATED;2.15;2.36 +40677-7;Toxoplasma gondii Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Serum by Immunoassay;T gondii IgG Ser Ql IA;;ACTIVE;2.15;2.73 +40678-5;Toxoplasma gondii Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Toxoplasma gondii IgM Ab [Presence] in Serum or Plasma by Immunoassay;T gondii IgM SerPl Ql IA;;ACTIVE;2.15;2.73 +40679-3;Treponema pallidum Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Treponema pallidum IgG Ab [Presence] in Serum by Immunoblot;T pallidum IgG Ser Ql IB;;ACTIVE;2.15;2.73 +40680-1;Treponema pallidum Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Treponema pallidum IgM Ab [Presence] in Serum by Immunoblot;T pallidum IgM Ser Ql IB;;ACTIVE;2.15;2.58 +40681-9;Turbidity;PrThr;Pt;Ser/Plas;Ord;;SPEC;1;Turbidity [Presence] of Serum or Plasma Qualitative;Turbidity SerPl Ql;;ACTIVE;2.15;2.56 +40682-7;Urate crystals;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Urate crystals [Presence] in Body fluid by Light microscopy;Urate Cry Fld Ql Micro;;ACTIVE;2.15;2.73 +4068-3;Triamterene;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Triamterene [Presence] in Urine;Triamterene Ur Ql;;ACTIVE;1.0;2.73 +40683-5;Bentiromide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Bentiromide;Deprecated Bentiromide SerPl-mCnc;;DEPRECATED;2.15;2.70 +40684-3;Acinetobacter sp.multidrug resistant identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Acinetobacter sp multidrug resistant identified in Specimen by Organism specific culture;MDR-AB Spec Cult;;ACTIVE;2.15;2.69 +40685-0;Interpretation;Imp;Pt;CSF;Nom;Immunoelectrophoresis;CHEM;1;Immunoelectrophoresis for Cerebral spinal fluid;Interpretation CSF IEP-Imp;;ACTIVE;2.15;2.54 +40686-8;Platelet factor 3;ACnc;Pt;PRP;Qn;;COAG;1;Platelet factor 3 [Units/volume] in Platelet rich plasma;PF3 PRP-aCnc;;ACTIVE;2.15;2.69 +40687-6;Myeloid cells/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Myeloid cells/100 cells in Bone marrow by Manual count;Myeloid cells NFr Mar Manual;;ACTIVE;2.15;2.40 +40688-4;Megakaryocytes;PrThr;Pt;Bone mar;Ord;Microscopy;HEM/BC;1;Megakaryocytes [Presence] in Bone marrow by Microscopy;Megakaryocytes Mar Ql Micro;;ACTIVE;2.15;2.56 +40689-2;Erythroid cells/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Erythroid cells/100 cells in Bone marrow by Manual count;Erythroid Cells NFr Mar Manual;;ACTIVE;2.15;2.40 +406-9;Pipemidate;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Pipemidate [Susceptibility] by Serum bactericidal titer;Pipemidate Titr SBT;;ACTIVE;1.0;2.32 +40690-0;Tumor Ag 90;ACnc;Pt;Ser;Qn;;SERO;1;Tumor Ag 90 [Units/volume] in Serum;Tumor Ag 90 Ser-aCnc;;ACTIVE;2.15;2.73 +4069-1;Triazolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triazolam [Mass/volume] in Serum or Plasma;Triazolam SerPl-mCnc;;ACTIVE;1.0;2.73 +40691-8;Specimen volume^post washing;Vol;Pt;Semen;Qn;;FERT;1;Volume of Semen--post washing;Specimen vol p Wash Smn;;ACTIVE;2.15;2.42 +40692-6;Specimen volume^pre washing;Vol;Pt;Semen;Qn;;FERT;1;Volume of Semen--pre washing;Specimen vol Pre Wash Smn;;ACTIVE;2.15;2.73 +40693-4;RET gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RET gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;RET gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +40694-2;Sulfamethoxazole Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sulfamethoxazole IgE Ab [Presence] in Serum;Sulfamethoxazole IgE Ql;;ACTIVE;2.15;2.56 +40695-9;Spermatozoa^post concentration;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa [#/volume] in Semen --post concentration;Sperm p conc # Smn;;ACTIVE;2.15;2.73 +40696-7;Spermatozoa.motile^post concentration;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile [#/volume] in Semen --post concentration;Sperm Motile p conc # Smn;;ACTIVE;2.15;2.70 +40697-5;Toxoplasma gondii Ab.IgM index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Toxoplasma gondii IgM Ab index [Units/volume] in Serum and CSF;T gondii IgM Index Ser+CSF-aCnc;;ACTIVE;2.15;2.69 +40698-3;Mycoplasma sp identified;Prid;Pt;XXX;Nom;;MICRO;1;Mycoplasma sp identified in Specimen;Mycoplasma Spec;;ACTIVE;2.15;2.69 +40699-1;Mycobacterium sp identified;Prid;Pt;XXX;Nom;;MICRO;1;Mycobacterium sp identified in Specimen;Mycobacterium Spec;;ACTIVE;2.15;2.73 +40700-7;Aromatic solvents;Prid;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Aromatic solvents [Identifier] in Serum or Plasma;Arom Solvents SerPl;;ACTIVE;2.15;2.15 +40701-5;Arsenic;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Dialysis fluid;Arsenic Dial fld-mCnc;;ACTIVE;2.15;2.70 +40702-3;Fibrin monomer;PrThr;Pt;PPP;Ord;HA;COAG;1;Fibrin monomer [Presence] in Platelet poor plasma by Hemagglutination;Fibrin Monomer PPP Ql HA;;ACTIVE;2.15;2.73 +40703-1;Lactoferrin;PrThr;Pt;Stool;Ord;IA;CHEM;1;Lactoferrin [Presence] in Stool by Immunoassay;Lactoferrin Stl Ql IA;;ACTIVE;2.15;2.73 +40704-9;Maternal cell contamination;Prid;Pt;Bld;Nom;;MOLPATH;1;Maternal cell contamination [Identifier] in Blood Nominal;Maternal Cell Contam Bld;;ACTIVE;2.15;2.73 +40705-6;Brodifacoum;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Brodifacoum [Mass/volume] in Blood;Brodifacoum Bld-mCnc;;ACTIVE;2.15;2.42 +40706-4;Colchicine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Colchicine [Mass/volume] in Urine;Colchicine Ur-mCnc;;ACTIVE;2.15;2.42 +40707-2;Amphotericin B^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amphotericin B [Mass/volume] in Serum or Plasma --peak;Amphotericin B Peak SerPl-mCnc;;ACTIVE;2.15;2.40 +40708-0;Polio virus Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus IgG Ab [Titer] in Serum --2nd specimen;PV IgG sp2 Titr Ser;;ACTIVE;2.15;2.30 +4070-9;Triazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Triazolam [Mass/volume] in Urine;Triazolam Ur-mCnc;;ACTIVE;1.0;2.73 +40709-8;Polio virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Polio virus Ab [Units/volume] in Cerebral spinal fluid;PV Ab CSF-aCnc;;ACTIVE;2.15;2.69 +40710-6;Chlamydia trachomatis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydia trachomatis IgM Ab [Presence] in Serum by Immunoassay;C trach IgM Ser Ql IA;;ACTIVE;2.15;2.56 +40711-4;Clostridium tetani Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Clostridium tetani Ab [Units/volume] in Serum by Immunoassay;C tetani Ab Ser IA-aCnc;;DISCOURAGED;2.15;2.70 +40712-2;Coccidioides immitis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coccidioides immitis Ab [Presence] in Serum by Immunoassay;C immitis Ab Ser Ql IA;;ACTIVE;2.15;2.56 +40713-0;Giardia lamblia Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Giardia lamblia IgG Ab [Presence] in Serum by Immunoassay;G lamblia IgG Ser Ql IA;;ACTIVE;2.15;2.73 +40714-8;Giardia lamblia Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Giardia lamblia IgM Ab [Presence] in Serum by Immunoassay;G lamblia IgM Ser Ql IA;;ACTIVE;2.15;2.73 +40715-5;Granulocytes.immature;PrThr;Pt;Bld;Ord;;HEM/BC;1;Immature granulocytes [Presence] in Blood;Imm Granulocytes Bld Ql;;ACTIVE;2.15;2.73 +40716-3;Hairy cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Hairy cells [Presence] in Blood by Light microscopy;Hairy Cells Bld Ql Smear;;ACTIVE;2.15;2.56 +4071-7;Chloral hydrate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chloral hydrate [Mass/volume] in Blood;Chloral Hydrate Bld-mCnc;;ACTIVE;1.0;2.40 +40717-1;Haptoglobin;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Haptoglobin [Presence] in Serum or Plasma;Haptoglob SerPl Ql;;ACTIVE;2.15;2.73 +40718-9;Heinz bodies/100 erythrocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Heinz bodies/100 erythrocytes in Blood;Heinz Bod/100 RBC NFr Bld;;ACTIVE;2.15;2.70 +40719-7;Hemoglobin;MCnc;Pt;BldCo;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Cord blood;Hgb BldCo-mCnc;;ACTIVE;2.15;2.73 +40720-5;Hemoglobin C;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin C [Presence] in Blood;Hgb C Bld Ql;;ACTIVE;2.15;2.56 +40721-3;Hemoglobin F;PrThr;Pt;XXX;Ord;Apt-Downey;HEM/BC;1;Hemoglobin F [Presence] in Specimen by Apt-Downey method;Hgb F Spec Ql Apt-Downey;;ACTIVE;2.15;2.73 +40722-1;Hemosiderin;PrThr;Pt;Sputum;Ord;;HEM/BC;1;Hemosiderin [Presence] in Sputum;Hemosiderin Spt Ql;;ACTIVE;2.15;2.56 +40723-9;Heparin Ab;PrThr;Pt;PPP;Ord;Platelet aggr;COAG;1;Heparin Ab [Presence] in Platelet poor plasma by Platelet aggregation;Heparin Ab PPP Ql Pl Agg;;ACTIVE;2.15;2.73 +40724-7;Hepatitis A virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay;HAV IgG Ser Ql IA;;ACTIVE;2.15;2.73 +4072-5;Chloral hydrate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chloral hydrate [Mass/volume] in Urine;Chloral Hydrate Ur-mCnc;;ACTIVE;1.0;2.73 +40725-4;Hepatitis B virus core Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis B virus core IgG Ab [Presence] in Serum by Immunoassay;HBV core IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40726-2;Hepatitis C virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis C virus IgG Ab [Presence] in Serum or Plasma by Immunoassay;HCV IgG SerPl Ql IA;;ACTIVE;2.15;2.73 +40727-0;Hepatitis D virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis D virus Ab [Presence] in Serum by Immunoassay;HDV Ab Ser Ql IA;;ACTIVE;2.15;2.73 +40728-8;Herpes simplex virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes simplex virus IgG Ab [Presence] in Serum by Immunoassay;HSV IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40729-6;Herpes simplex virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes simplex virus IgM Ab [Presence] in Serum by Immunoassay;HSV IgM Ser Ql IA;;ACTIVE;2.15;2.73 +40730-4;Herpes virus 6 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes virus 6 IgG Ab [Presence] in Serum by Immunoassay;HHV6 IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40731-2;Herpes virus 6 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes virus 6 IgM Ab [Presence] in Serum by Immunoassay;HHV6 IgM Ser Ql IA;;ACTIVE;2.15;2.56 +40732-0;HIV 1 Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 IgG Ab [Presence] in Serum by Immunoblot;HIV1 IgG Ser Ql IB;;ACTIVE;2.15;2.73 +4073-3;Tricyclic antidepressants;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Serum or Plasma;Tricyclics SerPl Ql;;ACTIVE;1.0;2.73 +40733-8;HIV 1+2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1+2 IgG Ab [Presence] in Serum or Plasma by Immunoassay;HIV1+2 IgG SerPl Ql IA;;ACTIVE;2.15;2.73 +40734-6;HLA Ab;ACnc;Pt;Ser;Qn;;HLA;1;HLA Ab [Units/volume] in Serum;HLA Ab Ser-aCnc;;ACTIVE;2.15;2.73 +40735-3;HTLV I+II Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II IgG Ab [Presence] in Serum by Immunoblot;HTLV I+II IgG Ser Ql IB;;ACTIVE;2.15;2.58 +40736-1;La Crosse virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;La Crosse virus Ab [Presence] in Serum by Hemagglutination inhibition;LACV Ab Ser Ql HAI;;ACTIVE;2.15;2.58 +40737-9;Mumps virus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Mumps virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;MuV IgG CSF Ql IA;;ACTIVE;2.15;2.56 +40738-7;Mumps virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Mumps virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;MuV IgM CSF Ql IA;;ACTIVE;2.15;2.56 +40739-5;Osmotic fragility^unincubated;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--unincubated;OF Unincubated NFr RBC;;ACTIVE;2.15;2.34 +40740-3;Osmotic fragility^incubated;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--Incubated;OF Incubated NFr RBC;;ACTIVE;2.15;2.34 +4074-1;Trifluoperazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trifluoperazine [Mass/volume] in Serum or Plasma;TriFperazine SerPl-mCnc;;ACTIVE;1.0;2.73 +40741-1;Platelet clump;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Platelet clump [Presence] in Blood by Automated count;Platelet Clump Bld Ql Auto;;ACTIVE;2.15;2.73 +40742-9;Rabies virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rabies virus IgG Ab [Presence] in Serum by Immunofluorescence;RABV IgG Ser Ql IF;;ACTIVE;2.15;2.56 +40743-7;Plasma cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Plasma cells [Presence] in Blood by Light microscopy;Plasma Cells Bld Ql Smear;;ACTIVE;2.15;2.73 +40744-5;Factor inhibitor XXX;PrThr;Pt;PPP;Ord;Coag;COAG;1;Factor inhibitor XXX [Presence] in Platelet poor plasma by Coagulation assay;Fact Inhib XXX PPP Ql;;ACTIVE;2.15;2.56 +40745-2;Filaria identified;Prid;Pt;Bld;Nom;;MICRO;1;Filaria identified in Blood;Filaria Bld;;ACTIVE;2.15;2.73 +40746-0;Fragments;PrThr;Pt;Bld;Ord;Automated count;HEM/BC;1;Fragments [Presence] in Blood by Automated count;Fragments Bld Ql Auto;;ACTIVE;2.15;2.73 +40747-8;Complement C2;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Complement C2 [Presence] in Serum or Plasma;C2 SerPl Ql;;ACTIVE;2.15;2.56 +40748-6;Dengue virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Dengue virus Ab [Presence] in Serum by Hemagglutination inhibition;DENV Ab Ser Ql HAI;;ACTIVE;2.15;2.56 +40749-4;Echinococcus sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Echinococcus sp Ab [Presence] in Serum by Complement fixation;Echinococcus Ab Ser Ql CF;;ACTIVE;2.15;2.56 +40750-2;Epstein Barr virus capsid Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus capsid IgG Ab [Presence] in Serum by Immunofluorescence;EBV VCA IgG Ser Ql IF;;ACTIVE;2.15;2.73 +40751-0;Epstein Barr virus capsid Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus capsid IgM Ab [Presence] in Serum by Immunofluorescence;EBV VCA IgM Ser Ql IF;;ACTIVE;2.15;2.73 +40752-8;Epstein Barr virus early Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epstein Barr virus early IgG Ab [Presence] in Serum by Immunoassay;EBV EA IgG Ser Ql IA;;ACTIVE;2.15;2.73 +40753-6;Epstein Barr virus nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum by Immunofluorescence;EBV NA IgG Ser IF-aCnc;;ACTIVE;2.15;2.69 +40754-4;17-Hydroxyprogesterone;MCnc;Pt;Amnio fld;Qn;;CHEM;1;17-Hydroxyprogesterone [Mass/volume] in Amniotic fluid;17OHP Amn-mCnc;;ACTIVE;2.15;2.42 +40755-1;Amiodarone^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amiodarone [Mass/volume] in Serum or Plasma --peak;Amiodarone Peak SerPl-mCnc;;ACTIVE;2.15;2.40 +40756-9;Amiodarone^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amiodarone [Mass/volume] in Serum or Plasma --trough;Amiodarone Trough SerPl-mCnc;;ACTIVE;2.15;2.40 +40757-7;Amphotericin B^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amphotericin B [Mass/volume] in Serum or Plasma --trough;Amphotericin B Trough SerPl-mCnc;;ACTIVE;2.15;2.40 +4075-8;Trimeperidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trimeperidine [Presence] in Urine;Trimeperidine Ur Ql;;ACTIVE;1.0;2.56 +40758-5;Coxsackievirus A Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A Ab [Titer] in Cerebral spinal fluid;CV A Ab Titr CSF;;ACTIVE;2.15;2.30 +40759-3;Coxsackievirus A Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A IgM Ab [Titer] in Serum --1st specimen;CV A IgM sp1 Titr Ser;;ACTIVE;2.15;2.30 +40760-1;Coxsackievirus A Ab^2nd specimen;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus A Ab [Titer] in Cerebral spinal fluid --2nd specimen;CV A Ab sp2 Titr CSF;;ACTIVE;2.15;2.30 +40761-9;Coxsackievirus A Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A Ab [Titer] in Serum --2nd specimen;CV A Ab sp2 Titr Ser;;ACTIVE;2.15;2.30 +40762-7;Coxsackievirus A Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A Ab [Titer] in Serum --1st specimen;CV A Ab sp1 Titr Ser;;ACTIVE;2.15;2.30 +40763-5;Coxsackievirus B Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B IgM Ab [Titer] in Serum --1st specimen;CV B IgM sp1 Titr Ser;;ACTIVE;2.15;2.30 +40764-3;Coxsackievirus B Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B IgG Ab [Titer] in Serum --2nd specimen;CV B IgG sp2 Titr Ser;;ACTIVE;2.15;2.30 +40765-0;Coxsackievirus B Ab;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B Ab [Titer] in Cerebral spinal fluid;CV B Ab Titr CSF;;ACTIVE;2.15;2.30 +4076-6;Trimeperidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trimeperidine [Mass/volume] in Urine;Trimeperidine Ur-mCnc;;ACTIVE;1.0;2.34 +40766-8;Coxsackievirus B Ab.IgM^1st specimen;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B IgM Ab [Titer] in Cerebral spinal fluid --1st specimen;CV B IgM sp1 Titr CSF;;ACTIVE;2.15;2.30 +40767-6;Coxsackievirus B Ab.IgG^2nd specimen;Titr;Pt;CSF;Qn;;MICRO;1;Coxsackievirus B IgG Ab [Titer] in Cerebral spinal fluid --2nd specimen;CV B IgG sp2 Titr CSF;;ACTIVE;2.15;2.30 +40768-4;Cryptococcus sp Ag;Titr;Pt;Ser;Qn;;MICRO;1;Cryptococcus sp Ag [Titer] in Serum;Cryptoc Ag Titr Ser;;ACTIVE;2.15;2.73 +40769-2;Ethosuximide^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethosuximide [Mass/volume] in Serum or Plasma --peak;Ethosuximide Peak SerPl-mCnc;;ACTIVE;2.15;2.40 +407-7;Piperacillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Piperacillin [Susceptibility] by Minimum lethal concentration (MLC);Piperacillin Islt MLC;;ACTIVE;1.0;2.19 +40770-0;Ethosuximide^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethosuximide [Mass/volume] in Serum or Plasma --trough;Ethosuximide Trough SerPl-mCnc;;ACTIVE;2.15;2.40 +40771-8;Haemophilus influenzae Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Haemophilus influenzae Ag [Presence] in Urine;Haem influ Ag Ur Ql;;ACTIVE;2.15;2.56 +40772-6;Heavy metals;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Heavy metals [Presence] in Urine;Heavy Metals Ur Ql;;ACTIVE;2.15;2.56 +40773-4;Histoplasma capsulatum Ab.IgM^1st specimen;Titr;Pt;CSF;Qn;;MICRO;1;Histoplasma capsulatum IgM Ab [Titer] in Cerebral spinal fluid --1st specimen;H capsul IgM sp1 Titr CSF;;ACTIVE;2.15;2.30 +4077-4;Trimeperidine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Trimeperidine [Mass/time] in 24 hour Urine;Trimeperidine 24h Ur-mRate;;ACTIVE;1.0;2.19 +40774-2;Histoplasma capsulatum Ab.IgG^2nd specimen;Titr;Pt;CSF;Qn;;MICRO;1;Histoplasma capsulatum IgG Ab [Titer] in Cerebral spinal fluid --2nd specimen;H capsul IgG sp2 Titr CSF;;ACTIVE;2.15;2.30 +40775-9;Histoplasma capsulatum Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum IgM Ab [Titer] in Serum --1st specimen;H capsul IgM sp1 Titr Ser;;ACTIVE;2.15;2.30 +40776-7;Histoplasma capsulatum Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum Ag [Presence] in Cerebral spinal fluid;H capsul Ag CSF Ql;;ACTIVE;2.15;2.56 +40777-5;Histoplasma sp Ab;ACnc;Pt;CSF;Ord;;MICRO;1;Deprecated Histoplasma capsulatum Ab [Presence] in Cerebral spinal fluid;Deprecated Histoplasma Ab CSF Ql;;DEPRECATED;2.15;2.36 +40778-3;Histoplasma capsulatum Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum IgG Ab [Titer] in Serum --2nd specimen;H capsul IgG sp2 Titr Ser;;ACTIVE;2.15;2.30 +40779-1;Mexiletine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mexiletine [Mass/volume] in Serum or Plasma --trough;Mexiletine Trough SerPl-mCnc;;ACTIVE;2.15;2.40 +40780-9;Mexiletine^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mexiletine [Mass/volume] in Serum or Plasma --peak;Mexiletine Peak SerPl-mCnc;;ACTIVE;2.15;2.40 +40781-7;Polio virus Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus IgM Ab [Titer] in Serum --1st specimen;PV IgM sp1 Titr Ser;;ACTIVE;2.15;2.30 +4078-2;Trimethadione;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimethadione [Mass/volume] in Serum or Plasma;TMO SerPl-mCnc;;ACTIVE;1.0;2.73 +40782-5;Polio virus Ab.IgM^1st specimen;Titr;Pt;CSF;Qn;;MICRO;1;Polio virus IgM Ab [Titer] in Cerebral spinal fluid --1st specimen;PV IgM sp1 Titr CSF;;ACTIVE;2.15;2.30 +40783-3;Polio virus Ab.IgG^2nd specimen;Titr;Pt;CSF;Qn;;MICRO;1;Polio virus IgG Ab [Titer] in Cerebral spinal fluid --2nd specimen;PV IgG sp2 Titr CSF;;ACTIVE;2.15;2.30 +40784-1;Streptococcus agalactiae Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Streptococcus agalactiae Ag [Presence] in Vaginal fluid;Gp B Strep Ag Vag Ql;;ACTIVE;2.15;2.73 +40785-8;Toxoplasma gondii Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgM Ab [Titer] in Serum --1st specimen;T gondii IgM sp1 Titr Ser;;ACTIVE;2.15;2.30 +40786-6;Toxoplasma gondii Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Titer] in Serum --2nd specimen;T gondii IgG sp2 Titr Ser;;ACTIVE;2.15;2.30 +40787-4;Calculus analysis;Imp;Pt;Calculus;Nom;Infrared spectroscopy;CHEM;1;Calculus analysis [Interpretation] in Stone by Infrared spectroscopy;Stone Analysis IR-Imp;;ACTIVE;2.15;2.73 +40788-2;Chamaecyparis obtusa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Japanese cypress IgE Ab [Units/volume] in Serum;Japanese cypress IgE Qn;;ACTIVE;2.15;2.56 +40789-0;Humulus japonicus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Japanese hop IgE Ab [Units/volume] in Serum;Japanese hop IgE Qn;;ACTIVE;2.15;2.42 +4079-0;Trimethoprim;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Trimethoprim [Presence] in Serum or Plasma;Trimethoprim SerPl Ql;;ACTIVE;1.0;2.73 +40790-8;Elaeis guineensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oil palm IgE Ab [Units/volume] in Serum;Oil palm IgE Qn;;ACTIVE;2.15;2.42 +40791-6;Coproporphyrin 3;SRat;24H;Urine;Qn;;CHEM;1;Coproporphyrin 3 [Moles/time] in 24 hour Urine;Copro3 24h Ur-sRate;;ACTIVE;2.15;2.70 +40792-4;Coproporphyrin 1;SRat;24H;Urine;Qn;;CHEM;1;Coproporphyrin 1 [Moles/time] in 24 hour Urine;Copro1 24h Ur-sRate;;ACTIVE;2.15;2.70 +40793-2;Alkaline phosphatase.placental;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.placental [Presence] in Serum or Plasma;ALP Plac SerPl Ql;;ACTIVE;2.15;2.73 +40794-0;Alkaline phosphatase.intestinal;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.intestinal [Presence] in Serum or Plasma;ALP Intest SerPl Ql;;ACTIVE;2.15;2.73 +40795-7;Alkaline phosphatase.liver 2;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.liver 2 [Presence] in Serum or Plasma;ALP Liver 2 SerPl Ql;;ACTIVE;2.15;2.56 +40796-5;Alkaline phosphatase.liver 1;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.liver 1 [Presence] in Serum or Plasma;ALP Liver 1 SerPl Ql;;ACTIVE;2.15;2.56 +40797-3;Alkaline phosphatase.bone;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.bone [Presence] in Serum or Plasma;ALP Bone SerPl Ql;;ACTIVE;2.15;2.73 +40798-1;Amphetamines;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Hair by Screen method;Amphetamines Hair Ql Scn;;ACTIVE;2.15;2.73 +40799-9;Amphetamines;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Saliva (oral fluid) by Screen method;Amphetamines Sal Ql Scn;;ACTIVE;2.15;2.73 +40800-5;Cannabinoids;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Hair by Screen method;Cannabinoids Hair Ql Scn;;ACTIVE;2.15;2.73 +40801-3;Cannabinoids;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Saliva (oral fluid) by Screen method;Cannabinoids Sal Ql Scn;;ACTIVE;2.15;2.73 +40802-1;Cocaine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Cocaine [Presence] in Saliva (oral fluid) by Screen method;Cocaine Sal Ql Scn;;ACTIVE;2.15;2.73 +40803-9;Methamphetamine;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Methamphetamine [Presence] in Hair by Screen method;Methamphet Hair Ql Scn;;ACTIVE;2.15;2.73 +40804-7;Methamphetamine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Methamphetamine [Presence] in Saliva (oral fluid) by Screen method;Methamphet Sal Ql Scn;;ACTIVE;2.15;2.73 +40805-4;Opiates;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Hair by Screen method;Opiates Hair Ql Scn;;ACTIVE;2.15;2.73 +40806-2;Opiates;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Saliva (oral fluid) by Screen method;Opiates Sal Ql Scn;;ACTIVE;2.15;2.73 +40807-0;Phencyclidine;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Hair by Screen method;PCP Hair Ql Scn;;ACTIVE;2.15;2.73 +4080-8;Trimethoprim;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trimethoprim [Presence] in Urine;Trimethoprim Ur Ql;;ACTIVE;1.0;2.73 +40808-8;Phencyclidine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Saliva (oral fluid) by Screen method;PCP Sal Ql Scn;;ACTIVE;2.15;2.73 +40809-6;11-Deoxycortisol^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;11DC 1h p chal SerPl-mCnc;;ACTIVE;2.15;2.73 +40810-4;11-Deoxycortisol^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --baseline;11DC BS SerPl-mCnc;;ACTIVE;2.15;2.73 +40811-2;11-Deoxycorticosterone;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;11-Deoxycorticosterone [Presence] in Serum or Plasma;11DOC SerPl Ql;;ACTIVE;2.15;2.56 +40812-0;11-Hydroxyandrosterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone/Creatinine [Mass Ratio] in 24 hour Urine;11OH-Androst/Creat 24h Ur;;ACTIVE;2.15;2.73 +40813-8;11-Hydroxyetiocholanolone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone/Creatinine [Mass Ratio] in 24 hour Urine;11OH-Etioch/Creat 24h Ur;;ACTIVE;2.15;2.73 +40814-6;11-Ketoandrosterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;11-Ketoandrosterone/Creatinine [Mass Ratio] in 24 hour Urine;11Ketoandros/Creat 24h Ur;;ACTIVE;2.15;2.44 +40815-3;11-Ketoetiocholanolone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone/Creatinine [Mass Ratio] in 24 hour Urine;11Ketoetioch/Creat 24h Ur;;ACTIVE;2.15;2.44 +4081-6;Trimethoprim+Sulfamethoxazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Trimethoprim+Sulfamethoxazole [Mass/volume] in Serum or Plasma;Deprecated TMP SMX SerPl-mCnc;;DEPRECATED;1.0;2.65 +40816-1;11-Deoxycorticosterone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;11DOC 1h p chal SerPl-mCnc;;ACTIVE;2.15;2.73 +40817-9;Tetrachlorodiphenylethane;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Tetrachlorodiphenylethane [Presence] in Serum or Plasma;DDD SerPl Ql;;ACTIVE;2.15;2.73 +40818-7;11-Deoxycorticosterone;SCnc;24H;Urine;Qn;;CHEM;1;11-Deoxycorticosterone [Moles/volume] in 24 hour Urine;11DOC 24h Ur-sCnc;;ACTIVE;2.15;2.42 +40819-5;Disialylganglioside GD1a Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Disialylganglioside GD1a IgM Ab [Units/volume] in Serum;Deprecated GD1a Disialyl IgM Ser-aCnc;;DEPRECATED;2.15;2.69 +40820-3;Helicobacter pylori Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Helicobacter pylori IgA Ab [Titer] in Serum;H pylori IgA Titr Ser;;ACTIVE;2.15;2.73 +40821-1;Helicobacter pylori Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Helicobacter pylori IgM Ab [Titer] in Serum;H pylori IgM Titr Ser;;ACTIVE;2.15;2.70 +40822-9;HTLV I Ab;PrThr;Pt;CSF;Ord;;MICRO;1;HTLV I Ab [Presence] in Cerebral spinal fluid;HTLV I Ab CSF Ql;;ACTIVE;2.15;2.56 +40823-7;HTLV II Ab;PrThr;Pt;CSF;Ord;;MICRO;1;HTLV II Ab [Presence] in Cerebral spinal fluid;HTLV II Ab CSF Ql;;ACTIVE;2.15;2.56 +4082-4;Trimipramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Trimipramine [Presence] in Serum or Plasma;Trimipramine SerPl Ql;;ACTIVE;1.0;2.73 +40824-5;von Willebrand factor cleaving protease inhibitor;ACnc;Pt;PPP;Qn;;COAG;1;von Willebrand factor (vWf) cleaving protease inhibitor [Units/volume] in Platelet poor plasma;vWF Cp Inhib PPP-aCnc;;ACTIVE;2.15;2.73 +40825-2;Candida sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Candida sp IgG Ab [Titer] in Serum;Candida IgG Titr Ser;;ACTIVE;2.15;2.73 +40826-0;Blastomyces dermatitidis Ab;ACnc;Pt;Body fld;Ord;;MICRO;1;Deprecated Blastomyces dermatitidis Ab [Presence] in Body fluid;Deprecated B dermat Ab Fld Ql;;DEPRECATED;2.15;2.36 +40827-8;Histoplasma capsulatum Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Histoplasma capsulatum Ab [Presence] in Body fluid;H capsul Ab Fld Ql;;ACTIVE;2.15;2.73 +40828-6;Aspergillus fumigatus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Aspergillus fumigatus Ab [Presence] in Body fluid;A fumigatus Ab Fld Ql;;ACTIVE;2.15;2.56 +40829-4;Ornithine;PrThr;Pt;Bld;Ord;;CHEM;1;Ornithine [Presence] in Blood;Ornithine Bld Ql;;ACTIVE;2.15;2.56 +40830-2;Toxocara sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Toxocara sp Ab [Units/volume] in Serum;Toxocara Ab Ser-aCnc;;ACTIVE;2.15;2.73 +40831-0;Adenovirus+Rotavirus Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Adenovirus+Rotavirus Ag [Presence] in Stool;HAdV+RV Ag Stl Ql;;ACTIVE;2.15;2.56 +4083-2;Trimipramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimipramine [Mass/volume] in Serum or Plasma;Trimipramine SerPl-mCnc;;ACTIVE;1.0;2.73 +40832-8;Pistacia vera Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pistachio IgE Ab/IgE total in Serum;Pistachio IgE/IgE total %;;ACTIVE;2.15;2.70 +40833-6;SOD1 gene allele 1;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SOD1 gene allele 1 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SOD1 allele 1 Bld/T;;ACTIVE;2.15;2.15 +40834-4;Herpes virus 8 Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Herpes virus 8 IgG Ab [Presence] in Serum by Immunofluorescence;HHV8 IgG Ser Ql IF;;ACTIVE;2.15;2.73 +40835-1;Fragaria vesca Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Strawberry IgG Ab [Mass/volume] in Serum;Strawberry IgG-mCnc;;ACTIVE;2.15;2.73 +40836-9;Sulfonamide crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Sulfonamide crystals [#/area] in Urine sediment by Microscopy low power field;Sulfonamide cry #/area UrnS LPF;;ACTIVE;2.15;2.70 +40837-7;Alternaria sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Alternaria sp IgG Ab [Presence] in Serum;Alternaria IgG Ser Ql;;ACTIVE;2.15;2.56 +40838-5;Argininosuccinate;SCnc;Pt;CSF;Qn;;CHEM;1;Argininosuccinate [Moles/volume] in Cerebral spinal fluid;Argininosuccinate CSF-sCnc;;ACTIVE;2.15;2.73 +40839-3;fentaNYL;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;fentaNYL [Presence] in Urine by Confirmatory method;fentaNYL Ur Ql Cfm;;ACTIVE;2.15;2.73 +4084-0;Trimipramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trimipramine [Presence] in Urine;Trimipramine Ur Ql;;ACTIVE;1.0;2.73 +40840-1;Legionella pneumophila 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 1 Ab [Presence] in Serum;L pneumo1 Ab Ser Ql;;ACTIVE;2.15;2.56 +40841-9;Lycopersicon lycopersicum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Tomato IgE Ab/IgE total in Serum;Tomato IgE/IgE total %;;ACTIVE;2.15;2.70 +40842-7;Galactose 1 phosphate;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Galactose 1 phosphate [Mass/volume] in DBS;Gal1PO4 DBS-mCnc;;ACTIVE;2.15;2.70 +40843-5;Chicken meat Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Chicken meat IgE Ab/IgE total in Serum;Chicken Meat IgE/IgE total %;;ACTIVE;2.15;2.70 +40844-3;Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda;MRto;Pt;Ser;Qn;;CHEM;1;Deprecated Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda [Mass Ratio] in Serum;Deprecated Kappa LC Free/Lambda Ser;;DEPRECATED;2.15;2.70 +40845-0;Turkey meat Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Turkey meat IgE Ab/IgE total in Serum;Turkey Meat IgE/IgE total %;;ACTIVE;2.15;2.70 +40846-8;Homovanillate;SCnc;Pt;CSF;Qn;;CHEM;1;Homovanillate [Moles/volume] in Cerebral spinal fluid;HVA CSF-sCnc;;ACTIVE;2.15;2.70 +40847-6;Bromus inermis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Brome IgG4 Ab [Mass/volume] in Serum;Brome IgG4-mCnc;;ACTIVE;2.15;2.73 +40848-4;3-Methylcrotonylglycine;MRat;24H;Urine;Qn;;CHEM;1;3-Methylcrotonylglycine [Mass/time] in 24 hour Urine;3Me-crotonylglycine 24h Ur-mRate;;ACTIVE;2.15;2.70 +40849-2;Glucose^1st specimen post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Glucose [Mass/volume] in Urine by Test strip --1st specimen post XXX challenge;Glucose sp1 p chal Ur Strip-mCnc;;ACTIVE;2.15;2.70 +408-5;Piperacillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Piperacillin [Susceptibility] by Minimum inhibitory concentration (MIC);Piperacillin Islt MIC;;ACTIVE;1.0;2.73 +40850-0;Glucose^2nd specimen post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Glucose [Mass/volume] in Urine by Test strip --2nd specimen post XXX challenge;Glucose sp2 p chal Ur Strip-mCnc;;ACTIVE;2.15;2.70 +40851-8;Normetanephrine.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Normetanephrine Free [Moles/volume] in Serum or Plasma;Normetaneph Free SerPl-sCnc;;ACTIVE;2.15;2.73 +40852-6;Leishmania sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania sp IgG Ab [Units/volume] in Serum;Leishmania IgG Ser-aCnc;;ACTIVE;2.15;2.73 +40853-4;Leishmania sp Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Leishmania sp IgG Ab [Units/volume] in Cerebral spinal fluid;Leishmania IgG CSF-aCnc;;ACTIVE;2.15;2.69 +40854-2;Chlamydia trachomatis L2 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis L2 IgG Ab [Titer] in Serum;C trach L2 IgG Titr Ser;;ACTIVE;2.15;2.70 +40855-9;Chlamydia trachomatis L2 Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis L2 IgA Ab [Titer] in Serum;C trach L2 IgA Titr Ser;;ACTIVE;2.15;2.70 +40856-7;Chlamydia trachomatis L2 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis L2 IgM Ab [Titer] in Serum;C trach L2 IgM Titr Ser;;ACTIVE;2.15;2.16 +4085-7;Tripelennamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tripelennamine [Mass/volume] in Serum or Plasma;Tripelennamine SerPl-mCnc;;ACTIVE;1.0;2.73 +40857-5;Prealbumin;MCnc;Pt;Urine;Qn;;CHEM;1;Prealbumin [Mass/volume] in Urine;Prealb Ur-mCnc;;ACTIVE;2.15;2.42 +40858-3;Glucose^baseline;MCnc;Pt;BldC;Qn;;CHAL;1;Glucose [Mass/volume] in Capillary blood --baseline;Glucose BS BldC-mCnc;;ACTIVE;2.15;2.73 +40859-1;SOD1 gene allele 2;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SOD1 gene allele 2 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SOD1 allele 2 Bld/T;;ACTIVE;2.15;2.15 +40860-9;Cytokines;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cytokines [Presence] in Serum or Plasma;Cytokines SerPl Ql;;ACTIVE;2.15;2.73 +40861-7;Cells.CD103/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD103 cells/100 cells in Tissue;CD103 Cells NFr Tiss;;ACTIVE;2.15;2.34 +40862-5;Methylparaben Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Methylparaben IgE Ab [Units/volume] in Serum;Methylparaben IgE Qn;;ACTIVE;2.15;2.42 +40863-3;Norovirus genogroup I Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Norovirus genogroup I Ag [Presence] in Stool;Norovirus GI Ag Stl Ql;;ACTIVE;2.15;2.56 +40864-1;11-Hydroxy delta-9 tetrahydrocannabinol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Mass/volume] in Serum or Plasma;11OH-THC SerPl-mCnc;;ACTIVE;2.15;2.73 +4086-5;Valproate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate [Mass/volume] in Serum or Plasma;Valproate SerPl-mCnc;;ACTIVE;1.0;2.73 +40865-8;11-Oxo-Androsterone;MRat;24H;Urine;Qn;;CHEM;1;11-Oxo-Androsterone [Mass/time] in 24 hour Urine;11oxoAndrost 24h Ur-mRate;;ACTIVE;2.15;2.73 +40866-6;11-Oxo-Androsterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;11-Oxo-Androsterone/Creatinine [Mass Ratio] in 24 hour Urine;11oxoAndrost/Creat 24h Ur;;ACTIVE;2.15;2.73 +40867-4;11-Oxo-Etiocholanolone;MRat;24H;Urine;Qn;;CHEM;1;11-Oxo-Etiocholanolone [Mass/time] in 24 hour Urine;11oxoEtioch 24h Ur-mRate;;ACTIVE;2.15;2.73 +40868-2;11-Oxo-Etiocholanolone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;11-Oxo-Etiocholanolone/Creatinine [Mass Ratio] in 24 hour Urine;11oxoEtioch/Creat 24h Ur;;ACTIVE;2.15;2.73 +40869-0;Carnitine esters/Carnitine.free (C0);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine esters/Carnitine.free (C0) [Molar ratio] in Serum or Plasma;Carn esters/C0 SerPl-sRto;;ACTIVE;2.15;2.73 +40870-8;Cystine.free;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cystine Free [Presence] in Serum or Plasma;Cystine Free SerPl Ql;;ACTIVE;2.15;2.56 +40871-6;CNBP gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CNBP gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CNBP Mut Anl Bld/T;;ACTIVE;2.15;2.63 +40872-4;CBS gene.c.833T>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CBS gene c.833T>C [Presence] in Blood or Tissue by Molecular genetics method;CBS c.833T>C Bld/T Ql;;ACTIVE;2.15;2.56 +4087-3;Valproate.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate Free [Mass/volume] in Serum or Plasma;Valproate Free SerPl-mCnc;;ACTIVE;1.0;2.73 +40873-2;CBS gene.c.919G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CBS gene c.919G>A [Presence] in Blood or Tissue by Molecular genetics method;CBS c.919G>A Bld/T Ql;;ACTIVE;2.15;2.56 +40874-0;Glucose^1st specimen;MCnc;Pt;XXX;Qn;;CHEM;1;Glucose [Mass/volume] in Specimen --1st specimen;Glucose sp1 Spec-mCnc;;ACTIVE;2.15;2.69 +40875-7;Glucose^3rd specimen;MCnc;Pt;XXX;Qn;;CHEM;1;Glucose [Mass/volume] in Specimen --3rd specimen;Glucose sp3 Spec-mCnc;;ACTIVE;2.15;2.69 +40876-5;AMPD1 gene.p.Gln12Ter+AMPD1 gene.p.Pro48Leu;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;AMPD1 gene p.Gln12Ter and p.Pro48Leu [Presence] in Blood or Tissue by Molecular genetics method;AMPD1 p.Q12X+P48L Bld/T Ql;;ACTIVE;2.15;2.56 +40877-3;CPT2 gene.p.Pro50His+Ser113Leu;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CPT2 gene p.Pro50His+Ser113Leu [Presence] in Blood or Tissue by Molecular genetics method;CPT2 p.P50H+S113L Bld/T Ql;;ACTIVE;2.15;2.73 +40878-1;CPT2 gene.p.Gln413FSer+Gly549Asp;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CPT2 gene p.Gln413FSer+Gly549Asp [Presence] in Blood or Tissue by Molecular genetics method;CPT2 p.Q413FS+G549D Bld/T Ql;;ACTIVE;2.15;2.56 +40879-9;Chicken Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicken IgE Ab [Units/volume] in Serum;Chicken IgE Qn;;ACTIVE;2.15;2.73 +40880-7;Cells.CD3-CD56+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD56+ cells/100 cells in Tissue;CD3-CD56+ Cells NFr Tiss;;ACTIVE;2.15;2.34 +4088-1;Valproate^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate [Mass/volume] in Serum or Plasma --trough;Valproate Trough SerPl-mCnc;;ACTIVE;1.0;2.73 +40881-5;Cells.CD3-CD57+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD57+ cells/100 cells in Bone marrow;CD3-CD57+ Cells NFr Mar;;ACTIVE;2.15;2.70 +40882-3;Cells.CD3-CD57+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3-CD57+ cells/100 cells in Body fluid;CD3-CD57+ Cells NFr Fld;;ACTIVE;2.15;2.70 +40883-1;Cells.CD19+CD103+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19+CD103+ cells/100 cells in Bone marrow;CD19+CD103+ Cells NFr Mar;;ACTIVE;2.15;2.34 +40884-9;Cells.CD19+CD103+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD19+CD103+ cells/100 cells in Tissue;CD19+CD103+ Cells NFr Tiss;;ACTIVE;2.15;2.34 +40885-6;Cells.CD19+CD103+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+CD103+ cells/100 cells in Blood;CD19+CD103+ Cells NFr Bld;;ACTIVE;2.15;2.34 +40886-4;Cells.CD19+CD103+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD103+ cells/100 cells in Body fluid;CD19+CD103+ Cells NFr Fld;;ACTIVE;2.15;2.34 +40887-2;Cells.CD11c+CD19+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD11c+CD19+ cells/100 cells in Tissue;CD11c+CD19+ Cells NFr Tiss;;ACTIVE;2.15;2.34 +40888-0;Cells.CD11c+CD19+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD11c+CD19+ cells/100 cells in Body fluid;CD11c+CD19+ Cells NFr Fld;;ACTIVE;2.15;2.70 +40889-8;Cells.CD25+CD19+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD25+CD19+ cells/100 cells in Tissue;CD25+CD19+ Cells NFr Tiss;;ACTIVE;2.15;2.70 +40890-6;Cells.CD25+CD19+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD25+CD19+ cells/100 cells in Body fluid;CD25+CD19+ Cells NFr Fld;;ACTIVE;2.15;2.34 +40891-4;Cells.CD3-CD57+;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD3-CD57+ cells [#/volume] in Body fluid;CD3-CD57+ Cells # Fld;;ACTIVE;2.15;2.42 +40892-2;Cells.CD3-CD16+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD16+ cells/100 cells in Bone marrow;CD3-CD16+ Cells NFr Mar;;ACTIVE;2.15;2.34 +40893-0;Cells.CD3-CD16+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD16+ cells/100 cells in Tissue;CD3-CD16+ Cells NFr Tiss;;ACTIVE;2.15;2.34 +40894-8;Cells.CD3-CD16+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3-CD16+ cells/100 cells in Body fluid;CD3-CD16+ Cells NFr Fld;;ACTIVE;2.15;2.34 +40895-5;Cells.CD3+CD56+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD56+ cells [#/volume] in Bone marrow;CD3+CD56+ Cells # Mar;;ACTIVE;2.15;2.42 +40896-3;Cells.CD3+CD56+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD56+ cells [#/volume] in Tissue;CD3+CD56+ Cells # Tiss;;ACTIVE;2.15;2.42 +40897-1;Cells.CD3+CD56+;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD56+ cells [#/volume] in Body fluid;CD3+CD56+ Cells # Fld;;ACTIVE;2.15;2.42 +40898-9;Cells.CD3+CD4+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells [#/volume] in Tissue;CD3+CD4+ Cells # Tiss;;ACTIVE;2.15;2.42 +4089-9;Vancomycin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin Free [Mass/volume] in Serum or Plasma;Vancomycin Free SerPl-mCnc;;ACTIVE;1.0;2.40 +40899-7;Cells.CD3+CD8+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells [#/volume] in Tissue;CD3+CD8+ Cells # Tiss;;ACTIVE;2.15;2.72 +40900-3;Cells.CD3+CD4+/Cells.CD3+CD8+;NRto;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Tissue;CD3+CD4+ Cells/CD3+CD8+ Cells Tiss;;ACTIVE;2.15;2.36 +40901-1;3-Hydroxybenzoylecgonine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;3-Hydroxybenzoylecgonine [Mass/mass] in Meconium;3OH-BZE Mec-mCnt;;ACTIVE;2.15;2.73 +40902-9;Streptococcus pneumoniae 12 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum12 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40903-7;Streptococcus pneumoniae 12 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum12 IgG Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40904-5;Streptococcus pneumoniae 12 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum12 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40905-2;Streptococcus pneumoniae Danish serotype 6B Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 6B IgG Ser IA-mCnc;;ACTIVE;2.15;2.73 +40906-0;Streptococcus pneumoniae Danish serotype 6B Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 6B IgG sp1 Ser IA-mCnc;;ACTIVE;2.15;2.73 +4090-7;Vancomycin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Serum or Plasma --peak;Vancomycin Peak SerPl-mCnc;;ACTIVE;1.0;2.73 +40907-8;Streptococcus pneumoniae Danish serotype 6B Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 6B IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 6B IgG sp2 Ser IA-mCnc;;ACTIVE;2.15;2.73 +40908-6;Streptococcus pneumoniae 4 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum4 IgG Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40909-4;Streptococcus pneumoniae 4 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum4 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40910-2;Streptococcus pneumoniae 4 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum4 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40911-0;Streptococcus pneumoniae Danish serotype 7F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 7F IgG Ser IA-mCnc;;ACTIVE;2.15;2.73 +40912-8;Streptococcus pneumoniae Danish serotype 18C Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 18C IgG sp2 Ser IA-mCnc;;ACTIVE;2.15;2.73 +40913-6;Streptococcus pneumoniae Danish serotype 18C Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 18C IgG Ser IA-mCnc;;ACTIVE;2.15;2.73 +40914-4;Streptococcus pneumoniae Danish serotype 18C Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 18C IgG sp1 Ser IA-mCnc;;ACTIVE;2.15;2.73 +4091-5;Vancomycin^random;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Serum or Plasma --random;Vancomycin Rand SerPl-mCnc;;DISCOURAGED;1.0;2.73 +40915-1;Streptococcus pneumoniae Danish serotype 19A Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19A IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 19A IgG Ser IA-mCnc;;ACTIVE;2.15;2.73 +40916-9;Streptococcus pneumoniae Danish serotype 19A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19A IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 19A IgG sp1 Ser IA-mCnc;;ACTIVE;2.15;2.73 +40917-7;Streptococcus pneumoniae Danish serotype 19A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19A IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 19A IgG sp2 Ser IA-mCnc;;ACTIVE;2.15;2.73 +40918-5;Streptococcus pneumoniae Danish serotype 9V Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 9V IgG sp1 Ser IA-mCnc;;ACTIVE;2.15;2.73 +40919-3;Streptococcus pneumoniae Danish serotype 9V Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 9V IgG sp2 Ser IA-mCnc;;ACTIVE;2.15;2.73 +40920-1;Streptococcus pneumoniae 8 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum8 IgG Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40921-9;Streptococcus pneumoniae 8 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum8 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40922-7;Streptococcus pneumoniae 8 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum8 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +4092-3;Vancomycin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Serum or Plasma --trough;Vancomycin Trough SerPl-mCnc;;ACTIVE;1.0;2.73 +40923-5;Streptococcus pneumoniae 9 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum9 IgG Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40924-3;Streptococcus pneumoniae 9 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum9 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40925-0;Streptococcus pneumoniae 9 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum9 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.15;2.70 +40926-8;Streptococcus pneumoniae Danish serotype 9V Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 9V IgG Ser IA-mCnc;;ACTIVE;2.15;2.73 +40927-6;3-Methylcrotonylglycine;SCnc;Pt;Bld;Qn;;CHEM;1;3-Methylcrotonylglycine [Moles/volume] in Blood;3Me-crotonylglycine Bld-sCnc;;ACTIVE;2.15;2.70 +40928-4;Cortisol^pre dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre dose dexamethasone;Cortis Pre Dex SerPl-mCnc;;ACTIVE;2.15;2.40 +40929-2;Parathyrin.intact^10M post excision;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --10 minutes post excision;PTH-Intact 10m p Excision SerPl-mCnc;;ACTIVE;2.15;2.73 +409-3;Piperacillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Piperacillin [Susceptibility] by Disk diffusion (KB);Piperacillin Islt KB;;ACTIVE;1.0;2.73 +40930-0;PYGM gene.p.Arg50Ter+Gly205Ser;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PYGM gene p.Arg50Ter+Gly205Ser [Presence] in Blood or Tissue by Molecular genetics method;PYGM p.R50X+G205S Bld/T Ql;;ACTIVE;2.15;2.56 +4093-1;Verapamil;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Verapamil [Presence] in Serum or Plasma;Verapamil SerPl Ql;;ACTIVE;1.0;2.56 +40931-8;Yersinia sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia sp Ab [Presence] in Serum;Yersinia Ab Ser Ql;;ACTIVE;2.15;2.56 +40932-6;Yersinia enterocolitica O:3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia enterocolitica O:3 Ab [Presence] in Serum;Y entero O:3 Ab Ser Ql;;ACTIVE;2.15;2.61 +40933-4;Yersinia enterocolitica O:5 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia enterocolitica O:5 Ab [Presence] in Serum;Y entero O:5 Ab Ser Ql;;ACTIVE;2.15;2.61 +40934-2;Yersinia enterocolitica O:8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia enterocolitica O:8 Ab [Presence] in Serum;Y entero O:8 Ab Ser Ql;;ACTIVE;2.15;2.61 +40935-9;Yersinia enterocolitica O:9 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia enterocolitica O:9 Ab [Presence] in Serum;Y entero O:9 Ab Ser Ql;;ACTIVE;2.15;2.61 +40936-7;Yersinia pseudotuberculosis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia pseudotuberculosis Ab [Presence] in Serum;Y pseudoTB Ab Ser Ql;;ACTIVE;2.15;2.56 +40937-5;Zinc;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Zinc [Presence] in Serum or Plasma;Zinc SerPl Ql;;ACTIVE;2.15;2.56 +40938-3;Yersinia sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yersinia sp IgG Ab [Units/volume] in Serum by Immunoassay;Yersinia IgG Ser IA-aCnc;;ACTIVE;2.15;2.69 +40939-1;Yersinia sp Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yersinia sp IgM Ab [Units/volume] in Serum by Immunoassay;Yersinia IgM Ser IA-aCnc;;ACTIVE;2.15;2.69 +40940-9;Yersinia sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia sp Ab [Titer] in Serum;Yersinia Ab Titr Ser;;ACTIVE;2.15;2.30 +40941-7;Yersinia enterocolitica Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia enterocolitica Ab [Presence] in Serum;Y enterocol Ab Ser Ql;;ACTIVE;2.15;2.56 +40942-5;Yersinia sp Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Yersinia sp IgM Ab [Titer] in Serum by Immunoassay;Yersinia IgM Titr Ser IA;;ACTIVE;2.15;2.56 +40943-3;Vespula spp Ab.IgE;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Jacket IgE Ab [Mass/volume] in Serum;Yellow Jacket IgE-mCnc;;ACTIVE;2.15;2.40 +40944-1;Yohimbine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Yohimbine [Mass/volume] in Serum or Plasma;Yohimbine SerPl-mCnc;;ACTIVE;2.15;2.42 +40945-8;Yersinia enterocolitica Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia enterocolitica IgA Ab [Presence] in Serum;Y enterocol IgA Ser Ql;;ACTIVE;2.15;2.56 +40946-6;Yersinia enterocolitica Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Yersinia enterocolitica IgG Ab [Presence] in Serum;Y enterocol IgG Ser Ql;;ACTIVE;2.15;2.56 +40947-4;Zinc;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Zinc [Presence] in Hair;Zinc Hair Ql;;ACTIVE;2.15;2.56 +40948-2;Yersinia enterocolitica O:3 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Yersinia enterocolitica O:3 Ab [Presence] in Cerebral spinal fluid;Y entero O:3 Ab CSF Ql;;ACTIVE;2.15;2.61 +4094-9;Verapamil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Verapamil [Mass/volume] in Serum or Plasma;Verapamil SerPl-mCnc;;ACTIVE;1.0;2.73 +40949-0;Yersinia enterocolitica O:5 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Yersinia enterocolitica O:5 Ab [Presence] in Cerebral spinal fluid;Y entero O:5 Ab CSF Ql;;ACTIVE;2.15;2.61 +40950-8;Yersinia enterocolitica O:8 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Yersinia enterocolitica O:8 Ab [Presence] in Cerebral spinal fluid;Y entero O:8 Ab CSF Ql;;ACTIVE;2.15;2.61 +40951-6;Yersinia enterocolitica O:9 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Yersinia enterocolitica O:9 Ab [Presence] in Cerebral spinal fluid;Y entero O:9 Ab CSF Ql;;ACTIVE;2.15;2.61 +40952-4;Vespula spp Ab.IgG4;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yellow Jacket IgG4 Ab [Presence] in Serum;Yellow Jacket IgG4 Ql;;ACTIVE;2.15;2.56 +40953-2;Yersinia enterocolitica O:3 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Yersinia enterocolitica O:3 Ab [Titer] in Serum by Complement fixation;Y entero O:3 Ab Titr Ser CF;;ACTIVE;2.15;2.61 +40954-0;Yersinia enterocolitica O:8 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Yersinia enterocolitica O:8 Ab [Titer] in Serum by Complement fixation;Y entero O:8 Ab Titr Ser CF;;ACTIVE;2.15;2.61 +40955-7;Yersinia enterocolitica O:9 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Yersinia enterocolitica O:9 Ab [Titer] in Serum by Complement fixation;Y entero O:9 Ab Titr Ser CF;;ACTIVE;2.15;2.61 +4095-6;Verapamil;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Verapamil [Presence] in Urine;Verapamil Ur Ql;;ACTIVE;1.0;2.73 +40956-5;Yersinia sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Yersinia sp Ab [Presence] in Serum by Complement fixation;Yersinia Ab Ser Ql CF;;ACTIVE;2.15;2.56 +40957-3;Zinc;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Zinc [Presence] in Urine;Zinc Ur Ql;;ACTIVE;2.15;2.56 +40958-1;Cryptosporidium parvum identified;Prid;Pt;Stool;Nom;;MICRO;1;Cryptosporidium parvum identified in Stool;C parvum Stl;;ACTIVE;2.15;2.73 +40959-9;MUTYH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MUTYH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MUTYH gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40960-7;Parietal cell Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Parietal cell IgG Ab [Units/volume] in Serum;PCA IgG Ser-aCnc;;ACTIVE;2.15;2.73 +40961-5;SFTPB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SFTPB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SFTPB gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40962-3;SFTPC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SFTPC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SFTPC gene Mut Anl Bld/T;;ACTIVE;2.15;2.66 +40963-1;Streptococcus pneumoniae 17 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 17 IgG Ab [Mass/volume] in Serum;Deprecated S pneum17 IgG Ser-mCnc;;DEPRECATED;2.15;2.70 +4096-4;Volatile drugs negative;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Volatile drugs negative [Identifier] in Urine by Screen method;Volatile Drugs Neg Ur Scn;;ACTIVE;1.0;2.19 +40964-9;Streptococcus pneumoniae 2 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 2 IgG Ab [Mass/volume] in Serum;Deprecated S pneum2 IgG Ser-mCnc;;DEPRECATED;2.15;2.70 +40965-6;Streptococcus pneumoniae 20 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 20 IgG Ab [Mass/volume] in Serum;Deprecated S pneum20 IgG Ser-mCnc;;DEPRECATED;2.15;2.70 +40966-4;Streptococcus pneumoniae 22 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 22 IgG Ab [Mass/volume] in Serum;Deprecated S pneum22 IgG Ser-mCnc;;DEPRECATED;2.15;2.70 +40967-2;Streptococcus pneumoniae 34 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 34 IgG Ab [Mass/volume] in Serum;Deprecated S pneum34 IgG Ser-mCnc;;DEPRECATED;2.15;2.66 +40968-0;Streptococcus pneumoniae 43 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 43 IgG Ab [Mass/volume] in Serum;Deprecated S pneum43 IgG Ser-mCnc;;DEPRECATED;2.15;2.66 +40969-8;Streptococcus pneumoniae Danish serotype 33F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 33F IgG Ab [Mass/volume] in Serum;S pneum Da 33F IgG Ser-mCnc;;ACTIVE;2.15;2.73 +40970-6;VWF gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;VWF gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;VWF gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +40971-4;XXX microorganism DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;XXX microorganism DNA [Presence] in Urine by NAA with probe detection;Other microorg DNA Ur Ql NAA+probe;;ACTIVE;2.15;2.63 +4097-2;Volatile drugs positive;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Volatile drugs positive [Identifier] in Urine by Screen method;Volatile Drugs Pos Ur Scn;;ACTIVE;1.0;2.73 +40972-2;XXX microorganism DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;XXX microorganism DNA [Presence] in Serum or Plasma by NAA with probe detection;Other microorg DNA SerPl Ql NAA+probe;;ACTIVE;2.15;2.73 +40973-0;Streptococcus pneumoniae Danish serotype 15B Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 15B IgG Ab [Mass/volume] in Serum;S pneum Da 15B IgG Ser-mCnc;;ACTIVE;2.15;2.73 +40974-8;Streptococcus pneumoniae Danish serotype 19A Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19A IgG Ab [Mass/volume] in Serum;S pneum Da 19A IgG Ser-mCnc;;ACTIVE;2.15;2.73 +40975-5;Adenovirus DNA;Prid;Pt;XXX;Nom;RFLP;MICRO;1;Adenovirus DNA [Identifier] in Specimen by RFLP;HAdV DNA Spec RFLP;;ACTIVE;2.15;2.69 +40976-3;Adenovirus DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Adenovirus DNA [Identifier] in Specimen by NAA with probe detection;HAdV DNA Spec NAA+probe;;ACTIVE;2.15;2.73 +40977-1;Adenovirus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Adenovirus IgG Ab [Presence] in Serum by Immunoassay;HAdV IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40978-9;Human metapneumovirus RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Identifier] in Specimen by NAA with probe detection;hMPV RNA Spec NAA+probe;;ACTIVE;2.15;2.73 +40979-7;Human metapneumovirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Human metapneumovirus Ag [Presence] in Specimen by Immunofluorescence;hMPV Ag Spec Ql IF;;ACTIVE;2.15;2.73 +4098-0;Warfarin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Warfarin [Mass/volume] in Serum or Plasma;Warfarin SerPl-mCnc;;ACTIVE;1.0;2.73 +40980-5;Human metapneumovirus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Human metapneumovirus IgG Ab [Presence] in Serum by Immunoassay;hMPV IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40981-3;Influenza virus A RNA;ACnc;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Deprecated Influenza virus A RNA [Presence] in Unspecified specimen by Probe & target amplification method;Deprecated FLUAV RNA XXX Ql PCR;;DEPRECATED;2.15;2.69 +40982-1;Influenza virus B RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Specimen by NAA with probe detection;FLUBV RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +40983-9;Parainfluenza virus 1 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 1 IgG Ab [Presence] in Serum by Immunoassay;HPIV1 IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40984-7;Parainfluenza virus 2 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 2 IgG Ab [Presence] in Serum by Immunoassay;HPIV2 IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40985-4;Parainfluenza virus 3 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 3 IgG Ab [Presence] in Serum by Immunoassay;HPIV3 IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40986-2;Parainfluenza virus 4 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Parainfluenza virus 4 Ag [Presence] in Specimen by Immunofluorescence;HPIV4 Ag Spec Ql IF;;ACTIVE;2.15;2.69 +40987-0;Respiratory syncytial virus RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection;RSV RNA Spec NAA+probe;;ACTIVE;2.15;2.73 +40988-8;Respiratory syncytial virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection;RSV RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +40989-6;Respiratory syncytial virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Respiratory syncytial virus IgG Ab [Presence] in Serum by Immunoassay;RSV IgG Ser Ql IA;;ACTIVE;2.15;2.56 +40990-4;Rhinovirus RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Rhinovirus RNA [Identifier] in Specimen by NAA with probe detection;Rhinovirus RNA Spec NAA+probe;;ACTIVE;2.15;2.73 +40991-2;Rhinovirus+Enterovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus RNA [Presence] in Specimen by NAA with probe detection;RV+EV RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +40992-0;Rhinovirus+Enterovirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Rhinovirus+Enterovirus Ag [Presence] in Specimen by Immunofluorescence;RV+EV Ag Spec Ql IF;;ACTIVE;2.15;2.69 +40993-8;Rhinovirus Ag;Prid;Pt;XXX;Nom;Neut;MICRO;1;Rhinovirus Ag [Identifier] in Specimen by Neutralization test;Rhinovirus Ag Spec Nt;;ACTIVE;2.15;2.69 +40994-6;CPEO syndrome gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CPEO syndrome gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CPEO Syn gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +40995-3;Mitochondria DNA targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Mitochondria Genes mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;mtDNA Mut Anl Bld/T;;ACTIVE;2.15;2.63 +40996-1;Alternaria alternata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata IgE Ab/IgE total in Serum;A alternata IgE/IgE total %;;ACTIVE;2.15;2.73 +40997-9;Apis mellifera Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Honey bee IgE Ab/IgE total in Serum;Honey bee IgE/IgE total %;;ACTIVE;2.15;2.70 +4099-8;Zimelidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zimelidine [Mass/volume] in Serum or Plasma;Zimelidine SerPl-mCnc;;ACTIVE;1.0;2.40 +40998-7;Calcium hydrogen phosphate dihydrate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium hydrogen phosphate dihydrate/Total in Stone;Ca H2 Phos dihyd MFr Stone;;ACTIVE;2.15;2.73 +40999-5;Calcium hydrogen phosphate dihydrate;MRat;24H;Urine;Qn;;CHEM;1;Calcium hydrogen phosphate dihydrate [Mass/time] in 24 hour Urine;Ca H2 Phos dihyd 24h Ur-mRate;;ACTIVE;2.15;2.73 +41000-1;Human coronavirus RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Human coronavirus RNA [Identifier] in Specimen by NAA with probe detection;HCoV RNA Spec NAA+probe;;ACTIVE;2.15;2.73 +41001-9;Human coronavirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human coronavirus RNA [Presence] in Specimen by NAA with probe detection;HCoV RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +41002-7;Human coronavirus 229E Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Human coronavirus 229E IgG Ab [Presence] in Serum by Immunoassay;HCoV 229E IgG Ser Ql IA;;ACTIVE;2.15;2.56 +41003-5;Human coronavirus 229E RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection;HCoV 229E RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +4100-4;2-Oxoisocaproate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;2-Oxoisocaproate [Mass] of Dose;2Oxoisocaproate Dose;;ACTIVE;1.0;2.69 +41004-3;Human coronavirus 229E Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Human coronavirus 229E Ag [Presence] in Specimen by Immunofluorescence;HCoV 229E Ag Spec Ql IF;;ACTIVE;2.15;2.69 +41005-0;Human coronavirus NL63 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection;HCoV NL63 RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +41006-8;Human coronavirus NL63 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Human coronavirus NL63 IgG Ab [Presence] in Serum by Immunoassay;HCoV NL63 IgG Ser Ql IA;;ACTIVE;2.15;2.56 +41007-6;Human coronavirus OC43 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Human coronavirus OC43 Ag [Presence] in Specimen by Immunofluorescence;HCoV OC43 Ag Spec Ql IF;;ACTIVE;2.15;2.69 +41008-4;Human coronavirus OC43 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Human coronavirus OC43 IgG Ab [Presence] in Serum by Immunoassay;HCoV OC43 IgG Ser Ql IA;;ACTIVE;2.15;2.56 +41009-2;Human coronavirus OC43 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection;HCoV OC43 RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +410-1;Piperacillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Piperacillin [Susceptibility] by Serum bactericidal titer;Piperacillin Titr SBT;;ACTIVE;1.0;2.32 +41010-0;Parainfluenza virus 4 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Specimen by NAA with probe detection;HPIV4 RNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +41011-8;Human metapneumovirus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Human metapneumovirus IgG Ab [Presence] in Serum;hMPV IgG Ser Ql;;ACTIVE;2.15;2.56 +4101-2;2-Pyridone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;2-Pyridone [Mass] of Dose;2Pyridone Dose;;ACTIVE;1.0;2.69 +41012-6;Respiratory syncytial virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Respiratory syncytial virus IgG Ab [Presence] in Serum;RSV IgG Ser Ql;;ACTIVE;2.15;2.56 +41013-4;Human coronavirus 229E Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Human coronavirus 229E IgG Ab [Presence] in Serum;HCoV 229E IgG Ser Ql;;ACTIVE;2.15;2.73 +41014-2;Human coronavirus NL63 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Human coronavirus NL63 IgG Ab [Presence] in Serum;HCoV NL63 IgG Ser Ql;;ACTIVE;2.15;2.56 +41015-9;Human coronavirus OC43 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Human coronavirus OC43 IgG Ab [Presence] in Serum;HCoV OC43 IgG Ser Ql;;ACTIVE;2.15;2.56 +41016-7;Bilirubin;SCnc;Pt;Urine;Qn;Test strip;UA;1;Bilirubin.total [Moles/volume] in Urine by Test strip;Bilirub Ur Strip-sCnc;;ACTIVE;2.15;2.73 +41017-5;Protoporphyrin;SCnc;Pt;RBC;Qn;;CHEM;1;Protoporphyrin [Moles/volume] in Red Blood Cells;Protopor RBC-sCnc;;ACTIVE;2.15;2.70 +41018-3;Testosterone.free+weakly bound;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone.free+weakly bound [Moles/volume] in Serum or Plasma;Testosterone.free+WB SerPl-sCnc;;ACTIVE;2.15;2.70 +41019-1;Beta endorphin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta endorphin [Moles/volume] in Serum or Plasma;B-Endorphin SerPl-sCnc;;ACTIVE;2.15;2.70 +4102-0;5-Fluorocytosine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;5-Fluorocytosine [Mass] of Dose;5-fluorocytosine Dose;;ACTIVE;1.0;2.69 +41020-9;Flunitrazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Flunitrazepam [Presence] in Urine;Flunitrazepam Ur Ql;;ACTIVE;2.15;2.56 +41021-7;Cocaine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Cocaine [Presence] in Hair;Cocaine Hair Ql;;ACTIVE;2.15;2.56 +41022-5;Citrate;Sub;XXX;Urine;Qn;;CHEM;1;Citrate [Molar amount] in Urine collected for unspecified duration;Citrate ?Tm sub Ur Qn;;ACTIVE;2.15;2.70 +41023-3;Aldosterone;Sub;XXX;Urine;Qn;;CHEM;1;Aldosterone [Molar amount] in Urine collected for unspecified duration;Aldost ?Tm sub Ur Qn;;ACTIVE;2.15;2.73 +41024-1;Glucose^2H post 50 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post 50 g glucose PO;Glucose 2h p 50 g Glu PO SerPl-mCnc;;ACTIVE;2.15;2.73 +41025-8;Ribonucleoprotein extractable nuclear Ab;MCnc;Pt;Ser;Qn;;SERO;1;Ribonucleoprotein extractable nuclear Ab [Mass/volume] in Serum;ENA RNP Ab Ser-mCnc;;ACTIVE;2.15;2.34 +41026-6;Fungus identified;Prid;Pt;Genital;Nom;Culture;MICRO;1;Fungus identified in Genital specimen by Culture;Fungus Genital Cult;;ACTIVE;2.15;2.21 +41027-4;Tau protein/Amyloid beta 42 peptide;Ratio;Pt;CSF;Qn;;CHEM;1;Tau protein/Amyloid beta 42 peptide [Ratio] in Cerebral spinal fluid;Tau Prot/AL beta42 CSF-Rto;;ACTIVE;2.15;2.73 +41028-2;Listeria monocytogenes O1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes O1 Ab [Titer] in Serum;L monocytog.O1 Ab Titr Ser;;ACTIVE;2.15;2.30 +41029-0;Listeria monocytogenes H1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes H1 Ab [Titer] in Serum;L monocytog.H1 Ab Titr Ser;;ACTIVE;2.15;2.30 +41030-8;Listeria monocytogenes O4b Ab;Titr;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes O4b Ab [Titer] in Serum;L monocytog.O4b Ab Titr Ser;;ACTIVE;2.15;2.30 +41031-6;Lopinavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Lopinavir [Susceptibility] by Genotype method;Lopinavir Islt Genotyp;;ACTIVE;2.15;2.73 +41032-4;Uroporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Uroporphyrin [Mass/time] in unspecified time Stool;Uropor ?Tm Stl-mRate;;ACTIVE;2.15;2.19 +41033-2;Herpes simplex virus 1 Ab;ACnc;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 1 Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;HSV1 Ab CSF IF-aCnc;;ACTIVE;2.15;2.69 +41034-0;Herpes simplex virus 2 Ab;ACnc;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 2 Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;HSV2 Ab CSF IF-aCnc;;ACTIVE;2.15;2.69 +41035-7;Norovirus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Norovirus RNA [Presence] in Specimen by Probe;Norovirus RNA Spec Ql Probe;;ACTIVE;2.15;2.69 +41036-5;Cocaine;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Blood by Confirmatory method;Cocaine Bld Ql Cfm;;ACTIVE;2.15;2.73 +41037-3;Cocaine;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Meconium by Confirmatory method;Cocaine Mec Ql Cfm;;ACTIVE;2.15;2.56 +4103-8;Acebutolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Acebutolol [Mass] of Dose;Acebutolol Dose;;ACTIVE;1.0;2.69 +41038-1;Codeine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Codeine [Mass/volume] in Blood;Codeine Bld-mCnc;;ACTIVE;2.15;2.73 +41039-9;3-Methylcrotonylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methylcrotonylglycine [Moles/volume] in Serum or Plasma;3Me-crotonylglycine SerPl-sCnc;;ACTIVE;2.15;2.70 +41040-7;Palmitoylcarnitine (C16);SCnc;Pt;Bld;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Moles/volume] in Blood;Palmitoylcarn Bld-sCnc;;ACTIVE;2.15;2.70 +41041-5;3-Hydroxypalmitoylcarnitine (C16-OH);SCnc;Pt;Bld;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in Blood;3OH-Palmitoylcarn Bld-sCnc;;ACTIVE;2.15;2.70 +41042-3;WFS1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;WFS1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;WFS1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41043-1;VHL gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;VHL gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;VHL gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41044-9;UGT1A1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;UGT1A1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;UGT1A1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41045-6;TYR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TYR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TYR gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +4104-6;Acepromazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Acepromazine [Mass] of Dose;Acepromazine Dose;;ACTIVE;1.0;2.69 +41046-4;TWIST1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TWIST1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TWIST1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41047-2;TSC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TSC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TSC gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41048-0;TPMT gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;TPMT gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TPMT gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41049-8;TNFRSF1A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TNFRSF1A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TNFRSF1A gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41050-6;TH gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TH gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TH gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41051-4;SPINK1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SPINK1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SPINK1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41052-2;SPAST gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SPAST gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SPAST gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +4105-3;Acetaminophen;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Acetaminophen [Mass] of Dose;APAP Dose;;ACTIVE;1.0;2.73 +41053-0;SMN1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SMN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SMN1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41054-8;SMA@ gene mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated SMA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Deprecated SMA@ gene Mut Anal Bld/T;;DEPRECATED;2.15;2.36 +41055-5;SLC26A4 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SLC26A4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SLC26A4 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41056-3;SLC22A18 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SLC22A18 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SLC22A18 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41057-1;SHOX gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SHOX gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SHOX gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41058-9;SH2D1A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SH2D1A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SH2D1A gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41059-7;SFTPC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SFTPC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SFTPC gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41060-5;SFTPB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SFTPB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SFTPB gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +4106-1;acetaZOLAMIDE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Acetazolamide [Mass] of Dose;acetaZOLAMIDE Dose;;ACTIVE;1.0;2.69 +41061-3;SDHD gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SDHD gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SDHD gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41062-1;SDHB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SDHB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SDHB gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41063-9;RPS6KA3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RPS6KA3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;RPS6KA3 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41064-7;PYGM gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PYGM gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PYGM gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41065-4;PTPN11 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PTPN11 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PTPN11 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41066-2;PRX gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PRX gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PRX gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41067-0;PRF1 gene targeted mutation analysis;Prid;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;PRF1 gene mutations found [Identifier] in Amniotic fluid by Molecular genetics method Nominal;PRF1 gene Mut Anl Amn;;ACTIVE;2.15;2.63 +41068-8;PRF1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PRF1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PRF1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41069-6;PPT1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PPT1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PPT1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41070-4;Peripheral neuropathy gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Peripheral neuropathy gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PNP gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41071-2;PARK2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PARK2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PARK2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41072-0;PANK2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PANK2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PANK2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41073-8;NR0B1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NR0B1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NR0B1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41074-6;NPHS1 gene targeted mutation analysis;Prid;Pt;Body fld;Nom;Molgen;MOLPATH.MUT;1;NPHS1 gene mutations found [Identifier] in Body fluid by Molecular genetics method Nominal;NPHS1 gene Mut Anl Fld;;ACTIVE;2.15;2.63 +41075-3;NPHS1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NPHS1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NPHS1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41076-1;NPDC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NPDC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NPDC gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41077-9;NOTCH3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NOTCH3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NOTCH3 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41078-7;NIPBL gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NIPBL gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NIPBL gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +4107-9;Acyclovir;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Acyclovir [Mass] of Dose;Acyclovir Dose;;ACTIVE;1.0;2.69 +41079-5;NEFL gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NEFL gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NEFL gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41080-3;Myotonic dystrophy gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Myotonic dystrophy gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MMD gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41081-1;MUTYH gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MUTYH gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MUTYH gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41082-9;MT-TK gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MT-TK gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MT-TK gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41083-7;MTM1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MTM1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MTM1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41084-5;MSH2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MSH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MSH2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41085-2;MPZ gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MPZ gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MPZ gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41086-0;MLH1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MLH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MLH1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +4108-7;Adenine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Adenine [Mass] of Dose;Adenine Dose;;ACTIVE;1.0;2.69 +41087-8;Mitochondrial myopathy gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Mitochondrial myopathy gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MM gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41088-6;MERRF gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MERRF gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MERRF gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41089-4;MEN1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MEN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MEN1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41090-2;MELAS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MELAS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MELAS gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41091-0;MEFV gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MEFV gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MEFV gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41092-8;MAPT gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MAPT gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MAPT gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41093-6;LHON syndrome gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LHON syndrome gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;LHON Syn gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41094-4;LAMA2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LAMA2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;LAMA2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +4109-5;Alfentanil;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Alfentanil [Mass] of Dose;Alfentanil Dose;;ACTIVE;1.0;2.69 +41095-1;L1CAM gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;L1CAM gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;L1CAM gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41096-9;KEL gene allele;Geno;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;KEL gene allele [Genotype] in Amniotic fluid by Molecular genetics method Nominal;KEL allele Geno Amn;;ACTIVE;2.15;2.68 +41097-7;HADHA gene.c.1528G>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HADHA gene c.1528G>C [Presence] in Blood or Tissue by Molecular genetics method;HADHA c.1528G>C Bld/T Ql;;ACTIVE;2.15;2.73 +41098-5;GPC3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GPC3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GPC3 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41099-3;GLA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GLA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GLA gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41100-9;GJB6 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GJB6 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GJB6 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41101-7;GJB2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GJB2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GJB2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41102-5;GJB1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GJB1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GJB1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +4110-3;Alphaprodine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Alphaprodine [Mass] of Dose;Alphaprodine Dose;;ACTIVE;1.0;2.69 +41103-3;Gene XXX targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Gene XXX mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Gene XXX Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41104-1;GBA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GBA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GBA gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41105-8;FSHD gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FSHD gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FSHD gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41106-6;FXN gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FXN gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FXN gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41107-4;FMR1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FMR1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FMR1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41108-2;FGF23 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGF23 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FGF23 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41109-0;FGD1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGD1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FGD1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41110-8;CSTB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CSTB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CSTB gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +4111-1;ALPRAZolam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;ALPRAZolam [Mass] of Dose;Alpraz Dose;;ACTIVE;1.0;2.69 +41111-6;COL5A1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COL5A1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;COL5A1 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41112-4;CMT axonal gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CMT axonal gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CMT2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41113-2;Chronic lymphocytic leukemia gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Chronic lymphocytic leukemia gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CLL gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41114-0;CATCH22 syndrome gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CATCH22 syndrome gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CATCH22 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41115-7;NOD2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NOD2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NOD2 gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41116-5;ATP7A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ATP7A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ATP7A gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41117-3;AS+PWS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;AS+PWS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;AS+PWS gene Mut Anl Bld/T;;ACTIVE;2.15;2.73 +41118-1;AR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;AR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;AR gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41119-9;APTX gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APTX gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;APTX gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41120-7;ALDOB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ALDOB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ALDOB gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41121-5;ACADS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ACADS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ACADS gene Mut Anl Bld/T;;ACTIVE;2.15;2.63 +41122-3;Treponema pallidum Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Treponema pallidum Ab [Units/volume] in Specimen;T pallidum Ab Spec-aCnc;;ACTIVE;2.15;2.73 +41123-1;Toxoplasma gondii HS Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii HS Ab [Units/volume] in Serum;T gondii HS Ab Ser-aCnc;;ACTIVE;2.15;2.69 +41124-9;Toxoplasma gondii AC Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii AC Ab [Units/volume] in Serum;T gondii AC Ab Ser-aCnc;;ACTIVE;2.15;2.69 +41125-6;Strongyloides sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Strongyloides sp IgG Ab [Units/volume] in Serum;Strongyloides IgG Ser-aCnc;;ACTIVE;2.15;2.73 +41126-4;Salmonella typhi O D Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Salmonella typhi O D Ab [Presence] in Serum;Deprecated S typhi O D Ab Ser Ql;;DEPRECATED;2.15;2.36 +41127-2;Salmonella gallinarum Ab;PrThr;Pt;Bld;Ord;;MICRO;1;Salmonella gallinarum Ab [Presence] in Blood;S Gallinarum Ab Bld Ql;;ACTIVE;2.15;2.56 +41128-0;Rabies virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Rabies virus IgG Ab [Presence] in Serum;RABV IgG Ser Ql;;ACTIVE;2.15;2.73 +4112-9;Alprenolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Alprenolol [Mass] of Dose;Alprenolol Dose;;ACTIVE;1.0;2.69 +41129-8;Parvovirus B19 Ab.IgM^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Serum --1st specimen;B19V IgM sp1 Ser-aCnc;;ACTIVE;2.15;2.69 +41130-6;Mycobacterium avium subspecies paratuberculosis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Units/volume] in Serum;M avium paraTB Ab Ser-aCnc;;ACTIVE;2.15;2.69 +41131-4;Mumps virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Mumps virus IgM Ab [Presence] in Cerebral spinal fluid;MuV IgM CSF Ql;;ACTIVE;2.15;2.56 +41132-2;Measles virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Measles virus IgG Ab [Presence] in Cerebral spinal fluid;MeV IgG CSF Ql;;ACTIVE;2.15;2.56 +41133-0;Jamestown canyon virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Jamestown canyon virus Ab [Presence] in Specimen;JCV Ab Spec Ql;;ACTIVE;2.15;2.69 +41134-8;Influenza virus A N9 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N9 Ab [Presence] in Serum;FLUAV N9 Ab Ser Ql;;ACTIVE;2.15;2.56 +41135-5;Influenza virus A N8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N8 Ab [Presence] in Serum;FLUAV N8 Ab Ser Ql;;ACTIVE;2.15;2.56 +41136-3;Influenza virus A N7 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N7 Ab [Presence] in Serum;FLUAV N7 Ab Ser Ql;;ACTIVE;2.15;2.56 +4113-7;Amantadine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amantadine [Mass] of Dose;Amantadine Dose;;ACTIVE;1.0;2.69 +41137-1;Influenza virus A N6 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N6 Ab [Presence] in Serum;FLUAV N6 Ab Ser Ql;;ACTIVE;2.15;2.56 +41138-9;Influenza virus A N5 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N5 Ab [Presence] in Serum;FLUAV N5 Ab Ser Ql;;ACTIVE;2.15;2.56 +41139-7;Influenza virus A N4 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N4 Ab [Presence] in Serum;FLUAV N4 Ab Ser Ql;;ACTIVE;2.15;2.56 +41140-5;Influenza virus A N3 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N3 Ab [Presence] in Serum;FLUAV N3 Ab Ser Ql;;ACTIVE;2.15;2.56 +41141-3;Influenza virus A N2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N2 Ab [Presence] in Serum;FLUAV N2 Ab Ser Ql;;ACTIVE;2.15;2.56 +41142-1;Influenza virus A N1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A N1 Ab [Presence] in Serum;FLUAV N1 Ab Ser Ql;;ACTIVE;2.15;2.56 +41143-9;HIV 1 Ab;ACnc;Pt;Saliva;Qn;;MICRO;1;HIV 1 Ab [Units/volume] in Saliva (oral fluid);HIV1 Ab Sal-aCnc;;ACTIVE;2.15;2.69 +41144-7;HIV 1 Ab;PrThr;Pt;Saliva;Ord;;MICRO;1;HIV 1 Ab [Presence] in Saliva (oral fluid);HIV1 Ab Sal Ql;;ACTIVE;2.15;2.56 +4114-5;Amdinocillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amdinocillin [Mass] of Dose;Amdinocillin Dose;;ACTIVE;1.0;2.69 +41145-4;HIV 1 Ab;PrThr;Pt;BldC;Ord;;MICRO;1;HIV 1 Ab [Presence] in Capillary blood;HIV1 Ab BldC Ql;;ACTIVE;2.15;2.56 +41146-2;Herpes virus 8 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes virus 8 IgG Ab [Presence] in Serum;HHV8 IgG Ser Ql;;ACTIVE;2.15;2.56 +41147-0;Herpes virus 6 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes virus 6 IgM Ab [Presence] in Serum;HHV6 IgM Ser Ql;;ACTIVE;2.15;2.56 +41148-8;Herpes virus 6 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes virus 6 IgG Ab [Presence] in Serum;HHV6 IgG Ser Ql;;ACTIVE;2.15;2.73 +41149-6;Herpes simplex virus 1+2 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Presence] in Serum;HSV1+2 IgM Ser Ql;;ACTIVE;2.15;2.73 +41150-4;Herpes simplex virus 1+2 Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Presence] in Cerebral spinal fluid;HSV1+2 IgM CSF Ql;;ACTIVE;2.15;2.56 +41151-2;Hepatitis B virus little e Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus e IgG Ab [Presence] in Serum;HBV e IgG Ser Ql;;ACTIVE;2.15;2.56 +4115-2;Amikacin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amikacin [Mass] of Dose;Amikacin Dose;;ACTIVE;1.0;2.73 +41152-0;Haemophilus paragallinarum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Haemophilus paragallinarum Ab [Units/volume] in Serum;H paragallinar Ab Ser-aCnc;;ACTIVE;2.15;2.69 +41153-8;Giardia lamblia Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Giardia lamblia IgM Ab [Presence] in Serum;G lamblia IgM Ser Ql;;ACTIVE;2.15;2.56 +41154-6;Giardia lamblia Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Giardia lamblia IgG Ab [Presence] in Serum;G lamblia IgG Ser Ql;;ACTIVE;2.15;2.56 +41155-3;Cytomegalovirus Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Cytomegalovirus IgM Ab [Units/volume] in Body fluid;CMV IgM Fld-aCnc;;ACTIVE;2.15;2.73 +41156-1;Coccidioides sp Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;Coccidioides sp IgG Ab [Presence] in Specimen;Coccidioides IgG Spec Ql;;ACTIVE;2.15;2.69 +41157-9;Chlamydia trachomatis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis IgM Ab [Presence] in Serum;C trach IgM Ser Ql;;ACTIVE;2.15;2.73 +41158-7;Canine herpesvirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Canine herpesvirus Ab [Presence] in Serum;CaHV Ab Ser Ql;;ACTIVE;2.15;2.67 +41159-5;Campylobacter sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Campylobacter sp IgG Ab [Presence] in Serum;Campylobacter IgG Ser Ql;;ACTIVE;2.15;2.56 +4116-0;aMILoride;Mass;Pt;Dose;Qn;;DRUGDOSE;1;aMILoride [Mass] of Dose;aMILoride Dose;;ACTIVE;1.0;2.69 +41160-3;Ascaris lumbricoides Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Ascaris lumbricoides IgM Ab [Units/volume] in Serum;A lumbric IgM Ser-aCnc;;ACTIVE;2.15;2.69 +41161-1;Ascaris lumbricoides Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Ascaris lumbricoides IgG Ab [Units/volume] in Serum;A lumbric IgG Ser-aCnc;;ACTIVE;2.15;2.69 +41162-9;Adenovirus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Adenovirus IgG Ab [Presence] in Serum;HAdV IgG Ser Ql;;ACTIVE;2.15;2.56 +41163-7;Treponema pallidum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Treponema pallidum DNA [Presence] in Specimen by NAA with probe detection;T pallidum DNA Spec Ql NAA+probe;;ACTIVE;2.15;2.73 +41164-5;Uranium.depleted;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Uranium depleted [Presence] in Urine;Depleted U Ur Ql;;ACTIVE;2.15;2.56 +41165-2;Uranium 235/Uranium 238;MRto;24H;Urine;Qn;;DRUG/TOX;1;Uranium 235/Uranium 238 [Mass Ratio] in 24 hour Urine;Uranium 235/Uranium 238 24h Ur;;ACTIVE;2.15;2.42 +41166-0;Uranium.depleted/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Uranium depleted/Creatinine [Mass Ratio] in Urine;Depleted U/Creat Ur;;ACTIVE;2.15;2.42 +41167-8;Listeria monocytogenes H Ab;Titr;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes H Ab [Titer] in Serum;L monocytog.H Ab Titr Ser;;ACTIVE;2.15;2.30 +41168-6;Arginine;PrThr;Pt;Bld;Ord;;CHEM;1;Arginine [Presence] in Blood;Arginine Bld Ql;;ACTIVE;2.15;2.56 +41169-4;Valine;PrThr;Pt;Bld;Ord;;CHEM;1;Valine [Presence] in Blood;Valine Bld Ql;;ACTIVE;2.15;2.56 +41170-2;Phenylalanine+Tyrosine;PrThr;Pt;Bld;Ord;;CHEM;1;Phenylalanine+Tyrosine [Presence] in Blood;Phe+Tyr Bld Ql;;ACTIVE;2.15;2.56 +41171-0;Collagen crosslinked C-telopeptide;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma;Collagen CTx SerPl-mCnc;;ACTIVE;2.15;2.73 +41172-8;Yeast.budding;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Yeast.budding [#/area] in Urine sediment by Microscopy high power field;Yeast Budding #/area UrnS HPF;;ACTIVE;2.15;2.73 +41173-6;Xylose^2H post dose xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --2 hours post dose xylose PO;Xylose 2h p Xyl PO SerPl-mCnc;;ACTIVE;2.15;2.70 +41174-4;Waxy casts.broad;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Waxy Casts Broad [Presence] in Urine sediment by Light microscopy;Broad Waxy Casts UrnS Ql Micro;;ACTIVE;2.15;2.56 +41175-1;Western equine encephalitis virus Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Western equine encephalitis virus Ab [Titer] in Body fluid;WEEV Ab Titr Fld;;ACTIVE;2.15;2.30 +41176-9;Trichophyton reaction wheal^2D post dose trichophyton ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Trichophyton reaction wheal [Diameter] --2 days post dose trichophyton intradermal;Wheal 2D p Trichophyt Diam;;ACTIVE;2.15;2.42 +41177-7;Trichophyton reaction wheal^1D post dose trichophyton ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Trichophyton reaction wheal [Diameter] --1 day post dose trichophyton intradermal;Wheal 1D p Trichophyt Diam;;ACTIVE;2.15;2.42 +4117-8;Aminopyrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Aminopyrine [Mass] of Dose;Aminopyrine Dose;;ACTIVE;1.0;2.69 +41178-5;Mumps reaction wheal^2D post dose mumps ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Mumps reaction wheal [Diameter] --2 days post dose mumps intradermal;Wheal 2D p Mumps Diam;;ACTIVE;2.15;2.42 +41179-3;Mumps reaction wheal^1D post mumps ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Mumps reaction wheal [Diameter] --1 day post dose mumps intradermal;Wheal 1D p Mumps Diam;;ACTIVE;2.15;2.42 +41180-1;Candida albicans reaction wheal^2D post dose Candida albicans ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Candida albicans reaction wheal [Diameter] --2 days post Candida albicans intradermal;Wheal 2D p C albicans Diam;;ACTIVE;2.15;2.42 +41181-9;Candida albicans reaction wheal^1D post dose Candida albicans ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Candida albicans reaction wheal [Diameter] --1 day post Candida albicans intradermal;Wheal 1D p C albicans Diam;;ACTIVE;2.15;2.42 +41182-7;Histoplasma capsulatum farciminosum reaction wheal^2D post dose histoplasmin ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Histoplasma capsulatum farciminosum reaction wheal [Diameter] --2 days post histoplasmin intradermal;Wheal 2D p HMIN Diam;;ACTIVE;2.15;2.42 +41183-5;Western equine encephalitis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum by Complement fixation;WEEV Ab Titr Ser CF;;ACTIVE;2.15;2.30 +41184-3;Warfarin;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Warfarin [Presence] in Serum or Plasma;Warfarin SerPl Ql;;ACTIVE;2.15;2.73 +41185-0;Xylose^5H post dose xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --5 hours post dose xylose PO;Xylose 5h p Xyl PO SerPl-mCnc;;ACTIVE;2.15;2.70 +4118-6;Aminosalicylate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Aminosalicylate [Mass] of Dose;Aminosalicylate Dose;;ACTIVE;1.0;2.69 +41186-8;Yeast;PrThr;Pt;Stool;Ord;;MICRO;1;Yeast [Presence] in Stool;Yeast Stl Ql;;ACTIVE;2.15;2.56 +41187-6;Waxy casts;NCnc;Pt;Urine sed;Qn;;UA;1;Waxy casts [#/volume] in Urine sediment;Waxy Casts # UrnS;;ACTIVE;2.15;2.42 +41188-4;Xylose^post CFst;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --fasting;Xylose p fast Ur-mCnc;;ACTIVE;2.15;2.34 +41189-2;Xylose^post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --fasting;Xylose p fast SerPl-mCnc;;ACTIVE;2.15;2.73 +411-9;Piperacillin+Tazobactam;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Piperacillin+Tazobactam [Susceptibility] by Minimum lethal concentration (MLC);Pip+Tazo Islt MLC;;ACTIVE;1.0;2.44 +41190-0;Waxy casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Waxy casts [Presence] in Urine by Computer assisted method;Waxy Casts Ur Ql Comp Assist;;ACTIVE;2.15;2.73 +41191-8;Xylose^2H post dose xylose PO;MRat;2H;Urine;Qn;;CHAL;1;Xylose [Mass/time] in 2 hour Urine --2 hours post dose xylose PO;Xylose 2h p Xyl PO 2h Ur-mRate;;ACTIVE;2.15;2.70 +41192-6;Dolichovespula arenaria Ab.IgG4;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yellow Hornet IgG4 Ab [Presence] in Serum;Yellow Hornet IgG4 Ql;;ACTIVE;2.15;2.56 +41193-4;Dolichovespula maculata Ab.IgG4;PrThr;Pt;Ser;Ord;;ALLERGY;1;Whitefaced Hornet IgG4 Ab [Presence] in Serum;Whitefaced Hornet IgG4 Ql;;ACTIVE;2.15;2.56 +4119-4;Amiodarone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amiodarone [Mass] of Dose;Amiodarone Dose;;ACTIVE;1.0;2.73 +41194-2;West Nile virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;West Nile virus Ab [Units/volume] in Serum by Immunoassay;WNV Ab Ser IA-aCnc;;ACTIVE;2.15;2.73 +41195-9;West Nile virus Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;West Nile virus IgM Ab [Titer] in Body fluid;WNV IgM Titr Fld;;ACTIVE;2.15;2.30 +41196-7;West Nile virus Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;West Nile virus IgG Ab [Titer] in Body fluid;WNV IgG Titr Fld;;ACTIVE;2.15;2.30 +41197-5;Xylose^30M post dose xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --30 minutes post dose xylose PO;Xylose 30m p Xyl PO SerPl-mCnc;;ACTIVE;2.15;2.70 +41198-3;Juglans spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Walnut IgE Ab/IgE total in Serum;Walnut IgE/IgE total %;;ACTIVE;2.15;2.70 +41199-1;Voriconazole;Susc;Pt;Isolate;OrdQn;MLC;ABXBACT;1;Voriconazole [Susceptibility] by Minimum lethal concentration (MLC);Voriconazole Islt MLC;;ACTIVE;2.15;2.19 +41200-7;Voriconazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Voriconazole [Susceptibility] by Disk diffusion (KB);Voriconazole Islt KB;;ACTIVE;2.15;2.19 +41201-5;Voltage-gated calcium channel Ab.IgG;SCnc;Pt;Ser;Qn;;SERO;1;Voltage-gated calcium channel IgG Ab [Moles/volume] in Serum;VGCC IgG Ser-sCnc;;ACTIVE;2.15;2.40 +4120-2;Amitriptyline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amitriptyline [Mass] of Dose;Amitrip Dose;;ACTIVE;1.0;2.69 +41202-3;Saccharomyces cerevisiae Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast IgE Ab/IgE total in Serum;Baker's yeast IgE/IgE total %;;ACTIVE;2.15;2.70 +41203-1;Vespula spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Yellow Jacket IgE Ab/IgE total in Serum;Yellow Jacket IgE/IgE total %;;ACTIVE;2.15;2.70 +41204-9;Polistes spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Paper wasp IgE Ab/IgE total in Serum;Paper Wasp IgE/IgE total %;;ACTIVE;2.15;2.70 +41205-6;Citrullus lanatus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Watermelon IgG Ab [Mass/volume] in Serum;Watermelon IgG-mCnc;;ACTIVE;2.15;2.73 +41206-4;West Nile virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;West Nile virus Ab [Units/volume] in Cerebral spinal fluid;WNV Ab CSF-aCnc;;ACTIVE;2.15;2.73 +41207-2;Triticum aestivum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Wheat IgE Ab/IgE total in Serum;Wheat IgE/IgE total %;;ACTIVE;2.15;2.73 +41208-0;Viscosity+Liquefaction;Prid;Pt;Semen;Nom;;SPEC;1;Viscosity+Liquefaction [Identifier] of Semen;Visc+Liquefaction Smn;;ACTIVE;2.15;2.73 +41209-8;VWF gene.p.Arg854Gln;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;VWF gene.p.Arg854Gln [Presence] in Blood or Tissue by Molecular genetics method;VWF p.R854Q Bld/T Ql;;ACTIVE;2.15;2.73 +4121-0;Amobarbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amobarbital [Mass] of Dose;Amobarbital Dose;;ACTIVE;1.0;2.69 +41210-6;VWF gene.p.Arg816Trp;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;VWF gene p.Arg816Trp [Presence] in Blood or Tissue by Molecular genetics method;VWF p.R816W Bld/T Ql;;ACTIVE;2.15;2.73 +41211-4;West Nile virus Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;West Nile virus IgG+IgM Ab [Presence] in Serum;WNV IgG+IgM Ser Ql;;ACTIVE;2.15;2.73 +41212-2;West Nile virus RNA;PrThr;Pt;Ser^Donor;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Serum from Donor by NAA with probe detection;WNV RNA Ser Donr Ql NAA+probe;;ACTIVE;2.15;2.73 +41213-0;Xanthan gum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Xanthan gum IgE Ab [Units/volume] in Serum;Xanthan Gum IgE Qn;;ACTIVE;2.15;2.73 +41214-8;Volatiles;Prid;Pt;Gast fld;Nom;Screen;DRUG/TOX;1;Volatiles and gases [Identifier] in Gastric fluid by Screen method;Volatiles Gast Scn;;ACTIVE;2.15;2.19 +41215-5;Yeast;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Yeast [#/area] in Urine sediment by Microscopy low power field;Yeast #/area UrnS LPF;;ACTIVE;2.15;2.73 +41216-3;Yellow fever virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Yellow fever virus IgM Ab [Presence] in Serum;YFV IgM Ser Ql;;ACTIVE;2.15;2.56 +41217-1;Yellow fever virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Yellow fever virus IgG Ab [Presence] in Serum;YFV IgG Ser Ql;;ACTIVE;2.15;2.56 +41218-9;Xipamid;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Xipamid [Presence] in Urine;Xipamid Ur Ql;;ACTIVE;2.15;2.56 +41219-7;Polistes spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp IgG Ab [Mass/volume] in Serum;Paper Wasp IgG-mCnc;;ACTIVE;2.15;2.73 +41220-5;Xanthurenate;PrThr;24H;Urine;Ord;;CHEM;1;Xanthurenate [Presence] in 24 hour Urine;Xanthuren 24h Ur Ql;;ACTIVE;2.15;2.56 +41221-3;Xanthurenate+Kynurenate;MRat;24H;Urine;Qn;;CHEM;1;Xanthurenate+Kynurenate [Mass/time] in 24 hour Urine;Xanthuren+Kynuren 24h Ur-mRate;;ACTIVE;2.15;2.70 +41222-1;Yeast;PrThr;Pt;Body fld;Ord;Microscopy.light;MICRO;1;Yeast [Presence] in Body fluid by Light microscopy;Yeast Fld Ql Micro;;ACTIVE;2.15;2.73 +41223-9;Waxy casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Waxy casts [#/area] in Urine sediment by Microscopy high power field;Waxy Casts #/area UrnS HPF;;ACTIVE;2.15;2.40 +41224-7;West Nile virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;West Nile virus Ab [Titer] in Cerebral spinal fluid;WNV Ab Titr CSF;;ACTIVE;2.15;2.30 +41225-4;West Nile virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;West Nile virus Ab [Titer] in Serum;WNV Ab Titr Ser;;ACTIVE;2.15;2.30 +41226-2;Viscosity;Visc;Pt;Water;Qn;;SPEC;1;Viscosity of Water;Visc Wat;;ACTIVE;2.15;2.44 +41227-0;Xanthine;SRat;24H;Urine;Qn;;CHEM;1;Xanthine [Moles/time] in 24 hour Urine;Xanthine 24h Ur-sRate;;ACTIVE;2.15;2.73 +4122-8;Amoxapine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amoxapine [Mass] of Dose;Amoxapine Dose;;ACTIVE;1.0;2.69 +41228-8;Xanthine;PrThr;Pt;Ser;Ord;;CHEM;1;Xanthine [Presence] in Serum;Xanthine Ser Ql;;ACTIVE;2.15;2.56 +41229-6;Vespula spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Jacket IgG Ab [Mass/volume] in Serum;Yellow Jacket IgG-mCnc;;ACTIVE;2.15;2.73 +41230-4;Xanthine;PrThr;Pt;XXX;Ord;;CHEM;1;Xanthine [Presence] in Specimen;Xanthine Spec Ql;;ACTIVE;2.15;2.69 +41231-2;Xanthurenate+Kynurenate;PrThr;24H;Urine;Ord;;CHEM;1;Xanthurenate+Kynurenate [Presence] in 24 hour Urine;Xanthuren+Kynuren 24h Ur Ql;;ACTIVE;2.15;2.56 +41232-0;West Nile virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;West Nile virus Ab [Presence] in Serum;WNV Ab Ser Ql;;ACTIVE;2.15;2.73 +41233-8;Volume expired during 3.0 s of forced expiration;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV3 Predicted;FEV3 Predicted;;ACTIVE;2.15;2.40 +41234-6;Volume expired during 3.0 s of forced expiration/Volume.forced expiration.total;VFr;Pt;Respiratory system;Qn;;PULM;2;FEV3/FEV total;FEV3/FEV total VFr;;ACTIVE;2.15;2.40 +41235-3;Polistes spp Ab.IgE;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp IgE Ab [Mass/volume] in Serum;Paper Wasp IgE-mCnc;;ACTIVE;2.15;2.40 +4123-6;Amoxicillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amoxicillin [Mass] of Dose;Amoxicillin Dose;;ACTIVE;1.0;2.21 +41236-1;West Nile virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;West Nile virus IgG Ab [Presence] in Cerebral spinal fluid;WNV IgG CSF Ql;;ACTIVE;2.15;2.73 +41237-9;Xylose^5H post dose xylose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --5 hours post dose xylose PO;Xylose 5h p Xyl PO Ur-mCnc;;ACTIVE;2.15;2.34 +41238-7;Viscosity;Visc;Pt;Synv fld;Qn;;SPEC;1;Viscosity of Synovial fluid;Visc Snv;;ACTIVE;2.15;2.73 +41239-5;Yellow fever virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Yellow fever virus Ab [Presence] in Cerebral spinal fluid;YFV Ab CSF Ql;;ACTIVE;2.15;2.56 +41240-3;Xanthurenate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Xanthurenate [Presence] in Serum or Plasma;Xanthuren SerPl Ql;;ACTIVE;2.15;2.56 +41241-1;Viscosity;Visc;Pt;Ser;Ord;;SPEC;1;Viscosity of Serum Qualitative;Visc Ser Ql;;ACTIVE;2.15;2.73 +41242-9;Yeast;PrThr;Pt;CSF;Ord;Microscopy.light;MICRO;1;Yeast [Presence] in Cerebral spinal fluid by Light microscopy;Yeast CSF Ql Micro;;ACTIVE;2.15;2.56 +41243-7;Yeast;Naric;Pt;Body fld;Qn;Microscopy.light.HPF;MICRO;1;Yeast [#/area] in Body fluid by Microscopy high power field;Yeast Fld HPF-#/area;;ACTIVE;2.15;2.40 +4124-4;Diethylpropion;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Diethylpropion [Mass] of Dose;Diethylpropion Dose;;ACTIVE;1.0;2.69 +41244-5;Western equine encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Western equine encephalitis virus IgG Ab [Presence] in Serum;WEEV IgG Ser Ql;;ACTIVE;2.15;2.56 +41245-2;Viscosity;Visc;Pt;Pericard fld;Ord;;SPEC;1;Viscosity of Pericardial fluid Qualitative;Visc Pcar Ql;;ACTIVE;2.15;2.54 +41246-0;Yellow fever virus Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Yellow fever virus Ab [Titer] in Serum --2nd specimen;YFV Ab sp2 Titr Ser;;ACTIVE;2.15;2.30 +41247-8;Yellow fever virus Ab^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Yellow fever virus Ab [Titer] in Serum --1st specimen;YFV Ab sp1 Titr Ser;;ACTIVE;2.15;2.30 +41248-6;Xanthurenate;PrThr;Pt;Urine;Ord;;CHEM;1;Xanthurenate [Presence] in Urine;Xanthuren Ur Ql;;ACTIVE;2.15;2.56 +41249-4;Yellow fever virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Yellow fever virus Ab [Presence] in Serum;YFV Ab Ser Ql;;ACTIVE;2.15;2.56 +41250-2;Xylose^baseline;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --baseline;Xylose BS Ur-mCnc;;ACTIVE;2.15;2.34 +4125-1;Amphetaminil;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amphetaminil [Mass] of Dose;Amphetaminil Dose;;ACTIVE;1.0;2.69 +41251-0;Xylose^5H post 25 g xylose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --5 hours post 25 g xylose PO;Xylose 5h p 25 g Xyl PO Ur-mCnc;;ACTIVE;2.15;2.73 +41252-8;Xylose^5H post 25 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --5 hours post 25 g xylose PO;Xylose 5h p 25 g Xyl PO SerPl-mCnc;;ACTIVE;2.15;2.70 +41253-6;Xylose^4H post 25 g xylose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --4 hours post 25 g xylose PO;Xylose 4h p 25 g Xyl PO Ur-mCnc;;ACTIVE;2.15;2.70 +41254-4;Xylose^4H post 25 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --4 hours post 25 g xylose PO;Xylose 4h p 25 g Xyl PO SerPl-mCnc;;ACTIVE;2.15;2.70 +41255-1;Xylose^3H post 25 g xylose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --3 hours post 25 g xylose PO;Xylose 3h p 25 g Xyl PO Ur-mCnc;;ACTIVE;2.15;2.34 +41256-9;Xylose^3H post 25 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --3 hours post 25 g xylose PO;Xylose 3h p 25 g Xyl PO SerPl-mCnc;;ACTIVE;2.15;2.70 +41257-7;Xylose^2H post 25 g xylose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --2 hours post 25 g xylose PO;Xylose 2h p 25 g Xyl PO Ur-mCnc;;ACTIVE;2.15;2.34 +41258-5;Xylose^1H post 25 g xylose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Mass/volume] in Urine --1 hour post 25 g xylose PO;Xylose 1h p 25 g Xyl PO Ur-mCnc;;ACTIVE;2.15;2.34 +41259-3;Western equine encephalitis virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Western equine encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid;WEEV IgM CSF Ql;;ACTIVE;2.15;2.56 +41260-1;Western equine encephalitis virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Western equine encephalitis virus IgG Ab [Presence] in Cerebral spinal fluid;WEEV IgG CSF Ql;;ACTIVE;2.15;2.73 +41261-9;Voltage-gated calcium channel Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Voltage-gated calcium channel IgG Ab [Presence] in Serum;VGCC IgG Ser Ql;;ACTIVE;2.15;2.56 +41262-7;Viscosity;Visc;Pt;Periton fld;Ord;;SPEC;1;Viscosity of Peritoneal fluid Qualitative;Visc Prt Ql;;ACTIVE;2.15;2.54 +41263-5;Viscosity;Visc;Pt;Plr fld;Ord;;SPEC;1;Viscosity of Pleural fluid Qualitative;Visc Plr Ql;;ACTIVE;2.15;2.54 +41264-3;Viscosity;Visc;Pt;CSF;Ord;;SPEC;1;Viscosity of Cerebral spinal fluid Qualitative;Visc CSF Ql;;ACTIVE;2.15;2.54 +41265-0;Width;EntLen;Pt;Calculus;Qn;;PATH;1;Deprecated Width of Stone;Deprecated Width Stone Qn;;DEPRECATED;2.15;2.36 +41266-8;Volatiles;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Volatiles and gases [Identifier] in Blood;Volatiles Bld;;ACTIVE;2.15;2.19 +41267-6;Xylose^post dose xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --post dose xylose PO;Xylose p Xyl PO SerPl-mCnc;;ACTIVE;2.15;2.40 +41268-4;VWF gene.p.Thr791Met;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;VWF gene.p.Thr791Met [Presence] in Blood by Molecular genetics method;VWF p.T791M Bld Ql;;ACTIVE;2.15;2.56 +4126-9;Amphotericin B;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Amphotericin B [Mass] of Dose;Amphotericin B Dose;;ACTIVE;1.0;2.69 +41269-2;Beta hydroxybutyrate+Gamma aminobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta hydroxybutyrate + Gamma aminobutyrate [Moles/volume] in Serum or Plasma;B-OH-Butyr+GABA SerPl-sCnc;;ACTIVE;2.15;2.42 +412-7;Piperacillin+Tazobactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Piperacillin+Tazobactam [Susceptibility] by Minimum inhibitory concentration (MIC);Pip+Tazo Islt MIC;;ACTIVE;1.0;2.73 +41270-0;Drugs identified;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Drugs identified in Urine;Drugs Ur;;ACTIVE;2.15;2.73 +41271-8;Dermatophagoides sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides sp IgE Ab [Units/volume] in Serum;Dermatophagoides sp IgE Qn;;ACTIVE;2.15;2.42 +41272-6;Dog dander+Dog epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog dander+Dog epithelium IgE Ab RAST class [Presence] in Serum;Dog Dander+Epith IgE RAST Ql;;ACTIVE;2.15;2.58 +41273-4;Alpha-1-Fetoprotein interpretation;Imp;Pt;Amnio fld;Nom;;CHEM;1;Alpha-1-Fetoprotein interpretation in Amniotic fluid;AFP Interp Amn-Imp;;ACTIVE;2.15;2.73 +41274-2;Alpha-1-Fetoprotein interpretation;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Alpha-1-Fetoprotein interpretation in Serum or Plasma;AFP Interp SerPl-Imp;;ACTIVE;2.15;2.73 +41275-9;Amino acids intense band position;Prid;Pt;Urine;Nom;;CHEM;1;Amino acids intense band position [Identifier] in Urine;Amino acids intense band position Ur;;ACTIVE;2.15;2.21 +41276-7;Anion gap;SCnc;Pt;Bld;Qn;;CHEM;1;Anion gap in Blood;Anion Gap Bld-sCnc;;ACTIVE;2.15;2.73 +4127-7;Ampicillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ampicillin [Mass] of Dose;Ampicillin Dose;;ACTIVE;1.0;2.21 +41277-5;Gross blood;PrThr;Pt;Body fld;Ord;;SPEC;1;Gross blood [Presence] of Body fluid Qualitative;Gross Blood Fld Ql;;ACTIVE;2.15;2.56 +41278-3;Gross blood;PrThr;Pt;Stool;Ord;;SPEC;1;Gross blood [Presence] of Stool Qualitative;Gross Blood Stl Ql;;ACTIVE;2.15;2.73 +41279-1;Borrelia burgdorferi Ab.IgG/Borrelia burgdorferi Ab.IgM;Ratio;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi IgG Ab/IgM Ab [Ratio] in Serum;B burgdor IgG/IgM Ser-Rto;;ACTIVE;2.15;2.73 +41280-9;Appearance;Aper;Pt;Synv fld.spun;Nom;;SPEC;1;Appearance of Spun Synovial fluid;Appearance spun Snv;;ACTIVE;2.15;2.26 +41281-7;Burr cells;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Burr cells [#/volume] in Cerebral spinal fluid by Manual count;Burr Cells # CSF Manual;;ACTIVE;2.15;2.70 +41282-5;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Body fld;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Body fluid by Manual count;nRBC/100 WBC Fld Manual-Rto;;ACTIVE;2.15;2.73 +41283-3;HLA-DQ8;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ8 [Presence];HLA-DQ8 Ql;;ACTIVE;2.15;2.73 +41284-1;Epithelial cells.non-squamous;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Epithelial cells.non-squamous [#/area] in Urine sediment by Microscopy high power field;Non-sq Epi Cells #/area UrnS HPF;;ACTIVE;2.15;2.73 +4128-5;Anileridine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Anileridine [Mass] of Dose;Anileridine Dose;;ACTIVE;1.0;2.69 +41285-8;Uranium.depleted/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Uranium depleted/Creatinine [Mass Ratio] in 24 hour Urine;Depleted U/Creat 24h Ur;;ACTIVE;2.15;2.70 +41286-6;Uranium 235/Uranium 238;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Uranium 235/Uranium 238 [Mass Ratio] in Urine;Uranium 235/Uranium 238 Ur;;ACTIVE;2.15;2.42 +41287-4;Epithelial cells.parabasal;PrThr;Pt;Vag;Ord;Microscopy.light;HEM/BC;1;Epithelial cells.parabasal [Presence] in Vaginal fluid by Light microscopy;Parabasal Cells Vag Ql Micro;;ACTIVE;2.15;2.56 +41288-2;Egg whole Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Whole Egg IgE Ab/IgE total in Serum;Whole Egg IgE/IgE total %;;ACTIVE;2.15;2.70 +41289-0;11-Deoxycortisol^post dose metyraPONE;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --post dose metyraPONE;11DC p metyraPONE SerPl-mCnc;;ACTIVE;2.15;2.73 +41290-8;HIV 1+2 Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 1+2 IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;HIV1+2 IgM SerPl IA-aCnc;;ACTIVE;2.16;2.73 +41291-6;Immunization;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Immunization;Hx of Immunization;;ACTIVE;2.16;2.56 +41292-4;Soluble mesothelin related proteins;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Soluble mesothelin related proteins [Moles/volume] in Serum or Plasma;SMRP SerPl-sCnc;;ACTIVE;2.16;2.73 +4129-3;Anthraquinone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Anthraquinone [Mass] of Dose;Anthraquinone Dose;;ACTIVE;1.0;2.69 +41293-2;Clot;Arb;Pt;XXX;Ord;;SPEC;1;Clotted specimen;Clot Spec Ql;;ACTIVE;2.16;2.73 +41294-0;Cells.S phase;PrThr;Pt;XXX;Ord;;MOLPATH;1;S-phase cells [Presence] in Specimen;S Phs Cells Spec Ql;;ACTIVE;2.16;2.69 +41295-7;Flexion.active range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Flexion Active Range of Motion Quantitative;Should-L Flx AROM Qn;;ACTIVE;2.16;2.48 +41296-5;Flexion.passive range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Flexion Passive Range of Motion Quantitative;Should-L Flx PROM Qn;;ACTIVE;2.16;2.48 +41297-3;Extension.active range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Extension Active Range of Motion Quantitative;Should-L Ext AROM Qn;;ACTIVE;2.16;2.48 +41298-1;Extension.passive range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Extension Passive Range of Motion Quantitative;Should-L Ext PROM Qn;;ACTIVE;2.16;2.48 +41299-9;Abduction.active range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Abduction Active Range of Motion Quantitative;Should-L Abduction AROM Qn;;ACTIVE;2.16;2.48 +41300-5;Abduction.passive range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Abduction Passive Range of Motion Quantitative;Should-L Abduction PROM Qn;;ACTIVE;2.16;2.48 +4130-1;Antipyrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Antipyrine [Mass] of Dose;Antipyrine Dose;;ACTIVE;1.0;2.69 +41301-3;Adduction.active range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Deprecated Shoulder - left Adduction Active Range of Motion Quantitative;;;DEPRECATED;2.16;2.36 +41302-1;Adduction.passive range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Deprecated Shoulder - left Adduction Passive Range of Motion Quantitative;;;DEPRECATED;2.16;2.36 +41303-9;Internal rotation.active range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Internal rotation Active Range of Motion Quantitative;Should-L Int Rot AROM Qn;;ACTIVE;2.16;2.48 +41304-7;Internal rotation.passive range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Internal rotation Passive Range of Motion Quantitative;Should-L Int Rot PROM Qn;;ACTIVE;2.16;2.48 +41305-4;External rotation.active range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left External rotation Active Range of Motion Quantitative;Should-L Ext Rot AROM Qn;;ACTIVE;2.16;2.48 +41306-2;External rotation.passive range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left External rotation Passive Range of Motion Quantitative;Should-L Ext Rot PROM Qn;;ACTIVE;2.16;2.48 +41307-0;Flexion.active range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Flexion Active Range of Motion Quantitative;Should-R Flx AROM Qn;;ACTIVE;2.16;2.48 +41308-8;Flexion.passive range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Flexion Passive Range of Motion Quantitative;Should-R Flx PROM Qn;;ACTIVE;2.16;2.48 +41309-6;Extension.active range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Extension Active Range of Motion Quantitative;Should-R Ext AROM Qn;;ACTIVE;2.16;2.48 +41310-4;Extension.passive range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Extension Passive Range of Motion Quantitative;Should-R Ext PROM Qn;;ACTIVE;2.16;2.48 +41311-2;Abduction.active range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Abduction Active Range of Motion Quantitative;Should-R Abduction AROM Qn;;ACTIVE;2.16;2.48 +41312-0;Abduction.passive range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Abduction Passive Range of Motion Quantitative;Should-R Abduction PROM Qn;;ACTIVE;2.16;2.48 +41313-8;Adduction.active range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Deprecated Shoulder - right Adduction Active Range of Motion Quantitative;;;DEPRECATED;2.16;2.36 +41314-6;Adduction.passive range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Deprecated Shoulder - right Adduction Passive Range of Motion Quantitative;;;DEPRECATED;2.16;2.36 +41315-3;Internal rotation.active range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Internal rotation Active Range of Motion Quantitative;Should-R Int Rot AROM Qn;;ACTIVE;2.16;2.48 +41316-1;Internal rotation.passive range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Internal rotation Passive Range of Motion Quantitative;Should-R Int Rot PROM Qn;;ACTIVE;2.16;2.48 +41317-9;External rotation.active range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right External rotation Active Range of Motion Quantitative;Should-R Ext Rot AROM Qn;;ACTIVE;2.16;2.48 +41318-7;External rotation.passive range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right External rotation Passive Range of Motion Quantitative;Should-R Ext Rot PROM Qn;;ACTIVE;2.16;2.48 +4131-9;Ascorbate.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ascorbate.PO [Mass] of Dose;Vit C PO Dose;;ACTIVE;1.0;2.73 +41319-5;Flexion.active range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Flexion Active Range of Motion Quantitative;Hip-L Flx AROM Qn;;ACTIVE;2.16;2.48 +41320-3;Flexion.passive range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Flexion Passive Range of Motion Quantitative;Hip-L Flx PROM Qn;;ACTIVE;2.16;2.48 +41321-1;Extension.active range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Extension Active Range of Motion Quantitative;Hip-L Ext AROM Qn;;ACTIVE;2.16;2.48 +41322-9;Extension.passive range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Extension Passive Range of Motion Quantitative;Hip-L Ext PROM Qn;;ACTIVE;2.16;2.48 +41323-7;Abduction.active range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Abduction Active Range of Motion Quantitative;Hip-L Abduction AROM Qn;;ACTIVE;2.16;2.48 +41324-5;Abduction.passive range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Abduction Passive Range of Motion Quantitative;Hip-L Abduction PROM Qn;;ACTIVE;2.16;2.48 +41325-2;Adduction.active range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Adduction Active Range of Motion Quantitative;Hip-L Adduction AROM Qn;;ACTIVE;2.16;2.48 +41326-0;Adduction.passive range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Adduction Passive Range of Motion Quantitative;Hip-L Adduction PROM Qn;;ACTIVE;2.16;2.48 +4132-7;Atenolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Atenolol [Mass] of Dose;Atenolol Dose;;ACTIVE;1.0;2.69 +41327-8;Internal rotation.active range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Internal rotation Active Range of Motion Quantitative;Hip-L Int Rot AROM Qn;;ACTIVE;2.16;2.48 +41328-6;Internal rotation.passive range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left Internal rotation Passive Range of Motion Quantitative;Hip-L Int Rot PROM Qn;;ACTIVE;2.16;2.48 +41329-4;External rotation.active range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left External rotation Active Range of Motion Quantitative;Hip-L Ext Rot AROM Qn;;ACTIVE;2.16;2.48 +41330-2;External rotation.passive range of motion;Angle;Pt;Hip.left;Qn;;H&P.PX;2;Hip - left External rotation Passive Range of Motion Quantitative;Hip-L Ext Rot PROM Qn;;ACTIVE;2.16;2.48 +41331-0;Flexion.active range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Flexion Active Range of Motion Quantitative;Hip-R Flx AROM Qn;;ACTIVE;2.16;2.48 +41332-8;Flexion.passive range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Flexion Passive Range of Motion Quantitative;Hip-R Flx PROM Qn;;ACTIVE;2.16;2.48 +41333-6;Extension.active range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Extension Active Range of Motion Quantitative;Hip-R Ext AROM Qn;;ACTIVE;2.16;2.48 +41334-4;Extension.passive range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Extension Passive Range of Motion Quantitative;Hip-R Ext PROM Qn;;ACTIVE;2.16;2.48 +4133-5;Atropine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Atropine [Mass] of Dose;Atropine Dose;;ACTIVE;1.0;2.69 +41335-1;Abduction.active range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Abduction Active Range of Motion Quantitative;Hip-R Abduction AROM Qn;;ACTIVE;2.16;2.48 +41336-9;Abduction.passive range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Abduction Passive Range of Motion Quantitative;Hip-R Abduction PROM Qn;;ACTIVE;2.16;2.48 +41337-7;Adduction.active range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Adduction Active Range of Motion Quantitative;Hip-R Adduction AROM Qn;;ACTIVE;2.16;2.48 +41338-5;Adduction.passive range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Adduction Passive Range of Motion Quantitative;Hip-R Adduction PROM Qn;;ACTIVE;2.16;2.48 +41339-3;Internal rotation.active range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Internal rotation Active Range of Motion Quantitative;Hip-R Int Rot AROM Qn;;ACTIVE;2.16;2.48 +41340-1;Internal rotation.passive range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right Internal rotation Passive Range of Motion Quantitative;Hip-R Int Rot PROM Qn;;ACTIVE;2.16;2.48 +41341-9;External rotation.active range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right External rotation Active Range of Motion Quantitative;Hip-R Ext Rot AROM Qn;;ACTIVE;2.16;2.48 +41342-7;External rotation.passive range of motion;Angle;Pt;Hip.right;Qn;;H&P.PX;2;Hip - right External rotation Passive Range of Motion Quantitative;Hip-R Ext Rot PROM Qn;;ACTIVE;2.16;2.48 +4134-3;Azlocillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Azlocillin [Mass] of Dose;Azlocillin Dose;;ACTIVE;1.0;2.69 +41343-5;Flexion.active range of motion;Angle;Pt;Knee.left;Qn;;H&P.PX;2;Knee - left Flexion Active Range of Motion Quantitative;Knee-L Flx AROM Qn;;ACTIVE;2.16;2.48 +41344-3;Flexion.passive range of motion;Angle;Pt;Knee.left;Qn;;H&P.PX;2;Knee - left Flexion Passive Range of Motion Quantitative;Knee-L Flx PROM Qn;;ACTIVE;2.16;2.48 +41345-0;Extension.active range of motion;Angle;Pt;Knee.left;Qn;;H&P.PX;2;Knee - left Extension Active Range of Motion Quantitative;Knee-L Ext AROM Qn;;ACTIVE;2.16;2.48 +41346-8;Extension.passive range of motion;Angle;Pt;Knee.left;Qn;;H&P.PX;2;Knee - left Extension Passive Range of Motion Quantitative;Knee-L Ext PROM Qn;;ACTIVE;2.16;2.48 +41347-6;Flexion.active range of motion;Angle;Pt;Knee.right;Qn;;H&P.PX;2;Knee - right Flexion Active Range of Motion Quantitative;Knee-R Flx AROM Qn;;ACTIVE;2.16;2.48 +41348-4;Flexion.passive range of motion;Angle;Pt;Knee.right;Qn;;H&P.PX;2;Knee - right Flexion Passive Range of Motion Quantitative;Knee-R Flx PROM Qn;;ACTIVE;2.16;2.48 +41349-2;Extension.active range of motion;Angle;Pt;Knee.right;Qn;;H&P.PX;2;Knee - right Extension Active Range of Motion Quantitative;Knee-R Ext AROM Qn;;ACTIVE;2.16;2.48 +413-5;Piperacillin+Tazobactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Piperacillin+Tazobactam [Susceptibility] by Disk diffusion (KB);Pip+Tazo Islt KB;;ACTIVE;1.0;2.73 +4135-0;Aztreonam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Aztreonam [Mass] of Dose;Aztreonam Dose;;ACTIVE;1.0;2.69 +41350-0;Extension.passive range of motion;Angle;Pt;Knee.right;Qn;;H&P.PX;2;Knee - right Extension Passive Range of Motion Quantitative;Knee-R Ext PROM Qn;;ACTIVE;2.16;2.48 +41351-8;Flexion.active range of motion;Angle;Pt;Elbow.left;Qn;;H&P.PX;2;Elbow - left Flexion Active Range of Motion Quantitative;Elbow-L Flx AROM Qn;;ACTIVE;2.16;2.48 +41352-6;Flexion.passive range of motion;Angle;Pt;Elbow.left;Qn;;H&P.PX;2;Elbow - left Flexion Passive Range of Motion Quantitative;Elbow-L Flx PROM Qn;;ACTIVE;2.16;2.48 +41353-4;Extension.active range of motion;Angle;Pt;Elbow.left;Qn;;H&P.PX;2;Elbow - left Extension Active Range of Motion Quantitative;Elbow-L Ext AROM Qn;;ACTIVE;2.16;2.48 +41354-2;Extension.passive range of motion;Angle;Pt;Elbow.left;Qn;;H&P.PX;2;Elbow - left Extension Passive Range of Motion Quantitative;Elbow-L Ext PROM Qn;;ACTIVE;2.16;2.48 +41355-9;Flexion.active range of motion;Angle;Pt;Elbow.right;Qn;;H&P.PX;2;Elbow - right Flexion Active Range of Motion Quantitative;Elbow-R Flx AROM Qn;;ACTIVE;2.16;2.48 +41356-7;Flexion.passive range of motion;Angle;Pt;Elbow.right;Qn;;H&P.PX;2;Elbow - right Flexion Passive Range of Motion Quantitative;Elbow-R Flx PROM Qn;;ACTIVE;2.16;2.48 +41357-5;Extension.active range of motion;Angle;Pt;Elbow.right;Qn;;H&P.PX;2;Elbow - right Extension Active Range of Motion Quantitative;Elbow-R Ext AROM Qn;;ACTIVE;2.16;2.48 +41358-3;Extension.passive range of motion;Angle;Pt;Elbow.right;Qn;;H&P.PX;2;Elbow - right Extension Passive Range of Motion Quantitative;Elbow-R Ext PROM Qn;;ACTIVE;2.16;2.48 +41359-1;Active range of motion panel;Angle;Pt;^Patient;Qn;;PANEL.H&P;2;Active range of motion panel Quantitative;Active Range of Motion Pnl Qn;;ACTIVE;2.16;2.27 +41360-9;Passive range of motion panel;Angle;Pt;^Patient;Qn;;PANEL.H&P;2;Passive range of motion panel Quantitative;Passive Range of Motion Pnl Qn;;ACTIVE;2.16;2.42 +41361-7;Extension.active range of motion;Angle;Pt;Elbow;Qn;;H&P.PX;2;Elbow Extension Active Range of Motion Quantitative;Elbow Ext AROM Qn;;ACTIVE;2.16;2.70 +41362-5;Extension.passive range of motion;Angle;Pt;Elbow;Qn;;H&P.PX;2;Elbow Extension Passive Range of Motion Quantitative;Elbow Ext PROM Qn;;ACTIVE;2.16;2.70 +41363-3;Flexion.active range of motion;Angle;Pt;Elbow;Qn;;H&P.PX;2;Elbow Flexion Active Range of Motion Quantitative;Elbow Flx AROM Qn;;ACTIVE;2.16;2.70 +41364-1;Flexion.passive range of motion;Angle;Pt;Elbow;Qn;;H&P.PX;2;Elbow Flexion Passive Range of Motion Quantitative;Elbow Flx PROM Qn;;ACTIVE;2.16;2.70 +41365-8;Abduction.active range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Abduction Active Range of Motion Quantitative;Hip Abduction AROM Qn;;ACTIVE;2.16;2.70 +41366-6;Abduction.passive range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Abduction Passive Range of Motion Quantitative;Hip Abduction PROM Qn;;ACTIVE;2.16;2.70 +41367-4;Adduction.active range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Adduction Active Range of Motion Quantitative;Hip Adduction AROM Qn;;ACTIVE;2.16;2.70 +4136-8;Barbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Barbital [Mass] of Dose;Barbital Dose;;ACTIVE;1.0;2.69 +41368-2;Adduction.passive range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Adduction Passive Range of Motion Quantitative;Hip Adduction PROM Qn;;ACTIVE;2.16;2.70 +41369-0;Extension.active range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Extension Active Range of Motion Quantitative;Hip Ext AROM Qn;;ACTIVE;2.16;2.70 +41370-8;Extension.passive range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Extension Passive Range of Motion Quantitative;Hip Ext PROM Qn;;ACTIVE;2.16;2.70 +41371-6;External rotation.active range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip External rotation Active Range of Motion Quantitative;Hip Ext Rot AROM Qn;;ACTIVE;2.16;2.70 +41372-4;External rotation.passive range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip External rotation Passive Range of Motion Quantitative;Hip Ext Rot PROM Qn;;ACTIVE;2.16;2.70 +41373-2;Flexion.active range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Flexion Active Range of Motion Quantitative;Hip Flx AROM Qn;;ACTIVE;2.16;2.70 +41374-0;Flexion.passive range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Flexion Passive Range of Motion Quantitative;Hip Flx PROM Qn;;ACTIVE;2.16;2.70 +41375-7;Internal rotation.active range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Internal rotation Active Range of Motion Quantitative;Hip Int Rot AROM Qn;;ACTIVE;2.16;2.70 +4137-6;Barbiturates;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Barbiturates [Mass] of Dose;Barbiturates Dose;;ACTIVE;1.0;2.69 +41376-5;Internal rotation.passive range of motion;Angle;Pt;Hip;Qn;;H&P.PX;2;Hip Internal rotation Passive Range of Motion Quantitative;Hip Int Rot PROM Qn;;ACTIVE;2.16;2.70 +41377-3;Extension.active range of motion;Angle;Pt;Knee;Qn;;H&P.PX;2;Knee Extension Active Range of Motion Quantitative;Knee Ext AROM Qn;;ACTIVE;2.16;2.70 +41378-1;Extension.passive range of motion;Angle;Pt;Knee;Qn;;H&P.PX;2;Knee Extension Passive Range of Motion Quantitative;Knee Ext PROM Qn;;ACTIVE;2.16;2.70 +41379-9;Flexion.active range of motion;Angle;Pt;Knee;Qn;;H&P.PX;2;Knee Flexion Active Range of Motion Quantitative;Knee Flx AROM Qn;;ACTIVE;2.16;2.70 +41380-7;Flexion.passive range of motion;Angle;Pt;Knee;Qn;;H&P.PX;2;Knee Flexion Passive Range of Motion Quantitative;Knee Flx PROM Qn;;ACTIVE;2.16;2.73 +41381-5;Abduction.active range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Abduction Active Range of Motion Quantitative;Should Abduction AROM Qn;;ACTIVE;2.16;2.70 +41382-3;Abduction.passive range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Abduction Passive Range of Motion Quantitative;Should Abduction PROM Qn;;ACTIVE;2.16;2.70 +41383-1;Adduction.active range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Deprecated Shoulder Adduction Active Range of Motion Quantitative;;;DEPRECATED;2.16;2.70 +4138-4;Bendroflumethiazide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Bendroflumethiazide [Mass] of Dose;Bendroflumethiaz Dose;;ACTIVE;1.0;2.69 +41384-9;Adduction.passive range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Deprecated Shoulder Adduction Passive Range of Motion Quantitative;;;DEPRECATED;2.16;2.70 +41385-6;Extension.active range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Extension Active Range of Motion Quantitative;Should Ext AROM Qn;;ACTIVE;2.16;2.70 +41386-4;Extension.passive range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Extension Passive Range of Motion Quantitative;Should Ext PROM Qn;;ACTIVE;2.16;2.70 +41387-2;External rotation.active range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder External rotation Active Range of Motion Quantitative;Should Ext Rot AROM Qn;;ACTIVE;2.16;2.70 +41388-0;External rotation.passive range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder External rotation Passive Range of Motion Quantitative;Should Ext Rot PROM Qn;;ACTIVE;2.16;2.70 +41389-8;Flexion.active range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Flexion Active Range of Motion Quantitative;Should Flx AROM Qn;;ACTIVE;2.16;2.70 +41390-6;Flexion.passive range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Flexion Passive Range of Motion Quantitative;Should Flx PROM Qn;;ACTIVE;2.16;2.70 +41391-4;Internal rotation.active range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Internal rotation Active Range of Motion Quantitative;Should Int Rot AROM Qn;;ACTIVE;2.16;2.70 +4139-2;Benzfetamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Benzfetamine [Mass] of Dose;Benzfetamine Dose;;ACTIVE;1.0;2.69 +41392-2;Internal rotation.passive range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Internal rotation Passive Range of Motion Quantitative;Should Int Rot PROM Qn;;ACTIVE;2.16;2.70 +41393-0;Collection date;TmStp;Pt;Body fld;Qn;;SPEC;1;Collection date of Body fluid;Collect Date Fld;;ACTIVE;2.16;2.73 +41394-8;Collection date;TmStp;Pt;Stool;Qn;;SPEC;1;Collection date of Stool;Collect Date Stl;;ACTIVE;2.16;2.73 +41395-5;Collection date;TmStp;Pt;Urine;Qn;;SPEC;1;Collection date of Urine;Collect Date Ur;;ACTIVE;2.16;2.26 +41396-3;Tenofovir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Tenofovir [Susceptibility] by Genotype method;Tenofovir Islt Genotyp;;ACTIVE;2.16;2.73 +41397-1;Beta lactoglobulin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beta lactoglobulin IgE Ab [Units/volume] in Serum;B-Lactoglob IgE Qn;;ACTIVE;2.16;2.73 +41398-9;Alloisoleucine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alloisoleucine [Presence] in Serum or Plasma;Alloisoleucine SerPl Ql;;ACTIVE;2.16;2.73 +41399-7;Herpes simplex virus 1+2 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Units/volume] in Serum by Immunoassay;HSV1+2 IgM Ser IA-aCnc;;ACTIVE;2.16;2.73 +41-4;Azlocillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Azlocillin [Susceptibility] by Disk diffusion (KB);Azlocillin Islt KB;;ACTIVE;1.0;2.21 +4140-0;Benzoylecgonine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Benzoylecgonine [Mass] of Dose;BZE Dose;;ACTIVE;1.0;2.69 +41400-3;Yersinia sp Ab.IgA;PrThr;Pt;Ser;Ord;IB;MICRO;1;Yersinia sp IgA Ab [Presence] in Serum by Immunoblot;Yersinia IgA Ser Ql IB;;ACTIVE;2.16;2.73 +41401-1;Yersinia sp Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Yersinia sp IgG Ab [Presence] in Serum by Immunoblot;Yersinia IgG Ser Ql IB;;ACTIVE;2.16;2.73 +41402-9;Emtricitabine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Emtricitabine [Susceptibility] by Genotype method;Emtricitabine Islt Genotyp;;ACTIVE;2.16;2.73 +41403-7;Atazanavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Atazanavir [Susceptibility] by Genotype method;Atazanavir Islt Genotyp;;ACTIVE;2.16;2.73 +41404-5;17-Hydroxycorticosteroids/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;17-Hydroxycorticosteroids/Creatinine [Mass Ratio] in 24 hour Urine;17OHCS/Creat 24h Ur;;ACTIVE;2.16;2.73 +41405-2;Parainfluenza virus 2 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parainfluenza virus 2 IgG Ab [Units/volume] in Serum by Immunoassay;HPIV2 IgG Ser IA-aCnc;;ACTIVE;2.16;2.70 +41406-0;Meropenem;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meropenem [Mass/volume] in Serum or Plasma;Meropenem SerPl-mCnc;;ACTIVE;2.16;2.70 +41407-8;Cortisol^pre dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre dose corticotropin;Cortis Pre ACTH SerPl-mCnc;;ACTIVE;2.16;2.73 +41408-6;Ofloxacin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ofloxacin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ofloxacin 1 ug/mL Islt SlowMyco;;ACTIVE;2.16;2.26 +41409-4;Ofloxacin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ofloxacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ofloxacin 2 ug/mL Islt SlowMyco;;ACTIVE;2.16;2.26 +41410-2;Ofloxacin 4.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ofloxacin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ofloxacin 4 ug/mL Islt SlowMyco;;ACTIVE;2.16;2.26 +41411-0;Angiostrongylus cantonensis Ab;PrThr;Pt;XXX;Ord;IB;MICRO;1;Angiostrongylus cantonensis Ab [Presence] in Specimen by Immunoblot;A cantonensis Ab Spec Ql IB;;ACTIVE;2.16;2.69 +41412-8;Angiostrongylus costaricensis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Angiostrongylus costaricensis Ab [Presence] in Serum by Agglutination;A costaricensis Ab Ser Ql Aggl;;ACTIVE;2.16;2.65 +41413-6;Babesia divergens Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia divergens Ab [Titer] in Serum by Immunofluorescence;B divergens Ab Titr Ser IF;;ACTIVE;2.16;2.64 +41414-4;Babesia microti Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia microti Ab [Titer] in Serum by Immunofluorescence;B microti Ab Titr Ser IF;;ACTIVE;2.16;2.73 +41415-1;Babesia duncani Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia duncani Ab [Titer] in Serum by Immunofluorescence;B duncani Ab Titr Ser IF;;ACTIVE;2.16;2.73 +41416-9;Echinococcus sp Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Echinococcus sp Ab [Presence] in Serum by Immunoblot;Echinococcus Ab Ser Ql IB;;ACTIVE;2.16;2.65 +41417-7;Filaria Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Filaria Ab [Units/volume] in Serum by Immunoassay;Filaria Ab Ser IA-aCnc;;ACTIVE;2.16;2.69 +4141-8;Benzthiazide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Benzthiazide [Mass] of Dose;Benzthiazide Dose;;ACTIVE;1.0;2.69 +41418-5;Gnathostoma sp Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Gnathostoma sp Ab [Presence] in Serum by Immunoblot;Gnathostoma Ab Ser Ql IB;;ACTIVE;2.16;2.65 +41419-3;Leishmania braziliensis Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania brasilensis Ab [Titer] in Serum by Immunofluorescence;L braziliensis Ab Titr Ser IF;;ACTIVE;2.16;2.30 +41420-1;Leishmania tropica Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania tropica Ab [Titer] in Serum by Immunofluorescence;L tropica Ab Titr Ser IF;;ACTIVE;2.16;2.30 +41421-9;Paragonimus sp Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Paragonimus sp Ab [Presence] in Serum by Immunoblot;Paragonimus Ab Ser Ql IB;;ACTIVE;2.16;2.65 +41422-7;Schistosoma haematobium Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma haematobium Ab [Presence] in Serum by Immunoblot;S haematobium Ab Ser Ql IB;;ACTIVE;2.16;2.65 +41423-5;Schistosoma japonicum Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Schistosoma japonicum Ab [Presence] in Serum by Immunoblot;S japonicum Ab Ser Ql IB;;ACTIVE;2.16;2.65 +41424-3;Schistosoma mansoni Ab;PrThr;Pt;XXX;Ord;IB;MICRO;1;Schistosoma mansoni Ab [Presence] in Specimen by Immunoblot;S mansoni Ab Spec Ql IB;;ACTIVE;2.16;2.69 +41425-0;Toxocara canis Ab;Titr;Pt;XXX;Qn;IA;MICRO;1;Toxocara canis Ab [Titer] in Specimen by Immunoassay;T canis Ab Titr Spec IA;;ACTIVE;2.16;2.69 +4142-6;Bisacodyl;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Bisacodyl [Mass] of Dose;Bisacodyl Dose;;ACTIVE;1.0;2.69 +41426-8;Trichinella spiralis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichinella spiralis Ab [Units/volume] in Serum by Immunoassay;T spiralis Ab Ser IA-aCnc;;ACTIVE;2.16;2.73 +41427-6;Trypanosoma brucei gambiense Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Trypanosoma brucei gambiense Ab [Presence] in Serum by Agglutination;T brucei gamb Ab Ser Ql Aggl;;ACTIVE;2.16;2.65 +41428-4;Trypanosoma brucei rhodesiense Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Trypanosoma brucei rhodesiense Ab [Titer] in Serum by Immunofluorescence;T brucei rhodes Ab Titr Ser IF;;ACTIVE;2.16;2.30 +41429-2;Acanthamoeba sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Acanthamoeba sp DNA [Presence] in Specimen by NAA with probe detection;Acanthamoeba DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +414-3;Piperacillin+Tazobactam;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Piperacillin+Tazobactam [Susceptibility] by Serum bactericidal titer;Pip+Tazo Titr SBT;;ACTIVE;1.0;2.44 +41430-0;Angiostrongylus cantonensis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Angiostrongylus cantonensis DNA [Presence] in Specimen by NAA with probe detection;A cantonensis DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41431-8;Angiostrongylus costaricensis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Angiostrongylus costaricensis DNA [Presence] in Specimen by NAA with probe detection;A costaricensis DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41432-6;Balamuthia mandrillaris DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Balamuthia mandrillaris DNA [Presence] in Specimen by NAA with probe detection;B mandrillaris DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +41433-4;Cryptosporidium hominis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cryptosporidium hominis DNA [Presence] in Specimen by NAA with probe detection;C hominis DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +4143-4;Bolasterone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Bolasterone [Mass] of Dose;Bolasterone Dose;;ACTIVE;1.0;2.69 +41434-2;Cryptosporidium parvum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cryptosporidium parvum DNA [Presence] in Specimen by NAA with probe detection;C parvum DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +41435-9;Cyclospora carcopitheci DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cyclospora carcopitheci DNA [Presence] in Specimen by NAA with probe detection;C carcopitheci DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41436-7;Cyclospora cayetanensis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cyclospora cayetanensis DNA [Presence] in Specimen by NAA with probe detection;C cayetanensis DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +41437-5;Cyclospora colobi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cyclospora colobi DNA [Presence] in Specimen by NAA with probe detection;C colobi DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41438-3;Cyclospora papionis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cyclospora papionis DNA [Presence] in Specimen by NAA with probe detection;C papionis DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41439-1;Encephalitozoon cuniculi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Encephalitozoon cuniculi DNA [Presence] in Specimen by NAA with probe detection;E cuniculi DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41440-9;Encephalitozoon hellem DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Encephalitozoon hellem DNA [Presence] in Specimen by NAA with probe detection;E hellem DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41441-7;Encephalitozoon intestinalis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Encephalitozoon intestinalis DNA [Presence] in Specimen by NAA with probe detection;E intestinalis DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +4144-2;Bromazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Bromazepam [Mass] of Dose;Bromazepam Dose;;ACTIVE;1.0;2.73 +41442-5;Entamoeba dispar DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Entamoeba dispar DNA [Presence] in Specimen by NAA with probe detection;E dispar DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41443-3;Enterocytozoon bieneusi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterocytozoon bieneusi DNA [Presence] in Specimen by NAA with probe detection;E bieneusi DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +41444-1;Naegleria fowleri DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Naegleria fowleri DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;N fowleri DNA CSF Ql NAA+probe;;ACTIVE;2.16;2.65 +41445-8;Ova+Parasites identified;Prid;Pt;XXX;Nom;;MICRO;1;Deprecated Microscopic observation [Identifier] in Unspecified specimen by Ova & Parasite Preparation;Deprecated O+P XXX;;DEPRECATED;2.16;2.69 +41446-6;Parasite identified;Prid;Pt;XXX;Nom;Culture;MICRO;1;Parasite identified in Specimen by Culture;Parasite Spec Cult;;ACTIVE;2.16;2.69 +41447-4;Plasmodium falciparum DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Plasmodium falciparum DNA [Presence] in Blood by NAA with probe detection;P falciparum DNA Bld Ql NAA+probe;;ACTIVE;2.16;2.73 +41448-2;Plasmodium malariae DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Plasmodium malariae DNA [Presence] in Blood by NAA with probe detection;P malariae DNA Bld Ql NAA+probe;;ACTIVE;2.16;2.73 +41449-0;Plasmodium ovale DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Plasmodium ovale DNA [Presence] in Blood by NAA with probe detection;P ovale DNA Bld Ql NAA+probe;;ACTIVE;2.16;2.73 +41450-8;Plasmodium vivax DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Plasmodium vivax DNA [Presence] in Blood by NAA with probe detection;P vivax DNA Bld Ql NAA+probe;;ACTIVE;2.16;2.73 +41451-6;Plasmodium stage;Prid;Pt;Bld;Nom;Microscopy.light;MICRO;1;Plasmodium stage [Identifier] in Blood by Light microscopy;Plasmodium Stage Bld Smear;;ACTIVE;2.16;2.21 +41452-4;Adenovirus serotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Adenovirus DNA [Identifier] in Unspecified specimen by Probe & target amplification method;Deprecated HAdV Sertyp XXX PCR;;DEPRECATED;2.16;2.69 +41453-2;Human coronavirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Human coronavirus Ag [Presence] in Specimen by Immunofluorescence;HCoV Ag Spec Ql IF;;ACTIVE;2.16;2.69 +41454-0;Human coronavirus identified;Prid;Pt;XXX;Nom;;MICRO;1;Human coronavirus identified in Specimen;HCoV Spec;;ACTIVE;2.16;2.69 +41455-7;Human metapneumovirus genotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Human metapneumovirus RNA [Identifier] in Unspecified specimen by Probe & target amplification method;Deprecated hMPV Gentyp XXX PCR;;DEPRECATED;2.16;2.72 +41456-5;Respiratory syncytial virus genotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Respiratory syncytial virus RNA [Identifier] in Unspecified specimen by Probe & target amplification method;Deprecated RSV Gentyp XXX PCR;;DEPRECATED;2.16;2.72 +41457-3;Rhinovirus serotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Rhinovirus RNA [Identifier] in Unspecified specimen by Probe & target amplification method;Deprecated Rhinovirus Sertyp XXX PCR;;DEPRECATED;2.16;2.69 +41458-1;SARS coronavirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus RNA [Presence] in Specimen by NAA with probe detection;SARS-CoV RNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +4145-9;Brompheniramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Brompheniramine [Mass] of Dose;Brompheniramine Dose;;ACTIVE;1.0;2.69 +41459-9;SARS coronavirus;PrThr;Pt;XXX;Ord;;MICRO;1;SARS coronavirus [Presence] in Specimen;SARS-CoV Spec Ql;;ACTIVE;2.16;2.69 +41460-7;SARS coronavirus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;SARS coronavirus IgG Ab [Presence] in Serum by Immunoassay;SARS-CoV IgG Ser Ql IA;;ACTIVE;2.16;2.68 +41461-5;Virus identified;Prid;Pt;XXX;Nom;;MICRO;1;Virus identified in Specimen;Virus Spec;;ACTIVE;2.16;2.73 +41462-3;Taenia solium larva Ab;PrThr;Pt;XXX;Ord;IB;MICRO;1;Taenia solium larva Ab [Presence] in Specimen by Immunoblot;T sol lar Ab Spec Ql IB;;ACTIVE;2.16;2.69 +41463-1;Wuchereria bancrofti+Brugia malayi Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Wuchereria bancrofti+Brugia malayi Ag [Presence] in Serum by Immunoassay;W bancr+B malayi Ag Ser Ql IA;;ACTIVE;2.16;2.65 +41464-9;Amphetamines/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Amphetamines/Creatinine [Mass Ratio] in Urine;Amphetamines/Creat Ur;;ACTIVE;2.16;2.42 +41465-6;Opiates/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Opiates/Creatinine [Mass Ratio] in Urine;Opiates/Creat Ur;;ACTIVE;2.16;2.42 +41466-4;Methadone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methadone/Creatinine [Mass Ratio] in Urine;Methadone/Creat Ur;;ACTIVE;2.16;2.73 +4146-7;Bumetanide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Bumetanide [Mass] of Dose;Bumetanide Dose;;ACTIVE;1.0;2.69 +41467-2;Benzodiazepines/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Benzodiazepines/Creatinine [Mass Ratio] in Urine;Benzodiaz/Creat Ur;;ACTIVE;2.16;2.42 +41468-0;Barbiturates/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Barbiturates/Creatinine [Mass Ratio] in Urine;Barbiturates/Creat Ur;;ACTIVE;2.16;2.73 +41469-8;Ribavirin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ribavirin [Mass/volume] in Serum or Plasma;Ribavirin SerPl-mCnc;;ACTIVE;2.16;2.42 +41470-6;Atazanavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Atazanavir [Mass/volume] in Serum or Plasma;Atazanavir SerPl-mCnc;;ACTIVE;2.16;2.42 +41471-4;Phenethicillin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenethicillin [Mass/volume] in Serum or Plasma;Phenethicillin SerPl-mCnc;;ACTIVE;2.16;2.42 +41472-2;carBAMazepine;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;carBAMazepine [Mass/volume] in DBS;carBAMazepine DBS-mCnc;;ACTIVE;2.16;2.61 +41473-0;carBAMazepine 10,11-Epoxide;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Carbamazepine 10,11-Epoxide [Mass/volume] in DBS;Carbamazepine EP DBS-mCnc;;ACTIVE;2.16;2.61 +41474-8;Diethylcarbamazepine;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Diethylcarbamazepine [Mass/volume] in DBS;Diethylcarbamazepine DBS-mCnc;;ACTIVE;2.16;2.61 +4147-5;Buprenorphine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Buprenorphine [Mass] of Dose;Buprenorphine Dose;;ACTIVE;1.0;2.73 +41475-5;Rickettsia rickettsii Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rickettsia rickettsii IgM Ab [Presence] in Serum by Immunoassay;R rickettsi IgM Ser Ql IA;;ACTIVE;2.16;2.73 +41476-3;Rickettsia rickettsii Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rickettsia rickettsii IgG Ab [Presence] in Serum by Immunoassay;R rickettsi IgG Ser Ql IA;;ACTIVE;2.16;2.73 +41477-1;Bacterial sialidase;PrThr;Pt;XXX;Ord;;MICRO;1;Bacterial sialidase [Presence] in Specimen;Bacterial sialidase Spec Ql;;ACTIVE;2.16;2.73 +41478-9;Bartonella henselae Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Bartonella henselae IgG and IgM panel - Serum;B henselae IgG+IgM Pnl Ser;;ACTIVE;2.16;2.73 +41479-7;BK virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;BKV DNA # SerPl NAA+probe;;ACTIVE;2.16;2.73 +41480-5;BK virus DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Urine by NAA with probe detection;BKV DNA # Ur NAA+probe;;ACTIVE;2.16;2.73 +41481-3;Blastomyces sp Ab;ACnc;Pt;Ser;Ord;Immune diffusion;MICRO;1;Deprecated Blastomyces sp Ab [Presence] in Serum by Immune diffusion (ID);Deprecated Blastomyces Ab Ser Ql ID;;DEPRECATED;2.16;2.36 +41482-1;Chlamydia sp Ab.IgG & IgM panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Chlamydia sp IgG and IgM panel [Titer] - Serum;Chlamydia sp IgG+IgM Pnl Titr Ser;;ACTIVE;2.16;2.73 +4148-3;Butabarbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Butabarbital [Mass] of Dose;Butabarbital Dose;;ACTIVE;1.0;2.69 +41483-9;Clostridium tetani toxoid Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Clostridium tetani toxoid Ab [Units/volume] in Serum by Immunoassay;C tetani Toxoid Ab Ser IA-aCnc;;ACTIVE;2.16;2.73 +41484-7;Coxsackievirus A Ab panel;Titr;Pt;Ser;Qn;Comp fix;PANEL.MICRO;1;Coxsackievirus A Ab panel [Titer] - Serum by Complement fixation;CV A IgG + IgM Pnl Titr Ser CF;;ACTIVE;2.16;2.73 +41485-4;Coxsackievirus B Ab panel;Titr;Pt;Ser;Qn;Comp fix;PANEL.MICRO;1;Coxsackievirus B Ab panel [Titer] - Serum by Complement fixation;CV B Virus Ab Pnl Titr Ser CF;;ACTIVE;2.16;2.73 +41486-2;Coxsackievirus B Ab.Neut panel;Titr;Pt;Ser;Qn;Neut;PANEL.MICRO;1;Coxsackievirus B neutralizing Ab panel [Titer] - Serum by Neutralization test;CV B Virus Ab.Neut Pnl Titr Ser Nt;;ACTIVE;2.16;2.73 +41487-0;Cryptosporidium parvum Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Cryptosporidium parvum Ag [Presence] in Stool by Immunoassay;C parvum Ag Stl Ql IA;;ACTIVE;2.16;2.73 +41488-8;Cryptosporidium sp;PrThr;Pt;XXX;Ord;Acid fast stain;MICRO;1;Cryptosporidium sp [Presence] in Specimen by Acid fast stain;Cryptosp Spec Ql Acid fast Stn;;ACTIVE;2.16;2.73 +41489-6;Echovirus 11 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 11 neutralizing antibody [Titer] in Serum by Neutralization test;ECV11 NAb Titr Ser Nt;;ACTIVE;2.16;2.73 +41490-4;Echovirus 16 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 16 neutralizing antibody [Titer] in Serum by Neutralization test;ECV16 NAb Titr Ser Nt;;ACTIVE;2.16;2.72 +4149-1;Butalbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Butalbital [Mass] of Dose;Butalbital Dose;;ACTIVE;1.0;2.69 +41491-2;Echovirus 30 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 30 neutralizing antibody [Titer] in Serum by Neutralization test;ECV30 NAb Titr Ser Nt;;ACTIVE;2.16;2.73 +41492-0;Echovirus 7 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 7 neutralizing antibody [Titer] in Serum by Neutralization test;ECV7 NAb Titr Ser Nt;;ACTIVE;2.16;2.73 +41493-8;Febrile agglutinin Ab panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Febrile agglutinin Ab panel [Titer] - Serum;Febrile Agglutinin Ab Pnl Titr Ser;;ACTIVE;2.16;2.42 +41494-6;Gatifloxacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Gatifloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Gatifloxacin Islt SlowMyco;;ACTIVE;2.16;2.26 +41495-3;Haemophilus influenzae B Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Haemophilus influenzae B Ag [Presence] in Body fluid;Haem influ B Ag Fld Ql;;ACTIVE;2.16;2.73 +41496-1;Herpes virus 6 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Herpes virus 6 IgG Ab [Titer] in Serum;HHV6 IgG Titr Ser;;ACTIVE;2.16;2.73 +41497-9;HIV 1 RNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HIV1 RNA CSF NAA+probe-Log#;;ACTIVE;2.16;2.73 +41498-7;HIV 1 RNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HIV1 RNA # CSF NAA+probe;;ACTIVE;2.16;2.73 +41499-5;Legionella pneumophila 1 Ag;PrThr;Pt;Urine;Ord;IA;MICRO;1;Legionella pneumophila 1 Ag [Presence] in Urine by Immunoassay;L pneumo1 Ag Ur Ql IA;;ACTIVE;2.16;2.73 +415-0;Pivampicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Pivampicillin [Susceptibility] by Minimum lethal concentration (MLC);Pivampicillin Islt MLC;;ACTIVE;1.0;2.19 +41500-0;Linezolid;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Linezolid [Susceptibility] by Method for Slow-growing mycobacteria;Linezolid Islt SlowMyco;;ACTIVE;2.16;2.26 +41501-8;Measles virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Measles virus Ab [Titer] in Serum by Hemagglutination inhibition;MeV Ab Titr Ser HAI;;ACTIVE;2.16;2.32 +41502-6;Moxifloxacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Moxifloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Moxifloxacin Islt SlowMyco;;ACTIVE;2.16;2.26 +41503-4;Neisseria meningitidis serogroup B Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Body fluid;N men sg B Ag Fld Ql;;ACTIVE;2.16;2.64 +41504-2;Norfloxacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Norfloxacin [Susceptibility] by Method for Slow-growing mycobacteria;Norfloxacin Islt SlowMyco;;ACTIVE;2.16;2.26 +41505-9;Parainfluenza virus Ag panel;-;Pt;XXX;-;IF;PANEL.MICRO;1;Parainfluenza virus Ag panel - Specimen by Immunofluorescence;HPIV Pnl Spec IF;;ACTIVE;2.16;2.69 +41506-7;Polio virus Ab.Neut panel;-;Pt;Ser;Qn;Neut;PANEL.MICRO;1;Polio virus neutralizing Ab panel - Serum by Neutralization test;PV Ab.Neut Pnl Ser Nt;;ACTIVE;2.16;2.73 +41507-5;Rabies virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rabies virus Ab [Presence] in Serum by Immunoassay;RABV Ab Ser Ql IA;;ACTIVE;2.16;2.73 +41508-3;Streptococcus agalactiae Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Streptococcus agalactiae Ag [Presence] in Body fluid;Gp B Strep Ag Fld Ql;;ACTIVE;2.16;2.56 +4150-9;Caffeine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Caffeine [Mass] of Dose;Caffeine Dose;;ACTIVE;1.0;2.73 +41509-1;Toxoplasma sp Ab.IgG;ACnc;Pt;Ser;Qn;EIA;MICRO;1;Deprecated Toxoplasma gondii IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated Toxoplasma IgG Ser EIA-aCnc;;DEPRECATED;2.16;2.69 +41510-9;Toxoplasma sp Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Deprecated Toxoplasma gondii IgM Ab [Titer] in Serum by Immunofluorescence;Deprecated Toxoplasma IgM Titr Ser IF;;DEPRECATED;2.16;2.36 +41511-7;Trichomonas vaginalis Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Trichomonas vaginalis Ag [Presence] in Vaginal fluid;T vaginalis Ag Vag Ql;;ACTIVE;2.16;2.73 +41512-5;Varicella zoster virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Varicella zoster virus IgG Ab [Presence] in Serum by Immunofluorescence;VZV IgG Ser Ql IF;;ACTIVE;2.16;2.56 +41513-3;HIV 1 RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp detection limit = 400 copies/mL;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by Probe with amplification detection limit = 400 copies/mL;HIV1 RNA # SerPl Probe amp DL=400;;ACTIVE;2.16;2.70 +41514-1;HIV 1 RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp detection limit = 2.6 log copies/mL;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Serum or Plasma by Probe with amplification detection limit = 2.6 log copies/mL;HIV1 RNA SerPl Probe amp DL=2.6-Log#;;ACTIVE;2.16;2.73 +41515-8;HIV 1 RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp detection limit = 75 copies/mL;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by Probe with amplification detection limit = 75 copies/mL;HIV1 RNA # SerPl Probe amp DL=75;;ACTIVE;2.16;2.73 +41516-6;HIV 1 RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp detection limit = 1.9 log copies/mL;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Serum or Plasma by Probe with amplification detection limit = 1.9 log copies/mL;HIV1 RNA SerPl Probe amp DL=1.9-Log#;;ACTIVE;2.16;2.73 +4151-7;Canrenone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Canrenone [Mass] of Dose;Canrenone Dose;;ACTIVE;1.0;2.69 +4152-5;carBAMazepine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;carBAMazepine [Mass] of Dose;carBAMazepine Dose;;ACTIVE;1.0;2.73 +4153-3;Carbenicillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Carbenicillin [Mass] of Dose;Carbenicillin Dose;;ACTIVE;1.0;2.69 +4154-1;Carbromal;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Carbromal [Mass] of Dose;Carbromal Dose;;ACTIVE;1.0;2.69 +4155-8;Carisoprodol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Carisoprodol [Mass] of Dose;Carisoprodol Dose;;ACTIVE;1.0;2.73 +4156-6;Cathine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cathine [Mass] of Dose;Cathine Dose;;ACTIVE;1.0;2.69 +4157-4;Cefamandole;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cefamandole [Mass] of Dose;Cefamandole Dose;;ACTIVE;1.0;2.69 +4158-2;ceFAZolin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated ceFAZolin [Mass] of Dose;Deprecated ceFAZolin Dose;;DEPRECATED;1.0;2.69 +4159-0;ceFAZolin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;ceFAZolin [Mass] of Dose;ceFAZolin Dose;;ACTIVE;1.0;2.69 +41598-4;Bacteria;PrThr;Pt;Pericard fld;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Pericardial fluid by Light microscopy;Bacteria Pcar Ql Micro;;ACTIVE;2.16;2.70 +41599-2;Bacteria;PrThr;Pt;Body fld;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Body fluid by Light microscopy;Bacteria Fld Ql Micro;;ACTIVE;2.16;2.73 +41600-8;Bacteria;PrThr;Pt;Synv fld;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Synovial fluid by Light microscopy;Bacteria Snv Ql Micro;;ACTIVE;2.16;2.70 +41601-6;Bacteria;PrThr;Pt;Periton fld;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Peritoneal fluid by Light microscopy;Bacteria Prt Ql Micro;;ACTIVE;2.16;2.70 +41602-4;Bacteria;PrThr;Pt;CSF;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Cerebral spinal fluid by Light microscopy;Bacteria CSF Ql Micro;;ACTIVE;2.16;2.73 +41603-2;Bacteria;PrThr;Pt;Plr fld;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Pleural fluid by Light microscopy;Bacteria Plr Ql Micro;;ACTIVE;2.16;2.70 +41604-0;Glucose^post CFst;MCnc;Pt;BldC;Qn;Glucometer;CHAL;1;Fasting glucose [Mass/volume] in Capillary blood by Glucometer;Glucose p fast BldC Glucomtr-mCnc;;ACTIVE;2.16;2.73 +41605-7;Lactose^pre CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Mass/volume] in Serum or Plasma --pre fast;Lactose Pre fast SerPl-mCnc;;ACTIVE;2.16;2.73 +41606-5;Lactose^3H post dose lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Mass/volume] in Serum or Plasma --3 hours post dose lactose PO;Lactose 3h p Lac PO SerPl-mCnc;;ACTIVE;2.16;2.34 +41607-3;Methemoglobin/Hemoglobin.total;MFr;Pt;BldMV;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Mixed venous blood;MetHgb MFr BldMV;;ACTIVE;2.16;2.73 +4160-8;Cefonicid;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cefonicid [Mass] of Dose;Cefonocid Dose;;ACTIVE;1.0;2.69 +41608-1;Prolactin^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Prolactin 30M p chal SerPl-mCnc;;ACTIVE;2.16;2.70 +41609-9;Prolactin^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Prolactin 1h p chal SerPl-mCnc;;ACTIVE;2.16;2.70 +41610-7;Tube number;ID;Pt;Pericard fld;Nom;;SPEC;1;Tube number of Pericardial fluid;Tube # Pcar;;ACTIVE;2.16;2.19 +41611-5;Tube number;ID;Pt;Periton fld;Nom;;SPEC;1;Tube number of Peritoneal fluid;Tube # Prt;;ACTIVE;2.16;2.19 +41612-3;Tube number;ID;Pt;Plr fld;Nom;;SPEC;1;Tube number of Pleural fluid;Tube # Plr;;ACTIVE;2.16;2.19 +41613-1;Tube number;ID;Pt;Semen;Nom;;SPEC;1;Tube number of Semen;Tube # Smn;;ACTIVE;2.16;2.19 +41614-9;Tube number;ID;Pt;Synv fld;Nom;;SPEC;1;Tube number of Synovial fluid;Tube # Snv;;ACTIVE;2.16;2.19 +41615-6;Xanthurenate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Xanthurenate [Mass/volume] in Serum or Plasma;Xanthuren SerPl-mCnc;;ACTIVE;2.16;2.42 +4161-6;Cefoperazone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cefoperazone [Mass] of Dose;Cefoperazone Dose;;ACTIVE;1.0;2.69 +41616-4;Platelet Ab;PrThr;Pt;Ser;Ord;Flow cytometry;SERO;1;Platelet Ab [Presence] in Serum by Flow cytometry (FC);Platelet Ab Ser Ql FC;;ACTIVE;2.16;2.56 +41617-2;Neutrophil Ab;PrThr;Pt;Ser;Ord;Flow cytometry;SERO;1;Neutrophil Ab [Presence] in Serum by Flow cytometry (FC);Neutrophil Ab Ser Ql FC;;ACTIVE;2.16;2.73 +41618-0;HLA Ab;PrThr;Pt;Ser;Ord;Flow cytometry;HLA;1;HLA Ab [Presence] in Serum by Flow cytometry (FC);HLA Ab Ser Ql FC;;ACTIVE;2.16;2.73 +41619-8;Hemoglobin.unstable;PrThr;Pt;RBC;Ord;Isopropanol stability;HEM/BC;1;Unstable Hemoglobin [Presence] in Red Blood Cells by Isopropanol stability;Hgb Unstab RBC Ql IPS;;ACTIVE;2.16;2.73 +41620-6;Xylose^5H post 5 g xylose PO;SCnc;Pt;Urine;Qn;;CHAL;1;Xylose [Moles/volume] in Urine --5 hours post 5 g xylose PO;Xylose 5h p 5 g Xyl PO Ur-sCnc;;ACTIVE;2.16;2.70 +41621-4;Arenavirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Arenavirus RNA [Presence] in Specimen by NAA with probe detection;Arenavirus RNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41622-2;Bacillus anthracis DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Bacillus anthracis DNA [Identifier] in Specimen by NAA with probe detection;B anthracis DNA Spec NAA+probe;;ACTIVE;2.16;2.69 +41623-0;Bacillus anthracis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bacillus anthracis DNA [Presence] in Specimen by NAA with probe detection;B anthracis DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +4162-4;Cefotaxime;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cefotaxime [Mass] of Dose;Cefotaxime Dose;;ACTIVE;1.0;2.69 +41624-8;Brucella sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Brucella sp Ag [Presence] in Specimen by Immunofluorescence;Brucella Ag Spec Ql IF;;ACTIVE;2.16;2.69 +41625-5;Brucella sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Brucella sp DNA [Identifier] in Specimen by NAA with probe detection;Brucella DNA Spec NAA+probe;;ACTIVE;2.16;2.69 +41626-3;Brucella sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Brucella sp DNA [Presence] in Specimen by NAA with probe detection;Brucella DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +41627-1;Burkholderia sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Burkholderia sp Ag [Presence] in Specimen by Immunofluorescence;Burkholderia Ag Spec Ql IF;;ACTIVE;2.16;2.69 +41628-9;Burkholderia sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Burkholderia sp DNA [Presence] in Specimen by NAA with probe detection;Burkholderia DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41629-7;Burkholderia sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Burkholderia sp DNA [Identifier] in Specimen by NAA with probe detection;Burkholderia DNA Spec NAA+probe;;ACTIVE;2.16;2.69 +41630-5;Clostridium botulinum toxin A;PrThr;Pt;XXX;Ord;IF;MICRO;1;Clostridium botulinum toxin A [Presence] in Specimen by Immunofluorescence;C bot Tox A Spec Ql IF;;ACTIVE;2.16;2.69 +41631-3;Clostridium botulinum toxin A botA gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin A botA gene [Presence] in Specimen by NAA with probe detection;C botA gene Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +4163-2;cefoTEtan;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cefoTEtan [Mass] of Dose;cefoTEtan Dose;;ACTIVE;1.0;2.69 +41632-1;Clostridium botulinum toxin B;PrThr;Pt;XXX;Ord;IF;MICRO;1;Clostridium botulinum toxin B [Presence] in Specimen by Immunofluorescence;C bot Tox B Spec Ql IF;;ACTIVE;2.16;2.69 +41633-9;Clostridium botulinum toxin B botB gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin B botB gene [Presence] in Specimen by NAA with probe detection;C botB gene Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +41634-7;Clostridium botulinum toxin E;PrThr;Pt;XXX;Ord;IF;MICRO;1;Clostridium botulinum toxin E [Presence] in Specimen by Immunofluorescence;C bot Tox E Spec Ql IF;;ACTIVE;2.16;2.69 +41635-4;Clostridium botulinum toxin F;PrThr;Pt;XXX;Ord;IF;MICRO;1;Clostridium botulinum toxin F [Presence] in Specimen by Immunofluorescence;C bot Tox F Spec Ql IF;;ACTIVE;2.16;2.69 +41636-2;Ebola virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ebola virus RNA [Presence] in Specimen by NAA with probe detection;EBOV RNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41637-0;Ebola virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Ebola virus Ag [Presence] in Specimen by Immunofluorescence;EBOV Ag Spec Ql IF;;ACTIVE;2.16;2.69 +41638-8;Marburg virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Marburg virus RNA [Presence] in Specimen by NAA with probe detection;MARV RNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41639-6;Ricin toxin Ab.IgM;PrThr;Pt;Ser;Ord;IF;DRUG/TOX;1;Ricin toxin IgM Ab [Presence] in Serum by Immunofluorescence;Ricin Tox IgM Ser Ql IF;;ACTIVE;2.16;2.65 +4164-0;cefOXitin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cefOXitin [Mass] of Dose;cefOXitin Dose;;ACTIVE;1.0;2.69 +41640-4;Ricin toxin Ab.IgG;PrThr;Pt;Ser;Ord;IF;DRUG/TOX;1;Ricin toxin IgG Ab [Presence] in Serum by Immunofluorescence;Ricin Tox IgG Ser Ql IF;;ACTIVE;2.16;2.65 +41641-2;Ricin toxin;PrThr;Pt;XXX;Ord;IF;DRUG/TOX;1;Ricin toxin [Presence] in Specimen by Immunofluorescence;Ricin Tox Spec Ql IF;;ACTIVE;2.16;2.69 +41642-0;West Nile virus Ab.IgM;PrThr;Pt;XXX;Ord;IF;MICRO;1;West Nile virus IgM Ab [Presence] in Specimen by Immunofluorescence;WNV IgM Spec Ql IF;;ACTIVE;2.16;2.69 +41643-8;West Nile virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;West Nile virus Ag [Presence] in Specimen by Immunofluorescence;WNV Ag Spec Ql IF;;ACTIVE;2.16;2.69 +41644-6;Calcium.ionized;SCnc;Pt;BldC;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Capillary blood;Ca-I BldC-sCnc;;ACTIVE;2.16;2.73 +41645-3;Calcium.ionized;SCnc;Pt;BldV;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Venous blood;Ca-I BldV-sCnc;;ACTIVE;2.16;2.73 +41646-1;Calcium.ionized;SCnc;Pt;BldMV;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Mixed venous blood;Ca-I BldMV-sCnc;;ACTIVE;2.16;2.73 +41647-9;Carbon dioxide;SCnc;Pt;BldA;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Arterial blood by calculation;CO2 BldA Calc-sCnc;;ACTIVE;2.16;2.73 +41648-7;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldMV;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Mixed venous blood;COHgb MFr BldMV;;ACTIVE;2.16;2.73 +41649-5;Chloride;SCnc;Pt;BldV;Qn;;CHEM;1;Chloride [Moles/volume] in Venous blood;Chloride BldV-sCnc;;ACTIVE;2.16;2.73 +41650-3;Chloride;SCnc;Pt;BldA;Qn;;CHEM;1;Chloride [Moles/volume] in Arterial blood;Chloride BldA-sCnc;;ACTIVE;2.16;2.73 +41651-1;Glucose;MCnc;Pt;BldA;Qn;;CHEM;1;Glucose [Mass/volume] in Arterial blood;Glucose BldA-mCnc;;ACTIVE;2.16;2.73 +41652-9;Glucose;MCnc;Pt;BldV;Qn;;CHEM;1;Glucose [Mass/volume] in Venous blood;Glucose BldV-mCnc;;ACTIVE;2.16;2.73 +41653-7;Glucose;MCnc;Pt;BldC;Qn;Glucometer;CHEM;1;Glucose [Mass/volume] in Capillary blood by Glucometer;Glucose BldC Glucomtr-mCnc;;ACTIVE;2.16;2.73 +41654-5;Hematocrit;VFr;Pt;BldV;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Venous blood;Hct VFr BldV;;ACTIVE;2.16;2.73 +41655-2;Hematocrit;VFr;Pt;BldMV;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Mixed venous blood;Hct VFr BldMV;;ACTIVE;2.16;2.70 +41656-0;Potassium;SCnc;Pt;BldMV;Qn;;CHEM;1;Potassium [Moles/volume] in Mixed venous blood;Potassium BldMV-sCnc;;ACTIVE;2.16;2.73 +4165-7;Cefsulodin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cefsulodin [Mass] of Dose;Cefsulodin Dose;;ACTIVE;1.0;2.69 +41657-8;Sodium;SCnc;Pt;BldMV;Qn;;CHEM;1;Sodium [Moles/volume] in Mixed venous blood;Sodium BldMV-sCnc;;ACTIVE;2.16;2.73 +41658-6;ABT492;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;ABT492 [Susceptibility] by Minimum inhibitory concentration (MIC);ABT492 Islt MIC;;ACTIVE;2.16;2.19 +41659-4;ABT492;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;ABT492 [Susceptibility] by Disk diffusion (KB);ABT492 Islt KB;;ACTIVE;2.16;2.73 +41660-2;ABT492;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;ABT492 [Susceptibility] by Gradient strip;ABT492 Islt Grad strip;;ACTIVE;2.16;2.56 +41661-0;Azlocillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Azlocillin [Susceptibility] by Gradient strip;Azlocillin Islt Grad strip;;ACTIVE;2.16;2.56 +41662-8;Aztreonam+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Aztreonam+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);Aztreonam+Clav Islt MIC;;ACTIVE;2.16;2.19 +41663-6;Aztreonam+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Aztreonam+Clavulanate [Susceptibility] by Disk diffusion (KB);Aztreonam+Clav Islt KB;;ACTIVE;2.16;2.19 +41664-4;Aztreonam+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Aztreonam+Clavulanate [Susceptibility] by Gradient strip;Aztreonam+Clav Islt Grad strip;;ACTIVE;2.16;2.56 +4166-5;cefTAZidime;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cefTAZidime [Mass] of Dose;cefTAZidime Dose;;ACTIVE;1.0;2.69 +41665-1;Biapenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Biapenem [Susceptibility] by Minimum inhibitory concentration (MIC);Biapenem Islt MIC;;ACTIVE;2.16;2.19 +41666-9;Biapenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Biapenem [Susceptibility] by Disk diffusion (KB);Biapenem Islt KB;;ACTIVE;2.16;2.19 +41667-7;Biapenem;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Biapenem [Susceptibility] by Gradient strip;Biapenem Islt Grad strip;;ACTIVE;2.16;2.56 +41668-5;Carbenicillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Carbenicillin [Susceptibility] by Gradient strip;Carbenicillin Islt Grad strip;;ACTIVE;2.16;2.56 +41669-3;Cefamandole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefamandole [Susceptibility] by Gradient strip;Cefamandole Islt Grad strip;;ACTIVE;2.16;2.56 +41670-1;ceFAZolin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;ceFAZolin [Susceptibility] by Gradient strip;ceFAZolin Islt Grad strip;;ACTIVE;2.16;2.56 +41671-9;Cefotaxime+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefotaxime+Clavulanate [Susceptibility] by Gradient strip;Cefotaxime+Clav Islt Grad strip;;ACTIVE;2.16;2.56 +41672-7;cefoTEtan+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefoTEtan+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);cefoTEtan+Clav Islt MIC;;ACTIVE;2.16;2.19 +4167-3;Ceftizoxime;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ceftizoxime [Mass] of Dose;Ceftizoxime Dose;;ACTIVE;1.0;2.69 +41673-5;cefoTEtan+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefoTEtan+Clavulanate [Susceptibility] by Disk diffusion (KB);cefoTEtan+Clav Islt KB;;ACTIVE;2.16;2.19 +41674-3;cefoTEtan+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefoTEtan+Clavulanate [Susceptibility] by Gradient strip;cefoTEtan+Clav Islt Grad strip;;ACTIVE;2.16;2.56 +41675-0;cefOXitin+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefOXitin+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);cefOXitin+Clav Islt MIC;;ACTIVE;2.16;2.73 +41676-8;cefOXitin+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefOXitin+Clavulanate [Susceptibility] by Disk diffusion (KB);cefOXitin+Clav Islt KB;;ACTIVE;2.16;2.19 +41677-6;cefOXitin+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefOXitin+Clavulanate [Susceptibility] by Gradient strip;cefOXitin+Clav Islt Grad strip;;ACTIVE;2.16;2.56 +41678-4;Cefpodoxime+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefpodoxime+Clavulanate [Susceptibility] by Gradient strip;Cefpodoxime+Clav Islt Grad strip;;ACTIVE;2.16;2.56 +41679-2;Cefpodoxime+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefpodoxime+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);Cefpodoxime+Clav Islt MIC;;ACTIVE;2.16;2.19 +416-8;Pivampicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Pivampicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Pivampicillin Islt MIC;;ACTIVE;1.0;2.19 +41680-0;Cefpodoxime+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefpodoxime+Clavulanate [Susceptibility] by Disk diffusion (KB);Cefpodoxime+Clav Islt KB;;ACTIVE;2.16;2.19 +4168-1;cefTRIAXone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cefTRIAXone [Mass] of Dose;cefTRIAXone Dose;;ACTIVE;1.0;2.69 +41681-8;cefTRIAXone+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefTRIAXone+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);cefTRIAXone+Clav Islt MIC;;ACTIVE;2.16;2.19 +41682-6;cefTRIAXone+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefTRIAXone+Clavulanate [Susceptibility] by Disk diffusion (KB);cefTRIAXone+Clav Islt KB;;ACTIVE;2.16;2.19 +41683-4;cefTRIAXone+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefTRIAXone+Clavulanate [Susceptibility] by Gradient strip;cefTRIAXone+Clav Islt Grad strip;;ACTIVE;2.16;2.56 +41684-2;Cephaloridine;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cephaloridine [Susceptibility] by Gradient strip;Cephaloridine Islt Grad strip;;ACTIVE;2.16;2.56 +41685-9;Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Clavulanate [Susceptibility] by Gradient strip;Clavulanate Islt Grad strip;;ACTIVE;2.16;2.56 +41686-7;Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clavulanate [Susceptibility] by Disk diffusion (KB);Clavulanate Islt KB;;ACTIVE;2.16;2.19 +41687-5;Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);Clavulanate Islt MIC;;ACTIVE;2.16;2.19 +41688-3;Dalbavancin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Dalbavancin [Susceptibility] by Disk diffusion (KB);Dalbavancin Islt KB;;ACTIVE;2.16;2.73 +41689-1;Dalbavancin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Dalbavancin [Susceptibility] by Minimum inhibitory concentration (MIC);Dalbavancin Islt MIC;;ACTIVE;2.16;2.19 +41690-9;Dalbavancin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Dalbavancin [Susceptibility] by Gradient strip;Dalbavancin Islt Grad strip;;ACTIVE;2.16;2.56 +41691-7;DAPTOmycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;DAPTOmycin [Susceptibility] by Gradient strip;DAPTOmycin Islt Grad strip;;ACTIVE;2.16;2.73 +41692-5;Enoxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Enoxacin [Susceptibility] by Gradient strip;Enoxacin Islt Grad strip;;ACTIVE;2.16;2.56 +41693-3;Ethionamide;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ethionamide [Susceptibility] by Disk diffusion (KB);Ethionamide Islt KB;;ACTIVE;2.16;2.19 +41694-1;Everninomicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Everninomicin [Susceptibility] by Minimum inhibitory concentration (MIC);Everninomicin Islt MIC;;ACTIVE;2.16;2.19 +41695-8;Everninomicin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Everninomicin [Susceptibility] by Gradient strip;Everninomicin Islt Grad strip;;ACTIVE;2.16;2.56 +41696-6;Everninomicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Everninomicin [Susceptibility] by Disk diffusion (KB);Everninomicin Islt KB;;ACTIVE;2.16;2.19 +41697-4;Gemifloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Gemifloxacin [Susceptibility] by Gradient strip;Gemifloxacin Islt Grad strip;;ACTIVE;2.16;2.56 +41698-2;Josamycine;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Josamycine [Susceptibility] by Disk diffusion (KB);Josamycine Islt KB;;ACTIVE;2.16;2.19 +4169-9;Cefuroxime.parenteral;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cefuroxime Parenteral [Mass] of Dose;Cefuroxime Parenter Dose;;ACTIVE;1.0;2.69 +41699-0;Josamycine;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Josamycine [Susceptibility] by Gradient strip;Josamycine Islt Grad strip;;ACTIVE;2.16;2.56 +41700-6;Lincomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Lincomycin [Susceptibility] by Gradient strip;Lincomycin Islt Grad strip;;ACTIVE;2.16;2.56 +41701-4;Lomefloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Lomefloxacin [Susceptibility] by Gradient strip;Lomefloxacin Islt Grad strip;;ACTIVE;2.16;2.56 +41702-2;Mezlocillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Mezlocillin [Susceptibility] by Gradient strip;Mezlocillin Islt Grad strip;;ACTIVE;2.16;2.56 +41703-0;Moxalactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Moxalactam [Susceptibility] by Gradient strip;Moxalactam Islt Grad strip;;ACTIVE;2.16;2.56 +41704-8;Nafcillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Nafcillin [Susceptibility] by Gradient strip;Nafcillin Islt Grad strip;;ACTIVE;2.16;2.56 +41705-5;Neomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Neomycin [Susceptibility] by Gradient strip;Neomycin Islt Grad strip;;ACTIVE;2.16;2.56 +41706-3;Novobiocin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Novobiocin [Susceptibility] by Gradient strip;Novobiocin Islt Grad strip;;ACTIVE;2.16;2.56 +4170-7;Cephalexin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cephalexin [Mass] of Dose;Cephalexin Dose;;ACTIVE;1.0;2.69 +41707-1;Oritavancin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Oritavancin [Susceptibility] by Disk diffusion (KB);Oritavancin Islt KB;;ACTIVE;2.16;2.19 +41708-9;Oritavancin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Oritavancin [Susceptibility] by Minimum inhibitory concentration (MIC);Oritavancin Islt MIC;;ACTIVE;2.16;2.19 +41709-7;Oritavancin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Oritavancin [Susceptibility] by Gradient strip;Oritavancin Islt Grad strip;;ACTIVE;2.16;2.56 +41710-5;Ramoplanin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ramoplanin [Susceptibility] by Minimum inhibitory concentration (MIC);Ramoplanin Islt MIC;;ACTIVE;2.16;2.19 +41711-3;Ramoplanin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ramoplanin [Susceptibility] by Gradient strip;Ramoplanin Islt Grad strip;;ACTIVE;2.16;2.56 +41712-1;Ramoplanin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ramoplanin [Susceptibility] by Disk diffusion (KB);Ramoplanin Islt KB;;ACTIVE;2.16;2.19 +41713-9;Rosamicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Rosamicin [Susceptibility] by Minimum inhibitory concentration (MIC);Rosamicin Islt MIC;;ACTIVE;2.16;2.19 +41714-7;Rosamicin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Rosamicin [Susceptibility] by Gradient strip;Rosamicin Islt Grad strip;;ACTIVE;2.16;2.56 +4171-5;Cephalothin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cephalothin [Mass] of Dose;Cephalothin Dose;;ACTIVE;1.0;2.69 +41715-4;Rosamicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Rosamicin [Susceptibility] by Disk diffusion (KB);Rosamicin Islt KB;;ACTIVE;2.16;2.19 +41716-2;Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Sulbactam [Susceptibility] by Disk diffusion (KB);Sulbactam Islt KB;;ACTIVE;2.16;2.19 +41717-0;Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Sulbactam [Susceptibility] by Gradient strip;Sulbactam Islt Grad strip;;ACTIVE;2.16;2.56 +41718-8;Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Sulbactam Islt MIC;;ACTIVE;2.16;2.19 +41719-6;Tazobactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tazobactam [Susceptibility] by Disk diffusion (KB);Tazobactam Islt KB;;ACTIVE;2.16;2.19 +41720-4;Tazobactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Tazobactam [Susceptibility] by Gradient strip;Tazobactam Islt Grad strip;;ACTIVE;2.16;2.56 +41721-2;Tazobactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tazobactam [Susceptibility] by Minimum inhibitory concentration (MIC);Tazobactam Islt MIC;;ACTIVE;2.16;2.19 +41722-0;Telithromycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Telithromycin [Susceptibility] by Gradient strip;Telithromycin Islt Grad strip;;ACTIVE;2.16;2.56 +4172-3;Chloral hydrate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chloral hydrate [Mass] of Dose;Chloral Hydrate Dose;;ACTIVE;1.0;2.69 +41723-8;Thiamphenicol;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Thiamphenicol [Susceptibility] by Disk diffusion (KB);Thiamphenicol Islt KB;;ACTIVE;2.16;2.19 +41724-6;Thiamphenicol;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Thiamphenicol [Susceptibility] by Gradient strip;Thiamphenicol Islt Grad strip;;ACTIVE;2.16;2.56 +41725-3;Thiamphenicol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Thiamphenicol [Susceptibility] by Minimum inhibitory concentration (MIC);Thiamphenicol Islt MIC;;ACTIVE;2.16;2.19 +41726-1;ABT492;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;ABT492 [Susceptibility];ABT492 Susc Islt;;ACTIVE;2.16;2.19 +41727-9;Aztreonam+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Aztreonam+Clavulanate [Susceptibility];Aztreonam+Clav Susc Islt;;ACTIVE;2.16;2.19 +41728-7;Biapenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Biapenem [Susceptibility];Biapenem Susc Islt;;ACTIVE;2.16;2.19 +41729-5;cefoTEtan+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefoTEtan+Clavulanate [Susceptibility];cefoTEtan+Clav Susc Islt;;ACTIVE;2.16;2.19 +41730-3;cefOXitin+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefOXitin+Clavulanate [Susceptibility];cefOXitin+Clav Susc Islt;;ACTIVE;2.16;2.19 +4173-1;Chloramphenicol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chloramphenicol [Mass] of Dose;Chloramphen Dose;;ACTIVE;1.0;2.69 +41731-1;Cefpodoxime+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefpodoxime+Clavulanate [Susceptibility];Cefpodoxime+Clav Susc Islt;;ACTIVE;2.16;2.19 +41732-9;cefTRIAXone+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefTRIAXone+Clavulanate [Susceptibility];cefTRIAXone+Clav Susc Islt;;ACTIVE;2.16;2.19 +41733-7;Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clavulanate [Susceptibility];Clavulanate Susc Islt;;ACTIVE;2.16;2.19 +41734-5;Dalbavancin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Dalbavancin [Susceptibility];Dalbavancin Susc Islt;;ACTIVE;2.16;2.19 +41735-2;Everninomicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Everninomicin [Susceptibility];Everninomicin Susc Islt;;ACTIVE;2.16;2.19 +41736-0;Oritavancin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Oritavancin [Susceptibility];Oritavancin Susc Islt;;ACTIVE;2.16;2.19 +41737-8;Ramoplanin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ramoplanin [Susceptibility];Ramoplanin Susc Islt;;ACTIVE;2.16;2.19 +41738-6;Rosamicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Rosamicin [Susceptibility];Rosamicin Susc Islt;;ACTIVE;2.16;2.19 +41739-4;Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sulbactam [Susceptibility];Sulbactam Susc Islt;;ACTIVE;2.16;2.19 +41740-2;Tazobactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tazobactam [Susceptibility];Tazobactam Susc Islt;;ACTIVE;2.16;2.19 +41741-0;Bacteria identified;Prid;Pt;XXX;Nom;;MICRO;1;Deprecated Bacteria identified in Unspecified specimen;Deprecated Bacteria XXX;;DEPRECATED;2.16;2.69 +41742-8;(Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Mold Allergen Mix 1 (Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) IgE Ab [Units/volume] in Serum by Multidisk;Mold Allerg Mix1 IgE Qn;;ACTIVE;2.16;2.73 +41743-6;BBS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BBS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BBS1 gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +41744-4;Beclomethasone dipropionate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Beclomethasone dipropionate [Mass/volume] in Serum or Plasma;Beclomethasone Dp SerPl-mCnc;;ACTIVE;2.16;2.34 +41745-1;Betamethasone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Betamethasone [Mass/volume] in Serum or Plasma;Betamethasone SerPl-mCnc;;ACTIVE;2.16;2.73 +41746-9;Blastomyces dermatitidis Ag;PrThr;Pt;Urine;Ord;IA;MICRO;1;Blastomyces dermatitidis Ag [Presence] in Urine by Immunoassay;B dermat Ag Ur Ql IA;;ACTIVE;2.16;2.73 +41747-7;Budesonide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Budesonide [Mass/volume] in Serum or Plasma;Budesonide SerPl-mCnc;;ACTIVE;2.16;2.73 +41748-5;CAPN3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CAPN3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CAPN3 gene Mut Anl Bld/T;;ACTIVE;2.16;2.66 +4174-9;Clorazepate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clorazepate [Mass] of Dose;Clorazepate Dose;;ACTIVE;1.0;2.69 +41749-3;CHIC2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CHIC2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CHIC2 gene Mut Anl Bld/T;;ACTIVE;2.16;2.66 +41750-1;COCH gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COCH gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;COCH gene Mut Anl Bld/T;;ACTIVE;2.16;2.63 +41751-9;COL3A1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;COL3A1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;COL3A1 gene Mut Anl Bld/T;;ACTIVE;2.16;2.66 +41752-7;Ehrlichia chaffeensis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia chaffeensis Ab [Titer] in Serum;E chaffeensis Ab Titr Ser;;ACTIVE;2.16;2.30 +41753-5;FKRP gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FKRP gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FKRP gene Mut Anl Bld/T;;ACTIVE;2.16;2.66 +41754-3;Fludrocortisone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fludrocortisone [Mass/volume] in Serum or Plasma;Fludrocortisone SerPl-mCnc;;ACTIVE;2.16;2.73 +41755-0;Flunisolide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flunisolide [Mass/volume] in Serum or Plasma;Flunisolide SerPl-mCnc;;ACTIVE;2.16;2.73 +4175-6;chlordiazePOXIDE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;chlordiazePOXIDE [Mass] of Dose;Chlordiazep Dose;;ACTIVE;1.0;2.69 +41756-8;Fluorometholone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fluorometholone [Mass/volume] in Serum or Plasma;Fluorometholone SerPl-mCnc;;ACTIVE;2.16;2.73 +41757-6;Fluticasone propionate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fluticasone propionate [Mass/volume] in Serum or Plasma;Fluticasone Prop SerPl-mCnc;;ACTIVE;2.16;2.73 +41758-4;GNAS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GNAS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GNAS1 gene Mut Anl Bld/T;;ACTIVE;2.16;2.66 +41759-2;Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda.free;MRto;Pt;Urine;Qn;;CHEM;1;Kappa light chains.free/Lambda light chains.free [Mass Ratio] in Urine;Kappa LC Free/Lambda Free Ur;;ACTIVE;2.16;2.73 +417-6;Pivampicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Pivampicillin [Susceptibility] by Disk diffusion (KB);Pivampicillin Islt KB;;ACTIVE;1.0;2.19 +41760-0;Interleukin 12;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 12 [Mass/volume] in Serum or Plasma;Il12 SerPl-mCnc;;ACTIVE;2.16;2.73 +41761-8;lamoTRIgine;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;lamoTRIgine [Mass/volume] in Serum or Plasma by Screen method;lamoTRIgine SerPl Scn-mCnc;;ACTIVE;2.16;2.40 +41762-6;Megestrol acetate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Megestrol acetate [Mass/volume] in Serum or Plasma;Megestrol Acetate SerPl-mCnc;;ACTIVE;2.16;2.73 +41763-4;Rubella virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rubella virus IgG Ab [Titer] in Serum;RUBV IgG Titr Ser;;ACTIVE;2.16;2.73 +4176-4;Chlormerodrin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chlormerodrin [Mass] of Dose;Chlormerodrin Dose;;ACTIVE;1.0;2.69 +41764-2;SBDS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SBDS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SBDS gene Mut Anl Bld/T;;ACTIVE;2.16;2.66 +41765-9;SCN1A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SCN1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SCN1A gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +41766-7;Triamcinolone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triamcinolone [Mass/volume] in Serum or Plasma;Triamcinolone SerPl-mCnc;;ACTIVE;2.16;2.73 +41767-5;Triamcinolone acetonide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triamcinolone acetonide [Mass/volume] in Serum or Plasma;Triamcinolone Aceto SerPl-mCnc;;ACTIVE;2.16;2.73 +41768-3;VWF gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;VWF gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;VWF gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +41769-1;Neuronal nuclear type 1 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Neuronal nuclear type 1 Ab [Presence] in Serum by Immunoblot;Hu1 Ab Ser Ql IB;;ACTIVE;2.16;2.73 +41770-9;Views^W cholecystokinin+W radionuclide IV;Find;Pt;Abdomen>Gallbladder;Doc;NM;RAD;2;NM Gallbladder Views W cholecystokinin and W radionuclide IV;NM GB Views W CCK+RNC IV;;ACTIVE;2.16;2.64 +41771-7;Views^W Tc-99m DMSA IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views W Tc-99m DMSA IV;NM Kidney Views W Tc99mDMCA IV;;ACTIVE;2.16;2.64 +4177-2;Chlorothiazide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chlorothiazide [Mass] of Dose;Chlorothiazide Dose;;ACTIVE;1.0;2.69 +41772-5;Multisection^W In-111 tagged WBC IV;Find;Pt;XXX>Bone;Doc;NM.SPECT;RAD;2;SPECT Bone W In-111 tagged WBC IV;SPECT Bone W In-111 WBC IV;;ACTIVE;2.16;2.61 +41773-3;Views;Find;Pt;Head>Facial bones;Doc;XR.portable;RAD;2;Portable XR Facial bones Views;XR port Face Views;;ACTIVE;2.16;2.64 +41774-1;View lateral;Find;Pt;Neck;Doc;XR.portable;RAD;2;Portable XR Neck Lateral;XR port Neck Lat;;ACTIVE;2.16;2.61 +41775-8;View;Find;Pt;Pelvis;Doc;XR.portable;RAD;2;Portable XR Pelvis Single view;XR port Pelvis 1V;;ACTIVE;2.16;2.64 +41776-6;Views AP + lateral frog;Find;Pt;Pelvis & Lower extremity.right>Hip;Doc;XR.portable;RAD;2;Portable XR Pelvis and Hip - right AP and Lateral frog;XR port Pelvis and Hip-R AP+Lat frog;;ACTIVE;2.16;2.64 +41777-4;Views AP + lateral;Find;Pt;Lower extremity.right>Hip;Doc;XR.portable;RAD;2;Portable XR Hip - right AP and Lateral;XR port Hip-R AP+Lat;;ACTIVE;2.16;2.61 +41778-2;Views;Find;Pt;Lower extremity.right>Femur;Doc;XR.portable;RAD;2;Portable XR Femur - right Views;XR port Femur-R Views;;ACTIVE;2.16;2.64 +41779-0;Views;Find;Pt;Lower extremity.right>Knee;Doc;XR.portable;RAD;2;Portable XR Knee - right Views;XR port Knee-R Views;;ACTIVE;2.16;2.64 +4178-0;Chlorpheniramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chlorpheniramine [Mass] of Dose;Chlorphenir Dose;;ACTIVE;1.0;2.69 +41780-8;Views;Find;Pt;Tibia.right;Nar;XR;RAD;2;Deprecated Tibia Right X-ray;Deprecated Tib-R XR;;DEPRECATED;2.16;2.40 +41781-6;Views portable;Find;Pt;Tibia.right;Nar;XR;RAD;2;Deprecated Tibia Right X-ray Portable;Deprecated Tib-R XR port;;DEPRECATED;2.16;2.40 +41782-4;Views;Find;Pt;Lower extremity.right>Ankle;Doc;XR.portable;RAD;2;Portable XR Ankle - right Views;XR port Ankle-R Views;;ACTIVE;2.16;2.64 +41783-2;Views;Find;Pt;Upper extremity.right>Shoulder;Doc;XR.portable;RAD;2;Portable XR Shoulder - right Views;XR port Should-R Views;;ACTIVE;2.16;2.64 +41784-0;Views;Find;Pt;Upper extremity.right>Humerus;Doc;XR.portable;RAD;2;Portable XR Humerus - right Views;XR port Humerus-R Views;;ACTIVE;2.16;2.64 +41785-7;Views limited;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Limited Views;XR Elbow-R Views Ltd;;ACTIVE;2.16;2.64 +41786-5;Views;Find;Pt;Upper extremity.right>Elbow;Doc;XR.portable;RAD;2;Portable XR Elbow - right Views;XR port Elbow-R Views;;ACTIVE;2.16;2.64 +41787-3;Views;Find;Pt;Upper extremity.right>Wrist;Doc;XR.portable;RAD;2;Portable XR Wrist - right Views;XR port Wrist-R Views;;ACTIVE;2.16;2.64 +41788-1;Views;Find;Pt;Upper extremity.right>Hand;Doc;XR.portable;RAD;2;Portable XR Hand - right Views;XR port Hand-R Views;;ACTIVE;2.16;2.64 +41789-9;Views limited;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right Limited Views;XR Hand-R Views Ltd;;ACTIVE;2.16;2.64 +41790-7;View^during surgery;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Single view during surgery;XR Chest 1V in Surg;;ACTIVE;2.16;2.64 +41791-5;Views;Find;Pt;Chest>Ribs.right;Doc;XR.portable;RAD;2;Portable XR Ribs - right Views;XR port Ribs-R Views;;ACTIVE;2.16;2.64 +41792-3;Views R-oblique + L-oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Right oblique and Left oblique;XR Chest R-Obl+L-Obl;;ACTIVE;2.16;2.61 +41793-1;View^during surgery;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Single view during surgery;XR Abd 1V in Surg;;ACTIVE;2.16;2.64 +41794-9;View AP portable;Find;Pt;Abdomen;Nar;XR;RAD;2;Deprecated Abdomen X-ray AP portable;Deprecated Abd XR AP port;;DEPRECATED;2.16;2.36 +41795-6;View^W air contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper+Small bowel;Doc;RF;RAD;2;RF Upper gastrointestinal tract and Small bowel Single view W air contrast PO;RF UGI+SB 1V W Air contr PO;;DISCOURAGED;2.16;2.64 +41796-4;Views & AP KUB^W air contrast PO;Find;Pt;Gastrointestine.upper;Nar;XR.fluor;RAD;2;Deprecated Gastrointestine upper Fluoroscopy & AP W contrast PO;Deprecated UGI Flr +AP W contr PO;;DEPRECATED;2.16;2.36 +41797-2;Views limited^W air contrast PR+W barium contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Limited Views W air and barium contrast PR;RF Colon Views Ltd W Air+Ba PR;;ACTIVE;2.16;2.64 +4179-8;chlorproMAZINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;chlorproMAZINE [Mass] of Dose;chlorproMAZINE Dose;;ACTIVE;1.0;2.69 +41798-0;Guidance for drainage+placement of drainage catheter;Find;Pt;Pelvis>Prostate;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Prostate;US Guided Prostate Drain+cath place;;ACTIVE;2.16;2.66 +41799-8;Guidance for placement of tube;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;RF Guidance for placement of tube in Liver;RF Guided Liver Tube place;;ACTIVE;2.16;2.64 +41800-4;Guidance for drainage+placement of drainage catheter;Find;Pt;Head+Neck>Pharynx;Doc;RF;RAD;2;RF Guidance for drainage and placement of drainage catheter of Pharynx;RF Guided Pharynx Drain+cath place;;ACTIVE;2.16;2.66 +41801-2;Guidance for placement of catheter^W contrast IV;Find;Pt;Abdomen>Portal vein;Doc;RF.angio;RAD;2;RFA Guidance for placement of catheter in Portal vein-- W contrast IV;RFA Guided Port v Cath place--W contr IV;;ACTIVE;2.16;2.64 +41802-0;Guidance for biopsy;Find;Pt;Pelvis>Prostate;Doc;RF;RAD;2;RF Guidance for biopsy of Prostate;RF Guided Prostate Bx;;ACTIVE;2.16;2.64 +41803-8;Guidance for percutaneous biopsy;Find;Pt;Breast;Doc;RF;RAD;2;RF Guidance for biopsy of Breast;RF Guided Brst Bx;;ACTIVE;2.16;2.64 +41804-6;Multisection & 3D reconstruction;Find;Pt;XXX;Doc;CT;RAD;2;Deprecated Unspecified body region CT and 3D reconstruction;Deprecated XXX CT +3DR;;DEPRECATED;2.16;2.58 +41805-3;Multisection^W radionuclide IV;Find;Pt;Bone;Nar;Radnuc.SPECT;RAD;2;Deprecated Bone SPECT;Deprecated Bone SPECT W RNC IV;;DEPRECATED;2.16;2.34 +4180-6;chlorproPAMIDE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;chlorproPAMIDE [Mass] of Dose;chlorproPAMIDE Dose;;ACTIVE;1.0;2.69 +41806-1;Multisection;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen;CT Abd;;ACTIVE;2.16;2.73 +41807-9;Multisection;Find;Pt;Head>Orbit;Doc;CT;RAD;2;CT Orbit;CT Orbit;;ACTIVE;2.16;2.73 +41808-7;Multisection;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region;CT Maxillofacial;;ACTIVE;2.16;2.73 +41809-5;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Retroperitoneum;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Retroperitoneum;US Guide Retroperitoneum Drn+cath place;;ACTIVE;2.16;2.66 +41810-3;Guidance for removal of fluid;Find;Pt;Abdomen;Doc;CT;RAD;2;Deprecated CT Guidance for removal of fluid from Abdomen;Deprecated Abd CT Fld rem guid;;DEPRECATED;2.16;2.58 +41811-1;Views && view PA;Find;Pt;Chest>Ribs.bilateral && Chest;Doc;XR;RAD;2;XR Ribs - bilateral Views and Chest PA;XR Ribs-Bl Views + Chest PA;;ACTIVE;2.16;2.64 +41812-9;Multisection limited;Find;Pt;Lower extremity>Lower extremity artery;Doc;US;RAD;2;US Lower extremity artery limited;US LE a Ltd;;ACTIVE;2.16;2.61 +41813-7;Multisection limited;Find;Pt;Upper extremity>Upper extremity artery;Doc;US;RAD;2;US Upper extremity artery limited;US UE a Ltd;;ACTIVE;2.16;2.61 +4181-4;Chlorprothixene;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chlorprothixene [Mass] of Dose;Chlorprothixene Dose;;ACTIVE;1.0;2.69 +41814-5;Multisection;Find;Pt;Upper extremity.right>Upper extremity artery;Doc;US;RAD;2;US Upper extremity artery - right;US UE a-R;;ACTIVE;2.16;2.61 +41815-2;Multisection;Find;Pt;Lower extremity.right>Lower extremity artery;Doc;US;RAD;2;US Lower extremity artery - right;US LE a-R;;ACTIVE;2.16;2.61 +41816-0;Multisection;Find;Pt;Extremity.right>Extremity veins;Doc;US;RAD;2;US Extremity veins - right;US Extr vv-R;;ACTIVE;2.16;2.61 +41817-8;Views AP + lateral;Find;Pt;Lower extremity.left>Hip;Doc;XR.portable;RAD;2;Portable XR Hip - left AP and Lateral;XR port Hip-L AP+Lat;;ACTIVE;2.16;2.61 +41818-6;Views;Find;Pt;Lower extremity.left>Femur;Doc;XR.portable;RAD;2;Portable XR Femur - left Views;XR port Femur-L Views;;ACTIVE;2.16;2.64 +41819-4;Views 2 + tunnel;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 2 Views and Tunnel;XR Knee-L 2V+Tunnel;;ACTIVE;2.16;2.61 +41820-2;Views;Find;Pt;Lower extremity.left>Knee;Doc;XR.portable;RAD;2;Portable XR Knee - left Views;XR port Knee-L Views;;ACTIVE;2.16;2.64 +41821-0;Views;Find;Pt;Tibia.left;Nar;XR;RAD;2;Deprecated Tibia Left X-ray;Deprecated Tib-L XR;;DEPRECATED;2.16;2.40 +4182-2;Chloroquine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chloroquine [Mass] of Dose;Chloroquine Dose;;ACTIVE;1.0;2.69 +41822-8;Views portable;Find;Pt;Tibia.left;Nar;XR;RAD;2;Deprecated Tibia Left X-ray Portable;Deprecated Tib-L XR port;;DEPRECATED;2.16;2.40 +41823-6;Views;Find;Pt;Lower extremity.left>Ankle;Doc;XR.portable;RAD;2;Portable XR Ankle - left Views;XR port Ankle-L Views;;ACTIVE;2.16;2.64 +41824-4;Views;Find;Pt;Upper extremity.left>Shoulder;Doc;XR.portable;RAD;2;Portable XR Shoulder - left Views;XR port Should-L Views;;ACTIVE;2.16;2.64 +41825-1;Views;Find;Pt;Upper extremity.left>Humerus;Doc;XR.portable;RAD;2;Portable XR Humerus - left Views;XR port Humerus-L Views;;ACTIVE;2.16;2.64 +41826-9;Views limited;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left Limited Views;XR Elbow-L Views Ltd;;ACTIVE;2.16;2.64 +41827-7;Views;Find;Pt;Upper extremity.left>Elbow;Doc;XR.portable;RAD;2;Portable XR Elbow - left Views;XR port Elbow-L Views;;ACTIVE;2.16;2.64 +41828-5;Views;Find;Pt;Upper extremity.left>Wrist;Doc;XR.portable;RAD;2;Portable XR Wrist - left Views;XR port Wrist-L Views;;ACTIVE;2.16;2.64 +41829-3;Views;Find;Pt;Upper extremity.left>Hand;Doc;XR.portable;RAD;2;Portable XR Hand - left Views;XR port Hand-L Views;;ACTIVE;2.16;2.64 +4183-0;Chlorthalidone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Chlorthalidone [Mass] of Dose;Chlorthalidone Dose;;ACTIVE;1.0;2.69 +41830-1;Views limited;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left Limited Views;XR Hand-L Views Ltd;;ACTIVE;2.16;2.64 +41831-9;Views;Find;Pt;Chest>Ribs.left;Doc;XR.portable;RAD;2;Portable XR Ribs - left Views;XR port Ribs-L Views;;ACTIVE;2.16;2.64 +41832-7;Views && view PA;Find;Pt;Chest>Ribs.left && Chest;Doc;XR;RAD;2;XR Ribs - left Views and Chest PA;XR Ribs-L Views + Chest PA;;ACTIVE;2.16;2.64 +41833-5;Multisection;Find;Pt;Upper extremity.left>Upper extremity artery;Doc;US;RAD;2;US Upper extremity artery - left;US UE a-L;;ACTIVE;2.16;2.61 +41834-3;Multisection;Find;Pt;Lower extremity.left>Lower extremity artery;Doc;US;RAD;2;US Lower extremity artery - left;US LE a-L;;ACTIVE;2.16;2.61 +41835-0;Multisection;Find;Pt;Extremity.left>Extremity veins;Doc;US;RAD;2;US Extremity veins - left;US Extr vv-L;;ACTIVE;2.16;2.61 +41836-8;Views limited^W In-111 tagged WBC IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Limited Views W In-111 tagged WBC IV;NM Bone Views Ltd W In-111 WBC IV;;ACTIVE;2.16;2.64 +41837-6;Multisection^W Tc-99m Arcitumomab IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body W Tc-99m Arcitumomab IV;SPECT Whole body W Tc99mCEA IV;;ACTIVE;2.16;2.61 +41838-4;Multisection^W In-111 Satumomab IV;Find;Pt;Pelvis>Prostate;Doc;NM.SPECT;RAD;2;SPECT Prostate W In-111 Satumomab IV;SPECT Prostate W In-111 Satmb IV;;ACTIVE;2.16;2.61 +41839-2;Burkholderia pseudomallei Ab.IgG & IgM panel;-;Pt;Ser;Qn;IF;PANEL.MICRO;1;Burkholderia pseudomallei IgG and IgM panel - Serum by Immunofluorescence;B pseudomal IgG+IgM Pnl Ser IF;;ACTIVE;2.16;2.42 +418-4;Pivampicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Pivampicillin [Susceptibility] by Serum bactericidal titer;Pivampicillin Titr SBT;;ACTIVE;1.0;2.32 +41840-0;Coxiella burnetii phase 1 & 2 Ab.IgG panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Coxiella burnetii phase 1 and 2 IgG panel [Titer] - Serum;C burnet Ph1+2 IgG Pnl Titr Ser;;ACTIVE;2.16;2.73 +41841-8;Coxiella burnetii phase 1 & 2 Ab.IgM panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Coxiella burnetii phase 1 and 2 IgM panel [Titer] - Serum;C burnet Ph1+2 IgM Pnl Titr Ser;;ACTIVE;2.16;2.42 +41842-6;Herpes virus 7 Ab.IgG & IgM panel;Titr;Pt;Ser;Qn;IF;PANEL.MICRO;1;Herpes virus 7 IgG and IgM panel [Titer] - Serum by Immunofluorescence;HHV7 IgG+IgM Pnl Titr Ser IF;;ACTIVE;2.16;2.73 +41843-4;Lymphocytic choriomeningitis virus Ab.IgG & IgM panel;Titr;Pt;CSF;Qn;IF;PANEL.MICRO;1;Lymphocytic choriomeningitis virus IgG and IgM panel [Titer] - Cerebral spinal fluid by Immunofluorescence;LCMV IgG+IgM Pnl Titr CSF IF;;ACTIVE;2.16;2.42 +41844-2;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag [Presence] in Serum by Agglutination;N men sg A+B+C+W135+Y+EcK1 Ag Ser Ql Agg;;ACTIVE;2.16;2.64 +41845-9;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag;PrThr;Pt;CSF;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag [Presence] in Cerebral spinal fluid by Agglutination;N men sg A+B+C+W135+Y+EcK1 Ag CSF Ql Agg;;ACTIVE;2.16;2.64 +41846-7;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag;PrThr;Pt;Urine;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag [Presence] in Urine by Agglutination;N men sg A+B+C+W135+Y+EcK1 Ag Ur Ql Aggl;;ACTIVE;2.16;2.64 +41847-5;Armoracia rusticana Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horseradish IgG Ab [Units/volume] in Serum;Horseradish IgG Qn;;ACTIVE;2.16;2.69 +4184-8;Cilastatin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cilastatin [Mass] of Dose;Cilastatin Dose;;ACTIVE;1.0;2.69 +41848-3;Capsicum annuum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paprika IgG Ab [Units/volume] in Serum;Paprika IgG Qn;;ACTIVE;2.16;2.69 +41849-1;Curry Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Curry IgG Ab [Units/volume] in Serum;Curry IgG Qn;;ACTIVE;2.16;2.69 +41850-9;Lidocaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lidocaine IgE Ab [Units/volume] in Serum;Lidocain IgE Qn;;ACTIVE;2.16;2.73 +41851-7;Thymus vulgaris Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Thyme IgG Ab [Units/volume] in Serum;Thyme IgG Qn;;ACTIVE;2.16;2.69 +41852-5;Microorganism or agent identified;Prid;Pt;XXX;Nom;;MICRO;1;Microorganism or agent identified in Specimen;Microorganism/Agent Spec;;ACTIVE;2.16;2.73 +41853-3;Orthopoxvirus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Orthopoxvirus DNA [Presence] in Specimen by NAA with probe detection;Orthopoxvirus DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41854-1;Ricinus communis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;DRUG/TOX;1;Castor Bean DNA [Presence] in Specimen by NAA with probe detection;Castor Bean DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +4185-5;Cimetidine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cimetidine [Mass] of Dose;Cimetidine Dose;;ACTIVE;1.0;2.69 +41855-8;Staphylococcus aureus enterotoxin B;PrThr;Pt;XXX;Ord;IF;MICRO;1;Staphylococcus aureus enterotoxin B [Presence] in Specimen by Immunofluorescence;S aureus Etx B Spec Ql IF;;ACTIVE;2.16;2.69 +41856-6;Variola virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Variola virus DNA [Presence] in Specimen by NAA with probe detection;VARV DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.69 +41857-4;Vibrio parahaemolyticus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Vibrio parahaemolyticus DNA [Presence] in Specimen by NAA with probe detection;V parahaem DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +41858-2;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Urine;EDDP Ur Ql;;ACTIVE;2.16;2.73 +41859-0;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Specimen;EDDP Spec Ql;;ACTIVE;2.16;2.73 +41860-8;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Serum or Plasma;EDDP SerPl Ql;;ACTIVE;2.16;2.73 +41861-6;Yeast.hyphae;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Yeast.hyphae [#/area] in Urine sediment by Microscopy high power field;Yeast Hyphae #/area UrnS HPF;;ACTIVE;2.16;2.73 +41862-4;Viscosity^20M post collection;Visc;Pt;Semen;Qn;;SPEC;1;Viscosity of Semen--20 minutes post collection;Visc 20M p coll Smn;;ACTIVE;2.16;2.54 +4186-3;Ciprofloxacin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ciprofloxacin [Mass] of Dose;Ciprofloxacin Dose;;ACTIVE;1.0;2.69 +41863-2;Yeast.pseudohyphae;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Yeast.pseudohyphae [Presence] in Urine sediment by Light microscopy;Yeast pseudohyphae UrnS Ql Micro;;ACTIVE;2.16;2.73 +41864-0;Yeast.hyphae;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Yeast.hyphae [Presence] in Urine by Computer assisted method;Yeast Hyphae Ur Ql Comp Assist;;ACTIVE;2.16;2.73 +41865-7;Yeast.hyphae;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Yeast.hyphae [Presence] in Urine sediment by Light microscopy;Yeast Hyphae UrnS Ql Micro;;ACTIVE;2.16;2.73 +41866-5;von Willebrand factor Ag actual/Normal;RelRto;Pt;PPP;Qn;EIA;COAG;1;Deprecated von Willebrand factor (vWf) Ag actual/normal in Platelet poor plasma by EIA;Deprecated vWF Ag Act/Nor PPP EIA;;DEPRECATED;2.16;2.36 +41867-3;von Willebrand factor Ag;ACnc;Pt;PPP;Qn;;COAG;1;von Willebrand factor (vWf) Ag [Units/volume] in Platelet poor plasma;vWF Ag PPP-aCnc;;ACTIVE;2.16;2.73 +41868-1;Waxy casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Waxy casts [#/volume] in Urine by Computer assisted method;Waxy Casts # Ur Comp Assist;;ACTIVE;2.16;2.42 +41869-9;Testosterone.bioavailable+Free/Testosterone.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Testosterone.bioavailable+Free/Testosterone.total in Serum or Plasma;Deprecated Testost Bioavail+Free MFr Ser;;DEPRECATED;2.16;2.70 +41870-7;Tryptase.mature;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptase.mature [Enzymatic activity/volume] in Serum or Plasma;Tryptase.mature SerPl-cCnc;;ACTIVE;2.16;2.73 +4187-1;CISplatin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;CISplatin [Mass] of Dose;CISplatin Dose;;ACTIVE;1.0;2.69 +41871-5;Voltage-gated potassium channel Ab;SCnc;Pt;Ser;Qn;;SERO;1;Voltage-gated potassium channel Ab [Moles/volume] in Serum;VGKC Ab Ser-sCnc;;ACTIVE;2.16;2.73 +41872-3;PDCD10 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PDCD10 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PDCD10 gene Mut Anl Bld/T;;ACTIVE;2.16;2.63 +41873-1;Alnus rugosa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Smooth Alder IgG Ab [Units/volume] in Serum;Smooth Alder IgG Qn;;ACTIVE;2.16;2.69 +41874-9;Betula populifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Birch IgE Ab [Units/volume] in Serum;White Birch IgE Qn;;ACTIVE;2.16;2.73 +41875-6;Bordetella pertussis & Bordetella parapertussis DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Bordetella pertussis and Bordetella parapertussis DNA panel - Specimen by NAA with probe detection;B pert+parapert DNA Pnl Spec NAA+probe;;ACTIVE;2.16;2.73 +41876-4;Rickettsia typhi & Rickettsia spotted fever group Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Rickettsia typhi and Rickettsia spotted fever group IgG and IgM panel - Serum;R typhi and SF IgG+IgM Pnl Ser;;ACTIVE;2.16;2.73 +41877-2;Bordetella pertussis Ab.IgA & IgG & IgM panel;ACnc;Pt;Ser;Qn;IA;PANEL.MICRO;1;Bordetella pertussis IgA and IgG and IgM panel [Units/volume] - Serum by Immunoassay;B pert IgA+IgG+IgM Pnl Ser IA-aCnc;;ACTIVE;2.16;2.73 +41878-0;Dengue virus Ab.IgG & IgM panel;-;Pt;Ser;Qn;IA;PANEL.MICRO;1;Dengue virus IgG and IgM panel - Serum by Immunoassay;DENV IgG+IgM Pnl Ser IA;;ACTIVE;2.16;2.73 +4188-9;Clavulanate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clavulanate [Mass] of Dose;Clavulanate Dose;;ACTIVE;1.0;2.69 +41896-2;Class;Type;Pt;Glucose meter device;Nom;;DEVICES;2;Type of Glucose meter device;Glucose Mtr Dev Class;;ACTIVE;2.16;2.73 +4189-7;Clindamycin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clindamycin [Mass] of Dose;Clindamycin Dose;;ACTIVE;1.0;2.69 +41897-0;Vendor device name;ID;Pt;Glucose meter device;Nom;;DEVICES;2;Glucose meter device Vendor name;Glucose Mtr Dev Vendor name;;ACTIVE;2.16;2.73 +41898-8;Vendor device model code;ID;Pt;Glucose meter device;Nom;;CHEM;1;Vendor device model code of Glucose meter;Model Cd Glucose Mtr Dev;;ACTIVE;2.16;2.29 +41899-6;Vendor serial number;ID;Pt;Glucose meter device;Nom;;DEVICES;2;Glucose meter device Vendor serial number;Glucose Mtr Dev Serial #;;ACTIVE;2.16;2.27 +41900-2;Vendor software version;ID;Pt;Glucose meter device;Nom;;DEVICES;2;Glucose meter device Vendor software version;Glucose Mtr Dev Software vers;;ACTIVE;2.16;2.29 +41901-0;Class;Type;Pt;Blood pressure device;Nom;;DEVICES;2;Type of Blood pressure device;BP device Class;;ACTIVE;2.16;2.27 +41902-8;Vendor device model code;Prid;Pt;Blood pressure device;Nom;;DEVICES;2;Blood pressure device Vendor model code;BP device Model Cd;;ACTIVE;2.16;2.29 +41903-6;Vendor software version;ID;Pt;Blood pressure device;Nom;;DEVICES;2;Blood pressure device Vendor software version;BP device Software vers;;ACTIVE;2.16;2.29 +41904-4;Blood pressure measurement site;Anat;Pt;^Patient;Nom;;BP.ATOM;2;Blood pressure measurement site;BP measurement site;;ACTIVE;2.16;2.66 +4190-5;cloBAZam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cloBAZam [Mass] of Dose;cloBAZam Dose;;ACTIVE;1.0;2.69 +41905-1;Altitude;Len;Pt;^Patient;Qn;;BP.ATOM;2;Altitude;Altitude;;ACTIVE;2.16;2.48 +41906-9;Vendor device name;ID;Pt;Weighing device;Nom;;DEVICES;2;Weighing device Vendor name;Weighing Device Vendor name;;ACTIVE;2.16;2.27 +41907-7;Vendor device model code;ID;Pt;Weighing device;Nom;;DEVICES;2;Weighing device Vendor model code;Weighing Device Model Cd;;ACTIVE;2.16;2.29 +41908-5;Vendor software version;ID;Pt;Weighing device;Nom;;DEVICES;2;Weighing device Vendor software version;Weighing Device Software vers;;ACTIVE;2.16;2.29 +41909-3;Body mass index;Ratio;Pt;^Patient;Qn;Calculated;BDYWGT.ATOM;2;Deprecated Body mass index (BMI);Deprecated BMI;;DEPRECATED;2.16;2.36 +41910-1;Class;Type;Pt;Height device;Nom;;DEVICES;2;Type of Height device;Height Device Class;;ACTIVE;2.16;2.27 +41911-9;Vendor device name;ID;Pt;Height device;Nom;;DEVICES;2;Height device Vendor name;Height Device Vendor name;;ACTIVE;2.16;2.27 +41912-7;Vendor device model code;ID;Pt;Height device;Nom;;DEVICES;2;Height device Vendor model code;Height Device Model Cd;;ACTIVE;2.16;2.29 +4191-3;Clobenzorex;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clobenzorex [Mass] of Dose;Clobenzorex Dose;;ACTIVE;1.0;2.69 +41913-5;Vendor serial number;ID;Pt;Height device;Nom;;DEVICES;2;Height device Vendor serial number;Height Device Serial #;;ACTIVE;2.16;2.27 +41914-3;Class;Type;Pt;Blood coagulation device;Nom;;DEVICES;2;Type of Blood coagulation device;Blood Coagulation Device Class;;ACTIVE;2.16;2.27 +41915-0;Vendor device name;ID;Pt;Blood coagulation device;Nom;;DEVICES;2;Blood coagulation device Vendor name;Blood Coagulation Device Vendor name;;ACTIVE;2.16;2.27 +41916-8;Vendor device model code;Prid;Pt;Blood coagulation device;Nom;;DEVICES;2;Blood coagulation device Vendor model code;Blood Coagulation Device Model Cd;;ACTIVE;2.16;2.29 +41917-6;Vendor serial number;ID;Pt;Blood coagulation device;Nom;;DEVICES;2;Blood coagulation device Vendor serial number;Blood Coagulation Device Serial #;;ACTIVE;2.16;2.27 +41918-4;Vendor software version;ID;Pt;Blood coagulation device;Nom;;DEVICES;2;Blood coagulation device Vendor software version;Blood Coagulation Device Software vers;;ACTIVE;2.16;2.29 +41919-2;Vendor software version;ID;Pt;Heart rate device;Nom;;DEVICES;2;Heart rate device Vendor software version;Hrt Rate Device Software vers;;ACTIVE;2.16;2.29 +419-2;Polymyxin B;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Polymyxin B [Susceptibility] by Minimum lethal concentration (MLC);Polymyxin B Islt MLC;;ACTIVE;1.0;2.19 +41920-0;Heart rate;NRat;1H^mean;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 1 hour mean;Heart rate 1h Mean;;ACTIVE;2.16;2.42 +4192-1;Clofibrate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clofibrate [Mass] of Dose;Clofibrate Dose;;ACTIVE;1.0;2.69 +41921-8;Heart rate;NRat;8H^mean;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 8 hour mean;Heart rate 8h Mean;;ACTIVE;2.16;2.42 +41922-6;Heart rate;NRat;10H^mean;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 10 hour mean;Heart rate 10h Mean;;ACTIVE;2.16;2.42 +41923-4;Heart rate;NRat;12H^mean;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 12 hour mean;Heart rate 12h Mean;;ACTIVE;2.16;2.42 +41924-2;Heart rate;NRat;24H^mean;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 24 hour mean;Heart rate 24h Mean;;ACTIVE;2.16;2.42 +41925-9;Class;Type;Pt;Oxygen saturation device;Nom;;DEVICES;2;Type of Oxygen saturation device;SaO2% Device Class;;ACTIVE;2.16;2.73 +41926-7;Vendor device name;ID;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation device Vendor name;SaO2% Device Vendor name;;ACTIVE;2.16;2.32 +41927-5;Vendor device model code;ID;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation device Vendor model code;SaO2% Device Model Cd;;ACTIVE;2.16;2.32 +41928-3;Vendor serial number;ID;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation device Vendor serial number;SaO2% Device Serial #;;ACTIVE;2.16;2.32 +41929-1;Vendor software version;ID;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation device Vendor software version;SaO2% Device Software vers;;ACTIVE;2.16;2.32 +41930-9;Class;Type;Pt;Peak flow meter;Nom;;DEVICES;2;Type of Peak flow meter;PFM Class;;ACTIVE;2.16;2.27 +41931-7;Vendor device name;ID;Pt;Peak flow meter;Nom;;DEVICES;2;Peak flow meter Vendor name;PFM Vendor name;;ACTIVE;2.16;2.27 +41932-5;Vendor device model code;ID;Pt;Peak flow meter;Nom;;DEVICES;2;Peak flow meter Vendor model code;PFM Model Cd;;ACTIVE;2.16;2.29 +41933-3;Vendor serial number;ID;Pt;Peak flow meter;Nom;;DEVICES;2;Peak flow meter Vendor serial number;PFM Serial #;;ACTIVE;2.16;2.27 +41934-1;Vendor software version;ID;Pt;Peak flow meter;Nom;;DEVICES;2;Peak flow meter Vendor software version;PFM Software vers;;ACTIVE;2.16;2.29 +41935-8;Peak flow measure duration;Time;*;Respiratory system.airway;Qn;Peak flow meter;PULM;2;Peak flow measure duration Respiratory system airway by Peak flow meter;Peak flow measure dur Airway PFM;;ACTIVE;2.16;2.48 +41936-6;Class;Type;Pt;Insulin delivery device;Nom;;DEVICES;2;Type of Insulin delivery device;Insulin Delivery Device Class;;ACTIVE;2.16;2.27 +41937-4;Vendor serial number;ID;Pt;Insulin delivery device;Nom;;DEVICES;2;Insulin delivery device Vendor serial number;Insulin Delivery Device Serial #;;ACTIVE;2.16;2.27 +41938-2;Bolus requested;Dosage;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication, Bolus requested;;;ACTIVE;2.16;2.27 +4193-9;clomiPRAMINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;clomiPRAMINE [Mass] of Dose;clomiPRAMINE Dose;;ACTIVE;1.0;2.69 +41939-0;Bolus delivered;Dosage;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication, Bolus delivered;;;ACTIVE;2.16;2.27 +41940-8;Bolus type;Type;Pt;Medication.current;Nom;;ATTACH.MEDS;3;Current medication, Bolus type;;;ACTIVE;2.16;2.27 +41941-6;Basal rate;NRat;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication, Basal rate;;;ACTIVE;2.16;2.27 +41942-4;Insulin type;Type;Pt;Medication.current;Nom;;ATTACH.MEDS;3;Current medication, Insulin type;;;ACTIVE;2.16;2.27 +41943-2;Insulin name + ID;ID;Pt;Medication.current;Nom;;ATTACH.MEDS;3;Current medication, Insulin Name+ID;;;ACTIVE;2.16;2.27 +41944-0;Totals.basal;Dosage;24H;Medication.current;Qn;;ATTACH.MEDS;3;Current medication 24 hour Totals basal;;;ACTIVE;2.16;2.27 +41945-7;Totals.bolus;Dosage;24H;Medication.current;Qn;;ATTACH.MEDS;3;Current medication 24 hour Totals bolus;;;ACTIVE;2.16;2.27 +41946-5;Class;Type;Pt;Pedometer device;Nom;;DEVICES;2;Type of Pedometer device;Pedometer Device Class;;ACTIVE;2.16;2.27 +4194-7;clonazePAM;Mass;Pt;Dose;Qn;;DRUGDOSE;1;clonazePAM [Mass] of Dose;clonazePAM Dose;;ACTIVE;1.0;2.69 +41947-3;Vendor device name;ID;Pt;Pedometer device;Nom;;DEVICES;2;Pedometer device Vendor name;Pedometer Device Vendor name;;ACTIVE;2.16;2.27 +41948-1;Vendor device model code;ID;Pt;Pedometer device;Nom;;DEVICES;2;Pedometer device Vendor model code;Pedometer Device Model Cd;;ACTIVE;2.16;2.29 +41949-9;Vendor software version;ID;Pt;Pedometer device;Nom;;DEVICES;2;Pedometer device Vendor software version;Pedometer Device Software vers;;ACTIVE;2.16;2.66 +41950-7;Number of steps;NRat;24H;^Patient;Qn;Measured;CLIN;2;Number of steps in 24 hour Measured;# steps 24h nRate Measured;;ACTIVE;2.16;2.48 +41951-5;Number of steps;NRat;24H^mean;^Patient;Qn;Measured;CLIN;2;Number of steps in 24 hour mean Measured;# steps 24h Mean nRate Measured;;ACTIVE;2.16;2.48 +41952-3;Number of steps;NRat;1W;^Patient;Qn;Measured;CLIN;2;Number of steps in 1 week Measured;# steps 1W nRate Measured;;ACTIVE;2.16;2.48 +41953-1;Walking distance;Len;24H;^Patient;Qn;Calculated;CLIN;2;Walking distance 24 hour Calculated;Walk distance 24h Calc;;ACTIVE;2.16;2.67 +4195-4;cloNIDine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cloNIDine [Mass] of Dose;cloNIDine Dose;;ACTIVE;1.0;2.69 +41954-9;Walking distance;Len;24H^mean;^Patient;Qn;Calculated;CLIN;2;Walking distance 24 hour mean Calculated;Walk distance 24h Mean Calc;;ACTIVE;2.16;2.67 +41955-6;Walking distance;Len;1W;^Patient;Qn;Calculated;CLIN;2;Distance walked in 1 week Calculated;Walk distance 1W Calc;;ACTIVE;2.16;2.67 +41956-4;Walking speed;Vel;24H^max;^Patient;Qn;Calculated;CLIN;2;Walking speed 24 hour maximum Calculated;Walking Speed 24h Max Calc;;ACTIVE;2.16;2.48 +41957-2;Walking speed;Vel;24H^mean;^Patient;Qn;Calculated;CLIN;2;Walking speed 24 hour mean Calculated;Walking Speed 24h Mean Calc;;ACTIVE;2.16;2.48 +41958-0;Walking speed;Vel;1W^max;^Patient;Qn;Calculated;CLIN;2;Walking speed in the past week maximum Calculated;Walking Speed 1W Max Calc;;ACTIVE;2.16;2.52 +41959-8;Walking speed;Vel;1W^mean;^Patient;Qn;Calculated;CLIN;2;Walking speed in the past week mean Calculated;Walking Speed 1W Mean Calc;;ACTIVE;2.16;2.52 +41960-6;Class;Type;Pt;HbA1c measurement device;Nom;;DEVICES;2;Type of HbA1c measurement device;HbA1c Measurement Device Class;;ACTIVE;2.16;2.73 +41961-4;Vendor device name;ID;Pt;HbA1c measurement device;Nom;;DEVICES;2;HbA1c measurement device Vendor name;HbA1c Measurement Device Vendor name;;ACTIVE;2.16;2.27 +4196-2;Clopenthixol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clopenthixol [Mass] of Dose;Clopenthixol Dose;;ACTIVE;1.0;2.69 +41962-2;Vendor device model code;ID;Pt;HbA1c measurement device;Nom;;DEVICES;2;HbA1c measurement device Vendor model code;HbA1c Measurement Device Model Cd;;ACTIVE;2.16;2.29 +41963-0;Vendor serial number;ID;Pt;HbA1c measurement device;Nom;;DEVICES;2;HbA1c measurement device Vendor serial number;HbA1c Measurement Device Serial #;;ACTIVE;2.16;2.27 +41964-8;Vendor software version;ID;Pt;HbA1c measurement device;Nom;;DEVICES;2;HbA1c measurement device Vendor software version;HbA1c Measurement Device Software vers;;ACTIVE;2.16;2.29 +41965-5;Class;Type;Pt;Metabolism measurement device;Nom;;DEVICES;2;Type of Metabolism measurement device;Metab Measure Dev Class;;ACTIVE;2.16;2.27 +41966-3;Vendor device name;ID;Pt;Metabolism measurement device;Nom;;DEVICES;2;Name of Metabolism measurement device;Metab Measure Dev Vendor name;;ACTIVE;2.16;2.73 +41967-1;Vendor device model code;ID;Pt;Metabolism measurement device;Nom;;DEVICES;2;Metabolism measurement device Vendor model code;Metab Measure Dev Model Cd;;ACTIVE;2.16;2.29 +41968-9;Vendor serial number;ID;Pt;Metabolism measurement device;Nom;;DEVICES;2;Metabolism measurement device Vendor serial number;Metab Measure Dev Serial #;;ACTIVE;2.16;2.27 +41969-7;Vendor software version;ID;Pt;Metabolism measurement device;Nom;;DEVICES;2;Metabolism measurement device Vendor software version;Metab Measure Dev Software vers;;ACTIVE;2.16;2.29 +4197-0;Clorprenaline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clorprenaline [Mass] of Dose;Clorprenaline Dose;;ACTIVE;1.0;2.69 +41970-5;Type;ID;Pt;Metabolism measurement device;Nom;;DEVICES;2;Metabolism measurement device Type;Metab Measure Dev Type;;ACTIVE;2.16;2.27 +41971-3;Total metabolism;Mass;24H;^Patient;Qn;;CLIN;2;Total metabolism [Mass] 24 hour;Total Metabolism 24h;;ACTIVE;2.16;2.27 +41972-1;Name;ID;Pt;Medication.current;Nom;Reported;ATTACH.MEDS;3;Current medication, Name - Reported;;;ACTIVE;2.16;2.27 +41973-9;Medication XXX;Dosage;Pt;Medication.current;Qn;Reported;ATTACH.MEDS;3;Current medication Dose - Reported;;;ACTIVE;2.16;2.27 +41974-7;Timing + Quantity;TQ2;Pt;Medication.current;Qn;Reported;ATTACH.MEDS;3;Current medication, Timing + Quantity - Reported;;;ACTIVE;2.16;2.42 +41975-4;Route;Prid;Pt;Medication.current;Nom;Reported;ATTACH.MEDS;3;Current medication, Route - Reported;;;ACTIVE;2.16;2.27 +41976-2;Vendor device name;ID;Pt;Insulin delivery device;Nom;;DEVICES;2;Insulin delivery device Vendor name;Insulin Delivery Device Vendor name;;ACTIVE;2.16;2.32 +41977-0;Vendor software version;ID;Pt;Insulin delivery device;Nom;;DEVICES;2;Insulin delivery device Vendor software version;Insulin Delivery Device Software vers;;ACTIVE;2.16;2.29 +41978-8;Vendor serial number;ID;Pt;Pedometer device;Nom;;DEVICES;2;Pedometer device Vendor serial number;Pedometer Device Serial #;;ACTIVE;2.16;2.27 +41979-6;Calories burned;EngRat;24H;^Patient;Qn;Calculated;CLIN;2;Calories burned in 24 hour Calculated;Calories burned 24h Calc;;ACTIVE;2.16;2.48 +41980-4;Calories burned;EngRat;1W;^Patient;Qn;Calculated;CLIN;2;Calories burned in 1 week Calculated;Calories burned 1W Calc;;ACTIVE;2.16;2.48 +41981-2;Calories burned;EngRat;Pt;^Patient;Qn;;CLIN;2;Calories burned;Calories burned;;ACTIVE;2.16;2.48 +41982-0;Body fat percentage;MFr;Pt;^Patient;Qn;Measured;BDYWGT.ATOM;2;Percentage of body fat Measured;Bdy fat % Measured;;ACTIVE;2.16;2.73 +41983-8;Vendor device model code;ID;Pt;Insulin delivery device;Nom;;DEVICES;2;Insulin delivery device Vendor model code;Insulin Delivery Device Model Cd;;ACTIVE;2.16;2.29 +41984-6;Lipoprotein analysis status &or results;Cmplx;Pt;Ser/Plas;Set;CPHS;ATTACH.CPHS;3;Lipoprotein analysis status/results Set CPHS;;;ACTIVE;2.16;2.40 +41985-3;Lead screen test status &or results;Cmplx;Pt;^Patient;Set;CPHS;ATTACH.CPHS;3;Lead screen test status and/or results Set CPHS;;;ACTIVE;2.16;2.40 +41986-1;Hematocrit test status &or results;Cmplx;Pt;Bld;Set;CPHS;ATTACH.CPHS;3;Hematocrit test status/results Set CPHS;;;ACTIVE;2.16;2.40 +41987-9;Hemoglobin test status &or results;Cmplx;Pt;Bld;Set;CPHS;ATTACH.CPHS;3;Hemoglobin test status/results Set CPHS;;;ACTIVE;2.16;2.40 +4198-8;Clostebol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Clostebol [Mass] of Dose;Clostebol Dose;;ACTIVE;1.0;2.69 +41988-7;Follow-up (referred to) provider &or specialist, catchment location indicator;Type;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, catchment location indicator CPHS;;;ACTIVE;2.16;2.27 +41989-5;Follow-up (referred to) provider &or specialist, state location indicator;Type;Pt;Clinical referral;Nom;CPHS;ATTACH.CPHS;3;Follow-up (referred to) provider /specialist, state location indicator CPHS;;;ACTIVE;2.16;2.27 +41990-3;Parainfluenza virus 4 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 4 IgG Ab [Presence] in Serum by Immunoassay;HPIV4 IgG Ser Ql IA;;ACTIVE;2.16;2.56 +41991-1;SARS coronavirus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;SARS coronavirus IgM Ab [Presence] in Serum by Immunoassay;SARS-CoV IgM Ser Ql IA;;ACTIVE;2.16;2.68 +41992-9;Arsenic.inorganic;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic [Mass/volume] in 24 hour Urine;Inorg Arsenic 24h Ur-mCnc;;ACTIVE;2.16;2.73 +41993-7;Atazanavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Atazanavir [Susceptibility];Atazanavir Susc Islt;;ACTIVE;2.16;2.19 +41994-5;Cells.CD4+CD45RO+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45RO+ cells/100 cells in Blood;CD4+CD45RO+ Cells NFr Bld;;ACTIVE;2.16;2.73 +41995-2;Hemoglobin A1c;MCnc;Pt;Bld;Qn;;CHEM;1;Hemoglobin A1c [Mass/volume] in Blood;HbA1c Bld-mCnc;;ACTIVE;2.16;2.73 +4199-6;Codeine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Codeine [Mass] of Dose;Codeine Dose;;ACTIVE;1.0;2.69 +41996-0;Hepatitis C virus DNA;LaCnc;Pt;Ser/Plas;Qn;Probe.amp.sig;MICRO;1;Deprecated Hepatitis C virus DNA [log units/volume] (viral load) in Serum or Plasma by Probe and signal amplification method;Deprecated HCV DNA SerPl bDNA-Log IU;;DEPRECATED;2.16;2.70 +41997-8;Heptacarboxylporphyrin;MCnc;24H;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/volume] in 24 hour Urine;Hepta-CP 24h Ur-mCnc;;ACTIVE;2.16;2.42 +41998-6;Hexacarboxylporphyrin;MCnc;24H;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/volume] in 24 hour Urine;Hexa-CP 24h Ur-mCnc;;ACTIVE;2.16;2.42 +41999-4;Lipoprotein.pre-beta;PrThr;Pt;Body fld;Ord;;CHEM;1;Lipoprotein.pre-beta [Presence] in Body fluid;VLDL Fld Ql;;ACTIVE;2.16;2.56 +4-2;Almecillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Almecillin [Susceptibility] by Disk diffusion (KB);Almecillin Islt KB;;ACTIVE;1.0;2.21 +420-0;Polymyxin B;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Polymyxin B [Susceptibility] by Minimum inhibitory concentration (MIC);Polymyxin B Islt MIC;;ACTIVE;1.0;2.19 +42000-0;Lopinavir+Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Lopinavir+Ritonavir [Susceptibility] by Genotype method;Lopinavir+Ritonavir Islt Genotyp;;ACTIVE;2.16;2.73 +42001-8;Nickel/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Nickel/Creatinine [Mass Ratio] in 24 hour Urine;Nickel/Creat 24h Ur;;ACTIVE;2.16;2.42 +4200-2;Prochlorperazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Prochlorperazine [Mass] of Dose;Prochlorperazine Dose;;ACTIVE;1.0;2.69 +42002-6;Pentacarboxylporphyrins;MCnc;24H;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/volume] in 24 hour Urine;Penta-CP 24h Ur-mCnc;;ACTIVE;2.16;2.42 +42003-4;Hepatitis C virus RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.sig;MICRO;1;Hepatitis C virus RNA [Log #/volume] (viral load) in Serum or Plasma by Probe with signal amplification;HCV RNA SerPl Probe+sig amp-Log#;;ACTIVE;2.16;2.73 +42004-2;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;EEEV IgM CSF Ql IA;;ACTIVE;2.16;2.56 +42005-9;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Serum by Immunoassay;SLEV IgM Ser Ql IA;;ACTIVE;2.16;2.56 +42006-7;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;SLEV IgM CSF Ql IA;;ACTIVE;2.16;2.56 +42007-5;Views limited;Find;Pt;Head>Mastoid.bilateral;Doc;XR;RAD;2;XR Mastoid - bilateral Limited Views;XR Mastoid-Bl Views Ltd;;ACTIVE;2.16;2.64 +42008-3;View^during surgery;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus Single view during surgery;XR Humerus 1V in Surg;;ACTIVE;2.16;2.64 +42009-1;Views 2 + apical lordotic;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest 2 Views and Apical lordotic;XR Chest 2V+Apical lord;;ACTIVE;2.16;2.61 +4201-0;Cropropamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cropropamide [Mass] of Dose;Cropropamide Dose;;ACTIVE;1.0;2.69 +42010-9;Views && view PA;Find;Pt;Chest>Ribs.right && Chest;Doc;XR;RAD;2;XR Ribs - right Views and Chest PA;XR Ribs-R Views + Chest PA;;ACTIVE;2.16;2.64 +42011-7;View PA && View AP;Find;Pt;Chest && Abdomen;Doc;XR;RAD;2;XR Chest PA and Abdomen AP;XR Chest PA + Abd AP;;ACTIVE;2.16;2.64 +42012-5;Views^W water soluble contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Gastrointestinal tract upper Views W water soluble contrast PO;RF UGI Views W H2O soluble contr PO;;ACTIVE;2.16;2.64 +42013-3;Views^W water soluble contrast PR;Find;Pt;Colon;Nar;XR.fluor;RAD;2;Deprecated Colon X-ray fluoroscopy W water soluble contrast PR;Deprecated Colon Flr W H2O sol contr PR;;DEPRECATED;2.16;2.36 +42014-1;Views^W contrast;Find;Pt;Pelvis>Urinary bladder+Urethra;Doc;RF;RAD;2;RF Urinary bladder and Urethra Views W contrast;RF Bladder+Urethra Views W contr;;ACTIVE;2.16;2.64 +42015-8;Views^W non-ionic contrast IT;Find;Pt;Spine.cervical;Nar;XR.fluor;RAD;2;Deprecated Spine Cervical X-ray fluoroscopy W contrast IT;Deprecated C-spine Flr W Non-ionic contr;;DEPRECATED;2.16;2.36 +42016-6;Views^W non-ionic contrast IT;Find;Pt;Spine.thoracic;Nar;XR.fluor;RAD;2;Deprecated Spine Thoracic X-ray fluoroscopy W contrast IT;Deprecated T-spine Flr W Non-ionic contr;;DEPRECATED;2.16;2.36 +42017-4;Guidance for percutaneous replacement of cholecystostomy;Find;Pt;Abdomen;Doc;RF;RAD;2;RF Guidance for percutaneous replacement of cholecystostomy of Abdomen;RF Guided Abd PCS replace;;ACTIVE;2.16;2.64 +42018-2;Guidance for percutaneous transluminal angioplasty^W contrast IA;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for percutaneous transluminal angioplasty of Vein-- W contrast IA;RFA Guided Vein PTA--W contr IA;;DISCOURAGED;2.16;2.64 +42019-0;Views upright + L-lateral-decubitus;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen upright and left lateral decubitus;XR Abd Upr+L Lat Decub;;ACTIVE;2.16;2.73 +42020-8;Guidance for needle localization;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Guidance for needle localization of Lumbar spine;CT Guided L-spine Needle loc;;ACTIVE;2.16;2.64 +42021-6;Guidance for needle localization;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Guidance for needle localization of Cervical spine;CT Guided C-spine Needle loc;;ACTIVE;2.16;2.64 +42022-4;NAACCR hospital tumor registration.permanent;ID;Pt;^Patient;Nom;;TUMRRGT;2;NAACCR hospital tumor registration.permanent [Identifier];NAACCR hospital tumor reg.permanent;;ACTIVE;2.16;2.73 +42023-2;NAACCR facility identification system coding system;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;NAACCR facility identification system coding system;NAACCR FIN system coding system Cancer;;ACTIVE;2.16;2.32 +42024-0;NAACCR hispanic identification algorithm hispanic origin;Prid;Pt;^Patient;Nom;Derived;TUMRRGT;2;NAACCR hispanic identification algorithm hispanic origin Derived;NHIA hispanic origin Derived;;ACTIVE;2.16;2.32 +42025-7;NAACCR Indian Health Service linkage;Prid;Pt;^Patient;Nom;;TUMRRGT;2;NAACCR Indian Health Service linkage;NAACCR HIS linkage;;ACTIVE;2.16;2.27 +42026-5;Census tract certainty 2000;Type;Pt;Census tract;Nom;;TUMRRGT;2;Census tract certainty 2000;Census tract certainty 2000;;ACTIVE;2.16;2.29 +42027-3;Geographic information system coordinate quality;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Geographic information system coordinate quality Cancer;GIS coordinate quality Cancer;;ACTIVE;2.16;2.29 +4202-8;Crotetamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Crotethamide [Mass] of Dose;Crotetamide Dose;;ACTIVE;1.0;2.69 +42028-1;NAACCR ambiguous terminology as basis for diagnosis;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;NAACCR ambiguous terminology as basis for diagnosis;NAACCR Ambiguous Terminology Dx Cancer;;ACTIVE;2.16;2.32 +42029-9;Date of conclusive diagnosis;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date of conclusive diagnosis Cancer;Date of conclusive Dx Cancer;;ACTIVE;2.16;2.27 +42030-7;Multiple tumors reported as single primary;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Multiple tumors reported as single primary Cancer;Mult Tum Rpt as One Prim Cancer;;ACTIVE;2.16;2.32 +42031-5;Date of diagnosis of multiple tumors;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date of diagnosis of multiple tumors Cancer;Date Dx multiple tumors Cancer;;ACTIVE;2.16;2.32 +42032-3;Number of tumors at diagnosis;Num;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Number of tumors at diagnosis Cancer;# tumors at Dx Cancer;;ACTIVE;2.16;2.48 +42033-1;Number of tumors & histologies;Num;Pt;^Patient;Qn;;TUMRRGT;2;Number of tumors and histologies;# tumors/hist;;ACTIVE;2.16;2.48 +42034-9;Coding system.current;Type;Pt;Cancer.XXX.morphology;Nom;;TUMRRGT;2;Coding system.current Cancer morphology;Coding sys.current Cancer morph;;ACTIVE;2.16;2.29 +42035-6;Casefinding source;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Casefinding source Cancer;Casefinding source Cancer;;ACTIVE;2.16;2.32 +4203-6;Cyanocobalamin.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cyanocobalamin.PO [Mass] of Dose;Cyanocobalamin PO Dose;;ACTIVE;1.0;2.73 +42036-4;Cancer-Directed surgery at this facility 98-02;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Cancer-Directed surgery at this facility 98-02;CDS at fac 98-02;;ACTIVE;2.16;2.61 +42037-2;Scope of regional lymph node surgery at this facility 98-02;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Scope of regional lymph node surgery at this facility 98-02 Cancer;Scope reg LN surg at fac 98-02 Cancer;;ACTIVE;2.16;2.61 +42038-0;Surgery of other regional site(s), distant site(s), or distant lymph node(s) at this facility 98-02;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery of other regional site(s), distant site(s), or distant lymph node(s) at this facility 98-02 Cancer;Surg other sites 98-02 Cancer;;ACTIVE;2.16;2.32 +42039-8;Systemic therapy &or surgery sequence;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Systemic therapy/surgery sequence Cancer;Systemic therapy/surgery sequence Cancer;;ACTIVE;2.16;2.32 +42040-6;Cancer-Directed surgery 98-02;Anat;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Cancer-Directed surgery 98-02 [Anatomy];CDS 98-02;;ACTIVE;2.16;2.27 +42041-4;Scope of regional lymph node surgery 98-02;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Scope of regional lymph node surgery 98-02 Cancer;Scope of reg LN surgery 98-02 Cancer;;ACTIVE;2.16;2.32 +42042-2;Surgery of other regional site(s), distant site(s) or distant lymph nodes 98-02;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgery of other regional site(s), distant site(s) or distant lymph nodes 98-02 Cancer;Surg other sites LN 98-02 Cancer;;ACTIVE;2.16;2.32 +42043-0;2nd course treatment.surgery;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;2nd course surgery Cancer Rx;2nd course Surg Cancer Rx;;ACTIVE;2.16;2.32 +4204-4;Cyclacillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cyclacillin [Mass] of Dose;Cyclacillin Dose;;ACTIVE;1.0;2.69 +42044-8;2nd course treatment.radiation;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;2nd course radiation Cancer Rx;2nd course Rad Cancer Rx;;ACTIVE;2.16;2.32 +42045-5;2nd course treatment.chemotherapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;2nd course chemotherapy Cancer Rx;2nd course Chemo Cancer Rx;;ACTIVE;2.16;2.32 +42046-3;2nd course treatment.hormonal therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;2nd course hormonal therapy Cancer Rx;2nd course Horm Cancer Rx;;ACTIVE;2.16;2.32 +42047-1;2nd course treatment.biological reponse modifier therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;2nd course biological reponse modifier therapy Cancer Rx;2nd course BRM Cancer Rx;;ACTIVE;2.16;2.32 +42048-9;2nd course treatment.other therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;2nd course other therapy Cancer Rx;2nd course Other Tx Cancer Rx;;ACTIVE;2.16;2.32 +42049-7;3rd course treatment.surgery;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;3rd course surgery Cancer Rx;3rd course Surg Cancer Rx;;ACTIVE;2.16;2.32 +42050-5;3rd course treatment.radiation;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;3rd course radiation Cancer Rx;3rd course Rad Cancer Rx;;ACTIVE;2.16;2.32 +4205-1;Cyclizine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Cyclizine [Mass] of Dose;Cyclizine Dose;;ACTIVE;1.0;2.69 +42051-3;3rd course treatment.chemotherapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;3rd course chemotherapy Cancer Rx;3rd course Chemo Cancer Rx;;ACTIVE;2.16;2.32 +42052-1;3rd course treatment.hormonal therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;3rd course hormonal therapy Cancer Rx;3rd course Horm Tx Cancer Rx;;ACTIVE;2.16;2.32 +42053-9;3rd course treatment.biological response modifier therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;3rd course biological response modifier therapy Cancer Rx;3rd course BRM Cancer Rx;;ACTIVE;2.16;2.32 +42054-7;3rd course treatment.other therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;3rd course other therapy Cancer Rx;3rd course Other Tx Cancer Rx;;ACTIVE;2.16;2.32 +42055-4;4th course treatment.surgery;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;4th course Surgery Cancer Rx;4th course Surg Cancer Rx;;ACTIVE;2.16;2.32 +42056-2;4th course treatment.radiation;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;4th course radiation Cancer Rx;4th course Rad Cancer Rx;;ACTIVE;2.16;2.32 +42057-0;4th course treatment.chemotherapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;4th course chemotherapy Cancer Rx;4th course Chemo Cancer Rx;;ACTIVE;2.16;2.32 +42058-8;4th course treatment.hormonal therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;4th course hormonal therapy Cancer Rx;4th course Horm Tx Cancer Rx;;ACTIVE;2.16;2.32 +42059-6;4th course treatment.biological response modifier therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;4th course biological response modifier therapy Cancer Rx;4th course BRM Cancer Rx;;ACTIVE;2.16;2.32 +42060-4;4th course treatment.other therapy;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;4th course other therapy Cancer Rx;4th course Other Tx Cancer Rx;;ACTIVE;2.16;2.32 +42061-2;Follow-up source;Prid;Pt;Cancer registry;Nom;;TUMRRGT;2;Follow-up source Cancer registry;Follow-up source Cancer Registry;;ACTIVE;2.16;2.32 +42062-0;County--current;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;County--current Cancer;County--current Cancer;;ACTIVE;2.16;2.32 +42063-8;Recurrence distant site 1;Anat;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Recurrence distant site 1 Cancer;Recur distant site 1 Cancer;;ACTIVE;2.16;2.32 +42064-6;Recurrence distant site 2;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Recurrence distant site 2 Cancer;Recur distant site 2 Cancer;;ACTIVE;2.16;2.32 +42065-3;Recurrence distant site 3;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Recurrence distant site 3 Cancer;Recur distant site 3 Cancer;;ACTIVE;2.16;2.32 +42066-1;Histology ICD-O-1;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Histology ICD-O-1 Cancer;Histology ICD-O-1 Cancer;;ACTIVE;2.16;2.27 +42067-9;Stage.summary & regional lymph nodes positive override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Summary stage and regional lymph nodes positive override flag Cancer case;SS/nodes pos O/R Cancer case;;ACTIVE;2.16;2.38 +42068-7;Stage.summary & TNM-N override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Summary stage and TNM-N override flag Cancer case;SS/TNM-N O/R Cancer case;;ACTIVE;2.16;2.38 +4206-9;cycloSERINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cycloSERINE [Mass] of Dose;cycloSERINE Dose;;ACTIVE;1.0;2.69 +42069-5;Stage.summary & TNM-M override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Summary stage and TNM-M override flag Cancer case;SS/TNM-M O/R Cancer case;;ACTIVE;2.16;2.38 +42070-3;Stage.summary & distant metastasis 1 override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Summary stage and distant metastasis 1 override flag Cancer case;SS/dist mets 1 O/R Cancer case;;ACTIVE;2.16;2.38 +42071-1;Accession number & class of case & sequence number override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Accession number and class of case and sequence number override flag Cancer case;Ascn/class/seq O/R Cancer case;;ACTIVE;2.16;2.73 +42072-9;Hospital sequence number & diagnostic confirmation override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Hospital sequence number and diagnostic confirmation override flag Cancer case;Hosp seq #/Dx conf O/R Cancer case;;ACTIVE;2.16;2.38 +42073-7;COC site & type override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Commission on Cancer (COC) site and type override flag;COC site/type O/R Cancer case;;ACTIVE;2.16;2.38 +42074-5;Hospital sequence & site override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Hospital sequence and site override flag Cancer case;Hosp seq/site O/R Cancer case;;ACTIVE;2.16;2.38 +42075-2;Primary site & TNM-stage group override flag;Arb;Pt;Cancer case.XXX;Ord;;TUMRRGT;2;Primary site and TNM-stage group override flag Cancer case;Site/TNM-stg grp O/R Cancer case;;ACTIVE;2.16;2.38 +42076-0;ICD-O-2 to ICD-O-3 conversion method;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;ICD-O-2 to ICD-O-3 conversion method;ICD-O-2 to ICD-O-3 conversion method;;ACTIVE;2.16;2.42 +4207-7;cycloSPORINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;cycloSPORINE [Mass] of Dose;cycloSPORINE Dose;;ACTIVE;1.0;2.73 +42077-8;Phone number;Tele;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient phone number;Phone #;;ACTIVE;2.16;2.73 +42078-6;Follow-up contact supplemental information;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Follow-up contact supplemental information;Follow-up contact sup info;;ACTIVE;2.16;2.32 +42079-4;Tumor size.collaborative staging;Len;Pt;Tumor;Qn;;TUMRRGT;2;Tumor size.collaborative staging;Tumor size.CS;;ACTIVE;2.16;2.48 +42080-2;Extension.collaborative staging;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Extension collaborative staging Cancer;Extension CS Cancer;;ACTIVE;2.16;2.42 +42081-0;Collaborative staging tumor size extension evaluation;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging tumor size extension evaluation Cancer;CS tumor size/ext eval Cancer;;ACTIVE;2.16;2.27 +42082-8;Collaborative staging lymph nodes;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging lymph nodes Cancer;CS LN Cancer;;ACTIVE;2.16;2.29 +42083-6;Collaborative staging regional nodes evaluation;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging regional nodes evaluation Cancer;CS reg node eval Cancer;;ACTIVE;2.16;2.27 +42084-4;Collaborative staging metastasis at diagnosis;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging metastasis at diagnosis Cancer;CS mets at Dx Cancer;;ACTIVE;2.16;2.27 +4208-5;Dantron;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dantron [Mass] of Dose;Dantron Dose;;ACTIVE;1.0;2.69 +42085-1;Collaborative staging metastasis evaluation;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging metastasis evaluation Cancer;CS mets eval Cancer;;ACTIVE;2.16;2.27 +42086-9;Collaborative staging site-specific factor 1;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-Specific factor 1 Cancer;CS site-Specific factor 1 Cancer;;ACTIVE;2.16;2.27 +42087-7;Collaborative staging site-specific factor 2;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-Specific factor 2 Cancer;CS site-Specific factor 2 Cancer;;ACTIVE;2.16;2.27 +42088-5;Collaborative staging site-specific factor 3;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-Specific factor 3 Cancer;CS site-Specific factor 3 Cancer;;ACTIVE;2.16;2.27 +42089-3;Collaborative staging site-specific factor 4;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-Specific factor 4 Cancer;CS site-Specific factor 4 Cancer;;ACTIVE;2.16;2.27 +42090-1;Collaborative staging site-specific factor 5;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-Specific factor 5 Cancer;Cssite-Specific factor 5 Cancer;;ACTIVE;2.16;2.27 +42091-9;Collaborative staging site-specific factor 6;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-Specific factor 6 Cancer;CS site-Specific factor 6 Cancer;;ACTIVE;2.16;2.27 +42092-7;Collaborative staging version.first;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging version.first Cancer;CS version 1st Cancer;;ACTIVE;2.16;2.27 +4209-3;clomiPRAMINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated clomiPRAMINE [Mass] of Dose;Deprecated clomiPRAMINE Dose;;DEPRECATED;1.0;2.69 +42093-5;Collaborative staging version.latest;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging version.latest Cancer;CS version latest Cancer;;ACTIVE;2.16;2.27 +42094-3;Derived American Joint Committee on Cancer T;Prid;Pt;Cancer.XXX;Nom;Derived;TUMRRGT;2;Derived American Joint Committee on Cancer T Derived;Derived AJCC T Cancer Derived;;ACTIVE;2.16;2.32 +42095-0;Derived American Joint Committee on Cancer T descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer T descriptor;Derived AJCC T descript Cancer;;ACTIVE;2.16;2.32 +42096-8;Derived American Joint Committee on Cancer N;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer N;Derived AJCC N Cancer;;ACTIVE;2.16;2.32 +42097-6;Derived American Joint Committee on Cancer N descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer N descriptor;Derived AJCC N descript Cancer;;ACTIVE;2.16;2.32 +42098-4;Derived American Joint Committee on Cancer M;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer M;Derived AJC M Cancer;;ACTIVE;2.16;2.32 +42099-2;Derived American Joint Committee on Cancer M descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer M descriptor;Derived AJCC M descript Cancer;;ACTIVE;2.16;2.32 +42100-8;Derived American Joint Committee on Cancer stage group;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer stage group;Derived AJCC stg grp Cancer;;ACTIVE;2.16;2.32 +4210-1;Nordoxepin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nordoxepin [Mass] of Dose;Nordoxepin Dose;;ACTIVE;1.0;2.69 +42101-6;Derived SEER summary stage 1977;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived SEER summary stage 1977 Cancer;Derived SS1977 Cancer;;ACTIVE;2.16;2.27 +42102-4;Derived SEER summary stage 2000;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived SEER summary stage 2000 Cancer;Derived SS2000 Cancer;;ACTIVE;2.16;2.27 +42103-2;Derived American Joint Committee on Cancer conversion method;Arb;Pt;Cancer.XXX;Ord;;TUMRRGT;2;Derived American Joint Committee on Cancer conversion method;Derived AJCC conv method Cancer;;ACTIVE;2.16;2.32 +42104-0;Derived SEER summary stage 1977 conversion method;Arb;Pt;Cancer.XXX;Ord;;TUMRRGT;2;Derived SEER summary stage 1977 conversion method Cancer;Derived SS1977 conv method Cancer;;ACTIVE;2.16;2.27 +42105-7;Derived SEER summary stage 2000 conversion method;Arb;Pt;Cancer.XXX;Ord;;TUMRRGT;2;Derived SEER summary stage 2000 conversion method Cancer;Derived SS2000 conv method Cancer;;ACTIVE;2.16;2.27 +42106-5;Archive facility identification number;ID;Pt;Cancer.XXX;Nom;;ADMIN.ID;2;Archive facility identification number Cancer;Archive FIN Cancer;;ACTIVE;2.16;2.66 +42107-3;Comorbidities and complications 2;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 2;Comorbidi/Complication 2;;ACTIVE;2.16;2.32 +42108-1;Comorbidities and complications 3;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 3;Comorbidi/Complication 3;;ACTIVE;2.16;2.32 +42109-9;Comorbidities and complications 4;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 4;Comorbidi/Complication 4;;ACTIVE;2.16;2.32 +42110-7;Comorbidities and complications 5;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 5;Comorbidi/Complication 5;;ACTIVE;2.16;2.32 +42111-5;Comorbidities and complications 6;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 6;Comorbidi/Complication 6;;ACTIVE;2.16;2.32 +42112-3;Comorbidities and complications 7;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 7;Comorbidi/Complication 7;;ACTIVE;2.16;2.32 +42113-1;Comorbidities and complications 8;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 8;Comorbidi/Complication 8;;ACTIVE;2.16;2.32 +42114-9;Comorbidities and complications 9;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 9;Comorbidi/Complication 9;;ACTIVE;2.16;2.32 +42115-6;Comorbidities and complications 10;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 10;Comorbidi/Complication 10;;ACTIVE;2.16;2.32 +42116-4;ICD revision comorbidities;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;ICD revision comorbidities Cancer;ICD revision comorbidities Cancer;;ACTIVE;2.16;2.27 +42117-2;Date of surgical discharge;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date of surgical discharge Cancer;Date of surg disch Cancer;;ACTIVE;2.16;2.32 +42118-0;Readmission to the same hospital within 30D of surgical discharge;Arb;Pt;Cancer.XXX;Ord;;TUMRRGT;2;Readmission to the same hospital within 30 days of surgical discharge Cancer;Readmit within 30D of surg dis Cancer;;ACTIVE;2.16;2.40 +4211-9;Desethylamiodarone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Desethylamiodarone [Mass] of Dose;Desethylamiodarone Dose;;ACTIVE;1.0;2.69 +42119-8;Boost radiation dose;EngCnt;Pt;Dose;Qn;;TUMRRGT;2;Boost radiation dose [Energy/mass];Boost radiation dose;;ACTIVE;2.16;2.30 +42120-6;Date radiation ended;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Date radiation ended Cancer;Date rad ended Cancer;;ACTIVE;2.16;2.32 +42121-4;Hematologic transplant & endocrine procedures;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Hematologic transplant and endocrine procedures Cancer;Transplnt/endocr proced Cancer;;ACTIVE;2.16;2.38 +42122-2;Pain assessment;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Pain assessment Cancer;Pain assessment Cancer;;ACTIVE;2.16;2.32 +42123-0;Palliative procedure at facility.XXX;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Palliative procedure at facility.XXX Cancer;Palliative proc at facility.XXX Cancer;;ACTIVE;2.16;2.29 +42124-8;Palliative procedure at this facility;Type;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Palliative procedure at this facility Cancer;Palliative proc Cancer;;ACTIVE;2.16;2.32 +42125-5;RuralUrban continuum 2000;Arb;Pt;^Patient;Ord;;TUMRRGT;2;RuralUrban continuum 2000;RuralUrban continuum 2000;;ACTIVE;2.16;2.27 +42126-3;Comorbidities and complications 1;Prid;Pt;^Patient;Nom;;TUMRRGT;2;Comorbidities and complications 1;Comorbidi/Complication 1;;ACTIVE;2.16;2.27 +4212-7;Desipramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Desipramine [Mass] of Dose;Desipramine Dose;;ACTIVE;1.0;2.69 +42127-1;Name of follow-up contact;Pn;Pt;^Patient;Nom;;TUMRRGT;2;Name of follow-up contact;Name of follow-up contact;;ACTIVE;2.16;2.29 +42128-9;Boost radiation treatment modality;Prid;Pt;Radiation.Rx;Nom;;TUMRRGT;2;Boost radiation treatment modality Radiation treatment;Boost radiation Tx modality Radiation Rx;;ACTIVE;2.16;2.32 +42129-7;Site coding system.current;Type;Pt;Cancer.XXX.anatomic site;Nom;;TUMRRGT;2;Site coding system.current Cancer site;Site coding system.current Cancer site;;ACTIVE;2.16;2.29 +42130-5;Latitude;Angle;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Latitude;Latitude;;ACTIVE;2.16;2.32 +42131-3;Longitude;Angle;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Longitude;Longitude;;ACTIVE;2.16;2.32 +42132-1;Multisection screening;Find;Pt;Breast;Doc;US;RAD;2;US Breast screening;US Brst Screening;;ACTIVE;2.16;2.61 +42133-9;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;US Guidance for drainage of abscess and placement of drainage catheter of Liver;US Guided Liver Absc drain+cath place;;ACTIVE;2.16;2.66 +42134-7;Guidance for percutaneous aspiration of fluid;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;US Guidance for fluid aspiration of Thyroid gland;US Guided Thyroid PC fluid asp;;ACTIVE;2.16;2.64 +4213-5;Nordiazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nordiazepam [Mass] of Dose;Nordiazepam Dose;;ACTIVE;1.0;2.69 +42135-4;Guidance for superficial biopsy;Find;Pt;XXX>Bone;Doc;US;RAD;2;US Guidance for superficial biopsy of Bone;US Guided Bone Super Bx;;ACTIVE;2.16;2.64 +42136-2;Guidance for percutaneous biopsy;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Guidance for biopsy of Heart;CT Guided Hrt Bx;;ACTIVE;2.16;2.64 +42137-0;Guidance for percutaneous biopsy;Find;Pt;Chest>Mediastinum;Doc;US;RAD;2;US Guidance for biopsy of Mediastinum;US Guided Mediastinum Bx;;ACTIVE;2.16;2.64 +42138-8;Guidance for localization of placenta;Find;Pt;Uterus;Nar;US;OB.US;2;US Guidance for localization of placenta;Placenta US local guid US;;ACTIVE;2.16;2.29 +42139-6;Guidance for percutaneous biopsy;Find;Pt;XXX>Muscle;Doc;US;RAD;2;Deprecated US guidance for percutaneous biopsy of Muscle;Deprecated US Muscle PC Bx;;DEPRECATED;2.16;2.63 +42140-4;Guidance for placement of tube;Find;Pt;Chest;Doc;US;RAD;2;US Guidance for placement of tube in Chest;US Guided Chest Tube place;;ACTIVE;2.16;2.64 +42141-2;Guidance for removal of tunneled central venous catheter;Find;Pt;XXX>Vein;Doc;US;RAD;2;US Guidance for removal of tunneled CV catheter;US Guided Tunneled CVC rem;;ACTIVE;2.16;2.67 +42142-0;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast;Nar;Mam;RAD;2;Deprecated Breast Mammogram Guidance for percutaneous biopsy.core needle;Deprecated Brst Mam PC Bx CN guid;;DEPRECATED;2.16;2.36 +4214-3;Dextromethorphan;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dextromethorphan [Mass] of Dose;D-methorphan Dose;;ACTIVE;1.0;2.69 +42143-8;Multisection^W saline IU;Find;Pt;Pelvis>Uterus+Fallopian tubes;Doc;US;RAD;2;US Uterus and Fallopian tubes W saline IU;US Uterus+FT W saline IU;;ACTIVE;2.16;2.61 +42144-6;Multisection;Find;Pt;Extremity.right>Extremity vein;Doc;US;RAD;2;US Extremity vein - right;US Extr v-R;;ACTIVE;2.16;2.61 +42145-3;Multisection;Find;Pt;Extremity.left>Extremity vein;Doc;US;RAD;2;US Extremity vein - left;US Extr v-L;;ACTIVE;2.16;2.61 +42146-1;Multisection;Find;Pt;Head+Neck>Carotid arteries;Doc;US.doppler;RAD;2;US.doppler Carotid arteries;DOP Carotid aa;;ACTIVE;2.16;2.73 +42147-9;Multisection;Find;Pt;Abdomen+Pelvis>Iliac graft;Doc;US.doppler;RAD;2;US.doppler Iliac graft;DOP Iliac graft;;ACTIVE;2.16;2.61 +42148-7;Multisection;Find;Pt;Chest>Heart;Doc;US;RAD;2;US Heart;US Hrt;;ACTIVE;2.16;2.73 +42149-5;Multisection limited;Find;Pt;Head+Neck>Carotid arteries.left;Doc;US;RAD;2;US Carotid arteries - left limited;US Carotid aa-L Ltd;;ACTIVE;2.16;2.61 +4215-0;Dextromoramide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dextromoramide [Mass] of Dose;D-moramide Dose;;ACTIVE;1.0;2.69 +42150-3;Multisection limited;Find;Pt;Abdomen+Pelvis>Iliac graft;Doc;US.doppler;RAD;2;US.doppler Iliac graft limited;DOP Iliac graft Ltd;;ACTIVE;2.16;2.61 +42151-1;Multisection limited;Find;Pt;Head+Neck>Carotid arteries.right;Doc;US;RAD;2;US Carotid arteries -right limited;US Carotid aa-R Ltd;;ACTIVE;2.16;2.61 +42152-9;Multisection limited;Find;Pt;Pelvis>Pelvis vessels;Doc;US.doppler;RAD;2;US.doppler Pelvis vessels limited;DOP Pelvis ves Ltd;;ACTIVE;2.16;2.61 +42153-7;View;Find;Pt;Extremity;Doc;XR;RAD;2;XR Extremity Single view;XR Extr 1V;;ACTIVE;2.16;2.64 +42154-5;View AP;Find;Pt;Abdomen;Nar;XR;RAD;2;Deprecated Abdomen X-ray AP;Deprecated Abd XR AP 1V;;DEPRECATED;2.16;2.36 +42155-2;View AP lateral-decubitus;Find;Pt;Chest;Nar;XR;RAD;2;Deprecated Chest X-ray AP lateral-decubitus;Deprecated Chest XR AP Lat Decub;;DEPRECATED;2.16;2.36 +42156-0;Views^W contrast IA;Find;Pt;XXX>Vessels;Doc;RF.angio;RAD;2;RFA Vessels Views W contrast IA;RFA Vesl Views W contr IA;;ACTIVE;2.16;2.64 +42157-8;Views^W contrast IV;Find;Pt;Extremity>Extremity vessels;Doc;RF.angio;RAD;2;RFA Extremity vessels Views W contrast IV;RFA Extremity ves Views W contr IV;;ACTIVE;2.16;2.64 +42158-6;Views^W radionuclide IV;Find;Pt;Abdomen>Adrenal gland;Doc;NM;RAD;2;NM Adrenal gland Views;NM Adrenal Views W RNC IV;;ACTIVE;2.16;2.64 +42159-4;Views;Find;Pt;Head>Sella turcica;Doc;XR;RAD;2;XR Sella turcica Views;XR ST Views;;ACTIVE;2.16;2.73 +42160-2;Views for shunt patency;Find;Pt;XXX;Doc;XR;RAD;2;XR Unspecified body region Views for shunt patency;XR Vs for shunt pat;;ACTIVE;2.16;2.66 +42161-0;Views^W DOBUTamine+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W dobutamine IV;NM Hrt Views W DBM+RNC IV;;ACTIVE;2.16;2.64 +42162-8;View AP && Views^W water soluble contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;Deprecated XR and RF Gastrointestinal tract upper AP and Views W water soluble contrast PO;Deprecated XR AP + UGI RF Views W H20 so;;DEPRECATED;2.16;2.61 +42163-6;Views + oblique;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views and Oblique;XR L-spine Views+Obl;;ACTIVE;2.16;2.64 +42164-4;Views + oblique;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Views and Oblique;XR C-spine Views+Obl;;ACTIVE;2.16;2.64 +42165-1;Views && view PA;Find;Pt;Chest>Ribs && Chest;Doc;XR;RAD;2;XR Ribs Views and Chest PA;XR Ribs Views + Chest PA;;ACTIVE;2.16;2.64 +42166-9;Views 2^at rest+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart 2 Views at rest and W Tl-201 IV;NM Hrt 2V Rest+W Tl201 IV;;ACTIVE;2.16;2.61 +42167-7;Views AP + lateral frog;Find;Pt;Pelvis & Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - bilateral AP and Lateral frog;XR Pelvis and Hip-Bl AP+Lat frog;;ACTIVE;2.16;2.64 +4216-8;Diamorphine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Diamorphine [Mass] of Dose;DAM Dose;;ACTIVE;1.0;2.69 +42168-5;Views diagnostic;Find;Pt;Breast.right;Doc;MG.FFD;RAD;2;FFD mammogram Breast - right Diagnostic;FFDM Brst-R Dx;;DISCOURAGED;2.16;2.61 +42169-3;Views diagnostic;Find;Pt;Breast.left;Doc;MG.FFD;RAD;2;FFD mammogram Breast - left Diagnostic;FFDM Brst-L Dx;;DISCOURAGED;2.16;2.61 +42170-1;Views for lymphoma^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for lymphoma;NM WB Views for lymphoma W RNC IV;;ACTIVE;2.16;2.64 +42171-9;Views for tumor^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for tumor;NM Whole body Views for tumor W RNC IV;;ACTIVE;2.16;2.64 +42172-7;Views portable;Find;Pt;Tibia.left+Fibula.left;Nar;XR;RAD;2;Deprecated Tibia Left & Fibula Left X-ray;Deprecated Tib+Fib-L XR port;;DEPRECATED;2.16;2.36 +42173-5;Views portable;Find;Pt;Tibia.right+Fibula.right;Nar;XR;RAD;2;Deprecated Tibia Right & Fibula Right X-ray;Deprecated Tib+Fib-R XR port;;DEPRECATED;2.16;2.36 +42174-3;Views screening;Find;Pt;Breast.bilateral;Doc;MG.FFD;RAD;2;FFD mammogram Breast - bilateral Screening;FFDM Brst-Bl screening;;DISCOURAGED;2.16;2.61 +42175-0;Views^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views;NM Whole body Views W RNC IV;;ACTIVE;2.16;2.64 +4217-6;diazePAM;Mass;Pt;Dose;Qn;;DRUGDOSE;1;diazePAM [Mass] of Dose;diazePAM Dose;;ACTIVE;1.0;2.21 +42176-8;1,3 beta glucan;MCnc;Pt;Ser;Qn;;MICRO;1;1,3 beta glucan [Mass/volume] in Serum;1,3 beta glucan Ser-mCnc;;ACTIVE;2.16;2.73 +42177-6;Fc epsilon RI Ab;PrThr;Pt;Ser;Ord;;SERO;1;Fc epsilon RI Ab [Presence] in Serum;Fc epsilon RI Ab Ser Ql;;ACTIVE;2.16;2.73 +42178-4;Lipoprotein.X;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Lipoprotein.X [Presence] in Serum or Plasma;Lp-X SerPl Ql;;ACTIVE;2.16;2.73 +42179-2;PLP1 gene duplication;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PLP1 gene duplication [Presence] in Blood or Tissue by Molecular genetics method;PLP1 gene Dp Bld/T Ql;;ACTIVE;2.16;2.21 +421-8;Polymyxin B;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Polymyxin B [Susceptibility] by Disk diffusion (KB);Polymyxin B Islt KB;;ACTIVE;1.0;2.73 +42180-0;C peptide^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --fasting;C peptide p fast SerPl-sCnc;;ACTIVE;2.16;2.70 +42181-8;Myocardium Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Myocardium Ab [Presence] in Serum by Immunofluorescence;Myocardium Ab Ser Ql IF;;ACTIVE;2.16;2.73 +42182-6;Gossypol.bound;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Gossypol bound [Mass/volume] in Specimen;Gossypol bound Spec-mCnc;;ACTIVE;2.16;2.69 +42183-4;Gossypol.negative isomer;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Gossypol negative isomer [Mass/volume] in Specimen;Gossypol (-) Spec-mCnc;;ACTIVE;2.16;2.69 +4218-4;Dibenzepin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dibenzepin [Mass] of Dose;Dibenzepin Dose;;ACTIVE;1.0;2.69 +42184-2;Gossypol.positive isomer;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Gossypol posiitve isomer [Mass/volume] in Specimen;Gossypol (+) Spec-mCnc;;ACTIVE;2.16;2.69 +42185-9;Number of specimens obtained;Num;Pt;XXX;Qn;;SPEC;1;Number of specimens obtained;# Spec obtained;;ACTIVE;2.16;2.69 +42186-7;Number of specimens received;Num;Pt;XXX;Qn;;SPEC;1;Number of specimens received;# Spec Recd;;ACTIVE;2.16;2.73 +42187-5;Number of specimens tested;Num;Pt;XXX;Qn;;SPEC;1;Number of specimens tested;# Spec Test;;ACTIVE;2.16;2.73 +42188-3;Cells.CD3+CD16+CD56+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD16+CD56+ cells [#/volume] in Blood;CD3+CD16+CD56+ Cells # Bld;;ACTIVE;2.16;2.73 +42189-1;Cells.CD3+CD16+CD56+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD16+CD56+ cells/100 cells in Blood;CD3+CD16+CD56+ Cells NFr Bld;;ACTIVE;2.16;2.73 +42190-9;Shigella sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Shigella sp DNA [Identifier] in Unspecified specimen by Probe and target amplification method;Deprecated Shigella DNA XXX PCR;;DEPRECATED;2.16;2.69 +42191-7;Hepatitis A & B & C 7a panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis A and B and C 7a panel - Serum;Hepatitis A+B+C 7a Pnl Ser;;ACTIVE;2.16;2.73 +4219-2;Dibucaine nbr;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Dibucaine nbr;Deprecated Dibucaine # Dose;;DEPRECATED;1.0;2.69 +42192-5;Nidus;PrThr;Pt;Calculus;Ord;;PATH;1;Nidus [Presence] in Stone;Nidus Stone Ql;;ACTIVE;2.16;2.73 +42193-3;Cells.CD3/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3 cells/100 cells in Cerebral spinal fluid;CD3 Cells NFr CSF;;ACTIVE;2.16;2.34 +42194-1;Cells.CD4/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;Deprecated CD4 cells/100 cells in Cerebral spinal fluid;Deprecated CD4 Cells NFr CSF;;DEPRECATED;2.16;2.36 +42195-8;Cells.CD8/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;Deprecated CD8 cells/100 cells in Cerebral spinal fluid;Deprecated CD8 Cells NFr CSF;;DEPRECATED;2.16;2.36 +42196-6;Centromere Ab;Titr;Pt;Ser;Qn;;SERO;1;Centromere Ab [Titer] in Serum;Centromere Ab Titr Ser;;ACTIVE;2.16;2.19 +42197-4;Centromere Ab;Titr;Pt;Body fld;Qn;;SERO;1;Centromere Ab [Titer] in Body fluid;Centromere Ab Titr Fld;;ACTIVE;2.16;2.19 +42198-2;Curvularia specifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Curvularia specifera IgE Ab [Units/volume] in Serum;C specifera IgE Qn;;ACTIVE;2.16;2.73 +42199-0;Soluble liver Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Soluble liver Ab [Presence] in Serum by Immunoassay;Soluble liver Ab Ser Ql IA;;ACTIVE;2.16;2.73 +42-2;Azlocillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Azlocillin [Susceptibility] by Serum bactericidal titer;Azlocillin Titr SBT;;ACTIVE;1.0;2.32 +4220-0;Dichlorphenamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dichlorphenamide [Mass] of Dose;Dichlorphenamide Dose;;ACTIVE;1.0;2.69 +42200-6;DNA double strand Ab;ACnc;Pt;Ser;Qn;RIA;SERO;1;DNA double strand Ab [Units/volume] in Serum by Radioimmunoassay (RIA);dsDNA Ab Ser RIA-aCnc;;ACTIVE;2.16;2.73 +42201-4;DNA single strand Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;DNA single strand IgG Ab [Units/volume] in Serum by Immunoassay;ssDNA IgG Ser IA-aCnc;;ACTIVE;2.16;2.73 +42202-2;GALOP Ab.IgM;Titr;Pt;Ser/Plas;Qn;;SERO;1;GALOP IgM Ab [Titer] in Serum or Plasma;GALOP IgM Titr SerPl;;ACTIVE;2.16;2.73 +42203-0;Ganglioside GM1 Ab;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 Ab [Titer] in Serum;GM1 Gangl Ab Titr Ser;;ACTIVE;2.16;2.32 +42204-8;Hairy cells/100 leukocytes;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Hairy cells/100 leukocytes in Bone marrow;Hairy Cells/leuk NFr Mar;;ACTIVE;2.16;2.50 +42205-5;Human antimouse Ab.IgG;MCnc;Pt;Ser;Qn;;SERO;1;Human antimouse IgG Ab [Mass/volume] in Serum;Human Antimouse IgG Ser-mCnc;;ACTIVE;2.16;2.70 +42206-3;IgA.CSF/IgA.serum;RelRto;Pt;Ser+CSF;Qn;;CHEM;1;IgA in CSF/IgA in serum;IgA CSF/SerPl;;ACTIVE;2.16;2.44 +42207-1;IgG.CSF/IgG.serum;RelRto;Pt;Ser+CSF;Qn;;CHEM;1;IgG in CSF/IgG in serum;IgG CSF/SerPl;;ACTIVE;2.16;2.73 +42208-9;IgM.CSF/IgM.serum;RelRto;Pt;Ser+CSF;Qn;;CHEM;1;IgM in CSF/IgM in serum;IgM CSF/SerPl;;ACTIVE;2.16;2.44 +42209-7;Microscopic observation;Prid;Pt;CSF;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by Cyto stain;Cyto CSF;;ACTIVE;2.16;2.19 +42210-5;Microscopic observation;Prid;Pt;Bronchial;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Bronchial specimen by Cyto stain;Cyto Bronch;;ACTIVE;2.16;2.73 +42211-3;Myelin associated glycoprotein-sulfated glucuronic paragloboside Ab;Titr;Pt;Ser;Qn;;SERO;1;Myelin associated glycoprotein/Sulfated glucuronic paragloboside Ab [Titer] in Serum;MAG/SGPG Ab Titr Ser;;ACTIVE;2.16;2.40 +42212-1;Nuclear Ab pattern.nucleolar;Titr;Pt;Body fld;Qn;;SERO;1;Nucleolar nuclear Ab pattern [Titer] in Body fluid;ANA nucleolar Titr Fld;;ACTIVE;2.16;2.58 +42213-9;Nuclear Ab pattern.smooth nuclear envelope;Titr;Pt;Body fld;Qn;;SERO;1;Smooth nuclear envelope nuclear Ab pattern [Titer] in Body fluid;ANA smooth nucl env Titr Fld;;ACTIVE;2.16;2.70 +42214-7;Nuclear Ab pattern.speckled;Titr;Pt;Body fld;Qn;;SERO;1;Speckled nuclear Ab pattern [Titer] in Body fluid;ANA Speckled Titr Fld;;ACTIVE;2.16;2.73 +42215-4;Erythrocytes.nucleated/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes/100 cells in Bone marrow by Manual count;nRBC/total cells NFr Mar Manual;;ACTIVE;2.16;2.40 +42216-2;Referral lab name;ID;Pt;Referral lab test;Nar;;MISC;1;Referral lab name [Identifier];Ref Lab Name;;ACTIVE;2.16;2.73 +42217-0;Striated muscle Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Striated muscle IgG Ab [Titer] in Serum;Stria Mus IgG Titr Ser;;ACTIVE;2.16;2.73 +4221-8;Digitoxin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Digitoxin [Mass] of Dose;Digitoxin Dose;;ACTIVE;1.0;2.69 +42218-8;Sulfatide Ab.IgG & Ab.IgM panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Sulfatide IgG and IgM panel - Serum;Sulfatide IgG+IgM Pnl Ser;;ACTIVE;2.16;2.42 +42219-6;Chromium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chromium [Moles/volume] in Urine;Chromium Ur-sCnc;;ACTIVE;2.16;2.70 +42220-4;Chromium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Chromium/Creatinine [Molar ratio] in Urine;Chromium/Creat Ur-sRto;;ACTIVE;2.16;2.70 +42221-2;Manganese;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Manganese [Moles/volume] in Urine;Manganese Ur-sCnc;;ACTIVE;2.16;2.70 +42222-0;Manganese;SRat;24H;Urine;Qn;;DRUG/TOX;1;Manganese [Moles/time] in 24 hour Urine;Manganese 24h Ur-sRate;;ACTIVE;2.16;2.70 +42223-8;Manganese/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Manganese/Creatinine [Molar ratio] in Urine;Manganese/Creat Ur-sRto;;ACTIVE;2.16;2.70 +42224-6;Thallium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Thallium [Moles/time] in 24 hour Urine;Thallium 24h Ur-sRate;;ACTIVE;2.16;2.70 +42225-3;Thallium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thallium [Moles/volume] in Urine;Thallium Ur-sCnc;;ACTIVE;2.16;2.70 +4222-6;Digoxin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Digoxin [Mass] of Dose;Digoxin Dose;;ACTIVE;1.0;2.73 +42226-1;Thallium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Thallium/Creatinine [Molar ratio] in Urine;Thallium/Creat Ur-sRto;;ACTIVE;2.16;2.70 +42227-9;Drug abuse and dependence section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Drug abuse and dependence section;FDA insert Drug abuse/dependence;;ACTIVE;2.16;2.34 +42228-7;Pregnancy section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Pregnancy section;FDA insert Pregnancy;;ACTIVE;2.16;2.34 +42229-5;SPL unclassified section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Structured patient labelling unclassified section;FDA insert SPL unclassified;;ACTIVE;2.16;2.34 +42230-3;SPL patient package insert section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Structured product laballing patient package insert section;FDA insert SPL patient pkg insert;;ACTIVE;2.16;2.34 +42231-1;SPL medguide section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Structured product labelling medguide section;FDA insert SPL medguide;;ACTIVE;2.16;2.34 +42232-9;Precautions section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Precautions section;FDA insert Precautions;;ACTIVE;2.16;2.34 +42233-7;Acetylcholine receptor ganglionic neuronal Ab;SCnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor ganglionic neuronal Ab [Moles/volume] in Serum;nAChR Ab Ser-sCnc;;ACTIVE;2.16;2.73 +4223-4;HYDROmorphone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;HYDROmorphone [Mass] of Dose;HYDROmorphone Dose;;ACTIVE;1.0;2.69 +42234-5;Alpha subunit.free;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha subunit free [Units/volume] in Serum or Plasma;Alpha subunit free SerPl-aCnc;;ACTIVE;2.16;2.70 +42235-2;Benzodiazepine metabolites;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Benzodiazepine metabolites [Presence] in Urine by Screen method;Benzodiaz metab Ur Ql Scn;;ACTIVE;2.16;2.73 +42236-0;Borrelia burgdorferi DNA;PrThr;Pt;^Tick;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Tick by NAA with probe detection;B burgdor DNA Tick Ql NAA+probe;;ACTIVE;2.16;2.73 +42237-8;Borrelia burgdorferi 18kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 18kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor18kD IgG Snv Ql IB;;ACTIVE;2.16;2.73 +42238-6;Borrelia burgdorferi 23kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD Ab [Presence] in Serum by Immunoblot;B burgdor23kD Ab Ser Ql IB;;ACTIVE;2.16;2.73 +42239-4;Borrelia burgdorferi 39kD Ab.IgG;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD IgG Ab [Presence] in Synovial fluid by Immunoblot;B burgdor39kD IgG Snv Ql IB;;ACTIVE;2.16;2.73 +42240-2;CHD7 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CHD7 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CHD7 gene Mut Anl Bld/T;;ACTIVE;2.16;2.66 +42241-0;Cocaine+Benzoylecgonine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Cocaine+Benzoylecgonine [Presence] in Urine by Screen method;Cocaine+BZE Ur Ql Scn;;ACTIVE;2.16;2.73 +4224-2;diphenhydrAMINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;diphenhydrAMINE [Mass] of Dose;Diphenhy Dose;;ACTIVE;1.0;2.69 +42242-8;Ethanol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Ethanol [Presence] in Urine by Screen method;Ethanol Ur Ql Scn;;ACTIVE;2.16;2.73 +42243-6;Hemoglobin;MCnc;Pt;Bld;Qn;HPLC;HEM/BC;1;Deprecated Hemoglobin [Mass/volume] in Blood;Deprecated Hgb Bld HPLC-mCnc;;DEPRECATED;2.16;2.36 +42244-4;Hemoglobin A/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin A/Hemoglobin.total in Blood by HPLC;Hgb A MFr Bld HPLC;;ACTIVE;2.16;2.73 +42245-1;Hemoglobin A2/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin A2/Hemoglobin.total in Blood by HPLC;Hgb A2 MFr Bld HPLC;;ACTIVE;2.16;2.73 +42246-9;Hemoglobin F/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin F/Hemoglobin.total in Blood by HPLC;Hgb F MFr Bld HPLC;;ACTIVE;2.16;2.73 +42247-7;Hemoglobin pattern;Imp;Pt;Bld;Nar;HPLC;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by HPLC Narrative;Hgb Fract Bld HPLC-Imp;;ACTIVE;2.16;2.73 +42248-5;Hemoglobin.other/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin.other/Hemoglobin.total in Blood by HPLC;Hgb Other MFr Bld HPLC;;ACTIVE;2.16;2.73 +42249-3;levETIRAcetam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;levETIRAcetam [Presence] in Urine by Screen method;levETIRAcetam Ur Ql Scn;;ACTIVE;2.16;2.73 +42250-1;Lymphocytes.variant/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Variant lymphocytes/100 leukocytes in Blood by Automated count;Variant Lymphs/leuk NFr Bld Auto;;ACTIVE;2.16;2.73 +42251-9;Methadone+Metabolite;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methadone+Metabolite [Presence] in Urine by Screen method;Methadone+metab Ur Ql Scn;;ACTIVE;2.16;2.73 +42252-7;Methaqualone+Metabolite;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methaqualone+Metabolite [Presence] in Urine by Screen method;Methaqualone+metab Ur Ql Scn;;ACTIVE;2.16;2.73 +42253-5;Methylenedioxyamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Urine;MDA Ur Ql;;ACTIVE;2.16;2.73 +42254-3;Nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Nuclear Ab [Presence] in Serum by Immunofluorescence;ANA Ser Ql IF;;ACTIVE;2.16;2.73 +42255-0;Salmonella & Shigella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Salmonella and Shigella sp identified in Specimen by Organism specific culture;Salm + Shig Spec Cult;;ACTIVE;2.16;2.69 +42256-8;Shigella boydii Ag;PrThr;Pt;Isolate;Ord;;MICRO;1;Shigella boydii Ag [Presence] in Isolate;S boydii Ag Islt Ql;;ACTIVE;2.16;2.56 +42257-6;Shigella dysenteriae Ag;PrThr;Pt;Isolate;Ord;;MICRO;1;Shigella dysenteriae Ag [Presence] in Isolate;S dysenter Ag Islt Ql;;ACTIVE;2.16;2.56 +42258-4;Shigella flexneri Ag;PrThr;Pt;Isolate;Ord;;MICRO;1;Shigella flexneri Ag [Presence] in Isolate;S flexneri Ag Islt Ql;;ACTIVE;2.16;2.56 +4225-9;Phenytoin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenytoin [Mass] of Dose;Phenytoin Dose;;ACTIVE;1.0;2.73 +42259-2;Shigella sonnei Ag;PrThr;Pt;Isolate;Ord;;MICRO;1;Shigella sonnei Ag [Presence] in Isolate;S sonnei Ag Islt Ql;;ACTIVE;2.16;2.56 +422-6;Polymyxin B;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Polymyxin B [Susceptibility] by Serum bactericidal titer;Polymyxin B Titr SBT;;ACTIVE;1.0;2.32 +42260-0;Guidance for percutaneous biopsy^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for biopsy of Unspecified body region-- W contrast IV;CT Guided Bx--W contr IV;;ACTIVE;2.16;2.64 +42261-8;Views for blood flow^W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views for blood flow;NM Kidney Vs bld flow W RNC IV;;ACTIVE;2.16;2.64 +42262-6;Views for blood flow^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views for blood flow;NM Liver Vs bld flow W RNC IV;;ACTIVE;2.16;2.64 +42263-4;Views for blood flow^W radionuclide IV;Find;Pt;Abdomen>Spleen;Doc;NM;RAD;2;NM Spleen Views for blood flow;NM Spleen Vs bld flow W RNC IV;;ACTIVE;2.16;2.64 +42264-2;Views^W non-ionic contrast IT;Find;Pt;Spine.lumbar;Nar;;RAD;2;Deprecated Spine Lumbar X-ray fluoroscopy W contrast IT;Deprecated L-spine W Non-ionic contr IT;;DEPRECATED;2.16;2.36 +42265-9;Guidance for superficial biopsy;Find;Pt;XXX>Bone;Doc;CT;RAD;2;CT Guidance for superficial biopsy of Bone;CT Guided Bone Super Bx;;ACTIVE;2.16;2.64 +42266-7;Guidance for superficial biopsy.needle;Find;Pt;XXX>Bone;Doc;CT;RAD;2;Deprecated CT Guidance for superficial biopsy.needle of Bone;Deprecated CT Bone Bx super need guide;;DEPRECATED;2.16;2.63 +4226-7;Diphenylhydramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated diphenhydrAMINE [Mass] of Dose;Deprecated Diphenylhydramine Dose;;DEPRECATED;1.0;2.69 +42267-5;Guidance for biopsy.needle;Find;Pt;XXX>Lymph node;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Lymph node;Deprecated CT LN Bx needle guide;;DEPRECATED;2.16;2.63 +42268-3;Multisection^WO & W contrast IV;Find;Pt;Extremity;Doc;CT;RAD;2;CT Extremity WO and W contrast IV;CT Extr WO+W contr IV;;ACTIVE;2.16;2.61 +42269-1;Views;Find;Pt;Chest+Abdomen;Doc;XR;RAD;2;XR Chest and Abdomen Views;XR Chest+Abd Views;;ACTIVE;2.16;2.64 +42270-9;Multisection^W flexion + W extension;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine W flexion and W extension;MR C-spine W FE;;ACTIVE;2.16;2.61 +42271-7;Views+views uptake^W I-123 IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views and Views uptake W I-123 IV;NM Thyroid Views+views uptake W I-123 IV;;ACTIVE;2.16;2.64 +42272-5;Views PA + lateral;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest PA and Lateral;XR Chest PA+Lat;;ACTIVE;2.16;2.61 +42273-3;Views 6;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral 6 Views;XR Ankle-Bl 6V;;ACTIVE;2.16;2.61 +42274-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen and Pelvis WO and W contrast IV;CT Abd+Pelvis WO+W contr IV;;ACTIVE;2.16;2.73 +4227-5;Dipipanone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dipipanone [Mass] of Dose;Dipipanone Dose;;ACTIVE;1.0;2.69 +42275-8;Multisection^W contrast IV;Find;Pt;Chest+Abdomen;Doc;CT;RAD;2;CT Chest and Abdomen W contrast IV;CT Chest+Abd W contr IV;;ACTIVE;2.16;2.61 +42276-6;Multisection^WO contrast;Find;Pt;Chest+Abdomen;Doc;CT;RAD;2;CT Chest and Abdomen WO contrast;CT Chest+Abd WO contr;;ACTIVE;2.16;2.61 +42277-4;Multisection^WO & W contrast IV;Find;Pt;Chest+Abdomen;Doc;CT;RAD;2;CT Chest and Abdomen WO and W contrast IV;CT Chest+Abd WO+W contr IV;;ACTIVE;2.16;2.61 +42278-2;Multisection^WO contrast;Find;Pt;Extremity;Doc;CT;RAD;2;CT Extremity WO contrast;CT Extr WO contr;;ACTIVE;2.16;2.61 +42279-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for biopsy of Kidney;CT Guided Kidney Bx;;ACTIVE;2.16;2.64 +42280-8;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen+Pelvis>Appendix;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Appendix;CT Guided Appendix Absc drain+cath place;;ACTIVE;2.16;2.66 +42281-6;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Chest;CT Guided Chest Absc drain+cath place;;ACTIVE;2.16;2.66 +42282-4;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Liver;CT Guided Liver Absc drain+cath place;;ACTIVE;2.16;2.66 +4228-3;Disopyramide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Disopyramide [Mass] of Dose;Disopyramide Dose;;ACTIVE;1.0;2.69 +42283-2;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Pancreas;CT Guided Pancreas Drain+cath place;;ACTIVE;2.16;2.66 +42284-0;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of chest tube of Pleural space;CT Guided Pl space Absc drn+CT place;;ACTIVE;2.16;2.66 +42285-7;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Kidney;CT Guided Kidney Absc drain+cath place;;ACTIVE;2.16;2.66 +42286-5;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Pelvis;CT Guided Pelvis Absc drain+cath place;;ACTIVE;2.16;2.66 +42287-3;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Retroperitoneum;CT Guide Retroperitoneum Drn+cath place;;ACTIVE;2.16;2.66 +42288-1;Guidance for biopsy.needle;Find;Pt;Abdomen;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Abdomen;Deprecated CT Abd Bx needle guide;;DEPRECATED;2.16;2.63 +42289-9;Guidance for biopsy.needle;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Kidney;Deprecated CT Kidney Bx needle guide;;DEPRECATED;2.16;2.63 +42290-7;Guidance for biopsy.needle;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Pancreas;Deprecated CT Pancreas Bx needle guide;;DEPRECATED;2.16;2.63 +4229-1;Disulfiram;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Disulfiram [Mass] of Dose;Disulfiram Dose;;ACTIVE;1.0;2.69 +42291-5;Multisection^WO contrast;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Retroperitoneum WO contrast;CT Retroperitoneum WO contr;;ACTIVE;2.16;2.61 +42292-3;Multisection for tumor^W Tl-201 IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body for tumor W Tl-201 IV;SPECT Whole body for Tumor W Tl-201 IV;;ACTIVE;2.16;2.64 +42293-1;Multisection^WO contrast;Find;Pt;Head>Head vessels;Doc;CT.angio;RAD;2;CTA Head vessels WO contrast;CTA Head ves WO contr;;ACTIVE;2.16;2.61 +42294-9;Multisection^W contrast IV;Find;Pt;Pelvis>Pelvis vessels;Doc;CT.angio;RAD;2;CTA Pelvis vessels W contrast IV;CTA Pelvis ves W contr IV;;ACTIVE;2.16;2.61 +42295-6;Multisection^W contrast IV;Find;Pt;Upper extremity>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels W contrast IV;CTA UE ves W contr IV;;ACTIVE;2.16;2.61 +42296-4;Guidance for localization;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for localization of Breast - left;MG Guided Brst-L Loc;;ACTIVE;2.16;2.64 +42297-2;Guidance for localization;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for localization of Breast - right;MG Guided Brst-R Loc;;ACTIVE;2.16;2.64 +42298-0;Multisection^WO & W contrast IV;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region WO and W contrast IV;MR WO+W contr IV;;ACTIVE;2.16;2.69 +42299-8;Multisection^WO & W contrast IV;Find;Pt;Chest>Clavicle;Doc;MR;RAD;2;MR Clavicle WO and W contrast IV;MR Clavicle WO+W contr IV;;ACTIVE;2.16;2.61 +42300-4;Multisection;Find;Pt;Neck>Thyroid gland;Doc;MR;RAD;2;MR Thyroid gland;MR Thyroid;;ACTIVE;2.16;2.61 +42301-2;Multisection;Find;Pt;Pelvis>Uterus;Doc;MR;RAD;2;MR Uterus;MR Uterus;;ACTIVE;2.16;2.61 +42302-0;Multisection^WO contrast;Find;Pt;Chest>Clavicle;Doc;MR;RAD;2;MR Clavicle WO contrast;MR Clavicle WO contr;;ACTIVE;2.16;2.61 +42303-8;Multisection;Find;Pt;Head>Orbit+Face;Doc;MR;RAD;2;MR Orbit and Face;MR Orbit+Face;;ACTIVE;2.16;2.61 +42304-6;Multisection;Find;Pt;Head>Head vessels & Neck>Neck vessels;Doc;MR.angio;RAD;2;MRA Head vessels and Neck vessels;MRA Head+Neck Ves;;ACTIVE;2.16;2.61 +42305-3;Views for tumor^W Tl-201 IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for tumor W Tl-201 IV;NM WB Views for tumor W Tl-201 IV;;ACTIVE;2.16;2.64 +42306-1;Views gated+wall motion^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Wall motion;NM Hrt Gated+WM W RNC IV;;ACTIVE;2.16;2.61 +42307-9;Guidance for placement of infusion port;Find;Pt;Hepatic artery;Nar;Radnuc;RAD;2;Deprecated Scan Guidance for placement of infusion port in Hepatic artery;Deprecated Hep a RI Infusion port plac g;;DEPRECATED;2.16;2.34 +42308-7;Views for blood flow^W radionuclide IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;NM;RAD;2;NM Scrotum and testicle Views for blood flow;NM Scrotum+Test Vs bld flow W RNC IV;;ACTIVE;2.16;2.64 +4230-9;Doxepin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Doxepin [Mass] of Dose;Doxepin Dose;;ACTIVE;1.0;2.69 +42309-5;Views^at rest+W stress+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views at rest and W stress and W Tl-201 IV;NM Hrt Views Rest+stress+W Tl201 IV;;ACTIVE;2.16;2.64 +42310-3;Multisection^W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM.SPECT;RAD;2;SPECT Kidney;SPECT Kidney W RNC IV;;ACTIVE;2.16;2.61 +42311-1;Views for foreign body;Find;Pt;Head>Orbit.left;Doc;XR;RAD;2;XR Orbit - left Views for foreign body;XR Orbit-L Views for FB;;ACTIVE;2.16;2.64 +42312-9;Views for foreign body;Find;Pt;Head>Orbit.right;Doc;XR;RAD;2;XR Orbit - right Views for foreign body;XR Orbit-R Views for FB;;ACTIVE;2.16;2.64 +42313-7;View;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left Single view;XR Ribs-L 1V;;ACTIVE;2.16;2.64 +42314-5;View;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right Single view;XR Ribs-R 1V;;ACTIVE;2.16;2.64 +42315-2;APOE gene alleles e2 & e3 & e4;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APOE gene alleles e2 and e3 and e4 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;APOE allele e2+e3+e4 Bld/T;;ACTIVE;2.16;2.73 +42316-0;RHD gene allele;Geno;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;RHD gene allele [Genotype] in Amniotic fluid by Molecular genetics method Nominal;RHD allele Geno Amn;;ACTIVE;2.16;2.68 +4231-7;Doxylamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Doxylamine [Mass] of Dose;Doxylamine Dose;;ACTIVE;1.0;2.69 +42317-8;Foscarnet;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Foscarnet [Susceptibility] by Genotype method;Foscarnet Islt Genotyp;;ACTIVE;2.16;2.73 +42318-6;GALT gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GALT gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GALT gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +42319-4;Glucose-6-Phosphate dehydrogenase phenotype;Imp;Pt;RBC;Nom;;CHEM;1;Glucose-6-Phosphate dehydrogenase phenotype [Interpretation] in Red Blood Cells;G6PD Phenotyp RBC-Imp;;ACTIVE;2.16;2.26 +42320-2;Glutathione reductase phenotype;Imp;Pt;RBC;Nom;;CHEM;1;Glutathione reductase phenotype [Interpretation] in Red Blood Cells;GR Phenotyp RBC-Imp;;ACTIVE;2.16;2.26 +42321-0;HTT gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HTT gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HTT gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +42322-8;Hepatitis B virus S+pol gene;Prid;Pt;Ser/Plas;Nom;Probe.amp.tar;MICRO;1;Hepatitis B virus S+pol gene [Identifier] in Serum or Plasma by NAA with probe detection;HBV S+pol gene SerPl NAA+probe;;ACTIVE;2.16;2.63 +42323-6;HLA-DR Ag;Type;Pt;Tiss;Nom;;HLA;1;HLA-DR Ag [Type] in Tissue;HLA-DR Ag Tiss;;ACTIVE;2.16;2.22 +42324-4;I group phenotype;Prid;Pt;Bld;Nom;;BLDBK;1;I group phenotype [Identifier] in Blood;I Gp Phenotyp Bld;;ACTIVE;2.16;2.71 +4232-5;Dyphylline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dyphylline [Mass] of Dose;Dyphylline Dose;;ACTIVE;1.0;2.69 +42325-1;RHD gene allele & RHCE gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RHD and RHCE gene alleles [Genotype] in Blood or Tissue by Molecular genetics method Nominal;RHD + RHCE alleles Geno Bld/T;;ACTIVE;2.16;2.68 +42326-9;Drugs identified;Prid;Pt;Mmlk;Nom;Screen;DRUG/TOX;1;Drugs identified in Mother's milk by Screen method;Drugs Mother Milk Scn;;ACTIVE;2.16;2.17 +42327-7;Leukocytes;PrThr;Pt;Stool;Ord;Methylene blue stain;HEM/BC;1;Leukocytes [Presence] in Stool by Methylene blue stain;WBC Stl Ql MB Stn;;ACTIVE;2.16;2.73 +42328-5;Bordetella pertussis Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis IgA Ab [Units/volume] in Serum by Immunoassay;B pert IgA Ser IA-aCnc;;ACTIVE;2.16;2.73 +42329-3;Bordetella pertussis Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis IgM Ab [Units/volume] in Serum by Immunoassay;B pert IgM Ser IA-aCnc;;ACTIVE;2.16;2.73 +42330-1;Bordetella pertussis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis IgG Ab [Units/volume] in Serum by Immunoassay;B pert IgG Ser IA-aCnc;;ACTIVE;2.16;2.73 +42331-9;Nuclear Ab.IgG;ACnc;Pt;Ser;Qn;Flow cytometry;SERO;1;Nuclear IgG Ab [Units/volume] in Serum by Flow cytometry (FC);Nuclear IgG Ser FC-aCnc;;ACTIVE;2.16;2.73 +42332-7;Alpha-1-Fetoprotein.L3/Alpha-1-Fetoprotein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein L3/Alpha-1-fetoprotein.total in Serum or Plasma;AFP L3 MFr SerPl;;ACTIVE;2.16;2.73 +4233-3;Emetine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Emetine [Mass] of Dose;Emetine Dose;;ACTIVE;1.0;2.69 +42333-5;Guidance for percutaneous biopsy;Find;Pt;Chest>Pleura;Doc;US;RAD;2;US Guidance for biopsy of Chest Pleura;US Guided Chest Pleura Bx;;ACTIVE;2.16;2.64 +42334-3;Guidance for injection;Find;Pt;Chest>Internal thoracic artery.left;Doc;RF.angio;RAD;2;RFA Guidance for injection of Internal thoracic artery - left;RFA Guided IT a-L Inj;;ACTIVE;2.16;2.64 +42335-0;Views limited^W contrast IT;Find;Pt;Neck>Spine.cervical;Doc;RF;RAD;2;RF Cervical spine Limited Views W contrast IT;RF C-spine Views Ltd W contr IT;;ACTIVE;2.16;2.64 +42336-8;Cytomegalovirus Ag;Naric;Pt;XXX;Qn;;MICRO;1;Cytomegalovirus Ag [#/area] in Specimen;CMV Ag Spec-#/area;;ACTIVE;2.16;2.69 +42337-6;Herpes simplex virus 1 glycoprotein G Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 glycoprotein G IgG Ab [Units/volume] in Serum;HSV1 gG IgG Ser-aCnc;;ACTIVE;2.16;2.73 +42338-4;Herpes simplex virus 2 glycoprotein G Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 glycoprotein G IgG Ab [Units/volume] in Serum;HSV2 gG IgG Ser-aCnc;;ACTIVE;2.16;2.73 +42339-2;HIV 1 p24 Ag;MCnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 1 p24 Ag [Mass/volume] in Serum or Plasma by Immunoassay;HIV1 p24 Ag SerPl IA-mCnc;;ACTIVE;2.16;2.73 +423-4;Pyrazinamide;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Pyrazinamide [Susceptibility] by Minimum lethal concentration (MLC);PZA Islt MLC;;ACTIVE;1.0;2.19 +42340-0;HTLV I p42 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I p42 Ab [Presence] in Serum by Immunoblot;HTLV I p42 Ab Ser Ql IB;;ACTIVE;2.16;2.58 +4234-1;Encainide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Encainide [Mass] of Dose;Encainide Dose;;ACTIVE;1.0;2.69 +42341-8;Neisseria meningitidis serogroups A+w135 Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Neisseria meningitidis serogroups A+w135 Ag [Presence] in Body fluid;N men sg A+W135 Ag Fld Ql;;ACTIVE;2.16;2.64 +42342-6;Rickettsia (Proteus) Ab panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Rickettsia (Proteus) Ab panel - Serum;Ricket (proteus) Ab Pnl Ser;;ACTIVE;2.16;2.42 +42343-4;Toxoplasma gondii identified;Prid;Pt;XXX;Nom;XXX stain;MICRO;1;Toxoplasma gondii identified in Specimen by Other stain;T gondii Spec Other Stn;;ACTIVE;2.16;2.69 +42344-2;Discharge diet;Find;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Discharge diet (narrative);;;ACTIVE;2.16;2.27 +42345-9;Discharge functional status;Find;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Discharge functional status (narrative);;;ACTIVE;2.16;2.27 +42346-7;Medications on admission;Find;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Medications on admission (narrative);;;ACTIVE;2.16;2.27 +42347-5;Admission diagnosis;Find;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Admission diagnosis (narrative);;;ACTIVE;2.16;2.27 +42348-3;Advance directives;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Advance directives;Advance directives;;ACTIVE;2.16;2.67 +42349-1;Reason for referral;Find;Pt;^Patient;Nar;;ATTACH.CLINRPT;3;Reason for referral (narrative);;;ACTIVE;2.16;2.73 +42350-9;Cefepime+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefepime+Clavulanate [Susceptibility] by Disk diffusion (KB);Cefepime+Clav Islt KB;;ACTIVE;2.16;2.19 +42351-7;Cefepime+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefepime+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);Cefepime+Clav Islt MIC;;ACTIVE;2.16;2.19 +42352-5;cefTAZidime+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefTAZidime+Clavulanate [Susceptibility] by Gradient strip;cefTAZidime+Clav Islt Grad strip;;ACTIVE;2.16;2.56 +42353-3;Cefepime+Clavulanate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefepime+Clavulanate [Susceptibility];Cefepime+Clav Susc Islt;;ACTIVE;2.16;2.19 +42354-1;Tigecycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Tigecycline [Susceptibility] by Gradient strip;Tigecycline Islt Grad strip;;ACTIVE;2.16;2.56 +42355-8;Tigecycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tigecycline [Susceptibility] by Minimum inhibitory concentration (MIC);Tigecycline Islt MIC;;ACTIVE;2.16;2.73 +42356-6;Tigecycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tigecycline [Susceptibility] by Disk diffusion (KB);Tigecycline Islt KB;;ACTIVE;2.16;2.19 +42357-4;Tigecycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tigecycline [Susceptibility];Tigecycline Susc Islt;;ACTIVE;2.16;2.73 +4235-8;Enoxacin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Enoxacin [Mass] of Dose;Enoxacin Dose;;ACTIVE;1.0;2.73 +42358-2;HLA-B*57:01;PrThr;Pt;XXX;Ord;;HLA;1;HLA-B*57:01 [Presence] in Specimen;HLA-B*57:01 Spec Ql;;ACTIVE;2.16;2.73 +42359-0;Streptococcus pneumoniae 14 serotypes Ab.IgG panel B;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 14 serotypes IgG panel B [Mass/volume] - Serum;S pneum 14 serotypes IgG Pnl B Ser-mCnc;;ACTIVE;2.16;2.61 +42360-8;Streptococcus pneumoniae 14 serotypes Ab.IgG panel A;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 14 serotypes IgG panel A [Mass/volume] - Serum;S pneum 14 serotypes IgG Pnl A Ser-mCnc;;ACTIVE;2.16;2.73 +42361-6;Streptococcus pneumoniae 12 serotypes Ab.IgG panel;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 12 serotypes IgG panel [Mass/volume] - Serum;S pneum 12 serotypes IgG Pnl Ser-mCnc;;ACTIVE;2.16;2.67 +42362-4;Streptococcus pneumoniae 7 serotypes Ab.IgG panel B;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 7 serotypes IgG panel B [Mass/volume] - Serum;S pneum 7 serotypes IgG Pnl B Ser-mCnc;;ACTIVE;2.16;2.61 +42363-2;Streptococcus pneumoniae 7 serotypes Ab.IgG panel A;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 7 serotypes IgG panel A [Mass/volume] - Serum;S pneum 7 serotypes IgG Pnl A Ser-mCnc;;ACTIVE;2.16;2.61 +42364-0;Streptococcus pneumoniae 6 serotypes Ab.IgG panel;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 6 serotypes IgG panel [Mass/volume] - Serum;S pneum 6 serotypes IgG Pnl Ser-mCnc;;ACTIVE;2.16;2.73 +42365-7;Streptococcus pneumoniae 4 serotypes Ab.IgG panel;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 4 serotypes IgG panel [Mass/volume] - Serum;S pneum 4 serotypes IgG Pnl Ser-mCnc;;ACTIVE;2.16;2.61 +4236-6;ePHEDrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;ePHEDrine [Mass] of Dose;Ephedrin Dose;;ACTIVE;1.0;2.69 +42366-5;Streptococcus pneumoniae 23 serotypes Ab.IgG panel;MCnc;Pt;Ser;Qn;;PANEL.MICRO;1;Streptococcus pneumoniae 23 serotypes IgG panel [Mass/volume] - Serum;S pneum 23 serotypes IgG Pnl Ser-mCnc;;ACTIVE;2.16;2.73 +42367-3;Streptococcus pneumoniae Danish serotype 19B Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19B IgG Ab [Mass/volume] in Serum;S pneum Da 19B IgG Ser-mCnc;;ACTIVE;2.16;2.61 +42368-1;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Isolate by Agglutination;N men sg W135 Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42369-9;Neisseria meningitidis serogroup A Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Isolate by Agglutination;N men sg A Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42370-7;Neisseria meningitidis serogroup B Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Isolate by Agglutination;N men sg B Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42371-5;Neisseria meningitidis serogroup C Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Isolate by Agglutination;N men sg C Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42372-3;Neisseria meningitidis serogroup D Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup D Ag [Presence] in Isolate by Agglutination;N men sg D Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42373-1;Neisseria meningitidis serogroup X Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup X Ag [Presence] in Isolate by Agglutination;N men sg X Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +4237-4;Erythromycin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Erythromycin [Mass] of Dose;Erythromycin Dose;;ACTIVE;1.0;2.69 +42374-9;Neisseria meningitidis serogroup Y Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup Y Ag [Presence] in Isolate by Agglutination;N men sg Y Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42375-6;Neisseria meningitidis serogroup Z Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup Z Ag [Presence] in Isolate by Agglutination;N men sg Z Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42376-4;Neisseria meningitidis serogroup Z' Ag;PrThr;Pt;Isolate;Ord;Aggl;MICRO;1;Neisseria meningitidis serogroup Z' Ag [Presence] in Isolate by Agglutination;N men sg Z' Ag Islt Ql Aggl;;ACTIVE;2.16;2.64 +42377-2;Multisection^W Xe-133 IH+WO & W contrast IV;Find;Pt;Head;Doc;CT.perfusion;RAD;2;CT perfusion Head W Xe-133 IH+WO and W contrast IV;CT.perfusion Head W 133Xe IH+WO+W IV;;ACTIVE;2.16;2.61 +42378-0;View AP^W L-bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP W left bending;XR L-spine AP W L-bending;;ACTIVE;2.16;2.61 +42379-8;View AP^W R-bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP W right bending;XR L-spine AP W R-bending;;ACTIVE;2.16;2.61 +42380-6;Views AP + lateral^W standing;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left AP and Lateral W standing;XR Ankle-L AP+Lat W Stand;;ACTIVE;2.16;2.61 +42381-4;Views;Find;Pt;Chest>Ribs.lower.posterior.left;Doc;XR;RAD;2;XR Ribs lower posterior - left Views;XR Ribs lower post-L Views;;ACTIVE;2.16;2.64 +4238-2;Estazolam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Estazolam [Mass] of Dose;Estazolam Dose;;ACTIVE;1.0;2.69 +42382-2;Views lateral + Mortise + Broden^W manual stress;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Lateral and Mortise and Broden W manual stress;XR Ankle-L Lat+Mort+Broden W man stress;;ACTIVE;2.16;2.71 +42383-0;Views^W contrast PO+W contrast PO;Find;Pt;Abdomen>Gallbladder;Doc;XR;RAD;2;XR Gallbladder Views W contrast PO and W contrast PO;XR GB Views W contr PO+W contr PO;;DISCOURAGED;2.16;2.64 +42384-8;Views^W contrast intra multiple ducts;Find;Pt;Breast.duct;Nar;XR;RAD;2;Deprecated Breast duct X-ray W contrast intra multiple ducts;Deprecated Brst.duct XR W contr intra Dc;;DEPRECATED;2.16;2.34 +42385-5;Multisection;Find;Pt;Head>Brain+Pituitary+Sella turcica;Doc;MR;RAD;2;MR Brain and Pituitary and Sella turcica;MR Brain+Pituitary+ST;;ACTIVE;2.16;2.61 +42386-3;Multisection cine for CSF flow;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain cine for CSF flow;MR Brain Cine for CSF flow;;ACTIVE;2.16;2.61 +42387-1;Multisection cine for CSF flow;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region cine for CSF flow;MR Cine for CSF flow;;ACTIVE;2.16;2.64 +42388-9;Multisection endorectal;Find;Pt;Pelvis>Prostate;Doc;MR;RAD;2;MR Prostate Endorectal;MR Prostate Endorectal;;ACTIVE;2.16;2.61 +42389-7;Multisection endorectal;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis Endorectal;MR Pelvis Endorectal;;ACTIVE;2.16;2.61 +4239-0;Etafedrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Etafedrine [Mass] of Dose;Etafedrine Dose;;ACTIVE;1.0;2.69 +42390-5;Multisection endovaginal;Find;Pt;XXX;Doc;MR;RAD;2;MR Endovaginal;MR Endovaginal;;ACTIVE;2.16;2.58 +42391-3;Multisection^W contrast IV;Find;Pt;Head>Brain+Pituitary+Sella turcica;Doc;MR;RAD;2;MR Brain and Pituitary and Sella turcica W contrast IV;MR Brain+Pituitary+ST W contr IV;;ACTIVE;2.16;2.61 +42392-1;Multisection^WO & W contrast IV;Find;Pt;Head>Brain+Pituitary+Sella turcica;Doc;MR;RAD;2;MR Brain and Pituitary and Sella turcica WO and W contrast IV;MR Brain+Pituitary+ST WO+W contr IV;;ACTIVE;2.16;2.61 +42393-9;Multisection^WO contrast;Find;Pt;Head>Brain+Pituitary+Sella turcica;Doc;MR;RAD;2;MR Brain and Pituitary and Sella turcica WO contrast;MR Brain+Pituitary+ST WO contr;;ACTIVE;2.16;2.61 +42394-7;Multisection^W Xe-133 IH;Find;Pt;Chest>Pulmonary system;Doc;CT;RAD;2;CT Pulmonary system W Xe-133 IH;CT Pulm system W 133Xe IH;;ACTIVE;2.16;2.61 +42395-4;View axial;Find;Pt;Lower extremity.bilateral>Foot.sesamoid bones;Doc;XR;RAD;2;XR Foot sesamoid bones - bilateral Axial;XR Ft.Sesamoids-Bl Axial;;ACTIVE;2.16;2.61 +42396-2;View axial;Find;Pt;Lower extremity.left>Foot.sesamoid bones;Doc;XR;RAD;2;XR Foot sesamoid bones - left Axial;XR Ft.Sesamoids-L Axial;;ACTIVE;2.16;2.61 +42397-0;Views frontal;Find;Pt;Chest;Doc;XR.stereoscopic;RAD;2;XR.stereoscopic Chest Frontal Views;XR.stereo Chest Views Frontal;;ACTIVE;2.16;2.64 +42398-8;(View oblique) + (Views AP + lateral^W standing);Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot Oblique and (AP and Lateral W standing);XR Foot Obl+(AP+Lat Stand);;ACTIVE;2.16;2.61 +42399-6;Views;Find;Pt;Lower extremity>Foot.sesamoid bones;Doc;XR;RAD;2;XR Foot sesamoid bones Views;XR Ft.Sesamoids Views;;ACTIVE;2.16;2.64 +42400-2;Views;Find;Pt;Lower extremity.bilateral>Foot.sesamoid bones;Doc;XR;RAD;2;XR Foot sesamoid bones - bilateral Views;XR Ft.Sesamoids-Bl Views;;ACTIVE;2.16;2.64 +42401-0;(Views AP^W R-bending + W L-bending + WO bending) + (view lateral);Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Lumbar (AP W R-bending and W L-bending and WO bending) and Lateral;XR L-spine (AP W+WO R+L-bending)+Lat;;ACTIVE;2.16;2.61 +42402-8;Views post mortem;Find;Pt;XXX;Doc;XR;RAD;2;XR Unspecified body region Post morten Views;XR Views PM;;ACTIVE;2.16;2.64 +42403-6;Views AP^W R-bending + W L-bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views AP W right bending and W left bending;XR L-spine Views AP W R+L-bending;;ACTIVE;2.16;2.64 +42404-4;Views AP + lateral for measurement;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left AP and Lateral Views for measurement;XR Hip-L AP+Lat for Measure;;ACTIVE;2.16;2.64 +42405-1;(Views AP^W standing) + (view lateral^W extension);Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee (AP W standing) and (Lateral W extension);XR Knee (AP stand)+(Lat ext);;ACTIVE;2.16;2.64 +42406-9;Views AP^WO & W L-bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views AP W and WO left bending;XR L-spine Views AP WO+W L-bending;;ACTIVE;2.16;2.64 +42407-7;Views AP^WO & W R-bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views AP W and WO right bending;XR L-spine Views AP WO+W R-bending;;ACTIVE;2.16;2.64 +4240-8;Etamivan;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Etamivan [Mass] of Dose;Etamivan Dose;;ACTIVE;1.0;2.69 +42408-5;Views AP^W R-bending + W L-bending + WO bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views AP W right bending and W left bending and WO bending;XR L-spine Views AP W+WO R+L-bending;;ACTIVE;2.16;2.64 +42409-3;Views AP + lateral;Find;Pt;Lower extremity>Foot.sesamoid bones;Doc;XR;RAD;2;XR Foot sesamoid bones AP and Lateral;XR Ft.Sesamoids AP+Lat;;ACTIVE;2.16;2.61 +42410-1;Views AP + lateral + oblique + spot^W standing;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine AP and Lateral and Oblique and Spot W standing;XR L-spine AP+Lat+Obl+Spot W Stand;;ACTIVE;2.16;2.61 +42411-9;(Views AP^W R-bending + W L-bending) + (view lateral^W flexion + W extension);Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine (AP^W R-bending and W L-bending) and (Lateral^W flexion and W extension);XR L-spine (AP W R+L-bending)+(Lat W FE);;ACTIVE;2.16;2.61 +42412-7;Views 90 degree abduction;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 90 degree abduction Views;XR Should-L Views 90 Deg Abduction;;ACTIVE;2.16;2.64 +42413-5;Views^W R-bending + W L-bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Views W right bending and W left bending;XR L-spine Views W R+L-bending;;ACTIVE;2.16;2.64 +42414-3;Views R-oblique + L-oblique^W nipple markers;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest Right oblique and Left oblique W nipple markers;XR Chest R-Obl+L-Obl W nipple markers;;ACTIVE;2.16;2.61 +42415-0;Views^post wire placement;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Views Post Wire Placement;MG Brst-Bl Views p wire place;;ACTIVE;2.16;2.64 +4241-6;Ethacrynate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ethacrynate [Mass] of Dose;Ethacrynate Dose;;ACTIVE;1.0;2.69 +42416-8;Views^post wire placement;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Views Post Wire Placement;MG Brst-L Views p wire place;;ACTIVE;2.16;2.64 +42417-6;(Views AP + lateral + oblique) + (view^W manual stress);Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral AP and Lateral and Oblique and (View W manual stress);XR Ankle-Bl AP+Lat+Obl+W Stress;;ACTIVE;2.16;2.61 +42418-4;(Views AP + lateral + oblique) + (view^W manual stress);Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left AP and Lateral and Oblique and (View W manual stress);XR Ankle-L AP+Lat+Obl+W Stress;;ACTIVE;2.16;2.61 +42419-2;View;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Single view;XR Wrist-Bl 1V;;ACTIVE;2.16;2.64 +424-2;Pyrazinamide;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Pyrazinamide [Susceptibility] by Minimum inhibitory concentration (MIC);PZA Islt MIC;;ACTIVE;1.0;2.73 +42420-0;View AP^W standing;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis AP W standing;XR Pelvis AP W Stand;;ACTIVE;2.16;2.61 +42421-8;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Unspecified body region;RF Guided PC Absc drn+cath place;;ACTIVE;2.16;2.66 +42422-6;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;Breast;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Breast;RF Guide Brst PC abscess drn+cath place;;ACTIVE;2.16;2.66 +42423-4;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;Chest;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Chest;RF Guide Chest PC Absc drain+cath place;;ACTIVE;2.16;2.66 +4242-4;Ethambutol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ethambutol [Mass] of Dose;Ethambutol Dose;;ACTIVE;1.0;2.69 +42424-2;(Views AP + lateral) for scoliosis^W sitting;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP and lateral for scoliosis W sitting;XR T+L-Spine AP+Lat for Scoli W sit;;ACTIVE;2.16;2.64 +42425-9;Views AP for scoliosis^W standing + W R-bending + W L-bending + WO bending;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP Views for scoliosis W standing and W right bending and W left bending and WO bending;XR T+L-sp AP stand+RL bend+WO bend for Scoli;;ACTIVE;2.16;2.64 +42426-7;View AP for scoliosis^W sitting;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP for scoliosis W sitting;XR T+L-Spine AP for Scoli W sit;;ACTIVE;2.16;2.64 +42427-5;View lateral for scoliosis^W sitting;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Lateral for scoliosis W sitting;XR T+L-Spine Lat for Scoli W sit;;ACTIVE;2.16;2.64 +42428-3;View AP for scoliosis^W standing in brace;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP for scoliosis W standing in brace;XR T+L-Spine AP for Scoli stand brace;;ACTIVE;2.16;2.64 +42429-1;View AP for scoliosis^W standing + W R-bending;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP for scoliosis W standing and W right bending;XR T+L-Spine AP for Scoli W stand+R-bend;;ACTIVE;2.16;2.64 +42430-9;(Views 2) + (views^W standing);Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 2 views and (Views W standing);XR Knee-R 2V+(views Stand);;ACTIVE;2.16;2.61 +42431-7;View PA 30 degree flexion^W standing;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right PA 30 degree flexion W standing;XR Knee-R PA 30 deg flex W Stand;;ACTIVE;2.16;2.64 +4243-2;Ethchlorvynol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ethchlorvynol [Mass] of Dose;Ethchlorvynol Dose;;ACTIVE;1.0;2.69 +42432-5;(View Sunrise) + (views^W standing);Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Sunrise and (Views W standing);XR Knee-R Sunrise+(views Stand);;ACTIVE;2.16;2.61 +42433-3;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast.right;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for percutaneous biopsy.core needle of Breast - right;MG.stereo Guided Brst-R PC Bx CN;;ACTIVE;2.16;2.64 +42434-1;Views;Find;Pt;Lower extremity.right>Foot.sesamoid bones;Doc;XR;RAD;2;XR Foot sesamoid bones - right Views;XR Ft.sesamoids-R Views;;ACTIVE;2.16;2.64 +42435-8;Views 2;Find;Pt;Head>Sella turcica;Doc;XR;RAD;2;XR Sella turcica 2 Views;XR ST 2V;;ACTIVE;2.16;2.61 +42436-6;Views lateral + Towne;Find;Pt;Head>Sella turcica;Doc;XR;RAD;2;XR Sella turcica Lateral and Towne;XR ST Lat+Towne;;ACTIVE;2.16;2.61 +42437-4;Multisection;Find;Pt;Head>Sella turcica;Doc;XR.tomography;RAD;2;XR tomography Sella turcica;XR tomo ST;;ACTIVE;2.16;2.61 +42438-2;Views AP + lateral;Find;Pt;Neck;Doc;XR;RAD;2;XR Neck AP and Lateral;XR Neck AP+Lat;;ACTIVE;2.16;2.61 +42439-0;View AP;Find;Pt;Neck;Doc;XR;RAD;2;XR Neck AP;XR Neck AP;;ACTIVE;2.16;2.61 +4244-0;Ethoheptazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ethoheptazine [Mass] of Dose;Ethoheptazine Dose;;ACTIVE;1.0;2.69 +42440-8;View lateral;Find;Pt;Neck;Nar;XR;RAD;2;Deprecated Neck X-ray lateral;Deprecated Neck XR Lat;;DEPRECATED;2.16;2.36 +42441-6;View magnification;Find;Pt;Neck;Doc;XR;RAD;2;XR Neck Magnification;XR Neck Mag;;ACTIVE;2.16;2.61 +42442-4;View lateral^W standing;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Lateral W standing;XR Spine Lat W Stand;;DISCOURAGED;2.16;2.61 +42443-2;Views 3^W standing;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 3 Views W standing;XR T-spine 3V W Stand;;ACTIVE;2.16;2.61 +42444-0;Views AP^W R-bending + W L-bending + WO bending;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Views AP W right bending and W left bending and WO bending;XR T-spine Views AP W+WO R+L-bending;;ACTIVE;2.16;2.64 +42445-7;Views AP^W L-bending + WO bending;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Views AP W left bending and WO bending;XR T-spine Views AP W+WO L-bending;;ACTIVE;2.16;2.64 +42446-5;Views AP^W R-bending + WO bending;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Views AP W right bending and WO bending;XR T-spine Views AP W+WO R-bending;;ACTIVE;2.16;2.64 +42447-3;Guidance for percutaneous aspiration of cyst;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;US Guidance for aspiration of cyst of Thyroid gland;US Guided Thyroid Cyst asp;;ACTIVE;2.16;2.64 +42448-1;Guidance for biopsy.excisional;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for excisional biopsy of Breast;US Guided Brst Excisional Bx;;ACTIVE;2.16;2.64 +42449-9;Guidance for percutaneous biopsy;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for biopsy of Breast - left;US Guided Brst-L Bx;;ACTIVE;2.16;2.73 +42450-7;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for aspiration of cyst of Breast - left;US Guided Brst-L Cyst asp;;ACTIVE;2.16;2.64 +42451-5;Study observation.general transvaginal 1st trimester;Imp;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general transvaginal 1st trimester US;US Fetus Study transvag 1st trim [Imp];;ACTIVE;2.16;2.50 +42452-3;Study observation.general 1st trimester;Imp;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general 1st trimester US;US Fetus Study 1st trim [Imp];;ACTIVE;2.16;2.50 +42453-1;Study observation.general 2nd trimester;Imp;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general 2nd trimester US;US Fetus Study 2nd trim [Imp];;ACTIVE;2.16;2.50 +42454-9;Study observation.general 3rd trimester;Imp;Pt;^Fetus;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general 3rd trimester US;US Fetus Study 3rd trim [Imp];;ACTIVE;2.16;2.50 +42455-6;Multisection transabdominal + transvaginal;Find;Pt;Pelvis;Doc;US;RAD;2;US Pelvis transabdominal and transvaginal;US Pelvis Transabdom+Transvag;;ACTIVE;2.16;2.73 +42456-4;Guidance for placement of needle wire;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for placement of needle wire in Breast;US Guided Brst Needle wire place;;ACTIVE;2.16;2.64 +4245-7;Ethosuximide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ethosuximide [Mass] of Dose;Ethosuximide Dose;;ACTIVE;1.0;2.73 +42457-2;Guidance for percutaneous biopsy;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for biopsy of Breast - right;US Guided Brst-R Bx;;ACTIVE;2.16;2.73 +42458-0;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for aspiration of cyst of Breast - right;US Guided Brst-R Cyst asp;;ACTIVE;2.16;2.64 +42459-8;Views^W contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Gastrointestinal tract upper Views W contrast PO;RF UGI Views W contr PO;;ACTIVE;2.16;2.64 +42460-6;Views^W contrast intra salivary duct;Find;Pt;Head>Submandibular gland.left;Doc;RF;RAD;2;RF Submandibular gland - left Views W contrast intra salivary duct;RF Submand gland-L Vs W contr intra SD;;ACTIVE;2.16;2.64 +42461-4;Multisection for graft;Find;Pt;Lower extremity.left>Lower extremity vessel;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessel - left for graft;DOP LE vessel-L for graft;;ACTIVE;2.16;2.61 +42462-2;Multisection for graft;Find;Pt;Lower extremity.right>Lower extremity vessel;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessel - right for graft;DOP LE vessel-R for graft;;ACTIVE;2.16;2.61 +42463-0;Guidance for percutaneous biopsy;Find;Pt;Chest>Endomyocardium;Doc;US;RAD;2;US Guidance for biopsy of Endomyocardium;US Guided Endomyocardium Bx;;ACTIVE;2.16;2.64 +42464-8;Study observation.general 1st trimester;Imp;Pt;^Fetuses;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general 1st trimester, multiple fetuses US;US Fetuses Study 1st trim [Imp];;ACTIVE;2.16;2.50 +4246-5;Ethotoin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ethotoin [Mass] of Dose;Ethotoin Dose;;ACTIVE;1.0;2.69 +42465-5;Study observation.general 2nd trimester;Imp;Pt;^Fetuses;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general 2nd trimester, multiple fetuses US;US Fetuses Study 2nd trim [Imp];;ACTIVE;2.16;2.50 +42466-3;Study observation.general 3rd trimester;Imp;Pt;^Fetuses;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general 3rd trimester, multiple fetuses US;US Fetuses Study 3rd trim [Imp];;ACTIVE;2.16;2.50 +42467-1;Study observation.general.limited;Imp;Pt;^Fetuses;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation.general.limited, multiple fetuses US;US Fetuses Study ltd [Imp];;ACTIVE;2.16;2.50 +42468-9;Multisection;Find;Pt;^Surgical specimen;Doc;US;RAD;2;US Surgical specimen;US Surg Spec;;ACTIVE;2.16;2.61 +42469-7;View^W contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper+Small bowel+Gallbladder;Doc;RF;RAD;2;RF Gastrointestinal tract upper and Small bowel and Gallbladder Single view W contrast PO;RF UGI+SB+GB 1V W contr PO;;ACTIVE;2.16;2.64 +42470-5;View^W contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper+Gallbladder;Doc;RF;RAD;2;RF Gastrointestinal tract upper and Gallbladder Single view W contrast PO;RF UGI+GB 1V W contr PO;;ACTIVE;2.16;2.64 +42471-3;View;Find;Pt;Pelvis;Doc;XR.stereoscopic;RAD;2;XR.stereoscopic Pelvis Single view;XR.stereo Pelvis 1V;;ACTIVE;2.16;2.64 +42472-1;Views AP for scoliosis^in traction;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP Views for scoliosis in traction;XR T+L-Spine Vs AP for Scoli In Traction;;ACTIVE;2.16;2.64 +4247-3;Ethylmorphine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ethylmorphine [Mass] of Dose;EMP Dose;;ACTIVE;1.0;2.69 +42473-9;View Waters;Find;Pt;Head>Sinuses;Doc;XR.stereoscopic;RAD;2;XR.stereoscopic Sinuses Waters;XR.stereo Sinuses Waters;;ACTIVE;2.16;2.61 +42474-7;View;Find;Pt;Head>Skull;Doc;XR.stereoscopic;RAD;2;XR.stereoscopic Skull Single view;XR.stereo Skull 1V;;ACTIVE;2.16;2.64 +42475-4;Multisection for graft;Find;Pt;Upper extremity.left>Upper extremity vessel;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessel - left for graft;DOP UE vessel-L for graft;;ACTIVE;2.16;2.61 +42476-2;Multisection for graft;Find;Pt;Upper extremity.right>Upper extremity vessel;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessel - right for graft;DOP UE vessel-R for graft;;ACTIVE;2.16;2.61 +42477-0;Multisection for transplanted kidney vessels;Find;Pt;Pelvis;Doc;US.doppler;RAD;2;US.doppler for transplanted kidney vessels;DOP for transplanted kidney ves;;ACTIVE;2.16;2.58 +42478-8;Guidance for drainage of cyst+placement of drainage catheter;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for drainage of cyst and placement of drainage catheter of Kidney;US Guided Kidney Cyst drain+cath place;;ACTIVE;2.16;2.66 +42479-6;Study observation.general;Imp;Pt;^Fetuses;Nar;US;OB.US;2;Fetal Narrative [Interpretation] Study observation general, multiple fetuses US;US Fetuses Study [Imp];;ACTIVE;2.16;2.73 +42480-4;Multisection transabdominal;Find;Pt;Pelvis;Nar;US;OB.US;2;Pelvis Narrative transabdominal US;Pelvis Transabdom US;;ACTIVE;2.16;2.73 +4248-1;N-ethylnicotinamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;N-ethylnicotinamide [Mass] of Dose;NEN Dose;;ACTIVE;1.0;2.73 +42481-2;Human papilloma virus 6+11+42+43+44 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 6+11+42+43+44 DNA [Presence] in Cervix by Probe with signal amplification;HPV Low Risk DNA Cvx Ql Probe+sig amp;;ACTIVE;2.16;2.73 +42482-0;Protein.monoclonal;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal [Mass/time] in 24 hour Urine by Electrophoresis;M Protein 24h Ur Elph-mRate;;ACTIVE;2.16;2.73 +42483-8;Protein.monoclonal/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal/Protein.total in Urine by Electrophoresis;M Protein MFr Ur Elph;;ACTIVE;2.16;2.73 +42484-6;Protein.monoclonal/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal/Protein.total in 24 hour Urine by Electrophoresis;M Protein 24h MFr Ur Elph;;ACTIVE;2.16;2.73 +42485-3;Anion gap;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Anion gap in Vitreous fluid;Anion Gap Vitf-sCnc;;ACTIVE;2.16;2.70 +42486-1;Aspergillus fumigatus 1 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Aspergillus fumigatus 1 Ab [Presence] in Cerebral spinal fluid;A fumigatus1 Ab CSF Ql;;ACTIVE;2.16;2.56 +42487-9;Aspergillus fumigatus 6 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Aspergillus fumigatus 6 Ab [Presence] in Cerebral spinal fluid;A fumigatus6 Ab CSF Ql;;ACTIVE;2.16;2.56 +42488-7;Aspergillus sp Ab;Titr;Pt;Plr fld;Qn;Comp fix;MICRO;1;Aspergillus sp Ab [Titer] in Pleural fluid by Complement fixation;Aspergillus Ab Titr Plr CF;;ACTIVE;2.16;2.30 +42489-5;Aureobasidium pullulans Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Aureobasidium pullulans Ab [Presence] in Cerebral spinal fluid;A pullulans Ab CSF Ql;;ACTIVE;2.16;2.56 +42490-3;Blastomyces dermatitidis Ab;Titr;Pt;Plr fld;Qn;Comp fix;MICRO;1;Blastomyces dermatitidis Ab [Titer] in Pleural fluid by Complement fixation;B dermat Ab Titr Plr CF;;ACTIVE;2.16;2.30 +42491-1;Cannabinoids;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Blood by Screen method;Cannabinoids Bld Ql Scn;;ACTIVE;2.16;2.73 +42492-9;Carboxy tetrahydrocannabinol;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Blood;CarboxyTHC Bld Ql;;ACTIVE;2.16;2.73 +42493-7;Catecholamines.free fractionated;MCnc;Pt;Plas;Qn;;CHEM;1;Catecholamines Free fractionated [Mass/volume] in Plasma;FCA Fract Plas-mCnc;;ACTIVE;2.16;2.73 +42494-5;Coccidioides immitis Ab;Titr;Pt;Plr fld;Qn;Comp fix;MICRO;1;Coccidioides immitis Ab [Titer] in Pleural fluid by Complement fixation;C immitis Ab Titr Plr CF;;ACTIVE;2.16;2.30 +42495-2;Cytomegalovirus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Cytomegalovirus IgG Ab [Presence] in Cerebral spinal fluid;CMV IgG CSF Ql;;ACTIVE;2.16;2.56 +42496-0;Echinococcus sp Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Echinococcus sp Ab [Presence] in Cerebral spinal fluid;Echinococcus Ab CSF Ql;;ACTIVE;2.16;2.56 +42497-8;Epstein Barr virus early Ab;Titr;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus early Ab [Titer] in Cerebral spinal fluid;EBV EA Ab Titr CSF;;ACTIVE;2.16;2.30 +42498-6;Epstein Barr virus nuclear Ab;Titr;Pt;CSF;Qn;;MICRO;1;Epstein Barr virus nuclear Ab [Titer] in Cerebral spinal fluid;EBV NA Ab Titr CSF;;ACTIVE;2.16;2.30 +4249-9;Etilefrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Etilefrine [Mass] of Dose;Etilefrine Dose;;ACTIVE;1.0;2.69 +42499-4;Fibrin D-dimer;PrThr;Pt;CSF;Ord;;COAG;1;Fibrin D-dimer [Presence] in Cerebral spinal fluid;D Dimer CSF Ql;;ACTIVE;2.16;2.73 +42500-9;Fosamprenavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Fosamprenavir [Susceptibility] by Phenotype method;Fosamprenavir Islt Phenotyp;;ACTIVE;2.16;2.73 +42501-7;Glutamate decarboxylase 65 Ab;ACnc;Pt;CSF;Qn;;SERO;1;Glutamate decarboxylase 65 Ab [Units/volume] in Cerebral spinal fluid;GAD65 Ab CSF-aCnc;;ACTIVE;2.16;2.73 +42502-5;Glycolate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycolate [Moles/volume] in Serum or Plasma;Glycolate SerPl-sCnc;;ACTIVE;2.16;2.70 +42503-3;Hantavirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hantavirus Ab [Presence] in Serum;Hantavirus Ab Ser Ql;;ACTIVE;2.16;2.56 +42504-1;Hepatitis B virus surface Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Hepatitis B virus surface Ab [Presence] in Cerebral spinal fluid;HBV surface Ab CSF Ql;;ACTIVE;2.16;2.56 +42505-8;Hepatitis B virus surface Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Hepatitis B virus surface Ag [Presence] in Cerebral spinal fluid;HBV surface Ag CSF Ql;;ACTIVE;2.16;2.56 +42506-6;Hepatitis C virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Hepatitis C virus Ab [Presence] in Cerebral spinal fluid;HCV Ab CSF Ql;;ACTIVE;2.16;2.56 +4250-7;Fencamfamin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Fencamfamin [Mass] of Dose;Fencamfamin Dose;;ACTIVE;1.0;2.69 +42507-4;Herpes simplex virus 1 Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 1 IgG Ab [Presence] in Cerebral spinal fluid;HSV1 IgG CSF Ql;;ACTIVE;2.16;2.56 +42508-2;Herpes virus 8 Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 8 IgG Ab [Units/volume] in Serum by Immunofluorescence;HHV8 IgG Ser IF-aCnc;;ACTIVE;2.16;2.69 +42509-0;Histoplasma capsulatum Ab;PrThr;Pt;Plr fld;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum Ab [Presence] in Pleural fluid by Immune diffusion (ID);H capsul Ab Plr Ql ID;;ACTIVE;2.16;2.56 +42510-8;IgD;MCnc;Pt;Urine;Qn;;CHEM;1;IgD [Mass/volume] in Urine;IgD Ur-mCnc;;ACTIVE;2.16;2.70 +42511-6;IgD;MCnc;Pt;CSF;Qn;;CHEM;1;IgD [Mass/volume] in Cerebral spinal fluid;IgD CSF-mCnc;;ACTIVE;2.16;2.70 +42512-4;IgE;ACnc;Pt;Urine;Qn;;CHEM;1;IgE [Units/volume] in Urine;IgE Ur-aCnc;;ACTIVE;2.16;2.68 +42513-2;IgE;ACnc;Pt;CSF;Qn;;CHEM;1;IgE [Units/volume] in Cerebral spinal fluid;IgE CSF-aCnc;;ACTIVE;2.16;2.68 +42514-0;Inhibin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Inhibin Ag [Presence] in Tissue by Immune stain;Inhibin Ag Tiss Ql ImStn;;ACTIVE;2.16;2.73 +4251-5;Fenetylline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Fenetylline [Mass] of Dose;Fenetylline Dose;;ACTIVE;1.0;2.69 +42515-7;Jamestown canyon virus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Jamestown canyon virus RNA [Presence] in Urine by NAA with probe detection;JCV RNA Ur Ql NAA+probe;;ACTIVE;2.16;2.63 +42516-5;Legionella sp Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Legionella sp Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Legionella Ab Titr CSF IF;;ACTIVE;2.16;2.30 +42517-3;Leishmania sp Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Leishmania sp Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Leishmania Ab CSF Ql IF;;ACTIVE;2.16;2.56 +42518-1;Leptospira sp Ab;Titr;Pt;CSF;Qn;Aggl;MICRO;1;Leptospira sp Ab [Titer] in Cerebral spinal fluid by Agglutination;Leptospira Ab Titr CSF Aggl;;ACTIVE;2.16;2.30 +42519-9;Measles virus Ab.IgG;ACnc;Pt;CSF;Ord;;MICRO;1;Deprecated Measles virus IgG Ab [Presence] in Cerebral spinal fluid;Deprecated MeV IgG CSF Ql;;DEPRECATED;2.16;2.36 +42520-7;Methylmalonate;SCnc;24H;Urine;Qn;;CHEM;1;Methylmalonate [Moles/volume] in 24 hour Urine;Methylmalonate 24h Ur-sCnc;;ACTIVE;2.16;2.70 +42521-5;Saccharopolyspora rectivirgula Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Saccharopolyspora rectivirgula Ab [Presence] in Cerebral spinal fluid;S rectivirgula Ab CSF Ql;;ACTIVE;2.16;2.56 +42522-3;Mitochondria Ab;Titr;Pt;CSF;Qn;;SERO;1;Mitochondria Ab [Titer] in Cerebral spinal fluid;Mitochondria Ab Titr CSF;;ACTIVE;2.16;2.30 +4252-3;Fenfluramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Fenfluramine [Mass] of Dose;Fenfluramine Dose;;ACTIVE;1.0;2.69 +42523-1;Molindone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Molindone [Mass/volume] in Urine;Molindone Ur-mCnc;;ACTIVE;2.16;2.73 +42524-9;Mucus;PrThr;Pt;Stool;Ord;Microscopy.light;CHEM;1;Mucus [Presence] in Stool by Light microscopy;Mucous Threads Stl Ql Micro;;ACTIVE;2.16;2.56 +42525-6;Mycoplasma pneumoniae Ab.IgM;Titr;Pt;Plr fld;Qn;IF;MICRO;1;Mycoplasma pneumoniae IgM Ab [Titer] in Pleural fluid by Immunofluorescence;M pneumo IgM Titr Plr IF;;ACTIVE;2.16;2.30 +42526-4;Mycoplasma pneumoniae Ab.IgG;Titr;Pt;Plr fld;Qn;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Titer] in Pleural fluid;M pneumo IgG Titr Plr;;ACTIVE;2.16;2.30 +42527-2;Parietal cell Ab;Titr;Pt;CSF;Qn;;SERO;1;Parietal cell Ab [Titer] in Cerebral spinal fluid;PCA Ab Titr CSF;;ACTIVE;2.16;2.30 +42528-0;Phenothiazines;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenothiazines [Mass/volume] in Serum or Plasma;Phenothiaz SerPl-mCnc;;ACTIVE;2.16;2.70 +42529-8;Pigeon serum Ab;PrThr;Pt;CSF;Ord;;ALLERGY;1;Pigeon serum Ab [Presence] in Cerebral spinal fluid;Pigeon Serum Ab CSF Ql;;ACTIVE;2.16;2.56 +42530-6;Smooth muscle Ab;Titr;Pt;CSF;Qn;;SERO;1;Smooth muscle Ab [Titer] in Cerebral spinal fluid;Smooth muscle Ab Titr CSF;;ACTIVE;2.16;2.30 +4253-1;Fenoprofen;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Fenoprofen [Mass] of Dose;Fenoprofen Dose;;ACTIVE;1.0;2.69 +42531-4;Spermatozoa.motile;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile [#/volume] in Semen;Sperm Motile # Smn;;ACTIVE;2.16;2.73 +42532-2;Thermoactinomyces candidus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Thermoactinomyces candidus Ab [Presence] in Cerebral spinal fluid;T candidus Ab CSF Ql;;ACTIVE;2.16;2.56 +42533-0;Saccharomonospora viridis Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Saccharomonospora viridis Ab [Presence] in Cerebral spinal fluid;S viridis Ab CSF Ql;;ACTIVE;2.16;2.56 +42534-8;Thermoactinomyces vulgaris Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Thermoactinomyces vulgaris Ab [Presence] in Cerebral spinal fluid;T vulgaris Ab CSF Ql;;ACTIVE;2.16;2.56 +42535-5;Tipranavir;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tipranavir [Susceptibility];Tipranavir Susc Islt;;ACTIVE;2.16;2.19 +42536-3;Tropheryma whipplei DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;T whipplei DNA CSF Ql NAA+probe;;ACTIVE;2.16;2.70 +42537-1;Varicella zoster virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Varicella zoster virus IgG Ab [Presence] in Cerebral spinal fluid;VZV IgG CSF Ql;;ACTIVE;2.16;2.56 +42538-9;Hydroxyperhexiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxyperhexiline [Mass/volume] in Serum or Plasma;OH-Phex SerPl-mCnc;;ACTIVE;2.16;2.73 +42539-7;Hydroxyperhexiline/Perhexiline;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxyperhexiline/Perhexiline [Mass Ratio] in Serum or Plasma;OH-Phex/Phex SerPl;;ACTIVE;2.16;2.73 +42540-5;Contributing factor.environment;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor environment MERSTH;Contrib Fact environment MERSTH;;ACTIVE;2.16;2.27 +42541-3;Contributing factor.patient-related;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor patient-related MERSTH;Contrib Fact patient-related MERSTH;;ACTIVE;2.16;2.27 +42542-1;Contributing factor.staff-related;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor staff-related MERSTH;Contrib Fact staff-related MERSTH;;ACTIVE;2.16;2.27 +42543-9;Contributing factor.delay &or premature;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor delay/Premature MERSTH;Contrib Fact delay/premature MERSTH;;ACTIVE;2.16;2.27 +42544-7;Contributing factor.other;Find;Pt;^Patient;Nar;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor other Narrative MERSTH;Contrib Fact other MERSTH;;ACTIVE;2.16;2.40 +42545-4;Event outcome;Find;Pt;^Patient;Ord;Observed.MERSTH;PATIENT SAFETY;2;Event outcome MERSTH;Event Outcome MERSTH;;ACTIVE;2.16;2.27 +42546-2;Event battery.MERS-TH;Find;Pt;^Patient;-;Observed.MERSTH;PANEL.PATIENT SAFETY;2;Event battery.MERS-TH MERSTH;Event Battery.MERS-TH MERSTH;;ACTIVE;2.16;2.27 +42547-0;Event;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event MERSTH;Event MERSTH;;ACTIVE;2.16;2.27 +42548-8;Service;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Service MERSTH;Service MERSTH;;ACTIVE;2.16;2.27 +4254-9;Fenproporex;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Fenproporex [Mass] of Dose;Fenproporex Dose;;ACTIVE;1.0;2.69 +42549-6;Event type;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event type MERSTH;Event Type MERSTH;;ACTIVE;2.16;2.27 +42550-4;Event description.medication;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description medication MERSTH;Event Desc med MERSTH;;ACTIVE;2.16;2.27 +42551-2;Event description.procedure &or treatment &or surgery;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description procedure/treatment/surgery MERSTH;Event Desc proc/Tx/surgery MERSTH;;ACTIVE;2.16;2.73 +42552-0;Event description.food &or nutrition;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description food/nutrition MERSTH;Event Desc food/nutrition MERSTH;;ACTIVE;2.16;2.27 +42553-8;Event description.fall;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description fall MERSTH;Event Desc fall MERSTH;;ACTIVE;2.16;2.27 +42554-6;Event description.accident;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description accident MERSTH;Event Desc accident MERSTH;;ACTIVE;2.16;2.27 +42555-3;Event description.general nursing care;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event Description general nursing care MERSTH;Event Desc general nursing care MERSTH;;ACTIVE;2.16;2.27 +4255-6;fentaNYL;Mass;Pt;Dose;Qn;;DRUGDOSE;1;fentaNYL [Mass] of Dose;fentaNYL Dose;;ACTIVE;1.0;2.73 +42556-1;Event description.equipment &or device;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description equipment/device MERSTH;Event Desc equipment/device MERSTH;;ACTIVE;2.16;2.27 +42557-9;Event description.laboratory;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description laboratory MERSTH;Event Desc lab MERSTH;;ACTIVE;2.16;2.27 +42558-7;Event description.transfusion service;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description transfusion service MERSTH;Event Desc transfusion service MERSTH;;ACTIVE;2.16;2.27 +42559-5;Event description.administrative;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description administrative MERSTH;Event Desc admin MERSTH;;ACTIVE;2.16;2.27 +42560-3;Event description.complaint;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description complaint MERSTH;Event Desc complaint MERSTH;;ACTIVE;2.16;2.27 +42561-1;Event description.environmental hazard &or safety;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description environmental hazard/safety MERSTH;Event Desc envir hazard/safety MERSTH;;ACTIVE;2.16;2.27 +42562-9;Event description.crime &or intentional harm/Patient disappearance;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description crime/intentional harm/Patient disappearance MERSTH;Evnt Dsc crime/intnt hrm/Pt disp MERSTH;;ACTIVE;2.16;2.50 +42563-7;Event description.adverse event;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Event description adverse event MERSTH;Event Desc AE MERSTH;;ACTIVE;2.16;2.27 +4256-4;Flecainide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Flecainide [Mass] of Dose;Flecainide Dose;;ACTIVE;1.0;2.69 +42564-5;Contributing factor.technical;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor technical MERSTH;Contrib Fact technical MERSTH;;ACTIVE;2.16;2.27 +42565-2;Contributing factor.organization;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor organization MERSTH;Contrib Fact organization MERSTH;;ACTIVE;2.16;2.27 +42566-0;Contributing factor.communication &or documentation;Find;Pt;^Patient;Nom;Observed.MERSTH;PATIENT SAFETY;2;Contributing Factor communication/Documentation MERSTH;Contrib Fact communication/doc MERSTH;;ACTIVE;2.16;2.27 +42567-8;Calcium.ionized;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium.ionized [Mass or Moles/volume] in Serum or Plasma;Ca-I SerPl-msCnc;;DISCOURAGED;2.16;2.42 +42568-6;Fibrinogen;MSCnc;Pt;PPP;Qn;Coag;COAG;1;Fibrinogen [Mass or Moles/volume] in Platelet poor plasma by Coagulation assay;Fibrinogen PPP-msCnc;;DISCOURAGED;2.16;2.42 +42569-4;Potassium;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Potassium [Mass or Moles/volume] in Serum or Plasma;Potassium SerPl-msCnc;;DISCOURAGED;2.16;2.42 +42570-2;Sodium;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sodium [Mass or Moles/volume] in Serum or Plasma;Sodium SerPl-msCnc;;DISCOURAGED;2.16;2.42 +42571-0;Urea;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea [Mass or Moles/volume] in Serum or Plasma;Urea SerPl-msCnc;;DISCOURAGED;2.16;2.42 +4257-2;5-Fluorocytosine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated 5-Fluorocytosine [Mass] of Dose;Deprecated 5-fluorocytosine Dose;;DEPRECATED;1.0;2.69 +42572-8;11-Deoxycortisol;MCnc;Pt;Urine;Qn;;CHEM;1;11-Deoxycortisol [Mass/volume] in Urine;11DC Ur-mCnc;;ACTIVE;2.16;2.73 +42573-6;18-Hydroxycorticosterone;MCnc;Pt;Urine;Qn;;CHEM;1;18-Hydroxycorticosterone [Mass/volume] in Urine;18OHB Ur-mCnc;;ACTIVE;2.16;2.70 +42574-4;1-Naphthol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;1-Naphthol [Presence] in Urine;1Naphthol Ur Ql;;ACTIVE;2.16;2.73 +42575-1;Amoxicillin Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Amoxicillin IgE Ab/IgE total in Serum;Amoxicillin IgE/IgE total %;;ACTIVE;2.16;2.70 +42576-9;Amphetamine;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Amphetamine [Mass/volume] in Blood by Confirmatory method;Amphet Bld Cfm-mCnc;;ACTIVE;2.16;2.73 +42577-7;Ampicillin Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Ampicillin IgE Ab/IgE total in Serum;Ampicillin IgE/IgE total %;;ACTIVE;2.16;2.70 +42578-5;Artifact;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Artifact [Presence] in Urine sediment by Light microscopy;Artifact UrnS Ql Micro;;ACTIVE;2.16;2.73 +42579-3;Aspergillus fumigatus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus fumigatus IgM Ab [Units/volume] in Serum;A fumigatus IgM Ser-aCnc;;ACTIVE;2.16;2.69 +4258-0;Flunitrazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Flunitrazepam [Mass] of Dose;Flunitrazepam Dose;;ACTIVE;1.0;2.69 +42580-1;Babesia sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia sp IgM Ab [Presence] in Serum;Babesia IgM Ser Ql;;ACTIVE;2.16;2.56 +42581-9;Babesia sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia sp IgG Ab [Presence] in Serum;Babesia IgG Ser Ql;;ACTIVE;2.16;2.56 +42582-7;Barbiturates;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Barbiturates [Mass/volume] in Blood by Confirmatory method;Barbiturates Bld Cfm-mCnc;;ACTIVE;2.16;2.73 +42583-5;Bean string Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bean string IgE Ab RAST class [Presence] in Serum;Bean string IgE RAST Ql;;ACTIVE;2.16;2.58 +42584-3;Beet Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Beet IgG Ab [Mass/volume] in Serum;Beet IgG-mCnc;;ACTIVE;2.16;2.73 +42585-0;Bendiocarb;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Bendiocarb [Presence] in Urine;Bendiocarb Ur Ql;;ACTIVE;2.16;2.73 +42586-8;Benzodiazepines;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Blood by Confirmatory method;Benzodiaz Bld Cfm-mCnc;;ACTIVE;2.16;2.73 +42587-6;BK virus DNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Units/volume] (viral load) in Specimen by NAA with probe detection;BKV DNA Spec NAA+probe-aCnc;;ACTIVE;2.16;2.73 +42588-4;Bordetella parapertussis DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Bordetella parapertussis DNA [Presence] in Nasopharynx by NAA with probe detection;B parapert DNA Nph Ql NAA+probe;;ACTIVE;2.16;2.73 +42589-2;Borrelia burgdorferi DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Body fluid by NAA with probe detection;B burgdor DNA Fld Ql NAA+probe;;ACTIVE;2.16;2.73 +425-9;Pyrazinamide;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Pyrazinamide [Susceptibility] by Disk diffusion (KB);PZA Islt KB;;ACTIVE;1.0;2.19 +42590-0;Borrelia sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Borrelia sp Ab [Titer] in Serum;Borrelia Ab Titr Ser;;ACTIVE;2.16;2.70 +42591-8;Botrytis cinerea Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Botrytis cinerea IgG Ab [Mass/volume] in Serum;B cinerea IgG-mCnc;;ACTIVE;2.16;2.73 +42592-6;Brucella abortus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Brucella abortus IgG Ab [Presence] in Cerebral spinal fluid;B abortus IgG CSF Ql;;ACTIVE;2.16;2.56 +42593-4;Calcium;SCnc;Pt;BldC;Qn;;CHEM;1;Calcium [Moles/volume] in Capillary blood;Calcium BldC-sCnc;;ACTIVE;2.16;2.42 +42594-2;Fraxinus americana Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;White Ash IgE Ab/IgE total in Serum;White Ash IgE/IgE total %;;ACTIVE;2.16;2.70 +42595-9;Hepatitis B virus DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HBV DNA SerPl NAA+probe-aCnc;;ACTIVE;2.16;2.73 +42596-7;Corticotropin^30M post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes post XXX challenge;ACTH 30M p chal Plas-mCnc;;ACTIVE;2.16;2.70 +42597-5;Corticotropin^1.5H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1.5 hours post XXX challenge;ACTH 1.5h p chal Plas-mCnc;;ACTIVE;2.16;2.70 +4259-8;Fluorouracil;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Fluorouracil [Mass] of Dose;Fluorouracil Dose;;ACTIVE;1.0;2.69 +42598-3;Corticotropin^baseline;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --baseline;ACTH BS Plas-mCnc;;ACTIVE;2.16;2.73 +42599-1;Corticotropin^1H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 hour post XXX challenge;ACTH 1h p chal Plas-mCnc;;ACTIVE;2.16;2.70 +42600-7;HIV 1+2 Ab;PrThr;Pt;XXX;Ord;IA;MICRO;1;HIV 1+2 Ab [Presence] in Specimen by Immunoassay;HIV1+2 Ab Spec Ql IA;;ACTIVE;2.16;2.73 +42601-5;Immune complex.IgG;ACnc;Pt;Synv fld;Qn;C1q binding assay;SERO;1;Immune complex.IgG [Units/volume] in Synovial fluid by C1q binding assay;IC IgG Snv C1Q Bind-aCnc;;ACTIVE;2.16;2.69 +42602-3;Tropheryma whipplei DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Blood by NAA with probe detection;T whipplei DNA Bld Ql NAA+probe;;ACTIVE;2.16;2.73 +42603-1;Coxsackievirus A6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A6 Ab [Titer] in Serum;CV A6 Ab Titr Ser;;ACTIVE;2.16;2.70 +42604-9;Glucose^3H post dose lactose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --3 hours post dose lactose PO;Glucose 3h p Lac PO Ur-mCnc;;ACTIVE;2.16;2.70 +42605-6;Dialysis bag number;ID;Pt;Periton fld;Nom;;SPEC;1;Peritoneal dialysis bag number;Dialysis Bag # Prt;;ACTIVE;2.16;2.19 +4260-6;FLUoxetine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;FLUoxetine [Mass] of Dose;FLUoxetine Dose;;ACTIVE;1.0;2.69 +42606-4;Herpes simplex virus 2 Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;Herpes simplex virus 2 IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;HSV2 IgM CSF Ql IF;;ACTIVE;2.16;2.73 +42607-2;Prolactin.monomeric;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin monomeric [Mass/volume] in Serum or Plasma;Prolactin.monomeric SerPl-mCnc;;ACTIVE;2.16;2.73 +42608-0;Cells.CD10+CD20+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD10+CD20+ cells/100 cells in Bone marrow;CD10+CD20+ Cells NFr Mar;;ACTIVE;2.16;2.34 +42609-8;Glucose^6H post dose lactose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --6 hours post dose lactose PO;Glucose 6h p Lac PO Ur-mCnc;;ACTIVE;2.16;2.70 +42610-6;Salicylurate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylurate [Mass/volume] in Serum or Plasma;Salicylurate SerPl-mCnc;;ACTIVE;2.16;2.70 +42611-4;Glucose^1H post dose lactose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1 hour post dose lactose PO;Glucose 1h p Lac PO Ur-mCnc;;ACTIVE;2.16;2.70 +42612-2;Salicylurate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Salicylurate [Mass/volume] in Urine;Salicylurate Ur-mCnc;;ACTIVE;2.16;2.70 +42613-0;Glucose^2H post dose lactose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --2 hours post dose lactose PO;Glucose 2h p Lac PO Ur-mCnc;;ACTIVE;2.16;2.70 +4261-4;Fluoxymesterone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Fluoxymesterone [Mass] of Dose;Fluoxymesterone Dose;;ACTIVE;1.0;2.69 +42614-8;Colorado tick fever virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Colorado tick fever virus Ab [Titer] in Cerebral spinal fluid;CTFV Ab Titr CSF;;ACTIVE;2.16;2.30 +42615-5;Glucose^30M post dose lactose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --30 minutes post dose lactose PO;Glucose 30M p Lac PO Ur-mCnc;;ACTIVE;2.16;2.73 +42616-3;Magnesium;MCnc;Pt;Dial fld;Qn;;CHEM;1;Magnesium [Mass/volume] in Dialysis fluid;Magnesium Dial fld-mCnc;;ACTIVE;2.16;2.70 +42617-1;Hepatitis C virus RNA;LaCnc;Pt;Ser/Plas;Qn;Probe.amp.sig;MICRO;1;Hepatitis C virus RNA [log units/volume] (viral load) in Serum or Plasma by Probe with signal amplification;HCV RNA SerPl Probe+sig amp-Log IU;;ACTIVE;2.16;2.73 +42618-9;Naloxone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Naloxone [Presence] in Urine by Screen method;Naloxone Ur Ql Scn;;ACTIVE;2.16;2.73 +42619-7;Cells.CD28/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD28 cells/100 cells in Bone marrow;CD28 Cells NFr Mar;;ACTIVE;2.16;2.73 +42620-5;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Bone marrow;TdT Cells NFr Mar;;ACTIVE;2.16;2.34 +42621-3;Mycoplasma hominis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Mycoplasma hominis DNA [Presence] in Blood by NAA with probe detection;M hominis DNA Bld Ql NAA+probe;;ACTIVE;2.16;2.73 +4262-2;Flupenthixol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Flupenthixol [Mass] of Dose;Flupenthixol Dose;;ACTIVE;1.0;2.69 +42622-1;Cells.CD13+CD56+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD13+CD56+ cells/100 cells in Bone marrow;CD13+CD56+ Cells NFr Mar;;ACTIVE;2.16;2.34 +42623-9;Coxsackievirus A3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A3 Ab [Titer] in Serum;CV A3 Ab Titr Ser;;ACTIVE;2.16;2.70 +42624-7;Gastrin^2M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --2 minutes post XXX challenge;Gastrin 2M p chal SerPl-mCnc;;ACTIVE;2.16;2.73 +42625-4;Coxsackievirus A6 Ab;Titr;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Coxsackievirus A6 Ab [Titer] in Serum;Deprecated CV A6 Ab Titr SerPl;;DEPRECATED;2.16;2.70 +42626-2;Toxoplasma gondii DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;T gondii DNA CSF Ql NAA+probe;;ACTIVE;2.16;2.63 +42627-0;HIV 1 Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;HIV 1 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;HIV1 Ab CSF Ql IF;;ACTIVE;2.16;2.56 +42628-8;Cells.CD9+CD41+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD9+CD41+ cells/100 cells in Blood;CD9+CD41+ Cells NFr Bld;;ACTIVE;2.16;2.34 +42629-6;Glucose^4H post dose lactose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --4 hours post dose lactose PO;Glucose 4h p Lac PO Ur-mCnc;;ACTIVE;2.16;2.70 +4263-0;fluPHENAZine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;fluPHENAZine [Mass] of Dose;fluPHENAZine Dose;;ACTIVE;1.0;2.69 +42630-4;Cannabinoids;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Cannabinoids [Presence] in Blood;Cannabinoids Bld Ql;;ACTIVE;2.16;2.73 +42631-2;Glucose^5H post dose lactose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --5 hours post dose lactose PO;Glucose 5h p Lac PO Ur-mCnc;;ACTIVE;2.16;2.70 +42632-0;Grade ICD-O-1;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Grade ICD-O-1 Cancer;Grade ICD-O-1 Cancer;;ACTIVE;2.16;2.32 +42633-8;Behavior ICD-O-1;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Behavior ICD-O-1 Cancer;Behavior ICD-O-1 Cancer;;ACTIVE;2.16;2.32 +42634-6;1p & 19q chromosome deletion;Arb;Pt;Tiss fixed;Ord;Molgen;MOLPATH.DEL;1;1p and 19q chromosome deletion [Presence] in Fixed tissue by Molecular genetics method;1p+19q Del Ftis Ql;;ACTIVE;2.16;2.73 +42635-3;Chromosome 12p tetrasomy;Arb;Pt;Tiss fixed;Ord;Molgen;MOLPATH;1;Chromosome 12p tetrasomy [Presence] in Fixed tissue by Molecular genetics method;Chr 12p tetrasomy Ftis Ql;;ACTIVE;2.16;2.66 +42636-1;Urease^3H post incubation;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --3 hours post incubation;Urease 3h p Inc Tiss Ql;;ACTIVE;2.16;2.56 +42637-9;Natriuretic peptide.B;MCnc;Pt;Bld;Qn;;CHEM;1;Natriuretic peptide B [Mass/volume] in Blood;BNP Bld-mCnc;;ACTIVE;2.16;2.73 +42638-7;Coagulation tissue factor induced;Time;Pt;PPP;Qn;Coag.saline 1:1;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation 1:1 saline;PT PPP 1:1 saline;;ACTIVE;2.16;2.70 +42639-5;Immune complex.IgG;ACnc;Pt;Ser/Plas;Qn;C1q binding assay;SERO;1;Immune complex.IgG [Units/volume] in Serum or Plasma by C1q binding assay;IC IgG SerPl C1Q Bind-aCnc;;ACTIVE;2.16;2.70 +42640-3;Urease^1D post incubation;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --1 day post incubation;Urease 1d p Inc Tiss Ql;;ACTIVE;2.16;2.56 +42641-1;Babesia sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Babesia sp DNA [Presence] in Specimen by NAA with probe detection;Babesia DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +42642-9;Amikacin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 2 ug/mL Islt SlowMyco;;ACTIVE;2.16;2.26 +42643-7;Capreomycin 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Capreomycin 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Capreomycin 10 ug/mL Islt Slo;;DEPRECATED;2.16;2.36 +42644-5;Ciprofloxacin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ciprofloxacin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ciprofloxacin 2 ug/mL Islt Sl;;DEPRECATED;2.16;2.36 +42645-2;Ethambutol 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ethambutol 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ethambutol 10 ug/mL Islt Slow;;DEPRECATED;2.16;2.36 +42646-0;Ethambutol 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ethambutol 5.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ethambutol 5 ug/mL Islt SlowM;;DEPRECATED;2.16;2.36 +42647-8;Ethionamide 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ethionamide 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ethionamide 10 ug/mL Islt Slo;;DEPRECATED;2.16;2.36 +4264-8;Flurazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Flurazepam [Mass] of Dose;Flurazepam Dose;;ACTIVE;1.0;2.69 +42648-6;Ethionamide 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ethionamide 5.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ethionamide 5 ug/mL Islt Slow;;DEPRECATED;2.16;2.36 +42649-4;Isoniazid 0.2 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Isoniazid 0.2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Isoniazid 0.2 ug/mL Islt Slow;;DEPRECATED;2.16;2.36 +42650-2;Isoniazid 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Isoniazid 1.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Isoniazid 1 ug/mL Islt SlowMy;;DEPRECATED;2.16;2.36 +42651-0;Isoniazid 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid 5 ug/mL Islt SlowMyco;;ACTIVE;2.16;2.26 +42652-8;Kanamycin 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Kanamycin 5.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Kanamycin 5 ug/mL Islt SlowMy;;DEPRECATED;2.16;2.36 +42653-6;Ofloxacin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Ofloxacin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Ofloxacin 2 ug/mL Islt SlowMy;;DEPRECATED;2.16;2.36 +42654-4;Para aminosalicylate 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Para aminosalicylate 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated PAS 2 ug/mL Islt SlowMyco;;DEPRECATED;2.16;2.36 +4265-5;Furfenorex;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Furfenorex [Mass] of Dose;Furfenorex Dose;;ACTIVE;1.0;2.69 +42655-1;Rifabutin 0.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Rifabutin 0.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Rifabutin 0.5 ug/mL Islt SlowMyco;;ACTIVE;2.16;2.26 +42656-9;Rifabutin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Rifabutin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Rifabutin 2 ug/mL Islt SlowMy;;DEPRECATED;2.16;2.36 +42657-7;rifAMPin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated rifAMPin 1.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated rifAMPin 1 ug/mL Islt SlowMyc;;DEPRECATED;2.16;2.36 +42658-5;Streptomycin 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Streptomycin 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Streptomycin 10 ug/mL Islt Sl;;DEPRECATED;2.16;2.36 +42659-3;Streptomycin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Streptomycin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Streptomycin 2 ug/mL Islt Slo;;DEPRECATED;2.16;2.36 +42660-1;Alpha 2 laminin;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alpha 2 laminin [Presence] in Tissue by Immune stain;A2 Laminin Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42661-9;Bacteria identified;Prid;Pt;Isolate;Nom;PFGE;MICRO;1;Bacteria identified in Isolate by Pulsed-Field Gel Electrophoresis (PFGE);Bacteria Islt PFGE;;ACTIVE;2.16;2.19 +42662-7;Benzodiazepines;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Blood;Benzodiaz Bld Ql;;ACTIVE;2.16;2.73 +4266-3;Furosemide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Furosemide [Mass] of Dose;Furosemide Dose;;ACTIVE;1.0;2.69 +42663-5;HLA-Cw locus;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-Cw locus [Type];HLA-Cw locus;;ACTIVE;2.16;2.73 +42664-3;HLA-Cw;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-Cw [Type];HLA-Cw;;ACTIVE;2.16;2.73 +42665-0;Dantron;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Dantron [Mass/mass] in Stool;Dantron Stl-mCnt;;ACTIVE;2.16;2.30 +42666-8;Fat.neutral;Naric;Pt;Plr fld;Qn;Microscopy.light.HPF;CHEM;1;Fat.neutral [#/area] in Pleural fluid by Microscopy high power field;Neutral Fat #/area Plr HPF;;ACTIVE;2.16;2.70 +42667-6;Fatty acids;PrThr;Pt;Urine;Ord;;CHEM;1;Fatty acids [Presence] in Urine;FA Ur Ql;;ACTIVE;2.16;2.56 +42668-4;Fatty acids;PrThr;Pt;Stool;Ord;;CHEM;1;Fatty acids [Presence] in Stool;FA Stl Ql;;ACTIVE;2.16;2.73 +42669-2;Fatty acids;PrThr;Pt;Plr fld;Ord;;CHEM;1;Fatty acids [Presence] in Pleural fluid;FA Plr Ql;;ACTIVE;2.16;2.56 +426-7;Pyrazinamide;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Pyrazinamide [Susceptibility] by Serum bactericidal titer;PZA Titr SBT;;ACTIVE;1.0;2.32 +42670-0;pH;LsCnc;Pt;Vitr fld;Qn;;CHEM;1;pH of Vitreous fluid;pH Vitf;;ACTIVE;2.16;2.42 +4267-1;Galactose.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Galactose.PO [Mass] of Dose;Galactose PO Dose;;ACTIVE;1.0;2.69 +42671-8;Serotonin;EntMass;Pt;Platelets;Qn;;CHEM;1;Serotonin [Entitic mass] in Platelets;Serotonin Plts Qn;;ACTIVE;2.16;2.70 +42672-6;Debris;PrThr;Pt;Semen;Ord;;FERT;1;Debris [Presence] in Semen;Debris Smn Ql;;ACTIVE;2.16;2.73 +42673-4;Calcium hydrogen phosphate dihydrate;SatFr;24H;Urine;Qn;;CHEM;1;Calcium hydrogen phosphate dihydrate [Saturation Fraction] in 24 hour Urine;Ca H2 Phos dihyd 24h SatFr Ur;;ACTIVE;2.16;2.73 +42674-2;Fat.neutral;Naric;Pt;Urine;Qn;Microscopy.light.HPF;UA;1;Fat.neutral [#/area] in Urine by Microscopy high power field;Neutral Fat #/area Ur HPF;;ACTIVE;2.16;2.73 +42675-9;HLA Ag;Imp;Pt;Bld/Tiss;Nom;;HLA;1;HLA Ag [Interpretation];HLA Ag-Imp;;ACTIVE;2.16;2.73 +42676-7;Spermatozoa.normal.motile;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Normal Motile [#/volume] in Semen;Sperm Norm Motile # Smn;;ACTIVE;2.16;2.73 +42677-5;Succinylacetone;Sub;Pt;Bld.dot;Qn;;CHEM;1;Succinylacetone [Molar amount] in DBS;Succinylacetone sub DBS Qn;;ACTIVE;2.16;2.70 +42678-3;Urate;SatFr;24H;Urine;Qn;;CHEM;1;Urate [Saturation Fraction] in 24 hour Urine;Urate 24h SatFr Ur;;ACTIVE;2.16;2.73 +42679-1;Heparin;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Heparin [Units/volume] in Platelet poor plasma by Chromogenic method;Heparin PPP Chro-aCnc;;DISCOURAGED;2.16;2.73 +42680-9;View XCCL;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast XCCL;MG Brst XCCL;;ACTIVE;2.16;2.61 +42681-7;Views^W gastrografin PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views W gastrografin PR;RF Colon Views W Gastrografin PR;;ACTIVE;2.16;2.64 +42682-5;Succinyladenosine;SCnc;Pt;CSF;Qn;;CHEM;1;Succinyladenosine [Moles/volume] in Cerebral spinal fluid;Succinyladenosine CSF-sCnc;;ACTIVE;2.16;2.70 +42683-3;View && Views^W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;Deprecated XR and RF Gastrointestinal tract upper View and Views W barium contrast PO;Deprecated XR and Flr UGI View + Views W;;DEPRECATED;2.16;2.61 +42684-1;Views^W gastrografin PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Gastrointestinal tract upper Views W gastrografin PO;RF UGI Views W Gastrografin PO;;ACTIVE;2.16;2.64 +42685-8;Views 2;Find;Pt;Pelvis & Lower extremity.left>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - left 2 Views;XR Pelvis and Hip-L 2V;;ACTIVE;2.16;2.61 +42686-6;Views 2;Find;Pt;Pelvis & Lower extremity.right>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - right 2 Views;XR Pelvis and Hip-R 2V;;ACTIVE;2.16;2.61 +42687-4;Views 2;Find;Pt;Chest>Ribs.bilateral;Doc;XR;RAD;2;XR Ribs - bilateral 2 Views;XR Ribs-Bl 2V;;ACTIVE;2.16;2.61 +42688-2;Guidance for nerve block;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Guidance for nerve block of Spine;CT Guided Spine Nerve block;;DISCOURAGED;2.16;2.64 +4268-9;Gentamicin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Gentamicin [Mass] of Dose;Gentamicin Dose;;ACTIVE;1.0;2.73 +42689-0;View oblique;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Oblique;XR Spine Obl;;DISCOURAGED;2.16;2.64 +42690-8;Views^W flexion + W extension;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Views W flexion and W extension;XR Spine Views W FE;;DISCOURAGED;2.16;2.64 +42691-6;Views 6;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 6 Views;XR C-spine 6V;;ACTIVE;2.16;2.61 +42692-4;Views;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine Views;XR T+L-Spine Views;;ACTIVE;2.16;2.64 +42693-2;Multisection cine;Find;Pt;Pelvis>Urinary bladder+Urethra;Doc;MR;RAD;2;MR Urinary bladder and Urethra cine;MR Bladder+Urethra Cine;;ACTIVE;2.16;2.61 +42694-0;Multisection^W contrast IV;Find;Pt;Chest>Clavicle;Doc;MR;RAD;2;MR Clavicle W contrast IV;MR Clavicle W contr IV;;ACTIVE;2.16;2.61 +42695-7;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Lower leg;Doc;MR;RAD;2;MR Lower leg - bilateral W contrast IV;MR Lower leg-Bl W contr IV;;ACTIVE;2.16;2.61 +42696-5;Multisection;Find;Pt;Lower extremity.bilateral>Lower leg;Doc;MR;RAD;2;MR Lower leg - bilateral;MR Lower leg-Bl;;ACTIVE;2.16;2.61 +4269-7;Glucose.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Glucose.PO [Mass] of Dose;Glucose PO Dose;;ACTIVE;1.0;2.73 +42697-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Lower leg;Doc;MR;RAD;2;MR Lower leg - bilateral WO and W contrast IV;MR Lower leg-Bl WO+W contr IV;;ACTIVE;2.16;2.61 +42698-1;Multisection;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Cervical and thoracic and lumbar spine;MR C+T+L-spine;;ACTIVE;2.16;2.61 +42699-9;View;Find;Pt;Chest+Abdomen;Doc;XR;RAD;2;XR Chest and Abdomen Single view;XR Chest+Abd 1V;;ACTIVE;2.16;2.64 +42700-5;Views^W Tc-99m tagged WBC IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Views W Tc-99m tagged WBC IV;NM Bone Views W Tc99m WBC IV;;ACTIVE;2.16;2.64 +42701-3;Guidance for localization of placenta;Find;Pt;Pelvis>Uterus;Doc;CT;RAD;2;CT Guidance for localization of placenta of Uterus;CT Guided Uterus Placenta loc;;ACTIVE;2.16;2.64 +42702-1;View;Find;Gt 1H;XXX;Doc;RF;RAD;2;RF Greater than 1 hour;RF >1h;;ACTIVE;2.16;2.64 +42703-9;View;Find;Lt 1H;XXX;Doc;RF;RAD;2;RF Less than 1 hour;RF <1h;;ACTIVE;2.16;2.64 +42704-7;Diameter^baseline;Len;Pt;Follicle;Qn;US.measured;OB.US;2;Follicle Diameter baseline US;Follicle Diam BS US.meas;;ACTIVE;2.16;2.48 +4270-5;Glutethimide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Glutethimide [Mass] of Dose;Glutethimide Dose;;ACTIVE;1.0;2.69 +42705-4;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen+Pelvis>Appendix;Doc;US;RAD;2;US Guidance for drainage of abscess and placement of drainage catheter of Appendix;US Guided Appendix Absc drain+cath place;;ACTIVE;2.16;2.66 +42706-2;Guidance for injection;Find;Pt;Chest>Pleural space;Doc;US;RAD;2;US Guidance for injection of Pleural space;US Guided Pl space Inj;;ACTIVE;2.16;2.64 +42707-0;Multisection limited;Find;Pt;Chest>Heart;Doc;US;RAD;2;US Heart limited;US Hrt Ltd;;ACTIVE;2.16;2.61 +42708-8;Views^W In-111 tiuxetan IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W In-111 tiuxetan IV;NM Whole body Views W In-111-T IV;;ACTIVE;2.16;2.64 +42709-6;Views blood pool^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Blood pool;NM Liver BP W RNC IV;;ACTIVE;2.16;2.61 +42710-4;Views limited;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Limited Views;XR C-spine Views Ltd;;ACTIVE;2.16;2.64 +42711-2;Views^W In-111 tagged WBC IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W In-111 tagged WBC IV;NM Whole body Views W In-111 WBC IV;;ACTIVE;2.16;2.64 +42712-0;AML+MDS gene 7q31 deletion;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DEL;1;AML/MDS gene 7q31 deletion [Identifier] in Blood or Tissue by Molecular genetics method Nominal;AML/MDS 7q31 Del Bld/T;;ACTIVE;2.16;2.73 +4271-3;Gonadotropin releasing hormone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Gonadotropin releasing hormone [Mass] of Dose;GnRH Dose;;ACTIVE;1.0;2.69 +42713-8;AML+MDS gene CEP 8 trisomy;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRISOMY;1;AML/MDS gene CEP 8 trisomy [Presence] in Blood or Tissue by Molecular genetics method;AML/MDS CEP8 Ts Bld/T Ql;;ACTIVE;2.16;2.73 +42714-6;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)p210 Bld/T Ql;;ACTIVE;2.16;2.73 +42715-3;Del(5)(q12-35) gene deletion;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DEL;1;Del(5)(q12-35) deletion [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Del(5)(q12-35) Del Bld/T;;ACTIVE;2.16;2.73 +42716-1;Mycobacterium sp rRNA;Prid;Pt;Isolate;Nar;Probe.amp.tar;MICRO;1;Mycobacterium sp rRNA [Identifier] in Isolate by NAA with probe detection;Mycobacterium rRNA Islt NAA+probe;;ACTIVE;2.16;2.63 +42717-9;Mycobacterium tuberculosis complex genotype;Prid;Pt;Isolate;Nar;;MICRO;1;Mycobacterium tuberculosis complex genotype [Identifier] in Isolate;M TB Cmplx Gentyp Islt;;ACTIVE;2.16;2.34 +42718-7;Alkaline phosphatase.heat labile/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;Heat stability;CHEM;1;Alkaline phosphatase.heat labile/Alkaline phosphatase.total in Serum or Plasma by Heat stability;ALP heat labile CFr SerPl HS;;ACTIVE;2.16;2.73 +42719-5;Bilirubin;MCnc;Pt;Bld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Blood;Bilirub Bld-mCnc;;ACTIVE;2.16;2.73 +42720-3;Clindamycin.induced;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clindamycin.induced [Susceptibility] by Disk diffusion (KB);Clindamycin.induced Islt KB;;ACTIVE;2.16;2.73 +4272-1;Haloperidol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Haloperidol [Mass] of Dose;Haloperidol Dose;;ACTIVE;1.0;2.69 +42721-1;Staphylococcus sp.oxacillin resistant isolate;PrThr;Pt;Isolate;Ord;LA;MICRO;1;Oxacillin Resistant Staphylococcus sp isolate [Presence] in Isolate by Latex agglutination;OxRes Staph Islt Ql LA;;ACTIVE;2.16;2.73 +42722-9;OmpC Ab;PrThr;Pt;Ser;Ord;;SERO;1;OmpC Ab [Presence] in Serum;OmpC Ab Ser Ql;;ACTIVE;2.16;2.56 +42723-7;OmpC Ab;ACnc;Pt;Ser;Qn;;SERO;1;OmpC Ab [Units/volume] in Serum;OmpC Ab Ser-aCnc;;ACTIVE;2.16;2.70 +42724-5;OmpC Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;OmpC Ab [Presence] in Serum by Immunoassay;OmpC Ab Ser Ql IA;;ACTIVE;2.16;2.56 +42725-2;Bromide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Bromide [Mass/volume] in Blood;Bromide Bld-mCnc;;ACTIVE;2.16;2.40 +42726-0;Cerebroside sulfatase;CCnc;24H;Urine;Qn;;CHEM;1;Cerebroside sulfatase [Enzymatic activity/volume] in 24 hour Urine;Arylsulfatase A 24h Ur-cCnc;;ACTIVE;2.16;2.73 +42727-8;Fibrin D-dimer DDU;MCnc;Pt;CSF;Qn;LA;COAG;1;Fibrin D-dimer DDU [Mass/volume] in Cerebral spinal fluid by Latex agglutination;D dimer DDU CSF LA-mCnc;;ACTIVE;2.16;2.70 +42728-6;pH;LsCnc;Pt;Ocular fld;Qn;;CHEM;1;pH of Ocular fluid;pH Ocflu;;ACTIVE;2.16;2.42 +42729-4;Cardiolipin Ab.IgA.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgA Ab B2GP1 dependent [Multiple of the median] in Serum;Cardiolipin IgA B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42730-2;Cardiolipin Ab.IgA.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgA Ab B2GP1 independent [Multiple of the median] in Serum;Cardiolipin IgA B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42731-0;Cardiolipin Ab.IgG.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgG Ab B2GP1 dependent [Multiple of the median] in Serum;Cardiolipin IgG B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42732-8;Cardiolipin Ab.IgG.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgG Ab B2GP1 independent [Multiple of the median] in Serum;Cardiolipin IgG B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42733-6;Cardiolipin Ab.IgM.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgM Ab B2GP1 dependent [Multiple of the median] in Serum;Cardiolipin IgM B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42734-4;Cardiolipin Ab.IgM.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgM Ab B2GP1 independent [Multiple of the median] in Serum;Cardiolipin IgM B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42735-1;Cells.CD20+CD117+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20+CD117+ cells/100 cells in Blood;CD20+CD117+ Cells NFr Bld;;ACTIVE;2.16;2.34 +42736-9;Cells.CD20+CD23+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20+CD23+ cells/100 cells in Blood;CD20+CD23+ Cells NFr Bld;;ACTIVE;2.16;2.34 +42737-7;Cells.CD4+CD7+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD7+ cells/100 cells in Blood;CD4+CD7+ Cells NFr Bld;;ACTIVE;2.16;2.73 +42738-5;Cells.CD7+CD8+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD7+CD8+ cells/100 cells in Blood;CD7+CD8+ Cells NFr Bld;;ACTIVE;2.16;2.34 +4273-9;Heptaminol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Heptaminol [Mass] of Dose;Heptaminol Dose;;ACTIVE;1.0;2.69 +42739-3;Phosphatidylcholine Ab.IgA.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgA Ab B2GP1 dependent [Multiple of the median] in Serum;PC IgA B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42740-1;Phosphatidylcholine Ab.IgA.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgA Ab B2GP1 independent [Multiple of the median] in Serum;PC IgA B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42741-9;Phosphatidylcholine Ab.IgG.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgG Ab B2GP1 dependent [Multiple of the median] in Serum;PC IgG B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42742-7;Phosphatidylcholine Ab.IgG.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgG Ab B2GP1 independent [Multiple of the median] in Serum;PC IgG B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42743-5;Phosphatidylcholine Ab.IgM.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgM Ab B2GP1 dependent [Multiple of the median] in Serum;PC IgM B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42744-3;Phosphatidylcholine Ab.IgM.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylcholine IgM Ab B2GP1 independent [Multiple of the median] in Serum;PC IgM B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42745-0;Phosphatidylethanolamine Ab.IgA.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgA Ab B2GP1 dependent [Multiple of the median] in Serum;PE IgA B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42746-8;Phosphatidylethanolamine Ab.IgA.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgA Ab B2GP1 independent [Multiple of the median] in Serum;PE IgA B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +4274-7;Hippurate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Hippurate [Mass] of Dose;Hippurate Dose;;ACTIVE;1.0;2.69 +42747-6;Phosphatidylethanolamine Ab.IgG.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgG Ab B2GP1 dependent [Multiple of the median] in Serum;PE IgG B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42748-4;Phosphatidylethanolamine Ab.IgG.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgG Ab B2GP1 independent [Multiple of the median] in Serum;PE IgG B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42749-2;Phosphatidylethanolamine Ab.IgM.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgM Ab B2GP1 dependent [Multiple of the median] in Serum;PE IgM B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +427-5;rifAMPin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;rifAMPin [Susceptibility] by Minimum lethal concentration (MLC);rifAMPin Islt MLC;;ACTIVE;1.0;2.19 +42750-0;Phosphatidylethanolamine Ab.IgM.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylethanolamine IgM Ab B2GP1 independent [Multiple of the median] in Serum;PE IgM B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42751-8;Phosphatidylserine Ab.IgA.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgA Ab B2GP1 dependent [Multiple of the median] in Serum;PS IgA B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42752-6;Phosphatidylserine Ab.IgA.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgA Ab B2GP1 independent [Multiple of the median] in Serum;PS IgA B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42753-4;Phosphatidylserine Ab.IgG.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgG Ab B2GP1 dependent [Multiple of the median] in Serum;PS IgG B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +4275-4;hydroCHLOROthiazide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;hydroCHLOROthiazide [Mass] of Dose;HTCZ Dose;;ACTIVE;1.0;2.69 +42754-2;Phosphatidylserine Ab.IgG.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgG Ab B2GP1 independent [Multiple of the median] in Serum;PS IgG B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42755-9;Phosphatidylserine Ab.IgM.B2GP1 dependent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgM Ab B2GP1 dependent [Multiple of the median] in Serum;PS IgM B2GP1 dep MoM Ser;;ACTIVE;2.16;2.70 +42756-7;Phosphatidylserine Ab.IgM.B2GP1 independent;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgM Ab B2GP1 independent [Multiple of the median] in Serum;PS IgM B2GP1 indep MoM Ser;;ACTIVE;2.16;2.70 +42757-5;Troponin I.cardiac;MCnc;Pt;Bld;Qn;;CHEM;1;Troponin I.cardiac [Mass/volume] in Blood;Troponin I Bld-mCnc;;ACTIVE;2.16;2.73 +42758-3;Reticulocytes;NCnc;Pt;Bld;Qn;Calculated;HEM/BC;1;Reticulocytes [#/volume] in Blood by calculation;Retics # Calc;;DISCOURAGED;2.16;2.73 +42759-1;Lymphocytes B;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;B lymphocytes [#/volume] in Bone marrow;B Lymphocytes # Mar;;ACTIVE;2.16;2.73 +42760-9;Inflammatory bowel disease Ab panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Inflammatory bowel disease Ab panel - Serum;IBD Ab Pnl Ser;;ACTIVE;2.16;2.73 +4276-2;HYDROcodone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;HYDROcodone [Mass] of Dose;HYDROcodone Dose;;ACTIVE;1.0;2.69 +42764-1;Crystals;Prid;Pt;Vitr fld;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Vitreous fluid by Light microscopy;Crystals Vitf Micro;;ACTIVE;2.16;2.73 +42765-8;Tube number;ID;Pt;Body fld;Nom;;SPEC;1;Tube number of Body fluid;Tube # Fld;;ACTIVE;2.16;2.73 +42766-6;Aspergillus sp Ab;Imp;Pt;Ser;Nar;Immune diffusion;MICRO;1;Aspergillus sp Ab [Interpretation] in Serum by Immune diffusion (ID) Narrative;Aspergillus Ab Ser ID-Imp;;ACTIVE;2.16;2.16 +42767-4;Borrelia burgdorferi Ab.IgG & IgM;Imp;Pt;CSF;Nom;;MICRO;1;Borrelia burgdorferi IgG and IgM [Interpretation] in Cerebral spinal fluid;B burgdor IgG+IgM CSF-Imp;;ACTIVE;2.16;2.73 +42768-2;HIV 1 & 2 Ab;Imp;Pt;Ser;Nar;;MICRO;1;HIV 1 and 2 Ab [Interpretation] in Serum Narrative;HIV 1 & 2 Ab Ser-Imp;;ACTIVE;2.16;2.73 +42769-0;HTLV I+II Ab;Imp;Pt;Ser;Nar;;MICRO;1;HTLV I+II Ab [Interpretation] in Serum Narrative;HTLV I+II Ab Ser-Imp;;ACTIVE;2.16;2.73 +4277-0;HYDROmorphone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated HYDROmorphone [Mass] of Dose;Deprecated HYDROmorphone Dose;;DEPRECATED;1.0;2.69 +42770-8;Human papilloma virus high & Low risk DNA panel;-;Pt;Cvx;-;;PANEL.MICRO;1;Human papilloma virus high and Low risk DNA panel - Cervix;HPV High+Low Risk DNA Pnl Cvx;;ACTIVE;2.16;2.73 +42771-6;Streptococcus pneumoniae serotype Ab.IgG;Imp;Pt;Ser;Nar;;MICRO;1;Streptococcus pneumoniae serotype IgG Ab [Interpretation] in Serum Narrative;S pneum serotype IgG Ser-Imp;;ACTIVE;2.16;2.73 +42772-4;Fibrinogen Ag;MCnc;Pt;PPP;Qn;Nephelometry;COAG;1;Fibrinogen Ag [Mass/volume] in Platelet poor plasma by Nephelometry;Fibrinogen Ag PPP Neph-mCnc;;ACTIVE;2.16;2.73 +42773-2;Multiple drug resistant organism identified;Prid;Pt;Urine;Nom;;MICRO;1;Multiple drug resistant organism identified in Urine;MDRO Ur;;ACTIVE;2.16;2.19 +42774-0;Multiple drug resistant organism identified;Prid;Pt;Wound;Nom;;MICRO;1;Multiple drug resistant organism identified in Wound;MDRO Wnd;;ACTIVE;2.16;2.19 +42775-7;Multiple drug resistant organism identified;Prid;Pt;Sputum;Nom;;MICRO;1;Multiple drug resistant organism identified in Sputum;MDRO Spt;;ACTIVE;2.16;2.19 +42776-5;Views for AV shunt^W radionuclide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for AV shunt;NM Views for AV shunt W RNC IV;;ACTIVE;2.16;2.64 +42777-3;AKT1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;AKT1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;AKT1 gene Mut Anl Bld/T;;ACTIVE;2.16;2.63 +42778-1;BRCA1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BRCA1 Ag [Presence] in Tissue by Immune stain;BRCA1 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42779-9;BRCA2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BRCA2 Ag [Presence] in Tissue by Immune stain;BRCA2 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42780-7;CCND1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CCND1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CCND1 gene Mut Anl Bld/T;;ACTIVE;2.16;2.63 +42781-5;Surgical operation date;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Surgical operation date Cancer;Surgical operation date Cancer;;ACTIVE;2.16;2.56 +42782-3;Epidermal growth factor receptor.phosphorylated Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Epidermal growth factor receptor.phosphorylated Ag [Presence] in Tissue by Immune stain;EGFR Phospho Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42783-1;ERBB2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ERBB2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ERBB2 gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +42784-9;Ethnic background;Type;Pt;^Patient;Nom;Stated;TUMRRGT;2;Ethnic background Stated;Ethnic Background Stated;;ACTIVE;2.16;2.73 +42785-6;FGFR1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGFR1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FGFR1 gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +42786-4;HER3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;HER3 Ag [Presence] in Tissue by Immune stain;Her3 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42787-2;HER4 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;HER4 Ag [Presence] in Tissue by Immune stain;Her4 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +4278-8;Hydroxychloroquine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Hydroxychloroquine [Mass] of Dose;OH-Chloroquine Dose;;ACTIVE;1.0;2.69 +42788-0;Insulin-like growth factor-I receptor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Insulin-like growth factor-I receptor Ag [Presence] in Tissue by Immune stain;IGF-IR Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42789-8;Mitogen-Activated protein kinase 14 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Mitogen-Activated protein kinase 14 Ag [Presence] in Tissue by Immune stain;MAPK 14 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42790-6;MAP kinase 14;ACnc;Pt;Tiss;Ord;Immune stain;PATH;1;Deprecated Mitogen-Activated protein kinase 14 Ag [Presence] in Tissue by Immune stain;Deprecated MAP kinase 14 Tiss Ql ImStn;;DEPRECATED;2.16;2.36 +42791-4;Mitogen-Activated protein kinase 3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Mitogen-Activated protein kinase 3 Ag [Presence] in Tissue by Immune stain;MAPK 3 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42792-2;Mitogen-Activated protein kinase 8 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Mitogen-Activated protein kinase 8 Ag [Presence] in Tissue by Immune stain;MAPK 8 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42793-0;Mitogen-Activated protein kinase 9 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Mitogen-Activated protein kinase 9 Ag [Presence] in Tissue by Immune stain;MAPK 9 Ag Tiss Ql ImStn;;ACTIVE;2.16;2.56 +42794-8;MYC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MYC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MYC gene Mut Anl Bld/T;;ACTIVE;2.16;2.73 +42795-5;Retinoblastoma protein;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Retinoblastoma protein [Presence] in Tissue by Immune stain;RB protein Tiss Ql ImStn;;ACTIVE;2.16;2.56 +4279-6;Hydroxymethoxyphenamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Hydroxymethoxyphenamine [Mass] of Dose;OH-Methoxyphenamine Dose;;ACTIVE;1.0;2.69 +42796-3;Trial name;-;-;^Clinical trial protocol;Nar;;DOC.REF.CTP;2;Clinical trial protocol Trial name;CTP Trial Name;;ACTIVE;2.16;2.27 +42797-1;Age at first pregnancy;Time;Pt;^Patient;Qn;;MISC;1;Age at first pregnancy;Age @ 1st pregnancy;;ACTIVE;2.16;2.70 +42798-9;Age at menarche;Time;Pt;^Patient;Qn;;MISC;1;Age at menarche;Age @ Menarche Time Patient;;ACTIVE;2.16;2.73 +42799-7;Quadrant;Arb;Pt;Breast;Nom;;TUMRRGT;2;Quadrant Breast;Quadrant Brst;;ACTIVE;2.16;2.27 +42800-3;ECOG performance status grade;Prid;Pt;^Patient;Nom;Observed;TUMRRGT;2;Deprecated ECOG performance status grade Observed;Deprecated ECOG perf status grade Observ;;DEPRECATED;2.16;2.64 +42801-1;Histology grade;Prid;Pt;Cancer specimen;Nom;Nottingham combined;PATH.PROTOCOLS.GENER;1;Deprecated Histology grade in Cancer specimen by Nottingham combined;Deprecated Histology grade Ca spec Notti;;DEPRECATED;2.16;2.61 +42802-9;Age at menopause;Time;Pt;^Patient;Qn;;MISC;1;Age at menopause;Age @ Menopause Time Patient;;ACTIVE;2.16;2.73 +42803-7;Bacteria identified;Prid;Pt;Isolate;Nom;;MICRO;1;Bacteria identified in Isolate;Bacteria Islt;;ACTIVE;2.16;2.73 +4280-4;hydrOXYzine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;hydrOXYzine [Mass] of Dose;hydrOXYzine Dose;;ACTIVE;1.0;2.69 +42804-5;Fungus identified;Prid;Pt;Isolate;Nom;;MICRO;1;Fungus identified in Isolate;Fungus Islt;;ACTIVE;2.16;2.73 +42805-2;Fungus identified;Prid;Pt;XXX;Nom;;MICRO;1;Fungus identified in Specimen;Fungus Spec;;ACTIVE;2.16;2.73 +42806-0;Bacteria identified;Prid;Pt;Isolate;Nom;;MICRO;1;Deprecated Bacteria identified in Isolate;Deprecated Bacteria Islt;;DEPRECATED;2.16;2.36 +42807-8;Parasite identified;Prid;Pt;Isolate;Nom;;MICRO;1;Parasite identified in Isolate;Parasite Islt;;ACTIVE;2.16;2.73 +42808-6;Virus identified;Prid;Pt;Isolate;Nom;;MICRO;1;Virus identified in Isolate;Virus Islt;;ACTIVE;2.16;2.19 +42809-4;Fungus identified;Prid;Pt;XXX;Nom;Culture;MICRO;1;Deprecated Fungus identified in Unspecified specimen by Culture;Deprecated Fungus XXX Cult;;DEPRECATED;2.16;2.69 +42810-2;Hemoglobin;EntMass;Pt;Retic;Qn;;HEM/BC;1;Hemoglobin [Entitic mass] in Reticulocytes;Hgb Retic Qn;;ACTIVE;2.16;2.73 +42811-0;View scaphoid;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right scaphoid single view;XR Wrist-R Scaphoid 1 view;;ACTIVE;2.16;2.61 +4281-2;Ibuprofen;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ibuprofen [Mass] of Dose;Ibuprofen Dose;;ACTIVE;1.0;2.73 +42812-8;View scaphoid;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist scaphoid single view;XR Wrist Scaphoid 1 view;;ACTIVE;2.16;2.61 +42813-6;View scaphoid;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral scaphoid single view;XR Wrist-Bl Scaphoid 1 view;;ACTIVE;2.16;2.61 +42814-4;View scaphoid;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left scaphoid single view;XR Wrist-L Scaphoid 1 view;;ACTIVE;2.16;2.61 +42815-1;Stachybotrys chartarum Ab.IgE;MCnc;Pt;Ser;Qn;;ALLERGY;1;Stachybotrys chartarum IgE Ab [Mass/volume] in Serum;S chartarum IgE-mCnc;;ACTIVE;2.16;2.70 +42816-9;Stachybotrys chartarum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Stachybotrys chartarum IgG Ab [Mass/volume] in Serum;S chartarum IgG-mCnc;;ACTIVE;2.16;2.73 +42817-7;Cells.CD38+Kappa+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38+Kappa+ cells/100 cells in Blood;CD38+Kappa+ Cells NFr Bld;;ACTIVE;2.16;2.34 +42818-5;Cells.CD38+Lambda+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38+ Lambda+ cells/100 cells in Blood;CD38+ Lambda+ Cells NFr Bld;;ACTIVE;2.16;2.34 +42819-3;Failure to thrive;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Failure to thrive [CCC];;;ACTIVE;2.16;2.56 +4282-0;Imipenem;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Imipenem [Mass] of Dose;Imipenem Dose;;ACTIVE;1.0;2.69 +42820-1;Intracranial adaptive capacity impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Intracranial adaptive capacity impairment [CCC];;;ACTIVE;2.16;2.56 +42821-9;Caregiver role strain;Find;Pt;^Caregiver;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Caregiver role strain Caregiver [CCC];;;ACTIVE;2.16;2.56 +42822-7;Relocation stress syndrome;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Relocation stress syndrome [CCC];;;ACTIVE;2.16;2.56 +42823-5;Suicide risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Suicide risk [CCC];;;ACTIVE;2.16;2.56 +42824-3;Self mutilation risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Self mutilation risk [CCC];;;ACTIVE;2.16;2.56 +42825-0;Perioperative injury risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Perioperative injury risk [CCC];;;ACTIVE;2.16;2.56 +42826-8;Perioperative positioning injury;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Perioperative positioning injury [CCC];;;ACTIVE;2.16;2.56 +42827-6;Surgical recovery delay;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Surgical recovery delay [CCC];;;ACTIVE;2.16;2.56 +42828-4;Substance abuse;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Substance abuse [CCC];;;ACTIVE;2.16;2.56 +42829-2;Tobacco abuse;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Tobacco abuse [CCC];;;ACTIVE;2.16;2.56 +428-3;rifAMPin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;rifAMPin [Susceptibility] by Minimum inhibitory concentration (MIC);rifAMPin Islt MIC;;ACTIVE;1.0;2.73 +42830-0;Alcohol abuse;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Alcohol abuse [CCC];;;ACTIVE;2.16;2.56 +42831-8;Drug abuse;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Drug abuse [CCC];;;ACTIVE;2.16;2.56 +42832-6;Latex allergy response;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Latex allergy response [CCC];;;ACTIVE;2.16;2.56 +42833-4;Reproductive risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Reproductive risk [CCC];;;ACTIVE;2.16;2.56 +42834-2;Fertility risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fertility risk [CCC];;;ACTIVE;2.16;2.56 +42835-9;Infertility risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Infertility risk [CCC];;;ACTIVE;2.16;2.56 +42836-7;Contraception risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Contraception risk [CCC];;;ACTIVE;2.16;2.56 +42837-5;Perinatal risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Perinatal risk [CCC];;;ACTIVE;2.16;2.56 +4283-8;Imipramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Imipramine [Mass] of Dose;Imipramine Dose;;ACTIVE;1.0;2.69 +42838-3;Pregnancy risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Pregnancy risk [CCC];;;ACTIVE;2.16;2.56 +42839-1;Labor risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Labor risk [CCC];;;ACTIVE;2.16;2.56 +42840-9;Delivery risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Delivery risk [CCC];;;ACTIVE;2.16;2.56 +42841-7;Postpartum risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Postpartum risk [CCC];;;ACTIVE;2.16;2.56 +42842-5;Newborn behavior alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Newborn behavior alteration [CCC];;;DISCOURAGED;2.16;2.56 +42843-3;Infant behavior alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Infant behavior alteration [CCC];;;DISCOURAGED;2.16;2.56 +42844-1;Child behavior alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HIV-SSC;4;Child behavior alteration [CCC];;;DISCOURAGED;2.16;2.56 +42845-8;Adolescent behavior alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Adolescent behavior alteration [CCC];;;DISCOURAGED;2.16;2.56 +4284-6;Indomethacin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Indomethacin [Mass] of Dose;Indomethacin Dose;;ACTIVE;1.0;2.69 +42846-6;Adult behavior alteration;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Adult behavior alteration [CCC];;;DISCOURAGED;2.16;2.56 +42847-4;Sleep deprivation;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Sleep deprivation [CCC];;;ACTIVE;2.16;2.56 +42848-2;Nausea;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Nausea [CCC];;;ACTIVE;2.16;2.56 +42849-0;Confusion;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Confusion [CCC];;;ACTIVE;2.16;2.56 +42850-8;Memory impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Memory impairment [CCC];;;ACTIVE;2.16;2.56 +42851-6;Infant feeding pattern impairment;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Infant feeding pattern impairment [CCC];;;ACTIVE;2.16;2.56 +42852-4;Older adult behavior alteration.sixty five Y and older;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Older adult behavior alteration.sixty five years and older [CCC];;;DISCOURAGED;2.16;2.56 +4285-3;Insulin Lente;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Insulin Lente [Mass] of Dose;Insulin Lente Dose;;ACTIVE;1.0;2.69 +42853-2;Ventilatory weaning impairment;Find;Pt;Respiratory system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Ventilatory weaning impairment [CCC];;;ACTIVE;2.16;2.56 +42854-0;Community coping impairment;Find;Pt;^Community;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Community coping impairment Community [CCC];;;ACTIVE;2.16;2.56 +42855-7;11-Deoxycorticosterone;MCnc;Pt;Urine;Qn;;CHEM;1;11-Deoxycorticosterone [Mass/volume] in Urine;11DOC Ur-mCnc;;ACTIVE;2.16;2.70 +42856-5;Benzoylecgonine;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Blood by Confirmatory method;BZE Bld Cfm-mCnc;;ACTIVE;2.16;2.73 +42857-3;Calcium;SCnc;Pt;BldV;Qn;;CHEM;1;Calcium [Moles/volume] in Venous blood;Calcium BldV-sCnc;;ACTIVE;2.16;2.42 +42859-9;Candida albicans Ab;Titr;Pt;Ser;Qn;;MICRO;1;Candida albicans Ab [Titer] in Serum;C albicans Ab Titr Ser;;ACTIVE;2.16;2.73 +42860-7;Cannabinoids;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cannabinoids [Mass/volume] in Urine;Cannabinoids Ur-mCnc;;ACTIVE;2.16;2.73 +4286-1;Insulin NPH;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Insulin NPH [Mass] of Dose;Insulin NPH Dose;;ACTIVE;1.0;2.69 +42861-5;Carbaryl;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Carbaryl [Presence] in Urine;Carbaryl Ur Ql;;ACTIVE;2.16;2.73 +42862-3;Carbofuran;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Carbofuran [Presence] in Urine;Carbofuran Ur Ql;;ACTIVE;2.16;2.73 +42863-1;Libocedrus decurrens Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cedar IgE Ab/IgE total in Serum;Cedar IgE/IgE total %;;ACTIVE;2.16;2.70 +42864-9;Cells.CD103/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD103 cells/100 cells in Body fluid;CD103 Cells NFr Fld;;ACTIVE;2.16;2.70 +42865-6;Cells.CD117/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD117 cells/100 cells in Tissue;CD117 Cells NFr Tiss;;ACTIVE;2.16;2.34 +42866-4;Cells.CD117/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD117 cells/100 cells in Bone marrow;CD117 Cells NFr Mar;;ACTIVE;2.16;2.34 +42867-2;Cells.CD117/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD117 cells/100 cells in Body fluid;CD117 Cells NFr Fld;;ACTIVE;2.16;2.34 +42868-0;Cells.CD11c+CD19+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD11c+CD19+ cells/100 cells in Bone marrow;CD11c+CD19+ Cells NFr Mar;;ACTIVE;2.16;2.70 +42869-8;Cells.CD138/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD138 cells/100 cells in Blood;CD138 Cells NFr Bld;;ACTIVE;2.16;2.73 +42870-6;Cells.CD138/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD138 cells/100 cells in Bone marrow;CD138 Cells NFr Mar;;ACTIVE;2.16;2.70 +42871-4;Cells.CD138/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD138 cells/100 cells in Body fluid;CD138 Cells NFr Fld;;ACTIVE;2.16;2.70 +42872-2;Cells.CD138/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD138 cells/100 cells in Tissue;CD138 Cells NFr Tiss;;ACTIVE;2.16;2.70 +42873-0;Cells.CD18/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD18 cells/100 cells in Tissue;CD18 Cells NFr Tiss;;ACTIVE;2.16;2.70 +42874-8;Cells.CD18/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD18 cells/100 cells in Bone marrow;CD18 Cells NFr Mar;;ACTIVE;2.16;2.70 +42875-5;Cells.CD22/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD22 cells/100 cells in Body fluid;CD22 Cells NFr Fld;;ACTIVE;2.16;2.70 +42876-3;Cells.CD25+CD19+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD25+CD19+ cells/100 cells in Bone marrow;CD25+CD19+ Cells NFr Mar;;ACTIVE;2.16;2.70 +42877-1;Cells.CD3-CD16+;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD3-CD16+ cells [#/volume] in Body fluid;CD3-CD16+ Cells # Fld;;ACTIVE;2.16;2.42 +42878-9;Cells.CD3-CD16+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD16+ cells [#/volume] in Bone marrow;CD3-CD16+ Cells # Mar;;ACTIVE;2.16;2.42 +4287-9;Insulin regular;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Insulin regular [Mass] of Dose;Insulin Regular Dose;;ACTIVE;1.0;2.69 +42879-7;Cells.CD3-CD16+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD16+ cells [#/volume] in Tissue;CD3-CD16+ Cells # Tiss;;ACTIVE;2.16;2.42 +42880-5;Cells.CD3-CD57+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD57+ cells [#/volume] in Bone marrow;CD3-CD57+ Cells # Mar;;ACTIVE;2.16;2.42 +42881-3;Cells.CD3-CD57+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD57+ cells [#/volume] in Tissue;CD3-CD57+ Cells # Tiss;;ACTIVE;2.16;2.42 +42882-1;Cells.CD3-CD57+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD57+ cells/100 cells in Tissue;CD3-CD57+ Cells NFr Tiss;;ACTIVE;2.16;2.34 +42883-9;Cells.CD52/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD52 cells/100 cells in Tissue;CD52 Cells NFr Tiss;;ACTIVE;2.16;2.34 +42884-7;Cells.CD52/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD52 cells/100 cells in Specimen;CD52 Cells NFr Spec;;ACTIVE;2.16;2.73 +42885-4;Cells.CD52/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD52 cells/100 cells in Body fluid;CD52 Cells NFr Fld;;ACTIVE;2.16;2.34 +42886-2;Cells.CD52/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD52 cells/100 cells in Bone marrow;CD52 Cells NFr Mar;;ACTIVE;2.16;2.34 +4288-7;Insulin semilente;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Insulin semilente [Mass] of Dose;Insulin Semilente Dose;;ACTIVE;1.0;2.69 +42887-0;Cells.CD79b/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD79b cells/100 cells in Tissue;CD79b Cells NFr Tiss;;ACTIVE;2.16;2.34 +42888-8;Cells.CD79b/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD79b cells/100 cells in Body fluid;CD79b Cells NFr Fld;;ACTIVE;2.16;2.34 +42889-6;Cells.CD79b/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD79b cells/100 cells in Bone marrow;CD79b Cells NFr Mar;;ACTIVE;2.16;2.34 +42890-4;Cells.myeloperoxidase/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;Myeloperoxidase cells/100 cells in Body fluid;Myeloperoxidase Cells NFr Fld;;ACTIVE;2.16;2.34 +42891-2;Choriogonadotropin;ACnc;Pt;Body fld;Qn;;CHEM;1;Choriogonadotropin [Units/volume] in Body fluid;HCG Fld-aCnc;;ACTIVE;2.16;2.73 +42892-0;Citrulline;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Citrulline [Moles/volume] in DBS;Citrulline DBS-sCnc;;ACTIVE;2.16;2.73 +42893-8;Cladosporium herbarum Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Cladosporium herbarum IgG Ab [Mass/volume] in Serum;C herbarum IgG Ser-mCnc;;ACTIVE;2.16;2.73 +42894-6;Clindamycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clindamycin IgE Ab [Units/volume] in Serum;Clindamycin IgE Qn;;ACTIVE;2.16;2.42 +4289-5;Insulin ultralente;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Insulin ultralente [Mass] of Dose;Insulin Ultralente Dose;;ACTIVE;1.0;2.69 +42895-3;Colorado tick fever virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Colorado tick fever virus IgG Ab [Presence] in Serum by Immunofluorescence;CTFV IgG Ser Ql IF;;ACTIVE;2.16;2.56 +42896-1;Colorado tick fever virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Colorado tick fever virus IgM Ab [Titer] in Serum by Immunofluorescence;CTFV IgM Titr Ser IF;;ACTIVE;2.16;2.73 +42897-9;Coxiella burnetii phase 1 Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Units/volume] in Serum by Immunofluorescence;C burnet Ph1 IgM Ser IF-aCnc;;ACTIVE;2.16;2.73 +42898-7;Cyclic citrullinated peptide Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Cyclic citrullinated peptide IgG Ab [Presence] in Serum;cCP IgG Ser Ql;;ACTIVE;2.16;2.73 +42899-5;Cytomegalovirus Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;Cytomegalovirus IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;CMV IgM CSF Ql IF;;ACTIVE;2.16;2.56 +42900-1;Daucus carota Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Carrot IgE Ab/IgE total in Serum;Carrot IgE/IgE total %;;ACTIVE;2.16;2.70 +42901-9;Dihydrocodeine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dihydrocodeine [Mass/volume] in Serum or Plasma;DHC SerPl-mCnc;;ACTIVE;2.16;2.40 +42902-7;Elastase.pancreatic;PrThr;Pt;Stool;Ord;;CHEM;1;Elastase.pancreatic [Presence] in Stool;Elastase Panc Stl Ql;;ACTIVE;2.16;2.73 +4290-3;Isoniazid;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Isoniazid [Mass] of Dose;Isoniazid Dose;;ACTIVE;1.0;2.69 +42903-5;Enterovirus NOS Ab;Titr;Pt;CSF;Qn;;MICRO;1;Enterovirus NOS Ab [Titer] in Cerebral spinal fluid;EV Ab Titr CSF;;ACTIVE;2.16;2.30 +42904-3;Epicoccum purpurascens Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Epicoccum purpurascens IgG Ab [Mass/volume] in Serum;E purpurascens IgG-mCnc;;ACTIVE;2.16;2.73 +42905-0;Formate/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Formate/Creatinine [Mass Ratio] in 24 hour Urine;Formate/Creat 24h Ur;;ACTIVE;2.16;2.42 +42906-8;Galactose 1 phosphate uridyl transferase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Galactose 1 phosphate uridyl transferase [Enzymatic activity/volume] in DBS;Gal1PUT DBS-cCnc;;ACTIVE;2.16;2.73 +42907-6;Helminthosporium sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Helminthosporium sp IgG Ab [Mass/volume] in Serum;Helminthosporium IgG-mCnc;;ACTIVE;2.16;2.40 +42908-4;Hematocrit;VFr;Pt;BldC;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Capillary blood;Hct VFr BldC;;ACTIVE;2.16;2.73 +42909-2;Hemoglobin.gastrointestinal^1st specimen;PrThr;Pt;Gast fld;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Gastric fluid --1st specimen;Gastrocult sp1 Gast Ql;;ACTIVE;2.16;2.56 +429-1;rifAMPin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;rifAMPin [Susceptibility] by Disk diffusion (KB);rifAMPin Islt KB;;ACTIVE;1.0;2.73 +42910-0;Hemoglobin.gastrointestinal^2nd specimen;PrThr;Pt;Gast fld;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Gastric fluid --2nd specimen;Gastrocult sp2 Gast Ql;;ACTIVE;2.16;2.56 +4291-1;Kanamycin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Kanamycin [Mass] of Dose;Kanamycin Dose;;ACTIVE;1.0;2.69 +42911-8;Hemoglobin.gastrointestinal^3rd specimen;PrThr;Pt;Gast fld;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Gastric fluid --3rd specimen;Gastrocult sp3 Gast Ql;;ACTIVE;2.16;2.56 +42912-6;Hemoglobin.gastrointestinal^2nd specimen;PrThr;Pt;XXX;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Specimen --2nd specimen;Hemoccult sp2 Spec Ql;;ACTIVE;2.16;2.69 +42913-4;Hemoglobin.gastrointestinal^1st specimen;PrThr;Pt;XXX;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Specimen --1st specimen;Hemoccult sp1 Spec Ql;;ACTIVE;2.16;2.73 +42914-2;HER2;MCnc;Pt;Ser;Qn;IA;PATH;1;HER2 [Mass/volume] in Serum by Immunoassay;Her2 Ser IA-mCnc;;ACTIVE;2.16;2.73 +42915-9;Herpes virus 6 Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes virus 6 IgM Ab [Presence] in Cerebral spinal fluid;HHV6 IgM CSF Ql;;ACTIVE;2.16;2.56 +42916-7;Histoplasma capsulatum Ag;ACnc;Pt;XXX;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Specimen by Immunoassay;H capsul Ag Spec IA-aCnc;;ACTIVE;2.16;2.73 +42917-5;HIV 1 RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HIV1 RNA CSF Ql NAA+probe;;ACTIVE;2.16;2.63 +42918-3;Hydroflumethiazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroflumethiazide [Mass/volume] in Serum or Plasma;Hydroflumethiazide SerPl-mCnc;;ACTIVE;2.16;2.42 +42919-1;Insulin^pre 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --pre 100 g glucose PO;Insulin pre 100 g Glc PO SerPl-mCnc;;ACTIVE;2.16;2.40 +42920-9;Isovalerylcarnitine (C5);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Isovalerylcarnitine (C5) [Moles/volume] in DBS;Isovalerylcarn DBS-sCnc;;ACTIVE;2.16;2.73 +42921-7;JC virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;JC virus DNA [Presence] in Specimen by NAA with probe detection;JCPyV DNA Spec Ql NAA+probe;;ACTIVE;2.16;2.73 +42922-5;Ketamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ketamine [Presence] in Serum or Plasma;Ketamine SerPl Ql;;ACTIVE;2.16;2.56 +42923-3;Kochia scoparia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Firebush IgE Ab/IgE total in Serum;Firebush IgE/IgE total %;;ACTIVE;2.16;2.70 +42924-1;Lactoferrin;MCnc;Pt;Stool;Qn;;CHEM;1;Lactoferrin [Mass/volume] in Stool;Lactoferrin Stl-mCnc;;ACTIVE;2.16;2.73 +42925-8;Myeloid cells/100 cells;NFr;Pt;Body fld;Qn;;HEM/BC;1;Myeloid cells/100 cells in Body fluid;Myeloid cells NFr Fld;;ACTIVE;2.16;2.70 +42926-6;Myeloid cells/100 cells;NFr;Pt;Bld;Qn;;HEM/BC;1;Myeloid cells/100 cells in Blood;Myeloid cells NFr Bld;;ACTIVE;2.16;2.70 +42927-4;Myeloid cells/100 cells;NFr;Pt;XXX;Qn;;HEM/BC;1;Myeloid cells/100 cells in Specimen;Myeloid cells NFr Spec;;ACTIVE;2.16;2.69 +42928-2;Filaria Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Filaria Ag [Presence] in Serum;Filaria Ag Ser Ql;;ACTIVE;2.16;2.56 +4292-9;Ketamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ketamine [Mass] of Dose;Ketamine Dose;;ACTIVE;1.0;2.69 +42929-0;Lactate dehydrogenase panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Lactate dehydrogenase panel - Serum or Plasma;LDH Pnl SerPl;;ACTIVE;2.16;2.73 +42930-8;Cells.CD11+CD18+;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD11+CD18+ cells [Presence] in Blood;CD11+CD18+ Cells Bld Ql;;ACTIVE;2.16;2.56 +42931-6;Chlamydia trachomatis rRNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Urine by NAA with probe detection;C trach rRNA Ur Ql NAA+probe;;ACTIVE;2.16;2.73 +42932-4;Cells.CD40/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD40 cells/100 cells in Specimen;CD40 Cells NFr Spec;;ACTIVE;2.16;2.70 +42933-2;Cells.CD79a/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD79a cells/100 cells in Specimen;CD79a Cells NFr Spec;;ACTIVE;2.16;2.73 +42934-0;Cells.CD83/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD83 cells/100 cells in Specimen;CD83 Cells NFr Spec;;ACTIVE;2.16;2.70 +42935-7;Pyrazinamide 100.0 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Pyrazinamide 100.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated PZA 100 ug/mL Islt SlowMyco;;DEPRECATED;2.16;2.36 +42936-5;Intercellular substance Ab.IgA;PrThr;Pt;Ser;Ord;IF;SERO;1;Intercellular substance IgA Ab [Presence] in Serum by Immunofluorescence;ICS IgA Ser Ql IF;;ACTIVE;2.16;2.73 +4293-7;Ketobemidone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ketobemidone [Mass] of Dose;Ketobemidone Dose;;ACTIVE;1.0;2.73 +42937-3;Acetylcholine receptor blocking Ab/Acetylcholine Ab.total;SFr;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor blocking Ab/Acetylcholine Ab.total in Serum;AChR Block Ab/AChR Total SFr Ser;;ACTIVE;2.16;2.73 +42938-1;CFTR gene allele 1;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene allele 1 [Presence] in Blood or Tissue by Molecular genetics method;CFTR allele 1 Bld/T Ql;;ACTIVE;2.16;2.73 +42939-9;CFTR gene allele 2;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene allele 2 [Presence] in Blood or Tissue by Molecular genetics method;CFTR allele 2 Bld/T Ql;;ACTIVE;2.16;2.73 +42940-7;GALT gene allele 1;Arb;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;GALT gene allele 1 [Presence] in Blood by Molecular genetics method;GALT allele 1 Bld Ql;;ACTIVE;2.16;2.73 +42941-5;GALT gene allele 2;Arb;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;GALT gene allele 2 [Presence] in Blood by Molecular genetics method;GALT allele 2 Bld Ql;;ACTIVE;2.16;2.73 +42942-3;Yersinia sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia sp IgM Ab [Titer] in Serum;Yersinia IgM Titr Ser;;ACTIVE;2.16;2.30 +42943-1;Yersinia enterocolitica O:5,27 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:5,27 Ab [Titer] in Serum;Y entero O:5,27 Ab Titr Ser;;ACTIVE;2.16;2.61 +42944-9;Vesicular stomatitis New Jersey virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Vesicular stomatitis New Jersey virus Ab [Titer] in Serum;VSNJV Ab Titr Ser;;ACTIVE;2.16;2.40 +4294-5;Levodopa.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Levodopa.PO [Mass] of Dose;Levodopa PO Dose;;ACTIVE;1.0;2.69 +42945-6;Vesicular stomatitis Indiana virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Vesicular stomatitis Indiana virus Ab [Titer] in Serum;VSIV Ab Titr Ser;;ACTIVE;2.16;2.40 +42946-4;Trypanosoma brucei rhodesiense Ab;Titr;Pt;Ser;Qn;;MICRO;1;Trypanosoma brucei rhodesiense Ab [Titer] in Serum;T brucei rhodes Ab Titr Ser;;ACTIVE;2.16;2.30 +42947-2;Trypanosoma brucei Ab;Titr;Pt;Ser;Qn;;MICRO;1;Trypanosoma brucei Ab [Titer] in Serum;T brucei Ab Titr Ser;;ACTIVE;2.16;2.30 +42948-0;Toxoplasma sp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Toxoplasma gondii IgM Ab [Titer] in Serum;Deprecated Toxoplasma IgM Titr Ser;;DEPRECATED;2.16;2.36 +42949-8;Toxoplasma gondii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii Ab [Titer] in Serum;T gondii Ab Titr Ser;;ACTIVE;2.16;2.30 +42950-6;Toxocara canis Ab;Titr;Pt;XXX;Qn;;MICRO;1;Toxocara canis Ab [Titer] in Specimen;T canis Ab Titr Spec;;ACTIVE;2.16;2.69 +42951-4;Taylorella equigenitalis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Taylorella equigenitalis Ab [Titer] in Serum;T equigenit Ab Titr Ser;;ACTIVE;2.16;2.30 +4295-2;Labetalol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Labetalol [Mass] of Dose;Labetalol Dose;;ACTIVE;1.0;2.69 +42952-2;Snowshoe hare virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Snowshoe hare virus Ab [Titer] in Serum;SSHV Ab Titr Ser;;ACTIVE;2.16;2.30 +42953-0;Snowshoe hare virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Snowshoe hare virus IgM Ab [Titer] in Serum;SSHV IgM Titr Ser;;ACTIVE;2.16;2.30 +42954-8;Sindbis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Sindbis virus Ab [Titer] in Serum;SINV Ab Titr Ser;;ACTIVE;2.16;2.30 +42955-5;Semliki forest virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Semliki Forest virus Ab [Titer] in Serum;SFV Ab Titr Ser;;ACTIVE;2.16;2.30 +42956-3;SARS coronavirus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;SARS coronavirus IgM Ab [Presence] in Serum;SARS-CoV IgM Ser Ql;;ACTIVE;2.16;2.68 +42957-1;SARS coronavirus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;SARS coronavirus IgG Ab [Presence] in Serum;SARS-CoV IgG Ser Ql;;ACTIVE;2.16;2.68 +42958-9;Salmonella typhimurium Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella typhimurium Ab [Titer] in Serum;S Typhimur Ab Titr Ser;;ACTIVE;2.16;2.30 +42959-7;Salmonella typhi O Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella typhi O Ab [Titer] in Serum;S Typhi O Ab Titr Ser;;ACTIVE;2.16;2.30 +4296-0;Methotrimeprazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methotrimeprazine [Mass] of Dose;Methotrimeprazine Dose;;ACTIVE;1.0;2.69 +42960-5;Salmonella typhi H Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella typhi H Ab [Titer] in Serum;S Typhi H Ab Titr Ser;;ACTIVE;2.16;2.30 +42961-3;Salmonella pullorum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella pullorum Ab [Titer] in Serum;S pullorum Ab Titr Ser;;ACTIVE;2.16;2.30 +42962-1;Salmonella paratyphi C O Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi C O Ab [Titer] in Serum;S paraty C O Ab Titr Ser;;ACTIVE;2.16;2.30 +42963-9;Salmonella paratyphi C H Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi C H Ab [Titer] in Serum;S paraty C H Ab Titr Ser;;ACTIVE;2.16;2.30 +42964-7;Salmonella paratyphi B O Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi B O Ab [Titer] in Serum;S paraty B O Ab Titr Ser;;ACTIVE;2.16;2.30 +42965-4;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Serum;SLEV IgM Ser Ql;;ACTIVE;2.16;2.56 +42966-2;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid;SLEV IgM CSF Ql;;ACTIVE;2.16;2.56 +42967-0;Rubella virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Rubella virus Ab [Titer] in Cerebral spinal fluid;RUBV Ab Titr CSF;;ACTIVE;2.16;2.30 +42968-8;Rickettsia rickettsii Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia rickettsii IgG Ab [Presence] in Serum;R rickettsi IgG Ser Ql;;ACTIVE;2.16;2.73 +42969-6;Rickettsia rickettsii Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Rickettsia rickettsii IgM Ab [Presence] in Serum;R rickettsi IgM Ser Ql;;ACTIVE;2.16;2.73 +42970-4;Pseudallescheria boydii Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Pseudallescheria boydii IgG Ab [Presence] in Serum;P boydii IgG Ser Ql;;ACTIVE;2.16;2.56 +42971-2;Powassan virus Ab.IgM;Titr;Pt;XXX;Qn;;MICRO;1;Powassan virus IgM Ab [Titer] in Specimen;POWV IgM Titr Spec;;ACTIVE;2.16;2.69 +42972-0;Powassan virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Powassan virus IgM Ab [Titer] in Serum;POWV IgM Titr Ser;;ACTIVE;2.16;2.30 +42973-8;Powassan virus Ab.IgG;Titr;Pt;XXX;Qn;;MICRO;1;Powassan virus IgG Ab [Titer] in Specimen;POWV IgG Titr Spec;;ACTIVE;2.16;2.69 +42974-6;Powassan virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Powassan virus IgG Ab [Titer] in Serum;POWV IgG Titr Ser;;ACTIVE;2.16;2.30 +42975-3;Powassan virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Powassan virus Ab [Titer] in Serum;POWV Ab Titr Ser;;ACTIVE;2.16;2.30 +42976-1;Porcine reproductive and respiratory syndrome virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;PRRSV Ab [Titer] in Serum;PRRSV Ab Titr Ser;;ACTIVE;2.16;2.64 +42977-9;Porcine influenza virus A Ab;Titr;Pt;Ser;Qn;;MICRO;1;Porcine influenza virus A Ab [Titer] in Serum;Porcine FLUAV Ab Titr Ser;;ACTIVE;2.16;2.64 +4297-8;Levomepromazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Levomepromazine [Mass] of Dose;Deprecated L-Mepromazine Dose;;DEPRECATED;1.0;2.69 +42978-7;Polio virus 2 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Polio virus 2 Ab [Titer] in Body fluid;PV2 Ab Titr Fld;;ACTIVE;2.16;2.30 +42979-5;Polio virus 3 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Polio virus 3 Ab [Titer] in Body fluid;PV3 Ab Titr Fld;;ACTIVE;2.16;2.30 +42980-3;Polio virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Polio virus Ab [Titer] in Serum;PV Ab Titr Ser;;ACTIVE;2.16;2.30 +42981-1;Polio virus 1 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Polio virus 1 Ab [Titer] in Body fluid;PV1 Ab Titr Fld;;ACTIVE;2.16;2.30 +42982-9;Parainfluenza virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus Ab [Titer] in Serum;HPIV Ab Titr Ser;;ACTIVE;2.16;2.67 +42983-7;Parainfluenza virus 4 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Parainfluenza virus 4 IgG Ab [Presence] in Serum;HPIV4 IgG Ser Ql;;ACTIVE;2.16;2.56 +42984-5;Parainfluenza virus 1 Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Serum --2nd specimen;HPIV1 Ab sp2 Titr Ser;;ACTIVE;2.16;2.30 +42985-2;Neisseria meningitidis serogroup C Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup C IgG Ab [Mass/volume] in Serum;N men sg C IgG Ser-mCnc;;ACTIVE;2.16;2.73 +4298-6;Levorphanol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Levorphanol [Mass] of Dose;Levorphanol Dose;;ACTIVE;1.0;2.69 +42986-0;Neisseria meningitidis serogroup A Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Neisseria meningitidis serogroup A IgG Ab [Mass/volume] in Serum;N men sg A IgG Ser-mCnc;;ACTIVE;2.16;2.73 +42987-8;Neisseria gonorrhoeae Ab;Titr;Pt;CSF;Qn;;MICRO;1;Neisseria gonorrhoeae Ab [Titer] in Cerebral spinal fluid;N gonorrhoea Ab Titr CSF;;ACTIVE;2.16;2.30 +42988-6;Mycoplasma synoviae Ab;Titr;Pt;Ser;Qn;;MICRO;1;Mycoplasma synoviae Ab [Titer] in Serum;M synoviae Ab Titr Ser;;ACTIVE;2.16;2.30 +42989-4;Mycoplasma pneumoniae Ab.IgG;Titr;Pt;Plr fld;Qn;IF;MICRO;1;Mycoplasma pneumoniae IgG Ab [Titer] in Pleural fluid by Immunofluorescence;M pneumo IgG Titr Plr IF;;ACTIVE;2.16;2.30 +42990-2;Mycoplasma pneumoniae Ab.IgM;Titr;Pt;Plr fld;Qn;;MICRO;1;Mycoplasma pneumoniae IgM Ab [Titer] in Pleural fluid;M pneumo IgM Titr Plr;;ACTIVE;2.16;2.30 +42991-0;Mycoplasma pneumoniae Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Mycoplasma pneumoniae IgM Ab [Titer] in Cerebral spinal fluid;M pneumo IgM Titr CSF;;ACTIVE;2.16;2.30 +42992-8;Mycoplasma pneumoniae Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Titer] in Cerebral spinal fluid;M pneumo IgG Titr CSF;;ACTIVE;2.16;2.30 +42993-6;Mycoplasma pneumoniae Ab;Titr;Pt;CSF;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Cerebral spinal fluid;M pneumo Ab Titr CSF;;ACTIVE;2.16;2.30 +4299-4;Lidocaine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Lidocaine [Mass] of Dose;Lidocain Dose;;ACTIVE;1.0;2.69 +42994-4;Leptospira sp Ab;Titr;Pt;CSF;Qn;;MICRO;1;Leptospira sp Ab [Titer] in Cerebral spinal fluid;Leptospira Ab Titr CSF;;ACTIVE;2.16;2.30 +42995-1;Leptospira borgpetersenii serovar Tarrasovi Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira borgpetersenii sv Tarrasovi Ab [Titer] in Serum;L borgp Tarra Ab Titr Ser;;ACTIVE;2.16;2.30 +42996-9;Leptospira borgpetersenii serovar Ballum Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira borgpetersenii sv Ballum Ab [Titer] in Serum;L borgp Ball Ab Titr Ser;;ACTIVE;2.16;2.30 +42997-7;Leptospira autumnalis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Leptospira autumnalis Ab [Titer] in Serum;Deprecated L autumnalis Ab Titr Ser;;DEPRECATED;2.16;2.58 +42998-5;Leishmania tropica Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania tropica Ab [Titer] in Serum;L tropica Ab Titr Ser;;ACTIVE;2.16;2.30 +42999-3;Leishmania sp Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Leishmania sp Ab [Presence] in Cerebral spinal fluid;Leishmania Ab CSF Ql;;ACTIVE;2.16;2.56 +43-0;Aztreonam;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Aztreonam [Susceptibility] by Minimum lethal concentration (MLC);Aztreonam Islt MLC;;ACTIVE;1.0;2.19 +4300-0;Lithium;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Lithium [Mass] of Dose;Lithium Dose;;ACTIVE;1.0;2.73 +43000-9;Leishmania braziliensis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leishmania brasilensis Ab [Titer] in Serum;L braziliensis Ab Titr Ser;;ACTIVE;2.16;2.30 +43001-7;Legionella sp Ab;Titr;Pt;CSF;Qn;;MICRO;1;Legionella sp Ab [Titer] in Cerebral spinal fluid;Legionella Ab Titr CSF;;ACTIVE;2.16;2.30 +43002-5;Legionella pneumophila 1 Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Legionella pneumophila 1 IgM Ab [Titer] in Cerebral spinal fluid;L pneumo1 IgM Titr CSF;;ACTIVE;2.16;2.30 +43003-3;Jamestown canyon virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Jamestown canyon virus IgM Ab [Titer] in Serum;JCV IgM Titr Ser;;ACTIVE;2.16;2.30 +43004-1;Jamestown canyon virus Ab.IgG;Titr;Pt;XXX;Qn;;MICRO;1;Jamestown canyon virus IgG Ab [Titer] in Specimen;JCV IgG Titr Spec;;ACTIVE;2.16;2.69 +43005-8;Jamestown canyon virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Jamestown canyon virus IgG Ab [Titer] in Serum;JCV IgG Titr Ser;;ACTIVE;2.16;2.30 +43006-6;Jamestown canyon virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Jamestown canyon virus Ab [Titer] in Serum;JCV Ab Titr Ser;;ACTIVE;2.16;2.30 +43007-4;HTLV I+II Ab;Titr;Pt;Ser;Qn;;MICRO;1;HTLV I+II Ab [Titer] in Serum;HTLV I+II Ab Titr Ser;;ACTIVE;2.16;2.52 +43008-2;HIV 1+2 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;HIV 1+2 IgM Ab [Units/volume] in Serum;HIV1+2 IgM Ser-aCnc;;ACTIVE;2.16;2.69 +43009-0;HIV 1+2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1+2 IgG Ab [Presence] in Serum;HIV1+2 IgG Ser Ql;;ACTIVE;2.16;2.73 +43010-8;HIV 1+2 Ab;PrThr;Pt;XXX;Ord;;MICRO;1;HIV 1+2 Ab [Presence] in Specimen;HIV1+2 Ab Spec Ql;;ACTIVE;2.16;2.73 +43011-6;HIV 1 p24 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 p24 Ab [Presence] in Serum;HIV1 p24 Ab Ser Ql;;ACTIVE;2.16;2.56 +43012-4;HIV 1 gp41 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 gp41 Ab [Presence] in Serum;HIV1 gp41 Ab Ser Ql;;ACTIVE;2.16;2.56 +43013-2;HIV 1 gp120+gp160 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 gp120+gp160 Ab [Presence] in Serum;HIV1 gp120+gp160 Ab Ser Ql;;ACTIVE;2.16;2.56 +43014-0;Histoplasma sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Histoplasma capsulatum Ab [Titer] in Serum;Deprecated Histoplasma Ab Titr Ser;;DEPRECATED;2.16;2.36 +43015-7;Histoplasma capsulatum yeast phase Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Histoplasma capsulatum yeast phase Ab [Titer] in Body fluid;H capsul Yst Ab Titr Fld;;ACTIVE;2.16;2.34 +43016-5;Histoplasma capsulatum yeast phase Ab;Titr;Pt;CSF;Qn;;MICRO;1;Histoplasma capsulatum yeast phase Ab [Titer] in Cerebral spinal fluid;H capsul Yst Ab Titr CSF;;ACTIVE;2.16;2.34 +43017-3;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Body fluid;H capsul Myc Ab Titr Fld;;ACTIVE;2.16;2.34 +4301-8;LORazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;LORazepam [Mass] of Dose;LORazepam Dose;;ACTIVE;1.0;2.69 +43018-1;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;CSF;Qn;;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Cerebral spinal fluid;H capsul Myc Ab Titr CSF;;ACTIVE;2.16;2.34 +43019-9;Histoplasma capsulatum Ab;PrThr;Pt;Plr fld;Ord;;MICRO;1;Histoplasma capsulatum Ab [Presence] in Pleural fluid;H capsul Ab Plr Ql;;ACTIVE;2.16;2.56 +43020-7;Heterophile Ab;Titr;Pt;Ser;Qn;;MICRO;1;Heterophile Ab [Titer] in Serum;Heteroph Ab Titr Ser;;ACTIVE;2.16;2.73 +43021-5;Herpes virus 8 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes virus 8 IgG Ab [Units/volume] in Serum;HHV8 IgG Ser-aCnc;;ACTIVE;2.16;2.69 +43022-3;Herpes virus 7 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Herpes virus 7 IgM Ab [Titer] in Serum;HHV7 IgM Titr Ser;;ACTIVE;2.16;2.30 +43023-1;Herpes virus 7 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Herpes virus 7 IgG Ab [Titer] in Serum;HHV7 IgG Titr Ser;;ACTIVE;2.16;2.30 +43024-9;Herpes virus 6 Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Herpes virus 6 IgG Ab [Titer] in Cerebral spinal fluid;HHV6 IgG Titr CSF;;ACTIVE;2.16;2.30 +43025-6;Herpes virus 6 Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Herpes virus 6 IgM Ab [Titer] in Cerebral spinal fluid;HHV6 IgM Titr CSF;;ACTIVE;2.16;2.30 +4302-6;Lormetazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Lormetazepam [Mass] of Dose;Lormetazepam Dose;;ACTIVE;1.0;2.69 +43026-4;Herpes simplex virus 2 Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 2 IgM Ab [Presence] in Cerebral spinal fluid;HSV2 IgM CSF Ql;;ACTIVE;2.16;2.56 +43027-2;Herpes simplex virus 2 Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Herpes simplex virus 2 IgM Ab [Titer] in Body fluid;HSV2 IgM Titr Fld;;ACTIVE;2.16;2.30 +43028-0;Herpes simplex virus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 Ab [Titer] in Serum;HSV2 Ab Titr Ser;;ACTIVE;2.16;2.30 +43029-8;Herpes simplex virus 2 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 2 Ab [Titer] in Cerebral spinal fluid;HSV2 Ab Titr CSF;;ACTIVE;2.16;2.30 +43030-6;Herpes simplex virus 1+2 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Units/volume] in Serum;HSV1+2 IgM Ser-aCnc;;ACTIVE;2.16;2.73 +43031-4;Herpes simplex virus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 Ab [Titer] in Serum;HSV1 Ab Titr Ser;;ACTIVE;2.16;2.30 +43032-2;Herpes simplex virus 1 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1 Ab [Titer] in Cerebral spinal fluid;HSV1 Ab Titr CSF;;ACTIVE;2.16;2.30 +43033-0;Herpes simplex virus 1+2 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1+2 Ab [Titer] in Cerebral spinal fluid;HSV1+2 Ab Titr CSF;;ACTIVE;2.16;2.30 +4303-4;Loxapine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Loxapine [Mass] of Dose;Loxapine Dose;;ACTIVE;1.0;2.69 +43034-8;Feline leukemia virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline leukemia virus Ab [Titer] in Serum;FeLV Ab Titr Ser;;ACTIVE;2.16;2.30 +43035-5;Feline immunodeficiency virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline immunodeficiency virus Ab [Titer] in Serum;FIV Ab Titr Ser;;ACTIVE;2.16;2.30 +43036-3;Feline herpesvirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Feline herpesvirus Ab [Titer] in Serum;FeHV Ab Titr Ser;;ACTIVE;2.16;2.30 +43037-1;Fasciola hepatica Ab;Titr;Pt;Ser;Qn;;MICRO;1;Fasciola hepatica Ab [Titer] in Serum;F hepatica Ab Titr Ser;;ACTIVE;2.16;2.30 +43038-9;Enterovirus NOS Ab;Titr;Pt;Ser;Qn;;MICRO;1;Enterovirus NOS Ab [Titer] in Serum;EV Ab Titr Ser;;ACTIVE;2.16;2.30 +43039-7;Ehrlichia sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia sp Ab [Titer] in Serum;Ehrlichia Ab Titr Ser;;ACTIVE;2.16;2.73 +43040-5;Echovirus 30 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Echovirus 30 Ab [Titer] in Body fluid;ECV30 Ab Titr Fld;;ACTIVE;2.16;2.30 +43041-3;Echovirus 9 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Echovirus 9 Ab [Titer] in Body fluid;ECV9 Ab Titr Fld;;ACTIVE;2.16;2.30 +4304-2;Maprotiline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Maprotiline [Mass] of Dose;Maprotiline Dose;;ACTIVE;1.0;2.73 +43042-1;Echovirus 4 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Echovirus 4 Ab [Titer] in Body fluid;ECV4 Ab Titr Fld;;ACTIVE;2.16;2.30 +43043-9;Echovirus 11 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Echovirus 11 Ab [Titer] in Body fluid;ECV11 Ab Titr Fld;;ACTIVE;2.16;2.30 +43044-7;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid;EEEV IgM CSF Ql;;ACTIVE;2.16;2.56 +43045-4;Cytomegalovirus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Cytomegalovirus IgM Ab [Presence] in Cerebral spinal fluid;CMV IgM CSF Ql;;ACTIVE;2.16;2.56 +43046-2;Coxsackievirus A16 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A16 Ab [Titer] in Body fluid;CV A16 Ab Titr Fld;;ACTIVE;2.16;2.30 +43047-0;Coxsackievirus A7 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A7 Ab [Titer] in Body fluid;CV A7 Ab Titr Fld;;ACTIVE;2.16;2.30 +43048-8;Coxsackievirus A9 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A9 Ab [Titer] in Body fluid;CV A9 Ab Titr Fld;;ACTIVE;2.16;2.30 +43049-6;Coxsackievirus A10 Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coxsackievirus A10 Ab [Titer] in Body fluid;CV A10 Ab Titr Fld;;ACTIVE;2.16;2.30 +43050-4;Coxiella burnetii phase 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 Ab [Titer] in Serum;C burnet Ph1 Ab Titr Ser;;ACTIVE;2.16;2.30 +43051-2;Colorado tick fever virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Colorado tick fever virus IgG Ab [Presence] in Serum;CTFV IgG Ser Ql;;ACTIVE;2.16;2.56 +43052-0;Coccidioides sp Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Coccidioides sp Ab [Presence] in Specimen;Coccidioides Ab Spec Ql;;ACTIVE;2.16;2.73 +43053-8;Coccidioides immitis Ab;Titr;Pt;Plr fld;Qn;;MICRO;1;Coccidioides immitis Ab [Titer] in Pleural fluid;C immitis Ab Titr Plr;;ACTIVE;2.16;2.30 +43054-6;Clostridium tetani toxin Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Clostridium tetani toxin Ab [Units/volume] in Serum;Deprecated C tetani Tox Ab Ser-aCnc;;DEPRECATED;2.16;2.69 +43055-3;Clostridioides difficile toxin Ab;Titr;Pt;Ser;Qn;;MICRO;1;Clostridioides difficile toxin Ab [Titer] in Serum;C diff Tox Ab Titr Ser;;ACTIVE;2.16;2.66 +43056-1;Cladosporium sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Cladosporium sp IgG Ab [Presence] in Serum;Cladosporium IgG Ser Ql;;ACTIVE;2.16;2.56 +43057-9;Chlamydophila psittaci Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid;C psittaci IgM Titr CSF;;ACTIVE;2.16;2.30 +43058-7;Chlamydia trachomatis D+K Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+K IgM Ab [Titer] in Serum;C trach D+K IgM Titr Ser;;ACTIVE;2.16;2.30 +4305-9;Medazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Medazepam [Mass] of Dose;Medazepam Dose;;ACTIVE;1.0;2.69 +43059-5;Chlamydia trachomatis D+K Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+K IgG Ab [Titer] in Serum;C trach D+K IgG Titr Ser;;ACTIVE;2.16;2.30 +43060-3;Chlamydia trachomatis D+K Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+K IgA Ab [Titer] in Serum;C trach D+K IgA Titr Ser;;ACTIVE;2.16;2.30 +43061-1;Chlamydia trachomatis Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydia trachomatis IgM Ab [Titer] in Cerebral spinal fluid;C trach IgM Titr CSF;;ACTIVE;2.16;2.30 +43062-9;Chlamydia trachomatis Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Chlamydia trachomatis IgG Ab [Titer] in Cerebral spinal fluid;C trach IgG Titr CSF;;ACTIVE;2.16;2.30 +43063-7;Chlamydia sp Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgA Ab [Titer] in Serum;Chlamydia IgA Titr Ser;;ACTIVE;2.16;2.30 +43064-5;Chikungunya virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Chikungunya virus Ab [Titer] in Serum;CHIKV Ab Titr Ser;;ACTIVE;2.16;2.73 +43065-2;Canine distemper virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Canine distemper virus IgM Ab [Titer] in Cerebral spinal fluid;CDV IgM Titr CSF;;ACTIVE;2.16;2.30 +43066-0;Canine distemper virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Canine distemper virus IgG Ab [Titer] in Cerebral spinal fluid;CDV IgG Titr CSF;;ACTIVE;2.16;2.30 +4306-7;Mefenorex;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mefenorex [Mass] of Dose;Mefenorex Dose;;ACTIVE;1.0;2.69 +43067-8;Candida sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Candida sp Ab [Titer] in Serum;Candida Ab Titr Ser;;ACTIVE;2.16;2.30 +43068-6;Campylobacter sp Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Campylobacter sp IgA Ab [Presence] in Serum;Campylobacter IgA Ser Ql;;ACTIVE;2.16;2.56 +43069-4;Burkholderia pseudomallei Ab.IgM;Titr;Pt;XXX;Qn;;MICRO;1;Burkholderia pseudomallei IgM Ab [Titer] in Specimen;B pseudomal IgM Titr Spec;;ACTIVE;2.16;2.69 +43070-2;Burkholderia pseudomallei Ab.IgG;Titr;Pt;XXX;Qn;;MICRO;1;Burkholderia pseudomallei IgG Ab [Titer] in Specimen;B pseudomal IgG Titr Spec;;ACTIVE;2.16;2.69 +43071-0;Brucella canis Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Brucella canis IgM Ab [Titer] in Cerebral spinal fluid;B canis IgM Titr CSF;;ACTIVE;2.16;2.30 +43072-8;Brucella canis Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Brucella canis IgG Ab [Titer] in Cerebral spinal fluid;B canis IgG Titr CSF;;ACTIVE;2.16;2.30 +43073-6;Bovine leukemia virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bovine leukemia virus Ab [Titer] in Serum;BLV Ab Titr Ser;;ACTIVE;2.16;2.30 +43074-4;Borrelia burgdorferi C6 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Borrelia burgdorferi C6 Ab [Units/volume] in Cerebral spinal fluid;B burgdor C6 Ab CSF-aCnc;;ACTIVE;2.16;2.69 +4307-5;Meperidine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Meperidine [Mass] of Dose;Meperidine Dose;;ACTIVE;1.0;2.69 +43075-1;Borrelia burgdorferi C6 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi C6 Ab [Units/volume] in Serum;B burgdor C6 Ab Ser-aCnc;;ACTIVE;2.16;2.73 +43076-9;Borrelia burgdorferi Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Borrelia burgdorferi IgM Ab [Titer] in Cerebral spinal fluid;B burgdor IgM Titr CSF;;ACTIVE;2.16;2.30 +43077-7;Borrelia burgdorferi Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Specimen;B burgdor Ab Spec-aCnc;;ACTIVE;2.16;2.73 +43078-5;Bluetongue virus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 2 Ab [Titer] in Serum;BTV2 Ab Titr Ser;;ACTIVE;2.16;2.30 +43079-3;Bluetongue virus 17 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 17 Ab [Titer] in Serum;BTV17 Ab Titr Ser;;ACTIVE;2.16;2.30 +43080-1;Bluetongue virus 13 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 13 Ab [Titer] in Serum;BTV13 Ab Titr Ser;;ACTIVE;2.16;2.30 +43081-9;Bluetongue virus 11 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 11 Ab [Titer] in Serum;BTV11 Ab Titr Ser;;ACTIVE;2.16;2.30 +43082-7;Bluetongue virus 10 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Bluetongue virus 10 Ab [Titer] in Serum;BTV10 Ab Titr Ser;;ACTIVE;2.16;2.30 +4308-3;Mephenytoin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mephenytoin [Mass] of Dose;Mephenytoin Dose;;ACTIVE;1.0;2.69 +43083-5;Blastomyces sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Blastomyces dermatitidis Ab [Titer] in Serum;Deprecated Blastomyces Ab Titr Ser;;DEPRECATED;2.16;2.36 +43084-3;Blastomyces dermatitidis Ab;Titr;Pt;Plr fld;Qn;;MICRO;1;Blastomyces dermatitidis Ab [Titer] in Pleural fluid;B dermat Ab Titr Plr;;ACTIVE;2.16;2.30 +43085-0;Babesia duncani Ab;Titr;Pt;Ser;Qn;;MICRO;1;Babesia duncani Ab [Titer] in Serum;B duncani Ab Titr Ser;;ACTIVE;2.16;2.42 +43086-8;Babesia divergens Ab;Titr;Pt;Ser;Qn;;MICRO;1;Babesia divergens Ab [Titer] in Serum;B divergens Ab Titr Ser;;ACTIVE;2.16;2.64 +43087-6;Babesia canis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Babesia canis Ab [Titer] in Serum;B canis Ab Titr Ser;;ACTIVE;2.16;2.64 +43088-4;Aspergillus sp Ab;Titr;Pt;Plr fld;Qn;;MICRO;1;Aspergillus sp Ab [Titer] in Pleural fluid;Aspergillus Ab Titr Plr;;ACTIVE;2.16;2.30 +43089-2;Aspergillus niger Ab;Titr;Pt;Ser;Qn;;MICRO;1;Aspergillus niger Ab [Titer] in Serum;A niger Ab Titr Ser;;ACTIVE;2.16;2.30 +430-9;rifAMPin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;rifAMPin [Susceptibility] by Serum bactericidal titer;rifAMPin Titr SBT;;ACTIVE;1.0;2.32 +43090-0;Aspergillus flavus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Aspergillus flavus Ab [Titer] in Serum;A flavus Ab Titr Ser;;ACTIVE;2.16;2.73 +4309-1;Mephobarbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mephobarbital [Mass] of Dose;Mephobarbital Dose;;ACTIVE;1.0;2.69 +43091-8;Ascaris sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Ascaris sp Ab [Titer] in Serum;Ascaris Ab Titr Ser;;ACTIVE;2.16;2.30 +43092-6;Arbovirus NOS Ab;Titr;Pt;Ser;Qn;;MICRO;1;Arbovirus NOS Ab [Titer] in Serum;Arbovirus NOS Ab Titr Ser;;ACTIVE;2.16;2.30 +43093-4;Angiostrongylus costaricensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Angiostrongylus costaricensis Ab [Presence] in Serum;A costaricensis Ab Ser Ql;;ACTIVE;2.16;2.56 +43094-2;Angiostrongylus cantonensis Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Angiostrongylus cantonensis Ab [Presence] in Specimen;A cantonensis Ab Spec Ql;;ACTIVE;2.16;2.69 +43095-9;Anaplasma marginale Ab;Titr;Pt;Ser;Qn;;MICRO;1;Anaplasma marginale Ab [Titer] in Serum;A marginale Ab Titr Ser;;ACTIVE;2.16;2.30 +43096-7;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Specimen;EEEV IgM Spec Ql;;ACTIVE;2.16;2.69 +43097-5;COL3A1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COL3A1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;COL3A1 gene Mut Anl Bld/T;;ACTIVE;2.16;2.63 +43098-3;Yersinia sp Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Yersinia sp Ab panel - Serum;Yersinia Ab Pnl Ser;;ACTIVE;2.16;2.44 +43099-1;Vanillylmandelate & Creatinine panel;-;24H;Urine;-;;PANEL.CHEM;1;Vanillylmandelate and Creatinine panel - 24 hour Urine;VMA + Creat Pnl 24h Ur;;ACTIVE;2.16;2.73 +43100-7;Sjogrens syndrome-A & B extractable nuclear Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Sjogrens syndrome-A and B extractable nuclear Ab panel - Serum;ENA SS-A + SSB Ab Pnl Ser;;ACTIVE;2.16;2.73 +43101-5;Phosphatidylserine Ab.IgA & IgG & IgM panel;-;Pt;Ser;-;;PANEL.COAG;1;Phosphatidylserine IgA and IgG and IgM panel - Serum;PS IgA+IgG+IgM Pnl Ser;;ACTIVE;2.16;2.73 +43102-3;Neuronal nuclear type 3 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Neuronal nuclear type 3 Ab [Presence] in Serum;Hu3 Ab Ser Ql;;ACTIVE;2.16;2.73 +43103-1;CV2 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;CV2 IgG Ab [Units/volume] in Serum;CV2 IgG Ser-aCnc;;ACTIVE;2.16;2.69 +43104-9;Paraneoplastic Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Paraneoplastic Ab panel - Serum;Paraneoplastic Ab Pnl Ser;;ACTIVE;2.16;2.73 +43105-6;Acetaldehyde & Paraldehyde panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Acetaldehyde and Paraldehyde panel [Mass/volume] - Serum or Plasma;Acetaldehyde+Paraldehyde Pnl SerPl-mCnc;;ACTIVE;2.16;2.42 +43106-4;Amitriptyline & Nortriptyline panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Amitriptyline and Nortriptyline panel - Serum or Plasma;Amitrip+Nor Pnl SerPl;;ACTIVE;2.16;2.56 +43107-2;Mycoplasma sp & Ureaplasma sp panel;-;Pt;XXX;-;Organism specific culture;PANEL.MICRO;1;Mycoplasma sp and Ureaplasma sp panel - Specimen by Organism specific culture;Mycoplas+Ureoplas Pnl Spec Cult;;ACTIVE;2.16;2.69 +43108-0;Metanephrine & Normetanephrine panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Metanephrine and Normetanephrine panel [Mass/volume] - Serum or Plasma;Metaneph+Normetaneph Pnl SerPl-mCnc;;ACTIVE;2.16;2.73 +4310-9;Meprobamate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Meprobamate [Mass] of Dose;Meprobamate Dose;;ACTIVE;1.0;2.69 +43109-8;Leishmania sp Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Leishmania sp IgG and IgM panel - Serum;Leishmania sp IgG+IgM Pnl Ser;;ACTIVE;2.16;2.44 +43110-6;Immunoglobulin light chains panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Immunoglobulin light chains panel - 24 hour Urine;Immunoglobulin LC Pnl 24h Ur;;ACTIVE;2.16;2.73 +43111-4;Herpes simplex virus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 1 Ab [Presence] in Serum;HSV1 Ab Ser Ql;;ACTIVE;2.16;2.73 +43112-2;Herpes simplex virus Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Herpes simplex virus Ab panel - Serum;HSV Ab Pnl Ser;;ACTIVE;2.16;2.44 +43113-0;Hemoglobin panel;-;Pt;Bld;Qn;Electrophoresis;PANEL.HEM/BC;1;Hemoglobin electrophoresis panel in Blood;Hgb Pnl Bld Elph;;ACTIVE;2.16;2.73 +43114-8;Porphyrin fractions;Imp;24H;Urine;Nom;;CHEM;1;Porphyrin fractions [Interpretation] in 24 hour Urine;Porphyrin Fract 24h Ur-Imp;;ACTIVE;2.16;2.73 +43115-5;Hexacarboxylporphyrin;PrThr;24H;Urine;Ord;;CHEM;1;Hexacarboxylporphyrin [Presence] in 24 hour Urine;Hexa-CP 24h Ur Ql;;ACTIVE;2.16;2.56 +43116-3;Porphyrin fractions panel;-;24H;Urine;-;;PANEL.CHEM;1;Porphyrin fractions panel - 24 hour Urine;Porphyrin Fract Pnl 24h Ur;;ACTIVE;2.16;2.73 +4311-7;Mersalyl;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mersalyl [Mass] of Dose;Mersalyl Dose;;ACTIVE;1.0;2.69 +43117-1;Fluoxetine & Norfluoxetine panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;FLUoxetine and Norfluoxetine panel [Mass/volume] - Serum or Plasma;FLUoxetine+Nor Pnl SerPl-mCnc;;ACTIVE;2.16;2.42 +43118-9;Fat panel;-;Pt;Stool;-;;PANEL.CHEM;1;Fat panel - Stool;Fat Pnl Stl;;ACTIVE;2.16;2.44 +43119-7;Extractable nuclear Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Extractable nuclear Ab panel - Serum;ENA Ab Pnl Ser;;ACTIVE;2.16;2.73 +43120-5;Echovirus Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Echovirus Ab panel - Serum;ECV Ab Pnl Ser;;ACTIVE;2.16;2.44 +43121-3;Echovirus 6 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Echovirus 6 Ab [Presence] in Serum;ECV6 Ab Ser Ql;;ACTIVE;2.16;2.73 +43122-1;Doxepin & Nordoxepin panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Doxepin and Nordoxepin panel - Serum or Plasma;Doxepin+Nor Pnl SerPl;;ACTIVE;2.16;2.56 +43123-9;Imipramine & Desipramine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Imipramine and Desipramine panel - Serum or Plasma;Imipramine+Desipr Pnl SerPl;;ACTIVE;2.16;2.65 +43124-7;Cystine panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Cystine panel - Urine;Cystine Pnl Ur;;ACTIVE;2.16;2.42 +4312-5;Mesantoin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Mephenytoin [Mass] of Dose;Deprecated Mesantoin Dose;;DEPRECATED;1.0;2.69 +43125-4;Nicotine & Metabolites panel;MCnc;Pt;Urine;Qn;;PANEL.DRUG/TOX;1;Nicotine and Metabolites panel [Mass/volume] - Urine;Nicotine+Metab Pnll Ur-mCnc;;ACTIVE;2.16;2.73 +43126-2;Cortisol.free panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Cortisol.free panel - 24 hour Urine;Cortisol Free Pnl 24h Ur;;ACTIVE;2.16;2.73 +43127-0;clomiPRAMINE & Norclomipramine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;clomiPRAMINE and Norclomipramine panel - Serum or Plasma;clomiPRAMINE+Nor Pnl SerPl;;ACTIVE;2.16;2.69 +43128-8;Chloride panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Chloride panel - 24 hour Urine;Chloride Pnl 24h Ur;;ACTIVE;2.16;2.63 +43129-6;Brucella abortus Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Brucella abortus IgG and IgM panel - Serum;B abortus IgG+IgM Pnl Ser;;ACTIVE;2.16;2.44 +43130-4;Bile acid fractions panel;SCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Bile acid fractions panel [Moles/volume] - Serum or Plasma;Bile Acid Fract Pnl SerPl-sCnc;;ACTIVE;2.16;2.73 +43131-2;Bacterial Ag panel;-;Pt;CSF;-;;PANEL.MICRO;1;Bacterial Ag panel - Cerebral spinal fluid;Bacterial Ag Pnl CSF;;ACTIVE;2.16;2.44 +43132-0;California encephalitis virus Ab;ACnc;Pt;Ser;Ord;;MICRO;1;California encephalitis virus Ab [Units/volume] in Serum Qualitative;CEV Ab Ser Ql-aCnc;;ACTIVE;2.16;2.68 +4313-3;Mesoridazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mesoridazine [Mass] of Dose;Mesoridazine Dose;;ACTIVE;1.0;2.69 +43133-8;Allopurinol & Oxipurinol panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Allopurinol and Oxipurinol panel [Mass/volume] - Serum or Plasma;Allopurinol+Oxipurinol Pnl SerPl-mCnc;;ACTIVE;2.16;2.42 +43134-6;Calcidiol & Calciferol & Calcitriol panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Calcidiol and Calciferol and Calcitriol panel [Mass/volume] - Serum or Plasma;Vit D25+D1,25 OH+D1,25 Pnl SerPl-mCnc;;ACTIVE;2.16;2.73 +43135-3;17-Ketosteroids & 17-Ketogenic steroids panel;-;24H;Urine;Qn;;PANEL.CHEM;1;17-Ketosteroids and 17-Ketogenic steroids panel - 24 hour Urine;17KS+17KGS Pnl 24h Ur;;ACTIVE;2.16;2.63 +43136-1;Clinical finding absent;Prid;Pt;^Population;Nom;Investigation;CLIN;2;Clinical finding absent [Identifier] Population Investigation;Clin finding absent Pop Invest;;ACTIVE;2.16;2.27 +43137-9;Clinical finding present;Prid;Pt;^Population;Nom;Investigation;CLIN;2;Clinical finding present [Identifier] Population Investigation;Clin finding present Pop Invest;;ACTIVE;2.16;2.27 +43138-7;Population size;Num;Pt;^Population;Qn;Investigation;CLIN;2;Population size Investigation;Population size Invest;;ACTIVE;2.16;2.48 +43139-5;Clinical finding absent;Prid;Pt;^Population;Nar;Investigation;CLIN;2;Clinical finding absent [Identifier] Population Narrative Investigation;Clin finding absent Pop Invest;;ACTIVE;2.16;2.40 +43140-3;Clinical finding present;Prid;Pt;^Population;Nar;Investigation;CLIN;2;Clinical finding present [Identifier] Population Narrative Investigation;Clin finding present Pop Invest;;ACTIVE;2.16;2.40 +4314-1;Mesterolone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mesterolone [Mass] of Dose;Mesterolone Dose;;ACTIVE;1.0;2.69 +43141-1;Synthetic glucocorticoid panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Synthetic glucocorticoid panel [Mass/volume] - Serum or Plasma;Syn Glucocorticoid Pnl SerPl-mCnc;;ACTIVE;2.16;2.42 +43142-9;Height measurement device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Height measurement device panel;Height Measurement Device Pnl;;ACTIVE;2.16;2.27 +43143-7;Weighing device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Weighing device panel;Weighing Device Pnl;;ACTIVE;2.16;2.27 +43144-5;Pedometer device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Pedometer device panel;Pedometer Device Pnl;;ACTIVE;2.16;2.27 +43145-2;Peak flow meter device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Peak flow meter device panel;Peak Flow Meter Device Pnl;;ACTIVE;2.16;2.27 +43146-0;Oxygen saturation device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Oxygen saturation device panel;SaO2% Device Pnl;;ACTIVE;2.16;2.32 +43147-8;Metabolism measurement device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Metabolism measurement device panel;Metabolism Measurement Device Pnl;;ACTIVE;2.16;2.27 +43148-6;Insulin delivery device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Insulin delivery device panel;Insulin Delivery Device Pnl;;ACTIVE;2.16;2.27 +43149-4;Heart rate device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Heart rate device panel;Heart Rate Device Pnl;;ACTIVE;2.16;2.27 +43150-2;HbA1c measurement device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Hemoglobin A1c measurement device panel;Hb A1c Measurement Device Pnl;;ACTIVE;2.16;2.73 +43151-0;Glucose meter device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Glucose meter device panel;Glucose Meter Device Pnl;;ACTIVE;2.16;2.73 +43152-8;Blood pressure device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Blood pressure device panel;BP device Pnl;;ACTIVE;2.16;2.27 +43153-6;Blood coagulation device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Blood coagulation device panel;Blood Coagulation Device Pnl;;ACTIVE;2.16;2.27 +43154-4;Spermatozoa^post concentration;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Spermatozoa [Presence] in Semen by Light microscopy --post concentration;Sperm p conc Smn Ql Micro;;ACTIVE;2.16;2.73 +43155-1;Spermatozoa.motile/100 spermatozoa^post concentration;NFr;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Spermatozoa Motile/100 spermatozoa in Semen by Microscopy high power field --post concentration;Sperm Motile p conc NFr Smn HPF;;ACTIVE;2.16;2.34 +43156-9;Lot number;ID;Pt;Reagent;Nom;;DEVICES;2;Reagent Lot number;Reagent Lot #;;ACTIVE;2.16;2.73 +43157-7;Vendor serial number;ID;Pt;Laboratory device;Nom;;DEVICES;2;Laboratory device Vendor serial number;Lab Device Serial #;;ACTIVE;2.16;2.63 +4315-8;Metandienone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Metandienone [Mass] of Dose;Metandienone Dose;;ACTIVE;1.0;2.69 +43158-5;Chlorine.free;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Chlorine.free [Mass/volume] in Water;Chlorine Free Wat-mCnc;;ACTIVE;2.16;2.34 +43159-3;Formaldehyde;MCnc;Pt;Flu.nonbiological;Qn;;DRUG/TOX;1;Formaldehyde [Mass/volume] in Nonbiological fluid;Formaldehyde Fld.NB-mCnc;;ACTIVE;2.16;2.73 +43160-1;Glutaraldehyde;MFr;Pt;XXX;Qn;;DRUG/TOX;1;Deprecated Glutaraldehyde in Unspecified specimen;Deprecated Glutaraldehyde MFr XXX;;DEPRECATED;2.16;2.69 +43161-9;Microorganism;NCnc;Pt;XXX;Qn;Viability count;MICRO;1;Microorganism [#/volume] in Specimen by Viability count;Microorganism # Spec Viab Cnt;;ACTIVE;2.16;2.69 +43162-7;Monochloramine;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Monochloramine [Mass/volume] in Water;Monochloramine Wat-mCnc;;ACTIVE;2.16;2.34 +43163-5;Quaternary ammonium compound;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Quaternary ammonium compound [Mass/volume] in Specimen;QAC Spec-mCnc;;ACTIVE;2.16;2.69 +43164-3;Silica;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Silica [Mass/volume] in Water;Silica Wat-mCnc;;ACTIVE;2.16;2.34 +43165-0;Dissolved solids;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Dissolved solids [Mass/volume] in Water;Dissolved Solids Wat-mCnc;;ACTIVE;2.16;2.34 +4316-6;Metaraminol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Metaraminol [Mass] of Dose;Metaraminol Dose;;ACTIVE;1.0;2.69 +43166-8;Carbon.organic;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Carbon.organic [Mass/volume] in Specimen;Carbon organic Spec-mCnc;;ACTIVE;2.16;2.69 +43169-2;Bromide;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bromide [Moles/volume] in Urine;Bromide Ur-sCnc;;ACTIVE;2.16;2.70 +431-7;Ristocetin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ristocetin [Susceptibility] by Minimum lethal concentration (MLC);Ristocetin Islt MLC;;ACTIVE;1.0;2.19 +43170-0;Human papilloma virus 31+33 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 31+33 DNA [Presence] in Tissue by Probe with signal amplification;HPV31+33 DNA Tiss Ql Probe+sig amp;;ACTIVE;2.17;2.73 +43171-8;Interleukin 2 receptor;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 receptor [Units/volume] in Serum or Plasma;Il2Recep SerPl-aCnc;;ACTIVE;2.17;2.73 +43172-6;Triiodothyronine Ab;PrThr;Pt;Ser;Ord;;SERO;1;Triiodothyronine (T3) Ab [Presence] in Serum;T3 Ab Ser Ql;;ACTIVE;2.17;2.73 +43173-4;Chlamydia trachomatis L2 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis L2 IgG Ab [Titer] in Serum by Immunofluorescence;C trach L2 IgG Titr Ser IF;;ACTIVE;2.17;2.73 +4317-4;Metenolone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Metenolone [Mass] of Dose;Metenolone Dose;;ACTIVE;1.0;2.69 +43174-2;Chlamydia trachomatis L2 Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis L2 IgA Ab [Titer] in Serum by Immunofluorescence;C trach L2 IgA Titr Ser IF;;ACTIVE;2.17;2.73 +43175-9;Chlamydia trachomatis L2 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis L2 IgM Ab [Titer] in Serum by Immunofluorescence;C trach L2 IgM Titr Ser IF;;ACTIVE;2.17;2.73 +43176-7;Lithium;SCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Lithium [Moles/volume] in Saliva (oral fluid);Lithium Sal-sCnc;;ACTIVE;2.17;2.70 +43177-5;Phenmetrazine;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Phenmetrazine [Presence] in Hair by Screen method;Phenmetrazine Hair Ql Scn;;ACTIVE;2.17;2.56 +43178-3;Phentermine;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Phentermine [Presence] in Hair by Screen method;Phentermine Hair Ql Scn;;ACTIVE;2.17;2.56 +43179-1;Asialoganglioside GM1 Ab.IgM;Titr;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgM Ab [Titer] in Serum by Immunoassay;GM1 Asialo IgM Titr Ser IA;;ACTIVE;2.17;2.73 +43180-9;Herpes simplex virus 2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Herpes simplex virus 2 IgG Ab [Presence] in Serum or Plasma by Immunoassay;HSV2 IgG SerPl Ql IA;;ACTIVE;2.17;2.73 +43181-7;Arsenic.organic;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Arsenic organic [Mass/volume] in 24 hour Urine;Arsenic organic 24h Ur-mCnc;;ACTIVE;2.17;2.42 +4318-2;Methadone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methadone [Mass] of Dose;Methadone Dose;;ACTIVE;1.0;2.69 +43182-5;Smith extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Smith extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA SM Ab Ser IA-aCnc;;ACTIVE;2.17;2.73 +43183-3;Cyanide;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Cyanide [Mass/volume] in Blood by Confirmatory method;Cyanide Bld Cfm-mCnc;;ACTIVE;2.17;2.42 +43184-1;6-Monoacetylmorphine;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Serum or Plasma by Confirmatory method;6MAM SerPl Ql Cfm;;ACTIVE;2.17;2.73 +43185-8;HIV 1 & 2 Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;HIV 1 and 2 Ab band pattern [Interpretation] in Serum by Immunoblot;HIV 1 & 2 Ab Patrn Ser IB-Imp;;ACTIVE;2.17;2.73 +43186-6;Acylcarnitine/Carnitine.free (C0);SRto;Pt;Urine;Qn;;CHEM;1;Acylcarnitine/Carnitine.free (C0) [Molar ratio] in Urine;Acylcarnitine/C0 Ur-sRto;;ACTIVE;2.17;2.44 +43187-4;Neuronal nuclear type 2 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Serum by Immunofluorescence;Hu2 Ab Ser Ql IF;;ACTIVE;2.17;2.73 +43188-2;Neuronal nuclear type 2 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear type 2 Ab [Titer] in Serum by Immunofluorescence;Hu2 Ab Titr Ser IF;;ACTIVE;2.17;2.73 +43189-0;Saccharomyces cerevisiae Ab.IgA;Titr;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast IgA Ab [Titer] in Serum;Baker's yeast IgA Titr;;ACTIVE;2.17;2.32 +4319-0;Methamphetamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methamphetamine [Mass] of Dose;Methamphet Dose;;ACTIVE;1.0;2.69 +43190-8;Myelin associated glycoprotein-sulfated glucuronic paragloboside Ab.IgM;Titr;Pt;Ser;Qn;IA;SERO;1;Myelin associated glycoprotein/Sulfated glucuronic paragloboside IgM Ab [Titer] in Serum by Immunoassay;MAG/SGPG IgM Titr Ser IA;;ACTIVE;2.17;2.73 +43191-6;FANCC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FANCC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FANCC gene Mut Anl Bld/T;;ACTIVE;2.17;2.73 +43192-4;Legionella pneumophila 2+3+4+5+6+8 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 2+3+4+5+6+8 Ab [Titer] in Serum by Immunofluorescence;L pneumo 2+3+4+5+6+8 Ab Titr Ser IF;;ACTIVE;2.17;2.73 +43193-2;Legionella non pneumophila sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella non-pneumophila Ab [Titer] in Serum by Immunofluorescence;Legionella Non-pneum Ab Titr Ser IF;;ACTIVE;2.17;2.32 +43194-0;Gamma hydroxybutyrate;MCnc;Pt;Ser/Plas;Qn;Confirm;CHEM;1;Gamma hydroxybutyrate [Mass/volume] in Serum or Plasma by Confirmatory method;G-OH-Butyr SerPl Cfm-mCnc;;ACTIVE;2.17;2.73 +43195-7;Nicotine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Nicotine [Presence] in Urine by Confirmatory method;Nicotine Ur Ql Cfm;;ACTIVE;2.17;2.73 +43196-5;Cotinine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Cotinine [Mass/volume] in Serum or Plasma by Confirmatory method;Cotinine SerPl Cfm-mCnc;;ACTIVE;2.17;2.73 +43197-3;Gamma hydroxybutyrate;PrThr;Pt;Urine;Ord;Screen;CHEM;1;Gamma hydroxybutyrate [Presence] in Urine by Screen method;G-OH-Butyr Ur Ql Scn;;ACTIVE;2.17;2.73 +43198-1;Gamma hydroxybutyrate;MCnc;Pt;Urine;Qn;Confirm;CHEM;1;Gamma hydroxybutyrate [Mass/volume] in Urine by Confirmatory method;G-OH-Butyr Ur Cfm-mCnc;;ACTIVE;2.17;2.42 +43199-9;Norfentanyl;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norfentanyl [Presence] in Urine;Norfentanyl Ur Ql;;ACTIVE;2.17;2.73 +43200-5;Norfentanyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Norfentanyl [Presence] in Urine by Confirmatory method;Norfentanyl Ur Ql Cfm;;ACTIVE;2.17;2.73 +43201-3;BK virus DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;BKV DNA Spec NAA+probe-Log#;;ACTIVE;2.17;2.73 +43202-1;Liver kidney microsomal 1 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Liver kidney microsomal 1 IgG Ab [Units/volume] in Serum;LKM-1 IgG Ser-aCnc;;ACTIVE;2.17;2.73 +43203-9;Parainfluenza virus 1 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Cerebral spinal fluid by Complement fixation;HPIV1 Ab Titr CSF CF;;ACTIVE;2.17;2.32 +43204-7;Parainfluenza virus 2 Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Parainfluenza virus 2 Ab [Units/volume] in Cerebral spinal fluid;HPIV2 Ab CSF-aCnc;;ACTIVE;2.17;2.69 +43205-4;Parainfluenza virus 3 Ab;PrThr;Pt;CSF;Ord;Comp fix;MICRO;1;Parainfluenza virus 3 Ab [Presence] in Cerebral spinal fluid by Complement fixation;HPIV3 Ab CSF Ql CF;;ACTIVE;2.17;2.56 +43206-2;Tetrachloroethylene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tetrachloroethylene [Mass/volume] in Urine;TTCE Ur-mCnc;;ACTIVE;2.17;2.42 +43207-0;Invasive trophoblast Ag;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Invasive trophoblast Ag [Presence] in Serum or Plasma;ITA SerPl Ql;;ACTIVE;2.17;2.56 +4320-8;Methapyrilene;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methapyrilene [Mass] of Dose;Methapyrilene Dose;;ACTIVE;1.0;2.69 +43208-8;Invasive trophoblast Ag;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Invasive trophoblast Ag [Multiple of the median] in Serum or Plasma;ITA MoM SerPl;;ACTIVE;2.17;2.73 +43209-6;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68+70 DNA;PrThr;Pt;Anal;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68+70 DNA [Presence] in Anal by Probe with signal amplification;HPV I/H Risk 3 DNA Anal Ql Probe+sig amp;;ACTIVE;2.17;2.63 +43210-4;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68+70 DNA;PrThr;Pt;Anal;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68+70 DNA [Presence] in Anal by NAA with probe detection;HPV I/H Risk 3 DNA Anal Ql NAA+probe;;ACTIVE;2.17;2.63 +43211-2;Human papilloma virus 6+11+42+43+44 DNA;PrThr;Pt;Anal;Ord;Probe;MICRO;1;Human papilloma virus 6+11+42+43+44 DNA [Presence] in Anal by Probe;HPV Low Risk DNA Anal Ql Probe;;ACTIVE;2.17;2.73 +43212-0;Albumin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Albumin [Mass/volume] in Body fluid by Electrophoresis;Albumin Fld Elph-mCnc;;ACTIVE;2.17;2.34 +43213-8;Polychlorinated biphenyl;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Mass/volume] in Blood;PCB Bld-mCnc;;ACTIVE;2.17;2.73 +43214-6;Bacteria identified;Prid;Pt;Nph;Nom;Culture;MICRO;1;Bacteria identified in Nasopharynx by Culture;Bacteria Nph Cult;;ACTIVE;2.17;2.73 +43215-3;Cortisol^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --baseline;Cortis BS SerPl-mCnc;;ACTIVE;2.17;2.73 +4321-6;Methaqualone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methaqualone [Mass] of Dose;Methaqualone Dose;;ACTIVE;1.0;2.69 +43216-1;Chlamydophila pneumoniae+Chlamydophila psittaci DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Throat by NAA with probe detection;C pn+psitt DNA Throat Ql NAA+probe;;ACTIVE;2.17;2.63 +43217-9;Cortisol^15M post dose corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --15 minutes post dose corticotropin IM;Cortis 15M p ACTH IM SerPl-mCnc;;ACTIVE;2.17;2.40 +43218-7;Nicotine+Cotinine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nicotine+Cotinine [Presence] in Urine;Nicotine+Cotinine Ur Ql;;ACTIVE;2.17;2.73 +43219-5;traMADol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;traMADol [Presence] in Urine;traMADol Ur Ql;;ACTIVE;2.17;2.73 +43220-3;Erythrocytes.nucleated;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Synovial fluid by Manual count;nRBC # Snv Manual;;ACTIVE;2.17;2.44 +43221-1;Chloride/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Chloride/Creatinine [Ratio] in Urine;Chloride/Creat Ur-Rto;;ACTIVE;2.17;2.73 +43222-9;Potassium/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Potassium/Creatinine [Ratio] in Urine;Potassium/Creat Ur-Rto;;ACTIVE;2.17;2.73 +43223-7;Sodium/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Sodium/Creatinine [Ratio] in Urine;Sodium/Creat Ur-Rto;;ACTIVE;2.17;2.73 +4322-4;Methicillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methicillin [Mass] of Dose;Methicillin Dose;;ACTIVE;1.0;2.69 +43224-5;Coccidioides sp Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Coccidioides sp Ab [Units/volume] in Serum by Complement fixation;Coccidioides Ab Ser CF-aCnc;;ACTIVE;2.17;2.69 +43225-2;Toxocara sp Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxocara sp Ab [Units/volume] in Serum by Immunoassay;Toxocara Ab Ser IA-aCnc;;ACTIVE;2.17;2.73 +43226-0;2-Hydroxyisocaproate;PrThr;Pt;Urine;Ord;;CHEM;1;2-Hydroxyisocaproate [Presence] in Urine;2OH-isocaproate Ur Ql;;ACTIVE;2.17;2.73 +43227-8;Ova & parasites identified;Prid;Pt;Stool;Nom;Trichrome stain;MICRO;1;Ova and parasites identified in Stool by Trichrome stain;O+P Stl Tri Stn;;ACTIVE;2.17;2.73 +43228-6;Cryptococcus sp Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Cryptococcus sp Ag [Presence] in Specimen by Latex agglutination;Cryptoc Ag Spec Ql LA;;ACTIVE;2.17;2.73 +43229-4;Cryptococcus sp Ag;Titr;Pt;XXX;Qn;LA;MICRO;1;Cryptococcus sp Ag [Titer] in Specimen by Latex agglutination;Cryptoc Ag Titr Spec LA;;ACTIVE;2.17;2.73 +43230-2;Benzoylecgonine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Specimen;BZE Spec-mCnc;;ACTIVE;2.17;2.73 +43231-0;Histone Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Histone Ab [Units/volume] in Serum by Immunoassay;Histone Ab Ser IA-aCnc;;ACTIVE;2.17;2.73 +4323-2;Methocarbamol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methocarbamol [Mass] of Dose;Methocarbamol Dose;;ACTIVE;1.0;2.69 +43232-8;Saint Louis encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Saint Louis encephalitis virus IgG Ab [Presence] in Serum;SLEV IgG Ser Ql;;ACTIVE;2.17;2.56 +43233-6;OTC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;OTC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;OTC gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +43234-4;Liver kidney microsomal 1 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Liver kidney microsomal 1 IgG Ab [Presence] in Serum;LKM-1 IgG Ser Ql;;ACTIVE;2.17;2.73 +43235-1;Acrylylcarnitine (C3:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acrylylcarnitine (C3:1) [Moles/volume] in Serum or Plasma;Acrylylcarn SerPl-sCnc;;ACTIVE;2.17;2.73 +43236-9;Streptococcus pneumoniae Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum IgG Ser IA-mCnc;;ACTIVE;2.17;2.73 +43237-7;Thrombopoietin;MCnc;Pt;PPP;Qn;IA;HEM/BC;1;Thrombopoietin [Mass/volume] in Platelet poor plasma by Immunoassay;Thrombopoietin PPP IA-mCnc;;ACTIVE;2.17;2.73 +43238-5;Treponema pallidum Ab;PrThr;Pt;Ser^Donor;Ord;IF;MICRO;1;Treponema pallidum Ab [Presence] in Serum from Donor by Immunofluorescence;T pallidum Ab Ser Donr Ql IF;;ACTIVE;2.17;2.73 +43239-3;Norsildenafil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norsildenafil [Mass/volume] in Serum or Plasma;Norsildenafil SerPl-mCnc;;ACTIVE;2.17;2.42 +4324-0;Methotrexate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methotrexate [Mass] of Dose;MTX Dose;;ACTIVE;1.0;2.73 +43240-1;Ganglioside GM1 Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 IgG Ab [Titer] in Serum by Immunoassay;GM1 Gangl IgG Titr Ser IA;;ACTIVE;2.17;2.73 +43241-9;Ganglioside GM1 Ab.IgM;Titr;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 IgM Ab [Titer] in Serum by Immunoassay;GM1 Gangl IgM Titr Ser IA;;ACTIVE;2.17;2.73 +43242-7;ACADM gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACADM gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ACADM gene Mut Anl Bld/T;;ACTIVE;2.17;2.73 +43243-5;Isobutyrylcarnitine (C4);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isobutyrylcarnitine (C4) [Moles/volume] in Serum or Plasma;Isobutyrylcarn SerPl-sCnc;;ACTIVE;2.17;2.73 +43244-3;Herpes virus 6 DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Presence] in Serum by NAA with probe detection;HHV6 DNA Ser Ql NAA+probe;;ACTIVE;2.17;2.73 +43245-0;Erythrocytes;NCnc;Pt;Semen;Qn;Microscopy.light;FERT;1;Erythrocytes [#/volume] in Semen by Light microscopy;RBC # Smn Micro;;ACTIVE;2.17;2.73 +43246-8;PHOX2B gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PHOX2B gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PHOX2B gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +43247-6;Catecholamines/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Catecholamines/Creatinine [Mass Ratio] in 24 hour Urine;Catechols/Creat 24h Ur;;ACTIVE;2.17;2.73 +43248-4;EPINEPHrine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;EPINEPHrine/Creatinine [Mass Ratio] in 24 hour Urine;Epineph/Creat 24h Ur;;ACTIVE;2.17;2.73 +43249-2;X ray dye crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;X ray dye crystals [Presence] in Urine sediment by Light microscopy;X Ray Cry UrnS Ql Micro;;ACTIVE;2.17;2.56 +432-5;Ristocetin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ristocetin [Susceptibility] by Minimum inhibitory concentration (MIC);Ristocetin Islt MIC;;ACTIVE;1.0;2.19 +43250-0;Xanthine derivatives;PrThr;Pt;Urine;Ord;;CHEM;1;Xanthine derivatives [Presence] in Urine;Xanthine Deriv Ur Ql;;ACTIVE;2.17;2.56 +43251-8;Volume^at 1.0 s post forced inspiration;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;FIV1 Predicted;FIV1 Predicted;;ACTIVE;2.17;2.40 +43252-6;Volume.residual/Capacity.total;VFr;Pt;Respiratory system;Qn;Predicted;PULM;2;Residual volume/Total capacity Predicted;Residual vol/Total capacity Predicted;;ACTIVE;2.17;2.73 +43253-4;Volume expired during 1.0 s of forced expiration^pre dose methacholine;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --pre dose methacholine;FEV1 pre MECH;;ACTIVE;2.17;2.64 +43254-2;Volume expired during 1.0 s of forced expiration^pre exercise;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --Pre excercise;FEV1 pre Exc;;ACTIVE;2.17;2.64 +43255-9;Volume expired during 1.0 s of forced expiration^post dose methacholine;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --post dose methacholine;FEV1 p MECH;;ACTIVE;2.17;2.68 +43256-7;Volume expired during 1.0 s of forced expiration^post 25 mg/mL methacholine;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --post 25 mg/mL methacholine;FEV1 p 25 mg/mL methacholine;;ACTIVE;2.17;2.40 +4325-7;Methoxyphenamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methoxyphenamine [Mass] of Dose;Methoxyphenamine Dose;;ACTIVE;1.0;2.69 +43257-5;Volume expired during 1.0 s of forced expiration^post 2.5 mg/mL methacholine;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --post 2.5 mg/mL methacholine;FEV1 p 2.5 mg/mL MECH;;ACTIVE;2.17;2.64 +43258-3;Volume expired during 1.0 s of forced expiration^post 10 mg/mL methacholine;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --post 10 mg/mL methacholine;FEV1 p 10 mg/mL MECH;;ACTIVE;2.17;2.64 +43259-1;Volume expired during 1.0 s of forced expiration^post 0.25 mg/mL methacholine;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --post 0.25 mg/mL methacholine;FEV1 p 0.25 mg/mL MECH;;ACTIVE;2.17;2.68 +43260-9;Volume expired during 1.0 s of forced expiration^post 0.025 mg/mL methacholine;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --post 0.025 mg/mL methacholine;FEV1 p 0.025 mg/mL MECH;;ACTIVE;2.17;2.64 +43261-7;Volume expired during 1.0 s of forced expiration^5M post exercise;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --5 minutes post exercise;FEV1 5M p excz;;ACTIVE;2.17;2.64 +43262-5;Volume expired during 1.0 s of forced expiration^15M post exercise;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --15 minutes post exercise;FEV1 15M p Exc;;ACTIVE;2.17;2.64 +43263-3;Volume expired during 1.0 s of forced expiration^10M post exercise;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV1 --10 minutes post exercise;FEV1 10M p Exc;;ACTIVE;2.17;2.64 +43264-1;Volume^at 1.0 s post forced inspiration/Volume.forced inspiration.total;VFr;Pt;Respiratory system;Qn;Predicted;PULM;2;FIV1/FIV Predicted;FIV1/FIV Predicted;;ACTIVE;2.17;2.48 +4326-5;Methsuximide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methsuximide [Mass] of Dose;Methsuximide Dose;;ACTIVE;1.0;2.69 +43265-8;Benztropine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Benztropine [Presence] in Urine;Benztropine Ur Ql;;ACTIVE;2.17;2.73 +43266-6;Leishmania chagasi K39 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania chagasi K39 Ab [Presence] in Serum;L chagasi K39 Ab Ser Ql;;ACTIVE;2.17;2.56 +43267-4;Uranium.depleted cutoff;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Uranium depleted cutoff [Mass/volume] in Urine;Depleted U CtO Ur-mCnc;;ACTIVE;2.17;2.42 +43268-2;Cells.CD3-CD57+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;Deprecated CD3-CD57+ cells/100 cells in Tissue;Deprecated CD3-CD57+ Cells Fr Tiss;;DEPRECATED;2.17;2.36 +43269-0;Ceftobiprole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceftobiprole [Susceptibility] by Disk diffusion (KB);Ceftobiprole Islt KB;;ACTIVE;2.17;2.19 +43270-8;Ceftobiprole;Susc;Pt;Isolate;OrdQn;MLC;ABXBACT;1;Ceftobiprole [Susceptibility] by Minimum lethal concentration (MLC);Ceftobiprole Islt MLC;;ACTIVE;2.17;2.19 +43271-6;Ceftobiprole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceftobiprole [Susceptibility] by Minimum inhibitory concentration (MIC);Ceftobiprole Islt MIC;;ACTIVE;2.17;2.19 +43272-4;Ceftobiprole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceftobiprole [Susceptibility];Ceftobiprole Susc Islt;;ACTIVE;2.17;2.19 +4327-3;Methyldopa;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methyldopa [Mass] of Dose;Methyldopa Dose;;ACTIVE;1.0;2.69 +43273-2;Cells.CD19+CD27+IgD+/100 cells;NFr;Pt;Bld/Tiss;Qn;;CELLMARK;1;CD19+CD27+IgD+ cells/100 cells in Blood or Tissue;CD19+CD27+IgD+ Cells NFr Bld/T;;ACTIVE;2.17;2.73 +43274-0;Cells.CD1c+CD22+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD1c+CD22+ cells/100 cells in Specimen;CD1c+CD22+ Cells NFr Spec;;ACTIVE;2.17;2.69 +43275-7;Cells.CD3/Cells.CD4;NRto;Pt;XXX;Qn;;CELLMARK;1;CD3 cells/CD4 cells [# Ratio] in Specimen;CD3 Cells/CD4 Cells Spec;;ACTIVE;2.17;2.69 +43276-5;Dermatophagoides sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dermatophagoides sp IgE Ab RAST class [Presence] in Serum;Dermatophagoides sp IgE RAST Ql;;ACTIVE;2.17;2.58 +43277-3;GDAP1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GDAP1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GDAP1 gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +43278-1;Glucose^2H post meal;MCnc;Pt;Milk;Qn;;CHAL;1;Glucose [Mass/volume] in Milk --2 hours post meal;Glucose 2h p meal Mlk-mCnc;;ACTIVE;2.17;2.34 +43279-9;Hepatitis B virus YMDD mutation;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;ABXBACT;1;Hepatitis B Virus YMDD [Presence] in Serum or Plasma by NAA with probe detection;HBV YMDD Mut SerPl Ql NAA+probe;;ACTIVE;2.17;2.73 +43280-7;Hepatitis D virus Ag;MCnc;Pt;Urine;Qn;;MICRO;1;Hepatitis D virus Ag [Mass/volume] in Urine;HDV Ag Ur-mCnc;;ACTIVE;2.17;2.40 +4328-1;MethylePHEDrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;MethylePHEDrine [Mass] of Dose;Me-ePHEDrine Dose;;ACTIVE;1.0;2.69 +43281-5;Hepatitis D virus Ag;MCnc;Pt;Ser;Qn;;MICRO;1;Hepatitis D virus Ag [Mass/volume] in Serum;HDV Ag Ser-mCnc;;ACTIVE;2.17;2.73 +43282-3;Heterophile Ab;PrThr;Pt;Ser^Control;Ord;;MICRO;1;Heterophile Ab [Presence] in Control Serum;Heteroph Ab Ser Cont Ql;;ACTIVE;2.17;2.56 +43283-1;Myeloid cells/100 cells;NFr;Pt;Tiss;Qn;;HEM/BC;1;Myeloid cells/100 cells in Tissue;Myeloid cells NFr Tiss;;ACTIVE;2.17;2.70 +43284-9;Spermatozoa IgA binding location;Prid;Pt;Semen;Nom;;FERT;1;Spermatozoa IgA binding location [Identifier] in Semen;Sperm IgA Bind Location Smn;;ACTIVE;2.17;2.73 +43285-6;Spermatozoa Ab.IgM/100 spermatozoa;NFr;Pt;Ser;Qn;;FERT;1;Spermatozoa IgM Ab/100 spermatozoa in Serum;Sperm IgM NFr Ser;;ACTIVE;2.17;2.40 +43286-4;Spermatozoa Ab.IgG/100 spermatozoa;NFr;Pt;Ser;Qn;;FERT;1;Spermatozoa IgG Ab/100 spermatozoa in Serum;Sperm IgG NFr Ser;;ACTIVE;2.17;2.40 +43287-2;Spermatozoa IgG binding location;Prid;Pt;Semen;Nom;;FERT;1;Spermatozoa IgG binding location [Identifier] in Semen;Sperm IgG Bind Location Smn;;ACTIVE;2.17;2.73 +43288-0;Spermatozoa Ab.IgA/100 spermatozoa;NFr;Pt;Ser;Qn;;FERT;1;Spermatozoa IgA Ab/100 spermatozoa in Serum;Sperm IgA NFr Ser;;ACTIVE;2.17;2.40 +43289-8;Methylcrotonylcarnitine (C5:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylcrotonylcarnitine (C5:1) [Moles/volume] in Serum or Plasma;Methylcrotonylcarn SerPl-sCnc;;ACTIVE;2.17;2.73 +43290-6;HLA-DRB1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DRB1 [Presence];HLA-DRB1 Ql;;ACTIVE;2.17;2.73 +43291-4;HLA-DQB1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQB1 [Presence];HLA-DQB1 Ql;;ACTIVE;2.17;2.73 +43292-2;Neutrophil oxidative burst stimulated/unstimulated;RelACnc;Pt;Bld;Qn;;HEM/BC;1;Neutrophil oxidative burst/unstimulated in Blood;Neutrophil OB Bld;;ACTIVE;2.17;2.73 +43293-0;HTLV I+II p28 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II p28 Ab [Presence] in Serum;HTLV I+II p28 Ab Ser Ql;;ACTIVE;2.17;2.56 +43294-8;HTLV I+II p26 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II p26 Ab [Presence] in Serum;HTLV I+II p26 Ab Ser Ql;;ACTIVE;2.17;2.56 +43295-5;HTLV I+II p53 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II p53 Ab [Presence] in Serum;HTLV I+II p53 Ab Ser Ql;;ACTIVE;2.17;2.56 +43296-3;HTLV I+II gp46 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II gp46 Ab [Presence] in Serum;HTLV I+II gp46 Ab Ser Ql;;ACTIVE;2.17;2.56 +43297-1;HTLV I+II p32 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II p32 Ab [Presence] in Serum;HTLV I+II p32 Ab Ser Ql;;ACTIVE;2.17;2.56 +43298-9;HTLV I+II rgp21 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II rgp21 Ab [Presence] in Serum;HTLV I+II rgp21 Ab Ser Ql;;ACTIVE;2.17;2.56 +4329-9;Methylphenidate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methylphenidate [Mass] of Dose;Me-phenidate Dose;;ACTIVE;1.0;2.69 +43299-7;HTLV I+II p19 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II p19 Ab [Presence] in Serum;HTLV I+II p19 Ab Ser Ql;;ACTIVE;2.17;2.56 +43300-3;HTLV I+II p24 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II p24 Ab [Presence] in Serum;HTLV I+II p24 Ab Ser Ql;;ACTIVE;2.17;2.56 +43301-1;HTLV I+II p36 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I+II p36 Ab [Presence] in Serum;HTLV I+II p36 Ab Ser Ql;;ACTIVE;2.17;2.56 +43302-9;Platelet glycoprotein Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Platelet glycoprotein Ab [Presence] in Serum by Immunoassay;Plat Gp Ab Ser Ql IA;;ACTIVE;2.17;2.73 +43303-7;Immune complex.C3d;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Immune Complex C3d [Units/volume] in Serum or Plasma;IC C3d SerPl-aCnc;;ACTIVE;2.17;2.69 +43304-5;Chlamydia trachomatis rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Specimen by NAA with probe detection;C trach rRNA Spec Ql NAA+probe;;ACTIVE;2.17;2.73 +43305-2;Neisseria gonorrhoeae rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Specimen by NAA with probe detection;N gonorrhoea rRNA Spec Ql NAA+probe;;ACTIVE;2.17;2.73 +43306-0;Chromosome 21 trisomy;Prctl;Pt;Bld/Tiss;Qn;Cytogenetics;MOLPATH.TRISOMY;1;Chromosome 21 trisomy [Percentile] by Cytogenetics;Chr 21 Ts Prctl Bld/T;;ACTIVE;2.17;2.66 +4330-7;Methyprylon;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methyprylon [Mass] of Dose;Methyprylon Dose;;ACTIVE;1.0;2.69 +43307-8;Bacteria identified;Prid;Pt;Sinus;Nom;Culture;MICRO;1;Bacteria identified in Sinus by Culture;Bacteria Sinus Cult;;ACTIVE;2.17;2.73 +43308-6;Lupus anticoagulant neutralization.buffer;Time;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization buffer [Time] in Platelet poor plasma by Coagulation assay;LA Nt Buffer PPP;;DISCOURAGED;2.17;2.73 +43309-4;Desmoglein 1 & Desmoglein 3 Ab panel;ACnc;Pt;Ser;Qn;;PANEL.SERO;1;Desmoglein 1 and Desmoglein 3 Ab panel [Units/volume] - Serum;Desmoglein 1+3 Ab Pnl Ser-aCnc;;ACTIVE;2.17;2.42 +43310-2;FBN2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FBN2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FBN2 gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +43311-0;Desmoglein 1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Desmoglein 1 Ab [Units/volume] in Serum;Desmoglein 1 Ab Ser-aCnc;;ACTIVE;2.17;2.73 +43312-8;Desmoglein 3 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Desmoglein 3 Ab [Units/volume] in Serum;Desmoglein 3 Ab Ser-aCnc;;ACTIVE;2.17;2.73 +43313-6;Avian adenovirus 127 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian adenovirus 127 Ab [Titer] in Serum by Hemagglutination inhibition;FAdV127 Ab Titr Ser HAI;;ACTIVE;2.17;2.67 +43314-4;Avian paramyxovirus 6 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian paramyxovirus 6 Ab [Titer] in Serum by Hemagglutination inhibition;APMV6 Ab Titr Ser HAI;;ACTIVE;2.17;2.67 +4331-5;Metoprolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Metoprolol [Mass] of Dose;Metoprolol Dose;;ACTIVE;1.0;2.69 +43315-1;Avian paramyxovirus 7 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian paramyxovirus 7 Ab [Titer] in Serum by Hemagglutination inhibition;APMV7 Ab Titr Ser HAI;;ACTIVE;2.17;2.67 +43316-9;Avian paramyxovirus 8 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian paramyxovirus 8 Ab [Titer] in Serum by Hemagglutination inhibition;APMV8 Ab Titr Ser HAI;;ACTIVE;2.17;2.67 +43317-7;Avian paramyxovirus 9 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Avian paramyxovirus 9 Ab [Titer] in Serum by Hemagglutination inhibition;APMV9 Ab Titr Ser HAI;;ACTIVE;2.17;2.67 +43318-5;Avian metapneumovirus A Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Avian metapneumovirus A Ab [Presence] in Serum by Immunofluorescence;aMPV A Ab Ser Ql IF;;ACTIVE;2.17;2.58 +43319-3;Avian metapneumovirus A Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian metapneumovirus A Ab [Titer] in Serum by Immunoassay;aMPV A Ab Titr Ser IA;;ACTIVE;2.17;2.58 +43320-1;Avian metapneumovirus B Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Avian metapneumovirus B Ab [Presence] in Serum by Immunofluorescence;aMPV B Ab Ser Ql IF;;ACTIVE;2.17;2.58 +43321-9;Avian metapneumovirus B Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian metapneumovirus B Ab [Titer] in Serum by Immunoassay;aMPV B Ab Titr Ser IA;;ACTIVE;2.17;2.58 +43322-7;Avian metapneumovirus C Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Avian metapneumovirus C Ab [Presence] in Serum by Immunofluorescence;aMPV C Ab Ser Ql IF;;ACTIVE;2.17;2.58 +4332-3;Mexiletine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mexiletine [Mass] of Dose;Mexiletine Dose;;ACTIVE;1.0;2.73 +43323-5;Avian metapneumovirus C Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian metapneumovirus C Ab [Titer] in Serum by Immunoassay;aMPV C Ab Titr Ser IA;;ACTIVE;2.17;2.58 +43324-3;Avian reovirus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Avian reovirus Ab [Presence] in Serum by Immunofluorescence;AVREOV Ab Ser Ql IF;;ACTIVE;2.17;2.67 +43325-0;Chicken anemia virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Chicken anemia virus Ab [Presence] in Serum by Immunofluorescence;CAV Ab Ser Ql IF;;ACTIVE;2.17;2.67 +43326-8;Classical swine fever virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Classical swine fever virus neutralizing antibody [Titer] in Serum by Neutralization test;CSFV NAb Titr Ser Nt;;ACTIVE;2.17;2.72 +43327-6;Classical swine fever virus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Classical swine fever virus Ag [Presence] in Specimen by Immune stain;CSFV Ag Spec Ql ImStn;;ACTIVE;2.17;2.69 +43328-4;Duck enteritis virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Duck enteritis virus Ab [Presence] in Serum by Immunofluorescence;DVE Ab Ser Ql IF;;ACTIVE;2.17;2.56 +43329-2;Eastern equine encephalitis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Eastern equine encephalitis virus Ab [Titer] in Serum by Complement fixation;EEEV Ab Titr Ser CF;;ACTIVE;2.17;2.32 +433-3;Ristocetin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ristocetin [Susceptibility] by Disk diffusion (KB);Ristocetin Islt KB;;ACTIVE;1.0;2.19 +43330-0;Eastern equine encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Eastern equine encephalitis virus IgM Ab [Titer] in Serum by Immunoassay;EEEV IgM Titr Ser IA;;ACTIVE;2.17;2.56 +4333-1;Mezlocillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Mezlocillin [Mass] of Dose;Mezlocillin Dose;;ACTIVE;1.0;2.69 +43331-8;Ehrlichia risticii Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Ehrlichia risticii Ab [Titer] in Serum by Immunofluorescence;E risticii Ab Titr Ser IF;;ACTIVE;2.17;2.32 +43332-6;Equine herpesvirus 1 Ab.Neut;Titr;Pt;CSF;Qn;Neut;MICRO;1;Equine herpesvirus 1 neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test;EHV1 NAb Titr CSF Nt;;ACTIVE;2.17;2.72 +43333-4;Equine herpesvirus 2 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Equine herpesvirus 2 neutralizing antibody [Titer] in Serum by Neutralization test;EHV2 NAb Titr Ser Nt;;ACTIVE;2.17;2.72 +43334-2;Equine herpesvirus 3 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Equine herpesvirus 3 neutralizing antibody [Titer] in Serum by Neutralization test;EHV3 NAb Titr Ser Nt;;ACTIVE;2.17;2.72 +43335-9;Fowl adenovirus 1 Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Fowl adenovirus Ab [Presence] in Serum by Immune diffusion (ID);FAdV1 Ab Ser Ql ID;;ACTIVE;2.17;2.67 +43336-7;Goose parvovirus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Goose parvovirus Ab [Presence] in Serum by Immunofluorescence;GPV Ab Ser Ql IF;;ACTIVE;2.17;2.56 +43337-5;Goose parvovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Goose parvovirus RNA [Presence] in Specimen by NAA with probe detection;GPV RNA Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +43338-3;Infectious bronchitis virus JMK Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Infectious bronchitis virus JMK Ab [Titer] in Serum by Hemagglutination inhibition;IBV JMK Ab Titr Ser HAI;;ACTIVE;2.17;2.67 +43339-1;Porcine adenovirus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Porcine adenovirus Ab [Presence] in Serum by Immunofluorescence;PAdV Ab Ser Ql IF;;ACTIVE;2.17;2.56 +43340-9;Psittacid herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Psittacid herpesvirus 1 Ab [Presence] in Serum by Immunofluorescence;PsHV-1 Ab Ser Ql IF;;ACTIVE;2.17;2.56 +43341-7;Venezuelan equine encephalitis virus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Venezuelan equine encephalitis virus Ab [Titer] in Serum by Immunoassay;VEEV Ab Titr Ser IA;;ACTIVE;2.17;2.56 +43342-5;West Nile virus Ab.IgM;Titr;Pt;CSF;Qn;IA;MICRO;1;West Nile virus IgM Ab [Titer] in Cerebral spinal fluid by Immunoassay;WNV IgM Titr CSF IA;;ACTIVE;2.17;2.56 +43343-3;West Nile virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;West Nile virus IgM Ab [Titer] in Serum by Immunoassay;WNV IgM Titr Ser IA;;ACTIVE;2.17;2.56 +43344-1;Avian adenovirus 127 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian adenovirus 127 Ab [Titer] in Serum;FAdV127 Ab Titr Ser;;ACTIVE;2.17;2.67 +43345-8;Avian paramyxovirus 6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 6 Ab [Titer] in Serum;APMV6 Ab Titr Ser;;ACTIVE;2.17;2.67 +43346-6;Avian paramyxovirus 7 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 7 Ab [Titer] in Serum;APMV7 Ab Titr Ser;;ACTIVE;2.17;2.67 +43347-4;Avian paramyxovirus 8 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 8 Ab [Titer] in Serum;APMV8 Ab Titr Ser;;ACTIVE;2.17;2.67 +43348-2;Avian paramyxovirus 9 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian paramyxovirus 9 Ab [Titer] in Serum;APMV9 Ab Titr Ser;;ACTIVE;2.17;2.67 +4334-9;Midazolam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Midazolam [Mass] of Dose;Midazolam Dose;;ACTIVE;1.0;2.69 +43349-0;Avian metapneumovirus A Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian metapneumovirus A Ab [Presence] in Serum;aMPV A Ab Ser Ql;;ACTIVE;2.17;2.58 +43350-8;Avian metapneumovirus A Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian metapneumovirus A Ab [Titer] in Serum;aMPV A Ab Titr Ser;;ACTIVE;2.17;2.58 +43351-6;Avian metapneumovirus B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian metapneumovirus B Ab [Presence] in Serum;aMPV B Ab Ser Ql;;ACTIVE;2.17;2.58 +43352-4;Avian metapneumovirus B Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian metapneumovirus B Ab [Titer] in Serum;aMPV B Ab Titr Ser;;ACTIVE;2.17;2.58 +43353-2;Avian metapneumovirus C Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Avian metapneumovirus C Ab [Presence] in Serum;aMPV C Ab Ser Ql;;ACTIVE;2.17;2.58 +43354-0;Avian metapneumovirus C Ab;Titr;Pt;Ser;Qn;;MICRO;1;Avian metapneumovirus C Ab [Titer] in Serum;aMPV C Ab Titr Ser;;ACTIVE;2.17;2.58 +43355-7;Chlamydia trachomatis D+E+F+G+H+I+J+K Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis D+E+F+G+H+I+J+K IgG Ab [Titer] in Serum by Immunofluorescence;C trach D+E+F+G+H+I+J+K IgG Titr Ser IF;;ACTIVE;2.17;2.73 +4335-6;Minocycline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Minocycline [Mass] of Dose;Minocycline Dose;;ACTIVE;1.0;2.69 +43356-5;Chlamydia trachomatis D+E+F+G+H+I+J+K Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis D+E+F+G+H+I+J+K IgA Ab [Titer] in Serum by Immunofluorescence;C trach D+E+F+G+H+I+J+K IgA Titr Ser IF;;ACTIVE;2.17;2.73 +43357-3;Chlamydia trachomatis D+E+F+G+H+I+J+K Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis D+E+F+G+H+I+J+K IgM Ab [Titer] in Serum by Immunofluorescence;C trach D+E+F+G+H+I+J+K IgM Titr Ser IF;;ACTIVE;2.17;2.73 +43358-1;UNC13D gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;UNC13D gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;UNC13D gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +43359-9;11-Ketoetiocholanolone;MCnc;24H;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone [Mass/volume] in 24 hour Urine;11Ketoetioch 24h Ur-mCnc;;ACTIVE;2.17;2.42 +43360-7;Bordetella sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bordetella sp Ag [Presence] in Specimen by Immunofluorescence;Bordetella Ag Spec Ql IF;;ACTIVE;2.17;2.73 +43361-5;Cardiolipin Ab.IgA;MCnc;Pt;Ser;Qn;;COAG;1;Cardiolipin IgA Ab [Mass/volume] in Serum;Cardiolipin IgA Ser-mCnc;;ACTIVE;2.17;2.73 +43362-3;Cardiolipin Ab.IgG;MCnc;Pt;Ser;Qn;;COAG;1;Cardiolipin IgG Ab [Mass/volume] in Serum;Cardiolipin IgG Ser-mCnc;;ACTIVE;2.17;2.73 +43363-1;Cardiolipin Ab.IgM;MCnc;Pt;Ser;Qn;;COAG;1;Cardiolipin IgM Ab [Mass/volume] in Serum;Cardiolipin IgM Ser-mCnc;;ACTIVE;2.17;2.73 +4336-4;Morazone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Morazone [Mass] of Dose;Morazone Dose;;ACTIVE;1.0;2.69 +43364-9;Enterovirus identified;Prid;Pt;XXX;Nom;IF;MICRO;1;Enterovirus identified in Specimen by Immunofluorescence;EV Spec IF;;ACTIVE;2.17;2.69 +43365-6;Nocardia sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Nocardia sp identified in Specimen by Organism specific culture;Nocardia Spec Cult;;ACTIVE;2.17;2.73 +43366-4;Parainfluenza virus Ag;Prid;Pt;XXX;Nom;IF;MICRO;1;Parainfluenza virus Ag [Identifier] in Specimen by Immunofluorescence;HPIV Ag Spec IF;;ACTIVE;2.17;2.69 +43367-2;Trichomonas sp;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Trichomonas sp [#/area] in Urine sediment by Microscopy low power field;Trichomonas #/area UrnS LPF;;ACTIVE;2.17;2.73 +43368-0;Microsatellite instability;Prid;Pt;Tiss;Nom;Molgen;MOLPATH;1;Microsatellite instability [Identifier] in Tissue by Molecular genetics method Nominal;MSI Tiss;;ACTIVE;2.17;2.73 +43369-8;PlA1 Ab;PrThr;Pt;PRP;Ord;;SERO;1;PlA1 Ab [Presence] in Platelet rich plasma;PlA1 Ab PRP Ql;;ACTIVE;2.17;2.56 +43370-6;CFTR gene.p.IVS8 polyT;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene p.IVS8 PolyT [Presence] in Blood or Tissue by Molecular genetics method;CFTR IVS8 PolyT Bld/T Ql;;ACTIVE;2.17;2.73 +43371-4;Salmonella & Shigella sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Salmonella and Shigella sp identified in Stool by Organism specific culture;Salm + Shig Stl Cult;;ACTIVE;2.17;2.73 +4337-2;Morphine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Morphine [Mass] of Dose;Morphine Dose;;ACTIVE;1.0;2.73 +43372-2;Figure associated with report or note;-;Pt;^Patient;-;;MISC;1;Figure associated with report or note;Associated figure Patient;;ACTIVE;2.17;2.26 +43373-0;Rat epithelium+Serum proteins+Urine proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Rat epithelium, serum proteins + urine proteins IgE Ab RAST class [Presence] in Serum;Rat Epith+Ser+Ur IgE RAST Ql;;ACTIVE;2.17;2.73 +43374-8;Parietaria officinalis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pellitory (Parietaria officinalis) IgE Ab RAST class [Presence] in Serum;Pellitory (offic) IgE RAST Ql;;ACTIVE;2.17;2.73 +43375-5;Phoenix dactylifera Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dates IgE Ab RAST class [Presence] in Serum;Dates IgE RAST Ql;;ACTIVE;2.17;2.73 +43376-3;Spermatozoa.progressive^post washing;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Progressive [Presence] in Semen --post washing;Sperm Prog p Wash Smn Ql;;ACTIVE;2.17;2.56 +43377-1;Spermatozoa.progressive^pre washing;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Progressive [Presence] in Semen --pre washing;Sperm Prog Pre Wash Smn Ql;;ACTIVE;2.17;2.56 +43378-9;Spermatozoa.motile^post washing;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile [#/volume] in Semen --post washing;Sperm Motile p Wash # Smn;;ACTIVE;2.17;2.70 +43379-7;HLA-DRB3;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DRB3 [Presence];HLA-DRB3 Ql;;ACTIVE;2.17;2.56 +4338-0;Moxalactam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Moxalactam [Mass] of Dose;Moxalactam Dose;;ACTIVE;1.0;2.69 +43380-5;Coccidioides immitis Ab.IgG;ACnc;Pt;XXX;Qn;;MICRO;1;Coccidioides immitis IgG Ab [Units/volume] in Specimen;C immitis IgG Spec-aCnc;;ACTIVE;2.17;2.73 +43381-3;Bordetella pertussis Ab;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bordetella pertussis Ab [Presence] in Specimen by Immunofluorescence;B pert Ab Spec Ql IF;;ACTIVE;2.17;2.73 +43382-1;Alkaline phosphatase.heat stable/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;Heat stability;CHEM;1;Alkaline phosphatase.heat stable/Alkaline phosphatase.total in Serum or Plasma by Heat stability;ALP heat stable CFr SerPl HS;;ACTIVE;2.17;2.73 +43383-9;Neisseria sp identified;Prid;Pt;Thrt;Nom;Organism specific culture;MICRO;1;Neisseria sp identified in Throat by Organism specific culture;Neisseria Throat Cult;;ACTIVE;2.17;2.17 +43384-7;Neisseria sp identified;Prid;Pt;Urethra;Nom;Organism specific culture;MICRO;1;Neisseria sp identified in Urethra by Organism specific culture;Neisseria Urth Cult;;ACTIVE;2.17;2.73 +43385-4;Neisseria sp identified;Prid;Pt;Cvx;Nom;Organism specific culture;MICRO;1;Neisseria sp identified in Cervix by Organism specific culture;Neisseria Cvx Cult;;ACTIVE;2.17;2.58 +43386-2;Neisseria sp identified;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Neisseria sp identified in Anal by Organism specific culture;Neisseria Anal Cult;;ACTIVE;2.17;2.17 +43387-0;Neisseria sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Neisseria sp identified in Specimen by Organism specific culture;Neisseria Spec Cult;;ACTIVE;2.17;2.73 +43389-6;Streptococcus sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Streptococcus sp identified in Isolate by Organism specific culture;Streptococcus Islt Cult;;ACTIVE;2.17;2.73 +43390-4;Streptococcus sp identified;Prid;Pt;Isolate;Nom;;MICRO;1;Streptococcus sp identified in Isolate;Streptococcus Islt;;ACTIVE;2.17;2.19 +43391-2;Bacterial vaginosis score;Score;Pt;Vag;Ord;;MICRO;1;Bacterial vaginosis score;BV score Vag Ql;;ACTIVE;2.17;2.73 +43392-0;LDL 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 1 [Mass/volume] in Serum or Plasma;LDL1 SerPl-mCnc;;DISCOURAGED;2.17;2.73 +43393-8;LDL 4;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 4 [Mass/volume] in Serum or Plasma;LDL4 SerPl-mCnc;;DISCOURAGED;2.17;2.73 +43394-6;Cholesterol.in LDL.acetylated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL acylated [Mass/volume] in Serum or Plasma;LDLc-Ac SerPl-mCnc;;ACTIVE;2.17;2.70 +43395-3;Cholesterol.in VLDL.acetylated;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL acylated [Mass/volume] in Serum or Plasma;Ac-VLDLc SerPl-mCnc;;ACTIVE;2.17;2.70 +43396-1;Cholesterol.non HDL;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol non HDL [Mass/volume] in Serum or Plasma;NonHDLc SerPl-mCnc;;ACTIVE;2.17;2.73 +43397-9;Coagulation dilute Russell viper venom induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;dRVVT imm NP PPP;;DISCOURAGED;2.17;2.73 +4339-8;N-acetylprocainamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;N-acetylprocainamide [Mass] of Dose;NAPA Dose;;ACTIVE;1.0;2.69 +43398-7;Gardnerella vaginalis+Prevotella sp morphotypes;PrThr;Pt;Vag;Ord;Microscopy.light;MICRO;1;Gardnerella vaginalis+Prevotella sp morphotypes [Presence] in Vaginal fluid by Light microscopy;G vaginalis+Prev sp mtyp Vag Ql Micro;;ACTIVE;2.17;2.56 +43399-5;JAK2 gene.p.Val617Phe;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;JAK2 gene p.Val617Phe [Presence] in Blood or Tissue by Molecular genetics method;JAK2 p.V617F Bld/T Ql;;ACTIVE;2.17;2.73 +43400-1;Lactobacillus sp morphotypes;PrThr;Pt;Vag;Ord;Microscopy.light;MICRO;1;Lactobacillus sp morphotypes [Presence] in Vaginal fluid by Light microscopy;Lactobacillus morphotyp Vag Ql Micro;;ACTIVE;2.17;2.56 +43401-9;Cryofibrinogen;PrThr;Pt;Plas;Ord;1W 37 deg C incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 1 week 37 degree C incubation;Cryofib Plas Ql 1W Inc;;ACTIVE;2.17;2.56 +43402-7;Erythrocyte sedimentation rate;Vel;Pt;Bld;Qn;15M reading;HEM/BC;1;Erythrocyte sedimentation rate by 15 minute reading;ESR Bld Qn 15M;;ACTIVE;2.17;2.73 +43403-5;Neisseria gonorrhoeae DNA;PrThr;Pt;XXX;Ord;Probe.amp.sig;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Specimen by Probe with signal amplification;N gonorrhoea DNA Spec Ql Probe+sig amp;;ACTIVE;2.17;2.73 +43404-3;Chlamydia trachomatis DNA;PrThr;Pt;XXX;Ord;Probe.amp.sig;MICRO;1;Chlamydia trachomatis DNA [Presence] in Specimen by Probe with signal amplification;C trach DNA Spec Ql Probe+sig amp;;ACTIVE;2.17;2.73 +43405-0;Chlamydia trachomatis & Neisseria gonorrhoeae DNA;Prid;Pt;XXX;Nom;Probe.amp.sig;MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae DNA [Identifier] in Specimen by Probe with signal amplification;C trach+GC DNA Spec Probe+sig amp;;ACTIVE;2.17;2.69 +4340-6;N-ethylnicotinamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated N-ethylnicotinamide [Mass] of Dose;Deprecated NEN Dose;;DEPRECATED;1.0;2.69 +43406-8;Chlamydia trachomatis+Neisseria gonorrhoeae DNA;PrThr;Pt;XXX;Ord;Probe.amp.sig;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Specimen by Probe with signal amplification;C trach+GC DNA Spec Ql Probe+sig amp;;ACTIVE;2.17;2.73 +43407-6;Bacteria identified;Prid;Pt;Wound.deep;Nom;Culture;MICRO;1;Bacteria identified in Wound deep by Culture;Bacteria Deep Wnd Cult;;ACTIVE;2.17;2.73 +43408-4;Bacteria identified;Prid;Pt;Tiss;Nom;Culture;MICRO;1;Bacteria identified in Tissue by Culture;Bacteria Tiss Cult;;ACTIVE;2.17;2.73 +43409-2;Bacteria identified;Prid;Pt;Isolate;Nom;Culture;MICRO;1;Bacteria identified in Isolate by Culture;Bacteria Islt Cult;;ACTIVE;2.17;2.73 +434-1;Ristocetin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ristocetin [Susceptibility] by Serum bactericidal titer;Ristocetin Titr SBT;;ACTIVE;1.0;2.32 +43410-0;Bacteria identified;Prid;Pt;Cvx;Nom;Culture;MICRO;1;Bacteria identified in Cervix by Culture;Bacteria Cvx Cult;;ACTIVE;2.17;2.73 +43411-8;Bacteria identified;Prid;Pt;Asp;Nom;Culture;MICRO;1;Bacteria identified in Aspirate by Culture;Bacteria Aspirate Cult;;ACTIVE;2.17;2.73 +43412-6;Blood product units issued;Num;Pt;^BPU;Qn;;BLDBK;1;Blood product units issued [#];Num BPU Issued;;ACTIVE;2.17;2.73 +43413-4;Blood product units requested;Num;Pt;^BPU;Qn;;BLDBK;1;Blood product units requested [#];Num BPU Requested;;ACTIVE;2.17;2.73 +4341-4;Nadolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nadolol [Mass] of Dose;Nadolol Dose;;ACTIVE;1.0;2.69 +43414-2;Blood product units available;Num;Pt;^BPU;Qn;;BLDBK;1;Blood product units available [#];Num BPU Avail;;ACTIVE;2.17;2.73 +43415-9;Unidentified cells/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Unidentified cells/100 cells in Bone marrow;Unident Cells NFr Mar;;ACTIVE;2.17;2.34 +43416-7;Hematocrit;VFr;Pt;^Stem cell product;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Stem cell product;Hct VFr Stem prod;;ACTIVE;2.17;2.73 +43417-5;Microscopic observation;Prid;Pt;Esophageal brush;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Esophageal brushing by Cyto stain;Cyto Esoph Brush;;ACTIVE;2.17;2.29 +43418-3;Stem cell product given;Vol;Pt;^Patient;Qn;;BLDBK;1;Stem cell product given [Volume];Stem Cell Prod Gvn Vol;;ACTIVE;2.17;2.70 +43419-1;Tuberculosis reaction wheal^3D post 1 TU ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tuberculosis reaction wheal [Diameter] --3 days post 1 TU intradermal;TB Wheal 3D p 1 TU Diam;;ACTIVE;2.17;2.73 +43420-9;Uranium dose assessment;Imp;Pt;Urine;Nom;;DRUG/TOX;1;Uranium dose assessment [Interpretation] in Urine;Uranium Dose Assessment Ur-Imp;;ACTIVE;2.17;2.19 +43421-7;Thiopurine methyltransferase;CCnt;Pt;RBC;Qn;;CHEM;1;Thiopurine methyltransferase [Enzymatic activity/mass] in Red Blood Cells;TPMT RBC-cCnt;;ACTIVE;2.17;2.73 +4342-2;Nalbuphine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nalbuphine [Mass] of Dose;Nalbuphine Dose;;ACTIVE;1.0;2.69 +43422-5;Rabbit dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit dander IgE Ab [Units/volume] in Serum;Rabbit Dander IgE Qn;;ACTIVE;2.17;2.70 +43423-3;Sodium urate;SatFr;24H;Urine;Qn;;CHEM;1;Sodium urate [Saturation Fraction] in 24 hour Urine;Na Urate 24h SatFr Ur;;ACTIVE;2.17;2.73 +43424-1;Bartonella sp Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Bartonella sp IgM Ab [Titer] in Cerebral spinal fluid;Bartonella IgM Titr CSF;;ACTIVE;2.17;2.32 +43425-8;Bartonella sp Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Bartonella sp IgG Ab [Titer] in Cerebral spinal fluid;Bartonella IgG Titr CSF;;ACTIVE;2.17;2.32 +43426-6;Bacteria identified;Prid;Pt;Nph;Nom;Aerobic culture;MICRO;1;Bacteria identified in Nasopharynx by Aerobe culture;Bacteria Nph Aerobe Cult;;ACTIVE;2.17;2.73 +43427-4;Microscopic observation;Prid;Pt;Tiss;Nom;Rapid stain;PATH;1;Microscopic observation [Identifier] in Tissue by Rapid stain;Rapid Stn Tiss;;ACTIVE;2.17;2.22 +43428-2;Bilirubin.microscopic observation;Prid;Pt;Tiss;Nom;Hall's stain;PATH;1;Bilirubin.microscopic observation [Identifier] in Tissue by Hall's stain;Bilirubin Tiss Hall's Stn;;ACTIVE;2.17;2.22 +43429-0;Haemophilus influenzae B Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Haemophilus influenzae B Ag [Presence] in Serum;Haem influ B Ag Ser Ql;;ACTIVE;2.17;2.73 +4343-0;Nalorphine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nalorphine [Mass] of Dose;Nalorphine Dose;;ACTIVE;1.0;2.69 +43430-8;Neisseria meningitidis serogroup B Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Serum;N men sg B Ag Ser Ql;;ACTIVE;2.17;2.64 +43431-6;Escherichia coli K1 Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Escherichia coli K1 Ag [Presence] in Serum;E coli K1 Ag Ser Ql;;ACTIVE;2.17;2.56 +43432-4;Escherichia coli K1 Ag;PrThr;Pt;Urine;Ord;;MICRO;1;Escherichia coli K1 Ag [Presence] in Urine;E coli K1 Ag Ur Ql;;ACTIVE;2.17;2.56 +43433-2;Acylcarnitine panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Acylcarnitine panel - Serum or Plasma;Acylcarnitine Pnl SerPl;;ACTIVE;2.17;2.73 +43434-0;Bacterial Ag panel;-;Pt;Ser;-;;PANEL.MICRO;1;Bacterial Ag panel - Serum;Bacterial Ag Pnl Ser;;ACTIVE;2.17;2.73 +43435-7;Bartonella henselae & Bartonella quintana Ab.IgM panel;-;Pt;CSF;-;;PANEL.MICRO;1;Bartonella henselae and Bartonella quintana IgM panel - Cerebral spinal fluid;B henselae+quintana IgM Pnl CSF;;ACTIVE;2.17;2.44 +43436-5;Bartonella henselae & Bartonella quintana Ab.IgG panel;-;Pt;CSF;-;;PANEL.MICRO;1;Bartonella henselae and Bartonella quintana IgG panel - Cerebral spinal fluid;B henselae+quintana IgG Pnl CSF;;ACTIVE;2.17;2.44 +43437-3;Bartonella henselae & Bartonella quintana Ab.IgG & IgM panel;-;Pt;CSF;-;;PANEL.MICRO;1;Bartonella henselae and Bartonella quintana IgG and IgM panel - Cerebral spinal fluid;B henselae+quintana IgG+IgM Pnl CSF;;ACTIVE;2.17;2.44 +43438-1;Bartonella henselae & Bartonella quintana Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Bartonella henselae and Bartonella quintana IgG and IgM panel - Serum;B henselae+quintana IgG+IgM Pnl Ser;;ACTIVE;2.17;2.73 +43439-9;Bartonella henselae & Bartonella quintana Ab.IgG panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Bartonella henselae and Bartonella quintana IgG panel [Titer] - Serum;B henselae+quintana IgG Pnl Titr Ser;;ACTIVE;2.17;2.42 +43440-7;Bartonella henselae & Bartonella quintana Ab.IgM panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Bartonella henselae and Bartonella quintana IgM panel [Titer] - Serum;B henselae+quintana IgM Pnl Titr Ser;;ACTIVE;2.17;2.42 +43441-5;Bacteria identified;Prid;Pt;BAL;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bronchoalveolar lavage by Aerobe culture;Bacteria BAL Aerobe Cult;;ACTIVE;2.17;2.73 +43442-3;Bacteria identified;Prid;Pt;Bronchial brush;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bronchial brush by Aerobe culture;Bacteria Bro Brush Aerobe Cult;;ACTIVE;2.17;2.19 +43443-1;Bacterial Ag panel;-;Pt;Urine;-;;PANEL.MICRO;1;Bacterial Ag panel - Urine;Bacterial Ag Pnl Ur;;ACTIVE;2.17;2.44 +43444-9;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for percutaneous drainage of abscess and placement of drainage catheter of Unspecified body region;CT Guided PC Absc drn+cath place;;ACTIVE;2.17;2.66 +43445-6;Multisection;Find;Pt;Chest>Pulmonary system;Doc;CT;RAD;2;CT Pulmonary system;CT Pulm system;;ACTIVE;2.17;2.61 +43446-4;Multisection for tumor whole body;Find;Pt;^Patient;Doc;CT;RAD;2;Deprecated CT for tumor whole body;Deprecated CT for Tumor WB;;DEPRECATED;2.17;2.58 +43447-2;Guidance for biopsy.needle;Find;Pt;Breast.right;Doc;MG;RAD;2;Deprecated MG Guidance for needle biopsy of Breast - right;Deprecated MG Brst-R Bx needle guide;;DEPRECATED;2.17;2.63 +4344-8;Nandrolone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nandrolone [Mass] of Dose;Nandrolone Dose;;ACTIVE;1.0;2.69 +43448-0;Multisection^WO & W ferumoxides IV;Find;Pt;Abdomen>Liver;Doc;MR;RAD;2;MR Liver WO and W ferumoxides IV;MR Liver WO+W Ferumoxides IV;;ACTIVE;2.17;2.61 +43449-8;Multisection dynamic^W contrast IV;Find;Pt;Lower extremity.right>Ankle;Doc;MR;RAD;2;MR Ankle - right dynamic W contrast IV;MR Ankle-R Dyn W contr IV;;ACTIVE;2.17;2.61 +43450-6;Multisection dynamic^W contrast IV;Find;Pt;Upper extremity.left>Elbow;Doc;MR;RAD;2;MR Elbow - left dynamic W contrast IV;MR Elbow-L Dyn W contr IV;;ACTIVE;2.17;2.61 +43451-4;Multisection dynamic^W contrast IV;Find;Pt;Upper extremity.right>Elbow;Doc;MR;RAD;2;MR Elbow - right dynamic W contrast IV;MR Elbow-R Dyn W contr IV;;ACTIVE;2.17;2.61 +43452-2;Multisection dynamic^W contrast IV;Find;Pt;Lower extremity.left>Knee;Doc;MR;RAD;2;MR Knee - left dynamic W contrast IV;MR Knee-L Dyn W contr IV;;ACTIVE;2.17;2.61 +43453-0;Multisection dynamic^W contrast IV;Find;Pt;Lower extremity.right>Knee;Doc;MR;RAD;2;MR Knee - right dynamic W contrast IV;MR Knee-R Dyn W contr IV;;ACTIVE;2.17;2.61 +43454-8;Multisection;Find;Pt;Chest>Pulmonary system;Doc;MR;RAD;2;MR Pulmonary system;MR Pulm system;;ACTIVE;2.17;2.61 +4345-5;Naproxen;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Naproxen [Mass] of Dose;Naproxen Dose;;ACTIVE;1.0;2.69 +43455-5;Multisection;Find;Pt;Head+Neck>Oropharynx;Doc;MR;RAD;2;MR Oropharynx;MR Oropharynx;;ACTIVE;2.17;2.61 +43456-3;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;MR;RAD;2;MR Cervical and thoracic spine WO and W contrast IV;MR C+T-spine WO+W contr IV;;ACTIVE;2.17;2.61 +43457-1;Multisection;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;MR;RAD;2;MR Cervical and thoracic spine;MR C+T-spine;;ACTIVE;2.17;2.61 +43458-9;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit vessels;Doc;MR.angio;RAD;2;MRA Orbit vessels WO and W contrast IV;MRA Orbit ves WO+W contr IV;;ACTIVE;2.17;2.61 +43459-7;Views^during electroconvulsive shock treatment;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views during electroconvulsive shock treatment;NM Brain Views During EST;;ACTIVE;2.17;2.64 +43460-5;Views^during electroconvulsive shock treatment;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scan during electroconvulsive shock treatment;Deprecated Hrt RI During EST;;DEPRECATED;2.17;2.34 +43461-3;Views^W furosemide IV+W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views W furosemide IV;NM Kidney Views W Furosemide+RNC IV;;ACTIVE;2.17;2.64 +43462-1;Guidance for biopsy.needle;Find;Pt;Breast.left;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Breast - left;Deprecated US Brst-L Bx needle guide;;DEPRECATED;2.17;2.63 +4346-3;Neopterin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Neopterin [Mass] of Dose;Neopterin Dose;;ACTIVE;1.0;2.69 +43463-9;View PA && Views supine + upright;Find;Pt;Chest && Abdomen;Doc;XR;RAD;2;XR Chest PA and Abdomen Supine and Upright;XR Chest PA + Abd Sup+Upr;;ACTIVE;2.17;2.64 +43464-7;Views lateral & PA chest;Find;Pt;Ribs.bilateral+Chest;Doc;XR;RAD;2;Deprecated Ribs - bilateral and Chest X-ray lateral and PA;Deprecated Ribs-Bl + Chest XR Lat+PA;;DEPRECATED;2.17;2.58 +43465-4;View AP L-lateral-decubitus;Find;Pt;Chest;Nar;XR;RAD;2;Deprecated Chest X-ray AP L-lateral-decubitus;Deprecated Chest XR AP L-Lat Decub;;DEPRECATED;2.17;2.36 +43466-2;View AP R-lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest AP right lateral-decubitus;XR Chest AP R-lat decub;;ACTIVE;2.17;2.61 +43467-0;Views 2 + R-Oblique + L-Oblique;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest 2 Views and Right oblique and Left oblique;XR Chest 2V+R-obl+L-obl;;ACTIVE;2.17;2.61 +43468-8;Views;Find;Pt;XXX;Doc;XR;RAD;2;XR Unspecified body region Views;XR Views;;ACTIVE;2.17;2.64 +43469-6;Views of foreign body;Find;Pt;XXX;Doc;XR;RAD;2;XR Unspecified body region Views for foreign body;XR Views for FB;;ACTIVE;2.17;2.64 +43470-4;Views LE 3;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull LE 3 Views;XR Skull LE 3V;;ACTIVE;2.17;2.61 +4347-1;Netilmicin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Netilmicin [Mass] of Dose;Netilmicin Dose;;ACTIVE;1.0;2.69 +43471-2;View;Find;2H;XXX;Doc;RF;RAD;2;RF 2 hour;RF 2h;;ACTIVE;2.17;2.64 +43472-0;View;Find;90M;XXX;Doc;RF;RAD;2;RF 90 minutes;RF 90M;;ACTIVE;2.17;2.64 +43473-8;Guidance for endoscopy^2H post contrast retrograde intrabiliary;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts and Pancreatic duct-- 2H post contrast retrograde intrabiliary;RF Guided BD+PD Endo--2h p con ret IB;;ACTIVE;2.17;2.64 +43474-6;Guidance for endoscopy^15M post contrast retrograde intrabiliary;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts and Pancreatic duct-- 15m post contrast retrograde intrabiliary;RF Guided BD+PD Endo--15m p con ret IB;;ACTIVE;2.17;2.64 +43475-3;Guidance for endoscopy^30M post contrast retrograde intrabiliary;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts and Pancreatic duct-- 30M post contrast retrograde intrabiliary;RF Guided BD+PD Endo--30m p con ret IB;;ACTIVE;2.17;2.64 +43476-1;Guidance for endoscopy^45M post contrast retrograde intrabiliary;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts and Pancreatic duct-- 45M post contrast retrograde intrabiliary;RF Guided BD+PD Endo--45m p con ret IB;;ACTIVE;2.17;2.64 +43477-9;Guidance for endoscopy^1H post contrast retrograde intrabiliary;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts and Pancreatic duct-- 1H post contrast retrograde intrabiliary;RF Guided BD+PD Endo--1h p con ret IB;;ACTIVE;2.17;2.64 +43478-7;Guidance for endoscopy^1.5H post contrast retrograde intrabiliary;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts and Pancreatic duct-- 1.5 hours post contrast retrograde intrabiliary;RF Guided BD+PD Endo--1.5h p con ret IB;;ACTIVE;2.17;2.64 +43479-5;Views runoff^W contrast IA;Find;Pt;Abdomen>Aorta.abdominal;Doc;RF.angio;RAD;2;RFA Abdominal Aorta Runoff W contrast IA;RFA Abd Aorta runoff W contr IA;;ACTIVE;2.17;2.61 +43480-3;Views lateral^W manual stress;Find;Pt;XXX>Joint;Doc;XR;RAD;2;XR Joint Lateral Views W manual stress;XR Joint Views Lat W man stress;;ACTIVE;2.17;2.71 +43481-1;Views^W flexion + W extension;Find;Pt;XXX>Joint;Doc;XR;RAD;2;XR Joint Views W flexion and W extension;XR Joint Views W FE;;ACTIVE;2.17;2.64 +43482-9;Views GE 3;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right GE 3 Views;XR Knee-R GE 3V;;ACTIVE;2.17;2.61 +43483-7;Views 3 or 4;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right 3 or 4 Views;XR Foot-R 3V or 4V;;ACTIVE;2.17;2.61 +43484-5;Guidance for localization of bleeding site^W radionuclide IV;Find;Pt;^Patient;Nar;Radnuc;RAD;2;Deprecated Scan Guidance for localization of bleeding site;Deprecated RI Bleeding local guid W RNC;;DEPRECATED;2.17;2.34 +43485-2;Views^during surgery W contrast retrograde;Find;Pt;Abdomen>Kidney;Doc;XR;RAD;2;XR Kidney Views during surgery W contrast retrograde;XR Kidney Views in Surg W contr retro;;ACTIVE;2.17;2.64 +43486-0;Views GE 3;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses GE 3 Views;XR Sinuses GE 3V;;ACTIVE;2.17;2.61 +43487-8;Guidance for placement of radiation therapy fields;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for placement of radiation therapy fields in Unspecified body region;US Guided RT fields place;;ACTIVE;2.17;2.64 +43488-6;Views GE 3;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left GE 3 Views;XR Thumb-L GE 3V;;ACTIVE;2.17;2.61 +4348-9;Nicomorphine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nicomorphine [Mass] of Dose;NMP Dose;;ACTIVE;1.0;2.69 +43489-4;Views GE 3;Find;Pt;Upper extremity.left>Finger.second;Doc;XR;RAD;2;XR Finger second - left GE 3 Views;XR Finger.2nd-L GE 3V;;ACTIVE;2.17;2.61 +43490-2;Views GE 3;Find;Pt;Upper extremity.left>Finger.third;Doc;XR;RAD;2;XR Finger third - left GE 3 Views;XR Finger.3rd-L GE 3V;;ACTIVE;2.17;2.61 +43491-0;Views GE 3;Find;Pt;Upper extremity.left>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - left GE 3 Views;XR Finger.4th-L GE 3V;;ACTIVE;2.17;2.61 +43492-8;Views GE 3;Find;Pt;Upper extremity.left>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - left GE 3 Views;XR Finger.5th-L GE 3V;;ACTIVE;2.17;2.61 +43493-6;Views GE 3;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right GE 3 Views;XR Thumb-R GE 3V;;ACTIVE;2.17;2.61 +43494-4;Views GE 3;Find;Pt;Upper extremity.right>Finger.second;Doc;XR;RAD;2;XR Finger second - right GE 3 Views;XR Finger.2nd-R GE 3V;;ACTIVE;2.17;2.61 +43495-1;Views GE 3;Find;Pt;Upper extremity.right>Finger.third;Doc;XR;RAD;2;XR Finger third - right GE 3 Views;XR Finger.3rd-R GE 3V;;ACTIVE;2.17;2.61 +43496-9;Views GE 3;Find;Pt;Upper extremity.right>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - right GE 3 Views;XR Finger.4th-R GE 3V;;ACTIVE;2.17;2.61 +4349-7;Nicotinamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nicotinamide [Mass] of Dose;Nicotinamide Dose;;ACTIVE;1.0;2.69 +43497-7;Views GE 3;Find;Pt;Upper extremity.right>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - right GE 3 Views;XR Finger.5th-R GE 3V;;ACTIVE;2.17;2.61 +43498-5;Views GE 3;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left GE 3 Views;XR Knee-L GE 3V;;ACTIVE;2.17;2.61 +43499-3;Views 3 or 4;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left 3 or 4 Views;XR Foot-L 3V or 4V;;ACTIVE;2.17;2.61 +43500-8;Views for blood flow^W radionuclide IV;Find;Pt;XXX>Vessel;Doc;NM;RAD;2;NM Vessel Views for blood flow;NM Ves Vs bld flow W RNC IV;;ACTIVE;2.17;2.64 +43501-6;Views^W radionuclide IV;Find;Pt;XXX>Vessel;Doc;NM;RAD;2;NM Vessel Views;NM Ves Views W RNC IV;;ACTIVE;2.17;2.64 +43502-4;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Subphrenic space;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Subphrenic space;CT Guide Subphrenic Absc drn+cath place;;ACTIVE;2.17;2.66 +43503-2;Multisection^W contrast IV;Find;Pt;Aorta+Lower extremity vessels;Doc;CT.angio;RAD;2;Deprecated Aorta and Lower extremity vessels CT angiogram W contrast IV;Deprecated Aorta+LE ves CT.Angio W contr;;DEPRECATED;2.17;2.58 +43504-0;Multisection^W contrast IV;Find;Pt;Chest>Axilla.left;Doc;MR;RAD;2;MR Axilla - left W contrast IV;MR Axilla-L W contr IV;;ACTIVE;2.17;2.61 +4350-5;Nicotine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nicotine [Mass] of Dose;Nicotine Dose;;ACTIVE;1.0;2.69 +43505-7;Multisection^W contrast IV;Find;Pt;Chest>Axilla.right;Doc;MR;RAD;2;MR Axilla - right W contrast IV;MR Axilla-R W contr IV;;ACTIVE;2.17;2.61 +43506-5;Multisection;Find;Pt;Pelvis>Ovary.bilateral;Doc;MR;RAD;2;MR Ovary - bilateral;MR Ovary-Bl;;ACTIVE;2.17;2.61 +43507-3;Multisection;Find;Pt;Chest>Thymus gland;Doc;MR;RAD;2;MR Thymus gland;MR Thymus gland;;ACTIVE;2.17;2.61 +43508-1;Multisection;Find;Pt;Chest>Axilla.left;Doc;MR;RAD;2;MR Axilla - left;MR Axilla-L;;ACTIVE;2.17;2.61 +43509-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Axilla.left;Doc;MR;RAD;2;MR Axilla - left WO and W contrast IV;MR Axilla-L WO+W contr IV;;ACTIVE;2.17;2.61 +43510-7;Multisection;Find;Pt;Chest>Axilla.right;Doc;MR;RAD;2;MR Axilla - right;MR Axilla-R;;ACTIVE;2.17;2.61 +43511-5;Multisection^WO & W contrast IV;Find;Pt;Chest>Axilla.right;Doc;MR;RAD;2;MR Axilla - right WO and W contrast IV;MR Axilla-R WO+W contr IV;;ACTIVE;2.17;2.61 +43512-3;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Lower leg vessels;Doc;MR.angio;RAD;2;MRA Lower leg vessels - bilateral W contrast IV;MRA Lower leg ves-Bl W contr IV;;ACTIVE;2.17;2.61 +4351-3;Nikethamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nikethamide [Mass] of Dose;Nikethamide Dose;;ACTIVE;1.0;2.69 +43513-1;Multisection;Find;Pt;Lower extremity.left>Lower leg vessels;Doc;MR.angio;RAD;2;MRA Lower leg vessels - left;MRA Lower leg ves-L;;ACTIVE;2.17;2.61 +43514-9;Multisection^WO contrast;Find;Pt;Lower extremity.left>Thigh vessels;Doc;MR.angio;RAD;2;MRA Thigh vessels - left WO contrast;MRA Thigh ves-L WO contr;;ACTIVE;2.17;2.61 +43515-6;Multisection^WO contrast;Find;Pt;Lower extremity.right>Thigh vessels;Doc;MR.angio;RAD;2;MRA Thigh vessels - right WO contrast;MRA Thigh ves-R WO contr;;ACTIVE;2.17;2.61 +43516-4;Multisection^WO contrast;Find;Pt;Upper extremity.left>Wrist vessels;Doc;MR.angio;RAD;2;MRA Wrist vessels - left WO contrast;MRA Wrist-L ves WO contr;;ACTIVE;2.17;2.61 +43517-2;Multisection^WO contrast;Find;Pt;Upper extremity.right>Wrist vessels;Doc;MR.angio;RAD;2;MRA Wrist vessels - right WO contrast;MRA Wrist-R ves WO contr;;ACTIVE;2.17;2.61 +43518-0;Views survey;Find;Pt;XXX>Bones;Doc;XR;RAD;2;XR Bones Survey Views;XR Bones Survey;;ACTIVE;2.17;2.73 +43519-8;Views survey limited;Find;Pt;XXX>Bones;Doc;XR;RAD;2;XR Bones Limited Survey Views;XR Bones Survey Ltd;;ACTIVE;2.17;2.64 +43520-6;Views AP (R-lateral-decubitus & L-lateral-decubitus);Find;Pt;Chest;Nar;XR;RAD;2;Deprecated Chest X-ray AP (R-lateral-decubitus & L-lateral-decubitus);Deprecated Chest XR AP (R+L-Lat Decub);;DEPRECATED;2.17;2.36 +4352-1;Nitrazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nitrazepam [Mass] of Dose;Nitrazepam Dose;;ACTIVE;1.0;2.69 +43521-4;Views 1 or 2;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible 1 or 2 Views;XR Mandible 1V or 2V;;ACTIVE;2.17;2.61 +43522-2;Views 1 or 2;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis 1 or 2 Views;XR Pelvis 1V or 2V;;ACTIVE;2.17;2.61 +43523-0;Views 1 or 2;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses 1 or 2 Views;XR Sinuses 1V or 2V;;ACTIVE;2.17;2.61 +43524-8;Views GE 5;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull GE 5 Views;XR Skull GE 5V;;ACTIVE;2.17;2.61 +43525-5;Multisection^WO contrast;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region WO contrast;CT WO contr;;ACTIVE;2.17;2.69 +43526-3;Multisection^W radionuclide IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Unspecified body region;SPECT W RNC IV;;ACTIVE;2.17;2.69 +43527-1;Multisection dynamic^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;Deprecated Unspecified body region CT dynamic W contrast IV;Deprecated XXX CT Dyn W contr IV;;DEPRECATED;2.17;2.58 +43528-9;Multisection^WO & W contrast IV;Find;Pt;Breast.unilateral;Doc;MR;RAD;2;MR Breast - unilateral WO and W contrast IV;MR Brst-Ul WO+W contr IV;;ACTIVE;2.17;2.61 +43529-7;Views;Find;Pt;Head>Orbit+Facial bones;Doc;XR;RAD;2;XR Orbit and Facial bones Views;XR Orbit+Face Views;;ACTIVE;2.17;2.64 +43530-5;Multisection;Find;Pt;Head>Orbit+Face & Neck;Doc;MR;RAD;2;MR Orbit and Face and Neck;MR Orbit+Face+Neck;;ACTIVE;2.17;2.61 +43531-3;Guidance for localization of bleeding site;Find;Pt;Eye;Nar;US;RAD;2;Deprecated US Guidance for localization of bleeding site of Eye;Deprecated Eye US Bleeding local guid;;DEPRECATED;2.17;2.34 +43532-1;View PA && View upright;Find;Pt;Chest && Abdomen;Doc;XR;RAD;2;XR Chest PA and Abdomen Upright;XR Chest PA + Abd Upr;;ACTIVE;2.17;2.64 +43533-9;Views;Find;Pt;Mandible.right;Doc;XR;RAD;2;Deprecated Mandible - right X-ray;Deprecated Mandible-R XR;;DEPRECATED;2.17;2.58 +43534-7;Views 4;Find;Pt;Mandible.left;Doc;XR;RAD;2;Deprecated Mandible - left X-ray 4 views;Deprecated Mandible-L XR 4V;;DEPRECATED;2.17;2.58 +43535-4;Views 4;Find;Pt;Mandible.right;Doc;XR;RAD;2;Deprecated Mandible - right X-ray 4 views;Deprecated Mandible-R XR 4V;;DEPRECATED;2.17;2.58 +43536-2;Views;Find;Pt;Abdomen>Spine.lumbar;Doc;RF.video;RAD;2;RF videography Lumbar spine Views;RF video L-spine Views;;ACTIVE;2.17;2.64 +43537-0;Guidance for drainage+placement of drainage catheter;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for drainage and placement of drainage catheter of Unspecified body region;RF Guided Drain+cath place;;ACTIVE;2.17;2.66 +43538-8;Views;Find;Pt;Neck>Spine.cervical;Doc;RF.video;RAD;2;RF videography Cervical spine Views;RF video C-spine Views;;ACTIVE;2.17;2.64 +4353-9;Nitrofurantoin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nitrofurantoin [Mass] of Dose;Nitrofurantoin Dose;;ACTIVE;1.0;2.69 +43539-6;Views 2 or 3;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 2 or 3 Views;XR C-spine 2V or 3V;;ACTIVE;2.17;2.61 +43540-4;Views GE 3;Find;Pt;Finger.fifth.right;Nar;XR;RAD;2;Deprecated Finger fifth Right X-ray GE 3 views;Deprecated Finger.5th-R XR GE 3V;;DEPRECATED;2.17;2.36 +43541-2;Views GE 3;Find;Pt;Finger.second.left;Nar;XR;RAD;2;Deprecated Finger second Left X-ray GE 3 views;Deprecated Finger.2nd-L XR GE 3V;;DEPRECATED;2.17;2.36 +43542-0;Views GE 3;Find;Pt;Finger.fifth.left;Nar;XR;RAD;2;Deprecated Finger fifth Left X-ray GE 3 views;Deprecated Finger.5th-L XR GE 3V;;DEPRECATED;2.17;2.36 +43543-8;Views GE 3;Find;Pt;Pelvis;Doc;XR;RAD;2;XR Pelvis GE 3 Views;XR Pelvis GE 3V;;ACTIVE;2.17;2.61 +43544-6;Views GE 3;Find;Pt;Finger.fourth.left;Nar;XR;RAD;2;Deprecated Finger fourth Left X-ray GE 3 views;Deprecated Finger.4th-L XR GE 3V;;DEPRECATED;2.17;2.36 +43545-3;Views GE 3;Find;Pt;Finger.third.left;Nar;XR;RAD;2;Deprecated Finger third Left X-ray GE 3 views;Deprecated Finger.3rd-L XR GE 3V;;DEPRECATED;2.17;2.36 +43546-1;Views GE 3;Find;Pt;Finger.second.right;Nar;XR;RAD;2;Deprecated Finger second Right X-ray GE 3 views;Deprecated Finger.2nd-R XR GE 3V;;DEPRECATED;2.17;2.36 +4354-7;Nordiazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Nordiazepam [Mass] of Dose;Deprecated Nordiazepam Dose;;DEPRECATED;1.0;2.69 +43547-9;Views GE 3;Find;Pt;Finger.third.right;Nar;XR;RAD;2;Deprecated Finger third Right X-ray GE 3 views;Deprecated Finger.3rd-R XR GE 3V;;DEPRECATED;2.17;2.36 +43548-7;Views GE 3;Find;Pt;Finger.fourth.right;Nar;XR;RAD;2;Deprecated Finger fourth Right X-ray GE 3 views;Deprecated Finger.4th-R XR GE 3V;;DEPRECATED;2.17;2.36 +43549-5;Views perfusion^W stress;Find;Pt;Heart;Nar;Radnuc;RAD;2;Deprecated Heart Scan perfusion W stress;Deprecated Hrt RI PF W Stress;;DEPRECATED;2.17;2.36 +43550-3;Views for blood flow+function^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views for blood flow and function;NM Brain Vs bld flow+fn W RNC IV;;ACTIVE;2.17;2.64 +43551-1;Guidance for abscess drainage;Find;Pt;Peritoneal cavity;Nar;US;RAD;2;Deprecated US Guidance for abscess drainage of Peritoneal cavity;Deprecated Perit Cavity US Abs drain gui;;DEPRECATED;2.17;2.34 +43552-9;Multisection;Find;Pt;Head+Neck>Carotid arteries.unilateral;Doc;US;RAD;2;US Carotid arteries - unilateral;US Carotid aa-Ul;;ACTIVE;2.17;2.61 +43553-7;Study observation.general;Imp;Pt;^Fetuses.twins;Nar;US;RAD;2;Deprecated Study observation general of fetuses US;Deprecated US Study Observation general;;DEPRECATED;2.17;2.36 +4355-4;Nordoxepin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Nordoxepin [Mass] of Dose;Deprecated Nordoxepin Dose;;DEPRECATED;1.0;2.69 +43554-5;Views^W contrast IV;Find;Pt;XXX>Vessels.left;Doc;RF.angio;RAD;2;RFA Vessels - left Views W contrast IV;RFA ves-L Views W contr IV;;ACTIVE;2.17;2.64 +43555-2;Multisection dynamic^W contrast IV;Find;Pt;Lower extremity.left>Ankle;Doc;MR;RAD;2;MR Ankle - left dynamic W contrast IV;MR Ankle-L Dyn W contr IV;;ACTIVE;2.17;2.61 +43556-0;Multisection;Find;Pt;Lower extremity.right>Lower leg vessels;Doc;MR.angio;RAD;2;MRA Lower leg vessels - right;MRA Lower leg ves-R;;ACTIVE;2.17;2.61 +43557-8;Views^W radionuclide IV;Find;Pt;Abdomen>Liver+Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Liver and Biliary ducts and Gallbladder Views;NM Liver+BDs+GB Views W RNC IV;;ACTIVE;2.17;2.64 +43558-6;Guidance for change of dialysis catheter^W contrast IV;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for change of dialysis catheter in Unspecified body region-- W contrast IV;RF Guided DC change--W contr IV;;ACTIVE;2.17;2.64 +43559-4;Views^W contrast intra bladder+during voiding;Find;Pt;Pelvis>Urinary bladder+Urethra;Doc;RF;RAD;2;RF Urinary bladder and Urethra Views W contrast intra bladder during voiding;RF Bladder+Urethra Views W contr IB void;;ACTIVE;2.17;2.73 +43560-2;Views^W gastrografin PO & W barium contrast PR;Find;Pt;Colon;Nar;XR.fluor;RAD;2;Deprecated Colon Fluoroscopy W gastrografin PO & W barium contrast PR;Deprecated Colon Flr W Gastrografin PO+B;;DEPRECATED;2.17;2.34 +43561-0;View AP && View upright;Find;Pt;Chest && Abdomen;Doc;XR;RAD;2;XR Chest AP and Abdomen Upright;XR Chest AP + Abd Upr;;ACTIVE;2.17;2.64 +4356-2;Norepinephrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Norepinephrine [Mass] of Dose;Norepineph Dose;;ACTIVE;1.0;2.69 +43562-8;Views for bone density;Find;Pt;Whole body>Skeletal system.axial;Doc;NM;RAD;2;NM Skeletal system.axial Views for bone density;NM Skeletal Sys Axial Views for BMD;;ACTIVE;2.17;2.64 +43563-6;Views for bone density;Find;Pt;Whole body>Skeletal system.peripheral;Doc;NM;RAD;2;NM Skeletal system.peripheral Views for bone density;NM Skeletal Sys Periph Views for BMD;;ACTIVE;2.17;2.64 +43564-4;Guidance for superficial biopsy;Find;Pt;XXX>Muscle;Doc;US;RAD;2;US Guidance for superficial biopsy of Muscle;US Guided Muscle Super Bx;;ACTIVE;2.17;2.64 +43565-1;Guidance for deep biopsy;Find;Pt;XXX>Bone;Doc;US;RAD;2;US Guidance for deep biopsy of Bone;US Guided Bone Deep Bx;;ACTIVE;2.17;2.64 +43566-9;Multisection;Find;Pt;Lower extremity>Hip+Thigh;Doc;US;RAD;2;US Hip and Thigh;US Hip+Thigh;;ACTIVE;2.17;2.61 +43567-7;Guidance for deep biopsy;Find;Pt;XXX>Bone;Doc;CT;RAD;2;CT Guidance for deep biopsy of Bone;CT Guided Bone Deep Bx;;ACTIVE;2.17;2.64 +43568-5;Guidance for deep biopsy.needle;Find;Pt;XXX>Bone;Doc;CT;RAD;2;Deprecated CT Guidance for deep biopsy.needle of Bone;Deprecated CT Bone Deep biopsy guide;;DEPRECATED;2.17;2.63 +43569-3;Views AP for scoliosis^upright & supine;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP Views for scoliosis upright and supine;XR T+L-Spine Views AP for Scoli upr+sup;;ACTIVE;2.17;2.64 +4357-0;Norethandrolone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Norethandrolone [Mass] of Dose;Norethandrolone Dose;;ACTIVE;1.0;2.69 +43570-1;Views;Find;Pt;Upper extremity>Hand;Doc;XR.portable;RAD;2;Portable XR Hand Views;XR port Hand Views;;ACTIVE;2.17;2.64 +43571-9;Guidance for biopsy.needle;Find;Pt;Soft bone;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Soft bone;Deprecated Soft Bone CT Bx needle guid;;DEPRECATED;2.17;2.58 +43572-7;Multisection limited;Find;Pt;Abdomen>Abdominal vessels;Doc;US.doppler;RAD;2;US.doppler Abdominal vessels limited;DOP Abd ves Ltd;;ACTIVE;2.17;2.61 +43573-5;Borrelia burgdorferi Ab.IgM;ACnc;Pt;CSF;Qn;IB;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoblot;B burgdor IgM CSF IB-aCnc;;ACTIVE;2.17;2.69 +43574-3;Views^W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper+Small bowel;Doc;RF;RAD;2;RF Upper gastrointestinal tract and Small bowel Views W barium contrast PO;RF UGI+SB Views W Ba PO;;ACTIVE;2.17;2.64 +43575-0;Complement C3;MCnc;Pt;Pericard fld;Qn;;HEM/BC;1;Complement C3 [Mass/volume] in Pericardial fluid;C3 Pcar-mCnc;;ACTIVE;2.17;2.70 +43576-8;Acylcarnitine/Carnitine.free (C0);Ratio;Pt;Urine;Qn;;CHEM;1;Acylcarnitine/Carnitine.free (C0) [Ratio] in Urine;Acylcarnitine/C0 Ur-Rto;;ACTIVE;2.17;2.73 +43577-6;Histamine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Histamine/Creatinine [Ratio] in Urine;Histamine/Creat Ur-Rto;;ACTIVE;2.17;2.73 +43578-4;Complement C3;MCnc;Pt;Periton fld;Qn;;HEM/BC;1;Complement C3 [Mass/volume] in Peritoneal fluid;C3 Prt-mCnc;;ACTIVE;2.17;2.70 +43579-2;Complement C3;MCnc;Pt;Plr fld;Qn;;HEM/BC;1;Complement C3 [Mass/volume] in Pleural fluid;C3 Plr-mCnc;;ACTIVE;2.17;2.73 +435-8;Rolitetracycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Rolitetracycline [Susceptibility] by Minimum lethal concentration (MLC);Rolitetracycline Islt MLC;;ACTIVE;1.0;2.19 +43580-0;Complement C4;MCnc;Pt;Pericard fld;Qn;;HEM/BC;1;Complement C4 [Mass/volume] in Pericardial fluid;C4 Pcar-mCnc;;ACTIVE;2.17;2.73 +43581-8;Complement C4;MCnc;Pt;Periton fld;Qn;;HEM/BC;1;Complement C4 [Mass/volume] in Peritoneal fluid;C4 Prt-mCnc;;ACTIVE;2.17;2.70 +43582-6;Complement C4;MCnc;Pt;Plr fld;Qn;;HEM/BC;1;Complement C4 [Mass/volume] in Pleural fluid;C4 Plr-mCnc;;ACTIVE;2.17;2.73 +43583-4;Lipoprotein (little a);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein a [Moles/volume] in Serum or Plasma;LPa SerPl-sCnc;;ACTIVE;2.17;2.73 +43584-2;Bizarre cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Bizarre cells [Presence] in Blood by Light microscopy;Bizarre Cells Bld Ql Smear;;ACTIVE;2.17;2.56 +43585-9;TYMP gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TYMP gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TYMP Mut Anl Bld/T;;ACTIVE;2.17;2.67 +43586-7;Yersinia pseudotuberculosis Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Yersinia pseudotuberculosis Ab [Presence] in Cerebral spinal fluid;Y pseudoTB Ab CSF Ql;;ACTIVE;2.17;2.56 +43587-5;Vitis vinifera Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Grape IgE Ab/IgE total in Serum;Grape IgE/IgE total %;;ACTIVE;2.17;2.70 +4358-8;Norfenefrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Norfenefrine [Mass] of Dose;Norfenefrine Dose;;ACTIVE;1.0;2.69 +43588-3;Varicella zoster virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Varicella zoster virus IgM Ab [Presence] in Serum by Immunofluorescence;VZV IgM Ser Ql IF;;ACTIVE;2.17;2.73 +43589-1;Shigella sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Shigella sp Ab [Presence] in Serum;Shigella Ab Ser Ql;;ACTIVE;2.17;2.56 +43590-9;Rabies virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rabies virus Ab [Units/volume] in Serum by Immunoassay;RABV Ab Ser IA-aCnc;;ACTIVE;2.17;2.73 +43591-7;Prunus persica Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Peach IgE Ab/IgE total in Serum;Peach IgE/IgE total %;;ACTIVE;2.17;2.70 +43592-5;Prunus domestica Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Plum IgE Ab/IgE total in Serum;Plum IgE/IgE total %;;ACTIVE;2.17;2.70 +43593-3;Plasmodium malariae Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium malariae IgG Ab [Titer] in Serum;P malariae IgG Titr Ser;;ACTIVE;2.17;2.32 +43594-1;Nidus;Mass;Pt;Calculus;Qn;;PATH;1;Nidus [Mass] in Stone;Nidus Stone Qn;;ACTIVE;2.17;2.73 +43595-8;Methadone;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Methadone [Presence] in Meconium;Methadone Mec Ql;;ACTIVE;2.17;2.73 +4359-6;Norfloxacin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Norfloxacin [Mass] of Dose;Norfloxacin Dose;;ACTIVE;1.0;2.69 +43596-6;Malus sylvestris Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Apple IgE Ab/IgE total in Serum;Apple IgE/IgE total %;;ACTIVE;2.17;2.70 +43597-4;Inner Ear 68kD Ab;PrThr;Pt;Ser/Plas;Ord;IB;SERO;1;Inner ear 68kD Ab [Presence] in Serum or Plasma by Immunoblot;Inner ear 68kD Ab SerPl Ql IB;;ACTIVE;2.17;2.73 +43598-2;Indicans;PrThr;24H;Urine;Ord;;CHEM;1;Indicans [Presence] in 24 hour Urine;Indicans 24h Ur Ql;;ACTIVE;2.17;2.56 +43599-0;HIV 1 Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;HIV 1 Ab [Units/volume] in Serum by Immunofluorescence;HIV1 Ab Ser IF-aCnc;;ACTIVE;2.17;2.69 +43600-6;Ganglioside GD1b Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GD1b IgM Ab [Presence] in Serum;GD1b Gangl IgM Ser Ql;;ACTIVE;2.17;2.56 +43601-4;Ganglioside GD1b Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GD1b IgG Ab [Presence] in Serum;GD1b Gangl IgG Ser Ql;;ACTIVE;2.17;2.56 +43602-2;Echinococcus granulosus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echinococcus granulosus Ab [Units/volume] in Serum by Immunoassay;E granulosus Ab Ser IA-aCnc;;ACTIVE;2.17;2.69 +43603-0;Androstenedione^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Androst sp1 p chal SerPl-mCnc;;ACTIVE;2.17;2.73 +4360-4;Normetanephrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Normetanephrine [Mass] of Dose;Normetanephrine Dose;;ACTIVE;1.0;2.69 +43604-8;Aldosterone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Aldost sp1 p chal SerPl-mCnc;;ACTIVE;2.17;2.73 +43605-5;Albumin;MCnc;4H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/volume] in 4 hour Urine;Microalbumin 4h Ur-mCnc;;ACTIVE;2.17;2.34 +43606-3;Albumin;MRat;4H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/time] in 4 hour Urine;Microalbumin 4h Ur-mRate;;ACTIVE;2.17;2.30 +43607-1;Albumin;MRat;12H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/time] in 12 hour Urine;Microalbumin 12h Ur-mRate;;ACTIVE;2.17;2.30 +43608-9;Adrenal cortex Ab;PrThr;Pt;Ser;Ord;;SERO;1;Adrenal cortex Ab [Presence] in Serum;Adrenal cortex Ab Ser Ql;;ACTIVE;2.17;2.56 +43609-7;Adipate;PrThr;24H;Urine;Ord;;CHEM;1;Adipate [Presence] in 24 hour Urine;Adipate 24h Ur Ql;;ACTIVE;2.17;2.56 +43610-5;Adenovirus Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Nasopharynx by Immunofluorescence;HAdV Ag Nph Ql IF;;ACTIVE;2.17;2.56 +43611-3;Adenovirus Ag;PrThr;Pt;Bronchial;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Bronchial specimen by Immunofluorescence;HAdV Ag Bronch Ql IF;;ACTIVE;2.17;2.73 +4361-2;Nortriptyline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Nortriptyline [Mass] of Dose;Nortrip Dose;;ACTIVE;1.0;2.69 +43612-1;Adenovirus Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Nose by Immunofluorescence;HAdV Ag Nose Ql IF;;ACTIVE;2.17;2.56 +43613-9;Adenovirus Ag;PrThr;Pt;Trac;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Trachea by Immunofluorescence;HAdV Ag Trachea Ql IF;;ACTIVE;2.17;2.56 +43614-7;Adenovirus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Adenovirus Ag [Presence] in Nose;HAdV Ag Nose Ql;;ACTIVE;2.17;2.56 +43615-4;Adenovirus Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Adenovirus Ag [Presence] in Genital specimen;HAdV Ag Genital Ql;;ACTIVE;2.17;2.56 +43616-2;Adenovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Adenovirus Ab [Presence] in Serum;HAdV Ab Ser Ql;;ACTIVE;2.17;2.56 +43617-0;Adenovirus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Adenovirus Ab [Presence] in Cerebral spinal fluid;HAdV Ab CSF Ql;;ACTIVE;2.17;2.56 +43618-8;Adenovirus Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Adenovirus Ab [Presence] in Serum by Complement fixation;HAdV Ab Ser Ql CF;;ACTIVE;2.17;2.73 +43619-6;Actinomyces sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinomyces sp Ab [Presence] in Serum;Actinomyces Ab Ser Ql;;ACTIVE;2.17;2.56 +4362-0;Ofloxacin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ofloxacin [Mass] of Dose;Ofloxacin Dose;;ACTIVE;1.0;2.69 +43620-4;Actinomyces israelii Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinomyces israelii Ab [Presence] in Serum;A israelii Ab Ser Ql;;ACTIVE;2.17;2.56 +43621-2;Actinomyces bovis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Actinomyces bovis Ab [Presence] in Serum;A bovis Ab Ser Ql;;ACTIVE;2.17;2.56 +43622-0;Aconitate;PrThr;24H;Urine;Ord;;CHEM;1;Aconitate [Presence] in 24 hour Urine;Aconitate 24h Ur Ql;;ACTIVE;2.17;2.56 +43623-8;Acetylcholine receptor blocking Ab;PrThr;Pt;Ser;Ord;;SERO;1;Acetylcholine receptor blocking Ab [Presence] in Serum;AChR Block Ab Ser Ql;;ACTIVE;2.17;2.56 +43624-6;Acetylcholine receptor binding Ab;PrThr;Pt;Ser;Ord;;SERO;1;Acetylcholine receptor binding Ab [Presence] in Serum;AChR Bind Ab Ser Ql;;ACTIVE;2.17;2.73 +43625-3;Acetylcholine receptor Ab;PrThr;Pt;Ser;Ord;;SERO;1;Acetylcholine receptor Ab [Presence] in Serum;AChR Ab Ser Ql;;ACTIVE;2.17;2.73 +43626-1;acetoHEXAMIDE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetohexamide [Presence] in Serum or Plasma;acetoHEXAMIDE SerPl Ql;;ACTIVE;2.17;2.73 +43627-9;acetaZOLAMIDE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetazolamide [Presence] in Serum or Plasma;acetaZOLAMIDE SerPl Ql;;ACTIVE;2.17;2.56 +43628-7;Acetaminophen crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Acetaminophen crystals [Presence] in Urine sediment by Light microscopy;Acetamin Cry UrnS Ql Micro;;ACTIVE;2.17;2.56 +43629-5;8-Hydroxyamoxapine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;8-Hydroxyamoxapine [Presence] in Serum or Plasma;8OH-Amoxapine SerPl Ql;;ACTIVE;2.17;2.56 +43630-3;6-Thioguanine;PrThr;Pt;RBC;Ord;;DRUG/TOX;1;6-Thioguanine [Presence] in Red Blood Cells;6-TGN RBC Ql;;ACTIVE;2.17;2.73 +43631-1;6-Methylmercaptopurine metabolite;PrThr;Pt;RBC;Ord;;DRUG/TOX;1;6-Methylmercaptopurine metabolite [Presence] in Red Blood Cells;6MMP metab RBC Ql;;ACTIVE;2.17;2.73 +43632-9;6-Methylmercaptopurine;PrThr;Pt;RBC;Ord;;DRUG/TOX;1;6-Methylmercaptopurine [Presence] in Red Blood Cells;6MMP RBC Ql;;ACTIVE;2.17;2.56 +43633-7;5-Oxoproline;PrThr;24H;Urine;Ord;;CHEM;1;5-Oxoproline [Presence] in 24 hour Urine;5Oxoproline 24h Ur Ql;;ACTIVE;2.17;2.56 +43634-5;3-Methoxy-4-Hydroxyphenylglycol;PrThr;Pt;Urine;Ord;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Presence] in Urine;3Me4OH-phenylglycol Ur Ql;;ACTIVE;2.17;2.56 +43635-2;2-Hydroxyglutarate;PrThr;24H;Urine;Ord;;CHEM;1;2-Hydroxyglutarate [Presence] in 24 hour Urine;2OH-gluterate 24h Ur Ql;;ACTIVE;2.17;2.56 +43636-0;Plasminogen activator tissue type;PrThr;Pt;PPP;Ord;Chromo;COAG;1;Plasminogen activator tissue type [Presence] in Platelet poor plasma by Chromogenic method;tPA PPP Ql Chro;;ACTIVE;2.17;2.56 +43637-8;Parrot droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parrot droppings IgG Ab [Presence] in Serum;Parrot Drop IgG Ql;;ACTIVE;2.17;2.56 +4363-8;Orphenadrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Orphenadrine [Mass] of Dose;Orphenadrine Dose;;ACTIVE;1.0;2.69 +43638-6;Aquaporin 4 water channel Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Aquaporin 4 water channel IgG Ab [Presence] in Serum or Plasma;AQP4 H2O channel IgG SerPl Ql;;ACTIVE;2.17;2.73 +43639-4;Mercaptopurine;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Mercaptopurine [Presence] in Blood;Mercaptopurine Bld Ql;;ACTIVE;2.17;2.56 +43640-2;Aldosterone-18-glucuronide;ACnc;Pt;Urine;Qn;;CHEM;1;Aldosterone-18-glucuronide [Units/volume] in Urine;Aldost-18 G Ur-aCnc;;DISCOURAGED;2.17;2.69 +43641-0;Views;Find;Pt;Lower extremity.left>Foot.sesamoid bones;Doc;XR;RAD;2;XR Foot sesamoid bones - left Views;XR Ft.Sesamoids-L Views;;ACTIVE;2.17;2.64 +43642-8;Views for blood flow^W Tc-99m DTPA IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views for blood flow W Tc-99m DTPA IV;NM Brain Vs bld flow W Tc99mDTPA IV;;ACTIVE;2.17;2.64 +43643-6;Views for blood flow^W Tc-99m glucoheptonate IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views for blood flow W Tc-99m glucoheptonate IV;NM Brain Vs bld flow W Tc99mGHA IV;;ACTIVE;2.17;2.64 +43644-4;Views limited for blood flow^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Limited Views for blood flow;NM Brain Vs for bld flow Ltd W RNC IV;;ACTIVE;2.17;2.64 +43645-1;Views qualitative for infarct^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Qualitative Views for infarct;NM Hrt Vs Ql for Infarct W RNC IV;;ACTIVE;2.17;2.64 +4364-6;Ouabain;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ouabain [Mass] of Dose;Ouabain Dose;;ACTIVE;1.0;2.69 +43646-9;Views qualitative+quantitative for infarct^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Qualitative and Quantitative Views for infarct;NM Hrt Vs Ql+Qn for Infarct W RNC IV;;ACTIVE;2.17;2.64 +43647-7;Views quantitative for infarct^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Quantitative Views for infarct;NM Hrt Vs Qn for Infarct W RNC IV;;ACTIVE;2.17;2.64 +43648-5;Views for endocrine tumor multiple areas^W I-131 MIBG IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for endocrine tumor multiple areas W I-131 MIBG IV;NM Vs Endo tum Mult area W I-131 mIBG IV;;ACTIVE;2.17;2.64 +43649-3;Views for endocrine tumor multiple areas^W In-111 pentetreotide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views for endocrine tumor multiple areas W In-111 pentetreotide IV;NM Vs Endo tum Mult areas W In-111-P IV;;ACTIVE;2.17;2.64 +43650-1;Views^W cholecystokinin+W radionuclide IV;Find;Pt;Abdomen>Liver+Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Liver and Biliary ducts and Gallbladder Views W cholecystokinin and W radionuclide IV;NM Liver+BDs+GB Views W CCK+RNC IV;;ACTIVE;2.17;2.64 +43651-9;Views^W sincalide+W radionuclide IV;Find;Pt;Abdomen>Liver+Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Liver and Biliary ducts and Gallbladder Views W sincalide and W radionuclide IV;NM Liver+BDs+GB Views W Sinc+RNC IV;;ACTIVE;2.17;2.64 +43652-7;Multisection for blood flow^W radionuclide IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM.SPECT;RAD;2;SPECT Liver and Spleen for blood flow;SPECT Liver+Spleen bld flow W RNC IV;;ACTIVE;2.17;2.61 +4365-3;Oxacillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxacillin [Mass] of Dose;Oxacillin Dose;;ACTIVE;1.0;2.69 +43653-5;Views for blood flow^W radionuclide IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM;RAD;2;NM Liver and Spleen Views for blood flow;NM Liver+Spleen Vs bld flow W RNC IV;;ACTIVE;2.17;2.64 +43654-3;Views for blood flow^W Tc-99m tagged RBC IV;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views for blood flow W Tc-99m tagged RBC IV;NM Liver Vs bld flow W Tc99m RBC IV;;ACTIVE;2.17;2.64 +43655-0;Multisection for blood flow^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM.SPECT;RAD;2;SPECT Liver for blood flow;SPECT Liver bld flow W RNC IV;;ACTIVE;2.17;2.61 +43656-8;Views perfusion quantitative^W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Perfusion quantitative;NM Lung PF Qn W RNC IV;;ACTIVE;2.17;2.61 +43657-6;Views quantitative^W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Quantitative Views;NM Lung Qn W RNC IV;;ACTIVE;2.17;2.64 +43658-4;Views perfusion quantitative^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion quantitative;NM Hrt PF Qn W RNC IV;;ACTIVE;2.17;2.61 +43659-2;Multisection perfusion qualitative^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion qualitative at rest and W radionuclide IV;SPECT Hrt PF Ql Rest+W RNC IV;;ACTIVE;2.17;2.61 +436-6;Rolitetracycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Rolitetracycline [Susceptibility] by Minimum inhibitory concentration (MIC);Rolitetracycline Islt MIC;;ACTIVE;1.0;2.19 +43660-0;Views perfusion qualitative^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion qualitative at rest and W radionuclide IV;NM Hrt PF Ql Rest+W RNC IV;;ACTIVE;2.17;2.61 +4366-1;Oxandrolone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxandrolone [Mass] of Dose;Oxandrolone Dose;;ACTIVE;1.0;2.69 +43661-8;Views perfusion quantitative^at rest+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion quantitative at rest and W radionuclide IV;NM Hrt PF Qn Rest+W RNC IV;;ACTIVE;2.17;2.61 +43662-6;Multisection for blood flow^W Tc-99m glucoheptonate IV;Find;Pt;Abdomen>Renal vessels;Doc;NM.SPECT;RAD;2;SPECT Renal vessels for blood flow W Tc-99m glucoheptonate IV;SPECT Renal ves bld flow W Tc99mGHA IV;;ACTIVE;2.17;2.61 +43663-4;Views for blood flow^W Tc-99m glucoheptonate IV;Find;Pt;Abdomen>Renal vessels;Doc;NM;RAD;2;NM Renal vessels Views for blood flow W Tc-99m glucoheptonate IV;NM Renal ves Vs bld flow W Tc99mGHA IV;;ACTIVE;2.17;2.64 +43664-2;Views for blood flow^W Tc-99m DTPA IV;Find;Pt;Abdomen>Renal vessels;Doc;NM;RAD;2;NM Renal vessels Views for blood flow W Tc-99m DTPA IV;NM Renal ves Vs bld flow W Tc99mDTPA IV;;ACTIVE;2.17;2.64 +43665-9;Views for blood flow^W Tc-99m Mertiatide IV;Find;Pt;Abdomen>Renal vessels;Doc;NM;RAD;2;NM Renal vessels Views for blood flow W Tc-99m Mertiatide IV;NM Renal ves Vs bld flow W Tc99mMAG3 IV;;ACTIVE;2.17;2.64 +43666-7;Views for blood flow^W Tc-99m glucoheptonate IV;Find;Pt;Abdomen>Kidney+Renal vessels;Doc;NM;RAD;2;NM Kidney+Renal vessels Views for blood flow W Tc-99m glucoheptonate IV;NM Kidney+ves Vs bld flow W Tc99mGHA IV;;ACTIVE;2.17;2.64 +43667-5;Views^W Tc-99m DTPA IV;Find;Pt;Abdomen>Kidney+Renal vessels;Doc;NM;RAD;2;NM Kidney+Renal vessels Views W Tc-99m DTPA IV;NM Kidney+ves Views W Tc99mDTPA IV;;ACTIVE;2.17;2.64 +43668-3;Views^W Tc-99m Mertiatide IV;Find;Pt;Kidney.bilateral+Collecting system+Renal vessels;Nar;Radnuc;RAD;2;Deprecated Kidney Bilateral & Collecting System & Renal Vessels Radnuc Views W Tc-99m Mertiatide IV;Deprecated KD-Bl+CS+Renal ves RI W Tc99m;;DEPRECATED;2.17;2.40 +43669-1;Views^W radionuclide IV;Find;Pt;Abdomen>Renal vessels;Doc;NM;RAD;2;NM Renal vessels Views;NM Renal ves Views W RNC IV;;ACTIVE;2.17;2.64 +43670-9;Multisection for blood flow^W radionuclide IV;Find;Pt;Abdomen>Spleen;Doc;NM.SPECT;RAD;2;SPECT Spleen for blood flow;SPECT Spleen bld flow W RNC IV;;ACTIVE;2.17;2.61 +43671-7;View spot^W radionuclide IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Spot;NM Thyroid Spot W RNC IV;;ACTIVE;2.17;2.61 +43672-5;Views+views uptake^W radionuclide IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views and Views uptake;NM Thyroid Views+views uptake W RNC IV;;ACTIVE;2.17;2.73 +43673-3;Multisection for blood flow^W radionuclide IV;Find;Pt;Neck>Thyroid gland;Doc;NM.SPECT;RAD;2;SPECT Thyroid gland for blood flow;SPECT Thyroid bld flow W RNC IV;;ACTIVE;2.17;2.61 +43674-1;Fatty acid panel.comprehensive C8-C26;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Fatty acid comprehensive (C8-C26) panel - Serum or Plasma;FA comp C8-C26 Pnl SerPl;;ACTIVE;2.17;2.73 +43675-8;Fatty acid panel.mitochondrial C8-C18;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Fatty acid mitochondrial (C8-C18) panel - Serum or Plasma;FA mito C8-C18 Pnl SerPl;;ACTIVE;2.17;2.54 +43676-6;Fatty acid panel.essential C12-C22;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Fatty acid essential (C12-C22) panel - Serum or Plasma;FA essential C12-C22 Pnl SerPl;;ACTIVE;2.17;2.73 +43677-4;Fatty acid panel.very long chain C22-C26;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Fatty acid very long chain (C22-C26) panel - Serum or Plasma;VLCFA C22-C26 Pnl SerPl;;ACTIVE;2.17;2.54 +43678-2;Dosage forms and strengths section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Dosage forms and strengths section;FDA insert Dose forms/strengths;;ACTIVE;2.17;2.34 +4367-9;Oxazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxazepam [Mass] of Dose;Oxazepam Dose;;ACTIVE;1.0;2.69 +43679-0;Mechanism of action section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Mechanism of action section;FDA insert Mechanism of action;;ACTIVE;2.17;2.34 +43680-8;Nonclinical toxicology section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Nonclinical toxicology section;FDA insert Nonclinical tox;;ACTIVE;2.17;2.34 +43681-6;Pharmacodynamics section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Pharmacodynamics section;FDA insert Pharmacodynamics;;ACTIVE;2.17;2.34 +43682-4;Pharmacokinetics section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Pharmacokinetics section;FDA insert Pharmacokinetics;;ACTIVE;2.17;2.34 +43683-2;Recent major changes section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Recent major changes section;FDA insert Recent major changes;;ACTIVE;2.17;2.34 +43684-0;Use in specific populations section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Use in specific populations section;FDA insert Use in specific pop;;ACTIVE;2.17;2.34 +43685-7;Warnings and precautions section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Warnings and precautions section;FDA insert Warnings/precautions;;ACTIVE;2.17;2.34 +43686-5;Salivary gland Ab.IgA;ACnc;Pt;Saliva;Qn;;SERO;1;Salivary gland IgA Ab [Units/volume] in Saliva (oral fluid);Salivary Gland IgA Sal-aCnc;;ACTIVE;2.17;2.69 +4368-7;Oxedrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxedrine [Mass] of Dose;Oxedrine Dose;;ACTIVE;1.0;2.69 +43687-3;Powassan virus polyvalent E Ab;PrThr;Pt;XXX;Ord;IA;MICRO;1;Powassan virus polyvalent E Ab [Presence] in Specimen by Immunoassay;POWV Polyval E Ab Spec Ql IA;;ACTIVE;2.17;2.69 +43688-1;16-Alpha hydroxypregnenolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;16-Alpha hydroxypregnenolone/Creatinine [Mass Ratio] in Urine;16A OH-Preg/Creat Ur;;ACTIVE;2.17;2.42 +43689-9;HLA-DQ2 & HLA-DQ8;Imp;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DQ2 and HLA-DQ8 [Interpretation];HLA-DQ2 & DQ8-Imp;;ACTIVE;2.17;2.73 +43690-7;Triamterene/Total;MFr;Pt;Calculus;Qn;;DRUG/TOX;1;Triamterene/Total in Stone;Triamterene MFr Stone;;ACTIVE;2.17;2.73 +43691-5;Cladosporium sp Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cladosporium sp IgE Ab [Presence] in Serum;Cladosporium IgE Ql;;ACTIVE;2.17;2.56 +43692-3;Fusarium sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fusarium sp IgE Ab RAST class [Presence] in Serum;Fusarium IgE RAST Ql;;ACTIVE;2.17;2.58 +43693-1;Varicella zoster virus identified;Prid;Pt;Skin;Nom;Shell vial culture;MICRO;1;Varicella zoster virus identified in Skin by Shell vial culture;VZV Skin Shell Vial Cult;;ACTIVE;2.17;2.21 +43694-9;Inner Ear 68kD Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Inner ear 68kD Ab [Presence] in Body fluid;Inner ear 68kD Ab Fld Ql;;ACTIVE;2.17;2.56 +4369-5;Oxprenolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxprenolol [Mass] of Dose;Oxprenolol Dose;;ACTIVE;1.0;2.69 +43695-6;Herpes virus identified;Prid;Pt;XXX;Nom;Shell vial culture;MICRO;1;Herpes virus identified in Specimen by Shell vial culture;HHV Spec Shell Vial Cult;;ACTIVE;2.17;2.73 +43696-4;Herpes simplex virus identified;Prid;Pt;CSF;Nom;Shell vial culture;MICRO;1;Herpes simplex virus identified in Cerebral spinal fluid by Shell vial culture;HSV CSF Shell Vial Cult;;ACTIVE;2.17;2.73 +43697-2;Herpes simplex virus identified;Prid;Pt;XXX;Nom;Shell vial culture;MICRO;1;Herpes simplex virus identified in Specimen by Shell vial culture;HSV Spec Shell Vial Cult;;ACTIVE;2.17;2.73 +43698-0;Enterovirus identified;Prid;Pt;XXX;Nom;Shell vial culture;MICRO;1;Enterovirus identified in Specimen by Shell vial culture;EV Spec Shell Vial Cult;;ACTIVE;2.17;2.73 +43699-8;Enterovirus identified;Prid;Pt;CSF;Nom;Shell vial culture;MICRO;1;Enterovirus identified in Cerebral spinal fluid by Shell vial culture;EV CSF Shell Vial Cult;;ACTIVE;2.17;2.17 +43700-4;Cytomegalovirus;PrThr;Pt;Urine;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Urine by Shell vial culture;CMV Ur Ql Shell Vial Cult;;ACTIVE;2.17;2.56 +43701-2;Cytomegalovirus;PrThr;Pt;XXX;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Specimen by Shell vial culture;CMV Spec Ql Shell Vial Cult;;ACTIVE;2.17;2.73 +43702-0;Cytomegalovirus;PrThr;Pt;CSF;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Cerebral spinal fluid by Shell vial culture;CMV CSF Ql Shell Vial Cult;;ACTIVE;2.17;2.56 +4370-3;oxyCODONE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;oxyCODONE [Mass] of Dose;oxyCODONE Dose;;ACTIVE;1.0;2.73 +43703-8;Cytomegalovirus;PrThr;Pt;Bld;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Blood by Shell vial culture;CMV Bld Ql Shell Vial Cult;;ACTIVE;2.17;2.56 +43704-6;Cytomegalovirus;PrThr;Pt;Body fld;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Body fluid by Shell vial culture;CMV Fld Ql Shell Vial Cult;;ACTIVE;2.17;2.56 +43705-3;Cytomegalovirus;PrThr;Pt;Bone mar;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Bone marrow by Shell vial culture;CMV Mar Ql Shell Vial Cult;;ACTIVE;2.17;2.56 +43706-1;Cytomegalovirus;PrThr;Pt;Anal;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Anal by Shell vial culture;CMV Anal Ql Shell Vial Cult;;ACTIVE;2.17;2.56 +43707-9;Cytomegalovirus;PrThr;Pt;Tiss;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Tissue by Shell vial culture;CMV Tiss Ql Shell Vial Cult;;ACTIVE;2.17;2.56 +43708-7;Alkaline phosphatase.liver+bone;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.liver+bone [Presence] in Serum or Plasma;ALP Liver+Bone SerPl Ql;;ACTIVE;2.17;2.56 +43709-5;Alkaline phosphatase.intestinal+renal;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.intestinal+renal [Presence] in Serum or Plasma;ALP Intest+renal SerPl Ql;;ACTIVE;2.17;2.56 +43710-3;Alkaline phosphatase.heat stable;PrThr;Pt;Ser/Plas;Ord;Heat stability;CHEM;1;Alkaline phosphatase.heat stable [Presence] in Serum or Plasma by Heat stability;ALP heat stable SerPl Ql HS;;ACTIVE;2.17;2.56 +4371-1;Oxymesterone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxymesterone [Mass] of Dose;Oxymesterone Dose;;ACTIVE;1.0;2.69 +43711-1;Albumin;PrThr;Pt;CSF;Ord;;CHEM;1;Albumin [Presence] in Cerebral spinal fluid;Albumin CSF Ql;;ACTIVE;2.17;2.56 +43712-9;Albumin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Albumin [Presence] in Serum or Plasma;Albumin SerPl Ql;;DISCOURAGED;2.17;2.73 +43713-7;Albumin;PrThr;Pt;Body fld;Ord;;CHEM;1;Albumin [Presence] in Body fluid;Albumin Fld Ql;;ACTIVE;2.17;2.73 +43714-5;Adenovirus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Adenovirus Ab [Presence] in Specimen;HAdV Ab Spec Ql;;ACTIVE;2.17;2.73 +43715-2;Acylcarnitine;PrThr;Pt;Bld;Ord;;CHEM;1;Acylcarnitine [Presence] in Blood;Acylcarnitine Bld Ql;;ACTIVE;2.17;2.73 +43716-0;Acylcarnitine;PrThr;Pt;Urine;Ord;;CHEM;1;Acylcarnitine [Presence] in Urine;Acylcarnitine Ur Ql;;ACTIVE;2.17;2.56 +43717-8;Acylcarnitine;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Acylcarnitine [Presence] in DBS;Acylcarnitine DBS Ql;;ACTIVE;2.17;2.61 +43718-6;Acid phosphatase.prostatic;PrThr;Pt;Ser;Ord;;CHEM;1;Prostatic acid phosphatase [Presence] in Serum;PACP Ser Ql;;ACTIVE;2.17;2.56 +43719-4;Acetaminophen+oxyCODONE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetaminophen+oxyCODONE [Presence] in Serum or Plasma;Acetamin+oxyCODONE SerPl Ql;;ACTIVE;2.17;2.56 +43720-2;Acetaminophen+Codeine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetaminophen+Codeine [Presence] in Serum or Plasma;Acetamin+Codeine SerPl Ql;;ACTIVE;2.17;2.56 +43721-0;Acetaldehyde+Paraldehyde;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetaldehyde+Paraldehyde [Presence] in Serum or Plasma;Acetamin+Paraldehyde SerPl Ql;;ACTIVE;2.17;2.56 +43722-8;5-Ethyl-5-Phenylhydantoin;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;5-Ethyl-5-Phenylhydantoin [Presence] in Specimen;5-ethyl-5-phenylhydantoin Spec Ql;;ACTIVE;2.17;2.69 +43723-6;5,10-Methylenetetrahydrofolate reductase;PrThr;Pt;Ser;Ord;;CHEM;1;5,10-Methylenetetrahydrofolate reductase [Presence] in Serum;MTHFR Ser Ql;;ACTIVE;2.17;2.73 +43724-4;2,5-Dichlorophenol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;2,5-Dichlorophenol [Presence] in Urine;2,5-dichlorophenol Ur Ql;;ACTIVE;2.17;2.56 +43725-1;2,4-Dichlorophenol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;2,4-Dichlorophenol [Presence] in Urine;2,4-dichlorophenol Ur Ql;;ACTIVE;2.17;2.56 +43726-9;17-Ketogenic steroids;PrThr;24H;Urine;Ord;;CHEM;1;17-Ketogenic steroids [Presence] in 24 hour Urine;17KGS 24h Ur Ql;;ACTIVE;2.17;2.73 +43727-7;Lipoprotein.beta.subparticle.small;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.beta.subparticle.small [Moles/volume] in Serum or Plasma;LDL Small SerPl-sCnc;;ACTIVE;2.17;2.73 +43728-5;Lipoprotein.pre-beta.subparticle.large;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.pre-beta.subparticle.large [Moles/volume] in Serum or Plasma;VLDL large SerPl-sCnc;;ACTIVE;2.17;2.73 +4372-9;Oxymetholone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxymetholone [Mass] of Dose;Oxymetholone Dose;;ACTIVE;1.0;2.73 +43729-3;Lipoprotein.alpha.subparticle.large;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.alpha.subparticle.large [Moles/volume] in Serum or Plasma;HLD.large SerPl-sCnc;;ACTIVE;2.17;2.73 +43730-1;Epstein Barr virus DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;EBV DNA SerPl NAA+probe-aCnc;;ACTIVE;2.17;2.73 +43731-9;Alkaline phosphatase.fetal+lung+lymphocyte;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.fetal+lung+lymphocyte [Presence] in Serum or Plasma;ALP Fetal+Lung+Lymphocyte SerPl Ql;;ACTIVE;2.17;2.56 +43732-7;4-Hydroxybenzoate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;4-Hydroxybenzoate [Presence] in Urine;4OHBenzoate Ur Ql;;ACTIVE;2.17;2.56 +43733-5;4-Hydroxybenzoate;PrThr;24H;Urine;Ord;;DRUG/TOX;1;4-Hydroxybenzoate [Presence] in 24 hour Urine;4OHBenzoate 24h Ur Ql;;ACTIVE;2.17;2.56 +43734-3;Coagulation surface induced;Time;Pt;PPP;Qn;Coag.saline 1:1;COAG;1;aPTT in Platelet poor plasma by Coagulation 1:1 saline;aPTT PPP 1:1 saline;;ACTIVE;2.17;2.73 +43735-0;Coagulation surface induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Deprecated Activated partial thrombplastin time (aPTT).factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:1 addition of normal plasma;Deprecated aPTT imm NP PPP Qn;;DEPRECATED;2.17;2.70 +43736-8;Fosamprenavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Fosamprenavir [Susceptibility] by Genotype method;Fosamprenavir Islt Genotyp;;ACTIVE;2.17;2.73 +4373-7;Oxyphenbutazone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Oxyphenbutazone [Mass] of Dose;Oxyphenbutazone Dose;;ACTIVE;1.0;2.69 +43737-6;Tipranavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Tipranavir [Susceptibility] by Genotype method;Tipranavir Islt Genotyp;;ACTIVE;2.17;2.73 +43738-4;Coagulation dilute Russell viper venom induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Deprecated Dilute Russell viper venom time (dRVVT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;Deprecated dRVV Tme imm NP PPP Qn;;DEPRECATED;2.17;2.36 +43739-2;Blood group Ag;Imp;Pt;RBC^BPU;Nom;;BLDBK;1;Blood group Ag [Interpretation] on Red Blood Cells from Blood product unit;Blood group Ag RBC BPU-Imp;;ACTIVE;2.17;2.73 +437-4;Rolitetracycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Rolitetracycline [Susceptibility] by Disk diffusion (KB);Rolitetracycline Islt KB;;ACTIVE;1.0;2.19 +43740-0;Glucose/Insulin;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Glucose/Insulin [Mass Ratio] in Serum or Plasma;Glucose/Insulin SerPl;;ACTIVE;2.17;2.70 +43741-8;Temperature;Temp;Pt;Semen;Qn;;FERT;1;Temperature of Semen;Temp Smn;;ACTIVE;2.17;2.73 +43742-6;Time next dose;TmStp;Pt;^Patient;Qn;;DRUGDOSE;1;Time next dose;Time Next Dose Patient;;ACTIVE;2.17;2.73 +43743-4;Lymphocytes.variant;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Variant lymphocytes [#/volume] in Blood by Automated count;Variant Lymphs # Bld Auto;;ACTIVE;2.17;2.73 +43744-2;COX10 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;COX10 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;COX10 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +4374-5;Para methylhippurate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Para methylhippurate [Mass] of Dose;p-Methylhippurate Dose;;ACTIVE;1.0;2.69 +43745-9;DYS gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DYS gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;DYS gene Mut Tested Bld/T;;ACTIVE;2.17;2.73 +43746-7;KCNQ1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;KCNQ1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;KCNQ1 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +43747-5;OCA2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;OCA2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;OCA2 gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +43748-3;SCO1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SCO1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SCO1 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +43749-1;SCO2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SCO2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SCO2 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +43750-9;SURF1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SURF1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SURF1 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +43751-7;Moxifloxacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Moxifloxacin [Mass/volume] in Serum or Plasma;Moxifloxacin SerPl-mCnc;;ACTIVE;2.17;2.42 +4375-2;Para hydroxyamphetamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Para hydroxyamphetamine [Mass] of Dose;P-OH-Amphet Dose;;ACTIVE;1.0;2.69 +43752-5;Aquaporin 4 water channel Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IF;SERO;1;Aquaporin 4 water channel IgG Ab [Units/volume] in Serum or Plasma by Immunofluorescence;AQP4 H2O channel IgG SerPl IF-aCnc;;ACTIVE;2.17;2.73 +43753-3;Spermatozoa IgM binding location;Prid;Pt;Semen;Nom;;FERT;1;Spermatozoa IgM binding location [Identifier] in Semen;Sperm IgM Bind Location Smn;;ACTIVE;2.17;2.19 +43754-1;Sulfate;MCnc;XXX;Urine;Qn;;CHEM;1;Sulfate [Mass/volume] in Urine collected for unspecified duration;Sulfate ?Tm Ur-mCnc;;ACTIVE;2.17;2.73 +43755-8;Casts;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Casts [#/area] in Urine sediment by Automated count;Casts #/area UrnS Auto;;ACTIVE;2.17;2.73 +43756-6;Guidance for percutaneous aspiration of fluid;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for fluid aspiration of Breast;US Guided Brst PC fluid asp;;ACTIVE;2.17;2.64 +43757-4;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Kidney;CT Guided Kidney FNA;;ACTIVE;2.17;2.64 +43758-2;Guidance for localization;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for localization of Breast - left;US Guided Brst-L Loc;;ACTIVE;2.17;2.64 +43759-0;Guidance for localization;Find;Pt;Breast.bilateral;Doc;US;RAD;2;US Guidance for localization of Breast - bilateral;US Guided Brst-Bl Loc;;ACTIVE;2.17;2.64 +4376-0;Paraldehyde;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Paraldehyde [Mass] of Dose;Paraldehyde Dose;;ACTIVE;1.0;2.69 +43760-8;Guidance for localization;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for localization of Breast - right;US Guided Brst-R Loc;;ACTIVE;2.17;2.64 +43761-6;Guidance for thrombectomy^W contrast IV;Find;Pt;XXX>Vein.bilateral;Doc;RF.angio;RAD;2;RFA Guidance for thrombectomy of Vein - bilateral-- W contrast IV;RFA Guided Vein-Bl Thrombect--W contr IV;;ACTIVE;2.17;2.64 +43762-4;Guidance for thrombectomy^W contrast IV;Find;Pt;XXX>Vein.left;Doc;RF.angio;RAD;2;RFA Guidance for thrombectomy of Vein - left-- W contrast IV;RFA Guided Vein-L Thrombect--W contr IV;;ACTIVE;2.17;2.64 +43763-2;Guidance for thrombectomy^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for thrombectomy of Vein-- W contrast IV;RFA Guided Vein Thrombect--W contr IV;;ACTIVE;2.17;2.64 +43764-0;Guidance for thrombectomy^W contrast IV;Find;Pt;XXX>Vein.right;Doc;RF.angio;RAD;2;RFA Guidance for thrombectomy of Vein - right-- W contrast IV;RFA Guided Vein-R Thrombect--W contr IV;;ACTIVE;2.17;2.64 +43765-7;Multisection;Find;Pt;Head+Neck>Carotid arteries.bilateral;Doc;US.doppler;RAD;2;US.doppler Carotid arteries - bilateral;DOP Carotid aa-Bl;;ACTIVE;2.17;2.73 +43766-5;Multisection^W contrast IV;Find;Pt;Abdomen>Kidney.bilateral;Doc;CT;RAD;2;CT Kidney - bilateral W contrast IV;CT Kdny-Bl W contr IV;;ACTIVE;2.17;2.61 +43767-3;Multisection;Find;Pt;Abdomen>Kidney.bilateral;Doc;CT;RAD;2;CT Kidney - bilateral;CT Kdny-Bl;;ACTIVE;2.17;2.61 +43768-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Kidney WO and W contrast IV;CT Kidney WO+W contr IV;;ACTIVE;2.17;2.61 +43769-9;Multisection^WO & W contrast IV;Find;Pt;Head>Brain+Internal auditory canal;Doc;MR;RAD;2;MR Brain and Internal auditory canal WO and W contrast IV;MR Brain+IAC WO+W contr IV;;ACTIVE;2.17;2.61 +43770-7;Multisection^WO contrast;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Kidney WO contrast;CT Kidney WO contr;;ACTIVE;2.17;2.61 +43771-5;Multisection;Find;Pt;Extremity>Extremity vessels;Doc;US.doppler;RAD;2;US.doppler Extremity vessels;DOP Extremity ves;;ACTIVE;2.17;2.61 +43772-3;Multisection;Find;Pt;Head>Brain+Internal auditory canal;Doc;MR;RAD;2;MR Brain and Internal auditory canal;MR Brain+IAC;;ACTIVE;2.17;2.61 +43773-1;Multisection^WO contrast;Find;Pt;Abdomen>Kidney;Doc;MR;RAD;2;MR Kidney WO contrast;MR Kidney WO contr;;ACTIVE;2.17;2.61 +43774-9;Multisection;Find;Pt;Abdomen>Kidney.bilateral;Doc;US;RAD;2;US Kidney - bilateral;US Kdny-Bl;;ACTIVE;2.17;2.73 +43775-6;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Kidney;Doc;MR;RAD;2;MR Kidney WO and W contrast IV;MR Kidney WO+W contr IV;;ACTIVE;2.17;2.61 +43776-4;Multisection limited;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;US.doppler;RAD;2;US.doppler Iliac artery limited;DOP Iliac a Ltd;;ACTIVE;2.17;2.61 +43777-2;Views perfusion^at rest+W adenosine+W Tl-201 IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion at rest and W adenosine and W Tl-201 IV;NM Hrt PF Rest+W ADE+Tl201 IV;;ACTIVE;2.17;2.61 +4377-8;Pefloxacin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pefloxacin [Mass] of Dose;Pefloxacin Dose;;ACTIVE;1.0;2.69 +43778-0;View AP supine;Find;Pt;Chest;Doc;XR.portable;RAD;2;Portable XR Chest AP supine;XR port Chest AP supine;;ACTIVE;2.17;2.61 +43779-8;View Sunrise;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Sunrise;XR Knee-L Sunrise;;ACTIVE;2.17;2.61 +43780-6;View Sunrise;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Sunrise;XR Knee Sunrise;;ACTIVE;2.17;2.61 +43781-4;Views;Find;Pt;Neck+Chest>Spine.cervicothoracic junction;Doc;XR;RAD;2;XR Spine cervicothoracic junction Views;XR CTJ Views;;ACTIVE;2.17;2.64 +43782-2;Views^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;RF.angio;RAD;2;RFA Iliac artery Views W contrast IA;RFA Iliac a Views W contr IA;;ACTIVE;2.17;2.64 +43783-0;Views for renin sampling^W contrast IV;Find;Pt;Abdomen>Renal vein;Doc;RF.angio;RAD;2;RFA Renal vein Views for renin sampling W contrast IV;RFA Renal v Vs renin samp W contr IV;;ACTIVE;2.17;2.64 +43784-8;Views 2;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Cervical and thoracic and lumbar spine 2 Views;XR C+T+L-spine 2V;;ACTIVE;2.17;2.61 +43785-5;Views AP + lateral;Find;Pt;Neck+Chest>Spine.cervicothoracic junction;Doc;XR;RAD;2;XR Spine cervicothoracic junction AP and Lateral;XR CTJ AP+Lat;;ACTIVE;2.17;2.61 +4378-6;Pemoline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pemoline [Mass] of Dose;Pemoline Dose;;ACTIVE;1.0;2.69 +43786-3;Views AP (supine KUB & upright) & PA upright chest;Find;Pt;Abdomen+Chest;Nar;XR;RAD;2;Deprecated Abdomen & Chest X-ray AP (supine & upright) & PA chest;Deprecated Abd+Chest XR AP(supKUB+Upr)+P;;DEPRECATED;2.17;2.36 +43787-1;Views for dental measurement;Find;Pt;Head>Skull+Facial bones+Mandible;Doc;XR;RAD;2;XR Skull and Facial bones and Mandible Views for dental measurement;XR Skull+Face+Mandible Vs for Dent meas;;ACTIVE;2.17;2.64 +43788-9;Views for patency^W contrast via tube;Find;Pt;XXX>Tube;Doc;RF;RAD;2;RF Tube Views for patency W contrast via tube;RF Tube Views for pat W contr via tb;;ACTIVE;2.17;2.64 +43789-7;Views for patency^W Tc-99m IV;Find;Pt;Abdomen>Liver+Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Liver and Biliary ducts and Gallbladder Views for patency W Tc-99m IV;NM Liver+BDs+GB Views for pat W Tc99mIV;;ACTIVE;2.17;2.64 +43790-5;Views Grashey + Y;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Grashey and Y;XR Should-R Grashey+Y;;ACTIVE;2.17;2.61 +43791-3;Views oblique;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Oblique Views;XR L-spine Views Obl;;ACTIVE;2.17;2.64 +43792-1;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity.right>Tibioperoneal arteries;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Tibioperoneal arteries - right-- W contrast IA;RFA Guided Tibioper aa-R Ang W contr IA;;ACTIVE;2.17;2.64 +43793-9;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity>Tibioperoneal arteries;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Tibioperoneal arteries-- W contrast IA;RFA Guided Tibioper aa Angio--W contr IA;;ACTIVE;2.17;2.64 +4379-4;Penicillin G benzathine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Penicillin G benzathine [Mass] of Dose;Penicillin G Benzathine Dose;;ACTIVE;1.0;2.69 +43794-7;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity.bilateral>Tibioperoneal arteries;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Tibioperoneal arteries - bilateral-- W contrast IA;RFA Guided Tibioper aa-Bl Ang W contr IA;;ACTIVE;2.17;2.64 +43795-4;Guidance for angioplasty^W contrast IA;Find;Pt;Lower extremity.left>Tibioperoneal arteries;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Tibioperoneal arteries - left-- W contrast IA;RFA Guided Tibioper aa-L Ang W contr IA;;ACTIVE;2.17;2.64 +43796-2;Views Carpal tunnel;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Carpal tunnel Views;XR Wrist-Bl Views tunnel.carpal;;ACTIVE;2.17;2.73 +43797-0;Guidance for superficial biopsy;Find;Pt;XXX>Lymph node;Doc;US;RAD;2;US Guidance for superficial biopsy of Lymph node;US Guided LN Super Bx;;ACTIVE;2.17;2.64 +43798-8;Alpha-1-Fetoprotein;PrThr;Pt;Amnio fld;Ord;;CHEM;1;Alpha-1-Fetoprotein [Presence] in Amniotic fluid;AFP Amn Ql;;ACTIVE;2.17;2.73 +43799-6;Choriogonadotropin.beta subunit;PrThr;Pt;XXX;Ord;;CHEM;1;Choriogonadotropin.beta subunit [Presence] in Specimen;B-HCG Spec Ql;;ACTIVE;2.17;2.73 +43800-2;Choriogonadotropin.beta subunit;PrThr;Pt;CSF;Ord;;CHEM;1;Choriogonadotropin.beta subunit [Presence] in Cerebral spinal fluid;B-HCG CSF Ql;;ACTIVE;2.17;2.56 +43801-0;Choriogonadotropin.intact;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin.intact [Units/volume] in Amniotic fluid;HCG Intact Amn-aCnc;;ACTIVE;2.17;2.70 +4380-2;Penicillin G potassium;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Penicillin G potassium [Mass] of Dose;Penicillin G Potassium Dose;;ACTIVE;1.0;2.69 +43802-8;Estriol;MCnc;24H;Urine;Qn;;CHEM;1;Estriol (E3) [Mass/volume] in 24 hour Urine;Estriol 24h Ur-mCnc;;ACTIVE;2.17;2.42 +43803-6;Estriol^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Estriol (E3) [Multiple of the median] adjusted in Serum or Plasma;Estriol adj MoM SerPl;;ACTIVE;2.17;2.42 +43804-4;Amino acid pattern;Imp;Pt;CSF;Nom;;CHEM;1;Amino acid pattern [Interpretation] in Cerebral spinal fluid;Amino acid Pat CSF-Imp;;ACTIVE;2.17;2.73 +43805-1;Urease^1H post incubation;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --1 hour post incubation;Urease 1h p Inc Tiss Ql;;ACTIVE;2.17;2.56 +43806-9;Urease^20M post incubation;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --20 minutes post incubation;Urease 20M p Inc Tiss Ql;;ACTIVE;2.17;2.56 +43807-7;Urease^4H post incubation;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --4 hours post incubation;Urease 4h p Inc Tiss Ql;;ACTIVE;2.17;2.56 +43808-5;Urease^30M post incubation;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --30 minutes post incubation;Urease 30M p Inc Tiss Ql;;ACTIVE;2.17;2.56 +43809-3;Arsenic;PrThr;Pt;Tiss;Ord;;DRUG/TOX;1;Arsenic [Presence] in Tissue;Arsenic Tiss Ql;;ACTIVE;2.17;2.56 +4381-0;Penicillin G procaine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Penicillin G procaine [Mass] of Dose;Penicillin G Procaine Dose;;ACTIVE;1.0;2.69 +43810-1;Rubella virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rubella virus Ab [Presence] in Serum by Immunoassay;RUBV Ab Ser Ql IA;;ACTIVE;2.17;2.73 +43811-9;Propoxyphene;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Propoxyphene [Presence] in Specimen;Propoxyph Spec Ql;;ACTIVE;2.17;2.73 +43812-7;Influenza virus A Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Influenza virus A Ab [Presence] in Serum;Deprecated FLUAV Ab Ser Ql;;DEPRECATED;2.17;2.36 +43813-5;Reagin Ab;PrThr;Pt;BldCo;Ord;;MICRO;1;Reagin Ab [Presence] in Cord blood;Reagin Ab BldCo Ql;;ACTIVE;2.17;2.56 +43814-3;Basement membrane Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Basement membrane IgG Ab [Presence] in Serum by Immunoassay;BM IgG Ser Ql IA;;ACTIVE;2.17;2.73 +43815-0;Arsenic;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Arsenic [Presence] in Specimen;Arsenic Spec Ql;;ACTIVE;2.17;2.69 +43816-8;Amylase;PrThr;Pt;Body fld;Ord;;CHEM;1;Amylase [Presence] in Body fluid;Amylase Fld Ql;;ACTIVE;2.17;2.73 +43817-6;Androstenedione;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Androstenedione [Presence] in Serum or Plasma;Androst SerPl Ql;;ACTIVE;2.17;2.56 +43818-4;Beta-2-Microglobulin;PrThr;Pt;Ser;Ord;;CHEM;1;Beta-2-Microglobulin [Presence] in Serum;B2 Microglob Ser Ql;;ACTIVE;2.17;2.73 +43819-2;Beta-2-Microglobulin;PrThr;Pt;Urine;Ord;;CHEM;1;Beta-2-Microglobulin [Presence] in Urine;B2 Microglob Ur Ql;;ACTIVE;2.17;2.56 +438-2;Rolitetracycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Rolitetracycline [Susceptibility] by Serum bactericidal titer;Rolitetracycline Titr SBT;;ACTIVE;1.0;2.32 +43820-0;Bilirubin.glucuronidated+Bilirubin.albumin bound;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Bilirubin.direct [Presence] in Serum or Plasma;Bilirub Direct SerPl Ql;;ACTIVE;2.17;2.73 +43821-8;Amylase;PrThr;24H;Urine;Ord;;CHEM;1;Amylase [Presence] in 24 hour Urine;Amylase 24h Ur Ql;;ACTIVE;2.17;2.56 +43822-6;Aspartate aminotransferase;PrThr;Pt;Body fld;Ord;;CHEM;1;Aspartate aminotransferase [Presence] in Body fluid;AST Fld Ql;;ACTIVE;2.17;2.73 +43823-4;Aspergillus glaucus Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus glaucus Ab [Presence] in Serum by Immune diffusion (ID);A glaucus Ab Ser Ql ID;;ACTIVE;2.17;2.73 +43824-2;Bilirubin;PrThr;Pt;Body fld;Ord;;CHEM;1;Bilirubin.total [Presence] in Body fluid;Bilirub Fld Ql;;ACTIVE;2.17;2.73 +43825-9;Arsenic;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Arsenic [Presence] in Gastric fluid;Arsenic Gast Ql;;ACTIVE;2.17;2.56 +43826-7;Androstanolone;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Androstanolone [Presence] in Serum or Plasma;Androstanolone SerPl Ql;;ACTIVE;2.17;2.56 +43827-5;Barbiturates;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Barbiturates [Mass/volume] in Specimen;Barbiturates Spec-mCnc;;ACTIVE;2.17;2.73 +4382-8;Penicillin V potassium;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Penicillin V potassium [Mass] of Dose;Penicillin V Potassium Dose;;ACTIVE;1.0;2.69 +43828-3;Benzodiazepines;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Specimen;Benzodiaz Spec Ql;;ACTIVE;2.17;2.73 +43829-1;Caffeine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Caffeine [Presence] in Specimen;Caffeine Spec Ql;;ACTIVE;2.17;2.69 +43830-9;Nicotine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Nicotine [Presence] in Specimen;Nicotine Spec Ql;;ACTIVE;2.17;2.73 +43831-7;Phenytoin;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Phenytoin [Presence] in Specimen;Phenytoin Spec Ql;;ACTIVE;2.17;2.69 +43832-5;quiNIDine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;quiNIDine [Presence] in Specimen;quiNIDine Spec Ql;;ACTIVE;2.17;2.69 +43833-3;quiNINE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;quiNINE [Presence] in Specimen;quiNINE Spec Ql;;ACTIVE;2.17;2.69 +43834-1;Tetrahydrocannabinol;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Specimen;THC Spec Ql;;ACTIVE;2.17;2.73 +43835-8;Apolipoprotein E;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Apolipoprotein E [Presence] in Serum or Plasma;Apo E SerPl Ql;;ACTIVE;2.17;2.56 +4383-6;Pentazocine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pentazocine [Mass] of Dose;Pentazocine Dose;;ACTIVE;1.0;2.69 +43836-6;Beta globulin;PrThr;Pt;Ser/Plas;Ord;Electrophoresis;CHEM;1;Beta globulin [Presence] in Serum or Plasma by Electrophoresis;B-Globulin SerPl Ql Elph;;ACTIVE;2.17;2.73 +43837-4;Influenza virus A Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A IgG Ab [Presence] in Serum;FLUAV IgG Ser Ql;;ACTIVE;2.17;2.73 +43838-2;Influenza virus A Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A IgM Ab [Presence] in Serum;FLUAV IgM Ser Ql;;ACTIVE;2.17;2.73 +43839-0;Influenza virus B Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus B IgG Ab [Presence] in Serum;FLUBV IgG Ser Ql;;ACTIVE;2.17;2.73 +43840-8;Influenza virus B Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus B IgM Ab [Presence] in Serum;FLUBV IgM Ser Ql;;ACTIVE;2.17;2.73 +43841-6;Betula populifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White Birch IgE Ab RAST class [Presence] in Serum;White Birch IgE RAST Ql;;ACTIVE;2.17;2.73 +43842-4;Borrelia burgdorferi Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi Ab [Titer] in Serum by Immunoassay;B burgdor Ab Titr Ser IA;;ACTIVE;2.17;2.56 +43843-2;Brucella abortus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella abortus IgG Ab [Units/volume] in Serum by Immunoassay;B abortus IgG Ser IA-aCnc;;ACTIVE;2.17;2.69 +4384-4;Pentetrazol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pentetrazol [Mass] of Dose;Pentetrazol Dose;;ACTIVE;1.0;2.69 +43844-0;Chlamydophila pneumoniae Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunofluorescence;C pneum IgM Ser Ql IF;;ACTIVE;2.17;2.56 +43845-7;Chlamydophila pneumoniae Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila pneumoniae Ab [Titer] in Serum by Immunofluorescence;C pneum Ab Titr Ser IF;;ACTIVE;2.17;2.32 +43846-5;Chlamydophila sp Ab;Imp;Pt;Ser;Nom;;MICRO;1;Chlamydophila sp Ab [Interpretation] in Serum;Chlamydophila Ab Ser-Imp;;ACTIVE;2.17;2.17 +43847-3;Chlamydophila sp Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Chlamydophila sp Ab [Presence] in Serum by Immunofluorescence;Chlamydophila Ab Ser Ql IF;;ACTIVE;2.17;2.56 +43848-1;Chlamydia trachomatis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis IgG Ab [Presence] in Serum;C trach IgG Ser Ql;;ACTIVE;2.17;2.56 +43849-9;Coccidioides sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coccidioides sp IgG Ab [Presence] in Serum by Immunoassay;Coccidioides IgG Ser Ql IA;;ACTIVE;2.17;2.56 +43850-7;Coccidioides sp Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coccidioides sp IgM Ab [Presence] in Serum by Immunoassay;Coccidioides IgM Ser Ql IA;;ACTIVE;2.17;2.56 +4385-1;PENTobarbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;PENTobarbital [Mass] of Dose;Pentobarb Dose;;ACTIVE;1.0;2.69 +43851-5;Influenza virus A Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A IgA Ab [Presence] in Serum;FLUAV IgA Ser Ql;;ACTIVE;2.17;2.56 +43852-3;Influenza virus B Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus B IgA Ab [Presence] in Serum;FLUBV IgA Ser Ql;;ACTIVE;2.17;2.56 +43853-1;Legionella pneumophila 1+3+4+5+6+8 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 1+3+4+5+6+8 IgM Ab [Presence] in Serum;L pneumo 1+3+4+5+6+8 IgM Ser Ql;;ACTIVE;2.17;2.56 +43854-9;Mycobacterium sp rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium sp rRNA [Presence] in Specimen by Probe;Mycobacterium rRNA Spec Ql Probe;;ACTIVE;2.17;2.73 +43855-6;Urease^2H post incubation;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --2 hours post incubation;Urease 2h p Inc Tiss Ql;;ACTIVE;2.17;2.56 +43856-4;Cells.CD3+CD25+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD25+ cells/100 cells in Body fluid;CD3+CD25+ Cells NFr Fld;;ACTIVE;2.17;2.70 +43857-2;Benztropine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Benztropine [Presence] in Serum or Plasma;Benztropine SerPl Ql;;ACTIVE;2.17;2.56 +43858-0;Beta-2 transferrin;PrThr;Pt;XXX;Ord;;CHEM;1;Beta-2 transferrin [Presence] in Specimen;B2 Transferrin Spec Ql;;ACTIVE;2.17;2.73 +43859-8;Bolasterone;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Bolasterone [Presence] in Specimen;Bolasterone Spec Ql;;ACTIVE;2.17;2.69 +43860-6;Amphetamine+Methamphetamine;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Amphetamine+Methamphetamine [Presence] in Gastric fluid by Screen method;Amphet+Methamphet Gast Ql Scn;;ACTIVE;2.17;2.56 +43861-4;Asialoganglioside GM1 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Asialoganglioside GM1 Ab [Presence] in Serum;GM1 Asialo Ab Ser Ql;;ACTIVE;2.17;2.56 +43862-2;Aspergillus sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus sp IgE Ab RAST class [Presence] in Serum;Aspergillus IgE RAST Ql;;ACTIVE;2.17;2.73 +43863-0;Benzthiazide;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Benzthiazide [Presence] in 24 hour Urine;Benzthiazide 24h Ur Ql;;ACTIVE;2.17;2.56 +43864-8;Blastomyces dermatitidis Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Blastomyces dermatitidis IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;B dermat IgG CSF Ql IA;;ACTIVE;2.17;2.56 +43865-5;Blastomyces dermatitidis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Blastomyces dermatitidis IgG Ab [Presence] in Serum by Immunoassay;B dermat IgG Ser Ql IA;;ACTIVE;2.17;2.56 +43866-3;Bartonella sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella sp Ab [Presence] in Serum;Bartonella Ab Ser Ql;;ACTIVE;2.17;2.73 +43867-1;Beta-2 transferrin;PrThr;Pt;Ser;Ord;;CHEM;1;Beta-2 transferrin [Presence] in Serum;B2 Transferrin Ser Ql;;ACTIVE;2.17;2.73 +43868-9;Chlamydophila psittaci Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila psittaci IgG Ab [Presence] in Serum;C psittaci IgG Ser Ql;;ACTIVE;2.17;2.73 +4386-9;Perphenazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Perphenazine [Mass] of Dose;Perphenazine Dose;;ACTIVE;1.0;2.69 +43869-7;Antithrombin Ag;PrThr;Pt;PPP;Ord;IA;COAG;1;Antithrombin Ag [Presence] in Platelet poor plasma by Immunoassay;AT III Ag PPP Ql IA;;ACTIVE;2.17;2.73 +43870-5;Aspergillus sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Aspergillus sp Ab [Presence] in Serum by Complement fixation;Aspergillus Ab Ser Ql CF;;ACTIVE;2.17;2.73 +43871-3;Aspergillus sp Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus sp IgA Ab [Presence] in Serum;Aspergillus IgA Ser Ql;;ACTIVE;2.17;2.56 +43872-1;Aspergillus sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus sp IgG Ab [Presence] in Serum;Aspergillus IgG Ser Ql;;ACTIVE;2.17;2.56 +43873-9;Aspergillus sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus sp IgM Ab [Presence] in Serum;Aspergillus IgM Ser Ql;;ACTIVE;2.17;2.56 +43874-7;Influenza virus A Ag;PrThr;Pt;Nph;Ord;;MICRO;1;Influenza virus A Ag [Presence] in Nasopharynx;FLUAV Ag Nph Ql;;ACTIVE;2.17;2.73 +43875-4;Basement membrane Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Basement membrane IgM Ab [Presence] in Serum;BM IgM Ser Ql;;ACTIVE;2.17;2.56 +43876-2;Antimony;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Antimony [Presence] in 24 hour Urine;Antimony 24h Ur Ql;;ACTIVE;2.17;2.56 +4387-7;Phenacetin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenacetin [Mass] of Dose;Phenac Dose;;ACTIVE;1.0;2.69 +43877-0;Bile acid;PrThr;Pt;Ser;Ord;;CHEM;1;Bile acid [Presence] in Serum;Bile Ac Ser Ql;;ACTIVE;2.17;2.73 +43878-8;Bismuth;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Bismuth [Presence] in 24 hour Urine;Bismuth 24h Ur Ql;;ACTIVE;2.17;2.56 +43879-6;Bordetella parapertussis;PrThr;Pt;Nph;Ord;Organism specific culture;MICRO;1;Bordetella parapertussis [Presence] in Nasopharynx by Organism specific culture;B parapert Nph Ql Cult;;ACTIVE;2.17;2.56 +43880-4;Bordetella pertussis.filamentous hemagglutinin Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgA Ab [Presence] in Serum;B pert FHA IgA Ser Ql;;ACTIVE;2.17;2.73 +43881-2;Bordetella pertussis.filamentous hemagglutinin Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgG Ab [Presence] in Serum;B pert FHA IgG Ser Ql;;ACTIVE;2.17;2.73 +43882-0;Bordetella pertussis.filamentous hemagglutinin Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgM Ab [Presence] in Serum;B pert FHA IgM Ser Ql;;ACTIVE;2.17;2.73 +43883-8;Ampicillin;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ampicillin [Presence] in Serum or Plasma;Ampicillin SerPl Ql;;ACTIVE;2.17;2.56 +43884-6;Ampicillin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ampicillin [Presence] in Urine;Ampicillin Ur Ql;;ACTIVE;2.17;2.56 +4388-5;Phenazocine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenazocine [Mass] of Dose;Phenazocine Dose;;ACTIVE;1.0;2.69 +43885-3;Beryllium;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Beryllium [Presence] in Specimen;Beryllium Spec Ql;;ACTIVE;2.17;2.69 +43886-1;Bismuth;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Bismuth [Presence] in Specimen;Bismuth Spec Ql;;ACTIVE;2.17;2.69 +43887-9;Bilirubin;PrThr;Pt;Amnio fld;Ord;Direct spectrophotometry;CHEM;1;Bilirubin.total [Presence] in Amniotic fluid by Spectrophotometry direct;Bilirub Amn Ql Spectrp dir;;ACTIVE;2.17;2.56 +43888-7;Bile acid;PrThr;Pt;Bil fld;Ord;;CHEM;1;Bile acid [Presence] in Bile fluid;Bile Ac Bifl Ql;;ACTIVE;2.17;2.56 +43889-5;Bile acid;PrThr;Pt;Urine;Ord;;CHEM;1;Bile acid [Presence] in Urine;Bile Ac Ur Ql;;ACTIVE;2.17;2.73 +43890-3;Bordetella pertussis;PrThr;Pt;Sputum;Ord;Organism specific culture;MICRO;1;Bordetella pertussis [Presence] in Sputum by Organism specific culture;B pert Spt Ql Cult;;ACTIVE;2.17;2.56 +43891-1;Bordetella pertussis Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Bordetella pertussis Ag [Presence] in Sputum by Immunofluorescence;B pert Ag Spt Ql IF;;ACTIVE;2.17;2.56 +43892-9;Borate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Borate [Presence] in Blood;Borate Bld Ql;;ACTIVE;2.17;2.56 +4389-3;Phencyclidine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phencyclidine [Mass] of Dose;PCP Dose;;ACTIVE;1.0;2.69 +43893-7;Babesia microti Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia microti IgG Ab [Presence] in Serum;B microti IgG Ser Ql;;ACTIVE;2.17;2.73 +43894-5;Bismuth;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Bismuth [Presence] in Serum or Plasma;Bismuth SerPl Ql;;ACTIVE;2.17;2.56 +43895-2;Influenza virus B Ag;PrThr;Pt;Nph;Ord;;MICRO;1;Influenza virus B Ag [Presence] in Nasopharynx;FLUBV Ag Nph Ql;;ACTIVE;2.17;2.73 +43896-0;Bordetella pertussis;PrThr;Pt;Plr fld;Ord;Organism specific culture;MICRO;1;Bordetella pertussis [Presence] in Pleural fluid by Organism specific culture;B pert Plr Ql Cult;;ACTIVE;2.17;2.56 +43897-8;Baclofen;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Baclofen [Presence] in Serum or Plasma;Baclofen SerPl Ql;;ACTIVE;2.17;2.56 +43898-6;Beta hydroxybutyrate;PrThr;24H;Urine;Ord;;CHEM;1;Beta hydroxybutyrate [Presence] in 24 hour Urine;B-OH-Butyr 24h Ur Ql;;ACTIVE;2.17;2.56 +43899-4;Beta lipotropin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Beta lipotropin [Presence] in Serum or Plasma;B-Lipotropin SerPl Ql;;ACTIVE;2.17;2.56 +439-0;Rosoxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Rosoxacin [Susceptibility] by Minimum lethal concentration (MLC);Rosoxacin Islt MLC;;ACTIVE;1.0;2.19 +43900-0;Blastomyces dermatitidis Ab;PrThr;Pt;CSF;Ord;Comp fix;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Cerebral spinal fluid by Complement fixation;B dermat Ab CSF Ql CF;;ACTIVE;2.17;2.56 +4390-1;Phendimetrazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phendimetrazine [Mass] of Dose;Phendimetrazine Dose;;ACTIVE;1.0;2.69 +43901-8;Barium;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Barium [Presence] in 24 hour Urine;Barium 24h Ur Ql;;ACTIVE;2.17;2.56 +43902-6;Azinphos-methyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Azinphos-methyl [Presence] in Blood;Azinphos-Mehyl Bld Ql;;ACTIVE;2.17;2.56 +43903-4;Azinphos-methyl;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Azinphos-methyl [Presence] in Serum or Plasma;Azinphos-Mehyl SerPl Ql;;ACTIVE;2.17;2.56 +43904-2;Azinphos-methyl;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Azinphos-methyl [Presence] in Urine;Azinphos-Mehyl Ur Ql;;ACTIVE;2.17;2.56 +43905-9;Arbovirus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Arbovirus IgG Ab [Presence] in Serum;Arbovirus IgG Ser Ql;;ACTIVE;2.17;2.56 +43906-7;Anserine;PrThr;Pt;Urine;Ord;;CHEM;1;Anserine [Presence] in Urine;Anserine Ur Ql;;ACTIVE;2.17;2.56 +43907-5;Argininosuccinate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Argininosuccinate [Presence] in Serum or Plasma;Argininosuccinate SerPl Ql;;ACTIVE;2.17;2.56 +43908-3;Avian encephalomyelitis virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Avian encephalomyelitis virus Ab [Presence] in Cerebral spinal fluid;AEV Ab CSF Ql;;ACTIVE;2.17;2.56 +43909-1;Bordetella pertussis Ag;PrThr;Pt;Nph;Ord;;MICRO;1;Bordetella pertussis Ag [Presence] in Nasopharynx;B pert Ag Nph Ql;;ACTIVE;2.17;2.56 +43910-9;Ascaris sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Ascaris sp IgM Ab [Presence] in Serum;Ascaris IgM Ser Ql;;ACTIVE;2.17;2.56 +43911-7;Aspergillus versicolor Ab;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus versicolor Ab [Presence] in Serum;A versicolor Ab Ql;;ACTIVE;2.17;2.56 +43912-5;Bisacodyl;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Bisacodyl [Presence] in Urine;Bisacodyl Ur Ql;;ACTIVE;2.17;2.56 +43913-3;Bordetella pertussis DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis DNA [Presence] in Nasopharynx by NAA with probe detection;B pert DNA Nph Ql NAA+probe;;ACTIVE;2.17;2.73 +43914-1;Beta 2 glycoprotein 1 Ab.IgG;PrThr;Pt;Ser;Ord;;COAG;1;Beta 2 glycoprotein 1 IgG Ab [Presence] in Serum;B2 Glycoprot1 IgG Ser Ql;;ACTIVE;2.17;2.73 +43915-8;Beta 2 glycoprotein 1 Ab.IgA;PrThr;Pt;Ser;Ord;;COAG;1;Beta 2 glycoprotein 1 IgA Ab [Presence] in Serum;B2 Glycoprot1 IgA Ser Ql;;ACTIVE;2.17;2.73 +43916-6;Beta 2 glycoprotein 1 Ab.IgM;PrThr;Pt;Ser;Ord;;COAG;1;Beta 2 glycoprotein 1 IgM Ab [Presence] in Serum;B2 Glycoprot1 IgM Ser Ql;;ACTIVE;2.17;2.73 +43917-4;Benzene;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Benzene [Presence] in Urine;Benzene Ur Ql;;ACTIVE;2.17;2.56 +43918-2;Babesia microti Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia microti Ab [Presence] in Serum;B microti Ab Ser Ql;;ACTIVE;2.17;2.73 +4391-9;Pheniramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pheniramine [Mass] of Dose;Pheniramine Dose;;ACTIVE;1.0;2.69 +43919-0;Beta-2-Microglobulin;PrThr;Pt;CSF;Ord;;CHEM;1;Beta-2-Microglobulin [Presence] in Cerebral spinal fluid;B2 Microglob CSF Ql;;ACTIVE;2.17;2.73 +43920-8;Bartonella sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella sp IgG Ab [Presence] in Serum;Bartonella IgG Ser Ql;;ACTIVE;2.17;2.56 +43921-6;Bartonella sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Bartonella sp IgM Ab [Presence] in Serum;Bartonella IgM Ser Ql;;ACTIVE;2.17;2.56 +43922-4;Beta endorphin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Beta endorphin [Presence] in Serum or Plasma;B-Endorphin SerPl Ql;;ACTIVE;2.17;2.56 +43923-2;Beta hydroxybutyrate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Beta hydroxybutyrate [Presence] in Serum or Plasma;B-OH-Butyr SerPl Ql;;ACTIVE;2.17;2.56 +43924-0;azaTHIOprine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;azaTHIOprine [Presence] in Serum or Plasma;azaTHIOprine SerPl Ql;;ACTIVE;2.17;2.56 +43925-7;Bordetella parapertussis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bordetella parapertussis [Presence] in Specimen by Organism specific culture;B parapert Spec Ql Cult;;ACTIVE;2.17;2.69 +43926-5;Babesia sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia sp Ab [Presence] in Serum;Babesia Ab Ser Ql;;ACTIVE;2.17;2.56 +4392-7;Phenmetrazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenmetrazine [Mass] of Dose;Phenmetrazine Dose;;ACTIVE;1.0;2.69 +43927-3;Arginine;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Arginine [Presence] in DBS;Arginine DBS Ql;;ACTIVE;2.17;2.73 +43928-1;Coxiella burnetii phase 2 Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Presence] in Serum by Immunofluorescence;C burnet Ph2 IgM Ser Ql IF;;ACTIVE;2.17;2.73 +43929-9;Anthraquinone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Anthraquinone [Mass/volume] in Urine;Anthraquinone Ur-mCnc;;ACTIVE;2.17;2.34 +43930-7;Yersinia enterocolitica Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Yersinia enterocolitica Ab [Presence] in Cerebral spinal fluid;Y enterocol Ab CSF Ql;;ACTIVE;2.17;2.56 +43931-5;California encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;California encephalitis virus Ab [Titer] in Serum;CEV Ab Titr Ser;;ACTIVE;2.17;2.68 +43932-3;Rheumatoid factor;Titr;Pt;Body fld;Qn;;SERO;1;Rheumatoid factor [Titer] in Body fluid;Rheumatoid fact Titr Fld;;ACTIVE;2.17;2.73 +43933-1;Cathine;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;Cathine [Mass/mass] in Meconium;Cathine Mec-mCnt;;ACTIVE;2.17;2.70 +43934-9;Amphetamines;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Amphetamines [Mass/mass] in Meconium by Confirmatory method;Amphetamines Mec Cfm-mCnt;;ACTIVE;2.17;2.73 +4393-5;PHENobarbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;PHENobarbital [Mass] of Dose;Phenobarb Dose;;ACTIVE;1.0;2.73 +43935-6;Cells.CD55/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD55 cells/100 cells in Body fluid;CD55 Cells NFr Fld;;ACTIVE;2.17;2.40 +43936-4;Cells.CD55/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD55 cells/100 cells in Tissue;CD55 Cells NFr Tiss;;ACTIVE;2.17;2.40 +43937-2;Cells.CD59/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD59 cells/100 cells in Tissue;CD59 Cells NFr Tiss;;ACTIVE;2.17;2.40 +43938-0;Cells.CD59/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD59 cells/100 cells in Body fluid;CD59 Cells NFr Fld;;ACTIVE;2.17;2.40 +43939-8;Alkaline phosphatase.liver;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Alkaline phosphatase.liver [Presence] in Serum or Plasma;ALP Liver SerPl Ql;;ACTIVE;2.17;2.73 +43940-6;Immunoglobulin light chains.kappa.free;MCnc;24H;Urine;Qn;;CHEM;1;Kappa light chains.free [Mass/volume] in 24 hour Urine;Kappa LC Free 24h Ur-mCnc;;ACTIVE;2.17;2.73 +43941-4;Agrostis stolonifera Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Red top grass IgE Ab/IgE total in Serum;Red top grass IgE/IgE total %;;ACTIVE;2.17;2.70 +43942-2;Insulin.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin Free [Mass/volume] in Serum or Plasma;Insulin Free SerPl-mCnc;;ACTIVE;2.17;2.73 +4394-3;Phenothiazines;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenothiazines [Mass] of Dose;Phenothiaz Dose;;ACTIVE;1.0;2.69 +43943-0;Cat epithelium Ab.IgE;Ratio;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cat epithelium IgE Ab [Ratio] in Serum;Deprecated Cat Epith IgE-Rto;;DEPRECATED;2.17;2.70 +43944-8;Cells.CD4+CD45+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD4+CD45+ cells/100 cells in Bone marrow;CD4+CD45+ Cells NFr Mar;;ACTIVE;2.17;2.40 +43945-5;Cells.CD4+CD45RO+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD45RO+ cells/100 cells in Body fluid;CD4+CD45RO+ Cells NFr Fld;;ACTIVE;2.17;2.40 +43946-3;Cells.CD4+CD45RO+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD4+CD45RO+ cells/100 cells in Cerebral spinal fluid;CD4+CD45RO+ Cells NFr CSF;;ACTIVE;2.17;2.40 +43947-1;Cells.CD4+CD45+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD4+CD45+ cells/100 cells in Tissue;CD4+CD45+ Cells NFr Tiss;;ACTIVE;2.17;2.70 +43948-9;Cells.CD4+CD45RO+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD4+CD45RO+ cells/100 cells in Specimen;CD4+CD45RO+ Cells NFr Spec;;ACTIVE;2.17;2.69 +43949-7;Cells.CD2;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD2 cells [#/volume] in Cerebral spinal fluid;CD2 Cells # CSF;;ACTIVE;2.17;2.70 +4395-0;Phensuximide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phensuximide [Mass] of Dose;Phensuximide Dose;;ACTIVE;1.0;2.69 +43950-5;Cells.CD2;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD2 cells [#/volume] in Body fluid;CD2 Cells # Fld;;ACTIVE;2.17;2.70 +43951-3;Cells.CD2;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD2 cells [#/volume] in Tissue;CD2 Cells # Tiss;;ACTIVE;2.17;2.70 +43952-1;Cells.CD4+CD45RO+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD4+CD45RO+ cells [#/volume] in Bone marrow;CD4+CD45RO+ Cells # Mar;;ACTIVE;2.17;2.70 +43953-9;Cells.CD4+CD45RO+;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD4+CD45RO+ cells [#/volume] in Cerebral spinal fluid;CD4+CD45RO+ Cells # CSF;;ACTIVE;2.17;2.70 +43954-7;Cells.CD4+CD45RO+;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD45RO+ cells [#/volume] in Body fluid;CD4+CD45RO+ Cells # Fld;;ACTIVE;2.17;2.70 +43955-4;Cells.CD4+CD45RO+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD4+CD45RO+ cells [#/volume] in Tissue;CD4+CD45RO+ Cells # Tiss;;ACTIVE;2.17;2.70 +43956-2;Cells.CD4+CD45RO+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD4+CD45RO+ cells [#/volume] in Specimen;CD4+CD45RO+ Cells # Spec;;ACTIVE;2.17;2.70 +43957-0;Cells.CD3+HLA-DR+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3+HLA-DR+ cells [#/volume] in Bone marrow;CD3+HLA-DR+ Cells # Mar;;ACTIVE;2.17;2.70 +43958-8;Cells.CD3+HLA-DR+;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD3+HLA-DR+ cells [#/volume] in Cerebral spinal fluid;CD3+HLA-DR+ Cells # CSF;;ACTIVE;2.17;2.70 +43959-6;Cells.CD3+HLA-DR+;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD3+HLA-DR+ cells [#/volume] in Body fluid;CD3+HLA-DR+ Cells # Fld;;ACTIVE;2.17;2.70 +43960-4;Cells.CD3+HLA-DR+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3+HLA-DR+ cells [#/volume] in Tissue;CD3+HLA-DR+ Cells # Tiss;;ACTIVE;2.17;2.70 +43961-2;Cells.CD3+HLA-DR+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD3+HLA-DR+ cells [#/volume] in Specimen;CD3+HLA-DR+ Cells # Spec;;ACTIVE;2.17;2.70 +43962-0;Cells.CD4+CD45RA+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD4+CD45RA+ cells/100 cells in Bone marrow;CD4+CD45RA+ Cells NFr Mar;;ACTIVE;2.17;2.40 +43963-8;Cells.CD4+CD45RA+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD4+CD45RA+ cells/100 cells in Cerebral spinal fluid;CD4+CD45RA+ Cells NFr CSF;;ACTIVE;2.17;2.70 +43964-6;Cells.CD4+CD45RA+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD45RA+ cells/100 cells in Body fluid;CD4+CD45RA+ Cells NFr Fld;;ACTIVE;2.17;2.40 +43965-3;Cells.CD4+CD45RA+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD4+CD45RA+ cells/100 cells in Tissue;CD4+CD45RA+ Cells NFr Tiss;;ACTIVE;2.17;2.70 +43966-1;Cells.CD4+CD45RA+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD4+CD45RA+ cells/100 cells in Specimen;CD4+CD45RA+ Cells NFr Spec;;ACTIVE;2.17;2.70 +43967-9;Cells.CD3+CD25+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD25+ cells/100 cells in Cerebral spinal fluid;CD3+CD25+ Cells NFr CSF;;ACTIVE;2.17;2.70 +4396-8;Phentermine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phentermine [Mass] of Dose;Phentermine Dose;;ACTIVE;1.0;2.69 +43968-7;Cells.CD3+HLA-DR+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+HLA-DR+ cells/100 cells in Cerebral spinal fluid;CD3+HLA-DR+ Cells NFr CSF;;ACTIVE;2.17;2.40 +43969-5;Cells.CD3+CD25+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD25+ cells [#/volume] in Tissue;CD3+CD25+ Cells # Tiss;;ACTIVE;2.17;2.70 +43970-3;Cells.CD3+CD4+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 cells in Cerebral spinal fluid;CD3+CD4+ Cells NFr CSF;;ACTIVE;2.17;2.40 +43971-1;Cells.CD3+CD8+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells/100 cells in Cerebral spinal fluid;CD3+CD8+ Cells NFr CSF;;ACTIVE;2.17;2.72 +43972-9;Cells.CD19;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD19 cells [#/volume] in Cerebral spinal fluid;CD19 Cells # CSF;;ACTIVE;2.17;2.70 +43973-7;Zinc;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Zinc [Moles/volume] in Specimen;Zinc Spec-sCnc;;ACTIVE;2.17;2.69 +43974-5;Coccidioides sp Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Coccidioides sp Ab [Presence] in Serum by Immune diffusion (ID);Coccidioides Ab Ser Ql ID;;ACTIVE;2.17;2.73 +43975-2;Aprobarbital;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Aprobarbital [Presence] in Specimen;Aprobarbital Spec Ql;;ACTIVE;2.17;2.69 +4397-6;Phenylbutazone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenylbutazone [Mass] of Dose;Phenylbutazone Dose;;ACTIVE;1.0;2.69 +43976-0;Measles virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Measles virus Ab [Presence] in Serum by Immunoassay;MeV Ab Ser Ql IA;;ACTIVE;2.17;2.73 +43977-8;Anabolic steroids;PrThr;Pt;Urine;Ord;;CHEM;1;Anabolic steroids [Presence] in Urine;Anabolic Steroids Ur Ql;;ACTIVE;2.17;2.56 +43978-6;Varicella zoster virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Varicella zoster virus Ab [Presence] in Serum by Immunoassay;VZV Ab Ser Ql IA;;ACTIVE;2.17;2.56 +43979-4;Aspergillus sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Aspergillus sp identified in Specimen by Organism specific culture;Aspergillus Spec Cult;;ACTIVE;2.17;2.73 +43980-2;Rabies virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Rabies virus neutralizing antibody [Titer] in Serum by Neutralization test;RABV NAb Titr Ser Nt;;ACTIVE;2.17;2.72 +43981-0;Choriogonadotropin.intact^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.intact [Multiple of the median] adjusted in Serum or Plasma;HCG Intact adj MoM SerPl;;ACTIVE;2.17;2.70 +43982-8;Choriogonadotropin.intact;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.intact [Multiple of the median] in Serum or Plasma;HCG Intact MoM SerPl;;ACTIVE;2.17;2.70 +43983-6;Amphetamines;PrThr;Pt;Urine;Ord;Screen>500 ng/mL;DRUG/TOX;1;Amphetamines [Presence] in Urine by Screen method >500 ng/mL;Amphetamines Ur Ql Scn>500 ng/mL;;ACTIVE;2.17;2.73 +4398-4;Phenylephrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenylephrine [Mass] of Dose;Phenylephrine Dose;;ACTIVE;1.0;2.69 +43984-4;Benzoylecgonine;PrThr;Pt;Urine;Ord;Screen>150 ng/mL;DRUG/TOX;1;Benzoylecgonine [Presence] in Urine by Screen method >150 ng/mL;BZE Ur Ql Scn>150 ng/mL;;ACTIVE;2.17;2.73 +43985-1;Benzoylecgonine;PrThr;Pt;Urine;Ord;Screen>300 ng/mL;DRUG/TOX;1;Benzoylecgonine [Presence] in Urine by Screen method >300 ng/mL;BZE Ur Ql Scn>300 ng/mL;;ACTIVE;2.17;2.73 +43986-9;Clofazimine 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clofazimine 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clofazamine 2 ug/mL Islt SlowMyco;;ACTIVE;2.17;2.26 +43987-7;Clarithromycin 12.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clarithromycin 12 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clarithro 12 ug/mL Islt SlowMyco;;ACTIVE;2.17;2.26 +43988-5;Clofazimine 0.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clofazimine 0.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clofazamine 0.5 ug/mL Islt SlowMyco;;ACTIVE;2.17;2.26 +43989-3;Clofazimine 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clofazimine 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clofazamine 1 ug/mL Islt SlowMyco;;ACTIVE;2.17;2.26 +43990-1;Clarithromycin 3.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clarithromycin 3 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clarithro 3 ug/mL Islt SlowMyco;;ACTIVE;2.17;2.26 +43991-9;Clarithromycin 6.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Clarithromycin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Clarithro 6 ug/mL Islt SlowMyco;;ACTIVE;2.17;2.26 +4399-2;Phenylpropanolamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Phenylpropanolamine [Mass] of Dose;PPA Dose;;ACTIVE;1.0;2.69 +43992-7;Anaplasma phagocytophilum Ab;Imp;Pt;Ser;Nom;IF;MICRO;1;Anaplasma phagocytophilum Ab [Interpretation] in Serum by Immunofluorescence;A phagocytoph Ab Ser IF-Imp;;ACTIVE;2.17;2.73 +43993-5;Age.at delivery;Time;Pt;^Patient;Qn;;OB.US;2;Age at delivery;Age at delivery;;ACTIVE;2.17;2.73 +43994-3;Fetal trisomy 18 risk;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Trisomy 18 risk [Likelihood] in Fetus;Ts 18 risk Fetus;;ACTIVE;2.17;2.73 +43995-0;Fetal trisomy 21 risk;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Trisomy 21 risk [Likelihood] in Fetus;Ts 21 risk Fetus;;ACTIVE;2.17;2.73 +43996-8;Alpha-1-Fetoprotein^^adjusted for diabetes+weight;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] adjusted for diabetes+weight in Serum or Plasma;AFP Diabetes+wt adj MoM SerPl;;ACTIVE;2.17;2.42 +43997-6;Alpha-1-Fetoprotein^^adjusted for weight;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] adjusted for weight in Serum or Plasma;AFP Wt adj MoM SerPl;;ACTIVE;2.17;2.73 +43998-4;Alpha-1-Fetoprotein^^adjusted for diabetes;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] adjusted for diabetes in Serum or Plasma;AFP Diabetes adj MoM SerPl;;ACTIVE;2.17;2.73 +43999-2;Choriogonadotropin;MoM;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin [Multiple of the median] in Amniotic fluid;HCG MoM Amn;;ACTIVE;2.17;2.42 +44000-8;Choriogonadotropin;ACnc;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin [Units/volume] in Amniotic fluid;HCG Amn-aCnc;;ACTIVE;2.17;2.38 +44001-6;Choriogonadotropin;ACnc;Pt;CSF;Qn;;CHEM;1;Choriogonadotropin [Units/volume] in Cerebral spinal fluid;HCG CSF-aCnc;;ACTIVE;2.17;2.73 +44002-4;Choriogonadotropin^^adjusted;MoM;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin [Multiple of the median] adjusted in Amniotic fluid;HCG adj MoM Amn;;ACTIVE;2.17;2.42 +44003-2;Choriogonadotropin.beta subunit.free;MoM;Pt;Amnio fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Multiple of the median] in Amniotic fluid;B-HCG Free MoM Amn;;ACTIVE;2.17;2.42 +44004-0;Estriol.unconjugated;MoM;Pt;Amnio fld;Qn;;CHEM;1;Estriol (E3).unconjugated [Multiple of the median] in Amniotic fluid;u Estriol MoM Amn;;ACTIVE;2.17;2.73 +44005-7;Chlamydia trachomatis D & K Ab.IgA & IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Chlamydia trachomatis D and K IgA and IgG and IgM [Interpretation] in Serum;CT D and K IgA+IgG+IgM Ser-Imp;;ACTIVE;2.17;2.73 +44006-5;Coxiella burnetii phase 1 & 2 Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Coxiella burnetii phase 1 and 2 IgG and IgM [Interpretation] in Serum;C burnet Ph1 + Ph2 IgG+IgM Ser-Imp;;ACTIVE;2.17;2.73 +44007-3;Erythrocytes.CD55 & CD59;Imp;Pt;Bld;Nom;;CELLMARK;1;CD55 and CD59 RBC [Interpretation] in Blood;CD55 & CD59 RBC Bld-Imp;;ACTIVE;2.17;2.73 +4400-8;Phenytoin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Phenytoin [Mass] of Dose;Deprecated Phenytoin Dose;;DEPRECATED;1.0;2.69 +44008-1;Herpes simplex virus 1 & 2 Ab.IgM;Imp;Pt;Ser;Nom;;MICRO;1;Herpes simplex virus 1 and 2 IgM Ab [Interpretation] in Serum;HSV 1+2 IgM Ser-Imp;;ACTIVE;2.17;2.73 +44009-9;Herpes simplex virus 1 & 2 Ab.IgG;Imp;Pt;Ser;Nom;IA;MICRO;1;Herpes simplex virus 1 and 2 IgG Ab [Interpretation] in Serum by Immunoassay;HSV 1+2 IgG Ser IA-Imp;;ACTIVE;2.17;2.73 +44010-7;Influenza virus A & B Ab;Imp;Pt;Body fld;Nom;;MICRO;1;Influenza virus A and B Ab [Interpretation] in Body fluid;FLUAV + FLUBV Ab Fld-Imp;;ACTIVE;2.17;2.73 +44011-5;Measles virus Ab.IgG & IgM;Imp;Pt;CSF;Nom;;MICRO;1;Measles virus IgG and IgM [Interpretation] in Cerebral spinal fluid;MeV IgG+IgM CSF-Imp;;ACTIVE;2.17;2.73 +44012-3;Measles virus Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Measles virus IgG and IgM [Interpretation] in Serum;MeV IgG+IgM Ser-Imp;;ACTIVE;2.17;2.73 +44013-1;Metanephrine & Normetanephrine;Imp;Pt;Urine;Nom;;CHEM;1;Metanephrine and Normetanephrine [Interpretation] in Urine;Metaneph+Normetaneph Ur-Imp;;ACTIVE;2.17;2.73 +44014-9;Porphyrins;Imp;Pt;Urine;Nom;;CHEM;1;Porphyrins [Interpretation] in Urine;Porphyrins Ur-Imp;;ACTIVE;2.17;2.73 +44015-6;Helicobacter pylori;PrThr;Pt;Gast fld;Ord;Organism specific culture;MICRO;1;Helicobacter pylori [Presence] in Gastric fluid by Organism specific culture;H pylori Gast Ql Cult;;ACTIVE;2.17;2.73 +4401-6;Pholedrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pholedrine [Mass] of Dose;Pholedrine Dose;;ACTIVE;1.0;2.69 +44016-4;Bile;PrThr;Pt;Body fld;Ord;;CHEM;1;Bile [Presence] in Body fluid;Bile Fld Ql;;ACTIVE;2.17;2.56 +44017-2;Blasts;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Blasts [Presence] in Blood by Light microscopy;Blasts Bld Ql Smear;;ACTIVE;2.17;2.73 +44018-0;Basophils;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Basophils [Presence] in Body fluid by Light microscopy;Basophils Fld Ql Micro;;ACTIVE;2.17;2.56 +44019-8;Bordetella parapertussis Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Bordetella parapertussis Ab [Presence] in Body fluid;B parapert Ab Fld Ql;;ACTIVE;2.17;2.56 +44020-6;Borrelia burgdorferi Ab;PrThr;Pt;Synv fld;Ord;IB;MICRO;1;Borrelia burgdorferi Ab [Presence] in Synovial fluid by Immunoblot;B burgdor Ab Snv Ql IB;;ACTIVE;2.17;2.58 +44021-4;Coxiella burnetii Ab;Imp;Pt;Ser;Nom;;MICRO;1;Coxiella burnetii Ab [Interpretation] in Serum;C burnet Ab Ser-Imp;;ACTIVE;2.17;2.17 +44022-2;Bacteria;PrThr;Pt;Cvx;Ord;Wet preparation;MICRO;1;Bacteria [Presence] in Cervix by Wet preparation;Bacteria Cvx Ql Wet Prep;;ACTIVE;2.17;2.58 +44023-0;Bacteria;PrThr;Pt;Vag;Ord;Wet preparation;MICRO;1;Bacteria [Presence] in Vaginal fluid by Wet preparation;Bacteria Vag Ql Wet Prep;;ACTIVE;2.17;2.73 +4402-4;Pindolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pindolol [Mass] of Dose;Pindolol Dose;;ACTIVE;1.0;2.69 +44024-8;Boldenone;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Boldenone [Presence] in Specimen;Boldenone Spec Ql;;ACTIVE;2.17;2.69 +44025-5;Aspergillus flavus B Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus flavus B Ab [Presence] in Serum by Immune diffusion (ID);A flavus B Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44026-3;Aspergillus flavus H Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus flavus H Ab [Presence] in Serum by Immune diffusion (ID);A flavus H Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44027-1;Aspergillus fumigatus B Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus fumigatus B Ab [Presence] in Serum by Immune diffusion (ID);A fumigatus B Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44028-9;Aspergillus fumigatus H Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus fumigatus H Ab [Presence] in Serum by Immune diffusion (ID);A fumigatus H Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44029-7;Aspergillus nidulans B Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus nidulans B Ab [Presence] in Serum by Immune diffusion (ID);A nidulans B Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44030-5;Aspergillus nidulans H Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus nidulans H Ab [Presence] in Serum by Immune diffusion (ID);A nidulans H Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44031-3;Aspergillus niger B Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus niger B Ab [Presence] in Serum by Immune diffusion (ID);A niger B Ab Ser Ql ID;;ACTIVE;2.17;2.56 +4403-2;Piperacillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Piperacillin [Mass] of Dose;Piperacillin Dose;;ACTIVE;1.0;2.69 +44032-1;Aspergillus niger H Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus niger H Ab [Presence] in Serum by Immune diffusion (ID);A niger H Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44033-9;Bilirubin;PrThr;24H;Urine;Ord;Test strip;UA;1;Bilirubin.total [Presence] in 24 hour Urine by Test strip;Bilirub 24h Ur Ql Strip;;ACTIVE;2.17;2.73 +44034-7;Bile canalicular Ab;PrThr;Pt;Ser;Ord;;SERO;1;Bile canalicular Ab [Presence] in Serum;Bile canalicular Ab Ser Ql;;ACTIVE;2.17;2.56 +44035-4;Analgesics.non-narcotic;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Analgesics Non-narcotic [Presence] in Serum or Plasma;Analgesics Non-narcotic SerPl Ql;;ACTIVE;2.17;2.56 +44036-2;Analgesics.non-narcotic;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Analgesics Non-narcotic [Presence] in Urine;Analgesics Non-narcotic Ur Ql;;ACTIVE;2.17;2.73 +44037-0;Glucosylceramidase;PrThr;Pt;Bld;Ord;;CHEM;1;Glucosylceramidase [Presence] in Blood;Glucosylceramidase Bld Ql;;ACTIVE;2.17;2.73 +44038-8;Bacteria;PrThr;Pt;XXX;Ord;;MICRO;1;Bacteria [Presence] in Specimen;Bacteria Spec Ql;;ACTIVE;2.17;2.73 +44039-6;Bacteria;PrThr;Pt;Eye;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Eye by Light microscopy;Bacteria Eye Ql Micro;;ACTIVE;2.17;2.56 +4404-0;Pipradrol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pipradrol [Mass] of Dose;Pipradrol Dose;;ACTIVE;1.0;2.69 +44040-4;Basophils;PrThr;Pt;CSF;Ord;Microscopy.light;HEM/BC;1;Basophils [Presence] in Cerebral spinal fluid by Light microscopy;Basophils CSF Ql Micro;;ACTIVE;2.17;2.56 +44041-2;Basophils;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Basophils [Presence] in Synovial fluid by Light microscopy;Basophils Snv Ql Micro;;ACTIVE;2.17;2.56 +44042-0;Basophils;PrThr;Pt;Pericard fld;Ord;Microscopy.light;HEM/BC;1;Basophils [Presence] in Pericardial fluid by Light microscopy;Basophils Pcar Ql Micro;;ACTIVE;2.17;2.56 +44043-8;Basophils;PrThr;Pt;Plr fld;Ord;Microscopy.light;HEM/BC;1;Basophils [Presence] in Pleural fluid by Light microscopy;Basophils Plr Ql Micro;;ACTIVE;2.17;2.56 +44044-6;Basophils;PrThr;Pt;Periton fld;Ord;Microscopy.light;HEM/BC;1;Basophils [Presence] in Peritoneal fluid by Light microscopy;Basophils Prt Ql Micro;;ACTIVE;2.17;2.56 +44045-3;Aspergillus fumigatus O Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus O Ab [Presence] in Serum;A fumigatus O Ab Ser Ql;;ACTIVE;2.17;2.56 +44046-1;Bordetella pertussis Higashi-Hama Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis Higashi-Hama Ab [Units/volume] in Serum;B pert Higashi-hama Ab Ser-aCnc;;ACTIVE;2.17;2.69 +44047-9;Bordetella pertussis Yamaguchi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Bordetella pertussis Yamaguchi Ab [Presence] in Serum;B pert Yamaguchi Ab Ser Ql;;ACTIVE;2.17;2.56 +44048-7;Basophils;PrThr;Pt;Nose;Ord;Microscopy.light;HEM/BC;1;Basophils [Presence] in Nose by Light microscopy;Basophils Nose Ql Micro;;ACTIVE;2.17;2.73 +44049-5;Tetrahydrocannabinol;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Serum or Plasma by Confirmatory method;THC SerPl Cfm-mCnc;;ACTIVE;2.17;2.42 +44050-3;Glucose phosphate isomerase;CCnt;Pt;RBC;Qn;;CHEM;1;Glucose phosphate isomerase [Enzymatic activity/mass] in Red Blood Cells;GPI RBC-cCnt;;ACTIVE;2.17;2.73 +44051-1;Adenylate kinase;CCnt;Pt;RBC;Qn;;CHEM;1;Adenylate kinase [Enzymatic activity/mass] in Red Blood Cells;Adenylate kinase RBC-cCnt;;ACTIVE;2.17;2.70 +44052-9;Phosphofructokinase;CCnt;Pt;Bld;Qn;;CHEM;1;Phosphofructokinase [Enzymatic activity/mass] in Blood;PFK Bld-cCnt;;ACTIVE;2.17;2.70 +44053-7;Phosphoglycerate kinase;CCnt;Pt;RBC;Qn;;CHEM;1;Phosphoglycerate kinase [Enzymatic activity/mass] in Red Blood Cells;PGK RBC-cCnt;;ACTIVE;2.17;2.70 +44054-5;Triosephosphate isomerase;CCnt;Pt;RBC;Qn;;CHEM;1;Triosephosphate isomerase [Enzymatic activity/mass] in Red Blood Cells;TPI RBC-cCnt;;ACTIVE;2.17;2.70 +44055-2;Pyrimidine-5'-Nucleotidase;CCnt;Pt;Bld;Qn;;CHEM;1;Pyrimidine-5'-Nucleotidase [Enzymatic activity/mass] in Blood;P5NT Bld-cCnt;;ACTIVE;2.17;2.70 +44056-0;Cells.CD4+CD45RA+CD45RB+CD45RC+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD4+CD45RA+CD45RB+CD45RC+ cells [#/volume] in Bone marrow;CD4+CD45RA+CD45RB+CD45RC+ Cells # Mar;;ACTIVE;2.17;2.70 +4405-7;Practolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Practolol [Mass] of Dose;Practolol Dose;;ACTIVE;1.0;2.69 +44057-8;Cells.CD4+CD45RA+CD45RB+CD45RC+;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD4+CD45RA+CD45RB+CD45RC+ cells [#/volume] in Cerebral spinal fluid;CD4+CD45RA+CD45RB+CD45RC+ Cells # CSF;;ACTIVE;2.17;2.70 +44058-6;Cells.CD4+CD45RA+CD45RB+CD45RC+;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD45RA+CD45RB+CD45RC+ cells [#/volume] in Body fluid;CD4+CD45RA+CD45RB+CD45RC+ Cells # Fld;;ACTIVE;2.17;2.70 +44059-4;Cells.CD4+CD45RA+CD45RB+CD45RC+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD4+CD45RA+CD45RB+CD45RC+ cells [#/volume] in Tissue;CD4+CD45RA+CD45RB+CD45RC+ Cells # Tiss;;ACTIVE;2.17;2.70 +44060-2;Cells.CD4+CD45RA+CD45RB+CD45RC+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD4+CD45RA+CD45RB+CD45RC+ cells [#/volume] in Specimen;CD4+CD45RA+CD45RB+CD45RC+ Cells # Spec;;ACTIVE;2.17;2.70 +44061-0;Cells.CD20+FMC7+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD20+FMC7+ cells/100 cells in Bone marrow;CD20+FMC7+ Cells NFr Mar;;ACTIVE;2.17;2.70 +44062-8;Cells.CD20+FMC7+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD20+FMC7+ cells/100 cells in Cerebral spinal fluid;CD20+FMC7+ Cells NFr CSF;;ACTIVE;2.17;2.70 +44063-6;Cells.CD20+FMC7+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD20+FMC7+ cells/100 cells in Body fluid;CD20+FMC7+ Cells NFr Fld;;ACTIVE;2.17;2.70 +44064-4;Cells.CD20+FMC7+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD20+FMC7+ cells/100 cells in Tissue;CD20+FMC7+ Cells NFr Tiss;;ACTIVE;2.17;2.70 +4406-5;Prazepam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Prazepam [Mass] of Dose;Prazepam Dose;;ACTIVE;1.0;2.69 +44065-1;Cells.CD20+FMC7+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD20+FMC7+ cells [#/volume] in Bone marrow;CD20+FMC7+ Cells # Mar;;ACTIVE;2.17;2.70 +44066-9;Cells.CD20+FMC7+;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD20+FMC7+ cells [#/volume] in Cerebral spinal fluid;CD20+FMC7+ Cells # CSF;;ACTIVE;2.17;2.42 +44067-7;Cells.CD20+FMC7+;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD20+FMC7+ cells [#/volume] in Body fluid;CD20+FMC7+ Cells # Fld;;ACTIVE;2.17;2.42 +44068-5;Cells.CD20+FMC7+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD20+FMC7+ cells [#/volume] in Tissue;CD20+FMC7+ Cells # Tiss;;ACTIVE;2.17;2.42 +44069-3;Cells.CD20+FMC7+;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD20+FMC7+ cells [#/volume] in Specimen;CD20+FMC7+ Cells # Spec;;ACTIVE;2.17;2.69 +44070-1;Cells.CD20+CD52+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD20+CD52+ cells/100 cells in Bone marrow;CD20+CD52+ Cells NFr Mar;;ACTIVE;2.17;2.70 +44071-9;Cells.CD20+CD52+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD20+CD52+ cells/100 cells in Cerebral spinal fluid;CD20+CD52+ Cells NFr CSF;;ACTIVE;2.17;2.70 +44072-7;Cells.CD20+CD52+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD20+CD52+ cells/100 cells in Body fluid;CD20+CD52+ Cells NFr Fld;;ACTIVE;2.17;2.70 +4407-3;Primidone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Primidone [Mass] of Dose;Primidone Dose;;ACTIVE;1.0;2.69 +44073-5;Cells.CD20+CD52+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD20+CD52+ cells/100 cells in Tissue;CD20+CD52+ Cells NFr Tiss;;ACTIVE;2.17;2.70 +44074-3;Arbovirus Ab;Imp;Pt;Ser;Nom;IF;MICRO;1;Arbovirus Ab [Interpretation] in Serum by Immunofluorescence;Arbovirus Ab Ser IF-Imp;;ACTIVE;2.17;2.73 +44075-0;Bilirubin casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Bilirubin casts [Presence] in Urine sediment by Light microscopy;Bilirubin Casts UrnS Ql Micro;;ACTIVE;2.17;2.56 +44076-8;Alpha tocopherol & Beta+gamma tocopherol;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Alpha tocopherol and Beta+gamma tocopherol [Interpretation] in Serum or Plasma;A & B+G Tocopherol SerPl-Imp;;ACTIVE;2.17;2.52 +44077-6;Brucella canis Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Brucella canis IgG and IgM [Interpretation] in Serum;B canis IgG+IgM Ser-Imp;;ACTIVE;2.17;2.38 +44078-4;Catecholamines;Imp;Pt;Urine;Nom;;CHEM;1;Catecholamines [Interpretation] in Urine;Catechols Ur-Imp;;ACTIVE;2.17;2.50 +44079-2;Chlamydia trachomatis Ab.IgA & IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Chlamydia trachomatis IgA and IgG and IgM [Interpretation] in Serum;C trach IgA+IgG+IgM Ser-Imp;;ACTIVE;2.17;2.73 +440-8;Rosoxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Rosoxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Rosoxacin Islt MIC;;ACTIVE;1.0;2.19 +44080-0;Chlamydophila pneumoniae Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Chlamydophila pneumoniae IgG and IgM [Interpretation] in Serum;C pneum IgG+IgM Ser-Imp;;ACTIVE;2.17;2.73 +4408-1;Probenecid;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Probenecid [Mass] of Dose;Probenecid Dose;;ACTIVE;1.0;2.69 +44081-8;Chlamydophila psittaci Ab.IgA & IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum;C psittaci IgA+IgG+IgM Ser-Imp;;ACTIVE;2.17;2.73 +44082-6;Cryoglobulin IgA & IgG & IgM;Imp;Pt;Ser;Nom;;CHEM;1;Cryoglobulin IgA and IgG and IgM [Interpretation] in Serum;Cryoglob IgA & IgG & IgM Ser-Imp;;ACTIVE;2.17;2.38 +44083-4;Extractable nuclear Ab;Imp;Pt;Ser;Nom;;SERO;1;Extractable nuclear Ab [Interpretation] in Serum;ENA Ab Ser-Imp;;ACTIVE;2.17;2.73 +44084-2;Fatty acids pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Fatty acids pattern [Interpretation] in Serum or Plasma;Fatty acids pattern SerPl-Imp;;ACTIVE;2.17;2.73 +44085-9;Xylose absorption;Imp;Pt;Urine+Ser/Plas;Nom;;CHAL;1;Xylose absorption [Interpretation] in Urine and Serum or Plasma;Xylose Absorption Ur+SerPl-Imp;;ACTIVE;2.17;2.38 +44086-7;ABO & Rh group;Imp;Pt;Bld^Newborn;Nom;;BLDBK;1;ABO and Rh group [Interpretation] in Blood from Newborn;ABO + Rh Bld NB-Imp;;ACTIVE;2.17;2.73 +44087-5;Escherichia coli O157 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Escherichia coli O157 Ag [Presence] in Specimen;E coli O157 Ag Spec Ql;;ACTIVE;2.17;2.73 +44088-3;Escherichia coli O157:H7 DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Escherichia coli O157:H7 DNA [Identifier] in Specimen by NAA with probe detection;E coli O157H7 DNA Spec NAA+probe;;ACTIVE;2.17;2.73 +44089-1;Escherichia coli O157:H7;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Escherichia coli O157:H7 [Identifier] in Specimen by Organism specific culture;E coli O157H7 Spec Cult;;ACTIVE;2.17;2.69 +44090-9;Escherichia coli O157:H7;PrThr;Pt;Isolate;Ord;Organism specific culture;MICRO;1;Escherichia coli O157:H7 [Presence] in Isolate by Organism specific culture;E coli O157H7 Islt Ql Cult;;ACTIVE;2.17;2.73 +44091-7;Influenza virus A hemagglutinin H5 RNA;ACnc;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Deprecated Influenza virus A hemagglutinin H5 RNA [Presence] in Unspecified specimen by Probe & target amplification method;Deprecated FLUAV HA H5 RNA XXX Ql PCR;;DEPRECATED;2.17;2.69 +44092-5;Leukocytes;Naric;Pt;Vag;Qn;Wet preparation;HEM/BC;1;Leukocytes [#/area] in Vaginal fluid by Wet preparation;WBC #/area Vag Wet Prep;;ACTIVE;2.17;2.73 +44093-3;Neisseria meningitidis;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Neisseria meningitidis [Identifier] in Isolate by Organism specific culture;N men Islt Cult;;ACTIVE;2.17;2.21 +44094-1;Epithelial cells.squamous;Naric;Pt;Vag;Qn;Microscopy.light;MICRO;1;Epithelial cells.squamous [#/area] in Vaginal fluid by Light microscopy;Squamous Vag Micro-#/area;;ACTIVE;2.17;2.26 +44095-8;Unidentified cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Unidentified cells/100 leukocytes in Blood by Manual count;Unident Cells/leuk NFr Bld Manual;;ACTIVE;2.17;2.73 +44096-6;Unidentified cells/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Unidentified cells/100 leukocytes in Blood by Automated count;Unident Cells/leuk NFr Bld Auto;;ACTIVE;2.17;2.70 +44097-4;Unidentified cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Unidentified cells/100 leukocytes in Blood;Unident Cells/leuk NFr Bld;;ACTIVE;2.17;2.73 +44098-2;Microscopic observation;Prid;Pt;XXX;Nom;Wayson stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Wayson stain;Wayson Stn Spec;;ACTIVE;2.17;2.69 +4409-9;Procainamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Procainamide [Mass] of Dose;Procainamide Dose;;ACTIVE;1.0;2.69 +44099-0;Galactomannan Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Galactomannan Ag [Presence] in Serum or Plasma by Immunoassay;Galactomannan Ag SerPl Ql IA;;ACTIVE;2.17;2.73 +44100-6;Medical problem;Find;Pt;^Patient;Nom;;H&P.HX;2;Medical problem;Medical problem;;ACTIVE;2.17;2.68 +44101-4;Guidance for ablation of tissue;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for ablation of tissue of Liver;CT Guided Liver Ablation;;ACTIVE;2.17;2.64 +44102-2;Guidance for procedure;Find;Pt;XXX>Joint space;Doc;CT;RAD;2;CT Guidance for procedure of Joint space;CT Guided Joint space Procedure;;DISCOURAGED;2.17;2.64 +44103-0;Guidance for percutaneous aspiration.fine needle;Find;Pt;XXX>Lymph node;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Lymph node;CT Guided LN FNA;;ACTIVE;2.17;2.64 +44104-8;Guidance for percutaneous aspiration.fine needle;Find;Pt;Chest>Mediastinum;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Mediastinum;CT Guided Mediastinum FNA;;ACTIVE;2.17;2.64 +44105-5;Guidance for percutaneous aspiration.fine needle;Find;Pt;XXX>Muscle;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Muscle;CT Guided Muscle FNA;;ACTIVE;2.17;2.64 +44106-3;Guidance for aspiration.fine needle;Find;Pt;Pelvis>Prostate;Doc;CT;RAD;2;CT Guidance for FNA of Prostate;CT Guided Prostate FNA;;ACTIVE;2.17;2.64 +4410-7;Prolintane;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Prolintane [Mass] of Dose;Prolintane Dose;;ACTIVE;1.0;2.69 +44107-1;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Retroperitoneum;CT Guided Retroperitoneum FNA;;ACTIVE;2.17;2.64 +44108-9;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Adrenal gland;Doc;CT;RAD;2;CT Guidance for fine needle aspiration of Adrenal gland;CT Guided Adrenal FNA;;ACTIVE;2.17;2.64 +44109-7;Guidance for deep biopsy;Find;Pt;XXX>Muscle;Doc;CT;RAD;2;CT Guidance for deep biopsy of Muscle;CT Guided Muscle Deep Bx;;ACTIVE;2.17;2.64 +44110-5;Guidance for needle localization;Find;Pt;Breast;Doc;CT;RAD;2;CT Guidance for needle localization of Breast;CT Guided Brst Needle loc;;ACTIVE;2.17;2.64 +44111-3;Multisection^WO & W contrast IV;Find;Pt;Head>Skull.base;Doc;CT;RAD;2;CT Skull base WO and W contrast IV;CT Skull.base WO+W contr IV;;ACTIVE;2.17;2.61 +44112-1;Multisection^WO contrast;Find;Pt;Head>Skull.base;Doc;CT;RAD;2;CT Skull base WO contrast;CT Skull.base WO contr;;ACTIVE;2.17;2.61 +44113-9;Multisection^WO & W contrast IT;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine WO and W contrast IT;CT T-spine WO+W contr IT;;ACTIVE;2.17;2.61 +44114-7;Multisection^WO & W contrast IT;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine WO and W contrast IT;CT L-spine WO+W contr IT;;ACTIVE;2.17;2.61 +4411-5;Promazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Promazine [Mass] of Dose;Promazine Dose;;ACTIVE;1.0;2.69 +44115-4;Multisection;Find;Pt;Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen and Pelvis;CT Abd+Pelvis;;ACTIVE;2.17;2.73 +44116-2;Multisection limited;Find;Pt;Head>Mandible;Doc;CT;RAD;2;CT Mandible limited;CT Mandible Ltd;;ACTIVE;2.17;2.61 +44117-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for biopsy of Retroperitoneum;CT Guided Retroperitoneum Bx;;ACTIVE;2.17;2.64 +44118-8;Guidance for needle localization^WO & W contrast IV;Find;Pt;Breast;Doc;CT;RAD;2;CT Guidance for needle localization of Breast-- WO and W contrast IV;CT Guided Brst Needle loc--WO+W contr IV;;ACTIVE;2.17;2.64 +44119-6;Multisection^WO contrast;Find;Pt;Breast.bilateral;Doc;CT;RAD;2;CT Breast - bilateral WO contrast;CT Brst-Bl WO contr;;ACTIVE;2.17;2.61 +44120-4;Multisection;Find;Pt;Colon;Doc;CT;RAD;2;Deprecated Colon CT;Deprecated Colon CT;;DEPRECATED;2.17;2.58 +44121-2;Guidance for percutaneous biopsy.needle;Find;Pt;Breast;Doc;MG;RAD;2;Deprecated MG Guidance for percutaneous biopsy.needle of Breast;Deprecated MG Brst PC Bx needle guide;;DEPRECATED;2.17;2.63 +44122-0;Guidance for stereotactic localization^WO & W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Guidance for stereotactic localization of Brain-- WO and W contrast IV;MR Guided Brain Str loc--WO+W contr IV;;ACTIVE;2.17;2.64 +4412-3;Promethazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Promethazine [Mass] of Dose;Promethazine Dose;;ACTIVE;1.0;2.69 +44123-8;Multisection^WO contrast;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;MR;RAD;2;MR Biliary ducts and Pancreatic duct WO contrast;MR BD+PD WO contr;;ACTIVE;2.17;2.61 +44124-6;Multisection^W contrast IV;Find;Pt;Abdomen>Adrenal gland;Doc;MR;RAD;2;MR Adrenal gland W contrast IV;MR Adrenal W contr IV;;ACTIVE;2.17;2.61 +44125-3;Multisection^W contrast IV;Find;Pt;Abdomen>Biliary ducts+pancreatic duct;Doc;MR;RAD;2;MR Biliary ducts and Pancreatic duct W contrast IV;MR BD+PD W contr IV;;ACTIVE;2.17;2.61 +44126-1;Multisection cine for blood flow velocity mapping^W contrast IV;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart cine for blood flow velocity mapping W contrast IV;MR Hrt Cine for Flow VM W contr IV;;ACTIVE;2.17;2.61 +44127-9;Multisection limited cine for function;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart limited cine for function;MR Hrt cine for function Ltd;;ACTIVE;2.17;2.64 +44128-7;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels WO and W contrast IV;MRA LE ves WO+W contr IV;;ACTIVE;2.17;2.61 +44129-5;Multisection^WO contrast;Find;Pt;Lower extremity>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels WO contrast;MRA LE ves WO contr;;ACTIVE;2.17;2.61 +44130-3;Multisection^WO contrast;Find;Pt;Chest>Aortic arch;Doc;MR.angio;RAD;2;MRA Aortic arch WO contrast;MRA Ao arch WO contr;;ACTIVE;2.17;2.61 +4413-1;Propanol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Propranolol [Mass] of Dose;Deprecated Propanol Dose;;DEPRECATED;1.0;2.69 +44131-1;Multisection^WO & W contrast IV;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;MR.angio;RAD;2;MRA Thoracic and abdominal aorta WO and W contrast IV;MRA TA + AA WO+W contr IV;;ACTIVE;2.17;2.61 +44132-9;Multisection^WO contrast;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;MR.angio;RAD;2;MRA Thoracic and abdominal aorta WO contrast;MRA TA + AA WO contr;;ACTIVE;2.17;2.61 +44133-7;Multisection^WO contrast;Find;Pt;Abdomen>Renal vessels;Doc;MR.angio;RAD;2;MRA Renal vessels WO contrast;MRA Renal ves WO contr;;ACTIVE;2.17;2.61 +44134-5;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Renal vessels;Doc;MR.angio;RAD;2;MRA Renal vessels WO and W contrast IV;MRA Renal ves WO+W contr IV;;ACTIVE;2.17;2.61 +44135-2;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels - bilateral W contrast IV;MRA LE ves-Bl W contr IV;;ACTIVE;2.17;2.61 +44136-0;Multisection^W radionuclide IV;Find;Pt;XXX;Doc;PT;RAD;2;PT Unspecified body region;PT W RNC IV;;ACTIVE;2.17;2.69 +44137-8;Multisection^W radionuclide IV;Find;Pt;Chest>Heart;Doc;PT;RAD;2;PT Heart;PT Hrt W RNC IV;;ACTIVE;2.17;2.61 +44138-6;Multisection^W radionuclide IV;Find;Pt;Head>Brain;Doc;PT;RAD;2;PT Brain;PT Brain W RNC IV;;ACTIVE;2.17;2.61 +44139-4;Multisection^W radionuclide IV;Find;Pt;Whole body;Doc;PT;RAD;2;PT Whole body;PT Whole body W RNC IV;;ACTIVE;2.17;2.61 +44140-2;Views for tumor;Find;Pt;Abdomen+Pelvis;Doc;NM;RAD;2;NM Abdomen and Pelvis Views for tumor;NM Abd+Pelvis Views for tumor;;ACTIVE;2.17;2.64 +44141-0;Views^W Tc-99m MAA IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM;RAD;2;NM Liver and Spleen Views W Tc-99m MAA IV;NM Liver+Spleen Views W Tc99mMAA IV;;ACTIVE;2.17;2.64 +44142-8;Views^W Tc-99m medronate IV;Find;Pt;XXX>Bone;Doc;NM;RAD;2;NM Bone Views W Tc-99m medronate IV;NM Bone Views W Tc99mMedronate IV;;ACTIVE;2.17;2.64 +44143-6;Views^W Tc-99m tagged RBC IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W Tc-99m tagged RBC IV;NM Hrt Views W Tc99m RBC IV;;ACTIVE;2.17;2.64 +44144-4;Views^W Xe-133 IH;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views W Xe-133 IH;NM Liver Views W 133Xe IH;;ACTIVE;2.17;2.64 +44145-1;Views^W Tc-99m Sestamibi IV;Find;Pt;Neck>Parathyroid gland;Doc;NM;RAD;2;NM Parathyroid gland Views W Tc-99m Sestamibi IV;NM Parathyroid gland Vs W Tc99mMIBI IV;;ACTIVE;2.17;2.64 +44146-9;Views^W Tc-99m SC IV;Find;Pt;XXX>Bone marrow;Doc;NM;RAD;2;NM Bone marrow Views W Tc-99m SC IV;NM Bone mar Views W Tc99mSC IV;;ACTIVE;2.17;2.64 +44147-7;Views+views uptake^W Tc-99m pertechnetate IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views and Views uptake W Tc-99m pertechnetate IV;NM Thyroid Vs+Vs uptake W Tc99mP IV;;ACTIVE;2.17;2.64 +44148-5;Views for blood flow^W Tc-99m bicisate IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views for blood flow W Tc-99m bicisate IV;NM Brain Vs bld flow W Tc99mBicisate IV;;ACTIVE;2.17;2.64 +4414-9;Propranolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Propranolol [Mass] of Dose;Propranolol Dose;;ACTIVE;1.0;2.69 +44149-3;Views for shunt patency^W Tc-99m MAA inj;Find;Pt;Abdomen+Pelvis;Doc;NM;RAD;2;NM Abdomen and Pelvis Views for shunt patency W Tc-99m MAA inj;NM Abd+Pelvis shunt pat W Tc99mMAA Inj;;ACTIVE;2.17;2.64 +44150-1;Views^W Tc-99m bicisate IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Views W Tc-99m bicisate IV;NM Brain Views W Tc99mBicisate IV;;ACTIVE;2.17;2.64 +44151-9;Multisection^W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart W Tc-99m Sestamibi IV;SPECT Hrt W Tc99mMIBI IV;;ACTIVE;2.17;2.61 +44152-7;Multisection^W Tc-99m bicisate IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W Tc-99m bicisate IV;SPECT Brain W Tc99mBicisate IV;;ACTIVE;2.17;2.61 +44153-5;Multisection^W Tc-99m glucoheptonate IV;Find;Pt;Abdomen>Kidney;Doc;NM.SPECT;RAD;2;SPECT Kidney W Tc-99m glucoheptonate IV;SPECT Kidney W Tc99mGHA IV;;ACTIVE;2.17;2.61 +44154-3;Multisection^W dipyridamole IV+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart W dipyridamole and W Tc-99m Sestamibi IV;SPECT Hrt W DIPY+Tc99mMIBI IV;;ACTIVE;2.17;2.64 +44155-0;Guidance for ablation of tissue;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;US Guidance for ablation of tissue of Liver;US Guided Liver Ablation;;ACTIVE;2.17;2.64 +4415-6;Propylhexedrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Propylhexedrine [Mass] of Dose;Propylhexedrine Dose;;ACTIVE;1.0;2.69 +44156-8;Guidance for ablation of tissue;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for ablation of tissue of Kidney;US Guided Kidney Ablation;;ACTIVE;2.17;2.64 +44157-6;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Pancreas;Doc;US;RAD;2;US Guidance for fine needle aspiration of Pancreas;US Guided Pancreas FNA;;ACTIVE;2.17;2.64 +44158-4;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;US Guidance for fine needle aspiration of Liver;US Guided Liver FNA;;ACTIVE;2.17;2.64 +44159-2;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for fine needle aspiration of Kidney;US Guided Kidney FNA;;ACTIVE;2.17;2.64 +441-6;Rosoxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Rosoxacin [Susceptibility] by Disk diffusion (KB);Rosoxacin Islt KB;;ACTIVE;1.0;2.19 +44160-0;Guidance for percutaneous aspiration.fine needle;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for fine needle aspiration of Breast;US Guided Brst FNA;;ACTIVE;2.17;2.64 +44161-8;Guidance for percutaneous biopsy;Find;Pt;Chest>Lung;Doc;US;RAD;2;US Guidance for biopsy of Lung;US Guided Lung Bx;;ACTIVE;2.17;2.64 +44162-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Retroperitoneum;Doc;US;RAD;2;US Guidance for biopsy of Retroperitoneum;US Guided Retroperitoneum Bx;;ACTIVE;2.17;2.64 +44163-4;Multisection;Find;Pt;Chest>Brachial plexus;Doc;US;RAD;2;US Brachial plexus;US Brachial plexus;;ACTIVE;2.17;2.61 +4416-4;Protriptyline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Protriptyline [Mass] of Dose;Protrip Dose;;ACTIVE;1.0;2.69 +44164-2;Multisection;Find;Pt;Head+Neck;Doc;US;RAD;2;US Head and Neck;US Head+Neck;;ACTIVE;2.17;2.73 +44165-9;Multisection & 3D reconstruction;Find;Pt;XXX;Doc;US;RAD;2;Deprecated Unspecified body region US and 3D reconstruction;Deprecated XXX US +3DR;;DEPRECATED;2.17;2.58 +44166-7;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Subphrenic space;Doc;US;RAD;2;US Guidance for drainage of abscess and placement of drainage catheter of Subphrenic space;US Guide Subphrenic Absc drn+cath place;;ACTIVE;2.17;2.66 +44167-5;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for drainage of abscess and placement of drainage catheter of Kidney;US Guided Kidney Absc drain+cath place;;ACTIVE;2.17;2.66 +44168-3;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Pelvis;Doc;US;RAD;2;US Guidance for drainage of abscess and placement of drainage catheter of Pelvis;US Guided Pelvis Absc drain+cath place;;ACTIVE;2.17;2.66 +44169-1;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Peritoneal space;Doc;US;RAD;2;US Guidance for drainage of abscess and placement of drainage catheter of Peritoneal space;US Guide Peritnl spc Absc drn+cath place;;ACTIVE;2.17;2.66 +44170-9;Guidance for biopsy.needle;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Liver;Deprecated US Liver Bx needle guide;;DEPRECATED;2.17;2.63 +44171-7;Guidance for biopsy.needle;Find;Pt;Chest>Pleura;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Chest Pleura;Deprecated US Chest Pleura Bx needle guide;;DEPRECATED;2.17;2.63 +4417-2;Pseudoephedrine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pseudoephedrine [Mass] of Dose;Pseudoephedrine Dose;;ACTIVE;1.0;2.69 +44172-5;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Pancreas;Doc;US;RAD;2;US Guidance for drainage and placement of drainage catheter of Pancreas;US Guided Pancreas Drain+cath place;;ACTIVE;2.17;2.66 +44173-3;Multisection limited;Find;Pt;Extremity>Extremity artery;Doc;US;RAD;2;US Extremity artery limited;US Extr a Ltd;;ACTIVE;2.17;2.61 +44174-1;Multisection;Find;Pt;Lower extremity>Lower extremity vessels;Doc;US.doppler;RAD;2;US.doppler Lower extremity vessels;DOP LE ves;;ACTIVE;2.17;2.61 +44175-8;Multisection;Find;Pt;Neck>Neck vessels;Doc;US.doppler;RAD;2;US.doppler Neck vessels;DOP Neck ves;;ACTIVE;2.17;2.61 +44176-6;View;Find;Pt;Lower extremity>Hip;Doc;XR.portable;RAD;2;Portable XR Hip Single view;XR port Hip 1V;;ACTIVE;2.17;2.64 +44177-4;View AP^W standing;Find;Pt;Lower extremity.bilateral;Doc;XR;RAD;2;XR Lower extremity - bilateral AP W standing;XR LE-Bl AP W Stand;;ACTIVE;2.17;2.61 +44178-2;(View oblique) + (views^W R-bending + W L-bending);Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine oblique and (views W right bending and W left bending);XR L-spine Obl+(views W R+L-bending);;ACTIVE;2.17;2.61 +44179-0;Views 2;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Sacrum and Coccyx 2 Views;XR Sacrum+Coccyx 2V;;ACTIVE;2.17;2.61 +4418-0;Pyrilamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pyrilamine [Mass] of Dose;Pyrilamine Dose;;ACTIVE;1.0;2.69 +44180-8;Views 2 limited;Find;Pt;Sinuses;Nar;XR;RAD;2;Deprecated Sinuses X-ray 2 views limited;Deprecated Sinuses XR V2 Ltd;;DEPRECATED;2.17;2.36 +44181-6;Views 2 or 3;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint 2 or 3 Views;XR SIJ 2V or 3V;;ACTIVE;2.17;2.61 +44182-4;Views 2;Find;Pt;Upper extremity>Hand;Doc;XR.portable;RAD;2;Portable XR Hand 2 Views;XR port Hand 2V;;ACTIVE;2.17;2.61 +44183-2;Views 2;Find;Pt;Upper extremity>Radius+Ulna;Doc;XR.portable;RAD;2;Portable XR Radius and Ulna 2 Views;XR port Radius+Ulna 2V;;ACTIVE;2.17;2.61 +44184-0;Views 2;Find;Pt;Upper extremity>Elbow;Doc;XR.portable;RAD;2;Portable XR Elbow 2 Views;XR port Elbow 2V;;ACTIVE;2.17;2.61 +44185-7;Views AP + lateral;Find;Pt;Lower extremity>Femur;Doc;XR.portable;RAD;2;Portable XR Femur AP and Lateral;XR port Femur AP+Lat;;ACTIVE;2.17;2.61 +44186-5;Views AP + lateral;Find;Pt;Lower extremity>Foot;Doc;XR.portable;RAD;2;Portable XR Foot AP and Lateral;XR port Foot AP+Lat;;ACTIVE;2.17;2.61 +44187-3;(Views AP + oblique + odontoid) + (View lateral^W flexion + W extension);Find;Pt;Neck>Spine.cervical;Doc;XR.portable;RAD;2;Portable XR Cervical spine AP and Oblique and Odontoid and (Lateral W flexion and W extension);XR port C-spine AP+obl+odont+lat W FE;;ACTIVE;2.17;2.61 +44188-1;Views GE 3;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot GE 3 Views;XR Foot GE 3V;;ACTIVE;2.17;2.61 +44189-9;Views GE 3;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint GE 3 Views;XR SIJ GE 3V;;ACTIVE;2.17;2.61 +44190-7;Views GE 3;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist GE 3 Views;XR Wrist GE 3V;;ACTIVE;2.17;2.61 +44191-5;Views GE 3 && view PA;Find;Pt;Chest>Ribs && Chest;Doc;XR;RAD;2;XR Ribs GE 3 Views and Chest PA;XR Ribs GE 3V + Chest PA;;ACTIVE;2.17;2.64 +44192-3;Views GE 3;Find;Pt;Pelvis;Doc;XR.portable;RAD;2;Portable XR Pelvis GE 3 Views;XR port Pelvis GE 3V;;ACTIVE;2.17;2.61 +44193-1;Views GE 3;Find;Pt;Upper extremity>Hand;Doc;XR.portable;RAD;2;Portable XR Hand GE 3 Views;XR port Hand GE 3V;;ACTIVE;2.17;2.61 +44194-9;Views GE 4^W R-Bending + W L-Bending;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine GE 4 Views W right bending and W left bending;XR Spine GE 4V W R+L-bending;;DISCOURAGED;2.17;2.64 +44195-6;Views GE 5;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee GE 5 Views;XR Knee GE 5V;;ACTIVE;2.17;2.61 +44196-4;Views GE 5^W R-Bending + W L-Bending;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine GE 5 Views W right bending and W left bending;XR L-spine GE 5V W R+L-bending;;ACTIVE;2.17;2.61 +44197-2;Views GE 5^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral GE 5 Views W standing;XR Knee-Bl GE 5V W Stand;;ACTIVE;2.17;2.61 +4419-8;quiNIDine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;quiNIDine [Mass] of Dose;quiNIDine Dose;;ACTIVE;1.0;2.73 +44198-0;Views 1 or 2;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee 1 or 2 Views;XR Knee 1V or 2V;;ACTIVE;2.17;2.61 +44199-8;Views 1 or 2;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones 1 or 2 Views;XR Face 1V or 2V;;ACTIVE;2.17;2.61 +44200-4;Views 1 or 2 limited;Find;Pt;Sinuses;Nar;XR;RAD;2;Deprecated Sinuses X-ray 1 or 2 views limited;Deprecated Sinuses XR 1V or 2V Ltd;;DEPRECATED;2.17;2.36 +44201-2;Views 1 or 2;Find;Pt;Pelvis;Doc;XR.portable;RAD;2;Portable XR Pelvis 1 or 2 Views;XR port Pelvis 1V or 2V;;ACTIVE;2.17;2.61 +44202-0;Views 1 or 2;Find;Pt;Lower extremity>Knee;Doc;XR.portable;RAD;2;Portable XR Knee 1 or 2 Views;XR port Knee 1V or 2V;;ACTIVE;2.17;2.61 +44203-8;Views;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR.portable;RAD;2;Portable XR Cervical and thoracic and lumbar spine Views;XR port C+T+L-spine Views;;ACTIVE;2.17;2.64 +44204-6;Guidance for percutaneous biopsy.needle;Find;Pt;Chest>Lung;Doc;RF;RAD;2;Deprecated RF Guidance for percutaneous biopsy.needle of Lung;Deprecated RF Lung PC Bx needle guide;;DEPRECATED;2.17;2.63 +44205-3;View^W standing;Find;Pt;Lower extremity.bilateral;Doc;XR;RAD;2;XR Lower extremity - bilateral Single view W standing;XR LE-Bl 1V W Stand;;ACTIVE;2.17;2.64 +4420-6;quiNINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;quiNINE [Mass] of Dose;quiNINE Dose;;ACTIVE;1.0;2.69 +44206-1;View for scoliosis;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine for scoliosis single view;XR T+L-Spine for Scoli 1 view;;ACTIVE;2.17;2.64 +44207-9;Views AP^standing;Find;Pt;Lower extremity.bilateral>Knee;Nar;XR;RAD;2;Deprecated Knee - bilateral X-ray AP standing;Deprecated Knee-Bl XR AP stand;;DEPRECATED;2.17;2.58 +44208-7;Views for foreign body;Find;Pt;Head>Orbit;Doc;XR;RAD;2;XR Orbit Views for foreign body;XR Orbit Views for FB;;ACTIVE;2.17;2.73 +44209-5;Views limited;Find;Pt;Head>Sinuses;Doc;XR;RAD;2;XR Sinuses Limited Views;XR Sinuses Views Ltd;;ACTIVE;2.17;2.64 +44210-3;Views GE 3;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle GE 3 Views;XR Ankle GE 3V;;ACTIVE;2.17;2.61 +44211-1;Views GE 4;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest GE 4 Views;XR Chest GE 4V;;ACTIVE;2.17;2.61 +44212-9;Views GE 4;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine GE 4 Views;XR C-spine GE 4V;;ACTIVE;2.17;2.61 +44213-7;Guidance for endoscopy^W contrast retrograde;Find;Pt;Abdomen>Pancreatic duct;Doc;RF;RAD;2;RF Guidance for endoscopy of Pancreatic duct-- W contrast retrograde;RF Guided PD Endo--W contr Retro;;ACTIVE;2.17;2.64 +4421-4;rifAMPin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;rifAMPin [Mass] of Dose;rifAMPin Dose;;ACTIVE;1.0;2.69 +44214-5;Guidance for endoscopy^W contrast retrograde;Find;Pt;Abdomen>Biliary ducts;Doc;RF;RAD;2;RF Guidance for endoscopy of Biliary ducts-- W contrast retrograde;RF Guided BDs Endo--W contr Retro;;ACTIVE;2.17;2.64 +44215-2;Guidance for percutaneous aspiration.fine needle;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for fine needle aspiration of Unspecified body region;RF Guided FNA;;ACTIVE;2.17;2.64 +44216-0;Guidance for percutaneous aspiration.fine needle;Find;Pt;Neck>Thyroid gland;Doc;RF;RAD;2;RF Guidance for fine needle aspiration of Thyroid gland;RF Guided Thyroid FNA;;ACTIVE;2.17;2.64 +44217-8;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Kidney;Doc;RF;RAD;2;RF Guidance for fine needle aspiration of Kidney;RF Guided Kidney FNA;;ACTIVE;2.17;2.64 +44218-6;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Pancreas;Doc;RF;RAD;2;RF Guidance for fine needle aspiration of Pancreas;RF Guided Pancreas FNA;;ACTIVE;2.17;2.64 +44219-4;Guidance for percutaneous aspiration.fine needle;Find;Pt;XXX>Lymph node;Doc;RF.angio;RAD;2;RFA Guidance for fine needle aspiration of Lymph node;RFA Guided LN FNA;;ACTIVE;2.17;2.64 +44220-2;Guidance for percutaneous aspiration.fine needle;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;RF Guidance for fine needle aspiration of Liver;RF Guided Liver FNA;;ACTIVE;2.17;2.64 +44221-0;Guidance for deep aspiration.fine needle;Find;Pt;XXX>Tissue;Doc;RF;RAD;2;RF Guidance for deep aspiration.fine needle of Tissue;RF Guided Tiss Deep FNA;;ACTIVE;2.17;2.64 +4422-2;Salicylamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Salicylamide [Mass] of Dose;Salicylamide Dose;;ACTIVE;1.0;2.69 +44222-8;Guidance for procedure;Find;Pt;XXX>Joint space;Doc;RF;RAD;2;RF Guidance for procedure of Joint space;RF Guided Joint space Procedure;;DISCOURAGED;2.17;2.64 +44223-6;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;Pelvis>Ovary;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Ovary;RF Guide Ovary PC abscess drn+cath place;;ACTIVE;2.17;2.66 +44224-4;Guidance for placement of tube;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for placement of tube in Unspecified body region;RF Guided Tube place;;ACTIVE;2.17;2.64 +44225-1;Guidance for percutaneous biopsy^W contrast IV;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;RF Guidance for biopsy of Liver-- W contrast IV;RF Guided Liver Bx--W contr IV;;ACTIVE;2.17;2.64 +44226-9;Views for reduction^W barium contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views for reduction W barium contrast PR;RF Colon Views for reduction W Ba PR;;ACTIVE;2.17;2.64 +44227-7;Views^W barium contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views W barium contrast PR;RF Colon Views W Ba PR;;ACTIVE;2.17;2.64 +44228-5;Guidance for ablation of tissue;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for ablation of tissue of Kidney;CT Guided Kidney Ablation;;ACTIVE;2.17;2.64 +44229-3;Multisection;Find;Pt;XXX>Bone;Doc;CT;RAD;2;CT Bone;CT Bone;;ACTIVE;2.17;2.61 +4423-0;Salicylates;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Salicylates [Mass] of Dose;Salicylates Dose;;ACTIVE;1.0;2.73 +44230-1;Multisection^WO contrast;Find;Pt;Abdomen>Superior mesenteric vessels;Doc;MR.angio;RAD;2;MRA Superior mesenteric vessels WO contrast;MRA SM ves WO contr;;ACTIVE;2.17;2.61 +44231-9;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Superior mesenteric vessels;Doc;MR.angio;RAD;2;MRA Superior mesenteric vessels WO and W contrast IV;MRA SM ves WO+W contr IV;;ACTIVE;2.17;2.61 +44232-7;Views^WO & W Tc-99m Mertiatide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views WO and W Tc-99m Mertiatide IV;NM Kidney Views WO+W Tc99mMertiatide IV;;ACTIVE;2.17;2.64 +44233-5;Views^WO & W Tc-99m DTPA IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views WO and W Tc-99m DTPA IV;NM Kidney Views WO+W Tc99mDTPA IV;;ACTIVE;2.17;2.64 +44234-3;Views^W Tc-99m glucoheptonate IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views W Tc-99m glucoheptonate IV;NM Kidney Views W Tc99mGHA IV;;ACTIVE;2.17;2.64 +44235-0;Multisection;Find;Pt;Abdomen>Superior mesenteric vessels;Doc;US.doppler;RAD;2;US.doppler Superior mesenteric vessels;DOP SM ves;;ACTIVE;2.17;2.61 +44236-8;Multisection for graft;Find;Pt;Upper extremity.bilateral>Upper extremity vessel;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessel - bilateral for graft;DOP UE ves-Bl for graft;;ACTIVE;2.17;2.61 +44237-6;Multisection limited for graft;Find;Pt;Upper extremity.bilateral>Upper extremity vessel;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessel - bilateral for graft limited;DOP UE ves-Bl Graft Ltd;;ACTIVE;2.17;2.64 +44238-4;Views;Find;Pt;Neck+Chest>Trachea;Doc;XR;RAD;2;XR Trachea Views;XR Trachea Views;;DISCOURAGED;2.17;2.64 +44239-2;Views GE 3 && view PA;Find;Pt;Chest>Ribs.unilateral && Chest;Doc;XR.portable;RAD;2;Portable XR Ribs - unilateral GE 3 Views and Chest PA;XR port Ribs-Ul GE 3V + Chest PA;;ACTIVE;2.17;2.64 +442-4;Rosoxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Rosoxacin [Susceptibility] by Serum bactericidal titer;Rosoxacin Titr SBT;;ACTIVE;1.0;2.32 +44240-0;Views^W contrast IA;Find;Pt;XXX>Peripheral arteries.bilateral;Doc;RF.angio;RAD;2;RFA Peripheral arteries - bilateral Views W contrast IA;RFA Peripheral aa-Bl Views W contr IA;;ACTIVE;2.17;2.64 +44241-8;Clue cells;Naric;Pt;Vag;Qn;Microscopy.light.LPF;MICRO;1;Clue cells [#/area] in Vaginal fluid by Microscopy low power field;Clue Cells Vag LPF-#/area;;ACTIVE;2.17;2.73 +44242-6;Erythrocytes;Naric;Pt;Vag;Qn;Wet preparation;HEM/BC;1;Erythrocytes [#/area] in Vaginal fluid by Wet preparation;RBC #/area Vag Wet Prep;;ACTIVE;2.17;2.73 +44243-4;Bacteria;Naric;Pt;Vag;Qn;Wet preparation;MICRO;1;Bacteria [#/area] in Vaginal fluid by Wet preparation;Bacteria Vag Wet Prep-#/area;;ACTIVE;2.17;2.73 +44244-2;Trichomonas vaginalis;Naric;Pt;Vag;Qn;Wet preparation;MICRO;1;Trichomonas vaginalis [#/area] in Vaginal fluid by Wet preparation;T vaginalis Vag Wet Prep-#/area;;ACTIVE;2.17;2.73 +44245-9;Fungi.filamentous;Naric;Pt;Vag;Qn;Wet preparation;MICRO;1;Fungi.filamentous [#/area] in Vaginal fluid by Wet preparation;Filament Fungi Vag Wet Prep-#/area;;ACTIVE;2.17;2.26 +44246-7;Yeast;Naric;Pt;Vag;Qn;Wet preparation;MICRO;1;Yeast [#/area] in Vaginal fluid by Wet preparation;Yeast Vag Wet Prep-#/area;;ACTIVE;2.17;2.73 +44247-5;Spermatozoa.motile;Naric;Pt;Vag;Qn;Wet preparation;MICRO;1;Spermatozoa Motile [#/area] in Vaginal fluid by Wet preparation;Sperm Motile Vag Wet Prep-#/area;;ACTIVE;2.17;2.26 +4424-8;Secobarbital;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Secobarbital [Mass] of Dose;Secobarbital Dose;;ACTIVE;1.0;2.69 +44248-3;Spermatozoa.immotile;Naric;Pt;Vag;Qn;;MICRO;1;Spermatozoa Immotile [#/area] in Vaginal fluid;Sperm Immotile Vag-#/area;;ACTIVE;2.17;2.38 +44249-1;PHQ-9 quick depression assessment panel;-;Pt;^Patient;-;Reported.PHQ;PANEL.SURVEY.PHQ;4;PHQ-9 quick depression assessment panel [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.44 +44250-9;Little interest or pleasure in doing things in last 2W;Find;2W;^Patient;Ord;;SURVEY.PHQ;4;Little interest or pleasure in doing things in last 2 weeks;;;ACTIVE;2.17;2.72 +44251-7;Poor appetite or overeating in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Poor appetite or overeating in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +44252-5;Trouble concentrating on things, such as reading the newspaper or watching television in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Trouble concentrating on things, such as reading the newspaper or watching television in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +44253-3;Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +44254-1;Feeling tired or having little energy in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Feeling tired or having little energy in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +4425-5;Sotalol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Sotalol [Mass] of Dose;Sotalol Dose;;ACTIVE;1.0;2.69 +44255-8;Feeling down, depressed, or hopeless in last 2W;Find;2W;^Patient;Ord;;SURVEY.PHQ;4;Feeling down, depressed, or hopeless in last 2 weeks;;;ACTIVE;2.17;2.72 +44256-6;Perceived difficulty in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Perceived difficulty in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +44257-4;Patient health questionnaire 9 item;-;Pt;^Patient;-;Reported.PHQ;SURVEY.PHQ;4;Deprecated Patient Health Questionnaire 9 item (PHQ-9) [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;DEPRECATED;2.17;2.70 +44258-2;Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +44259-0;Trouble falling or staying asleep, or sleeping too much in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Trouble falling or staying asleep, or sleeping too much in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +44260-8;Thoughts that you would be better off dead, or of hurting yourself in some way in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Thoughts that you would be better off dead, or of hurting yourself in some way in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.54 +44261-6;Patient health questionnaire 9 item total score;Score;Pt;^Patient;Qn;Reported.PHQ;SURVEY.PHQ;4;Patient Health Questionnaire 9 item (PHQ-9) total score [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.17;2.73 +44262-4;PHQ-9 interpretation;Imp;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Deprecated PHQ-9 interpretation;;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;DEPRECATED;2.17;2.40 +4426-3;Spironolactone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Spironolactone [Mass] of Dose;Spironolactone Dose;;ACTIVE;1.0;2.69 +44263-2;Influenza virus A RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;FLUAV RNA Spec NAA+probe-aCnc;;ACTIVE;2.17;2.69 +44264-0;Influenza virus A H5 RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H5 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;FLUAV H5 RNA Spec NAA+probe-aCnc;;ACTIVE;2.17;2.69 +44265-7;Influenza virus A H6 RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H6 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;FLUAV H6 RNA Spec NAA+probe-aCnc;;ACTIVE;2.17;2.69 +44266-5;Influenza virus A H7 RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H7 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;FLUAV H7 RNA Spec NAA+probe-aCnc;;ACTIVE;2.17;2.69 +44267-3;Avian paramyxovirus 1 RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Avian paramyxovirus 1 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;APMV1 RNA Spec NAA+probe-aCnc;;ACTIVE;2.17;2.69 +44268-1;Avian paramyxovirus 1.exotic RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Avian paramyxovirus 1.exotic RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;Exotic APMV1 RNA Spec NAA+probe-aCnc;;ACTIVE;2.17;2.69 +44269-9;Bacillus anthracis cell wall Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bacillus anthracis cell wall Ag [Presence] in Specimen by Immunofluorescence;B anthracis cell wall Ag Spec Ql IF;;ACTIVE;2.17;2.69 +44270-7;Bacillus anthracis spore Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bacillus anthracis spore Ag [Presence] in Specimen by Immunofluorescence;B anthracis spore Ag Spec Ql IF;;ACTIVE;2.17;2.69 +4427-1;Stanozolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Stanozolol [Mass] of Dose;Stanozolol Dose;;ACTIVE;1.0;2.69 +44271-5;Brucella sp Ag;Prid;Pt;XXX;Nom;IF;MICRO;1;Brucella sp Ag [Identifier] in Specimen by Immunofluorescence;Brucella Ag Spec IF;;ACTIVE;2.17;2.69 +44272-3;Cache valley virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Cache valley virus neutralizing antibody [Titer] in Serum by Neutralization test;CVV NAb Titr Ser Nt;;ACTIVE;2.17;2.72 +44273-1;Classical swine fever virus RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Classical swine fever virus RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;CSFV RNA Spec NAA+probe-aCnc;;ACTIVE;2.17;2.69 +44274-9;Clostridium botulinum toxin;Prid;Pt;XXX;Nom;IA;MICRO;1;Clostridium botulinum toxin [Identifier] in Specimen by Immunoassay;C bot Tox Spec IA;;ACTIVE;2.17;2.69 +44275-6;Coxiella burnetii;PrThr;Pt;XXX;Ord;Microscopy.light;MICRO;1;Coxiella burnetii [Presence] in Specimen by Light microscopy;C burnet Spec Ql Micro;;ACTIVE;2.17;2.69 +44276-4;Equine adenovirus Ag;Titr;Pt;Ser;Qn;Neut;MICRO;1;Equine adenovirus Ag [Titer] in Serum by Neutralization test;EAdV Ag Titr Ser Nt;;ACTIVE;2.17;2.32 +44277-2;15 Beta, 17 Alpha-Dihydroxypregnanolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;15 Beta, 17 Alpha-Dihydroxypregnanolone/Creatinine [Mass Ratio] in Urine;15B,17aDiOHpregnanolone/Creat Ur;;ACTIVE;2.17;2.42 +44278-0;16-Alpha hydroxydehydroepiandrosterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;16-Alpha hydroxydehydroepiandrosterone/Creatinine [Mass Ratio] in Urine;16A OH-DHEA/Creat Ur;;ACTIVE;2.17;2.42 +44279-8;16-Alpha hydroxypregnenolone/16-Alpha hydroxydehydroepiandrosterone;MRto;Pt;Urine;Qn;;CHEM;1;16-Alpha hydroxypregnenolone/16-Alpha hydroxydehydroepiandrosterone [Mass Ratio] in Urine;16A OH-Preg/16A OH-DHEA Ur;;ACTIVE;2.17;2.42 +44280-6;17 alpha-Hydroxypregnanolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;17 Alpha-hydroxypregnanolone/Creatinine [Mass Ratio] in Urine;17A-OH-pregnanolone/Creat Ur;;ACTIVE;2.17;2.66 +44281-4;17-Ketosteroids/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;17-Ketosteroids/Creatinine [Mass Ratio] in 24 hour Urine;17KS/Creat 24h Ur;;ACTIVE;2.17;2.73 +44282-2;2-Hydroxyisocaproate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;2-Hydroxyisocaproate/Creatinine [Mass Ratio] in 24 hour Urine;2OH-isocaproate/Creat 24h Ur;;DISCOURAGED;2.17;2.44 +44283-0;2-Hydroxyphenylacetate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;2-Hydroxyphenylacetate/Creatinine [Mass Ratio] in Urine;2OH-phenylacetate/Creat Ur;;DISCOURAGED;2.17;2.42 +44284-8;2-Methylcitrate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Methylcitrate/Creatinine [Molar ratio] in 24 hour Urine;2Me-citrate/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44285-5;3-Methylcrotonylglycine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;3-Methylcrotonylglycine/Creatinine [Mass Ratio] in 24 hour Urine;3Me-crotonylglycine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44286-3;3-Methylhistidine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;3-Methylhistidine/Creatinine [Mass Ratio] in 24 hour Urine;3Me-histidine/Creat 24h Ur;;ACTIVE;2.17;2.42 +44287-1;5-Hydroxyhexanoate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;5-Hydroxyhexanoate/Creatinine [Mass Ratio] in 24 hour Urine;5OH-Hexanoate/Creat 24h Ur;;ACTIVE;2.17;2.42 +44288-9;5-Hydroxyindoleacetate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate/Creatinine [Mass Ratio] in 24 hour Urine;5OH-indoleacetate/Creat 24h Ur;;ACTIVE;2.17;2.73 +4428-9;Streptomycin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Streptomycin [Mass] of Dose;Streptomycin Dose;;ACTIVE;1.0;2.73 +44289-7;Adenovirus Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Adenovirus Ab [Units/volume] in Serum by Complement fixation;HAdV Ab Ser CF-aCnc;;ACTIVE;2.17;2.73 +44290-5;Adenovirus Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Deprecated Adenovirus Ab [Units/volume] in Body fluid;Deprecated HAdV Ab Fld-aCnc;;DEPRECATED;2.17;2.69 +44291-3;Alanine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Alanine/Creatinine [Mass Ratio] in 24 hour Urine;Alanine/Creat 24h Ur;;DISCOURAGED;2.17;2.44 +44292-1;Albumin/Creatinine;MRto;12H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin/Creatinine [Mass Ratio] in 12 hour Urine;Microalbumin/Creat 12h Ur;;ACTIVE;2.17;2.42 +44293-9;Albumin/Globulin;MRto;Pt;Urine;Qn;Electrophoresis;CHEM;1;Albumin/Globulin [Mass Ratio] in Urine by Electrophoresis;Albumin/Glob Ur Elph;;ACTIVE;2.17;2.73 +44294-7;Albumin/Globulin;MRto;24H;Urine;Qn;Electrophoresis;CHEM;1;Albumin/Globulin [Mass Ratio] in 24 hour Urine by Electrophoresis;Albumin/Glob 24h Ur Elph;;ACTIVE;2.17;2.44 +44295-4;Aldosterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Aldosterone/Creatinine [Mass Ratio] in 24 hour Urine;Aldost/Creat 24h Ur;;ACTIVE;2.17;2.73 +44296-2;Alpha aminobutyrate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Alpha aminobutyrate/Creatinine [Mass Ratio] in 24 hour Urine;A-Aminobutyr/Creat 24h Ur;;ACTIVE;2.17;2.42 +4429-7;Sulbactam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Sulbactam [Mass] of Dose;Sulbactam Dose;;ACTIVE;1.0;2.69 +44297-0;Androsterone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Androsterone/Creatinine [Mass Ratio] in 24 hour Urine;Androsterone/Creat 24h Ur;;ACTIVE;2.17;2.73 +44298-8;Apis mellifera Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee IgG Ab RAST class [Presence] in Serum;Honey bee IgG RAST Ql;;ACTIVE;2.17;2.58 +44299-6;Arginine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Arginine/Creatinine [Mass Ratio] in 24 hour Urine;Arginine/Creat 24h Ur;;ACTIVE;2.17;2.42 +44300-2;Arsenic.inorganic/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic/Creatinine [Mass Ratio] in 24 hour Urine;Inorg Arsenic/Creat 24h Ur;;ACTIVE;2.17;2.42 +44301-0;Asparagine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Asparagine/Creatinine [Mass Ratio] in 24 hour Urine;Asparagine/Creat 24h Ur;;ACTIVE;2.17;2.42 +44302-8;Aspartate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Aspartate/Creatinine [Mass Ratio] in 24 hour Urine;Aspartate/Creat 24h Ur;;ACTIVE;2.17;2.42 +44303-6;Beta-2-Microglobulin/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Beta-2-Microglobulin/Creatinine [Mass Ratio] in 24 hour Urine;B2 Microglob/Creat 24h Ur;;ACTIVE;2.17;2.44 +44304-4;Carnosine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Carnosine/Creatinine [Mass Ratio] in 24 hour Urine;Carnosine/Creat 24h Ur;;ACTIVE;2.17;2.44 +4430-5;sulfADIAZINE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;sulfADIAZINE [Mass] of Dose;sulfADIAZINE Dose;;ACTIVE;1.0;2.69 +44305-1;Chloral hydrate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Chloral hydrate/Creatinine [Mass Ratio] in Urine;Chloral Hydrate/Creat Ur;;ACTIVE;2.17;2.42 +44306-9;Citrate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Citrate/Creatinine [Mass Ratio] in 24 hour Urine;Citrate/Creat 24h Ur;;ACTIVE;2.17;2.73 +44307-7;Citrulline/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Citrulline/Creatinine [Mass Ratio] in 24 hour Urine;Citrulline/Creat 24h Ur;;DISCOURAGED;2.17;2.44 +44308-5;Collagen crosslinked N-telopeptide/Creatinine;SRto;24H;Urine;Qn;IA;CHEM;1;Collagen crosslinked N-telopeptide/Creatinine [Molar ratio] in 24 hour Urine by Immunoassay;Collagen NTx/Creat 24h Ur IA-sRto;;ACTIVE;2.17;2.73 +44309-3;Cortisol.free/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Cortisol Free/Creatinine [Mass Ratio] in Urine;Cortis F/Creat Ur;;ACTIVE;2.17;2.73 +44310-1;Cortisol/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Cortisol/Creatinine [Mass Ratio] in 24 hour Urine;Cortis/Creat 24h Ur;;ACTIVE;2.17;2.73 +44311-9;Cotinine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Cotinine/Creatinine [Mass Ratio] in Urine;Cotinine/Creat Ur;;ACTIVE;2.17;2.42 +44312-7;Cystine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Cystine/Creatinine [Mass Ratio] in 24 hour Urine;Cystine/Creat 24h Ur;;ACTIVE;2.17;2.44 +4431-3;Sulfamethoxazole;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Sulfamethoxazole [Mass] of Dose;Sulfamethoxazole Dose;;ACTIVE;1.0;2.69 +44313-5;Delta aminolevulinate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Delta aminolevulinate/Creatinine [Mass Ratio] in 24 hour Urine;D-ALA/Creat 24h Ur;;ACTIVE;2.17;2.44 +44314-3;D-lactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;D-Lactate/Creatinine [Molar ratio] in Urine;D-Lactate/Creat Ur-sRto;;ACTIVE;2.17;2.42 +44315-0;Dolichovespula maculata Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Whitefaced Hornet IgG Ab RAST class [Presence] in Serum;Whitefaced Hornet IgG RAST Ql;;ACTIVE;2.17;2.58 +44316-8;DOPamine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;DOPamine/Creatinine [Mass Ratio] in 24 hour Urine;DOPamine/Creat 24h Ur;;ACTIVE;2.17;2.73 +44317-6;Insulin human Ab;PrThr;Pt;Ser;Ord;;SERO;1;Insulin human Ab [Presence] in Serum;Insulin Human Ab Ser Ql;;ACTIVE;2.17;2.56 +44318-4;Insulin porcine Ab;PrThr;Pt;Ser;Ord;;SERO;1;Insulin porcine Ab [Presence] in Serum;Insulin Porcine Ab Ser Ql;;ACTIVE;2.17;2.56 +44319-2;Insulin.bound;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Insulin.bound [Presence] in Serum or Plasma;Insulin Bnd SerPl Ql;;ACTIVE;2.17;2.56 +443-2;Roxithromycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Roxithromycin [Susceptibility] by Minimum lethal concentration (MLC);Roxithromycin Islt MLC;;ACTIVE;1.0;2.19 +44320-0;Interferon.alpha;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Interferon alpha [Presence] in Serum or Plasma;IFN-A SerPl Ql;;ACTIVE;2.17;2.56 +4432-1;sulfiSOXAZOLE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;sulfiSOXAZOLE [Mass] of Dose;Sulfisoxaz Dose;;ACTIVE;1.0;2.69 +44321-8;Interleukin 5;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Interleukin 5 [Presence] in Serum or Plasma;Il5 SerPl Ql;;ACTIVE;2.17;2.56 +44322-6;Interleukin 6;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Interleukin 6 [Presence] in Serum or Plasma;Il6 SerPl Ql;;ACTIVE;2.17;2.56 +44323-4;Iodine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Iodine [Presence] in Serum or Plasma;Iodine SerPl Ql;;ACTIVE;2.17;2.56 +44324-2;Iodine.inorganic;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Iodine.inorganic [Presence] in Serum or Plasma;Inorg Iodine SerPl Ql;;ACTIVE;2.17;2.56 +44325-9;Iron;PrThr;Pt;Hair;Ord;;CHEM;1;Iron [Presence] in Hair;Iron Hair Ql;;ACTIVE;2.17;2.56 +44326-7;Iron;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Iron [Presence] in Serum or Plasma;Iron SerPl Ql;;ACTIVE;2.17;2.73 +44327-5;Iron;PrThr;Pt;Body fld;Ord;;CHEM;1;Iron [Presence] in Body fluid;Iron Fld Ql;;ACTIVE;2.17;2.56 +44328-3;Isocitrate;PrThr;24H;Urine;Ord;;CHEM;1;Isocitrate [Presence] in 24 hour Urine;Isocitrate 24h Ur Ql;;ACTIVE;2.17;2.56 +44329-1;Isoleucine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Isoleucine/Creatinine [Mass Ratio] in 24 hour Urine;Isoleucine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44330-9;Isospora belli;PrThr;Pt;Stool;Ord;;MICRO;1;Isospora belli [Presence] in Stool;I belli Stl Ql;;ACTIVE;2.17;2.73 +44331-7;Isovalerylglycine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Isovalerylglycine/Creatinine [Mass Ratio] in 24 hour Urine;Isovalerylgly/Creat 24h Ur;;ACTIVE;2.17;2.69 +44332-5;Jo-1 extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Jo-1 extractable nuclear IgG Ab [Presence] in Serum;ENA Jo1 IgG Ser Ql;;ACTIVE;2.17;2.73 +44333-3;Lactate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Lactate/Creatinine [Mass Ratio] in 24 hour Urine;Lactate/Creat 24h Ur;;ACTIVE;2.17;2.44 +44334-1;Leucine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Leucine/Creatinine [Mass Ratio] in 24 hour Urine;Leucine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44335-8;Lysine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Lysine/Creatinine [Mass Ratio] in 24 hour Urine;Lysine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44336-6;Magnesium/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Magnesium/Creatinine [Mass Ratio] in 24 hour Urine;Magnesium/Creat 24h Ur;;ACTIVE;2.17;2.73 +44337-4;Metanephrine.free/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Metanephrine Free/Creatinine [Mass Ratio] in Urine;Metaneph Free/Creat Ur;;ACTIVE;2.17;2.73 +44338-2;Methionine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Methionine/Creatinine [Mass Ratio] in 24 hour Urine;Methionine/Creat 24h Ur;;ACTIVE;2.17;2.44 +4433-9;Sulfonamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Sulfonamide [Mass] of Dose;Sulfonamide Dose;;ACTIVE;1.0;2.69 +44340-8;N-methylhistamine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;N-methylhistamine/Creatinine [Mass Ratio] in 24 hour Urine;Me-histamine/Creat 24h Ur;;ACTIVE;2.17;2.73 +44341-6;Norepinephrine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Norepinephrine/Creatinine [Mass Ratio] in 24 hour Urine;Norepineph/Creat 24h Ur;;ACTIVE;2.17;2.42 +44342-4;Normetanephrine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Normetanephrine/Creatinine [Mass Ratio] in 24 hour Urine;Normetanephrine/Creat 24h Ur;;ACTIVE;2.17;2.73 +44343-2;Organic acids/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Organic acids/Creatinine [Mass Ratio] in Urine;Organic Acids/Creat Ur;;DISCOURAGED;2.17;2.44 +44344-0;Ornithine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Ornithine/Creatinine [Mass Ratio] in 24 hour Urine;Ornithine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44345-7;Orotate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Orotate/Creatinine [Molar ratio] in 24 hour Urine;Orotate/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44346-5;Phenol/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Phenol/Creatinine [Molar ratio] in Urine;Phenol/Creat Ur-sRto;;ACTIVE;2.17;2.42 +4434-7;Sulfonamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Deprecated Sulfonamide [Mass] of Dose;Deprecated Sulfonamide Dose;;DEPRECATED;1.0;2.69 +44347-3;Phenol/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Phenol/Creatinine [Molar ratio] in 24 hour Urine;Phenol/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44348-1;Phenylalanine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Phenylalanine/Creatinine [Mass Ratio] in 24 hour Urine;Phe/Creat 24h Ur;;ACTIVE;2.17;2.44 +44349-9;Phenylalanine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Phenylalanine/Creatinine [Mass Ratio] in Urine;Phe/Creat Ur;;ACTIVE;2.17;2.44 +44350-7;Phenylpropionylglycine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Phenylpropionylglycine/Creatinine [Mass Ratio] in 24 hour Urine;PPG/Creat 24h Ur;;DISCOURAGED;2.17;2.44 +44351-5;Phosphoethanolamine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Phosphoethanolamine/Creatinine [Molar ratio] in 24 hour Urine;PETN/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44352-3;Phosphoethanolamine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Phosphoethanolamine/Creatinine [Mass Ratio] in 24 hour Urine;PETN/Creat 24h Ur;;ACTIVE;2.17;2.44 +44353-1;Porphyrins/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Porphyrins/Creatinine [Mass Ratio] in 24 hour Urine;Porphyrins/Creat 24h Ur;;ACTIVE;2.17;2.73 +4435-4;Teicoplanin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Teicoplanin [Mass] of Dose;Teicoplanin Dose;;ACTIVE;1.0;2.69 +44354-9;Ethylmalonate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Ethylmalonate/Creatinine [Mass Ratio] in 24 hour Urine;Ethylmalonate/Creat 24h Ur;;ACTIVE;2.17;2.42 +44355-6;Etiocholanolone/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Etiocholanolone/Creatinine [Mass Ratio] in 24 hour Urine;Etiocholanolone/Creat 24h Ur;;ACTIVE;2.17;2.73 +44356-4;Follitropin/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Follitropin/Creatinine [Mass Ratio] in 24 hour Urine;FSH/Creat 24h Ur;;DISCOURAGED;2.17;2.42 +44357-2;Galactomannan Ag;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Galactomannan Ag [Units/volume] in Serum or Plasma by Immunoassay;Galactomannan Ag SerPl IA-aCnc;;ACTIVE;2.17;2.73 +44358-0;Gamma hydroxybutyrate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Gamma hydroxybutyrate/Creatinine [Mass Ratio] in Urine;G-OH-Butyr/Creat Ur;;DISCOURAGED;2.17;2.44 +44359-8;Glutamate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Glutamate/Creatinine [Mass Ratio] in 24 hour Urine;Glutamate/Creat 24h Ur;;ACTIVE;2.17;2.44 +44360-6;Glutamate+Glutamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutamate+Glutamine/Creatinine [Molar ratio] in Urine;Glu+Gln/Creat Ur-sRto;;ACTIVE;2.17;2.42 +44361-4;Glutamate+Glutamine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Glutamate+Glutamine/Creatinine [Mass Ratio] in Urine;Glu+Gln/Creat Ur;;ACTIVE;2.17;2.44 +4436-2;Tetracaine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tetracaine [Mass] of Dose;Tetracaine Dose;;ACTIVE;1.0;2.69 +44362-2;Glutamine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Glutamine/Creatinine [Mass Ratio] in 24 hour Urine;Glutamine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44363-0;Glutarate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Glutarate/Creatinine [Mass Ratio] in 24 hour Urine;Glutarate/Creat 24h Ur;;ACTIVE;2.17;2.65 +44364-8;Glutarate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Glutarate/Creatinine [Molar ratio] in 24 hour Urine;Glutarate/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44365-5;Glycine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Glycine/Creatinine [Mass Ratio] in 24 hour Urine;Glycine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44366-3;Glycosaminoglycans/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Glycosaminoglycans/Creatinine [Mass Ratio] in 24 hour Urine;GAG/Creat 24h Ur;;ACTIVE;2.17;2.44 +44367-1;Glycosaminoglycans/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glycosaminoglycans/Creatinine [Molar ratio] in Urine;GAG/Creat Ur-sRto;;ACTIVE;2.17;2.73 +44368-9;Hexanoylglycine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Hexanoylglycine/Creatinine [Mass Ratio] in 24 hour Urine;Hexanoylgly/Creat 24h Ur;;ACTIVE;2.17;2.42 +44369-7;Hexokinase;PrThr;Pt;Plas;Ord;;CHEM;1;Hexokinase [Presence] in Plasma;Hexokinase Plas Ql;;ACTIVE;2.17;2.56 +4437-0;Tetracycline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tetracycline [Mass] of Dose;Tetracycline Dose;;ACTIVE;1.0;2.69 +44370-5;Hippurate/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Hippurate/Creatinine [Mass Ratio] in 24 hour Urine;Hippurate/Creat 24h Ur;;ACTIVE;2.17;2.42 +44371-3;Histamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Histamine/Creatinine [Molar ratio] in Urine;Histamine/Creat Ur-sRto;;ACTIVE;2.17;2.42 +44372-1;Histidine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Histidine/Creatinine [Mass Ratio] in 24 hour Urine;Histidine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44373-9;Homocysteine;PrThr;Pt;Urine;Ord;;CHEM;1;Homocysteine [Presence] in Urine;Hcys Ur Ql;;ACTIVE;2.17;2.56 +44374-7;Homocysteine;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Homocysteine [Presence] in Serum or Plasma;Hcys SerPl Ql;;ACTIVE;2.17;2.73 +44375-4;Homocysteine;PrThr;Pt;Bld;Ord;;CHEM;1;Homocysteine [Presence] in Blood;Hcys Bld Ql;;ACTIVE;2.17;2.56 +44376-2;Homocysteine;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Homocysteine [Presence] in DBS;Hcys DBS Ql;;ACTIVE;2.17;2.61 +44377-0;Homocysteine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Homocysteine/Creatinine [Molar ratio] in 24 hour Urine;Hcys/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44378-8;Homocystine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Homocystine/Creatinine [Mass Ratio] in 24 hour Urine;(Hcys)2/Creat 24h Ur;;ACTIVE;2.17;2.42 +44379-6;Horse hair+Horse dander Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse hair+Horse dander IgE Ab RAST class [Presence] in Serum;Horse Hair+Dander IgE RAST Ql;;ACTIVE;2.17;2.73 +44380-4;House dust Hollister Stier Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;House dust Hollister Stier IgG Ab RAST class [Presence] in Serum;House Dust HS IgG RAST Ql;;ACTIVE;2.17;2.58 +44381-2;Humulus japonicus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Japanese hop IgE Ab RAST class [Presence] in Serum;Japanese hop IgE RAST Ql;;ACTIVE;2.17;2.58 +44382-0;Hyaline casts.broad;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Hyaline casts.broad [Presence] in Urine sediment by Light microscopy;Broad Hyaline Casts UrnS Ql Micro;;ACTIVE;2.17;2.73 +44383-8;Hyaluronate;PrThr;Pt;Plr fld;Ord;;DRUG/TOX;1;Hyaluronate [Presence] in Pleural fluid;Hyaluronate Plr Ql;;ACTIVE;2.17;2.56 +44384-6;hydroCHLOROthiazide;PrThr;24H;Urine;Ord;;DRUG/TOX;1;hydroCHLOROthiazide [Presence] in 24 hour Urine;HTCZ 24h Ur Ql;;ACTIVE;2.17;2.56 +44385-3;Hydroflumethiazide;PrThr;24H;Urine;Ord;;DRUG/TOX;1;Hydroflumethiazide [Presence] in 24 hour Urine;Hydroflumethiazide 24h Ur Ql;;ACTIVE;2.17;2.56 +44386-1;Hydroxyproline/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Hydroxyproline/Creatinine [Mass Ratio] in 24 hour Urine;OH-Proline/Creat 24h Ur;;ACTIVE;2.17;2.44 +44387-9;Hypnotics;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Hypnotics [Presence] in Gastric fluid by Screen method;Hypnotics Gast Ql Scn;;ACTIVE;2.17;2.56 +4438-8;Tetrahydrocannabinol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tetrahydrocannabinol [Mass] of Dose;THC Dose;;ACTIVE;1.0;2.69 +44388-7;IgA;PrThr;24H;Urine;Ord;Immunofixation;CHEM;1;IgA [Presence] in 24 hour Urine by Immunofixation;IgA 24h Ur Ql IFE;;ACTIVE;2.17;2.56 +44389-5;IgA;PrThr;Pt;Ser;Ord;;CHEM;1;IgA [Presence] in Serum;IgA Ser Ql;;ACTIVE;2.17;2.73 +44390-3;Imipramine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Imipramine [Presence] in Specimen;Imipramine Spec Ql;;ACTIVE;2.17;2.73 +44391-1;Immune complex;PrThr;Pt;Ser/Plas;Ord;C1q binding assay;SERO;1;Immune complex [Presence] in Serum or Plasma by C1q binding assay;IC SerPl Ql C1Q Bind;;ACTIVE;2.17;2.73 +44392-9;Immune complex;PrThr;Pt;Ser/Plas;Ord;Raji cell assay;SERO;1;Immune complex [Presence] in Serum or Plasma by Raji cell assay;IC SerPl Ql Raji Cell;;ACTIVE;2.17;2.73 +44393-7;Immune complex;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Immune complex [Presence] in Serum or Plasma;IC SerPl Ql;;ACTIVE;2.17;2.56 +44394-5;Immunoglobulin light chains.kappa;PrThr;24H;Urine;Ord;;CHEM;1;Kappa light chains [Presence] in 24 hour Urine;Kappa LC 24h Ur Ql;;ACTIVE;2.17;2.63 +44395-2;Immunoglobulin light chains.lambda;PrThr;24H;Urine;Ord;;CHEM;1;Lambda light chains [Presence] in 24 hour Urine;Lambda LC 24h Ur Ql;;ACTIVE;2.17;2.63 +4439-6;Tetrahydrocortisone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tetrahydrocortisone [Mass] of Dose;THcortisone Dose;;ACTIVE;1.0;2.69 +44396-0;Insulin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Insulin [Presence] in Serum or Plasma;Insulin SerPl Ql;;ACTIVE;2.17;2.73 +44397-8;Insulin bovine Ab;PrThr;Pt;Ser;Ord;;SERO;1;Insulin bovine Ab [Presence] in Serum;Insulin Bovine Ab Ser Ql;;ACTIVE;2.17;2.56 +44398-6;Proline/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Proline/Creatinine [Mass Ratio] in 24 hour Urine;Proline/Creat 24h Ur;;ACTIVE;2.17;2.44 +44399-4;Propionylglycine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Propionylglycine/Creatinine [Mass Ratio] in 24 hour Urine;Propionylgly/Creat 24h Ur;;DISCOURAGED;2.17;2.44 +444-0;Roxithromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Roxithromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Roxithromycin Islt MIC;;ACTIVE;1.0;2.19 +44400-0;Pyruvate/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Pyruvate/Creatinine [Mass Ratio] in 24 hour Urine;Pyruvate/Creat 24h Ur;;ACTIVE;2.17;2.44 +44401-8;Sarcosine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Sarcosine/Creatinine [Mass Ratio] in 24 hour Urine;Sarcosine/Creat 24h Ur;;DISCOURAGED;2.17;2.44 +44402-6;Selenium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Selenium/Creatinine [Molar ratio] in 24 hour Urine;Selenium/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44403-4;Serine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Serine/Creatinine [Mass Ratio] in 24 hour Urine;Serine/Creat 24h Ur;;ACTIVE;2.17;2.44 +4440-4;Theophylline;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Theophylline [Mass] of Dose;Theophylline Dose;;ACTIVE;1.0;2.73 +44404-2;Silicon/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Silicon/Creatinine [Mass Ratio] in Urine;Silicon/Creat Ur;;ACTIVE;2.17;2.44 +44405-9;Sodium/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Sodium/Creatinine [Molar ratio] in 24 hour Urine;Sodium/Creat 24h Ur-sRto;;ACTIVE;2.17;2.73 +44406-7;Sodium/Potassium;SRto;24H;Urine;Qn;;CHEM;1;Sodium/Potassium [Molar ratio] in 24 hour Urine;Sodium/Potassium 24h Ur-sRto;;ACTIVE;2.17;2.42 +44407-5;Somatotropin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Somatotropin/Creatinine [Mass Ratio] in Urine;GH/Creat Ur;;ACTIVE;2.17;2.42 +44408-3;Suberate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Suberate/Creatinine [Molar ratio] in 24 hour Urine;Suberate/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44409-1;Succinate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Succinate/Creatinine [Molar ratio] in 24 hour Urine;Succinate/Creat 24h Ur-sRto;;ACTIVE;2.17;2.42 +44410-9;Superoxide dismutase;PrThr;Pt;Plas;Ord;;CHEM;1;Superoxide dismutase [Presence] in Plasma;SOD Plas Ql;;ACTIVE;2.17;2.56 +44411-7;Taurine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Taurine/Creatinine [Mass Ratio] in 24 hour Urine;Taurine/Creat 24h Ur;;ACTIVE;2.17;2.44 +4441-2;Thiopental;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Thiopental [Mass] of Dose;Thiopental Dose;;ACTIVE;1.0;2.69 +44412-5;Tetrahydrodeoxycortisol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrodeoxycortisol/Creatinine [Mass Ratio] in Urine;TH-DC/Creat Ur;;ACTIVE;2.17;2.44 +44413-3;Threonine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Threonine/Creatinine [Mass Ratio] in 24 hour Urine;Threonine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44414-1;Tryptophan/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Tryptophan/Creatinine [Mass Ratio] in 24 hour Urine;Tryptophan/Creat 24h Ur;;ACTIVE;2.17;2.44 +44415-8;Tyrosine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Tyrosine/Creatinine [Mass Ratio] in 24 hour Urine;Tyrosine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44416-6;Urea nitrogen/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Urea nitrogen/Creatinine [Mass Ratio] in Urine;UUN/Creat Ur;;ACTIVE;2.17;2.42 +44417-4;Valine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Valine/Creatinine [Mass Ratio] in 24 hour Urine;Valine/Creat 24h Ur;;ACTIVE;2.17;2.44 +44418-2;Vanillylmandelate/Creatine;MRto;24H;Urine;Qn;;CHEM;1;Vanillylmandelate/Creatine [Mass Ratio] in 24 hour Urine;VMA/Creatine 24h Ur;;ACTIVE;2.17;2.42 +44419-0;CIAS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CIAS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CIAS1 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +4442-0;Thioridazine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Thioridazine [Mass] of Dose;Thioridazine Dose;;ACTIVE;1.0;2.69 +44420-8;CACNA1A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CACNA1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CACNA1A gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +44421-6;PKD1 gene+PKD2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PKD1 gene+PKD2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PKD1+PKD2 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +44422-4;Interleukin 2 receptor alpha chain.soluble;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 receptor alpha chain soluble [Units/volume] in Serum or Plasma;Sol IL2RA SerPl-aCnc;;ACTIVE;2.17;2.73 +44423-2;Herpes virus 7 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [Presence] in Specimen by NAA with probe detection;HHV7 DNA Spec Ql NAA+probe;;ACTIVE;2.17;2.73 +44424-0;Methylenedioxymethamphetamine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine/Creatinine [Mass Ratio] in Urine;MDMA/Creat Ur;;ACTIVE;2.17;2.73 +44425-7;Storage and handling section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Storage and handling section;FDA insert Storage/handling;;ACTIVE;2.17;2.34 +44426-5;3-Hydroxyphenylacetate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;3-Hydroxyphenylacetate/Creatinine [Molar ratio] in Urine;3OH-phenylacetate/Creat Ur-sRto;;ACTIVE;2.17;2.42 +44427-3;3-Hydroxyphenylacetate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;3-Hydroxyphenylacetate/Creatinine [Mass Ratio] in Urine;3OH-phenylacetate/Creat Ur;;DISCOURAGED;2.17;2.44 +44428-1;Adenosine monophosphate.cyclic.nephrogenous/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adenosine monophosphate.cyclic.nephrogenous/Creatinine [Molar ratio] in Urine;cAMP Nephrogenous/Creat Ur-sRto;;ACTIVE;2.17;2.42 +44429-9;Albumin/Globulin;MRto;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Albumin/Globulin [Mass Ratio] in Serum or Plasma by Electrophoresis;Albumin/Glob SerPl Elph;;ACTIVE;2.17;2.73 +44430-7;Alpha cortolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha cortolone/Creatinine [Mass Ratio] in Urine;A-cortolone/Creat Ur;;ACTIVE;2.17;2.44 +44431-5;Annexin V Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Annexin V IgG Ab [Units/volume] in Serum or Plasma;Annexin V IgG SerPl-aCnc;;ACTIVE;2.17;2.73 +44432-3;Annexin V Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Annexin V IgM Ab [Units/volume] in Serum or Plasma;Annexin V IgM SerPl-aCnc;;ACTIVE;2.17;2.73 +44433-1;Antibiotic XXX^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Other Antibiotic [Mass/volume] in Serum or Plasma --peak;Other Antibiotic Peak SerPl-mCnc;;ACTIVE;2.17;2.42 +44434-9;Antibiotic XXX^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Other Antibiotic [Mass/volume] in Serum or Plasma --trough;Other Antibiotic Trough SerPl-mCnc;;ACTIVE;2.17;2.42 +44435-6;Ascaris lumbricoides adult Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Ascaris lumbricoides adult IgG Ab [Units/volume] in Serum by Immunoassay;A lumbrica adult IgG Ser IA-aCnc;;ACTIVE;2.17;2.69 +44436-4;Ascaris lumbricoides larva Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Ascaris lumbricoides larva IgG Ab [Units/volume] in Serum by Immunoassay;A lumbric larva IgG Ser IA-aCnc;;ACTIVE;2.17;2.69 +44437-2;Ascaris sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Ascaris sp IgG Ab [Units/volume] in Serum;Ascaris IgG Ser-aCnc;;ACTIVE;2.17;2.69 +4443-8;Ticarcillin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Ticarcillin [Mass] of Dose;Ticarcillin Dose;;ACTIVE;1.0;2.69 +44438-0;Aspergillus fumigatus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus fumigatus 1 Ab [Units/volume] in Serum;A fumigatus1 Ab Ser-aCnc;;ACTIVE;2.17;2.73 +44439-8;Aspergillus fumigatus 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus fumigatus 3 Ab [Units/volume] in Serum;A fumigatus3 Ab Ser-aCnc;;ACTIVE;2.17;2.73 +44440-6;Aspergillus fumigatus 6 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus fumigatus 6 Ab [Units/volume] in Serum;A fumigatus6 Ab Ser-aCnc;;ACTIVE;2.17;2.73 +44441-4;Aspergillus niger Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Aspergillus niger Ab [Units/volume] in Serum by Complement fixation;A niger Ab Ser CF-aCnc;;ACTIVE;2.17;2.69 +44442-2;Bartonella henselae Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bartonella henselae Ab [Units/volume] in Serum by Immunoassay;B henselae Ab Ser IA-aCnc;;ACTIVE;2.17;2.69 +44443-0;Bartonella sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bartonella sp IgG Ab [Units/volume] in Serum by Immunoassay;Bartonella IgG Ser IA-aCnc;;ACTIVE;2.17;2.69 +44444-8;Bartonella sp Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bartonella sp IgM Ab [Units/volume] in Serum by Immunoassay;Bartonella IgM Ser IA-aCnc;;ACTIVE;2.17;2.69 +44445-5;Basement membrane Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Basement membrane IgA Ab [Units/volume] in Serum;BM IgA Ser-aCnc;;ACTIVE;2.17;2.68 +4444-6;Timolol;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Timolol [Mass] of Dose;Timolol Dose;;ACTIVE;1.0;2.69 +44446-3;Basement membrane Ab.IgG;ACnc;Pt;Ser;Qn;IF;SERO;1;Basement membrane IgG Ab [Units/volume] in Serum by Immunofluorescence;BM IgG Ser IF-aCnc;;ACTIVE;2.17;2.73 +44447-1;Beta 2 glycoprotein 1 Ab.IgA;ACnc;Pt;Ser/Plas;Qn;IA;COAG;1;Beta 2 glycoprotein 1 IgA Ab [Units/volume] in Serum or Plasma by Immunoassay;B2 Glycoprot1 IgA SerPl IA-aCnc;;ACTIVE;2.17;2.73 +44448-9;Beta 2 glycoprotein 1 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;COAG;1;Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;B2 Glycoprot1 IgG SerPl IA-aCnc;;ACTIVE;2.17;2.73 +44449-7;Beta 2 glycoprotein 1 Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;COAG;1;Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;B2 Glycoprot1 IgM SerPl IA-aCnc;;ACTIVE;2.17;2.73 +44450-5;Beta cortolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Beta cortolone/Creatinine [Mass Ratio] in Urine;B-cortolone/Creat Ur;;ACTIVE;2.17;2.44 +44451-3;Blastomyces dermatitidis Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Blastomyces dermatitidis Ab [Units/volume] in Serum by Complement fixation;B dermat Ab Ser CF-aCnc;;ACTIVE;2.17;2.69 +44452-1;Borrelia burgdorferi Ab;ACnc;Pt;Ser;Qn;IB;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Serum by Immunoblot;B burgdor Ab Ser IB-aCnc;;ACTIVE;2.17;2.73 +4445-3;Tobramycin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tobramycin [Mass] of Dose;Tobramycin Dose;;ACTIVE;1.0;2.73 +44453-9;Borrelia burgdorferi Ab;ACnc;Pt;CSF;Qn;IB;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Cerebral spinal fluid by Immunoblot;B burgdor Ab CSF IB-aCnc;;ACTIVE;2.17;2.69 +44454-7;Borrelia burgdorferi Ab;ACnc;Pt;Synv fld;Qn;;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Synovial fluid;B burgdor Ab Snv-aCnc;;ACTIVE;2.17;2.69 +44455-4;Borrelia burgdorferi Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Serum by Immunoassay --1st specimen;B burgdor Ab sp1 Ser IA-aCnc;;ACTIVE;2.17;2.69 +44456-2;Borrelia burgdorferi Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Serum --1st specimen;B burgdor Ab sp1 Ser-aCnc;;ACTIVE;2.17;2.69 +44457-0;Borrelia sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia sp Ab [Units/volume] in Serum;Borrelia Ab Ser-aCnc;;ACTIVE;2.17;2.73 +44458-8;Brucella abortus Ab.IgG+IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella abortus IgG+IgM Ab [Units/volume] in Serum;B abortus IgG+IgM Ser-aCnc;;ACTIVE;2.17;2.73 +44459-6;C peptide/Creatinine^2nd specimen post XXX challenge;MRto;Pt;Urine;Qn;;CHAL;1;C peptide/Creatinine [Mass Ratio] in Urine --2nd specimen post XXX challenge;C peptide/Creat sp2 p chal Ur;;ACTIVE;2.17;2.42 +44460-4;Cladosporium herbarum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Cladosporium herbarum Ab [Presence] in Serum by Immune diffusion (ID);C herbarum Ab Ql ID;;ACTIVE;2.17;2.56 +4446-1;Tocainide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tocainide [Mass] of Dose;Tocainide Dose;;ACTIVE;1.0;2.69 +44461-2;Dermatophagoides farinae Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;American house dust mite Ab [Presence] in Serum by Immune diffusion (ID);D farinae Ab Ql ID;;ACTIVE;2.17;2.56 +44462-0;Insulin.free+Bound;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Insulin Free+Bound [Presence] in Serum or Plasma;Insulin Free+Bnd SerPl Ql;;ACTIVE;2.17;2.56 +44463-8;Herpes simplex virus 1;PrThr;Pt;Vag;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 1 [Presence] in Vaginal fluid by Organism specific culture;HSV1 Vag Ql Cult;;ACTIVE;2.17;2.56 +44464-6;Herpes simplex virus 1;PrThr;Pt;Skin;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 1 [Presence] in Skin by Organism specific culture;HSV1 Skin Ql Cult;;ACTIVE;2.17;2.56 +44465-3;Herpes simplex virus 1;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 1 [Presence] in Genital specimen by Organism specific culture;HSV1 Genital Ql Cult;;ACTIVE;2.17;2.56 +44466-1;Herpes simplex virus 1;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 1 [Presence] in Throat by Organism specific culture;HSV1 Throat Ql Cult;;ACTIVE;2.17;2.56 +44467-9;Herpes simplex virus 1;PrThr;Pt;Cvx;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 1 [Presence] in Cervix by Organism specific culture;HSV1 Cvx Ql Cult;;ACTIVE;2.17;2.58 +44468-7;Herpes simplex virus 1;PrThr;Pt;Anal;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 1 [Presence] in Anal by Organism specific culture;HSV1 Anal Ql Cult;;ACTIVE;2.17;2.56 +44469-5;Herpes simplex virus 1 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Herpes simplex virus 1 Ab [Presence] in Body fluid;HSV1 Ab Fld Ql;;ACTIVE;2.17;2.56 +44470-3;Herpes simplex virus 1 Ag;PrThr;Pt;Anal;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Anal;HSV1 Ag Anal Ql;;ACTIVE;2.17;2.56 +44471-1;Herpes simplex virus 1 Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Cervix;HSV1 Ag Cvx Ql;;ACTIVE;2.17;2.58 +44472-9;Herpes simplex virus 1 Ag;PrThr;Pt;Eye;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Eye;HSV1 Ag Eye Ql;;ACTIVE;2.17;2.56 +44473-7;Herpes simplex virus 1 Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Penis;HSV1 Ag Penis Ql;;ACTIVE;2.17;2.56 +44474-5;Herpes simplex virus 1 Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Throat;HSV1 Ag Throat Ql;;ACTIVE;2.17;2.56 +44475-2;Herpes simplex virus 1 Ag;PrThr;Pt;Tiss;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Tissue;HSV1 Ag Tiss Ql;;ACTIVE;2.17;2.56 +44476-0;Herpes simplex virus 1 Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Urethra;HSV1 Ag Urth Ql;;ACTIVE;2.17;2.56 +44477-8;Herpes simplex virus 1 Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Vaginal fluid;HSV1 Ag Vag Ql;;ACTIVE;2.17;2.56 +44478-6;Herpes simplex virus 1 DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Amniotic fluid by NAA with probe detection;HSV1 DNA Amn Ql NAA+probe;;ACTIVE;2.17;2.73 +4447-9;TOLBUTamide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;TOLBUTamide [Mass] of Dose;TOLBUTamide Dose;;ACTIVE;1.0;2.69 +44479-4;Herpes simplex virus 1+2 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 1+2 Ab [Presence] in Cerebral spinal fluid;HSV1+2 Ab CSF Ql;;ACTIVE;2.17;2.56 +44480-2;Herpes simplex virus 1+2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus 1+2 Ab [Presence] in Serum;HSV1+2 Ab Ser Ql;;ACTIVE;2.17;2.73 +44481-0;Herpes simplex virus 1+2 Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Presence] in Cerebral spinal fluid;HSV1+2 IgG CSF Ql;;ACTIVE;2.17;2.56 +44482-8;Herpes simplex virus 1+2 Ab.IgG;PrThr;Pt;Body fld;Ord;;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Presence] in Body fluid;HSV1+2 IgG Fld Ql;;ACTIVE;2.17;2.56 +44483-6;Herpes simplex virus 1+2 Ab.IgM;PrThr;Pt;Body fld;Ord;;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Presence] in Body fluid;HSV1+2 IgM Fld Ql;;ACTIVE;2.17;2.56 +44484-4;Herpes simplex virus 2;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 2 [Presence] in Specimen by Organism specific culture;HSV2 Spec Ql Cult;;ACTIVE;2.17;2.73 +44485-1;Herpes simplex virus 2;PrThr;Pt;Vag;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 2 [Presence] in Vaginal fluid by Organism specific culture;HSV2 Vag Ql Cult;;ACTIVE;2.17;2.56 +44486-9;Herpes simplex virus 2;PrThr;Pt;Skin;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 2 [Presence] in Skin by Organism specific culture;HSV2 Skin Ql Cult;;ACTIVE;2.17;2.56 +4448-7;TOLBUTamide.IV;Mass;Pt;Dose;Qn;;DRUGDOSE;1;TOLBUTamide.IV [Mass] of Dose;TOLBUTamide IV Dose;;ACTIVE;1.0;2.69 +44487-7;Herpes simplex virus 2;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 2 [Presence] in Genital specimen by Organism specific culture;HSV2 Genital Ql Cult;;ACTIVE;2.17;2.73 +44488-5;Herpes simplex virus 2;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 2 [Presence] in Throat by Organism specific culture;HSV2 Throat Ql Cult;;ACTIVE;2.17;2.56 +44489-3;Herpes simplex virus 2;PrThr;Pt;Cvx;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 2 [Presence] in Cervix by Organism specific culture;HSV2 Cvx Ql Cult;;ACTIVE;2.17;2.58 +44490-1;Herpes simplex virus 2;PrThr;Pt;Anal;Ord;Organism specific culture;MICRO;1;Herpes simplex virus 2 [Presence] in Anal by Organism specific culture;HSV2 Anal Ql Cult;;ACTIVE;2.17;2.56 +44491-9;Herpes simplex virus 2 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Herpes simplex virus 2 Ab [Presence] in Body fluid;HSV2 Ab Fld Ql;;ACTIVE;2.17;2.56 +44492-7;Herpes simplex virus 2 Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Herpes simplex virus 2 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;HSV2 Ab CSF Ql IF;;ACTIVE;2.17;2.56 +44493-5;Herpes simplex virus 2 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus 2 Ab [Presence] in Cerebral spinal fluid;HSV2 Ab CSF Ql;;ACTIVE;2.17;2.56 +44494-3;Herpes simplex virus 2 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes simplex virus 2 IgM Ab [Presence] in Serum by Immunoassay;HSV2 IgM Ser Ql IA;;ACTIVE;2.17;2.56 +4449-5;Tranylcypromine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tranylcypromine [Mass] of Dose;Tranylcypromine Dose;;ACTIVE;1.0;2.69 +44495-0;Herpes simplex virus 2 Ag;PrThr;Pt;Eye;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Eye;HSV2 Ag Eye Ql;;ACTIVE;2.17;2.56 +44496-8;Herpes simplex virus 2 Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Penis;HSV2 Ag Penis Ql;;ACTIVE;2.17;2.56 +44497-6;Herpes simplex virus 2 Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Vaginal fluid;HSV2 Ag Vag Ql;;ACTIVE;2.17;2.56 +44498-4;Herpes simplex virus 2 Ag;PrThr;Pt;Anal;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Anal;HSV2 Ag Anal Ql;;ACTIVE;2.17;2.56 +44499-2;Herpes simplex virus 2 Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Urethra;HSV2 Ag Urth Ql;;ACTIVE;2.17;2.56 +44500-7;Herpes simplex virus 2 Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Cervix;HSV2 Ag Cvx Ql;;ACTIVE;2.17;2.58 +44501-5;Herpes simplex virus 2 Ag;PrThr;Pt;Thrt;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Throat;HSV2 Ag Throat Ql;;ACTIVE;2.17;2.56 +44502-3;Herpes simplex virus 2 Ag;PrThr;Pt;Tiss;Ord;;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Tissue;HSV2 Ag Tiss Ql;;ACTIVE;2.17;2.56 +4450-3;traZODone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;traZODone [Mass] of Dose;traZODone Dose;;ACTIVE;1.0;2.69 +44503-1;Herpes simplex virus 2 DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Amniotic fluid by NAA with probe detection;HSV2 DNA Amn Ql NAA+probe;;ACTIVE;2.17;2.73 +44504-9;Herpes simplex virus Ab;PrThr;Pt;Body fld;Ord;IF;MICRO;1;Herpes simplex virus Ab [Presence] in Body fluid by Immunofluorescence;HSV Ab Fld Ql IF;;ACTIVE;2.17;2.56 +44505-6;Herpes simplex virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus IgG Ab [Presence] in Cerebral spinal fluid;HSV IgG CSF Ql;;ACTIVE;2.17;2.56 +44506-4;Herpes simplex virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus Ab [Presence] in Cerebral spinal fluid;HSV Ab CSF Ql;;ACTIVE;2.17;2.56 +44507-2;Herpes simplex virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Herpes simplex virus IgM Ab [Presence] in Serum by Immunofluorescence;HSV IgM Ser Ql IF;;ACTIVE;2.17;2.73 +44508-0;Herpes simplex virus Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Cervix;HSV Ag Cvx Ql;;ACTIVE;2.17;2.58 +44509-8;Herpes simplex virus Ag;PrThr;Pt;Penis;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Penis;HSV Ag Penis Ql;;ACTIVE;2.17;2.56 +44510-6;Herpes simplex virus Ag;PrThr;Pt;Vag;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Vaginal fluid;HSV Ag Vag Ql;;ACTIVE;2.17;2.56 +4451-1;Triamterene;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Triamterene [Mass] of Dose;Triamterene Dose;;ACTIVE;1.0;2.69 +44511-4;Herpes simplex virus Ag;PrThr;Pt;Eye;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Eye;HSV Ag Eye Ql;;ACTIVE;2.17;2.56 +44512-2;Herpes simplex virus Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Nose;HSV Ag Nose Ql;;ACTIVE;2.17;2.56 +44513-0;Herpes simplex virus Ag;PrThr;Pt;Bronchial;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Bronchial specimen by Immunofluorescence;HSV Ag Bronch Ql IF;;ACTIVE;2.17;2.56 +44514-8;Herpes simplex virus Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Herpes simplex virus Ag [Presence] in Cerebral spinal fluid by Immunoassay;HSV Ag CSF Ql IA;;ACTIVE;2.17;2.56 +44515-5;Herpes simplex virus Ag;PrThr;Pt;Cvx;Ord;IA;MICRO;1;Herpes simplex virus Ag [Presence] in Cervix by Immunoassay;HSV Ag Cvx Ql IA;;ACTIVE;2.17;2.58 +44516-3;Herpes simplex virus Ag;PrThr;Pt;Cvx;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Cervix by Immunofluorescence;HSV Ag Cvx Ql IF;;ACTIVE;2.17;2.58 +44517-1;Herpes simplex virus DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Amniotic fluid by NAA with probe detection;HSV DNA Amn Ql NAA+probe;;ACTIVE;2.17;2.63 +44518-9;Herpes simplex virus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Serum or Plasma by NAA with probe detection;HSV DNA SerPl Ql NAA+probe;;ACTIVE;2.17;2.73 +44519-7;Herpes virus 6 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes virus 6 Ab [Presence] in Serum;HHV6 Ab Ser Ql;;ACTIVE;2.17;2.56 +44520-5;Herpes virus 6 Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes virus 6 IgG Ab [Presence] in Cerebral spinal fluid;HHV6 IgG CSF Ql;;ACTIVE;2.17;2.56 +44521-3;Herpes virus 6 Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Herpes virus 6 IgG Ab [Presence] in Serum by Immunofluorescence;HHV6 IgG Ser Ql IF;;ACTIVE;2.17;2.56 +44522-1;Histoplasma capsulatum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Histoplasma capsulatum Ab [Presence] in Serum by Immunoassay;H capsul Ab Ser Ql IA;;ACTIVE;2.17;2.73 +44523-9;Histoplasma capsulatum Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Histoplasma capsulatum IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;H capsul IgG CSF Ql IA;;ACTIVE;2.17;2.56 +44524-7;Histoplasma capsulatum Ag;PrThr;Pt;Urine;Ord;IA;MICRO;1;Histoplasma capsulatum Ag [Presence] in Urine by Immunoassay;H capsul Ag Ur Ql IA;;ACTIVE;2.17;2.73 +44525-4;Histoplasma capsulatum Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Histoplasma capsulatum Ag [Presence] in Serum by Immunoassay;H capsul Ag Ser Ql IA;;ACTIVE;2.17;2.73 +44526-2;Histoplasma capsulatum H Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum H Ab [Presence] in Cerebral spinal fluid;H capsul H Ab CSF Ql;;ACTIVE;2.17;2.56 +44527-0;Histoplasma capsulatum H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum H Ab [Presence] in Serum;H capsul H Ab Ser Ql;;ACTIVE;2.17;2.56 +44528-8;Histoplasma capsulatum M Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Histoplasma capsulatum M Ab [Presence] in Serum;H capsul M Ab Ser Ql;;ACTIVE;2.17;2.73 +4452-9;Triazolam;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Triazolam [Mass] of Dose;Triazolam Dose;;ACTIVE;1.0;2.69 +44529-6;Histoplasma capsulatum mycelial phase Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Presence] in Serum by Immune diffusion (ID);H capsul Myc Ab Ser Ql ID;;ACTIVE;2.17;2.73 +44530-4;Histoplasma capsulatum yeast phase Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum yeast phase Ab [Presence] in Serum by Immune diffusion (ID);H capsul Yst Ab Ser Ql ID;;ACTIVE;2.17;2.56 +44531-2;HIV 1 Ag;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;HIV 1 Ag [Presence] in Serum from Donor;HIV1 Ag Ser Donr Ql;;ACTIVE;2.17;2.56 +44532-0;HIV 1 gp120 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 gp120 Ab [Presence] in Serum;HIV1 gp120 Ab Ser Ql;;ACTIVE;2.17;2.56 +44533-8;HIV 1+2 Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;HIV 1+2 Ab [Presence] in Serum from Donor;HIV1+2 Ab Ser Donr Ql;;ACTIVE;2.17;2.73 +44534-6;HLA Ab;PrThr;Pt;Ser;Ord;;HLA;1;HLA Ab [Presence] in Serum;HLA Ab Ser Ql;;ACTIVE;2.17;2.56 +44535-3;HTLV I Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;HTLV I Ab [Presence] in Serum from Donor;HTLV I Ab Ser Donr Ql;;ACTIVE;2.17;2.56 +44536-1;HTLV I DNA;PrThr;Pt;Bld;Ord;Probe;MICRO;1;HTLV I DNA [Presence] in Blood by Probe;HTLV I DNA Bld Ql Probe;;ACTIVE;2.17;2.63 +4453-7;Trimeperidine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Trimeperidine [Mass] of Dose;Trimeperidine Dose;;ACTIVE;1.0;2.69 +44537-9;HTLV I DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HTLV I DNA [Presence] in Blood by NAA with probe detection;HTLV I DNA Bld Ql NAA+probe;;ACTIVE;2.17;2.73 +44538-7;HTLV I+II Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;HTLV I+II Ab [Presence] in Serum from Donor;HTLV I+II Ab Ser Donr Ql;;ACTIVE;2.17;2.73 +44539-5;HTLV II Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;HTLV II Ab [Presence] in Serum by Immunoassay;HTLV II Ab Ser Ql IA;;ACTIVE;2.17;2.56 +44540-3;HTLV II Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;HTLV II IgG Ab [Presence] in Serum by Immunoassay;HTLV II IgG Ser Ql IA;;ACTIVE;2.17;2.56 +44541-1;HTLV II DNA;PrThr;Pt;Bld;Ord;Probe;MICRO;1;HTLV II DNA [Presence] in Blood by Probe;HTLV II DNA Bld Ql Probe;;ACTIVE;2.17;2.63 +44542-9;HTLV II DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HTLV II DNA [Presence] in Blood by NAA with probe detection;HTLV II DNA Bld Ql NAA+probe;;ACTIVE;2.17;2.73 +44543-7;Human papilloma virus 31+33 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 31+33 Ag [Presence] in Specimen;HPV31+33 Ag Spec Ql;;ACTIVE;2.17;2.73 +44544-5;Human papilloma virus 35 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human papilloma virus 35 Ag [Presence] in Specimen;HPV35 Ag Spec Ql;;ACTIVE;2.17;2.69 +4454-5;Trimethadione;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Trimethadione [Mass] of Dose;TMO Dose;;ACTIVE;1.0;2.69 +44545-2;Human papilloma virus DNA;PrThr;Pt;Urethra;Ord;Probe;MICRO;1;Human papilloma virus DNA [Presence] in Urethra by Probe;HPV DNA Urth Ql Probe;;ACTIVE;2.17;2.63 +44546-0;Human papilloma virus DNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Human papilloma virus DNA [Presence] in Vaginal fluid by Probe;HPV DNA Vag Ql Probe;;ACTIVE;2.17;2.63 +44547-8;Human papilloma virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus DNA [Presence] in Specimen by Probe with signal amplification;HPV DNA Spec Ql Probe+sig amp;;ACTIVE;2.17;2.73 +44548-6;Human papilloma virus DNA;PrThr;Pt;Urethra;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus DNA [Presence] in Urethra by Probe with signal amplification;HPV DNA Urth Ql Probe+sig amp;;ACTIVE;2.17;2.63 +44549-4;Human papilloma virus DNA;PrThr;Pt;Vag;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus DNA [Presence] in Vaginal fluid by Probe with signal amplification;HPV DNA Vag Ql Probe+sig amp;;ACTIVE;2.17;2.63 +44550-2;Human papilloma virus DNA;PrThr;Pt;Cvx;Ord;Probe;MICRO;1;Human papilloma virus DNA [Presence] in Cervix by Probe;HPV DNA Cvx Ql Probe;;ACTIVE;2.17;2.73 +44551-0;Human papilloma virus DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus DNA [Presence] in Tissue by Probe;HPV DNA Tiss Ql Probe;;ACTIVE;2.17;2.73 +4455-2;Trimethoprim;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Trimethoprim [Mass] of Dose;Trimethoprim Dose;;ACTIVE;1.0;2.69 +44552-8;hydroCHLOROthiazide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;hydroCHLOROthiazide [Presence] in Serum or Plasma;HTCZ SerPl Ql;;ACTIVE;2.17;2.56 +44553-6;Hydroxyitraconazole;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Hydroxyitraconazole [Presence] in Serum or Plasma;OH-Itraconaz SerPl Ql;;ACTIVE;2.17;2.56 +44554-4;Hymenopterase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Deprecated Hymenopterase IgE Ab RAST class [Presence] in Serum;Deprecated Hymenopterase IgE RAST Ql;;DEPRECATED;2.17;2.65 +44555-1;Immunoglobulin light chains.kappa.free;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;Kappa light chains.free [Presence] in Serum by Immunofixation;Kappa LC Free Ser Ql IFE;;ACTIVE;2.17;2.73 +44556-9;Influenza virus A Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Influenza virus A Ab [Presence] in Serum by Complement fixation;FLUAV Ab Ser Ql CF;;ACTIVE;2.17;2.56 +44557-7;Influenza virus A Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Influenza virus A Ab [Presence] in Body fluid;FLUAV Ab Fld Ql;;ACTIVE;2.17;2.56 +44558-5;Influenza virus A Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Nasopharynx by Immunofluorescence;FLUAV Ag Nph Ql IF;;ACTIVE;2.17;2.73 +44559-3;Influenza virus A Ag;PrThr;Pt;Bronchial;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Bronchial specimen by Immunofluorescence;FLUAV Ag Bronch Ql IF;;ACTIVE;2.17;2.56 +4456-0;Trimipramine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Trimipramine [Mass] of Dose;Trimipramine Dose;;ACTIVE;1.0;2.69 +44560-1;Influenza virus A Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Nose by Immunofluorescence;FLUAV Ag Nose Ql IF;;ACTIVE;2.17;2.56 +44561-9;Influenza virus A Ag;PrThr;Pt;Trac;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Trachea by Immunofluorescence;FLUAV Ag Trachea Ql IF;;ACTIVE;2.17;2.56 +44562-7;Influenza virus A Ag;PrThr;Pt;Bronchial;Ord;;MICRO;1;Influenza virus A Ag [Presence] in Bronchial specimen;FLUAV Ag Bronch Ql;;ACTIVE;2.17;2.56 +44563-5;Influenza virus A Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Influenza virus A Ag [Presence] in Nose;FLUAV Ag Nose Ql;;ACTIVE;2.17;2.73 +44564-3;Influenza virus A Ag;PrThr;Pt;Nose;Ord;IA;MICRO;1;Influenza virus A Ag [Presence] in Nose by Immunoassay;FLUAV Ag Nose Ql IA;;ACTIVE;2.17;2.73 +44565-0;Influenza virus A+B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A+B Ab [Presence] in Serum;FLUAV+FLUBV Ab Ser Ql;;ACTIVE;2.17;2.56 +44566-8;Influenza virus A+B Ag;PrThr;Pt;Bronchial;Ord;;MICRO;1;Influenza virus A+B Ag [Presence] in Bronchial specimen;FLUAV+FLUBV Ag Bronch Ql;;ACTIVE;2.17;2.56 +44567-6;Influenza virus A+B Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Influenza virus A+B Ag [Presence] in Nose;FLUAV+FLUBV Ag Nose Ql;;ACTIVE;2.17;2.73 +44568-4;Influenza virus B Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Influenza virus B Ab [Presence] in Serum by Complement fixation;FLUBV Ab Ser Ql CF;;ACTIVE;2.17;2.56 +44569-2;Influenza virus B Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Influenza virus B Ab [Presence] in Body fluid;FLUBV Ab Fld Ql;;ACTIVE;2.17;2.56 +445-7;Roxithromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Roxithromycin [Susceptibility] by Disk diffusion (KB);Roxithromycin Islt KB;;ACTIVE;1.0;2.19 +44570-0;Influenza virus B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus B Ab [Presence] in Serum;FLUBV Ab Ser Ql;;ACTIVE;2.17;2.73 +44571-8;Influenza virus B Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Nasopharynx by Immunofluorescence;FLUBV Ag Nph Ql IF;;ACTIVE;2.17;2.56 +44572-6;Influenza virus B Ag;PrThr;Pt;Bronchial;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Bronchial specimen by Immunofluorescence;FLUBV Ag Bronch Ql IF;;ACTIVE;2.17;2.56 +44573-4;Influenza virus B Ag;PrThr;Pt;Nose;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Nose by Immunofluorescence;FLUBV Ag Nose Ql IF;;ACTIVE;2.17;2.73 +44574-2;Influenza virus B Ag;PrThr;Pt;Trac;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Trachea by Immunofluorescence;FLUBV Ag Trachea Ql IF;;ACTIVE;2.17;2.56 +44575-9;Influenza virus B Ag;PrThr;Pt;Nose;Ord;IA;MICRO;1;Influenza virus B Ag [Presence] in Nose by Immunoassay;FLUBV Ag Nose Ql IA;;ACTIVE;2.17;2.73 +44576-7;Influenza virus B Ag;PrThr;Pt;Bronchial;Ord;;MICRO;1;Influenza virus B Ag [Presence] in Bronchial specimen;FLUBV Ag Bronch Ql;;ACTIVE;2.17;2.56 +44577-5;Influenza virus B Ag;PrThr;Pt;Nose;Ord;;MICRO;1;Influenza virus B Ag [Presence] in Nose;FLUBV Ag Nose Ql;;ACTIVE;2.17;2.73 +4457-8;Tripelennamine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Tripelennamine [Mass] of Dose;Tripelennamine Dose;;ACTIVE;1.0;2.69 +44578-3;Influenza virus C Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Influenza virus C Ab [Presence] in Serum by Complement fixation;FLUCV Ab Ser Ql CF;;ACTIVE;2.17;2.56 +44579-1;Influenza virus C Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus C Ab [Presence] in Serum;FLUCV Ab Ser Ql;;ACTIVE;2.17;2.56 +44580-9;HTLV I+II p21 env Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II p21 env Ab [Presence] in Serum by Immunoblot;HTLV I+II p21 Env Ab Ser Ql IB;;ACTIVE;2.17;2.58 +44581-7;HTLV I+II p38 tax Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I+II p38 tax Ab [Presence] in Serum by Immunoblot;HTLV I+II p38 Tax Ab Ser Ql IB;;ACTIVE;2.17;2.58 +44582-5;IgA;PrThr;Pt;Skin;Ord;IF;CHEM;1;IgA [Presence] in Skin by Immunofluorescence;IgA Skin Ql IF;;ACTIVE;2.17;2.73 +44583-3;IgA Ab;PrThr;Pt;Ser/Plas;Ord;HAI;CHEM;1;IgA Ab [Presence] in Serum or Plasma by Hemagglutination inhibition;IgA Ab SerPl Ql HAI;;ACTIVE;2.17;2.56 +44584-1;IgA Ab;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;IgA Ab [Presence] in Serum or Plasma;IgA Ab SerPl Ql;;ACTIVE;2.17;2.73 +44585-8;IgA Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;IgA IgG Ab [Presence] in Serum or Plasma;IgA IgG SerPl Ql;;ACTIVE;2.17;2.56 +4458-6;Valproate;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Valproate [Mass] of Dose;Valproate Dose;;ACTIVE;1.0;2.73 +44586-6;IgA Ab.IgM;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;IgA IgM Ab [Presence] in Serum or Plasma;IgA IgM SerPl Ql;;ACTIVE;2.17;2.56 +44587-4;IgA.monoclonal;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgA.monoclonal [Presence] in Serum by Immunofixation;M-IgA Ser Ql IFE;;ACTIVE;2.17;2.56 +44588-2;IgA.monoclonal;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgA.monoclonal [Presence] in Urine by Immunofixation;M-IgA Ur Ql IFE;;ACTIVE;2.17;2.56 +44589-0;IgA.monoclonal;PrThr;Pt;CSF;Ord;Immunofixation;CHEM;1;IgA.monoclonal [Presence] in Cerebral spinal fluid by Immunofixation;M-IgA CSF Ql IFE;;ACTIVE;2.17;2.56 +44590-8;IgA.secretory;PrThr;Pt;Saliva;Ord;;CHEM;1;IgA.secretory [Presence] in Saliva (oral fluid);SIgA Sal Ql;;ACTIVE;2.17;2.56 +44591-6;IgD;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgD [Presence] in Urine by Immunofixation;IgD Ur Ql IFE;;ACTIVE;2.17;2.56 +44592-4;IgD;PrThr;Pt;Ser;Ord;;CHEM;1;IgD [Presence] in Serum;IgD Ser Ql;;ACTIVE;2.17;2.73 +44593-2;IgE;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgE [Presence] in Urine by Immunofixation;IgE Ur Ql IFE;;ACTIVE;2.17;2.56 +4459-4;Vancomycin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Vancomycin [Mass] of Dose;Vancomycin Dose;;ACTIVE;1.0;2.73 +44594-0;IgE;PrThr;Pt;Ser;Ord;;CHEM;1;IgE [Presence] in Serum;IgE Ser Ql;;ACTIVE;2.17;2.73 +44595-7;IgG;PrThr;24H;Urine;Ord;Immunofixation;CHEM;1;IgG [Presence] in 24 hour Urine by Immunofixation;IgG 24h Ur Ql IFE;;ACTIVE;2.17;2.56 +44596-5;IgG Ag;PrThr;Pt;Skin;Ord;IF;PATH;1;IgG Ag [Presence] in Skin by Immunofluorescence;IgG Ag Skin Ql IF;;ACTIVE;2.17;2.73 +44597-3;IgG.monoclonal;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgG.monoclonal [Presence] in Serum by Immunofixation;M-IgG Ser Ql IFE;;ACTIVE;2.17;2.56 +44598-1;IgG.monoclonal;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgG.monoclonal [Presence] in Urine by Immunofixation;M-IgG Ur Ql IFE;;ACTIVE;2.17;2.56 +44599-9;IgG.monoclonal;PrThr;Pt;CSF;Ord;Immunofixation;CHEM;1;IgG.monoclonal [Presence] in Cerebral spinal fluid by Immunofixation;M-IgG CSF Ql IFE;;ACTIVE;2.17;2.56 +44600-5;IgM;PrThr;24H;Urine;Ord;Immunofixation;CHEM;1;IgM [Presence] in 24 hour Urine by Immunofixation;IgM 24h Ur Ql IFE;;ACTIVE;2.17;2.73 +44601-3;IgM.monoclonal;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;IgM.monoclonal [Presence] in Serum by Immunofixation;M-IgM Ser Ql IFE;;ACTIVE;2.17;2.56 +4460-2;Verapamil;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Verapamil [Mass] of Dose;Verapamil Dose;;ACTIVE;1.0;2.69 +44602-1;IgM.monoclonal;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;IgM.monoclonal [Presence] in Urine by Immunofixation;M-IgM Ur Ql IFE;;ACTIVE;2.17;2.56 +44603-9;IgM.monoclonal;PrThr;Pt;CSF;Ord;Immunofixation;CHEM;1;IgM.monoclonal [Presence] in Cerebral spinal fluid by Immunofixation;M-IgM CSF Ql IFE;;ACTIVE;2.17;2.56 +44604-7;Immunoglobulin light chains.kappa.free;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;Kappa light chains.free [Presence] in Urine by Immunofixation;Kappa LC Free Ur Ql IFE;;ACTIVE;2.17;2.63 +44605-4;Immunoglobulin light chains.kappa;PrThr;Pt;CSF;Ord;Immunofixation;CHEM;1;Kappa light chains [Presence] in Cerebral spinal fluid by Immunofixation;Kappa LC CSF Ql IFE;;ACTIVE;2.17;2.63 +44606-2;ALOX3+ALOX12B gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ALOX3+ALOX12B gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ALOX3+ALOX12B gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +44607-0;HIV 1;Imp;Pt;Ser/Plas;Nom;IA;MICRO;1;HIV 1 [Interpretation] in Serum or Plasma by Immunoassay;HIV1 SerPl IA-Imp;;ACTIVE;2.17;2.73 +44608-8;KCNQ1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KCNQ1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;KCNQ1 gene Mut Tested Bld/T;;ACTIVE;2.17;2.17 +44609-6;Heart rate;NRat;Episode^max;Capillary bed;Qn;Oximetry;HRTRATE.MOLEC;2;Deprecated Heart rate Episode maximum by Oximetry;Deprecated Heart rate Episode Max Oximet;;DEPRECATED;2.17;2.54 +4461-0;Warfarin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Warfarin [Mass] of Dose;Warfarin Dose;;ACTIVE;1.0;2.73 +44610-4;Heart rate;NRat;Episode^min;Capillary bed;Qn;Oximetry;HRTRATE.MOLEC;2;Deprecated Heart rate Episode minimum by Oximetry;Deprecated Heart rate Episode Min Oximet;;DEPRECATED;2.17;2.54 +44611-2;Heart rate;NRat;Episode^mean;Capillary bed;Qn;Oximetry;HRTRATE.MOLEC;2;Deprecated Heart rate Episode mean by Oximetry;Deprecated Heart rate Episode Mean Oxime;;DEPRECATED;2.17;2.54 +44612-0;Oxygen saturation;MFr;Episode^max;BldC;Qn;Oximetry;HEMODYN.MOLEC;2;Deprecated Oxygen saturation (Episode maximum) in Capillary blood Oximetry;Deprecated SaO2 Episode Max % BldC Oxime;;DEPRECATED;2.17;2.54 +44613-8;Oxygen saturation;MFr;Episode^min;BldC;Qn;Oximetry;HEMODYN.MOLEC;2;Deprecated Oxygen saturation (Episode minimum) in Capillary blood Oximetry;Deprecated SaO2 Episode Min % BldC Oxime;;DEPRECATED;2.17;2.54 +44614-6;Oxygen saturation;MFr;Episode^mean;BldC;Qn;Oximetry;HEMODYN.MOLEC;2;Deprecated Oxygen saturation in Episode mean Capillary blood by Oximetry;Deprecated SaO2 Episode Mean % BldC Oxim;;DEPRECATED;2.17;2.54 +44615-3;Device error code;Prid;Pt;{Device};Nom;;HEMODYN.MOLEC;2;Device error code [Identifier];Device error code;;ACTIVE;2.17;2.27 +44616-1;Pulse oximetry panel;-;Pt;Capillary bed+BldC;Qn;Oximetry;PANEL.CV;2;Deprecated Pulse oximetry panel;Deprecated Pulse oximetry Pnl;;DEPRECATED;2.17;2.68 +44617-9;PWS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PWS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PWS gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +44618-7;Total linear mm of carcinoma;Len;Pt;Specimen;Qn;;PATH.PROTOCOLS.PROST;1;Total linear mm of carcinoma;Total len of Ca;;ACTIVE;2.17;2.70 +44619-5;Length of tissue core(s);Len;Pt;Specimen;Qn;;PATH.PROTOCOLS.GENER;1;Length of tissue core(s);Length of tissue core(s);;ACTIVE;2.17;2.70 +44620-3;Other quantitation;Find;Pt;Specimen;Nar;CAP cancer protocols;PATH.PROTOCOLS.PROST;1;Deprecated Other quantitation by CAP cancer protocols;Deprecated Other quantitation CAP prot;;DEPRECATED;2.17;2.61 +44621-1;Regional lymph nodes examined;Num;Pt;Specimen;Qn;CAP cancer protocols;PATH.PROTOCOLS.PROST;1;Deprecated Regional lymph nodes examined by CAP cancer protocols;Deprecated Reg LN examined CAP prot;;DEPRECATED;2.17;2.69 +44622-9;Regional lymph nodes containing metastases;Num;Pt;Specimen;Qn;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Deprecated Regional lymph nodes containing metastases by CAP cancer protocols;Deprecated Reg LN containing metastases;;DEPRECATED;2.17;2.69 +44623-7;Matted nodes;Prid;Pt;Specimen;Nom;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Matted nodes by CAP cancer protocols;Matted nodes CAP prot;;ACTIVE;2.17;2.36 +44624-5;Additional pathological findings;Find;Pt;Tumor;Nom;;PATH.PROTOCOLS.SKIN;1;Additional pathological findings in Tumor;Addl path findings Tumor;;ACTIVE;2.17;2.63 +44625-2;Periprostatic fat invasion;Prid;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Periprostatic fat invasion [Identifier] in Specimen by CAP cancer protocols;Periprost fat invasion Spec CAP prot;;ACTIVE;2.17;2.61 +44626-0;Seminal vesicle invasion;Prid;Pt;Specimen;Nom;CAP cancer protocols;PATH.HISTO;1;Seminal vesicle invasion [Identifier] in Specimen by CAP cancer protocols;Seminal vesicle invasion Spec CAP prot;;ACTIVE;2.17;2.61 +44627-8;Extraprostatic extension;Prid;Pt;Prostate tumor;Nom;CAP cancer protocols;PATH.PROTOCOLS.PROST;1;Extraprostatic extension by CAP cancer protocols;Extraprostatic ext CAP prot;;ACTIVE;2.17;2.61 +4462-8;Xylose.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Xylose.PO [Mass] of Dose;Xylose PO Dose;;ACTIVE;1.0;2.73 +44628-6;Reason specimen size cannot be determined;Find;Pt;Breast tumor;Nar;;PATH.PROTOCOLS.BRST;1;Reason specimen size cannot be determined in Breast tumor;Reas spec size not det BT;;ACTIVE;2.17;2.61 +44629-4;Specimen size.max dimension;Len;Pt;Breast tumor;Qn;;PATH.PROTOCOLS.BRST;1;Specimen size.maximum dimension in Breast tumor;Spec size.max dim BT;;ACTIVE;2.17;2.70 +44630-2;Specimen size.additional dimension 1;Area;Pt;Breast tumor;Qn;;PATH.PROTOCOLS.BRST;1;Specimen size additional dimension 1 in Breast tumor;Spec size addl dim 1 BT;;ACTIVE;2.17;2.70 +44631-0;Specimen size.additional dimension 2;Area;Pt;Breast tumor;Qn;;PATH.PROTOCOLS.BRST;1;Specimen size additional dimension 2 in Breast tumor;Spec size addl dim 2 BT;;ACTIVE;2.17;2.70 +44632-8;Satellite nodule presence;Prid;Pt;Skin melanoma;Nom;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Deprecated Satellite nodule presence by CAP cancer protocols;Deprecated Satellite nodule presence CAP prot;;DEPRECATED;2.17;2.66 +44633-6;Tumor pigmentation;Prid;Pt;Skin melanoma;Nom;;PATH.PROTOCOLS.SKIN;1;Tumor pigmentation;Tumor pigmentation;;ACTIVE;2.17;2.61 +44634-4;Reason invasive component size cannot be determined;Find;Pt;Breast tumor;Nar;;PATH.HISTO;1;Reason invasive component size cannot be determined in Breast tumor Narrative;Reas inv comp size not det BT;;ACTIVE;2.17;2.61 +44635-1;Invasive component size.max.dimension;Len;Pt;Breast tumor;Qn;;PATH.HISTO;1;Invasive component size.maximum dimension [Length] in Breast tumor;Inv comp size max dim BT;;ACTIVE;2.17;2.70 +4463-6;Motility & count panel;-;Pt;Semen;-;;PANEL.FERT;1;Spermatozoa motility and count panel;Motility + Cnt Pnl Smn;;ACTIVE;1.0;2.73 +44636-9;Invasive component size.additional dimension 1;Len;Pt;Breast tumor;Qn;;PATH.HISTO;1;Invasive component size additional dimension 1 [Length] in Breast tumor;Inv comp size addl dim 1 BT;;ACTIVE;2.17;2.70 +44637-7;Invasive component size.additional dimension 2;Len;Pt;Breast tumor;Qn;;PATH.HISTO;1;Invasive component size additional dimension 2 [Length] in Breast tumor;Inv comp size addl dim 2 BT;;ACTIVE;2.17;2.70 +44638-5;Histologic type;Type;Pt;Breast tumor;Nom;;PATH.HISTO;1;Histologic type in Breast tumor;Histo type BT;;ACTIVE;2.17;2.61 +44639-3;Histologic type;Type;Pt;Prostate tumor;Nom;;PATH.HISTO;1;Histologic type in Prostate tumor;Histo type PrT;;ACTIVE;2.17;2.61 +44640-1;Histologic type;Type;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Histologic type in Skin melanoma;Histo type Mel;;ACTIVE;2.17;2.61 +44641-9;Gleason pattern.primary;Type;Pt;Prostate tumor;Nom;;PATH.PROTOCOLS.PROST;1;Gleason pattern.primary in Prostate tumor;Gleason.primary PrT;;ACTIVE;2.17;2.61 +44642-7;Gleason pattern.secondary;Type;Pt;Prostate tumor;Nom;;PATH.PROTOCOLS.PROST;1;Gleason pattern.secondary in Prostate tumor;Gleason.secondary PrT;;ACTIVE;2.17;2.61 +44643-5;Gleason pattern.tertiary;Type;Pt;Prostate tumor;Nom;;PATH.PROTOCOLS.PROST;1;Gleason pattern.tertiary in Prostate tumor;Gleason.tertiary PrT;;ACTIVE;2.17;2.61 +4464-4;Spermatozoa evaluation.cervical mucus penetration test;Imp;Pt;Semen;Nom;;FERT;1;Cervical Mucus Penetration Test [Interpretation] in Semen;CMSPT Smn-Imp;;ACTIVE;1.0;2.26 +44644-3;Tubule formation;Arb;Pt;Breast tumor;Ord;CAP cancer protocols;PATH.PROTOCOLS.BRST;1;Deprecated Tubule formation in Breast tumor by CAP cancer protocols;Deprecated Tubule formation BT CAP prot;;DEPRECATED;2.17;2.61 +44645-0;Nuclear pleomorphism;Score;Pt;Breast tumor;Ord;Nottingham;PATH.PROTOCOLS.BRST;1;Nuclear pleomorphism in Breast tumor Qualitative by Nottingham;Nuc pleomorph BT Nottingham;;ACTIVE;2.17;2.61 +44646-8;Nottingham mitotic count.25x obj;Find;Pt;Breast tumor;Nom;CAP cancer protocols;PATH.PROTOCOLS.BRST;1;Deprecated Nottingham mitotic count.25x obj in Breast tumor by CAP cancer protocols;Deprecated Nottingham mitotic count.25x;;DEPRECATED;2.17;2.61 +44647-6;Nottingham mitotic count.40x obj;Find;Pt;Breast tumor;Nom;CAP cancer protocols;PATH.PROTOCOLS.BRST;1;Deprecated Nottingham mitotic count.40x obj in Breast tumor by CAP cancer protocols;Deprecated Nottingham mitotic count.40x;;DEPRECATED;2.17;2.61 +44648-4;Histologic grade;Score;Pt;Breast cancer specimen;Ord;Nottingham;PATH.HISTO;1;Histologic grade [Score] in Breast cancer specimen Qualitative by Nottingham;Histo grade Br ca spec Ql Nottingham;;ACTIVE;2.17;2.61 +44649-2;Grading system;Find;Pt;Breast tumor;Nom;;PATH.PROTOCOLS.BRST;1;Grading system in Breast tumor;Grading system BT;;ACTIVE;2.17;2.61 +446-5;Roxithromycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Roxithromycin [Susceptibility] by Serum bactericidal titer;Roxithromycin Titr SBT;;ACTIVE;1.0;2.32 +44650-0;Mitotic count per 10 HPF;Area;Pt;Breast tumor;Qn;;PATH.PROTOCOLS.BRST;1;Mitotic count per 10 HPF in Breast tumor;Mitotic count /10 HPF BT;;ACTIVE;2.17;2.69 +4465-1;Spermatozoa evaluation.hamster ova penetration test;Imp;Pt;Semen;Nom;;FERT;1;Hamster Ova Penetration Test [Interpretation] in Semen;SPA Smn-Imp;;ACTIVE;1.0;2.26 +44651-8;Tissue cores.positive.carcinoma;Num;Pt;Tissue core;Qn;;PATH.PROTOCOLS.PROST;1;Tissue cores.positive.carcinoma in Tissue core;Tissue cores.pos.Ca Tissue Core;;ACTIVE;2.17;2.69 +44652-6;Total number of cores;Num;Pt;Tissue core;Qn;;PATH.PROTOCOLS.PROST;1;Total number of cores in Tissue core;Total # of cores Tissue Core;;ACTIVE;2.17;2.69 +44653-4;Tumor quantitation.incidental;Find;Pt;Prostate tumor;Nom;CAP cancer protocols;PATH.PROTOCOLS.PROST;1;Tumor quantitation.incidental in Prostate tumor by CAP cancer protocols;Tumor quant.incident PT CAP prot;;ACTIVE;2.17;2.61 +44654-2;Prostatic tissue involved by tumor;NFr;Pt;Prostate tumor;Qn;;PATH.PROTOCOLS.PROST;1;Tissue involved by tumor in Prostate tumor;Tissue involved by tumor PrT;;ACTIVE;2.17;2.58 +44655-9;Tissue chips.positive.carcinoma;Num;Pt;Tissue chip;Qn;;PATH.PROTOCOLS.PROST;1;Number of carcinoma positive tissue chips CAP cancer protocols;# CA pos tissue chips CAP prot;;ACTIVE;2.17;2.69 +44656-7;Number of tissue chips;Num;Pt;Tissue chip;Qn;;PATH.PROTOCOLS.PROST;1;Number of tissue chips CAP cancer protocols;# tissue chips CAP protocol;;ACTIVE;2.17;2.69 +44657-5;Dominant nodule.max.dimension;Len;Pt;Prostate tumor;Qn;;PATH.PROTOCOLS.PROST;1;Dominant nodule.maximum.dimension in Prostate tumor;Dom nodule.max.dim PrT;;ACTIVE;2.17;2.70 +44658-3;Dominant nodule.additional dimension 1;Len;Pt;Prostate tumor;Qn;;PATH.PROTOCOLS.PROST;1;Dominant nodule additional dimension 1 in Prostate tumor;Dom nodule addl dim 1 PrT;;ACTIVE;2.17;2.70 +44659-1;Dominant nodule.additional dimension 2;Len;Pt;Prostate tumor;Qn;;PATH.PROTOCOLS.PROST;1;Dominant nodule additional dimension 2 in Prostate tumor;Dom nodule addl dim 2 PrT;;ACTIVE;2.17;2.70 +44660-9;Tumor involved by ulceration;Prid;Pt;Skin melanoma;Nom;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Tumor involvement by ulceration by CAP cancer protocols;Tumor inv by ulcer CAP prot;;ACTIVE;2.17;2.61 +44661-7;Depth of invasion by tumor;Len;Pt;Skin melanoma;Qn;;PATH.HISTO;1;Depth of invasion by tumor [Length] in Skin melanoma;Depth of invasion by tumor Mel;;ACTIVE;2.17;2.70 +44662-5;Depth of invasion by tumor cannot be determined comment;Find;Pt;Skin melanoma;Nar;;PATH.HISTO;1;Depth of invasion by tumor cannot be determined comment in Skin melanoma Narrative;Depth of inv by tumor can't be det;;ACTIVE;2.17;2.61 +44663-3;T classification;Find;Pt;Breast tumor;Nom;CAP cancer protocols;PATH.PROTOCOLS.BRST;1;Deprecated T classification in Breast tumor by CAP cancer protocols;Deprecated T classification BT CAP prot;;DEPRECATED;2.17;2.61 +44664-1;T classification;Find;Pt;Prostate tumor;Nom;CAP cancer protocols;PATH.PROTOCOLS.PROST;1;Deprecated T classification in Prostate tumor by CAP cancer protocols;Deprecated T classification PrT CAP prot;;DEPRECATED;2.17;2.61 +44665-8;T classification;Find;Pt;Skin melanoma;Nom;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Deprecated T classification by CAP cancer protocols;Deprecated T classification CAP prot;;DEPRECATED;2.17;2.61 +44666-6;M stage of distant metastasis;Find;Pt;Breast tumor;Ord;CAP cancer protocols;PATH.PROTOCOLS.BRST;1;Deprecated M stage of distant metastasis in Breast tumor Qualitative by CAP cancer protocols;Deprecated M stage of distant mets BT CA;;DEPRECATED;2.17;2.61 +44667-4;Site of distant metastasis;Find;Pt;Breast tumor;Nom;;PATH.PROTOCOLS.BRST;1;Site of distant metastasis in Breast tumor;Site of distant mets BT;;ACTIVE;2.17;2.61 +44668-2;M stage of distant metastasis;Find;Pt;Skin melanoma;Ord;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Deprecated M stage of distant metastasis Qualitative by CAP cancer protocols;Deprecated M stage of distant mets CAP p;;DEPRECATED;2.17;2.61 +4466-9;Stain.vital;Prid;Pt;Semen;Nom;;FERT;1;Vital stain used for semen analysis;Vital Stn Smn;;ACTIVE;1.0;2.73 +44669-0;Margin involvement;Find;Pt;Breast tumor;Nom;;PATH.PROTOCOLS.BRST;1;Margin involvement in Breast tumor;Margin involved BT;;ACTIVE;2.17;2.61 +44670-8;Margin involvement;Find;Pt;Prostate tumor;Nom;CAP cancer protocols;PATH.PROTOCOLS.PROST;1;Margin involvement in Prostate tumor by CAP cancer protocols;Margin involve PT CAP prot;;ACTIVE;2.17;2.61 +44671-6;Margin involvement;Find;Pt;Skin melanoma;Nom;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Margin involvement by CAP cancer protocols;Margin involve CAP prot;;ACTIVE;2.17;2.61 +44672-4;Invasive carcinoma.uninvolved margin distance.closest;Len;Pt;Breast tumor;Qn;;PATH.HISTO;1;Invasive carcinoma uninvolved margin distance closest [Length] in Breast tumor;IC uninv marg dist closest BT;;ACTIVE;2.17;2.70 +44673-2;DCIS.uninvolved margin distance.closest;Len;Pt;Breast tumor;Qn;;PATH.PROTOCOLS.BRST;1;DCIS.uninvolved margin distance.closest in Breast tumor;DCIS.uninv marg dist.closest BT;;ACTIVE;2.17;2.70 +44674-0;Invasive carcinoma.uninvolved margin.closest;Find;Pt;Breast tumor;Nom;;PATH.HISTO;1;Invasive carcinoma uninvolved margin closest in Breast tumor;IC uninv marg closest BT;;ACTIVE;2.17;2.61 +44675-7;DCIS.uninvolved margin.closest;Find;Pt;Breast tumor;Nom;;PATH.PROTOCOLS.BRST;1;DCIS.uninvolved margin.closest in Breast tumor;DCIS.uninv marg.closest BT;;ACTIVE;2.17;2.61 +44676-5;Margin(s) involved by invasive carcinoma;Find;Pt;Breast tumor;Nom;;PATH.HISTO;1;Margin(s) involved by invasive carcinoma in Breast tumor;Margin(s) involved by IC BT;;ACTIVE;2.17;2.61 +4467-7;Spinnbarkeit test;Len;Pt;Cvm;Qn;;FERT;1;Deprecated Spinnbarkeit [Length] in Cervical mucus;Deprecated Spinnbarkeit Cerv mucus Qn;;DEPRECATED;1.0;2.36 +44677-3;Margin(s) involved by DCIS;Find;Pt;Breast tumor;Nom;;PATH.PROTOCOLS.BRST;1;Margin(s) involved by DCIS in Breast tumor;Margin(s) involved by DCIS BT;;ACTIVE;2.17;2.61 +44678-1;Margin(s) involved by invasive carcinoma;Find;Pt;Prostate tumor;Nom;;PATH.HISTO;1;Margin(s) involved by invasive carcinoma in Prostate tumor;Margin(s) involved by IC PrT;;ACTIVE;2.17;2.61 +44679-9;Margin(s) involved by invasive melanoma;Find;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Margin(s) involved by invasive melanoma in Skin melanoma;Margin(s) involved by IM Mel;;ACTIVE;2.17;2.61 +44680-7;Margin(s) involved by melanoma in situ;Find;Pt;Skin melanoma;Nom;;PATH.PROTOCOLS.SKIN;1;Margin(s) involved by melanoma in situ;Margin(s) involved by MIS;;ACTIVE;2.17;2.61 +44681-5;Invasive melanoma.uninvolved margin.closest;Find;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Invasive melanoma.uninvolved margin.closest in Skin melanoma;IM.uninv marg.closest Mel;;ACTIVE;2.17;2.61 +44682-3;Invasive melanoma in situ.uninvolved margin.closest;Find;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Invasive melanoma in situ.uninvolved margin.closest in Skin melanoma;IMIS.uninv marg.closest Mel;;ACTIVE;2.17;2.61 +44683-1;Distance of invasive melanoma to closest lateral margin;Len;Pt;Skin melanoma;Qn;;PATH.HISTO;1;Distance of invasive melanoma to closest lateral margin [Length] in Skin melanoma;Dist IM to closest lat marg Mel;;ACTIVE;2.17;2.70 +44684-9;Distance of melanoma in situ to closest lateral margin;Len;Pt;Skin melanoma;Qn;;PATH.PROTOCOLS.SKIN;1;Distance of melanoma in situ to closest lateral margin;Dist of MIS to closest lat mar;;ACTIVE;2.17;2.70 +4468-5;Carbonyl hemoglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Deprecated Carboxyhemoglobin/Hemoglobin.total in Blood;Deprecated Carbonyl Hgb Fr Bld;;DEPRECATED;1.0;2.70 +44685-6;Distance of invasive melanoma to closest deep margin;Len;Pt;Skin melanoma;Qn;;PATH.HISTO;1;Distance of invasive melanoma to closest deep margin [Length] in Skin melanoma;Dist IM to closest deep marg Mel;;ACTIVE;2.17;2.70 +44686-4;Invasive melanoma.location relative to closest uninvolved lateral margin;Find;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Invasive melanoma.location relative to closest uninvolved lateral margin in Skin melanoma;IM.loc rel to closest uninv lat marg;;ACTIVE;2.17;2.61 +44687-2;Melanoma in situ.location relative to closest uninvolved lateral margin;Find;Pt;Skin melanoma;Nom;;PATH.PROTOCOLS.SKIN;1;Melanoma in situ.location relative to closest uninvolved lateral margin;MIS.loc rel to closest uninvv lat marg;;ACTIVE;2.17;2.61 +44688-0;Invasive melanoma.location relative to involved lateral margin;Find;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Invasive melanoma.location relative to involved lateral margin in Skin melanoma;IM.loc rel to involved lat marg Mel;;ACTIVE;2.17;2.61 +44689-8;Melanoma in situ.location relative to involved lateral margin;Find;Pt;Skin melanoma;Nom;;PATH.PROTOCOLS.SKIN;1;Melanoma in situ.location relative to involved lateral margin;MIS.loc rel to involved lat margin;;ACTIVE;2.17;2.61 +44690-6;Invasive melanoma.location relative to closest uninvolved deep margin;Find;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Invasive melanoma.location relative to closest uninvolved deep margin in Skin melanoma;IM.loc rel to closest uninv deep marg;;ACTIVE;2.17;2.61 +44691-4;Invasive melanoma.location relative to involved deep margin;Find;Pt;Skin melanoma;Nom;;PATH.HISTO;1;Invasive melanoma.location relative to involved deep margin in Skin melanoma;IM.loc rel to involved deep marg;;ACTIVE;2.17;2.61 +44692-2;Microcalcifications;Find;Pt;Breast tumor;Nom;;PATH.PROTOCOLS.BRST;1;Microcalcifications in Breast tumor;Microcalcifications BT;;ACTIVE;2.17;2.61 +4469-3;Cellano Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Cellano Ag [Presence] on Red Blood Cells;Cellano Ag RBC Ql;;ACTIVE;1.0;2.56 +44693-0;Tumor infiltrating lymphocytes;Find;Pt;Skin melanoma;Nom;;PATH.PROTOCOLS.SKIN;1;Tumor infiltrating lymphocytes;Tumor infiltrating lymph;Copyright © 2017 College of American Pathologists Used with permission;ACTIVE;2.17;2.61 +44694-8;Tumor regression;Find;Pt;Skin melanoma;Nom;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Tumor regression by CAP cancer protocols;Tumor regression CAP prot;;ACTIVE;2.17;2.38 +44695-5;Mitotic index;Find;Pt;Skin melanoma;Nom;CAP cancer protocols;PATH.PROTOCOLS.SKIN;1;Mitotic index by CAP cancer protocols;Mitotic index CAP prot;;ACTIVE;2.17;2.38 +44696-3;Inflammation type;Find;Pt;Prostate tumor;Nom;;PATH.PROTOCOLS.PROST;1;Inflammation type in Prostate tumor;Inflammation type PrT;;ACTIVE;2.17;2.61 +44697-1;Lesion size.max.dimension;Len;Pt;Skin;Qn;;PATH.PROTOCOLS.SKIN;1;Lesion size.maximum dimension in Skin;Les size.max.dim Skin;;ACTIVE;2.17;2.70 +44698-9;Lesion size.additional dimension 1;Area;Pt;Skin;Qn;;PATH.PROTOCOLS.SKIN;1;Lesion size additional dimension 1 in Skin;Les size addl dim 1 Skin;;ACTIVE;2.17;2.70 +44699-7;Extent of margin involvement;Find;Pt;^Cancer;Nom;CAP cancer protocols;PATH.PROTOCOLS.GENER;1;Deprecated Extent of margin involvement by CAP cancer protocols;Deprecated Extent of margin involvement;;DEPRECATED;2.17;2.61 +44700-3;ACTA1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACTA1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ACTA1 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +4470-1;Choleglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Choleglobin/Hemoglobin.total in Blood;Choleglobin MFr Bld;;ACTIVE;1.0;2.70 +44701-1;BHD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BHD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BHD gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +44702-9;Complement C1q Ab;ACnc;Pt;Ser;Qn;;HEM/BC;1;Complement C1q Ab [Units/volume] in Serum;C1q Ab Ser-aCnc;;ACTIVE;2.17;2.73 +44703-7;MC4R gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MC4R gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MC4R gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +44704-5;NEB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NEB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NEB gene Mut Anl Bld/T;;ACTIVE;2.17;2.73 +44705-2;ALS4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ALS4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ALS4 gene Mut Anl Bld/T;;ACTIVE;2.17;2.66 +44706-0;Actin.smooth muscle Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Actin smooth muscle IgG Ab [Units/volume] in Serum;SMA IgG Ser-aCnc;;ACTIVE;2.17;2.73 +44707-8;Albumin/Creatinine;MRto;Pt;CSF;Qn;;CHEM;1;Albumin/Creatinine [Mass Ratio] in Cerebral spinal fluid;Albumin/Creat CSF;;ACTIVE;2.17;2.42 +44708-6;Asialoganglioside GM1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgG Ab [Units/volume] in Serum by Immunoassay;GM1 Asialo IgG Ser IA-aCnc;;ACTIVE;2.17;2.73 +44709-4;Asialoganglioside GM1 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgM Ab [Units/volume] in Serum by Immunoassay;GM1 Asialo IgM Ser IA-aCnc;;ACTIVE;2.17;2.73 +44710-2;Carnitine/Acylcarnitine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine/Acylcarnitine [Molar ratio] in Serum or Plasma;Carnitine/Acylcarnitine SerPl-sRto;;ACTIVE;2.17;2.42 +44711-0;Cholesterol.in LDL/Apolipoprotein B;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL/Apolipoprotein B [Mass Ratio] in Serum or Plasma;LDLc/Apo B SerPl;;ACTIVE;2.17;2.42 +44712-8;Collagen crosslinked N-telopeptide/Creatinine;SRto;Pt;Urine;Qn;IA;CHEM;1;Collagen crosslinked N-telopeptide/Creatinine [Molar ratio] in Urine by Immunoassay;Collagen NTx/Creat Ur IA-sRto;;ACTIVE;2.17;2.73 +44713-6;Collagen crosslinked N-telopeptide/Creatinine;SRto;Pt;XXX;Qn;IA;CHEM;1;Collagen crosslinked N-telopeptide/Creatinine [Molar ratio] in Specimen by Immunoassay;Collagen NTx/Creat Spec IA-sRto;;ACTIVE;2.17;2.69 +44714-4;Complement C3/Protein;MRto;Pt;Synv fld;Qn;;HEM/BC;1;Complement C3/Protein [Mass Ratio] in Synovial fluid;C3/Prot Snv;;ACTIVE;2.17;2.42 +44715-1;Complement C4/Protein;MRto;Pt;Synv fld;Qn;;HEM/BC;1;Complement C4/Protein [Mass Ratio] in Synovial fluid;C4/Prot Snv;;ACTIVE;2.17;2.42 +44716-9;Creatinine/Calcium;MRto;Pt;Urine;Qn;;CHEM;1;Creatinine/Calcium [Mass Ratio] in Urine;Creat/Calcium Ur;;ACTIVE;2.17;2.42 +44717-7;Lipoprotein.beta/Lipoprotein.alpha;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.beta/Lipoprotein.alpha [Mass Ratio] in Serum or Plasma;LDL/HDL SerPl;;ACTIVE;2.17;2.73 +44718-5;Lipoprotein.pre-beta/Triglyceride;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.pre-beta/Triglyceride [Mass Ratio] in Serum or Plasma;VLDL/Trigl SerPl;;ACTIVE;2.17;2.42 +4471-9;Complement activity.cell surface induced;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement Activity Cell Surface Induced [Units/volume] in Serum or Plasma;Comp Actv Surf Ind SerPl-aCnc;;ACTIVE;1.0;2.69 +44719-3;Methylmalonate/Homocysteine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonate/Homocysteine [Mass Ratio] in Serum or Plasma;Methylmalonate/Homocysteine SerPl;;ACTIVE;2.17;2.42 +44720-1;Methylmalonate/Homocystine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonate/Homocystine [Molar ratio] in Serum or Plasma;Methylmalonate/Homocystine SerPl-sRto;;ACTIVE;2.17;2.42 +44721-9;Histiocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Histiocytes [Presence] in Blood by Light microscopy;Histiocytes Bld Ql Smear;;ACTIVE;2.17;2.56 +44722-7;Histiocytes;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Histiocytes [Presence] in Body fluid by Light microscopy;Histiocytes Fld Ql Micro;;ACTIVE;2.17;2.56 +44723-5;Histiocytes;PrThr;Pt;Bone mar;Ord;Microscopy.light;HEM/BC;1;Histiocytes [Presence] in Bone marrow by Light microscopy;Histiocytes Mar Ql Micro;;ACTIVE;2.17;2.56 +44724-3;HLA-A29;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A29 [Presence];HLA-A29 Ql;;ACTIVE;2.17;2.73 +44725-0;HLA-B1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B1 [Presence];HLA-B1 Ql;;ACTIVE;2.17;2.56 +44726-8;HLA-B51;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B51 [Presence];HLA-B51 Ql;;ACTIVE;2.17;2.73 +4472-7;Complement C'2 esterase;-;Pt;Ser;Qn;;HEM/BC;1;Deprecated Complement C'2 esterase;Deprecated C'2 esterase Ser Qn;;DEPRECATED;1.0;2.66 +44727-6;HLA-DP2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DP2 [Presence];HLA-DP2 Ql;;ACTIVE;2.17;2.56 +44728-4;HLA-DQA1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQA1 [Presence];HLA-DQA1 Ql;;ACTIVE;2.17;2.73 +44729-2;Progesterone/11-Deoxycorticosterone;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Progesterone/11-Deoxycorticosterone [Mass Ratio] in Serum or Plasma;Progest/11DOC SerPl;;ACTIVE;2.17;2.42 +447-3;Sisomicin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Sisomicin [Susceptibility] by Minimum lethal concentration (MLC);Sisomicin Islt MLC;;ACTIVE;1.0;2.19 +44730-0;Progesterone/Estradiol;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Progesterone/Estradiol (E2) [Mass Ratio] in Serum or Plasma;Progest/Estradiol SerPl;;ACTIVE;2.17;2.42 +44731-8;Transferrin.carbohydrate deficient.asialo/Transferrin.carbohydrate deficient.disialo;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.asialo/Transferrin.carbohydrate deficient.disialo [Mass Ratio] in Serum or Plasma;CDT Asialo/CDT Disialo SerPl;;ACTIVE;2.17;2.52 +44732-6;Transferrin.carbohydrate deficient.monosialo/Transferrin.carbohydrate deficient.disialo;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.monosialo/Transferrin.carbohydrate deficient.disialo [Mass Ratio] in Serum or Plasma;CDT Monosialo/CDT Disialo SerPl;;ACTIVE;2.17;2.52 +44733-4;Triglyceride/Cholesterol.in HDL;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride/Cholesterol in HDL [Mass Ratio] in Serum or Plasma;Trigl/HDLc SerPl;;ACTIVE;2.17;2.42 +44734-2;Urea nitrogen/Creatinine;MRto;Pt;Bld;Qn;;CHEM;1;Urea nitrogen/Creatinine [Mass Ratio] in Blood;BUN/Creat Bld;;ACTIVE;2.17;2.73 +4473-5;Complement C'3 esterase;-;Pt;Ser;Qn;;HEM/BC;1;Deprecated Complement C'3 esterase;Deprecated C'3 esterase Ser Qn;;DEPRECATED;1.0;2.66 +44735-9;Urea nitrogen/Creatinine;MRto;Pt;Body fld;Qn;;CHEM;1;Urea nitrogen/Creatinine [Mass Ratio] in Body fluid;Urea nit/Creat Fld;;ACTIVE;2.17;2.42 +44736-7;Asialoganglioside GM1 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Asialoganglioside GM1 Ab [Presence] in Serum by Immunoassay;GM1 Asialo Ab Ser Ql IA;;ACTIVE;2.17;2.56 +44737-5;Asialoganglioside GM1 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 Ab [Units/volume] in Serum by Immunoassay;GM1 Asialo Ab Ser IA-aCnc;;ACTIVE;2.17;2.73 +44738-3;Asialoganglioside GM1 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Asialoganglioside GM1 IgG Ab [Presence] in Serum;GM1 Asialo IgG Ser Ql;;ACTIVE;2.17;2.56 +44739-1;Beta tubulin Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Beta tubulin IgM Ab [Presence] in Serum;B-Tubulin IgM Ser Ql;;ACTIVE;2.17;2.56 +44740-9;Ganglioside GD1a Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GD1a Ab [Presence] in Serum;GD1a Gangl Ab Ser Ql;;ACTIVE;2.17;2.56 +44741-7;Disialylganglioside GD1b Ab;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Disialylganglioside GD1b Ab [Presence] in Serum;Deprecated GD1b Disialyl Ab Ser Ql;;DEPRECATED;2.17;2.36 +44742-5;Disialylganglioside GD1b Ab.IgG;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Disialylganglioside GD1b IgG Ab [Presence] in Serum;Deprecated GD1b Disialyl IgG Ser Ql;;DEPRECATED;2.17;2.36 +4474-3;Complement C'4 esterase;-;Pt;Ser;Qn;;HEM/BC;1;Deprecated Complement C'4 esterase;Deprecated C'4 esterase Ser Qn;;DEPRECATED;1.0;2.66 +44743-3;Disialylganglioside GD1b Ab.IgM;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Disialylganglioside GD1b IgM Ab [Presence] in Serum;Deprecated GD1b Disialyl IgM Ser Ql;;DEPRECATED;2.17;2.36 +44744-1;La Crosse virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;La Crosse virus Ab [Presence] in Serum by Immunofluorescence;LACV Ab Ser Ql IF;;ACTIVE;2.17;2.58 +44745-8;La Crosse virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;La Crosse virus Ab [Presence] in Serum by Immunoassay;LACV Ab Ser Ql IA;;ACTIVE;2.17;2.58 +44746-6;La Crosse virus Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;La Crosse virus Ab [Units/volume] in Serum by Immunofluorescence;LACV Ab Ser IF-aCnc;;ACTIVE;2.17;2.69 +44747-4;La Crosse virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;La Crosse virus Ab [Presence] in Serum;LACV Ab Ser Ql;;ACTIVE;2.17;2.58 +44748-2;La Crosse virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;La Crosse virus Ab [Units/volume] in Serum by Immunoassay;LACV Ab Ser IA-aCnc;;ACTIVE;2.17;2.69 +44749-0;Ganglioside GM1 Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GM1 IgA Ab [Presence] in Serum;GM1 Gangl IgA Ser Ql;;ACTIVE;2.17;2.56 +4475-0;Complement C1;-;Pt;Plas;Qn;;HEM/BC;1;Deprecated Complement C1;Deprecated C1 Plas Qn;;DEPRECATED;1.0;2.66 +44750-8;Ganglioside GM1 Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GM1 IgM Ab [Presence] in Serum;GM1 Gangl IgM Ser Ql;;ACTIVE;2.17;2.56 +44751-6;Nuclear Ab;PrThr;Pt;Ser;Ord;IF rat kidney substrate;SERO;1;Nuclear Ab [Presence] in Serum by Immunofluorescence (IF) rat kidney;ANA Ser Ql IF Rat Kidney;;ACTIVE;2.17;2.73 +44752-4;Nuclear Ab;ACnc;Pt;Ser;Qn;IF rat kidney substrate;SERO;1;Nuclear Ab [Units/volume] in Serum by Immunofluorescence (IF) rat kidney;ANA Ser IF Rat Kidney-aCnc;;ACTIVE;2.17;2.69 +44753-2;Sulfatide Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Sulfatide IgM Ab [Presence] in Serum;Sulfatide IgM Ser Ql;;ACTIVE;2.17;2.56 +44754-0;Hepatitis D virus Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis D virus Ag [Presence] in Serum by Immunoassay;HDV Ag Ser Ql IA;;ACTIVE;2.17;2.73 +44755-7;Hepatitis D virus Ag;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis D virus Ag [Units/volume] in Serum by Immunoassay;HDV Ag Ser IA-aCnc;;ACTIVE;2.17;2.73 +44756-5;Reason for transplant;Find;Pt;^Patient;Nom;;TRNSPLNT.ORGAN;2;Reason for transplant;Reason for transplant;;ACTIVE;2.17;2.27 +44757-3;Blood product units given;Num;Pt;^BPU;Qn;;BLDBK;1;Blood product units given [#];Num BPU Gvn;;ACTIVE;2.17;2.69 +44758-1;Transplant risk factors;Find;Pt;^Patient;Nom;;TRNSPLNT.ORGAN;2;Transplant risk factors;Transplant risk factors;;ACTIVE;2.17;2.27 +44759-9;Volume;Vol;Pt;Periton fld;Qn;Estimated;TRNSPLNT.ORGAN;2;Volume Peritoneal fluid Estimated;Volume Prt Est;;ACTIVE;2.17;2.48 +44760-7;Model for end-stage liver disease score;Score;Pt;^Patient;Qn;;TRNSPLNT.ORGAN;2;Model for end-stage liver disease score;MELD score;;ACTIVE;2.17;2.73 +44761-5;Graft portion;Find;Pt;Liver;Nom;;TRNSPLNT.ORGAN;2;Graft portion Liver;Graft portion Liver;;ACTIVE;2.17;2.27 +44762-3;Liver transplant anastomosis site;Anat;Pt;Hepatic artery;Nom;;TRNSPLNT.ORGAN;2;Liver transplant anastomosis site Hepatic artery;LT anastomosis site Hep a;;ACTIVE;2.17;2.27 +44763-1;Native inferior vena cava liver graft attachment;Type;Pt;^Patient;Nom;;TRNSPLNT.ORGAN;2;Native inferior vena cava liver graft attachment;Native IVC liver graft attachment;;ACTIVE;2.17;2.29 +44764-9;Biliary anastomosis procedure;Type;Pt;^Patient;Nom;;TRNSPLNT.ORGAN;2;Biliary anastomosis procedure;Biliary anastomosis procedure;;ACTIVE;2.17;2.27 +44765-6;Time clamp removed from portal vein;TmStp;Pt;Portal vein;Qn;;TRNSPLNT.ORGAN;2;Time clamp removed from portal vein;Time clamp removed from portal vein;;ACTIVE;2.17;2.27 +44766-4;Time clamp removed from artery;TmStp;Pt;Artery;Qn;;TRNSPLNT.ORGAN;2;Time clamp removed from artery;Time clamp removed from artery;;ACTIVE;2.17;2.56 +44767-2;Relationship of subject to patient;Type;Pt;^Patient;Nom;;TRNSPLNT.ORGAN;2;Relationship of subject to patient;Relationship of subject to patient;;ACTIVE;2.17;2.27 +4476-8;Complement C1 esterase inhibitor.functional;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor.functional [Mass/volume] in Serum or Plasma;C1INH Functional SerPl-mCnc;;ACTIVE;1.0;2.73 +44768-0;Neuronal nuclear type 1 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Neuronal nuclear type 1 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Hu1 Ab CSF Ql IF;;ACTIVE;2.17;2.73 +44769-8;Neuronal nuclear type 1 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Neuronal nuclear type 1 Ab [Presence] in Cerebral spinal fluid by Immunoblot;Hu1 Ab CSF Ql IB;;ACTIVE;2.17;2.58 +44770-6;Neuronal nuclear Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear IgG Ab [Titer] in Serum by Immunofluorescence;Hu IgG Titr Ser IF;;ACTIVE;2.17;2.70 +44771-4;Varicella zoster virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Varicella zoster virus Ab [Titer] in Serum by Immunofluorescence;VZV Ab Titr Ser IF;;ACTIVE;2.17;2.73 +44772-2;Hepatic artery anatomy;Anat;Pt;^{Subject};Nom;;TRNSPLNT.ORGAN;2;Hepatic artery anatomy;Hepatic artery anatomy;;ACTIVE;2.17;2.29 +44773-0;Liver transplant anastomosis site;Anat;Pt;Hepatic artery^Graft;Nom;;TRNSPLNT.ORGAN;2;Liver transplant anastomosis site Hepatic artery from Graft;LT anastomosis site Hep a Graft;;ACTIVE;2.17;2.27 +44774-8;Interposition graft;Type;Pt;{Blood vessel};Nom;;TRNSPLNT.ORGAN;2;Interposition graft {Blood vessel};Interposition graft {Blood Vessel};;ACTIVE;2.17;2.29 +44775-5;Liver transplant anastomosis site;Anat;Pt;Portal vein^Graft;Nom;;TRNSPLNT.ORGAN;2;Liver transplant anastomosis site Portal vein from Graft;LT anastomosis site Portal v Graft;;ACTIVE;2.17;2.27 +4477-6;Complement C1 esterase inhibitor;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor [Mass/volume] in Serum or Plasma;C1INH SerPl-mCnc;;ACTIVE;1.0;2.73 +44776-3;Time cross clamp applied;TmStp;Pt;{Organ};Qn;;TRNSPLNT.ORGAN;2;Time cross clamp applied {Organ};Time cross clamp applied {organ};;ACTIVE;2.17;2.27 +44777-1;Time removed from cold;TmStp;Pt;{Organ};Qn;;TRNSPLNT.ORGAN;2;Time removed from cold {Organ};Time removed from cold {organ};;ACTIVE;2.17;2.27 +44778-9;Cold ischemic time;Time;Pt;{Organ};Qn;;TRNSPLNT.ORGAN;2;Cold ischemic time {Organ};Cold ischemic time {organ};;ACTIVE;2.17;2.48 +44779-7;Warm ischemic time;Time;Pt;{Organ};Qn;;TRNSPLNT.ORGAN;2;Warm ischemic time {Organ};Warm ischemic time {organ};;ACTIVE;2.17;2.48 +44780-5;Organ donor ID number;ID;Pt;^Donor;Nar;;ADMIN.ID;2;Organ donor ID number Narrative;Organ donor ID # Donr;;ACTIVE;2.17;2.66 +44781-3;Functional status of graft;Find;Pt;{Graft};Nom;;TRNSPLNT.ORGAN;2;Functional status of graft;Functional status of graft;;ACTIVE;2.17;2.27 +44782-1;Cause of graft failure;Find;Pt;{Graft};Nom;;TRNSPLNT.ORGAN;2;Cause of graft failure;Cause of graft failure;;ACTIVE;2.17;2.27 +44783-9;Sodium;SCnc;Stdy^max;Ser/Plas;Qn;;CHEM;1;Sodium [Moles/volume] (Maximum value during study) in Serum or Plasma;Sodium (Study max) SerPl-sCnc;;ACTIVE;2.17;2.54 +4478-4;Complement C1q;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1q [Mass/volume] in Serum or Plasma;C1q SerPl-mCnc;;ACTIVE;1.0;2.73 +44784-7;Creatinine;MCnc;Stdy^max;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass/volume] (Maximum value during study) in Serum or Plasma;Creat (Study max) SerPl-mCnc;;ACTIVE;2.17;2.54 +44785-4;Alanine aminotransferase;CCnc;Stdy^max;Ser/Plas;Qn;No addition of P-5'-P;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] (Maximum value during study) in Serum or Plasma by No addition of P-5'-P;ALT (Study max) SerPl w/o P-5'-P-cCnc;;ACTIVE;2.17;2.68 +44786-2;Aspartate aminotransferase;CCnc;Stdy^max;Ser/Plas;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] (Maximum value during study) in Serum or Plasma;AST (Study max) SerPl-cCnc;;ACTIVE;2.17;2.68 +44787-0;Preservation fluid;Type;Pt;{Organ};Nom;;TRNSPLNT.ORGAN;2;Preservation fluid {Organ};Preservation fluid {organ};;ACTIVE;2.17;2.29 +44788-8;Organ donor;Type;Pt;^Donor;Nom;;TRNSPLNT.ORGAN;2;Organ donor;Organ donor Donr;;ACTIVE;2.17;2.29 +44789-6;Amylase & Creatinine clearance panel;-;Pt;Urine+Ser/Plas;Qn;;PANEL.CHEM;1;Amylase and Creatinine clearance panel - Urine and Serum or Plasma;Amylase + CrCl Pnl Ur+SerPl;;ACTIVE;2.17;2.42 +44790-4;Iodide;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Iodide [Mass/volume] in Specimen;Iodide Spec-mCnc;;ACTIVE;2.17;2.73 +44791-2;Menorrhagia coagulation panel;-;Pt;PPP;Qn;;PANEL.COAG;1;Menorrhagia coagulation panel - Platelet poor plasma;Menorrhagia Pnl PPP;;ACTIVE;2.17;2.42 +4479-2;Complement C1q Ag;SCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1q Ag [Moles/volume] in Serum or Plasma;C1q Ag SerPl-sCnc;;ACTIVE;1.0;2.73 +44792-0;Immunoglobulin light chains panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Immunoglobulin light chains panel - Urine;Immunoglobulin LC Pnl Ur;;ACTIVE;2.17;2.42 +44793-8;Immunoglobulin light chains panel;MCnc;Pt;Ser;Qn;;PANEL.CHEM;1;Immunoglobulin light chains panel [Mass/volume] - Serum;Immunoglobulin LC Pnl Ser-mCnc;;ACTIVE;2.17;2.73 +44794-6;Aquaporin 4 water channel Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Aquaporin 4 water channel IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;AQP4 H2O channel IgG Titr SerPl IF;;ACTIVE;2.17;2.73 +44795-3;Influenza virus A H5 Asian RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H5 Asian RNA [Presence] in Specimen by NAA with probe detection;FLUAV H5 Asian RNA Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +44796-1;Clostridium botulinum toxin;Prid;Pt;XXX;Nom;;MICRO;1;Clostridium botulinum toxin [Identifier] in Specimen;C bot Tox Spec;;ACTIVE;2.17;2.69 +44797-9;Brucella sp;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Brucella sp [Presence] in Specimen by Organism specific culture;Brucella Spec Ql Cult;;ACTIVE;2.17;2.69 +44798-7;Burkholderia sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Burkholderia sp identified in Specimen by Organism specific culture;Burkholderia Spec Cult;;ACTIVE;2.17;2.73 +44799-5;Coxiella burnetii;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Coxiella burnetii [Presence] in Specimen by Organism specific culture;C burnet Spec Ql Cult;;ACTIVE;2.17;2.69 +44-8;Aztreonam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Aztreonam [Susceptibility] by Minimum inhibitory concentration (MIC);Aztreonam Islt MIC;;ACTIVE;1.0;2.73 +4480-0;Complement C1q binding;-;Pt;Ser;Qn;ID;HEM/BC;1;Deprecated Complement C1q Ag [Molecules/volume] in Serum or Plasma;Deprecated C1q binding Ser Qn;;DEPRECATED;1.0;2.66 +44800-1;Burkholderia sp;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Burkholderia sp [Presence] in Specimen by Organism specific culture;Burkholderia Spec Ql Cult;;ACTIVE;2.17;2.69 +44801-9;Aldolase;CCnc;Pt;Plr fld;Qn;;CHEM;1;Aldolase [Enzymatic activity/volume] in Pleural fluid;Aldolase Plr-cCnc;;ACTIVE;2.17;2.68 +44802-7;Enolase.neuron specific;MCnc;Pt;CSF;Qn;;CHEM;1;Enolase.neuron specific [Mass/volume] in Cerebral spinal fluid;NSE CSF-mCnc;;ACTIVE;2.17;2.73 +44803-5;GNE gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GNE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GNE gene Mut Anl Bld/T;;ACTIVE;2.17;2.73 +44804-3;Taenia solium Ab.IgG;ACnc;Pt;Ser;Qn;IB;MICRO;1;Taenia solium IgG Ab [Units/volume] in Serum by Immunoblot;T sol IgG Ser IB-aCnc;;ACTIVE;2.17;2.69 +44805-0;BK virus DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;BKV DNA SerPl NAA+probe-Log#;;ACTIVE;2.17;2.73 +44806-8;Chlamydia trachomatis+Neisseria gonorrhoeae DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection;C trach+GC DNA Ur Ql NAA+probe;;ACTIVE;2.17;2.73 +44807-6;Chlamydia trachomatis+Neisseria gonorrhoeae DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Genital specimen by NAA with probe detection;C trach+GC DNA Genital Ql NAA+probe;;ACTIVE;2.17;2.73 +44808-4;Histoplasma capsulatum H Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Histoplasma capsulatum H Ab band pattern [Interpretation] in Serum by Immunoblot;H capsul H Ab Patrn Ser IB-Imp;;ACTIVE;2.17;2.58 +44809-2;Histoplasma capsulatum M Ab band pattern;Imp;Pt;Ser;Nom;IB;MICRO;1;Histoplasma capsulatum M Ab band pattern [Interpretation] in Serum by Immunoblot;H capsul M Ab Patrn Ser IB-Imp;;ACTIVE;2.17;2.73 +448-1;Sisomicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sisomicin [Susceptibility] by Minimum inhibitory concentration (MIC);Sisomicin Islt MIC;;ACTIVE;1.0;2.19 +44810-0;HTLV I gp21e Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV I gp21e Ab [Presence] in Serum;HTLV I gp21e Ab Ser Ql;;ACTIVE;2.17;2.56 +44811-8;Coccidioides sp Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Coccidioides sp IgA Ab [Presence] in Serum by Immunoassay;Coccidioides IgA Ser Ql IA;;ACTIVE;2.17;2.56 +44812-6;Yeast.hyphae;PrThr;Pt;XXX;Ord;Wet preparation;MICRO;1;Yeast.hyphae [Presence] in Specimen by Wet preparation;Yeast Hyphae Spec Ql Wet Prep;;ACTIVE;2.17;2.73 +44813-4;Hepatitis C virus c22p Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus c22p Ab [Presence] in Serum by Immunoblot;HCV C22p Ab Ser Ql IB;;ACTIVE;2.17;2.73 +44814-2;Coxiella burnetii phase 2 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Titer] in Serum by Immunofluorescence;C burnet Ph2 IgM Titr Ser IF;;ACTIVE;2.17;2.73 +44815-9;Brucella abortus Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Brucella abortus IgM Ab [Units/volume] in Serum by Immunofluorescence;B abortus IgM Ser IF-aCnc;;ACTIVE;2.17;2.69 +44816-7;Trypanosoma cruzi Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Trypanosoma cruzi IgG Ab [Presence] in Serum by Immunofluorescence;T cruzi IgG Ser Ql IF;;ACTIVE;2.17;2.56 +44817-5;Cytomegalovirus Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Cytomegalovirus IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;CMV IgM CSF IA-aCnc;;ACTIVE;2.17;2.73 +4481-8;Complement C1r;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1r [Mass/volume] in Serum or Plasma;C1r SerPl-mCnc;;ACTIVE;1.0;2.44 +44818-3;Brucella abortus Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Brucella abortus IgG Ab [Units/volume] in Serum by Immunofluorescence;B abortus IgG Ser IF-aCnc;;ACTIVE;2.17;2.69 +44819-1;Leishmania donovani Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania donovani IgM Ab [Titer] in Serum by Immunofluorescence;L donovani IgM Titr Ser IF;;ACTIVE;2.17;2.32 +44820-9;Leishmania braziliensis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania brasilensis IgM Ab [Titer] in Serum by Immunofluorescence;L braziliensis IgM Titr Ser IF;;ACTIVE;2.17;2.32 +44821-7;Leishmania braziliensis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania brasilensis IgG Ab [Titer] in Serum by Immunofluorescence;L braziliensis IgG Titr Ser IF;;ACTIVE;2.17;2.32 +44822-5;La Crosse virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;La Crosse virus IgM Ab [Titer] in Serum by Immunoassay;LACV IgM Titr Ser IA;;ACTIVE;2.17;2.58 +44823-3;Bartonella quintana Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Bartonella quintana IgM Ab [Units/volume] in Serum by Immunofluorescence;B quintana IgM Ser IF-aCnc;;ACTIVE;2.17;2.69 +44824-1;Leishmania donovani Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania donovani IgG Ab [Titer] in Serum by Immunofluorescence;L donovani IgG Titr Ser IF;;ACTIVE;2.17;2.32 +44825-8;Bartonella quintana Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella quintana IgM Ab [Titer] in Serum by Immunofluorescence;B quintana IgM Titr Ser IF;;ACTIVE;2.17;2.73 +4482-6;Complement C1r2+C1s2;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1r2+C1s2 [Units/volume] in Serum or Plasma;C1r2+C1s2 SerPl-aCnc;;ACTIVE;1.0;2.69 +44826-6;Hepatitis D virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis D virus IgM Ab [Units/volume] in Serum by Immunoassay;HDV IgM Ser IA-aCnc;;ACTIVE;2.17;2.73 +44827-4;Bartonella quintana Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella quintana IgG Ab [Titer] in Serum by Immunofluorescence;B quintana IgG Titr Ser IF;;ACTIVE;2.17;2.73 +44828-2;Teriflunomide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Teriflunomide [Mass/volume] in Serum or Plasma;Teriflunomide SerPl-mCnc;;ACTIVE;2.17;2.73 +44829-0;Acremonium sp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Acremonium sp IgG Ab RAST class [Presence] in Serum;Acremonium IgG RAST Ql;;ACTIVE;2.17;2.58 +44830-8;Phosphorylase;CCnc;Pt;Bld;Qn;;CHEM;1;Phosphorylase [Enzymatic activity/volume] in Blood;Phosphorylase Bld-cCnc;;ACTIVE;2.17;2.70 +44831-6;Hepatitis C virus c100p+5-1-1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus c100p+5-1-1 Ab [Presence] in Serum;HCV c100p+5-1-1 Ab Ser Ql;;ACTIVE;2.17;2.73 +44832-4;Glycogen synthase I/Glycogen synthase.total;CFr;Pt;Bld;Qn;;CHEM;1;Glycogen synthase I/Glycogen synthase.total in Blood;Glycogen Synthase I CFr Bld;;ACTIVE;2.17;2.42 +44833-2;Diagnosis.preliminary;Imp;Pt;^Patient;Nom;;H&P.PX;2;Preliminary diagnosis;Dx preliminary;;ACTIVE;2.17;2.73 +4483-4;Complement C1s;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1s [Mass/volume] in Serum or Plasma;C1s SerPl-mCnc;;ACTIVE;1.0;2.73 +44834-0;Acid phosphatase.tartrate resistant;PrThr;Pt;Bone mar;Ord;;CHEM;1;Acid phosphatase tartrate resistant [Presence] in Bone marrow;ACP TRAP Mar Ql;;ACTIVE;2.17;2.56 +44835-7;Acid phosphatase.tartrate resistant;PrThr;Pt;Bld;Ord;;CHEM;1;Acid phosphatase tartrate resistant [Presence] in Blood;ACP TRAP Bld Ql;;ACTIVE;2.17;2.73 +44836-5;5-Hydroxymethyl-2-Furoate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;5-Hydroxymethyl-2-Furoate [Presence] in Urine;5OH-methyl-2-furoate Ur Ql;;ACTIVE;2.17;2.56 +44837-3;Epinephrine+Norepinephrine;MCnc;24H;Urine;Qn;;CHEM;1;Epinephrine+Norepinephrine [Mass/volume] in 24 hour Urine;Epineph+Nor 24h Ur-mCnc;;ACTIVE;2.17;2.73 +44838-1;Catecholamines;Imp;Pt;Plas;Nom;;CHEM;1;Catecholamines [Interpretation] in Plasma;Catechols Plas-Imp;;ACTIVE;2.17;2.73 +44839-9;Choriogonadotropin;PrThr;Pt;Ser^Control;Ord;;CHEM;1;Choriogonadotropin [Presence] in Control Serum;HCG Ser Cont Ql;;ACTIVE;2.17;2.73 +44840-7;Fungus identified^^^5;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus # 5 identified in Specimen by Culture;Fungus Spec Cult org #5;;ACTIVE;2.17;2.69 +44841-5;Bacteria identified^^^2;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria # 2 identified in Specimen by Culture;Bacteria Spec Cult org #2;;ACTIVE;2.17;2.73 +4484-2;Complement C2;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C2 [Mass/volume] in Serum or Plasma;C2 SerPl-mCnc;;ACTIVE;1.0;2.73 +44842-3;Bacteria identified^^^3;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria # 3 identified in Specimen by Culture;Bacteria Spec Cult org #3;;ACTIVE;2.17;2.73 +44843-1;Bacteria identified^^^2;Prid;Pt;XXX;Nom;Anaerobic culture;MICRO;1;Bacteria # 2 identified in Specimen by Anaerobe culture;Bacteria Spec Anaerobe Cult org #2;;ACTIVE;2.17;2.73 +44844-9;Bacteria identified^^^4;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria # 4 identified in Specimen by Culture;Bacteria Spec Cult org #4;;ACTIVE;2.17;2.73 +44845-6;Bacteria identified^^^5;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria # 5 identified in Specimen by Culture;Bacteria Spec Cult org #5;;ACTIVE;2.17;2.73 +44846-4;Bacteria identified^^^6;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria # 6 identified in Specimen by Culture;Bacteria Spec Cult org #6;;ACTIVE;2.17;2.69 +44847-2;Bacteria identified^^^7;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria # 7 identified in Urine by Culture;Bacteria Ur Cult org #7;;ACTIVE;2.17;2.30 +44848-0;Bacteria identified^^^7;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria # 7 identified in Specimen by Culture;Bacteria Spec Cult org #7;;ACTIVE;2.17;2.69 +44849-8;Bacteria identified^^^8;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria # 8 identified in Urine by Culture;Bacteria Ur Cult org #8;;ACTIVE;2.17;2.30 +44850-6;Bacteria identified^^^8;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria # 8 identified in Specimen by Culture;Bacteria Spec Cult org #8;;ACTIVE;2.17;2.69 +44851-4;Mycobacterium sp identified^^^2;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Mycobacterium sp # 2 identified in Specimen by Organism specific culture;Mycobacterium Spec Cult org #2;;ACTIVE;2.17;2.69 +44852-2;Mycobacterium sp identified^^^3;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Mycobacterium sp # 3 identified in Specimen by Organism specific culture;Mycobacterium Spec Cult org #3;;ACTIVE;2.17;2.69 +44853-0;Bacteria identified^^^3;Prid;Pt;XXX;Nom;Anaerobic culture;MICRO;1;Bacteria # 3 identified in Specimen by Anaerobe culture;Bacteria Spec Anaerobe Cult org #3;;ACTIVE;2.17;2.69 +44854-8;Mycobacterium sp identified^^^4;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Mycobacterium sp # 4 identified in Specimen by Organism specific culture;Mycobacterium Spec Cult org #4;;ACTIVE;2.17;2.69 +44855-5;Mycobacterium sp identified^^^5;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Mycobacterium sp # 5 identified in Specimen by Organism specific culture;Mycobacterium Spec Cult org #5;;ACTIVE;2.17;2.69 +44856-3;Bacteria identified^^^4;Prid;Pt;XXX;Nom;Anaerobic culture;MICRO;1;Bacteria # 4 identified in Specimen by Anaerobe culture;Bacteria Spec Anaerobe Cult org #4;;ACTIVE;2.17;2.69 +44857-1;Bacteria identified^^^5;Prid;Pt;XXX;Nom;Anaerobic culture;MICRO;1;Bacteria # 5 identified in Specimen by Anaerobe culture;Bacteria Spec Anaerobe Cult org #5;;ACTIVE;2.17;2.69 +44858-9;Bacteria identified^^^6;Prid;Pt;XXX;Nom;Anaerobic culture;MICRO;1;Bacteria # 6 identified in Specimen by Anaerobe culture;Bacteria Spec Anaerobe Cult org #6;;ACTIVE;2.17;2.69 +4485-9;Complement C3;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C3 [Mass/volume] in Serum or Plasma;C3 SerPl-mCnc;;ACTIVE;1.0;2.73 +44859-7;Bacteria identified^^^7;Prid;Pt;XXX;Nom;Anaerobic culture;MICRO;1;Bacteria # 7 identified in Specimen by Anaerobe culture;Bacteria Spec Anaerobe Cult org #7;;ACTIVE;2.17;2.73 +44860-5;Methoxyacetate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methoxyacetate/Creatinine [Mass Ratio] in Urine;Methoxyacetate/Creat Ur;;ACTIVE;2.17;2.42 +44861-3;4-Hydroxymandelate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxymandelate/Creatinine [Mass Ratio] in Urine;4OHMandelate/Creat Ur;;DISCOURAGED;2.17;2.42 +44862-1;5-Alpha tetrahydro-11-Dehydrocorticosterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;5-Alpha tetrahydro-11-Dehydrocorticosterone/Creatinine [Mass Ratio] in Urine;5-A THB/Creat Ur;;ACTIVE;2.17;2.44 +44863-9;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone/Creatinine [Mass Ratio] in Urine;6A-OH-THA/Creat Ur;;ACTIVE;2.17;2.44 +44864-7;6-Alpha hydroxytetrahydro-11-Deoxycortisol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol/Creatinine [Mass Ratio] in Urine;6A-OH-THS/Creat Ur;;ACTIVE;2.17;2.44 +44865-4;Ammonium urate;PrThr;Pt;Calculus;Ord;;CHEM;1;Ammonium urate [Presence] in Stone;Amm Urate Stone Ql;;ACTIVE;2.17;2.56 +4486-7;Complement C3 fragment;PrThr;Pt;RBC;Ord;;HEM/BC;1;Complement C3 fragment [Presence] in Red Blood Cells;C3 Frg RBC Ql;;ACTIVE;1.0;2.56 +44867-0;Iron.microscopic observation;PrThr;Pt;Body fld;Ord;XXX stain;PATH;1;Iron.microscopic observation [Presence] in Body fluid by Other stain;Iron Fld Ql Other Stn;;ACTIVE;2.17;2.56 +44868-8;Herpes simplex virus 1+2 DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [Presence] in Vaginal fluid by NAA with probe detection;HSV1+2 DNA Vag Ql NAA+probe;;ACTIVE;2.17;2.73 +44869-6;Histoplasma capsulatum Ab;PrThr;Pt;Ser;Ord;CIE;MICRO;1;Histoplasma capsulatum Ab [Presence] in Serum by Counterimmunoelectrophoresis (CIE);H capsul Ab Ser Ql CIE;;ACTIVE;2.17;2.56 +44870-4;Histoplasma capsulatum Ag;PrThr;Pt;Urine;Ord;RIA;MICRO;1;Histoplasma capsulatum Ag [Presence] in Urine by Radioimmunoassay (RIA);H capsul Ag Ur Ql RIA;;ACTIVE;2.17;2.56 +44871-2;HIV 1 proviral DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Presence] in Blood by NAA with probe detection;HIV 1 pro DNA Bld Ql NAA+probe;;ACTIVE;2.17;2.73 +44872-0;HIV 1 p24 Ag;PrThr;Pt;Ser/Plas^Donor;Ord;IA;MICRO;1;HIV 1 p24 Ag [Presence] in Serum or Plasma from Donor by Immunoassay;HIV1 p24 Ag SerPl Donr Ql IA;;ACTIVE;2.17;2.56 +44873-8;HIV 1+2 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1+2 Ab [Presence] in Serum by Immunoblot;HIV1+2 Ab Ser Ql IB;;ACTIVE;2.17;2.73 +44874-6;HTLV I+II RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;HTLV I+II RNA [Presence] in Serum by NAA with probe detection;HTLV I+II RNA Ser Ql NAA+probe;;ACTIVE;2.17;2.63 +4487-5;Complement C3 fragment;MCnc;Pt;RBC;Qn;;HEM/BC;1;Complement C3 fragment [Mass/volume] in Red Blood Cells;C3 Frg RBC-mCnc;;ACTIVE;1.0;2.73 +44875-3;IgM Ag;PrThr;Pt;Skin;Ord;IF;CHEM;1;IgM Ag [Presence] in Skin by Immunofluorescence;IgM Ag Skin Ql IF;;ACTIVE;2.17;2.73 +44876-1;Influenza virus A Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Influenza virus A Ab [Presence] in Cerebral spinal fluid;FLUAV Ab CSF Ql;;ACTIVE;2.17;2.56 +44877-9;Insulin dependent diabetes mellitus;PrThr;Pt;^Patient;Ord;;MISC;1;Insulin dependent diabetes mellitus [Presence];IDDM Patient Ql;;ACTIVE;2.17;2.73 +44878-7;Staphylococcus aureus enterotoxin A sea gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus enterotoxin A sea gene [Presence] in Specimen by NAA with probe detection;S aureus Etx A gene Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +44879-5;Staphylococcus aureus enterotoxin E see gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus enterotoxin E see gene [Presence] in Specimen by NAA with probe detection;S aureus Etx E gene Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +44880-3;Staphylococcus aureus enterotoxin B seb gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus enterotoxin B seb gene [Presence] in Specimen by NAA with probe detection;S aureus Etx B gene Spec Ql NAA+probe;;ACTIVE;2.17;2.73 +44881-1;Staphylococcus aureus toxic shock syndrome toxin gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus toxic shock syndrome toxin gene [Presence] in Specimen by NAA with probe detection;S aureus TSST gene Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +44882-9;Malignant cells;NCnc;Pt;Periton fld;Qn;;HEM/BC;1;Malignant cells [#/volume] in Peritoneal fluid;Malignant cells # Prt;;ACTIVE;2.17;2.44 +4488-3;Complement C3a;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C3a [Mass/volume] in Serum or Plasma;C3a SerPl-mCnc;;ACTIVE;1.0;2.73 +44883-7;Malignant cells;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Malignant cells [#/volume] in Cerebral spinal fluid by Manual count;Malignant cells # CSF Manual;;ACTIVE;2.17;2.44 +44884-5;Malignant cells;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Malignant cells [#/volume] in Pleural fluid by Manual count;Malignant cells # Plr Manual;;ACTIVE;2.17;2.44 +44885-2;Malignant cells;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Malignant cells [#/volume] in Synovial fluid by Manual count;Malignant cells # Snv Manual;;ACTIVE;2.17;2.44 +44886-0;Malignant cells;NCnc;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Malignant cells [#/volume] in Pericardial fluid by Manual count;Malignant cells # Pcar Manual;;ACTIVE;2.17;2.44 +44887-8;Malignant cells;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Malignant cells [#/volume] in Peritoneal fluid by Manual count;Malignant cells # Prt Manual;;ACTIVE;2.17;2.44 +44888-6;Malignant cells;NCnc;Pt;Synv fld;Qn;;HEM/BC;1;Malignant cells [#/volume] in Synovial fluid;Malignant cells # Snv;;ACTIVE;2.17;2.44 +44889-4;Malignant cells;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Malignant cells [#/volume] in Pleural fluid;Malignant cells # Plr;;ACTIVE;2.17;2.44 +44890-2;Malignant cells;NCnc;Pt;CSF;Qn;;HEM/BC;1;Malignant cells [#/volume] in Cerebral spinal fluid;Malignant cells # CSF;;ACTIVE;2.17;2.44 +4489-1;Complement C3b;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C3b [Mass/volume] in Serum or Plasma;C3b SerPl-mCnc;;ACTIVE;1.0;2.44 +44891-0;Malignant cells;NCnc;Pt;Pericard fld;Qn;;HEM/BC;1;Malignant cells [#/volume] in Pericardial fluid;Malignant cells # Pcar;;ACTIVE;2.17;2.44 +44892-8;Malignant cells/100 cells;NFr;Pt;CSF;Qn;;HEM/BC;1;Malignant cells/100 cells in Cerebral spinal fluid;Malignant cells NFr CSF;;ACTIVE;2.17;2.73 +44893-6;Malignant cells/100 cells;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Malignant cells/100 cells in Synovial fluid;Malignant cells NFr Snv;;ACTIVE;2.17;2.73 +44894-4;Malignant cells/100 cells;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Cerebral spinal fluid by Manual count;Malignant cells NFr CSF Manual;;ACTIVE;2.17;2.34 +44895-1;Malignant cells/100 cells;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Pleural fluid by Manual count;Malignant cells NFr Plr Manual;;ACTIVE;2.17;2.34 +44896-9;Malignant cells/100 cells;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Synovial fluid by Manual count;Malignant cells NFr Snv Manual;;ACTIVE;2.17;2.34 +44897-7;Malignant cells/100 cells;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Pericardial fluid by Manual count;Malignant cells NFr Pcar Manual;;ACTIVE;2.17;2.34 +44898-5;Malignant cells/100 cells;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Peritoneal fluid by Manual count;Malignant cells NFr Prt Manual;;ACTIVE;2.17;2.34 +44899-3;Malignant cells/100 cells;NFr;Pt;Urine;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Urine by Manual count;Malignant cells NFr Ur Manual;;ACTIVE;2.17;2.34 +44900-9;Malignant cells/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Bone marrow by Manual count;Malignant cells NFr Mar Manual;;ACTIVE;2.17;2.34 +44901-7;Malignant cells/100 cells;NFr;Pt;Liver;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Liver by Manual count;Malignant cells NFr Liver Manual;;ACTIVE;2.17;2.34 +44902-5;Malignant cells/100 cells;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Malignant cells/100 cells in Pleural fluid;Malignant cells NFr Plr;;ACTIVE;2.17;2.34 +44903-3;Malignant cells/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Malignant cells/100 cells in Bone marrow;Malignant cells NFr Mar;;ACTIVE;2.17;2.34 +44904-1;Malignant cells/100 cells;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Malignant cells/100 cells in Pericardial fluid;Malignant cells NFr Pcar;;ACTIVE;2.17;2.34 +44905-8;Malignant cells/100 cells;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Malignant cells/100 cells in Peritoneal fluid;Malignant cells NFr Prt;;ACTIVE;2.17;2.34 +44906-6;Homovanillate panel;-;24H;Urine;-;;PANEL.CHEM;1;Homovanillate panel - 24 hour Urine;Homovanillate Pnl 24h Ur;;ACTIVE;2.17;2.73 +44907-4;5-Hydroxyindoleacetate panel;-;24H;Urine;-;;PANEL.CHEM;1;5-Hydroxyindoleacetate panel - 24 hour Urine;5HIAA Pnl 24h Ur;;ACTIVE;2.17;2.73 +44908-2;Homovanillate & Creatinine;Imp;Pt;Urine;Nom;;CHEM;1;Homovanillate and Creatinine [Interpretation] in Urine;HVA & Creat Ur-Imp;;ACTIVE;2.17;2.38 +4490-9;Complement C3b-C4b receptor;EntNum;Pt;RBC;Qn;;HEM/BC;1;Complement C3b-C4b receptor [Entitic number] in Red Blood Cells;C3b-C4b Recep EntNum RBC;;ACTIVE;1.0;2.26 +44909-0;5-Hydroxyindoleacetate & Creatinine;Imp;Pt;Urine;Nom;;CHEM;1;5-Hydroxyindoleacetate and Creatinine [Interpretation] in Urine;5HIAA & Creatinine Ur-Imp;;ACTIVE;2.17;2.73 +44910-8;Alpha-1-Fetoprotein;ACnc;Pt;Body fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Body fluid;AFP Fld-aCnc;;ACTIVE;2.17;2.70 +44911-6;Beta 2 globulin+Gamma globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta 2 globulin+Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis;Beta2+Gamma Glob SerPl Elph-mCnc;;ACTIVE;2.17;2.73 +44912-4;Beta 2 globulin+Gamma globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta 2 globulin+Gamma globulin/Protein.total in Serum or Plasma by Electrophoresis;Beta2+Gamma Glob MFr SerPl Elph;;ACTIVE;2.17;2.70 +44913-2;Beta globulin+Gamma globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin+Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis;B+G-Globulin SerPl Elph-mCnc;;ACTIVE;2.17;2.70 +44914-0;Beta globulin+Gamma globulin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin+Gamma globulin/Protein.total in Serum or Plasma by Electrophoresis;B+G-Globulin MFr SerPl Elph;;ACTIVE;2.17;2.70 +44915-7;Cholesterol.in LDL/Cholesterol.in HDL;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL/Cholesterol in HDL [Molar ratio] in Serum or Plasma;LDLc/HDLc SerPl-sRto;;ACTIVE;2.17;2.73 +44916-5;Cortisol^pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre XXX challenge;Cortis pre chal SerPl-sCnc;;ACTIVE;2.17;2.70 +4491-7;Complement C3c;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C3c [Mass/volume] in Serum or Plasma;C3c SerPl-mCnc;;ACTIVE;1.0;2.73 +44917-3;Cortisol^post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --post dose dexamethasone;Cortis p Dex SerPl-sCnc;;ACTIVE;2.17;2.70 +44918-1;DOPamine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;DOPamine/Creatinine [Molar ratio] in 24 hour Urine;DOPamine/Creat 24h Ur-sRto;;ACTIVE;2.17;2.70 +44919-9;Glucose^1.5H post meal;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post meal;Glucose 1.5h p meal SerPl-sCnc;;ACTIVE;2.17;2.73 +44920-7;Hemoglobin C/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin C/Hemoglobin.total in Blood by HPLC;Hgb C MFr Bld HPLC;;ACTIVE;2.17;2.73 +44921-5;Hemoglobin D/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin D/Hemoglobin.total in Blood by HPLC;Hgb D MFr Bld HPLC;;ACTIVE;2.17;2.73 +44922-3;Hemoglobin E/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin E/Hemoglobin.total in Blood by HPLC;Hgb E MFr Bld HPLC;;ACTIVE;2.17;2.73 +44923-1;Hemoglobin S/Hemoglobin.total;MFr;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin S/Hemoglobin.total in Blood by HPLC;Hgb S MFr Bld HPLC;;ACTIVE;2.17;2.73 +44924-9;Normetanephrine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Normetanephrine/Creatinine [Molar ratio] in 24 hour Urine;Normetanephrine/Creat 24h Ur-sRto;;ACTIVE;2.17;2.73 +4492-5;Complement C3d;EntNum;Pt;RBC;Qn;;HEM/BC;1;Complement C3d [Entitic number] in Red Blood Cells;C3d EntNum RBC;;ACTIVE;1.0;2.26 +44925-6;Prolactin^1H post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --1 hour post dose TRH IV;Prolactin 1h p TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44926-4;Prolactin^1.5H post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --1.5 hours post dose TRH IV;Prolactin 1.5h p TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44927-2;Prolactin^30M post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --30 minutes post dose TRH IV;Prolactin 30M p TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44928-0;Prolactin^15M pre dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --15 minutes pre dose TRH IV;Prolactin 15M pre TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44929-8;Prolactin^15M post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --15 minutes post dose TRH IV;Prolactin 15M p TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44930-6;Prolactin^2H post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --2 hours post dose TRH IV;Prolactin 2h p TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44931-4;Prolactin^pre dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --pre dose TRH IV;Prolactin pre TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44932-2;Protein.monoclonal band 2/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 2/Protein.total in Serum or Plasma by Electrophoresis;M Protein 2 MFr SerPl Elph;;ACTIVE;2.17;2.73 +4493-3;Complement C3d+G;ACnc;Pt;Plas;Qn;;HEM/BC;1;Deprecated Complement C3d+G [Units/volume] in Plasma;Deprecated C3d+G Plas-aCnc;;DEPRECATED;1.0;2.69 +44933-0;Specific gravity;Rden;24H;Urine;Qn;Refractometry;CHEM;1;Specific gravity of 24 hour Urine by Refractometry;Sp Gr 24h Ur Refractometry;;ACTIVE;2.17;2.73 +44934-8;Thymidine kinase;CCnc;Pt;Ser;Qn;;CHEM;1;Thymidine kinase [Enzymatic activity/volume] in Serum;Thymidine kinase Ser-cCnc;;ACTIVE;2.17;2.73 +44935-5;Thyrotropin^15M post dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --15 minutes post dose TRH IV;TSH 15M p TRH IV SerPl-aCnc;;ACTIVE;2.17;2.73 +44936-3;Thyrotropin^15M pre dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --15 minutes pre dose TRH IV;TSH 15M pre TRH IV SerPl-aCnc;;ACTIVE;2.17;2.70 +44937-1;Thyrotropin^pre dose TRH IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Thyrotropin [Units/volume] in Serum or Plasma --pre dose TRH IV;Deprecated TSH pre TRH IV SerPl-aCnc;;DEPRECATED;2.17;2.70 +44938-9;Hepatitis D virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis D virus IgM Ab [Presence] in Serum by Immunoassay;HDV IgM Ser Ql IA;;ACTIVE;2.17;2.73 +44939-7;Adverse drug reaction;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Adverse drug reaction Narrative;Hx of Adverse drug rxn;;ACTIVE;2.17;2.56 +44940-5;Alcoholic drinks per W;NRat;1W;^Patient;Qn;Reported;H&P.HX;2;Alcoholic drinks per week - Reported;Alcoholic drinks per W Reported;;ACTIVE;2.17;2.48 +4494-1;Complement C3d+G;MCnc;Pt;Plas;Qn;;HEM/BC;1;Deprecated Complement C3d+G [Mass/volume] in Plasma;Deprecated C3d+G Plas-mCnc;;DEPRECATED;1.0;2.65 +44941-3;Barriers to self management;Find;Pt;^Patient;Ord;;H&P.HX;2;Barriers to self management;Barriers to self management;;ACTIVE;2.17;2.27 +44942-1;First nations living status;Find;Pt;^Family;Ord;;H&P.HX;2;First nations living status from Family;Family First nations living status;;ACTIVE;2.17;2.29 +44943-9;Self management;Find;Pt;^Patient;Ord;;DOC.MISC;2;Self management;Self management;;ACTIVE;2.17;2.73 +44944-7;Other alert;Find;Pt;^Patient;Nom;;H&P.HX;2;Other alert;Other alert;;ACTIVE;2.17;2.46 +44945-4;Australian cervix cytology code;Imp;Pt;XXX;Nom;;CYTO;1;Australian cervix cytology code [Interpretation] of Specimen;AUSCvxCyt Spec-Imp;;ACTIVE;2.17;2.69 +44946-2;Borrelia burgdorferi 31kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 31kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor31kD IgG Ser Ql IB;;ACTIVE;2.17;2.58 +44947-0;Borrelia burgdorferi 31kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 31kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor31kD IgM Ser Ql IB;;ACTIVE;2.17;2.58 +44948-8;Borrelia burgdorferi 34kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 34kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor34kD IgM Ser Ql IB;;ACTIVE;2.17;2.58 +44949-6;Borrelia burgdorferi 34kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 34kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor34kD IgG Ser Ql IB;;ACTIVE;2.17;2.58 +44950-4;Coagulation surface induced.factor substitution^1H post incubation after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --1H post incubation with normal plasma;aPTT 1h NP Cont PPP;;ACTIVE;2.17;2.73 +44951-2;Physician NPI;ID;Pt;Provider;Nom;;ADMIN.ID;2;Physician NPI [Identifier];Physician NPI;;ACTIVE;2.17;2.73 +44952-0;Surgeon primary NPI;ID;Pt;Provider;Nom;;ADMIN.ID;2;Surgeon primary NPI [Identifier] Provider;Surgeon primary NPI Provider;;ACTIVE;2.17;2.66 +44953-8;Physician follow up NPI;ID;Pt;Provider;Nom;;ADMIN.ID;2;Physician follow up NPI [Identifier];Physician follow up NPI;;ACTIVE;2.17;2.66 +44954-6;Physician managing NPI;ID;Pt;Provider;Nom;;ADMIN.ID;2;Physician managing NPI [Identifier];Physician managing NPI;;ACTIVE;2.17;2.66 +44955-3;Archive facility identification number NPI;ID;Pt;Cancer.XXX;Nom;;ADMIN.FACILITY;2;Archive facility identification number NPI Cancer;Archive FIN NPI Cancer;;ACTIVE;2.17;2.66 +44956-1;Following registry NPI;ID;Pt;Cancer registry;Nom;;ADMIN.ID;2;Following registry NPI [Identifier] Cancer registry;Following registry NPI Cancer Registry;;ACTIVE;2.17;2.66 +44957-9;Institution referred to NPI;ID;Pt;Cancer registry;Nom;;ADMIN.ID;2;Institution referred to NPI Cancer registry;Inst referred to NPI Cancer Registry;;ACTIVE;2.17;2.66 +4495-8;Complement C3d+G;SCnc;Pt;Plas;Qn;;HEM/BC;1;Deprecated Complement C3d+G [Moles/volume] in Plasma;Deprecated C3d+G Plas-sCnc;;DEPRECATED;1.0;2.65 +44958-7;Institution referred from NPI;ID;Pt;Cancer registry;Nom;;ADMIN.ID;2;Institution referred from NPI Cancer registry;Inst referred from NPI Cancer Registry;;ACTIVE;2.17;2.66 +44959-5;Hospital.reporting NPI;ID;Pt;Cancer.XXX;Nom;;ADMIN.ID;2;Hospital.reporting NPI [Identifier] Cancer;Hospital.reporting NPI Cancer;;ACTIVE;2.17;2.66 +44960-3;Institution data source NPI;ID;Pt;Registry message;Nom;;ADMIN.ID;2;Institution data source NPI Registry message;Inst data source NPI Registry Message;;ACTIVE;2.17;2.66 +44961-1;Homans sign;Find;Pt;Lower extremity.right;Ord;;H&P.PX;2;Homans sign of Lower extremity - right;Homans sign LE-R;;ACTIVE;2.17;2.27 +44962-9;Homans sign;Find;Pt;Lower extremity.left;Ord;;H&P.PX;2;Homans sign of Lower extremity - left;Homans sign LE-L;;ACTIVE;2.17;2.27 +44963-7;Capillary refill;Time;Pt;Nail bed;Qn;Observed;H&P.PX;2;Capillary refill [Time] of Nail bed;Capillary refill Time Nail Bed;;ACTIVE;2.17;2.70 +44964-5;Capillary refill;Time;Pt;Chest;Qn;Observed;H&P.PX;2;Capillary refill [Time] of Chest;Capillary refill Time Chest;;ACTIVE;2.17;2.70 +44965-2;Jugular vein distention^head raised 30 degrees;Len;Pt;^Patient;Qn;Observed;H&P.PX;2;Jugular vein distention --head raised 30 degrees;Jugular distention head up 30 deg;;ACTIVE;2.17;2.70 +4496-6;Complement C3d-C3d+Gg-IC3b receptors;PrThr;Pt;WBC;Ord;;HEM/BC;1;Deprecated Complement C3d-C3d+Gg-IC3b receptors [Presence] in Leukocytes;Deprecated C3d-C3d+Gg-iC3b Recep WBC Ql;;DEPRECATED;1.0;2.65 +44966-0;Edema;Find;Pt;^Patient;Ord;;H&P.PX;2;Edema;Edema;;ACTIVE;2.17;2.73 +44967-8;Electrocardiograph lead;Find;Pt;^Patient;Nom;;EKG.MEAS;2;Electrocardiograph lead;EKG lead;;ACTIVE;2.17;2.73 +44968-6;Temperature;Find;Pt;Skin;Ord;Palpation;H&P.PX;2;Temperature of Skin palpation;Temp Skin Palpation;;ACTIVE;2.17;2.38 +44969-4;Heart rate rhythm;Type;Pt;XXX;Nom;Palpation;H&P.PX;2;Heart rate rhythm palpation;Heart rate rhythm Palpation;;ACTIVE;2.17;2.38 +44970-2;Cardiac monitor interpretation;Imp;Pt;Heart;Nar;;H&P.PX;2;Cardiac monitor interpretation Narrative;Cardiac monitor interpretation;;ACTIVE;2.17;2.40 +44971-0;Capillary refill;Time;Pt;{Body site};Qn;Observed;H&P.PX;2;Capillary refill [Time];Capillary refill Time;;ACTIVE;2.17;2.70 +44972-8;Edema site;Find;Pt;{Body site};Nom;;H&P.PX;2;Edema site;Edema site;;ACTIVE;2.17;2.29 +44973-6;QRS duration;Time;Pt;{Electrocardiograph lead};Qn;;EKG.MEAS;2;QRS duration {Electrocardiograph lead};QRS dur {EKG lead};;ACTIVE;2.17;2.48 +4497-4;Complement C3PA;-;Pt;Ser;Qn;ID;HEM/BC;1;Deprecated Complement C3PA;Deprecated C3PA Ser Qn;;DEPRECATED;1.0;2.66 +44974-4;Arterial pulse intensity;Force;Pt;{Artery};Ord;Palpation;H&P.PX;2;Pulse intensity of Unspecified artery palpation;Pulse intensity Palpation;;ACTIVE;2.17;2.38 +44975-1;QT interval;Time;Pt;{Electrocardiograph lead};Qn;;EKG.MEAS;2;Q-T interval {Electrocardiograph lead};Q-T interval {EKG lead};;ACTIVE;2.17;2.48 +44976-9;PR interval;Time;Pt;{Electrocardiograph lead};Qn;;EKG.MEAS;2;P-R Interval {Electrocardiograph lead};P-R interval {EKG lead};;ACTIVE;2.17;2.48 +44977-7;Chlamydophila psittaci Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila psittaci IgM Ab [Presence] in Serum;C psittaci IgM Ser Ql;;ACTIVE;2.17;2.73 +44978-5;Chlamydophila psittaci Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila psittaci IgA Ab [Presence] in Serum;C psittaci IgA Ser Ql;;ACTIVE;2.17;2.73 +44979-3;Chlamydophila pneumoniae Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila pneumoniae Ab [Presence] in Serum --2nd specimen;C pneum Ab sp2 Ser Ql;;ACTIVE;2.17;2.56 +44980-1;Chlamydophila pneumoniae Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila pneumoniae Ab [Presence] in Serum --1st specimen;C pneum Ab sp1 Ser Ql;;ACTIVE;2.17;2.56 +44981-9;Chlamydophila pneumoniae Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila pneumoniae IgG Ab [Presence] in Serum;C pneum IgG Ser Ql;;ACTIVE;2.17;2.73 +4498-2;Complement C4;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4 [Mass/volume] in Serum or Plasma;C4 SerPl-mCnc;;ACTIVE;1.0;2.73 +44982-7;Chlamydophila pneumoniae Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila pneumoniae IgA Ab [Presence] in Serum;C pneum IgA Ser Ql;;ACTIVE;2.17;2.73 +44983-5;Chlamydia trachomatis L2 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis L2 IgM Ab [Presence] in Serum;C trach L2 IgM Ser Ql;;ACTIVE;2.17;2.56 +44984-3;Chlamydia trachomatis L2 Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis L2 IgG Ab [Presence] in Serum;C trach L2 IgG Ser Ql;;ACTIVE;2.17;2.56 +44985-0;Chlamydia trachomatis L2 Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis L2 IgA Ab [Presence] in Serum;C trach L2 IgA Ser Ql;;ACTIVE;2.17;2.56 +44986-8;Chlamydia trachomatis G+F+K Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis G+F+K IgM Ab [Presence] in Serum;C trach G+F+K IgM Ser Ql;;ACTIVE;2.17;2.56 +44987-6;Chlamydia trachomatis G+F+K Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis G+F+K IgA Ab [Presence] in Serum;C trach G+F+K IgA Ser Ql;;ACTIVE;2.17;2.56 +44988-4;Chlamydia trachomatis D+K Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis D+K IgM Ab [Presence] in Serum;C trach D+K IgM Ser Ql;;ACTIVE;2.17;2.56 +44989-2;Chlamydia trachomatis D+K Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis D+K IgG Ab [Presence] in Serum;C trach D+K IgG Ser Ql;;ACTIVE;2.17;2.56 +449-9;Sisomicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Sisomicin [Susceptibility] by Disk diffusion (KB);Sisomicin Islt KB;;ACTIVE;1.0;2.19 +4499-0;Complement C4 activated;-;Pt;Ser;Qn;;HEM/BC;1;Deprecated Complement C4a [Mass/volume] in Plasma;Deprecated C4 activated Ser Qn;;DEPRECATED;1.0;2.66 +44990-0;Chlamydia trachomatis D+K Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis D+K IgA Ab [Presence] in Serum;C trach D+K IgA Ser Ql;;ACTIVE;2.17;2.56 +44991-8;Chlamydia trachomatis C Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis C IgM Ab [Presence] in Serum;C trach C IgM Ser Ql;;ACTIVE;2.17;2.56 +44992-6;Chlamydia trachomatis C Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis C IgG Ab [Presence] in Serum;C trach C IgG Ser Ql;;ACTIVE;2.17;2.56 +44993-4;Chlamydia trachomatis C Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis C IgA Ab [Presence] in Serum;C trach C IgA Ser Ql;;ACTIVE;2.17;2.56 +44994-2;Chlamydia trachomatis B Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis B IgM Ab [Presence] in Serum;C trach B IgM Ser Ql;;ACTIVE;2.17;2.56 +44995-9;Chlamydia trachomatis B Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis B IgG Ab [Presence] in Serum;C trach B IgG Ser Ql;;ACTIVE;2.17;2.56 +44996-7;Chlamydia trachomatis B Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis B IgA Ab [Presence] in Serum;C trach B IgA Ser Ql;;ACTIVE;2.17;2.56 +44997-5;Chlamydia trachomatis Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis Ab [Units/volume] in Serum --2nd specimen;C trach Ab sp2 Ser-aCnc;;ACTIVE;2.17;2.69 +44998-3;Chlamydia trachomatis Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis Ab [Presence] in Serum --1st specimen;C trach Ab sp1 Ser Ql;;ACTIVE;2.17;2.56 +44999-1;Chlamydia trachomatis Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Chlamydia trachomatis IgM Ab [Presence] in Cerebral spinal fluid;C trach IgM CSF Ql;;ACTIVE;2.17;2.56 +45000-7;Chlamydia trachomatis Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis IgM Ab [Titer] in Serum by Immunoassay;C trach IgM Titr Ser IA;;ACTIVE;2.17;2.56 +45001-5;Chlamydia trachomatis Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis IgM Ab [Units/volume] in Serum by Immunoassay;C trach IgM Ser IA-aCnc;;ACTIVE;2.17;2.73 +45002-3;Chlamydia trachomatis Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Chlamydia trachomatis IgG Ab [Presence] in Cerebral spinal fluid;C trach IgG CSF Ql;;ACTIVE;2.17;2.56 +45003-1;Chlamydia trachomatis Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis IgG Ab [Titer] in Serum by Immunoassay;C trach IgG Titr Ser IA;;ACTIVE;2.17;2.56 +45004-9;Chlamydia trachomatis Ab.IgA;PrThr;Pt;CSF;Ord;;MICRO;1;Chlamydia trachomatis IgA Ab [Presence] in Cerebral spinal fluid;C trach IgA CSF Ql;;ACTIVE;2.17;2.56 +4500-5;Complement C4 CH50;MCnc;Pt;CSF;Qn;;HEM/BC;1;Complement C4 CH50 [Mass/volume] in Cerebral spinal fluid;C4 CH50 CSF-mCnc;;ACTIVE;1.0;2.34 +45005-6;Chlamydia trachomatis Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia trachomatis IgA Ab [Presence] in Serum;C trach IgA Ser Ql;;ACTIVE;2.17;2.56 +45006-4;Chlamydia trachomatis Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis IgA Ab [Units/volume] in Serum by Immunoassay;C trach IgA Ser IA-aCnc;;ACTIVE;2.17;2.69 +45007-2;Chlamydia trachomatis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis Ab [Units/volume] in Serum by Immunoassay;C trach Ab Ser IA-aCnc;;ACTIVE;2.17;2.69 +45008-0;Chlamydia trachomatis Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Chlamydia trachomatis Ab [Presence] in Serum by Complement fixation;C trach Ab Ser Ql CF;;ACTIVE;2.17;2.56 +45009-8;Chlamydia trachomatis Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Chlamydia trachomatis Ab [Presence] in Serum by Immunofluorescence;C trach Ab Ser Ql IF;;ACTIVE;2.17;2.56 +45010-6;Chlamydia sp Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Chlamydia sp IgG Ab [Presence] in Cerebral spinal fluid;Chlamydia IgG CSF Ql;;ACTIVE;2.17;2.56 +45011-4;Chlamydia sp Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Chlamydia sp Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Chlamydia Ab CSF IA-aCnc;;ACTIVE;2.17;2.69 +45012-2;Chlamydia sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydia sp Ab [Presence] in Serum;Chlamydia Ab Ser Ql;;ACTIVE;2.17;2.73 +4501-3;Complement C4a;MCnc;Pt;Plas;Qn;;HEM/BC;1;Complement C4a [Mass/volume] in Plasma;C4a Plas-mCnc;;ACTIVE;1.0;2.73 +45013-0;Adenosine monophosphate.cyclic^2H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --2 hours post XXX challenge;cAMP 2h p chal Ur-sCnc;;ACTIVE;2.17;2.73 +45014-8;Adenosine monophosphate.cyclic^6H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --6 hours post XXX challenge;cAMP 6h p chal Ur-sCnc;;ACTIVE;2.17;2.73 +45015-5;Adenosine monophosphate.cyclic^baseline;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --baseline;cAMP BS Ur-sCnc;;ACTIVE;2.17;2.73 +45016-3;Adenosine monophosphate.cyclic^4H post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --4 hours post XXX challenge;cAMP 4h p chal Ur-sCnc;;ACTIVE;2.17;2.73 +45017-1;Adenosine monophosphate.cyclic/Creatinine^baseline;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --baseline;cAMP/Creat BS Ur-Rto;;ACTIVE;2.17;2.73 +45018-9;Adenosine monophosphate.cyclic/Creatinine^6H post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --6 hours post XXX challenge;cAMP/Creat 6h p chal Ur-Rto;;ACTIVE;2.17;2.73 +45019-7;Adenosine monophosphate.cyclic/Creatinine^2H post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --2 hours post XXX challenge;cAMP/Creat 2h p chal Ur-Rto;;ACTIVE;2.17;2.73 +45020-5;Adenosine monophosphate.cyclic/Creatinine^4H post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --4 hours post XXX challenge;cAMP/Creat 4h p chal Ur-Rto;;ACTIVE;2.17;2.73 +4502-1;Complement C4b binding protein;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4b binding protein [Units/volume] in Serum or Plasma;C4b BP SerPl-aCnc;;ACTIVE;1.0;2.69 +45021-3;Metanephrine & Normetanephrine;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Metanephrine and Normetanephrine [Interpretation] in Serum or Plasma;Metaneph+Normetaneph SerPl-Imp;;ACTIVE;2.17;2.73 +45022-1;Methadone+Metabolite;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Methadone+Metabolite [Presence] in Serum or Plasma by Confirmatory method;Methadone+metab SerPl Ql Cfm;;ACTIVE;2.17;2.56 +45023-9;HLA typing for celiac disease panel;-;Pt;Bld/Tiss;-;;PANEL.HLA;1;HLA typing for celiac disease panel - Blood or Tissue;HLA for Celiac Disease Pnl Bld/T;;ACTIVE;2.17;2.73 +45024-7;HLA typing for narcolepsy panel;-;Pt;Bld;-;;PANEL.HLA;1;HLA typing for narcolepsy panel - Blood;HLA for Narcolepsy Pnl Bld;;ACTIVE;2.17;2.73 +45025-4;HLA-A SBT;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-A SBT [Type] by High resolution;HLA-A SBT High Res;;ACTIVE;2.17;2.73 +45026-2;HLA-A2 SBT;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-A2 SBT [Type] by High resolution;HLA-A2 SBT High Res;;ACTIVE;2.17;2.73 +45027-0;HLA-A2 panel;-;Pt;Bld;-;;PANEL.HLA;1;HLA-A2 panel - Blood;HLA-A2 Pnl Bld;;ACTIVE;2.17;2.42 +45028-8;HLA-B SBT;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-B SBT [Type] by High resolution;HLA-B SBT High Res;;ACTIVE;2.17;2.73 +45029-6;HLA-DQB1 SBT;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DQB1 SBT [Type] by High resolution;HLA-DQB1 SBT High Res;;ACTIVE;2.17;2.73 +45030-4;HLA-DRB1 SBT;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB1 SBT [Type] by High resolution;HLA-DRB1 SBT High Res;;ACTIVE;2.17;2.73 +45031-2;HLA-C SBT;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-C SBT [Type] by High resolution;HLA-C SBT High Res;;ACTIVE;2.17;2.73 +45032-0;Tyrosine;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Tyrosine [Mass/volume] in DBS;Tyrosine DBS-mCnc;;ACTIVE;2.17;2.73 +45033-8;Cardiovascular assessment panel;-;Pt;^Patient;-;;PANEL.CV;2;Cardiovascular physiologic and EKG assessment panel;CV Assessment + EKG Pnl;;ACTIVE;2.17;2.61 +45034-6;Bacteria producing catalase;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing catalase [Presence] in Isolate;Bacteria catalase Islt Ql;;ACTIVE;2.17;2.73 +45035-3;Bacterial virulence;PrThr;Pt;XXX;Ord;Mouse bioassay;MICRO;1;Bacterial virulence [Presence] in Specimen by Mouse bioassay;BacteriaL Virulence Spec Ql MA;;ACTIVE;2.17;2.69 +45036-1;Bacteria producing oxidase;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing oxidase [Presence] in Isolate;Bacteria Oxidase Islt Ql;;ACTIVE;2.17;2.56 +45037-9;Bacteria producing urease;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing urease [Presence] in Isolate;Bacteria Urease Islt Ql;;ACTIVE;2.17;2.56 +45038-7;Bacteria producing arginine decarboxylase;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing arginine decarboxylase [Presence] in Isolate;Bacteria arginine decase Islt Ql;;ACTIVE;2.17;2.56 +4503-9;Complement C4b binding protein;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4b binding protein [Mass/volume] in Serum or Plasma;C4b BP SerPl-mCnc;;ACTIVE;1.0;2.73 +45039-5;Clostridium botulinum toxin;PrThr;Pt;XXX;Ord;IA;MICRO;1;Clostridium botulinum toxin [Presence] in Specimen by Immunoassay;C bot Tox Spec Ql IA;;ACTIVE;2.17;2.69 +45040-3;Francisella tularensis Ab;PrThr;Pt;Ser;Ord;Aggl.micro;MICRO;1;Francisella tularensis Ab [Presence] in Serum by Microagglutination;F tular Ab Ser Ql Microaggl;;ACTIVE;2.17;2.73 +45041-1;Francisella tularensis Ag;PrThr;Pt;XXX;Ord;Aggl.slide;MICRO;1;Francisella tularensis Ag [Presence] in Specimen by Slide agglutination;F tular Ag Spec Ql Slide aggl;;ACTIVE;2.17;2.69 +45042-9;XXX microorganism Ag;Prid;Pt;XXX;Nom;IF;MICRO;1;XXX microorganism Ag [Identifier] in Specimen by Immunofluorescence;Other microorg Ag Spec IF;;ACTIVE;2.17;2.69 +45043-7;Microscopic observation;Prid;Pt;XXX;Nom;Tzanck smear;MICRO;1;Microscopic observation [Identifier] in Specimen by Tzanck smear;Tzanck Smear Spec;;ACTIVE;2.17;2.73 +45044-5;Bacteria producing indole;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing indole [Presence] in Isolate;Bacteria indole Islt Ql;;ACTIVE;2.17;2.56 +45045-2;Yersinia pestis Ab;PrThr;Pt;XXX;Ord;HA;MICRO;1;Yersinia pestis Ab [Presence] in Specimen by Hemagglutination;Y pestis Ab Spec Ql HA;;ACTIVE;2.17;2.69 +45046-0;Bacteria producing X & V factors;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing X and V factors [Presence] in Isolate;Bacteria X & V Factors Islt Ql;;ACTIVE;2.17;2.56 +4504-7;Complement C4d;EntNum;Pt;RBC;Qn;;HEM/BC;1;Complement C4d [Entitic number] in Red Blood Cells;C4d EntNum RBC;;ACTIVE;1.0;2.26 +45047-8;Cortisol^12 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --12 AM specimen;Cortis 12 AM SerPl-sCnc;;ACTIVE;2.17;2.70 +45048-6;Cortisol^12 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --12 PM specimen;Cortis 12 PM SerPl-sCnc;;ACTIVE;2.17;2.70 +45049-4;Cortisol^4 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --4 PM specimen;Cortis 4 PM SerPl-sCnc;;ACTIVE;2.17;2.70 +45050-2;Cortisol^8 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --8 AM specimen;Cortis 8 AM SerPl-sCnc;;ACTIVE;2.17;2.70 +45051-0;Cortisol^8 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --8 PM specimen;Cortis 8 PM SerPl-sCnc;;ACTIVE;2.17;2.70 +45052-8;Glucose^12 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --12 AM specimen;Glucose 12 AM SerPl-sCnc;;ACTIVE;2.17;2.70 +45053-6;Glucose^8 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8 AM specimen;Glucose 8 AM SerPl-sCnc;;ACTIVE;2.17;2.70 +4505-4;Complement C5;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C5 [Mass/volume] in Serum or Plasma;C5 SerPl-mCnc;;ACTIVE;1.0;2.73 +45054-4;Glucose^12 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --12 PM specimen;Glucose 12 PM SerPl-sCnc;;ACTIVE;2.17;2.70 +45055-1;Glucose^4 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4 PM specimen;Glucose 4 PM SerPl-sCnc;;ACTIVE;2.17;2.70 +45056-9;Glucose^8 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8 PM specimen;Glucose 8 PM SerPl-sCnc;;ACTIVE;2.17;2.70 +45057-7;Cardiolipin Ab.IgA & IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Cardiolipin IgA and IgG and IgM panel - Serum;Cardiolipin IgA+IgG+IgM Pnl Ser;;ACTIVE;2.17;2.73 +45058-5;cycloSPORINE.monoclonal & polyclonal panel;MCnc;Pt;Bld;Qn;;PANEL.DRUG/TOX;1;cycloSPORINE Monoclonal and Polyclonal panel [Mass/volume] - Blood;cycloSPORINE Moncl+Polycl Pnl Bld-mCnc;;ACTIVE;2.17;2.42 +45059-3;Ehrlichia chaffeensis Ab.IgG & IgM panel;Titr;XXX;Ser;Qn;IF;PANEL.MICRO;1;Ehrlichia chaffeensis IgG and IgM panel [Titer] - unspecified time Serum by Immunofluorescence;E chaff IgG+IgM Pnl ?Tm Titr Ser IF;;ACTIVE;2.17;2.73 +45060-1;Protein & Glucose panel;-;Pt;Urine;-;Test strip;PANEL.CHEM;1;Protein and Glucose panel - Urine by Test strip;Prot + Glucose Pnl Ur Strip;;ACTIVE;2.17;2.73 +45061-9;Spermatozoa Ab.IgA & IgG & IgM panel;-;Pt;Ser;-;;PANEL.FERT;1;Spermatozoa IgA and IgG and IgM panel - Serum;Sperm IgA+IgG+IgM Pnl Ser;;ACTIVE;2.17;2.44 +4506-2;Complement C5a;MCnc;Pt;Plas;Qn;;HEM/BC;1;Complement C5a [Mass/volume] in Plasma;C5a Plas-mCnc;;ACTIVE;1.0;2.73 +45062-7;C reactive protein;MCnc;Pt;CSF;Qn;;CHEM;1;C reactive protein [Mass/volume] in Cerebral spinal fluid;CRP CSF-mCnc;;ACTIVE;2.17;2.73 +45063-5;Varicella zoster virus Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Varicella zoster virus IgG and IgM panel - Serum;VZV IgG+IgM Pnl Ser;;ACTIVE;2.17;2.73 +45064-3;Basic metabolic panel & Glomerular filtration rate.predicted;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Deprecated Basic metabolic panel & Glomerular filtration rate.predicted;Deprecated Bas Metab Pnl & eGFR SerPl;;DEPRECATED;2.17;2.36 +45065-0;Comprehensive metabolic panel & Glomerular filtration rate.predicted;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Deprecated Comprehensive metabolic panel & Glomerular filtration rate.predicted;Deprecated Comp Metab Pnl & eGFR SerPl;;DEPRECATED;2.17;2.36 +45066-8;Creatinine & Glomerular filtration rate.predicted panel;-;Pt;Ser/Plas/Bld;Qn;;PANEL.CHEM;1;Creatinine and Glomerular filtration rate.predicted panel - Serum, Plasma or Blood;Creatinine + eGFR Pnl SerPlBld;;ACTIVE;2.17;2.73 +45067-6;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Cvx;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Cervix by Probe;C trach+GC rRNA Cvx Ql Probe;;DISCOURAGED;2.17;2.63 +45068-4;Chlamydia trachomatis+Neisseria gonorrhoeae DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Cervix by NAA with probe detection;C trach+GC DNA Cvx Ql NAA+probe;;ACTIVE;2.17;2.73 +45069-2;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Genital;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Genital specimen by Probe;C trach+GC rRNA Genital Ql Probe;;ACTIVE;2.17;2.73 +450-7;Sisomicin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Sisomicin [Susceptibility] by Serum bactericidal titer;Sisomicin Titr SBT;;ACTIVE;1.0;2.32 +4507-0;Complement C6;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C6 [Mass/volume] in Serum or Plasma;C6 SerPl-mCnc;;ACTIVE;1.0;2.73 +45070-0;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by Probe;C trach+GC rRNA Vag Ql Probe;;DISCOURAGED;2.17;2.63 +45071-8;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;ACnc;Pt;Penis;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Penis by DNA probe;Deprecated C trach+GC rRNA Penis Ql Prb;;DEPRECATED;2.17;2.52 +45072-6;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Anal;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Anal by Probe;C trach+GC rRNA Anal Ql Probe;;ACTIVE;2.17;2.63 +45073-4;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Tissue by Probe;C trach+GC rRNA Tiss Ql Probe;;ACTIVE;2.17;2.63 +45074-2;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Urine;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Urine by Probe;C trach+GC rRNA Ur Ql Probe;;DISCOURAGED;2.17;2.73 +45075-9;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Urethra;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Urethra by Probe;C trach+GC rRNA Urth Ql Probe;;ACTIVE;2.17;2.63 +45076-7;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Specimen by Probe;C trach+GC rRNA Spec Ql Probe;;ACTIVE;2.17;2.73 +45077-5;Chlamydia trachomatis rRNA;ACnc;Pt;Cnjt;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Conjunctival specimen by DNA probe;Deprecated C trach rRNA Conjunct Ql Prb;;DEPRECATED;2.17;2.36 +45078-3;Chlamydia trachomatis rRNA;PrThr;Pt;Cvx;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Cervix by Probe;C trach rRNA Cvx Ql Probe;;DISCOURAGED;2.17;2.63 +45079-1;Chlamydia trachomatis rRNA;ACnc;Pt;Genital;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Genital specimen by DNA probe;Deprecated C trach rRNA Genital Ql Prb;;DEPRECATED;2.17;2.36 +45080-9;Chlamydia trachomatis rRNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by Probe;C trach rRNA Vag Ql Probe;;DISCOURAGED;2.17;2.63 +45081-7;Chlamydia trachomatis rRNA;ACnc;Pt;Urethra;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Urethra by DNA probe;Deprecated C trach rRNA Urth Ql Prb;;DEPRECATED;2.17;2.36 +45082-5;Chlamydia trachomatis rRNA;ACnc;Pt;Cvx;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Cervix by DNA probe;Deprecated C trach rRNA Cervix Ql Prb;;DEPRECATED;2.17;2.36 +45083-3;Chlamydia trachomatis rRNA;ACnc;Pt;Vag;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by DNA probe;Deprecated C trach rRNA Vag Ql Prb;;DEPRECATED;2.17;2.36 +45084-1;Chlamydia trachomatis DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Vaginal fluid by NAA with probe detection;C trach DNA Vag Ql NAA+probe;;ACTIVE;2.17;2.73 +45085-8;Chlamydia trachomatis rRNA;PrThr;Pt;Nph;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Nasopharynx by Probe;C trach rRNA Nph Ql Probe;;ACTIVE;2.17;2.73 +45086-6;Chlamydia trachomatis DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Nasopharynx by NAA with probe detection;C trach DNA Nph Ql NAA+probe;;ACTIVE;2.17;2.73 +45087-4;Chlamydia trachomatis DNA;ACnc;Pt;Penis;Ord;Probe.amp.tar;MICRO;1;Deprecated Chlamydia trachomatis DNA [Presence] in Penis by Probe and target amplification method;Deprecated C trach DNA Penis Ql PCR;;DEPRECATED;2.17;2.52 +4508-8;Complement C7;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C7 [Mass/volume] in Serum or Plasma;C7 SerPl-mCnc;;ACTIVE;1.0;2.73 +45088-2;Chlamydia trachomatis rRNA;ACnc;Pt;Penis;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Penis by DNA probe;Deprecated C trach rRNA Penis Ql Prb;;DEPRECATED;2.17;2.52 +45089-0;Chlamydia trachomatis rRNA;PrThr;Pt;Anal;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Anal by Probe;C trach rRNA Anal Ql Probe;;ACTIVE;2.17;2.73 +45090-8;Chlamydia trachomatis DNA;PrThr;Pt;Anal;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Anal by NAA with probe detection;C trach DNA Anal Ql NAA+probe;;ACTIVE;2.17;2.73 +45091-6;Chlamydia trachomatis Ag;PrThr;Pt;Genital;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Genital specimen;C trach Ag Genital Ql;;ACTIVE;2.17;2.56 +45092-4;Chlamydia trachomatis Ag;PrThr;Pt;Nph;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Nasopharynx by Immunoassay;C trach Ag Nph Ql IA;;ACTIVE;2.17;2.56 +45093-2;Chlamydia trachomatis;PrThr;Pt;Anal;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Anal by Organism specific culture;C trach Anal Ql Cult;;ACTIVE;2.17;2.56 +45094-0;Chlamydia trachomatis;PrThr;Pt;Cnjt;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Conjunctival specimen by Organism specific culture;C trach Conjunct Ql Cult;;ACTIVE;2.17;2.73 +45095-7;Chlamydia trachomatis;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Genital specimen by Organism specific culture;C trach Genital Ql Cult;;ACTIVE;2.17;2.56 +4509-6;Complement C8;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C8 [Mass/volume] in Serum or Plasma;C8 SerPl-mCnc;;ACTIVE;1.0;2.73 +45096-5;Chlamydia trachomatis;PrThr;Pt;Nph;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Nasopharynx by Organism specific culture;C trach Nph Ql Cult;;ACTIVE;2.17;2.56 +45097-3;Chlamydia sp identified;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Anal by Organism specific culture;Chlamydia Anal Cult;;ACTIVE;2.17;2.73 +45098-1;Chlamydia sp identified;Prid;Pt;Cvx;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Cervix by Organism specific culture;Chlamydia Cvx Cult;;ACTIVE;2.17;2.73 +45099-9;Chlamydia sp identified;Prid;Pt;Body fld;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Body fluid by Organism specific culture;Chlamydia Fld Cult;;ACTIVE;2.17;2.19 +45100-5;Chlamydia sp identified;Prid;Pt;Vag;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Vaginal fluid by Organism specific culture;Chlamydia Vag Cult;;ACTIVE;2.17;2.73 +45101-3;Chlamydia sp identified;Prid;Pt;Nph;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Nasopharynx by Organism specific culture;Chlamydia Nph Cult;;ACTIVE;2.17;2.29 +45102-1;Chlamydia sp identified;Prid;Pt;Penis;Nom;Organism specific culture;MICRO;1;Deprecated Chlamydia sp identified in Penis by Organism specific culture;Deprecated Chlamydia Penis Cult;;DEPRECATED;2.17;2.52 +45103-9;Chlamydia sp Ag;PrThr;Pt;Anal;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Anal by Immunofluorescence;Chlamydia Ag Anal Ql IF;;ACTIVE;2.17;2.56 +4510-4;Complement C9;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C9 [Mass/volume] in Serum or Plasma;C9 SerPl-mCnc;;ACTIVE;1.0;2.73 +45104-7;Chlamydia sp Ag;PrThr;Pt;Anal;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Anal by Immunoassay;Chlamydia Ag Anal Ql IA;;ACTIVE;2.17;2.56 +45105-4;Chlamydia sp Ag;PrThr;Pt;Anal;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Anal;Chlamydia Ag Anal Ql;;ACTIVE;2.17;2.56 +45106-2;Chlamydia sp Ag;PrThr;Pt;Cvx;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Cervix by Immunoassay;Chlamydia Ag Cvx Ql IA;;ACTIVE;2.17;2.58 +45107-0;Chlamydia sp Ag;PrThr;Pt;Cvx;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Cervix;Chlamydia Ag Cvx Ql;;ACTIVE;2.17;2.58 +45108-8;Chlamydia sp Ag;PrThr;Pt;Cvx;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Cervix by Immunofluorescence;Chlamydia Ag Cvx Ql IF;;ACTIVE;2.17;2.58 +45109-6;Chlamydia sp Ag;PrThr;Pt;Body fld;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Body fluid by Immunofluorescence;Chlamydia Ag Fld Ql IF;;ACTIVE;2.17;2.56 +45110-4;Chlamydia sp Ag;ACnc;Pt;Penis;Ord;;MICRO;1;Deprecated Chlamydia sp Ag [Presence] in Penis;Deprecated Chlamydia Ag Penis Ql;;DEPRECATED;2.17;2.52 +45111-2;Chlamydia sp Ag;ACnc;Pt;Penis;Ord;IF;MICRO;1;Deprecated Chlamydia sp Ag [Presence] in Penis by Immunofluorescence;Deprecated Chlamydia Ag Penis Ql IF;;DEPRECATED;2.17;2.52 +4511-2;Complement total hemolytic CH50;ACnc;Pt;Body fld;Qn;;HEM/BC;1;Complement total hemolytic CH50 [Units/volume] in Body fluid;CH50 Fld-aCnc;;ACTIVE;1.0;2.69 +45112-0;Chlamydia sp Ag;PrThr;Pt;Urine;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Urine by Immunofluorescence;Chlamydia Ag Ur Ql IF;;ACTIVE;2.17;2.73 +45113-8;Chlamydia sp Ag;PrThr;Pt;Urethra;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Urethra by Immunoassay;Chlamydia Ag Urth Ql IA;;ACTIVE;2.17;2.56 +45114-6;Chlamydia sp Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Urethra;Chlamydia Ag Urth Ql;;ACTIVE;2.17;2.56 +45115-3;Chlamydia sp Ag;PrThr;Pt;Urethra;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Urethra by Immunofluorescence;Chlamydia Ag Urth Ql IF;;ACTIVE;2.17;2.56 +45116-1;Mycobacterium gordonae rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium gordonae rRNA [Presence] in Specimen by NAA with probe detection;M gordonae rRNA Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +45117-9;Mycobacterium kansasii rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium kansasii rRNA [Presence] in Specimen by NAA with probe detection;M kansasii rRNA Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +45118-7;Vesicular stomatitis Indiana virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Vesicular stomatitis Indiana virus Ag [Presence] in Specimen by Complement fixation;VSIV Ag Spec Ql CF;;ACTIVE;2.17;2.69 +45119-5;Vesicular stomatitis Indiana virus 1 Ab;Titr;Pt;Ser;Qn;Neut;MICRO;1;Deprecated Vesicular stomatitis virus Indiana 1 Ab [Titer] in Serum by Neutralization test;Deprecated VSIV 1 Ab Titr Ser Nt;;DEPRECATED;2.17;2.40 +4512-0;Complement CH50;-;Pt;Ser;Qn;;HEM/BC;1;Deprecated Complement total hemolytic CH50 [Units/volume] in Serum or Plasma;Deprecated CH50 Ser Qn;;DEPRECATED;1.0;2.66 +45120-3;Vesicular stomatitis Indiana virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Vesicular stomatitis Indiana virus Ag [Presence] in Specimen by Immunoassay;VSIV Ag Spec Ql IA;;ACTIVE;2.17;2.69 +45121-1;Cocal virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Cocal virus Ag [Presence] in Specimen by Complement fixation;COCV Ag Spec Ql CF;;ACTIVE;2.17;2.69 +45122-9;Cocal virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Cocal virus Ag [Presence] in Specimen by Immunoassay;COCV Ag Spec Ql IA;;ACTIVE;2.17;2.69 +45123-7;Cocal virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Cocal virus neutralizing antibody [Titer] in Serum by Neutralization test;COCV NAb Titr Ser Nt;;ACTIVE;2.17;2.72 +45124-5;Vesicular stomatitis Alagoas virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Vesicular stomatitis Alagoas virus neutralizing antibody [Titer] in Serum by Neutralization test;VSAV NAb Titr Ser Nt;;ACTIVE;2.17;2.72 +45125-2;Vesicular stomatitis Alagoas virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Vesicular stomatitis Alagoas virus Ag [Presence] in Specimen by Complement fixation;VSAV Ag Spec Ql CF;;ACTIVE;2.17;2.69 +45126-0;Vesicular stomatitis Alagoas virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Vesicular stomatitis Alagoas virus Ag [Presence] in Specimen by Immunoassay;VSAV Ag Spec Ql IA;;ACTIVE;2.17;2.69 +45127-8;Vesicular stomatitis New Jersey virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Vesicular stomatitis New Jersey virus Ag [Presence] in Specimen by Immunoassay;VSNJV Ag Spec Ql IA;;ACTIVE;2.17;2.69 +45128-6;Vesicular stomatitis New Jersey virus Ag;PrThr;Pt;XXX;Ord;Comp fix;MICRO;1;Vesicular stomatitis New Jersey virus Ag [Presence] in Specimen by Complement fixation;VSNJV Ag Spec Ql CF;;ACTIVE;2.17;2.69 +45129-4;Human prescription drug label with highlights;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Human prescription drug label with highlights;FDA label Human Rx drug W highlights;;ACTIVE;2.17;2.34 +45130-2;Chlamydia trachomatis Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Chlamydia trachomatis Ab [Presence] in Body fluid;C trach Ab Fld Ql;;ACTIVE;2.17;2.56 +45131-0;Chlamydia sp Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Nasopharynx by Immunofluorescence;Chlamydia Ag Nph Ql IF;;ACTIVE;2.17;2.56 +45132-8;Chlamydia sp Ag;PrThr;Pt;Nph;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Nasopharynx by Immunoassay;Chlamydia Ag Nph Ql IA;;ACTIVE;2.17;2.56 +45133-6;Chlamydia sp Ag;PrThr;Pt;Nph;Ord;;MICRO;1;Chlamydia sp Ag [Presence] in Nasopharynx;Chlamydia Ag Nph Ql;;ACTIVE;2.17;2.56 +45134-4;Campylobacter jejuni Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Campylobacter jejuni IgM Ab [Titer] in Serum;C jejuni IgM Titr Ser;;ACTIVE;2.17;2.32 +45135-1;Chlamydia trachomatis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydia trachomatis IgG Ab [Presence] in Serum by Immunoassay;C trach IgG Ser Ql IA;;ACTIVE;2.17;2.56 +45136-9;Endomysium Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Endomysium IgG Ab [Units/volume] in Serum;Endomysium IgG Ser-aCnc;;ACTIVE;2.17;2.73 +45137-7;IgA.secretory;MCnc;Pt;Body fld;Qn;;CHEM;1;IgA.secretory [Mass/volume] in Body fluid;SIgA Fld-mCnc;;ACTIVE;2.17;2.42 +4513-8;Complement C1r2+C1s2;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1r2+C1s2 [Mass/volume] in Serum or Plasma;C1r2+C1s2 SerPl-mCnc;;ACTIVE;1.0;2.44 +45138-5;Listeria monocytogenes O4b Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes O4b IgG Ab [Titer] in Serum;L monocytog.O4b IgG Titr Ser;;ACTIVE;2.17;2.32 +45139-3;Listeria monocytogenes O4b Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes O4b IgM Ab [Titer] in Serum;L monocytog.O4b IgM Titr Ser;;ACTIVE;2.17;2.32 +45140-1;Phenols;MRat;24H;Urine;Qn;;DRUG/TOX;1;Phenols [Mass/time] in 24 hour Urine;Phenols 24h Ur-mRate;;ACTIVE;2.17;2.70 +45141-9;Platelet associated Ab;PrThr;Pt;Bld;Ord;Flow cytometry;SERO;1;Platelet associated Ab [Presence] in Blood by Flow cytometry (FC);PA Ab Bld Ql FC;;ACTIVE;2.17;2.56 +45142-7;Sjogrens syndrome-B extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA SS-B Ab Ser IA-aCnc;;ACTIVE;2.17;2.73 +45143-5;Methylenedioxyethylamphetamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Urine by Confirmatory method;MDEA Ur Cfm-mCnc;;ACTIVE;2.17;2.73 +45144-3;clomiPRAMINE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;clomiPRAMINE [Presence] in Urine;clomiPRAMINE Ur Ql;;ACTIVE;2.17;2.73 +45145-0;Methdilazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methdilazine [Presence] in Serum or Plasma;Methdilazine SerPl Ql;;ACTIVE;2.17;2.56 +4514-6;Complement decay accelerating factor;EntNum;Pt;RBC;Qn;;HEM/BC;1;Complement decay accelerating factor [Entitic number] in Red Blood Cells;Comp DAF EntNum RBC;;ACTIVE;1.0;2.26 +45146-8;Triflupromazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Triflupromazine [Presence] in Serum or Plasma;TriFpromazine SerPl Ql;;ACTIVE;2.17;2.56 +45147-6;Propiomazine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Propiomazine [Presence] in Serum or Plasma;Propiomazine SerPl Ql;;ACTIVE;2.17;2.56 +45148-4;OmpC Ab.IgA;PrThr;Pt;Ser;Ord;;SERO;1;OmpC IgA Ab [Presence] in Serum;OmpC IgA Ser Ql;;ACTIVE;2.17;2.73 +45149-2;Ej Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ej Ab [Presence] in Serum;Ej Ab Ser Ql;;ACTIVE;2.17;2.73 +451-5;Spectinomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Spectinomycin [Susceptibility] by Minimum lethal concentration (MLC);Spectinomycin Islt MLC;;ACTIVE;1.0;2.19 +45150-0;Neutrophil Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Neutrophil Ab [Units/volume] in Serum by Immunoassay;Neutrophil Ab Ser IA-aCnc;;ACTIVE;2.17;2.70 +45151-8;Neutrophil cytoplasmic Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Neutrophil cytoplasmic Ab [Units/volume] in Serum by Immunoassay;ANCA Ab Ser IA-aCnc;;ACTIVE;2.17;2.70 +45152-6;OJ Ab;PrThr;Pt;Ser;Ord;;SERO;1;OJ Ab [Presence] in Serum;OJ Ab Ser Ql;;ACTIVE;2.17;2.73 +4515-3;Complement factor B;MCnc;Pt;Plas;Qn;;HEM/BC;1;Deprecated Complement factor B [Mass/volume] in Serum or Plasma;Deprecated Comp Fact B Plas-mCnc;;DEPRECATED;1.0;2.36 +45153-4;HLA Ab;NFr;Pt;Ser;Qn;;HLA;1;HLA Ab in Serum;HLA Ab NFr Ser;;ACTIVE;2.17;2.73 +45154-2;Phenylalanine hydroxylase Ab;ACnc;Pt;Ser;Qn;;SERO;1;Phenylalanine hydroxylase Ab [Units/volume] in Serum;PheOH Ab Ser-aCnc;;ACTIVE;2.17;2.70 +45155-9;Platelet factor 4 heparin complex induced Ab;ACnc;Pt;Ser;Qn;;SERO;1;Heparin induced platelet Ab [Units/volume] in Serum;PF4 heparin cmplx Ab Ser-aCnc;;ACTIVE;2.17;2.73 +45156-7;Rheumatoid factor;PrThr;Pt;Body fld;Ord;LA;SERO;1;Rheumatoid factor [Presence] in Body fluid by Latex agglutination;Rheumatoid fact Fld Ql LA;;ACTIVE;2.17;2.56 +45157-5;U2 small nuclear ribonucleoprotein Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;U2 small nuclear ribonucleoprotein IgG Ab [Presence] in Serum;U2 snRNP IgG Ser Ql;;ACTIVE;2.17;2.73 +45158-3;Immune complex;ACnc;Pt;Ser/Plas;Qn;C3d binding assay;SERO;1;Immune complex [Units/volume] in Serum or Plasma by C3d binding assay;IC SerPl C3D Bind-aCnc;;ACTIVE;2.17;2.70 +45159-1;Hepatitis B virus & Hepatitis D virus Ab;Imp;Pt;Ser;Nar;;MICRO;1;Hepatitis B virus and Hepatitis D virus Ab [Interpretation] in Serum Narrative;HBV & HDV Ab Ser-Imp;;ACTIVE;2.17;2.48 +45160-9;Acremonium sp Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Acremonium sp Ab [Presence] in Serum by Immune diffusion (ID);Acremonium Ab Ql ID;;ACTIVE;2.17;2.73 +4516-1;Complement factor Ba;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement factor Ba [Mass/volume] in Serum or Plasma;Comp Fact Ba SerPl-mCnc;;ACTIVE;1.0;2.34 +45161-7;Hepatitis B virus DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HBV DNA SerPl NAA+probe-Log#;;ACTIVE;2.17;2.73 +45162-5;Escherichia coli O157 Ag;PrThr;Pt;Isolate;Ord;LA;MICRO;1;Escherichia coli O157 Ag [Presence] in Isolate by Latex agglutination;E coli O157 Ag Islt Ql LA;;ACTIVE;2.17;2.56 +45163-3;Alternaria alternata Ab;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alternaria alternata Ab [Presence] in Serum;A alternata Ab Ql;;ACTIVE;2.17;2.56 +45164-1;Asialoganglioside GM2 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Asialoganglioside GM2 Ab [Presence] in Serum;GM2 Asialo Ab Ser Ql;;ACTIVE;2.17;2.56 +45165-8;Borrelia burgdorferi Ab.IgA;ACnc;Pt;Ser;Qn;IF;MICRO;1;Borrelia burgdorferi IgA Ab [Units/volume] in Serum by Immunofluorescence;B burgdor IgA Ser IF-aCnc;;ACTIVE;2.17;2.69 +45166-6;Corynebacterium diphtheriae Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Corynebacterium diphtheriae IgG Ab [Presence] in Serum;C diphtheriae IgG Ser Ql;;ACTIVE;2.17;2.73 +45167-4;IgE;MCnc;Pt;XXX;Qn;;CHEM;1;IgE [Mass/volume] in Specimen;IgE Spec-mCnc;;ACTIVE;2.17;2.73 +45168-2;Malonate;MCnc;Pt;Urine;Qn;;CHEM;1;Malonate [Mass/volume] in Urine;Malonate Ur-mCnc;;ACTIVE;2.17;2.44 +45169-0;Ganglioside GM1 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GM1 IgG Ab [Presence] in Serum;GM1 Gangl IgG Ser Ql;;ACTIVE;2.17;2.56 +45170-8;Myelin associated glycoprotein Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Myelin associated glycoprotein Ab [Units/volume] in Serum by Immunofluorescence;MAG Ab Ser IF-aCnc;;ACTIVE;2.17;2.69 +45171-6;Pancreatic islet cell Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Pancreatic islet cell Ab [Units/volume] in Serum by Immunofluorescence;Panc Islet Cell Ab Ser IF-aCnc;;ACTIVE;2.17;2.73 +45172-4;Purkinje cells Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Purkinje cells Ab [Units/volume] in Serum by Immunofluorescence;Purkinje Cells Ab Ser IF-aCnc;;ACTIVE;2.17;2.69 +45173-2;Thyrotropin.alpha subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyrotropin.alpha subunit [Mass/volume] in Serum or Plasma;TSH Alpha SerPl-mCnc;;ACTIVE;2.17;2.40 +45174-0;Herpes gestationis Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Herpes gestationis Ab panel - Serum;Herpes gestationis Ab Pnl Ser;;ACTIVE;2.17;2.42 +45175-7;HIV nucleoside reverse transcriptase gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV nucleoside reverse transcriptase gene mutations detected [Identifier];HIV NRTI gene Mut Det Islt;;ACTIVE;2.17;2.73 +45176-5;HIV nonnucleoside reverse transcriptase gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV nonnucleoside reverse transcriptase gene mutations detected [Identifier];HIV NNRTI gene Mut Det Islt;;ACTIVE;2.17;2.73 +45177-3;Herpes gestationis Ab.IgG.non-complement fixing;PrThr;Pt;Ser;Ord;IF;SERO;1;Herpes gestationis IgG Ab non-complement fixing [Presence] in Serum by Immunofluorescence;HG IgG NCF Ser Ql IF;;ACTIVE;2.17;2.56 +45178-1;Basement membrane zone Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Basement membrane zone IgG Ab [Presence] in Serum by Immunofluorescence;BMZ IgG Ser Ql IF;;ACTIVE;2.17;2.73 +4517-9;Complement factor Bb;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement factor Bb [Mass/volume] in Serum or Plasma;Comp Fact Bb SerPl-mCnc;;ACTIVE;1.0;2.34 +45179-9;Herpes gestationis Ab.IgG.complement fixing;PrThr;Pt;Ser;Ord;IF;SERO;1;Herpes gestationis IgG Ab complement fixing [Presence] in Serum by Immunofluorescence;HG IgG CF Ser Ql IF;;ACTIVE;2.17;2.56 +45180-7;1p chromosome deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;1p chromosome deletion [Presence] in Blood or Tissue by Molecular genetics method;1p Chrom Del Bld/T Ql;;ACTIVE;2.17;2.17 +45181-5;19q chromosome deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;19q chromosome deletion [Presence] in Blood or Tissue by Molecular genetics method;19q Chrom Del Bld/T Ql;;ACTIVE;2.17;2.17 +45182-3;HIV phenotype;Susc;Pt;Isolate;Nom;Phenotyping;ABXBACT;1;HIV phenotype [Susceptibility];HIV Phenotyp Islt;;ACTIVE;2.17;2.73 +45183-1;Neisseria meningitidis;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Neisseria meningitidis [Identifier] in Isolate by Agglutination;N men Islt Aggl;;ACTIVE;2.17;2.21 +45184-9;11-Deoxycortisol/Cortisol;MRto;Pt;Ser/Plas;Qn;;CHEM;1;11-Deoxycortisol/Cortisol [Mass Ratio] in Serum or Plasma;11DC/Cortis SerPl;;ACTIVE;2.17;2.73 +45185-6;2-Oxo-3-Hydroxy-Lysergate diethylamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2-Oxo-3-Hydroxy-Lysergate diethylamide [Mass/volume] in Urine;2-oxo-3-OH-LDS Ur-mCnc;;ACTIVE;2.17;2.70 +45186-4;Actinidia chinensis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Kiwifruit IgE Ab/IgE total in Serum;Kiwifruit IgE/IgE total %;;ACTIVE;2.17;2.70 +4518-7;Complement factor D;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement factor D [Mass/volume] in Serum or Plasma;Comp Fact D SerPl-mCnc;;ACTIVE;1.0;2.34 +45187-2;Antibiotic XXX;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Other Antibiotic [Susceptibility] by Disk diffusion (KB);Other Antibiotic Islt KB;;ACTIVE;2.17;2.73 +45188-0;Basement membrane zone BP180 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Basement membrane zone BP180 Ab [Units/volume] in Serum;BMZ BP180 Ab Ser-aCnc;;ACTIVE;2.17;2.73 +45189-8;Borrelia burgdorferi Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;B burgdor Ab CSF Ql IF;;ACTIVE;2.17;2.56 +45190-6;CASR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CASR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CASR gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +45191-4;CAPN3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CAPN3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CAPN3 gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +45192-2;Carnitine esters/Carnitine.free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Carnitine esters/Carnitine.free (C0) [Molar ratio] in DBS;Carn esters/C0 DBS-sRto;;ACTIVE;2.17;2.70 +45193-0;Cells.CD20+CD52+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20+CD52+ cells/100 cells in Blood;CD20+CD52+ Cells NFr Bld;;ACTIVE;2.17;2.70 +45194-8;Choriogonadotropin.intact+Beta subunit;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.intact+Beta subunit [Units/volume] in Serum or Plasma;HCG Intact+B SerPl-aCnc;;ACTIVE;2.17;2.73 +4519-5;Complement factor H;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement factor H [Mass/volume] in Serum or Plasma;Comp Fact H SerPl-mCnc;;ACTIVE;1.0;2.73 +45195-5;Cow epithelium+Cow dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow epithelium+Cow dander IgE Ab [Units/volume] in Serum;Cow Epith+Dander IgE Qn;;ACTIVE;2.17;2.70 +45196-3;Cytokines;PrThr;Pt;XXX;Ord;;CHEM;1;Cytokines [Presence] in Specimen;Cytokines Spec Ql;;ACTIVE;2.17;2.69 +45197-1;Decanoylcarnitine (C10);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Decanoylcarnitine (C10) [Moles/volume] in DBS;Decanoylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45198-9;Decenoylcarnitine (C10:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Decenoylcarnitine (C10:1) [Moles/volume] in DBS;Decenoylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45199-7;Dodecanoylcarnitine (C12);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dodecanoylcarnitine (C12) [Moles/volume] in DBS;Dodecanoylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45200-3;Dodecenoylcarnitine (C12:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1) [Moles/volume] in DBS;Dodecenoylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45201-1;Egg whole Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Whole Egg IgG Ab [Mass/volume] in Serum;Whole Egg IgG-mCnc;;ACTIVE;2.17;2.73 +45202-9;Ganglioside GD1a Ab;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Ganglioside GD1a Ab [Presence] in Serum;Deprecated GD1a Gangl Ab Ser Ql;;DEPRECATED;2.17;2.36 +4520-3;Complement factor I;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement factor I [Mass/volume] in Serum or Plasma;Comp Fact I SerPl-mCnc;;ACTIVE;1.0;2.73 +45203-7;Ganglioside GQ1b Ab;ACnc;Pt;Ser;Ord;;SERO;1;Deprecated Ganglioside GQ1b Ab [Presence] in Serum;Deprecated GQ1b Gangl Ab Ser Ql;;DEPRECATED;2.17;2.36 +45204-5;Glucose^3rd specimen post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Glucose [Mass/volume] in Urine by Test strip --3rd specimen post XXX challenge;Glucose sp3 p chal Ur Strip-mCnc;;ACTIVE;2.17;2.34 +45205-2;Glucose^4th specimen post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Glucose [Mass/volume] in Urine by Test strip --4th specimen post XXX challenge;Glucose sp4 p chal Ur Strip-mCnc;;ACTIVE;2.17;2.34 +45206-0;Glucose^5th specimen post XXX challenge;MCnc;Pt;Urine;Qn;Test strip;CHAL;1;Glucose [Mass/volume] in Urine by Test strip --5th specimen post XXX challenge;Glucose sp5 p chal Ur Strip-mCnc;;ACTIVE;2.17;2.34 +45207-8;Glutarylcarnitine (C5-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC) [Moles/volume] in DBS;Glutarylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45208-6;Hemoglobin A;PrThr;Pt;Bld;Ord;Electrophoresis;HEM/BC;1;Hemoglobin A [Presence] in Blood by Electrophoresis;Hgb A Bld Ql Elph;;ACTIVE;2.17;2.56 +45209-4;Heptacarboxylporphyrin;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Heptacarboxylporphyrin [Moles/volume] in DBS;Hepta-CP DBS-sCnc;;ACTIVE;2.17;2.70 +45210-2;Herpes simplex virus 2 Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Herpes simplex virus 2 IgM Ab [Presence] in Serum by Immunofluorescence;HSV2 IgM Ser Ql IF;;ACTIVE;2.17;2.73 +4521-1;Complement factor P;MCnc;Pt;Plas;Qn;;HEM/BC;1;Complement factor P [Mass/volume] in Plasma;Comp Fact P Plas-mCnc;;ACTIVE;1.0;2.34 +45211-0;Hexanoylcarnitine (C6);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Hexanoylcarnitine (C6) [Moles/volume] in DBS;Hexanoylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45212-8;HIV 2 p31+p34 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p31+p34 Ab [Presence] in Serum by Immunoblot;HIV 2 p31+p34 Ab Ser Ql IB;;ACTIVE;2.17;2.58 +45213-6;Isobutyrylcarnitine (C4);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Isobutyrylcarnitine (C4) [Moles/volume] in DBS;Isobutyrylcarn DBS-sCnc;;ACTIVE;2.17;2.70 +45214-4;Isoleucine+Leucine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Isoleucine+Leucine [Moles/volume] in DBS;Ile+Leu DBS-sCnc;;ACTIVE;2.17;2.70 +45215-1;Isoniazid 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid 2 ug/mL Islt SlowMyco;;ACTIVE;2.17;2.26 +45216-9;Isovalerylcarnitine+Methylbutyrylcarnitine (C5);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5) [Moles/volume] in DBS;Isovaleryl+MeButyrylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45217-7;Linoleoylcarnitine (C18:2);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Linoleoylcarnitine (C18:2) [Moles/volume] in DBS;Linoleoylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45218-5;Lymphocytic choriomeningitis virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Presence] in Serum;LCMV IgG Ser Ql;;ACTIVE;2.17;2.56 +45219-3;Lymphocytic choriomeningitis virus Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Presence] in Cerebral spinal fluid;LCMV IgG CSF Ql;;ACTIVE;2.17;2.56 +45220-1;Lymphocytic choriomeningitis virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Presence] in Serum;LCMV IgM Ser Ql;;ACTIVE;2.17;2.56 +45221-9;Lymphocytic choriomeningitis virus Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Presence] in Cerebral spinal fluid;LCMV IgM CSF Ql;;ACTIVE;2.17;2.56 +45222-7;Methylmalonylcarnitine (C4-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC) [Moles/volume] in DBS;Me-malonylcarn DBS-sCnc;;ACTIVE;2.17;2.73 +45223-5;Moxifloxacin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Moxifloxacin [Mass/volume] in Serum or Plasma;Deprecated Moxifloxacin SerPl-mCnc;;DEPRECATED;2.17;2.36 +45224-3;Mycoplasma pneumoniae Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma pneumoniae IgG Ab [Presence] in Serum by Immunoassay;M pneumo IgG Ser Ql IA;;ACTIVE;2.17;2.73 +45225-0;Pancreatic islet cell complement fixing Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Pancreatic islet cell complement fixing Ab [Titer] in Serum by Immunofluorescence;Panc Islet Cell CF Ab Titr Ser IF;;ACTIVE;2.17;2.32 +45226-8;Ribosomal P Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Ribosomal P IgG Ab [Presence] in Serum;Ribosomal P IgG Ser Ql;;ACTIVE;2.17;2.73 +45227-6;Rubus fruticosus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Blackberry IgE Ab/IgE total in Serum;Blackberry IgE/IgE total %;;ACTIVE;2.17;2.70 +45228-4;Streptolysin O Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptolysin O Ab [Mass/volume] in Serum;ASO Ab Ser-mCnc;;ACTIVE;2.17;2.73 +4522-9;Complement iC3;MCnc;Pt;Plas;Qn;;HEM/BC;1;Complement iC3 [Mass/volume] in Plasma;iC3 Plas-mCnc;;ACTIVE;1.0;2.73 +45229-2;Toxocara cati Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Toxocara cati Ab [Presence] in Serum;T cati Ab Ser Ql;;ACTIVE;2.17;2.56 +452-3;Spectinomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Spectinomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Spectinomycin Islt MIC;;ACTIVE;1.0;2.19 +45230-0;District where patient entered HIV Rx;ID;Pt;^Patient;Nom;Reported;ART;2;District where patient entered HIV treatment;District where patient entered HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45231-8;HIV Rx prior to enrollment;Type;Pt;^Patient;Nom;Reported;ART;2;HIV treatment prior to enrollment;HIV Rx prior to enrollment;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45232-6;Reason medically eligible for HIV Rx;Find;Pt;^Patient;Nom;Reported;ART;2;Reason medically eligible for HIV treatment;Reason medically eligible for HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45233-4;WHO HIV stage;Find;Pt;^Patient;Ord;Reported;ART;2;World Health Organization HIV stage;WHO HIV stage;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45234-2;Date eligible and selected to start HIV Rx;Date;Pt;^Patient;Qn;Reported;ART;2;Date eligible and selected to start HIV treatment;Date eligible & selected to start HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45235-9;Date original clinic HIV Rx start;Date;Pt;^Patient;Qn;Reported;ART;2;Date original clinic HIV treatment start;Date original clinic HIV Rx start;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45236-7;HIV Rx cohort;ID;Pt;^Patient;Nom;Reported;ART;2;HIV treatment cohort;HIV Rx cohort;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +4523-7;Complement iC3b receptors;EntNum;Pt;WBC;Qn;;HEM/BC;1;Complement iC3b receptors [Entitic number] in Leukocytes;iC3b Recep EntNum WBC;;ACTIVE;1.0;2.26 +45237-5;Date lost to HIV Rx follow-up;Date;Pt;^Patient;Qn;Reported;ART;2;Date lost to HIV treatment follow-up;Date lost to HIV Rx follow-up;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45238-3;Date lost to HIV Rx therapy;Date;Pt;^Patient;Qn;Reported;ART;2;Date lost to HIV treatment therapy;Date lost to HIV Rx therapy;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45239-1;Current HIV Rx therapy duration;Time;Pt;^Patient;Qn;Computed;ART;2;Current HIV treatment therapy duration;Current HIV Rx duration;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45240-9;Isoniazid therapy start date;Date;Pt;^Patient;Qn;Reported;ART;2;Isoniazid therapy start date;INH Rx start date;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45241-7;Tuberculosis status;Type;Pt;^Patient;Nom;Reported;ART;2;Tuberculosis status;TB status;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45242-5;Tuberculosis treatment start date;Date;Pt;^Patient;Qn;Reported;ART;2;Tuberculosis treatment start date;TB Tx start date;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45243-3;Reason for discontinuation of anti-infective phrophylaxis medication;Type;Pt;^Patient;Nom;Reported;ART;2;Reason for discontinuation of anti-infective phrophylaxis medication;Reason for d/c of anti-infect proph Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45244-1;HIV ART medication dose number taken/Medication dose number prescribed;NFr;Pt;^Patient;Qn;Reported;ART;2;Percent HIV ART medication dose number taken/Medication dose number prescribed - Reported;% HIV ART Rx dose taken/presc;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +4524-5;Complement membrane attack complex (C5b-C6-C7-C8-C9n);MCnc;Pt;Plas;Qn;;HEM/BC;1;Complement membrane attack complex (C5b-C6-C7-C8-C9n) [Mass/volume] in Plasma;Comp MAC Plas-mCnc;;ACTIVE;1.0;2.34 +45245-8;Degree of adherence to co-trimoxazole;Find;Pt;^Patient;Ord;Reported;ART;2;Degree of adherence to co-trimoxazole;Degree of adherence to TMP-SMX;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45246-6;Degree of adherence to anti-retroviral drug regimen;Find;Pt;^Patient;Ord;Reported;ART;2;Degree of adherence to anti-retroviral drug regimen;Degree of adherence to ART;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45247-4;Reason for missing HIV Rx administration schedule;Find;Pt;^Patient;Nom;Reported;ART;2;Reason for missing HIV treatment administration schedule;Reason for missing HIV Rx schedule;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45248-2;Number of hospital D since last outpatient visit;Num;Pt;^Patient;Qn;Reported;H&P.HX;2;Number of hospital days since last outpatient visit - Reported;# hosp days since last OP visit Reported;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45249-0;Evidence of tuberculosis resistance;Find;Pt;^Patient;Nom;Reported;ART;2;Evidence of tuberculosis resistance;Evidence of TB resis;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45250-8;HIV confirmation facility;Addr;Pt;Facility;Nom;Reported;ART;2;HIV confirmation facility Address;HIV confirmation facility Add;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45251-6;HIV confirmation facility;ID;Pt;Facility;Nom;Reported;ART;2;HIV confirmation facility;HIV confirmation facility;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +4525-2;Complement membrane C3b-C4b cofactor protein;EntNum;Pt;WBC;Qn;;HEM/BC;1;Complement membrane C3b-C4b cofactor protein [Entitic number] in Leukocytes;MCP C3b-C4b EntNum WBC;;ACTIVE;1.0;2.26 +45252-4;Institutional entry point HIV Rx;Type;Pt;Facility;Nom;Reported;ART;2;Institutional entry point HIV treatment;Inst entry point HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45253-2;HIV Rx prior clinic transferred from;Addr;Pt;Facility;Nom;Reported;ART;2;HIV treatment prior clinic transferred from Address;HIV Rx prior clinic transferred from Add;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45254-0;HIV Rx prior clinic transferred from;ID;Pt;Facility;Nom;Reported;ART;2;HIV treatment prior clinic transferred from;HIV Rx prior clinic;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45255-7;HIV Rx clinic transferred to;Addr;Pt;Facility;Nom;Reported;ART;2;HIV treatment clinic transferred to Address;HIV Rx clinic transferred to Add;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45256-5;HIV Rx clinic transferred to;ID;Pt;Facility;Nom;Reported;ART;2;HIV treatment clinic transferred to;HIV Rx clinic transferred to;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45257-3;Date dropped from HIV Rx;Date;Pt;^Patient;Qn;Reported;ART;2;Date dropped from HIV treatment;Date dropped from HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45258-1;HIV ART medication dose number taken/Medication dose number prescribed;NFr;Pt;^Patient;Qn;MEMS Cap;ART;2;Percent HIV ART medication dose number taken/Medication dose number prescribed MEMS cap;#% HIV ART Rx dose taken/pres MEMS cap;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45259-9;HIV ART actual prescription fills number/Ideal prescription fills number;NFr;Pt;^Patient;Qn;Pharmacy records;ART;2;Percent HIV ART actual prescription fills number/Ideal prescription fills number;% HIV ART Rx fills/Ideal;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +4526-0;Complement protein;-;Pt;Plas;Qn;;HEM/BC;1;Deprecated Complement protein;Deprecated Complement protein Plas Qn;;DEPRECATED;1.0;2.66 +45260-7;HIV ART medication;Type;Pt;^Patient;Qn;Reported.ACTG;ART;2;HIV ART medication;HIV ART Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45261-5;{HIV ART medication} doses missed yesterday;Num;Pt;^Patient;Qn;Reported.ACTG;ART;2;Number of HIV antiretroviral medication doses missed yesterday ACTG;HIV ART Rx doses missed yesterday;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45262-3;{HIV ART medication} doses missed 2D ago;Num;Pt;^Patient;Qn;Reported.ACTG;ART;2;Number of HIV antiretroviral medication doses missed 2 days ago ACTG;HIV ART Rx doses missed 2 days ago;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45263-1;{HIV ART medication} doses missed 3D ago;Num;Pt;^Patient;Qn;Reported.ACTG;ART;2;Number of HIV antiretroviral medication doses missed 3 days ago ACTG;HIV ART Rx doses missed 3 days ago;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45264-9;{HIV ART medication} doses missed 4D ago;Num;Pt;^Patient;Qn;Reported.ACTG;ART;2;Number of HIV antiretroviral medication doses missed 4 days ago ACTG;HIV ART Rx doses missed 4 days ago;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.17;2.67 +45265-6;Immunodeficiency markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Immunodeficiency markers [Interpretation] in Specimen Narrative;Immunodeficiency Markers Spec-Imp;;ACTIVE;2.17;2.73 +45266-4;Chronic leukemia markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Chronic leukemia markers [Interpretation] in Specimen Narrative;Chronic Leukemia Markers Spec-Imp;;ACTIVE;2.17;2.73 +45267-2;Acute leukemia markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Acute leukemia markers [Interpretation] in Specimen Narrative;Acute leukemia markers Spec-Imp;;ACTIVE;2.17;2.73 +45268-0;Immunodeficiency panel;-;Pt;Bld;-;Flow cytometry;PANEL.CELLMARK;1;Immunodeficiency panel - Blood by Flow cytometry (FC);Immunodeficiency Pnl Bld FC;;ACTIVE;2.17;2.42 +45269-8;Chronic leukemia panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Chronic leukemia panel - Specimen by Flow cytometry (FC);Chronic Leukemia Pnl Spec FC;;ACTIVE;2.17;2.69 +45270-6;Acute leukemia panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Acute leukemia panel - Specimen by Flow cytometry (FC);Acute leukemia Pnl Spec FC;;ACTIVE;2.17;2.73 +45271-4;Bordetella bronchiseptica DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Bordetella bronchiseptica DNA [Presence] in Nasopharynx by NAA with probe detection;B bronch DNA Nph Ql NAA+probe;;ACTIVE;2.17;2.63 +45272-2;Sympathomimetics;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Sympathomimetics [Presence] in Urine by Confirmatory method;Sympathomimetics Ur Ql Cfm;;ACTIVE;2.17;2.73 +45273-0;Pregnancy associated plasma protein A multiple of the median;Prctl;Pt;Ser/Plas;Qn;;CHEM;1;Pregnancy associated plasma protein A multiple of the median [Percentile];PAPP-A MoM Prctl SerPl;;ACTIVE;2.17;2.42 +45274-8;Low molecular weight heparin induced platelet Ab;PrThr;Pt;Ser;Ord;;COAG;1;Low molecular weight heparin induced platelet Ab [Presence] in Serum;LMW heparin ind plt Ab Ser Ql;;ACTIVE;2.17;2.66 +45275-5;Bacteria identified;Prid;Pt;Bld;Nom;Aerobic culture 25 deg C incubation;MICRO;1;Bacteria identified in Blood by Aerobe culture 25 degree C incubation;Bacteria Bld Aerobe Cult 25 Deg;;ACTIVE;2.17;2.26 +45276-3;Bacteria identified;Prid;Pt;Bld;Nom;Anaerobic culture 25 deg C incubation;MICRO;1;Bacteria identified in Blood by Anaerobe culture 25 degree C incubation;Bacteria Bld Anaerobe Cult 25 Deg;;ACTIVE;2.17;2.26 +45277-1;Lymphocytic choriomeningitis virus Ab.IgM;PrThr;Pt;Body fld;Ord;;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Presence] in Body fluid;LCMV IgM Fld Ql;;ACTIVE;2.17;2.56 +4527-8;Complement receptor 1;-;Pt;WBC;-;;HEM/BC;1;Deprecated Complement receptor 1;Deprecated Complement receptor 1 WBC;;DEPRECATED;1.0;2.66 +45278-9;Lymphocytic choriomeningitis virus Ab.IgG;PrThr;Pt;Body fld;Ord;;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Presence] in Body fluid;LCMV IgG Fld Ql;;ACTIVE;2.17;2.56 +45279-7;Influenza virus A+B Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Influenza virus A+B Ab [Presence] in Body fluid;FLUAV+FLUBV Ab Fld Ql;;ACTIVE;2.17;2.56 +45280-5;Echovirus 9 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Echovirus 9 Ab [Presence] in Body fluid;ECV9 Ab Fld Ql;;ACTIVE;2.17;2.56 +45281-3;Echovirus 7 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Echovirus 7 Ab [Presence] in Body fluid;ECV7 Ab Fld Ql;;ACTIVE;2.17;2.56 +45282-1;Echovirus 30 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Echovirus 30 Ab [Presence] in Body fluid;ECV30 Ab Fld Ql;;ACTIVE;2.17;2.56 +45283-9;Echovirus 11 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Echovirus 11 Ab [Presence] in Body fluid;ECV11 Ab Fld Ql;;ACTIVE;2.17;2.56 +45284-7;DPYD gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DPYD gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;DPYD gene Mut Anl Bld/T;;ACTIVE;2.17;2.73 +45285-4;Date and time;TmStp;Pt;Dose;Qn;;DRUGDOSE;1;Date and time of Dose;Date+time Dose;;ACTIVE;2.17;2.73 +4528-6;Complement receptor 2;-;Pt;WBC;-;;HEM/BC;1;Deprecated Complement receptor 2;Deprecated Complement receptor 2 WBC;;DEPRECATED;1.0;2.66 +45286-2;Cytomegalovirus Ab.IgA;PrThr;Pt;Body fld;Ord;;MICRO;1;Cytomegalovirus IgA Ab [Presence] in Body fluid;CMV IgA Fld Ql;;ACTIVE;2.17;2.56 +45287-0;Coxsackievirus B6 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coxsackievirus B6 Ab [Presence] in Body fluid;CV B6 Ab Fld Ql;;ACTIVE;2.17;2.56 +45288-8;Coxsackievirus B5 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coxsackievirus B5 Ab [Presence] in Body fluid;CV B5 Ab Fld Ql;;ACTIVE;2.17;2.56 +45289-6;Coxsackievirus B4 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coxsackievirus B4 Ab [Presence] in Body fluid;CV B4 Ab Fld Ql;;ACTIVE;2.17;2.56 +45290-4;Coxsackievirus B3 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coxsackievirus B3 Ab [Presence] in Body fluid;CV B3 Ab Fld Ql;;ACTIVE;2.17;2.56 +45291-2;Coxsackievirus B2 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coxsackievirus B2 Ab [Presence] in Body fluid;CV B2 Ab Fld Ql;;ACTIVE;2.17;2.73 +45292-0;Coxsackievirus B1 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coxsackievirus B1 Ab [Presence] in Body fluid;CV B1 Ab Fld Ql;;ACTIVE;2.17;2.73 +45293-8;Choriogonadotropin.beta subunit.free multiple of the median;Prctl;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit.free multiple of the median [Percentile];B-HCG Free MoM Prctl SerPl;;ACTIVE;2.17;2.42 +4529-4;Complement receptor 3;-;Pt;WBC;-;;HEM/BC;1;Deprecated Complement receptor 3;Deprecated Complement receptor 3 WBC;;DEPRECATED;1.0;2.66 +45294-6;Bordetella bronchiseptica DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bordetella bronchiseptica DNA [Presence] in Specimen by NAA with probe detection;B bronch DNA Spec Ql NAA+probe;;ACTIVE;2.17;2.69 +45295-3;Acetylcholinesterase/Cholinesterase;CRto;Pt;Amnio fld;Qn;;CHEM;1;Acetylcholinesterase/Cholinesterase [Enzymatic activity ratio] in Amniotic fluid;AChE/Cholinesterase Amn-cRto;;ACTIVE;2.17;2.70 +45296-1;Cortisol^pre dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre dose dexamethasone;Cortis Pre Dex SerPl-sCnc;;ACTIVE;2.17;2.70 +45297-9;Glucose;SCnc;24H;Dial fld;Qn;;CHEM;1;Glucose [Moles/volume] in 24 hour Dialysis fluid;Glucose 24h Dial fld-sCnc;;ACTIVE;2.17;2.70 +45298-7;Glucose^2.5H post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hours post 50 g lactose PO;Glucose 2.5h p 50 g Lac PO SerPl-sCnc;;ACTIVE;2.17;2.70 +45299-5;Glucose^45M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose lactose PO;Glucose 45M p Lac PO SerPl-sCnc;;ACTIVE;2.17;2.70 +45300-1;Glycerol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycerol [Moles/volume] in Serum or Plasma;Glycerol SerPl-sCnc;;ACTIVE;2.17;2.70 +45301-9;Nortriptyline;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nortriptyline [Moles/volume] in Urine;Nortrip Ur-sCnc;;ACTIVE;2.17;2.70 +4530-2;Complement receptor 4;-;Pt;WBC;-;;HEM/BC;1;Deprecated Complement receptor 4;Deprecated Complement receptor 4 WBC;;DEPRECATED;1.0;2.66 +45302-7;Urea;SCnc;Pt;Dial fld;Qn;;CHEM;1;Urea [Moles/volume] in Dialysis fluid;Urea Dial fld-sCnc;;ACTIVE;2.17;2.70 +45303-5;Urea^2H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Urea [Moles/volume] in Dialysis fluid --2 hour specimen;Urea 2h spec Dial fld-sCnc;;ACTIVE;2.17;2.70 +45304-3;Urea^4H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Urea [Moles/volume] in Dialysis fluid --4 hour specimen;Urea 4h spec Dial fld-sCnc;;ACTIVE;2.17;2.70 +45305-0;Coproporphyrin 1;SCnt;Pt;Stool;Qn;;CHEM;1;Coproporphyrin 1 [Moles/mass] in Stool;Copro1 Stl-sCnt;;ACTIVE;2.17;2.70 +45306-8;Coproporphyrin 3;SCnt;Pt;Stool;Qn;;CHEM;1;Coproporphyrin 3 [Moles/mass] in Stool;Copro3 Stl-sCnt;;ACTIVE;2.17;2.70 +45307-6;Deuteroporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Deuteroporphyrin [Moles/mass] in Stool;Deuteropor Stl-sCnt;;ACTIVE;2.17;2.70 +45308-4;Heptacarboxylate;SCnt;Pt;Stool;Qn;;CHEM;1;Heptacarboxylate [Moles/mass] in Stool;Heptacarboxylate Stl-sCnt;;ACTIVE;2.17;2.70 +45309-2;Hexacarboxylate;SCnt;Pt;Stool;Qn;;CHEM;1;Hexacarboxylate [Moles/mass] in Stool;Hexacarboxylate Stl-sCnt;;ACTIVE;2.17;2.70 +453-1;Spectinomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Spectinomycin [Susceptibility] by Disk diffusion (KB);Spectinomycin Islt KB;;ACTIVE;1.0;2.73 +4531-0;Complement total hemolytic;ACnc;Pt;Bld;Qn;;HEM/BC;1;Complement total hemolytic [Units/volume] in Blood;Total Hem Comp Bld-aCnc;;ACTIVE;1.0;2.68 +45310-0;Mesoporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Mesoporphyrin [Moles/mass] in Stool;Mesopor Stl-sCnt;;ACTIVE;2.17;2.70 +45311-8;Pentacarboxylate;SCnt;Pt;Stool;Qn;;CHEM;1;Pentacarboxylate [Moles/mass] in Stool;Pentacarboxylate Stl-sCnt;;ACTIVE;2.17;2.70 +45312-6;Uroporphyrin 3 isomer;SCnt;Pt;Stool;Qn;;CHEM;1;Uroporphyrin 3 isomer [Moles/mass] in Stool;Uropor3 Stl-sCnt;;ACTIVE;2.17;2.70 +45313-4;Coproporphyrin 1/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 1/Creatinine [Molar ratio] in Urine;Copro1/Creat Ur-sRto;;ACTIVE;2.17;2.73 +45314-2;Coproporphyrin 3/Coproporphyrin 1;SRto;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 3/Coproporphyrin 1 [Molar ratio] in Urine;Copro3/Copro1 Ur-sRto;;ACTIVE;2.17;2.42 +45315-9;Coproporphyrin 3/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 3/Creatinine [Molar ratio] in Urine;Copro3/Creat Ur-sRto;;ACTIVE;2.17;2.73 +45316-7;Hexacarboxylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexacarboxylate/Creatinine [Molar ratio] in Urine;Hexacarboxylate/Creat Ur-sRto;;ACTIVE;2.17;2.70 +45317-5;Pentacarboxylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pentacarboxylate/Creatinine [Molar ratio] in Urine;Pentacarboxylate/Creat Ur-sRto;;ACTIVE;2.17;2.70 +45318-3;Uroporphyrin 3 isomer/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Uroporphyrin 3 isomer/Creatinine [Molar ratio] in Urine;Uropor3/Creat Ur-sRto;;ACTIVE;2.17;2.70 +45319-1;Uroporphyrin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Uroporphyrin/Creatinine [Molar ratio] in Urine;Uropor/Creat Ur-sRto;;ACTIVE;2.17;2.73 +45320-9;Ecgonine methyl ester;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Ecgonine methyl ester [Presence] in Serum or Plasma by Confirmatory method;EME SerPl Ql Cfm;;ACTIVE;2.17;2.56 +45321-7;FMR1 gene allele 1.CGG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;FMR1 gene allele 1 CGG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;FMR1 allele1 CGG Rpt EntNum Bld/T;;ACTIVE;2.17;2.73 +45322-5;FMR1 gene allele 2.CGG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;FMR1 gene allele 2 CGG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;FMR1 allele 2 CGG Rpt EntNum Bld/T;;ACTIVE;2.17;2.73 +45323-3;Mycobacterium tuberculosis tuberculin stimulated gamma interferon;PrThr;Pt;Bld;Ord;;MICRO;1;Mycobacterium tuberculosis tuberculin stimulated gamma interferon [Presence] in Blood;M TB tuberc IFN-g Bld Ql;;ACTIVE;2.17;2.73 +45324-1;Ethyl glucuronide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethyl glucuronide [Mass/volume] in Urine;Ethyl glucuronide Ur-mCnc;;ACTIVE;2.17;2.73 +45325-8;Campylobacter jejuni Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Campylobacter jejuni IgG Ab [Titer] in Serum;C jejuni IgG Titr Ser;;ACTIVE;2.17;2.32 +45326-6;Cytomegalovirus Ab.IgG avidity;Ratio;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgG Ab avidity [Ratio] in Serum or Plasma;CMV IgG Avidity SerPl-Rto;;DISCOURAGED;2.17;2.73 +45327-4;FMR1 gene targeted mutation analysis;Find;Pt;Amnio fld;Doc;Molgen;MOLPATH.MUT;1;FMR1 gene targeted mutation analysis in Amniotic fluid by Molecular genetics method;FMR1 gene Mut Anl Amn;;ACTIVE;2.17;2.73 +4532-8;Complement total hemolytic CH50;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement total hemolytic CH50 [Units/volume] in Serum or Plasma;CH50 SerPl-aCnc;;ACTIVE;1.0;2.73 +45328-2;Glutathione peroxidase;CCnc;Pt;Bld;Qn;;CHEM;1;Glutathione peroxidase [Enzymatic activity/volume] in Blood;Glutathione Px Bld-cCnc;;ACTIVE;2.17;2.68 +45329-0;Glutathione reductase;CCnc;Pt;Ser;Qn;;CHEM;1;Glutathione reductase [Enzymatic activity/volume] in Serum;GR Ser-cCnc;;ACTIVE;2.17;2.68 +45330-8;Leptospira interrogans Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Leptospira interrogans IgG Ab [Titer] in Serum by Immunofluorescence;L inter IgG Titr Ser IF;;ACTIVE;2.17;2.32 +45331-6;NF1 gene targeted mutation analysis;Prid;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;NF1 gene mutations found [Identifier] in Amniotic fluid by Molecular genetics method Nominal;NF1 gene Mut Anl Amn;;ACTIVE;2.17;2.63 +45332-4;NF2 gene targeted mutation analysis;Prid;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;NF2 gene mutations found [Identifier] in Amniotic fluid by Molecular genetics method Nominal;NF2 gene Mut Anl Amn;;ACTIVE;2.17;2.63 +45333-2;Superoxide dismutase;CCnc;Pt;Bld;Qn;;CHEM;1;Superoxide dismutase [Enzymatic activity/volume] in Blood;SOD Bld-cCnc;;ACTIVE;2.17;2.68 +45334-0;Tryptase;MCnc;Pt;Body fld;Qn;;CHEM;1;Tryptase [Mass/volume] in Body fluid;Tryptase Fld-mCnc;;ACTIVE;2.17;2.42 +45335-7;Bacteria identification test;PrThr;Pt;Isolate;Ord;Culture;MICRO;1;Bacteria Identification [Presence] in Isolate by Culture;Bacteria ID test Islt Ql Cult;;ACTIVE;2.17;2.73 +4533-6;Complement+Immunoglobulin;ACnc;Pt;RBC;Qn;;HEM/BC;1;Complement+Immunoglobulin [Units/volume] in Red Blood Cells;Comp+Ig RBC-aCnc;;ACTIVE;1.0;2.69 +45336-5;Bacteria producing hemolysis;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing hemolysis [Presence] in Isolate;Bacteria Hemolysis Islt Ql;;ACTIVE;2.17;2.73 +45337-3;Bacterial biochemical profile;Prid;Pt;Isolate;Nom;Culture;MICRO;1;Bacterial biochemical profile [Identifier] in Isolate by Culture;Bacteria biochem profile Islt Cult;;ACTIVE;2.17;2.73 +45338-1;Proinsulin/Insulin;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Proinsulin/Insulin [Ratio] in Serum or Plasma;Proinsulin/Insulin SerPl-Rto;;ACTIVE;2.17;2.73 +45339-9;Tick identified^^^4;Prid;Pt;XXX;Nom;;MICRO;1;Tick # 4 identified in Specimen;Tick Identified Spec org #4;;ACTIVE;2.17;2.69 +45340-7;Tick identified^^^3;Prid;Pt;XXX;Nom;;MICRO;1;Tick # 3 identified in Specimen;Tick Identified Spec org #3;;ACTIVE;2.17;2.69 +45341-5;Tick identified^^^2;Prid;Pt;XXX;Nom;;MICRO;1;Tick # 2 identified in Specimen;Tick Identified Spec org #2;;ACTIVE;2.17;2.69 +45342-3;Tick identified;Prid;Pt;XXX;Nom;;MICRO;1;Tick identified in Specimen;Tick Identified Spec;;ACTIVE;2.17;2.73 +45343-1;Sex&Stage;Prid;Pt;^Tick;Nom;;MICRO;1;Sex+stage of tick;Sex+stage Tick;;ACTIVE;2.17;2.26 +4534-4;Cyanmethemoglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Cyanmethemoglobin/Hemoglobin.total in Blood;CyanmetHgb MFr Bld;;ACTIVE;1.0;2.70 +45344-9;Mouth intact;PrThr;Pt;^Tick;Ord;;MICRO;1;Tick mouth intact [Identifier];Mouth Intact Tick Ql;;ACTIVE;2.17;2.56 +45345-6;Engorgement;PrThr;Pt;^Tick;Ord;;MICRO;1;Tick engorgement [presence];Engorgement Tick Ql;;ACTIVE;2.17;2.56 +45346-4;Date tick removed;Date;Pt;^Tick;Qn;;MICRO;1;Date tick removed;Date Tick Removed;;ACTIVE;2.17;2.50 +45347-2;Date tick attached;Date;Pt;^Tick;Qn;;MICRO;1;Date tick attached;Date Tick Attached;;ACTIVE;2.17;2.50 +45348-0;Date tick acquired;Date;Pt;^Tick;Qn;;MICRO;1;Date tick acquired;Date tick acquired;;ACTIVE;2.17;2.50 +45349-8;Condition of tick;Prid;Pt;^Tick;Nom;;MICRO;1;Condition of tick [Identifier];Condition Of Tick;;ACTIVE;2.17;2.17 +45350-6;Tick identification panel;-;Pt;^Tick;-;;PANEL.MICRO;1;Tick identification panel;Tick ID Pnl;;ACTIVE;2.17;2.73 +4535-1;Cytotoxic percent reactive Ab;PrThr;Pt;Ser;Ord;Quick method;HEM/BC;1;Cytotoxic percent reactive Ab [Presence] in Serum by Quick method;Ctox Pct React Ab Ser Ql Qck;;ACTIVE;1.0;2.56 +45351-4;Date of skin test;TmStp;Pt;Skin;Qn;;CHALSKIN;1;Date of skin test;Date Of Skin Test;;ACTIVE;2.17;2.73 +45352-2;Date skin test interpreted;TmStp;Pt;Skin;Qn;;CHALSKIN;1;Date skin test interpreted;Date Skin Test Interpreted;;ACTIVE;2.17;2.73 +45353-0;Date of analysis;TmStp;Pt;XXX;Qn;;MISC;1;Date of analysis of unspecified specimen;Date Of Analysis Spec;;ACTIVE;2.17;2.73 +45354-8;Date next dose;Date;Pt;^Patient;Qn;;VACCIN;2;Date next dose;Date Next Dose;;ACTIVE;2.17;2.50 +45355-5;Date Rh immune globulin given;Date;Pt;^Patient;Qn;;BLDBK;1;Date Rh immune globulin given;Date Rh imm gl Gvn;;ACTIVE;2.17;2.73 +45356-3;Time Rh immune globulin given;TmStp;Pt;^Patient;Qn;;BLDBK;1;Time Rh immune globulin given;Time Rh Imm Gl Gvn;;ACTIVE;2.17;2.52 +45357-1;Erythrocytes.filamented;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Erythrocytes.filamented [Presence] in Blood by Light microscopy;filamented rbc Bld Ql Smear;;ACTIVE;2.17;2.56 +45358-9;Length of calorie fast;Time;Pt;^Patient;Qn;;MISC;1;Length of calorie fast;Length of Fast Time Patient;;ACTIVE;2.17;2.73 +45359-7;Length of time post dose;Time;Pt;^Patient;Qn;;MISC;1;Length of time post dose;Length of time p dose;;ACTIVE;2.17;2.73 +45360-5;Lymphocyte proliferation. 0.125 ug pokeweed mitogen stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.125 ug pokeweed mitogen in Blood;LPT 0.125 Ug PW Bld-nRate;;ACTIVE;2.17;2.70 +45361-3;Lymphocyte proliferation. 0.25 ug pokeweed mitogen stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.25 ug pokeweed mitogen in Blood;LPT 0.25 ug PW Bld-nRate;;ACTIVE;2.17;2.70 +45362-1;Lymphocyte proliferation. 0.50 ug pokeweed mitogen stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.50 ug pokeweed mitogen in Blood;LPT 0.50 ug PW Bld-nRate;;ACTIVE;2.17;2.70 +45363-9;Lymphocyte proliferation. 1.0 ug phytohemagglutinin stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 1.0 ug phytohemagglutinin in Blood;LPT 1.0 ug PHA Bld-nRate;;ACTIVE;2.17;2.70 +45364-7;Lymphocyte proliferation. 1.0 ug pokeweed mitogen stimulation;ACnc;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 1.0 ug pokeweed mitogen [Units/volume] in Blood;LPT 1.0 ug PW Bld-aCnc;;ACTIVE;2.17;2.69 +45365-4;Lymphocyte proliferation. 10 ug concanavalin A stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 10 ug concanavalin A in Blood;LPT 10 ug CA Bld-nRate;;ACTIVE;2.17;2.70 +45366-2;Lymphocyte proliferation. 2.0 ug phytohemagglutinin stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 2.0 ug phytohemagglutinin in Blood;LPT 2.0 ug PHA Bld-nRate;;ACTIVE;2.17;2.70 +45367-0;Lymphocyte proliferation. 20 ug concanavalin A stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 20 ug concanavalin A in Blood;LPT 20 ug CA Bld-nRate;;ACTIVE;2.17;2.70 +45368-8;Lymphocyte proliferation. 5 ug concanavalin A stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 5 ug concanavalin A in Blood;LPT 5 ug CA Bld-nRate;;ACTIVE;2.17;2.73 +4536-9;Deoxyhemoglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Deoxyhemoglobin/Hemoglobin.total in Blood;DO-Hgb MFr Bld;;ACTIVE;1.0;2.73 +45369-6;Lymphocyte proliferation. 0.5 ug phytohemagglutinin stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.5 ug phytohemagglutinin in Blood;LPT 0.5 ug PHA Bld-nRate;;ACTIVE;2.17;2.70 +45370-4;Platelet crossmatch;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;Platelet crossmatch [Interpretation];Platelet Xmatch SerPl-Imp;;ACTIVE;2.17;2.26 +45371-2;Multiple pregnancy;Find;Pt;^Patient;Ord;;CLIN;2;Multiple pregnancy;Multiple Pregnancy;;ACTIVE;2.17;2.73 +45372-0;Blood pressure systolic & diastolic^post phlebotomy;Pres;Pt;Arterial system;Qn;;BP.ATOM;2;Blood pressure systolic and diastolic--post phlebotomy;BP sys/dias--p phlebotomy;;ACTIVE;2.17;2.48 +45373-8;Medication route;Prid;Pt;Dose;Nom;;DRUGDOSE;1;Medication route [Identifier] of Dose;Medication Route Dose;;ACTIVE;2.17;2.73 +45374-6;Specimen expiration date;Date;Pt;Bld;Qn;;SPEC;1;Specimen expiration date of Blood;Specimen Exp Date Bld;;ACTIVE;2.17;2.73 +45375-3;Time of analysis;TmStp;Pt;XXX;Qn;;MISC;1;Time of analysis of unspecified specimen;Time Of Analysis Spec;;ACTIVE;2.17;2.73 +45376-1;Date of transfusion reaction;TmStp;Pt;^Patient;Qn;;BLDBK;1;Date of transfusion reaction;Date Of Transf Rx;;ACTIVE;2.17;2.26 +4537-7;Erythrocyte sedimentation rate;Vel;Pt;Bld;Qn;Westergren;HEM/BC;1;Erythrocyte sedimentation rate by Westergren method;ESR Bld Qn Westrgrn;;ACTIVE;1.0;2.73 +45377-9;Time of transfusion reaction;TmStp;Pt;^Patient;Qn;;BLDBK;1;Time of transfusion reaction;Time Of Transf Rx Patient;;ACTIVE;2.17;2.73 +45378-7;Glutathione peroxidase;CCnt;Pt;RBC;Qn;;CHEM;1;Glutathione peroxidase [Enzymatic activity/mass] in Red Blood Cells;Glutathione Px RBC-cCnt;;ACTIVE;2.17;2.70 +45379-5;Eosinophils;PrThr;Pt;Stool;Ord;Microscopy.light;HEM/BC;1;Eosinophils [Presence] in Stool by Light microscopy;Eosinophil Stl Ql Micro;;ACTIVE;2.17;2.73 +45380-3;Basophilic stippling.fine;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Basophilic stippling fine [Presence] in Blood by Light microscopy;Baso Stipl Fine Bld Ql Smear;;ACTIVE;2.17;2.56 +45381-1;Basophilic stippling.coarse;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Basophilic stippling coarse [Presence] in Blood by Light microscopy;Baso Stipl coarse Bld Ql Smear;;ACTIVE;2.17;2.73 +45382-9;Epidermis Ab;PrThr;Pt;Ser;Ord;;SERO;1;Epidermis Ab [Presence] in Serum;Epidis Ab Ser Ql;;ACTIVE;2.17;2.56 +45383-7;Leukocytes;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Leukocytes [#/area] in Urine sediment by Microscopy low power field;WBC #/area UrnS LPF;;ACTIVE;2.17;2.73 +45384-5;Leucine crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Leucine crystals [#/area] in Urine sediment by Microscopy low power field;Leucine Cry #/area UrnS LPF;;ACTIVE;2.17;2.70 +4538-5;Erythrocyte sedimentation rate;Vel;Pt;Bld;Qn;Wintrobe;HEM/BC;1;Erythrocyte sedimentation rate by Wintrobe method;ESR Bld Qn Wintrobe;;ACTIVE;1.0;2.73 +45385-2;Hippurate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Hippurate crystals [#/area] in Urine sediment by Microscopy low power field;Hippurate Cry #/area UrnS LPF;;ACTIVE;2.17;2.70 +45386-0;Epithelial casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Epithelial casts [#/area] in Urine sediment by Microscopy high power field;Epith Casts #/area UrnS HPF;;ACTIVE;2.17;2.70 +45387-8;Cystine crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Cystine crystals [#/area] in Urine sediment by Microscopy low power field;Cystine Cry #/area UrnS LPF;;ACTIVE;2.17;2.73 +45388-6;Calcium phosphate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Calcium phosphate crystals [#/area] in Urine sediment by Microscopy low power field;Ca Phos Cry #/area UrnS LPF;;ACTIVE;2.17;2.73 +45389-4;Calcium carbonate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Calcium carbonate crystals [#/area] in Urine sediment by Microscopy low power field;Ca Carbonate Cry #/area UrnS LPF;;ACTIVE;2.17;2.70 +45390-2;Epithelial cells.squamous;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Epithelial cells.squamous [#/area] in Urine sediment by Microscopy low power field;Squamous #/area UrnS LPF;;ACTIVE;2.17;2.73 +45391-0;Epithelial cells.renal;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Epithelial cells.renal [#/area] in Urine sediment by Microscopy low power field;Renal Epi Cells #/area UrnS LPF;;ACTIVE;2.17;2.73 +45392-8;First name;Pn;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient First (Given) name;Patient First name;;ACTIVE;2.17;2.70 +4539-3;Erythrocyte sedimentation rate.Zeta;Vel;Pt;Bld;Qn;Zetafuge;HEM/BC;1;Erythrocyte sedimentation rate Zeta by Zetafuge;ZSR Bld Qn Zeta;;ACTIVE;1.0;2.73 +45393-6;Middle initial;Pn;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Middle initial;Middle initial;;ACTIVE;2.17;2.66 +45394-4;Last name;Pn;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient Last (Family) name;Patient Last name;;ACTIVE;2.17;2.70 +45395-1;Name suffix;Pn;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient Name suffix;Patient Name suffix;;ACTIVE;2.17;2.70 +45396-9;Social Security number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Social Security number [Identifier];Social Security #;;ACTIVE;2.17;2.73 +45397-7;Medicare or comparable number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Medicare or comparable number;Medicare or comparable #;;ACTIVE;2.17;2.66 +45398-5;State provider number;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;State provider number for Facility;State provider # Facility;;ACTIVE;2.17;2.66 +45399-3;Federal provider number;ID;Pt;Facility;Nom;;SURVEY.MDS;4;Federal provider number Facility;;;ACTIVE;2.17;2.34 +45400-9;Medicaid number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Medicaid number;Medicaid #;;ACTIVE;2.17;2.66 +4540-1;Ethanol gelation;-;Pt;Ser;Qn;;HEM/BC;1;Deprecated Ethanol gelation;Deprecated Ethanol gelation Ser Qn;;DEPRECATED;1.0;2.66 +45401-7;Postal code;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Postal code [Location];Postal code;;ACTIVE;2.17;2.73 +45402-5;Language.primary;Find;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Language.primary;Primary language;;ACTIVE;2.17;2.70 +45403-3;Room number;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Room number [Location];Room #;;ACTIVE;2.17;2.66 +45404-1;Marital status;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Marital status;Marital status;;ACTIVE;2.17;2.66 +45405-8;Ability to understand others;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Ability to understand others [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45406-6;Change in communication &or hearing;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Change in communication/hearing [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45407-4;Vision;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Vision [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45408-2;Primary reason for assessment;Type;Pt;^Patient;Nom;MDS.basic;SURVEY.MDS;4;Primary reason for assessment [Minimum Data Set (MDS) basic];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45409-0;Codes for assessments required for Medicare PPS or the State;Type;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Codes for assessments required for Medicare PPS or the State [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45410-8;Admitted from (at entry);Type;Pt;Facility;Nom;MDS;SURVEY.MDS;4;Admitted from (at entry) Facility [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45411-6;Lived alone prior to admission;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Lived alone prior to admission [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45412-4;History of prior stay at this nursing home;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;History of prior stay at this nursing home [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45413-2;History of stay in other nursing home;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;History of stay in other nursing home [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45414-0;History of stay in other residential facility;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;History of stay in other residential facility [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45415-7;History of stay at mental health &or psychiatric setting;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;History of stay at mental health/psychiatric setting [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45416-5;History of stay in mental retardation and developmental disabilities setting;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;History of stay in mental retardation and developmental disabilities setting [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DISCOURAGED;2.17;2.65 +45417-3;None of the listed prior residential settings;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;None of the listed prior residential settings [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45418-1;Lifetime occupations;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Deprecated Lifetime occupations [CMS Assessment];;;DEPRECATED;2.17;2.70 +4541-9;Euglobulin clot lysis;Time;Pt;Plas;Qn;;HEM/BC;1;Deprecated Clot Lysis [Time] in Platelet poor plasma by Coagulation assay;Deprecated Euglobulin clot lysis Plas Qn;;DEPRECATED;1.0;2.36 +45419-9;Language.other;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Language.other [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45420-7;Mental health history;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Mental health history [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45421-5;No mental retardation and developmental disabilities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;No mental retardation and developmental disabilities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DISCOURAGED;2.17;2.65 +45422-3;Down's syndrome;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Down's syndrome [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45423-1;Autism;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Autism [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45424-9;Epilepsy;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Epilepsy [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45425-6;Other organic condition related to mental retardation and developmental disabilities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other organic condition related to mental retardation and developmental disabilities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DISCOURAGED;2.17;2.65 +45426-4;Mental retardation and developmental disabilities with no organic condition;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Mental retardation and developmental disabilities with no organic condition [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DISCOURAGED;2.17;2.65 +4542-7;Haptoglobin;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Haptoglobin [Mass/volume] in Serum or Plasma;Haptoglob SerPl-mCnc;;ACTIVE;1.0;2.73 +45427-2;Date background information form completed;Date;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Date background information form completed [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45428-0;Stays up late at night;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Stays up late at night [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45429-8;Naps regularly during day;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Naps regularly during day [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45430-6;Goes out 1 or more D a W;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Goes out 1 or more days a week [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45431-4;Stays busy with hobbies, reading or fixed daily routine;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Stays busy with hobbies, reading or fixed daily routine [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45432-2;Spends most time alone or watching TV;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Spends most time alone or watching TV [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45433-0;Moves independently indoors;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Moves independently indoors [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45434-8;Use of tobacco products at least daily;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Use of tobacco products at least daily [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4543-5;Haptoglobin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;HEM/BC;1;Haptoglobin [Mass/volume] in Serum or Plasma by Electrophoresis;Haptoglob SerPl Elph-mCnc;;ACTIVE;1.0;2.34 +45435-5;None of the listed cycle of daily events;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;None of the listed cycle of daily events [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45436-3;Distinct food preferences;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Distinct food preferences [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45437-1;Eats between meals all or most D;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Eats between meals all or most days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45438-9;Use of alcohol at least weekly;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Use of alcohol at least weekly [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45439-7;None of the listed eating patterns;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;None of the listed eating patterns [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45440-5;In bedclothes much of day;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;In bedclothes much of day [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45441-3;Wakens to toilet all or most nights;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Wakens to toilet all or most nights [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45442-1;Has irregular bowel movement pattern;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Has irregular bowel movement pattern [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4544-3;Hematocrit;VFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Hematocrit [Volume Fraction] of Blood by Automated count;Hct VFr Bld Auto;;ACTIVE;1.0;2.73 +45443-9;Showers for bathing;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Showers for bathing [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45444-7;Bathing in PM;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bathing in PM [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45445-4;None of the listed additional ADL patterns;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;None of the listed additional ADL patterns [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45446-2;Daily contact with relatives &or close friends;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Daily contact with relatives/close friends [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45447-0;Usually attends church, temple, etc.;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Usually attends church, temple, etc. [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45448-8;Finds strength in faith;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Finds strength in faith [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45449-6;Daily animal companion &or presence;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Daily animal companion/presence [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4545-0;Hematocrit;VFr;Pt;Bld;Qn;Spun;HEM/BC;1;Hematocrit [Volume Fraction] of Blood by Centrifugation;Hct VFr Bld Spun;;ACTIVE;1.0;2.73 +45450-4;Involved in group activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Involved in group activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45451-2;None of the listed involvement patterns;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;None of the listed involvement patterns [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45452-0;Unknown customary routine - resident &or family unable to provide information;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Unknown customary routine - resident/family unable to provide information [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45453-8;Date of last day of MDS observation period;Date;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Date of last day of MDS observation period [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45454-6;Original or corrected copy of form;Num;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Original or corrected copy of form # [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45455-3;Date of reentry to facility;Date;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Date of reentry to facility [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45456-1;Medicaid per diem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Medicaid per diem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45457-9;Medicare per diem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Medicare per diem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45458-7;Medicare ancillary part A;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Medicare ancillary part A [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45459-5;Medicare ancillary part B;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Medicare ancillary part B [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45460-3;CHAMPUS Per Diem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;CHAMPUS Per Diem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45461-1;VA Per Diem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;VA Per Diem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45462-9;Self or family pays for full per diem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Self or family pays for full per diem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45463-7;Medicaid resident liability or Medicare copayment;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Medicaid resident liability or Medicare copayment [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45464-5;Private insurance per diem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Private insurance per diem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45465-2;Other per diem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other per diem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45466-0;Legal guardian;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Legal guardian [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45467-8;Other legal oversight;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other legal oversight [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4546-8;Hemoglobin A/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A/Hemoglobin.total in Blood;Hgb A MFr Bld;;ACTIVE;1.0;2.73 +45468-6;Health care durable power attorney;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Health care durable power attorney [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45469-4;Financial durable power attorney;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Financial durable power attorney [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45470-2;Family member responsible;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Family member responsible [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45471-0;Patient responsible for self;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Patient responsible for self [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45472-8;Responsibility - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Responsibility - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45473-6;Advance directive &or living will completed;Find;Pt;^Patient;Ord;;CLIN;2;Advance directive/living will completed;Advn Dir/Living Will completed;;ACTIVE;2.17;2.67 +45474-4;Advance directive - do not resuscitate;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - do not resuscitate [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45475-1;Advance directive - do not hospitalize;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - do not hospitalize [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4547-6;Hemoglobin A1/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A1/Hemoglobin.total in Blood;Hgb A1 MFr Bld;;ACTIVE;1.0;2.73 +45476-9;Advance directive - organ donation;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - organ donation [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45477-7;Advance directive - autopsy request;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - autopsy request [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45478-5;Advance directive - feeding restrictions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - feeding restrictions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45479-3;Advance directive - medication restrictions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - medication restrictions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45480-1;Advance directive - other treatment restrictions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - other treatment restrictions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45481-9;Advance directive - none;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Advance directive - none [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45482-7;Comatose;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.MDS;4;Comatose [CMS Assessment];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.69 +45483-5;Short-term memory OK;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Short-term memory OK [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4548-4;Hemoglobin A1c/Hemoglobin.total;MFr;Pt;Bld;Qn;;CHEM;1;Hemoglobin A1c/Hemoglobin.total in Blood;HbA1c MFr Bld;;ACTIVE;1.0;2.73 +45484-3;Long-term memory OK;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Long-term memory OK [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45485-0;Can recall current season;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Can recall current season [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45486-8;Can recall location of own room;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Can recall location of own room [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45487-6;Can recall staff names &or faces;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Can recall staff names/faces [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45488-4;Can recall that he or she is in nursing home;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Can recall that he or she is in nursing home [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45489-2;Memory &or recall - none of above are recalled;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Memory/recall - none of above are recalled [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +454-9;Spectinomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Spectinomycin [Susceptibility] by Serum bactericidal titer;Spectinomycin Titr SBT;;ACTIVE;1.0;2.32 +45490-0;Cognitive skills for daily decision making;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Cognitive skills for daily decision making [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45491-8;Easily distracted;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Easily distracted [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4549-2;Hemoglobin A1c/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;CHEM;1;Hemoglobin A1c/Hemoglobin.total in Blood by Electrophoresis;HbA1c MFr Bld Elph;;ACTIVE;1.0;2.73 +45492-6;Periods of altered perception or awareness of surroundings;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Periods of altered perception or awareness of surroundings [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45493-4;Episodes of disorganized speech;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Episodes of disorganized speech [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45494-2;Periods of restlessness;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Periods of restlessness [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45495-9;Periods of lethargy;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Periods of lethargy [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45496-7;Mental function varies over the course of the day;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Mental function varies over the course of the day [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45497-5;Change in cognitive status;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Change in cognitive status [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45498-3;Hearing;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hearing [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45499-1;Hearing aid present & used;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hearing aid present and used [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45-5;Aztreonam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Aztreonam [Susceptibility] by Disk diffusion (KB);Aztreonam Islt KB;;ACTIVE;1.0;2.73 +4550-0;Hemoglobin A2;SCnc;Pt;Bld;Qn;Chromatography.column;HEM/BC;1;Hemoglobin A2 [Moles/volume] in Blood by Chromatography column;Hgb A2 Bld Column Chrom-sCnc;;ACTIVE;1.0;2.73 +45500-6;Hearing aid present & not used regularly;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hearing aid present and not used regularly [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45501-4;Other receptive communication techniques used;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other receptive communication techniques used [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45502-2;No communication device;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;No communication device [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45503-0;Uses speech;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Uses speech [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45504-8;Uses written messages to express or clarify needs;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Uses written messages to express or clarify needs [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45505-5;Uses American sign language or Braille;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Uses American sign language or Braille [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45506-3;Uses signs &or gestures &or sounds;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Uses signs/gestures/sounds [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45507-1;Uses communication board;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Uses communication board [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45508-9;Uses other modes of expression;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Uses other modes of expression [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45509-7;Modes of expression - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Modes of expression - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45510-5;Making self understood;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Making self understood [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45511-3;Speech clarity;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Speech clarity [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45512-1;Side vision problems;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Side vision problems [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45513-9;Sees halos or rings around lights, flashes of light, or curtains over eyes;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Sees halos or rings around lights, flashes of light, or curtains over eyes [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45514-7;No visual limitations;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;No visual limitations [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45515-4;Visual appliances;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Visual appliances [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45516-2;Resident made negative statements;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident made negative statements [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45517-0;Repetitive questions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Repetitive questions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4551-8;Hemoglobin A2/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A2/Hemoglobin.total in Blood;Hgb A2 MFr Bld;;ACTIVE;1.0;2.73 +45518-8;Repetitive verbalizations;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Repetitive verbalizations [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45519-6;Persistent anger with self or others;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Persistent anger with self or others [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45520-4;Self deprecation;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Self deprecation [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45521-2;Expression of what appear to be unrealistic fears;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Expression of what appear to be unrealistic fears [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45522-0;Recurrent statements that something terrible is about to happen;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Recurrent statements that something terrible is about to happen [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45523-8;Balance while sitting - position, trunk control;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Balance while sitting - position, trunk control [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45524-6;Range of motion;Find;Pt;Neck;Ord;MDS;SURVEY.MDS;4;Range of motion Neck [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45525-3;Voluntary movement;Find;Pt;Neck;Ord;MDS;SURVEY.MDS;4;Voluntary movement Neck [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4552-6;Hemoglobin A2/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A2/Hemoglobin.total in Blood by Electrophoresis;Hgb A2 MFr Bld Elph;;ACTIVE;1.0;2.73 +45526-1;Range of motion;Find;Pt;Upper extremity;Ord;MDS;SURVEY.MDS;4;Range of motion Upper extremity [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45527-9;Voluntary movement;Find;Pt;Upper extremity;Ord;MDS;SURVEY.MDS;4;Voluntary movement Upper extremity [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45528-7;Range of motion;Find;Pt;Hand;Ord;MDS;SURVEY.MDS;4;Range of motion Hand [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45529-5;Voluntary movement;Find;Pt;Hand;Ord;MDS;SURVEY.MDS;4;Voluntary movement Hand [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45530-3;Range of motion;Find;Pt;Lower extremity;Ord;MDS;SURVEY.MDS;4;Range of motion Lower extremity [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45531-1;Voluntary movement;Find;Pt;Lower extremity;Ord;MDS;SURVEY.MDS;4;Voluntary movement Lower extremity [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45532-9;Range of motion;Find;Pt;Foot;Ord;MDS;SURVEY.MDS;4;Range of motion Foot [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45533-7;Voluntary movement;Find;Pt;Foot;Ord;MDS;SURVEY.MDS;4;Voluntary movement Foot [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4553-4;Hemoglobin A2/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin A2/Hemoglobin.total in Blood by Electrophoresis acid (pH 6.3);Hgb A2 MFr Bld Elph Acid;;ACTIVE;1.0;2.70 +45534-5;Other limitation or loss - range of motion;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other limitation or loss - range of motion [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45535-2;Other limitation or loss - voluntary movement;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other limitation or loss - voluntary movement [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45536-0;Uses cane, walker or crutch;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Uses cane, walker or crutch [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45537-8;Wheeled self;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Wheeled self [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45538-6;Other person wheeled;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other person wheeled [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45539-4;Wheelchair primary mode of locomotion;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Wheelchair primary mode of locomotion [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45540-2;No modes of locomotion;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;No modes of locomotion [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45541-0;Bedfast all or most of the time;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bedfast all or most of the time [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4554-2;Hemoglobin A2/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin A2/Hemoglobin.total in Blood by Electrophoresis alkaline (pH 8.9);Hgb A2 MFr Bld Elph Alk;;ACTIVE;1.0;2.73 +45542-8;Bed rails used for bed mobility or transfer;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bed rails used for bed mobility or transfer [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45543-6;Lifted manually;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Lifted manually [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45544-4;Lifted mechanically;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Lifted mechanically [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45545-1;Transfer aid;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Transfer aid [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45546-9;No mode of transfer;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;No mode of transfer [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45547-7;Repetitive health complaints;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Repetitive health complaints [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45548-5;Repetitive anxious complaints or concerns;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Repetitive anxious complaints or concerns [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45549-3;Unpleasant mood in morning;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Unpleasant mood in morning [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45550-1;Insomnia &or change in sleeping pattern;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Insomnia/change in sleeping pattern [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45551-9;Sad, pained, or worried facial expressions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Sad, pained, or worried facial expressions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45552-7;Crying or tearfulness;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Crying or tearfulness [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45553-5;Repetitive physical movements;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Repetitive physical movements [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45554-3;Withdrawal from activities of interest;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Withdrawal from activities of interest [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45555-0;Reduced social interaction;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Reduced social interaction [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45556-8;Mood persistence;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Mood persistence [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45557-6;Change in mood;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Change in mood [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45558-4;Frequency of wandering;NRat;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Frequency of wandering [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4555-9;Hemoglobin A3/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A3/Hemoglobin.total in Blood;Hgb A3 MFr Bld;;ACTIVE;1.0;2.70 +45559-2;Alterability of wandering;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Alterability of wandering [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +455-6;Spiramycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Spiramycin [Susceptibility] by Minimum lethal concentration (MLC);Spiramycin Islt MLC;;ACTIVE;1.0;2.19 +45560-0;Frequency of verbally abusive behavioral symptoms;NRat;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Frequency of verbally abusive behavioral symptoms [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45561-8;Alterability of verbally abusive behavioral symptoms;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Alterability of verbally abusive behavioral symptoms [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45562-6;Frequency of physically abusive behavioral symptoms;NRat;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Frequency of physically abusive behavioral symptoms [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45563-4;Alterability of physically abusive behavioral symptoms;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Alterability of physically abusive behavioral symptoms [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45564-2;Frequency of socially inappropriate or disruptive behavioral symptoms;NRat;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Frequency of socially inappropriate or disruptive behavioral symptoms [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45565-9;Alterability of socially inappropriate or disruptive behavioral symptoms;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Alterability of socially inappropriate or disruptive behavioral symptoms [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45566-7;Frequency of resists care;NRat;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Frequency of resists care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4556-7;Hemoglobin Abruzzo;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Abruzzo [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Abruz Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45567-5;Alterability of resists care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Alterability of resists care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45568-3;Change in behavioral symptoms;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Change in behavioral symptoms [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45569-1;At ease interacting with others;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;At ease interacting with others [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45570-9;At ease doing planned or structured activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;At ease doing planned or structured activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45571-7;At ease doing self-initiated activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;At ease doing self-initiated activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45572-5;Establishes own goals;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Establishes own goals [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45573-3;Pursues involvement in life of facility;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pursues involvement in life of facility [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45574-1;Accepts invitations to most group activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Accepts invitations to most group activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4557-5;Hemoglobin Abruzzo;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Abruzzo [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Abruz Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45575-8;Sense of initiative - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Sense of initiative - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45576-6;Covert &or open conflict with or repeated criticism of staff;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Covert/open conflict with or repeated criticism of staff [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45577-4;Unhappy with roommate;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Unhappy with roommate [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45578-2;Unhappy with residents other than roommate;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Unhappy with residents other than roommate [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45579-0;Openly expresses conflict &or anger with family &or friends;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Openly expresses conflict/anger with family/friends [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45580-8;Absence of contact with family &or friends;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Absence of contact with family/friends [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45581-6;Recent loss of close family member &or friend;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Recent loss of close family member/friend [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45582-4;Does not adjust easily to change in routines;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Does not adjust easily to change in routines [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4558-3;Hemoglobin Barts;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Barts [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Barts Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45583-2;No unsettled relationships;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;No unsettled relationships [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45584-0;Strong identification with past roles and life status;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Strong identification with past roles and life status [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45585-7;Expresses sadness &or anger &or empty feeling over lost roles &or status;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Expresses sadness/anger/empty feeling over lost roles/status [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45586-5;Resident perceives that daily routine (customary routine, activities) is very different from prior pattern in the community;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident perceives that daily routine (customary routine, activities) is very different from prior pattern in the community [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45587-3;Past roles - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Past roles - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45588-1;Bed mobility - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bed mobility - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45589-9;Bed mobility - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bed mobility - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45590-7;Transfer - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Transfer - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +4559-1;Hemoglobin Barts;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Barts [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Barts Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45591-5;Transfer - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Transfer - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45592-3;Walk in room - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk in room - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45593-1;Walk in room - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk in room - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45594-9;Walk in corridor - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk in corridor - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45595-6;Walk in corridor - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk in corridor - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45596-4;Locomotion on unit - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Locomotion on unit - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45597-2;Locomotion on unit - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Locomotion on unit - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45598-0;Locomotion off unit - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Locomotion off unit - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45599-8;Locomotion off unit - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Locomotion off unit - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45600-4;Dressing - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Dressing - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45601-2;Dressing - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Dressing - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45602-0;Eating - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45603-8;Eating - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45604-6;Toilet use - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet use - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45605-3;Toilet use - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet use - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45606-1;Personal hygiene - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Personal hygiene - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45607-9;Personal hygiene - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Personal hygiene - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45608-7;Bathing - self-performance during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bathing - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +4560-9;Hemoglobin Bethesda;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Bethesda [Presence] in Blood;Hgb Bethes Bld Ql;;ACTIVE;1.0;2.56 +45609-5;Bathing - support provided during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bathing - support provided during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +45610-3;Balance while standing;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Balance while standing [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45611-1;Task segmentation;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Task segmentation [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45612-9;Resident believes he or she is capable of increased independence in at least some ADLs;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident believes he or she is capable of increased independence in at least some ADLs [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45613-7;Direct care staff believe resident is capable of increased independence in at least some ADLs;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Direct care staff believe resident is capable of increased independence in at least some ADLs [CMS Assessment];;;ACTIVE;2.17;2.63 +45614-5;Resident able to perform tasks or activity but is very slow;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident able to perform tasks or activity but is very slow [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45615-2;Difference in ADL Self-Performance or ADL Support, comparing mornings to evenings;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Difference in ADL Self-Performance or ADL Support, comparing mornings to evenings [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45616-0;Activities of daily living rehabilitation potential - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activities of daily living rehabilitation potential - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4561-7;Hemoglobin C/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin C/Hemoglobin.total in Blood by Electrophoresis acid (pH 6.3);Hgb C MFr Bld Elph Acid;;ACTIVE;1.0;2.73 +45617-8;Change in activities of daily living function;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Change in activities of daily living function [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45618-6;Bowel continence;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bowel continence [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45619-4;Bladder continence;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bladder continence [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45620-2;Bowel elimination pattern regular - at least one movement every three D;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bowel elimination pattern regular - at least one movement every three days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45621-0;Constipation;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Constipation [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45622-8;Diarrhea;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Diarrhea [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45623-6;Fecal impaction;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Fecal impaction [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45624-4;Bowel elimination pattern - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bowel elimination pattern - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4562-5;Hemoglobin C/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin C/Hemoglobin.total in Blood by Electrophoresis alkaline (pH 8.9);Hgb C MFr Bld Elph Alk;;ACTIVE;1.0;2.73 +45625-1;Any scheduled toileting plan;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Any scheduled toileting plan [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45626-9;Bladder retraining program;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bladder retraining program [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45627-7;External catheter;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;External catheter [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45628-5;Indwelling catheter;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Indwelling catheter [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45629-3;Intermittent catheter;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Intermittent catheter [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45630-1;Did not use toilet room &or commode &or urinal;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Did not use toilet room/commode/urinal [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45631-9;Pads &or briefs used;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pads/briefs used [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45632-7;Enemas &or irrigation;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Enemas/irrigation [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4563-3;Hemoglobin C/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin C/Hemoglobin.total in Blood;Hgb C MFr Bld;;ACTIVE;1.0;2.73 +45633-5;Ostomy present;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Ostomy present [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45634-3;Continence appliances and programs - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Continence appliances and programs - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45635-0;Change in urinary continence;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Change in urinary continence [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45636-8;Diabetes mellitus;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Diabetes mellitus [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45637-6;Hyperthyroidism;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hyperthyroidism [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45638-4;Hypothyroidism;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hypothyroidism [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45639-2;Arteriosclerotic heart disease;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Arteriosclerotic heart disease [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +456-4;Spiramycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Spiramycin [Susceptibility] by Minimum inhibitory concentration (MIC);Spiramycin Islt MIC;;ACTIVE;1.0;2.19 +45640-0;Cardiac dysrhythmias;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Cardiac dysrhythmias [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4564-1;Hemoglobin C-Harlem;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin C - Harlem [Presence] in Blood;Hgb C-Harlem Bld Ql;;ACTIVE;1.0;2.73 +45641-8;Congestive heart failure;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Congestive heart failure [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45642-6;Deep vein thrombosis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Deep vein thrombosis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45643-4;Hypertension;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hypertension [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45644-2;Hypotension;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hypotension [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45645-9;Peripheral vascular disease;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Peripheral vascular disease [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45646-7;Other cardiovascular disease;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other cardiovascular disease [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45647-5;Arthritis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Arthritis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45648-3;Hip fracture;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hip fracture [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45649-1;Missing limb;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Missing limb [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45650-9;Osteoporosis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Osteoporosis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45651-7;Pathological bone fracture;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pathological bone fracture [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45652-5;Alzheimer's disease;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Alzheimer's disease [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45653-3;Aphasia;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Aphasia [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45654-1;Cerebral palsy;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Cerebral palsy [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45655-8;Cerebrovascular accident;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Cerebrovascular accident [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.73 +45656-6;Dementia other than Alzheimer's disease;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Dementia other than Alzheimer's disease [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45657-4;Hemiplegia or hemiparesis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hemiplegia or hemiparesis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4565-8;Hemoglobin Chesapeake;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Chesapeake [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Chesap Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45658-2;Multiple sclerosis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Multiple sclerosis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45659-0;Paraplegia;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Paraplegia [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45660-8;Parkinson's disease;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Parkinson's disease [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45661-6;Quadriplegia;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Quadriplegia [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45662-4;Seizure disorder;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Seizure disorder [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45663-2;Transient ischemic attack;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Transient ischemic attack [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45664-0;Traumatic brain injury;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Traumatic brain injury [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45665-7;Anxiety disorder;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Anxiety disorder [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4566-6;Hemoglobin Chesapeake;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Chesapeake [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Chesap Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45666-5;Depression;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Depression [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45667-3;Manic depression;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Manic depression [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45668-1;Schizophrenia;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Schizophrenia [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45669-9;Asthma;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Asthma [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45670-7;Emphysema or COPD;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Emphysema or COPD [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45671-5;Cataracts;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Cataracts [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45672-3;Diabetic retinopathy;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Diabetic retinopathy [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45673-1;Glaucoma;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Glaucoma [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4567-4;Hemoglobin Constant Spring;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Constant Spring [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb CSp Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45674-9;Macular degeneration;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Macular degeneration [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45675-6;Allergies;Find;Pt;^Patient;Ord;;H&P.HX;2;Allergies;Allergies;;ACTIVE;2.17;2.70 +45676-4;Anemia;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Anemia [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45677-2;Cancer;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Cancer [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45678-0;Renal failure;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Renal failure [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45679-8;None of the listed diseases or conditions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;None of the listed diseases or conditions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45680-6;Antibiotic resistant infection;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Antibiotic resistant infection [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45681-4;Infection with Clostridioides difficile;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Infection with Clostridioides difficile [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.66 +4568-2;Hemoglobin Constant Spring;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Constant Spring [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb CSp Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45682-2;Conjunctivitis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Conjunctivitis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45683-0;HIV infection;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;HIV infection [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45684-8;Pneumonia;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pneumonia [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45685-5;Respiratory infection;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Respiratory infection [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45686-3;Septicemia;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Septicemia [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45687-1;Sexually transmitted diseases;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Sexually transmitted diseases [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45688-9;Tuberculosis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Tuberculosis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45689-7;Urinary tract infection in last 30D;Find;30D;^Patient;Ord;MDS;SURVEY.MDS;4;Urinary tract infection in last 30 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +4569-0;Hemoglobin D/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin D/Hemoglobin.total in Blood;Hgb D MFr Bld;;ACTIVE;1.0;2.73 +45690-5;Viral hepatitis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Viral hepatitis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45691-3;Wound infection;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Wound infection [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45692-1;Infections - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Infections - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45693-9;Other current or more detailed diagnoses & ICD9 codes;Prid;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Other current or more detailed diagnoses and ICD9 codes [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45694-7;Weight gain or loss of 3+ Lbs. within a 7D period;Find;7D;^Patient;Ord;MDS;SURVEY.MDS;4;Weight gain or loss of 3+ Lbs. within a 7 day period [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.61 +45695-4;Inability to lie flat due to shortness of breath;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Inability to lie flat due to shortness of breath [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45696-2;Dehydrated;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Dehydrated [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45697-0;"Insufficient fluid; did NOT consume all or almost all liquids provided during last 3D";Find;3D;^Patient;Ord;MDS;SURVEY.MDS;4;"Insufficient fluid; did NOT consume all or almost all liquids provided during last 3 days [Minimum Data Set]";;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45698-8;Delusions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Delusions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45699-6;Dizziness or vertigo;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Dizziness or vertigo [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45700-2;Edema;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Edema [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45701-0;Fever;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Fever [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45702-8;Hallucinations;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hallucinations [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45703-6;Internal bleeding;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Internal bleeding [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45704-4;Recurrent lung aspirations in last 90D;Find;90D;^Patient;Ord;MDS;SURVEY.MDS;4;Recurrent lung aspirations in last 90 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45705-1;Shortness of breath;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Shortness of breath [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45706-9;Syncope;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Syncope [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45707-7;Unsteady gait;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Unsteady gait [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4570-8;Hemoglobin D-Punjab;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin D - Punjab [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb D-Punjab Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45708-5;Vomiting;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Vomiting [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45709-3;Problem conditions - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Problem conditions - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45710-1;Pain frequency;NRat;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pain frequency [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45711-9;Pain intensity;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pain intensity [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45712-7;Back pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Back pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45713-5;Bone pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bone pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45714-3;Chest pain while doing usual activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Chest pain while doing usual activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45715-0;Headache;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Headache [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4571-6;Hemoglobin D-Punjab;ACnc;Pt;Bld;Qn;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin D - Punjab [Units/volume] in Blood by Electrophoresis alkaline (pH 8.9);Hgb D-Punjab Bld Elph Alk-aCnc;;ACTIVE;1.0;2.69 +45716-8;Hip pain;Find;Pt;^Patient;Ord;;SURVEY.MDS;4;Hip pain;;;ACTIVE;2.17;2.73 +45717-6;Incisional pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Incisional pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45718-4;Joint pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Joint pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45719-2;Soft tissue pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Soft tissue pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +457-2;Spiramycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Spiramycin [Susceptibility] by Disk diffusion (KB);Spiramycin Islt KB;;ACTIVE;1.0;2.19 +45720-0;Stomach pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Stomach pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45721-8;Other pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45722-6;Fell in past 30D;Find;30D;^Patient;Ord;MDS;SURVEY.MDS;4;Fell in past 30 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45723-4;Fell in past 31D-180D;Find;180D;^Patient;Ord;MDS;SURVEY.MDS;4;Fell in past 31-180 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +4572-4;Hemoglobin Denver;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Denver [Presence] in Blood;Hgb Denver Bld Ql;;ACTIVE;1.0;2.56 +45724-2;Hip fracture in last 180D;Find;180D;^Patient;Ord;MDS;SURVEY.MDS;4;Hip fracture in last 180 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45725-9;Other fracture in last 180D;Find;180D;^Patient;Ord;MDS;SURVEY.MDS;4;Other fracture in last 180 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45726-7;Accidents - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Accidents - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45727-5;Conditions &or diseases make resident's cognitive, ADL, mood or behavior patterns unstable;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Conditions/diseases make resident's cognitive, ADL, mood or behavior patterns unstable [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45728-3;Resident experiencing an acute episode or a flare-up of a recurrent or chronic problem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident experiencing an acute episode or a flare-up of a recurrent or chronic problem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45729-1;End-Stage disease, 6 or fewer Mo to live;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;End-Stage disease, 6 or fewer months to live [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45730-9;Stability of conditions - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Stability of conditions - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45731-7;Chewing problem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Chewing problem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4573-2;Hemoglobin E/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin E/Hemoglobin.total in Blood by Electrophoresis acid (pH 6.3);Hgb E MFr Bld Elph Acid;;ACTIVE;1.0;2.73 +45732-5;Swallowing problem;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Swallowing problem [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45733-3;Mouth pain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Mouth pain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45734-1;Oral problems - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Oral problems - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45735-8;Weight loss;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Weight loss [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45736-6;Weight gain;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Weight gain [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45737-4;Complains about the taste of many foods;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Complains about the taste of many foods [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45738-2;Regular or repetitive complaints of hunger;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Regular or repetitive complaints of hunger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45739-0;Leaves 25%+ food uneaten at most meals;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Leaves 25%+ food uneaten at most meals [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4574-0;Hemoglobin E/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin E/Hemoglobin.total in Blood by Electrophoresis alkaline (pH 8.9);Hgb E MFr Bld Elph Alk;;ACTIVE;1.0;2.73 +45740-8;Nutritional problems - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Nutritional problems - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45741-6;Parenteral IV;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Parenteral IV [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45742-4;Feeding tube;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Feeding tube [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45743-2;Mechanically altered diet;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Mechanically altered diet [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45744-0;Syringe or oral feeding;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Syringe or oral feeding [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45745-7;Therapeutic diet;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Therapeutic diet [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45746-5;Dietary supplement between meals;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Dietary supplement between meals [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45747-3;Plate guard, stabilized built-up utensil, etc.;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Plate guard, stabilized built-up utensil, etc. [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45748-1;On a planned weight change program;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;On a planned weight change program [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45749-9;Nutritional approaches - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Nutritional approaches - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45750-7;Proportion of total calories received through parenteral or tube feeding in last 7D;Find;7D;^Patient;Ord;MDS;SURVEY.MDS;4;Proportion of total calories received through parenteral or tube feeding in last 7 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45751-5;Average fluid intake per D by IV or tube in last 7D;Find;7D;^Patient;Ord;MDS;SURVEY.MDS;4;Deprecated Average fluid intake per day by IV or tube in last 7 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.70 +45752-3;Ventilator or respirator;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Ventilator or respirator [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45753-1;Alcohol or drug treatment program;Find;Pt;^Patient;Ord;;SURVEY.MDS;4;Alcohol or drug treatment program;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.66 +45754-9;Alzheimer's or dementia special care unit;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Alzheimer's or dementia special care unit [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45755-6;Hospice care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Hospice care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45756-4;Pediatric unit;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pediatric unit [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4575-7;Hemoglobin E/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin E/Hemoglobin.total in Blood;Hgb E MFr Bld;;ACTIVE;1.0;2.73 +45757-2;Respite care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Respite care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45758-0;Training in skills required to return to the community;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Training in skills required to return to the community [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45759-8;Special treatments &or programs - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Special treatments/programs - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45760-6;Number of D with at least 15M of speech language pathology and audiology services in the last 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of speech language pathology and audiology services in the last 7 days [CMS Assessment];;;ACTIVE;2.17;2.63 +45761-4;Total minutes of speech language pathology and audiology services in the last 7D;Time;7D;^Patient;Qn;MDS;SURVEY.MDS;4;Total minutes of speech language pathology and audiology services in the last 7 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45762-2;Number of D with at least 15M of occupational therapy in the last 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of occupational therapy in the last 7 days [CMS Assessment];;;ACTIVE;2.17;2.63 +45763-0;Total minutes of occupational therapy in the last 7D;Time;7D;^Patient;Qn;MDS;SURVEY.MDS;4;Total minutes of occupational therapy in the last 7 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45764-8;Number of D with at least 15M of physical therapy in the last 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of physical therapy in the last 7 days [CMS Assessment];;;ACTIVE;2.17;2.63 +4576-5;Hemoglobin F/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin F/Hemoglobin.total in Blood;Hgb F MFr Bld;;ACTIVE;1.0;2.73 +45765-5;Total minutes of physical therapy in the last 7D;Time;7D;^Patient;Qn;MDS;SURVEY.MDS;4;Total minutes of physical therapy in the last 7 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45766-3;Number of D with at least 15M of respiratory therapy in the last 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of respiratory therapy in the last 7 days [CMS Assessment];;;ACTIVE;2.17;2.63 +45767-1;Total minutes of respiratory therapy in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Total minutes of respiratory therapy in the last 7 days [CMS Assessment];;;ACTIVE;2.17;2.63 +45768-9;Number of D with at least 15M of psychological therapy by any licensed mental health professional in the last 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of psychological therapy by any licensed mental health professional in the last 7 days [CMS Assessment];;;ACTIVE;2.17;2.63 +45769-7;Debris - soft, easily movable substances - present in mouth prior to going to bed at night;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Debris - soft, easily movable substances - present in mouth prior to going to bed at night [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45770-5;Has dentures or removable bridge;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Has dentures or removable bridge [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45771-3;Some or all natural teeth lost but does not have or use dentures or partial plates;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Some or all natural teeth lost but does not have or use dentures or partial plates [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45772-1;Broken, loose, or carious teeth;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Broken, loose, or carious teeth [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4577-3;Hemoglobin F-Texas;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin F - Texas [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb F-Texas Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45773-9;"Inflamed, swollen, or bleeding gums, oral abscesses; ulcers or rashes";Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;"Inflamed, swollen, or bleeding gums, oral abscesses; ulcers or rashes [Minimum Data Set]";;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45774-7;Daily cleaning of teeth or dentures or mouth care by resident or staff;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Daily cleaning of teeth or dentures or mouth care by resident or staff [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45775-4;Oral status &or disease prevention - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Oral status/disease prevention - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45776-2;Ulcers.stage 1;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Ulcers.stage 1 # [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45777-0;Ulcers.stage 2;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Ulcers.stage 2 # [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45778-8;Ulcers.stage 3;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Ulcers.stage 3 # [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45779-6;Ulcers.stage 4;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Ulcers.stage 4 # [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45780-4;Pressure injury stage;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Pressure injury stage [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.64 +4578-1;Hemoglobin F-Texas;ACnc;Pt;Bld;Qn;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin F - Texas [Units/volume] in Blood by Electrophoresis alkaline (pH 8.9);Hgb F-Texas Bld Elph Alk-aCnc;;ACTIVE;1.0;2.69 +45781-2;Stasis pressure injury stage;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Stasis ulcer stage [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.73 +45782-0;History of resolved ulcers;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;History of resolved ulcers [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45783-8;Abrasions or bruises;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Abrasions or bruises [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45784-6;Second or third degree burns;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Second or third degree burns [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45785-3;Open lesions other than ulcers, rashes, cuts;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Open lesions other than ulcers, rashes, cuts [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45786-1;Rashes;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Rashes [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45787-9;Skin desensitized to pain or pressure;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Skin desensitized to pain or pressure [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45788-7;Skin tears or cuts (other than surgery);Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Skin tears or cuts (other than surgery) [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45789-5;Surgical wounds;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Surgical wounds [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45790-3;Other skin problems - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other skin problems - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45791-1;Pressure relieving devices for chair;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pressure relieving devices for chair [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45792-9;Pressure relieving devices for bed;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pressure relieving devices for bed [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45793-7;Turning or repositioning program;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Turning or repositioning program [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45794-5;Nutrition or hydration intervention to manage skin problems;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Nutrition or hydration intervention to manage skin problems [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45795-2;Pressure injury care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Ulcer care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.73 +45796-0;Surgical wound care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Surgical wound care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45797-8;Application of dressings (with or without topical medications) other than to feet;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Application of dressings (with or without topical medications) other than to feet [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45798-6;Application of ointments or medications other than to feet;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Application of ointments or medications other than to feet [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4579-9;Hemoglobin F;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin F [Presence] in Blood;Hgb F Bld Ql;;ACTIVE;1.0;2.73 +45799-4;Other preventative or protective skin care other than to feet;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Other preventative or protective skin care other than to feet [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +458-0;Spiramycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Spiramycin [Susceptibility] by Serum bactericidal titer;Spiramycin Titr SBT;;ACTIVE;1.0;2.32 +45800-0;Skin treatments - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Skin treatments - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45801-8;One or more foot problems;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;One or more foot problems [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45802-6;Infection of foot;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Infection of foot [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45803-4;Open lesions on the foot;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Open lesions on the foot [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45804-2;Nails &or calluses trimmed during last 90D;Find;90D;^Patient;Ord;MDS;SURVEY.MDS;4;Nails/calluses trimmed during last 90 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45805-9;Received preventative or protective foot care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Received preventative or protective foot care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45806-7;Application of dressings (foot) - with or without topical medications;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Application of dressings (foot) - with or without topical medications [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4580-7;Hemoglobin F1/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin F1/Hemoglobin.total in Blood;Hgb F1 MFr Bld;;ACTIVE;1.0;2.70 +45807-5;Foot problems and care - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Foot problems and care - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45808-3;Awake in morning;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Awake in morning [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45809-1;Awake in afternoon;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Awake in afternoon [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45810-9;Awake in evening;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Awake in evening [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45811-7;Time awake - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Time awake - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45812-5;Average time involved in activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Average time involved in activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45813-3;Preferred activity setting - own room;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Preferred activity setting - own room [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45814-1;Preferred activity setting - day or activity room;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Preferred activity setting - day or activity room [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4581-5;Hemoglobin G-Coushatta;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin G - Coushatta [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb G-Coush Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45815-8;Preferred activity setting - inside NH &or off unit;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Preferred activity setting - inside NH/off unit [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45816-6;Preferred activity setting - outside facility;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Preferred activity setting - outside facility [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45817-4;Preferred activitty setting - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Preferred activitty setting - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45818-2;Activity preferences - cards or other games;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - cards or other games [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45819-0;Activity preferences - crafts or arts;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - crafts or arts [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45820-8;Activity preferences - exercise or sports;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - exercise or sports [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45821-6;Activity preferences - music;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - music [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45822-4;Activity preferences - reading or writing;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - reading or writing [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4582-3;Hemoglobin G-Coushatta;ACnc;Pt;Bld;Qn;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin G - Coushatta [Units/volume] in Blood by Electrophoresis alkaline (pH 8.9);Hgb G-Coush Bld Elph Alk-aCnc;;ACTIVE;1.0;2.69 +45823-2;Activity preferences - spiritual or religious activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - spiritual or religious activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45824-0;Activity preferences - trips or shopping;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - trips or shopping [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45825-7;Activity preferences - walking or wheeling outdoors;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - walking or wheeling outdoors [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45826-5;Activity preferences - watching TV;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - watching TV [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45827-3;Activity preferences - gardening or plants;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - gardening or plants [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45828-1;Activity preferences - talking or conversing;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - talking or conversing [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45829-9;Activity preferences - helping others;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - helping others [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45830-7;Activity preferences - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Activity preferences - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4583-1;Hemoglobin G-Georgia;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin G - Georgia [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb G-Georg Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45831-5;Type of activities in which resident is currently involved;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Type of activities in which resident is currently involved [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45832-3;Extent of resident involvement in activities;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Extent of resident involvement in activities [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45833-1;Number of medications;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of medications [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45834-9;New medications;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;New medications [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45835-6;Number of D injections received;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days injections received [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45836-4;Number of D antipsychotic medication received;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days antipsychotic medication received [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45837-2;Number of D antianxiety medication received;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days antianxiety medication received [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45838-0;Number of D antidepressant medication received;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days antidepressant medication received [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45839-8;Number of D hypnotic medication received;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days hypnotic medication received [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45840-6;Number of D diuretic medication received;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days diuretic medication received [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45841-4;Chemotherapy;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Chemotherapy [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45842-2;Dialysis;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Dialysis [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45843-0;IV medication;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;IV medication [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45844-8;Intake &or output;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Intake/output [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45845-5;Monitoring of acute medical condition;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Monitoring of acute medical condition [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45846-3;Ostomy care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Ostomy care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45847-1;Oxygen therapy;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Oxygen therapy [Minimum Data Set];;;ACTIVE;2.17;2.73 +45848-9;Radiation;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Radiation [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4584-9;Hemoglobin G-Georgia;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin G - Georgia [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb G-Georg Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45849-7;Suctioning;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Suctioning [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45850-5;Tracheostomy care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Tracheostomy care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45851-3;Transfusions;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Transfusions [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45852-1;Total minutes of psychological therapy by any licensed mental health professional in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Total minutes of psychological therapy by any licensed mental health professional in the last 7 days [CMS Assessment];;;ACTIVE;2.17;2.63 +45853-9;Special behavior symptom evaluation program;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Special behavior symptom evaluation program [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45854-7;Evaluation by a licensed mental health specialist in last 90D;Find;90D;^Patient;Ord;MDS;SURVEY.MDS;4;Evaluation by a licensed mental health specialist in last 90 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45855-4;Group therapy;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Group therapy [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4585-6;Hemoglobin G-Philadelphia;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin G - Philadelphia [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb G-Philad Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45856-2;Resident-specific deliberate changes in the environment to address mood &or behavior patterns;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident-specific deliberate changes in the environment to address mood/behavior patterns [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45857-0;Reorientation;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Reorientation [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45858-8;Mood, behavior, cognitive loss programs - none of above;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Mood, behavior, cognitive loss programs - none of above [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45859-6;Number of D of passive range of motion;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of passive range of motion [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45860-4;Number of D of active range of motion;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of active range of motion [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45861-2;Number of D of splint or brace assistance;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of splint or brace assistance [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45862-0;Number of D of training & skill practice in bed mobility;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of training and skill practice in bed mobility [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45863-8;Number of D of training & skill practice in transfer;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of training and skill practice in transfer [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4586-4;Hemoglobin G-Philadelphia;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin G - Philadelphia [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb G-Philad Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45864-6;Number of D of training & skill practice in walking;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of training and skill practice in walking [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45865-3;Number of D of training & skill practice in dressing or grooming;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of training and skill practice in dressing or grooming [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45866-1;Number of D of training & skill practice in eating or swallowing;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of training and skill practice in eating or swallowing [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45867-9;Number of D of training & skill practice in amputation or prosthesis care;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of training and skill practice in amputation or prosthesis care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45868-7;Number of D of training & skill practice in communication;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of training and skill practice in communication [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45869-5;Number of D of other rehabilitation or restorative techniques or procedures;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days of other rehabilitation or restorative techniques or procedures [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45870-3;Bed rails - full bed rails on all open sides of bed;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bed rails - full bed rails on all open sides of bed [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45871-1;Bed rails - other types of side rails used;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Bed rails - other types of side rails used [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4587-2;Hemoglobin H/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin H/Hemoglobin.total in Blood by Electrophoresis;Hgb H MFr Bld Elph;;ACTIVE;1.0;2.70 +45872-9;Trunk restraint;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Trunk restraint [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45873-7;Limb restraint;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Limb restraint [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45874-5;Chair prevents rising;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Chair prevents rising [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45875-2;Number hospital admissions in last 90D;Num;90D;^Patient;Qn;MDS;SURVEY.MDS;4;Number hospital admissions in last 90 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45876-0;Number of emergency room visits in last 90D;NRat;90D;^Patient;Qn;MDS;SURVEY.MDS;4;Number of emergency room visits in last 90 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45877-8;Number of physician visits in last 14D;NRat;14D;^Patient;Qn;MDS;SURVEY.MDS;4;Number of physician visits in last 14 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45878-6;Number of D physician orders changed in last 14D;Num;14D;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days physician orders changed in last 14 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45879-4;Abnormal lab values in last 90D;Find;90D;^Patient;Ord;MDS;SURVEY.MDS;4;Abnormal lab values in last 90 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +4588-0;Hemoglobin H/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin H/Hemoglobin.total in Blood;Hgb H MFr Bld;;ACTIVE;1.0;2.73 +45880-2;Resident expresses &or indicates preference to return to the community;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident expresses/indicates preference to return to the community [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45881-0;Resident has a support person who is positive towards discharge;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident has a support person who is positive towards discharge [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45882-8;Stay projected to be of a short duration - discharge projected within 90D;Find;90D;^Patient;Nar;MDS;SURVEY.MDS;4;Stay projected to be of a short duration - discharge projected within 90 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45883-6;Overall change in care needs;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Overall change in care needs [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45884-4;Participation in assessment;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Participation in assessment [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45885-1;Participation in assessment;Find;Pt;^Family;Ord;MDS;SURVEY.MDS;4;Participation in assessment Family [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45886-9;Number of D recreation therapy administered for greater than 15M;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Number of days recreation therapy administered for greater than 15 minutes [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.66 +45887-7;Total recreation therapy in last 7D;Time;7D;^Patient;Qn;MDS;SURVEY.MDS;4;Total recreation therapy in last 7 days [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.54 +45888-5;Therapy orders to begin in 1st 14D of stay;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Therapy orders to begin in 1st 14 days of stay [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45889-3;Through D 15, provide an estimate of the number of D when at least 1 therapy service can be expected to have been delivered;Num;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Through day 15, provide an estimate of the number of days when at least 1 therapy service can be expected to have been delivered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45890-1;Through day 15, provide an estimate of the number of therapy minutes (across the therapies) that can be expected to be delivered;Time;Pt;^Patient;Qn;MDS;SURVEY.MDS;4;Through day 15, provide an estimate of the number of therapy minutes (across the therapies) that can be expected to be delivered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45891-9;Furthest distance walked without sitting down during this episode;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Furthest distance walked without sitting down during this episode [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45892-7;Time walked without sitting down during this episode;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Time walked without sitting down during this episode [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45893-5;Self-Performance in walking during this episode;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Self-Performance in walking during this episode [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45894-3;Walking support provided;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Walking support provided [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45895-0;Parallel bars used by resident in association with this episode;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Parallel bars used by resident in association with this episode [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45896-8;Delirium trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Delirium trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45897-6;Cognitive loss or dementia trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Cognitive loss or dementia trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4589-8;Hemoglobin Hasharon;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Hasharon [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Hashar Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45898-4;Visual function trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Visual function trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45899-2;Communication trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Communication trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45900-8;ADL-rehabilitation trigger A;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;ADL-rehabilitation trigger A [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45901-6;ADL-rehabilitation trigger B;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;ADL-rehabilitation trigger B [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45902-4;Urinary incontinence and indwelling catherter trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Urinary incontinence and indwelling catherter trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45903-2;Psychosocial well being trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Psychosocial well-being trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45904-0;Mood state trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Mood state trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45905-7;Behavioral symptoms trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Behavioral symptoms trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4590-6;Hemoglobin Hasharon;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Hasharon [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Hashar Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45906-5;Activities trigger A;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Activities trigger A [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45907-3;Activities trigger B;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Activities trigger B [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45908-1;Falls trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Falls trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45909-9;Nutritional status trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Nutritional status trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45910-7;Feeding tubes trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Feeding tubes trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45911-5;Dehydration &or fluid maintenance trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Dehydration/fluid maintenance trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45912-3;Dental care trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Dental care trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45913-1;Pressure injuries trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Pressure injuries trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.64 +4591-4;Hemoglobin Hope;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Hope [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Hope Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45914-9;Psychotropic drug use trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Psychotropic drug use trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45915-6;Physical restraints trigger;Find;Pt;^Patient;Nar;MDS;SURVEY.MDS;4;Physical restraints trigger [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45916-4;Resident assessment protocol 1--Delirium - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 1--Delirium - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45917-2;Resident assessment protocol 1--Delirium - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 1--Delirium - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45918-0;Resident assessment protocol 2--Cognitive loss - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 2--Cognitive loss - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45919-8;Resident assessment protocol 2--Cognitive loss - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 2--Cognitive loss - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45920-6;Resident assessment protocol 3--Visual function - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 3--Visual function - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45921-4;Resident assessment protocol 3--Visual function - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 3--Visual function - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4592-2;Hemoglobin Hope;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Hope [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Hope Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45922-2;Resident assessment protocol 4--Communication - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 4--Communication - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45923-0;Resident assessment protocol 4--Communication - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 4--Communication - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45924-8;Resident assessment protocol 5--ADL functional &or rehab - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 5--ADL functional/Rehab - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45925-5;Resident assessment protocol 5--ADL functional &or rehab - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 5--ADL functional/Rehab - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45926-3;Resident assessment protocol 6--Urinary incontinence - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 6--Urinary incontinence - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45927-1;Resident assessment protocol 6--Urinary incontinence - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 6--Urinary incontinence - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45928-9;Resident assessment protocol 7--Psychosocial - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 7--Psychosocial - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45929-7;Resident assessment protocol 7--Psychosocial - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 7--Psychosocial - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4593-0;Hemoglobin I;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin I [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb I Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45930-5;Resident assessment protocol 8--Mood state - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 8--Mood state - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45931-3;Resident assessment protocol 8--Mood state - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 8--Mood state - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45932-1;Resident assessment protocol 9--Behavioral symptoms - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 9--Behavioral symptoms - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45933-9;Resident assessment protocol 9--Behavioral symptoms - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 9--Behavioral symptoms - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45934-7;Resident assessment protocol 10--Activities - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 10--Activities - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45935-4;Resident assessment protocol 10--Activities - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 10--Activities - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45936-2;Resident assessment protocol 11--Falls - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 11--Falls - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45937-0;Resident assessment protocol 11--Falls - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 11--Falls - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45938-8;Resident assessment protocol 12--Nutritional status - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 12--Nutritional status - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45939-6;Resident assessment protocol 12--Nutritional status - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 12--Nutritional status - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45940-4;Resident assessment protocol 13--Feeding tubes - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 13--Feeding tubes - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45941-2;Resident assessment protocol 13--Feeding tubes - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 13--Feeding tubes - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45942-0;Resident assessment protocol 14--Dehydration &or Fluid maint - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 14--Dehydration/Fluid maint - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45943-8;Resident assessment protocol 14--Dehydration &or Fluid maint - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 14--Dehydration/Fluid maint - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45944-6;Resident assessment protocol 15--Dental care - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 15--Dental care - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45945-3;Resident assessment protocol 15--Dental care - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 15--Dental care - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45946-1;Resident assessment protocol 16--Pressure injuries - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 16--Pressure injuries - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.64 +45947-9;Resident assessment protocol 16--Pressure injuries - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 16--Pressure injuries - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.64 +4594-8;Hemoglobin I;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin I [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb I Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45948-7;Resident assessment protocol 17--Psychotropic drug - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 17--Psychotropic drug - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45949-5;Resident assessment protocol 17--Psychotropic drug - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 17--Psychotropic drug - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45950-3;Resident assessment protocol 18--Physical restraints - triggered;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Resident assessment protocol 18--Physical restraints - triggered [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45951-1;Resident assessment protocol 18--Physical restraints - proceed with care;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Resident assessment protocol 18--Physical restraints - proceed with care [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45952-9;National provider ID;ID;Pt;Provider;Nom;;SURVEY.MDS;4;National provider ID;;;ACTIVE;2.17;2.50 +45953-7;Influenza virus vaccine received in facility;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Deprecated Influenza virus vaccine received in facility [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +45954-5;Reason influenza virus vaccine not received;Find;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Deprecated Reason influenza virus vaccine not received [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +4595-5;Hemoglobin J-Baltimore;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin J - Baltimore [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb J-Balt Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45955-2;Pneumococcal vaccine status up to date;Find;Pt;^Patient;Ord;MDS;SURVEY.MDS;4;Pneumococcal vaccine status up to date [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45956-0;Reason pneumococcal vaccine not received;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Reason pneumococcal vaccine not received [CMS Assessment];;;ACTIVE;2.17;2.61 +45957-8;Participation in assessment;Find;Pt;^Significant other;Ord;MDS;SURVEY.MDS;4;Participation in assessment Significant other [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45958-6;Other current or more detailed diagnoses & ICD9 codes^^^2;Prid;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Other current or more detailed diagnoses and ICD9 codes # 2 [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45959-4;Other current or more detailed diagnoses & ICD9 codes^^^3;Prid;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Other current or more detailed diagnoses and ICD9 codes # 3 [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45960-2;Other current or more detailed diagnoses & ICD9 codes^^^4;Prid;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Other current or more detailed diagnoses and ICD9 codes # 4 [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45961-0;Other current or more detailed diagnoses & ICD9 codes^^^5;Prid;Pt;^Patient;Nom;MDS;SURVEY.MDS;4;Other current or more detailed diagnoses and ICD9 codes # 5 [Minimum Data Set];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +45962-8;Minimum data set for nursing home resident assessment and care screen;-;Pt;^Patient;-;;SURVEY.MDS;4;Minimum data set for nursing home resident assessment and care screen;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.50 +4596-3;Hemoglobin J-Baltimore;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin J - Baltimore [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb J-Balt Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45963-6;MDS basic assessment tracking form - version 2.0;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated MDS basic assessment tracking form - version 2.0;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +45964-4;Identification information section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Identification information section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +45965-1;Name;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Name Set;;;ACTIVE;2.17;2.73 +45966-9;Social Security & Medicare numbers;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Social Security and Medicare numbers;;;ACTIVE;2.17;2.67 +45967-7;Facility provider numbers;-;Pt;Facility;Set;;PANEL.SURVEY.MDS;4;Facility provider numbers Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45968-5;Reasons for assessment (basic);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Reasons for assessment (basic) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45969-3;MDS background information at admission form - version 2.0;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated MDS background information at admission form - version 2.0;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +45970-1;Demographic information section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Demographic information section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +4597-1;Hemoglobin J-Capetown;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin J - Capetown [Presence] in Blood;Hgb J-Cape Bld Ql;;ACTIVE;1.0;2.56 +45971-9;Residential history 5Y prior to entry;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Residential history 5 years prior to entry Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.61 +45972-7;Language;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Language Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45973-5;Conditions related to mental retardation and developmental disabilities status;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Conditions related to mental retardation and developmental disabilities status Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DISCOURAGED;2.17;2.65 +45974-3;Mental retardation and developmental disabilities with organic condition;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Mental retardation and developmental disabilities with organic condition Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DISCOURAGED;2.17;2.65 +45975-0;Customary routine section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Customary routine section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +45976-8;Customary routine in year prior to date of entry;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Customary routine in year prior to date of entry Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45977-6;Cycle of daily events;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Cycle of daily events Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45978-4;Eating patterns;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Eating patterns Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45979-2;ADL patterns;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;ADL patterns Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +459-8;Streptomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Streptomycin [Susceptibility] by Minimum lethal concentration (MLC);Streptomycin Islt MLC;;ACTIVE;1.0;2.19 +45980-0;Involvement patterns;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Involvement patterns Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45981-8;MDS full assessment form - version 2.0;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated MDS full assessment form - version 2.0;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +45982-6;Identification and background information section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Identification and background information section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.73 +45983-4;Assessment reference date;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Deprecated Assessment reference date Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +45984-2;Current payment sources for nursing home stay;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Current payment sources for nursing home stay Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45985-9;Responsibility &or legal guardian;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Responsibility/legal guardian Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45986-7;Advance directives;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Advance directives Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45987-5;Cognitive patterns section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Cognitive patterns section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +45988-3;Memory;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Memory Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4598-9;Hemoglobin J-Oxford;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin J - Oxford [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb J-Oxf Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +45989-1;Memory recall &or ability;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Memory recall/ability Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45990-9;Indicators of delirium - periodic disorded thinking or awareness;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Indicators of delirium - periodic disorded thinking or awareness Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45991-7;Communication and hearing patterns section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Communication and hearing patterns section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +45992-5;Communication devices and techniques;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Communication devices and techniques Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45993-3;Modes of expression;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Modes of expression Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45994-1;Vision patterns section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Vision patterns section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +45995-8;Visual limitations and dificulties;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Visual limitations and dificulties Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45996-6;Mood and behavior patterns section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Mood and behavior patterns section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +4599-7;Hemoglobin J-Oxford;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin J - Oxford [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb J-Oxf Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +45997-4;Indicators of depression, anxiety, sad mood;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Indicators of depression, anxiety, sad mood Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45998-2;Verbal expressions of distress;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Verbal expressions of distress Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +45999-0;Sleep-cycle issues;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Sleep-cycle issues Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46000-6;Sad, apethetic, anxious appearance;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Sad, apethetic, anxious appearance Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46001-4;Behavioral symptoms;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Behavioral symptoms Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46002-2;Psychosocial well being section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Psychosocial well-being section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +4600-3;Hemoglobin Kansas;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Kansas [Presence] in Blood;Hgb Kansas Bld Ql;;ACTIVE;1.0;2.56 +46003-0;Sense of initiative &or involvement;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Sense of initiative/involvement Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46004-8;Unsettled releationships;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Unsettled releationships Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46005-5;Past roles;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Past roles Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46006-3;Physical functioning and stuctural problems section;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Physical functioning and stuctural problems section Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46007-1;ADL self performance or support;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;ADL self performance or support Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46008-9;Bathing;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Bathing during assessment period [CMS Assessment];;;ACTIVE;2.17;2.70 +46009-7;Test for balance;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Test for balance Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46010-5;Functional limitation in range of motion;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Functional limitation in range of motion Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4601-1;Hemoglobin Kempsey;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Kempsey [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Kempsey Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +46011-3;Modes of locomotion;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Modes of locomotion Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46012-1;Modes of transfer;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Modes of transfer Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46013-9;ADL functional rehabilitation potential;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;ADL functional rehabilitation potential Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46014-7;Continence in last 14D section;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Continence in last 14 days section Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46015-4;Continence self-control categories;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Continence self-control categories Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46016-2;Bowel elimination pattern;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Bowel elimination pattern Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46017-0;Continence appliances and programs;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Continence appliances and programs Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46018-8;Disease or condition diagnoses section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Disease or condition diagnoses section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46019-6;Diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46020-4;Endocrine, metabolic or nutritional diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Endocrine, metabolic or nutritional diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46021-2;Heart or circulation diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Heart or circulation diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46022-0;Musculoskeletal diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Musculoskeletal diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46023-8;Neurological diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Neurological diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46024-6;Psychiatric or mood diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Psychiatric or mood diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46025-3;Pulmonary diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Pulmonary diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46026-1;Sensory diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Sensory diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46027-9;Other diseases or conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Other diseases or conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46028-7;Infections;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Infections Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4602-9;Hemoglobin Kempsey;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Kempsey [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Kempsey Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46029-5;Other current or more detailed diagnoses & ICD9 codes;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Other current or more detailed diagnoses and ICD9 codes Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46030-3;Health conditions section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Health conditions section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46031-1;Indicators of fluid status;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Indicators of fluid status Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46032-9;Other indicators;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Other indicators Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46033-7;Pain symptoms;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Pain symptoms Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46034-5;Pain site;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Pain site Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46035-2;Accidents;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Accidents Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46036-0;Stability of conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Stability of conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4603-7;Hemoglobin Koln;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Koln [Presence] in Blood;Hgb Koln Bld Ql;;ACTIVE;1.0;2.56 +46037-8;Oral and nutritional status section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Oral and nutritional status section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46038-6;Oral problems;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Oral problems Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46039-4;Height & weight;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Height and weight Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46040-2;Weight change;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Weight change Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46041-0;Nutritional problems;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Nutritional problems Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46042-8;Nutritional approaches;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Nutritional approaches Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46043-6;Parenteral or enteral intake;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Parenteral or enteral intake Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.67 +46044-4;Oral or dental status section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Oral or dental status section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +4604-5;Hemoglobin Lepore;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Lepore [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Lepore Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +46045-1;Oral status and disease prevention;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Oral status and disease prevention Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46046-9;Skin condition section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Skin condition section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46047-7;Ulcers;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Ulcers Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46048-5;Type of pressure injury;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Type of ulcer Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.73 +46049-3;Other skin problems or lesions present;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Other skin problems or lesions present Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46050-1;Skin treatments;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Skin treatments Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46051-9;Foot problems and care;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Foot problems and care Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4605-2;Hemoglobin Lepore;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Lepore [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Lepore Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46052-7;Activity pursuit patterns section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Activity pursuit patterns section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46053-5;Time awake;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Time awake Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46054-3;Preferred activity settings;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Preferred activity settings Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46055-0;General activity preferences;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;General activity preferences Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46056-8;Prefers change in daily routine;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Prefers change in daily routine Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46057-6;Medications section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Medications section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46058-4;Days received the following medication;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Days received the following medication Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46059-2;Special treatments and procedures section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Special treatments and procedures section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +460-6;Streptomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Streptomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Streptomycin Islt MIC;;ACTIVE;1.0;2.73 +4606-0;Hemoglobin M-Boston;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin M - Boston [Presence] in Blood;Hgb M-Boston Bld Ql;;ACTIVE;1.0;2.56 +46060-0;Special treatments, procedures and programs;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Special treatments, procedures and programs Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46061-8;Special care;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Special care Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46062-6;Treatments;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Treatments Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46063-4;Programs;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Programs Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46064-2;Therapies;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Therapies Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46065-9;Intervention programs for mood, behavior and cognitive loss;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Intervention programs for mood, behavior and cognitive loss Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46066-7;Nursing rehabilitation and restorative care;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Nursing rehabilitation and restorative care Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46067-5;Devices and restraints;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Devices and restraints Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46068-3;Discharge potential and overall status section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Discharge potential and overall status section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46069-1;Discharge potential;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Discharge potential Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46070-9;Assessment information section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Assessment information section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46071-7;Participation in assessment;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Participation in assessment Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46072-5;Therapy supplement for Medicare PPS section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Therapy supplement for Medicare PPS section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46073-3;Special treatments and procedures;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Special treatments and procedures Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46074-1;Recreational therapy;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Recreational therapy Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46075-8;Walking when most self sufficient;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Walking when most self sufficient Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46076-6;MDS supplemental items section - version 2.0;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated Minimum Data Set (MDS) supplemental items section - version 2.0;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +46077-4;Influenza vaccine;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Influenza vaccine Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.73 +4607-8;Hemoglobin M-Hyde park;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin M - Hyde Park [Presence] in Blood;Hgb M-Hyde Park Bld Ql;;ACTIVE;1.0;2.56 +46078-2;Pneumococcal vaccine;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Pneumococcal vaccine Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46079-0;Resident assessment protocol summary section;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Resident assessment protocol summary section;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46080-8;Erythrocytes.CD55/100 erythrocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;CD55 RBC/100 erythrocytes in Blood;CD55 RBC/100 RBC NFr Bld;;ACTIVE;2.17;2.73 +46081-6;Theophylline;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Theophylline [Moles/volume] in Urine;Theophylline Ur-sCnc;;ACTIVE;2.17;2.70 +46082-4;Influenza virus A Ag;PrThr;Pt;Nph;Ord;IA;MICRO;1;Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay;FLUAV Ag Nph Ql IA;;ACTIVE;2.17;2.73 +46083-2;Influenza virus B Ag;PrThr;Pt;Nph;Ord;IA;MICRO;1;Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay;FLUBV Ag Nph Ql IA;;ACTIVE;2.17;2.73 +46084-0;Immunoglobulin light chains;MRat;24H;Urine;Qn;;CHEM;1;Immunoglobulin light chains [Mass/time] in 24 hour Urine;BJ Protein 24h Ur-mRate;;ACTIVE;2.17;2.70 +46085-7;Gamma hydroxybutyrate;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Gamma hydroxybutyrate [Presence] in Serum or Plasma;G-OH-Butyr SerPl Ql;;ACTIVE;2.17;2.73 +4608-6;Hemoglobin M-Iwate;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin M - Iwate [Presence] in Blood;Hgb M-Iwate Bld Ql;;ACTIVE;1.0;2.56 +46086-5;Creatinine^2H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Dialysis fluid --2 hour specimen;Creat 2h spec Dial fld-sCnc;;ACTIVE;2.17;2.70 +46087-3;Erythrocytes^2nd tube;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Cerebral spinal fluid by Manual count --2nd tube;RBC tube2 # CSF Manual;;ACTIVE;2.17;2.70 +46088-1;Leukocytes^2nd tube;NCnc;Pt;CSF;Qn;;HEM/BC;1;Leukocytes [#/volume] in Cerebral spinal fluid --2nd tube;WBC tube2 # CSF;;ACTIVE;2.17;2.70 +46089-9;Leukocytes^3rd tube;NCnc;Pt;CSF;Qn;;HEM/BC;1;Leukocytes [#/volume] in Cerebral spinal fluid --3rd tube;WBC tube3 # CSF;;ACTIVE;2.17;2.73 +46090-7;Leukocytes^4th tube;NCnc;Pt;CSF;Qn;;HEM/BC;1;Leukocytes [#/volume] in Cerebral spinal fluid --4th tube;WBC tube4 # CSF;;ACTIVE;2.17;2.73 +46091-5;Erythrocytes^3rd tube;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Cerebral spinal fluid by Manual count --3rd tube;RBC tube3 # CSF Manual;;ACTIVE;2.17;2.73 +46092-3;Erythrocytes^4th tube;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Cerebral spinal fluid by Manual count --4th tube;RBC tube4 # CSF Manual;;ACTIVE;2.17;2.73 +46093-1;Calcium.ionized;SCnc;Pt;Dial fld;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Dialysis fluid;Ca-I Dial fld-sCnc;;ACTIVE;2.17;2.73 +4609-4;Hemoglobin M-Milwaukee;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin M - Milwaukee [Presence] in Blood;Hgb M-Milw Bld Ql;;ACTIVE;1.0;2.56 +46094-9;Plasmodium sp Ag;PrThr;Pt;Bld;Ord;IA;MICRO;1;Plasmodium sp Ag [Presence] in Blood by Immunoassay;Plasmodium Ag Bld Ql IA;;ACTIVE;2.17;2.73 +46095-6;Anabolic steroids;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Anabolic steroids [Moles/volume] in Serum or Plasma;Anabolic Steroids SerPl-sCnc;;ACTIVE;2.17;2.70 +46096-4;Arsenic;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Arsenic [Moles/mass] in Hair;Arsenic Hair-sCnt;;ACTIVE;2.17;2.70 +46097-2;Time corticotropin given;TmStp;Pt;Dose;Qn;;DRUGDOSE;1;Time corticotropin given;Time ACTH Gvn Dose;;ACTIVE;2.17;2.73 +46098-0;Sex;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Sex;Sex;;ACTIVE;2.17;2.73 +46099-8;Calcium^^corrected for albumin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Mass/volume] corrected for albumin in Serum or Plasma;Calcium Album cor SerPl-mCnc;;ACTIVE;2.17;2.73 +46100-4;Pregnenolone^1H post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;Preg 1h p 250 ug ACTH SerPl-mCnc;;ACTIVE;2.17;2.73 +46101-2;Ordered therapies;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Ordered therapies Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4610-2;Hemoglobin M-Saskatoon;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin M - Saskatoon [Presence] in Blood;Hgb M-Sask Bld Ql;;ACTIVE;1.0;2.56 +46102-0;MDS quarterly assessment form - version 2.0;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated MDS quarterly assessment form - version 2.0;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +46103-8;MDS quarterly assessment form - version 2.0 - optional version for RUG-III;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated MDS quarterly assessment form - version 2.0 - optional version for RUG-III;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +46104-6;MDS quarterly assessment form - version 2.0 - optional version for RUG-III 1997 update;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated MDS quarterly assessment form - version 2.0 - optional version for RUG-III 1997 update;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.17;2.73 +46105-3;Problem conditions;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Problem conditions Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46106-1;Medical record number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Medical record number [Identifier];MRN;;ACTIVE;2.17;2.66 +46107-9;Loss of interest;-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Loss of interest Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46108-7;18q chromosome deletion;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DEL;1;18q chromosome deletion [Identifier] in Blood or Tissue by Molecular genetics method Nominal;18q Chrom Del Bld/T;;ACTIVE;2.17;2.17 +46109-5;Rubella virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Rubella virus IgM Ab [Titer] in Cerebral spinal fluid;RUBV IgM Titr CSF;;ACTIVE;2.17;2.32 +4611-0;Hemoglobin Malmo;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Malmo [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Malmo Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +46110-3;Rubella virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Rubella virus IgG Ab [Titer] in Cerebral spinal fluid;RUBV IgG Titr CSF;;ACTIVE;2.17;2.32 +46111-1;Mycoplasma sp DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Mycoplasma sp DNA [Presence] in Body fluid by NAA with probe detection;Mycoplasma DNA Fld Ql NAA+probe;;ACTIVE;2.17;2.63 +46112-9;Borrelia burgdorferi 18kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 18kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor18kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46113-7;Borrelia burgdorferi 23kD Ab.IgM;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 23kD IgM Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor23kD IgM Ser Ql EIA;;DEPRECATED;2.17;2.36 +46114-5;Borrelia burgdorferi 23kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 23kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor23kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46115-2;Borrelia burgdorferi 28kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 28kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor28kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46116-0;Borrelia burgdorferi 30kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 30kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor30kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46117-8;Borrelia burgdorferi 39kD Ab.IgM;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 39kD IgM Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor39kD IgM Ser Ql EIA;;DEPRECATED;2.17;2.36 +46118-6;Borrelia burgdorferi 39kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 39kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor39kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46119-4;Borrelia burgdorferi 41kD Ab.IgM;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 41kD IgM Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor41kD IgM Ser Ql EIA;;DEPRECATED;2.17;2.36 +46120-2;Borrelia burgdorferi 41kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 41kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor41kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46121-0;Borrelia burgdorferi 45kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 45kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor45kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46122-8;Borrelia burgdorferi 58kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 58kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor58kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46123-6;Borrelia burgdorferi 66kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 66kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor66kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46124-4;Borrelia burgdorferi 93kD Ab.IgG;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Borrelia burgdorferi 93kD IgG Ab [Presence] in Serum by Immunoassay;Deprecated B burgdor93kD IgG Ser Ql EIA;;DEPRECATED;2.17;2.36 +46125-1;Cardiolipin Ab;PrThr;Pt;Ser;Ord;IA;COAG;1;Cardiolipin Ab [Presence] in Serum by Immunoassay;Cardiolipin Ab Ser Ql IA;;ACTIVE;2.17;2.73 +46126-9;Endomysium Ab.IgA;PrThr;Pt;Ser;Ord;IF;SERO;1;Endomysium IgA Ab [Presence] in Serum by Immunofluorescence;Endomysium IgA Ser Ql IF;;ACTIVE;2.17;2.73 +46127-7;Haptoglobin;MCnc;Pt;Ser/Plas;Qn;Nephelometry;HEM/BC;1;Haptoglobin [Mass/volume] in Serum or Plasma by Nephelometry;Haptoglob SerPl Neph-mCnc;;ACTIVE;2.17;2.73 +4612-8;Hemoglobin Malmo;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Malmo [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Malmo Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46128-5;Tissue transglutaminase Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Tissue transglutaminase IgA Ab [Units/volume] in Serum by Immunoassay;tTG IgA Ser IA-aCnc;;ACTIVE;2.17;2.73 +46129-3;Alpha 1 antitrypsin;MCnc;Pt;Ser/Plas;Qn;Nephelometry;CHEM;1;Deprecated Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephlometry;Deprecated A1AT SerPl Neph-mCnc;;DEPRECATED;2.17;2.36 +46130-1;Prealbumin;MCnc;Pt;Ser/Plas;Qn;Nephelometry;CHEM;1;Prealbumin [Mass/volume] in Serum or Plasma by Nephelometry;Prealb SerPl Neph-mCnc;;ACTIVE;2.17;2.73 +46131-9;Clostridioides difficile toxin B;PrThr;Pt;Stool;Ord;Cytotoxin tissue culture assay;MICRO;1;Clostridioides difficile toxin B [Presence] in Stool by Cytotoxin tissue culture assay;C diff Tox B Stl Ql CT Tiss Cult;;ACTIVE;2.17;2.73 +46132-7;Glycosaminoglycans/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Glycosaminoglycans/Creatinine [Ratio] in Urine;GAG/Creat Ur-Rto;;ACTIVE;2.17;2.73 +46133-5;Epithelial cells;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Epithelial cells [#/area] in Urine sediment by Microscopy low power field;Epi Cells #/area UrnS LPF;;ACTIVE;2.17;2.73 +46134-3;Granular casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Granular casts [#/area] in Urine sediment by Microscopy high power field;Gran Casts #/area UrnS HPF;;ACTIVE;2.17;2.40 +46135-0;Hyaline casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Hyaline casts [#/area] in Urine sediment by Microscopy high power field;Hyaline Casts #/area UrnS HPF;;ACTIVE;2.17;2.73 +4613-6;Hemoglobin N-Baltimore;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin N - Baltimore [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb N-Balt Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +46136-8;Transitional cells;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Transitional cells [#/area] in Urine sediment by Microscopy low power field;Trans Cells #/area UrnS LPF;;ACTIVE;2.17;2.73 +46137-6;Triple phosphate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Triple phosphate crystals [#/area] in Urine sediment by Microscopy high power field;Tri-Phos Cry #/area UrnS HPF;;ACTIVE;2.17;2.73 +46138-4;Urate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Urate crystals [#/area] in Urine sediment by Microscopy high power field;Urate Cry #/area UrnS HPF;;ACTIVE;2.17;2.73 +46139-2;Nutritional approaches (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Nutritional approaches (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +461-4;Streptomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Streptomycin [Susceptibility] by Disk diffusion (KB);Streptomycin Islt KB;;ACTIVE;1.0;2.21 +46140-0;Problem conditions (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Problem conditions (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46141-8;Other current diagnoses & ICD9 codes (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Other current diagnoses and ICD9 codes (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46142-6;Infections (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Infections (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46143-4;Continence appliances and programs (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Continence appliances and programs (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4614-4;Hemoglobin N-Baltimore;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin N - Baltimore [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb N-Balt Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46144-2;Bowel elimination pattern (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Bowel elimination pattern (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46145-9;Modes of transfer (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Modes of transfer (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46146-7;Bathing (quarterly);-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Bathing (quarterly);;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.68 +46147-5;ADL self performance or support (quarterly);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;ADL self performance or support (quarterly) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46148-3;Nutritional approaches (quarterly RUG-III);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Nutritional approaches (quarterly RUG-III) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46149-1;Problem conditions (quarterly RUG-III);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Problem conditions (quarterly RUG-III) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46150-9;Diseases (quarterly RUG-III);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Diseases (quarterly RUG-III) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +4615-1;Hemoglobin N-Seattle;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin N - Seattle [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb N-Seattle Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +46151-7;Bowel elimination pattern (quarterly RUG-III);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Bowel elimination pattern (quarterly RUG-III) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46152-5;Diseases (quarterly RUG-III 97 update);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Diseases (quarterly RUG-III 97 update) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46153-3;Oral problems (quarterly RUG-II);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Oral problems (quarterly RUG-II) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.17;2.52 +46154-1;Trichomonas vaginalis rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis rRNA [Presence] in Specimen by NAA with probe detection;T vaginalis rRNA Spec Ql NAA+probe;;ACTIVE;2.17;2.73 +46155-8;Ascaris lumbricoides adult Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Ascaris lumbricoides adult IgG Ab [Units/volume] in Serum;A lumbrica adult IgG Ser-aCnc;;ACTIVE;2.17;2.69 +46156-6;Ascaris lumbricoides larva Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Ascaris lumbricoides larva IgG Ab [Units/volume] in Serum;A lumbric larva IgG Ser-aCnc;;ACTIVE;2.17;2.69 +46157-4;Aspergillus glaucus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus glaucus Ab [Presence] in Serum;A glaucus Ab Ser Ql;;ACTIVE;2.17;2.56 +46158-2;Bartonella sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Bartonella sp IgG Ab [Units/volume] in Serum;Bartonella IgG Ser-aCnc;;ACTIVE;2.17;2.69 +46159-0;Bartonella sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Bartonella sp IgM Ab [Units/volume] in Serum;Bartonella IgM Ser-aCnc;;ACTIVE;2.17;2.69 +46160-8;Blastomyces dermatitidis Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Blastomyces dermatitidis IgG Ab [Presence] in Cerebral spinal fluid;B dermat IgG CSF Ql;;ACTIVE;2.17;2.56 +46161-6;Borrelia burgdorferi 18kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 18kD IgG Ab [Presence] in Serum;Deprecated B burgdor18kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46162-4;Borrelia burgdorferi 23kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 23kD IgG Ab [Presence] in Serum;Deprecated B burgdor23kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46163-2;Borrelia burgdorferi 23kD Ab.IgM;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 23kD IgM Ab [Presence] in Serum;Deprecated B burgdor23kD IgM Ser Ql;;DEPRECATED;2.17;2.36 +46164-0;Borrelia burgdorferi 28kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 28kD IgG Ab [Presence] in Serum;Deprecated B burgdor28kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46165-7;Borrelia burgdorferi 30kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 30kD IgG Ab [Presence] in Serum;Deprecated B burgdor30kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46166-5;Borrelia burgdorferi 39kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 39kD IgG Ab [Presence] in Serum;Deprecated B burgdor39kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46167-3;Borrelia burgdorferi 39kD Ab.IgM;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 39kD IgM Ab [Presence] in Serum;Deprecated B burgdor39kD IgM Ser Ql;;DEPRECATED;2.17;2.36 +46168-1;Borrelia burgdorferi 41kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 41kD IgG Ab [Presence] in Serum;Deprecated B burgdor41kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +4616-9;Hemoglobin N-Seattle;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin N - Seattle [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb N-Seattle Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46169-9;Borrelia burgdorferi 41kD Ab.IgM;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 41kD IgM Ab [Presence] in Serum;Deprecated B burgdor41kD IgM Ser Ql;;DEPRECATED;2.17;2.36 +46170-7;Borrelia burgdorferi 45kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 45kD IgG Ab [Presence] in Serum;Deprecated B burgdor45kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46171-5;Borrelia burgdorferi 58kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 58kD IgG Ab [Presence] in Serum;Deprecated B burgdor58kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46172-3;Borrelia burgdorferi 66kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 66kD IgG Ab [Presence] in Serum;Deprecated B burgdor66kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46173-1;Borrelia burgdorferi 93kD Ab.IgG;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Borrelia burgdorferi 93kD IgG Ab [Presence] in Serum;Deprecated B burgdor93kD IgG Ser Ql;;DEPRECATED;2.17;2.36 +46174-9;Borrelia burgdorferi Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi IgA Ab [Units/volume] in Serum;B burgdor IgA Ser-aCnc;;ACTIVE;2.17;2.69 +46175-6;Cache valley virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Cache valley virus Ab [Titer] in Serum;CVV Ab Titr Ser;;ACTIVE;2.17;2.32 +46176-4;Chlamydia trachomatis D+E+F+G+H+I+J+K Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+E+F+G+H+I+J+K IgA Ab [Titer] in Serum;C trach D+E+F+G+H+I+J+K IgA Titr Ser;;ACTIVE;2.17;2.32 +4617-7;Hemoglobin O-Arab;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin O - Arab [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb O-Arab Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +46177-2;Chlamydia trachomatis D+E+F+G+H+I+J+K Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+E+F+G+H+I+J+K IgG Ab [Titer] in Serum;C trach D+E+F+G+H+I+J+K IgG Titr Ser;;ACTIVE;2.17;2.32 +46178-0;Chlamydia trachomatis D+E+F+G+H+I+J+K Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis D+E+F+G+H+I+J+K IgM Ab [Titer] in Serum;C trach D+E+F+G+H+I+J+K IgM Titr Ser;;ACTIVE;2.17;2.32 +46179-8;Chlamydophila sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Chlamydophila sp Ab [Presence] in Serum;Chlamydophila Ab Ser Ql;;ACTIVE;2.17;2.56 +46180-6;Classical swine fever virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Classical swine fever virus Ab [Titer] in Serum;CSFV Ab Titr Ser;;ACTIVE;2.17;2.32 +46181-4;Coccidioides sp Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Coccidioides sp IgA Ab [Presence] in Serum;Coccidioides IgA Ser Ql;;ACTIVE;2.17;2.56 +46182-2;Coccidioides sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Coccidioides sp IgG Ab [Presence] in Serum;Coccidioides IgG Ser Ql;;ACTIVE;2.17;2.56 +46183-0;Coccidioides sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Coccidioides sp IgM Ab [Presence] in Serum;Coccidioides IgM Ser Ql;;ACTIVE;2.17;2.56 +46184-8;Echinococcus granulosus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echinococcus granulosus Ab [Units/volume] in Serum;E granulosus Ab Ser-aCnc;;ACTIVE;2.17;2.69 +4618-5;Hemoglobin O-Arab;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin O - Arab [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb O-Arab Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46185-5;Ehrlichia risticii Ab;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia risticii Ab [Titer] in Serum;E risticii Ab Titr Ser;;ACTIVE;2.17;2.32 +46186-3;Equine herpesvirus 1 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Equine herpesvirus 1 Ab [Titer] in Cerebral spinal fluid;EHV1 Ab Titr CSF;;ACTIVE;2.17;2.32 +46187-1;Equine herpesvirus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Equine herpesvirus 2 Ab [Titer] in Serum;EHV2 Ab Titr Ser;;ACTIVE;2.17;2.32 +46188-9;Equine herpesvirus 3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Equine herpesvirus 3 Ab [Titer] in Serum;EHV3 Ab Titr Ser;;ACTIVE;2.17;2.32 +46189-7;Goose parvovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Goose parvovirus Ab [Presence] in Serum;GPV Ab Ser Ql;;ACTIVE;2.17;2.56 +46190-5;Herpes simplex virus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Herpes simplex virus Ab [Presence] in Body fluid;HSV Ab Fld Ql;;ACTIVE;2.17;2.56 +46191-3;Histoplasma capsulatum Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum IgG Ab [Presence] in Cerebral spinal fluid;H capsul IgG CSF Ql;;ACTIVE;2.17;2.56 +46192-1;HTLV II Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;HTLV II IgG Ab [Presence] in Serum;HTLV II IgG Ser Ql;;ACTIVE;2.17;2.56 +4619-3;Hemoglobin Ranier;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Ranier [Presence] in Blood;Hgb Ranier Bld Ql;;ACTIVE;1.0;2.56 +46193-9;Infectious bronchitis virus JMK Ab;Titr;Pt;Ser;Qn;;MICRO;1;Infectious bronchitis virus JMK Ab [Titer] in Serum;IBV JMK Ab Titr Ser;;ACTIVE;2.17;2.32 +46194-7;Legionella non pneumophila sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella non-pneumophila Ab [Titer] in Serum;Legionella Non-pneum Ab Titr Ser;;ACTIVE;2.17;2.32 +46195-4;Legionella pneumophila 2+3+4+5+6+8 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 2+3+4+5+6+8 Ab [Titer] in Serum;L pneumo 2+3+4+5+6+8 Ab Titr Ser;;ACTIVE;2.17;2.32 +46196-2;Leptospira interrogans Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira interrogans IgG Ab [Titer] in Serum;L inter IgG Titr Ser;;ACTIVE;2.17;2.32 +46197-0;Measles virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Measles virus Ab [Presence] in Serum;MeV Ab Ser Ql;;ACTIVE;2.17;2.73 +46198-8;Mycoplasma pneumoniae Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Presence] in Serum;M pneumo IgG Ser Ql;;ACTIVE;2.17;2.73 +46199-6;Parainfluenza virus 1 Ab;Titr;Pt;CSF;Qn;;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Cerebral spinal fluid;HPIV1 Ab Titr CSF;;ACTIVE;2.17;2.32 +46200-2;Parainfluenza virus 3 Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Parainfluenza virus 3 Ab [Presence] in Cerebral spinal fluid;HPIV3 Ab CSF Ql;;ACTIVE;2.17;2.56 +4620-1;Hemoglobin S;SFr;Pt;Bld;Qn;;HEM/BC;1;Deprecated Hemoglobin S/Hemoglobin.total in Blood;Deprecated Hgb S Fr Bld;;DEPRECATED;1.0;2.46 +46201-0;Porcine adenovirus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Porcine adenovirus Ab [Presence] in Serum;PAdV Ab Ser Ql;;ACTIVE;2.17;2.56 +46202-8;Psittacid herpesvirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Psittacid herpesvirus 1 Ab [Presence] in Serum;PsHV-1 Ab Ser Ql;;ACTIVE;2.17;2.56 +46203-6;Reagin Ab;Titr;Pt;CSF;Qn;;MICRO;1;Reagin Ab [Titer] in Cerebral spinal fluid;Reagin Ab Titr CSF;;ACTIVE;2.17;2.32 +46204-4;Salmonella typhi O D Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella typhi O D Ab [Titer] in Serum;S Typhi O D Ab Titr Ser;;ACTIVE;2.17;2.32 +46205-1;Streptococcus pneumoniae Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae IgG Ab [Mass/volume] in Serum;S pneum IgG Ser-mCnc;;ACTIVE;2.17;2.34 +46206-9;Treponema pallidum Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;Treponema pallidum Ab [Presence] in Serum from Donor;T pallidum Ab Ser Donr Ql;;ACTIVE;2.17;2.56 +46207-7;PKD1 gene+PKD2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PKD1 gene+PKD2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PKD1+PKD2 gene Mut Anl Bld/T;;ACTIVE;2.17;2.63 +46208-5;Nursing notes;Find;-;^Patient;Doc;;ATTACH.CLINRPT;3;Deprecated Nursing notes;Deprecated;;DEPRECATED;2.17;2.67 +46209-3;Provider orders;Find;-;^Patient;Doc;;DOC.MISC;2;Provider orders;Provider orders;;ACTIVE;2.17;2.73 +46210-1;Note;Find;Pt;{Setting};Doc;Case manager;DOC.ONTOLOGY;2;Case manager Note;Case Manager Note;;ACTIVE;2.17;2.67 +46211-9;Postoperative photo;-;Pt;XXX;-;;ATTACH.CLINRPT;3;Post operative photo;;;ACTIVE;2.17;2.56 +46212-7;Preoperative photo;-;Pt;XXX;-;;ATTACH.CLINRPT;3;Pre operative photo;;;ACTIVE;2.17;2.66 +46213-5;Tilt table study;Find;Pt;Cardiovascular system;Doc;;DOC.MISC;2;Tilt table study;Tilt table study;;ACTIVE;2.17;2.73 +46214-3;Intracardiac ablation study;Find;Pt;Heart;Doc;;CARD.PROC;2;Intracardiac ablation study;Intracardiac ablation study;;ACTIVE;2.17;2.72 +46215-0;Note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Note;Wound care management Note;;ACTIVE;2.17;2.67 +46216-8;Mycobacterium tuberculosis tuberculin stimulated gamma interferon/Mitogen stimulated gamma interferon;ACnc;Pt;Bld^Control;Qn;;MICRO;1;Mycobacterium tuberculosis tuberculin stimulated gamma interferon/Mitogen stimulated gamma interferon [Units/volume] in Control Blood;M TB tuberc IGNF/Mitogen IGNF Control;;ACTIVE;2.19;2.73 +46217-6;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] in Blood;M TB IFN-g CD4+ T-cells Bld-aCnc;;ACTIVE;2.19;2.73 +46218-4;5-Fluorocytosine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;5-Fluorocytosine [Moles/volume] in Serum or Plasma;5-fluorocytosine SerPl-sCnc;;ACTIVE;2.19;2.70 +4621-9;Hemoglobin S;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin S [Presence] in Blood;Hgb S Bld Ql;;ACTIVE;1.0;2.73 +46219-2;Creatinine^4H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Dialysis fluid --4 hour specimen;Creat 4h spec Dial fld-sCnc;;ACTIVE;2.19;2.70 +462-2;Streptomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Streptomycin [Susceptibility] by Serum bactericidal titer;Streptomycin Titr SBT;;ACTIVE;1.0;2.32 +46220-0;Creatinine^overnight;SCnc;Pt;Dial fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Dialysis fluid --overnight;Creat Overnight Dial fld-sCnc;;ACTIVE;2.19;2.70 +46221-8;Glucose^2H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Moles/volume] in Dialysis fluid --2 hour specimen;Glucose 2h spec Dial fld-sCnc;;ACTIVE;2.19;2.70 +46222-6;Glucose^4H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Moles/volume] in Dialysis fluid --4 hour specimen;Glucose 4h spec Dial fld-sCnc;;ACTIVE;2.19;2.70 +46223-4;Glucose^overnight;SCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Moles/volume] in Dialysis fluid --overnight;Glucose Overnight Dial fld-sCnc;;ACTIVE;2.19;2.70 +46224-2;Coagulation thrombin induced^after addition of heparinase;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time in Platelet poor plasma by Coagulation assay --after addition of heparinase;TT P Hpase PPP;;ACTIVE;2.19;2.73 +46225-9;ABCA3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ABCA3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ABCA3 gene Mut Anl Bld/T;;ACTIVE;2.19;2.66 +46226-7;SGCA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SGCA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SGCA gene Mut Anl Bld/T;;ACTIVE;2.19;2.73 +4622-7;Hemoglobin S;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin S [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb S Bld Ql Elph Acid;;ACTIVE;1.0;2.73 +46227-5;DULoxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;DULoxetine [Mass/volume] in Serum or Plasma;DULoxetine SerPl-mCnc;;ACTIVE;2.19;2.73 +46228-3;Clenbuterol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Clenbuterol [Mass/volume] in Urine;Clenbuterol Ur-mCnc;;ACTIVE;2.19;2.42 +46229-1;Furazabol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Furazabol [Mass/volume] in Urine;Furazabol Ur-mCnc;;ACTIVE;2.19;2.34 +46230-9;Methanolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methanolone [Mass/volume] in Urine;Methanolone Ur-mCnc;;ACTIVE;2.19;2.34 +46231-7;Cells.ZAP70/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;ZAP70 cells/100 cells in Tissue;ZAP70 Cells NFr Tiss;;ACTIVE;2.19;2.70 +46232-5;Cells.ZAP70/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;ZAP70 cells/100 cells in Specimen;ZAP70 Cells NFr Spec;;ACTIVE;2.19;2.73 +46233-3;Cells.ZAP70/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;ZAP70 cells/100 cells in Body fluid;ZAP70 Cells NFr Fld;;ACTIVE;2.19;2.70 +46234-1;Cells.ZAP70/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;ZAP70 cells/100 cells in Bone marrow;ZAP70 Cells NFr Mar;;ACTIVE;2.19;2.70 +4623-5;Hemoglobin S;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin S [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb S Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46235-8;Cells.ZAP70/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;ZAP70 cells/100 cells in Blood;ZAP70 Cells NFr Bld;;ACTIVE;2.19;2.70 +46236-6;HLA-B*51;Type;Pt;WBC;Nom;;HLA;1;HLA-B*51 [Type] in Leukocytes;HLA-B*51 WBC;;ACTIVE;2.19;2.19 +46237-4;Lymphocytes.kappa/100 lymphocytes;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Kappa lymphocytes/100 lymphocytes in Bone marrow;Lymphs Kappa/lymph NFr Mar;;ACTIVE;2.19;2.70 +46238-2;Lymphocytes.kappa/100 lymphocytes;NFr;Pt;Body fld;Qn;;CELLMARK;1;Kappa lymphocytes/100 lymphocytes in Body fluid;Lymphs Kappa/lymph NFr Fld;;ACTIVE;2.19;2.70 +46239-0;Chief complaint+Reason for visit;Find;Pt;^Patient;Nar;;H&P.HX;2;Chief complaint+Reason for visit Narrative;Chief complaint+Reason for visit;;ACTIVE;2.19;2.63 +46240-8;Hospitalizations+Outpatient visits;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Hospitalizations+Outpatient visits Narrative;Hx of Hospitalizations+OP visits;;ACTIVE;2.19;2.63 +46241-6;Hospital admission Dx;Imp;Pt;^Patient;Nar;Reported;H&P.HX;2;Hospital admission diagnosis Narrative - Reported;Hospital admission Dx Reported;;ACTIVE;2.19;2.63 +46242-4;Vital signs measurements;Find;Pt;^Fetus;Doc;;H&P.HX;2;Fetal Document Vital signs measurements;Fet Doc Vital signs measurements;;ACTIVE;2.19;2.63 +4624-3;Hemoglobin S;MCnc;Pt;Bld;Ord;;HEM/BC;1;Deprecated Hemoglobin S;Deprecated Hgb S Bld Ql;;DEPRECATED;1.0;2.36 +46243-2;Urea^overnight;SCnc;Pt;Dial fld;Qn;;CHEM;1;Urea [Moles/volume] in Dialysis fluid --overnight;Urea Overnight Dial fld-sCnc;;ACTIVE;2.19;2.70 +46244-0;Mycobacterium tuberculosis complex rpoB gene rifAMPin resistance mutation identified;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Mycobacterium tuberculosis complex rpoB gene rifAMPin resistance mutation identified by Molecular method;MTB cmplx rpoB RIF mut Islt/Spm;;ACTIVE;2.19;2.67 +46245-7;Mycobacterium tuberculosis pncA gene pyrazinamide resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Mycobacterium tuberculosis pncA gene pyrazinamide resistance mutation [Identifier] by Molecular method;MTB pncA pyr res mut Islt/Spm;;ACTIVE;2.19;2.65 +46246-5;Mycobacterium tuberculosis katG gene isoniazid high level resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Mycobacterium tuberculosis katG gene isoniazid high level resistance mutation [Identifier] by Molecular method;M TB katG INH high res mut Islt/Spm;;ACTIVE;2.19;2.65 +46247-3;Mycobacterium tuberculosis embB gene ethambutol resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Mycobacterium tuberculosis embB gene ethambutol resistance mutation [Identifier] by Molecular method;MTB embB etham res mut Islt/Spm;;ACTIVE;2.19;2.65 +46248-1;Borrelia burgdorferi Ab.IgG & IgM;Imp;Pt;Ser;Nom;IA;MICRO;1;Borrelia burgdorferi IgG and IgM [Interpretation] in Serum by Immunoassay;B burgdor IgG+IgM Ser IA-Imp;;ACTIVE;2.19;2.73 +46249-9;Vaccination take-response type;Prid;Pt;^Patient;Nom;;VACCIN;2;Vaccination take-response type;Vaccination take-response type;;ACTIVE;2.19;2.27 +4625-0;Hemoglobin S/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin S/Hemoglobin.total in Blood;Hgb S MFr Bld;;ACTIVE;1.0;2.73 +46250-7;Vaccination take-response date;Date;Pt;^Patient;Qn;;VACCIN;2;Vaccination take-response date;Vaccination take-response date;;ACTIVE;2.19;2.50 +46251-5;Age group;Type;Pt;^Patient;Ord;;CLIN;2;Age group;Age group;;ACTIVE;2.19;2.27 +46252-3;Acylcarnitine pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Acylcarnitine pattern [Interpretation] in Serum or Plasma;Acylcarnitine pattern SerPl-Imp;;ACTIVE;2.19;2.73 +46253-1;Bordetella pertussis.filamentous hemagglutinin Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Bordetella pertussis filamentous hemagglutinin IgG Ab [Units/volume] in Serum by Immunofluorescence;B pert FHA IgG Ser IF-aCnc;;ACTIVE;2.19;2.70 +46254-9;Bordetella pertussis.pertussis toxin Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Bordetella pertussis.pertussis toxin IgG Ab [Units/volume] in Serum by Immunofluorescence;B pert.PT IgG Ser IF-aCnc;;ACTIVE;2.19;2.70 +46255-6;Methyl ethyl ketone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyl ethyl ketone [Mass/volume] in Serum or Plasma;MEK SerPl-mCnc;;ACTIVE;2.19;2.73 +46256-4;oxyCODONE.free;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;oxyCODONE Free [Presence] in Serum or Plasma by Screen method;oxyCODONE Free SerPl Ql Scn;;ACTIVE;2.19;2.56 +46257-2;Dihydrocodeine+Hydrocodol;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Dihydrocodeine+Hydrocodol [Presence] in Serum or Plasma by Screen method;DHC+hydrocodol SerPl Ql Scn;;ACTIVE;2.19;2.56 +46258-0;oxyMORphone.free;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;oxyMORphone Free [Presence] in Serum or Plasma by Screen method;oxyMORphone Free SerPl Ql Scn;;ACTIVE;2.19;2.56 +46259-8;Morphine.free;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Morphine Free [Presence] in Serum or Plasma by Screen method;Morphine Free SerPl Ql Scn;;ACTIVE;2.19;2.56 +46260-6;HYDROmorphone.free;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;HYDROmorphone Free [Presence] in Serum or Plasma by Screen method;HYDROmorphone Free SerPl Ql Scn;;ACTIVE;2.19;2.56 +46261-4;HYDROcodone.free;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;HYDROcodone Free [Presence] in Serum or Plasma;HYDROcodone Free SerPl Ql;;ACTIVE;2.19;2.56 +46262-2;Codeine.free;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Codeine Free [Presence] in Serum or Plasma by Screen method;Codeine Free SerPl Ql Scn;;ACTIVE;2.19;2.56 +46263-0;6-Monoacetylmorphine.free;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;6-monoacetylmorphine free [Presence] in Serum or Plasma;6MAM Free SerPl Ql;;ACTIVE;2.19;2.56 +46264-8;History of medical device use;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;History of medical device use;Hx medical device use;;ACTIVE;2.19;2.67 +46265-5;Cryofibrinogen;PrThr;Pt;Plas;Ord;1W cold incubation;CHEM;1;Cryofibrinogen [Presence] in Plasma by 1 week cold incubation;Cryofib Plas Ql 1W Cold Inc;;ACTIVE;2.19;2.56 +46266-3;Myeloperoxidase Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Myeloperoxidase Ab [Units/volume] in Serum by Immunoassay;Myeloperoxidase Ab Ser IA-aCnc;;ACTIVE;2.19;2.73 +46267-1;Proteinase 3 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Proteinase 3 Ab [Units/volume] in Serum by Immunoassay;Proteinase3 Ab Ser IA-aCnc;;ACTIVE;2.19;2.73 +4626-8;Hemoglobin Yakima;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Yakima [Presence] in Blood;Hgb Yakima Bld Ql;;ACTIVE;1.0;2.56 +46268-9;ABO & Rh group^post transfusion reaction;Type;Pt;Bld^BPU;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood from Blood product unit--after transfusion reaction;ABO + Rh p transf rx Bld BPU;;ACTIVE;2.19;2.73 +46269-7;Ercalcidiol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;25-hydroxyvitamin D2 [Moles/volume] in Serum or Plasma;25(OH)D2 SerPl-sCnc;;ACTIVE;2.19;2.73 +46270-5;ABO group^post transfusion reaction;Type;Pt;Bld;Nom;;BLDBK;1;ABO group [Type] in Blood--after transfusion reaction;ABO Group p transf rx Bld;;ACTIVE;2.19;2.73 +46271-3;Blood group antibody screen^post transfusion reaction;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma --after transfusion reaction;Bld gp Ab Scn p transf rx SerPl Ql;;ACTIVE;2.19;2.73 +46272-1;Appearance^post transfusion reaction;Aper;Pt;Urine;Nom;;SPEC;1;Appearance of Urine--after transfusion reaction;Appearance p transf rx Ur;;ACTIVE;2.19;2.27 +46273-9;Appearance^post transfusion reaction;Aper;Pt;Ser;Nom;;SPEC;1;Appearance of Serum--after transfusion reaction;Appearance p transf rx Ser;;ACTIVE;2.19;2.73 +46274-7;Direct antiglobulin test.polyspecific reagent^post transfusion reaction;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.polyspecific reagent [Presence] on Red Blood Cells --after transfusion reaction;DAT Poly-Sp Reag p transf rx RBC Ql;;ACTIVE;2.19;2.73 +46275-4;Major crossmatch^post transfusion reaction;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;Major crossmatch [Interpretation] --after transfusion reaction;Maj XM p transf rx SerPl-Imp;;ACTIVE;2.19;2.27 +4627-6;Hemoglobin Yoshizuka;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Yoshizuka [Presence] in Blood;Hgb Yoshiz Bld Ql;;ACTIVE;1.0;2.56 +46276-2;Rh^post transfusion reaction;Type;Pt;Bld;Nom;;BLDBK;1;Rh [Type] in Blood--after transfusion reaction;Rh p transf rx Bld;;ACTIVE;2.19;2.27 +46277-0;Rh immune globulin given by;ID;Pt;Provider;Nom;;BLDBK;1;RhoGam given by provider [Identifier];Rh Imm Gl gvn by Provider;;ACTIVE;2.19;2.52 +46278-8;Views for bone density;ArMass;Pt;Lower extremity.left>Hip;Qn;DXA;RAD;2;DXA Hip - left [Mass/Area] Bone density;DXA Hip-L ArMass BMD;;ACTIVE;2.19;2.64 +46279-6;Views for bone density;ArMass;Pt;Lower extremity.right>Hip;Qn;DXA;RAD;2;DXA Hip - right [Mass/Area] Bone density;DXA Hip-R ArMass BMD;;ACTIVE;2.19;2.64 +46280-4;Bone density;MAric;Pt;Radius.right+Ulna.right;Qn;XR.DEXA;RAD;2;Deprecated Radius & Ulna right DEXA Bone density;Deprecated Radius+Ulna-R DEXA BDM;;DEPRECATED;2.19;2.40 +46281-2;Guidance for aspiration or injection of cyst;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for aspiration or injection of cyst of Unspecified body region;CT Guided Cyst asp or Inj;;DISCOURAGED;2.19;2.64 +46282-0;Guidance for aspiration or injection of cyst;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for aspiration or injection of cyst of Unspecified body region;US Guided Cyst asp or Inj;;DISCOURAGED;2.19;2.64 +46283-8;Guidance for percutaneous aspiration.fine needle;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for fine needle aspiration of Breast - right;MG Guided Brst-R FNA;;ACTIVE;2.19;2.64 +4628-4;Hemoglobin Ypsilanti;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin Ypsilanti [Presence] in Blood;Hgb Ypsilan Bld Ql;;ACTIVE;1.0;2.56 +46284-6;Guidance for percutaneous aspiration.fine needle;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for fine needle aspiration of Breast - left;MG Guided Brst-L FNA;;ACTIVE;2.19;2.64 +46285-3;Guidance for biopsy.core needle;Find;Pt;Neck>Thyroid gland;Doc;US;RAD;2;US Guidance for core needle biopsy of Thyroid gland;US Guided Thyroid CN Bx;;ACTIVE;2.19;2.64 +46286-1;Guidance for biopsy.needle;Find;Pt;Breast;Doc;MG;RAD;2;Deprecated MG Guidance for needle biopsy of Breast;Deprecated MG Brst Bx needle guide;;DEPRECATED;2.19;2.63 +46287-9;Guidance for biopsy.needle;Find;Pt;XXX;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Unspecified body region;Deprecated CT XXX Bx needle guide;;DEPRECATED;2.19;2.63 +46288-7;Guidance for biopsy;Find;Pt;Pelvis>Prostate;Doc;US;RAD;2;US Guidance for biopsy of Prostate;US Guided Prostate Bx;;ACTIVE;2.19;2.73 +46289-5;Guidance for percutaneous biopsy^WO & W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for biopsy of Unspecified body region-- WO and W contrast IV;CT Guided Bx--WO+W contr IV;;ACTIVE;2.19;2.64 +46290-3;Guidance for percutaneous biopsy^WO contrast;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for biopsy of Unspecified body region-- WO contrast;CT Guided Bx--WO contr;;ACTIVE;2.19;2.64 +46291-1;Guidance for drainage+placement of drainage catheter^WO & W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Unspecified body region-- WO and W contrast IV;CT Guide Drain+cath place--WO+W contr IV;;ACTIVE;2.19;2.66 +4629-2;Hemoglobin Zurich;PrThr;Pt;Bld;Ord;Electrophoresis pH 6.3;HEM/BC;1;Hemoglobin Zurich [Presence] in Blood by Electrophoresis acid (pH 6.3);Hgb Zurich Bld Ql Elph Acid;;ACTIVE;1.0;2.56 +46292-9;Guidance for drainage+placement of drainage catheter^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Unspecified body region-- W contrast IV;CT Guided Drain+cath place--W contr IV;;ACTIVE;2.19;2.66 +46293-7;Guidance for drainage+placement of drainage catheter^WO contrast;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Unspecified body region-- WO contrast;CT Guided Drain+cath place--WO contr;;ACTIVE;2.19;2.66 +46294-5;Guidance for percutaneous replacement of drainage catheter;Find;Pt;Abdomen>Stomach;Doc;RF;RAD;2;RF Guidance for percutaneous replacement of drainage catheter of Stomach;RF Guided Stom PC drain cath replace;;ACTIVE;2.19;2.68 +46295-2;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast.left;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for percutaneous biopsy.core needle of Breast - left;MG.stereo Guided Brst-L PC Bx CN;;ACTIVE;2.19;2.64 +46296-0;Guidance for percutaneous biopsy.core needle;Find;Pt;Breast;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for percutaneous biopsy.core needle of Breast;MG.stereo Guided Brst PC Bx CN;;ACTIVE;2.19;2.64 +46297-8;Multisection^W radionuclide IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body;SPECT Whole body W RNC IV;;ACTIVE;2.19;2.73 +46298-6;Multisection;Find;Pt;Head>Mastoid.bilateral;Doc;CT;RAD;2;CT Mastoid - bilateral;CT Mastoid-Bl;;ACTIVE;2.19;2.61 +46299-4;Multisection;Find;Pt;Breast.unilateral;Doc;MR;RAD;2;MR Breast - unilateral;MR Brst-Ul;;ACTIVE;2.19;2.61 +46-3;Aztreonam;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Aztreonam [Susceptibility] by Serum bactericidal titer;Aztreonam Titr SBT;;ACTIVE;1.0;2.32 +463-0;sulfADIAZINE;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;sulfADIAZINE [Susceptibility] by Minimum lethal concentration (MLC);sulfADIAZINE Islt MLC;;ACTIVE;1.0;2.19 +4630-0;Hemoglobin Zurich;PrThr;Pt;Bld;Ord;Electrophoresis pH 8.9;HEM/BC;1;Hemoglobin Zurich [Presence] in Blood by Electrophoresis alkaline (pH 8.9);Hgb Zurich Bld Ql Elph Alk;;ACTIVE;1.0;2.56 +46300-0;Multisection coronal;Find;Pt;Sinuses;Doc;CT;RAD;2;Deprecated Sinuses CT coronal;Deprecated Sinuses CT Coronal;;DEPRECATED;2.19;2.58 +46301-8;Multisection limited;Find;Pt;Extremity.bilateral>Extremity vein;Doc;US.doppler;RAD;2;US.doppler Extremity vein - bilateral limited;DOP Extr v-Bl Ltd;;ACTIVE;2.19;2.61 +46302-6;Multisection limited;Find;Pt;Upper extremity.bilateral>Upper extremity artery;Doc;US.doppler;RAD;2;US.doppler Upper extremity artery - bilateral limited;DOP UE a-Bl Ltd;;ACTIVE;2.19;2.61 +46303-4;Multisection limited;Find;Pt;Upper extremity>Upper extremity vessels;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessels limited;DOP UE ves Ltd;;ACTIVE;2.19;2.61 +46304-2;Multisection limited^WO contrast;Find;Pt;Head>Sinuses;Doc;CT;RAD;2;CT Sinuses limited WO contrast;CT Sinuses Ltd WO contr;;ACTIVE;2.19;2.61 +46305-9;Multisection;Find;Pt;Whole body;Doc;CT;RAD;2;CT Whole body;CT Whole body;;ACTIVE;2.19;2.73 +46306-7;Multisection^W contrast IV;Find;Pt;Whole body;Doc;CT;RAD;2;CT Whole body W contrast IV;CT Whole body W contr IV;;ACTIVE;2.19;2.61 +46307-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - right WO and W contrast IV;CTA LE ves-R WO+W contr IV;;ACTIVE;2.19;2.61 +46308-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - left WO and W contrast IV;CTA LE ves-L WO+W contr IV;;ACTIVE;2.19;2.61 +46309-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - right WO and W contrast IV;CTA UE ves-R WO+W contr IV;;ACTIVE;2.19;2.61 +46310-9;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit+Face & Neck;Doc;MR;RAD;2;MR Orbit and Face and Neck WO and W contrast IV;MR Orbit+Face+Neck WO+W contr IV;;ACTIVE;2.19;2.61 +46311-7;Multisection^WO & W contrast IV;Find;Pt;Neck>Parotid gland;Doc;CT;RAD;2;CT Parotid gland WO and W contrast IV;CT Parotid gland WO+W contr IV;;ACTIVE;2.19;2.61 +46312-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - left WO and W contrast IV;CTA UE ves-L WO+W contr IV;;ACTIVE;2.19;2.61 +46313-3;Multisection^WO & W reduced contrast volume IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis WO and W reduced contrast volume IV;CT Pelvis WO+W red contr vol IV;;ACTIVE;2.19;2.61 +46314-1;Multisection^WO & W reduced contrast volume IV;Find;Pt;Head>Internal auditory canal;Doc;CT;RAD;2;CT Internal auditory canal WO and W reduced contrast volume IV;CT IAC WO+W red contr vol IV;;ACTIVE;2.19;2.61 +46315-8;Multisection^WO & W reduced contrast volume IV;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region WO and W reduced contrast volume IV;CT Maxillofacial WO+W red contr vol IV;;ACTIVE;2.19;2.61 +46316-6;Multisection^WO & W reduced contrast volume IV;Find;Pt;Head;Doc;CT;RAD;2;CT Head WO and W reduced contrast volume IV;CT Head WO+W red contr vol IV;;ACTIVE;2.19;2.61 +46317-4;Multisection^WO & W reduced contrast volume IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest WO and W reduced contrast volume IV;CT Chest WO+W red contr vol IV;;ACTIVE;2.19;2.61 +4631-8;Hemoglobin F;PrThr;Pt;Stool;Ord;Apt-Downey;HEM/BC;1;Hemoglobin F [Presence] in Stool by Apt-Downey method;Hgb F Stl Ql Apt-Downey;;ACTIVE;1.0;2.73 +46318-2;Multisection^WO & W reduced contrast volume IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen WO and W reduced contrast volume IV;CT Abd WO+W red contr vol IV;;ACTIVE;2.19;2.61 +46319-0;Multisection^W contrast IS;Find;Pt;Upper extremity>Elbow;Doc;MR;RAD;2;MR Elbow Arthrogram;MR Elbow W contr IS;;ACTIVE;2.19;2.61 +46320-8;Multisection^W contrast IV;Find;Pt;Head>Orbit+Face;Doc;CT;RAD;2;CT Orbit and Face W contrast IV;CT Orbit+Face W contr IV;;ACTIVE;2.19;2.61 +46321-6;Multisection^W contrast IV;Find;Pt;Head>Orbit+Face & Neck;Doc;MR;RAD;2;MR Orbit and Face and Neck W contrast IV;MR Orbit+Face+Neck W contr IV;;ACTIVE;2.19;2.61 +46322-4;Multisection^W contrast IV;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Kidney W contrast IV;CT Kidney W contr IV;;ACTIVE;2.19;2.61 +46323-2;Multisection^W contrast IV;Find;Pt;Breast.unilateral;Doc;MR;RAD;2;MR Breast - unilateral W contrast IV;MR Brst-Ul W contr IV;;ACTIVE;2.19;2.61 +46324-0;Multisection^W contrast IV;Find;Pt;Lower extremity>Lower extremity vessels;Doc;MR.angio;RAD;2;MRA Lower extremity vessels W contrast IV;MRA LE ves W contr IV;;ACTIVE;2.19;2.61 +46325-7;Multisection^W reduced contrast volume IV;Find;Pt;Head>Internal auditory canal;Doc;CT;RAD;2;CT Internal auditory canal W reduced contrast volume IV;CT IAC W red contr vol IV;;ACTIVE;2.19;2.61 +4632-6;Hemoglobin F;PrThr;Pt;Bld;Ord;Alkali denat;HEM/BC;1;Hemoglobin F [Presence] in Blood by Alkali denaturation;Hgb F Bld Ql Alk Denat;;ACTIVE;1.0;2.73 +46326-5;Multisection^W reduced contrast volume IV;Find;Pt;Head>Maxillofacial region;Doc;CT;RAD;2;CT Maxillofacial region W reduced contrast volume IV;CT Maxillofacial W red contr vol IV;;ACTIVE;2.19;2.61 +46327-3;Multisection^W reduced contrast volume IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest W reduced contrast volume IV;CT Chest W red contr vol IV;;ACTIVE;2.19;2.61 +46328-1;Multisection^W reduced contrast volume IV;Find;Pt;Head;Doc;CT;RAD;2;CT Head W reduced contrast volume IV;CT Head W red contr vol IV;;ACTIVE;2.19;2.61 +46329-9;Multisection^W reduced contrast volume IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis W reduced contrast volume IV;CT Pelvis W red contr vol IV;;ACTIVE;2.19;2.61 +46330-7;Multisection^W reduced contrast volume IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen W reduced contrast volume IV;CT Abd W red contr vol IV;;ACTIVE;2.19;2.61 +46331-5;Multisection^WO contrast;Find;Pt;Head>Orbit;Doc;CT;RAD;2;CT Orbit WO contrast;CT Orbit WO contr;;ACTIVE;2.19;2.61 +46332-3;Multisection^WO contrast;Find;Pt;Head>Orbit+Face & Neck;Doc;MR;RAD;2;MR Orbit and Face and Neck WO contrast;MR Orbit+Face+Neck WO contr;;ACTIVE;2.19;2.61 +46333-1;Multisection^WO contrast;Find;Pt;Breast.unilateral;Doc;MR;RAD;2;MR Breast - unilateral WO contrast;MR Brst-Ul WO contr;;ACTIVE;2.19;2.61 +4633-4;Hemoglobin F/Hemoglobin.total;MFr;Pt;Bld;Qn;Kleihauer-Betke;HEM/BC;1;Hemoglobin F/Hemoglobin.total in Blood by Kleihauer-Betke method;Hgb F MFr Bld Kleih Betke;;ACTIVE;1.0;2.73 +46334-9;Guidance for stone removal^W contrast intra biliary duct;Find;Pt;Biliary duct.common;Nar;XR;RAD;2;Deprecated X-ray Guidance for stone removal of Biliary duct common-- W contrast intra biliary duct;Deprecated CBD XR Stone rem guid W contr;;DEPRECATED;2.19;2.36 +46335-6;View;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Single view;MG Brst-Bl 1V;;ACTIVE;2.19;2.64 +46336-4;View;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Single view;MG Brst-L 1V;;ACTIVE;2.19;2.64 +46337-2;View;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Single view;MG Brst-R 1V;;ACTIVE;2.19;2.64 +46338-0;View;Find;Pt;Breast.unilateral;Doc;MG;RAD;2;MG Breast - unilateral Single view;MG Brst-Ul 1V;;ACTIVE;2.19;2.64 +46339-8;Views;Find;Pt;Breast.unilateral;Doc;MG;RAD;2;MG Breast - unilateral Views;MG Brst-Ul Views;;ACTIVE;2.19;2.64 +46340-6;Views;Find;Pt;Abdomen+Pelvis>Spine.lumbosacral junction;Doc;XR;RAD;2;XR Spine lumbosacral junction Views;XR LSJ Views;;ACTIVE;2.19;2.64 +46341-4;Views;Find;Pt;Abdomen;Doc;RF;RAD;2;RF Abdomen Views;RF Abd Views;;ACTIVE;2.19;2.64 +4634-2;Hemoglobin.fetal;ACnc;Pt;RBC;Nom;Kleihauer-Betke;HEM/BC;1;Deprecated Hemoglobin F/Hemoglobin.total in Blood by Kleihauer-Betke method;Deprecated HgB RBC Kleih Betke;;DEPRECATED;1.0;2.36 +46342-2;Views;Find;Pt;Breast;Doc;MG.FFD;RAD;2;FFD mammogram Breast Views;FFDM Brst Views;;DISCOURAGED;2.19;2.64 +46343-0;Views GE 3;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right GE 3 Views;XR Wrist-R GE 3V;;ACTIVE;2.19;2.61 +46344-8;Views GE 3;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left GE 3 Views;XR Elbow-L GE 3V;;ACTIVE;2.19;2.61 +46345-5;Views GE 3;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right GE 3 Views;XR Elbow-R GE 3V;;ACTIVE;2.19;2.61 +46346-3;Views GE 3;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left GE 3 Views;XR Wrist-L GE 3V;;ACTIVE;2.19;2.61 +46347-1;Views GE 3;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right GE 3 Views;XR Ankle-R GE 3V;;ACTIVE;2.19;2.61 +46348-9;Views GE 2 + PA + lateral;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest GE 2 and PA and Lateral;XR Chest GE 2+PA+Lat;;ACTIVE;2.19;2.64 +46349-7;Views AP + transthoracic;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;XR;RAD;2;XR Shoulder - bilateral AP and Transthoracic;XR Shoulder-Bl AP+Transthoracic;;ACTIVE;2.19;2.61 +46350-5;Views diagnostic;Find;Pt;Breast.unilateral;Doc;MG;RAD;2;MG Breast - unilateral Diagnostic;MG Brst-Ul Dx;;ACTIVE;2.19;2.73 +46351-3;Views displacement for implant;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Displacement Views for Implant;MG Brst-Bl Vs displacement for implant;;ACTIVE;2.19;2.64 +46352-1;Views^during surgery W contrast intra duct;Find;Pt;Breast>Breast duct;Doc;MG;RAD;2;MG Breast duct Views during surgery W contrast intra duct;MG Brst duct Vs in Surg W cont intra Dct;;ACTIVE;2.19;2.64 +46353-9;Views PA & lateral & oblique;Find;Pt;Chest;Nar;XR;RAD;2;Deprecated Chest X-ray PA & lateral & oblique;Deprecated Chest XR PA+Lat+Obl;;DEPRECATED;2.19;2.36 +46354-7;Views screening;Find;Pt;Breast.right;Doc;MG.FFD;RAD;2;FFD mammogram Breast - right Screening;FFDM Brst-R screening;;DISCOURAGED;2.19;2.61 +46355-4;Views screening;Find;Pt;Breast.left;Doc;MG.FFD;RAD;2;FFD mammogram Breast - left Screening;FFDM Brst-L screening;;DISCOURAGED;2.19;2.61 +46356-2;Views screening;Find;Pt;Breast.unilateral;Doc;MG;RAD;2;MG Breast - unilateral Screening;MG Brst-Ul screening;;ACTIVE;2.19;2.61 +46357-0;Views^W air contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Views W air contrast PR;RF Colon Views W Air contr PR;;ACTIVE;2.19;2.64 +46358-8;Multisection;Find;Pt;Whole body;Doc;MR;RAD;2;MR Whole body;MR Whole body;;ACTIVE;2.19;2.61 +4635-9;Hemoglobin.free;MCnc;Pt;Ser;Qn;;HEM/BC;1;Free Hemoglobin [Mass/volume] in Serum;Hgb Free Ser-mCnc;;ACTIVE;1.0;2.73 +46359-6;Multisection;Find;Pt;Abdomen>Superior mesenteric vessels;Doc;MR.angio;RAD;2;MRA Superior mesenteric vessels;MRA SM ves;;ACTIVE;2.19;2.61 +46360-4;Multisection^WO & W contrast IV;Find;Pt;Chest>Aortic arch;Doc;MR.angio;RAD;2;MRA Aortic arch WO and W contrast IV;MRA Ao arch WO+W contr IV;;ACTIVE;2.19;2.61 +46361-2;Views ventilation^W Xe-133 IH;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Ventilation W Xe-133 IH;NM Lung V W 133Xe IH;;ACTIVE;2.19;2.61 +46362-0;Multisection;Find;Pt;Lower extremity>Foot vessels;Doc;US.doppler;RAD;2;US.doppler Foot vessels;DOP Ft ves;;ACTIVE;2.19;2.61 +46363-8;Multisection;Find;Pt;Lower extremity>Lower extremity vein;Doc;US;RAD;2;US Lower extremity vein;US LE v;;ACTIVE;2.19;2.61 +46364-6;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity vein;Doc;US;RAD;2;US Lower extremity vein - bilateral;US LE v-Bl;;ACTIVE;2.19;2.73 +46365-3;Guidance for ablation of tissue;Find;Pt;Abdomen>Celiac plexus;Doc;CT;RAD;2;CT Guidance for ablation of tissue of Celiac plexus;CT Guided Celiac plexus Ablation;;ACTIVE;2.19;2.64 +46366-1;Guidance for percutaneous biopsy^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM.SPECT;RAD;2;SPECT guidance for percutaneous biopsy of Bone;SPECT Bone PC Bx W RNC IV;;ACTIVE;2.19;2.63 +4636-7;Hemoglobin.free;MCnc;Pt;Urine;Qn;;HEM/BC;1;Free Hemoglobin [Mass/volume] in Urine;Hgb Free Ur-mCnc;;ACTIVE;1.0;2.73 +46367-9;Guidance for biopsy.needle;Find;Pt;Abdomen>Adrenal gland;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Adrenal gland;Deprecated CT Adrenal Bx needle guide;;DEPRECATED;2.19;2.63 +46368-7;Guidance for biopsy.needle;Find;Pt;Breast;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Breast;Deprecated CT Brst Bx needle guide;;DEPRECATED;2.19;2.63 +46369-5;Guidance for biopsy;Find;Pt;Pelvis>Ovary;Doc;US;RAD;2;US Guidance for biopsy of Ovary;US Guided Ovary Bx;;ACTIVE;2.19;2.64 +46370-3;Guidance for biopsy;Find;Pt;Pelvis;Doc;US;RAD;2;US Guidance for biopsy of Pelvis;US Guided Pelvis Bx;;ACTIVE;2.19;2.64 +46371-1;Guidance for change of percutaneous tube^W contrast;Find;Pt;XXX;Doc;XR;RAD;2;XR Guidance for change of percutaneous tube in Unspecified body region-- W contrast;XR Guided PC tube change--W contr;;ACTIVE;2.19;2.64 +46372-9;Guidance for percutaneous drainage+placement of drainage catheter;Find;Pt;Abdomen>Biliary ducts;Doc;RF;RAD;2;RF Guidance for percutaneous drainage and placement of drainage catheter of Biliary ducts;RF Guided BDs PC drn+cath place;;ACTIVE;2.19;2.66 +46373-7;Guidance for placement of tube^W radionuclide IV;Find;Pt;Chest;Doc;NM.SPECT;RAD;2;SPECT Guidance for placement of tube in Chest;SPECT Guided Chest Tube place--W RNC IV;;ACTIVE;2.19;2.64 +46374-5;Multisection;Find;Pt;Head>Cerebral arteries;Doc;US;RAD;2;US Cerebral arteries;US Cerebral aa;;ACTIVE;2.19;2.73 +4637-5;Hemoglobin.glycated;-;Pt;Bld;Qn;;HEM/BC;1;Deprecated Hemoglobin A1/Hemoglobin.total in Blood;Deprecated Hgb.glycated Bld Qn;;DEPRECATED;1.0;2.66 +46375-2;Multisection;Find;Pt;XXX>Artery;Doc;US;RAD;2;US Artery;US Artery;;ACTIVE;2.19;2.61 +46376-0;Views^W contrast antegrade;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Kidney - bilateral Views W contrast antegrade;RF Kdny-Bl Views W contr Ante;;ACTIVE;2.19;2.64 +46377-8;Views GE 3;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull GE 3 Views;XR Skull GE 3V;;ACTIVE;2.19;2.61 +46378-6;Views PA^W standing + W flexion;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral PA Views W standing and W flexion;XR Knee-Bl Views PA W stand+W flx;;ACTIVE;2.19;2.64 +46379-4;Multisection;Find;Pt;Upper extremity.bilateral>Upper extremity vessels;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessels - bilateral;DOP UE ves-Bl;;ACTIVE;2.19;2.61 +46380-2;Views for implant;Find;Pt;Breast.unilateral;Doc;MG;RAD;2;MG Breast - unilateral Views for implant;MG Brst-Ul Views for implant;;ACTIVE;2.19;2.64 +46381-0;Views;Find;Pt;Upper extremity>Elbow+Radius+Ulna;Doc;XR;RAD;2;XR Elbow and Radius and Ulna Views;XR Elbow+Radius+Ulna Views;;ACTIVE;2.19;2.64 +46382-8;Multisection;Find;Pt;Upper extremity>Hand vessels;Doc;US.doppler;RAD;2;US.doppler Hand vessels;DOP Hand ves;;ACTIVE;2.19;2.61 +4638-3;Hemoglobin.thermolabile/Hemoglobin.total;MFr;Pt;RBC;Qn;;HEM/BC;1;Thermolabile hemoglobin/Hemoglobin.total in Red Blood Cells;Hgb TL MFr RBC;;ACTIVE;1.0;2.70 +46383-6;Views for bone density;ArMass;Pt;XXX>Bone;Qn;DXA;RAD;2;DXA Bone [Mass/Area] Bone density;DXA Bone ArMass BMD;;ACTIVE;2.19;2.73 +46384-4;Guidance for superficial biopsy^W radionuclide IV;Find;Pt;XXX>Bone;Doc;NM.SPECT;RAD;2;SPECT Guidance for superficial biopsy of Bone;SPECT Guided Bone Super Bx--W RNC IV;;ACTIVE;2.19;2.64 +46385-1;Multisection for graft;Find;Pt;Upper extremity>Upper extremity vessel;Doc;US.doppler;RAD;2;US.doppler Upper extremity vessel for graft;DOP UE ves for graft;;ACTIVE;2.19;2.61 +46386-9;Views bitewing;Find;Pt;Head>Teeth;Doc;XR;RAD;2;XR Teeth Bitewing Views;XR Teeth Views bitewing;;ACTIVE;2.19;2.64 +46387-7;Guidance for percutaneous aspiration.fine needle;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for fine needle aspiration of Breast;MG Guided Brst FNA;;ACTIVE;2.19;2.64 +46388-5;Multisection;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;US.doppler;RAD;2;US.doppler Thoracic and abdominal aorta;DOP TA + AA;;ACTIVE;2.19;2.61 +46389-3;Views + radial head capitellar;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral Views and Radial head capitellar;XR Elbow-Bl Views+Radial head capitellar;;ACTIVE;2.19;2.64 +46390-1;Views GE 3;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left GE 3 Views;XR Ankle-L GE 3V;;ACTIVE;2.19;2.61 +4639-1;Hemoglobin.unstable;PrThr;Pt;RBC;Ord;;HEM/BC;1;Unstable Hemoglobin [Presence] in Red Blood Cells;Hgb Unstab RBC Ql;;ACTIVE;1.0;2.73 +46391-9;Views;Find;Pt;Upper extremity>Shoulder;Doc;XR.portable;RAD;2;Portable XR Shoulder Views;XR port Should Views;;ACTIVE;2.19;2.73 +46392-7;Guidance for injection;Find;Pt;Head>Sinuses;Doc;RF;RAD;2;RF Guidance for injection of Sinuses;RF Guided Sinuses Inj;;ACTIVE;2.19;2.64 +46393-5;Multisection^W Xe-133 IH;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Liver W Xe-133 IH;CT Liver W 133Xe IH;;ACTIVE;2.19;2.61 +46394-3;Multisection dynamic^W contrast IV;Find;Pt;Head;Doc;CT;RAD;2;Deprecated Head CT dynamic W contrast IV;Deprecated Head CT Dyn W contr IV;;DEPRECATED;2.19;2.58 +46395-0;Multisection gated+ejection fraction^at rest+W stress+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart gated and ejection fraction at rest and W stress and W radionuclide IV;SPECT Hrt Gated+EF Rest+stress+W RNC IV;;ACTIVE;2.19;2.61 +46396-8;Multisection gated^at rest+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart gated at rest and W Tc-99m Sestamibi IV;SPECT Hrt Gated Rest+W Tc99mMIBI IV;;ACTIVE;2.19;2.61 +46397-6;Cortisol^15M post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --15 minutes post 1 ug/kg CRH IV;Cortis 15M p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.19;2.40 +46398-4;Cortisol^1.5H post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1.5 hours post 1 ug/kg CRH IV;Cortis 1.5h p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.19;2.40 +46399-2;Cortisol^2H post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2 hours post 1 ug/kg CRH IV;Cortis 2h p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.19;2.40 +46400-8;Corticotropin^15M post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --15 minutes post 1 ug/kg CRH IV;ACTH 15M p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.19;2.40 +46401-6;Corticotropin^1.5H post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1.5 hours post 1 ug/kg CRH IV;ACTH 1.5h p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.19;2.40 +46402-4;Corticotropin^2H post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2 hours post 1 ug/kg CRH IV;ACTH 2h p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.19;2.40 +46403-2;Cortisol^2H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2 hours post dose insulin IV;Cortis 2h p Ins IV SerPl-mCnc;;ACTIVE;2.19;2.40 +46404-0;Somatotropin^2H post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose insulin IV;GH 2h p Ins IV SerPl-mCnc;;ACTIVE;2.19;2.40 +46405-7;Somatotropin^30M pre 1 g/kg glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes pre 1 g/kg glucose PO;GH 30M pre 1 g/kg Glc PO SerPl-mCnc;;ACTIVE;2.19;2.40 +46406-5;Somatotropin^30M post 1 g/kg glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post 1 g/kg glucose PO;GH 30M p 1 g/kg Glc PO SerPl-mCnc;;ACTIVE;2.19;2.40 +46407-3;Somatotropin^1.5H post 1 g/kg glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post 1 g/kg glucose PO;GH 1.5h p 1 g/kg Glc PO SerPl-mCnc;;ACTIVE;2.19;2.40 +46408-1;Somatotropin^15M pre dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15 minutes pre dose arginine;GH 15M pre arg SerPl-mCnc;;ACTIVE;2.19;2.40 +4640-9;Hemolysin.cold;MCnc;Pt;Plas;Qn;;HEM/BC;1;Hemolysin cold [Mass/volume] in Plasma;Hemolysin Cold Plas-mCnc;;ACTIVE;1.0;2.34 +46409-9;Somatotropin^15M post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15 minutes post dose arginine;GH 15M p Arg SerPl-mCnc;;ACTIVE;2.19;2.40 +46410-7;Somatotropin^30M post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose arginine;GH 30M p Arg SerPl-mCnc;;ACTIVE;2.19;2.73 +46411-5;Somatotropin^45M post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --45 minutes post dose arginine;GH 45M p Arg SerPl-mCnc;;ACTIVE;2.19;2.40 +46412-3;Somatotropin^105M post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --105 minutes post dose arginine;GH 105M p Arg SerPl-mCnc;;ACTIVE;2.19;2.58 +46413-1;Calcitonin^7M post 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --7 minutes post 0.5 ug/kg pentagastrin IV;Calcit 7M p 0.5 ug/kg Pg IV SerPl-mCnc;;ACTIVE;2.19;2.34 +46414-9;Lutropin^15M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --15 minutes post dose gonadotropin releasing hormone;LH 15M p GnRH SerPl-aCnc;;ACTIVE;2.19;2.68 +46415-6;Lutropin^45M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --45 minutes post dose gonadotropin releasing hormone;LH 45M p GnRH SerPl-aCnc;;ACTIVE;2.19;2.68 +46416-4;Cortisol^8H post 8 mg dexamethasone PO overnight high dose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 hours post 8 mg dexamethasone PO overnight high dose;Cortis 8h p 8 mg Dex SerPl-mCnc;;ACTIVE;2.19;2.40 +4641-7;Hemolysin.warm;MCnc;Pt;Plas;Qn;;HEM/BC;1;Hemolysin warm [Mass/volume] in Plasma;Hemolysin Warm Plas-mCnc;;ACTIVE;1.0;2.34 +46417-2;Coagulation tissue factor induced;Time;Pt;BldC;Qn;Coag;COAG;1;Prothrombin time (PT) in Capillary blood by Coagulation assay;PT BldC;;ACTIVE;2.19;2.73 +46418-0;Coagulation tissue factor induced.INR;RelTime;Pt;BldC;Qn;Coag;COAG;1;INR in Capillary blood by Coagulation assay;INR BldC;;ACTIVE;2.19;2.73 +46419-8;Erythrocytes;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Erythrocytes [#/area] in Urine sediment by Automated count;RBC #/area UrnS Auto;;ACTIVE;2.19;2.73 +46420-6;Leukocyte clumps;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Leukocyte clumps [#/area] in Urine sediment by Microscopy high power field;WBC clumps #/area UrnS HPF;;ACTIVE;2.19;2.73 +46421-4;Mucus;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Mucus [#/area] in Urine sediment by Microscopy high power field;Mucous Threads #/area UrnS HPF;;ACTIVE;2.19;2.73 +46422-2;Trichomonas vaginalis;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Trichomonas vaginalis [#/area] in Urine sediment by Microscopy high power field;T vaginalis #/area UrnS HPF;;ACTIVE;2.19;2.73 +46423-0;Hemoglobin distribution width;MCnc;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin distribution width [Mass/volume] in Blood;HDW Bld-mCnc;;ACTIVE;2.19;2.70 +46424-8;Hemolysis interference index;ACnc;Pt;Ser/Plas;Qn;;SPEC;1;Hemolysis interference index of Serum or Plasma;Hemolysis interf index SerPl-aCnc;;ACTIVE;2.19;2.73 +4642-5;Hemopexin;MCnc;Pt;Ser;Qn;;HEM/BC;1;Deprecated Hemopexin [Mass/volume] in Serum;Deprecated Hemopexin Ser-mCnc;;DEPRECATED;1.0;2.36 +46425-5;Lipemic interference index;ACnc;Pt;Ser/Plas;Qn;;SPEC;1;Lipemic interference index of Serum or Plasma;Lipemic interf index SerPl-aCnc;;ACTIVE;2.19;2.73 +46426-3;Icteric interference index;ACnc;Pt;Ser/Plas;Qn;;SPEC;1;Icteric interference index of Serum or Plasma;Icteric interf index SerPl-aCnc;;ACTIVE;2.19;2.73 +46427-1;Beta fructofuranosidase;CCnt;Pt;Tiss;Qn;;CHEM;1;Beta fructofuranosidase [Enzymatic activity/mass] in Tissue;B-Fructofuranosidase Tiss-cCnt;;ACTIVE;2.19;2.42 +46428-9;Xylose^15M post 25 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --15 minutes post 25 g xylose PO;Xylose 15M p 25 g Xyl PO SerPl-mCnc;;ACTIVE;2.19;2.40 +46429-7;Alpha 1 antitrypsin;MCnt;24H;Stool;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/mass] in 24 hour Stool;A1AT 24h Stl-mCnt;;ACTIVE;2.19;2.73 +46430-5;Alpha 1 antitrypsin;MCnt;48H;Stool;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/mass] in 48 hour Stool;A1AT 48h Stl-mCnt;;ACTIVE;2.19;2.42 +46431-3;Alpha 1 antitrypsin;MCnt;72H;Stool;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/mass] in 72 hour Stool;A1AT 72h Stl-mCnt;;ACTIVE;2.19;2.42 +46432-1;Hydrogen/Expired gas^post 50 g lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post 50 g lactose PO;Breath H2 p 50 g Lact PO;;ACTIVE;2.19;2.42 +4643-3;Hemosiderin;MCnc;Pt;Ser;Qn;;HEM/BC;1;Hemosiderin [Mass/volume] in Serum;Hemosiderin Ser-mCnc;;ACTIVE;1.0;2.34 +46433-9;Hydrogen/Expired gas^post 10 g lactulose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post 10 g lactulose PO;Breath H2 p 10 g Lactulose PO;;ACTIVE;2.19;2.42 +46434-7;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(9;22)(ABL1,BCR)/control Bld/T";;ACTIVE;2.19;2.73 +46435-4;Rheumatoid factor & Cyclic citrullinated peptide Ab.IgG;Imp;Pt;Ser;Nom;;SERO;1;Rheumatoid factor and Cyclic citrullinated peptide IgG Ab [Interpretation] in Serum;RF+cCP IgG Ser-Imp;;ACTIVE;2.19;2.38 +46436-2;Histamine;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Histamine [Moles/volume] in Blood;Histamine Bld-sCnc;;ACTIVE;2.19;2.73 +46437-0;Rheumatoid factor & Cyclic citrullinated peptide Ab.IgG panel;ACnc;Pt;Ser;Qn;;PANEL.SERO;1;Rheumatoid Factor and Cyclic Citrullinated Peptide IgG panel [Units/volume] - Serum;RF + cCP IgG Pnl Ser-aCnc;;ACTIVE;2.19;2.73 +46438-8;Cancer identification section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Cancer identification section Set NAACCR v.11;Cancer ID section NAACCR v.11;;ACTIVE;2.19;2.61 +46439-6;Demographic section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Demographic section Set NAACCR v.11;Demographic section NAACCR v.11;;ACTIVE;2.19;2.61 +46440-4;Edit overrides &or Conversion history &or System admin section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Edit overrides/Conversion history/System admin section Set NAACCR v.11;Edit ovrds/Conv Hx/Sys admin NAACCR v.11;;ACTIVE;2.19;2.61 +4644-1;Hemosiderin;PrThr;Pt;Urine;Ord;;HEM/BC;1;Hemosiderin [Presence] in Urine;Hemosiderin Ur Ql;;ACTIVE;1.0;2.73 +46441-2;Follow-up &or Recurrence &or Death section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Follow-up/Recurrence/Death section Set NAACCR v.11;Follow-up/Recur/Death sec NAACCR v.11;;ACTIVE;2.19;2.61 +46442-0;Hospital-confidential section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Hospital-confidential section Set NAACCR v.11;Hosp-confidential section NAACCR v.11;;ACTIVE;2.19;2.61 +46443-8;Hospital-specific section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Hospital-specific section Set NAACCR v.11;Hosp-specific section NAACCR v.11;;ACTIVE;2.19;2.61 +46444-6;Other-confidential section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Other-confidential section Set NAACCR v.11;Other-confidential sec NAACCR v.11;;ACTIVE;2.19;2.61 +46445-3;Patient-confidential section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Patient-confidential section Set NAACCR v.11;Patient-confidential section NAACCR v.11;;ACTIVE;2.19;2.61 +46446-1;Record ID section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Record ID section Set NAACCR v.11;Record ID section NAACCR v.11;;ACTIVE;2.19;2.61 +46447-9;Special use section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Special use section Set NAACCR v.11;Special use section NAACCR v.11;;ACTIVE;2.19;2.61 +46448-7;Stage &or prognostic factors section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Stage/prognostic factors section Set NAACCR v.11;Stage/prognost fact section NAACCR v.11;;ACTIVE;2.19;2.61 +46449-5;Text-diagnosis section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Text-diagnosis section Set NAACCR v.11;Text-Dx section NAACCR v.11;;ACTIVE;2.19;2.61 +46450-3;Text-miscellaneous section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Text-miscellaneous section Set NAACCR v.11;Text-miscellaneous section NAACCR v.11;;ACTIVE;2.19;2.73 +46451-1;Text-treatment section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Text-treatment section Set NAACCR v.11;Text-Tx section NAACCR v.11;;ACTIVE;2.19;2.61 +46452-9;Treatment-1st course section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Treatment-1st course section Set NAACCR v.11;Tx-1st course section NAACCR v.11;;ACTIVE;2.19;2.61 +46453-7;Treatment-subsequent & other section;-;Pt;^Patient;Set;NAACCR v.11;PANEL.TUMRRGT;2;Treatment-subsequent and other section Set NAACCR v.11;Tx-subseq + other section NAACCR v.11;;ACTIVE;2.19;2.61 +46454-5;Shigella sp;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Shigella sp [Presence] in Specimen by Organism specific culture;Shigella Spec Ql Cult;;ACTIVE;2.19;2.69 +46455-2;Shigella sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Shigella sp DNA [Presence] in Specimen by NAA with probe detection;Shigella DNA Spec Ql NAA+probe;;ACTIVE;2.19;2.73 +46456-0;CMS certification number;ID;Pt;Agency;Nom;OASIS;SURVEY.OASIS;4;CMS certification number (CCN) Agency [OASIS];;;ACTIVE;2.19;2.61 +46457-8;Inpatient discharge facility;Type;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Inpatient discharge facility [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +4645-8;Hemosiderin;MCnc;Pt;Urine;Qn;;HEM/BC;1;Hemosiderin [Mass/volume] in Urine;Hemosiderin Ur-mCnc;;ACTIVE;1.0;2.73 +46458-6;Inpatient facililty diagnoses;-;Pt;^Patient;-;;SURVEY.OASIS;4;Inpatient facililty diagnoses;;;ACTIVE;2.19;2.61 +46459-4;Changed medical regimen diagnoses;-;Pt;^Patient;-;;SURVEY.OASIS;4;Changed medical regimen diagnoses;;;ACTIVE;2.19;2.61 +46460-2;Number of pressure injuries at each stage;-;Pt;^Patient;-;;SURVEY.OASIS;4;Number of pressure injuries at each stage;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.64 +46461-0;Emergent care;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Emergent care [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46462-8;Outcome and assessment information set (OASIS) form - version B1;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version B1;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;DEPRECATED;2.19;2.73 +46463-6;Race or ethnicity;Type;Pt;^Patient;Nom;;ADMIN.DEMOG;2;Race or ethnicity;Race or ethnicity;;ACTIVE;2.19;2.69 +46464-4;Current payment sources for home care;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Current payment sources for home care [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46465-1;Conditions prior to medical or treatment regimen change or inpatient stay within past 14D;Find;14D;^Patient;Nom;OASIS;SURVEY.CMS;4;Conditions prior to medical or treatment regimen change or inpatient stay within past 14 days [OASIS];;;ACTIVE;2.19;2.61 +4646-6;Heparin;MCnc;Pt;Plas;Qn;;HEM/BC;1;Deprecated Heparin unfractionated [Units/volume] in Platelet poor plasma by Coagulation assay;Deprecated Heparin Plas-mCnc;;DEPRECATED;1.0;2.36 +46466-9;Therapeutic substance administered at home;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Therapeutic substance administered at home [CMS Assessment];;;ACTIVE;2.19;2.61 +46467-7;Risk factors;Find;Pt;^Patient;Nom;;H&P.HX;2;Risk factors;Risk factors;;ACTIVE;2.19;2.69 +46468-5;Current living arrangement;Type;Pt;^Patient;Nom;;SURVEY.OASIS;4;Current living arrangement;;;ACTIVE;2.19;2.70 +46469-3;Assisting person(s) other than home care agency staff;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Assisting person(s) other than home care agency staff [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46470-1;Type of primary caregiver assistance;-;Pt;^Patient;-;;SURVEY.OASIS;4;Type of primary caregiver assistance;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46471-9;At home respiratory treatments;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;At home respiratory treatments [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46472-7;Depressive feelings;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Depressive feelings [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46473-5;Cognitive, behavioral, and psychiatric symptoms demonstrated at least one time per W;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Cognitive, behavioral, and psychiatric symptoms demonstrated at least one time per week [CMS Assessment];;;ACTIVE;2.19;2.64 +4647-4;Heparin;MRat;24H;Urine;Qn;;HEM/BC;1;Deprecated Heparin unfractionated [Mass/time] in 24 hour Urine;Deprecated Heparin 24H Ur-mRate;;DEPRECATED;1.0;2.36 +46474-3;Emergent care reason;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Emergent care reason [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46475-0;Discharge support services or assistance;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Discharge support services or assistance [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46476-8;Reason for hospitalization;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Reason for hospitalization [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46477-6;Reason for nursing home admission;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Reason for nursing home admission [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46478-4;Grooming;-;Pt;^Patient;-;;SURVEY.OASIS;4;Grooming;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46479-2;Ability to dress upper body;-;Pt;^Patient;-;;SURVEY.OASIS;4;Ability to dress upper body;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +464-8;sulfADIAZINE;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;sulfADIAZINE [Susceptibility] by Minimum inhibitory concentration (MIC);sulfADIAZINE Islt MIC;;ACTIVE;1.0;2.19 +46480-0;Ability to dress lower body;-;Pt;^Patient;-;;SURVEY.OASIS;4;Ability to dress lower body;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46481-8;Toileting;-;Pt;^Patient;-;OASIS;SURVEY.OASIS;4;Toileting [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.58 +4648-2;Homologous restriction factor;-;Pt;-;-;;HEM/BC;1;Deprecated Homologous restriction factor;Deprecated Homologous restriction factor;;DEPRECATED;1.0;2.66 +46482-6;Transferring;-;Pt;^Patient;-;OASIS;SURVEY.OASIS;4;Transferring [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.58 +46483-4;Locomotion;-;Pt;^Patient;-;;SURVEY.OASIS;4;Locomotion;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46484-2;Feeding or eating;-;Pt;^Patient;-;OASIS;SURVEY.OASIS;4;Feeding or eating [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.58 +46485-9;Planning & preparing light meals;-;Pt;^Patient;-;;SURVEY.OASIS;4;Planning and preparing light meals;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46486-7;Transportation;-;Pt;^Patient;-;;SURVEY.OASIS;4;Transportation;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46487-5;Laundry;-;Pt;^Patient;-;;SURVEY.OASIS;4;Laundry;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46488-3;Housekeeping;-;Pt;^Patient;-;;SURVEY.OASIS;4;Housekeeping;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46489-1;Shopping;-;Pt;^Patient;-;;SURVEY.OASIS;4;Shopping;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +4649-0;Interferon;ACnc;Pt;Ser;Qn;;HEM/BC;1;Interferon [Units/volume] in Serum;IFN Ser-aCnc;;ACTIVE;1.0;2.73 +46490-9;Ability to use telephone;-;Pt;^Patient;-;;SURVEY.OASIS;4;Ability to use telephone;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46491-7;Management of oral medications;-;Pt;^Patient;-;;SURVEY.OASIS;4;Management of oral medications;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46492-5;Management of inhalant &or mist medications;-;Pt;^Patient;-;;SURVEY.OASIS;4;Management of inhalant /mist medications;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46493-3;Medicaid provider number;ID;Pt;Agency;Nom;OASIS;SURVEY.OASIS;4;Medicaid provider number Agency [OASIS];;;ACTIVE;2.19;2.44 +46494-1;State location of agency branch;Loc;Pt;Agency;Nom;CMS Assessment;SURVEY.CMS;4;State location of agency branch [CMS Assessment];;;ACTIVE;2.19;2.61 +46495-8;Branch number;ID;Pt;Agency;Nom;CMS Assessment;SURVEY.CMS;4;Branch number Agency [CMS Assessment];;;ACTIVE;2.19;2.61 +46496-6;Agency patient number;ID;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Agency patient number [CMS Assessment];;;ACTIVE;2.19;2.61 +46497-4;Start of care date;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Start of care date [CMS Assessment];;;ACTIVE;2.19;2.61 +46498-2;Resumption of care date;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Resumption of care date [CMS Assessment];;;ACTIVE;2.19;2.61 +46499-0;State of residence;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;State of residence;State of residence;;ACTIVE;2.19;2.73 +46500-5;Discipline of person completing assessment;Type;Pt;Provider;Nom;CMS Assessment;SURVEY.CMS;4;Discipline of Person Completing Assessment Provider [CMS Assessment];;;ACTIVE;2.19;2.61 +46501-3;Date assessment information completed;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Date assessment information completed [CMS Assessment];;;ACTIVE;2.19;2.61 +46502-1;Reason for assessment;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Reason for assessment [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46503-9;Most recent inpatient discharge date;Date;Pt;^Patient;Qn;OASIS;SURVEY.CMS;4;Deprecated Most recent inpatient discharge date [OASIS];;;DEPRECATED;2.19;2.70 +46504-7;Inpatient stay within last 14D - ICD code;Prid;14D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Inpatient stay within last 14 days - ICD code [CMS Assessment];;;ACTIVE;2.19;2.61 +46505-4;Inpatient stay within last 14D - ICD code^^^2;Prid;14D;^Patient;Nom;OASIS;SURVEY.OASIS;4;Inpatient stay within last 14 days - ICD code # 2 [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46506-2;Medical or treatment regimen change in past 14D;Find;14D;^Patient;Ord;OASIS;SURVEY.OASIS;4;Medical or treatment regimen change in past 14 days [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46507-0;Regimen change in past 14D - ICD code;Prid;14D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Regimen change in past 14 days - ICD code [CMS Assessment];;;ACTIVE;2.19;2.61 +4650-8;Interleukin 1;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 1 [Units/volume] in Serum or Plasma;Il1 SerPl-aCnc;;DISCOURAGED;1.0;2.69 +46508-8;Regimen change in past 14D - ICD code^^^2;Prid;14D;^Patient;Nom;OASIS;SURVEY.OASIS;4;Regimen change in past 14 days - ICD code # 2 [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46509-6;Regimen change in past 14D - ICD code^^^3;Prid;14D;^Patient;Nom;OASIS;SURVEY.OASIS;4;Regimen change in past 14 days - ICD code # 3 [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46510-4;Regimen change in past 14D - ICD code ^^^4;Prid;14D;^Patient;Nom;OASIS;SURVEY.OASIS;4;Regimen change in past 14 days - ICD code # 4 [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46511-2;Primary diagnosis ICD code;Prid;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Deprecated Primary diagnosis ICD code [CMS Assessment];;;DEPRECATED;2.19;2.73 +46512-0;Primary diagnosis severity rating;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Primary diagnosis severity rating [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46513-8;Other diagnosis 1 - ICD code;Prid;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Other diagnosis 1 - ICD code [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46514-6;Other diagnosis 1 - severity rating;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Other diagnosis 1 - severity rating [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46515-3;Other diagnosis 2 - ICD code;Prid;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Other diagnosis 2 - ICD code [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +4651-6;Interleukin 2;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 [Units/volume] in Serum or Plasma;Il2 SerPl-aCnc;;DISCOURAGED;1.0;2.69 +46516-1;Other diagnosis 2 - severity rating;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Other diagnosis 2 - severity rating [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46517-9;Other diagnosis 3 - ICD code;Prid;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Other diagnosis 3 - ICD code [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46518-7;Other diagnosis 3 - severity rating;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Other diagnosis 3 - severity rating [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46519-5;Other diagnosis 4 - ICD code;Prid;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Other diagnosis 4 - ICD code [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46520-3;Other diagnosis 4 - severity rating;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Other diagnosis 4 - severity rating [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46521-1;Other diagnosis 5 - ICD code;Prid;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Other diagnosis 5 - ICD code [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46522-9;Other diagnosis 5 - severity rating;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Other diagnosis 5 - severity rating [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46523-7;Overall prognosis for recovery from this episode;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Overall prognosis for recovery from this episode [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +4652-4;Interleukin 3;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 3 [Units/volume] in Serum or Plasma;Il3 SerPl-aCnc;;DISCOURAGED;1.0;2.69 +46524-5;Rehabilitative prognosis;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Rehabilitative prognosis [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46525-2;Life expectancy;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Life expectancy [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46526-0;Current residence;Type;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Current residence [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46527-8;Primary caregiver;Find;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Primary caregiver [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46528-6;Frequency of primary caregiver assistance;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Frequency of primary caregiver assistance [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46529-4;Sensory status - vision;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Sensory status - vision [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46530-2;Sensory status - hearing and ability to understand spoken language;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Sensory status - hearing and ability to understand spoken language [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46531-0;Sensory status - speech and oral expression of language;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Sensory status - speech and oral expression of language [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +4653-2;Interleukin 4;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 4 [Units/volume] in Serum or Plasma;Il4 SerPl-aCnc;;DISCOURAGED;1.0;2.69 +46532-8;Sensory status - frequency of pain;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Sensory status - frequency of pain [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46533-6;Experiencing intractable pain;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Experiencing intractable pain [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46534-4;Skin lesion or open wound;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Skin lesion or open wound [CMS Assessment];;;ACTIVE;2.19;2.61 +46535-1;Pressure injury;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Pressure injury [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.64 +46536-9;Number of pressure injuries - stage 1;Num;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - stage 1 Ord [CMS Assessment];;;ACTIVE;2.19;2.63 +46537-7;Number of pressure ulcers - stage 2;Num;Pt;^Patient;Qn;OASIS;SURVEY.OASIS;4;Number of pressure ulcers - stage 2 [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;DISCOURAGED;2.19;2.63 +46538-5;Number of pressure ulcers - stage 3;Num;Pt;^Patient;Qn;OASIS;SURVEY.OASIS;4;Number of pressure ulcers - stage 3 [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;DISCOURAGED;2.19;2.63 +46539-3;Number of pressure ulcers - stage 4;Num;Pt;^Patient;Qn;OASIS;SURVEY.OASIS;4;Number of pressure ulcers - stage 4 [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;DISCOURAGED;2.19;2.63 +4654-0;Interleukin 5;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 5 [Units/volume] in Serum or Plasma;Il5 SerPl-aCnc;;DISCOURAGED;1.0;2.69 +46540-1;Unobserved pressure injury;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Unobserved pressure injury [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.64 +46541-9;Stage of most problematic pressure injury;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Stage of most problematic pressure injury [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.64 +46542-7;Status of most problematic pressure injury;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Status of most problematic pressure injury [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.64 +46543-5;Stasis pressure injury;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Stasis ulcer [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.73 +46544-3;Number of stasis ulcers;Num;Pt;^Patient;Qn;OASIS;SURVEY.OASIS;4;Number of stasis ulcers [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46545-0;Unobserved stasis pressure injury;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Unobserved stasis pressure injury [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.73 +46546-8;Status of most problematic stasis pressure injury;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Status of most problematic stasis ulcer [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.73 +46547-6;Surgical wound;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Surgical wound [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.73 +46548-4;Number of surgical wounds;Num;Pt;^Patient;Qn;OASIS;SURVEY.OASIS;4;Number of surgical wounds [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46549-2;Unobserved surgical wound;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Unobserved surgical wound [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +465-5;sulfADIAZINE;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;sulfADIAZINE [Susceptibility] by Disk diffusion (KB);sulfADIAZINE Islt KB;;ACTIVE;1.0;2.19 +46550-0;Status of most problematic surgical wound;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Status of most problematic surgical wound [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46551-8;When short of breath;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;When short of breath [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46552-6;Treated for urinary tract infection in past 14D;Find;14D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Treated for urinary tract infection in past 14 days [CMS Assessment];;;ACTIVE;2.19;2.61 +46553-4;Urinary incontinence or urinary catheter present;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Urinary incontinence or urinary catheter present [CMS Assessment];;;ACTIVE;2.19;2.61 +46554-2;Prior - ambulation;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - ambulation [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46555-9;Current ability - ambulation;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - ambulation [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46556-7;Prior - feeding;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - feeding [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +4655-7;Interleukin 6;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 6 [Units/volume] in Serum or Plasma;Il6 SerPl-aCnc;;DISCOURAGED;1.0;2.69 +46557-5;Current ability - feeding;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - feeding [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46558-3;Prior - prepare light meals;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - prepare light meals [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46559-1;Current ability - prepare light meals;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - prepare light meals [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46560-9;Prior - transportation;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - transportation [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46561-7;Current ability - transportation;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - transportation [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46562-5;Prior - laundry;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - laundry [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46563-3;Current ability - laundry;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - laundry [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46564-1;Prior - housekeeping;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - housekeeping [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +4656-5;Interleukin 7;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 7 [Units/volume] in Serum or Plasma;Il7 SerPl-aCnc;;DISCOURAGED;1.0;2.69 +46565-8;Current ability - housekeeping;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - housekeeping [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46566-6;Prior - shopping;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - shopping [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46567-4;Current ability - shopping;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - shopping [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46568-2;Prior - telephone use;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - telephone use [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46569-0;Telephone use - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Telephone use - functional ability [CMS Assessment];;;ACTIVE;2.19;2.61 +46570-8;Prior - management of oral medications;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - management of oral medications [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46571-6;Current ability - management of oral medications;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - management of oral medications [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46572-4;Prior - management of inhalant medications;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - management of inhalant medications [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +4657-3;Kallikrein;CCnc;Pt;Plas;Qn;;HEM/BC;1;Kallikrein [Enzymatic activity/volume] in Plasma;Kallikrein Plas-cCnc;;ACTIVE;1.0;2.68 +46573-2;Current ability - management of inhalant medications;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - management of inhalant medications [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46574-0;Prior - management of injectable medications;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - management of injectable medications [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46575-7;Current ability - management of injectable medications;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - management of injectable medications [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46576-5;Management of equipment;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Management of equipment [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46577-3;Management of equipment;Find;Pt;^Caregiver;Ord;OASIS;SURVEY.OASIS;4;Management of equipment Caregiver [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46578-1;Admitted to;Type;Pt;Inpatient facility;Nom;CMS Assessment;SURVEY.CMS;4;Admitted to Inpatient facility [CMS Assessment];;;ACTIVE;2.19;2.61 +46579-9;Discharge disposition;Type;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Deprecated Discharge disposition [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;DEPRECATED;2.19;2.73 +46580-7;Acute care hospitalization reason;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Acute care hospitalization reason [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +4658-1;Kallikrein.tissue type;ACnc;Pt;Plas;Qn;;HEM/BC;1;Kallikrein Tissue type [Units/volume] in Plasma;Kallikrein Tiss Typ Plas-aCnc;;ACTIVE;1.0;2.69 +46581-5;Date of last home visit;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Date of last home visit [CMS Assessment];;;ACTIVE;2.19;2.61 +46582-3;Discharge, transfer, death date;Date;Pt;^Patient;Qn;;SURVEY.CMS;4;Discharge, transfer, death date;;;ACTIVE;2.19;2.71 +46583-1;Therapy need;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Therapy need [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46584-9;Payment diagnosis - primary ICD code;Prid;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Payment diagnosis - primary ICD code [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46585-6;Payment diagnosis - first secondary ICD;Prid;Pt;^Patient;Nom;OASIS;SURVEY.OASIS;4;Payment diagnosis - first secondary ICD [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46586-4;When urinary incontinence occurs;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;When urinary incontinence occurs [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46587-2;Bowel incontinence frequency;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bowel incontinence frequency [CMS Assessment];;;ACTIVE;2.19;2.63 +46588-0;Ostomy for bowel elimination;Find;Pt;^Patient;Ord;OASIS;SURVEY.CMS;4;Ostomy for bowel elimination [OASIS];;;ACTIVE;2.19;2.61 +46589-8;Cognitive functioning;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Cognitive functioning [CMS Assessment];;;ACTIVE;2.19;2.61 +46590-6;When confused;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;When confused [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46591-4;When anxious;Find;Pt;^Patient;Ord;OASIS;SURVEY.CMS;4;When anxious [OASIS];;;ACTIVE;2.19;2.61 +46592-2;Frequency of behavior problems;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Frequency of behavior problems [CMS Assessment];;;ACTIVE;2.19;2.64 +46593-0;Receives psychiatric nursing;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Receives psychiatric nursing [CMS Assessment];;;ACTIVE;2.19;2.63 +46594-8;Prior - grooming;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - grooming [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46595-5;Grooming - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Grooming - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.19;2.70 +46596-3;Prior - dress upper body;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - dress upper body [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46597-1;Dress upper body - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Dress upper body - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.19;2.72 +46598-9;Prior - dress lower body;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - dress lower body [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +4659-9;Phosphatase.leukocyte;CCnc;Pt;WBC;Qn;;HEM/BC;1;Leukocyte phosphatase [Enzymatic activity/volume] in Leukocytes;LAP WBC-cCnc;;ACTIVE;1.0;2.73 +46599-7;Dress lower body - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Dress lower body - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.19;2.70 +46600-3;Prior - bathing;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - bathing [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46601-1;Current ability - bathing;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - bathing [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46602-9;Prior - toileting;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - toileting [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46603-7;Current ability - toileting;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - toileting [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46604-5;Prior - transferring;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Prior - transferring [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46605-2;Current ability - transferring;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Current ability - transferring [OASIS];;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.54 +46606-0;Bathing ability;-;Pt;^Patient;-;;SURVEY.OASIS;4;Bathing ability;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +4660-7;Leukocyte.detection Ab;-;Pt;Ser;Nom;;HEM/BC;1;Deprecated Leukocyte.detection Ab;Deprecated Leukocyte.detection Ab Ser;;DEPRECATED;1.0;2.66 +46607-8;Gender;Type;Pt;^Patient;Nar;OASIS;SURVEY.OASIS;4;Deprecated Gender OASIS;;;DEPRECATED;2.19;2.44 +46608-6;Primary referring physician ID;ID;Pt;Provider;Nom;;SURVEY.OASIS;4;Primary referring physician ID Provider;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.73 +46609-4;Diagnosis and severity index;-;Pt;^Patient;-;;SURVEY.OASIS;4;Diagnosis and severity index;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.73 +46610-2;Payment diagnosis;-;Pt;^Patient;-;;SURVEY.OASIS;4;Payment diagnosis;;Copyright © 2002 Center for Health Services Research, UCHSC, Denver, CO. Used with permission.;ACTIVE;2.19;2.50 +46611-0;Mental residual functional capacity (RFC) assessment form;-;Pt;^Patient;-;;PANEL.SURVEY.RFC;4;Mental residual functional capacity (RFC) assessment form;;;ACTIVE;2.19;2.29 +46612-8;Summary conclusions;-;Pt;^Patient;Set;;SURVEY.RFC;4;Summary conclusions Set;;;ACTIVE;2.19;2.27 +46613-6;Remembers locations & worklike procedures;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Remembers locations and worklike procedures [RFC];;;ACTIVE;2.19;2.44 +46614-4;Understands & remembers very short & simple instructions;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Understands and remembers very short and simple instructions [RFC];;;ACTIVE;2.19;2.44 +4661-5;Lupus erythematosus factor;-;Pt;Ser;Qn;;SERO;1;Deprecated Lupus erythematosus factor in Serum;Deprecated LE Scn Ser;;DEPRECATED;1.0;2.66 +46615-1;Understands & remembers detailed instructions;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Understands and remembers detailed instructions [RFC];;;ACTIVE;2.19;2.44 +46616-9;Carries out very short & simple instructions;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Carries out very short and simple instructions [RFC];;;ACTIVE;2.19;2.44 +46617-7;Carries out detailed instructions;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Carries out detailed instructions [RFC];;;ACTIVE;2.19;2.44 +46618-5;Maintains attention & concentration for extended periods;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Maintains attention and concentration for extended periods [RFC];;;ACTIVE;2.19;2.44 +46619-3;Performs activities within a schedule, maintains regular attendance, is punctual within customary tolerances;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Performs activities within a schedule, maintains regular attendance, is punctual within customary tolerances [RFC];;;ACTIVE;2.19;2.44 +46620-1;Sustains an ordinary routine without special supervision;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Sustains an ordinary routine without special supervision [RFC];;;ACTIVE;2.19;2.44 +46621-9;Works in coordination with or proximity to others without being distracted by them;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Works in coordination with or proximity to others without being distracted by them [RFC];;;ACTIVE;2.19;2.44 +46622-7;Makes simple work-related decisions;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Makes simple work-related decisions [RFC];;;ACTIVE;2.19;2.44 +4662-3;Lymphocytes+Monocytes/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Lymphocytes+Monocytes/100 leukocytes in Blood;Lymphs+Monos/leuk NFr Bld;;ACTIVE;1.0;2.50 +46623-5;Completes normal workday & week WO interruptions from psych symptoms & performs at consistent pace WO unreasonable number & length of rests;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Completes normal workday and week WO interruptions from psych symptoms and performs at consistent pace WO unreasonable number and length of rests [RFC];;;ACTIVE;2.19;2.44 +46624-3;Interacts appropriately with the general public;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Interacts appropriately with the general public [RFC];;;ACTIVE;2.19;2.44 +46625-0;Asks simple questions or request assistance;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Asks simple questions or request assistance [RFC];;;ACTIVE;2.19;2.44 +46626-8;Accepts instructions & respond appropriately to criticism from supervisors;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Accepts instructions and respond appropriately to criticism from supervisors [RFC];;;ACTIVE;2.19;2.44 +46627-6;Gets along with coworkers or peers WO distracting them or exhibiting behavioral extremes;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Gets along with coworkers or peers WO distracting them or exhibiting behavioral extremes [RFC];;;ACTIVE;2.19;2.44 +46628-4;Maintains socially appropriate behavior & adheres to basic standards of neatness & cleanliness;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Maintains socially appropriate behavior and adheres to basic standards of neatness and cleanliness [RFC];;;ACTIVE;2.19;2.44 +46629-2;Responds appropriately to changes in the work setting;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Responds appropriately to changes in the work setting [RFC];;;ACTIVE;2.19;2.44 +466-3;sulfADIAZINE;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;sulfADIAZINE [Susceptibility] by Serum bactericidal titer;sulfADIAZINE Titr SBT;;ACTIVE;1.0;2.32 +46630-0;Aware of normal hazards & take appropriate precautions;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Aware of normal hazards and take appropriate precautions [RFC];;;ACTIVE;2.19;2.44 +4663-1;Lymphocytotoxicity;-;Pt;Ser;Qn;Without titration;HEM/BC;1;Deprecated Lymphocytotoxicity without titration;Deprecated Lymphocyt Ser Qn w/o Titr;;DEPRECATED;1.0;2.66 +46631-8;Travels in unfamiliar places or use public transportation;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Travels in unfamiliar places or use public transportation [RFC];;;ACTIVE;2.19;2.44 +46632-6;Sets realistic goals or make plans independently of others;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Sets realistic goals or make plans independently of others [RFC];;;ACTIVE;2.19;2.44 +46633-4;Remarks;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Remarks [RFC];;;ACTIVE;2.19;2.44 +46634-2;Functional capacity assessment;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Functional capacity assessment [RFC];;;ACTIVE;2.19;2.44 +46635-9;Categories;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Categories [RFC];;;ACTIVE;2.19;2.54 +46636-7;Date form completed;Date;Pt;Form;Qn;RFC assessment;SURVEY.RFC;4;Deprecated Date form completed [RFC];;;DEPRECATED;2.19;2.70 +46637-5;Residual physical functional capacity (RFC) assessment form;-;Pt;^Patient;-;RFC assessment;PANEL.SURVEY.RFC;4;Residual physical functional capacity (RFC) assessment form [RFC];;;ACTIVE;2.19;2.44 +46638-3;IP CDB claim numberholder;ID;Pt;^Patient;Nom;RFC assessment;SURVEY.RFC;4;IP CDB claim numberholder [RFC];;;ACTIVE;2.19;2.44 +46639-1;Diagnosis.primary;Imp;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Primary diagnosis [RFC];;;ACTIVE;2.19;2.44 +46640-9;Secondary diagnosis;Imp;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Secondary diagnosis [RFC];;;ACTIVE;2.19;2.73 +46641-7;Other alleged impairments;Imp;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Other alleged impairments [RFC];;;ACTIVE;2.19;2.44 +46642-5;Limitations section;-;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Limitations section Set [RFC];;;ACTIVE;2.19;2.44 +46643-3;Exertional limitations;-;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Exertional limitations Set [RFC];;;ACTIVE;2.19;2.44 +46644-1;No exertional limitations;Arb;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;No exertional limitations [RFC];;;ACTIVE;2.19;2.44 +46645-8;Occasionally lift &or carry;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Occasionally lift/carry [RFC];;;ACTIVE;2.19;2.44 +46646-6;Frequently lift &or carry;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Frequently lift/carry [RFC];;;ACTIVE;2.19;2.44 +46647-4;Stand &or walk;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Stand/walk [RFC];;;ACTIVE;2.19;2.44 +46648-2;Sit;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Sit [RFC];;;ACTIVE;2.19;2.44 +4664-9;Lymphocytotoxicity;-;Pt;Ser;Qn;With titration;HEM/BC;1;Deprecated Lymphocytotoxicity with titration;Deprecated Lymphocyt Ser Qn w Titr;;DEPRECATED;1.0;2.66 +46649-0;Push &or pull;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Push/pull [RFC];;;ACTIVE;2.19;2.44 +46650-8;Exertional limitations;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Exertional limitations [RFC];;;ACTIVE;2.19;2.44 +46651-6;Postural limitations;-;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Postural limitations Set [RFC];;;ACTIVE;2.19;2.44 +46652-4;No postural limitations;Arb;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;No postural limitations [RFC];;;ACTIVE;2.19;2.44 +46653-2;Climbing;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Climbing [RFC];;;ACTIVE;2.19;2.44 +46654-0;Balancing;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Balancing [RFC];;;ACTIVE;2.19;2.44 +46655-7;Stooping;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Stooping [RFC];;;ACTIVE;2.19;2.44 +4665-6;Lysozyme;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lysozyme [Enzymatic activity/volume] in Serum or Plasma;Lysozyme SerPl-cCnc;;ACTIVE;1.0;2.68 +46656-5;Kneeling;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Kneeling [RFC];;;ACTIVE;2.19;2.44 +46657-3;Crouching;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Crouching [RFC];;;ACTIVE;2.19;2.44 +46658-1;Crawling;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Crawling [RFC];;;ACTIVE;2.19;2.44 +46659-9;Postural limitations;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Postural limitations [RFC];;;ACTIVE;2.19;2.44 +46660-7;Manipulative limitations;-;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Manipulative limitations Set [RFC];;;ACTIVE;2.19;2.44 +46661-5;No manipulative limitations;Arb;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;No manipulative limitations [RFC];;;ACTIVE;2.19;2.44 +46662-3;Reaching in all directions;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Reaching in all directions [RFC];;;ACTIVE;2.19;2.44 +46663-1;Handling;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Handling [RFC];;;ACTIVE;2.19;2.44 +4666-4;Osmotic fragility;NFr;Pt;RBC;Ord;;HEM/BC;1;Deprecated Osmotic fragility;Deprecated OF Fr RBC;;DEPRECATED;1.0;2.46 +46664-9;Fingering;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Fingering [RFC];;;ACTIVE;2.19;2.44 +46665-6;Feeling;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Feeling [RFC];;;ACTIVE;2.19;2.44 +46666-4;Manipulative limitations;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Manipulative limitations [RFC];;;ACTIVE;2.19;2.44 +46667-2;Visual limitations;-;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Visual limitations Set [RFC];;;ACTIVE;2.19;2.44 +46668-0;No visual limitations;Arb;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;No visual limitations [RFC];;;ACTIVE;2.19;2.44 +46669-8;Near acuity;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Near acuity [RFC];;;ACTIVE;2.19;2.44 +46670-6;Far acuity;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Far acuity [RFC];;;ACTIVE;2.19;2.44 +46671-4;Depth perception;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Depth perception [RFC];;;ACTIVE;2.19;2.44 +4667-2;Osmotic fragility;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells;OF NFr RBC;;ACTIVE;1.0;2.73 +46672-2;Accommodation;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Accommodation [RFC];;;ACTIVE;2.19;2.44 +46673-0;Color vision;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Color vision [RFC];;;ACTIVE;2.19;2.44 +46674-8;Field of vision;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Field of vision [RFC];;;ACTIVE;2.19;2.44 +46675-5;Visual limitations;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Visual limitations [RFC];;;ACTIVE;2.19;2.44 +46676-3;Communicative limitation;-;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Communicative limitation Set [RFC];;;ACTIVE;2.19;2.44 +46677-1;No communicative limitations;Arb;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;No communicative limitations [RFC];;;ACTIVE;2.19;2.44 +46678-9;Hearing;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Hearing [RFC];;;ACTIVE;2.19;2.44 +46679-7;Speaking;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Speaking [RFC];;;ACTIVE;2.19;2.44 +4668-0;Plasminogen Ag;MCnc;Pt;PPP;Qn;;COAG;1;Plasminogen Ag [Mass/volume] in Platelet poor plasma;PLG Ag PPP-mCnc;;ACTIVE;1.0;2.73 +46680-5;Communicative limitation;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Communicative limitation [RFC];;;ACTIVE;2.19;2.44 +46681-3;Environmental limitations;Find;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Environmental limitations Set [RFC];;;ACTIVE;2.19;2.44 +46682-1;Extreme cold;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Extreme cold [RFC];;;ACTIVE;2.19;2.44 +46683-9;Extreme heat;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Extreme heat [RFC];;;ACTIVE;2.19;2.44 +46684-7;Wetness;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Wetness [RFC];;;ACTIVE;2.19;2.44 +46685-4;Humidity;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Humidity [RFC];;;ACTIVE;2.19;2.44 +46686-2;Noise;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Noise [RFC];;;ACTIVE;2.19;2.44 +46687-0;Vibrations;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Vibrations [RFC];;;ACTIVE;2.19;2.44 +46688-8;Fumes, odors, dusts, gases, poor ventilation, etc;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Fumes, odors, dusts, gases, poor ventilation, etc [RFC];;;ACTIVE;2.19;2.44 +46689-6;Hazards;Find;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Hazards [RFC];;;ACTIVE;2.19;2.44 +46690-4;Environmental limitations;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Environmental limitations [RFC];;;ACTIVE;2.19;2.44 +46691-2;Symptoms;Find;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Symptoms [RFC];;;ACTIVE;2.19;2.44 +46692-0;Treatment or examining source statements;-;Pt;^Patient;Set;RFC assessment;SURVEY.RFC;4;Treatment or examining source statements Set [RFC];;;ACTIVE;2.19;2.44 +46693-8;Treating or examining source statement regarding claimant's physical capacities in file;Arb;Pt;^Patient;Ord;RFC assessment;SURVEY.RFC;4;Treating or examining source statement regarding claimant's physical capacities in file [RFC];;;ACTIVE;2.19;2.44 +46694-6;Treating or examining source conclusions about the claimant's limitations or restrictions which are significantly different from your file;Arb;Pt;^Patient;Nom;RFC assessment;SURVEY.RFC;4;Treating or examining source conclusions about the claimant's limitations or restrictions which are significantly different from your file [RFC];;;ACTIVE;2.19;2.44 +46695-3;Why conclusions are not supported by the evidence in file;Imp;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Why conclusions are not supported by the evidence in file [RFC];;;ACTIVE;2.19;2.44 +46696-1;Additional comments;Imp;Pt;^Patient;Nar;RFC assessment;SURVEY.RFC;4;Additional comments [RFC];;;ACTIVE;2.19;2.73 +46697-9;Date;Date;Pt;^Patient;Qn;RFC assessment;SURVEY.RFC;4;Date [RFC];;;ACTIVE;2.19;2.50 +4669-8;Prekallikrein;MCnc;Pt;PPP;Qn;;COAG;1;Prekallikrein (Fletcher Factor) [Mass/volume] in Platelet poor plasma;PK PPP-mCnc;;ACTIVE;1.0;2.34 +46698-7;Cyanide;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Cyanide [Presence] in Blood;Cyanide Bld Ql;;ACTIVE;2.19;2.56 +46699-5;Fibroblast growth factor 23;ACnc;Pt;Plas;Qn;;CHEM;1;Fibroblast growth factor 23 [Units/volume] in Plasma;FGF-23 Plas-aCnc;;ACTIVE;2.19;2.73 +46700-1;7-Dehydrocholesterol;SCnc;Pt;Amnio fld;Qn;;CHEM;1;7-Dehydrocholesterol [Moles/volume] in Amniotic fluid;7-DHC Amn-sCnc;;ACTIVE;2.19;2.70 +46701-9;Adenosine triphosphate;SCnc;Pt;RBC;Qn;;CHEM;1;Adenosine triphosphate [Moles/volume] in Red Blood Cells;ATP RBC-sCnc;;ACTIVE;2.19;2.70 +46702-7;Leukocytes;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Leukocytes [#/area] in Urine sediment by Automated count;WBC #/area UrnS Auto;;ACTIVE;2.19;2.73 +46703-5;Dihydrocodeine.free+Hydrocodol.free;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Dihydrocodeine Free+Hydrocodol Free [Presence] in Serum or Plasma by Screen method;DHC+Hydrocodol Free SerPl Ql Scn;;ACTIVE;2.19;2.56 +46704-3;Dihydrocodeine.free+Hydrocodol.free;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Dihydrocodeine Free+Hydrocodol Free [Mass/volume] in Serum or Plasma by Screen method;DHC+Hydrocodol Free SerPl Scn-mCnc;;ACTIVE;2.19;2.70 +46705-0;Clostridium botulinum toxin gene;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin gene [Identifier] in Specimen by NAA with probe detection;C bot Tox gene Spec NAA+probe;;ACTIVE;2.19;2.69 +4670-6;Thrombomodulin factor B;MCnc;Pt;Plas;Qn;;HEM/BC;1;Deprecated Thrombomodulin factor B [Mass/volume] in Serum or Plasma;Deprecated Thrombomodulin B Plas-mCnc;;DEPRECATED;1.0;2.40 +46706-8;Clostridium perfringens toxin gene;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Clostridium perfringens toxin gene [Identifier] in Specimen by NAA with probe detection;C perfringens Tox gene Spec NAA+probe;;ACTIVE;2.19;2.69 +46707-6;(Anacardium occidentale+Carya illinoinensis+Juglans spp+Pistacia vera) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 22 (Cashew+Pecan or Hickory nut+Walnut+Pistachio) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix22 IgE Qn;;ACTIVE;2.19;2.73 +46708-4;(Arachis hypogaea+Bertholletia excelsa+Cocos nucifera+Corylus avellana+Prunus dulcis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 1 (Peanut+Brazil nut+Coconut+Hazelnut+Almond) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix1 IgE Qn;;ACTIVE;2.19;2.73 +46709-2;(Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Solidago virgaurea+Urtica dioica) Ab.IgE;MCnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 3 (Mugwort+Goosefoot or Lambs quarters+English plantain+Goldenrod+Nettle) IgE Ab [Mass/volume] in Serum by Multidisk;Weed Allerg Mix3 IgE-mCnc;;ACTIVE;2.19;2.40 +467-1;Sulfamethoxazole;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Sulfamethoxazole [Susceptibility] by Minimum lethal concentration (MLC);Sulfamethoxazole Islt MLC;;ACTIVE;1.0;2.19 +46710-0;(Beef+Chicken meat+Pork+Turkey meat) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 23 (Beef+Chicken meat+Pork+Turkey meat) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix23 IgE Qn;;ACTIVE;2.19;2.73 +46711-8;(Brassica oleracea var italica+Daucus carota+Phaseolus vulgaris+Pisum sativum+Zea mays) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 11 (Broccoli+Carrot+White bean+Peas+Corn) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix11 IgE Qn;;ACTIVE;2.19;2.73 +46712-6;(Gadus morhua+Mytilus edulis+Pandalus borealis+Salmo salar+Thunnus albacares) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 2 (Cod+Blue Mussel+Shrimp+Salmon+Tuna) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix2 IgE Qn;;ACTIVE;2.19;2.73 +46713-4;(Hordeum vulgare+Oryza sativa+Secale cereale+Triticum aestivum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 20 (Barley+Rice+Rye+Wheat) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix20 IgE Qn;;ACTIVE;2.19;2.70 +4671-4;Protein C;MCnc;Pt;Plas;Qn;;COAG;1;Protein C [Mass/volume] in Plasma;Prot C Plas-mCnc;;ACTIVE;1.0;2.73 +46714-2;(Malus sylvestris+Musa spp+Prunus persica+Pyrus communis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 17 (Apple+Banana+Pear+Peach) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix17 IgE Qn;;ACTIVE;2.19;2.73 +46715-9;B cell crossmatch;PrThr;Pt;Bld;Ord;;BLDBK;1;B cell crossmatch [Presence] in Blood;B Cell XM Bld Ql;;ACTIVE;2.19;2.56 +46716-7;Ceruloplasmin;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Ceruloplasmin [Mass/volume] in DBS;Ceruloplasmin DBS-mCnc;;ACTIVE;2.19;2.61 +46717-5;Coagulation thrombin induced.factor substitution^immediately after addition of bovine thrombin;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of bovine thrombin;TT imm Bovine Thrombin PPP;;ACTIVE;2.19;2.73 +46718-3;Aquaporin 4 water channel Ab.IgG;PrThr;Pt;CSF;Ord;;SERO;1;Aquaporin 4 water channel IgG Ab [Presence] in Cerebral spinal fluid;AQP4 H2O channel IgG CSF Ql;;ACTIVE;2.19;2.73 +46719-1;Streptomycin 4.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Streptomycin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Streptomycin 4 ug/mL Islt SlowMyco;;ACTIVE;2.19;2.26 +46720-9;T cell crossmatch;PrThr;Pt;Bld;Ord;;BLDBK;1;T cell crossmatch [Presence] in Blood;T Cell XM Bld Ql;;ACTIVE;2.19;2.56 +46721-7;Ustilago nuda Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Barley smut IgE Ab [Units/volume] in Serum;Barley smut IgE Qn;;ACTIVE;2.19;2.73 +4672-2;Protein C Ag;MCnc;Pt;PPP;Qn;;COAG;1;Protein C Ag [Mass/volume] in Platelet poor plasma;Prot C Ag PPP-mCnc;;ACTIVE;1.0;2.73 +46722-5;Cells.ZAP70;PrThr;Pt;Bld;Ord;;CELLMARK;1;ZAP70 cells [Presence] in Blood;ZAP70 Cells Bld Ql;;ACTIVE;2.19;2.73 +46723-3;Alpha-1-Microglobulin;MCnc;Pt;Urine;Qn;;CHEM;1;Alpha-1-Microglobulin [Mass/volume] in Urine;A1 Microglob Ur-mCnc;;ACTIVE;2.19;2.34 +46724-1;CYP2C9 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2C9 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP2C9 allele Geno Bld/T;;ACTIVE;2.19;2.73 +46725-8;Tropheryma whipplei DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Specimen by NAA with probe detection;T whipplei DNA Spec Ql NAA+probe;;ACTIVE;2.19;2.73 +46726-6;HTR2A gene+HTR2C gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;HTR2A gene+HTR2C gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HTR2A+HTR2C gene Mut Anl Bld/T;;ACTIVE;2.19;2.67 +46727-4;Prolactin.monomeric;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Prolactin monomeric [Mass/volume] in Serum or Plasma;Deprecated Prolactin.monomeric SerPl-mCn;;DEPRECATED;2.19;2.70 +46728-2;Weight;Mass;Pt;Water;Qn;;SPEC;1;Weight of Water;Wt Wat Qn;;ACTIVE;2.19;2.73 +46729-0;Weight container+Specimen;Mass;Pt;Stool;Qn;;SPEC;1;Weight container+Specimen of Stool;Wt Container+specimen Stl Qn;;ACTIVE;2.19;2.44 +4673-0;HLA-B27;ACnc;Pt;Bld^Donor;Ord;;HLA;1;Deprecated HLA-B27 [Presence] in Blood from donor;Deprecated HLA-B27 Bld Donr Ql;;DEPRECATED;1.0;2.36 +46730-8;Bacterial vaginosis whiff test;PrThr;Pt;Vag;Ord;;MICRO;1;Bacterial vaginosis whiff test [Presence] in Vaginal fluid;BV Whiff test Vag Ql;;ACTIVE;2.19;2.73 +46731-6;RHCE gene allele Cc;Geno;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;RHCE gene allele Cc [Genotype] in Amniotic fluid by Molecular genetics method Nominal;RHCE allele Cc Geno Amn;;ACTIVE;2.19;2.68 +46732-4;Francisella tularensis subtype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Francisella tularensis subtype [Identifier] in Specimen by NAA with probe detection;F tular subtyp Spec NAA+probe;;ACTIVE;2.19;2.69 +46733-2;Amino acidemias;Imp;Pt;Bld.dot;Nom;;CHEM;1;Amino acidemias newborn screen interpretation;Amino acidemias DBS-Imp;;ACTIVE;2.19;2.73 +46734-0;Citrullinemias &or arginosuccinic aciduria;Imp;Pt;Bld.dot;Nom;;CHEM;1;Citrullinemias/Arginosuccinic aciduria newborn screen interpretation;CIT/ASA DBS-Imp;;DISCOURAGED;2.19;2.44 +46735-7;Endocrine disorders;Imp;Pt;Bld.dot;Ord;;CHEM;1;Endocrine disorders newborn screen interpretation;Endocrine Disorders DBS-Imp;;DISCOURAGED;2.19;2.73 +46736-5;Fatty acid oxidation defects;Imp;Pt;Bld.dot;Nom;;CHEM;1;Fatty acid oxidation defects newborn screen interpretation;FOD DBS-Imp;;ACTIVE;2.19;2.73 +46737-3;Galactosemias;Imp;Pt;Bld.dot;Nom;;CHEM;1;Galactosemias newborn screen interpretation;Galactosemias DBS-Imp;;ACTIVE;2.19;2.73 +46738-1;Genetic disorders;Imp;Pt;Bld.dot;Ord;;CHEM;1;Genetic.Disorders newborn screen interpretation;Genetic.Disorders DBS-Imp;;DISCOURAGED;2.19;2.73 +46739-9;Glutaric acidemia type 1;Imp;Pt;Bld.dot;Nom;;CHEM;1;Glutaric acidemia type 1 newborn screen interpretation;GA 1 DBS-Imp;;DISCOURAGED;2.19;2.44 +46740-7;Hemoglobin disorders;Imp;Pt;Bld.dot;Nom;;CHEM;1;Hemoglobin disorders newborn screen interpretation;Hemoglobin disorders DBS-Imp;;ACTIVE;2.19;2.73 +46741-5;Homocystinuria &or other hypermethioninemias;Imp;Pt;Bld.dot;Ord;;CHEM;1;Homocystinuria and/or other hypermethioninemias newborn screen interpretation;HCY/MET DBS-Imp;;DISCOURAGED;2.19;2.44 +46742-3;Isovaleric acidemia &or 2-Methylbutyric acidemia;Imp;Pt;Bld.dot;Nom;;CHEM;1;Isovaleric Acidemia/2-Methylbutyric Acidemia newborn screen interpretation;IVA/2-Me-butyr Acidemia DBS-Imp;;DISCOURAGED;2.19;2.44 +46743-1;Maple syrup urine disease;Imp;Pt;Bld.dot;Nom;;CHEM;1;Maple syrup urine disease newborn screen interpretation;MSUD DBS-Imp;;ACTIVE;2.19;2.73 +46744-9;Organic acidemias;Imp;Pt;Bld.dot;Nom;;CHEM;1;Organic acidemias newborn screen interpretation;OA DBS-Imp;;ACTIVE;2.19;2.73 +46745-6;Other amino acidopathies;Imp;Pt;Bld.dot;Ord;;CHEM;1;Other amino acidopathies newborn screen interpretation;Other Amino Acidopathies DBS-Imp;;ACTIVE;2.19;2.29 +46746-4;Phenylketonuria and variants &or biopterin defects;Imp;Pt;Bld.dot;Nom;;CHEM;1;Phenylketonuria and variants/Biopterin defects newborn screen interpretation;PKU+Var/BIOPT Defects DBS-Imp;;ACTIVE;2.19;2.73 +46747-2;Propionic &or methylmalonic acidemias;Imp;Pt;Bld.dot;Nom;;CHEM;1;Propionic/Methylmalonic Acidemias newborn screen interpretation;PROP/MUT DBS-Imp;;DISCOURAGED;2.19;2.44 +4674-8;Protein C inhibitor.activated;-;Pt;Plas;Qn;;HEM/BC;1;Deprecated Protein C inhibitor [Mass/volume] in Platelet poor plasma by Immunologic method;Deprecated Prot C Inhib Plas Qn;;DEPRECATED;1.0;2.66 +46748-0;Tyrosinemias;Imp;Pt;Bld.dot;Nom;;CHEM;1;Tyrosinemias newborn screen interpretation;TYR DBS-Imp;;DISCOURAGED;2.19;2.44 +46749-8;3-Methylcrotonic &or hydroxymethylglutaric &or methylglutaconic;Imp;Pt;Bld.dot;Ord;;CHEM;1;3-Methylcrotonic/Hydroxymethylglutaric/Methylglutaconic newborn screen interpretation;3-Methylcrotonic/HMG/3MGA DBS-Imp;;ACTIVE;2.19;2.29 +46750-6;2-Methyl-3-Hydroxybutyric acidemias &or beta ketothiolase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;2-methyl-3-hydroxybutyric Acidemias/Beta-Ketothiolase Deficiency newborn screen interpretation;2Me3OH-Butyr Acidemias/BKT DBS-Imp;;DISCOURAGED;2.19;2.54 +46751-4;Other organic acidemias;Imp;Pt;Bld.dot;Ord;;CHEM;1;Other organic acidemias newborn screen interpretation;Other Organic Acidemias DBS-Imp;;ACTIVE;2.19;2.29 +46752-2;Medium chain acyl dehydrogenase deficiency &or glutaric acidemia type 2;Imp;Pt;Bld.dot;Ord;;CHEM;1;Medium chain acyl dehydrogenase Deficiency/Glutaric Acidemia type 2 newborn screen interpretation;MCADD/GA 2 DBS-Imp;;ACTIVE;2.19;2.73 +46753-0;Very long chain hydroxy acyl dehydrogenase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Very long chain hydroxy acyl dehydrogenase deficiency newborn screen interpretation;VLCADD DBS-Imp;;DISCOURAGED;2.19;2.44 +46754-8;Long chain hydroxy acyl dehydrogenase &or trifunctional protein deficiencies;Imp;Pt;Bld.dot;Nom;;CHEM;1;Long Chain Hydroxy Acyl Dehydrogenase/Trifunctional Protein Deficiencies newborn screen interpretation;LCHADD/TFP DBS-Imp;;DISCOURAGED;2.19;2.44 +4675-5;HLA-B35;ACnc;Pt;Bld^Donor;Ord;;HLA;1;Deprecated HLA-B35 [Presence] in Blood from donor;Deprecated HLA-B35 Bld Donr Ql;;DEPRECATED;1.0;2.36 +46755-5;Carnitine uptake defect &or CPT1 deficiency;Imp;Pt;Bld.dot;Ord;;CHEM;1;Carnitine uptake defect/CPT1 deficiency newborn screen interpretation;CUD/CPT1 DBS-Imp;;ACTIVE;2.19;2.29 +46756-3;Other fatty acid oxidation disorders;Imp;Pt;Bld.dot;Ord;;CHEM;1;Other fatty acid oxidation disorders newborn screen interpretation;Other FA Oxidation Disorders DBS-Imp;;ACTIVE;2.19;2.29 +46757-1;Congenital hypothyroidism;Imp;Pt;Bld.dot;Ord;;CHEM;1;Deprecated Congenital hypothyroidism newborn screen interpretation;Deprecated CH DBS-Imp;;DEPRECATED;2.19;2.36 +46758-9;Congenital adrenal hyperplasia;Imp;Pt;Bld.dot;Nom;;CHEM;1;Congenital adrenal hyperplasia newborn screen interpretation;CAH DBS-Imp;;ACTIVE;2.19;2.73 +46759-7;Hb SS, Hb SC, Hb SB thal;Imp;Pt;Bld.dot;Ord;;CHEM;1;Hb SS, Hb SC, Hb SB thal newborn screen interpretation;Hb Ss, Hb S/C, Hb S/bTh DBS-Imp;;ACTIVE;2.19;2.29 +46760-5;Other hemoglobinopathies;Imp;Pt;Bld.dot;Ord;;CHEM;1;Other hemoglobinopathies newborn screen interpretation;Other Hemoglobinopathies DBS-Imp;;ACTIVE;2.19;2.29 +46761-3;Biotinidase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Biotinidase deficiency newborn screen interpretation;BIOT DBS-Imp;;ACTIVE;2.19;2.73 +46762-1;Congenital hypothyroidism;Imp;Pt;Bld.dot;Nom;;CHEM;1;Congenital hypothyroidism newborn screen interpretation;CH DBS-Imp;;ACTIVE;2.19;2.73 +4676-3;HLA-B35;ACnc;Pt;Bld^Patient;Ord;;HLA;1;Deprecated HLA-B35 [Presence] in Blood;Deprecated HLA-B35 Bld Patient Ql;;DEPRECATED;1.0;2.36 +46763-9;Secondary congenital hypothyroidism;Imp;Pt;Bld.dot;Ord;;CHEM;1;Secondary congenital hypothyroidism newborn screen interpretation;Secondary CH DBS-Imp;;DISCOURAGED;2.19;2.44 +46764-7;Thyroid binding globulin deficiency;Imp;Pt;Bld.dot;Ord;;CHEM;1;Thyroid binding globulin deficiency newborn screen interpretation;TBG Deficiency DBS-Imp;;DISCOURAGED;2.19;2.44 +46765-4;Sickle cell anemia;Imp;Pt;Bld.dot;Ord;;CHEM;1;Sickle cell anemia newborn screen interpretation;Sickle Cell Anemia DBS-Imp;;DISCOURAGED;2.19;2.73 +46766-2;Hemoglobin SC disease;Imp;Pt;Bld.dot;Ord;;CHEM;1;Hemoglobin SC disease newborn screen interpretation;Hemoglobin SC Disease DBS-Imp;;DISCOURAGED;2.19;2.44 +46767-0;Hemoglobin S beta thalassemia;Imp;Pt;Bld.dot;Ord;;CHEM;1;Hemoglobin S/Beta Thalassemia newborn screen interpretation;Hb S/bTh DBS-Imp;;DISCOURAGED;2.19;2.44 +46768-8;Sickle cell carrier (trait);Imp;Pt;Bld.dot;Ord;;CHEM;1;Sickle cell carrier (trait) newborn screen interpretation;Sickle Cell Carrier (trait) DBS-Imp;;DISCOURAGED;2.19;2.44 +46769-6;Cystic fibrosis;Imp;Pt;Bld.dot;Nom;;CHEM;1;Cystic fibrosis newborn screen interpretation;CF DBS-Imp;;ACTIVE;2.19;2.73 +46770-4;Hearing loss;Imp;Pt;Ear;Nom;;H&P.HX.LAB;1;Hearing loss newborn screening interpretation;Hearing Loss -Imp;;DISCOURAGED;2.19;2.56 +4677-1;Protein S.free Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Protein S Free Ag [Units/volume] in Platelet poor plasma by Immunoassay;Prot S Free Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +46771-2;Classical galactosemia;Imp;Pt;Bld.dot;Ord;;CHEM;1;Classical galactosemia newborn screen interpretation;GALT DBS-Imp;;DISCOURAGED;2.19;2.73 +46772-0;Galactokinase deficiency;Imp;Pt;Bld.dot;Ord;;CHEM;1;Galactokinase deficiency newborn screen interpretation;GALK DBS-Imp;;DISCOURAGED;2.19;2.44 +46773-8;Galactose epimerase deficiency;Imp;Pt;Bld.dot;Ord;;CHEM;1;Galactose epimerase deficiency newborn screen interpretation;GALE DBS-Imp;;DISCOURAGED;2.19;2.44 +46774-6;Carnitine uptake deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Carnitine uptake deficiency newborn screen interpretation;Carnitine uptake deficiency DBS-Imp;;DISCOURAGED;2.19;2.44 +46775-3;Carnitine palmitoyltransferase 1 deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Carnitine palmitoyltransferase 1 deficiency newborn screen interpretation;CPT1 DBS-Imp;;DISCOURAGED;2.19;2.44 +46776-1;CPT2 &or CACT;Imp;Pt;Bld.dot;Nom;;CHEM;1;CPT2/CACT newborn screen interpretation;CPT2/CACT DBS-Imp;;DISCOURAGED;2.19;2.44 +46777-9;Glutaric acidemia 2 &or ethylmalonic encephalopathy;Imp;Pt;Bld.dot;Nom;;CHEM;1;Glutaric acidemia 2/Ethylmalonic Encephalopathy newborn screen interpretation;GA 2/EMA DBS-Imp;;DISCOURAGED;2.19;2.44 +46778-7;MCAD;Imp;Pt;Bld.dot;Nom;;CHEM;1;MCAD newborn screen interpretation;MCAD DBS-Imp;;DISCOURAGED;2.19;2.44 +46779-5;Medium &or short chain acyl-CoA dehydrogenase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Medium/Short chain acyl-CoA dehydrogenase deficiency newborn screen interpretation;M/SCHADD DBS-Imp;;DISCOURAGED;2.19;2.73 +46780-3;Short-chain acyl-CoA deficiency &or ethylmalonic encephalopathy &or isobutyryl-CoA dehydrogenase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;"Short-chain acyl-CoA deficiency (SCAD); ethylmalonic encephalopathy; isobutyryl-CoA dehydrogenase deficiency newborn screen interpretation";SCAD/EMA/IBG DBS-Imp;;DISCOURAGED;2.19;2.44 +46781-1;Malonic acidemia;Imp;Pt;Bld.dot;Nom;;CHEM;1;Malonic acidemia newborn screen interpretation;MAL DBS-Imp;;DISCOURAGED;2.19;2.44 +46782-9;Argininemia;Imp;Pt;Bld.dot;Ord;;CHEM;1;Argininemia newborn screen interpretation;ARG DBS-Imp;;ACTIVE;2.19;2.29 +46783-7;Abuse.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46784-5;Abuse.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46785-2;Abuse.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Abuse Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46786-0;Bowel function.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46787-8;Bowel function.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46788-6;Bowel function.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Bowel Function Status Community [OMAHA];;;ACTIVE;2.19;2.44 +4678-9;Protein S;ACnc;Pt;Plas;Qn;Coag;COAG;1;Deprecated Protein S [Units/volume] in Platelet poor plasma by Coagulation assay;Deprecated Prot S Plas-aCnc;;DEPRECATED;1.0;2.69 +46789-4;Caretaking &or parenting.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46790-2;Caretaking &or parenting.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46791-0;Caretaking &or parenting.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Caretaking/parenting.status Community [OMAHA];;;ACTIVE;2.19;2.44 +46792-8;Circulation.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46793-6;Circulation.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46794-4;Circulation.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Circulation Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46795-1;Cognition.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46796-9;Cognition.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +4679-7;Reticulocytes/100 erythrocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes/100 erythrocytes in Blood;Retics/100 RBC NFr;;ACTIVE;1.0;2.73 +46797-7;Cognition.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Cognition Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46798-5;Communicable &or infectious condition function.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46799-3;Communicable &or infectious condition function.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46800-9;Communicable &or infectious condition function.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.status Community [OMAHA];;;ACTIVE;2.19;2.44 +46801-7;Communication with community resources.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46802-5;Communication with community resources.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46803-3;Communication with community resources.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communication With Community Resources Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46804-1;Consciousness.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +4680-5;von Willebrand factor.ristocetin cofactor;ACnc;Pt;PPP;Qn;;COAG;1;von Willebrand factor (vWf) ristocetin cofactor [Units/volume] in Platelet poor plasma;vWf:RCo PPP-aCnc;;ACTIVE;1.0;2.73 +46805-8;Consciousness.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46806-6;Consciousness.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Consciousness Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46807-4;Digestion-hydration.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46808-2;Digestion-hydration.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46809-0;Digestion-hydration.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Digestion-hydration Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46810-8;Family planning.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46811-6;Family planning.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46812-4;Family planning.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Family Planning Status Community [OMAHA];;;ACTIVE;2.19;2.44 +4681-3;Streptokinase;CCnc;Pt;Plas;Qn;;HEM/BC;1;Streptokinase [Enzymatic activity/volume] in Plasma;Streptokinase Plas-cCnc;;ACTIVE;1.0;2.68 +46813-2;Grief.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46814-0;Grief.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46815-7;Grief.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Grief Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46816-5;Growth and development.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46817-3;Growth and development.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46818-1;Growth and development.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Growth And Development Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46819-9;Health care supervision.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46820-7;Health care supervision.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +4682-1;Streptokinase;Titr;Pt;Ser;Qn;;HEM/BC;1;Streptokinase [Titer] in Serum;Streptokinase Titr Ser;;ACTIVE;1.0;2.70 +46821-5;Health care supervision.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Health Care Supervision Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46822-3;Hearing.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46823-1;Hearing.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46824-9;Hearing.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Hearing Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46825-6;Income.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46826-4;Income.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46827-2;Income.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Income Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46828-0;Interpersonal relationship.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46829-8;Interpersonal relationship.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46830-6;Interpersonal relationship.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Interpersonal Relationship Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46831-4;Medication regimen.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46832-2;Medication regimen.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46833-0;Medication regimen.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Medication Regimen Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46834-8;Mental health.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46835-5;Mental health.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46836-3;Mental health.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Mental Health Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46837-1;Neglect.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46838-9;Neglect.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +4683-9;Sulfhemoglobin;MCnc;Pt;Bld;Qn;;CHEM;1;Sulfhemoglobin [Mass/volume] in Blood;SulfHgb Bld-mCnc;;ACTIVE;1.0;2.34 +46839-7;Neglect.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neglect Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46840-5;Neighborhood &or workplace safety.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety.behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46841-3;Neighborhood &or workplace safety.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety..knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46842-1;Neighborhood &or workplace safety.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neighborhood/workplace safety.status Community [OMAHA];;;ACTIVE;2.19;2.44 +46843-9;Neuro-musculo-skeletal function.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46844-7;Neuro-musculo-skeletal function.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46845-4;Neuro-musculo-skeletal function.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Neuro-musculo-skeletal Function Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46846-2;Nutrition.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +4684-7;Sulfhemoglobin;PrThr;Pt;Bld;Ord;;CHEM;1;Sulfhemoglobin [Presence] in Blood;SulfHgb Bld Ql;;ACTIVE;1.0;2.56 +46847-0;Nutrition.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46848-8;Nutrition.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Nutrition Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46849-6;Oral health.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46850-4;Oral health.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46851-2;Oral health.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46852-0;Pain.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46853-8;Pain.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +4685-4;Sulfhemoglobin/Hemoglobin.total;MFr;Pt;Bld;Qn;;CHEM;1;Sulfhemoglobin/Hemoglobin.total in Blood;SulfHgb MFr Bld;;ACTIVE;1.0;2.73 +46854-6;Pain.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pain Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46855-3;Personal care.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46856-1;Personal care.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46857-9;Personal care.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Personal Care Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46858-7;Physical activity.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46859-5;Physical activity.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46860-3;Physical activity.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Physical Activity Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46861-1;Postpartum function.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +4686-2;Thromboglobulin;MCnc;Pt;Plas;Qn;;HEM/BC;1;Thromboglobulin [Mass/volume] in Plasma;Thromboglob Plas-mCnc;;ACTIVE;1.0;2.42 +46862-9;Postpartum function.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46863-7;Postpartum function.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46864-5;Pregnancy function.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46865-2;Pregnancy function.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46866-0;Pregnancy function.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46867-8;Reproductive function.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46868-6;Reproductive function.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46869-4;Reproductive function.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Status Community [OMAHA];;;ACTIVE;2.19;2.44 +4687-0;Thromboglobulin beta;-;Pt;Plas;Qn;;HEM/BC;1;Deprecated Thromboglobulin beta;Deprecated Thromboglob beta Plas Qn;;DEPRECATED;1.0;2.66 +46870-2;Residence.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46871-0;Residence.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46872-8;Residence.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Residence Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46873-6;Respiration.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46874-4;Respiration.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46875-1;Respiration.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Respiration Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46876-9;Role change.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46877-7;Role change.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46878-5;Role change.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Role Change Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46879-3;Sanitation.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46880-1;Sanitation.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46881-9;Sanitation.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sanitation Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46882-7;Sexuality.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46883-5;Sexuality.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46884-3;Sexuality.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sexuality Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46885-0;Skin.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46886-8;Skin.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46887-6;Skin.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Skin Status Community [OMAHA];;;ACTIVE;2.19;2.44 +4688-8;Thrombomodulin;-;Pt;Plas;Qn;;HEM/BC;1;Deprecated Thrombomodulin;Deprecated Thrombomodulin Plas Qn;;DEPRECATED;1.0;2.66 +46888-4;Sleep and rest pattern.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46889-2;Sleep and rest pattern.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +468-9;Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sulfamethoxazole [Susceptibility] by Minimum inhibitory concentration (MIC);Sulfamethoxazole Islt MIC;;ACTIVE;1.0;2.19 +46890-0;Sleep and rest pattern.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Sleep And Rest Pattern Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46891-8;Social contact.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46892-6;Social contact.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46893-4;Social contact.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Social Contact Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46894-2;Speech and language.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46895-9;Speech and language.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +4689-6;Verdohemoglobin;-;Pt;Bld;-;;HEM/BC;1;Deprecated Verdohemoglobin;Deprecated Verdohemoglobin Bld;;DEPRECATED;1.0;2.66 +46896-7;Speech and language.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Speech And Language Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46897-5;Spirituality.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46898-3;Spirituality.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46899-1;Spirituality.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Spirituality Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46900-7;Substance use.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46901-5;Substance use.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46902-3;Substance use.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Substance Use Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46903-1;Urinary function.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +4690-4;Viscosity;Visc;Pt;Bld;Qn;;SPEC;1;Viscosity of Blood;Visc Bld;;ACTIVE;1.0;2.73 +46904-9;Urinary function.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46905-6;Urinary function.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46906-4;Vision.behavior;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Behavior Community [OMAHA];;;ACTIVE;2.19;2.44 +46907-2;Vision.knowledge;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Knowledge Community [OMAHA];;;ACTIVE;2.19;2.44 +46908-0;Vision.status;Find;Pt;^Community;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Vision Status Community [OMAHA];;;ACTIVE;2.19;2.44 +46909-8;Communicable &or infectious condition function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.behavior Family [OMAHA];;;ACTIVE;2.19;2.44 +46910-6;Communicable &or infectious condition function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.knowledge Family [OMAHA];;;ACTIVE;2.19;2.44 +46911-4;Communicable &or infectious condition function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.status Family [OMAHA];;;ACTIVE;2.19;2.44 +4691-2;Viscosity;Visc;Pt;Plas;Qn;;SPEC;1;Viscosity of Plasma;Visc Plas;;ACTIVE;1.0;2.73 +46912-2;Oral health.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Behavior Family [OMAHA];;;ACTIVE;2.19;2.44 +46913-0;Oral health.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Knowledge Family [OMAHA];;;ACTIVE;2.19;2.44 +46914-8;Oral health.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Status Family [OMAHA];;;ACTIVE;2.19;2.44 +46915-5;Postpartum function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Behavior Family [OMAHA];;;ACTIVE;2.19;2.44 +46916-3;Postpartum function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Knowledge Family [OMAHA];;;ACTIVE;2.19;2.44 +46917-1;Postpartum function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Status Family [OMAHA];;;ACTIVE;2.19;2.44 +46918-9;Pregnancy function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Behavior Family [OMAHA];;;ACTIVE;2.19;2.44 +46919-7;Pregnancy function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Knowledge Family [OMAHA];;;ACTIVE;2.19;2.44 +4692-0;HLA Ag;ACnt;Pt;Tiss;Qn;;HLA;1;HLA Ag [Units/mass] in Tissue;HLA Ag Tiss-aCnt;;ACTIVE;1.0;2.22 +46920-5;Pregnancy function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Status Family [OMAHA];;;ACTIVE;2.19;2.44 +46921-3;Reproductive function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Behavior Family [OMAHA];;;ACTIVE;2.19;2.44 +46922-1;Reproductive function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Knowledge Family [OMAHA];;;ACTIVE;2.19;2.44 +46923-9;Reproductive function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Status Family [OMAHA];;;ACTIVE;2.19;2.44 +46924-7;Urinary function.behavior;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Behavior Family [OMAHA];;;ACTIVE;2.19;2.44 +46925-4;Urinary function.knowledge;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Knowledge Family [OMAHA];;;ACTIVE;2.19;2.44 +46926-2;Urinary function.status;Find;Pt;^Family;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Status Family [OMAHA];;;ACTIVE;2.19;2.44 +46927-0;Communicable &or infectious condition function.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.behavior [OMAHA];;;ACTIVE;2.19;2.44 +46928-8;Communicable &or infectious condition function.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.knowledge [OMAHA];;;ACTIVE;2.19;2.44 +46929-6;Communicable &or infectious condition function.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Communicable/infectious condition function.status [OMAHA];;;ACTIVE;2.19;2.44 +46930-4;Oral health.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Behavior [OMAHA];;;ACTIVE;2.19;2.44 +46931-2;Oral health.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Knowledge [OMAHA];;;ACTIVE;2.19;2.44 +46932-0;Oral health.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Oral Health Status [OMAHA];;;ACTIVE;2.19;2.44 +46933-8;Postpartum function.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Behavior [OMAHA];;;ACTIVE;2.19;2.44 +46934-6;Postpartum function.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Knowledge [OMAHA];;;ACTIVE;2.19;2.44 +46935-3;Postpartum function.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Postpartum Function Status [OMAHA];;;ACTIVE;2.19;2.44 +46936-1;Pregnancy function.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Behavior [OMAHA];;;ACTIVE;2.19;2.44 +46937-9;Pregnancy function.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Knowledge [OMAHA];;;ACTIVE;2.19;2.44 +4693-8;HLA Ag absent;Prid;Pt;Bld/Tiss;Nom;;HLA;1;HLA Ag absent [Identifier];HLA Ag absent;;ACTIVE;1.0;2.50 +46938-7;Pregnancy function.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Pregnancy Function Status [OMAHA];;;ACTIVE;2.19;2.44 +46939-5;Reproductive function.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Behavior [OMAHA];;;ACTIVE;2.19;2.44 +46940-3;Reproductive function.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Knowledge [OMAHA];;;ACTIVE;2.19;2.44 +46941-1;Reproductive function.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Reproductive Function Status [OMAHA];;;ACTIVE;2.19;2.44 +46942-9;Urinary function.behavior;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Behavior [OMAHA];;;ACTIVE;2.19;2.44 +46943-7;Urinary function.knowledge;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Knowledge [OMAHA];;;ACTIVE;2.19;2.44 +46944-5;Urinary function.status;Find;Pt;^Patient;Ord;Observed.OMAHA;SURVEY.NURSE.OMAHA;4;Urinary Function Status [OMAHA];;;ACTIVE;2.19;2.44 +46945-2;Beclomethasone dipropionate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Beclomethasone dipropionate [Mass/volume] in Urine;Beclomethasone Dp Ur-mCnc;;ACTIVE;2.19;2.42 +4694-6;HLA Ag present;Prid;Pt;Bld/Tiss;Nom;;HLA;1;HLA Ag present [Identifier];HLA Ag present;;ACTIVE;1.0;2.73 +46946-0;Betamethasone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Betamethasone [Mass/volume] in Urine;Betamethasone Ur-mCnc;;ACTIVE;2.19;2.42 +46947-8;Budesonide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Budesonide [Mass/volume] in Urine;Budesonide Ur-mCnc;;ACTIVE;2.19;2.42 +46948-6;Dexamethasone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dexamethasone [Mass/volume] in Urine;Dexamethasone Ur-mCnc;;ACTIVE;2.19;2.42 +46949-4;Fludrocortisone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fludrocortisone [Mass/volume] in Urine;Fludrocortisone Ur-mCnc;;ACTIVE;2.19;2.42 +46950-2;Flunisolide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Flunisolide [Mass/volume] in Urine;Flunisolide Ur-mCnc;;ACTIVE;2.19;2.34 +46951-0;Fluorometholone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fluorometholone [Mass/volume] in Urine;Fluorometholone Ur-mCnc;;ACTIVE;2.19;2.42 +46952-8;Fluticasone propionate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fluticasone propionate [Mass/volume] in Urine;Fluticasone Prop Ur-mCnc;;ACTIVE;2.19;2.42 +4695-3;HLA-A19;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A19 [Presence] in Donor;HLA-A19 Donr Ql;;ACTIVE;1.0;2.56 +46953-6;Megestrol acetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Megestrol acetate [Mass/volume] in Urine;Megestrol Acetate Ur-mCnc;;ACTIVE;2.19;2.42 +46954-4;Methylprednisolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methylprednisolone [Mass/volume] in Urine;Me-prednisolone Ur-mCnc;;ACTIVE;2.19;2.42 +46955-1;prednisoLONE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;prednisoLONE [Mass/volume] in Urine;prednisoLONE Ur-mCnc;;ACTIVE;2.19;2.42 +46956-9;predniSONE;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;predniSONE [Mass/volume] in Urine;predniSONE Ur-mCnc;;ACTIVE;2.19;2.42 +46957-7;Triamcinolone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Triamcinolone [Mass/volume] in Urine;Triamcinolone Ur-mCnc;;ACTIVE;2.19;2.42 +46958-5;Triamcinolone acetonide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Triamcinolone acetonide [Mass/volume] in Urine;Triamcinolone Aceto Ur-mCnc;;ACTIVE;2.19;2.42 +46959-3;Synthetic glucocorticoid panel;MCnc;Pt;Urine;Qn;;PANEL.CHEM;1;Synthetic glucocorticoid panel [Mass/volume] - Urine;Syn Glucocorticoid Pnl Ur-mCnc;;ACTIVE;2.19;2.42 +46960-1;TCR alpha beta Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;TCR alpha beta Ag [Presence] in Tissue by Immune stain;TCR A-B Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +4696-1;HLA-A19;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A19 [Presence];HLA-A19 Ql;;ACTIVE;1.0;2.56 +46961-9;TCR gamma delta Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;TCR gamma delta Ag [Presence] in Tissue by Immune stain;TCR G-D Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +46962-7;Vasoactive intestinal peptide Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Vasoactive intestinal peptide Ag [Presence] in Tissue by Immune stain;VIP Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +46963-5;Tube number;ID;Pt;Ser/Plas/Bld;Nom;;SPEC;1;Tube number of Serum, Plasma or Blood;Tube # SerPlBld;;ACTIVE;2.19;2.73 +46964-3;Cryptococcus sp Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Cryptococcus sp Ag [Presence] in Cerebral spinal fluid by Latex agglutination;Cryptoc Ag CSF Ql LA;;ACTIVE;2.19;2.73 +46965-0;MCOLN1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MCOLN1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MCOLN1 gene Mut Anl Bld/T;;ACTIVE;2.19;2.73 +46966-8;Cells.CD69;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD69 cells [#/volume] in Blood;CD69 Cells # Bld;;ACTIVE;2.19;2.70 +46967-6;Cells.CD40;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD40 cells [#/volume] in Blood;CD40 Cells # Bld;;ACTIVE;2.19;2.70 +46968-4;Cells.CD122;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD122 cells [#/volume] in Blood;CD122 Cells # Bld;;ACTIVE;2.19;2.70 +46969-2;Asialoganglioside GM1 Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgG Ab [Titer] in Serum by Immunoassay;GM1 Asialo IgG Titr Ser IA;;ACTIVE;2.19;2.73 +469-7;Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Sulfamethoxazole [Susceptibility] by Disk diffusion (KB);Sulfamethoxazole Islt KB;;ACTIVE;1.0;2.21 +46970-0;BK virus DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;BK virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;BKV DNA CSF Ql NAA+probe;;ACTIVE;2.19;2.63 +46971-8;HYDROmorphone.free;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;HYDROmorphone Free [Mass/volume] in Urine by Confirmatory method;HYDROmorphone Free Ur Cfm-mCnc;;ACTIVE;2.19;2.70 +46972-6;6-Monoacetylmorphine.free;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Deprecated 6-monoacetylmorphine free [Mass/volume] in Serum or Plasma by Confirm method;Deprecated 6MAM Free SerPl Cfm-mCnc;;DEPRECATED;2.19;2.70 +46973-4;oxyCODONE.free;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;oxyCODONE Free [Mass/volume] in Urine by Confirmatory method;oxyCODONE Free Ur Cfm-mCnc;;ACTIVE;2.19;2.73 +46974-2;oxyMORphone.free;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;oxyMORphone Free [Mass/volume] in Serum or Plasma by Confirmatory method;oxyMORphone Free SerPl Cfm-mCnc;;ACTIVE;2.19;2.73 +46975-9;oxyMORphone.free;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;oxyMORphone Free [Mass/volume] in Urine by Confirmatory method;oxyMORphone Free Ur Cfm-mCnc;;ACTIVE;2.19;2.70 +46976-7;Benzodiazepines;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Benzodiazepines [Presence] in Serum or Plasma by Screen method;Benzodiaz SerPl Ql Scn;;ACTIVE;2.19;2.73 +46977-5;Benzodiazepines;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Serum or Plasma by Confirmatory method;Benzodiaz SerPl Cfm-mCnc;;ACTIVE;2.19;2.73 +46978-3;Salicylates;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Salicylates [Mass/volume] in Serum or Plasma by Confirmatory method;Salicylates SerPl Cfm-mCnc;;ACTIVE;2.19;2.70 +4697-9;HLA-A33(19);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A33(19) [Presence] in Donor;HLA-A33(19) Donr Ql;;ACTIVE;1.0;2.56 +46979-1;Flurazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Flurazepam [Mass/volume] in Serum or Plasma by Confirmatory method;Flurazepam SerPl Cfm-mCnc;;ACTIVE;2.19;2.73 +46980-9;N-desalkylflurazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Serum or Plasma by Confirmatory method;Desalkylfluraz SerPl Cfm-mCnc;;ACTIVE;2.19;2.73 +46981-7;Silicon;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Silicon [Mass/volume] in Urine;Silicon Ur-mCnc;;ACTIVE;2.19;2.73 +46982-5;Liver kidney microsomal Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Liver kidney microsomal IgG Ab [Titer] in Serum by Immunofluorescence;LKM IgG Titr Ser IF;;ACTIVE;2.19;2.70 +46983-3;Ethanol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethanol [Mass/volume] in Urine by Confirmatory method;Ethanol Ur Cfm-mCnc;;ACTIVE;2.19;2.73 +46984-1;LDL 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 2 [Mass/volume] in Serum or Plasma;LDL2 SerPl-mCnc;;DISCOURAGED;2.19;2.73 +46985-8;LDL 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 3 [Mass/volume] in Serum or Plasma;LDL3 SerPl-mCnc;;DISCOURAGED;2.19;2.73 +46986-6;Cholesterol.in VLDL 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL 3 [Mass/volume] in Serum or Plasma;VLDL3c SerPl-mCnc;;ACTIVE;2.19;2.73 +4698-7;HLA-A33(19);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A33(19) [Presence];HLA-A33(19) Ql;;ACTIVE;1.0;2.56 +46987-4;Helicobacter pylori Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Helicobacter pylori IgM Ab [Presence] in Serum by Immunoassay;H pylori IgM Ser Ql IA;;ACTIVE;2.19;2.73 +46988-2;GBA gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GBA gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;GBA gene Mut Tested Bld/T;;ACTIVE;2.19;2.73 +46989-0;CFTR gene targeted mutation analysis;Find;Pt;Amnio fld;Doc;Molgen;MOLPATH.MUT;1;CFTR gene targeted mutation analysis in Amniotic fluid by Molecular genetics method;CFTR Mut Anl Amn;;ACTIVE;2.19;2.73 +46990-8;ASPA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ASPA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ASPA gene Mut Anl Bld/T;;ACTIVE;2.19;2.73 +46991-6;BLM gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BLM gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BLM gene Mut Anl Bld/T;;ACTIVE;2.19;2.73 +46992-4;DYS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;DYS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;DYS gene Mut Anl Bld/T;;ACTIVE;2.19;2.73 +46993-2;HLA Ab panel;-;Pt;Ser;-;;PANEL.HLA;1;HLA Ab panel - Serum;HLA Ab Pnl Ser;;ACTIVE;2.19;2.73 +46994-0;HLA-A+B+C Ab;NFr;Pt;Ser;Qn;;HLA;1;HLA-A+B+C (class I) Ab in Serum;HLA-A+B+C Ab NFr Ser;;ACTIVE;2.19;2.73 +4699-5;HLA-A34(10);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A34(10) [Presence] in Donor;HLA-A34(10) Donr Ql;;ACTIVE;1.0;2.56 +46995-7;HLA-DP+DQ+DR Ab;NFr;Pt;Ser;Qn;;HLA;1;HLA-DP+DQ+DR (class II) Ab in Serum;HLA-DP+DQ+DR Ab NFr Ser;;ACTIVE;2.19;2.73 +46996-5;HLA Ab positive cells;Num;Pt;Ser;Qn;;HLA;1;HLA Ab positive cells [#] in Serum;Num HLA Ab positive cells;;ACTIVE;2.19;2.73 +46997-3;HLA Ab cells tested;Num;Pt;Ser;Qn;;HLA;1;HLA Ab cells tested [#] in Serum;Num HLA Ab cells tested;;ACTIVE;2.19;2.70 +46998-1;TCRB & Immunoglobulin heavy chain gene rearrangements;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.REARRANGE;1;TCRB and HC gene rearrangements in Blood or Tissue by Molecular genetics method;TCRB+HC gene Rear Bld/T;;ACTIVE;2.19;2.66 +46999-9;Bacterial vaginosis & vaginitis rRNA panel;-;Pt;Vag;-;Probe;PANEL.MICRO;1;Bacterial vaginosis and vaginitis rRNA panel - Vaginal fluid by Probe;Vaginosis/itis rRNA Pnl Vag Probe;;ACTIVE;2.19;2.73 +47000-5;Candida sp rRNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Candida sp rRNA [Presence] in Vaginal fluid by Probe;Candida rRNA Vag Ql Probe;;ACTIVE;2.19;2.73 +4700-1;HLA-A34(10);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A34(10) [Presence];HLA-A34(10) Ql;;ACTIVE;1.0;2.56 +47001-3;Brucella sp Ag;PrThr;Pt;XXX;Ord;Aggl;MICRO;1;Brucella sp Ag [Presence] in Specimen by Agglutination;Brucella Ag Spec Ql Aggl;;ACTIVE;2.19;2.69 +47002-1;Varicella zoster virus DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;VZV DNA # CSF NAA+probe;;ACTIVE;2.19;2.73 +47003-9;Varicella zoster virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;VZV DNA # SerPl NAA+probe;;ACTIVE;2.19;2.73 +47004-7;6-Monoacetylmorphine.free;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;6-monoacetylmorphine free [Mass/volume] in Urine by Confirmatory method;6MAM Free Ur Cfm-mCnc;;ACTIVE;2.19;2.70 +47005-4;Spermatozoa Ab.IgM/100 spermatozoa;NFr;Pt;Ser;Qn;Immunobead;FERT;1;Spermatozoa IgM Ab/100 spermatozoa in Serum by Immunobead;Sperm IgM NFr Ser IBT;;ACTIVE;2.19;2.70 +47006-2;Spermatozoa Ab.IgG/100 spermatozoa;NFr;Pt;Ser;Qn;Immunobead;FERT;1;Spermatozoa IgG Ab/100 spermatozoa in Serum by Immunobead;Sperm IgG NFr Ser IBT;;ACTIVE;2.19;2.73 +47007-0;Spermatozoa Ab.IgA/100 spermatozoa;NFr;Pt;Ser;Qn;Immunobead;FERT;1;Spermatozoa IgA Ab/100 spermatozoa in Serum by Immunobead;Sperm IgA NFr Ser IBT;;ACTIVE;2.19;2.73 +47008-8;Platelet associated Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Platelet associated IgG Ab [Presence] in Serum by Immunoassay;PA IgG Ser Ql IA;;ACTIVE;2.19;2.73 +47009-6;BCL6 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BCL6 Ag [Presence] in Tissue by Immune stain;BCL6 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47010-4;Ber-EP4 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Ber-EP4 Ag [Presence] in Tissue by Immune stain;BER-EP4 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47011-2;Calretinin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Calretinin Ag [Presence] in Tissue by Immune stain;Calretinin Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47012-0;Cancer Ag 72-4;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cancer Ag 72-4 [Presence] in Tissue by Immune stain;Cancer Ag72-4 Tiss Ql ImStn;;ACTIVE;2.19;2.56 +47013-8;CD1a Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD1a Ag [Presence] in Tissue by Immune stain;CD1a Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +47014-6;CD21 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD21 Ag [Presence] in Tissue by Immune stain;CD21 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47015-3;CD31 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD31 Ag [Presence] in Tissue by Immune stain;CD31 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47016-1;CD4 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD4 Ag [Presence] in Tissue by Immune stain;CD4 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47017-9;CD68 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD68 Ag [Presence] in Tissue by Immune stain;CD68 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47018-7;CD79a Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD79a Ag [Presence] in Tissue by Immune stain;CD79a Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +4701-9;HLA-A36;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A36 [Presence] in Donor;HLA-A36 Donr Ql;;ACTIVE;1.0;2.56 +47019-5;CD8 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD8 Ag [Presence] in Tissue by Immune stain;CD8 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47020-3;CD99 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD99 Ag [Presence] in Tissue by Immune stain;CD99 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +47021-1;CDX2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CDX2 Ag [Presence] in Tissue by Immune stain;CDX2 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47022-9;Cells.CD11c+CD19+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11c+CD19+ cells/100 cells in Specimen;CD11c+CD19+ Cells NFr Spec;;ACTIVE;2.19;2.70 +47023-7;Cells.CD19+CD23+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+CD23+ cells/100 cells in Specimen;CD19+CD23+ Cells NFr Spec;;ACTIVE;2.19;2.70 +47024-5;Choriogonadotropin.beta subunit Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Choriogonadotropin.beta subunit Ag [Presence] in Tissue by Immune stain;B-HCG Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47025-2;Cytokeratin 5+6 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytokeratin 5/6 Ag [Presence] in Tissue by Immune stain;CK 5/6 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47026-0;Cytokeratin HMW Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytoketatin HMW Ag [Presence] in Tissue by Immune stain;CK HMW Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +4702-7;HLA-A36;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A36 [Presence];HLA-A36 Ql;;ACTIVE;1.0;2.56 +47027-8;DBA44 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;DBA44 Ag [Presence] in Tissue by Immune stain;DBA44 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47028-6;Follitropin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Follitropin Ag [Presence] in Tissue by Immune stain;FSH Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47029-4;HIV 2 Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;HIV 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot;HIV 2 Ab CSF Ql IB;;ACTIVE;2.19;2.58 +47030-2;Phosphatidate Ab.IgA;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidate IgA Ab [Units/volume] in Serum by Immunoassay;Phosphatidate IgA Ser IA-aCnc;;ACTIVE;2.19;2.73 +47031-0;Melan-A Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Melan-A Ag [Presence] in Tissue by Immune stain;Melan-A Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47032-8;MyoD1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;MyoD1 Ag [Presence] in Tissue by Immune stain;MyoD1 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +47033-6;Myogenin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Myogenin Ag [Presence] in Tissue by Immune stain;Myogenin Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47034-4;Neurofilament Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Neurofilament Ag [Presence] in Tissue by Immune stain;Neurofilament Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +4703-5;HLA-A43;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A43 [Presence] in Donor;HLA-A43 Donr Ql;;ACTIVE;1.0;2.56 +47035-1;NKI-C3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;NKI/C3 Ag [Presence] in Tissue by Immune stain;NKI/C3 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +47036-9;Streptococcus pneumoniae 34 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 34 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum34 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47037-7;Streptococcus pneumoniae Danish serotype 9V Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Ratio] in Serum by Immunoassay --2nd specimen/1st specimen;S pneum Da 9V IgG 2:1 Ser IA-Rto;;ACTIVE;2.19;2.61 +47038-5;Villin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Villin Ag [Presence] in Tissue by Immune stain;Villin Ag Tiss Ql ImStn;;ACTIVE;2.19;2.56 +47039-3;Admission history and physical note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Admission history and physical note;Hosp Admit H&P note;;ACTIVE;2.19;2.67 +47040-1;Confirmatory consultation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Consultation 2nd opinion;Confirm consult note;;ACTIVE;2.19;2.73 +47041-9;Confirmatory consultation note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Consultation 2nd opinion;Hosp Confirm consult note;;ACTIVE;2.19;2.67 +47042-7;Counseling note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Counseling note;Counseling note;;ACTIVE;2.19;2.73 +4704-3;HLA-A43;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A43 [Presence];HLA-A43 Ql;;ACTIVE;1.0;2.56 +47043-5;Group counseling note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Group counseling note;Group counseling note;;ACTIVE;2.19;2.67 +47044-3;Initial evaluation note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Initial evaluation note;Hosp Initial eval note;;ACTIVE;2.19;2.67 +47045-0;Study report;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Study report;Study report;;ACTIVE;2.19;2.73 +47046-8;Summary of death note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Summary of death note;Summary of death;;ACTIVE;2.19;2.67 +47047-6;Supervisory note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Supervisory note;Supervisory note;;ACTIVE;2.19;2.67 +47048-4;Diagnostic interventional radiology study;Find;Pt;^Patient;Doc;Interventional radiology;DOC.MISC;2;Diagnostic interventional radiology study;Dx interventional study IR;;ACTIVE;2.19;2.73 +47049-2;Communication note;Find;Pt;{Setting};Doc;{Non-patient};DOC.ONTOLOGY;2;Deprecated Non-patient Communication note;Deprecated Non-patient Communication;;DEPRECATED;2.19;2.50 +470-5;Sulfamethoxazole;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Sulfamethoxazole [Susceptibility] by Serum bactericidal titer;Sulfamethoxazole Titr SBT;;ACTIVE;1.0;2.32 +4705-0;HLA-A66(10);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A66(10) [Presence] in Donor;HLA-A66(10) Donr Ql;;ACTIVE;1.0;2.56 +47050-0;Herpes virus 8 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 8 IgG Ab [Titer] in Serum by Immunofluorescence;HHV8 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47051-8;Treponema pallidum Ab.IgG;ACnc;Pt;CSF;Qn;IF;MICRO;1;Treponema pallidum IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;T pallidum IgG CSF IF-aCnc;;ACTIVE;2.19;2.70 +47052-6;Chlamydophila pneumoniae Ab;ACnc;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila pneumoniae Ab [Units/volume] in Serum by Immunofluorescence;C pneum Ab Ser IF-aCnc;;ACTIVE;2.19;2.70 +47053-4;Enolase.neuron specific;MCnc;Pt;CSF;Qn;IA;CHEM;1;Enolase.neuron specific [Mass/volume] in Cerebral spinal fluid by Immunoassay;NSE CSF IA-mCnc;;ACTIVE;2.19;2.73 +47054-2;Legionella pneumophila 10 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 10 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo 10 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47055-9;Legionella pneumophila 11 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 11 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo 11 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47056-7;Legionella pneumophila 11 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 11 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo 11 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47057-5;Legionella pneumophila 12 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 12 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo 12 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47058-3;Legionella pneumophila 12 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 12 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo 12 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47059-1;Legionella pneumophila 13 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 13 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo 13 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47060-9;Legionella pneumophila 13 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 13 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo 13 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47061-7;Legionella pneumophila 14 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 14 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo 14 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47062-5;Legionella pneumophila 14 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 14 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo 14 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47063-3;Treponema pallidum Ab.IgM;ACnc;Pt;CSF;Qn;IF;MICRO;1;Treponema pallidum IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;T pallidum IgM CSF IF-aCnc;;ACTIVE;2.19;2.70 +47064-1;Epstein Barr virus capsid Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Epstein Barr virus capsid IgG Ab [Titer] in Body fluid by Immunofluorescence;EBV VCA IgG Titr Fld IF;;ACTIVE;2.19;2.70 +47065-8;Rickettsia typhi Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;R typhi IgG Titr CSF IF;;ACTIVE;2.19;2.70 +47066-6;Epstein Barr virus capsid Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Epstein Barr virus capsid IgM Ab [Titer] in Body fluid by Immunofluorescence;EBV VCA IgM Titr Fld IF;;ACTIVE;2.19;2.70 +47067-4;Rickettsia typhi Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia typhi IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;R typhi IgM Titr CSF IF;;ACTIVE;2.19;2.70 +4706-8;HLA-A66(10);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A66(10) [Presence];HLA-A66(10) Ql;;ACTIVE;1.0;2.56 +47068-2;Epstein Barr virus early Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Epstein Barr virus early IgG Ab [Titer] in Body fluid by Immunofluorescence;EBV EA IgG Titr Fld IF;;ACTIVE;2.19;2.70 +47069-0;Rickettsia rickettsii Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia rickettsii IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;R rickettsi IgG Titr CSF IF;;ACTIVE;2.19;2.70 +47070-8;Rickettsia rickettsii Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia rickettsii IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;R rickettsi IgM Titr CSF IF;;ACTIVE;2.19;2.70 +47071-6;Babesia microti Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Babesia microti IgG Ab [Titer] in Cerebral spinal fluid;B microti IgG Titr CSF;;ACTIVE;2.19;2.70 +47072-4;Epstein Barr virus early Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus early IgA Ab [Titer] in Serum by Immunofluorescence;EBV EA IgA Titr Ser IF;;ACTIVE;2.19;2.73 +47073-2;Babesia microti Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Babesia microti IgM Ab [Titer] in Cerebral spinal fluid;B microti IgM Titr CSF;;ACTIVE;2.19;2.70 +47074-0;PCNA extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;PCNA extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA PCNA Ab Ser Ql IF;;ACTIVE;2.19;2.73 +47075-7;Coxiella burnetii phase 1 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Titer] in Serum by Immunofluorescence;C burnet Ph1 IgM Titr Ser IF;;ACTIVE;2.19;2.73 +4707-6;HLA-A68(28);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A68(28) [Presence] in Donor;HLA-A68(28) Donr Ql;;ACTIVE;1.0;2.56 +47076-5;Legionella pneumophila 7 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 7 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo7 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47077-3;Legionella pneumophila 7 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 7 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo7 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47078-1;Legionella pneumophila 8 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 8 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo8 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47079-9;Legionella pneumophila 8 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 8 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo8 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47080-7;Legionella pneumophila 9 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 9 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo9 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47081-5;Legionella pneumophila 9 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 9 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo9 IgM Titr Ser IF;;ACTIVE;2.19;2.70 +47082-3;Legionella pneumophila 10 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 10 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo 10 IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47083-1;IgG;MCnc;24H;Urine;Qn;;CHEM;1;IgG [Mass/volume] in 24 hour Urine;IgG 24h Ur-mCnc;;ACTIVE;2.19;2.73 +4708-4;HLA-A68(28);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A68(28) [Presence];HLA-A68(28) Ql;;ACTIVE;1.0;2.56 +47084-9;Platelet glycoprotein Ia-IIa Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Platelet glycoprotein Ia/IIa Ab [Presence] in Serum by Immunoassay;Plat Gp Ia/IIa Ab Ser Ql IA;;ACTIVE;2.19;2.73 +47085-6;Plasmodium sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Plasmodium sp DNA [Presence] in Blood by NAA with probe detection;Plasmodium DNA Bld Ql NAA+probe;;ACTIVE;2.19;2.73 +47086-4;11-Hydroxyandrostenedione;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Hydroxyandrostenedione [Moles/volume] in Serum or Plasma;11OH-Ad SerPl-sCnc;;ACTIVE;2.19;2.70 +47087-2;Angiotensinogen;SCnc;Pt;Plas;Qn;;CHEM;1;Angiotensinogen [Moles/volume] in Plasma;Angiotensinogen Plas-sCnc;;ACTIVE;2.19;2.70 +47088-0;Delta aminolevulinate;SCnc;Pt;Ser;Qn;;CHEM;1;Delta aminolevulinate [Moles/volume] in Serum;D-ALA Ser-sCnc;;ACTIVE;2.19;2.70 +47089-8;Indicans;SRat;24H;Urine;Qn;;CHEM;1;Indicans [Moles/time] in 24 hour Urine;Indicans 24h Ur-sRate;;ACTIVE;2.19;2.70 +47090-6;Indicans/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Indicans/Creatinine [Molar ratio] in 24 hour Urine;Indicans/Creat 24h Ur-sRto;;ACTIVE;2.19;2.70 +47091-4;Methylmalonate;SRat;24H;Urine;Qn;;CHEM;1;Methylmalonate [Moles/time] in 24 hour Urine;Methylmalonate 24h Ur-sRate;;ACTIVE;2.19;2.70 +4709-2;HLA-A69(28);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A69(28) [Presence] in Donor;HLA-A69(28) Donr Ql;;ACTIVE;1.0;2.56 +47092-2;Natriuretic peptide.B;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Natriuretic peptide B [Moles/volume] in Serum or Plasma;BNP SerPl-sCnc;;ACTIVE;2.19;2.73 +47093-0;Parathyrin.biointact;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.biointact [Moles/volume] in Serum or Plasma;PTH-Biointact SerPl-sCnc;;DISCOURAGED;2.19;2.70 +47094-8;Calciferol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calciferol (Vit D2) [Moles/volume] in Serum or Plasma;Vitamin D2 SerPl-sCnc;;ACTIVE;2.19;2.73 +47095-5;Acetaminophen;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Acetaminophen [Moles/volume] in Gastric fluid;APAP Gast-sCnc;;ACTIVE;2.19;2.70 +47096-3;Aluminum;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Red Blood Cells;Aluminum RBC-sCnc;;ACTIVE;2.19;2.70 +47097-1;carBAMazepine 10,11-Epoxide.free;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbamazepine 10,11-epoxide free [Moles/volume] in Serum or Plasma;Carbamazepine EP Free SerPl-sCnc;;ACTIVE;2.19;2.70 +47098-9;Chromium;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Chromium [Moles/volume] in Body fluid;Chromium Fld-sCnc;;ACTIVE;2.19;2.70 +47099-7;Chromium;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Chromium [Moles/volume] in 24 hour Urine;Chromium 24h Ur-sCnc;;ACTIVE;2.19;2.70 +47-1;Bacampicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Bacampicillin [Susceptibility] by Minimum lethal concentration (MLC);Bacampicillin Islt MLC;;ACTIVE;1.0;2.19 +4710-0;HLA-A69(28);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A69(28) [Presence];HLA-A69(28) Ql;;ACTIVE;1.0;2.56 +47100-3;Copper;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Copper [Moles/volume] in Blood;Copper Bld-sCnc;;ACTIVE;2.19;2.70 +47101-1;Copper;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Copper [Moles/volume] in Body fluid;Copper Fld-sCnc;;ACTIVE;2.19;2.70 +47102-9;Copper;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Copper [Moles/volume] in Red Blood Cells;Copper RBC-sCnc;;ACTIVE;2.19;2.70 +47103-7;Copper;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Copper [Moles/mass] in Hair;Copper Hair-sCnt;;ACTIVE;2.19;2.70 +47104-5;Doxepin;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Doxepin [Moles/volume] in Gastric fluid;Doxepin Gast-sCnc;;ACTIVE;2.19;2.70 +47105-2;ePHEDrine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;ePHEDrine [Presence] in Gastric fluid;Ephedrin Gast Ql;;ACTIVE;2.19;2.56 +47106-0;ePHEDrine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;ePHEDrine [Presence] in Serum or Plasma;Ephedrin SerPl Ql;;ACTIVE;2.19;2.56 +47107-8;Ethanol;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Ethanol [Moles/volume] in Gastric fluid;Ethanol Gast-sCnc;;ACTIVE;2.19;2.70 +47108-6;Furosemide;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Furosemide [Presence] in Gastric fluid;Furosemide Gast Ql;;ACTIVE;2.19;2.56 +47109-4;Gentamicin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Moles/volume] in Serum or Plasma;Gentamicin SerPl-sCnc;;ACTIVE;2.19;2.73 +47110-2;Glutethimide;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Glutethimide [Moles/volume] in Gastric fluid;Glutethimide Gast-sCnc;;ACTIVE;2.19;2.70 +47111-0;Glutethimide;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Glutethimide [Moles/volume] in Urine;Glutethimide Ur-sCnc;;ACTIVE;2.19;2.70 +47112-8;Gold;SRat;24H;Urine;Qn;;DRUG/TOX;1;Gold [Moles/time] in 24 hour Urine;Gold 24h Ur-sRate;;ACTIVE;2.19;2.70 +47113-6;Gold/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Gold/Creatinine [Molar ratio] in 24 hour Urine;Gold/Creat 24h Ur-sRto;;ACTIVE;2.19;2.70 +47114-4;LORazepam;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;LORazepam [Moles/volume] in Gastric fluid;LORazepam Gast-sCnc;;ACTIVE;2.19;2.70 +47115-1;LORazepam;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;LORazepam [Moles/volume] in Urine;LORazepam Ur-sCnc;;ACTIVE;2.19;2.73 +47116-9;Manganese;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Manganese [Moles/volume] in Gastric fluid;Manganese Gast-sCnc;;ACTIVE;2.19;2.70 +47117-7;Maprotiline;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Maprotiline [Moles/volume] in Gastric fluid;Maprotiline Gast-sCnc;;ACTIVE;2.19;2.70 +4711-8;HLA-A74(19);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A74(19) [Presence] in Donor;HLA-A74(19) Donr Ql;;ACTIVE;1.0;2.56 +47118-5;Maprotiline;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Maprotiline [Moles/volume] in Urine;Maprotiline Ur-sCnc;;ACTIVE;2.19;2.70 +47119-3;Meprobamate;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Meprobamate [Moles/volume] in Gastric fluid;Meprobamate Gast-sCnc;;ACTIVE;2.19;2.70 +47120-1;Meprobamate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Meprobamate [Moles/volume] in Urine;Meprobamate Ur-sCnc;;ACTIVE;2.19;2.70 +47121-9;Mercury;SCnt;Pt;XXX;Qn;;DRUG/TOX;1;Mercury [Moles/mass] in Specimen;Mercury Spec-sCnt;;ACTIVE;2.19;2.70 +47122-7;Methyprylon;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methyprylon [Moles/volume] in Gastric fluid;Methyprylon Gast-sCnc;;ACTIVE;2.19;2.70 +47123-5;Nickel;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Nickel [Moles/mass] in Hair;Nickel Hair-sCnt;;ACTIVE;2.19;2.70 +47124-3;PHENobarbital;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;PHENobarbital [Moles/volume] in Gastric fluid;Phenobarb Gast-sCnc;;ACTIVE;2.19;2.70 +47125-0;Primidone;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Primidone [Moles/volume] in Gastric fluid;Primidone Gast-sCnc;;ACTIVE;2.19;2.70 +4712-6;HLA-A74(19);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A74(19) [Presence];HLA-A74(19) Ql;;ACTIVE;1.0;2.56 +47126-8;Protriptyline;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Protriptyline [Moles/volume] in Gastric fluid;Protrip Gast-sCnc;;ACTIVE;2.19;2.70 +47127-6;Protriptyline;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Protriptyline [Moles/volume] in Urine;Protrip Ur-sCnc;;ACTIVE;2.19;2.70 +47128-4;Salicylates;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Salicylates [Moles/volume] in Gastric fluid;Salicylates Gast-sCnc;;ACTIVE;2.19;2.70 +47129-2;Silver;SRat;24H;Urine;Qn;;DRUG/TOX;1;Silver [Moles/time] in 24 hour Urine;Silver 24h Ur-sRate;;ACTIVE;2.19;2.70 +471-3;sulfiSOXAZOLE;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;sulfiSOXAZOLE [Susceptibility] by Minimum lethal concentration (MLC);Sulfisoxaz Islt MLC;;ACTIVE;1.0;2.19 +47130-0;Thallium;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Thallium [Moles/volume] in Red Blood Cells;Thallium RBC-sCnc;;ACTIVE;2.19;2.70 +47131-8;Thioridazine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Thioridazine [Moles/volume] in Gastric fluid;Thioridazine Gast-sCnc;;ACTIVE;2.19;2.70 +47132-6;Thioridazine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thioridazine [Moles/volume] in Urine;Thioridazine Ur-sCnc;;ACTIVE;2.19;2.70 +47133-4;Trimipramine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Trimipramine [Moles/volume] in Gastric fluid;Trimipramine Gast-sCnc;;ACTIVE;2.19;2.70 +4713-4;HLA-A10;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A10 [Presence] in Donor;HLA-A10 Donr Ql;;ACTIVE;1.0;2.56 +47134-2;Trimipramine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trimipramine [Moles/volume] in Urine;Trimipramine Ur-sCnc;;ACTIVE;2.19;2.70 +47135-9;Ascorbate^post dose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Ascorbate [Moles/volume] in Serum or Plasma --post dose;Vit C p dose SerPl-sCnc;;ACTIVE;2.19;2.70 +47136-7;Epinephrine^1H post 300 ug cloNIDine PO;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --1 hour post 300 ug cloNIDine PO;Epineph 1h p 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +47137-5;Epinephrine^2H post 300 ug cloNIDine PO;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --2 hours post 300 ug cloNIDine PO;Epineph 2h p 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +47138-3;EPINEPHrine^2H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --2 hours post XXX challenge;Epineph 2h p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47139-1;EPINEPHrine^2nd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --2nd specimen post XXX challenge;Epineph sp2 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47140-9;EPINEPHrine^2nd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Urine --2nd specimen post XXX challenge;Epineph sp2 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47141-7;Epinephrine^3H post 300 ug cloNIDine PO;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --3 hours post 300 ug cloNIDine PO;Epineph 3h p 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +4714-2;HLA-A10;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A10 [Presence];HLA-A10 Ql;;ACTIVE;1.0;2.56 +47142-5;EPINEPHrine^3rd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --3rd specimen post XXX challenge;Epineph sp3 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47143-3;EPINEPHrine^3rd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Urine --3rd specimen post XXX challenge;Epineph sp3 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47144-1;EPINEPHrine^4H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --4 hours post XXX challenge;Epineph 4h p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47145-8;EPINEPHrine^4th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Urine --4th specimen post XXX challenge;Epineph sp4 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47146-6;EPINEPHrine^4th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --4th specimen post XXX challenge;Epineph sp4 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47147-4;EPINEPHrine^5th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --5th specimen post XXX challenge;Epineph sp5 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47148-2;EPINEPHrine^5th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Urine --5th specimen post XXX challenge;Epineph sp5 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47149-0;EPINEPHrine^6th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --6th specimen post XXX challenge;Epineph sp6 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47150-8;EPINEPHrine^6th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Urine --6th specimen post XXX challenge;Epineph sp6 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47151-6;EPINEPHrine^7th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --7th specimen post XXX challenge;Epineph sp7 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47152-4;EPINEPHrine^7th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Urine --7th specimen post XXX challenge;Epineph sp7 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47153-2;Epinephrine^pre 300 ug cloNIDine PO;SCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Plasma --pre 300 ug cloNIDine PO;Epineph pre 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +47154-0;Lead^post EDTA therapy;SCnc;Pt;Urine;Qn;;CHAL;1;Lead [Moles/volume] in Urine --post EDTA therapy;Lead p EDTA Ur-sCnc;;ACTIVE;2.19;2.70 +47155-7;Norepinephrine^10M post standing;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --10 minutes post standing;Norepineph 10M p Sta Plas-sCnc;;ACTIVE;2.19;2.70 +47156-5;Norepinephrine^1H post 300 ug clonidine PO;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --1 hour post 300 ug cloNIDine PO;Norepineph 1h p 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +47157-3;Norepinephrine^1H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --1 hour post XXX challenge;Norepineph 1h p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47158-1;Norepinephrine^2H post 300 ug clonidine PO;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --2 hours post 300 ug cloNIDine PO;Norepineph 2h p 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +4715-9;HLA-A11;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A11 [Presence] in Donor;HLA-A11 Donr Ql;;ACTIVE;1.0;2.56 +47159-9;Norepinephrine^2H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --2 hours post XXX challenge;Norepineph 2h p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47160-7;Norepinephrine^2nd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --2nd specimen post XXX challenge;Norepineph sp2 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47161-5;Norepinephrine^2nd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Urine --2nd specimen post XXX challenge;Norepineph sp2 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47162-3;Norepinephrine^3H post 300 ug clonidine PO;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --3 hours post 300 ug cloNIDine PO;Norepineph 3h p 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +47163-1;Norepinephrine^3H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --3 hours post XXX challenge;Norepineph 3h p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47164-9;Norepinephrine^3rd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --3rd specimen post XXX challenge;Norepineph sp3 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47165-6;Norepinephrine^3rd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Urine --3rd specimen post XXX challenge;Norepineph sp3 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47166-4;Norepinephrine^4H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --4 hours post XXX challenge;Norepineph 4h p chal Plas-sCnc;;ACTIVE;2.19;2.70 +4716-7;HLA-A11;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A11 [Presence];HLA-A11 Ql;;ACTIVE;1.0;2.56 +47167-2;Norepinephrine^4th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --4th specimen post XXX challenge;Norepineph sp4 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47168-0;Norepinephrine^4th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Urine --4th specimen post XXX challenge;Norepineph sp4 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47169-8;Norepinephrine^5th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --5th specimen post XXX challenge;Norepineph sp5 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47170-6;Norepinephrine^5th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Urine --5th specimen post XXX challenge;Norepineph sp5 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47171-4;Norepinephrine^6th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --6th specimen post XXX challenge;Norepineph sp6 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47172-2;Norepinephrine^6th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Urine --6th specimen post XXX challenge;Norepineph sp6 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47173-0;Catecholamines^7th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Catecholamines [Moles/volume] in Plasma --7th specimen post XXX challenge;Catechols sp7 p chal Plas-sCnc;;ACTIVE;2.19;2.70 +47174-8;Norepinephrine^7th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Urine --7th specimen post XXX challenge;Norepineph sp7 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +4717-5;HLA-A1;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A1 [Presence] in Donor;HLA-A1 Donr Ql;;ACTIVE;1.0;2.56 +47175-5;Norepinephrine^pre 300 ug clonidine PO;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --pre 300 ug cloNIDine PO;Norepineph pre 300 ug CLN PO Plas-sCnc;;ACTIVE;2.19;2.70 +47176-3;Parathyrin.intact^10M post excision;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Moles/volume] in Serum or Plasma --10 minutes post excision;PTH-Intact 10m p Excision SerPl-sCnc;;ACTIVE;2.19;2.70 +47177-1;Parathyrin.intact^5M post excision;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Moles/volume] in Serum or Plasma --5 minutes post excision;PTH-Intact 5m p Excision SerPl-sCnc;;ACTIVE;2.19;2.70 +47178-9;Parathyrin.intact^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Moles/volume] in Serum or Plasma --baseline;PTH-Intact BS SerPl-sCnc;;ACTIVE;2.19;2.70 +47179-7;Parathyrin^10M post excision;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin [Moles/volume] in Serum or Plasma --10 minutes post excision;PTH 10m p Excision SerPl-sCnc;;ACTIVE;2.19;2.70 +47180-5;Parathyrin^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin [Moles/volume] in Serum or Plasma --baseline;PTH BS SerPl-sCnc;;ACTIVE;2.19;2.70 +47181-3;Progesterone^1.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge;Progest 1.5h p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47182-1;Progesterone^10th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge;Progest sp10 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +4718-3;HLA-A1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A1 [Presence];HLA-A1 Ql;;ACTIVE;1.0;2.73 +47183-9;Progesterone^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;Progest 15M p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47184-7;Progesterone^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Progest 1h p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47185-4;Progesterone^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Progest 2h p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47186-2;Progesterone^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Progest 30M p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47187-0;Progesterone^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;Progest 45M p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47188-8;Progesterone^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;Progest sp5 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47189-6;Progesterone^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --baseline;Progest BS SerPl-sCnc;;ACTIVE;2.19;2.70 +47190-4;Proinsulin^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --baseline;Proinsulin BS SerPl-sCnc;;ACTIVE;2.19;2.70 +4719-1;HLA-A23(9);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A23(9) [Presence] in Donor;HLA-A23(9) Donr Ql;;ACTIVE;1.0;2.56 +47191-2;Triiodothyronine^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;T3 sp2 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47192-0;Triiodothyronine^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;T3 sp3 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47193-8;Triiodothyronine^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;T3 sp4 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47194-6;Triiodothyronine^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;T3 sp5 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47195-3;Triiodothyronine^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;T3 sp6 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47196-1;Triiodothyronine^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;T3 sp7 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47197-9;Triiodothyronine^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;T3 sp8 p chal SerPl-sCnc;;ACTIVE;2.19;2.70 +47198-7;Vasopressin^1st specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Mass/volume] in Plasma --1st specimen post XXX challenge;Vasopressin sp1 p chal Plas-mCnc;;ACTIVE;2.19;2.70 +47199-5;Methionine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methionine [Mass] of Dose;Methionine Dose;;ACTIVE;2.19;2.69 +47200-1;Methionine+Homocysteine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methionine+Homocysteine [Mass] of Dose;Methionine+Homocysteine Dose;;ACTIVE;2.19;2.69 +47201-9;Bentiromide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Bentiromide [Mass] of Dose;Bentiromide Dose;;ACTIVE;2.19;2.69 +47202-7;Sincalide;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Sincalide [Mass] of Dose;Sincalide Dose;;ACTIVE;2.19;2.69 +47203-5;Pyridoxine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Pyridoxine [Mass] of Dose;Vit B6 Dose;;ACTIVE;2.19;2.69 +47204-3;glipiZIDE;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;glipiZIDE [Presence] in Urine;glipiZIDE Ur Ql;;ACTIVE;2.19;2.56 +47205-0;metyraPONE;Mass;Pt;Dose;Qn;;DRUGDOSE;1;metyraPONE [Mass] of Dose;metyraPONE Dose;;ACTIVE;2.19;2.70 +47206-8;Corticotropin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Corticotropin [Mass] of Dose;ACTH Dose;;ACTIVE;2.19;2.70 +47207-6;Secretin;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Secretin [Mass] of Dose;Secretin Dose;;ACTIVE;2.19;2.69 +47208-4;Arginine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Arginine [Mass] of Dose;Arginine Dose;;ACTIVE;2.19;2.69 +4720-9;HLA-A23(9);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A23(9) [Presence];HLA-A23(9) Ql;;ACTIVE;1.0;2.56 +47209-2;Glucagon;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Glucagon [Mass] of Dose;Glucagon Dose;;ACTIVE;2.19;2.19 +472-1;sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;sulfiSOXAZOLE [Susceptibility] by Minimum inhibitory concentration (MIC);Sulfisoxaz Islt MIC;;ACTIVE;1.0;2.19 +47210-0;Triglyceride^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride [Moles/volume] in Serum or Plasma --fasting;Trigl p fast SerPl-sCnc;;ACTIVE;2.19;2.70 +47211-8;Chlamydia trachomatis L2 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis L2 DNA [Presence] in Specimen by NAA with probe detection;C trach L2 DNA Spec Ql NAA+probe;;ACTIVE;2.19;2.73 +47212-6;Chlamydia trachomatis DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Identifier] in Specimen by NAA with probe detection;C trach DNA Spec NAA+probe;;ACTIVE;2.19;2.69 +47213-4;Cholesterol.in LDL real size pattern;Prid;Pt;Ser/Plas;Nom;;CHEM;1;Cholesterol in LDL real size pattern [Identifier] in Serum or Plasma;LDLc real size Pat SerPl;;ACTIVE;2.19;2.73 +47214-2;Homeostasis model assessment;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Homeostasis model assessment;HOMA SerPl-aCnc;;ACTIVE;2.19;2.73 +47215-9;Lipoprotein.beta.subparticle.medium;EntLen;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.beta.subparticle.medium [Entitic length] in Serum or Plasma;LDL med SerPl Qn;;ACTIVE;2.19;2.73 +47216-7;Hepatitis B virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 200 copies/mL;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 200 copies/ml;HBV DNA # SerPl NAA DL=200;;ACTIVE;2.19;2.73 +4721-7;HLA-A24(9);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A24(9) [Presence] in Donor;HLA-A24(9) Donr Ql;;ACTIVE;1.0;2.56 +47217-5;Immune complex.C3d;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Immune Complex C3d [Mass/volume] in Serum or Plasma;IC C3d SerPl-mCnc;;ACTIVE;2.19;2.73 +47218-3;Cholesterol.in VLDL 3+4;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL 3+4 [Mass/volume] in Serum or Plasma;VLDL3+4c SerPl-mCnc;;ACTIVE;2.19;2.34 +47219-1;Cholesterol.in VLDL 5+6;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL 5+6 [Mass/volume] in Serum or Plasma;VLDL5+6c SerPl-mCnc;;ACTIVE;2.19;2.34 +47220-9;Cholesterol.in HDL 4+5;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 4+5 [Mass/volume] in Serum or Plasma;HDL4+5c SerPl-mCnc;;ACTIVE;2.19;2.34 +47221-7;Cholesterol.in HDL 1+2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 1+2 [Mass/volume] in Serum or Plasma;HDL1+2c SerPl-mCnc;;ACTIVE;2.19;2.34 +47222-5;Trisomy 21 risk based on maternal age + Alpha-1-Fetoprotein + Choriogonadotropin + Estriol.unconjugated;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Trisomy 21 risk based on maternal age+Alpha-1-Fetoprotein+Choriogonadotropin+Estriol.unconjugated [Likelihood] in Fetus;Ts 21risk-age+AFP+HCG+uE3 Fetus;;ACTIVE;2.19;2.73 +47223-3;Fetal trisomy 18 risk;Likelihood;Pt;^Fetus;Qn;Based on maternal age;CHEM;1;Fetal Trisomy 18 risk [Likelihood] Based on maternal age;Fet Ts 18 risk from Mat age;;ACTIVE;2.19;2.73 +47224-1;In vitro fertilization pregnancy;PrThr;Pt;^Patient;Ord;;CLIN;2;In vitro fertilization pregnancy;IVF pregnancy;;ACTIVE;2.19;2.73 +4722-5;HLA-A25(10);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A25(10) [Presence] in Donor;HLA-A25(10) Donr Ql;;ACTIVE;1.0;2.56 +47225-8;Bilirubin;Imp;Pt;Amnio fld;Nom;;CHEM;1;Bilirubin.total [Interpretation] in Amniotic fluid;Bilirub Amn-Imp;;ACTIVE;2.19;2.50 +47226-6;Fetal lung maturity;Imp;Pt;Amnio fld;Nom;;CHEM;1;Fetal lung maturity [Interpretation] in Amniotic fluid;FLM Amn-Imp;;ACTIVE;2.19;2.73 +47227-4;Blood.dried;PrThr;Pt;Calculus;Ord;;SPEC;1;Blood.dried [Presence] of Stone Qualitative;Bld.dried Stone Ql;;ACTIVE;2.19;2.73 +47228-2;Cholesterol.non HDL/Cholesterol.total;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma;NonHDLc SerPl;;ACTIVE;2.19;2.73 +47229-0;Herpes simplex virus Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Herpes simplex virus Ag [Presence] in Cerebral spinal fluid;HSV Ag CSF Ql;;ACTIVE;2.19;2.56 +47230-8;Herpes simplex virus glycoprotein G Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Herpes simplex virus glycoprotein G IgG Ab [Presence] in Serum;HSV gp G IgG Ser Ql;;ACTIVE;2.19;2.56 +47231-6;IgM Ab;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;IgM Ab [Presence] in Serum or Plasma;IgM Ab SerPl Ql;;ACTIVE;2.19;2.56 +47232-4;Influenza virus A Ab^1st specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A Ab [Presence] in Serum --1st specimen;FLUAV Ab sp1 Ser Ql;;ACTIVE;2.19;2.56 +4723-3;HLA-A25(10);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A25(10) [Presence];HLA-A25(10) Ql;;ACTIVE;1.0;2.56 +47233-2;Influenza virus A Ab^2nd specimen;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A Ab [Presence] in Serum --2nd specimen;FLUAV Ab sp2 Ser Ql;;ACTIVE;2.19;2.56 +47234-0;Chlamydia trachomatis Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Chlamydia trachomatis Ag [Presence] in Body fluid;C trach Ag Fld Ql;;ACTIVE;2.19;2.56 +47235-7;Reagin Ab;Titr;Pt;XXX;Qn;VDRL;MICRO;1;Reagin Ab [Titer] in Specimen by VDRL;VDRL Spec-Titr;;ACTIVE;2.19;2.69 +47236-5;Treponema pallidum Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Treponema pallidum IgG+IgM Ab [Presence] in Serum by Immunoassay;T pallidum IgG+IgM Ser Ql IA;;ACTIVE;2.19;2.73 +47237-3;Treponema pallidum Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Treponema pallidum IgM Ab [Presence] in Serum by Immunoassay;T pallidum IgM Ser Ql IA;;ACTIVE;2.19;2.73 +47238-1;Treponema pallidum Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Treponema pallidum IgG Ab [Presence] in Serum by Immunoassay;T pallidum IgG Ser Ql IA;;ACTIVE;2.19;2.73 +47239-9;Reason for stopping HIV Rx;Type;Pt;^Patient;Nom;Reported;ART;2;Reason for stopping HIV treatment;Reason for stopping HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47240-7;Date determined medically eligible to start HIV Rx;Date;Pt;^Patient;Qn;Reported;ART;2;Date determined medically eligible to start HIV treatment;Date eligible to start HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +4724-1;HLA-A26(10);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A26(10) [Presence] in Donor;HLA-A26(10) Donr Ql;;ACTIVE;1.0;2.56 +47241-5;Date determined medically eligible and ready to start HIV Rx;Date;Pt;^Patient;Qn;Reported;ART;2;Date determined medically eligible and ready to start HIV treatment;Date eligible & ready to start HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47242-3;Medication or other side effects associated with HIV Rx;Type;Pt;^Patient;Nom;Reported;ART;2;Medication or other side effects associated with HIV treatment;Med/other side effects assoc with HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47243-1;Severity of side effect to HIV Rx;Type;Pt;^Patient;Nom;Reported;ART;2;Severity of side effect to HIV treatment;Severity of side effect to HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47244-9;Symptom, diagnosis, or opportunistic infection related to HIV Rx;Type;Pt;^Patient;Nom;Reported;ART;2;Symptom, diagnosis, or opportunistic infection related to HIV treatment;Symptom, Dx, or infect related to HIV Rx;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47245-6;HIV Rx Form;-;Pt;Form;Doc;;PANEL.ART;2;HIV treatment form Document;HIV Rx Form Doc;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47246-4;Demographic information section;-;Pt;^Patient;Set;HIV-ART;ART;2;HIV Antiretroviral therapy Demographic information section;Demographic information section;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47247-2;Outpatient encounter-level information section;-;Pt;^Patient;Set;HIV-ART;ART;2;HIV Antiretroviral therapy Outpatient encounter-level information section;OP encounter-level info section;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47248-0;Antiretroviral therapy status section;-;Pt;^Patient;Set;HIV-ART;ART;2;HIV Antiretroviral therapy Antiretroviral therapy status section;Antiretroviral therapy status section;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47249-8;HIV care & family status section;-;Pt;^Patient;Set;HIV-ART;ART;2;HIV Antiretroviral therapy HIV care and family status section;HIV care & family status section;"Copyright © 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.";ACTIVE;2.22;2.67 +47250-6;Adenosine monophosphate.cyclic^2nd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --2nd specimen post XXX challenge;cAMP sp2 p chal Ur-sCnc;;ACTIVE;2.19;2.73 +47251-4;BK virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;BK virus DNA [Presence] in Specimen by NAA with probe detection;BKV DNA Spec Ql NAA+probe;;ACTIVE;2.19;2.73 +47252-2;Hepatitis C virus RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HCV RNA SerPl NAA+probe-Log#;;ACTIVE;2.19;2.73 +47253-0;Coproporphyrin 1;MCnc;24H;Urine;Qn;;CHEM;1;Coproporphyrin 1 [Mass/volume] in 24 hour Urine;Copro1 24h Ur-mCnc;;ACTIVE;2.19;2.73 +47254-8;Coproporphyrin 3;MCnc;24H;Urine;Qn;;CHEM;1;Coproporphyrin 3 [Mass/volume] in 24 hour Urine;Copro3 24h Ur-mCnc;;ACTIVE;2.19;2.73 +47255-5;Procollagen type I.N-terminal propeptide;MCnc;Pt;Ser;Qn;;CHEM;1;Procollagen type I.N-terminal propeptide [Mass/volume] in Serum;PINP Ser-mCnc;;ACTIVE;2.19;2.73 +47256-3;Creatinine^2nd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --2nd specimen post XXX challenge;Creat sp2 p chal Ur-mCnc;;ACTIVE;2.19;2.73 +47257-1;Creatinine^1st specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --1st specimen post XXX challenge;Creat sp1 p chal Ur-mCnc;;ACTIVE;2.19;2.73 +4725-8;HLA-A26(10);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A26(10) [Presence];HLA-A26(10) Ql;;ACTIVE;1.0;2.56 +47258-9;Creatinine^3rd specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --3rd specimen post XXX challenge;Creat sp3 p chal Ur-mCnc;;ACTIVE;2.19;2.73 +47259-7;Creatinine^4th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --4th specimen post XXX challenge;Creat sp4 p chal Ur-mCnc;;ACTIVE;2.19;2.70 +47260-5;Plasmodium sp DNA;Prid;Pt;Bld;Nom;Probe.amp.tar;MICRO;1;Plasmodium sp DNA [Identifier] in Blood by NAA with probe detection;Plasmodium DNA Bld NAA+probe;;ACTIVE;2.19;2.73 +47261-3;Creatinine^6th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --6th specimen post XXX challenge;Creat sp6 p chal Ur-mCnc;;ACTIVE;2.19;2.70 +47262-1;Adenosine monophosphate.cyclic^6th specimen post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Deprecated Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --6th specimen post XXX challenge;Deprecated cAMP sp6 p chal Ur-Rto;;DEPRECATED;2.19;2.70 +47263-9;Adenosine monophosphate.cyclic^3rd specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --3rd specimen post XXX challenge;cAMP sp3 p chal Ur-sCnc;;ACTIVE;2.19;2.73 +47264-7;Adenosine monophosphate.cyclic^1st specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --1st specimen post XXX challenge;cAMP sp1 p chal Ur-sCnc;;ACTIVE;2.19;2.73 +47265-4;Adenosine monophosphate.cyclic^4th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --4th specimen post XXX challenge;cAMP sp4 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +4726-6;HLA-A28;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A28 [Presence] in Donor;HLA-A28 Donr Ql;;ACTIVE;1.0;2.56 +47266-2;Adenosine monophosphate.cyclic^5th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --5th specimen post XXX challenge;cAMP sp5 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47267-0;Adenosine monophosphate.cyclic^6th specimen post XXX challenge;SCnc;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic [Moles/volume] in Urine --6th specimen post XXX challenge;cAMP sp6 p chal Ur-sCnc;;ACTIVE;2.19;2.70 +47268-8;Adenosine monophosphate.cyclic/Creatinine^6th specimen post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --6th specimen post XXX challenge;cAMP/Creat sp6 p chal Ur-Rto;;ACTIVE;2.19;2.70 +47269-6;Adenosine monophosphate.cyclic/Creatinine^2nd specimen post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --2nd specimen post XXX challenge;cAMP/Creat sp2 p chal Ur-Rto;;ACTIVE;2.19;2.73 +47270-4;Adenosine monophosphate.cyclic/Creatinine^3rd specimen post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --3rd specimen post XXX challenge;cAMP/Creat sp3 p chal Ur-Rto;;ACTIVE;2.19;2.73 +47271-2;Adenosine monophosphate.cyclic/Creatinine^4th specimen post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --4th specimen post XXX challenge;cAMP/Creat sp4 p chal Ur-Rto;;ACTIVE;2.19;2.70 +47272-0;Adenosine monophosphate.cyclic/Creatinine^5th specimen post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --5th specimen post XXX challenge;cAMP/Creat sp5 p chal Ur-Rto;;ACTIVE;2.19;2.70 +47273-8;Creatinine^5th specimen post XXX challenge;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --5th specimen post XXX challenge;Creat sp5 p chal Ur-mCnc;;ACTIVE;2.19;2.70 +4727-4;HLA-A28;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A28 [Presence];HLA-A28 Ql;;ACTIVE;1.0;2.56 +47274-6;S100 calcium binding protein B;MCnc;Pt;CSF;Qn;;CHEM;1;S100 calcium binding protein B [Mass/volume] in Cerebral spinal fluid;S100 Ca binding protein B CSF-mCnc;;ACTIVE;2.19;2.70 +47275-3;S100 calcium binding protein B;MCnc;Pt;Ser;Qn;;CHEM;1;S100 calcium binding protein B [Mass/volume] in Serum;S100 Ca binding protein B Ser-mCnc;;ACTIVE;2.19;2.73 +47276-1;Complement Sc5b-9 Ab;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Complement Sc5b-9 Ab [Presence] in Serum or Plasma;SC5b9 Ab SerPl Ql;;ACTIVE;2.19;2.56 +47277-9;Erythrocyte distribution width;Ratio;Pt;BldCo;Qn;;HEM/BC;1;Erythrocyte distribution width [Ratio] in Cord blood;RDW BldCo-Rto;;ACTIVE;2.19;2.73 +47278-7;Erythrocyte mean corpuscular hemoglobin;EntMass;Pt;BldCo;Qn;;HEM/BC;1;MCH [Entitic mass] in Cord blood;MCH BldCo Qn;;ACTIVE;2.19;2.73 +47279-5;Erythrocyte mean corpuscular hemoglobin concentration;MCnc;Pt;BldCo;Qn;;HEM/BC;1;MCHC [Mass/volume] in Cord blood;MCHC BldCo-mCnc;;ACTIVE;2.19;2.70 +47280-3;Erythrocytes;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Cord blood;RBC # BldCo;;ACTIVE;2.19;2.70 +47281-1;Leukocytes;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Leukocytes [#/volume] in Cord blood;WBC # BldCo;;ACTIVE;2.19;2.70 +4728-2;HLA-A29(19);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A29(19) [Presence] in Donor;HLA-A29(19) Donr Ql;;ACTIVE;1.0;2.56 +47282-9;Erythrocyte mean corpuscular volume;EntVol;Pt;BldCo;Qn;;HEM/BC;1;MCV [Entitic volume] in Cord blood;MCV BldCo;;ACTIVE;2.19;2.73 +47283-7;Platelet mean volume;EntVol;Pt;BldCo;Qn;;HEM/BC;1;Platelet mean volume [Entitic volume] in Cord blood;PMV BldCo;;ACTIVE;2.19;2.70 +47284-5;Platelets;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Platelets [#/volume] in Cord blood;Platelet # BldCo;;ACTIVE;2.19;2.70 +47285-2;Heparin cofactor II Ag;ACnc;Pt;PPP;Qn;;COAG;1;Heparin cofactor II Ag [Units/volume] in Platelet poor plasma;Heparin CF II Ag PPP-aCnc;;ACTIVE;2.19;2.70 +47286-0;Differential panel;-;Pt;Bone mar;Qn;;PANEL.HEM/BC;1;Differential panel - Bone marrow;Diff Pnl Mar;;ACTIVE;2.19;2.67 +47287-8;Hemogram WO platelets panel;-;Pt;BldCo;Qn;;PANEL.HEM/BC;1;Deprecated Hemogram without Platelets panel in Cord blood;Deprecated CBC WO Platelets BldCo;;DEPRECATED;2.19;2.36 +47288-6;Complete blood count WO Differential panel;-;Pt;BldCo;Qn;;PANEL.HEM/BC;1;CBC WO Differential panel - Cord blood;CBC WO diff BldCo;;ACTIVE;2.19;2.73 +47289-4;IgG & IgG subclass panel;MCnc;Pt;Ser;Qn;;PANEL.CHEM;1;IgG and IgG subclass panel [Mass/volume] - Serum;IgG+IgG subclass Pnl Ser-mCnc;;ACTIVE;2.19;2.73 +4729-0;HLA-A29(19);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A29(19) [Presence];HLA-A29(19) Ql;;ACTIVE;1.0;2.56 +47290-2;IgG subclass panel;MCnc;Pt;Ser;Qn;;PANEL.CHEM;1;IgG subclass panel [Mass/volume] - Serum;IgG subclass Pnl Ser-mCnc;;ACTIVE;2.19;2.73 +47291-0;Fungus identified^^^6;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus # 6 identified in Specimen by Culture;Fungus Spec Cult org #6;;ACTIVE;2.19;2.69 +47292-8;Fungus identified^^^7;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus # 7 identified in Specimen by Culture;Fungus Spec Cult org #7;;ACTIVE;2.19;2.69 +47293-6;Bacteria identified^^^7;Prid;Pt;Genital;Nom;Aerobic culture;MICRO;1;Bacteria # 7 identified in Genital specimen by Aerobe culture;Bacteria Genital Aerobe Cult org #7;;ACTIVE;2.19;2.21 +47294-4;Bacteria identified^^^7;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria # 7 identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult org #7;;ACTIVE;2.19;2.19 +47295-1;Bacteria identified^^^8;Prid;Pt;Wound.shlw;Nom;Aerobic culture;MICRO;1;Bacteria # 8 identified in Wound shallow by Aerobe culture;Bacteria Shlw Wnd Aerobe Cult org #8;;ACTIVE;2.19;2.19 +47296-9;Clostridium tetani toxoid Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Clostridium tetani toxoid Ab [Ratio] in Serum --2nd specimen/1st specimen;C tetani Toxoid Ab 2:1 Ser-Rto;;ACTIVE;2.19;2.64 +47297-7;Corynebacterium diphtheriae toxin Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Corynebacterium diphtheriae toxin Ab [Units/volume] in Serum by Immunoassay --1st specimen;C diphtheriae Tox Ab sp1 Ser IA-aCnc;;ACTIVE;2.19;2.73 +47298-5;Corynebacterium diphtheriae Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae Ab [Ratio] in Serum --2nd specimen/1st specimen;C diphtheriae Ab 2:1 Ser-Rto;;ACTIVE;2.19;2.69 +47299-3;DNA double strand Ab;ACnc;Pt;Ser;Qn;Farr;SERO;1;DNA double strand Ab [Units/volume] in Serum by Farr method;dsDNA Ab Ser Farr-aCnc;;ACTIVE;2.19;2.73 +47300-9;Phosphatidate Ab.IgM;ACnc;Pt;Ser;Qn;IA;COAG;1;Phosphatidate IgM Ab [Units/volume] in Serum by Immunoassay;Phosphatidate IgM Ser IA-aCnc;;ACTIVE;2.19;2.73 +47301-7;Ribosomal P Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Ribosomal P Ab [Units/volume] in Serum by Immunoassay;Ribosomal P Ab Ser IA-aCnc;;ACTIVE;2.19;2.73 +47302-5;(Allium cepa+Allium sativum+Apium graveolens+Lycopersicon lycopersicum+Yeast) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 7 (Onion+Garlic+Celery+Tomato+Yeast) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix7 IgE Qn;;ACTIVE;2.19;2.70 +47303-3;Anaplastic lymphoma kinase Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Anaplastic lymphoma kinase Ag [Presence] in Tissue by Immune stain;ALK Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47304-1;Borrelia burgdorferi Ab.IgG index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Borrelia burgdorferi IgG Ab index [Units/volume] in Serum and CSF;B burgdor IgG Index Ser+CSF-aCnc;;ACTIVE;2.19;2.73 +47305-8;BRST 2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BRST 2 Ag [Presence] in Tissue by Immune stain;BRST 2 Ag Tiss Ql ImStn;;ACTIVE;2.19;2.73 +47306-6;Cartilage oligomeric matrix protein;ACnc;Pt;Ser;Qn;IA;SERO;1;Cartilage oligomeric matrix protein [Units/volume] in Serum by Immunoassay;COMP Ser IA-aCnc;;ACTIVE;2.19;2.70 +47307-4;Cytomegalovirus Ab.IgG Index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Cytomegalovirus IgG Ab index [Units/volume] in Serum and CSF;CMV IgG Index Ser+CSF-aCnc;;ACTIVE;2.19;2.73 +4730-8;HLA-A2;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A2 [Presence] in Donor;HLA-A2 Donr Ql;;ACTIVE;1.0;2.56 +47308-2;Echinococcus granulosus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echinococcus granulosus IgG Ab [Units/volume] in Serum by Immunoassay;E granulosus IgG Ser IA-aCnc;;ACTIVE;2.19;2.73 +47309-0;Haemophilus influenzae B Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae B IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Haem influ B IgG 2:1 Ser-Rto;;ACTIVE;2.19;2.70 +47310-8;Haemophilus influenzae B Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Haemophilus influenzae B IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Haem influ B IgG sp1 Ser IA-mCnc;;ACTIVE;2.19;2.70 +47311-6;Haemophilus influenzae B Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Haemophilus influenzae B IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Haem influ B IgG sp2 Ser IA-mCnc;;ACTIVE;2.19;2.70 +47312-4;Influenza virus A Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A IgM Ab [Units/volume] in Serum by Immunoassay;FLUAV IgM Ser IA-aCnc;;ACTIVE;2.19;2.73 +47313-2;Influenza virus A Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A IgG Ab [Units/volume] in Serum by Immunoassay;FLUAV IgG Ser IA-aCnc;;ACTIVE;2.19;2.73 +47314-0;Influenza virus B Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus B IgG Ab [Units/volume] in Serum by Immunoassay;FLUBV IgG Ser IA-aCnc;;ACTIVE;2.19;2.73 +47315-7;Influenza virus B Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus B IgM Ab [Units/volume] in Serum by Immunoassay;FLUBV IgM Ser IA-aCnc;;ACTIVE;2.19;2.73 +4731-6;HLA-A2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A2 [Presence];HLA-A2 Ql;;ACTIVE;1.0;2.73 +47316-5;Inner Ear 68kD Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Inner ear 68kD Ab [Units/volume] in Serum or Plasma by Immunoassay;Inner ear 68kD Ab SerPl IA-aCnc;;ACTIVE;2.19;2.73 +47317-3;Interleukin 12;MCnc;Pt;Body fld;Qn;IA;CHEM;1;Interleukin 12 [Mass/volume] in Body fluid by Immunoassay;Il12 Fld IA-mCnc;;ACTIVE;2.19;2.70 +47318-1;Liver kidney microsomal 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Liver kidney microsomal 1 IgG Ab [Units/volume] in Serum by Immunoassay;LKM-1 IgG Ser IA-aCnc;;ACTIVE;2.19;2.73 +47319-9;Myelin basic protein Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Myelin basic protein Ab [Units/volume] in Serum by Immunoassay;MBP Ab Ser IA-aCnc;;ACTIVE;2.19;2.70 +47320-7;Saccharomyces cerevisiae Ab.IgA;ACnc;Pt;Ser;Qn;IA;ALLERGY;1;Baker's yeast IgA Ab [Units/volume] in Serum by Immunoassay;Baker's yeast IgA Qn IA;;ACTIVE;2.19;2.73 +47321-5;Saccharomyces cerevisiae Ab.IgG;ACnc;Pt;Ser;Qn;IA;ALLERGY;1;Baker's yeast IgG Ab [Units/volume] in Serum by Immunoassay;Baker's yeast IgG Qn IA;;ACTIVE;2.19;2.73 +47322-3;SCL-70 extractable nuclear Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;SCL-70 extractable nuclear IgG Ab [Units/volume] in Serum by Immunoassay;ENA Scl70 IgG Ser IA-aCnc;;ACTIVE;2.19;2.73 +47323-1;Streptococcus pneumoniae 17 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 17 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum17 IgG Ser IA-mCnc;;DEPRECATED;2.19;2.70 +4732-4;HLA-A30(19);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A30(19) [Presence] in Donor;HLA-A30(19) Donr Ql;;ACTIVE;1.0;2.56 +47324-9;Streptococcus pneumoniae 17 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 17 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum17 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47325-6;Streptococcus pneumoniae 17 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 17 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum17 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47326-4;Streptococcus pneumoniae 17 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 17 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum17 IgG 2:1 Ser-Rto;;DEPRECATED;2.19;2.70 +47327-2;Streptococcus pneumoniae 2 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 2 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum2 IgG Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47328-0;Streptococcus pneumoniae 2 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 2 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum2 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47329-8;Streptococcus pneumoniae 2 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 2 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum2 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47330-6;Streptococcus pneumoniae 2 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 2 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum2 IgG 2:1 Ser-Rto;;DEPRECATED;2.19;2.70 +47331-4;Streptococcus pneumoniae 20 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 20 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum20 IgG Ser IA-mCnc;;DEPRECATED;2.19;2.70 +4733-2;HLA-A30(19);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A30(19) [Presence];HLA-A30(19) Ql;;ACTIVE;1.0;2.56 +47332-2;Streptococcus pneumoniae 20 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 20 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum20 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47333-0;Streptococcus pneumoniae 20 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 20 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum20 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47334-8;Streptococcus pneumoniae 20 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 20 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum20 IgG 2:1 Ser-Rto;;DEPRECATED;2.19;2.70 +47335-5;Streptococcus pneumoniae 22 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 22 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum22 IgG Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47336-3;Streptococcus pneumoniae 22 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 22 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum22 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47337-1;Streptococcus pneumoniae 22 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 22 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum22 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47338-9;Streptococcus pneumoniae 22 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 22 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum22 IgG 2:1 Ser-Rto;;DEPRECATED;2.19;2.70 +47339-7;Streptococcus pneumoniae 34 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 34 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum34 IgG Ser IA-mCnc;;DEPRECATED;2.19;2.70 +4734-0;HLA-A31(19);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A31(19) [Presence] in Donor;HLA-A31(19) Donr Ql;;ACTIVE;1.0;2.56 +47340-5;Streptococcus pneumoniae 34 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 34 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum34 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47341-3;Streptococcus pneumoniae 34 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 34 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum34 IgG 2:1 Ser-Rto;;DEPRECATED;2.19;2.70 +47342-1;Streptococcus pneumoniae 43 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 43 IgG Ab [Mass/volume] in Serum by Immunoassay;Deprecated S pneum43 IgG Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47343-9;Streptococcus pneumoniae 43 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 43 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum43 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47344-7;Streptococcus pneumoniae 43 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 43 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum43 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47345-4;Streptococcus pneumoniae 43 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 43 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum43 IgG 2:1 Ser-Rto;;DEPRECATED;2.19;2.70 +47346-2;Streptococcus pneumoniae Danish serotype 15B Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 15B IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 15B IgG sp2 Ser IA-mCnc;;ACTIVE;2.19;2.70 +47347-0;Streptococcus pneumoniae Danish serotype 15B Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 15B IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 15B IgG 2:1 Ser-Rto;;ACTIVE;2.19;2.70 +47348-8;Streptococcus pneumoniae Danish serotype 19A Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19A IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 19A IgG 2:1 Ser-Rto;;ACTIVE;2.19;2.70 +47349-6;Streptococcus pneumoniae Danish serotype 33F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 33F IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 33F IgG Ser IA-mCnc;;ACTIVE;2.19;2.73 +47350-4;Streptococcus pneumoniae Danish serotype 33F Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 33F IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 33F IgG 2:1 Ser-Rto;;ACTIVE;2.19;2.70 +47351-2;Streptococcus pneumoniae Danish serotype 33F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 33F IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 33F IgG sp1 Ser IA-mCnc;;ACTIVE;2.19;2.70 +47352-0;Streptococcus pneumoniae Danish serotype 33F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 33F IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 33F IgG sp2 Ser IA-mCnc;;ACTIVE;2.19;2.70 +47353-8;Streptococcus pneumoniae 5 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 5 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum5 IgG sp1 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47354-6;Streptococcus pneumoniae 5 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 5 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum5 IgG sp2 Ser IA-mCnc;;DEPRECATED;2.19;2.70 +47355-3;Streptococcus pneumoniae 5 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 5 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;Deprecated S pneum5 IgG 2:1 Ser-Rto;;DEPRECATED;2.19;2.70 +47356-1;Streptococcus pneumoniae Danish serotype 15B Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 15B IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 15B IgG Ser IA-mCnc;;ACTIVE;2.19;2.73 +4735-7;HLA-A31(19);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A31(19) [Presence];HLA-A31(19) Ql;;ACTIVE;1.0;2.56 +47357-9;Streptococcus pneumoniae Danish serotype 15B Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 15B IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 15B IgG sp1 Ser IA-mCnc;;ACTIVE;2.19;2.70 +47358-7;Hepatitis B virus core Ab;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Hepatitis B virus core Ab [Presence] in Serum from Donor by Immunoassay;HBV core Ab Ser Donr Ql IA;;ACTIVE;2.19;2.73 +47359-5;HIV 1 RNA;PrThr;Pt;Ser/Plas^Donor;Ord;Probe.amp;MICRO;1;HIV 1 RNA [Presence] in Serum or Plasma from Donor by Probe with amplification;HIV1 RNA SerPl Donr Ql Probe amp;;ACTIVE;2.19;2.63 +47360-3;Reagin Ab;PrThr;Pt;Ser^Donor;Ord;RPR;MICRO;1;Reagin Ab [Presence] in Serum from Donor by RPR;RPR Ser Donr Ql;;ACTIVE;2.19;2.73 +47361-1;Treponema pallidum Ab.IgG;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Treponema pallidum IgG Ab [Presence] in Serum from Donor by Immunoassay;T pallidum IgG Ser Donr Ql IA;;ACTIVE;2.19;2.73 +47362-9;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;XXX^Donor;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Specimen from Donor by NAA with probe detection;C trach+GC rRNA Spec Donr Ql NAA+probe;;ACTIVE;2.19;2.69 +47363-7;Cytomegalovirus Ab;PrThr;Pt;Ser^Donor;Ord;HA;MICRO;1;Cytomegalovirus Ab [Presence] in Serum from Donor by Hemagglutination;CMV Ab Ser Donr Ql HA;;ACTIVE;2.19;2.56 +47364-5;Hepatitis B virus surface Ag;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Hepatitis B virus surface Ag [Presence] in Serum from Donor by Immunoassay;HBV surface Ag Ser Donr Ql IA;;ACTIVE;2.19;2.73 +4736-5;HLA-A32(19);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A32(19) [Presence] in Donor;HLA-A32(19) Donr Ql;;ACTIVE;1.0;2.56 +47365-2;Hepatitis C virus Ab;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Hepatitis C virus Ab [Presence] in Serum from Donor by Immunoassay;HCV Ab Ser Donr Ql IA;;ACTIVE;2.19;2.73 +47366-0;Multisection limited^WO contrast;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest limited WO contrast;CT Chest Ltd WO contr;;ACTIVE;2.19;2.61 +47367-8;Views GE 4 && Views;Find;Pt;Chest;Doc;XR && RF;RAD;2;XR and RF Chest GE 4 Views and Views;XR and Flr Chest GE 4V + Views;;ACTIVE;2.19;2.61 +47368-6;Views GE 4 + PA + lateral;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest GE 4 and PA and Lateral;XR Chest GE 4+PA+Lat;;ACTIVE;2.19;2.64 +47369-4;Calcitonin;MCnc;Pt;Body fld;Qn;;CHEM;1;Calcitonin [Mass/volume] in Body fluid;Calcit Fld-mCnc;;ACTIVE;2.19;2.70 +47370-2;Views GE 3;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left GE 3 Views;XR Hand-L GE 3V;;ACTIVE;2.19;2.61 +47371-0;Views GE 3;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right GE 3 Views;XR Hand-R GE 3V;;ACTIVE;2.19;2.61 +47372-8;Views^during surgery;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Views during surgery;XR Hip Views in Surg;;ACTIVE;2.19;2.64 +4737-3;HLA-A32(19);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A32(19) [Presence];HLA-A32(19) Ql;;ACTIVE;1.0;2.56 +47373-6;Views 1 or 2;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 1 or 2 Views;XR Knee-L 1V or 2V;;ACTIVE;2.19;2.61 +47374-4;Views GE 4;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left GE 4 Views;XR Knee-L GE 4V;;ACTIVE;2.19;2.61 +47375-1;Views 1 or 2;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right 1 or 2 Views;XR Knee-R 1V or 2V;;ACTIVE;2.19;2.61 +47376-9;Views GE 4;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right GE 4 Views;XR Knee-R GE 4V;;ACTIVE;2.19;2.61 +47377-7;Views LE 4;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right LE 4 Views;XR Knee-R LE 4V;;ACTIVE;2.19;2.61 +47378-5;Multisection blood pool^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM.SPECT;RAD;2;SPECT Liver blood pool;SPECT Liver BP W RNC IV;;ACTIVE;2.19;2.61 +47379-3;Views GE 4;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible GE 4 Views;XR Mandible GE 4V;;ACTIVE;2.19;2.61 +47380-1;Views LE 3;Find;Pt;Head>Mandible;Doc;XR;RAD;2;XR Mandible LE 3 Views;XR Mandible LE 3V;;ACTIVE;2.19;2.61 +4738-1;HLA-A3;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A3 [Presence] in Donor;HLA-A3 Donr Ql;;ACTIVE;1.0;2.56 +47381-9;Views GE 3;Find;Pt;Head>Mastoid;Doc;XR;RAD;2;XR Mastoid GE 3 Views;XR Mastoid GE 3V;;ACTIVE;2.19;2.61 +47382-7;Views GE 4;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine GE 4 Views;XR L-spine GE 4V;;ACTIVE;2.19;2.61 +47383-5;Nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Nuclear Ab [Presence] in Serum by Immunoassay;ANA Ser Ql IA;;ACTIVE;2.19;2.73 +47384-3;Cephalosporine mold Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cephalosporine mold IgE Ab RAST class [Presence] in Serum;Cephalospor Mold IgE RAST Ql;;ACTIVE;2.19;2.73 +47385-0;Netilmicin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Netilmicin [Mass/volume] in Serum or Plasma;Netilmicin SerPl-mCnc;;ACTIVE;2.19;2.70 +47386-8;Carboxy tetrahydrocannabinol;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Serum or Plasma by Confirmatory method;CarboxyTHC SerPl Cfm-mCnc;;ACTIVE;2.19;2.70 +47387-6;Neisseria gonorrhoeae DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Genital specimen by NAA with probe detection;N gonorrhoea DNA Genital Ql NAA+probe;;ACTIVE;2.19;2.73 +47388-4;Salmonella typhi H D Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Salmonella typhi H D Ab [Titer] in Serum by Agglutination;S Typhi H d Ab Titr Ser Aggl;;ACTIVE;2.19;2.70 +47389-2;Toxoplasma gondii Ab.IgG avidity;PrThr;Pt;Ser;Ord;;MICRO;1;Toxoplasma gondii IgG Ab avidity [Presence] in Serum;T gondii IgG Avidity Ser Ql;;DISCOURAGED;2.19;2.56 +473-9;sulfiSOXAZOLE;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;sulfiSOXAZOLE [Susceptibility] by Disk diffusion (KB);Sulfisoxaz Islt KB;;ACTIVE;1.0;2.73 +47390-0;Toxoplasma gondii Ab.IgG;ACnc;Pt;Ser;Qn;Dye test;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Serum by Sabin dye test;T gondii IgG Ser Dye Test-aCnc;;ACTIVE;2.19;2.69 +47391-8;Sulfonylurea;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Sulfonylurea [Presence] in Urine;Sulfonylurea Ur Ql;;ACTIVE;2.19;2.56 +47392-6;chlorproPAMIDE;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;chlorproPAMIDE [Mass/volume] in Specimen;chlorproPAMIDE Spec-mCnc;;ACTIVE;2.19;2.69 +47393-4;Gliadin peptide Ab.IgA;PrThr;Pt;Ser;Ord;IA;SERO;1;Gliadin peptide IgA Ab [Presence] in Serum by Immunoassay;Gliadin peptide IgA Ser Ql IA;;ACTIVE;2.19;2.73 +47394-2;Gliadin peptide Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Gliadin peptide IgG Ab [Presence] in Serum by Immunoassay;Gliadin peptide IgG Ser Ql IA;;ACTIVE;2.19;2.73 +47395-9;Kanamycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Kanamycin [Mass/volume] in Serum or Plasma;Kanamycin SerPl-mCnc;;ACTIVE;2.19;2.70 +47396-7;Babesia microti DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Babesia microti DNA [Presence] in Specimen by NAA with probe detection;B microti DNA Spec Ql NAA+probe;;ACTIVE;2.19;2.73 +47397-5;BCS1L gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BCS1L gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BCS1L gene Mut Anl Bld/T;;ACTIVE;2.19;2.73 +47398-3;Beta mannosidase actual/Normal;RelCCnc;Pt;WBC;Qn;;CHEM;1;Beta mannosidase actual/normal in Leukocytes;B-Mannosidase Act/Nor WBC;;ACTIVE;2.19;2.44 +4739-9;HLA-A3;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A3 [Presence];HLA-A3 Ql;;ACTIVE;1.0;2.73 +47399-1;Cells.ZAP70+CD19+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;ZAP70+CD19+ cells/100 cells in Blood;ZAP70+CD19+ Cells NFr Bld;;ACTIVE;2.19;2.73 +47400-7;Cocaine+Benzoylecgonine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cocaine+Benzoylecgonine [Presence] in Urine by Confirmatory method;Cocaine+BZE Ur Ql Cfm;;ACTIVE;2.19;2.56 +47401-5;CV2 Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;CV2 IgG Ab [Presence] in Serum by Immunoblot;CV2 IgG Ser Ql IB;;ACTIVE;2.19;2.73 +47402-3;CV2 Ab;PrThr;Pt;Ser/Plas;Ord;IB;SERO;1;CV2 Ab [Presence] in Serum or Plasma by Immunoblot;CV2 Ab SerPl Ql IB;;ACTIVE;2.19;2.73 +47403-1;CYP2D6 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP2D6 Mut Anl Bld/T;;ACTIVE;2.19;2.73 +47404-9;N-desalkylflurazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Blood by Confirmatory method;Desalkylfluraz Bld Cfm-mCnc;;ACTIVE;2.19;2.73 +47405-6;Ehrlichia chaffeensis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Ehrlichia chaffeensis IgG Ab [Titer] in Serum by Immunofluorescence;E chaffeensis IgG Titr Ser IF;;ACTIVE;2.19;2.73 +47406-4;Entamoeba histolytica Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Entamoeba histolytica Ab [Presence] in Cerebral spinal fluid;E histolyt Ab CSF Ql;;ACTIVE;2.19;2.56 +4740-7;HLA-A9;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-A9 [Presence] in Donor;HLA-A9 Donr Ql;;ACTIVE;1.0;2.56 +47407-2;Fibers;Naric;Pt;Stool;Qn;Microscopy.light;CHEM;1;Fibers [#/area] in Stool by Light microscopy;Fibers #/area Stl Micro;;ACTIVE;2.19;2.70 +47408-0;Fosphenytoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fosphenytoin [Mass/volume] in Serum or Plasma;Fosphenytoin SerPl-mCnc;;ACTIVE;2.19;2.70 +47409-8;Herpes simplex virus 1+2 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HSV1+2 DNA # SerPl NAA+probe;;ACTIVE;2.19;2.73 +47410-6;Herpes virus 6 DNA;Prid;Pt;Ser/Plas;Nom;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Identifier] in Serum or Plasma by NAA with probe detection;HHV6 DNA SerPl NAA+probe;;ACTIVE;2.19;2.63 +47411-4;Methadone;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Methadone [Presence] in Serum or Plasma by Confirmatory method;Methadone SerPl Ql Cfm;;ACTIVE;2.19;2.56 +47412-2;Mumps virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mumps virus Ab [Units/volume] in Serum by Immunoassay;MuV Ab Ser IA-aCnc;;ACTIVE;2.19;2.69 +47413-0;Plasma cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Plasma cells/100 leukocytes in Cerebral spinal fluid;Plasma Cells/leuk NFr CSF;;ACTIVE;2.19;2.73 +47414-8;Pregabalin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pregabalin [Mass/volume] in Serum or Plasma;Pregabalin SerPl-mCnc;;ACTIVE;2.19;2.73 +4741-5;HLA-A9;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-A9 [Presence];HLA-A9 Ql;;ACTIVE;1.0;2.56 +47415-5;Propoxyphene+Norpropoxyphene;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Mass/volume] in Serum or Plasma by Confirmatory method;Propoxyph+Nor SerPl Cfm-mCnc;;ACTIVE;2.19;2.42 +47416-3;RB1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RB1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;RB1 gene Mut Anl Bld/T;;ACTIVE;2.19;2.66 +47417-1;Red dye Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Red dye IgE Ab RAST class [Presence] in Serum;Red Dye IgE RAST Ql;;ACTIVE;2.19;2.58 +47418-9;Triacylglycerol lipase;CCnc;Pt;Plr fld;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Pleural fluid;Lipase Plr-cCnc;;ACTIVE;2.19;2.73 +47419-7;Varicella zoster virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Varicella zoster virus Ab [Units/volume] in Serum by Immunoassay;VZV Ab Ser IA-aCnc;;ACTIVE;2.19;2.73 +47420-5;Functional status assessment note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Functional status assessment note;Functional status note;;ACTIVE;2.19;2.67 +47421-3;Aspergillus flavus B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus flavus B Ab [Presence] in Serum;A flavus B Ab Ser Ql;;ACTIVE;2.19;2.56 +47422-1;Aspergillus flavus H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus flavus H Ab [Presence] in Serum;A flavus H Ab Ser Ql;;ACTIVE;2.19;2.56 +4742-3;HLA-B22;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B22 [Presence] in Donor;HLA-B22 Donr Ql;;ACTIVE;1.0;2.56 +47423-9;Aspergillus fumigatus B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus B Ab [Presence] in Serum;A fumigatus B Ab Ser Ql;;ACTIVE;2.19;2.56 +47424-7;Aspergillus fumigatus H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus H Ab [Presence] in Serum;A fumigatus H Ab Ser Ql;;ACTIVE;2.19;2.56 +47425-4;Aspergillus nidulans B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus nidulans B Ab [Presence] in Serum;A nidulans B Ab Ser Ql;;ACTIVE;2.19;2.56 +47426-2;Aspergillus nidulans H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus nidulans H Ab [Presence] in Serum;A nidulans H Ab Ser Ql;;ACTIVE;2.19;2.56 +47427-0;Aspergillus niger B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus niger B Ab [Presence] in Serum;A niger B Ab Ser Ql;;ACTIVE;2.19;2.56 +47428-8;Aspergillus niger H Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus niger H Ab [Presence] in Serum;A niger H Ab Ser Ql;;ACTIVE;2.19;2.56 +47429-6;Corynebacterium diphtheriae toxin Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae toxin Ab [Units/volume] in Serum --1st specimen;C diphtheriae Tox Ab sp1 Ser-aCnc;;ACTIVE;2.19;2.69 +47430-4;Cytomegalovirus Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;MICRO;1;Cytomegalovirus Ab [Presence] in Serum or Plasma from Donor;CMV Ab SerPl Donr Ql;;ACTIVE;2.19;2.73 +4743-1;HLA-B22;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B22 [Presence];HLA-B22 Ql;;ACTIVE;1.0;2.56 +47431-2;Echinococcus granulosus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Echinococcus granulosus IgG Ab [Units/volume] in Serum;E granulosus IgG Ser-aCnc;;ACTIVE;2.19;2.69 +47432-0;Epstein Barr virus capsid Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Titer] in Body fluid;EBV VCA IgG Titr Fld;;ACTIVE;2.19;2.32 +47433-8;Epstein Barr virus capsid Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Epstein Barr virus capsid IgM Ab [Titer] in Body fluid;EBV VCA IgM Titr Fld;;ACTIVE;2.19;2.32 +47434-6;Epstein Barr virus early diffuse Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus early diffuse Ab [Presence] in Serum;EBV EA-D Ab Ser Ql;;ACTIVE;2.19;2.73 +47435-3;Epstein Barr virus early Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus early IgA Ab [Titer] in Serum;EBV EA IgA Titr Ser;;ACTIVE;2.19;2.32 +47436-1;Epstein Barr virus early Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Epstein Barr virus early IgG Ab [Titer] in Body fluid;EBV EA IgG Titr Fld;;ACTIVE;2.19;2.32 +47437-9;Epstein Barr virus early restricted Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus early restricted Ab [Presence] in Serum;EBV EA-R Ab Ser Ql;;ACTIVE;2.19;2.56 +47438-7;Fowl adenovirus 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Fowl adenovirus Ab [Presence] in Serum;FAdV1 Ab Ser Ql;;ACTIVE;2.19;2.56 +47439-5;Haemophilus influenzae B Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae B IgG Ab [Mass/volume] in Serum --1st specimen;Haem influ B IgG sp1 Ser-mCnc;;ACTIVE;2.19;2.40 +47440-3;Hepatitis B virus core Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;Hepatitis B virus core Ab [Presence] in Serum from Donor;HBV core Ab Ser Donr Ql;;ACTIVE;2.19;2.73 +47441-1;Hepatitis C virus Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;Hepatitis C virus Ab [Presence] in Serum from Donor;HCV Ab Ser Donr Ql;;ACTIVE;2.19;2.73 +47442-9;Herpes virus 8 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Herpes virus 8 IgG Ab [Titer] in Serum;HHV8 IgG Titr Ser;;ACTIVE;2.19;2.32 +47443-7;Influenza virus A Ab;PrThr;Pt;Eggylk;Ord;;MICRO;1;Influenza virus A Ab [Presence] in Egg yolk;FLUAV Ab Egg Yolk Ql;;ACTIVE;2.19;2.56 +47444-5;Influenza virus A H1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H1 Ab [Titer] in Serum;FLUAV H1 Ab Titr Ser;;ACTIVE;2.19;2.32 +47445-2;Influenza virus A H10 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H10 Ab [Titer] in Serum;FLUAV H10 Ab Titr Ser;;ACTIVE;2.19;2.32 +47446-0;Influenza virus A H11 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H11 Ab [Titer] in Serum;FLUAV H11 Ab Titr Ser;;ACTIVE;2.19;2.32 +47447-8;Influenza virus A H12 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H12 Ab [Titer] in Serum;FLUAV H12 Ab Titr Ser;;ACTIVE;2.19;2.56 +47448-6;Influenza virus A H13 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H13 Ab [Titer] in Serum;FLUAV H13 Ab Titr Ser;;ACTIVE;2.19;2.32 +4744-9;HLA-B41;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B41 [Presence] in Donor;HLA-B41 Donr Ql;;ACTIVE;1.0;2.56 +47449-4;Influenza virus A H14 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H14 Ab [Titer] in Serum;FLUAV H14 Ab Titr Ser;;ACTIVE;2.19;2.32 +47450-2;Influenza virus A H15 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H15 Ab [Titer] in Serum;FLUAV H15 Ab Titr Ser;;ACTIVE;2.19;2.32 +47451-0;Influenza virus A H2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H2 Ab [Titer] in Serum;FLUAV H2 Ab Titr Ser;;ACTIVE;2.19;2.32 +47452-8;Influenza virus A H3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H3 Ab [Titer] in Serum;FLUAV H3 Ab Titr Ser;;ACTIVE;2.19;2.32 +47453-6;Influenza virus A H4 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H4 Ab [Titer] in Serum;FLUAV H4 Ab Titr Ser;;ACTIVE;2.19;2.32 +47454-4;Influenza virus A H5 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H5 Ab [Titer] in Serum;FLUAV H5 Ab Titr Ser;;ACTIVE;2.19;2.32 +47455-1;Influenza virus A H6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H6 Ab [Titer] in Serum;FLUAV H6 Ab Titr Ser;;ACTIVE;2.19;2.32 +4745-6;HLA-B41;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B41 [Presence];HLA-B41 Ql;;ACTIVE;1.0;2.56 +47456-9;Influenza virus A H7 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H7 Ab [Titer] in Serum;FLUAV H7 Ab Titr Ser;;ACTIVE;2.19;2.32 +47457-7;Influenza virus A H8 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H8 Ab [Titer] in Serum;FLUAV H8 Ab Titr Ser;;ACTIVE;2.19;2.32 +47458-5;Influenza virus A H9 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H9 Ab [Titer] in Serum;FLUAV H9 Ab Titr Ser;;ACTIVE;2.19;2.32 +47459-3;Legionella pneumophila 10 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 10 IgG Ab [Titer] in Serum;L pneumo 10 IgG Titr Ser;;ACTIVE;2.19;2.32 +47460-1;Legionella pneumophila 10 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 10 IgM Ab [Titer] in Serum;L pneumo 10 IgM Titr Ser;;ACTIVE;2.19;2.32 +47461-9;Legionella pneumophila 11 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 11 IgG Ab [Titer] in Serum;L pneumo 11 IgG Titr Ser;;ACTIVE;2.19;2.32 +47462-7;Legionella pneumophila 11 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 11 IgM Ab [Titer] in Serum;L pneumo 11 IgM Titr Ser;;ACTIVE;2.19;2.32 +47463-5;Legionella pneumophila 12 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 12 IgG Ab [Titer] in Serum;L pneumo 12 IgG Titr Ser;;ACTIVE;2.19;2.32 +4746-4;HLA-B42;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B42 [Presence] in Donor;HLA-B42 Donr Ql;;ACTIVE;1.0;2.56 +47464-3;Legionella pneumophila 12 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 12 IgM Ab [Titer] in Serum;L pneumo 12 IgM Titr Ser;;ACTIVE;2.19;2.32 +47465-0;Legionella pneumophila 13 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 13 IgG Ab [Titer] in Serum;L pneumo 13 IgG Titr Ser;;ACTIVE;2.19;2.32 +47466-8;Legionella pneumophila 13 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 13 IgM Ab [Titer] in Serum;L pneumo 13 IgM Titr Ser;;ACTIVE;2.19;2.32 +47467-6;Legionella pneumophila 14 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 14 IgG Ab [Titer] in Serum;L pneumo 14 IgG Titr Ser;;ACTIVE;2.19;2.32 +47468-4;Legionella pneumophila 14 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 14 IgM Ab [Titer] in Serum;L pneumo 14 IgM Titr Ser;;ACTIVE;2.19;2.32 +47469-2;Legionella pneumophila 7 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 7 IgG Ab [Titer] in Serum;L pneumo7 IgG Titr Ser;;ACTIVE;2.19;2.32 +474-7;sulfiSOXAZOLE;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;sulfiSOXAZOLE [Susceptibility] by Serum bactericidal titer;Sulfisoxaz Titr SBT;;ACTIVE;1.0;2.32 +47470-0;Legionella pneumophila 7 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 7 IgM Ab [Titer] in Serum;L pneumo7 IgM Titr Ser;;ACTIVE;2.19;2.32 +47471-8;Legionella pneumophila 8 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 8 IgG Ab [Titer] in Serum;L pneumo8 IgG Titr Ser;;ACTIVE;2.19;2.32 +4747-2;HLA-B42;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B42 [Presence];HLA-B42 Ql;;ACTIVE;1.0;2.56 +47472-6;Legionella pneumophila 8 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 8 IgM Ab [Titer] in Serum;L pneumo8 IgM Titr Ser;;ACTIVE;2.19;2.32 +47473-4;Legionella pneumophila 9 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 9 IgG Ab [Titer] in Serum;L pneumo9 IgG Titr Ser;;ACTIVE;2.19;2.32 +47474-2;Legionella pneumophila 9 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 9 IgM Ab [Titer] in Serum;L pneumo9 IgM Titr Ser;;ACTIVE;2.19;2.32 +47475-9;Powassan virus polyvalent E Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Powassan virus polyvalent E Ab [Presence] in Specimen;POWV Polyval E Ab Spec Ql;;ACTIVE;2.19;2.69 +47476-7;Reagin Ab;Titr;Pt;XXX;Qn;;MICRO;1;Reagin Ab [Titer] in Specimen;Reagin Ab Titr Spec;;ACTIVE;2.19;2.69 +47477-5;Rickettsia rickettsii Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia rickettsii IgG Ab [Titer] in Cerebral spinal fluid;R rickettsi IgG Titr CSF;;ACTIVE;2.19;2.32 +47478-3;Rickettsia rickettsii Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia rickettsii IgM Ab [Titer] in Cerebral spinal fluid;R rickettsi IgM Titr CSF;;ACTIVE;2.19;2.32 +47479-1;Rickettsia typhi Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Cerebral spinal fluid;R typhi IgG Titr CSF;;ACTIVE;2.19;2.32 +4748-0;HLA-B46;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B46 [Presence] in Donor;HLA-B46 Donr Ql;;ACTIVE;1.0;2.56 +47480-9;Rickettsia typhi Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Rickettsia typhi IgM Ab [Titer] in Cerebral spinal fluid;R typhi IgM Titr CSF;;ACTIVE;2.19;2.32 +47481-7;Streptococcus pneumoniae 1 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum 1 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47482-5;Streptococcus pneumoniae 1 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum 1 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47483-3;Streptococcus pneumoniae 14 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum14 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47484-1;Streptococcus pneumoniae 14 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum14 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47485-8;Streptococcus pneumoniae 17 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 17 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum17 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47486-6;Streptococcus pneumoniae 17 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 17 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum17 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47487-4;Streptococcus pneumoniae 2 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 2 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum2 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47488-2;Streptococcus pneumoniae 2 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 2 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum2 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47489-0;Streptococcus pneumoniae 20 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 20 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum20 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47490-8;Streptococcus pneumoniae 20 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 20 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum20 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47491-6;Streptococcus pneumoniae 22 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 22 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum22 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47492-4;Streptococcus pneumoniae 22 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 22 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum22 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47493-2;Streptococcus pneumoniae 3 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum3 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47494-0;Streptococcus pneumoniae 3 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum3 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47495-7;Streptococcus pneumoniae 34 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 34 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum34 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47496-5;Streptococcus pneumoniae 34 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 34 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum34 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47497-3;Streptococcus pneumoniae 43 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 43 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum43 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +4749-8;HLA-B46;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B46 [Presence];HLA-B46 Ql;;ACTIVE;1.0;2.56 +47498-1;Streptococcus pneumoniae 43 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 43 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum43 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47499-9;Streptococcus pneumoniae 5 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 5 IgG Ab [Mass/volume] in Serum --1st specimen;Deprecated S pneum5 IgG sp1 Ser-mCnc;;DEPRECATED;2.19;2.66 +47500-4;Streptococcus pneumoniae 5 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 5 IgG Ab [Mass/volume] in Serum --2nd specimen;Deprecated S pneum5 IgG sp2 Ser-mCnc;;DEPRECATED;2.19;2.66 +47501-2;Streptococcus pneumoniae Danish serotype 15B Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 15B IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 15B IgG sp1 Ser-mCnc;;ACTIVE;2.19;2.61 +47502-0;Streptococcus pneumoniae Danish serotype 15B Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 15B IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 15B IgG sp2 Ser-mCnc;;ACTIVE;2.19;2.61 +47503-8;Streptococcus pneumoniae Danish serotype 19A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19A IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 19A IgG sp1 Ser-mCnc;;ACTIVE;2.19;2.61 +47504-6;Streptococcus pneumoniae Danish serotype 19A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19A IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 19A IgG sp2 Ser-mCnc;;ACTIVE;2.19;2.61 +47505-3;Streptococcus pneumoniae 6 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Deprecated Streptococcus pneumoniae 6 IgG Ab [Mass/volume] in Serum;Deprecated S pneum6 IgG Ser-mCnc;;DEPRECATED;2.19;2.66 +4750-6;HLA-B47;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B47 [Presence] in Donor;HLA-B47 Donr Ql;;ACTIVE;1.0;2.56 +47506-1;Streptococcus pneumoniae Danish serotype 9V Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 9V IgG sp1 Ser-mCnc;;ACTIVE;2.19;2.61 +47507-9;Streptococcus pneumoniae Danish serotype 9V Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 9V IgG sp2 Ser-mCnc;;ACTIVE;2.19;2.61 +47508-7;Streptococcus pneumoniae Danish serotype 9V Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9V IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 9V IgG 2:1 Ser-Rto;;ACTIVE;2.19;2.61 +47509-5;Streptococcus pneumoniae Danish serotype 33F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 33F IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 33F IgG sp1 Ser-mCnc;;ACTIVE;2.19;2.61 +47510-3;Streptococcus pneumoniae Danish serotype 33F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 33F IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 33F IgG sp2 Ser-mCnc;;ACTIVE;2.19;2.61 +47511-1;Treponema pallidum Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Treponema pallidum Ab [Units/volume] in Body fluid;T pallidum Ab Fld-aCnc;;ACTIVE;2.19;2.69 +47512-9;Treponema pallidum Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Treponema pallidum IgG Ab [Units/volume] in Cerebral spinal fluid;T pallidum IgG CSF-aCnc;;ACTIVE;2.19;2.69 +47513-7;Treponema pallidum Ab.IgG;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;Treponema pallidum IgG Ab [Presence] in Serum from Donor;T pallidum IgG Ser Donr Ql;;ACTIVE;2.19;2.73 +4751-4;HLA-B47;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B47 [Presence];HLA-B47 Ql;;ACTIVE;1.0;2.56 +47514-5;Treponema pallidum Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Treponema pallidum IgM Ab [Units/volume] in Cerebral spinal fluid;T pallidum IgM CSF-aCnc;;ACTIVE;2.19;2.69 +47515-2;Vesicular stomatitis Indiana virus 1 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Deprecated Vesicular stomatitis virus Indiana 1 Ab [Titer] in Serum;Deprecated VSIV 1 Ab Titr Ser;;DEPRECATED;2.19;2.40 +47516-0;Cocal virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Cocal virus Ab [Titer] in Serum;COCV Ab Titr Ser;;ACTIVE;2.19;2.52 +47517-8;Vesicular stomatitis Alagoas virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Vesicular stomatitis Alagoas virus Ab [Titer] in Serum;VSAV Ab Titr Ser;;ACTIVE;2.19;2.40 +47518-6;Yersinia pestis Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Yersinia pestis Ab [Presence] in Specimen;Y pestis Ab Spec Ql;;ACTIVE;2.19;2.69 +47519-4;History of procedures;Find;Pt;{Setting};Doc;{Role};H&P.HX;2;History of Procedures Document;Procedures Hx Doc;;ACTIVE;2.19;2.63 +47520-2;Cytology report;Find;Pt;Sputum;Doc;Cyto stain;CYTO;1;Cytology report of Sputum Cyto stain;Cytology Spt Doc Cyto;;ACTIVE;2.19;2.73 +47521-0;Cytology report;Find;Pt;Breast.FNA;Doc;Cyto stain;CYTO;1;Cytology report of Breast fine needle aspirate Cyto stain;Cytology Breast FNA Doc Cyto;;ACTIVE;2.19;2.73 +4752-2;HLA-B48;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B48 [Presence] in Donor;HLA-B48 Donr Ql;;ACTIVE;1.0;2.56 +47522-8;Cytology report;Find;Pt;Nipple discharge;Doc;Cyto stain;CYTO;1;Cytology report of Nipple discharge Cyto stain;Cytology Nipple dis Doc Cyto;;ACTIVE;2.19;2.73 +47523-6;Cytology report;Find;Pt;Body fld;Doc;Cyto stain;CYTO;1;Cytology report of Body fluid Cyto stain;Cytology Fld Doc Cyto;;ACTIVE;2.19;2.73 +47524-4;Cytology report;Find;Pt;Thyroid.FNA;Doc;Cyto stain;CYTO;1;Cytology report of Thyroid fine needle aspirate Cyto stain;Cytology Thyroid FNA Doc Cyto;;ACTIVE;2.19;2.73 +47525-1;Cytology report;Find;Pt;Urine;Doc;Cyto stain;CYTO;1;Cytology report of Urine Cyto stain;Cytology Ur Doc Cyto;;ACTIVE;2.19;2.73 +47526-9;Cytology report;Find;Pt;XXX;Doc;Cyto stain;CYTO;1;Cytology report of Specimen Cyto stain;Cytology Spec Doc Cyto;;ACTIVE;2.19;2.73 +47527-7;Cytology report;Find;Pt;Cvx/Vag;Doc;Cyto stain.thin prep;CYTO;1;Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin prep;Cytology Cvx/Vag Doc Thin Prep;;ACTIVE;2.19;2.73 +47528-5;Cytology report;Find;Pt;Cvx/Vag;Doc;Cyto stain;CYTO;1;Cytology report of Cervical or vaginal smear or scraping Cyto stain;Cytology Cvx/Vag Doc Cyto;;ACTIVE;2.19;2.73 +47529-3;Cytology report;Find;Pt;Tiss;Doc;XXX stain;CYTO;1;Cytology report of Tissue Other stain;Cytology Tiss Doc Other Stn;;ACTIVE;2.19;2.73 +4753-0;HLA-B48;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B48 [Presence];HLA-B48 Ql;;ACTIVE;1.0;2.56 +47530-1;Cytology report;Find;Pt;Breast.ductal lavage;Doc;Cyto stain;CYTO;1;Cytology report of Breast ductal lavage Cyto stain;Cytology Breast DL Doc Cyto;;ACTIVE;2.19;2.27 +47531-9;Wet mount panel;-;Pt;Vag;-;;PANEL.MICRO;1;Wet mount panel - Vaginal fluid;Wet mount Pnl Vag;;ACTIVE;2.19;2.73 +47532-7;Mumps virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mumps virus RNA [Presence] in Specimen by NAA with probe detection;MuV RNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +47533-5;17-Hydroxyprogesterone^pre 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM;17OHP pre 250 ug ACTH IM SerPl-mCnc;;ACTIVE;2.21;2.70 +47534-3;2-Hydroxyphenylacetate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;2-Hydroxyphenylacetate/Creatinine [Molar ratio] in Urine;2OH-phenylacetate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47535-0;2-Methyl,3-Hydroxybutyrate/Creatinine;SCrto;Pt;Urine;Qn;;CHEM;1;Deprecated 2-methyl,3-hydroxybutyrate (C5-OH)/Creatinine [Molecular ratio] in Urine;Deprecated 2Me3OH-butyrate/creat Ur-sRto;;DEPRECATED;2.21;2.70 +47536-8;3-Hydroxypropionate;SCnc;Pt;Plas;Qn;;CHEM;1;3-Hydroxypropionate (3-OH-C3) [Moles/volume] in Plasma;3OH-Propionate Plas-sCnc;;ACTIVE;2.21;2.70 +47537-6;3-Hydroxysebacate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxysebacate ( 3-OH-C8)/Creatinine [Molar ratio] in Urine;3OHsebacate/Creat Ur-sRto;;ACTIVE;2.21;2.73 +47538-4;3-Methoxy-4-Hydroxyphenylglycol;SCnc;Pt;CSF;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Moles/volume] in Cerebral spinal fluid;3Me4OH-phenylglycol CSF-sCnc;;ACTIVE;2.21;2.70 +47539-2;3-Methylhistidine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in DBS;3Me-histidine DBS-sCnc;;ACTIVE;2.21;2.70 +475-4;Sulfonamide;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Sulfonamide [Susceptibility] by Minimum lethal concentration (MLC);Sulfonamide Islt MLC;;ACTIVE;1.0;2.19 +47540-0;3-Methylhistidine;SCnc;Pt;Body fld;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in Body fluid;3Me-histidine Fld-sCnc;;ACTIVE;2.21;2.70 +47541-8;4-Hydroxybenzoate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;4-Hydroxybenzoate/Creatinine [Molar ratio] in Urine;4OHBenzoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47542-6;Gamma hydroxybutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Gamma hydroxybutyrate/Creatinine [Molar ratio] in Urine;G-OH-Butyr/Creat Ur-sRto;;ACTIVE;2.21;2.73 +47543-4;4-Hydroxymandelate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxymandelate/Creatinine [Molar ratio] in Urine;4OHMandelate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47544-2;5-Hydroxyindoleacetate;SCnc;Pt;CSF;Qn;;CHEM;1;5-Hydroxyindoleacetate [Moles/volume] in Cerebral spinal fluid;5OH-indoleacetate CSF-sCnc;;ACTIVE;2.21;2.70 +47545-9;5-Hydroxyindoleacetate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;5-Hydroxyindoleacetate/Creatinine [Molar ratio] in 24 hour Urine;5OH-indoleacetate/Creat 24h Ur-sRto;;ACTIVE;2.21;2.70 +47546-7;5-Hydroxytryptophan;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Moles/volume] in Cerebral spinal fluid;5OH-Tryptophan CSF-sCnc;;ACTIVE;2.21;2.70 +47547-5;5-Methyltetrahydrofolate;SCnc;Pt;CSF;Qn;;CHEM;1;5-Methyltetrahydrofolate [Moles/volume] in Cerebral spinal fluid;5Me-tetrahydrofolate CSF-sCnc;;ACTIVE;2.21;2.70 +4754-8;HLA-B w4;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B w4 [Presence] in Donor;HLA-B w4 Donr Ql;;ACTIVE;1.0;2.56 +47548-3;Adenosine deaminase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/mass] in Fibroblast;Adenosine deaminase Fib-cCnt;;ACTIVE;2.21;2.70 +47549-1;Adenosine deaminase;CCnt;Pt;RBC;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/mass] in Red Blood Cells;Adenosine deaminase RBC-cCnt;;ACTIVE;2.21;2.73 +47550-9;Adenosine deaminase;EntCat;Pt;WBC;Qn;;CHEM;1;Adenosine deaminase [Entitic Catalytic Activity] in Leukocytes;Adenosine deaminase WBC Qn;;ACTIVE;2.21;2.70 +47551-7;Alanine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Alanine [Moles/volume] in DBS;Alanine DBS-sCnc;;ACTIVE;2.21;2.70 +47552-5;Alanine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Alanine/Amino acids.total in Hair;Alanine SFr Hair;;ACTIVE;2.21;2.70 +47553-3;Alanine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Alanine/Amino acids.total in Cerebral spinal fluid;Alanine SFr CSF;;ACTIVE;2.21;2.70 +47554-1;Alanine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Alanine/Amino acids.total in Amniotic fluid;Alanine SFr Amn;;ACTIVE;2.21;2.70 +4755-5;HLA-B w4;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B w4 [Presence];HLA-B w4 Ql;;ACTIVE;1.0;2.56 +47555-8;Alanine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Alanine/Amino acids.total in Serum or Plasma;Alanine SFr SerPl;;ACTIVE;2.21;2.73 +47556-6;Alanine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Alanine/Amino acids.total in DBS;Alanine SFr DBS;;ACTIVE;2.21;2.70 +47557-4;Alanine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Alanine/Amino acids.total in Specimen;Alanine SFr Spec;;ACTIVE;2.21;2.70 +47558-2;Albumin/Protein.total;MFr;24H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin/Protein.total in 24 hour Urine;Microalbumin 24h MFr Ur;;ACTIVE;2.21;2.73 +47559-0;Alpha aminobutyrate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in DBS;A-Aminobutyr DBS-sCnc;;ACTIVE;2.21;2.70 +47560-8;Androstenedione^pre 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM;Androst pre 250 ug ACTH IM SerPl-mCnc;;ACTIVE;2.21;2.73 +47561-6;Anion gap;SCnc;Pt;Body fld;Qn;;CHEM;1;Anion gap in Body fluid;Anion Gap Fld-sCnc;;ACTIVE;2.21;2.73 +47562-4;Arginine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Arginine [Moles/volume] in DBS;Arginine DBS-sCnc;;ACTIVE;2.21;2.73 +4756-3;HLA-B50(21);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B50(21) [Presence] in Donor;HLA-B50(21) Donr Ql;;ACTIVE;1.0;2.56 +47563-2;Arginine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Arginine/Amino acids.total in Serum or Plasma;Arginine SFr SerPl;;ACTIVE;2.21;2.70 +47564-0;Arginine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Arginine/Amino acids.total in Hair;Arginine SFr Hair;;ACTIVE;2.21;2.70 +47565-7;Arginine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Arginine/Amino acids.total in Cerebral spinal fluid;Arginine SFr CSF;;ACTIVE;2.21;2.70 +47566-5;Arginine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Arginine/Amino acids.total in Amniotic fluid;Arginine SFr Amn;;ACTIVE;2.21;2.70 +47567-3;Arginine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Arginine/Amino acids.total in DBS;Arginine SFr DBS;;ACTIVE;2.21;2.70 +47568-1;Arginine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Arginine/Amino acids.total in Specimen;Arginine SFr Spec;;ACTIVE;2.21;2.70 +47569-9;Argininosuccinate lyase;CCnt;Pt;Liver;Qn;;CHEM;1;Argininosuccinate lyase [Enzymatic activity/mass] in Liver;ASA Lyase Liver-cCnt;;ACTIVE;2.21;2.70 +47570-7;Argininosuccinate lyase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Argininosuccinate lyase [Enzymatic activity/mass] in Fibroblast;ASA Lyase Fib-cCnt;;ACTIVE;2.21;2.70 +4757-1;HLA-B50(21);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B50(21) [Presence];HLA-B50(21) Ql;;ACTIVE;1.0;2.56 +47571-5;Argininosuccinate synthase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Argininosuccinate synthase [Enzymatic activity/mass] in Fibroblast;ASA Synthase Fib-cCnt;;ACTIVE;2.21;2.70 +47572-3;Asparagine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Asparagine [Moles/volume] in DBS;Asparagine DBS-sCnc;;ACTIVE;2.21;2.70 +47573-1;Aspartate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Aspartate [Moles/volume] in DBS;Aspartate DBS-sCnc;;ACTIVE;2.21;2.70 +47574-9;Aspartate/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Aspartate/Amino acids.total in Hair;Aspartate SFr Hair;;ACTIVE;2.21;2.70 +47575-6;Aspartate/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Aspartate/Amino acids.total in Cerebral spinal fluid;Aspartate SFr CSF;;ACTIVE;2.21;2.70 +47576-4;Aspartate/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Aspartate/Amino acids.total in Amniotic fluid;Aspartate SFr Amn;;ACTIVE;2.21;2.70 +47577-2;Aspartate/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Aspartate/Amino acids.total in Serum or Plasma;Aspartate SFr SerPl;;ACTIVE;2.21;2.70 +47578-0;Aspartate/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Aspartate/Amino acids.total in DBS;Aspartate SFr DBS;;ACTIVE;2.21;2.70 +47579-8;Bicarbonate;SRat;24H;Urine;Qn;;CHEM;1;Bicarbonate [Moles/time] in 24 hour Urine;HCO3 24h Ur-sRate;;ACTIVE;2.21;2.73 +47580-6;Bicarbonate;SCnc;24H;Urine;Qn;;CHEM;1;Bicarbonate [Moles/volume] in 24 hour Urine;HCO3 24h Ur-sCnc;;ACTIVE;2.21;2.70 +47581-4;Biopterin;SCnc;Pt;CSF;Qn;;CHEM;1;Biopterin [Moles/volume] in Cerebral spinal fluid;Biopterin CSF-sCnc;;ACTIVE;2.21;2.70 +47582-2;Biopterin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Biopterin/Creatinine [Molar ratio] in Urine;Biopterin/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47583-0;C peptide^1.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1.5 hours post dose glucose;C peptide 1.5h p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47584-8;C peptide^10M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --10 minutes post dose glucose;C peptide 10M p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47585-5;C peptide^15M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --15 minutes post dose glucose;C peptide 15M p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47586-3;C peptide^1H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1 hour post dose glucose;C peptide 1h p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47587-1;C peptide^1M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1 minute post dose glucose;C peptide 1M p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47588-9;C peptide^2H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --2 hours post dose glucose;C peptide 2h p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +4758-9;HLA-B52(5);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B52(5) [Presence] in Donor;HLA-B52(5) Donr Ql;;ACTIVE;1.0;2.56 +47589-7;C peptide^30M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --30 minutes post dose glucose;C peptide 30M p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47590-5;C peptide^3H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --3 hours post dose glucose;C peptide 3h p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47591-3;C peptide^3M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --3 minutes post dose glucose;C peptide 3M p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47592-1;C peptide^5M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5 minutes post dose glucose;C peptide 5M p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47593-9;C peptide^5M pre dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5 minutes pre dose glucose;C peptide 5M pre Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47594-7;C peptide^pre dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --pre dose glucagon;C peptide pre Gc SerPl-sCnc;;ACTIVE;2.21;2.70 +47595-4;C peptide^pre dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --pre dose glucose;C peptide pre Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +47596-2;Calcium.ionized;SCnc;Pt;Bld;Qn;ISE;CHEM;1;Calcium.ionized [Moles/volume] in Blood by Ion-selective membrane electrode (ISE);Ca-I Bld ISE-sCnc;;ACTIVE;2.21;2.73 +4759-7;HLA-B52(5);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B52(5) [Presence];HLA-B52(5) Ql;;ACTIVE;1.0;2.56 +47597-0;Calcium^^corrected for total protein;SCnc;Pt;Bld;Qn;;CHEM;1;Calcium [Moles/volume] corrected for total protein in Blood;Calcium TP cor Bld-sCnc;;ACTIVE;2.21;2.70 +47598-8;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;Bld;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood;Ca-I adj pH7.4 Bld-sCnc;;ACTIVE;2.21;2.73 +47599-6;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldCo;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Cord blood;pCO2 temp adj BldCo;;ACTIVE;2.21;2.70 +47600-2;Ceruloplasmin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ceruloplasmin [Moles/volume] in Serum or Plasma;Ceruloplasmin SerPl-sCnc;;ACTIVE;2.21;2.70 +47601-0;Choriogonadotropin.beta subunit.free;ACnc;Pt;Body fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Units/volume] in Body fluid;B-HCG Free Fld-aCnc;;ACTIVE;2.21;2.70 +47602-8;Citrate synthase;CCnt;Pt;WBC;Qn;;CHEM;1;Citrate synthase [Enzymatic activity/mass] in Leukocytes;Citrate Synthase WBC-cCnt;;ACTIVE;2.21;2.70 +47603-6;Citrate synthase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Citrate synthase [Enzymatic activity/mass] in Fibroblast;Citrate Synthase Fib-cCnt;;ACTIVE;2.21;2.70 +47604-4;Cortisol^1.5H post 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1.5 hours post 1 ug/kg CRH IV;Cortis 1.5h p 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.21;2.70 +4760-5;HLA-B53;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B53 [Presence] in Donor;HLA-B53 Donr Ql;;ACTIVE;1.0;2.56 +47605-1;Cortisol^15M post 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --15 minutes post 1 ug/kg CRH IV;Cortis 15M p 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.21;2.70 +47606-9;Cortisol^1H post 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1 hour post 1 ug/kg CRH IV;Cortis 1h p 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.21;2.70 +47607-7;Cortisol^30M post 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --30 minutes post 1 ug/kg CRH IV;Cortis 30M p 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.21;2.70 +47608-5;Cortisol^pre dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre dose corticotropin;Cortis Pre ACTH SerPl-sCnc;;ACTIVE;2.21;2.70 +47609-3;Cortisol^pre 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre 1 ug/kg CRH IV;Cortis pre 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.21;2.70 +47610-1;Creatinine;SCnc;Pt;Stool;Qn;;CHEM;1;Creatinine [Moles/volume] in Stool;Creat Stl-sCnc;;ACTIVE;2.21;2.70 +47611-9;Crystals;Prid;Pt;Tiss;Nom;Microscopy.light;PATH;1;Crystals [type] in Tissue by Light microscopy;Crystals Tiss Micro;;ACTIVE;2.21;2.26 +47612-7;Cystatin C;MCnc;Pt;Urine;Qn;;CHEM;1;Cystatin C [Mass/volume] in Urine;Cystatin C Ur-mCnc;;ACTIVE;2.21;2.73 +4761-3;HLA-B53;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B53 [Presence];HLA-B53 Ql;;ACTIVE;1.0;2.56 +47613-5;Decanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Decanoate (C10:0)/Creatinine [Molar ratio] in Urine;Decanoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47614-3;Decenoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Decenoate (C10:1)/Creatinine [Molar ratio] in Urine;Decenoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47615-0;Dermatan sulfate;PrThr;Pt;Urine;Ord;;CHEM;1;Dermatan sulfate [Presence] in Urine;Dermatan Sulfate Ur Ql;;ACTIVE;2.21;2.56 +47616-8;Estradiol^1H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin;Estradiol 1h p ACTH SerPl-mCnc;;ACTIVE;2.21;2.70 +47617-6;Estradiol^pre dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --pre dose corticotropin;Estradiol Pre ACTH SerPl-mCnc;;ACTIVE;2.21;2.70 +47618-4;Follitropin^15M post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --15 minutes post 100 ug luteinizing releasing hormone IV;FSH 15M p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47619-2;Follitropin^2.5H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --2.5 hours post 100 ug luteinizing releasing hormone IV;FSH 2.5h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +476-2;Sulfonamide;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sulfonamide [Susceptibility] by Minimum inhibitory concentration (MIC);Sulfonamide Islt MIC;;ACTIVE;1.0;2.19 +47620-0;Glucose;SCnc;Pt;Stool;Qn;;CHEM;1;Glucose [Moles/volume] in Stool;Glucose Stl-sCnc;;ACTIVE;2.21;2.70 +4762-1;HLA-B54(22);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B54(22) [Presence] in Donor;HLA-B54(22) Donr Ql;;ACTIVE;1.0;2.56 +47621-8;Glucose.IV;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Glucose.IV [Mass] of Dose;Glucose IV Dose;;ACTIVE;2.21;2.69 +47622-6;Glucose^pre dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre dose glucose;Glucose pre Glc SerPl-sCnc;;ACTIVE;2.21;2.73 +47623-4;Glutamate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glutamate [Moles/volume] in DBS;Glutamate DBS-sCnc;;ACTIVE;2.21;2.70 +47624-2;Glutamate/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Glutamate/Amino acids.total in Hair;Glutamate SFr Hair;;ACTIVE;2.21;2.70 +47625-9;Glutamate/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Glutamate/Amino acids.total in Cerebral spinal fluid;Glutamate SFr CSF;;ACTIVE;2.21;2.70 +47626-7;Glutamate/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Glutamate/Amino acids.total in Amniotic fluid;Glutamate SFr Amn;;ACTIVE;2.21;2.70 +47627-5;Glutamate/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Glutamate/Amino acids.total in Serum or Plasma;Glutamate SFr SerPl;;ACTIVE;2.21;2.70 +47628-3;Glutamate/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Glutamate/Amino acids.total in DBS;Glutamate SFr DBS;;ACTIVE;2.21;2.70 +47629-1;Glutamate/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Glutamate/Amino acids.total in Specimen;Glutamate SFr Spec;;ACTIVE;2.21;2.70 +47630-9;Glutamine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glutamine [Moles/volume] in DBS;Glutamine DBS-sCnc;;ACTIVE;2.21;2.70 +47631-7;Glutathione.oxidized;SCnt;Pt;RBC;Qn;;CHEM;1;Glutathione.oxidized [Moles/mass] in Red Blood Cells;GSS RBC-sCnt;;ACTIVE;2.21;2.70 +47632-5;Glycerol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glycerol/Creatinine [Molar ratio] in Urine;Glycerol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47633-3;Glycine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glycine [Moles/volume] in DBS;Glycine DBS-sCnc;;ACTIVE;2.21;2.73 +47634-1;Glycine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Glycine/Amino acids.total in Serum or Plasma;Glycine SFr SerPl;;ACTIVE;2.21;2.70 +47635-8;Glycine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Glycine/Amino acids.total in Hair;Glycine SFr Hair;;ACTIVE;2.21;2.70 +47636-6;Glycine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Glycine/Amino acids.total in Cerebral spinal fluid;Glycine SFr CSF;;ACTIVE;2.21;2.70 +47637-4;Glycine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Glycine/Amino acids.total in Amniotic fluid;Glycine SFr Amn;;ACTIVE;2.21;2.70 +47638-2;Glycine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Glycine/Amino acids.total in DBS;Glycine SFr DBS;;ACTIVE;2.21;2.70 +4763-9;HLA-B54(22);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B54(22) [Presence];HLA-B54(22) Ql;;ACTIVE;1.0;2.56 +47639-0;Glycine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Glycine/Amino acids.total in Specimen;Glycine SFr Spec;;ACTIVE;2.21;2.70 +47640-8;Hematocrit;VFr;Pt;Dial fld;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Dialysis fluid;Hct VFr Dial fld;;ACTIVE;2.21;2.70 +47641-6;Palmitate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Palmitate (C16:0)/Creatinine [Molar ratio] in Urine;Palmitate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47642-4;Hexadecenoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexadecenoate (C16:1w9)/Creatinine [Molar ratio] in Urine;Hexadecenoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47643-2;Histidine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Histidine [Moles/volume] in DBS;Histidine DBS-sCnc;;ACTIVE;2.21;2.70 +47644-0;Histidine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Histidine/Amino acids.total in Hair;Histidine SFr Hair;;ACTIVE;2.21;2.70 +47645-7;Histidine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Histidine/Amino acids.total in Cerebral spinal fluid;Histidine SFr CSF;;ACTIVE;2.21;2.70 +47646-5;Histidine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Histidine/Amino acids.total in Amniotic fluid;Histidine SFr Amn;;ACTIVE;2.21;2.70 +4764-7;HLA-B55(22);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B55(22) [Presence] in Donor;HLA-B55(22) Donr Ql;;ACTIVE;1.0;2.56 +47647-3;Histidine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Histidine/Amino acids.total in Serum or Plasma;Histidine SFr SerPl;;ACTIVE;2.21;2.70 +47648-1;Histidine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Histidine/Amino acids.total in DBS;Histidine SFr DBS;;ACTIVE;2.21;2.70 +47649-9;Histidine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Histidine/Amino acids.total in Specimen;Histidine SFr Spec;;ACTIVE;2.21;2.70 +47650-7;Homogentisate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homogentisate/Creatinine [Molar ratio] in Urine;Homogentisate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47651-5;Hydroxyproline;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Hydroxyproline [Moles/volume] in DBS;OH-Proline DBS-sCnc;;ACTIVE;2.21;2.70 +47652-3;Hypoxanthine phosphoribosyltransferase;CCnt;Pt;Placenta;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase [Enzymatic activity/mass] in Placenta;HPRT Placenta-cCnt;;ACTIVE;2.21;2.70 +47653-1;Insulin^10M post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --10 minutes post dose glucagon;Insulin 10M p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +4765-4;HLA-B55(22);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B55(22) [Presence];HLA-B55(22) Ql;;ACTIVE;1.0;2.56 +47654-9;Insulin^10M post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --10 minutes post dose glucose;Insulin 10M p Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +47655-6;Insulin^15M post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --15 minutes post dose glucagon;Insulin 15M p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47656-4;Insulin^1M post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1 minute post dose glucose;Insulin 1M p Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +47657-2;Insulin^1H post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1 hour post dose glucose;Insulin 1h p Glc SerPl-aCnc;;ACTIVE;2.21;2.73 +47658-0;Insulin^1.5H post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1.5 hours post dose glucose;Insulin 1.5h p Glc SerPl-aCnc;;ACTIVE;2.21;2.73 +47659-8;Insulin^2H post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2 hours post dose glucose;Insulin 2h p Glc SerPl-aCnc;;ACTIVE;2.21;2.73 +47660-6;Insulin^2.5H post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2.5 hours post dose glucose;Insulin 2.5h p Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +47661-4;Insulin^20M post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --20 minutes post dose glucose;Insulin 20M p Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +4766-2;HLA-B56(22);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B56(22) [Presence] in Donor;HLA-B56(22) Donr Ql;;ACTIVE;1.0;2.56 +47662-2;Insulin^3H post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3 hours post dose glucose;Insulin 3h p Glc SerPl-aCnc;;ACTIVE;2.21;2.73 +47663-0;Insulin^30M post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --30 minutes post dose glucose;Insulin 30M p Glc SerPl-aCnc;;ACTIVE;2.21;2.73 +47664-8;Insulin^3M post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3 minutes post dose glucose;Insulin 3M p Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +47665-5;Insulin^5M post dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --5 minutes post dose glucose;Insulin 5M p Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +47666-3;Insulin^5M pre dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --5 minutes pre dose glucose;Insulin 5M pre Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +47667-1;Insulin^6M post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --6 minutes post dose glucagon;Insulin 6M p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47668-9;Insulin^pre dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --pre dose glucose;Insulin pre Glc SerPl-aCnc;;ACTIVE;2.21;2.73 +47669-7;Insulin^pre dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --pre dose glucagon;Insulin pre Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +4767-0;HLA-B56(22);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B56(22) [Presence];HLA-B56(22) Ql;;ACTIVE;1.0;2.56 +47670-5;Insulin^pre-meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --pre-meal;Insulin pre-meal SerPl-aCnc;;ACTIVE;2.21;2.70 +47671-3;Isoleucine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Isoleucine [Moles/volume] in DBS;Isoleucine DBS-sCnc;;ACTIVE;2.21;2.70 +47672-1;Isoleucine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Isoleucine/Amino acids.total in Hair;Isoleucine SFr Hair;;ACTIVE;2.21;2.70 +47673-9;Isoleucine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Isoleucine/Amino acids.total in Cerebral spinal fluid;Isoleucine SFr CSF;;ACTIVE;2.21;2.70 +47674-7;Isoleucine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Isoleucine/Amino acids.total in Amniotic fluid;Isoleucine SFr Amn;;ACTIVE;2.21;2.70 +47675-4;Isoleucine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Isoleucine/Amino acids.total in Serum or Plasma;Isoleucine SFr SerPl;;ACTIVE;2.21;2.70 +47676-2;Isoleucine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Isoleucine/Amino acids.total in DBS;Isoleucine SFr DBS;;ACTIVE;2.21;2.70 +47677-0;Isoleucine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Isoleucine/Amino acids.total in Specimen;Isoleucine SFr Spec;;ACTIVE;2.21;2.70 +47678-8;Lactate dehydrogenase;CCnc;24H;Urine;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in 24 hour Urine;LDH 24h Ur-cCnc;;ACTIVE;2.21;2.70 +47679-6;Leucine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Leucine [Moles/volume] in DBS;Leucine DBS-sCnc;;ACTIVE;2.21;2.73 +47680-4;Leucine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Leucine/Amino acids.total in Hair;Leucine SFr Hair;;ACTIVE;2.21;2.70 +47681-2;Leucine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Leucine/Amino acids.total in Cerebral spinal fluid;Leucine SFr CSF;;ACTIVE;2.21;2.70 +47682-0;Leucine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Leucine/Amino acids.total in Amniotic fluid;Leucine SFr Amn;;ACTIVE;2.21;2.70 +47683-8;Leucine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Leucine/Amino acids.total in Serum or Plasma;Leucine SFr SerPl;;ACTIVE;2.21;2.70 +47684-6;Leucine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Leucine/Amino acids.total in DBS;Leucine SFr DBS;;ACTIVE;2.21;2.70 +47685-3;Leucine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Leucine/Amino acids.total in Specimen;Leucine SFr Spec;;ACTIVE;2.21;2.70 +47686-1;Linoleate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Linoleate (C18:2w6)/Creatinine [Molar ratio] in Urine;Linoleate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47687-9;Lutropin^15M post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --15 minutes post 100 ug luteinizing releasing hormone IV;LH 15M p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +4768-8;HLA-B57(17);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B57(17) [Presence] in Donor;HLA-B57(17) Donr Ql;;ACTIVE;1.0;2.56 +47688-7;Lutropin^pre 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --pre 100 ug luteinizing releasing hormone IV;LH pre 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47689-5;Lysine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Lysine [Moles/volume] in DBS;Lysine DBS-sCnc;;ACTIVE;2.21;2.70 +47690-3;Lysine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Lysine/Amino acids.total in Hair;Lysine SFr Hair;;ACTIVE;2.21;2.70 +47691-1;Lysine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Lysine/Amino acids.total in Cerebral spinal fluid;Lysine SFr CSF;;ACTIVE;2.21;2.70 +47692-9;Lysine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Lysine/Amino acids.total in Amniotic fluid;Lysine SFr Amn;;ACTIVE;2.21;2.70 +47693-7;Lysine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Lysine/Amino acids.total in Serum or Plasma;Lysine SFr SerPl;;ACTIVE;2.21;2.70 +47694-5;Lysine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Lysine/Amino acids.total in DBS;Lysine SFr DBS;;ACTIVE;2.21;2.70 +47695-2;Lysine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Lysine/Amino acids.total in Specimen;Lysine SFr Spec;;ACTIVE;2.21;2.70 +4769-6;HLA-B57(17);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B57(17) [Presence];HLA-B57(17) Ql;;ACTIVE;1.0;2.56 +47696-0;Malonate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Malonate/Creatinine [Molar ratio] in Urine;Malonate/Creat Ur-sRto;;ACTIVE;2.21;2.73 +47697-8;Mandelate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Mandelate/Creatinine [Molar ratio] in Urine;Mandelate/Creat Ur-sRto;;ACTIVE;2.21;2.73 +47698-6;Mannitol/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Mannitol/Creatinine [Molar ratio] in Urine;Mannitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47699-4;Metanephrine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Metanephrine/Creatinine [Molar ratio] in 24 hour Urine;Metaneph/Creat 24h Ur-sRto;;ACTIVE;2.21;2.73 +477-0;Sulfonamide;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Sulfonamide [Susceptibility] by Disk diffusion (KB);Sulfonamide Islt KB;;ACTIVE;1.0;2.19 +47700-0;Methionine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Methionine [Moles/volume] in DBS;Methionine DBS-sCnc;;ACTIVE;2.21;2.73 +47701-8;Methionine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Methionine/Amino acids.total in Hair;Methionine SFr Hair;;ACTIVE;2.21;2.70 +47702-6;Methionine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Methionine/Amino acids.total in Cerebral spinal fluid;Methionine SFr CSF;;ACTIVE;2.21;2.70 +47703-4;Methionine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Methionine/Amino acids.total in Amniotic fluid;Methionine SFr Amn;;ACTIVE;2.21;2.70 +4770-4;HLA-B58(17);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B58(17) [Presence] in Donor;HLA-B58(17) Donr Ql;;ACTIVE;1.0;2.56 +47704-2;Methionine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Methionine/Amino acids.total in Serum or Plasma;Methionine SFr SerPl;;ACTIVE;2.21;2.70 +47705-9;Methionine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Methionine/Amino acids.total in DBS;Methionine SFr DBS;;ACTIVE;2.21;2.70 +47706-7;Methionine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Methionine/Amino acids.total in Specimen;Methionine SFr Spec;;ACTIVE;2.21;2.70 +47707-5;Methylmalonate/Urea;SRto;Pt;Amnio fld;Qn;;CHEM;1;Methylmalonate/Urea [Molar ratio] in Amniotic fluid;Methylmalonate/Urea Amn-sRto;;ACTIVE;2.21;2.70 +47708-3;Methylmalonate/Urea;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonate/Urea [Molar ratio] in Serum or Plasma;Methylmalonate/Urea SerPl-sRto;;ACTIVE;2.21;2.70 +47709-1;Methylmalonate/Urea;SRto;Pt;Urine;Qn;;CHEM;1;Methylmalonate/Urea [Molar ratio] in Urine;Methylmalonate/Urea Ur-sRto;;ACTIVE;2.21;2.70 +47710-9;N-acetylaspartate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deprecated N-acetylaspartate/Creatinine [Molar ratio] in Urine;Deprecated N-Ac-Asp/Creat Ur-sRto;;DEPRECATED;2.21;2.70 +47711-7;Neopterin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Neopterin/Creatinine [Molar ratio] in Urine;Neopterin/Creat Ur-sRto;;ACTIVE;2.21;2.70 +4771-2;HLA-B58(17);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B58(17) [Presence];HLA-B58(17) Ql;;ACTIVE;1.0;2.56 +47712-5;Nitrogen;PrThr;Pt;Sweat;Ord;;CHEM;1;Nitrogen [Presence] in Sweat;N2 Sweat Ql;;ACTIVE;2.21;2.56 +47713-3;Oleate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Oleate (C18:1w9)/Creatinine [Molar ratio] in Urine;Oleate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47714-1;Ornithine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Ornithine [Moles/volume] in DBS;Ornithine DBS-sCnc;;ACTIVE;2.21;2.73 +47715-8;Oxalate;SCnc;Pt;Dial fld;Qn;;CHEM;1;Oxalate [Moles/volume] in Dialysis fluid;Oxalate Dial fld-sCnc;;ACTIVE;2.21;2.70 +47716-6;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldCo;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Cord blood;pO2 temp adj BldCo;;ACTIVE;2.21;2.70 +47717-4;Parathyrin^2H post dose calcium;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin [Mass/volume] in Serum or Plasma --2 hours post dose calcium;PTH 2h p Ca SerPl-mCnc;;ACTIVE;2.21;2.70 +47718-2;Parathyrin^4H post dose calcium;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin [Mass/volume] in Serum or Plasma --4 hours post dose calcium;PTH 4h p Ca SerPl-mCnc;;ACTIVE;2.21;2.70 +47719-0;Parathyrin^pre dose calcium;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin [Mass/volume] in Serum or Plasma --pre dose calcium;PTH pre Ca SerPl-mCnc;;ACTIVE;2.21;2.70 +4772-0;HLA-B59;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B59 [Presence] in Donor;HLA-B59 Donr Ql;;ACTIVE;1.0;2.56 +47720-8;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldCo;Qn;;CHEM;1;pH of Cord blood adjusted to patient's actual temperature;pH temp adj BldCo;;ACTIVE;2.21;2.73 +47721-6;Phenylalanine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Phenylalanine/Amino acids.total in Hair;Phe SFr Hair;;ACTIVE;2.21;2.70 +47722-4;Phenylalanine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Phenylalanine/Amino acids.total in Cerebral spinal fluid;Phe SFr CSF;;ACTIVE;2.21;2.70 +47723-2;Phenylalanine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Phenylalanine/Amino acids.total in Amniotic fluid;Phe SFr Amn;;ACTIVE;2.21;2.70 +47724-0;Phenylalanine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Phenylalanine/Amino acids.total in Serum or Plasma;Phe SFr SerPl;;ACTIVE;2.21;2.70 +47725-7;Phenylalanine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Phenylalanine/Amino acids.total in Specimen;Phe SFr Spec;;ACTIVE;2.21;2.70 +47726-5;Phytanate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Phytanate (C16:0(CH3)4)/Creatinine [Molar ratio] in Urine;Phytanate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47727-3;Pipecolate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pipecolate/Creatinine [Molar ratio] in Urine;Pipecolate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47728-1;Procollagen type III/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Procollagen type III/Creatinine [Ratio] in Urine;Procollagen III/Creat Ur-Rto;;ACTIVE;2.21;2.70 +47729-9;Prolactin^1.5H post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1.5 hours post dose TRH IV;Prolactin 1.5h p TRH IV SerPl-mCnc;;ACTIVE;2.21;2.70 +47730-7;Prolactin^15M post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --15 minutes post dose TRH IV;Prolactin 15M p TRH IV SerPl-mCnc;;ACTIVE;2.21;2.70 +47731-5;Prolactin^2H post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --2 hours post dose TRH IV;Prolactin 2h p TRH IV SerPl-mCnc;;ACTIVE;2.21;2.70 +47732-3;Proline;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Proline [Moles/volume] in DBS;Proline DBS-sCnc;;ACTIVE;2.21;2.73 +47733-1;Proline/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Proline/Amino acids.total in Hair;Proline SFr Hair;;ACTIVE;2.21;2.70 +47734-9;Proline/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Proline/Amino acids.total in Amniotic fluid;Proline SFr Amn;;ACTIVE;2.21;2.70 +47735-6;Proline/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Proline/Amino acids.total in Serum or Plasma;Proline SFr SerPl;;ACTIVE;2.21;2.70 +47736-4;Proline/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Proline/Amino acids.total in DBS;Proline SFr DBS;;ACTIVE;2.21;2.70 +47737-2;Proline/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Proline/Amino acids.total in Specimen;Proline SFr Spec;;ACTIVE;2.21;2.70 +4773-8;HLA-B59;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B59 [Presence];HLA-B59 Ql;;ACTIVE;1.0;2.56 +47738-0;Prostate specific Ag;MCnc;Pt;Body fld;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in Body fluid;PSA Fld-mCnc;;ACTIVE;2.21;2.73 +47739-8;Protein;MCnc;Pt;Stool;Qn;;CHEM;1;Protein [Mass/volume] in Stool;Prot Stl-mCnc;;ACTIVE;2.21;2.73 +47740-6;Purine nucleoside phosphorylase;CCnt;Pt;RBC;Qn;;CHEM;1;Purine nucleoside phosphorylase [Enzymatic activity/mass] in Red Blood Cells;PNP RBC-cCnt;;ACTIVE;2.21;2.70 +47741-4;Purine nucleoside phosphorylase;EntCat;Pt;WBC;Qn;;CHEM;1;Purine nucleoside phosphorylase [Entitic Catalytic Activity] in Leukocytes;PNP WBC Qn;;ACTIVE;2.21;2.70 +47742-2;Serine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Serine [Moles/volume] in DBS;Serine DBS-sCnc;;ACTIVE;2.21;2.70 +47743-0;Serine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Serine/Amino acids.total in Hair;Serine SFr Hair;;ACTIVE;2.21;2.70 +47744-8;Serine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Serine/Amino acids.total in Cerebral spinal fluid;Serine SFr CSF;;ACTIVE;2.21;2.70 +47745-5;Serine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Serine/Amino acids.total in Amniotic fluid;Serine SFr Amn;;ACTIVE;2.21;2.70 +4774-6;HLA-B60(40);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B60(40) [Presence] in Donor;HLA-B60(40) Donr Ql;;ACTIVE;1.0;2.56 +47746-3;Serine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Serine/Amino acids.total in Serum or Plasma;Serine SFr SerPl;;ACTIVE;2.21;2.70 +47747-1;Serine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Serine/Amino acids.total in DBS;Serine SFr DBS;;ACTIVE;2.21;2.70 +47748-9;Serine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Serine/Amino acids.total in Specimen;Serine SFr Spec;;ACTIVE;2.21;2.70 +47749-7;Somatotropin^1.5H post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose glucagon;GH 1.5h p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47750-5;Somatotropin^1.5H post dose glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose glucose PO;GH 1.5h p Glc PO SerPl-aCnc;;ACTIVE;2.21;2.70 +47751-3;Somatotropin^1.5H post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose TRH;GH 1.5h p TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +47752-1;Somatotropin^1.5H post dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose arginine;GH 1.5h p Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +4775-3;HLA-B60(40);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B60(40) [Presence];HLA-B60(40) Ql;;ACTIVE;1.0;2.56 +47753-9;Somatotropin^1.5H post dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose insulin IV;GH 1.5h p Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47754-7;Somatotropin^10M post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --10 minutes post dose TRH;GH 10M p TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +47755-4;Somatotropin^10th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --10th specimen post XXX challenge;GH sp10 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47756-2;Somatotropin^15M pre dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose arginine;GH 15M pre arg SerPl-aCnc;;ACTIVE;2.21;2.70 +47757-0;Somatotropin^15M post dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose arginine;GH 15M p Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +47758-8;Somatotropin^15M post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose glucagon;GH 15M p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47759-6;Somatotropin^15M post dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose insulin IV;GH 15M p Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47760-4;Somatotropin^1H post dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose arginine;GH 1h p Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +4776-1;HLA-B61(40);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B61(40) [Presence] in Donor;HLA-B61(40) Donr Ql;;ACTIVE;1.0;2.56 +47761-2;Somatotropin^1H post dose glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose glucose PO;GH 1h p Glc PO SerPl-aCnc;;ACTIVE;2.21;2.70 +47762-0;Somatotropin^1H post dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose insulin IV;GH 1h p Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47763-8;Somatotropin^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1st specimen post XXX challenge;GH sp1 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47764-6;Somatotropin^2H post dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose arginine;GH 2h p Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +47765-3;Somatotropin^2H post dose glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose glucose PO;GH 2h p Glc PO SerPl-aCnc;;ACTIVE;2.21;2.70 +47766-1;Somatotropin^2H post dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose insulin IV;GH 2h p Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47767-9;Somatotropin^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge;GH sp2 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47768-7;Somatotropin^30M post dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose arginine;GH 30M p Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +47769-5;Somatotropin^30M post dose glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose glucose PO;GH 30M p Glc PO SerPl-aCnc;;ACTIVE;2.21;2.70 +47770-3;Somatotropin^30M post dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose insulin IV;GH 30M p Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47771-1;Somatotropin^3H post dose glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --3 hours post dose glucose PO;GH 3h p Glc PO SerPl-aCnc;;ACTIVE;2.21;2.70 +47772-9;Somatotropin^45M post dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --45 minutes post dose arginine;GH 45M p Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +47773-7;Somatotropin^45M post dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --45 minutes post dose insulin IV;GH 45M p Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47774-5;Somatotropin^pre dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose arginine;GH pre Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +47775-2;Somatotropin^pre dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose glucagon;GH pre Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47776-0;Somatotropin^pre dose glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose glucose PO;GH Pre Glc PO SerPl-aCnc;;ACTIVE;2.21;2.70 +47777-8;Somatotropin^pre dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose insulin IV;GH pre Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47778-6;Somatotropin^pre dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose TRH;GH pre TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +4777-9;HLA-B61(40);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B61(40) [Presence];HLA-B61(40) Ql;;ACTIVE;1.0;2.56 +47779-4;Octadecanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Octadecanoate (C18:0)/Creatinine [Molar ratio] in Urine;Octadecanoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47780-2;Sulfate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sulfate [Moles/volume] in Urine;Sulfate Ur-sCnc;;ACTIVE;2.21;2.73 +47781-0;Sulfocysteine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Sulfocysteine [Moles/volume] in Amniotic fluid;Sulfocysteine Amn-sCnc;;ACTIVE;2.21;2.70 +47782-8;Taurine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Taurine [Moles/volume] in DBS;Taurine DBS-sCnc;;ACTIVE;2.21;2.70 +47783-6;Myristate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Myristate (C14:0)/Creatinine [Molar ratio] in Urine;Myristate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47784-4;Threonine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Threonine [Moles/volume] in DBS;Threonine DBS-sCnc;;ACTIVE;2.21;2.73 +47785-1;Threonine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Threonine/Amino acids.total in Hair;Threonine SFr Hair;;ACTIVE;2.21;2.70 +47786-9;Threonine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Threonine/Amino acids.total in Cerebral spinal fluid;Threonine SFr CSF;;ACTIVE;2.21;2.70 +4778-7;HLA-B62(15);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B62(15) [Presence] in Donor;HLA-B62(15) Donr Ql;;ACTIVE;1.0;2.56 +47787-7;Threonine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Threonine/Amino acids.total in Amniotic fluid;Threonine SFr Amn;;ACTIVE;2.21;2.70 +47788-5;Threonine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Threonine/Amino acids.total in Serum or Plasma;Threonine SFr SerPl;;ACTIVE;2.21;2.70 +47789-3;Threonine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Threonine/Amino acids.total in DBS;Threonine SFr DBS;;ACTIVE;2.21;2.70 +47790-1;Threonine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Threonine/Amino acids.total in Specimen;Threonine SFr Spec;;ACTIVE;2.21;2.70 +47791-9;Tocopherols;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tocopherols [Mass/volume] in Serum or Plasma;Tocopherols SerPl-mCnc;;ACTIVE;2.21;2.73 +47792-7;Tyrosine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Tyrosine/Amino acids.total in Hair;Tyrosine SFr Hair;;ACTIVE;2.21;2.70 +47793-5;Tyrosine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Tyrosine/Amino acids.total in Cerebral spinal fluid;Tyrosine SFr CSF;;ACTIVE;2.21;2.70 +47794-3;Tyrosine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Tyrosine/Amino acids.total in Amniotic fluid;Tyrosine SFr Amn;;ACTIVE;2.21;2.70 +4779-5;HLA-B62(15);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B62(15) [Presence];HLA-B62(15) Ql;;ACTIVE;1.0;2.56 +47795-0;Tyrosine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Tyrosine/Amino acids.total in Serum or Plasma;Tyrosine SFr SerPl;;ACTIVE;2.21;2.70 +47796-8;Tyrosine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Tyrosine/Amino acids.total in DBS;Tyrosine SFr DBS;;ACTIVE;2.21;2.70 +47797-6;Tyrosine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Tyrosine/Amino acids.total in Specimen;Tyrosine SFr Spec;;ACTIVE;2.21;2.70 +47798-4;Urea;SCnc;Pt;Stool;Qn;;CHEM;1;Urea [Moles/volume] in Stool;Urea Stl-sCnc;;ACTIVE;2.21;2.70 +47799-2;Valine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Valine [Moles/volume] in DBS;Valine DBS-sCnc;;ACTIVE;2.21;2.73 +47800-8;Valine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Valine/Amino acids.total in Hair;Valine SFr Hair;;ACTIVE;2.21;2.70 +47801-6;Valine/Amino acids.total;SFr;Pt;CSF;Qn;;CHEM;1;Valine/Amino acids.total in Cerebral spinal fluid;Valine SFr CSF;;ACTIVE;2.21;2.70 +47802-4;Valine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Valine/Amino acids.total in Amniotic fluid;Valine SFr Amn;;ACTIVE;2.21;2.70 +4780-3;HLA-B63(15);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B63(15) [Presence] in Donor;HLA-B63(15) Donr Ql;;ACTIVE;1.0;2.56 +47803-2;Valine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Valine/Amino acids.total in Serum or Plasma;Valine SFr SerPl;;ACTIVE;2.21;2.70 +47804-0;Valine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Valine/Amino acids.total in DBS;Valine SFr DBS;;ACTIVE;2.21;2.70 +47805-7;Valine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Valine/Amino acids.total in Specimen;Valine SFr Spec;;ACTIVE;2.21;2.70 +47806-5;Xylose;PrThr;Pt;Urine;Ord;;CHEM;1;Xylose [Presence] in Urine;Xylose Ur Ql;;ACTIVE;2.21;2.56 +47807-3;2-Deoxytetronate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Deoxytetronate/Creatinine [Molar ratio] in Urine;2-deoxytetronate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47808-1;2-Ethylhydracrylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Ethylhydracrylate/Creatinine [Molar ratio] in Urine;2-ethylhydracrylate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47809-9;2-Hydroxysebacate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxysebacate/Creatinine [Molar ratio] in Urine;2OH-sebacate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47810-7;2-Methyl-3-Hydroxyvalerate;SCnc;Pt;Plas;Qn;;CHEM;1;2-Methyl-3-Hydroxyvalerate [Moles/volume] in Plasma;2-Me3OH-valerate Plas-sCnc;;ACTIVE;2.21;2.70 +4781-1;HLA-B63(15);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B63(15) [Presence];HLA-B63(15) Ql;;ACTIVE;1.0;2.56 +47811-5;2-Methyl-3-Oxobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methyl-3-Oxobutyrate/Creatinine [Molar ratio] in Urine;2Me3-oxobutyrate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47812-3;2-Methylglutaconate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methylglutaconate/Creatinine [Molar ratio] in Urine;2Me-glutaconate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47813-1;2-Methylglutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methylglutarate/Creatinine [Molar ratio] in Urine;2Me-glutarate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47814-9;3,4-Dihydroxyphenyllactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deprecated 3,4-Dihydroxyphenyllactate/Creatinine [Molar ratio] in Urine;Deprecated 3,4-Di-OH-phenyllactate/Creat Ur-sRto;;DEPRECATED;2.21;2.70 +47815-6;3,4-Hydroxymandelate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,4-Hydroxymandelate/Creatinine [Molar ratio] in Urine;3,4-OH-mandelate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47816-4;3-Deoxytetronate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Deoxytetronate/Creatinine [Molar ratio] in Urine;3-deoxytetronate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47817-2;3-Hydroxy,4-Methoxybenzoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxy,4-Methoxybenzoate/Creatinine [Molar ratio] in Urine;3OH4methoxybenzoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47818-0;3-Hydroxyhexanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyhexanoate (3-OH-C6:0)/Creatinine [Molar ratio] in Urine;3OH-hexanoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47819-8;3-Hydroxysuberate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxysuberate/Creatinine [Molar ratio] in Urine;3OHsuberate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47820-6;3-Hydroxyvalerate;SCnc;Pt;Plas;Qn;;CHEM;1;3-Hydroxyvalerate [Moles/volume] in Plasma;3OH-Valerate Plas-sCnc;;ACTIVE;2.21;2.70 +47821-4;3-Indolelactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Indolelactate/Creatinine [Molar ratio] in Urine;3-Indolelactate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47822-2;3-Methyladipate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methyladipate/Creatinine [Molar ratio] in Urine;3-Methyladipate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47823-0;4-Hydroxy-3-Methoxyphenyllactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxy-3-Methoxyphenyllactate/Creatinine [Molar ratio] in Urine;4OH3methoxyphenyllactate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47824-8;5-Hydroxycaproate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deprecated 5-Hydroxycaproate/Creatinine [Molar ratio] in Urine;Deprecated 5OH-caproate/Creat Ur-sRto;;DEPRECATED;2.21;2.70 +47825-5;7-Hydroxyoctanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;7-Hydroxyoctanoate/Creatinine [Molar ratio] in Urine;7OH-octanoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47826-3;Adenosine deaminase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Serum or Plasma;Adenosine deaminase SerPl-cCnc;;ACTIVE;2.21;2.73 +47827-1;Adenosyl homocysteine hydrolase;CCnt;Pt;RBC;Qn;;CHEM;1;Adenosyl homocysteine hydrolase [Enzymatic activity/mass] in Red Blood Cells;Adenosyl homocysteine hydrolase RBC-cCnt;;ACTIVE;2.21;2.70 +47828-9;Adiponectin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adiponectin [Mass/volume] in Serum or Plasma;Adiponectin SerPl-mCnc;;ACTIVE;2.21;2.73 +4782-9;HLA-B64(14);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B64(14) [Presence] in Donor;HLA-B64(14) Donr Ql;;ACTIVE;1.0;2.56 +47829-7;Arabitol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Arabitol/Creatinine [Molar ratio] in Urine;Arabitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47830-5;Argininosuccinate synthase;CCnt;Pt;CVS;Qn;;CHEM;1;Argininosuccinate synthase [Enzymatic activity/mass] in Chorionic villus sample;ASA Synthase CVS-cCnt;;ACTIVE;2.21;2.70 +47831-3;Argininosuccinate synthase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Argininosuccinate synthase [Enzymatic activity/mass] in Amniotic fluid cells;ASA Synthase Amnc-cCnt;;ACTIVE;2.21;2.70 +47832-1;C peptide^4M post 1 mg glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --4 minutes post 1 mg glucagon;C peptide 4M p 1 mg Gc SerPl-sCnc;;ACTIVE;2.21;2.70 +47833-9;C peptide^6M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --6 minutes post dose glucagon;C peptide 6M p Gc SerPl-sCnc;;ACTIVE;2.21;2.70 +47834-7;C peptide^8M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --8 minutes post dose glucagon;C peptide 8M p Gc SerPl-sCnc;;ACTIVE;2.21;2.70 +47835-4;Carnitine acyltransferase I;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Deprecated Carnitine acyltransferase I [Enzymatic activity/mass] in Fibroblast;Deprecated Carnitine acyltransferase I F;;DEPRECATED;2.21;2.70 +47836-2;Carnitine acyltransferase I;CCnt;Pt;WBC;Qn;;CHEM;1;Deprecated Carnitine acyltransferase I [Enzymatic activity/mass] in Leukocytes;Deprecated Carnitine acyltransferase I W;;DEPRECATED;2.21;2.70 +4783-7;HLA-B64(14);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B64(14) [Presence];HLA-B64(14) Ql;;ACTIVE;1.0;2.56 +47837-0;Carnitine acyltransferase II;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Deprecated Carnitine acyltransferase II [Enzymatic activity/mass] in Amniotic fluid cells;Deprecated Carnitine acyltransferase II;;DEPRECATED;2.21;2.70 +47838-8;Carnitine acyltransferase II;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Deprecated Carnitine acyltransferase II [Enzymatic activity/mass] in Fibroblast;Deprecated Carnitine acyltransferase II;;DEPRECATED;2.21;2.70 +47839-6;Carnitine acyltransferase II;CCnt;Pt;WBC;Qn;;CHEM;1;Deprecated Carnitine acyltransferase II [Enzymatic activity/mass] in Leukocytes;Deprecated Carnitine acyltransferase II;;DEPRECATED;2.21;2.70 +47840-4;Carnitine acyltransferase II;CCnt;Pt;CVS;Qn;;CHEM;1;Deprecated Carnitine acyltransferase II [Enzymatic activity/mass] in Chorionic villus sample;Deprecated Carnitine acyltransferase II;;DEPRECATED;2.21;2.70 +47841-2;Citrate synthase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Citrate synthase [Enzymatic activity/mass] in Amniotic fluid cells;Citrate Synthase Amnc-cCnt;;ACTIVE;2.21;2.70 +47842-0;Collection duration;Time;*;Dial fld;Qn;;SPEC;1;Collection duration of Dialysis fluid;Collect duration Time Dial fld;;ACTIVE;2.21;2.70 +47843-8;Corticotropin^post dose dexamethasone;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --post dose dexamethasone;ACTH p Dex Plas-mCnc;;ACTIVE;2.21;2.70 +47844-6;Cortisol^post 1 mg dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Cortisol [Mass/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight;Cortis p 1 mg Dex SerPl-mCnc;;ACTIVE;2.21;2.73 +4784-5;HLA-B65(14);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B65(14) [Presence] in Donor;HLA-B65(14) Donr Ql;;ACTIVE;1.0;2.56 +47845-3;Cortisol^post 1 mg dexamethasone PO overnight;SCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight;Cortis p 1 mg Dex SerPl-sCnc;;ACTIVE;2.21;2.70 +47846-1;Cortisol^post 2 mg dexamethasone PO 2.5 day high dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis p 2 mg Dex high SerPl-mCnc;;ACTIVE;2.21;2.70 +47847-9;Cortisol^post 2 mg dexamethasone PO 2.5 day high dose q6h;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --post 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis p 2 mg Dex high SerPl-sCnc;;ACTIVE;2.21;2.70 +47848-7;Cortisol^post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Cortisol [Mass/volume] in Serum or Plasma --post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis p 500 ug Dex SerPl-mCnc;;ACTIVE;2.21;2.70 +47849-5;Cortisol^post 500 ug dexamethasone PO 2.5 day low dose q6h;SCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;Cortisol [Moles/volume] in Serum or Plasma --post 500 ug dexamethasone PO 2.5 day low dose q6h;Cortis p 500 ug Dex SerPl-sCnc;;ACTIVE;2.21;2.70 +47850-3;Cortisol^post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --post dose corticotropin;Cortis p ACTH SerPl-mCnc;;ACTIVE;2.21;2.73 +47851-1;Cortisol^post dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --post dose dexamethasone;Cortis p Dex SerPl-mCnc;;ACTIVE;2.21;2.73 +4785-2;HLA-B65(14);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B65(14) [Presence];HLA-B65(14) Ql;;ACTIVE;1.0;2.56 +47852-9;Dehydroepiandrosterone^pre 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin;DHEA pre 250 ug ACTH SerPl-mCnc;;ACTIVE;2.21;2.70 +47853-7;Diphosphoglycerate phosphatase;CCnt;Pt;RBC;Qn;;CHEM;1;Diphosphoglycerate phosphatase [Enzymatic activity/mass] in Red Blood Cells;Diphosphoglycerate phosphatase RBC-cCnt;;ACTIVE;2.21;2.70 +47854-5;Fibroblast growth factor 23.intact;ACnc;Pt;Plas;Qn;;CHEM;1;Fibroblast growth factor 23.intact [Units/volume] in Plasma;FGF-23.intact Plas-aCnc;;ACTIVE;2.21;2.70 +47855-2;Fibroblast growth factor 23.C-terminal;ACnc;Pt;Plas;Qn;;CHEM;1;Fibroblast growth factor 23.C-terminal [Units/volume] in Plasma;FGF-23 c-term Plas-aCnc;;ACTIVE;2.21;2.70 +47856-0;Follitropin^pre 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --pre 100 ug luteinizing releasing hormone IV;FSH pre 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47857-8;Galactitol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Galactitol/Creatinine [Molar ratio] in Urine;Galactitol/Creat Ur-sRto;;ACTIVE;2.21;2.73 +47858-6;Gentisate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Gentisate/Creatinine [Molar ratio] in Urine;Gentisate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47859-4;Glucose^5M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5 minutes post dose glucose;Glucose 5M p Glc SerPl-sCnc;;ACTIVE;2.21;2.70 +4786-0;HLA-B67;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B67 [Presence] in Donor;HLA-B67 Donr Ql;;ACTIVE;1.0;2.56 +47860-2;Glutamate dehydrogenase;CCnt;Pt;CVS;Qn;;CHEM;1;Glutamate dehydrogenase [Enzymatic activity/mass] in Chorionic villus sample;GLDH CVS-cCnt;;ACTIVE;2.21;2.70 +47861-0;Hypoxanthine phosphoribosyltransferase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase [Enzymatic activity/mass] in Amniotic fluid cells;HPRT Amnc-cCnt;;ACTIVE;2.21;2.70 +47862-8;Insulin^post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --post meal;Insulin p meal SerPl-aCnc;;ACTIVE;2.21;2.70 +47863-6;Lactate dehydrogenase;CRat;24H;Urine;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/time] in 24 hour Urine;LDH 24h Ur-cRate;;ACTIVE;2.21;2.70 +47864-4;Lutropin^2.5H post 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --2.5 hours post 100 ug luteinizing releasing hormone IV;LH 2.5h p 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47865-1;Malondialdehyde;SCnc;Pt;Plas;Qn;;CHEM;1;Malondialdehyde [Moles/volume] in Plasma;Malondialdehyde Plas-sCnc;;ACTIVE;2.21;2.70 +47866-9;Phosphoribosylpyrophosphate synthetase;CCnt;Pt;RBC;Qn;;CHEM;1;Phosphoribosylpyrophosphate synthetase [Enzymatic activity/mass] in Red Blood Cells;PRPS RBC-cCnt;;ACTIVE;2.21;2.70 +47867-7;Phosphoribosylpyrophosphate synthetase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Phosphoribosylpyrophosphate synthetase [Enzymatic activity/mass] in Fibroblast;PRPS Fib-cCnt;;ACTIVE;2.21;2.70 +47868-5;Prolactin^1.5H post dose metoclopramide;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --1.5 hours post dose metoclopramide;Prolactin 1.5h p MCP SerPl-aCnc;;ACTIVE;2.21;2.70 +47869-3;Prolactin^1H post dose metoclopramide;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --1 hour post dose metoclopramide;Prolactin 1h p MCP SerPl-aCnc;;ACTIVE;2.21;2.70 +47870-1;Prolactin^2.5H post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --2.5 hours post dose TRH IV;Prolactin 2.5h p TRH IV SerPl-mCnc;;ACTIVE;2.21;2.70 +47871-9;Prolactin^30M post dose metoclopramide;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --30 minutes post dose metoclopramide;Prolactin 30M p MCP SerPl-aCnc;;ACTIVE;2.21;2.70 +47872-7;Prolactin^pre dose metoclopramide;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --pre dose metoclopramide;Prolactin pre MCP SerPl-aCnc;;ACTIVE;2.21;2.70 +47873-5;Propionyl CO-A carboxylase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Propionyl CoA Carboxylase [Enzymatic activity/mass] in Amniotic fluid cells;PCCA Amnc-cCnt;;ACTIVE;2.21;2.70 +47874-3;Propionyl CO-A carboxylase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Propionyl CoA Carboxylase [Enzymatic activity/mass] in Fibroblast;PCCA Fib-cCnt;;ACTIVE;2.21;2.70 +47875-0;Propionyl CO-A carboxylase;CCnt;Pt;WBC;Qn;;CHEM;1;Propionyl CoA Carboxylase [Enzymatic activity/mass] in Leukocytes;PCCA WBC-cCnt;;ACTIVE;2.21;2.70 +47876-8;Propionyl CO-A carboxylase;CCnt;Pt;Placenta;Qn;;CHEM;1;Propionyl CoA Carboxylase [Enzymatic activity/mass] in Placenta;PCCA Placenta-cCnt;;ACTIVE;2.21;2.70 +47877-6;Propionyl CO-A carboxylase;CCnt;Pt;CVS;Qn;;CHEM;1;Propionyl CoA Carboxylase [Enzymatic activity/mass] in Chorionic villus sample;PCCA CVS-cCnt;;ACTIVE;2.21;2.70 +4787-8;HLA-B67;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B67 [Presence];HLA-B67 Ql;;ACTIVE;1.0;2.56 +47878-4;Propionylglycine;SCnc;Pt;Plas;Qn;;CHEM;1;Propionylglycine [Moles/volume] in Plasma;Propionylgly Plas-sCnc;;ACTIVE;2.21;2.70 +47879-2;Pyruvate carboxylase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Pyruvate carboxylase [Enzymatic activity/mass] in Amniotic fluid cells;Pyruvate Carboxylase Amnc-cCnt;;ACTIVE;2.21;2.70 +478-8;Sulfonamide;Titr;Pt;Isolate;Qn;SBT;ABXBACT;1;Sulfonamide [Susceptibility] by Serum bactericidal titer;Sulfonamide Titr Islt SBT;;ACTIVE;1.0;2.32 +47880-0;Pyruvate carboxylase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Pyruvate carboxylase [Enzymatic activity/mass] in Fibroblast;Pyruvate Carboxylase Fib-cCnt;;ACTIVE;2.21;2.70 +47881-8;Pyruvate carboxylase;CCnt;Pt;WBC;Qn;;CHEM;1;Pyruvate carboxylase [Enzymatic activity/mass] in Leukocytes;Pyruvate Carboxylase WBC-cCnt;;ACTIVE;2.21;2.70 +47882-6;Pyruvate carboxylase;CCnt;Pt;Placenta;Qn;;CHEM;1;Pyruvate carboxylase [Enzymatic activity/mass] in Placenta;Pyruvate Carboxylase Placenta-cCnt;;ACTIVE;2.21;2.70 +47883-4;Renin^upright;MCnc;Pt;Plas;Qn;;CHEM;1;Renin [Mass/volume] in Plasma --upright;Renin upr Plas-mCnc;;ACTIVE;2.21;2.70 +47884-2;Ribitol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Ribitol/Creatinine [Molar ratio] in Urine;Ribitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +47885-9;Somatotropin^1.5H post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose arginine+insulin;GH 1.5h p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +4788-6;HLA-B w6;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B w6 [Presence] in Donor;HLA-B w6 Donr Ql;;ACTIVE;1.0;2.56 +47886-7;Somatotropin^1.5H post dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose betaxolol+glucagon;GH 1.5h p betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47887-5;Somatotropin^1.5H post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose ornithine;GH 1.5h p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47888-3;Somatotropin^1.75H post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.75 hours post dose arginine+insulin;GH 1.75h p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +47889-1;Somatotropin^1.75H post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.75 hours post dose ornithine;GH 1.75h p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47890-9;Somatotropin^15M post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose arginine+insulin;GH 15M p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +47891-7;Somatotropin^15M post dose growth hormone releasing factor;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose growth hormone releasing factor;GH 15M p GRF SerPl-aCnc;;ACTIVE;2.21;2.70 +47892-5;Somatotropin^15M post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose ornithine;GH 15M p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47893-3;Somatotropin^1H post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose glucagon;GH 1h p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +4789-4;HLA-B w6;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B w6 [Presence];HLA-B w6 Ql;;ACTIVE;1.0;2.56 +47894-1;Somatotropin^1H post dose growth hormone releasing factor;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose growth hormone releasing factor;GH 1h p GRF SerPl-aCnc;;ACTIVE;2.21;2.70 +47895-8;Somatotropin^1H post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose ornithine;GH 1h p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47896-6;Somatotropin^1H post dose propranolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose propranolol+glucagon;GH 1h p propranolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47897-4;Somatotropin^1H post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose TRH;GH 1h p TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +47898-2;Somatotropin^2.25H post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2.25 hours post dose arginine+insulin;GH 2.25h p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +47899-0;Somatotropin^2.5H post dose propranolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post dose propranolol+glucagon;GH 2.5h p propranolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47900-6;Somatotropin^20M post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --20 minutes post dose TRH;GH 20M p TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +47901-4;Somatotropin^2H post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose arginine+insulin;GH 2h p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +4790-2;HLA-B70;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B70 [Presence] in Donor;HLA-B70 Donr Ql;;ACTIVE;1.0;2.56 +47902-2;Somatotropin^2H post dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose betaxolol+glucagon;GH 2h p betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47903-0;Somatotropin^2H post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose glucagon;GH 2h p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47904-8;Somatotropin^2H post dose growth hormone releasing factor;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose growth hormone releasing factor;GH 2h p GRF SerPl-aCnc;;ACTIVE;2.21;2.70 +47905-5;Somatotropin^2H post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose ornithine;GH 2h p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47906-3;Somatotropin^2H post dose propranolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose propranolol+glucagon;GH 2h p propranolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47907-1;Somatotropin^2H post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose TRH;GH 2h p TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +47908-9;Somatotropin^2H pre dose propranolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours pre dose propranolol+glucagon;GH 2h pre dose propranolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47909-7;Somatotropin^30M post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose arginine+insulin;GH 30M p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +4791-0;HLA-B70;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B70 [Presence];HLA-B70 Ql;;ACTIVE;1.0;2.56 +47910-5;Somatotropin^30M post dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose betaxolol+glucagon;GH 30M p betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47911-3;Somatotropin^30M post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose glucagon;GH 30M p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47912-1;Somatotropin^30M post dose growth hormone releasing factor;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose growth hormone releasing factor;GH 30M p GRF SerPl-aCnc;;ACTIVE;2.21;2.70 +47913-9;Somatotropin^30M post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose ornithine;GH 30M p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47914-7;Somatotropin^30M post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose TRH;GH 30M p TRH SerPl-aCnc;;ACTIVE;2.21;2.40 +47915-4;Somatotropin^3H post dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --3 hours post dose betaxolol+glucagon;GH 3h p betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47916-2;Somatotropin^3H post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --3 hours post dose glucagon;GH 3h p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47917-0;Somatotropin^3H post dose propranolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --3 hours post dose propranolol+glucagon;GH 3h p propranolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47918-8;Somatotropin^3rd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge;GH sp3 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47919-6;Somatotropin^45M post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --45 minutes post dose arginine+insulin;GH 45M p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +47920-4;Somatotropin^45M post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --45 minutes post dose glucagon;GH 45M p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47921-2;Somatotropin^45M post dose growth hormone releasing factor;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --45 minutes post dose growth hormone releasing factor;GH 45M p GRF SerPl-aCnc;;ACTIVE;2.21;2.70 +47922-0;Somatotropin^45M post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --45 minutes post dose ornithine;GH 45M p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47923-8;Somatotropin^4th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --4th specimen post XXX challenge;GH sp4 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47924-6;Somatotropin^5M post dose arginine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --5 minutes post dose arginine;GH 5M p Arg SerPl-aCnc;;ACTIVE;2.21;2.70 +47925-3;Somatotropin^5M post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --5 minutes post dose arginine+insulin;GH 5M p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +47926-1;Somatotropin^5M post dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --5 minutes post dose ornithine;GH 5M p Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47927-9;Somatotropin^5th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --5th specimen post XXX challenge;GH sp5 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +4792-8;HLA-B71(70);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B71(70) [Presence] in Donor;HLA-B71(70) Donr Ql;;ACTIVE;1.0;2.56 +47928-7;Somatotropin^1H post dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose betaxolol+glucagon;GH 1h p betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47929-5;Somatotropin^6th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --6th specimen post XXX challenge;GH sp6 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47930-3;Somatotropin^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --7th specimen post XXX challenge;GH sp7 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47931-1;Somatotropin^8th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --8th specimen post XXX challenge;GH sp8 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47932-9;Somatotropin^9th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --9th specimen post XXX challenge;GH sp9 p chal SerPl-aCnc;;ACTIVE;2.21;2.70 +47933-7;Somatotropin^pre dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose arginine+insulin;GH pre dose Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +47934-5;Somatotropin^pre dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose betaxolol+glucagon;GH pre dose betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47935-2;Somatotropin^pre dose growth hormone releasing factor;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose growth hormone releasing factor;GH pre dose GRF SerPl-aCnc;;ACTIVE;2.21;2.73 +4793-6;HLA-B71(70);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B71(70) [Presence];HLA-B71(70) Ql;;ACTIVE;1.0;2.56 +47936-0;Somatotropin^pre dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose ornithine;GH pre Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +47937-8;Somatotropin^pre dose propranolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --pre dose propranolol+glucagon;GH pre dose propranolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +47938-6;Specimen source;Prid;Pt;Body fld;Nom;;SPEC;1;Specimen source [Identifier] of Body fluid;Specimen source Fld;;ACTIVE;2.21;2.73 +47939-4;Sulfocysteine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sulfocysteine [Moles/volume] in Serum or Plasma;Sulfocysteine SerPl-sCnc;;ACTIVE;2.21;2.70 +47940-2;Testosterone^12H post 5000 U HCG IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --12 hours post 5000 U HCG IM;Testost 12h p 5000 U HCG IM SerPl-mCnc;;ACTIVE;2.21;2.70 +47941-0;Testosterone^1H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin;Testost 1h p ACTH SerPl-mCnc;;ACTIVE;2.21;2.73 +47942-8;Testosterone^1D post 5000 U HCG IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --1 day post 5000 U HCG IM;Testost 1D p 5000 U HCG IM SerPl-mCnc;;ACTIVE;2.21;2.70 +47943-6;Testosterone^2D post 5000 U HCG IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --2 days post 5000 U HCG IM;Testost 2D p 5000 U HCG IM SerPl-mCnc;;ACTIVE;2.21;2.70 +4794-4;HLA-B72(70);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B72(70) [Presence] in Donor;HLA-B72(70) Donr Ql;;ACTIVE;1.0;2.56 +47944-4;Testosterone^4H post 5000 U HCG IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --4 hours post 5000 U HCG IM;Testost 4h p 5000 U HCG IM SerPl-mCnc;;ACTIVE;2.21;2.70 +47945-1;Testosterone^3D post 5000 U HCG IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --3 days post 5000 U HCG IM;Testost 3D p 5000 U HCG IM SerPl-mCnc;;ACTIVE;2.21;2.70 +47946-9;Testosterone^pre dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --pre dose corticotropin;Testost Pre ACTH SerPl-mCnc;;ACTIVE;2.21;2.73 +47947-7;Thyrotropin^1.5H post dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1.5 hours post dose luteinizing releasing hormone IV;TSH 1.5h p LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47948-5;Thyrotropin^15M post dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --15 minutes post dose luteinizing releasing hormone IV;TSH 15M p LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47949-3;Thyrotropin^15M pre dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --15 minutes pre dose luteinizing releasing hormone IV;TSH 15M pre dose LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47950-1;Thyrotropin^1H post dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1 hour post dose luteinizing releasing hormone IV;TSH 1h p LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +4795-1;HLA-B72(70);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B72(70) [Presence];HLA-B72(70) Ql;;ACTIVE;1.0;2.56 +47951-9;Thyrotropin^2H post dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --2 hours post dose luteinizing releasing hormone IV;TSH 2h p LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47952-7;Thyrotropin^30M post dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --30 minutes post dose luteinizing releasing hormone IV;TSH 30M p LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47953-5;Thyrotropin^pre dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --pre dose luteinizing releasing hormone IV;TSH pre dose LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +47954-3;Tiglylglycine;SCnc;Pt;Plas;Qn;;CHEM;1;Tiglylglycine [Moles/volume] in Plasma;Tiglylgly Plas-sCnc;;ACTIVE;2.21;2.70 +47955-0;EYA1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;EYA1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;EYA1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.67 +47956-8;CNR1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CNR1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CNR1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +47957-6;Deoxyuridine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deoxyuridine [Moles/volume] in Serum or Plasma;Deoxyuridine SerPl-sCnc;;ACTIVE;2.21;2.73 +47958-4;FLT3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FLT3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FLT3 gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +47959-2;GFAP gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GFAP gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GFAP gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +479-6;Talampicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Talampicillin [Susceptibility] by Minimum lethal concentration (MLC);Talampicillin Islt MLC;;ACTIVE;1.0;2.19 +47960-0;GLRA1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GLRA1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GLRA1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +47961-8;ACVRL1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACVRL1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ACVRL1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +47962-6;JAG1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;JAG1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;JAG1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +47963-4;JAK3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;JAK3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;JAK3 gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +47964-2;MVK gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MVK gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MVK gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +47965-9;Mycoplasma penetrans DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma penetrans DNA [Presence] in Specimen by NAA with probe detection;M penetrans DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +47966-7;NCF2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NCF2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NCF2 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +47967-5;NSD1 gene targeted mutation analysis;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;NSD1 gene targeted mutation analysis [Presence] in Blood or Tissue by Molecular genetics method;NSD1 gene Mut Anl Bld/T Ql;;ACTIVE;2.21;2.63 +47968-3;PINK1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PINK1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PINK1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +4796-9;HLA-B73;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B73 [Presence] in Donor;HLA-B73 Donr Ql;;ACTIVE;1.0;2.56 +47969-1;PTEN gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PTEN gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PTEN gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +47970-9;SGCB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SGCB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SGCB gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +47971-7;SGSH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SGSH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SGSH gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +47972-5;TGFBR1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TGFBR1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TGFBR1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +47973-3;TGFBR2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TGFBR2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TGFBR2 gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +47974-1;THRB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;THRB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;THRB gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +47975-8;tiZANidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;tiZANidine [Mass/volume] in Serum or Plasma;tiZANidine SerPl-mCnc;;ACTIVE;2.21;2.40 +47976-6;Selenium;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in 24 hour Urine;Selenium 24h Ur-mCnc;;ACTIVE;2.21;2.70 +4797-7;HLA-B73;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B73 [Presence];HLA-B73 Ql;;ACTIVE;1.0;2.56 +47977-4;Smooth muscle Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Smooth muscle IgG Ab [Titer] in Serum;Smooth muscle IgG Titr Ser;;ACTIVE;2.21;2.73 +47978-2;17-Ketosteroids;MCnc;Pt;Ser;Qn;;CHEM;1;17-Ketosteroids [Mass/volume] in Serum;17KS Ser-mCnc;;ACTIVE;2.21;2.70 +47979-0;Tranylcypromine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Tranylcypromine [Presence] in Serum or Plasma;Tranylcypromine SerPl Ql;;ACTIVE;2.21;2.56 +47980-8;Mirtazapine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Mirtazapine [Presence] in Serum or Plasma;Mirtazapine SerPl Ql;;ACTIVE;2.21;2.73 +47981-6;Phenylalanine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Phenylalanine/Creatinine [Ratio] in 24 hour Urine;Phe/Creat 24h Ur-Rto;;ACTIVE;2.21;2.70 +47982-4;Epstein Barr virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;EBV DNA # SerPl NAA+probe;;ACTIVE;2.21;2.73 +47983-2;Views 1 or 2;Find;Pt;Head>Mastoid.bilateral;Doc;XR;RAD;2;XR Mastoid - bilateral 1 or 2 Views;XR Mastoid-Bl 1V or 2V;;ACTIVE;2.21;2.61 +47984-0;Views;Find;Pt;Abdomen>Spine.lumbar & Pelvis;Doc;XR;RAD;2;XR Pelvis and Spine Lumbar Views;XR Pelvis+L-spine Views;;ACTIVE;2.21;2.73 +4798-5;HLA-B75(15);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B75(15) [Presence] in Donor;HLA-B75(15) Donr Ql;;ACTIVE;1.0;2.56 +47985-7;Multisection^W contrast IT;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Spine W contrast IT;CT Spine W contr IT;;DISCOURAGED;2.21;2.61 +47986-5;Views^W contrast IA;Find;Pt;Lower extremity.left>Lower extremity arteries;Doc;RF.angio;RAD;2;RFA Lower extremity arteries - left Views W contrast IA;RFA LE aa-L Views W contr IA;;ACTIVE;2.21;2.64 +47987-3;Views^W contrast IA;Find;Pt;Lower extremity.right>Lower extremity arteries;Doc;RF.angio;RAD;2;RFA Lower extremity arteries - right Views W contrast IA;RFA LE aa-R Views W contr IA;;ACTIVE;2.21;2.64 +47988-1;Progesterone^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;Progest sp6 p chal SerPl-sCnc;;ACTIVE;2.21;2.70 +47989-9;Progesterone^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;Progest sp7 p chal SerPl-sCnc;;ACTIVE;2.21;2.70 +47990-7;Progesterone^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;Progest sp8 p chal SerPl-sCnc;;ACTIVE;2.21;2.70 +47991-5;Progesterone^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;Progest sp9 p chal SerPl-sCnc;;ACTIVE;2.21;2.70 +4799-3;HLA-B75(15);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B75(15) [Presence];HLA-B75(15) Ql;;ACTIVE;1.0;2.56 +47994-9;Bilirubin;SCnc;Pt;BldCo;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Cord blood;Bilirub BldCo-sCnc;;ACTIVE;2.21;2.70 +47995-6;Glucose;SCnc;Pt;BldCo;Qn;;CHEM;1;Glucose [Moles/volume] in Cord blood;Glucose BldCo-sCnc;;ACTIVE;2.21;2.70 +47996-4;Adenosine deaminase binding protein;ACnc;Pt;Urine;Qn;;CHEM;1;Adenosine deaminase binding protein [Units/volume] in Urine;Adenosine deaminase BP Ur-aCnc;;ACTIVE;2.21;2.70 +47997-2;Genetic variant clinical significance;Imp;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Genetic variant clinical significance [Interpretation] in Blood or Tissue by Molecular genetics method;Genetic variant clin sig Bld/T-Imp;;ACTIVE;2.21;2.73 +47998-0;DNA sequence variation display name;Txt;Pt;Bld/Tiss;Nar;Molgen;HL7.GENETICS;1;DNA sequence variation display name [Text] Narrative;DNA seq var display name;;ACTIVE;2.21;2.56 +47999-8;DNA region name;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;DNA region name [Identifier];DNA region name;;ACTIVE;2.21;2.73 +48000-4;Chromosome;ID;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Chromosome [Identifier] in Blood or Tissue by Molecular genetics method;Chromosome Bld/T;;ACTIVE;2.21;2.73 +48001-2;Chromosome region;ID;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Cytogenetic (chromosome) location;Cyto loc ID;;ACTIVE;2.21;2.58 +48002-0;Genomic source class;Type;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genomic source class [Type];Genomic source class;;ACTIVE;2.21;2.73 +48003-8;DNA sequence variation identifier;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;DNA sequence variation identifier [Identifier];DNA seq var ID;;ACTIVE;2.21;2.73 +48004-6;DNA change;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;DNA change (c.HGVS);DNA change;;ACTIVE;2.21;2.73 +48005-3;Amino acid change;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Amino acid change (pHGVS);Amino acid change;;ACTIVE;2.21;2.73 +48006-1;Amino acid change type;Type;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Amino acid change [Type];Amino acid change type;;ACTIVE;2.21;2.58 +48007-9;Genetic variant allelic state;Type;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Genetic variant allelic state [Type] in Blood or Tissue by Molecular genetics method;Genetic variant allelic state Bld/T;;ACTIVE;2.21;2.26 +48008-7;Allele name;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Allele name [Identifier];Allele name;;ACTIVE;2.21;2.56 +4800-9;HLA-B76(15);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B76(15) [Presence] in Donor;HLA-B76(15) Donr Ql;;ACTIVE;1.0;2.56 +48009-5;Genechip manufacturer ID;ID;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Genechip manufacturer ID [Identifier] in Blood or Tissue by Molecular genetics method;Genechip Manufacturer ID Bld/T;;ACTIVE;2.21;2.26 +48010-3;Genechip ID;ID;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Genechip ID [Identifier] in Blood or Tissue by Molecular genetics method;Genechip ID Bld/T;;ACTIVE;2.21;2.26 +48011-1;Genechip version;ID;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Genechip version [Identifier] in Blood or Tissue by Molecular genetics method;Genechip Version Bld/T;;ACTIVE;2.21;2.26 +48012-9;Reference sequence;Seq;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Reference sequence [Nucleotide sequence] in Blood or Tissue by Molecular genetics method Nominal;Ref Sequence Seq Bld/T;;ACTIVE;2.21;2.56 +48013-7;Genomic reference sequence identifier;ID;Pt;Bld/Tiss;Nom;;HL7.GENETICS;1;Genomic reference sequence [ID];Genomic reference sequence ID;;ACTIVE;2.21;2.58 +48014-5;Sequence variation panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;Sequence variation panel - Blood or Tissue by Molecular genetics method;Sequence Variation Panel Bld/T;;ACTIVE;2.21;2.61 +48015-2;Individual allele panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;Individual allele panel;Individual Allele Pnl;;ACTIVE;2.21;2.61 +48016-0;Genechip kit panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;Genechip kit panel - Blood or Tissue by Molecular genetics method;Genechip Kit Pnl Bld/T;;ACTIVE;2.21;2.61 +4801-7;HLA-B76(15);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B76(15) [Presence];HLA-B76(15) Ql;;ACTIVE;1.0;2.56 +48017-8;Sequencing methodology panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;Sequencing methodology panel - Blood or Tissue by Molecular genetics method;Sequencing Method Pnl Bld/T;;ACTIVE;2.21;2.73 +48018-6;Gene identifier;ID;Pt;Bld/Tiss;Nom;;HL7.GENETICS;1;Gene studied [ID];Gene studied ID;;ACTIVE;2.21;2.73 +48019-4;DNA change type;Type;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;DNA change type;DNA Change Type;;ACTIVE;2.21;2.64 +48020-2;Forward primer;Seq;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Forward primer [Nucleotide sequence] in Blood or Tissue by Molecular genetics method Nominal;Forward Primer Seq Bld/T;;ACTIVE;2.21;2.26 +48021-0;Reverse primer;Seq;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Reverse primer [Nucleotide sequence] in Blood or Tissue by Molecular genetics method Nominal;Reverse Primer Seq Bld/T;;ACTIVE;2.21;2.42 +48022-8;Coagulation surface induced.lupus sensitive actual/Normal;RelTime;Pt;PPP;Qn;;COAG;1;aPTT.lupus sensitive actual/normal (normalized LA screen);Screen aPTT/normal;;ACTIVE;2.21;2.73 +48023-6;HIV 1 proviral DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection;HIV 1 pro DNA SerPl Ql NAA+probe;;ACTIVE;2.21;2.73 +48024-4;AS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;AS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;AS gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +4802-5;HLA-B77(15);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B77(15) [Presence] in Donor;HLA-B77(15) Donr Ql;;ACTIVE;1.0;2.56 +48025-1;Gene mutations tested for;Num;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;Gene mutations tested for [#] in Blood or Tissue by Molecular genetics method;Gene Mut Tested Bld/T;;ACTIVE;2.21;2.69 +48026-9;ITGA2B gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ITGA2B gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ITGA2B gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48027-7;MT-ND4 gene.c.G15257A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND4 gene c.G15257A [Presence] in Blood or Tissue by Molecular genetics method;MT-ND4 c.G15257A Bld/T Ql;;ACTIVE;2.21;2.56 +48028-5;SERPINE1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SERPINE1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SERPINE1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +48029-3;PKLR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PKLR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PKLR gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48030-1;RHCE gene allele Ee;Geno;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;RHCE gene allele Ee [Genotype] in Amniotic fluid by Molecular genetics method Nominal;RHCE allele Ee Geno Amn;;ACTIVE;2.21;2.68 +48031-9;SCA10 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA10 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA10 gene CAG Rpt Bld/T Ql;;ACTIVE;2.21;2.56 +48032-7;THRB gene.p.Ala317Thr;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;THRB gene p.Ala317Thr [Presence] in Blood or Tissue by Molecular genetics method;THRB p.A317T Bld/T Ql;;ACTIVE;2.21;2.56 +4803-3;HLA-B77(15);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B77(15) [Presence];HLA-B77(15) Ql;;ACTIVE;1.0;2.56 +48033-5;TTR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TTR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TTR gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +48034-3;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;CSF;Qn;;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Cerebral spinal fluid;WBC nRBC cor # CSF;;ACTIVE;2.21;2.40 +48035-0;Hemoglobin;PrThr;Pt;CSF;Ord;;HEM/BC;1;Hemoglobin [Presence] in Cerebral spinal fluid;Hgb CSF Ql;;ACTIVE;2.21;2.73 +48036-8;Glucose;MCnc;Pt;Stool;Qn;;CHEM;1;Glucose [Mass/volume] in Stool;Glucose Stl-mCnc;;ACTIVE;2.21;2.34 +48037-6;pH;LsCnc;Pt;Vag;Qn;;FERT;1;pH of Vaginal fluid;pH Vag;;ACTIVE;2.21;2.73 +48038-4;Pathologist interpretation;Imp;Pt;Synv fld;Nom;;PATH;1;Pathologist interpretation of Synovial fluid tests;Path Interp Snv-Imp;;ACTIVE;2.21;2.73 +48039-2;Fibronectin.fetal;PrThr;Pt;XXX;Ord;;CHEM;1;Fibronectin.fetal [Presence] in Specimen;Fibronectin Fetal Spec Ql;;ACTIVE;2.21;2.73 +480-4;Talampicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Talampicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Talampicillin Islt MIC;;ACTIVE;1.0;2.19 +48040-0;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Synovial fluid by Manual count;nRBC/100 WBC Snv Manual-Rto;;ACTIVE;2.21;2.40 +4804-1;HLA-B12;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B12 [Presence] in Donor;HLA-B12 Donr Ql;;ACTIVE;1.0;2.56 +48041-8;Anthraquinone cutoff;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Anthraquinone cutoff [Mass/mass] in Stool;Anthraquinone CtO Stl-mCnt;;ACTIVE;2.21;2.40 +48042-6;Bisacodyl cutoff;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Bisacodyl cutoff [Mass/mass] in Stool;Bisacodyl CtO Stl-mCnt;;ACTIVE;2.21;2.40 +48043-4;Oxyphenisatin cutoff;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Oxyphenisatin cutoff [Mass/mass] in Stool;Oxyphenisatin CtO Stl-mCnt;;ACTIVE;2.21;2.40 +48044-2;Phenolphthalein cutoff;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Phenolphthalein cutoff [Mass/mass] in Stool;Phenolphthalein CtO Stl-mCnt;;ACTIVE;2.21;2.40 +48045-9;Magnesium cutoff;MCnt;Pt;Stool;Qn;;CHEM;1;Magnesium cutoff [Mass/mass] in Stool;Magnesium CtO Stl-mCnt;;ACTIVE;2.21;2.40 +48046-7;Phosphate cutoff;MCnt;Pt;Stool;Qn;;CHEM;1;Phosphate cutoff [Mass/mass] in Stool;Phosphate CtO Stl-mCnt;;ACTIVE;2.21;2.40 +48047-5;Hemoglobin.gastrointestinal;PrThr;Pt;Vomitus;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Vomitus;Hemoccult Vom Ql;;ACTIVE;2.21;2.73 +48048-3;Neutrophils;PrThr;Pt;Nose;Ord;Wright stain;HEM/BC;1;Neutrophils [Presence] in Nose by Wright stain;Neutrophils Nose Ql Wright Stn;;ACTIVE;2.21;2.73 +48049-1;Eosinophils;PrThr;Pt;Stool;Ord;Wright stain;HEM/BC;1;Eosinophils [Presence] in Stool by Wright stain;Eosinophil Stl Ql Wright Stn;;ACTIVE;2.21;2.73 +48050-9;Neutrophils;PrThr;Pt;Stool;Ord;Wright stain;HEM/BC;1;Neutrophils [Presence] in Stool by Wright stain;Neutrophils Stl Ql Wright Stn;;ACTIVE;2.21;2.73 +48051-7;Erythrocytes;PrThr;Pt;Vag;Ord;;HEM/BC;1;Erythrocytes [Presence] in Vaginal fluid;RBC Vag Ql;;ACTIVE;2.21;2.73 +48052-5;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Body fluid;WBC nRBC cor # Fld;;ACTIVE;2.21;2.44 +48053-3;Turbidity;PrThr;Pt;Synv fld;Ord;;SPEC;1;Turbidity [Presence] of Synovial fluid Qualitative;Turbidity Snv Ql;;ACTIVE;2.21;2.73 +48054-1;Coagulation kaolin induced;ACnc;Pt;Bld;Qn;;COAG;1;Kaolin activated time [Units/volume] in Blood;KCT Bld-aCnc;;ACTIVE;2.21;2.73 +48055-8;Pneumocystis jiroveci;PrThr;Pt;XXX;Ord;Calcofluor white preparation;MICRO;1;Pneumocystis jiroveci [Presence] in Specimen by Calcofluor white;P jiroveci Spec Ql Calcofluor white;;ACTIVE;2.21;2.69 +48056-6;Human bocavirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Human bocavirus Ag [Presence] in Specimen by Immunofluorescence;HBoV Ag Spec Ql IF;;ACTIVE;2.21;2.69 +48057-4;Human bocavirus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Human bocavirus IgG Ab [Presence] in Specimen by Immunoassay;HBoV IgG Spec Ql IA;;ACTIVE;2.21;2.69 +4805-8;HLA-B12;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B12 [Presence];HLA-B12 Ql;;ACTIVE;1.0;2.56 +48058-2;Fibrin D-dimer DDU;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrin D-dimer DDU [Mass/volume] in Platelet poor plasma by Immunoassay;D dimer DDU PPP IA-mCnc;;ACTIVE;2.21;2.73 +48059-0;Giardia lamblia+Cryptosporidium sp Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool by Immunoassay;G lamblia+Cryptosp Ag Stl Ql IA;;ACTIVE;2.21;2.73 +48060-8;Giardia lamblia+Cryptosporidium sp Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool;G lamblia+Cryptosp Ag Stl Ql;;ACTIVE;2.21;2.73 +48061-6;Giardia lamblia+Cryptosporidium sp Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool by Immunofluorescence;G lamblia+Cryptosp Ag Stl Ql IF;;ACTIVE;2.21;2.73 +48062-4;Giardia lamblia+Cryptosporidium parvum Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool by Immunofluorescence;G lamblia+C parvum Ag Stl Ql IF;;ACTIVE;2.21;2.73 +48063-2;Giardia lamblia+Cryptosporidium parvum Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool by Immunoassay;G lamblia+C parvum Ag Stl Ql IA;;ACTIVE;2.21;2.73 +48064-0;Giardia lamblia+Cryptosporidium parvum Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool;G lamblia+C parvum Ag Stl Ql;;ACTIVE;2.21;2.73 +48065-7;Fibrin D-dimer FEU;MCnc;Pt;PPP;Qn;;COAG;1;Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma;D dimer FEU PPP-mCnc;;ACTIVE;2.21;2.73 +4806-6;HLA-B13;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B13 [Presence] in Donor;HLA-B13 Donr Ql;;ACTIVE;1.0;2.56 +48066-5;Fibrin D-dimer DDU;MCnc;Pt;PPP;Qn;;COAG;1;Fibrin D-dimer DDU [Mass/volume] in Platelet poor plasma;D dimer DDU PPP-mCnc;;ACTIVE;2.21;2.73 +48067-3;Fibrin D-dimer FEU;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma by Immunoassay;D dimer FEU PPP IA-mCnc;;ACTIVE;2.21;2.73 +48068-1;Heinz bodies;PrThr;Pt;Bld;Ord;;HEM/BC;1;Heinz bodies [Presence] in Blood;Heinz Bod Bld Ql;;ACTIVE;2.21;2.73 +48069-9;Spherocytes.micro;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Spherocytes.micro [Presence] in Blood by Light microscopy;Spherocytes.micro Bld Ql Smear;;ACTIVE;2.21;2.73 +48070-7;Hepatitis B virus surface Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis B virus surface IgG Ab [Presence] in Serum by Immunoassay;HBV surface IgG Ser Ql IA;;ACTIVE;2.21;2.56 +48071-5;Complement total hemolytic CH50;Titr;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement total hemolytic CH50 [Titer] in Serum or Plasma;CH50 Titr SerPl;;ACTIVE;2.21;2.32 +48072-3;Synthetic glucocorticoid drug;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Synthetic glucocorticoid drug [Mass/volume] in Unknown substance;Synthetic Glucocorticoid Usub-mCnc;;ACTIVE;2.21;2.34 +48073-1;Thyroxine binding globulin panel;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;PANEL.CHEM;1;Thyroxine binding globulin panel [Mass/volume] - Serum or Plasma by Electrophoresis;T4BG Pnl SerPl Elph-mCnc;;ACTIVE;2.21;2.42 +4807-4;HLA-B13;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B13 [Presence];HLA-B13 Ql;;ACTIVE;1.0;2.56 +48074-9;Somatotropin^2.5H post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post dose arginine+insulin;GH 2.5h p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +48075-6;Somatotropin^2.5H post dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post dose betaxolol+glucagon;GH 2.5h p betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +48076-4;Somatotropin^2.5H post dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post dose glucagon;GH 2.5h p Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +48077-2;Thyrotropin^2.5H post dose luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --2.5 hours post dose luteinizing releasing hormone IV;TSH 2.5h p LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +48078-0;3,6-Epoxydecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,6-Epoxydecanedioate/Creatinine [Molar ratio] in Urine;3,6-epoxydecanedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48079-8;3,6-Epoxydodecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,6-Epoxydodecanedioate/Creatinine [Molar ratio] in Urine;3,6-epoxydodecanedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48080-6;3,6-Epoxyoctanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,6-Epoxyoctanedioate/Creatinine [Molar ratio] in Urine;3,6-epoxyoctanedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48081-4;3,6-Epoxytetradecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,6-Epoxytetradecanedioate/Creatinine [Molar ratio] in Urine;3,6-epoxytetradecanedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +4808-2;HLA-B14;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B14 [Presence] in Donor;HLA-B14 Donr Ql;;ACTIVE;1.0;2.56 +48082-2;3-Hydroxyadipate 3,6-lactone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyadipate 3,6-lactone/Creatinine [Molar ratio] in Urine;3OH-adipate 3,6-lactone/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48083-0;3-Hydroxydodecanedienedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydodecanedienedioate/Creatinine [Molar ratio] in Urine;3OH-dodecanedienedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48084-8;3-Hydroxydodecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydodecanedioate (3-OH-D-C12)/Creatinine [Molar ratio] in Urine;3OH-dodecanedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48085-5;3-Hydroxydodecenedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydodecenedioate/Creatinine [Molar ratio] in Urine;3OH-dodecenedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48086-3;3-Hydroxytetradecadienedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxytetradecadienedioate/Creatinine [Molar ratio] in Urine;3OH-Tdecadienedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48087-1;3-Hydroxytetradecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxytetradecanedioate/Creatinine [Molar ratio] in Urine;3OH-Tdecanedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48088-9;3-Hydroxytetradecenedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxytetradecenedioate/Creatinine [Molar ratio] in Urine;3OH-Tdecenedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48089-7;Cholesterol/Apolipoprotein B;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol/Apolipoprotein B [Molar ratio] in Serum or Plasma;Cholest/Apo B SerPl-sRto;;ACTIVE;2.21;2.42 +4809-0;HLA-B14;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B14 [Presence];HLA-B14 Ql;;ACTIVE;1.0;2.73 +48090-5;Cholesterol.in HDL/Cholesterol.in HDL+Cholesterol.in VLDL;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL/Cholesterol in HDL+VLDL [Molar ratio] in Serum or Plasma;HDLc/HDLc+VLDLc SerPl-sRto;;ACTIVE;2.21;2.42 +48091-3;Corticotropin^12 AM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --12 AM specimen;ACTH 12 AM Plas-mCnc;;ACTIVE;2.21;2.70 +48092-1;Corticotropin^12 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --12 PM specimen;ACTH 12 PM Plas-mCnc;;ACTIVE;2.21;2.70 +48093-9;Corticotropin^15M pre 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --15 minutes pre 1 ug/kg CRH IV;ACTH 15M pre 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.21;2.70 +48094-7;Corticotropin^4 AM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --4 AM specimen;ACTH 4 AM specimen Plas-mCnc;;ACTIVE;2.21;2.70 +48095-4;Corticotropin^4 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --4 PM specimen;ACTH 4 PM Plas-mCnc;;ACTIVE;2.21;2.70 +48096-2;Corticotropin^8 AM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --8 AM specimen;ACTH 8 AM Plas-mCnc;;ACTIVE;2.21;2.70 +48097-0;Corticotropin^8 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --8 PM specimen;ACTH 8 PM Plas-mCnc;;ACTIVE;2.21;2.70 +48098-8;Cortisol^12 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --12 AM specimen;Cortis 12 AM SerPl-mCnc;;ACTIVE;2.21;2.70 +48099-6;Cortisol^12 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --12 PM specimen;Cortis 12 PM SerPl-mCnc;;ACTIVE;2.21;2.70 +48100-2;Cortisol^15M pre 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --15 minutes pre 1 ug/kg CRH IV;Cortis 15M pre 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.21;2.70 +48101-0;Cortisol^15M pre 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --15 minutes pre 1 ug/kg CRH IV;Cortis 15M pre 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.21;2.70 +48102-8;Cortisol^4 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --4 AM specimen;Cortis 4 AM specimen SerPl-mCnc;;ACTIVE;2.21;2.70 +48103-6;Cortisol^4 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --4 AM specimen;Cortis 4 AM specimen SerPl-sCnc;;ACTIVE;2.21;2.70 +48104-4;Cortisol^8 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 AM specimen;Cortis 8 AM SerPl-mCnc;;ACTIVE;2.21;2.73 +48105-1;Cortisol^8 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8 PM specimen;Cortis 8 PM SerPl-mCnc;;ACTIVE;2.21;2.70 +48106-9;4,5-Dihydroxyhexanolactone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4,5-Dihydroxyhexanolactone/Creatinine [Molar ratio] in Urine;4,5-DiOH-hexanolactone/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48107-7;Erythritol/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Erythritol/Creatinine [Molar ratio] in Urine;Erythritol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +4810-8;HLA-B15;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B15 [Presence] in Donor;HLA-B15 Donr Ql;;ACTIVE;1.0;2.56 +48108-5;Follitropin^15M pre 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --15 minutes pre 100 ug luteinizing releasing hormone IV;FSH 15M pre 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +48109-3;Glucose^15M pre dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose glucose;Glucose 15M pre glc SerPl-sCnc;;ACTIVE;2.21;2.70 +48110-1;Glutathione.oxidized/glutathione.reduced;SRto;Pt;RBC;Qn;;CHEM;1;Glutathione.oxidized/Glutathione.reduced [Molar ratio] in Red Blood Cells;GSS/GSH RBC-sRto;;ACTIVE;2.21;2.42 +48111-9;Glutathione.reduced;SCnt;Pt;RBC;Qn;;CHEM;1;Glutathione.reduced [Moles/mass] in Red Blood Cells;GSH RBC-sCnt;;ACTIVE;2.21;2.70 +48112-7;Glutathione.reduced;ACnt;Pt;RBC;Qn;;CHEM;1;Glutathione.reduced [Units/mass] in Red Blood Cells;GSH RBC-aCnt;;ACTIVE;2.21;2.70 +48113-5;Heptadecenoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Heptadecenoate/Creatinine [Molar ratio] in Urine;Heptadecenoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48114-3;Hexadecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexadecanedioate/Creatinine [Molar ratio] in Urine;Hexadecanedioate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48115-0;Homocysteine.free/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homocysteine.free/Creatinine [Molar ratio] in Urine;Hcys.free/Creat Ur-sRto;;ACTIVE;2.21;2.70 +4811-6;HLA-B15;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B15 [Presence];HLA-B15 Ql;;ACTIVE;1.0;2.56 +48116-8;Insulin^10M pre dose glucose;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --10 minutes pre dose glucose;Insulin 10M pre Glc SerPl-aCnc;;ACTIVE;2.21;2.70 +48117-6;Isovalerylglycine/Urea;SRto;Pt;Plas;Qn;;CHEM;1;Isovalerylglycine/Urea [Molar ratio] in Plasma;Isovalerylgly/Urea Plas-sRto;;ACTIVE;2.21;2.70 +48118-4;Lutropin^15M pre 100 ug luteinizing releasing hormone IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --15 minutes pre 100 ug luteinizing releasing hormone IV;LH 15M pre 100 ug LRH IV SerPl-aCnc;;ACTIVE;2.21;2.70 +48119-2;Pentadecanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pentadecanoate/Creatinine [Molar ratio] in Urine;Pentadecanoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +481-2;Talampicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Talampicillin [Susceptibility] by Disk diffusion (KB);Talampicillin Islt KB;;ACTIVE;1.0;2.19 +48120-0;Prolactin^15M pre dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --15 minutes pre dose TRH IV;Prolactin 15M pre TRH IV SerPl-mCnc;;ACTIVE;2.21;2.70 +48121-8;Quinolinate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Quinolinate/Creatinine [Molar ratio] in Urine;Quinolinate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48122-6;Somatotropin^15M post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post dose TRH;GH 15m p TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +48123-4;Somatotropin^15M pre dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose arginine+insulin;GH 15M pre Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +4812-4;HLA-B16;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B16 [Presence] in Donor;HLA-B16 Donr Ql;;ACTIVE;1.0;2.56 +48124-2;Somatotropin^15M pre dose glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose glucagon;GH 15M pre Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +48125-9;Somatotropin^15M pre dose insulin IV;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose insulin IV;GH 15M pre Ins IV SerPl-aCnc;;ACTIVE;2.21;2.70 +48126-7;Somatotropin^15M pre dose ornithine;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose ornithine;GH 15M pre Orn SerPl-aCnc;;ACTIVE;2.21;2.70 +48127-5;Somatotropin^15M pre dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre dose TRH;GH 15M pre TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +48128-3;Somatotropin^1H post dose arginine+insulin;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose arginine+insulin;GH 1h p Arg+Ins SerPl-aCnc;;ACTIVE;2.21;2.70 +48129-1;Somatotropin^30M pre dose betaxolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes pre dose betaxolol+glucagon;GH 30M Pre betaxolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +48130-9;Somatotropin^30M pre dose propranolol+glucagon;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes pre dose propranolol+glucagon;GH 30M pre propranolol+Gc SerPl-aCnc;;ACTIVE;2.21;2.70 +48131-7;Somatotropin^30M pre dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes pre dose TRH;GH 30M pre TRH SerPl-aCnc;;ACTIVE;2.21;2.70 +4813-2;HLA-B16;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B16 [Presence];HLA-B16 Ql;;ACTIVE;1.0;2.56 +48132-5;Xylitol/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Xylitol/Creatinine [Molar ratio] in Urine;Xylitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48133-3;3-Oxovalerate;SCnc;Pt;Plas;Qn;;CHEM;1;3-Oxovalerate [Moles/volume] in Plasma;3-Oxovalerate Plas-sCnc;;ACTIVE;2.21;2.70 +48134-1;Alanine aminotransferase.macromolecular;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alanine aminotransferase.macromolecular [Enzymatic activity/volume] in Serum or Plasma;ALT Macro SerPl-cCnc;;ACTIVE;2.21;2.73 +48135-8;Acadesine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Acadesine [Presence] in Urine;Acadesine Ur Ql;;ACTIVE;2.21;2.56 +48136-6;Aspartate aminotransferase.macromolecular;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aspartate aminotransferase.macromolecular [Enzymatic activity/volume] in Serum or Plasma;AST Macro SerPl-cCnc;;ACTIVE;2.21;2.73 +48137-4;4,5-Dihydroxyhexanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4,5-Dihydroxyhexanoate/Creatinine [Molar ratio] in Urine;4,5-DiOH-hexanoate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48138-2;Enolase.neuron specific;MCnc;Pt;Ser/Plas;Qn;RIA;CHEM;1;Enolase.neuron specific [Mass/volume] in Serum or Plasma by Radioimmunoassay (RIA);NSE SerPl RIA-mCnc;;ACTIVE;2.21;2.70 +48139-0;Erythro-4,5-Dihydroxyhexanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Erythro-4,5-Dihydroxyhexanoate/Creatinine [Molar ratio] in Urine;Erythro-4,5-DHA/Creat Ur-sRto;;ACTIVE;2.21;2.70 +4814-0;HLA-B17;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B17 [Presence] in Donor;HLA-B17 Donr Ql;;ACTIVE;1.0;2.56 +48140-8;Erythro-4-Deoxytetronate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Erythro-4-Deoxytetronate/Creatinine [Molar ratio] in Urine;Erythro-4-deoxytetronate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48141-6;Ferritin;EntMass;Pt;RBC;Qn;;CHEM;1;Ferritin [Entitic mass] in Red Blood Cells;Ferritin RBC Qn;;ACTIVE;2.21;2.70 +48142-4;Indole-3-Acetate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Indole-3-Acetate/Creatinine [Molar ratio] in Urine;Indole-3-acetate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48143-2;LDL.oxidized Ab;ACnc;Pt;Ser;Qn;;SERO;1;LDL.oxidized Ab [Units/volume] in Serum;LDL.oxidized Ab Ser-aCnc;;ACTIVE;2.21;2.73 +48144-0;Mannose;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mannose [Presence] in Urine;Mannose Ur Ql;;ACTIVE;2.21;2.56 +48145-7;Mevalonolactone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Mevalonolactone/Creatinine [Molar ratio] in Urine;Mevalonolactone/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48146-5;Myeloperoxidase;ACnc;Pt;Ser;Qn;;CHEM;1;Myeloperoxidase [Units/volume] in Serum;Myeloperoxidase Ser-aCnc;;ACTIVE;2.21;2.70 +48147-3;Oligosaccharides/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Oligosaccharides/Creatinine [Molar ratio] in Urine;Oligosaccharide/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48148-1;Osmolality;Osmol;Pt;Urine;Qn;Calculated;CHEM;1;Osmolality of Urine by calculation;Osmolality Ur Calc;;ACTIVE;2.21;2.73 +48149-9;Osmolality.urine/Osmolality.ser;Ratio;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Osmolality.urine/Osmolality.serum;Osmolality Ur/SerPl-Rto;;ACTIVE;2.21;2.44 +48150-7;Perseitol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Perseitol/Creatinine [Molar ratio] in Urine;Perseitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48151-5;Sedoheptitol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sedoheptitol/Creatinine [Molar ratio] in Urine;Sedoheptitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48152-3;Sorbitol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sorbitol/Creatinine [Molar ratio] in Urine;Sorbitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48153-1;Threitol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Threitol/Creatinine [Molar ratio] in Urine;Threitol/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48154-9;Threo-4,5-Dihydrohexanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Threo-4,5-Dihydrohexanoate/Creatinine [Molar ratio] in Urine;Threo-4,5-DHA/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48155-6;Threo-4,5-Dihydrohexanolactone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Threo-4,5-Dihydrohexanolactone/Creatinine [Molar ratio] in Urine;Threo-4,5-DHL/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48156-4;Threo-4-Deoxytetronate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Threo-4-Deoxytetronate/Creatinine [Molar ratio] in Urine;Threo-4-deoxytetronate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +4815-7;HLA-B17;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B17 [Presence];HLA-B17 Ql;;ACTIVE;1.0;2.56 +48157-2;Thymine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Thymine/Creatinine [Molar ratio] in Urine;Thymine/Creat Ur-sRto;;ACTIVE;2.21;2.73 +48158-0;Vanillate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Vanillate/Creatinine [Molar ratio] in Urine;Vanillate/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48159-8;Hepatitis C virus Ab Signal/Cutoff;RelACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay;HCV Ab s/co SerPl IA;;ACTIVE;2.21;2.73 +48160-6;HTLV I rgp21 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I rgp21 Ab [Presence] in Serum by Immunoblot;HTLV I rgp21 Ab Ser Ql IB;;ACTIVE;2.21;2.73 +48161-4;PROS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PROS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PROS1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +48162-2;Thymidine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thymidine [Moles/volume] in Serum or Plasma;Thymidine SerPl-sCnc;;ACTIVE;2.21;2.73 +48163-0;Cytokeratin 19;MCnc;Pt;Body fld;Qn;;CHEM;1;Cytokeratin 19 [Mass/volume] in Body fluid;CK 19 Fld-mCnc;;ACTIVE;2.21;2.34 +48164-8;Enolase.neuron specific;MCnc;Pt;Body fld;Qn;;CHEM;1;Enolase.neuron specific [Mass/volume] in Body fluid;NSE Fld-mCnc;;ACTIVE;2.21;2.42 +4816-5;HLA-B18;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B18 [Presence] in Donor;HLA-B18 Donr Ql;;ACTIVE;1.0;2.56 +48165-5;Squamous cell carcinoma Ag;MCnc;Pt;Body fld;Qn;;CHEM;1;Squamous cell carcinoma Ag [Mass/volume] in Body fluid;SCC Ag Fld-mCnc;;ACTIVE;2.21;2.70 +48166-3;Beta-2-Microglobulin;MCnc;Pt;Body fld;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Body fluid;B2 Microglob Fld-mCnc;;ACTIVE;2.21;2.34 +48167-1;Prostate specific Ag/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Prostate specific Ag/Creatinine [Mass Ratio] in Urine;PSA/Creat Ur;;ACTIVE;2.21;2.42 +48168-9;5-Hydroxyindoleacetate;PrThr;Pt;Urine;Ord;;CHEM;1;5-Hydroxyindoleacetate [Presence] in Urine;5OH-indoleacetate Ur Ql;;ACTIVE;2.21;2.73 +48169-7;Amikacin 1.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 1.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 1.5 ug/mL Islt SlowMyco;;ACTIVE;2.21;2.40 +48170-5;Capreomycin 3.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Capreomycin 3 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Capreomycin 3 ug/mL Islt SlowMyco;;ACTIVE;2.21;2.26 +48171-3;Isoniazid 0.1 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Isoniazid 0.1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Isoniazid 0.1 ug/mL Islt Slow;;DEPRECATED;2.21;2.36 +48172-1;Isoniazid 0.4 ug/mL;Susc;Pt;Isolate;OrdQn;Slow-growing Mycobacteria;ABXBACT;1;Deprecated Isoniazid 0.4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Deprecated Isoniazid 0.4 ug/mL Islt Slow;;DEPRECATED;2.21;2.36 +4817-3;HLA-B18;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B18 [Presence];HLA-B18 Ql;;ACTIVE;1.0;2.56 +48173-9;levoFLOXacin 1.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;levoFLOXacin 1.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;levoFLOXacin 1.5 ug/mL Islt SlowMyco;;ACTIVE;2.21;2.26 +48174-7;Mycobacterium tuberculosis complex rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis complex rRNA [Presence] in Specimen by NAA with probe detection;M TB Cmplx rRNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +48175-4;Mycobacterium tuberculosis katG+inhA genes isoniazid resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis katG + inhA gene isoniazid resistance mutation [Presence] by Molecular method;MTB katG+inhA INH h res mut Islt/Spm Ql;;ACTIVE;2.21;2.65 +48176-2;Mycobacterium tuberculosis rifAMPin resistance (rpoB) gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;ABXBACT;1;Deprecated Mycobacterium tuberculosis rifAMPin resistance (rpoB) gene [Presence] in Unspecified specimen by NAA with probe detection;Deprecated M TB rpoB XXX Ql NAA+probe;;DEPRECATED;2.21;2.64 +48177-0;Streptomycin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Streptomycin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Streptomycin 1 ug/mL Islt SlowMyco;;ACTIVE;2.21;2.73 +48178-8;Reference change value 0.99;Num;XXX;^Population;Qn;;NR STATS;1;Reference change value 0.99 [#] in unspecified time Population;RCV 0.99 ?Tm Pop;;ACTIVE;2.21;2.27 +48179-6;Reference change value 0.99;NFr;XXX;^Population;Qn;;NR STATS;1;Reference change value 0.99 in unspecified time Population;RCV 0.99 ?Tm NFr Pop;;ACTIVE;2.21;2.40 +48180-4;Reference change value 0.95;NFr;XXX;^Population;Qn;;NR STATS;1;Reference change value 0.95 in unspecified time Population;RCV 0.95 ?Tm NFr Pop;;ACTIVE;2.21;2.40 +4818-1;HLA-B21;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B21 [Presence] in Donor;HLA-B21 Donr Ql;;ACTIVE;1.0;2.56 +48181-2;Reference change value 0.95;Num;XXX;^Population;Qn;;NR STATS;1;Reference change value 0.95 [#] in unspecified time Population;RCV 0.95 ?Tm Pop;;ACTIVE;2.21;2.69 +48182-0;Vespa crabro leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;European Hornet triggered leukotriene release [Mass/volume] by Leukocytes;European Hornet LR-mCnc;;ACTIVE;2.21;2.70 +48183-8;Polistes spp leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Paper wasp triggered leukotriene release [Mass/volume] by Leukocytes;Paper Wasp LR-mCnc;;ACTIVE;2.21;2.70 +48184-6;Vespula spp leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Yellow Jacket triggered leukotriene release [Mass/volume] by Leukocytes;Yellow Jacket LR-mCnc;;ACTIVE;2.21;2.70 +48185-3;Apis mellifera leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Honey bee triggered leukotriene release [Mass/volume] by Leukocytes;Honey bee LR-mCnc;;ACTIVE;2.21;2.70 +48186-1;Amylase leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Amylase triggered leukotriene release [Mass/volume] by Leukocytes;Amylase LR-mCnc;;ACTIVE;2.21;2.70 +48187-9;Chloramin T leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Chloramin T triggered leukotriene release [Mass/volume] by Leukocytes;Chloramin T LR-mCnc;;ACTIVE;2.21;2.70 +48188-7;Latex leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Latex triggered leukotriene release [Mass/volume] by Leukocytes;Ltx LR-mCnc;;ACTIVE;2.21;2.70 +48189-5;Formaldehyde leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Formaldehyde triggered leukotriene release [Mass/volume] by Leukocytes;Formaldehyde LR-mCnc;;ACTIVE;2.21;2.70 +48190-3;Phthalic anhydride leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Phthalic anhydride triggered leukotriene release [Mass/volume] by Leukocytes;PAN LR-mCnc;;ACTIVE;2.21;2.70 +48191-1;Monosodium glutamate leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Monosodium glutamate (MSG) triggered leukotriene release [Mass/volume] by Leukocytes;MSG LR-mCnc;;ACTIVE;2.21;2.73 +48192-9;Sunset yellow FCF leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Sunset yellow FCF triggered leukotriene release [Mass/volume] by Leukocytes;Sunset yellow FCF LR-mCnc;;ACTIVE;2.21;2.70 +48193-7;Succinylcholine leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Succinylcholine triggered leukotriene release [Mass/volume] by Leukocytes;Succinylcholine LR-mCnc;;ACTIVE;2.21;2.70 +48194-5;Lidocaine leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Lidocaine triggered leukotriene release [Mass/volume] by Leukocytes;Lidocain LR-mCnc;;ACTIVE;2.21;2.70 +48195-2;Trimethoprim leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Trimethoprim triggered leukotriene release [Mass/volume] by Leukocytes;Trimethoprim LR-mCnc;;ACTIVE;2.21;2.70 +48196-0;Cephalosporin C leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cephalosporin C triggered leukotriene release [Mass/volume] by Leukocytes;Cephalosporin C LR-mCnc;;ACTIVE;2.21;2.73 +48197-8;Cefuroxime leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cefuroxime triggered leukotriene release [Mass/volume] by Leukocytes;Cefuroxime LR-mCnc;;ACTIVE;2.21;2.70 +48198-6;Amoxicillin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Amoxicillin triggered leukotriene release [Mass/volume] by Leukocytes;Amoxicillin LR-mCnc;;ACTIVE;2.21;2.70 +4819-9;HLA-B21;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B21 [Presence];HLA-B21 Ql;;ACTIVE;1.0;2.56 +48199-4;Ampicillin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Ampicillin triggered leukotriene release [Mass/volume] by Leukocytes;Ampicillin LR-mCnc;;ACTIVE;2.21;2.70 +482-0;Talampicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Talampicillin [Susceptibility] by Serum bactericidal titer;Talampicillin Titr SBT;;ACTIVE;1.0;2.32 +48200-0;Penicillin V leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Penicillin V triggered leukotriene release [Mass/volume] by Leukocytes;Penicillin V LR-mCnc;;ACTIVE;2.21;2.70 +48201-8;Penicillin G leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Penicillin G triggered leukotriene release [Mass/volume] by Leukocytes;Penicillin G LR-mCnc;;ACTIVE;2.21;2.70 +48202-6;Ambrosia elatior+Ambrosia trifida leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Short+Giant Ragweed triggered leukotriene release [Mass/volume] by Leukocytes;Short+Giant Ragweed LR-mCnc;;ACTIVE;2.21;2.70 +48203-4;Apium graveolens leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Celery triggered leukotriene release [Mass/volume] by Leukocytes;Celery LR-mCnc;;ACTIVE;2.21;2.70 +48204-2;Casein leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Casein triggered leukotriene release [Mass/volume] by Leukocytes;Casein LR-mCnc;;ACTIVE;2.21;2.70 +48205-9;Beta lactoglobulin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Beta lactoglobulin triggered leukotriene release [Mass/volume] by Leukocytes;B-Lactoglob LR-mCnc;;ACTIVE;2.21;2.70 +48206-7;Lactalbumin alpha leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Lactalbumin alpha triggered leukotriene release [Mass/volume] by Leukocytes;A-Lactalb LR-mCnc;;ACTIVE;2.21;2.70 +4820-7;HLA-B27;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B27 [Presence] in Donor;HLA-B27 Donr Ql;;ACTIVE;1.0;2.56 +48207-5;Egg yolk leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Egg yolk triggered leukotriene release [Mass/volume] by Leukocytes;Egg Yolk LR-mCnc;;ACTIVE;2.21;2.70 +48208-3;Saccharomyces cerevisiae leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Baker's yeast triggered leukotriene release [Mass/volume] by Leukocytes;Baker's yeast LR-mCnc;;ACTIVE;2.21;2.70 +48209-1;Citrus sinensis leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Orange triggered leukotriene release [Mass/volume] by Leukocytes;Orange LR-mCnc;;ACTIVE;2.21;2.70 +48210-9;Daucus carota leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Carrot triggered leukotriene release [Mass/volume] by Leukocytes;Carrot LR-mCnc;;ACTIVE;2.21;2.70 +48211-7;Beef leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Beef triggered leukotriene release [Mass/volume] by Leukocytes;Beef LR-mCnc;;ACTIVE;2.21;2.70 +48212-5;Pork leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Pork triggered leukotriene release [Mass/volume] by Leukocytes;Pork LR-mCnc;;ACTIVE;2.21;2.70 +48213-3;Lycopersicon lycopersicum leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Tomato triggered leukotriene release [Mass/volume] by Leukocytes;Tomato LR-mCnc;;ACTIVE;2.21;2.70 +48214-1;Pandalus borealis leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Shrimp triggered leukotriene release [Mass/volume] by Leukocytes;Shrimp LR-mCnc;;ACTIVE;2.21;2.70 +4821-5;HLA-B27;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B27 [Presence];HLA-B27 Ql;;ACTIVE;1.0;2.73 +48215-8;Cancer pagurus leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Crab triggered leukotriene release [Mass/volume] by Leukocytes;Crab LR-mCnc;;ACTIVE;2.21;2.70 +48216-6;Corylus avellana leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Hazelnut triggered leukotriene release [Mass/volume] by Leukocytes;Hazelnut LR-mCnc;;ACTIVE;2.21;2.70 +48217-4;Glycine max leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Soybean triggered leukotriene release [Mass/volume] by Leukocytes;Soybean LR-mCnc;;ACTIVE;2.21;2.70 +48218-2;Arachis hypogaea leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Peanut triggered leukotriene release [Mass/volume] by Leukocytes;Peanut LR-mCnc;;ACTIVE;2.21;2.70 +48219-0;Sesamum indicum leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Sesame Seed triggered leukotriene release [Mass/volume] by Leukocytes;Sesame Seed LR-mCnc;;ACTIVE;2.21;2.70 +48220-8;Avena sativa leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Oat triggered leukotriene release [Mass/volume] by Leukocytes;Oat LR-mCnc;;ACTIVE;2.21;2.70 +48221-6;Hordeum vulgare leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Barley triggered leukotriene release [Mass/volume] by Leukocytes;Barley LR-mCnc;;ACTIVE;2.21;2.70 +48222-4;Secale cereale leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Rye triggered leukotriene release [Mass/volume] by Leukocytes;Rye LR-mCnc;;ACTIVE;2.21;2.70 +4822-3;HLA-B35;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B35 [Presence] in Donor;HLA-B35 Donr Ql;;ACTIVE;1.0;2.56 +48223-2;Triticum aestivum leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Wheat triggered leukotriene release [Mass/volume] by Leukocytes;Wheat LR-mCnc;;ACTIVE;2.21;2.70 +48224-0;Gadus morhua leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Codfish triggered leukotriene release [Mass/volume] by Leukocytes;Codfish LR-mCnc;;ACTIVE;2.21;2.70 +48225-7;Cow milk leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cow milk triggered leukotriene release [Mass/volume] by Leukocytes;Cow Milk LR-mCnc;;ACTIVE;2.21;2.70 +48226-5;Egg white leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Egg white triggered leukotriene release [Mass/volume] by Leukocytes;Egg White LR-mCnc;;ACTIVE;2.21;2.70 +48227-3;Human serum albumin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Human serum albumin triggered leukotriene release [Mass/volume] by Leukocytes;HAS LR-mCnc;;ACTIVE;2.21;2.70 +48228-1;Bovine serum albumin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Bovine serum albumin (BSA) triggered leukotriene release [Mass/volume] by Leukocytes;BSA LR-mCnc;;ACTIVE;2.21;2.70 +48229-9;Dog epithelium leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Dog epithelium triggered leukotriene release [Mass/volume] by Leukocytes;Dog Epith LR-mCnc;;ACTIVE;2.21;2.70 +48230-7;Cat dander leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cat dander triggered leukotriene release [Mass/volume] by Leukocytes;Cat Dander LR-mCnc;;ACTIVE;2.21;2.70 +4823-1;HLA-B35;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B35 [Presence];HLA-B35 Ql;;ACTIVE;1.0;2.56 +48231-5;Glycyphagus domesticus leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Glycyphagus domesticus triggered leukotriene release [Mass/volume] by Leukocytes;G domesticus LR-mCnc;;ACTIVE;2.21;2.70 +48232-3;Tyrophagus putrescentiae leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Tyrophagus putrescentiae triggered leukotriene release [Mass/volume] by Leukocytes;T putrescentiae LR-mCnc;;ACTIVE;2.21;2.70 +48233-1;Lepidoglyphus destructor leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Lepidoglyphus destructor triggered leukotriene release [Mass/volume] by Leukocytes;L destructor LR-mCnc;;ACTIVE;2.21;2.70 +48234-9;Acarus siro leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Acarus siro triggered leukotriene release [Mass/volume] by Leukocytes;A siro LR-mCnc;;ACTIVE;2.21;2.70 +48235-6;Dermatophagoides farinae leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;American house dust mite triggered leukotriene release [Mass/volume] by Leukocytes;D farinae LR-mCnc;;ACTIVE;2.21;2.70 +48236-4;Dermatophagoides pteronyssinus leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;European house dust mite triggered leukotriene release [Mass/volume] by Leukocytes;D pteronyss LR-mCnc;;ACTIVE;2.21;2.70 +48237-2;Ctenocephalides sp leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Flea triggered leukotriene release [Mass/volume] by Leukocytes;Flea LR-mCnc;;ACTIVE;2.21;2.70 +48238-0;Blatella germanica leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cockroach triggered leukotriene release [Mass/volume] by Leukocytes;Roach LR-mCnc;;ACTIVE;2.21;2.70 +48239-8;Alternaria alternata leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Alternaria alternata triggered leukotriene release [Mass/volume] by Leukocytes;A alternata LR-mCnc;;ACTIVE;2.21;2.70 +48240-6;Candida albicans leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Candida albicans triggered leukotriene release [Mass/volume] by Leukocytes;C albicans LR-mCnc;;ACTIVE;2.21;2.70 +48241-4;Aspergillus fumigatus leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Aspergillus fumigatus triggered leukotriene release [Mass/volume] by Leukocytes;A fumigatus LR-mCnc;;ACTIVE;2.21;2.70 +48242-2;Cladosporium herbarum leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cladosporium herbarum triggered leukotriene release [Mass/volume] by Leukocytes;C herbarum LR-mCnc;;ACTIVE;2.21;2.70 +48243-0;Penicillium notatum leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Penicillium notatum triggered leukotriene release [Mass/volume] by Leukocytes;P notatum LR-mCnc;;ACTIVE;2.21;2.70 +48244-8;Juniperus virginiana leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Red Cedar triggered leukotriene release [Mass/volume] by Leukocytes;Red Cedar LR-mCnc;;ACTIVE;2.21;2.70 +48245-5;Cryptomeria japonica leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Japanese Cedar triggered leukotriene release [Mass/volume] by Leukocytes;Japanese Cedar LR-mCnc;;ACTIVE;2.21;2.70 +48246-3;Olea europaea pollen leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Olive Pollen triggered leukotriene release [Mass/volume] by Leukocytes;Olive Poln LR-mCnc;;ACTIVE;2.21;2.70 +48247-1;Quercus alba leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;White Oak triggered leukotriene release [Mass/volume] by Leukocytes;White Oak LR-mCnc;;ACTIVE;2.21;2.70 +48248-9;Corylus avellana pollen leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Hazelnut Pollen triggered leukotriene release [Mass/volume] by Leukocytes;Hazelnut Poln LR-mCnc;;ACTIVE;2.21;2.70 +4824-9;HLA-B37;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B37 [Presence] in Donor;HLA-B37 Donr Ql;;ACTIVE;1.0;2.56 +48249-7;Betula verrucosa leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Silver Birch triggered leukotriene release [Mass/volume] by Leukocytes;Silver Birch LR-mCnc;;ACTIVE;2.21;2.70 +48250-5;Parietaria judaica leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Pellitory (Parietaria judaica) triggered leukotriene release [Mass/volume] by Leukocytes;Pellitory (judaic) LR-mCnc;;ACTIVE;2.21;2.70 +48251-3;Parietaria officinalis leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Pellitory (Parietaria officinalis) triggered leukotriene release [Mass/volume] by Leukocytes;Pellitory (offic) LR-mCnc;;ACTIVE;2.21;2.70 +48252-1;Salsola kali leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Saltwort triggered leukotriene release [Mass/volume] by Leukocytes;Saltwort LR-mCnc;;ACTIVE;2.21;2.70 +48253-9;Plantago lanceolata leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;English plantain triggered leukotriene release [Mass/volume] by Leukocytes;Engl plantain LR-mCnc;;ACTIVE;2.21;2.70 +48254-7;Artemisia vulgaris leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Mugwort triggered leukotriene release [Mass/volume] by Leukocytes;Mugwort LR-mCnc;;ACTIVE;2.21;2.70 +48255-4;Ambrosia trifida leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Giant Ragweed triggered leukotriene release [Mass/volume] by Leukocytes;Giant Ragweed LR-mCnc;;ACTIVE;2.21;2.70 +4825-6;HLA-B37;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B37 [Presence];HLA-B37 Ql;;ACTIVE;1.0;2.56 +48256-2;Ambrosia elatior leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Common Ragweed triggered leukotriene release [Mass/volume] by Leukocytes;Common Ragweed LR-mCnc;;ACTIVE;2.21;2.70 +48257-0;Holcus lanatus leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Velvet grass triggered leukotriene release [Mass/volume] by Leukocytes;Velvet grass LR-mCnc;;ACTIVE;2.21;2.70 +48258-8;Secale cereale pollen leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cultivated Rye triggered leukotriene release [Mass/volume] by Leukocytes;Cultivated Rye LR-mCnc;;ACTIVE;2.21;2.70 +48259-6;Poa pratensis leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Kentucky blue grass triggered leukotriene release [Mass/volume] by Leukocytes;Kent blue grass LR-mCnc;;ACTIVE;2.21;2.70 +48260-4;Phleum pratense leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Timothy triggered leukotriene release [Mass/volume] by Leukocytes;Timothy LR-mCnc;;ACTIVE;2.21;2.70 +48261-2;Lolium perenne leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Perennial rye grass triggered leukotriene release [Mass/volume] by Leukocytes;Per rye grass LR-mCnc;;ACTIVE;2.21;2.70 +48262-0;Festuca elatior leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Meadow Fescue triggered leukotriene release [Mass/volume] by Leukocytes;Meadow Fescue LR-mCnc;;ACTIVE;2.21;2.70 +48263-8;Dactylis glomerata leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cocksfoot triggered leukotriene release [Mass/volume] by Leukocytes;Cocksfoot LR-mCnc;;ACTIVE;2.21;2.70 +4826-4;HLA-B38(16);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B38(16) [Presence] in Donor;HLA-B38(16) Donr Ql;;ACTIVE;1.0;2.56 +48264-6;Cynodon dactylon leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Bermuda grass triggered leukotriene release [Mass/volume] by Leukocytes;Bermuda grass LR-mCnc;;ACTIVE;2.21;2.70 +48265-3;(Acarus siro+Lepidoglyphus destructor+Tyrophagus putrescentiae+Glycyphagus domesticus) leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Dust Allergen Mix B (Acarus siro+Lepidoglyphus destructor+Tyrophagus putrescentiae+Glycyphagus domesticus) triggered leukotriene release [Mass/volume] by Leukocytes;Storage Mite Mix LR-mCnc;;ACTIVE;2.21;2.70 +48266-1;(Dactylis glomerata+Festuca elatior+Holcus lanatus+Lolium perenne+Phleum pratense+Poa pratensis) leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Grass Allergen Mix E (Cocksfoot+Meadow Fescue+Velvet grass+Perennial rye grass+Timothy+Kentucky blue grass ) triggered leukotriene release [Mass/volume] by Leukocytes;Grass Allerg Mix LR-mCnc;;ACTIVE;2.21;2.70 +48267-9;Benzylpenicilloyl-polylysine leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Benzylpenicilloyl-polylysine triggered leukotriene release [Mass/volume] by Leukocytes;PPL LR-mCnc;;ACTIVE;2.21;2.73 +48268-7;Minor determinant mixture leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Minor determinant mixture triggered leukotriene release [Mass/volume] by Leukocytes;MDM LR-mCnc;;ACTIVE;2.21;2.70 +48269-5;Cefamandole leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Cefamandole triggered leukotriene release [Mass/volume] by Leukocytes;Cefamandole LR-mCnc;;ACTIVE;2.21;2.70 +48270-3;ceFAZolin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;ceFAZolin triggered leukotriene release [Mass/volume] by Leukocytes;ceFAZolin LR-mCnc;;ACTIVE;2.21;2.70 +48271-1;Tetracycline leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Tetracycline triggered leukotriene release [Mass/volume] by Leukocytes;Tetracycline LR-mCnc;;ACTIVE;2.21;2.70 +4827-2;HLA-B38(16);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B38(16) [Presence];HLA-B38(16) Ql;;ACTIVE;1.0;2.56 +48272-9;Ciprofloxacin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Ciprofloxacin triggered leukotriene release [Mass/volume] by Leukocytes;Ciprofloxacin LR-mCnc;;ACTIVE;2.21;2.70 +48273-7;Lysine acetylsalicylate leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Lysine acetylsalicylate triggered leukotriene release [Mass/volume] by Leukocytes;Lysine acetylsalicyl LR-mCnc;;ACTIVE;2.21;2.70 +48274-5;Diclofenac leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Diclofenac triggered leukotriene release [Mass/volume] by Leukocytes;Diclofenac LR-mCnc;;ACTIVE;2.21;2.70 +48275-2;Ibuprofen leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Ibuprofen triggered leukotriene release [Mass/volume] by Leukocytes;Ibuprofen LR-mCnc;;ACTIVE;2.21;2.70 +48276-0;Indomethacin leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Indomethacin triggered leukotriene release [Mass/volume] by Leukocytes;Indomethacin LR-mCnc;;ACTIVE;2.21;2.70 +48277-8;Acetaminophen leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Acetaminophen triggered leukotriene release [Mass/volume] by Leukocytes;APAP LR-mCnc;;ACTIVE;2.21;2.70 +48278-6;Mefenamate leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Mefenamate triggered leukotriene release [Mass/volume] by Leukocytes;Mefenamate LR-mCnc;;ACTIVE;2.21;2.70 +48279-4;Propyphenazone leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Propyphenazone triggered leukotriene release [Mass/volume] by Leukocytes;Propyphenazone LR-mCnc;;ACTIVE;2.21;2.70 +4828-0;HLA-B39(16);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B39(16) [Presence] in Donor;HLA-B39(16) Donr Ql;;ACTIVE;1.0;2.56 +48280-2;Dipyrone leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Dipyrone triggered leukotriene release [Mass/volume] by Leukocytes;Dipyrone LR-mCnc;;ACTIVE;2.21;2.70 +48281-0;Sulfamethoxazole leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Sulfamethoxazole triggered leukotriene release [Mass/volume] by Leukocytes;Sulfamethoxazole LR-mCnc;;ACTIVE;2.21;2.70 +48282-8;Atracurium leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Atracurium triggered leukotriene release [Mass/volume] by Leukocytes;Atracurium LR-mCnc;;ACTIVE;2.21;2.70 +48283-6;Mivacurium leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Mivacurium triggered leukotriene release [Mass/volume] by Leukocytes;Mivacurium LR-mCnc;;ACTIVE;2.21;2.70 +48284-4;Pancuronium leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Pancuronium triggered leukotriene release [Mass/volume] by Leukocytes;Pancuronium LR-mCnc;;ACTIVE;2.21;2.70 +48285-1;Propofol leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Propofol triggered leukotriene release [Mass/volume] by Leukocytes;Propofol LR-mCnc;;ACTIVE;2.21;2.70 +48286-9;Rocuronium leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Rocuronium triggered leukotriene release [Mass/volume] by Leukocytes;Rocuronium LR-mCnc;;ACTIVE;2.21;2.70 +48287-7;Suxamethonium leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Deprecated Suxamethonium triggered leukotriene release [Mass/volume] by Leukocytes;Deprecated Suxamethonium LR-mCnc;;DEPRECATED;2.21;2.70 +48288-5;Vecuronium leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Vecuronium triggered leukotriene release [Mass/volume] by Leukocytes;Vecuronium LR-mCnc;;ACTIVE;2.21;2.70 +48289-3;Sodium benzoate leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Sodium benzoate triggered leukotriene release [Mass/volume] by Leukocytes;Sodium benzoate LR-mCnc;;ACTIVE;2.21;2.73 +48290-1;Sodium nitrite leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Sodium nitrite triggered leukotriene release [Mass/volume] by Leukocytes;Sodium nitrite LR-mCnc;;ACTIVE;2.21;2.70 +48291-9;Potassium metabisulfite leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Potassium metabisulfite triggered leukotriene release [Mass/volume] by Leukocytes;K metabisulfite LR-mCnc;;ACTIVE;2.21;2.70 +48292-7;Sodium salicylate leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Sodium salicylate triggered leukotriene release [Mass/volume] by Leukocytes;Sodium salicylate LR-mCnc;;ACTIVE;2.21;2.70 +48293-5;Tartrazine leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Tartrazine triggered leukotriene release [Mass/volume] by Leukocytes;Tartrazine LR-mCnc;;ACTIVE;2.21;2.73 +48294-3;Food colorant mix I leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Food colorant mix I triggered leukotriene release [Mass/volume] by Leukocytes;Food colorant mix I LR-mCnc;;ACTIVE;2.21;2.70 +48295-0;Food colorant mix II leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Food colorant mix II triggered leukotriene release [Mass/volume] by Leukocytes;Food colorant mix II LR-mCnc;;ACTIVE;2.21;2.70 +48296-8;Quinoline yellow leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Quinoline yellow triggered leukotriene release [Mass/volume] by Leukocytes;Quinoline yellow LR-mCnc;;ACTIVE;2.21;2.73 +48297-6;Chromotrope 2B leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Chromotrope 2B triggered leukotriene release [Mass/volume] by Leukocytes;Chromotrope 2B LR-mCnc;;ACTIVE;2.21;2.73 +4829-8;HLA-B39(16);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B39(16) [Presence];HLA-B39(16) Ql;;ACTIVE;1.0;2.56 +48298-4;Pigweed leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Pigweed triggered leukotriene release [Mass/volume] by Leukocytes;Pigweed LR-mCnc;;ACTIVE;2.21;2.70 +48299-2;New coccine leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;New coccine triggered leukotriene release [Mass/volume] by Leukocytes;New coccine LR-mCnc;;ACTIVE;2.21;2.73 +48300-8;Erythrosine leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Erythrosine triggered leukotriene release [Mass/volume] by Leukocytes;Erythrosine LR-mCnc;;ACTIVE;2.21;2.73 +48301-6;Patent blue V leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Patent blue V triggered leukotriene release [Mass/volume] by Leukocytes;Patent blue V LR-mCnc;;ACTIVE;2.21;2.73 +48302-4;Indigo carmine leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Indigo carmine triggered leukotriene release [Mass/volume] by Leukocytes;Indigo carmine LR-mCnc;;ACTIVE;2.21;2.73 +48303-2;Brilliant black BN leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Brilliant black BN triggered leukotriene release [Mass/volume] by Leukocytes;Brilliant black BN LR-mCnc;;ACTIVE;2.21;2.70 +48304-0;Glutamate leukotriene release;MCnc;Pt;WBC;Qn;;ALLERGY;1;Glutamate triggered leukotriene release [Mass/volume] by Leukocytes;Glutamate LR-mCnc;;ACTIVE;2.21;2.70 +48305-7;Coproporphyrin 1/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 1/Creatinine [Mass Ratio] in Urine;Copro1/Creat Ur;;ACTIVE;2.21;2.73 +4830-6;HLA-B40;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B40 [Presence] in Donor;HLA-B40 Donr Ql;;ACTIVE;1.0;2.56 +48306-5;Coproporphyrin 3/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 3/Creatinine [Mass Ratio] in Urine;Copro3/Creat Ur;;ACTIVE;2.21;2.73 +48307-3;Didanosine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Didanosine [Mass/volume] in Serum or Plasma;Didanosine SerPl-mCnc;;ACTIVE;2.21;2.70 +48308-1;DNA double strand Ab;ACnc;Pt;Body fld;Qn;Farr;SERO;1;DNA double strand Ab [Units/volume] in Body fluid by Farr method;dsDNA Ab Fld Farr-aCnc;;ACTIVE;2.21;2.70 +48309-9;BK virus DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Specimen by NAA with probe detection;BKV DNA # Spec NAA+probe;;ACTIVE;2.21;2.73 +48310-7;Influenza virus A;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Influenza virus A [Presence] in Specimen by Organism specific culture;FLUAV Spec Ql Cult;;ACTIVE;2.21;2.73 +48311-5;Lysosomal enzymes screen;Prid;Pt;Bld;Nom;;CHEM;1;Lysosomal enzymes screen [Identifier] in Blood;Lysosomal Enzymes Scn Bld;;ACTIVE;2.21;2.21 +48312-3;Yersinia enterocolitica O:5 Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Yersinia enterocolitica O:5 Ab [Titer] in Serum by Agglutination;Y entero O:5 Ab Titr Ser Aggl;;ACTIVE;2.21;2.70 +48313-1;Yersinia enterocolitica O:9 Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Yersinia enterocolitica O:9 Ab [Titer] in Serum by Agglutination;Y entero O:9 Ab Titr Ser Aggl;;ACTIVE;2.21;2.70 +4831-4;HLA-B40;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B40 [Presence];HLA-B40 Ql;;ACTIVE;1.0;2.73 +48314-9;Leishmania mexicana Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania mexicana IgG Ab [Titer] in Serum by Immunofluorescence;L mexicana IgG Titr Ser IF;;ACTIVE;2.21;2.70 +48315-6;Leishmania mexicana Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania mexicana IgM Ab [Titer] in Serum by Immunofluorescence;L mexicana IgM Titr Ser IF;;ACTIVE;2.21;2.70 +48316-4;Leishmania tropica Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania tropica IgG Ab [Titer] in Serum by Immunofluorescence;L tropica IgG Titr Ser IF;;ACTIVE;2.21;2.70 +48317-2;Leishmania tropica Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania tropica IgM Ab [Titer] in Serum by Immunofluorescence;L tropica IgM Titr Ser IF;;ACTIVE;2.21;2.70 +48318-0;Cat hair+Cat epithelium Ab.IgE.RAST class;ACnc;Pt;Ser;Ord;;ALLERGY;1;Deprecated Cat hair + Cat dander IgE Ab RAST class in Serum;Deprecated Cat Hair+Epith IgE RAST Ql;;DEPRECATED;2.21;2.36 +48319-8;glipiZIDE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;glipiZIDE [Presence] in Specimen;glipiZIDE Spec Ql;;ACTIVE;2.21;2.69 +48320-6;glyBURIDE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;glyBURIDE [Presence] in Specimen;glyBURIDE Spec Ql;;ACTIVE;2.21;2.69 +48321-4;TOLBUTamide;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;TOLBUTamide [Presence] in Specimen;TOLBUTamide Spec Ql;;ACTIVE;2.21;2.69 +4832-2;HLA-B44(12);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B44(12) [Presence] in Donor;HLA-B44(12) Donr Ql;;ACTIVE;1.0;2.56 +48322-2;acetoHEXAMIDE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Acetohexamide [Presence] in Specimen;acetoHEXAMIDE Spec Ql;;ACTIVE;2.21;2.69 +48323-0;TOLAZamide;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;TOLAZamide [Presence] in Specimen;TOLAZamide Spec Ql;;ACTIVE;2.21;2.69 +48324-8;chlorproPAMIDE;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;chlorproPAMIDE [Presence] in Specimen;chlorproPAMIDE Spec Ql;;ACTIVE;2.21;2.69 +48325-5;Glimepiride;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Glimepride [Presence] in Serum or Plasma;Glimepiride SerPl Ql;;ACTIVE;2.21;2.73 +48326-3;glipiZIDE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;glipiZIDE [Presence] in Serum or Plasma;glipiZIDE SerPl Ql;;ACTIVE;2.21;2.73 +48327-1;glyBURIDE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;glyBURIDE [Presence] in Serum or Plasma;glyBURIDE SerPl Ql;;ACTIVE;2.21;2.73 +48328-9;Repaglinide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Repaglinide [Presence] in Serum or Plasma;Repaglinide SerPl Ql;;ACTIVE;2.21;2.73 +48329-7;chlorproPAMIDE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;chlorproPAMIDE [Presence] in Serum or Plasma;chlorproPAMIDE SerPl Ql;;ACTIVE;2.21;2.73 +4833-0;HLA-B44(12);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B44(12) [Presence];HLA-B44(12) Ql;;ACTIVE;1.0;2.56 +48330-5;MCOLN1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MCOLN1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MCOLN1 gene Mut Tested Bld/T;;ACTIVE;2.21;2.73 +48331-3;BLM gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BLM gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;BLM gene Mut Tested Bld/T;;ACTIVE;2.21;2.73 +48332-1;Apgar panel^10M post birth;-;Pt;^Patient;-;Apgar;PANEL.NEONAT;2;10 minute Apgar panel;10M Apgar Pnl;;ACTIVE;2.21;2.63 +48333-9;Apgar panel^5M post birth;-;Pt;^Patient;-;Apgar;PANEL.NEONAT;2;5 minute Apgar panel;5M Apgar Pnl;;ACTIVE;2.21;2.63 +48334-7;Apgar panel^1M post birth;-;Pt;^Patient;-;Apgar;PANEL.NEONAT;2;1 minute Apgar panel;1M Apgar Pnl;;ACTIVE;2.21;2.63 +48335-4;Aspergillus sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Aspergillus sp Ag [Presence] in Tissue by Immune stain;Aspergillus Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +48336-2;Candida sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Candida sp Ag [Presence] in Tissue by Immune stain;Candida Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +48337-0;Cryptococcus neoformans Ag;ACnc;Pt;Tiss;Ord;Immune stain;MICRO;1;Deprecated Cryptococcus neoformans Ag [Presence] in Tissue by Immune stain;Deprecated C neoform Ag Tiss Ql ImStn;;DEPRECATED;2.21;2.40 +48338-8;Histoplasma capsulatum Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Histoplasma capsulatum Ag [Presence] in Tissue by Immune stain;H capsul Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +48339-6;Sporothrix schenckii Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Sporothrix schenckii Ag [Presence] in Tissue by Immune stain;S schenckii Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +48340-4;17-Hydroxyprogesterone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;17OHP 30M p chal SerPl-mCnc;;ACTIVE;2.21;2.73 +48341-2;17-Hydroxyprogesterone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;17OHP 1h p chal SerPl-mCnc;;ACTIVE;2.21;2.73 +48342-0;Ethanol+Methanol+Isopropyl alcohol+Acetone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethanol+Methanol+Isopropyl alcohol+Acetone [Moles/volume] in Serum or Plasma;Alcohol.XXX SerPl-sCnc;;ACTIVE;2.21;2.46 +48343-8;Hemoglobin.other/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin.other/Hemoglobin.total in Blood;Hgb Other MFr Bld;;ACTIVE;2.21;2.73 +48344-6;Activated clotting time.kaolin induced;Time;Pt;PPP;Qn;Coag;COAG;1;Activated clotting time.kaolin induced of Platelet poor plasma;ACT Kaolin Ind PPP;;ACTIVE;2.21;2.73 +48345-3;HIV 1+O+2 Ab;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;HIV 1+O+2 Ab [Presence] in Serum or Plasma;HIV 1+O+2 Ab SerPl Ql;;ACTIVE;2.21;2.73 +48346-1;HIV 1+O+2 Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;HIV 1+O+2 Ab [Units/volume] in Serum or Plasma;HIV 1+O+2 Ab SerPl-aCnc;;ACTIVE;2.21;2.73 +48347-9;levETIRAcetam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;levETIRAcetam [Moles/volume] in Serum or Plasma;levETIRAcetam SerPl-sCnc;;ACTIVE;2.21;2.73 +4834-8;HLA-B45(12);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B45(12) [Presence] in Donor;HLA-B45(12) Donr Ql;;ACTIVE;1.0;2.56 +48348-7;10-Hydroxycarbazepine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;10-Hydroxycarbazepine [Moles/volume] in Serum or Plasma;10OH-Carbazepine SerPl-sCnc;;ACTIVE;2.21;2.73 +48349-5;Pregabalin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pregabalin [Moles/volume] in Serum or Plasma;Pregabalin SerPl-sCnc;;ACTIVE;2.21;2.34 +48350-3;Venlafaxine+O-desmethylvenlafaxine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Venlafaxine+O-desmethylvenlafaxine [Moles/volume] in Serum or Plasma;Vnlfxn+ODV SerPl-sCnc;;ACTIVE;2.21;2.69 +48351-1;Methotrimeprazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrimeprazine [Moles/volume] in Serum or Plasma;Methotrimeprazine SerPl-sCnc;;ACTIVE;2.21;2.52 +48352-9;Reboxetine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Reboxetine [Moles/volume] in Serum or Plasma;Reboxetine SerPl-sCnc;;ACTIVE;2.21;2.42 +48353-7;Chlorprothixene;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorprothixene [Moles/volume] in Serum or Plasma;Chlorprothixene SerPl-sCnc;;ACTIVE;2.21;2.42 +48354-5;ARIPiprazole;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ARIPiprazole [Moles/volume] in Serum or Plasma;ARIPiprazole SerPl-sCnc;;ACTIVE;2.21;2.34 +4835-5;HLA-B45(12);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B45(12) [Presence];HLA-B45(12) Ql;;ACTIVE;1.0;2.56 +48355-2;traMADol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;traMADol [Moles/volume] in Serum or Plasma;traMADol SerPl-sCnc;;ACTIVE;2.21;2.44 +48356-0;Prazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prazepam [Moles/volume] in Serum or Plasma;Prazepam SerPl-sCnc;;ACTIVE;2.21;2.42 +48357-8;Testosterone;SCnc;Pt;Saliva;Qn;;CHEM;1;Testosterone [Moles/volume] in Saliva (oral fluid);Testost Sal-sCnc;;ACTIVE;2.21;2.42 +48358-6;Herpes virus 8 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 8 IgM Ab [Titer] in Serum by Immunofluorescence;HHV8 IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48359-4;Echinococcus granulosus Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Echinococcus granulosus Ab [Titer] in Serum by Hemagglutination;E granulosus Ab Titr Ser HA;;ACTIVE;2.21;2.32 +48360-2;Borrelia afzelii Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia afzelii IgG Ab [Presence] in Serum by Immunoblot;B afzelii IgG Ser Ql IB;;ACTIVE;2.21;2.58 +48361-0;Borrelia valaisiana Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia valaisiana IgG Ab [Presence] in Serum by Immunoblot;B valaisiana IgG Ser Ql IB;;ACTIVE;2.21;2.58 +48362-8;O-desmethylvenlafaxine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;O-desmethylvenlafaxine [Moles/volume] in Serum or Plasma;ODV SerPl-sCnc;;ACTIVE;2.21;2.69 +4836-3;HLA-B49(21);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B49(21) [Presence] in Donor;HLA-B49(21) Donr Ql;;ACTIVE;1.0;2.56 +48363-6;Morphine-6-Glucuronide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Morphine-6-Glucuronide [Moles/volume] in Serum or Plasma;Morphine-6-glucuronide SerPl-sCnc;;ACTIVE;2.21;2.42 +48364-4;Morphine-3-Glucuronide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Morphine-3-Glucuronide [Moles/volume] in Serum or Plasma;Morphine-3-glucuronide SerPl-sCnc;;ACTIVE;2.21;2.42 +48365-1;Methadone.R;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methadone.R [Moles/volume] in Serum or Plasma;R-methadone SerPl-sCnc;;ACTIVE;2.21;2.42 +48366-9;Pentadecanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pentadecanoate [Moles/volume] in Serum or Plasma;Pentadecanoate SerPl-sCnc;;ACTIVE;2.21;2.42 +48367-7;cis-Vaccenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;cis-Vaccenate (C18:1w7) [Moles/volume] in Serum or Plasma;cis-Vaccenate SerPl-sCnc;;ACTIVE;2.21;2.42 +48368-5;trans-Octadecanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;trans-Octadecanoate (C18:0) [Moles/volume] in Serum or Plasma;trans-Octadecanoate SerPl-sCnc;;ACTIVE;2.21;2.42 +48369-3;trans-Vaccenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;trans-Vaccenate (C18:1w7) [Moles/volume] in Serum or Plasma;trans-Vaccenate SerPl-sCnc;;ACTIVE;2.21;2.42 +48370-1;Dihomogammalinolenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dihomogammalinolenate (C20:3n-6) [Moles/volume] in Serum or Plasma;Dihomogammalinolenate SerPl-sCnc;;ACTIVE;2.21;2.42 +4837-1;HLA-B49(21);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B49(21) [Presence];HLA-B49(21) Ql;;ACTIVE;1.0;2.56 +48371-9;Docosapentaenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosapentaenoate (C22:5 n-3) [Moles/volume] in Serum or Plasma;Docosapentaenoate SerPl-sCnc;;ACTIVE;2.21;2.40 +48372-7;Spermatozoa.isolated head/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Isolated Head/100 spermatozoa in Semen;Sperm Isolated Head NFr Smn;;ACTIVE;2.21;2.40 +48373-5;Spermatozoa.angled midpiece/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Angled Midpiece/100 spermatozoa in Semen;Sperm.Angled Midpiece NFr Smn;;ACTIVE;2.21;2.40 +48374-3;Spermatozoa.isolated tail/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Isolated Tail/100 spermatozoa in Semen;Sperm.Isolated Tail NFr Smn;;ACTIVE;2.21;2.40 +48375-0;Spermatozoa.short tail/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Short Tail/100 spermatozoa in Semen;Sperm.Short Tail NFr Smn;;ACTIVE;2.21;2.40 +48376-8;Collagen type 1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Collagen type 1 Ab [Units/volume] in Serum;Collagen1 Ab Ser-aCnc;;ACTIVE;2.21;2.69 +48377-6;Mullerian inhibiting substance;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Mullerian inhibiting substance [Moles/volume] in Serum or Plasma;MIS SerPl-sCnc;;ACTIVE;2.21;2.73 +48378-4;Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda.free;MRto;Pt;Ser;Qn;;CHEM;1;Kappa light chains.free/Lambda light chains.free [Mass Ratio] in Serum;Kappa LC Free/Lambda Free Ser;;ACTIVE;2.21;2.73 +48379-2;Zopiclone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zopiclone [Moles/volume] in Serum or Plasma;Zopiclone SerPl-sCnc;;ACTIVE;2.21;2.42 +483-8;Teicoplanin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Teicoplanin [Susceptibility] by Minimum lethal concentration (MLC);Teicoplanin Islt MLC;;ACTIVE;1.0;2.19 +48380-0;3-Methoxytyramine;SCnc;24H;Urine;Qn;;CHEM;1;3-Methoxytyramine [Moles/volume] in 24 hour Urine;3Me-tyramine 24h Ur-sCnc;;ACTIVE;2.21;2.42 +48381-8;3-Methoxytyramine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Methoxytyramine/Creatinine [Molar ratio] in 24 hour Urine;3Me-tyramine/Creat 24h Ur-sRto;;ACTIVE;2.21;2.42 +48382-6;Fatty acids.omega 6/Fatty acids.omega 3;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Omega 6 fatty acids (w6)/Omega 3 fatty acids (w3) [Molar ratio] in Serum or Plasma;w6 FA/w3 FA SerPl-sRto;;ACTIVE;2.21;2.73 +48383-4;Collagen.bovine type 1 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Collagen.bovine type 1 Ab [Units/volume] in Serum;Collagen.bovine1 Ab Ser-aCnc;;ACTIVE;2.21;2.69 +48384-2;Collagen.bovine type 2 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Collagen.bovine type 2 Ab [Units/volume] in Serum;Collagen.bovine2 Ab Ser-aCnc;;ACTIVE;2.21;2.69 +48385-9;Collagen.injectable Ab;ACnc;Pt;Ser;Qn;;SERO;1;Collagen.injectable Ab [Units/volume] in Serum;Collagen.injectable Ab Ser-aCnc;;ACTIVE;2.21;2.69 +48386-7;Platelets.large/Platelets;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Platelets Large/Platelets in Blood by Automated count;Lg Platelets/Platelet NFr Bld Auto;;ACTIVE;2.21;2.58 +48387-5;Thyroglobulin recovery;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Thyroglobulin recovery [Presence] in Serum or Plasma;Thyroglob Recovery SerPl Ql;;ACTIVE;2.21;2.56 +48388-3;Heparin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Heparin IgE Ab [Units/volume] in Serum;Heparin IgE Qn;;ACTIVE;2.21;2.42 +4838-9;HLA-B51(5);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B51(5) [Presence] in Donor;HLA-B51(5) Donr Ql;;ACTIVE;1.0;2.56 +48389-1;Macroprolactin/Prolactin;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Macroprolactin/Prolactin [Moles] in Serum or Plasma;Macroprolactin/Prolactin SFr SerPl;;ACTIVE;2.21;2.73 +48390-9;B cell crossmatch;PrThr;Pt;Bld^Donor;Ord;;BLDBK;1;B cell crossmatch [Presence] in Blood from Donor;B Cell XM Bld Donr Ql;;ACTIVE;2.21;2.73 +48391-7;Carbon dioxide;SCnc;Pt;BldV;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Venous blood by calculation;CO2 BldV Calc-sCnc;;ACTIVE;2.21;2.73 +48392-5;Coccidioides immitis Ab;Titr;Pt;Body fld;Qn;Comp fix;MICRO;1;Coccidioides immitis Ab [Titer] in Body fluid by Complement fixation;C immitis Ab Titr Fld CF;;ACTIVE;2.21;2.73 +48393-3;Coccidioides immitis Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Coccidioides immitis IgM Ab [Units/volume] in Body fluid;C immitis IgM Fld-aCnc;;ACTIVE;2.21;2.44 +48394-1;Coccidioides sp Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;MICRO;1;Coccidioides sp Ab [Presence] in Body fluid by Immune diffusion (ID);Coccidioides Ab Fld Ql ID;;ACTIVE;2.21;2.73 +48395-8;Coproporphyrin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Coproporphyrin/Creatinine [Molar ratio] in Urine;Copro/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48396-6;Ganglioside GD1b Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Ganglioside GD1b Ab [Units/volume] in Serum;Deprecated GD1b Gangl Ab Ser-aCnc;;DEPRECATED;2.21;2.40 +4839-7;HLA-B51(5);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B51(5) [Presence];HLA-B51(5) Ql;;ACTIVE;1.0;2.56 +48397-4;Ganglioside GQ1b Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Ganglioside GQ1b Ab [Units/volume] in Serum;Deprecated GQ1b Gangl Ab Ser-aCnc;;DEPRECATED;2.21;2.70 +48398-2;Hepatitis B virus DNA;LaCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [log units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HBV DNA SerPl NAA+probe-Log IU;;ACTIVE;2.21;2.73 +48399-0;Herpes simplex virus 1 glycoprotein G Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1 glycoprotein G IgG Ab [Units/volume] in Cerebral spinal fluid;HSV1 gG IgG CSF-aCnc;;ACTIVE;2.21;2.73 +48400-6;Herpes simplex virus 1+2 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Herpes simplex virus 1+2 Ag [Presence] in Tissue by Immunofluorescence;HSV1+2 Ag Tiss Ql IF;;ACTIVE;2.21;2.56 +48401-4;Herpes simplex virus 2 glycoprotein G Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 2 glycoprotein G IgG Ab [Units/volume] in Cerebral spinal fluid;HSV2 gG IgG CSF-aCnc;;ACTIVE;2.21;2.73 +48402-2;Latex Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Latex IgE Ab/IgE total in Serum;Ltx IgE/IgE total %;;ACTIVE;2.21;2.65 +48403-0;Methadone+Metabolite;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methadone+Metabolite [Mass/volume] in Serum or Plasma;Methadone+metab SerPl-mCnc;;ACTIVE;2.21;2.70 +48404-8;Myeloperoxidase Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Myeloperoxidase IgG Ab [Units/volume] in Serum;Myeloperoxidase IgG Ser-aCnc;;ACTIVE;2.21;2.73 +4840-5;HLA-B5;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B5 [Presence] in Donor;HLA-B5 Donr Ql;;ACTIVE;1.0;2.56 +48405-5;Neuronal nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Neuronal nuclear IgG Ab [Presence] in Serum by Immunofluorescence;Hu IgG Ser Ql IF;;ACTIVE;2.21;2.56 +48406-3;Parietal cell Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Parietal cell IgG Ab [Titer] in Serum;PCA IgG Titr Ser;;ACTIVE;2.21;2.32 +48407-1;Pregnancy associated plasma protein A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pregnancy associated plasma protein A [Mass/volume] in Serum or Plasma;PAPP-A SerPl-mCnc;;ACTIVE;2.21;2.73 +48408-9;Proteinase 3 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Proteinase 3 IgG Ab [Units/volume] in Serum;Proteinase3 IgG Ser-aCnc;;ACTIVE;2.21;2.73 +48409-7;T cell crossmatch;PrThr;Pt;Bld^Donor;Ord;;BLDBK;1;T cell crossmatch [Presence] in Blood from Donor;T Cell XM Bld Donr Ql;;ACTIVE;2.21;2.73 +48410-5;Yersinia sp Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Yersinia sp IgM Ab [Presence] in Serum by Immunoblot;Yersinia IgM Ser Ql IB;;ACTIVE;2.21;2.73 +48411-3;Fungus identified;Prid;Pt;Tiss;Nom;Immune stain;MICRO;1;Fungus identified in Tissue by Immune stain;Fungus Tiss ImStn;;ACTIVE;2.21;2.22 +48412-1;Zygomycete sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Zygomycete sp Ag [Presence] in Tissue by Immune stain;Zygomycete Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +4841-3;HLA-B5;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B5 [Presence];HLA-B5 Ql;;ACTIVE;1.0;2.56 +48413-9;Alpha-1-Microglobulin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Microglobulin [Mass/volume] in Serum or Plasma;A1 Microglob SerPl-mCnc;;ACTIVE;2.21;2.70 +48414-7;Alpha-1-Microglobulin;MRat;24H;Urine;Qn;;CHEM;1;Alpha-1-Microglobulin [Mass/time] in 24 hour Urine;A1 Microglob 24h Ur-mRate;;ACTIVE;2.21;2.70 +48415-4;Alpha-1-Microglobulin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha-1-Microglobulin/Creatinine [Mass Ratio] in Urine;A1 Microglob/Creat Ur;;ACTIVE;2.21;2.70 +48416-2;Alpha-1-Acid glycoprotein;MCnc;Pt;Body fld;Qn;;CHEM;1;Alpha-1-acid glycoprotein [Mass/volume] in Body fluid;A1acid Glycoprotein Fld-mCnc;;ACTIVE;2.21;2.70 +48417-0;Staphylolysin Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Staphylolysin Ab [Units/volume] in Body fluid;Staphylolysin Ab Fld-aCnc;;ACTIVE;2.21;2.70 +48418-8;Staphylolysin Ab;Titr;Pt;Ser;Qn;;MICRO;1;Staphylolysin Ab [Titer] in Serum;Staphylolysin Ab Titr Ser;;ACTIVE;2.21;2.70 +48419-6;Immune complex.IgG;MCnc;Pt;Ser/Plas;Qn;C1q binding assay;SERO;1;Immune complex.IgG [Mass/volume] in Serum or Plasma by C1q binding assay;IC IgG SerPl C1Q Bind-mCnc;;ACTIVE;2.21;2.70 +48420-4;Complement C3c;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C3c [Mass/volume] in Body fluid;C3c Fld-mCnc;;ACTIVE;2.21;2.70 +4842-1;HLA-B7;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B7 [Presence] in Donor;HLA-B7 Donr Ql;;ACTIVE;1.0;2.56 +48421-2;C reactive protein;MCnc;Pt;BldC;Qn;;CHEM;1;C reactive protein [Mass/volume] in Capillary blood;CRP BldC-mCnc;;ACTIVE;2.21;2.70 +48422-0;Protein fractions.oligoclonal bands;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Oligoclonal bands [Presence] in Serum or Plasma;Oligoclonal Bands SerPl Ql;;ACTIVE;2.21;2.70 +48423-8;Protein pattern;Imp;Pt;Body fld;Nom;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in Body fluid by Electrophoresis;Prot Pattern Fld Elph-Imp;;ACTIVE;2.21;2.70 +48424-6;Protein pattern;Imp;Pt;Body fld;Nom;;CHEM;1;Protein Fractions [Interpretation] in Body fluid;Prot Pattern Fld-Imp;;ACTIVE;2.21;2.70 +48425-3;Troponin T.cardiac;MCnc;Pt;Bld;Qn;;CHEM;1;Troponin T.cardiac [Mass/volume] in Blood;Troponin T Bld-mCnc;;ACTIVE;2.21;2.73 +48426-1;Troponin T.cardiac;PrThr;Pt;Bld;Ord;;CHEM;1;Troponin T.cardiac [Presence] in Blood;Troponin T Bld Ql;;ACTIVE;2.21;2.73 +48427-9;Erythrocytes.Plasmodium sp infected/1000 erythrocytes;NFr;Pt;Bld;Qn;;MICRO;1;Erythrocytes.Plasmodium sp infected/1000 erythrocytes in Blood;Plasmodium infected RBC/1000 RBC Bld-NFr;;ACTIVE;2.21;2.34 +48428-7;Rumenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Rumenate (C18:2 cis-9 trans-11) [Moles/volume] in Serum or Plasma;Rumenate SerPl-sCnc;;ACTIVE;2.21;2.44 +48429-5;Lavandula angustifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lavender IgE Ab [Units/volume] in Serum;Lavender IgE Qn;;ACTIVE;2.21;2.42 +48430-3;Carnitine;Sub;XXX;Semen;Qn;;CHEM;1;Carnitine [Molar amount] in unspecified time Semen;Carnitine ?Tm sub Smn Qn;;ACTIVE;2.21;2.70 +48431-1;Zinc;Sub;XXX;Semen;Qn;;DRUG/TOX;1;Zinc [Molar amount] in unspecified time Semen;Zinc ?Tm sub Smn Qn;;ACTIVE;2.21;2.70 +48432-9;Fructose;Sub;XXX;Semen;Qn;;CHEM;1;Fructose [Molar amount] in unspecified time Semen;Fructose ?Tm sub Smn Qn;;ACTIVE;2.21;2.70 +48433-7;Views 2;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral 2 Views;XR Heel-Bl 2V;;ACTIVE;2.21;2.61 +48434-5;Guidance for percutaneous aspiration of fluid;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for fluid aspiration of Kidney;US Guided Kidney PC fluid asp;;ACTIVE;2.21;2.64 +48435-2;Guidance for injection;Find;Pt;Head>Salivary gland.bilateral;Doc;RF;RAD;2;RF Guidance for injection of Salivary gland - bilateral;RF Guided Salivary gland-Bl Inj;;ACTIVE;2.21;2.64 +48436-0;Multisection^W contrast IT;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine W contrast IT;MR L-spine W contr IT;;ACTIVE;2.21;2.61 +48437-8;Multisection^W contrast IV;Find;Pt;Temporal bone;Nar;MRI;RAD;2;Deprecated Temporal bones MRI W contrast IV;Deprecated Temporal bones MRI W contr IV;;DEPRECATED;2.21;2.38 +48438-6;Multisection^WO contrast;Find;Pt;Temporal bone;Nar;MRI;RAD;2;Deprecated Temporal bones MRI W contr IV;Deprecated Temporal bones MRI W contr IV;;DEPRECATED;2.21;2.38 +4843-9;HLA-B7;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B7 [Presence];HLA-B7 Ql;;ACTIVE;1.0;2.73 +48439-4;Multisection^W contrast IT;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine W contrast IT;MR T-spine W contr IT;;ACTIVE;2.21;2.61 +48440-2;Multisection^W contrast IV;Find;Pt;Head>Skull.base;Doc;MR;RAD;2;MR Skull base W contrast IV;MR Skull.base W contr IV;;ACTIVE;2.21;2.61 +48441-0;Multisection^WO & W contrast IT;Find;Pt;Chest>Spine.thoracic;Doc;MR;RAD;2;MR Thoracic spine WO and W contrast IT;MR T-spine WO+W contr IT;;ACTIVE;2.21;2.61 +48442-8;Multisection^WO & W contrast IT;Find;Pt;XXX>Spine;Doc;CT;RAD;2;CT Spine WO and W contrast IT;CT Spine WO+W contr IT;;DISCOURAGED;2.21;2.61 +48443-6;Multisection^WO & W contrast IV;Find;Pt;Head+Neck>Nasopharynx;Doc;CT;RAD;2;CT Nasopharynx WO and W contrast IV;CT Nasopharynx WO+W contr IV;;ACTIVE;2.21;2.61 +48444-4;Multisection^W contrast IV;Find;Pt;Head>Brain.temporal;Doc;MR;RAD;2;MR Brain.temporal W contrast IV;MR Brain.temporal W contr IV;;ACTIVE;2.21;2.61 +48445-1;Multisection^WO contrast;Find;Pt;Head+Neck>Larynx;Doc;MR;RAD;2;MR Larynx WO contrast;MR Larynx WO contr;;ACTIVE;2.21;2.61 +48446-9;Multisection^W contrast IV;Find;Pt;Head+Neck>Nasopharynx;Doc;CT;RAD;2;CT Nasopharynx W contrast IV;CT Nasopharynx W contr IV;;ACTIVE;2.21;2.61 +4844-7;HLA-B8;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-B8 [Presence] in Donor;HLA-B8 Donr Ql;;ACTIVE;1.0;2.56 +48447-7;Multisection^W contrast IT;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine W contrast IT;MR C-spine W contr IT;;ACTIVE;2.21;2.61 +48448-5;Multisection;Find;Pt;Upper extremity>Upper extremity artery;Doc;US;RAD;2;US Upper extremity artery;US UE a;;ACTIVE;2.21;2.61 +48449-3;Multisection^W contrast IV;Find;Pt;Head>Orbit;Doc;CT;RAD;2;CT Orbit W contrast IV;CT Orbit W contr IV;;ACTIVE;2.21;2.61 +48450-1;Multisection^WO & W contrast IT;Find;Pt;Neck>Spine.cervical;Doc;MR;RAD;2;MR Cervical spine WO and W contrast IT;MR C-spine WO+W contr IT;;ACTIVE;2.21;2.61 +48451-9;Multisection^WO & W contrast IV;Find;Pt;Head>Orbit;Doc;CT;RAD;2;CT Orbit WO and W contrast IV;CT Orbit WO+W contr IV;;ACTIVE;2.21;2.61 +48452-7;Multisection^WO & W contrast IT;Find;Pt;Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Lumbar spine WO and W contrast IT;MR L-spine WO+W contr IT;;ACTIVE;2.21;2.61 +48453-5;Multisection^WO contrast;Find;Pt;Head>Brain.temporal;Doc;MR;RAD;2;MR Brain.temporal WO contrast;MR Brain.temporal WO contr;;ACTIVE;2.21;2.61 +4845-4;HLA-B8;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B8 [Presence];HLA-B8 Ql;;ACTIVE;1.0;2.73 +48454-3;Multisection^WO & W contrast IV;Find;Pt;Chest>Clavicle.right;Doc;MR;RAD;2;MR Clavicle - right WO and W contrast IV;MR Clavicle-R WO+W contr IV;;ACTIVE;2.21;2.61 +48455-0;Multisection^WO & W contrast IV;Find;Pt;Chest>Clavicle.left;Doc;MR;RAD;2;MR Clavicle - left WO and W contrast IV;MR Clavicle-L WO+W contr IV;;ACTIVE;2.21;2.61 +48456-8;Multisection^W contrast IV;Find;Pt;Chest>Clavicle.right;Doc;MR;RAD;2;MR Clavicle - right W contrast IV;MR Clavicle-R W contr IV;;ACTIVE;2.21;2.61 +48457-6;Multisection^W contrast IV;Find;Pt;Chest>Clavicle.left;Doc;MR;RAD;2;MR Clavicle - left W contrast IV;MR Clavicle-L W contr IV;;ACTIVE;2.21;2.61 +48458-4;Multisection^WO contrast;Find;Pt;Chest>Clavicle.right;Doc;MR;RAD;2;MR Clavicle - right WO contrast;MR Clavicle-R WO contr;;ACTIVE;2.21;2.61 +48459-2;Multisection^WO contrast;Find;Pt;Chest>Clavicle.left;Doc;MR;RAD;2;MR Clavicle - left WO contrast;MR Clavicle-L WO contr;;ACTIVE;2.21;2.61 +484-6;Teicoplanin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Teicoplanin [Susceptibility] by Minimum inhibitory concentration (MIC);Teicoplanin Islt MIC;;ACTIVE;1.0;2.19 +48460-0;Multisection limited;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region limited;MR Ltd Unsp region;;ACTIVE;2.21;2.64 +48461-8;Multisection limited;Find;Pt;Neck;Doc;MR;RAD;2;MR Neck limited;MR Neck Ltd;;ACTIVE;2.21;2.61 +4846-2;HLA-Cw10(w3);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw10(w3) [Presence] in Donor;HLA-Cw10(w3) Donr Ql;;ACTIVE;1.0;2.56 +48462-6;View AP;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP;XR Knee-L AP;;ACTIVE;2.21;2.73 +48463-4;View AP;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP;XR Knee-R AP;;ACTIVE;2.21;2.73 +48464-2;Views;Find;Pt;Neck+Chest>Trachea;Doc;RF;RAD;2;RF Trachea Views;RF Trachea Views;;ACTIVE;2.21;2.64 +48465-9;Views;Find;Pt;Head+Neck>Larynx;Doc;RF;RAD;2;RF Larynx Views;RF Larynx Views;;ACTIVE;2.21;2.64 +48466-7;Views limited;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull Limited Views;XR Skull Views Ltd;;ACTIVE;2.21;2.64 +48467-5;Views 1 or 2;Find;Pt;Pelvis>Sacroiliac joint;Doc;XR;RAD;2;XR Sacroiliac Joint 1 or 2 Views;XR SIJ 1V or 2V;;ACTIVE;2.21;2.61 +48468-3;Views 2 && View PA;Find;Pt;Chest>Ribs.bilateral && Chest;Doc;XR;RAD;2;XR Ribs - bilateral 2 Views and Chest PA;XR Ribs 2V + Chest PA;;ACTIVE;2.21;2.64 +48469-1;Views 2 or 3;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine 2 or 3 Views;XR L-spine 2V or 3V;;ACTIVE;2.21;2.61 +4847-0;HLA-Cw10(w3);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw10(w3) [Presence];HLA-Cw10(w3) Ql;;ACTIVE;1.0;2.56 +48470-9;Views 3;Find;Pt;Head>Mastoid.left;Doc;XR;RAD;2;XR Mastoid - left 3 Views;XR Mastoid-L 3V;;ACTIVE;2.21;2.61 +48471-7;Views 3;Find;Pt;Head>Mastoid.right;Doc;XR;RAD;2;XR Mastoid - right 3 Views;XR Mastoid-R 3V;;ACTIVE;2.21;2.61 +48472-5;Views 3 + Swimmers;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 3 Views and Swimmers;XR T-spine 3V+Swimmers;;ACTIVE;2.21;2.61 +48473-3;Views 4;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum 4 Views;XR L-spine+Sacrum 4V;;ACTIVE;2.21;2.61 +48474-1;Views AP + lateral;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral AP and Lateral;XR Hand-Bl AP+Lat;;ACTIVE;2.21;2.61 +48475-8;Views diagnostic for implant;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Diagnostic for implant;MG Brst-Bl Dx for implant;;ACTIVE;2.21;2.61 +48476-6;Views GE 3;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right GE 3 Views;XR Foot-R GE 3V;;ACTIVE;2.21;2.61 +48477-4;Views GE 3;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left GE 3 Views;XR Foot-L GE 3V;;ACTIVE;2.21;2.61 +48478-2;Views GE 3;Find;Pt;Lower extremity.bilateral>Foot;Doc;XR;RAD;2;XR Foot - bilateral GE 3 Views;XR Foot-Bl GE 3V;;ACTIVE;2.21;2.61 +48479-0;Views GE 3;Find;Pt;Head>Facial bones;Doc;XR;RAD;2;XR Facial bones GE 3 Views;XR Face GE 3V;;ACTIVE;2.21;2.61 +48480-8;Views GE 3;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral GE 3 Views;XR Ankle-Bl GE 3V;;ACTIVE;2.21;2.61 +48481-6;Views GE 3;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral GE 3 Views;XR Elbow-Bl GE 3V;;ACTIVE;2.21;2.61 +48482-4;Views GE 3;Find;Pt;Chest>Sternoclavicular joint.bilateral;Doc;XR;RAD;2;XR Sternoclavicular joint - bilateral GE 3 Views;XR SC joint-Bl GE 3V;;ACTIVE;2.21;2.61 +48483-2;Views GE 3;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral GE 3 Views;XR Wrist-Bl GE 3V;;ACTIVE;2.21;2.61 +48484-0;Views GE 3 && view PA;Find;Pt;Chest>Ribs.right && Chest;Doc;XR;RAD;2;XR Ribs - right GE 3 Views and Chest PA;XR Ribs-R GE 3V + Chest PA;;ACTIVE;2.21;2.64 +48485-7;Views GE 3 && view PA;Find;Pt;Chest>Ribs.bilateral && Chest;Doc;XR;RAD;2;XR Ribs - bilateral GE 3 Views and Chest PA;XR Ribs-Bl GE 3V + Chest PA;;ACTIVE;2.21;2.64 +48486-5;Views GE 3 && view PA;Find;Pt;Chest>Ribs.left && Chest;Doc;XR;RAD;2;XR Ribs - left GE 3 Views and Chest PA;XR Ribs-L GE 3V + Chest PA;;ACTIVE;2.21;2.64 +48487-3;Views GE 4;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull GE 4 Views;XR Skull GE 4V;;ACTIVE;2.21;2.61 +4848-8;HLA-Cw11;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw11 [Presence] in Donor;HLA-Cw11 Donr Ql;;ACTIVE;1.0;2.56 +48488-1;Views 1 or 2;Find;Pt;Head>Mastoid.right;Doc;XR;RAD;2;XR Mastoid - right 1 or 2 Views;XR Mastoid-R 1V or 2V;;ACTIVE;2.21;2.61 +48489-9;Views 1 or 2;Find;Pt;Head>Mastoid.left;Doc;XR;RAD;2;XR Mastoid - left 1 or 2 Views;XR Mastoid-L 1V or 2V;;ACTIVE;2.21;2.61 +48490-7;Views open mouth + closed mouth;Find;Pt;Head>Temporomandibular joint.right;Doc;XR;RAD;2;XR Temporomandibular joint - right Open and Closed mouth;XR TMJ-R Open+Closed Mouth;;ACTIVE;2.21;2.61 +48491-5;Views open mouth + closed mouth;Find;Pt;Head>Temporomandibular joint.left;Doc;XR;RAD;2;XR Temporomandibular joint - left Open and Closed mouth;XR TMJ-L Open+Closed Mouth;;ACTIVE;2.21;2.61 +48492-3;Views screening for implant;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Screening for implant;MG Brst-Bl screening for implant;;ACTIVE;2.21;2.61 +48493-1;Beta-trace protein;MCnc;Pt;CSF;Qn;;CHEM;1;Beta-trace protein [Mass/volume] in Cerebral spinal fluid;Beta-trace protein CSF-mCnc;;ACTIVE;2.21;2.70 +48494-9;Complement C1 esterase inhibitor actual/Normal;RelCCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor actual/normal in Serum or Plasma;C1INH Act/Nor SerPl;;ACTIVE;2.21;2.73 +48495-6;Transferrin.carbohydrate deficient/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient/Transferrin.total in Serum or Plasma;CDT/Tf MFr SerPl;;ACTIVE;2.21;2.73 +4849-6;HLA-Cw11;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw11 [Presence];HLA-Cw11 Ql;;ACTIVE;1.0;2.56 +48496-4;Complement total hemolytic CH50 actual/Normal;RelCCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement total hemolytic CH50 actual/normal in Serum or Plasma;CH50 Act/Nor SerPl;;ACTIVE;2.21;2.73 +48497-2;Pro-hepcidin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pro-hepcidin [Mass/volume] in Serum or Plasma;Pro-hepcidin SerPl-mCnc;;ACTIVE;2.21;2.70 +48498-0;Amyloid A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Amyloid A [Mass/volume] in Serum or Plasma;Amyloid A SerPl-mCnc;;ACTIVE;2.21;2.70 +48499-8;Beta-trace protein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-trace protein [Mass/volume] in Serum or Plasma;Beta-trace protein SerPl-mCnc;;ACTIVE;2.21;2.70 +48500-3;Borrelia burgdorferi 18kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 18kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor18kD IgG CSF Ql IB;;ACTIVE;2.21;2.73 +48501-1;HLA Ab;PrThr;Pt;Ser;Ord;IA;HLA;1;HLA Ab [Presence] in Serum by Immunoassay;HLA Ab Ser Ql IA;;ACTIVE;2.21;2.73 +48502-9;Platelet glycoprotein Ia-IIa Ab.IgG;PrThr;Pt;Bld;Ord;IA;SERO;1;Platelet glycoprotein Ia/IIa IgG Ab [Presence] in Blood by Immunoassay;Plat Gp Ia/IIa IgG Bld Ql IA;;ACTIVE;2.21;2.73 +48503-7;Platelet glycoprotein Ib-Ix Ab.IgG;PrThr;Pt;Bld;Ord;IA;SERO;1;Platelet glycoprotein Ib/Ix IgG Ab [Presence] in Blood by Immunoassay;Plat Gp Ib/Ix IgG Bld Ql IA;;ACTIVE;2.21;2.73 +4850-4;HLA-Cw1;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw1 [Presence] in Donor;HLA-Cw1 Donr Ql;;ACTIVE;1.0;2.56 +48504-5;Platelet glycoprotein IIb-IIIa Ab.IgG;PrThr;Pt;Bld;Ord;IA;SERO;1;Platelet glycoprotein IIb/IIIa IgG Ab [Presence] in Blood by Immunoassay;Plat Gp IIb/IIIa IgG Bld Ql IA;;ACTIVE;2.21;2.73 +48505-2;Platelet glycoprotein IIb-IIIa Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Platelet glycoprotein IIb/IIIa Ab [Presence] in Serum by Immunoassay;Plat Gp IIb/IIIa Ab Ser Ql IA;;ACTIVE;2.21;2.73 +48506-0;Platelet glycoprotein Ib-Ix Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Platelet glycoprotein Ib/Ix Ab [Presence] in Serum by Immunoassay;Plat Gp Ib/Ix Ab Ser Ql IA;;ACTIVE;2.21;2.73 +48507-8;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Body fluid by Immunoassay;SLEV IgM Fld Ql IA;;ACTIVE;2.21;2.56 +48508-6;Measles virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Measles virus RNA [Presence] in Specimen by NAA with probe detection;MeV RNA Spec Ql NAA+probe;;ACTIVE;2.21;2.69 +48509-4;Influenza virus A & B RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Influenza virus A and B RNA [Identifier] in Specimen by NAA with probe detection;FLUAV + FLUBV RNA Spec NAA+probe;;ACTIVE;2.21;2.73 +48510-2;HIV 1 RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 1.7 log copies/mL;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 1.7 log copies/mL;HIV1 RNA SerPl NAA DL=1.7-Log#;;ACTIVE;2.21;2.73 +48511-0;HIV 1 RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 50 copies/mL;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 50 copies/mL;HIV1 RNA # SerPl NAA DL=50;;ACTIVE;2.21;2.73 +4851-2;HLA-Cw1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw1 [Presence];HLA-Cw1 Ql;;ACTIVE;1.0;2.73 +48512-8;Are you basically satisfied with your life;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Are you basically satisfied with your life [GDS];;;ACTIVE;2.21;2.64 +48513-6;Have you dropped many of your activities and interests;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Have you dropped many of your activities and interests [GDS];;;ACTIVE;2.21;2.64 +48514-4;Do you feel that your life is empty;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you feel that your life is empty [GDS];;;ACTIVE;2.21;2.64 +48515-1;Do you often get bored;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you often get bored [GDS];;;ACTIVE;2.21;2.64 +48516-9;Are you hopeful about the future;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Are you hopeful about the future [GDS];;;ACTIVE;2.21;2.64 +48517-7;Are you bothered by thoughts you cannot get out of your head;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Are you bothered by thoughts you cannot get out of your head [GDS];;;ACTIVE;2.21;2.64 +48518-5;Are you in good spirits most of the time;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Are you in good spirits most of the time [GDS];;;ACTIVE;2.21;2.64 +48519-3;Are you afraid that something bad is going to happen to you;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Are you afraid that something bad is going to happen to you [GDS];;;ACTIVE;2.21;2.64 +4852-0;HLA-Cw2;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw2 [Presence] in Donor;HLA-Cw2 Donr Ql;;ACTIVE;1.0;2.56 +48520-1;Do you feel happy most of the time;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you feel happy most of the time [GDS];;;ACTIVE;2.21;2.64 +48521-9;Do you often feel helpless;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you often feel helpless [GDS];;;ACTIVE;2.21;2.64 +48522-7;Do you often get restless and fidgety;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you often get restless and fidgety [GDS];;;ACTIVE;2.21;2.64 +48523-5;Do you prefer to stay at home, rather than going out and doing new things;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you prefer to stay at home, rather than going out and doing new things [GDS];;;ACTIVE;2.21;2.64 +48524-3;Do you frequently worry about the future;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you frequently worry about the future [GDS];;;ACTIVE;2.21;2.64 +48525-0;Do you feel you have more problems with memory than most;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you feel you have more problems with memory than most [GDS];;;ACTIVE;2.21;2.64 +48526-8;Do you think it is wonderful to be alive now;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you think it is wonderful to be alive now [GDS];;;ACTIVE;2.21;2.64 +48527-6;Often feel depressed;Find;Pt;^Patient;Ord;;H&P.HX;2;Often feel depressed;Often feel depressed;;ACTIVE;2.21;2.70 +48528-4;Do you feel pretty worthless the way you are now;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you feel pretty worthless the way you are now [GDS];;;ACTIVE;2.21;2.64 +48529-2;Do you worry a lot about the past;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you worry a lot about the past [GDS];;;ACTIVE;2.21;2.64 +485-3;Teicoplanin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Teicoplanin [Susceptibility] by Disk diffusion (KB);Teicoplanin Islt KB;;ACTIVE;1.0;2.21 +48530-0;Do you find life very exciting;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you find life very exciting [GDS];;;ACTIVE;2.21;2.64 +48531-8;Is it hard for you to get started on new projects;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Is it hard for you to get started on new projects [GDS];;;ACTIVE;2.21;2.64 +48532-6;Do you feel full of energy;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you feel full of energy [GDS];;;ACTIVE;2.21;2.64 +48533-4;Do you feel that your situation is hopeless;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you feel that your situation is hopeless [GDS];;;ACTIVE;2.21;2.64 +48534-2;Do you think that most people are better off than you are;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you think that most people are better off than you are [GDS];;;ACTIVE;2.21;2.64 +48535-9;Do you frequently get upset over little things;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you frequently get upset over little things [GDS];;;ACTIVE;2.21;2.64 +48536-7;Do you frequently feel like crying;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you frequently feel like crying [GDS];;;ACTIVE;2.21;2.64 +48537-5;Do you have trouble concentrating;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you have trouble concentrating [GDS];;;ACTIVE;2.21;2.64 +4853-8;HLA-Cw2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw2 [Presence];HLA-Cw2 Ql;;ACTIVE;1.0;2.73 +48538-3;Do you enjoy getting up in the morning;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you enjoy getting up in the morning [GDS];;;ACTIVE;2.21;2.64 +48539-1;Do you prefer to avoid social gatherings;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Do you prefer to avoid social gatherings [GDS];;;ACTIVE;2.21;2.64 +48540-9;Is it easy for you to make decisions;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Is it easy for you to make decisions [GDS];;;ACTIVE;2.21;2.64 +48541-7;Is your mind as clear as it used to be;Find;Pt;^Patient;Ord;GDS;SURVEY.GDS;4;Is your mind as clear as it used to be [GDS];;;ACTIVE;2.21;2.64 +48542-5;Geriatric depression scale (GDS) panel;-;Pt;^Patient;-;;PANEL.SURVEY.GDS;4;Geriatric depression scale (GDS) panel;;;ACTIVE;2.21;2.63 +48543-3;Geriatric depression scale (GDS).short version panel;-;Pt;^Patient;-;;PANEL.SURVEY.GDS;4;Geriatric depression scale (GDS).short version panel;;;ACTIVE;2.21;2.63 +48544-1;Geriatric depression scale total;Score;Pt;^Patient;Qn;;SURVEY.GDS;4;Geriatric depression scale (GDS) total;;;ACTIVE;2.21;2.50 +48545-8;Geriatric depression scale.short version total;Score;Pt;^Patient;Qn;;SURVEY.GDS;4;Geriatric depression scale (GDS) short version total;;;ACTIVE;2.21;2.61 +4854-6;HLA-Cw3;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw3 [Presence] in Donor;HLA-Cw3 Donr Ql;;ACTIVE;1.0;2.56 +48546-6;Clinical Care Classification (CCC) v2.5 panel;-;Pt;^Patient;-;;PANEL.SURVEY.HHCC;4;Clinical Care Classification (CCC) v2.5 panel;;;ACTIVE;2.21;2.63 +48547-4;Omaha System 2005 panel;-;Pt;XXX;-;;PANEL.SURVEY.OMAHA;4;Omaha System 2005 panel;;;ACTIVE;2.21;2.63 +48548-2;Living with HIV (LIV-HIV) panel;-;Pt;^Patient;-;;PANEL.SURVEY.LIV-HIV;4;Living with HIV (LIV-HIV) panel;;;ACTIVE;2.21;2.63 +48549-0;HIV-Signs and Symptoms Checklist (SSC) panel;-;Pt;^Patient;-;;PANEL.SURVEY.HIV-SSC;4;HIV-Signs and Symptoms Checklist (SSC) panel;;;ACTIVE;2.21;2.63 +48550-8;Quality Audit Marker (QAM) panel;-;Pt;^Patient;-;;PANEL.SURVEY.QAM;4;Quality Audit Marker (QAM) panel;;;ACTIVE;2.21;2.63 +48551-6;HIV 1 RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 400 copies/mL;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 400 copies/mL;HIV1 RNA # SerPl NAA DL=400;;ACTIVE;2.21;2.70 +48552-4;HIV 1 RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 2.6 log copies/mL;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 2.6 log copies/mL;HIV1 RNA SerPl NAA DL=2.6-Log#;;ACTIVE;2.21;2.70 +4855-3;HLA-Cw3;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw3 [Presence];HLA-Cw3 Ql;;ACTIVE;1.0;2.56 +48553-2;Muscle sarcolemma Ab;ACnc;Pt;Plr fld;Qn;;SERO;1;Muscle sarcolemma Ab [Units/volume] in Pleural fluid;Mus Sarcolemma Ab Plr-aCnc;;ACTIVE;2.21;2.69 +48554-0;Myocardium Ab;Titr;Pt;Plr fld;Qn;IF;SERO;1;Myocardium Ab [Titer] in Pleural fluid by Immunofluorescence;Myocardium Ab Titr Plr IF;;ACTIVE;2.21;2.32 +48555-7;Fetal blood;Vol;Pt;^Patient;Qn;Kleihauer-Betke;HEM/BC;1;Fetal blood [Volume] by Kleihauer-Betke method;Fetal blood Vol Patient Kleih Betke;;ACTIVE;2.21;2.73 +48556-5;Erythrocytes.fetal/1000 erythrocytes;Ratio;Pt;Bld;Qn;Kleihauer-Betke;HEM/BC;1;Erythrocytes.fetal/1000 erythrocytes [Ratio] in Blood by Kleihauer-Betke method;Fetal RBC/1000 RBC Bld Kleih Betke-Rto;;ACTIVE;2.21;2.73 +48557-3;Origin;Type;Pt;Calculus;Nom;;PATH;1;Origin of Stone;Origin Stone;;ACTIVE;2.21;2.73 +48558-1;HIV genotype;Susc;Pt;Isolate;Nom;Genotyping;ABXBACT;1;HIV genotype [Susceptibility];HIV Gentyp Islt;;ACTIVE;2.21;2.73 +48559-9;HIV genotype;Susc;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Deprecated HIV gentotype [Susceptibility];Deprecated HIV genotype Islt Genotyp;;DEPRECATED;2.21;2.36 +48560-7;Human papilloma virus genotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Human papilloma virus genotype [Identifier] in Specimen by NAA with probe detection;HPV Gentyp Spec NAA+probe;;ACTIVE;2.21;2.73 +4856-1;HLA-Cw4;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw4 [Presence] in Donor;HLA-Cw4 Donr Ql;;ACTIVE;1.0;2.56 +48561-5;Bacteria identified^^^2;Prid;Pt;XXX;Nom;Respiratory culture;MICRO;1;Bacteria # 2 identified in Specimen by Respiratory culture;Bacteria Spec Resp Cult org #2;;ACTIVE;2.21;2.69 +48562-3;Bacteria identified^^^3;Prid;Pt;XXX;Nom;Respiratory culture;MICRO;1;Bacteria # 3 identified in Specimen by Respiratory culture;Bacteria Spec Resp Cult org #3;;ACTIVE;2.21;2.69 +48563-1;Bacteria identified^^^4;Prid;Pt;XXX;Nom;Respiratory culture;MICRO;1;Bacteria # 4 identified in Specimen by Respiratory culture;Bacteria Spec Resp Cult org #4;;ACTIVE;2.21;2.69 +48564-9;Bacteria identified^^^5;Prid;Pt;XXX;Nom;Respiratory culture;MICRO;1;Bacteria # 5 identified in Specimen by Respiratory culture;Bacteria Spec Resp Cult org #5;;ACTIVE;2.21;2.69 +48565-6;Bacteria identified^^^6;Prid;Pt;XXX;Nom;Respiratory culture;MICRO;1;Bacteria # 6 identified in Specimen by Respiratory culture;Bacteria Spec Resp Cult org #6;;ACTIVE;2.21;2.69 +48566-4;Bacteria identified^^^7;Prid;Pt;XXX;Nom;Respiratory culture;MICRO;1;Bacteria # 7 identified in Specimen by Respiratory culture;Bacteria Spec Resp Cult org #7;;ACTIVE;2.21;2.69 +48567-2;Bacteria identified^^^3;Prid;Pt;XXX;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Specimen by Aerobe culture;Bacteria Spec Aerobe Cult org #3;;ACTIVE;2.21;2.69 +48568-0;Bacteria identified^^^7;Prid;Pt;XXX;Nom;Aerobic culture;MICRO;1;Bacteria # 7 identified in Specimen by Aerobe culture;Bacteria Spec Aerobe Cult org #7;;ACTIVE;2.21;2.69 +48569-8;Bacteria identified^^^8;Prid;Pt;XXX;Nom;Aerobic culture;MICRO;1;Bacteria # 8 identified in Specimen by Aerobe culture;Bacteria Spec Aerobe Cult org #8;;ACTIVE;2.21;2.69 +48570-6;Follitropin^on cycle day 10;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin [Units/volume] in Serum or Plasma --on cycle day 10;FSH D10 SerPl-aCnc;;ACTIVE;2.21;2.70 +48571-4;Follitropin^on cycle day 11;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin [Units/volume] in Serum or Plasma --on cycle day 11;FSH D11 SerPl-aCnc;;ACTIVE;2.21;2.70 +48572-2;Follitropin^on cycle day 21;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin [Units/volume] in Serum or Plasma --on cycle day 21;FSH D21 SerPl-aCnc;;ACTIVE;2.21;2.70 +48573-0;Follitropin^on cycle day 3;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Follitropin [Units/volume] in Serum or Plasma --on cycle day 3;FSH D3 SerPl-aCnc;;ACTIVE;2.21;2.70 +48574-8;Hepatitis C virus genotype;Prid;Pt;Bld;Nom;Probe.amp.tar;MICRO;1;Hepatitis C virus genotype [Identifier] in Blood by NAA with probe detection;HCV Gentyp Bld NAA+probe;;ACTIVE;2.21;2.73 +48575-5;Hepatitis C virus genotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Hepatitis C virus genotype [Identifier] in Specimen by NAA with probe detection;HCV Gentyp Spec NAA+probe;;ACTIVE;2.21;2.73 +48576-3;Hepatitis C virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.sig;MICRO;1;Hepatitis C virus RNA [Presence] in Specimen by Probe with signal amplification;HCV RNA Spec Ql Probe+sig amp;;ACTIVE;2.21;2.73 +48577-1;HFE gene.c.845G>A;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated HFE gene c.845G>A [Presence] in Blood or Tissue by Molecular genetics method;Deprecated HFE c.845G>A Bld/T Ql;;DEPRECATED;2.21;2.50 +48578-9;HFE gene.c.187G>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HFE gene c.187G>C [Presence] in Blood or Tissue by Molecular genetics method;HFE c.187G>C Bld/T Ql;;ACTIVE;2.21;2.56 +4857-9;HLA-Cw4;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw4 [Presence];HLA-Cw4 Ql;;ACTIVE;1.0;2.56 +48579-7;HFE gene.c.187C>G;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;Deprecated HFE gene c.187C>G [Presence] in Blood or Tissue by Molecular genetics method;Deprecated HFE c.187C>G Bld/T Ql;;DEPRECATED;2.21;2.40 +48580-5;KCNQ1OT1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KCNQ1OT1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KCNQ1OT1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48581-3;Lutropin^on cycle day 11;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin [Units/volume] in Serum or Plasma --on cycle day 11;LH D11 SerPl-aCnc;;ACTIVE;2.21;2.70 +48582-1;Lutropin^on cycle day 3;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin [Units/volume] in Serum or Plasma --on cycle day 3;LH D3 SerPl-aCnc;;ACTIVE;2.21;2.70 +48583-9;Lutropin^on cycle day 21;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Lutropin [Units/volume] in Serum or Plasma --on cycle day 21;LH D21 SerPl-aCnc;;ACTIVE;2.21;2.70 +48584-7;Gastric emptying time^post 100 mg sodium octanoate PO;Time;Pt;Exhl gas;Qn;NM;RAD;2;NM Exhaled gas Gastric emptying time post 100 mg sodium octanoate PO;NM ExG GE time p 100mg Na octanoate PO;;ACTIVE;2.21;2.61 +48585-4;Gastric emptying time^post 100 mg sodium acetate PO;Time;Pt;Exhl gas;Qn;NM;RAD;2;NM Exhaled gas Gastric emptying time post 100 mg sodium acetate PO;NM ExG GE time p 100mg Na acetate PO;;ACTIVE;2.21;2.61 +48586-2;Collagen crosslinked C-telopeptide;MCnc;Pt;Urine;Qn;;CHEM;1;Collagen crosslinked C-telopeptide [Mass/volume] in Urine;Collagen CTx Ur-mCnc;;ACTIVE;2.21;2.70 +4858-7;HLA-Cw5;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw5 [Presence] in Donor;HLA-Cw5 Donr Ql;;ACTIVE;1.0;2.56 +48587-0;Collagen crosslinked C-telopeptide/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Collagen crosslinked C-telopeptide/Creatinine [Ratio] in Urine;Collagen CTx/Creat Ur-Rto;;ACTIVE;2.21;2.73 +48588-8;Coccidioides sp rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Coccidioides sp rRNA [Presence] in Specimen by NAA with probe detection;Coccidioides rRNA Spec Ql NAA+probe;;ACTIVE;2.21;2.69 +48589-6;Coccidioides sp rRNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Coccidioides sp rRNA [Presence] in Isolate by NAA with probe detection;Coccidioides rRNA Islt Ql NAA+probe;;ACTIVE;2.21;2.63 +48590-4;Coagulation surface induced^after addition of APC;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --after addition of APC;aPTT after addition of APC PPP;;ACTIVE;2.21;2.73 +48591-2;Activated protein C resistance;Imp;Pt;PPP;Nom;;COAG;1;Activated protein C resistance [Interpretation] in Platelet poor plasma;aPCR PPP-Imp;;ACTIVE;2.21;2.73 +48592-0;Fibrin+Fibrinogen fragments;Titr;Pt;PPP;Qn;LA;COAG;1;Fibrin+Fibrinogen fragments [Titer] in Platelet poor plasma by Latex agglutination;FSP Titr PPP LA;;ACTIVE;2.21;2.32 +48593-8;von Willebrand panel;-;Pt;PPP;-;;PANEL.COAG;1;von Willebrand panel - Platelet poor plasma;von Willebrand Pnl PPP;;ACTIVE;2.21;2.73 +48594-6;Platelet glycoprotein IIb-IIIa Ab;PrThr;Pt;Bld;Ord;IA;SERO;1;Platelet glycoprotein IIb/IIIa Ab [Presence] in Blood by Immunoassay;Plat Gp IIb/IIIa Ab Bld Ql IA;;ACTIVE;2.21;2.73 +4859-5;HLA-Cw5;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw5 [Presence];HLA-Cw5 Ql;;ACTIVE;1.0;2.56 +48595-3;von Willebrand evaluation;Imp;Pt;PPP;Nom;;COAG;1;von Willebrand evaluation [Interpretation] in Platelet poor plasma;von Willebrand eval PPP-Imp;;ACTIVE;2.21;2.73 +48596-1;Activated protein C resistance panel;-;Pt;PPP;-;;PANEL.COAG;1;Activated protein C resistance panel - Platelet poor plasma;aPCR Pnl PPP;;ACTIVE;2.21;2.42 +48597-9;cycloSPORINE^trough;MCnc;Pt;Bld;Qn;IA;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood by Immunoassay --trough;cycloSPORINE Trough Bld IA-mCnc;;ACTIVE;2.21;2.73 +48598-7;BBS2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BBS2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BBS2 gene Mut Anl Bld/T;;ACTIVE;2.21;2.68 +48599-5;CLCN1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CLCN1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CLCN1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.68 +48600-1;VPS13B gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;VPS13B gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;VPS13B gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +48601-9;OPA1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;OPA1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;OPA1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.68 +48602-7;TGM1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TGM1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TGM1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +4860-3;HLA-Cw6;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw6 [Presence] in Donor;HLA-Cw6 Donr Ql;;ACTIVE;1.0;2.56 +48604-3;Yellow dye Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yellow dye IgE Ab RAST class [Presence] in Serum;Yellow Dye IgE RAST Ql;;ACTIVE;2.21;2.58 +48605-0;Glucose^1H post dose fructose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post dose fructose PO;Glucose 1h p fructose PO SerPl-mCnc;;ACTIVE;2.21;2.34 +48606-8;Glucose^pre dose fructose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre dose fructose PO;Glucose Pre fructose PO SerPl-mCnc;;ACTIVE;2.21;2.34 +48607-6;Glucose^30M post dose fructose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose fructose PO;Glucose 30M p fructose PO SerPl-mCnc;;ACTIVE;2.21;2.34 +48608-4;2-Hydroxyvalerate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxyvalerate/Creatinine [Mass Ratio] in Urine;2OH-valerate/Creat Ur;;DISCOURAGED;2.21;2.42 +48609-2;Adenovirus DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Urine by NAA with probe detection;HAdV DNA # Ur NAA+probe;;ACTIVE;2.21;2.73 +486-1;Teicoplanin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Teicoplanin [Susceptibility] by Serum bactericidal titer;Teicoplanin Titr SBT;;ACTIVE;1.0;2.32 +48610-0;7-Dehydrocholesterol;MCnc;Pt;Amnio fld;Qn;;CHEM;1;7-Dehydrocholesterol [Mass/volume] in Amniotic fluid;7-DHC Amn-mCnc;;ACTIVE;2.21;2.44 +4861-1;HLA-Cw6;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw6 [Presence];HLA-Cw6 Ql;;ACTIVE;1.0;2.56 +48611-8;Antibiotic tested;Prid;Pt;Isolate;Nom;;ABXBACT;1;Antibiotic tested [Identifier] against isolate;Antibiotic tested Islt;;ACTIVE;2.21;2.21 +48612-6;Hydrogen/Expired gas^45M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --45 minutes post dose lactose PO;Breath H2 45M p Lac PO;;ACTIVE;2.21;2.42 +48613-4;Hydrogen/Expired gas^15M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --15 minutes post dose lactose PO;Breath H2 15M p Lac PO;;ACTIVE;2.21;2.42 +48614-2;Cryoglobulin;PrThr;Pt;Ser;Ord;Immune diffusion;CHEM;1;Cryoglobulin [Presence] in Serum by Immune diffusion (ID);Cryoglob Ser Ql ID;;ACTIVE;2.21;2.73 +48615-9;Insulin.free & Insulin.total panel;ACnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Insulin.free and Insulin.total panel [Units/volume] - Serum or Plasma;Insulin.free+total Pnl SerPl-aCnc;;ACTIVE;2.21;2.73 +48616-7;17-Hydroxyprogesterone;ACnc;Pt;Bld.dot;Qn;;CHEM;1;17-Hydroxyprogesterone [Units/volume] in DBS;17OHP DBS-aCnc;;DISCOURAGED;2.21;2.69 +48617-5;Phosphate^post dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphate [Mass/volume] in Serum or Plasma --post dialysis;Phosphate p dialysis SerPl-mCnc;;ACTIVE;2.21;2.34 +48618-3;Cholesterol.in VLDL;MCnc;Pt;Ser/Plas.ultracentrifugate;Qn;;CHEM;1;Cholesterol in VLDL [Mass/volume] in Serum or Plasma ultracentrifugate;VLDLc SerPl.Ultracent-mCnc;;ACTIVE;2.21;2.34 +48619-1;Apolipoprotein E1;PrThr;Pt;Bld;Ord;;CHEM;1;Apolipoprotein E1 [Presence] in Blood;Apo E1 Bld Ql;;ACTIVE;2.21;2.56 +48620-9;Cholesterol;MCnc;Pt;Ser/Plas.ultracentrifugate;Qn;;CHEM;1;Cholesterol [Mass/volume] in Serum or Plasma ultracentrifugate;Cholest SerPl.Ultracent-mCnc;;ACTIVE;2.21;2.40 +48621-7;Hexacarboxylporphyrin/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin/Creatinine [Molar ratio] in 24 hour Urine;Hexa-CP/Creat 24h Ur-sRto;;ACTIVE;2.21;2.42 +48622-5;Urea nitrogen^24H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peritoneal fluid --24 hours post peritoneal dialysis;Urea nit 24h p PD Prt-mCnc;;ACTIVE;2.21;2.73 +48623-3;Bilirubin.glucuronidated+Bilirubin.albumin bound;MCnc;Pt;BldCo;Qn;;CHEM;1;Bilirubin.direct [Mass/volume] in Cord blood;Bilirub Direct BldCo-mCnc;;ACTIVE;2.21;2.73 +48624-1;Bilirubin;MCnc;Pt;BldCo;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Cord blood;Bilirub BldCo-mCnc;;ACTIVE;2.21;2.73 +48625-8;Choriogonadotropin.intact;PrThr;Pt;Body fld;Ord;;CHEM;1;Choriogonadotropin.intact [Presence] in Body fluid;HCG Intact Fld Ql;;ACTIVE;2.21;2.70 +48626-6;Creatinine^24H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal fluid --24 hours post peritoneal dialysis;Creat 24h p PD Prt-mCnc;;ACTIVE;2.21;2.73 +48627-4;Protein.monoclonal;ACnc;Pt;Urine;Qn;;CHEM;1;Protein.monoclonal [Units/volume] in Urine;M Protein Ur-aCnc;;DISCOURAGED;2.21;2.69 +48628-2;Insulin-like growth factor binding protein 3;PrThr;Pt;Urine;Ord;;CHEM;1;Insulin-like growth factor binding protein 3 [Presence] in Urine;IGF BP3 Ur Ql;;ACTIVE;2.21;2.56 +4862-9;HLA-Cw7;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw7 [Presence] in Donor;HLA-Cw7 Donr Ql;;ACTIVE;1.0;2.56 +48629-0;Urea nitrogen^post dialysis;MCnc;Pt;BldV;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Venous blood --post dialysis;BUN p dialysis BldV-mCnc;;ACTIVE;2.21;2.42 +48630-8;Creatinine^pre dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal fluid --pre dialysis;Creat pre dial Prt-mCnc;;ACTIVE;2.21;2.34 +48631-6;Bicarbonate^post dialysis;SCnc;Pt;Ser;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Serum --post dialysis;HCO3 p dialysis Ser-sCnc;;ACTIVE;2.21;2.34 +48632-4;Heptacarboxylporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/time] in 24 hour Stool;Hepta-CP 24h Stl-mRate;;ACTIVE;2.21;2.42 +48633-2;Trypsinogen I.free;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Trypsinogen I Free [Mass/volume] in DBS;Trypsinogen I Free DBS-mCnc;;ACTIVE;2.21;2.73 +48634-0;Coproporphyrin/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Coproporphyrin/Creatinine [Mass Ratio] in 24 hour Urine;Copro/Creat 24h Ur;;ACTIVE;2.21;2.42 +48635-7;Cholesterol.in LDL pattern A;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Cholesterol in LDL pattern A [Presence] in Serum or Plasma;LDLc A SerPl Ql;;ACTIVE;2.21;2.56 +48636-5;Cholesterol.in LDL pattern BII;PrThr;Pt;Ser/Plas;Ord;Electrophoresis;CHEM;1;Cholesterol in LDL pattern BII [Presence] in Serum or Plasma by Electrophoresis;LDLc BII SerPl Ql Elph;;ACTIVE;2.21;2.56 +4863-7;HLA-Cw7;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw7 [Presence];HLA-Cw7 Ql;;ACTIVE;1.0;2.56 +48637-3;Cholesterol.in LDL pattern BI;PrThr;Pt;Ser/Plas;Ord;Electrophoresis;CHEM;1;Cholesterol in LDL pattern BI [Presence] in Serum or Plasma by Electrophoresis;LDLc BI SerPl Ql Elph;;ACTIVE;2.21;2.56 +48638-1;Cryoglobulin type;Prid;Pt;Ser;Nom;Immunofixation;CHEM;1;Cryoglobulin type [Identifier] in Serum by Immunofixation;Cryoglob Typ Ser IFE;;ACTIVE;2.21;2.73 +48639-9;Urea nitrogen^post dialysis;MCnc;Pt;BldP;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Peripheral blood --post dialysis;BUN p dialysis BldP-mCnc;;ACTIVE;2.21;2.42 +48640-7;Second trimester triple maternal screen;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Deprecated Second trimester triple maternal screen [interpretation] in Serum Narrative;Deprecated 2nd trimester 3 screen Ser-Im;;DEPRECATED;2.21;2.36 +48641-5;Phosphate^pre dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphate [Mass/volume] in Serum or Plasma --pre dialysis;Phosphate pre dial SerPl-mCnc;;ACTIVE;2.21;2.34 +48642-3;Glomerular filtration rate/1.73 sq M.predicted.non black;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (MDRD);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among non-blacks [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD);GFR/BSA pr.non blk SerPlBld MDRD-ArV;;ACTIVE;2.21;2.73 +48643-1;Glomerular filtration rate/1.73 sq M.predicted.black;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (MDRD);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among blacks [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD);GFR/BSA pred.black SerPlBld MDRD-ArVRat;;ACTIVE;2.21;2.73 +48644-9;Vanillylmandelate, Homovanillate & Creatinine panel;-;24H;Urine;-;;PANEL.CHEM;1;Vanillylmandelate, Homovanillate and Creatinine panel - 24 hour Urine;VMA + HVA + Creat Pnl 24h Ur;;ACTIVE;2.21;2.63 +4864-5;HLA-Cw8;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw8 [Presence] in Donor;HLA-Cw8 Donr Ql;;ACTIVE;1.0;2.56 +48645-6;Pseudomonas sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Pseudomonas sp DNA [Identifier] in Specimen by NAA with probe detection;Pseudomonas DNA Spec NAA+probe;;ACTIVE;2.21;2.69 +48646-4;Yersinia sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Yersinia sp DNA [Identifier] in Specimen by NAA with probe detection;Yersinia DNA Spec NAA+probe;;ACTIVE;2.21;2.73 +48647-2;Ej Ab;PrThr;Pt;Ser;Ord;RIPA;SERO;1;Ej Ab [Presence] in Serum by Radioimmunoprecipitation assay (RIPA);Ej Ab Ser Ql RIPA;;ACTIVE;2.21;2.73 +48648-0;MART-1;ACnc;Pt;Tiss;Ord;Immune stain;PATH;1;Deprecated MART-1 [Presence] in Tissue by Immune stain;Deprecated MART-1 Tiss Ql ImStn;;DEPRECATED;2.21;2.36 +48649-8;OJ Ab;PrThr;Pt;Ser;Ord;RIPA;SERO;1;OJ Ab [Presence] in Serum by Radioimmunoprecipitation assay (RIPA);OJ Ab Ser Ql RIPA;;ACTIVE;2.21;2.73 +48650-6;Hepatitis B virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 500 copies/mL;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 500 copies/mL;HBV DNA # SerPl NAA DL=500;;ACTIVE;2.21;2.63 +48651-4;Borrelia burgdorferi Ab.IgM index;ACnc;Pt;Body fld;Qn;;MICRO;1;Borrelia burgdorferi IgM Ab index [Units/volume] in Body fluid;B burgdor IgM Index Fld-aCnc;;ACTIVE;2.21;2.69 +4865-2;HLA-Cw8;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw8 [Presence];HLA-Cw8 Ql;;ACTIVE;1.0;2.56 +48652-2;Clostridium tetani toxoid Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Clostridium tetani toxoid IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;C tetani Toxoid IgG sp2 Ser IA-aCnc;;ACTIVE;2.21;2.70 +48653-0;Clostridium tetani toxoid Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Clostridium tetani toxoid IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;C tetani Toxoid IgG sp1 Ser IA-aCnc;;ACTIVE;2.21;2.70 +48654-8;Corynebacterium diphtheriae toxin Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Corynebacterium diphtheriae toxin IgG Ab [Units/volume] in Serum by Immunoassay;C diphtheriae Tox IgG Ser IA-aCnc;;ACTIVE;2.21;2.73 +48655-5;Corynebacterium diphtheriae toxin Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Corynebacterium diphtheriae toxin Ab [Units/volume] in Serum by Immunoassay --2nd specimen;C diphtheriae Tox Ab sp2 Ser IA-aCnc;;ACTIVE;2.21;2.73 +48656-3;Ganglioside GD1a Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1a Ab [Units/volume] in Serum by Immunoassay;GD1a Gangl Ab Ser IA-aCnc;;ACTIVE;2.21;2.73 +48657-1;Ganglioside GM2 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM2 Ab [Units/volume] in Serum by Immunoassay;GM2 Gangl Ab Ser IA-aCnc;;ACTIVE;2.21;2.70 +48658-9;Ganglioside GQ1b Ab;ACnc;Pt;Ser;Qn;Molgen;SERO;1;Deprecated Ganglioside GQ1b Ab [Units/volume] in Serum by Molgen;Deprecated GQ1b Gangl Ab Ser-aCnc;;DEPRECATED;2.21;2.70 +48659-7;Hepatitis B virus precore codon 28;Prid;Pt;Ser;Nom;Probe.amp.tar;MICRO;1;Deprecated Hepatitis B virus precore codon 28 [Identifier] in Serum by Probe and target amplification method;Deprecated HBV preC codon 28 Ser PCR;;DEPRECATED;2.21;2.42 +4866-0;HLA-Cw9(w3);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Cw9(w3) [Presence] in Donor;HLA-Cw9(w3) Donr Ql;;ACTIVE;1.0;2.56 +48660-5;Ganglioside GM1 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 Ab [Units/volume] in Serum by Immunoassay;GM1 Gangl Ab Ser IA-aCnc;;ACTIVE;2.21;2.70 +48661-3;Lymphocyte proliferation.100 umol beryllium stimulation^5D post incubation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 100 umol beryllium [Ratio] in Blood --5 days post incubation;LPT 100 umol Be 5D Bld-Rto;;ACTIVE;2.21;2.70 +48662-1;Lymphocyte proliferation.phytohemagglutinin stimulation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by phytohemagglutinin [Ratio] in Blood;LPT PHA Bld-Rto;;ACTIVE;2.21;2.73 +48663-9;YKL-40;MCnc;Pt;Ser;Qn;;CHEM;1;YKL-40 [Mass/volume] in Serum;YKL-40 Ser-mCnc;;ACTIVE;2.21;2.70 +48664-7;Fibrinogen;MCnc;Pt;PPP;Qn;Coag.derived;COAG;1;Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation.derived;Fibrinogen PPP Coag.derived-mCnc;;ACTIVE;2.21;2.73 +48665-4;IgA.intrathecally synthesized;MCnc;Pt;Ser+CSF;Qn;;CHEM;1;IgA.intrathecally synthesized [Mass/volume] in Serum and CSF;IgA.IT Ser+CSF-mCnc;;ACTIVE;2.21;2.70 +48666-2;IgG.intrathecally synthesized;MCnc;Pt;Ser+CSF;Qn;;CHEM;1;IgG.intrathecally synthesized [Mass/volume] in Serum and CSF;IgG.IT Ser+CSF-mCnc;;ACTIVE;2.21;2.70 +48667-0;IgM.intrathecally synthesized;MCnc;Pt;Ser+CSF;Qn;;CHEM;1;IgM.intrathecally synthesized [Mass/volume] in Serum and CSF;IgM.IT Ser+CSF-mCnc;;ACTIVE;2.21;2.70 +48668-8;Protein fractions.oligoclonal bands.IT;PrThr;Pt;Ser+CSF;Ord;;CHEM;1;Protein fractions.oligoclonal bands.intrathecal [Presence] in Serum and CSF;Oligoclonal Bands.IT Ser+CSF Ql;;ACTIVE;2.21;2.73 +48669-6;Albumin & Immunoglobulin Quotient;Imp;Pt;Ser+CSF;Nom;;CHEM;1;Albumin and Immunoglobulin Quotient [Interpretation] in Serum and CSF;Albumin & Ig Quotient Ser+CSF-Imp;;ACTIVE;2.21;2.38 +48670-4;IgVH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;IgVH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;IgVH gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +48671-2;Prostate cancer risk;Likelihood;Pt;^Patient;Qn;Estimated;CHEM;1;Prostate cancer risk [Likelihood] by Estimated;Prostate cancer risk Patient Est;;ACTIVE;2.21;2.73 +48672-0;Clinical cytogeneticist;ID;Pt;XXX;Nom;;MOLPATH;1;Clinical cytogeneticist [Identifier] in Specimen;Clinical cytogeneticist Spec;;ACTIVE;2.21;2.73 +48673-8;EBV-LMP Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;EBV-LMP Ag [Presence] in Tissue by Immune stain;EBV-LMP Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +48674-6;Genetic diseases;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH;1;Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal;Genetic diseases Bld/T FISH;;ACTIVE;2.21;2.73 +48675-3;HER2;Arb;Pt;Tiss;Nom;FISH;MOLPATH;1;Deprecated HER2 in Tissue by FISH Nominal;Deprecated Her2 Tiss FISH;;DEPRECATED;2.21;2.61 +48676-1;HER2;Imp;Pt;Tiss;Nom;;PATH;1;HER2 [Interpretation] in Tissue;Her2 Tiss-Imp;;ACTIVE;2.21;2.73 +48677-9;Cancer Ag 125;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cancer Ag 125 [Presence] in Tissue by Immune stain;Cancer Ag125 Tiss Ql ImStn;;ACTIVE;2.21;2.73 +4867-8;HLA-Cw9(w3);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Cw9(w3) [Presence];HLA-Cw9(w3) Ql;;ACTIVE;1.0;2.56 +48678-7;P57 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;P57 Ag [Presence] in Tissue by Immune stain;P57 Ag Tiss Ql ImStn;;ACTIVE;2.21;2.73 +48679-5;Pancytokeratin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Pancytokeratin Ag [Presence] in Tissue by Immune stain;Pan CK Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +48680-3;PAX5 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PAX5 Ag [Presence] in Tissue by Immune stain;PAX5 Ag Tiss Ql ImStn;;ACTIVE;2.21;2.73 +48681-1;Plasma cell Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Plasma cell Ag [Presence] in Tissue by Immune stain;Plasma cell Ag Tiss Ql ImStn;;ACTIVE;2.21;2.56 +48682-9;Smooth muscle myosin heavy chain Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Smooth muscle myosin heavy chain Ag [Presence] in Tissue by Immune stain;SM-MHC Ag Tiss Ql ImStn;;ACTIVE;2.21;2.73 +48683-7;Streptococcus agalactiae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Specimen by NAA with probe detection;Gp B Strep DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +48684-5;X & Y chromosome^post bone marrow transplant;Imp;Pt;Bld/Bone mar;Nom;FISH;MOLPATH;1;X and Y chromosome [Interpretation] in Blood or Marrow by FISH--post bone marrow transplant;X & Y chrom p BM trpt Bld/Mar FISH-Imp;;ACTIVE;2.21;2.73 +48685-2;Para aminosalicylate 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Para aminosalicylate 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;PAS 10 ug/mL Islt SlowMyco;;ACTIVE;2.21;2.26 +4868-6;HLA-Dw10;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw10 [Presence] in Donor;HLA-Dw10 Donr Ql;;ACTIVE;1.0;2.56 +48686-0;Salmonella paratyphi C Ab;Titr;Pt;Ser;Qn;;MICRO;1;Salmonella paratyphi C Ab [Titer] in Serum;S Paraty C Ab Titr Ser;;ACTIVE;2.21;2.32 +48687-8;Multisection^WO contrast;Find;Pt;Head>Skull.base;Doc;MR;RAD;2;MR Skull base WO contrast;MR Skull.base WO contr;;ACTIVE;2.21;2.61 +48688-6;Multisection;Find;Pt;Upper extremity.right>Upper extremity vein;Doc;US;RAD;2;US Upper extremity vein - right;US UE v-R;;ACTIVE;2.21;2.61 +48689-4;Multisection;Find;Pt;Upper extremity.left>Upper extremity vein;Doc;US;RAD;2;US Upper extremity vein - left;US UE v-L;;ACTIVE;2.21;2.61 +48690-2;Multisection;Find;Pt;Upper extremity.bilateral>Upper extremity vein;Doc;US;RAD;2;US Upper extremity vein - bilateral;US UE v-Bl;;ACTIVE;2.21;2.61 +48691-0;Multisection;Find;Pt;Lower extremity.right>Lower extremity vein;Doc;US;RAD;2;US Lower extremity vein - right;US LE v-R;;ACTIVE;2.21;2.61 +48692-8;Multisection;Find;Pt;Lower extremity.left>Lower extremity vein;Doc;US;RAD;2;US Lower extremity vein - left;US LE v-L;;ACTIVE;2.21;2.61 +48693-6;Multisection;Find;Pt;Lower extremity>Lower extremity artery;Doc;US;RAD;2;US Lower extremity artery;US LE a;;ACTIVE;2.21;2.61 +4869-4;HLA-Dw10;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw10 [Presence];HLA-Dw10 Ql;;ACTIVE;1.0;2.56 +48694-4;Multisection^WO & W contrast IV;Find;Pt;Head>Brain.temporal;Doc;MR;RAD;2;MR Brain.temporal WO and W contrast IV;MR Brain.temporal WO+W contr IV;;ACTIVE;2.21;2.61 +48695-1;View;Find;Pt;Head>Skull.base;Doc;XR;RAD;2;XR Skull base Single view;XR Skull.base 1V;;ACTIVE;2.21;2.64 +48696-9;Views^W contrast intra salivary duct;Find;Pt;Head>Submandibular gland.right;Doc;RF;RAD;2;RF Submandibular gland - right Views W contrast intra salivary duct;RF Submand gland-R Vs W contr intra SD;;ACTIVE;2.21;2.64 +48697-7;Views;Find;Pt;Head>Skull.base;Doc;XR;RAD;2;XR Skull base Views;XR Skull.base Views;;ACTIVE;2.21;2.64 +48698-5;Views^W contrast intra salivary duct;Find;Pt;Head>Submandibular gland.bilateral;Doc;RF;RAD;2;RF Submandibular gland - bilateral Views W contrast intra salivary duct;RF Submand gland-Bl Vs W contr intra SD;;ACTIVE;2.21;2.64 +48699-3;Views open mouth + closed mouth;Find;Pt;Head>Temporomandibular joint.unilateral;Doc;XR;RAD;2;XR Temporomandibular joint - unilateral Open and Closed mouth;XR TMJ-Ul Open+Closed Mouth;;ACTIVE;2.21;2.61 +48700-9;Thyrotropin releasing hormone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Thyrotropin releasing hormone [Mass] of Dose;Thyrotropin releasing horm Dose;;ACTIVE;2.21;2.69 +48701-7;Luteinizing releasing hormone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Luteinizing releasing hormone [Mass] of Dose;Luteinizing releasing horm Dose;;ACTIVE;2.21;2.69 +4870-2;HLA-Dw11(w7);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw11(w7) [Presence] in Donor;HLA-Dw11(w7) Donr Ql;;ACTIVE;1.0;2.56 +48702-5;Spermatozoa.immature/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Immature/100 spermatozoa in Semen;Sperm Immature NFr Smn;;ACTIVE;2.21;2.73 +48703-3;Hematocrit;VFr;Pt;Bld;Qn;Estimated;HEM/BC;1;Hematocrit [Volume Fraction] of Blood by Estimated;Hct VFr Bld Est;;ACTIVE;2.21;2.73 +48704-1;Unidentified cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Unidentified cells [#/volume] in Blood;Unident Cells # Bld;;ACTIVE;2.21;2.70 +48705-8;Leukocytes+Platelets;Morph;Pt;Bld;Nom;;HEM/BC;1;Leukocytes+Platelets [Morphology] in Blood;WBC+Platelets Bld;;ACTIVE;2.21;2.73 +48706-6;Reticulocyte mean volume;EntVol;Pt;Retic;Qn;;HEM/BC;1;Reticulocyte mean volume [Entitic volume] in Reticulocytes;RMV Retic;;ACTIVE;2.21;2.73 +48707-4;Hemoglobin C crystals;PrThr;Pt;RBC;Ord;Microscopy.light;HEM/BC;1;Hemoglobin C crystals [Presence] in Red Blood Cells by Light microscopy;Hgb C Cry RBC Ql Micro;;ACTIVE;2.21;2.73 +48708-2;Erythrocytes.fresh/100 erythrocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Erythrocytes.fresh/100 erythrocytes in Cerebral spinal fluid by Manual count;RBC.fresh/100 RBC NFr CSF Manual;;ACTIVE;2.21;2.73 +48709-0;Burr cells/100 erythrocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Burr cells/100 erythrocytes in Cerebral spinal fluid by Manual count;Burr Cells/100 RBC NFr CSF Manual;;ACTIVE;2.21;2.34 +4871-0;HLA-Dw11(w7);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw11(w7) [Presence];HLA-Dw11(w7) Ql;;ACTIVE;1.0;2.56 +48710-8;Eosinophils;PrThr;Pt;XXX;Ord;Microscopy.light;HEM/BC;1;Eosinophils [Presence] in Specimen by Light microscopy;Eosinophil Spec Ql Micro;;ACTIVE;2.21;2.73 +48711-6;Hemoglobin.free^post transfusion reaction;MCnc;Pt;Plas;Qn;;HEM/BC;1;Free Hemoglobin [Mass/volume] in Plasma --after transfusion reaction;Hgb Free p transf rx Plas-mCnc;;ACTIVE;2.21;2.70 +48712-4;Microscopic observation;Prid;Pt;Genital;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Genital specimen by Gram stain;Gram Stn Genital;;ACTIVE;2.21;2.73 +48713-2;Bartonella quintana Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IF;MICRO;1;Bartonella quintana IgG Ab [Units/volume] in Serum or Plasma by Immunofluorescence;B quintana IgG SerPl IF-aCnc;;ACTIVE;2.21;2.69 +48714-0;Leishmania tropica Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Leishmania tropica IgM Ab [Units/volume] in Serum by Immunofluorescence;L tropica IgM Ser IF-aCnc;;ACTIVE;2.21;2.69 +48715-7;Leishmania tropica Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Leishmania tropica IgG Ab [Units/volume] in Serum by Immunofluorescence;L tropica IgG Ser IF-aCnc;;ACTIVE;2.21;2.69 +48716-5;La Crosse virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;La Crosse virus IgG Ab [Units/volume] in Serum by Immunoassay;LACV IgG Ser IA-aCnc;;ACTIVE;2.21;2.73 +48717-3;Leishmania mexicana Ab.IgM;ACnc;Pt;Ser;Qn;IF;MICRO;1;Leishmania mexicana IgM Ab [Units/volume] in Serum by Immunofluorescence;L mexicana IgM Ser IF-aCnc;;ACTIVE;2.21;2.69 +48718-1;Leishmania mexicana Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Leishmania mexicana IgG Ab [Units/volume] in Serum by Immunofluorescence;L mexicana IgG Ser IF-aCnc;;ACTIVE;2.21;2.69 +48719-9;Coxiella burnetii phase 2 Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Presence] in Serum by Immunofluorescence;C burnet Ph2 IgG Ser Ql IF;;ACTIVE;2.21;2.73 +48720-7;Coxiella burnetii phase 1 Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Presence] in Serum by Immunofluorescence;C burnet Ph1 IgG Ser Ql IF;;ACTIVE;2.21;2.73 +48721-5;Bartonella henselae Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Bartonella henselae IgG Ab [Units/volume] in Serum by Immunofluorescence;B henselae IgG Ser IF-aCnc;;ACTIVE;2.21;2.73 +48722-3;Microscopic observation;Prid;Pt;Body fld;Nom;Crystal violet stain;MICRO;1;Microscopic observation [Identifier] in Body fluid by Crystal violet stain;CV Stn Fld;;ACTIVE;2.21;2.21 +48723-1;Epstein Barr virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus Ab [Presence] in Serum by Immunofluorescence;EBV Ab Ser Ql IF;;ACTIVE;2.21;2.56 +48724-9;Bacteria identified^^^3;Prid;Pt;Bld;Nom;Culture;MICRO;1;Bacteria # 3 identified in Blood by Culture;Bacteria Bld Cult org #3;;ACTIVE;2.21;2.21 +48725-6;Hemoglobin^pre therapeutic phlebotomy;MCnc;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Blood --pre therapeutic phlebotomy;Hgb pre therapeutic phlebotomy Bld-mCnc;;ACTIVE;2.21;2.73 +48726-4;JAK2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;JAK2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;JAK2 gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +48727-2;Bacteria identified^^^2;Prid;Pt;Bld;Nom;Culture;MICRO;1;Bacteria # 2 identified in Blood by Culture;Bacteria Bld Cult org #2;;ACTIVE;2.21;2.68 +4872-8;HLA-Dw12;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw12 [Presence] in Donor;HLA-Dw12 Donr Ql;;ACTIVE;1.0;2.56 +48728-0;NCF1+NCF2+CYBB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NCF1+NCF2+CYBB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NCF1+NCF2+CYBB gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +48729-8;CYBA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CYBA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYBA gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +48730-6;X linked heterotaxy;Prid;Pt;Bld/Tiss;Nar;FISH;MOLPATH;1;X linked heterotaxy [Identifier] in Blood or Tissue by FISH Narrative;X linked heterotaxy Bld/T FISH;;ACTIVE;2.21;2.61 +48731-4;Complement C4;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Complement C4 [Presence] in Serum or Plasma;C4 SerPl Ql;;ACTIVE;2.21;2.73 +48732-2;NCF1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NCF1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NCF1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48733-0;NCF2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NCF2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NCF2 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48734-8;CYBB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CYBB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CYBB gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +48735-5;Guidance for localization;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for localization of Breast;MG Guided Brst Loc;;ACTIVE;2.21;2.64 +4873-6;HLA-Dw12;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw12 [Presence];HLA-Dw12 Ql;;ACTIVE;1.0;2.56 +48736-3;Guidance for injection of sentinel lymph node;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for sentinel lymph node injection of Breast - left;MG Guided Brst-L Sentinel LN inj;;ACTIVE;2.21;2.64 +48737-1;Views 3;Find;Pt;Upper extremity>Wrist+Hand;Doc;XR;RAD;2;XR Wrist and Hand 3 Views;XR Wrist+Hand 3V;;ACTIVE;2.21;2.61 +48738-9;Views 3;Find;Pt;Upper extremity.bilateral>Wrist+Hand;Doc;XR;RAD;2;XR Wrist - bilateral and Hand - bilateral 3 Views;XR Wrist+Hand-Bl 3V;;ACTIVE;2.21;2.61 +48739-7;Guidance for injection of sentinel lymph node;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for sentinel lymph node injection of Breast - right;MG Guided Brst-R Sentinel LN inj;;ACTIVE;2.21;2.64 +48740-5;Guidance for injection of sentinel lymph node;Find;Pt;Breast;Doc;MG;RAD;2;MG Guidance for sentinel lymph node injection of Breast;MG Guided Brst Sentinel LN inj;;ACTIVE;2.21;2.64 +48741-3;Bordetella pertussis;PrThr;Pt;Nph;Ord;Organism specific culture;MICRO;1;Bordetella pertussis [Presence] in Nasopharynx by Organism specific culture;B pert Nph Ql Cult;;ACTIVE;2.21;2.73 +48742-1;Multisection;Find;Pt;Pelvis>Scrotum+Testicle;Doc;US.doppler;RAD;2;US.doppler Scrotum and testicle;DOP Scrotum+Test;;ACTIVE;2.21;2.61 +48743-9;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Retroperitoneum WO and W contrast IV;CT Retroperitoneum WO+W contr IV;;ACTIVE;2.21;2.61 +4874-4;HLA-Dw13;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw13 [Presence] in Donor;HLA-Dw13 Donr Ql;;ACTIVE;1.0;2.56 +48744-7;View 1;Find;Pt;Pelvis;Nar;XR;RAD;2;Deprecated Pelvis X-ray View;Deprecated Pelvis XR 1V;;DEPRECATED;2.21;2.36 +48745-4;Views;Find;Pt;Mandible.left;Doc;XR;RAD;2;Deprecated Mandible - left X-ray;Deprecated Mandible-L XR;;DEPRECATED;2.21;2.58 +48746-2;Views GE 3;Find;Pt;Pelvis>Sacroiliac joint.bilateral;Doc;XR;RAD;2;XR Sacroiliac joint - bilateral GE 3 Views;XR SIJ-Bl GE 3V;;ACTIVE;2.21;2.61 +48747-0;Views GE 4;Find;Pt;Head>Orbit.bilateral;Doc;XR;RAD;2;XR Orbit - bilateral GE 4 Views;XR Orbit-Bl GE 4V;;ACTIVE;2.21;2.61 +48748-8;Views oblique;Find;Pt;XXX>Spine;Doc;XR;RAD;2;XR Spine Oblique Views;XR Spine Views Obl;;DISCOURAGED;2.21;2.64 +48749-6;Views oblique;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Oblique Views;XR T-spine Views Obl;;ACTIVE;2.21;2.64 +48750-4;3-Hydroxy fatty acids pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;3-Hydroxy fatty acids pattern [Interpretation] in Serum or Plasma;3OH FA pattern SerPl-Imp;;ACTIVE;2.21;2.50 +4875-1;HLA-Dw13;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw13 [Presence];HLA-Dw13 Ql;;ACTIVE;1.0;2.56 +48751-2;3-Hydroxypalmitate.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxypalmitate.free (3-OH-C16:0) [Moles/volume] in Serum or Plasma;3OH-palmitate.free SerPl-sCnc;;ACTIVE;2.21;2.42 +48752-0;3-Hydroxymyristate.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxymyristate.free (3-OH-C14:0) [Moles/volume] in Serum or Plasma;3OH-myristate.free SerPl-sCnc;;ACTIVE;2.21;2.42 +48753-8;3-Hydroxydodecanoate.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydodecanoate.free (3-OH-C12:0) [Moles/volume] in Serum or Plasma;3OH-dodecanoate.free SerPl-sCnc;;ACTIVE;2.21;2.42 +48754-6;3-Hydroxydodecanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydodecanoate (3-OH-C12:0) [Moles/volume] in Serum or Plasma;3OH-dodecanoate SerPl-sCnc;;ACTIVE;2.21;2.42 +48755-3;3-Hydroxydecanoate.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydecanoate.free (3-OH-C10:0) [Moles/volume] in Serum or Plasma;3OH-decanoate.free SerPl-sCnc;;ACTIVE;2.21;2.42 +48756-1;3-Hydroxyoctanoate.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyoctanoate.free (3-OH-C8:0) [Moles/volume] in Serum or Plasma;3OH-octanoate.free SerPl-sCnc;;ACTIVE;2.21;2.42 +48757-9;3-Hydroxyoctanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyoctanoate (3-OH-C8:0) [Moles/volume] in Serum or Plasma;3OH-octanoate SerPl-sCnc;;ACTIVE;2.21;2.42 +48758-7;3-Hydroxyhexanoate.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyhexanoate.free (3-OH-C6:0) [Moles/volume] in Serum or Plasma;3OH-hexanoate.free SerPl-sCnc;;ACTIVE;2.21;2.42 +48759-5;3-Hydroxyhexanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyhexanoate (3-OH-C6:0) [Moles/volume] in Serum or Plasma;3OH-hexanoate SerPl-sCnc;;ACTIVE;2.21;2.42 +48760-3;3-Hydroxy fatty acid panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;3-Hydroxy fatty acid panel - Serum or Plasma;3OH FA Pnl SerPl;;ACTIVE;2.21;2.42 +48761-1;3-Hydroxypalmitate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxypalmitate (3-OH-C16:0) [Moles/volume] in Serum or Plasma;3OH-palmitate SerPl-sCnc;;ACTIVE;2.21;2.42 +48762-9;3-Hydroxymyristate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxymyristate (3-OH-C14:0) [Moles/volume] in Serum or Plasma;3OH-myristate SerPl-sCnc;;ACTIVE;2.21;2.42 +48763-7;3-Hydroxydecanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydecanoate (3-OH-C10:0) [Moles/volume] in Serum or Plasma;3OH-decanoate SerPl-sCnc;;ACTIVE;2.21;2.42 +48764-5;Summary purpose;Find;Pt;^CCD;Doc;;DOC.MISC;2;Summary purpose CCD Document;Summary purpose CCD Doc;;ACTIVE;2.21;2.73 +48765-2;Allergies &or adverse reactions;Find;Pt;^Patient;Doc;;DOC.MISC;2;Allergies and adverse reactions Document;Allergies &or adverse reactions Doc;;ACTIVE;2.21;2.73 +48766-0;Information source;Type;Pt;{system};Nom;;DOC.MISC;2;Information source;Source of info;;ACTIVE;2.21;2.73 +48767-8;Annotation comment;Imp;Pt;{system};Nar;;DOC.MISC;2;Annotation comment [Interpretation] Narrative;Annotation comment Imp;;ACTIVE;2.21;2.73 +48768-6;Payment sources;Find;Pt;^Patient;Doc;;DOC.MISC;2;Payment sources Document;Payment sources Doc;;ACTIVE;2.21;2.73 +4876-9;HLA-Dw14;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw14 [Presence] in Donor;HLA-Dw14 Donr Ql;;ACTIVE;1.0;2.56 +48769-4;Continuity of Care panel;-;Pt;^Patient;-;;PANEL.DOC;2;Continuity of Care panel;Continuity of Care Pnl;;ACTIVE;2.21;2.63 +48770-2;Biophysical profile panel;-;Pt;^Fetus;-;US;PANEL.OB.US;2;Fetal Biophysical profile panel US;Fet BPP Pnl US;;ACTIVE;2.21;2.73 +48771-0;Immunoglobulin light chains.kappa;MCnc;Pt;CSF;Qn;;CHEM;1;Kappa light chains [Mass/volume] in Cerebral spinal fluid;Kappa LC CSF-mCnc;;ACTIVE;2.21;2.63 +48772-8;Immunoglobulin light chains.lambda;MCnc;Pt;CSF;Qn;;CHEM;1;Lambda light chains [Mass/volume] in Cerebral spinal fluid;Lambda LC CSF-mCnc;;ACTIVE;2.21;2.63 +48773-6;Immunoglobulin light chains.kappa/Immunoglobulin light chains.lambda;MRto;Pt;CSF;Qn;;CHEM;1;Kappa light chains/Lambda light chains [Mass Ratio] in Cerebral spinal fluid;Kappa LC/Lambda CSF;;ACTIVE;2.21;2.63 +48774-4;Immunoglobulin light chains.kappa.free;MCnc;Pt;CSF;Qn;;CHEM;1;Kappa light chains.free [Mass/volume] in Cerebral spinal fluid;Kappa LC Free CSF-mCnc;;ACTIVE;2.21;2.63 +48775-1;Immunoglobulin light chains.lambda.free;MCnc;Pt;CSF;Qn;;CHEM;1;Lambda light chains.free [Mass/volume] in Cerebral spinal fluid;Lambda LC Free CSF-mCnc;;ACTIVE;2.21;2.63 +48776-9;Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda.free;MRto;Pt;CSF;Qn;;CHEM;1;Kappa light chains.free/Lambda light chains.free [Mass Ratio] in Cerebral spinal fluid;Kappa LC Free/Lambda Free CSF;;ACTIVE;2.21;2.73 +4877-7;HLA-Dw14;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw14 [Presence];HLA-Dw14 Ql;;ACTIVE;1.0;2.56 +48777-7;Immunoglobulin light chains.kappa.free/Albumin;RelRto;Pt;Ser+CSF;Qn;;CHEM;1;Kappa light chains.free/Albumin in Serum and CSF;Kappa LC Free/Alb Ser+CSF;;ACTIVE;2.21;2.63 +48778-5;Erythrocytes.nucleated/100 cells;NFr;Pt;CSF;Qn;;HEM/BC;1;Nucleated erythrocytes/100 cells in Cerebral spinal fluid;nRBC/total cells NFr CSF;;ACTIVE;2.21;2.73 +48779-3;SPL indexing data elements section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Structured product labelling indexing data elements section;FDA insert SPL indexing data elements;;ACTIVE;2.21;2.34 +48780-1;SPL listing data elements section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Structured product labelling listing data elements section;FDA insert SPL listing data elements;;ACTIVE;2.21;2.34 +48781-9;CYP21A2 gene targeted mutation analysis;Prid;Pt;Amnio fld;Nom;Molgen;MOLPATH.MUT;1;CYP21A2 gene mutations found [Identifier] in Amniotic fluid by Molecular genetics method Nominal;CYP21A2 Mut Anl Amn;;ACTIVE;2.21;2.68 +48782-7;Dipyrone Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dipyrone IgE Ab RAST class [Presence] in Serum;Dipyrone IgE RAST Ql;;ACTIVE;2.21;2.58 +48783-5;Dipyrone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dipyrone IgE Ab [Units/volume] in Serum;Dipyrone IgE Qn;;ACTIVE;2.21;2.42 +48784-3;Herpes simplex virus 2 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes simplex virus 2 Ab [Presence] in Serum by Immunoassay;HSV2 Ab Ser Ql IA;;ACTIVE;2.21;2.56 +4878-5;HLA-Dw15;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw15 [Presence] in Donor;HLA-Dw15 Donr Ql;;ACTIVE;1.0;2.56 +48785-0;Prostaglandin D2;MCnc;Pt;Body fld;Qn;;CHEM;1;Prostaglandin D2 [Mass/volume] in Body fluid;Prostaglandin D2 Fld-mCnc;;ACTIVE;2.21;2.42 +48786-8;Renin^30M pre XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --30 minutes pre XXX challenge;Renin 30M pre chal Plas-cCnc;;ACTIVE;2.21;2.42 +48787-6;Glucose^24H post peritoneal dialysis;MCnc;Pt;Periton fld;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal fluid --24 hours post peritoneal dialysis;Glucose 24h p PD Prt-mCnc;;ACTIVE;2.21;2.34 +48788-4;Creatinine peritoneal dialysis clearance;VRat;Pt;Dial fld prt+Ser/Plas;Qn;;CHEM;1;Creatinine peritoneal dialysis clearance;Creat Cl DiafP+SerPl-vRate;;ACTIVE;2.21;2.30 +48789-2;Creatinine peritoneal dialysis clearance/1.73 sq M;ArVRat;Pt;Dial fld prt+Ser/Plas;Qn;;CHEM;1;Creatinine peritoneal dialysis clearance/1.73 sq M;Creat Cl/1.73 sq M DiafP+SerPl-ArVRat;;ACTIVE;2.21;2.34 +487-9;Temafloxacin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Temafloxacin [Susceptibility] by Minimum lethal concentration (MLC);Temafloxacin Islt MLC;;ACTIVE;1.0;2.19 +48790-0;Creatinine;MRat;XXX;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/time] in unspecified time Peritoneal dialysis fluid;Creat ?Tm DiafP-mRate;;ACTIVE;2.21;2.21 +48791-8;Urea nitrogen peritoneal dialysis clearance/1.73 sq M;ArVRat;Pt;Dial fld prt+Ser/Plas;Qn;;CHEM;1;Urea nitrogen peritoneal dialysis clearance/1.73 sq M;Urea nit Cl/1.73 sq M DiafP+SerPl-ArVRat;;ACTIVE;2.21;2.44 +48792-6;Necroinflammatory activity score;Score;Pt;Ser/Plas;Qn;;CHEM;1;Necroinflammatory activity score;Necroinflammatory act score SerPl;;ACTIVE;2.21;2.73 +4879-3;HLA-Dw15;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw15 [Presence];HLA-Dw15 Ql;;ACTIVE;1.0;2.56 +48793-4;Necroinflammatory activity grade;Find;Pt;Ser/Plas;Ord;;CHEM;1;Necroinflammatory activity grade;Necroinflammatory act grade SerPl Ql;;ACTIVE;2.21;2.73 +48794-2;Fibrosis stage;Find;Pt;Ser/Plas;Ord;;CHEM;1;Fibrosis stage;Fibrosis stage SerPl Ql;;ACTIVE;2.21;2.73 +48795-9;Liver fibrosis score;Score;Pt;Ser/Plas;Qn;Calculated.FibroSure;CHEM;1;Fibrosis score;Liver fibr score SerPl Calc.FibroSure;;ACTIVE;2.21;2.73 +48796-7;Hepatitis C virus FibroSURE panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Hepatitis C virus FibroSURE panel - Serum or Plasma;HCV FibroSURE Pnl SerPl;;ACTIVE;2.21;2.73 +48797-5;Organic acids panel;-;Pt;Urine;-;;PANEL.CHEM;1;Organic acids panel - Urine;Organic Acids Pnl Ur;;ACTIVE;2.21;2.73 +48798-3;First trimester maternal screen panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;First trimester maternal screen panel - Serum or Plasma;1st trimester maternal scn Pnl SerPl;;ACTIVE;2.21;2.73 +48799-1;Second trimester penta maternal screen panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Second trimester penta maternal screen panel - Serum or Plasma;2nd trimester 5 screen Pnl SerPl;;ACTIVE;2.21;2.73 +48800-7;Second trimester quad maternal screen panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Second trimester quad maternal screen panel - Serum or Plasma;2nd trimester 4 screen Pnl SerPl;;ACTIVE;2.21;2.73 +4880-1;HLA-Dw16;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw16 [Presence] in Donor;HLA-Dw16 Donr Ql;;ACTIVE;1.0;2.56 +48802-3;Alpha-1-fetoprotein panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Alpha-1-Fetoprotein panel - Serum or Plasma;AFP Pnl SerPl;;ACTIVE;2.21;2.73 +48803-1;Neural tube defect risk;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Neural tube defect risk [Likelihood] in Fetus;Neural tube defect risk Fetus;;ACTIVE;2.21;2.73 +48804-9;Taenia solium Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Taenia solium Ag [Presence] in Stool;T sol Ag Stl Ql;;ACTIVE;2.21;2.56 +48805-6;Platelet aggregation panel;-;Pt;PRP;-;;PANEL.COAG;1;Platelet aggregation panel - Platelet rich plasma;Platelet aggregation Pnl PRP;;ACTIVE;2.21;2.73 +48806-4;Salmonella sp+Shigella sp+Escherichia coli enterotoxic identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Salmonella sp+Shigella sp+Escherichia coli enterotoxic identified in Stool by Organism specific culture;Salm+Shig+E coli ETEC Stl Cult;;ACTIVE;2.21;2.73 +48807-2;Bone marrow aspiration report;Find;Pt;Bone mar;Doc;;DOC.MISC;2;Bone marrow aspiration report;Bone marrow aspiration report;;ACTIVE;2.21;2.73 +48808-0;Leukogram panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Leukogram panel - Blood;Leukogram Pnl Bld;;DISCOURAGED;2.21;2.42 +48809-8;Erythrogram panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Erythrogram panel - Blood;Erythrogram Pnl Bld;;DISCOURAGED;2.21;2.42 +48810-6;Glucose^5H post 50 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post 50 g glucose PO;Glucose 5h p 50 g Glu PO SerPl-mCnc;;ACTIVE;2.21;2.34 +48811-4;Protein fractions 3 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Protein fractions 3 panel - Serum or Plasma;Protein fractions 3 Pnl SerPl;;ACTIVE;2.21;2.42 +48812-2;Spermatozoa morphology panel;-;Pt;Semen;-;;PANEL.FERT;1;Spermatozoa morphology panel;Sperm morph Pnl Smn;;ACTIVE;2.21;2.73 +48813-0;Bacterial methicillin resistance mecA gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Methicillin resistance mecA gene [Presence] by Molecular method;mecA Islt/Spm Ql;;ACTIVE;2.21;2.73 +48814-8;Bacterial vancomycin resistance vanA gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Vancomycin resistance vanA gene [Presence] by Molecular method;vanA Islt/Spm Ql;;ACTIVE;2.21;2.73 +48815-5;Herpes simplex virus+Varicella zoster virus DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Herpes simplex virus+Varicella zoster virus DNA [Identifier] in Unspecified specimen by Probe and target amplification method;Deprecated HSV+VZV DNA XXX PCR;;DEPRECATED;2.21;2.69 +48816-3;Staphylococcus aureus Panton-Valentine leukocidin gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;MICRO;1;Staphylococcus aureus Panton-Valentine leukocidin gene [Presence] in Isolate or Specimen by Molecular genetics method;S aureus PVL gene Islt/Spm Ql;;ACTIVE;2.21;2.73 +48817-1;Donath Landsteiner Ab;Titr;Pt;Ser^Control;Qn;;BLDBK;1;Donath Landsteiner Ab [Titer] in Control Serum;D-L Ab Titr Ser Cont;;ACTIVE;2.21;2.38 +48818-9;Karyotype;Prid;Pt;Bld/Tiss;Nom;High resolution;MOLPATH;1;Karyotype [Identifier] in Blood or Tissue by High resolution Nominal;Karyotyp Bld/T High Res;;ACTIVE;2.21;2.73 +4881-9;HLA-Dw16;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw16 [Presence];HLA-Dw16 Ql;;ACTIVE;1.0;2.56 +48819-7;Karyotype;Prid;Pt;Tiss^Fetus;Nom;;MOLPATH;1;Karyotype [Identifier] in Tissue from Fetus Nominal;Karyotyp Tiss Fetus;;ACTIVE;2.21;2.73 +48820-5;Karyotype;Prid;Pt;BldCo;Nom;;MOLPATH;1;Karyotype [Identifier] in Cord blood Nominal;Karyotyp BldCo;;ACTIVE;2.21;2.73 +48821-3;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript";Arb;Pt;Bone mar;Ord;Molgen;MOLPATH.TRNLOC;1;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"t(12;21)(ETV6,RUNX1) Mar Ql";;ACTIVE;2.21;2.52 +48822-1;Tubular basement membrane Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Tubular basement membrane IgG Ab [Units/volume] in Serum by Immunoassay;TBM IgG Ser IA-aCnc;;ACTIVE;2.21;2.69 +48823-9;Tubular basement membrane Ab.IgG;ACnc;Pt;Ser;Qn;IF;SERO;1;Tubular basement membrane IgG Ab [Units/volume] in Serum by Immunofluorescence;TBM IgG Ser IF-aCnc;;ACTIVE;2.21;2.69 +48824-7;Respiratory allergen panel, US - North Atlantic states a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - North Atlantic states a - Serum;Resp allergen N Atl a Pnl Ser;;ACTIVE;2.21;2.69 +48825-4;Respiratory allergen panel, US - Mid Atlantic states;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Mid Atlantic states - Serum;Resp allergen Mid Atl Pnl Ser;;ACTIVE;2.21;2.69 +48826-2;Respiratory allergen panel, US - South Atlantic states a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - South Atlantic states a - Serum;Resp allergen S Atl a Pnl Ser;;ACTIVE;2.21;2.69 +4882-7;HLA-Dw17(w7);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw17(w7) [Presence] in Donor;HLA-Dw17(w7) Donr Ql;;ACTIVE;1.0;2.56 +48827-0;Respiratory allergen panel, US - Subtropical Florida;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Subtropical Florida - Serum;Resp allergen Subtropical FL Pnl Ser;;ACTIVE;2.21;2.69 +48828-8;Respiratory allergen panel, US - Greater Ohio valley a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Greater Ohio valley a - Serum;Resp allergen Greater OH val a Pnl Ser;;ACTIVE;2.21;2.69 +48829-6;Respiratory allergen panel, US - South central states;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - South central states - Serum;Resp allergen S Central Pnl Ser;;ACTIVE;2.21;2.69 +48830-4;Respiratory allergen panel, US - Northern midwest states a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Northern midwest states a - Serum;Resp allergen N midwest a Pnl Ser;;ACTIVE;2.21;2.69 +48831-2;Respiratory allergen panel, US - Central midwest a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Central midwest a - Serum;Resp allergen Central midwest a Pnl Ser;;ACTIVE;2.21;2.69 +48832-0;Respiratory allergen panel, US - Great plains states a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Great plains states a - Serum;Resp allergen Great plains a Pnl Ser;;ACTIVE;2.21;2.69 +48833-8;Respiratory allergen panel, US - Southwestern grassland states;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Southwestern grassland states - Serum;Resp allergen SW grassland Pnl Ser;;ACTIVE;2.21;2.69 +48834-6;Respiratory allergen panel, US - Rocky mountain states a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Rocky mountain states a - Serum;Resp allergen Rockies a Pnl Ser;;ACTIVE;2.21;2.69 +4883-5;HLA-Dw17(w7);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw17(w7) [Presence];HLA-Dw17(w7) Ql;;ACTIVE;1.0;2.56 +48835-3;Respiratory allergen panel, US - Arid southwest;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Arid southwest - Serum;Resp allergen Arid SW Pnl Ser;;ACTIVE;2.21;2.69 +48836-1;Respiratory allergen panel, US - Southern coastal California;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Southern coastal California - Serum;Resp allergen S coast CA Pnl Ser;;ACTIVE;2.21;2.69 +48837-9;Respiratory allergen panel, US - California central valley;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - California central valley - Serum;Resp allergen CA central valley Pnl Ser;;ACTIVE;2.21;2.69 +48838-7;Respiratory allergen panel, US - Intermountain west a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Intermountain west a - Serum;Resp allergen Intermountain W a Pnl Ser;;ACTIVE;2.21;2.69 +48839-5;Respiratory allergen panel, US - Inland northwest a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Inland northwest a - Serum;Resp allergen Inland NW a Pnl Ser;;ACTIVE;2.21;2.69 +48840-3;Respiratory allergen panel, US - Cascade Pacific northwest a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Cascade Pacific northwest a - Serum;Resp allergen Casc Pacif NW a Pnl Ser;;ACTIVE;2.21;2.69 +48841-1;Respiratory allergen panel, US - Alaska a;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Alaska a - Serum;Resp allergen AK a Pnl Ser;;ACTIVE;2.21;2.69 +48842-9;Bartonella bacilliformis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella bacilliformis IgG Ab [Titer] in Serum by Immunofluorescence;B bacilliformis IgG Titr Ser IF;;ACTIVE;2.21;2.32 +4884-3;HLA-Dw18(w6);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw18(w6) [Presence] in Donor;HLA-Dw18(w6) Donr Ql;;ACTIVE;1.0;2.56 +48843-7;Bartonella bacilliformis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella bacilliformis IgM Ab [Titer] in Serum by Immunofluorescence;B bacilliformis IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48844-5;Bartonella elizabethae Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella elizabethae IgG Ab [Titer] in Serum by Immunofluorescence;B elizabethae IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48845-2;Bartonella elizabethae Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella elizabethae IgM Ab [Titer] in Serum by Immunofluorescence;B elizabethae IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48846-0;Bartonella vinsonii berkhoffii Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella vinsonii berkhoffii IgM Ab [Titer] in Serum by Immunofluorescence;B vinsonii berkhoffii IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48847-8;Bartonella vinsonii berkhoffii Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella vinsonii berkhoffii IgG Ab [Titer] in Serum by Immunofluorescence;B vinsonii berkhoffii IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48848-6;Coxiella burnetii phase 1 Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 1 IgA Ab [Titer] in Serum by Immunofluorescence;C burnet Ph1 IgA Titr Ser IF;;ACTIVE;2.21;2.32 +48849-4;Coxiella burnetii phase 2 Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii phase 2 IgA Ab [Titer] in Serum by Immunofluorescence;C burnet Ph2 IgA Titr Ser IF;;ACTIVE;2.21;2.32 +4885-0;HLA-Dw18(w6);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw18(w6) [Presence];HLA-Dw18(w6) Ql;;ACTIVE;1.0;2.73 +48850-2;Ehrlichia chaffeensis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Ehrlichia chaffeensis IgM Ab [Titer] in Serum by Immunofluorescence;E chaffeensis IgM Titr Ser IF;;ACTIVE;2.21;2.73 +48851-0;Orientia tsutsugamushi Gilliam Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Gilliam IgM Ab [Titer] in Serum by Immunofluorescence;O tsut Gill IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48852-8;Orientia tsutsugamushi Gilliam Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Gilliam IgG Ab [Titer] in Serum by Immunofluorescence;O tsut Gill IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48853-6;Orientia tsutsugamushi Karp Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Karp IgG Ab [Titer] in Serum by Immunofluorescence;O tsut Karp IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48854-4;Orientia tsutsugamushi Karp Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Karp IgM Ab [Titer] in Serum by Immunofluorescence;O tsut Karp IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48855-1;Orientia tsutsugamushi Kato Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Kato IgG Ab [Titer] in Serum by Immunofluorescence;O tsut Kato IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48856-9;Orientia tsutsugamushi Kato Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Orientia tsutsugamushi Kato IgM Ab [Titer] in Serum by Immunofluorescence;O tsut Kato IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48857-7;Rickettsia africae Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia africae IgM Ab [Titer] in Serum by Immunofluorescence;R africae IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48858-5;Rickettsia africae Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia africae IgG Ab [Titer] in Serum by Immunofluorescence;R africae IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48859-3;Rickettsia akari Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia akari IgG Ab [Titer] in Serum by Immunofluorescence;R akari IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48860-1;Rickettsia akari Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia akari IgM Ab [Titer] in Serum by Immunofluorescence;R akari IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48861-9;Rickettsia parkeri Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia parkeri IgM Ab [Titer] in Serum by Immunofluorescence;R parkeri IgM Titr Ser IF;;ACTIVE;2.21;2.32 +48862-7;Rickettsia parkeri Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia parkeri IgG Ab [Titer] in Serum by Immunofluorescence;R parkeri IgG Titr Ser IF;;ACTIVE;2.21;2.32 +48863-5;Rickettsia sp DNA;Prid;Pt;XXX;Nom;RFLP;MICRO;1;Rickettsia sp DNA [Identifier] in Specimen by RFLP;Rickettsia DNA Spec RFLP;;ACTIVE;2.21;2.69 +48864-3;Bartonella sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bartonella sp DNA [Presence] in Specimen by NAA with probe detection;Bartonella DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +48865-0;Ehrlichia ewingii DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ehrlichia ewingii DNA [Presence] in Specimen by NAA with probe detection;E ewingii DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +48866-8;Ehrlichia sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ehrlichia sp DNA [Presence] in Specimen by NAA with probe detection;Ehrlichia DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +48867-6;Orientia tsutsugamushi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Orientia tsutsugamushi DNA [Presence] in Specimen by NAA with probe detection;O tsut DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.69 +4886-8;HLA-Dw19(w6);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw19(w6) [Presence] in Donor;HLA-Dw19(w6) Donr Ql;;ACTIVE;1.0;2.56 +48868-4;Rickettsia rickettsii DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rickettsia rickettsii DNA [Presence] in Specimen by NAA with probe detection;R rickettsi DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +48869-2;Rickettsia sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rickettsia sp DNA [Presence] in Specimen by NAA with probe detection;Rickettsia DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.69 +488-7;Temafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Temafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Temafloxacin Islt MIC;;ACTIVE;1.0;2.19 +48870-0;Rickettsia spotted fever group DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rickettsia spotted fever group DNA [Presence] in Specimen by NAA with probe detection;Rick SF DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.69 +48871-8;Rickettsia typhus group DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rickettsia typhus group DNA [Presence] in Specimen by NAA with probe detection;Rick Typhus DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.69 +48872-6;Anaplasma phagocytophilum;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Anaplasma phagocytophilum [Presence] in Specimen by Organism specific culture;A phagocytoph Spec Ql Cult;;ACTIVE;2.21;2.73 +48873-4;Ehrlichia sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Ehrlichia sp identified in Specimen by Organism specific culture;Ehrlichia Spec Cult;;ACTIVE;2.21;2.69 +48874-2;Neorickettsia sp;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Neorickettsia sp [Presence] in Specimen by Organism specific culture;Neorickettsia sp Spec Ql Cult;;ACTIVE;2.21;2.69 +48875-9;Orientia tsutsugamushi;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Orientia tsutsugamushi [Presence] in Specimen by Organism specific culture;O tsut Spec Ql Cult;;ACTIVE;2.21;2.69 +4887-6;HLA-Dw19(w6);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw19(w6) [Presence];HLA-Dw19(w6) Ql;;ACTIVE;1.0;2.56 +48876-7;Anaplasma phagocytophilum Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Anaplasma phagocytophilum IgM Ab [Titer] in Body fluid by Immunofluorescence;A phagocytoph IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48877-5;Anaplasma phagocytophilum Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Anaplasma phagocytophilum IgG Ab [Titer] in Body fluid by Immunofluorescence;A phagocytoph IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48878-3;Bartonella bacilliformis Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella bacilliformis IgG Ab [Titer] in Body fluid by Immunofluorescence;B bacilliformis IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48879-1;Bartonella bacilliformis Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella bacilliformis IgM Ab [Titer] in Body fluid by Immunofluorescence;B bacilliformis IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48880-9;Bartonella elizabethae Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella elizabethae IgG Ab [Titer] in Body fluid by Immunofluorescence;B elizabethae IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48881-7;Bartonella elizabethae Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella elizabethae IgM Ab [Titer] in Body fluid by Immunofluorescence;B elizabethae IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48882-5;Bartonella henselae Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella henselae IgM Ab [Titer] in Body fluid by Immunofluorescence;B henselae IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48883-3;Bartonella henselae Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella henselae IgG Ab [Titer] in Body fluid by Immunofluorescence;B henselae IgG Titr Fld IF;;ACTIVE;2.21;2.32 +4888-4;HLA-Dw1;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw1 [Presence] in Donor;HLA-Dw1 Donr Ql;;ACTIVE;1.0;2.56 +48884-1;Bartonella quintana Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella quintana IgG Ab [Titer] in Body fluid by Immunofluorescence;B quintana IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48885-8;Bartonella quintana Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella quintana IgM Ab [Titer] in Body fluid by Immunofluorescence;B quintana IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48886-6;Bartonella vinsonii berkhoffii Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella vinsonii berkhoffii IgM Ab [Titer] in Body fluid by Immunofluorescence;B vinsonii berkhoffii IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48887-4;Bartonella vinsonii berkhoffii Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Bartonella vinsonii berkhoffii IgG Ab [Titer] in Body fluid by Immunofluorescence;B vinsonii berkhoffii IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48888-2;Coxiella burnetii phase 1 Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Titer] in Body fluid by Immunofluorescence;C burnet Ph1 IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48889-0;Coxiella burnetii phase 1 Ab.IgA;Titr;Pt;Body fld;Qn;IF;MICRO;1;Coxiella burnetii phase 1 IgA Ab [Titer] in Body fluid by Immunofluorescence;C burnet Ph1 IgA Titr Fld IF;;ACTIVE;2.21;2.32 +48890-8;Coxiella burnetii phase 1 Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Titer] in Body fluid by Immunofluorescence;C burnet Ph1 IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48891-6;Coxiella burnetii phase 2 Ab.IgA;Titr;Pt;Body fld;Qn;IF;MICRO;1;Coxiella burnetii phase 2 IgA Ab [Titer] in Body fluid by Immunofluorescence;C burnet Ph2 IgA Titr Fld IF;;ACTIVE;2.21;2.32 +4889-2;HLA-Dw1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw1 [Presence];HLA-Dw1 Ql;;ACTIVE;1.0;2.56 +48892-4;Coxiella burnetii phase 2 Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Titer] in Body fluid by Immunofluorescence;C burnet Ph2 IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48893-2;Coxiella burnetii phase 2 Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Titer] in Body fluid by Immunofluorescence;C burnet Ph2 IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48894-0;Ehrlichia chaffeensis Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Ehrlichia chaffeensis IgG Ab [Titer] in Body fluid by Immunofluorescence;E chaffeensis IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48895-7;Ehrlichia chaffeensis Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Ehrlichia chaffeensis IgM Ab [Titer] in Body fluid by Immunofluorescence;E chaffeensis IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48896-5;Orientia tsutsugamushi Gilliam Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Orientia tsutsugamushi Gilliam IgM Ab [Titer] in Body fluid by Immunofluorescence;O tsut Gill IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48897-3;Orientia tsutsugamushi Gilliam Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Orientia tsutsugamushi Gilliam IgG Ab [Titer] in Body fluid by Immunofluorescence;O tsut Gill IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48898-1;Orientia tsutsugamushi Karp Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Orientia tsutsugamushi Karp IgG Ab [Titer] in Body fluid by Immunofluorescence;O tsut Karp IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48899-9;Orientia tsutsugamushi Karp Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Orientia tsutsugamushi Karp IgM Ab [Titer] in Body fluid by Immunofluorescence;O tsut Karp IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48-9;Bacampicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Bacampicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Bacampicillin Islt MIC;;ACTIVE;1.0;2.19 +4890-0;HLA-Dw20;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw20 [Presence] in Donor;HLA-Dw20 Donr Ql;;ACTIVE;1.0;2.56 +48900-5;Orientia tsutsugamushi Kato Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Orientia tsutsugamushi Kato IgG Ab [Titer] in Body fluid by Immunofluorescence;O tsut Kato IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48901-3;Orientia tsutsugamushi Kato Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Orientia tsutsugamushi Kato IgM Ab [Titer] in Body fluid by Immunofluorescence;O tsut Kato IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48902-1;Rickettsia africae Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia africae IgM Ab [Titer] in Body fluid by Immunofluorescence;R africae IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48903-9;Rickettsia africae Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia africae IgG Ab [Titer] in Body fluid by Immunofluorescence;R africae IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48904-7;Rickettsia akari Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia akari IgG Ab [Titer] in Body fluid by Immunofluorescence;R akari IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48905-4;Rickettsia akari Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia akari IgM Ab [Titer] in Body fluid by Immunofluorescence;R akari IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48906-2;Rickettsia conorii Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia conorii IgM Ab [Titer] in Body fluid by Immunofluorescence;R conorii IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48907-0;Rickettsia conorii Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia conorii IgG Ab [Titer] in Body fluid by Immunofluorescence;R conorii IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48908-8;Rickettsia parkeri Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia parkeri IgM Ab [Titer] in Body fluid by Immunofluorescence;R parkeri IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48909-6;Rickettsia parkeri Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia parkeri IgG Ab [Titer] in Body fluid by Immunofluorescence;R parkeri IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48910-4;Rickettsia prowazekii Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia prowazekii IgM Ab [Titer] in Body fluid by Immunofluorescence;R prowazek IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48911-2;Rickettsia prowazekii Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia prowazekii IgG Ab [Titer] in Body fluid by Immunofluorescence;R prowazek IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48912-0;Rickettsia rickettsii Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia rickettsii IgM Ab [Titer] in Body fluid by Immunofluorescence;R rickettsi IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48913-8;Rickettsia rickettsii Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia rickettsii IgG Ab [Titer] in Body fluid by Immunofluorescence;R rickettsi IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48914-6;Rickettsia typhi Ab.IgG;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Body fluid by Immunofluorescence;R typhi IgG Titr Fld IF;;ACTIVE;2.21;2.32 +48915-3;Rickettsia typhi Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Rickettsia typhi IgM Ab [Titer] in Body fluid by Immunofluorescence;R typhi IgM Titr Fld IF;;ACTIVE;2.21;2.32 +48916-1;Respiratory allergen panel, US - North Atlantic states b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - North Atlantic states b - Serum;Resp allergen N Atl b Pnl Ser;;ACTIVE;2.21;2.69 +48917-9;Respiratory allergen panel, US - South Atlantic states b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - South Atlantic states b - Serum;Resp allergen S Atl b Pnl Ser;;ACTIVE;2.21;2.69 +4891-8;HLA-Dw20;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw20 [Presence];HLA-Dw20 Ql;;ACTIVE;1.0;2.56 +48918-7;Respiratory allergen panel, US - NC, PA, SC, VA, WV;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - NC, PA, SC, VA, WV - Serum;Resp allergen NC,PA,SC,VA,WV Pnl Ser;;ACTIVE;2.21;2.69 +48919-5;Respiratory allergen panel, US - Central Florida;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Central Florida - Serum;Resp allergen mid FL Pnl Ser;;ACTIVE;2.21;2.69 +48920-3;Respiratory allergen panel, US - Southern Florida;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Southern Florida - Serum;Resp allergen S FL Pnl Ser;;ACTIVE;2.21;2.69 +48921-1;Respiratory allergen panel, US - Southeast coast;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Southeast coast - Serum;Resp allergen SE coast Pnl Ser;;ACTIVE;2.21;2.69 +48922-9;Respiratory allergen panel, US - West south central states;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - West south central states - Serum;Resp allergen WS central Pnl Ser;;ACTIVE;2.21;2.69 +48923-7;Respiratory allergen panel, US - Greater Ohio valley b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Greater Ohio valley b - Serum;Resp allergen Greater OH val b Pnl Ser;;ACTIVE;2.21;2.69 +48924-5;Respiratory allergen panel, US - Northern midwest states b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Northern midwest states b - Serum;Resp allergen N midwest b Pnl Ser;;ACTIVE;2.21;2.69 +48925-2;Respiratory allergen panel, US - Central midwest b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Central midwest b - Serum;Resp allergen Central midwest b Pnl Ser;;ACTIVE;2.21;2.69 +4892-6;HLA-Dw21;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw21 [Presence] in Donor;HLA-Dw21 Donr Ql;;ACTIVE;1.0;2.56 +48926-0;Respiratory allergen panel, US - Great plains states b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Great plains states b - Serum;Resp allergen Great plains b Pnl Ser;;ACTIVE;2.21;2.69 +48927-8;Respiratory allergen panel, US - Rocky mountain states b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Rocky mountain states b - Serum;Resp allergen Rockies b Pnl Ser;;ACTIVE;2.21;2.69 +48928-6;Respiratory allergen panel, US - Inland northwest b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Inland northwest b - Serum;Resp allergen Inland NW b Pnl Ser;;ACTIVE;2.21;2.69 +48929-4;Respiratory allergen panel, US - Cascade Pacific northwest b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Cascade Pacific northwest b - Serum;Resp allergen Casc Pacif NW b Pnl Ser;;ACTIVE;2.21;2.69 +48930-2;Respiratory allergen panel, US - Intermountain west b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Intermountain west b - Serum;Resp allergen Intermountain W b Pnl Ser;;ACTIVE;2.21;2.69 +48931-0;Respiratory allergen panel, US - AZ, Southeastern CA, Western NM;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - AZ, Southeastern CA, Western NM - Serum;Resp allergen AZ,CA,NM Pnl Ser;;ACTIVE;2.21;2.69 +48932-8;Respiratory allergen panel, US - Alaska b;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Alaska b - Serum;Resp allergen AK b Pnl Ser;;ACTIVE;2.21;2.69 +48933-6;Respiratory allergen panel, US - Hawaii;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Hawaii - Serum;Resp allergen HI Pnl Ser;;ACTIVE;2.21;2.69 +4893-4;HLA-Dw21;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw21 [Presence];HLA-Dw21 Ql;;ACTIVE;1.0;2.56 +48934-4;11-Hydroxy delta-9 tetrahydrocannabinol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Mass/volume] in Specimen;11OH-THC Spec-mCnc;;ACTIVE;2.21;2.73 +48935-1;11-Hydroxy delta-9 tetrahydrocannabinol;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Specimen;11OH-THC Spec Ql;;ACTIVE;2.21;2.69 +48936-9;Acylcarnitine pattern;Imp;Pt;Tiss;Nom;;CHEM;1;Acylcarnitine pattern [Interpretation] in Tissue;Acylcarnitine pattern Tiss-Imp;;ACTIVE;2.21;2.26 +48937-7;Alpha hydroxyalprazolam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Specimen;A-OH Alpraz Spec-mCnc;;ACTIVE;2.21;2.69 +48938-5;ALPRAZolam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Specimen;Alpraz Spec-mCnc;;ACTIVE;2.21;2.73 +48939-3;Amphetamines;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Specimen;Amphetamines Spec-mCnc;;ACTIVE;2.21;2.73 +48940-1;Benzodiazepines;MCnc;Pt;XXX;Qn;Confirm;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Specimen by Confirmatory method;Benzodiaz Spec Cfm-mCnc;;ACTIVE;2.21;2.73 +48941-9;Benzodiazepines;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Specimen;Benzodiaz Spec-mCnc;;ACTIVE;2.21;2.73 +4894-2;HLA-Dw22;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw22 [Presence] in Donor;HLA-Dw22 Donr Ql;;ACTIVE;1.0;2.56 +48942-7;Cannabinoids;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cannabinoids [Mass/volume] in Specimen;Cannabinoids Spec-mCnc;;ACTIVE;2.21;2.73 +48943-5;Cannabinoids;PrThr;Pt;XXX;Ord;Confirm;DRUG/TOX;1;Cannabinoids [Presence] in Specimen by Confirmatory method;Cannabinoids Spec Ql Cfm;;ACTIVE;2.21;2.73 +48944-3;Carboxy tetrahydrocannabinol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Specimen;CarboxyTHC Spec-mCnc;;ACTIVE;2.21;2.73 +48945-0;chlordiazePOXIDE;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Specimen;Chlordiazep Spec-mCnc;;ACTIVE;2.21;2.73 +48946-8;Cocaethylene;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cocaethylene [Mass/volume] in Specimen;Cocaethylene Spec-mCnc;;ACTIVE;2.21;2.73 +48947-6;Cocaine;PrThr;Pt;XXX;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Specimen by Confirmatory method;Cocaine Spec Ql Cfm;;ACTIVE;2.21;2.73 +48948-4;diazePAM;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Specimen;diazePAM Spec-mCnc;;ACTIVE;2.21;2.73 +48949-2;Estazolam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Estazolam [Mass/volume] in Specimen;Estazolam Spec-mCnc;;ACTIVE;2.21;2.69 +489-5;Temafloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Temafloxacin [Susceptibility] by Disk diffusion (KB);Temafloxacin Islt KB;;ACTIVE;1.0;2.19 +48950-0;Flurazepam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Flurazepam [Mass/volume] in Specimen;Flurazepam Spec-mCnc;;ACTIVE;2.21;2.73 +48951-8;Guidance for injection;Find;Pt;Joint.space.XXX;Nar;Radnuc;RAD;2;Deprecated Scan Guidance for injection of Joint space;Deprecated Joint.space RI Inj guid;;DEPRECATED;2.21;2.36 +48952-6;Histoplasma capsulatum Ag;MCnc;Pt;Urine;Qn;;MICRO;1;Histoplasma capsulatum Ag [Mass/volume] in Urine;H capsul Ag Ur-mCnc;;ACTIVE;2.21;2.73 +48953-4;Hydroxyethylflurazepam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Specimen;OH-Ethylfluraz Spec-mCnc;;ACTIVE;2.21;2.73 +48954-2;Hydroxytriazolam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Specimen;OH-Triazolam Spec-mCnc;;ACTIVE;2.21;2.69 +48955-9;LORazepam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Specimen;LORazepam Spec-mCnc;;ACTIVE;2.21;2.73 +48956-7;Methadone;MCnc;Pt;XXX;Qn;Confirm;DRUG/TOX;1;Methadone [Mass/volume] in Specimen by Confirmatory method;Methadone Spec Cfm-mCnc;;ACTIVE;2.21;2.73 +48957-5;Methadone;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Specimen;Methadone Spec-mCnc;;ACTIVE;2.21;2.73 +48958-3;Midazolam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Midazolam [Mass/volume] in Specimen;Midazolam Spec-mCnc;;ACTIVE;2.21;2.73 +4895-9;HLA-Dw22;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw22 [Presence];HLA-Dw22 Ql;;ACTIVE;1.0;2.56 +48959-1;Nordiazepam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Specimen;Nordiazepam Spec-mCnc;;ACTIVE;2.21;2.73 +48960-9;Norpropoxyphene;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/volume] in Specimen;Norpropoxyph Spec-mCnc;;ACTIVE;2.21;2.69 +48961-7;Opiates;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Opiates [Mass/volume] in Specimen;Opiates Spec-mCnc;;ACTIVE;2.21;2.73 +48962-5;Oxazepam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Specimen;Oxazepam Spec-mCnc;;ACTIVE;2.21;2.73 +48963-3;Propoxyphene;MCnc;Pt;XXX;Qn;Confirm;DRUG/TOX;1;Propoxyphene [Mass/volume] in Specimen by Confirmatory method;Propoxyph Spec Cfm-mCnc;;ACTIVE;2.21;2.69 +48964-1;Propoxyphene;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Propoxyphene [Mass/volume] in Specimen;Propoxyph Spec-mCnc;;ACTIVE;2.21;2.73 +48965-8;Temazepam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Specimen;Temazepam Spec-mCnc;;ACTIVE;2.21;2.73 +48966-6;Triazolam;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Triazolam [Mass/volume] in Specimen;Triazolam Spec-mCnc;;ACTIVE;2.21;2.73 +4896-7;HLA-Dw23;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw23 [Presence] in Donor;HLA-Dw23 Donr Ql;;ACTIVE;1.0;2.56 +48967-4;Brucella abortus Ab;PrThr;Pt;CSF;Ord;Aggl.card;MICRO;1;Brucella abortus Ab [Presence] in Cerebral spinal fluid by Card agglutination;B abortus Ab CSF Ql Card aggl;;ACTIVE;2.21;2.56 +48968-2;PKHD1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PKHD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PKHD1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +48969-0;DCX gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;DCX gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;DCX gene Mut Anl Bld/T;;ACTIVE;2.21;2.68 +48970-8;ELN gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ELN gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ELN gene Mut Anl Bld/T;;ACTIVE;2.21;2.68 +48971-6;EYA1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;EYA1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;EYA1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.66 +48972-4;FGFR2 gene+FGFR3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGFR2 gene+FGFR3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FGFR2+FGFR3 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48973-2;Leukocytes^2nd specimen;PrThr;Pt;Stool;Ord;Methylene blue stain;HEM/BC;1;Leukocytes [Presence] in Stool by Methylene blue stain --2nd specimen;WBC sp2 Stl Ql MB Stn;;ACTIVE;2.21;2.56 +48974-0;MDCR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MDCR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MDCR gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +4897-5;HLA-Dw23;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw23 [Presence];HLA-Dw23 Ql;;ACTIVE;1.0;2.56 +48975-7;GPR143 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;GPR143 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;GPR143 gene Mut Anl Bld/T;;ACTIVE;2.21;2.68 +48976-5;POLG gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;POLG gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;POLG gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48977-3;SGCG gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SGCG gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SGCG gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48978-1;CDKL5 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CDKL5 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CDKL5 gene Mut Anl Bld/T;;ACTIVE;2.21;2.68 +48979-9;TSC1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TSC1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TSC1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48980-7;TSC2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TSC2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TSC2 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +48981-5;Anaplasma sp;PrThr;Pt;XXX;Ord;Microscopy.light;MICRO;1;Anaplasma sp [Presence] in Specimen by Light microscopy;Anaplasma Spec Ql Micro;;ACTIVE;2.21;2.73 +48982-3;Ehrlichia sp;PrThr;Pt;XXX;Ord;Microscopy.light;MICRO;1;Ehrlichia sp [Presence] in Specimen by Light microscopy;Ehrlichia Spec Ql Micro;;ACTIVE;2.21;2.69 +4898-3;HLA-Dw24;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw24 [Presence] in Donor;HLA-Dw24 Donr Ql;;ACTIVE;1.0;2.56 +48983-1;Glucose^20M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20 minutes pre XXX challenge;Glucose 20M pre chal SerPl-mCnc;;ACTIVE;2.21;2.70 +48984-9;Glucose^10M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 minutes post dose glucose;Glucose 10M p Glc SerPl-mCnc;;ACTIVE;2.21;2.70 +48985-6;Glucose^20M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20 minutes post dose glucose;Glucose 20M p Glc SerPl-mCnc;;ACTIVE;2.21;2.70 +48986-4;Glucose^8 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --8 AM specimen;Glucose 8 AM SerPl-mCnc;;ACTIVE;2.21;2.70 +48987-2;Pyridinoline.free/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pyridinoline.free/Creatinine [Molar ratio] in Urine;PYD.free/Creat Ur-sRto;;ACTIVE;2.21;2.70 +48988-0;Glucose^12 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12 PM specimen;Glucose 12 PM SerPl-mCnc;;ACTIVE;2.21;2.70 +48989-8;Glucose^6 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 PM specimen;Glucose 6 PM SerPl-mCnc;;ACTIVE;2.21;2.70 +48990-6;Glucose^8 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --8 PM specimen;Glucose 8 PM SerPl-mCnc;;ACTIVE;2.21;2.70 +4899-1;HLA-Dw24;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw24 [Presence];HLA-Dw24 Ql;;ACTIVE;1.0;2.56 +48991-4;Glucose^10 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 PM specimen;Glucose 10 PM SerPl-mCnc;;ACTIVE;2.21;2.70 +48992-2;Glucose^12 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --12 AM specimen;Glucose 12 AM SerPl-mCnc;;ACTIVE;2.21;2.70 +48993-0;Glucose^3 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 AM specimen;Glucose 3 AM SerPl-mCnc;;ACTIVE;2.21;2.70 +48994-8;Glucose^6 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 AM specimen;Glucose 6 AM SerPl-mCnc;;ACTIVE;2.21;2.70 +48995-5;N-acetyl-beta-glucosaminidase/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;N-acetyl-beta-glucosaminidase/Creatinine [Ratio] in Urine;B-NAG/Creat Ur-Rto;;ACTIVE;2.21;2.70 +48996-3;Amylase.pancreatic;CCnc;Pt;Body fld;Qn;;CHEM;1;Amylase.pancreatic [Enzymatic activity/volume] in Body fluid;Amylase P Fld-cCnc;;ACTIVE;2.21;2.68 +48997-1;Immune complex.IgG;MCnc;Pt;Body fld;Qn;C1q binding assay;SERO;1;Immune complex.IgG [Mass/volume] in Body fluid by C1q binding assay;IC IgG Fld C1Q Bind-mCnc;;ACTIVE;2.21;2.70 +48998-9;6-Phosphogluconate dehydrogenase;CCnt;Pt;RBC;Qn;;CHEM;1;6-Phosphogluconate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells;6PGD RBC-cCnt;;ACTIVE;2.21;2.70 +48999-7;Urea;MRat;24H;Urine;Qn;;CHEM;1;Urea [Mass/time] in 24 hour Urine;Urea 24h Ur-mRate;;ACTIVE;2.21;2.73 +49000-3;Hemoglobin.free;PrThr;Pt;CSF;Ord;;HEM/BC;1;Free Hemoglobin [Presence] in Cerebral spinal fluid;Hgb Free CSF Ql;;ACTIVE;2.21;2.70 +49001-1;Osmolality;Osmol;Pt;Sweat;Qn;;CHEM;1;Osmolality of Sweat;Osmolality Sweat;;ACTIVE;2.21;2.70 +49002-9;Albumin;MRat;XXX;Urine;Qn;;CHEM;1;Albumin [Mass/time] in Urine collected for unspecified duration;Albumin ?Tm Ur-mRate;;ACTIVE;2.21;2.73 +49003-7;Urate;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urate [Mass/volume] in Peritoneal dialysis fluid;Urate DiafP-mCnc;;ACTIVE;2.21;2.70 +49004-5;Creatinine;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid;Creat DiafP-mCnc;;ACTIVE;2.21;2.70 +49005-2;Calcium;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Calcium [Moles/volume] in Peritoneal dialysis fluid;Calcium DiafP-sCnc;;ACTIVE;2.21;2.70 +49006-0;Phosphate;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Phosphate [Moles/volume] in Peritoneal dialysis fluid;Phosphate DiafP-sCnc;;ACTIVE;2.21;2.70 +4900-7;HLA-Dw25;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw25 [Presence] in Donor;HLA-Dw25 Donr Ql;;ACTIVE;1.0;2.56 +49007-8;Magnesium;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Magnesium [Moles/volume] in Peritoneal dialysis fluid;Magnesium DiafP-sCnc;;ACTIVE;2.21;2.73 +49008-6;Coagulum retraction;VFr;Pt;Bld;Qn;;COAG;1;Clot Retraction [Volume Fraction] in Blood;Clot Retract VFr Bld;;ACTIVE;2.21;2.42 +49009-4;Norepinephrine^7th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Plasma --7th specimen post XXX challenge;Norepineph sp7 p chal Plas-sCnc;;ACTIVE;2.21;2.34 +49010-2;Platelet aggregation.adenosine diphosphate induced;ACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced [Units/volume] in Platelet rich plasma;PA ADP PRP-aCnc;;ACTIVE;2.21;2.73 +49011-0;Platelet aggregation.arachidonate induced;ACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation arachidonate induced [Units/volume] in Platelet rich plasma;PA AA PRP-aCnc;;ACTIVE;2.21;2.73 +49012-8;Influenza virus A & B identified;Prid;Pt;XXX;Nom;Bioassay;MICRO;1;Influenza virus A and B identified in Specimen by Bioassay;FLUAV + FLUBV Spec Bioassay;;ACTIVE;2.21;2.69 +49013-6;Pancreastatin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreastatin [Mass/volume] in Serum or Plasma;Pancreastatin SerPl-mCnc;;ACTIVE;2.21;2.73 +49014-4;PAH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PAH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PAH gene Mut Anl Bld/T;;ACTIVE;2.21;2.73 +4901-5;HLA-Dw25;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw25 [Presence];HLA-Dw25 Ql;;ACTIVE;1.0;2.56 +49015-1;SCA15 gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;SCA15 gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;SCA15 gene CAG Rpt Bld/T Ql;;ACTIVE;2.21;2.68 +49016-9;Streptococcus sp exoenzyme Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus sp exoenzyme Ab [Units/volume] in Serum;Streptococcus sp exoenzyme Ab Ser-aCnc;;ACTIVE;2.21;2.73 +49017-7;Respiratory allergen panel, US - North Atlantic states c;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - North Atlantic states c - Serum;Resp allergen N Atl c Pnl Ser;;ACTIVE;2.21;2.69 +49018-5;Respiratory allergen panel, US - Intermountain west c;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Intermountain west c - Serum;Resp allergen Intermountain W c Pnl Ser;;ACTIVE;2.21;2.69 +49019-3;Respiratory allergen panel, US - Puerto Rico;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Puerto Rico - Serum;Resp allergen PR Pnl Ser;;ACTIVE;2.21;2.69 +49020-1;Respiratory allergen panel, US - Coastal California;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Coastal California - Serum;Resp allergen Coastal CA Pnl Ser;;ACTIVE;2.21;2.69 +49021-9;Respiratory allergen panel, US - Greater Ohio valley c;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Greater Ohio valley c - Serum;Resp allergen Greater OH val c Pnl Ser;;ACTIVE;2.21;2.69 +49022-7;Respiratory allergen panel, US - Northern midwest states c;-;Pt;Ser;-;;PANEL.ALLERGY;1;Respiratory allergen panel, US - Northern midwest states c - Serum;Resp allergen N midwest c Pnl Ser;;ACTIVE;2.21;2.69 +4902-3;HLA-Dw26;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw26 [Presence] in Donor;HLA-Dw26 Donr Ql;;ACTIVE;1.0;2.56 +49023-5;Albumin;MRat;XXX;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/time] in Urine collected for unspecified duration;Microalbumin ?Tm Ur-mRate;;ACTIVE;2.21;2.73 +49024-3;Differential cell count method;Type;Pt;Bld;Nom;;HEM/BC;1;Differential cell count method - Blood;Differential method Bld;;ACTIVE;2.21;2.73 +49025-0;Cells.CD25+CD127Low/Cells.CD4;NRto;Pt;XXX;Qn;;CELLMARK;1;CD25+CD127Low cells/CD4 cells [# Ratio] in Specimen;CD25+CD127Low Cells/CD4 Cells Spec;;ACTIVE;2.21;2.69 +49026-8;LDL 6;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 6 [Mass/volume] in Serum or Plasma;LDL6 SerPl-mCnc;;DISCOURAGED;2.21;2.73 +49027-6;LDL 7;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 7 [Mass/volume] in Serum or Plasma;LDL7 SerPl-mCnc;;DISCOURAGED;2.21;2.73 +49028-4;Microdeletion syndromes;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;Microdeletion syndromes [Identifier] in Blood or Tissue by FISH Nominal;Microdeletion synd Bld/T FISH;;ACTIVE;2.21;2.73 +49029-2;Cortisol.free/Cortisone.free;MRto;Pt;Urine;Qn;;CHEM;1;Cortisol Free/Cortisone free [Mass Ratio] in Urine;Cortis F/Cortisone Free Ur;;ACTIVE;2.21;2.73 +490-3;Temafloxacin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Temafloxacin [Susceptibility] by Serum bactericidal titer;Temafloxacin Titr SBT;;ACTIVE;1.0;2.32 +49030-0;Trisomy 21 risk based on maternal age + Pregnancy associated plasma protein A + Choriogonadotropin + Nuchal translucency;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Trisomy 21 risk based on maternal age+Pregnancy associated plasma protein A+Choriogonadotropin+Nuchal translucency [Likelihood] in Fetus;Ts 21 risk-age+PAPPA+HCG+NT Fetus;;ACTIVE;2.21;2.50 +4903-1;HLA-Dw26;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw26 [Presence];HLA-Dw26 Ql;;ACTIVE;1.0;2.56 +49031-8;Erythrocytes.CD59/100 erythrocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;CD59 RBC/100 erythrocytes in Blood;CD59 RBC/100 RBC NFr Bld;;ACTIVE;2.21;2.73 +49032-6;Second trimester penta maternal screen;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Second trimester penta maternal screen [Interpretation] in Serum or Plasma;2nd trimester 5 screen SerPl-Imp;;ACTIVE;2.21;2.73 +49033-4;Menstrual History;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Menstrual History - Reported;Menstrual Hx Reported;;ACTIVE;2.21;2.73 +49034-2;Microorganism identified;Prid;Pt;Cvx/Vag;Nom;Cyto stain;CYTO;1;Microorganism identified in Cervical or vaginal smear or scraping by Cyto stain;Microorganism Cvx/Vag Cyto;;ACTIVE;2.21;2.73 +49035-9;Thickness;MoM;Pt;Nuchal fold^Fetus;Qn;US.measured;OB.US;2;Fetal Nuchal fold [Multiple of the median] Thickness US;Fet Nuchal fold MoM Thickness US.meas;;ACTIVE;2.21;2.73 +49036-7;Parathyrin.intact^post excision;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --post excision;PTH-Intact p Excision SerPl-mCnc;;ACTIVE;2.21;2.73 +49037-5;Respiratory syncytial virus Ab.IgG & IgM panel;ACnc;Pt;Ser;Qn;;PANEL.MICRO;1;Respiratory syncytial virus IgG and IgM panel [Units/volume] - Serum;RSV IgG+IgM Pnl Ser-aCnc;;ACTIVE;2.21;2.42 +49038-3;Riboflavin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Riboflavin [Moles/volume] in Serum or Plasma;Vit B2 SerPl-sCnc;;ACTIVE;2.21;2.73 +49039-1;Subtelomere analysis;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH;1;Subtelomere analysis [Identifier] in Blood or Tissue by FISH Nominal;Subtelomere analysis Bld/T FISH;;ACTIVE;2.21;2.73 +49040-9;Subtelomere analysis;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH;1;Subtelomere analysis [Interpretation] in Blood or Tissue by FISH Narrative;Subtelomere analysis Bld/T FISH-Imp;;ACTIVE;2.21;2.73 +49041-7;Testosterone;MCnc;Pt;Ser/Plas;Qn;Detection limit <= 1.0 ng/dL;CHEM;1;Testosterone [Mass/volume] in Serum or Plasma by Detection limit <= 1.0 ng/dL;Testost SerPl DL<=1.0 ng/dL-mCnc;;ACTIVE;2.21;2.73 +49042-5;Testosterone.free;MCnc;Pt;Ser/Plas;Qn;Detection limit <= 1.0 ng/dL;CHEM;1;Testosterone Free [Mass/volume] in Serum or Plasma by Detection limit <= 1.0 ng/dL;Testost Free SerPl DL<=1.0 ng/dL-mCnc;;ACTIVE;2.21;2.73 +49043-3;Testosterone.free/Testosterone.total;MFr;Pt;Ser/Plas;Qn;Detection limit <= 1.0 ng/dL;CHEM;1;Testosterone Free/Testosterone.total in Serum or Plasma by Detection limit <= 1.0 ng/dL;Testost Free MFr SerPl DL<=1.0 ng/dL;;ACTIVE;2.21;2.73 +49044-1;Diazepam & Nordiazepam panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;diazePAM and Nordiazepam panel - Serum or Plasma;diazePAM+Nor Pnl SerPl;;ACTIVE;2.21;2.73 +49045-8;PT & aPTT & Fibrinogen panel;-;Pt;PPP;Qn;Coag;PANEL.COAG;1;PT and aPTT and Fibrinogen panel - Platelet poor plasma by Coagulation assay;PT + aPTT + Fibrinogen Pnl PPP;;ACTIVE;2.21;2.42 +49046-6;Drugs of abuse panel;-;Pt;Meconium;-;;PANEL.DRUG/TOX;1;Drugs of abuse panel - Meconium;Drugs of abuse Pnl Mec;;ACTIVE;2.21;2.73 +49047-4;Globulin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Globulin [Mass/volume] in Urine by Electrophoresis;Globulin Ur Elph-mCnc;;ACTIVE;2.21;2.73 +49048-2;Protein feed time;TmStp;Pt;^Patient;Qn;;CHEM;1;Protein feed time;Protein feed time Patient;;ACTIVE;2.21;2.73 +4904-9;HLA-Dw2;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw2 [Presence] in Donor;HLA-Dw2 Donr Ql;;ACTIVE;1.0;2.56 +49049-0;Collection time;TmStp;Pt;^Specimen;Qn;;SPEC;1;Collection time of Specimen;Collect Tme Spec;;ACTIVE;2.21;2.73 +49050-8;Microscopic observation;Prid;Pt;Endocervical brush;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Endocervical brush by Cyto stain;Cyto Endocvx brush;;ACTIVE;2.21;2.73 +49051-6;Gestational age in W;Time;Pt;^Fetus;Qn;;OB.US;2;Gestational age in weeks;GA (weeks);;ACTIVE;2.21;2.73 +49052-4;Gestational age in D;Time;Pt;^Fetus;Qn;;OB.US;2;Gestational age in days;GA (days);;ACTIVE;2.21;2.73 +49053-2;Neural tube defect;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Neural tube defect Narrative;Hx of NTD Narr;;ACTIVE;2.21;2.73 +49054-0;Ercalcidiol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;25-hydroxyvitamin D2 [Mass/volume] in Serum or Plasma;25(OH)D2 SerPl-mCnc;;ACTIVE;2.21;2.73 +49055-7;Ribonucleoprotein extractable nuclear 52kD Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ribonucleoprotein extractable nuclear 52kD Ab [Presence] in Serum;ENA RNP 52kD Ab Ser Ql;;DISCOURAGED;2.21;2.73 +4905-6;HLA-Dw2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw2 [Presence];HLA-Dw2 Ql;;ACTIVE;1.0;2.56 +49056-5;Shigella sp serotype;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Shigella sp serotype [Identifier] in Isolate by Agglutination;Shigella Sertyp Islt Aggl;;ACTIVE;2.21;2.21 +49057-3;Blood group antibody score;Score;Pt;Ser/Plas;Ord;;BLDBK;1;Blood group antibody score;Bld gp Ab score SerPl Ql;;ACTIVE;2.21;2.73 +49058-1;Coagulation surface induced;Time;Pt;BldCRRT;Qn;Coag;COAG;1;aPTT in Blood drawn from CRRT circuit by Coagulation assay;aPTT BldCRRT;;ACTIVE;2.21;2.73 +49059-9;Trisomy 21+Trisomy 18 risk;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Trisomy 21+Trisomy 18 risk [Likelihood] in Fetus;Ts 21+Ts 18 risk Fetus;;ACTIVE;2.21;2.50 +49060-7;Fondaparinux;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fondaparinux [Mass/volume] in Serum or Plasma;Fondaparinux SerPl-mCnc;;ACTIVE;2.21;2.73 +49061-5;Hepatic iron index;Ratio;Pt;Liver;Qn;;CHEM;1;Hepatic iron index;Hepatic iron index Liver-Rto;;ACTIVE;2.21;2.73 +49062-3;Lipid risk factors;Find;Pt;^Patient;Nom;;CHEM;1;Lipid risk factors [Finding];Lipid risk factors Patient;;ACTIVE;2.21;2.73 +49063-1;Microdeletion syndromes;Arb;Pt;XXX;Nom;FISH;MOLPATH.DEL;1;Microdeletion syndromes in Specimen by FISH Nominal;Microdeletion synd Spec FISH;;ACTIVE;2.21;2.69 +4906-4;HLA-Dw3;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw3 [Presence] in Donor;HLA-Dw3 Donr Ql;;ACTIVE;1.0;2.56 +49064-9;Gamma 2 globulin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis;Gamma 2 glob SerPl Elph-mCnc;;ACTIVE;2.21;2.34 +49065-6;Eastern equine encephalitis virus Ab.IgG & IgM;Imp;Pt;CSF;Nom;;MICRO;1;Eastern equine encephalitis virus IgG and IgM [Interpretation] in Cerebral spinal fluid;EEEV IgG+IgM CSF-Imp;;ACTIVE;2.21;2.73 +49066-4;Western equine encephalitis virus Ab.IgG & IgM;Imp;Pt;CSF;Nom;;MICRO;1;Western equine encephalitis virus IgG and IgM [Interpretation] in Cerebral spinal fluid;WEEV IgG+IgM CSF-Imp;;ACTIVE;2.21;2.73 +49067-2;La Crosse virus Ab.IgG & IgM;Imp;Pt;CSF;Nom;;MICRO;1;La Crosse virus IgG and IgM [Interpretation] in Cerebral spinal fluid;LACV IgG+IgM CSF-Imp;;ACTIVE;2.21;2.73 +49068-0;Saint Louis encephalitis virus Ab.IgG & IgM;Imp;Pt;CSF;Nom;;MICRO;1;Saint Louis encephalitis virus IgG and IgM [Interpretation] in Cerebral spinal fluid;SLEV IgG+IgM CSF-Imp;;ACTIVE;2.21;2.73 +49069-8;Epstein Barr virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus Ab [Titer] in Serum;EBV Ab Titr Ser;;ACTIVE;2.21;2.73 +49070-6;Specimen drawn;TmStp;Pt;CSF;Qn;;SPEC;1;Specimen drawn [Date and time] of Cerebral spinal fluid;Specimen drawn CSF;;ACTIVE;2.21;2.26 +49071-4;Urea nitrogen^post dialysis/pre dialysis;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass ratio] in Serum or Plasma--post dialysis/pre dialysis;BUN post/pre dialysis SerPl-mRto;;ACTIVE;2.21;2.73 +4907-2;HLA-Dw3;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw3 [Presence];HLA-Dw3 Ql;;ACTIVE;1.0;2.56 +49072-2;Cocaethylene;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Cocaethylene [Presence] in Hair;Cocaethylene Hair Ql;;ACTIVE;2.21;2.56 +49073-0;Influenza virus A Ab.IgG;MCnc;Pt;CSF;Qn;;MICRO;1;Influenza virus A IgG Ab [Mass/volume] in Cerebral spinal fluid;FLUAV IgG CSF-mCnc;;ACTIVE;2.21;2.70 +49074-8;Influenza virus A Ab.IgA;MCnc;Pt;CSF;Qn;;MICRO;1;Influenza virus A IgA Ab [Mass/volume] in Cerebral spinal fluid;FLUAV IgA CSF-mCnc;;ACTIVE;2.21;2.70 +49075-5;Influenza virus A Ab.IgM;MCnc;Pt;CSF;Qn;;MICRO;1;Influenza virus A IgM Ab [Mass/volume] in Cerebral spinal fluid;FLUAV IgM CSF-mCnc;;ACTIVE;2.21;2.70 +49076-3;Influenza virus B Ab.IgA;MCnc;Pt;CSF;Qn;;MICRO;1;Influenza virus B IgA Ab [Mass/volume] in Cerebral spinal fluid;FLUBV IgA CSF-mCnc;;ACTIVE;2.21;2.70 +49077-1;Influenza virus B Ab.IgG;MCnc;Pt;CSF;Qn;;MICRO;1;Influenza virus B IgG Ab [Mass/volume] in Cerebral spinal fluid;FLUBV IgG CSF-mCnc;;ACTIVE;2.21;2.70 +49078-9;Influenza virus B Ab.IgM;MCnc;Pt;CSF;Qn;;MICRO;1;Influenza virus B IgM Ab [Mass/volume] in Cerebral spinal fluid;FLUBV IgM CSF-mCnc;;ACTIVE;2.21;2.70 +49079-7;Periplaneta americana Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;American Cockroach IgE Ab RAST class [Presence] in Serum;Amer Roach IgE RAST Ql;;ACTIVE;2.21;2.73 +4908-0;HLA-Dw4;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw4 [Presence] in Donor;HLA-Dw4 Donr Ql;;ACTIVE;1.0;2.56 +49080-5;Kanamycin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Kanamycin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Kanamycin 1 ug/mL Islt SlowMyco;;ACTIVE;2.21;2.32 +49081-3;Beta-2-Microglobulin;MCnc;Pt;Dial fld;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Dialysis fluid;B2 Microglob Dial fld-mCnc;;ACTIVE;2.21;2.70 +49082-1;Western equine encephalitis virus Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Western equine encephalitis virus IgG and IgM [Interpretation] in Serum;WEEV IgG+IgM Ser-Imp;;ACTIVE;2.21;2.73 +49083-9;North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panel;-;Pt;^Patient;-;;PANEL.TUMRRGT;2;North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panel;NAACCR v 11 Pnl;;ACTIVE;2.21;2.63 +49084-7;Census block group 1970&80&90;Arb;Pt;^Patient;Ord;;TUMRRGT;2;Census block group 1970and80and90;Census block group 1970/80/90;;ACTIVE;2.21;2.68 +49085-4;First & Second trimester integrated maternal screen panel;-;Pt;^Patient;-;;PANEL.CHEM;1;First and Second trimester integrated maternal screen panel;Integrated scn Pnl Patient;;ACTIVE;2.21;2.73 +49086-2;First trimester maternal screen with nuchal translucency panel;-;Pt;^Patient;-;;PANEL.CHEM;1;First trimester maternal screen with nuchal translucency panel;1st trimester scn+NT Pnl Patient;;ACTIVE;2.21;2.73 +49087-0;Maternal screen clinical predictors panel;-;Pt;^Patient;-;;PANEL.CHEM;1;Maternal screen clinical predictors panel;Mat scn clin predictors Pnl Patient;;ACTIVE;2.21;2.73 +49088-8;Sonographer name;Pn;Pt;^Patient;Nom;;OB.US;2;Sonographer name;Sonographer name;;ACTIVE;2.21;2.73 +49089-6;Sonographer;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Sonographer [Identifier];Sonographer;;ACTIVE;2.21;2.73 +49090-4;Fetal trisomy 21 risk;Likelihood;Pt;^Fetus;Qn;Based on maternal age;CHEM;1;Fetal Trisomy 21 risk [Likelihood] Based on maternal age;Fet Ts 21 risk from Mat age;;ACTIVE;2.21;2.73 +49091-2;Neural tube defect risk;Likelihood;Pt;^Fetus;Qn;Based on maternal age;CHEM;1;Fetal Neural tube defect risk [Likelihood] Based on maternal age;Fet Neural tube def risk from Mat age Qn;;ACTIVE;2.21;2.73 +49092-0;Second trimester quad maternal screen;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Second trimester quad maternal screen [Interpretation] in Serum or Plasma Narrative;2nd trimester 4 screen SerPl-Imp;;ACTIVE;2.21;2.73 +49093-8;Arbovirus Ab.IgG & IgM panel;-;Pt;Ser;-;IF;PANEL.MICRO;1;Arbovirus IgG and IgM panel - Serum by Immunofluorescence;Arbovirus IgG+IgM Pnl Ser IF;;ACTIVE;2.21;2.42 +49094-6;Arbovirus Ab.IgG & IgM panel;-;Pt;CSF;-;IF;PANEL.MICRO;1;Arbovirus IgG and IgM panel - Cerebral spinal fluid by Immunofluorescence;Arbovirus IgG+IgM Pnl CSF IF;;ACTIVE;2.21;2.42 +49095-3;Saint Louis encephalitis virus Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Saint Louis encephalitis virus IgG and IgM [Interpretation] in Serum;SLEV IgG+IgM Ser-Imp;;ACTIVE;2.21;2.73 +49096-1;Chlamydia trachomatis DNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Units/volume] in Specimen by NAA with probe detection;C trach DNA Spec NAA+probe-aCnc;;ACTIVE;2.21;2.73 +49097-9;Creatine;MCnc;24H;Urine;Qn;;CHEM;1;Creatine [Mass/volume] in 24 hour Urine;Creatine 24h Ur-mCnc;;ACTIVE;2.21;2.73 +4909-8;HLA-Dw4;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw4 [Presence];HLA-Dw4 Ql;;ACTIVE;1.0;2.56 +49098-7;Cryptococcus neoformans rRNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Cryptococcus neoformans rRNA [Units/volume] in Specimen by NAA with probe detection;C neoform rRNA Spec NAA+probe-aCnc;;ACTIVE;2.21;2.73 +49099-5;Gadus morhua Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Codfish IgG Ab [Mass/volume] in Serum;Codfish IgG-mCnc;;ACTIVE;2.21;2.73 +49100-1;H2a-H2b DNA Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;H2a-H2b DNA IgG Ab [Presence] in Serum;H2a-H2b DNA IgG Ser Ql;;ACTIVE;2.21;2.73 +49101-9;Helicobacter pylori DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Helicobacter pylori DNA [Presence] in Specimen by NAA with probe detection;H pylori DNA Spec Ql NAA+probe;;ACTIVE;2.21;2.73 +49102-7;Herpes virus 8 DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV8 DNA SerPl NAA+probe-aCnc;;ACTIVE;2.21;2.73 +49103-5;Leukocyte casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;WBC casts [#/area] in Urine sediment by Microscopy high power field;WBC Casts #/area UrnS HPF;;ACTIVE;2.21;2.73 +49104-3;Mycoplasma pneumoniae DNA;ACnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Units/volume] in Blood by NAA with probe detection;M pneumo DNA Bld NAA+probe-aCnc;;ACTIVE;2.21;2.73 +49105-0;Phenolphthalein;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Phenolphthalein [Mass/volume] in Specimen;Phenolphthalein Spec-mCnc;;ACTIVE;2.21;2.69 +4910-6;HLA-Dw5;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw5 [Presence] in Donor;HLA-Dw5 Donr Ql;;ACTIVE;1.0;2.56 +49106-8;Phenols;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Phenols [Mass/volume] in Specimen;Phenols Spec-mCnc;;ACTIVE;2.21;2.69 +49107-6;Rubella virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rubella virus IgM Ab [Titer] in Serum;RUBV IgM Titr Ser;;ACTIVE;2.21;2.73 +49108-4;Titanium;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Titanium [Mass/volume] in Specimen;Titanium Spec-mCnc;;ACTIVE;2.21;2.73 +49109-2;Toxoplasma gondii Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Toxoplasma gondii Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;T gondii Ab CSF IA-aCnc;;ACTIVE;2.21;2.73 +491-1;Temocillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Temocillin [Susceptibility] by Minimum lethal concentration (MLC);Temocillin Islt MLC;;ACTIVE;1.0;2.19 +49110-0;Mycoplasma sp identified;Prid;Pt;Urine;Nom;Organism specific culture;MICRO;1;Mycoplasma sp identified in Urine by Organism specific culture;Mycoplasma Ur Cult;;ACTIVE;2.21;2.21 +49111-8;Spermatozoa;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Spermatozoa [#/area] in Urine sediment by Microscopy high power field;Sperm #/area UrnS HPF;;ACTIVE;2.21;2.73 +49112-6;Borna disease virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Borna disease virus Ab [Units/volume] in Serum;Borna DV Ab Ser-aCnc;;ACTIVE;2.21;2.69 +49113-4;ZAP70 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;ZAP70 Ag [Presence] in Tissue by Immune stain;ZAP70 Ag Tiss Ql ImStn;;ACTIVE;2.21;2.73 +4911-4;HLA-Dw5;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw5 [Presence];HLA-Dw5 Ql;;ACTIVE;1.0;2.56 +49114-2;Flavivirus rRNA;ACnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Flavivirus rRNA [Units/volume] (viral load) in Blood by NAA with probe detection;Flavivirus rRNA Bld NAA+probe-aCnc;;ACTIVE;2.21;2.68 +49115-9;Thiamine.free;MCnc;Pt;Bld;Qn;;CHEM;1;Thiamine.free [Mass/volume] in Blood;Vit B1 free Bld-mCnc;;ACTIVE;2.21;2.73 +49116-7;Trichosporon sp DNA;ACnc;Pt;Ser;Qn;Probe.amp.tar;MICRO;1;Trichosporon sp DNA [Units/volume] in Serum by NAA with probe detection;Trichosporon sp DNA Ser NAA+probe-aCnc;;ACTIVE;2.21;2.73 +49117-5;Norovirus Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Norovirus Ag [Presence] in Stool;Norovirus Ag Stl Ql;;ACTIVE;2.21;2.73 +49118-3;Views^W radionuclide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views;NM Views W RNC IV;;ACTIVE;2.21;2.64 +49119-1;Monosaccharides.sulfated;PrThr;Pt;Urine;Ord;;CHEM;1;Monosaccharides.sulfated [Presence] in Urine;Monosaccharides.sulfated Ur Ql;;ACTIVE;2.21;2.56 +49120-9;Immunodeficiency follow-up panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Immunodeficiency follow-up panel - Specimen by Flow cytometry (FC);Immunodeficiency follow-up Pnl Spec FC;;ACTIVE;2.21;2.73 +49121-7;Erythrocyte inclusion bodies;Prid;Pt;Bld;Nom;;HEM/BC;1;Erythrocyte inclusion bodies [Identifier] in Blood;RBC inclusions Bld;;ACTIVE;2.21;2.73 +4912-2;HLA-Dw6;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw6 [Presence] in Donor;HLA-Dw6 Donr Ql;;ACTIVE;1.0;2.56 +49122-5;Anaplasma sp identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Anaplasma sp identified in Specimen by Sequencing;Anaplasma Spec Seq;;ACTIVE;2.21;2.69 +49123-3;Bartonella sp identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Bartonella sp identified in Specimen by Sequencing;Bartonella Spec Seq;;ACTIVE;2.21;2.69 +49124-1;Coxiella burnetii identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Coxiella burnetii identified in Specimen by Sequencing;C burnet Spec Seq;;ACTIVE;2.21;2.69 +49125-8;Ehrlichia sp identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Ehrlichia sp identified in Specimen by Sequencing;Ehrlichia Spec Seq;;ACTIVE;2.21;2.69 +49126-6;Orientia tsutsugamushi identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Orientia tsutsugamushi identified in Specimen by Sequencing;O tsut Spec Seq;;ACTIVE;2.21;2.69 +49127-4;Rickettsia sp identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Rickettsia sp identified in Specimen by Sequencing;Rickettsia Spec Seq;;ACTIVE;2.21;2.69 +49128-2;Rickettsia typhus group identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Rickettsia typhus group identified in Specimen by Sequencing;Rick Typhus Spec Seq;;ACTIVE;2.21;2.69 +49129-0;Creatine kinase.MiMi/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.MiMi/Creatine kinase.total in Serum or Plasma;CK MiMi CFr SerPl;;ACTIVE;2.21;2.34 +4913-0;HLA-Dw6;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw6 [Presence];HLA-Dw6 Ql;;ACTIVE;1.0;2.56 +49130-8;Cholesterol.in HDL;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in HDL [Mass/volume] in Serum or Plasma by Electrophoresis;HDLc SerPl Elph-mCnc;;ACTIVE;2.21;2.73 +49131-6;Chylomicrons/Lipoprotein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Chylomicrons/total Lipoprotein in Serum or Plasma;Chylo MFr SerPl;;ACTIVE;2.21;2.73 +49132-4;Cholesterol.in LDL;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in LDL [Mass/volume] in Serum or Plasma by Electrophoresis;LDLc SerPl Elph-mCnc;;ACTIVE;2.21;2.73 +49133-2;Cholesterol.in VLDL;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in VLDL [Mass/volume] in Serum or Plasma by Electrophoresis;VLDLc SerPl Elph-mCnc;;ACTIVE;2.21;2.73 +49134-0;Glucose^2H post dose glucose;MCnc;Pt;Bld;Qn;;CHAL;1;Glucose [Mass/volume] in Blood --2 hours post dose glucose;Glucose 2h p Glc Bld-mCnc;;ACTIVE;2.21;2.73 +49135-7;Fractional excretion of sodium;Ratio;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Fractional excretion of sodium [Ratio] in Urine and Serum or Plasma;Fract excret Na Ur+SerPl-Rto;;ACTIVE;2.21;2.73 +49136-5;Creatine kinase.MB/Creatine kinase.total;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.MB/Creatine kinase.total [Ratio] in Serum or Plasma;CK MB SerPl-Rto;;ACTIVE;2.21;2.73 +49137-3;Hemoglobin;MCnc;Pt;Urine;Qn;Test strip;UA;1;Hemoglobin [Mass/volume] in Urine by Test strip;Hgb Ur Strip-mCnc;;ACTIVE;2.21;2.73 +49138-1;California encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;California encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CEV IgG Titr CSF IF;;ACTIVE;2.21;2.73 +49139-9;California encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;California encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CEV IgM Titr CSF IF;;ACTIVE;2.21;2.73 +49140-7;California encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;California encephalitis virus IgG Ab [Titer] in Serum by Immunofluorescence;CEV IgG Titr Ser IF;;ACTIVE;2.21;2.73 +49141-5;California encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;California encephalitis virus IgM Ab [Titer] in Serum by Immunofluorescence;CEV IgM Titr Ser IF;;ACTIVE;2.21;2.73 +49142-3;La Crosse virus Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;La Crosse virus IgG and IgM [Interpretation] in Serum;LACV IgG+IgM Ser-Imp;;ACTIVE;2.21;2.73 +49143-1;North American Association of Central Cancer Registries, Inc (NAACCR, Inc) Pathology Laboratory Electronic Reporting panel;-;Pt;^Patient;-;;PANEL.TUMRRGT;2;North American Association of Central Cancer Registries, Inc (NAACCR, Inc) Pathology Laboratory Electronic Reporting panel;NAACCR Path Lab Electronic Reporting Pnl;;ACTIVE;2.21;2.27 +49144-9;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;Body fld;Ord;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Body fluid;SLEV IgM Fld Ql;;ACTIVE;2.21;2.56 +49145-6;Rickettsia rickettsii Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia rickettsii IgG Ab [Titer] in Body fluid;R rickettsi IgG Titr Fld;;ACTIVE;2.21;2.32 +49146-4;Rickettsia rickettsii Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia rickettsii IgM Ab [Titer] in Body fluid;R rickettsi IgM Titr Fld;;ACTIVE;2.21;2.32 +49147-2;Rickettsia prowazekii Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia prowazekii IgM Ab [Titer] in Body fluid;R prowazek IgM Titr Fld;;ACTIVE;2.21;2.32 +4914-8;HLA-Dw7;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw7 [Presence] in Donor;HLA-Dw7 Donr Ql;;ACTIVE;1.0;2.56 +49148-0;Rickettsia prowazekii Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia prowazekii IgG Ab [Titer] in Body fluid;R prowazek IgG Titr Fld;;ACTIVE;2.21;2.32 +49149-8;Rickettsia parkeri Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia parkeri IgG Ab [Titer] in Body fluid;R parkeri IgG Titr Fld;;ACTIVE;2.21;2.32 +49150-6;Rickettsia parkeri Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia parkeri IgM Ab [Titer] in Body fluid;R parkeri IgM Titr Fld;;ACTIVE;2.21;2.32 +49151-4;Rickettsia parkeri Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia parkeri IgG Ab [Titer] in Serum;R parkeri IgG Titr Ser;;ACTIVE;2.21;2.32 +49152-2;Rickettsia parkeri Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia parkeri IgM Ab [Titer] in Serum;R parkeri IgM Titr Ser;;ACTIVE;2.21;2.32 +49153-0;Rickettsia conorii Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia conorii IgM Ab [Titer] in Body fluid;R conorii IgM Titr Fld;;ACTIVE;2.21;2.32 +49154-8;Rickettsia conorii Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia conorii IgG Ab [Titer] in Body fluid;R conorii IgG Titr Fld;;ACTIVE;2.21;2.32 +4915-5;HLA-Dw7;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw7 [Presence];HLA-Dw7 Ql;;ACTIVE;1.0;2.56 +49155-5;Rickettsia akari Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia akari IgM Ab [Titer] in Serum;R akari IgM Titr Ser;;ACTIVE;2.21;2.32 +49156-3;Rickettsia akari Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia akari IgM Ab [Titer] in Body fluid;R akari IgM Titr Fld;;ACTIVE;2.21;2.32 +49157-1;Rickettsia akari Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia akari IgG Ab [Titer] in Serum;R akari IgG Titr Ser;;ACTIVE;2.21;2.32 +49158-9;Rickettsia akari Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia akari IgG Ab [Titer] in Body fluid;R akari IgG Titr Fld;;ACTIVE;2.21;2.32 +49159-7;Rickettsia africae Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia africae IgG Ab [Titer] in Body fluid;R africae IgG Titr Fld;;ACTIVE;2.21;2.32 +49160-5;Rickettsia africae Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Rickettsia africae IgM Ab [Titer] in Body fluid;R africae IgM Titr Fld;;ACTIVE;2.21;2.32 +49161-3;Rickettsia africae Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia africae IgG Ab [Titer] in Serum;R africae IgG Titr Ser;;ACTIVE;2.21;2.32 +49162-1;Rickettsia africae Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Rickettsia africae IgM Ab [Titer] in Serum;R africae IgM Titr Ser;;ACTIVE;2.21;2.32 +4916-3;HLA-Dw8;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw8 [Presence] in Donor;HLA-Dw8 Donr Ql;;ACTIVE;1.0;2.56 +49163-9;Orientia tsutsugamushi Kato Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Kato IgM Ab [Titer] in Serum;O tsut Kato IgM Titr Ser;;ACTIVE;2.21;2.32 +49164-7;Orientia tsutsugamushi Kato Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Orientia tsutsugamushi Kato IgM Ab [Titer] in Body fluid;O tsut Kato IgM Titr Fld;;ACTIVE;2.21;2.32 +49165-4;Orientia tsutsugamushi Kato Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Kato IgG Ab [Titer] in Serum;O tsut Kato IgG Titr Ser;;ACTIVE;2.21;2.32 +49166-2;Orientia tsutsugamushi Kato Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Orientia tsutsugamushi Kato IgG Ab [Titer] in Body fluid;O tsut Kato IgG Titr Fld;;ACTIVE;2.21;2.32 +49167-0;Orientia tsutsugamushi Karp Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Karp IgM Ab [Titer] in Serum;O tsut Karp IgM Titr Ser;;ACTIVE;2.21;2.32 +49168-8;Orientia tsutsugamushi Karp Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Orientia tsutsugamushi Karp IgM Ab [Titer] in Body fluid;O tsut Karp IgM Titr Fld;;ACTIVE;2.21;2.32 +49169-6;Orientia tsutsugamushi Karp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Karp IgG Ab [Titer] in Serum;O tsut Karp IgG Titr Ser;;ACTIVE;2.21;2.32 +49170-4;Orientia tsutsugamushi Karp Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Orientia tsutsugamushi Karp IgG Ab [Titer] in Body fluid;O tsut Karp IgG Titr Fld;;ACTIVE;2.21;2.32 +4917-1;HLA-Dw8;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw8 [Presence];HLA-Dw8 Ql;;ACTIVE;1.0;2.56 +49171-2;Orientia tsutsugamushi Gilliam Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Gilliam IgM Ab [Titer] in Serum;O tsut Gill IgM Titr Ser;;ACTIVE;2.21;2.32 +49172-0;Orientia tsutsugamushi Gilliam Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Orientia tsutsugamushi Gilliam IgM Ab [Titer] in Body fluid;O tsut Gill IgM Titr Fld;;ACTIVE;2.21;2.32 +49173-8;Orientia tsutsugamushi Gilliam Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Gilliam IgG Ab [Titer] in Serum;O tsut Gill IgG Titr Ser;;ACTIVE;2.21;2.32 +49174-6;Orientia tsutsugamushi Gilliam Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Orientia tsutsugamushi Gilliam IgG Ab [Titer] in Body fluid;O tsut Gill IgG Titr Fld;;ACTIVE;2.21;2.32 +49175-3;Human bocavirus Ab.IgG;PrThr;Pt;XXX;Ord;;MICRO;1;Human bocavirus IgG Ab [Presence] in Specimen;HBoV IgG Spec Ql;;ACTIVE;2.21;2.69 +49176-1;Herpes virus 8 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Herpes virus 8 IgM Ab [Titer] in Serum;HHV8 IgM Titr Ser;;ACTIVE;2.21;2.32 +49177-9;Hepatitis B virus surface Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus surface IgG Ab [Presence] in Serum;HBV surface IgG Ser Ql;;ACTIVE;2.21;2.56 +49178-7;Epstein Barr virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus Ab [Presence] in Serum;EBV Ab Ser Ql;;ACTIVE;2.21;2.73 +49179-5;Ehrlichia chaffeensis Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Ehrlichia chaffeensis IgM Ab [Titer] in Body fluid;E chaffeensis IgM Titr Fld;;ACTIVE;2.21;2.32 +49180-3;Ehrlichia chaffeensis Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Ehrlichia chaffeensis IgG Ab [Titer] in Body fluid;E chaffeensis IgG Titr Fld;;ACTIVE;2.21;2.32 +49181-1;Echinococcus granulosus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echinococcus granulosus Ab [Titer] in Serum;E granulosus Ab Titr Ser;;ACTIVE;2.21;2.32 +49182-9;Coxiella burnetii phase 2 Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Titer] in Body fluid;C burnet Ph2 IgM Titr Fld;;ACTIVE;2.21;2.32 +49183-7;Coxiella burnetii phase 2 Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Titer] in Body fluid;C burnet Ph2 IgG Titr Fld;;ACTIVE;2.21;2.32 +49184-5;Coxiella burnetii phase 2 Ab.IgA;Titr;Pt;Body fld;Qn;;MICRO;1;Coxiella burnetii phase 2 IgA Ab [Titer] in Body fluid;C burnet Ph2 IgA Titr Fld;;ACTIVE;2.21;2.32 +49185-2;Coxiella burnetii phase 1 Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Titer] in Body fluid;C burnet Ph1 IgM Titr Fld;;ACTIVE;2.21;2.32 +49186-0;Coxiella burnetii phase 1 Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Titer] in Body fluid;C burnet Ph1 IgG Titr Fld;;ACTIVE;2.21;2.32 +49187-8;Coxiella burnetii phase 1 Ab.IgA;Titr;Pt;Body fld;Qn;;MICRO;1;Coxiella burnetii phase 1 IgA Ab [Titer] in Body fluid;C burnet Ph1 IgA Titr Fld;;ACTIVE;2.21;2.32 +49188-6;Corynebacterium diphtheriae toxin Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae toxin Ab [Units/volume] in Serum --2nd specimen;C diphtheriae Tox Ab sp2 Ser-aCnc;;ACTIVE;2.21;2.69 +4918-9;HLA-Dw9;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-Dw9 [Presence] in Donor;HLA-Dw9 Donr Ql;;ACTIVE;1.0;2.56 +49189-4;Corynebacterium diphtheriae toxin Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae toxin IgG Ab [Units/volume] in Serum;C diphtheriae Tox IgG Ser-aCnc;;ACTIVE;2.21;2.69 +49190-2;Coccidioides sp Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Coccidioides sp Ab [Presence] in Body fluid;Coccidioides Ab Fld Ql;;ACTIVE;2.21;2.56 +49191-0;Clostridium tetani toxoid Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani toxoid IgG Ab [Units/volume] in Serum --1st specimen;C tetani Toxoid IgG sp1 Ser-aCnc;;ACTIVE;2.21;2.73 +49192-8;Clostridium tetani toxoid Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani toxoid IgG Ab [Units/volume] in Serum --2nd specimen;C tetani Toxoid IgG sp2 Ser-aCnc;;ACTIVE;2.21;2.73 +49193-6;California encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;California encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid;CEV IgM Titr CSF;;ACTIVE;2.21;2.68 +49194-4;California encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;;MICRO;1;California encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid;CEV IgG Titr CSF;;ACTIVE;2.21;2.68 +49195-1;California encephalitis virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;California encephalitis virus IgG Ab [Units/volume] in Serum;CEV IgG Ser-aCnc;;ACTIVE;2.21;2.69 +49196-9;Brucella abortus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Brucella abortus Ab [Presence] in Cerebral spinal fluid;B abortus Ab CSF Ql;;ACTIVE;2.21;2.56 +4919-7;HLA-Dw9;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-Dw9 [Presence];HLA-Dw9 Ql;;ACTIVE;1.0;2.56 +49197-7;Bartonella vinsonii berkhoffii Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella vinsonii berkhoffii IgG Ab [Titer] in Body fluid;B vinsonii berkhoffii IgG Titr Fld;;ACTIVE;2.21;2.32 +49198-5;Bartonella vinsonii berkhoffii Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella vinsonii berkhoffii IgM Ab [Titer] in Body fluid;B vinsonii berkhoffii IgM Titr Fld;;ACTIVE;2.21;2.32 +49199-3;Bartonella vinsonii berkhoffii Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella vinsonii berkhoffii IgG Ab [Titer] in Serum;B vinsonii berkhoffii IgG Titr Ser;;ACTIVE;2.21;2.32 +49200-9;Bartonella vinsonii berkhoffii Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella vinsonii berkhoffii IgM Ab [Titer] in Serum;B vinsonii berkhoffii IgM Titr Ser;;ACTIVE;2.21;2.32 +49201-7;Bartonella quintana Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella quintana IgM Ab [Titer] in Body fluid;B quintana IgM Titr Fld;;ACTIVE;2.21;2.32 +49202-5;Bartonella quintana Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella quintana IgG Ab [Titer] in Body fluid;B quintana IgG Titr Fld;;ACTIVE;2.21;2.32 +49203-3;Bartonella henselae Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella henselae IgG Ab [Titer] in Body fluid;B henselae IgG Titr Fld;;ACTIVE;2.21;2.32 +49204-1;Bartonella henselae Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella henselae IgM Ab [Titer] in Body fluid;B henselae IgM Titr Fld;;ACTIVE;2.21;2.32 +4920-5;HLA-DPw1;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DPw1 [Presence] in Donor;HLA-DPw1 Donr Ql;;ACTIVE;1.0;2.56 +49205-8;Bartonella elizabethae Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella elizabethae IgM Ab [Titer] in Body fluid;B elizabethae IgM Titr Fld;;ACTIVE;2.21;2.32 +49206-6;Bartonella elizabethae Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella elizabethae IgG Ab [Titer] in Body fluid;B elizabethae IgG Titr Fld;;ACTIVE;2.21;2.32 +49207-4;Bartonella elizabethae Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella elizabethae IgM Ab [Titer] in Serum;B elizabethae IgM Titr Ser;;ACTIVE;2.21;2.32 +49208-2;Bartonella elizabethae Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella elizabethae IgG Ab [Titer] in Serum;B elizabethae IgG Titr Ser;;ACTIVE;2.21;2.32 +49209-0;Bartonella bacilliformis Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella bacilliformis IgM Ab [Titer] in Body fluid;B bacilliformis IgM Titr Fld;;ACTIVE;2.21;2.32 +49210-8;Bartonella bacilliformis Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Bartonella bacilliformis IgG Ab [Titer] in Body fluid;B bacilliformis IgG Titr Fld;;ACTIVE;2.21;2.32 +49211-6;Bartonella bacilliformis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella bacilliformis IgM Ab [Titer] in Serum;B bacilliformis IgM Titr Ser;;ACTIVE;2.21;2.32 +49212-4;Bartonella bacilliformis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella bacilliformis IgG Ab [Titer] in Serum;B bacilliformis IgG Titr Ser;;ACTIVE;2.21;2.32 +4921-3;HLA-DPw1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DPw1 [Presence];HLA-DPw1 Ql;;ACTIVE;1.0;2.56 +49213-2;Anaplasma phagocytophilum Ab.IgG;Titr;Pt;Body fld;Qn;;MICRO;1;Anaplasma phagocytophilum IgG Ab [Titer] in Body fluid;A phagocytoph IgG Titr Fld;;ACTIVE;2.21;2.32 +49214-0;Anaplasma phagocytophilum Ab.IgM;Titr;Pt;Body fld;Qn;;MICRO;1;Anaplasma phagocytophilum IgM Ab [Titer] in Body fluid;A phagocytoph IgM Titr Fld;;ACTIVE;2.21;2.32 +49215-7;PKHD1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PKHD1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PKHD1 gene Mut Anl Bld/T;;ACTIVE;2.21;2.63 +49216-5;Hexokinase;CCnt;Pt;RBC;Qn;;CHEM;1;Hexokinase [Enzymatic activity/mass] in Red Blood Cells;Hexokinase RBC-cCnt;;ACTIVE;2.21;2.73 +49217-3;2,3-Diphosphoglycerate;SCnt;Pt;RBC;Qn;;CHEM;1;2,3-Diphosphoglycerate [Moles/mass] in Red Blood Cells;2,3DPG RBC-sCnt;;ACTIVE;2.21;2.40 +49218-1;Phosphatidylinositol/Surfactant.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylinositol/Surfactant.total in Amniotic fluid;PI MFr Amn;;ACTIVE;2.21;2.30 +49219-9;Galactose;MCnc;Pt;RBC;Qn;;CHEM;1;Galactose [Mass/volume] in Red Blood Cells;Galactose RBC-mCnc;;ACTIVE;2.21;2.34 +49220-7;Prolactin;MCnc;Pt;Ser/Plas;Qn;3rd IS;CHEM;1;Prolactin [Mass/volume] in Serum or Plasma by 3rd IS;Prolactin SerPl 3rd IS-mCnc;;DISCOURAGED;2.21;2.73 +4922-1;HLA-DPw2;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DPw2 [Presence] in Donor;HLA-DPw2 Donr Ql;;ACTIVE;1.0;2.56 +49221-5;Catalase;CCnt;Pt;RBC;Qn;;CHEM;1;Catalase [Enzymatic activity/mass] in Red Blood Cells;Catalase RBC-cCnt;;ACTIVE;2.21;2.40 +49222-3;Food allergen panel;-;Pt;Ser;-;;PANEL.ALLERGY;1;Food allergen panel - Serum;Food allergen Pnl Ser;;ACTIVE;2.21;2.73 +49223-1;Colony count;NCnc;Pt;XXX;Qn;VC;MICRO;1;Colony count [#/volume] in Specimen by Visual count;CC # Spec VC;;ACTIVE;2.21;2.73 +49224-9;Leukocytes;Naric;Pt;Semen;Qn;Microscopy.light.HPF;HEM/BC;1;Leukocytes [#/area] in Semen by Microscopy high power field;WBC #/area Smn HPF;;ACTIVE;2.21;2.73 +49225-6;Heptacarboxylate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Heptacarboxylate/Creatinine [Molar ratio] in 24 hour Urine;Heptacarboxylate/Creat 24h Ur-sRto;;ACTIVE;2.21;2.42 +49226-4;lamiVUDine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;lamiVUDine [Mass/volume] in Serum or Plasma;lamiVUDine SerPl-mCnc;;ACTIVE;2.21;2.40 +49227-2;Stavudine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Stavudine [Mass/volume] in Serum or Plasma;Stavudine SerPl-mCnc;;ACTIVE;2.21;2.34 +49228-0;Porphobilinogen deaminase;CCnt;Pt;RBC;Qn;;CHEM;1;Porphobilinogen deaminase [Enzymatic activity/mass] in Red Blood Cells;PBG Deaminase RBC-cCnt;;ACTIVE;2.21;2.73 +49229-8;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Body fld;Qn;;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Body fluid;nRBC/100 WBC Fld-Rto;;ACTIVE;2.21;2.73 +49230-6;Acetylcholinesterase;CCnt;Pt;RBC;Qn;;CHEM;1;Acetylcholinesterase [Enzymatic activity/mass] in Red Blood Cells;AChE RBC-cCnt;;ACTIVE;2.21;2.73 +49231-4;Cholinesterase;CCnt;Pt;RBC;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/mass] in Red Blood Cells;Cholinesterase RBC-cCnt;;ACTIVE;2.21;2.73 +49232-2;Giardia lamblia+Cryptosporidium sp Ag;PrThr;Pt;Stool;Ord;Rapid, less than 30 minutes;MICRO;1;Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool by Rapid, less than 30 minutes;G lamblia+Cryptosp Ag Stl Ql Rapid;;ACTIVE;2.21;2.73 +49233-0;Giardia lamblia+Cryptosporidium parvum Ag;PrThr;Pt;Stool;Ord;Rapid, less than 30 minutes;MICRO;1;Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool by Rapid, less than 30 minutes;G lamblia+C parvum Ag Stl Ql Rapid;;ACTIVE;2.21;2.73 +49234-8;Patient symptoms^1.5H post dose lactose PO;Imp;Pt;^Patient;Nar;;CHAL;1;Patient symptoms [Interpretation] Narrative--1.5 hours post dose lactose PO;Symptoms 1.5h p Lac PO Patient-Imp;;ACTIVE;2.21;2.38 +49235-5;Patient symptoms^1H post dose lactose PO;Imp;Pt;^Patient;Nar;;CHAL;1;Patient symptoms [Interpretation] Narrative--1 hour post dose lactose PO;Symptoms 1h p Lac PO Patient-Imp;;ACTIVE;2.21;2.38 +49236-3;Patient symptoms^2.5H post dose lactose PO;Imp;Pt;^Patient;Nar;;CHAL;1;Patient symptoms [Interpretation] Narrative--2.5 hours post dose lactose PO;Symptoms 2.5h p Lac PO Patient-Imp;;ACTIVE;2.21;2.38 +49237-1;Patient symptoms^2H post dose lactose PO;Imp;Pt;^Patient;Nar;;CHAL;1;Patient symptoms [Interpretation] Narrative--2 hours post dose lactose PO;Symptoms 2h p Lac PO Patient-Imp;;ACTIVE;2.21;2.38 +49238-9;Patient symptoms^30M post dose lactose PO;Imp;Pt;^Patient;Nar;;CHAL;1;Patient symptoms [Interpretation] Narrative--30 minutes post dose lactose PO;Symptoms 30M p Lac PO Patient-Imp;;ACTIVE;2.21;2.38 +4923-9;HLA-DPw2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DPw2 [Presence];HLA-DPw2 Ql;;ACTIVE;1.0;2.56 +49239-7;Patient symptoms^3H post dose lactose PO;Imp;Pt;^Patient;Nar;;CHAL;1;Patient symptoms [Interpretation] Narrative--3 hours post dose lactose PO;Symptoms 3h p Lac PO Patient-Imp;;ACTIVE;2.21;2.38 +49240-5;Patient symptoms^pre dose lactose PO;Imp;Pt;^Patient;Nar;;CHAL;1;Patient symptoms [Interpretation] Narrative--pre dose lactose PO;Symptoms pre Lac PO Patient-Imp;;ACTIVE;2.21;2.38 +49241-3;Xylose absorption;Imp;Pt;Urine+Ser/Plas;Nar;;CHAL;1;Xylose absorption [Interpretation] in Urine and Serum or Plasma Narrative;Xylose Absorption Ur+SerPl-Imp;;ACTIVE;2.21;2.38 +49242-1;Acylcarnitine pattern;Imp;Pt;Urine;Nar;;CHEM;1;Acylcarnitine pattern [Interpretation] in Urine Narrative;Acylcarnitine pattern Ur-Imp;;ACTIVE;2.21;2.26 +49243-9;Alkaline phosphatase isoenzymes;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Alkaline phosphatase isoenzymes [Interpretation] in Serum or Plasma Narrative;ALP Isos SerPl-Imp;;ACTIVE;2.21;2.73 +49244-7;Alpha 1 antitrypsin phenotype;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Alpha 1 antitrypsin phenotype [Interpretation] in Serum or Plasma Narrative;A1AT Phenotyp SerPl-Imp;;ACTIVE;2.21;2.73 +49245-4;Alpha tocopherol & Beta+gamma tocopherol;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Alpha tocopherol and Beta+gamma tocopherol [Interpretation] in Serum or Plasma Narrative;A & B+G Tocopherol SerPl-Imp;;ACTIVE;2.21;2.73 +49246-2;Alpha-1-Fetoprotein interpretation;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Alpha-1-Fetoprotein interpretation in Serum or Plasma Narrative;AFP Interp SerPl-Imp;;ACTIVE;2.21;2.73 +4924-7;HLA-DPw3;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DPw3 [Presence] in Donor;HLA-DPw3 Donr Ql;;ACTIVE;1.0;2.56 +49247-0;Amino acid pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Amino acid pattern [Interpretation] in Serum or Plasma Narrative;Amino acid Pat SerPl-Imp;;ACTIVE;2.21;2.73 +49248-8;Amino acid pattern;Imp;Pt;Urine;Nar;;CHEM;1;Amino acid pattern [Interpretation] in Urine Narrative;Amino acid Pat Ur-Imp;;ACTIVE;2.21;2.73 +49249-6;Amino acids;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Deprecated Amino acids [interpretation] in Serum or Plasma Narrative;Deprecated Amino acids SerPl-Imp;;DEPRECATED;2.21;2.48 +49250-4;Amino acids;Imp;Pt;Urine;Nar;;CHEM;1;Deprecated Amino acids [interpretation] in Urine Narrative;Deprecated Amino acids Ur-Imp;;DEPRECATED;2.21;2.48 +49251-2;Amylase isoenzymes;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Amylase isoenzymes [Interpretation] in Serum or Plasma Narrative;Amylase Isos SerPl-Imp;;ACTIVE;2.21;2.73 +49252-0;Calculus analysis;Imp;Pt;Calculus;Nar;;CHEM;1;Calculus analysis [Interpretation] in Stone Narrative;Stone Analysis-Imp;;ACTIVE;2.21;2.73 +49253-8;Beta-N-acetylhexosaminidase A & B;Imp;Pt;Bld;Nar;;CHEM;1;Beta-N-acetylhexosaminidase A and B [Interpretation] in Blood Narrative;Hexosaminidase A & B Bld-Imp;;ACTIVE;2.21;2.38 +4925-4;HLA-DPw3;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DPw3 [Presence];HLA-DPw3 Ql;;ACTIVE;1.0;2.56 +49254-6;Bile acid pattern;Imp;Pt;Urine;Nar;;CHEM;1;Bile acid pattern [Interpretation] in Urine Narrative;Bile Ac Pattern Ur-Imp;;ACTIVE;2.21;2.73 +49255-3;Calculus analysis;Imp;Pt;Calculus;Nar;Infrared spectroscopy;CHEM;1;Calculus analysis [Interpretation] in Stone Narrative by Infrared spectroscopy;Stone Analysis IR-Imp;;ACTIVE;2.21;2.73 +49256-1;Catecholamines;Imp;Pt;Urine;Nar;;CHEM;1;Catecholamines [Interpretation] in Urine Narrative;Catechols Ur-Imp;;ACTIVE;2.21;2.73 +49257-9;Catecholamines;Imp;Pt;Plas;Nar;;CHEM;1;Catecholamines [Interpretation] in Plasma Narrative;Catechols Plas-Imp;;ACTIVE;2.21;2.73 +49258-7;Creatine kinase isoenzymes;Imp;Pt;Ser/Plas;Nar;Electrophoresis;CHEM;1;Creatine kinase isoenzymes [Interpretation] in Serum or Plasma by Electrophoresis Narrative;CK Isos SerPl Elph-Imp;;ACTIVE;2.21;2.21 +49259-5;Creatine kinase isoenzymes;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Creatine kinase isoenzymes [Interpretation] in Serum or Plasma Narrative;CK Isos SerPl-Imp;;ACTIVE;2.21;2.73 +49260-3;Cryoglobulin IgA & IgG & IgM;Imp;Pt;Ser;Nar;;CHEM;1;Cryoglobulin IgA and IgG and IgM [Interpretation] in Serum Narrative;Cryoglob IgA & IgG & IgM Ser-Imp;;ACTIVE;2.21;2.38 +49261-1;Cryoproteins;Imp;Pt;Ser;Nar;Electrophoresis.agarose gel;CHEM;1;Cryoproteins [Interpretation] in Serum by Electrophoresis agarose gel Narrative;Cryoproteins Ser AG Elph-Imp;;ACTIVE;2.21;2.21 +4926-2;HLA-DPw4;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DPw4 [Presence] in Donor;HLA-DPw4 Donr Ql;;ACTIVE;1.0;2.56 +49262-9;Fatty acids pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Fatty acids pattern [Interpretation] in Serum or Plasma Narrative;Fatty acids pattern SerPl-Imp;;ACTIVE;2.21;2.73 +49263-7;Fatty acids.very long chain pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Fatty acids.very long chain pattern [Interpretation] in Serum or Plasma Narrative;VLCFA Pattern SerPl-Imp;;ACTIVE;2.21;2.73 +49264-5;Folate+Cyanocobalamin;Imp;Pt;Ser/Bld;Nar;;CHEM;1;Folate+Cyanocobalamin [Interpretation] in Serum or Blood Narrative;Folate+Vit B12 SerBld-Imp;;ACTIVE;2.21;2.21 +49265-2;Gammopathy;Imp;Pt;Ser;Nar;Electrophoresis;CHEM;1;Gammopathy [Interpretation] in Serum by Electrophoresis Narrative;Gammopathy Ser Elph-Imp;;ACTIVE;2.21;2.21 +49266-0;Glucose-6-Phosphate dehydrogenase phenotype;Imp;Pt;RBC;Nar;;CHEM;1;Glucose-6-Phosphate dehydrogenase phenotype [Interpretation] in Red Blood Cells Narrative;G6PD Phenotyp RBC-Imp;;ACTIVE;2.21;2.21 +49267-8;Glutathione reductase phenotype;Imp;Pt;RBC;Nar;;CHEM;1;Glutathione reductase phenotype [Interpretation] in Red Blood Cells Narrative;GR Phenotyp RBC-Imp;;ACTIVE;2.21;2.21 +49268-6;Glycosaminoglycans pattern;Imp;Pt;Urine;Nar;;CHEM;1;Glycosaminoglycans pattern [Interpretation] in Urine Narrative;GAG Pattern Ur-Imp;;ACTIVE;2.21;2.73 +49269-4;Homovanillate & Creatinine;Imp;Pt;Urine;Nar;;CHEM;1;Homovanillate and Creatinine [Interpretation] in Urine Narrative;HVA & Creat Ur-Imp;;ACTIVE;2.21;2.73 +4927-0;HLA-DPw4;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DPw4 [Presence];HLA-DPw4 Ql;;ACTIVE;1.0;2.56 +49270-2;Immunoglobulin light chains;Imp;Pt;Urine;Nar;;CHEM;1;Immunoglobulin light chains [Interpretation] in Urine Narrative;BJ Protein Ur-Imp;;ACTIVE;2.21;2.73 +49271-0;Interpretation;Imp;Pt;CSF;Nar;Immunofixation;CHEM;1;Immunofixation for Cerebral spinal fluid Narrative;Interpretation CSF IFE-Imp;;ACTIVE;2.21;2.54 +49272-8;Interpretation;Imp;Pt;CSF;Nar;Immunoelectrophoresis;CHEM;1;Immunoelectrophoresis for Cerebral spinal fluid Narrative;Interpretation CSF IEP-Imp;;ACTIVE;2.21;2.54 +49273-6;Interpretation;Imp;Pt;Body fld;Nar;Immunofixation;CHEM;1;Immunofixation for Body fluid Narrative;Interpretation Fld IFE-Imp;;ACTIVE;2.21;2.54 +49274-4;Interpretation;Imp;Pt;Ser/Plas;Nar;Immunoelectrophoresis;CHEM;1;Immunoelectrophoresis for Serum or Plasma Narrative;Interpretation SerPl IEP-Imp;;ACTIVE;2.21;2.73 +49275-1;Interpretation;Imp;Pt;Ser/Plas;Nar;Immunofixation;CHEM;1;Immunofixation for Serum or Plasma Narrative;Interpretation SerPl IFE-Imp;;ACTIVE;2.21;2.73 +49276-9;Interpretation;Imp;Pt;Urine;Nar;Immunofixation;CHEM;1;Immunofixation for Urine Narrative;Interpretation Ur IFE-Imp;;ACTIVE;2.21;2.73 +49277-7;Interpretation;Imp;24H;Urine;Nar;Immunofixation;CHEM;1;Immunofixation for 24 hour Urine Narrative;Interpretation 24h Ur IFE-Imp;;ACTIVE;2.21;2.73 +49278-5;Interpretation;Imp;Pt;Urine;Nar;Immunoelectrophoresis;CHEM;1;Immunoelectrophoresis for Urine Narrative;Interpretation Ur IEP-Imp;;ACTIVE;2.21;2.73 +49279-3;Lactate dehydrogenase isoenzymes;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Lactate dehydrogenase isoenzymes [Interpretation] in Serum or Plasma Narrative;LDH Isos SerPl-Imp;;ACTIVE;2.21;2.73 +49280-1;Lipoprotein pattern;Imp;Pt;Ser/Plas;Nar;Electrophoresis;CHEM;1;Lipoprotein fractions [Interpretation] in Serum or Plasma by Electrophoresis Narrative;LP SerPl Elph-Imp;;ACTIVE;2.21;2.21 +49281-9;Lipoprotein pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Lipoprotein fractions [Interpretation] in Serum or Plasma Narrative;LP SerPl-Imp;;ACTIVE;2.21;2.21 +49282-7;Metanephrine & Normetanephrine;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Metanephrine and Normetanephrine [Interpretation] in Serum or Plasma Narrative;Metaneph+Normetaneph SerPl-Imp;;ACTIVE;2.21;2.73 +49283-5;Metanephrine & Normetanephrine;Imp;Pt;Urine;Nar;;CHEM;1;Metanephrine and Normetanephrine [Interpretation] in Urine Narrative;Metaneph+Normetaneph Ur-Imp;;ACTIVE;2.21;2.73 +49284-3;Oligosaccharides pattern;Imp;Pt;Urine;Nar;;CHEM;1;Oligosaccharides pattern [Interpretation] in Urine Narrative;Oligosaccharide Pattern Ur-Imp;;ACTIVE;2.21;2.21 +49285-0;Organic acids pattern;Imp;Pt;CSF;Nar;;CHEM;1;Organic acids pattern [Interpretation] in Cerebral spinal fluid Narrative;Organic Acids Pattern CSF-Imp;;ACTIVE;2.21;2.21 +49286-8;Organic acids pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Organic acids pattern [Interpretation] in Serum or Plasma Narrative;Organic Acids Pattern SerPl-Imp;;ACTIVE;2.21;2.73 +49287-6;Organic acids pattern;Imp;Pt;Urine;Nar;;CHEM;1;Organic acids pattern [Interpretation] in Urine Narrative;Organic Acids Pattern Ur-Imp;;ACTIVE;2.21;2.73 +4928-8;HLA-DPw5;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DPw5 [Presence] in Donor;HLA-DPw5 Donr Ql;;ACTIVE;1.0;2.56 +49288-4;Parathyrin;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Parathyrin [Interpretation] in Serum or Plasma Narrative;PTH SerPl-Imp;;ACTIVE;2.21;2.73 +49289-2;Porphyrins;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Porphyrins [Interpretation] in Serum or Plasma Narrative;Porphyrins SerPl-Imp;;ACTIVE;2.21;2.73 +492-9;Temocillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Temocillin [Susceptibility] by Minimum inhibitory concentration (MIC);Temocillin Islt MIC;;ACTIVE;1.0;2.19 +49290-0;Porphyrins;Imp;Pt;Stool;Nar;;CHEM;1;Porphyrins [Interpretation] in Stool Narrative;Porphyrins Stl-Imp;;ACTIVE;2.21;2.21 +49291-8;Porphyrins;Imp;Pt;Urine;Nar;;CHEM;1;Porphyrins [Interpretation] in Urine Narrative;Porphyrins Ur-Imp;;ACTIVE;2.21;2.73 +49292-6;Porphyrin fractions;Imp;24H;Urine;Nar;;CHEM;1;Porphyrin fractions [Interpretation] in 24 hour Urine Narrative;Porphyrin Fract 24h Ur-Imp;;ACTIVE;2.21;2.73 +49293-4;Protein fractions.oligoclonal bands;Imp;Pt;CSF;Nar;Electrophoresis;CHEM;1;Oligoclonal bands [Interpretation] in Cerebral spinal fluid by Electrophoresis Narrative;Oligoclonal Bands CSF Elph-Imp;;ACTIVE;2.21;2.73 +49294-2;Protein fractions.oligoclonal bands;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Oligoclonal bands [Interpretation] in Serum or Plasma Narrative;Oligoclonal Bands SerPl-Imp;;ACTIVE;2.21;2.54 +49295-9;Protein pattern;Imp;Pt;CSF;Nar;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in Cerebral spinal fluid by Electrophoresis Narrative;Prot Pattern CSF Elph-Imp;;ACTIVE;2.21;2.73 +4929-6;HLA-DPw5;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DPw5 [Presence];HLA-DPw5 Ql;;ACTIVE;1.0;2.56 +49296-7;Protein pattern;Imp;Pt;Ser/Plas;Nar;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in Serum or Plasma by Electrophoresis Narrative;Prot Pattern SerPl Elph-Imp;;ACTIVE;2.21;2.73 +49297-5;Protein pattern;Imp;Pt;Ser/Plas;Nar;Immunofixation;CHEM;1;Protein Fractions [Interpretation] in Serum or Plasma by Immunofixation Narrative;Prot Pattern SerPl IFE-Imp;;ACTIVE;2.21;2.73 +49298-3;Protein pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Protein Fractions [Interpretation] in Serum or Plasma Narrative;Prot Pattern SerPl-Imp;;ACTIVE;2.21;2.73 +49299-1;Protein pattern;Imp;Pt;Urine;Nar;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in Urine by Electrophoresis Narrative;Prot Pattern Ur Elph-Imp;;ACTIVE;2.21;2.73 +49300-7;Protein pattern;Imp;Pt;Urine;Nar;Immunofixation;CHEM;1;Protein Fractions [Interpretation] in Urine by Immunofixation Narrative;Prot Pattern Ur IFE-Imp;;ACTIVE;2.21;2.73 +49301-5;Protein pattern;Imp;24H;Urine;Nar;Electrophoresis;CHEM;1;Protein Fractions [Interpretation] in 24 hour Urine by Electrophoresis Narrative;Prot Pattern 24h Ur Elph-Imp;;ACTIVE;2.21;2.73 +49302-3;Protein pattern;Imp;Pt;XXX;Nar;Immunofixation;CHEM;1;Protein Fractions [Interpretation] in Specimen by Immunofixation Narrative;Prot Pattern Spec IFE-Imp;;ACTIVE;2.21;2.69 +49303-1;Amino acid pattern;Imp;Pt;CSF;Nar;;CHEM;1;Amino acid pattern [Interpretation] in Cerebral spinal fluid Narrative;Amino acid Pat CSF-Imp;;ACTIVE;2.21;2.73 +4930-4;HLA-DPw6;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DPw6 [Presence] in Donor;HLA-DPw6 Donr Ql;;ACTIVE;1.0;2.56 +49304-9;Uranium dose assessment;Imp;Pt;Urine;Nar;;DRUG/TOX;1;Uranium dose assessment [Interpretation] in Urine Narrative;Uranium Dose Assessment Ur-Imp;;ACTIVE;2.21;2.21 +49305-6;Spermatozoa evaluation.cervical mucus penetration test;Imp;Pt;Semen;Nar;;FERT;1;Cervical Mucus Penetration Test [Interpretation] in Semen Narrative;CMSPT Smn-Imp;;ACTIVE;2.21;2.21 +49306-4;Spermatozoa evaluation.hamster ova penetration test;Imp;Pt;Semen;Nar;;FERT;1;Hamster Ova Penetration Test [Interpretation] in Semen Narrative;SPA Smn-Imp;;ACTIVE;2.21;2.21 +49307-2;Myocardium Ab pattern;Imp;Pt;Ser;Nar;;SERO;1;Myocardium Ab pattern [Interpretation] in Serum Narrative;Myocardium Ab pattern Ser-Imp;;ACTIVE;2.21;2.21 +49308-0;Neutrophil cytoplasmic Ab pattern;Imp;Pt;Ser;Nar;IF;SERO;1;Neutrophil cytoplasmic Ab pattern [Interpretation] in Serum by Immunofluorescence Narrative;ANCA Ab pattern Ser IF-Imp;;ACTIVE;2.21;2.73 +49309-8;Nuclear Ab pattern;Imp;Pt;Body fld;Nar;IF;SERO;1;Nuclear Ab pattern [Interpretation] in Body fluid by Immunofluorescence Narrative;ANA Pat Fld IF-Imp;;ACTIVE;2.21;2.22 +49310-6;Nuclear Ab pattern;Imp;Pt;Ser;Nar;;SERO;1;Nuclear Ab pattern [Interpretation] in Serum Narrative;ANA Pat Ser-Imp;;ACTIVE;2.21;2.73 +49311-4;Nuclear Ab pattern;Imp;Pt;Ser;Nar;IF;SERO;1;Nuclear Ab pattern [Interpretation] in Serum by Immunofluorescence Narrative;ANA Pat Ser IF-Imp;;ACTIVE;2.21;2.73 +4931-2;HLA-DPw6;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DPw6 [Presence];HLA-DPw6 Ql;;ACTIVE;1.0;2.56 +49312-2;Acute leukemia markers;Imp;Pt;XXX;Nom;;CELLMARK;1;Acute leukemia markers [Interpretation] in Specimen;Acute leukemia markers Spec-Imp;;ACTIVE;2.21;2.73 +49313-0;Chronic leukemia markers;Imp;Pt;XXX;Nom;;CELLMARK;1;Chronic leukemia markers [Interpretation] in Specimen;Chronic Leukemia Markers Spec-Imp;;ACTIVE;2.21;2.73 +49314-8;Immunodeficiency markers;Imp;Pt;XXX;Nom;;CELLMARK;1;Immunodeficiency markers [Interpretation] in Specimen;Immunodeficiency Markers Spec-Imp;;ACTIVE;2.21;2.73 +49315-5;Hemolytic disease of newborn screen;Imp;Pt;Bld;Nar;;BLDBK;1;Hemolytic disease of newborn screen [Interpretation] in Blood Narrative;HDNB Scn Bld-Imp;;ACTIVE;2.21;2.73 +49316-3;Hemoglobin pattern;Imp;Pt;Bld;Nom;Electrophoresis;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by Electrophoresis;Hgb Fract Bld Elph-Imp;;ACTIVE;2.21;2.73 +49317-1;Hemoglobin pattern;Imp;Pt;Bld;Nar;;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood Narrative;Hgb Fract Bld-Imp;;ACTIVE;2.21;2.73 +49318-9;Alpha-1-Fetoprotein interpretation;Imp;Pt;Amnio fld;Nar;;CHEM;1;Alpha-1-Fetoprotein interpretation in Amniotic fluid Narrative;AFP Interp Amn-Imp;;ACTIVE;2.21;2.73 +49319-7;Beta glucosidase activator;Imp;Pt;Fibroblasts;Nar;;CHEM;1;Beta glucosidase activator [Interpretation] in Fibroblast Narrative;B-Glucosidase Act Fib-Imp;;ACTIVE;2.21;2.21 +4932-0;HLA-DQ1;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ1 [Presence] in Donor;HLA-DQ1 Donr Ql;;ACTIVE;1.0;2.56 +49320-5;Beta-N-acetylhexosaminidase.A activator;Imp;Pt;Fibroblasts;Nar;;CHEM;1;Beta-N-acetylhexosaminidase.A activator [Interpretation] in Fibroblast Narrative;Hexosaminidase A Act Fib-Imp;;ACTIVE;2.21;2.21 +49321-3;Cerebroside sulfatase activator;Imp;Pt;Fibroblasts;Nar;;CHEM;1;Cerebroside sulfatase activator [Interpretation] in Fibroblast Narrative;Cerebro Sulfatase Act Fib-Imp;;ACTIVE;2.21;2.21 +49322-1;Hemoglobin pattern;Imp;Pt;Bld;Nom;HPLC;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by HPLC;Hgb Fract Bld HPLC-Imp;;ACTIVE;2.21;2.73 +49323-9;Hemoglobin pattern;Imp;Pt;Bld;Nom;Electrophoresis.citrate agar;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by Electrophesis citrate agar;Hgb Fract Bld Elph Citrate-Imp;;ACTIVE;2.21;2.73 +49324-7;11-Deoxycortisol^2H post dose metyraPONE;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --2 hours post dose metyraPONE;11DC 2h p MTP SerPl-mCnc;;ACTIVE;2.22;2.40 +49325-4;17-Hydroxypregnenolone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;17OH-Preg 1h p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +49326-2;Aldosterone^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Aldost 2h p chal SerPl-mCnc;;ACTIVE;2.22;2.34 +49327-0;Androstenedione^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Androst 1h p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +49328-8;Clavulanate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clavulanate IgE Ab [Units/volume] in Serum;Clavulanate IgE Qn;;ACTIVE;2.22;2.70 +49329-6;Interferon.alpha Ab;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Interferon alpha Ab [Presence] in Serum or Plasma by Immunoassay;IFN-A Ab SerPl Ql IA;;ACTIVE;2.22;2.56 +49330-4;Renin^3H post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --3 hours post XXX challenge;Renin 3h p chal Plas-cCnc;;ACTIVE;2.22;2.42 +49331-2;Renin^2H post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --2 hours post XXX challenge;Renin 2h p chal Plas-cCnc;;ACTIVE;2.22;2.42 +49332-0;Vasopressin^30M post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Mass/volume] in Plasma --30 minutes post XXX challenge;Vasopressin 30M p chal Plas-mCnc;;ACTIVE;2.22;2.42 +49333-8;Galactitol;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Galactitol [Moles/volume] in Amniotic fluid;Galactitol Amn-sCnc;;ACTIVE;2.22;2.42 +49334-6;Adenovirus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HAdV DNA # SerPl NAA+probe;;ACTIVE;2.22;2.73 +49335-3;Adenovirus DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HAdV DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49336-1;Adenovirus DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;HAdV DNA # BAL NAA+probe;;ACTIVE;2.22;2.70 +49337-9;Adenovirus DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HAdV DNA # Mar NAA+probe;;ACTIVE;2.22;2.73 +4933-8;HLA-DQ1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ1 [Presence];HLA-DQ1 Ql;;ACTIVE;1.0;2.73 +49338-7;Adenovirus DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HAdV DNA # CSF NAA+probe;;ACTIVE;2.22;2.70 +49339-5;Adenovirus DNA;NCnc;Pt;Stool;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Stool by NAA with probe detection;HAdV DNA # Stl NAA+probe;;ACTIVE;2.22;2.73 +49340-3;Adenovirus DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HAdV DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49341-1;Adenovirus DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Blood by NAA with probe detection;HAdV DNA # Bld NAA+probe;;ACTIVE;2.22;2.70 +49342-9;BK virus DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Tissue by NAA with probe detection;BKV DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49343-7;BK virus DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;BKV DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49344-5;BK virus DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;BKV DNA # CSF NAA+probe;;ACTIVE;2.22;2.73 +49345-2;BK virus DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Blood by NAA with probe detection;BKV DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +4934-6;HLA-DQ2;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ2 [Presence] in Donor;HLA-DQ2 Donr Ql;;ACTIVE;1.0;2.56 +49346-0;BK virus DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;BKV DNA # BAL NAA+probe;;ACTIVE;2.22;2.70 +49347-8;Cytomegalovirus DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Urine by NAA with probe detection;CMV DNA # Ur NAA+probe;;ACTIVE;2.22;2.73 +49348-6;Cytomegalovirus DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Amniotic fluid by NAA with probe detection;CMV DNA # Amn NAA+probe;;ACTIVE;2.22;2.63 +49349-4;Cytomegalovirus DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;CMV DNA # BAL NAA+probe;;ACTIVE;2.22;2.63 +49350-2;Cytomegalovirus DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;CMV DNA # Mar NAA+probe;;ACTIVE;2.22;2.73 +49351-0;Cytomegalovirus DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Tissue by NAA with probe detection;CMV DNA # Tiss NAA+probe;;ACTIVE;2.22;2.63 +49352-8;Epstein Barr virus DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Urine by NAA with probe detection;EBV DNA # Ur NAA+probe;;ACTIVE;2.22;2.63 +4935-3;HLA-DQ2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ2 [Presence];HLA-DQ2 Ql;;ACTIVE;1.0;2.73 +49353-6;Epstein Barr virus DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;EBV DNA # Mar NAA+probe;;ACTIVE;2.22;2.63 +49354-4;Epstein Barr virus DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;EBV DNA # BAL NAA+probe;;ACTIVE;2.22;2.63 +49355-1;Epstein Barr virus DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Amniotic fluid by NAA with probe detection;EBV DNA # Amn NAA+probe;;ACTIVE;2.22;2.63 +49356-9;Epstein Barr virus DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [#/volume] (viral load) in Tissue by NAA with probe detection;EBV DNA # Tiss NAA+probe;;ACTIVE;2.22;2.63 +49357-7;Hepatitis B virus DNA;ACnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HBV DNA CSF NAA+probe-aCnc;;ACTIVE;2.22;2.70 +49358-5;Hepatitis B virus DNA;ACnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Units/volume] (viral load) in Bone marrow by NAA with probe detection;HBV DNA Mar NAA+probe-aCnc;;ACTIVE;2.22;2.70 +49359-3;Hepatitis B virus DNA;LnCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Log #/volume] (viral load) in Bone marrow by NAA with probe detection;HBV DNA Mar NAA+probe-Log#;;ACTIVE;2.22;2.63 +49360-1;Hepatitis B virus DNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Units/volume] (viral load) in Specimen by NAA with probe detection;HBV DNA Spec NAA+probe-aCnc;;ACTIVE;2.22;2.73 +4936-1;HLA-DQ3;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ3 [Presence] in Donor;HLA-DQ3 Donr Ql;;ACTIVE;1.0;2.56 +49361-9;Hepatitis B virus DNA;LnCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Log #/volume] (viral load) in Tissue by NAA with probe detection;HBV DNA Tiss NAA+probe-Log#;;ACTIVE;2.22;2.63 +49362-7;Hepatitis B virus DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HBV DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49363-5;Hepatitis B virus DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HBV DNA # CSF NAA+probe;;ACTIVE;2.22;2.70 +49364-3;Hepatitis B virus DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HBV DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49365-0;Hepatitis B virus DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HBV DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49366-8;Hepatitis B virus DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HBV DNA Spec NAA+probe-Log#;;ACTIVE;2.22;2.69 +49367-6;Hepatitis B virus DNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HBV DNA CSF NAA+probe-Log#;;ACTIVE;2.22;2.63 +49368-4;Hepatitis B virus DNA;ACnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Units/volume] (viral load) in Tissue by NAA with probe detection;HBV DNA Tiss NAA+probe-aCnc;;ACTIVE;2.22;2.70 +49369-2;Hepatitis C virus RNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HCV RNA # CSF NAA+probe;;ACTIVE;2.22;2.70 +493-7;Temocillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Temocillin [Susceptibility] by Disk diffusion (KB);Temocillin Islt KB;;ACTIVE;1.0;2.19 +49370-0;Hepatitis C virus RNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HCV RNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49371-8;Hepatitis C virus RNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [#/volume] (viral load) in Tissue by NAA with probe detection;HCV RNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49372-6;Hepatitis C virus RNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HCV RNA Spec NAA+probe-Log#;;ACTIVE;2.22;2.73 +49373-4;Hepatitis C virus RNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HCV RNA CSF NAA+probe-Log#;;ACTIVE;2.22;2.63 +49374-2;Hepatitis C virus RNA;LnCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Log #/volume] (viral load) in Bone marrow by NAA with probe detection;HCV RNA Mar NAA+probe-Log#;;ACTIVE;2.22;2.63 +49375-9;Hepatitis C virus RNA;LnCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Log #/volume] (viral load) in Tissue by NAA with probe detection;HCV RNA Tiss NAA+probe-Log#;;ACTIVE;2.22;2.63 +49376-7;Hepatitis C virus RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;HCV RNA Spec NAA+probe-aCnc;;ACTIVE;2.22;2.73 +49377-5;Hepatitis C virus RNA;ACnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HCV RNA CSF NAA+probe-aCnc;;ACTIVE;2.22;2.70 +49378-3;Hepatitis C virus RNA;ACnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Bone marrow by NAA with probe detection;HCV RNA Mar NAA+probe-aCnc;;ACTIVE;2.22;2.70 +4937-9;HLA-DQ3;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ3 [Presence];HLA-DQ3 Ql;;ACTIVE;1.0;2.56 +49379-1;Hepatitis C virus RNA;ACnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Tissue by NAA with probe detection;HCV RNA Tiss NAA+probe-aCnc;;ACTIVE;2.22;2.73 +49380-9;Hepatitis C virus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [#/volume] (viral load) in Specimen by NAA with probe detection;HCV RNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49381-7;Herpes simplex virus 1+2 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HSV1+2 DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49382-5;Herpes simplex virus 1+2 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HSV1+2 DNA # Tiss NAA+probe;;ACTIVE;2.22;2.73 +49383-3;Herpes simplex virus 1+2 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Urine by NAA with probe detection;HSV1+2 DNA # Ur NAA+probe;;ACTIVE;2.22;2.63 +49384-1;Herpes simplex virus 1+2 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HSV1+2 DNA # Mar NAA+probe;;ACTIVE;2.22;2.63 +49385-8;Herpes simplex virus 1+2 DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Amniotic fluid by NAA with probe detection;HSV1+2 DNA # Amn NAA+probe;;ACTIVE;2.22;2.63 +49386-6;Herpes simplex virus 1+2 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;HSV1+2 DNA # BAL NAA+probe;;ACTIVE;2.22;2.63 +4938-7;HLA-DQ4;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ4 [Presence] in Donor;HLA-DQ4 Donr Ql;;ACTIVE;1.0;2.56 +49387-4;Herpes virus 6 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;HHV6 DNA # BAL NAA+probe;;ACTIVE;2.22;2.73 +49388-2;Herpes virus 6 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HHV6 DNA # CSF NAA+probe;;ACTIVE;2.22;2.73 +49389-0;Herpes virus 6 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HHV6 DNA # Mar NAA+probe;;ACTIVE;2.22;2.73 +49390-8;Herpes virus 6 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HHV6 DNA # Tiss NAA+probe;;ACTIVE;2.22;2.63 +49391-6;Herpes virus 6 DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Blood by NAA with probe detection;HHV6 DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +49392-4;Herpes virus 6 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV6 DNA # SerPl NAA+probe;;ACTIVE;2.22;2.73 +49393-2;Herpes virus 6 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [#/volume] (viral load) in Urine by NAA with probe detection;HHV6 DNA # Ur NAA+probe;;ACTIVE;2.22;2.63 +49394-0;Herpes virus 7 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Urine by NAA with probe detection;HHV7 DNA # Ur NAA+probe;;ACTIVE;2.22;2.63 +4939-5;HLA-DQ4;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ4 [Presence];HLA-DQ4 Ql;;ACTIVE;1.0;2.56 +49395-7;Herpes virus 7 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;HHV7 DNA # BAL NAA+probe;;ACTIVE;2.22;2.63 +49396-5;Herpes virus 7 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HHV7 DNA # Mar NAA+probe;;ACTIVE;2.22;2.63 +49397-3;Herpes virus 7 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV7 DNA # SerPl NAA+probe;;ACTIVE;2.22;2.73 +49398-1;Herpes virus 7 DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Blood by NAA with probe detection;HHV7 DNA # Bld NAA+probe;;ACTIVE;2.22;2.63 +49399-9;Herpes virus 7 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HHV7 DNA # Spec NAA+probe;;ACTIVE;2.22;2.69 +49400-5;Herpes virus 7 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HHV7 DNA # CSF NAA+probe;;ACTIVE;2.22;2.63 +49401-3;Herpes virus 7 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HHV7 DNA # Tiss NAA+probe;;ACTIVE;2.22;2.63 +49402-1;Herpes virus 8 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HHV8 DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +4940-3;HLA-DQ5(1);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ5(1) [Presence] in Donor;HLA-DQ5(1) Donr Ql;;ACTIVE;1.0;2.56 +49403-9;Herpes virus 8 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HHV8 DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49404-7;Herpes virus 8 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HHV8 DNA # SerPl NAA+probe;;ACTIVE;2.22;2.73 +49405-4;Herpes virus 8 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Urine by NAA with probe detection;HHV8 DNA # Ur NAA+probe;;ACTIVE;2.22;2.63 +49406-2;Herpes virus 8 DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Blood by NAA with probe detection;HHV8 DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +49407-0;Herpes virus 8 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HHV8 DNA # CSF NAA+probe;;ACTIVE;2.22;2.63 +49408-8;Herpes virus 8 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HHV8 DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49409-6;Herpes virus 8 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;HHV8 DNA # BAL NAA+probe;;ACTIVE;2.22;2.70 +49410-4;JC virus DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;JCPyV DNA # CSF NAA+probe;;ACTIVE;2.22;2.73 +4941-1;HLA-DQ5(1);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ5(1) [Presence];HLA-DQ5(1) Ql;;ACTIVE;1.0;2.56 +49411-2;JC virus DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Urine by NAA with probe detection;JCPyV DNA # Ur NAA+probe;;ACTIVE;2.22;2.73 +49412-0;JC virus DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Specimen by NAA with probe detection;JCPyV DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49413-8;JC virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;JCPyV DNA # SerPl NAA+probe;;ACTIVE;2.22;2.73 +49414-6;JC virus DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Blood by NAA with probe detection;JCPyV DNA # Bld NAA+probe;;ACTIVE;2.22;2.70 +49415-3;JC virus DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;JCPyV DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49416-1;JC virus DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;JCPyV DNA # BAL NAA+probe;;ACTIVE;2.22;2.70 +49417-9;JC virus DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [#/volume] (viral load) in Tissue by NAA with probe detection;JCPyV DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49418-7;Papova virus SV40 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;SV40 DNA # BAL NAA+probe;;ACTIVE;2.22;2.70 +49419-5;Papova virus SV40 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;SV40 DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49420-3;Papova virus SV40 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;SV40 DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49421-1;Papova virus SV40 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;SV40 DNA # CSF NAA+probe;;ACTIVE;2.22;2.70 +49422-9;Papova virus SV40 DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Blood by NAA with probe detection;SV40 DNA # Bld NAA+probe;;ACTIVE;2.22;2.70 +49423-7;Papova virus SV40 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Urine by NAA with probe detection;SV40 DNA # Ur NAA+probe;;ACTIVE;2.22;2.70 +49424-5;Papova virus SV40 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;SV40 DNA # SerPl NAA+probe;;ACTIVE;2.22;2.70 +49425-2;Papova virus SV40 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;SV40 DNA # Spec NAA+probe;;ACTIVE;2.22;2.70 +49426-0;Papova virus SV40 DNA;NCnc;Pt;Stool;Qn;Probe.amp.tar;MICRO;1;Papova virus SV 40 DNA [#/volume] (viral load) in Stool by NAA with probe detection;SV40 DNA # Stl NAA+probe;;ACTIVE;2.22;2.70 +49427-8;Parvovirus B19 DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Amniotic fluid by NAA with probe detection;B19V DNA # Amn NAA+probe;;ACTIVE;2.22;2.70 +49428-6;Parvovirus B19 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;B19V DNA # BAL NAA+probe;;ACTIVE;2.22;2.70 +4942-9;HLA-DQ6(1);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ6(1) [Presence] in Donor;HLA-DQ6(1) Donr Ql;;ACTIVE;1.0;2.56 +49429-4;Parvovirus B19 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;B19V DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49430-2;Parvovirus B19 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;B19V DNA # CSF NAA+probe;;ACTIVE;2.22;2.70 +49431-0;Parvovirus B19 DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Blood by NAA with probe detection;B19V DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +49432-8;Parvovirus B19 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;B19V DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49433-6;Parvovirus B19 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Urine by NAA with probe detection;B19V DNA # Ur NAA+probe;;ACTIVE;2.22;2.70 +49434-4;Parvovirus B19 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;B19V DNA # SerPl NAA+probe;;ACTIVE;2.22;2.73 +49435-1;Parvovirus B19 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;B19V DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49436-9;Pneumocystis jiroveci DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Blood by NAA with probe detection;P jiroveci DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +4943-7;HLA-DQ6(1);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ6(1) [Presence];HLA-DQ6(1) Ql;;ACTIVE;1.0;2.56 +49437-7;Pneumocystis jiroveci DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Tissue by NAA with probe detection;P jiroveci DNA # Tiss NAA+probe;;ACTIVE;2.22;2.70 +49438-5;Pneumocystis jiroveci DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Bronchoalveolar lavage by NAA with probe detection;P jiroveci DNA # BAL NAA+probe;;ACTIVE;2.22;2.73 +49439-3;Pneumocystis jiroveci DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Cerebral spinal fluid by NAA with probe detection;P jiroveci DNA # CSF NAA+probe;;ACTIVE;2.22;2.70 +49440-1;Pneumocystis jiroveci DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Serum or Plasma by NAA with probe detection;P jiroveci DNA # SerPl NAA+probe;;ACTIVE;2.22;2.70 +49441-9;Pneumocystis jiroveci DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Specimen by NAA with probe detection;P jiroveci DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49442-7;Pneumocystis jiroveci DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Bone marrow by NAA with probe detection;P jiroveci DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49443-5;Toxoplasma gondii DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Urine by NAA with probe detection;T gondii DNA # Ur NAA+probe;;ACTIVE;2.22;2.70 +49444-3;Toxoplasma gondii DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Amniotic fluid by NAA with probe detection;T gondii DNA # Amn NAA+probe;;ACTIVE;2.22;2.70 +4944-5;HLA-DQ7(3);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ7(3) [Presence] in Donor;HLA-DQ7(3) Donr Ql;;ACTIVE;1.0;2.56 +49445-0;Toxoplasma gondii DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Bronchoalveolar lavage by NAA with probe detection;T gondii DNA # BAL NAA+probe;;ACTIVE;2.22;2.73 +49446-8;Toxoplasma gondii DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Bone marrow by NAA with probe detection;T gondii DNA # Mar NAA+probe;;ACTIVE;2.22;2.70 +49447-6;Toxoplasma gondii DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Blood by NAA with probe detection;T gondii DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +49448-4;Toxoplasma gondii DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Specimen by NAA with probe detection;T gondii DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +49449-2;Toxoplasma gondii DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Serum or Plasma by NAA with probe detection;T gondii DNA # SerPl NAA+probe;;ACTIVE;2.22;2.70 +494-5;Temocillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Temocillin [Susceptibility] by Serum bactericidal titer;Temocillin Titr SBT;;ACTIVE;1.0;2.32 +49450-0;Varicella zoster virus DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Tissue by NAA with probe detection;VZV DNA # Tiss NAA+probe;;ACTIVE;2.22;2.63 +49451-8;Varicella zoster virus DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Specimen by NAA with probe detection;VZV DNA # Spec NAA+probe;;ACTIVE;2.22;2.73 +4945-2;HLA-DQ7(3);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ7(3) [Presence];HLA-DQ7(3) Ql;;ACTIVE;1.0;2.56 +49452-6;Varicella zoster virus DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Urine by NAA with probe detection;VZV DNA # Ur NAA+probe;;ACTIVE;2.22;2.63 +49453-4;Varicella zoster virus DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;VZV DNA # Mar NAA+probe;;ACTIVE;2.22;2.63 +49454-2;Varicella zoster virus DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Amniotic fluid by NAA with probe detection;VZV DNA # Amn NAA+probe;;ACTIVE;2.22;2.63 +49455-9;Varicella zoster virus DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;VZV DNA # BAL NAA+probe;;ACTIVE;2.22;2.63 +49456-7;Alpha synuclein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alpha synuclein Ag [Presence] in Tissue by Immune stain;a-synuclein Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49457-5;Androgen receptor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Androgen receptor Ag [Presence] in Tissue by Immune stain;AR Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49458-3;Annexin 1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Annexin 1 Ag [Presence] in Tissue by Immune stain;Annexin 1 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49459-1;Alzheimer precursor protein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alzheimer precursor protein Ag [Presence] in Tissue by Immune stain;APP Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +4946-0;HLA-DQ8(3);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ8(3) [Presence] in Donor;HLA-DQ8(3) Donr Ql;;ACTIVE;1.0;2.56 +49460-9;Beta catenin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Beta catenin Ag [Presence] in Tissue by Immune stain;b-catenin Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49461-7;C4d Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;C4d Ag [Presence] in Tissue by Immune stain;C4d Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49462-5;Calponin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Calponin Ag [Presence] in Tissue by Immune stain;Calponin Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49463-3;CD1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD1 Ag [Presence] in Tissue by Immune stain;CD1 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49464-1;CD13 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD13 Ag [Presence] in Tissue by Immune stain;CD13 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49465-8;CD14 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD14 Ag [Presence] in Tissue by Immune stain;CD14 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49466-6;CD2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD2 Ag [Presence] in Tissue by Immune stain;CD2 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49467-4;CD22 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD22 Ag [Presence] in Tissue by Immune stain;CD22 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49468-2;CD27 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD27 Ag [Presence] in Tissue by Immune stain;CD27 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49469-0;CD33 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD33 Ag [Presence] in Tissue by Immune stain;CD33 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49470-8;CD35 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD35 Ag [Presence] in Tissue by Immune stain;CD35 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49471-6;IgG subclass 4 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;IgG subclass 4 Ag [Presence] in Tissue by Immune stain;IgG4 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49472-4;Mammaglobin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Mammaglobin Ag [Presence] in Tissue by Immune stain;Mammaglobin Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49473-2;CD123 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD123 Ag [Presence] in Tissue by Immune stain;CD123 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49474-0;CD163 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD163 Ag [Presence] in Tissue by Immune stain;CD163 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49475-7;CD41-Bf Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD41-Bf Ag [Presence] in Tissue by Immune stain;CD41-Bf Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49476-5;Cyclooxygenase 2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cyclooxygenase 2 Ag [Presence] in Tissue by Immune stain;COX2 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49477-3;CXCL13 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CXCL13 Ag [Presence] in Tissue by Immune stain;CXCL13 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +4947-8;HLA-DQ8(3);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ8(3) [Presence];HLA-DQ8(3) Ql;;ACTIVE;1.0;2.56 +49478-1;CXCR5 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CXCR5 Ag [Presence] in Tissue by Immune stain;CXCR5 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49479-9;FOXP3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;FOXP3 Ag [Presence] in Tissue by Immune stain;FOXP3 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49480-7;Herpes virus 8 latent nuclear Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Herpes virus 8 latent nuclear Ag [Presence] in Tissue by Immune stain;HHV8 LN Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49481-5;TCL-1A Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;TCL-1A Ag [Presence] in Tissue by Immune stain;TCL-1A Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49482-3;Vascular endothelial growth factor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Vascular endothelial growth factor Ag [Presence] in Tissue by Immune stain;VEGF Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49483-1;HIV 1;Imp;Pt;Ser/Plas;Nar;IA;MICRO;1;HIV 1 [Interpretation] in Serum or Plasma by Immunoassay Narrative;HIV1 SerPl IA-Imp;;ACTIVE;2.22;2.56 +49484-9;Phenylalanine;PrThr;Pt;Bld;Ord;;CHEM;1;Phenylalanine [Presence] in Blood;Phe Bld Ql;;ACTIVE;2.22;2.56 +49485-6;Platelet aggregation.ristocetin induced^1800 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --1800 ug/mL;PA Rist 1800 ug/mL PRP;;ACTIVE;2.22;2.54 +4948-6;HLA-DQ9(3);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DQ9(3) [Presence] in Donor;HLA-DQ9(3) Donr Ql;;ACTIVE;1.0;2.56 +49486-4;Alphapinene;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Alphapinene [Presence] in Blood;Alphapinene Bld Ql;;ACTIVE;2.22;2.56 +49487-2;Nateglinide;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Nateglinide [Presence] in Serum or Plasma;Nateglinide SerPl Ql;;ACTIVE;2.22;2.73 +49488-0;Collection time;TmStp;Pt;Body fld;Qn;;SPEC;1;Collection time of Body fluid;Collect Tme Fld;;ACTIVE;2.22;2.73 +49489-8;Microbiology section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Microbiology section;FDA insert Microbiology;;ACTIVE;2.22;2.34 +49490-6;BCR-ABL1 b2a2 fusion protein;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;BCR-ABL1 b2a2 fusion protein [Presence] in Blood or Tissue by Molecular genetics method;BCR-ABL1 b2a2 Bld/T Ql;;ACTIVE;2.22;2.56 +49491-4;BCR-ABL1 b3a2 fusion protein;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;BCR-ABL1 b3a2 fusion protein [Presence] in Blood or Tissue by Molecular genetics method;BCR-ABL1 b3a2 Bld/T Ql;;ACTIVE;2.22;2.56 +49492-2;Leukemia markers;Imp;Pt;CSF;Nar;;CELLMARK;1;Leukemia markers [Interpretation] in Cerebral spinal fluid Narrative;Leukemia markers CSF-Imp;;ACTIVE;2.22;2.22 +49493-0;Leukemia markers;Imp;Pt;Bld;Nar;;CELLMARK;1;Leukemia markers [Interpretation] in Blood Narrative;Leukemia markers Bld-Imp;;ACTIVE;2.22;2.73 +4949-4;HLA-DQ9(3);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ9(3) [Presence];HLA-DQ9(3) Ql;;ACTIVE;1.0;2.56 +49494-8;Leukemia markers;Imp;Pt;Plr fld;Nar;;CELLMARK;1;Leukemia markers [Interpretation] in Pleural fluid Narrative;Leukemia markers Plr-Imp;;ACTIVE;2.22;2.26 +49495-5;Hepatitis B virus surface Ab Actual/Negative control;RelACnc;Pt;Ser/Plas;Qn;;MICRO;1;Hepatitis B virus surface Ab actual/Negative control in Serum or Plasma;HBV surface Ab S SerPl;;ACTIVE;2.22;2.68 +49496-3;BCR-ABL1 e1a1 fusion protein;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;BCR-ABL1 e1a1 fusion protein [Presence] in Blood or Tissue by Molecular genetics method;BCR-ABL1 e1a1 Bld/T Ql;;ACTIVE;2.22;2.56 +49497-1;Platelets;NCnc;Pt;Bld;Qn;Estimate;HEM/BC;1;Platelets [#/volume] in Blood by Estimate;Platelet # Bld Est;;ACTIVE;2.22;2.73 +49498-9;Leukocytes;NCnc;Pt;Bld;Qn;Estimate;HEM/BC;1;Leukocytes [#/volume] in Blood by Estimate;WBC # Bld Est;;ACTIVE;2.22;2.73 +49499-7;Blood.dried/Total;MFr;Pt;Calculus;Qn;;SPEC;1;Blood.dried/Total of Stone;Bld.dried MFr Stone;;ACTIVE;2.22;2.73 +49500-2;Calcium oxalate dihydrate/Total;MFr;Pt;Calculus;Qn;Infrared spectroscopy;CHEM;1;Calcium oxalate dihydrate/Total in Stone by Infrared spectroscopy;Calcium Oxalate Dihydrate MFr Stone IR;;ACTIVE;2.22;2.73 +49501-0;Calcium oxalate monohydrate/Total;MFr;Pt;Calculus;Qn;Infrared spectroscopy;CHEM;1;Calcium oxalate monohydrate/Total in Stone by Infrared spectroscopy;COM MFr Stone IR;;ACTIVE;2.22;2.70 +4950-2;HLA-DR10;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR10 [Presence] in Donor;HLA-DR10 Donr Ql;;ACTIVE;1.0;2.56 +49502-8;Glucose-6-Phosphate dehydrogenase;EntCat;Pt;Bld;Qn;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Entitic Catalytic Activity] in Blood;G6PD Bld Qn;;ACTIVE;2.22;2.73 +49503-6;Neutrophil cytoplasmic Ab.perinuclear.atypical;Titr;Pt;Ser;Qn;IF;SERO;1;Neutrophil cytoplasmic Ab.perinuclear.atypical [Titer] in Serum by Immunofluorescence;p-ANCA atypical Titr Ser IF;;ACTIVE;2.22;2.73 +49504-4;CMT demyelinating gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CMT demyelinating gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CMT1 gene Mut Anl Bld/T;;ACTIVE;2.22;2.63 +49505-1;Erythrocyte clumps;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Erythrocyte clumps [#/area] in Urine sediment by Automated count;RBC clumps #/area UrnS Auto;;ACTIVE;2.22;2.73 +49506-9;MYOC gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MYOC gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MYOC gene Mut Anl Bld/T;;ACTIVE;2.22;2.63 +49507-7;Multisection^W contrast IV;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region W contrast IV;MR W contr IV;;ACTIVE;2.22;2.69 +49508-5;Study observation.general;Imp;Pt;^Fetus;Nar;US.doppler;OB.US;2;Fetal Narrative [Interpretation] Study observation general US.doppler;DOP Fetus Study [Imp];;ACTIVE;2.22;2.50 +49509-3;View^W contrast intra duct;Find;Pt;Breast>Breast duct.right;Doc;MG;RAD;2;MG Breast duct - right Single view W contrast intra duct;MG Brst duct-R 1V W contr intra Dct;;ACTIVE;2.22;2.64 +4951-0;HLA-DR10;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR10 [Presence];HLA-DR10 Ql;;ACTIVE;1.0;2.56 +49510-1;View^W contrast intra duct;Find;Pt;Breast>Breast duct.left;Doc;MG;RAD;2;MG Breast duct - left Single view W contrast intra duct;MG Brst duct-L 1V W contr intra Dct;;ACTIVE;2.22;2.64 +49511-9;View runoff^WO & W contrast IA;Find;Pt;Lower extremity>Femoral artery;Doc;RF.angio;RAD;2;RFA Femoral artery Runoff WO and W contrast IA;RFA Fem a Runoff WO+W contr IA;;ACTIVE;2.22;2.61 +49512-7;Views;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Views;RF Views;;ACTIVE;2.22;2.64 +49513-5;Study observation;Find;Pt;Abdomen^Fetuses;Nar;US;OB.US;2;Fetal Abdomen Narrative Study observation, multiple fetuses US;US Abd Fetuses Study;;ACTIVE;2.22;2.40 +49514-3;Acetaldehyde;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Acetaldehyde [Presence] in Gastric fluid;Acetaldehyde Gast Ql;;ACTIVE;2.22;2.56 +49515-0;Bisacodyl;MCnc;Pt;Stool;Qn;;DRUG/TOX;1;Bisacodyl [Mass/volume] in Stool;Bisacodyl Stl-mCnc;;ACTIVE;2.22;2.70 +49516-8;Topiramate^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Topiramate [Mass/volume] in Serum or Plasma --peak;Topiramate Peak SerPl-mCnc;;ACTIVE;2.22;2.70 +49517-6;Topiramate^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Topiramate [Mass/volume] in Serum or Plasma --trough;Topiramate Trough SerPl-mCnc;;ACTIVE;2.22;2.70 +49518-4;Influenza virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus Ab [Titer] in Serum;FLUV Ab Titr Ser;;ACTIVE;2.22;2.32 +49519-2;Influenza virus A H16 Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A H16 Ab [Titer] in Serum by Hemagglutination inhibition;FLUAV H16 Ab Titr Ser HAI;;ACTIVE;2.22;2.32 +495-2;Tetracycline;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Tetracycline [Susceptibility] by Minimum lethal concentration (MLC);Tetracycline Islt MLC;;ACTIVE;1.0;2.19 +49520-0;Influenza virus A H1 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Presence] in Isolate by NAA with probe detection;FLUAV H1 RNA Islt Ql NAA+probe;;ACTIVE;2.22;2.73 +49521-8;Influenza virus A H1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Presence] in Specimen by NAA with probe detection;FLUAV H1 RNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49522-6;Influenza virus A H3 Ag;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Influenza virus A H3 Ag [Presence] in Isolate by Immunofluorescence;FLUAV H3 Ag Islt Ql IF;;ACTIVE;2.22;2.56 +49523-4;Influenza virus A H3 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Isolate by NAA with probe detection;FLUAV H3 RNA Islt Ql NAA+probe;;ACTIVE;2.22;2.73 +49524-2;Influenza virus A H3 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Specimen by NAA with probe detection;FLUAV H3 RNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49525-9;Influenza virus A H5 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Influenza virus A H5 Ab [Presence] in Serum;FLUAV H5 Ab Ser Ql;;ACTIVE;2.22;2.56 +49526-7;Influenza virus A H5 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H5 RNA [Presence] in Isolate by NAA with probe detection;FLUAV H5 RNA Islt Ql NAA+probe;;ACTIVE;2.22;2.63 +49527-5;Influenza virus A H7 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H7 RNA [Presence] in Isolate by NAA with probe detection;FLUAV H7 RNA Islt Ql NAA+probe;;ACTIVE;2.22;2.63 +4952-8;HLA-DR11(5);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR11(5) [Presence] in Donor;HLA-DR11(5) Donr Ql;;ACTIVE;1.0;2.56 +49528-3;Influenza virus A H9 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H9 RNA [Presence] in Specimen by NAA with probe detection;FLUAV H9 RNA Spec Ql NAA+probe;;ACTIVE;2.22;2.69 +49529-1;Influenza virus A Ag;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Isolate by Immunofluorescence;FLUAV Ag Islt Ql IF;;ACTIVE;2.22;2.56 +49530-9;Influenza virus A neuraminidase cDNA;ACnc;Pt;Isolate;Ord;Amplification/Sequencing;MICRO;1;Deprecated Influenza virus A neuraminidase cDNA [Presence] in Isolate by Amplification/Sequencing;Deprecated FLUAV NA cDNA Islt Ql Amp/Seq;;DEPRECATED;2.22;2.36 +49531-7;Influenza virus A RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Isolate by NAA with probe detection;FLUAV RNA Islt Ql NAA+probe;;ACTIVE;2.22;2.73 +49532-5;Influenza virus A hemagglutinin type RNA;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A hemagglutinin type RNA [Identifier] in Isolate by Sequencing;FLUAV HA RNA Islt Seq;;DISCOURAGED;2.22;2.42 +49533-3;Influenza virus B Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Influenza virus B Ab [Presence] in Serum by Immunoassay;FLUBV Ab Ser Ql IA;;ACTIVE;2.22;2.56 +49534-1;Influenza virus B Ag;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Isolate by Immunofluorescence;FLUBV Ag Islt Ql IF;;ACTIVE;2.22;2.56 +49535-8;Influenza virus B RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Isolate by NAA with probe detection;FLUBV RNA Islt Ql NAA+probe;;ACTIVE;2.22;2.73 +4953-6;HLA-DR11(5);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR11(5) [Presence];HLA-DR11(5) Ql;;ACTIVE;1.0;2.56 +49536-6;Influenza virus B RNA;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus B RNA [Identifier] in Isolate by Sequencing;FLUBV RNA Islt Seq;;DISCOURAGED;2.22;2.40 +49537-4;Influenza virus A & B RNA;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Influenza virus A and B RNA [Identifier] in Isolate by NAA with probe detection;FLUAV + FLUBV RNA Islt NAA+probe;;ACTIVE;2.22;2.67 +49538-2;Influenza virus identified;Prid;Pt;XXX;Nom;Shell vial culture;MICRO;1;Influenza virus identified in Specimen by Shell vial culture;FLUV Spec Shell Vial Cult;;ACTIVE;2.22;2.73 +49539-0;Cytomegalovirus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Cytomegalovirus IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;CMV IgM SerPl Ql IF;;ACTIVE;2.22;2.73 +49540-8;Acid citrate dextrose;Vol;Pt;^BPU;Qn;;BLDBK;1;Acid citrate dextrose [Volume] in Blood product unit;Acid citrate dextrose Vol BPU;;ACTIVE;2.22;2.73 +49541-6;Fasting status;PrThr;Pt;^Patient;Ord;Reported;MISC;1;Fasting status - Reported;Fasting status Patient Ql Reported;;ACTIVE;2.22;2.73 +49542-4;Date and time of pheresis procedure;TmStp;Pt;^Patient;Qn;;BLDBK;1;Date and time of pheresis procedure;Date+time Pheresis;;ACTIVE;2.22;2.73 +49543-2;Calcidiol+Calciferol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Calcidiol+Calciferol [Mass/volume] in Serum or Plasma;Deprecated Calcidiol+Calciferol SerPl-mC;;DEPRECATED;2.22;2.70 +4954-4;HLA-DR12(5);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR12(5) [Presence] in Donor;HLA-DR12(5) Donr Ql;;ACTIVE;1.0;2.56 +49544-0;Newborn screening recommended follow-up;Imp;Pt;^Patient;Nom;;CHEM;1;Newborn screening recommended follow-up [Interpretation];NB screen recommended f/u Patient-Imp;;ACTIVE;2.22;2.73 +49545-7;JC virus DNA;ACnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [Units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;JCPyV DNA CSF NAA+probe-aCnc;;ACTIVE;2.22;2.69 +49546-5;Specimen age;Time;Pt;Bld;Qn;;SPEC;1;Age of Blood specimen;Age Bld specimen;;ACTIVE;2.22;2.73 +49547-3;JC virus DNA;ACnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;JC virus DNA [Units/volume] (viral load) in Blood by NAA with probe detection;JCPyV DNA Bld NAA+probe-aCnc;;ACTIVE;2.22;2.73 +49548-1;Date referral lab test sent;TmStp;XXX;Referral lab test;Qn;;MISC;1;Date referral lab test sent;Date ref lab test sent;;ACTIVE;2.22;2.73 +49549-9;Referral lab test method;Type;Pt;Referral lab test;Nar;;MISC;1;Referral lab test method;Ref lab test method;;ACTIVE;2.22;2.73 +49550-7;Leukocytes.CD59 deficient/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD59 Deficient leukocytes/100 cells in Blood;CD59 deficient WBC NFr Bld;;ACTIVE;2.22;2.73 +4955-1;HLA-DR12(5);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR12(5) [Presence];HLA-DR12(5) Ql;;ACTIVE;1.0;2.56 +49551-5;Creatine kinase.MB;MCnc;Pt;Bld;Qn;;CHEM;1;Creatine kinase.MB [Mass/volume] in Blood;CK MB Bld-mCnc;;ACTIVE;2.22;2.73 +49552-3;Epinephrine+Norepinephrine;MCnc;Pt;Urine;Qn;;CHEM;1;Epinephrine+Norepinephrine [Mass/volume] in Urine;Epineph+Nor Ur-mCnc;;ACTIVE;2.22;2.42 +49553-1;Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda.free;MRto;24H;Urine;Qn;;CHEM;1;Kappa light chains.free/Lambda light chains.free [Mass Ratio] in 24 hour Urine;Kappa LC Free/Lambda Free 24h Ur;;ACTIVE;2.22;2.73 +49554-9;Beta F1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Beta F1 Ag [Presence] in Tissue by Immune stain;Beta F1 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49555-6;HLA-A+B+C Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;HLA-A+B+C (class I) Ag [Presence] in Tissue by Immune stain;HLA-A+B+C Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49556-4;p16INK4a Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;p16INK4a Ag [Presence] in Tissue by Immune stain;p16INK4a Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +49557-2;PDGFR-beta Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PDGFR-beta Ag [Presence] in Tissue by Immune stain;PDGFR-beta Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49558-0;TAU 3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;TAU 3 Ag [Presence] in Tissue by Immune stain;TAU 3 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49559-8;TAU 4 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;TAU 4 Ag [Presence] in Tissue by Immune stain;TAU 4 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +49560-6;Payment procedure;Prid;Pt;^Patient;Nom;;CLIN;2;Payment procedure;Payment procedure;;ACTIVE;2.22;2.73 +49561-4;Payment diagnosis;Prid;Pt;^Patient;Nom;;CLIN;2;Payment diagnosis [identifier];Payment Dx;;ACTIVE;2.22;2.40 +49562-2;Holoprosencephaly gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Holoprosencephaly gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HPE gene Mut Anl Bld/T;;ACTIVE;2.22;2.66 +49563-0;Troponin I.cardiac;MCnc;Pt;Ser/Plas;Qn;Detection limit <= 0.01 ng/mL;CHEM;1;Troponin I.cardiac [Mass/volume] in Serum or Plasma by Detection limit <= 0.01 ng/mL;Troponin I SerPl DL<=0.01 ng/mL-mCnc;;ACTIVE;2.22;2.73 +49564-8;Epstein Barr virus band pattern;Imp;Pt;XXX;Nar;IB;MICRO;1;Epstein Barr virus band pattern [Interpretation] in Specimen by Immunoblot Narrative;EBV Patrn Spec IB-Imp;;ACTIVE;2.22;2.73 +49565-5;Multisection;Find;Pt;Chest>Spine.thoracic vessels;Doc;MR.angio;RAD;2;MRA Thoracic spine vessels;MRA T-spine ves;;ACTIVE;2.22;2.61 +49566-3;Multisection^at rest+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart at rest and W Tc-99m Sestamibi IV;SPECT Hrt Rest+W Tc99mMIBI IV;;ACTIVE;2.22;2.61 +49567-1;Multisection perfusion^W adenosine+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion W adenosine and W Tc-99m Sestamibi IV;SPECT Hrt PF W ADE+Tc99mMIBI IV;;ACTIVE;2.22;2.61 +49568-9;Multisection perfusion^at rest+W stress+W Tl-201 IV+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion at rest and W stress and W Tl-201 IV and W Tc-99m Sestamibi IV;SPECT Hrt PF R+S+W Tl201+Tc99mMIBI IV;;ACTIVE;2.22;2.61 +4956-9;HLA-DR13(6);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR13(6) [Presence] in Donor;HLA-DR13(6) Donr Ql;;ACTIVE;1.0;2.56 +49569-7;Multisection perfusion+wall motion^at rest+W stress+W Tl-201 IV+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart perfusion and wall motion at rest and W stress and W Tl-201 IV and W Tc-99m Sestamibi IV;SPECT Hrt PF+WM R+S+W Tl201+Tc99mMIBI IV;;ACTIVE;2.22;2.61 +49570-5;Views GE 6;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral GE 6 Views;XR Ankle-Bl GE 6V;;ACTIVE;2.22;2.61 +49571-3;Views limited^W I-131 MIBG IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Limited Views W I-131 MIBG IV;NM Views Ltd W I-131 mIBG IV;;ACTIVE;2.22;2.64 +49572-1;Second trimester triple maternal screen;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Second trimester triple maternal screen [Interpretation] in Serum or Plasma Narrative;2nd trimester 3 screen SerPl-Imp;;ACTIVE;2.22;2.73 +49573-9;HIV genotype;Susc;Pt;Isolate;Nar;Genotyping;ABXBACT;1;HIV genotype [Susceptibility] in Isolate by Genotype method Narrative;HIV Gentyp Islt Nar;;ACTIVE;2.22;2.73 +49574-7;Phosphatidylinositol+Phosphatidylserine/Surfactant.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylinositol+Phosphatidylserine/Surfactant.total in Amniotic fluid;PI+PS MFr Amn;;ACTIVE;2.22;2.70 +49575-4;Sphingomyelin/Surfactant.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Sphingomyelin/Surfactant.total in Amniotic fluid;Sphingomyelin MFr Amn;;ACTIVE;2.22;2.70 +49576-2;Phosphatidylethanolamine/Surfactants.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylethanolamine/Surfactants.total in Amniotic fluid;PE MFr Amn;;ACTIVE;2.22;2.70 +4957-7;HLA-DR13(6);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR13(6) [Presence];HLA-DR13(6) Ql;;ACTIVE;1.0;2.56 +49577-0;Lecithin/Surfactant.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Lecithin/Surfactant.total in Amniotic fluid;Lecithin MFr Amn;;ACTIVE;2.22;2.70 +49578-8;Aminocaproate cutoff;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aminocaproate cutoff [Mass/volume] in Serum or Plasma;Amicaproate CtO SerPl-mCnc;;ACTIVE;2.22;2.73 +49579-6;Aminocaproate;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Aminocaproate [Presence] in Serum or Plasma;Amicaproate SerPl Ql;;ACTIVE;2.22;2.56 +49580-4;HIV 1+2 Ab;PrThr;Pt;XXX;Ord;IA.rapid;MICRO;1;HIV 1+2 Ab [Presence] in Specimen by Rapid immunoassay;HIV1+2 Ab Spec Ql IA.rapid;;ACTIVE;2.22;2.73 +49581-2;Referral lab test identifier and name;ID;Pt;Referral lab test;Nom;;MISC;1;Referral lab test identifier and name [Identifier];Ref Lab Test ID+Name;;ACTIVE;2.22;2.73 +49582-0;Trisomy 18 risk cutoff;Find;Pt;^Fetus;Qn;;CHEM;1;Trisomy 18 risk cutoff in Fetus;Ts 18 risk CtO Fetus;;ACTIVE;2.22;2.73 +49583-8;Trisomy 21 risk cutoff;Find;Pt;^Fetus;Qn;;CHEM;1;Trisomy 21 risk cutoff in Fetus;Ts 21 risk CtO Fetus;;ACTIVE;2.22;2.73 +49584-6;Neural tube defect risk cutoff;Find;Pt;^Fetus;Qn;;CHEM;1;Neural tube defect risk cutoff in Fetus;Neural tube defect risk CtO Fetus;;ACTIVE;2.22;2.73 +4958-5;HLA-DR14(6);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR14(6) [Presence] in Donor;HLA-DR14(6) Donr Ql;;ACTIVE;1.0;2.56 +49585-3;Alpha-1-Fetoprotein multiple of the median cutoff;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein multiple of the median cutoff [Multiple of the median] in Serum or Plasma;AFP MoM c/o MoM SerPl;;ACTIVE;2.22;2.73 +49586-1;First & Second trimester integrated maternal screen;Imp;Pt;^Patient;Nom;;CHEM;1;First and Second trimester integrated maternal screen [Interpretation];Integrated scn Patient-Imp;;ACTIVE;2.22;2.73 +49587-9;Protein.abnormal band;MCnc;Pt;Ser;Qn;;CHEM;1;Protein.abnormal band [Mass/volume] in Serum;Abn Prot Ser-mCnc;;ACTIVE;2.22;2.73 +49588-7;First trimester maternal screen with nuchal translucency;Imp;Pt;^Patient;Nar;;CHEM;1;First trimester maternal screen with nuchal translucency [Interpretation] Narrative;1st trimester scn+NT Patient-Imp;;ACTIVE;2.22;2.73 +49589-5;Bacterial susceptibility panel;-;Pt;Isolate;OrdQn;Gradient strip;PANEL.ABXBACT;1;Bacterial susceptibility panel by Gradient strip;Bacterial Susc Pnl Islt Grad strip;;ACTIVE;2.22;2.73 +49590-3;Calcidiol & Calciferol panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Calcidiol and Calciferol panel - Serum or Plasma;Vit D25+D1,25 OH Pnl SerPl;;ACTIVE;2.22;2.73 +49591-1;Calcidiol & Calciferol;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Calcidiol and Calciferol [Interpretation] in Serum or Plasma Narrative;Calcidiol & Calciferol SerPl-Imp;;ACTIVE;2.22;2.38 +49592-9;Satratoxin Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Satratoxin IgM Ab [Units/volume] in Serum by Immunoassay;Satratoxin IgM Ser IA-aCnc;;ACTIVE;2.22;2.69 +4959-3;HLA-DR14(6);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR14(6) [Presence];HLA-DR14(6) Ql;;ACTIVE;1.0;2.56 +49593-7;Trichothecene Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichothecene IgA Ab [Units/volume] in Serum by Immunoassay;Trichothecene IgA Ser IA-aCnc;;ACTIVE;2.22;2.69 +49594-5;Trichothecene Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichothecene IgG Ab [Units/volume] in Serum by Immunoassay;Trichothecene IgG Ser IA-aCnc;;ACTIVE;2.22;2.69 +49595-2;Trichothecene Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichothecene IgM Ab [Units/volume] in Serum by Immunoassay;Trichothecene IgM Ser IA-aCnc;;ACTIVE;2.22;2.69 +49596-0;Uroporphyrinogen decarboxylase;ACnc;Pt;RBC;Qn;;CHEM;1;Uroporphyrinogen decarboxylase [Units/volume] in Red Blood Cells;URO-D RBC-aCnc;;ACTIVE;2.22;2.73 +49597-8;Trichothecene Ab.IgE;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trichothecene IgE Ab [Units/volume] in Serum by Immunoassay;Trichothecene IgE Ser IA-aCnc;;ACTIVE;2.22;2.56 +49598-6;Natalizumab Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Natalizumab Ab [Presence] in Serum by Immunoassay;Natalizumab Ab Ser Ql IA;;ACTIVE;2.22;2.73 +49599-4;Granulocytes.CD55;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD55 Granulocytes [Presence] in Blood;CD55 Granulocytes Bld Ql;;ACTIVE;2.22;2.73 +496-0;Tetracycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tetracycline [Susceptibility] by Minimum inhibitory concentration (MIC);Tetracycline Islt MIC;;ACTIVE;1.0;2.73 +49600-0;Hepatitis B virus DNA;LaCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [log units/volume] (viral load) in Specimen by NAA with probe detection;HBV DNA Spec NAA+probe-Log IU;;ACTIVE;2.22;2.73 +4960-1;HLA-DR15(2);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR15(2) [Presence] in Donor;HLA-DR15(2) Donr Ql;;ACTIVE;1.0;2.56 +49601-8;Hepatitis B virus DNA;LaCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [log units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HBV DNA CSF NAA+probe-Log IU;;ACTIVE;2.22;2.70 +49602-6;Hepatitis B virus DNA;LaCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [log units/volume] (viral load) in Bone marrow by NAA with probe detection;HBV DNA Mar NAA+probe-Log IU;;ACTIVE;2.22;2.70 +49603-4;Hepatitis C virus RNA;LaCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [log units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HCV RNA CSF NAA+probe-Log IU;;ACTIVE;2.22;2.70 +49604-2;Hepatitis C virus RNA;LaCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [log units/volume] (viral load) in Bone marrow by NAA with probe detection;HCV RNA Mar NAA+probe-Log IU;;ACTIVE;2.22;2.70 +49605-9;Hepatitis C virus RNA;LaCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [log units/volume] (viral load) in Specimen by NAA with probe detection;HCV RNA Spec NAA+probe-Log IU;;ACTIVE;2.22;2.73 +49606-7;Hepatitis B virus DNA;LaCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [log units/volume] (viral load) in Tissue by NAA with probe detection;HBV DNA Tiss NAA+probe-Log IU;;ACTIVE;2.22;2.70 +49607-5;Hepatitis C virus genotype;Prid;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;Hepatitis C virus genotype [Identifier] in Tissue by NAA with probe detection;HCV Gentyp Tiss NAA+probe;;ACTIVE;2.22;2.72 +49608-3;Hepatitis C virus RNA;LaCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [log units/volume] (viral load) in Tissue by NAA with probe detection;HCV RNA Tiss NAA+probe-Log IU;;ACTIVE;2.22;2.70 +49609-1;Vibrio sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Vibrio sp DNA [Identifier] in Specimen by NAA with probe detection;Vibrio DNA Spec NAA+probe;;ACTIVE;2.22;2.73 +49610-9;Streptococcus pyogenes DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Identifier] in Specimen by NAA with probe detection;S pyo DNA Spec NAA+probe;;ACTIVE;2.22;2.73 +49611-7;Streptococcus pneumoniae DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Streptococcus pneumoniae DNA [Identifier] in Unspecified specimen by Probe and target amplification method;Deprecated S pneum DNA XXX PCR;;DEPRECATED;2.22;2.69 +49612-5;Salmonella sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Salmonella sp DNA [Presence] in Specimen by NAA with probe detection;Salmonella DNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49613-3;Enterococcus sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Enterococcus sp DNA [Identifier] in Unspecified specimen by Probe and target amplification method;Deprecated Enterococcus DNA XXX PCR;;DEPRECATED;2.22;2.69 +49614-1;Campylobacter sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Campylobacter sp DNA [Identifier] in Specimen by NAA with probe detection;Campylobacter DNA Spec NAA+probe;;ACTIVE;2.22;2.73 +49615-8;Borrelia sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Borrelia sp DNA [Identifier] in Specimen by NAA with probe detection;Borrelia DNA Spec NAA+probe;;ACTIVE;2.22;2.73 +49616-6;Legionella sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Legionella sp DNA [Identifier] in Specimen by NAA with probe detection;Legionella DNA Spec NAA+probe;;ACTIVE;2.22;2.73 +49617-4;Bacterial carbapenem resistance blaKPC gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaKPC gene [Presence] by Molecular method;blaKPC Islt/Spm Ql;;ACTIVE;2.22;2.73 +49618-2;Atazanavir+Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Atazanavir+Ritonavir [Susceptibility] by Genotype method;Atazanavir+Ritonavir Islt Genotyp;;ACTIVE;2.22;2.73 +4961-9;HLA-DR15(2);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR15(2) [Presence];HLA-DR15(2) Ql;;ACTIVE;1.0;2.56 +49619-0;Indinavir+Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Indinavir+Ritonavir [Susceptibility] by Genotype method;Indinavir+Ritonavir Islt Genotyp;;ACTIVE;2.22;2.73 +49620-8;lamiVUDine or Emtricitabine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;lamiVUDine or Emtricitabine [Susceptibility] by Genotype method;lamiVUDine/Emtricitabine Islt Genotyp;;ACTIVE;2.22;2.73 +49621-6;Saquinavir+Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Saquinavir+Ritonavir [Susceptibility] by Genotype method;Saquinavir+Ritonavir Islt Genotyp;;ACTIVE;2.22;2.73 +49622-4;Tipranavir+Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Tipranavir+Ritonavir [Susceptibility] by Genotype method;Tipranavir+Ritonavir Islt Genotyp;;ACTIVE;2.22;2.73 +49623-2;Amprenavir or Fosamprenavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Amprenavir or Fosamprenavir [Susceptibility] by Genotype method;Amprenavir/Fosamprenavir Islt Genotyp;;ACTIVE;2.22;2.73 +49624-0;Cholesterol.in VLDL 1+2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL 1+2 [Mass/volume] in Serum or Plasma;VLDL1+2c SerPl-mCnc;;ACTIVE;2.22;2.73 +49625-7;Granulocytes.CD59;Imp;Pt;Bld;Ord;;CELLMARK;1;CD59 Granulocytes [Interpretation] in Blood Qualitative;CD59 Granulocytes Bld-Imp;;ACTIVE;2.22;2.73 +49626-5;Muscle sarcolemma Ab;Titr;Pt;Plr fld;Qn;IF;SERO;1;Muscle sarcolemma Ab [Titer] in Pleural fluid by Immunofluorescence;Mus Sarcolemma Ab Titr Plr IF;;ACTIVE;2.22;2.32 +4962-7;HLA-DR16(2);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR16(2) [Presence] in Donor;HLA-DR16(2) Donr Ql;;ACTIVE;1.0;2.56 +49627-3;Muscle sarcolemma Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Muscle sarcolemma Ab [Titer] in Serum by Immunofluorescence;Mus Sarcolemma Ab Titr Ser IF;;ACTIVE;2.22;2.32 +49628-1;Remnant lipoprotein;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Remnant lipoprotein [Mass/volume] in Serum or Plasma;Remnant lipoprotein SerPl-mCnc;;ACTIVE;2.22;2.73 +49629-9;Citrulline;PrThr;Pt;Urine;Ord;;CHEM;1;Citrulline [Presence] in Urine;Citrulline Ur Ql;;ACTIVE;2.22;2.56 +49630-7;Darunavir+Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Darunavir+Ritonavir [Susceptibility] by Genotype method;Darunavir+Ritonavir Islt Genotyp;;ACTIVE;2.22;2.73 +49631-5;ATN1 gene allele 1.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;ATN1 gene allele 1.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;ATN1 allele 1 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49632-3;ATN1 gene allele 2.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;ATN1 gene allele 2.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;ATN1 allele 2 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49633-1;Ethanolamine;PrThr;Pt;Urine;Ord;;CHEM;1;Ethanolamine [Presence] in Urine;Ethanolamine Ur Ql;;ACTIVE;2.22;2.70 +49634-9;FXN gene allele 1.GAA repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;FXN gene allele 1.GAA repeats [Entitic number] in Blood or Tissue by Molecular genetics method;FXN allele 1 GAA Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +4963-5;HLA-DR16(2);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR16(2) [Presence];HLA-DR16(2) Ql;;ACTIVE;1.0;2.56 +49635-6;FXN gene allele 2.GAA repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;FXN gene allele 2.GAA repeats [Entitic number] in Blood or Tissue by Molecular genetics method;FXN allele 2 GAA Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49636-4;Ganglioside GM1 Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM1 Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM1 Gangl Ab CSF IA-aCnc;;ACTIVE;2.22;2.68 +49637-2;HTT gene allele 1.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;HTT gene allele 1.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;HTT allele 1 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.73 +49638-0;HTT gene allele 2.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;HTT gene allele 2.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;HTT allele 2 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.73 +49639-8;Protein C/Coagulation factor X;MRto;Pt;PPP;Qn;;COAG;1;Protein C/Coagulation factor X [Mass Ratio] in Platelet poor plasma;Prot C/Fact X PPP;;ACTIVE;2.22;2.42 +49640-6;Protein S Ag/Coagulation factor X Ag;MRto;Pt;PPP;Qn;Coag;COAG;1;Protein S Ag/Coagulation factor X Ag [Mass Ratio] in Platelet poor plasma by Coagulation assay;Prot S Ag/Fact X Ag PPP;;ACTIVE;2.22;2.68 +49641-4;SCA1 gene allele 1.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA1 gene allele 1 CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA1 allele1 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49642-2;SCA1 gene allele 2.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA1 gene allele 2 CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA1 allele2 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +4964-3;HLA-DR17(3);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR17(3) [Presence] in Donor;HLA-DR17(3) Donr Ql;;ACTIVE;1.0;2.56 +49643-0;SCA10 gene allele 1.ATTCT repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA10 gene allele 1.ATTCT repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA10 allele 1 ATTCT Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49644-8;SCA10 gene allele 2.ATTCT repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA10 gene allele 2.ATTCT repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA10 allele 2 ATTCT Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49645-5;SCA2 gene allele 1.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA2 gene allele 1 CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA2 allele1 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49646-3;SCA2 gene allele 2.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA2 gene allele 2 CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA2 allele2 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49647-1;MJD gene allele 1.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;MJD gene allele 1 CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;MJD allele1 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49648-9;MJD gene allele 2.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;MJD gene allele 2 CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;MJD allele2 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49649-7;CACNA1A gene allele 1.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;CACNA1A gene allele 1.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;CACNA1A allele 1 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +4965-0;HLA-DR17(3);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR17(3) [Presence];HLA-DR17(3) Ql;;ACTIVE;1.0;2.56 +49650-5;CACNA1A gene allele 2.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;CACNA1A gene allele 2.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;CACNA1A allele 2 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.70 +49651-3;SCA7 gene allele 1.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA7 gene allele 1.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA7 allele 1 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.52 +49652-1;SCA7 gene allele 2.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;SCA7 gene allele 2.CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;SCA7 allele 2 CAG Rpt EntNum Bld/T;;ACTIVE;2.22;2.52 +49653-9;TPMT gene.c.719A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;TPMT gene c.719A>G [Presence] in Blood or Tissue by Molecular genetics method;TPMT c.719A>G Bld/T Ql;;ACTIVE;2.22;2.67 +49654-7;TPMT gene.c.238G>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;TPMT gene c.238G>C [Presence] in Blood or Tissue by Molecular genetics method;TPMT c.238G>C Bld/T Ql;;ACTIVE;2.22;2.67 +49655-4;TPMT gene.c.460G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;TPMT gene c.460G>A [Presence] in Blood or Tissue by Molecular genetics method;TPMT c.460G>A Bld/T Ql;;ACTIVE;2.22;2.67 +49656-2;HIV protease gene mutations;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;HIV protease gene mutations by Genotype method;HIV PI gene mut Islt Genotyp;;ACTIVE;2.22;2.73 +49657-0;HIV nonnucleoside reverse transcriptase susceptibility panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;HIV nonnucleoside reverse transcriptase susceptibility panel by Genotype method;HIV NNRTI Susc Pnl Islt Genotyp;;ACTIVE;2.22;2.73 +49658-8;HIV nucleoside reverse transcriptase susceptibility panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;HIV nucleoside reverse transcriptase susceptibility panel by Genotype method;HIV NRTI Susc Pnl Islt Genotyp;;ACTIVE;2.22;2.73 +49659-6;HIV reverse transcriptase susceptibility panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;HIV reverse transcriptase susceptibility panel by Genotype method;HIV RT Susc Pnl Islt Genotyp;;ACTIVE;2.22;2.73 +49660-4;HIV susceptibility panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;HIV susceptibility panel by Genotype method;HIV Susc Pnl Islt Genotyp;;ACTIVE;2.22;2.73 +49661-2;HIV protease gene mutations;-;Pt;Isolate;-;Phenotyping;PANEL.ABXBACT;1;HIV protease gene mutations by Phenotype method;HIV PI gene mut Islt Phenotyp;;ACTIVE;2.22;2.73 +49662-0;HIV nonnucleoside reverse transcriptase susceptibility panel;-;Pt;Isolate;-;Phenotyping;PANEL.ABXBACT;1;HIV nonnucleoside reverse transcriptase susceptibility panel by Phenotype method;HIV NNRTI Susc Pnl Islt Phenotyp;;ACTIVE;2.22;2.52 +49663-8;HIV nucleoside reverse transcriptase susceptibility panel;-;Pt;Isolate;-;Phenotyping;PANEL.ABXBACT;1;HIV nucleoside reverse transcriptase susceptibility panel by Phenotype method;HIV NRTI Susc Pnl Islt Phenotyp;;ACTIVE;2.22;2.52 +49664-6;HIV reverse transcriptase susceptibility panel;-;Pt;Isolate;-;Phenotyping;PANEL.ABXBACT;1;HIV reverse transcriptase susceptibility panel by Phenotype method;HIV RT Susc Pnl Islt Phenotyp;;ACTIVE;2.22;2.73 +49665-3;HIV susceptibility panel;-;Pt;Isolate;-;Phenotyping;PANEL.ABXBACT;1;HIV susceptibility panel by Phenotype method;HIV Susc Pnl Islt Phenotyp;;ACTIVE;2.22;2.73 +49666-1;Darunavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Darunavir [Susceptibility] by Phenotype method;Darunavir Islt Phenotyp;;ACTIVE;2.22;2.22 +49667-9;Tipranavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Tipranavir [Susceptibility] by Phenotype method;Tipranavir Islt Phenotyp;;ACTIVE;2.22;2.22 +4966-8;HLA-DR18(3);PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR18(3) [Presence] in Donor;HLA-DR18(3) Donr Ql;;ACTIVE;1.0;2.56 +49668-7;Atazanavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Atazanavir [Susceptibility] by Phenotype method;Atazanavir Islt Phenotyp;;ACTIVE;2.22;2.73 +49669-5;Emtricitabine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Emtricitabine [Susceptibility] by Phenotype method;Emtricitabine Islt Phenotyp;;ACTIVE;2.22;2.22 +49670-3;Uranium.depleted panel;-;24H;Urine;-;;PANEL.DRUG/TOX;1;Uranium.depleted panel - 24 hour Urine;Uranium. depleted Pnl 24h Ur;;ACTIVE;2.22;2.67 +49671-1;Neisseria meningitidis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Presence] in Specimen by NAA with probe detection;N men DNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49672-9;Streptococcus pneumoniae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection;S pneum DNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49673-7;Lymphocyte proliferation.100 umol beryllium stimulation^7D post incubation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 100 umol beryllium [Ratio] in Blood --7 day post incubation;LPT 100 umol Be 7D Bld-Rto;;ACTIVE;2.22;2.70 +49674-5;Lymphocyte proliferation.10 umol beryllium stimulation^5D post incubation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 10 umol beryllium [Ratio] in Blood --5 days post incubation;LPT 10 umol Be 5D Bld-Rto;;ACTIVE;2.22;2.70 +49675-2;Lymphocyte proliferation.10 umol beryllium stimulation^7D post incubation;ACnc;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 10 umol beryllium [Units/volume] in Blood --7 day post incubation;LPT 10 umol Be 7D Bld-aCnc;;ACTIVE;2.22;2.69 +4967-6;HLA-DR18(3);PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR18(3) [Presence];HLA-DR18(3) Ql;;ACTIVE;1.0;2.56 +49676-0;Lymphocyte proliferation.1 umol beryllium stimulation^5D post incubation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 1 umol beryllium [Ratio] in Blood --5 days post incubation;LPT 1 umol Be 5D Bld-Rto;;ACTIVE;2.22;2.70 +49677-8;Lymphocyte proliferation.1 umol beryllium stimulation^7D post incubation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 1 umol beryllium [Ratio] in Blood --7 day post incubation;LPT 1 umol Be 7D Bld-Rto;;ACTIVE;2.22;2.70 +49678-6;CPT2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CPT2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CPT2 gene Mut Anl Bld/T;;ACTIVE;2.22;2.63 +49679-4;Cells.CD36/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD36 cells/100 cells in Bone marrow;CD36 Cells NFr Mar;;ACTIVE;2.22;2.40 +49680-2;Cells.CD36/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD36 cells/100 cells in Tissue;CD36 Cells NFr Tiss;;ACTIVE;2.22;2.40 +49681-0;Cells.CD36/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD36 cells/100 cells in Body fluid;CD36 Cells NFr Fld;;ACTIVE;2.22;2.40 +49682-8;Lymphocyte proliferation.phytohemagglutinin stimulation^3D post incubation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by phytohemagglutinin [Ratio] in Blood --3 days post incubation;LPT PHA 3D Bld-Rto;;ACTIVE;2.22;2.70 +49683-6;ERBB2 gene copy number/Chromosome 17 copy number;NRto;Pt;Tiss;Qn;FISH;MOLPATH;1;ERBB2 gene copy number/Chromosome 17 copy number in Tissue by FISH;ERBB2 copy num/Chr 17 copy num Tiss FISH;;ACTIVE;2.22;2.73 +4968-4;HLA-DR52;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR52 [Presence] in Donor;HLA-DR52 Donr Ql;;ACTIVE;1.0;2.56 +49684-4;CPT2 gene.p.Arg503Cys;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;CPT2 gene p.Arg503Cys [Presence] in Blood by Molecular genetics method;CPT2 p.R503C Bld Ql;;ACTIVE;2.22;2.70 +49685-1;CPT2 gene.p.R549DC;Pr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;Deprecated CPT2 gene p.R549DC [Presence] in Blood by Molecular genetics method;Deprecated CPT2 p.R549DC Bld Ql;;DEPRECATED;2.22;2.70 +49686-9;CPT2 gene.p.Arg631Cys;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;CPT2 gene p.Arg631Cys [Presence] in Blood by Molecular genetics method;CPT2 p.R631C Bld Ql;;ACTIVE;2.22;2.70 +49687-7;Trichoderma viride Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Trichoderma viride IgG Ab [Mass/volume] in Serum;T viride IgG Ser-mCnc;;ACTIVE;2.22;2.73 +49688-5;Glucose tolerance^post 75 g glucose PO;Imp;Pt;Ser/Plas;Nar;;CHAL;1;Glucose tolerance [Interpretation] in Serum or Plasma Narrative--post 75 g glucose PO;GTT p 75 g Glc PO SerPl-Imp;;ACTIVE;2.22;2.73 +49689-3;Glucose tolerance^post 100 g glucose PO;Imp;Pt;Ser/Plas;Nar;;CHAL;1;Glucose tolerance [Interpretation] in Serum or Plasma Narrative--post 100 g glucose PO;GTT p 100 g Glc PO SerPl-Imp;;ACTIVE;2.22;2.73 +49690-1;Mirtazapine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mirtazapine [Mass/volume] in Urine;Mirtazapine Ur-mCnc;;ACTIVE;2.22;2.73 +49691-9;Nortrimipramine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Nortrimipramine [Presence] in Serum or Plasma;Nortrimipramine SerPl Ql;;ACTIVE;2.22;2.56 +4969-2;HLA-DR52;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR52 [Presence];HLA-DR52 Ql;;ACTIVE;1.0;2.73 +49692-7;Striated muscle Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Striated muscle IgG Ab [Presence] in Serum by Immunofluorescence;Stria Mus IgG Ser Ql IF;;ACTIVE;2.22;2.73 +49693-5;Hepatitis E virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis E virus IgG Ab [Presence] in Serum by Immunoassay;HEV IgG Ser Ql IA;;ACTIVE;2.22;2.73 +49694-3;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldCoA;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Arterial cord blood;pCO2 temp adj BldCoA;;ACTIVE;2.22;2.73 +49695-0;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldCoV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Venous cord blood;pCO2 temp adj BldCoV;;ACTIVE;2.22;2.54 +49696-8;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldCoA;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Arterial cord blood;pO2 temp adj BldCoA;;ACTIVE;2.22;2.73 +49697-6;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldCoV;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous cord blood;pO2 temp adj BldCoV;;ACTIVE;2.22;2.54 +49698-4;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldCoA;Qn;;CHEM;1;pH of Arterial cord blood adjusted to patient's actual temperature;pH temp adj BldCoA;;ACTIVE;2.22;2.54 +49699-2;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldCoV;Qn;;CHEM;1;pH of Venous cord blood adjusted to patient's actual temperature;pH temp adj BldCoV;;ACTIVE;2.22;2.54 +49-7;Bacampicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Bacampicillin [Susceptibility] by Disk diffusion (KB);Bacampicillin Islt KB;;ACTIVE;1.0;2.19 +4970-0;HLA-DR53;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR53 [Presence] in Donor;HLA-DR53 Donr Ql;;ACTIVE;1.0;2.56 +49700-8;Metanephrine.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Metanephrine Free [Moles/volume] in Serum or Plasma;Metaneph Free SerPl-sCnc;;ACTIVE;2.22;2.73 +49701-6;pH^^adjusted to patient's actual temperature;LsCnc;Pt;Bld;Qn;;CHEM;1;pH of Blood adjusted to patient's actual temperature;pH temp adj Bld;;ACTIVE;2.22;2.73 +49702-4;Nateglinide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nateglinide [Mass/volume] in Serum or Plasma;Nateglinide SerPl-mCnc;;ACTIVE;2.22;2.73 +49704-0;SH3TC2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SH3TC2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SH3TC2 gene Mut Anl Bld/T;;ACTIVE;2.22;2.63 +49705-7;LMNA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LMNA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LMNA gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +49706-5;ARSA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ARSA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ARSA gene Mut Anl Bld/T;;ACTIVE;2.22;2.73 +49707-3;KCNQ2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KCNQ2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KCNQ2 gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +49708-1;TTR gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TTR gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TTR gene Mut Anl Bld/T;;ACTIVE;2.22;2.66 +49709-9;predniSONE;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;predniSONE [Presence] in Serum or Plasma;predniSONE SerPl Ql;;ACTIVE;2.22;2.73 +49710-7;SOD1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SOD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SOD1 gene Mut Anl Bld/T;;ACTIVE;2.22;2.66 +49711-5;Listeria sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Listeria sp Ab [Titer] in Serum by Complement fixation;Listeria Ab Titr Ser CF;;ACTIVE;2.22;2.73 +49712-3;Coccidioides sp Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Coccidioides sp Ab [Presence] in Serum by Latex agglutination;Coccidioides Ab Ser Ql LA;;ACTIVE;2.22;2.56 +49713-1;Parainfluenza virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus Ab [Titer] in Serum by Complement fixation;HPIV Ab Titr Ser CF;;ACTIVE;2.22;2.32 +49714-9;Interleukin 8;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 8 [Mass/volume] in Body fluid;Il8 Fld-mCnc;;ACTIVE;2.22;2.34 +49715-6;Musca domestica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Housefly IgE Ab [Units/volume] in Serum;Housefly IgE Qn;;ACTIVE;2.22;2.42 +49716-4;Dehydroepiandrosterone;MCnc;Pt;Saliva;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Saliva (oral fluid);DHEA Sal-mCnc;;ACTIVE;2.22;2.73 +49717-2;Interleukin 1 beta;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 1 beta [Mass/volume] in Body fluid;Il1Beta Fld-mCnc;;ACTIVE;2.22;2.34 +4971-8;HLA-DR53;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR53 [Presence];HLA-DR53 Ql;;ACTIVE;1.0;2.73 +49718-0;HIV 1 p24 Ag;PrThr;Pt;CSF;Ord;;MICRO;1;HIV 1 p24 Ag [Presence] in Cerebral spinal fluid;HIV1 p24 Ag CSF Ql;;ACTIVE;2.22;2.56 +49719-8;Poa pratensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Kentucky blue grass IgG Ab [Mass/volume] in Serum;Kent blue grass IgG-mCnc;;ACTIVE;2.22;2.73 +49720-6;Festuca elatior Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Meadow Fescue IgG Ab [Mass/volume] in Serum;Meadow Fescue IgG-mCnc;;ACTIVE;2.22;2.40 +49721-4;Haemophilus influenzae type;Prid;Pt;Isolate;Nom;;MICRO;1;Haemophilus influenzae type [Identifier] in Isolate;Haem influ type Islt;;ACTIVE;2.22;2.73 +49722-2;Neisseria meningitidis type;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Deprecated Neisseria meningitidis type [Identifier] in Isolate by Agglutination;Deprecated N men type Islt Aggl;;DEPRECATED;2.22;2.42 +49723-0;Camellia sinensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tea IgG Ab [Mass/volume] in Serum;Tea IgG-mCnc;;ACTIVE;2.22;2.73 +49724-8;Aldolase;CCnc;Pt;Body fld;Qn;;CHEM;1;Aldolase [Enzymatic activity/volume] in Body fluid;Aldolase Fld-cCnc;;ACTIVE;2.22;2.68 +49725-5;Melatonin;MCnc;Pt;CSF;Qn;;CHEM;1;Melatonin [Mass/volume] in Cerebral spinal fluid;Melatonin CSF-mCnc;;ACTIVE;2.22;2.42 +4972-6;HLA-DR6;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR6 [Presence] in Donor;HLA-DR6 Donr Ql;;ACTIVE;1.0;2.56 +49726-3;Endomysium Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Endomysium IgG Ab [Titer] in Serum;Endomysium IgG Titr Ser;;ACTIVE;2.22;2.73 +49727-1;Homocysteine;SCnc;Pt;CSF;Qn;;CHEM;1;Homocysteine [Moles/volume] in Cerebral spinal fluid;Hcys CSF-sCnc;;ACTIVE;2.22;2.42 +49728-9;Neurokinin A;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Neurokinin A [Mass/volume] in Serum or Plasma;Neurokinin A SerPl-mCnc;;ACTIVE;2.22;2.73 +49729-7;Penicillin G Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillin G IgG Ab [Mass/volume] in Serum;Penicillin G IgG-mCnc;;ACTIVE;2.22;2.34 +49730-5;Aspergillus sp Ab;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Aspergillus sp Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);Aspergillus Ab CSF Ql ID;;ACTIVE;2.22;2.56 +49731-3;Herpes simplex virus 1+2 Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;HSV1+2 IgM Titr CSF IF;;ACTIVE;2.22;2.32 +49732-1;Interleukin 6;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 6 [Mass/volume] in Body fluid;Il6 Fld-mCnc;;ACTIVE;2.22;2.34 +49733-9;Interleukin 10;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 10 [Mass/volume] in Body fluid;Il10 Fld-mCnc;;ACTIVE;2.22;2.34 +4973-4;HLA-DR6;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR6 [Presence];HLA-DR6 Ql;;ACTIVE;1.0;2.56 +49734-7;11-Dehydro thromboxane beta 2/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;11-Dehydro thromboxane beta 2/Creatinine [Mass Ratio] in Urine;11-dehydro TBX2/Creat Ur;;ACTIVE;2.22;2.73 +49735-4;FBN1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FBN1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FBN1 gene Mut Anl Bld/T;;ACTIVE;2.22;2.66 +49736-2;Clarity;Type;Pt;CSF;Nom;;SPEC;1;Clarity of Cerebral spinal fluid;Clarity CSF;;ACTIVE;2.22;2.73 +49737-0;Sirolimus;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Sirolimus [Mass] of Dose;Sirolimus Dose;;ACTIVE;2.22;2.73 +49738-8;Neuronal nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Neuronal nuclear Ab [Presence] in Serum by Immunofluorescence;Hu Ab Ser Ql IF;;ACTIVE;2.22;2.73 +49739-6;Apis mellifera Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee IgG Ab [Mass/volume] in Serum;Honey bee IgG-mCnc;;ACTIVE;2.22;2.73 +49740-4;Dolichovespula arenaria Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Hornet IgG Ab [Mass/volume] in Serum;Yellow Hornet IgG-mCnc;;ACTIVE;2.22;2.73 +49741-2;Plasmodium malariae Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium malariae IgG Ab [Titer] in Serum by Immunofluorescence;P malariae IgG Titr Ser IF;;ACTIVE;2.22;2.32 +4974-2;HLA-DR8;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR8 [Presence] in Donor;HLA-DR8 Donr Ql;;ACTIVE;1.0;2.56 +49742-0;Plasmodium vivax Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium vivax IgG Ab [Titer] in Serum by Immunofluorescence;P vivax IgG Titr Ser IF;;ACTIVE;2.22;2.32 +49743-8;Plasmodium falciparum Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium falciparum IgG Ab [Titer] in Serum by Immunofluorescence;P falciparum IgG Titr Ser IF;;ACTIVE;2.22;2.32 +49744-6;Plasmodium ovale Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium ovale IgG Ab [Titer] in Serum by Immunofluorescence;P ovale IgG Titr Ser IF;;ACTIVE;2.22;2.32 +49745-3;Dolichovespula maculata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Whitefaced Hornet IgG Ab [Mass/volume] in Serum;Whitefaced Hornet IgG-mCnc;;ACTIVE;2.22;2.73 +49746-1;Carboxy tetrahydrocannabinol;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Serum or Plasma by Screen method;CarboxyTHC SerPl Ql Scn;;ACTIVE;2.22;2.56 +49747-9;Cocaine+Benzoylecgonine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Cocaine+Benzoylecgonine [Presence] in Serum or Plasma by Screen method;Cocaine+BZE SerPl Ql Scn;;ACTIVE;2.22;2.73 +49748-7;Lipoprotein.alpha;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.alpha [Moles/volume] in Serum or Plasma;HDL SerPl-sCnc;;ACTIVE;2.22;2.73 +49749-5;6-Monoacetylmorphine.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;6-monoacetylmorphine free [Mass/volume] in Serum or Plasma;6MAM Free SerPl-mCnc;;ACTIVE;2.22;2.73 +49750-3;Dihydrocodeine.free+Hydrocodol.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dihydrocodeine Free+Hydrocodol Free [Mass/volume] in Serum or Plasma;DHC+Hydrocodol Free SerPl-mCnc;;ACTIVE;2.22;2.40 +49751-1;Norbuprenorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norbuprenorphine [Mass/volume] in Urine by Confirmatory method;Norbuprenorphine Ur Cfm-mCnc;;ACTIVE;2.22;2.73 +49752-9;Buprenorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Buprenorphine [Mass/volume] in Urine by Confirmatory method;Buprenorphine Ur Cfm-mCnc;;ACTIVE;2.22;2.73 +49753-7;Norbuprenorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norbuprenorphine [Mass/volume] in Urine;Norbuprenorphine Ur-mCnc;;ACTIVE;2.22;2.73 +49754-5;Epithelial cells.squamous;ACnc;Pt;Urine sed;Ord;Microscopy.light;UA;1;Deprecated Epithelial cells.squamous [Presence] in Urine sediment by Light microscopy;Deprecated Squamous UrnS Ql Micro;;DEPRECATED;2.22;2.38 +49755-2;Crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Crystals [Presence] in Urine sediment by Light microscopy;Crystals UrnS Ql Micro;;ACTIVE;2.22;2.73 +49756-0;Norethindrone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norethindrone [Mass/volume] in Urine;Norethindrone Ur-mCnc;;ACTIVE;2.22;2.42 +49757-8;Minocycline;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Minocycline [Mass/volume] in Specimen;Minocycline Spec-mCnc;;ACTIVE;2.22;2.69 +49758-6;Hepatitis C virus RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 5 IU/mL;MICRO;1;Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 5 iU/mL;HCV RNA SerPl NAA DL=5-aCnc;;ACTIVE;2.22;2.73 +4975-9;HLA-DR8;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR8 [Presence];HLA-DR8 Ql;;ACTIVE;1.0;2.56 +49759-4;Adenosine deaminase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Peritoneal fluid;Adenosine deaminase Prt-cCnc;;ACTIVE;2.22;2.73 +49760-2;Adenosine deaminase;CCnc;Pt;Pericard fld;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Pericardial fluid;Adenosine deaminase Pcar-cCnc;;ACTIVE;2.22;2.73 +49761-0;Alpha-1-Fetoprotein;MCnc;Pt;Periton fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Peritoneal fluid;AFP Prt-mCnc;;ACTIVE;2.22;2.73 +49762-8;Alpha-1-Fetoprotein;MCnc;Pt;Plr fld;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Pleural fluid;AFP Plr-mCnc;;ACTIVE;2.22;2.73 +49763-6;Bilirubin;MCnc;Pt;Pericard fld;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Pericardial fluid;Bilirub Pcar-mCnc;;ACTIVE;2.22;2.73 +49764-4;Calcium;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Calcium [Mass/volume] in Amniotic fluid;Calcium Amn-mCnc;;ACTIVE;2.22;2.34 +49765-1;Calcium;MCnc;Pt;Bld;Qn;;CHEM;1;Calcium [Mass/volume] in Blood;Calcium Bld-mCnc;;ACTIVE;2.22;2.73 +49766-9;Chymotrypsin;PrThr;Pt;Stool;Ord;;CHEM;1;Chymotrypsin [Presence] in Stool;Chymotryp Stl Ql;;ACTIVE;2.22;2.56 +4976-7;HLA-DR1;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR1 [Presence] in Donor;HLA-DR1 Donr Ql;;ACTIVE;1.0;2.56 +49767-7;Filaria Ab.IgG2;ACnc;Pt;Ser;Qn;IA;MICRO;1;Filaria IgG2 Ab [Units/volume] in Serum by Immunoassay;Filaria IgG2 Ser IA-aCnc;;ACTIVE;2.22;2.69 +49768-5;Filaria Ab.IgG3;ACnc;Pt;Ser;Qn;IA;MICRO;1;Filaria IgG3 Ab [Units/volume] in Serum by Immunoassay;Filaria IgG3 Ser IA-aCnc;;ACTIVE;2.22;2.69 +49769-3;Filaria Ab.IgG4;ACnc;Pt;Ser;Qn;IA;MICRO;1;Filaria IgG4 Ab [Units/volume] in Serum by Immunoassay;Filaria IgG4 Ser IA-aCnc;;ACTIVE;2.22;2.69 +49770-1;Filaria Ab.IgG1;ACnc;Pt;Ser;Qn;IA;MICRO;1;Filaria IgG1 Ab [Units/volume] in Serum by Immunoassay;Filaria IgG1 Ser IA-aCnc;;ACTIVE;2.22;2.69 +49771-9;Onchocerca sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Onchocerca sp IgG Ab [Units/volume] in Serum by Immunoassay;Onchocerca IgG Ser IA-aCnc;;ACTIVE;2.22;2.69 +49772-7;Fructose;MCnc;Pt;Urine;Qn;;CHEM;1;Fructose [Mass/volume] in Urine;Fructose Ur-mCnc;;ACTIVE;2.22;2.70 +49773-5;Galactitol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Galactitol [Moles/volume] in Serum or Plasma;Galactitol SerPl-sCnc;;ACTIVE;2.22;2.70 +49774-3;Glomerular basement membrane Ab;ACnc;Pt;Ser;Qn;;SERO;1;Glomerular basement membrane Ab [Units/volume] in Serum;GBM Ab Ser-aCnc;;ACTIVE;2.22;2.73 +4977-5;HLA-DR1;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR1 [Presence];HLA-DR1 Ql;;ACTIVE;1.0;2.73 +49775-0;Hepatitis D virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis D virus IgG Ab [Units/volume] in Serum by Immunoassay;HDV IgG Ser IA-aCnc;;ACTIVE;2.22;2.69 +49776-8;Hepatitis E virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis E virus Ab [Units/volume] in Serum by Immunoassay;HEV Ab Ser IA-aCnc;;ACTIVE;2.22;2.69 +49777-6;Hepatitis G virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis G virus Ab [Units/volume] in Serum;HGV Ab Ser-aCnc;;ACTIVE;2.22;2.69 +49778-4;Immune complex;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Immune complex [Mass/volume] in Serum or Plasma;IC SerPl-mCnc;;ACTIVE;2.22;2.73 +49779-2;Ketones;MCnc;Pt;Urine;Qn;;UA;1;Ketones [Mass/volume] in Urine;Ketones Ur-mCnc;;ACTIVE;2.22;2.73 +497-8;Tetracycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tetracycline [Susceptibility] by Disk diffusion (KB);Tetracycline Islt KB;;ACTIVE;1.0;2.73 +49780-0;Leishmania sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Leishmania sp DNA [Presence] in Blood by NAA with probe detection;Leishmania DNA Bld Ql NAA+probe;;ACTIVE;2.22;2.63 +49781-8;Mitochondria M2 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Mitochondria M2 Ab [Units/volume] in Serum;Mitochondria M2 Ab Ser-aCnc;;ACTIVE;2.22;2.73 +49782-6;Mononuclear cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Pericardial fluid;Mononuc Cells/leuk NFr Pcar;;ACTIVE;2.22;2.70 +4978-3;HLA-DR2;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR2 [Presence] in Donor;HLA-DR2 Donr Ql;;ACTIVE;1.0;2.56 +49783-4;Onchocerca sp Ab.IgG4;ACnc;Pt;Ser;Qn;IA;MICRO;1;Onchocerca sp IgG4 Ab [Units/volume] in Serum by Immunoassay;Onchocerca IgG4 Ser IA-aCnc;;ACTIVE;2.22;2.69 +49784-2;Onchocerca sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Onchocerca sp IgG Ab [Units/volume] in Serum;Onchocerca IgG Ser-aCnc;;ACTIVE;2.22;2.69 +49785-9;Onchocerca sp Ab.IgG2;ACnc;Pt;Ser;Qn;IA;MICRO;1;Onchocerca sp IgG2 Ab [Units/volume] in Serum by Immunoassay;Onchocerca IgG2 Ser IA-aCnc;;ACTIVE;2.22;2.69 +49786-7;Onchocerca sp Ab.IgG3;ACnc;Pt;Ser;Qn;IA;MICRO;1;Onchocerca sp IgG3 Ab [Units/volume] in Serum by Immunoassay;Onchocerca IgG3 Ser IA-aCnc;;ACTIVE;2.22;2.69 +49787-5;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Pericardial fluid;Polys/leuk NFr Pcar;;ACTIVE;2.22;2.50 +49788-3;Potassium;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Potassium [Moles/volume] in Amniotic fluid;Potassium Amn-sCnc;;ACTIVE;2.22;2.34 +49789-1;Potassium;SCnc;Pt;Periton fld;Qn;;CHEM;1;Potassium [Moles/volume] in Peritoneal fluid;Potassium Prt-sCnc;;ACTIVE;2.22;2.34 +49790-9;Sodium;SCnc;Pt;Periton fld;Qn;;CHEM;1;Sodium [Moles/volume] in Peritoneal fluid;Sodium Prt-sCnc;;ACTIVE;2.22;2.34 +4979-1;HLA-DR2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR2 [Presence];HLA-DR2 Ql;;ACTIVE;1.0;2.73 +49791-7;Sodium;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Sodium [Moles/volume] in Amniotic fluid;Sodium Amn-sCnc;;ACTIVE;2.22;2.34 +49792-5;Somatostatin;SCnc;Pt;Plas;Qn;;CHEM;1;Somatostatin [Moles/volume] in Plasma;Somatostat Plas-sCnc;;ACTIVE;2.22;2.42 +49793-3;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points";Arb;Pt;Bone mar;Ord;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points [Presence] in Bone marrow by Molecular genetics method";"t(14;18)(IGH,BCL2) Major Mar Ql";;ACTIVE;2.22;2.50 +49794-1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points";Arb;Pt;Bone mar;Ord;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points [Presence] in Bone marrow by Molecular genetics method";"t(14;18)(IGH,BCL2) Minor Mar Ql";;ACTIVE;2.22;2.50 +49795-8;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)e1a2 Bld/T Ql;;ACTIVE;2.22;2.73 +49796-6;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript";NCnc;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript [#/volume] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)p210 # Bld/T;;ACTIVE;2.22;2.73 +49797-4;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript [Presence] in Bone marrow by Molecular genetics method";t(ABL1,BCR)p210 Mar Ql;;ACTIVE;2.22;2.73 +49798-2;Taenia solium larva Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Taenia solium larva Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;T sol lar Ab CSF IA-aCnc;;ACTIVE;2.22;2.73 +49799-0;Treponema pallidum DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Treponema pallidum DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;T pallidum DNA CSF Ql NAA+probe;;ACTIVE;2.22;2.63 +49800-6;Treponema pallidum Ab;ACnc;Pt;CSF;Qn;HA;MICRO;1;Treponema pallidum Ab [Units/volume] in Cerebral spinal fluid by Hemagglutination;T pallidum Ab CSF HA-aCnc;;ACTIVE;2.22;2.69 +49801-4;Trypanosoma cruzi DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Trypanosoma cruzi DNA [Presence] in Blood by NAA with probe detection;T cruzi DNA Bld Ql NAA+probe;;ACTIVE;2.22;2.63 +49802-2;Urea;MCnc;Pt;Periton fld;Qn;;CHEM;1;Urea [Mass/volume] in Peritoneal fluid;Urea Prt-mCnc;;ACTIVE;2.22;2.70 +49803-0;Streptococcus pneumoniae 1 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Units/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum 1 Ab sp1 Ser IA-aCnc;;DEPRECATED;2.22;2.70 +49804-8;Streptococcus pneumoniae 19 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Units/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum19 Ab sp1 Ser IA-aCnc;;DEPRECATED;2.22;2.70 +49805-5;Streptococcus pneumoniae 23 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Units/volume] in Serum by Immunoassay --1st specimen;Deprecated S pneum23 Ab sp1 Ser IA-aCnc;;DEPRECATED;2.22;2.70 +49806-3;Streptococcus pneumoniae 1 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 1 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum 1 Ab sp2 Ser IA-aCnc;;DEPRECATED;2.22;2.70 +49807-1;Streptococcus pneumoniae 19 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 19 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum19 Ab sp2 Ser IA-aCnc;;DEPRECATED;2.22;2.70 +49808-9;Streptococcus pneumoniae 23 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 23 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;Deprecated S pneum23 Ab sp2 Ser IA-aCnc;;DEPRECATED;2.22;2.70 +4980-9;HLA-DR3;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR3 [Presence] in Donor;HLA-DR3 Donr Ql;;ACTIVE;1.0;2.56 +49809-7;2-Ethyl-3-Hydroxypropionate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Ethyl-3-Hydroxypropionate/Creatinine [Molar ratio] in 24 hour Urine;2Ethyl3OH-Prop/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49810-5;2-Hydroxy-3-Methylvalerate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Hydroxy-3-Methylvalerate/Creatinine [Molar ratio] in 24 hour Urine;2OH3Me-valerate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49811-3;2-Hydroxyadipate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Hydroxyadipate/Creatinine [Molar ratio] in 24 hour Urine;2OH-adipate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49812-1;2-Hydroxyglutarate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Hydroxyglutarate/Creatinine [Molar ratio] in 24 hour Urine;2OH-gluterate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49813-9;2-Hydroxyisocaproate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Hydroxyisocaproate/Creatinine [Molar ratio] in 24 hour Urine;2OH-isocaproate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49814-7;2-Hydroxyisovalerate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Hydroxyisovalerate/Creatinine [Molar ratio] in 24 hour Urine;2OH-isovalerate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.73 +49815-4;2-Methyl-3-Hydroxybutyrate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-methyl-3-hydroxybutyrate (C5-OH)/Creatinine [Molar ratio] in 24 hour Urine;2Me3OH-butyrate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.54 +49816-2;2-Oxo,3-Methylvalerate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Oxo,3-Methylvalerate/Creatinine [Molar ratio] in 24 hour Urine;2Oxo3Me-valerate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +4981-7;HLA-DR3;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR3 [Presence];HLA-DR3 Ql;;ACTIVE;1.0;2.73 +49817-0;2-Oxoisocaproate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Oxoisocaproate/Creatinine [Molar ratio] in 24 hour Urine;2Oxoisocaproate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49818-8;2-Oxoisovalerate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;2-Oxoisovalerate/Creatinine [Molar ratio] in 24 hour Urine;2Oxoisovalerate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49819-6;3-Hydroxy,3-Methylglutarate/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;3-Hydroxy,3-Methylglutarate/Creatinine [Molar ratio] in 24 hour Urine;3OH3Me-glutarate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49820-4;3-Hydroxyadipate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Hydroxyadipate/Creatinine [Molar ratio] in 24 hour Urine;3OH-Adipate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49821-2;3-Hydroxyglutarate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Hydroxyglutarate/Creatinine [Molar ratio] in 24 hour Urine;3OH-Glutarate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49822-0;3-Hydroxyisobutyrate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Hydroxyisobutyrate/Creatinine [Molar ratio] in 24 hour Urine;3OH-Isobutyrate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49823-8;3-Hydroxyisovalerate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Hydroxyisovalerate/Creatinine [Molar ratio] in 24 hour Urine;3OH-Isovalerate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49824-6;3-Hydroxypropionate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Hydroxypropionate (3-OH-C3)/Creatinine [Molar ratio] in 24 hour Urine;3OH-Propionate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +4982-5;HLA-DR4;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR4 [Presence] in Donor;HLA-DR4 Donr Ql;;ACTIVE;1.0;2.56 +49825-3;16-Alpha hydroxyestrone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;16-Alpha hydroxyestrone [Mass/volume] in Serum or Plasma;16-alphaOHestrone SerPl-mCnc;;ACTIVE;2.22;2.70 +49826-1;2-Hydroxyestrone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxyestrone [Mass/volume] in Serum or Plasma;2OH-estrone SerPl-mCnc;;ACTIVE;2.22;2.70 +49827-9;2-Hydroxyestrone/16-Alpha hydroxyestrone;MRto;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxyestrone/16-Alpha hydroxyestrone [Mass Ratio] in Serum or Plasma;2OH-estrone/16-alphaOHestrone SerPl;;ACTIVE;2.22;2.42 +49828-7;2-Hydroxyestrone & 16-Alpha hydroxyestrone panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;2-Hydroxyestrone and 16-Alpha hydroxyestrone panel - Serum or Plasma;2OH+16-alphaOH estrone Pnl SerPl;;ACTIVE;2.22;2.63 +49829-5;Norcodeine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norcodeine [Mass/volume] in Urine;Norcodeine Ur-mCnc;;ACTIVE;2.22;2.73 +49830-3;Norcodeine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norcodeine [Mass/volume] in Serum or Plasma;Norcodeine SerPl-mCnc;;ACTIVE;2.22;2.70 +49831-1;Normorphine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Normorphine [Mass/volume] in Urine;Normorphine Ur-mCnc;;ACTIVE;2.22;2.70 +49832-9;Specimen drawn^1st specimen;TmStp;Pt;Ser/Plas;Qn;;SPEC;1;Specimen drawn [Date and time] of Serum or Plasma--1st specimen;Specimen drawn sp1 SerPl;;ACTIVE;2.22;2.26 +4983-3;HLA-DR4;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR4 [Presence];HLA-DR4 Ql;;ACTIVE;1.0;2.73 +49833-7;Specimen drawn^2nd specimen;TmStp;Pt;Ser/Plas;Qn;;SPEC;1;Specimen drawn [Date and time] of Serum or Plasma--2nd specimen;Specimen drawn sp2 SerPl;;ACTIVE;2.22;2.73 +49834-5;Leucine;PrThr;Pt;Urine;Ord;;CHEM;1;Leucine [Presence] in Urine;Leucine Ur Ql;;ACTIVE;2.22;2.56 +49835-2;Cells.CD19+IgD+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+IgD+ cells/100 cells in Specimen;CD19+IgD+ cells NFr Spec;;ACTIVE;2.22;2.73 +49836-0;Platelet function;Imp;Pt;Bld;Nar;;COAG;1;Platelet function (closure time) [Interpretation] in Blood Narrative;Closure Tme Bld-Imp;;ACTIVE;2.22;2.73 +49837-8;Dimethylphosphatidyl ethanolamine/Surfactant.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Dimethylphosphatidyl ethanolamine/Surfactant.total in Amniotic fluid;DMPE MFr Amn;;ACTIVE;2.22;2.70 +49838-6;Neural tube defect risk;Likelihood;Pt;^Population;Qn;;CHEM;1;Neural tube defect risk [Likelihood] in Population;Neural tube defect risk Pop;;ACTIVE;2.22;2.73 +49839-4;Eosinophils;PrThr;Pt;Urine sed;Ord;Wright stain;HEM/BC;1;Eosinophils [Presence] in Urine sediment by Wright stain;Eosinophil UrnS Ql Wright Stn;;ACTIVE;2.22;2.73 +49840-2;Cells.CD19+IgG+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+IgG+ cells/100 cells in Specimen;CD19+IgG+ cells NFr Spec;;ACTIVE;2.22;2.73 +4984-1;HLA-DR5;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR5 [Presence] in Donor;HLA-DR5 Donr Ql;;ACTIVE;1.0;2.56 +49841-0;Cells.CD19+IgM+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+IgM+ cells/100 cells in Specimen;CD19+IgM+ cells NFr Spec;;ACTIVE;2.22;2.73 +49842-8;Cells.CD19+IgA+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19+IgA+ cells/100 cells in Specimen;CD19+IgA+ cells NFr Spec;;ACTIVE;2.22;2.73 +49843-6;Coagulation surface induced.factor substitution^2H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with 1:4 normal plasma;aPTT 2h p 1:4 NP PPP;;ACTIVE;2.22;2.73 +49844-4;Coagulation surface induced.factor substitution^1H post incubation after 1:4 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with 1:4 normal plasma;aPTT 1h p 1:4 NP PPP;;ACTIVE;2.22;2.73 +49845-1;Coagulation surface induced.factor substitution^after addition of normal plasma 1H post incubation separate tubes;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --with normal plasma 1H post incubation separate tubes;aPTT NP 1h separate PPP;;ACTIVE;2.22;2.73 +49846-9;Hepatitis C virus core Ag;PrThr;Pt;Bld/Bone mar^Donor;Ord;;MICRO;1;Hepatitis C virus core Ag [Presence] in Blood or Marrow from Donor;HCV core Ag Bld/Mar Donr Ql;;ACTIVE;2.22;2.73 +49847-7;Enterovirus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Serum by NAA with probe detection;EV RNA Ser Ql NAA+probe;;ACTIVE;2.22;2.63 +49848-5;Herpes simplex virus 1+2 Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Presence] in Serum by Immunoblot;HSV1+2 IgG Ser Ql IB;;ACTIVE;2.22;2.73 +49849-3;Hydroxylysine.free/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Hydroxylysine.free/Creatinine [Molar ratio] in 24 hour Urine;OH-Lysine Free/Creat 24h Ur-sRto;;ACTIVE;2.22;2.42 +49850-1;Insulin-like growth factor-I^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --baseline;IGF-I BS SerPl-mCnc;;ACTIVE;2.22;2.73 +49851-9;Cholinesterase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/volume] in Peritoneal fluid;Cholinesterase Prt-cCnc;;ACTIVE;2.22;2.68 +49852-7;Protein fractions.oligoclonal bands;Num;Pt;CSF;Qn;Isoelectric focusing;CHEM;1;Oligoclonal bands [#] in Cerebral spinal fluid by Isoelectric focusing;Oligoclonal Bands CSF IEF;;ACTIVE;2.22;2.73 +49853-5;Transforming growth factor beta 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transforming growth factor beta 1 [Mass/volume] in Serum or Plasma;TGF-beta-1 SerPl-mCnc;;ACTIVE;2.22;2.73 +49854-3;COL5A1 gene+COL5A2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;COL5A1 gene+COL5A2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;COL5A1+COL5A2 gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +49855-0;Tetracycline Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tetracycline IgE Ab [Units/volume] in Serum;Tetracycline IgE Qn;;ACTIVE;2.22;2.73 +49856-8;methylTESTOSTERone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methyltestosterone [Presence] in Serum or Plasma;MeT SerPl Ql;;ACTIVE;2.22;2.56 +49857-6;SMN1 gene+SMN2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SMN1 gene+SMN2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SMN1+SMN2 gene Mut Anl Bld/T;;ACTIVE;2.22;2.73 +4985-8;HLA-DR5;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR5 [Presence];HLA-DR5 Ql;;ACTIVE;1.0;2.73 +49858-4;Peptide YY;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Peptide YY [Mass/volume] in Serum or Plasma;Peptide YY SerPl-mCnc;;ACTIVE;2.22;2.70 +49859-2;Amphotericin B;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Amphotericin B [Mass/volume] in Specimen;Amphotericin B Spec-mCnc;;ACTIVE;2.22;2.69 +498-6;Tetracycline;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Tetracycline [Susceptibility] by Serum bactericidal titer;Tetracycline Titr SBT;;ACTIVE;1.0;2.32 +49860-0;Sporothrix schenckii Ab;PrThr;Pt;CSF;Ord;LA;MICRO;1;Sporothrix schenckii Ab [Presence] in Cerebral spinal fluid by Latex agglutination;S schenckii Ab CSF Ql LA;;ACTIVE;2.22;2.56 +49861-8;Toxocara canis Ab;ACnc;Pt;XXX;Qn;IA;MICRO;1;Toxocara canis Ab [Units/volume] in Specimen by Immunoassay;T canis Ab Spec IA-aCnc;;ACTIVE;2.22;2.73 +49862-6;G6PC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;G6PC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;G6PC gene Mut Anl Bld/T;;ACTIVE;2.22;2.73 +49863-4;Aspergillus sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Aspergillus sp DNA [Presence] in Specimen by NAA with probe detection;Aspergillus DNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49864-2;Procaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Procaine IgE Ab [Units/volume] in Serum;Procaine IgE Qn;;ACTIVE;2.22;2.73 +49865-9;Coagulation factor VIII activity actual/Normal;RelACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor VIII activity actual/normal in Platelet poor plasma by Chromogenic method;Fact VIII Act/Nor PPP Chro;;ACTIVE;2.22;2.73 +4986-6;HLA-DR7;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR7 [Presence] in Donor;HLA-DR7 Donr Ql;;ACTIVE;1.0;2.56 +49866-7;Neuropeptide Y;MCnc;Pt;Ser;Qn;;CHEM;1;Neuropeptide Y [Mass/volume] in Serum;Neuropeptide Y Ser-mCnc;;ACTIVE;2.22;2.73 +49867-5;Endothelin I;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Endothelin I [Mass/volume] in Serum or Plasma;Endothelin I SerPl-mCnc;;ACTIVE;2.22;2.70 +49868-3;Ibuprofen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ibuprofen IgE Ab [Units/volume] in Serum;Ibuprofen IgE Qn;;ACTIVE;2.22;2.73 +49869-1;Camel dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Camel dander IgE Ab [Units/volume] in Serum;Camel dander IgE Qn;;ACTIVE;2.22;2.73 +49870-9;Coagulation factor VII Ag actual/Normal;RelACnc;Pt;PPP;Qn;IA;COAG;1;Coagulation factor VII Ag actual/normal in Platelet poor plasma by Immunoassay;Fact VII Ag Act/Nor PPP IA;;ACTIVE;2.22;2.73 +49871-7;Codeine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Codeine IgE Ab [Units/volume] in Serum;Codeine IgE Qn;;ACTIVE;2.22;2.73 +49872-5;FH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FH gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +49873-3;POU3F4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;POU3F4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;POU3F4 gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +4987-4;HLA-DR7;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR7 [Presence];HLA-DR7 Ql;;ACTIVE;1.0;2.56 +49874-1;ABCB4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ABCB4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ABCB4 gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +49875-8;Juniperus californica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;California juniper IgE Ab [Units/volume] in Serum;CA Juniper IgE Qn;;ACTIVE;2.22;2.42 +49876-6;Alpha hydroxytriazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha hydroxytriazolam [Mass/volume] in Urine by Confirmatory method;A-OH-triazolam Ur Cfm-mCnc;;ACTIVE;2.22;2.73 +49877-4;Hepatitis B virus codon 173;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 173 [Identifier] by Genotype method;HBV 173 Islt Genotyp;;ACTIVE;2.22;2.38 +49878-2;Hepatitis B virus codon 180;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 180 [Identifier] by Genotype method;HBV 180 Islt Genotyp;;ACTIVE;2.22;2.38 +49879-0;Hepatitis B virus codon 181;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 181 [Identifier] by Genotype method;HBV 181 Islt Genotyp;;ACTIVE;2.22;2.42 +49880-8;Hepatitis B virus codon 204;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 204 [Identifier] by Genotype method;HBV 204 Islt Genotyp;;ACTIVE;2.22;2.38 +49881-6;Hepatitis B virus codon 236;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 236 [Identifier] by Genotype method;HBV 236 Islt Genotyp;;ACTIVE;2.22;2.38 +4988-2;HLA-DR9;PrThr;Pt;Bld/Tiss^Donor;Ord;;HLA;1;HLA-DR9 [Presence] in Donor;HLA-DR9 Donr Ql;;ACTIVE;1.0;2.56 +49882-4;Hepatitis B virus codon 80;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 80 [Identifier] by Genotype method;HBV 80 Islt Genotyp;;ACTIVE;2.22;2.38 +49883-2;Hepatitis B virus resistance panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;Hepatitis B virus resistance panel by Genotype method;HBV res Pnl Islt Genotyp;;ACTIVE;2.22;2.73 +49884-0;Lymphocyte proliferation.tetanus toxoid stimulation^7D post incubation;Ratio;Pt;Bld;Qn;;MICRO;1;Lymphocyte proliferation stimulated by tetanus toxoid [Ratio] in Blood --7 day post incubation;LPT TT 7D Bld-Rto;;ACTIVE;2.22;2.70 +49885-7;Lymphocyte proliferation.beryllium stimulation panel;-;Pt;Bld;-;;PANEL.SERO;1;Lymphocyte proliferation.beryllium stimulation panel - Blood;LPT Be Pnl Bld;;ACTIVE;2.22;2.73 +49886-5;Adenosine monophosphate.cyclic/Creatinine^1st specimen post XXX challenge;Ratio;Pt;Urine;Qn;;CHAL;1;Adenosine monophosphate.cyclic/Creatinine [Ratio] in Urine --1st specimen post XXX challenge;cAMP/Creat sp1 p chal Ur-Rto;;ACTIVE;2.22;2.73 +49887-3;Dehydroepiandrosterone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;DHEA sp1 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +49888-1;Dehydroepiandrosterone sulfate^1H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin;DHEA-S 1h p ACTH SerPl-mCnc;;ACTIVE;2.22;2.73 +49889-9;Dehydroepiandrosterone sulfate^pre dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --pre dose corticotropin;DHEA-S Pre ACTH SerPl-mCnc;;ACTIVE;2.22;2.73 +4989-0;HLA-DR9;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DR9 [Presence];HLA-DR9 Ql;;ACTIVE;1.0;2.56 +49890-7;HIV 1 RNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HIV1 RNA Spec NAA+probe-Log#;;ACTIVE;2.22;2.73 +49891-5;Human papilloma virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection;HPV DNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49892-3;Somatotropin^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;GH sp1 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +49893-1;Somatotropin^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;GH sp7 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +49894-9;Somatotropin^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;GH sp9 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +49895-6;Somatotropin^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;GH sp10 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +49896-4;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Specimen by NAA with probe detection;HPV I/H Risk 1 DNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +49897-2;Insulin^pre XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --pre XXX challenge;Insulin pre chal SerPl-aCnc;;ACTIVE;2.22;2.73 +49898-0;Metabolic syndrome;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Metabolic syndrome [Presence] in Serum or Plasma;Metabolic syndrome SerPl Ql;;ACTIVE;2.22;2.73 +49899-8;Setomelanomma rostrata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Setomelanomma rostrata IgE Ab/IgE total in Serum;S rostrata IgE/IgE total %;;ACTIVE;2.22;2.73 +49900-4;Heptacarboxylporphyrin I;MRat;24H;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin I [Mass/time] in 24 hour Stool;Hepta-CP I 24h Stl-mRate;;ACTIVE;2.22;2.73 +49901-2;Heptacarboxylporphyrin III;MRat;24H;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin III [Mass/time] in 24 hour Stool;Hepta-CP3 24h Stl-mRate;;ACTIVE;2.22;2.73 +49902-0;Hexanoylglycine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Hexanoylglycine/Creatinine [Molar ratio] in 24 hour Urine;Hexanoylgly/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +49903-8;Hippurate/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Hippurate/Creatinine [Molar ratio] in 24 hour Urine;Hippurate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +49904-6;Histoplasma capsulatum M Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum M Ab [Presence] in Cerebral spinal fluid;H capsul M Ab CSF Ql;;ACTIVE;2.22;2.56 +49905-3;HIV 1 Ab;PrThr;Pt;XXX;Ord;IA.rapid;MICRO;1;HIV 1 Ab [Presence] in Specimen by Rapid immunoassay;HIV1 Ab Spec Ql IA.rapid;;ACTIVE;2.22;2.73 +49906-1;Hydroxydecanedioate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Hydroxydecanedioate/Creatinine [Molar ratio] in 24 hour Urine;OH-Decanedioate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +49907-9;IgA Ag;PrThr;Pt;Tiss;Ord;IF;PATH;1;IgA Ag [Presence] in Tissue by Immunofluorescence;IgA Ag Tiss Ql IF;;ACTIVE;2.22;2.56 +4990-8;Blastomyces dermatitidis rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Blastomyces dermatitidis rRNA [Presence] in Specimen by Probe;B dermat rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +49908-7;Immunoglobulin light chains.kappa/Immunoglobulin light chains.lambda;MRto;24H;Urine;Qn;;CHEM;1;Kappa light chains/Lambda light chains [Mass Ratio] in 24 hour Urine;Kappa LC/Lambda 24h Ur;;ACTIVE;2.22;2.73 +49909-5;Interleukin 10;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 10 [Mass/volume] in Cerebral spinal fluid;Il10 CSF-mCnc;;ACTIVE;2.22;2.70 +49910-3;Isocitrate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Isocitrate/Creatinine [Molar ratio] in 24 hour Urine;Isocitrate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +49911-1;Isovalerylglycine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Isovalerylglycine/Creatinine [Molar ratio] in 24 hour Urine;Isovalerylgly/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +49912-9;Japanese encephalitis virus Ab;Titr;Pt;CSF;Qn;;MICRO;1;Japanese encephalitis virus Ab [Titer] in Cerebral spinal fluid;JEV Ab Titr CSF;;ACTIVE;2.22;2.70 +49913-7;Legionella pneumophila Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila IgG Ab [Presence] in Serum;L pneumo IgG Ser Ql;;ACTIVE;2.22;2.73 +49914-5;Legionella pneumophila 1+2+3+4+5+6 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 1+2+3+4+5+6 IgM Ab [Presence] in Serum;L pneumo pool 1-6 IgM Ser Ql;;ACTIVE;2.22;2.73 +49915-2;Legionella sp Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella sp IgG Ab [Presence] in Serum;Legionella IgG Ser Ql;;ACTIVE;2.22;2.56 +4991-6;Borrelia burgdorferi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Borrelia burgdorferi DNA [Presence] in Specimen by NAA with probe detection;B burgdor DNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +49916-0;Liquidambar styraciflua Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sweet gum IgE Ab/IgE total in Serum;Sweet gum IgE/IgE total %;;ACTIVE;2.22;2.70 +49917-8;Lymphocyte proliferation.10 umol beryllium stimulation^6D post incubation;Ratio;Pt;WBC;Qn;;SERO;1;Lymphocyte proliferation stimulated by 10 umol beryllium [Ratio] in Leukocytes --6 days post incubation;LPT 10 umol Be 6D WBC-Rto;;ACTIVE;2.22;2.70 +49918-6;Heptacarboxylporphyrin II;MRat;XXX;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin II [Mass/time] in unspecified time Stool;Hepta-CP II ?Tm Stl-mRate;;ACTIVE;2.22;2.70 +49919-4;Interleukin 6;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 6 [Mass/volume] in Cerebral spinal fluid;Il6 CSF-mCnc;;ACTIVE;2.22;2.70 +49920-2;Isopropyl ether;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Isopropyl ether [Presence] in Serum or Plasma;Isopropyl Ether SerPl Ql;;ACTIVE;2.22;2.56 +49921-0;Lymphocyte proliferation.concanavalin A stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by concanavalin A in Blood;LPT CA Bld-nRate;;ACTIVE;2.22;2.73 +49922-8;Lymphocyte proliferation.phytohemagglutinin stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by phytohemagglutinin in Blood;LPT PHA Bld-nRate;;ACTIVE;2.22;2.73 +49923-6;Lymphocyte proliferation.pokeweed mitogen stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by pokeweed mitogen in Blood;LPT PW Bld-nRate;;ACTIVE;2.22;2.73 +4992-4;Campylobacter sp rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Campylobacter sp rRNA [Presence] in Specimen by Probe;Campylobacter rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +49924-4;Alkaline phosphatase.macro/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.macro/Alkaline phosphatase.total in Serum or Plasma;ALP macro CFr SerPl;;ACTIVE;2.22;2.70 +49925-1;Glucose-6-Phosphate dehydrogenase;CCnt;Pt;RBC;Qn;Glock & McLean;CHEM;1;Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells by Glock and McLean;G6PD RBC Glock & McLean-cCnt;;ACTIVE;2.22;2.70 +49926-9;Glucose-6-Phosphate dehydrogenase;CCnt;Pt;RBC;Qn;WHO method;CHEM;1;Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells by WHO method;G6PD RBC WHO method-cCnt;;ACTIVE;2.22;2.70 +49927-7;Amylase.fld/Amylase.serum;RelRto;Pt;Body fld+Ser/Plas;Qn;;CHEM;1;Amylase in fluid/Amylase in serum;Amylase Fld/SerPl;;ACTIVE;2.22;2.44 +49928-5;Leukocytes;NCnc;Pt;Dial fld prt;Qn;;HEM/BC;1;Leukocytes [#/volume] in Peritoneal dialysis fluid;WBC # DiafP;;ACTIVE;2.22;2.73 +49929-3;Protein.plr fld/Protein.serum;RelRto;Pt;Ser/Plas+Plr fld;Qn;;CHEM;1;Protein in pleural fluid/Protein in serum;Prot Plr/SerPl;;ACTIVE;2.22;2.73 +49930-1;Lactate dehydrogenase.plr fld/Lactate dehydrogenase.serum;RelRto;Pt;Ser/Plas+Plr fld;Qn;;CHEM;1;Lactate dehydrogenase in pleural fluid/Lactate dehydrogenase in serum;LDH Plr/SerPl;;ACTIVE;2.22;2.73 +49931-9;3-Hydroxysebacate.unsaturated/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxysebacate (3-OH-C8) unsaturated/Creatinine [Molar ratio] in Urine;3OHsebacate.unsaturated/Creat Ur-sRto;;ACTIVE;2.22;2.70 +4993-2;Chlamydia trachomatis rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Specimen by Probe;C trach rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +49932-7;3-Hydroxysuberate.unsaturated/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxysuberate.unsaturated/Creatinine [Molar ratio] in Urine;3-OHsuberate.unsaturated/Creat Ur-sRto;;ACTIVE;2.22;2.70 +49933-5;Adipate.unsaturated/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adipate.unsaturated/Creatinine [Molar ratio] in Urine;Adipate.unsaturated/Creat Ur-sRto;;ACTIVE;2.22;2.70 +49934-3;Adipolactone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adipolactone/Creatinine [Molar ratio] in Urine;Adipolactone/Creat Ur-sRto;;ACTIVE;2.22;2.70 +49935-0;Calcium.ionized/Calcium.total^^corrected for albumin;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Calcium.ionized/Calcium.total corrected for albumin in Serum or Plasma;Ca-I Album cor MFr SerPl;;ACTIVE;2.22;2.70 +49936-8;Calcium.ionized/Calcium.total^^corrected for albumin;MFr;Pt;Bld;Qn;;CHEM;1;Calcium.ionized/Calcium.total corrected for albumin in Blood;Ca-I Album cor MFr Bld;;ACTIVE;2.22;2.73 +49937-6;Calcium/Oxalate;SRto;Pt;Urine;Qn;;CHEM;1;Calcium/Oxalate [Molar ratio] in Urine;Calcium/Oxalate Ur-sRto;;ACTIVE;2.22;2.42 +49938-4;Citrate synthase;CCnt;Pt;Amnio fld;Qn;;CHEM;1;Citrate synthase [Enzymatic activity/mass] in Amniotic fluid;Citrate Synthase Amn-cCnt;;ACTIVE;2.22;2.70 +49939-2;Dodecenedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dodecenedioate/Creatinine [Molar ratio] in Urine;Dodecenedioate/Creat Ur-sRto;;ACTIVE;2.22;2.70 +499-4;Ticarcillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ticarcillin [Susceptibility] by Minimum lethal concentration (MLC);Ticarcillin Islt MLC;;ACTIVE;1.0;2.19 +4994-0;Coccidioides immitis rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Coccidioides immitis rRNA [Presence] in Specimen by Probe;C immitis rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +49940-0;Glutamate dehydrogenase;CCnt;Pt;WBC;Qn;;CHEM;1;Glutamate dehydrogenase [Enzymatic activity/mass] in Leukocytes;GLDH WBC-cCnt;;ACTIVE;2.22;2.70 +49941-8;Sepiapterin;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Sepiapterin [Moles/volume] in Cerebral spinal fluid;Sepiapterin CSF-sCnc;;ACTIVE;2.22;2.70 +49942-6;Somatotropin^1 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 AM specimen;GH 1 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49943-4;Somatotropin^1.30 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1:30 am specimen;GH 1:30 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49944-2;Somatotropin^10 PM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --10 PM specimen;GH 10 PM SerPl-aCnc;;ACTIVE;2.22;2.70 +49945-9;Somatotropin^10.30 PM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --10:30 PM specimen;GH 10:30 PM SerPl-aCnc;;ACTIVE;2.22;2.70 +49946-7;Somatotropin^11 PM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --11 PM specimen;GH 11 PM SerPl-aCnc;;ACTIVE;2.22;2.70 +49947-5;Somatotropin^11.30 PM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --11:30 PM specimen;GH 11:30 PM SerPl-aCnc;;ACTIVE;2.22;2.70 +49948-3;Somatotropin^12 PM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --12 PM specimen;GH 12 PM SerPl-aCnc;;ACTIVE;2.22;2.70 +49949-1;Somatotropin^12.30 PM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --12:30 PM specimen;GH 12:30 PM SerPl-aCnc;;ACTIVE;2.22;2.70 +49950-9;Somatotropin^2 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 AM specimen;GH 2 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49951-7;Somatotropin^2.30 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2:30 am specimen;GH 2:30 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49952-5;Somatotropin^3 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --3 AM specimen;GH 3 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49953-3;Somatotropin^3.30 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --3:30 AM specimen;GH 3:30 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49954-1;Somatotropin^4 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --4 AM specimen;GH 4 AM specimen SerPl-aCnc;;ACTIVE;2.22;2.70 +49955-8;Somatotropin^4.30 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --4:30 AM specimen;GH 4:30 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49956-6;Somatotropin^5 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --5 AM specimen;GH 5 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +4995-7;Cryptococcus neoformans rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Cryptococcus neoformans rRNA [Presence] in Specimen by Probe;C neoform rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +49957-4;Somatotropin^5.30 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --5:30 AM specimen;GH 5:30 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49958-2;Somatotropin^6 AM specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --6 AM specimen;GH 6 AM SerPl-aCnc;;ACTIVE;2.22;2.70 +49959-0;Specific gravity^^adjusted to pH 7.4;Rden;Pt;Urine;Qn;;UA;1;Specific gravity of Urine adjusted to pH 7.4;Sp Gr adj pH7.4 Ur;;ACTIVE;2.22;2.69 +49960-8;Suberate.unsaturated/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Suberate.unsaturated/Creatinine [Molar ratio] in Urine;Suberate.unsaturated/Creat Ur-sRto;;ACTIVE;2.22;2.70 +49961-6;Urate renal clearance;VRat;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Urate renal clearance in Urine and Serum or Plasma collected for unspecified duration;Urate Cl ?Tm Ur+SerPl-vRate;;ACTIVE;2.22;2.70 +49962-4;Urate renal clearance/1.73 sq M;ArVRat;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Urate renal clearance/1.73 sq M in Urine and Serum or Plasma collected for unspecified duration;Urate Cl/1.73 sq M ?Tm Ur+SerPl-ArVRat;;ACTIVE;2.22;2.70 +49963-2;Fibrillarin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Fibrillarin Ab [Presence] in Serum;Fibrillarin Ab Ser Ql;;ACTIVE;2.22;2.73 +49964-0;Siderocytes;NCnc;Pt;Bld;Qn;;HEM/BC;1;Siderocytes [#/volume] in Blood;Siderocytes # Bld;;ACTIVE;2.22;2.73 +4996-5;Cytomegalovirus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Blood by NAA with probe detection;CMV DNA Bld Ql NAA+probe;;ACTIVE;1.0;2.73 +49965-7;HIV 1 Ab/HIV 2 Ab;Ratio;Pt;Ser;Qn;IB;MICRO;1;Deprecated HIV 1 Ab/HIV 2 Ab Ab [Ratio] in Serum by Immunoblot (IB);Deprecated HIV1 Ab/HIV 2 Ab Ser IB-Rto;;DEPRECATED;2.22;2.42 +49966-5;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Pericardial fluid by Manual count;Polys/leuk NFr Pcar Manual;;ACTIVE;2.22;2.73 +49967-3;Charcoal;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Charcoal [Presence] in Urine sediment by Light microscopy;Charcoal UrnS Ql Micro;;ACTIVE;2.22;2.70 +49968-1;Cortisol^1H post 250 ug corticotropin IM;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Molar concentration difference] in Serum or Plasma --1 hour post 250 ug corticotropin IM;Cortis 1h p 250 ug ACTH IM SerPl-SCDiff;;ACTIVE;2.22;2.70 +49969-9;Cortisol^30M post 250 ug corticotropin IM;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Molar concentration difference] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;Cortis 30M p 250 ug ACTH IM SerPl-SCDiff;;ACTIVE;2.22;2.70 +49970-7;Collection time^4th specimen;TmStp;Pt;Bld;Qn;;SPEC;1;Collection time of Blood--4th specimen;Collect Tme sp4 Bld;;ACTIVE;2.22;2.26 +49971-5;Collection time^3rd specimen;TmStp;Pt;Bld;Qn;;SPEC;1;Collection time of Blood--3rd specimen;Collect Tme sp3 Bld;;ACTIVE;2.22;2.73 +49972-3;Collection time^2nd specimen;TmStp;Pt;Bld;Qn;;SPEC;1;Collection time of Blood--2nd specimen;Collect Tme sp2 Bld;;ACTIVE;2.22;2.73 +4997-3;Cytomegalovirus DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Cytomegalovirus DNA [Presence] in Tissue by Probe;CMV DNA Tiss Ql Probe;;ACTIVE;1.0;2.63 +49973-1;Borrelia burgdorferi 31kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 31kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor31kD IgG CSF Ql IB;;ACTIVE;2.22;2.58 +49974-9;Borrelia burgdorferi 31kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 31kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor31kD IgM CSF Ql IB;;ACTIVE;2.22;2.58 +49975-6;Borrelia burgdorferi 34kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 34kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor34kD IgG CSF Ql IB;;ACTIVE;2.22;2.58 +49976-4;Borrelia burgdorferi 34kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 34kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor34kD IgM CSF Ql IB;;ACTIVE;2.22;2.58 +49977-2;Borrelia burgdorferi 35kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 35kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor35kD IgG Ser Ql IB;;ACTIVE;2.22;2.58 +49978-0;Borrelia burgdorferi 35kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 35kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor35kD IgG CSF Ql IB;;ACTIVE;2.22;2.58 +49979-8;Borrelia burgdorferi 35kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 35kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor35kD IgM Ser Ql IB;;ACTIVE;2.22;2.58 +49980-6;Borrelia burgdorferi 35kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 35kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor35kD IgM CSF Ql IB;;ACTIVE;2.22;2.58 +4998-1;Cytomegalovirus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Tissue by NAA with probe detection;CMV DNA Tiss Ql NAA+probe;;ACTIVE;1.0;2.73 +49981-4;Borrelia burgdorferi 37kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 37kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor37kD IgG Ser Ql IB;;ACTIVE;2.22;2.58 +49982-2;Borrelia burgdorferi 37kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 37kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor37kD IgG CSF Ql IB;;ACTIVE;2.22;2.58 +49983-0;Borrelia burgdorferi 37kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 37kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor37kD IgM Ser Ql IB;;ACTIVE;2.22;2.58 +49984-8;Borrelia burgdorferi 37kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 37kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor37kD IgM CSF Ql IB;;ACTIVE;2.22;2.58 +49985-5;Herpes simplex virus 1 DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Blood by NAA with probe detection;HSV1 DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +49986-3;Herpes simplex virus 1 DNA;NCnc;Pt;Body fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Body fluid by NAA with probe detection;HSV1 DNA # Fld NAA+probe;;ACTIVE;2.22;2.73 +49987-1;Herpes simplex virus 1 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HSV1 DNA # CSF NAA+probe;;ACTIVE;2.22;2.73 +49988-9;Herpes simplex virus 2 DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Blood by NAA with probe detection;HSV2 DNA # Bld NAA+probe;;ACTIVE;2.22;2.73 +49989-7;Herpes simplex virus 2 DNA;NCnc;Pt;Body fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Body fluid by NAA with probe detection;HSV2 DNA # Fld NAA+probe;;ACTIVE;2.22;2.73 +49990-5;Herpes simplex virus 2 DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HSV2 DNA # CSF NAA+probe;;ACTIVE;2.22;2.73 +49991-3;Borrelia burgdorferi 18_20kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 18/20kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor18/20kD IgG CSF Ql IB;;ACTIVE;2.22;2.58 +49992-1;Borrelia burgdorferi 18_20kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 18/20kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor18/20kD IgG Ser Ql IB;;ACTIVE;2.22;2.73 +49993-9;Borrelia burgdorferi 18_20kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 18/20kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor18/20kD IgM CSF Ql IB;;ACTIVE;2.22;2.58 +49994-7;Borrelia burgdorferi 18_20kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 18/20kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor18/20kD IgM Ser Ql IB;;ACTIVE;2.22;2.58 +49995-4;Borrelia burgdorferi 83_93kD Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 83/93kD IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor83/93kD IgG CSF Ql IB;;ACTIVE;2.22;2.58 +49996-2;Borrelia burgdorferi 83_93kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 83/93kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor83/93kD IgG Ser Ql IB;;ACTIVE;2.22;2.58 +49997-0;Borrelia burgdorferi 83_93kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 83/93kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor83/93kD IgM Ser Ql IB;;ACTIVE;2.22;2.58 +49998-8;Borrelia burgdorferi 83_93kD Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Borrelia burgdorferi 83/93kD IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;B burgdor83/93kD IgM CSF Ql IB;;ACTIVE;2.22;2.58 +4999-9;Cytomegalovirus DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Urine by NAA with probe detection;CMV DNA Ur Ql NAA+probe;;ACTIVE;1.0;2.63 +49999-6;Platelet aggregation.collagen induced;Prid;Pt;PRP;Nom;;COAG;1;Platelet aggregation collagen induced [Identifier] in Platelet rich plasma;PA Coll PRP Nom;;ACTIVE;2.22;2.73 +50000-9;Hydrogen/Expired gas^30M post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post XXX challenge;Breath H2 30M p chal;;ACTIVE;2.22;2.70 +50001-7;Hydrogen/Expired gas^1H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1 hour post XXX challenge;Breath H2 1h p chal;;ACTIVE;2.22;2.70 +50002-5;Hydrogen/Expired gas^1.5H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post XXX challenge;Breath H2 1.5h p chal;;ACTIVE;2.22;2.70 +50003-3;Hydrogen/Expired gas^2H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2 hours post XXX challenge;Breath H2 2h p chal;;ACTIVE;2.22;2.70 +50004-1;Hydrogen/Expired gas^3H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3 hours post XXX challenge;Breath H2 3h p chal;;ACTIVE;2.22;2.70 +5000-5;Cytomegalovirus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Specimen by NAA with probe detection;CMV DNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50005-8;Methaqualone;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Methaqualone [Presence] in Body fluid by Screen method;Methaqualone Fld Ql Scn;;ACTIVE;2.22;2.56 +50006-6;Human antimouse Ab;PrThr;Pt;Ser;Ord;;SERO;1;Human antimouse Ab [Presence] in Serum;Human Antimouse Ab Ser Ql;;ACTIVE;2.22;2.56 +50007-4;Cytology report;Find;Pt;BAL;Doc;Cyto stain;CYTO;1;Cytology report of Bronchoalveolar lavage Cyto stain;Cytology BAL Doc Cyto;;ACTIVE;2.22;2.73 +50008-2;Mixing studies;Imp;Pt;PPP;Nar;;COAG;1;Mixing studies [Interpretation] in Platelet poor plasma Narrative;Mixing studies PPP-Imp;;ACTIVE;2.22;2.73 +50009-0;Fetal lung maturity panel;-;Pt;Amnio fld;Qn;;PANEL.CHEM;1;Fetal lung maturity panel - Amniotic fluid;Fetal lung maturity Pnl Amn;;ACTIVE;2.22;2.42 +50010-8;Transfusion end time;TmStp;Pt;^BPU;Qn;;BLDBK;1;Transfusion end time;Transf end time BPU;;ACTIVE;2.22;2.73 +50011-6;Transfusion start time;TmStp;Pt;^BPU;Qn;;BLDBK;1;Transfusion start time;Transf start time BPU;;ACTIVE;2.22;2.73 +50012-4;Indirect antiglobulin test.polyspecific reagent;PrThr;Pt;Ser/Plas;Ord;PEG;BLDBK;1;Indirect antiglobulin test.polyspecific reagent [Presence] in Serum or Plasma by Polyethylene glycol (PEG) method;IAT Poly-Sp Reag SerPl Ql PEG;;ACTIVE;2.22;2.73 +5001-3;Enterococcus sp rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Enterococcus sp rRNA [Presence] in Specimen by Probe;Enterococ rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +50013-2;Hydrogen/Expired gas^2.5H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.5 hours post XXX challenge;Breath H2 2.5h p chal;;ACTIVE;2.22;2.70 +50014-0;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript";Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript in Blood or Tissue by Molecular genetics method";"t(9;22)(ABL1,BCR) Bld/T";;ACTIVE;2.22;2.73 +50015-7;West Nile virus Ag;PrThr;Pt;Bld/Bone mar^Donor;Ord;;MICRO;1;West Nile virus Ag [Presence] in Blood or Marrow from Donor;WNV Ag Bld/Mar Donr Ql;;ACTIVE;2.22;2.73 +50016-5;Sugar;Type;Pt;Dose;Nom;;DRUGDOSE;1;Sugar [Type] of Dose;Sugar Dose;;ACTIVE;2.22;2.22 +50017-3;Hemoglobin.gastrointestinal;PrThr;Pt;Sputum/Gast fld;Ord;;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Sputum or Gastric fluid;Hemoccult Sput/Gast Ql;;ACTIVE;2.22;2.56 +50018-1;Cytomegalovirus Ab.IgG;PrThr;Pt;Body fld;Ord;;MICRO;1;Cytomegalovirus IgG Ab [Presence] in Body fluid;CMV IgG Fld Ql;;ACTIVE;2.22;2.56 +50019-9;HLA-DP+DQ+DR;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DP+DQ+DR (class II) [Type];HLA-DP+DQ+DR;;ACTIVE;2.22;2.73 +50020-7;Microdeletion syndromes;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DEL;1;Microdeletion syndromes in Blood or Tissue by FISH;Microdeletion synd Bld/T FISH;;ACTIVE;2.22;2.73 +5002-1;Epstein Barr virus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Blood by NAA with probe detection;EBV DNA Bld Ql NAA+probe;;ACTIVE;1.0;2.73 +50021-5;oxyCODONE;MCnc;Pt;Ser/Plas/Bld;Qn;Screen;DRUG/TOX;1;oxyCODONE [Mass/volume] in Serum, Plasma or Blood by Screen method;oxyCODONE SerPlBld Scn-mCnc;;ACTIVE;2.22;2.73 +50022-3;Ethanol+Methanol+Isopropyl alcohol+Acetone;PrThr;Pt;Ser/Plas/Bld;Ord;;DRUG/TOX;1;Ethanol+Methanol+Isopropyl alcohol+Acetone [Presence] in Serum, Plasma or Blood;Alcohol.XXX SerPlBld Ql;;ACTIVE;2.22;2.73 +50023-1;Hepatitis C virus RNA panel;-;Pt;Ser/Plas;Qn;Probe.amp.tar;PANEL.MICRO;1;Hepatitis C virus RNA panel (viral load) in Serum or Plasma by NAA with probe detection;HCV RNA Pnl SerPl NAA+probe;;ACTIVE;2.22;2.73 +50024-9;Virus identified;Prid;Pt;XXX;Nom;Shell vial culture;MICRO;1;Virus identified in Specimen by Shell vial culture;Virus Spec Shell Vial Cult;;ACTIVE;2.22;2.73 +50025-6;Volatiles panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Volatiles panel - Serum or Plasma;Volatiles Pnl SerPl;;ACTIVE;2.22;2.42 +50026-4;(Arachis hypogaea+Bean white+Glycine max+Lens esculenta+Pisum sativum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 30 (Peanut+White bean+Soybean+Lentil+ Peas) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix30 IgE Qn;;ACTIVE;2.22;2.73 +50027-2;Narcissus sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Narcissus IgE Ab [Units/volume] in Serum;Narcissus IgE Qn;;ACTIVE;2.22;2.73 +50028-0;Escherichia coli Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Escherichia coli IgE Ab [Units/volume] in Serum;E coli IgE Qn;;ACTIVE;2.22;2.73 +50029-8;Mahogany wood dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mahogany wood dust IgE Ab [Units/volume] in Serum;Mahogany dust IgE Qn;;ACTIVE;2.22;2.73 +50030-6;Oak wood dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oak wood dust IgE Ab [Units/volume] in Serum;Oak dust IgE Qn;;ACTIVE;2.22;2.73 +50031-4;Sulfamethoxazole Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sulfamethoxazole IgE Ab [Units/volume] in Serum;Sulfamethoxazole IgE Qn;;ACTIVE;2.22;2.73 +50032-2;Callistephus chinesi Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;China aster IgE Ab [Units/volume] in Serum;China aster IgE Qn;;ACTIVE;2.22;2.73 +50033-0;Cephalosporin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cephalosporin IgE Ab [Units/volume] in Serum;Cephalosporin IgE Qn;;ACTIVE;2.22;2.73 +50034-8;Arbovirus Ab.Neut;Prid;Pt;XXX;Nom;Neut;MICRO;1;Arbovirus neutralizing antibody [Identifier] in Specimen by Neutralization test;Arbovirus NAb Spec Nt;;ACTIVE;2.22;2.72 +50035-5;Colorado tick fever virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Colorado tick fever virus neutralizing antibody [Presence] in Specimen by Neutralization test;CTFV NAb Spec Ql Nt;;ACTIVE;2.22;2.72 +50036-3;Dengue virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Dengue virus neutralizing antibody [Presence] in Specimen by Neutralization test;DENV NAb Spec Ql Nt;;ACTIVE;2.22;2.72 +50037-1;Powassan virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Powassan virus neutralizing antibody [Presence] in Specimen by Neutralization test;POWV NAb Spec Ql Nt;;ACTIVE;2.22;2.72 +50038-9;Snowshoe hare virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Snowshoe hare virus neutralizing antibody [Presence] in Specimen by Neutralization test;SSHV NAb Spec Ql Nt;;ACTIVE;2.22;2.72 +5003-9;Epstein Barr virus DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Epstein Barr virus DNA [Presence] in Tissue by Probe;EBV DNA Tiss Ql Probe;;ACTIVE;1.0;2.73 +50039-7;5-Methyltetrahydrofolate/Folate;SFr;Pt;Ser/Plas;Qn;;CHEM;1;5-Methyltetrahydrofolate/Folate in Serum or Plasma;5Me-tetrahydrofolate/Folate SFr SerPl;;ACTIVE;2.22;2.70 +50040-5;Advanced oxidation protein products;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Advanced oxidation protein products [Moles/volume] in Serum or Plasma;OAPP SerPl-sCnc;;ACTIVE;2.22;2.70 +50041-3;Bilirubin+Urobilinogen;PrThr;Pt;Urine;Ord;;UA;1;Bilirubin+Urobilinogen [Presence] in Urine;Bilirub+Urobilinogen Ur Ql;;ACTIVE;2.22;2.56 +50042-1;Basal metabolic rate index;ACnc;Pt;^Patient;Qn;;MISC;1;Basal metabolic rate index;BMR index Patient-aCnc;;ACTIVE;2.22;2.73 +50043-9;Protein carbonyl/protein;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Protein carbonyl/Protein [Ratio] in Serum or Plasma;Protein carbonyl/Prot SerPl-Rto;;ACTIVE;2.22;2.70 +50044-7;Glomerular filtration rate/1.73 sq M.predicted.female;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (MDRD);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among females [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD);GFR/BSA pred.fem SerPlBld MDRD-ArVRat;;ACTIVE;2.22;2.73 +50045-4;Hemicystine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Hemicystine [Moles/volume] in Amniotic fluid;Hemicystine Amn-sCnc;;ACTIVE;2.22;2.70 +50046-2;Hemicystine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hemicystine [Moles/volume] in Serum or Plasma;Hemicystine SerPl-sCnc;;ACTIVE;2.22;2.70 +5004-7;Epstein Barr virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Tissue by NAA with probe detection;EBV DNA Tiss Ql NAA+probe;;ACTIVE;1.0;2.73 +50047-0;Hemicystine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Hemicystine [Moles/volume] in DBS;Hemicystine DBS-sCnc;;ACTIVE;2.22;2.70 +50048-8;Hemicystine;SCnc;Pt;XXX;Qn;;CHEM;1;Hemicystine [Moles/volume] in Specimen;Hemicystine Spec-sCnc;;ACTIVE;2.22;2.70 +50049-6;Hemicystine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Hemicystine/Amino acids.total in Hair;Hemicystine SFr Hair;;ACTIVE;2.22;2.70 +50050-4;Hemicystine/Amino acids.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Hemicystine/Amino acids.total in Amniotic fluid;Hemicystine SFr Amn;;ACTIVE;2.22;2.70 +50051-2;Hemicystine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Hemicystine/Amino acids.total in Serum or Plasma;Hemicystine SFr SerPl;;ACTIVE;2.22;2.70 +50052-0;Hemicystine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Hemicystine/Amino acids.total in DBS;Hemicystine SFr DBS;;ACTIVE;2.22;2.70 +50053-8;Hemicystine/Amino acids.total;SFr;Pt;XXX;Qn;;CHEM;1;Hemicystine/Amino acids.total in Specimen;Hemicystine SFr Spec;;ACTIVE;2.22;2.70 +5005-4;Epstein Barr virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Specimen by NAA with probe detection;EBV DNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50054-6;Hemicystine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hemicystine/Creatinine [Molar ratio] in Urine;Hemicystine/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50055-3;Iohexol renal clearance;VRat;Pt;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Iohexol renal clearance in Urine and Serum or Plasma;Iohexol Cl Ur+SerPl-vRate;;ACTIVE;2.22;2.70 +50056-1;Nutritional risk index;ACnc;Pt;^Patient;Qn;;MISC;1;Nutritional risk index;Nutritional risk index;;ACTIVE;2.22;2.69 +50057-9;Fractional excretion of phosphate;Ratio;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Fractional excretion of phosphate [Ratio] in Urine and Serum or Plasma collected for unspecified duration;Fract excret PO4 ?Tm Ur+SerPl-Rto;;ACTIVE;2.22;2.70 +50058-7;Phosphate renal clearance;VRat;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Phosphate renal clearance in Urine and Serum or Plasma collected for unspecified duration;Phosphate Cl ?Tm Ur+SerPl-vRate;;ACTIVE;2.22;2.70 +50059-5;Protein fractions.oligoclonal bands/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Oligoclonal bands/Protein.total in Urine by Electrophoresis;Oligoclonal Bands MFr Ur Elph;;ACTIVE;2.22;2.70 +50060-3;Fatty acids.very long chain.C24:0/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate)/Creatinine [Molar ratio] in Urine;VLCFA C24:0/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50061-1;Tetradecanedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetradecanedioate/Creatinine [Molar ratio] in Urine;Tdecanedioate/Creat Ur-sRto;;ACTIVE;2.22;2.70 +5006-2;Haemophilus influenzae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Haemophilus influenzae rRNA [Presence] in Specimen by Probe;Haem influ rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50062-9;Tetradecenedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetradecenedioate/Creatinine [Molar ratio] in Urine;Tdecenedioate/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50063-7;Urea renal clearance/1.73 sq M;ArVRat;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Urea renal clearance/1.73 sq M in Urine and Serum or Plasma collected for unspecified duration;Urea Cl/1.73 sq M ?Tm Ur+SerPl-ArVRat;;ACTIVE;2.22;2.70 +50064-5;Body weight ideal;Mass;Pt;^Patient;Qn;;BDYWGT.ATOM;2;Ideal body weight;Ideal bdy weight;;ACTIVE;2.22;2.73 +50065-2;1-Methylhistidine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in DBS;1Me-hist DBS-sCnc;;ACTIVE;2.22;2.70 +50066-0;1-Methylhistidine;SCnc;Pt;Body fld;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in Body fluid;1Me-hist Fld-sCnc;;ACTIVE;2.22;2.70 +50067-8;11-Hydroxyandrostenedione;SCnc;Pt;Body fld;Qn;;CHEM;1;11-Hydroxyandrostenedione [Moles/volume] in Body fluid;11OH-Ad Fld-sCnc;;ACTIVE;2.22;2.70 +50068-6;11-Hydroxyandrostenedione^pre 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Hydroxyandrostenedione [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin;11OH-Ad pre 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50069-4;11-Hydroxyandrostenedione^30M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Hydroxyandrostenedione [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;11OH-Ad 30M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +5007-0;Hepatitis B virus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Presence] in Blood by NAA with probe detection;HBV DNA Bld Ql NAA+probe;;ACTIVE;1.0;2.73 +50070-2;11-Hydroxyandrostenedione^1H post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Hydroxyandrostenedione [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;11OH-Ad 1h p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50071-0;11-Deoxycortisol;SCnc;Pt;Amnio fld;Qn;;CHEM;1;11-Deoxycortisol [Moles/volume] in Amniotic fluid;11DC Amn-sCnc;;ACTIVE;2.22;2.70 +50072-8;11-Deoxycortisol^pre 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin;11DC pre 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50073-6;11-Deoxycortisol^30M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;11DC 30M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50074-4;11-Deoxycortisol^45M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --45 minutes post 250 ug corticotropin;11DC 45M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50075-1;11-Deoxycortisol^1H post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;11DC 1h p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50076-9;17-Ketosteroids^post dose dexamethasone;MCnc;Pt;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/volume] in Urine --post dose dexamethasone;17KS p Dex Ur-mCnc;;ACTIVE;2.22;2.70 +50077-7;17-Ketosteroids^2D post dose dexamethasone;MCnc;Pt;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/volume] in Urine --2 days post dose dexamethasone;17KS 2D p Dex Ur-mCnc;;ACTIVE;2.22;2.70 +50078-5;17-Hydroxypregnenolone^pre 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin;17OH-Preg pre 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50079-3;17-Hydroxypregnenolone^1H post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL.ROUTINE;1;17-Hydroxypregnenolone [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;17OH-Preg 1h p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50080-1;17-Hydroxyprogesterone^pre 250 ug corticotropin IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin IM;17OHP pre 250 ug ACTH IM SerPl-sCnc;;ACTIVE;2.22;2.70 +50081-9;18-Hydroxydeoxycorticosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;18-Hydroxydeoxycorticosterone [Moles/volume] in Serum or Plasma;18OH-DOC SerPl-sCnc;;ACTIVE;2.22;2.70 +50082-7;18-Hydroxycorticosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;18-Hydroxycorticosterone [Moles/volume] in Serum or Plasma;18OHB SerPl-sCnc;;ACTIVE;2.22;2.70 +50083-5;Alpha aminoadipate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in DBS;AAA DBS-sCnc;;ACTIVE;2.22;2.70 +50084-3;Alpha aminoadipate;SCnc;Pt;Body fld;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in Body fluid;AAA Fld-sCnc;;ACTIVE;2.22;2.70 +50085-0;2-Methyl-3-Hydroxyvalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methyl-3-Hydroxyvalerate/Creatinine [Molar ratio] in Urine;2-Me3OH-valerate/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50086-8;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH) [Moles/volume] in DBS;2Me3OH-Butyrcarn DBS-sCnc;;ACTIVE;2.22;2.70 +50087-6;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH) [Moles/volume] in Amniotic fluid;2Me3OH-Butyrcarn Amn-sCnc;;ACTIVE;2.22;2.70 +5008-8;Hepatitis B virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Presence] in Tissue by NAA with probe detection;HBV DNA Tiss Ql NAA+probe;;ACTIVE;1.0;2.63 +50088-4;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH);SCnc;Pt;CSF;Qn;;CHEM;1;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH) [Moles/volume] in Cerebral spinal fluid;2Me3OH-Butyrcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50089-2;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH);SCnc;Pt;Urine;Qn;;CHEM;1;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH) [Moles/volume] in Urine;2Me3OH-Butyrcarn Ur-sCnc;;ACTIVE;2.22;2.70 +500-9;Ticarcillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ticarcillin [Susceptibility] by Minimum inhibitory concentration (MIC);Ticarcillin Islt MIC;;ACTIVE;1.0;2.73 +50090-0;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH) [Moles/volume] in Serum or Plasma;2Me3OH-Butyrcarn SerPl-sCnc;;ACTIVE;2.22;2.70 +50091-8;2-methyl-3-hydroxybutyrylcarnitine (C5-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methyl-3-Hydroxybutyrylcarnitine (C5-OH)/Creatinine [Molar ratio] in Urine;2Me3OH-Butyrcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50092-6;2-Methylcitrate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Methylcitrate [Moles/volume] in Cerebral spinal fluid;2Me-citrate CSF-sCnc;;ACTIVE;2.22;2.70 +50093-4;21-Deoxycortisol;SCnc;Pt;Amnio fld;Qn;;CHEM;1;21-Deoxycortisol [Moles/volume] in Amniotic fluid;21DC Amn-sCnc;;ACTIVE;2.22;2.70 +50094-2;21-Deoxycortisol^45M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma --45 minutes post 250 ug corticotropin;21DC 45M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50095-9;21-Deoxycortisol^pre 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin;21DC pre 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +5009-6;Hepatitis B virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Hepatitis B virus DNA [Presence] in Specimen by NAA with probe detection;HBV DNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50096-7;21-Deoxycortisol^30M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;21DC 30M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50097-5;21-Deoxycortisol^1H post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;21DC 1h p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +50098-3;3-Hydroxyvalerate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxyvalerate [Moles/volume] in Cerebral spinal fluid;3OH-Valerate CSF-sCnc;;ACTIVE;2.22;2.70 +50099-1;Beta hydroxybutyrate/Acetoacetate;SRto;Pt;Bld;Qn;;CHEM;1;Beta hydroxybutyrate/Acetoacetate [Molar ratio] in Blood;B-OH-Butyr/Acetoacet Bld-sRto;;ACTIVE;2.22;2.73 +50100-7;Beta hydroxybutyrate/Acetoacetate;SRto;Pt;CSF;Qn;;CHEM;1;Beta hydroxybutyrate/Acetoacetate [Molar ratio] in Cerebral spinal fluid;B-OH-Butyr/Acetoacet CSF-sRto;;ACTIVE;2.22;2.70 +50101-5;3-Hydroxybutyrylcarnitine (C4-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in Cerebral spinal fluid;3OH-Butyrcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50102-3;3-Hydroxybutyrylcarnitine (C4-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in DBS;3OH-Butyrcarn DBS-sCnc;;ACTIVE;2.22;2.70 +50103-1;3-Hydroxybutyrylcarnitine (C4-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in Amniotic fluid;3OH-Butyrcarn Amn-sCnc;;ACTIVE;2.22;2.70 +5010-4;Hepatitis C virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Presence] in Blood by NAA with probe detection;HCV RNA Bld Ql NAA+probe;;ACTIVE;1.0;2.73 +50104-9;3-Hydroxyisovalerylcarnitine (C5-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in Cerebral spinal fluid;3OH-Isovalerylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50105-6;3-Hydroxyisovalerylcarnitine (C5-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in Amniotic fluid;3OH-Isovalerylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50106-4;3-Hydroxyisovalerylcarnitine (C5-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in DBS;3OH-Isovalerylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50107-2;3-Hydroxyisovalerylcarnitine (C5-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in Urine;3OH-Isovalerylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50108-0;3-Hydroxylinoleoylcarnitine (C18:2-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in Urine;3OH-Linoleoylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50109-8;3-Hydroxylinoleoylcarnitine (C18:2-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in DBS;3OH-Linoleoylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50110-6;3-Hydroxylinoleoylcarnitine (C18:2-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in Cerebral spinal fluid;3OH-Linoleoylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50111-4;3-Hydroxylinoleoylcarnitine (C18:2-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in Amniotic fluid;3OH-Linoleoylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +5011-2;Hepatitis C virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Presence] in Tissue by NAA with probe detection;HCV RNA Tiss Ql NAA+probe;;ACTIVE;1.0;2.73 +50112-2;3-Hydroxylinoleoylcarnitine (C18:2-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxylinoleoylcarnitine (C18:2-OH)/Creatinine [Molar ratio] in Urine;3OH-Linoleoylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50113-0;3-Hydroxyoleoylcarnitine (C18:1-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in DBS;3OH-Oleoylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50114-8;3-Hydroxyoleoylcarnitine (C18:1-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in Cerebral spinal fluid;3OH-Oleoylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50115-5;3-Hydroxyoleoylcarnitine (C18:1-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in Amniotic fluid;3OH-Oleoylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50116-3;3-Hydroxyoleoylcarnitine (C18:1-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in Urine;3OH-Oleoylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50117-1;3-Hydroxyoleoylcarnitine (C18:1-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyoleoylcarnitine (C18:1-OH)/Creatinine [Molar ratio] in Urine;3OH-Oleoylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50118-9;3-Hydroxypalmitoleylcarnitine (C16:1-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in Urine;3OH-Palmitoleylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50119-7;3-Hydroxypalmitoleylcarnitine (C16:1-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in Cerebral spinal fluid;3OH-Palmitoleylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +5012-0;Hepatitis C virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Presence] in Specimen by NAA with probe detection;HCV RNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50120-5;3-Hydroxypalmitoleylcarnitine (C16:1-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in Amniotic fluid;3OH-Palmitoleylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50121-3;3-Hydroxypalmitoleylcarnitine (C16:1-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in DBS;3OH-Palmitoleylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50122-1;3-Hydroxypalmitoleylcarnitine (C16:1-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxypalmitoleylcarnitine (C16:1-OH)/Creatinine [Molar ratio] in Urine;3OH-Palmitoleylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50123-9;3-Hydroxypalmitoylcarnitine (C16-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in Urine;3OH-Palmitoylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50124-7;3-Hydroxypalmitoylcarnitine (C16-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in Cerebral spinal fluid;3OH-Palmitoylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50125-4;3-Hydroxypalmitoylcarnitine (C16-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in DBS;3OH-Palmitoylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50126-2;3-Hydroxypalmitoylcarnitine (C16-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in Amniotic fluid;3OH-Palmitoylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50127-0;3-Hydroxypalmitoylcarnitine (C16-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH)/Creatinine [Molar ratio] in Urine;3OH-Palmitoylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50128-8;3-Hydroxypropionate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxypropionate (3-OH-C3) [Moles/volume] in Cerebral spinal fluid;3OH-Propionate CSF-sCnc;;ACTIVE;2.22;2.70 +50129-6;3-Hydroxypropionate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxypropionate (3-OH-C3) [Moles/volume] in Amniotic fluid;3OH-Propionate Amn-sCnc;;ACTIVE;2.22;2.70 +50130-4;3-Hydroxystearoylcarnitine (C18-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in Urine;3OH-stearoylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50131-2;3-Hydroxystearoylcarnitine (C18-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in Cerebral spinal fluid;3OH-stearoylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50132-0;3-Hydroxystearoylcarnitine (C18-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in DBS;3OH-stearoylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50133-8;3-Hydroxystearoylcarnitine (C18-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in Amniotic fluid;3OH-stearoylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50134-6;3-Hydroxystearoylcarnitine (C18-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxystearoylcarnitine (C18-OH)/Creatinine [Molar ratio] in Urine;3OH-stearoylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50135-3;3-Methoxy-4-Hydroxyphenylglycol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Moles/volume] in Serum or Plasma;3Me4OH-phenylglycol SerPl-sCnc;;ACTIVE;2.22;2.70 +50136-1;3-Methoxy-4-Hydroxyphenylglycol;SCnc;Pt;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Moles/volume] in Urine;3Me4OH-phenylglycol Ur-sCnc;;ACTIVE;2.22;2.70 +50137-9;3-Methoxy-4-Hydroxyphenylglycol;SRat;Pt;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Moles/time] in Urine;3Me4OH-phenylglycol Ur-sRate;;DISCOURAGED;2.22;2.70 +5013-8;Herpes simplex virus DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HSV DNA CSF Ql NAA+probe;;ACTIVE;1.0;2.73 +50138-7;3-Methoxy-4-Hydroxyphenylglycol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol/Creatinine [Molar ratio] in Urine;3Me4OH-phenylglycol/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50139-5;3-Methoxytyramine;SCnc;Pt;CSF;Qn;;CHEM;1;3-Methoxytyramine [Moles/volume] in Cerebral spinal fluid;3Me-tyramine CSF-sCnc;;ACTIVE;2.22;2.70 +50140-3;3-Methoxytyramine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methoxytyramine [Moles/volume] in Serum or Plasma;3Me-tyramine SerPl-sCnc;;ACTIVE;2.22;2.70 +50141-1;3-O-Methyldopa;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;3-O-Methyldopa [Moles/volume] in Serum or Plasma;3-o-methyldopa SerPl-sCnc;;ACTIVE;2.22;2.70 +50142-9;3-O-Methyldopa;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;3-O-Methyldopa [Moles/volume] in Urine;3-o-methyldopa Ur-sCnc;;ACTIVE;2.22;2.70 +50143-7;3-O-Methyldopa;SRat;Pt;Urine;Qn;;DRUG/TOX;1;3-O-Methyldopa [Moles/time] in Urine;3-o-methyldopa Ur-sRate;;DISCOURAGED;2.22;2.70 +50144-5;3-O-Methyldopa/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;3-O-Methyldopa/Creatinine [Molar ratio] in Urine;3-o-methyldopa/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50145-2;3-Dechloroethylifosfamide^pre dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --pre dose ifosfamide;3D-Ifosfamide pre IFF Bld-mCnc;;ACTIVE;2.22;2.70 +5014-6;Herpes simplex virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Specimen by NAA with probe detection;HSV DNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50146-0;Gamma aminobutyrate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in DBS;GABA DBS-sCnc;;ACTIVE;2.22;2.70 +50147-8;Gamma aminobutyrate;SCnc;Pt;Body fld;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in Body fluid;GABA Fld-sCnc;;ACTIVE;2.22;2.70 +50148-6;Gamma hydroxybutyrate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Gamma hydroxybutyrate [Moles/volume] in Amniotic fluid;G-OH-Butyr Amn-sCnc;;ACTIVE;2.22;2.70 +50149-4;5-Hydroxyindoleacetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Hydroxyindoleacetate [Moles/volume] in Serum or Plasma;5OH-indoleacetate SerPl-sCnc;;ACTIVE;2.22;2.70 +50150-2;5-Hydroxytryptophan;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Moles/volume] in Serum or Plasma;5OH-Tryptophan SerPl-sCnc;;ACTIVE;2.22;2.70 +50151-0;5-Hydroxytryptophan;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Moles/volume] in Urine;5OH-Tryptophan Ur-sCnc;;ACTIVE;2.22;2.70 +50152-8;5-Hydroxytryptophan/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan/Creatinine [Molar ratio] in Urine;5OH-Tryptophan/Creat Ur-sRto;;ACTIVE;2.22;2.70 +5015-3;Histoplasma capsulatum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Histoplasma capsulatum DNA [Presence] in Specimen by NAA with probe detection;H capsul DNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50153-6;5-Methyltetrahydrofolate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Methyltetrahydrofolate [Moles/volume] in Serum or Plasma;5Me-tetrahydrofolate SerPl-sCnc;;ACTIVE;2.22;2.70 +50154-4;Acetoacetate;SCnc;Pt;CSF;Qn;;CHEM;1;Acetoacetate [Moles/volume] in Cerebral spinal fluid;Acetoacet CSF-sCnc;;ACTIVE;2.22;2.70 +50155-1;Acetylcarnitine (C2);SCnc;Pt;CSF;Qn;;CHEM;1;Acetylcarnitine (C2) [Moles/volume] in Cerebral spinal fluid;Acetylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50156-9;Acetylcarnitine (C2);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Acetylcarnitine (C2) [Moles/volume] in Amniotic fluid;Acetylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50157-7;Acetylcarnitine (C2);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Acetylcarnitine (C2) [Moles/volume] in DBS;Acetylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50158-5;Acetylcarnitine (C2);SCnc;Pt;Urine;Qn;;CHEM;1;Acetylcarnitine (C2) [Moles/volume] in Urine;Acetylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50159-3;Acetylcarnitine (C2)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Acetylcarnitine (C2)/Creatinine [Molar ratio] in Urine;Acetylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50160-1;Amino acids;SCnc;Pt;Hair;Qn;;CHEM;1;Deprecated Amino acids;Deprecated Amino acids Hair-sCnc;;DEPRECATED;2.22;2.70 +5016-1;Histoplasma capsulatum rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Histoplasma capsulatum rRNA [Presence] in Specimen by Probe;H capsul rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +50161-9;Organic acids pattern;Imp;Pt;XXX;Nom;;CHEM;1;Organic acids pattern [Interpretation] in Specimen;Organic Acids Pattern Spec-Imp;;ACTIVE;2.22;2.69 +50162-7;Acylcarnitine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Acylcarnitine [Moles/volume] in Amniotic fluid;Acylcarnitine Amn-sCnc;;ACTIVE;2.22;2.70 +50163-5;Acylcarnitine;SCnc;Pt;CSF;Qn;;CHEM;1;Acylcarnitine [Moles/volume] in Cerebral spinal fluid;Acylcarnitine CSF-sCnc;;ACTIVE;2.22;2.70 +50164-3;Acylcarnitine pattern;Imp;Pt;XXX;Nom;;CHEM;1;Acylcarnitine pattern [Interpretation] in Specimen;Acylcarnitine pattern Spec-Imp;;ACTIVE;2.22;2.69 +50165-0;Adenine phosphoribosyltransferase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Adenine phosphoribosyltransferase [Enzymatic activity/mass] in Amniotic fluid cells;APRT Amnc-cCnt;;ACTIVE;2.22;2.70 +50166-8;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC) [Moles/volume] in Serum or Plasma;Adipoyl+MeGlutarylcarn SerPl-sCnc;;ACTIVE;2.22;2.70 +50167-6;Alanine;SCnc;Pt;Hair;Qn;;CHEM;1;Deprecated Alanine;Deprecated Alanine Hair-sCnc;;DEPRECATED;2.22;2.70 +50168-4;Alanine aminotransferase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Dialysis fluid;ALT Dial fld-cCnc;;ACTIVE;2.22;2.70 +50169-2;Aldosterone^post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --post XXX challenge;Aldost p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +501-7;Ticarcillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ticarcillin [Susceptibility] by Disk diffusion (KB);Ticarcillin Islt KB;;ACTIVE;1.0;2.73 +50170-0;Aldosterone^pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --pre XXX challenge;Aldost pre chal SerPl-sCnc;;ACTIVE;2.22;2.70 +50171-8;Aldosterone^pre 250 ug corticotropin IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin IM;Aldost pre 250 ug ACTH IM SerPl-sCnc;;ACTIVE;2.22;2.70 +50172-6;Aldosterone^30M post 250 ug corticotropin IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM;Aldost 30M p 250 ug ACTH IM SerPl-sCnc;;ACTIVE;2.22;2.70 +50173-4;Aldosterone^1H post 250 ug corticotropin IM;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IM;Aldost 1h p 250 ug ACTH IM SerPl-sCnc;;ACTIVE;2.22;2.70 +50174-2;Alloisoleucine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in Amniotic fluid;Alloisoleucine Amn-sCnc;;ACTIVE;2.22;2.70 +50175-9;Alloisoleucine;SCnc;Pt;Body fld;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in Body fluid;Alloisoleucine Fld-sCnc;;ACTIVE;2.22;2.70 +50176-7;Alpha-2-Macroglobulin/Protein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-2-Macroglobulin/Protein.total in Serum or Plasma;A2 Macroglob MFr SerPl;;ACTIVE;2.22;2.70 +50177-5;Hemicystine;SCnc;Pt;CSF;Qn;;CHEM;1;Hemicystine [Moles/volume] in Cerebral spinal fluid;Hemicystine CSF-sCnc;;ACTIVE;2.22;2.70 +50178-3;Lymphocyte proliferation.100 umol beryllium stimulation^6D post incubation;Ratio;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 100 umol beryllium [Ratio] in Blood --6 days post incubation;LPT 100 umol Be 6D Bld-Rto;;ACTIVE;2.22;2.70 +5017-9;HIV 1 RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA [Presence] in Blood by NAA with probe detection;HIV1 RNA Bld Ql NAA+probe;;ACTIVE;1.0;2.73 +50179-1;Calcitonin Calcium & Pentagastrin challenge panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Calcitonin Calcium and Pentagastrin challenge panel - Serum or Plasma;Calcit Ca+Pentagastrin Pnl SerPl;;ACTIVE;2.22;2.42 +50180-9;Calcitonin^10M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --10 minutes post 2 mg/kg calcium and 0.5 ug/kg pentagastrin IV;Calcit 10M p CPG IV SerPl-mCnc;;ACTIVE;2.22;2.38 +50181-7;Calcitonin^5M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --5 minutes post 2 mg/kg calcium and 0.5 ug/kg pentagastrin IV;Calcit 5M p CPG IV SerPl-mCnc;;ACTIVE;2.22;2.38 +50182-5;Calcitonin^2M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --2 minutes post 2 mg/kg calcium and 0.5 ug/kg pentagastrin IV;Calcit 2M p CPG IV SerPl-mCnc;;ACTIVE;2.22;2.38 +50183-3;Calcitonin^1M post 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --1 minute post 2 mg/kg calcium and 0.5 ug/kg pentagastrin IV;Calcit 1M p CPG IV SerPl-mCnc;;ACTIVE;2.22;2.38 +50184-1;Calcitonin^pre 2 mg/kg calcium & 0.5 ug/kg pentagastrin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --pre 2 mg/kg calcium and 0.5 ug/kg pentagastrin IV;Calcit pre CPG IV SerPl-mCnc;;ACTIVE;2.22;2.38 +50185-8;Magnolia grandiflora Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Magnolia IgE Ab [Units/volume] in Serum;Magnolia IgE Qn;;ACTIVE;2.22;2.73 +50186-6;Wine vinegar Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wine vinegar IgE Ab [Units/volume] in Serum;Wine vinegar IgE Qn;;ACTIVE;2.22;2.73 +5018-7;HIV 1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA [Presence] in Specimen by NAA with probe detection;HIV1 RNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50187-4;Arterial-mixed venous oxygen saturation difference;MFr;Pt;Bld;Qn;;HEMODYN.MOLEC;2;Arterial-mixed venous oxygen saturation difference;Art-mixed ven O2 sat diff %;;ACTIVE;2.22;2.44 +50188-2;Arterial-venous oxygen saturation difference;MFr;Pt;Bld;Qn;;HEMODYN.MOLEC;2;Arterial-venous oxygen saturation difference;Art-ven O2 sat diff %;;ACTIVE;2.22;2.68 +50189-0;Neonatal bilirubin panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Neonatal bilirubin panel [Mass/volume] - Serum or Plasma;Neonatal bilirubin Pnl SerPl-mCnc;;ACTIVE;2.22;2.73 +50190-8;Iron & Iron binding capacity panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Iron and Iron binding capacity panel - Serum or Plasma;Iron+TIBC Pnl SerPl;;ACTIVE;2.22;2.73 +50191-6;Occult blood panel;-;Pt;Gast fld;-;;PANEL.CHEM;1;Occult blood panel - Gastric fluid;OB Pnl Gast;;ACTIVE;2.22;2.73 +50192-4;Cholesterol.in VLDL 1+2+3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL 1+2+3 [Mass/volume] in Serum or Plasma;VLDL1+2+3c SerPl-mCnc;;ACTIVE;2.22;2.70 +50193-2;Cholesterol.in LDL.narrow density;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL.narrow density [Mass/volume] in Serum or Plasma;LDLc ND SerPl-mCnc;;ACTIVE;2.22;2.70 +50194-0;Cholesterol.in IDL+Cholesterol.in VLDL 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in IDL+Cholesterol in VLDL 3 [Mass/volume] in Serum or Plasma;IDLc+VLDL3c SerPl-mCnc;;ACTIVE;2.22;2.73 +5019-5;HTLV I+II RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;HTLV I+II RNA [Presence] in Specimen by NAA with probe detection;HTLV I+II RNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50195-7;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript";LnRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript [Log Number Ratio] in Blood or Tissue by Molecular genetics method";"t(9;22)(ABL1,BCR)/control Bld/T-LnRto";;ACTIVE;2.22;2.73 +50196-5;Occult blood panel;-;Pt;Stool;-;;PANEL.CHEM;1;Occult blood panel - Stool;OB Pnl Stl;;ACTIVE;2.22;2.73 +50197-3;aPTT panel;-;Pt;PPP;Qn;;PANEL.COAG;1;aPTT panel - Platelet poor plasma;aPTT Pnl PPP;;ACTIVE;2.22;2.73 +50198-1;Iron^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --1st specimen;Iron sp1 SerPl-mCnc;;ACTIVE;2.22;2.70 +50199-9;Iron^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --2nd specimen;Iron sp2 SerPl-mCnc;;ACTIVE;2.22;2.70 +50200-5;Iron^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --3rd specimen;Iron sp3 SerPl-mCnc;;ACTIVE;2.22;2.70 +50201-3;Iron^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --4th specimen;Iron sp4 SerPl-mCnc;;ACTIVE;2.22;2.70 +50202-1;Iron^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --5th specimen;Iron sp5 SerPl-mCnc;;ACTIVE;2.22;2.70 +5020-3;Legionella sp rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Legionella sp rRNA [Presence] in Specimen by Probe;Legionella rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50203-9;Iron^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --6th specimen;Iron sp6 SerPl-mCnc;;ACTIVE;2.22;2.70 +50204-7;Iron^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --7th specimen;Iron sp7 SerPl-mCnc;;ACTIVE;2.22;2.70 +50205-4;Iron^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iron [Mass/volume] in Serum or Plasma --8th specimen;Iron sp8 SerPl-mCnc;;ACTIVE;2.22;2.70 +50206-2;Glucose^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --1st specimen;Glucose sp1 SerPl-mCnc;;ACTIVE;2.22;2.73 +50207-0;Glucose^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --7th specimen;Glucose sp7 SerPl-mCnc;;ACTIVE;2.22;2.73 +50208-8;Glucose^10th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --10th specimen;Glucose sp10 SerPl-mCnc;;ACTIVE;2.22;2.70 +50209-6;Albumin^supine;MRat;XXX;Urine;Qn;;CHAL;1;Albumin [Mass/time] in Urine collected for unspecified duration --supine;Albumin sup ?Tm Ur-mRate;;ACTIVE;2.22;2.68 +50210-4;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;Cystatin C-based formula;CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Cystatin C-based formula;GFR/BSA.pred SerPlBld Cys-based-ArV;;ACTIVE;2.22;2.73 +5021-1;Listeria monocytogenes rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Listeria monocytogenes rRNA [Presence] in Specimen by Probe;L monocytog rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +50211-2;Functional shunt volume;VFr;Pt;BldA+BldMV;Qn;;HEMODYN.MOLEC;2;Functional shunt volume;Fshunt vol;;ACTIVE;2.22;2.70 +50212-0;Glucose^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --2nd specimen;Glucose sp2 SerPl-mCnc;;ACTIVE;2.22;2.73 +50213-8;Glucose^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --3rd specimen;Glucose sp3 SerPl-mCnc;;ACTIVE;2.22;2.73 +50214-6;Glucose^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --4th specimen;Glucose sp4 SerPl-mCnc;;ACTIVE;2.22;2.73 +50215-3;Glucose^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --5th specimen;Glucose sp5 SerPl-mCnc;;ACTIVE;2.22;2.73 +50216-1;Glucose^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --6th specimen;Glucose sp6 SerPl-mCnc;;ACTIVE;2.22;2.73 +50217-9;Glucose^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --8th specimen;Glucose sp8 SerPl-mCnc;;ACTIVE;2.22;2.70 +50218-7;Glucose^9th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] in Serum or Plasma --9th specimen;Glucose sp9 SerPl-mCnc;;ACTIVE;2.22;2.70 +50219-5;Respiratory pathogens DNA & RNA 12a panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA 12a panel - Specimen by NAA with probe detection;Resp path 12a Pnl Spec NAA+probe;;ACTIVE;2.22;2.73 +50220-3;Collection interval from baseline;Time;Pt;^Specimen;Qn;;SPEC;1;Collection interval from baseline of Unspecified specimen;Collect interval from BL Time Spec;;ACTIVE;2.22;2.73 +50221-1;Bacteria;PrThr;Pt;Urine;Ord;Automated;UA;1;Bacteria [Presence] in Urine by Automated;Bacteria Ur Ql Auto;;ACTIVE;2.22;2.73 +50222-9;Broad casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Broad casts [Presence] in Urine by Computer assisted method;Broad Casts Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50223-7;Cholesterol crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Cholesterol crystals [Presence] in Urine by Computer assisted method;Cholest Cry Ur Ql Comp Assist;;ACTIVE;2.22;2.56 +50224-5;Epithelial casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Epithelial casts [Presence] in Urine by Computer assisted method;Epith Casts Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50225-2;Epithelial cells.non-squamous;PrThr;Pt;Urine;Ord;Automated;UA;1;Epithelial cells.non-squamous [Presence] in Urine by Automated;Non-sq Epi Cells Ur Ql Auto;;ACTIVE;2.22;2.73 +50226-0;Erythrocyte clumps;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Erythrocyte clumps [Presence] in Urine by Computer assisted method;RBC clumps Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50227-8;Fat;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Fat [Presence] in Urine by Computer assisted method;Fat Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50228-6;Oval fat bodies (globules);PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Oval fat bodies (globules) [Presence] in Urine by Computer assisted method;Oval fat bodies Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +5022-9;Mycobacterium avium complex rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium avium complex rRNA [Presence] in Specimen by Probe;M avium Cmplx rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50229-4;Fatty casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Fatty casts [Presence] in Urine by Computer assisted method;Fatty Casts Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50230-2;Granular casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Granular casts [Presence] in Urine by Computer assisted method;Gran Casts Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50231-0;Hyaline casts;PrThr;Pt;Urine;Ord;Automated;UA;1;Hyaline casts [Presence] in Urine by Automated;Hyaline Casts Ur Ql Auto;;ACTIVE;2.22;2.73 +50232-8;Leucine crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Leucine crystals [Presence] in Urine by Computer assisted method;Leucine Cry Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50233-6;Leukocyte clumps;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Leukocyte clumps [#/area] in Urine sediment by Automated count;WBC clumps #/area UrnS Auto;;ACTIVE;2.22;2.73 +50234-4;Mixed cellular casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Mixed cellular casts [Presence] in Urine by Computer assisted method;Mixed Cell Casts Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50235-1;Mucus;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Mucus [#/area] in Urine sediment by Automated count;Mucous Threads #/area UrnS Auto;;ACTIVE;2.22;2.73 +50236-9;Phosphate crystals.amorphous;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Phosphate crystals amorphous [Presence] in Urine by Computer assisted method;Amorph Phos Cry Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +5023-7;Mycobacterium avium subspecies avium rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium avium ss avium rRNA [Presence] in Specimen by Probe;M avium av rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +50237-7;Trichomonas sp;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Trichomonas sp [Presence] in Urine by Computer assisted method;Trichomonas Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50238-5;Tyrosine crystals;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Tyrosine crystals [Presence] in Urine by Computer assisted method;Tyrosine Cry Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50239-3;Urate crystals.amorphous;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Urate crystals amorphous [Presence] in Urine by Computer assisted method;Amorph Urate Cry Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50240-1;Yeast.budding;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Yeast.budding [Presence] in Urine by Computer assisted method;Yeast Budding Ur Ql Comp Assist;;ACTIVE;2.22;2.73 +50241-9;17-Ketosteroids^post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/volume] in 24 hour Urine --post high dose dexamethasone;17KS p high Dex 24h Ur-mCnc;;ACTIVE;2.22;2.70 +50242-7;17-Ketosteroids^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;17KS 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.22;2.70 +50243-5;17-Ketosteroids^post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/time] in 24 hour Urine --post dose dexamethasone;17KS p Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +50244-3;17-Ketosteroids^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;17KS 2D p Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +5024-5;Mycobacterium gordonae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium gordonae rRNA [Presence] in Specimen by Probe;M gordonae rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50245-0;17-Hydroxycorticosteroids^post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/time] in 24 hour Urine --post high dose dexamethasone;17OHCS p high Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +50246-8;17-Hydroxycorticosteroids^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;17OHCS 2D p high Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +50247-6;17-Hydroxycorticosteroids^post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/time] in 24 hour Urine --post dose dexamethasone;17OHCS p Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +50248-4;17-Hydroxycorticosteroids^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;17OHCS 2D p Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +50249-2;17-Hydroxypregnenolone^30M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;17OH-Preg 30M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.22;2.70 +502-5;Ticarcillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ticarcillin [Susceptibility] by Serum bactericidal titer;Ticarcillin Titr SBT;;ACTIVE;1.0;2.32 +50250-0;21-Deoxycortisol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma;21DC SerPl-sCnc;;ACTIVE;2.22;2.70 +50251-8;3-Hydroxybutyrylcarnitine (C4-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH)/Creatinine [Molar ratio] in Urine;3OH-Butyrcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +5025-2;Mycobacterium intracellulare rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium intracellulare rRNA [Presence] in Specimen by Probe;M intracell rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50252-6;3-Hydroxyisovalerylcarnitine (C5-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH)/Creatinine [Molar ratio] in Urine;3OH-Isovalerylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50253-4;Fatty acids.nonesterified^1st specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --1st specimen fasting;NEFA sp1 p fast SerPl-sCnc;;ACTIVE;2.22;2.70 +50254-2;Fatty acids.nonesterified^2nd specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --2nd specimen fasting;NEFA sp2 p fast SerPl-sCnc;;ACTIVE;2.22;2.70 +50255-9;Fatty acids.nonesterified^3rd specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --3rd specimen fasting;NEFA sp3 p fast SerPl-sCnc;;ACTIVE;2.22;2.70 +50256-7;Fatty acids.nonesterified^4th specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --4th specimen fasting;NEFA sp4 p fast SerPl-sCnc;;ACTIVE;2.22;2.70 +50257-5;Fatty acids.nonesterified^5th specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --5th specimen fasting;NEFA sp5 p fast SerPl-sCnc;;ACTIVE;2.22;2.70 +50258-3;Aldosterone^post 25 mg captopril PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --post 25 mg captopril PO;Aldost p 25 mg Cpl PO SerPl-sCnc;;ACTIVE;2.22;2.70 +50259-1;Aldosterone^pre 25 mg captopril PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --pre 25 mg captopril PO;Aldost pre 25 mg Cpl PO SerPl-sCnc;;ACTIVE;2.22;2.70 +5026-0;Mycobacterium kansasii rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium kansasii rRNA [Presence] in Specimen by Probe;M kansasii rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50260-9;Prekeratocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Prekeratocytes [Presence] in Blood by Light microscopy;Prekeratocytes Bld Ql Smear;;ACTIVE;2.22;2.73 +50261-7;Renal function panel & Glomerular filtration rate.predicted;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Deprecated Renal function panel & Glomerular filtration rate.predicted;Deprecated Renal func Pnl & eGFR SerPl;;DEPRECATED;2.22;2.36 +50262-5;Reticulocytes panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Reticulocytes panel - Blood;Retic Pnl;;ACTIVE;2.22;2.73 +50263-3;17-Ketosteroids^post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/time] in 24 hour Urine --post high dose dexamethasone;17KS p high Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +50264-1;17-Ketosteroids^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;17-Ketosteroids [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;17KS 2D p high Dex 24h Ur-mRate;;ACTIVE;2.22;2.70 +50265-8;2-Dechloroethylifosfamide^pre dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --pre dose ifosfamide;2-DCE-IF pre IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50266-6;2-Dechloroethylifosfamide^1D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --1 day post dose ifosfamide;2-DCE-IF 1D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50267-4;2-Dechloroethylifosfamide^2D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --2 days post dose ifosfamide;2-DCE-IF 2D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50268-2;2-Dechloroethylifosfamide^3D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --3 days post dose ifosfamide;2-DCE-IF 3D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50269-0;2-Dechloroethylifosfamide^4D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --4 days post dose ifosfamide;2-DCE-IF 4D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50270-8;2-Dechloroethylifosfamide^5D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --5 days post dose ifosfamide;2-DCE-IF 5D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50271-6;2-Dechloroethylifosfamide^3H post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --3 hours post dose ifosfamide;2-DCE-IF 3H p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50272-4;2-Dechloroethylifosfamide^6H post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --6 hours post dose ifosfamide;2-DCE-IF 6H p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50273-2;3-Hydroxymyristoleylcarnitine (C14:1-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxymyristoleylcarnitine (C14:1-OH) [Moles/volume] in Urine;3OH-myristoleylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50274-0;3-Hydroxymyristoleylcarnitine (C14:1-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxymyristoleylcarnitine (C14:1-OH) [Moles/volume] in Amniotic fluid;3OH-myristoleylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50275-7;3-Hydroxymyristoleylcarnitine (C14:1-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxymyristoleylcarnitine (C14:1-OH) [Moles/volume] in DBS;3OH-myristoleylcarn DBS-sCnc;;ACTIVE;2.22;2.70 +50276-5;3-Hydroxymyristoleylcarnitine (C14:1-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxymyristoleylcarnitine (C14:1-OH) [Moles/volume] in Cerebral spinal fluid;3OH-myristoleylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50277-3;3-Hydroxymyristoleylcarnitine (C14:1-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxymyristoleylcarnitine (C14:1-OH) [Moles/volume] in Serum or Plasma;3OH-myristoleylcarn SerPl-sCnc;;ACTIVE;2.22;2.70 +5027-8;Mycobacterium tuberculosis rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycobacterium tuberculosis rRNA [Presence] in Specimen by Probe;M tb rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50278-1;3-Hydroxymyristoleylcarnitine (C14:1-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxymyristoleylcarnitine (C14:1-OH)/Creatinine [Molar ratio] in Urine;3OH-myristoleylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50279-9;3-Hydroxytetradecanoylcarnitine (C14-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in Urine;3OH-Tdecanoylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +50280-7;3-Hydroxytetradecanoylcarnitine (C14-OH);SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in Cerebral spinal fluid;3OH-Tdecanoylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50281-5;3-Hydroxytetradecanoylcarnitine (C14-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in DBS;3OH-Tdecanoylcarn DBS-sCnc;;ACTIVE;2.22;2.73 +50282-3;3-Hydroxytetradecanoylcarnitine (C14-OH);SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in Amniotic fluid;3OH-Tdecanoylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50283-1;3-Hydroxytetradecanoylcarnitine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated 3-Hydroxytetradecanoylcarnitine (C14-OH) [Molecules/volume] in Serum or Plasma;Deprecated 3OH-Tdecanoylcarn SerPl-sCnc;;DEPRECATED;2.22;2.70 +50284-9;3-Hydroxytetradecanoylcarnitine (C14-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxytetradecanoylcarnitine (C14-OH)/Creatinine [Molar ratio] in Urine;3OH-Tdecanoylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50285-6;3-Dechloroethylifosfamide^1D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --1 day post dose ifosfamide;3D-Ifosfamide 1D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +5028-6;Neisseria gonorrhoeae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Specimen by Probe;N gonorrhoea rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50286-4;3-Dechloroethylifosfamide^2D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --2 days post dose ifosfamide;3D-Ifosfamide 2D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50287-2;3-Dechloroethylifosfamide^3D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --3 days post dose ifosfamide;3D-Ifosfamide 3D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50288-0;3-Dechloroethylifosfamide^4D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --4 days post dose ifosfamide;3D-Ifosfamide 4D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50289-8;3-Dechloroethylifosfamide^6D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --6 days post dose ifosfamide;3D-Ifosfamide 6D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50290-6;3-Dechloroethylifosfamide^3H post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --3 hours post dose ifosfamide;3D-Ifosfamide 3H p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50291-4;3-Dechloroethylifosfamide^6H post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;3-Dechloroethylifosfamide [Mass/volume] in Blood --6 hours post dose ifosfamide;3D-Ifosfamide 6H p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50292-2;4-Hydroxyifosfamide^pre dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --pre dose ifosfamide;4OH-Ifosfamide pre IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50293-0;4-Hydroxyifosfamide^1D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --1 day post dose ifosfamide;4OH-Ifosfamide 1D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +5029-4;Neisseria meningitidis rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Neisseria meningitidis rRNA [Presence] in Specimen by Probe;N men rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +50294-8;4-Hydroxyifosfamide^2D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --2 days post dose ifosfamide;4OH-Ifosfamide 2D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50295-5;4-Hydroxyifosfamide^3D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --3 days post dose ifosfamide;4OH-Ifosfamide 3D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50296-3;4-Hydroxyifosfamide^4D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --4 days post dose ifosfamide;4OH-Ifosfamide 4D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50297-1;4-Hydroxyifosfamide^5D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --5 days post dose ifosfamide;4OH-Ifosfamide 5D p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50298-9;4-Hydroxyifosfamide^3H post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --3 hours post dose ifosfamide;4OH-Ifosfamide 3H p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50299-7;4-Hydroxyifosfamide^6H post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxyifosfamide [Mass/volume] in Blood --6 hours post dose ifosfamide;4OH-Ifosfamide 6H p IFF Bld-mCnc;;ACTIVE;2.22;2.70 +50300-3;6-Hydroxyheptanoate;SCnc;Pt;Urine;Qn;;CHEM;1;6-Hydroxyheptanoate [Moles/volume] in Urine;6OH-heptanoate Ur-sCnc;;ACTIVE;2.22;2.70 +50301-1;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC) [Moles/volume] in Urine;Adipoyl+MeGlutarylcarn Ur-sCnc;;ACTIVE;2.22;2.70 +5030-2;Parvovirus B19 RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 RNA [Presence] in Blood by NAA with probe detection;B19V RNA Bld Ql NAA+probe;;ACTIVE;1.0;2.63 +50302-9;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC) [Moles/volume] in Amniotic fluid;Adipoyl+MeGlutarylcarn Amn-sCnc;;ACTIVE;2.22;2.70 +50303-7;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC) [Moles/volume] in Cerebral spinal fluid;Adipoyl+MeGlutarylcarn CSF-sCnc;;ACTIVE;2.22;2.70 +50304-5;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC) [Moles/volume] in DBS;Adipoyl+MeGlutarylcarn DBS-sCnc;;ACTIVE;2.22;2.70 +50305-2;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adipoylcarnitine+Methylglutarylcarnitine (C6-DC)/Creatinine [Molar ratio] in Urine;Adipoyl+MeGlutarylcarn/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50306-0;Allantoine;SCnc;Pt;Urine;Qn;;CHEM;1;Allantoine [Moles/volume] in Urine;Allantoine Ur-sCnc;;ACTIVE;2.22;2.70 +50307-8;BCL10 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BCL10 Ag [Presence] in Tissue by Immune stain;BCL10 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +50308-6;Caldesmon Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Caldesmon Ag [Presence] in Tissue by Immune stain;Caldesmon Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50309-4;CD138 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD138 Ag [Presence] in Tissue by Immune stain;CD138 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +5031-0;Parvovirus B19 RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 RNA [Presence] in Tissue by NAA with probe detection;B19V RNA Tiss Ql NAA+probe;;ACTIVE;1.0;2.63 +50310-2;CD7 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD7 Ag [Presence] in Tissue by Immune stain;CD7 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50311-0;Chlamydia trachomatis DNA;PrThr;Pt;XXX^Donor;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Specimen from Donor by NAA with probe detection;C trach DNA Spec Donr Ql NAA+probe;;ACTIVE;2.22;2.69 +50312-8;Clusterin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Clusterin Ag [Presence] in Tissue by Immune stain;Clusterin Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +50313-6;Cyclospora sp identified;Prid;Pt;Stool;Nom;Safranin stain;MICRO;1;Cyclospora sp identified in Stool by Safranin stain;Cyclospora Stl Safranin Stn;;ACTIVE;2.22;2.68 +50314-4;Cytokeratin 19 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytokeratin 19 Ag [Presence] in Tissue by Immune stain;CK 19 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50315-1;Cytokeratin 5 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Cytokeratin 5 Ag [Presence] in Tissue by Immune stain;CK5 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +50316-9;Galectin 3 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Galectin 3 Ag [Presence] in Tissue by Immune stain;Galectin 3 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50317-7;CD235a Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;CD235a Ag [Presence] in Tissue by Immune stain;CD235a Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50318-5;Granzyme B Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Granzyme B Ag [Presence] in Tissue by Immune stain;Granzyme B Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50319-3;HBME-1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;HBME-1 Ag [Presence] in Tissue by Immune stain;HBME-1 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50320-1;Helicobacter pylori Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Helicobacter pylori Ag [Presence] in Tissue by Immune stain;H pylori Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50321-9;Hepatocyte Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Hepatocyte Ag [Presence] in Tissue by Immune stain;Hepatocyte Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +50322-7;MLH-1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;MLH-1 Ag [Presence] in Tissue by Immune stain;MLH-1 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50323-5;MSH-2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;MSH-2 Ag [Presence] in Tissue by Immune stain;MSH-2 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50324-3;MSH-6 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;MSH-6 Ag [Presence] in Tissue by Immune stain;MSH-6 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50325-0;MUM-1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;MUM-1 Ag [Presence] in Tissue by Immune stain;MUM-1 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50326-8;Neisseria gonorrhoeae DNA;PrThr;Pt;XXX^Donor;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Specimen from Donor by NAA with probe detection;N gonorrhoea DNA Spec Donr Ql NAA+probe;;ACTIVE;2.22;2.73 +50327-6;Neu-N Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Neu-N Ag [Presence] in Tissue by Immune stain;Neu-N Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +5032-8;Parvovirus B19 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 RNA [Presence] in Specimen by NAA with probe detection;B19V RNA Spec Ql NAA+probe;;ACTIVE;1.0;2.73 +50328-4;PMS-2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PMS-2 Ag [Presence] in Tissue by Immune stain;PMS-2 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50329-2;Respiratory syncytial virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Respiratory syncytial virus Ag [Presence] in Tissue by Immune stain;RSV Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +503-3;Ticarcillin+Clavulanate;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Ticarcillin+Clavulanate [Susceptibility] by Minimum lethal concentration (MLC);Ticarcillin+Clav Islt MLC;;ACTIVE;1.0;2.19 +50330-0;SLC6A4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC6A4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC6A4 gene Mut Anl Bld/T;;ACTIVE;2.22;2.73 +50331-8;WT-1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;WT-1 Ag [Presence] in Tissue by Immune stain;WT-1 Ag Tiss Ql ImStn;;ACTIVE;2.22;2.73 +50332-6;Hexadecanedioate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Hexadecanedioate/Creatinine [Mass Ratio] in Urine;Hexadecanedioate/Creat Ur;;ACTIVE;2.22;2.73 +50333-4;Tetradecanedioate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tetradecanedioate/Creatinine [Mass Ratio] in Urine;Tdecanedioate/Creat Ur;;ACTIVE;2.22;2.73 +50334-2;Acylglycines panel;MRto;Pt;Urine;-;;PANEL.CHEM;1;Acylglycines panel [Mass Ratio] - Urine;Acylglycines Pnl Ur;;ACTIVE;2.22;2.73 +50335-9;Alpha-beta crystallin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Alpha-beta crystallin Ag [Presence] in Tissue by Immune stain;a-b crystallin Ag Tiss Ql ImStn;;ACTIVE;2.22;2.56 +5033-6;Staphylococcus aureus rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Staphylococcus aureus rRNA [Presence] in Specimen by Probe;S aureus rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +50336-7;Beta cortolone/Cortisol;MRto;Pt;Urine;Qn;;CHEM;1;Beta cortolone/Cortisol [Mass Ratio] in Urine;B-cortolone/Cortis Ur;;ACTIVE;2.22;2.44 +50337-5;carBAMazepine & metabolites panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;carBAMazepine and metabolites panel - Serum or Plasma;Carbmzpn + Metab Pnl SerPl;;ACTIVE;2.22;2.72 +50338-3;Cannabinoids;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Cannabinoids [Mass/volume] in Dialysis fluid;Cannabinoids Dial fld-mCnc;;ACTIVE;2.22;2.70 +50339-1;Cholesterol;MCnc;Pt;Bld;Qn;;CHEM;1;Deprecated Cholesterol [Mass/volume] in blood;Deprecated Cholest Bld-mCnc;;DEPRECATED;2.22;2.70 +50340-9;Eosinophils;PrThr;Pt;Nose;Ord;Hansel stain;HEM/BC;1;Eosinophils [Presence] in Nose by Hansel stain;Eosinophil Nose Ql Hansel Stn;;ACTIVE;2.22;2.56 +50341-7;Eosinophils;PrThr;Pt;Sputum;Ord;Hansel stain;HEM/BC;1;Eosinophils [Presence] in Sputum by Hansel stain;Eosinophil Spt Ql Hansel Stn;;ACTIVE;2.22;2.56 +50342-5;Ependymal+Choroid plexus cells/100 leukocytes;Ratio;Pt;CSF;Qn;;HEM/BC;1;Ependymal+Choroid plexus cells/100 leukocytes [Ratio] in Cerebral spinal fluid;Ependy+Chor plex cells/leuk CSF-Rto;;ACTIVE;2.22;2.70 +50343-3;Ethanol;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Ethanol [Presence] in Saliva (oral fluid) by Screen method;Ethanol Sal Ql Scn;;ACTIVE;2.22;2.73 +5034-4;Streptococcus agalactiae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Streptococcus agalactiae rRNA [Presence] in Specimen by Probe;Gp B Strep rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50344-1;Parvovirus B19 DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Body fluid by NAA with probe detection;B19V DNA Fld Ql NAA+probe;;ACTIVE;2.22;2.63 +50345-8;Parvovirus B19 DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Urine by NAA with probe detection;B19V DNA Ur Ql NAA+probe;;ACTIVE;2.22;2.63 +50346-6;Parvovirus B19 DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;B19V DNA CSF Ql NAA+probe;;ACTIVE;2.22;2.63 +50347-4;Parvovirus B19 DNA;PrThr;Pt;Bone mar;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Bone marrow by NAA with probe detection;B19V DNA Mar Ql NAA+probe;;ACTIVE;2.22;2.73 +50348-2;Parvovirus B19 DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Blood by NAA with probe detection;B19V DNA Bld Ql NAA+probe;;ACTIVE;2.22;2.73 +50349-0;Parvovirus B19 DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Amniotic fluid by NAA with probe detection;B19V DNA Amn Ql NAA+probe;;ACTIVE;2.22;2.63 +50350-8;Mustard Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Mustard IgE Ab/IgE total in Serum;Mustard IgE/IgE total %;;ACTIVE;2.22;2.70 +5035-1;Streptococcus pneumoniae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Streptococcus pneumoniae rRNA [Presence] in Specimen by Probe;S pneum rRNA Spec Ql Probe;;ACTIVE;1.0;2.69 +50351-6;Casuarina equisetifolia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Australian pine IgE Ab/IgE total in Serum;Australian pine IgE/IgE total %;;ACTIVE;2.22;2.70 +50352-4;Papain Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Papain IgE Ab/IgE total in Serum;Papain IgE/IgE total %;;ACTIVE;2.22;2.70 +50353-2;Parrot feather Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Parrot feather IgE Ab/IgE total in Serum;Parrot Feather IgE/IgE total %;;ACTIVE;2.22;2.70 +50354-0;Paspalum notatum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Bahia grass IgE Ab/IgE total in Serum;Bahia grass IgE/IgE total %;;ACTIVE;2.22;2.73 +50355-7;Perca spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Perch IgE Ab/IgE total in Serum;Perch IgE/IgE total %;;ACTIVE;2.22;2.70 +50356-5;Phalaris arundinacea Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Canary grass IgE Ab/IgE total in Serum;Canary grass IgE/IgE total %;;ACTIVE;2.22;2.70 +50357-3;Phenolphthalein;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Phenolphthalein [Presence] in Serum or Plasma;Phenolphthalein SerPl Ql;;ACTIVE;2.22;2.56 +50358-1;Phenylacetate/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Phenylacetate/Creatinine [Molar ratio] in 24 hour Urine;Phenylacetate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50359-9;Phenyllactate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Phenyllactate/Creatinine [Molar ratio] in 24 hour Urine;Phenyllactate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50360-7;Phenylpropionylglycine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Phenylpropionylglycine/Creatinine [Molar ratio] in 24 hour Urine;PPG/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50361-5;Phenylpyruvate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Phenylpyruvate/Creatinine [Molar ratio] in 24 hour Urine;Phenylpyruvate/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50362-3;Phoma betae Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Phoma betae IgE Ab/IgE total in Serum;P betae IgE/IgE total %;;ACTIVE;2.22;2.70 +50363-1;Pigweed common Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Common Pigweed IgE Ab/IgE total in Serum;Common Pigweed IgE/IgE total %;;ACTIVE;2.22;2.73 +50364-9;Piper nigrum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Black Pepper IgE Ab/IgE total in Serum;Black Pepper IgE/IgE total %;;ACTIVE;2.22;2.70 +50365-6;Platelet glycoprotein IIb-IIIa Ab;PrThr;Pt;Ser;Ord;;SERO;1;Platelet glycoprotein IIb/IIIa Ab [Presence] in Serum;Plat Gp IIb/IIIa Ab Ser Ql;;ACTIVE;2.22;2.56 +50366-4;Prolactin.monomeric/Prolactin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin monomeric/Prolactin.total in Serum or Plasma;Prolactin.monomeric/Total MFr SerPl;;ACTIVE;2.22;2.73 +50367-2;Propionylglycine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Propionylglycine/Creatinine [Molar ratio] in 24 hour Urine;Propionylgly/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50368-0;Protoporphyrin;MCnc;24H;Urine;Qn;;CHEM;1;Protoporphyrin [Mass/volume] in 24 hour Urine;Protopor 24h Ur-mCnc;;ACTIVE;2.22;2.70 +5036-9;Streptococcus pyogenes rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Streptococcus pyogenes rRNA [Presence] in Specimen by Probe;S pyo rRNA Spec Ql Probe;;ACTIVE;1.0;2.73 +50369-8;Quercus alba Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;White Oak IgE Ab/IgE total in Serum;White Oak IgE/IgE total %;;ACTIVE;2.22;2.73 +50370-6;Syagrus romanzoffianum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Queen Palm IgE Ab/IgE total in Serum;Queen Palm IgE/IgE total %;;ACTIVE;2.22;2.70 +50371-4;Protoporphyrin;MCnc;Pt;Urine;Qn;;CHEM;1;Protoporphyrin [Mass/volume] in Urine;Protopor Ur-mCnc;;ACTIVE;2.22;2.70 +50372-2;Protoporphyrin;MRat;24H;Urine;Qn;;CHEM;1;Protoporphyrin [Mass/time] in 24 hour Urine;Protopor 24h Ur-mRate;;ACTIVE;2.22;2.70 +50373-0;Eosinophils.band form/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Eosinophils.band form/100 cells in Bone marrow by Manual count;Eosinophil band NFr Mar Manual;;ACTIVE;2.22;2.70 +50374-8;Myelocytes.eosinophilic/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Myelocytes.eosinophilic/100 cells in Bone marrow by Manual count;Myelocytes.eos NFr Mar Manual;;ACTIVE;2.22;2.70 +50375-5;Nucleated cells;NCnc;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Bronchial specimen by Manual count;Nuc cell # Bronch Manual;;ACTIVE;2.22;2.70 +50376-3;Lupus anticoagulant neutralization.dilute phospholipid actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization dilute phospholipid actual/normal in Platelet poor plasma by Coagulation assay;LA Nt dPL Act/Nor PPP;;DISCOURAGED;2.22;2.70 +5037-7;Acetylcholine receptor binding Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Acetylcholine receptor binding Ab [Titer] in Serum by Immunofluorescence;AChR Bind Ab Titr Ser IF;;ACTIVE;1.0;2.70 +50377-1;von Willebrand factor.collagen binding activity actual/Normal;RelRto;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf).collagen binding activity actual/normal in Platelet poor plasma by Immunoassay;vWF CBA Act/Nor PPP IA;;ACTIVE;2.22;2.73 +50378-9;von Willebrand factor.collagen binding activity/von Willebrand factor Ag;Ratio;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf).collagen binding activity/von Willebrand factor Ag [Ratio] in Platelet poor plasma by Immunoassay;vWF CBA/vWF Ag PPP IA-Rto;;ACTIVE;2.22;2.73 +50379-7;Creatinine dialysis fluid clearance/1.73 sq M;ArVRat;Pt;Dial fld+Ser/Plas;Qn;;CHEM;1;Creatinine dialysis fluid clearance/1.73 sq M;Creat Cl/1.73 sq M Dial fld+SerPl-ArVRat;;ACTIVE;2.22;2.70 +50380-5;Creatinine renal clearance/1.73 sq M.predicted.female;ArVRat;Pt;Ser/Plas;Qn;Cockcroft-Gault formula, BSA formula;CHEM;1;Creatinine renal clearance/1.73 sq M.predicted among females by Cockcroft-Gault formula, BSA formula;Creat Cl/BSA pred.fem SerPl C-G-ArVRat;;ACTIVE;2.22;2.70 +50381-3;Creatinine renal clearance/1.73 sq M.predicted.male;ArVRat;Pt;Ser/Plas;Qn;Cockcroft-Gault formula, BSA formula;CHEM;1;Creatinine renal clearance/1.73 sq M.predicted among males by Cockcroft-Gault formula, BSA formula;Creat Cl/BSA pred.male SerPl C-G-ArVRat;;ACTIVE;2.22;2.70 +50382-1;Glutathione reductase;CCnt;Pt;RBC;Qn;;CHEM;1;Glutathione reductase [Enzymatic activity/mass] in Red Blood Cells;GR RBC-cCnt;;ACTIVE;2.22;2.70 +50383-9;Glomerular filtration rate.predicted;VRat;Pt;Ser/Plas;Qn;Creatinine-based formula (Schwartz);CHEM;1;Deprecated Glomerular filtration rate/1.73 sq M.predicted in 24 hour by Creatinine-based formula (Schwartz);Deprecated GFR predicted SerPl Schwartz;;DEPRECATED;2.22;2.36 +50384-7;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (Schwartz);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (Schwartz);GFR/BSA.pred SerPlBld Schwartz-ArVRat;;ACTIVE;2.22;2.64 +5038-5;Acetylcholine receptor blocking Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Acetylcholine receptor blocking Ab [Titer] in Serum by Immunofluorescence;AChR Block Ab Titr Ser IF;;ACTIVE;1.0;2.73 +50385-4;Alpha-1-Microglobulin.placental;PrThr;Pt;Vag;Ord;;CHEM;1;Alpha-1-Microglobulin.placental [Presence] in Vaginal fluid;A1 Microglob placental Vag Ql;;ACTIVE;2.22;2.73 +50386-2;Parakeet+Parrot droppings Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Parakeet+Parrot droppings IgE Ab/IgE total in Serum;Parakeet+Parrot Drop IgE/IgE total %;;ACTIVE;2.22;2.70 +50387-0;Chlamydia trachomatis rRNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Cervix by NAA with probe detection;C trach rRNA Cvx Ql NAA+probe;;ACTIVE;2.22;2.73 +50388-8;Neisseria gonorrhoeae rRNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Cervix by NAA with probe detection;N gonorrhoea rRNA Cvx Ql NAA+probe;;ACTIVE;2.22;2.73 +50389-6;Microscopic observation;Prid;Pt;Bronchial brush;Nom;Cyto stain.thin prep;CYTO;1;Microscopic observation [Identifier] in Bronchial brush by Cyto stain.thin prep;Thin Prep Bro Brush;;ACTIVE;2.22;2.22 +50390-4;Coagulation factor II circulating inhibitor;PrThr;Pt;PPP;Ord;;COAG;1;Coagulation factor II circulating inhibitor [Presence] in Platelet poor plasma;Fact II circ inhib PPP Ql;;ACTIVE;2.22;2.73 +50391-2;Coagulation surface induced circulating inhibitor;PrThr;Pt;PPP;Ord;;COAG;1;PTT circulating inhibitor [Presence] in Platelet poor plasma;PTT circulating inhib PPP Ql;;ACTIVE;2.22;2.73 +50392-0;3-Keto n-Valerate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Keto n-Valerate [Moles/volume] in Cerebral spinal fluid;3-Keto n-Valerate CSF-sCnc;;ACTIVE;2.22;2.70 +5039-3;Acetylcholine receptor modulation Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Acetylcholine receptor modulation Ab [Titer] in Serum by Immunofluorescence;AChR Mod Ab Titr Ser IF;;ACTIVE;1.0;2.73 +50393-8;3-Keto n-Valerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Keto n-Valerate/Creatinine [Molar ratio] in Urine;3-Keto n-Valerate/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50394-6;Adenine phosphoribosyltransferase;CCnt;Pt;CVS;Qn;;CHEM;1;Adenine phosphoribosyltransferase [Enzymatic activity/mass] in Chorionic villus sample;APRT CVS-cCnt;;ACTIVE;2.22;2.70 +50395-3;Adenosine deaminase;CCnt;Pt;CVS;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/mass] in Chorionic villus sample;Adenosine deaminase CVS-cCnt;;ACTIVE;2.22;2.70 +50396-1;Molecular diagnostic major findings for display;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MISC;1;Molecular diagnostic major findings for display [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Mol dx major findings for display Bld/T;;ACTIVE;2.22;2.73 +50397-9;Molecular diagnostic overall interpretation;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MISC;1;Molecular diagnostic overall interpretation [Presence] in Blood or Tissue by Molecular genetics method;Mol dx interp Bld/T Ql;;ACTIVE;2.22;2.73 +50398-7;Narrative diagnostic report;Imp;Pt;Bld/Tiss;Nar;Molgen;HL7.GENETICS;1;Narrative diagnostic report [Interpretation];Narrative diagnostic report-Imp;;ACTIVE;2.22;2.73 +50399-5;Clinical genetic report summary panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;Deprecated Clinical genetic report summary panel in Blood or Tissue by Molecular genetics method;Deprecated Clin genetic rpt sum Pnl Bld/;;DEPRECATED;2.22;2.36 +50400-1;Body temperature^post transfusion reaction;Temp;Pt;^Patient;Qn;;BDYTMP.ATOM;2;Body temperature --after transfusion reaction;Bdy temp p transf rx;;ACTIVE;2.22;2.73 +5040-1;Actinomyces sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Actinomyces sp Ab [Titer] in Serum by Immunofluorescence;Actinomyces Ab Titr Ser IF;;ACTIVE;1.0;2.70 +50401-9;Blood group antibody titered;Prid;Pt;Ser/Plas;Nom;;BLDBK;1;Blood group antibody titered [Identifier] in Serum or Plasma;Bld gp Ab titered SerPl;;ACTIVE;2.22;2.73 +50402-7;Blood pressure systolic & diastolic^post transfusion;Pres;Pt;Arterial system;Qn;;BP.ATOM;2;Blood pressure systolic and diastolic--after transfusion;BP sys/dias--p transf;;ACTIVE;2.22;2.73 +50403-5;Blood pressure systolic & diastolic^pre transfusion;Pres;Pt;Arterial system;Qn;;BP.ATOM;2;Blood pressure systolic and diastolic--before transfusion;BP sys/dias--pre transf;;ACTIVE;2.22;2.73 +50404-3;Other cells/100 leukocytes;Prid;Pt;Synv fld;Nom;;HEM/BC;1;Other cells/100 leukocytes [Identifier] in Synovial fluid;Other cells/leuk Snv;;ACTIVE;2.22;2.73 +50405-0;Patient symptoms^post transfusion reaction;Imp;Pt;^Patient;Nar;;BLDBK;1;Patient symptoms [Interpretation] Narrative--after transfusion reaction;Symptoms p transf rx Patient-Imp;;ACTIVE;2.22;2.73 +50406-8;Cannabinoids;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Cannabinoids [Presence] in Meconium by Confirmatory method;Cannabinoids Mec Ql Cfm;;ACTIVE;2.22;2.56 +50407-6;Other cells/100 leukocytes;Prid;Pt;CSF;Nom;;HEM/BC;1;Other cells/100 leukocytes [Identifier] in Cerebral spinal fluid;Other cells/leuk CSF;;ACTIVE;2.22;2.73 +50408-4;Protein.abnormal band/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.abnormal band/Protein.total in Urine by Electrophoresis;Abn Prot MFr Ur Elph;;ACTIVE;2.22;2.73 +50409-2;Cholesterol.in HDL 2+3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 2+3 [Mass/volume] in Serum or Plasma;HDL2+3c SerPl-mCnc;;ACTIVE;2.22;2.70 +504-1;Ticarcillin+Clavulanate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ticarcillin+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC);Ticarcillin+Clav Islt MIC;;ACTIVE;1.0;2.73 +50410-0;Coagulation dilute Russell viper venom induced/Coagulation dilute Russell viper venom induced.excess phospholipid;Ratio;Pt;PPP;Qn;Coag;COAG;1;dRVVT/dRVVT W excess phospholipid (screen to confirm ratio);dRVVT screen to confirm ratio;;ACTIVE;2.22;2.73 +50411-8;Chlamydia trachomatis rRNA;PrThr;Pt;XXX^Donor;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Specimen from Donor by NAA with probe detection;C trach rRNA Spec Donr Ql NAA+probe;;ACTIVE;2.22;2.73 +50412-6;Neisseria gonorrhoeae rRNA;PrThr;Pt;XXX^Donor;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Specimen from Donor by NAA with probe detection;N gonorrhoea rRNA Spec Donr Ql NAA+probe;;ACTIVE;2.22;2.73 +50413-4;Corticotropin^pre 1 mg dexamethasone PO overnight;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre 1 mg dexamethasone PO overnight;ACTH pre 1 mg Dex Plas-mCnc;;ACTIVE;2.22;2.40 +50414-2;Corticotropin^post 1 mg dexamethasone PO overnight;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --post 1 mg dexamethasone PO overnight;ACTH p 1 mg Dex Plas-mCnc;;ACTIVE;2.22;2.40 +50415-9;Cortisol^pre 2 mg dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 2 mg dexamethasone PO overnight;Cortis pre 2 mg Dex SerPl-mCnc;;ACTIVE;2.22;2.40 +50416-7;Cortisol^post 2 mg dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --post 2 mg dexamethasone PO overnight;Cortis p 2 mg Dex SerPl-mCnc;;ACTIVE;2.22;2.40 +50417-5;Corticotropin^pre 2 mg dexamethasone PO overnight;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre 2 mg dexamethasone PO overnight;ACTH pre 2 mg Dex Plas-mCnc;;ACTIVE;2.22;2.40 +50418-3;Corticotropin^post 2 mg dexamethasone PO overnight;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --post 2 mg dexamethasone PO overnight;ACTH p 2 mg Dex Plas-mCnc;;ACTIVE;2.22;2.40 +5041-9;Adenovirus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Adenovirus Ab [Titer] in Serum by Complement fixation;HAdV Ab Titr Ser CF;;ACTIVE;1.0;2.73 +50419-1;Corticotropin^pre 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre 500 ug dexamethasone PO 2.5 day low dose q6h;ACTH pre 500 ug Dex Plas-mCnc;;ACTIVE;2.22;2.40 +50420-9;Corticotropin^post 500 ug dexamethasone PO 2.5 day low dose q6h;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --post 500 ug dexamethasone PO 2.5 day low dose q6h;ACTH p 500 ug Dex Plas-mCnc;;ACTIVE;2.22;2.40 +50421-7;Cortisol^pre 100 ug CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --pre 100 ug CRH IV;Cortis pre 100 ug CRH IV SerPl-mCnc;;ACTIVE;2.22;2.40 +50422-5;Cortisol^20M post 100 ug CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --20 minutes post 100 ug CRH IV;Cortis 20M p 100 ug CRH IV SerPl-mCnc;;ACTIVE;2.22;2.40 +50423-3;Cortisol^40M post 100 ug CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --40 minutes post 100 ug CRH IV;Cortis 40M p 100 ug CRH IV SerPl-mCnc;;ACTIVE;2.22;2.40 +50424-1;Cortisol^1H post 100 ug CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post 100 ug CRH IV;Cortis 1h p 100 ug CRH IV SerPl-mCnc;;ACTIVE;2.22;2.40 +50425-8;Corticotropin^pre 100 ug CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre 100 ug CRH IV;ACTH pre 100 ug CRH IV Plas-mCnc;;ACTIVE;2.22;2.40 +50426-6;Corticotropin^20M post 100 ug CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --20 minutes post 100 ug CRH IV;ACTH 20M p 100 ug CRH IV Plas-mCnc;;ACTIVE;2.22;2.40 +5042-7;Adenovirus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Adenovirus IgM Ab [Units/volume] in Serum;HAdV IgM Ser-aCnc;;ACTIVE;1.0;2.73 +50427-4;Corticotropin^40M post 100 ug CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --40 minutes post 100 ug CRH IV;ACTH 40M p 100 ug CRH IV Plas-mCnc;;ACTIVE;2.22;2.40 +50428-2;Corticotropin^1H post 100 ug CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 hour post 100 ug CRH IV;ACTH 1h p 100 ug CRH IV Plas-mCnc;;ACTIVE;2.22;2.40 +50429-0;Cortisol^9 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9 AM specimen;Cortis 9 AM SerPl-mCnc;;ACTIVE;2.22;2.40 +50430-8;Cortisol^3 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --3 PM specimen;Cortis 3 PM SerPl-mCnc;;ACTIVE;2.22;2.73 +50431-6;Cortisol^6 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --6 PM specimen;Cortis 6 PM SerPl-mCnc;;ACTIVE;2.22;2.40 +50432-4;Cortisol^9 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9 PM specimen;Cortis 9 PM SerPl-mCnc;;ACTIVE;2.22;2.40 +50433-2;Cortisol^3 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --3 AM specimen;Cortis 3 AM SerPl-mCnc;;ACTIVE;2.22;2.40 +50434-0;Cortisol^6 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --6 AM specimen;Cortis 6 AM SerPl-mCnc;;ACTIVE;2.22;2.40 +5043-5;Adrenal Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Adrenal Ab [Titer] in Serum by Immunofluorescence;Adrenal Ab Titr Ser IF;;ACTIVE;1.0;2.73 +50435-7;Corticotropin^9 AM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --9 AM specimen;ACTH 9 AM Plas-mCnc;;ACTIVE;2.22;2.40 +50436-5;Corticotropin^3 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3 PM specimen;ACTH 3 PM Plas-mCnc;;ACTIVE;2.22;2.40 +50437-3;Corticotropin^6 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --6 PM specimen;ACTH 6 PM Plas-mCnc;;ACTIVE;2.22;2.40 +50438-1;Corticotropin^9 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --9 PM specimen;ACTH 9 PM Plas-mCnc;;ACTIVE;2.22;2.40 +50439-9;Corticotropin^3 AM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3 AM specimen;ACTH 3 AM Plas-mCnc;;ACTIVE;2.22;2.40 +50440-7;Corticotropin^6 AM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --6 AM specimen;ACTH 6 AM Plas-mCnc;;ACTIVE;2.22;2.40 +50441-5;Cortisol^30M pre dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes pre dose insulin IV;Cortis 30M pre Ins IV SerPl-mCnc;;ACTIVE;2.22;2.40 +50442-3;Cortisol^20M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --20 minutes post dose insulin IV;Cortis 20M p Ins IV SerPl-mCnc;;ACTIVE;2.22;2.40 +5044-3;Adrenal cortex Ab;ACnc;Pt;Ser;Qn;RIA;SERO;1;Adrenal cortex Ab [Units/volume] in Serum by Radioimmunoassay (RIA);Adrenal cortex Ab Ser RIA-aCnc;;ACTIVE;1.0;2.69 +50443-1;Somatotropin^30M pre dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes pre dose arginine;GH 30M pre Arg SerPl-mCnc;;ACTIVE;2.22;2.40 +50444-9;Somatotropin^20M post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --20 minutes post dose arginine;GH 20M p Arg SerPl-mCnc;;ACTIVE;2.22;2.40 +50445-6;Corticotropin^1st specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1st specimen;ACTH sp1 Plas-mCnc;;ACTIVE;2.22;2.73 +50446-4;Corticotropin^2nd specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2nd specimen;ACTH sp2 Plas-mCnc;;ACTIVE;2.22;2.73 +50447-2;Corticotropin^3rd specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3rd specimen;ACTH sp3 Plas-mCnc;;ACTIVE;2.22;2.73 +50448-0;Corticotropin^4th specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --4th specimen;ACTH sp4 Plas-mCnc;;ACTIVE;2.22;2.40 +50449-8;Corticotropin^5th specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --5th specimen;ACTH sp5 Plas-mCnc;;ACTIVE;2.22;2.40 +5045-0;Ancylostoma sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Ancylostoma sp Ab [Units/volume] in Serum;Ancylostoma Ab Ser-aCnc;;ACTIVE;1.0;2.69 +50450-6;Corticotropin^6th specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --6th specimen;ACTH sp6 Plas-mCnc;;ACTIVE;2.22;2.40 +50451-4;Corticotropin^7th specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --7th specimen;ACTH sp7 Plas-mCnc;;ACTIVE;2.22;2.40 +50452-2;Corticotropin^8th specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --8th specimen;ACTH sp8 Plas-mCnc;;ACTIVE;2.22;2.40 +50453-0;Cortisol^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1st specimen;Cortis sp1 SerPl-mCnc;;ACTIVE;2.22;2.73 +50454-8;Cortisol^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2nd specimen;Cortis sp2 SerPl-mCnc;;ACTIVE;2.22;2.73 +50455-5;Cortisol^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --3rd specimen;Cortis sp3 SerPl-mCnc;;ACTIVE;2.22;2.73 +50456-3;Cortisol^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --4th specimen;Cortis sp4 SerPl-mCnc;;ACTIVE;2.22;2.73 +50457-1;Cortisol^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --5th specimen;Cortis sp5 SerPl-mCnc;;ACTIVE;2.22;2.73 +50458-9;Cortisol^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --6th specimen;Cortis sp6 SerPl-mCnc;;ACTIVE;2.22;2.73 +50459-7;Cortisol^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --7th specimen;Cortis sp7 SerPl-mCnc;;ACTIVE;2.22;2.40 +50460-5;Cortisol^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --8th specimen;Cortis sp8 SerPl-mCnc;;ACTIVE;2.22;2.40 +50461-3;C peptide^1st specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1st specimen;C peptide sp1 SerPl-sCnc;;ACTIVE;2.22;2.34 +50462-1;C peptide^2nd specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --2nd specimen;C peptide sp2 SerPl-sCnc;;ACTIVE;2.22;2.34 +50463-9;C peptide^3rd specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --3rd specimen;C peptide sp3 SerPl-sCnc;;ACTIVE;2.22;2.34 +50464-7;C peptide^4th specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --4th specimen;C peptide sp4 SerPl-sCnc;;ACTIVE;2.22;2.34 +50465-4;C peptide^5th specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5th specimen;C peptide sp5 SerPl-sCnc;;ACTIVE;2.22;2.34 +50466-2;C peptide^6th specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --6th specimen;C peptide sp6 SerPl-sCnc;;ACTIVE;2.22;2.34 +50467-0;C peptide^7th specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --7th specimen;C peptide sp7 SerPl-sCnc;;ACTIVE;2.22;2.34 +5046-8;Hantavirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus Ab [Units/volume] in Serum;Hantavirus Ab Ser-aCnc;;ACTIVE;1.0;2.73 +50468-8;C peptide^8th specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --8th specimen;C peptide sp8 SerPl-sCnc;;ACTIVE;2.22;2.34 +50469-6;Calcitonin^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --1st specimen;Calcit sp1 SerPl-mCnc;;ACTIVE;2.22;2.34 +50470-4;Calcitonin^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --2nd specimen;Calcit sp2 SerPl-mCnc;;ACTIVE;2.22;2.34 +50471-2;Calcitonin^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --3rd specimen;Calcit sp3 SerPl-mCnc;;ACTIVE;2.22;2.34 +50472-0;Calcitonin^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --4th specimen;Calcit sp4 SerPl-mCnc;;ACTIVE;2.22;2.34 +50473-8;Calcitonin^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --5th specimen;Calcit sp5 SerPl-mCnc;;ACTIVE;2.22;2.34 +50474-6;Calcitonin^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --6th specimen;Calcit sp6 SerPl-mCnc;;ACTIVE;2.22;2.34 +50475-3;Calcitonin^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --7th specimen;Calcit sp7 SerPl-mCnc;;ACTIVE;2.22;2.34 +5047-6;Nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Nuclear Ab [Units/volume] in Serum by Immunoassay;ANA Ser IA-aCnc;;ACTIVE;1.0;2.73 +50476-1;Calcitonin^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --8th specimen;Calcit sp8 SerPl-mCnc;;ACTIVE;2.22;2.34 +50477-9;Follitropin^1st specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1st specimen;FSH sp1 SerPl-aCnc;;ACTIVE;2.22;2.73 +50478-7;Follitropin^2nd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --2nd specimen;FSH sp2 SerPl-aCnc;;ACTIVE;2.22;2.73 +50479-5;Follitropin^3rd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --3rd specimen;FSH sp3 SerPl-aCnc;;ACTIVE;2.22;2.73 +50480-3;Follitropin^4th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --4th specimen;FSH sp4 SerPl-aCnc;;ACTIVE;2.22;2.73 +50481-1;Follitropin^5th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --5th specimen;FSH sp5 SerPl-aCnc;;ACTIVE;2.22;2.73 +50482-9;Follitropin^6th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --6th specimen;FSH sp6 SerPl-aCnc;;ACTIVE;2.22;2.73 +50483-7;Follitropin^7th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --7th specimen;FSH sp7 SerPl-aCnc;;ACTIVE;2.22;2.73 +5048-4;Nuclear Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Nuclear Ab [Titer] in Serum by Immunofluorescence;ANA Titr Ser IF;;ACTIVE;1.0;2.73 +50484-5;Follitropin^8th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --8th specimen;FSH sp8 SerPl-aCnc;;ACTIVE;2.22;2.38 +50485-2;Gastrin^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --1st specimen;Gastrin sp1 SerPl-mCnc;;ACTIVE;2.22;2.73 +50486-0;Gastrin^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --2nd specimen;Gastrin sp2 SerPl-mCnc;;ACTIVE;2.22;2.73 +50487-8;Gastrin^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --3rd specimen;Gastrin sp3 SerPl-mCnc;;ACTIVE;2.22;2.73 +50488-6;Gastrin^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --4th specimen;Gastrin sp4 SerPl-mCnc;;ACTIVE;2.22;2.73 +50489-4;Gastrin^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --5th specimen;Gastrin sp5 SerPl-mCnc;;ACTIVE;2.22;2.73 +50490-2;Gastrin^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --6th specimen;Gastrin sp6 SerPl-mCnc;;ACTIVE;2.22;2.73 +50491-0;Gastrin^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --7th specimen;Gastrin sp7 SerPl-mCnc;;ACTIVE;2.22;2.73 +5049-2;Ascaris lumbricoides Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Ascaris lumbricoides Ab [Units/volume] in Serum by Immunoassay;A lumbric Ab Ser IA-aCnc;;ACTIVE;1.0;2.69 +50492-8;Gastrin^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --8th specimen;Gastrin sp8 SerPl-mCnc;;ACTIVE;2.22;2.73 +50493-6;Somatotropin^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1st specimen;GH sp1 SerPl-mCnc;;ACTIVE;2.22;2.73 +50494-4;Somatotropin^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2nd specimen;GH sp2 SerPl-mCnc;;ACTIVE;2.22;2.73 +50495-1;Somatotropin^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3rd specimen;GH sp3 SerPl-mCnc;;ACTIVE;2.22;2.73 +50496-9;Somatotropin^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --4th specimen;GH sp4 SerPl-mCnc;;ACTIVE;2.22;2.73 +50497-7;Somatotropin^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --5th specimen;GH sp5 SerPl-mCnc;;ACTIVE;2.22;2.73 +50498-5;Somatotropin^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --6th specimen;GH sp6 SerPl-mCnc;;ACTIVE;2.22;2.73 +50499-3;Somatotropin^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --7th specimen;GH sp7 SerPl-mCnc;;ACTIVE;2.22;2.73 +50-5;Bacampicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Bacampicillin [Susceptibility] by Serum bactericidal titer;Bacampicillin Titr SBT;;ACTIVE;1.0;2.32 +5050-0;Aspergillus fumigatus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus fumigatus Ab [Units/volume] in Serum;A fumigatus Ab Ser-aCnc;;ACTIVE;1.0;2.73 +50500-8;Somatotropin^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --8th specimen;GH sp8 SerPl-mCnc;;ACTIVE;2.22;2.73 +50501-6;Insulin^1st specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1st specimen;Insulin sp1 SerPl-aCnc;;ACTIVE;2.22;2.73 +50502-4;Insulin^2nd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2nd specimen;Insulin sp2 SerPl-aCnc;;ACTIVE;2.22;2.73 +50503-2;Insulin^3rd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3rd specimen;Insulin sp3 SerPl-aCnc;;ACTIVE;2.22;2.73 +50504-0;Insulin^4th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --4th specimen;Insulin sp4 SerPl-aCnc;;ACTIVE;2.22;2.73 +50505-7;Insulin^5th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --5th specimen;Insulin sp5 SerPl-aCnc;;ACTIVE;2.22;2.73 +50506-5;Insulin^6th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --6th specimen;Insulin sp6 SerPl-aCnc;;ACTIVE;2.22;2.73 +50507-3;Insulin^7th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --7th specimen;Insulin sp7 SerPl-aCnc;;ACTIVE;2.22;2.73 +50508-1;Insulin^8th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --8th specimen;Insulin sp8 SerPl-aCnc;;ACTIVE;2.22;2.73 +50509-9;Lutropin^1st specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1st specimen;LH sp1 SerPl-aCnc;;ACTIVE;2.22;2.73 +50510-7;Lutropin^2nd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --2nd specimen;LH sp2 SerPl-aCnc;;ACTIVE;2.22;2.73 +50511-5;Lutropin^3rd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --3rd specimen;LH sp3 SerPl-aCnc;;ACTIVE;2.22;2.73 +50512-3;Lutropin^4th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --4th specimen;LH sp4 SerPl-aCnc;;ACTIVE;2.22;2.73 +50513-1;Lutropin^5th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --5th specimen;LH sp5 SerPl-aCnc;;ACTIVE;2.22;2.73 +50514-9;Lutropin^6th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --6th specimen;LH sp6 SerPl-aCnc;;ACTIVE;2.22;2.73 +50515-6;Lutropin^7th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --7th specimen;LH sp7 SerPl-aCnc;;ACTIVE;2.22;2.73 +50516-4;Lutropin^8th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --8th specimen;LH sp8 SerPl-aCnc;;ACTIVE;2.22;2.68 +50517-2;Prolactin^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --1st specimen;Prolactin sp1 SerPl-mCnc;;ACTIVE;2.22;2.73 +5051-8;Aspergillus niger Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus niger Ab [Units/volume] in Serum;A niger Ab Ser-aCnc;;ACTIVE;1.0;2.73 +50518-0;Prolactin^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --2nd specimen;Prolactin sp2 SerPl-mCnc;;ACTIVE;2.22;2.73 +50519-8;Prolactin^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --3rd specimen;Prolactin sp3 SerPl-mCnc;;ACTIVE;2.22;2.73 +50520-6;Prolactin^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --4th specimen;Prolactin sp4 SerPl-mCnc;;ACTIVE;2.22;2.73 +50521-4;Prolactin^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --5th specimen;Prolactin sp5 SerPl-mCnc;;ACTIVE;2.22;2.73 +50522-2;Prolactin^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --6th specimen;Prolactin sp6 SerPl-mCnc;;ACTIVE;2.22;2.40 +50523-0;Prolactin^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --7th specimen;Prolactin sp7 SerPl-mCnc;;ACTIVE;2.22;2.40 +50524-8;Prolactin^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --8th specimen;Prolactin sp8 SerPl-mCnc;;ACTIVE;2.22;2.40 +50525-5;Parathyrin.intact^1st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --1st specimen;PTH-Intact sp1 SerPl-mCnc;;ACTIVE;2.22;2.73 +5052-6;Aspergillus sp Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Aspergillus sp Ab [Presence] in Serum by Immune diffusion (ID);Aspergillus Ab Ser Ql ID;;ACTIVE;1.0;2.73 +50526-3;Parathyrin.intact^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --2nd specimen;PTH-Intact sp2 SerPl-mCnc;;ACTIVE;2.22;2.73 +50527-1;Parathyrin.intact^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --3rd specimen;PTH-Intact sp3 SerPl-mCnc;;ACTIVE;2.22;2.73 +50528-9;Parathyrin.intact^4th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --4th specimen;PTH-Intact sp4 SerPl-mCnc;;ACTIVE;2.22;2.73 +50529-7;Parathyrin.intact^5th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --5th specimen;PTH-Intact sp5 SerPl-mCnc;;ACTIVE;2.22;2.73 +50530-5;Parathyrin.intact^6th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --6th specimen;PTH-Intact sp6 SerPl-mCnc;;ACTIVE;2.22;2.73 +50531-3;Parathyrin.intact^7th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --7th specimen;PTH-Intact sp7 SerPl-mCnc;;ACTIVE;2.22;2.34 +50532-1;Parathyrin.intact^8th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --8th specimen;PTH-Intact sp8 SerPl-mCnc;;ACTIVE;2.22;2.34 +50533-9;Thyrotropin^1st specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --1st specimen;TSH sp1 SerPl-aCnc;;ACTIVE;2.22;2.68 +5053-4;Aspergillus sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Aspergillus sp Ab [Titer] in Serum by Complement fixation;Aspergillus Ab Titr Ser CF;;ACTIVE;1.0;2.73 +50534-7;Thyrotropin^2nd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --2nd specimen;TSH sp2 SerPl-aCnc;;ACTIVE;2.22;2.68 +50535-4;Thyrotropin^3rd specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --3rd specimen;TSH sp3 SerPl-aCnc;;ACTIVE;2.22;2.68 +50536-2;Thyrotropin^4th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --4th specimen;TSH sp4 SerPl-aCnc;;ACTIVE;2.22;2.68 +50537-0;Thyrotropin^5th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --5th specimen;TSH sp5 SerPl-aCnc;;ACTIVE;2.22;2.68 +50538-8;Thyrotropin^6th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --6th specimen;TSH sp6 SerPl-aCnc;;ACTIVE;2.22;2.68 +50539-6;Thyrotropin^7th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --7th specimen;TSH sp7 SerPl-aCnc;;ACTIVE;2.22;2.68 +50540-4;Thyrotropin^8th specimen;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --8th specimen;TSH sp8 SerPl-aCnc;;ACTIVE;2.22;2.68 +50541-2;Thyrotropin^20M post dose TRH;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --20 minutes post dose TRH;TSH 20M p TRH SerPl-aCnc;;ACTIVE;2.22;2.68 +5054-2;Babesia sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia sp Ab [Titer] in Serum by Immunofluorescence;Babesia Ab Titr Ser IF;;ACTIVE;1.0;2.73 +50542-0;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Mass/volume] in Urine;EDDP Ur-mCnc;;ACTIVE;2.22;2.73 +50543-8;Tricyclic antidepressants;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tricyclic antidepressants [Mass/volume] in Urine;Tricyclics Ur-mCnc;;ACTIVE;2.22;2.73 +50544-6;Everolimus;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Everolimus [Mass/volume] in Blood;Everolimus Bld-mCnc;;ACTIVE;2.22;2.73 +50545-3;Bacterial susceptibility panel;-;Pt;Isolate;OrdQn;MIC;PANEL.ABXBACT;1;Bacterial susceptibility panel by Minimum inhibitory concentration (MIC);Bacterial Susc Pnl Islt MIC;;ACTIVE;2.22;2.73 +50546-1;Bacterial susceptibility panel;-;Pt;Isolate;OrdQn;Agar diffusion;PANEL.ABXBACT;1;Bacterial susceptibility panel by Disk diffusion (KB);Bacterial Susc Pnl Islt KB;;ACTIVE;2.22;2.73 +50547-9;Eastern equine encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Eastern equine encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;EEEV RNA Spec Ql NAA+probe;;ACTIVE;2.22;2.73 +50548-7;Respiratory virus DNA+RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection;Resp virus DNA+RNA Spec NAA+probe;;ACTIVE;2.22;2.73 +50549-5;Cytomegalovirus+Epstein Barr virus DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Cytomegalovirus+Epstein Barr virus DNA [Identifier] in Unspecified specimen by Probe and target amplification method;Deprecated CMV+EBV DNA XXX PCR;;DEPRECATED;2.22;2.69 +50550-3;Malondialdehyde.free;SCnc;Pt;Plas;Qn;;CHEM;1;Malondialdehyde.free [Moles/volume] in Plasma;Malondialdehyde.free Plas-sCnc;;ACTIVE;2.22;2.42 +50551-1;Bilirubin;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Bilirubin.total [Presence] in Urine by Automated test strip;Bilirub Ur Ql Strip.auto;;ACTIVE;2.22;2.73 +50552-9;Clarity;Type;Pt;Urine;Nom;Refractometry.automated;UA;1;Clarity in Urine by Refractometry automated;Clarity Ur Refract.auto;;ACTIVE;2.22;2.73 +50553-7;Color;Type;Pt;Urine;Nom;Auto;UA;1;Color of Urine by Auto;Color Ur Auto;;ACTIVE;2.22;2.73 +50554-5;Urinalysis microscopic panel;NCnc;Pt;Urine;Qn;Automated count;PANEL.UA;1;Urinalysis microscopic panel [#/volume] - Urine by Automated count;UA Microscopic Pnl # Ur Auto;;ACTIVE;2.22;2.42 +50555-2;Glucose;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Glucose [Presence] in Urine by Automated test strip;Glucose Ur Ql Strip.auto;;ACTIVE;2.22;2.73 +50556-0;Urinalysis dipstick panel;-;Pt;Urine;-;Test strip.automated;PANEL.UA;1;Urinalysis dipstick panel - Urine by Automated test strip;UA dipstick Pnl Ur Strip.auto;;ACTIVE;2.22;2.73 +50557-8;Ketones;MCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Ketones [Mass/volume] in Urine by Automated test strip;Ketones Ur Strip.auto-mCnc;;ACTIVE;2.22;2.73 +50558-6;Nitrite;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Nitrite [Presence] in Urine by Automated test strip;Nitrite Ur Ql Strip.auto;;ACTIVE;2.22;2.73 +5055-9;Bacillus anthracis Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Bacillus anthracis Ab [Units/volume] in Serum by Hemagglutination;B anthracis Ab Ser HA-aCnc;;ACTIVE;1.0;2.69 +50559-4;Hemoglobin;MCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Hemoglobin [Mass/volume] in Urine by Automated test strip;Hgb Ur Strip.auto-mCnc;;ACTIVE;2.22;2.73 +50560-2;pH;LsCnc;Pt;Urine;Qn;Test strip.automated;UA;1;pH of Urine by Automated test strip;pH Ur Strip.auto;;ACTIVE;2.22;2.73 +50561-0;Protein;MCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Protein [Mass/volume] in Urine by Automated test strip;Prot Ur Strip.auto-mCnc;;ACTIVE;2.22;2.73 +50562-8;Specific gravity;Rden;Pt;Urine;Qn;Refractometry.automated;UA;1;Specific gravity of Urine by Refractometry automated;Sp Gr Ur Refract.auto;;ACTIVE;2.22;2.73 +50563-6;Urobilinogen;MCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Urobilinogen [Mass/volume] in Urine by Automated test strip;Urobilinogen Ur Strip.auto-mCnc;;ACTIVE;2.22;2.73 +50564-4;Urinalysis panel;-;Pt;Urine;-;Auto;PANEL.UA;1;Urinalysis panel - Urine by Auto;Urinalysis Pnl Ur Auto;;ACTIVE;2.22;2.73 +50565-1;OTC - Keep out of reach of children section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Keep out of reach of children section;FDA label OTC - KOR of children;;ACTIVE;2.22;2.34 +50566-9;OTC - Stop use section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Stop use section;FDA label OTC - Stop use;;ACTIVE;2.22;2.34 +5056-7;Basement membrane Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Basement membrane Ab [Presence] in Serum by Immunofluorescence;BM Ab Ser Ql IF;;ACTIVE;1.0;2.73 +50567-7;OTC - When using section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - When using section;FDA label OTC - When using;;ACTIVE;2.22;2.34 +50568-5;OTC - Ask doctor or pharmacist section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Ask doctor or pharmacist section;FDA label OTC - Ask MD/pharmacist;;ACTIVE;2.22;2.34 +50569-3;OTC - Ask doctor section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Ask doctor section;FDA label OTC - Ask MD;;ACTIVE;2.22;2.34 +50570-1;OTC - Do not use section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Do not use section;FDA label OTC - Do not use;;ACTIVE;2.22;2.34 +50571-9;VFD Type C medicated feed animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label VFD Type C medicated feed animal drug label;FDA label VFD C MF animal drug;;ACTIVE;2.22;2.34 +50572-7;VFD Type B medicated feed animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label VFD Type B medicated feed animal drug label;FDA label VFD B MF animal drug;;ACTIVE;2.22;2.34 +50573-5;OTC Type C medicated feed animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC Type C medicated feed animal drug label;FDA label OTC_C MF animal drug label;;ACTIVE;2.22;2.34 +50574-3;OTC Type B medicated feed animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC Type B medicated feed animal drug label;FDA label OTC_B MF animal drug label;;ACTIVE;2.22;2.34 +5057-5;Blastomyces dermatitidis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Blastomyces dermatitidis Ab [Titer] in Serum by Complement fixation;B dermat Ab Titr Ser CF;;ACTIVE;1.0;2.73 +50575-0;VFD Type A medicated article animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label VFD Type A medicated article animal drug label;FDA label VFD A MA animal drug;;ACTIVE;2.22;2.34 +50576-8;OTC Type A medicated article animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC Type A medicated article animal drug label;FDA label OTC_A MA animal drug label;;ACTIVE;2.22;2.34 +50577-6;OTC animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC animal drug label;FDA label OTC animal drug;;ACTIVE;2.22;2.34 +50578-4;Prescription animal drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Prescription animal drug label;FDA label Rx animal drug;;ACTIVE;2.22;2.34 +50579-2;Gastric analysis panel;-;Pt;Gast fld;-;;PANEL.CHEM;1;Gastric analysis panel - Gastric fluid;Gastric analysis Pnl Gast;;ACTIVE;2.22;2.42 +505-8;Ticarcillin+Clavulanate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ticarcillin+Clavulanate [Susceptibility] by Disk diffusion (KB);Ticarcillin+Clav Islt KB;;ACTIVE;1.0;2.73 +50580-0;Maternal screen for fetal abnormalities such as Open Neural Tube Defects, Trisomy 21 or Trisomy 18 panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Maternal screen for fetal abnormalities such as Open Neural Tube Defects, Trisomy 21 or Trisomy 18 panel - Serum or Plasma;Mat scn for fetal abnormalities SerPl;;ACTIVE;2.22;2.73 +50581-8;Adenosine monophosphate.cyclic stimulation panel;-;Pt;Urine;Qn;;PANEL.CHAL;1;Adenosine monophosphate.cyclic stimulation panel - Urine;cAMP stimulation Pnl Ur;;ACTIVE;2.22;2.42 +50582-6;Glucose tolerance gestational panel;-;Pt;Urine+Ser/Plas;-;;PANEL.CHAL;1;Glucose tolerance gestational panel - Urine and Serum or Plasma;Gestational GTT Pnl Ur+SerPl;;ACTIVE;2.22;2.73 +5058-3;Blastomyces dermatitidis Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Serum by Immune diffusion (ID);B dermat Ab Ser Ql ID;;ACTIVE;1.0;2.73 +50583-4;Glucose screen gestational panel;-;Pt;Urine+Ser/Plas;-;;PANEL.CHAL;1;Glucose screen gestational panel - Urine and Serum or Plasma;Glu screen gest Pnl Ur+SerPl;;ACTIVE;2.22;2.73 +50584-2;Lactose challenge panel;-;Pt;Exhl gas;Qn;;PANEL.CHAL;1;Lactose challenge (hydrogen breath test) panel - Exhaled gas;Lactose challenge Pnl ExG;;ACTIVE;2.22;2.73 +50585-9;Triple bolus stimulation panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Triple bolus stimulation panel - Serum or Plasma;Triple bolus stim Pnl SerPl;;ACTIVE;2.22;2.42 +50586-7;Glucose tolerance 3H panel;-;-;Ser/Plas;Qn;;PANEL.CHAL;1;Glucose tolerance 3 hours panel - Serum or Plasma;GTT 3h Pnl SerPl;;ACTIVE;2.22;2.73 +50587-5;Glucose tolerance 4H panel;-;-;Ser/Plas;Qn;;PANEL.CHAL;1;Glucose tolerance 4 hours panel - Serum or Plasma;GTT 4h Pnl SerPl;;ACTIVE;2.22;2.73 +50588-3;Glucose tolerance 5H panel;-;-;Ser/Plas;Qn;;PANEL.CHAL;1;Glucose tolerance 5 hours panel - Serum or Plasma;GTT 5h Pnl SerPl;;ACTIVE;2.22;2.73 +50589-1;Glucose tolerance 6H panel;-;-;Ser/Plas;Qn;;PANEL.CHAL;1;Glucose tolerance 6 hours panel - Serum or Plasma;GTT 6h Pnl SerPl;;ACTIVE;2.22;2.73 +50590-9;Adenine phosphoribosyltransferase;CCnt;Pt;Trophoblasts;Qn;;CHEM;1;Adenine phosphoribosyltransferase [Enzymatic activity/mass] in Trophoblasts;APRT Trophoblasts-cCnt;;ACTIVE;2.22;2.70 +5059-1;Bordetella pertussis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella pertussis Ab [Units/volume] in Serum by Immunoassay;B pert Ab Ser IA-aCnc;;ACTIVE;1.0;2.69 +50591-7;Adenosine deaminase;CCnt;Pt;Trophoblasts;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/mass] in Trophoblasts;Adenosine deaminase Trophoblasts-cCnt;;ACTIVE;2.22;2.70 +50592-5;Ecgonine methyl ester;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ecgonine methyl ester [Mass/volume] in Urine by Confirmatory method;EME Ur Cfm-mCnc;;ACTIVE;2.22;2.70 +50593-3;3-Hydroxybenzoylecgonine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;3-Hydroxybenzoylecgonine [Mass/volume] in Serum or Plasma by Confirmatory method;3OH-BZE SerPl Cfm-mCnc;;ACTIVE;2.22;2.73 +50594-1;3-Hydroxybenzoylecgonine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;3-Hydroxybenzoylecgonine [Mass/volume] in Urine by Confirmatory method;3OH-BZE Ur Cfm-mCnc;;ACTIVE;2.22;2.70 +50595-8;Pathologist interpretation;Imp;Pt;XXX;Nom;;PATH;1;Pathologist interpretation of Specimen tests;Path Interp Spec-Imp;;ACTIVE;2.22;2.73 +50596-6;HPA-1a;Type;Pt;Bld;Nom;;HPA;1;HPA-1a [Type] in Blood;HPA-1a Bld;;ACTIVE;2.22;2.26 +50597-4;HPA-2;Type;Pt;Bld;Nom;;HPA;1;HPA-2 [Type] in Blood;HPA-2 Bld;;ACTIVE;2.22;2.22 +50598-2;HPA-15;Type;Pt;Bld;Nom;;HPA;1;HPA-15 [Type] in Blood;HPA-15 Bld;;ACTIVE;2.22;2.22 +50599-0;HPA-1;Type;Pt;Bld;Nom;;HPA;1;HPA-1 [Type] in Blood;HPA-1 Bld;;ACTIVE;2.22;2.73 +50600-6;HPA-3;Type;Pt;Bld;Nom;;HPA;1;HPA-3 [Type] in Blood;HPA-3 Bld;;ACTIVE;2.22;2.22 +50601-4;HPA-4;Type;Pt;Bld;Nom;;HPA;1;HPA-4 [Type] in Blood;HPA-4 Bld;;ACTIVE;2.22;2.22 +50602-2;HPA-5;Type;Pt;Bld;Nom;;HPA;1;HPA-5 [Type] in Blood;HPA-5 Bld;;ACTIVE;2.22;2.22 +50603-0;HPA-6;Type;Pt;Bld;Nom;;HPA;1;HPA-6 [Type] in Blood;HPA-6 Bld;;ACTIVE;2.22;2.22 +50604-8;HPA panel;Type;Pt;Bld;Nom;;PANEL.HPA;1;HPA panel [Type] in Blood;HPA Pnl Bld;;ACTIVE;2.22;2.22 +50605-5;Hydrogen/Expired gas^pre XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --pre XXX challenge;Breath H2 pre chal;;ACTIVE;2.22;2.73 +50606-3;Hydrogen/Expired gas^4H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --4 hours post XXX challenge;Breath H2 4h p chal;;ACTIVE;2.22;2.70 +50607-1;Neisseria meningitidis serogroups Ag panel;-;Pt;XXX;-;LA;PANEL.MICRO;1;Neisseria meningitidis serogroups Ag panel - Specimen by Latex agglutination;N men sg Ag Pnl Spec LA;;ACTIVE;2.22;2.69 +50608-9;Glucose tolerance 3H gestational panel;-;-;Ser/Plas;Qn;;PANEL.CHAL;1;Glucose tolerance 3 hours gestational panel - Serum or Plasma;GTT gest 3h Pnl SerPl;;ACTIVE;2.22;2.73 +5060-9;Borrelia burgdorferi Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Serum by Immunoassay;B burgdor Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +50609-7;Nitroblue tetrazolium test;ACnc;Pt;Bld;Qn;;HEM/BC;1;Nitroblue Tetrazolium Test (NBT) [Units/volume] in Blood;NBT Bld-aCnc;;ACTIVE;2.22;2.70 +50610-5;Alpha-1-Fetoprotein^^adjusted for multiple gestations;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-Fetoprotein [Multiple of the median] adjusted for multiple gestations in Serum or Plasma;AFP mult gest adj MoM SerPl;;ACTIVE;2.22;2.73 +50611-3;Felbamate;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Felbamate [Mass/volume] in Serum or Plasma by Confirmatory method;Felbamate SerPl Cfm-mCnc;;ACTIVE;2.22;2.70 +50612-1;Chlamydophila pneumoniae Ab.IgA & IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Chlamydophila pneumoniae IgA and IgG and IgM [Interpretation] in Serum;C pneum IgA+IgG+IgM Ser-Imp;;ACTIVE;2.22;2.73 +50613-9;Hydrogen/Expired gas^3.5H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3.5 hours post XXX challenge;Breath H2 3.5h p chal;;ACTIVE;2.22;2.70 +50614-7;Hydrogen/Expired gas^4.5H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --4.5 hours post XXX challenge;Breath H2 4.5h p chal;;ACTIVE;2.22;2.70 +50615-4;Hydrogen/Expired gas^5H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --5 hours post XXX challenge;Breath H2 5h p chal;;ACTIVE;2.22;2.70 +50616-2;Hydrogen/Expired gas^5.5H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --5.5 hours post XXX challenge;Breath H2 5.5h p chal;;ACTIVE;2.22;2.70 +5061-7;Borrelia burgdorferi Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Borrelia burgdorferi Ab [Titer] in Serum by Immunofluorescence;B burgdor Ab Titr Ser IF;;ACTIVE;1.0;2.70 +50617-0;Hydrogen/Expired gas^6H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --6 hours post XXX challenge;Breath H2 6h p chal;;ACTIVE;2.22;2.70 +50618-8;Phosphatidylcholine.saturated/Surfactant.total;MFr;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylcholine.saturated/Surfactant.total in Amniotic fluid;PC Satd MFr Amn;;ACTIVE;2.22;2.70 +50619-6;Karyotype;Prid;Pt;Bld/Tiss;Nar;;MOLPATH;1;Karyotype [Identifier] in Blood or Tissue Narrative;Karyotyp Bld/T;;ACTIVE;2.22;2.73 +50620-4;Opiates cutoff;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Opiates cutoff [Mass/mass] in Meconium for Confirmatory method;Opiates CtO Mec Cfm-mCnt;;ACTIVE;2.22;2.70 +50621-2;HTT gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HTT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HTT gene Mut Anl Bld/T;;ACTIVE;2.22;2.73 +50622-0;Allergen.miscellaneous Ab.IgG;Prid;Pt;Ser;Nar;;ALLERGY;1;Miscellaneous allergen IgG Ab [Identifier] in Serum;Misc Allergen IgG;;ACTIVE;2.22;2.68 +50623-8;AS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;AS gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +50624-6;HIV 1 RNA panel;-;Pt;CSF;Qn;Probe.amp.tar;PANEL.MICRO;1;HIV 1 RNA panel (viral load) in Cerebral spinal fluid by NAA with probe detection;HIV 1 RNA Pnl CSF NAA+probe;;ACTIVE;2.22;2.73 +5062-5;Borrelia burgdorferi Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi IgG Ab [Units/volume] in Serum by Immunoassay;B burgdor IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +50625-3;Ova & parasites identified;Prid;Pt;Bld/Tiss;Nom;Wright stain;MICRO;1;Ova and parasites identified in Blood or Tissue by Wright stain;O+P Bld/T Wright Stn;;ACTIVE;2.22;2.73 +50626-1;DMD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;DMD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;DMD gene Mut Anl Bld/T;;ACTIVE;2.22;2.66 +50627-9;Immunoglobulin heavy chain gene rearrangements;Find;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.REARRANGE;1;HC gene rearrangements in Blood or Tissue by Molecular genetics method Narrative;HC gene Rear Bld/T;;ACTIVE;2.22;2.73 +50628-7;Heptacarboxylporphyrin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin/Creatinine [Molar ratio] in Urine;Hepta-CP/Creat Ur-sRto;;ACTIVE;2.22;2.73 +50629-5;Liver kidney microsomal Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Liver kidney microsomal IgG Ab [Titer] in Serum;LKM IgG Titr Ser;;ACTIVE;2.22;2.40 +50630-3;Gentamicin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Gentamicin [Susceptibility] by Method for Slow-growing mycobacteria;Gentamicin Islt SlowMyco;;ACTIVE;2.22;2.26 +50631-1;Cefepime;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Cefepime [Susceptibility] by Method for Slow-growing mycobacteria;Cefepime Islt SlowMyco;;ACTIVE;2.22;2.26 +50632-9;Cefotaxime;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Cefotaxime [Susceptibility] by Method for Slow-growing mycobacteria;Cefotaxime Islt SlowMyco;;ACTIVE;2.22;2.26 +5063-3;Borrelia burgdorferi Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Borrelia burgdorferi IgG Ab [Titer] in Serum by Immunofluorescence;B burgdor IgG Titr Ser IF;;ACTIVE;1.0;2.73 +50633-7;cefTRIAXone;Susc;Pt;Isolate.meningitis;OrdQn;;ABXBACT;1;cefTRIAXone [Susceptibility] for meningitis;cefTRIAXone Susc Islt.mening;;ACTIVE;2.22;2.73 +50634-5;Populus balsamifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Balsam poplar IgE Ab [Units/volume] in Serum;Balsam poplar IgE Qn;;ACTIVE;2.22;2.42 +50635-2;Cupressus macrocarpa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Monterey cypress IgE Ab [Units/volume] in Serum;Monterey cypress IgE Qn;;ACTIVE;2.22;2.42 +50636-0;Macrocheira kaempferi Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Giant Japanese spider crab IgE Ab [Units/volume] in Serum;Giant Jap spider crab IgE Qn;;ACTIVE;2.22;2.42 +50637-8;Coagulation factor XIII inhibitor;PrThr;Pt;PPP;Ord;Chromo;COAG;1;Coagulation factor XIII inhibitor [Presence] in Platelet poor plasma by Chromogenic method;Fact XIII Inhib PPP Ql Chro;;ACTIVE;2.22;2.73 +50638-6;Bixa orellana seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Annatto seed IgE Ab [Units/volume] in Serum;Annatto seed IgE Qn;;ACTIVE;2.22;2.73 +50639-4;Harmonia axyridis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Asian ladybug IgE Ab [Units/volume] in Serum;Asian ladybug IgE Qn;;ACTIVE;2.22;2.42 +50640-2;Cells.CD3+CD57+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD57+ cells [#/volume] in Blood;CD3+CD57+ Cells # Bld;;ACTIVE;2.22;2.73 +5064-1;Borrelia burgdorferi Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Serum by Immunoassay;B burgdor IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +50641-0;Cells.CD3+CD8+CD57+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD57+ cells [#/volume] in Blood;CD3+CD8+CD57+ Cells # Bld;;ACTIVE;2.22;2.73 +50642-8;Human papilloma virus 6+11+42+43+44 DNA;PrThr;Pt;Anal;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 6+11+42+43+44 DNA [Presence] in Anal by Probe with signal amplification;HPV Low Risk DNA Anal Ql Probe+sig amp;;ACTIVE;2.22;2.73 +50643-6;Pregnanetriolone;MRat;24H;Urine;Qn;;CHEM;1;Pregnanetriolone [Mass/time] in 24 hour Urine;Pregntrlone 24h Ur-mRate;;ACTIVE;2.22;2.70 +50644-4;Tetrahydrocorticosterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone/Creatinine [Mass Ratio] in Urine;THB/Creat Ur;;ACTIVE;2.22;2.70 +50645-1;Tetrahydrocortisol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocortisol/Creatinine [Mass Ratio] in Urine;THF/Creat Ur;;ACTIVE;2.22;2.70 +50646-9;Latex recombinant (rHev b) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 1 IgE Ab [Units/volume] in Serum;Latex (rHev b) 1 IgE Qn;;ACTIVE;2.22;2.70 +50647-7;Latex recombinant (rHev b) 11 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 11 IgE Ab [Units/volume] in Serum;Latex (rHev b) 11 IgE Qn;;ACTIVE;2.22;2.70 +50648-5;Latex recombinant (rHev b) 6.01 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 6.01 IgE Ab [Units/volume] in Serum;Latex (rHev b) 6.01 IgE Qn;;ACTIVE;2.22;2.70 +50649-3;Latex recombinant (rHev b) 6.02 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 6.02 IgE Ab [Units/volume] in Serum;Latex (rHev b) 6.02 IgE Qn;;ACTIVE;2.22;2.70 +50650-1;Lupinus albus seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lupin seed IgE Ab [Units/volume] in Serum;Lupin seed IgE Qn;;ACTIVE;2.22;2.73 +50651-9;(Arachis hypogaea+Cow milk+Egg white+Mustard) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 26 (Peanut+Cow milk+Egg white+Mustard) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix26 IgE Qn;;ACTIVE;2.22;2.70 +50652-7;(Actinidia chinensis+Beef+Pandalus borealis+Sesamum indicum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 28 (Kiwi+Beef+Shrimp+Sesame seed) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix28 IgE Qn;;ACTIVE;2.22;2.70 +50653-5;(Acer negundo+Betula verrucosa+Corylus avellana+Quercus alba+Platanus acerifolia) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 8 (Boxelder+Silver birch+Hazelnut+White oak+London plane or Maple leaf sycamore) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix8 IgE Qn;;ACTIVE;2.22;2.70 +50654-3;(Anthoxanthum odoratum+Lolium perenne+Phleum pratense+Secale cereale+Holcus lanatus) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 3 (Sweet vernal grass+Perennial rye grass+Timothy+Rye+Velvet grass) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allerg Mix3 IgE Qn;;ACTIVE;2.22;2.73 +50655-0;(Actinidia chinensis+Corylus avellana+Musa spp+Pandalus borealis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 24 (Kiwi+Hazelnut+Banana+Shrimp) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix24 IgE Qn;;ACTIVE;2.22;2.70 +50656-8;(Corylus avellana+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 27 (Hazelnut+Codfish+Soybean+Wheat) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix27 IgE Qn;;ACTIVE;2.22;2.70 +50657-6;(Allium cepa+Allium sativum+Sesamum indicum+Yeast) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 25A (Onion+Garlic+Sesame seed+Yeast) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix25A IgE Qn;;ACTIVE;2.22;2.70 +5065-8;Borrelia burgdorferi Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Borrelia burgdorferi IgM Ab [Titer] in Serum by Immunofluorescence;B burgdor IgM Titr Ser IF;;ACTIVE;1.0;2.73 +50658-4;Basophils.band form/100 leukocytes;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Basophils.band form/100 leukocytes in Bone marrow;Basophils band/leuk NFr Mar;;ACTIVE;2.22;2.70 +50659-2;Chromosome analysis.interphase;Imp;Pt;Bone mar;Nar;FISH;MOLPATH;1;Chromosome analysis.interphase [Interpretation] in Bone marrow by FISH Narrative;Chrom analy interphase Mar FISH-Imp;;ACTIVE;2.22;2.73 +506-6;Ticarcillin+Clavulanate;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Ticarcillin+Clavulanate [Susceptibility] by Serum bactericidal titer;Ticarcillin+Clav Titr SBT;;ACTIVE;1.0;2.32 +50660-0;Herpes simplex virus 1 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HSV1 DNA # SerPl NAA+probe;;ACTIVE;2.22;2.73 +50661-8;Herpes simplex virus 1 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Urine by NAA with probe detection;HSV1 DNA # Ur NAA+probe;;ACTIVE;2.22;2.70 +50662-6;Herpes simplex virus 2 DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HSV2 DNA # SerPl NAA+probe;;ACTIVE;2.22;2.70 +50663-4;Herpes simplex virus 2 DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Urine by NAA with probe detection;HSV2 DNA # Ur NAA+probe;;ACTIVE;2.22;2.70 +50664-2;Cells.CD19+Kappa+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+Kappa+ cells [#/volume] in Blood;CD19+Kappa+ Cells # Bld;;ACTIVE;2.22;2.70 +50665-9;Cells.CD19+Lambda+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+Lambda+ cells [#/volume] in Blood;CD19+Lambda+ Cells # Bld;;ACTIVE;2.22;2.70 +5066-6;Brucella abortus Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Brucella abortus Ab [Presence] in Serum by Latex agglutination;B abortus Ab Ser Ql LA;;ACTIVE;1.0;2.56 +50666-7;Nuclear matrix protein 22;PrThr;Pt;Urine;Ord;;SERO;1;Nuclear matrix protein 22 [Presence] in Urine;NMP22 Ur Ql;;ACTIVE;2.22;2.56 +50667-5;Glucose tolerance;Imp;Pt;Ser/Plas;Nar;;CHAL;1;Glucose tolerance [Interpretation] in Serum or Plasma Narrative;GTT SerPl-Imp;;ACTIVE;2.22;2.73 +50668-3;Microscopic observation;Find;Pt;XXX;Nar;Microscopy.electron;MICRO;1;Microscopic observation in Specimen by Electron microscopy Narrative;EM Spec;;ACTIVE;2.22;2.69 +50669-1;Transfuse antithrombin;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse antithrombin [Volume];Trans AT III Vol Patient;;ACTIVE;2.22;2.42 +50670-9;Erythrocyte agglutination;PrThr;Pt;Bld;Ord;;HEM/BC;1;Erythrocyte agglutination [Presence] in Blood;RBC agglut Bld Ql;;ACTIVE;2.22;2.73 +50671-7;Corticotropin releasing hormone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Corticotropin releasing hormone [Mass] of Dose;ACTH RH Dose;;ACTIVE;2.22;2.69 +50672-5;Leukocyte toxic vacuoles;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Leukocyte toxic vacuoles [Presence] in Blood by Light microscopy;WBC toxic vacuoles Bld Ql Smear;;ACTIVE;2.22;2.73 +50673-3;Insulin XXX challenge panel;-;Pt;Ser;Qn;;PANEL.CHAL;1;Insulin XXX challenge panel - Serum;Insulin XXX challenge Pnl Ser;;ACTIVE;2.22;2.73 +5067-4;Brucella abortus Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Brucella abortus Ab [Titer] in Serum by Latex agglutination;B abortus Ab Titr Ser LA;;ACTIVE;1.0;2.70 +50674-1;Spherocytes;PrThr;Pt;BldCo;Ord;Microscopy.light;HEM/BC;1;Spherocytes [Presence] in Cord blood by Light microscopy;Spherocytes BldCo Ql Micro;;ACTIVE;2.22;2.56 +50675-8;Calcium-phosphorus product;MCncSq;Pt;Ser/Plas;Qn;;CHEM;1;Calcium-phosphorus product [(Mass/volume)*2] in Serum or Plasma;CaxP SerPl-MCncSq;;ACTIVE;2.22;2.73 +50676-6;Calcium-phosphorus product panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Calcium-phosphorus product panel - Serum or Plasma;CaxP Pnl SerPl;;ACTIVE;2.22;2.54 +50677-4;Semen analysis post vasectomy panel;-;Pt;Semen;-;;PANEL.FERT;1;Semen analysis post vasectomy panel;Semen analysis p vas Pnl;;ACTIVE;2.22;2.73 +50678-2;Spondylocladium sp Ab.IgE.Rast Class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Spondylocladium sp IgE Ab RAST class [Presence] in Serum;Spondylocladium IgE RAST Ql;;ACTIVE;2.22;2.58 +50679-0;First trimester maternal screen with nuchal translucency;Imp;Pt;^Patient;Nom;;CHEM;1;First trimester maternal screen with nuchal translucency [Interpretation];1st trimester scn+NT Patient-Imp;;ACTIVE;2.22;2.73 +50680-8;Paecilomyces variottii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paecilomyces variottii IgE Ab [Units/volume] in Serum;P variottii IgE Qn;;ACTIVE;2.22;2.73 +50681-6;Thyroxine binding protein pattern;Imp;Pt;Ser/Plas;Nom;Electrophoresis;CHEM;1;Thyroxine binding protein pattern [Interpretation] in Serum or Plasma by Electrophoresis;T4BP pattern SerPl Elph-Imp;;ACTIVE;2.22;2.26 +5068-2;Brucella canis Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Brucella canis Ab [Titer] in Serum by Latex agglutination;B canis Ab Titr Ser LA;;ACTIVE;1.0;2.70 +50682-4;PRKCG gene.CAG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;PRKCG gene CAG repeats [Presence] in Blood or Tissue by Molecular genetics method;PRKCG gene CAG Rpt Bld/T Ql;;ACTIVE;2.22;2.56 +50683-2;Staphylococcus aureus toxic shock syndrome toxin 1+Staphylococcus aureus enterotoxin B Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Staphylococcus aureus toxic shock syndrome toxin 1+Staphylococcus aureus enterotoxin B Ab [Presence] in Serum;S aureus TSST-1+Etx B Ab Ser Ql;;ACTIVE;2.22;2.65 +50684-0;Chromosome analysis.interphase;Imp;Pt;Bld;Nar;FISH;MOLPATH;1;Chromosome analysis.interphase [Interpretation] in Blood by FISH Narrative;Chrom analy interphase Bld FISH-Imp;;ACTIVE;2.22;2.73 +50685-7;Somatotropin;MRat;24H;Urine;Qn;;CHEM;1;Somatotropin [Mass/time] in 24 hour Urine;GH 24h Ur-mRate;;ACTIVE;2.22;2.73 +50686-5;11-Dehydro thromboxane beta 2/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Deprecated 11-Dehydro thromboxane beta 2/Creatinine [Mass Ratio] in Urine;Deprecated 11-dehydro TBX2/Creat Ur;;DEPRECATED;2.22;2.70 +50687-3;Plasmodium sp Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Plasmodium sp Ag [Presence] in Blood;Plasmodium Ag Bld Ql;;ACTIVE;2.22;2.56 +50688-1;Plasmodium sp lactate dehydrogenase;Prid;Pt;Bld;Nom;;MICRO;1;Plasmodium sp lactate dehydrogenase [Identifier] in Blood;Plasmodium LDH Bld;;ACTIVE;2.22;2.22 +50689-9;Treponema pallidum Ab;PrThr;Pt;CSF;Ord;HA;MICRO;1;Treponema pallidum Ab [Presence] in Cerebral spinal fluid by Hemagglutination;T pallidum Ab CSF Ql HA;;ACTIVE;2.22;2.56 +5069-0;Brucella melitensis Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Brucella melitensis Ab [Titer] in Serum by Latex agglutination;B melitensis Ab Titr Ser LA;;ACTIVE;1.0;2.70 +50690-7;Reagin Ab;Titr;Pt;Ser;Qn;VDRL;MICRO;1;Reagin Ab [Titer] in Serum by VDRL;VDRL Ser-Titr;;ACTIVE;2.22;2.73 +50691-5;Coxsackievirus A9+B1+B2+B3+B4+B5+B6 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A9+B1+B2+B3+B4+B5+B6 Ab [Titer] in Serum by Complement fixation;CV A9+B1-6 Ab Titr Ser CF;;ACTIVE;2.22;2.32 +50692-3;Parainfluenza virus 1+2+3 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 1+2+3 Ab [Titer] in Serum by Complement fixation;HPIV1+2+3 Ab Titr Ser CF;;ACTIVE;2.22;2.32 +50693-1;Influenza virus A+B Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus A+B Ab [Titer] in Serum by Complement fixation;FLUAV+FLUBV Ab Titr Ser CF;;ACTIVE;2.22;2.73 +50694-9;Rubella virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Rubella virus Ab [Titer] in Serum by Hemagglutination inhibition;RUBV Ab Titr Ser HAI;;ACTIVE;2.22;2.32 +50695-6;Treponema pallidum Ab;Titr;Pt;CSF;Qn;HA;MICRO;1;Treponema pallidum Ab [Titer] in Cerebral spinal fluid by Hemagglutination;T pallidum Ab Titr CSF HA;;ACTIVE;2.22;2.70 +50696-4;Influenza virus A Ab.Neut;Prid;Pt;Ser;Nom;Neut;MICRO;1;Influenza virus A neutralizing antibody [Identifier] in Serum by Neutralization test;FLUAV NAb Ser Nt;;ACTIVE;2.22;2.72 +50697-2;Influenza virus A Ag;Prid;Pt;Isolate;Nom;;MICRO;1;Influenza virus A Ag [Identifier] in Isolate;FLUAV Ag Islt;;ACTIVE;2.22;2.22 +50698-0;Influenza virus A.adamantane resistance;PrThr;Pt;Isolate;Ord;Phenotyping;ABXBACT;1;Influenza virus A.adamantane resistance [Presence] by Phenotype method;FLUAV ADM resis Islt Ql Phenotyp;;ACTIVE;2.22;2.56 +50699-8;Influenza virus A.adamantane resistance;PrThr;Pt;Isolate;Ord;;ABXBACT;1;Influenza virus A.adamantane resistance [Presence];FLUAV ADM resis Islt Ql;;ACTIVE;2.22;2.56 +50700-4;Influenza virus A.adamantane resistant RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;ABXBACT;1;Influenza virus A.adamantane resistant RNA [Presence] by NAA with probe detection;FLUAV ADM resis RNA Islt Ql NAA+probe;;ACTIVE;2.22;2.63 +50701-2;Influenza virus A H1 Ag;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Influenza virus A H1 Ag [Presence] in Isolate by Immunofluorescence;FLUAV H1 Ag Islt Ql IF;;ACTIVE;2.22;2.56 +50702-0;Influenza virus A matrix protein RNA;PrThr;Pt;Isolate;Ord;Sequencing;MICRO;1;Influenza virus A matrix protein RNA [Presence] in Isolate by Sequencing;FLUAV MP RNA Islt Ql Seq;;DISCOURAGED;2.22;2.56 +50703-8;Influenza virus A.neuraminidase inhibitor resistance;Susc;Pt;Isolate;Ord;Phenotyping;ABXBACT;1;Influenza virus A.neuraminidase inhibitor resistance [Susceptibility] Qualitative by Phenotype method;FLUAV NI resis Islt Ql Phenotyp;;ACTIVE;2.22;2.29 +50704-6;Influenza virus A nucleoprotein RNA;PrThr;Pt;Isolate;Ord;Sequencing;MICRO;1;Influenza virus A nucleoprotein RNA [Presence] in Isolate by Sequencing;FLUAV NP RNA Islt Ql Seq;;DISCOURAGED;2.22;2.56 +50705-3;Influenza virus A non-structural protein RNA;PrThr;Pt;Isolate;Ord;Sequencing;MICRO;1;Influenza virus A non-structural protein RNA [Presence] in Isolate by Sequencing;FLUAV NS RNA Islt Ql Seq;;DISCOURAGED;2.22;2.56 +50706-1;Influenza virus A polymerase A RNA;PrThr;Pt;Isolate;Ord;Sequencing;MICRO;1;Influenza virus A polymerase A RNA [Presence] in Isolate by Sequencing;FLUAV PA RNA Islt Ql Seq;;DISCOURAGED;2.22;2.56 +50707-9;Influenza virus A polymerase B1 cDNA;PrThr;Pt;Isolate;Ord;Sequencing;MICRO;1;Influenza virus A polymerase B1 cDNA [Presence] in Isolate by Sequencing;FLUAV PB1 cDNA Islt Ql Seq;;DISCOURAGED;2.22;2.56 +5070-8;Brucella sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella sp IgM Ab [Units/volume] in Serum;Brucella IgM Ser-aCnc;;ACTIVE;1.0;2.73 +50708-7;Influenza virus A polymerase B2 RNA;PrThr;Pt;Isolate;Ord;Sequencing;MICRO;1;Influenza virus A polymerase B2 RNA [Presence] in Isolate by Sequencing;FLUAV PB2 RNA Islt Ql Seq;;DISCOURAGED;2.22;2.56 +50709-5;Influenza virus B Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus B Ab [Titer] in Serum by Hemagglutination inhibition;FLUBV Ab Titr Ser HAI;;ACTIVE;2.22;2.32 +50710-3;Influenza virus susceptibility panel;-;Pt;Isolate;-;;PANEL.ABXBACT;1;Influenza virus susceptibility panel;FLUV susc Pnl Islt;;ACTIVE;2.22;2.42 +50711-1;Influenza virus A polymerase RNA;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A polymerase RNA [Identifier] in Isolate by Sequencing;FLUAV polymerase RNA Islt Seq;;DISCOURAGED;2.22;2.40 +50712-9;Influenza virus.neuraminidase inhibitor resistance;Susc;Pt;Isolate;Ord;;ABXBACT;1;Influenza virus.neuraminidase inhibitor resistance [Susceptibility] Qualitative;FLUV NI resist Islt Ql;;ACTIVE;2.22;2.29 +50713-7;Influenza virus.neuraminidase inhibitor resistance;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Influenza virus.neuraminidase inhibitor resistance [Susceptibility] by Genotype method;FLUV NI resist Islt Genotyp;;ACTIVE;2.22;2.66 +50714-5;Rumex obtusifolius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bitter dock IgE Ab [Units/volume] in Serum;Bitter dock IgE Qn;;ACTIVE;2.22;2.42 +50715-2;Trisomy 21;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Trisomy 21 Narrative;Hx of Trisomy 21 Narr;;ACTIVE;2.22;2.73 +5071-6;Brucella suis Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Brucella suis Ab [Titer] in Serum by Latex agglutination;B suis Ab Titr Ser LA;;ACTIVE;1.0;2.70 +50716-0;11-Deoxycortisol^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;11DC sp7 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +50717-8;11-Deoxycortisol^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;11DC sp6 p chal SerPl-mCnc;;ACTIVE;2.22;2.70 +50718-6;11-Deoxycortisol^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;11DC sp5 p chal SerPl-mCnc;;ACTIVE;2.22;2.70 +50719-4;11-Deoxycortisol^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;11DC sp4 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +50720-2;11-Deoxycortisol^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;11DC sp3 p chal SerPl-mCnc;;ACTIVE;2.22;2.70 +50721-0;11-Deoxycortisol^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;11DC sp1 p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +50722-8;VKORC1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;VKORC1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;VKORC1 gene Mut Anl Bld/T;;ACTIVE;2.22;2.73 +50723-6;Cells.CD38+Lambda+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD38+ Lambda+ cells [#/volume] in Blood;CD38+ Lambda+ Cells # Bld;;ACTIVE;2.22;2.42 +5072-4;Brush border Ab;ACnc;Pt;Ser;Qn;;SERO;1;Brush border Ab [Units/volume] in Serum;Brush border Ab Ser-aCnc;;ACTIVE;1.0;2.69 +50724-4;Lymphoblasts/100 leukocytes;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Lymphoblasts/100 leukocytes in Bone marrow by Manual count;Lymphoblasts/leuk NFr Mar Manual;;ACTIVE;2.22;2.70 +50725-1;Monoblasts/100 leukocytes;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Monoblasts/100 leukocytes in Bone marrow by Manual count;Monoblasts/leuk NFr Mar Manual;;ACTIVE;2.22;2.70 +50726-9;Reticulum cell/100 cells;NFr;Pt;Bone mar;Qn;Gomori stain;HEM/BC;1;Reticulum cell/100 cells in Bone marrow by Gomori stain;Reticulum cell NFr Mar Gomori Stn;;ACTIVE;2.22;2.70 +50727-7;Serotonin release 100 IU/mL heparin.unfractionated;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 100 IU/mL heparin.unfractionated [Units/volume] in Serum;SRA 100IU/mL UFH Ser-aCnc;;ACTIVE;2.22;2.73 +50728-5;Serotonin release 0.1 IU/mL heparin.unfractionated;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 0.1 IU/mL heparin.unfractionated [Units/volume] in Serum;SRA 0.1IU/mL UFH Ser-aCnc;;ACTIVE;2.22;2.73 +50729-3;Serotonin release 100 U/mL heparin.porcine;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Serotonin release 100 U/mL heparin.porcine [Units/volume] in Serum;Deprecated SRA 100U/mL porcine heparin S;;DEPRECATED;2.22;2.70 +50730-1;Serotonin release 0.1 U/mL heparin.porcine;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Serotonin release 0.1 U/mL heparin.porcine [Units/volume] in Serum;Deprecated SRA 0.1U/mL porcine heparin S;;DEPRECATED;2.22;2.70 +50731-9;Serotonin release 100 IU/mL heparin.low molecular weight;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 100 IU/mL heparin.low molecular weight [Units/volume] in Serum;SRA 100IU/mL LMW heparin Ser-aCnc;;DISCOURAGED;2.22;2.70 +5073-2;La Crosse virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;La Crosse virus Ab [Units/volume] in Serum;LACV Ab Ser-aCnc;;ACTIVE;1.0;2.69 +50732-7;Serotonin release 0.1 IU/mL heparin.low molecular weight;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 0.1 U/mL heparin.low molecular weight [Units/volume] in Serum;SRA 0.1U/mL LMW heparin Ser-a;;DISCOURAGED;2.22;2.73 +50733-5;Serotonin release interpretation;Imp;Pt;Ser;Nom;;SERO;1;Serotonin release interpretation in Serum;SRA interp Ser-Imp;;ACTIVE;2.22;2.73 +50734-3;Serotonin release.heparin.porcine interpretation;Imp;Pt;Ser;Nom;;SERO;1;Serotonin release.heparin.porcine in Serum;SRA porcine interp Ser-Imp;;ACTIVE;2.22;2.73 +50735-0;Serotonin release.heparin.low molecular weight interpretation;Imp;Pt;Ser;Nom;;SERO;1;Serotonin release.heparin.low molecular weight in Serum;SRA LMW interp Ser-Imp;;DISCOURAGED;2.22;2.73 +50736-8;Serotonin release.heparin.unfractionated panel;-;Pt;Ser;-;;PANEL.SERO;1;Serotonin release.heparin.unfractionated panel - Serum;SRA UFH Pnl Ser;;ACTIVE;2.22;2.52 +50737-6;Serotonin release.heparin.porcine panel;-;Pt;Ser;-;;PANEL.SERO;1;Serotonin release.heparin.porcine panel - Serum;SRA porcine Pnl Ser;;ACTIVE;2.22;2.42 +50738-4;Serotonin release.heparin.low molecular weight panel;-;Pt;Ser;-;;PANEL.SERO;1;Serotonin release.heparin.low molecular weight panel - Serum;SRA LMW Pnl Ser;;DISCOURAGED;2.22;2.52 +50739-2;Serotonin release.heparin.porcine & low molecular weight panel;-;Pt;Ser;-;;PANEL.SERO;1;Serotonin release.heparin.porcine and low molecular weight panel - Serum;SRA porcine+LMW Pnl Ser;;ACTIVE;2.22;2.42 +507-4;Tobramycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Tobramycin [Susceptibility] by Minimum lethal concentration (MLC);Tobramycin Islt MLC;;ACTIVE;1.0;2.19 +5074-0;Candida albicans Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Candida albicans Ab [Presence] in Serum by Immune diffusion (ID);C albicans Ab Ser Ql ID;;ACTIVE;1.0;2.73 +50740-0;Guaranteed analysis of feed section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Guaranteed analysis of feed section;FDA label Guaranteed anl of feed;;ACTIVE;2.22;2.63 +50741-8;Safe handling warning section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Safe handling warning section;FDA label Safe handling warning;;ACTIVE;2.22;2.34 +50742-6;Environmental warning section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Environmental warning section;FDA label Environmental warning;;ACTIVE;2.22;2.34 +50743-4;Food safety warning section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Food safety warning section;FDA label Food safety warning;;ACTIVE;2.22;2.34 +50744-2;Information for owners or caregivers section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Information for owners or caregivers section;FDA label Info for owners/caregivers;;ACTIVE;2.22;2.34 +50745-9;Veterinary indications section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Veterinary indications section;FDA label Veterinary indications;;ACTIVE;2.22;2.34 +50746-7;Hirudin;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Hirudin [Units/volume] in Platelet poor plasma by Chromogenic method;Hirudin PPP Chro-aCnc;;ACTIVE;2.22;2.69 +50747-5;Platelet factor 4 Ag;PrThr;Pt;PPP;Ord;IA;COAG;1;Platelet factor 4 Ag [Presence] in Platelet poor plasma by Immunoassay;PF4 Ag PPP Ql IA;;ACTIVE;2.22;2.73 +50748-3;Alpha-2-Macroglobulin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha-2-Macroglobulin/Creatinine [Mass Ratio] in Urine;A2 Macroglob/Creat Ur;;ACTIVE;2.22;2.44 +50749-1;Protein;Imp;Pt;Urine;Nom;;CHEM;1;Protein [Interpretation] in Urine;Prot Ur-Imp;;ACTIVE;2.22;2.73 +50750-9;F13A1 gene.p.Val34Leu;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;F13A1 gene p.Val34Leu [Presence] in Blood or Tissue by Molecular genetics method;F13A1 p.V34L Bld/T Ql;;ACTIVE;2.22;2.73 +50751-7;Glucose^15M post 0.1 U/kg insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 minutes post 0.1 U/kg insulin;Glucose 15M p 0.1 U/kg Ins SerPl-mCnc;;ACTIVE;2.22;2.34 +50752-5;Cortisol^15M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --15 minutes post dose insulin IV;Cortis 15M p Ins IV SerPl-mCnc;;ACTIVE;2.22;2.40 +50753-3;Somatotropin^15M post dose insulin IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15 minutes post dose insulin IV;GH 15M p Ins IV SerPl-mCnc;;ACTIVE;2.22;2.40 +50754-1;Coagulation surface induced;Time;Pt;PPP^Pool;Qn;Coag;COAG;1;aPTT in Pooled Platelet poor plasma by Coagulation assay;aPTT Pool PPP;;ACTIVE;2.22;2.73 +50755-8;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral;Doc;CT;RAD;2;CT Lower extremity - bilateral W contrast IV;CT LE-Bl W contr IV;;ACTIVE;2.22;2.61 +50756-6;Creatine kinase;MCnc;Pt;Bld;Qn;;CHEM;1;Creatine kinase [Mass/volume] in Blood;CK Bld-mCnc;;DISCOURAGED;2.22;2.34 +5075-7;Candida albicans Ag;Titr;Pt;Ser;Qn;LA;MICRO;1;Candida albicans Ag [Titer] in Serum by Latex agglutination;C albicans Ag Titr Ser LA;;ACTIVE;1.0;2.73 +50757-4;Creatine kinase.total/Creatine kinase.MB;CRto;Pt;Bld;Qn;;CHEM;1;Creatine kinase.total/Creatine kinase.MB [Enzymatic activity ratio] in Blood;CK/CK MB Bld-cRto;;ACTIVE;2.22;2.44 +50758-2;Herpes simplex virus 1 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus 1 IgM Ab [Titer] in Serum by Immunofluorescence;HSV1 IgM Titr Ser IF;;ACTIVE;2.22;2.73 +50759-0;Beta-N-acetylhexosaminidase.A;CCnt;Pt;WBC;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A [Enzymatic activity/mass] in Leukocytes;Hexosaminidase A WBC-cCnt;;ACTIVE;2.22;2.42 +50760-8;Coagulation surface induced.lupus sensitive.factor substitution^1H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with normal plasma;aPTT-LA 1h NP PPP;;DISCOURAGED;2.22;2.73 +50761-6;A Ab.IgG;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;A IgG Ab [Titer] in Serum or Plasma;A IgG Titr SerPl;;ACTIVE;2.22;2.73 +50762-4;A Ab.IgM;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;A IgM Ab [Titer] in Serum or Plasma;A IgM Titr SerPl;;ACTIVE;2.22;2.73 +50763-2;B Ab.IgM;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;B IgM Ab [Titer] in Serum or Plasma;B IgM Titr SerPl;;ACTIVE;2.22;2.73 +50764-0;B Ab.IgG;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;B IgG Ab [Titer] in Serum or Plasma;B IgG Titr SerPl;;ACTIVE;2.22;2.73 +5076-5;Cardiolipin Ab.IgA;ACnc;Pt;Ser;Qn;IA;COAG;1;Cardiolipin IgA Ab [Units/volume] in Serum by Immunoassay;Cardiolipin IgA Ser IA-aCnc;;ACTIVE;1.0;2.73 +50765-7;Hemoglobin Hasharon/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin Hasharon/Hemoglobin.total in Blood by Electrophoresis;Hgb Hashar MFr Bld Elph;;ACTIVE;2.22;2.73 +50766-5;Fungus identified ^^^8;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus # 8 identified in Specimen by Culture;Fungus Spec Cult org #8;;ACTIVE;2.22;2.69 +50767-3;Ganglioside GD1a Ab.IgG/Ganglioside GD1a Ab.IgM;Ratio;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1a IgG Ab/IgM Ab [Ratio] in Serum by Immunoassay;GD1a Gangl IgG/IgM Ser IA-Rto;;ACTIVE;2.22;2.73 +50768-1;Ganglioside GD1b Ab.IgG/Ganglioside GD1b Ab.IgM;Ratio;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1b IgG Ab/IgM Ab [Ratio] in Serum by Immunoassay;GD1b Gangl IgG/IgM Ser IA-Rto;;ACTIVE;2.22;2.73 +50769-9;Asialoganglioside GM1 Ab.IgG/Asialoganglioside GM1 Ab.IgM;Ratio;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgG Ab/IgM Ab [Ratio] in Serum by Immunoassay;GM1 Asialo IgG/IgM Ser IA-Rto;;ACTIVE;2.22;2.73 +50770-7;Ganglioside GM1 Ab.IgG/Ganglioside GM1 Ab.IgM;Ratio;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 IgG Ab/IgM Ab [Ratio] in Serum by Immunoassay;GM1 Gangl IgG/IgM Ser IA-Rto;;ACTIVE;2.22;2.73 +50771-5;Ganglioside GM2 Ab.IgG/Ganglioside GM2 Ab.IgM;Ratio;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM2 IgG Ab/IgM Ab [Ratio] in Serum by Immunoassay;GM2 Gangl IgG/IgM Ser IA-Rto;;ACTIVE;2.22;2.73 +50772-3;Ganglioside GQ1b Ab.IgG/Ganglioside GQ1b Ab.IgM;Ratio;Pt;Ser;Qn;IA;SERO;1;Ganglioside GQ1b IgG Ab/IgM Ab [Ratio] in Serum by Immunoassay;GQ1b Gangl IgG/IgM Ser IA-Rto;;ACTIVE;2.22;2.73 +5077-3;Centromere Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Centromere Ab [Titer] in Serum by Immunofluorescence;Centromere Ab Titr Ser IF;;ACTIVE;1.0;2.73 +50773-1;ABO & Rh group^post transfusion reaction;Type;Pt;Bld^Newborn;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood from Newborn--after transfusion reaction;ABO + Rh p transf rx Bld NB;;ACTIVE;2.22;2.72 +50774-9;Nucleated cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Nucleated cells [#/volume] in Blood;Nuc cell # Bld;;ACTIVE;2.22;2.73 +50775-6;Cancer Ag 125;ACnc;Pt;CSF;Qn;;CHEM;1;Cancer Ag 125 [Units/volume] in Cerebral spinal fluid;Cancer Ag125 CSF-aCnc;;ACTIVE;2.22;2.68 +50776-4;Cancer Ag 15-3;ACnc;Pt;CSF;Qn;;CHEM;1;Cancer Ag 15-3 [Units/volume] in Cerebral spinal fluid;Cancer Ag15-3 CSF-aCnc;;ACTIVE;2.22;2.68 +50777-2;Cancer Ag 15-3;ACnc;Pt;Pericard fld;Qn;;CHEM;1;Cancer Ag 15-3 [Units/volume] in Pericardial fluid;Cancer Ag15-3 Pcar-aCnc;;ACTIVE;2.22;2.68 +50778-0;Cancer Ag 15-3;ACnc;Pt;Periton fld;Qn;;CHEM;1;Cancer Ag 15-3 [Units/volume] in Peritoneal fluid;Cancer Ag15-3 Prt-aCnc;;ACTIVE;2.22;2.68 +50779-8;Cancer Ag 19-9;ACnc;Pt;CSF;Qn;;CHEM;1;Cancer Ag 19-9 [Units/volume] in Cerebral spinal fluid;Cancer Ag19-9 CSF-aCnc;;ACTIVE;2.22;2.73 +50780-6;Cancer Ag 19-9;ACnc;Pt;Pericard fld;Qn;;CHEM;1;Cancer Ag 19-9 [Units/volume] in Pericardial fluid;Cancer Ag19-9 Pcar-aCnc;;ACTIVE;2.22;2.73 +5078-1;Chlamydophila pneumoniae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila pneumoniae Ab [Units/volume] in Serum;C pneum Ab Ser-aCnc;;ACTIVE;1.0;2.73 +50781-4;Cancer Ag 19-9;ACnc;Pt;Periton fld;Qn;;CHEM;1;Cancer Ag 19-9 [Units/volume] in Peritoneal fluid;Cancer Ag19-9 Prt-aCnc;;ACTIVE;2.22;2.73 +50782-2;Cancer Ag 27-29;ACnc;Pt;CSF;Qn;;CHEM;1;Cancer Ag 27-29 [Units/volume] in Cerebral spinal fluid;Cancer Ag27-29 CSF-aCnc;;ACTIVE;2.22;2.73 +50783-0;Cells.CD15 actual/normal;RelACnc;Pt;Bld;Qn;;CELLMARK;1;CD15 cells actual/normal in Blood;CD15 Cells Act/Nor Bld;;ACTIVE;2.22;2.73 +50784-8;Cells.CD16 actual/normal;RelACnc;Pt;Bld;Qn;;CELLMARK;1;CD16 cells actual/normal in Blood;CD16 Cells Act/Nor Bld;;ACTIVE;2.22;2.70 +50785-5;Cells.CD18 actual/normal;RelACnc;Pt;Bld;Qn;;CELLMARK;1;CD18 cells actual/normal in Blood;CD18 Cells Act/Nor Bld;;ACTIVE;2.22;2.73 +50786-3;Date of entry;TmStp;Pt;^Patient;Qn;;SURVEY.CMS;4;Date of entry;;;ACTIVE;2.22;2.63 +50787-1;Primary reason for assessment;Type;Pt;^Patient;Nom;MDS.full;SURVEY.MDS;4;Primary reason for assessment [Minimum Data Set (MDS) full];;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.22;2.50 +50788-9;Cytokeratin cells/100 cells;NFr;Pt;Bld;Qn;;HEM/BC;1;Cytokeratin cells/100 cells in Blood;Cytokeratin cells NFr Bld;;ACTIVE;2.22;2.73 +50789-7;Cytokeratin cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Cytokeratin cells [#/volume] in Blood;Cytokeratin cells # Bld;;ACTIVE;2.22;2.70 +50790-5;HIV 1 RNA tropism;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV 1 RNA tropism [Identifier];HIV1 RNA tropism Islt;;ACTIVE;2.22;2.73 +50791-3;Hemoglobin pattern;Imp;Pt;Bld;Nom;Electrophoresis pH 6.0;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by Electrophoresis acid (pH 6.0);Hgb Fract Bld Elph pH6.0-Imp;;ACTIVE;2.22;2.73 +50792-1;Protein.monoclonal band 3/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 3/Protein.total in Serum or Plasma by Electrophoresis;M Protein 3 MFr SerPl Elph;;ACTIVE;2.22;2.73 +50793-9;Protein.monoclonal band 4/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 4/Protein.total in Serum or Plasma by Electrophoresis;M Protein 4 MFr SerPl Elph;;ACTIVE;2.22;2.30 +50794-7;Osmotic fragility.beginning hemolysis;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility beginning hemolysis of Red Blood Cells;OF start NFr RBC;;ACTIVE;2.22;2.70 +50795-4;Osmotic fragility.full hemolysis;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility full hemolysis of Red Blood Cells;OF full NFr RBC;;ACTIVE;2.22;2.34 +50796-2;Protein.monoclonal band 3;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis;M Protein 3 SerPl Elph-mCnc;;ACTIVE;2.22;2.73 +50797-0;Protein.monoclonal band 4;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis;M Protein 4 SerPl Elph-mCnc;;ACTIVE;2.22;2.73 +50798-8;17-Ketogenic steroids;SCnc;24H;Urine;Qn;;CHEM;1;17-Ketogenic steroids [Moles/volume] in 24 hour Urine;17KGS 24h Ur-sCnc;;ACTIVE;2.22;2.70 +5079-9;Chlamydophila psittaci Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation;C psittaci Ab Titr Ser CF;;ACTIVE;1.0;2.73 +50799-6;7-Dehydrocholesterol;SCnc;Pt;Body fld;Qn;;CHEM;1;7-Dehydrocholesterol [Moles/volume] in Body fluid;7-DHC Fld-sCnc;;ACTIVE;2.22;2.70 +50800-2;Acetone;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acetone [Moles/volume] in Body fluid;Acetone Fld-sCnc;;ACTIVE;2.22;2.70 +50801-0;Aluminum;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Aluminum [Moles/mass] in Hair;Aluminum Hair-sCnt;;ACTIVE;2.22;2.70 +50802-8;Amikacin^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Moles/volume] in Serum or Plasma --peak;Amikacin Peak SerPl-sCnc;;ACTIVE;2.22;2.70 +50803-6;Amikacin^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Moles/volume] in Serum or Plasma --trough;Amikacin Trough SerPl-sCnc;;ACTIVE;2.22;2.70 +50804-4;Amitriptyline;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amitriptyline [Moles/volume] in Urine;Amitrip Ur-sCnc;;ACTIVE;2.22;2.70 +50805-1;Amitriptyline;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Amitriptyline [Moles/volume] in Gastric fluid;Amitrip Gast-sCnc;;ACTIVE;2.22;2.70 +50806-9;Antimony;SRat;24H;Urine;Qn;;DRUG/TOX;1;Antimony [Moles/time] in 24 hour Urine;Antimony 24h Ur-sRate;;ACTIVE;2.22;2.70 +5080-7;Chlamydophila psittaci Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci IgG Ab [Units/volume] in Serum;C psittaci IgG Ser-aCnc;;ACTIVE;1.0;2.73 +50807-7;Antimony;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Antimony [Moles/volume] in Urine;Antimony Ur-sCnc;;ACTIVE;2.22;2.70 +50808-5;Antimony;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Antimony [Moles/volume] in 24 hour Urine;Antimony 24h Ur-sCnc;;ACTIVE;2.22;2.70 +50809-3;Antimony;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Antimony [Moles/volume] in Blood;Antimony Bld-sCnc;;ACTIVE;2.22;2.70 +50810-1;Antimony;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Antimony [Moles/mass] in Hair;Antimony Hair-sCnt;;ACTIVE;2.22;2.70 +50811-9;Antimony;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Antimony [Moles/volume] in Red Blood Cells;Antimony RBC-sCnc;;ACTIVE;2.22;2.70 +50812-7;Arsenic;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Arsenic [Moles/volume] in Red Blood Cells;Arsenic RBC-sCnc;;ACTIVE;2.22;2.70 +50813-5;Arsenic;SCnt;Pt;Nail;Qn;;DRUG/TOX;1;Arsenic [Moles/mass] in Nail;Arsenic Nail-sCnt;;ACTIVE;2.22;2.70 +50814-3;Arsenic.inorganic;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic [Moles/volume] in Urine;Inorg Arsenic Ur-sCnc;;ACTIVE;2.22;2.70 +5081-5;Chlamydophila psittaci Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci IgM Ab [Units/volume] in Serum;C psittaci IgM Ser-aCnc;;ACTIVE;1.0;2.73 +50815-0;Arsenic.inorganic;SRat;24H;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic [Moles/time] in 24 hour Urine;Inorg Arsenic 24h Ur-sRate;;ACTIVE;2.22;2.70 +50816-8;Arsenic.organic;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic organic [Moles/volume] in Urine;Arsenic organic Ur-sCnc;;ACTIVE;2.22;2.73 +50817-6;Arsenic/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Arsenic/Creatinine [Molar ratio] in 24 hour Urine;Arsenic/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50818-4;Barium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Barium [Moles/mass] in Hair;Barium Hair-sCnt;;ACTIVE;2.22;2.70 +50819-2;Barium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Barium [Moles/time] in 24 hour Urine;Barium 24h Ur-sRate;;ACTIVE;2.22;2.70 +508-2;Tobramycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tobramycin [Susceptibility] by Minimum inhibitory concentration (MIC);Tobramycin Islt MIC;;ACTIVE;1.0;2.73 +50820-0;Base excess;SCnc;Pt;BldC^Fetus;Qn;Calculated;CHEM;1;Base excess in Capillary blood from Fetus by calculation;Base excess BldC Fetus Calc-sCnc;;ACTIVE;2.22;2.70 +50821-8;Beryllium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Beryllium [Moles/volume] in Urine;Beryllium Ur-sCnc;;ACTIVE;2.22;2.70 +50822-6;Beryllium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Beryllium [Moles/time] in 24 hour Urine;Beryllium 24h Ur-sRate;;ACTIVE;2.22;2.70 +5082-3;Chlamydia sp Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia sp Ab [Units/volume] in Serum by Immunoassay;Chlamydia Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +50823-4;Beryllium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Beryllium [Moles/mass] in Hair;Beryllium Hair-sCnt;;ACTIVE;2.22;2.70 +50824-2;Beta-2-Microglobulin;SCnc;24H;Urine;Qn;;CHEM;1;Beta-2-Microglobulin [Moles/volume] in 24 hour Urine;B2 Microglob 24h Ur-sCnc;;ACTIVE;2.22;2.70 +50825-9;Bile acid;SCnc;Pt;Body fld;Qn;;CHEM;1;Bile acid [Moles/volume] in Body fluid;Bile Ac Fld-sCnc;;ACTIVE;2.22;2.70 +50826-7;Bismuth;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Bismuth [Moles/mass] in Hair;Bismuth Hair-sCnt;;ACTIVE;2.22;2.70 +50827-5;Boron;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Boron [Moles/volume] in Body fluid;Boron Fld-sCnc;;ACTIVE;2.22;2.70 +50828-3;Boron;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Boron [Moles/mass] in Hair;Boron Hair-sCnt;;ACTIVE;2.22;2.70 +50829-1;Boron;SRat;24H;Urine;Qn;;DRUG/TOX;1;Boron [Moles/time] in 24 hour Urine;Boron 24h Ur-sRate;;ACTIVE;2.22;2.70 +50830-9;Boron;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Boron [Moles/volume] in Urine;Boron Ur-sCnc;;ACTIVE;2.22;2.70 +5083-1;Chlamydia sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Chlamydia sp Ab [Titer] in Serum by Complement fixation;Chlamydia Ab Titr Ser CF;;ACTIVE;1.0;2.73 +50831-7;Boron/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Boron/Creatinine [Molar ratio] in 24 hour Urine;Boron/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50832-5;Boron/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Boron/Creatinine [Molar ratio] in Urine;Boron/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50833-3;Cadmium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cadmium [Moles/mass] in Hair;Cadmium Hair-sCnt;;ACTIVE;2.22;2.70 +50834-1;Cadmium;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Cadmium [Moles/volume] in Red Blood Cells;Cadmium RBC-sCnc;;ACTIVE;2.22;2.70 +50835-8;Cadmium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Cadmium/Creatinine [Molar ratio] in 24 hour Urine;Cadmium/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50836-6;Calcium;SCnt;Pt;Hair;Qn;;CHEM;1;Calcium [Moles/mass] in Hair;Calcium Hair-sCnt;;ACTIVE;2.22;2.70 +50837-4;Calcium.ionized;SCnc;Pt;Body fld;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Body fluid;Ca-I Fld-sCnc;;ACTIVE;2.22;2.70 +50838-2;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;Body fld;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Body fluid;Ca-I adj pH7.4 Fld-sCnc;;ACTIVE;2.22;2.70 +50839-0;Calcium/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Calcium/Creatinine [Molar ratio] in 24 hour Urine;Calcium/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50840-8;Cholesterol.in HDL;SCnc;Pt;Body fld;Qn;;CHEM;1;Cholesterol in HDL [Moles/volume] in Body fluid;HDLc Fld-sCnc;;ACTIVE;2.22;2.70 +50841-6;Chromium;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Chromium [Moles/volume] in Red Blood Cells;Chromium RBC-sCnc;;ACTIVE;2.22;2.70 +50842-4;Chromium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Chromium [Moles/mass] in Hair;Chromium Hair-sCnt;;ACTIVE;2.22;2.70 +50843-2;clonazePAM;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;clonazePAM [Moles/volume] in Urine;clonazePAM Ur-sCnc;;ACTIVE;2.22;2.70 +50844-0;cloZAPine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;cloZAPine [Moles/volume] in Urine;cloZAPine Ur-sCnc;;ACTIVE;2.22;2.70 +50845-7;Cobalt;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cobalt [Moles/mass] in Hair;Cobalt Hair-sCnt;;ACTIVE;2.22;2.70 +50846-5;Cobalt;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Cobalt [Moles/mass] in Tissue;Cobalt Tiss-sCnt;;ACTIVE;2.22;2.70 +50847-3;Cobalt;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Cobalt [Moles/volume] in Red Blood Cells;Cobalt RBC-sCnc;;ACTIVE;2.22;2.70 +50848-1;Cortisol;SCnc;24H;Urine;Qn;;CHEM;1;Cortisol [Moles/volume] in 24 hour Urine;Cortis 24h Ur-sCnc;;ACTIVE;2.22;2.70 +5084-9;Chlamydia sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia sp Ab [Titer] in Serum by Immunofluorescence;Chlamydia Ab Titr Ser IF;;ACTIVE;1.0;2.73 +50849-9;Diazepam+Nordiazepam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;diazePAM+Nordiazepam [Moles/volume] in Serum or Plasma;diazePAM+Nor SerPl-sCnc;;ACTIVE;2.22;2.70 +50850-7;Fluoride/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Fluoride/Creatinine [Molar ratio] in Urine;Fluoride/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50851-5;Germanium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Germanium [Moles/mass] in Hair;Germanium Hair-sCnt;;ACTIVE;2.22;2.70 +50852-3;Gold;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Gold [Moles/volume] in 24 hour Urine;Gold 24h Ur-sCnc;;ACTIVE;2.22;2.70 +50853-1;Heptacarboxylporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin [Moles/mass] in Stool;Hepta-CP Stl-sCnt;;ACTIVE;2.22;2.70 +50854-9;Heptaporphyrin;SRat;24H;Urine;Qn;;CHEM;1;Deprecated Heptaporphyrin [Moles/time] in 24 hour Urine;Deprecated Heptapor 24h Ur-sRate;;DEPRECATED;2.22;2.70 +50855-6;Hexacarboxylporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin [Moles/mass] in Stool;Hexa-CP Stl-sCnt;;ACTIVE;2.22;2.70 +5085-6;Chlamydia sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Serum;Chlamydia IgG Ser-aCnc;;ACTIVE;1.0;2.73 +50856-4;Hexaporphyrin;SRat;24H;Urine;Qn;;CHEM;1;Deprecated Hexaporphyrin [Moles/time] in 24 hour Urine;Deprecated Hexapor 24h Ur-sRate;;DEPRECATED;2.22;2.70 +50857-2;Histamine;SCnc;3H;Urine;Qn;;DRUG/TOX;1;Histamine [Moles/volume] in 3 hour Urine;Histamine 3h Ur-sCnc;;ACTIVE;2.22;2.70 +50858-0;Hydrogen ion;SCnc;Pt;BldCoMV;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Mixed venous cord blood;H ion BldCoMV-sCnc;;ACTIVE;2.22;2.70 +50859-8;Hydrogen ion;SCnc;Pt;BldCoV;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Venous cord blood;H ion BldCoV-sCnc;;ACTIVE;2.22;2.70 +50860-6;Hydrogen ion;SCnc;Pt;BldCoA;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Arterial cord blood;H ion BldCoA-sCnc;;ACTIVE;2.22;2.70 +50861-4;Hydrogen ion;SCnc;Pt;BldC;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Capillary blood;H ion BldC-sCnc;;ACTIVE;2.22;2.70 +50862-2;Hydrogen ion;SCnc;Pt;BldCo;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Cord blood;H ion BldCo-sCnc;;ACTIVE;2.22;2.70 +50863-0;Hydrogen ion;SCnc;Pt;Bld;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Blood;H ion Bld-sCnc;;ACTIVE;2.22;2.70 +5086-4;Chlamydia sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia sp IgM Ab [Units/volume] in Serum;Chlamydia IgM Ser-aCnc;;ACTIVE;1.0;2.69 +50864-8;Hydrogen ion;SCnc;Pt;BldV;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Venous blood;H ion BldV-sCnc;;ACTIVE;2.22;2.70 +50865-5;Hydrogen ion;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Serum or Plasma;H ion SerPl-sCnc;;ACTIVE;2.22;2.70 +50866-3;Indicans/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Indicans/Creatinine [Molar ratio] in Urine;Indicans/Creat Ur-sRto;;ACTIVE;2.22;2.70 +50867-1;Insulin;SCnc;Pt;Body fld;Qn;;CHEM;1;Insulin [Moles/volume] in Body fluid;Insulin Fld-sCnc;;ACTIVE;2.22;2.70 +50868-9;Iodine;SCnt;Pt;Hair;Qn;;CHEM;1;Iodine [Moles/mass] in Hair;Iodine Hair-sCnt;;ACTIVE;2.22;2.70 +50869-7;Iron;SCnt;Pt;Hair;Qn;;CHEM;1;Iron [Moles/mass] in Hair;Iron Hair-sCnt;;ACTIVE;2.22;2.70 +50870-5;Isopropanol;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Isopropanol [Moles/volume] in Body fluid;Isopropanol Fld-sCnc;;ACTIVE;2.22;2.70 +50871-3;Lead;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Lead [Moles/mass] in Hair;Lead Hair-sCnt;;ACTIVE;2.22;2.70 +5087-2;Chlamydia trachomatis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Chlamydia trachomatis Ab [Titer] in Serum by Complement fixation;C trach Ab Titr Ser CF;;ACTIVE;1.0;2.70 +50872-1;Lithium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Lithium [Moles/mass] in Hair;Lithium Hair-sCnt;;ACTIVE;2.22;2.70 +50873-9;Magnesium/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Magnesium/Creatinine [Molar ratio] in 24 hour Urine;Magnesium/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50874-7;Manganese;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Manganese [Moles/mass] in Hair;Manganese Hair-sCnt;;ACTIVE;2.22;2.70 +50875-4;Manganese;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Manganese [Moles/volume] in Red Blood Cells;Manganese RBC-sCnc;;ACTIVE;2.22;2.70 +50876-2;Mercury;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Mercury [Moles/mass] in Hair;Mercury Hair-sCnt;;ACTIVE;2.22;2.70 +50877-0;Mercury;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Mercury [Moles/mass] in Tissue;Mercury Tiss-sCnt;;ACTIVE;2.22;2.70 +50878-8;Mercury;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Red Blood Cells;Mercury RBC-sCnc;;ACTIVE;2.22;2.70 +50879-6;Methyl ethyl ketone;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Methyl ethyl ketone [Moles/volume] in Body fluid;MEK Fld-sCnc;;ACTIVE;2.22;2.70 +5088-0;Chlamydia trachomatis Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis Ab [Titer] in Serum by Immunofluorescence;C trach Ab Titr Ser IF;;ACTIVE;1.0;2.73 +50880-4;Methyl ethyl ketone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyl ethyl ketone [Moles/volume] in Serum or Plasma;MEK SerPl-sCnc;;ACTIVE;2.22;2.70 +50881-2;Molybdenum;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Molybdenum [Moles/mass] in Hair;Molybdenum Hair-sCnt;;ACTIVE;2.22;2.70 +50882-0;Molybdenum;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Molybdenum [Moles/volume] in Urine;Molybdenum Ur-sCnc;;ACTIVE;2.22;2.70 +50883-8;Molybdenum;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Molybdenum [Moles/volume] in Red Blood Cells;Molybdenum RBC-sCnc;;ACTIVE;2.22;2.70 +50884-6;Molybdenum;SRat;24H;Urine;Qn;;DRUG/TOX;1;Molybdenum [Moles/time] in 24 hour Urine;Molybdenum 24h Ur-sRate;;ACTIVE;2.22;2.70 +50885-3;Naproxen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Naproxen [Moles/volume] in Serum or Plasma;Naproxen SerPl-sCnc;;ACTIVE;2.22;2.70 +50886-1;Nickel;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Nickel [Moles/mass] in Tissue;Nickel Tiss-sCnt;;ACTIVE;2.22;2.70 +50887-9;Nickel;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Nickel [Moles/volume] in Red Blood Cells;Nickel RBC-sCnc;;ACTIVE;2.22;2.70 +50888-7;Nitrogen;SRat;24H;Body fld;Qn;;CHEM;1;Nitrogen [Moles/time] in 24 hour Body fluid;N2 24h Fld-sRate;;ACTIVE;2.22;2.70 +50889-5;Nitrogen;SCnc;24H;Urine;Qn;;CHEM;1;Nitrogen [Moles/volume] in 24 hour Urine;N2 24h Ur-sCnc;;ACTIVE;2.22;2.70 +50890-3;Norclozapine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norclozapine [Moles/volume] in Urine;Norclozapine Ur-sCnc;;ACTIVE;2.22;2.70 +50891-1;OLANZapine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;OLANZapine [Moles/volume] in Urine;OLANZapine Ur-sCnc;;ACTIVE;2.22;2.70 +50892-9;Palladium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Palladium [Moles/mass] in Hair;Palladium Hair-sCnt;;ACTIVE;2.22;2.70 +50893-7;Paraquat;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Paraquat [Moles/volume] in Serum or Plasma;Paraquat SerPl-sCnc;;ACTIVE;2.22;2.70 +50894-5;Pentacarboxylporphyrins;SCnt;Pt;Stool;Qn;;CHEM;1;Pentacarboxylporphyrins [Moles/mass] in Stool;Penta-CP Stl-sCnt;;ACTIVE;2.22;2.70 +50895-2;pH;LsCnc;Pt;Plr fld;Qn;Test strip;CHEM;1;pH of Pleural fluid by Test strip;pH Plr Strip;;ACTIVE;2.22;2.42 +50896-0;pH;LsCnc;Pt;Body fld;Qn;Test strip;CHEM;1;pH of Body fluid by Test strip;pH Fld Strip;;ACTIVE;2.22;2.73 +50897-8;pH;LsCnc;24H;Urine;Qn;Test strip;CHEM;1;pH of 24 hour Urine by Test strip;pH 24h Ur Strip;;ACTIVE;2.22;2.73 +5089-8;Chlamydia trachomatis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis IgG Ab [Units/volume] in Serum;C trach IgG Ser-aCnc;;ACTIVE;1.0;2.73 +50898-6;Phosphate;SCnt;Pt;Hair;Qn;;CHEM;1;Phosphate [Moles/mass] in Hair;Phosphate Hair-sCnt;;ACTIVE;2.22;2.70 +50899-4;Platinum;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Platinum [Moles/mass] in Tissue;Platinum Tiss-sCnt;;ACTIVE;2.22;2.70 +509-0;Tobramycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tobramycin [Susceptibility] by Disk diffusion (KB);Tobramycin Islt KB;;ACTIVE;1.0;2.73 +50900-0;Platinum;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Platinum [Moles/mass] in Hair;Platinum Hair-sCnt;;ACTIVE;2.22;2.70 +50901-8;Porphyrins;SCnc;24H;Urine;Qn;;CHEM;1;Porphyrins [Moles/volume] in 24 hour Urine;Porphyrins 24h Ur-sCnc;;ACTIVE;2.22;2.70 +50902-6;Potassium;SCnt;Pt;Hair;Qn;;CHEM;1;Potassium [Moles/mass] in Hair;Potassium Hair-sCnt;;ACTIVE;2.22;2.70 +50903-4;Selenium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Selenium [Moles/volume] in Urine;Selenium Ur-sCnc;;ACTIVE;2.22;2.70 +50904-2;Selenium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Selenium [Moles/mass] in Hair;Selenium Hair-sCnt;;ACTIVE;2.22;2.70 +50905-9;Silicon;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Silicon [Moles/mass] in Hair;Silicon Hair-sCnt;;ACTIVE;2.22;2.70 +5090-6;Chlamydia trachomatis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis IgM Ab [Units/volume] in Serum;C trach IgM Ser-aCnc;;ACTIVE;1.0;2.73 +50906-7;Silicon;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Silicon [Moles/volume] in Urine;Silicon Ur-sCnc;;ACTIVE;2.22;2.70 +50907-5;Silicon;SRat;24H;Urine;Qn;;DRUG/TOX;1;Silicon [Moles/time] in 24 hour Urine;Silicon 24h Ur-sRate;;ACTIVE;2.22;2.70 +50908-3;Silver;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Silver [Moles/mass] in Hair;Silver Hair-sCnt;;ACTIVE;2.22;2.70 +50909-1;Silver;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Silver [Moles/volume] in Urine;Silver Ur-sCnc;;ACTIVE;2.22;2.70 +50910-9;Silver;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Silver [Moles/volume] in 24 hour Urine;Silver 24h Ur-sCnc;;ACTIVE;2.22;2.70 +50911-7;Sodium;SCnc;Pt;Gast fld;Qn;;CHEM;1;Sodium [Moles/volume] in Gastric fluid;Sodium Gast-sCnc;;ACTIVE;2.22;2.70 +50912-5;Sodium;SCnt;Pt;Hair;Qn;;CHEM;1;Sodium [Moles/mass] in Hair;Sodium Hair-sCnt;;ACTIVE;2.22;2.70 +50913-3;Strontium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Strontium [Moles/mass] in Hair;Strontium Hair-sCnt;;ACTIVE;2.22;2.70 +5091-4;Chymotrypsin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Chymotrypsin Ab [Units/volume] in Serum;Chymotryp Ab Ser-aCnc;;ACTIVE;1.0;2.73 +50914-1;Strontium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Strontium [Moles/volume] in Urine;Strontium Ur-sCnc;;ACTIVE;2.22;2.70 +50915-8;Strontium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Strontium [Moles/time] in 24 hour Urine;Strontium 24h Ur-sRate;;ACTIVE;2.22;2.70 +50916-6;Sucrose;SCnc;Pt;Urine;Qn;;CHEM;1;Sucrose [Moles/volume] in Urine;Sucrose Ur-sCnc;;ACTIVE;2.22;2.70 +50917-4;Thallium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Thallium [Moles/mass] in Hair;Thallium Hair-sCnt;;ACTIVE;2.22;2.70 +50918-2;Thallium;SCnc;24H;Urine;Qn;;DRUG/TOX;1;Thallium [Moles/volume] in 24 hour Urine;Thallium 24h Ur-sCnc;;ACTIVE;2.22;2.70 +50919-0;Thorium;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Thorium [Moles/mass] in Tissue;Thorium Tiss-sCnt;;ACTIVE;2.22;2.70 +50920-8;Thorium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Thorium [Moles/mass] in Hair;Thorium Hair-sCnt;;ACTIVE;2.22;2.70 +50921-6;Tin;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tin [Moles/volume] in Urine;Tin Ur-sCnc;;ACTIVE;2.22;2.70 +5092-2;Clostridium tetani Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani Ab [Units/volume] in Serum;C tetani Ab Ser-aCnc;;DISCOURAGED;1.0;2.73 +50922-4;Tin;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Tin [Moles/mass] in Hair;Tin Hair-sCnt;;ACTIVE;2.22;2.70 +50923-2;Tin;SRat;24H;Urine;Qn;;DRUG/TOX;1;Tin [Moles/time] in 24 hour Urine;Tin 24h Ur-sRate;;ACTIVE;2.22;2.70 +50924-0;Titanium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Titanium [Moles/volume] in Serum or Plasma;Titanium SerPl-sCnc;;ACTIVE;2.22;2.70 +50925-7;Titanium;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Titanium [Moles/mass] in Tissue;Titanium Tiss-sCnt;;ACTIVE;2.22;2.70 +50926-5;Titanium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Titanium [Moles/mass] in Hair;Titanium Hair-sCnt;;ACTIVE;2.22;2.70 +50927-3;Tobramycin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Moles/volume] in Serum or Plasma;Tobramycin SerPl-sCnc;;ACTIVE;2.22;2.73 +50928-1;Uranium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Uranium [Moles/volume] in Urine;Uranium Ur-sCnc;;ACTIVE;2.22;2.70 +50929-9;Uranium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Uranium [Moles/mass] in Hair;Uranium Hair-sCnt;;ACTIVE;2.22;2.70 +5093-0;Clostridium tetani Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Clostridium tetani Ab [Presence] in Serum;C tetani Ab Ser Ql;;DISCOURAGED;1.0;2.58 +50930-7;Uranium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Uranium [Moles/time] in 24 hour Urine;Uranium 24h Ur-sRate;;ACTIVE;2.22;2.70 +50931-5;Uroporphyrin 1 isomer;SCnt;Pt;Stool;Qn;;CHEM;1;Uroporphyrin 1 isomer [Moles/mass] in Stool;Uropor1 Stl-sCnt;;ACTIVE;2.22;2.70 +50932-3;Uroporphyrin/Porphyrins.total;SFr;24H;Urine;Qn;;CHEM;1;Uroporphyrin/Porphyrins.total in 24 hour Urine;Uropor 24h SFr Ur;;ACTIVE;2.22;2.70 +50933-1;Vanadium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Vanadium [Moles/volume] in Blood;Vanadium Bld-sCnc;;ACTIVE;2.22;2.70 +50934-9;Vanadium;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Vanadium [Moles/mass] in Hair;Vanadium Hair-sCnt;;ACTIVE;2.22;2.70 +50935-6;Vanadium;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Vanadium [Moles/volume] in Red Blood Cells;Vanadium RBC-sCnc;;ACTIVE;2.22;2.70 +50936-4;Vanadium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Vanadium [Moles/volume] in Urine;Vanadium Ur-sCnc;;ACTIVE;2.22;2.70 +50937-2;Vanadium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Vanadium [Moles/time] in 24 hour Urine;Vanadium 24h Ur-sRate;;ACTIVE;2.22;2.70 +50938-0;Vancomycin;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Vancomycin [Moles/volume] in Body fluid;Vancomycin Fld-sCnc;;ACTIVE;2.22;2.70 +50939-8;Zinc;SCnt;Pt;Hair;Qn;;DRUG/TOX;1;Zinc [Moles/mass] in Hair;Zinc Hair-sCnt;;ACTIVE;2.22;2.70 +50940-6;Zinc/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Zinc/Creatinine [Molar ratio] in 24 hour Urine;Zinc/Creat 24h Ur-sRto;;ACTIVE;2.22;2.70 +50941-4;Mycobacterium sp;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Mycobacterium sp [Presence] in Specimen by Organism specific culture;Mycobacterium Spec Ql Cult;;ACTIVE;2.22;2.73 +50942-2;Acarboxyprothrombin;MCnc;Pt;Ser;Qn;;COAG;1;Deprecated Acarboxyprothrombin [Mass/volume] in Serum;Deprecated Acarboxyprothrombin Ser-mCnc;;DEPRECATED;2.22;2.70 +50943-0;Reasons for assessment (full);-;Pt;^Patient;Set;;PANEL.SURVEY.MDS;4;Reasons for assessment (full) Set;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";ACTIVE;2.22;2.68 +50944-8;Platelet aggregation.adenosine diphosphate induced^20 umol/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ADP induced [Presence] in Platelet rich plasma --20 umol/L;PA ADP 20 umol/L PRP Ql;;ACTIVE;2.22;2.56 +50945-5;Platelet aggregation.adenosine diphosphate induced^2 umol/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ADP induced [Presence] in Platelet rich plasma --2 umol/L;PA ADP 2 umol/L PRP Ql;;ACTIVE;2.22;2.73 +50946-3;Platelet aggregation.adenosine diphosphate induced^4 umol/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ADP induced [Presence] in Platelet rich plasma --4 umol/L;PA ADP 4 umol/L PRP Ql;;ACTIVE;2.22;2.73 +50947-1;Platelet aggregation.collagen induced^190 ug/mL;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation collagen induced [Presence] in Platelet rich plasma --190 ug/mL;PA Coll 190 ug/mL PRP Ql;;ACTIVE;2.22;2.73 +5094-8;Coccidioides immitis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coccidioides immitis Ab [Units/volume] in Serum by Immunoassay;C immitis Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +50948-9;Vanillylmandelate & Creatinine;Imp;24H;Urine;Nar;;CHEM;1;Vanillylmandelate and Creatinine [Interpretation] in 24 hour Urine Narrative;VMA & Creat 24h Ur-Imp;;ACTIVE;2.22;2.73 +50949-7;Albumin;PrThr;Pt;Urine;Ord;Test strip;CHEM;1;Albumin [Presence] in Urine by Test strip;Albumin Ur Ql Strip;;ACTIVE;2.22;2.73 +50950-5;Phosphoethanolamine Ab.IgA;PrThr;Pt;Ser/Plas;Ord;;COAG;1;Phosphoethanolamine IgA Ab [Presence] in Serum or Plasma;PETN IgA SerPl Ql;;ACTIVE;2.22;2.73 +50951-3;Phosphoserine Ab.IgA;PrThr;Pt;Ser/Plas;Ord;;COAG;1;Phosphoserine IgA Ab [Presence] in Serum or Plasma;Phosphoserine IgA SerPl Ql;;ACTIVE;2.22;2.56 +50952-1;Phosphoserine Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;COAG;1;Phosphoserine IgG Ab [Presence] in Serum or Plasma;Phosphoserine IgG SerPl Ql;;ACTIVE;2.22;2.56 +50953-9;Phosphoethanolamine Ab.IgM;PrThr;Pt;Ser/Plas;Ord;;COAG;1;Phosphoethanolamine IgM Ab [Presence] in Serum or Plasma;PETN IgM SerPl Ql;;ACTIVE;2.22;2.56 +50954-7;Phosphoethanolamine Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;COAG;1;Phosphoethanolamine IgG Ab [Presence] in Serum or Plasma;PETN IgG SerPl Ql;;ACTIVE;2.22;2.56 +5095-5;Coccidioides immitis Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Coccidioides immitis Ab [Presence] in Serum by Immune diffusion (ID);C immitis Ab Ser Ql ID;;ACTIVE;1.0;2.73 +50955-4;Phosphoserine Ab.IgM;PrThr;Pt;Ser/Plas;Ord;;COAG;1;Phosphoserine IgM Ab [Presence] in Serum or Plasma;Phosphoserine IgM SerPl Ql;;ACTIVE;2.22;2.56 +50956-2;HLA-B*57:01;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B*57:01 [Presence];HLA-B*57:01 Ql;;ACTIVE;2.22;2.73 +50957-0;Manual differential performed;PrThr;Pt;Bld;Ord;;HEM/BC;1;Manual differential performed [Presence] in Blood;Manual differential performed Bld Ql;;ACTIVE;2.22;2.73 +50958-8;Indirect antiglobulin test.XXX reagent^post transfusion;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Indirect antiglobulin test.unspecified reagent [Presence] in Serum or Plasma --after transfusion;IAT p transf SerPl Ql;;ACTIVE;2.22;2.56 +50959-6;Indirect antiglobulin test.XXX reagent;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Indirect antiglobulin test.unspecified reagent [Presence] in Serum or Plasma;IAT SerPl Ql;;ACTIVE;2.22;2.73 +50960-4;Rabbit Ab;PrThr;Pt;Ser;Ord;;SERO;1;Rabbit Ab [Presence] in Serum;Rabbit Ab Ser Ql;;ACTIVE;2.22;2.73 +50961-2;Rabbit Ab;Titr;Pt;Ser;Qn;;SERO;1;Rabbit Ab [Titer] in Serum;Rabbit Ab Titr Ser;;ACTIVE;2.22;2.73 +50962-0;XXX blood group Ab.IgG;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;XXX blood group IgG Ab [Titer] in Serum or Plasma;XXX blood group IgG Titr SerPl;;ACTIVE;2.22;2.73 +5096-3;Coccidioides immitis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coccidioides immitis Ab [Titer] in Serum by Complement fixation;C immitis Ab Titr Ser CF;;ACTIVE;1.0;2.73 +50963-8;XXX blood group Ab.IgM;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;XXX blood group IgM Ab [Titer] in Serum or Plasma;XXX blood group IgM Titr SerPl;;ACTIVE;2.22;2.73 +50964-6;Liley Zone;PrThr;Pt;Amnio fld;Ord;Spectrophotometry;CHEM;1;Liley Zone [Presence] in Amniotic fluid by Spectrophotometry;Liley Zone Amn Ql Spect;;ACTIVE;2.22;2.56 +50965-3;Gamma hydroxybutyrate cutoff;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma hydroxybutyrate cutoff [Mass/volume] in Serum or Plasma;G-OH-Butyr CtO SerPl-mCnc;;ACTIVE;2.22;2.40 +50966-1;Flunitrazepam;PrThr;Pt;Ser/Plas/Bld;Ord;;DRUG/TOX;1;Flunitrazepam [Presence] in Serum, Plasma or Blood;Flunitrazepam SerPlBld Ql;;ACTIVE;2.22;2.73 +50967-9;Hepatitis B virus surface Ag;PrThr;Pt;Bld^Donor;Ord;Neut;MICRO;1;Hepatitis B virus surface Ag [Presence] in Blood from Donor by Neutralization test;HBV surface Ag Bld Donr Ql Nt;;ACTIVE;2.22;2.73 +50968-7;HLA Ab;Type;Pt;Ser;Nom;;HLA;1;HLA Ab [Type] in Serum;HLA Ab Ser;;ACTIVE;2.22;2.73 +50969-5;Epstein Barr virus early diffuse Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus early diffuse IgG Ab [Units/volume] in Serum;EBV EA-D IgG Ser-aCnc;;ACTIVE;2.22;2.73 +50970-3;XXX blood group Ab;Titr;Pt;Ser/Plas;Qn;Antihuman globulin;BLDBK;1;XXX blood group Ab [Titer] in Serum or Plasma by Antihuman globulin;XXX blood group Ab Titr SerPl AHG;;ACTIVE;2.22;2.73 +5097-1;Cold agglutinin;PrThr;Pt;Ser/Plas;Ord;Aggl;SERO;1;Cold agglutinin [Presence] in Serum or Plasma by Agglutination;CA SerPl Ql Aggl;;ACTIVE;1.0;2.73 +50971-1;Cytology report;Find;Pt;Bronchial brush;Doc;Cyto stain;CYTO;1;Cytology report of Bronchial brush Cyto stain;Cyto Bro Brush;;ACTIVE;2.22;2.73 +50972-9;Cells.CD138;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD138 cells [#/volume] in Blood;CD138 Cells # Bld;;ACTIVE;2.22;2.70 +50973-7;Cells.CD38+CD138+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD38+CD138+ cells [#/volume] in Blood;CD38+CD138+ Cells # Bld;;ACTIVE;2.22;2.70 +50974-5;Cells.CD38+CD138+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38+CD138+ cells/100 cells in Blood;CD38+CD138+ Cells NFr Bld;;ACTIVE;2.22;2.73 +50975-2;Cells.TCR alpha beta;NCnc;Pt;Bld;Qn;;CELLMARK;1;TCR alpha beta cells [#/volume] in Blood;TCR A-B Cells # Bld;;ACTIVE;2.22;2.70 +50976-0;Cells.TCR gamma delta;NCnc;Pt;Bld;Qn;;CELLMARK;1;TCR gamma delta cells [#/volume] in Blood;TCR G-D Cells # Bld;;ACTIVE;2.22;2.70 +50977-8;Echovirus 5 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 5 Ab [Titer] in Serum;ECV5 Ab Titr Ser;;ACTIVE;2.22;2.32 +50978-6;Immunoglobulin light chains.lambda.free;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;Lambda light chains.free [Presence] in Serum by Immunofixation;Lambda LC Free Ser Ql IFE;;ACTIVE;2.22;2.63 +50979-4;CBir1 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;CBir1 Ab [Units/volume] in Serum by Immunoassay;CBir1 Ab Ser IA-aCnc;;ACTIVE;2.22;2.73 +50980-2;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldMV;Qn;;CHEM;1;pH of Mixed venous blood adjusted to patient's actual temperature;pH temp adj BldMV;;ACTIVE;2.22;2.73 +50981-0;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldMV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Mixed venous blood;pCO2 temp adj BldMV;;ACTIVE;2.22;2.73 +50982-8;Horowitz index;Ratio;Pt;Bld+Inhl gas;Qn;;CHEM;1;Horowitz index in Blood;Horowitz index Bld+IhG-Rto;;ACTIVE;2.22;2.73 +50983-6;Horowitz index;Ratio;Pt;BldC+Inhl gas;Qn;;CHEM;1;Horowitz index in Capillary blood;Horowitz index BldC+IhG-Rto;;ACTIVE;2.22;2.70 +50984-4;Horowitz index;Ratio;Pt;BldA+Inhl gas;Qn;;CHEM;1;Horowitz index in Arterial blood;Horowitz index BldA+IhG-Rto;;ACTIVE;2.22;2.73 +50985-1;Horowitz index;Ratio;Pt;BldMV+Inhl gas;Qn;;CHEM;1;Horowitz index in Mixed venous blood;Horowitz index BldMV+IhG-Rto;;ACTIVE;2.22;2.70 +50986-9;Horowitz index;Ratio;Pt;BldV+Inhl gas;Qn;;CHEM;1;Horowitz index in Venous blood;Horowitz index BldV+IhG-Rto;;ACTIVE;2.22;2.73 +50987-7;Horowitz index^^adjusted to patient's actual temperature;Ratio;Pt;Bld+Inhl gas;Qn;;CHEM;1;Horowitz index adjusted to patients actual temperature in Blood;Horowitz index temp adj Bld+IhG-Rto;;ACTIVE;2.22;2.70 +50988-5;Horowitz index^^adjusted to patient's actual temperature;Ratio;Pt;BldC+Inhl gas;Qn;;CHEM;1;Horowitz index adjusted to patients actual temperature in Capillary blood;Horowitz index temp adj BldC+IhG-Rto;;ACTIVE;2.22;2.70 +5098-9;Cold agglutinin;Titr;Pt;Ser/Plas;Qn;Aggl;SERO;1;Cold agglutinin [Titer] in Serum or Plasma by Agglutination;CA Titr SerPl Aggl;;ACTIVE;1.0;2.73 +50989-3;Horowitz index^^adjusted to patient's actual temperature;Ratio;Pt;BldA+Inhl gas;Qn;;CHEM;1;Horowitz index adjusted to patients actual temperature in Arterial blood;Horowitz index temp adj BldA+IhG-Rto;;ACTIVE;2.22;2.73 +50990-1;Horowitz index^^adjusted to patient's actual temperature;Ratio;Pt;BldMV+Inhl gas;Qn;;CHEM;1;Horowitz index adjusted to patients actual temperature in Mixed venous blood;Horowitz index temp adj BldMV+IhG-Rto;;ACTIVE;2.22;2.54 +50991-9;Horowitz index^^adjusted to patient's actual temperature;Ratio;Pt;BldV+Inhl gas;Qn;;CHEM;1;Horowitz index adjusted to patients actual temperature in Venous blood;Horowitz index temp adj BldV+IhG-Rto;;ACTIVE;2.22;2.73 +50992-7;IgM;MCnc;Pt;BldCo;Qn;;CHEM;1;IgM [Mass/volume] in Cord blood;IgM BldCo-mCnc;;ACTIVE;2.22;2.70 +50993-5;Laxatives;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Laxatives [Mass/mass] in Stool;Laxatives Stl-mCnt;;ACTIVE;2.22;2.70 +50994-3;CMT demyelinating gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CMT demyelinating gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CMT1 gene Mut Anl Bld/T;;ACTIVE;2.22;2.68 +50995-0;BRCA1+BRCA2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BRCA1+BRCA2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BRCA1+BRCA2 Mut Anl Bld/T;;ACTIVE;2.22;2.73 +50996-8;HBB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HBB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HBB gene Mut Anl Bld/T;;ACTIVE;2.22;2.73 +5099-7;Coronavirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coronavirus Ab [Units/volume] in Serum;Coronavirus Ab Ser-aCnc;;ACTIVE;1.0;2.73 +50997-6;Complement C8.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C8.functional [Units/volume] in Serum or Plasma;C8 functional SerPl-aCnc;;ACTIVE;2.22;2.73 +50998-4;CFTR gene mutations tested for;Num;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;CFTR gene mutations tested for [#] in Blood or Tissue by Molecular genetics method;Num CFTR Mut Tested Bld/T;;ACTIVE;2.22;2.73 +50999-2;Leishmania donovani Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Leishmania donovani IgG and IgM [Interpretation] in Serum;L donovani IgG+IgM Ser-Imp;;ACTIVE;2.22;2.73 +51000-8;Leishmania tropica Ab.IgG & IgM;Imp;Pt;Ser;Nar;;MICRO;1;Leishmania tropica IgG and IgM [Interpretation] in Serum Narrative;L tropica IgG+IgM Ser-Imp;;ACTIVE;2.22;2.73 +51001-6;Iodide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Iodide [Mass/volume] in Urine;Iodide Ur-mCnc;;ACTIVE;2.22;2.70 +51002-4;Lipoprotein midband A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein midband A [Mass/volume] in Serum or Plasma;Lipoprotein midband A SerPl-mCnc;;ACTIVE;2.22;2.73 +5100-3;Coxiella burnetii Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxiella burnetii Ab [Titer] in Serum by Complement fixation;C burnet Ab Titr Ser CF;;ACTIVE;1.0;2.70 +51003-2;Lipoprotein midband B;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein midband B [Mass/volume] in Serum or Plasma;Lipoprotein midband B SerPl-mCnc;;ACTIVE;2.22;2.73 +51004-0;Lipoprotein midband C;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein midband C [Mass/volume] in Serum or Plasma;Lipoprotein midband C SerPl-mCnc;;ACTIVE;2.22;2.73 +51005-7;Testosterone.free+weakly bound;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;Testosterone.free+weakly bound [Mass/volume] in Serum or Plasma by High sensitivity method;Testosterone.free+WB SerPl HS-mCnc;;ACTIVE;2.22;2.70 +51006-5;Direct antiglobulin test.XXX reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.unspecified reagent [Presence] on Red Blood Cells;DAT RBC Ql;;ACTIVE;2.22;2.73 +51007-3;Direct antiglobulin test.XXX reagent^post transfusion;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.unspecified reagent [Presence] on Red Blood Cells --after transfusion;DAT p transf RBC Ql;;ACTIVE;2.22;2.73 +51008-1;Triticum aestivum native (nTri a) 19 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat native (nTri a) 19 IgE Ab [Units/volume] in Serum;Wheat (nTri a) 19 IgE Qn;;ACTIVE;2.22;2.70 +51009-9;Cells.CD3-CD16+CD56+CD244+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD16+CD56+CD244+ cells/100 cells in Bone marrow;CD3-CD16+CD56+CD244+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51010-7;Cells.CD3-CD16+CD56+CD244+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3-CD16+CD56+CD244+ cells/100 cells in Blood;CD3-CD16+CD56+CD244+ Cells NFr Bld;;ACTIVE;2.22;2.70 +5101-1;Coxsackievirus A7 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus A7 neutralizing antibody [Titer] in Serum by Neutralization test;CV A7 NAb Titr Ser Nt;;ACTIVE;1.0;2.72 +51011-5;Cells.CD3-CD16+CD56+CD244+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3-CD16+CD56+CD244+ cells/100 cells in Specimen;CD3-CD16+CD56+CD244+ Cells NFr Spec;;ACTIVE;2.22;2.70 +51012-3;Cells.BCLXL/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;BCLXL cells/100 cells in Specimen;BCLXL Cells NFr Spec;;ACTIVE;2.22;2.70 +51013-1;Blasts.CD1/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD1 blasts/100 blasts in Bone marrow;CD1 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51014-9;Blasts.CD1/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD1 blasts/100 blasts in Blood;CD1 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51015-6;Blasts.CD1/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD1 blasts/100 blasts in Specimen;CD1 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51016-4;Blasts.CD1;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD1 blasts [Units/volume] in Blood;CD1 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51017-2;Blasts.CD1;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD1 blasts [Units/volume] in Specimen;CD1 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51018-0;Blasts.CD10/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD10 blasts/100 blasts in Bone marrow;CD10 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51019-8;Blasts.CD10/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD10 blasts/100 blasts in Specimen;CD10 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51020-6;Blasts.CD10;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD10 blasts [Units/volume] in Blood;CD10 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51021-4;Blasts.CD10;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD10 blasts [Units/volume] in Specimen;CD10 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51022-2;Blasts.cytoplasmic CD117/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD117 blasts/100 cells in Bone marrow;cyCD117 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51023-0;Blasts.cytoplasmic CD117/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD117 blasts/100 cells in Blood;cyCD117 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51024-8;Blasts.cytoplasmic CD117/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD117 blasts/100 cells in Specimen;cyCD117 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51025-5;Blasts.CD117/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD117 blasts/100 blasts in Bone marrow;CD117 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51026-3;Blasts.CD117/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD117 blasts/100 blasts in Blood;CD117 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51027-1;Blasts.CD117/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD117 blasts/100 blasts in Specimen;CD117 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51028-9;Blasts.CD117;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD117 blasts [Units/volume] in Bone marrow;CD117 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +5102-9;Coxsackievirus A9 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus A9 neutralizing antibody [Titer] in Serum by Neutralization test;CV A9 NAb Titr Ser Nt;;ACTIVE;1.0;2.72 +51029-7;Blasts.CD117;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD117 blasts [Units/volume] in Blood;CD117 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51030-5;Blasts.CD117;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD117 blasts [Units/volume] in Specimen;CD117 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51031-3;Blasts.CD11a/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD11a blasts/100 blasts in Bone marrow;CD11a Blasts NFr Mar;;ACTIVE;2.22;2.70 +51032-1;Blasts.CD11a/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11a blasts/100 blasts in Blood;CD11a Blasts NFr Bld;;ACTIVE;2.22;2.70 +51033-9;Blasts.CD11a/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11a blasts/100 blasts in Specimen;CD11a Blasts NFr Spec;;ACTIVE;2.22;2.70 +51034-7;Blasts.CD11a;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD11a blasts [Units/volume] in Bone marrow;CD11a Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51035-4;Blasts.CD11a;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD11a blasts [Units/volume] in Blood;CD11a Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51036-2;Blasts.CD11a;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD11a blasts [Units/volume] in Specimen;CD11a Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +5103-7;Coxsackievirus B1 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B1 neutralizing antibody [Titer] in Serum by Neutralization test;CV B1 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51037-0;Blasts.CD11b/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD11b blasts/100 blasts in Bone marrow;CD11b Blasts NFr Mar;;ACTIVE;2.22;2.70 +51038-8;Blasts.CD11b/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11b blasts/100 blasts in Blood;CD11b Blasts NFr Bld;;ACTIVE;2.22;2.70 +51039-6;Blasts.CD11b/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11b blasts/100 blasts in Specimen;CD11b Blasts NFr Spec;;ACTIVE;2.22;2.70 +51040-4;Blasts.CD11c/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD11c blasts/100 blasts in Bone marrow;CD11c Blasts NFr Mar;;ACTIVE;2.22;2.70 +51041-2;Blasts.CD11c/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11c blasts/100 blasts in Blood;CD11c Blasts NFr Bld;;ACTIVE;2.22;2.70 +51042-0;Blasts.CD11c/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11c blasts/100 blasts in Specimen;CD11c Blasts NFr Spec;;ACTIVE;2.22;2.70 +51043-8;Blasts.CD123/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD123 blasts/100 blasts in Bone marrow;CD123 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51044-6;Blasts.CD123/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD123 blasts/100 blasts in Blood;CD123 Blasts NFr Bld;;ACTIVE;2.22;2.73 +5104-5;Coxsackievirus B1 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B1 Ab [Titer] in Serum by Complement fixation;CV B1 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51045-3;Blasts.CD123/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD123 blasts/100 blasts in Specimen;CD123 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51046-1;Blasts.CD123;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD123 blasts [Units/volume] in Bone marrow;CD123 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51047-9;Blasts.CD123;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD123 blasts [Units/volume] in Blood;CD123 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51048-7;Blasts.CD123;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD123 blasts [Units/volume] in Specimen;CD123 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51049-5;Blasts.CD126/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD126 blasts/100 blasts in Bone marrow;CD126 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51050-3;Blasts.CD126/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD126 blasts/100 blasts in Blood;CD126 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51051-1;Blasts.CD126/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD126 blasts/100 blasts in Specimen;CD126 Blasts NFr Spec;;ACTIVE;2.22;2.70 +5105-2;Coxsackievirus B2 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B2 neutralizing antibody [Titer] in Serum by Neutralization test;CV B2 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51052-9;Blasts.CD126;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD126 blasts [Units/volume] in Bone marrow;CD126 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51053-7;Blasts.CD126;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD126 blasts [Units/volume] in Blood;CD126 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51054-5;Blasts.CD126;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD126 blasts [Units/volume] in Specimen;CD126 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51055-2;Blasts.CD127/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD127 blasts/100 blasts in Bone marrow;CD127 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51056-0;Blasts.CD127/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD127 blasts/100 blasts in Blood;CD127 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51057-8;Blasts.CD127/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD127 blasts/100 blasts in Specimen;CD127 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51058-6;Blasts.CD127;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD127 blasts [Units/volume] in Bone marrow;CD127 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51059-4;Blasts.CD127;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD127 blasts [Units/volume] in Blood;CD127 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +5106-0;Coxsackievirus B2 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B2 Ab [Titer] in Serum by Complement fixation;CV B2 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51060-2;Blasts.CD127;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD127 blasts [Units/volume] in Specimen;CD127 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51061-0;Blasts.cytoplasmic CD13/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD13 blasts/100 blasts in Bone marrow;cyCD13 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51062-8;Blasts.cytoplasmic CD13/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD13 blasts/100 blasts in Blood;cyCD13 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51063-6;Blasts.cytoplasmic CD13/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD13 blasts/100 blasts in Specimen;cyCD13 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51064-4;Blasts.CD13/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD13 blasts/100 blasts in Bone marrow;CD13 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51065-1;Blasts.CD13/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD13 blasts/100 blasts in Specimen;CD13 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51066-9;Blasts.CD13;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD13 blasts [Units/volume] in Bone marrow;CD13 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51067-7;Blasts.CD13;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD13 blasts [Units/volume] in Blood;CD13 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51068-5;Blasts.CD13;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD13 blasts [Units/volume] in Specimen;CD13 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51069-3;Blasts.CD135/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD135 blasts/100 blasts in Bone marrow;CD135 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51070-1;Blasts.CD135/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD135 blasts/100 blasts in Blood;CD135 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51071-9;Blasts.CD135/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD135 blasts/100 blasts in Specimen;CD135 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51072-7;Blasts.CD135;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD135 blasts [Units/volume] in Bone marrow;CD135 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51073-5;Blasts.CD135;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD135 blasts [Units/volume] in Blood;CD135 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51074-3;Blasts.CD135;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD135 blasts [Units/volume] in Specimen;CD135 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51075-0;Blasts.CD14/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD14 blasts/100 blasts in Bone marrow;CD14 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51076-8;Blasts.CD14/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD14 blasts/100 blasts in Specimen;CD14 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51077-6;Blasts.CD14;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD14 blasts [Units/volume] in Bone marrow;CD14 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +5107-8;Coxsackievirus B3 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B3 neutralizing antibody [Titer] in Serum by Neutralization test;CV B3 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51078-4;Blasts.CD14;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD14 blasts [Units/volume] in Blood;CD14 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51079-2;Blasts.CD14;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD14 blasts [Units/volume] in Specimen;CD14 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +510-8;Tobramycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Tobramycin [Susceptibility] by Serum bactericidal titer;Tobramycin Titr SBT;;ACTIVE;1.0;2.32 +51080-0;Blasts.CD15/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD15 blasts/100 blasts in Bone marrow;CD15 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51081-8;Blasts.CD15/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD15 blasts/100 blasts in Blood;CD15 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51082-6;Blasts.CD15/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD15 blasts/100 blasts in Specimen;CD15 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51083-4;Blasts.CD15;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD15 blasts [Units/volume] in Bone marrow;CD15 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51084-2;Blasts.CD15;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD15 blasts [Units/volume] in Blood;CD15 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51085-9;Blasts.CD15;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD15 blasts [Units/volume] in Specimen;CD15 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +5108-6;Coxsackievirus B3 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B3 Ab [Titer] in Serum by Complement fixation;CV B3 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51086-7;Blasts.CD16/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD16 blasts/100 blasts in Bone marrow;CD16 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51087-5;Blasts.CD16/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16 blasts/100 blasts in Blood;CD16 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51088-3;Blasts.CD16/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD16 blasts/100 blasts in Specimen;CD16 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51089-1;Blasts.cytoplasmic CD179a/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD179a blasts/100 blasts in Bone marrow;cyCD179a Blasts NFr Mar;;ACTIVE;2.22;2.70 +51090-9;Blasts.cytoplasmic CD179a/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD179a blasts/100 blasts in Blood;cyCD179a Blasts NFr Bld;;ACTIVE;2.22;2.70 +51091-7;Blasts.cytoplasmic CD179a/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD179a blasts/100 blasts in Specimen;cyCD179a Blasts NFr Spec;;ACTIVE;2.22;2.70 +51092-5;Blasts.cytoplasmic CD179a;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD179a blasts [Units/volume] in Bone marrow;cyCD179a Blasts Mar-aCnc;;ACTIVE;2.22;2.69 +51093-3;Blasts.cytoplasmic CD179a;ACnc;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD179a blasts [Units/volume] in Blood;cyCD179a Blasts Bld-aCnc;;ACTIVE;2.22;2.69 +5109-4;Coxsackievirus B4 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B4 neutralizing antibody [Titer] in Serum by Neutralization test;CV B4 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51094-1;Blasts.cytoplasmic CD179a;ACnc;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD179a blasts [Units/volume] in Specimen;cyCD179a Blasts Spec-aCnc;;ACTIVE;2.22;2.69 +51095-8;Blasts.CD179a/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD179a blasts/100 blasts in Bone marrow;CD179a Blasts NFr Mar;;ACTIVE;2.22;2.70 +51096-6;Blasts.CD179a/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD179a blasts/100 blasts in Blood;CD179a Blasts NFr Bld;;ACTIVE;2.22;2.70 +51097-4;Blasts.CD179a/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD179a blasts/100 blasts in Specimen;CD179a Blasts NFr Spec;;ACTIVE;2.22;2.70 +51098-2;Blasts.CD179a;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD179a blasts [Units/volume] in Bone marrow;CD179a Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51099-0;Blasts.CD179a;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD179a blasts [Units/volume] in Blood;CD179a Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51100-6;Blasts.CD179a;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD179a blasts [Units/volume] in Specimen;CD179a Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51101-4;Blasts.CD19/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19 blasts/100 blasts in Bone marrow;CD19 Blasts NFr Mar;;ACTIVE;2.22;2.70 +5110-2;Coxsackievirus B4 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B4 Ab [Titer] in Serum by Complement fixation;CV B4 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51102-2;Blasts.CD19/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD19 blasts/100 blasts in Specimen;CD19 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51103-0;Blasts.CD19;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD19 blasts [Units/volume] in Bone marrow;CD19 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51104-8;Blasts.CD19;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD19 blasts [Units/volume] in Blood;CD19 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51105-5;Blasts.CD19;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD19 blasts [Units/volume] in Specimen;CD19 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51106-3;Blasts.CD1a/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD1a blasts/100 blasts in Bone marrow;CD1a Blasts NFr Mar;;ACTIVE;2.22;2.70 +51107-1;Blasts.CD1a/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD1a blasts/100 blasts in Blood;CD1a Blasts NFr Bld;;ACTIVE;2.22;2.70 +51108-9;Blasts.CD1a/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD1a blasts/100 blasts in Specimen;CD1a Blasts NFr Spec;;ACTIVE;2.22;2.70 +51109-7;Blasts.cytoplasmic CD2/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD2 blasts/100 blasts in Specimen;cyCD2 Blasts NFr Spec;;ACTIVE;2.22;2.70 +5111-0;Coxsackievirus B5 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B5 neutralizing antibody [Titer] in Serum by Neutralization test;CV B5 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51110-5;Blasts.CD2/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD2 blasts/100 blasts in Bone marrow;CD2 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51111-3;Blasts.CD2/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD2 blasts/100 blasts in Specimen;CD2 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51112-1;Blasts.CD2;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD2 blasts [Units/volume] in Bone marrow;CD2 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51113-9;Blasts.CD2;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD2 blasts [Units/volume] in Blood;CD2 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51114-7;Blasts.CD2;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD2 blasts [Units/volume] in Specimen;CD2 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51115-4;Blasts.CD20/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD20 blasts/100 blasts in Bone marrow;CD20 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51116-2;Blasts.CD20/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD20 blasts/100 blasts in Specimen;CD20 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51117-0;Blasts.CD21/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD21 blasts/100 blasts in Specimen;CD21 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51118-8;Blasts.cytoplasmic CD22/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD22 blasts/100 blasts in Bone marrow;cyCD22 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51119-6;Blasts.cytoplasmic CD22/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD22 blasts/100 blasts in Blood;cyCD22 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51120-4;Blasts.cytoplasmic CD22/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD22 blasts/100 blasts in Specimen;cyCD22 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51121-2;Blasts.cytoplasmic CD22;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD22 blasts [Units/volume] in Bone marrow;cyCD22 Blasts Mar-aCnc;;ACTIVE;2.22;2.69 +51122-0;Blasts.cytoplasmic CD22;ACnc;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD22 blasts [Units/volume] in Blood;cyCD22 Blasts Bld-aCnc;;ACTIVE;2.22;2.69 +51123-8;Blasts.cytoplasmic CD22;ACnc;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD22 blasts [Units/volume] in Specimen;cyCD22 Blasts Spec-aCnc;;ACTIVE;2.22;2.69 +51124-6;Blasts.CD22/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD22 blasts/100 blasts in Bone marrow;CD22 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51125-3;Blasts.CD22/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD22 blasts/100 blasts in Blood;CD22 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51126-1;Blasts.CD22/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD22 blasts/100 blasts in Specimen;CD22 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51127-9;Blasts.CD22;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD22 blasts [Units/volume] in Bone marrow;CD22 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +5112-8;Coxsackievirus B5 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B5 Ab [Titer] in Serum by Complement fixation;CV B5 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51128-7;Blasts.CD22;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD22 blasts [Units/volume] in Blood;CD22 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51129-5;Blasts.CD22;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD22 blasts [Units/volume] in Specimen;CD22 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51130-3;Blasts.CD23/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD23 blasts/100 blasts in Bone marrow;CD23 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51131-1;Blasts.CD23/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD23 blasts/100 blasts in Blood;CD23 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51132-9;Blasts.CD23/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD23 blasts/100 blasts in Specimen;CD23 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51133-7;Blasts.CD24/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD24 blasts/100 blasts in Specimen;CD24 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51134-5;Blasts.CD25/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD25 blasts/100 blasts in Bone marrow;CD25 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51135-2;Blasts.CD25/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25 blasts/100 blasts in Blood;CD25 Blasts NFr Bld;;ACTIVE;2.22;2.70 +5113-6;Coxsackievirus B6 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Coxsackievirus B6 neutralizing antibody [Titer] in Serum by Neutralization test;CV B6 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51136-0;Blasts.CD25/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD25 blasts/100 blasts in Specimen;CD25 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51137-8;Blasts.cytoplasmic CD3/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD3 blasts/100 blasts in Bone marrow;cyCD3 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51138-6;Blasts.cytoplasmic CD3/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD3 blasts/100 blasts in Blood;cyCD3 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51139-4;Blasts.cytoplasmic CD3/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD3 blasts/100 blasts in Specimen;cyCD3 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51140-2;Blasts.cytoplasmic CD3;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD3 blasts [Units/volume] in Bone marrow;cyCD3 Blasts Mar-aCnc;;ACTIVE;2.22;2.69 +51141-0;Blasts.cytoplasmic CD3;ACnc;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD3 blasts [Units/volume] in Blood;cyCD3 Blasts Bld-aCnc;;ACTIVE;2.22;2.69 +51142-8;Blasts.cytoplasmic CD3;ACnc;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD3 blasts [Units/volume] in Specimen;cyCD3 Blasts Spec-aCnc;;ACTIVE;2.22;2.69 +51143-6;Blasts.CD3/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3 blasts/100 blasts in Bone marrow;CD3 Blasts NFr Mar;;ACTIVE;2.22;2.70 +5114-4;Coxsackievirus B6 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus B6 Ab [Titer] in Serum by Complement fixation;CV B6 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51144-4;Blasts.CD3/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3 blasts/100 blasts in Blood;CD3 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51145-1;Blasts.CD3/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3 blasts/100 blasts in Specimen;CD3 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51146-9;Blasts.CD3;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3 blasts [Units/volume] in Bone marrow;CD3 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51147-7;Blasts.CD3;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD3 blasts [Units/volume] in Blood;CD3 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51148-5;Blasts.CD3;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD3 blasts [Units/volume] in Specimen;CD3 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51149-3;Blasts.CD3+CD16+CD56+/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD16+CD56+ blasts/100 blasts in Bone marrow;CD3+CD16+CD56+ Blasts NFr Mar;;ACTIVE;2.22;2.70 +51150-1;Blasts.CD3+CD16+CD56+/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD16+CD56+ blasts/100 blasts in Blood;CD3+CD16+CD56+ Blasts NFr Bld;;ACTIVE;2.22;2.70 +5115-1;Corynebacterium diphtheriae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Corynebacterium diphtheriae Ab [Units/volume] in Serum;C diphtheriae Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51151-9;Blasts.CD3+CD16+CD56+/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3+CD16+CD56+ blasts/100 blasts in Specimen;CD3+CD16+CD56+ Blasts NFr Spec;;ACTIVE;2.22;2.70 +51152-7;Blasts.CD30/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD30 blasts/100 blasts in Bone marrow;CD30 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51153-5;Blasts.CD30/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD30 blasts/100 blasts in Blood;CD30 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51154-3;Blasts.CD30/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD30 blasts/100 blasts in Specimen;CD30 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51155-0;Blasts.CD33/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD33 blasts/100 blasts in Bone marrow;CD33 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51156-8;Blasts.CD33/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD33 blasts/100 blasts in Specimen;CD33 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51157-6;Blasts.CD33;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD33 blasts [Units/volume] in Bone marrow;CD33 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51158-4;Blasts.CD33;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD33 blasts [Units/volume] in Blood;CD33 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51159-2;Blasts.CD33;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD33 blasts [Units/volume] in Specimen;CD33 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +511-6;Trimethoprim;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Trimethoprim [Susceptibility] by Minimum lethal concentration (MLC);Trimethoprim Islt MLC;;ACTIVE;1.0;2.19 +51160-0;Blasts.CD33+CD34+/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD33+CD34+ blasts/100 blasts in Specimen;CD33+CD34+ Blasts NFr Spec;;ACTIVE;2.22;2.73 +51161-8;Blasts.cytoplasmic CD34/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;Cytoplasmic CD34 blasts/100 blasts in Specimen;cyCD34 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51162-6;Blasts.CD34/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD34 blasts/100 blasts in Bone marrow;CD34 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51163-4;Blasts.CD34/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD34 blasts/100 blasts in Specimen;CD34 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51164-2;Blasts.CD34;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD34 blasts [Units/volume] in Bone marrow;CD34 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51165-9;Blasts.CD34;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD34 blasts [Units/volume] in Blood;CD34 Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51166-7;Blasts.CD34;ACnc;Pt;XXX;Qn;;CELLMARK;1;CD34 blasts [Units/volume] in Specimen;CD34 Blasts Spec-aCnc;;ACTIVE;2.22;2.73 +51167-5;Blasts.CD34+CD117+/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD34+CD117+ blasts/100 blasts in Bone marrow;CD34+CD117+ Blasts NFr Mar;;ACTIVE;2.22;2.70 +51168-3;Blasts.CD34+CD117+/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD34+CD117+ blasts/100 blasts in Blood;CD34+CD117+ Blasts NFr Bld;;ACTIVE;2.22;2.70 +5116-9;Corynebacterium diphtheriae Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Corynebacterium diphtheriae Ab [Units/volume] in Serum by Immunoassay;C diphtheriae Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +51169-1;Blasts.CD34+CD117+/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD34+CD117+ blasts/100 blasts in Specimen;CD34+CD117+ Blasts NFr Spec;;ACTIVE;2.22;2.73 +51170-9;Blasts.CD34+CD117+;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD34+CD117+ blasts [Units/volume] in Bone marrow;CD34+CD117+ Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51171-7;Blasts.CD34+CD117+;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD34+CD117+ blasts [Units/volume] in Blood;CD34+CD117+ Blasts Bld-aCnc;;ACTIVE;2.22;2.73 +51172-5;Blasts.CD34+CD117+;Arb;Pt;XXX;Qn;;CELLMARK;1;CD34+CD117+ blasts in Specimen;CD34+CD117+ Blasts Spec;;ACTIVE;2.22;2.73 +51173-3;Blasts.CD36/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD36 blasts/100 blasts in Bone marrow;CD36 Blasts NFr Mar;;ACTIVE;2.22;2.70 +51174-1;Blasts.CD36/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD36 blasts/100 blasts in Blood;CD36 Blasts NFr Bld;;ACTIVE;2.22;2.70 +51175-8;Blasts.CD36/100 blasts;NFr;Pt;XXX;Qn;;CELLMARK;1;CD36 blasts/100 blasts in Specimen;CD36 Blasts NFr Spec;;ACTIVE;2.22;2.70 +51176-6;Blasts.CD36;Arb;Pt;Bone mar;Qn;;CELLMARK;1;CD36 blasts in Bone marrow;CD36 Blasts Mar;;ACTIVE;2.22;2.73 +5117-7;Cryoglobulin;PrThr;Pt;Ser;Ord;;CHEM;1;Cryoglobulin [Presence] in Serum;Cryoglob Ser Ql;;ACTIVE;1.0;2.73 +51177-4;Blasts.CD36;Arb;Pt;Bld;Qn;;CELLMARK;1;CD36 blasts in Blood;CD36 Blasts Bld;;ACTIVE;2.22;2.73 +51178-2;Blasts.CD36;Arb;Pt;XXX;Qn;;CELLMARK;1;CD36 blasts in Specimen;CD36 Blasts Spec;;ACTIVE;2.22;2.73 +51179-0;Blasts.CD36+CD235a+/100 blasts;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD36+CD235a+ blasts/100 blasts in Bone marrow;CD36+CD235a+ Blasts NFr Mar;;ACTIVE;2.22;2.70 +51180-8;Blasts.CD36+CD235a+/100 blasts;NFr;Pt;Bld;Qn;;CELLMARK;1;CD36+CD235a+ blasts/100 blasts in Blood;CD36+CD235a+ Blasts NFr Bld;;ACTIVE;2.22;2.70 +51181-6;Blasts.CD1;Arb;Pt;Bone mar;Qn;;CELLMARK;1;CD1 blasts in Bone marrow;CD1 Blasts Mar;;ACTIVE;2.22;2.73 +51182-4;Blasts.CD10;ACnc;Pt;Bone mar;Qn;;CELLMARK;1;CD10 blasts [Units/volume] in Bone marrow;CD10 Blasts Mar-aCnc;;ACTIVE;2.22;2.73 +51183-2;CD117 Ag;PrThr;Pt;Bone mar;Ord;Immune stain;CELLMARK;1;CD117 Ag [Presence] in Bone marrow by Immune stain;CD117 Ag Mar Ql ImStn;;ACTIVE;2.22;2.56 +51184-0;CD117 Ag;PrThr;Pt;Bld;Ord;Immune stain;CELLMARK;1;CD117 Ag [Presence] in Blood by Immune stain;CD117 Ag Bld Ql ImStn;;ACTIVE;2.22;2.56 +5118-5;Cryptococcus neoformans Ag;Titr;Pt;CSF;Qn;LA;MICRO;1;Deprecated Cryptococcus neoformans Ag [Titer] in Cerebral spinal fluid by Latex agglutination;Deprecated C neoform Ag Titr CSF LA;;DEPRECATED;1.0;2.70 +51185-7;CD117 Ag;PrThr;Pt;XXX;Ord;Immune stain;CELLMARK;1;CD117 Ag [Presence] in Specimen by Immune stain;CD117 Ag Spec Ql ImStn;;ACTIVE;2.22;2.73 +51186-5;CD15 Ag;PrThr;Pt;Bone mar;Ord;Immune stain;CELLMARK;1;CD15 Ag [Presence] in Bone marrow by Immune stain;CD15 Ag Mar Ql ImStn;;ACTIVE;2.22;2.56 +51187-3;CD15 Ag;PrThr;Pt;Bld;Ord;Immune stain;CELLMARK;1;CD15 Ag [Presence] in Blood by Immune stain;CD15 Ag Bld Ql ImStn;;ACTIVE;2.22;2.56 +51188-1;CD15 Ag;PrThr;Pt;XXX;Ord;Immune stain;CELLMARK;1;CD15 Ag [Presence] in Specimen by Immune stain;CD15 Ag Spec Ql ImStn;;ACTIVE;2.22;2.69 +51189-9;4-Hydroxybupivacaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;4-Hydroxybupivacaine [Mass/volume] in Serum or Plasma;4OH-bupivacaine SerPl-mCnc;;ACTIVE;2.22;2.70 +51190-7;Albumin;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Albumin [Mass/volume] in 24 hour Urine by Electrophoresis;Albumin 24h Ur Elph-mCnc;;ACTIVE;2.22;2.73 +51191-5;Antimony;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Antimony [Mass/volume] in Body fluid;Antimony Fld-mCnc;;ACTIVE;2.22;2.70 +51192-3;Barium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Barium [Mass/volume] in Body fluid;Barium Fld-mCnc;;ACTIVE;2.22;2.70 +5119-3;Cryptococcus neoformans Ag;Titr;Pt;Ser;Qn;LA;MICRO;1;Deprecated Cryptococcus neoformans Ag [Titer] in Serum by Latex agglutination;Deprecated C neoform Ag Titr Ser LA;;DEPRECATED;1.0;2.70 +51193-1;Cadmium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Body fluid;Cadmium Fld-mCnc;;ACTIVE;2.22;2.70 +51194-9;Cobalt;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Body fluid;Cobalt Fld-mCnc;;ACTIVE;2.22;2.73 +51195-6;Desbutylbupivacaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desbutylbupivacaine [Mass/volume] in Serum or Plasma;Desbutylbupivacaine SerPl-mCnc;;ACTIVE;2.22;2.70 +51196-4;Hemoglobin A1/Hemoglobin.total;MFr;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A1/Hemoglobin.total in Blood by Electrophoresis;Hgb A1 MFr Bld Elph;;ACTIVE;2.22;2.73 +51197-2;Iron;MCnc;Pt;Body fld;Qn;;CHEM;1;Iron [Mass/volume] in Body fluid;Iron Fld-mCnc;;ACTIVE;2.22;2.70 +51198-0;Manganese;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Body fluid;Manganese Fld-mCnc;;ACTIVE;2.22;2.70 +51199-8;Molybdenum;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Molybdenum [Mass/volume] in Body fluid;Molybdenum Fld-mCnc;;ACTIVE;2.22;2.70 +51200-4;Nickel;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Body fluid;Nickel Fld-mCnc;;ACTIVE;2.22;2.70 +5120-1;Taenia solium larva Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Taenia solium larva Ab [Units/volume] in Serum by Hemagglutination;T sol lar Ab Ser HA-aCnc;;ACTIVE;1.0;2.69 +51201-2;Palladium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Palladium [Mass/volume] in Body fluid;Palladium Fld-mCnc;;ACTIVE;2.22;2.70 +51202-0;Platinum;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Platinum [Mass/volume] in Body fluid;Platinum Fld-mCnc;;ACTIVE;2.22;2.70 +51203-8;Ropivacaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ropivacaine [Mass/volume] in Serum or Plasma;Ropivacaine SerPl-mCnc;;ACTIVE;2.22;2.70 +51204-6;Silicon;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Silicon [Mass/mass] in Hair;Silicon Hair-mCnt;;ACTIVE;2.22;2.70 +51205-3;Sodium;MCnt;Pt;Hair;Qn;;CHEM;1;Sodium [Mass/mass] in Hair;Sodium Hair-mCnt;;ACTIVE;2.22;2.70 +51206-1;Strontium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Strontium [Mass/volume] in Body fluid;Strontium Fld-mCnc;;ACTIVE;2.22;2.70 +51207-9;Thallium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in Body fluid;Thallium Fld-mCnc;;ACTIVE;2.22;2.70 +51208-7;Tin;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Tin [Mass/volume] in Body fluid;Tin Fld-mCnc;;ACTIVE;2.22;2.70 +51209-5;Tin;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Tin [Mass/mass] in Hair;Tin Hair-mCnt;;ACTIVE;2.22;2.70 +51210-3;Titanium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Titanium [Mass/volume] in Body fluid;Titanium Fld-mCnc;;ACTIVE;2.22;2.73 +51211-1;Uranium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Uranium [Mass/volume] in Body fluid;Uranium Fld-mCnc;;ACTIVE;2.22;2.70 +51212-9;Vanadium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Vanadium [Mass/volume] in Body fluid;Vanadium Fld-mCnc;;ACTIVE;2.22;2.70 +51213-7;Acetaminophen crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Acetaminophen crystals [#/area] in Urine sediment by Microscopy high power field;Acetamin Cry #/area UrnS HPF;;ACTIVE;2.22;2.70 +51214-5;Cells.CD10/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD10 cells/100 cells in Tissue;CD10 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51215-2;Cells.CD10/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD10 cells/100 cells in Cerebral spinal fluid;CD10 Cells NFr CSF;;ACTIVE;2.22;2.70 +51216-0;Cells.CD10/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD10 cells/100 cells in Bone marrow;CD10 Cells NFr Mar;;ACTIVE;2.22;2.70 +51217-8;Cells.CD10/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD10 cells/100 cells in Body fluid;CD10 Cells NFr Fld;;ACTIVE;2.22;2.70 +51218-6;Cells.CD10+CD19+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD10+CD19+ cells/100 cells in Cerebral spinal fluid;CD10+CD19+ Cells NFr CSF;;ACTIVE;2.22;2.70 +5121-9;Cytomegalovirus Ab;Titr;Pt;Ser/Plas;Qn;LA;MICRO;1;Cytomegalovirus Ab [Titer] in Serum or Plasma by Latex agglutination;CMV Ab Titr SerPl LA;;ACTIVE;1.0;2.70 +51219-4;Cells.CD10+CD19+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD10+CD19+ cells/100 cells in Body fluid;CD10+CD19+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51220-2;Cells.CD103/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD103 cells/100 cells in Cerebral spinal fluid;CD103 Cells NFr CSF;;ACTIVE;2.22;2.70 +51221-0;Cells.CD103/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD103 cells/100 cells in Bone marrow;CD103 Cells NFr Mar;;ACTIVE;2.22;2.70 +51222-8;Cells.CD105/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD105 cells/100 cells in Tissue;CD105 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51223-6;Cells.CD105/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD105 cells/100 cells in Cerebral spinal fluid;CD105 Cells NFr CSF;;ACTIVE;2.22;2.70 +51224-4;Cells.CD105/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD105 cells/100 cells in Bone marrow;CD105 Cells NFr Mar;;ACTIVE;2.22;2.70 +51225-1;Cells.CD105/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD105 cells/100 cells in Body fluid;CD105 Cells NFr Fld;;ACTIVE;2.22;2.70 +51226-9;Cells.CD117/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD117 cells/100 cells in Cerebral spinal fluid;CD117 Cells NFr CSF;;ACTIVE;2.22;2.70 +5122-7;Cytomegalovirus Ab;ACnc;Pt;Ser/Plas;Qn;IF;MICRO;1;Cytomegalovirus Ab [Units/volume] in Serum or Plasma by Immunofluorescence;CMV Ab SerPl IF-aCnc;;ACTIVE;1.0;2.69 +51227-7;Cells.CD11b/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD11b cells/100 cells in Tissue;CD11b Cells NFr Tiss;;ACTIVE;2.22;2.70 +51228-5;Cells.CD11b/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD11b cells/100 cells in Cerebral spinal fluid;CD11b Cells NFr CSF;;ACTIVE;2.22;2.70 +51229-3;Cells.CD11b/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD11b cells/100 cells in Bone marrow;CD11b Cells NFr Mar;;ACTIVE;2.22;2.70 +51230-1;Cells.CD11b/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD11b cells/100 cells in Body fluid;CD11b Cells NFr Fld;;ACTIVE;2.22;2.70 +51231-9;Cells.CD11c/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD11c cells/100 cells in Cerebral spinal fluid;CD11c Cells NFr CSF;;ACTIVE;2.22;2.70 +51232-7;Cells.CD11c/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD11c cells/100 cells in Body fluid;CD11c Cells NFr Fld;;ACTIVE;2.22;2.70 +51233-5;Cells.CD11c+CD19+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD11c+CD19+ cells/100 cells in Cerebral spinal fluid;CD11c+CD19+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51234-3;Cells.CD11c+CD19+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11c+CD19+ cells/100 cells in Blood;CD11c+CD19+ Cells NFr Bld;;ACTIVE;2.22;2.70 +5123-5;Cytomegalovirus Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Deprecated Cytomegalovirus Ab [Titer] in Serum by Latex agglutination;Deprecated CMV Ab Titr Ser LA;;DEPRECATED;1.0;2.70 +51235-0;Cells.CD13/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD13 cells/100 cells in Tissue;CD13 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51236-8;Cells.CD13/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD13 cells/100 cells in Cerebral spinal fluid;CD13 Cells NFr CSF;;ACTIVE;2.22;2.70 +51237-6;Cells.CD13/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD13 cells/100 cells in Bone marrow;CD13 Cells NFr Mar;;ACTIVE;2.22;2.70 +51238-4;Cells.CD13/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD13 cells/100 cells in Body fluid;CD13 Cells NFr Fld;;ACTIVE;2.22;2.70 +51239-2;Cells.CD13+CD33+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD13+CD33+ cells/100 cells in Cerebral spinal fluid;CD13+CD33+ Cells NFr CSF;;ACTIVE;2.22;2.70 +512-4;Trimethoprim;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Trimethoprim [Susceptibility] by Minimum inhibitory concentration (MIC);Trimethoprim Islt MIC;;ACTIVE;1.0;2.73 +51240-0;Cells.CD13+CD33+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD13+CD33+ cells/100 cells in Body fluid;CD13+CD33+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51241-8;Cells.CD13+CD33+HLA-DR+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD13+CD33+HLA-DR+ cells/100 cells in Tissue;CD13+CD33+HLA-DR+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51242-6;Cells.CD13+CD33+HLA-DR+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD13+CD33+HLA-DR+ cells/100 cells in Cerebral spinal fluid;CD13+CD33+HLA-DR+ Cells NFr CSF;;ACTIVE;2.22;2.70 +5124-3;Cytomegalovirus Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;CMV IgG SerPl IA-aCnc;;ACTIVE;1.0;2.73 +51243-4;Cells.CD13+CD33+HLA-DR+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD13+CD33+HLA-DR+ cells/100 cells in Bone marrow;CD13+CD33+HLA-DR+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51244-2;Cells.CD13+CD33+HLA-DR+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD13+CD33+HLA-DR+ cells/100 cells in Body fluid;CD13+CD33+HLA-DR+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51245-9;Cells.CD13+CD33+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD13+CD33+HLA-DR+ cells/100 cells in Blood;CD13+CD33+HLA-DR+ Cells NFr Bld;;ACTIVE;2.22;2.70 +51246-7;Cells.CD138/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD138 cells/100 cells in Cerebral spinal fluid;CD138 Cells NFr CSF;;ACTIVE;2.22;2.70 +51247-5;Cells.CD14/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD14 cells/100 cells in Cerebral spinal fluid;CD14 Cells NFr CSF;;ACTIVE;2.22;2.70 +51248-3;Cells.CD14/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD14 cells/100 cells in Body fluid;CD14 Cells NFr Fld;;ACTIVE;2.22;2.70 +51249-1;Cells.CD15/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD15 cells/100 cells in Tissue;CD15 Cells NFr Tiss;;ACTIVE;2.22;2.70 +5125-0;Cytomegalovirus Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Cytomegalovirus IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;CMV IgG Titr SerPl IF;;ACTIVE;1.0;2.70 +51250-9;Cells.CD15/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD15 cells/100 cells in Cerebral spinal fluid;CD15 Cells NFr CSF;;ACTIVE;2.22;2.70 +51251-7;Cells.CD15/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD15 cells/100 cells in Bone marrow;CD15 Cells NFr Mar;;ACTIVE;2.22;2.70 +51252-5;Cells.CD15/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD15 cells/100 cells in Body fluid;CD15 Cells NFr Fld;;ACTIVE;2.22;2.70 +51253-3;Cells.CD16+CD56+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD16+CD56+ cells/100 cells in Tissue;CD16+CD56+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51254-1;Cells.CD16+CD56+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD16+CD56+ cells/100 cells in Cerebral spinal fluid;CD16+CD56+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51255-8;Cells.CD16+CD56+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD16+CD56+ cells/100 cells in Bone marrow;CD16+CD56+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51256-6;Cells.CD16+CD57+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD16+CD57+ cells/100 cells in Tissue;CD16+CD57+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51257-4;Cells.CD16+CD57+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD16+CD57+ cells/100 cells in Cerebral spinal fluid;CD16+CD57+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51258-2;Cells.CD16+CD57+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD16+CD57+ cells/100 cells in Bone marrow;CD16+CD57+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51259-0;Cells.CD16+CD57+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD16+CD57+ cells/100 cells in Body fluid;CD16+CD57+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51260-8;Cells.CD16b/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD16B cells/100 cells in Tissue;CD16B Cells NFr Tiss;;ACTIVE;2.22;2.70 +51261-6;Cells.CD16b/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD16B cells/100 cells in Cerebral spinal fluid;CD16B Cells NFr CSF;;ACTIVE;2.22;2.70 +51262-4;Cells.CD16b/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD16B cells/100 cells in Bone marrow;CD16B Cells NFr Mar;;ACTIVE;2.22;2.70 +51263-2;Cells.CD16b/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD16B cells/100 cells in Body fluid;CD16B Cells NFr Fld;;ACTIVE;2.22;2.70 +51264-0;Cells.CD19/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD19 cells/100 cells in Tissue;CD19 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51265-7;Cells.CD19/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD19 cells/100 cells in Cerebral spinal fluid;CD19 Cells NFr CSF;;ACTIVE;2.22;2.70 +51266-5;Cells.CD23/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD23 cells/100 cells in Tissue;CD23 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51267-3;Cells.CD23/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD23 cells/100 cells in Cerebral spinal fluid;CD23 Cells NFr CSF;;ACTIVE;2.22;2.70 +5126-8;Cytomegalovirus Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;CMV IgM SerPl IA-aCnc;;ACTIVE;1.0;2.73 +51268-1;Cells.CD23/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD23 cells/100 cells in Bone marrow;CD23 Cells NFr Mar;;ACTIVE;2.22;2.73 +51269-9;Cells.CD23/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD23 cells/100 cells in Body fluid;CD23 Cells NFr Fld;;ACTIVE;2.22;2.70 +51270-7;Cells.CD25/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD25 cells/100 cells in Cerebral spinal fluid;CD25 Cells NFr CSF;;ACTIVE;2.22;2.70 +51271-5;Cells.CD25/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD25 cells/100 cells in Body fluid;CD25 Cells NFr Fld;;ACTIVE;2.22;2.70 +51272-3;Cells.CD25+CD19+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD25+CD19+ cells/100 cells in Cerebral spinal fluid;CD25+CD19+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51273-1;Cells.CD3/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3 cells/100 cells in Tissue;CD3 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51274-9;Cells.CD3+CD16+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD16+ cells/100 cells in Tissue;CD3+CD16+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51275-6;Cells.CD3+CD16+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD16+ cells/100 cells in Cerebral spinal fluid;CD3+CD16+ Cells NFr CSF;;ACTIVE;2.22;2.70 +5127-6;Cytomegalovirus Ab.IgM;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Cytomegalovirus IgM Ab [Titer] in Serum or Plasma by Immunofluorescence;CMV IgM Titr SerPl IF;;ACTIVE;1.0;2.73 +51276-4;Cells.CD3+CD16+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD16+ cells/100 cells in Bone marrow;CD3+CD16+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51277-2;Cells.CD3+CD16+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD16+ cells/100 cells in Body fluid;CD3+CD16+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51278-0;Cells.CD3+CD56+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD56+ cells/100 cells in Tissue;CD3+CD56+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51279-8;Cells.CD3+CD56+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD56+ cells/100 cells in Cerebral spinal fluid;CD3+CD56+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51280-6;Cells.CD3+CD56+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD56+ cells/100 cells in Bone marrow;CD3+CD56+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51281-4;Cells.CD3+CD56+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD56+ cells/100 cells in Body fluid;CD3+CD56+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51282-2;Cells.CD3+CD57+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD57+ cells/100 cells in Tissue;CD3+CD57+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51283-0;Cells.CD3+CD57+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD57+ cells/100 cells in Cerebral spinal fluid;CD3+CD57+ Cells NFr CSF;;ACTIVE;2.22;2.70 +5128-4;Neutrophil cytoplasmic Ab;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic Ab [Units/volume] in Serum;ANCA Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51284-8;Cells.CD3+CD57+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD57+ cells/100 cells in Bone marrow;CD3+CD57+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51285-5;Cells.CD3+CD57+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+CD57+ cells/100 cells in Body fluid;CD3+CD57+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51286-3;Cells.CD3+CD57+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD57+ cells/100 cells in Blood;CD3+CD57+ Cells NFr Bld;;ACTIVE;2.22;2.73 +51287-1;Cells.CD30/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD30 cells/100 cells in Tissue;CD30 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51288-9;Cells.CD30/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD30 cells/100 cells in Cerebral spinal fluid;CD30 Cells NFr CSF;;ACTIVE;2.22;2.70 +51289-7;Cells.CD30/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD30 cells/100 cells in Bone marrow;CD30 Cells NFr Mar;;ACTIVE;2.22;2.70 +51290-5;Cells.CD30/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD30 cells/100 cells in Body fluid;CD30 Cells NFr Fld;;ACTIVE;2.22;2.70 +51291-3;Cells.CD33/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD33 cells/100 cells in Tissue;CD33 Cells NFr Tiss;;ACTIVE;2.22;2.70 +5129-2;Deoxyribonuclease Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deoxyribonuclease Ab [Units/volume] in Serum;DNAse Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51292-1;Cells.CD33/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD33 cells/100 cells in Cerebral spinal fluid;CD33 Cells NFr CSF;;ACTIVE;2.22;2.70 +51293-9;Cells.CD33/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD33 cells/100 cells in Bone marrow;CD33 Cells NFr Mar;;ACTIVE;2.22;2.70 +51294-7;Cells.CD33/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD33 cells/100 cells in Body fluid;CD33 Cells NFr Fld;;ACTIVE;2.22;2.70 +51295-4;Cells.CD36/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD36 cells/100 cells in Cerebral spinal fluid;CD36 Cells NFr CSF;;ACTIVE;2.22;2.70 +51296-2;Cells.CD38/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD38 cells/100 cells in Tissue;CD38 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51297-0;Cells.CD38/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD38 cells/100 cells in Cerebral spinal fluid;CD38 Cells NFr CSF;;ACTIVE;2.22;2.70 +51298-8;Cells.CD38/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD38 cells/100 cells in Bone marrow;CD38 Cells NFr Mar;;ACTIVE;2.22;2.70 +51299-6;Cells.CD38/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD38 cells/100 cells in Body fluid;CD38 Cells NFr Fld;;ACTIVE;2.22;2.70 +51-3;Butirosin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Butirosin [Susceptibility] by Minimum lethal concentration (MLC);Butirosin Islt MLC;;ACTIVE;1.0;2.19 +5130-0;DNA double strand Ab;ACnc;Pt;Ser;Qn;;SERO;1;DNA double strand Ab [Units/volume] in Serum;dsDNA Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51300-2;Cells.CD3+CD4+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 cells in Tissue;CD3+CD4+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51301-0;Cells.CD4/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Deprecated CD4 cells/100 cells in Bone marrow;Deprecated CD4 Cells NFr Mar;;DEPRECATED;2.22;2.70 +51302-8;Cells.CD4+CD7-/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD4+CD7- cells/100 cells in Tissue;CD4+CD7- Cells NFr Tiss;;ACTIVE;2.22;2.70 +51303-6;Cells.CD4+CD7-/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD4+CD7- cells/100 cells in Cerebral spinal fluid;CD4+CD7- Cells NFr CSF;;ACTIVE;2.22;2.70 +51304-4;Cells.CD4+CD7-/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD4+CD7- cells/100 cells in Bone marrow;CD4+CD7- Cells NFr Mar;;ACTIVE;2.22;2.70 +51305-1;Cells.CD4+CD7-/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD7- cells/100 cells in Body fluid;CD4+CD7- Cells NFr Fld;;ACTIVE;2.22;2.70 +51306-9;Cells.CD4+CD7-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD7- cells/100 cells in Blood;CD4+CD7- Cells NFr Bld;;ACTIVE;2.22;2.70 +51307-7;Cells.CD4+CD7-CD26-/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD4+CD7-CD26- cells/100 cells in Tissue;CD4+CD7-CD26- Cells NFr Tiss;;ACTIVE;2.22;2.70 +51308-5;Cells.CD4+CD7-CD26-/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD4+CD7-CD26- cells/100 cells in Cerebral spinal fluid;CD4+CD7-CD26- Cells NFr CSF;;ACTIVE;2.22;2.70 +51309-3;Cells.CD4+CD7-CD26-/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD4+CD7-CD26- cells/100 cells in Bone marrow;CD4+CD7-CD26- Cells NFr Mar;;ACTIVE;2.22;2.70 +51310-1;Cells.CD4+CD7-CD26-/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD7-CD26- cells/100 cells in Body fluid;CD4+CD7-CD26- Cells NFr Fld;;ACTIVE;2.22;2.70 +51311-9;Cells.CD4+CD7-CD26-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD7-CD26- cells/100 cells in Blood;CD4+CD7-CD26- Cells NFr Bld;;ACTIVE;2.22;2.70 +51312-7;Cells.CD4+CD7-CD49d-/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD4+CD7-CD49D- cells/100 cells in Tissue;CD4+CD7-CD49D- Cells NFr Tiss;;ACTIVE;2.22;2.70 +51313-5;Cells.CD4+CD7-CD49d-/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD4+CD7-CD49D- cells/100 cells in Cerebral spinal fluid;CD4+CD7-CD49D- Cells NFr CSF;;ACTIVE;2.22;2.70 +51314-3;Cells.CD4+CD7-CD49d-/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD4+CD7-CD49D- cells/100 cells in Bone marrow;CD4+CD7-CD49D- Cells NFr Mar;;ACTIVE;2.22;2.70 +51315-0;Cells.CD4+CD7-CD49d-/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD7-CD49D- cells/100 cells in Body fluid;CD4+CD7-CD49D- Cells NFr Fld;;ACTIVE;2.22;2.70 +51316-8;Cells.CD4+CD7-CD49d-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4+CD7-CD49D- cells/100 cells in Blood;CD4+CD7-CD49D- Cells NFr Bld;;ACTIVE;2.22;2.70 +51317-6;Cells.CD41/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD41 cells/100 cells in Tissue;CD41 Cells NFr Tiss;;ACTIVE;2.22;2.70 +5131-8;DNA double strand Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;DNA double strand Ab [Presence] in Serum by Immunofluorescence;dsDNA Ab Ser Ql IF;;ACTIVE;1.0;2.73 +51318-4;Cells.CD41/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD41 cells/100 cells in Cerebral spinal fluid;CD41 Cells NFr CSF;;ACTIVE;2.22;2.70 +51319-2;Cells.CD41/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD41 cells/100 cells in Bone marrow;CD41 Cells NFr Mar;;ACTIVE;2.22;2.70 +513-2;Trimethoprim;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Trimethoprim [Susceptibility] by Disk diffusion (KB);Trimethoprim Islt KB;;ACTIVE;1.0;2.73 +51320-0;Cells.CD41/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD41 cells/100 cells in Body fluid;CD41 Cells NFr Fld;;ACTIVE;2.22;2.70 +51321-8;Cells.CD42/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD42 cells/100 cells in Tissue;CD42 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51322-6;Cells.CD42/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD42 cells/100 cells in Cerebral spinal fluid;CD42 Cells NFr CSF;;ACTIVE;2.22;2.70 +51323-4;Cells.CD42/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD42 cells/100 cells in Bone marrow;CD42 Cells NFr Mar;;ACTIVE;2.22;2.70 +51324-2;Cells.CD42/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD42 cells/100 cells in Body fluid;CD42 Cells NFr Fld;;ACTIVE;2.22;2.70 +51325-9;Cells.CD42b/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD42b cells/100 cells in Tissue;CD42b Cells NFr Tiss;;ACTIVE;2.22;2.70 +5132-6;DNA single strand Ab;ACnc;Pt;Ser;Qn;;SERO;1;DNA single strand Ab [Units/volume] in Serum;ssDNA Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51326-7;Cells.CD42b/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD42b cells/100 cells in Cerebral spinal fluid;CD42b Cells NFr CSF;;ACTIVE;2.22;2.70 +51327-5;Cells.CD42b/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD42b cells/100 cells in Bone marrow;CD42b Cells NFr Mar;;ACTIVE;2.22;2.70 +51328-3;Cells.CD42b/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD42b cells/100 cells in Body fluid;CD42b Cells NFr Fld;;ACTIVE;2.22;2.70 +51329-1;Cells.CD43/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD43 cells/100 cells in Tissue;CD43 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51330-9;Cells.CD43/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD43 cells/100 cells in Cerebral spinal fluid;CD43 Cells NFr CSF;;ACTIVE;2.22;2.70 +51331-7;Cells.CD43/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD43 cells/100 cells in Bone marrow;CD43 Cells NFr Mar;;ACTIVE;2.22;2.70 +51332-5;Cells.CD43/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD43 cells/100 cells in Body fluid;CD43 Cells NFr Fld;;ACTIVE;2.22;2.70 +51333-3;Cells.CD19+CD43+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD19+CD43+ cells/100 cells in Tissue;CD19+CD43+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +5133-4;DNAse B Ab.Streptococcal;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcal DNAse B [Units/volume] in Serum;Strep DNAse B Ser-aCnc;;ACTIVE;1.0;2.73 +51334-1;Cells.CD19+CD43+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD19+CD43+ cells/100 cells in Cerebral spinal fluid;CD19+CD43+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51335-8;Cells.CD19+CD43+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19+CD43+ cells/100 cells in Bone marrow;CD19+CD43+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51336-6;Cells.CD19+CD43+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD43+ cells/100 cells in Body fluid;CD19+CD43+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51337-4;Cells.CD19+CD43+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+CD43+ cells/100 cells in Blood;CD19+CD43+ Cells NFr Bld;;ACTIVE;2.22;2.70 +51338-2;Cells.CD45/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD45 (Lymphs) cells/100 cells in Tissue;CD45 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51339-0;Cells.CD45/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD45 (Lymphs) cells/100 cells in Cerebral spinal fluid;CD45 Cells NFr CSF;;ACTIVE;2.22;2.70 +51340-8;Cells.CD45/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD45 (Lymphs) cells/100 cells in Bone marrow;CD45 Cells NFr Mar;;ACTIVE;2.22;2.73 +51341-6;Cells.CD5+CD19+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD5+CD19+ cells/100 cells in Cerebral spinal fluid;CD5+CD19+ Cells NFr CSF;;ACTIVE;2.22;2.70 +5134-2;Eastern equine encephalitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus Ab [Units/volume] in Serum;EEEV Ab Ser-aCnc;;ACTIVE;1.0;2.69 +51342-4;Cells.CD5+CD19+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD5+CD19+ cells/100 cells in Body fluid;CD5+CD19+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51343-2;Cells.CD55/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD55 cells/100 cells in Cerebral spinal fluid;CD55 Cells NFr CSF;;ACTIVE;2.22;2.70 +51344-0;Cells.CD55/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD55 cells/100 cells in Bone marrow;CD55 Cells NFr Mar;;ACTIVE;2.22;2.70 +51345-7;Cells.CD56+CD57+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD56+CD57+ cells/100 cells in Tissue;CD56+CD57+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51346-5;Cells.CD56+CD57+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD56+CD57+ cells/100 cells in Cerebral spinal fluid;CD56+CD57+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51347-3;Cells.CD56+CD57+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD56+CD57+ cells/100 cells in Bone marrow;CD56+CD57+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51348-1;Cells.CD56+CD57+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD56+CD57+ cells/100 cells in Body fluid;CD56+CD57+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51349-9;Cells.CD56+CD57+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD56+CD57+ cells/100 cells in Blood;CD56+CD57+ Cells NFr Bld;;ACTIVE;2.22;2.70 +51350-7;Cells.CD57/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD57 cells/100 cells in Cerebral spinal fluid;CD57 Cells NFr CSF;;ACTIVE;2.22;2.70 +51351-5;Cells.CD57/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD57 cells/100 cells in Body fluid;CD57 Cells NFr Fld;;ACTIVE;2.22;2.70 +51352-3;Cells.CD19+CD58+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD19+CD58+ cells/100 cells in Tissue;CD19+CD58+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51353-1;Cells.CD19+CD58+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD19+CD58+ cells/100 cells in Cerebral spinal fluid;CD19+CD58+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51354-9;Cells.CD19+CD58+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19+CD58+ cells/100 cells in Bone marrow;CD19+CD58+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51355-6;Cells.CD19+CD58+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD58+ cells/100 cells in Body fluid;CD19+CD58+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51356-4;Cells.CD19+CD58+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+CD58+ cells/100 cells in Blood;CD19+CD58+ Cells NFr Bld;;ACTIVE;2.22;2.70 +51357-2;Cells.CD59/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD59 cells/100 cells in Cerebral spinal fluid;CD59 Cells NFr CSF;;ACTIVE;2.22;2.70 +51358-0;Cells.CD59/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD59 cells/100 cells in Bone marrow;CD59 Cells NFr Mar;;ACTIVE;2.22;2.70 +5135-9;Echinococcus sp Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Echinococcus sp Ab [Units/volume] in Serum by Hemagglutination;Echinococcus Ab Ser HA-aCnc;;ACTIVE;1.0;2.69 +51359-8;Cells.CD61/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD61 cells/100 cells in Tissue;CD61 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51360-6;Cells.CD61/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD61 cells/100 cells in Cerebral spinal fluid;CD61 Cells NFr CSF;;ACTIVE;2.22;2.70 +51361-4;Cells.CD61/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD61 cells/100 cells in Bone marrow;CD61 Cells NFr Mar;;ACTIVE;2.22;2.70 +51362-2;Cells.CD61/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD61 cells/100 cells in Body fluid;CD61 Cells NFr Fld;;ACTIVE;2.22;2.70 +51363-0;Cells.CD64/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD64 cells/100 cells in Tissue;CD64 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51364-8;Cells.CD64/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD64 cells/100 cells in Cerebral spinal fluid;CD64 Cells NFr CSF;;ACTIVE;2.22;2.70 +51365-5;Cells.CD64/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD64 cells/100 cells in Bone marrow;CD64 Cells NFr Mar;;ACTIVE;2.22;2.70 +51366-3;Cells.CD64/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD64 cells/100 cells in Body fluid;CD64 Cells NFr Fld;;ACTIVE;2.22;2.70 +5136-7;Echovirus 1 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 1 neutralizing antibody [Titer] in Serum by Neutralization test;ECV1 NAb Titr Ser Nt;;ACTIVE;1.0;2.72 +51367-1;Cells.CD79a/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD79a cells/100 cells in Bone marrow;CD79a Cells NFr Mar;;ACTIVE;2.22;2.70 +51368-9;Cells.CD79a/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD79a cells/100 cells in Body fluid;CD79a Cells NFr Fld;;ACTIVE;2.22;2.70 +51369-7;Cells.CD79b/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD79b cells/100 cells in Cerebral spinal fluid;CD79b Cells NFr CSF;;ACTIVE;2.22;2.70 +51370-5;Cells.CD8+HLA-DR+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD8+HLA-DR+ cells/100 cells in Tissue;CD8+HLA-DR+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51371-3;Cells.CD8+HLA-DR+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD8+HLA-DR+ cells/100 cells in Cerebral spinal fluid;CD8+HLA-DR+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51372-1;Cells.CD8+HLA-DR+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD8+HLA-DR+ cells/100 cells in Bone marrow;CD8+HLA-DR+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51373-9;Cells.CD8+HLA-DR+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD8+HLA-DR+ cells/100 cells in Body fluid;CD8+HLA-DR+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51374-7;Cells.CD9/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD9 cells/100 cells in Tissue;CD9 Cells NFr Tiss;;ACTIVE;2.22;2.70 +5137-5;Echovirus 1 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 1 Ab [Titer] in Serum by Complement fixation;ECV1 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51375-4;Cells.CD9/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD9 cells/100 cells in Cerebral spinal fluid;CD9 Cells NFr CSF;;ACTIVE;2.22;2.70 +51376-2;Cells.CD9/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD9 cells/100 cells in Bone marrow;CD9 Cells NFr Mar;;ACTIVE;2.22;2.70 +51377-0;Cells.CD9/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD9 cells/100 cells in Body fluid;CD9 Cells NFr Fld;;ACTIVE;2.22;2.70 +51378-8;Cells.HLA-DR+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;HLA-DR+ cells/100 cells in Tissue;HLA-DR+ Cells NFr Tiss;;ACTIVE;2.22;2.70 +51379-6;Cells.HLA-DR+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;HLA-DR+ cells/100 cells in Cerebral spinal fluid;HLA-DR+ Cells NFr CSF;;ACTIVE;2.22;2.70 +51380-4;Cells.HLA-DR+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;HLA-DR+ cells/100 cells in Bone marrow;HLA-DR+ Cells NFr Mar;;ACTIVE;2.22;2.70 +51381-2;Cells.HLA-DR+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;HLA-DR+ cells/100 cells in Body fluid;HLA-DR+ Cells NFr Fld;;ACTIVE;2.22;2.70 +51382-0;Erythrocytes;Naric;Pt;Synv fld;Qn;Microscopy.light;HEM/BC;1;Erythrocytes [#/area] in Synovial fluid by Light microscopy;RBC #/area Snv Micro;;ACTIVE;2.22;2.73 +5138-3;Echovirus 19 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 19 neutralizing antibody [Titer] in Serum by Neutralization test;ECV19 NAb Titr Ser Nt;;ACTIVE;1.0;2.72 +51383-8;Leukocytes other;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Leukocytes other [#/volume] in Blood by Automated count;WBC Other # Bld Auto;;ACTIVE;2.22;2.70 +51384-6;Mononuclear cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Blood by Manual count;Mononuc Cells/leuk NFr Bld Manual;;ACTIVE;2.22;2.73 +51385-3;Plasma cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Plasma cells/100 leukocytes in Cerebral spinal fluid by Manual count;Plasma Cells/leuk NFr CSF Manual;;ACTIVE;2.22;2.70 +51386-1;Plasma cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Plasma cells/100 leukocytes in Body fluid by Manual count;Plasma Cells/leuk NFr Fld Manual;;ACTIVE;2.22;2.73 +51387-9;(Views) + (view AP^W standing);Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Views and (AP W standing);XR Knee-Bl Views+AP Stand;;ACTIVE;2.22;2.61 +51388-7;Views;Find;Pt;Upper extremity.right>Wrist+Hand;Doc;XR;RAD;2;XR Wrist - right and Hand - right Views;XR Wrist+Hand-R Views;;ACTIVE;2.22;2.64 +51389-5;Views^W Tl-201 IV;Find;Pt;Breast;Doc;NM;RAD;2;NM Breast Views W Tl-201 IV;NM Brst Views W Tl-201 IV;;ACTIVE;2.22;2.64 +51390-3;Views AP & lateral;Find;Pt;Abdomen;Nar;XR;RAD;2;Deprecated Abdomen X-ray AP & lateral;Deprecated Abd XR AP+Lat;;DEPRECATED;2.22;2.36 +5139-1;Echovirus 19 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 19 Ab [Titer] in Serum by Complement fixation;ECV19 Ab Titr Ser CF;;ACTIVE;1.0;2.70 +51391-1;Guidance for transjugular placement of transjugular intrahepatic portosystemic shunt;Find;Pt;Abdomen>Portal vein+Hepatic vein;Doc;RF.angio;RAD;2;RFA Guidance for placement of TIPS of Portal vein and Hepatic vein;RFA Guided Portal v+Hepatic v TIPS place;;ACTIVE;2.22;2.64 +51392-9;Views;Find;Pt;Upper extremity.left>Wrist+Hand;Doc;XR;RAD;2;XR Wrist - left and Hand - left Views;XR Wrist+Hand-L Views;;ACTIVE;2.22;2.64 +51393-7;Esophageal manometry study;Find;Stdy;Esophagus;Doc;Manometry;ENDO.GI;2;Esophageal manometry study;Manometry study;;ACTIVE;2.22;2.72 +51394-5;Views;Find;Pt;Lower extremity.right>Ankle+Foot;Doc;XR;RAD;2;XR Ankle and Foot - right Views;XR Ankle+Foot-R Views;;ACTIVE;2.22;2.64 +51395-2;Views;Find;Pt;Lower extremity.left>Ankle+Foot;Doc;XR;RAD;2;XR Ankle and Foot - left Views;XR Ankle+Foot-L Views;;ACTIVE;2.22;2.64 +51396-0;Cells.CD65w/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD65w cells/100 cells in Tissue;CD65w Cells NFr Tiss;;ACTIVE;2.22;2.70 +51397-8;Cells.CD65w/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD65w cells/100 cells in Cerebral spinal fluid;CD65w Cells NFr CSF;;ACTIVE;2.22;2.70 +51398-6;Cells.CD65w/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD65w cells/100 cells in Bone marrow;CD65w Cells NFr Mar;;ACTIVE;2.22;2.70 +51399-4;Cells.CD65w/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD65w cells/100 cells in Body fluid;CD65w Cells NFr Fld;;ACTIVE;2.22;2.70 +514-0;Trimethoprim;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Trimethoprim [Susceptibility] by Serum bactericidal titer;Trimethoprim Titr SBT;;ACTIVE;1.0;2.32 +51400-0;Cells.CD65w/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD65w cells/100 cells in Blood;CD65w Cells NFr Bld;;ACTIVE;2.22;2.70 +51401-8;Cells.CD81/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD81 cells/100 cells in Tissue;CD81 Cells NFr Tiss;;ACTIVE;2.22;2.70 +51402-6;Cells.CD81/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD81 cells/100 cells in Cerebral spinal fluid;CD81 Cells NFr CSF;;ACTIVE;2.22;2.70 +51403-4;Cells.CD81/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD81 cells/100 cells in Bone marrow;CD81 Cells NFr Mar;;ACTIVE;2.22;2.70 +51404-2;Cells.CD81/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD81 cells/100 cells in Body fluid;CD81 Cells NFr Fld;;ACTIVE;2.22;2.70 +51405-9;Cells.CD81/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD81 cells/100 cells in Blood;CD81 Cells NFr Bld;;ACTIVE;2.22;2.70 +51406-7;Immunoglobulin light chains.free;MRat;24H;Urine;Qn;;CHEM;1;Immunoglobulin light chains.free [Mass/time] in 24 hour Urine;BJ Protein Free 24h Ur-mRate;;ACTIVE;2.22;2.73 +51407-5;Streptococcus pneumoniae capsular polysaccharide Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae capsular polysaccharide IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum CPS IgG Ser IA-mCnc;;ACTIVE;2.22;2.70 +51408-3;Streptococcus pneumoniae capsular polysaccharide Ab.IgG2;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae capsular polysaccharide IgG2 Ab [Mass/volume] in Serum by Immunoassay;S pneum CPS IgG2 Ser IA-mCnc;;ACTIVE;2.22;2.70 +5140-9;Echovirus 3 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 3 neutralizing antibody [Titer] in Serum by Neutralization test;ECV3 NAb Titr Ser Nt;;ACTIVE;1.0;2.72 +51409-1;Fosamprenavir+Ritonavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Fosamprenavir+Ritonavir [Susceptibility] by Genotype method;Fosamprenavir+Ritonavir Islt Genotyp;;ACTIVE;2.22;2.73 +51410-9;Environmental stressors panel;-;Pt;Water;-;;PANEL.DRUG/TOX;1;Environmental stressors panel - Water;Envir stressors Pnl Wat;;ACTIVE;2.22;2.42 +51411-7;Environmental stressors panel;-;Pt;Air;-;;PANEL.DRUG/TOX;1;Environmental stressors panel - Air;Envir stressors Pnl Air;;ACTIVE;2.22;2.42 +51412-5;3-Hydroxyisovalerylcarnitine+2-Methyl,3-Hydroxybutyrylcarnitine (C5-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine+2-Methyl,3-Hydroxybutyrylcarnitine (C5-OH) [Moles/volume] in Serum or Plasma;3OH-IV+2Me3OH-Butyr carn SerPl-sCnc;;ACTIVE;2.22;2.73 +51413-3;Butyrylcarnitine+Isobutyrylcarnitine (C4);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Butyrylcarnitine+Isobutyrylcarnitine (C4) [Moles/volume] in Serum or Plasma;Butyryl+Isobutyrylcarn SerPl-sCnc;;ACTIVE;2.22;2.73 +51414-1;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in Serum or Plasma;Glut+3OHdecanoylcarn SerPl-sCnc;;ACTIVE;2.22;2.70 +51415-8;Methylmalonylcarnitine+Succinylcarnitine (C4-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonylcarnitine+Succinylcarnitine (C4-DC) [Moles/volume] in Serum or Plasma;Me-malonylcarn+Succinylcarn SerPl-sCnc;;ACTIVE;2.22;2.70 +51416-6;Tiglylcarnitine (C5:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tiglylcarnitine (C5:1) [Moles/volume] in Serum or Plasma;Tiglylcarn SerPl-sCnc;;ACTIVE;2.22;2.70 +5141-7;Echovirus 3 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 3 Ab [Titer] in Serum by Complement fixation;ECV3 Ab Titr Ser CF;;ACTIVE;1.0;2.70 +51417-4;Coproporphyrin/Porphyrins.total;SFr;24H;Urine;Qn;;CHEM;1;Coproporphyrin/Porphyrins.total in 24 hour Urine;Copro 24h SFr Ur;;ACTIVE;2.22;2.70 +51418-2;Domperidone;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Domperidone [Moles/volume] in Body fluid;Domperidone Fld-sCnc;;ACTIVE;2.22;2.70 +51419-0;Sodium^^corrected for glucose;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sodium [Moles/volume] corrected for glucose in Serum or Plasma;Sodium Glucose cor SerPl-sCnc;;ACTIVE;2.22;2.70 +51420-8;17-Hydroxyprogesterone^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --pre or post XXX challenge;17OHP pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +51421-6;Testosterone^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Testost pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +51422-4;Aldosterone^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Aldost pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +51423-2;Corticotropin^pre or post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre or post XXX challenge;ACTH pre/p chal Plas-sCnc;;ACTIVE;2.22;2.70 +51424-0;Cortisol^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Cortis pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +5142-5;Echovirus 4 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 4 neutralizing antibody [Titer] in Serum by Neutralization test;ECV4 NAb Titr Ser Nt;;ACTIVE;1.0;2.72 +51425-7;EPINEPHrine^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;EPINEPHrine [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Epineph pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.73 +51426-5;Glucose^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Glucose pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +51427-3;Insulin^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Insulin pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +51428-1;Lactate^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Lactate pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.70 +51429-9;Norepinephrine^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Norepinephrine [Moles/volume] in Serum or Plasma --pre or post XXX challenge;Norepineph pre/p chal SerPl-sCnc;;ACTIVE;2.22;2.73 +51430-7;Calcitonin^pre or post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --pre or post XXX challenge;Calcit pre/p chal SerPl-mCnc;;ACTIVE;2.22;2.70 +51431-5;Gastrin^pre or post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --pre or post XXX challenge;Gastrin pre/p chal SerPl-mCnc;;ACTIVE;2.22;2.70 +51432-3;Prolactin^pre or post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --pre or post XXX challenge;Prolactin pre/p chal SerPl-mCnc;;ACTIVE;2.22;2.70 +5143-3;Echovirus 4 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 4 Ab [Titer] in Serum by Complement fixation;ECV4 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51433-1;Renin^pre or post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --pre or post XXX challenge;Renin pre/p chal Plas-mCnc;;ACTIVE;2.22;2.70 +51434-9;Somatotropin^pre or post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre or post XXX challenge;GH pre/p chal SerPl-mCnc;;ACTIVE;2.22;2.73 +51435-6;Protein.monoclonal band 1;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis;M Protein 1 SerPl Elph-mCnc;;ACTIVE;2.22;2.73 +51436-4;Protein.monoclonal;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal [Mass/volume] in 24 hour Urine by Electrophoresis;M Protein 24h Ur Elph-mCnc;;ACTIVE;2.22;2.73 +51437-2;Protein.monoclonal band 2;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 2 [Mass/volume] in Urine by Electrophoresis;M Protein 2 Ur Elph-mCnc;;ACTIVE;2.22;2.73 +51438-0;Protein.monoclonal band 2;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 2 [Mass/volume] in 24 hour Urine by Electrophoresis;M Protein 2 24h Ur Elph-mCnc;;ACTIVE;2.22;2.73 +51439-8;Protein.monoclonal band 3;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 3 [Mass/volume] in 24 hour Urine by Electrophoresis;M Protein 3 24h Ur Elph-mCnc;;ACTIVE;2.22;2.73 +51440-6;Protein.monoclonal band 3;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 3 [Mass/volume] in Urine by Electrophoresis;M Protein 3 Ur Elph-mCnc;;ACTIVE;2.22;2.73 +5144-1;Echovirus 6 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 6 neutralizing antibody [Titer] in Serum by Neutralization test;ECV6 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51441-4;Macroprolactin/Prolactin;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Macroprolactin/Prolactin [Mass] in Serum or Plasma;Macroprolactin/Prolactin MFr SerPl;;ACTIVE;2.22;2.73 +51442-2;Domperidone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Domperidone [Moles/volume] in Serum or Plasma;Domperidone SerPl-sCnc;;ACTIVE;2.22;2.70 +51443-0;Cells.CD117;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD117 cells [Units/volume] in Blood;CD117 Cells Bld-aCnc;;ACTIVE;2.22;2.70 +51444-8;Cells.CD19+CD38+;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD38+ cells [Units/volume] in Blood;CD19+CD38+ Cells Bld-aCnc;;ACTIVE;2.22;2.70 +51445-5;Cells.CD41a;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD41a cells [Units/volume] in Blood;CD41a Cells Bld-aCnc;;ACTIVE;2.22;2.70 +51446-3;Cells.CD64;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD64 cells [Units/volume] in Blood;CD64 Cells Bld-aCnc;;ACTIVE;2.22;2.70 +51447-1;Cells.CD79a;ACnc;Pt;Bld;Qn;;CELLMARK;1;CD79a cells [Units/volume] in Blood;CD79a Cells Bld-aCnc;;ACTIVE;2.22;2.70 +51448-9;Dihydrocodeine+Hydrocodol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dihydrocodeine+Hydrocodol [Mass/volume] in Urine;DHC+hydrocodol Ur-mCnc;;ACTIVE;2.22;2.73 +51449-7;Paragonimus sp Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Paragonimus sp Ab [Titer] in Serum by Immunoassay;Paragonimus Ab Titr Ser IA;;ACTIVE;2.22;2.56 +51450-5;Paragonimus sp Ab;Titr;Pt;Plr fld;Qn;IA;MICRO;1;Paragonimus sp Ab [Titer] in Pleural fluid by Immunoassay;Paragonimus Ab Titr Plr IA;;ACTIVE;2.22;2.56 +51451-3;Bartonella quintana Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Bartonella quintana IgG Ab [Units/volume] in Serum or Plasma;B quintana IgG SerPl-aCnc;;ACTIVE;2.22;2.69 +51452-1;Coccidioides immitis Ab;Titr;Pt;Body fld;Qn;;MICRO;1;Coccidioides immitis Ab [Titer] in Body fluid;C immitis Ab Titr Fld;;ACTIVE;2.22;2.73 +51453-9;Coxsackievirus A9+B1+B2+B3+B4+B5+B6 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A9+B1+B2+B3+B4+B5+B6 Ab [Titer] in Serum;CV A9+B1-6 Ab Titr Ser;;ACTIVE;2.22;2.32 +51454-7;Epstein Barr virus early diffuse Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Epstein Barr virus early diffuse Ab [Presence] in Cerebral spinal fluid;EBV EA-D Ab CSF Ql;;ACTIVE;2.22;2.56 +51455-4;Filaria Ab.IgG1;ACnc;Pt;Ser;Qn;;MICRO;1;Filaria IgG1 Ab [Units/volume] in Serum;Filaria IgG1 Ser-aCnc;;ACTIVE;2.22;2.69 +51456-2;Filaria Ab.IgG2;ACnc;Pt;Ser;Qn;;MICRO;1;Filaria IgG2 Ab [Units/volume] in Serum;Filaria IgG2 Ser-aCnc;;ACTIVE;2.22;2.69 +51457-0;Filaria Ab.IgG3;ACnc;Pt;Ser;Qn;;MICRO;1;Filaria IgG3 Ab [Units/volume] in Serum;Filaria IgG3 Ser-aCnc;;ACTIVE;2.22;2.69 +5145-8;Echovirus 6 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 6 Ab [Titer] in Serum by Complement fixation;ECV6 Ab Titr Ser CF;;ACTIVE;1.0;2.70 +51458-8;Hepatitis D virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis D virus IgG Ab [Units/volume] in Serum;HDV IgG Ser-aCnc;;ACTIVE;2.22;2.69 +51459-6;Hepatitis E virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis E virus Ab [Units/volume] in Serum;HEV Ab Ser-aCnc;;ACTIVE;2.22;2.69 +51460-4;Influenza virus A H16 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H16 Ab [Titer] in Serum;FLUAV H16 Ab Titr Ser;;ACTIVE;2.22;2.32 +51461-2;Listeria sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Listeria sp Ab [Titer] in Serum;Listeria Ab Titr Ser;;ACTIVE;2.22;2.32 +51462-0;Onchocerca sp Ab.IgG2;ACnc;Pt;Ser;Qn;;MICRO;1;Onchocerca sp IgG2 Ab [Units/volume] in Serum;Onchocerca IgG2 Ser-aCnc;;ACTIVE;2.22;2.69 +51463-8;Onchocerca sp Ab.IgG3;ACnc;Pt;Ser;Qn;;MICRO;1;Onchocerca sp IgG3 Ab [Units/volume] in Serum;Onchocerca IgG3 Ser-aCnc;;ACTIVE;2.22;2.69 +51464-6;Onchocerca sp Ab.IgG4;ACnc;Pt;Ser;Qn;;MICRO;1;Onchocerca sp IgG4 Ab [Units/volume] in Serum;Onchocerca IgG4 Ser-aCnc;;ACTIVE;2.22;2.69 +51465-3;Paragonimus sp Ab;Titr;Pt;Plr fld;Qn;;MICRO;1;Paragonimus sp Ab [Titer] in Pleural fluid;Paragonimus Ab Titr Plr;;ACTIVE;2.22;2.32 +5146-6;Echovirus 9 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 9 neutralizing antibody [Titer] in Serum by Neutralization test;ECV9 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +51466-1;Parainfluenza virus 1+2+3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1+2+3 Ab [Titer] in Serum;HPIV1+2+3 Ab Titr Ser;;ACTIVE;2.22;2.32 +51467-9;Plasmodium falciparum Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium falciparum IgG Ab [Titer] in Serum;P falciparum IgG Titr Ser;;ACTIVE;2.22;2.32 +51468-7;Plasmodium ovale Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium ovale IgG Ab [Titer] in Serum;P ovale IgG Titr Ser;;ACTIVE;2.22;2.32 +51469-5;Plasmodium vivax Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium vivax IgG Ab [Titer] in Serum;P vivax IgG Titr Ser;;ACTIVE;2.22;2.32 +51470-3;Satratoxin Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Satratoxin IgM Ab [Units/volume] in Serum;Satratoxin IgM Ser-aCnc;;ACTIVE;2.22;2.69 +51471-1;Sporothrix schenckii Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Sporothrix schenckii Ab [Presence] in Cerebral spinal fluid;S schenckii Ab CSF Ql;;ACTIVE;2.22;2.56 +51472-9;Streptococcus pneumoniae capsular polysaccharide Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae capsular polysaccharide IgG Ab [Mass/volume] in Serum;S pneum CPS IgG Ser-mCnc;;ACTIVE;2.22;2.34 +51473-7;Streptococcus pneumoniae capsular polysaccharide Ab.IgG2;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae capsular polysaccharide IgG2 Ab [Mass/volume] in Serum;S pneum CPS IgG2 Ser-mCnc;;ACTIVE;2.22;2.34 +5147-4;Echovirus 9 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 9 Ab [Titer] in Serum by Complement fixation;ECV9 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +51474-5;Treponema pallidum Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Treponema pallidum Ab [Units/volume] in Cerebral spinal fluid;T pallidum Ab CSF-aCnc;;ACTIVE;2.22;2.69 +51475-2;Treponema pallidum Ab;Titr;Pt;CSF;Qn;;MICRO;1;Treponema pallidum Ab [Titer] in Cerebral spinal fluid;T pallidum Ab Titr CSF;;ACTIVE;2.22;2.73 +51476-0;ABCB4 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ABCB4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ABCB4 gene Mut Anl Bld/T;;ACTIVE;2.22;2.63 +51477-8;Coccidioides sp Ab.IgM;PrThr;Pt;XXX;Ord;Immune diffusion;MICRO;1;Coccidioides sp IgM Ab [Presence] in Specimen by Immune diffusion (ID);Coccidioides IgM Spec Ql ID;;ACTIVE;2.22;2.69 +51478-6;Mucus;NCnc;Pt;Urine;Qn;Automated count;UA;1;Mucus [#/volume] in Urine by Automated count;Mucous Threads # Ur Auto;;ACTIVE;2.22;2.73 +51479-4;Spermatozoa;NCnc;Pt;Urine;Qn;Automated count;UA;1;Spermatozoa [#/volume] in Urine by Automated count;Sperm # Ur Auto;;ACTIVE;2.22;2.73 +51480-2;Bacteria;NCnc;Pt;Urine;Qn;Automated count;UA;1;Bacteria [#/volume] in Urine by Automated count;Bacteria # Ur Auto;;ACTIVE;2.22;2.73 +51481-0;Yeast;NCnc;Pt;Urine;Qn;Automated count;UA;1;Yeast [#/volume] in Urine by Automated count;Yeast # Ur Auto;;ACTIVE;2.22;2.73 +5148-2;Echovirus NOS Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Echovirus NOS neutralizing antibody [Titer] in Serum by Neutralization test;ECV NOS NAb Titr Ser Nt;;ACTIVE;1.0;2.72 +51482-8;Crystals;NCnc;Pt;Urine;Qn;Automated count;UA;1;Crystals [#/volume] in Urine by Automated count;Crystals # Ur Auto;;ACTIVE;2.22;2.42 +51483-6;Casts;NCnc;Pt;Urine;Qn;Automated count;UA;1;Casts [#/volume] in Urine by Automated count;Casts # Ur Auto;;ACTIVE;2.22;2.42 +51484-4;Hyaline casts;NCnc;Pt;Urine;Qn;Automated count;UA;1;Hyaline casts [#/volume] in Urine by Automated count;Hyaline Casts # Ur Auto;;ACTIVE;2.22;2.73 +51485-1;Epithelial cells.non-squamous;NCnc;Pt;Urine;Qn;Automated count;UA;1;Epithelial cells.non-squamous [#/volume] in Urine by Automated count;Non-sq Epi Cells # Ur Auto;;ACTIVE;2.22;2.73 +51486-9;Epithelial cells.squamous;NCnc;Pt;Urine;Qn;Automated count;UA;1;Epithelial cells.squamous [#/volume] in Urine by Automated count;Squamous # Ur Auto;;ACTIVE;2.22;2.73 +51487-7;Leukocytes;NCnc;Pt;Urine;Qn;Automated count;UA;1;Leukocytes [#/volume] in Urine by Automated count;WBC # Ur Auto;;ACTIVE;2.22;2.73 +51488-5;Cortisol^6th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --6th specimen post XXX challenge;Cortis sp6 p chal Sal-mCnc;;ACTIVE;2.24;2.73 +51489-3;Cortisol^7th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --7th specimen post XXX challenge;Cortis sp7 p chal Sal-mCnc;;ACTIVE;2.24;2.73 +5149-0;Echovirus NOS Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus NOS Ab [Titer] in Serum by Complement fixation;ECV NOS Ab Titr Ser CF;;ACTIVE;1.0;2.70 +51490-1;Cortisol^5th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --5th specimen post XXX challenge;Cortis sp5 p chal Sal-mCnc;;ACTIVE;2.24;2.73 +51491-9;Cortisol^4th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --4th specimen post XXX challenge;Cortis sp4 p chal Sal-mCnc;;ACTIVE;2.24;2.73 +51492-7;Cortisol^3rd specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --3rd specimen post XXX challenge;Cortis sp3 p chal Sal-mCnc;;ACTIVE;2.24;2.73 +51493-5;Cortisol^2nd specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --2nd specimen post XXX challenge;Cortis sp2 p chal Sal-mCnc;;ACTIVE;2.24;2.73 +51494-3;Cortisol^1st specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --1st specimen post XXX challenge;Cortis sp1 p chal Sal-mCnc;;ACTIVE;2.24;2.73 +51495-0;Cortisol^baseline;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --baseline;Cortis BS Sal-mCnc;;ACTIVE;2.24;2.73 +51496-8;Estradiol^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Estradiol sp4 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51497-6;Estradiol^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Estradiol sp5 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51498-4;Estradiol^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Estradiol sp3 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51499-2;Estradiol^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Estradiol sp1 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51500-7;Estradiol^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Estradiol sp7 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51501-5;Estradiol^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Estradiol sp2 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51502-3;Estradiol^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Estradiol sp6 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51503-1;Penicillin G procaine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Penicillin G procaine [Susceptibility];Penicillin G Procaine Susc Islt;;ACTIVE;2.24;2.73 +51504-9;Penicillin G benzathine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Penicillin G benzathine [Susceptibility];Penicillin G Benzathine Susc Islt;;ACTIVE;2.24;2.27 +51505-6;Creatine kinase.BB;CCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Creatine kinase.BB [Enzymatic activity/volume] in Cerebral spinal fluid by Electrophoresis;CK BB CSF Elph-cCnc;;ACTIVE;2.24;2.73 +51506-4;Creatine kinase.MB;CCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Creatine kinase.MB [Enzymatic activity/volume] in Cerebral spinal fluid by Electrophoresis;CK MB CSF Elph-cCnc;;ACTIVE;2.24;2.70 +51507-2;Creatine kinase.MM;CCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Creatine kinase.MM [Enzymatic activity/volume] in Cerebral spinal fluid by Electrophoresis;CK MM CSF Elph-cCnc;;ACTIVE;2.24;2.73 +5150-8;Entamoeba histolytica Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Entamoeba histolytica Ab [Units/volume] in Serum by Immunoassay;E histolyt Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +51508-0;Lactate dehydrogenase 1/Lactate dehydrogenase.total;CFr;Pt;Plr fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 1/Lactate dehydrogenase.total in Pleural fluid by Electrophoresis;LDH1 CFr Plr Elph;;ACTIVE;2.24;2.70 +51509-8;Lactate dehydrogenase 1/Lactate dehydrogenase.total;CFr;Pt;Periton fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 1/Lactate dehydrogenase.total in Peritoneal fluid by Electrophoresis;LDH1 CFr Prt Elph;;ACTIVE;2.24;2.34 +51510-6;Lactate dehydrogenase 1/Lactate dehydrogenase.total;CFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 1/Lactate dehydrogenase.total in Cerebral spinal fluid by Electrophoresis;LDH1 CFr CSF Elph;;ACTIVE;2.24;2.70 +51511-4;Lactate dehydrogenase 2/Lactate dehydrogenase.total;CFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 2/Lactate dehydrogenase.total in Cerebral spinal fluid by Electrophoresis;LDH2 CFr CSF Elph;;ACTIVE;2.24;2.70 +51512-2;Lactate dehydrogenase 2/Lactate dehydrogenase.total;CFr;Pt;Plr fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 2/Lactate dehydrogenase.total in Pleural fluid by Electrophoresis;LDH2 CFr Plr Elph;;ACTIVE;2.24;2.70 +51513-0;Lactate dehydrogenase 2/Lactate dehydrogenase.total;CFr;Pt;Periton fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 2/Lactate dehydrogenase.total in Peritoneal fluid by Electrophoresis;LDH2 CFr Prt Elph;;ACTIVE;2.24;2.70 +51514-8;Lactate dehydrogenase 3/Lactate dehydrogenase.total;CFr;Pt;Plr fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 3/Lactate dehydrogenase.total in Pleural fluid by Electrophoresis;LDH3 CFr Plr Elph;;ACTIVE;2.24;2.70 +51515-5;Lactate dehydrogenase 3/Lactate dehydrogenase.total;CFr;Pt;Periton fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 3/Lactate dehydrogenase.total in Peritoneal fluid by Electrophoresis;LDH3 CFr Prt Elph;;ACTIVE;2.24;2.70 +5151-6;Entamoeba histolytica Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Entamoeba histolytica Ab [Units/volume] in Serum by Hemagglutination;E histolyt Ab Ser HA-aCnc;;ACTIVE;1.0;2.73 +51516-3;Lactate dehydrogenase 3/Lactate dehydrogenase.total;CFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 3/Lactate dehydrogenase.total in Cerebral spinal fluid by Electrophoresis;LDH3 CFr CSF Elph;;ACTIVE;2.24;2.70 +51517-1;Lactate dehydrogenase 4/Lactate dehydrogenase.total;CFr;Pt;Periton fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 4/Lactate dehydrogenase.total in Peritoneal fluid by Electrophoresis;LDH4 CFr Prt Elph;;ACTIVE;2.24;2.70 +51518-9;Lactate dehydrogenase 4/Lactate dehydrogenase.total;CFr;Pt;Plr fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 4/Lactate dehydrogenase.total in Pleural fluid by Electrophoresis;LDH4 CFr Plr Elph;;ACTIVE;2.24;2.70 +51519-7;Lactate dehydrogenase 4/Lactate dehydrogenase.total;CFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 4/Lactate dehydrogenase.total in Cerebral spinal fluid by Electrophoresis;LDH4 CFr CSF Elph;;ACTIVE;2.24;2.70 +51520-5;Lactate dehydrogenase 5/Lactate dehydrogenase.total;CFr;Pt;Periton fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 5/Lactate dehydrogenase.total in Peritoneal fluid by Electrophoresis;LDH5 CFr Prt Elph;;ACTIVE;2.24;2.70 +51521-3;Lactate dehydrogenase 5/Lactate dehydrogenase.total;CFr;Pt;Plr fld;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 5/Lactate dehydrogenase.total in Pleural fluid by Electrophoresis;LDH5 CFr Plr Elph;;ACTIVE;2.24;2.70 +51522-1;Lactate dehydrogenase 5/Lactate dehydrogenase.total;CFr;Pt;CSF;Qn;Electrophoresis;CHEM;1;Lactate dehydrogenase 5/Lactate dehydrogenase.total in Cerebral spinal fluid by Electrophoresis;LDH5 CFr CSF Elph;;ACTIVE;2.24;2.70 +51523-9;(Cynodon dactylon+Lolium perenne+Phleum pratense+Poa pratensis+Sorghum halepense+Paspalum notatum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 2 (Bermuda grass+Perennial rye grass+Timothy+Kentucky blue grass+Johnson grass+Bahia grass) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix2 IgE Ql;;ACTIVE;2.24;2.73 +5152-4;Epidermis Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Epidermis Ab [Titer] in Serum by Immunofluorescence;Epidis Ab Titr Ser IF;;ACTIVE;1.0;2.73 +51524-7;Betula verrucosa recombinant (rBet v) 2+4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 2 + 4 IgE Ab [Units/volume] in Serum;Silver Birch (rBet v) 2+4 IgE Qn;;ACTIVE;2.24;2.42 +51525-4;(Ambrosia elatior+Chenopodium album+Cynodon dactylon+Lolium perenne+Plantago lanceolata+Paspalum notatum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 3 (Common Ragweed+Goosefoot+Bermuda grass+Perennial rye grass+English Plantain+Bahia grass) IgE Ab [Presence] in Serum by Multidisk;Region Allerg Mix3 IgE Ql;;ACTIVE;2.24;2.56 +51526-2;(Aspergillus fumigatus+Blatella germanica+Cat dander+Dermatophagoides pteronyssinus) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergy Mix 5 (Aspergillus fumigatus+Cockroach+Cat dander+European house dust mite) IgE Ab [Presence] in Serum by Multidisk;Region Allerg Mix5 IgE Ql;;ACTIVE;2.24;2.56 +51527-0;(Quercus alba+Ulmus americana+Platanus acerifolia+Salix caprea+Populus deltoides) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 4 (White oak+White elm+London plane or Maple leaf sycamore+Willow+Cottonwood) IgE Ab [Presence] in Serum by Multidisk;Tree Allerg Mix4 IgE Ql;;ACTIVE;2.24;2.56 +51528-8;(Citrus sinensis+Citrus limon+Citrus paradisi+Citrus reticulata) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Citrus Allergen Mix (Orange+Lemon+Grapefruit+Clementine) IgE Ab [Presence] in Serum by Multidisk;Citrus mix IgE Ql;;ACTIVE;2.24;2.56 +51529-6;(Aspergillus fumigatus+Aspergillus niger+Aspergillus terreus+Aspergillus flavus) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 4 (Aspergillus fumigatus+Aspergillus niger+Aspergillus terreus+Aspergillus flavus) IgE Ab [Presence] in Serum by Multidisk;Mold Allerg Mix4 IgE Ql;;ACTIVE;2.24;2.56 +51530-4;Lactalbumin alpha Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lactalbumin alpha IgG Ab [Presence] in Serum;A-Lactalb IgG Ql;;ACTIVE;2.24;2.56 +51531-2;Beta lactoglobulin Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Beta lactoglobulin IgG Ab [Presence] in Serum;B-Lactoglob IgG Ql;;ACTIVE;2.24;2.56 +5153-2;Epstein Barr virus early Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epstein Barr virus early Ab [Presence] in Serum by Immunoassay;EBV EA Ab Ser Ql IA;;ACTIVE;1.0;2.73 +51532-0;Casein Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Casein IgG Ab [Presence] in Serum;Casein IgG Ql;;ACTIVE;2.24;2.56 +51533-8;Dermatophagoides pteronyssinus Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;European house dust mite IgG Ab [Presence] in Serum;D pteronyss IgG Ql;;ACTIVE;2.24;2.56 +51534-6;Dermatophagoides farinae Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;American house dust mite IgG Ab [Presence] in Serum;D farinae IgG Ql;;ACTIVE;2.24;2.56 +51535-3;Phleum pratense Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy IgG Ab [Presence] in Serum;Timothy IgG Ql;;ACTIVE;2.24;2.56 +51536-1;Egg white Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Egg white IgG Ab [Presence] in Serum;Egg White IgG Ql;;ACTIVE;2.24;2.56 +51537-9;Betula verrucosa Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch IgG Ab [Presence] in Serum;Silver Birch IgG Ql;;ACTIVE;2.24;2.56 +51538-7;Cladosporium herbarum Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cladosporium herbarum IgG Ab [Presence] in Serum;C herbarum IgG Ql;;ACTIVE;2.24;2.73 +51539-5;Candida albicans Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Candida albicans IgG Ab [Presence] in Serum;C albicans IgG Ser Ql;;ACTIVE;2.24;2.73 +5154-0;Epstein Barr virus early Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus early Ab [Presence] in Serum by Immunofluorescence;EBV EA Ab Ser Ql IF;;ACTIVE;1.0;2.73 +51540-3;Alternaria alternata Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alternaria alternata IgG Ab [Presence] in Serum;A alternata IgG Ql;;ACTIVE;2.24;2.56 +51541-1;Stachybotrys chartarum Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Stachybotrys chartarum IgG Ab [Presence] in Serum;S chartarum IgG Ql;;ACTIVE;2.24;2.56 +51542-9;Aspergillus versicolor Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus versicolor IgG Ab [Presence] in Serum;A versicolor IgG Ql;;ACTIVE;2.24;2.56 +51543-7;Cladosporium cladosporioides Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cladosporium cladosporioides IgG Ab [Presence] in Serum;C cladosporioides IgG Ql;;ACTIVE;2.24;2.56 +51544-5;Penicillium sp Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Penicillium sp IgG Ab [Presence] in Serum;Penicillium IgG Ql;;ACTIVE;2.24;2.56 +51545-2;Budgerigar droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Budgerigar droppings IgG Ab [Presence] in Serum;Budgie Drop IgG Ql;;ACTIVE;2.24;2.56 +51546-0;Chicken feather Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken feather IgG Ab [Presence] in Serum;Chicken Feather IgG Ql;;ACTIVE;2.24;2.56 +51547-8;Canary feather Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canary feather IgG Ab [Presence] in Serum;Canary Feather IgG Ql;;ACTIVE;2.24;2.56 +51548-6;Parrot feather Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parrot feather IgG Ab [Presence] in Serum;Parrot Feather IgG Ql;;ACTIVE;2.24;2.56 +51549-4;Pigeon feather Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon feather IgG Ab [Presence] in Serum;Pigeon Feather IgG Ql;;ACTIVE;2.24;2.56 +51550-2;Mouse epithelium+Serum proteins+Urine proteins Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mouse epithelium, serum proteins + urine proteins IgE Ab RAST class [Presence] in Serum;Mouse Epith+Ser+Ur Prot IgE RAST Ql;;ACTIVE;2.24;2.73 +51551-0;Chinchilla epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chinchilla epithelium IgE Ab RAST class [Presence] in Serum;Chinchilla Epith IgE RAST Ql;;ACTIVE;2.24;2.58 +51552-8;Fox epithelium Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Fox epithelium IgE Ab RAST class [Presence] in Serum;Fox Epith IgE RAST Ql;;ACTIVE;2.24;2.58 +51553-6;Mace Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mace IgE Ab RAST class [Presence] in Serum;Mace IgE RAST Ql;;ACTIVE;2.24;2.73 +51554-4;Merluccius merluccius Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hake IgE Ab RAST class [Presence] in Serum;Hake IgE RAST Ql;;ACTIVE;2.24;2.73 +51555-1;Phleum pratense recombinant (rPhl p) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 1 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 1 IgE RAST Ql;;ACTIVE;2.24;2.58 +51556-9;Phleum pratense recombinant (rPhl p) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 2 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 2 IgE RAST Ql;;ACTIVE;2.24;2.58 +5155-7;Epstein Barr virus nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Epstein Barr virus nuclear IgG Ab [Presence] in Serum by Immunofluorescence;EBV NA IgG Ser Ql IF;;ACTIVE;1.0;2.73 +51557-7;Phleum pratense native (nPhl p) 4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy native (nPhl p) 4 IgE Ab RAST class [Presence] in Serum;Timothy native (nPhl p) 4 IgE RAST Ql;;ACTIVE;2.24;2.58 +51558-5;Phleum pratense recombinant (rPhl p) 6 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 6 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 6 IgE RAST Ql;;ACTIVE;2.24;2.58 +51559-3;Phleum pratense recombinant (rPhl p) 7 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 7 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 7 IgE RAST Ql;;ACTIVE;2.24;2.58 +51560-1;Phleum pratense recombinant (rPhl p) 11 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 11 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 11 IgE RAST Ql;;ACTIVE;2.24;2.58 +51561-9;Phleum pratense recombinant (rPhl p) 12 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 12 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 12 IgE RAST Ql;;ACTIVE;2.24;2.58 +51562-7;Phleum pratense recombinant (rPhl p) 1+5b Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 1 + 5b IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 1+5b IgE RAST Ql;;ACTIVE;2.24;2.58 +51563-5;Phleum pratense recombinant (rPhl p) 7+12 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 7 + 12 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 7+12 IgE RAST Ql;;ACTIVE;2.24;2.58 +51564-3;Phleum pratense recombinant (rPhl p) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Timothy recombinant (rPhl p) 5 IgE Ab RAST class [Presence] in Serum;Timothy (rPhl p) 5 IgE RAST Ql;;ACTIVE;2.24;2.58 +5156-5;Epstein Barr virus nuclear Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epstein Barr virus nuclear IgG Ab [Presence] in Serum by Immunoassay;EBV NA IgG Ser Ql IA;;ACTIVE;1.0;2.73 +51565-0;Ficus sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ficus sp IgE Ab RAST class [Presence] in Serum;Ficus IgE RAST Ql;;ACTIVE;2.24;2.73 +51566-8;Amylase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Amylase IgE Ab RAST class [Presence] in Serum;Amylase IgE RAST Ql;;ACTIVE;2.24;2.73 +51567-6;Trichosporon pullulans Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Trichosporon pullulans IgE Ab RAST class [Presence] in Serum;T pullulans IgE RAST Ql;;ACTIVE;2.24;2.58 +51568-4;Aspergillus fumigatus recombinant (rAsp f) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 1 IgE Ab RAST class [Presence] in Serum;A fumigatus (rAsp f) 1 IgE RAST Ql;;ACTIVE;2.24;2.58 +51569-2;Aspergillus fumigatus recombinant (rAsp f) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 2 IgE Ab RAST class [Presence] in Serum;A fumigatus (rAsp f) 2 IgE RAST Ql;;ACTIVE;2.24;2.58 +515-7;Trimethoprim+Sulfamethoxazole;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility] by Minimum lethal concentration (MLC);TMP SMX Islt MLC;;ACTIVE;1.0;2.19 +51570-0;Aspergillus fumigatus recombinant (rAsp f) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 3 IgE Ab RAST class [Presence] in Serum;A fumigatus (rAsp f) 3 IgE RAST Ql;;ACTIVE;2.24;2.58 +51571-8;Aspergillus fumigatus recombinant (rAsp f) 4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 4 IgE Ab RAST class [Presence] in Serum;A fumigatus (rAsp f) 4 IgE RAST Ql;;ACTIVE;2.24;2.58 +51572-6;Aspergillus fumigatus recombinant (rAsp f) 6 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus fumigatus recombinant (rAsp f) 6 IgE Ab RAST class [Presence] in Serum;A fumigatus (rAsp f) 6 IgE RAST Ql;;ACTIVE;2.24;2.58 +5157-3;Epstein Barr virus capsid Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Serum by Immunoassay;EBV VCA IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +51573-4;Betula verrucosa recombinant (rBet v) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch recombinant (rBet v) 1 IgE Ab RAST class [Presence] in Serum;Silver Birch (rBet v) 1 IgE RAST Ql;;ACTIVE;2.24;2.58 +51574-2;Betula verrucosa recombinant (rBet v) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch recombinant (rBet v) 2 IgE Ab RAST class [Presence] in Serum;Silver Birch (rBet v) 2 IgE RAST Ql;;ACTIVE;2.24;2.58 +51575-9;Betula verrucosa recombinant (rBet v) 4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch recombinant (rBet v) 4 IgE Ab RAST class [Presence] in Serum;Silver Birch (rBet v) 4 IgE RAST Ql;;ACTIVE;2.24;2.58 +51576-7;Betula verrucosa recombinant (rBet v) 2+4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch recombinant (rBet v) 2 + 4 IgE Ab RAST class [Presence] in Serum;Silver Birch (rBet v) 2+4 IgE RAST Ql;;ACTIVE;2.24;2.58 +51577-5;Elaeis guineensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Oil palm IgE Ab RAST class [Presence] in Serum;Oil palm IgE RAST Ql;;ACTIVE;2.24;2.58 +51578-3;Chlamydia trachomatis DNA;PrThr;Pt;Semen;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Semen by NAA with probe detection;C trach DNA Smn Ql NAA+probe;;ACTIVE;2.24;2.63 +51579-1;Normoblasts/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Normoblasts/100 cells in Bone marrow by Manual count;Normoblasts NFr Mar Manual;;ACTIVE;2.24;2.70 +51580-9;Macrophages/100 leukocytes;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Bone marrow by Manual count;Macrophages/WBC NFr Mar Manual;;ACTIVE;2.24;2.70 +5158-1;Epstein Barr virus capsid Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus capsid IgG Ab [Titer] in Serum by Immunofluorescence;EBV VCA IgG Titr Ser IF;;ACTIVE;1.0;2.73 +51581-7;Other cells/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Other cells/100 cells in Bone marrow;Other cells NFr Mar;;ACTIVE;2.24;2.73 +51582-5;Anisochromasia;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Anisochromasia [Presence] in Blood by Light microscopy;Anisochromasia Bld Ql Smear;;ACTIVE;2.24;2.73 +51583-3;Anulocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Anulocytes [Presence] in Blood by Light microscopy;Anulocytes Bld Ql Smear;;ACTIVE;2.24;2.56 +51584-1;Granulocytes.immature;NCnc;Pt;Bld;Qn;;HEM/BC;1;Immature granulocytes [#/volume] in Blood;Imm Granulocytes # Bld;;ACTIVE;2.24;2.73 +51585-8;Other cells;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Other cells [#/volume] in Blood by Manual count;Other cells # Bld Manual;;ACTIVE;2.24;2.73 +51586-6;Other cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Blood by Manual count;Other cells/leuk NFr Bld Manual;;ACTIVE;2.24;2.73 +51587-4;Plasmodium sp;PrThr;Pt;Bld;Ord;Microscopy.light;MICRO;1;Plasmodium sp [Presence] in Blood by Light microscopy;Plasmodium Bld Ql Smear;;ACTIVE;2.24;2.73 +51588-2;Granulocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Granulocytes [#/volume] in Blood by Manual count;Granulocytes # Bld Manual;;ACTIVE;2.24;2.40 +51589-0;Dyserythropoiesis;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Dyserythropoiesis [Presence] in Blood by Light microscopy;Dyserythropoiesis Bld Ql Smear;;ACTIVE;2.24;2.56 +51590-8;Chloride;SCnc;Pt;BldC;Qn;;CHEM;1;Chloride [Moles/volume] in Capillary blood;Chloride BldC-sCnc;;ACTIVE;2.24;2.73 +51591-6;Cholesterol;SCnc;Pt;Synv fld;Qn;;CHEM;1;Cholesterol [Moles/volume] in Synovial fluid;Cholest Snv-sCnc;;ACTIVE;2.24;2.70 +51592-4;Creatinine;SRat;12H;Urine;Qn;;CHEM;1;Creatinine [Moles/time] in 12 hour Urine;Creat 12h Ur-sRate;;ACTIVE;2.24;2.70 +51593-2;Fructose;PrThr;Pt;Stool;Ord;;CHEM;1;Fructose [Presence] in Stool;Fructose Stl Ql;;ACTIVE;2.24;2.56 +51594-0;Galactose;PrThr;Pt;Stool;Ord;;CHEM;1;Galactose [Presence] in Stool;Galactose Stl Ql;;ACTIVE;2.24;2.56 +51595-7;Glucose;PrThr;Pt;Stool;Ord;;CHEM;1;Glucose [Presence] in Stool;Glucose Stl Ql;;ACTIVE;2.24;2.56 +51596-5;Glucose;SCnc;Pt;BldC;Qn;;CHEM;1;Glucose [Moles/volume] in Capillary blood;Glucose BldC-sCnc;;ACTIVE;2.24;2.70 +51597-3;Glucose^1H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post 75 g glucose PO;Glucose 1h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.24;2.73 +51598-1;Lactose;PrThr;Pt;Stool;Ord;;CHEM;1;Lactose [Presence] in Stool;Lactose Stl Ql;;ACTIVE;2.24;2.56 +5159-9;Epstein Barr virus capsid Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay;EBV VCA IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +51599-9;Methotrexate^12H post dose;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --12 hours post dose;MTX 12h p SerPl-sCnc;;ACTIVE;2.24;2.70 +51600-5;Methotrexate^24H post dose;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --24 hours post dose;MTX 24h p SerPl-sCnc;;ACTIVE;2.24;2.73 +51601-3;Methotrexate^4H post dose;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --4 hours post dose;MTX 4h p SerPl-sCnc;;ACTIVE;2.24;2.70 +51602-1;Methotrexate^72H post dose;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --72 hours post dose;MTX 72h p SerPl-sCnc;;ACTIVE;2.24;2.73 +51603-9;Cytochrome b5 reductase;PrThr;Pt;RBC;Ord;;CHEM;1;Cytochrome B5 reductase [Presence] in Red Blood Cells;CyB5 Reduct RBC Ql;;ACTIVE;2.24;2.66 +51604-7;Phosphate;SRat;12H;Urine;Qn;;CHEM;1;Phosphate [Moles/time] in 12 hour Urine;Phosphate 12h Ur-sRate;;ACTIVE;2.24;2.70 +51605-4;Triglyceride;SCnc;Pt;Synv fld;Qn;;CHEM;1;Triglyceride [Moles/volume] in Synovial fluid;Trigl Snv-sCnc;;ACTIVE;2.24;2.70 +51606-2;Xylose^3H post dose xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --3 hours post dose xylose PO;Xylose 3h p Xyl PO Bld-sCnc;;ACTIVE;2.24;2.70 +5160-7;Epstein Barr virus capsid Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus capsid IgM Ab [Titer] in Serum by Immunofluorescence;EBV VCA IgM Titr Ser IF;;ACTIVE;1.0;2.73 +51607-0;Xylose^3H post XXX challenge;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --3 hours post XXX challenge;Xylose 3h p chal Bld-sCnc;;ACTIVE;2.24;2.70 +51608-8;Xylose^30M post dose xylose PO;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --30 minutes post dose xylose PO;Xylose 30m p Xyl PO Bld-sCnc;;ACTIVE;2.24;2.70 +51609-6;Xylose^30M post XXX challenge;SCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Moles/volume] in Blood --30 minutes post XXX challenge;Xylose 30M p chal Bld-sCnc;;ACTIVE;2.24;2.70 +51610-4;Calcium;SRat;12H;Urine;Qn;;CHEM;1;Calcium [Moles/time] in 12 hour Urine;Calcium 12h Ur-sRate;;ACTIVE;2.24;2.70 +51611-2;Methotrexate^48H post dose;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --48 hours post dose;MTX 48h p SerPl-sCnc;;ACTIVE;2.24;2.73 +51612-0;Sucrose;PrThr;Pt;Urine;Ord;;CHEM;1;Sucrose [Presence] in Urine;Sucrose Ur Ql;;ACTIVE;2.24;2.56 +51613-8;Hemoglobin J/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin J/Hemoglobin.total in Blood;Hgb J MFr Bld;;ACTIVE;2.24;2.30 +51614-6;Hemoglobin M/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin M/Hemoglobin.total in Blood;Hgb M MFr Bld;;ACTIVE;2.24;2.30 +5161-5;Erythrocyte Ab;ACnc;Pt;Ser;Qn;;SERO;1;Erythrocyte Ab [Units/volume] in Serum;Erythrocyte Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51615-3;Hemoglobin A2+C/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A2+C/Hemoglobin.total in Blood;Hgb A2+C MFr Bld;;ACTIVE;2.24;2.73 +51616-1;Hemoglobin A2+E/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A2+E/Hemoglobin.total in Blood;Hgb A2+E MFr Bld;;ACTIVE;2.24;2.73 +51617-9;Color;Type;Pt;Dial fld;Nom;;SPEC;1;Color of Dialysis fluid;Color Dial fld;;ACTIVE;2.24;2.26 +51618-7;Potassium^pre dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Potassium [Moles/volume] in Serum or Plasma --pre dialysis;Potassium pre dial SerPl-sCnc;;ACTIVE;2.24;2.70 +51619-5;Creatinine^pre dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Moles/volume] in Serum or Plasma --pre dialysis;Creat pre dial SerPl-sCnc;;ACTIVE;2.24;2.70 +51620-3;Creatinine^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Moles/volume] in Serum or Plasma --post dialysis;Creat p dialysis SerPl-sCnc;;ACTIVE;2.24;2.70 +51621-1;Macrophages/100 leukocytes;NFr;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Macrophages/100 leukocytes in Dialysis fluid by Manual count;Macrophages/leuk NFr Dial fld Manual;;ACTIVE;2.24;2.50 +51622-9;Mesothelial cells/100 leukocytes;NFr;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Dialysis fluid by Manual count;Mesothl Cell/leuk NFr Dial fld Manual;;ACTIVE;2.24;2.50 +5162-3;Fasciola hepatica Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Fasciola hepatica Ab [Units/volume] in Serum;F hepatica Ab Ser-aCnc;;ACTIVE;1.0;2.69 +51623-7;Spermatozoa^post vasectomy;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa [#/volume] in Semen --post vasectomy;Sperm p vas # Smn;;ACTIVE;2.24;2.73 +51624-5;Malignant cells/100 cells;NFr;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Dialysis fluid by Manual count;Malignant cells NFr Dial fld Manual;;ACTIVE;2.24;2.34 +51625-2;Malignant cells/100 cells;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Body fluid by Manual count;Malignant cells NFr Fld Manual;;ACTIVE;2.24;2.34 +51626-0;Coagulation tissue factor induced.factor substitution^after addition of 1:4 normal plasma 1H post incubation separate tubes;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --with 1:4 normal plasma 1H post incubation separate tubes;PT 1:4 NP 1h separate PPP;;ACTIVE;2.24;2.70 +51627-8;Lymphocytes;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Lymphocytes [#/volume] in Peritoneal fluid by Manual count;Lymphocytes # Prt Manual;;ACTIVE;2.24;2.44 +51628-6;Morphology;Imp;Pt;Bone mar;Nar;;HEM/BC;1;Morphology [Interpretation] in Bone marrow Narrative;Morphology Mar-Imp;;ACTIVE;2.24;2.73 +51629-4;Macroblasts/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Macroblasts/100 cells in Bone marrow by Manual count;Macroblasts NFr Mar Manual;;ACTIVE;2.24;2.70 +51630-2;Schistocytes/1000 erythrocytes;NFr;Pt;Bld;Qn;Microscopy.light;HEM/BC;1;Schistocytes/1000 erythrocytes in Blood by Light microscopy;Schistocytes/1000 RBC NFr Bld Smear;;ACTIVE;2.24;2.73 +5163-1;Fasciola sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Fasciola sp Ab [Units/volume] in Serum;Fasciola Ab Ser-aCnc;;ACTIVE;1.0;2.69 +51631-0;Platelet distribution width;Ratio;Pt;Bld;Qn;;HEM/BC;1;Platelet distribution width [Ratio] in Blood;PDW Bld-Rto;;ACTIVE;2.24;2.70 +51632-8;Platelets.reticulated;NCnc;Pt;Bld;Qn;;HEM/BC;1;Platelets reticulated [#/volume] in Blood;Platelets.reticulated # Bld;;DISCOURAGED;2.24;2.73 +51633-6;Platelets.reticulated/100 platelets;NFr;Pt;Bld;Qn;;HEM/BC;1;Platelets reticulated/100 platelets in Blood;Platelets.reticulated NFr Bld;;DISCOURAGED;2.24;2.73 +51634-4;Reticulocytes.mid;NCnc;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.mid [#/volume] in Blood;Mid Retics #;;ACTIVE;2.24;2.70 +51635-1;Reticulocytes.mature;NCnc;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.mature [#/volume] in Blood;Mat Retics #;;ACTIVE;2.24;2.70 +51636-9;Reticulocytes.immature;NCnc;Pt;Bld;Qn;;HEM/BC;1;Immature reticulocytes [#/volume] in Blood;Imm Retics #;;ACTIVE;2.24;2.73 +51637-7;Plateletcrit;VFr;Pt;Bld;Qn;;HEM/BC;1;Plateletcrit [Volume Fraction] in Blood;Plateletcrit VFr Bld;;ACTIVE;2.24;2.73 +51638-5;Erythrocyte aggregates;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Erythrocyte aggregates [Presence] in Blood by Light microscopy;Erythrocyte aggregates Bld Ql Smear;;ACTIVE;2.24;2.56 +51639-3;Acanthocytes/1000 erythrocytes;NFr;Pt;Bld;Qn;Microscopy.light;HEM/BC;1;Acanthocytes/1000 erythrocytes in Blood by Light microscopy;Acanthocytes/1000 RBC NFr Bld Smear;;ACTIVE;2.24;2.73 +51640-1;Platelet anisocytosis;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Platelet anisocytosis [Presence] in Blood by Light microscopy;Platelet anisocytosis Bld Ql Smear;;ACTIVE;2.24;2.73 +51641-9;Mean sphered cell volume;EntVol;Pt;RBC;Qn;;HEM/BC;1;Mean sphered cell volume [Entitic volume] in Red Blood Cells;MSCV RBC;;ACTIVE;2.24;2.73 +51642-7;Reticulocytes.high light scatter/Reticulocytes.total;NFr;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.high light scatter/Reticulocytes.total in Blood;HL Retics NFr;;ACTIVE;2.24;2.52 +51643-5;Reticulocytes.high light scatter;NCnc;Pt;Bld;Qn;;HEM/BC;1;Reticulocytes.high light scatter [#/volume] in Blood;HL Retics #;;ACTIVE;2.24;2.52 +51644-3;Megakaryocytic nuclei;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Megakaryocytic nuclei [Presence] in Blood by Light microscopy;Megakar nuclei Bld Ql Smear;;ACTIVE;2.24;2.56 +51645-0;Micromegakaryocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Micromegakaryocytes [Presence] in Blood by Light microscopy;Micromegakaryocytes Bld Ql Smear;;ACTIVE;2.24;2.73 +51646-8;Rabies virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rabies virus RNA [Presence] in Specimen by NAA with probe detection;RABV RNA Spec Ql NAA+probe;;ACTIVE;2.24;2.69 +51647-6;Rabies virus RNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Rabies virus RNA [Presence] in Specimen by Probe;RABV RNA Spec Ql Probe;;ACTIVE;2.24;2.69 +51648-4;Monocytoid cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Monocytoid cells/100 leukocytes in Cerebral spinal fluid by Manual count;Monocytoid cells/leuk NFr CSF Manual;;ACTIVE;2.24;2.70 +5164-9;Fc fragment Ab;ACnc;Pt;Ser;Qn;;SERO;1;Fc fragment Ab [Units/volume] in Serum;Fc Frg Ab Ser-aCnc;;ACTIVE;1.0;2.69 +51649-2;Hepatitis C virus c100p+5-1-1 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus c100p+5-1-1 Ab [Presence] in Serum by Immunoblot;HCV c100p+5-1-1 Ab Ser Ql IB;;ACTIVE;2.24;2.73 +516-5;Trimethoprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility] by Minimum inhibitory concentration (MIC);TMP SMX Islt MIC;;ACTIVE;1.0;2.73 +51650-0;HLA-B;Imp;Pt;Bld/Tiss;Nom;Probe.amp.tar;HLA;1;HLA-B [Interpretation] by NAA with probe detection;HLA-B NAA+probe-Imp;;ACTIVE;2.24;2.63 +51651-8;IgE Ab;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;IgE Ab [Presence] in Serum or Plasma;IgE Ab SerPl Ql;;ACTIVE;2.24;2.73 +51652-6;SLC14A1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SLC14A1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SLC14A1 gene Mut Anl Bld/T;;ACTIVE;2.24;2.63 +51653-4;Hepatitis E virus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis E virus Ab [Presence] in Body fluid;HEV Ab Fld Ql;;ACTIVE;2.24;2.56 +51654-2;Hepatitis D virus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis D virus Ab [Presence] in Body fluid;HDV Ab Fld Ql;;ACTIVE;2.24;2.56 +51655-9;Hepatitis C virus RNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Hepatitis C virus RNA [Presence] in Body fluid by NAA with probe detection;HCV RNA Fld Ql NAA+probe;;ACTIVE;2.24;2.63 +5165-6;Filaria Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Filaria Ab [Units/volume] in Serum by Hemagglutination;Filaria Ab Ser HA-aCnc;;ACTIVE;1.0;2.69 +51656-7;Hepatitis C virus Ab Signal/Cutoff;RelACnc;Pt;Body fld;Qn;;MICRO;1;Hepatitis C virus Ab Signal/Cutoff in Body fluid;HCV Ab s/co Fld;;ACTIVE;2.24;2.73 +51657-5;Hepatitis C virus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis C virus Ab [Presence] in Body fluid;HCV Ab Fld Ql;;ACTIVE;2.24;2.56 +51658-3;Hepatitis B virus core Ab.IgM;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis B virus core IgM Ab [Presence] in Body fluid;HBV core IgM Fld Ql;;ACTIVE;2.24;2.73 +51659-1;Hepatitis B virus surface Ag;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis B virus surface Ag [Presence] in Body fluid;HBV surface Ag Fld Ql;;ACTIVE;2.24;2.73 +51660-9;Hepatitis A virus Ab.IgM;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis A virus IgM Ab [Presence] in Body fluid;HAV IgM Fld Ql;;ACTIVE;2.24;2.56 +51661-7;Hepatitis A virus Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Hepatitis A virus Ab [Presence] in Body fluid;HAV Ab Fld Ql;;ACTIVE;2.24;2.56 +51662-5;Core respiratory allergens panel;-;Pt;Ser;-;;PANEL.ALLERGY;1;Core respiratory allergens panel - Serum;Core resp allergen Pnl Ser;;ACTIVE;2.24;2.73 +51663-3;Alphavirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Alphavirus RNA [Presence] in Specimen by NAA with probe detection;Alphavirus RNA Spec Ql NAA+probe;;ACTIVE;2.24;2.69 +5166-4;Francisella tularensis Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Francisella tularensis Ab [Presence] in Serum by Latex agglutination;F tular Ab Ser Ql LA;;ACTIVE;1.0;2.73 +51664-1;Chikungunya virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus RNA [Presence] in Specimen by NAA with probe detection;CHIKV RNA Spec Ql NAA+probe;;ACTIVE;2.24;2.69 +51665-8;Flavivirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Flavivirus RNA [Presence] in Specimen by NAA with probe detection;Flavivirus RNA Spec Ql NAA+probe;;ACTIVE;2.24;2.69 +51666-6;Japanese encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Japanese encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;JEV RNA Spec Ql NAA+probe;;ACTIVE;2.24;2.69 +51667-4;Lymphocytic choriomeningitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Lymphocytic choriomeningitis virus RNA [Presence] in Specimen by NAA with probe detection;LCMV RNA Spec Ql NAA+probe;;ACTIVE;2.24;2.69 +51668-2;Streptococcus pneumoniae DNA & Haemophilus influenza DNA & Pseudomonas aeruginosa DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA and Haemophilus influenza DNA and Pseudomonas aeruginosa DNA [Identifier] in Unspecified specimen by NAA with probe detection;S pn+HFLU+P aerug DNA XXX NAA+pr;;ACTIVE;2.24;2.69 +51669-0;Parechovirus A RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parechovirus A RNA [Presence] in Specimen by NAA with probe detection;Parechovirus A RNA Spec Ql NAA+probe;;ACTIVE;2.24;2.73 +51670-8;17-Hydroxypregnenolone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --baseline;17OH-Preg BS SerPl-mCnc;;ACTIVE;2.24;2.73 +51671-6;Brucella sp Ab;Titr;Pt;Ser;Qn;Aggl.standard tube;MICRO;1;Brucella sp Ab [Titer] in Serum by Tube agglutination;Brucella Ab Titr Ser Tube aggl;;ACTIVE;2.24;2.72 +5167-2;Francisella tularensis Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Francisella tularensis Ab [Titer] in Serum by Latex agglutination;F tular Ab Titr Ser LA;;ACTIVE;1.0;2.73 +51672-4;17-Hydroxypregnenolone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;17OH-Preg sp4 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51673-2;17-Hydroxypregnenolone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;17OH-Preg sp5 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51674-0;17-Hydroxypregnenolone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;17OH-Preg sp6 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51675-7;17-Hydroxypregnenolone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;17OH-Preg sp7 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51676-5;17-Hydroxypregnenolone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;17OH-Preg sp2 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51677-3;17-Hydroxypregnenolone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;17OH-Preg sp1 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51678-1;17-Hydroxypregnenolone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;17OH-Preg sp3 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51679-9;17-Hydroxyprogesterone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;17OHP sp6 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +5168-0;Gall canaliculi Ab;ACnc;Pt;Ser;Qn;;SERO;1;Gall canaliculi Ab [Units/volume] in Serum;Gall Canaliculi Ab Ser-aCnc;;ACTIVE;1.0;2.69 +51680-7;17-Hydroxyprogesterone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;17OHP sp1 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51681-5;17-Hydroxyprogesterone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;17OHP sp7 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51682-3;Pregnenolone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Preg sp3 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51683-1;Pregnenolone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --baseline;Preg BS SerPl-mCnc;;ACTIVE;2.24;2.70 +51684-9;Pregnenolone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Preg sp6 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51685-6;Pregnenolone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Preg sp1 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51686-4;Pregnenolone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Preg sp2 p chal SerPl-mCnc;;ACTIVE;2.24;2.73 +51687-2;Pregnenolone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Preg sp7 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51688-0;Pregnenolone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Preg sp4 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51689-8;Pregnenolone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Pregnenolone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Preg sp5 p chal SerPl-mCnc;;ACTIVE;2.24;2.70 +51690-6;Amphetamines;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Blood by Screen method;Amphetamines Bld Ql Scn;;ACTIVE;2.24;2.73 +51691-4;Opiates;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Blood by Screen method;Opiates Bld Ql Scn;;ACTIVE;2.24;2.73 +51692-2;Phencyclidine;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Blood by Screen method;PCP Bld Ql Scn;;ACTIVE;2.24;2.73 +51693-0;Albumin;MCnc;Pt;Pericard fld;Qn;;CHEM;1;Albumin [Mass/volume] in Pericardial fluid;Albumin Pcar-mCnc;;ACTIVE;2.24;2.73 +51694-8;Carumonam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Carumonam [Susceptibility];Carumonam Susc Islt;;ACTIVE;2.24;2.24 +51695-5;Chloride;MRat;24H;Urine;Qn;;CHEM;1;Chloride [Mass/time] in 24 hour Urine;Chloride 24h Ur-mRate;;ACTIVE;2.24;2.73 +51696-3;Corticotropin^afternoon specimen;MCnc;Pt;Plas;Qn;;CHEM;1;Corticotropin [Mass/volume] in Plasma --afternoon specimen;ACTH afternoon Plas-mCnc;;ACTIVE;2.24;2.42 +51697-1;CV2 Ab;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;CV2 Ab [Titer] in Serum or Plasma by Immunofluorescence;CV2 Ab Titr SerPl IF;;ACTIVE;2.24;2.32 +5169-8;Giardia lamblia Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Giardia lamblia Ab [Units/volume] in Serum;G lamblia Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51698-9;Dapsone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Dapsone [Susceptibility];DDS Susc Islt;;ACTIVE;2.24;2.24 +51699-7;Endomysium Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Endomysium IgG Ab [Titer] in Serum by Immunofluorescence;Endomysium IgG Titr Ser IF;;ACTIVE;2.24;2.73 +51700-3;Microscopic observation;Prid;Pt;XXX;Nom;Lactophenol blue;MICRO;1;Microscopic observation [Identifier] in Specimen by Lactophenol blue;Lactophenol blue Spec;;ACTIVE;2.24;2.69 +51701-1;Ganglioside Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Ganglioside IgG Ab [Presence] in Serum by Immunoblot;Ganglioside IgG Ser Ql IB;;ACTIVE;2.24;2.58 +51702-9;Ganglioside Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Ganglioside IgM Ab [Presence] in Serum by Immunoblot;Ganglioside IgM Ser Ql IB;;ACTIVE;2.24;2.58 +51703-7;Ganglioside GM1 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 IgM Ab [Units/volume] in Serum by Immunoassay;GM1 Gangl IgM Ser IA-aCnc;;ACTIVE;2.24;2.73 +51704-5;Herpes virus 6 Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes virus 6 Ab [Units/volume] in Serum by Immunoassay;HHV6 Ab Ser IA-aCnc;;ACTIVE;2.24;2.69 +51705-2;Homogentisate;MRat;24H;Urine;Qn;;CHEM;1;Homogentisate [Mass/time] in 24 hour Urine;Homogentisate 24h Ur-mRate;;ACTIVE;2.24;2.42 +5170-6;Gliadin Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Gliadin IgG Ab [Units/volume] in Serum;Gliadin IgG Ser-aCnc;;ACTIVE;1.0;2.73 +51706-0;Hyaluronate;MCnc;Pt;Plr fld;Qn;;DRUG/TOX;1;Hyaluronate [Mass/volume] in Pleural fluid;Hyaluronate Plr-mCnc;;ACTIVE;2.24;2.42 +51707-8;Inner Ear 68kD Ab;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Inner ear 68kD Ab [Titer] in Serum or Plasma by Immunofluorescence;Inner ear 68kD Ab Titr SerPl IF;;ACTIVE;2.24;2.32 +51708-6;Intercellular substance Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Intercellular substance Ab [Titer] in Serum by Immunofluorescence;ICS Ab Titr Ser IF;;ACTIVE;2.24;2.32 +51709-4;Leishmania sp identified;Prid;Pt;XXX;Nom;Giemsa stain;MICRO;1;Leishmania sp identified in Specimen by Giemsa stain;Leishmania Spec Gie Stn;;ACTIVE;2.24;2.69 +51710-2;Leishmania sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Leishmania sp identified in Specimen by Organism specific culture;Leishmania Spec Cult;;ACTIVE;2.24;2.69 +51711-0;Leishmania sp Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;Leishmania sp Ab [Presence] in Body fluid;Leishmania Ab Fld Ql;;ACTIVE;2.24;2.56 +51712-8;Ma+Ta Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Ma+Ta Ab [Titer] in Serum by Immunofluorescence;Ma+Ta Ab Titr Ser IF;;ACTIVE;2.24;2.32 +51713-6;Metamyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Metamyelocytes/100 leukocytes in Blood by Automated count;Deprecated Metamyelocytes Fr Bld Auto;;DEPRECATED;2.24;2.36 +5171-4;Neutrophil Ab;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil Ab [Units/volume] in Serum;Neutrophil Ab Ser-aCnc;;ACTIVE;1.0;2.73 +51714-4;Microscopic observation;Prid;Pt;Bld;Nom;Giemsa stain;HEM/BC;1;Microscopic observation [Identifier] in Blood by Giemsa stain;Gie Stn Bld;;ACTIVE;2.24;2.24 +51715-1;Mitochondria M2 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Mitochondria M2 Ab [Units/volume] in Serum by Immunoassay;Mitochondria M2 Ab Ser IA-aCnc;;ACTIVE;2.24;2.73 +51716-9;Muscle specific receptor tyrosine kinase Ab;SCnc;Pt;Ser;Qn;;SERO;1;Muscle specific receptor tyrosine kinase Ab [Moles/volume] in Serum;MuSK Ab Ser-sCnc;;ACTIVE;2.24;2.73 +51717-7;Normoblasts.orthochromic/100 cells;NFr;Pt;Bld;Qn;Microscopy;HEM/BC;1;Normoblasts Orthochromic/100 cells in Blood by Microscopy;Ortho Normoblasts NFr Bld Micro;;ACTIVE;2.24;2.34 +51718-5;Normoblasts.polychromatophilic/100 cells;NFr;Pt;Bld;Qn;Microscopy;HEM/BC;1;Normoblasts Polychromatophilic/100 cells in Blood by Microscopy;Poly Normoblasts NFr Bld Micro;;ACTIVE;2.24;2.34 +51719-3;Paromomycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Paromomycin [Susceptibility];Paromomycin Susc Islt;;ACTIVE;2.24;2.29 +51720-1;Potassium;MRat;24H;Urine;Qn;;CHEM;1;Potassium [Mass/time] in 24 hour Urine;Potassium 24h Ur-mRate;;ACTIVE;2.24;2.73 +51721-9;Purkinje cells Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Purkinje cells Ab [Titer] in Serum by Immunofluorescence;Purkinje Cells Ab Titr Ser IF;;ACTIVE;2.24;2.73 +5172-2;Streptococcus pyogenes enzyme Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Streptococcus pyogenes enzyme Ab [Presence] in Serum by Latex agglutination;S pyog.enz Ab Ser Ql LA;;ACTIVE;1.0;2.73 +51722-7;Reticulin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Reticulin Ab [Titer] in Serum by Immunofluorescence;Reticulin Ab Titr Ser IF;;ACTIVE;2.24;2.73 +51723-5;Fungus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Fungus [Presence] in Specimen by Organism specific culture;Fungus Spec Ql Cult;;ACTIVE;2.24;2.73 +51724-3;Cefuroxime;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefuroxime [Susceptibility];Cefuroxime Susc Islt;;ACTIVE;2.24;2.73 +51725-0;Establishment registration;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Establishment registration;FDA label Establishment reg;;ACTIVE;2.24;2.34 +51726-8;NDC labeler code request;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label NDC labeler code request;FDA label NDC labeler code request;;ACTIVE;2.24;2.34 +51727-6;Inactive ingredient section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Inactive ingredient section;FDA label Inactive ingredient;;ACTIVE;2.24;2.34 +51728-4;Platelet aggregation.adenosine diphosphate induced^10 umol/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ADP induced [Presence] in Platelet rich plasma --10 umol/L;PA ADP 10 umol/L PRP Ql;;ACTIVE;2.24;2.56 +51729-2;Ganglioside GM1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM1 IgG Ab [Units/volume] in Serum by Immunoassay;GM1 Gangl IgG Ser IA-aCnc;;ACTIVE;2.24;2.73 +517-3;Trimethoprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility] by Disk diffusion (KB);TMP SMX Islt KB;;ACTIVE;1.0;2.73 +5173-0;Streptococcus pyogenes enzyme Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Streptococcus pyogenes enzyme Ab [Titer] in Serum by Latex agglutination;S pyog.enz Ab Titr Ser LA;;ACTIVE;1.0;2.73 +51730-0;Herpes virus 6 Ab.IgG & IgM;Imp;Pt;Ser;Nar;;MICRO;1;Herpes virus 6 IgG and IgM [Interpretation] in Serum Narrative;HHV6 IgG+IgM Ser-Imp;;ACTIVE;2.24;2.73 +51731-8;Oxygen saturation;MFr;Pt;BldV;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation Calculated from oxygen partial pressure in Venous blood;SaO2 % BldV from pO2;;ACTIVE;2.24;2.73 +51732-6;Oxygen saturation;MFr;Pt;BldC;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation Calculated from oxygen partial pressure in Capillary blood;SaO2 % BldC from pO2;;ACTIVE;2.24;2.73 +51733-4;Oxygen saturation;MFr;Pt;BldA;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation Calculated from oxygen partial pressure in Arterial blood;SaO2 % BldA from pO2;;ACTIVE;2.24;2.73 +51734-2;Chlamydia trachomatis L2 Ab.IgA & IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Chlamydia trachomatis L2 IgA and IgG and IgM [Interpretation] in Serum;C trach L2 IgA+IgG+IgM Ser-Imp;;ACTIVE;2.24;2.73 +51735-9;Urea nitrogen renal clearance;VRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Urea nitrogen renal clearance in 24 hour Urine and Serum or Plasma;UUN Cl 24h Ur+SerPl-vRate;;ACTIVE;2.24;2.73 +51736-7;oxyMORphone.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;oxyMORphone Free [Mass/volume] in Urine;oxyMORphone Free Ur-mCnc;;ACTIVE;2.24;2.73 +51737-5;HYDROmorphone.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;HYDROmorphone Free [Mass/volume] in Urine;HYDROmorphone Free Ur-mCnc;;ACTIVE;2.24;2.70 +51738-3;HYDROcodone.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;HYDROcodone Free [Mass/volume] in Urine;HYDROcodone Free Ur-mCnc;;ACTIVE;2.24;2.70 +51739-1;Codeine.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Codeine Free [Mass/volume] in Urine;Codeine Free Ur-mCnc;;ACTIVE;2.24;2.70 +51740-9;6-Monoacetylmorphine.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;6-monoacetylmorphine free [Mass/volume] in Urine;6MAM Free Ur-mCnc;;ACTIVE;2.24;2.70 +51741-7;Blastomyces dermatitidis Ab;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);B dermat Ab CSF Ql ID;;ACTIVE;2.24;2.73 +51742-5;Borrelia burgdorferi 49736 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi 49736 IgM Ab [Units/volume] in Serum by Immunoassay;B burgdor 49736 IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51743-3;Borrelia burgdorferi 49736 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi 49736 IgG Ab [Units/volume] in Serum by Immunoassay;B burgdor 49736 IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51744-1;Borrelia burgdorferi 49736 Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia burgdorferi 49736 IgA Ab [Units/volume] in Serum by Immunoassay;B burgdor 49736 IgA Ser IA-aCnc;;ACTIVE;2.24;2.73 +51745-8;Borrelia burgdorferi G39_40 Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi G39/40 IgG Ab [Presence] in Serum by Immunoblot;B burgdor G39/40 IgG Ser Ql IB;;ACTIVE;2.24;2.58 +51746-6;Borrelia burgdorferi 49736 Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 49736 IgG Ab [Presence] in Serum by Immunoblot;B burgdor 49736 IgG Ser Ql IB;;ACTIVE;2.24;2.58 +51747-4;Borrelia burgdorferi Ab.IgA & IgG & IgM;Imp;Pt;Ser;Nom;IA;MICRO;1;Borrelia burgdorferi IgA and IgG and IgM [Interpretation] in Serum by Immunoassay;B burgdor IgA+IgG+IgM Ser IA-Imp;;ACTIVE;2.24;2.56 +5174-8;Helicobacter pylori Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Helicobacter pylori Ab [Units/volume] in Serum by Immunoassay;H pylori Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +51748-2;Purkinje cell cytoplasmic type Tr Ab;Titr;Pt;CSF;Qn;;SERO;1;PCA-Tr Ab [Titer] in Cerebral spinal fluid;PCA-Tr Ab Titr CSF;;ACTIVE;2.24;2.73 +51749-0;Jo-1 extractable nuclear Ab;PrThr;Pt;CSF;Ord;;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Cerebral spinal fluid;ENA Jo1 Ab CSF Ql;;ACTIVE;2.24;2.56 +51750-8;Pyruvate;SCnc;Pt;BldA;Qn;;CHEM;1;Pyruvate [Moles/volume] in Arterial blood;Pyruvate BldA-sCnc;;ACTIVE;2.24;2.42 +51751-6;Pyruvate;SCnc;Pt;BldV;Qn;;CHEM;1;Pyruvate [Moles/volume] in Venous blood;Pyruvate BldV-sCnc;;ACTIVE;2.24;2.42 +51752-4;Heptaporphyrin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Deprecated Heptaporphyrin/Creatinine [Mass Ratio] in Urine;Deprecated Heptapor/Creat Ur;;DEPRECATED;2.24;2.70 +51753-2;Histoplasma capsulatum Ag;MCnc;Pt;Ser;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Mass/volume] in Serum by Immunoassay;H capsul Ag Ser IA-mCnc;;ACTIVE;2.24;2.73 +51754-0;Histoplasma capsulatum Ag;MCnc;Pt;CSF;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Mass/volume] in Cerebral spinal fluid by Immunoassay;H capsul Ag CSF IA-mCnc;;ACTIVE;2.24;2.73 +5175-5;Helicobacter pylori Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Helicobacter pylori Ab [Titer] in Serum by Latex agglutination;H pylori Ab Titr Ser LA;;ACTIVE;1.0;2.70 +51755-7;Cells.CD3+CD4-CD8-CD45+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4-CD8-CD45+ cells/100 cells in Blood;CD3+CD4-CD8-CD45+ Cells NFr Bld;;ACTIVE;2.24;2.34 +51756-5;ATP7B gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ATP7B gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ATP7B gene Mut Anl Bld/T;;ACTIVE;2.24;2.73 +51757-3;POMT1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;POMT1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;POMT1 gene Mut Anl Bld/T;;ACTIVE;2.24;2.66 +51758-1;POMT2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;POMT2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;POMT2 gene Mut Anl Bld/T;;ACTIVE;2.24;2.68 +51759-9;RAI1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RAI1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;RAI1 gene Mut Anl Bld/T;;ACTIVE;2.24;2.68 +51760-7;Ehrlichia chaffeensis Ab.IgG+IgM;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Ehrlichia chaffeensis IgG+IgM Ab [Presence] in Serum or Plasma;E chaffeensis IgG+IgM SerPl Ql;;ACTIVE;2.24;2.73 +51761-5;Giardia lamblia Ab.IgA & IgG & IgM;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Giardia lamblia IgA and IgG and IgM [Interpretation] in Serum or Plasma;G lamblia IgA+IgG+IgM SerPl-Imp;;ACTIVE;2.24;2.73 +51762-3;Helicobacter pylori Ab.IgA & IgG & IgM;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Helicobacter pylori IgA and IgG and IgM [Interpretation] in Serum or Plasma;H pylori IgA+IgG+IgM SerPl-Imp;;ACTIVE;2.24;2.73 +5176-3;Helicobacter pylori Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Helicobacter pylori IgG Ab [Units/volume] in Serum by Immunoassay;H pylori IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +51763-1;Muscle specific receptor tyrosine kinase Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Muscle specific receptor tyrosine kinase Ab [Titer] in Serum or Plasma;MuSK Ab Titr SerPl;;ACTIVE;2.24;2.73 +51764-9;Trypanosoma cruzi Ab.IgG & IgM;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Trypanosoma cruzi IgG and IgM [Interpretation] in Serum or Plasma;T cruzi IgG+IgM SerPl-Imp;;ACTIVE;2.24;2.73 +51765-6;Dihydrocodeine+Hydrocodol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dihydrocodeine+Hydrocodol [Mass/volume] in Serum or Plasma;DHC+hydrocodol SerPl-mCnc;;ACTIVE;2.24;2.73 +51766-4;Glucose^2.5H post dose fructose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.5 hours post dose fructose PO;Glucose 2.5h p fructose PO SerPl-mCnc;;ACTIVE;2.24;2.34 +51767-2;Glucose^1.5H post dose fructose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose fructose PO;Glucose 1.5h p fructose PO SerPl-mCnc;;ACTIVE;2.24;2.34 +51768-0;Glucose^3H post dose fructose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post dose fructose PO;Glucose 3h p fructose PO SerPl-mCnc;;ACTIVE;2.24;2.34 +51769-8;Glucose^2H post dose fructose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post dose fructose PO;Glucose 2h p fructose PO SerPl-mCnc;;ACTIVE;2.24;2.34 +51770-6;Leukocytes;Naric;Pt;Stool;Qn;Microscopy.light.HPF;HEM/BC;1;Leukocytes [#/area] in Stool by Microscopy high power field;WBC #/area Stl HPF;;ACTIVE;2.24;2.73 +5177-1;Helicobacter pylori Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Helicobacter pylori IgM Ab [Units/volume] in Serum by Immunoassay;H pylori IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +51771-4;Histoplasma capsulatum DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Histoplasma capsulatum DNA [#/volume] in Specimen by NAA with probe detection;H capsul DNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +51772-2;F9 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F9 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;F9 gene Mut Tested Bld/T;;ACTIVE;2.24;2.24 +51773-0;HEXA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HEXA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HEXA gene Mut Anl Bld/T;;ACTIVE;2.24;2.73 +51774-8;Cefuroxime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefuroxime [Susceptibility] by Minimum inhibitory concentration (MIC);Cefuroxime Islt MIC;;ACTIVE;2.24;2.73 +51775-5;Chromatin Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Chromatin Ab [Units/volume] in Serum or Plasma;Chromatin Ab SerPl-aCnc;;ACTIVE;2.24;2.73 +51776-3;7-Aminoclonazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Urine by Confirmatory method;7Aminoclonazepam Ur Cfm-mCnc;;ACTIVE;2.24;2.73 +51777-1;7-Aminoflunitrazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;7-Aminoflunitrazepam [Mass/volume] in Urine by Confirmatory method;7Aminoflunitrazepam Ur Cfm-mCnc;;ACTIVE;2.24;2.73 +51778-9;YY1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;YY1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;YY1 gene Mut Anl Bld/T;;ACTIVE;2.24;2.68 +51779-7;CFH gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CFH gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CFH gene Mut Anl Bld/T;;ACTIVE;2.24;2.63 +51780-5;HIV 1 RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar detection limit = 0.5 log copies/mL;MICRO;1;HIV 1 RNA [Log #/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 0.5 log copies/mL;HIV1 RNA SerPl NAA DL=0.5-Log#;;ACTIVE;2.24;2.73 +51781-3;Carbon dioxide;SCnc;Pt;BldC;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Capillary blood by calculation;CO2 BldC Calc-sCnc;;ACTIVE;2.24;2.73 +51782-1;Drugs of abuse 7 & Alcohol & Tricyclics panel;-;Pt;Urine;-;Screen;PANEL.DRUG/TOX;1;Drugs of abuse 7 and Alcohol and Tricyclics panel - Urine by Screen method;Drugs of abuse 7+Alc+Tricyc Pnl Ur Scn;;ACTIVE;2.24;2.73 +51783-9;Reagin Ab;PrThr;Pt;BldCo;Ord;VDRL;MICRO;1;Reagin Ab [Presence] in Cord blood by VDRL;VDRL BldCo Ql;;ACTIVE;2.24;2.56 +51784-7;Lot number;ID;Pt;Rh immune globulin;Nom;;BLDBK;1;Lot number of Rh immune globulin;Lot # Rh Imm Gl;;ACTIVE;2.24;2.73 +51785-4;Dengue virus Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Dengue virus IgG and IgM [Interpretation] in Serum;DENV IgG+IgM Ser-Imp;;ACTIVE;2.24;2.40 +51786-2;HIV 2 Ab Signal/Cutoff;RelACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 2 Ab Signal/Cutoff in Serum or Plasma by Immunoassay;HIV 2 Ab s/co SerPl IA;;ACTIVE;2.24;2.73 +51787-0;Blastomyces dermatitidis Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Blastomyces dermatitidis Ab [Titer] in Serum by Immune diffusion (ID);B dermat Ab Titr Ser ID;;ACTIVE;2.24;2.73 +51788-8;Coccidioides sp Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Coccidioides sp Ab [Titer] in Serum by Immune diffusion (ID);Coccidioides Ab Titr Ser ID;;ACTIVE;2.24;2.73 +5178-9;Haemophilus influenzae Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Haemophilus influenzae Ab [Units/volume] in Serum by Immunoassay;Haem influ Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +51789-6;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;Ser;Qn;Immune diffusion;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Serum by Immune diffusion (ID);H capsul Myc Ab Titr Ser ID;;ACTIVE;2.24;2.34 +51790-4;Erythrocyte casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;RBC casts [#/area] in Urine sediment by Microscopy high power field;RBC Casts #/area UrnS HPF;;ACTIVE;2.24;2.73 +51791-2;Tetrahydrocannabinol;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Serum or Plasma by Confirmatory method;THC SerPl Ql Cfm;;ACTIVE;2.24;2.56 +51792-0;Citrate/Creatinine;MRto;XXX;Urine;Qn;;CHEM;1;Citrate/Creatinine [Mass Ratio] in Urine collected for unspecified duration;Citrate/Creat ?Tm Ur;;ACTIVE;2.24;2.73 +51793-8;Xylose^1H post 5 g xylose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Xylose [Mass/volume] in Serum or Plasma --1 hour post 5 g xylose PO;Xylose 1h p 5 g Xyl PO SerPl-mCnc;;ACTIVE;2.24;2.40 +51794-6;Mitochondria M2 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Mitochondria M2 Ab [Titer] in Serum by Immunofluorescence;Mitochondria M2 Ab Titr Ser IF;;ACTIVE;2.24;2.73 +51795-3;Complement C1 esterase inhibitor bound Ab;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1 esterase inhibitor bound Ab [Mass/volume] in Serum or Plasma;C1INH Bnd Ab SerPl-mCnc;;ACTIVE;2.24;2.34 +51796-1;Purkinje cell cytoplasmic type Tr Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;PCA-Tr Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;PCA-Tr Ab CSF IA-aCnc;;ACTIVE;2.24;2.69 +5179-7;Hepatitis A virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis A virus IgG Ab [Units/volume] in Serum by Immunoassay;HAV IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +51797-9;CV2 Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;CV2 Ab [Units/volume] in Serum or Plasma;CV2 Ab SerPl-aCnc;;ACTIVE;2.24;2.73 +51798-7;Hepatitis E virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis E virus IgM Ab [Units/volume] in Serum;HEV IgM Ser-aCnc;;ACTIVE;2.24;2.70 +51799-5;Adenosine deaminase;CCnc;Pt;Synv fld;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Synovial fluid;Adenosine deaminase Snv-cCnc;;ACTIVE;2.24;2.68 +51800-1;Homogentisate;MCnc;24H;Urine;Qn;;CHEM;1;Homogentisate [Mass/volume] in 24 hour Urine;Homogentisate 24h Ur-mCnc;;ACTIVE;2.24;2.42 +51801-9;Myeloperoxidase Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Myeloperoxidase Ab [Titer] in Serum by Immunofluorescence;Myeloperoxidase Ab Titr Ser IF;;ACTIVE;2.24;2.73 +51802-7;Phosphatidylserine Ab.IgM;Titr;Pt;Ser;Qn;IF;COAG;1;Phosphatidylserine IgM Ab [Titer] in Serum by Immunofluorescence;PS IgM Titr Ser IF;;ACTIVE;2.24;2.32 +51803-5;Fibrillarin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Fibrillarin Ab [Titer] in Serum by Immunofluorescence;Fibrillarin Ab Titr Ser IF;;ACTIVE;2.24;2.32 +51804-3;Rickettsia conorii Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rickettsia conorii IgG Ab [Units/volume] in Serum by Immunoassay;R conorii IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +5180-5;Hepatitis A virus Ab.IgG;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis A virus IgG Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HAV IgG Ser RIA-aCnc;;ACTIVE;1.0;2.69 +51805-0;Rickettsia conorii Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rickettsia conorii IgM Ab [Units/volume] in Serum by Immunoassay;R conorii IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51806-8;Chlamydophila pneumoniae Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydophila pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay;C pneum IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51807-6;Chlamydophila pneumoniae Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydophila pneumoniae IgM Ab [Units/volume] in Serum by Immunoassay;C pneum IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51808-4;Chlamydophila psittaci Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay;C psittaci IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51809-2;Chlamydophila psittaci Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay;C psittaci IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +518-1;Trimethoprim+Sulfamethoxazole;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility] by Serum bactericidal titer;TMP SMX Titr SBT;;ACTIVE;1.0;2.32 +51810-0;Coxiella burnetii phase 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Units/volume] in Serum by Immunoassay;C burnet Ph1 IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51811-8;Coxiella burnetii phase 1 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Units/volume] in Serum by Immunoassay;C burnet Ph1 IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51812-6;Coxiella burnetii phase 2 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Units/volume] in Serum by Immunoassay;C burnet Ph2 IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +5181-3;Hepatitis A virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis A virus IgM Ab [Units/volume] in Serum by Immunoassay;HAV IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +51813-4;Coxiella burnetii phase 2 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Units/volume] in Serum by Immunoassay;C burnet Ph2 IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51814-2;Legionella pneumophila Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Legionella pneumophila IgM Ab [Units/volume] in Serum by Immunoassay;L pneumo IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51815-9;Leptospira sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Leptospira sp IgG Ab [Units/volume] in Serum by Immunoassay;Leptospira IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51816-7;Bartonella quintana Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bartonella quintana IgG Ab [Units/volume] in Serum by Immunoassay;B quintana IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51817-5;Coxsackievirus B Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coxsackievirus B IgG Ab [Units/volume] in Serum by Immunoassay;CV B IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51818-3;Coxsackievirus B Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Coxsackievirus B IgM Ab [Units/volume] in Serum by Immunoassay;CV B IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51819-1;Leptospira sp Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Leptospira sp IgM Ab [Units/volume] in Serum by Immunoassay;Leptospira IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51820-9;Listeria monocytogenes Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Listeria monocytogenes IgG Ab [Units/volume] in Serum by Immunoassay;L monocytog IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +5182-1;Hepatitis A virus Ab.IgM;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis A virus IgM Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HAV IgM Ser RIA-aCnc;;ACTIVE;1.0;2.73 +51821-7;Bartonella quintana Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bartonella quintana IgM Ab [Units/volume] in Serum by Immunoassay;B quintana IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51822-5;Adenovirus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Adenovirus IgG Ab [Units/volume] in Serum by Immunoassay;HAdV IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51823-3;Adenovirus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Adenovirus IgM Ab [Units/volume] in Serum by Immunoassay;HAdV IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51824-1;Hepatitis C virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis C virus IgM Ab [Units/volume] in Serum by Immunoassay;HCV IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51825-8;Bordetella parapertussis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bordetella parapertussis Ab [Units/volume] in Serum by Immunoassay;B parapert Ab Ser IA-aCnc;;ACTIVE;2.24;2.69 +51826-6;Herpes virus 8 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes virus 8 IgG Ab [Units/volume] in Serum by Immunoassay;HHV8 IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +51827-4;Trypanosoma cruzi Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trypanosoma cruzi IgM Ab [Units/volume] in Serum by Immunoassay;T cruzi IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51828-2;(Clupea harengus+Gadus morhua+Pleuronectes platessa+Scomber scombrus) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Food Allergen Mix 74 (Herring+Cod+Plaice+Mackerel) IgE Ab [Units/volume] in Serum;Food Allerg Mix74 IgE Qn;;ACTIVE;2.24;2.42 +51829-0;Lactate;MCnc;Pt;BldC;Qn;;CHEM;1;Lactate [Mass/volume] in Capillary blood;Lactate BldC-mCnc;;ACTIVE;2.24;2.73 +51830-8;Prolymphocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Prolymphocytes/100 leukocytes in Blood by Automated count;Deprecated Prolymphocytes Fr Bld Auto;;DEPRECATED;2.24;2.36 +51831-6;Beta-2 transferrin;MCnc;Pt;Body fld;Qn;;CHEM;1;Beta-2 transferrin [Mass/volume] in Body fluid;B2 Transferrin Fld-mCnc;;ACTIVE;2.24;2.73 +51832-4;Brucella abortus Ab;PrThr;Pt;CSF;Ord;Aggl.plate.buffered acidified;MICRO;1;Brucella abortus Ab [Presence] in Cerebral spinal fluid by Acidified buffered plate agglutination;B abortus Ab CSF Ql Buff plate aggl;;ACTIVE;2.24;2.67 +51833-2;14-3-3 protein;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated 14-3-3 protein [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated 14-3-3 protein CSF Ql IB;;DEPRECATED;2.24;2.64 +51834-0;Tryptase;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptase [Moles/volume] in Serum or Plasma;Tryptase SerPl-sCnc;;ACTIVE;2.24;2.70 +51835-7;Angiotensin converting enzyme;CCnc;Pt;Plr fld;Qn;;CHEM;1;Angiotensin converting enzyme [Enzymatic activity/volume] in Pleural fluid;ACE Plr-cCnc;;ACTIVE;2.24;2.73 +51836-5;Angiotensin II^upright;MCnc;Pt;Plas;Qn;;CHEM;1;Angiotensin II [Mass/volume] in Plasma --upright;Angiotensin II upr Plas-mCnc;;ACTIVE;2.24;2.42 +51837-3;Bordetella parapertussis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Bordetella parapertussis IgG Ab [Titer] in Serum by Immunofluorescence;B parapert IgG Titr Ser IF;;ACTIVE;2.24;2.32 +51838-1;Treponema pallidum Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Treponema pallidum IgG Ab [Units/volume] in Serum by Immunoassay;T pallidum IgG Ser IA-aCnc;;ACTIVE;2.24;2.73 +5183-9;Hepatitis A virus Ab;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis A virus Ab [Units/volume] in Serum or Plasma by Immunoassay;HAV Ab SerPl IA-aCnc;;ACTIVE;1.0;2.73 +51839-9;Treponema pallidum Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Treponema pallidum IgM Ab [Units/volume] in Serum by Immunoassay;T pallidum IgM Ser IA-aCnc;;ACTIVE;2.24;2.69 +51840-7;Echovirus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Echovirus IgG Ab [Titer] in Serum by Immunofluorescence;ECV IgG Titr Ser IF;;ACTIVE;2.24;2.32 +51841-5;Echovirus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Echovirus IgM Ab [Titer] in Serum by Immunofluorescence;ECV IgM Titr Ser IF;;ACTIVE;2.24;2.32 +51842-3;Plasmodium falciparum Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium falciparum IgM Ab [Titer] in Serum by Immunofluorescence;P falciparum IgM Titr Ser IF;;ACTIVE;2.24;2.32 +51843-1;Malonate/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Malonate/Creatinine [Mass Ratio] in Urine;Malonate/Creat Ur;;ACTIVE;2.24;2.70 +51844-9;Cortisol;SCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Moles/volume] in Saliva (oral fluid);Cortis Sal-sCnc;;ACTIVE;2.24;2.73 +51845-6;Consultation note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Consult note;OP Consult note;;ACTIVE;2.24;2.58 +51846-4;Consultation note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Consult note;ED Consult note;;ACTIVE;2.24;2.58 +5184-7;Hepatitis A virus Ab;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis A virus Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HAV Ab Ser RIA-aCnc;;ACTIVE;1.0;2.73 +51847-2;Evaluation+Plan note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation + Plan note;Eval+Plan note;;ACTIVE;2.24;2.63 +51848-0;Evaluation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation note;Eval note;;ACTIVE;2.24;2.73 +51849-8;Admission history and physical note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Admission history and physical note;Admit H&P note;;ACTIVE;2.24;2.58 +51850-6;Physical findings;Find;Pt;Head & Ears & Eyes & Nose & Throat;Doc;Observed;H&P.PX;2;Physical findings of Head and Ears and Eyes and Nose and Throat;Phys find Head+EENT;;ACTIVE;2.24;2.38 +51851-4;Administrative note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Administrative note;Administrative note;;ACTIVE;2.24;2.54 +51852-2;Letter;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Letter;Letter;;ACTIVE;2.24;2.73 +51853-0;Consultation note;Find;Pt;Inpatient hospital;Doc;{Provider};DOC.ONTOLOGY;2;Deprecated Inpatient hospital Consult note;Deprecated IP hospital Consult note;;DEPRECATED;2.24;2.68 +5185-4;Hepatitis B virus core Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis B virus core IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;HBV core IgM SerPl IA-aCnc;;ACTIVE;1.0;2.73 +51854-8;Consultation note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Consult note;LTC fac Consult note;;ACTIVE;2.24;2.58 +51855-5;Note;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Patient Note;Patient Note;;ACTIVE;2.24;2.50 +51856-3;Staphylococcus aureus TSST-1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Staphylococcus aureus TSST-1 IgE Ab [Units/volume] in Serum;S aureus TSST-1 IgE Qn;;ACTIVE;2.24;2.65 +51857-1;Malassezia sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Malassezia sp IgE Ab [Units/volume] in Serum;Malassezia sp IgE Qn;;ACTIVE;2.24;2.73 +51858-9;Budgerigar serum proteins+feathers+droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Budgerigar serum proteins+feathers+droppings IgG Ab [Presence] in Serum;Budgie ser prot+feathers+dropp IgG Ql;;ACTIVE;2.24;2.56 +51859-7;Pigeon serum proteins+feathers+droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pigeon serum proteins+feathers+droppings IgG Ab [Presence] in Serum;Pigeon ser prot+feathers+dropp IgG Ql;;ACTIVE;2.24;2.56 +51860-5;Parrot serum proteins+feathers+droppings Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parrot serum proteins+feathers+droppings IgG Ab [Presence] in Serum;Parrot ser prot+feathers+dropp IgG Ql;;ACTIVE;2.24;2.56 +51861-3;(Alternaria alternata+Cladosporium herbarum+Mucor racemosus+Penicillium notatum) Ab.IgG;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 6 (Alternaria alternata+Cladosporium herbarum+Mucor racemosus+Penicillium notatum) IgG Ab [Presence] in Serum by Multidisk;Mold Allerg Mix6 IgG Ql;;ACTIVE;2.24;2.56 +5186-2;Hepatitis B virus core Ab.IgM;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis B virus core IgM Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HBV core IgM Ser RIA-aCnc;;ACTIVE;1.0;2.73 +51862-1;(Saccharopolyspora rectivirgula+Thermoactinomyces vulgaris) Ab.IgG;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 7 (Saccharopolyspora rectivirgula+Thermoactinomyces vulgaris) IgG Ab [Presence] in Serum by Multidisk;Mold Allerg Mix7 IgG Ql;;ACTIVE;2.24;2.56 +51863-9;Staphylococcus aureus TSST-1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Staphylococcus aureus TSST-1 IgE Ab RAST class [Presence] in Serum;S aureus TSST-1 IgE RAST Ql;;ACTIVE;2.24;2.65 +51864-7;Malassezia sp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Malassezia sp IgE Ab RAST class [Presence] in Serum;Malassezia sp IgE RAST Ql;;ACTIVE;2.24;2.58 +51865-4;Plasmodium sp Ag;Prid;Pt;Bld;Nom;;MICRO;1;Plasmodium sp Ag [Identifier] in Blood;Plasmodium Ag Bld;;ACTIVE;2.24;2.24 +51866-2;HIV 1 Ab+Ag;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated HIV 1 Ab+Ag [Presence] in Serum;Deprecated HIV 1 Ab+Ag Ser Ql;;DEPRECATED;2.24;2.42 +51867-0;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript in Blood or Tissue by FISH";"t(9;22)(ABL1,BCR) Bld/T FISH";;ACTIVE;2.24;2.73 +51868-8;Coagulation thrombin induced.factor substitution^immediately after addition of XXX;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of XXX;TT imm XXX PPP;;ACTIVE;2.24;2.73 +51869-6;Washed packed erythrocytes given;Vol;Pt;^Patient;Qn;;BLDBK;1;Washed packed erythrocytes given [Volume];Washed packed RBC Gvn Vol;;ACTIVE;2.24;2.42 +5187-0;Hepatitis B virus core Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis B virus core Ab [Units/volume] in Serum by Immunoassay;HBV core Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +51870-4;Frozen erythrocytes given;Vol;Pt;^Patient;Qn;;BLDBK;1;Frozen erythrocytes given [Volume];Frozen RBC Gvn Vol;;ACTIVE;2.24;2.42 +51871-2;Direct antiglobulin test.polyspecific reagent;PrThr;Pt;RBCCo;Ord;;BLDBK;1;Direct antiglobulin test.polyspecific reagent [presence] on Cord red blood cells;DAT Poly-Sp Reag RBCCo Ql;;ACTIVE;2.24;2.73 +51872-0;Transfuse platelet concentrate units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse platelet concentrate units [#];Num units trans platelet conc;;ACTIVE;2.24;2.73 +51873-8;Platelet concentrate units given;Num;Pt;^BPU;Qn;;BLDBK;1;Platelet concentrate units given [#];Platelet conc Gvn BPU;;ACTIVE;2.24;2.73 +51874-6;Varicella zoster virus immune globulin ordered;Num;Pt;^BPU;Qn;;BLDBK;1;Varicella zoster virus immune globulin ordered [#] in Blood product unit;Num Units VZIg ordered;;ACTIVE;2.24;2.69 +51875-3;Varicella zoster virus immune globulin units given;Num;Pt;^BPU;Qn;;BLDBK;1;Varicella zoster virus immune globulin units given [#];VZIg Gvn BPU;;ACTIVE;2.24;2.69 +51876-1;Whole blood units given;Num;Pt;^BPU;Qn;;BLDBK;1;Whole blood units given [#];Whole bld Gvn BPU;;ACTIVE;2.24;2.38 +51877-9;Transfuse fresh frozen plasma units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse fresh frozen plasma units [#];Num units trans FFP;;ACTIVE;2.24;2.73 +51878-7;Fresh frozen plasma units given;Num;Pt;^BPU;Qn;;BLDBK;1;Fresh frozen plasma units given [#];FFP Gvn BPU;;ACTIVE;2.24;2.73 +51879-5;Transfuse packed erythrocytes units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse packed erythrocytes units [#];Num units trans packed RBC;;ACTIVE;2.24;2.73 +51880-3;Packed erythrocytes units given;Num;Pt;^BPU;Qn;;BLDBK;1;Packed erythrocytes units given [#];Packed RBC Gvn BPU;;ACTIVE;2.24;2.73 +51881-1;Transfuse cryoprecipitate units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse cryoprecipitate units [#];Num units trans cryoppt;;ACTIVE;2.24;2.69 +51882-9;Cryoprecipitate units given;Num;Pt;^BPU;Qn;;BLDBK;1;Cryoprecipitate units given [#];Cryoppt Gvn BPU;;ACTIVE;2.24;2.73 +51883-7;Transfuse whole blood units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse whole blood units [#];Num units trans whole bld;;ACTIVE;2.24;2.69 +51884-5;Transfuse pooled platelets units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse pooled platelets units [#];Num units trans pooled platelets;;ACTIVE;2.24;2.69 +51885-2;Transfuse whole blood autologous units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse whole blood autologous units [#];Num units trans bld Autol;;ACTIVE;2.24;2.69 +51886-0;Autologous whole blood units given;Num;Pt;^BPU;Qn;;BLDBK;1;Autologous whole blood units given [#];Autol Bld units Gvn BPU;;ACTIVE;2.24;2.69 +51887-8;Transfuse Rh immune globulin units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse Rh immune globulin units [#];Num units trans Rhogam;;ACTIVE;2.24;2.73 +5188-8;Hepatitis B virus core Ab;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis B virus core Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HBV core Ab Ser RIA-aCnc;;ACTIVE;1.0;2.73 +51888-6;Rh immune globulin units given;Num;Pt;^BPU;Qn;;BLDBK;1;Rh immune globulin units given [#];Rhogam Gvn BPU;;ACTIVE;2.24;2.69 +51889-4;Transfuse factor VIII units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse factor VIII [#];Num units trans Fact VIII;;ACTIVE;2.24;2.69 +51890-2;Factor VIII units given;Num;Pt;^BPU;Qn;;BLDBK;1;Factor VIII units given [#];Fact VIII Gvn BPU;;ACTIVE;2.24;2.69 +51891-0;Transfuse factor IX units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse factor IX units [#];Num units trans Fact IX;;ACTIVE;2.24;2.69 +51892-8;ABO group;Type;Pt;BldCo;Nom;;BLDBK;1;ABO group [Type] in Cord blood;ABO Group BldCo;;ACTIVE;2.24;2.73 +51893-6;Transfuse cryoprecipitate poor plasma units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse cryoprecipitate poor plasma units [#];Num units trans CP;;ACTIVE;2.24;2.69 +51894-4;Fresh frozen plasma given;Num;Pt;^BPU;Qn;;BLDBK;1;Deprecated Fresh frozen plasma units given [#];Deprecated FFP given BPU Qn;;DEPRECATED;2.24;2.69 +51895-1;Lot number;ID;Pt;^BPU;Nom;;BLDBK;1;Lot number of Blood product unit;Lot # BPU;;ACTIVE;2.24;2.24 +5189-6;Hepatitis B virus little e Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis B virus e Ab [Units/volume] in Serum by Immunoassay;HBV e Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +51896-9;Healthcare associated infection report - recommended CDA R2 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Healthcare Associated Infection report - recommended CDA R2 sections;HAI report - CDA R2 sections;;ACTIVE;2.24;2.63 +51897-7;Healthcare Associated Infection report;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Healthcare Associated Infection report Document;HAI report Doc;;ACTIVE;2.24;2.73 +51898-5;Risk factors;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Risk factors Document;Risk factors Doc;;ACTIVE;2.24;2.73 +51899-3;Details;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Details Document;Details Doc;;ACTIVE;2.24;2.73 +51900-9;Population summary report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Population Summary note;Pop summary report;;ACTIVE;2.24;2.67 +51901-7;Avena sativa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oat IgG Ab [Mass/volume] in Serum;Oat IgG-mCnc;;ACTIVE;2.24;2.73 +51902-5;Cadmium;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Air;Cadmium Air-mCnc;;ACTIVE;2.24;2.70 +51903-3;Chromium;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Air;Chromium Air-mCnc;;ACTIVE;2.24;2.70 +5190-4;Hepatitis B virus little e Ab;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis B virus e Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HBV e Ab Ser RIA-aCnc;;ACTIVE;1.0;2.73 +51904-1;Citrus sinensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Orange IgG Ab [Mass/volume] in Serum;Orange IgG-mCnc;;ACTIVE;2.24;2.73 +51905-8;Collection end time;TmStp;Pt;Air;Qn;;SPEC;1;Collection of air specimen end time;Collect End Tme Air;;ACTIVE;2.24;2.70 +51906-6;Collection start time;TmStp;Pt;Air;Qn;;SPEC;1;Collection of air specimen start time;Collect Start Tme Air;;ACTIVE;2.24;2.70 +51907-4;Efavirenz^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Efavirenz [Mass/volume] in Serum or Plasma --trough;Efavirenz Trough SerPl-mCnc;;ACTIVE;2.24;2.70 +51908-2;Efavirenz^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Efavirenz [Mass/volume] in Serum or Plasma --peak;Efavirenz Peak SerPl-mCnc;;ACTIVE;2.24;2.70 +51909-0;Ependymal cells/100 cells;NFr;Pt;CSF;Qn;;HEM/BC;1;Ependymal cells/100 cells in Cerebral spinal fluid;Ependymal cells NFr CSF;;ACTIVE;2.24;2.73 +51910-8;Erythrocytes;Naric;Pt;BAL;Qn;Microscopy.light.HPF;HEM/BC;1;Erythrocytes [#/area] in Bronchoalveolar lavage by Microscopy high power field;RBC #/area BAL HPF;;ACTIVE;2.24;2.70 +51911-6;Giardia lamblia+Cryptosporidium sp Ag^3rd specimen;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool --3rd specimen;G lamblia+Cryptosp Ag sp3 Stl Ql;;ACTIVE;2.24;2.56 +5191-2;Hepatitis B virus little e Ag;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis B virus e Ag [Units/volume] in Serum by Immunoassay;HBV e Ag Ser IA-aCnc;;ACTIVE;1.0;2.73 +51912-4;Giardia lamblia+Cryptosporidium sp Ag^2nd specimen;PrThr;Pt;Stool;Ord;;MICRO;1;Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool --2nd specimen;G lamblia+Cryptosp Ag sp2 Stl Ql;;ACTIVE;2.24;2.56 +51913-2;Hepatitis A virus Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis A virus IgG+IgM Ab [Presence] in Serum;HAV IgG+IgM Ser Ql;;ACTIVE;2.24;2.73 +51914-0;Hepatitis B virus core Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus core IgG+IgM Ab [Presence] in Serum;HBV core IgG+IgM Ser Ql;;ACTIVE;2.24;2.73 +51915-7;Herpes simplex virus Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus IgG Ab [Titer] in Serum by Immunoassay;HSV IgG Titr Ser IA;;ACTIVE;2.24;2.70 +51916-5;Herpes simplex virus 1 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Herpes simplex virus 1 IgG Ab [Presence] in Serum or Plasma by Immunoassay;HSV1 IgG SerPl Ql IA;;ACTIVE;2.24;2.73 +51917-3;Hordeum vulgare Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Barley IgG Ab [Mass/volume] in Serum;Barley IgG-mCnc;;ACTIVE;2.24;2.73 +51918-1;Indinavir^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Indinavir [Mass/volume] in Serum or Plasma --trough;Indinavir Trough SerPl-mCnc;;ACTIVE;2.24;2.70 +51919-9;Lactuca sativa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lettuce IgG Ab [Mass/volume] in Serum;Lettuce IgG-mCnc;;ACTIVE;2.24;2.73 +5192-0;Hepatitis B virus little e Ag;PrThr;Pt;Ser;Ord;RIA;MICRO;1;Hepatitis B virus e Ag [Presence] in Serum by Radioimmunoassay (RIA);HBV e Ag Ser Ql RIA;;ACTIVE;1.0;2.73 +51920-7;Legionella sp Ab^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Legionella sp Ab [Titer] in Serum --2nd specimen;Legionella Ab sp2 Titr Ser;;ACTIVE;2.24;2.70 +51921-5;Lopinavir^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lopinavir [Mass/volume] in Serum or Plasma --trough;Lopinavir Trough SerPl-mCnc;;ACTIVE;2.24;2.70 +51922-3;Malt Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Malt IgG Ab [Mass/volume] in Serum;Malt IgG-mCnc;;ACTIVE;2.24;2.73 +51923-1;Nelfinavir^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nelfinavir [Mass/volume] in Serum or Plasma --peak;Nelfinavir Peak SerPl-mCnc;;ACTIVE;2.24;2.70 +51924-9;Neutrophil cytoplasmic Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Neutrophil cytoplasmic Ab [Titer] in Serum by Immunofluorescence;ANCA Ab Titr Ser IF;;ACTIVE;2.24;2.73 +51925-6;Nevirapine^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nevirapine [Mass/volume] in Serum or Plasma --peak;Nevirapine Peak SerPl-mCnc;;ACTIVE;2.24;2.70 +51926-4;Nucleated cells;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Peritoneal fluid by Manual count;Nuc cell # Prt Manual;;ACTIVE;2.24;2.73 +51927-2;Other cells/100 leukocytes;NFr;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Bronchial specimen by Manual count;Other cells/leuk NFr Bronch Manual;;ACTIVE;2.24;2.70 +51928-0;Ribonucleoprotein extractable nuclear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum by Immunoassay;ENA RNP Ab Ser IA-aCnc;;ACTIVE;2.24;2.73 +51929-8;Ritonavir^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ritonavir [Mass/volume] in Serum or Plasma --peak;Ritonavir Peak SerPl-mCnc;;ACTIVE;2.24;2.70 +51930-6;Ritonavir^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ritonavir [Mass/volume] in Serum or Plasma --trough;Ritonavir Trough SerPl-mCnc;;ACTIVE;2.24;2.70 +51931-4;Rubella virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rubella virus Ab [Units/volume] in Serum by Immunoassay;RUBV Ab Ser IA-aCnc;;ACTIVE;2.24;2.73 +51932-2;Saquinavir^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Saquinavir [Mass/volume] in Serum or Plasma --trough;Saquinavir Trough SerPl-mCnc;;ACTIVE;2.24;2.70 +51933-0;Secale cereale Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rye IgG Ab [Mass/volume] in Serum;Rye IgG-mCnc;;ACTIVE;2.24;2.73 +51934-8;Spermatozoa.slow/100 spermatozoa ^1H post ejaculation;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Slow/100 spermatozoa in Semen --1 hour post ejaculation;Sperm Slow 1h p ejac NFr Smn;;ACTIVE;2.24;2.70 +51935-5;Trypsinogen I.free;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Trypsinogen I Free [Presence] in DBS;Trypsinogen I Free DBS Ql;;ACTIVE;2.24;2.73 +51936-3;Yeast bakers Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Bakers Yeast IgG Ab [Mass/volume] in Serum;Deprecated Bakers Yeast IgG-mCnc;;DEPRECATED;2.24;2.70 +51937-1;HLA-A+B+Bw+DR;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-A+B+Bw+DR [Type];HLA-A+B+Bw+DR;;ACTIVE;2.24;2.73 +5193-8;Hepatitis B virus surface Ab;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis B virus surface Ab [Units/volume] in Serum or Plasma by Immunoassay;HBV surface Ab SerPl IA-aCnc;;ACTIVE;1.0;2.73 +51938-9;HLA-A+B+Bw+DR;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-A+B+Bw+DR [Type] in Donor;HLA-A+B+Bw+DR Donr;;ACTIVE;2.24;2.73 +51939-7;Escherichia coli shiga-like toxin 2;PrThr;Pt;Stool;Ord;IA;MICRO;1;Escherichia coli shiga-like toxin 2 [Presence] in Stool by Immunoassay;E coli SXT2 Stl Ql IA;;ACTIVE;2.24;2.73 +51940-5;Escherichia coli shiga-like toxin 1;PrThr;Pt;Stool;Ord;IA;MICRO;1;Escherichia coli shiga-like toxin 1 [Presence] in Stool by Immunoassay;E coli SXT1 Stl Ql IA;;ACTIVE;2.24;2.73 +51941-3;Package label.Back panel;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Back panel of package;FDA label Back panel;;ACTIVE;2.24;2.34 +51942-1;Package label.Side panel.right;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Side panel of package Right;FDA label Side panel-R;;ACTIVE;2.24;2.34 +51943-9;Package label.Side panel.left;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Side panel of package Left;FDA label Side panel-L;;ACTIVE;2.24;2.34 +51944-7;Package label.Side panel;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Side panel of package;FDA label Side panel;;ACTIVE;2.24;2.34 +51945-4;Package label.Principal display panel;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Principal display panel of package;FDA label Principal display panel;;ACTIVE;2.24;2.34 +5194-6;Hepatitis B virus surface Ab;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis B virus surface Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HBV surface Ab Ser RIA-aCnc;;ACTIVE;1.0;2.73 +51946-2;Package label.Top panel;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Top panel of package;FDA label Top panel;;ACTIVE;2.24;2.68 +51947-0;Package label.Bottom panel;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Bottom panel of package;FDA label Bottom panel;;ACTIVE;2.24;2.34 +51948-8;Package label.Flap panel;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Flap panel of package;FDA label Flap panel;;ACTIVE;2.24;2.67 +51949-6;History of trisomy 21;Find;Pt;^Patient;Nar;;CHEM;1;Deprecated History of trisomy 21 [Finding] Narrative;Deprecated Hx Trisomy 21 Patient;;DEPRECATED;2.24;2.36 +51950-4;Calcium^post dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Mass/volume] in Serum or Plasma --post dialysis;Calcium p dialysis SerPl-mCnc;;ACTIVE;2.24;2.40 +51951-2;UGT1A1 gene allele 1;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;UGT1A1 gene allele 1 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;UGT1A1 allele 1 Bld/T;;ACTIVE;2.24;2.73 +51952-0;UGT1A1 gene allele 2;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;UGT1A1 gene allele 2 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;UGT1A1 allele 2 Bld/T;;ACTIVE;2.24;2.73 +5195-3;Hepatitis B virus surface Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis B virus surface Ag [Presence] in Serum;HBV surface Ag Ser Ql;;ACTIVE;1.0;2.73 +51953-8;Collection date;TmStp;Pt;Bld;Qn;;SPEC;1;Collection date of Blood;Collect Date Bld;;ACTIVE;2.24;2.73 +51954-6;oxyCODONE.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;oxyCODONE Free [Mass/volume] in Urine;oxyCODONE Free Ur-mCnc;;ACTIVE;2.24;2.70 +51955-3;Dihydrocodeine.free+Hydrocodol.free;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dihydrocodeine Free+Hydrocodol Free [Mass/volume] in Urine;DHC+Hydrocodol Free Ur-mCnc;;ACTIVE;2.24;2.70 +51956-1;DNA region analysis test coverage panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;DNA region analysis test coverage panel;DNA reg analysis cover Pnl;;ACTIVE;2.24;2.73 +51957-9;Placer DNA analysis test identifier;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Placer DNA analysis test identifier [Identifier];Placer DNA anl test ID;;ACTIVE;2.24;2.63 +51958-7;Transcript reference sequence identifier;ID;Pt;Bld/Tiss;Nom;;HL7.GENETICS;1;Transcript reference sequence [ID];Transcript ref sequence ID;;ACTIVE;2.24;2.73 +51959-5;DNA region of interest;NumRange;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Range(s) of DNA sequence examined;DNA region of interest NumRange;;ACTIVE;2.24;2.58 +51960-3;DNA marker results panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;DNA marker results panel;DNA marker ID Pnl;;ACTIVE;2.24;2.56 +5196-1;Hepatitis B virus surface Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis B virus surface Ag [Presence] in Serum or Plasma by Immunoassay;HBV surface Ag SerPl Ql IA;;ACTIVE;1.0;2.73 +51961-1;Drug efficacy sequence variation interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;HL7.GENETICS;1;Genetic variation's effect on drug efficacy;Drug eff seq var interp-Imp;;ACTIVE;2.24;2.73 +51962-9;Pharmacogenetic DNA analysis panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;Pharmacogenetic DNA analysis panel;Pharmacogenetic DNA anl Pnl;;ACTIVE;2.24;2.63 +51963-7;Medication assessed;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Medication assessed [ID];Medication assessed;;ACTIVE;2.24;2.58 +51964-5;Drug efficacy analysis overall interpretation;Imp;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Drug efficacy analysis overall interpretation;Drug eff analysis imp-Imp;;ACTIVE;2.24;2.56 +51965-2;Pharmacogenetic analysis report;Find;Pt;Bld/Tiss;Doc;Molgen;HL7.GENETICS;1;Pharmacogenetic analysis report Document;Pharmacogenetic anl rpt Doc;;ACTIVE;2.24;2.63 +51966-0;Genetic disease DNA analysis panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;Genetic disease DNA analysis panel;Gene dis DNA anl Pnl;;ACTIVE;2.24;2.63 +51967-8;Genetic disease assessed;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genetic disease assessed [ID];Gene dis assessed;;ACTIVE;2.24;2.58 +51968-6;Genetic disease analysis overall interpretation;Imp;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Discrete variation analysis overall interpretation;Gene dis anl interp-Imp;;ACTIVE;2.24;2.73 +51969-4;Genetic analysis summary report;Find;Pt;Bld/Tiss;Doc;Molgen;HL7.GENETICS;1;Genetic analysis report;Gene analysis narr rpt Doc;;ACTIVE;2.24;2.73 +51970-2;Individual allele identifier;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Individual allele identifier [Identifier];Individual allele ID;;ACTIVE;2.24;2.56 +51971-0;Gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;Gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;Gene prod met act imp Bld/T-Imp;;ACTIVE;2.24;2.73 +51972-8;Gas panel;-;Pt;BldCoV;Qn;;PANEL.CHEM;1;Gas panel - Venous cord blood;Gas Pnl BldCoV;;ACTIVE;2.24;2.73 +51973-6;Gas panel;-;Pt;BldMV;Qn;;PANEL.CHEM;1;Gas panel - Mixed venous blood;Gas Pnl BldMV;;ACTIVE;2.24;2.73 +51974-4;Gas panel;-;Pt;BldCoA;Qn;;PANEL.CHEM;1;Gas panel - Arterial cord blood;Gas Pnl BldCoA;;ACTIVE;2.24;2.73 +51975-1;Individual allele results panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;Individual allele results panel;Individual allele ID Pnl;;ACTIVE;2.24;2.61 +51976-9;Bacillus anthracis capsule Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bacillus anthracis capsule Ag [Presence] in Specimen by Immunofluorescence;B anthracis capsule Ag Spec Ql IF;;ACTIVE;2.24;2.69 +51977-7;Chromium;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chromium [Presence] in Urine;Chromium Ur Ql;;ACTIVE;2.24;2.56 +51978-5;Coxsackievirus A Ab;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A Ab [Titer] in Serum;CV A Ab Titr Ser;;ACTIVE;2.24;2.73 +5197-9;Hepatitis B virus surface Ag;PrThr;Pt;Ser;Ord;RIA;MICRO;1;Hepatitis B virus surface Ag [Presence] in Serum by Radioimmunoassay (RIA);HBV surface Ag Ser Ql RIA;;ACTIVE;1.0;2.73 +51979-3;Donepezil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Donepezil [Mass/volume] in Serum or Plasma;Donepezil SerPl-mCnc;;ACTIVE;2.24;2.70 +51980-1;Glomerular basement membrane Ab;MCnc;Pt;Ser;Qn;;SERO;1;Glomerular basement membrane Ab [Mass/volume] in Serum;GBM Ab Ser-mCnc;;ACTIVE;2.24;2.73 +51981-9;HER2;PrThr;Pt;Ser;Ord;IA;PATH;1;HER2 [Presence] in Serum by Immunoassay;Her2 Ser Ql IA;;ACTIVE;2.24;2.73 +51982-7;lamoTRIgine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;lamoTRIgine [Presence] in Serum or Plasma;lamoTRIgine SerPl Ql;;ACTIVE;2.24;2.73 +51983-5;Levodopa;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Levodopa [Presence] in Serum or Plasma;L-Dopa SerPl Ql;;ACTIVE;2.24;2.56 +51984-3;Meperidine+Normeperidine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Meperidine+Normeperidine [Presence] in Serum or Plasma by Screen method;Meperidine+Nor SerPl Ql Scn;;ACTIVE;2.24;2.56 +51985-0;Modafinil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Modafinil [Mass/volume] in Serum or Plasma;Modafinil SerPl-mCnc;;ACTIVE;2.24;2.70 +51986-8;niCARdipine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;niCARdipine [Presence] in Serum or Plasma;niCARdipine SerPl Ql;;ACTIVE;2.24;2.56 +5198-7;Hepatitis C virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis C virus Ab [Units/volume] in Serum by Immunoassay;HCV Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +51987-6;Ubiquinone 10;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Coenzyme Q10 [Presence] in Serum or Plasma;Ubiquinone10 SerPl Ql;;ACTIVE;2.24;2.73 +51988-4;Ureaplasma urealyticum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ureaplasma urealyticum DNA [Presence] in Specimen by NAA with probe detection;U urealyticum DNA Spec Ql NAA+probe;;ACTIVE;2.24;2.73 +51989-2;Vasoactive intestinal peptide;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Vasoactive intestinal peptide [Presence] in Serum or Plasma;VIP SerPl Ql;;ACTIVE;2.24;2.73 +519-9;Troleandomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Troleandomycin [Susceptibility] by Minimum lethal concentration (MLC);Troleandomycin Islt MLC;;ACTIVE;1.0;2.19 +51990-0;Basic metabolic panel;-;Pt;Bld;Qn;;PANEL.CHEM;1;Basic metabolic panel - Blood;Bas Metab Pnl Bld;;ACTIVE;2.24;2.73 +51991-8;Referral lab test panel;-;Pt;Referral lab test;-;;PANEL.MISC;1;Referral lab test panel;Ref lab test Pnl;;ACTIVE;2.24;2.73 +51992-6;Heavy metals panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Heavy metals panel - Serum or Plasma;Heavy Met Pnl SerPl;;ACTIVE;2.24;2.73 +51993-4;Metanephrine & Normetanephrine panel;-;Pt;Urine;-;;PANEL.CHEM;1;Metanephrine and Normetanephrine panel - Urine;Metaneph+Normetaneph Pnl Ur;;ACTIVE;2.24;2.73 +51994-2;Homovanillate/Creatinine;MRto;XXX;Urine;Qn;;CHEM;1;Homovanillate/Creatinine [Mass Ratio] in Urine collected for unspecified duration;HVA/Creat ?Tm Ur;;ACTIVE;2.24;2.52 +5199-5;Hepatitis C virus Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus Ab [Presence] in Serum by Immunoblot;HCV Ab Ser Ql IB;;ACTIVE;1.0;2.73 +51995-9;Rationale for type of transport;Type;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Rationale for type of transport (narrative);;;ACTIVE;2.24;2.27 +51996-7;Distance and time transported information;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Distance and time transported information Set;;;ACTIVE;2.24;2.40 +51997-5;Distance transported - loaded indicator;Arb;Pt;Ambulance transport;Ord;;ATTACH.AMB;3;Ambulance transport, Distance transported - loaded indicator;;;ACTIVE;2.24;2.27 +51998-3;Rationale for excess or additional mileage;Find;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Rationale for excess or additional mileage;;;ACTIVE;2.24;2.27 +51999-1;Time ambulance arrived at scene;TmStp;Pt;Ambulance transport;Qn;;ATTACH.AMB;3;Ambulance transport, Time ambulance arrived at scene Date and time;;;ACTIVE;2.24;2.27 +52000-7;Origination site latitude;Angle;Pt;Ambulance transport;Qn;;ATTACH.AMB;3;Ambulance transport, Origination site latitude;;;ACTIVE;2.24;2.27 +5200-1;Hepatitis D virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis D virus Ab [Units/volume] in Serum by Immunoassay;HDV Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +52001-5;Origination site longitude;Angle;Pt;Ambulance transport;Qn;;ATTACH.AMB;3;Ambulance transport, Origination site longitude;;;ACTIVE;2.24;2.27 +52002-3;Destination site latitude;Angle;Pt;Ambulance transport;Qn;;ATTACH.AMB;3;Ambulance transport, Destination site latitude coordinate;;;ACTIVE;2.24;2.27 +52003-1;Destination site longitude;Angle;Pt;Ambulance transport;Qn;;ATTACH.AMB;3;Ambulance transport, Destination site longitude coordinate;;;ACTIVE;2.24;2.27 +52004-9;Rationale for wait time;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Rationale for wait time Set;;;ACTIVE;2.24;2.40 +52005-6;Rationale for wait time;Find;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Rationale for wait time;;;ACTIVE;2.24;2.24 +52006-4;Rationale for wait time;Find;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Rationale for wait time (narrative);;;ACTIVE;2.24;2.27 +52007-2;Number of patients;Num;Pt;Ambulance transport;Qn;;ATTACH.AMB;3;Ambulance transport, Number of patients;;;ACTIVE;2.24;2.24 +52008-0;Reason for multiple patients;Find;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Reason for multiple patients (narrative);;;ACTIVE;2.24;2.27 +52009-8;Other patients information;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Other patients information Set;;;ACTIVE;2.24;2.40 +52010-6;Other patient name;Pn;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Other patient name;;;ACTIVE;2.24;2.24 +52011-4;Other patient identifier;ID;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Other patient identifier;;;ACTIVE;2.24;2.24 +52012-2;Receiving individual accepting responsibility for patient;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Receiving individual accepting responsibility for patient Set;;;ACTIVE;2.24;2.40 +52013-0;Receiving individual accepting responsibility for patient;Pn;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Receiving individual accepting responsibility for patient;;;ACTIVE;2.24;2.27 +52014-8;Receiving individual accepting responsibility for patient;ID;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Receiving individual accepting responsibility for patient Identifier;;;ACTIVE;2.24;2.27 +52015-5;Ordering practitioner or agency;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Ordering practitioner or agency Set;;;ACTIVE;2.24;2.40 +52016-3;Physician certification for transport information;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Physician certification for transport information Set;;;ACTIVE;2.24;2.40 +52017-1;Physician certification for transport statement;Find;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Physician certification for transport statement (narrative);;;ACTIVE;2.24;2.27 +52018-9;Physician certification for transport indicator;Arb;Pt;Ambulance transport;Ord;;ATTACH.AMB;3;Ambulance transport, Physician certification for transport indicator;;;ACTIVE;2.24;2.24 +5201-9;Hepatitis D virus Ab;ACnc;Pt;Ser;Qn;RIA;MICRO;1;Hepatitis D virus Ab [Units/volume] in Serum by Radioimmunoassay (RIA);HDV Ab Ser RIA-aCnc;;ACTIVE;1.0;2.69 +52019-7;Description of services performed to support level of service;Find;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Description of services performed to support level of service (narrative);;;ACTIVE;2.24;2.27 +52020-5;Medical reason for unscheduled trip;Imp;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Medical reason for unscheduled trip;;;ACTIVE;2.24;2.26 +52021-3;Justification for extra attendants;Find;Pt;Ambulance transport;Nar;;ATTACH.AMB;3;Ambulance transport, Justification for extra attendants (narrative);;;ACTIVE;2.24;2.27 +52022-1;Type of extra attendant(s);Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Type of extra attendant(s);;;ACTIVE;2.24;2.27 +52023-9;Origination site name and address;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Origination site name and address;;;ACTIVE;2.24;2.27 +52024-7;Rationale for choice of destination;Type;Pt;Ambulance transport;Nom;;ATTACH.AMB;3;Ambulance transport, Rationale for choice of destination;;;ACTIVE;2.24;2.24 +52025-4;Confined to bed or chair^at ambulance transport;Arb;Pt;^Patient;Ord;;ATTACH.AMB;3;Confined to bed or chair at ambulance transport;;;ACTIVE;2.24;2.27 +52026-2;Destination site name & address;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Destination site name and address;;;ACTIVE;2.24;2.70 +5202-7;Herpes simplex virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus Ab [Units/volume] in Serum by Immunoassay;HSV Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +52027-0;Abortion consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Abortion consent Document;Abortion consent;;ACTIVE;2.24;2.65 +52028-8;Hysterectomy consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Hysterectomy consent Document;Hysterectomy consent;;ACTIVE;2.24;2.65 +52029-6;Sterilization consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Sterilization consent Document;Sterilization consent;;ACTIVE;2.24;2.65 +52030-4;Explanation of benefits attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Explanation of benefits;Explanation of benefits;;ACTIVE;2.24;2.67 +52031-2;Explanation of benefits to subscriber attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Explanation of benefits to subscriber;Explanation of benefits to subscriber;;ACTIVE;2.24;2.67 +52032-0;Appeal denial letter attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Appeal denial letter;Appeal denial letter;;ACTIVE;2.24;2.67 +52033-8;General correspondence attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;General correspondence attachment;General correspnd attachment;;ACTIVE;2.24;2.67 +52034-6;Payer letter attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Payer letter;Payer letter;;ACTIVE;2.24;2.67 +5203-5;Herpes simplex virus Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Herpes simplex virus Ab [Units/volume] in Serum by Latex agglutination;HSV Ab Ser LA-aCnc;;ACTIVE;1.0;2.69 +52035-3;Home health claims attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Home health claims;Home health claims;;ACTIVE;2.24;2.67 +52036-1;Home health prior authorization attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Home health prior authorization;Home health prior authorization;;ACTIVE;2.24;2.67 +52037-9;Member ID card copy attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Member ID card copy;Member ID card copy;;ACTIVE;2.24;2.67 +52038-7;Subscriber Information including retroactive and presumptive eligibility attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Subscriber Information including retroactive and presumptive eligibility;Subscriber Information eligibility;;ACTIVE;2.24;2.67 +52039-5;Skilled Nursing Facility record attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Skilled Nursing Facility (SNF) record;SNF record;;ACTIVE;2.24;2.67 +52040-3;Dental X-rays and other images (not DICOM) attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Dental X-rays and other images (not DICOM);Dent X-rays and other images (not DICOM);;ACTIVE;2.24;2.68 +52041-1;Blood glucose monitors attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Blood glucose monitor attachment;Blood glucose monitor attachment;;ACTIVE;2.24;2.67 +52042-9;Continuous positive airway pressure attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Continuous positive airway pressure (CPAP) attachment;CPAP attachment;;ACTIVE;2.24;2.73 +5204-3;Herpes simplex virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Herpes simplex virus Ab [Titer] in Serum by Complement fixation;HSV Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52043-7;Enteral nutrition attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Enteral nutrition attachment;Enteral nutrition attachment;;ACTIVE;2.24;2.67 +52044-5;External infusion pump attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;External infusion pump attachment;External infusion pump attachment;;ACTIVE;2.24;2.67 +52045-2;Gait trainers attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Gait trainers attachment;Gait trainers attachment;;ACTIVE;2.24;2.67 +52046-0;Hospital beds attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Hospital beds attachment;Hospital beds attachment;;ACTIVE;2.24;2.67 +52047-8;Immunosuppressive drugs attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Immunosuppressive drug attachment;Immunosuppressive drug attachment;;ACTIVE;2.24;2.67 +52048-6;Lymphedema pumps attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Lymphedema pump attachment;Lymphedema pump attachment;;ACTIVE;2.24;2.67 +52049-4;Manual wheelchair attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Manual wheelchair attachment;Manual wheelchair attachment;;ACTIVE;2.24;2.67 +5205-0;Herpes simplex virus 1 Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 1 Ab [Units/volume] in Serum by Immunoassay;HSV1 Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +52050-2;Motorized wheelchair attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Motorized wheelchair attachment;Motorized wheelchair attachment;;ACTIVE;2.24;2.67 +52051-0;Orthotics + prosthetics attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Orthotic/Prosthetic attachment;Orthotic/Prosthetic attachment;;ACTIVE;2.24;2.67 +52052-8;Osteogenesis stimulators attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Osteogenesis stimulator attachment;Osteogenesis stimulator attachment;;ACTIVE;2.24;2.67 +52053-6;Oxygen attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Oxygen attachment;Oxygen attachment;;ACTIVE;2.24;2.67 +52054-4;Parenteral attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Parenteral nutrition attachment;Parenteral nutrition attachment;;ACTIVE;2.24;2.67 +52055-1;Power operated vehicles attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Power operated vehicle attachment;Power operated vehicle attachment;;ACTIVE;2.24;2.67 +52056-9;Repair of durable medical equipment attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Repair of durable medical equipment attachment;Repair of DME attachment;;ACTIVE;2.24;2.68 +52057-7;Seat lift mechanism attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Seat lift mechanism attachment;Seat lift mechanism attachment;;ACTIVE;2.24;2.67 +52058-5;Seating systems attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Seating system attachment;Seating system attachment;;ACTIVE;2.24;2.67 +52059-3;Speech generating device attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Speech generating device attachment;Speech generating device attachment;;ACTIVE;2.24;2.67 +52060-1;Standers + standing frames attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Standers/standing frame attachment;Standers/standing frame attachment;;ACTIVE;2.24;2.67 +52061-9;Support surfaces attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Support surface attachment;Support surface attachment;;ACTIVE;2.24;2.67 +52062-7;Transcutaneous electrical neural stimulation attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Transcutaneous electrical neural stimulation (TENS) attachment;TC electrical neural stim Doc;;ACTIVE;2.24;2.67 +52063-5;Prescription for durable medical equipment attachment;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Prescription for durable medical equipment (DME);Rx for DME attachment;;ACTIVE;2.24;2.68 +52064-3;First report of injury attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Worker's compensation first report of injury attachment;Work comp 1st rpt injury attachment;;ACTIVE;2.24;2.67 +52065-0;Automobile liability attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Automobile liability attachment;Automobile liability attachment;;ACTIVE;2.24;2.67 +52066-8;Notice of Discharge Medicare Appeal Rights Form attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Notice of Discharge Medicare Appeal Rights (NODMAR) form;NODMAR form;;ACTIVE;2.24;2.67 +52067-6;Past filing limit justification attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Past filing limit justification;Past filing limit justification;;ACTIVE;2.24;2.67 +5206-8;Herpes simplex virus 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 1 IgG Ab [Units/volume] in Serum by Immunoassay;HSV1 IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +52068-4;Property and casualty state mandated forms attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Property and casualty state mandated forms;Property+casualty state mandated forms;;ACTIVE;2.24;2.67 +52069-2;Tax ID number - IRS form W9 attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Tax ID number - IRS form W9;Tax ID # - IRS form W9 attachment;;ACTIVE;2.24;2.67 +520-7;Troleandomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Troleandomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Troleandomycin Islt MIC;;ACTIVE;1.0;2.19 +52070-0;Workers compensation attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Workers compensation attachment;Workers compensation attachment;;ACTIVE;2.24;2.67 +52071-8;Employee assistance program attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Employee assistance program attachment;Employee assistance prog attachment;;ACTIVE;2.24;2.67 +52072-6;Non-emergency transportation attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Non-emergency transportation attachment;Non-emerg transport attachment;;ACTIVE;2.24;2.68 +52073-4;Vision attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Vision services attachment;Vision services attachment;;ACTIVE;2.24;2.67 +52074-2;Extra attendants information;Cmplx;Pt;Ambulance transport;Set;;ATTACH.AMB;3;Ambulance transport, Extra attendants information Set;;;ACTIVE;2.24;2.40 +52075-9;Purchase invoice attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Purchase invoice;Purchase invoice;;ACTIVE;2.24;2.67 +5207-6;Herpes simplex virus 1 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 1 IgM Ab [Units/volume] in Serum by Immunoassay;HSV1 IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +52076-7;Date range;DateRange;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52077-5;Date range;DateRange;Pt;Hospitalization leading to alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52078-3;Referral information;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52079-1;Referral information;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52080-9;Referring person name;Pn;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52081-7;Referring person identifier;ID;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52082-5;Date patient referred for treatment;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52083-3;Communication to referring physician indicator;Arb;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Communication to referring physician indicator;Deprecated;;DEPRECATED;2.24;2.66 +5208-4;Herpes simplex virus 2 Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 2 Ab [Units/volume] in Serum by Immunoassay;HSV2 Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +52084-1;Responsible attending physician information;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52085-8;Responsible rehabilitation professional information;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52086-6;Medication rate;VRat;Pt;Alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52087-4;Medication timing;TQ2;Pt;Alcohol-substance abuse rehabilitation treatment;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52088-2;Date range certifying the plan of care;DateRange;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52089-0;Physician certification statement;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52090-8;Actual start of care date;Date;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52091-6;Past medical history;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5209-2;Herpes simplex virus 2 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Serum by Immunoassay;HSV2 IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +52092-4;Level of function;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52093-2;Prior level of function;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52094-0;Current level of function;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52095-7;Assessment information;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +52096-5;Assessment;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52097-3;Assessment indicator;Arb;Pt;Alcohol-substance abuse rehabilitation treatment plan;Ord;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52098-1;Treatment encounter;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52099-9;Progress note+attainment of goals;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52-1;Butirosin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Butirosin [Susceptibility] by Minimum inhibitory concentration (MIC);Butirosin Islt MIC;;ACTIVE;1.0;2.19 +5210-0;Herpes simplex virus 2 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 2 IgM Ab [Units/volume] in Serum by Immunoassay;HSV2 IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +52100-5;Progress note+attainment of goals date range;DateRange;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52101-3;Chief complaint+Reason for relapse if known;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Chief complaint+Reason for relapse if known (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52102-1;Past treatment attempts;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Past treatment attempts (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52103-9;Follow-up approach;Cmplx;Pt;Alcohol-substance abuse rehabilitation treatment plan;Set;;ATTACH.REHAB.ABUSE;3;Alcohol-substance abuse rehabilitation treatment plan, Follow-up approach Set;;;ACTIVE;2.24;2.40 +52104-7;Level of patient participation;Find;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Level of patient participation (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52105-4;Next plan of treatment;Txt;Pt;Alcohol-substance abuse rehabilitation treatment plan;Nar;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Next plan of treatment (narrative) Text;Deprecated;;DEPRECATED;2.24;2.66 +52106-2;Date range of next planned treatment;DateRange;Pt;Alcohol-substance abuse rehabilitation treatment plan;Qn;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Date range (from/through) of next planned treatment DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52107-0;Bacterial capsule;Prid;Pt;XXX;Nom;Microscopy.light;MICRO;1;Bacterial capsule [Identifier] in Specimen by Light microscopy;Bacterial capsule Spec Micro;;ACTIVE;2.24;2.69 +52108-8;C little o super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Co sup(b) Ab [Presence] in Serum or Plasma;Co sup(b) Ab SerPl Ql;;ACTIVE;2.24;2.56 +52109-6;C little o super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Co sup(a) Ab [Presence] in Serum or Plasma;Co sup(a) Ab SerPl Ql;;ACTIVE;2.24;2.56 +52110-4;Blood product unit 4 expiration;TmStp;Pt;^BPU;Qn;;BLDBK;1;Blood product unit 4 expiration [Date and time];BPU4 Expire BPU;;ACTIVE;2.24;2.26 +52111-2;Blood product unit 3 expiration;TmStp;Pt;^BPU;Qn;;BLDBK;1;Blood product unit 3 expiration [Date and time];BPU3 Expire BPU;;ACTIVE;2.24;2.26 +52112-0;Blood product unit 2 expiration;TmStp;Pt;^BPU;Qn;;BLDBK;1;Blood product unit 2 expiration [Date and time];BPU2 Expire BPU;;ACTIVE;2.24;2.26 +52113-8;Blood product unit 1 expiration;TmStp;Pt;^BPU;Qn;;BLDBK;1;Blood product unit 1 expiration [Date and time];BPU1 Expire BPU;;ACTIVE;2.24;2.26 +52114-6;Direct antiglobulin test.IgG specific reagent;PrThr;Pt;RBCCo;Ord;;BLDBK;1;Direct antiglobulin test.IgG specific reagent [presence] on Cord red blood cells;DAT IgG-Sp Reag RBCCo Ql;;ACTIVE;2.24;2.73 +52115-3;D Ab;PrThr;Pt;Ser/Plas;Ord;Antihuman globulin;BLDBK;1;D Ab [Presence] in Serum or Plasma by Antihuman globulin;D Ab SerPl Ql AHG;;ACTIVE;2.24;2.56 +52116-1;Date blood product unit received;TmStp;Pt;^BPU;Qn;;BLDBK;1;Date blood unit received;Date unit received;;ACTIVE;2.24;2.26 +52117-9;B little x Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Bx Ab [Presence] in Serum or Plasma;Bx Ab SerPl Ql;;ACTIVE;2.24;2.56 +5211-8;Herpes virus 6 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes virus 6 IgG Ab [Units/volume] in Serum;HHV6 IgG Ser-aCnc;;ACTIVE;1.0;2.73 +52118-7;Pooled platelets units available;Num;Pt;^BPU;Qn;;BLDBK;1;Pooled platelets units available [#];Pooled platelets avail BPU;;ACTIVE;2.24;2.69 +52119-5;Apheresis available;Num;Pt;^BPU;Qn;;BLDBK;1;Apheresis available [#] in Blood product unit;Apheresis Avail BPU;;ACTIVE;2.24;2.69 +52120-3;Coagulation tissue factor induced.factor substitution^after addition of normal plasma 1H post incubation separate tubes;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --with normal plasma 1H post incubation separate tubes;PT NP 1h separate PPP;;ACTIVE;2.24;2.70 +52121-1;Biopsy;Imp;Pt;XXX;Nar;;PATH;1;Biopsy [Interpretation] in Specimen Narrative;Biopsy Spec-Imp;;ACTIVE;2.24;2.73 +52122-9;Coagulation tissue factor induced^post heparin neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma by Coagulation assay --post heparin neutralization;PT p hep neut PPP;;ACTIVE;2.24;2.73 +52123-7;Coagulation surface induced^post heparin neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay --post heparin neutralization;aPTT p hep neut PPP;;ACTIVE;2.24;2.73 +52124-5;Osmotic fragility^0.90% sodium chloride;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.90% sodium chloride;OF .90% NaCl NFr RBC;;ACTIVE;2.24;2.34 +52125-2;Osmotic fragility^0.90% sodium chloride 24H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--0.90% sodium chloride 24 hour 37 degree C incubation;OF .90% NaCl 24h Inc NFr RBC;;ACTIVE;2.24;2.34 +5212-6;Herpes virus 6 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes virus 6 IgM Ab [Units/volume] in Serum;HHV6 IgM Ser-aCnc;;ACTIVE;1.0;2.73 +52126-0;Acid glycerol lysis;Time;Pt;RBC;Qn;;HEM/BC;1;Acid glycerol lysis [Time] in Red Blood Cells;Acid glycerol lysis Time RBC;;ACTIVE;2.24;2.42 +52127-8;Megaloblasts/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Megaloblasts/100 cells in Bone marrow;Megaloblasts NFr Mar;;ACTIVE;2.24;2.34 +52128-6;Cefotaxime;Susc;Pt;Isolate.meningitis;OrdQn;;ABXBACT;1;Cefotaxime [Susceptibility] for meningitis;Cefotaxime Susc Islt.mening;;ACTIVE;2.24;2.73 +52129-4;Coagulation tissue factor induced.INR^post heparin neutralization;RelTime;Pt;PPP;Qn;Coag;COAG;1;INR in Platelet poor plasma by Coagulation assay --post heparin neutralization;INR p hep neut PPP;;ACTIVE;2.24;2.69 +52130-2;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)b2a2/control Bld/T;;ACTIVE;2.24;2.73 +52131-0;"t(9;22)(q34.1;q11)(ABL1,BCR) b3a2 fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b3a2 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)b3a2/control Bld/T;;ACTIVE;2.24;2.73 +52132-8;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)e1a2/control Bld/T;;ACTIVE;2.24;2.73 +52133-6;Coagulation dilute Russell viper venom induced.factor substitution^immediately after 4:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT factor substitution in Platelet poor plasma by Coagulation assay --immediately after 4:1 addition of normal plasma;dRVVT imm 4:1 NP PPP;;DISCOURAGED;2.24;2.52 +5213-4;Heterophile Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Heterophile Ab [Presence] in Serum by Latex agglutination;Heteroph Ab Ser Ql LA;;ACTIVE;1.0;2.73 +52134-4;Coagulation surface induced.lupus sensitive.factor substitution^immediately after 4:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.factor substitution in Platelet poor plasma by Coagulation assay --immediately after 4:1 addition of normal plasma;aPTT-LA imm 4:1 NP PPP;;DISCOURAGED;2.24;2.73 +52135-1;"t(9;22)(q34.1;q11)(ABL1,BCR) transcript detection panel";-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;"t(9;22)(q34.1;q11)(ABL1,BCR) transcript detection panel - Blood or Tissue by Molecular genetics method";t(ABL1,BCR) detect Pnl Bld/T;;ACTIVE;2.24;2.73 +52136-9;New &or revised;Type;Pt;Pulmonary therapy treatment plan;Ord;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, New/revised;Deprecated;;DEPRECATED;2.24;2.66 +52137-7;Diagnosis.primary;Cmplx;Pt;Pulmonary therapy treatment;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Primary diagnosis Set;;;ACTIVE;2.24;2.40 +52138-5;Diagnosis.primary;ID;Pt;Pulmonary therapy treatment;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Primary diagnosis Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52139-3;Date.onset or exacerbation;Date;Pt;Primary Dx for pulmonary therapy treatment plan;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Date onset or exacerbation of primary diagnosis;Deprecated;;DEPRECATED;2.24;2.66 +52140-1;Date range;DateRange;Pt;Pulmonary therapy treatment;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52141-9;Visit frequency;TQ2;Pt;Pulmonary therapy treatment plan;Ord;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Visit frequency TQ2;Deprecated;;DEPRECATED;2.24;2.66 +5214-2;Heterophile Ab;ACnc;Pt;Ser;Ord;LA;MICRO;1;Deprecated Heterophile Ab [Presence] in Serum by Latex agglutination;Deprecated Heteroph Ab Ser Ql LA;;DEPRECATED;1.0;2.36 +52142-7;Diagnosis.addressed by plan;ID;Pt;Pulmonary therapy treatment;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52143-5;Author of treatment plan;Cmplx;Pt;Pulmonary therapy treatment plan;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Author of treatment plan Set;;;ACTIVE;2.24;2.40 +52144-3;Author name;Pn;Pt;Pulmonary therapy treatment plan;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Author name;Deprecated;;DEPRECATED;2.24;2.66 +52145-0;Author ID;ID;Pt;Pulmonary therapy treatment plan;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Author ID Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52146-8;Author profession;Prid;Pt;Pulmonary therapy treatment plan;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Author profession Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52147-6;Date range;DateRange;Pt;Hospitalization leading to pulmonary therapy treatment;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52148-4;Continuation status;Type;Pt;Pulmonary therapy treatment plan;Ord;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Continuation status;Deprecated;;DEPRECATED;2.24;2.66 +52149-2;Referral information;Cmplx;Pt;Pulmonary therapy treatment plan;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +521-5;Troleandomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Troleandomycin [Susceptibility] by Disk diffusion (KB);Troleandomycin Islt KB;;ACTIVE;1.0;2.19 +52150-0;Referral information;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52151-8;Referring person name;Pn;Pt;Pulmonary therapy treatment plan;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52152-6;Referring person identifier;ID;Pt;Pulmonary therapy treatment plan;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52153-4;Date patient referred for treatment;Date;Pt;Pulmonary therapy treatment plan;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52154-2;Responsible attending physician information;Cmplx;Pt;Pulmonary therapy treatment plan;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52155-9;Signature of responsible attending physician on file;Arb;Pt;Pulmonary therapy treatment plan;Ord;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Signature of responsible attending physician on file;Deprecated;;DEPRECATED;2.24;2.66 +52156-7;Date attending MD signed;TmStp;Pt;Pulmonary therapy treatment plan;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Date attending MD signed Date and time;Deprecated;;DEPRECATED;2.24;2.66 +52157-5;Responsible rehabilitation professional information;Cmplx;Pt;Pulmonary therapy treatment plan;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52158-3;Signature of responsible rehabilitation professional on file;Arb;Pt;Pulmonary therapy treatment plan;Ord;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Signature of responsible rehabilitation professional on file;Deprecated;;DEPRECATED;2.24;2.66 +5215-9;Heterophile Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Heterophile Ab [Titer] in Serum by Latex agglutination;Heteroph Ab Titr Ser LA;;ACTIVE;1.0;2.73 +52159-1;Date rehabilitation professional signed;TmStp;Pt;Pulmonary therapy treatment plan;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Date rehabilitation professional signed Date and time;Deprecated;;DEPRECATED;2.24;2.66 +52160-9;Medication administered;Cmplx;Pt;Pulmonary therapy treatment;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Medication administered Set;;;ACTIVE;2.24;2.40 +52161-7;Medication name + ID;ID;Pt;Pulmonary therapy treatment;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52162-5;Medication XXX;Dosage;Pt;Pulmonary therapy treatment;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.24;2.66 +52163-3;Medication rate;VRat;Pt;Pulmonary therapy treatment;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52164-1;Medication timing;TQ2;Pt;Pulmonary therapy treatment;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52165-8;Medication route;Prid;Pt;Pulmonary therapy treatment;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Medication route Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52166-6;Prognosis for rehabilitation;Imp;Pt;Pulmonary therapy treatment plan;Ord;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Prognosis for rehabilitation;Deprecated;;DEPRECATED;2.24;2.66 +5216-7;Heterophile Ab after absorption;Titr;Pt;Ser;Qn;LA;MICRO;1;Heterophile Ab after absorption [Titer] in Serum by Latex agglutination;Heteroph Ab Abs Titr Ser LA;;ACTIVE;1.0;2.70 +52167-4;Date range certifying the plan of care;DateRange;Pt;Pulmonary therapy treatment plan;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52168-2;Physician certification statement;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52169-0;Actual start of care date;Date;Pt;Pulmonary therapy treatment plan;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52170-8;Past medical history;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52171-6;Level of function;Cmplx;Pt;Pulmonary therapy treatment plan;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52172-4;Prior level of function;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52173-2;Current level of function;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52174-0;Assessment information;Cmplx;Pt;Pulmonary therapy treatment plan;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +5217-5;Histone Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Histone Ab [Presence] in Serum by Immunofluorescence;Histone Ab Ser Ql IF;;ACTIVE;1.0;2.56 +52175-7;Assessment;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52176-5;Assessment indicator;Arb;Pt;Pulmonary therapy treatment plan;Ord;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52177-3;Plan of treatment;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Plan of treatment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52178-1;Treatment encounter;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52179-9;Progress note+attainment of goals;Cmplx;Pt;Pulmonary therapy treatment plan;Set;;ATTACH.REHAB.PULM;3;Pulmonary therapy treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52180-7;Progress note+attainment of goals;Find;Pt;Pulmonary therapy treatment;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan Progress note and attainment of goals (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52181-5;Progress note+attainment of goals date range;DateRange;Pt;Pulmonary therapy treatment;Qn;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52182-3;Reason to continue;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Reason to continue (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5218-3;Histoplasma capsulatum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Histoplasma capsulatum Ab [Presence] in Serum by Immune diffusion (ID);H capsul Ab Ser Ql ID;;ACTIVE;1.0;2.73 +52183-1;Justification;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Justification (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52184-9;Rehabilitation.pulmonary therapy service attachment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Pulmonary therapy service attachment;Rehab.pulm therapy service Doc;;ACTIVE;2.24;2.73 +52185-6;Functional status;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52186-4;Activities permitted;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52187-2;Mental status;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52188-0;Additional assessment;Find;Pt;Pulmonary therapy treatment plan;Nar;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52189-8;Date range;DateRange;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52190-6;Date range;DateRange;Pt;Hospitalization leading to cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +5219-1;Histoplasma capsulatum Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Histoplasma capsulatum Ab [Titer] in Serum by Complement fixation;H capsul Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52191-4;Referral information;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52192-2;Referral information;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52193-0;Referring person name;Pn;Pt;Cardiac rehabilitation treatment plan;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52194-8;Referring person identifier;ID;Pt;Cardiac rehabilitation treatment plan;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52195-5;Date patient referred for treatment;Date;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52196-3;Responsible attending physician information;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52197-1;Responsible rehabilitation professional information;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52198-9;Medication rate;VRat;Pt;Cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52199-7;Medication timing;TQ2;Pt;Cardiac rehabilitation treatment;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52200-3;Date range certifying the plan of care;DateRange;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52201-1;Physician certification statement;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52202-9;Actual start of care date;Date;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52203-7;Past medical history;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52204-5;Level of function;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52205-2;Prior level of function;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52206-0;Current level of function;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52207-8;Assessment information;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +52208-6;Assessment indicator;Arb;Pt;Cardiac rehabilitation treatment plan;Ord;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +5220-9;HIV 1 Ab;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 1 Ab [Units/volume] in Serum or Plasma by Immunoassay;HIV1 Ab SerPl IA-aCnc;;ACTIVE;1.0;2.73 +52209-4;Functional status;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52210-2;Activities permitted;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52211-0;Mental status;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52212-8;Additional assessment;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52213-6;Treatment encounter;Find;Pt;Cardiac rehabilitation treatment plan;Nar;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52214-4;Progress note+attainment of goals;Cmplx;Pt;Cardiac rehabilitation treatment plan;Set;;ATTACH.REHAB.CARDIAC;3;Cardiac rehabilitation treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52215-1;Progress note+attainment of goals date range;DateRange;Pt;Cardiac rehabilitation treatment plan;Qn;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52216-9;Date range;DateRange;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +5221-7;HIV 1 Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HIV 1 Ab [Presence] in Serum or Plasma by Immunoblot;HIV1 Ab SerPl Ql IB;;ACTIVE;1.0;2.73 +52217-7;Date range;DateRange;Pt;Hospitalization leading to medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52218-5;Referral information;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52219-3;Referral information;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52220-1;Referring person name;Pn;Pt;Medical social services treatment plan;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52221-9;Referring person identifier;ID;Pt;Medical social services treatment plan;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52222-7;Date patient referred for treatment;Date;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52223-5;Responsible attending physician information;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52224-3;Responsible rehabilitation professional information;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +5222-5;HIV 1 Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1 Ag [Presence] in Serum or Plasma by Immunoassay;HIV1 Ag SerPl Ql IA;;ACTIVE;1.0;2.73 +52225-0;Medication rate;VRat;Pt;Medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52226-8;Medication timing;TQ2;Pt;Medical social services treatment;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52227-6;Date range certifying the plan of care;DateRange;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52228-4;Physician certification statement;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52229-2;Actual start of care date;Date;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +522-3;Troleandomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Troleandomycin [Susceptibility] by Serum bactericidal titer;Troleandomycin Titr SBT;;ACTIVE;1.0;2.32 +52230-0;Past medical history;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52231-8;Level of function;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52232-6;Prior level of function;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5223-3;HIV 1+2 Ab;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 1+2 Ab [Units/volume] in Serum or Plasma by Immunoassay;HIV1+2 Ab SerPl IA-aCnc;;ACTIVE;1.0;2.73 +52233-4;Current level of function;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52234-2;Assessment information;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +52235-9;Assessment indicator;Arb;Pt;Medical social services treatment plan;Ord;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52236-7;Functional status;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52237-5;Activities permitted;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52238-3;Mental status;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52239-1;Additional assessment;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52240-9;Treatment encounter;Find;Pt;Medical social services treatment plan;Nar;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5224-1;HIV 2 Ab;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 2 Ab [Units/volume] in Serum or Plasma by Immunoassay;HIV 2 Ab SerPl IA-aCnc;;ACTIVE;1.0;2.73 +52241-7;Progress note+attainment of goals;Cmplx;Pt;Medical social services treatment plan;Set;;ATTACH.REHAB.SOCIAL;3;Medical social services treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52242-5;Progress note+attainment of goals date range;DateRange;Pt;Medical social services treatment plan;Qn;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52243-3;Date range;DateRange;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52244-1;Referral information;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52245-8;Referral information;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52246-6;Referring person name;Pn;Pt;Occupational therapy treatment plan;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52247-4;Referring person identifier;ID;Pt;Occupational therapy treatment plan;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52248-2;Responsible attending physicican information;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Responsible attending physicican information Set;;;ACTIVE;2.24;2.40 +52249-0;Responsible rehabilitation professional information;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52250-8;Medication timing;TQ2;Pt;Occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52251-6;Date range certifying the plan of care;DateRange;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52252-4;Physician certification statement;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52253-2;Actual start of care date;Date;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52254-0;Past medical history;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52255-7;Level of function;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52256-5;Prior level of function;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52257-3;Current level of function;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5225-8;HIV 2 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 Ab [Presence] in Serum by Immunoblot;HIV 2 Ab Ser Ql IB;;ACTIVE;1.0;2.73 +52258-1;Assessment information;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +52259-9;Assessment indicator;Arb;Pt;Occupational therapy treatment plan;Ord;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52260-7;Functional status;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52261-5;Activities permitted;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52262-3;Mental status;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52263-1;Additional assessment;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52264-9;Treatment encounter;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52265-6;Individual education plan information;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan, Individual education plan information Set;;;ACTIVE;2.24;2.40 +5226-6;HTLV I+II Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;HTLV I+II Ab [Units/volume] in Serum by Immunoassay;HTLV I+II Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +52266-4;Defined school year;DateRange;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Defined school year DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52267-2;Individual education plan;Find;Pt;Occupational therapy treatment plan;Nar;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Individual education plan (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52268-0;Progress note+attainment of goals date range;DateRange;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52269-8;Date patient referred for treatment;Date;Pt;Occupational therapy treatment plan;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52270-6;Medication rate;VRat;Pt;Occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52271-4;Date range;DateRange;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52272-2;Date range;DateRange;Pt;Hospitalization leading to physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52273-0;Referral information;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +5227-4;Streptococcal hyaluronidase Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcal hyaluronidase Ab [Presence] in Serum;Str Hyaluronidase Ab Ser Ql;;ACTIVE;1.0;2.56 +52274-8;Referral information;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52275-5;Referring person name;Pn;Pt;Physical therapy treatment plan;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52276-3;Referring person identifier;ID;Pt;Physical therapy treatment plan;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52277-1;Date patient referred for treatment;Date;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52278-9;Responsible attending physician information;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52279-7;Responsible rehabilitation professional information;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52280-5;Medication rate;VRat;Pt;Physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52281-3;Medication timing;TQ2;Pt;Physical therapy treatment;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +5228-2;Immune complex;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Immune complex [Units/volume] in Serum or Plasma;IC SerPl-aCnc;;ACTIVE;1.0;2.73 +52282-1;Date range certifying the plan of care;DateRange;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52283-9;Physician certification statement;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52284-7;Actual start of care date;Date;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52285-4;Past medical history;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52286-2;Level of function;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52287-0;Prior level of function;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52288-8;Current level of function;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52289-6;Assessment information;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +5229-0;Influenza virus A Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus A Ab [Titer] in Serum by Complement fixation;FLUAV Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52290-4;Assessment indicator;Arb;Pt;Physical therapy treatment plan;Ord;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52291-2;Functional status;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52292-0;Activities permitted;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52293-8;Mental status;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52294-6;Additional assessment;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52295-3;Treatment encounter;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52296-1;Individual education plan information;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan, Individual education plan information Set;;;ACTIVE;2.24;2.40 +52297-9;Defined school year;DateRange;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Defined school year DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52298-7;Individual education plan;Find;Pt;Physical therapy treatment plan;Nar;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Individual education plan (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52299-5;Progress note+attainment of goals;Cmplx;Pt;Physical therapy treatment plan;Set;;ATTACH.REHAB.PT;3;Physical therapy treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52300-1;Progress note+attainment of goals date range;DateRange;Pt;Physical therapy treatment plan;Qn;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52301-9;Date range;DateRange;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52302-7;Diagnosis.addressed by plan;ID;Pt;Psychiatric rehabilitation treatment;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Diagnosis addressed by plan Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52303-5;Date range;DateRange;Pt;Hospitalization leading to psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52304-3;Referral information;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52305-0;Referral information;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52306-8;Referring person name;Pn;Pt;Psychiatric rehabilitation treatment plan;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52307-6;Referring person identifier;ID;Pt;Psychiatric rehabilitation treatment plan;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +5230-8;Influenza virus B Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus B Ab [Titer] in Serum by Complement fixation;FLUBV Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52308-4;Date patient referred for treatment;Date;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52309-2;Communication to referring physician indicator;Arb;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Communication to referring physician indicator;Deprecated;;DEPRECATED;2.24;2.66 +523-1;Vancomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Vancomycin [Susceptibility] by Minimum lethal concentration (MLC);Vancomycin Islt MLC;;ACTIVE;1.0;2.19 +52310-0;Responsible attending physician information;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52311-8;Responsible rehabilitation professional information;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52312-6;Medication name + ID;ID;Pt;Psychiatric rehabilitation treatment;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Medication name + identifier Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52313-4;Medication XXX;Dosage;Pt;Psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Medication Dosage;Deprecated;;DEPRECATED;2.24;2.66 +52314-2;Medication rate;VRat;Pt;Psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52315-9;Medication timing;TQ2;Pt;Psychiatric rehabilitation treatment;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +5231-6;Influenza virus C Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus C Ab [Titer] in Serum by Complement fixation;FLUCV Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52316-7;Date range certifying the plan of care;DateRange;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52317-5;Physician certification statement;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52318-3;Actual start of care date;Date;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52319-1;Past medical history;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52320-9;Level of function;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52321-7;Prior level of function;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52322-5;Current level of function;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52323-3;Assessment information;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +5232-4;Insulin Ab;ACnc;Pt;Ser;Qn;RIA;SERO;1;Insulin Ab [Units/volume] in Serum by Radioimmunoassay (RIA);Insulin Ab Ser RIA-aCnc;;ACTIVE;1.0;2.73 +52324-1;Assessment indicator;Arb;Pt;Psychiatric rehabilitation treatment plan;Ord;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52325-8;Functional status;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52326-6;Activities permitted;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52327-4;Mental status;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52328-2;Additional assessment;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52329-0;Treatment encounter;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52330-8;Past treatment attempts;Find;Pt;Psychiatric rehabilitation treatment plan;Nar;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Past treatment attempts (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52331-6;Progress note+attainment of goals;Cmplx;Pt;Psychiatric rehabilitation treatment plan;Set;;ATTACH.REHAB.PSYCH;3;Psychiatric rehabilitation treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +5233-2;Intrinsic factor Ab;PrThr;Pt;Ser;Ord;RIA;SERO;1;Intrinsic factor Ab [Presence] in Serum by Radioimmunoassay (RIA);IF Ab Ser Ql RIA;;ACTIVE;1.0;2.73 +52332-4;Progress note+attainment of goals date range;DateRange;Pt;Psychiatric rehabilitation treatment plan;Qn;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52333-2;Date range;DateRange;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52334-0;Date range;DateRange;Pt;Hospitalization leading to respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52335-7;Referral information;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52336-5;Referral information;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52337-3;Referring person name;Pn;Pt;Respiratory therapy treatment plan;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52338-1;Referring person identifier;ID;Pt;Respiratory therapy treatment plan;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52339-9;Date patient referred for treatment;Date;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +5234-0;Jo-1 extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA Jo1 Ab Ser Ql IA;;ACTIVE;1.0;2.73 +52340-7;Responsible attending physician information;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52341-5;Responsible rehabilitation professional information;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52342-3;Medication rate;VRat;Pt;Respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52343-1;Medication timing;TQ2;Pt;Respiratory therapy treatment;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52344-9;Date range certifying the plan of care;DateRange;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52345-6;Physician certification statement;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52346-4;Actual start of care date;Date;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52347-2;Level of function;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52348-0;Prior level of function;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52349-8;Current level of function;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52350-6;Assessment information;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +52351-4;Assessment indicator;Arb;Pt;Respiratory therapy treatment plan;Ord;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52352-2;Assessment;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52353-0;Treatment encounter;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52354-8;Progress note+attainment of goals;Cmplx;Pt;Respiratory therapy treatment plan;Set;;ATTACH.REHAB.RT;3;Respiratory therapy treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52355-5;Progress note+attainment of goals date range;DateRange;Pt;Respiratory therapy treatment plan;Qn;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52356-3;Date range;DateRange;Pt;Hospitalization leading to skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +5235-7;Jo-1 extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA Jo1 Ab Ser Ql ID;;ACTIVE;1.0;2.73 +52357-1;Date range;DateRange;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52358-9;Referral information;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52359-7;Referral information;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52360-5;Referring person name;Pn;Pt;Skilled nursing treatment plan;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52361-3;Referring person identifier;ID;Pt;Skilled nursing treatment plan;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52362-1;Date patient referred for treatment;Date;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52363-9;Responsible attending physician information;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52364-7;Responsible rehabilitation professional information;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +5236-5;Legionella pneumophila Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Legionella pneumophila Ab [Presence] in Serum by Immunofluorescence;L pneumo Ab Ser Ql IF;;ACTIVE;1.0;2.73 +52365-4;Medication rate;VRat;Pt;Skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52366-2;Medication timing;TQ2;Pt;Skilled nursing treatment;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52367-0;Date range certifying the plan of care;DateRange;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52368-8;Physician certification statement;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52369-6;Actual start of care date;Date;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52370-4;Past medical history;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52371-2;Level of function;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +52372-0;Prior level of function;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5237-3;Legionella pneumophila Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila Ab [Titer] in Serum by Immunofluorescence;L pneumo Ab Titr Ser IF;;ACTIVE;1.0;2.73 +52373-8;Current level of function;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52374-6;Assessment information;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +52375-3;Assessment indicator;Arb;Pt;Skilled nursing treatment plan;Ord;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52376-1;Functional status;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52377-9;Activities permitted;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52378-7;Mental status;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52379-5;Additional assessment;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52380-3;Treatment encounter;Find;Pt;Skilled nursing treatment plan;Nar;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5238-1;Leishmania sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Leishmania sp Ab [Units/volume] in Serum;Leishmania Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52381-1;Progress note+attainment of goals date range;DateRange;Pt;Skilled nursing treatment plan;Qn;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52382-9;Progress note+attainment of goals;Cmplx;Pt;Skilled nursing treatment plan;Set;;ATTACH.REHAB.NURS;3;Skilled nursing treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52383-7;Date range;DateRange;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date range (from/through) DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52384-5;Date range;DateRange;Pt;Hospitalization leading to speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52385-2;Referral information;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Referral information Set;;;ACTIVE;2.24;2.40 +52386-0;Referral information;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Referral information (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52387-8;Referring person name;Pn;Pt;Speech therapy treatment plan;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Referring person name;Deprecated;;DEPRECATED;2.24;2.66 +52388-6;Referring person identifier;ID;Pt;Speech therapy treatment plan;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Referring person identifier;Deprecated;;DEPRECATED;2.24;2.66 +52389-4;Date patient referred for treatment;Date;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date patient referred for treatment;Deprecated;;DEPRECATED;2.24;2.66 +52390-2;Responsible attending physician information;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Responsible attending physician information Set;;;ACTIVE;2.24;2.40 +52391-0;Responsible rehabilitation professional information;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Responsible rehabilitation professional information Set;;;ACTIVE;2.24;2.40 +52392-8;Medication rate;VRat;Pt;Speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication rate Flow;Deprecated;;DEPRECATED;2.24;2.66 +52393-6;Medication timing;TQ2;Pt;Speech therapy treatment;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication timing TQ2;Deprecated;;DEPRECATED;2.24;2.66 +52394-4;Date range certifying the plan of care;DateRange;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Date range certifying the plan of care DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52395-1;Physician certification statement;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Physician certification statement (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52396-9;Actual start of care date;Date;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Actual start of care date;Deprecated;;DEPRECATED;2.24;2.66 +52397-7;Past medical history;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52398-5;Level of function;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Level of function Set;;;ACTIVE;2.24;2.40 +5239-9;Leptospira sp Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Leptospira sp Ab [Titer] in Serum by Latex agglutination;Leptospira Ab Titr Ser LA;;ACTIVE;1.0;2.70 +52399-3;Prior level of function;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Prior level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52400-9;Current level of function;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Current level of function (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52401-7;Assessment indicator;Arb;Pt;Speech therapy treatment plan;Ord;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Assessment indicator;Deprecated;;DEPRECATED;2.24;2.66 +52402-5;Functional status;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Functional status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52403-3;Activities permitted;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Activities permitted (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52404-1;Mental status;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Mental status (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52405-8;Additional assessment;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Additional assessment (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52406-6;Treatment encounter;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Treatment encounter (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5240-7;Listeria monocytogenes Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Listeria monocytogenes Ab [Units/volume] in Serum;L monocytog Ab Ser-aCnc;;ACTIVE;1.0;2.73 +52407-4;Individual education plan information;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Individual education plan information Set;;;ACTIVE;2.24;2.40 +52408-2;Individual education plan;Find;Pt;Speech therapy treatment plan;Nar;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Individual education plan (narrative);Deprecated;;DEPRECATED;2.24;2.66 +52409-0;Defined school year;DateRange;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Defined school year DateRange;Deprecated;;DEPRECATED;2.24;2.66 +52410-8;Progress note+attainment of goals;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52411-6;Progress note+attainment of goals date range;DateRange;Pt;Speech therapy treatment plan;Qn;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan Progress note and attainment of goals date range;Deprecated;;DEPRECATED;2.24;2.66 +52412-4;Assessment information;Cmplx;Pt;Speech therapy treatment plan;Set;;ATTACH.REHAB.SPEECH;3;Speech therapy treatment plan, Assessment information Set;;;ACTIVE;2.24;2.40 +52413-2;Date range;DateRange;Pt;Hospitalization leading to occupational therapy treatment;Qn;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Date range (from/through) of hospitalization leading to treatment;Deprecated;;DEPRECATED;2.24;2.66 +52414-0;Past medical history;Find;Pt;Respiratory therapy treatment plan;Nar;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Past medical history (narrative);Deprecated;;DEPRECATED;2.24;2.66 +5241-5;Lymphocytic choriomeningitis virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Lymphocytic choriomeningitis virus Ab [Titer] in Serum by Complement fixation;LCMV Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52415-7;Progress note+attainment of goals;Cmplx;Pt;Occupational therapy treatment plan;Set;;ATTACH.REHAB.OT;3;Occupational therapy treatment plan Progress note and attainment of goals Set;;;ACTIVE;2.24;2.40 +52416-5;Body weight;Cmplx;Pt;^Patient;Set;;ATTACH;3;Body weight Set;;;ACTIVE;2.24;2.40 +52417-3;Identifier;ID;Pt;Medication.current;Nom;;ATTACH.MEDS;3;Current medication, Identifier;;;ACTIVE;2.24;2.27 +52418-1;Name;ID;Pt;Medication.current;Nom;;ATTACH.MEDS;3;Current medication, Name;;;ACTIVE;2.26;2.27 +52419-9;Rate;VRat;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication, Rate;;;ACTIVE;2.24;2.27 +52420-7;Timing;TQ2;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication, Timing;;;ACTIVE;2.24;2.27 +52421-5;Name;ID;Pt;Medication.discharge;Nom;;ATTACH.MEDS;3;Discharge medication, Name;;;ACTIVE;2.24;2.27 +52422-3;Rate;VRat;Pt;Medication.discharge;Qn;;ATTACH.MEDS;3;Discharge medication, Rate;;;ACTIVE;2.24;2.27 +5242-3;Measles virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Measles virus Ab [Units/volume] in Serum by Immunoassay;MeV Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +52423-1;Timing;TQ2;Pt;Medication.discharge;Qn;;ATTACH.MEDS;3;Discharge medication, Timing;;;ACTIVE;2.24;2.27 +52424-9;Identifier;ID;Pt;Medication.administered;Nom;;ATTACH.MEDS;3;Administered medication, Identifier;;;ACTIVE;2.24;2.27 +52425-6;Name;ID;Pt;Medication.administered;Nom;;ATTACH.MEDS;3;Administered medication, Name;;;ACTIVE;2.24;2.27 +52426-4;Rate;VRat;Pt;Medication.administered;Qn;;ATTACH.MEDS;3;Administered medication, Rate;;;ACTIVE;2.24;2.27 +52428-0;Identifier;ID;Pt;Medication.discharge;Nom;;ATTACH.MEDS;3;Discharge medication, Identifier;;;ACTIVE;2.24;2.27 +52429-8;Medication identifier;ID;Pt;Alcohol-substance abuse rehabilitation treatment;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52430-6;Medication name;ID;Pt;Alcohol-substance abuse rehabilitation treatment;Nom;;ATTACH.REHAB.ABUSE;3;Deprecated Alcohol-substance abuse rehabilitation treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +5243-1;Measles virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Measles virus Ab [Titer] in Serum by Complement fixation;MeV Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52431-4;Medication identifier;ID;Pt;Cardiac rehabilitation treatment;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52432-2;Medication name;ID;Pt;Cardiac rehabilitation treatment;Nom;;ATTACH.REHAB.CARDIAC;3;Deprecated Cardiac rehabilitation treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52433-0;Medication identifier;ID;Pt;Medical social services treatment;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52434-8;Medication name;ID;Pt;Medical social services treatment;Nom;;ATTACH.REHAB.SOCIAL;3;Deprecated Medical social services treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52435-5;Medication name;ID;Pt;Occupational therapy treatment;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52436-3;Medication name ID;ID;Pt;Occupational therapy treatment plan;Nom;;ATTACH.REHAB.OT;3;Deprecated Occupational therapy treatment plan, Medication name ID Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52437-1;Medication name;ID;Pt;Physical therapy treatment;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52438-9;Medication identifier;ID;Pt;Physical therapy treatment;Nom;;ATTACH.REHAB.PT;3;Deprecated Physical therapy treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52439-7;Medication name;ID;Pt;Psychiatric rehabilitation treatment;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52440-5;Medication identifier;ID;Pt;Psychiatric rehabilitation treatment;Nom;;ATTACH.REHAB.PSYCH;3;Deprecated Psychiatric rehabilitation treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52441-3;Medication identifier;ID;Pt;Respiratory therapy treatment;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52442-1;Medication name;ID;Pt;Respiratory therapy treatment;Nom;;ATTACH.REHAB.RT;3;Deprecated Respiratory therapy treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52443-9;Medication identifier;ID;Pt;Pulmonary therapy treatment;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52444-7;Medication name;ID;Pt;Pulmonary therapy treatment;Nom;;ATTACH.REHAB.PULM;3;Deprecated Pulmonary therapy treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52445-4;Medication identifier;ID;Pt;Skilled nursing treatment;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52446-2;Medication name;ID;Pt;Skilled nursing treatment;Nom;;ATTACH.REHAB.NURS;3;Deprecated Skilled nursing treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +52447-0;Medication identifier;ID;Pt;Speech therapy treatment;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication identifier;Deprecated;;DEPRECATED;2.24;2.66 +52448-8;Medication name;ID;Pt;Speech therapy treatment;Nom;;ATTACH.REHAB.SPEECH;3;Deprecated Speech therapy treatment plan, Medication name Identifier;Deprecated;;DEPRECATED;2.24;2.66 +5244-9;Measles virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Measles virus IgG Ab [Units/volume] in Serum by Immunoassay;MeV IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +52449-6;Prior Functioning;-;Pt;^Patient;-;;SURVEY.CARE;4;Prior Functioning;;;DISCOURAGED;2.27;2.64 +52450-4;Current Medical Information;-;Pt;^Patient;-;;SURVEY.CARE;4;Current Medical Information;;;DISCOURAGED;2.26;2.64 +52451-2;Continuity assessment record and evaluation tool - master document - core and supplemental items;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Master Document - Core and Supplemental Items;;;ACTIVE;2.27;2.42 +52452-0;Administrative Items;-;Pt;^Patient;-;;SURVEY.CARE;4;Administrative Items;;;DISCOURAGED;2.26;2.67 +52453-8;Assessment Type;-;Pt;^Patient;-;;SURVEY.CARE;4;Assessment Type;;;DISCOURAGED;2.26;2.73 +52454-6;Reason for assessment;Find;Pt;^Patient;Nom;;SURVEY.CMS;4;Reason for assessment;;;ACTIVE;2.26;2.63 +52455-3;Admission date;TmStp;Pt;^Patient;Qn;;ADMIN;2;Admission date;Admission date;;ACTIVE;2.26;2.63 +5245-6;Measles virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Measles virus IgM Ab [Titer] in Serum by Immunofluorescence;MeV IgM Titr Ser IF;;ACTIVE;1.0;2.73 +52456-1;Assessment reference date;Date;Pt;^Patient;Qn;;SURVEY.CMS;4;Deprecated Assessment reference date;;;DEPRECATED;2.26;2.73 +52457-9;Provider Information;-;Pt;^Patient;-;;SURVEY.CARE;4;Provider Information;;;DISCOURAGED;2.26;2.64 +52458-7;Name;Pn;Pt;Provider;Nom;;SURVEY.CARE;4;Name Provider;;;ACTIVE;2.26;2.27 +52459-5;CMS certification number;ID;Pt;Provider;Nom;;SURVEY.CARE;4;CMS certification number (CCN) Provider;;;ACTIVE;2.27;2.61 +52460-3;Patient information;-;Pt;^Patient;-;;SURVEY.CARE;4;Patient Information;;;DISCOURAGED;2.26;2.67 +52461-1;Middle name;Pn;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient middle name;Patient middle name;;ACTIVE;2.26;2.70 +52462-9;Nickname;Pn;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Nickname;Nickname;;ACTIVE;2.26;2.66 +52463-7;Patient Identification Number or Provider Account Number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Patient Identification Number or Provider Account Number;Patient ID # or Provider Acct #;;ACTIVE;2.27;2.66 +5246-4;Saccharopolyspora rectivirgula Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Saccharopolyspora rectivirgula Ab [Units/volume] in Serum;S rectivirgula Ab Ser-aCnc;;ACTIVE;1.0;2.73 +52464-5;Primary and Other Diagnoses, Comorbidities, and Complications;-;Pt;^Patient;-;;SURVEY.CARE;4;Primary and Other Diagnoses, Comorbidities, and Complications;;;DISCOURAGED;2.26;2.64 +52465-2;Other Diagnoses, Comorbidities, and Complications;-;Pt;^Patient;-;;SURVEY.CARE;4;Other Diagnoses, Comorbidities, and Complications;;;DISCOURAGED;2.26;2.64 +52466-0;Major Procedures (Diagnostic, Surgical, and Therapeutic Interventions);-;Pt;^Patient;-;;SURVEY.CARE;4;Major Procedures (Diagnostic, Surgical, and Therapeutic Interventions);;;DISCOURAGED;2.26;2.64 +52467-8;Procedure;-;Pt;^Patient;-;CARE;SURVEY.CARE;4;Procedure [CARE];;;DISCOURAGED;2.26;2.64 +52468-6;Major Treatments;-;Pt;^Patient;-;;SURVEY.CARE;4;Major Treatments;;;DISCOURAGED;2.26;2.64 +52469-4;Major treatments admitted &or discharged with panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Major treatments admitted/discharged with panel;;;ACTIVE;2.27;2.27 +52470-2;Major treatments used at any time during stay panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Major treatments used at any time during stay panel;;;DISCOURAGED;2.26;2.64 +52471-0;Medications;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Medications;;;ACTIVE;2.26;2.68 +5247-2;Mitochondria Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Mitochondria Ab [Titer] in Serum by Immunofluorescence;Mitochondria Ab Titr Ser IF;;ACTIVE;1.0;2.73 +52472-8;Allergies & Adverse Drug Reactions;-;Pt;^Patient;-;;SURVEY.CARE;4;Allergies and Adverse Drug Reactions;;;DISCOURAGED;2.27;2.64 +52473-6;Allergy or cause of reaction;Find;Pt;^Patient;Nom;;SURVEY.CARE;4;Allergy or cause of reaction;;;ACTIVE;2.27;2.27 +52474-4;Skin integrity panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Skin integrity panel;;;DISCOURAGED;2.26;2.64 +52475-1;Presence of pressure ulcers;-;Pt;^Patient;-;;SURVEY.CARE;4;Presence of pressure ulcers;;;DISCOURAGED;2.26;2.64 +52476-9;Number of unhealed pressure ulcers at each stage - at assessment and onset during this service;-;Pt;^Patient;-;;SURVEY.CARE;4;Number of unhealed pressure ulcers at each stage - at assessment and onset during this service;;;DISCOURAGED;2.26;2.64 +52477-7;Largest pressure ulcer measurements;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Largest Ulcer Measurements;;;ACTIVE;2.26;2.73 +52478-5;Number of Major Wounds;-;Pt;^Patient;-;;SURVEY.CARE;4;Number of Major Wounds;;;DISCOURAGED;2.26;2.64 +52479-3;Physiologic Factors;-;Pt;^Patient;-;;SURVEY.CARE;4;Physiologic Factors;;;DISCOURAGED;2.26;2.64 +5248-0;Mucor sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mucor sp Ab [Units/volume] in Serum;Mucor Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52480-1;Anthropometric Measures;-;Pt;^Patient;-;;SURVEY.CARE;4;Anthropometric Measures;;;DISCOURAGED;2.26;2.64 +52481-9;Vital signs - acute;-;Pt;^Patient;-;CARE;SURVEY.CARE;4;Vital signs - acute [CARE];;;DISCOURAGED;2.26;2.64 +52482-7;Laboratory;-;Pt;^Patient;-;;SURVEY.CARE;4;Laboratory;;;DISCOURAGED;2.26;2.73 +52483-5;Other;-;Pt;^Patient;-;;SURVEY.CARE;4;Other;;;DISCOURAGED;2.26;2.64 +52484-3;Arterial Blood Gases (ABGs);-;Pt;^Patient;-;;SURVEY.CARE;4;Arterial Blood Gases (ABGs);;;DISCOURAGED;2.26;2.64 +52485-0;Pulmonary Function Tests;-;Pt;^Patient;-;;SURVEY.CARE;4;Pulmonary Function Tests;;;DISCOURAGED;2.26;2.64 +52486-8;Volume expired during 2.0 s of forced expiration/Volume.forced expiration.total;VFr;Pt;Respiratory system;Qn;;PULM;2;FEV2/FEV total;FEV2/FEV total VFr;;ACTIVE;2.24;2.48 +52487-6;Cognitive Status, Mood and Pain;-;Pt;^Patient;-;;SURVEY.CARE;4;Cognitive Status, Mood and Pain;;;DISCOURAGED;2.26;2.64 +52488-4;Temporal Orientation &or Mental Status;-;Pt;^Patient;-;;SURVEY.CARE;4;Temporal Orientation/Mental Status;;;DISCOURAGED;2.27;2.64 +52489-2;Interview attempted;-;Pt;^Patient;-;;SURVEY.CARE;4;Interview attempted;;;DISCOURAGED;2.27;2.64 +524-9;Vancomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Vancomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Vancomycin Islt MIC;;ACTIVE;1.0;2.73 +52490-0;Temporal orientation - CARE;-;Pt;^Patient;-;;SURVEY.CARE;4;Temporal orientation - CARE;;;ACTIVE;2.27;2.27 +52491-8;Brief interview for mental status;-;Pt;^Patient;-;BIMS;PANEL.SURVEY.BIMS;4;Brief interview for mental status [BIMS];;;ACTIVE;2.24;2.67 +52492-6;Year, Month, Day;-;Pt;^Patient;-;;PANEL.SURVEY.BIMS;4;Year, Month, Day;;;DISCOURAGED;2.24;2.64 +52493-4;Recall;-;Pt;^Patient;-;BIMS;PANEL.SURVEY.BIMS;4;Recall [BIMS];;;ACTIVE;2.24;2.67 +52494-2;Observational Assessment of Cognitive Status at 2D Assessment Period;-;2D;^Patient;-;;SURVEY.CARE;4;Observational Assessment of Cognitive Status at 2 day Assessment Period;;;DISCOURAGED;2.27;2.64 +52495-9;Confusion Assessment Method (CAM);-;Pt;^Patient;-;Observed.CAM.CARE;PANEL.SURVEY.CAM;4;Confusion Assessment Method (CAM);;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";DISCOURAGED;2.24;2.64 +52496-7;Behavioral Signs & Symptoms;-;Pt;^Patient;-;;SURVEY.CARE;4;Behavioral Signs and Symptoms;;;DISCOURAGED;2.27;2.64 +52497-5;Mood;-;Pt;^Patient;-;;SURVEY.CARE;4;Mood;;;DISCOURAGED;2.27;2.64 +5249-8;Mumps virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Mumps virus Ab [Titer] in Serum by Complement fixation;MuV Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52498-3;Patient health questionnaire 2 item;-;Pt;^Patient;-;Reported.PHQ-2.CARE;SURVEY.CARE;4;Patient Health Questionnaire 2 item (PHQ-2) [Reported PHQ-2 CARE];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;DISCOURAGED;2.27;2.64 +52499-1;Feeling sad;-;Pt;^Patient;-;;SURVEY.CARE;4;Feeling sad panel;;;DISCOURAGED;2.27;2.73 +52500-6;Pain;-;Pt;^Patient;-;;SURVEY.CARE;4;Pain;;;DISCOURAGED;2.26;2.64 +52501-4;Pain Effect on Function during last 2D;-;2D;^Patient;-;;SURVEY.CARE;4;Pain Effect on Function during last 2 days;;;ACTIVE;2.27;2.54 +52502-2;Impairments;-;Pt;^Patient;-;;SURVEY.CARE;4;Impairments;;;DISCOURAGED;2.26;2.64 +52503-0;Bladder and Bowel Management - Use of Device(s) and Incontinence;-;Pt;^Patient;-;;SURVEY.CARE;4;Bladder and Bowel Management - Use of Device(s) and Incontinence;;;DISCOURAGED;2.26;2.64 +52504-8;Swallowing;-;Pt;^Patient;-;;SURVEY.CARE;4;Swallowing;;;DISCOURAGED;2.26;2.64 +52505-5;Hearing, Vision, and Communication;-;Pt;^Patient;-;;SURVEY.CARE;4;Hearing, Vision, and Communication;;;DISCOURAGED;2.26;2.64 +5250-6;Mumps virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Mumps virus Ab [Titer] in Serum by Immunofluorescence;MuV Ab Titr Ser IF;;ACTIVE;1.0;2.70 +52506-3;Weight-bearing;-;Pt;^Patient;-;;SURVEY.CARE;4;Weight-bearing;;;DISCOURAGED;2.26;2.64 +52507-1;Weight-bearing restrictions panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Weight-bearing restrictions panel;;;DISCOURAGED;2.26;2.64 +52508-9;Grip Strength;-;Pt;^Patient;-;;SURVEY.CARE;4;Grip strength;;;DISCOURAGED;2.26;2.64 +52509-7;Grip strength panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Grip strength panel;;;DISCOURAGED;2.26;2.64 +52510-5;Respiratory status;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Respiratory status;;;ACTIVE;2.26;2.68 +52511-3;Endurance;-;Pt;^Patient;-;;SURVEY.CARE;4;Endurance;;;DISCOURAGED;2.26;2.64 +52512-1;Mobility devices and aids needed;-;Pt;^Patient;-;;SURVEY.CARE;4;Mobility Devices and Aids Needed;;;DISCOURAGED;2.26;2.64 +52513-9;Functional Status - Usual Performance;-;Pt;^Patient;-;;SURVEY.CARE;4;Functional Status - Usual Performance;;;DISCOURAGED;2.26;2.64 +5251-4;Muscle sarcolemma Ab;ACnc;Pt;Ser;Qn;;SERO;1;Muscle sarcolemma Ab [Units/volume] in Serum;Mus Sarcolemma Ab Ser-aCnc;;ACTIVE;1.0;2.73 +52514-7;Core Self Care;-;Pt;^Patient;-;;SURVEY.CARE;4;Core Self Care;;;DISCOURAGED;2.26;2.64 +52515-4;Core Functional Mobility;-;Pt;^Patient;-;;SURVEY.CARE;4;Core Functional Mobility;;;DISCOURAGED;2.26;2.64 +52516-2;Mode of Mobility - All Patients;-;Pt;^Patient;-;;SURVEY.CARE;4;Mode of Mobility - All Patients;;;DISCOURAGED;2.26;2.64 +52517-0;Level of independence on longest distance walked;-;Pt;^Patient;-;;SURVEY.CARE;4;Level of independence on longest distance walked;;;DISCOURAGED;2.26;2.64 +52518-8;Level of independence on longest distance wheeled;-;Pt;^Patient;-;;SURVEY.CARE;4;Level of independence on longest distance wheeled;;;DISCOURAGED;2.26;2.64 +52519-6;Supplemental Functional Ability;-;Pt;^Patient;-;;SURVEY.CARE;4;Supplemental Functional Ability;;;DISCOURAGED;2.26;2.64 +52520-4;Mode of Mobility - PAC Patients;-;Pt;^Patient;-;;SURVEY.CARE;4;Mode of Mobility - PAC Patients;;;DISCOURAGED;2.26;2.64 +52521-2;Overall Plan of Care &or Advance Care Directives;-;Pt;^Patient;-;;SURVEY.CARE;4;Deprecated Overall Plan of Care/Advance Care Directives;;;DEPRECATED;2.26;2.70 +5252-2;Mycoplasma pneumoniae Ab;ACnc;Pt;Ser;Qn;LA;MICRO;1;Mycoplasma pneumoniae Ab [Units/volume] in Serum by Latex agglutination;M pneumo Ab Ser LA-aCnc;;ACTIVE;1.0;2.69 +52522-0;Overall Plan of Care &or Advance Care Directives - Subheading;-;Pt;^Patient;-;;SURVEY.CARE;4;Overall Plan of Care/Advance Care Directives - Subheading;;;DISCOURAGED;2.26;2.64 +52523-8;Discharge status;-;Pt;^Patient;-;;SURVEY.CARE;4;Discharge Status;;;DISCOURAGED;2.27;2.64 +52524-6;Discharge Information;-;Pt;^Patient;-;;SURVEY.CARE;4;Discharge Information;;;DISCOURAGED;2.27;2.64 +52525-3;Discharge date;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Discharge date;Discharge date;;ACTIVE;2.24;2.63 +52526-1;Attending physician name;Pn;Pt;Provider;Nom;;CLIN;2;Attending physician name;Attending physician name;;ACTIVE;2.24;2.73 +52527-9;Residential Information;-;Pt;^Patient;-;;SURVEY.CARE;4;Residential Information;;;DISCOURAGED;2.27;2.64 +52528-7;Support Needs &or Caregiver Assistance;-;Pt;^Patient;-;;SURVEY.CARE;4;Support Needs/Caregiver Assistance;;;DISCOURAGED;2.27;2.64 +52529-5;Discharge Care Options;-;Pt;^Patient;-;;SURVEY.CARE;4;Discharge Care Options;;;DISCOURAGED;2.27;2.64 +5253-0;Mycoplasma pneumoniae Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay;M pneumo Ab Ser Ql IA;;ACTIVE;1.0;2.73 +52530-3;Discharge Location Information;-;Pt;^Patient;-;;SURVEY.CARE;4;Discharge Location Information;;;DISCOURAGED;2.27;2.64 +52531-1;Provider city;Loc;Pt;Provider;Nom;;CLIN;2;Provider city;Provider city;;ACTIVE;2.24;2.73 +52532-9;Provider state;Loc;Pt;Provider;Nom;;CLIN;2;Provider state;Provider state;;ACTIVE;2.24;2.73 +52533-7;Medical Coding Information;-;Pt;^Patient;-;;SURVEY.CARE;4;Medical Coding Information;;;DISCOURAGED;2.26;2.73 +52534-5;Principal Diagnosis;-;Pt;^Patient;-;;SURVEY.CARE;4;Principal Diagnosis;;;DISCOURAGED;2.26;2.73 +52535-2;Other useful information;-;Pt;^Patient;-;;SURVEY.CARE;4;Other useful information;;;DISCOURAGED;2.26;2.73 +52536-0;Admission Information;-;Pt;^Patient;-;;SURVEY.CARE;4;Admission Information;;;DISCOURAGED;2.27;2.64 +52537-8;Pre-admission Service Use;-;Pt;^Patient;-;;SURVEY.CARE;4;Pre-admission Service Use;;;DISCOURAGED;2.27;2.64 +52538-6;Patient History Prior to this Current Illness, Exacerbation, or Injury;-;Pt;^Patient;-;;SURVEY.CARE;4;Patient History Prior to this Current Illness, Exacerbation, or Injury;;;DISCOURAGED;2.27;2.64 +52539-4;Prior postal code;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Prior postal code [Location];Prior postal code;;ACTIVE;2.26;2.66 +52540-2;ZIP Code unknown;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;ZIP Code unknown;;;TRIAL;2.27;2.64 +52541-0;Prior help;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Prior help [CARE];;;DISCOURAGED;2.27;2.64 +52542-8;Patient lived with prior to this illness;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Patient lived with prior to this illness [CARE];;;DISCOURAGED;2.27;2.64 +52543-6;Structural barriers in prior residence that could interfere with the patient's discharge;Find;Pt;^Patient;Nom;;SURVEY.CARE;4;Structural barriers in prior residence that could interfere with the patient's discharge;;;TRIAL;2.27;2.64 +52544-4;Structural barrier.other specified;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Structural barrier.other specified [CARE];;;DISCOURAGED;2.27;2.64 +52545-1;Prior functioning.self care;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Self care [CARE];;;DISCOURAGED;2.27;2.64 +52546-9;Prior functioning.mobility - ambulation;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Prior functioning.mobility - ambulation [CARE];;;DISCOURAGED;2.27;2.64 +52547-7;Prior functioning.stairs - ambulation;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Prior functioning.stairs - ambulation [CARE];;;DISCOURAGED;2.27;2.64 +5254-8;Mycoplasma pneumoniae Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum by Complement fixation;M pneumo Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52548-5;Prior functioning.mobility - wheelchair;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Prior functioning.mobility - wheelchair [CARE];;;DISCOURAGED;2.27;2.64 +52549-3;Prior functioning.functional cognition;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Functional cognition [CARE];;;DISCOURAGED;2.27;2.64 +52550-1;Mobility devices and aids used prior to current illness, exacerbation, or injury;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Mobility devices and aids used prior to current illness, exacerbation, or injury [CARE];;;DISCOURAGED;2.27;2.64 +52551-9;Prior mobility device.other specified;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Prior mobility device.other specified [CARE];;;DISCOURAGED;2.27;2.64 +52552-7;Falls in the past Y;Hx;1Y;^Patient;Ord;;SURVEY.CMS;4;Falls in the past year;;;ACTIVE;2.27;2.70 +52553-5;Language.primary is English;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Language.primary is English;;;TRIAL;2.27;2.64 +52554-3;Language.primary not English;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Language.primary not English [CARE];;;DISCOURAGED;2.27;2.64 +5255-5;Mycoplasma pneumoniae Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay;M pneumo IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +52555-0;Interpreter needed;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Deprecated Interpreter needed [CARE];;;DEPRECATED;2.27;2.70 +52556-8;Payment sources;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Payment sources;;;ACTIVE;2.26;2.63 +52557-6;Clinician diagnosis, comorbidity, and complication list is complete;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Deprecated Clinician diagnosis, comorbidity, and complication list is complete;;;DEPRECATED;2.26;2.36 +52558-4;Procedure this admission;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Procedure this admission [CARE];;;DISCOURAGED;2.26;2.64 +52559-2;Procedure.other;Type;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Deprecated Procedure.other CARE;;;DEPRECATED;2.27;2.36 +525-6;Vancomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Vancomycin [Susceptibility] by Disk diffusion (KB);Vancomycin Islt KB;;ACTIVE;1.0;2.73 +52560-0;Procedure.left;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Procedure.left [CARE];;;DISCOURAGED;2.26;2.64 +52561-8;Procedure.right;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Procedure.right [CARE];;;DISCOURAGED;2.26;2.64 +52562-6;Procedure.side not applicable;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Procedure.side not applicable [CARE];;;DISCOURAGED;2.26;2.64 +5256-3;Mycoplasma pneumoniae Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma pneumoniae IgM Ab [Units/volume] in Serum by Immunoassay;M pneumo IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +52563-4;Procedure list is complete;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Deprecated Procedure list is complete;;;DEPRECATED;2.26;2.36 +52564-2;Major treatments admitted &or discharged with;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Major treatments admitted/discharged with [CARE];;;TRIAL;2.27;2.44 +52565-9;Reason for continuous cardiac monitoring;Find;Pt;^Patient;Nom;;SURVEY.CARE;4;Reason for continuous cardiac monitoring;;;TRIAL;2.26;2.64 +52566-7;Suctioning frequency per H during stay.max;NRat;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Maximum suctioning frequency per hour during stay [CARE];;;DISCOURAGED;2.26;2.64 +52567-5;Reason for one on one 24H supervision;Find;Pt;^Patient;Nom;;SURVEY.CARE;4;Reason for one on one 24 hour supervision;;;TRIAL;2.26;2.64 +52568-3;Other major treatments received.other specified;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Other major treatments received.other specified [CARE];;;DISCOURAGED;2.26;2.64 +52569-1;Major treatments used at any time during stay;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Major treatments used at any time during stay [CARE];;;DISCOURAGED;2.26;2.64 +52570-9;Drug list is complete;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Deprecated Drug list is complete;;;DEPRECATED;2.26;2.36 +5257-1;Mycoplasma pneumoniae Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay;M pneumo IgM Ser Ql IA;;ACTIVE;1.0;2.73 +52571-7;Known allergies or adverse drug reactions;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Known allergies or adverse drug reactions [CARE];;;DISCOURAGED;2.27;2.64 +52572-5;Allergy list is complete;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Deprecated Allergy list is complete;;;DEPRECATED;2.27;2.36 +52573-3;Risk of developing pressure ulcers;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Risk of developing pressure ulcers [CARE];;;DISCOURAGED;2.26;2.64 +52574-1;One or more unhealed pressure ulcer(s) at stage 2 or higher;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;One or more unhealed pressure ulcer(s) at stage 2 or higher [CARE];;;DISCOURAGED;2.26;2.64 +52575-8;Number of pressure ulcers at assessment - stage 2;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers at assessment - stage 2 [CARE];;;DISCOURAGED;2.26;2.63 +52576-6;Number of pressure ulcers at assessment - stage 3;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers at assessment - stage 3 [CARE];;;DISCOURAGED;2.26;2.63 +52577-4;Number of pressure ulcers at assessment - stage 4;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers at assessment - stage 4 [CARE];;;DISCOURAGED;2.26;2.63 +52578-2;Number of pressure ulcers at assessment - unstageable;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers at assessment - unstageable [CARE];;;DISCOURAGED;2.26;2.63 +52579-0;Number of pressure ulcers onset during this service - stage 2;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers onset during this service - stage 2 [CARE];;;DISCOURAGED;2.26;2.63 +52580-8;Number of pressure ulcers onset during this service - stage 3;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers onset during this service - stage 3 [CARE];;;DISCOURAGED;2.26;2.63 +52581-6;Number of pressure ulcers onset during this service - stage 4;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers onset during this service - stage 4 [CARE];;;DISCOURAGED;2.26;2.63 +52582-4;Number of pressure ulcers onset during this service - unstageable;Num;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Number of pressure ulcers onset during this service - unstageable [CARE];;;DISCOURAGED;2.26;2.63 +52583-2;Number of unhealed stage 2 ulcers known to be present for more than 1 month;Num;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Number of unhealed stage 2 ulcers known to be present for more than 1 month [CARE];;;DISCOURAGED;2.26;2.64 +52584-0;Date of ulcer measurement;Date;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Date of ulcer measurement [CARE];;;DISCOURAGED;2.26;2.64 +52585-7;Major wound (excluding pressure ulcers);Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Major wound (excluding pressure ulcers) [CARE];;;DISCOURAGED;2.26;2.64 +52586-5;Delayed healing of surgical wound;Num;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Delayed healing of surgical wound # [CARE];;;DISCOURAGED;2.26;2.64 +52587-3;Trauma-related wound;Num;Pt;^Patient;Qn;;SURVEY.CARE;4;Trauma-related wound #;;;TRIAL;2.26;2.64 +52588-1;Diabetic foot ulcer(s);Num;Pt;^Patient;Qn;;SURVEY.CARE;4;Diabetic foot ulcer(s) #;;;TRIAL;2.26;2.64 +5258-9;Mycoplasma pneumoniae Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Mycoplasma pneumoniae IgM Ab [Titer] in Serum by Immunofluorescence;M pneumo IgM Titr Ser IF;;ACTIVE;1.0;2.73 +52589-9;Vascular ulcer (arterial or venous including diabetic ulcers not located on the foot);Num;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Vascular ulcer (arterial or venous including diabetic ulcers not located on the foot) # [CARE];;;DISCOURAGED;2.26;2.64 +52590-7;Major wound.other;Num;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Major wound.other # [CARE];;;DISCOURAGED;2.26;2.64 +52591-5;Major wound.other;Type;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Major wound.other [CARE];;;DISCOURAGED;2.26;2.64 +52592-3;Turning surfaces not intact;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Turning surfaces not intact [CARE];;;DISCOURAGED;2.26;2.64 +52593-1;Oxygen therapy source and amount;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Oxygen therapy source and amount [CARE];;;DISCOURAGED;2.26;2.64 +52594-9;Brief interview for mental status was attempted;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Brief Interview for Mental Status (BIMS) was attempted [CARE];;;DISCOURAGED;2.27;2.64 +52595-6;Reason brief interview for mental status was not attempted;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Reason Brief Interview for Mental Status (BIMS) was not attempted [CARE];;;DISCOURAGED;2.27;2.64 +52596-4;Memory &or recall ability during 2D assessment period;Find;2D;^Patient;Nom;CARE;SURVEY.CARE;4;Memory/recall ability during 2 day assessment period [CARE];;;DISCOURAGED;2.27;2.64 +5259-7;Myelin basic protein Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Myelin basic protein Ab [Titer] in Serum by Immunofluorescence;MBP Ab Titr Ser IF;;ACTIVE;1.0;2.70 +52597-2;Unable to assess memory &or recall ability during 2D assessment period .specified reason;Find;2D;^Patient;Nom;CARE;SURVEY.CARE;4;Unable to assess memory/recall ability during 2 day assessment period .specified reason [CARE];;;DISCOURAGED;2.27;2.64 +52598-0;Physical behavioral symptoms directed toward others during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Physical behavioral symptoms directed toward others during 2 day assessment period [CARE];;;DISCOURAGED;2.27;2.64 +52599-8;Verbal behavioral symptoms directed towards others during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Verbal behavioral symptoms directed towards others during 2 day assessment period [CARE];;;DISCOURAGED;2.27;2.64 +52600-4;Other disruptive or dangerous behavioral symptoms not directed towards others, including self-injurious behaviors during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Other disruptive or dangerous behavioral symptoms not directed towards others, including self-injurious behaviors during 2 day assessment period [CARE];;;DISCOURAGED;2.27;2.64 +52601-2;Mood interview was attempted;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Mood interview was attempted [CARE];;;DISCOURAGED;2.27;2.64 +52602-0;Feeling sad;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Feeling sad [CARE];;;DISCOURAGED;2.27;2.64 +52603-8;Pain interview was attempted;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Pain interview was attempted [CARE];;;DISCOURAGED;2.26;2.64 +52604-6;Pain presence during last 2D;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Pain presence during last 2 days [CARE];;;DISCOURAGED;2.26;2.64 +5260-5;Myocardium Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Myocardium Ab [Titer] in Serum by Immunofluorescence;Myocardium Ab Titr Ser IF;;ACTIVE;1.0;2.73 +52605-3;Pain has made it hard to sleep during last 2D;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Pain has made it hard to sleep during last 2 days [CARE];;;DISCOURAGED;2.26;2.64 +52606-1;Limited activities because of pain during last 2D;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Limited activities because of pain during last 2 days [CARE];;;DISCOURAGED;2.26;2.64 +52607-9;Pain Observational Assessment;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Pain Observational Assessment [CARE];;;DISCOURAGED;2.26;2.64 +52608-7;Impairments with bladder or bowel management;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Impairments with bladder or bowel management;;;TRIAL;2.26;2.64 +52609-5;Bladder - external or indwelling device or intermittent catheterization;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Bladder - external or indwelling device or intermittent catheterization [CARE];;;DISCOURAGED;2.26;2.64 +52610-3;Bowel - external or indwelling device or intermittent catheterization;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Bowel - external or indwelling device or intermittent catheterization [CARE];;;DISCOURAGED;2.26;2.64 +52611-1;Bladder - frequency of incontinence during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Bladder - frequency of incontinence during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52612-9;Bowel - frequency of incontinence during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Bowel - frequency of incontinence during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +5261-3;Neisseria gonorrhoeae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Neisseria gonorrhoeae Ab [Units/volume] in Serum;N gonorrhoea Ab Ser-aCnc;;DISCOURAGED;1.0;2.69 +52613-7;Bladder - needs assistance to manage bladder care equipment;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Bladder - needs assistance to manage bladder care equipment [CARE];;;DISCOURAGED;2.26;2.64 +52614-5;Bowel - needs assistance to manage bowel care equipment;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Bowel - needs assistance to manage bowel care equipment [CARE];;;DISCOURAGED;2.26;2.64 +52615-2;Bladder - incontinent immediately prior to current illness, exacerbation, or injury;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Bladder - incontinent immediately prior to current illness, exacerbation, or injury [CARE];;;DISCOURAGED;2.26;2.64 +52616-0;Bowel - incontinent immediately prior to current illness, exacerbation, or injury;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Bowel - incontinent immediately prior to current illness, exacerbation, or injury [CARE];;;DISCOURAGED;2.26;2.64 +52617-8;Any impairments with swallowing;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Any impairments with swallowing [CARE];;;TRIAL;2.27;2.44 +52618-6;Swallowing disorder;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Swallowing disorder [CARE];;;DISCOURAGED;2.26;2.64 +52619-4;Swallowing disorder.other specified;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Swallowing disorder.other specified [CARE];;;DISCOURAGED;2.26;2.64 +52620-2;Swallowing usual ability;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Swallowing usual ability [CARE];;;DISCOURAGED;2.26;2.64 +5262-1;Neutrophil cytoplasmic Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Neutrophil cytoplasmic Ab [Units/volume] in Serum by Immunofluorescence;ANCA Ab Ser IF-aCnc;;ACTIVE;1.0;2.69 +52621-0;Any impairments with hearing, vision, or communication;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Any impairments with hearing, vision, or communication;;;TRIAL;2.26;2.64 +52622-8;Understanding verbal content - excluding language barriers;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Understanding verbal content - excluding language barriers [CARE];;;DISCOURAGED;2.26;2.64 +52623-6;Expression of ideas and wants;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Expression of ideas and wants [CARE];;;DISCOURAGED;2.26;2.64 +52624-4;Seeing in adequate light - with glasses or other visual appliances;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Seeing in adequate light - with glasses or other visual appliances [CARE];;;DISCOURAGED;2.26;2.64 +52625-1;Hearing - with hearing aid or hearing appliance if normally used;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Hearing - with hearing aid or hearing appliance if normally used [CARE];;;DISCOURAGED;2.26;2.64 +52626-9;Any impairments with weight-bearing;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Any impairments with weight-bearing;;;TRIAL;2.26;2.64 +52627-7;Weight-bearing restrictions during 2D assessment period;Find;2D;Upper extremity.left;Ord;CARE;SURVEY.CARE;4;Weight-bearing restrictions during 2 day assessment period Upper extremity - left [CARE];;;DISCOURAGED;2.26;2.64 +52628-5;Weight-bearing restrictions during 2D assessment period;Find;2D;Upper extremity.right;Ord;CARE;SURVEY.CARE;4;Weight-bearing restrictions during 2 day assessment period Upper extremity - right [CARE];;;DISCOURAGED;2.26;2.64 +52629-3;Weight-bearing restrictions during 2D assessment period;Find;2D;Lower extremity.left;Ord;CARE;SURVEY.CARE;4;Weight-bearing restrictions during 2 day assessment period Lower extremity - left [CARE];;;DISCOURAGED;2.26;2.64 +52630-1;Weight-bearing restrictions during 2D assessment period;Find;2D;Lower extremity.right;Ord;CARE;SURVEY.CARE;4;Weight-bearing restrictions during 2 day assessment period Lower extremity - right [CARE];;;DISCOURAGED;2.26;2.64 +52631-9;Any impairments with grip strength;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Any impairments with grip strength;;;TRIAL;2.26;2.64 +52632-7;Grip strength during 2D assessment period;Find;2D;Hand.left;Ord;CARE;SURVEY.CARE;4;Grip strength during 2 day assessment period Hand - left [CARE];;;DISCOURAGED;2.26;2.64 +52633-5;Grip strength during 2D assessment period;Find;2D;Hand.right;Ord;CARE;SURVEY.CARE;4;Grip strength during 2 day assessment period Hand - right [CARE];;;DISCOURAGED;2.26;2.64 +52634-3;Any impairments with respiratory status;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Any impairments with respiratory status;;;TRIAL;2.26;2.64 +52635-0;Respiratory status with oxygen therapy during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Respiratory status with oxygen therapy during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52636-8;Respiratory status without oxygen therapy during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Respiratory status without oxygen therapy during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52637-6;Any impairments with endurance;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Any impairments with endurance;;;TRIAL;2.26;2.64 +52638-4;Mobility endurance - able to walk or wheel 50 feet during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Mobility endurance - able to walk or wheel 50 feet during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +5263-9;Nocardia sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Nocardia sp Ab [Units/volume] in Serum;Nocardia Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52639-2;Sitting endurance - able to tolerate sitting for 15M during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Sitting endurance - able to tolerate sitting for 15 minutes during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +526-4;Vancomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Vancomycin [Susceptibility] by Serum bactericidal titer;Vancomycin Titr SBT;;ACTIVE;1.0;2.32 +52640-0;Mobility devices and aids needed;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Mobility Devices and Aids Needed [CARE];;;DISCOURAGED;2.26;2.64 +52641-8;Mobility device.other specified;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Mobility device.other specified [CARE];;;DISCOURAGED;2.26;2.64 +52642-6;Eating during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Eating during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52643-4;Tube feeding during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Tube feeding during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52644-2;Oral hygiene during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Oral hygiene during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52645-9;Toilet hygiene during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Toilet hygiene during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52646-7;Upper body dressing during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Upper body dressing during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +5264-7;Onchocerca sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Onchocerca sp Ab [Units/volume] in Serum;Onchocerca Ab Ser-aCnc;;ACTIVE;1.0;2.73 +52647-5;Lower body dressing during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Lower body dressing during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52648-3;Lying to sitting on side of bed during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Lying to sitting on side of bed during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52649-1;Sit to stand during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Sit to stand during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52650-9;Chair-bed to chair transfer during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Chair-bed to chair transfer during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52651-7;Toilet transfer during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Toilet transfer during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52652-5;Primarily uses wheelchair for mobility during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Primarily uses wheelchair for mobility during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52653-3;Walk 150 ft (45 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Walk 150 ft (45 m) during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +5265-4;Pancreatic islet cell Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Pancreatic islet cell Ab [Presence] in Serum by Immunofluorescence;Panc Islet Cell Ab Ser Ql IF;;ACTIVE;1.0;2.73 +52654-1;Walk 100 ft (30 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Walk 100 ft (30 m) during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52655-8;Walk 50 ft (15 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Walk 50 ft (15 m) during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52656-6;Walk 10 ft (3 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Walk 10 ft (3 m) during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52657-4;Wheel 150 ft (45 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wheel 150 ft (45 m) during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52658-2;Wheel 100 ft (30 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wheel 100 ft (30 m) during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52659-0;Wheel 50 ft (15 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wheel 50 ft (15 m) during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52660-8;Wheel 10 ft (3 m) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wheel 10 ft (3 m) during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52661-6;Wash upper body during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wash upper body during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +5266-2;Paracoccidioides brasiliensis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Paracoccidioides brasiliensis Ab [Titer] in Serum by Complement fixation;P brasilien Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52662-4;Shower &or bathe self during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Shower/bathe self during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52663-2;Roll left and right during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Roll left and right during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52664-0;Sit to lying during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Sit to lying during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52665-7;Picking up objects during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Picking up objects during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52666-5;Putting on &or taking off footwear during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Putting on/taking off footwear during 2 day assessment period [CARE];;;TRIAL;2.26;2.54 +52667-3;One step (curb) during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;One step (curb) during two day assessment period [CARE];;;TRIAL;2.26;2.54 +52668-1;Walk 50 feet with two turns during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Walk 50 feet with two turns during two day assessment period [CARE];;;TRIAL;2.26;2.54 +52669-9;12 steps-interior during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;12 steps-interior during two day assessment period [CARE];;;TRIAL;2.26;2.54 +5267-0;Paragonimus sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Paragonimus sp Ab [Titer] in Serum by Complement fixation;Paragonimus Ab Titr Ser CF;;ACTIVE;1.0;2.70 +52670-7;Four steps-exterior during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Four steps-exterior during two day assessment period [CARE];;;TRIAL;2.26;2.54 +52671-5;Walking 10 feet on uneven surfaces during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Walking 10 feet on uneven surfaces during two day assessment period [CARE];;;TRIAL;2.26;2.54 +52672-3;Car transfer during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Car transfer during two day assessment period [CARE];;;TRIAL;2.26;2.54 +52673-1;Wheel short ramp during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wheel short ramp during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52674-9;Wheel long ramp during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wheel long ramp during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52675-6;Telephone-answering during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Telephone-answering during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52676-4;Telephone-placing call during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Telephone-placing call during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52677-2;Medication management-oral medications during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Medication management-oral medications during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52678-0;Medication management-inhalant &or mist medications during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Medication management-inhalant/mist medications during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52679-8;Medication management-injectable medications during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Medication management-injectable medications during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52680-6;Make light meal during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Make light meal during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52681-4;Wipe down surface during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Wipe down surface during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52682-2;Light shopping during 2D assesssment;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Light shopping during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52683-0;Laundry during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Laundry during two day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52684-8;Use public transportation during 2D assessment period;Find;2D;^Patient;Ord;CARE;SURVEY.CARE;4;Use public transportation during 2 day assessment period [CARE];;;DISCOURAGED;2.26;2.64 +52685-5;Care goals documented;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Care goals documented;;;TRIAL;2.26;2.64 +52686-3;Overall status;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Overall status [CARE];;;DISCOURAGED;2.26;2.64 +52687-1;Decision authority documented;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Decision authority documented [CARE];;;DISCOURAGED;2.26;2.64 +5268-8;Parainfluenza virus 1 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 1 Ab [Titer] in Serum by Complement fixation;HPIV1 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52688-9;Discharge disposition;Type;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Discharge disposition [CARE];;;DISCOURAGED;2.27;2.66 +52689-7;Frequency of assistance at discharge;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Frequency of assistance at discharge [CARE];;;DISCOURAGED;2.27;2.64 +52690-5;Discharge destination influenced by caregiver availability;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Discharge destination influenced by caregiver availability [CARE];;;DISCOURAGED;2.27;2.64 +52691-3;Willing caregiver;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Willing caregiver [CARE];;;DISCOURAGED;2.27;2.64 +52692-1;Types of caregiver;Find;Pt;^Patient;Nom;;SURVEY.CARE;4;Types of caregiver;;;TRIAL;2.27;2.64 +52693-9;Patient will live with at discharge;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Patient will live with at discharge [CARE];;;DISCOURAGED;2.27;2.64 +52694-7;ADL assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;ADL assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +52695-4;IADL assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;IADL assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +5269-6;Parainfluenza virus 2 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 2 Ab [Titer] in Serum by Complement fixation;HPIV2 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52696-2;Medication administration assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Medication administration assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +52697-0;Medical procedures &or treatments assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Medical procedures/treatments assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +52698-8;Management of equipment assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Management of equipment assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +52699-6;Supervision and safety assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Supervision and safety assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +52700-2;Advocacy assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Advocacy assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +52701-0;No assistance needed;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;No assistance needed [CARE];;;DISCOURAGED;2.27;2.64 +52702-8;Home health care considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Home health care considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52703-6;Skilled nursing facility considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Skilled nursing facility considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +5270-4;Parainfluenza virus 3 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Parainfluenza virus 3 Ab [Titer] in Serum by Complement fixation;HPIV3 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52704-4;Inpatient rehabilitation hospital considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Inpatient rehabilitation hospital considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52705-1;Long term care hospital considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Long term care hospital considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52706-9;Psychiatric hospital considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Psychiatric hospital considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52707-7;Outpatient services considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Outpatient services considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52708-5;Acute hospital admission considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Acute hospital admission considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52709-3;Hospice considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Hospice considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52710-1;Long-term personal care services considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Long-term personal care services considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52711-9;Long term care nursing facility considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Long term care nursing facility considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +5271-2;Parietal cell Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Parietal cell Ab [Titer] in Serum by Immunofluorescence;PCA Ab Titr Ser IF;;ACTIVE;1.0;2.73 +52712-7;Other service considered appropriate;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Other service considered appropriate [CARE];;;DISCOURAGED;2.27;2.64 +52713-5;Discharged with referral for additional services;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Discharged with referral for additional services [CARE];;;DISCOURAGED;2.27;2.64 +52714-3;Provider type;Type;Pt;Provider;Nom;CARE;SURVEY.CARE;4;Provider type [CARE];;;DISCOURAGED;2.27;2.64 +52715-0;Provider type.other specified;Type;Pt;Provider;Nom;CARE;SURVEY.CARE;4;Provider type.other specified [CARE];;;DISCOURAGED;2.27;2.64 +52716-8;Discharge delayed at least 24H;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Discharge delayed at least 24 hours;;;TRIAL;2.27;2.64 +52717-6;Reason for discharge delay;Find;Pt;^Patient;Nom;;SURVEY.CARE;4;Reason for discharge delay;;;TRIAL;2.27;2.64 +52718-4;Reason for discharge delay.other specified;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Reason for discharge delay.other specified [CARE];;;DISCOURAGED;2.27;2.64 +52719-2;Patient requested information not be shared with next provider;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Patient requested information not be shared with next provider [CARE];;;DISCOURAGED;2.27;2.64 +527-2;Viomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Viomycin [Susceptibility] by Minimum lethal concentration (MLC);Viomycin Islt MLC;;ACTIVE;1.0;2.19 +5272-0;Parvovirus B19 Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 Ab [Units/volume] in Serum by Immunoassay;B19V Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +52720-0;Other useful information;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Other useful information [CARE];;;DISCOURAGED;2.26;2.64 +52721-8;Current payment source.other specified;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Current payment source.other specified [CARE];;;DISCOURAGED;2.26;2.64 +52722-6;Admitted from;Type;Pt;Facility;Nom;CARE;SURVEY.CARE;4;Admitted from Facility [CARE];;;DISCOURAGED;2.27;2.64 +52723-4;Admitted from.other specified;Type;Pt;Facility;Nom;CARE;SURVEY.CARE;4;Admitted from.other specified Facility [CARE];;;DISCOURAGED;2.27;2.64 +52724-2;Primary diagnosis code from previous setting;Prid;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Primary diagnosis code from previous setting [CARE];;;DISCOURAGED;2.27;2.64 +52725-9;Medical services received in the last 2Mo;Find;2Mo;^Patient;Nom;CARE;SURVEY.CARE;4;Medical services received in the last 2 months [CARE];;;DISCOURAGED;2.27;2.64 +52726-7;Prior residence;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Prior residence [CARE];;;DISCOURAGED;2.27;2.64 +52727-5;Lives outside U.S.;Find;Pt;^Patient;Ord;;SURVEY.CARE;4;Lives outside U.S.;;;TRIAL;2.27;2.64 +52728-3;Diameter.any.max;Len;Pt;Pressure injury.largest stage 3 or 4;Qn;CMS Assessment;SURVEY.CMS;4;Diameter.any.max Pressure injury.largest stage 3 or 4 [CMS Assessment];;;TRIAL;2.26;2.63 +52729-1;Diameter.transverse;Len;Pt;Pressure injury.largest stage 3 or 4;Qn;CMS Assessment;SURVEY.CMS;4;Diameter transverse Pressure injury.largest stage 3 or 4 [CMS Assessment];;;TRIAL;2.26;2.63 +52730-9;Undermining or tunneling present;Find;Pt;Pressure injury.stage 3 or 4;Ord;CARE;SURVEY.CARE;4;Undermining or tunneling present Pressure injury.stage 3 or 4 [CARE];;;DISCOURAGED;2.26;2.64 +52731-7;Repetition of three words;Num;Pt;^Patient;Ord;BIMS;SURVEY.CMS;4;Repetition of three words # [BIMS];;;ACTIVE;2.27;2.63 +52732-5;Temporal orientation - current year;Find;Pt;^Patient;Ord;BIMS;SURVEY.CMS;4;Temporal orientation - current year [BIMS];;;ACTIVE;2.27;2.63 +52733-3;Temporal orientation - current month;Find;Pt;^Patient;Ord;BIMS;SURVEY.CMS;4;Temporal orientation - current month [BIMS];;;ACTIVE;2.27;2.63 +52734-1;Temporal orientation - current day of the week;Find;Pt;^Patient;Ord;Observed.BIMS;SURVEY.CARE;4;Deprecated Temporal orientation - current day of the week [Observed.BIMS];;;DEPRECATED;2.27;2.70 +52735-8;Recall - sock;Find;Pt;^Patient;Ord;BIMS;SURVEY.CMS;4;Recall - sock [BIMS];;;ACTIVE;2.27;2.63 +52736-6;Recall - blue;Find;Pt;^Patient;Ord;BIMS;SURVEY.CMS;4;Recall - blue [BIMS];;;ACTIVE;2.27;2.63 +52737-4;Recall - bed;Find;Pt;^Patient;Ord;BIMS;SURVEY.CMS;4;Recall - bed [BIMS];;;ACTIVE;2.27;2.63 +5273-8;Parvovirus B19 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Serum by Immunoassay;B19V IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +52738-2;Inattention during 2D assessment period;Find;2D;^Patient;Ord;Observed.CAM.CARE;SURVEY.CARE;4;Inattention during 2 day assessment period;;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";TRIAL;2.29;2.54 +52739-0;Disorganized thinking during 2D assessment period;Find;2D;^Patient;Ord;Observed.CAM.CARE;SURVEY.CARE;4;Disorganized thinking during 2 day assessment period;;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";TRIAL;2.29;2.54 +52740-8;Altered level of consciousness &or alertness during 2D assessment period;Find;2D;^Patient;Ord;Observed.CAM.CARE;SURVEY.CARE;4;Altered level of consciousness/alertness during 2 day assessment period;;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";TRIAL;2.29;2.54 +52741-6;Psychomotor retardation during 2D assessment period;Find;2D;^Patient;Ord;Observed.CAM.CARE;SURVEY.CARE;4;Psychomotor retardation during 2 day assessment period;;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";TRIAL;2.29;2.54 +52742-4;Pain severity during last 2D;Score;2D;^Patient;Ord;Reported;SURVEY.CARE;4;Pain severity during last 2 days [Reported];;;TRIAL;2.26;2.52 +52743-2;Continuity assessment record and evaluation tool - Acute care;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Acute Care;;;DISCOURAGED;2.27;2.67 +52744-0;Continuity assessment record and evaluation tool - Post acute care - admission;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Post Acute Care (PAC) - Admission;;;DISCOURAGED;2.27;2.67 +52745-7;Continuity assessment record and evaluation tool - Post acute care - discharge;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Post Acute Care (PAC) - Discharge;;;DISCOURAGED;2.27;2.73 +5274-6;Parvovirus B19 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Serum by Immunoassay;B19V IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +52746-5;Continuity assessment record and evaluation tool - Interim;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Interim;;;DISCOURAGED;2.26;2.73 +52747-3;Continuity assessment record and evaluation tool - Expired;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Expired;;;DISCOURAGED;2.26;2.73 +52748-1;Continuity assessment record and evaluation tool - Home health admission;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Home Health Admission;;;DISCOURAGED;2.27;2.67 +52749-9;Etravirine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Etravirine [Susceptibility] by Genotype method;Etravirine Islt Genotyp;;ACTIVE;2.24;2.73 +52750-7;Activated protein C resistance;PrThr;Pt;PPP;Ord;Coag;COAG;1;Activated protein C resistance [Presence] in Platelet poor plasma by Coagulation assay;aPCR PPP Ql;;ACTIVE;2.24;2.73 +52751-5;Coagulation surface induced.factor sensitive;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor sensitive in Platelet poor plasma by Coagulation assay;aPTT-FS PPP;;ACTIVE;2.24;2.70 +52752-3;Coagulation tissue factor induced.PIVKA insensitive actual/Normal;RelTime;Pt;BldC;Qn;Coag;COAG;1;Prothrombin time (PT) PIVKA insensitive actual/normal in Capillary blood by Coagulation assay;PT PIVKA insensitive Act/Nor BldC;;ACTIVE;2.24;2.70 +5275-3;PCNA extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;PCNA extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA PCNA Ab Ser Ql IA;;ACTIVE;1.0;2.56 +52753-1;Coagulation tissue factor induced.PIVKA insensitive actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) PIVKA insensitive actual/normal in Platelet poor plasma by Coagulation assay;PT PIVKA insensitive Act/Nor PPP;;ACTIVE;2.24;2.70 +52754-9;Kininogen.high molecular weight activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Kininogen HMW activity actual/normal in Platelet poor plasma by Coagulation assay;HMWK activity Act/Nor PPP;;ACTIVE;2.24;2.73 +52755-6;Coagulation surface induced.lupus sensitive;PrThr;Pt;PPP;Ord;Coag;COAG;1;aPTT.lupus sensitive [Presence] in Platelet poor plasma by Coagulation assay;aPTT-LA PPP Ql;;DISCOURAGED;2.24;2.56 +52756-4;Coagulation dilute Russell viper venom induced.excess phospholipid;PrThr;Pt;PPP;Ord;Coag;COAG;1;dRVVT excess phospholipid [Presence] in Platelet poor plasma by Coagulation assay;dRVVT confirm PPP Ql;;DISCOURAGED;2.24;2.73 +52757-2;SERPINE1 gene.c.-675 4G+5G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;SERPINE1 gene c.-675 4G+5G [Presence] in Blood or Tissue by Molecular genetics method;SERPINE1 c.-675 4G+5G Bld/T Ql;;ACTIVE;2.24;2.73 +52758-0;SERPINE1 gene.c.-844A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;SERPINE1 gene c.-844A>G [Presence] in Blood or Tissue by Molecular genetics method;SERPINE1 c.-844A>G Bld/T Ql;;ACTIVE;2.24;2.56 +52759-8;Prekallikrein activity actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Prekallikrein (Fletcher Factor) activity actual/normal in Platelet poor plasma by Coagulation assay;PK activity Act/Nor PPP;;ACTIVE;2.24;2.70 +52760-6;Coagulation tissue factor induced.PIVKA sensitive actual/Normal;RelTime;Pt;BldC;Qn;Coag;COAG;1;Prothrombin time (PT) PIVKA sensitive actual/normal in Capillary blood by Coagulation assay;PT PIVKA sensitive Act/Nor BldC;;ACTIVE;2.24;2.70 +5276-1;PCNA extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;PCNA extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA PCNA Ab Ser Ql ID;;ACTIVE;1.0;2.73 +52761-4;Coagulation tissue factor induced.PIVKA sensitive actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) PIVKA sensitive actual/normal in Platelet poor plasma by Coagulation assay;PT PIVKA sensitive Act/Nor PPP;;ACTIVE;2.24;2.73 +52762-2;Intrinsic coagulation system thromboelastography panel;-;Pt;Bld;-;;PANEL.COAG;1;Intrinsic coagulation system thromboelastography panel - Blood;Intrinsic TEG Pnl Bld;;ACTIVE;2.24;2.73 +52763-0;Extrinsic coagulation system thromboelastography panel;-;Pt;Bld;-;;PANEL.COAG;1;Extrinsic coagulation system thromboelastography panel - Blood;Extrinsic TEG Pnl Bld;;ACTIVE;2.24;2.42 +52764-8;Extrinsic coagulation system with fibrinolysis inhibition thromboelastography panel;-;Pt;Bld;-;;PANEL.COAG;1;Extrinsic coagulation system with fibrinolysis inhibition thromboelastography panel - Blood;Fibrinolysis inhib TEG Pnl Bld;;ACTIVE;2.24;2.42 +52765-5;Thromboelastography without activation panel;-;Pt;Bld;-;;PANEL.COAG;1;Thromboelastography without activation panel - Blood;TEG WO activation Pnl Bld;;ACTIVE;2.24;2.42 +52766-3;Coagulation surface induced^after addition of protein C activator+Factor V depleted plasma/Coagulation surface induced;TRto;Pt;PPP;Qn;Coag;COAG;1;aPTT in Platelet poor plasma by Coagulation assay -- after addition of protein C activator + Factor V depleted plasma/aPTT;aPTT protein C activator+FV DP/aPTT PPP;;ACTIVE;2.24;2.73 +52767-1;Coagulation surface induced^after addition of protein C activator/Coagulation surface induced;TRto;Pt;PPP;Qn;Coag;COAG;1;Activated partial thromboplastin time (aPTT) in Platelet poor plasma by Coagulation assay -- after addition of protein C activator/Activated partial thromboplastin time (aPTT);aPTTprotein C activator/aPTT PPP;;ACTIVE;2.24;2.73 +52768-9;Clot formation;Time;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot formation [Time] in Blood by Thromboelastography;CFT Bld TEG;;ACTIVE;2.24;2.73 +52769-7;Clot formation.extrinsic coagulation system activated.fibrinolysis suppressed;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clot formation.extrinsic coagulation system activated.fibrinolysis suppressed [Time] in Blood by Rotational TEG;CFT.fibinolysis sup Bld ROTEM;;ACTIVE;2.24;2.70 +52770-5;Clot formation.extrinsic coagulation system activated;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clot formation.extrinsic coagulation system activated [Time] in Blood by Rotational TEG;CFT.extrinsic Bld ROTEM;;ACTIVE;2.24;2.73 +52771-3;Clot formation.intrinsic coagulation system activated;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clot formation.intrinsic coagulation system activated [Time] in Blood by Rotational TEG;CFT.intrinsic Bld ROTEM;;ACTIVE;2.24;2.73 +52772-1;Clot formation.intrinsic coagulation system activated.heparin insensitive;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clot formation.intrinsic coagulation system activated.heparin insensitive [Time] in Blood by Rotational TEG;CFT.heparin insens Bld ROTEM;;ACTIVE;2.24;2.73 +52773-9;Clotting time.extrinsic coagulation system activated;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clotting time.extrinsic coagulation system activated of Blood by Rotational TEG;CT.extrinsic Bld ROTEM;;ACTIVE;2.24;2.73 +52774-7;Clotting time.extrinsic coagulation system activated.fibrinolysis suppressed;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clotting time.extrinsic coagulation system activated.fibrinolysis suppressed of Blood by Rotational TEG;CT.fibinolysis supp Bld ROTEM;;ACTIVE;2.24;2.73 +52775-4;Clotting time.intrinsic coagulation system activated.heparin insensitive;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clotting time.intrinsic coagulation system activated.heparin insensitive of Blood by Rotational TEG;CT.heparin insens Bld ROTEM;;ACTIVE;2.24;2.70 +52776-2;Clotting time.intrinsic coagulation system activated;Time;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Clotting time.intrinsic coagulation system activated of Blood by Rotational TEG;CT.intrinsic Bld ROTEM;;ACTIVE;2.24;2.73 +52777-0;Intrinsic coagulation system with heparin inhibition thromboelastography panel;-;Pt;Bld;-;;PANEL.COAG;1;Intrinsic coagulation system with heparin inhibition thromboelastography panel - Blood;Heparin inhibition TEG Pnl Bld;;ACTIVE;2.24;2.42 +52778-8;Maximum clot firmness;Len;Pt;Bld;Qn;Thromboelastography;COAG;1;Maximum clot firmness [Length] in Blood by Thromboelastography;MCF Bld TEG;;ACTIVE;2.24;2.73 +5277-9;Penicillium roqueforti Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Penicillium roqueforti Ab [Units/volume] in Serum;P roqueforte Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52779-6;Maximum clot firmness.extrinsic coagulation system activated.fibrinolysis suppressed;Len;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum clot firmness.extrinsic coagulation system activated.fibrinolysis suppressed [Length] in Blood by Rotational TEG;MCF.fibrinolysis supp Bld ROTEM;;ACTIVE;2.24;2.70 +52780-4;Maximum clot firmness.extrinsic coagulation system activated.platelets inhibited;Len;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum clot firmness.extrinsic coagulation system activated.platelets inhibited [Length] in Blood by Rotational TEG;MCF.platelet inhib Bld ROTEM;;ACTIVE;2.24;2.73 +52781-2;Maximum clot firmness.intrinsic coagulation system activated;Len;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum clot firmness.intrinsic coagulation system activated [Length] in Blood by Rotational TEG;MCF.intrinsic Bld ROTEM;;ACTIVE;2.24;2.73 +52782-0;Maximum clot firmness.intrinsic coagulation system activated.heparin insensitive;Len;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum clot firmness.intrinsic coagulation system activated.heparin insensitive [Length] in Blood by Rotational TEG;MCF.heparin insens Bld ROTEM;;ACTIVE;2.24;2.70 +52783-8;Maximum clot firmness.extrinsic coagulation system activated;Len;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum clot firmness.extrinsic coagulation system activated [Length] in Blood by Rotational TEG;MCF.extrinsic Bld ROTEM;;ACTIVE;2.24;2.70 +52784-6;Maximum lysis;LenFr;Pt;Bld;Qn;Thromboelastography;COAG;1;Maximum lysis [Length fraction] in Blood by Thromboelastography;ML LenFr Bld TEG;;ACTIVE;2.24;2.73 +52785-3;Maximum lysis.extrinsic coagulation system activated.fibrinolysis suppressed;LenFr;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum lysis.extrinsic coagulation system activated.fibrinolysis suppressed [Length fraction] in Blood by Rotational TEG;ML.fibrinolysis supp LenFr Bld ROTEM;;ACTIVE;2.24;2.73 +52786-1;Maximum lysis.extrinsic coagulation system activated;LenFr;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum lysis.extrinsic coagulation system activated [Length fraction] in Blood by Rotational TEG;ML.extrinsic LenFr Bld ROTEM;;ACTIVE;2.24;2.73 +5278-7;Plasmodium falciparum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Plasmodium falciparum Ab [Units/volume] in Serum;P falciparum Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52787-9;Maximum lysis.intrinsic coagulation system activated;LenFr;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum lysis.intrinsic coagulation system activated [Length fraction] in Blood by Rotational TEG;ML.intrinsic LenFr Bld ROTEM;;ACTIVE;2.24;2.73 +52788-7;Maximum lysis.intrinsic coagulation system activated.heparin insensitive;LenFr;Pt;Bld;Qn;Thromboelastography.rotational;COAG;1;Maximum lysis.intrinsic coagulation system activated.heparin insensitive [Length fraction] in Blood by Rotational TEG;ML.heparin insens LenFr Bld ROTEM;;ACTIVE;2.24;2.70 +52789-5;Clot initiation;Time;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot initiation [Time] in Blood by Thromboelastography;Clot init Bld TEG;;ACTIVE;2.24;2.73 +52790-3;Guidance for percutaneous replacement of drainage catheter;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for percutaneous replacement of drainage catheter of Abdomen;CT Guided Abd PC drain cath replace;;ACTIVE;2.24;2.68 +52791-1;Guidance for percutaneous replacement of drainage catheter;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for percutaneous replacement of drainage catheter of Pelvis;CT Guided Pelvis PC drain cath replace;;ACTIVE;2.24;2.68 +52792-9;Rh;Type;Pt;Bld^Father;Nom;;BLDBK;1;Father's Rh Type;Rh Bld Father;;ACTIVE;2.24;2.61 +52793-7;ABO group;Type;Pt;Bld^Father;Nom;;BLDBK;1;Father's ABO group Type;ABO Group Bld Father;;ACTIVE;2.24;2.72 +52794-5;Ova & parasites identified^3rd specimen;Prid;Pt;XXX;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Specimen by Light microscopy--3rd specimen;O+P sp3 Spec Micro;;ACTIVE;2.24;2.73 +5279-5;Plasmodium sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Plasmodium sp Ab [Units/volume] in Serum;Plasmodium Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52795-2;Ova & parasites identified^2nd specimen;Prid;Pt;XXX;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Specimen by Light microscopy--2nd specimen;O+P sp2 Spec Micro;;ACTIVE;2.24;2.73 +52796-0;Planned stop date;Date;Pt;Medication.current;Qn;;SURVEY.CARE;4;Planned stop date Current medication;;;DISCOURAGED;2.26;2.64 +52797-8;Diagnosis ICD code;Prid;Pt;^Patient;Nom;;CLIN;2;Diagnosis ICD code [Identifier];Dx ICD code;;ACTIVE;2.26;2.73 +52798-6;Medical coding diagnosis, comorbidity, and complication list is complete;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Deprecated Medical coding diagnosis, comorbidity, and complication list is complete;;;DEPRECATED;2.26;2.36 +52799-4;Major treatments used on or 1D prior to day of death panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Major treatments used on or 1 day prior to day of death panel;;;ACTIVE;2.26;2.48 +528-0;Viomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Viomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Viomycin Islt MIC;;ACTIVE;1.0;2.19 +52800-0;Major treatments used on or 1D prior to day of death;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Major treatments used on or 1 day prior to day of death [CARE];;;DISCOURAGED;2.26;2.64 +52801-8;Major treatments admitted with panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Major treatments admitted with panel;;;ACTIVE;2.27;2.48 +52802-6;Major treatments admitted with;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Major treatments admitted with [CARE];;;DISCOURAGED;2.27;2.64 +5280-3;Plasmodium vivax Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Plasmodium vivax Ab [Units/volume] in Serum;P vivax Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52803-4;Major treatments discharged with panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Major treatments discharged with panel;;;DISCOURAGED;2.27;2.64 +52804-2;Major treatments discharged with;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Major treatments discharged with [CARE];;;DISCOURAGED;2.27;2.64 +52805-9;Major treatments used within 2D interim period panel;-;2D;^Patient;-;;PANEL.SURVEY.CARE;4;Major treatments used within 2 days interim period panel;;;DISCOURAGED;2.26;2.64 +52806-7;Major treatments used within 2D interim period;Find;2D;^Patient;Nom;CARE;SURVEY.CARE;4;Major treatments used within 2 days interim period [CARE];;;DISCOURAGED;2.26;2.64 +52807-5;Medical Coding Other Diagnoses, Comorbidities, and Complications;-;Pt;^Patient;-;;SURVEY.CARE;4;Medical Coding Other Diagnoses, Comorbidities, and Complications;;;DISCOURAGED;2.26;2.64 +52808-3;Medical Coding Major Procedures (Diagnostic, Surgical, and Therapeutic Interventions);-;Pt;^Patient;-;;SURVEY.CARE;4;Medical Coding Major Procedures (Diagnostic, Surgical, and Therapeutic Interventions);;;DISCOURAGED;2.26;2.64 +52809-1;Dose form;Type;Pt;Medication.current;Nom;;MEDS;2;Dose form Current medication;Dose form Medication.current;;ACTIVE;2.26;2.73 +52810-9;Frequency;NRat;Pt;Medication.current;Qn;;ATTACH.MEDS;3;Current medication, Frequency;;;ACTIVE;2.26;2.73 +5281-1;Polio virus 1 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 1 neutralizing antibody [Titer] in Serum by Neutralization test;PV1 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +52811-7;HIPAA attachments;-;Pt;^Patient;-;;ATTACH;3;Deprecated HIPAA attachments;Deprecated;;DEPRECATED;2.24;2.66 +52812-5;Appearance;Aper;Pt;Dial fld.spun;Nom;;SPEC;1;Appearance of Spun Dialysis fluid;Appearance spun Dial fld;;ACTIVE;2.24;2.26 +52813-3;Appearance;Aper;Pt;Plr fld.spun;Nom;;SPEC;1;Appearance of Spun Pleural fluid;Appearance spun Plr;;ACTIVE;2.24;2.26 +52814-1;Appearance;Aper;Pt;Periton fld.spun;Nom;;SPEC;1;Appearance of Spun Peritoneal fluid;Appearance spun Prt;;ACTIVE;2.24;2.26 +52815-8;Nucleated cells;NCnc;Pt;Pericard fld;Qn;Automated count;HEM/BC;1;Nucleated cells [#/volume] in Pericardial fluid by Automated count;Nuc cell # Pcar Auto;;ACTIVE;2.24;2.70 +52816-6;Nucleated cells;NCnc;Pt;CSF;Qn;Automated count;HEM/BC;1;Nucleated cells [#/volume] in Cerebral spinal fluid by Automated count;Nuc cell # CSF Auto;;ACTIVE;2.24;2.73 +52817-4;Nucleated cells;NCnc;Pt;Dial fld;Qn;Automated count;HEM/BC;1;Nucleated cells [#/volume] in Dialysis fluid by Automated count;Nuc cell # Dial fld Auto;;ACTIVE;2.24;2.70 +52818-2;Nucleated cells;NCnc;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Nucleated cells [#/volume] in Peritoneal fluid by Automated count;Nuc cell # Prt Auto;;ACTIVE;2.24;2.70 +52819-0;Nucleated cells;NCnc;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Nucleated cells [#/volume] in Pleural fluid by Automated count;Nuc cell # Plr Auto;;ACTIVE;2.24;2.70 +52820-8;Appearance;Aper;Pt;Pericard fld.spun;Nom;;SPEC;1;Appearance of Spun Pericardial fluid;Appearance spun Pcar;;ACTIVE;2.24;2.26 +52821-6;Saint Louis encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgG Ab [Presence] in Serum by Immunoassay;SLEV IgG Ser Ql IA;;ACTIVE;2.24;2.56 +52822-4;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Serum by Immunoassay;EEEV IgG Ser Ql IA;;ACTIVE;2.24;2.56 +52823-2;La Crosse virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;La Crosse virus IgG Ab [Presence] in Serum by Immunoassay;LACV IgG Ser Ql IA;;ACTIVE;2.24;2.58 +52824-0;La Crosse virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;La Crosse virus IgM Ab [Presence] in Serum by Immunoassay;LACV IgM Ser Ql IA;;ACTIVE;2.24;2.58 +52825-7;La Crosse virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;La Crosse virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;LACV IgM CSF Ql IA;;ACTIVE;2.24;2.58 +52826-5;Nursing management minimum data set panel;-;Pt;Facility;-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing Management Minimum Data Set panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.52 +52827-3;Facility unique identifier panel;-;Pt;Facility;-;NMMDS;PANEL.SURVEY.NMMDS;4;Facility unique identifier panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.52 +52828-1;Federal provider name;ID;Pt;Facility;Nom;;SURVEY.NMMDS;4;Federal provider name Facility;;;ACTIVE;2.24;2.27 +5282-9;Polio virus 1 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Polio virus 1 Ab [Titer] in Serum by Complement fixation;PV1 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52829-9;Place of service;Type;Pt;Facility;Nom;;SURVEY.NMMDS;4;Place of service;;;ACTIVE;2.24;2.68 +52830-7;State, district or territory federal abbreviation;Loc;Pt;Facility;Nom;;SURVEY.NMMDS;4;State, district or territory federal abbreviation Facility;;;ACTIVE;2.24;2.27 +52831-5;Postal code;Loc;Pt;Facility;Nom;;ADMIN.FACILITY;2;Postal code [Location] Facility;Postal code Facility;;ACTIVE;2.24;2.73 +52832-3;Survey reporting period start date;Date;Pt;Facility;Qn;;SURVEY.NMMDS;4;Survey reporting period start date Facility;;;ACTIVE;2.24;2.50 +52833-1;Survey reporting period end date;Date;Pt;Facility;Qn;;SURVEY.NMMDS;4;Survey reporting period end date Facility;;;ACTIVE;2.24;2.50 +52834-9;Nursing delivery unit or service panel;-;Pt;Facility;-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing delivery unit or service panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.52 +52835-6;Nursing unit name;ID;Pt;{Nursing unit};Nom;;SURVEY.NMMDS;4;Nursing unit name;;;ACTIVE;2.24;2.27 +52836-4;Nursing unit cost center;ID;Pt;Nursing unit;Nom;;SURVEY.NMMDS;4;Nursing unit cost center;;;ACTIVE;2.24;2.27 +5283-7;Polio virus 2 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 2 neutralizing antibody [Titer] in Serum by Neutralization test;PV2 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +52837-2;Type of nursing unit or service;Type;Pt;Nursing unit;Nom;NDNQI;SURVEY.NMMDS;4;Type of nursing unit or service [NDNQI];;;ACTIVE;2.24;2.46 +52838-0;Population distribution panel;-;Pt;{Type of nursing unit or service};-;NMMDS;PANEL.SURVEY.NMMDS;4;Population distribution panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.52 +52839-8;Total patient population;Num;Pt;{Type of nursing unit or service};Qn;;SURVEY.NMMDS;4;Total patient population #;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52840-6;Total population of fetal age;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of fetal age Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52841-4;Total population of age birth to 28D;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age birth to 28 days Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52842-2;Total population of age 29D to 1Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 29 days to 1 year Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52843-0;Total population of age 1-4Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 1-4 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52844-8;Total population of age 5-9Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 5-9 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +5284-5;Polio virus 2 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Polio virus 2 Ab [Titer] in Serum by Complement fixation;PV2 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52845-5;Total population of age 10-14Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 10-14 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52846-3;Total population of age 15-19Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 15-19 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52847-1;Total population of age 20-24Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 20-24 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52848-9;Total population of age 25-29Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 25-29 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52849-7;Total population of age 30-34Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 30-34 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52850-5;Total population of age 35-39Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 35-39 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52851-3;Total population of age 40-44Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 40-44 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +5285-2;Polio virus 3 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Polio virus 3 neutralizing antibody [Titer] in Serum by Neutralization test;PV3 NAb Titr Ser Nt;;ACTIVE;1.0;2.73 +52852-1;Total population of age 45-49Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 45-49 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52853-9;Total population of age 50-54Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 50-54 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52854-7;Total population of age 55-59Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 55-59 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52855-4;Total population of age 60-64Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 60-64 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52856-2;Total population of age 65-69Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 65-69 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52857-0;Total population of age 70-74Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 70-74 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52858-8;Total population of age 75-79Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 75-79 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52859-6;Total population of age 80-84Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age 80-84 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +5286-0;Polio virus 3 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Polio virus 3 Ab [Titer] in Serum by Complement fixation;PV3 Ab Titr Ser CF;;ACTIVE;1.0;2.73 +52860-4;Total population of age GE 85Y;NFr;Pt;{Nursing unit}^Population;Qn;;SURVEY.NMMDS;4;Total population of age GE 85 years Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52861-2;Catchment area panel;-;Pt;{Nursing unit}^Population;-;NMMDS;PANEL.SURVEY.NMMDS;4;Catchment area panel [NMMDS] Population;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.52 +52862-0;Neighborhood catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;Neighborhood catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52863-8;City or town catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;City or town catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52864-6;District catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;District catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52865-3;County catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;County catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52866-1;Parish catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;Parish catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52867-9;State catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;State catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52868-7;Region catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;Region catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52869-5;Nation catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;Nation catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52870-3;World catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;World catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52871-1;Aerospace catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;Aerospace catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52872-9;Nautical catchment area;NFr;Pt;{Nursing unit}^Population;Qn;Estimated;SURVEY.NMMDS;4;Nautical catchment area Population [Estimated];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.24;2.70 +52873-7;Cells.CD1a/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD1a cells/100 cells in Body fluid;CD1a Cells NFr Fld;;ACTIVE;2.24;2.70 +52874-5;Cells.CD1a/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD1a cells/100 cells in Bone marrow;CD1a Cells NFr Mar;;ACTIVE;2.24;2.70 +52875-2;Cells.CD1a/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD1a cells/100 cells in Cerebral spinal fluid;CD1a Cells NFr CSF;;ACTIVE;2.24;2.70 +52876-0;Cells.CD1a/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD1a cells/100 cells in Tissue;CD1a Cells NFr Tiss;;ACTIVE;2.24;2.70 +52877-8;Cells.cytoplasmic CD22/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD22 cells/100 cells in Blood;cyCD22 Cells NFr Bld;;ACTIVE;2.24;2.73 +5287-8;Burkholderia pseudomallei Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Burkholderia pseudomallei Ab [Units/volume] in Serum by Hemagglutination;B pseudomal Ab Ser HA-aCnc;;ACTIVE;1.0;2.69 +52878-6;Cells.cytoplasmic CD22/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;Cytoplasmic CD22 cells/100 cells in Body fluid;cyCD22 Cells NFr Fld;;ACTIVE;2.24;2.70 +52879-4;Cells.cytoplasmic CD22/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD22 cells/100 cells in Bone marrow;cyCD22 Cells NFr Mar;;ACTIVE;2.24;2.70 +52880-2;Cells.cytoplasmic CD22/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;Cytoplasmic CD22 cells/100 cells in Cerebral spinal fluid;cyCD22 Cells NFr CSF;;ACTIVE;2.24;2.70 +52881-0;Cells.cytoplasmic CD22/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;Cytoplasmic CD22 cells/100 cells in Tissue;cyCD22 Cells NFr Tiss;;ACTIVE;2.24;2.70 +52882-8;Cells.cytoplasmic CD3/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;Cytoplasmic CD3 cells/100 cells in Body fluid;cyCD3 Cells NFr Fld;;ACTIVE;2.24;2.70 +52883-6;Cells.cytoplasmic CD3/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD3 cells/100 cells in Bone marrow;cyCD3 Cells NFr Mar;;ACTIVE;2.24;2.70 +52884-4;Cells.cytoplasmic CD3/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;Cytoplasmic CD3 cells/100 cells in Cerebral spinal fluid;cyCD3 Cells NFr CSF;;ACTIVE;2.24;2.70 +52885-1;Cells.cytoplasmic CD3/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;Cytoplasmic CD3 cells/100 cells in Tissue;cyCD3 Cells NFr Tiss;;ACTIVE;2.24;2.70 +5288-6;Rabies virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rabies virus Ab [Units/volume] in Serum;RABV Ab Ser-aCnc;;ACTIVE;1.0;2.73 +52886-9;Tellurium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Tellurium [Moles/time] in 24 hour Urine;Tellurium 24h Ur-sRate;;ACTIVE;2.24;2.70 +52887-7;Bismuth;SRat;24H;Urine;Qn;;DRUG/TOX;1;Bismuth [Moles/time] in 24 hour Urine;Bismuth 24h Ur-sRate;;ACTIVE;2.24;2.70 +52888-5;Silicon;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Silicon [Moles/mass] in Tissue;Silicon Tiss-sCnt;;ACTIVE;2.24;2.70 +52889-3;Selenium;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Selenium [Moles/mass] in Tissue;Selenium Tiss-sCnt;;ACTIVE;2.24;2.70 +52890-1;Lead;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Lead [Moles/mass] in Tissue;Lead Tiss-sCnt;;ACTIVE;2.24;2.70 +52891-9;Chromium;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Chromium [Moles/mass] in Tissue;Chromium Tiss-sCnt;;ACTIVE;2.24;2.70 +52892-7;Aluminum;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Aluminum [Moles/mass] in Tissue;Aluminum Tiss-sCnt;;ACTIVE;2.24;2.70 +52893-5;Vanadium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vanadium [Moles/volume] in Serum or Plasma;Vanadium SerPl-sCnc;;ACTIVE;2.24;2.70 +5289-4;Reagin Ab;ACnc;Pt;CSF;Qn;VDRL;MICRO;1;Reagin Ab [Units/volume] in Cerebral spinal fluid by VDRL;VDRL CSF-aCnc;;ACTIVE;1.0;2.73 +52894-3;Titanium;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Titanium [Moles/volume] in Red Blood Cells;Titanium RBC-sCnc;;ACTIVE;2.24;2.70 +52895-0;Tellurium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tellurium [Moles/volume] in Urine;Tellurium Ur-sCnc;;ACTIVE;2.24;2.70 +52896-8;Silver;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Silver [Moles/volume] in Red Blood Cells;Silver RBC-sCnc;;ACTIVE;2.24;2.70 +52897-6;Platinum;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Platinum [Moles/volume] in Urine;Platinum Ur-sCnc;;ACTIVE;2.24;2.70 +52898-4;Bismuth;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bismuth [Moles/volume] in Urine;Bismuth Ur-sCnc;;ACTIVE;2.24;2.70 +52899-2;Beryllium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Beryllium [Moles/volume] in Serum or Plasma;Beryllium SerPl-sCnc;;ACTIVE;2.24;2.70 +52900-8;Vanadium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Vanadium/Creatinine [Molar ratio] in 24 hour Urine;Vanadium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52901-6;Vanadium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Vanadium/Creatinine [Molar ratio] in Urine;Vanadium/Creat Ur-sRto;;ACTIVE;2.24;2.70 +5290-2;Reagin Ab;PrThr;Pt;CSF;Ord;VDRL;MICRO;1;Reagin Ab [Presence] in Cerebral spinal fluid by VDRL;VDRL CSF Ql;;ACTIVE;1.0;2.73 +52902-4;Uranium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Uranium/Creatinine [Molar ratio] in 24 hour Urine;Uranium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52903-2;Uranium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Uranium/Creatinine [Molar ratio] in Urine;Uranium/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52904-0;Silver/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Silver/Creatinine [Molar ratio] in 24 hour Urine;Silver/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52905-7;Silver/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Silver/Creatinine [Molar ratio] in Urine;Silver/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52906-5;Bismuth/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Bismuth/Creatinine [Molar ratio] in 24 hour Urine;Bismuth/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52907-3;Bismuth/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Bismuth/Creatinine [Molar ratio] in Urine;Bismuth/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52908-1;Selenium;SRat;24H;Urine;Qn;;DRUG/TOX;1;Selenium [Moles/time] in 24 hour Urine;Selenium 24h Ur-sRate;;ACTIVE;2.24;2.70 +52909-9;Platinum;SRat;24H;Urine;Qn;;DRUG/TOX;1;Platinum [Moles/time] in 24 hour Urine;Platinum 24h Ur-sRate;;ACTIVE;2.24;2.70 +5291-0;Reagin Ab;ACnc;Pt;Ser;Qn;VDRL;MICRO;1;Reagin Ab [Units/volume] in Serum by VDRL;VDRL Ser-aCnc;;ACTIVE;1.0;2.73 +52910-7;Zinc;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Zinc [Moles/mass] in Tissue;Zinc Tiss-sCnt;;ACTIVE;2.24;2.70 +52911-5;Magnesium;SCnt;Pt;Tiss;Qn;;CHEM;1;Magnesium [Moles/mass] in Tissue;Magnesium Tiss-sCnt;;ACTIVE;2.24;2.70 +52912-3;Copper;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Copper [Moles/mass] in Tissue;Copper Tiss-sCnt;;ACTIVE;2.24;2.70 +52913-1;Selenium;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Selenium [Moles/volume] in Red Blood Cells;Selenium RBC-sCnc;;ACTIVE;2.24;2.70 +52914-9;Boron;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Boron [Moles/volume] in Serum or Plasma;Boron SerPl-sCnc;;ACTIVE;2.24;2.70 +52915-6;Aluminum;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Urine;Aluminum Ur-sCnc;;ACTIVE;2.24;2.70 +52916-4;Tin/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Tin/Creatinine [Molar ratio] in 24 hour Urine;Tin/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52917-2;Tin/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Tin/Creatinine [Molar ratio] in Urine;Tin/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52918-0;Thallium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Thallium/Creatinine [Molar ratio] in 24 hour Urine;Thallium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52919-8;Tellurium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Tellurium/Creatinine [Molar ratio] in Urine;Tellurium/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52920-6;Tellurium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Tellurium/Creatinine [Molar ratio] in 24 hour Urine;Tellurium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52921-4;Strontium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Strontium/Creatinine [Molar ratio] in 24 hour Urine;Strontium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52922-2;Strontium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Strontium/Creatinine [Molar ratio] in Urine;Strontium/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52923-0;Selenium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Selenium/Creatinine [Molar ratio] in Urine;Selenium/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52924-8;Platinum/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Platinum/Creatinine [Molar ratio] in 24 hour Urine;Platinum/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52925-5;Platinum/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Platinum/Creatinine [Molar ratio] in Urine;Platinum/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52926-3;Nickel/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Nickel/Creatinine [Molar ratio] in Urine;Nickel/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52927-1;Molybdenum/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Molybdenum/Creatinine [Molar ratio] in 24 hour Urine;Molybdenum/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +5292-8;Reagin Ab;PrThr;Pt;Ser;Ord;VDRL;MICRO;1;Reagin Ab [Presence] in Serum by VDRL;VDRL Ser Ql;;ACTIVE;1.0;2.73 +52928-9;Molybdenum/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Molybdenum/Creatinine [Molar ratio] in Urine;Molybdenum/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52929-7;Mercury/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Mercury/Creatinine [Molar ratio] in 24 hour Urine;Mercury/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52930-5;Manganese/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Manganese/Creatinine [Molar ratio] in 24 hour Urine;Manganese/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52931-3;Lead/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Lead/Creatinine [Molar ratio] in 24 hour Urine;Lead/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52932-1;Copper/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Copper/Creatinine [Molar ratio] in 24 hour Urine;Copper/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52933-9;Cobalt/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Cobalt/Creatinine [Molar ratio] in 24 hour Urine;Cobalt/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52934-7;Chromium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Chromium/Creatinine [Molar ratio] in 24 hour Urine;Chromium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52935-4;Beryllium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Beryllium/Creatinine [Molar ratio] in Urine;Beryllium/Creat Ur-sRto;;ACTIVE;2.24;2.70 +5293-6;Reovirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Reovirus Ab [Units/volume] in Serum;Reovirus Ab Ser-aCnc;;ACTIVE;1.0;2.69 +52936-2;Beryllium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Beryllium/Creatinine [Molar ratio] in 24 hour Urine;Beryllium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52937-0;Barium/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Barium/Creatinine [Molar ratio] in 24 hour Urine;Barium/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52938-8;Barium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Barium/Creatinine [Molar ratio] in Urine;Barium/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52939-6;Arsenic.inorganic/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic/Creatinine [Molar ratio] in Urine;Inorg Arsenic/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52940-4;Arsenic.inorganic/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic/Creatinine [Molar ratio] in 24 hour Urine;Inorg Arsenic/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52941-2;Antimony/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Antimony/Creatinine [Molar ratio] in Urine;Antimony/Creat Ur-sRto;;ACTIVE;2.24;2.70 +52942-0;Antimony/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Antimony/Creatinine [Molar ratio] in 24 hour Urine;Antimony/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52943-8;Aluminum/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Aluminum/Creatinine [Molar ratio] in Urine;Aluminum/Creat Ur-sRto;;ACTIVE;2.24;2.70 +5294-4;Respiratory syncytial virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Respiratory syncytial virus Ab [Titer] in Serum by Complement fixation;RSV Ab Titr Ser CF;;DISCOURAGED;1.0;2.73 +52944-6;Aluminum/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;Aluminum/Creatinine [Molar ratio] in 24 hour Urine;Aluminum/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +52945-3;LORazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;LORazepam [Presence] in Gastric fluid;LORazepam Gast Ql;;ACTIVE;2.24;2.56 +52946-1;diazePAM;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;diazePAM [Presence] in Gastric fluid;diazePAM Gast Ql;;ACTIVE;2.24;2.56 +52947-9;Dextromethorphan;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Dextromethorphan [Presence] in Gastric fluid;D-methorphan Gast Ql;;ACTIVE;2.24;2.56 +52948-7;cloBAZam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;cloBAZam [Presence] in Gastric fluid;cloBAZam Gast Ql;;ACTIVE;2.24;2.56 +52949-5;chlordiazePOXIDE;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;chlordiazePOXIDE [Presence] in Gastric fluid;Chlordiazep Gast Ql;;ACTIVE;2.24;2.56 +52950-3;Barbital;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Barbital [Presence] in Gastric fluid;Barbital Gast Ql;;ACTIVE;2.24;2.56 +5295-1;Respiratory syncytial virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Respiratory syncytial virus Ab [Titer] in Serum by Immunofluorescence;RSV Ab Titr Ser IF;;ACTIVE;1.0;2.70 +52951-1;Phencyclidine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phencyclidine [Moles/volume] in Urine;PCP Ur-sCnc;;ACTIVE;2.24;2.70 +52952-9;Opiates;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Opiates [Moles/volume] in Urine;Opiates Ur-sCnc;;ACTIVE;2.24;2.73 +52953-7;Cocaine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cocaine [Moles/volume] in Urine;Cocaine Ur-sCnc;;ACTIVE;2.24;2.70 +52954-5;Cannabinoids;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cannabinoids [Moles/volume] in Urine;Cannabinoids Ur-sCnc;;ACTIVE;2.24;2.73 +52955-2;Benzodiazepines;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzodiazepines [Moles/volume] in Urine;Benzodiaz Ur-sCnc;;ACTIVE;2.24;2.73 +52956-0;Barbiturates;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Barbiturates [Moles/volume] in Urine;Barbiturates Ur-sCnc;;ACTIVE;2.24;2.73 +52957-8;Amphetamine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amphetamine [Moles/volume] in Urine;Amphet Ur-sCnc;;ACTIVE;2.24;2.70 +52958-6;Methadone;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methadone [Moles/volume] in Urine;Methadone Ur-sCnc;;ACTIVE;2.24;2.70 +52959-4;cloBAZam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;cloBAZam [Presence] in Urine;cloBAZam Ur Ql;;ACTIVE;2.24;2.73 +52960-2;cloNIDine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;cloNIDine [Presence] in Urine;cloNIDine Ur Ql;;ACTIVE;2.24;2.73 +52961-0;Paraquat;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Paraquat [Presence] in Urine;Paraquat Ur Ql;;ACTIVE;2.24;2.56 +52962-8;Tobramycin;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Cerebral spinal fluid;Tobramycin CSF-mCnc;;ACTIVE;2.24;2.42 +52963-6;Flurazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Flurazepam [Presence] in Gastric fluid;Flurazepam Gast Ql;;ACTIVE;2.24;2.56 +52964-4;cloBAZam;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;cloBAZam [Moles/volume] in Gastric fluid;cloBAZam Gast-sCnc;;ACTIVE;2.24;2.70 +52965-1;clonazePAM;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;clonazePAM [Presence] in Gastric fluid;clonazePAM Gast Ql;;ACTIVE;2.24;2.56 +52966-9;Bacteria identified;Prid;Pt;Anal;Nom;Culture;MICRO;1;Bacteria identified in Anal by Culture;Bacteria Anal Cult;;ACTIVE;2.24;2.73 +52967-7;Bacteria identified;Prid;Pt;Gast fld;Nom;Culture;MICRO;1;Bacteria identified in Gastric fluid by Culture;Bacteria Gast Cult;;ACTIVE;2.24;2.24 +52968-5;Streptococcus agalactiae;PrThr;Pt;Anal;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Anal by Organism specific culture;Gp B Strep Anal Ql Cult;;ACTIVE;2.24;2.73 +5296-9;Reticulin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Reticulin Ab [Units/volume] in Serum;Reticulin Ab Ser-aCnc;;ACTIVE;1.0;2.73 +52969-3;Staphylococcus aureus.methicillin resistant isolate;PrThr;Pt;Nose;Ord;Organism specific culture;MICRO;1;Methicillin resistant Staphylococcus aureus [Presence] in Nose by Organism specific culture;MRSA Nose Ql Cult;;ACTIVE;2.24;2.73 +52970-1;CV2 Ab;ACnc;Pt;CSF;Qn;;SERO;1;CV2 Ab [Units/volume] in Cerebral spinal fluid;CV2 Ab CSF-aCnc;;ACTIVE;2.24;2.69 +52971-9;Immune complex;MCnc;Pt;Ser/Plas;Qn;IA;SERO;1;Immune complex [Mass/volume] in Serum or Plasma by Immunoassay;IC SerPl IA-mCnc;;ACTIVE;2.24;2.56 +52972-7;(Avena sativa+Fagopyrum esculentum+Sesamum indicum+Triticum aestivum+Zea mays) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 3 (Oat+Buckwheat+Sesame seed+Wheat+Corn) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix3 IgE Qn;;ACTIVE;2.24;2.73 +52973-5;Bacteria identified;Prid;Pt;Sptt;Nom;Culture;MICRO;1;Bacteria identified in Sputum tracheal aspirate by Culture;Bacteria Sputum trach asp Cult;;ACTIVE;2.24;2.73 +52974-3;Influenza virus B Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Influenza virus B Ab [Units/volume] in Serum by Complement fixation;FLUBV Ab Ser CF-aCnc;;ACTIVE;2.24;2.69 +52975-0;Respiratory syncytial virus Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Respiratory syncytial virus Ab [Units/volume] in Serum by Complement fixation;RSV Ab Ser CF-aCnc;;DISCOURAGED;2.24;2.69 +52976-8;Cytomegalovirus Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Cytomegalovirus Ab [Units/volume] in Serum by Complement fixation;CMV Ab Ser CF-aCnc;;ACTIVE;2.24;2.69 +5297-7;Rheumatoid factor;PrThr;Pt;Ser;Ord;LA;SERO;1;Rheumatoid factor [Presence] in Serum by Latex agglutination;Rheumatoid fact Ser Ql LA;;ACTIVE;1.0;2.73 +52977-6;Herpes simplex virus Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Herpes simplex virus Ab [Units/volume] in Serum by Complement fixation;HSV Ab Ser CF-aCnc;;ACTIVE;2.24;2.69 +52978-4;Varicella zoster virus Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Varicella zoster virus Ab [Units/volume] in Serum by Complement fixation;VZV Ab Ser CF-aCnc;;ACTIVE;2.24;2.69 +52979-2;Trichinella spiralis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Trichinella spiralis IgG Ab [Titer] in Serum by Immunofluorescence;T spiralis IgG Titr Ser IF;;ACTIVE;2.24;2.32 +529-8;Viomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Viomycin [Susceptibility] by Disk diffusion (KB);Viomycin Islt KB;;ACTIVE;1.0;2.19 +52980-0;Plasmodium sp Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Plasmodium sp IgG Ab [Titer] in Serum by Immunofluorescence;Plasmodium IgG Titr Ser IF;;ACTIVE;2.24;2.32 +52981-8;Herpes simplex virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus IgG Ab [Units/volume] in Serum by Immunoassay;HSV IgG Ser IA-aCnc;;ACTIVE;2.24;2.69 +52982-6;Echinococcus sp Ab.IgG1;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echinococcus sp IgG1 Ab [Units/volume] in Serum by Immunoassay;Echinococcus IgG1 Ser IA-aCnc;;ACTIVE;2.24;2.69 +52983-4;Echinococcus sp Ab.IgG4;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echinococcus sp IgG4 Ab [Units/volume] in Serum by Immunoassay;Echinococcus IgG4 Ser IA-aCnc;;ACTIVE;2.24;2.69 +52984-2;Cytomegalovirus Ab.IgG avidity;Ratio;Pt;Ser/Plas;Qn;IA;MICRO;1;Cytomegalovirus IgG Ab avidity [Ratio] in Serum or Plasma by Immunoassay;CMV IgG Avidity SerPl IA-Rto;;ACTIVE;2.24;2.73 +5298-5;Rheumatoid factor;PrThr;Pt;Ser;Ord;Sheep cell aggl;SERO;1;Rheumatoid factor [Presence] in Serum by Sheep Cell Agglutination;Rheumatoid fact Ser Ql Shp Aggl;;ACTIVE;1.0;2.56 +52985-9;Leishmania sp Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania sp IgG Ab [Titer] in Serum by Immunofluorescence;Leishmania IgG Titr Ser IF;;ACTIVE;2.24;2.32 +52986-7;Rubella virus Ab.IgG avidity;Ratio;Pt;Ser;Qn;IA;MICRO;1;Rubella virus IgG Ab avidity [Ratio] in Serum by Immunoassay;RUBV IgG Avidity Ser IA-Rto;;ACTIVE;2.24;2.73 +52987-5;Mycoplasma pneumoniae Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Mycoplasma pneumoniae Ab [Units/volume] in Serum by Complement fixation;M pneumo Ab Ser CF-aCnc;;ACTIVE;2.24;2.69 +52988-3;Leptospira sp DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Leptospira sp DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Leptospira DNA CSF Ql NAA+probe;;ACTIVE;2.24;2.63 +52989-1;Leptospira sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Leptospira sp DNA [Presence] in Blood by NAA with probe detection;Leptospira DNA Bld Ql NAA+probe;;ACTIVE;2.24;2.63 +52990-9;Leptospira sp DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Leptospira sp DNA [Presence] in Urine by NAA with probe detection;Leptospira DNA Ur Ql NAA+probe;;ACTIVE;2.24;2.63 +52991-7;Cells.cytoplasmic CD79a/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cytoplasmic CD79a cells/100 cells in Blood;cyCD79a cells NFr Bld;;ACTIVE;2.24;2.73 +52992-5;Cells.cytoplasmic CD79a/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;Cytoplasmic CD79a cells/100 cells in Body fluid;cyCD79a cells NFr Fld;;ACTIVE;2.24;2.70 +5299-3;Rheumatoid factor;Titr;Pt;Ser;Qn;LA;SERO;1;Rheumatoid factor [Titer] in Serum by Latex agglutination;Rheumatoid fact Titr Ser LA;;ACTIVE;1.0;2.73 +52993-3;Cells.cytoplasmic CD79a/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cytoplasmic CD79a cells/100 cells in Bone marrow;cyCD79a cells NFr Mar;;ACTIVE;2.24;2.70 +52994-1;Cells.cytoplasmic CD79a/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;Cytoplasmic CD79a cells/100 cells in Cerebral spinal fluid;cyCD79a cells NFr CSF;;ACTIVE;2.24;2.70 +52995-8;Cells.cytoplasmic CD79a/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;Cytoplasmic CD79a cells/100 cells in Tissue;cyCD79a cells NFr Tiss;;ACTIVE;2.24;2.70 +52996-6;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Blood by Flow cytometry (FC);TdT Cells NFr Bld FC;;ACTIVE;2.24;2.73 +52997-4;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;Body fld;Qn;Flow cytometry;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Body fluid by Flow cytometry (FC);TdT Cells NFr Fld FC;;ACTIVE;2.24;2.70 +52998-2;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;Tiss;Qn;Flow cytometry;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Tissue by Flow cytometry (FC);TdT Cells NFr Tiss FC;;ACTIVE;2.24;2.70 +52999-0;Leukocytes.disintegrated;NCnc;Pt;Bld;Qn;;HEM/BC;1;Leukocytes.disintegrated [#/volume] in Blood;WBC.disintegrated # Bld;;ACTIVE;2.24;2.70 +53000-6;Mitochondria M4 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Mitochondria M4 Ab [Units/volume] in Serum;Mitochondria M4 Ab Ser-aCnc;;ACTIVE;2.24;2.70 +53001-4;Mitochondria M9 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Mitochondria M9 Ab [Units/volume] in Serum;Mitochondria M9 Ab Ser-aCnc;;ACTIVE;2.24;2.70 +53002-2;Nuclear Ab pattern.fine speckled;Titr;Pt;Ser;Qn;IF;SERO;1;Fine speckled nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA fine speckled Titr Ser IF;;ACTIVE;2.24;2.70 +53003-0;Mitotic spindle apparatus Ab;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Mitotic spindle apparatus Ab [Titer] in Serum or Plasma by Immunofluorescence;Mitotic spindle app Ab Titr SerPl IF;;ACTIVE;2.24;2.73 +53004-8;Mitotic spindle apparatus Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Mitotic spindle apparatus Ab [Presence] in Serum or Plasma by Immunofluorescence;Mitotic spindle app Ab SerPl Ql IF;;ACTIVE;2.24;2.56 +53005-5;Fibrillarin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Fibrillarin Ab [Presence] in Serum by Immunofluorescence;Fibrillarin Ab Ser Ql IF;;ACTIVE;2.24;2.56 +53006-3;PCNA extractable nuclear Ab;Titr;Pt;Ser;Qn;IF;SERO;1;PCNA extractable nuclear Ab [Titer] in Serum by Immunofluorescence;ENA PCNA Ab Titr Ser IF;;ACTIVE;2.24;2.73 +53007-1;PM-SCL extractable nuclear Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;PM-SCL extractable nuclear Ab [Presence] in Serum by Immunofluorescence;ENA PM/SCL Ab Ser Ql IF;;ACTIVE;2.24;2.56 +53008-9;PM-SCL extractable nuclear Ab;Titr;Pt;Ser;Qn;IF;SERO;1;PM-SCL extractable nuclear Ab [Titer] in Serum by Immunofluorescence;ENA PM/SCL Ab Titr Ser IF;;ACTIVE;2.24;2.34 +5300-9;Rheumatoid factor;Titr;Pt;Ser;Qn;Sheep cell aggl;SERO;1;Rheumatoid factor [Titer] in Serum by Sheep Cell Agglutination;Rheumatoid fact Titr Ser Shp Aggl;;ACTIVE;1.0;2.73 +53009-7;Ribosomal Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Ribosomal Ab [Presence] in Serum by Immunofluorescence;Ribosomal Ab Ser Ql IF;;ACTIVE;2.24;2.56 +53010-5;Signal recognition particle Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Signal Recognition Particle (SRP) Ab [Presence] in Serum or Plasma by Immunofluorescence;SRP Ab SerPl Ql IF;;ACTIVE;2.24;2.56 +53011-3;Signal recognition particle Ab;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Signal Recognition Particle (SRP) Ab [Titer] in Serum or Plasma by Immunofluorescence;SRP Ab Titr SerPl IF;;ACTIVE;2.24;2.70 +53012-1;Neutrophil cytoplasmic Ab.atypical;Titr;Pt;Ser;Qn;IF;SERO;1;Neutrophil Cytoplasmic Ab atypical [Titer] in Serum by Immunofluorescence;Atyp ANCA Titr Ser IF;;ACTIVE;2.24;2.73 +53013-9;Bactericidal permeability increasing protein Ab;PrThr;Pt;Ser;Ord;;SERO;1;Bactericidal permeability increasing protein Ab [Presence] in Serum;BPI Ab Ser Ql;;ACTIVE;2.24;2.56 +53014-7;Nucleosome Ab;ACnc;Pt;Ser;Qn;;SERO;1;Nucleosome Ab [Units/volume] in Serum;Nucleosome Ab Ser-aCnc;;ACTIVE;2.24;2.70 +53015-4;Nucleosome Ab;PrThr;Pt;Ser;Ord;;SERO;1;Nucleosome Ab [Presence] in Serum;Nucleosome Ab Ser Ql;;ACTIVE;2.24;2.56 +53016-2;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;Ser;Ord;;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Serum;ENA SS-A 52kD Ab Ser Ql;;ACTIVE;2.24;2.73 +5301-7;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA RNP Ab Ser Ql IA;;ACTIVE;1.0;2.73 +53017-0;Sjogrens syndrome-A extractable nuclear 52kD Ab;ACnc;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Units/volume] in Serum;ENA SS-A 52kD Ab Ser-aCnc;;ACTIVE;2.24;2.73 +53018-8;Sjogrens syndrome-A extractable nuclear 60kD Ab;PrThr;Pt;Ser;Ord;;SERO;1;Sjogrens syndrome-A extractable nuclear 60kD Ab [Presence] in Serum;ENA SS-a 60kD Ab Ser Ql;;ACTIVE;2.24;2.56 +53019-6;Sjogrens syndrome-A extractable nuclear 60kD Ab;ACnc;Pt;Ser;Qn;;SERO;1;Sjogrens syndrome-A extractable nuclear 60kD Ab [Units/volume] in Serum;ENA SS-a 60kD Ab Ser-aCnc;;ACTIVE;2.24;2.73 +53020-4;Complement C1q Ab;PrThr;Pt;Ser;Ord;;HEM/BC;1;Complement C1q Ab [Presence] in Serum;C1q Ab Ser Ql;;ACTIVE;2.24;2.56 +53021-2;Salivary gland Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Salivary gland Ab [Titer] in Serum by Immunofluorescence;Salivary Gland Ab Titr Ser IF;;ACTIVE;2.24;2.70 +53022-0;U1 small nuclear ribonucleoprotein Ab;PrThr;Pt;Ser;Ord;;SERO;1;U1 small nuclear ribonucleoprotein Ab [Presence] in Serum;U1 snRNP Ab Ser Ql;;ACTIVE;2.24;2.73 +53023-8;Tissue transglutaminase Ab;PrThr;Pt;Ser;Ord;;SERO;1;Tissue transglutaminase Ab [Presence] in Serum;tTG Ab Ser Ql;;ACTIVE;2.24;2.73 +53024-6;Saccharomyces cerevisiae Ab;PrThr;Pt;Ser;Ord;;ALLERGY;1;Baker's yeast Ab [Presence] in Serum;Baker's yeast Ab Ql;;ACTIVE;2.24;2.56 +5302-5;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA RNP Ab Ser Ql ID;;ACTIVE;1.0;2.73 +53025-3;Gliadin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Gliadin Ab [Presence] in Serum;Gliadin Ab Ser Ql;;ACTIVE;2.24;2.73 +53026-1;Tissue transglutaminase Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Tissue transglutaminase IgG Ab [Presence] in Serum;tTG IgG Ser Ql;;ACTIVE;2.24;2.73 +53027-9;Cyclic citrullinated peptide Ab;ACnc;Pt;Ser;Qn;;SERO;1;Cyclic citrullinated peptide Ab [Units/volume] in Serum;cCP Ab Ser-aCnc;;ACTIVE;2.24;2.73 +53028-7;Cyclic citrullinated peptide Ab;PrThr;Pt;Ser;Ord;;SERO;1;Cyclic citrullinated peptide Ab [Presence] in Serum;cCP Ab Ser Ql;;ACTIVE;2.24;2.73 +53029-5;Neutrophil cytoplasmic Ab.perinuclear.atypical;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil cytoplasmic Ab.perinuclear.atypical [Presence] in Serum by Immunofluorescence;p-ANCA atypical Ser Ql IF;;ACTIVE;2.24;2.73 +53030-3;Liver kidney microsomal Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Liver kidney microsomal Ab [Presence] in Serum by Immunofluorescence;LKM Ab Ser Ql IF;;ACTIVE;2.24;2.73 +53031-1;Signal recognition particle Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Signal Recognition Particle (SRP) Ab [Units/volume] in Serum or Plasma;SRP Ab SerPl-aCnc;;ACTIVE;2.24;2.70 +53032-9;U1 small nuclear ribonucleoprotein 70kD Ab;PrThr;Pt;Ser;Ord;;SERO;1;U1 small nuclear ribonucleoprotein 70kD Ab [Presence] in Serum;U1 snRNP70 Ab Ser Ql;;ACTIVE;2.24;2.56 +5303-3;Rickettsia (Proteus OX19) Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rickettsia (Proteus OX19) Ab [Presence] in Serum by Latex agglutination;Proteus OX19 Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53033-7;Include all data of the selected type that represents observations made two Y or less before the starting date of service;Scope.modifier.time window;Pt;X12^277;-;;ATTACH.MODIFIER;3;Include all data of the selected type that represents observations made two years or less before the starting date of service;;;ACTIVE;2.24;2.44 +53034-5;Allelic state;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Allelic state;Allelic state;;ACTIVE;2.24;2.68 +53035-2;DNA marker assessed;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;DNA marker assessed [Identifier];DNA marker assessed;;ACTIVE;2.24;2.73 +53036-0;Filler DNA analysis test identifier;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Filler DNA analysis test identifier [Identifier];Filler DNA analysis test ID;;ACTIVE;2.24;2.68 +53037-8;Genetic disease sequence variation interpretation;Imp;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genetic variation clinical significance [Imp];Gene dis seq var interp-Imp;;ACTIVE;2.24;2.73 +53038-6;Genetic disease analysis overall diagnostic interpretation;Imp;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;Deprecated Genetic disease analysis overall interpretation [interpretation] in Blood or Tissue by Molecular genetics method;Deprecated Gene dis anal overall Dx int;;DEPRECATED;2.24;2.68 +53039-4;Genetic disease analysis overall carrier interpretation;Imp;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genetic disease analysis overall carrier interpretation;Gene dis anl carrier interp-Imp;;ACTIVE;2.24;2.73 +53040-2;Drug metabolism sequence variation interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;HL7.GENETICS;1;Genetic variation's effect on drug metabolism;Drug metab seq var interp-Imp;;ACTIVE;2.24;2.73 +5304-1;Rickettsia (Proteus OX2) Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rickettsia (Proteus OX2) Ab [Presence] in Serum by Latex agglutination;Proteus OX2 Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53041-0;DNA region of interest panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;DNA region of interest panel;DNA region of interest Pnl;;ACTIVE;2.24;2.68 +53042-8;DNA marker assessed panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;DNA marker assessed panel;DNA marker assessed Pnl;;ACTIVE;2.24;2.68 +53043-6;DNA marker analysis test coverage panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;DNA marker analysis test coverage panel;DNA mark analysis cover Pnl;;ACTIVE;2.24;2.68 +53044-4;DNA marker identified panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;DNA marker identified panel;DNA marker Pnl;;ACTIVE;2.24;2.68 +53045-1;Reference sequence alteration;Prid;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Reference sequence alteration [Identifier];Ref sequence alteration;;ACTIVE;2.24;2.68 +53046-9;Beta globulin+Gamma globulin;MCnc;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta globulin+Gamma globulin [Mass/volume] in Body fluid by Electrophoresis;B+G-Globulin Fld Elph-mCnc;;ACTIVE;2.24;2.70 +53047-7;Chromogranin A;MCnc;Pt;Body fld;Qn;;CHEM;1;Chromogranin A [Mass/volume] in Body fluid;CgA Fld-mCnc;;ACTIVE;2.24;2.70 +53048-5;Ferritin;MCnc;Pt;Body fld;Qn;;CHEM;1;Ferritin [Mass/volume] in Body fluid;Ferritin Fld-mCnc;;ACTIVE;2.24;2.70 +53049-3;Glucose^pre-meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --pre-meal;Glucose pre-meal SerPl-mCnc;;ACTIVE;2.24;2.70 +53050-1;Glucose;MCnc;Pt;TPN;Qn;;CHEM;1;Glucose [Mass/volume] in Total parental nutrition;Glucose TPN-mCnc;;ACTIVE;2.24;2.70 +53051-9;Beta globulin+Gamma globulin/Protein.total;MFr;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Beta globulin+Gamma globulin/Protein.total in Body fluid by Electrophoresis;B+G-Globulin MFr Fld Elph;;ACTIVE;2.24;2.70 +53052-7;Collagen crosslinked C-telopeptide;MRat;24H;Urine;Qn;;CHEM;1;Collagen crosslinked C-telopeptide [Mass/time] in 24 hour Urine;Collagen CTx 24h Ur-mRate;;ACTIVE;2.24;2.70 +53053-5;Carnitine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Carnitine [Moles/volume] in Amniotic fluid;Carnitine Amn-sCnc;;ACTIVE;2.24;2.70 +53054-3;Carnitine.free (C0);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Carnitine free (C0) [Moles/volume] in Amniotic fluid;Carnitine Free Amn-sCnc;;ACTIVE;2.24;2.70 +53055-0;Creatine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Creatine [Moles/volume] in Amniotic fluid;Creatine Amn-sCnc;;ACTIVE;2.24;2.70 +53056-8;Decanoylcarnitine (C10);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Decanoylcarnitine (C10) [Moles/volume] in Amniotic fluid;Decanoylcarn Amn-sCnc;;ACTIVE;2.24;2.70 +53057-6;Decenoylcarnitine (C10:1);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Decenoylcarnitine (C10:1) [Moles/volume] in Amniotic fluid;Decenoylcarn Amn-sCnc;;ACTIVE;2.24;2.70 +5305-8;Rickettsia (Proteus OXK) Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rickettsia (Proteus OXK) Ab [Presence] in Serum by Latex agglutination;Proteus OXK Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53058-4;Dodecanoylcarnitine (C12);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dodecanoylcarnitine (C12) [Moles/volume] in Amniotic fluid;Dodecanoylcarn Amn-sCnc;;ACTIVE;2.24;2.70 +53059-2;Dodecenoylcarnitine (C12:1);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1) [Moles/volume] in Amniotic fluid;Dodecenoylcarn Amn-sCnc;;ACTIVE;2.24;2.70 +530-6;Viomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Viomycin [Susceptibility] by Serum bactericidal titer;Viomycin Titr SBT;;ACTIVE;1.0;2.32 +53060-0;Butyrylcarnitine (C4);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Butyrylcarnitine (C4) [Moles/volume] in Amniotic fluid;Butyrylcarn Amn-sCnc;;ACTIVE;2.24;2.70 +53061-8;Ketones;SCnc;Pt;Bld;Qn;;CHEM;1;Ketones [Moles/volume] in Blood;Ketones Bld-sCnc;;ACTIVE;2.24;2.73 +53062-6;Argininosuccinate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Argininosuccinate [Moles/volume] in DBS;Argininosuccinate DBS-sCnc;;ACTIVE;2.24;2.73 +53063-4;Beta alanine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Beta alanine [Moles/volume] in DBS;B-Alanine DBS-sCnc;;ACTIVE;2.24;2.70 +53064-2;Beta aminoisobutyrate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/volume] in DBS;B-AIB DBS-sCnc;;ACTIVE;2.24;2.70 +53065-9;Butyrylcarnitine (C4);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Butyrylcarnitine (C4) [Moles/volume] in DBS;Butyrylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +5306-6;Rickettsia sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Rickettsia sp Ab [Titer] in Serum by Complement fixation;Rickettsia Ab Titr Ser CF;;ACTIVE;1.0;2.70 +53066-7;Cystathionine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Cystathionine [Moles/volume] in DBS;Cystathionin DBS-sCnc;;ACTIVE;2.24;2.70 +53067-5;Argininosuccinate;SCnc;Pt;Body fld;Qn;;CHEM;1;Argininosuccinate [Moles/volume] in Body fluid;Argininosuccinate Fld-sCnc;;ACTIVE;2.24;2.70 +53068-3;Beta alanine;SCnc;Pt;Body fld;Qn;;CHEM;1;Beta alanine [Moles/volume] in Body fluid;B-Alanine Fld-sCnc;;ACTIVE;2.24;2.70 +53069-1;Cystathionine;SCnc;Pt;Body fld;Qn;;CHEM;1;Cystathionine [Moles/volume] in Body fluid;Cystathionin Fld-sCnc;;ACTIVE;2.24;2.70 +53070-9;Butyrylcarnitine (C4);SCnc;Pt;CSF;Qn;;CHEM;1;Butyrylcarnitine (C4) [Moles/volume] in Cerebral spinal fluid;Butyrylcarn CSF-sCnc;;ACTIVE;2.24;2.70 +53071-7;Carnitine;SCnc;Pt;CSF;Qn;;CHEM;1;Carnitine [Moles/volume] in Cerebral spinal fluid;Carnitine CSF-sCnc;;ACTIVE;2.24;2.70 +53072-5;Carnitine.free (C0);SCnc;Pt;CSF;Qn;;CHEM;1;Carnitine free (C0) [Moles/volume] in Cerebral spinal fluid;Carnitine Free CSF-sCnc;;ACTIVE;2.24;2.70 +53073-3;Ceruloplasmin;SCnc;Pt;CSF;Qn;;CHEM;1;Ceruloplasmin [Moles/volume] in Cerebral spinal fluid;Ceruloplasmin CSF-sCnc;;ACTIVE;2.24;2.70 +5307-4;Rickettsia rickettsii Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia rickettsii IgG Ab [Titer] in Serum by Immunofluorescence;R rickettsi IgG Titr Ser IF;;ACTIVE;1.0;2.73 +53074-1;Creatine;SCnc;Pt;CSF;Qn;;CHEM;1;Creatine [Moles/volume] in Cerebral spinal fluid;Creatine CSF-sCnc;;ACTIVE;2.24;2.70 +53075-8;Decanoylcarnitine (C10);SCnc;Pt;CSF;Qn;;CHEM;1;Decanoylcarnitine (C10) [Moles/volume] in Cerebral spinal fluid;Decanoylcarn CSF-sCnc;;ACTIVE;2.24;2.70 +53076-6;Decenoylcarnitine (C10:1);SCnc;Pt;CSF;Qn;;CHEM;1;Decenoylcarnitine (C10:1) [Moles/volume] in Cerebral spinal fluid;Decenoylcarn CSF-sCnc;;ACTIVE;2.24;2.70 +53077-4;Levodopa;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Levodopa [Moles/volume] in Cerebral spinal fluid;L-Dopa CSF-sCnc;;ACTIVE;2.24;2.70 +53078-2;Dodecanoylcarnitine (C12);SCnc;Pt;CSF;Qn;;CHEM;1;Dodecanoylcarnitine (C12) [Moles/volume] in Cerebral spinal fluid;Dodecanoylcarn CSF-sCnc;;ACTIVE;2.24;2.70 +53079-0;Dodecenoylcarnitine (C12:1);SCnc;Pt;CSF;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1) [Moles/volume] in Cerebral spinal fluid;Dodecenoylcarn CSF-sCnc;;ACTIVE;2.24;2.70 +53080-8;Cystine;SCnt;Pt;CVS;Qn;;CHEM;1;Cystine [Moles/mass] in Chorionic villus sample;Cystine CVS-sCnt;;ACTIVE;2.24;2.70 +53081-6;Ammonia;SCnc;Pt;Dial fld;Qn;;CHEM;1;Ammonia [Moles/volume] in Dialysis fluid;Ammonia Dial fld-sCnc;;ACTIVE;2.24;2.70 +5308-2;Rickettsia rickettsii Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia rickettsii IgM Ab [Titer] in Serum by Immunofluorescence;R rickettsi IgM Titr Ser IF;;ACTIVE;1.0;2.73 +53082-4;Cholesterol;SCnc;Pt;Dial fld;Qn;;CHEM;1;Cholesterol [Moles/volume] in Dialysis fluid;Cholest Dial fld-sCnc;;ACTIVE;2.24;2.70 +53083-2;Bilirubin.glucuronidated;SCnc;Pt;Dial fld;Qn;;CHEM;1;Bilirubin.conjugated [Moles/volume] in Dialysis fluid;Bilirub Conj Dial fld-sCnc;;ACTIVE;2.24;2.70 +53084-0;Glucose;SCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Glucose [Moles/volume] in Nonbiological fluid;Glucose Fld.NB-sCnc;;ACTIVE;2.24;2.70 +53085-7;Base excess;SCnc;Pt;Flu.nonbiological;Qn;Calculated;CHEM;1;Base excess in Nonbiological fluid by calculation;Base excess Fld.NB Calc-sCnc;;ACTIVE;2.24;2.70 +53086-5;Bicarbonate;SCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Nonbiological fluid;HCO3 Fld.NB-sCnc;;ACTIVE;2.24;2.70 +53087-3;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Nonbiological fluid;Ca-I adj pH7.4 Fld.NB-sCnc;;ACTIVE;2.24;2.70 +53088-1;Calcium.ionized;SCnc;Pt;Flu.nonbiological;Qn;ISE;CHEM;1;Calcium.ionized [Moles/volume] in Nonbiological fluid by Ion-selective membrane electrode (ISE);Ca-I Fld.NB ISE-sCnc;;ACTIVE;2.24;2.70 +53089-9;Carbon dioxide;SCnc;Pt;Flu.nonbiological;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Nonbiological fluid by calculation;CO2 Fld.NB Calc-sCnc;;ACTIVE;2.24;2.70 +5309-0;Rickettsia spotted fever group Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rickettsia spotted fever group Ab [Units/volume] in Serum by Immunoassay;Rick SF Ab Ser IA-aCnc;;ACTIVE;1.0;2.69 +53090-7;Carbon dioxide;SCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Nonbiological fluid;CO2 Fld.NB-sCnc;;ACTIVE;2.24;2.70 +53091-5;Nitrogen.nonprotein;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Nitrogen.nonprotein [Moles/volume] in Serum or Plasma;Nitrogen Nonprotein SerPl-sCnc;;ACTIVE;2.24;2.70 +53092-3;Collagen crosslinked C-telopeptide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Collagen crosslinked C-telopeptide [Moles/volume] in Serum or Plasma;Collagen CTx SerPl-sCnc;;ACTIVE;2.24;2.73 +53093-1;Glucose^post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --post XXX challenge;Glucose p chal SerPl-sCnc;;ACTIVE;2.24;2.70 +53094-9;Glucose^post meal;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --post meal;Glucose p meal SerPl-sCnc;;ACTIVE;2.24;2.70 +53095-6;Carnitine.free (C0)/Carnitine.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Carnitine free (C0)/Carnitine.total in DBS;Carnitine Free SFr DBS;;ACTIVE;2.24;2.70 +53096-4;Carnitine.free (C0)/Carnitine.total;SFr;Pt;CSF;Qn;;CHEM;1;Carnitine free (C0)/Carnitine.total in Cerebral spinal fluid;Carnitine Free SFr CSF;;ACTIVE;2.24;2.70 +53097-2;3-O-Methyldopa;SRat;24H;Urine;Qn;;DRUG/TOX;1;3-O-Methyldopa [Moles/time] in 24 hour Urine;3-o-methyldopa 24h Ur-sRate;;ACTIVE;2.24;2.70 +53098-0;3-Methoxy-4-Hydroxyphenylglycol;SRat;24H;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Moles/time] in 24 hour Urine;3Me4OH-phenylglycol 24h Ur-sRate;;ACTIVE;2.24;2.70 +53099-8;Chloride;SCnc;Pt;TPN;Qn;;CHEM;1;Chloride [Moles/volume] in Total parental nutrition;Chloride TPN-sCnc;;ACTIVE;2.24;2.70 +53100-4;Calcium;SCnc;Pt;TPN;Qn;;CHEM;1;Calcium [Moles/volume] in Total parental nutrition;Calcium TPN-sCnc;;ACTIVE;2.24;2.70 +53101-2;Kynurenate;SCnc;Pt;Urine;Qn;;CHEM;1;Kynurenate [Moles/volume] in Urine;Kynuren Ur-sCnc;;ACTIVE;2.24;2.70 +53102-0;Decanoylcarnitine (C10);SCnc;Pt;Urine;Qn;;CHEM;1;Decanoylcarnitine (C10) [Moles/volume] in Urine;Decanoylcarn Ur-sCnc;;ACTIVE;2.24;2.70 +53103-8;Decenoylcarnitine (C10:1);SCnc;Pt;Urine;Qn;;CHEM;1;Decenoylcarnitine (C10:1) [Moles/volume] in Urine;Decenoylcarn Ur-sCnc;;ACTIVE;2.24;2.70 +53104-6;Dodecenoylcarnitine (C12:1);SCnc;Pt;Urine;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1) [Moles/volume] in Urine;Dodecenoylcarn Ur-sCnc;;ACTIVE;2.24;2.70 +53105-3;3-Hydroxybutyrylcarnitine (C4-OH);SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in Urine;3OH-Butyrcarn Ur-sCnc;;ACTIVE;2.24;2.70 +53106-1;Butyrylcarnitine (C4);SCnc;Pt;Urine;Qn;;CHEM;1;Butyrylcarnitine (C4) [Moles/volume] in Urine;Butyrylcarn Ur-sCnc;;ACTIVE;2.24;2.70 +53107-9;Kynurenate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Kynurenate/Creatinine [Molar ratio] in Urine;Kynuren/Creat Ur-sRto;;ACTIVE;2.24;2.70 +5310-8;Rickettsia spotted fever group Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rickettsia spotted fever group Ab [Presence] in Serum by Latex agglutination;Rick SF Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53108-7;Decenoylcarnitine (C10:1)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Decenoylcarnitine (C10:1)/Creatinine [Molar ratio] in Urine;Decenoylcarn/Creat Ur-sRto;;ACTIVE;2.24;2.70 +53109-5;Docosenoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Docosenoate (C22:1)/Creatinine [Molar ratio] in Urine;Docosenoate/Creat Ur-sRto;;ACTIVE;2.24;2.70 +53110-3;5-Hydroxytryptophan/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan/Creatinine [Molar ratio] in 24 hour Urine;5OH-Tryptophan/Creat 24h Ur-sRto;;ACTIVE;2.24;2.70 +53111-1;Butyrylcarnitine (C4)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Butyrylcarnitine (C4)/Creatinine [Molar ratio] in Urine;Butyrylcarn/Creat Ur-sRto;;ACTIVE;2.24;2.70 +53112-9;Carnitine.free (C0)/Carnitine.total;SFr;Pt;Amnio fld;Qn;;CHEM;1;Carnitine free (C0)/Carnitine.total in Amniotic fluid;Carnitine Free SFr Amn;;ACTIVE;2.24;2.70 +53113-7;Spermatids/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatids/100 spermatozoa in Semen;Spermatids NFr Smn;;ACTIVE;2.24;2.40 +53114-5;Glucose^post CFst;SCnc;Pt;Urine;Qn;;CHAL;1;Fasting glucose [Moles/volume] in Urine;Glucose p fast Ur-sCnc;;ACTIVE;2.24;2.34 +53115-2;Granulocytes.immature;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Immature granulocytes [#/volume] in Blood by Automated count;Imm Granulocytes # Bld Auto;;ACTIVE;2.24;2.73 +5311-6;Rickettsia spotted fever group Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia spotted fever group Ab [Titer] in Serum by Immunofluorescence;Rick SF Ab Titr Ser IF;;ACTIVE;1.0;2.70 +53116-0;Base deficit;SCnc;Pt;BldMV;Qn;;CHEM;1;Base deficit in Mixed venous blood;Base deficit BldMV-sCnc;;ACTIVE;2.24;2.73 +53117-8;Hemoglobin.thermolabile;PrThr;Pt;RBC;Ord;;HEM/BC;1;Thermolabile hemoglobin [Presence] in Red Blood Cells;Hgb TL RBC Ql;;ACTIVE;2.24;2.56 +53118-6;Sulfonamide crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Sulfonamide crystals [#/area] in Urine sediment by Microscopy high power field;Sulfonamide cry #/area UrnS HPF;;ACTIVE;2.24;2.40 +53119-4;Tyrosine crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Tyrosine crystals [#/area] in Urine sediment by Microscopy high power field;Tyrosine Cry #/area UrnS HPF;;ACTIVE;2.24;2.73 +53120-2;Creatinine;SRat;1H;Urine;Qn;;CHEM;1;Creatinine [Moles/time] in 1 hour Urine;Creat 1h Ur-sRate;;ACTIVE;2.24;2.42 +53121-0;Protein;MRat;1H;Urine;Qn;;CHEM;1;Protein [Mass/time] in 1 hour Urine;Prot 1h Ur-mRate;;ACTIVE;2.24;2.30 +53122-8;Sodium;SRat;1H;Urine;Qn;;CHEM;1;Sodium [Moles/time] in 1 hour Urine;Sodium 1h Ur-sRate;;ACTIVE;2.24;2.42 +53123-6;Potassium;SRat;1H;Urine;Qn;;CHEM;1;Potassium [Moles/time] in 1 hour Urine;Potassium 1h Ur-sRate;;ACTIVE;2.24;2.42 +5312-4;Rickettsia spotted fever group Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rickettsia spotted fever group IgG Ab [Units/volume] in Serum by Immunoassay;Rick SF IgG Ser IA-aCnc;;ACTIVE;1.0;2.69 +53124-4;Calcium;SRat;1H;Urine;Qn;;CHEM;1;Calcium [Moles/time] in 1 hour Urine;Calcium 1h Ur-sRate;;ACTIVE;2.24;2.44 +53125-1;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Bone marrow;Monos+Macros/leuk NFr Mar;;ACTIVE;2.24;2.50 +53126-9;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Blood;Monos+Macros/leuk NFr Bld;;ACTIVE;2.24;2.50 +53127-7;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Tiss;Qn;;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Tissue;Monos+Macros/leuk NFr Tiss;;ACTIVE;2.24;2.50 +53128-5;Bacterial casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Bacterial casts [#/area] in Urine sediment by Microscopy low power field;Bacterial casts #/area UrnS LPF;;ACTIVE;2.24;2.73 +53129-3;Sodium urate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Sodium urate crystals [#/area] in Urine sediment by Microscopy high power field;Na Urate Cry #/area UrnS HPF;;ACTIVE;2.24;2.73 +53130-1;Ammonium urate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Ammonium urate crystals [#/area] in Urine sediment by Microscopy low power field;Amm Urate Cry #/area UrnS LPF;;ACTIVE;2.24;2.40 +53131-9;Calcium oxalate crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Calcium oxalate crystals [#/area] in Urine sediment by Microscopy low power field;CaOx Cry #/area UrnS LPF;;ACTIVE;2.24;2.73 +5313-2;Rickettsia spotted fever group Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia spotted fever group IgG Ab [Titer] in Serum by Immunofluorescence;Rick SF IgG Titr Ser IF;;ACTIVE;1.0;2.73 +53132-7;Epithelial cells.non-squamous;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Epithelial cells.non-squamous [#/area] in Urine sediment by Microscopy low power field;Non-sq Epi Cells #/area UrnS LPF;;ACTIVE;2.24;2.73 +53133-5;Cholesterol.in LDL;SCnc;Pt;Body fld;Qn;;CHEM;1;Cholesterol in LDL [Moles/volume] in Body fluid;LDLc Fld-sCnc;;ACTIVE;2.24;2.38 +53134-3;Amylase isoenzymes;Imp;Pt;Body fld;Nar;;CHEM;1;Amylase isoenzymes [Interpretation] in Body fluid Narrative;Amylase Isos Fld-Imp;;ACTIVE;2.24;2.24 +53135-0;Cholesterol.in HDL;SCnc;Pt;Dial fld;Qn;;CHEM;1;Cholesterol in HDL [Moles/volume] in Dialysis fluid;HDLc Dial fld-sCnc;;ACTIVE;2.24;2.42 +53136-8;Organic acids pattern;Imp;Pt;Body fld;Nom;;CHEM;1;Organic acids pattern [Interpretation] in Body fluid;Organic Acids Pattern Fld-Imp;;ACTIVE;2.24;2.24 +53137-6;Urea;SRat;1H;Urine;Qn;;CHEM;1;Urea [Moles/time] in 1 hour Urine;Urea 1h Ur-sRate;;ACTIVE;2.24;2.42 +53138-4;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;BldA;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Arterial blood;Ca-I adj pH7.4 BldA-sCnc;;ACTIVE;2.24;2.42 +53139-2;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;BldC;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Capillary blood;Ca-I adj pH7.4 BldC-sCnc;;ACTIVE;2.24;2.42 +531-4;Zidovudine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Zidovudine [Susceptibility];Zidovudine Susc Islt;;ACTIVE;1.0;2.19 +5314-0;Rickettsia spotted fever group Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rickettsia spotted fever group IgM Ab [Units/volume] in Serum by Immunoassay;Rick SF IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +53140-0;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;BldV;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Venous blood;Ca-I adj pH7.4 BldV-sCnc;;ACTIVE;2.24;2.42 +53141-8;17-Hydroxyprogesterone^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;17OHP 30M p chal SerPl-sCnc;;ACTIVE;2.24;2.34 +53142-6;Nitrogen;SRat;24H;Stool;Qn;;CHEM;1;Nitrogen [Moles/time] in 24 hour Stool;N2 24h Stl-sRate;;ACTIVE;2.24;2.42 +53143-4;Hydrogen ion;SCnc;Pt;BldMV;Qn;;CHEM;1;Hydrogen ion [Moles/volume] in Mixed venous blood;H ion BldMV-sCnc;;ACTIVE;2.24;2.42 +53144-2;Somatotropin^75M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --75 minutes post XXX challenge;GH 75M p chal SerPl-mCnc;;ACTIVE;2.24;2.58 +53145-9;Lutropin^45M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --45 minutes post XXX challenge;LH 45M p chal SerPl-aCnc;;ACTIVE;2.24;2.68 +53146-7;Follitropin^45M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --45 minutes post XXX challenge;FSH 45M p chal SerPl-aCnc;;ACTIVE;2.24;2.38 +53147-5;Follitropin^2H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --2 hours post XXX challenge;FSH 2h p chal SerPl-aCnc;;ACTIVE;2.24;2.73 +53148-3;DNA double strand Ab;PrThr;Pt;Body fld;Ord;;SERO;1;DNA double strand Ab [Presence] in Body fluid;dsDNA Ab Fld Ql;;ACTIVE;2.24;2.73 +53149-1;Iron/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Iron/Creatinine [Molar ratio] in 24 hour Urine;Iron/Creat 24h Ur-sRto;;ACTIVE;2.24;2.42 +53150-9;Alanine+Beta Alanine+Sarcosine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Alanine+Beta Alanine+Sarcosine [Moles/volume] in DBS;Ala+B-Ala+Sar DBS-sCnc;;ACTIVE;2.24;2.73 +53151-7;Valine/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Valine/Phenylalanine [Molar ratio] in DBS;Valine/Phe DBS-sRto;;ACTIVE;2.24;2.73 +53152-5;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline [Moles/volume] in DBS;Aile+Ile+Leu+Hyp DBS-sCnc;;ACTIVE;2.24;2.73 +53153-3;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Phenylalanine [Molar ratio] in DBS;Aile+Ile+Leu+Hyp/Phe DBS-sRto;;ACTIVE;2.24;2.73 +53154-1;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in DBS;Aile+Ile+Leu+Hyp/Alanine DBS-sRto;;ACTIVE;2.24;2.73 +53155-8;Asparagine+Ornithine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Asparagine+Ornithine [Moles/volume] in DBS;Asn+Orn DBS-sCnc;;ACTIVE;2.24;2.73 +53156-6;Methionine/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Methionine/Phenylalanine [Molar ratio] in DBS;Methionine/Phe DBS-sRto;;ACTIVE;2.24;2.73 +5315-7;Rickettsia spotted fever group Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia spotted fever group IgM Ab [Titer] in Serum by Immunofluorescence;Rick SF IgM Titr Ser IF;;ACTIVE;1.0;2.73 +53157-4;Citrulline/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Citrulline/Phenylalanine [Molar ratio] in DBS;Citrulline/Phe DBS-sRto;;ACTIVE;2.24;2.73 +53158-2;Homocitrulline;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Homocitrulline [Moles/volume] in DBS;Homocitrulline DBS-sCnc;;ACTIVE;2.24;2.70 +53159-0;Tryptophan;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Tryptophan [Moles/volume] in DBS;Tryptophan DBS-sCnc;;ACTIVE;2.24;2.73 +53160-8;Propionylcarnitine (C3);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Propionylcarnitine (C3) [Moles/volume] in DBS;Propionylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53161-6;Propionylcarnitine (C3)/Methionine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Propionylcarnitine (C3)/Methionine [Molar ratio] in DBS;Propionylcarn/Methionine DBS-sRto;;ACTIVE;2.24;2.61 +53162-4;Propionylcarnitine (C3)/Carnitine.free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Propionylcarnitine (C3)/Carnitine.free (C0) [Molar ratio] in DBS;Propionylcarn/C0 DBS-sRto;;ACTIVE;2.24;2.73 +53163-2;Propionylcarnitine (C3)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Propionylcarnitine (C3)/Acetylcarnitine (C2) [Molar ratio] in DBS;Propionylcarn/C2 DBS-sRto;;ACTIVE;2.24;2.73 +53164-0;Propionylcarnitine (C3)/Palmitoylcarnitine (C16);SRto;Pt;Bld.dot;Qn;;CHEM;1;Propionylcarnitine (C3)/Palmitoylcarnitine (C16) [Molar ratio] in DBS;Propionylcarn/C16 DBS-sRto;;ACTIVE;2.24;2.73 +5316-5;Rickettsia typhus group Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rickettsia typhus group Ab [Presence] in Serum by Immunoassay;Rick Typhus Ab Ser Ql IA;;ACTIVE;1.0;2.56 +53165-7;Formiminoglutamate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Formiminoglutamate [Moles/volume] in DBS;Formiminoglutamate DBS-sCnc;;ACTIVE;2.24;2.70 +53166-5;Butyrylcarnitine+Isobutyrylcarnitine (C4);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Butyrylcarnitine+Isobutyrylcarnitine (C4) [Moles/volume] in DBS;Butyryl+Isobutyrylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53167-3;Butyrylcarnitine+Isobutyrylcarnitine (C4)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Butyrylcarnitine+Isobutyrylcarnitine (C4)/Acetylcarnitine (C2) [Molar ratio] in DBS;Butyryl+Isobutyrylcarn/C2 DBS-sRto;;ACTIVE;2.24;2.61 +53168-1;Butyrylcarnitine+Isobutyrylcarnitine (C4)/Propionylcarnitine (C3);SRto;Pt;Bld.dot;Qn;;CHEM;1;Butyrylcarnitine+Isobutyrylcarnitine (C4)/Propionylcarnitine (C3) [Molar ratio] in DBS;Butyryl+Isobutyrylcarn/C3 DBS-sRto;;ACTIVE;2.24;2.61 +53169-9;Butyrylcarnitine+Isobutyrylcarnitine (C4)/Octanoylcarnitine (C8);SRto;Pt;Bld.dot;Qn;;CHEM;1;Butyrylcarnitine+Isobutyrylcarnitine (C4)/Octanoylcarnitine (C8) [Molar ratio] in DBS;Butyryl+Isobutyrylcarn/C8 DBS-sRto;;ACTIVE;2.24;2.61 +53170-7;Tiglylcarnitine (C5:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Tiglylcarnitine (C5:1) [Moles/volume] in DBS;Tiglylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53171-5;3-Hydroxyisovalerylcarnitine (C5-OH)/Carnitine.free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH)/Carnitine.free (C0) [Molar ratio] in DBS;3OH-Isovalerylcarn/C0 DBS-sRto;;ACTIVE;2.24;2.73 +53172-3;3-Hydroxyisovalerylcarnitine (C5-OH)/Octanoylcarnitine (C8);SRto;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyisovalerylcarnitine (C5-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS;3OH-Isovalerylcarn/C8 DBS-sRto;;ACTIVE;2.24;2.73 +5317-3;Rickettsia typhus group Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rickettsia typhus group Ab [Presence] in Serum by Latex agglutination;Rick Typhus Ab Ser Ql LA;;ACTIVE;1.0;2.56 +53173-1;3-Hydroxyhexanoylcarnitine (C6-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in DBS;3OH-Hexanoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53174-9;Octenoylcarnitine (C8:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Octenoylcarnitine (C8:1) [Moles/volume] in DBS;Octenoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53175-6;Octanoylcarnitine (C8);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Octanoylcarnitine (C8) [Moles/volume] in DBS;Octanoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53176-4;Octanoylcarnitine (C8)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Octanoylcarnitine (C8)/Acetylcarnitine (C2) [Molar ratio] in DBS;Octanoylcarn/C2 DBS-sRto;;ACTIVE;2.24;2.73 +53177-2;Octanoylcarnitine (C8)/Decanoylcarnitine (C10);SRto;Pt;Bld.dot;Qn;;CHEM;1;Octanoylcarnitine (C8)/Decanoylcarnitine (C10) [Molar ratio] in DBS;Octanoylcarn/C10 DBS-sRto;;ACTIVE;2.24;2.73 +53178-0;3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC) [Moles/volume] in DBS;3OHoctanoyl+Malonylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53179-8;3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10);SRto;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS;3OHoctanoyl+Malonylcarn/C10 DBS-sRto;;ACTIVE;2.24;2.61 +53180-6;Decadienoylcarnitine (C10:2);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Decadienoylcarnitine (C10:2) [Moles/volume] in DBS;Decadienoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +5318-1;Rickettsia typhus group Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhus group Ab [Titer] in Serum by Immunofluorescence;Rick Typhus Ab Titr Ser IF;;ACTIVE;1.0;2.70 +53181-4;Methylmalonylcarnitine (C4-DC)/3-Hydroxyisovalerylcarnitine (C5-OH);SRto;Pt;Bld.dot;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS;Me-malonylcarn/C5OH DBS-sRto;;ACTIVE;2.24;2.73 +53182-2;3-Hydroxydecenoylcarnitine (C10:1-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxydecenoylcarnitine (C10:1-OH) [Moles/volume] in DBS;3-OH-decenoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53183-0;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in DBS;Glut+3OHdecanoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53184-8;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/3-Hydroxyisovalerylcarnitine (C5-OH);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS;Glut+3OHdecanoylcarn/C5OH DBS-sRto;;ACTIVE;2.24;2.73 +53185-5;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Octanoylcarnitine (C8);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS;Glut+3OHdecanoylcarn/C8 DBS-sRto;;ACTIVE;2.24;2.73 +53186-3;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Palmitoylcarnitine (C16);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS;Glut+3OHdecanoylcarn/C16 DBS-sRto;;ACTIVE;2.24;2.73 +53187-1;Methylglutarylcarnitine (C6-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Methylglutarylcarnitine (C6-DC) [Moles/volume] in DBS;MeGlutarylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53188-9;3-Hydroxydodecenoylcarnitine (C12:1-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxydodecenoylcarnitine (C12:1-OH) [Moles/volume] in DBS;3-OH-dodecenoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53189-7;3-Hydroxydodecanoylcarnitine (C12-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxydodecanoylcarnitine (C12-OH) [Moles/volume] in DBS;3OH-Dodecanoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53190-5;Tetradecadienoylcarnitine (C14:2);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2) [Moles/volume] in DBS;Tdecadienoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53191-3;Tetradecenoylcarnitine (C14:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1) [Moles/volume] in DBS;Tdecenoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53192-1;Tetradecanoylcarnitine (C14);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Tetradecanoylcarnitine (C14) [Moles/volume] in DBS;Tdecanoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53193-9;Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2) [Molar ratio] in DBS;Tdecenoylcarn/C2 DBS-sRto;;ACTIVE;2.24;2.73 +53194-7;Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1);SRto;Pt;Bld.dot;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1) [Molar ratio] in DBS;Tdecenoylcarn/C12:1 DBS-sRto;;ACTIVE;2.24;2.73 +53195-4;Tetradecenoylcarnitine (C14:1)/Palmitoylcarnitine (C16);SRto;Pt;Bld.dot;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Palmitoylcarnitine (C16) [Molar ratio] in DBS;Tdecenoylcarn/C16 DBS-sRto;;ACTIVE;2.24;2.73 +53196-2;3-Hydroxytetradecadienoylcarnitine (C14:2-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Moles/volume] in DBS;3OH-Tdecadienoylcar DBS-sCnc;;ACTIVE;2.24;2.73 +53197-0;3-Hydroxytetradecenoylcarnitine (C14:1-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Moles/volume] in DBS;3OH-Tdecenoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53198-8;Palmitoleylcarnitine (C16:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Palmitoleylcarnitine (C16:1) [Moles/volume] in DBS;Palmitoleylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +5319-9;Rickettsia typhus group Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rickettsia typhus group IgG Ab [Units/volume] in Serum by Immunoassay;Rick Typhus IgG Ser IA-aCnc;;ACTIVE;1.0;2.69 +53199-6;Palmitoylcarnitine (C16);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Moles/volume] in DBS;Palmitoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53200-2;Argininosuccinate/Arginine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Argininosuccinate/Arginine [Molar ratio] in DBS;Argininosuccinate/Arginine DBS-sRto;;ACTIVE;2.24;2.73 +53201-0;3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16);SRto;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS;3OH-Palmitoylcarn/C16 DBS-sRto;;ACTIVE;2.24;2.73 +53202-8;Oleoylcarnitine (C18:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Oleoylcarnitine (C18:1) [Moles/volume] in DBS;Oleoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53203-6;Hexenoylcarnitine (C6:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Hexenoylcarnitine (C6:1) [Moles/volume] in DBS;Hexenoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53204-4;Heptanoylcarnitine (C7);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Heptanoylcarnitine (C7) [Moles/volume] in DBS;Heptanoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53205-1;Phenylacetylcarnitine (PheC2);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Phenylacetylcarnitine (PheC2) [Moles/volume] in DBS;Phenylacetylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53206-9;Salicylylcarnitine (Salc);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Salicylylcarnitine (SalC) [Moles/volume] in DBS;Salicylylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +5320-7;Rickettsia typhus group Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhus group IgG Ab [Titer] in Serum by Immunofluorescence;Rick Typhus IgG Titr Ser IF;;ACTIVE;1.0;2.73 +53207-7;Nonanoylcarnitine (C9);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Nonanoylcarnitine (C9) [Moles/volume] in DBS;Nonanoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53208-5;Decatrienoylcarnitine (C10:3);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Decatrienoylcarnitine (C10:3) [Moles/volume] in DBS;Decatrienoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53209-3;Dehydrosuberylcarnitine (C8:1-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dehydrosuberylcarnitine (C8:1-DC) [Moles/volume] in DBS;Dehydrosuberylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53210-1;Suberylcarnitine (C8-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Suberylcarnitine (C8-DC) [Moles/volume] in DBS;Suberylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53211-9;Dehydrosebacylcarnitine (C10:1-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dehydrosebacylcarnitine (C10:1-DC) [Moles/volume] in DBS;Dehydrosebacylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53212-7;Sebacylcarnitine (C10-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Sebacylcarnitine (C10-DC) [Moles/volume] in DBS;Sebacylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53213-5;Dicarboxydodecenoylcarnitine (C12:1-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxydodecenoylcarnitine (C12:1-DC) [Moles/volume] in DBS;Dicarboxydodecenoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53214-3;Dicarboxydodecanoylcarnitine (C12-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxydodecanoylcarnitine (C12-DC) [Moles/volume] in DBS;Dicarboxydodecanoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +5321-5;Rickettsia typhus group Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rickettsia typhus group IgM Ab [Units/volume] in Serum by Immunoassay;Rick Typhus IgM Ser IA-aCnc;;ACTIVE;1.0;2.69 +53215-0;Dicarboxytetradecenoylcarnitine (C14:1-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxytetradecenoylcarnitine (C14:1-DC) [Moles/volume] in DBS;Dicarboxytetradecenoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53216-8;Dicarboxytetradecanoylcarnitine (C14-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxytetradecanoylcarnitine (C14-DC) [Moles/volume] in DBS;Dicarboxytetradecanoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53217-6;Dicarboxypalmitoleylcarnitine (C16:1-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxypalmitoleylcarnitine (C16:1-DC) [Moles/volume] in DBS;Dicarboxypalmitoleylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53218-4;Dicarboxypalmitoylcarnitine (C16-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxypalmitoylcarnitine (C16-DC) [Moles/volume] in DBS;Dicarboxypalmitoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53219-2;Dicarboxyoleylcarnitine (C18:1-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxyoleylcarnitine (C18:1-DC) [Moles/volume] in DBS;Dicarboxyoleylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +532-2;Mycobacterium sp identified;Prid;Pt;Asp;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Aspirate by Organism specific culture;Mycobacterium Aspirate Cult;;ACTIVE;1.0;2.17 +53220-0;Dicarboxystearoylcarnitine (C18-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxystearoylcarnitine (C18-DC) [Moles/volume] in DBS;Dicarboxystearoylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53221-8;Coagulation dilute Russell viper venom induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;dRVVT in Control Platelet poor plasma by Coagulation assay;dRVVT Cont PPP;;ACTIVE;2.24;2.73 +53222-6;Coagulation factor XI activated activity;ACnc;Pt;PPP;Qn;Coag;COAG;1;Coagulation factor XI activated [Units/volume] in Platelet poor plasma by Coagulation assay;Fact XIa PPP-aCnc;;ACTIVE;2.24;2.73 +5322-3;Rickettsia typhus group Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhus group IgM Ab [Titer] in Serum by Immunofluorescence;Rick Typhus IgM Titr Ser IF;;ACTIVE;1.0;2.73 +53223-4;Hemoglobin G/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin G/Hemoglobin.total in Blood;Hgb G MFr Bld;;ACTIVE;2.24;2.73 +53224-2;Hemoglobin M;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin M [Presence] in Blood;Hgb M Bld Ql;;ACTIVE;2.24;2.56 +53225-9;Leukocytes;Naric;Pt;XXX;Qn;Wet preparation;HEM/BC;1;Leukocytes [#/area] in Specimen by Wet preparation;WBC #/area Spec Wet Prep;;ACTIVE;2.24;2.73 +53226-7;Leukocytes;Naric;Pt;Urethra;Qn;Wet preparation;HEM/BC;1;Leukocytes [#/area] in Urethra by Wet preparation;WBC #/area Urth Wet Prep;;ACTIVE;2.24;2.70 +53227-5;Leukocytes;Naric;Pt;Cvx;Qn;Wet preparation;HEM/BC;1;Leukocytes [#/area] in Cervix by Wet preparation;WBC #/area Cvx Wet Prep;;ACTIVE;2.24;2.70 +53229-1;Prealbumin;MRat;24H;Urine;Qn;;CHEM;1;Prealbumin [Mass/time] in 24 hour Urine;Prealb 24h Ur-mRate;;ACTIVE;2.24;2.70 +53230-9;Coagulation tissue factor induced.factor substitution^immediately after 1:4 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:4 addition of normal plasma;PT imm 1:4 NP PPP;;ACTIVE;2.24;2.44 +5323-1;Orientia tsutsugamushi Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Orientia tsutsugamushi Ab [Titer] in Serum by Complement fixation;O tsut Ab Titr Ser CF;;ACTIVE;1.0;2.70 +53231-7;Succinylacetone;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Succinylacetone [Moles/volume] in DBS;Succinylacetone DBS-sCnc;;ACTIVE;2.24;2.73 +53232-5;5-Oxoproline+Pipecolate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;5-Oxoproline+Pipecolate [Moles/volume] in DBS;5-Oxoproline+Pipecolate DBS-sCnc;;ACTIVE;2.24;2.73 +53233-3;Carnitine.free (C0)/Palmitoylcarnitine (C16);SRto;Pt;Bld.dot;Qn;;CHEM;1;Carnitine free (C0)/Palmitoylcarnitine (C16) [Molar ratio] in DBS;Carnitine Free/C16 DBS-sRto;;ACTIVE;2.24;2.61 +53234-1;Carnitine.free (C0)/Stearoylcarnitine (C18);SRto;Pt;Bld.dot;Qn;;CHEM;1;Carnitine free (C0)/Stearoylcarnitine (C18) [Molar ratio] in DBS;Carnitine Free/C18 DBS-sRto;;ACTIVE;2.24;2.61 +53235-8;Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18);SRto;Pt;Bld.dot;Qn;;CHEM;1;Carnitine free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18) [Molar ratio] in DBS;Carnitine Free/C16+C18 DBS-sRto;;ACTIVE;2.24;2.73 +53236-6;Carnitine.free (C0)+Acetylcarnitine (C2)+Propionylcarnitine (C3)+Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)+Stearoylcarnitine (C18)/Citrulline;SRto;Pt;Bld.dot;Qn;;CHEM;1;Carnitine.free (C0)+Acetylcarnitine (C2)+Propionylcarnitine (C3)+Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)+Stearoylcarnitine (C18)/Citrulline [Molar ratio] in DBS;C0+C2+C3+C16+C18/Cit DBS-sRto;;ACTIVE;2.24;2.73 +53237-4;Acrylylcarnitine (C3:1);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Acrylylcarnitine (C3:1) [Moles/volume] in DBS;Acrylylcarn DBS-sCnc;;ACTIVE;2.24;2.70 +53238-2;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Carnitine.free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Carnitine.free (C0) [Molar ratio] in DBS;Isovaleryl+MeButyrylcarn/C0 DBS-sRto;;ACTIVE;2.24;2.73 +53239-0;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Acetylcarnitine (C2) [Molar ratio] in DBS;Isovaleryl+MeButyrylcarn/C2 DBS-sRto;;ACTIVE;2.24;2.73 +53240-8;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3);SRto;Pt;Bld.dot;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3) [Molar ratio] in DBS;Isovaleryl+MeButyrylcarn/C3 DBS-sRto;;ACTIVE;2.24;2.73 +53241-6;Stearoylcarnitine (C18);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Stearoylcarnitine (C18) [Moles/volume] in DBS;Stearoylcarn DBS-sCnc;;ACTIVE;2.24;2.73 +53242-4;Charge ticket or encounter form attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Charge ticket or encounter form;Charge ticket or encounter form;;ACTIVE;2.24;2.67 +53243-2;Advanced beneficiary notice attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Advanced beneficiary notice;Advanced beneficiary notice;;ACTIVE;2.24;2.67 +53244-0;Notice of privacy practices receipt attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Notice of privacy practices receipt;Notice of privacy practices receipt;;ACTIVE;2.24;2.67 +53245-7;Driver license;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Driver license;Driver license;;ACTIVE;2.24;2.58 +53246-5;Non-medical services attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Non-medical services attachment;Non-medical services attachment;;ACTIVE;2.24;2.67 +53247-3;Eligibility acknowledgement attachment;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Eligibility acknowledgement;Eligibility acknowledgement;;ACTIVE;2.24;2.67 +53248-1;Plasmodium sp lactate dehydrogenase;PrThr;Pt;Bld;Ord;;MICRO;1;Plasmodium sp lactate dehydrogenase [Presence] in Blood;Plasmodium LDH Bld Ql;;ACTIVE;2.24;2.56 +5324-9;Rickettsia typhi Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhi IgG Ab [Titer] in Serum by Immunofluorescence;R typhi IgG Titr Ser IF;;ACTIVE;1.0;2.73 +53249-9;Human metapneumovirus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [#/volume] (viral load) in Specimen by NAA with probe detection;hMPV RNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53250-7;Influenza virus A RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A RNA [#/volume] (viral load) in Specimen by NAA with probe detection;FLUAV RNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53251-5;Influenza virus B RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus B RNA [#/volume] (viral load) in Specimen by NAA with probe detection;FLUBV RNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53252-3;Parainfluenza virus 1 RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [#/volume] (viral load) in Specimen by NAA with probe detection;HPIV1 RNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53253-1;Parainfluenza virus 2 RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [#/volume] (viral load) in Specimen by NAA with probe detection;HPIV2 RNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53254-9;Parainfluenza virus 3 RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [#/volume] (viral load) in Specimen by NAA with probe detection;HPIV3 RNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53255-6;Mycoplasma pneumoniae DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [#/volume] in Specimen by NAA with probe detection;M pneumo DNA # Spec NAA+probe;;ACTIVE;2.24;2.73 +5325-6;Rickettsia typhi Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhi IgM Ab [Titer] in Serum by Immunofluorescence;R typhi IgM Titr Ser IF;;ACTIVE;1.0;2.73 +53256-4;Enterovirus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Enterovirus RNA [#/volume] (viral load) in Specimen by NAA with probe detection;EV RNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53257-2;Mycobacterium tuberculosis DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [#/volume] in Specimen by NAA with probe detection;M tb DNA # Spec NAA+probe;;ACTIVE;2.24;2.70 +53258-0;Beta vulgaris Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Sugar Beet IgE Ab RAST class [Presence] in Serum;Sugar Beet IgE RAST Ql;;ACTIVE;2.24;2.73 +53259-8;Glomerular basement membrane Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Glomerular basement membrane Ab [Titer] in Serum by Immunofluorescence;GBM Ab Titr Ser IF;;ACTIVE;2.24;2.32 +53260-6;Glomerular basement membrane Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Glomerular basement membrane Ab [Presence] in Serum by Immunofluorescence;GBM Ab Ser Ql IF;;ACTIVE;2.24;2.56 +53261-4;Amino acid newborn screen panel;SCnc;Pt;Bld.dot;-;;PANEL.CHEM;1;Amino acid newborn screen panel;AA NB scn Pnl DBS-sCnc;;ACTIVE;2.24;2.73 +53262-2;Carnitine newborn screen panel;SCnc;Pt;Bld.dot;-;;PANEL.CHEM;1;Carnitine newborn screen panel;Carnitine NB scn Pnl DBS-sCnc;;ACTIVE;2.24;2.40 +53263-0;Urinalysis yeast variants panel;-;Pt;Urine;-;Computer assisted;PANEL.UA;1;Urinalysis yeast variants panel - Urine by Computer assisted method;UA yeast Pnl Ur Comp Assist;;ACTIVE;2.24;2.44 +5326-4;Bartonella henselae Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Bartonella henselae IgG Ab [Units/volume] in Serum;B henselae IgG Ser-aCnc;;ACTIVE;1.0;2.73 +53264-8;Urinalysis yeast variants panel;NCnc;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis yeast variants panel [#/volume] - Urine by Computer assisted method;UA yeast Pnl # Ur Comp Assist;;ACTIVE;2.24;2.42 +53265-5;Yeast.hyphae;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Yeast.hyphae [#/volume] in Urine by Computer assisted method;Yeast Hyphae # Ur Comp Assist;;ACTIVE;2.24;2.42 +53266-3;Yeast.budding;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Yeast.budding [#/volume] in Urine by Computer assisted method;Yeast Budding # Ur Comp Assist;;ACTIVE;2.24;2.42 +53267-1;Urinalysis yeast variants panel;Naric;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis yeast variants panel [#/area] - Urine by Computer assisted method;UA yeast Pnl #/area Ur Comp Assist;;ACTIVE;2.24;2.42 +53268-9;Yeast.hyphae;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Yeast.hyphae [#/area] in Urine by Computer assisted method;Yeast Hyphae #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53269-7;Yeast.budding;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Yeast.budding [#/area] in Urine by Computer assisted method;Yeast Budding #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53270-5;Urinalysis type of non-squamous epithelial cells panel;-;Pt;Urine;-;Computer assisted;PANEL.UA;1;Urinalysis type of non-squamous epithelial cells panel - Urine by Computer assisted method;UA epith Pnl Ur Comp Assist;;ACTIVE;2.24;2.73 +53271-3;Epithelial cells.renal;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Epithelial cells.renal [Presence] in Urine by Computer assisted method;Renal Epi Cells Ur Ql Comp Assist;;ACTIVE;2.24;2.73 +5327-2;Bartonella henselae Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Bartonella henselae IgM Ab [Units/volume] in Serum;B henselae IgM Ser-aCnc;;ACTIVE;1.0;2.73 +53272-1;Transitional cells;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Transitional cells [Presence] in Urine by Computer assisted method;Trans Cells Ur Ql Comp Assist;;ACTIVE;2.24;2.73 +53273-9;Urinalysis type of non-squamous epithelial cells panel;NCnc;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis type of non-squamous epithelial cells panel [#/volume] - Urine by Computer assisted method;UA epith Pnl # Ur Comp Assist;;ACTIVE;2.24;2.73 +53274-7;Epithelial cells.renal;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Epithelial cells.renal [#/volume] in Urine by Computer assisted method;Renal Epi Cells # Ur Comp Assist;;ACTIVE;2.24;2.42 +53275-4;Transitional cells;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Transitional cells [#/volume] in Urine by Computer assisted method;Trans Cells # Ur Comp Assist;;ACTIVE;2.24;2.73 +53276-2;Urinalysis type of non-squamous epithelial cells panel;Naric;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis type of non-squamous epithelial cells panel [#/area] - Urine by Computer assisted method;UA epith Pnl #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53277-0;Urinalysis type of cast panel;-;Pt;Urine;-;Computer assisted;PANEL.UA;1;Urinalysis type of cast panel - Urine by Computer assisted method;UA casts Pnl Ur Comp Assist;;ACTIVE;2.24;2.42 +53278-8;Erythrocyte casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;RBC casts [Presence] in Urine by Computer assisted method;RBC Casts Ur Ql Comp Assist;;ACTIVE;2.24;2.73 +53279-6;Leukocyte casts;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;WBC casts [Presence] in Urine by Computer assisted method;WBC Casts Ur Ql Comp Assist;;ACTIVE;2.24;2.73 +5328-0;Rotavirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rotavirus Ab [Units/volume] in Serum;RV Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53280-4;Casts type not specified;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Casts type not specified [Presence] in Urine by Computer assisted method;Casts not specif Ur Ql Comp Assist;;ACTIVE;2.24;2.73 +53281-2;Urinalysis type of cast panel;NCnc;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis type of cast panel [#/volume] - Urine by Computer assisted method;UA casts Pnl # Ur Comp Assist;;ACTIVE;2.24;2.42 +53282-0;Granular casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Granular casts [#/volume] in Urine by Computer assisted method;Gran Casts # Ur Comp Assist;;ACTIVE;2.24;2.42 +53283-8;Mixed cellular casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Mixed cellular casts [#/volume] in Urine by Computer assisted method;Mixed Cell Casts # Ur Comp Assist;;ACTIVE;2.24;2.42 +53284-6;Broad casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Broad casts [#/volume] in Urine by Computer assisted method;Broad Casts # Ur Comp Assist;;ACTIVE;2.24;2.42 +53285-3;Erythrocyte casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;RBC casts [#/volume] in Urine by Computer assisted method;RBC Casts # Ur Comp Assist;;ACTIVE;2.24;2.42 +53286-1;Leukocyte casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;WBC casts [#/volume] in Urine by Computer assisted method;WBC Casts # Ur Comp Assist;;ACTIVE;2.24;2.42 +53287-9;Epithelial casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Epithelial casts [#/volume] in Urine by Computer assisted method;Epith Casts # Ur Comp Assist;;ACTIVE;2.24;2.42 +53288-7;Fatty casts;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Fatty casts [#/volume] in Urine by Computer assisted method;Fatty Casts # Ur Comp Assist;;ACTIVE;2.24;2.73 +53289-5;Mixed cellular casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Mixed cellular casts [#/area] in Urine by Computer assisted method;Mixed Cell Casts #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53290-3;Broad casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Broad casts [#/area] in Urine by Computer assisted method;Broad Casts #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53291-1;Epithelial casts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Epithelial casts [#/area] in Urine by Computer assisted method;Epith Casts #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53292-9;Erythrocytes;PrThr;Pt;Urine;Ord;Automated;UA;1;Erythrocytes [Presence] in Urine by Automated;RBC Ur Ql Auto;;ACTIVE;2.24;2.73 +53293-7;Urinalysis microscopic panel;Naric;Pt;Urine sed;Qn;Automated count;PANEL.UA;1;Urinalysis microscopic panel [#/area] - Urine sediment by Automated count;UA Microscopic Pnl #/area UrnS Auto;;ACTIVE;2.24;2.73 +53294-5;Epithelial cells.non-squamous;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Epithelial cells.non-squamous [#/area] in Urine sediment by Automated count;Non-sq Epi Cells #/area UrnS Auto;;ACTIVE;2.24;2.73 +53295-2;Urinalysis type of crystal panel;NCnc;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis type of crystal panel [#/volume] - Urine by Computer assisted method;UA crystal Pnl # Ur Comp Assist;;ACTIVE;2.24;2.42 +53296-0;Calcium oxalate crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Calcium oxalate crystals [#/volume] in Urine by Computer assisted method;CaOx Cry # Ur Comp Assist;;ACTIVE;2.24;2.73 +53297-8;Crystals unspecified;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Crystals unspecified [#/volume] in Urine by Computer assisted method;Unspecified cry # Ur Comp Assist;;ACTIVE;2.24;2.42 +5329-8;Rotavirus Ab;ACnc;Pt;Ser;Qn;CIE;MICRO;1;Rotavirus Ab [Units/volume] in Serum by Counterimmunoelectrophoresis (CIE);RV Ab Ser CIE-aCnc;;DISCOURAGED;1.0;2.69 +53298-6;Triple phosphate crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Triple phosphate crystals [#/volume] in Urine by Computer assisted method;Tri-Phos Cry # Ur Comp Assist;;ACTIVE;2.24;2.42 +53299-4;Calcium phosphate crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Calcium phosphate crystals [#/volume] in Urine by Computer assisted method;Ca Phos Cry # Ur Comp Assist;;ACTIVE;2.24;2.42 +533-0;Mycobacterium sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Blood by Organism specific culture;Mycobacterium Bld Cult;;ACTIVE;1.0;2.73 +53300-0;Leucine crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Leucine crystals [#/volume] in Urine by Computer assisted method;Leucine Cry # Ur Comp Assist;;ACTIVE;2.24;2.42 +53301-8;Urate crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Urate crystals [#/volume] in Urine by Computer assisted method;Urate Cry # Ur Comp Assist;;ACTIVE;2.24;2.73 +53302-6;Calcium carbonate crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Calcium carbonate crystals [#/volume] in Urine by Computer assisted method;Ca Carbonate Cry # Ur Comp Assist;;ACTIVE;2.24;2.42 +53303-4;Cystine crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Cystine crystals [#/volume] in Urine by Computer assisted method;Cystine Cry # Ur Comp Assist;;ACTIVE;2.24;2.42 +53304-2;Tyrosine crystals;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Tyrosine crystals [#/volume] in Urine by Computer assisted method;Tyrosine Cry # Ur Comp Assist;;ACTIVE;2.24;2.42 +53305-9;Urinalysis type of crystal panel;Naric;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis type of crystal panel [#/area] - Urine by Computer assisted method;UA crystal Pnl #/area Ur Comp Assist;;ACTIVE;2.24;2.42 +5330-6;Rubella virus Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Rubella virus Ab [Units/volume] in Serum by Hemagglutination inhibition;RUBV Ab Ser HAI-aCnc;;ACTIVE;1.0;2.69 +53306-7;Calcium oxalate crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Calcium oxalate crystals [#/area] in Urine by Computer assisted method;CaOx Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53307-5;Crystals unspecified;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Crystals unspecified [#/area] in Urine by Computer assisted method;Unspecified cry #/area Ur Comp Assist;;ACTIVE;2.24;2.69 +53308-3;Triple phosphate crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Triple phosphate crystals [#/area] in Urine by Computer assisted method;Tri-Phos Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53309-1;Calcium phosphate crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Calcium phosphate crystals [#/area] in Urine by Computer assisted method;Ca Phos Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53310-9;Leucine crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Leucine crystals [#/area] in Urine by Computer assisted method;Leucine Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53311-7;Urate crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Urate crystals [#/area] in Urine by Computer assisted method;Urate Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53312-5;Calcium carbonate crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Calcium carbonate crystals [#/area] in Urine by Computer assisted method;Ca Carbonate Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.69 +53313-3;Cystine crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Cystine crystals [#/area] in Urine by Computer assisted method;Cystine Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +5331-4;Rubella virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Rubella virus Ab [Presence] in Serum by Hemagglutination inhibition;RUBV Ab Ser Ql HAI;;ACTIVE;1.0;2.73 +53314-1;Tyrosine crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Tyrosine crystals [#/area] in Urine by Computer assisted method;Tyrosine Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53315-8;Urinalysis microscopic panel;-;Pt;Urine;Ord;Automated;PANEL.UA;1;Urinalysis microscopic panel - Urine Qualitative by Automated;UA Microscopic Pnl Ur Auto;;ACTIVE;2.24;2.73 +53316-6;Leukocytes;PrThr;Pt;Urine;Ord;Automated;UA;1;Leukocytes [Presence] in Urine by Automated;WBC Ur Ql Auto;;ACTIVE;2.24;2.73 +53317-4;Leukocyte clumps;PrThr;Pt;Urine;Ord;Automated;UA;1;Leukocyte clumps [Presence] in Urine by Automated;WBC clumps Ur Ql Auto;;ACTIVE;2.24;2.73 +53318-2;Epithelial cells.squamous;PrThr;Pt;Urine;Ord;Automated;UA;1;Epithelial cells.squamous [Presence] in Urine by Automated;Squamous Ur Ql Auto;;ACTIVE;2.24;2.73 +53319-0;Crystals;PrThr;Pt;Urine;Ord;Automated;UA;1;Crystals [Presence] in Urine by Automated;Crystals Ur Ql Auto;;ACTIVE;2.24;2.73 +53320-8;Casts;PrThr;Pt;Urine;Ord;Automated;UA;1;Casts [Presence] in Urine by Automated;Casts Ur Ql Auto;;ACTIVE;2.24;2.73 +53321-6;Mucus;PrThr;Pt;Urine;Ord;Automated;UA;1;Mucus [Presence] in Urine by Automated;Mucous Threads Ur Ql Auto;;ACTIVE;2.24;2.73 +5332-2;Rubella virus Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rubella virus Ab [Presence] in Serum by Latex agglutination;RUBV Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53322-4;Crystals;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Crystals [#/area] in Urine sediment by Automated count;Crystals #/area UrnS Auto;;ACTIVE;2.24;2.73 +53323-2;Casts type not specified;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Casts type not specified [#/volume] in Urine by Computer assisted method;Casts not specif # Ur Comp Assist;;ACTIVE;2.24;2.42 +53324-0;Spermatozoa;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Spermatozoa [#/area] in Urine sediment by Automated count;Sperm #/area UrnS Auto;;ACTIVE;2.24;2.69 +53325-7;Urinalysis type of crystal panel;-;Pt;Urine;-;Computer assisted;PANEL.UA;1;Urinalysis type of crystal panel - Urine by Computer assisted method;UA crystal Pnl Ur Comp Assist;;ACTIVE;2.24;2.42 +53326-5;Specific gravity;Rden;Pt;Urine;Qn;Test strip.automated;UA;1;Specific gravity of Urine by Automated test strip;Sp Gr Ur Strip.auto;;ACTIVE;2.24;2.73 +53327-3;Bilirubin;MCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Bilirubin.total [Mass/volume] in Urine by Automated test strip;Bilirub Ur Strip.auto-mCnc;;ACTIVE;2.24;2.73 +53328-1;Glucose;MCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Glucose [Mass/volume] in Urine by Automated test strip;Glucose Ur Strip.auto-mCnc;;ACTIVE;2.24;2.73 +53329-9;Crystals.amorphous;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Crystals.amorphous [Presence] in Urine by Computer assisted method;Amorph Cry Ur Ql Comp Assist;;ACTIVE;2.24;2.73 +5333-0;Rubella virus Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Rubella virus Ab [Titer] in Serum by Latex agglutination;RUBV Ab Titr Ser LA;;ACTIVE;1.0;2.73 +53330-7;Urinalysis type of cast panel;Naric;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis type of cast panel [#/area] - Urine by Computer assisted method;UA casts Pnl #/area Ur Comp Assist;;ACTIVE;2.24;2.42 +53331-5;Crystals.amorphous;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Crystals.amorphous [#/volume] in Urine by Computer assisted method;Amorph Cry # Ur Comp Assist;;ACTIVE;2.24;2.73 +53332-3;Crystals.amorphous;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Crystals.amorphous [#/area] in Urine by Computer assisted method;Amorph Cry #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53333-1;Urinalysis other formed elements panel;-;Pt;Urine;-;Computer assisted;PANEL.UA;1;Urinalysis other formed elements panel - Urine by Computer assisted method;UA othr elem Pnl Ur Comp Assist;;ACTIVE;2.24;2.42 +53334-9;Crystals unspecified;PrThr;Pt;Urine;Ord;Computer assisted;UA;1;Crystals unspecified [Presence] in Urine by Computer assisted method;Unspecified cry Ur Ql Comp Assist;;ACTIVE;2.24;2.73 +53335-6;Casts type not specified;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Casts type not specified [#/area] in Urine by Computer assisted method;Casts not specif #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53336-4;17-Hydroxyprogesterone+Androstenedione/Cortisol;MRto;Pt;Bld.dot;Qn;;CHEM;1;17-Hydroxyprogesterone+Androstenedione/Cortisol [Mass Ratio] in DBS;17OHCS+Androst/Cortis DBS;;ACTIVE;2.24;2.73 +53337-2;17-Hydroxyprogesterone+Androstenedione/Cortisol;SRto;Pt;Bld.dot;Qn;;CHEM;1;17-Hydroxyprogesterone+Androstenedione/Cortisol [Molar ratio] in DBS;17OHCS+Androst/Cortis DBS-sRto;;ACTIVE;2.24;2.73 +53338-0;11-Deoxycortisol;MCnc;Pt;Bld.dot;Qn;;CHEM;1;11-Deoxycortisol [Mass/volume] in DBS;11DC DBS-mCnc;;ACTIVE;2.24;2.73 +53339-8;11-Deoxycortisol;SCnc;Pt;Bld.dot;Qn;;CHEM;1;11-Deoxycortisol [Moles/volume] in DBS;11DC DBS-sCnc;;ACTIVE;2.24;2.73 +53340-6;17-Hydroxyprogesterone;SCnc;Pt;Bld.dot;Qn;;CHEM;1;17-Hydroxyprogesterone [Moles/volume] in DBS;17OHP DBS-sCnc;;ACTIVE;2.24;2.70 +53341-4;21-Deoxycortisol;MCnc;Pt;Bld.dot;Qn;;CHEM;1;21-Deoxycortisol [Mass/volume] in DBS;21DC DBS-mCnc;;ACTIVE;2.24;2.73 +53342-2;21-Deoxycortisol;SCnc;Pt;Bld.dot;Qn;;CHEM;1;21-Deoxycortisol [Moles/volume] in DBS;21DC DBS-sCnc;;ACTIVE;2.24;2.73 +53343-0;Androstenedione;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Androstenedione [Mass/volume] in DBS;Androst DBS-mCnc;;ACTIVE;2.24;2.73 +53344-8;Androstenedione;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Androstenedione [Moles/volume] in DBS;Androst DBS-sCnc;;ACTIVE;2.24;2.73 +53345-5;Cortisol;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Cortisol [Mass/volume] in DBS;Cortis DBS-mCnc;;ACTIVE;2.24;2.73 +53346-3;Cortisol;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Cortisol [Moles/volume] in DBS;Cortis DBS-sCnc;;ACTIVE;2.24;2.73 +53347-1;11-Deoxycorticosterone;MCnc;Pt;Bld.dot;Qn;;CHEM;1;11-Deoxycorticosterone [Mass/volume] in DBS;11DOC DBS-mCnc;;ACTIVE;2.24;2.73 +5334-8;Rubella virus Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Rubella virus IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;RUBV IgG SerPl IA-aCnc;;ACTIVE;1.0;2.73 +53348-9;11-Deoxycorticosterone;SCnc;Pt;Bld.dot;Qn;;CHEM;1;11-Deoxycorticosterone [Moles/volume] in DBS;11DOC DBS-sCnc;;ACTIVE;2.24;2.73 +53349-7;Thyroxine.free;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Thyroxine (T4) free [Mass/volume] in DBS;T4 Free DBS-mCnc;;ACTIVE;2.24;2.73 +53350-5;Thyroxine.free;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Thyroxine (T4) free [Moles/volume] in DBS;T4 Free DBS-sCnc;;ACTIVE;2.24;2.70 +53351-3;Urinalysis other formed elements panel;NCnc;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis other formed elements panel [#/volume] - Urine by Computer assisted method;UA othr elem Pnl # Ur Comp Assist;;ACTIVE;2.24;2.42 +53352-1;Oval fat bodies (globules);NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Oval fat bodies (globules) [#/volume] in Urine by Computer assisted method;Oval fat bodies # Ur Comp Assist;;ACTIVE;2.24;2.42 +53353-9;Urinalysis other formed elements panel;Naric;Pt;Urine;Qn;Computer assisted;PANEL.UA;1;Urinalysis other formed elements panel [#/area] - Urine by Computer assisted method;UA othr elem Pnl #/area Ur Comp Assist;;ACTIVE;2.24;2.69 +53354-7;Oval fat bodies (globules);Naric;Pt;Urine;Qn;Computer assisted;UA;1;Oval fat bodies (globules) [#/area] in Urine by Computer assisted method;Oval fat bodies #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +5335-5;Rubella virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rubella virus IgM Ab [Units/volume] in Serum by Immunoassay;RUBV IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +53355-4;Trichomonas sp;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Trichomonas sp [#/volume] in Urine by Computer assisted method;Trichomonas # Ur Comp Assist;;ACTIVE;2.24;2.73 +53356-2;Fat;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Fat [#/volume] in Urine by Computer assisted method;Fat # Ur Comp Assist;;ACTIVE;2.24;2.42 +53357-0;Trichomonas sp;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Trichomonas sp [#/area] in Urine by Computer assisted method;Trichomonas #/area Ur Comp Assist;;ACTIVE;2.24;2.69 +53358-8;Erythrocyte clumps;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Erythrocyte clumps [#/area] in Urine by Computer assisted method;RBC clumps #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53359-6;Fat;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Fat [#/area] in Urine by Computer assisted method;Fat #/area Ur Comp Assist;;ACTIVE;2.24;2.73 +53360-4;Erythrocyte clumps;NCnc;Pt;Urine;Qn;Computer assisted;UA;1;Erythrocyte clumps [#/volume] in Urine by Computer assisted method;RBC clumps # Ur Comp Assist;;ACTIVE;2.24;2.42 +53361-2;Bordetella parapertussis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Bordetella parapertussis IgG Ab [Titer] in Serum;B parapert IgG Titr Ser;;ACTIVE;2.24;2.32 +53362-0;Borrelia burgdorferi 49736 Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi 49736 IgA Ab [Units/volume] in Serum;B burgdor 49736 IgA Ser-aCnc;;ACTIVE;2.24;2.69 +5336-3;Saccharomonospora viridis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Saccharomonospora viridis Ab [Units/volume] in Serum;S viridis Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53363-8;Borrelia burgdorferi 49736 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi 49736 IgG Ab [Units/volume] in Serum;B burgdor 49736 IgG Ser-aCnc;;ACTIVE;2.24;2.69 +53364-6;Borrelia burgdorferi 49736 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi 49736 IgM Ab [Units/volume] in Serum;B burgdor 49736 IgM Ser-aCnc;;ACTIVE;2.24;2.69 +53367-9;Coccidioides sp Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;Coccidioides sp IgM Ab [Presence] in Specimen;Coccidioides IgM Spec Ql;;ACTIVE;2.24;2.69 +53368-7;Colorado tick fever virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Colorado tick fever virus Ab [Presence] in Specimen;CTFV Ab Spec Ql;;ACTIVE;2.24;2.69 +53369-5;Echinococcus sp Ab.IgG1;ACnc;Pt;Ser;Qn;;MICRO;1;Echinococcus sp IgG1 Ab [Units/volume] in Serum;Echinococcus IgG1 Ser-aCnc;;ACTIVE;2.24;2.69 +53370-3;Echinococcus sp Ab.IgG4;ACnc;Pt;Ser;Qn;;MICRO;1;Echinococcus sp IgG4 Ab [Units/volume] in Serum;Echinococcus IgG4 Ser-aCnc;;ACTIVE;2.24;2.69 +5337-1;Salivary gland Ab;ACnc;Pt;Ser;Qn;;SERO;1;Salivary gland Ab [Units/volume] in Serum;Salivary Gland Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53371-1;Echovirus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus IgG Ab [Titer] in Serum;ECV IgG Titr Ser;;ACTIVE;2.24;2.32 +53372-9;Echovirus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus IgM Ab [Titer] in Serum;ECV IgM Titr Ser;;ACTIVE;2.24;2.32 +53373-7;Francisella tularensis Ab;PrThr;Pt;Isolate;Ord;;MICRO;1;Francisella tularensis Ab [Presence] in Isolate;F tular Ab Islt Ql;;ACTIVE;2.24;2.56 +53374-5;Francisella tularensis Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Francisella tularensis Ab [Presence] in Specimen;F tular Ab Spec Ql;;ACTIVE;2.24;2.69 +53376-0;Hepatitis C virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis C virus IgM Ab [Units/volume] in Serum;HCV IgM Ser-aCnc;;ACTIVE;2.24;2.69 +53377-8;Herpes simplex virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus IgG Ab [Titer] in Serum;HSV IgG Titr Ser;;ACTIVE;2.24;2.32 +53378-6;Herpes virus 6 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes virus 6 Ab [Units/volume] in Serum;HHV6 Ab Ser-aCnc;;ACTIVE;2.24;2.69 +53379-4;HIV 1 Ab;PrThr;Pt;XXX;Ord;;MICRO;1;HIV 1 Ab [Presence] in Specimen;HIV1 Ab Spec Ql;;ACTIVE;2.24;2.69 +53381-0;Influenza virus A Ab;Prid;Pt;Ser;Nom;;MICRO;1;Influenza virus A Ab [Identifier] in Serum;FLUAV Ab Ser;;ACTIVE;2.24;2.32 +53382-8;Plasmodium falciparum Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium falciparum IgM Ab [Titer] in Serum;P falciparum IgM Titr Ser;;ACTIVE;2.24;2.32 +53383-6;Plasmodium sp Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Plasmodium sp IgG Ab [Titer] in Serum;Plasmodium IgG Titr Ser;;ACTIVE;2.24;2.73 +53384-4;Powassan virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Powassan virus Ab [Presence] in Specimen;POWV Ab Spec Ql;;ACTIVE;2.24;2.69 +53385-1;Snowshoe hare virus Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Snowshoe hare virus Ab [Presence] in Specimen;SSHV Ab Spec Ql;;ACTIVE;2.24;2.69 +53386-9;Toxocara canis Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Toxocara canis Ab [Units/volume] in Specimen;T canis Ab Spec-aCnc;;ACTIVE;2.24;2.69 +53387-7;Trichinella spiralis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Trichinella spiralis IgG Ab [Titer] in Serum;T spiralis IgG Titr Ser;;ACTIVE;2.24;2.32 +53388-5;Trichothecene Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Trichothecene IgA Ab [Units/volume] in Serum;Trichothecene IgA Ser-aCnc;;ACTIVE;2.24;2.69 +5338-9;Salmonella sp Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Salmonella sp Ab [Titer] in Serum by Latex agglutination;Salmonella Ab Titr Ser LA;;ACTIVE;1.0;2.70 +53389-3;Trichothecene Ab.IgE;ACnc;Pt;Ser;Qn;;MICRO;1;Trichothecene IgE Ab [Units/volume] in Serum;Trichothecene IgE Ser-aCnc;;ACTIVE;2.24;2.42 +53390-1;Trichothecene Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Trichothecene IgG Ab [Units/volume] in Serum;Trichothecene IgG Ser-aCnc;;ACTIVE;2.24;2.69 +53391-9;Trichothecene Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Trichothecene IgM Ab [Units/volume] in Serum;Trichothecene IgM Ser-aCnc;;ACTIVE;2.24;2.69 +53392-7;Proline/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Proline/Phenylalanine [Molar ratio] in DBS;Proline/Phe DBS-sRto;;ACTIVE;2.24;2.70 +53393-5;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline+Valine/Phenylalanine+Tyrosine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Alloisoleucine+Isoleucine+Leucine+Hydroxyproline+Valine/Phenylalanine+Tyrosine [Molar ratio] in DBS;Aile+Ile+Leu+Hyp+Val/Phe+Tyr DBS-sRto;;ACTIVE;2.24;2.73 +53394-3;5-Oxoproline+Pipecolate/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;5-Oxoproline+Pipecolate/Phenylalanine [Molar ratio] in DBS;5-Oxoproline+Pipecolate/Phe DBS-sRto;;ACTIVE;2.24;2.70 +53395-0;Asparagine+Ornithine/Serine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Asparagine+Ornithine/Serine [Molar ratio] in DBS;Asn+Orn/Serine DBS-sRto;;ACTIVE;2.24;2.70 +53396-8;Asparagine+Ornithine/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Asparagine+Ornithine/Phenylalanine [Molar ratio] in DBS;Asn+Orn/Phe DBS-sRto;;ACTIVE;2.24;2.70 +5339-7;Salmonella paratyphi A H Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella paratyphi A H Ab [Presence] in Serum by Latex agglutination;S paraty A H Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53397-6;Methionine/Alloisoleucine+Isoleucine+Leucine+Hydroxyproline;SRto;Pt;Bld.dot;Qn;;CHEM;1;Methionine/Alloisoleucine+Isoleucine+Leucine+Hydroxyproline [Molar ratio] in DBS;Methionine/Aile+Ile+Leu+Hyp DBS-sRto;;ACTIVE;2.24;2.73 +53398-4;Arginine/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Arginine/Phenylalanine [Molar ratio] in DBS;Arginine/Phe DBS-sRto;;ACTIVE;2.24;2.73 +53399-2;Citrulline/Tyrosine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Citrulline/Tyrosine [Molar ratio] in DBS;Citrulline/Tyr DBS-sRto;;ACTIVE;2.24;2.73 +53400-8;Stearoylcarnitine (C18)/Propionylcarnitine (C3);SRto;Pt;Bld.dot;Qn;;CHEM;1;Stearoylcarnitine (C18)/Propionylcarnitine (C3) [Molar ratio] in DBS;Stearoylcarn/C3 DBS-sRto;;ACTIVE;2.24;2.70 +53401-6;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Octanoylcarnitine (C8);SRto;Pt;Bld.dot;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Octanoylcarnitine (C8) [Molar ratio] in DBS;Isovaleryl+MeButyrylcarn/C8 DBS-sRto;;ACTIVE;2.24;2.73 +53402-4;3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Butyrylcarnitine+Isobutyrylcarnitine (C4);SRto;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS;3OHoctanoyl+Malonylcarn/C4 DBS-sRto;;ACTIVE;2.24;2.70 +53403-2;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Butyrylcarnitine+Isobutyrylcarnitine (C4);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS;Glut+3OHdecanoylcarn/C4 DBS-sRto;;ACTIVE;2.24;2.73 +53404-0;Vaccine label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Vaccine label;FDA label Vaccine;;ACTIVE;2.26;2.34 +5340-5;Salmonella paratyphi A O Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella paratyphi A O Ab [Presence] in Serum by Latex agglutination;S paraty A O Ab Ser Ql LA;;ACTIVE;1.0;2.56 +53405-7;Non-standardized allergenic label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Non-standardized allergenic label;FDA label Non-standard allergenic;;ACTIVE;2.26;2.34 +53406-5;Licensed vaccine bulk intermediate label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Licensed vaccine bulk intermediate label;FDA label Lic vaccine bulk int;;ACTIVE;2.26;2.34 +53407-3;Licensed blood intermediate &or paste label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Licensed blood intermediate/paste label;FDA label Lic Bld interm/paste;;ACTIVE;2.26;2.34 +53408-1;Licensed minimally manipulated cells label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Licensed minimally manipulated cells label;FDA label Lic min manipulated cells;;ACTIVE;2.26;2.34 +53409-9;Bulk ingredient;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Bulk ingredient;FDA label Bulk ingredient;;ACTIVE;2.26;2.34 +53410-7;No change notification;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label No change notification;FDA label No change notification;;ACTIVE;2.26;2.34 +53411-5;Out of business notification;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Out of business notification;FDA label Out of bus notif;;ACTIVE;2.26;2.34 +53412-3;Residue warning section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Residue warning section;FDA label Residue warning;;ACTIVE;2.26;2.34 +5341-3;Salmonella paratyphi B H Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella paratyphi B H Ab [Presence] in Serum by Latex agglutination;S paraty B H Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53413-1;OTC - Questions section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Questions section;FDA label OTC - Questions;;ACTIVE;2.26;2.34 +53414-9;OTC - Pregnancy or breast feeding section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Pregnancy or breast feeding section;FDA label OTC - Preg/breast feed;;ACTIVE;2.26;2.34 +53415-6;Bilirubin;PrThr;Pt;CSF;Ord;;CHEM;1;Bilirubin.total [Presence] in Cerebral spinal fluid;Bilirub CSF Ql;;ACTIVE;2.26;2.56 +53416-4;Alpha naphthylesterase;CCnc;Pt;Bld;Qn;;CHEM;1;Alpha naphthylesterase [Enzymatic activity/volume] in Blood;A-Naphthylesterase Bld-cCnc;;ACTIVE;2.26;2.68 +53417-2;Alpha naphthylesterase;CCnc;Pt;Bone mar;Qn;;CHEM;1;Alpha naphthylesterase [Enzymatic activity/volume] in Bone marrow;A-Naphthylesterase Mar-cCnc;;ACTIVE;2.26;2.26 +53418-0;Fibroblast growth factor 23.intact ^pre XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Fibroblast growth factor 23.intact [Mass/volume] in Plasma --pre XXX challenge;FGF-23.intact pre chal Plas-mCnc;;ACTIVE;2.26;2.70 +53419-8;Fibroblast growth factor 23.intact ^1st specimen post XXX challenge;MCnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23.intact [Mass/volume] in Plasma by Immunoassay --1st specimen post XXX challenge;FGF-23.intact sp1 p chal Plas IA-mCnc;;ACTIVE;2.26;2.70 +53420-6;Fibroblast growth factor 23.intact ^2nd specimen post XXX challenge;MCnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23.intact [Mass/volume] in Plasma by Immunoassay --2nd specimen post XXX challenge;FGF-23.intact sp2 p chal Plas IA-mCnc;;ACTIVE;2.26;2.70 +5342-1;Salmonella paratyphi B O Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella paratyphi B O Ab [Presence] in Serum by Latex agglutination;S paraty B O Ab Ser Ql LA;;ACTIVE;1.0;2.56 +53421-4;Fibroblast growth factor 23.intact ^3rd specimen post XXX challenge;MCnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23.intact [Mass/volume] in Plasma by Immunoassay --3rd specimen post XXX challenge;FGF-23.intact sp3 p chal Plas IA-mCnc;;ACTIVE;2.26;2.70 +53422-2;Fibroblast growth factor 23.intact ^4th specimen post XXX challenge;MCnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23.intact [Mass/volume] in Plasma by Immunoassay --4th specimen post XXX challenge;FGF-23.intact sp4 p chal Plas IA-mCnc;;ACTIVE;2.26;2.70 +53423-0;Fibroblast growth factor 23.intact ^5th specimen post XXX challenge;MCnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23.intact [Mass/volume] in Plasma by Immunoassay --5th specimen post XXX challenge;FGF-23.intact sp5 p chal Plas IA-mCnc;;ACTIVE;2.26;2.70 +53424-8;Fibroblast growth factor 23.intact ^6th specimen post XXX challenge;MCnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23.intact [Mass/volume] in Plasma by Immunoassay --6th specimen post XXX challenge;FGF-23.intact sp6 p chal Plas IA-mCnc;;ACTIVE;2.26;2.70 +53425-5;Fibroblast growth factor 23 ^pre XXX challenge;ACnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23 [Units/volume] in Plasma by Immunoassay --pre XXX challenge;FGF-23 pre chal Plas IA-aCnc;;ACTIVE;2.26;2.70 +53426-3;Fibroblast growth factor 23 ^1st specimen post XXX challenge;ACnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23 [Units/volume] in Plasma by Immunoassay --1st specimen post XXX challenge;FGF-23 sp1 p chal Plas IA-aCnc;;ACTIVE;2.26;2.70 +53427-1;Fibroblast growth factor 23 ^2nd specimen post XXX challenge;ACnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23 [Units/volume] in Plasma by Immunoassay --2nd specimen post XXX challenge;FGF-23 sp2 p chal Plas IA-aCnc;;ACTIVE;2.26;2.70 +53428-9;Fibroblast growth factor 23 ^3rd specimen post XXX challenge;ACnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23 [Units/volume] in Plasma by Immunoassay --3rd specimen post XXX challenge;FGF-23 sp3 p chal Plas IA-aCnc;;ACTIVE;2.26;2.70 +53429-7;Fibroblast growth factor 23 ^4th specimen post XXX challenge;ACnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23 [Units/volume] in Plasma by Immunoassay --4th specimen post XXX challenge;FGF-23 sp4 p chal Plas IA-aCnc;;ACTIVE;2.26;2.70 +53430-5;Fibroblast growth factor 23 ^5th specimen post XXX challenge;ACnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23 [Units/volume] in Plasma by Immunoassay --5th specimen post XXX challenge;FGF-23 sp5 p chal Plas IA-aCnc;;ACTIVE;2.26;2.70 +53431-3;Fibroblast growth factor 23 ^6th specimen post XXX challenge;ACnc;Pt;Plas;Qn;IA;CHAL;1;Fibroblast growth factor 23 [Units/volume] in Plasma by Immunoassay --6th specimen post XXX challenge;FGF-23 sp6 p chal Plas IA-aCnc;;ACTIVE;2.26;2.70 +53432-1;Gamma glutamyl transferase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/volume] in Dialysis fluid;GGT Dial fld-cCnc;;ACTIVE;2.26;2.70 +53433-9;Creatine kinase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Creatine kinase [Enzymatic activity/volume] in Dialysis fluid;CK Dial fld-cCnc;;ACTIVE;2.26;2.73 +53434-7;Carnitine palmitoyltransferase 2;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Carnitine palmitoyltransferase 2 [Enzymatic activity/mass] in Amniotic fluid cells;CPT2 Amnc-cCnt;;ACTIVE;2.26;2.70 +53435-4;Argininosuccinate lyase;CCnt;Pt;CVS;Qn;;CHEM;1;Argininosuccinate lyase [Enzymatic activity/mass] in Chorionic villus sample;ASA Lyase CVS-cCnt;;ACTIVE;2.26;2.70 +53436-2;Carnitine palmitoyltransferase 2;CCnt;Pt;CVS;Qn;;CHEM;1;Carnitine palmitoyltransferase 2 [Enzymatic activity/mass] in Chorionic villus sample;CPT2 CVS-cCnt;;ACTIVE;2.26;2.70 +53437-0;Carnitine palmitoyltransferase 1;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Carnitine palmitoyltransferase 1 [Enzymatic activity/mass] in Fibroblast;CPT1 Fib-cCnt;;ACTIVE;2.26;2.70 +53438-8;Carnitine palmitoyltransferase 2;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Carnitine palmitoyltransferase 2 [Enzymatic activity/mass] in Fibroblast;CPT2 Fib-cCnt;;ACTIVE;2.26;2.70 +5343-9;Salmonella paratyphi C H Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella paratyphi C H Ab [Presence] in Serum by Latex agglutination;S paraty C H Ab Ser Ql LA;;ACTIVE;1.0;2.56 +53439-6;Argininosuccinate lyase;CCnt;Pt;Liver^Fetus;Qn;;CHEM;1;Argininosuccinate lyase [Enzymatic activity/mass] in Liver from Fetus;ASA Lyase Liver Fetus-cCnt;;ACTIVE;2.26;2.70 +53440-4;Argininosuccinate synthase;CCnt;Pt;Liver^Fetus;Qn;;CHEM;1;Argininosuccinate synthase [Enzymatic activity/mass] in Liver from Fetus;ASA Synthase Liver Fetus-cCnt;;ACTIVE;2.26;2.70 +53441-2;Carnitine palmitoyltransferase 1;CCnt;Pt;WBC;Qn;;CHEM;1;Carnitine palmitoyltransferase 1 [Enzymatic activity/mass] in Leukocytes;CPT1 WBC-cCnt;;ACTIVE;2.26;2.70 +53442-0;Carnitine palmitoyltransferase 2;CCnt;Pt;WBC;Qn;;CHEM;1;Carnitine palmitoyltransferase 2 [Enzymatic activity/mass] in Leukocytes;CPT2 WBC-cCnt;;ACTIVE;2.26;2.70 +53443-8;Carnitine palmitoyltransferase 2;CCnt;Pt;WBC^Control;Qn;;CHEM;1;Carnitine palmitoyltransferase 2 [Enzymatic activity/mass] in Control Leukocytes;CPT2 WBC Cont-cCnt;;ACTIVE;2.26;2.70 +53444-6;Citrate synthase;CCnt;Pt;WBC^Control;Qn;;CHEM;1;Citrate synthase [Enzymatic activity/mass] in Control Leukocytes;Citrate Synthase WBC Cont-cCnt;;ACTIVE;2.26;2.70 +53445-3;Carnitine palmitoyltransferase 2/Citrate synthase;CRto;Pt;Fibroblasts;Qn;;CHEM;1;Carnitine palmitoyltransferase 2/Citrate synthase [Enzymatic activity ratio] in Fibroblast;CPT2/Cit Syn Fib-cRto;;ACTIVE;2.26;2.48 +53446-1;Carnitine palmitoyltransferase 2/Citrate synthase;CRto;Pt;RBC;Qn;;CHEM;1;Carnitine palmitoyltransferase 2/Citrate synthase [Enzymatic activity ratio] in Red Blood Cells;CPT2/Cit Syn RBC-cRto;;ACTIVE;2.26;2.48 +5344-7;Salmonella paratyphi C O Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella paratyphi C O Ab [Presence] in Serum by Latex agglutination;S paraty C O Ab Ser Ql LA;;ACTIVE;1.0;2.56 +53447-9;Carboxymefloquine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carboxymefloquine [Mass/volume] in Serum or Plasma;Carboxymefloquine SerPl-mCnc;;ACTIVE;2.26;2.70 +53448-7;Cycloguanil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cycloguanil [Mass/volume] in Serum or Plasma;Cycloguanil SerPl-mCnc;;ACTIVE;2.26;2.70 +53449-5;Cyclophosphamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyclophosphamide [Mass/volume] in Serum or Plasma;Cyclophosphamide SerPl-mCnc;;ACTIVE;2.26;2.70 +53450-3;Cytarabine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cytarabine [Mass/volume] in Serum or Plasma;Cytarabine SerPl-mCnc;;ACTIVE;2.26;2.70 +53451-1;Uracil arabinoside;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Uracil arabinoside [Mass/volume] in Serum or Plasma;Uracil arabinoside SerPl-mCnc;;ACTIVE;2.26;2.70 +53452-9;Gamma 3 globulin.abnormal band;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma 3 globulin.abnormal band [Mass/volume] in Serum or Plasma by Electrophoresis;Gamma 3 glob abnormal SerPl Elph-mCnc;;ACTIVE;2.26;2.70 +53453-7;Cyclophosphamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cyclophosphamide [Mass/volume] in Urine;Cyclophosphamide Ur-mCnc;;ACTIVE;2.26;2.70 +5345-4;Salmonella typhi H Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella typhi H Ab [Presence] in Serum by Latex agglutination;S Typhi H Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53454-5;Iron^post dose deferoxamine;MCnc;Pt;Urine;Qn;;CHAL;1;Iron [Mass/volume] in Urine --post dose deferoxamine;Iron p deferoxamine Ur-mCnc;;ACTIVE;2.26;2.70 +53455-2;Calcium;MCnt;Pt;XXX;Qn;;CHEM;1;Calcium [Mass/mass] in Specimen;Calcium Spec-mCnt;;ACTIVE;2.26;2.70 +53456-0;Iron;MCnt;Pt;XXX;Qn;;CHEM;1;Iron [Mass/mass] in Specimen;Iron Spec-mCnt;;ACTIVE;2.26;2.73 +53457-8;Gamma 3 globulin.abnormal band/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma 3 globulin.abnormal band/Protein.total in Serum or Plasma by Electrophoresis;Gamma 3 glob abnormal MFr SerPl Elph;;ACTIVE;2.26;2.70 +53458-6;Carbon dioxide;PPres;Pt;Flu.nonbiological;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Nonbiological fluid;pCO2 Fld.NB;;ACTIVE;2.26;2.70 +53459-4;Decadienoylcarnitine (C10:2);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Decadienoylcarnitine (C10:2) [Moles/volume] in Amniotic fluid;Decadienoylcarn Amn-sCnc;;ACTIVE;2.26;2.70 +53460-2;Sebacylcarnitine (C10-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Sebacylcarnitine (C10-DC) [Moles/volume] in Amniotic fluid;Sebacylcarn Amn-sCnc;;ACTIVE;2.26;2.70 +53461-0;Eicosanoylcarnitine (C20);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Eicosanoylcarnitine (C20) [Moles/volume] in Amniotic fluid;Eicosanoylcarn Amn-sCnc;;ACTIVE;2.26;2.70 +5346-2;Salmonella typhi O Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Salmonella typhi O Ab [Presence] in Serum by Latex agglutination;S Typhi O Ab Ser Ql LA;;ACTIVE;1.0;2.73 +53462-8;Eicosanoylcarnitine (C20);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Eicosanoylcarnitine (C20) [Moles/volume] in DBS;Eicosanoylcarn DBS-sCnc;;ACTIVE;2.26;2.70 +53463-6;Beta aminoisobutyrate;SCnc;Pt;Body fld;Qn;;CHEM;1;Beta aminoisobutyrate [Moles/volume] in Body fluid;B-AIB Fld-sCnc;;ACTIVE;2.26;2.70 +53464-4;Decadienoylcarnitine (C10:2);SCnc;Pt;CSF;Qn;;CHEM;1;Decadienoylcarnitine (C10:2) [Moles/volume] in Cerebral spinal fluid;Decadienoylcarn CSF-sCnc;;ACTIVE;2.26;2.70 +53465-1;Sebacylcarnitine (C10-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Sebacylcarnitine (C10-DC) [Moles/volume] in Cerebral spinal fluid;Sebacylcarn CSF-sCnc;;ACTIVE;2.26;2.70 +53466-9;Eicosanoylcarnitine (C20);SCnc;Pt;CSF;Qn;;CHEM;1;Eicosanoylcarnitine (C20) [Moles/volume] in Cerebral spinal fluid;Eicosanoylcarn CSF-sCnc;;ACTIVE;2.26;2.70 +53467-7;3-Keto n-Valerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Keto n-Valerate [Moles/volume] in Serum or Plasma;3-Keto n-Valerate SerPl-sCnc;;ACTIVE;2.26;2.70 +53468-5;Anthranilate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Anthranilate [Moles/volume] in Serum or Plasma;Anthranilate SerPl-sCnc;;ACTIVE;2.26;2.70 +53469-3;Kynurenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Kynurenate [Moles/volume] in Serum or Plasma;Kynuren SerPl-sCnc;;ACTIVE;2.26;2.70 +5347-0;Schistosoma sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Schistosoma sp Ab [Units/volume] in Serum;Schistosoma Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53470-1;Kynurenin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Kynurenin [Moles/volume] in Serum or Plasma;Kynurenin SerPl-sCnc;;ACTIVE;2.26;2.70 +53471-9;Decadienoylcarnitine (C10:2);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decadienoylcarnitine (C10:2) [Moles/volume] in Serum or Plasma;Decadienoylcarn SerPl-sCnc;;ACTIVE;2.26;2.73 +53472-7;Sebacylcarnitine (C10-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sebacylcarnitine (C10-DC) [Moles/volume] in Serum or Plasma;Sebacylcarn SerPl-sCnc;;ACTIVE;2.26;2.70 +53473-5;Eicosanoylcarnitine (C20);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Eicosanoylcarnitine (C20) [Moles/volume] in Serum or Plasma;Eicosanoylcarn SerPl-sCnc;;ACTIVE;2.26;2.70 +53474-3;Glucose^4 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4 AM specimen;Glucose 4 AM specimen SerPl-sCnc;;ACTIVE;2.26;2.70 +53475-0;Glucose^pre dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre dose betaxolol;Glucose pre betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53476-8;Glucose^2H post dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post dose betaxolol;Glucose 2h p betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53477-6;Levodopa/Tyrosine;SRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Levodopa/Tyrosine [Molar ratio] in Serum or Plasma;L-Dopa/Tyr SerPl-sRto;;ACTIVE;2.26;2.42 +53478-4;Anthranilate;SRat;24H;Urine;Qn;;CHEM;1;Anthranilate [Moles/time] in 24 hour Urine;Anthranilate 24h Ur-sRate;;ACTIVE;2.26;2.70 +53479-2;Dihydroxycholestanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dihydroxycholestanoate [Moles/volume] in Serum or Plasma;Di-OH-cholestanoate SerPl-sCnc;;ACTIVE;2.26;2.70 +534-8;Mycobacterium sp identified;Prid;Pt;CSF;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Cerebral spinal fluid by Organism specific culture;Mycobacterium CSF Cult;;ACTIVE;1.0;2.73 +53480-0;Glucose^2.5H post dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose betaxolol;Glucose 2.5h p betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53481-8;Glucose^15M pre dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose betaxolol;Glucose 15M pre betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53482-6;Glucose^3H post dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post dose betaxolol;Glucose 3h p betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53483-4;Glucose^30M post dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose betaxolol;Glucose 30M p betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53484-2;Glucose^30M pre dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes pre dose betaxolol;Glucose 30M pre betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53485-9;Glucose^45M post dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose betaxolol;Glucose 45M p betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53486-7;Glucose^1H post dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post dose betaxolol;Glucose 1h p betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +53487-5;Glucose^1.5H post dose betaxolol;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose betaxolol;Glucose 1.5h p betaxolol SerPl-sCnc;;ACTIVE;2.26;2.70 +5348-8;SCL-70 extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA Scl70 Ab Ser Ql IA;;ACTIVE;1.0;2.73 +53488-3;3-O-Methyldopa;SCnc;24H;Urine;Qn;;DRUG/TOX;1;3-O-Methyldopa [Moles/volume] in 24 hour Urine;3-o-methyldopa 24h Ur-sCnc;;ACTIVE;2.26;2.70 +53489-1;Kynurenate;SRat;24H;Urine;Qn;;CHEM;1;Kynurenate [Moles/time] in 24 hour Urine;Kynuren 24h Ur-sRate;;ACTIVE;2.26;2.70 +53490-9;Kynurenin;SCnc;Pt;Urine;Qn;;CHEM;1;Kynurenin [Moles/volume] in Urine;Kynurenin Ur-sCnc;;ACTIVE;2.26;2.70 +53491-7;Kynurenin;SRat;24H;Urine;Qn;;CHEM;1;Kynurenin [Moles/time] in 24 hour Urine;Kynurenin 24h Ur-sRate;;ACTIVE;2.26;2.70 +53492-5;Decadienoylcarnitine (C10:2);SCnc;Pt;Urine;Qn;;CHEM;1;Decadienoylcarnitine (C10:2) [Moles/volume] in Urine;Decadienoylcarn Ur-sCnc;;ACTIVE;2.26;2.70 +53493-3;Sebacylcarnitine (C10-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Sebacylcarnitine (C10-DC) [Moles/volume] in Urine;Sebacylcarn Ur-sCnc;;ACTIVE;2.26;2.70 +53494-1;Eicosanoylcarnitine (C20);SCnc;Pt;Urine;Qn;;CHEM;1;Eicosanoylcarnitine (C20) [Moles/volume] in Urine;Eicosanoylcarn Ur-sCnc;;ACTIVE;2.26;2.70 +53495-8;Iron^post dose deferoxamine;SCnc;Pt;Urine;Qn;;CHAL;1;Iron [Moles/volume] in Urine --post dose deferoxamine;Iron p deferoxamine Ur-sCnc;;ACTIVE;2.26;2.70 +5349-6;SCL-70 extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA Scl70 Ab Ser Ql ID;;ACTIVE;1.0;2.73 +53496-6;3-Methoxy-4-Hydroxyphenylglycol;SCnc;24H;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Moles/volume] in 24 hour Urine;3Me4OH-phenylglycol 24h Ur-sCnc;;ACTIVE;2.26;2.70 +53497-4;5-Hydroxytryptophan;SCnc;24H;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Moles/volume] in 24 hour Urine;5OH-Tryptophan 24h Ur-sCnc;;ACTIVE;2.26;2.70 +53498-2;Anthranilate;SCnc;Pt;Urine;Qn;;CHEM;1;Anthranilate [Moles/volume] in Urine;Anthranilate Ur-sCnc;;ACTIVE;2.26;2.70 +53499-0;Creatinine;SCnc;12H;Urine;Qn;;CHEM;1;Creatinine [Moles/volume] in 12 hour Urine;Creat 12h Ur-sCnc;;ACTIVE;2.26;2.70 +53500-5;Ammonia;SCnc;Pt;Water;Qn;;CHEM;1;Ammonia [Moles/volume] in Water;Ammonia Wat-sCnc;;ACTIVE;2.26;2.70 +53501-3;Iron;SCnc;Pt;Water;Qn;;CHEM;1;Iron [Moles/volume] in Water;Iron Wat-sCnc;;ACTIVE;2.26;2.73 +53502-1;Calcium;SCnt;Pt;XXX;Qn;;CHEM;1;Calcium [Moles/mass] in Specimen;Calcium Spec-sCnt;;ACTIVE;2.26;2.70 +53503-9;Iron;SCnt;Pt;XXX;Qn;;CHEM;1;Iron [Moles/mass] in Specimen;Iron Spec-sCnt;;ACTIVE;2.26;2.70 +5350-4;Shigella sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Shigella sp Ab [Units/volume] in Serum;Shigella Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53504-7;Decanoylcarnitine (C10)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Decanoylcarnitine (C10)/Creatinine [Molar ratio] in Urine;Decanoylcarn/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53505-4;Asparagine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Asparagine/Amino acids.total in Serum or Plasma;Asparagine SFr SerPl;;ACTIVE;2.26;2.70 +53506-2;Citrulline/Amino acids.total;SFr;Pt;Plas;Qn;;CHEM;1;Citrulline/Amino acids.total in Plasma;Citrulline SFr Plas;;ACTIVE;2.26;2.70 +53507-0;Kynurenin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Kynurenin/Creatinine [Molar ratio] in Urine;Kynurenin/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53508-8;Decadienoylcarnitine (C10:2)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Decadienoylcarnitine (C10:2)/Creatinine [Molar ratio] in Urine;Decadienoylcarn/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53509-6;Sebacylcarnitine (C10-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sebacylcarnitine (C10-DC)/Creatinine [Molar ratio] in Urine;Sebacylcarn/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53510-4;Dodecanoylcarnitine (C12)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dodecanoylcarnitine (C12)/Creatinine [Molar ratio] in Urine;Dodecanoylcarn/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53511-2;Dodecenoylcarnitine (C12:1)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1)/Creatinine [Molar ratio] in Urine;Dodecenoylcarn/Creat Ur-sRto;;ACTIVE;2.26;2.70 +5351-2;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA SS-A Ab Ser Ql IA;;ACTIVE;1.0;2.73 +53512-0;Eicosanoylcarnitine (C20)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Eicosanoylcarnitine (C20)/Creatinine [Molar ratio] in Urine;Eicosanoylcarn/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53513-8;Anthranilate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Anthranilate/Creatinine [Molar ratio] in Urine;Anthranilate/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53514-6;Carnitine palmitoyltransferase 2;CCnt;Pt;Fibroblasts^Control;Qn;;CHEM;1;Carnitine palmitoyltransferase 2 [Enzymatic activity/mass] in Control Fibroblast;CPT2 Fib Cont-cCnt;;ACTIVE;2.26;2.70 +53515-3;Citrate synthase;CCnt;Pt;Fibroblasts^Control;Qn;;CHEM;1;Citrate synthase [Enzymatic activity/mass] in Control Fibroblast;Citrate Synthase Fib Cont-cCnt;;ACTIVE;2.26;2.70 +53516-1;Basophils/100 leukocytes;NFr;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Dialysis fluid by Manual count;Basophils/leuk NFr Dial fld Manual;;ACTIVE;2.26;2.50 +53517-9;Erythrocytes;NCnc;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Dialysis fluid by Manual count;RBC # Dial fld Manual;;ACTIVE;2.26;2.70 +53518-7;Leukocytes;NCnc;Pt;Dial fld;Qn;;HEM/BC;1;Leukocytes [#/volume] in Dialysis fluid;WBC # Dial fld;;ACTIVE;2.26;2.70 +53519-5;Monocytes/100 leukocytes;NFr;Pt;Dial fld;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Dialysis fluid;Monocytes/leuk NFr Dial fld;;ACTIVE;2.26;2.50 +5352-0;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA SS-A Ab Ser Ql ID;;ACTIVE;1.0;2.73 +53520-3;Neutrophils/100 leukocytes;NFr;Pt;Dial fld;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Dialysis fluid;Neutrophils/leuk NFr Dial fld;;ACTIVE;2.26;2.50 +53521-1;Polymorphonuclear cells;NCnc;Pt;Semen;Qn;;FERT;1;Polymorphonuclear cells [#/volume] in Semen;Polys # Smn;;ACTIVE;2.26;2.70 +53522-9;Microscopic observation;Prid;Pt;Bronchial;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Bronchial specimen by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Bronch;;ACTIVE;2.26;2.26 +53523-7;Vasoactive intestinal peptide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vasoactive intestinal peptide [Moles/volume] in Serum or Plasma;VIP SerPl-sCnc;;ACTIVE;2.26;2.70 +53524-5;Alkaline phosphatase.bile/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.bile/Alkaline phosphatase.total in Serum or Plasma;ALP Bile CFr SerPl;;ACTIVE;2.26;2.70 +53525-2;Protein;PrThr;Pt;Urine;Ord;SSA;CHEM;1;Protein [Presence] in Urine by SSA method;Prot Ur Ql SSA;;ACTIVE;2.26;2.73 +53526-0;Triglyceride.in VLDL;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride in VLDL [Moles/volume] in Serum or Plasma;Trigl in VLDL SerPl-sCnc;;ACTIVE;2.26;2.40 +53527-8;Triglyceride.in HDL 2;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride in HDL 2 [Moles/volume] in Serum or Plasma;Trigl in HDL2 SerPl-sCnc;;ACTIVE;2.26;2.40 +53528-6;Triglyceride.in HDL 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride in HDL 3 [Moles/volume] in Serum or Plasma;Trigl in HDL3 SerPl-sCnc;;ACTIVE;2.26;2.40 +53529-4;Albumin;MCnc;Pt;Body fld;Qn;Detection limit <= 1.0 mg/L;CHEM;1;Microalbumin [Mass/volume] in Body fluid by Detection limit <= 1.0 mg/L;Microalbumin Fld DL<=1mg/L-mCnc;;ACTIVE;2.26;2.73 +53530-2;Albumin;MCnc;24H;Urine;Qn;Detection limit <= 1.0 mg/L;CHEM;1;Microalbumin [Mass/volume] in 24 hour Urine by Detection limit <= 1.0 mg/L;Microalbumin 24h Ur DL<=1mg/L-mCnc;;ACTIVE;2.26;2.73 +53531-0;Albumin;MCnc;Pt;Urine;Qn;Detection limit <= 1.0 mg/L;CHEM;1;Microalbumin [Mass/volume] in Urine by Detection limit <= 1.0 mg/L;Microalbumin Ur DL<=1mg/L-mCnc;;ACTIVE;2.26;2.73 +53532-8;Albumin;MRat;24H;Urine;Qn;Detection limit <= 1.0 mg/L;CHEM;1;Microalbumin [Mass/time] in 24 hour Urine by Detection limit <= 1.0 mg/L;Microalbumin 24h Ur DL<=1mg/L-mRate;;ACTIVE;2.26;2.73 +53533-6;Herpes simplex virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Herpes simplex virus IgG Ab [Presence] in Body fluid by Immunoassay;HSV IgG Fld Ql IA;;ACTIVE;2.26;2.56 +53534-4;Varicella zoster virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Varicella zoster virus IgG Ab [Presence] in Body fluid by Immunoassay;VZV IgG Fld Ql IA;;ACTIVE;2.26;2.56 +53535-1;Varicella zoster virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Varicella zoster virus IgM Ab [Presence] in Body fluid by Immunoassay;VZV IgM Fld Ql IA;;ACTIVE;2.26;2.56 +53536-9;Measles virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Measles virus IgG Ab [Presence] in Body fluid by Immunoassay;MeV IgG Fld Ql IA;;ACTIVE;2.26;2.56 +53537-7;Measles virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Measles virus IgM Ab [Presence] in Body fluid by Immunoassay;MeV IgM Fld Ql IA;;ACTIVE;2.26;2.56 +5353-8;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA SS-B Ab Ser Ql IA;;ACTIVE;1.0;2.73 +53538-5;Herpes simplex virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Herpes simplex virus IgM Ab [Presence] in Body fluid by Immunoassay;HSV IgM Fld Ql IA;;ACTIVE;2.26;2.56 +53539-3;Alpha globulin.abnormal band;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha globulin.abnormal band [Mass/volume] in Serum or Plasma by Electrophoresis;Alpha Glob.abnormal SerPl Elph-mCnc;;ACTIVE;2.26;2.73 +53540-1;Alpha globulin.abnormal band/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha globulin.abnormal band/Protein.total in Serum or Plasma by Electrophoresis;Alpha Glob.abnormal MFr SerPl Elph;;ACTIVE;2.26;2.73 +53541-9;Epithelial cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Epithelial cells [Presence] in Blood by Light microscopy;Epi Cells Bld Ql Smear;;ACTIVE;2.26;2.56 +53542-7;Dodeicosanoylcarnitine (C22);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dodeicosanoylcarnitine (C22) [Moles/volume] in Amniotic fluid;Dodeicosanoylcarn Amn-sCnc;;ACTIVE;2.26;2.70 +53543-5;Dodeicosanoylcarnitine (C22);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dodeicosanoylcarnitine (C22) [Moles/volume] in DBS;Dodeicosanoylcarn DBS-sCnc;;ACTIVE;2.26;2.70 +53544-3;3,4-Dihydroxyphenylacetate;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;3,4-Dihydroxyphenylacetate [Moles/volume] in Cerebral spinal fluid;3,4-DiOH-phenylacetate CSF-sCnc;;ACTIVE;2.26;2.70 +53545-0;Dodeicosanoylcarnitine (C22);SCnc;Pt;CSF;Qn;;CHEM;1;Dodeicosanoylcarnitine (C22) [Moles/volume] in Cerebral spinal fluid;Dodeicosanoylcarn CSF-sCnc;;ACTIVE;2.26;2.70 +5354-6;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA SS-B Ab Ser Ql ID;;ACTIVE;1.0;2.73 +53546-8;Dodeicosanoylcarnitine (C22);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dodeicosanoylcarnitine (C22) [Moles/volume] in Serum or Plasma;Dodeicosanoylcarn SerPl-sCnc;;ACTIVE;2.26;2.70 +53547-6;3,4-Dihydroxyphenylacetate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;3,4-Dihydroxyphenylacetate [Moles/volume] in Serum or Plasma;3,4-DiOH-phenylacetate SerPl-sCnc;;ACTIVE;2.26;2.70 +53548-4;3,4-Dihydroxyphenylacetate;SRat;24H;Urine;Qn;;DRUG/TOX;1;3,4-Dihydroxyphenylacetate [Moles/time] in 24 hour Urine;3,4-DiOH-phenylacetate 24h Ur-sRate;;ACTIVE;2.26;2.70 +53549-2;Dodeicosanoylcarnitine (C22);SCnc;Pt;Urine;Qn;;CHEM;1;Dodeicosanoylcarnitine (C22) [Moles/volume] in Urine;Dodeicosanoylcarn Ur-sCnc;;ACTIVE;2.26;2.70 +535-5;Mycobacterium sp identified;Prid;Pt;Body fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Body fluid by Organism specific culture;Mycobacterium Fld Cult;;ACTIVE;1.0;2.73 +53550-0;Fructosamine/Protein;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Fructosamine/Protein [Ratio] in Serum or Plasma;Fructosamine/Prot SerPl-Rto;;ACTIVE;2.26;2.70 +53551-8;3,4-Dihydroxyphenylacetate/Creatinine;SRto;24H;Urine;Qn;;DRUG/TOX;1;3,4-Dihydroxyphenylacetate/Creatinine [Molar ratio] in 24 hour Urine;3,4-DiOH-phenylacetate/Creat 24h Ur-sRto;;ACTIVE;2.26;2.70 +53552-6;Dodeicosanoylcarnitine (C22)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dodeicosanoylcarnitine (C22)/Creatinine [Molar ratio] in Urine;Dodeicosanoylcarn/Creat Ur-sRto;;ACTIVE;2.26;2.70 +5355-3;Smith extractable nuclear Ab;PrThr;Pt;Ser;Ord;CIE;SERO;1;Smith extractable nuclear Ab [Presence] in Serum by Counterimmunoelectrophoresis (CIE);ENA SM Ab Ser Ql CIE;;ACTIVE;1.0;2.56 +53553-4;Estimated average glucose;SCnc;Pt;Bld;Qn;Estimated from glycated hemoglobin;CHEM;1;Glucose mean value [Moles/volume] in Blood Estimated from glycated hemoglobin;Est. average glucose Bld gHb Est-sCnc;;ACTIVE;2.26;2.73 +53554-2;Nitrogen;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Nitrogen [Mass/volume] in Air;N2 Air-mCnc;;ACTIVE;2.26;2.70 +53555-9;Specific gravity;Rden;Pt;RBC;Qn;;CHEM;1;Specific gravity of Red Blood Cells;Sp Gr RBC;;ACTIVE;2.26;2.26 +53556-7;Erythrocytes.Plasmodium sp infected/100 erythrocytes;NFr;Pt;Bld;Qn;;MICRO;1;Erythrocytes.Plasmodium sp infected/100 erythrocytes in Blood;Plasmodium infected RBC/100 RBC Bld-NFr;;ACTIVE;2.26;2.73 +53557-5;Nucleated cells;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Synovial fluid by Manual count;Nuc cell # Snv Manual;;ACTIVE;2.26;2.73 +53558-3;Bacteria identified;Prid;Pt;Semen;Nom;Culture;MICRO;1;Bacteria identified in Semen by Culture;Bacteria Smn Cult;;ACTIVE;2.26;2.73 +53559-1;Beta-2 transferrin;MCnc;Pt;CSF;Qn;;CHEM;1;Beta-2 transferrin [Mass/volume] in Cerebral spinal fluid;B2 Transferrin CSF-mCnc;;ACTIVE;2.26;2.70 +53560-9;Herpes simplex virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus IgM Ab [Units/volume] in Serum by Immunoassay;HSV IgM Ser IA-aCnc;;ACTIVE;2.26;2.69 +5356-1;Smith extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Smith extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA SM Ab Ser Ql IA;;ACTIVE;1.0;2.73 +53561-7;Lactate dehydrogenase/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Lactate dehydrogenase/Creatinine [Ratio] in Urine;LDH/Creat Ur-Rto;;ACTIVE;2.26;2.70 +53562-5;Rheumatoid factor;ACnc;Pt;Plr fld;Qn;;SERO;1;Rheumatoid factor [Units/volume] in Pleural fluid;Rheumatoid fact Plr-aCnc;;ACTIVE;2.26;2.70 +53563-3;Platelet aggregation.adenosine diphosphate induced^20 umol/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --20 umol/mL;PA ADP 20 umol/mL PRP;;ACTIVE;2.26;2.70 +53564-1;Platelet aggregation.adenosine diphosphate induced^50 umol/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --50 umol/mL;PA ADP 50 umol/mL PRP;;ACTIVE;2.26;2.70 +53565-8;Platelet aggregation.adenosine diphosphate induced^100 umol/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --100 umol/mL;PA ADP 100 umol/mL PRP;;ACTIVE;2.26;2.70 +53566-6;Platelet aggregation.collagen induced^8.0 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation collagen induced in Platelet rich plasma --8.0 ug/mL;PA Coll 8.0 ug/mL PRP;;ACTIVE;2.26;2.70 +53567-4;Platelet aggregation.EPINEPHrine induced^0.1 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --0.1 ug/mL;PA Epineph 0.1 ug/mL PRP;;ACTIVE;2.26;2.73 +53568-2;Platelet aggregation.arachidonate induced^500 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation arachidonate induced in Platelet rich plasma --500 ug/mL;PA AA 500 ug/mL PRP;;ACTIVE;2.26;2.73 +53569-0;Platelet aggregation.ristocetin induced^800 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --800 ug/mL;PA Rist 800 ug/mL PRP;;ACTIVE;2.26;2.70 +53570-8;Coagulation surface induced.lupus insensitive;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus insensitive in Platelet poor plasma by Coagulation assay;aPTT-LA insens PPP;;ACTIVE;2.26;2.73 +53571-6;Yeast identified;Prid;Pt;Genital;Nom;Organism specific culture;MICRO;1;Yeast identified in Genital specimen by Organism specific culture;Yeast Genital Cult;;ACTIVE;2.26;2.73 +53572-4;Staphylococcus aureus.methicillin resistant isolate;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Methicillin resistant Staphylococcus aureus [Presence] in Genital specimen by Organism specific culture;MRSA Genital Ql Cult;;ACTIVE;2.26;2.56 +53573-2;cycloSPORINE^post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --post dose;cycloSPORINE p dose Bld-mCnc;;ACTIVE;2.26;2.73 +53574-0;Immunoglobulin light chains.lambda.free;MCnc;24H;Urine;Qn;;CHEM;1;Lambda light chains.free [Mass/volume] in 24 hour Urine;Lambda LC Free 24h Ur-mCnc;;ACTIVE;2.26;2.73 +53575-7;VAP panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Deprecated VAP cholesterol panel - Serum or Plasma;Deprecated VAP Pnl SerPl;;DEPRECATED;2.26;2.65 +53576-5;Personal health monitoring report;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Personal health monitoring report Document;PH monitoring report Doc;;ACTIVE;2.26;2.73 +53577-3;Reason for study additional note;Txt;Pt;Bld/Tiss;Nar;Molgen;HL7.GENETICS;1;Reason for study;Reason for study;;ACTIVE;2.26;2.73 +53578-1;Alkaline phosphatase.intestinal 2/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.intestinal 2/Alkaline phosphatase.total in Serum or Plasma;ALP Intest 2 CFr SerPl;;ACTIVE;2.26;2.42 +5357-9;Smith extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Smith extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA SM Ab Ser Ql ID;;ACTIVE;1.0;2.73 +53579-9;Alkaline phosphatase.intestinal 3/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.intestinal 3/Alkaline phosphatase.total in Serum or Plasma;ALP Intest 3 CFr SerPl;;ACTIVE;2.26;2.34 +53580-7;Galactosylceramidase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Galactosylceramidase [Enzymatic activity/mass] in Amniotic fluid cells;GALC Amnc-cCnt;;ACTIVE;2.26;2.42 +53581-5;Angiotensin converting enzyme;CCnc;Pt;Periton fld;Qn;;CHEM;1;Angiotensin converting enzyme [Enzymatic activity/volume] in Peritoneal fluid;ACE Prt-cCnc;;ACTIVE;2.26;2.68 +53582-3;Echovirus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echovirus Ab [Units/volume] in Serum by Immunoassay;ECV Ab Ser IA-aCnc;;ACTIVE;2.26;2.69 +53583-1;Echovirus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echovirus IgM Ab [Units/volume] in Serum by Immunoassay;ECV IgM Ser IA-aCnc;;ACTIVE;2.26;2.69 +53584-9;Loa loa DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Loa loa DNA [Presence] in Blood by NAA with probe detection;L loa DNA Bld Ql NAA+probe;;ACTIVE;2.26;2.63 +53585-6;Toxocara canis Ab.IgE;ACnc;Pt;Ser;Qn;;MICRO;1;Toxocara canis IgE Ab [Units/volume] in Serum;T canis IgE Ser-aCnc;;ACTIVE;2.26;2.70 +53586-4;HLA-B6;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B6 [Presence];HLA-B6 Ql;;ACTIVE;2.26;2.56 +5358-7;Smooth muscle Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Smooth muscle Ab [Titer] in Serum by Immunofluorescence;Smooth muscle Ab Titr Ser IF;;ACTIVE;1.0;2.73 +53587-2;Beta globulin.abnormal band;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin.abnormal band [Mass/volume] in Serum or Plasma by Electrophoresis;Beta glob abnormal SerPl Elph-mCnc;;ACTIVE;2.26;2.70 +53588-0;Beta globulin+Gamma globulin.abnormal band;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin+Gamma globulin.abnormal band [Mass/volume] in Serum or Plasma by Electrophoresis;B+G-Globulin abnormal SerPl Elph-mCnc;;ACTIVE;2.26;2.73 +53589-8;Beta globulin.abnormal band/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin.abnormal band/Protein.total in Serum or Plasma by Electrophoresis;Beta glob abnormal MFr SerPl Elph;;ACTIVE;2.26;2.73 +53590-6;Gamma globulin.abnormal band/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma globulin.abnormal band/Protein.total in Serum or Plasma by Electrophoresis;Gamma glob abnormal MFr SerPl Elph;;ACTIVE;2.26;2.73 +53591-4;Gamma globulin.abnormal band;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma globulin.abnormal band [Mass/volume] in Serum or Plasma by Electrophoresis;Gamma glob abnormal SerPl Elph-mCnc;;ACTIVE;2.26;2.73 +53592-2;Gamma 2 globulin.abnormal band;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma 2 globulin.abnormal band [Mass/volume] in Serum or Plasma by Electrophoresis;Gamma 2 glob abnormal SerPl Elph-mCnc;;ACTIVE;2.26;2.73 +53593-0;Gamma 2 globulin.abnormal band/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma 2 globulin.abnormal band/Protein.total in Serum or Plasma by Electrophoresis;Gamma 2 glob abnormal MFr SerPl Elph;;ACTIVE;2.26;2.73 +53594-8;Chitobioside Ab.IgA;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Chitobioside IgA Ab [Units/volume] in Serum or Plasma by Immunoassay;Chitobioside IgA SerPl IA-aCnc;;ACTIVE;2.26;2.73 +5359-5;Somatotropin Ab;ACnc;Pt;Ser/Plas;Qn;RIA;SERO;1;Somatotropin Ab [Units/volume] in Serum or Plasma by Radioimmunoassay (RIA);GH Ab SerPl RIA-aCnc;;ACTIVE;1.0;2.69 +53595-5;Homovanillate;MCnc;24H;Urine;Qn;;CHEM;1;Homovanillate [Mass/volume] in 24 hour Urine;HVA 24h Ur-mCnc;;ACTIVE;2.26;2.73 +53596-3;Laminaribioside Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Laminaribioside IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Laminaribioside IgG SerPl IA-aCnc;;ACTIVE;2.26;2.73 +53597-1;Mannobioside Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Mannobioside IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Mannobioside IgG SerPl IA-aCnc;;ACTIVE;2.26;2.73 +53598-9;Irritable bowel disease prognostic panel;-;Pt;Ser/Plas;Qn;IA;PANEL.SERO;1;Irritable bowel disease prognostic panel - Serum or Plasma by Immunoassay;IBD prognostic Pnl SerPl IA;;ACTIVE;2.26;2.56 +53599-7;ZIP code of prior primary residence;Loc;Pt;^Patient;Nom;;SURVEY.MDS;4;Deprecated ZIP code of prior primary residence;;"InterRAI holds the copyright to Version 2.0 of the RAI for long term care outside of the US. Supplemental help and contextual information for MDS items in LOINC was derived from Version 2.0 of the RAI/MDS manual, and should not be reproduced outside of the United States without permission of InterRAI. Within the US, Version 2.0 is in the public domain. As a not for profit corporation under the US Tax Code, interRAI holds the copyright to a number of assessment systems, including the Resident Assessment Instrument (RAI) for long term care facilities outside of the US (the RAI is in the public domain within the US), as well as the assessment systems for Home Care (HC), Assisted Living (AL), Palliative Care (PC), Mental Health (MH) (outside of Canada), and Acute Care (RAI-AC). The scales, algorithms, and case-mix measures based on these assessment instruments cannot be copyrighted and are thus available to everyone (although the individual items on which they are based are usually copyrighted). The major clauses of our royalty-free licenses follow: * the instrument is not to be changed substantially (excepting individual identifiers and demographics); * the license is limited to non-commercial use (i.e., the instrument will not be not incorporated into products to be sold to others); * no royalties will be charged; * the organization will make appropriate efforts to inform others of the copyright status of the instrument; * interRAI's logo and copyright notice are to appear on the form; * authors, author institutions, and translators (as appropriate) are to be acknowledged in any document where authors would regularly be indicated (e.g., publication of a training manual); * publication of any training manual is limited to the period until a commercially-published version is available; * data from use of the instrument are to be shared with interRAI, subject to existing laws on confidentiality. Commercial use usually requires royalties. In this instance, interRAI may omit the data requirement, but retains the other requirements for a logo, attribution, etc. We will be pleased in any contract negotiations to acknowledge the participation of individuals or organizations which have played a substantial role in getting the instrument to the point of implementation. For more information on licensing with interRAI, please contact the president of the Board: Brant E. Fries, Ph.D. Institute of Gerontology University of Michigan 300 North Ingalls Ann Arbor, Michigan USA 48109 Email: bfries@umich.edu";DEPRECATED;2.26;2.50 +53600-3;pH;LsCnc;Pt;^BPU;Qn;;CHEM;1;pH of Blood product unit;pH BPU;;ACTIVE;2.26;2.42 +53601-1;HIV 1 p24 Ag;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay;HIV1 p24 Ag SerPl IA-aCnc;;ACTIVE;2.26;2.69 +53602-9;Taenia solium larva Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Taenia solium larva Ag [Units/volume] in Serum;T sol lar Ag Ser-aCnc;;ACTIVE;2.26;2.69 +5360-3;Spermatozoa Ab;ACnc;Pt;Cvm;Qn;;FERT;1;Spermatozoa Ab [Units/volume] in Cervical mucus;Sperm Ab Cerv mucus-aCnc;;ACTIVE;1.0;2.69 +53603-7;Mumps virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Mumps virus RNA [Presence] in Serum by NAA with probe detection;MuV RNA Ser Ql NAA+probe;;ACTIVE;2.26;2.73 +53604-5;Brucella sp DNA;Prid;Pt;Ser;Nom;Probe.amp.tar;MICRO;1;Brucella sp DNA [Identifier] in Serum by NAA with probe detection;Brucella DNA Ser NAA+probe;;ACTIVE;2.26;2.63 +53605-2;Treponema pallidum DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Treponema pallidum DNA [Presence] in Blood by NAA with probe detection;T pallidum DNA Bld Ql NAA+probe;;ACTIVE;2.26;2.73 +53606-0;Neisseria meningitidis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Presence] in Blood by NAA with probe detection;N men DNA Bld Ql NAA+probe;;ACTIVE;2.26;2.73 +53607-8;Haemophilus influenzae B DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae B DNA [Presence] in Blood by NAA with probe detection;Haem influ B DNA Bld Ql NAA+probe;;ACTIVE;2.26;2.63 +53608-6;Rickettsia sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Rickettsia sp DNA [Presence] in Blood by NAA with probe detection;Rickettsia DNA Bld Ql NAA+probe;;ACTIVE;2.26;2.63 +53609-4;Parasite identified;Prid;Pt;Bone mar;Nom;Microscopy.light;MICRO;1;Parasite identified in Bone marrow by Light microscopy;Parasite Mar Micro;;ACTIVE;2.26;2.26 +53610-2;Erythroid cells;NCnc;Pt;Bld/Bone mar;Qn;;HEM/BC;1;Erythroid cells [#/volume] in Blood or Marrow;Erythroid Cells # Bld/Mar;;ACTIVE;2.26;2.44 +5361-1;Spermatozoa Ab;ACnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Ab [Units/volume] in Semen;Sperm Ab Smn-aCnc;;ACTIVE;1.0;2.73 +53611-0;Toxoplasma gondii;PrThr;Pt;CSF;Ord;IF;MICRO;1;Toxoplasma gondii [Presence] in Cerebral spinal fluid by Immunofluorescence;T gondii CSF Ql IF;;ACTIVE;2.26;2.56 +53612-8;Urate;MCnc;Pt;Body fld;Qn;;CHEM;1;Urate [Mass/volume] in Body fluid;Urate Fld-mCnc;;ACTIVE;2.26;2.73 +53613-6;Benzoylcarnitine (BzCn);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Benzoylcarnitine (BzCn) [Moles/volume] in DBS;Benzoylcarn DBS-sCnc;;ACTIVE;2.26;2.61 +53614-4;Bacteria identified^^^2;Prid;Pt;Duod fld;Nom;Aerobic culture;MICRO;1;Bacteria # 2 identified in Duodenal fluid by Aerobe culture;Bacteria Duod fl Aerobe Cult org #2;;ACTIVE;2.26;2.73 +53615-1;Bacteria identified^^^3;Prid;Pt;Duod fld;Nom;Aerobic culture;MICRO;1;Bacteria # 3 identified in Duodenal fluid by Aerobe culture;Bacteria Duod fl Aerobe Cult org #3;;ACTIVE;2.26;2.73 +53616-9;Bacteria identified^^^4;Prid;Pt;Duod fld;Nom;Aerobic culture;MICRO;1;Bacteria # 4 identified in Duodenal fluid by Aerobe culture;Bacteria Duod fl Aerobe Cult org #4;;ACTIVE;2.26;2.73 +53617-7;Bacteria identified;Prid;Pt;Duod fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Duodenal fluid by Aerobe culture;Bacteria Duod fl Aerobe Cult;;ACTIVE;2.26;2.73 +53618-5;Cells.ZAP70;PrThr;Pt;XXX;Ord;;CELLMARK;1;ZAP70 cells [Presence] in Specimen;ZAP70 Cells Spec Ql;;ACTIVE;2.26;2.73 +53619-3;Cells.ZAP70;PrThr;Pt;Bone mar;Ord;;CELLMARK;1;ZAP70 cells [Presence] in Bone marrow;ZAP70 Cells Mar Ql;;ACTIVE;2.26;2.56 +53620-1;KRAS gene targeted mutation analysis;Prid;Pt;Bone mar;Nom;Molgen;MOLPATH.MUT;1;KRAS gene mutations found [Identifier] in Bone marrow by Molecular genetics method Nominal;KRAS gene Mut Anl Mar;;ACTIVE;2.26;2.63 +53621-9;NRAS gene targeted mutation analysis;Prid;Pt;Bone mar;Nom;Molgen;MOLPATH.MUT;1;NRAS gene mutations found [Identifier] in Bone marrow by Molecular genetics method Nominal;NRAS gene Mut Anl Mar;;ACTIVE;2.26;2.73 +53622-7;von Willebrand factor cleaving protease actual/normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;von Willebrand factor (vWf) cleaving protease actual/normal in Platelet poor plasma by Chromogenic method;vWF Cp Act/Nor PPP Chro;;ACTIVE;2.26;2.73 +53623-5;HRAS gene targeted mutation analysis;Prid;Pt;Bone mar;Nom;Molgen;MOLPATH.MUT;1;HRAS gene mutations found [Identifier] in Bone marrow by Molecular genetics method Nominal;HRAS gene Mut Anl Mar;;ACTIVE;2.26;2.63 +53624-3;Carnitine esters;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Carnitine esters [Moles/volume] in DBS;Carn esters DBS-sCnc;;ACTIVE;2.26;2.70 +53625-0;Leishmania sp identified;Prid;Pt;Tiss;Nom;;MICRO;1;Leishmania sp identified in Tissue;Leishmania Tiss;;ACTIVE;2.26;2.26 +53626-8;Cerebral atrophic index;VFr;Pt;^Patient;Qn;CT;RAD;2;CT Cerebral atrophic index;CT VFr Cerebral atrophic index;;ACTIVE;2.26;2.50 +53627-6;Chloride;SCnc;Pt;Plr fld;Qn;;CHEM;1;Chloride [Moles/volume] in Pleural fluid;Chloride Plr-sCnc;;ACTIVE;2.26;2.70 +53628-4;20q chromosome deletion;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;20q chromosome deletion [Identifier] in Blood or Tissue by FISH Nominal;20q chromosome Del Bld/T FISH;;ACTIVE;2.26;2.73 +5362-9;Spermatozoa Ab;ACnc;Pt;Ser;Qn;;FERT;1;Spermatozoa Ab [Units/volume] in Serum;Sperm Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53629-2;Alpha cortol;MRat;24H;Urine;Qn;;CHEM;1;Alpha cortol [Mass/time] in 24 hour Urine;A-Cortol 24h Ur-mRate;;ACTIVE;2.26;2.70 +536-3;Mycobacterium sp identified;Prid;Pt;Bone mar;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Bone marrow by Organism specific culture;Mycobacterium Mar Cult;;ACTIVE;1.0;2.19 +53630-0;Alpha cortol/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Alpha cortol/Creatinine [Mass Ratio] in 24 hour Urine;A-Cortol/Creat 24h Ur;;ACTIVE;2.26;2.70 +53631-8;Alpha cortol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha cortol/Creatinine [Mass Ratio] in Urine;A-Cortol/Creat Ur;;ACTIVE;2.26;2.70 +53632-6;Breast Cancer Ag 225;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Breast Cancer Ag 225 [Presence] in Tissue by Immune stain;BCA 255 Tiss Ql ImStn;;ACTIVE;2.26;2.73 +53633-4;BCL1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BCL1 Ag [Presence] in Tissue by Immune stain;BCL1 Ag Tiss Ql ImStn;;ACTIVE;2.26;2.73 +53634-2;Beta cortol;MRat;24H;Urine;Qn;;CHEM;1;Beta cortol [Mass/time] in 24 hour Urine;Beta cortol 24h Ur-mRate;;ACTIVE;2.26;2.70 +53635-9;Beta cortol/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Beta cortol/Creatinine [Mass Ratio] in 24 hour Urine;Beta cortol/Creat 24h Ur;;ACTIVE;2.26;2.70 +53636-7;Beta cortol/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Beta cortol/Creatinine [Mass Ratio] in Urine;Beta cortol/Creat Ur;;ACTIVE;2.26;2.70 +5363-7;Spirillum minus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Spirillum minus Ab [Units/volume] in Serum;Spirillum minus Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53637-5;BOB1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;BOB1 Ag [Presence] in Tissue by Immune stain;BOB1 Ag Tiss Ql ImStn;;ACTIVE;2.26;2.73 +53638-3;CD45RB Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD45RB Ag [Presence] in Tissue by Immune stain;CD45RB Ag Tiss Ql ImStn;;ACTIVE;2.26;2.56 +53639-1;CD52 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD52 Ag [Presence] in Tissue by Immune stain;CD52 Ag Tiss Ql ImStn;;ACTIVE;2.26;2.56 +53640-9;Chloride/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Chloride/Creatinine [Ratio] in 24 hour Urine;Chloride/Creat 24h Ur-Rto;;ACTIVE;2.26;2.73 +53641-7;OCT2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;OCT2 Ag [Presence] in Tissue by Immune stain;OCT2 Ag Tiss Ql ImStn;;ACTIVE;2.26;2.56 +53642-5;Glutathione.reduced/glutathione.oxidized;SRto;Pt;Bld;Qn;;CHEM;1;Glutathione.reduced/glutathione.oxidized [Molar ratio] in Blood;GSH/GSS Bld-sRto;;ACTIVE;2.26;2.42 +53643-3;Dichlorodiphenyltrichloroethane;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Dichlorodiphenyltrichloroethane [Presence] in Gastric fluid;DDT Gast Ql;;ACTIVE;2.26;2.56 +53644-1;Carbaryl;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Carbaryl [Presence] in Gastric fluid;Carbaryl Gast Ql;;ACTIVE;2.26;2.56 +5364-5;Sporothrix schenckii Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Sporothrix schenckii Ab [Units/volume] in Serum;S schenckii Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53645-8;Polio virus identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Polio virus identified in Stool by Organism specific culture;PV Stl Cult;;ACTIVE;2.26;2.26 +53646-6;Aldicarb;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Aldicarb [Presence] in Gastric fluid;Aldicarb Gast Ql;;ACTIVE;2.26;2.56 +53647-4;Flavin adenine dinucleotide;MCnc;Pt;Bld;Qn;;CHEM;1;Flavin adenine dinucleotide [Mass/volume] in Blood;FAD Bld-mCnc;;ACTIVE;2.26;2.70 +53648-2;Flavin mononucleotide;MCnc;Pt;Bld;Qn;;CHEM;1;Flavin mononucleotide [Mass/volume] in Blood;Flavin mononucleotide Bld-mCnc;;ACTIVE;2.26;2.70 +53649-0;Parathion;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Parathion [Mass/volume] in Gastric fluid;Parathion Gast-mCnc;;ACTIVE;2.26;2.70 +53650-8;Methyl parathion;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methyl parathion [Mass/volume] in Gastric fluid;Methyl Parathion Gast-mCnc;;ACTIVE;2.26;2.70 +53651-6;pH;LsCnc;2H;Urine;Qn;;CHEM;1;pH of 2 hour Urine;pH 2h Ur;;ACTIVE;2.26;2.42 +5365-2;Saint Louis encephalitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus Ab [Units/volume] in Serum;SLEV Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53652-4;pH;LsCnc;4H;Urine;Qn;;CHEM;1;pH of 4 hour Urine;pH 4h Ur;;ACTIVE;2.26;2.42 +53653-2;pH;LsCnc;Pt;Bil fld;Qn;;CHEM;1;pH of Bile fluid;pH Bifl;;ACTIVE;2.26;2.42 +53654-0;pH;LsCnc;Pt;Dial fld;Qn;;CHEM;1;pH of Dialysis fluid;pH Dial fld;;ACTIVE;2.26;2.42 +53655-7;Diameter.transverse;Len;Pt;Heart^Fetus;Qn;US.measured;OB.US;2;Fetal Heart Diameter transverse US;Fet Hrt Diam transverse US.meas;;ACTIVE;2.26;2.48 +53656-5;Diameter.anterior-posterior;Len;Pt;Heart^Fetus;Qn;US.measured;OB.US;2;Fetal Heart Diameter.anterior-posterior US;Fet Hrt Diam AP US.meas;;ACTIVE;2.26;2.48 +53657-3;Perimeter;Len;Pt;Heart^Fetus;Qn;US.measured;OB.US;2;Fetal Heart Circumference US;Fet Hrt Circum US.meas;;ACTIVE;2.26;2.48 +53658-1;Diameter;Len;Pt;Aorta^Fetus;Qn;US.measured;OB.US;2;Fetal Aorta Diameter US;Fet Aorta Diam US.meas;;ACTIVE;2.26;2.48 +53659-9;Blood flow velocity.mean;Vel;Pt;Cerebral artery middle^Fetus;Qn;US.doppler;OB.US;2;Fetal Cerebral artery middle Mean blood flow velocity US.doppler;Fet Cerebral a Middle Vmean DOP;;ACTIVE;2.26;2.67 +5366-0;Staphylolysin Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Staphylolysin Ab [Units/volume] in Serum;Staphylolysin Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53660-7;Study observation;Find;Pt;Heart^Fetus;Nar;US;OB.US;2;Fetal Heart Narrative Study observation US;US Hrt Fetus Study;;ACTIVE;2.26;2.40 +53661-5;Reliability of last menstrual period observation;Find;Pt;^Patient;Nom;;OB.US;2;Reliability of last menstrual period observation;Reliability LMP obs;;ACTIVE;2.26;2.27 +53662-3;Conception method;Find;Pt;^Patient;Nom;Reported;OB.US;2;Conception method;Conception method;;ACTIVE;2.26;2.29 +53663-1;Date of prior gestational age estimate;Date;Pt;^Patient;Qn;Reported;OB.US;2;Date of prior gestational age estimate;Date prior GA est;;ACTIVE;2.26;2.50 +53664-9;Method of prior gestational age estimate;Find;Pt;^Patient;Nom;Reported;OB.US;2;Method of prior gestational age estimate;Method prior GA estimate;;ACTIVE;2.26;2.29 +53665-6;Date of best overall gestational age estimate;Date;Pt;^Patient;Qn;Reported;OB.US;2;Date of best overall gestational age estimate;Date best overall GA est;;ACTIVE;2.26;2.73 +53666-4;Method of best overall gestational age estimate;Find;Pt;^Patient;Nom;Reported;OB.US;2;Method of best overall gestational age estimate;Method best overall GA estimate;;ACTIVE;2.26;2.29 +53667-2;Method of best overall fetal weight estimate;Find;Pt;^Fetus;Nom;Reported;OB.US;2;Method of best overall fetal weight estimate;Method best overall EFW;;ACTIVE;2.26;2.42 +53668-0;Length.max;Len;Pt;Ear.right^Fetus;Qn;US.measured;OB.US;2;Fetal Ear - right Maximum length US;Fet Ear-R Length.max US.meas;;ACTIVE;2.26;2.48 +53669-8;Diameter;Len;Pt;Eye.right^Fetus;Qn;US.measured;OB.US;2;Fetal Right eye Diameter US;Fet R eye Diam US.meas;;ACTIVE;2.26;2.68 +53670-6;Length.max;Len;Pt;Mandible^Fetus;Qn;US.measured;OB.US;2;Fetal Mandible Maximum length US;Fet Mandible Length.max US.meas;;ACTIVE;2.26;2.48 +53671-4;Diameter;Len;Pt;Lung.left^Fetus;Qn;US.measured;OB.US;2;Fetal Lung - left Diameter US;Fet Lung-L Diam US.meas;;ACTIVE;2.26;2.48 +53672-2;Diameter;Len;Pt;Lung.right^Fetus;Qn;US.measured;OB.US;2;Fetal Lung - right Diameter US;Fet Lung-R Diam US.meas;;ACTIVE;2.26;2.48 +53673-0;Diameter.diastole;Len;Pt;Heart.ventricle.right^Fetus;Qn;US.measured;OB.US;2;Fetal Right ventricle Diameter during diastole US;Fet RV Diam diastole US.meas;;ACTIVE;2.26;2.54 +53674-8;Length;Len;Pt;Finger.fifth.right^Fetus;Qn;US.measured;OB.US;2;Fetal Finger fifth - right Length US;Fet Finger.5th-R Length US.meas;;ACTIVE;2.26;2.48 +53675-5;Length.max;Len;Pt;Scapula.left^Fetus;Qn;US.measured;OB.US;2;Fetal Scapula - left Maximum length US;Fet Scapula-L Length.max US.meas;;ACTIVE;2.26;2.48 +53676-3;Length.max;Len;Pt;Scapula.right^Fetus;Qn;US.measured;OB.US;2;Fetal Scapula - right Maximum length US;Fet Scapula-R Length.max US.meas;;ACTIVE;2.26;2.48 +53677-1;Long axis;Len;Pt;Clavicle.diaphysis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Clavicle.diaphysis - right [Length] US;Fet Clavicle-R Length US.meas;;ACTIVE;2.26;2.48 +5367-8;Streptobacillus moniliformis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptobacillus moniliformis Ab [Units/volume] in Serum;S moniliformis Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53678-9;Long axis;Len;Pt;Tibia.diaphysis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Tibia diaphysis - right [Length] US;Fet Tibia-R Length US.meas;;ACTIVE;2.26;2.48 +53679-7;Long axis;Len;Pt;Fibula.diaphysis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Fibula.diaphysis - right [Length] US;Fet Fibula-R Length US.meas;;ACTIVE;2.26;2.48 +53680-5;Width.transverse;Len;Pt;Head.lateral cerebral ventricle.right^Fetus;Qn;US.measured;OB.US;2;Fetal Lateral cerebral ventricle - right Transverse width US;Fet LV-R Width.transverse US.meas;;ACTIVE;2.26;2.48 +53681-3;Long axis;Len;Pt;Foot.right^Fetus;Qn;US.measured;OB.US;2;Fetal Foot - right [Length] US;Fet Ft-R Length US.meas;;ACTIVE;2.26;2.48 +53682-1;Diameter.transverse;Len;Pt;Head.third cerebral ventricle^Fetus;Qn;US.measured;OB.US;2;Fetal Third cerebral ventricle Diameter transverse US;Fet Head 3rd CV Diam transverse US.meas;;ACTIVE;2.26;2.48 +53683-9;Diameter.anterior-posterior;Len;Pt;Head.fourth cerebral ventricle^Fetus;Qn;US.measured;OB.US;2;Fetal Head.fourth cerebral ventricle Diameter.anterior-posterior US;Fet Head 4th CV Diam AP US.meas;;ACTIVE;2.26;2.48 +53684-7;Length.max;Len;Pt;Ear.left^Fetus;Qn;US.measured;OB.US;2;Fetal Ear - left Maximum length US;Fet Ear-L Length.max US.meas;;ACTIVE;2.26;2.48 +53685-4;Diameter.diastole;Len;Pt;Heart.ventricle.left^Fetus;Qn;US.measured;OB.US;2;Fetal Left ventricle Diameter during diastole US;Fet LV Diam diastole US.meas;;ACTIVE;2.26;2.54 +5368-6;Streptococcus pneumoniae Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay;S pneum IgG Ser IA-aCnc;;ACTIVE;1.0;2.69 +53686-2;Study observation;Find;Pt;Neck^Fetus;Nar;US;OB.US;2;Fetal Neck Narrative Study observation US;US Neck Fetus Study;;ACTIVE;2.26;2.40 +53687-0;Study observation;Find;Pt;Gastrointestinal tract^Fetus;Nar;US;OB.US;2;Fetal Gastrointestinal tract Narrative Study observation US;US GI Fetus Study;;ACTIVE;2.26;2.56 +53688-8;Study observation;Find;Pt;Genitalia^Fetus;Nar;US;OB.US;2;Fetal Genitalia Narrative Study observation US;US Genitalia Fetus Study;;ACTIVE;2.26;2.40 +53689-6;Study observation;Find;Pt;Extremities^Fetus;Nar;US;OB.US;2;Fetal Extremities Narrative Study observation US;US Extremities Fetus Study;;ACTIVE;2.26;2.40 +53690-4;Study observation;Find;Pt;Skeletal system^Fetus;Nar;US;OB.US;2;Fetal Skeletal system Narrative Study observation US;US Skeletal Fetus Study;;ACTIVE;2.26;2.40 +53691-2;Gestational age;Time;Pt;^Fetus;Qn;Estimated from patient reported EDC;OB.US;2;Gestational age Estimated from patient reported estimated date of conception;GA Estimated from patient reported EDC;;ACTIVE;2.26;2.40 +53692-0;Delivery date;Date;Pt;^Patient;Qn;Estimated from conception date;OB.US;2;Delivery date Estimated from conception date;Deliv date Est from conception date;;ACTIVE;2.26;2.50 +53693-8;Gestational age;Time;Pt;^Fetus;Qn;Estimated from conception date;OB.US;2;Gestational age Estimated from conception date;GA Est from conception date;;ACTIVE;2.26;2.73 +5369-4;Streptokinase Ab;ACnc;Pt;Ser;Qn;;COAG;1;Streptokinase Ab [Units/volume] in Serum;Streptokinase Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53694-6;Delivery date;Date;Pt;^Patient;Qn;Clinical.estimated from prior gest age assessment;OB.US;2;Delivery date Estimated from prior gestational age assessment;Deliv date Est from prior GA;;ACTIVE;2.26;2.50 +53695-3;Gestational age;Time;Pt;^Fetus;Qn;Clinical.estimated from prior assessment;OB.US;2;Gestational age Estimated from prior assessment;GA Est from prior assess;;ACTIVE;2.26;2.40 +53696-1;Long axis;Len;Pt;Femur.diaphysis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Femur.diaphysis - right [Length] US;Fet Femur-R Length US.meas;;ACTIVE;2.26;2.48 +53697-9;Long axis;Len;Pt;Nasal bone.diaphysis^Fetus;Qn;US.measured;OB.US;2;Fetal Nasal bone diaphysis [Length] US;Fet Nasal bone Length US.meas;;ACTIVE;2.26;2.73 +53698-7;Long axis;Len;Pt;Humerus.diaphysis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Humerus diaphysis - right [Length] US;Fet Humerus-R Length US.meas;;ACTIVE;2.26;2.48 +53699-5;Long axis;Len;Pt;Radius.diaphysis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Radius.diaphysis - right [Length] US;Fet Radius-R Length US.meas;;ACTIVE;2.26;2.48 +53700-1;Long axis;Len;Pt;Ulna.diaphysis.right^Fetus;Qn;US.measured;OB.US;2;Fetal Ulna diaphysis - right [Length] US;Fet Ulna-R Length US.meas;;ACTIVE;2.26;2.48 +53701-9;Length;Len;Pt;Finger.fifth.left^Fetus;Qn;US.measured;OB.US;2;Fetal Finger fifth - left Length US;Fet Finger.5th-L Length US.meas;;ACTIVE;2.26;2.48 +5370-2;Streptolysin O Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Streptolysin O Ab [Units/volume] in Serum or Plasma;ASO Ab SerPl-aCnc;;ACTIVE;1.0;2.73 +53702-7;Mycobacterium bovis tuberculin stimulated gamma interferon-Mycobacterium avium tuberculin stimulated gamma interferon;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium bovis tuberculin stimulated gamma interferon-Mycobacterium avium tuberculin stimulated gamma interferon [Units/volume] in Blood;M bovis - M avium tuberc IFN-g Bld-aCnc;;ACTIVE;2.26;2.64 +53703-5;Mycobacterium bovis tuberculin stimulated gamma interferon panel;-;Pt;Bld;-;;PANEL.MICRO;1;Mycobacterium bovis tuberculin stimulated gamma interferon panel - Blood;M bovis tuberc IFN-g Pnl Bld;;ACTIVE;2.26;2.73 +53704-3;Mycobacterium bovis tuberculin stimulated gamma interferon-control stimulated gamma interferon;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium bovis tuberculin stimulated gamma interferon-control stimulated gamma interferon [Units/volume] in Blood;M bovis tuberc - control IFN-g Bld-aCnc;;ACTIVE;2.26;2.73 +53705-0;Myasthenia gravis evaluation pediatric panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Myasthenia gravis evaluation pediatric panel - Serum;MG eval pediatric Pnl Ser;;ACTIVE;2.26;2.42 +53706-8;Myasthenia gravis evaluation adult reflex panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Myasthenia grav eval adult rflx panel - Serum;MG eval adult rflx Pnl Ser;;ACTIVE;2.26;2.73 +53707-6;CV2 Ab.IgG;PrThr;Pt;CSF;Ord;IB;SERO;1;CV2 IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;CV2 IgG CSF Ql IB;;ACTIVE;2.26;2.73 +53708-4;Glutamate decarboxylase 65 Ab;SCnc;Pt;CSF;Qn;;SERO;1;Glutamate decarboxylase 65 Ab [Moles/volume] in Cerebral spinal fluid;GAD65 Ab CSF-sCnc;;ACTIVE;2.26;2.73 +53709-2;Glial nuclear type 1 Ab;Titr;Pt;Ser;Qn;;SERO;1;Glial nuclear type 1 Ab [Titer] in Serum;Glial nuc type 1 Ab Titr Ser;;ACTIVE;2.26;2.73 +537-1;Mycobacterium sp identified;Prid;Pt;Periton fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Peritoneal fluid by Organism specific culture;Mycobacterium Prt Cult;;ACTIVE;1.0;2.19 +5371-0;Streptolysin O Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Streptolysin O Ab [Titer] in Serum by Latex agglutination;ASO Ab Titr Ser LA;;ACTIVE;1.0;2.73 +53710-0;Hyperoxaluria panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Hyperoxaluria panel - Urine;Hyperoxaluria Pnl Ur;;ACTIVE;2.26;2.63 +53711-8;Neuronal nuclear type 1 Ab;Titr;Pt;CSF;Qn;;SERO;1;Neuronal nuclear type 1 Ab [Titer] in Cerebral spinal fluid;Hu1 Ab Titr CSF;;ACTIVE;2.26;2.73 +53712-6;Neuronal nuclear type 2 Ab;Titr;Pt;CSF;Qn;;SERO;1;Neuronal nuclear type 2 Ab [Titer] in Cerebral spinal fluid;Hu2 Ab Titr CSF;;ACTIVE;2.26;2.32 +53713-4;Purkinje cell cytoplasmic type 1 Ab;Titr;Pt;CSF;Qn;;SERO;1;PCA-1 Ab [Titer] in Cerebral spinal fluid;PCA-1 Ab Titr CSF;;ACTIVE;2.26;2.70 +53714-2;Glial nuclear type 1 Ab;Titr;Pt;CSF;Qn;;SERO;1;Glial nuclear type 1 Ab [Titer] in Cerebral spinal fluid;Glial nuc type 1 Ab Titr CSF;;ACTIVE;2.26;2.73 +53715-9;Paraneoplastic Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Paraneoplastic Ab [Presence] in Cerebral spinal fluid by Immunoblot;Paraneoplastic Ab CSF Ql IB;;ACTIVE;2.26;2.73 +53716-7;levoFLOXacin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;levoFLOXacin [Susceptibility] by Method for Slow-growing mycobacteria;levoFLOXacin Islt SlowMyco;;ACTIVE;2.26;2.26 +53717-5;Purkinje cell cytoplasmic type 1 Ab;Titr;Pt;Ser;Qn;;SERO;1;PCA-1 Ab [Titer] in Serum;PCA-1 Ab Titr Ser;;ACTIVE;2.26;2.73 +53718-3;Acylglycines;Imp;Pt;Urine;Nar;;CHEM;1;Acylglycines [Interpretation] in Urine Narrative;Acylglycines Ur-Imp;;ACTIVE;2.26;2.73 +53719-1;Date of death - Canada;TmStp;Pt;^Patient;Qn;;TUMRRGT;2;Date of death - Canada;Date of death - Canada;;ACTIVE;2.26;2.29 +53720-9;Race;Type;Pt;^Patient;Nom;NAPIIA;TUMRRGT;2;Race NAPIIA;Race NAPIIA;;ACTIVE;2.26;2.73 +53721-7;Amino acid marker assessed;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Amino acid marker assessed [Identifier];Amino acid marker assessed;;ACTIVE;2.26;2.56 +53722-5;SLC26A4 gene.p.Glu384Gly;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;SLC26A4 gene p.Glu384Gly [Presence] in Blood by Molecular genetics method;SLC26A4 p.E384G Bld Ql;;ACTIVE;2.26;2.56 +53723-3;SLC26A4 gene.p.Leu236Pro;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;SLC26A4 gene.p.Leu236Pro [Presence] in Blood by Molecular genetics method;SLC26A4 p.L236P Bld Ql;;ACTIVE;2.26;2.56 +53724-1;SLC26A4 gene.p.Thr416Pro;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;SLC26A4 gene p.Thr416Pro [Presence] in Blood by Molecular genetics method;SLC26A4 p.T416P Bld Ql;;ACTIVE;2.26;2.56 +53725-8;SLC25A4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC25A4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC25A4 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53726-6;KCNC3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KCNC3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KCNC3 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +53727-4;SOS1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SOS1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SOS1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +5372-8;Striated muscle Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Striated muscle Ab [Titer] in Serum by Immunofluorescence;Stria Mus Ab Titr Ser IF;;ACTIVE;1.0;2.73 +53728-2;WS2A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;WS2A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;WS2A gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53729-0;Borrelia burgdorferi 49736 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Deprecated Borrelia burgdorferi 49736 Ab.IgG;Deprecated B burgdorferi 49736 IgG;;DEPRECATED;2.26;2.69 +53730-8;Borrelia burgdorferi G39_40 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Borrelia burgdorferi G39/40 IgG Ab [Units/volume] in Serum or Plasma;B burgdor G39/40 IgG SerPl-aCnc;;ACTIVE;2.26;2.69 +53731-6;Posaconazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Posaconazole [Mass/volume] in Serum or Plasma;Posaconazole SerPl-mCnc;;ACTIVE;2.26;2.73 +53732-4;GCK gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GCK gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GCK gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53733-2;Color;Type;Pt;Body fld.spun;Nom;;SPEC;1;Color of Spun Body fluid;Color spun Fld;;ACTIVE;2.26;2.73 +53734-0;Kynurenine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Kynurenine [Molecules/volume] in Serum or Plasma;Deprecated Kynurenine SerPl-sCnc;;DEPRECATED;2.26;2.36 +53735-7;Barbiturates.other;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Barbiturates.other [Mass/volume] in Urine;Barbiturates.other Ur-mCnc;;ACTIVE;2.26;2.70 +5373-6;Strongyloides sp Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Strongyloides sp Ab [Units/volume] in Serum by Hemagglutination;Strongyloides Ab Ser HA-aCnc;;ACTIVE;1.0;2.69 +53736-5;Benzodiazepines.other;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzodiazepines.other [Mass/volume] in Urine;Benzodiaz.other Ur-mCnc;;ACTIVE;2.26;2.70 +53737-3;HLA-DQA1*01:02;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQA1*01:02 [Presence];HLA-DQA1*01:02 Ql;;ACTIVE;2.26;2.73 +53738-1;HLA-DQB1*2;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQB1*2 [Presence];HLA-DQB1*2 Ql;;ACTIVE;2.26;2.56 +53739-9;HLA-DQB1*9;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQB1*9 [Presence];HLA-DQB1*9 Ql;;ACTIVE;2.26;2.56 +53740-7;HLA-DRB1*17;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DRB1*17 [Presence];HLA-DRB1*17 Ql;;ACTIVE;2.26;2.56 +53741-5;HLA-DRB1*7;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DRB1*7 [Presence];HLA-DRB1*7 Ql;;ACTIVE;2.26;2.56 +53742-3;Legionella pneumophila 2+3+4+5+6+8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 2+3+4+5+6+8 Ab [Presence] in Serum;L pneumo 2+3+4+5+6+8 Ab Ser Ql;;ACTIVE;2.26;2.56 +53743-1;Cocaine metabolites.other;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cocaine metabolites.other [Mass/volume] in Urine;Cocaine metab.other Ur-mCnc;;ACTIVE;2.26;2.73 +5374-4;Taenia saginata Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Taenia saginata Ab [Units/volume] in Serum by Immunoassay;T saginata Ab Ser IA-aCnc;;ACTIVE;1.0;2.69 +53744-9;Direct antiglobulin test.complement specific reagent;PrThr;Pt;RBC;Ord;5M RT incubation;BLDBK;1;Direct antiglobulin test.complement specific reagent [Presence] on Red Blood Cells by 5 minute RT incubation;DAT Comp-Sp Reag RBC Ql 5M RT inc;;ACTIVE;2.26;2.56 +53745-6;Benzodiazepines panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Benzodiazepines panel - Urine;Benzodiazepines Pnl Ur;;ACTIVE;2.26;2.73 +53746-4;Barbiturates panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Barbiturates panel - Urine;Barbiturates Pnl Ur;;ACTIVE;2.26;2.73 +53747-2;Cocaine panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Cocaine panel - Urine;Cocaine Pnl Ur;;ACTIVE;2.26;2.42 +53748-0;Lupus anticoagulant neutralization.dilute phospholipid;Time;Pt;PPP;Qn;;COAG;1;Lupus anticoagulant neutralization dilute phospholipid [Time] in Platelet poor plasma;LA Nt dPL PPP;;DISCOURAGED;2.26;2.73 +53749-8;Collection time^5th specimen;TmStp;Pt;Bld;Qn;;SPEC;1;Collection time of Blood--5th specimen;Collect Tme sp5 Bld;;ACTIVE;2.26;2.26 +53750-6;Hydrogen/Expired gas^15M post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --15 minutes post XXX challenge;Breath H2 15M p chal;;ACTIVE;2.26;2.42 +5375-1;Taenia solium adult Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Taenia solium adult Ab [Units/volume] in Serum by Immunoassay;T sol adult Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +53751-4;Hydrogen/Expired gas^2.75H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.75 hours post XXX challenge;Breath H2 2.75h p chal;;ACTIVE;2.26;2.42 +53752-2;Hydrogen/Expired gas^1.75H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.75 hours post XXX challenge;Breath H2 1.75h p chal;;ACTIVE;2.26;2.42 +53753-0;Hydrogen/Expired gas^2.25H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.25 hours post XXX challenge;Breath H2 2.25h p chal;;ACTIVE;2.26;2.42 +53754-8;Hydrogen/Expired gas^45M post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --45 minutes post XXX challenge;Breath H2 45M p chal;;ACTIVE;2.26;2.42 +53755-5;Hydrogen/Expired gas^1.25H post XXX challenge;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.25 hours post XXX challenge;Breath H2 1.25h p chal;;ACTIVE;2.26;2.42 +53756-3;Respiratory status;Find;Pt;^Patient;Nom;;H&P.HX;2;Respiratory status finding;Resp status;;ACTIVE;2.26;2.38 +53758-9;HLA-DRB1 SBT;Type;Pt;XXX;Nom;High resolution;HLA;1;HLA-DRB1 SBT [Type] in Specimen by High resolution;HLA-DRB1 SBT Spec High Res;;ACTIVE;2.26;2.69 +53759-7;Natural killer cell panel;-;Pt;Bld;-;Flow cytometry;PANEL.CELLMARK;1;Natural killer cell panel - Blood by Flow cytometry (FC);Natural killer cell Pnl Bld FC;;ACTIVE;2.26;2.73 +53760-5;Cladosporium sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium sp IgE Ab [Units/volume] in Serum;Cladosporium IgE Qn;;ACTIVE;2.26;2.73 +53761-3;JAK2 gene.p.Val617Phe mutant/normal;RelRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;JAK2 gene.p.Val617Phe mutant/Normal in Blood or Tissue by Molecular genetics method;JAK2 p.V617F mut/Nor Bld/T;;ACTIVE;2.26;2.73 +53762-1;Neisseria gonorrhoeae Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Neisseria gonorrhoeae IgG Ab [Titer] in Serum;N gonorrhoea IgG Titr Ser;;DISCOURAGED;2.26;2.36 +53763-9;Cytomegalovirus DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;CMV DNA Spec NAA+probe-Log#;;ACTIVE;2.26;2.73 +53764-7;Prostate specific Ag panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Prostate specific Ag panel - Serum or Plasma;PSA Pnl SerPl;;ACTIVE;2.26;2.73 +53765-4;Estrogen;MCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Estrogen [Mass/volume] in Serum or Plasma by calculation;Estrogen SerPl Calc-mCnc;;ACTIVE;2.26;2.73 +53766-2;Estrogen fraction panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Estrogen fraction panel - Serum or Plasma;Estrogen fraction Pnl SerPl;;ACTIVE;2.26;2.73 +53767-0;HLA-A+B+C SBT;Imp;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-A+B+C SBT [Interpretation] by High resolution;HLA-A+B+C SBT High Res-Imp;;ACTIVE;2.26;2.73 +53768-8;Erythrocytes.CD55+CD59 actual/normal;RelRto;Pt;Bld;Qn;;CELLMARK;1;CD55+CD59 RBC actual/normal in Blood;CD55+CD59 RBC Act/Nor Bld;;ACTIVE;2.26;2.34 +5376-9;Thermoactinomyces candidus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Thermoactinomyces candidus Ab [Units/volume] in Serum;T candidus Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53769-6;Erythrocytes.CD55+CD59 deficient actual/normal;RelRto;Pt;Bld;Qn;;CELLMARK;1;CD55+CD59 deficient RBC actual/normal in Blood;CD55+CD59 def RBC Act/Nor Bld;;ACTIVE;2.26;2.34 +53770-4;Legionella pneumophila 1+2+3+4+5+6 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1+2+3+4+5+6 IgG Ab [Titer] in Serum;L pneumo pool 1-6 IgG Titr Ser;;ACTIVE;2.26;2.73 +53771-2;Alpha 2 globulin;PrThr;Pt;Urine;Ord;Electrophoresis;CHEM;1;Alpha 2 globulin [Presence] in Urine by Electrophoresis;Alpha2 Glob Ur Ql Elph;;ACTIVE;2.26;2.73 +53772-0;Beta globulin;PrThr;Pt;Urine;Ord;Electrophoresis;CHEM;1;Beta globulin [Presence] in Urine by Electrophoresis;B-Globulin Ur Ql Elph;;ACTIVE;2.26;2.73 +53773-8;Gamma globulin;PrThr;Pt;Urine;Ord;Electrophoresis;CHEM;1;Gamma globulin [Presence] in Urine by Electrophoresis;Gamma glob Ur Ql Elph;;ACTIVE;2.26;2.73 +53774-6;Epstein Barr virus DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;EBV DNA Spec NAA+probe-Log#;;ACTIVE;2.26;2.73 +53775-3;Hepatitis A virus Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis A virus Ab panel - Serum;HAV Ab Pnl Ser;;ACTIVE;2.26;2.68 +53776-1;Hepatitis A virus Ab;Imp;Pt;Ser;Nom;;MICRO;1;Hepatitis A virus Ab [Interpretation] in Serum;HAV Ab Ser-Imp;;ACTIVE;2.26;2.73 +5377-7;Laceyella sacchari Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Laceyella sacchari Ab [Units/volume] in Serum;Laceyella sacchari Ab Ser-aCnc;;ACTIVE;1.0;2.74 +53777-9;Cortisone.free;MCnc;Pt;Urine;Qn;;CHEM;1;Cortisone free [Mass/volume] in Urine;Cortisone free Ur-mCnc;;ACTIVE;2.26;2.73 +53778-7;Arsenic.organic;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic organic [Mass/volume] in Urine;Arsenic organic Ur-mCnc;;ACTIVE;2.26;2.73 +53779-5;Arsenic.methylated;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic.methylated [Mass/volume] in Urine;Arsenic.methylated Ur-mCnc;;ACTIVE;2.26;2.73 +53780-3;Chromium panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Chromium panel - Urine;Chromium Pnl Ur;;ACTIVE;2.26;2.42 +53781-1;Acetaminophen & Propoxyphene panel;MCnc;Pt;Urine;Qn;;PANEL.DRUG/TOX;1;Acetaminophen and Propoxyphene panel [Mass/volume] - Urine;Acetamin+Propoxyph Pnl Ur-mCnc;;ACTIVE;2.26;2.42 +53782-9;HTT gene.CAG repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;HTT gene CAG repeats [Entitic number] in Blood or Tissue by Molecular genetics method;HTT gene CAG Rpt EntNum Bld/T;;ACTIVE;2.26;2.64 +53783-7;HTT gene mutation panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;HTT gene mutation panel - Blood or Tissue by Molecular genetics method;HTT gene mutation Pnl Bld/T;;ACTIVE;2.26;2.42 +53784-5;Legionella pneumophila 1+2+3+4+5+6 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 1+2+3+4+5+6 IgM Ab [Titer] in Serum;L pneumo pool 1-6 IgM Titr Ser;;ACTIVE;2.26;2.73 +5378-5;Thermoactinomyces vulgaris Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Thermoactinomyces vulgaris Ab [Units/volume] in Serum;T vulgaris Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53785-2;Microscopic observation;Prid;Pt;Urine;Nom;Wright stain;UA;1;Microscopic observation [Identifier] in Urine by Wright stain;Wright Stn Ur;;ACTIVE;2.26;2.73 +53786-0;Microscopic observation;Prid;Pt;Stool;Nom;Wright stain;HEM/BC;1;Microscopic observation [Identifier] in Stool by Wright stain;Wright Stn Stl;;ACTIVE;2.26;2.73 +53787-8;Zolpidem;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Zolpidem [Presence] in Urine by Confirmatory method;Zolpidem Ur Ql Cfm;;ACTIVE;2.26;2.73 +53788-6;Sodium urate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Sodium urate crystals [Presence] in Urine sediment by Light microscopy;Na Urate Cry UrnS Ql Micro;;ACTIVE;2.26;2.73 +53789-4;CFTR gene.p.IVS8 polyT 7T/9T variant;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene.p.IVS8 polyT 7T/9T [presence] in Blood or Tissue by Molecular genetics method;CFTR IVS8 polyT 7T/9T Bld/T Ql;;ACTIVE;2.26;2.73 +53790-2;CILD2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CILD2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CILD2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53791-0;PTPN11 gene targeted mutation analysis.tier 1;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PTPN11 gene mutations tier 1 found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PTPN11 gene Mut Anl tier1 Bld/T;;ACTIVE;2.26;2.63 +53792-8;PTPN11 gene targeted mutation analysis.tier 3;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PTPN11 gene mutations tier 3 found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PTPN11 gene Mut Anl tier3 Bld/T;;ACTIVE;2.26;2.63 +5379-3;Platelet Ab;ACnc;Pt;Ser;Qn;;SERO;1;Platelet Ab [Units/volume] in Serum;Platelet Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53793-6;RPS6KA3 gene targeted mutation analysis.tier 1;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RPS6KA3 gene mutations tier 1 found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;RPS6KA3 gene Mut Anl tier1 Bld/T;;ACTIVE;2.26;2.63 +53794-4;RPS6KA3 gene targeted mutation analysis.tier 2;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RPS6KA3 gene mutations tier 2 found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;RPS6KA3 gene Mut Anl tier2 Bld/T;;ACTIVE;2.26;2.63 +53795-1;STK11 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;STK11 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;STK11 gene Mut Anl Bld/T;;ACTIVE;2.26;2.73 +53796-9;Interferon drug given;ID;Pt;^Patient;Nom;;HEM/BC;1;Interferon drug given [Identifier];Interferon drug Gvn;;ACTIVE;2.26;2.73 +53797-7;Neutrophils.immature/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Neutrophils.immature/100 leukocytes in Blood;Neutrophils.immature/leuk NFr Bld;;ACTIVE;2.26;2.73 +53798-5;HIV reverse transcriptase+Protease gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV reverse transcriptase+protease gene mutations detected [Identifier];HIV RT+PR Mut Det Islt;;ACTIVE;2.26;2.73 +53799-3;Major crossmatch;Imp;Pt;Ser/Plas;Nom;Electronic;BLDBK;1;Major crossmatch [Interpretation] by Electronic;Maj XM SerPl Electronic-Imp;;ACTIVE;2.26;2.61 +53800-9;Platelets panel;-;Pt;Bld;Qn;Automated count;PANEL.HEM/BC;1;Platelets panel - Blood by Automated count;Platelets Pnl Bld Auto;;ACTIVE;2.26;2.68 +5380-1;Thyroglobulin Ab;ACnc;Pt;Ser;Qn;RIA;SERO;1;Thyroglobulin Ab [Units/volume] in Serum by Radioimmunoassay (RIA);Thyroglob Ab Ser RIA-aCnc;;ACTIVE;1.0;2.73 +53801-7;Multisection;Find;Pt;Penile vessels;Nar;US.doppler;US.URO;2;Penile vessels by US.doppler;Penile vessels DOP;;ACTIVE;2.26;2.29 +53802-5;Arbovirus Ab.IgG;Imp;Pt;Ser;Nar;IF;MICRO;1;Arbovirus IgG Ab [Interpretation] in Serum by Immunofluorescence Narrative;Arbovirus IgG Ser IF-Imp;;ACTIVE;2.26;2.26 +53803-3;Transferrin.carbohydrate deficient panel;-;-;Ser/Plas;-;;PANEL.CHEM;1;Transferrin.carbohydrate deficient panel - Serum or Plasma;CDT Pnl SerPl;;ACTIVE;2.26;2.73 +53804-1;Arbovirus Ab.IgG panel;-;Pt;Ser;-;IF;PANEL.MICRO;1;Arbovirus IgG panel - Serum by Immunofluorescence;Arbovirus IgG Pnl Ser IF;;ACTIVE;2.26;2.42 +53805-8;LDL apheresis procedure;Type;Pt;^Patient;Nom;;CHEM;1;LDL apheresis procedure [Type];LDL apheresis procedure type;;ACTIVE;2.26;2.26 +53806-6;LDL apheresis procedure;ID;Pt;^Patient;Nom;;CHEM;1;LDL apheresis procedure [Identifier];LDL apheresis procedure ID;;ACTIVE;2.26;2.48 +53807-4;Basement membrane zone BP230 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Basement membrane zone BP230 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;BMZ BP230 IgG SerPl IA-aCnc;;ACTIVE;2.26;2.73 +53808-2;Oligosaccharides pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Oligosaccharides pattern [Interpretation] in Serum or Plasma Narrative;Oligosaccharide Pattern SerPl-Imp;;ACTIVE;2.26;2.73 +53809-0;Oxygen.alveolar - arterial^^adjusted to patient's actual temperature;PPresDiff;Pt;Respiratory system;Qn;;PULM;2;Oxygen.alveolar - arterial [Partial pressure difference] adjusted to patient's actual temperature Respiratory system;O2 A-a temp adj PPresDiff Respiratory;;ACTIVE;2.26;2.70 +53810-8;Lymphocyte proliferation;Imp;Pt;Bld;Nom;;SERO;1;Lymphocyte proliferation [Interpretation] in Blood;Lymphocyte prolif Bld-Imp;;ACTIVE;2.26;2.73 +53811-6;Triple phosphate;SatFr;24H;Urine;Qn;;CHEM;1;Triple phosphate [Saturation Fraction] in 24 hour Urine;Tri-Phos 24h SatFr Ur;;ACTIVE;2.26;2.73 +53812-4;Micafungin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Micafungin [Susceptibility] by Minimum inhibitory concentration (MIC);Micafungin Islt MIC;;ACTIVE;2.26;2.73 +53813-2;Platelet aggregation.adenosine diphosphate induced;ACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ADP induced [Units/volume] in Blood;PA ADP Bld-aCnc;;ACTIVE;2.26;2.73 +53814-0;Platelet aggregation.arachidonate induced;ACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation arachidonate induced [Units/volume] in Blood;PA AA Bld-aCnc;;ACTIVE;2.26;2.73 +53815-7;Platelet glycoprotein IIb-IIIa Ab;ACnc;Pt;Bld;Qn;;SERO;1;Platelet glycoprotein IIb/IIIa Ab [Units/volume] in Blood;Plat Gp IIb/IIIa Ab Bld-aCnc;;ACTIVE;2.26;2.73 +53816-5;Alpha hydroxytriazolam;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Alpha hydroxytriazolam [Mass/volume] in Serum;A-OH-triazolam Ser-mCnc;;ACTIVE;2.26;2.73 +53817-3;Carnosine;PrThr;Pt;CSF;Ord;;CHEM;1;Carnosine [Presence] in Cerebral spinal fluid;Carnosine CSF Ql;;ACTIVE;2.26;2.70 +53818-1;Arbekacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Arbekacin [Susceptibility] by Minimum inhibitory concentration (MIC);Arbekacin Islt MIC;;ACTIVE;2.26;2.32 +5381-9;Thyroglobulin Ab;Titr;Pt;Ser;Qn;LA;SERO;1;Thyroglobulin Ab [Titer] in Serum by Latex agglutination;Thyroglob Ab Titr Ser LA;;ACTIVE;1.0;2.73 +53819-9;Thiopurine methyltransferase;CCnc;Pt;Bld;Qn;;CHEM;1;Thiopurine methyltransferase [Enzymatic activity/volume] in Blood;TPMT Bld-cCnc;;ACTIVE;2.26;2.73 +53820-7;Cefozopran;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefozopran [Susceptibility] by Minimum inhibitory concentration (MIC);Cefozopran Islt MIC;;ACTIVE;2.26;2.26 +53821-5;Chloroamphetamine;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Chloroamphetamine [Mass/volume] in Serum;Chloroamphetamine Ser-mCnc;;ACTIVE;2.26;2.42 +53822-3;Flomoxef;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Flomoxef [Susceptibility] by Minimum inhibitory concentration (MIC);Flomoxef Islt MIC;;ACTIVE;2.26;2.26 +53823-1;Panipenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Panipenem [Susceptibility] by Minimum inhibitory concentration (MIC);Panipenem Islt MIC;;ACTIVE;2.26;2.26 +53824-9;Paromomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Paromomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Paromomycin Islt MIC;;ACTIVE;2.26;2.29 +53825-6;HIV 1+Hepatitis C virus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;HIV 1+Hepatitis C virus RNA [Presence] in Serum or Plasma by NAA with probe detection;HIV 1+HCV RNA SerPl Ql NAA+probe;;ACTIVE;2.26;2.73 +53826-4;Trisomy 21;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Trisomy 21 Qualitative;Hx of Trisomy 21 Ql;;ACTIVE;2.26;2.73 +5382-7;Thyroperoxidase Ab;ACnc;Pt;Ser/Plas;Qn;RIA;SERO;1;Thyroperoxidase Ab [Units/volume] in Serum or Plasma by Radioimmunoassay (RIA);Thyroperoxidase Ab SerPl RIA-aCnc;;ACTIVE;1.0;2.73 +53827-2;Neural tube defect;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Neural tube defect Qualitative;Hx of NTD Ql;;ACTIVE;2.26;2.73 +53828-0;cycloSPORINE^trough;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --trough;cycloSPORINE Trough Bld-mCnc;;ACTIVE;2.26;2.73 +53829-8;Casein Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Casein IgG Ab [Mass/volume] in Serum;Casein IgG-mCnc;;ACTIVE;2.26;2.73 +53830-6;Granulocytes.CD55 deficient/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD55 deficient Granulocytes/100 cells in Blood;CD55 deficient Granulocytes NFr Bld;;ACTIVE;2.26;2.70 +53831-4;Granulocytes.CD59 deficient/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD59 deficient Granulocytes/100 cells in Blood;CD59 deficient Granulocytes NFr Bld;;ACTIVE;2.26;2.73 +53832-2;Erythrocytes.CD55 deficient/100 erythrocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;CD55 deficient RBC/100 erythrocytes in Blood;CD55 def RBC/100 RBC NFr Bld;;ACTIVE;2.26;2.70 +53833-0;Myoglobin;MCnc;Pt;Bld;Qn;;CHEM;1;Myoglobin [Mass/volume] in Blood;Myoglobin Bld-mCnc;;ACTIVE;2.26;2.73 +53834-8;cycloSPORINE^peak;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --peak;cycloSPORINE Peak Bld-mCnc;;ACTIVE;2.26;2.70 +5383-5;Thyroperoxidase Ab;Titr;Pt;Ser/Plas;Qn;LA;SERO;1;Thyroperoxidase Ab [Titer] in Serum or Plasma by Latex agglutination;Thyroperoxidase Ab Titr SerPl LA;;ACTIVE;1.0;2.73 +53835-5;1,5-Anhydroglucitol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;1,5-Anhydroglucitol [Mass/volume] in Serum or Plasma;1,5-Anhydroglucitol SerPl-mCnc;;ACTIVE;2.26;2.73 +53836-3;ABCD1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ABCD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ABCD1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53837-1;ACVRL1 gene+ENG gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACVRL1 gene+ENG gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ACVRL1+ENG gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53838-9;Arsenic.inorganic;MRat;24H;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic [Mass/time] in 24 hour Urine;Inorg Arsenic 24h Ur-mRate;;ACTIVE;2.26;2.73 +53839-7;Arsenic.organic;MRat;24H;Urine;Qn;;DRUG/TOX;1;Arsenic organic [Mass/time] in 24 hour Urine;Arsenic organic 24h Ur-mRate;;ACTIVE;2.26;2.73 +53840-5;TGFB3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TGFB3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TGFB3 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53841-3;ATRX gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ATRX gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ATRX gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +53842-1;Basement membrane zone BP180 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Basement membrane zone BP180 IgG Ab [Units/volume] in Serum or Plasma;BMZ BP180 IgG SerPl-aCnc;;ACTIVE;2.26;2.73 +5384-3;Thyrotropin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Thyrotropin Ab [Units/volume] in Serum;TSH Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53843-9;Basement membrane zone BP230 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Basement membrane zone BP230 IgG Ab [Units/volume] in Serum or Plasma;BMZ BP230 IgG SerPl-aCnc;;ACTIVE;2.26;2.73 +53844-7;BRAF gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BRAF gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BRAF gene Mut Anl Bld/T;;ACTIVE;2.26;2.73 +53845-4;BTD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BTD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BTD gene Mut Anl Bld/T;;ACTIVE;2.26;2.73 +53846-2;Buprenorphine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Buprenorphine [Mass/volume] in Serum or Plasma by Confirmatory method;Buprenorphine SerPl Cfm-mCnc;;ACTIVE;2.26;2.73 +53847-0;CACT gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CACT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CACT gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53848-8;Mixed cellular casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Mixed cellular casts [#/area] in Urine sediment by Microscopy high power field;Mixed Cell Casts #/area UrnS HPF;;ACTIVE;2.26;2.73 +53849-6;HTC2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HTC2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;HTC2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +5385-0;Thyrotropin receptor Ab;ACnc;Pt;Ser;Qn;;SERO;1;Thyrotropin receptor Ab [Units/volume] in Serum;TSH Recep Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53850-4;HTC2 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;HTC2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;HTC2 gene Mut Tested Bld/T;;ACTIVE;2.26;2.27 +53851-2;COL10A1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;COL10A1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;COL10A1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53852-0;COL2A1 gene+COL11A1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COL2A1 gene+COL11A1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;COL2A1+COL11A1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +53853-8;COL4A5 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;COL4A5 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;COL4A5 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53854-6;CPS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CPS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CPS1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53855-3;DNAI1+DNAH5 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DNAI1+DNAH5 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;DNAI1+DNAH5 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +53856-1;DYSF gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;DYSF gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;DYSF gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53857-9;Hemoglobin F;MCnc;Pt;Bld;Qn;;CHEM;1;Hemoglobin F [Mass/volume] in Blood;Hgb F Bld-mCnc;;ACTIVE;2.26;2.68 +53858-7;EXT1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;EXT1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;EXT1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53859-5;Fatty acids.very long chain.C22:0;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C22:0 (Docosanoate) [Mass/volume] in Serum or Plasma;VLCFA C22:0 SerPl-mCnc;;ACTIVE;2.26;2.73 +53860-3;Fatty acids.very long chain.C24:0;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate) [Mass/volume] in Serum or Plasma;VLCFA C24:0 SerPl-mCnc;;ACTIVE;2.26;2.73 +53861-1;FKTN gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FKTN gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FKTN gene Mut Anl Bld/T;;ACTIVE;2.26;2.73 +53862-9;FIG4 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FIG4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FIG4 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53863-7;FLNA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FLNA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;FLNA gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53864-5;GAA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GAA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GAA Mut Anl Bld/T;;ACTIVE;2.26;2.73 +53865-2;Galactomannan Ag;ACnc;Pt;CSF;Qn;;MICRO;1;Galactomannan Ag [Units/volume] in Cerebral spinal fluid;Galactomannan Ag CSF-aCnc;;ACTIVE;2.26;2.73 +53866-0;GCH1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GCH1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GCH1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53867-8;GYS2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GYS2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GYS2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +5386-8;Toxocara canis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxocara canis Ab [Units/volume] in Serum by Immunoassay;T canis Ab Ser IA-aCnc;;ACTIVE;1.0;2.73 +53868-6;Glucose tetrasaccharide/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glucose tetrasaccharide/Creatinine [Molar ratio] in Urine;Glucose tetrasaccharide/Creat Ur-sRto;;ACTIVE;2.26;2.70 +53869-4;HPRT1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HPRT1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HPRT1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53870-2;HPS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HPS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HPS1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53871-0;HRAS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HRAS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HRAS gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53872-8;Iodine;MCnc;XXX;Urine;Qn;;CHEM;1;Iodine [Mass/volume] in Urine collected for unspecified duration;Iodine ?Tm Ur-mCnc;;ACTIVE;2.26;2.73 +53873-6;IRF6 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;IRF6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;IRF6 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53874-4;Jamestown canyon virus RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Jamestown canyon virus RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;JCV RNA Spec NAA+probe-aCnc;;ACTIVE;2.26;2.70 +53875-1;LMX1B gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LMX1B gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LMX1B gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +5387-6;Toxoplasma gondii Ab;PrThr;Pt;Ser;Ord;Dye test;MICRO;1;Toxoplasma gondii Ab [Presence] in Serum by Sabin dye test;T gondii Ab Ser Ql Dye Test;;ACTIVE;1.0;2.56 +53876-9;LRRK2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LRRK2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;LRRK2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +53877-7;NAGS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NAGS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NAGS gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53878-5;Neisseria gonorrhoeae rRNA;ACnc;Pt;Penis;Ord;Probe.amp.tar;MICRO;1;Deprecated Neisseria gonorrhoeae rRNA [Presence] in Penis by Probe and target amplification method;Deprecated N gonorrhoea rRNA Penis Ql PC;;DEPRECATED;2.26;2.52 +53879-3;Neisseria gonorrhoeae rRNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by NAA with probe detection;N gonorrhoea rRNA Vag Ql NAA+probe;;ACTIVE;2.26;2.73 +53880-1;Norbuprenorphine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Norbuprenorphine [Mass/volume] in Serum or Plasma by Confirmatory method;Norbuprenorphine SerPl Cfm-mCnc;;ACTIVE;2.26;2.73 +53881-9;Norbuprenorphine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norbuprenorphine [Mass/volume] in Serum or Plasma;Norbuprenorphine SerPl-mCnc;;ACTIVE;2.26;2.73 +53882-7;O-desmethylvenlafaxine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;O-desmethylvenlafaxine [Mass/volume] in Urine;ODV Ur-mCnc;;ACTIVE;2.26;2.69 +53883-5;OCRL1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;OCRL1 mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;OCRL1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +5388-4;Toxoplasma gondii Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;T gondii IgG SerPl IA-aCnc;;ACTIVE;1.0;2.73 +53884-3;OTOF gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;OTOF gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;OTOF gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53885-0;Parvovirus B19 Ab.IgG;ACnc;Pt;Body fld;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Body fluid;B19V IgG Fld-aCnc;;ACTIVE;2.26;2.69 +53886-8;Parvovirus B19 Ab.IgM;ACnc;Pt;Body fld;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Body fluid;B19V IgM Fld-aCnc;;ACTIVE;2.26;2.69 +53887-6;PCCA gene+PCCB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PCCA gene+PCCB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PCCA+PCCB gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53888-4;PHEX gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PHEX gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PHEX gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53889-2;Platelet aggregation.arachidonate induced;ThrACnc;Pt;PRP;Qn;;DRUG/TOX;1;Deprecated Platelet aggregation.arachidonate induced;Deprecated Platelet Agg AA PRP;;DEPRECATED;2.26;2.36 +538-9;Mycobacterium sp identified;Prid;Pt;Synv fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Synovial fluid by Organism specific culture;Mycobacterium Snv Cult;;ACTIVE;1.0;2.73 +53890-0;PLOD1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PLOD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PLOD1 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53891-8;PNKD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PNKD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PNKD gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +5389-2;Toxoplasma gondii Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Toxoplasma gondii IgG Ab [Titer] in Serum by Immunofluorescence;T gondii IgG Titr Ser IF;;ACTIVE;1.0;2.73 +53892-6;Ribosomal P Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Ribosomal P IgG Ab [Units/volume] in Serum;Ribosomal P IgG Ser-aCnc;;ACTIVE;2.26;2.73 +53893-4;RNA polymerase III Ab;ACnc;Pt;Ser;Qn;;SERO;1;RNA polymerase III Ab [Units/volume] in Serum;RNAp III Ab Ser-aCnc;;ACTIVE;2.26;2.73 +53894-2;TRAPPC2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TRAPPC2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TRAPPC2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53895-9;SH3BP2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SH3BP2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SH3BP2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53896-7;SMC1A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SMC1A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SMC1A gene Mut Anl Bld/T;;ACTIVE;2.26;2.68 +53897-5;SPAST gene+KIAA0196 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SPAST gene + KIAA0196 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SPAST+KIAA0196 gene Mut Anl Bld/T;;ACTIVE;2.26;2.63 +53898-3;KIAA0196 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;KIAA0196 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;KIAA0196 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53899-1;TGFBR1 gene+TGFBR2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TGFBR1 gene+TGFBR2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TGFBR1+TGFBR2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.73 +53-9;Butirosin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Butirosin [Susceptibility] by Disk diffusion (KB);Butirosin Islt KB;;ACTIVE;1.0;2.19 +5390-0;Toxoplasma gondii Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxoplasma gondii IgM Ab [Units/volume] in Serum by Immunoassay;T gondii IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +53900-7;C10orf2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;C10orf2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;C10orf2 gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53901-5;USH2A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;USH2A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;USH2A gene Mut Anl Bld/T;;ACTIVE;2.26;2.66 +53902-3;Voriconazole;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Voriconazole [Mass/volume] in Cerebral spinal fluid;Voriconazole CSF-mCnc;;ACTIVE;2.26;2.73 +53903-1;Collection method;Type;Pt;Specimen;Nom;;SPEC;1;Collection method - Specimen;Collection method Spec;;ACTIVE;2.26;2.73 +53904-9;Microscopic observation;Prid;Pt;Sputum;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Sputum by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Spt;;ACTIVE;2.26;2.26 +53905-6;Microscopic observation;Prid;Pt;Urine;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Urine by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Ur;;ACTIVE;2.26;2.26 +53906-4;Microscopic observation;Prid;Pt;CSF;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn CSF;;ACTIVE;2.26;2.26 +53907-2;Microscopic observation;Prid;Pt;Plr fld;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Pleural fluid by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Plr;;ACTIVE;2.26;2.26 +53908-0;Bacteria identified;Prid;Pt;Esophageal brush;Nom;Culture;MICRO;1;Bacteria identified in Esophageal brushing by Culture;Bacteria Esoph Brush Cult;;ACTIVE;2.26;2.29 +53909-8;Mycobacterium sp identified;Prid;Pt;Plr fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Pleural fluid by Organism specific culture;Mycobacterium Plr Cult;;ACTIVE;2.26;2.26 +53910-6;Microscopic observation;Prid;Pt;Periton fld;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Peritoneal fluid by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Prt;;ACTIVE;2.26;2.26 +53911-4;Bacteria identified;Prid;Pt;Bil fld;Nom;Culture;MICRO;1;Bacteria identified in Bile fluid by Culture;Bacteria Bifl Cult;;ACTIVE;2.26;2.26 +53912-2;Microscopic observation;Prid;Pt;Body fld;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Body fluid by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Fld;;ACTIVE;2.26;2.26 +53913-0;Microscopic observation;Prid;Pt;Synv fld;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Synovial fluid by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Snv;;ACTIVE;2.26;2.26 +53914-8;Microscopic observation;Prid;Pt;Endomet;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Endometrium by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Endometrium;;ACTIVE;2.26;2.26 +53915-5;Microscopic observation;Prid;Pt;Pericard fld;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Pericardial fluid by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Pcar;;ACTIVE;2.26;2.26 +53916-3;Microscopic observation;Prid;Pt;Gast fld;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Gastric fluid by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Gast;;ACTIVE;2.26;2.26 +53917-1;Streptococcus pneumoniae DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] in Blood by NAA with probe detection;S pneum DNA Bld Ql NAA+probe;;ACTIVE;2.26;2.73 +5391-8;Toxoplasma gondii Ab.IgM;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Toxoplasma gondii IgM Ab [Titer] in Serum or Plasma by Immunofluorescence;T gondii IgM Titr SerPl IF;;ACTIVE;1.0;2.73 +53918-9;Microscopic observation;Prid;Pt;Bone mar;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Bone marrow by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Mar;;ACTIVE;2.26;2.26 +53919-7;Thyroglobulin Ab;ACnc;Pt;Tiss.FNA;Qn;;SERO;1;Thyroglobulin Ab [Units/volume] in Tissue fine needle aspirate;Thyroglob Ab Tiss FNA-aCnc;;ACTIVE;2.26;2.70 +53920-5;Thyroglobulin;MCnc;Pt;Lymph node.FNA;Qn;;CHEM;1;Thyroglobulin [Mass/volume] in Lymph node fine needle aspirate;Thyroglob LN FNA-mCnc;;ACTIVE;2.26;2.73 +53921-3;Thyroglobulin Ab;ACnc;Pt;Lymph node.FNA;Qn;;SERO;1;Thyroglobulin Ab [Units/volume] in Lymph node fine needle aspirate;Thyroglob Ab LN FNA-aCnc;;ACTIVE;2.26;2.70 +53922-1;Thyroglobulin;MCnc;Pt;Tiss.FNA;Qn;;CHEM;1;Thyroglobulin [Mass/volume] in Tissue fine needle aspirate;Thyroglob Tiss FNA-mCnc;;ACTIVE;2.26;2.73 +53923-9;HIV 1 tropism;Prid;Pt;Bld;Nar;;MICRO;1;HIV 1 tropism [Identifier] in Blood Narrative;HIV1 tropism Bld;;ACTIVE;2.26;2.73 +53924-7;Rheumatoid factor;Titr;Pt;Synv fld;Qn;LA;SERO;1;Rheumatoid factor [Titer] in Synovial fluid by Latex agglutination;Rheumatoid fact Titr Snv LA;;ACTIVE;2.26;2.32 +53925-4;Chlamydia trachomatis rRNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Urethra by NAA with probe detection;C trach rRNA Urth Ql NAA+probe;;ACTIVE;2.26;2.73 +5392-6;Treponema pallidum Ab;ACnc;Pt;Ser;Qn;Immobilization;MICRO;1;Treponema pallidum Ab [Units/volume] in Serum by Immobilization;T pallidum Ab Ser Immob-aCnc;;ACTIVE;1.0;2.69 +53926-2;Chlamydia trachomatis rRNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by NAA with probe detection;C trach rRNA Vag Ql NAA+probe;;ACTIVE;2.26;2.73 +53927-0;Neisseria gonorrhoeae rRNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Urethra by NAA with probe detection;N gonorrhoea rRNA Urth Ql NAA+probe;;ACTIVE;2.26;2.73 +53928-8;Glucose^20M post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20 minutes post 50 g lactose PO;Glucose 20M p 50 g lac PO SerPl-mCnc;;ACTIVE;2.26;2.34 +53929-6;Glucose^40M post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --40 minutes post 50 g lactose PO;Glucose 40M p 50 g lac PO SerPl-mCnc;;ACTIVE;2.26;2.34 +53930-4;Histoplasma capsulatum Ag;ACnc;Pt;BAL;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Bronchoalveolar lavage by Immunoassay;H capsul Ag BAL IA-aCnc;;ACTIVE;2.26;2.73 +53931-2;Histoplasma capsulatum Ag;ACnc;Pt;CSF;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Cerebral spinal fluid by Immunoassay;H capsul Ag CSF IA-aCnc;;ACTIVE;2.26;2.73 +53932-0;Streptococcus pneumoniae 14 serotypes & Corynebacterium diphtheriae toxin & Clostridium tetani toxin Ab.IgG panel;-;Pt;Ser;-;;PANEL.MICRO;1;Streptococcus pneumoniae 14 serotypes and Corynebacterium diphtheriae toxin and Clostridium tetani toxin Ab.IgG panel - Serum;S pn 14 seros+C diph+C tet IgG Pnl Ser;;ACTIVE;2.26;2.61 +53933-8;Lactate dehydrogenase.pericard fld/Lactate dehydrogenase.serum;RelRto;Pt;Pericard fld+Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase in pericardial fluid/Lactate dehydrogenase in serum;LDH Pcar/SerPl;;ACTIVE;2.26;2.44 +5393-4;Treponema pallidum Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Treponema pallidum Ab [Presence] in Serum by Immunofluorescence;T pallidum Ab Ser Ql IF;;ACTIVE;1.0;2.73 +53934-6;Lactate dehydrogenase.periton fld/Lactate dehydrogenase.serum;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase in peritoneal fluid/Lactate dehydrogenase in serum;LDH Prt/SerPl;;ACTIVE;2.26;2.44 +53935-3;Clostridium tetani toxoid Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Clostridium tetani toxoid IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;C tetani Toxoid IgG SerPl IA-aCnc;;ACTIVE;2.26;2.73 +53936-1;Cells.CD3-CD56+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3-CD56+ cells [#/volume] in Blood;CD3-CD56+ Cells # Bld;;ACTIVE;2.26;2.73 +53937-9;HLA-B w4+w6;Type;Pt;WBC;Nom;;HLA;1;HLA-B w4+w6 [Type] in Leukocytes;HLA-B w4+w6 WBC;;ACTIVE;2.26;2.73 +53938-7;HLA-DQB1;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DQB1 [Type];HLA-DQB1;;ACTIVE;2.26;2.73 +53939-5;CD4 stimulated ATP immune response;MCnc;Pt;Bld;Qn;;SERO;1;CD4 stimulated ATP immune response [Mass/volume] in Blood;CD4 ATP immune response Bld-mCnc;;ACTIVE;2.26;2.73 +53940-3;CD4 stimulated ATP immune response;PrThr;Pt;Bld;Ord;;SERO;1;CD4 stimulated ATP immune response [Presence] in Blood;CD4 ATP immune response Bld Ql;;ACTIVE;2.26;2.68 +53941-1;Vibrio cholerae toxin Ag;PrThr;Pt;Isolate;Ord;;MICRO;1;Vibrio cholerae toxin Ag [Presence] in Isolate;V cholerae Tox Ag Islt Ql;;ACTIVE;2.26;2.56 +5394-2;Treponema pallidum Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Treponema pallidum Ab [Titer] in Serum by Latex agglutination;T pallidum Ab Titr Ser LA;;ACTIVE;1.0;2.70 +53942-9;Vibrio cholerae toxin ctx gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Vibrio cholerae toxin ctx gene [Presence] in Specimen by NAA with probe detection;V cholerae ctx gene Spec Ql NAA+probe;;ACTIVE;2.26;2.73 +53943-7;Bacterial cytolethal distending toxin cdt gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bacterial cytolethal distending toxin cdt gene [Presence] in Specimen by NAA with probe detection;cdt gene Spec Ql NAA+probe;;ACTIVE;2.26;2.69 +53944-5;Escherichia coli enteroinvasive;PrThr;Pt;Isolate;Ord;;MICRO;1;Escherichia coli enteroinvasive [Presence] in Isolate;E coli EIEC Islt Ql;;ACTIVE;2.26;2.73 +53945-2;Escherichia coli adherence pattern;Prid;Pt;Isolate;Nom;Hep2 substrate;MICRO;1;Escherichia coli adherence pattern [Identifier] in Isolate by Hep2 substrate;E coli adher pattern Islt HEp2 subst;;ACTIVE;2.26;2.32 +53946-0;Escherichia coli shiga-like toxin identified;Prid;Pt;XXX;Nom;;MICRO;1;Escherichia coli shiga-like toxin identified in Specimen;E coli SXT Spec;;ACTIVE;2.26;2.73 +53947-8;Escherichia coli Stx1 & Stx2 toxin stx1 & stx2 & H7 flagellar fliC genes;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Escherichia coli Stx1 and Stx2 toxin stx1 and stx2 and H7 flagellar fliC genes [Identifier] in Specimen by NAA with probe detection;EC stx1+stx2 + H7 fliC Spec NAA+probe;;ACTIVE;2.26;2.73 +53948-6;Donated egg;Arb;Pt;^Patient;Ord;;FERT;1;Donated egg [Presence];Donated egg Patient Ql;;ACTIVE;2.26;2.73 +53949-4;HPA 1a-1a+HPA 3b-3b;PrThr;Pt;Bld;Ord;;HPA;1;HPA 1a/1a+HPA 3b/3b [Presence] in Blood;HPA 1a/1a+HPA 3b/3b Bld Ql;;ACTIVE;2.26;2.56 +53950-2;HPA 1a-1a+Glycoprotein IIb-IIIa;PrThr;Pt;Bld;Ord;;HPA;1;HPA 1a/1a+Gp IIb/IIIa [Presence] in Blood;HPA 1a/1a+Gp IIb/IIIa Bld Ql;;ACTIVE;2.26;2.56 +53951-0;HPA 1b-1b+HPA 3a-3a;PrThr;Pt;Bld;Ord;;HPA;1;HPA 1b/1b+HPA 3a/3a [Presence] in Blood;HPA 1b/1b+HPA 3a/3a Bld Ql;;ACTIVE;2.26;2.56 +53952-8;HPA 1b-1b+Glycoprotein IIb-IIIa;PrThr;Pt;Bld;Ord;;HPA;1;HPA 1b/1b+Gp IIb/IIa [Presence] in Blood;HPA 1b/1b+Gp IIb/IIIa Bld Ql;;ACTIVE;2.26;2.56 +53953-6;HPA 5a-5a+Glycoprotein Ia-IIa;PrThr;Pt;Bld;Ord;;HPA;1;HPA 5a/5a+Gp Ia/IIa [Presence] in Blood;HPA 5a/5a+Gp Ia/IIa Bld Ql;;ACTIVE;2.26;2.73 +53954-4;HPA 5a-5b+Glycoprotein Ia-IIa;PrThr;Pt;Bld;Ord;;HPA;1;HPA 5a/5b+Gp Ia/IIa [Presence] in Blood;HPA 5a/5b+Gp Ia/IIa Bld Ql;;ACTIVE;2.26;2.56 +53955-1;Escherichia coli O157 identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Escherichia coli O157 identified in Isolate by Organism specific culture;E coli O157 Islt Cult;;ACTIVE;2.26;2.26 +53956-9;Salmonella typhi;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Salmonella typhi [Identifier] in Isolate by Agglutination;S Typhi Islt Aggl;;ACTIVE;2.26;2.44 +53957-7;Choriogonadotropin.tumor marker;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.tumor marker [Mass/volume] in Serum or Plasma;HCG-TM SerPl-mCnc;;ACTIVE;2.26;2.42 +53958-5;Choriogonadotropin.tumor marker;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.tumor marker [Moles/volume] in Serum or Plasma;HCG-TM SerPl-sCnc;;ACTIVE;2.26;2.40 +5395-9;Trichinella spiralis Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Trichinella spiralis Ab [Titer] in Serum by Latex agglutination;T spiralis Ab Titr Ser LA;;ACTIVE;1.0;2.70 +53959-3;Choriogonadotropin.tumor marker;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.tumor marker [Units/volume] in Serum or Plasma;HCG-TM SerPl-aCnc;;ACTIVE;2.26;2.73 +53960-1;Alpha-1-Fetoprotein.tumor marker;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-fetoprotein.tumor marker [Moles/volume] in Serum or Plasma;AFP-TM SerPl-sCnc;;ACTIVE;2.26;2.73 +53961-9;Alpha-1-Fetoprotein.tumor marker;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-fetoprotein.tumor marker [Units/volume] in Serum or Plasma;AFP-TM SerPl-aCnc;;ACTIVE;2.26;2.73 +53962-7;Alpha-1-Fetoprotein.tumor marker;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-1-fetoprotein.tumor marker [Mass/volume] in Serum or Plasma;AFP-TM SerPl-mCnc;;ACTIVE;2.26;2.73 +53963-5;Blood;PrThr;Pt;Urine;Ord;Visual;UA;1;Blood [Presence] in Urine by Visual;Blood Ur Ql Visual;;ACTIVE;2.26;2.73 +53964-3;Leukocytes;PrThr;Pt;Urine;Ord;Visual;UA;1;Leukocytes [Presence] in Urine by Visual;WBC Ur Ql Visual;;ACTIVE;2.26;2.56 +53965-0;Brickdust deposit;PrThr;Pt;Urine;Ord;Visual;UA;1;Brickdust deposit [Presence] in Urine by Visual;Brickdust deposit Ur Ql Visual;;ACTIVE;2.26;2.56 +53966-8;Erythrocytes.dysmorphic G1/100 erythrocytes;NFr;Pt;Urine sed;Qn;Microscopy.light;UA;1;Erythrocytes.dysmorphic G1/100 erythrocytes in Urine sediment by Light microscopy;G1 RBC/100 RBC NFr UrnS Micro;;ACTIVE;2.26;2.40 +5396-7;Triiodothyronine Ab;ACnc;Pt;Ser;Qn;;SERO;1;Triiodothyronine (T3) Ab [Units/volume] in Serum;T3 Ab Ser-aCnc;;ACTIVE;1.0;2.73 +53967-6;Erythrocytes.dysmorphic/100 erythrocytes;NFr;Pt;Urine sed;Qn;Microscopy.light;UA;1;Erythrocytes.dysmorphic/100 erythrocytes in Urine sediment by Light microscopy;Dysmorphic RBC/100 RBC NFr UrnS Micro;;ACTIVE;2.26;2.73 +53968-4;Erythrocytes.non-dysmorphic;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Erythrocytes.non-dysmorphic [Presence] in Urine sediment by Light microscopy;Non-dys RBC UrnS Ql Micro;;ACTIVE;2.26;2.72 +53969-2;Microcytes;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Microcytes [Presence] in Urine sediment by Light microscopy;Microcytes UrnS Ql Micro;;ACTIVE;2.26;2.56 +539-7;Mycobacterium sp identified;Prid;Pt;Sputum;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Sputum by Organism specific culture;Mycobacterium Spt Cult;;ACTIVE;1.0;2.73 +53970-0;Macrocytes;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Macrocytes [Presence] in Urine sediment by Light microscopy;Macrocytes UrnS Ql Micro;;ACTIVE;2.26;2.56 +53971-8;Spherocytes;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Spherocytes [Presence] in Urine sediment by Light microscopy;Spherocytes UrnS Ql Micro;;ACTIVE;2.26;2.56 +53972-6;Burr cells;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Burr cells [Presence] in Urine sediment by Light microscopy;Burr Cells UrnS Ql Micro;;ACTIVE;2.26;2.73 +53973-4;Erythrocytes.ghost cells;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Erythrocytes.ghost cells [Presence] in Urine sediment by Light microscopy;RBCGhost UrnS Ql Micro;;ACTIVE;2.26;2.56 +53974-2;Erythrocyte morphology;Imp;Pt;Urine sed;Nar;Microscopy.light;UA;1;Erythrocyte morphology [Interpretation] in Urine sediment by Light microscopy Narrative;RBC morph UrnS Micro-Imp;;ACTIVE;2.26;2.73 +5397-5;Trypanosoma brucei Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Trypanosoma brucei Ab [Units/volume] in Serum;T brucei Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53975-9;Drug crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Drug crystals [Presence] in Urine sediment by Light microscopy;Drug crys UrnS Ql Micro;;ACTIVE;2.26;2.56 +53976-7;Pseudocasts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Pseudocasts [Presence] in Urine sediment by Light microscopy;Pseudocasts UrnS Ql Micro;;ACTIVE;2.26;2.56 +53977-5;Dimagnesium phosphate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Dimagnesium phosphate crystals [Presence] in Urine sediment by Light microscopy;Di-Mg phos cry UrnS Ql Micro;;ACTIVE;2.26;2.56 +53978-3;Epithelial cells.non-squamous;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Epithelial cells.non-squamous [Presence] in Urine sediment by Light microscopy;Non-sq Epi Cells UrnS Ql Micro;;ACTIVE;2.26;2.73 +53979-1;Actin Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Actin Ab [Presence] in Serum or Plasma by Immunofluorescence;Actin Ab SerPl Ql IF;;ACTIVE;2.26;2.56 +53980-9;Actin Ab;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Actin Ab [Titer] in Serum or Plasma by Immunofluorescence;Actin Ab Titr SerPl IF;;ACTIVE;2.26;2.70 +53981-7;Centromere protein B Ab;PrThr;Pt;Ser;Ord;;SERO;1;Centromere protein B Ab [Presence] in Serum;Centromere B Ab Ser Ql;;ACTIVE;2.26;2.73 +53982-5;Centromere protein B Ab;ACnc;Pt;Ser;Qn;;SERO;1;Centromere protein B Ab [Units/volume] in Serum;Centromere B Ab Ser-aCnc;;ACTIVE;2.26;2.73 +5398-3;Trypanosoma cruzi Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Trypanosoma cruzi Ab [Titer] in Serum by Complement fixation;T cruzi Ab Titr Ser CF;;ACTIVE;1.0;2.70 +53983-3;Nuclear Ab pattern.homogeneous;Titr;Pt;Ser;Qn;IF;SERO;1;Homogenous nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA Homogen Titr Ser IF;;ACTIVE;2.26;2.73 +53984-1;Nuclear Ab pattern.fine speckled;PrThr;Pt;Ser;Ord;IF;SERO;1;Fine speckled nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA fine speckled Ser Ql IF;;ACTIVE;2.26;2.73 +53985-8;Nuclear Ab pattern.coarse speckled;Titr;Pt;Ser;Qn;IF;SERO;1;Coarse speckled nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA coarse speckled Titr Ser IF;;ACTIVE;2.26;2.70 +53986-6;Nuclear Ab pattern.coarse speckled;PrThr;Pt;Ser;Ord;IF;SERO;1;Coarse speckled nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA coarse speckled Ser Ql IF;;ACTIVE;2.26;2.58 +53987-4;Nuclear Ab pattern.atypic speckled;Titr;Pt;Ser;Qn;IF;SERO;1;Atypic speckled nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA atypic speckled Titr Ser IF;;ACTIVE;2.26;2.70 +53988-2;Nuclear Ab pattern.atypic speckled;PrThr;Pt;Ser;Ord;IF;SERO;1;Atypic speckled nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA atypic speckled Ser Ql IF;;ACTIVE;2.26;2.58 +53989-0;Nuclear Ab pattern.chromosomal;Titr;Pt;Ser;Qn;IF;SERO;1;Chromosomal nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA chromosomal Titr Ser IF;;ACTIVE;2.26;2.70 +53990-8;Nuclear Ab pattern.chromosomal;PrThr;Pt;Ser;Ord;IF;SERO;1;Chromosomal nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA chromosomal Ser Ql IF;;ACTIVE;2.26;2.73 +5399-1;Trypanosoma sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Trypanosoma sp Ab [Units/volume] in Serum;Trypanos Ab Ser-aCnc;;ACTIVE;1.0;2.69 +53991-6;Nuclear Ab pattern.nucleolar;Titr;Pt;Ser;Qn;IF;SERO;1;Nucleolar nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA nucleolar Titr Ser IF;;ACTIVE;2.26;2.73 +53992-4;Nuclear Ab pattern.nucleolar;PrThr;Pt;Ser;Ord;IF;SERO;1;Nucleolar nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA nucleolar Ser Ql IF;;ACTIVE;2.26;2.58 +53993-2;Nuclear Ab pattern.centrosomal;Titr;Pt;Ser;Qn;IF;SERO;1;Centrosomal nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA centrosomal Titr Ser IF;;ACTIVE;2.26;2.73 +53994-0;Nuclear Ab pattern.centrosomal;PrThr;Pt;Ser;Ord;IF;SERO;1;Centrosomal nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA centrosomal Ser Ql IF;;ACTIVE;2.26;2.58 +53995-7;Nuclear Ab pattern.nuclear matrix;Titr;Pt;Ser;Qn;IF;SERO;1;Nuclear matrix Ab pattern [Titer] in Serum by Immunofluorescence;ANA nuclear matrix Titr Ser IF;;ACTIVE;2.26;2.70 +53996-5;Nuclear Ab pattern.nuclear matrix;PrThr;Pt;Ser;Ord;IF;SERO;1;Nuclear matrix Ab pattern [Presence] in Serum by Immunofluorescence;ANA nuclear matrix Ser Ql IF;;ACTIVE;2.26;2.58 +53997-3;Nuclear Ab pattern.nuclear dots;PrThr;Pt;Ser;Ord;IF;SERO;1;Nuclear dots nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA nuclear dots Ser Ql IF;;ACTIVE;2.26;2.58 +53998-1;Nuclear Ab pattern.nuclear dots;Titr;Pt;Ser;Qn;IF;SERO;1;Nuclear dots nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA nuclear dots Titr Ser IF;;ACTIVE;2.26;2.73 +53999-9;Nuclear Ab pattern.multiple nuclear dots;PrThr;Pt;Ser;Ord;IF;SERO;1;Multiple nuclear dots nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA multiple nuclear dots Ser Ql IF;;ACTIVE;2.26;2.73 +54000-5;Nuclear Ab pattern.multiple nuclear dots;Titr;Pt;Ser;Qn;IF;SERO;1;Multiple nuclear dots nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA multiple nuclear dots Titr Ser IF;;ACTIVE;2.26;2.73 +54001-3;Centromere protein F Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Centromere protein F Ab [Presence] in Serum by Immunofluorescence;Centromere F Ab Ser Ql IF;;ACTIVE;2.26;2.56 +54002-1;Centromere protein F Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Centromere protein F Ab [Titer] in Serum by Immunofluorescence;Centromere F Ab Titr Ser IF;;ACTIVE;2.26;2.70 +54003-9;Human upstream binding factor Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Human upstream binding factor Ab [Presence] in Serum by Immunofluorescence;hUBF Ab Ser Ql IF;;ACTIVE;2.26;2.56 +54004-7;Human upstream binding factor Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Human upstream binding factor Ab [Titer] in Serum by Immunofluorescence;hUBF Ab Titr Ser IF;;ACTIVE;2.26;2.70 +54005-4;Nuclear Ab pattern.nuclear membrane pores;PrThr;Pt;Ser;Ord;IF;SERO;1;Nuclear membrane pores nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA nuclear membrane pores Ser Ql IF;;ACTIVE;2.26;2.73 +54006-2;Nuclear Ab pattern.nuclear membrane pores;Titr;Pt;Ser;Qn;IF;SERO;1;Nuclear membrane pores nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA nuclear membrane pores Titr Ser IF;;ACTIVE;2.26;2.73 +5400-7;Vaccinia virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Vaccinia virus Ab [Units/volume] in Serum;VACV Ab Ser-aCnc;;ACTIVE;1.0;2.69 +54007-0;Golgi apparatus Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Golgi apparatus Ab [Presence] in Serum by Immunofluorescence;Golgi apparatus Ab Ser Ql IF;;ACTIVE;2.26;2.56 +54008-8;Golgi apparatus Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Golgi apparatus Ab [Titer] in Serum by Immunofluorescence;Golgi apparatus Ab Titr Ser IF;;ACTIVE;2.26;2.70 +54009-6;Lysosome Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Lysosome Ab [Presence] in Serum by Immunofluorescence;Lysosome Ab Ser Ql IF;;ACTIVE;2.26;2.56 +54010-4;Lysosome Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Lysosome Ab [Titer] in Serum by Immunofluorescence;Lysosome Ab Titr Ser IF;;ACTIVE;2.26;2.70 +54011-2;Vimentin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Vimentin Ab [Presence] in Serum by Immunofluorescence;Vimentin Ab Ser Ql IF;;ACTIVE;2.26;2.56 +54012-0;Vimentin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Vimentin Ab [Titer] in Serum by Immunofluorescence;Vimentin Ab Titr Ser IF;;ACTIVE;2.26;2.32 +54013-8;Vinculin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Vinculin Ab [Presence] in Serum by Immunofluorescence;Vinculin Ab Ser Ql IF;;ACTIVE;2.26;2.56 +54014-6;Vinculin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Vinculin Ab [Titer] in Serum by Immunofluorescence;Vinculin Ab Titr Ser IF;;ACTIVE;2.26;2.32 +5401-5;Varicella zoster virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Varicella zoster virus Ab [Titer] in Serum by Complement fixation;VZV Ab Titr Ser CF;;ACTIVE;1.0;2.73 +54015-3;Azurocidin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Azurocidin Ab [Presence] in Serum;Azurocidin Ab Ser Ql;;ACTIVE;2.26;2.56 +54016-1;Cathepsin G Ab;PrThr;Pt;Ser;Ord;;SERO;1;Cathepsin G Ab [Presence] in Serum;Cathepsin G Ab Ser Ql;;ACTIVE;2.26;2.56 +54017-9;Elastase Ab;PrThr;Pt;Ser;Ord;;SERO;1;Elastase Ab [Presence] in Serum;Elastase Ab Ser Ql;;ACTIVE;2.26;2.56 +54018-7;Lactoferrin Ab;PrThr;Pt;Ser;Ord;;SERO;1;Lactoferrin Ab [Presence] in Serum;Lactoferrin Ab Ser Ql;;ACTIVE;2.26;2.56 +54019-5;Lysozyme Ab;PrThr;Pt;Ser;Ord;;SERO;1;Lysozyme Ab [Presence] in Serum;Lysozyme Ab Ser Ql;;ACTIVE;2.26;2.56 +54020-3;Actin.filamentous Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;Actin.filamentous Ab [Presence] in Serum or Plasma;F-actin Ab SerPl Ql;;ACTIVE;2.26;2.73 +54021-1;Actin.filamentous Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Actin.filamentous Ab [Units/volume] in Serum or Plasma;F-actin Ab SerPl-aCnc;;ACTIVE;2.26;2.70 +54022-9;Mutated citrullinated vimentin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Mutated citrullinated vimentin Ab [Units/volume] in Serum;Mut cit vimentin Ab Ser-aCnc;;ACTIVE;2.26;2.70 +5402-3;Varicella zoster virus Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Varicella zoster virus Ab [Titer] in Serum by Latex agglutination;VZV Ab Titr Ser LA;;ACTIVE;1.0;2.70 +54023-7;U1 small nuclear ribonucleoprotein C Ab;PrThr;Pt;Ser;Ord;;SERO;1;U1 small nuclear ribonucleoprotein C Ab [Presence] in Serum;U1 snRNP-C Ab Ser Ql;;ACTIVE;2.26;2.56 +54024-5;sp100 Ab;PrThr;Pt;Ser;Ord;;SERO;1;sp100 Ab [Presence] in Serum;sp100 Ab Ser Ql;;ACTIVE;2.26;2.56 +54025-2;Nuclear pore protein gp210 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Nuclear pore protein gp210 Ab [Presence] in Serum;Nuclear pore prot gp210 Ab Ser Ql;;ACTIVE;2.26;2.69 +54026-0;Soluble liver Ab;ACnc;Pt;Ser;Qn;;SERO;1;Deprecated Soluble liver Ab [Units/volume] in Serum;Deprecated Soluble liver Ab Ser-aCnc;;DEPRECATED;2.26;2.70 +54027-8;Lamin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Lamin Ab [Presence] in Serum by Immunofluorescence;Lamin Ab Ser Ql IF;;ACTIVE;2.26;2.56 +54028-6;Lamin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Lamin Ab [Titer] in Serum by Immunofluorescence;Lamin Ab Titr Ser IF;;ACTIVE;2.26;2.70 +54029-4;Soluble liver Ab;PrThr;Pt;Ser;Ord;;SERO;1;Deprecated Soluble liver Ab [Presence] in Serum;Deprecated Soluble liver Ab Ser Ql;;DEPRECATED;2.26;2.58 +54030-2;Smith extractable nuclear B Ab;PrThr;Pt;Ser;Ord;;SERO;1;Smith extractable nuclear B Ab [Presence] in Serum;ENA SM-B Ab Ser Ql;;ACTIVE;2.26;2.56 +5403-1;Varicella zoster virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Serum by Immunoassay;VZV IgG Ser IA-aCnc;;ACTIVE;1.0;2.73 +54031-0;Smith extractable nuclear D Ab;PrThr;Pt;Ser;Ord;;SERO;1;Smith extractable nuclear D Ab [Presence] in Serum;ENA SM-D Ab Ser Ql;;ACTIVE;2.26;2.56 +54032-8;U1 small nuclear ribonucleoprotein A Ab;PrThr;Pt;Ser;Ord;;SERO;1;U1 small nuclear ribonucleoprotein A Ab [Presence] in Serum;U1 snRNP-A Ab Ser Ql;;ACTIVE;2.26;2.56 +54033-6;Rickettsia spotted fever group Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Rickettsia spotted fever group Ag [Presence] in Tissue by Immune stain;Rick SF Ag Tiss Ql ImStn;;ACTIVE;2.26;2.56 +54034-4;Anaplasma phagocytophilum Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Anaplasma phagocytophilum Ag [Presence] in Tissue by Immune stain;A phagocytoph Ag Tiss Ql ImStn;;ACTIVE;2.26;2.56 +54035-1;Ehrlichia chaffeensis Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Ehrlichia chaffeensis Ag [Presence] in Tissue by Immune stain;E chaffeensis Ag Tiss Ql ImStn;;ACTIVE;2.26;2.56 +54036-9;Western equine encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Western equine encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;WEEV RNA Spec Ql NAA+probe;;ACTIVE;2.26;2.69 +54037-7;HEDIS 2009 panel;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 panel;HEDIS 2009 Pnl;;DISCOURAGED;2.26;2.67 +54038-5;HEDIS 2009-2013 Codes to identify cervical cancer screening tests (CCS-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009-2013 Codes to identify cervical cancer screening tests (CCS-A);HEDIS 2009-13 CCS-A;;DISCOURAGED;2.26;2.67 +54039-3;HEDIS 2009-2011 Codes to identify HbA1c tests (CDC-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009-2011 Codes to identify HbA1c tests (CDC-D);HEDIS 2009-2011CDC-D;;DISCOURAGED;2.26;2.67 +54040-1;HEDIS 2009 Codes to identify LDLc screening (CDC-H);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify LDLc screening (CDC-H);HEDIS 2009 CDC-H;;DISCOURAGED;2.26;2.67 +54041-9;HEDIS 2009 Codes to identify nephropathy screening tests (CDC-J);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify nephropathy screening tests (CDC-J);HEDIS 2009 CDC-J;;DISCOURAGED;2.26;2.67 +54042-7;HEDIS 2009 Codes to identify evidence of nephropathy (CDC-K);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify evidence of nephropathy (CDC-K);HEDIS 2009 CDC-K;;DISCOURAGED;2.26;2.67 +54043-5;HEDIS 2009 Codes to identify sexually active women (CHL-B);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify sexually active women (CHL-B);HEDIS 2009 CHL-B;;DISCOURAGED;2.26;2.67 +54044-3;HEDIS 2009 Codes to identify Chlamydia screening (CHL-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify Chlamydia screening (CHL-C);HEDIS 2009 CHL-C;;DISCOURAGED;2.26;2.67 +54045-0;HEDIS 2009, 2010 Codes to identify exclusions (CHL-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009, 2010 Codes to identify exclusions (CHL-D);HEDIS 2009-10 CHL-D;;DISCOURAGED;2.26;2.67 +54046-8;HEDIS 2009 Codes to identify LDLc screening (CMC-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify LDLc screening (CMC-D);HEDIS 2009 CMC-D;;DISCOURAGED;2.26;2.67 +54047-6;HEDIS 2009 Codes to identify colorectal cancer screening (COL-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify colorectal cancer screening (COL-A);HEDIS 2009 COL-A;;DISCOURAGED;2.26;2.67 +54048-4;HEDIS 2009 Codes to identify group A Streptococcus tests (CWP-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify group A Streptococcus tests (CWP-D);HEDIS 2009 CWP-D;;DISCOURAGED;2.26;2.67 +5404-9;Varicella zoster virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Varicella zoster virus IgM Ab [Units/volume] in Serum by Immunoassay;VZV IgM Ser IA-aCnc;;ACTIVE;1.0;2.73 +54049-2;HEDIS 2009-2013 Codes to identify lead (LSC-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009-2013 Codes to identify lead (LSC-A);HEDIS 2009-13 LSC-A;;DISCOURAGED;2.26;2.67 +540-5;Mycobacterium sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Tissue by Organism specific culture;Mycobacterium Tiss Cult;;ACTIVE;1.0;2.73 +54050-0;HEDIS 2009 Codes to identify physiologic monitoring tests (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify physiologic monitoring tests (MPM-A);HEDIS 2009 MPM-A;;DISCOURAGED;2.26;2.67 +54051-8;HEDIS 2009 Codes to identify physiologic monitoring tests - Blood urea nitrogen (BUN) (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify physiologic monitoring tests - Blood urea nitrogen (BUN) (MPM-A);HEDIS 2009 MPM-A BUN;;DISCOURAGED;2.26;2.67 +54052-6;HEDIS 2009 Codes to identify physiologic monitoring tests - Serum creatinine (SCr) (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify physiologic monitoring tests - Serum creatinine (SCr) (MPM-A);HEDIS 2009 MPM-A SCr;;DISCOURAGED;2.26;2.67 +54053-4;HEDIS 2009 Codes to identify physiologic monitoring tests - Serum potassium (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify physiologic monitoring tests - Serum potassium (MPM-A);HEDIS 2009 MPM-A K;;DISCOURAGED;2.26;2.67 +54054-2;HEDIS 2009 Codes to identify anticonvulsant serum concentration monitoring tests (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify anticonvulsant serum concentration monitoring tests (MPM-E);HEDIS 2009 MPM-E;;DISCOURAGED;2.26;2.67 +54055-9;HEDIS 2009 Codes to identify anticonvulsant serum concentration monitoring tests - carBAMazepine (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Codes to identify anticonvulsant serum concentration monitoring tests - carBAMazepine (MPM-E);HEDIS 2009 MPM-E carBAMazepine;;DISCOURAGED;2.26;2.67 +5405-6;Vibrio cholerae Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Vibrio cholerae Ab [Mass/volume] in Serum;V cholerae Ab Ser-mCnc;;ACTIVE;1.0;2.40 +54056-7;HEDIS 2009-2011 Codes to identify anticonvulsant serum concentration monitoring tests - PHENobarbital (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009-2011 Codes to identify anticonvulsant serum concentration monitoring tests - PHENobarbital (MPM-E);HEDIS 2009-11 MPM-E PHENobarbital;;DISCOURAGED;2.26;2.67 +54057-5;HEDIS 2009, 2010 Codes to identify anticonvulsant serum concentration monitoring tests - Phenytoin (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009, 2010 Codes to identify anticonvulsant serum concentration monitoring tests - Phenytoin (MPM-E);HEDIS 2009-10 MPM-E Phenytoin;;DISCOURAGED;2.26;2.67 +54058-3;HEDIS 2009-2013 Codes to identify anticonvulsant serum concentration monitoring tests - Valproate (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009-2013 Codes to identify anticonvulsant serum concentration monitoring tests - Valproate (MPM-E);HEDIS 2009-13 MPM-E Valproate;;DISCOURAGED;2.26;2.67 +54059-1;HEDIS 2009 Tests used in early prenatal care (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Tests used in early prenatal care (PPC-C);HEDIS 2009 PPC-C;;DISCOURAGED;2.26;2.67 +54060-9;HEDIS 2009 Tests used in early prenatal care - ABO & Rh (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Tests used in early prenatal care - ABO and Rh (PPC-C);HEDIS 2009 PPC-C ABO+Rh;;DISCOURAGED;2.26;2.67 +54061-7;HEDIS 2009-2011 Tests used in early prenatal care - Cytomegalovirus (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009-2011 Tests used in early prenatal care - Cytomegalovirus (PPC-C);HEDIS 2009-11 PPC-C CMV;;DISCOURAGED;2.26;2.67 +54062-5;HEDIS 2009, 2010 Tests used in early prenatal care - Herpes simplex (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009, 2010 Tests used in early prenatal care - Herpes simplex (PPC-C);HEDIS 2009-10 PPC-C HSV;;DISCOURAGED;2.26;2.67 +54063-3;HEDIS 2009 Tests used in early prenatal care - Rubella (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Tests used in early prenatal care - Rubella (PPC-C);HEDIS 2009 PPC-C RUBV;;DISCOURAGED;2.26;2.67 +5406-4;Western equine encephalitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus Ab [Units/volume] in Serum;WEEV Ab Ser-aCnc;;ACTIVE;1.0;2.69 +54064-1;HEDIS 2009 Tests used in early prenatal care - Toxoplasma (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009 Tests used in early prenatal care - Toxoplasma (PPC-C);HEDIS 2009 PPC-C Toxo;;DISCOURAGED;2.26;2.67 +54065-8;HEDIS 2009-2013 Codes to identify postpartum visits (PPC-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2009-2013 Codes to identify postpartum visits (PPC-E);HEDIS 2009-13 PPC-E;;DISCOURAGED;2.26;2.67 +54066-6;Post acute care or personal assistance anticipated following discharge;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Post acute care or personal assistance anticipated following discharge [CARE];;;DISCOURAGED;2.26;2.64 +54067-4;Clostridioides difficile toxin genes;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection;C diff Tox gens Stl Ql NAA+probe;;ACTIVE;2.26;2.73 +54068-2;Hemoglobin O-Arab/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin O - Arab/Hemoglobin.total in DBS;Hgb O-Arab MFr DBS;;ACTIVE;2.26;2.61 +54069-0;Hemoglobin Barts/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin Barts/Hemoglobin.total in DBS;Hgb Barts MFr DBS;;ACTIVE;2.26;2.61 +54070-8;Hemoglobin D/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin D/Hemoglobin.total in DBS;Hgb D MFr DBS;;ACTIVE;2.26;2.61 +54071-6;Hemoglobin E/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin E/Hemoglobin.total in DBS;Hgb E MFr DBS;;ACTIVE;2.26;2.61 +5407-2;Yersinia enterocolitica O:3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:3 Ab [Units/volume] in Serum;Y entero O:3 Ab Ser-aCnc;;ACTIVE;1.0;2.69 +54072-4;Hemoglobin A/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin A/Hemoglobin.total in DBS;Hgb A MFr DBS;;ACTIVE;2.26;2.61 +54073-2;Hemoglobin C/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin C/Hemoglobin.total in DBS;Hgb C MFr DBS;;ACTIVE;2.26;2.61 +54074-0;Hemoglobin F/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin F/Hemoglobin.total in DBS;Hgb F MFr DBS;;ACTIVE;2.26;2.61 +54075-7;Endocrine newborn screening panel (SI units);-;Pt;Bld.dot;-;;PANEL.CHEM;1;Endocrine newborn screening panel (SI units);NB pnl Endocrine SI DBS;;ACTIVE;2.26;2.40 +54076-5;Endocrine newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Endocrine newborn screening panel;NB pnl Endocrine DBS;;ACTIVE;2.26;2.40 +54077-3;Thyroid newborn screening panel (SI units);-;Pt;Bld.dot;-;;PANEL.CHEM;1;Thyroid newborn screening panel (SI units);NB pnl Thyroid SI DBS;;ACTIVE;2.26;2.40 +54078-1;Cystic fibrosis newborn screening panel;-;Pt;^Patient;-;;PANEL.CHEM;1;Cystic fibrosis newborn screening panel;NB pnl CF Patient;;ACTIVE;2.26;2.73 +54079-9;Galactosemia newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Galactosemia newborn screening panel;NB pnl Galactosemia DBS;;ACTIVE;2.26;2.73 +5408-0;Yersinia enterocolitica O:8 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:8 Ab [Units/volume] in Serum;Y entero O:8 Ab Ser-aCnc;;ACTIVE;1.0;2.73 +54080-7;Galactosemia newborn screening panel (SI units);-;Pt;Bld.dot;-;;PANEL.CHEM;1;Galactosemia newborn screening panel (SI units);NB pnl Galactosemia SI DBS;;ACTIVE;2.26;2.40 +54081-5;Hemoglobinopathies newborn screening panel;-;Pt;Bld.dot;-;;PANEL.HEM/BC;1;Hemoglobinopathies newborn screening panel;NB pnl Hemoglobinopathies DBS;;ACTIVE;2.26;2.73 +54082-3;Infectious diseases newborn screening panel;-;Pt;Bld.dot;-;;PANEL.MICRO;1;Infectious diseases newborn screening panel;NB pnl Infectious diseases DBS;;ACTIVE;2.26;2.40 +54083-1;CFTR gene targeted mutation analysis;Prid;Pt;Bld.dot;Nom;Molgen;MOLPATH.MUT;1;CFTR gene mutations found [Identifier] in DBS by Molecular genetics method Nominal;CFTR Mut Anl DBS;;ACTIVE;2.26;2.73 +54084-9;Galactose;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Galactose [Mass/volume] in DBS;Galactose DBS-mCnc;;ACTIVE;2.26;2.73 +54085-6;Galactose;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Galactose [Moles/volume] in DBS;Galactose DBS-sCnc;;ACTIVE;2.26;2.73 +54086-4;HIV 1+2 Ab.IgG;PrThr;Pt;Bld.dot;Ord;;MICRO;1;HIV 1+2 IgG Ab [Presence] in DBS;HIV1+2 IgG DBS Ql;;ACTIVE;2.26;2.61 +54087-2;Toxoplasma gondii Ab.IgG;PrThr;Pt;Bld.dot;Ord;;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in DBS;T gondii IgG DBS Ql;;ACTIVE;2.26;2.61 +54088-0;Toxoplasma gondii Ab.IgM;PrThr;Pt;Bld.dot;Ord;;MICRO;1;Toxoplasma gondii IgM Ab [Presence] in DBS;T gondii IgM DBS Ql;;ACTIVE;2.26;2.61 +54089-8;Newborn screening panel;-;Pt;^Patient;-;AHIC;PANEL.CHEM;1;Newborn screening panel American Health Information Community (AHIC);NB Screen Pnl Patient AHIC;;ACTIVE;2.26;2.73 +54090-6;Thyroid newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Thyroid newborn screening panel;NB pnl Thyroid DBS;;ACTIVE;2.26;2.40 +54091-4;Rubella virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rubella virus RNA [Presence] in Specimen by NAA with probe detection;RUBV RNA Spec Ql NAA+probe;;ACTIVE;2.26;2.73 +54092-2;Citrulline/Arginine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Citrulline/Arginine [Molar ratio] in DBS;Citrulline/Arginine DBS-sRto;;ACTIVE;2.26;2.73 +54093-0;Pesticides;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Pesticides [Presence] in Gastric fluid by Screen method;Pesticides Gast Ql Scn;;ACTIVE;2.26;2.56 +54094-8;Triage note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Triage note;ED Triage note;;ACTIVE;2.26;2.73 +54095-5;Chemotherapy effectiveness panel;Prid;-;Bld/Tiss;Doc;;PANEL.DRUG/TOX;1;Chemotherapy effectiveness panel [Identifier] - Blood or Tissue;Chemotherapy effectiveness Pnl Bld/T;;ACTIVE;2.26;2.63 +54096-3;Identity testing;Prid;Pt;Index case^Comparison case;Nar;Molgen;MOLPATH;1;Identity testing [Identifier] in Index case from Comparison case by Molecular genetics method Narrative;Identity testing Index Compar;;ACTIVE;2.26;2.36 +54097-1;Organophosphonate nerve agent metabolite panel;MCnc;Pt;Urine;-;;PANEL.DRUG/TOX;1;Organophosphonate nerve agent metabolite panel [Mass/volume] - Urine;OP nerve agent metab Pnl Ur-mCnc;;ACTIVE;2.26;2.71 +5409-8;Yersinia enterocolitica O:9 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:9 Ab [Units/volume] in Serum;Y entero O:9 Ab Ser-aCnc;;ACTIVE;1.0;2.73 +54098-9;Isopropyl methylphosphonate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Isopropyl methylphosphonate [Mass/volume] in Urine;IMPA Ur-mCnc;;ACTIVE;2.26;2.42 +54099-7;1,2,2-Trimethylpropyl methylphosphonate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;1,2,2-Trimethylpropyl methylphosphonate [Mass/volume] in Urine;TMPA Ur-mCnc;;ACTIVE;2.26;2.56 +54100-3;Monocyclohexyl methylphosphonate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Monocyclohexyl methylphosphonate [Mass/volume] in Urine;Monocyclohexyl Me-phosphonate Ur-mCnc;;ACTIVE;2.26;2.56 +54101-1;2-Methylpropyl methylphosphonate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2-Methylpropyl methylphosphonate [Mass/volume] in Urine;VX acid Ur-mCnc;;ACTIVE;2.26;2.56 +54102-9;Monoethyl methylphosphonate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Monoethyl methylphosphonate [Mass/volume] in Urine;Monoethyl Me-phosphonate Ur-mCnc;;ACTIVE;2.26;2.56 +54103-7;Hemoglobin pattern;Find;Pt;Bld.dot;Nom;Electrophoresis;HEM/BC;1;Hemoglobin pattern in DBS by Electrophoresis;Hgb Fract DBS Elph;;DISCOURAGED;2.26;2.65 +54104-5;Hemoglobin pattern;Find;Pt;Bld.dot;Nom;HPLC;HEM/BC;1;Hemoglobin pattern in DBS by HPLC;Hgb Fract DBS HPLC;;DISCOURAGED;2.26;2.73 +54105-2;Hemoglobin pattern;Find;Pt;Bld.dot;Nom;Isoelectric focusing;HEM/BC;1;Hemoglobin pattern in DBS by Isoelectric focusing;Hgb Fract DBS IEF;;DISCOURAGED;2.26;2.73 +5410-6;Yersinia pseudotuberculosis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia pseudotuberculosis Ab [Units/volume] in Serum;Y pseudoTB Ab Ser-aCnc;;ACTIVE;1.0;2.73 +54106-0;Newborn hearing screen method;Type;Pt;Ear;Nom;;H&P.HX;2;Newborn hearing screen method;NB hearing scn meth;;ACTIVE;2.26;2.73 +54107-8;Newborn hearing screen;Arb;Pt;Ear.bilateral;Ord;;H&P.HX;2;Deprecated Newborn hearing screen - bilateral;Deprecated NB hearing scn -BL;;DEPRECATED;2.26;2.36 +54108-6;Newborn hearing screen;Arb;Pt;Ear.left;Ord;;H&P.HX;2;Newborn hearing screen of Ear - left;NB hearing scn Ear-L;;ACTIVE;2.26;2.73 +54109-4;Newborn hearing screen;Arb;Pt;Ear.right;Ord;;H&P.HX;2;Newborn hearing screen of Ear - right;NB hearing scn Ear-R;;ACTIVE;2.26;2.73 +54110-2;Newborn hearing screen;Arb;Pt;Ear;Ord;;H&P.HX;2;Deprecated Newborn hearing screen;DeprecatedNewborn hearing screen;;DEPRECATED;2.26;2.36 +54111-0;Newborn hearing screening panel;-;Pt;^Patient;-;;PANEL.H&P;2;Newborn hearing screening panel;NB hear screen Pnl;;ACTIVE;2.26;2.44 +54112-8;Cause of death;Find;Pt;^Family member;Nom;USSG-FHT;SURVEY.USSGFHT;4;Cause of death Family member [USSG-FHT];;;ACTIVE;2.26;2.44 +54113-6;Age range at death;Type;Pt;^Family member;Nom;USSG-FHT;SURVEY.USSGFHT;4;Age range at death Family member [USSG-FHT];;;ACTIVE;2.26;2.44 +5411-4;Yersinia sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Yersinia sp Ab [Units/volume] in Serum;Yersinia Ab Ser-aCnc;;ACTIVE;1.0;2.69 +54114-4;Family member health history;-;Pt;^Family member;-;USSG-FHT;PANEL.SURVEY.USSGFHT;4;Family member health history [USSG-FHT] Family member;;;ACTIVE;2.26;2.44 +54115-1;Age range at onset of disease;Type;Pt;^Family member;Nom;USSG-FHT;SURVEY.USSGFHT;4;Age range at onset of disease Family member [USSG-FHT];;;ACTIVE;2.26;2.44 +54116-9;History of diseases;Hx;Pt;^Family member;Nom;USSG-FHT;SURVEY.USSGFHT;4;History of diseases Family member [USSG-FHT];;;ACTIVE;2.26;2.56 +54117-7;Diseases history panel;-;Pt;^Family member;-;USSG-FHT;PANEL.SURVEY.USSGFHT;4;Diseases history panel [USSG-FHT] Family member;;;ACTIVE;2.26;2.44 +54118-5;Parents related;Arb;Pt;^Family member;Nom;USSG-FHT;SURVEY.USSGFHT;4;Parents related Family member [USSG-FHT];;;ACTIVE;2.26;2.44 +54119-3;Race;Type;Pt;^Family member;Nom;USSG-FHT;SURVEY.USSGFHT;4;Race Family member [USSG-FHT];;;ACTIVE;2.26;2.44 +54120-1;Ethnicity;Type;Pt;^Family member;Nom;USSG-FHT;SURVEY.USSGFHT;4;Ethnicity Family member [USSG-FHT];;;ACTIVE;2.26;2.44 +54121-9;Twin;Arb;Pt;^Family member;Ord;;SURVEY.USSGFHT;4;Twin Family member;;;ACTIVE;2.26;2.30 +5412-2;B-B4;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated B-B4 in Blood;Deprecated B-B4 WBC-aCnc;;DEPRECATED;1.0;2.69 +54122-7;Adopted;Arb;Pt;^Family member;Nom;;SURVEY.USSGFHT;4;Adopted Family member;;;ACTIVE;2.26;2.38 +54123-5;Sex;Type;Pt;^Family member;Nom;;ADMIN.DEMOG;2;Sex of Family member;Sex of Fam Mem;;ACTIVE;2.26;2.66 +54124-3;Birth date;Date;Pt;^Family member;Qn;;SURVEY.USSGFHT;4;Birth date Family member;;;ACTIVE;2.26;2.50 +54125-0;Name;Pn;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient name;Patient name;;ACTIVE;2.26;2.73 +54126-8;My health history;-;Pt;^Patient;-;USSG-FHT;PANEL.SURVEY.USSGFHT;4;My health history [USSG-FHT];;;ACTIVE;2.26;2.44 +54127-6;US Surgeon General family health portrait;-;Pt;^Patient;-;USSG-FHT;PANEL.SURVEY.USSGFHT;4;US Surgeon General family health portrait [USSG-FHT];;;ACTIVE;2.26;2.44 +54128-4;Adopted;Arb;Pt;^Patient;Nom;;SURVEY.USSGFHT;4;Adopted;;;ACTIVE;2.26;2.38 +54129-2;Age range at death;Type;Pt;^Patient;Nom;USSG-FHT;SURVEY.USSGFHT;4;Deprecated Age range at death;;;DEPRECATED;2.26;2.36 +541-3;Mycobacterium sp identified;Prid;Pt;Urine;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Urine by Organism specific culture;Mycobacterium Ur Cult;;ACTIVE;1.0;2.73 +5413-0;CD1;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD1 cells/100 cells in Blood;Deprecated CD1 WBC-aCnc;;DEPRECATED;1.0;2.69 +54130-0;Age range at onset of disease;Type;Pt;^Patient;Nom;USSG-FHT;SURVEY.USSGFHT;4;Age range at onset of disease [USSG-FHT];;;ACTIVE;2.26;2.44 +54131-8;Sex;Type;Pt;^Patient;Nom;USSG-FHT;SURVEY.USSGFHT;4;Sex [USSG-FHT];;;ACTIVE;2.26;2.56 +54132-6;Twin;Arb;Pt;^Patient;Ord;;SURVEY.USSGFHT;4;Twin;;;ACTIVE;2.26;2.30 +54133-4;Ethnicity;Type;Pt;^Patient;Nom;USSG-FHT;SURVEY.USSGFHT;4;Ethnicity [USSG-FHT];;;ACTIVE;2.26;2.73 +54134-2;Race;Type;Pt;^Patient;Nom;USSG-FHT;SURVEY.USSGFHT;4;Race [USSG-FHT];;;ACTIVE;2.26;2.44 +54135-9;Parents related;Arb;Pt;^Patient;Nom;USSG-FHT;SURVEY.USSGFHT;4;Parents related [USSG-FHT];;;ACTIVE;2.26;2.44 +54136-7;Relationship to patient;Type;Pt;^Family member;Nom;;ADMIN;2;Relationship to patient Family member;Relationship to pt Fam Mem;;ACTIVE;2.26;2.67 +54137-5;Diseases history panel;-;Pt;^Patient;-;USSG-FHT;PANEL.SURVEY.USSGFHT;4;Diseases history panel [USSG-FHT];;;ACTIVE;2.26;2.44 +54138-3;Name;Pn;Pt;^Family member;Nom;;SURVEY.USSGFHT;4;Name Family member;;;ACTIVE;2.26;2.30 +54139-1;Living;Arb;Pt;^Family member;Ord;;SURVEY.USSGFHT;4;Living Family member;;;ACTIVE;2.26;2.27 +54140-9;History of diseases;Hx;Pt;^Patient;Nom;USSG-FHT;SURVEY.USSGFHT;4;History of diseases [USSG-FHT];;;ACTIVE;2.26;2.56 +54141-7;Current age;Time;Pt;^Family member;Qn;USSG-FHT;SURVEY.USSGFHT;4;Current age Family member [USSG-FHT];;;ACTIVE;2.26;2.44 +54142-5;Candida sp DNA;PrThr;Pt;Vag;Ord;Probe.amp.sig;MICRO;1;Candida sp DNA [Presence] in Vaginal fluid by Probe with signal amplification;Candida DNA Vag Ql Probe+sig amp;;ACTIVE;2.27;2.73 +54143-3;Gardnerella vaginalis DNA;PrThr;Pt;Vag;Ord;Probe.amp.sig;MICRO;1;Gardnerella vaginalis DNA [Presence] in Vaginal fluid by Probe with signal amplification;G vaginalis DNA Vag Ql Probe+sig amp;;ACTIVE;2.27;2.73 +54144-1;Trichomonas vaginalis DNA;PrThr;Pt;Vag;Ord;Probe.amp.sig;MICRO;1;Trichomonas vaginalis DNA [Presence] in Vaginal fluid by Probe with signal amplification;T vaginalis DNA Vag Ql Probe+sig amp;;ACTIVE;2.27;2.73 +54145-8;Bacterial vaginosis & vaginitis DNA panel;-;Pt;Vag;-;Probe.amp.sig;PANEL.MICRO;1;Bacterial vaginosis and vaginitis DNA panel - Vaginal fluid by Probe with signal amplification;Vaginosis/itis DNA Pnl Vag Probe+sig amp;;ACTIVE;2.27;2.73 +54146-6;Mycobacterium tuberculosis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mycobacterium tuberculosis IgG Ab [Units/volume] in Serum by Immunoassay;M tb IgG Ser IA-aCnc;;ACTIVE;2.27;2.69 +54147-4;Autoantibodies;Imp;Pt;Ser;Nar;IF rat liver+stomach+kidney substrate;SERO;1;Autoantibodies [Interpretation] in Serum by Immunofluorescence (IF) rat liver+stomach+kidney substrate Narrative;Auto Ab Ser Rat liv+stom+kid-Imp;;ACTIVE;2.27;2.70 +5414-8;CD10;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD10 cells/100 cells in Blood;Deprecated CD10 WBC-aCnc;;DEPRECATED;1.0;2.69 +54148-2;Autoantibodies;Imp;Pt;Ser;Nar;IF Hep2 substrate;SERO;1;Autoantibodies [Interpretation] in Serum by Immunofluorescence (IF) Hep2 substrate Narrative;Auto Ab Ser HEp2 subst-Imp;;ACTIVE;2.27;2.27 +54149-0;Nuclear Ab pattern.homogeneous;PrThr;Pt;Ser;Ord;IF;SERO;1;Homogenous nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA Homogen Ser Ql IF;;ACTIVE;2.27;2.58 +54150-8;Centriole Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Deprecated Centriole Ab [Presence] in Serum by Immunofluorescence;Deprecated Centriole Ab Ser Ql IF;;DEPRECATED;2.27;2.70 +54151-6;Centriole Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Deprecated Centriole Ab [Titer] in Serum by Immunofluorescence;Deprecated Centriole Ab Titr Ser IF;;DEPRECATED;2.27;2.70 +54152-4;Nuclear mitotic apparatus Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Nuclear mitotic apparatus Ab [Presence] in Serum by Immunofluorescence;NuMA Ab Ser Ql IF;;ACTIVE;2.27;2.73 +54153-2;Nuclear mitotic apparatus Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Nuclear mitotic apparatus Ab [Titer] in Serum by Immunofluorescence;NuMA Ab Titr Ser IF;;ACTIVE;2.27;2.70 +54154-0;Nuclear Ab pattern.intercellular bridge;PrThr;Pt;Ser;Ord;IF;SERO;1;Intercellular bridge nuclear Ab pattern [Presence] in Serum by Immunofluorescence;ANA intercell bridge Ser Ql IF;;ACTIVE;2.27;2.70 +5415-5;CD10+CD20+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD10+CD20+;Deprecated CD10+CD20+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54155-7;Nuclear Ab pattern.intercellular bridge;Titr;Pt;Ser;Qn;IF;SERO;1;Intercellular bridge nuclear Ab pattern [Titer] in Serum by Immunofluorescence;ANA intercell bridge Titr Ser IF;;ACTIVE;2.27;2.73 +54156-5;RNA polymerase I Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;RNA polymerase I Ab [Presence] in Serum by Immunofluorescence;RNAp I Ab Ser Ql IF;;ACTIVE;2.27;2.56 +54157-3;RNA polymerase I Ab;Titr;Pt;Ser;Qn;IF;SERO;1;RNA polymerase I Ab [Titer] in Serum by Immunofluorescence;RNAp I Ab Titr Ser IF;;ACTIVE;2.27;2.70 +54158-1;Pancytokeratin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Pancytokeratin Ab [Presence] in Serum by Immunofluorescence;Pan CK Ab Ser Ql IF;;ACTIVE;2.27;2.56 +54159-9;Pancytokeratin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Pancytokeratin Ab [Titer] in Serum by Immunofluorescence;Pan CK Ab Titr Ser IF;;ACTIVE;2.27;2.32 +54160-7;Ki Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ki Ab [Presence] in Serum;Ki Ab Ser Ql;;ACTIVE;2.27;2.56 +54161-5;Cytoplasmic Ab pattern.PL-7+PL-12;PrThr;Pt;Ser;Ord;IF;SERO;1;Cytoplasmic Ab pattern.PL-7+PL-12 [Presence] in Serum by Immunofluorescence;CA Pat PL-7+PL-12 Ser Ql IF;;ACTIVE;2.27;2.56 +54162-3;Cytoplasmic Ab pattern.PL-7+PL-12;Titr;Pt;Ser;Qn;IF;SERO;1;Cytoplasmic Ab pattern.PL-7+PL-12 [Titer] in Serum by Immunofluorescence;CA Pat PL-7+PL-12 Titr Ser IF;;ACTIVE;2.27;2.32 +5416-3;CD100;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD100 cells/100 cells in Blood;Deprecated CD100 WBC-aCnc;;DEPRECATED;1.0;2.69 +54163-1;Cytomegalovirus DNA;NCnc;Pt;Urine;Qn;Probe.amp.tar detection limit = 200 copies/mL;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Urine by Probe and target amplification method detection limit = 200 copies/ml;CMV DNA # Ur NAA DL=200;;ACTIVE;2.27;2.70 +54164-9;Cytomegalovirus immediate-early Ag;PrThr;Pt;Bld;Ord;;MICRO;1;Cytomegalovirus immediate-early Ag [Presence] in Blood;CMV IE Ag Bld Ql;;ACTIVE;2.27;2.73 +54165-6;Tumor necrosis factor binding protein;ACnc;Pt;Ser;Qn;;CHEM;1;Tumor necrosis factor binding protein [Units/volume] in Serum;TBP-1 Ser-aCnc;;DISCOURAGED;2.27;2.69 +54166-4;Cefoperazone+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefoperazone+Sulbactam [Susceptibility];Cefoperazone+Sulbac Susc Islt;;ACTIVE;2.27;2.27 +54167-2;Cefoperazone+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefoperazone+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Cefoperazone+Sulbac Islt MIC;;ACTIVE;2.27;2.27 +54168-0;Cefoperazone+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefoperazone+Sulbactam [Susceptibility] by Disk diffusion (KB);Cefoperazone+Sulbac Islt KB;;ACTIVE;2.27;2.27 +54169-8;Thiamphenicol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Thiamphenicol [Susceptibility];Thiamphenicol Susc Islt;;ACTIVE;2.27;2.27 +54170-6;Imipenem+EDTA;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Imipenem+EDTA [Susceptibility];Imipenem+EDTA Susc Islt;;ACTIVE;2.27;2.27 +5417-1;CD102;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD102 cells/100 cells in Blood;Deprecated CD102 WBC-aCnc;;DEPRECATED;1.0;2.69 +54171-4;Imipenem+EDTA;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Imipenem+EDTA [Susceptibility] by Minimum inhibitory concentration (MIC);Imipenem+EDTA Islt MIC;;ACTIVE;2.27;2.27 +54172-2;Imipenem+EDTA;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Imipenem+EDTA [Susceptibility] by Disk diffusion (KB);Imipenem+EDTA Islt KB;;ACTIVE;2.27;2.27 +54173-0;Arbekacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Arbekacin [Susceptibility] by Disk diffusion (KB);Arbekacin Islt KB;;ACTIVE;2.27;2.27 +54174-8;Cefmenoxime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefmenoxime [Susceptibility] by Disk diffusion (KB);Cefmenoxime Islt KB;;ACTIVE;2.27;2.27 +54175-5;Caspofungin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Caspofungin [Susceptibility] by Disk diffusion (KB);Caspofungin Islt KB;;ACTIVE;2.27;2.27 +54176-3;Caspofungin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Caspofungin [Susceptibility] by Minimum inhibitory concentration (MIC);Caspofungin Islt MIC;;ACTIVE;2.27;2.73 +54177-1;Clotrimazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clotrimazole [Susceptibility] by Disk diffusion (KB);Clotrimazole Islt KB;;ACTIVE;2.27;2.27 +54178-9;Econazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Econazole [Susceptibility] by Disk diffusion (KB);Econazole Islt KB;;ACTIVE;2.27;2.27 +54179-7;Itraconazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Itraconazole [Susceptibility] by Disk diffusion (KB);Itraconaz Islt KB;;ACTIVE;2.27;2.27 +54180-5;Miconazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Miconazole [Susceptibility] by Disk diffusion (KB);Miconazole Islt KB;;ACTIVE;2.27;2.27 +54181-3;Nitroxoline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Nitroxoline [Susceptibility] by Disk diffusion (KB);Nitroxoline Islt KB;;ACTIVE;2.27;2.27 +54182-1;Para aminosalicylate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Para aminosalicylate [Susceptibility] by Disk diffusion (KB);PAS Islt KB;;ACTIVE;2.27;2.27 +54183-9;Rifabutin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Rifabutin [Susceptibility] by Disk diffusion (KB);Rifabutin Islt KB;;ACTIVE;2.27;2.27 +54184-7;Thiacetazone;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Thiacetazone [Susceptibility] by Disk diffusion (KB);Thiacetazone Islt KB;;ACTIVE;2.27;2.27 +54185-4;Caspofungin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Caspofungin [Susceptibility] by Gradient strip;Caspofungin Islt Grad strip;;ACTIVE;2.27;2.56 +54186-2;Posaconazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Posaconazole [Susceptibility] by Gradient strip;Posaconazole Islt Grad strip;;ACTIVE;2.27;2.56 +54187-0;Posaconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Posaconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Posaconazole Islt MIC;;ACTIVE;2.27;2.73 +54188-8;Posaconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Posaconazole [Susceptibility];Posaconazole Susc Islt;;ACTIVE;2.27;2.27 +5418-9;CD103;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD103 cells/100 cells in Blood;Deprecated CD103 WBC-aCnc;;DEPRECATED;1.0;2.69 +54189-6;Posaconazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Posaconazole [Susceptibility] by Disk diffusion (KB);Posaconazole Islt KB;;ACTIVE;2.27;2.27 +54190-4;Temocillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Temocillin [Susceptibility] by Gradient strip;Temocillin Islt Grad strip;;ACTIVE;2.27;2.56 +54191-2;Cefotaxime+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefotaxime+Sulbactam [Susceptibility];Cefotaxime+Sulbac Susc Islt;;ACTIVE;2.27;2.27 +54192-0;Cefotaxime+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefotaxime+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Cefotaxime+Sulbac Islt MIC;;ACTIVE;2.27;2.27 +54193-8;Cefotaxime+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefotaxime+Sulbactam [Susceptibility] by Disk diffusion (KB);Cefotaxime+Sulbac Islt KB;;ACTIVE;2.27;2.27 +54194-6;Mezlocillin+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Mezlocillin+Sulbactam [Susceptibility];Mezlocillin+Sulbac Susc Islt;;ACTIVE;2.27;2.27 +54195-3;Mezlocillin+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Mezlocillin+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Mezlocillin+Sulbac Islt MIC;;ACTIVE;2.27;2.27 +54196-1;Mezlocillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Mezlocillin+Sulbactam [Susceptibility] by Disk diffusion (KB);Mezlocillin+Sulbac Islt KB;;ACTIVE;2.27;2.27 +5419-7;CD104;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD104 cells/100 cells in Blood;Deprecated CD104 WBC-aCnc;;DEPRECATED;1.0;2.69 +54197-9;Piperacillin+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Piperacillin+Sulbactam [Susceptibility];Piperacillin+Sulbac Susc Islt;;ACTIVE;2.27;2.27 +54198-7;Piperacillin+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Piperacillin+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Piperacillin+Sulbac Islt MIC;;ACTIVE;2.27;2.27 +54199-5;Piperacillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Piperacillin+Sulbactam [Susceptibility] by Disk diffusion (KB);Piperacillin+Sulbac Islt KB;;ACTIVE;2.27;2.27 +54200-1;Griseofulvin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Griseofulvin [Susceptibility];Griseofulvin Susc Islt;;ACTIVE;2.27;2.27 +54201-9;Griseofulvin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Griseofulvin [Susceptibility] by Minimum inhibitory concentration (MIC);Griseofulvin Islt MIC;;ACTIVE;2.27;2.73 +54202-7;Griseofulvin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Griseofulvin [Susceptibility] by Disk diffusion (KB);Griseofulvin Islt KB;;ACTIVE;2.27;2.27 +54203-5;Cefmenoxime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefmenoxime [Susceptibility] by Minimum inhibitory concentration (MIC);Cefmenoxime Islt MIC;;ACTIVE;2.27;2.27 +54204-3;Thiacetazone;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Thiacetazone [Susceptibility] by Minimum inhibitory concentration (MIC);Thiacetazone Islt MIC;;ACTIVE;2.27;2.27 +5420-5;CD105;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD105 cells/100 cells in Blood;Deprecated CD105 WBC-aCnc;;DEPRECATED;1.0;2.69 +54205-0;Legionella pneumophila 7+8+9+10+11+12+13+14 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Legionella pneumophila 7+8+9+10+11+12+13+14 Ab [Titer] in Serum;L pneumo 7-14 Ab Titr Ser;;ACTIVE;2.27;2.32 +54206-8;Cytomegalovirus DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;CMV DNA SerPl NAA+probe-Log#;;ACTIVE;2.27;2.73 +54207-6;Coagulation surface induced.factor substitution^immediately after addition of factor V depleted plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor V depleted plasma;aPTT imm FV DP PPP;;ACTIVE;2.27;2.52 +54208-4;Coagulation surface induced.factor substitution^immediately after addition of factor V depleted plasma+APC;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor V depleted plasma+APC;aPTT imm FV DP+APC PPP;;ACTIVE;2.27;2.52 +54209-2;Hemoglobin C-Harlem/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin C - Harlem/Hemoglobin.total in Blood;Hgb C-Harlem MFr Bld;;ACTIVE;2.27;2.30 +542-1;Mycobacterium sp identified;Prid;Pt;Wound;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Wound by Organism specific culture;Mycobacterium Wnd Cult;;ACTIVE;1.0;2.73 +54210-0;Hepatitis B virus basal core promoter mutation;Prid;Pt;Ser;Nom;Probe.amp.tar;MICRO;1;Hepatitis B virus basal core promoter mutation [Identifier] in Serum by NAA with probe detection;HBV BCP Mut Ser NAA+probe;;ACTIVE;2.27;2.73 +54211-8;Cortisol^24H post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --24 hours post dose dexamethasone;Cortis 24h p DEX SerPl-sCnc;;ACTIVE;2.27;2.70 +54212-6;Cortisol^3D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --3 days post dose dexamethasone;Cortis 3D p Dex SerPl-sCnc;;ACTIVE;2.27;2.70 +5421-3;CD106;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD106 cells/100 cells in Blood;Deprecated CD106 WBC-aCnc;;DEPRECATED;1.0;2.69 +54213-4;Cortisol^4D post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --4 days post dose corticotropin;Cortis 4D p Dex SerPl-sCnc;;ACTIVE;2.27;2.70 +54214-2;Cortisol^5D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --5 days post dose dexamethasone;Cortis 5D p Dex SerPl-sCnc;;ACTIVE;2.27;2.70 +54215-9;Cortisol^5H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --5 hours post dose corticotropin;Cortis 5h p Dex SerPl-sCnc;;ACTIVE;2.27;2.70 +54216-7;Insulin-like growth factor binding protein 1^pre or post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 1 [Mass/volume] in Serum or Plasma --pre or post XXX challenge;IGF BP1 pre/p chal SerPl-mCnc;;ACTIVE;2.27;2.70 +54217-5;Public health notifiable condition;Prid;Pt;XXX;Nom;;CLIN;2;Public health notifiable condition;PH notifiable condition;;ACTIVE;2.27;2.56 +54218-3;Cells.CD3+CD4+/Cells.CD3+CD8+;NRto;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Blood;CD3+CD4+ Cells/CD3+CD8+ Cells Bld;;ACTIVE;2.27;2.73 +54219-1;Coagulation thrombin induced.factor substitution^immediately after 1:4 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time.factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:4 addition of normal plasma;TT imm 1:4 NP PPP;;ACTIVE;2.27;2.73 +54220-9;Immune response markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Immune response markers [Interpretation] in Specimen Narrative;Immune response markers Spec-Imp;;ACTIVE;2.27;2.69 +5422-1;CD107a;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD107a cells/100 cells in Blood;Deprecated CD107a WBC-aCnc;;DEPRECATED;1.0;2.69 +54221-7;Lymphoma markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Lymphoma markers [Interpretation] in Specimen Narrative;Lymphoma markers Spec-Imp;;ACTIVE;2.27;2.69 +54222-5;Lymphoma - acute screen markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Lymphoma - acute screen markers [Interpretation] in Specimen Narrative;Lymphoma - acute screen markers Spec-Imp;;ACTIVE;2.27;2.73 +54223-3;Lymphoma - CLL screen markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Lymphoma - CLL screen markers [Interpretation] in Specimen Narrative;Lymphoma - CLL screen markers Spec-Imp;;ACTIVE;2.27;2.69 +54224-1;Lymphoma - T-cell markers;Imp;Pt;XXX;Nar;;CELLMARK;1;Lymphoma - T-cell markers [Interpretation] in Specimen Narrative;Lymphoma - T-cell markers Spec-Imp;;ACTIVE;2.27;2.69 +54225-8;Immune response panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Immune response panel - Specimen by Flow cytometry (FC);Immune response Pnl Spec FC;;ACTIVE;2.27;2.69 +54226-6;Lymphoma panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Lymphoma panel - Specimen by Flow cytometry (FC);Lymphoma Pnl Spec FC;;ACTIVE;2.27;2.73 +54227-4;Lymphoma - acute screen panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Lymphoma - acute screen panel - Specimen by Flow cytometry (FC);Lymphoma - acute screen Pnl Spec FC;;ACTIVE;2.27;2.69 +54228-2;Lymphoma - CLL screen panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Lymphoma - CLL screen panel - Specimen by Flow cytometry (FC);Lymphoma - CLL screen Pnl Spec FC;;ACTIVE;2.27;2.73 +54229-0;Lymphoma - T-cell screen panel;-;Pt;XXX;-;Flow cytometry;PANEL.CELLMARK;1;Lymphoma - T-cell screen panel - Specimen by Flow cytometry (FC);Lymphoma - T-cell screen Pnl Spec FC;;ACTIVE;2.27;2.69 +54230-8;Cell count & Differential panel with Glucose & Protein;-;Pt;CSF;Qn;;PANEL.HEM/BC;1;Cell count and Diff panel with Gluc and Prot - Cerebral spinal fluid;Cell cnt & Diff Pnl with Glu & Prot CSF;;ACTIVE;2.27;2.72 +54231-6;Semen analysis fertility panel;-;Pt;Semen;-;;PANEL.FERT;1;Semen analysis fertility panel;Semen analysis fertility Pnl;;ACTIVE;2.27;2.73 +54232-4;Metabolic panel.large animal;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Metabolic panel.large animal - Serum or Plasma;Metab Pnl.large animal SerPl;;ACTIVE;2.27;2.42 +54233-2;Metabolic panel.small animal;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Metabolic panel.small animal - Serum or Plasma;Metab Pnl.small animal SerPl;;ACTIVE;2.27;2.42 +54234-0;Cell count & Differential panel with Glucose & Protein;-;Pt;Body fld;-;;PANEL.HEM/BC;1;Cell count and Diff panel with Gluc and Prot - Body fluid;Cell cnt & Diff Pnl with Glu & Prot Fld;;ACTIVE;2.27;2.42 +54235-7;Cortisol challenge panel;-;Pt;Saliva;-;;PANEL.CHAL;1;Cortisol challenge panel - Saliva (oral fluid);Cortis chal Pnl Sal;;ACTIVE;2.27;2.42 +54236-5;Cortisol^9 AM 2nd day specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --9 AM 2nd day specimen;Cortis 9 AM day 2 SerPl-mCnc;;ACTIVE;2.27;2.40 +54237-3;Corticotropin^9 AM 2nd day specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --9 AM 2nd day specimen;ACTH 9 AM day 2 Plas-mCnc;;ACTIVE;2.27;2.40 +54238-1;LDL.oxidized;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL.oxidized [Units/volume] in Serum or Plasma;LDL.oxidized SerPl-aCnc;;ACTIVE;2.27;2.73 +5423-9;CD107b;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD107b cells/100 cells in Blood;Deprecated CD107b WBC-aCnc;;DEPRECATED;1.0;2.69 +54239-9;Cytopathic effect;PrThr;Pt;XXX;Ord;;MICRO;1;Cytopathic effect [Presence] in Specimen;Cytopathic effect Spec Ql;;ACTIVE;2.27;2.69 +54240-7;Influenza virus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Influenza virus Ag [Presence] in Specimen;FLUV Ag Spec Ql;;ACTIVE;2.27;2.73 +54241-5;Influenza virus B Ag;PrThr;Pt;Isolate;Ord;;MICRO;1;Influenza virus B Ag [Presence] in Isolate;FLUBV Ag Islt Ql;;ACTIVE;2.27;2.56 +54242-3;Influenza virus identified;Prid;Pt;Isolate;Nom;;MICRO;1;Influenza virus identified in Isolate;FLUV Islt;;ACTIVE;2.27;2.27 +54243-1;Influenza virus RNA;Prid;Pt;XXX;Nom;Probe;MICRO;1;Influenza virus RNA [Identifier] in Specimen by Probe;FLUV RNA Spec Probe;;ACTIVE;2.27;2.73 +54244-9;Influenza virus identified;Prid;Pt;XXX;Nom;;MICRO;1;Influenza virus identified in Specimen;FLUV Spec;;ACTIVE;2.27;2.69 +54245-6;Respiratory virus Ag;Prid;Pt;XXX;Nom;IF;MICRO;1;Respiratory virus Ag [Identifier] in Specimen by Immunofluorescence;Resp virus Ag Spec IF;;ACTIVE;2.27;2.69 +54246-4;Protein & Glucose panel;MCnc;Pt;Body fld;Qn;;PANEL.CHEM;1;Protein and Glucose panel [Mass/volume] - Body fluid;Prot + Glucose Pnl Fld-mCnc;;ACTIVE;2.27;2.42 +5424-7;CD115;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD115 cells/100 cells in Blood;Deprecated CD115 WBC-aCnc;;DEPRECATED;1.0;2.69 +54247-2;Drug screen comment;Imp;Pt;Urine;Nom;;DRUG/TOX;1;Drug screen comment [Interpretation] in Urine;Drug screen comment Ur-Imp;;ACTIVE;2.27;2.73 +54248-0;Glucose^10M pre dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10 minutes pre dose glucagon;Glucose 10M pre Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54249-8;Glucose^15M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose glucagon;Glucose 15M p Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54250-6;Glucose^15M pre dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose glucagon;Glucose 15M pre Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54251-4;Glucose^20M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20 minutes post dose glucagon;Glucose 20M p Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54252-2;Glucose^2M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 minutes post dose glucagon;Glucose 2M p Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54253-0;Glucose^4M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4 minutes post dose glucagon;Glucose 4M p Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +5425-4;CD117;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD117 cells/100 cells in Blood;Deprecated CD117 WBC-aCnc;;DEPRECATED;1.0;2.69 +54254-8;Glucose^5M pre dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5 minutes pre dose glucagon;Glucose 5M pre Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54255-5;Glucose^6M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --6 minutes post dose glucagon;Glucose 6M p Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54256-3;Glucose^8M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8 minutes post dose glucagon;Glucose 8M p Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54257-1;Glucose^pre dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre dose insulin IV;Glucose pre Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54258-9;Glucose^2H post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hours post dose insulin IV;Glucose 2h p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54259-7;Glucose^2.5H post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose insulin IV;Glucose 2.5h p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54260-5;Glucose^15M post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose insulin IV;Glucose 15M p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54261-3;Glucose^15M pre dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose insulin IV;Glucose 15M pre Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +5426-2;CD11a;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD11a cells/100 cells in Blood;Deprecated CD11a WBC-aCnc;;DEPRECATED;1.0;2.69 +54262-1;Glucose^3H pre dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours pre dose insulin IV;Glucose 3h pre Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54263-9;Glucose^30M post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose insulin IV;Glucose 30M p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54264-7;Glucose^45M post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose insulin IV;Glucose 45M p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54265-4;Glucose^1H post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post dose insulin IV;Glucose 1h p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54266-2;Glucose^1.3H post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.3 hours post dose insulin IV;Glucose 1.3h p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54267-0;Glucose^1.5H post dose insulin IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose insulin IV;Glucose 1.5h p Ins IV SerPl-sCnc;;ACTIVE;2.27;2.70 +54268-8;Glucose^pre dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre dose ornithine alpha-ketoglutarate;Glucose pre OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54269-6;Glucose^2H post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2 hour post dose ornithine alpha-ketoglutarate;Glucose 2h p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +5427-0;CD11b;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD11b cells/100 cells in Blood;Deprecated CD11b WBC-aCnc;;DEPRECATED;1.0;2.69 +54270-4;Glucose^2.5H post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hour post dose ornithine alpha-ketoglutarate;Glucose 2.5h p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54271-2;Glucose^15M post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose ornithine alpha-ketoglutarate;Glucose 15M p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54272-0;Glucose^15M pre dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose ornithine alpha-ketoglutarate;Glucose 15M pre OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54273-8;Glucose^3H post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 hours post dose ornithine alpha-ketoglutarate;Glucose 3h p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54274-6;Glucose^30M post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose ornithine alpha-ketoglutarate;Glucose 30M p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54275-3;Glucose^45M post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose ornithine alpha-ketoglutarate;Glucose 45M p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54276-1;Glucose^1H post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1 hour post dose ornithine alpha-ketoglutarate;Glucose 1h p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54277-9;Glucose^1.5H post dose ornithine alpha-ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hour post dose ornithine alpha-ketoglutarate;Glucose 1.5h p OKG SerPl-sCnc;;ACTIVE;2.27;2.70 +54278-7;Glutarate;SCnc;Pt;CSF;Qn;;CHEM;1;Glutarate [Moles/volume] in Cerebral spinal fluid;Glutarate CSF-sCnc;;ACTIVE;2.27;2.70 +54279-5;Glutarylcarnitine (C5-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Creatinine [Molar ratio] in Urine;Glutarylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54280-3;Glutarylcarnitine (C5-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Glutarylcarnitine (C5-DC) [Moles/volume] in Cerebral spinal fluid;Glutarylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54281-1;Glutarylcarnitine (C5-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Glutarylcarnitine (C5-DC) [Moles/volume] in Amniotic fluid;Glutarylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54282-9;Glutarylcarnitine (C5-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Glutarylcarnitine (C5-DC) [Moles/volume] in Urine;Glutarylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54283-7;Glycerol;MCnc;Pt;Body fld;Qn;;CHEM;1;Glycerol [Mass/volume] in Body fluid;Glycerol Fld-mCnc;;ACTIVE;2.27;2.70 +54284-5;Glycerol;SCnc;Pt;Body fld;Qn;;CHEM;1;Glycerol [Moles/volume] in Body fluid;Glycerol Fld-sCnc;;ACTIVE;2.27;2.73 +54285-2;Glycerol;SCnc;Pt;Urine;Qn;;CHEM;1;Glycerol [Moles/volume] in Urine;Glycerol Ur-sCnc;;ACTIVE;2.27;2.70 +54286-0;Glycolate;SCnc;Pt;CSF;Qn;;CHEM;1;Glycolate [Moles/volume] in Cerebral spinal fluid;Glycolate CSF-sCnc;;ACTIVE;2.27;2.70 +54287-8;Guanidinoacetate;SCnc;Pt;CSF;Qn;;CHEM;1;Guanidinoacetate [Moles/volume] in Cerebral spinal fluid;Guanidinoacetate CSF-sCnc;;ACTIVE;2.27;2.70 +5428-8;CD11c;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD11c cells/100 cells in Blood;Deprecated CD11c WBC-aCnc;;DEPRECATED;1.0;2.69 +54288-6;Guanidinoacetate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Guanidinoacetate [Moles/volume] in Amniotic fluid;Guanidinoacetate Amn-sCnc;;ACTIVE;2.27;2.70 +54289-4;Hemoglobin;MCnc;Pt;Bld^BPU;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Blood from Blood product unit;Hgb Bld BPU-mCnc;;ACTIVE;2.27;2.70 +54290-2;Heptanoylcarnitine (C7)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Heptanoylcarnitine (C7)/Creatinine [Molar ratio] in Urine;Heptanoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54291-0;Heptanoylcarnitine (C7);SCnc;Pt;CSF;Qn;;CHEM;1;Heptanoylcarnitine (C7) [Moles/volume] in Cerebral spinal fluid;Heptanoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54292-8;Heptanoylcarnitine (C7);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Heptanoylcarnitine (C7) [Moles/volume] in Amniotic fluid;Heptanoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54293-6;Heptanoylcarnitine (C7);SCnc;Pt;Urine;Qn;;CHEM;1;Heptanoylcarnitine (C7) [Moles/volume] in Urine;Heptanoylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54294-4;Fatty acids.very long chain.C26:0/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate)/Creatinine [Molar ratio] in Urine;VLCFA C26:0/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54295-1;Hexanoylcarnitine (C6)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexanoylcarnitine (C6)/Creatinine [Molar ratio] in Urine;Hexanoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +5429-6;CD120a;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD120A cells/100 cells in Blood;Deprecated CD120a WBC-aCnc;;DEPRECATED;1.0;2.69 +54296-9;Hexanoylcarnitine (C6);SCnc;Pt;CSF;Qn;;CHEM;1;Hexanoylcarnitine (C6) [Moles/volume] in Cerebral spinal fluid;Hexanoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54297-7;Hexanoylcarnitine (C6);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Hexanoylcarnitine (C6) [Moles/volume] in Amniotic fluid;Hexanoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54298-5;Hexanoylcarnitine (C6);SCnc;Pt;Urine;Qn;;CHEM;1;Hexanoylcarnitine (C6) [Moles/volume] in Urine;Hexanoylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54299-3;Homocitrulline;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Homocitrulline [Moles/volume] in Amniotic fluid;Homocitrulline Amn-sCnc;;ACTIVE;2.27;2.70 +54300-9;Homocysteine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Homocysteine [Moles/volume] in Amniotic fluid;Hcys Amn-sCnc;;ACTIVE;2.27;2.70 +54301-7;Homocysteine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Homocysteine [Moles/volume] in DBS;Hcys DBS-sCnc;;ACTIVE;2.27;2.70 +54302-5;Homocystine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Homocystine [Moles/volume] in DBS;(Hcys)2 DBS-sCnc;;ACTIVE;2.27;2.70 +54303-3;Hydroxylysine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Hydroxylysine [Moles/volume] in DBS;OH-Lysine DBS-sCnc;;ACTIVE;2.27;2.70 +5430-4;CD120b;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD120B cells/100 cells in Blood;Deprecated CD120b WBC-aCnc;;DEPRECATED;1.0;2.69 +54304-1;Isobutyrylglycine;SCnc;Pt;Urine;Qn;;CHEM;1;Isobutyrylglycine [Moles/volume] in Urine;Isobutyrylgly Ur-sCnc;;ACTIVE;2.27;2.70 +54305-8;Isovalerylcarnitine+Methylbutyrylcarnitine (C5);SCnc;Pt;CSF;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5) [Moles/volume] in Cerebral spinal fluid;Isovaleryl+MeButyrylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54306-6;Isovalerylcarnitine+Methylbutyrylcarnitine (C5);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5) [Moles/volume] in Amniotic fluid;Isovaleryl+MeButyrylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54307-4;Isovalerylcarnitine+Methylbutyrylcarnitine (C5);SCnc;Pt;Urine;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5) [Moles/volume] in Urine;Isovaleryl+MeButyrylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54308-2;Isovalerylglycine;SCnc;Pt;CSF;Qn;;CHEM;1;Isovalerylglycine [Moles/volume] in Cerebral spinal fluid;Isovalerylgly CSF-sCnc;;ACTIVE;2.27;2.70 +54309-0;Lactate/Pyruvate;SRto;Pt;CSF;Qn;;CHEM;1;Lactate/Pyruvate [Molar ratio] in Cerebral spinal fluid;Lactate/Pyruvate CSF-sRto;;ACTIVE;2.27;2.42 +54310-8;Linoleoylcarnitine (C18:2)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Linoleoylcarnitine (C18:2)/Creatinine [Molar ratio] in Urine;Linoleoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54311-6;Linoleoylcarnitine (C18:2);SCnc;Pt;CSF;Qn;;CHEM;1;Linoleoylcarnitine (C18:2) [Moles/volume] in Cerebral spinal fluid;Linoleoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +5431-2;CD122;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD122 cells/100 cells in Blood;Deprecated CD122 WBC-aCnc;;DEPRECATED;1.0;2.69 +54312-4;Linoleoylcarnitine (C18:2);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Linoleoylcarnitine (C18:2) [Moles/volume] in Amniotic fluid;Linoleoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54313-2;Linoleoylcarnitine (C18:2);SCnc;Pt;Urine;Qn;;CHEM;1;Linoleoylcarnitine (C18:2) [Moles/volume] in Urine;Linoleoylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54314-0;Malonylcarnitine (C3-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Malonylcarnitine (C3-DC)/Creatinine [Molar ratio] in Urine;Malonylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54315-7;Methylmalonate;SCnc;Pt;CSF;Qn;;CHEM;1;Methylmalonate [Moles/volume] in Cerebral spinal fluid;Methylmalonate CSF-sCnc;;ACTIVE;2.27;2.70 +54316-5;Methylmalonylcarnitine (C4-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC)/Creatinine [Molar ratio] in Urine;Me-malonylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54317-3;Methylmalonylcarnitine (C4-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC) [Moles/volume] in Cerebral spinal fluid;Me-malonylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54318-1;Methylmalonylcarnitine (C4-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC) [Moles/volume] in Amniotic fluid;Me-malonylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54319-9;Methylmalonylcarnitine (C4-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC) [Moles/volume] in Urine;Me-malonylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +5432-0;CD126;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD126 cells/100 cells in Blood;Deprecated CD126 WBC-aCnc;;DEPRECATED;1.0;2.69 +54320-7;Octanoylcarnitine (C8)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Octanoylcarnitine (C8)/Creatinine [Molar ratio] in Urine;Octanoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54321-5;Octanoylcarnitine (C8);SCnc;Pt;CSF;Qn;;CHEM;1;Octanoylcarnitine (C8) [Moles/volume] in Cerebral spinal fluid;Octanoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54322-3;Octanoylcarnitine (C8);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Octanoylcarnitine (C8) [Moles/volume] in Amniotic fluid;Octanoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54323-1;Palmitoylcarnitine (C16)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Palmitoylcarnitine (C16)/Creatinine [Molar ratio] in Urine;Palmitoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54324-9;Palmitoylcarnitine (C16);SCnc;Pt;CSF;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Moles/volume] in Cerebral spinal fluid;Palmitoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54325-6;Palmitoylcarnitine (C16);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Moles/volume] in Amniotic fluid;Palmitoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54326-4;Phosphoethanolamine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Phosphoethanolamine [Moles/volume] in DBS;PETN DBS-sCnc;;ACTIVE;2.27;2.70 +54327-2;Pipecolate;SCnc;Pt;CSF;Qn;;CHEM;1;Pipecolate [Moles/volume] in Cerebral spinal fluid;Pipecolate CSF-sCnc;;ACTIVE;2.27;2.70 +54328-0;Pipecolate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Pipecolate [Moles/volume] in DBS;Pipecolate DBS-sCnc;;ACTIVE;2.27;2.70 +54329-8;Propionylcarnitine (C3)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Propionylcarnitine (C3)/Creatinine [Molar ratio] in Urine;Propionylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54330-6;Propionylcarnitine (C3);SCnc;Pt;CSF;Qn;;CHEM;1;Propionylcarnitine (C3) [Moles/volume] in Cerebral spinal fluid;Propionylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54331-4;Propionylcarnitine (C3);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Propionylcarnitine (C3) [Moles/volume] in Amniotic fluid;Propionylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54332-2;Propionylglycine;SCnc;Pt;CSF;Qn;;CHEM;1;Propionylglycine [Moles/volume] in Cerebral spinal fluid;Propionylgly CSF-sCnc;;ACTIVE;2.27;2.70 +54333-0;Stearoylcarnitine (C18)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Stearoylcarnitine (C18)/Creatinine [Molar ratio] in Urine;Stearoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54334-8;Stearoylcarnitine (C18);SCnc;Pt;CSF;Qn;;CHEM;1;Stearoylcarnitine (C18) [Moles/volume] in Cerebral spinal fluid;Stearoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54335-5;Stearoylcarnitine (C18);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Stearoylcarnitine (C18) [Moles/volume] in Amniotic fluid;Stearoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54336-3;Sulfocysteine;SCnc;Pt;CSF;Qn;;CHEM;1;Sulfocysteine [Moles/volume] in Cerebral spinal fluid;Sulfocysteine CSF-sCnc;;ACTIVE;2.27;2.70 +54337-1;Sulfocysteine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Sulfocysteine [Moles/volume] in DBS;Sulfocysteine DBS-sCnc;;ACTIVE;2.27;2.70 +5433-8;CD128;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD128 cells/100 cells in Blood;Deprecated CD128 WBC-aCnc;;DEPRECATED;1.0;2.69 +54338-9;Tetradecanoylcarnitine (C14)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetradecanoylcarnitine (C14)/Creatinine [Molar ratio] in Urine;Tdecanoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54339-7;Tetradecanoylcarnitine (C14);SCnc;Pt;CSF;Qn;;CHEM;1;Tetradecanoylcarnitine (C14) [Moles/volume] in Cerebral spinal fluid;Tdecanoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54340-5;Tetradecanoylcarnitine (C14);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Tetradecanoylcarnitine (C14) [Moles/volume] in Amniotic fluid;Tdecanoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54341-3;Myristoleate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Myristoleate (C14:1)/Creatinine [Molar ratio] in Urine;Myristoleate/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54342-1;Tiglylglycine;SCnc;Pt;CSF;Qn;;CHEM;1;Tiglylglycine [Moles/volume] in Cerebral spinal fluid;Tiglylgly CSF-sCnc;;ACTIVE;2.27;2.70 +54343-9;3-Methoxytyramine/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;3-Methoxytyramine/Creatinine [Mass Ratio] in 24 hour Urine;3Me-tyramine/Creat 24h Ur;;ACTIVE;2.27;2.70 +54344-7;3-Methoxytyramine;MCnc;24H;Urine;Qn;;CHEM;1;3-Methoxytyramine [Mass/volume] in 24 hour Urine;3Me-tyramine 24h Ur-mCnc;;ACTIVE;2.27;2.70 +54345-4;Acetylcarnitine (C2);SCnc;Pt;Semen;Qn;;CHEM;1;Acetylcarnitine (C2) [Moles/volume] in Semen;Acetylcarn Smn-sCnc;;ACTIVE;2.27;2.70 +5434-6;CD13;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD13 cells/100 cells in Blood;Deprecated CD13 WBC-aCnc;;DEPRECATED;1.0;2.69 +54346-2;Albumin;MCnc;Pt;Stool;Qn;;CHEM;1;Albumin [Mass/volume] in Stool;Albumin Stl-mCnc;;ACTIVE;2.27;2.70 +54347-0;Albumin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Albumin [Moles/volume] in Serum or Plasma;Albumin SerPl-sCnc;;ACTIVE;2.27;2.73 +54348-8;Alpha-1-Fetoprotein;MCnc;Pt;BldCo;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Cord blood;AFP BldCo-mCnc;;ACTIVE;2.27;2.70 +54349-6;Ammonia;MCnc;Pt;Dial fld;Qn;;CHEM;1;Ammonia [Mass/volume] in Dialysis fluid;Ammonia Dial fld-mCnc;;ACTIVE;2.27;2.70 +54350-4;Ascorbate+Dehydroascorbate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ascorbate+Dehydroascorbate [Moles/volume] in Serum or Plasma;Vit C+DHA SerPl-sCnc;;ACTIVE;2.27;2.70 +54351-2;Ascorbate+Dehydroascorbate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ascorbate+Dehydroascorbate [Mass/volume] in Serum or Plasma;Vit C+DHA SerPl-mCnc;;ACTIVE;2.27;2.70 +54352-0;Nitrogen;MCnc;Pt;Urine;Qn;;CHEM;1;Nitrogen [Mass/volume] in Urine;N2 Ur-mCnc;;ACTIVE;2.27;2.70 +5435-3;CD14;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD14 in Blood;Deprecated CD14 WBC-aCnc;;DEPRECATED;1.0;2.69 +54353-8;Beta 1 globulin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta 1 globulin [Mass/volume] in Urine by Electrophoresis;Beta1 Glob Ur Elph-mCnc;;ACTIVE;2.27;2.73 +54354-6;Beta 2 globulin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta 2 globulin [Mass/volume] in Urine by Electrophoresis;Beta2 Glob Ur Elph-mCnc;;ACTIVE;2.27;2.70 +54355-3;Beta-2-Microglobulin.CSF/Beta-2-Microglobulin.serum;RelRto;Pt;Ser+CSF;Qn;;CHEM;1;Beta-2-Microglobulin in CSF/Beta-2-Microglobulin in serum;B2 Microglob CSF/Ser;;ACTIVE;2.27;2.70 +54356-1;Beta-2-Microglobulin;MCnc;24H;Urine;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in 24 hour Urine;B2 Microglob 24h Ur-mCnc;;ACTIVE;2.27;2.70 +54357-9;Beta 2 globulin+Gamma globulin/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta 2 globulin+Gamma globulin/Protein.total in Urine by Electrophoresis;Beta2+Gamma Glob MFr Ur Elph;;ACTIVE;2.27;2.70 +54358-7;Beta globulin/Protein.total;MFr;Pt;Dial fld;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total in Dialysis fluid by Electrophoresis;B-Globulin MFr Dial fld Elph;;ACTIVE;2.27;2.70 +54359-5;Bicarbonate^post dialysis;SCnc;Pt;Plas;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Plasma --post dialysis;HCO3 p dialysis Plas-sCnc;;ACTIVE;2.27;2.70 +54360-3;Bicarbonate;SCnc;Pt;Periton fld;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Peritoneal fluid;HCO3 Prt-sCnc;;ACTIVE;2.27;2.70 +5436-1;CD15;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD15 cells/100 cells in Blood;Deprecated CD15 WBC-aCnc;;DEPRECATED;1.0;2.69 +54361-1;Bicarbonate;SCnc;Pt;Plr fld;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Pleural fluid;HCO3 Plr-sCnc;;ACTIVE;2.27;2.70 +54362-9;Bilirubin;SCnc;Pt;Dial fld;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Dialysis fluid;Bilirub Dial fld-sCnc;;ACTIVE;2.27;2.70 +54363-7;Bilirubin;SCnc;Pt;Bld;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Blood;Bilirub Bld-sCnc;;ACTIVE;2.27;2.70 +54364-5;Calcium;SCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Calcium [Moles/volume] in Nonbiological fluid;Calcium Fld.NB-sCnc;;ACTIVE;2.27;2.70 +54365-2;Calcium;SCnc;Pt;BldCo;Qn;;CHEM;1;Calcium [Moles/volume] in Cord blood;Calcium BldCo-sCnc;;ACTIVE;2.27;2.70 +54366-0;Calcium.ionized^^adjusted to pH 7.4;SCnc;Pt;BldCo;Qn;;CHEM;1;Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Cord blood;Ca-I adj pH7.4 BldCo-sCnc;;ACTIVE;2.27;2.70 +54367-8;Calcium.ionized;SCnc;Pt;BldCo;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Cord blood;Ca-I BldCo-sCnc;;ACTIVE;2.27;2.73 +54368-6;Catalase;CCnc;Pt;Plas;Qn;;CHEM;1;Catalase [Enzymatic activity/volume] in Plasma;Catalase Plas-cCnc;;ACTIVE;2.27;2.70 +54369-4;Chloride^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chloride [Moles/volume] in Serum or Plasma --post dialysis;Chloride p dialysis SerPl-sCnc;;ACTIVE;2.27;2.70 +54370-2;Chloride;MCnc;Pt;Body fld;Qn;;CHEM;1;Chloride [Mass/volume] in Body fluid;Chloride Fld-mCnc;;ACTIVE;2.27;2.73 +54371-0;Cholesterol;SCnc;Pt;Periton fld;Qn;;CHEM;1;Cholesterol [Moles/volume] in Peritoneal fluid;Cholest Prt-sCnc;;ACTIVE;2.27;2.70 +54372-8;Cholesterol.in HDL;MCnc;Pt;Body fld;Qn;;CHEM;1;Cholesterol in HDL [Mass/volume] in Body fluid;HDLc Fld-mCnc;;ACTIVE;2.27;2.73 +54373-6;Cholesterol.non-esterified;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.non-esterified [Moles/volume] in Serum or Plasma;NE Cholest SerPl-sCnc;;ACTIVE;2.27;2.70 +54374-4;Creatinine/body weight;RelSRat;24H;Urine;Qn;;CHEM;1;Creatinine/Body weight [Moles/kg/time] in 24 hour Urine;Creat/BW 24h Ur-RelSRat;;ACTIVE;2.27;2.70 +54375-1;Creatinine;SCnc;Pt;Plr fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Pleural fluid;Creat Plr-sCnc;;ACTIVE;2.27;2.70 +54376-9;Cobalamins;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Cobalamin (Vitamin B12) [Moles/volume] in Body fluid;Vit B12 Fld-sCnc;;ACTIVE;2.27;2.70 +54377-7;Cobalamins;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Cobalamin (Vitamin B12) [Mass/volume] in Body fluid;Vit B12 Fld-mCnc;;ACTIVE;2.27;2.70 +54378-5;Cobalamins;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cobalamin (Vitamin B12) [Moles/volume] in Urine;Vit B12 Ur-sCnc;;ACTIVE;2.27;2.70 +5437-9;CD16;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD16 cells/100 cells in Blood;Deprecated CD16 WBC-aCnc;;DEPRECATED;1.0;2.69 +54379-3;Cystatin C/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Cystatin C/Creatinine [Ratio] in Urine;Cystatin C/Creat Ur-Rto;;ACTIVE;2.27;2.70 +54380-1;Cystatin C;MCnc;24H;Urine;Qn;;CHEM;1;Cystatin C [Mass/volume] in 24 hour Urine;Cystatin C 24h Ur-mCnc;;ACTIVE;2.27;2.70 +54381-9;Cystatin C;MRat;24H;Urine;Qn;;CHEM;1;Cystatin C [Mass/time] in 24 hour Urine;Cystatin C 24h Ur-mRate;;ACTIVE;2.27;2.70 +54382-7;Cytochrome C oxidase;CCnt;Pt;Amnio fld cells;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/mass] in Amniotic fluid cells;CyC Oxidase Amnc-cCnt;;ACTIVE;2.27;2.70 +54383-5;Cytochrome C oxidase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/mass] in Fibroblast;CyC Oxidase Fib-cCnt;;ACTIVE;2.27;2.70 +54384-3;Cytochrome C oxidase;CCnt;Pt;Amnio fld;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/mass] in Amniotic fluid;CyC Oxidase Amn-cCnt;;ACTIVE;2.27;2.70 +54385-0;Dehydroascorbate/Ascorbate;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroascorbate/Ascorbate in Serum or Plasma;DHA/Vit C SFr SerPl;;ACTIVE;2.27;2.70 +54386-8;Dehydroascorbate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroascorbate [Moles/volume] in Serum or Plasma;DHA SerPl-sCnc;;ACTIVE;2.27;2.70 +5438-7;CD16+CD56+CD3-;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD3-CD16+CD56+ cells/100 cells in Blood;Deprecated CD16+CD56+CD3- WBC-aCnc;;DEPRECATED;1.0;2.69 +54387-6;Dihydroxycholestanoate;SCnc;Pt;Body fld;Qn;;CHEM;1;Dihydroxycholestanoate [Moles/volume] in Body fluid;Di-OH-cholestanoate Fld-sCnc;;ACTIVE;2.27;2.70 +54388-4;Dihydroxycholestanoate;SCnc;Pt;Urine;Qn;;CHEM;1;Dihydroxycholestanoate [Moles/volume] in Urine;Di-OH-cholestanoate Ur-sCnc;;ACTIVE;2.27;2.70 +54389-2;Dodecanoylcarnitine (C12);SCnc;Pt;Urine;Qn;;CHEM;1;Dodecanoylcarnitine (C12) [Moles/volume] in Urine;Dodecanoylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +543-9;Mycobacterium sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Specimen by Organism specific culture;Mycobacterium Spec Cult;;ACTIVE;1.0;2.73 +54390-0;Fibroblast growth factor 23.intact;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fibroblast growth factor 23.intact [Mass/volume] in Serum or Plasma;FGF-23.intact SerPl-mCnc;;ACTIVE;2.27;2.70 +54391-8;Gamma globulin/Protein.total;MFr;Pt;Dial fld;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total in Dialysis fluid by Electrophoresis;Gamma glob MFr Dial fld Elph;;ACTIVE;2.27;2.70 +54392-6;Glucose^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;Glucose sp1 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54393-4;Glucose^10th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge;Glucose sp10 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54394-2;Glucose^11th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --11th specimen post XXX challenge;Glucose sp11 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +5439-5;CD16+CD57+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD16+CD57+ cells/100 cells in Blood;Deprecated CD16+CD57+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54395-9;Glucose^12th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --12th specimen post XXX challenge;Glucose sp12 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54396-7;Glucose^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;Glucose sp2 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54397-5;Glucose^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;Glucose sp3 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54398-3;Glucose^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;Glucose sp4 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54399-1;Glucose^9th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge;Glucose sp9 p chal SerPl-sCnc;;ACTIVE;2.27;2.73 +54400-7;Glucose^pre dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre dose glucagon;Glucose pre Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54401-5;Glucose^10M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --10 minutes post dose glucagon;Glucose 10M p Gc SerPl-sCnc;;ACTIVE;2.27;2.70 +54402-3;4-Hydroxymidazolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;4-Hydroxymidazolam [Mass/volume] in Serum or Plasma;4OH-midazolam SerPl-mCnc;;ACTIVE;2.27;2.73 +5440-3;CD16+CD57-;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD16+CD57- cells/100 cells in Blood;Deprecated CD16+CD57- WBC-aCnc;;DEPRECATED;1.0;2.69 +54403-1;Transfuse 5% plasma protein fraction units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse 5% plasma protein fraction units [#];Num units trans 5% PPF;;ACTIVE;2.27;2.69 +54404-9;Pooled platelet concentrate units given;Num;Pt;^BPU;Qn;;BLDBK;1;Pooled platelet concentrate units given [#];Pooled Platelet Conc Gvn BPU;;ACTIVE;2.27;2.69 +54405-6;Transfuse pooled cryoprecipitate units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse pooled cryoprecipitate units [#];Num units trans pooled cryoppt;;ACTIVE;2.27;2.69 +54406-4;Pooled cryoprecipitate units given;Num;Pt;^BPU;Qn;;BLDBK;1;Pooled cryoprecipitate units given [#];Pooled Cryoppt Gvn BPU;;ACTIVE;2.27;2.69 +54407-2;Transfuse pooled fresh frozen plasma units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse pooled fresh frozen plasma units [#];Num units trans pooled FFP;;ACTIVE;2.27;2.69 +54408-0;Pooled fresh frozen plasma units given;Num;Pt;^BPU;Qn;;BLDBK;1;Pooled fresh frozen plasma units given [#];Pooled FFP Gvn BPU;;ACTIVE;2.27;2.69 +54409-8;Direct antiglobulin test.complement C3+C4 specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.complement C3+C4 specific reagent [Presence] on Red Blood Cells;DAT C3+C4 Comp-Sp Reag RBC Ql;;ACTIVE;2.27;2.56 +54410-6;Direct antiglobulin test.complement C3 specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.complement C3 specific reagent [Presence] on Red Blood Cells;DAT C3-Sp Reag RBC Ql;;ACTIVE;2.27;2.73 +5441-1;CD16-CD57-;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD16-CD57+ cells/100 cells in Blood;Deprecated CD16-CD57- WBC-aCnc;;DEPRECATED;1.0;2.69 +54411-4;Rh immune globulin given;Find;Pt;^Patient;Ord;;BLDBK;1;Rh immune globulin given Qualitative;Rh Ig Gvn Ql;;ACTIVE;2.27;2.73 +54412-2;Cryoprecipitate poor plasma units given;Num;Pt;^BPU;Qn;;BLDBK;1;Cryoprecipitate poor plasma units given [#];CP Gvn BPU;;ACTIVE;2.27;2.69 +54413-0;Transfuse leukocyte-poor plateletpheresis units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse leukocyte-poor plateletpheresis units [#];Num units trans WBC-poor platpheresis;;ACTIVE;2.27;2.73 +54414-8;Leukocyte-poor plateletpheresis units given;Num;Pt;^BPU;Qn;;BLDBK;1;Leukocyte-poor plateletpheresis units given [#];LP Platpheresis Gvn BPU;;ACTIVE;2.27;2.73 +54415-5;Transfuse leukocyte-poor platelets units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse leukocyte-poor platelets units [#];Num units trans LP platelets;;ACTIVE;2.27;2.69 +54416-3;Rh;Type;Pt;Bld^Fetus;Nom;;BLDBK;1;Rh [Type] in Blood from Fetus;Rh Bld Fetus;;ACTIVE;2.27;2.34 +54417-1;ABO & Rh group;Type;Pt;Bld^Fetus;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood from Fetus;ABO + Rh Bld Fetus;;ACTIVE;2.27;2.72 +54418-9;Transfuse fresh frozen plasma pediatric units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse fresh frozen plasma pediatric units [#];Num ped units trans FFP;;ACTIVE;2.27;2.69 +54419-7;Whole blood pediatric units given;Num;Pt;^BPU;Qn;;BLDBK;1;Whole blood pediatric units given [#];Whole blood ped Gvn BPU;;ACTIVE;2.27;2.69 +54420-5;Frozen erythrocytes newborn units given;Num;Pt;^BPU;Qn;;BLDBK;1;Frozen erythrocytes newborn units given [#];Frozen RBC NB Gvn BPU;;ACTIVE;2.27;2.69 +54421-3;Transfuse frozen erythrocytes pediatric units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse frozen erythrocytes pediatric units [#];Num ped units trans frozen RBC;;ACTIVE;2.27;2.69 +54422-1;Frozen erythrocytes pediatric units given;Num;Pt;^BPU;Qn;;BLDBK;1;Frozen erythrocytes pediatric units given [#];Frozen RBC ped Gvn BPU;;ACTIVE;2.27;2.69 +54423-9;Transfuse plateletpheresis half units;Num;Pt;^BPU;Qn;;BLDBK;1;Transfuse plateletpheresis half units [#];Num 1/2 units trans platpheresis;;ACTIVE;2.27;2.69 +54424-7;Plateletpheresis half units given;Num;Pt;^BPU;Qn;;BLDBK;1;Plateletpheresis half units given [#];1/2 Platpheresis Gvn BPU;;ACTIVE;2.27;2.69 +54425-4;Weak D Ag;PrThr;Pt;RBC^Fetus;Ord;;BLDBK;1;Weak D Ag [Presence] on Red Blood Cells from Fetus;Weak D Ag RBC Fetus Ql;;ACTIVE;2.27;2.73 +54426-2;Fresh frozen plasma pediatric units given;Num;Pt;^BPU;Qn;;BLDBK;1;Fresh frozen plasma pediatric units given [#];FFP ped Gvn BPU;;ACTIVE;2.27;2.69 +54427-0;Transfuse frozen erythrocytes newborn units;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse frozen erythrocytes newborn units [Volume];Trans NB units frozen RBC Vol Patient;;ACTIVE;2.27;2.42 +54428-8;Frozen packed erythrocytes given;Vol;Pt;^Patient;Qn;;BLDBK;1;Frozen packed erythrocytes given [Volume];Frozen packed RBC Gvn Vol;;ACTIVE;2.27;2.42 +5442-9;CD16b;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD16b;Deprecated CD16b WBC-aCnc;;DEPRECATED;1.0;2.69 +54429-6;5% plasma protein fraction given;Vol;Pt;^Patient;Qn;;BLDBK;1;5% plasma protein fraction given [Volume];5% PPF Gvn Vol;;ACTIVE;2.27;2.42 +54430-4;Pooled platelets given;Vol;Pt;^Patient;Qn;;BLDBK;1;Pooled platelets given [Volume];Pooled platelets Gvn Vol;;ACTIVE;2.27;2.42 +54431-2;Pooled cryoprecipitate given;Vol;Pt;^Patient;Qn;;BLDBK;1;Pooled cryoprecipitate given [Volume];Pooled Cryoppt Gvn Vol;;ACTIVE;2.27;2.42 +54432-0;Pooled fresh frozen plasma given;Vol;Pt;^Patient;Qn;;BLDBK;1;Pooled fresh frozen plasma given [Volume];Pooled FFP Gvn Vol;;ACTIVE;2.27;2.73 +54433-8;User safety warnings section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert User safety warnings section;FDA insert User safety warnings;;ACTIVE;2.27;2.34 +54434-6;Lipoprotein.beta.subparticle;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.beta.subparticle [Moles/volume] in Serum or Plasma;LDL SerPl-sCnc;;ACTIVE;2.27;2.73 +54435-3;Aspergillus fumigatus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Aspergillus fumigatus Ab [Titer] in Serum;A fumigatus Ab Titr Ser;;ACTIVE;2.27;2.73 +54436-1;Urate dihydrate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Urate dihydrate/Total in Stone;Urate dihyd MFr Stone;;ACTIVE;2.27;2.73 +5443-7;CD18;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD18 cells/100 cells in Blood;Deprecated CD18 WBC-aCnc;;DEPRECATED;1.0;2.69 +54437-9;Sodium urate/Total;MFr;Pt;Calculus;Qn;Infrared spectroscopy;CHEM;1;Sodium urate/Total in Stone by Infrared spectroscopy;Na Urate MFr Stone IR;;ACTIVE;2.27;2.73 +54438-7;Cholesterol/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Cholesterol/Total in Stone;Cholest MFr Stone;;ACTIVE;2.27;2.73 +54439-5;Calcium bilirubinate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium bilirubinate/Total in Stone;Ca Bilirub MFr Stone;;ACTIVE;2.27;2.73 +54440-3;Newberyite/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Newberyite/Total in Stone;Newberyite MFr Stone;;ACTIVE;2.27;2.73 +54441-1;Lipoprotein goals;Find;Pt;^Patient;Ord;;CHEM;1;Lipoprotein goals;Lipoprotein goals;;ACTIVE;2.27;2.27 +54442-9;Carnitine esters/Carnitine.free (C0);SRto;Pt;Urine;Qn;;CHEM;1;Carnitine esters/Carnitine.free (C0) [Molar ratio] in Urine;Carn esters/C0 Ur-sRto;;ACTIVE;2.27;2.73 +54443-7;Echovirus 2 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 2 Ab [Titer] in Serum;ECV2 Ab Titr Ser;;ACTIVE;2.27;2.32 +54444-5;Echovirus 8 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 8 Ab [Titer] in Serum;ECV8 Ab Titr Ser;;ACTIVE;2.27;2.32 +5444-5;CD19;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD19 cells/100 cells in Blood;Deprecated CD19 WBC-aCnc;;DEPRECATED;1.0;2.69 +54445-2;Fatty acids.very long chain.C22:1n9;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain.C22:1n9 (Erucate) [Mass/volume] in Serum or Plasma;VLCFA.C22:1n9 SerPl-mCnc;;ACTIVE;2.27;2.73 +54446-0;Fatty acids.very long chain.C26:1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:1 (Hexacosenoate) [Mass/volume] in Serum or Plasma;VLCFA C26:1 SerPl-mCnc;;ACTIVE;2.27;2.70 +54447-8;FLT3 gene targeted mutation analysis;Find;Pt;Bone mar;Doc;Molgen;MOLPATH.MUT;1;FLT3 gene targeted mutation analysis in Bone marrow by Molecular genetics method;FLT3 gene Mut Anl Mar;;ACTIVE;2.27;2.73 +54448-6;NPM1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NPM1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NPM1 gene Mut Anl Bld/T;;ACTIVE;2.27;2.73 +54449-4;SMN2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SMN2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SMN2 gene Mut Anl Bld/T;;ACTIVE;2.27;2.73 +54450-2;CYP2C9 & VKORC1 panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH.PHARMG;1;CYP2C9 and VKORC1 panel - Blood or Tissue by Molecular genetics method;CYP2C9 + VKORC1 Pnl Bld/T;;ACTIVE;2.27;2.67 +54451-0;CYP2C9 & VKORC1;Imp;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.PHARMG;1;CYP2C9 and VKORC1 [Interpretation] in Blood or Tissue by Molecular genetics method Narrative;CYP2C9 & VKORC1 Bld/T-Imp;;ACTIVE;2.27;2.73 +5445-2;CD19+SmIg kappa+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD19+Kappa+ cells/100 cells in Blood;Deprecated CD19+SmIg kappa+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54452-8;Ferning;PrThr;Pt;Cvm;Ord;;FERT;1;Ferning [Presence] in Cervical mucus;Ferning Cerv mucus Ql;;ACTIVE;2.27;2.73 +54453-6;Test method;Type;Pt;Semen;Nom;*;FERT;1;Semen analysis test method;Smn Analysis method;;ACTIVE;2.27;2.73 +54454-4;Arsenic fractions panel;-;Pt;Urine;Qn;;PANEL.DRUG/TOX;1;Arsenic fractions panel - Urine;Arsenic fractions Pnl Ur;;ACTIVE;2.27;2.73 +54455-1;Blastomyces dermatitidis Ag;ACnc;Pt;Body fld;Qn;;MICRO;1;Blastomyces dermatitidis Ag [Units/volume] in Body fluid;B dermat Ag Fld-aCnc;;ACTIVE;2.27;2.73 +54456-9;Urea reduction ratio;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Urea reduction ratio in Serum or Plasma;Urea reduction ratio SerPl;;ACTIVE;2.27;2.73 +54457-7;Biotinidase;CCnc;Pt;Ser/Plas^Normal control;Qn;;CHEM;1;Biotinidase [Enzymatic activity/volume] in Serum or Plasma from Normal control;Biotinidase SerPl Norm cont-cCnc;;ACTIVE;2.27;2.73 +54458-5;Granulocyte colony stimulating factor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Granulocyte colony stimulating factor [Mass/volume] in Serum or Plasma;G-CSF SerPl-mCnc;;ACTIVE;2.27;2.73 +54459-3;Dicarboxypalmitoylcarnitine (C16-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dicarboxypalmitoylcarnitine (C16-DC)/Creatinine [Molar ratio] in Urine;Dicarboxypalmitoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +5446-0;CD19+SmIg lambda+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD19+Lambda+ cells/100 cells in Blood;Deprecated CD19+SmIg lambda+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54460-1;Malonylcarnitine (C3-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Malonylcarnitine (C3-DC) [Moles/volume] in Cerebral spinal fluid;Malonylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54461-9;Malonylcarnitine (C3-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Malonylcarnitine (C3-DC) [Moles/volume] in Amniotic fluid;Malonylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54462-7;Malonylcarnitine (C3-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Malonylcarnitine (C3-DC) [Moles/volume] in DBS;Malonylcarn DBS-sCnc;;ACTIVE;2.27;2.70 +54463-5;Malonylcarnitine (C3-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Malonylcarnitine (C3-DC) [Moles/volume] in Urine;Malonylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54464-3;Albumin/Protein.total;MFr;Pt;Dial fld;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total in Dialysis fluid by Electrophoresis;Albumin MFr Dial fld Elph;;ACTIVE;2.27;2.70 +54465-0;Alpha 1 globulin/Protein.total;MFr;Pt;Dial fld;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total in Dialysis fluid by Electrophoresis;Alpha1 Glob MFr Dial fld Elph;;ACTIVE;2.27;2.70 +54466-8;Alpha 2 globulin/Protein.total;MFr;Pt;Dial fld;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total in Dialysis fluid by Electrophoresis;Alpha2 Glob MFr Dial fld Elph;;ACTIVE;2.27;2.70 +54467-6;Cholesterol.in HDL 2a/Cholesterol.in HDL.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in HDL 2a/Cholesterol in total HDL in Serum or Plasma by Electrophoresis;HDLc 2a MFr SerPl Elph;;ACTIVE;2.27;2.73 +54468-4;Cholesterol.in HDL 2b/Cholesterol.in HDL.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in HDL 2b/Cholesterol in total HDL in Serum or Plasma by Electrophoresis;HDLc 2b MFr SerPl Elph;;ACTIVE;2.27;2.73 +54469-2;Cholesterol.in HDL 3a/Cholesterol.in HDL.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in HDL 3a/Cholesterol in total HDL in Serum or Plasma by Electrophoresis;HDLc 3a MFr SerPl Elph;;ACTIVE;2.27;2.73 +544-7;Bacteroides fragilis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bacteroides fragilis Ag [Presence] in Specimen by Immunofluorescence;B fragilis Ag Spec Ql IF;;ACTIVE;1.0;2.69 +54470-0;Cholesterol.in HDL 3b/Cholesterol.in HDL.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in HDL 3b/Cholesterol in total HDL in Serum or Plasma by Electrophoresis;HDLc 3b MFr SerPl Elph;;ACTIVE;2.27;2.73 +54471-8;Cholesterol.in HDL 3c/Cholesterol.in HDL.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Cholesterol in HDL 3c/Cholesterol in total HDL in Serum or Plasma by Electrophoresis;HDLc 3c MFr SerPl Elph;;ACTIVE;2.27;2.73 +54472-6;Amylase.macromolecular/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.macromolecular/Amylase.total in Serum or Plasma;Amylase Macro CFr SerPl;;ACTIVE;2.27;2.70 +54473-4;Pimeloylcarnitine (C7-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Pimeloylcarnitine (C7-DC) [Moles/volume] in Cerebral spinal fluid;Pimeloylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54474-2;Pimeloylcarnitine (C7-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Pimeloylcarnitine (C7-DC) [Moles/volume] in Amniotic fluid;Pimeloylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54475-9;Pimeloylcarnitine (C7-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Pimeloylcarnitine (C7-DC) [Moles/volume] in DBS;Pimeloylcarn DBS-sCnc;;ACTIVE;2.27;2.70 +54476-7;Pimeloylcarnitine (C7-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Pimeloylcarnitine (C7-DC) [Moles/volume] in Urine;Pimeloylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54477-5;Dicarboxypalmitoylcarnitine (C16-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Dicarboxypalmitoylcarnitine (C16-DC) [Moles/volume] in Cerebral spinal fluid;Dicarboxypalmitoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +5447-8;CD2;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD2 cells/100 cells in Blood;Deprecated CD2 WBC-aCnc;;DEPRECATED;1.0;2.69 +54478-3;Dicarboxypalmitoylcarnitine (C16-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dicarboxypalmitoylcarnitine (C16-DC) [Moles/volume] in Amniotic fluid;Dicarboxypalmitoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54479-1;Dicarboxypalmitolycarnitine (C16-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Deprecated Dicarboxypalmitoylcarnitine (C16-DC) [Molecules/volume] in Blood dot (filter paper);Deprecated Dicarboxypalmitoylcarn Bld.do;;DEPRECATED;2.27;2.70 +54480-9;Dicarboxypalmitoylcarnitine (C16-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Dicarboxypalmitoylcarnitine (C16-DC) [Moles/volume] in Urine;Dicarboxypalmitoylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +54481-7;Dicarboxystearoylcarnitine (C18-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dicarboxystearoylcarnitine (C18-DC)/Creatinine [Molar ratio] in Urine;Dicarboxystearoylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54482-5;Dicarboxystearoylcarnitine (C18-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Dicarboxystearoylcarnitine (C18-DC) [Moles/volume] in Cerebral spinal fluid;Dicarboxystearoylcarn CSF-sCnc;;ACTIVE;2.27;2.70 +54483-3;Dicarboxystearoylcarnitine (C18-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dicarboxystearoylcarnitine (C18-DC) [Moles/volume] in Amniotic fluid;Dicarboxystearoylcarn Amn-sCnc;;ACTIVE;2.27;2.70 +54484-1;Octadecanedioylcarnitine (C18-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Deprecated Dicarboxystearoylcarnitine (C18-DC) [Molecules/volume] in Blood dot (filter paper);Deprecated Dicarboxystearoylcarn Bld.Dot;;DEPRECATED;2.27;2.70 +54485-8;Dicarboxystearoylcarnitine (C18-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Dicarboxystearoylcarnitine (C18-DC) [Moles/volume] in Urine;Dicarboxystearoylcarn Ur-sCnc;;ACTIVE;2.27;2.70 +5448-6;CD20;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD20 cells/100 cells in Blood;Deprecated CD20 WBC-aCnc;;DEPRECATED;1.0;2.69 +54486-6;Glucose;MCnc;Pt;Water;Qn;;CHEM;1;Glucose [Mass/volume] in Water;Glucose Wat-mCnc;;ACTIVE;2.27;2.70 +54487-4;Glucose;SCnc;Pt;Water;Qn;;CHEM;1;Glucose [Moles/volume] in Water;Glucose Wat-sCnc;;ACTIVE;2.27;2.70 +54488-2;Pimeloylcarnitine (C7-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pimeloylcarnitine (C7-DC)/Creatinine [Molar ratio] in Urine;Pimeloylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +54489-0;Phosphoserine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Phosphoserine [Moles/volume] in DBS;Phosphoserine DBS-sCnc;;ACTIVE;2.27;2.70 +54490-8;Pipecolate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Pipecolate [Moles/volume] in Amniotic fluid;Pipecolate Amn-sCnc;;ACTIVE;2.27;2.70 +54491-6;Alanine aminotransferase;CCnc;Pt;Periton fld;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Peritoneal fluid;ALT Prt-cCnc;;ACTIVE;2.27;2.70 +54492-4;Alanine aminotransferase;CCnc;Pt;Plr fld;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Pleural fluid;ALT Plr-cCnc;;ACTIVE;2.27;2.70 +54493-2;Allantoine;SRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Allantoine [Moles/time] in 24 hour Urine by Electrophoresis;Allantoine 24h Ur Elph-sRate;;ACTIVE;2.27;2.70 +5449-4;CD21;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD21 cells/100 cells in Blood;Deprecated CD21 WBC-aCnc;;DEPRECATED;1.0;2.69 +54494-0;Chloride;MCnc;Pt;Water;Qn;;CHEM;1;Chloride [Mass/volume] in Water;Chloride Wat-mCnc;;ACTIVE;2.27;2.70 +54495-7;Glucose^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucose [Moles/volume] in Serum or Plasma --post dialysis;Glucose p dialysis SerPl-sCnc;;ACTIVE;2.27;2.70 +54496-5;Glucose^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;Glucose sp5 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54497-3;Glucose^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;Glucose sp6 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54498-1;Glucose^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;Glucose sp7 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54499-9;Glucose^8th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge;Glucose sp8 p chal SerPl-sCnc;;ACTIVE;2.27;2.70 +54500-4;Aspartate aminotransferase.macromolecular/Aspartate aminotransferase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Aspartate aminotransferase.macromolecular/Aspartate aminotransferase.total in Serum or Plasma;AST Macro/AST.total CFr SerPl;;ACTIVE;2.27;2.70 +54501-2;Identification information;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Identification information;;;ACTIVE;2.27;2.73 +5450-2;CD22;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD22 in Blood;Deprecated CD22 WBC-aCnc;;DEPRECATED;1.0;2.69 +54502-0;Assessment &or tracking type;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Assessment/tracking type;;;ACTIVE;2.27;2.68 +54503-8;Legal name of patient;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Legal name of patient;;;ACTIVE;2.27;2.67 +54504-6;Social Security and Medicare numbers;-;Pt;^Patient;-;;SURVEY.MDS;4;Deprecated Social Security and Medicare numbers;;;DEPRECATED;2.27;2.70 +54505-3;Language;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Language;;;ACTIVE;2.27;2.73 +54506-1;Optional resident items;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Optional resident items;;;ACTIVE;2.27;2.74 +54507-9;Medicare stay;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Medicare stay [CMS Assessment];;;ACTIVE;2.27;2.74 +54508-7;Hearing, speech, and vision;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Hearing, speech, and vision [CMS Assessment];;;ACTIVE;2.27;2.68 +54509-5;Cognitive patterns;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Cognitive patterns;;;ACTIVE;2.27;2.68 +5451-0;CD22+CD19+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD22+CD19+ cells/100 cells in Blood;Deprecated CD22+CD19+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54510-3;Temporal orientation (orientation to year, month, and day);-;Pt;^Patient;-;BIMS;PANEL.SURVEY.CMS;4;Temporal orientation (orientation to year, month, and day) [BIMS];;;ACTIVE;2.27;2.67 +54511-1;Behavior;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Behavior;;;ACTIVE;2.27;2.68 +54512-9;Psychosis in last 7D;-;7D;^Patient;-;;PANEL.SURVEY.MDS;4;Psychosis in last 7 days;;;ACTIVE;2.27;2.68 +54513-7;Behavioral symptoms;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Behavioral symptoms;;;ACTIVE;2.27;2.68 +54514-5;Behavioral symptom - presence & frequency;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Behavioral symptom - presence and frequency during assessment period [CMS Assessment];;;ACTIVE;2.27;2.74 +54515-2;Impact on resident;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Impact on resident during assessment period [CMS Assessment];;;ACTIVE;2.27;2.74 +54516-0;Impact on others;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Impact on others during assessment period [CMS Assessment];;;ACTIVE;2.27;2.74 +54517-8;Wandering - impact;-;7D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Wandering - impact [CMS Assessment];;;ACTIVE;2.27;2.74 +54518-6;Preferences for customary routine and activities;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Preferences for customary routine and activities;;;ACTIVE;2.27;2.68 +54519-4;Interview for daily preferences;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Interview for daily preferences [CMS Assessment];;;ACTIVE;2.27;2.74 +54520-2;Interview for activity preferences;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Interview for activity preferences [CMS Assessment];;;ACTIVE;2.27;2.74 +54521-0;Staff assessment of daily and activity preferences;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Staff assessment of daily and activity preferences;;;ACTIVE;2.27;2.68 +54522-8;Functional status;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Functional status;;;ACTIVE;2.27;2.68 +54523-6;Activities of Daily Living (ADL) assistance in last 7D;-;7D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Activities of Daily Living (ADL) Assistance in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.68 +54524-4;Balance during transitions and walking;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Balance during transitions and walking during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54525-1;Functional limitation in range of motion;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional limitation in range of motion [CMS Assessment];;;ACTIVE;2.27;2.68 +54526-9;Mobility devices;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Mobility devices;;;DISCOURAGED;2.27;2.73 +54527-7;Functional rehabilitation potential;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional rehabilitation potential [CMS Assessment];;;ACTIVE;2.27;2.68 +5452-8;CD23;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD23 in Blood;Deprecated CD23 WBC-aCnc;;DEPRECATED;1.0;2.69 +54528-5;Bladder and bowel;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Bladder and bowel;;;ACTIVE;2.27;2.68 +54529-3;Appliances;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Appliances;;;ACTIVE;2.27;2.68 +54530-1;Urinary toileting program;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Urinary toileting program [CMS Assessment];;;ACTIVE;2.27;2.74 +54531-9;Active disease diagnosis;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Active disease diagnosis;;;ACTIVE;2.27;2.68 +54532-7;Cancer;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Cancer;;;ACTIVE;2.27;2.68 +54533-5;Heart &or circulation;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Heart/circulation;;;ACTIVE;2.27;2.68 +54534-3;Gastrointestinal;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Gastrointestinal;;;ACTIVE;2.27;2.68 +54535-0;Genitourinary;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Genitourinary;;;ACTIVE;2.27;2.68 +5453-6;CD24;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD24 cells/100 cells in Blood;Deprecated CD24 WBC-aCnc;;DEPRECATED;1.0;2.69 +54536-8;Infections;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Infections;;;ACTIVE;2.27;2.68 +54537-6;Metabolic;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Metabolic;;;ACTIVE;2.27;2.68 +54538-4;Musculoskeletal;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Musculoskeletal;;;ACTIVE;2.27;2.68 +54539-2;Neurological;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Neurological;;;ACTIVE;2.27;2.68 +545-4;Bacteroides melaninogenicus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bacteroides melaninogenicus Ag [Presence] in Specimen by Immunofluorescence;B melaninogenicus Ag Spec Ql IF;;ACTIVE;1.0;2.69 +54540-0;Nutritional;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Nutritional;;;ACTIVE;2.27;2.68 +54541-8;Psychiatric &or mood disorder;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Psychiatric/mood disorder;;;ACTIVE;2.27;2.68 +54542-6;Pulmonary;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Pulmonary;;;ACTIVE;2.27;2.68 +54543-4;Vision;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Vision;;;ACTIVE;2.27;2.68 +5454-4;CD25;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD25 cells/100 cells in Blood;Deprecated CD25 WBC-aCnc;;DEPRECATED;1.0;2.69 +54544-2;None of above active diagnoses;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;None of above active diagnoses;;;ACTIVE;2.27;2.68 +54545-9;Additional diagnoses;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Additional diagnoses;;;ACTIVE;2.27;2.68 +54546-7;Additional ICD diagnosis 1 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 1 in last 7 days;;;ACTIVE;2.27;2.54 +54547-5;Additional ICD diagnosis 2 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 2 in last 7 days;;;ACTIVE;2.27;2.54 +54548-3;Additional ICD diagnosis 3 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 3 in last 7 days;;;ACTIVE;2.27;2.54 +54549-1;Additional ICD diagnosis 4 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 4 in last 7 days;;;ACTIVE;2.27;2.54 +54550-9;Additional ICD diagnosis 5 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 5 in last 7 days;;;ACTIVE;2.27;2.54 +5455-1;CD26;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD26 cells/100 cells in Blood;Deprecated CD26 WBC-aCnc;;DEPRECATED;1.0;2.69 +54551-7;Additional ICD diagnosis 6 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 6 in last 7 days;;;ACTIVE;2.27;2.54 +54552-5;Additional ICD diagnosis 7 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 7 in last 7 days;;;ACTIVE;2.27;2.54 +54553-3;Additional ICD diagnosis 8 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 8 in last 7 days;;;ACTIVE;2.27;2.54 +54554-1;Additional ICD diagnosis 9 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 9 in last 7 days;;;ACTIVE;2.27;2.54 +54555-8;Additional ICD diagnosis 10 in last 7D;Prid;7D;^Patient;Nom;;SURVEY.MDS;4;Additional ICD diagnosis 10 in last 7 days;;;ACTIVE;2.27;2.54 +54556-6;Health conditions;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Health conditions;;;ACTIVE;2.27;2.68 +54557-4;Pain management;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Pain management during assessment period [CMS Assessment];;;ACTIVE;2.27;2.74 +54558-2;MDS v3.0 - RAI v1.17.1, 1.17.2 - Pain assessment interview during assessment period;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Pain assessment interview during assessment period [CMS Assessment];;;ACTIVE;2.27;2.74 +54559-0;Pain effect on function;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Pain effect on function during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54560-8;Pain intensity;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Pain intensity during assessment period [CMS Assessment];;;ACTIVE;2.27;2.74 +54561-6;Staff assessment for pain;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Staff assessment for pain;;;ACTIVE;2.27;2.68 +54562-4;Indicators of pain or possible pain;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Indicators of pain or possible pain;;;ACTIVE;2.27;2.68 +54563-2;Other health conditions;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Other health conditions;;;ACTIVE;2.27;2.68 +54564-0;Shortness of breath;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Shortness of breath;;;ACTIVE;2.27;2.68 +54565-7;Swallowing &or nutritional status;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Swallowing/nutritional status;;;ACTIVE;2.27;2.68 +54566-5;Swallowing disorder;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Swallowing disorder;;;ACTIVE;2.27;2.68 +54567-3;Height and weight;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Height and weight;;;ACTIVE;2.27;2.74 +54568-1;Nutritional approaches panel;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Nutritional approaches panel [CMS Assessment];;;ACTIVE;2.27;2.74 +5456-9;CD27;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD27 cells/100 cells in Blood;Deprecated CD27 WBC-aCnc;;DEPRECATED;1.0;2.69 +54569-9;Percent intake by artificial route;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Percent intake by artificial route;;;ACTIVE;2.27;2.68 +54570-7;Oral &or dental status;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Oral/dental status;;;ACTIVE;2.27;2.68 +54571-5;Dental;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Dental;;;ACTIVE;2.27;2.68 +54572-3;Skin conditions;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Skin conditions;;;ACTIVE;2.27;2.73 +54573-1;Determination of pressure injury risk;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Determination of pressure injury risk;;;ACTIVE;2.27;2.68 +54574-9;Presence of pressure injury;-;Pt;^Patient;-;;SURVEY.MDS;4;Presence of pressure injury;;;ACTIVE;2.27;2.64 +54575-6;Current number of unhealed (non-epithelialized) pressure injuries at each stage;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Current number of unhealed (non-epithelialized) pressure injuries at each stage;;;ACTIVE;2.27;2.68 +54576-4;Pressure injuries - stage 2;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Pressure injuries - stage 2;;;ACTIVE;2.27;2.68 +5457-7;CD28;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD28 cells/100 cells in Blood;Deprecated CD28 WBC-aCnc;;DEPRECATED;1.0;2.69 +54577-2;Pressure injuries - stage 3;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Pressure injuries - stage 3;;;ACTIVE;2.27;2.68 +54578-0;Pressure injuries - stage 4;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Pressure injuries - stage 4;;;ACTIVE;2.27;2.68 +54579-8;Pressure injuries - unstageable due to non-removable dressing;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Pressure injuries - unstageable due to non-removable dressing;;;ACTIVE;2.27;2.68 +54580-6;Minimum Data Set - version 3.0;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated Minimum Data Set - version 3.0;;;DEPRECATED;2.27;2.73 +54581-4;Facility provider numbers;-;Pt;Facility;-;;PANEL.ADMIN;2;Facility provider numbers;Facility provider #s;;ACTIVE;2.27;2.74 +54582-2;Provider type;Type;Pt;Provider;Nom;MDSv3;SURVEY.MDS;4;Provider type [MDSv3];;;ACTIVE;2.27;2.44 +54583-0;Federal OBRA reason for assessment;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Federal OBRA reason for assessment [CMS Assessment];;;ACTIVE;2.27;2.63 +54584-8;PPS Assessment;Type;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;PPS Assessment [CMS Assessment];;;ACTIVE;2.27;2.63 +5458-5;CD29;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD29 cells/100 cells in Blood;Deprecated CD29 WBC-aCnc;;DEPRECATED;1.0;2.69 +54585-5;PPS Other Medicare Required Assessment - OMRA;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;PPS Other Medicare Required Assessment - OMRA [CMS Assessment];;;ACTIVE;2.27;2.63 +54586-3;State required assessment;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated State required assessment MDSv3;;;DEPRECATED;2.27;2.36 +54587-1;First assessment since the most recent admission &or reentry;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;First assessment since the most recent admission/reentry [CMS Assessment];;;ACTIVE;2.27;2.63 +54588-9;Interpreter needed;Find;Pt;^Patient;Ord;;ADMIN.PATIENT;2;Interpreter needed;Interpreter needed;;ACTIVE;2.27;2.66 +54589-7;Preadmission Screening and Resident Review (PASRR);Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Preadmission Screening and Resident Review (PASRR) [CMS Assessment];;;ACTIVE;2.27;2.63 +54590-5;Entry type;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Entry type [CMS Assessment];;;ACTIVE;2.27;2.63 +54591-3;Admitted from;Type;Pt;Facility;Nom;MDSv3;SURVEY.MDS;4;Deprecated Admitted from Facility [MDSv3];;;DEPRECATED;2.27;2.73 +54592-1;Previous assessment reference date for significant correction;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Previous assessment reference date for significant correction [CMS Assessment];;;ACTIVE;2.27;2.63 +5459-3;CD3;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD3 cells/100 cells in Blood;Deprecated CD3 WBC-aCnc;;DEPRECATED;1.0;2.69 +54593-9;Assessment reference date - observation end date;Date;Pt;^Patient;Qn;CMS Assessment;PANEL.SURVEY.CMS;4;Assessment reference date - observation end date [CMS Assessment];;;ACTIVE;2.27;2.74 +54594-7;Medicare-covered stay since the most recent entry;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medicare-covered stay since the most recent entry [CMS Assessment];;;ACTIVE;2.27;2.63 +54595-4;Start date of most recent Medicare stay;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Start date of most recent Medicare stay [CMS Assessment];;;ACTIVE;2.27;2.63 +54596-2;End date of most recent Medicare stay;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;End date of most recent Medicare stay [CMS Assessment];;;ACTIVE;2.27;2.63 +54597-0;Comatose;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Comatose during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54598-8;Hearing.ability to hear in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Hearing.ability to hear in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54599-6;Hearing aid used during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Hearing aid used during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54600-2;Speech clarity.description of speech pattern;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Speech clarity.description of speech pattern during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +5460-1;CD3+DR+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD3+DR+ cells/100 cells in Blood;Deprecated CD3+DR+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54601-0;Express ideas and wants in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Express ideas and wants in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54602-8;Understanding verbal content;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Understanding verbal content during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54603-6;Vision.ability to see in adequate light in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Vision.ability to see in adequate light in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54604-4;Corrective lenses used;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Corrective lenses used during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54605-1;Brief interview for mental status should be conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Brief Interview for Mental Status (BIMS) should be conducted [CMS Assessment];;;ACTIVE;2.27;2.63 +54606-9;Repetition of three words;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Repetition of three words [MDSv3];;;ACTIVE;2.27;2.44 +54607-7;Temporal orientation - current year;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Temporal orientation - current year;;;DEPRECATED;2.27;2.44 +54608-5;Temporal orientation - current month;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Temporal orientation - current month;;;DEPRECATED;2.27;2.44 +54609-3;Temporal orientation - current day of the week;Find;Pt;^Patient;Ord;BIMS;SURVEY.CMS;4;Temporal orientation - current day of the week [BIMS];;;ACTIVE;2.27;2.63 +54610-1;Recall;-;Pt;^Patient;-;MDSv3;SURVEY.MDS;4;Recall [MDSv3];;;ACTIVE;2.27;2.50 +54611-9;Recall - sock;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Recall - sock;;;DEPRECATED;2.27;2.36 +54612-7;Recall - blue;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Recall - blue;;;DEPRECATED;2.27;2.36 +54613-5;Recall - bed;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Recall - bed;;;DEPRECATED;2.27;2.36 +54614-3;Brief interview for mental status - summary score;Score;Pt;^Patient;Qn;BIMS;SURVEY.CMS;4;Brief Interview for Mental Status - summary score [BIMS];;;ACTIVE;2.27;2.63 +54615-0;Should staff assessment for mental status be conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Should staff assessment for mental status be conducted [CMS Assessment];;;ACTIVE;2.27;2.63 +54616-8;Short-term memory OK;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Short-term memory OK during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54617-6;Long-term memory OK;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Long-term memory OK during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54618-4;Memory &or recall ability;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Memory/recall ability [MDSv3];;;ACTIVE;2.27;2.68 +5461-9;CD30;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD30 cells/100 cells in Blood;Deprecated CD30 WBC-aCnc;;DEPRECATED;1.0;2.69 +54619-2;Can recall current season in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Can recall current season in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +546-2;Streptococcus.beta-hemolytic;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture;B-Hem Strep Throat Ql Cult;;ACTIVE;1.0;2.73 +54620-0;Can recall location of own room in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Can recall location of own room in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54621-8;Can recall staff names and faces in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Can recall staff names and faces in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54622-6;Can recall that he or she is in a nursing home in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Can recall that he or she is in a nursing home in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54623-4;None of the above were recalled in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;None of the above were recalled in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54624-2;Cognitive skills for daily decision making;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Cognitive skills for daily decision making during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54625-9;Procedural memory OK in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Procedural memory OK in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54626-7;Delirium;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Delirium [MDSv3];;;ACTIVE;2.27;2.68 +5462-7;CD31;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD31 cells/100 cells in Blood;Deprecated CD31 WBC-aCnc;;DEPRECATED;1.0;2.69 +54627-5;Signs and symptoms of delirium (from CAM);-;Pt;^Patient;-;Observed.CAM.MDSv3;PANEL.SURVEY.MDS;4;Signs and symptoms of delirium (from CAM) [CAM.MDSv3];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.29;2.68 +54628-3;Inattention in last 7D;Find;7D;^Patient;Nom;CAM.CMS;SURVEY.CMS;4;Inattention in last 7 days [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.29;2.67 +54629-1;Disorganized thinking in last 7D;Find;7D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Disorganized thinking in last 7 days [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.29;2.67 +54630-9;Altered level of consciousness in last 7D;Find;7D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Altered level of consciousness in last 7 days [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.29;2.72 +54631-7;Psychomotor retardation in last 7D;Find;7D;^Patient;Ord;Observed.CAM.MDSv3;SURVEY.MDS;4;Psychomotor retardation in last 7 days [CAM.MDSv3];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.29;2.54 +54632-5;Acute onset mental status change;Find;Pt;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Acute onset mental status change [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.27;2.67 +54633-3;Mood;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Mood [CMS Assessment];;;ACTIVE;2.27;2.68 +54634-1;Should resident mood interview be conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Should resident mood interview be conducted [CMS Assessment];;;ACTIVE;2.27;2.63 +5463-5;CD32;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD32 cells/100 cells in Blood;Deprecated CD32 WBC-aCnc;;DEPRECATED;1.0;2.69 +54635-8;Resident mood interview (PHQ-9);-;2W;^Patient;-;Reported.PHQ-9.CMS;PANEL.SURVEY.CMS;4;Resident mood interview (PHQ-9) [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.72 +54636-6;Little interest or pleasure in doing things in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Little interest or pleasure in doing things in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54637-4;Little interest or pleasure in doing things in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Little interest or pleasure in doing things in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54638-2;Feeling down, depressed or hopeless in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Feeling down, depressed or hopeless in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54639-0;Feeling down, depressed or hopeless in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Feeling down, depressed or hopeless in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54640-8;Trouble falling or staying asleep, or sleeping too much in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Trouble falling or staying asleep, or sleeping too much in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54641-6;Trouble falling or staying asleep, or sleeping too much in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Trouble falling or staying asleep, or sleeping too much in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54642-4;Feeling tired or having little energy in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Feeling tired or having little energy in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +5464-3;CD33;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD33 cells/100 cells in Blood;Deprecated CD33 WBC-aCnc;;DEPRECATED;1.0;2.69 +54643-2;Feeling tired or having little energy in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Feeling tired or having little energy in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54644-0;Poor appetite or overeating in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Poor appetite or overeating in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54645-7;Poor appetite or overeating in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Poor appetite or overeating in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54646-5;Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54647-3;Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54648-1;Trouble concentrating on things, such as reading the newspaper or watching television in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Trouble concentrating on things, such as reading the newspaper or watching television in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54649-9;Trouble concentrating on things, such as reading the newspaper or watching television in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Trouble concentrating on things, such as reading the newspaper or watching television in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +5465-0;CD34;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD34 cells/100 cells in Blood;Deprecated CD34 WBC-aCnc;;DEPRECATED;1.0;2.69 +54650-7;Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54651-5;Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54652-3;Thoughts that you would be better off dead, or of hurting yourself in some way in last 2W.presence;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Thoughts that you would be better off dead, or of hurting yourself in some way in last 2 weeks.presence [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54653-1;Thoughts that you would be better off dead, or of hurting yourself in some way in last 2W.frequency;Find;2W;^Patient;Ord;Reported.PHQ-9.CMS;SURVEY.CMS;4;Thoughts that you would be better off dead, or of hurting yourself in some way in last 2 weeks.frequency [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54654-9;Mood interview total severity score;Score;Pt;^Patient;Qn;Reported.PHQ-9.CMS;SURVEY.CMS;4;Mood interview total severity score [Reported PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54655-6;Responsible staff or provider was informed of potential for resident self harm;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Responsible staff or provider was informed of potential for resident self harm [CMS Assessment];;;ACTIVE;2.27;2.63 +54656-4;Staff assessment of mood should be conducted;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Staff assessment of mood should be conductedr MDSv3;;;DEPRECATED;2.27;2.36 +54657-2;Staff assessment of resident mood (PHQ-9-OV);-;Pt;^Patient;-;Observed.PHQ-9.CMS;PANEL.SURVEY.CMS;4;Staff assessment of resident mood (PHQ-9-OV) [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.74 +54658-0;Little interest or pleasure in doing things in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Little interest or pleasure in doing things in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54659-8;Little interest or pleasure in doing things in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Little interest or pleasure in doing things in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54660-6;Feeling or appearing down, depressed or hopeless in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Feeling or appearing down, depressed or hopeless in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54661-4;Feeling or appearing down, depressed, or hopeless in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Feeling or appearing down, depressed, or hopeless in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54662-2;Trouble falling or staying asleep, or sleeping too much in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Trouble falling or staying asleep, or sleeping too much in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54663-0;Trouble falling or staying asleep, or sleeping too much in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Trouble falling or staying asleep, or sleeping too much in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54664-8;Feeling tired or having little energy in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Feeling tired or having little energy in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54665-5;Feeling tired or having little energy in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Feeling tired or having little energy in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54666-3;Poor appetite or overeating in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Poor appetite or overeating in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54667-1;Poor appetite or overeating in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Poor appetite or overeating in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +5466-8;CD34+DR+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD34+DR+ cells/100 cells in Blood;Deprecated CD34+DR+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54668-9;Indicating that (s)he feels bad about self, is a failure, or has let self or family down in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Indicating that (s)he feels bad about self, is a failure, or has let self or family down in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54669-7;Indicating that (s)he feels bad about self, is a failure, or has let self or family down in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Indicating that (s)he feels bad about self, is a failure, or has let self or family down in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54670-5;Trouble concentrating on things, such as reading the newspaper or watching television in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Trouble concentrating on things, such as reading the newspaper or watching television in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54671-3;Trouble concentrating on things, such as reading the newspaper or watching television in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Trouble concentrating on things, such as reading the newspaper or watching television in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54672-1;Moving or speaking so slowly that other people have noticed. Or the opposite - being so fidgety or restless that (s)he has been moving around a lot more than usual in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Moving or speaking so slowly that other people have noticed. Or the opposite - being so fidgety or restless that (s)he has been moving around a lot more than usual in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54673-9;States that life isn't worth living, wishes for death, or attempts to harm self in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;States that life isn't worth living, wishes for death, or attempts to harm self in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54674-7;States that life isn't worth living, wishes for death, or attempts to harm self in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;States that life isn't worth living, wishes for death, or attempts to harm self in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54675-4;Being short-tempered, easily annoyed in last 2W.presence;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Being short-tempered, easily annoyed in last 2 weeks.presence [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +5467-6;CD35;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD35 cells/100 cells in Blood;Deprecated CD35 WBC-aCnc;;DEPRECATED;1.0;2.69 +54676-2;Being short-tempered, easily annoyed in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Being short-tempered, easily annoyed in last 2 weeks.frequency [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54677-0;Staff assessment of resident mood total severity score;Score;Pt;^Patient;Qn;Observed.PHQ-9.CMS;SURVEY.CMS;4;Staff assessment of resident mood total severity score [Observed PHQ-9 CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.63 +54678-8;Hallucinations in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hallucinations in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54679-6;Illusions in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Illusions in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54680-4;Delusions in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Delusions in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54681-2;Psychoses - none of the above in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Psychoses - none of the above in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54682-0;Physical behavioral symptoms directed toward others;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physical behavioral symptoms directed toward others during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54683-8;Verbal behavioral symptoms directed toward others;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Verbal behavioral symptoms directed toward others during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +5468-4;CD36;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD36 cells/100 cells in Blood;Deprecated CD36 WBC-aCnc;;DEPRECATED;1.0;2.69 +54684-6;Other behavioral symptoms not directed toward others;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Other behavioral symptoms not directed toward others during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54685-3;Overall presence of behavioral symptoms;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Overall presence of behavioral symptoms during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54686-1;Put the resident at significant risk for physical illness or injury;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Put the resident at significant risk for physical illness or injury during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54687-9;Significantly interfere with the resident's care;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Significantly interfere with the resident's care during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54688-7;Significantly interfere with the resident's participation in activities or social interactions;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Significantly interfere with the resident's participation in activities or social interactions during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54689-5;Put others at significant risk for physical injury;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Put others at significant risk for physical injury during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54690-3;Significantly intrude on the privacy or activity of others;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Significantly intrude on the privacy or activity of others during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54691-1;Significantly disrupt care or living environment;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Significantly disrupt care or living environment during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +5469-2;CD37;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD37 cells/100 cells in Blood;Deprecated CD37 WBC-aCnc;;DEPRECATED;1.0;2.69 +54692-9;Rejection of care - presence and frequency in last 7D;NRat;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Rejection of care - presence and frequency in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54693-7;Wandering - presence and frequency in last 7D;NRat;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wandering - presence and frequency in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54694-5;Wandering places resident at significant risk of getting to a potentially dangerous place in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wandering places resident at significant risk of getting to a potentially dangerous place in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54695-2;Wandering significantly intrudes on the privacy or activities of others in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wandering significantly intrudes on the privacy or activities of others in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54696-0;Change in behavioral or other symptoms in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Change in behavioral or other symptoms in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54697-8;Interview for daily and activity preferences should be conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Interview for daily and activity preferences should be conducted [CMS Assessment];;;ACTIVE;2.27;2.63 +54698-6;How important it is to choose what clothes to wear while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to choose what clothes to wear while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54699-4;How important it is to take care of your personal belongings or things while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to take care of your personal belongings or things while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54-7;Butirosin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Butirosin [Susceptibility] by Serum bactericidal titer;Butirosin Titr SBT;;ACTIVE;1.0;2.32 +547-0;Streptococcus.beta-hemolytic;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Streptococcus.beta-hemolytic [Presence] in Specimen by Organism specific culture;B-Hem Strep Spec Ql Cult;;ACTIVE;1.0;2.73 +5470-0;CD38;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD38 cells/100 cells in Blood;Deprecated CD38 aCnc;;DEPRECATED;1.0;2.69 +54700-0;How important it is to choose between a tub bath, shower, bed bath, or sponge bath while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to choose between a tub bath, shower, bed bath, or sponge bath while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54701-8;How important it is to have snacks available between meals while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to have snacks available between meals while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54702-6;How important it is to choose your own bedtime while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to choose your own bedtime while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54703-4;How important it is to have your family or a close friend involved in discussions about your care while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to have your family or a close friend involved in discussions about your care while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54704-2;How important it is to be able to use the phone in private while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to be able to use the phone in private while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54705-9;How important it is to have a place to lock your things to keep them safe while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to have a place to lock your things to keep them safe while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54706-7;How important it is to have books, newspapers, and magazines to read while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to have books, newspapers, and magazines to read while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54707-5;How important it is to listen to music you like while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to listen to music you like while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54708-3;How important it is to be around animals such as pets while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to be around animals such as pets while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54709-1;How important it is to keep up with the news while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to keep up with the news while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54710-9;How important it is to do things with groups of people while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to do things with groups of people while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54711-7;How important it is to do your favorite activities while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to do your favorite activities while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54712-5;How important it is to go outside to get fresh air when the weather is good while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to go outside to get fresh air when the weather is good while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54713-3;How important it is to participate in religious services or practices while in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How important it is to participate in religious services or practices while in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54714-1;Primary respondent for daily and activity preferences;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Primary respondent for daily and activity preferences [CMS Assessment];;;ACTIVE;2.27;2.63 +54715-8;Staff assessment of daily and activity preferences should be conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Staff assessment of daily and activity preferences should be conducted [CMS Assessment];;;ACTIVE;2.27;2.63 +54716-6;Resident prefers choosing clothes to wear;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers choosing clothes to wear [MDSv3];;;ACTIVE;2.27;2.44 +54717-4;Resident prefers caring for personal belongings;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers caring for personal belongings [MDSv3];;;ACTIVE;2.27;2.44 +5471-8;CD39;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD39 cells/100 cells in Blood;Deprecated CD39 WBC-aCnc;;DEPRECATED;1.0;2.69 +54718-2;Resident prefers receiving tub bath;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers receiving tub bath [MDSv3];;;ACTIVE;2.27;2.44 +54719-0;Resident prefers receiving shower;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers receiving shower [MDSv3];;;ACTIVE;2.27;2.44 +54720-8;Resident prefers receiving bed bath;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers receiving bed bath [MDSv3];;;ACTIVE;2.27;2.44 +54721-6;Resident prefers receiving sponge bath;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers receiving sponge bath [MDSv3];;;ACTIVE;2.27;2.44 +54722-4;Resident prefers snacks between meals;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers snacks between meals [MDSv3];;;ACTIVE;2.27;2.44 +54723-2;Resident prefers staying up past 8:00 p.m.;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers staying up past 8:00 p.m. [MDSv3];;;ACTIVE;2.27;2.44 +54724-0;Resident prefers family or significant other involvement in care discussions;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers family or significant other involvement in care discussions [MDSv3];;;ACTIVE;2.27;2.44 +54725-7;Resident prefers use of phone in private;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers use of phone in private [MDSv3];;;ACTIVE;2.27;2.44 +5472-6;CD4;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD4 in Blood;Deprecated CD4 WBC-aCnc;;DEPRECATED;1.0;2.69 +54726-5;Resident prefers place to lock personal belongings;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers place to lock personal belongings [MDSv3];;;ACTIVE;2.27;2.44 +54727-3;Resident prefers reading books, newspapers, magazines;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers reading books, newspapers, magazines [MDSv3];;;ACTIVE;2.27;2.44 +54728-1;Resident prefers listening to music;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers listening to music [MDSv3];;;ACTIVE;2.27;2.44 +54729-9;Resident prefers being around animals such as pets;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers being around animals such as pets [MDSv3];;;ACTIVE;2.27;2.44 +54730-7;Resident prefers keeping up with the news;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers keeping up with the news [MDSv3];;;ACTIVE;2.27;2.44 +54731-5;Resident prefers doing things with groups of people;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers doing things with groups of people [MDSv3];;;ACTIVE;2.27;2.44 +54732-3;Resident prefers participating in favorite activities;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers participating in favorite activities [MDSv3];;;ACTIVE;2.27;2.44 +54733-1;Resident prefers spending time away from the nursing home;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers spending time away from the nursing home [MDSv3];;;ACTIVE;2.27;2.44 +5473-4;CD4+CD8+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD4+CD8+ cells/100 cells in Blood;Deprecated CD4+CD8+ WBC-aCnc;;DEPRECATED;1.0;2.69 +54734-9;Resident prefers spending time outdoors;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers spending time outdoors [MDSv3];;;ACTIVE;2.27;2.44 +54735-6;Resident prefers participating in religious activities or practices;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers participating in religious activities or practices [MDSv3];;;ACTIVE;2.27;2.44 +54736-4;Resident prefers none of the above;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident prefers none of the above [MDSv3];;;ACTIVE;2.27;2.44 +54737-2;Bed mobility in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Bed mobility in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54738-0;Transfer in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Transfer in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54739-8;Toilet transfer in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Toilet transfer in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54740-6;Toileting in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Toileting in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54741-4;Walk in room in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Walk in room in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +5474-2;CD4/CD8 ratio;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD4 cells/CD8 Ratio in Blood;Deprecated CD4 WBC-aCnc;;DEPRECATED;1.0;2.69 +54742-2;Walk in facility in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Walk in facility in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54743-0;Locomotion in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Locomotion in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54744-8;Dressing upper body in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dressing upper body in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54745-5;Dressing lower body in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Dressing lower body in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54746-3;Eating in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Eating in last 7D MDSv3;;;DEPRECATED;2.27;2.40 +54747-1;Grooming &or personal hygiene in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Grooming &or personal hygiene in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54748-9;Bathing in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Bathing in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54749-7;Moving from seated to standing position;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Moving from seated to standing position during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54750-5;Walking (with assistive device if used);Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walking (with assistive device if used) during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54751-3;Turning around and facing the opposite direction while walking;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Turning around and facing the opposite direction while walking during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54752-1;Moving on and off toilet;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Moving on and off toilet during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54753-9;Surface-to-surface transfer;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Surface-to-surface transfer during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54754-7;Range of motion;Find;Pt;Upper extremity;Ord;CMS Assessment;SURVEY.CMS;4;Range of motion Upper extremity [CMS Assessment];;;ACTIVE;2.27;2.63 +54755-4;Range of motion;Find;Pt;Lower extremity;Ord;CMS Assessment;SURVEY.CMS;4;Range of motion Lower extremity [CMS Assessment];;;ACTIVE;2.27;2.63 +54756-2;Cane &or crutch normally used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cane/crutch normally used in last 7 days [MDSv3];;;DISCOURAGED;2.27;2.73 +54757-0;Walker normally used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Walker normally used in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54758-8;Wheelchair (manual or electric) normally used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Wheelchair (manual or electric) normally used in last 7 days [MDSv3];;;DISCOURAGED;2.27;2.73 +5475-9;CD40;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD40 cells/100 cells in Blood;Deprecated CD40 WBC-aCnc;;DEPRECATED;1.0;2.69 +54759-6;Limb prosthesis normally used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Limb prosthesis normally used in last 7 days [MDSv3];;;DISCOURAGED;2.27;2.73 +54760-4;Mobility aids - none of the above were normally used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Mobility aids - none of the above were normally used in last 7 days [MDSv3];;;DISCOURAGED;2.27;2.73 +54761-2;Bedfast;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Bedfast [MDSv3];;;ACTIVE;2.27;2.44 +54762-0;Indwelling catheter used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Indwelling catheter used in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54763-8;External catheter used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;External catheter used in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54764-6;Ostomy (including suprapubic catheter, ileostomy, and colostomy) present in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Ostomy (including suprapubic catheter, ileostomy, and colostomy) present in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54765-3;Intermittent catheterization used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Intermittent catheterization used in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54766-1;Appliances - none of the above used in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Appliances - none of the above used in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5476-7;CD41;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD41 cells/100 cells in Blood;Deprecated CD41 WBC-aCnc;;DEPRECATED;1.0;2.69 +54767-9;Trial of toileting program has been attempted on admission or reentry or since urinary incontinence was noted in this facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Trial of toileting program has been attempted on admission or reentry or since urinary incontinence was noted in this facility [CMS Assessment];;;ACTIVE;2.27;2.63 +54768-7;Response to toileting program;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Response to toileting program [CMS Assessment];;;ACTIVE;2.27;2.63 +54769-5;Current toileting program or trial;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Current toileting program or trial during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54770-3;Urinary continence in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Urinary continence in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54771-1;Bowel continence in last 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bowel continence in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54772-9;Bowel toileting program currently being used;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bowel toileting program currently being used [CMS Assessment];;;ACTIVE;2.27;2.63 +54773-7;Constipation present;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Constipation present during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54774-5;Cancer in last 30D;Find;30D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cancer in last 30 days [MDSv3];;;ACTIVE;2.27;2.54 +5477-5;CD42a;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD42a cells/100 cells in Blood;Deprecated CD42a WBC-aCnc;;DEPRECATED;1.0;2.69 +54775-2;Anemia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Anemia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54776-0;Atrial fibrillation and other dysrhythmias in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Atrial fibrillation and other dysrhythmias in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54777-8;Coronary artery disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Coronary artery disease in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54778-6;Deep venous thrombosis &or pulmonary embolus or pulmonary thrombo-embolism in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deep venous thrombosis/pulmonary embolus or pulmonary thrombo-embolism in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54779-4;Heart failure in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Heart failure in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54780-2;Hypertension in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hypertension in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54781-0;Orthostatic hypotension in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Orthostatic hypotension in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54782-8;Peripheral vascular disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Peripheral vascular disease in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5478-3;CD42b;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD42b cells/100 cells in Blood;Deprecated CD42b WBC-aCnc;;DEPRECATED;1.0;2.69 +54783-6;Cirrhosis in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cirrhosis in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54784-4;Gastroesophageal reflux disease &or pressure injury in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Gastroesophageal reflux disease/ulcer in last 7 days [MDSv3];;;ACTIVE;2.27;2.73 +54785-1;Ulcerative colitis &or Crohn's disease &or inflammatory bowel disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Ulcerative colitis/Crohn's disease/inflammatory bowel disease in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54786-9;Benign prostatic hyperplasia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Benign prostatic hyperplasia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54787-7;Renal insufficiency or renal failure &or end-stage renal disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Renal insufficiency or renal failure/end-stage renal disease in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54788-5;HIV infection in last 30D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated HIV infection in last 30D MDSv3;;;DEPRECATED;2.27;2.36 +54789-3;Staphylococcus aureus.methicillin resistant or Enterococcus species.vancomycin resistant or Clostridium difficile infections &or colonization in last 30D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Staphylococcus aureus.methicillin resistant or Enterococcus species.vancomycin resistant or Clostridium difficile infections &or colonization in last 30D MDSv3;;;DEPRECATED;2.27;2.36 +54790-1;Pneumonia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pneumonia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5479-1;CD42c;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD42c cells/100 cells in Blood;Deprecated CD42c WBC-aCnc;;DEPRECATED;1.0;2.69 +54791-9;Septicemia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Septicemia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54792-7;Tuberculosis in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Tuberculosis in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54793-5;Urinary tract infection in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Urinary tract infection in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54794-3;Viral hepatitis in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Viral hepatitis in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54795-0;Diabetes mellitus in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Diabetes mellitus in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54796-8;Hyponatremia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hyponatremia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54797-6;Hyperkalemia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hyperkalemia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54798-4;Hyperlipidemia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hyperlipidemia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54799-2;Thyroid disorder in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Thyroid disorder in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54800-8;Arthritis in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Arthritis in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54801-6;Osteoporosis in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Osteoporosis in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54802-4;Hip fracture in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hip fracture in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54803-2;Other fracture in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Other fracture in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54804-0;Alzheimer's disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Alzheimer's disease in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54805-7;Aphasia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Aphasia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54806-5;Cerebral palsy in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cerebral palsy in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54807-3;Cerebrovascular accident &or transient ischemic attack &or stroke in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cerebrovascular accident/transient ischemic attack/stroke in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54808-1;Non-Alzheimer's dementia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Non-Alzheimer's dementia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5480-9;CD42d;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD42d cells/100 cells in Blood;Deprecated CD42d WBC-aCnc;;DEPRECATED;1.0;2.69 +54809-9;Hemiplegia &or hemiparesis in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hemiplegia/hemiparesis in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54810-7;Paraplegia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Paraplegia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54811-5;Quadriplegia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Quadriplegia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54812-3;Multiple sclerosis in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Multiple sclerosis in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54813-1;Parkinson's disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Parkinson's disease in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54814-9;Seizure disorder in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Seizure disorder in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54815-6;Traumatic brain injury in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Traumatic brain injury in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54816-4;Protein or calorie malnutrition or at risk for malnutrition in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Protein or calorie malnutrition or at risk for malnutrition in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5481-7;CD43;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD43 cells/100 cells in Blood;Deprecated CD43 WBC-aCnc;;DEPRECATED;1.0;2.69 +54817-2;Anxiety disorder in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Anxiety disorder in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54818-0;Depression other than bipolar in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Depression other than bipolar in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54819-8;Manic depression other than schizophrenia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Manic depression other than schizophrenia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54820-6;Schizophrenia in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Schizophrenia in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54821-4;Post-traumatic stress disorder in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Post-traumatic stress disorder in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54822-2;Asthma &or chronic obstructive lung disease or chronic lung disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Asthma/chronic obstructive lung disease or chronic lung disease in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54823-0;Cataracts &or glaucoma or macular degeneration in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cataracts/glaucoma or macular degeneration in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54824-8;None of the above active diagnoses in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;None of the above active diagnoses in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5482-5;CD44;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD44 cells/100 cells in Blood;Deprecated CD44 WBC-aCnc;;DEPRECATED;1.0;2.69 +54825-5;On scheduled pain medication regimen in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;On scheduled pain medication regimen in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54826-3;Received PRN pain medications in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Received PRN pain medications in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54827-1;Received non-medication intervention for pain in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Received non-medication intervention for pain in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54828-9;Pain assessment interview should be conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pain assessment interview should be conducted [CMS Assessment];;;ACTIVE;2.27;2.63 +54829-7;Pain presence;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pain presence during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54830-5;Pain frequency;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pain frequency during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54831-3;Pain has made it hard to sleep;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pain has made it hard to sleep during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54832-1;Limited activities because of pain;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Limited activities because of pain during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +5483-3;CD44R;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD44R cells/100 cells in Blood;Deprecated CD44R WBC-aCnc;;DEPRECATED;1.0;2.69 +54833-9;Pain severity;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pain severity during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54834-7;Rate pain severity using verbal descriptor scale;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Rate pain severity during assessment period using verbal descriptor scale;;;ACTIVE;2.27;2.70 +54835-4;Non-verbal sounds of pain in last 5D;Find;5D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Non-verbal sounds of pain in last 5 days [MDSv3];;;ACTIVE;2.27;2.54 +54836-2;Vocal complaints of pain in last 5D;Find;5D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Vocal complaints of pain in last 5 days [MDSv3];;;ACTIVE;2.27;2.54 +54837-0;Facial expressions of pain in last 5D;Find;5D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Facial expressions of pain in last 5 days [MDSv3];;;ACTIVE;2.27;2.54 +54838-8;Protective body movements or postures in last 5D;Find;5D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Protective body movements or postures in last 5 days [MDSv3];;;ACTIVE;2.27;2.54 +54839-6;None of these signs of pain observed or documented in last 5D;Find;5D;^Patient;Ord;MDSv3;SURVEY.MDS;4;None of these signs of pain observed or documented in last 5 days [MDSv3];;;ACTIVE;2.27;2.54 +54840-4;Adequacy of current therapeutic regimen to control pain in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Adequacy of current therapeutic regimen to control pain in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +5484-1;CD45;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD45 cells/100 cells in Blood;Deprecated CD45 WBC-aCnc;;DEPRECATED;1.0;2.69 +54841-2;Shortness of breath or trouble breathing with exertion in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Shortness of breath or trouble breathing with exertion in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54842-0;Shortness of breath or trouble breathing when sitting at rest in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Shortness of breath or trouble breathing when sitting at rest in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54843-8;Shortness of breath or trouble breathing when lying flat in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Shortness of breath or trouble breathing when lying flat in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54844-6;None of the above shortness of breath symptoms in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;None of the above shortness of breath symptoms in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54845-3;Tobacco use;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Tobacco use during assessment period [CMS Assessment];;;ACTIVE;2.27;2.70 +54846-1;Life expectancy of less than 6M;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Life expectancy of less than 6 months [CMS Assessment];;;ACTIVE;2.27;2.63 +54847-9;Problem conditions;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Problem conditions [MDSv3];;;ACTIVE;2.27;2.68 +54848-7;Problem conditions - none of above;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Problem conditions - none of above [MDSv3];;;ACTIVE;2.27;2.44 +54849-5;Fall history on admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Fall history on admission [CMS Assessment];;;ACTIVE;2.27;2.74 +54850-3;Fall one or more times in the last Mo prior to admission;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Fall one or more times in the last month prior to admission [CMS Assessment];;;ACTIVE;2.27;2.63 +54851-1;Fall one or more times in the last 2 to 6Mo prior to admission;Find;6Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Fall one or more times in the last 2 to 6 months prior to admission [CMS Assessment];;;ACTIVE;2.27;2.63 +54852-9;Any fracture related to a fall in the 6Mo prior to admission;Find;6Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Any fracture related to a fall in the 6 months prior to admission [CMS Assessment];;;ACTIVE;2.27;2.63 +54853-7;Has the patient had any falls since admission or prior assessment;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Has the patient had any falls since admission or prior assessment [CMS Assessment];;;ACTIVE;2.27;2.63 +54854-5;Number of falls since admission or prior assessment;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Number of falls since admission or prior assessment [CMS Assessment];;;ACTIVE;2.27;2.67 +54855-2;Number of falls since admission or prior assessment - no injury;Num;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Number of falls since admission or prior assessment - no injury [CMS Assessment];;;ACTIVE;2.27;2.67 +54856-0;Number of falls since admission or prior assessment - injury except major;Num;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Number of falls since admission or prior assessment - injury except major [CMS Assessment];;;ACTIVE;2.27;2.61 +54857-8;Number of falls since admission or prior assessment - major injury;Num;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Number of falls since admission or prior assessment - major injury [CMS Assessment];;;ACTIVE;2.27;2.61 +5485-8;CD45RA;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD45RA cells/100 cells in Blood;Deprecated CD45RA WBC-aCnc;;DEPRECATED;1.0;2.69 +54858-6;Loss of liquids &or solids from mouth when eating or drinking in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Loss of liquids/solids from mouth when eating or drinking in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54859-4;Holding food in mouth &or cheeks or residual food in mouth after meals in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Holding food in mouth/cheeks or residual food in mouth after meals in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54860-2;Coughing or choking during meals or when swallowing medications in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Coughing or choking during meals or when swallowing medications in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54861-0;Complaints of difficulty or pain with swallowing in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Complaints of difficulty or pain with swallowing in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54862-8;Signs or symptoms of possible swallowing disorder - none of the above;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Signs or symptoms of possible swallowing disorder - none of the above [MDSv3];;;ACTIVE;2.27;2.44 +54863-6;Weight loss of 5% or more in the last Mo or loss of 10% or more in last 6Mo;Find;6Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Weight loss of 5% or more in the last month or loss of 10% or more in last 6 months [CMS Assessment];;;ACTIVE;2.27;2.63 +54864-4;Parenteral &or IV feeding in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Parenteral/IV feeding in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54865-1;Nasogastric or abdominal feeding tube in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Nasogastric or abdominal feeding tube in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5486-6;CD45RB;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD45RB cells/100 cells in Blood;Deprecated CD45RB WBC-aCnc;;DEPRECATED;1.0;2.69 +54866-9;Mechanically altered diet - require change in texture of food or liquids in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Mechanically altered diet - require change in texture of food or liquids in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54867-7;Therapeutic diet in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Therapeutic diet in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54868-5;Nutritional approaches in last 7D - none of the above;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Nutritional approaches in last 7 days - none of the above [MDSv3];;;ACTIVE;2.27;2.54 +54869-3;Average fluid intake per day by parenteral or tube feedings in the 7D;VRat;7D;^Patient;Qn;MDSv3;SURVEY.MDS;4;Average fluid intake per day by parenteral or tube feedings in the 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54870-1;Able to perform dental exam;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Able to perform dental exam MDSv3;;;DEPRECATED;2.27;2.36 +54871-9;Broken or loosely fitting full or partial denture in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Broken or loosely fitting full or partial denture in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54872-7;No natural teeth or tooth fragments in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;No natural teeth or tooth fragments in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54873-5;Abnormal mouth tissue in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Abnormal mouth tissue in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5487-4;CD45RO;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD45RO cells/100 cells in Blood;Deprecated CD45RO WBC-aCnc;;DEPRECATED;1.0;2.69 +54874-3;Obvious or likely cavity or broken natural teeth in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Obvious or likely cavity or broken natural teeth in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54875-0;Inflamed or bleeding gums or loose natural teeth in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Inflamed or bleeding gums or loose natural teeth in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54876-8;Mouth or facial pain, discomfort or difficulty with chewing in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Mouth or facial pain, discomfort or difficulty with chewing in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54877-6;Dental status - none of the above in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dental status - none of the above in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54878-4;Pressure injury risk by resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing, device in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure injury risk by resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing, device in last 7 days [MDSv3];;;ACTIVE;2.27;2.64 +54879-2;Pressure injury risk by formal assessment;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure injury risk by formal assessment [MDSv3];;;ACTIVE;2.27;2.64 +548-8;Bordetella pertussis;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Bordetella pertussis [Presence] in Throat by Organism specific culture;B pert Throat Ql Cult;;ACTIVE;1.0;2.73 +54880-0;Pressure injury risk by clinical judgment;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure injury risk by clinical judgment [MDSv3];;;ACTIVE;2.27;2.64 +54881-8;Pressure injury risk - none of the above;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure injury risk - none of the above [MDSv3];;;ACTIVE;2.27;2.64 +5488-2;CD46;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD46 cells/100 cells in Blood;Deprecated CD46 WBC-aCnc;;DEPRECATED;1.0;2.69 +54882-6;Risk of developing pressure injuries;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Risk of developing pressure injuries [MDSv3];;;DEPRECATED;2.27;2.73 +54883-4;Date of most recent routine pressure ulcer assessment;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Date of most recent routine pressure ulcer assessment MDSv3;;;DEPRECATED;2.27;2.36 +54884-2;Number of pressure injuries - stage 1;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - stage 1 [CMS Assessment];;;ACTIVE;2.27;2.63 +54885-9;One or more unhealed pressure ulcer(s) at Stage 2 or higher, or one or more likely pressure ulcers that are unstageable;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated One or more unhealed pressure ulcer(s) at Stage 2 or higher, or one or more likely pressure ulcers that are unstageable MDSv3;;;DEPRECATED;2.27;2.36 +54886-7;Number of pressure injuries present upon admission &or reentry - stage 2;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries present upon admission/reentry - stage 2 [CMS Assessment];;;ACTIVE;2.27;2.63 +54887-5;Number of pressure injuries present upon admission &or reentry - stage 3;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries present upon admission/reentry - stage 3 [CMS Assessment];;;ACTIVE;2.27;2.63 +54888-3;Date of onset of pressure injuries onset in this facility - oldest or only stage 3;Date;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Date of onset of pressure injuries onset in this facility - oldest or only stage 3 [MDSv3];;;ACTIVE;2.27;2.64 +54889-1;Date of onset of pressure ulcers onset in this facility - newest stage 3;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Date of onset of pressure ulcers onset in this facility - newest stage 3 MDSv3;;;DEPRECATED;2.27;2.36 +5489-0;CD47;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD47 cells/100 cells in Blood;Deprecated CD47 WBC-aCnc;;DEPRECATED;1.0;2.69 +54890-9;Number of pressure injuries present upon admission &or reentry - stage 4;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries present upon admission/reentry - stage 4 [CMS Assessment];;;ACTIVE;2.27;2.63 +54891-7;Date of onset of pressure injuries onset in this facility - oldest or only stage 4;Date;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Date of onset of pressure injuries onset in this facility - oldest or only stage 4 [MDSv3];;;ACTIVE;2.27;2.64 +54892-5;Date of onset of pressure ulcers onset in this facility - newest stage 4;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Date of onset of pressure ulcers onset in this facility - newest stage 4 MDSv3;;;DEPRECATED;2.27;2.36 +54893-3;Number of pressure injuries - unstageable due to non-removable dressing or device;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - unstageable due to non-removable dressing or device [CMS Assessment];;;ACTIVE;2.27;2.63 +54894-1;Number of pressure injuries present upon admission &or reentry - unstageable due to non-removable dressing;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries present upon admission/reentry - unstageable due to non-removable dressing [CMS Assessment];;;ACTIVE;2.27;2.63 +54895-8;Staff assessment for mental status;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Staff assessment for mental status [MDSv3];;;ACTIVE;2.27;2.68 +54896-6;Submission requirement;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Submission requirement [MDSv3];;;ACTIVE;2.27;2.44 +54897-4;Proportion of total calories the resident received through parenteral or tube feedings in the last 7D;EngFr;7D;^Patient;Qn;MDSv3;SURVEY.MDS;4;Proportion of total calories the resident received through parenteral or tube feedings in the last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54898-2;Other disease diagnoses in last 7D;-;7D;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Other disease diagnoses in last 7 days [MDSv3];;;ACTIVE;2.27;2.68 +54899-0;Language.preferred;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Preferred language;Preferred language;;ACTIVE;2.27;2.73 +54900-6;IgA;MCnc;Pt;Periton fld;Qn;;CHEM;1;IgA [Mass/volume] in Peritoneal fluid;IgA Prt-mCnc;;ACTIVE;2.27;2.70 +54901-4;IgG;MCnc;Pt;Periton fld;Qn;;CHEM;1;IgG [Mass/volume] in Peritoneal fluid;IgG Prt-mCnc;;ACTIVE;2.27;2.70 +54902-2;IgM;MCnc;Pt;Periton fld;Qn;;CHEM;1;IgM [Mass/volume] in Peritoneal fluid;IgM Prt-mCnc;;ACTIVE;2.27;2.70 +54904-8;Moving or speaking so slowly that other people have noticed. Or the opposite - being so fidgety or restless that (s)he has been moving around a lot more than usual in last 2W.frequency;Find;2W;^Patient;Ord;Observed.PHQ-9.CMS;SURVEY.CMS;4;Moving or speaking so slowly that other people have noticed. Or the opposite - being so fidgety or restless that (s)he has been moving around a lot more than usual in last 2 weeks.frequency [Observed PHQ-9 CMS];;;ACTIVE;2.27;2.63 +54905-5;Norovirus genogroup I RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup I RNA [Presence] in Stool by NAA with probe detection;Norovirus GI RNA Stl Ql NAA+probe;;ACTIVE;2.27;2.73 +54906-3;Norovirus genogroup II RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup II RNA [Presence] in Stool by NAA with probe detection;Norovirus GII RNA Stl Ql NAA+probe;;ACTIVE;2.27;2.73 +54907-1;Alkaline phosphatase;CCnc;Pt;Amnio fld;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Amniotic fluid;ALP Amn-cCnc;;ACTIVE;2.27;2.68 +5490-8;CD48;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD48 cells/100 cells in Blood;Deprecated CD48 WBC-aCnc;;DEPRECATED;1.0;2.69 +54908-9;Cefminox;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefminox [Susceptibility];Cefminox Susc Islt;;ACTIVE;2.27;2.27 +54909-7;Culex pipiens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Culex mosquito IgE Ab [Units/volume] in Serum;Culex mosquito IgE Qn;;ACTIVE;2.27;2.42 +54910-5;DNA double strand Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;DNA double strand Ab [Units/volume] in Serum by Immunofluorescence;dsDNA Ab Ser IF-aCnc;;ACTIVE;2.27;2.69 +54911-3;Epinephelus lanceolatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Giant grouper IgE Ab [Units/volume] in Serum;Giant grouper IgE Qn;;ACTIVE;2.27;2.73 +54912-1;Fosfomycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fosfomycin IgE Ab [Units/volume] in Serum;Fosfomycin IgE Qn;;ACTIVE;2.27;2.42 +54913-9;Gentamicin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gentamicin IgE Ab [Units/volume] in Serum;Gentamicin IgE Qn;;ACTIVE;2.27;2.42 +54914-7;Hepatitis C virus core Ag;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis C virus core Ag [Units/volume] in Serum by Immunoassay;HCV core Ag Ser IA-aCnc;;ACTIVE;2.27;2.69 +54915-4;Chlorophora excelsa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Iroko IgE Ab [Units/volume] in Serum;Iroko IgE Qn;;ACTIVE;2.27;2.42 +5491-6;CD49a;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD49a cells/100 cells in Blood;Deprecated CD49a WBC-aCnc;;DEPRECATED;1.0;2.69 +54916-2;Lophius piscatorius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Angler IgE Ab [Units/volume] in Serum;Angler IgE Qn;;ACTIVE;2.27;2.42 +54917-0;Lysozyme;MCnc;Pt;Plr fld;Qn;;CHEM;1;Lysozyme [Mass/volume] in Pleural fluid;Lysozyme Plr-mCnc;;ACTIVE;2.27;2.42 +54918-8;Ma+Ta Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Ma+Ta Ab [Units/volume] in Serum by Immunoassay;Ma+Ta Ab Ser IA-aCnc;;ACTIVE;2.27;2.69 +54919-6;Magnesium;MCnc;Pt;Semen;Qn;;CHEM;1;Magnesium [Mass/volume] in Semen;Magnesium Smn-mCnc;;ACTIVE;2.27;2.42 +54920-4;Myrmecia pilosula Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Jumper ant IgE Ab [Units/volume] in Serum;Jumper ant IgE Qn;;ACTIVE;2.27;2.42 +54921-2;Neuronal nuclear type 2 Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Neuronal nuclear type 2 Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Hu2 Ab CSF IA-aCnc;;ACTIVE;2.27;2.69 +54922-0;Phosphate;MRat;12H;Urine;Qn;;CHEM;1;Phosphate [Mass/time] in 12 hour Urine;Phosphate 12h Ur-mRate;;ACTIVE;2.27;2.70 +54923-8;Propyphenazone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Propyphenazone IgE Ab [Units/volume] in Serum;Propyphenazone IgE Qn;;ACTIVE;2.27;2.70 +5492-4;CD49B;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD49b cells/100 cells in Blood;Deprecated CD49B WBC-aCnc;;DEPRECATED;1.0;2.69 +54924-6;Purkinje cells Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Purkinje cells Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Purkinje Cells Ab CSF IA-aCnc;;ACTIVE;2.27;2.69 +54925-3;Selenium;MCnc;Pt;Semen;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Semen;Selenium Smn-mCnc;;ACTIVE;2.27;2.42 +54926-1;"t(9;22)(q34.1;q11)(ABL1,BCR) e19a2 fusion transcript";NCnc;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) e19a2 fusion transcript [#/volume] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)e19a2 # Bld/T;;ACTIVE;2.27;2.40 +54927-9;Tetranychus urticae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tetranychus urticae IgE Ab [Units/volume] in Serum;T urticae IgE Qn;;ACTIVE;2.27;2.42 +54928-7;Tinidazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tinidazole [Susceptibility];Tinidazole Susc Islt;;ACTIVE;2.27;2.27 +54929-5;Tissue transglutaminase Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Tissue transglutaminase Ab [Titer] in Serum by Immunofluorescence;tTG Ab Titr Ser IF;;ACTIVE;2.27;2.32 +54930-3;Vicia faba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fava bean IgE Ab [Units/volume] in Serum;Fava bean IgE Qn;;ACTIVE;2.27;2.42 +54931-1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Creatinine [Molar ratio] in Urine;Isovaleryl+MeButyrylcarn/Creat Ur-sRto;;ACTIVE;2.27;2.70 +5493-2;CD49c;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD49c cells/100 cells in Blood;Deprecated CD49c WBC-aCnc;;DEPRECATED;1.0;2.69 +54932-9;CEH abrine & ricinine panel;MCnc;Pt;Urine;-;;PANEL.DRUG/TOX;1;Centers for Environmental Health abrine and ricinine panel [Mass/volume] - Urine;CEH abrine+ricinine Pnl Ur-mCnc;;ACTIVE;2.27;2.42 +54933-7;Abrine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Abrine [Mass/volume] in Urine;Abrine Ur-mCnc;;ACTIVE;2.27;2.70 +54934-5;Ricinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ricinine [Mass/volume] in Urine;Ricinine Ur-mCnc;;ACTIVE;2.27;2.70 +54935-2;1,2-Dichloroethane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,2-Dichloroethane [Mass/volume] in Serum or Plasma;1,2DCA SerPl-mCnc;;ACTIVE;2.27;2.70 +54936-0;Carbon tetrachloride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbon tetrachloride [Mass/volume] in Serum or Plasma;Carbon Tet SerPl-mCnc;;ACTIVE;2.27;2.70 +54937-8;Chloroform;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloroform [Mass/volume] in Serum or Plasma;Chloroform SerPl-mCnc;;ACTIVE;2.27;2.70 +54938-6;Ethyl benzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethyl benzene [Mass/volume] in Serum or Plasma;Ethyl Benzene SerPl-mCnc;;ACTIVE;2.27;2.70 +54939-4;Meta methylhippurate+Para methylhippurate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meta methylhippurate+Para methylhippurate [Mass/volume] in Serum or Plasma;m+p-Methylhippurate SerPl-mCnc;;ACTIVE;2.27;2.73 +5494-0;CD49d;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD49d cells/100 cells in Blood;Deprecated CD49d WBC-aCnc;;DEPRECATED;1.0;2.69 +54940-2;Styrene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Styrene [Mass/volume] in Serum or Plasma;Styrene SerPl-mCnc;;ACTIVE;2.27;2.70 +54941-0;Tungsten;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tungsten [Mass/volume] in Urine;Tungsten Ur-mCnc;;ACTIVE;2.27;2.70 +54942-8;N-ethyldiethanolamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;N-ethyldiethanolamine [Mass/volume] in Urine;N-ethyldiethanolamine Ur-mCnc;;ACTIVE;2.27;2.70 +54943-6;N-methyldiethanolamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;N-methyldiethanolamine [Mass/volume] in Urine;N-methyldiethanolamine Ur-mCnc;;ACTIVE;2.27;2.70 +54944-4;Monofluoroacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Monofluoroacetate [Mass/volume] in Urine;Monofluoroacetate Ur-mCnc;;ACTIVE;2.27;2.70 +54945-1;Monochloroacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Monochloroacetate [Mass/volume] in Urine;Monochloroacetate Ur-mCnc;;ACTIVE;2.27;2.70 +54946-9;Number of pressure injuries - unstageable due to coverage of wound bed by slough &or eschar;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - unstageable due to coverage of wound bed by slough/eschar [CMS Assessment];;;ACTIVE;2.27;2.63 +54947-7;Number of pressure injuries present upon admission &or reentry - unstageable due to coverage of wound bed by slough &or eschar;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries present upon admission/reentry - unstageable due to coverage of wound bed by slough/eschar [CMS Assessment];;;ACTIVE;2.27;2.63 +54948-5;Date of onset of pressure ulcers onset in this facility - oldest or only unstageable due to coverage of wound bed by slough &or eschar;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Date of onset of pressure ulcers onset in this facility - oldest or only unstageable due to coverage of wound bed by slough &or eschar MDSv3;;;DEPRECATED;2.27;2.36 +54949-3;Date of onset of pressure ulcers onset in this facility - newest unstageable due to coverage of wound bed by slough &or eschar;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Date of onset of pressure ulcers onset in this facility - newest unstageable due to coverage of wound bed by slough/eschar MDSv3;;;DEPRECATED;2.27;2.36 +54950-1;Number of pressure injuries - unstageable with suspected deep tissue injury in evolution;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - unstageable with suspected deep tissue injury in evolution [CMS Assessment];;;ACTIVE;2.27;2.63 +54951-9;Number of pressure injuries present upon admission &or reentry - unstageable with suspected deep tissue injury in evolution;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries present upon admission/reentry - unstageable with suspected deep tissue injury in evolution [CMS Assessment];;;ACTIVE;2.27;2.63 +54952-7;Worsening in pressure injury status since last assessment (OBRA, PPS, or Discharge);-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Worsening in pressure injury status since last assessment (OBRA, PPS, or Discharge);;;ACTIVE;2.27;2.64 +54953-5;Number of current pressure injuries not present or were at a lesser stage on prior assessment - stage 2;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of current pressure injuries not present or were at a lesser stage on prior assessment - stage 2 [CMS Assessment];;;ACTIVE;2.27;2.63 +54954-3;Number of current pressure injuries not present or were at a lesser stage on prior assessment - stage 3;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of current pressure injuries not present or were at a lesser stage on prior assessment - stage 3 [CMS Assessment];;;ACTIVE;2.27;2.63 +54955-0;Number of current pressure injuries not present or were at a lesser stage on prior assessment - stage 4;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of current pressure injuries not present or were at a lesser stage on prior assessment - stage 4 [CMS Assessment];;;ACTIVE;2.27;2.63 +54956-8;Healed pressure injuries;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Healed pressure injuries [CMS Assessment];;;ACTIVE;2.27;2.63 +5495-7;CD49E;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD49e cells/100 cells in Blood;Deprecated CD49E WBC-aCnc;;DEPRECATED;1.0;2.69 +54957-6;Pressure injuries were present on the prior assessment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pressure injuries were present on the prior assessment [CMS Assessment];;;ACTIVE;2.27;2.63 +54958-4;Number of pressure injuries noted on prior assessment that have completely closed - stage 2;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries noted on prior assessment that have completely closed - stage 2 [CMS Assessment];;;ACTIVE;2.27;2.63 +54959-2;Number of pressure injuries noted on prior assessment that have completely closed - stage 3;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries noted on prior assessment that have completely closed - stage 3 [CMS Assessment];;;ACTIVE;2.27;2.63 +549-6;Bordetella pertussis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bordetella pertussis [Presence] in Specimen by Organism specific culture;B pert Spec Ql Cult;;ACTIVE;1.0;2.73 +54960-0;Number of pressure injuries noted on prior assessment that have completely closed - stage 4;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries noted on prior assessment that have completely closed - stage 4 [CMS Assessment];;;ACTIVE;2.27;2.63 +54961-8;Other Ulcers, Wounds and Skin Problems;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Other ulcers, wounds and skin problems;;;ACTIVE;2.27;2.68 +54962-6;Venous or arterial ulcers in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Venous or arterial ulcers in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54963-4;Diabetic foot pressure injury(ies) in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Diabetic foot ulcer(s) in last 7 days [MDSv3];;;ACTIVE;2.27;2.73 +54964-2;Other foot or lower extremity open lesion(s) or infections in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Other foot or lower extremity open lesion(s) or infections in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +5496-5;CD49f;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD49f cells/100 cells in Blood;Deprecated CD49f WBC-aCnc;;DEPRECATED;1.0;2.69 +54965-9;Wound infection other than on foot or lower extremity in last 7D;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Wound infection other than on foot or lower extremity in last 7D MDSv3;;;DEPRECATED;2.27;2.36 +54966-7;Surgical wound(s) in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Surgical wound(s) in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54967-5;Open lesion(s) other than ulcers, rashes, cuts in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Open lesion(s) other than ulcers, rashes, cuts in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54968-3;Second or third degree burns in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Second or third degree burns in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54969-1;Other ulcers, wounds, and skin problems - none of above in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Other ulcers, wounds, and skin problems - none of above in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54970-9;Number of venous and arterial ulcers in last 7D;Num;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of venous and arterial ulcers in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +54971-7;Skin and pressure injury treatments in last 7D;-;7D;^Patient;-;;PANEL.SURVEY.MDS;4;Skin and ulcer treatments in last 7 days;;;ACTIVE;2.27;2.73 +54972-5;Pressure reducing device for chair provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure reducing device for chair provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5497-3;CD5;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD5 cells/100 cells in Blood;Deprecated CD5 WBC-aCnc;;DEPRECATED;1.0;2.69 +54973-3;Pressure reducing device for bed provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure reducing device for bed provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54974-1;Turning &or repositioning provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Turning/repositioning provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54975-8;Nutrition or hydration intervention to manage skin problems provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Nutrition or hydration intervention to manage skin problems provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54976-6;Pressure injury care provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Ulcer care provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.73 +54977-4;Surgical wound care provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Surgical wound care provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54978-2;Application of nonsurgical dressings (with or without topical medications) other than to feet provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Application of nonsurgical dressings (with or without topical medications) other than to feet provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54979-0;Applications of ointments &or medications other than to feet provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Applications of ointments/medications other than to feet provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54980-8;Application of dressings to feet (with or without topical medications) provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Application of dressings to feet (with or without topical medications) provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.54 +5498-1;CD5+CD2-;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD5+CD2- cells/100 cells in Blood;Deprecated CD5+CD2- WBC-aCnc;;DEPRECATED;1.0;2.69 +54981-6;Skin and pressure injury treatments - none of above provided in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Skin and ulcer treatments - none of above provided in last 7 days [MDSv3];;;ACTIVE;2.27;2.73 +54982-4;Number of D injectable substances received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days injectable substances received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.27;2.64 +54983-2;Medications received in last 7D or since admission &or reentry if less than 7D;-;7D;^Patient;-;;PANEL.SURVEY.MDS;4;Medications received in last 7 days or since admission/reentry if less than 7 days;;;DISCOURAGED;2.27;2.73 +54984-0;Antipsychotic received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Antipsychotic received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54985-7;Antianxiety received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Antianxiety received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54986-5;Antidepressant received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Antidepressant received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54987-3;Hypnotic received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hypnotic received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54988-1;Anticoagulant received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Anticoagulant received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.27;2.73 +54989-9;Medications received - none of the above were received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Medications received - none of the above were received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.27;2.54 +54990-7;Special treatments and procedures;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Special treatments and procedures;;;ACTIVE;2.27;2.68 +54991-5;Special treatments and programs in last 14D;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Special treatments and programs in last 14 days;;;ACTIVE;2.27;2.68 +54992-3;Chemotherapy in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Chemotherapy in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +54993-1;Chemotherapy in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Chemotherapy in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +54994-9;Radiation in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Radiation in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +54995-6;Radiation in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Radiation in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +54996-4;Oxygen therapy in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Oxygen therapy in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +54997-2;Oxygen therapy in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Oxygen therapy in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +54998-0;Suctioning in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Suctioning in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +5499-9;CD50;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD50 cells/100 cells in Blood;Deprecated CD50 WBC-aCnc;;DEPRECATED;1.0;2.69 +54999-8;Suctioning in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Suctioning in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55000-4;Tracheostomy care in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Tracheostomy care in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55001-2;Tracheostomy care in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Tracheostomy care in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55002-0;Ventilator or respirator in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Ventilator or respirator in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55003-8;Ventilator or respirator in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Ventilator or respirator in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +5500-4;CD51;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD51 cells/100 cells in Blood;Deprecated CD51 WBC-aCnc;;DEPRECATED;1.0;2.69 +55004-6;BIPAP &or CPAP machine in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;BIPAP/CPAP machine in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55005-3;BIPAP &or CPAP machine in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;BIPAP/CPAP machine in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55006-1;IV medications in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;IV medications in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55007-9;IV medications in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;IV medications in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55008-7;Transfusions in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Transfusions in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55009-5;Transfusions in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Transfusions in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55010-3;Dialysis in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dialysis in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55011-1;Dialysis in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dialysis in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +5501-2;CD52;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD52 cells/100 cells in Blood;Deprecated CD52 WBC-aCnc;;DEPRECATED;1.0;2.69 +55012-9;Hospice care in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hospice care in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55013-7;Hospice care in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Hospice care in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55014-5;Respite care in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Respite care in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55015-2;Respite care in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Respite care in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55016-0;Isolation or quarantine for active infectious disease in last 14D - while not a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Isolation or quarantine for active infectious disease in last 14 days - while not a resident [MDSv3];;;ACTIVE;2.27;2.54 +55017-8;Isolation or quarantine for active infectious disease in last 14D - while a resident;Find;14D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Isolation or quarantine for active infectious disease in last 14 days - while a resident [MDSv3];;;ACTIVE;2.27;2.54 +55018-6;Influenza vaccine;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Influenza vaccine;;;ACTIVE;2.27;2.73 +55019-4;Influenza virus vaccine received in facility;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Influenza virus vaccine received in facility [CMS Assessment];;;ACTIVE;2.27;2.61 +5502-0;CD53;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD53 cells/100 cells in Blood;Deprecated CD53 WBC-aCnc;;DEPRECATED;1.0;2.69 +55020-2;Reason influenza virus vaccine not received;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Reason influenza virus vaccine not received [CMS Assessment];;;ACTIVE;2.27;2.61 +55021-0;Pneumococcal vaccine;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Pneumococcal vaccine;;;ACTIVE;2.27;2.74 +55022-8;Pneumococcal vaccination up to date;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pneumococcal vaccination up to date [CMS Assessment];;;ACTIVE;2.27;2.63 +55023-6;Reason pneumococcal vaccine not received;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Reason pneumococcal vaccine not received [MDSv3];;;DEPRECATED;2.27;2.73 +55024-4;Therapies in last 7D;-;7D;^Patient;-;;PANEL.SURVEY.MDS;4;Therapies in last 7 days;;;ACTIVE;2.27;2.68 +55025-1;Start date of speech language pathology and audiology services;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Start date of speech language pathology and audiology services [CMS Assessment];;;ACTIVE;2.27;2.63 +55026-9;End date of speech language pathology and audiology services;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;End date of speech language pathology and audiology services [CMS Assessment];;;ACTIVE;2.27;2.63 +55027-7;Start date of occupational therapy;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Start date of occupational therapy [CMS Assessment];;;ACTIVE;2.27;2.63 +55028-5;End date of occupational therapy;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;End date of occupational therapy [CMS Assessment];;;ACTIVE;2.27;2.63 +55029-3;Start date of physical therapy;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Start date of physical therapy [CMS Assessment];;;ACTIVE;2.27;2.63 +55030-1;End date of physical therapy;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;End date of physical therapy [CMS Assessment];;;ACTIVE;2.27;2.63 +55031-9;Start date of respiratory therapy;Date;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Start date of respiratory therapy [MDSv3];;;ACTIVE;2.27;2.50 +55032-7;End date of respiratory therapy;Date;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;End date of respiratory therapy [MDSv3];;;ACTIVE;2.27;2.50 +55033-5;Start date of psychological therapy by any licensed mental health professional;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Start date of psychological therapy by any licensed mental health professional MDSv3;;;DEPRECATED;2.27;2.36 +55034-3;End date of psychological therapy by any licensed mental health professional;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated End date of psychological therapy by any licensed mental health professional MDSv3;;;DEPRECATED;2.27;2.36 +55035-0;Total minutes of recreational and music therapy in last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Total minutes of recreational and music therapy in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +55036-8;Number of D with at least 15M of recreational and music therapy in last 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of recreational and music therapy in last 7 days [CMS Assessment];;;ACTIVE;2.27;2.63 +55037-6;Start date of recreational and music therapy;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Start date of recreational and music therapy MDSv3;;;DEPRECATED;2.27;2.36 +5503-8;CD54;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD54 cells/100 cells in Blood;Deprecated CD54 WBC-aCnc;;DEPRECATED;1.0;2.69 +55038-4;End date of recreational and music therapy;TmStp;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated End date of recreational and music therapy MDSv3;;;DEPRECATED;2.27;2.36 +55039-2;Nursing rehabilitation &or restorative care in last 7D;-;7D;^Patient;-;;PANEL.SURVEY.MDS;4;Nursing rehabilitation/restorative care in last 7 days;;;ACTIVE;2.27;2.68 +550-4;Bordetella pertussis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Bordetella pertussis Ag [Presence] in Specimen by Immunofluorescence;B pert Ag Spec Ql IF;;ACTIVE;1.0;2.73 +55040-0;Number of D physician examined the patient in last 14D;NRat;14D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days physician examined the patient in last 14 days [CMS Assessment];;;ACTIVE;2.27;2.63 +55041-8;Number of D physician orders changed in last 14D;NRat;14D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days physician orders changed in last 14 days [CMS Assessment];;;ACTIVE;2.27;2.63 +55042-6;Restraints;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Restraints;;;ACTIVE;2.27;2.68 +55043-4;Physical restraints;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Physical restraints;;;ACTIVE;2.27;2.68 +55044-2;Physical restraints used in bed - bed rail of any type;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in bed - bed rail of any type [MDSv3];;;ACTIVE;2.27;2.44 +55045-9;Physical restraints used in bed - trunk restraint;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in bed - trunk restraint [MDSv3];;;ACTIVE;2.27;2.44 +5504-6;CD55;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD55 cells/100 cells in Blood;Deprecated CD55 WBC-aCnc;;DEPRECATED;1.0;2.69 +55046-7;Physical restraints used in bed - limb restraint;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in bed - limb restraint [MDSv3];;;ACTIVE;2.27;2.44 +55047-5;Physical restraints used in bed - other;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in bed - other [MDSv3];;;ACTIVE;2.27;2.44 +55048-3;Physical restraints used in chair or out of bed - trunk restraint;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in chair or out of bed - trunk restraint [MDSv3];;;ACTIVE;2.27;2.44 +55049-1;Physical restraints used in chair or out of bed - limb restraint;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in chair or out of bed - limb restraint [MDSv3];;;ACTIVE;2.27;2.44 +55050-9;Physical restraints used in chair or out of bed - chair prevents rising;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in chair or out of bed - chair prevents rising [MDSv3];;;ACTIVE;2.27;2.44 +55051-7;Physical restraints used in chair or out of bed - other;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints used in chair or out of bed - other [MDSv3];;;ACTIVE;2.27;2.44 +55052-5;Participation in assessment and goal setting;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Participation in assessment and goal setting;;;ACTIVE;2.27;2.68 +5505-3;CD56;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD56 cells/100 cells in Blood;Deprecated CD56 WBC-aCnc;;DEPRECATED;1.0;2.69 +55053-3;Participation in assessment;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Participation in assessment;;;ACTIVE;2.27;2.63 +55054-1;Participation in assessment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Participation in assessment [CMS Assessment];;;ACTIVE;2.27;2.63 +55055-8;Return to community;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Return to community [MDSv3];;;ACTIVE;2.27;2.44 +55056-6;Resident's overall goals;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.MDS;4;Resident's overall goals [CMS Assessment];;;ACTIVE;2.27;2.74 +55057-4;Goals established during assessment process;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Goals established during assessment process [CMS Assessment];;;ACTIVE;2.27;2.67 +55058-2;Information source for resident's overall goal;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Information source for resident's overall goal [CMS Assessment];;;ACTIVE;2.27;2.63 +55059-0;Therapy supplement for Medicare PPS;-;Pt;^Patient;-;;SURVEY.MDS;4;Deprecated Therapy supplement for Medicare PPS;;;DEPRECATED;2.27;2.36 +55060-8;Ordered therapies;-;Pt;^Patient;-;;SURVEY.MDS;4;Deprecated Ordered therapies;;;DEPRECATED;2.27;2.36 +5506-1;CD57;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD57 cells/100 cells in Blood;Deprecated CD57 WBC-aCnc;;DEPRECATED;1.0;2.69 +55061-6;Therapies ordered to begin in first 14D of stay;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Therapies ordered to begin in first 14D of stay MDSv3;;;DEPRECATED;2.27;2.36 +55062-4;Therapy evaluations completed;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Deprecated Therapy evaluations completed MDSv3;;;DEPRECATED;2.27;2.36 +55063-2;Assessment administration;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Assessment administration;;;ACTIVE;2.27;2.68 +55064-0;Medicare part A billing;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Medicare part A billing;;;ACTIVE;2.27;2.63 +55065-7;Medicare part A - HIPPS code for billing;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Medicare part A - HIPPS code for billing;;;ACTIVE;2.27;2.63 +55066-5;Medicare part A - RUG version code;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Medicare part A - RUG version code;;;ACTIVE;2.27;2.63 +55067-3;State Medicaid billing;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;State Medicaid billing;;;ACTIVE;2.27;2.63 +55068-1;State case mix - RUG group;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;State case mix - RUG group;;;ACTIVE;2.27;2.63 +55069-9;State case mix - RUG version code;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;State case mix - RUG version code;;;ACTIVE;2.27;2.63 +55070-7;Insurance billing;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Insurance billing;;;ACTIVE;2.27;2.63 +55071-5;Insurance case mix - RUG group;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Insurance case mix - RUG group;;;ACTIVE;2.27;2.63 +55072-3;Insurance case mix - RUG version code;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Insurance case mix - RUG version code;;;ACTIVE;2.27;2.63 +55073-1;Tissue type;Type;Pt;Pressure injury.Largest at most advanced stage;Nom;CMS Assessment;SURVEY.CMS;4;Tissue type Pressure injury.Largest at most advanced stage [CMS Assessment];;;ACTIVE;2.27;2.63 +55074-9;Participation in assessment;Find;Pt;^Family or significant other;Ord;CMS Assessment;SURVEY.CMS;4;Participation in assessment Family or significant other [CMS Assessment];;;ACTIVE;2.27;2.67 +55075-6;Version code;ID;Pt;Specifications;Nom;;SURVEY.MDS;4;Version code Specifications;;;ACTIVE;2.27;2.27 +55076-4;Production or test indicator;Type;Pt;Submission;Nom;MDSv3;SURVEY.MDS;4;Production or test indicator Submission [MDSv3];;;ACTIVE;2.27;2.44 +55077-2;State assigned facility submission ID;ID;Pt;Facility;Nom;;SURVEY.MDS;4;State assigned facility submission ID;;;ACTIVE;2.27;2.63 +55078-0;Federal employer tax ID;ID;Pt;Software vendor;Nom;;SURVEY.MDS;4;Federal employer tax ID Software vendor;;;ACTIVE;2.27;2.27 +5507-9;CD58;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD58 cells/100 cells in Blood;Deprecated CD58 WBC-aCnc;;DEPRECATED;1.0;2.69 +55079-8;Vendor company name;ID;Pt;Software;Nom;;SURVEY.MDS;4;Vendor company name Software;;;ACTIVE;2.27;2.27 +55080-6;Product name;ID;Pt;Software;Nom;;SURVEY.MDS;4;Product name Software;;;ACTIVE;2.27;2.27 +55081-4;Product version code;ID;Pt;Software;Nom;;SURVEY.MDS;4;Product version code Software;;;ACTIVE;2.27;2.27 +55082-2;Transaction code;Type;Pt;Transaction;Nom;MDSv3;SURVEY.MDS;4;Transaction code Transaction [MDSv3];;;ACTIVE;2.27;2.44 +55083-0;Item subset code;Type;Pt;^Patient;Nom;;SURVEY.MDS;4;Item subset code;;;ACTIVE;2.27;2.27 +55084-8;Other special treatments and programs in last 14D;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Other special treatments and programs in last 14 days;;;ACTIVE;2.27;2.68 +55085-5;Respiratory treatments in last 14D;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Respiratory treatments in last 14 days;;;ACTIVE;2.27;2.68 +55086-3;Cancer treatments in last 14D;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Cancer treatments in last 14 days;;;ACTIVE;2.27;2.68 +5508-7;CD59;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD59 cells/100 cells in Blood;Deprecated CD59 WBC-aCnc;;DEPRECATED;1.0;2.69 +55087-1;Number of pressure injuries noted on prior assessment that have completely closed;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Deprecated Number of pressure injuries noted on prior assessment that have completely closed;;;DEPRECATED;2.27;2.70 +55088-9;Pressure injuries - unstageable with suspected deep tissue injury in evolution;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Pressure injuries - unstageable with suspected deep tissue injury in evolution;;;ACTIVE;2.27;2.68 +55089-7;Pressure injuries - unstageable due to coverage of wound bed by slough &or eschar;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Pressure injuries - unstageable due to coverage of wound bed by slough/eschar;;;ACTIVE;2.27;2.68 +55090-5;Cells.CD3-CD56+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3-CD56+ cells/100 cells in Blood;CD3-CD56+ Cells NFr Bld;;ACTIVE;2.27;2.73 +55091-3;Darunavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Darunavir [Susceptibility] by Genotype method;Darunavir Islt Genotyp;;ACTIVE;2.27;2.73 +55092-1;PDGFRA gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;PDGFRA gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;PDGFRA gene Rear Bld/T Ql;;ACTIVE;2.27;2.73 +55093-9;Vendor email address;EmailAddr;Pt;Software;Nom;;SURVEY.MDS;4;Vendor email address Software;;;ACTIVE;2.27;2.27 +55094-7;Medications;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Medications [MDSv3];;;ACTIVE;2.27;2.68 +5509-5;CD6;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD6 cells/100 cells in Blood;Deprecated CD6 WBC-aCnc;;DEPRECATED;1.0;2.69 +55095-4;Adenovirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Adenovirus [Presence] in Specimen by Organism specific culture;HAdV Spec Ql Cult;;ACTIVE;2.27;2.73 +55096-2;Nocardia sp identified;Prid;Pt;Isolate;Nom;;MICRO;1;Nocardia sp identified in Isolate;Nocardia Islt;;ACTIVE;2.27;2.73 +55097-0;Parainfluenza virus 1;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Parainfluenza virus 1 [Presence] in Specimen by Organism specific culture;HPIV1 Spec Ql Cult;;ACTIVE;2.27;2.73 +55098-8;Parainfluenza virus 2;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Parainfluenza virus 2 [Presence] in Specimen by Organism specific culture;HPIV2 Spec Ql Cult;;ACTIVE;2.27;2.73 +55099-6;Parainfluenza virus 3;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Parainfluenza virus 3 [Presence] in Specimen by Organism specific culture;HPIV3 Spec Ql Cult;;ACTIVE;2.27;2.73 +55100-2;Respiratory syncytial virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Respiratory syncytial virus [Presence] in Specimen by Organism specific culture;RSV Spec Ql Cult;;ACTIVE;2.27;2.73 +55101-0;Respiratory pathogens panel;-;Pt;XXX;-;Organism specific culture;PANEL.MICRO;1;Respiratory pathogens panel - Specimen by Organism specific culture;Respiratory path Pnl Spec Cult;;ACTIVE;2.27;2.73 +55102-8;Surgical operation note disposition;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note disposition Narrative;Operative note disposition;;ACTIVE;2.27;2.63 +5510-3;CD61;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD61 cells/100 cells in Blood;Deprecated CD61 WBC-aCnc;;DEPRECATED;1.0;2.69 +55103-6;Surgical operation note estimated blood loss;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note estimated blood loss Narrative;Operative note estimated blood loss;;ACTIVE;2.27;2.63 +55104-4;Surgical operation note planned procedure;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note planned procedure Narrative;Operative note planned procedure;;ACTIVE;2.27;2.63 +55105-1;OTC - Purpose section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Purpose section;FDA label OTC - Purpose;;ACTIVE;2.27;2.34 +55106-9;OTC - Active ingredient section;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC - Active ingredient section;FDA label OTC - Active ingredient;;ACTIVE;2.27;2.34 +55107-7;Addendum;Find;Pt;^Patient;Doc;;DOC.MISC;2;Addendum Document;Addendum Doc;;ACTIVE;2.27;2.73 +55108-5;Clinical presentation;Find;Pt;^Patient;Doc;;DOC.MISC;2;Clinical presentation Document;Clinical presentation Doc;;ACTIVE;2.27;2.73 +55109-3;Complications;Find;Pt;^Patient;Doc;;DOC.MISC;2;Complications Document;Complications Doc;;ACTIVE;2.27;2.73 +55110-1;Conclusions;Imp;Pt;^Patient;Doc;;DOC.MISC;2;Conclusions [Interpretation] Document;Conclusions Imp Doc;;ACTIVE;2.27;2.73 +5511-1;CD62E;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD62E cells/100 cells in Blood;Deprecated CD61E WBC-aCnc;;DEPRECATED;1.0;2.69 +55111-9;Current imaging procedure descriptions;Desc;Pt;^Patient;Doc;;DOC.MISC;2;Current imaging procedure descriptions Document;Current imaging proc desc Doc;;ACTIVE;2.27;2.73 +55112-7;Document summary;Find;Pt;^Patient;Doc;;DOC.MISC;2;Document summary;Document summary;;ACTIVE;2.27;2.73 +55113-5;Key images;Find;Pt;^Patient;Doc;Radiology;DOC.MISC;2;Key images Document Radiology;Key images Doc Radiology;;ACTIVE;2.27;2.73 +55114-3;Prior imaging procedure descriptions;Desc;Pt;^Patient;Doc;;DOC.MISC;2;Prior imaging procedure descriptions Document;Prior imaging procedure descriptions Doc;;ACTIVE;2.27;2.73 +55115-0;Requested imaging studies information;Find;Pt;^Patient;Doc;;DOC.MISC;2;Requested imaging studies information Document;Requested imaging studies info Doc;;ACTIVE;2.27;2.73 +55116-8;CEH volatile organic compounds panel;MCnc;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Centers for Environmental Health volatile organic compounds panel [Mass/volume] - Serum or Plasma;CEH volatile organic cmpd Pnl SerPl-mCnc;;ACTIVE;2.27;2.42 +55117-6;CEH trace metals screen panel;MCnc;Pt;Urine;-;;PANEL.DRUG/TOX;1;Centers for Environmental Health trace metals screen panel [Mass/volume] - Urine;CEH trace metals scn Pnl Ur-mCnc;;ACTIVE;2.27;2.42 +55118-4;CEH trace metals panel;MCnc;Pt;Urine;-;;PANEL.DRUG/TOX;1;Centers for Environmental Health trace metals panel [Mass/volume] - Urine;CEH trace metals Pnl Ur-mCnc;;ACTIVE;2.27;2.42 +55119-2;CEH nitrogen mustard metabolite panel;MCnc;Pt;Urine;-;;PANEL.DRUG/TOX;1;Centers for Environmental Health nitrogen mustard metabolite panel [Mass/volume] - Urine;CEH N2 mustard metab Pnl Ur-mCnc;;ACTIVE;2.27;2.42 +551-2;Brucella sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Brucella sp identified in Blood by Organism specific culture;Brucella Bld Cult;;ACTIVE;1.0;1.0ma +55120-0;CEH metabolic toxin panel;MCnc;Pt;Urine;-;;PANEL.DRUG/TOX;1;Centers for Environmental Health metabolic toxin panel [Mass/volume] - Urine;CEH met toxin Pnl Ur-mCnc;;ACTIVE;2.27;2.42 +55121-8;Multiple sclerosis panel;-;Pt;Ser+CSF;-;;PANEL.CHEM;1;Multiple sclerosis panel - Serum and CSF;MS Pnl Ser+CSF;;ACTIVE;2.27;2.73 +55122-6;Surgical operation note implants;Find;Pt;^Patient;Nar;;DOC.MISC;2;Surgical operation note implants Narrative;Operative note implants;;ACTIVE;2.27;2.73 +55123-4;Resident believes he or she is capable of increased independence in at least some ADLs;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Resident believes he or she is capable of increased independence in at least some ADLs [CMS Assessment];;;ACTIVE;2.27;2.63 +55124-2;Number of pressure injuries - stage 2;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - stage 2 [CMS Assessment];;;ACTIVE;2.27;2.63 +55125-9;Number of pressure injuries - stage 3;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - stage 3 [CMS Assessment];;;ACTIVE;2.27;2.63 +55126-7;Number of pressure injuries - stage 4;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries - stage 4 [CMS Assessment];;;ACTIVE;2.27;2.63 +55127-5;Number of unhealed stage 2 ulcers known to be present for more than 1 month;Num;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Deprecated Number of unhealed stage 2 ulcers known to be present for more than 1 month MDSv3;;;DEPRECATED;2.27;2.36 +55128-3;Discharge disposition;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Discharge disposition;;;ACTIVE;2.27;2.66 +5512-9;CD62L;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD62L cells/100 cells in Blood;Deprecated CD62L WBC-aCnc;;DEPRECATED;1.0;2.69 +55129-1;Physical restraints used in bed;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Physical restraints used in bed;;;ACTIVE;2.27;2.68 +55130-9;Physical restraints used in chair or out of bed;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Physical restraints used in chair or out of bed;;;ACTIVE;2.27;2.68 +55131-7;Number of D of rehabilitative or restorative techniques;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Number of days of rehabilitative or restorative techniques;;;ACTIVE;2.27;2.68 +55132-5;Number of D of rehabilitative or restorative training and skill practice;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Number of days of rehabilitative or restorative training and skill practice;;;ACTIVE;2.27;2.68 +55133-3;Influenza virus A hemagglutinin cDNA;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Influenza virus A hemagglutinin cDNA [Identifier] in Isolate by NAA with probe detection;FLUAV HA cDNA Islt NAA+probe;;ACTIVE;2.27;2.63 +55134-1;Influenza virus A neuraminidase RNA;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Influenza virus A neuraminidase RNA [Identifier] in Isolate by NAA with probe detection;FLUAV NA RNA Islt NAA+probe;;DISCOURAGED;2.27;2.63 +55135-8;BCR-ABL1 kinase domain targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BCR-ABL1 kinase domain mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BCR/ABL1 kinase domain Mut Anl Bld/T;;ACTIVE;2.27;2.73 +55136-6;Penicillin.parenteral;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Penicillin Parenteral [Susceptibility] by Minimum inhibitory concentration (MIC);Penicillin Parenteral Islt MIC;;ACTIVE;2.27;2.73 +5513-7;CD62P;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD62P cells/100 cells in Blood;Deprecated CD62P WBC-aCnc;;DEPRECATED;1.0;2.69 +55137-4;Penicillin.parenteral;Susc;Pt;Isolate.meningitis;OrdQn;MIC;ABXBACT;1;Penicillin Parenteral [Susceptibility] for meningitis by Minimum inhibitory concentration (MIC);Penicillin Parenteral Islt.mening MIC;;ACTIVE;2.27;2.73 +55138-2;Cortisol^post dose dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --post dose dexamethasone PO overnight;Cortis p Dex overnight SerPl-mCnc;;ACTIVE;2.27;2.40 +55139-0;SCN5A gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SCN5A gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SCN5A gene Mut Anl Bld/T;;ACTIVE;2.27;2.66 +55140-8;Vaccine Adverse Event Reporting System panel;-;Pt;^Patient;-;;PANEL.VACCIN;2;Vaccine Adverse Event Reporting System (VAERS) panel;VAERS Pnl;;ACTIVE;2.27;2.27 +55141-6;Fc epsilon RI + RII Ab;ACnc;Pt;Ser;Qn;;SERO;1;Fc epsilon RI + RII Ab [Units/volume] in Serum;Fc epsilon RI + RII Ab Ser-aCnc;;ACTIVE;2.27;2.73 +55142-4;Cache valley virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cache valley virus RNA [Presence] in Specimen by NAA with probe detection;CVV RNA Spec Ql NAA+probe;;ACTIVE;2.27;2.69 +55143-2;California serogroup virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;California serogroup RNA [Presence] in Specimen by NAA with probe detection;CSGV RNA Spec Ql NAA+probe;;ACTIVE;2.27;2.69 +55144-0;Powassan virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Powassan virus RNA [Presence] in Specimen by NAA with probe detection;POWV RNA Spec Ql NAA+probe;;ACTIVE;2.27;2.69 +5514-5;CD63;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD63 cells/100 cells in Blood;Deprecated CD63 WBC-aCnc;;DEPRECATED;1.0;2.69 +55145-7;Saint Louis encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Saint Louis encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;SLEV RNA Spec Ql NAA+probe;;ACTIVE;2.27;2.69 +55146-5;Familial long QTS syndrome gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Familial long QTS syndrome gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;Familial LQTS Mut Anl Bld/T;;ACTIVE;2.27;2.66 +55147-3;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)p210/control Bld/T;;ACTIVE;2.27;2.73 +55148-1;BCR-ABL1 b2a2+b3a2 fusion transcript;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;Deprecated fusion transcript [Presence] in Blood or Tissue by Molecular genetics method;Deprecated Bld/T Ql;;DEPRECATED;2.27;2.40 +55149-9;BCR-ABL1 e1a2 fusion protein;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;BCR-ABL1 e1a2 fusion protein [Presence] in Blood or Tissue by Molecular genetics method;e1a2 Bld/T Ql;;ACTIVE;2.27;2.73 +55150-7;Anaplasma phagocytophilum Ab.IgG & IgM panel;-;Pt;Ser;Ord;;PANEL.MICRO;1;Anaplasma phagocytophilum IgG and IgM panel - Serum Qualitative;A phagocytoph IgG+IgM Pnl Ser;;ACTIVE;2.27;2.73 +55151-5;Aldosterone & renin activity panel;-;Pt;Plas;Qn;;PANEL.CHEM;1;Aldosterone and renin activity panel - Plasma;Aldosterone + RA + ARR Pnl Plas;;ACTIVE;2.27;2.73 +5515-2;CD64;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD64 cells/100 cells in Blood;Deprecated CD64 WBC-aCnc;;DEPRECATED;1.0;2.69 +55152-3;Amiodarone & Desethylamiodarone panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Amiodarone and Desethylamiodarone panel [Mass/volume] - Serum or Plasma;Amiodarone + Deseth Pnl SerPl-mCnc;;ACTIVE;2.27;2.73 +55153-1;Biotinidase panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Biotinidase panel - Serum or Plasma;Biotinidase Pnl SerPl;;ACTIVE;2.27;2.42 +55154-9;Ethambutol+rifAMPin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol+rifAMPin [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol+rifAMPin Islt SlowMyco;;ACTIVE;2.27;2.27 +55155-6;Flunitrazepam & 7-Aminoflunitrazepam panel;MCnc;Pt;Urine;Qn;;PANEL.DRUG/TOX;1;Flunitrazepam and 7-Aminoflunitrazepam panel [Mass/volume] - Urine;Flunitrazepam+7Amino Pnl Ur-mCnc;;ACTIVE;2.27;2.48 +55156-4;Minocycline;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Minocycline [Susceptibility] by Method for Slow-growing mycobacteria;Minocycline Islt SlowMyco;;ACTIVE;2.27;2.27 +55157-2;Risperidone & 9-Hydroxyrisperidone panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;risperiDONE and 9-Hydroxyrisperidone panel - Serum or Plasma;risperiDONE+9OH-Ris Pnl SerPl;;ACTIVE;2.27;2.73 +55158-0;Tigecycline;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Tigecycline [Susceptibility] by Method for Slow-growing mycobacteria;Tigecycline Islt SlowMyco;;ACTIVE;2.27;2.27 +55159-8;Ursodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ursodeoxycholate [Moles/volume] in Serum or Plasma;Ursodeoxycholate SerPl-sCnc;;ACTIVE;2.27;2.73 +5516-0;CD66a;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD66a cells/100 cells in Blood;Deprecated CD66a WBC-aCnc;;DEPRECATED;1.0;2.69 +55160-6;Adenovirus Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Adenovirus IgG and IgM panel - Serum;HAdV IgG+IgM Pnl Ser;;ACTIVE;2.27;2.70 +55161-4;Bordetella pertussis Ab.IgA & IgG panel;-;Pt;Ser;Qn;IA;PANEL.MICRO;1;Bordetella pertussis IgA and IgG panel - Serum by Immunoassay;B pert IgA+IgG Pnl Ser IA;;ACTIVE;2.27;2.73 +55162-2;HTLV I+II Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;HTLV I+II Ab panel - Serum;HTLV I+II Ab Pnl Ser;;ACTIVE;2.27;2.70 +55163-0;Streptococcus pyogenes enzyme Ab panel;-;Pt;Ser;Ord;;PANEL.MICRO;1;Streptococcus pyogenes enzyme Ab panel - Serum Qualitative;S pyog enzyme Ab Pnl Ser;;ACTIVE;2.27;2.42 +55164-8;Paroxysmal nocturnal panel;-;Pt;Bld;Qn;;PANEL.CELLMARK;1;Paroxysmal nocturnal panel - Blood;Paroxysmal nocturnal Pnl Bld;;ACTIVE;2.27;2.73 +55165-5;Echinococcus sp Ab.IgG4;PrThr;Pt;Ser;Ord;;MICRO;1;Echinococcus sp IgG4 Ab [Presence] in Serum;Echinococcus IgG4 Ser Ql;;ACTIVE;2.27;2.70 +55166-3;Hepatitis G virus E2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis G virus E2 Ab [Presence] in Serum;HGV E2 Ab Ser Ql;;ACTIVE;2.27;2.70 +55167-1;Mycoplasma sp Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Mycoplasma sp Ab [Presence] in Cerebral spinal fluid;Mycoplasma Ab CSF Ql;;ACTIVE;2.27;2.70 +55168-9;Data Elements for Emergency Department Systems (DEEDS) Release 1.1;-;Pt;^Patient;-;;PANEL.ED;2;Data Elements for Emergency Department Systems (DEEDS) Release 1.1;DEEDS 1.1;;ACTIVE;2.27;2.73 +55169-7;Data Elements for Emergency Department Systems (DEEDS) Release 1.0;-;Pt;^Patient;-;;PANEL.ED;2;Data Elements for Emergency Department Systems (DEEDS) Release 1.0;DEEDS 1.0;;ACTIVE;2.27;2.27 +55170-5;Cytoplasmic Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Cytoplasmic Ab [Titer] in Serum by Immunofluorescence;Cytoplasmic Ab Titr Ser IF;;ACTIVE;2.27;2.73 +55171-3;Cytoplasmic Ab pattern;Imp;Pt;Ser;Nom;IF;SERO;1;Cytoplasmic Ab pattern [Interpretation] in Serum by Immunofluorescence;Cytoplasmic Ab pattern Ser IF-Imp;;ACTIVE;2.27;2.73 +55172-1;ED procedures and results;-;Pt;^Patient;Set;DEEDS;PANEL.ED;2;ED procedures and results Set DEEDS;ED procedures & results DEEDS;;ACTIVE;2.27;2.27 +55173-9;ED disposition and diagnosis data;-;Pt;^Patient;Set;DEEDS;PANEL.ED;2;ED disposition and diagnosis data Set DEEDS;ED dispo & Dx data DEEDS;;ACTIVE;2.27;2.27 +55174-7;Patient identification data;-;Pt;^Patient;Set;DEEDS;PANEL.ED;2;Patient identification data Set DEEDS;Patient ID data DEEDS;;ACTIVE;2.27;2.73 +55175-4;Facility and Practitioner identification data;-;Pt;^Patient;Set;DEEDS;PANEL.ED;2;Facility and Practitioner identification data Set DEEDS;Facility & Practitioner ID data DEEDS;;ACTIVE;2.27;2.27 +55176-2;ED arrival and first assessment data;-;Enctr^frst;^Patient;Set;DEEDS;PANEL.ED;2;ED arrival and first assessment data at First encounter Set DEEDS;ED arrival and 1st assessment data DEEDS;;ACTIVE;2.27;2.38 +55177-0;ED History and Physical Examination Data;-;Pt;^Patient;Set;DEEDS;PANEL.ED;2;ED History and Physical Examination Data Set DEEDS;ED H&P Exam Data DEEDS;;ACTIVE;2.27;2.27 +5517-8;CD66b;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD66b cells/100 cells in Blood;Deprecated CD66b WBC-aCnc;;DEPRECATED;1.0;2.69 +55178-8;Calcium phosphate crystals;PrThr;Pt;XXX;Ord;Microscopy.light;UA;1;Calcium phosphate crystals [Presence] in Specimen by Light microscopy;Ca Phos Cry Spec Ql Micro;;ACTIVE;2.27;2.69 +55179-6;Sodium urate crystals;PrThr;Pt;XXX;Ord;Microscopy.light;UA;1;Sodium urate crystals [Presence] in Specimen by Light microscopy;Na Urate Cry Spec Ql Micro;;ACTIVE;2.27;2.73 +55180-4;Human epididymis protein 4;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Human epididymis protein 4 [Moles/volume] in Serum or Plasma;HE4 SerPl-sCnc;;ACTIVE;2.27;2.73 +55181-2;Quality Reporting Document Architecture panel;-;Pt;XXX;-;;PANEL.SURVEY.QRDA;4;Quality Reporting Document Architecture panel;;;ACTIVE;2.27;2.27 +55182-0;Quality Reporting Document Architecture incidence report;Find;Pt;^Patient;Doc;;SURVEY.QRDA;4;Quality Reporting Document Architecture incidence report Document;;;ACTIVE;2.27;2.63 +55183-8;Quality Reporting Document Architecture patient list report;Find;Pt;{Setting}^Population;Doc;;SURVEY.QRDA;4;Quality Reporting Document Architecture patient list report Population Document;;;ACTIVE;2.27;2.48 +55184-6;Quality Reporting Document Architecture calculated summary report;Find;Pt;{Setting}^Population;Doc;;SURVEY.QRDA;4;Quality Reporting Document Architecture calculated summary report Population Document;;;ACTIVE;2.27;2.48 +55185-3;Measure set;Find;Pt;XXX;Doc;;SURVEY.QRDA;4;Measure set Document;;;ACTIVE;2.27;2.63 +5518-6;CD66c;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD66c cells/100 cells in Blood;Deprecated CD66c WBC-aCnc;;DEPRECATED;1.0;2.69 +55186-1;Measure;Find;Pt;XXX;Doc;;SURVEY.QRDA;4;Measure Document;;;ACTIVE;2.27;2.63 +55187-9;Reporting parameters;Find;Pt;XXX;Doc;;SURVEY.QRDA;4;Reporting parameters Document;;;ACTIVE;2.27;2.63 +55188-7;Patient data;Find;Pt;XXX;Doc;;SURVEY.QRDA;4;Patient data Document;;;ACTIVE;2.27;2.63 +55189-5;Cefotaxime;Susc;Pt;Isolate.meningitis;OrdQn;Agar diffusion;ABXBACT;1;Cefotaxime [Susceptibility] for meningitis by Disk diffusion (KB);Cefotaxime Islt.mening KB;;ACTIVE;2.27;2.58 +55190-3;cefTRIAXone;Susc;Pt;Isolate.meningitis;OrdQn;Agar diffusion;ABXBACT;1;cefTRIAXone [Susceptibility] for meningitis by Disk diffusion (KB);cefTRIAXone Islt.mening KB;;ACTIVE;2.27;2.58 +55192-9;Chromosome analysis.interphase;Imp;Pt;Amnio fld;Nar;FISH;MOLPATH;1;Chromosome analysis.interphase [Interpretation] in Amniotic fluid by FISH Narrative;Chrom analy interphase Amn FISH-Imp;;ACTIVE;2.27;2.73 +55193-7;Chromosome analysis.interphase;Imp;Pt;CVS;Nar;FISH;MOLPATH;1;Chromosome analysis.interphase [Interpretation] in Chorionic villus sample by FISH Narrative;Chrom analy interphase CVS FISH-Imp;;ACTIVE;2.27;2.73 +5519-4;CD66d;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD66d cells/100 cells in Blood;Deprecated CD66d WBC-aCnc;;DEPRECATED;1.0;2.69 +55194-5;Ciprofloxacin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ciprofloxacin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ciprofloxacin 1 ug/mL Islt SlowMyco;;ACTIVE;2.27;2.29 +55195-2;DHCR7 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;DHCR7 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;DHCR7 gene Mut Anl Bld/T;;ACTIVE;2.27;2.73 +55196-0;Terconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Terconazole [Susceptibility];Terconazole Susc Islt;;ACTIVE;2.27;2.27 +55197-8;Transfusion status;Find;Pt;^Patient;Ord;;BLDBK;1;Transfusion status Qualitative;Transfusion status Patient Ql;;ACTIVE;2.27;2.73 +55198-6;Zygosity;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;Zygosity [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Zygosity Bld/T;;ACTIVE;2.27;2.70 +55199-4;Cells karyotyped.total;Num;Pt;Bld/Tiss;Qn;;MOLPATH;1;Cells karyotyped.total [#] in Blood or Tissue;Cells karyotyped.total Bld/T;;ACTIVE;2.27;2.73 +552-0;Brucella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Brucella sp identified in Specimen by Organism specific culture;Brucella Spec Cult;;ACTIVE;1.0;2.73 +55200-0;Carnitine;SCnc;Pt;Body fld;Qn;;CHEM;1;Carnitine [Moles/volume] in Body fluid;Carnitine Fld-sCnc;;ACTIVE;2.27;2.70 +55201-8;KIT gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;KIT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;KIT gene Mut Anl Bld/T;;ACTIVE;2.27;2.73 +5520-2;CD66e;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD66e cells/100 cells in Blood;Deprecated CD66e WBC-aCnc;;DEPRECATED;1.0;2.69 +55202-6;Coagulation surface induced.factor substitution^5M post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --5 minutes post incubation after addition of normal plasma;aPTT 5M p NP PPP;;ACTIVE;2.27;2.52 +55203-4;Coagulation surface induced.factor substitution^5M post incubation after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --5 minutes post incubation after addition of normal plasma;aPTT 5M p NP Cont PPP;;ACTIVE;2.27;2.52 +55204-2;Macroamylase;PrThr;Pt;Plr fld;Ord;;CHEM;1;Macroamylase [Presence] in Pleural fluid;Macroamylase Plr Ql;;ACTIVE;2.27;2.56 +55205-9;Vasoactive intestinal peptide;MCnc;Pt;CSF;Qn;;CHEM;1;Vasoactive intestinal peptide [Mass/volume] in Cerebral spinal fluid;VIP CSF-mCnc;;ACTIVE;2.27;2.42 +55206-7;Platelet mass;VFr;Pt;Bld;Qn;;HEM/BC;1;Deprecated Platelet mass [Volume Fraction] in Blood;Deprecated Platelet mass VFr Bld;;DEPRECATED;2.27;2.70 +55207-5;Genetic analysis discrete result panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;Genetic analysis discrete result panel;Genetic analysis discrete result Pnl;;ACTIVE;2.27;2.56 +55208-3;DNA analysis discrete sequence variation panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;DNA analysis discrete sequence variation panel;DNA analysis discrete seq var Pnl;;ACTIVE;2.27;2.56 +55209-1;Date and time of most recent arrival in U.S.;TmStp;Pt;^Patient;Qn;;PUBLICHEALTH;2;Date and time of most recent arrival in U.S.;Date and time of most recent arrival US;;ACTIVE;2.27;2.58 +5521-0;CD68;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD68 cells/100 cells in Blood;Deprecated CD68 WBC-aCnc;;DEPRECATED;1.0;2.69 +55210-9;Geotemporal history;Find;Pt;^Patient;Nom;;PUBLICHEALTH;2;Geotemporal history;Geotemporal hx;;ACTIVE;2.27;2.29 +55211-7;Shared razor, toothbrushes or nail care items;Find;Pt;^Patient;Nom;;PUBLICHEALTH;2;Shared razor, toothbrushes or nail care items;Shared razor, toothbrushes or nail items;;ACTIVE;2.27;2.38 +55212-5;Occupation related direct blood or body fluid exposure frequency;Find;Pt;^Patient;Nom;;PUBLICHEALTH;2;Occupation related direct blood or body fluid exposure frequency;Occ related direct Bdy fl expos freq;;ACTIVE;2.27;2.38 +55213-3;Number of male sexual partners in 6Mo before symptom onset;NRat;Pt;^Patient;Qn;;PUBLICHEALTH;2;Number of male sexual partners in 6 months before symptom onset;# M Sex Prtnrs 6M Bfr Symp nRate;;ACTIVE;2.27;2.48 +55214-1;Number of female sexual partners in 6Mo before symptom onset;NRat;Pt;^Patient;Qn;;PUBLICHEALTH;2;Number of female sexual partners in 6 months before symptom onset;# F Sex Prtnrs 6M Bfr Symp nRate;;ACTIVE;2.27;2.48 +55215-8;Total number of lifetime sexual partners;Num;Pt;^Patient;Qn;;PUBLICHEALTH;2;Total number of lifetime sexual partners;Total # of lifetime sex partners;;ACTIVE;2.27;2.73 +55216-6;Physical assault on exposed person involving blood or semen;Find;Pt;^Patient;Nom;;PUBLICHEALTH;2;Physical assault on exposed person involving blood or semen;Assault involving Bld or semen;;ACTIVE;2.27;2.38 +55217-4;Stick or puncture with a needle or other object contaminated with blood;Find;Pt;^Patient;Nom;;PUBLICHEALTH;2;Stick or puncture with a needle or other object contaminated with blood;Stick/puncture w Bld contam object;;ACTIVE;2.27;2.73 +55218-2;Date of actual exposure to blood &or body fluid;Date;Pt;^Patient;Qn;;PUBLICHEALTH;2;Date of actual exposure to blood/body fluid;Date exposure to Bdy fl;;ACTIVE;2.27;2.50 +55219-0;Antioxidants;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Antioxidants [Moles/volume] in Serum or Plasma;Antioxidants SerPl-sCnc;;ACTIVE;2.27;2.34 +55220-8;Asialoglycoprotein receptor Ab;ACnc;Pt;Ser;Qn;;SERO;1;Asialoglycoprotein receptor Ab [Units/volume] in Serum;ASGPR Ab Ser-aCnc;;ACTIVE;2.27;2.69 +55221-6;Carbohydrates;PrThr;Pt;Stool;Ord;;CHEM;1;Carbohydrates [Presence] in Stool;Carbohydrates Stl Ql;;ACTIVE;2.27;2.56 +55222-4;Microscopic observation;Prid;Pt;Asp;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Aspirate by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Aspirate;;ACTIVE;2.27;2.27 +55223-2;Mycobacterium tuberculosis A60 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycobacterium tuberculosis A60 IgM Ab [Presence] in Serum by Immunoassay;M tb A60 IgM Ser Ql IA;;ACTIVE;2.27;2.73 +55224-0;Mycobacterium tuberculosis A60 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycobacterium tuberculosis A60 Ab [Presence] in Serum by Immunoassay;M tb A60 Ab Ser Ql IA;;ACTIVE;2.27;2.73 +55225-7;Aucoumea klaineana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Okoume IgE Ab [Units/volume] in Serum;Okoume IgE Qn;;ACTIVE;2.27;2.56 +55226-5;Pancreatic polypeptide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Moles/volume] in Serum or Plasma;Panc Polypept SerPl-sCnc;;ACTIVE;2.27;2.70 +55227-3;Entandrophragma cylindricum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sapeli IgE Ab [Units/volume] in Serum;Sapeli IgE Qn;;ACTIVE;2.27;2.42 +5522-8;CD69;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD69 cells/100 cells in Blood;Deprecated CD69 WBC-aCnc;;DEPRECATED;1.0;2.69 +55228-1;Cytogenetics study;Find;Pt;^Patient;Doc;Cytogenetics;DOC.MISC;2;Cytogenetics study;Cytogenetics study;;ACTIVE;2.27;2.73 +55229-9;Immune stain study;Find;Pt;Tiss;Doc;Immune stain;DOC.MISC;2;Immune stain study;Immune stain study;;ACTIVE;2.27;2.72 +55230-7;Immunophenotyping study;Find;Pt;Bld/Tiss;Doc;Immunophenotyping;DOC.MISC;2;Immunophenotyping study;Immunophenotyping study;;ACTIVE;2.27;2.73 +55231-5;Electrolytes panel;-;Pt;Bld;Qn;;PANEL.CHEM;1;Electrolytes panel - Blood;Lytes Pnl Bld;;ACTIVE;2.27;2.73 +55232-3;Genetic analysis summary panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;Genetic analysis summary panel;Genetic analysis summary Pnl;;ACTIVE;2.27;2.56 +55233-1;Genetic analysis master panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.GENETICS;1;Genetic analysis master panel;Genetic analysis master Pnl;;ACTIVE;2.27;2.56 +55234-9;Alpha thalassemia gene panel;-;Pt;Bld;-;Molgen;PANEL.MOLPATH;1;Alpha thalassemia gene panel - Blood by Molecular genetics method;Alpha thalassemia gene Pnl Bld;;ACTIVE;2.27;2.73 +55235-6;Abnormal hemoglobin gene panel;-;Pt;Bld;-;Molgen;PANEL.MOLPATH;1;Abnormal hemoglobin gene panel - Blood by Molecular genetics method;Abnormal hemoglobin Pnl Bld;;ACTIVE;2.27;2.42 +5523-6;CD7;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD7 cells/100 cells in Blood;Deprecated CD7 WBC-aCnc;;DEPRECATED;1.0;2.69 +55236-4;HBA2 gene alpha 4.2kb deletion;Arb;Pt;Bld;Ord;Molgen;MOLPATH.DEL;1;HBA2 gene alpha 4.2kb deletion [Presence] in Blood by Molecular genetics method;HBA2 alpha 4.2kb Del Bld Ql;;ACTIVE;2.27;2.58 +55237-2;HBA2 gene.c.427T>C;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBA2 gene c.427T>C [Presence] in Blood by Molecular genetics method;HBA2 c.427T>C Bld Ql;;ACTIVE;2.27;2.66 +55238-0;HBA2 gene.c.429A>T;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBA2 gene c.429A>T [Presence] in Blood by Molecular genetics method;HBA2 c.429A>T Bld Ql;;ACTIVE;2.27;2.56 +55239-8;HBB gene.c.441_442insAC;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBB gene c.441_442insAC [Presence] in Blood by Molecular genetics method;HBB c.441_442insAC Bld Ql;;ACTIVE;2.27;2.56 +55240-6;HBB gene.c.251G>A;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBB gene c.251G>A [Presence] in Blood by Molecular genetics method;HBB c.251G>A Bld Ql;;ACTIVE;2.27;2.56 +55241-4;HBB gene.c.19G>A;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBB gene c.19G>A [Presence] in Blood by Molecular genetics method;HBB c.19G>A Bld Ql;;ACTIVE;2.27;2.56 +55242-2;HBB gene.c.20A>T;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBB gene c.20A>T [Presence] in Blood by Molecular genetics method;HBB c.20A>T Bld Ql;;ACTIVE;2.27;2.56 +55243-0;HBB gene.c.364G>C;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBB gene c.364G>C [Presence] in Blood by Molecular genetics method;HBB c.364G>C Bld Ql;;ACTIVE;2.27;2.56 +5524-4;CD7+CD3-;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD3-CD7+cells/100 cells in Blood;Deprecated CD7+CD3- WBC-aCnc;;DEPRECATED;1.0;2.69 +55244-8;HPFH-6 gene;Arb;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HPFH-6 gene [Presence] in Blood by Molecular genetics method;HPFH-6 gene Bld Ql;;ACTIVE;2.27;2.73 +55245-5;HBB gene.c.220G>A;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBB gene c.220G>A [Presence] in Blood by Molecular genetics method;HBB c.220G>A Bld Ql;;ACTIVE;2.27;2.56 +55246-3;HBA2 gene.c.84G>C;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBA2 gene c.84G>C [Presence] in Blood by Molecular genetics method;HBA2 c.84G>C Bld Ql;;ACTIVE;2.27;2.56 +55247-1;HBA1 gene.c.223G>C;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBA1 gene c.223G>C [Presence] in Blood by Molecular genetics method;HBA1 c.223G>C Bld Ql;;ACTIVE;2.27;2.56 +55248-9;HBB gene.c.79G>A;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBB gene c.79G>A [Presence] in Blood by Molecular genetics method;HBB c.79G>A Bld Ql;;ACTIVE;2.27;2.73 +55249-7;HBA2 gene SEA deletion;Arb;Pt;Bld;Ord;Molgen;MOLPATH.DEL;1;HBA2 gene SEA deletion [Presence] in Blood by Molecular genetics method;HBA2 SEA Del Bld Ql;;ACTIVE;2.27;2.27 +55250-5;HBA2 gene THAI+FIL+MED+alpha 20.5 deletion;Arb;Pt;Bld;Ord;Molgen;MOLPATH.DEL;1;HBA2 gene THAI+FIL+MED+alpha 20.5 deletion [Presence] in Blood by Molecular genetics method;HBA2 THAI+FIL+MED+alpha 20.5 Del Bld Ql;;ACTIVE;2.27;2.27 +5525-1;CD71;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD71 cells/100 cells in Blood;Deprecated CD71 WBC-aCnc;;DEPRECATED;1.0;2.69 +55251-3;HBA2 gene alpha 3.7kb deletion;Arb;Pt;Bld;Ord;Molgen;MOLPATH.DEL;1;HBA2 gene alpha 3.7kb deletion [Presence] in Blood by Molecular genetics method;HBA2 alpha 3.7kb Del Bld Ql;;ACTIVE;2.27;2.58 +55252-1;Methoxsalen 0.02 mg per mL given;Vol;Pt;^Patient;Qn;;DRUGDOSE;1;Methoxsalen 0.02 mg/mL given [Volume];Methoxsalen 0.02 mg/mL Gvn Vol;;ACTIVE;2.27;2.70 +55253-9;Heparin 10000 U per mL given;Vol;Pt;^Patient;Qn;;DRUGDOSE;1;Heparin 10000 U/mL given [Volume];Heparin 10000 u/mL Gvn Vol;;ACTIVE;2.27;2.70 +55254-7;Heparin 5000 U per mL given;Vol;Pt;^Patient;Qn;;DRUGDOSE;1;Heparin 5000 U/mL given [Volume];Heparin 5000 U/mL Gvn Vol;;ACTIVE;2.27;2.70 +55255-4;Pyridinoline panel;-;Pt;Urine;-;;PANEL.CHEM;1;Pyridinoline panel - Urine;PYD Pnl Ur;;DISCOURAGED;2.27;2.70 +55256-2;ED payment data;-;Pt;^Patient;Set;DEEDS;PANEL.ED;2;ED payment data Set DEEDS;ED payment data DEEDS;;ACTIVE;2.27;2.27 +55257-0;Date of last Clostridium tetani immunization;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of last Clostridium tetani immunization;Date last C tetani immunization;;ACTIVE;2.27;2.50 +55258-8;Problem alleviating factors;Find;Pt;^Patient;Nar;;H&P.HX;2;Problem alleviating factors Narrative;Problem alleviating factors;;ACTIVE;2.27;2.40 +55259-6;Time last ate solid food;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Time last ate solid food;Time last ate solid food;;ACTIVE;2.27;2.27 +55260-4;Time last drank liquid;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Time last drank liquid;Time last drank liquid;;ACTIVE;2.27;2.27 +55261-2;Rabies virus immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Rabies virus immunization status;RABV immunization status;;ACTIVE;2.27;2.27 +55262-0;Influenza virus immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Influenza virus immunization status;FLUV immunization status;;ACTIVE;2.27;2.27 +55263-8;Bordetella pertussis immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Bordetella pertussis immunization status;B pert immunization status;;ACTIVE;2.27;2.27 +55264-6;Hepatitis A virus immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Hepatitis A virus immunization status;HAV immunization status;;ACTIVE;2.27;2.27 +55265-3;Measles virus status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Measles virus status;MeV status;;ACTIVE;2.27;2.27 +55266-1;Haemophilus influenzae B immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Haemophilus influenzae B immunization status;HIB immunization status;;ACTIVE;2.27;2.27 +55267-9;Human papilloma virus immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Human papilloma virus immunization status;HPV immunization status;;ACTIVE;2.27;2.27 +55268-7;Rotavirus immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Rotavirus immunization status;RV immunization status;;ACTIVE;2.27;2.27 +5526-9;CD72;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD72 cells/100 cells in Blood;Deprecated CD72 WBC-aCnc;;DEPRECATED;1.0;2.69 +55269-5;Neisseria meningitidis immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Neisseria meningitidis immunization status;N men immunization status;;ACTIVE;2.27;2.27 +55270-3;Streptococcus pneumoniae polyvalent immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Streptococcus pneumoniae polyvalent immunization status;S pneum polyvalent immunization status;;ACTIVE;2.27;2.27 +55271-1;Streptococcus pneumoniae conjugated immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Streptococcus pneumoniae conjugated immunization status;S pneum conjugated immunization status;;ACTIVE;2.27;2.27 +55272-9;Corynebacterium diphtheriae immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Corynebacterium diphtheriae immunization status;C diphtheriae immunization status;;ACTIVE;2.27;2.27 +55273-7;Polio virus immunization status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Polio virus immunization status;PV immunization status;;ACTIVE;2.27;2.27 +55274-5;Varicella zoster virus status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Varicella zoster virus status;VZV status;;ACTIVE;2.27;2.73 +55275-2;Hepatitis B virus status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Hepatitis B virus status;HBV status;;ACTIVE;2.27;2.73 +55276-0;Hepatitis C virus status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Hepatitis C virus status;HCV status;;ACTIVE;2.27;2.73 +5527-7;CD73;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD73 cells/100 cells in Blood;Deprecated CD73 WBC-aCnc;;DEPRECATED;1.0;2.69 +55277-8;HIV status;Hx;Pt;^Patient;Nom;;H&P.HX;2;HIV status;HIV status;;ACTIVE;2.27;2.27 +55278-6;Rubella virus status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Rubella virus status;RUBV status;;ACTIVE;2.27;2.73 +55279-4;Cytomegalovirus status;Hx;Pt;^Patient;Nom;;H&P.HX;2;Cytomegalovirus status;CMV status;;ACTIVE;2.27;2.73 +55280-2;Military service;Find;Pt;^Patient;Nar;;H&P.HX;2;Military service Narrative;Military service;;ACTIVE;2.27;2.40 +55281-0;Fetuses;Num;Pt;^Patient;Qn;;H&P.HX;2;Number of fetuses;# Fetuses;;ACTIVE;2.27;2.73 +55282-8;Date symptoms of pregnancy first noted;Date;Pt;^Patient;Qn;;H&P.HX;2;Date symptoms of pregnancy first noted;Date symptoms of pregnancy 1st noted;;ACTIVE;2.27;2.50 +55283-6;Heart rate;NRat;Pt;^Fetus;Qn;;H&P.HX;2;Fetal Heart rate;Fet Heart rate;;ACTIVE;2.27;2.73 +55284-4;Blood pressure systolic & diastolic;-;Pt;Arterial system;-;;BP.ATOM;2;Blood pressure systolic and diastolic;BP sys/dias;;DISCOURAGED;2.27;2.44 +5528-5;CD74;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD74 cells/100 cells in Blood;Deprecated CD74 WBC-aCnc;;DEPRECATED;1.0;2.69 +55285-1;Glasgow coma score special circumstances;Type;Pt;^Patient;Nom;;FUNCTION;2;Glasgow coma score special circumstances;GCS special circumstances;;ACTIVE;2.27;2.27 +55286-9;Physical examination by body areas;-;Pt;^Patient;Set;;H&P.HX;2;Physical exam by body areas;Physical exam by body areas;;ACTIVE;2.27;2.29 +55287-7;Time of death;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Time of death;Time of death;;DISCOURAGED;2.27;2.56 +55288-5;ED medication data;-;Pt;^Patient;Set;DEEDS;PANEL.ED;2;ED medication data Set DEEDS;ED medication data DEEDS;;ACTIVE;2.27;2.27 +55289-3;Sulopenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sulopenem [Susceptibility];Sulopenem Susc Islt;;ACTIVE;2.27;2.27 +55290-1;Sulopenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sulopenem [Susceptibility] by Minimum inhibitory concentration (MIC);Sulopenem Islt MIC;;ACTIVE;2.27;2.27 +55291-9;Sulopenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Sulopenem [Susceptibility] by Disk diffusion (KB);Sulopenem Islt KB;;ACTIVE;2.27;2.27 +55292-7;Linopristin+Flopristin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Linopristin+Flopristin [Susceptibility];Linopristin+Flopristin Susc Islt;;ACTIVE;2.27;2.27 +5529-3;CD77;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD77 cells/100 cells in Blood;Deprecated CD77 WBC-aCnc;;DEPRECATED;1.0;2.69 +55293-5;Linopristin+Flopristin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Linopristin+Flopristin [Susceptibility] by Minimum inhibitory concentration (MIC);Linopristin+Flopristin Islt MIC;;ACTIVE;2.27;2.27 +55294-3;Linopristin+Flopristin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Linopristin+Flopristin [Susceptibility] by Disk diffusion (KB);Linopristin+Flopristin Islt KB;;ACTIVE;2.27;2.27 +55295-0;Protein fractions & Immunoglobulins panel;-;Pt;Ser;-;;PANEL.CHEM;1;Protein electrophoresis and Immunoglobulins panel - Serum;Prot Elph + Immunoglobulins Pnl Ser;;ACTIVE;2.27;2.42 +55296-8;CAV3 gene targeted mutation analysis;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CAV3 gene targeted mutation analysis [Presence] in Blood or Tissue by Molecular genetics method;CAV3 gene Mut Anl Bld/T Ql;;ACTIVE;2.27;2.63 +55297-6;FIP1L1+PDGFRA gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;Deprecated FIP1L1+PDGFRA gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;Deprecated FIP1L1+PDGFRA gene Rear Bld/T;;DEPRECATED;2.27;2.68 +55298-4;Human papilloma virus 6+11+42+43+44 DNA;PrThr;Pt;Urethra;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 6+11+42+43+44 DNA [Presence] in Urethra by Probe with signal amplification;HPV Low Risk DNA Urth Ql Probe+sig amp;;ACTIVE;2.27;2.63 +55299-2;Human papilloma virus 6+11+42+43+44 DNA;PrThr;Pt;XXX;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 6+11+42+43+44 DNA [Presence] in Specimen by Probe with signal amplification;HPV Low Risk DNA Spec Ql Probe+sig amp;;ACTIVE;2.27;2.73 +55300-8;JAK2 gene exon 12 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;JAK2 gene exon 12 targeted mutation analysis in Blood or Tissue by Molecular genetics method;JAK2 exon 12 Mut Anl Bld/T;;ACTIVE;2.27;2.73 +5530-1;CD79a;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD79a cells/100 cells in Blood;Deprecated CD79a WBC-aCnc;;DEPRECATED;1.0;2.69 +55301-6;JAK2 gene exon 13 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;JAK2 gene exon 13 targeted mutation analysis in Blood or Tissue by Molecular genetics method;JAK2 exon 13 Mut Anl Bld/T;;ACTIVE;2.27;2.73 +55302-4;Paraneoplastic pemphigus Ab;Titr;Pt;Ser;Qn;;SERO;1;Deprecated Paraneoplastic pemphigus Ab [Titer] in Serum;Deprecated Paraneoplastic pemphigus Ab Titr Ser;;DEPRECATED;2.27;2.68 +55303-2;Fungus;PrThr;Pt;Skin;Ord;KOH preparation;MICRO;1;Fungus [Presence] in Skin by KOH preparation;Fungus Skin Ql KOH Prep;;ACTIVE;2.27;2.58 +55304-0;Fungus;PrThr;Pt;Sputum;Ord;KOH preparation;MICRO;1;Fungus [Presence] in Sputum by KOH preparation;Fungus Spt Ql KOH Prep;;ACTIVE;2.27;2.58 +55305-7;Fungus;PrThr;Pt;XXX;Ord;KOH preparation;MICRO;1;Fungus [Presence] in Specimen by KOH preparation;Fungus Spec Ql KOH Prep;;ACTIVE;2.27;2.73 +55306-5;Fungus;PrThr;Pt;Nail;Ord;KOH preparation;MICRO;1;Fungus [Presence] in Nail by KOH preparation;Fungus Nail Ql KOH Prep;;ACTIVE;2.27;2.73 +55307-3;Fungus;PrThr;Pt;Vag;Ord;KOH preparation;MICRO;1;Fungus [Presence] in Vaginal fluid by KOH preparation;Fungus Vag Ql KOH Prep;;ACTIVE;2.27;2.58 +55308-1;Yeast.pseudohyphae;PrThr;Pt;XXX;Ord;KOH preparation;MICRO;1;Yeast.pseudohyphae [Presence] in Specimen by KOH preparation;Yeast pseudohyphae Spec Ql KOH Prep;;ACTIVE;2.27;2.69 +55309-9;Yeast.pseudohyphae;PrThr;Pt;Sputum;Ord;KOH preparation;MICRO;1;Yeast.pseudohyphae [Presence] in Sputum by KOH preparation;Yeast pseudohyphae Spt Ql KOH Prep;;ACTIVE;2.27;2.58 +55310-7;Yeast.pseudohyphae;PrThr;Pt;Nail;Ord;KOH preparation;MICRO;1;Yeast.pseudohyphae [Presence] in Nail by KOH preparation;Yeast pseudohyphae Nail Ql KOH Prep;;ACTIVE;2.27;2.58 +55311-5;Yeast.pseudohyphae;PrThr;Pt;Skin;Ord;KOH preparation;MICRO;1;Yeast.pseudohyphae [Presence] in Skin by KOH preparation;Yeast pseudohyphae Skin Ql KOH Prep;;ACTIVE;2.27;2.58 +55312-3;Yeast.pseudohyphae;PrThr;Pt;Vag;Ord;KOH preparation;MICRO;1;Yeast.pseudohyphae [Presence] in Vaginal fluid by KOH preparation;Yeast pseudohyphae Vag Ql KOH Prep;;ACTIVE;2.27;2.58 +55313-1;Yeast;PrThr;Pt;Vag;Ord;KOH preparation;MICRO;1;Yeast [Presence] in Vaginal fluid by KOH preparation;Yeast Vag Ql KOH Prep;;ACTIVE;2.27;2.73 +55314-9;Yeast;PrThr;Pt;Nail;Ord;KOH preparation;MICRO;1;Yeast [Presence] in Nail by KOH preparation;Yeast Nail Ql KOH Prep;;ACTIVE;2.27;2.58 +55315-6;Yeast;PrThr;Pt;XXX;Ord;KOH preparation;MICRO;1;Yeast [Presence] in Specimen by KOH preparation;Yeast Spec Ql KOH Prep;;ACTIVE;2.27;2.73 +55316-4;Yeast;PrThr;Pt;Sputum;Ord;KOH preparation;MICRO;1;Yeast [Presence] in Sputum by KOH preparation;Yeast Spt Ql KOH Prep;;ACTIVE;2.27;2.58 +55317-2;Yeast;PrThr;Pt;Skin;Ord;KOH preparation;MICRO;1;Yeast [Presence] in Skin by KOH preparation;Yeast Skin Ql KOH Prep;;ACTIVE;2.27;2.73 +55318-0;Fungus;PrThr;Pt;Bronchial;Ord;KOH preparation;MICRO;1;Fungus [Presence] in Bronchial specimen by KOH preparation;Fungus Bronch Ql KOH Prep;;ACTIVE;2.27;2.73 +5531-9;CD79b;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD79b cells/100 cells in Blood;Deprecated CD79b WBC-aCnc;;DEPRECATED;1.0;2.69 +55319-8;Yeast.pseudohyphae;PrThr;Pt;Bronchial;Ord;KOH preparation;MICRO;1;Yeast.pseudohyphae [Presence] in Bronchial specimen by KOH preparation;Yeast pseudohyphae Bronch Ql KOH Prep;;ACTIVE;2.27;2.58 +55320-6;Yeast;PrThr;Pt;Bronchial;Ord;KOH preparation;MICRO;1;Yeast [Presence] in Bronchial specimen by KOH preparation;Yeast Bronch Ql KOH Prep;;ACTIVE;2.27;2.58 +55321-4;C super little w Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;C sup(w) Ab [Titer] in Serum or Plasma;C sup(w) Ab Titr SerPl;;ACTIVE;2.27;2.70 +55322-2;F little y super little b Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Fy sup(b) Ab [Titer] in Serum or Plasma;Fy sup(b) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55323-0;J little k super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Jk sup(a) Ab [Titer] in Serum or Plasma;Jk sup(a) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55324-8;J little k super little b Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Jk sup(b) Ab [Titer] in Serum or Plasma;Jk sup(b) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55325-5;J little s super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Js sup(a) Ab [Titer] in Serum or Plasma;Js sup(a) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55326-3;K little p super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Kp sup(a) Ab [Titer] in Serum or Plasma;Kp sup(a) Ab Titr SerPl;;ACTIVE;2.27;2.42 +5532-7;CD8;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD8 in Blood;Deprecated CD8 WBC-aCnc;;DEPRECATED;1.0;2.69 +55327-1;K little p super little b Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Kp sup(b) Ab [Titer] in Serum or Plasma;Kp sup(b) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55328-9;L little e super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Le sup(a) Ab [Titer] in Serum or Plasma;Le sup(a) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55329-7;L little e super little b Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Le sup(b) Ab [Titer] in Serum or Plasma;Le sup(b) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55330-5;L little u super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Lu sup(a) Ab [Titer] in Serum or Plasma;Lu sup(a) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55331-3;L little u super little b Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Lu sup(b) Ab [Titer] in Serum or Plasma;Lu sup(b) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55332-1;little c Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;little c Ab [Titer] in Serum or Plasma;little c Ab Titr SerPl;;ACTIVE;2.27;2.32 +55333-9;little f Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;little f Ab [Titer] in Serum or Plasma;little f Ab Titr SerPl;;ACTIVE;2.27;2.32 +55334-7;little k Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;little k Ab [Titer] in Serum or Plasma;little k Ab Titr SerPl;;ACTIVE;2.27;2.32 +5533-5;CD80;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD80 cells/100 cells in Blood;Deprecated CD80 WBC-aCnc;;DEPRECATED;1.0;2.69 +55335-4;little s Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;little s Ab [Titer] in Serum or Plasma;little s Ab Titr SerPl;;ACTIVE;2.27;2.32 +55336-2;N Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;N Ab [Titer] in Serum or Plasma;N Ab Titr SerPl;;ACTIVE;2.27;2.32 +55337-0;P1 Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;P1 Ab [Titer] in Serum or Plasma;P1 Ab Titr SerPl;;ACTIVE;2.27;2.32 +55338-8;S little d super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Sd sup(a) Ab [Presence] in Serum or Plasma;Sd sup(a) Ab SerPl Ql;;ACTIVE;2.27;2.56 +55339-6;S little d super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Sd sup(a) Ab [Titer] in Serum or Plasma;Sd sup(a) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55340-4;V Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;V Ab [Titer] in Serum or Plasma;V Ab Titr SerPl;;ACTIVE;2.27;2.32 +55341-2;X little g super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Xg sup(a) Ab [Titer] in Serum or Plasma;Xg sup(a) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55342-0;S little d super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Sd sup(a) Ag [Presence] on Red Blood Cells;Sd sup(a) Ag RBC Ql;;ACTIVE;2.27;2.56 +5534-3;CD81;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD81;Deprecated CD81 WBC-aCnc;;DEPRECATED;1.0;2.69 +55343-8;Anidulafungin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Anidulafungin [Susceptibility] by Minimum inhibitory concentration (MIC);Anidulafungin Islt MIC;;ACTIVE;2.27;2.73 +55344-6;Platelet aggregation.ristocetin induced^1000 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --1000 ug/mL;PA Rist 1000 ug/mL PRP;;ACTIVE;2.27;2.70 +55345-3;VIM gene methylation;Arb;Pt;Stool;Ord;Molgen;MOLPATH;1;VIM gene methylation [Presence] in Stool by Molecular genetics method;VIM gene methylation Stl Ql;;ACTIVE;2.27;2.27 +55346-1;Clobazam+Norclobazam;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cloBAZam+Norclobazam [Moles/volume] in Serum or Plasma;cloBAZam+Norclobazam SerPl-sCnc;;ACTIVE;2.27;2.40 +55347-9;Coagulation ecarin induced;Time;Pt;Bld;Qn;Coag;COAG;1;Ecarin clotting time (ECT) in Blood by Coagulation assay;ECT Bld;;ACTIVE;2.27;2.66 +55348-7;Cortisol^20M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge;Cortis 20M p chal SerPl-sCnc;;ACTIVE;2.27;2.40 +55349-5;Ethyl glucuronide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethyl glucuronide [Presence] in Urine;Ethyl glucuronide Ur Ql;;ACTIVE;2.27;2.73 +5535-0;CD82;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD82 cells/100 cells in Blood;Deprecated CD82 WBC-aCnc;;DEPRECATED;1.0;2.69 +55350-3;Fenfluramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Fenfluramine [Presence] in Urine;Fenfluramine Ur Ql;;ACTIVE;2.27;2.56 +55351-1;Glucose^1.5H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO;Glucose 1.5h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.27;2.34 +55352-9;Glucose^45M post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post 75 g glucose PO;Glucose 45M p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.27;2.34 +55353-7;Hirudin;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Hirudin [Mass/volume] in Platelet poor plasma by Chromogenic method;Hirudin PPP Chro-mCnc;;ACTIVE;2.27;2.34 +55354-5;Osmolality^post 4H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--4 hours post fluid fast;Osmolality p 4h FFST Ur;;ACTIVE;2.27;2.40 +55355-2;Osmolality^post 7H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--7 hours post fluid fast;Osmolality p 7h FFST Ur;;ACTIVE;2.27;2.40 +55356-0;Osmolality^post 5H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--5 hours post fluid fast;Osmolality p 5h FFST Ur;;ACTIVE;2.27;2.40 +55357-8;Osmolality^post 3H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--3 hours post fluid fast;Osmolality p 3h FFST Ur;;ACTIVE;2.27;2.40 +55358-6;Osmolality^post 2H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--2 hours post fluid fast;Osmolality p 2h FFST Ur;;ACTIVE;2.27;2.40 +55359-4;Osmolality^post 1H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--1 hour post fluid fast;Osmolality p 1h FFST Ur;;ACTIVE;2.27;2.67 +55360-2;Osmolality^post 6H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--6 hours post fluid fast;Osmolality p 6h FFST Ur;;ACTIVE;2.27;2.40 +55361-0;Osmolality^baseline;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--baseline;Osmolality BS Ur;;ACTIVE;2.27;2.40 +55362-8;Thyrotropin^pre XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --pre XXX challenge;TSH pre chal SerPl-aCnc;;ACTIVE;2.27;2.68 +55363-6;Argatroban;MCnc;Pt;PPP;Qn;;DRUG/TOX;1;Argatroban [Mass/volume] in Platelet poor plasma;Argatroban PPP-mCnc;;ACTIVE;2.27;2.73 +55364-4;Cells.CD5+CD19+CD38+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5+CD19+CD38+ cells/100 cells in Blood;CD5+CD19+CD38+ Cells NFr Bld;;ACTIVE;2.27;2.34 +55365-1;Cells.CD138+Kappa+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD138+Kappa+ Cells/100 cells in Blood;CD138+Kappa+ Cells NFr Bld;;ACTIVE;2.27;2.34 +55366-9;Cells.CD138+Lambda+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD138+Lambda+ Cells/100 cells in Blood;CD138+Lambda+ Cells NFr Bld;;ACTIVE;2.27;2.34 +55367-7;Cholesterol crystals;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Cholesterol crystals [#/area] in Urine by Computer assisted method;Cholest Cry #/area Ur Comp Assist;;ACTIVE;2.27;2.69 +5536-8;CD83;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD83 cells/100 cells in Blood;Deprecated CD83 WBC-aCnc;;DEPRECATED;1.0;2.69 +55368-5;Crystals.amorphous;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Crystals.amorphous [#/area] in Urine sediment by Microscopy high power field;Amorph Cry #/area UrnS HPF;;ACTIVE;2.27;2.73 +55369-3;Dengue virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Dengue virus Ab [Titer] in Serum by Hemagglutination inhibition;DENV Ab Titr Ser HAI;;ACTIVE;2.27;2.32 +55370-1;Hemoglobin A2+C+E+O/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A2+C+E+O/Hemoglobin.total in Blood;Hgb A2+C+E+O MFr Bld;;ACTIVE;2.27;2.30 +55371-9;Hemoglobin A2+E+O/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A2+E+O/Hemoglobin.total in Blood;Hgb A2+E+O MFr Bld;;ACTIVE;2.27;2.30 +55372-7;Hemoglobin Constant Spring/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin Constant Spring/Hemoglobin.total in Blood;Hgb CSp MFr Bld;;ACTIVE;2.27;2.30 +55373-5;Hemoglobin D+G/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin D+G/Hemoglobin.total in Blood;Hgb D+G MFr Bld;;ACTIVE;2.27;2.30 +55374-3;Hemoglobin N+I/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin N+I/Hemoglobin.total in Blood;Hgb N+I MFr Bld;;ACTIVE;2.27;2.30 +55375-0;Megaloblasts;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Megaloblasts [#/volume] in Blood by Manual count;Megaloblasts # Bld Manual;;ACTIVE;2.27;2.40 +5537-6;CD85;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD85 cells/100 cells in Blood;Deprecated CD85 WBC-aCnc;;DEPRECATED;1.0;2.69 +55376-8;Megaloblasts/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Megaloblasts/100 leukocytes in Blood by Manual count;Megaloblasts/leuk NFr Bld Manual;;ACTIVE;2.27;2.50 +55377-6;Mononuclear cells.immature/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Mononuclear cells immature/100 leukocytes in Blood by Manual count;Immature mononuc/leuk NFr Bld Manual;;ACTIVE;2.27;2.73 +55378-4;Phosphate crystals.amorphous;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Phosphate crystals amorphous [#/area] in Urine by Computer assisted method;Amorph Phos Cry #/area Ur Comp Assist;;ACTIVE;2.27;2.69 +55379-2;Snowshoe hare virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Snowshoe hare virus IgM Ab [Presence] in Serum by Immunoassay;SSHV IgM Ser Ql IA;;ACTIVE;2.27;2.56 +553-8;Candida sp identified;Prid;Pt;Saliva;Nom;Organism specific culture;MICRO;1;Candida sp identified in Saliva (oral fluid) by Organism specific culture;Candida Sal Cult;;ACTIVE;1.0;2.42 +55380-0;West Nile virus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;West Nile virus Ab [Titer] in Serum by Hemagglutination inhibition;WNV Ab Titr Ser HAI;;ACTIVE;2.27;2.32 +55381-8;Glucose^2.5H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hours post 75 g glucose PO;Glucose 2.5h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.27;2.34 +55382-6;Insulin^5M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge;Insulin 5M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55383-4;Insulin^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;Insulin 10M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +5538-4;CD86;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD86 cells/100 cells in Blood;Deprecated CD86 WBC-aCnc;;DEPRECATED;1.0;2.69 +55384-2;Insulin^3M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --3 minutes post XXX challenge;Insulin 3M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55385-9;Insulin^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;Insulin 15M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55386-7;Insulin^2M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2 minutes post XXX challenge;Insulin 2M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55387-5;Insulin^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;Insulin 45M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55388-3;Insulin^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Insulin 4h p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55389-1;Insulin^5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --5 hours post XXX challenge;Insulin 5h p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55390-9;Insulin^6H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --6 hours post XXX challenge;Insulin 6h p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55391-7;Insulin^4M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --4 minutes post XXX challenge;Insulin 4M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +5539-2;CD87;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD87 cells/100 cells in Blood;Deprecated CD87 WBC-aCnc;;DEPRECATED;1.0;2.69 +55392-5;Insulin^1M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1 minute post XXX challenge;Insulin 1M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55393-3;Lead;SCnt;Pt;Nail;Qn;;DRUG/TOX;1;Lead [Moles/mass] in Nail;Lead Nail-sCnt;;ACTIVE;2.27;2.40 +55394-1;Protein & Glucose panel;-;Pt;CSF;Qn;;PANEL.CHEM;1;Protein and Glucose panel - Cerebral spinal fluid;Prot + Glucose Pnl CSF;;ACTIVE;2.27;2.73 +55395-8;Phospholipid Ab.IgA & IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.COAG;1;Phospholipid IgA and IgG and IgM panel - Serum;Phospholipid IgA+IgG+IgM Pnl Ser;;ACTIVE;2.27;2.73 +55396-6;Beta 2 glycoprotein 1 Ab.IgA & IgG panel;-;Pt;Ser;Qn;;PANEL.COAG;1;Beta 2 glycoprotein 1 IgA and IgG panel - Serum;B2 glycoprot1 IgA+IgG Pnl Ser;;ACTIVE;2.27;2.66 +55397-4;Short myasthenia gravis panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Short myasthenia gravis panel - Serum;Short myasthenia gravis Pnl Ser;;ACTIVE;2.27;2.73 +55398-2;Short Fibrin D-dimer FEU & DDU panel;-;Pt;PPP;Qn;;PANEL.COAG;1;Short Fibrin D-dimer FEU and DDU panel - Platelet poor plasma;Short Fibrin D-dimer FEU & DDU Pnl PPP;;ACTIVE;2.27;2.66 +55399-0;Diabetes tracking panel;-;Pt;^Patient;-;;PANEL.PHR;2;Diabetes tracking panel;Diabetes tracking Pnl;;ACTIVE;2.27;2.66 +55-4;Capreomycin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Capreomycin [Susceptibility] by Minimum lethal concentration (MLC);Capreomycin Islt MLC;;ACTIVE;1.0;2.19 +5540-0;CD88;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD88 cells/100 cells in Blood;Deprecated CD88 WBC-aCnc;;DEPRECATED;1.0;2.69 +55400-6;Date of last eye examination;Date;Pt;^Patient;Qn;;CLIN;2;Date of last eye examination;Date of last eye exam;;ACTIVE;2.27;2.73 +55401-4;Warfarin tracking panel;-;Pt;PPP;-;;PANEL.COAG;1;Warfarin tracking panel - Platelet poor plasma;Warfarin tracking Pnl PPP;;ACTIVE;2.27;2.66 +55402-2;West Nile virus Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;West Nile virus IgG and IgM panel - Serum;WNV IgG+IgM Pnl Ser;;ACTIVE;2.27;2.73 +55403-0;Asthma tracking panel;-;Pt;^Patient;-;;PANEL.PHR;2;Asthma tracking panel;Asthma tracking Pnl;;ACTIVE;2.27;2.66 +55404-8;Asthma spells;NRat;1W;^Patient;Qn;;PULM;2;Asthma spells per week;Asthma spells 1W nRate;;ACTIVE;2.27;2.70 +55405-5;Heart failure tracking panel;-;Pt;^Patient;-;;PANEL.PHR;2;Heart failure tracking panel;Heart failure tracking Pnl;;ACTIVE;2.27;2.66 +55406-3;Cardiac ejection fraction method;Type;Pt;Heart.ventricle.left;Nom;;HEMODYN.MOLEC;2;Left ventricular Cardiac ejection fraction method;LV Cardiac EF method;;ACTIVE;2.27;2.66 +55407-1;Pitting edema severity;Find;Pt;Ankle;Ord;;H&P.PX;2;Pitting edema severity of Ankle;Pitting edema severity Ankle;;ACTIVE;2.27;2.66 +55408-9;Exercise tolerance;Find;Pt;^Patient;Nom;;CLIN;2;Exercise tolerance;Exercise tolerance;;ACTIVE;2.27;2.73 +55409-7;Exercise tracking panel;-;Pt;^Patient;-;;PANEL.PHR;2;Exercise tracking panel;Exercise tracking Pnl;;ACTIVE;2.27;2.66 +55410-5;Exercise type;Type;Pt;^Patient;Nom;;CLIN;2;Deprecated Exercise type;Deprecated Exercise type;;DEPRECATED;2.27;2.66 +55411-3;Exercise duration;Time;Pt;^Patient;Qn;;CLIN;2;Exercise duration;Exercise duration;;ACTIVE;2.27;2.73 +55412-1;Exercise distance;Len;XXX;^Patient;Qn;;CLIN;2;Exercise distance unspecified time;Exercise distance ?Tm;;ACTIVE;2.27;2.73 +55413-9;Pedometer tracking panel;-;Pt;^Patient;-;;PANEL.PHR;2;Pedometer tracking panel;Pedometer tracking Pnl;;ACTIVE;2.27;2.66 +55414-7;Seizures per month;NRat;Pt;^Patient;Qn;;CLIN;2;Seizures per month;Seizures/month nRate;;ACTIVE;2.27;2.73 +55415-4;Oxygen saturation & therapy panel;-;Pt;^Patient;-;;PANEL.PHR;2;Oxygen saturation and therapy panel;SaO2 & therapy Pnl;;ACTIVE;2.27;2.71 +55416-2;Oxymetry special circumstances;Type;Pt;^Patient;Nom;;PULM;2;Oxymetry special circumstances;Oxymetry special circumstances;;ACTIVE;2.27;2.66 +55417-0;Short blood pressure panel;-;Pt;^Patient;-;;PANEL.PHR;2;Short blood pressure panel;Short BP Pnl;;ACTIVE;2.27;2.66 +5541-8;CD89;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD89;Deprecated CD89 WBC-aCnc;;DEPRECATED;1.0;2.69 +55418-8;Weight & Height tracking panel;-;Pt;^Patient;-;;PANEL.PHR;2;Weight and Height tracking panel;Weight & Height tracking Pnl;;ACTIVE;2.27;2.66 +55419-6;Home drug screening panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Home drug screening panel - Urine;Home drug screen Pnl Ur;;ACTIVE;2.27;2.66 +55420-4;Hours after meal;Time;Pt;^Patient;Qn;;CHAL;1;Hours after meal [Time];Hours p meal Time Patient;;ACTIVE;2.27;2.73 +55421-2;Calories burned;EngRat;Pt;^Patient;Qn;Machine estimate;CLIN;2;Calories burned Machine estimate;Calories burned Machine est;;ACTIVE;2.27;2.70 +55422-0;Heart rate;NRat;Enctr^max;Arterial system;Qn;;HRTRATE.MOLEC;2;Heart rate Encounter maximum;Heart rate Enctr Max;;ACTIVE;2.27;2.73 +55423-8;Number of steps;NRat;XXX;^Patient;Qn;Pedometer;CLIN;2;Number of steps in unspecified time Pedometer;# steps ?Tm nRate Pedometer;;ACTIVE;2.27;2.70 +55424-6;Calories burned;EngRat;XXX;^Patient;Qn;Pedometer;CLIN;2;Calories burned in unspecified time Pedometer;Calories burned ?Tm Pedometer;;ACTIVE;2.27;2.70 +55425-3;Heart rate;NRat;XXX^mean;Arterial system;Qn;Pedometer;HRTRATE.MOLEC;2;Heart rate unspecified time mean by Pedometer;Heart rate ?Tm Mean Pedometer;;ACTIVE;2.27;2.70 +5542-6;CD9;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD9 cells/100 cells in Blood;Deprecated CD9 WBC-aCnc;;DEPRECATED;1.0;2.69 +55426-1;Heart rate;NRat;XXX^max;Arterial system;Qn;Pedometer;HRTRATE.MOLEC;2;Heart rate unspecified time maximum by Pedometer;Heart rate ?Tm Max Pedometer;;ACTIVE;2.27;2.70 +55427-9;Seizure disorder tracking panel;-;Pt;^Patient;-;;PANEL.PHR;2;Seizure disorder tracking panel;Seizure disorder tracking Pnl;;ACTIVE;2.27;2.66 +55428-7;Drug test kit name;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Drug test kit name [Identifier] in Urine;Drug test kit name Ur;;ACTIVE;2.27;2.66 +55429-5;Short blood count panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Short blood count panel - Blood;Short blood count Pnl Bld;;ACTIVE;2.27;2.70 +55430-3;Walking distance;Len;XXX;^Patient;Qn;Pedometer;CLIN;2;Walking distance unspecified time Pedometer;Walk distance ?Tm Pedometer;;ACTIVE;2.27;2.70 +55431-1;Cells.HLA-B27;NCnc;Pt;Bld;Qn;;CELLMARK;1;HLA-B27 cells [#/volume] in Blood;HLA-B27 Cells # Bld;;ACTIVE;2.27;2.40 +55432-9;Immature cells;NCnc;Pt;Bld;Qn;;HEM/BC;1;Immature cells [#/volume] in Blood;Immature cells # Bld;;ACTIVE;2.27;2.73 +55433-7;Immature cells/100 leukocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Immature cells/100 leukocytes in Blood;Immature cells/leuk NFr Bld;;ACTIVE;2.27;2.73 +5543-4;CD91;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD91 cells/100 cells in Blood;Deprecated CD91 WBC-aCnc;;DEPRECATED;1.0;2.69 +55434-5;Insulin^20M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge;Insulin 20M p chal SerPl-sCnc;;ACTIVE;2.27;2.34 +55435-2;Mononuclear cells.immature;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Mononuclear cells immature [#/volume] in Blood by Manual count;Immature mononuc # Bld Manual;;ACTIVE;2.27;2.73 +55436-0;Myeloblasts/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Myeloblasts/100 leukocytes in Cerebral spinal fluid by Manual count;Myeloblasts/leuk NFr CSF Manual;;ACTIVE;2.27;2.50 +55437-8;Neoplastic cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Neoplastic cells/100 leukocytes in Cerebral spinal fluid by Manual count;Neoplastic cells/leuk NFr CSF Manual;;ACTIVE;2.27;2.50 +55438-6;Dengue virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Dengue virus neutralizing antibody [Titer] in Serum by Neutralization test;DENV NAb Titr Ser Nt;;ACTIVE;2.27;2.72 +55439-4;Medical device;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Medical device;FDA label Medical device;;ACTIVE;2.27;2.34 +55440-2;Cholesterol.in LDL;MCnc;Pt;Ser/Plas;Qn;VAP;CHEM;1;Cholesterol.in LDL (real) [Mass/volume] in Serum or Plasma by VAP;LDLc-R SerPl VAP-mCnc;;ACTIVE;2.27;2.73 +55441-0;Antithrombin Ag;-;Pt;PPP;-;;LABORDERS;1;Deprecated Antithrombin Ag in Platelet poor plasma;Deprecated AT III Ag PPP;;DEPRECATED;2.27;2.66 +5544-2;CD93;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD93 cells/100 cells in Blood;Deprecated CD93 WBC-aCnc;;DEPRECATED;1.0;2.69 +55442-8;Antithrombin;-;Pt;PPP;-;;LABORDERS;1;Deprecated Antithrombin in Platelet poor plasma;Deprecated AT III PPP;;DEPRECATED;2.27;2.66 +55443-6;Cardiolipin Ab;-;Pt;Ser;-;;LABORDERS;1;Deprecated Cardiolipin Ab in Serum;Deprecated Cardiolipin Ab Ser;;DEPRECATED;2.27;2.66 +55444-4;Cardiolipin Ab.IgA;-;Pt;Ser;-;;LABORDERS;1;Deprecated Cardiolipin IgA Ab in Serum;Deprecated Cardiolipin IgA Ser;;DEPRECATED;2.27;2.66 +55445-1;Cardiolipin Ab.IgM;-;Pt;Ser;-;;LABORDERS;1;Deprecated Cardiolipin IgM Ab in Serum;Deprecated Cardiolipin IgM Ser;;DEPRECATED;2.27;2.66 +55446-9;Cardiolipin Ab.IgG;-;Pt;Ser;-;;LABORDERS;1;Deprecated Cardiolipin IgG Ab in Serum;Deprecated Cardiolipin IgG Ser;;DEPRECATED;2.27;2.66 +55447-7;Coagulation factor VIII Ag;-;Pt;PPP;-;;LABORDERS;1;Deprecated Coagulation factor VIII Ag in Platelet poor plasma;Deprecated Fact VIII Ag PPP;;DEPRECATED;2.27;2.66 +55448-5;Complement total hemolytic CH50;-;Pt;Ser/Plas;-;;LABORDERS;1;Deprecated Complement total hemolytic CH50 in Serum or Plasma;Deprecated CH50 SerPl;;DEPRECATED;2.27;2.66 +55449-3;Fibrin D-dimer;-;Pt;PPP;-;;LABORDERS;1;Deprecated Fibrin D-dimer in Platelet poor plasma;Deprecated D Dimer PPP;;DEPRECATED;2.27;2.66 +55450-1;Fibrin+Fibrinogen fragments;-;Pt;Ser;-;;LABORDERS;1;Deprecated Fibrin+Fibrinogen fragments in Serum;Deprecated FSP Ser;;DEPRECATED;2.27;2.66 +55451-9;Fibrin+Fibrinogen fragments;-;Pt;PPP;-;;LABORDERS;1;Deprecated Fibrin+Fibrinogen fragments in Platelet poor plasma;Deprecated FSP PPP;;DEPRECATED;2.27;2.66 +55452-7;Fibrinogen;-;Pt;PPP;-;;LABORDERS;1;Deprecated Fibrinogen in Platelet poor plasma;Deprecated Fibrinogen PPP;;DEPRECATED;2.27;2.66 +55453-5;Haptoglobin;-;Pt;Ser/Plas;-;;LABORDERS;1;Deprecated Haptoglobin in Serum or Plasma;Deprecated Haptoglob SerPl;;DEPRECATED;2.27;2.66 +55454-3;Hemoglobin A1c;-;Pt;Bld;-;;LABORDERS;1;Deprecated Hemoglobin A1c in Blood;Deprecated Hgb A1c Bld;;DEPRECATED;2.27;2.66 +55455-0;Hemoglobin F;-;Pt;XXX;-;;LABORDERS;1;Deprecated Hemoglobin F in Unspecified specimen;Deprecated Hgb F XXX;;DEPRECATED;2.27;2.69 +55456-8;Hemoglobin S;-;Pt;Bld;-;;LABORDERS;1;Deprecated Hemoglobin S in Blood;Deprecated Hgb S Bld;;DEPRECATED;2.27;2.66 +55457-6;Hemoglobin.free;-;Pt;Plas;-;;LABORDERS;1;Deprecated Free Hemoglobin in Plasma;Deprecated Hgb Free Plas;;DEPRECATED;2.27;2.66 +55458-4;Interferon.alpha;-;Pt;Ser/Plas;-;;LABORDERS;1;Deprecated Interferon alpha in Serum or Plasma;Deprecated IFN-A SerPl;;DEPRECATED;2.27;2.66 +5545-9;CD94;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD94 cells/100 cells in Blood;Deprecated CD94 WBC-aCnc;;DEPRECATED;1.0;2.69 +55459-2;Prekallikrein;-;Pt;PPP;-;;LABORDERS;1;Deprecated Prekallikrein (Fletcher Factor) in Platelet poor plasma;Deprecated PK PPP;;DEPRECATED;2.27;2.66 +554-6;Candida sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Candida sp identified in Stool by Organism specific culture;Candida Stl Cult;;ACTIVE;1.0;2.19 +55460-0;Protein C Ag;-;Pt;PPP;-;;LABORDERS;1;Deprecated Protein C Ag in Platelet poor plasma;Deprecated Prot C Ag PPP;;DEPRECATED;2.27;2.66 +55461-8;Protein C;-;Pt;PPP;-;;LABORDERS;1;Deprecated Protein C in Platelet poor plasma;Deprecated Prot C PPP;;DEPRECATED;2.27;2.66 +55462-6;Thyrotropin;-;Pt;Ser/Plas;-;;LABORDERS;1;Deprecated Thyrotropin in Serum or Plasma;Deprecated TSH SerPl;;DEPRECATED;2.27;2.66 +55463-4;Influenza virus A swine origin RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Influenza virus A swine origin RNA [Identifier] in Specimen by NAA with probe detection;FLUAV swine RNA Spec NAA+probe;;ACTIVE;2.27;2.73 +55464-2;Influenza virus A swine origin RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A swine origin RNA [Presence] in Specimen by NAA with probe detection;FLUAV swine RNA Spec Ql NAA+probe;;ACTIVE;2.27;2.69 +55465-9;Influenza virus A H1 2009 pandemic RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic RNA [Presence] in Specimen by NAA with probe detection;FLUAV H1 2009 pand RNA Spec Ql NAA+probe;;ACTIVE;2.27;2.73 +55466-7;Influenza virus A H1 2009 pandemic RNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus A H1 2009 pandemic RNA panel - Specimen by NAA with probe detection;FLUAV H1 2009 pan RNA pnl Spec NAA+probe;;ACTIVE;2.27;2.73 +5546-7;CD95;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD95 cells/100 cells in Blood;Deprecated CD95 WBC-aCnc;;DEPRECATED;1.0;2.69 +55467-5;11-Deoxycortisol^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --baseline;11DC BS SerPl-sCnc;;ACTIVE;2.27;2.40 +55468-3;11-Deoxycortisol^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;11DC 1h p ACTH SerPl-sCnc;;ACTIVE;2.27;2.40 +55469-1;17-Hydroxyprogesterone^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;17OHP 30M p ACTH SerPl-sCnc;;ACTIVE;2.27;2.34 +55470-9;17-Hydroxyprogesterone^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;17OHP 1h p ACTH SerPl-sCnc;;ACTIVE;2.27;2.34 +55471-7;Aldosterone^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;Aldost 1h p ACTH SerPl-sCnc;;ACTIVE;2.27;2.34 +55472-5;Cortisol^2.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge;Cortis 2.5h p chal SerPl-sCnc;;ACTIVE;2.27;2.40 +55473-3;Cortisol^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;Cortis 3h p chal SerPl-sCnc;;ACTIVE;2.27;2.40 +55474-1;Dehydroepiandrosterone^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Moles/volume] in Serum or Plasma --baseline;DHEA BS SerPl-sCnc;;ACTIVE;2.27;2.34 +5547-5;CD96;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD96 cells/100 cells in Blood;Deprecated CD96 WBC-aCnc;;DEPRECATED;1.0;2.69 +55475-8;Dehydroepiandrosterone^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;DHEA 1h p ACTH SerPl-sCnc;;ACTIVE;2.27;2.34 +55476-6;Estradiol^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Moles/volume] in Serum or Plasma --baseline;Estradiol BS SerPl-sCnc;;ACTIVE;2.27;2.36 +55477-4;Estradiol^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Estradiol 4h p chal SerPl-sCnc;;ACTIVE;2.27;2.36 +55478-2;Follitropin^4H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --4 hours post XXX challenge;FSH 4h p chal SerPl-aCnc;;ACTIVE;2.27;2.38 +55479-0;Insulin^7M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --7 minutes post dose glucose IV;Insulin 7M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55480-8;Insulin^5M pre dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --5 minutes pre dose glucose;Insulin 5M pre Glc SerPl-sCnc;;ACTIVE;2.27;2.34 +55481-6;Insulin^10M pre dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --10 minutes pre dose glucose;Insulin 10M pre Glc SerPl-sCnc;;ACTIVE;2.27;2.34 +55482-4;Insulin^4H post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --4 hours post dose glucose IV;Insulin 4h p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +5548-3;CD97;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD97 cells/100 cells in Blood;Deprecated CD97 WBC-aCnc;;DEPRECATED;1.0;2.69 +55483-2;Insulin^1.5H post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1.5 hours post dose glucose IV;Insulin 1.5h p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55484-0;Insulin^10M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --10 minutes post dose glucose IV;Insulin 10M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55485-7;Insulin^1H post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1 hour post dose glucose IV;Insulin 1h p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55486-5;Insulin^1M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1 minute post dose glucose IV;Insulin 1M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55487-3;Insulin^2.5H post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2.5 hours post dose glucose IV;Insulin 2.5h p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55488-1;Insulin^1H post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1 hour post dose glucagon;Insulin 1h p Gc SerPl-sCnc;;ACTIVE;2.27;2.34 +55489-9;Insulin^1.5H post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1.5 hours post dose glucagon;Insulin 1.5h p Gc SerPl-sCnc;;ACTIVE;2.27;2.34 +55490-7;Insulin^45M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --45 minutes post dose glucagon;Insulin 45M p Gc SerPl-sCnc;;ACTIVE;2.27;2.34 +5549-1;CD98;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD98 cells/100 cells in Blood;Deprecated CD98 WBC-aCnc;;DEPRECATED;1.0;2.69 +55491-5;Insulin^2H post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2 hours post dose glucagon;Insulin 2h p Gc SerPl-sCnc;;ACTIVE;2.27;2.34 +55492-3;Insulin^30M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --30 minutes post dose glucose IV;Insulin 30M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55493-1;Insulin^3H post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --3 hours post dose glucose IV;Insulin 3hp Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55494-9;Insulin^5M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --5 minutes post dose glucose IV;Insulin 5M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55495-6;Insulin^45M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --45 minutes post dose glucose IV;Insulin 45M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55496-4;Insulin^2H post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2 hours post dose glucose IV;Insulin 2h p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55497-2;Insulin^3M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --3 minutes post dose glucose IV;Insulin 3M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55498-0;Insulin^7M pre dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --7 minutes pre dose glucose;Insulin 7M pre Glc SerPl-sCnc;;ACTIVE;2.27;2.34 +55499-8;Insulin^15M post dose glucose IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --15 minutes post dose glucose IV;Insulin 15M p Glc IV SerPl-sCnc;;ACTIVE;2.27;2.34 +55500-3;Insulin^30M post dose glucagon;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --30 minutes post dose glucagon;Insulin 30M p Gc SerPl-sCnc;;ACTIVE;2.27;2.34 +55501-1;Lutropin^4H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --4 hours post XXX challenge;LH 4h p chal SerPl-aCnc;;ACTIVE;2.27;2.68 +55502-9;Prolactin^20M post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --20 minutes post dose TRH IV;Prolactin 20M pTRH IV SerPl-mCnc;;ACTIVE;2.27;2.40 +55503-7;Prolactin^40M post dose TRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Mass/volume] in Serum or Plasma --40 minutes post dose TRH IV;Prolactin 40M p TRH IV SerPl-mCnc;;ACTIVE;2.27;2.40 +55504-5;Somatotropin^2H post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose glucagon;GH 2h p Gc SerPl-mCnc;;ACTIVE;2.27;2.73 +55505-2;Somatotropin^30M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose glucose;GH 30M p Glc SerPl-mCnc;;ACTIVE;2.27;2.40 +55506-0;Somatotropin^10M post exercise;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --10 minutes post exercise;GH 10M p Exc SerPl-mCnc;;ACTIVE;2.27;2.40 +55507-8;Somatotropin^2H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose glucose;GH 2h p Glc SerPl-mCnc;;ACTIVE;2.27;2.40 +55508-6;Somatotropin^1H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose glucose;GH 1h p Glc SerPl-mCnc;;ACTIVE;2.27;2.40 +5550-9;CD99;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD99 cells/100 cells in Blood;Deprecated CD99 WBC-aCnc;;DEPRECATED;1.0;2.69 +55509-4;Somatotropin^45M post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --45 minutes post dose cloNIDine;GH 45M p CLN SerPl-mCnc;;ACTIVE;2.27;2.40 +55510-2;Somatotropin^1.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose glucose;GH 1.5h p Glc SerPl-mCnc;;ACTIVE;2.27;2.40 +55511-0;Somatotropin^3H post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3 hours post dose glucagon;GH 3h p Gc SerPl-mCnc;;ACTIVE;2.27;2.40 +55512-8;Somatotropin^30M post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose glucagon;GH 30M p Gc SerPl-mCnc;;ACTIVE;2.27;2.73 +55513-6;Somatotropin^30M post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose cloNIDine;GH 30M p CLN SerPl-mCnc;;ACTIVE;2.27;2.73 +55514-4;Somatotropin^20M post exercise;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --20 minutes post exercise;GH 20M p Exc SerPl-mCnc;;ACTIVE;2.27;2.40 +55515-1;Somatotropin^2.5H post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2.5 hours post dose glucagon;GH 2.5h p Gc SerPl-mCnc;;ACTIVE;2.27;2.40 +55516-9;Somatotropin^1.5H post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose glucagon;GH 1.5h p Gc SerPl-mCnc;;ACTIVE;2.27;2.73 +5551-7;CyCD3;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated cyCD3 cells/100 cells in Blood;Deprecated cyCD3 WBC-aCnc;;DEPRECATED;1.0;2.69 +55517-7;Somatotropin^1H post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose glucagon;GH 1h p Gc SerPl-mCnc;;ACTIVE;2.27;2.73 +55518-5;Testosterone^4H post dose gonadotropin releasing hormone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Moles/volume] in Serum or Plasma --4 hours post dose gonadotropin releasing hormone;Testost 4h p GnRH SerPl-sCnc;;ACTIVE;2.27;2.40 +55519-3;Testosterone^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Moles/volume] in Serum or Plasma --baseline;Testost BS SerPl-sCnc;;ACTIVE;2.27;2.40 +55520-1;6-Monoacetylmorphine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Moles/volume] in Urine;6MAM Ur-sCnc;;ACTIVE;2.27;2.42 +55521-9;Acebutolol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Acebutolol [Moles/volume] in Specimen;Acebutolol Spec-sCnc;;ACTIVE;2.27;2.69 +55522-7;acetaZOLAMIDE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetazolamide [Moles/volume] in Serum or Plasma;acetaZOLAMIDE SerPl-sCnc;;ACTIVE;2.27;2.44 +55523-5;Anileridine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Anileridine [Moles/volume] in Serum or Plasma;Anileridine SerPl-sCnc;;ACTIVE;2.27;2.34 +55524-3;Atropine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Atropine [Moles/volume] in Serum or Plasma;Atropine SerPl-sCnc;;ACTIVE;2.27;2.42 +5552-5;CyCD79;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated cyCD79 cells/100 cells in Blood;Deprecated cyCD79 WBC-aCnc;;DEPRECATED;1.0;2.69 +55525-0;Benzoylecgonine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzoylecgonine [Moles/volume] in Serum or Plasma;BZE SerPl-sCnc;;ACTIVE;2.27;2.44 +55526-8;Brompheniramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Brompheniramine [Moles/volume] in Serum or Plasma;Brompheniramine SerPl-sCnc;;ACTIVE;2.27;2.42 +55527-6;buPROPion;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;buPROPion [Moles/volume] in Serum or Plasma;buPROPion SerPl-sCnc;;ACTIVE;2.27;2.42 +55528-4;Chloral hydrate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chloral hydrate [Moles/volume] in Serum or Plasma;Chloral Hydrate SerPl-sCnc;;ACTIVE;2.27;2.42 +55529-2;Clopenthixol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clopenthixol [Moles/volume] in Serum or Plasma;Clopenthixol SerPl-sCnc;;ACTIVE;2.27;2.42 +555-3;Candida sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Candida sp identified in Specimen by Organism specific culture;Candida Spec Cult;;ACTIVE;1.0;2.73 +55530-0;Cocaethylene;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cocaethylene [Moles/volume] in Serum or Plasma;Cocaethylene SerPl-sCnc;;ACTIVE;2.27;2.42 +55531-8;Cyclobenzaprine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyclobenzaprine [Moles/volume] in Serum or Plasma;Cyclobenzaprine SerPl-sCnc;;ACTIVE;2.27;2.34 +55532-6;Diethylpropion;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diethylpropion [Moles/volume] in Serum or Plasma;Diethylpropion SerPl-sCnc;;ACTIVE;2.27;2.42 +5553-3;CyIg;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated cyIg cells/100 cells in Blood;Deprecated CyIg WBC-aCnc;;DEPRECATED;1.0;2.69 +55533-4;dilTIAZem;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;dilTIAZem [Moles/volume] in Serum or Plasma;dilTIAZem SerPl-sCnc;;ACTIVE;2.27;2.42 +55534-2;Doxylamine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Doxylamine [Moles/volume] in Serum or Plasma;Doxylamine SerPl-sCnc;;ACTIVE;2.27;2.34 +55535-9;ePHEDrine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ePHEDrine [Moles/volume] in Serum or Plasma;Ephedrin SerPl-sCnc;;ACTIVE;2.27;2.40 +55536-7;Fenoprofen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fenoprofen [Moles/volume] in Serum or Plasma;Fenoprofen SerPl-sCnc;;ACTIVE;2.27;2.42 +55537-5;fentaNYL;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;fentaNYL [Moles/volume] in Serum or Plasma;fentaNYL SerPl-sCnc;;ACTIVE;2.27;2.42 +55538-3;Flupenthixol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flupenthixol [Moles/volume] in Serum or Plasma;Flupenthixol SerPl-sCnc;;ACTIVE;2.27;2.34 +55539-1;Flurbiprofen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flurbiprofen [Moles/volume] in Serum or Plasma;Flurbiprofen SerPl-sCnc;;ACTIVE;2.27;2.42 +55540-9;Furosemide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Furosemide [Moles/volume] in Serum or Plasma;Furosemide SerPl-sCnc;;ACTIVE;2.27;2.34 +5554-1;CyIg mu;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated cyIg mu cells/100 cells in Blood;Deprecated CyIg mu WBC-aCnc;;DEPRECATED;1.0;2.69 +55541-7;hydroCHLOROthiazide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;hydroCHLOROthiazide [Moles/volume] in Serum or Plasma;HTCZ SerPl-sCnc;;ACTIVE;2.27;2.44 +55542-5;Hydroxybupropion;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxybupropion [Moles/volume] in Serum or Plasma;OH-bupropion SerPl-sCnc;;ACTIVE;2.27;2.42 +55543-3;Hydroxychloroquine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxychloroquine [Moles/volume] in Serum or Plasma;OH-Chloroquine SerPl-sCnc;;ACTIVE;2.27;2.42 +55544-1;hydrOXYzine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;hydrOXYzine [Moles/volume] in Serum or Plasma;hydrOXYzine SerPl-sCnc;;ACTIVE;2.27;2.42 +55545-8;Indomethacin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Indomethacin [Moles/volume] in Serum or Plasma;Indomethacin SerPl-sCnc;;ACTIVE;2.27;2.42 +55546-6;Ketoprofen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ketoprofen [Moles/volume] in Serum or Plasma;Ketoprofen SerPl-sCnc;;ACTIVE;2.27;2.42 +55547-4;Labetalol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Labetalol [Moles/volume] in Serum or Plasma;Labetalol SerPl-sCnc;;ACTIVE;2.27;2.42 +55548-2;metFORMIN;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;metFORMIN [Moles/volume] in Serum or Plasma;metFORMIN SerPl-sCnc;;ACTIVE;2.27;2.42 +55549-0;Methocarbamol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methocarbamol [Moles/volume] in Serum or Plasma;Methocarbamol SerPl-sCnc;;ACTIVE;2.27;2.42 +55550-8;Methsuximide+Normethsuximide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methsuximide+Normethsuximide [Moles/volume] in Serum or Plasma;Methsuximide+Nor SerPl-sCnc;;ACTIVE;2.27;2.42 +55551-6;Methylenedioxyamphetamine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Moles/volume] in Serum or Plasma;MDA SerPl-sCnc;;ACTIVE;2.27;2.44 +55552-4;Methylphenidate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylphenidate [Moles/volume] in Serum or Plasma;Me-phenidate SerPl-sCnc;;ACTIVE;2.27;2.42 +55553-2;Metoprolol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metoprolol [Moles/volume] in Serum or Plasma;Metoprolol SerPl-sCnc;;ACTIVE;2.27;2.42 +55554-0;Mirtazapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mirtazapine [Moles/volume] in Serum or Plasma;Mirtazapine SerPl-sCnc;;ACTIVE;2.27;2.42 +55555-7;Molybdenum;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Molybdenum [Moles/volume] in Blood;Molybdenum Bld-sCnc;;ACTIVE;2.27;2.42 +55556-5;Nadolol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nadolol [Moles/volume] in Serum or Plasma;Nadolol SerPl-sCnc;;ACTIVE;2.27;2.42 +55557-3;Nicotine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nicotine [Moles/volume] in Serum or Plasma;Nicotine SerPl-sCnc;;ACTIVE;2.27;2.42 +5555-8;FMC7;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated FMC7 cells/100 cells in Blood;Deprecated FMC7 WBC-aCnc;;DEPRECATED;1.0;2.69 +55558-1;Nicotine;SCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Nicotine [Moles/volume] in Serum or Plasma by Screen method;Nicotine SerPl Scn-sCnc;;ACTIVE;2.27;2.73 +55559-9;Norpropoxyphene;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norpropoxyphene [Moles/volume] in Serum or Plasma;Norpropoxyph SerPl-sCnc;;ACTIVE;2.27;2.42 +55560-7;Orphenadrine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Orphenadrine [Moles/volume] in Serum or Plasma;Orphenadrine SerPl-sCnc;;ACTIVE;2.27;2.42 +55561-5;Oxprenolol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxprenolol [Moles/volume] in Serum or Plasma;Oxprenolol SerPl-sCnc;;ACTIVE;2.27;2.42 +55562-3;Oxyphenbutazone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxyphenbutazone [Moles/volume] in Serum or Plasma;Oxyphenbutazone SerPl-sCnc;;ACTIVE;2.27;2.44 +55563-1;Paraldehyde;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Paraldehyde [Moles/volume] in Serum or Plasma;Paraldehyde SerPl-sCnc;;ACTIVE;2.27;2.42 +55564-9;Pentazocine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pentazocine [Moles/volume] in Serum or Plasma;Pentazocine SerPl-sCnc;;ACTIVE;2.27;2.42 +55565-6;Phenacetin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenacetin [Moles/volume] in Serum or Plasma;Phenac SerPl-sCnc;;ACTIVE;2.27;2.42 +5556-6;GPA;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated GPA in Blood;Deprecated GPA WBC-aCnc;;DEPRECATED;1.0;2.69 +55566-4;Phenelzine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenelzine [Moles/volume] in Serum or Plasma;Phenelzine SerPl-sCnc;;ACTIVE;2.27;2.42 +55567-2;Pheniramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pheniramine [Moles/volume] in Serum or Plasma;Pheniramine SerPl-sCnc;;ACTIVE;2.27;2.42 +55568-0;Phenolphthalein;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenolphthalein [Moles/volume] in Serum or Plasma;Phenolphthalein SerPl-sCnc;;ACTIVE;2.27;2.42 +55569-8;Phentermine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phentermine [Moles/volume] in Serum or Plasma;Phentermine SerPl-sCnc;;ACTIVE;2.27;2.42 +55570-6;predniSONE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;predniSONE [Moles/volume] in Serum or Plasma;predniSONE SerPl-sCnc;;ACTIVE;2.27;2.42 +55571-4;Prilocaine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Prilocaine [Moles/volume] in Serum or Plasma;Prilocaine SerPl-sCnc;;ACTIVE;2.27;2.42 +55572-2;Procaine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procaine [Moles/volume] in Serum or Plasma;Procaine SerPl-sCnc;;ACTIVE;2.27;2.42 +55573-0;Promethazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Promethazine [Moles/volume] in Serum or Plasma;Promethazine SerPl-sCnc;;ACTIVE;2.27;2.42 +5557-4;HLA-DR;ACnc;Pt;WBC;Qn;;HLA;1;HLA-DR [Units/volume] in Leukocytes;HLA-DR WBC-aCnc;;ACTIVE;1.0;2.69 +55574-8;Propoxyphene+Norpropoxyphene;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Moles/volume] in Serum or Plasma;Propoxyph+Nor SerPl-sCnc;;ACTIVE;2.27;2.42 +55575-5;Pseudoephedrine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pseudoephedrine [Moles/volume] in Serum or Plasma;Pseudoephedrine SerPl-sCnc;;ACTIVE;2.27;2.34 +55576-3;QUEtiapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;QUEtiapine [Moles/volume] in Serum or Plasma;QUEtiapine SerPl-sCnc;;ACTIVE;2.27;2.42 +55577-1;Salicylamide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylamide [Moles/volume] in Serum or Plasma;Salicylamide SerPl-sCnc;;ACTIVE;2.27;2.34 +55578-9;Sildenafil citrate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sildenafil citrate [Moles/volume] in Serum or Plasma;Sildenafil cit SerPl-sCnc;;ACTIVE;2.27;2.44 +55579-7;Sotalol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sotalol [Moles/volume] in Serum or Plasma;Sotalol SerPl-sCnc;;ACTIVE;2.27;2.44 +55580-5;Sulfapyridine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfapyridine [Moles/volume] in Serum or Plasma;Sulfapyridine SerPl-sCnc;;ACTIVE;2.27;2.42 +55581-3;sulfaSALAzine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;sulfaSALAzine [Moles/volume] in Serum or Plasma;sulfaSALAzine SerPl-sCnc;;ACTIVE;2.27;2.34 +5558-2;Myeloperoxidase;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated Myeloperoxidase cells/100 cells in Unspecified specimen;Deprecated Myeloperoxidase WBC-aCnc;;DEPRECATED;1.0;2.69 +55582-1;Timolol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Timolol [Moles/volume] in Serum or Plasma;Timolol SerPl-sCnc;;ACTIVE;2.27;2.42 +55583-9;Tranylcypromine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tranylcypromine [Moles/volume] in Serum or Plasma;Tranylcypromine SerPl-sCnc;;ACTIVE;2.27;2.42 +55584-7;Trimethoprim;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimethoprim [Moles/volume] in Serum or Plasma;Trimethoprim SerPl-sCnc;;ACTIVE;2.27;2.42 +55585-4;Tripelennamine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tripelennamine [Moles/volume] in Serum or Plasma;Tripelennamine SerPl-sCnc;;ACTIVE;2.27;2.42 +55586-2;Verapamil;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Verapamil [Moles/volume] in Serum or Plasma;Verapamil SerPl-sCnc;;ACTIVE;2.27;2.42 +55587-0;Methamphetamine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methamphetamine [Moles/volume] in Urine;Methamphet Ur-sCnc;;ACTIVE;2.27;2.42 +55588-8;OXcarbazepine+10-Hydroxycarbazepine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OXcarbazepine + 10-Hydroxycarbazepine [Moles/volume] in Serum or Plasma;OXcarbazepine+OH-carbazepine SerPl-sCnc;;ACTIVE;2.27;2.42 +55589-6;Budgerigar feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Budgerigar feather IgE Ab [Presence] in Serum;Budgie Feather IgE Ql;;ACTIVE;2.27;2.56 +5559-0;RFD9;ACnc;Pt;WBC;Qn;;CELLMARK;1;RFD9 [Units/volume] in Leukocytes;RFD9 WBC-aCnc;;ACTIVE;1.0;2.69 +55590-4;Canary feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Canary feather IgE Ab [Presence] in Serum;Canary Feather IgE Ql;;ACTIVE;2.27;2.56 +55591-2;Chicken feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chicken feather IgE Ab [Presence] in Serum;Chicken Feather IgE Ql;;ACTIVE;2.27;2.56 +55592-0;Cockatiel feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cockatiel feather IgE Ab [Presence] in Serum;Cockatiel Feather IgE Ql;;ACTIVE;2.27;2.56 +55593-8;Creatinine;SCnc;XXX;Urine;Qn;;CHEM;1;Creatinine [Moles/volume] in Urine collected for unspecified duration;Creat ?Tm Ur-sCnc;;ACTIVE;2.27;2.73 +55594-6;Duck feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Duck feather IgE Ab [Presence] in Serum;Duck Feather IgE Ql;;ACTIVE;2.27;2.56 +55595-3;Finch feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Finch feather IgE Ab [Presence] in Serum;Finch Feather IgE Ql;;ACTIVE;2.27;2.56 +55596-1;Goose feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Goose feather IgE Ab [Presence] in Serum;Goose Feather IgE Ql;;ACTIVE;2.27;2.56 +55597-9;J little s super little b Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Js sup(b) Ab [Titer] in Serum or Plasma;Js sup(b) Ab Titr SerPl;;ACTIVE;2.27;2.42 +55598-7;Leukocytes.disintegrated/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Leukocytes.disintegrated/100 leukocytes in Body fluid by Manual count;WBC.disintegrated/leuk NFr Fld Manual;;ACTIVE;2.27;2.50 +55599-5;Leukocytes.disintegrated/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Leukocytes.disintegrated/100 leukocytes in Cerebral spinal fluid by Manual count;WBC.disintegrated/leuk NFr CSF Manual;;ACTIVE;2.27;2.50 +55600-1;Microscopic observation;Prid;Pt;Periton fld;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Peritoneal fluid by Cyto stain;Cyto Prt;;ACTIVE;2.27;2.27 +55601-9;Microscopic observation;Prid;Pt;Pericard fld;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Pericardial fluid by Cyto stain;Cyto Pcar;;ACTIVE;2.27;2.27 +55602-7;Microscopic observation;Prid;Pt;Plr fld;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Pleural fluid by Cyto stain;Cyto Plr;;ACTIVE;2.27;2.27 +55603-5;Microscopic observation;Prid;Pt;Synv fld;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Synovial fluid by Cyto stain;Cyto Snv;;ACTIVE;2.27;2.27 +55604-3;Microscopic observation;Prid;Pt;Endomet;Nom;Cyto stain;CYTO;1;Microscopic observation [Identifier] in Endometrium by Cyto stain;Cyto Endometrium;;ACTIVE;2.27;2.27 +55605-0;Parakeet feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parakeet feather IgE Ab [Presence] in Serum;Parakeet Feather IgE Ql;;ACTIVE;2.27;2.56 +55606-8;Parrot feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Parrot feather IgE Ab [Presence] in Serum;Parrot Feather IgE Ql;;ACTIVE;2.27;2.56 +55607-6;Triglyceride/Cholesterol.in HDL;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Triglyceride/Cholesterol in HDL [Molar ratio] in Serum or Plasma;Trigl/HDLc SerPl-sRto;;ACTIVE;2.27;2.73 +5560-8;SmIg;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated SmIg;Deprecated SmIg WBC-aCnc;;DEPRECATED;1.0;2.69 +55608-4;Turkey feather Ab.IgE;PrThr;Pt;Ser;Ord;;ALLERGY;1;Turkey feather IgE Ab [Presence] in Serum;Turkey Feather IgE Ql;;ACTIVE;2.27;2.56 +55609-2;Urea;SCnc;XXX;Urine;Qn;;CHEM;1;Urea [Moles/volume] in Urine collected for unspecified duration;Urea ?Tm Ur-sCnc;;ACTIVE;2.27;2.52 +556-1;Chlamydia sp identified;Prid;Pt;Cnjt;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Conjunctival specimen by Organism specific culture;Chlamydia Conjunct Cult;;ACTIVE;1.0;2.17 +55610-0;Follitropin^2nd specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge;FSH sp2 p chal SerPl-aCnc;;ACTIVE;2.27;2.73 +55611-8;Follitropin^1st specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1st specimen post XXX challenge;FSH sp1 p chal SerPl-aCnc;;ACTIVE;2.27;2.73 +55612-6;Follitropin^7th specimen post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --7th specimen post XXX challenge;FSH sp7 p chal SerPl-aCnc;;ACTIVE;2.27;2.73 +55613-4;Number of D to wean patient who is now independent from ventilator;Num;Pt;^Patient;Qn;CARE;SURVEY.CARE;4;Number of days to wean patient who is now independent from ventilator [CARE];;;DISCOURAGED;2.27;2.64 +55614-2;Amoxicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amoxicillin+Sulbactam [Susceptibility];Amoxicillin+Sulbactam Susc Islt;;ACTIVE;2.27;2.27 +55615-9;Amoxicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Amoxicillin+Sulbactam [Susceptibility] by Gradient strip;Amoxicillin+Sulbactam Islt Grad strip;;ACTIVE;2.27;2.56 +5561-6;SmIg kappa;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated SmIg kappa;Deprecated SmIg kappa WBC-aCnc;;DEPRECATED;1.0;2.69 +55616-7;Amoxicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Amoxicillin+Sulbactam [Susceptibility] by Disk diffusion (KB);Amoxicillin+Sulbactam Islt KB;;ACTIVE;2.27;2.27 +55617-5;Antibiotic XXX;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Other Antibiotic [Susceptibility] by Gradient strip;Other Antibiotic Islt Grad strip;;ACTIVE;2.27;2.73 +55618-3;Atovaquone;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Atovaquone [Susceptibility] by Minimum inhibitory concentration (MIC);Atovaquone Islt MIC;;ACTIVE;2.27;2.27 +55619-1;Avilamycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Avilamycin [Susceptibility] by Gradient strip;Avilamycin Islt Grad strip;;ACTIVE;2.27;2.56 +55620-9;Bacampicillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Bacampicillin [Susceptibility] by Gradient strip;Bacampicillin Islt Grad strip;;ACTIVE;2.27;2.56 +55621-7;Bambermycins;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Bambermycins [Susceptibility] by Gradient strip;Bambermycins Islt Grad strip;;ACTIVE;2.27;2.56 +55622-5;Butirosin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Butirosin [Susceptibility] by Gradient strip;Butirosin Islt Grad strip;;ACTIVE;2.27;2.56 +55623-3;Capreomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Capreomycin [Susceptibility] by Gradient strip;Capreomycin Islt Grad strip;;ACTIVE;2.27;2.56 +5562-4;SmIg lambda;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated SmIg lambda;Deprecated SmIg lambda WBC-aCnc;;DEPRECATED;1.0;2.69 +55624-1;Cefacetrile;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefacetrile [Susceptibility] by Minimum inhibitory concentration (MIC);Cefacetrile Islt MIC;;ACTIVE;2.27;2.27 +55625-8;Cefacetrile;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefacetrile [Susceptibility];Cefacetrile Susc Islt;;ACTIVE;2.27;2.27 +55626-6;Cefacetrile;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefacetrile [Susceptibility] by Disk diffusion (KB);Cefacetrile Islt KB;;ACTIVE;2.27;2.27 +55627-4;Cefacetrile;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefacetrile [Susceptibility] by Gradient strip;Cefacetrile Islt Grad strip;;ACTIVE;2.27;2.56 +55628-2;Cefadroxil;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefadroxil [Susceptibility] by Gradient strip;Cefadroxil Islt Grad strip;;ACTIVE;2.27;2.56 +55629-0;Cephaloglycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cephaloglycin [Susceptibility] by Gradient strip;Cephaloglycin Islt Grad strip;;ACTIVE;2.27;2.56 +55630-8;Cephalothin+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cephalothin+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Cephalothin+Sulbactam Islt MIC;;ACTIVE;2.27;2.27 +55631-6;Cephalothin+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cephalothin+Sulbactam [Susceptibility];Cephalothin+Sulbactam Susc Islt;;ACTIVE;2.27;2.27 +5563-2;SmIg-CD79;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated SmIg-CD79;Deprecated SmIg-CD79 WBC-aCnc;;DEPRECATED;1.0;2.69 +55632-4;Cephalothin+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cephalothin+Sulbactam [Susceptibility] by Disk diffusion (KB);Cephalothin+Sulbactam Islt KB;;ACTIVE;2.27;2.27 +55633-2;Cephalothin+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cephalothin+Sulbactam [Susceptibility] by Gradient strip;Cephalothin+Sulbactam Islt Grad strip;;ACTIVE;2.27;2.56 +55634-0;Cefamandole+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefamandole+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Cefamandole+Sulbactam Islt MIC;;ACTIVE;2.27;2.27 +55635-7;Cefamandole+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefamandole+Sulbactam [Susceptibility];Cefamandole+Sulbactam Susc Islt;;ACTIVE;2.27;2.27 +55636-5;Cefamandole+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefamandole+Sulbactam [Susceptibility] by Disk diffusion (KB);Cefamandole+Sulbactam Islt KB;;ACTIVE;2.27;2.27 +55637-3;Cefamandole+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefamandole+Sulbactam [Susceptibility] by Gradient strip;Cefamandole+Sulbactam Islt Grad strip;;ACTIVE;2.27;2.56 +55638-1;Cephapirin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cephapirin [Susceptibility] by Gradient strip;Cephapirin Islt Grad strip;;ACTIVE;2.27;2.56 +55639-9;Cefatrizine;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefatrizine [Susceptibility] by Gradient strip;Cefatrizine Islt Grad strip;;ACTIVE;2.27;2.56 +5564-0;TCR-CD3;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated TCR-CD3;Deprecated TCR-CD3 WBC-aCnc;;DEPRECATED;1.0;2.69 +55640-7;Cefetamet;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefetamet [Susceptibility] by Gradient strip;Cefetamet Islt Grad strip;;ACTIVE;2.27;2.56 +55641-5;Cefmenoxime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefmenoxime [Susceptibility] by Gradient strip;Cefmenoxime Islt Grad strip;;ACTIVE;2.27;2.56 +55642-3;Cefonicid;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefonicid [Susceptibility] by Gradient strip;Cefonocid Islt Grad strip;;ACTIVE;2.27;2.56 +55643-1;Ceforanide;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ceforanide [Susceptibility] by Gradient strip;Ceforanide Islt Grad strip;;ACTIVE;2.27;2.56 +55644-9;Cefotaxime+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefotaxime+Sulbactam [Susceptibility] by Gradient strip;Cefotaxime+Sulbac Islt Grad strip;;ACTIVE;2.27;2.56 +55645-6;Cefotiam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefotiam [Susceptibility] by Gradient strip;Cefotiam Islt Grad strip;;ACTIVE;2.27;2.56 +55646-4;Cephradine;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cephradine [Susceptibility] by Gradient strip;Cephradine Islt Grad strip;;ACTIVE;2.27;2.56 +55647-2;Cefsulodin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefsulodin [Susceptibility] by Gradient strip;Cefsulodin Islt Grad strip;;ACTIVE;2.27;2.56 +55648-0;cefTAZidime+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefTAZidime+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);cefTAZidime+Sulbactam Islt MIC;;ACTIVE;2.27;2.27 +55649-8;cefTAZidime+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefTAZidime+Sulbactam [Susceptibility];cefTAZidime+Sulbactam Susc Islt;;ACTIVE;2.27;2.27 +55650-6;cefTAZidime+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefTAZidime+Sulbactam [Susceptibility] by Disk diffusion (KB);cefTAZidime+Sulbactam Islt KB;;ACTIVE;2.27;2.27 +55651-4;cefTAZidime+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefTAZidime+Sulbactam [Susceptibility] by Gradient strip;cefTAZidime+Sulbactam Islt Grad strip;;ACTIVE;2.27;2.56 +55652-2;Ceftiofur;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ceftiofur [Susceptibility] by Gradient strip;Ceftiofur Islt Grad strip;;ACTIVE;2.27;2.56 +55653-0;Cefuroxime.oral;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefuroxime Oral [Susceptibility] by Gradient strip;Cefuroxime Oral Islt Grad strip;;ACTIVE;2.27;2.56 +55654-8;Cefuroxime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefuroxime [Susceptibility] by Gradient strip;Cefuroxime Islt Grad strip;;ACTIVE;2.27;2.56 +55655-5;Chlortetracycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Chlortetracycline [Susceptibility] by Gradient strip;Chlortetracycline Islt Grad strip;;ACTIVE;2.27;2.56 +55656-3;Cinoxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cinoxacin [Susceptibility] by Gradient strip;Cinoxacin Islt Grad strip;;ACTIVE;2.27;2.56 +5565-7;Terminal deoxyribonucleotidyl transferase;ACnc;Pt;WBC;Qn;;CELLMARK;1;Terminal deoxyribonucleotidyl transferase [Units/volume] in Leukocytes;TdT WBC-aCnc;;ACTIVE;1.0;2.69 +55657-1;Clindamycin.high potency;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clindamycin.high potency [Susceptibility];Clindamycin.high potency Susc Islt;;ACTIVE;2.27;2.27 +55658-9;Clindamycin.high potency;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Clindamycin.high potency [Susceptibility] by Gradient strip;Clindamycin.high potency Islt Grad strip;;ACTIVE;2.27;2.56 +55659-7;Clindamycin.high potency;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clindamycin.high potency [Susceptibility] by Disk diffusion (KB);Clindamycin.high potency Islt KB;;ACTIVE;2.27;2.27 +55660-5;Clindamycin.high potency;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Clindamycin.high potency [Susceptibility] by Minimum inhibitory concentration (MIC);Clindamycin.high potency Islt MIC;;ACTIVE;2.27;2.27 +55661-3;Clofazimine;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Clofazimine [Susceptibility] by Disk diffusion (KB);Clofazamine Islt KB;;ACTIVE;2.27;2.27 +55662-1;Clofazimine;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Clofazimine [Susceptibility] by Gradient strip;Clofazamine Islt Grad strip;;ACTIVE;2.27;2.56 +55663-9;Clotrimazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Clotrimazole [Susceptibility] by Gradient strip;Clotrimazole Islt Grad strip;;ACTIVE;2.27;2.56 +55664-7;Cloxacillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cloxacillin [Susceptibility] by Gradient strip;Cloxacillin Islt Grad strip;;ACTIVE;2.27;2.56 +5566-5;Acetone;PrThr;Pt;Exhl gas;Ord;;DRUG/TOX;1;Acetone [Presence] in Exhaled gas;Acetone ExG Ql;;ACTIVE;1.0;2.56 +55665-4;Colistimethate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Colistimethate by Gradient strip;Colistimethate Islt Grad strip;;ACTIVE;2.27;2.56 +55666-2;Cyclacillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cyclacillin [Susceptibility] by Gradient strip;Cyclacillin Islt Grad strip;;ACTIVE;2.27;2.56 +55667-0;cycloSERINE;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cycloSERINE [Susceptibility] by Gradient strip;cycloSERINE Islt Grad strip;;ACTIVE;2.27;2.56 +55668-8;Dicloxacillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Dicloxacillin [Susceptibility] by Gradient strip;Dicloxacillin Islt Grad strip;;ACTIVE;2.27;2.56 +55669-6;Dibekacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Dibekacin [Susceptibility] by Minimum inhibitory concentration (MIC);Dibekacin Islt MIC;;ACTIVE;2.27;2.27 +55670-4;Dibekacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Dibekacin [Susceptibility];Dibekacin Susc Islt;;ACTIVE;2.27;2.27 +55671-2;Dibekacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Dibekacin [Susceptibility] by Disk diffusion (KB);Dibekacin Islt KB;;ACTIVE;2.27;2.27 +55672-0;Dibekacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Dibekacin [Susceptibility] by Gradient strip;Dibekacin Islt Grad strip;;ACTIVE;2.27;2.56 +5567-3;Acetone;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Acetone [Presence] in Serum or Plasma;Acetone SerPl Ql;;ACTIVE;1.0;2.73 +55673-8;Econazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Econazole [Susceptibility] by Gradient strip;Econazole Islt Grad strip;;ACTIVE;2.27;2.56 +55674-6;Ethambutol 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol 2 ug/mL Islt SlowMyco;;ACTIVE;2.27;2.27 +55675-3;Flumequine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Flumequine [Susceptibility] by Minimum inhibitory concentration (MIC);Flumequine Islt MIC;;ACTIVE;2.27;2.27 +55676-1;Flumequine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Flumequine [Susceptibility];Flumequine Susc Islt;;ACTIVE;2.27;2.27 +55677-9;Flumequine;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Flumequine [Susceptibility] by Disk diffusion (KB);Flumequine Islt KB;;ACTIVE;2.27;2.27 +55678-7;Flumequine;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Flumequine [Susceptibility] by Gradient strip;Flumequine Islt Grad strip;;ACTIVE;2.27;2.56 +55679-5;Framycetin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Framycetin [Susceptibility] by Gradient strip;Framycetin Islt Grad strip;;ACTIVE;2.27;2.56 +55680-3;Isepamicin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Isepamicin [Susceptibility] by Gradient strip;Isepamicin Islt Grad strip;;ACTIVE;2.27;2.56 +5568-1;Acetone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetone [Mass/volume] in Serum or Plasma;Acetone SerPl-mCnc;;ACTIVE;1.0;2.73 +55681-1;Isoconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Isoconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Isoconazole Islt MIC;;ACTIVE;2.27;2.27 +55682-9;Isoconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Isoconazole [Susceptibility];Isoconazole Susc Islt;;ACTIVE;2.27;2.27 +55683-7;Isoconazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Isoconazole [Susceptibility] by Disk diffusion (KB);Isoconazole Islt KB;;ACTIVE;2.27;2.27 +55684-5;Isoconazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Isoconazole [Susceptibility] by Gradient strip;Isoconazole Islt Grad strip;;ACTIVE;2.27;2.56 +55685-2;Isoniazid 10.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Isoniazid 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Isoniazid 10 ug/mL Islt SlowMyco;;ACTIVE;2.27;2.27 +55686-0;Miconazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Miconazole [Susceptibility] by Gradient strip;Miconazole Islt Grad strip;;ACTIVE;2.27;2.56 +55687-8;Miocamycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Miocamycin [Susceptibility] by Gradient strip;Miocamycin Islt Grad strip;;ACTIVE;2.27;2.56 +55688-6;Nitroxoline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Nitroxoline [Susceptibility] by Gradient strip;Nitroxoline Islt Grad strip;;ACTIVE;2.27;2.56 +55689-4;Nystatin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Nystatin [Susceptibility] by Gradient strip;Nystatin Islt Grad strip;;ACTIVE;2.27;2.56 +55690-2;Oleandomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Oleandomycin [Susceptibility] by Gradient strip;Oleandomycin Islt Grad strip;;ACTIVE;2.27;2.56 +55691-0;Ornidazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ornidazole [Susceptibility];Ornidazole Susc Islt;;ACTIVE;2.27;2.27 +55692-8;Ornidazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ornidazole [Susceptibility] by Gradient strip;Ornidazole Islt Grad strip;;ACTIVE;2.27;2.56 +55693-6;Ornidazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ornidazole [Susceptibility] by Disk diffusion (KB);Ornidazole Islt KB;;ACTIVE;2.27;2.27 +55694-4;Ornidazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ornidazole [Susceptibility] by Minimum inhibitory concentration (MIC);Ornidazole Islt MIC;;ACTIVE;2.27;2.27 +55695-1;Oxolinate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Oxolinate [Susceptibility] by Minimum inhibitory concentration (MIC);Oxolinate Islt MIC;;ACTIVE;2.27;2.27 +55696-9;Oxolinate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Oxolinate [Susceptibility];Oxolinate Susc Islt;;ACTIVE;2.27;2.27 +55697-7;Oxolinate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Oxolinate [Susceptibility] by Disk diffusion (KB);Oxolinate Islt KB;;ACTIVE;2.27;2.27 +55698-5;Oxolinate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Oxolinate [Susceptibility] by Gradient strip;Oxolinate Islt Grad strip;;ACTIVE;2.27;2.56 +5569-9;Acetone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Acetone [Presence] in Urine;Acetone Ur Ql;;ACTIVE;1.0;2.73 +55699-3;Oxytetracycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Oxytetracycline [Susceptibility] by Gradient strip;Oxytetracycline Islt Grad strip;;ACTIVE;2.27;2.56 +55700-9;Paromomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Deprecated Paramomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Deprecated Paramomycin Islt MIC;;DEPRECATED;2.27;2.36 +55701-7;Paromomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Paromomycin [Susceptibility] by Disk diffusion (KB);Paromomycin Islt KB;;ACTIVE;2.27;2.29 +55702-5;Paromomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Paromomycin [Susceptibility] by Gradient strip;Paromomycin Islt Grad strip;;ACTIVE;2.27;2.56 +55703-3;Pipemidate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Pipemidate [Susceptibility] by Gradient strip;Pipemidate Islt Grad strip;;ACTIVE;2.27;2.56 +55704-1;Piperacillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Piperacillin+Sulbactam [Susceptibility] by Gradient strip;Piperacillin+Sulbac Islt Grad strip;;ACTIVE;2.27;2.56 +55705-8;Piromidate;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Piromidate [Susceptibility] by Minimum inhibitory concentration (MIC);Piromidate Islt MIC;;ACTIVE;2.27;2.27 +55706-6;Piromidate;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Piromidate [Susceptibility];Piromidate Susc Islt;;ACTIVE;2.27;2.27 +5570-7;Acetone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetone [Mass/volume] in Urine;Acetone Ur-mCnc;;ACTIVE;1.0;2.73 +55707-4;Piromidate;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Piromidate [Susceptibility] by Disk diffusion (KB);Piromidate Islt KB;;ACTIVE;2.27;2.27 +55708-2;Piromidate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Piromidate [Susceptibility] by Gradient strip;Piromidate Islt Grad strip;;ACTIVE;2.27;2.56 +55709-0;Pristinamycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Pristinamycin [Susceptibility] by Gradient strip;Pristinamycin Islt Grad strip;;ACTIVE;2.27;2.56 +55710-8;Pyrazinamide;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Pyrazinamide [Susceptibility] by Gradient strip;PZA Islt Grad strip;;ACTIVE;2.27;2.56 +55711-6;Pyrazinamide 200.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Pyrazinamide 200 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;PZA 200 ug/mL Islt SlowMyco;;ACTIVE;2.27;2.27 +55712-4;rifAMPin 40.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;rifAMPin 40 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;rifAMPin 40 ug/mL Islt SlowMyco;;ACTIVE;2.27;2.27 +55713-2;Rosoxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Rosoxacin [Susceptibility] by Gradient strip;Rosoxacin Islt Grad strip;;ACTIVE;2.27;2.56 +55714-0;Sisomicin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Sisomicin [Susceptibility] by Gradient strip;Sisomicin Islt Grad strip;;ACTIVE;2.27;2.56 +5571-5;Acrylonitrile;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acrylonitrile [Mass/volume] in Blood;Acrylonitrile Bld-mCnc;;ACTIVE;1.0;2.34 +55715-7;Spiramycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Spiramycin [Susceptibility] by Gradient strip;Spiramycin Islt Grad strip;;ACTIVE;2.27;2.56 +55716-5;Ticarcillin+Sulbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ticarcillin+Sulbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Ticarcillin+Sulbactam Islt MIC;;ACTIVE;2.27;2.27 +55717-3;Ticarcillin+Sulbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ticarcillin+Sulbactam [Susceptibility];Ticarcillin+Sulbactam Susc Islt;;ACTIVE;2.27;2.27 +55718-1;Ticarcillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ticarcillin+Sulbactam [Susceptibility] by Disk diffusion (KB);Ticarcillin+Sulbactam Islt KB;;ACTIVE;2.27;2.27 +55719-9;Ticarcillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ticarcillin+Sulbactam [Susceptibility] by Gradient strip;Ticarcillin+Sulbactam Islt Grad strip;;ACTIVE;2.27;2.56 +55720-7;Tinidazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tinidazole [Susceptibility] by Minimum inhibitory concentration (MIC);Tinidazole Islt MIC;;ACTIVE;2.27;2.27 +55721-5;Tinidazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tinidazole [Susceptibility] by Disk diffusion (KB);Tinidazole Islt KB;;ACTIVE;2.27;2.27 +55722-3;Tinidazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Tinidazole [Susceptibility] by Gradient strip;Tinidazole Islt Grad strip;;ACTIVE;2.27;2.56 +5572-3;Aluminum;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Dialysis fluid;Aluminum Dial fld-mCnc;;ACTIVE;1.0;2.73 +55723-1;Virginiamycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Virginiamycin [Susceptibility] by Gradient strip;Virginiamycin Islt Grad strip;;ACTIVE;2.27;2.56 +55724-9;Apolipoprotein A-I & A-II & B & C panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Apolipoprotein A-I and A-II and B and C panel [Mass/volume] - Serum or Plasma;Apol A-I+A-II+B+C Pnl SerPl-mCnc;;ACTIVE;2.27;2.73 +55725-6;Cerebroside sulfatase & N-Acetylgalactosamine-4-Sulfatase panel;CCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Cerebroside sulfatase and N-Acetylgalactosamine-4-Sulfatase panel [Enzymatic activity/volume] - Serum or Plasma;Arylsulfatase A+ B Pnl SerPl-cCnc;;ACTIVE;2.27;2.63 +55726-4;Borrelia burgdorferi Ab.IgA & IgG & IgM panel;-;Pt;CSF;-;;PANEL.MICRO;1;Borrelia burgdorferi IgA and IgG and IgM panel - Cerebral spinal fluid;B burgdor IgA+IgG+IgM Pnl CSF;;ACTIVE;2.27;2.63 +55727-2;Tissue transglutaminase Ab.IgA & IgG panel;-;Pt;Ser;-;;PANEL.SERO;1;Tissue transglutaminase IgA and IgG panel - Serum;tTG IgA+IgG Pnl Ser;;ACTIVE;2.27;2.73 +55728-0;Yersinia sp Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Yersinia sp IgG and IgM panel - Serum;Yersinia sp IgG+IgM Pnl Ser;;ACTIVE;2.27;2.44 +55729-8;Erythrocytes.fetal/100 erythrocytes;Ratio;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Erythrocytes.fetal/100 erythrocytes [Ratio] in Blood by Flow cytometry (FC);Fetal RBC/100 RBC Bld FC-Rto;;ACTIVE;2.27;2.73 +55730-6;Fetal blood;Vol;Pt;Bld;Qn;;HEM/BC;1;Fetal blood [Volume] in Blood;Fetal blood Vol Bld;;ACTIVE;2.27;2.73 +5573-1;Aluminum;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Aluminum [Mass/mass] in Hair;Aluminum Hair-mCnt;;ACTIVE;1.0;2.19 +55731-4;Inject Rh immune globulin;Mass;Pt;Dose;Qn;;BLDBK;1;Inject Rh immune globulin [Mass];Inject Rh Ig Dose Qn;;ACTIVE;2.27;2.73 +55737-1;Cefotiam hexetil;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefotiam hexetil [Susceptibility] by Minimum inhibitory concentration (MIC);Cefotiam hexetil Islt MIC;;ACTIVE;2.27;2.27 +55738-9;Cefotiam hexetil;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefotiam hexetil [Susceptibility];Cefotiam hexetil Susc Islt;;ACTIVE;2.27;2.27 +55739-7;Cefotiam hexetil;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefotiam hexetil [Susceptibility] by Disk diffusion (KB);Cefotiam hexetil Islt KB;;ACTIVE;2.27;2.27 +55740-5;Cefotiam hexetil;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefotiam hexetil [Susceptibility] by Gradient strip;Cefotiam hexetil Islt Grad strip;;ACTIVE;2.27;2.56 +55744-7;howRu panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;howRu;;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.27;2.71 +55745-4;How are you today: pain or discomfort;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are you today: pain or discomfort;;;ACTIVE;2.27;2.70 +55746-2;How are you today: feeling low or worried;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are you today: feeling low or worried;;;ACTIVE;2.27;2.70 +55747-0;How are you today: limited in what I can do;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are you today: limited in what I can do;;;ACTIVE;2.27;2.70 +55748-8;Require help from others;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Require help from others;;;ACTIVE;2.27;2.72 +5574-9;Aluminum;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Serum or Plasma;Aluminum SerPl-mCnc;;ACTIVE;1.0;2.73 +55749-6;howRu score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;howRu score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.27;2.70 +55750-4;Patient safety report;Find;Pt;^Event;Doc;;PATIENT SAFETY;2;Patient safety report Document;Patient safety report Doc;;ACTIVE;2.27;2.66 +55751-2;Case report;Find;Pt;{Setting};Doc;Public health;DOC.ONTOLOGY;2;Public health Case report;Public health Case rprt;;ACTIVE;2.27;2.67 +55752-0;Clinical information;Find;Pt;^Patient;Nar;;PUBLICHEALTH;2;Clinical information;Clinical info;;ACTIVE;2.27;2.73 +55753-8;Treatment information;Find;Pt;^Patient;Nar;;PUBLICHEALTH;2;Treatment information;Treatment info;;ACTIVE;2.27;2.68 +55754-6;Frequency of assistance at admission for home health;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Frequency of assistance at admission for home health [CARE];;;DISCOURAGED;2.27;2.64 +55755-3;Residential Information - Home Health Admission;-;Pt;^Patient;-;CARE;SURVEY.CARE;4;Residential Information - Home Health Admission [CARE];;;DISCOURAGED;2.27;2.64 +5575-6;Aluminum;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Red Blood Cells;Aluminum RBC-mCnc;;ACTIVE;1.0;2.73 +55756-1;Patient lives with on admission for home health;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Patient lives with on admission for home health [CARE];;;DISCOURAGED;2.27;2.64 +55757-9;Patient health questionnaire 2 item;-;Pt;^Patient;-;Reported.PHQ;PANEL.SURVEY.PHQ;4;Patient Health Questionnaire 2 item (PHQ-2) [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.54 +55758-7;Patient health questionnaire 2 item total score;Score;Pt;^Patient;Qn;Reported.PHQ;SURVEY.PHQ;4;Patient Health Questionnaire 2 item (PHQ-2) total score [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.27;2.73 +55759-5;Temporal Orientation - CARE Acute Care;-;Pt;^Patient;-;;SURVEY.CARE;4;Temporal Orientation - CARE Acute Care;;;DISCOURAGED;2.27;2.64 +55760-3;Other service considered appropriate.other specified;Type;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Other service considered appropriate.other specified [CARE];;;DISCOURAGED;2.27;2.64 +55761-1;No services needed after discharge;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;No services needed after discharge [CARE];;;DISCOURAGED;2.27;2.64 +55762-9;Comatose;-;Pt;^Patient;-;;SURVEY.CARE;4;Comatose;;;DISCOURAGED;2.27;2.64 +55763-7;Number of unhealed pressure ulcers at each stage - at assessment;-;Pt;^Patient;-;;SURVEY.CARE;4;Number of unhealed pressure ulcers at each stage - at assessment;;;DISCOURAGED;2.27;2.64 +5576-4;Aluminum;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Aluminum [Mass/volume] in Serum;Deprecated Aluminum Ser-mCnc;;DEPRECATED;1.0;2.36 +55764-5;EGFR gene exon 19 deletion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;EGFR gene exon 19 deletion [Presence] in Blood or Tissue by Molecular genetics method;EGFR exon 19 Del Bld/T Ql;;ACTIVE;2.29;2.73 +55765-2;EGFR gene.c.2156G>C+2155G>A+2155G>T;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;EGFR gene c.2156G>C+2155G>A+2155G>T [Presence] in Blood or Tissue by Molecular genetics method;EGFR c.2156G>C+2155G>A+2155G>T Bld/T Ql;;ACTIVE;2.29;2.40 +55766-0;EGFR gene.c.2573T>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;EGFR gene c.2573T>G [Presence] in Blood or Tissue by Molecular genetics method;EGFR c.2573T>G Bld/T Ql;;ACTIVE;2.29;2.56 +55767-8;EGFR gene.c.2582T>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;EGFR gene c.2582T>A [Presence] in Blood or Tissue by Molecular genetics method;EGFR c.2582T>A Bld/T Ql;;ACTIVE;2.29;2.56 +55768-6;EGFR gene.c.2303G>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;EGFR gene c.2303G>T [Presence] in Blood or Tissue by Molecular genetics method;EGFR c.2303G>T Bld/T Ql;;ACTIVE;2.29;2.56 +55769-4;EGFR gene.c.2369C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;EGFR gene c.2369C>T [Presence] in Blood or Tissue by Molecular genetics method;EGFR c.2369C>T Bld/T Ql;;ACTIVE;2.29;2.56 +55770-2;EGFR gene exon 20 insertion;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;EGFR gene exon 20 insertion [Presence] in Blood or Tissue by Molecular genetics method;EGFR exon 20 Ins Bld/T Ql;;ACTIVE;2.29;2.40 +55771-0;Basophils;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Basophils [#] in Cerebral spinal fluid by Manual count;Basophils CSF Manual;;ACTIVE;2.29;2.69 +5577-2;Aluminum;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Urine;Aluminum Ur-mCnc;;ACTIVE;1.0;2.73 +55772-8;Cardiolipin Ab.IgG;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgG Ab [Multiple of the median] in Serum;Cardiolipin IgG MoM Ser;;ACTIVE;2.29;2.42 +55773-6;Cardiolipin Ab.IgM;MoM;Pt;Ser;Qn;;COAG;1;Cardiolipin IgM Ab [Multiple of the median] in Serum;Cardiolipin IgM MoM Ser;;ACTIVE;2.29;2.42 +55774-4;Direct antiglobulin test.complement C3d specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.complement C3d specific reagent [Presence] on Red Blood Cells;DAT C3d-Sp Reag RBC Ql;;ACTIVE;2.29;2.73 +55775-1;Direct antiglobulin test.IgA specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.IgA specific reagent [Presence] on Red Blood Cells;DAT IgA-Sp Reag RBC Ql;;ACTIVE;2.29;2.56 +55776-9;Direct antiglobulin test.IgG specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.IgG specific reagent [Presence] on Red Blood Cells;DAT IgG-Sp Reag RBC Ql;;ACTIVE;2.29;2.73 +55777-7;Direct antiglobulin test.IgM specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.IgM specific reagent [Presence] on Red Blood Cells;DAT IgM-Sp Reag RBC Ql;;ACTIVE;2.29;2.56 +55778-5;Eosinophils;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Eosinophils [#] in Cerebral spinal fluid by Manual count;Eosinophil CSF Manual;;ACTIVE;2.29;2.73 +55779-3;Erythrocytes;NCnc;Pt;Amnio fld;Qn;;HEM/BC;1;Erythrocytes [#/volume] in Amniotic fluid;RBC # Amn;;ACTIVE;2.29;2.73 +5578-0;Antimony;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Antimony [Mass/volume] in Blood;Antimony Bld-mCnc;;ACTIVE;1.0;2.73 +55780-1;Erythrocytes.nucleated;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes [#] in Cerebral spinal fluid by Manual count;nRBC CSF Manual;;ACTIVE;2.29;2.69 +55781-9;Hematocrit;VFr;Pt;Bone mar;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Bone marrow;Hct VFr Mar;;ACTIVE;2.29;2.42 +55782-7;Hemoglobin;MCnc;Pt;Bld;Qn;Oximetry;HEM/BC;1;Hemoglobin [Mass/volume] in Blood by Oximetry;Hgb Bld Oximetry-mCnc;;ACTIVE;2.29;2.73 +55783-5;Hemoglobin Barts;PrThr;Pt;Bld;Ord;HPLC;HEM/BC;1;Hemoglobin Barts [Presence] in Blood by HPLC;Hgb Barts Bld Ql HPLC;;ACTIVE;2.29;2.56 +55784-3;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;Bone mar;Qn;;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Bone marrow;WBC nRBC cor # Mar;;ACTIVE;2.29;2.44 +55785-0;Lupus anticoagulant neutralization.high phospholipid.factor substitution^immediately after 1:2 addition of saline;Time;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization high phospholipid.factor substitution [Time] in Platelet poor plasma by Coagulation assay --immediately after 1:2 addition of saline;LA Nt HPL imm 1:2 saline PPP;;DISCOURAGED;2.29;2.52 +55786-8;Lupus anticoagulant neutralization.high phospholipid.factor substitution^immediately after 1:2 addition of platelet lysate;Time;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization high phospholipid.factor substitution [Time] in Platelet poor plasma by Coagulation assay --immediately after 1:2 addition of platelet lysate;LA Nt HPL imm 1:2 Plat lysate PPP;;DISCOURAGED;2.29;2.52 +55787-6;Lymphocytes;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Lymphocytes [#] in Cerebral spinal fluid by Manual count;Lymphocytes CSF Manual;;ACTIVE;2.29;2.69 +55788-4;Mononuclear cells;NCnc;Pt;Bone mar;Qn;;HEM/BC;1;Mononuclear cells [#/volume] in Bone marrow;Mononuc Cells # Mar;;ACTIVE;2.29;2.40 +55789-2;Myelocytes;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Myelocytes [#] in Cerebral spinal fluid by Manual count;Myelocytes CSF Manual;;ACTIVE;2.29;2.69 +557-9;Chlamydia sp identified;Prid;Pt;Genital;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Genital specimen by Organism specific culture;Chlamydia Genital Cult;;ACTIVE;1.0;2.73 +55790-0;Neutrophils.band form;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Band form neutrophils [#] in Cerebral spinal fluid by Manual count;Neuts Band CSF Manual;;ACTIVE;2.29;2.69 +55791-8;Neutrophils;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Neutrophils [#] in Cerebral spinal fluid by Manual count;Neutrophils CSF Manual;;ACTIVE;2.29;2.73 +55792-6;Nucleated cells;NCnc;Pt;Bone mar;Qn;;HEM/BC;1;Nucleated cells [#/volume] in Bone marrow;Nuc cell # Mar;;ACTIVE;2.29;2.73 +55793-4;Nucleated cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Nucleated cells [#/volume] in Body fluid;Nuc cell # Fld;;ACTIVE;2.29;2.73 +55794-2;Other cells;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Other cells [#] in Cerebral spinal fluid by Manual count;Other cells CSF Manual;;ACTIVE;2.29;2.73 +55795-9;Phosphatidylserine Ab.IgG;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgG Ab [Multiple of the median] in Serum;PS IgG MoM Ser;;ACTIVE;2.29;2.42 +55796-7;Phosphatidylserine Ab.IgM;MoM;Pt;Ser;Qn;;COAG;1;Phosphatidylserine IgM Ab [Multiple of the median] in Serum;PS IgM MoM Ser;;ACTIVE;2.29;2.42 +55797-5;Platelet aggregation.adenosine diphosphate induced^2.5 umol/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ADP induced [Presence] in Platelet rich plasma --2.5 umol/L;PA ADP 2.5 umol/L PRP Ql;;ACTIVE;2.29;2.56 +5579-8;Antimony;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Antimony [Mass/mass] in Hair;Antimony Hair-mCnt;;ACTIVE;1.0;2.73 +55798-3;Platelet aggregation.adenosine diphosphate induced^5 umol/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ADP induced [Presence] in Platelet rich plasma --5 umol/L;PA ADP 5 umol/L PRP Ql;;ACTIVE;2.29;2.56 +55799-1;Platelet aggregation.ristocetin induced^1125 mg/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ristocetin induced [Presence] in Platelet rich plasma --1125 mg/L;PA Rist 1125 mg/L PRP Ql;;ACTIVE;2.29;2.56 +55800-7;Platelet aggregation.ristocetin induced^1000 mg/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ristocetin induced [Presence] in Platelet rich plasma --1000 mg/L;PA Rist 1000 mg/L PRP Ql;;ACTIVE;2.29;2.56 +55801-5;Platelet aggregation.ristocetin induced^500 mg/L;PrThr;Pt;PRP;Ord;;COAG;1;Platelet aggregation ristocetin induced [Presence] in Platelet rich plasma --500 mg/L;PA Rist 500 mg/L PRP Ql;;ACTIVE;2.29;2.56 +55802-3;Platelets;NCnc;Pt;BldCo;Qn;Estimate;HEM/BC;1;Platelets [#/volume] in Cord blood by Estimate;Platelet # BldCo Est;;ACTIVE;2.29;2.46 +55803-1;Promyelocytes;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Promyelocytes [#] in Cerebral spinal fluid by Manual count;Promyelocytes CSF Manual;;ACTIVE;2.29;2.69 +55804-9;Phosphatase.leukocyte;PrThr;Pt;WBC;Ord;;HEM/BC;1;Leukocyte phosphatase [Presence] in Leukocytes;LAP WBC Ql;;ACTIVE;2.29;2.73 +55805-6;cycloSPORINE;MCnc;Pt;Bld;Qn;LC/MS/MS;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood by LC/MS/MS;cycloSPORINE Bld LC/MS/MS-mCnc;;ACTIVE;2.29;2.73 +5580-6;Antimony;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Antimony [Mass/volume] in Serum or Plasma;Antimony SerPl-mCnc;;ACTIVE;1.0;2.73 +55806-4;Mycophenolate;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Mycophenolate [Mass/volume] in Serum or Plasma by LC/MS/MS;Mycophenolate SerPl LC/MS/MS-mCnc;;ACTIVE;2.29;2.73 +55807-2;Mycophenolate glucuronide;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Mycophenolate glucuronide [Mass/volume] in Serum or Plasma by LC/MS/MS;Mycophenolate-G SerPl LC/MS/MS-mCnc;;ACTIVE;2.29;2.73 +55808-0;11-Deoxycorticosterone;SRat;24H;Urine;Qn;;CHEM;1;11-Deoxycorticosterone [Moles/time] in 24 hour Urine;11DOC 24h Ur-sRate;;ACTIVE;2.29;2.70 +55809-8;11-Deoxycortisol;MCnc;Pt;Amnio fld;Qn;;CHEM;1;11-Deoxycortisol [Mass/volume] in Amniotic fluid;11DC Amn-mCnc;;ACTIVE;2.29;2.70 +55810-6;18-Hydroxycortisol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;18-Hydroxycortisol [Moles/volume] in Serum or Plasma;18OH-Cortis SerPl-sCnc;;ACTIVE;2.29;2.70 +55811-4;18-Hydroxycortisol;SRat;24H;Urine;Qn;;CHEM;1;18-Hydroxycortisol [Moles/time] in 24 hour Urine;18OH-Cortis 24h Ur-sRate;;ACTIVE;2.29;2.70 +55812-2;18-Hydroxycortisol;SCnc;24H;Urine;Qn;;CHEM;1;18-Hydroxycortisol [Moles/volume] in 24 hour Urine;18OH-Cortis 24h Ur-sCnc;;ACTIVE;2.29;2.70 +55813-0;Alpha aminobutyrate/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Alpha aminobutyrate/Amino acids.total in Serum or Plasma;A-Aminobutyr SFr SerPl;;ACTIVE;2.29;2.40 +5581-4;Antimony;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Antimony [Mass/volume] in Urine;Antimony Ur-mCnc;;ACTIVE;1.0;2.73 +55814-8;Calcidiol;SCnc;Pt;BldCo;Qn;;CHEM;1;25-hydroxyvitamin D3 [Moles/volume] in Cord blood;25(OH)D3 BldCo-sCnc;;ACTIVE;2.29;2.70 +55815-5;Dehydroepiandrosterone;MCnc;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in 24 hour Urine;DHEA 24h Ur-mCnc;;ACTIVE;2.29;2.34 +55816-3;3,4-Dihydroxyphenylacetate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;3,4-Dihydroxyphenylacetate [Moles/volume] in Urine;3,4-DiOH-phenylacetate Ur-sCnc;;ACTIVE;2.29;2.70 +55817-1;Amino acids;SCnt;Pt;Hair;Qn;;CHEM;1;Amino acids [Moles/mass] in Hair;Amino acids Hair-sCnt;;ACTIVE;2.29;2.70 +55818-9;Organic acids;SCnt;Pt;Stool;Qn;;CHEM;1;Organic acids [Moles/mass] in Stool;Organic Acids Stl-sCnt;;ACTIVE;2.29;2.70 +55819-7;Adiponectin.high molecular weight;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adiponectin.high molecular weight [Mass/volume] in Serum or Plasma;Adiponectin.HMW SerPl-mCnc;;ACTIVE;2.29;2.70 +55820-5;Allo-pregnanediol;MRat;24H;Urine;Qn;;CHEM;1;Allo-pregnanediol [Mass/time] in 24 hour Urine;Allo-pregnanediol 24h Ur-mRate;;ACTIVE;2.29;2.70 +55821-3;Allo-pregnanediol;MCnc;24H;Urine;Qn;;CHEM;1;Allo-pregnanediol [Mass/volume] in 24 hour Urine;Allo-pregnanediol 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5582-2;Arsenic;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Arsenic [Presence] in Blood;Arsenic Bld Ql;;ACTIVE;1.0;2.56 +55822-1;Allo-tetrahydrodeoxycortisol;MRat;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrodeoxycortisol [Mass/time] in 24 hour Urine;Allo-TH-DC 24h Ur-mRate;;ACTIVE;2.29;2.70 +55823-9;Allo-tetrahydrodeoxycortisol;MCnc;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrodeoxycortisol [Mass/volume] in 24 hour Urine;Allo-TH-DC 24h Ur-mCnc;;ACTIVE;2.29;2.70 +55824-7;Allo-tetrahydrocorticosterone;MRat;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrocorticosterone [Mass/time] in 24 hour Urine;Allo-THB 24h Ur-mRate;;ACTIVE;2.29;2.70 +55825-4;Allo-tetrahydrocorticosterone;MCnc;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrocorticosterone [Mass/volume] in 24 hour Urine;Allo-THB 24h Ur-mCnc;;ACTIVE;2.29;2.70 +55826-2;Allo-tetrahydrocortisol;MCnc;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrocortisol [Mass/volume] in 24 hour Urine;Allo-THF 24h Ur-mCnc;;ACTIVE;2.29;2.70 +55827-0;Acid alpha glucosidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Acid alpha glucosidase [Enzymatic activity/volume] in DBS;Acid A-Glucosidase DBS-cCnc;;ACTIVE;2.29;2.70 +55828-8;Aliphatic carboxylate C14-C26.esters;PrThr;Pt;Stool;Ord;;CHEM;1;Aliphatic carboxylate, C14-C26.esters [Presence] in Stool;Al Carb C14-C26 Ester Stl Ql;;ACTIVE;2.29;2.56 +55829-6;Catalase;CCnt;Pt;Tiss;Qn;;CHEM;1;Catalase [Enzymatic activity/mass] in Tissue;Catalase Tiss-cCnt;;ACTIVE;2.29;2.70 +5583-0;Arsenic;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Blood;Arsenic Bld-mCnc;;ACTIVE;1.0;2.73 +55830-4;Catecholamines;SCnc;Pt;CSF;Qn;;CHEM;1;Catecholamines [Moles/volume] in Cerebral spinal fluid;Catechols CSF-sCnc;;ACTIVE;2.29;2.70 +55831-2;Catecholamines;SCnc;Pt;Body fld;Qn;;CHEM;1;Catecholamines [Moles/volume] in Body fluid;Catechols Fld-sCnc;;ACTIVE;2.29;2.70 +55832-0;Cathepsin K;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cathepsin K [Moles/volume] in Serum or Plasma;Cathepsin K SerPl-sCnc;;ACTIVE;2.29;2.70 +55833-8;Cathepsin L;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cathepsin L [Mass/volume] in Serum or Plasma;Cathepsin L SerPl-mCnc;;ACTIVE;2.29;2.70 +55834-6;Cathepsin S;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cathepsin S [Mass/volume] in Serum or Plasma;Cathepsin S SerPl-mCnc;;ACTIVE;2.29;2.70 +55835-3;Vegetable fibers;PrThr;Pt;Stool;Ord;Microscopy.light;CHEM;1;Vegetable fibers [Presence] in Stool by Light microscopy;Vegetable Fibers Stl Ql Micro;;ACTIVE;2.29;2.56 +55836-1;Chitotriosidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Chitotriosidase [Enzymatic activity/volume] in DBS;Chitotriosidase DBS-cCnc;;ACTIVE;2.29;2.70 +55837-9;Chloride;SCnc;24H;Stool;Qn;;CHEM;1;Chloride [Moles/volume] in 24 hour Stool;Chloride 24h Stl-sCnc;;ACTIVE;2.29;2.70 +55838-7;Cholesterol/Phospholipid;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol/Phospholipid [Molar ratio] in Serum or Plasma;Cholest/Phospholipid SerPl-sRto;;ACTIVE;2.29;2.42 +55839-5;Cholesterol ester transfer protein;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol ester transfer protein [Units/volume] in Serum or Plasma;Cholest est trnsfr prot SerPl-aCnc;;ACTIVE;2.29;2.69 +55840-3;Cholesterol esters;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol esters [Moles/volume] in Serum or Plasma;Cholest Ester SerPl-sCnc;;ACTIVE;2.29;2.40 +55841-1;Corticosterone;MCnc;24H;Urine;Qn;;CHEM;1;Corticosterone [Mass/volume] in 24 hour Urine;Corticoster 24h Ur-mCnc;;ACTIVE;2.29;2.70 +55842-9;Corticosterone;SRat;24H;Urine;Qn;;CHEM;1;Corticosterone [Moles/time] in 24 hour Urine;Corticoster 24h Ur-sRate;;ACTIVE;2.29;2.70 +55843-7;Corticosterone;SCnc;24H;Urine;Qn;;CHEM;1;Corticosterone [Moles/volume] in 24 hour Urine;Corticoster 24h Ur-sCnc;;ACTIVE;2.29;2.70 +55844-5;Cortisol.free;MRat;24H;Urine;Qn;RIA;CHEM;1;Cortisol Free [Mass/time] in 24 hour Urine by Radioimmunoassay (RIA);Cortis F 24h Ur RIA-mRate;;ACTIVE;2.29;2.70 +55845-2;Cortisol.free;MCnc;24H;Urine;Qn;RIA;CHEM;1;Cortisol Free [Mass/volume] in 24 hour Urine by Radioimmunoassay (RIA);Cortis F 24h Ur RIA-mCnc;;ACTIVE;2.29;2.70 +55846-0;Cryoglobulin.IgA.monoclonal;PrThr;Pt;Ser;Ord;;SERO;1;Cryoglobulin.IgA.monoclonal [Presence] in Serum;Cryoglob IgA moncl Ser Ql;;ACTIVE;2.29;2.56 +55847-8;Cryoglobulin.IgG.monoclonal;PrThr;Pt;Ser;Ord;;SERO;1;Cryoglobulin.IgG.monoclonal [Presence] in Serum;Cryoglob IgG moncl Ser Ql;;ACTIVE;2.29;2.56 +5584-8;Arsenic;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Arsenic [Mass/mass] in Hair;Arsenic Hair-mCnt;;ACTIVE;1.0;2.73 +55848-6;Cryoglobulin.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Cryoglobulin.IgG [Presence] in Serum;Cryoglob IgG Ser Ql;;ACTIVE;2.29;2.56 +55849-4;Cryoglobulin.IgM.monoclonal;PrThr;Pt;Ser;Ord;;SERO;1;Cryoglobulin.IgM.monoclonal [Presence] in Serum;Cryoglob IgM moncl Ser Ql;;ACTIVE;2.29;2.56 +55850-2;Cobalamins;MCnc;Pt;Urine;Qn;;CHEM;1;Cobalamin (Vitamin B12) [Mass/volume] in Urine;Vit B12 Ur-mCnc;;ACTIVE;2.29;2.70 +55851-0;Androstenediol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstenediol [Moles/volume] in Serum or Plasma;Androstenediol SerPl-sCnc;;ACTIVE;2.29;2.70 +55852-8;Dicarboxydodecanoylcarnitine (C12-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dicarboxydodecanoylcarnitine (C12-DC)/Creatinine [Molar ratio] in Urine;Dicarboxydodecanoylcarn/Creat Ur-sRto;;ACTIVE;2.29;2.70 +55853-6;Dicarboxydodecanoylcarnitine (C12-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Dicarboxydodecanoylcarnitine (C12-DC) [Moles/volume] in Cerebral spinal fluid;Dicarboxydodecanoylcarn CSF-sCnc;;ACTIVE;2.29;2.70 +55854-4;Dicarboxydodecanoylcarnitine (C12-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dicarboxydodecanoylcarnitine (C12-DC) [Moles/volume] in Amniotic fluid;Dicarboxydodecanoylcarn Amn-sCnc;;ACTIVE;2.29;2.70 +5585-5;Arsenic;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Serum or Plasma;Arsenic SerPl-mCnc;;ACTIVE;1.0;2.73 +55855-1;Dicarboxydodecanoylcarnitine (C12-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxydodecanoylcarnitine (C12-DC) [Moles/volume] in Serum or Plasma;Dicarboxydodecanoylcarn SerPl-sCnc;;ACTIVE;2.29;2.70 +55856-9;Dicarboxydodecanoylcarnitine (C12-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Dicarboxydodecanoylcarnitine (C12-DC) [Moles/volume] in Urine;Dicarboxydodecanoylcarn Ur-sCnc;;ACTIVE;2.29;2.70 +55857-7;Estradiol;MCnc;Pt;Body fld;Qn;;CHEM;1;Estradiol (E2) [Mass/volume] in Body fluid;Estradiol Fld-mCnc;;ACTIVE;2.29;2.70 +55858-5;Estradiol;SCnc;Pt;Body fld;Qn;;CHEM;1;Estradiol (E2) [Moles/volume] in Body fluid;Estradiol Fld-sCnc;;ACTIVE;2.29;2.70 +55859-3;Folate;MCnc;Pt;CSF;Qn;;CHEM;1;Folate [Mass/volume] in Cerebral spinal fluid;Folate CSF-mCnc;;ACTIVE;2.29;2.70 +55860-1;Glucose;MRat;24H;Stool;Qn;;CHEM;1;Glucose [Mass/time] in 24 hour Stool;Glucose 24h Stl-mRate;;ACTIVE;2.29;2.70 +55861-9;Glutamate;SCnt;Pt;Hair;Qn;;CHEM;1;Glutamate [Moles/mass] in Hair;Glutamate Hair-sCnt;;ACTIVE;2.29;2.70 +55862-7;Glycine;SCnt;Pt;Hair;Qn;;CHEM;1;Glycine [Moles/mass] in Hair;Glycine Hair-sCnt;;ACTIVE;2.29;2.70 +5586-3;Arsenic;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Urine;Arsenic Ur-mCnc;;ACTIVE;1.0;2.73 +55863-5;Glycolate;MCnc;Pt;Body fld;Qn;;CHEM;1;Glycolate [Mass/volume] in Body fluid;Glycolate Fld-mCnc;;ACTIVE;2.29;2.70 +55864-3;Glycolate;SCnc;Pt;Body fld;Qn;;CHEM;1;Glycolate [Moles/volume] in Body fluid;Glycolate Fld-sCnc;;ACTIVE;2.29;2.70 +55865-0;Glycolate;SCnc;Pt;Urine;Qn;;CHEM;1;Glycolate [Moles/volume] in Urine;Glycolate Ur-sCnc;;ACTIVE;2.29;2.70 +55866-8;Choriogonadotropin.beta subunit.free;MCnc;Pt;CSF;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Mass/volume] in Cerebral spinal fluid;B-HCG Free CSF-mCnc;;ACTIVE;2.29;2.70 +55867-6;Choriogonadotropin.beta subunit.free;MCnc;Pt;Body fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit free [Mass/volume] in Body fluid;B-HCG Free Fld-mCnc;;ACTIVE;2.29;2.70 +55868-4;Choriogonadotropin.beta subunit;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Multiple of the median] in Serum or Plasma;B-HCG MoM SerPl;;ACTIVE;2.29;2.73 +55869-2;Choriogonadotropin.beta subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Mass/volume] in Serum or Plasma;B-HCG SerPl-mCnc;;ACTIVE;2.29;2.73 +558-7;Chlamydia sp identified;Prid;Pt;Thrt;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Throat by Organism specific culture;Chlamydia Throat Cult;;ACTIVE;1.0;2.73 +55870-0;Choriogonadotropin;ACnc;Pt;BldCo;Qn;;CHEM;1;Choriogonadotropin [Units/volume] in Cord blood;HCG BldCo-aCnc;;ACTIVE;2.29;2.70 +5587-1;Arsenic;MRat;24H;Urine;Qn;;DRUG/TOX;1;Arsenic [Mass/time] in 24 hour Urine;Arsenic 24h Ur-mRate;;ACTIVE;1.0;2.73 +55871-8;Heptanoylcarnitine (C7);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Heptanoylcarnitine (C7) [Moles/volume] in Serum or Plasma;Heptanoylcarn SerPl-sCnc;;ACTIVE;2.29;2.70 +55872-6;Dicarboxypalmitoylcarnitine (C16-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxypalmitoylcarnitine (C16-DC) [Moles/volume] in Serum or Plasma;Dicarboxypalmitoylcarn SerPl-sCnc;;ACTIVE;2.29;2.70 +55873-4;Palmitate/Laurate;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Palmitate (C16:0)/Laurate (C12:0) [Molar ratio] in Serum or Plasma;Palmitate/Laurate SerPl-sRto;;ACTIVE;2.29;2.42 +55874-2;Histidine;SCnt;Pt;Hair;Qn;;CHEM;1;Histidine [Moles/mass] in Hair;Histidine Hair-sCnt;;ACTIVE;2.29;2.70 +55875-9;Homocitrulline;SCnc;Pt;CSF;Qn;;CHEM;1;Homocitrulline [Moles/volume] in Cerebral spinal fluid;Homocitrulline CSF-sCnc;;ACTIVE;2.29;2.73 +55876-7;Homocitrulline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocitrulline [Moles/volume] in Serum or Plasma;Homocitrulline SerPl-sCnc;;ACTIVE;2.29;2.73 +55877-5;Homocysteine;SCnc;Pt;Body fld;Qn;;CHEM;1;Homocysteine [Moles/volume] in Body fluid;Hcys Fld-sCnc;;ACTIVE;2.29;2.73 +55878-3;Homocysteine;SCnc;24H;Urine;Qn;;CHEM;1;Homocysteine [Moles/volume] in 24 hour Urine;Hcys 24h Ur-sCnc;;ACTIVE;2.29;2.73 +55879-1;Homocystine;SCnc;Pt;Body fld;Qn;;CHEM;1;Homocystine [Moles/volume] in Body fluid;(Hcys)2 Fld-sCnc;;ACTIVE;2.29;2.70 +55880-9;Homovanillate;SCnc;Pt;Ser;Qn;;CHEM;1;Homovanillate [Moles/volume] in Serum;HVA Ser-sCnc;;ACTIVE;2.29;2.70 +55881-7;Hydroxocobalamin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxocobalamin [Moles/volume] in Serum or Plasma;Vit B12b SerPl-sCnc;;ACTIVE;2.29;2.70 +55882-5;Hydroxocobalamin;SCnc;Pt;Body fld;Qn;;CHEM;1;Hydroxocobalamin [Moles/volume] in Body fluid;Vit B12b Fld-sCnc;;ACTIVE;2.29;2.70 +55883-3;Hydroxocobalamin;MCnc;Pt;Body fld;Qn;;CHEM;1;Hydroxocobalamin [Mass/volume] in Body fluid;Vit B12b Fld-mCnc;;ACTIVE;2.29;2.70 +55884-1;Hydroxocobalamin;SCnc;Pt;Urine;Qn;;CHEM;1;Hydroxocobalamin [Moles/volume] in Urine;Vit B12b Ur-sCnc;;ACTIVE;2.29;2.70 +55885-8;Hydroxocobalamin;MCnc;Pt;Urine;Qn;;CHEM;1;Hydroxocobalamin [Mass/volume] in Urine;Vit B12b Ur-mCnc;;ACTIVE;2.29;2.70 +55886-6;3-Hydroxyanthranilate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyanthranilate/Creatinine [Molar ratio] in Urine;3OH-anthranilate/Creat Ur-sRto;;ACTIVE;2.29;2.70 +55887-4;3-Hydroxyanthranilate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyanthranilate [Moles/volume] in Serum or Plasma;3OH-anthranilate SerPl-sCnc;;ACTIVE;2.29;2.70 +55888-2;3-Hydroxyanthranilate;SRat;24H;Urine;Qn;;CHEM;1;3-Hydroxyanthranilate [Moles/time] in 24 hour Urine;3OH-anthranilate 24h Ur-sRate;;ACTIVE;2.29;2.70 +5588-9;Barium;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Barium [Presence] in Serum or Plasma;Barium SerPl Ql;;ACTIVE;1.0;2.56 +55889-0;3-Hydroxyanthranilate;SCnc;Pt;Urine;Qn;;CHEM;1;3-Hydroxyanthranilate [Moles/volume] in Urine;3OH-anthranilate Ur-sCnc;;ACTIVE;2.29;2.70 +55890-8;Hydroxylysine/Amino acids.total;SFr;Pt;Hair;Qn;;CHEM;1;Hydroxylysine/Amino acids.total in Hair;OH-Lysine SFr Hair;;ACTIVE;2.29;2.70 +55891-6;Hydroxylysine;SCnt;Pt;Hair;Qn;;CHEM;1;Hydroxylysine [Moles/mass] in Hair;OH-Lysine Hair-sCnt;;ACTIVE;2.29;2.70 +55892-4;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase;CRto;Pt;Amnio fld cells;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase [Enzymatic activity ratio] in Amniotic fluid cells;HPRT/APRT Amnc-cRto;;ACTIVE;2.29;2.42 +55893-2;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase;CRto;Pt;RBC;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase [Enzymatic activity ratio] in Red Blood Cells;HPRT/APRT RBC-cRto;;ACTIVE;2.29;2.42 +55894-0;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase;CRto;Pt;Placenta;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase [Enzymatic activity ratio] in Placenta;HPRT/APRT Placenta-cRto;;ACTIVE;2.29;2.63 +55895-7;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase;CRto;Pt;CVS;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase/Adenine phosphoribosyltransferase [Enzymatic activity ratio] in Chorionic villus sample;HPRT/APRT CVS-cRto;;ACTIVE;2.29;2.42 +55896-5;Hypoxanthine phosphoribosyltransferase;CCnt;Pt;CVS;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase [Enzymatic activity/mass] in Chorionic villus sample;HPRT CVS-cCnt;;ACTIVE;2.29;2.42 +5589-7;Barium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Barium [Mass/volume] in Serum or Plasma;Barium SerPl-mCnc;;ACTIVE;1.0;2.73 +55897-3;Immunoglobulin light chains.free;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;Immunoglobulin light chains.free [Presence] in Serum by Immunoelectrophoresis;BJ Protein Free Ser Ql IEP;;ACTIVE;2.29;2.56 +55898-1;Immunoglobulin light chains.free;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;Immunoglobulin light chains.free [Presence] in Serum by Immunofixation;BJ Protein Free Ser Ql IFE;;ACTIVE;2.29;2.73 +55899-9;Immunoglobulin light chains.free;PrThr;Pt;Urine;Ord;Electrophoresis;CHEM;1;Immunoglobulin light chains.free [Presence] in Urine by Electrophoresis;BJ Protein Free Ur Ql Elph;;ACTIVE;2.29;2.56 +55900-5;Immunoglobulin light chains.free;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;Immunoglobulin light chains.free [Presence] in Urine by Immunofixation;BJ Protein Free Ur Ql IFE;;ACTIVE;2.29;2.73 +55901-3;IgA.monoclonal;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgA.monoclonal [Presence] in Serum by Immunoelectrophoresis;M-IgA Ser Ql IEP;;ACTIVE;2.29;2.56 +55902-1;IgA;MCnc;Pt;Ser;Qn;Electrophoresis;CHEM;1;IgA [Mass/volume] in Serum by Electrophoresis;IgA Ser Elph-mCnc;;ACTIVE;2.29;2.70 +55903-9;IgD.monoclonal;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgD.monoclonal [Presence] in Serum by Immunoelectrophoresis;M-IgD Ser Ql IEP;;ACTIVE;2.29;2.56 +55904-7;IgE.monoclonal;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgE.monoclonal [Presence] in Serum by Immunoelectrophoresis;M-IgE Ser Ql IEP;;ACTIVE;2.29;2.56 +5590-5;Barium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Barium [Mass/volume] in Urine;Barium Ur-mCnc;;ACTIVE;1.0;2.73 +55905-4;Alpha cortol;MCnc;24H;Urine;Qn;;CHEM;1;Alpha cortol [Mass/volume] in 24 hour Urine;A-Cortol 24h Ur-mCnc;;ACTIVE;2.29;2.70 +55906-2;Alpha cortolone;MRat;24H;Urine;Qn;;CHEM;1;Alpha cortolone [Mass/time] in 24 hour Urine;A-cortolone 24h Ur-mRate;;ACTIVE;2.29;2.70 +55907-0;Alpha cortolone;MCnc;24H;Urine;Qn;;CHEM;1;Alpha cortolone [Mass/volume] in 24 hour Urine;A-cortolone 24h Ur-mCnc;;ACTIVE;2.29;2.70 +55908-8;Alpha galactosidase A;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Alpha galactosidase A [Enzymatic activity/volume] in DBS;A-Galactosidase A DBS-cCnc;;ACTIVE;2.29;2.70 +55909-6;Alpha-L-iduronidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Alpha-L-iduronidase [Enzymatic activity/volume] in DBS;A-L-Iduronidase DBS-cCnc;;ACTIVE;2.29;2.70 +55910-4;Alpha mannosidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Alpha mannosidase [Enzymatic activity/volume] in DBS;A-Mannosidase DBS-cCnc;;ACTIVE;2.29;2.70 +55911-2;Arginine;SCnt;Pt;Hair;Qn;;CHEM;1;Arginine [Moles/mass] in Hair;Arginine Hair-sCnt;;ACTIVE;2.29;2.70 +55912-0;Arylsulfatase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Arylsulfatase [Enzymatic activity/volume] in DBS;Arylsulfatase DBS-cCnc;;ACTIVE;2.29;2.70 +5591-3;Benzene;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Benzene [Presence] in Serum or Plasma;Benzene SerPl Ql;;ACTIVE;1.0;2.56 +55913-8;Aspartate;SCnt;Pt;Hair;Qn;;CHEM;1;Aspartate [Moles/mass] in Hair;Aspartate Hair-sCnt;;ACTIVE;2.29;2.70 +55914-6;Beta 1 globulin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Beta 1 globulin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;Beta1 Glob CSF Elph-mCnc;;ACTIVE;2.29;2.70 +55915-3;Beta 2 globulin;MCnc;Pt;CSF;Qn;Electrophoresis;CHEM;1;Beta 2 globulin [Mass/volume] in Cerebral spinal fluid by Electrophoresis;Beta2 Glob CSF Elph-mCnc;;ACTIVE;2.29;2.70 +55916-1;Beta galactosidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Beta galactosidase [Enzymatic activity/volume] in DBS;B-Galactosidase DBS-cCnc;;ACTIVE;2.29;2.70 +55917-9;Glucosylceramidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Glucosylceramidase [Enzymatic activity/volume] in DBS;Glucosylceramidase DBS-cCnc;;ACTIVE;2.29;2.70 +55918-7;C peptide^post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --post meal;C peptide p meal SerPl-mCnc;;ACTIVE;2.29;2.70 +55919-5;C peptide^post meal;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --post meal;C peptide p meal SerPl-sCnc;;ACTIVE;2.29;2.70 +55920-3;C peptide;MCnc;24H;Urine;Qn;;CHEM;1;C peptide [Mass/volume] in 24 hour Urine;C peptide 24h Ur-mCnc;;ACTIVE;2.29;2.73 +5592-1;Benzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzene [Mass/volume] in Serum or Plasma;Benzene SerPl-mCnc;;ACTIVE;1.0;2.73 +55921-1;IgG.monoclonal;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgG.monoclonal [Presence] in Serum by Immunoelectrophoresis;M-IgG Ser Ql IEP;;ACTIVE;2.29;2.56 +55922-9;IgG;MCnc;Pt;Ser;Qn;Electrophoresis;CHEM;1;IgG [Mass/volume] in Serum by Electrophoresis;IgG Ser Elph-mCnc;;ACTIVE;2.29;2.70 +55923-7;IgG;MRat;24H;Urine;Qn;;CHEM;1;IgG [Mass/time] in 24 hour Urine;IgG 24h Ur-mRate;;ACTIVE;2.29;2.70 +55924-5;IgM.monoclonal;PrThr;Pt;Ser;Ord;Immunoelectrophoresis;CHEM;1;IgM.monoclonal [Presence] in Serum by Immunoelectrophoresis;M-IgM Ser Ql IEP;;ACTIVE;2.29;2.56 +55925-2;IgM;MCnc;Pt;Ser;Qn;Electrophoresis;CHEM;1;IgM [Mass/volume] in Serum by Electrophoresis;IgM Ser Elph-mCnc;;ACTIVE;2.29;2.70 +55926-0;Interleukin 1 receptor alpha chain;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 1 receptor alpha chain [Mass/volume] in Serum or Plasma;Il2RecepA SerPl-mCnc;;ACTIVE;2.29;2.70 +55927-8;Interleukin 1 receptor alpha chain.soluble;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 1 receptor alpha chain soluble [Mass/volume] in Serum or Plasma;Sol IL1RA SerPl-mCnc;;ACTIVE;2.29;2.73 +55928-6;Iodine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Iodine/Creatinine [Mass Ratio] in Urine;Iodine/Creat Ur;;ACTIVE;2.29;2.73 +55929-4;Isoleucine;SCnt;Pt;Hair;Qn;;CHEM;1;Isoleucine [Moles/mass] in Hair;Isoleucine Hair-sCnt;;ACTIVE;2.29;2.70 +55930-2;Isovalerylglycine;SCnc;Pt;Plas;Qn;;CHEM;1;Isovalerylglycine [Moles/volume] in Plasma;Isovalerylgly Plas-sCnc;;ACTIVE;2.29;2.70 +55931-0;Lactate;SCnc;Pt;Dial fld;Qn;;CHEM;1;Lactate [Moles/volume] in Dialysis fluid;Lactate Dial fld-sCnc;;ACTIVE;2.29;2.70 +55932-8;Lactate;SCnc;Pt;BldCo;Qn;;CHEM;1;Lactate [Moles/volume] in Cord blood;Lactate BldCo-sCnc;;ACTIVE;2.29;2.70 +55933-6;Leucine;SCnt;Pt;Hair;Qn;;CHEM;1;Leucine [Moles/mass] in Hair;Leucine Hair-sCnt;;ACTIVE;2.29;2.70 +55934-4;Triacylglycerol lipase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Dialysis fluid;Lipase Dial fld-cCnc;;ACTIVE;2.29;2.70 +55935-1;Lysine;SCnt;Pt;Hair;Qn;;CHEM;1;Lysine [Moles/mass] in Hair;Lysine Hair-sCnt;;ACTIVE;2.29;2.70 +55936-9;Lysozyme;MCnc;Pt;CSF;Qn;;CHEM;1;Lysozyme [Mass/volume] in Cerebral spinal fluid;Lysozyme CSF-mCnc;;ACTIVE;2.29;2.70 +55937-7;Magnesium^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Magnesium [Moles/volume] in Serum or Plasma --post dialysis;Magnesium p dialysis SerPl-sCnc;;ACTIVE;2.29;2.70 +55938-5;Magnesium;SCnc;Pt;TPN;Qn;;CHEM;1;Magnesium [Moles/volume] in Total parental nutrition;Magnesium TPN-sCnc;;ACTIVE;2.29;2.70 +5593-9;Beryllium;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Beryllium [Presence] in Serum or Plasma;Beryllium SerPl Ql;;ACTIVE;1.0;2.56 +55939-3;Malondialdehyde;SCnt;Pt;RBC;Qn;;CHEM;1;Malondialdehyde [Moles/mass] in Red Blood Cells;Malondialdehyde RBC-sCnt;;ACTIVE;2.29;2.70 +55940-1;Malonylcarnitine (C3-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Malonylcarnitine (C3-DC) [Moles/volume] in Serum or Plasma;Malonylcarn SerPl-sCnc;;ACTIVE;2.29;2.73 +55941-9;Mannitol;MCnc;Pt;Urine;Qn;;CHEM;1;Mannitol [Mass/volume] in Urine;Mannitol Ur-mCnc;;ACTIVE;2.29;2.70 +55942-7;Methemoglobin/Hemoglobin.total;MFr;Pt;BldCo;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Cord blood;MetHgb MFr BldCo;;ACTIVE;2.29;2.70 +55943-5;Methionine;SCnt;Pt;Hair;Qn;;CHEM;1;Methionine [Moles/mass] in Hair;Methionine Hair-sCnt;;ACTIVE;2.29;2.70 +55944-3;Neopterin;SRat;24H;Urine;Qn;;CHEM;1;Neopterin [Moles/time] in 24 hour Urine;Neopterin 24h Ur-sRate;;ACTIVE;2.29;2.70 +55945-0;Neopterin;SCnc;24H;Urine;Qn;;CHEM;1;Neopterin [Moles/volume] in 24 hour Urine;Neopterin 24h Ur-sCnc;;ACTIVE;2.29;2.70 +55946-8;Neopterin;SCnc;Pt;Urine;Qn;;CHEM;1;Neopterin [Moles/volume] in Urine;Neopterin Ur-sCnc;;ACTIVE;2.29;2.70 +5594-7;Beryllium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in Serum or Plasma;Beryllium SerPl-mCnc;;ACTIVE;1.0;2.73 +55947-6;Nitrite;MCnc;Pt;Dial fld;Qn;;CHEM;1;Nitrite [Mass/volume] in Dialysis fluid;Nitrite Dial fld-mCnc;;ACTIVE;2.29;2.70 +55948-4;Nitrite;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Nitrite [Moles/volume] in Serum or Plasma;Nitrite SerPl-sCnc;;ACTIVE;2.29;2.73 +55949-2;Dicarboxystearoylcarnitine (C18-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxystearoylcarnitine (C18-DC) [Moles/volume] in Serum or Plasma;Dicarboxystearoylcarn SerPl-sCnc;;ACTIVE;2.29;2.70 +559-5;Chlamydia sp identified;Prid;Pt;Urethra;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Urethra by Organism specific culture;Chlamydia Urth Cult;;ACTIVE;1.0;2.19 +55950-0;Octanoylcarnitine (C8);SCnc;Pt;Urine;Qn;;CHEM;1;Octanoylcarnitine (C8) [Moles/volume] in Urine;Octanoylcarn Ur-sCnc;;ACTIVE;2.29;2.70 +55951-8;Octenoylcarnitine (C8:1)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Octenoylcarnitine (C8:1)/Creatinine [Molar ratio] in Urine;Octenoylcarn/Creat Ur-sRto;;ACTIVE;2.29;2.70 +55952-6;Octenoylcarnitine (C8:1);SCnc;Pt;CSF;Qn;;CHEM;1;Octenoylcarnitine (C8:1) [Moles/volume] in Cerebral spinal fluid;Octenoylcarn CSF-sCnc;;ACTIVE;2.29;2.70 +55953-4;Octenoylcarnitine (C8:1);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Octenoylcarnitine (C8:1) [Moles/volume] in Amniotic fluid;Octenoylcarn Amn-sCnc;;ACTIVE;2.29;2.70 +5595-4;Beryllium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in Urine;Beryllium Ur-mCnc;;ACTIVE;1.0;2.73 +55954-2;Octenoylcarnitine (C8:1);SCnc;Pt;Urine;Qn;;CHEM;1;Octenoylcarnitine (C8:1) [Moles/volume] in Urine;Octenoylcarn Ur-sCnc;;ACTIVE;2.29;2.70 +55955-9;Oleoylcarnitine (C18:1)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Oleoylcarnitine (C18:1)/Creatinine [Molar ratio] in Urine;Oleoylcarn/Creat Ur-sRto;;ACTIVE;2.29;2.70 +55956-7;Oleoylcarnitine (C18:1);SCnc;Pt;CSF;Qn;;CHEM;1;Oleoylcarnitine (C18:1) [Moles/volume] in Cerebral spinal fluid;Oleoylcarn CSF-sCnc;;ACTIVE;2.29;2.70 +55957-5;Oleoylcarnitine (C18:1);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Oleoylcarnitine (C18:1) [Moles/volume] in Amniotic fluid;Oleoylcarn Amn-sCnc;;ACTIVE;2.29;2.70 +55958-3;Oleoylcarnitine (C18:1);SCnc;Pt;Urine;Qn;;CHEM;1;Oleoylcarnitine (C18:1) [Moles/volume] in Urine;Oleoylcarn Ur-sCnc;;ACTIVE;2.29;2.70 +55959-1;Ornithine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Ornithine/Amino acids.total in Serum or Plasma;Ornithine SFr SerPl;;ACTIVE;2.29;2.70 +55960-9;Osmolality;Osmol;Pt;Dial fld;Qn;;CHEM;1;Osmolality of Dialysis fluid;Osmolality Dial fld;;ACTIVE;2.29;2.70 +55961-7;Oxalate;SCnc;Pt;Water;Qn;;CHEM;1;Oxalate [Moles/volume] in Water;Oxalate Wat-sCnc;;ACTIVE;2.29;2.70 +5596-2;Beryllium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Beryllium [Mass/time] in 24 hour Urine;Beryllium 24h Ur-mRate;;ACTIVE;1.0;2.42 +55962-5;Oxygen content;SCnc;Pt;BldCo;Qn;;CHEM;1;Oxygen content in Cord blood;O2 Ct BldCo-sCnc;;ACTIVE;2.29;2.73 +55963-3;Palmitoleylcarnitine (C16:1)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Palmitoleylcarnitine (C16:1)/Creatinine [Molar ratio] in Urine;Palmitoleylcarn/Creat Ur-sRto;;ACTIVE;2.29;2.70 +55964-1;Palmitoleylcarnitine (C16:1);SCnc;Pt;CSF;Qn;;CHEM;1;Palmitoleylcarnitine (C16:1) [Moles/volume] in Cerebral spinal fluid;Palmitoleylcarn CSF-sCnc;;ACTIVE;2.29;2.70 +55965-8;Palmitoleylcarnitine (C16:1);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Palmitoleylcarnitine (C16:1) [Moles/volume] in Amniotic fluid;Palmitoleylcarn Amn-sCnc;;ACTIVE;2.29;2.70 +55966-6;Palmitoleylcarnitine (C16:1);SCnc;Pt;Urine;Qn;;CHEM;1;Palmitoleylcarnitine (C16:1) [Moles/volume] in Urine;Palmitoleylcarn Ur-sCnc;;ACTIVE;2.29;2.70 +55967-4;Palmitoylcarnitine (C16);SCnc;Pt;Urine;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Moles/volume] in Urine;Palmitoylcarn Ur-sCnc;;ACTIVE;2.29;2.70 +55968-2;pH;LsCnc;Pt;TPN;Qn;;CHEM;1;pH of Total parental nutrition;pH TPN;;ACTIVE;2.29;2.42 +55969-0;Phenylalanine/Amino acids.total;SFr;Pt;Bld.dot;Qn;;CHEM;1;Phenylalanine/Amino acids.total in DBS;Phe SFr DBS;;ACTIVE;2.29;2.70 +5597-0;Bismuth;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bismuth [Mass/volume] in Serum or Plasma;Bismuth SerPl-mCnc;;ACTIVE;1.0;2.73 +55970-8;Phenylalanine;SCnt;Pt;Hair;Qn;;CHEM;1;Phenylalanine [Moles/mass] in Hair;Phe Hair-sCnt;;ACTIVE;2.29;2.70 +55971-6;Alkaline phosphatase;CCnc;Pt;BldCo;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Cord blood;ALP BldCo-cCnc;;ACTIVE;2.29;2.68 +55972-4;Phosphate^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phosphate [Moles/volume] in Serum or Plasma --post dialysis;Phosphate p dialysis SerPl-sCnc;;ACTIVE;2.29;2.70 +55973-2;Phosphate;SCnc;Pt;Periton fld;Qn;;CHEM;1;Phosphate [Moles/volume] in Peritoneal fluid;Phosphate Prt-sCnc;;ACTIVE;2.29;2.70 +55974-0;IgG;MCnc;Pt;Ser;Qn;Immune diffusion;CHEM;1;IgG [Mass/volume] in Serum by Immune diffusion (ID);IgG Ser ID-mCnc;;ACTIVE;2.29;2.70 +55975-7;IgG;MCnc;Pt;Body fld;Qn;Immune diffusion;CHEM;1;IgG [Mass/volume] in Body fluid by Immune diffusion (ID);IgG Fld ID-mCnc;;ACTIVE;2.29;2.70 +55976-5;pH;LsCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;pH of Nonbiological fluid;pH Fld.NB;;ACTIVE;2.29;2.42 +55977-3;Sphere far;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Sphere far by Lensmeter;L corr lens Sphere far by LM;;ACTIVE;2.29;2.71 +55978-1;Visual acuity.near;LenRto;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens Visual acuity near by Lensmeter;L corr lens Near VA by LM;;ACTIVE;2.29;2.72 +55979-9;Visual acuity.far;LenRto;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Visual acuity far by Lensmeter;R corr lens Far VA by LM;;ACTIVE;2.29;2.71 +55980-7;SBM sphere far;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens SBM sphere far by Lensmeter;R corr lens SBM sphere far by LM;;ACTIVE;2.29;2.71 +55981-5;SBM visual acuity far;LenRto;Pt;Corrective lens.left;Qn;Lensmeter;EYE.GLASSES;2;Left corrective lens SBM visual acuity far by Lensmeter;L corr lens SBM VA far by LM;;ACTIVE;2.29;2.71 +55982-3;Prism base direction;Angle;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens Prism base direction by Lensmeter;R corr lens Prism base dir by LM;;ACTIVE;2.29;2.71 +55983-1;N PO;Len;Pt;Corrective lens.right;Qn;Lensmeter;EYE.GLASSES;2;Right corrective lens N PO by Lensmeter;R corr lens N PO by LM;;ACTIVE;2.29;2.70 +55984-9;Sphere near 1;InvLen;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Sphere near 1;L glasses Rx Sphere N 1;;ACTIVE;2.29;2.70 +55985-6;Pupillary distance.monocular near;Len;Pt;Glasses prescription.lens.left;Qn;;EYE.GLASSES;2;Left glasses lens prescription Pupillary distance.monocular near;L glasses Rx PD monoc near;;ACTIVE;2.29;2.71 +55986-4;N PO;Len;Pt;Glasses prescription.lens.right;Qn;;EYE.GLASSES;2;Right glasses lens prescription N PO;R glasses Rx N PO;;ACTIVE;2.29;2.70 +55987-2;Visual acuity.near;LenRto;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Visual acuity near by Phoropter;L eye Near VA by Phoropter;;ACTIVE;2.29;2.72 +5598-8;Bismuth;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bismuth [Mass/volume] in Urine;Bismuth Ur-mCnc;;ACTIVE;1.0;2.73 +55988-0;Prism base direction;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base distance Phoropter;R eye Prism base dist Phoropter;;ACTIVE;2.29;2.71 +55989-8;Pressure border code;Find;Pt;Eye.right;Nom;Perimetry;EYE.VISUAL_FIELD;2;Right eye Pressure border code Perimetry;R eye Pressure border code Perimetry;;ACTIVE;2.29;2.68 +55990-6;GF border code;Find;Pt;Eye.left;Nom;Perimetry;EYE.VISUAL_FIELD;2;Left eye GF border code Perimetry;L eye GF border code Perimetry;;ACTIVE;2.29;2.68 +55991-4;Comment N;Imp;Pt;Eye.right;Nar;Phoropter;EYE.REFRACTION;2;Phoropter Right eye Comment near vision [Interpretation];Phoropter R eye Cmnt near vision;;ACTIVE;2.29;2.71 +55992-2;Lens fitting;Prid;Pt;Contact lens.prescription.left;Nom;;EYE.CONTACT_LENS;2;Left contact lens prescription Lens fitting;L cont lens Rx Lens fitting;;ACTIVE;2.29;2.68 +55993-0;Linsensitz;Prid;Pt;Contact lens.prescription.right;Nom;;EYE.CONTACT_LENS;2;Right contact lens prescription Linsensitz;R cont lens Rx Linsensitz;;ACTIVE;2.29;2.68 +55994-8;Producer text;Prid;Pt;Contact lens.left;Nar;;EYE.CONTACT_LENS;2;Left contact lens Producer text;L cont lens Producer text;;ACTIVE;2.29;2.68 +55995-5;Diameter;Len;Pt;Contact lens.left;Qn;;EYE.CONTACT_LENS;2;Left contact lens Diameter;L cont lens Diam;;ACTIVE;2.29;2.70 +5599-6;Boldenone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Boldenone [Presence] in Urine;Boldenone Ur Ql;;ACTIVE;1.0;2.73 +55996-3;Radius;Len;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Radius;R cont lens Radius;;ACTIVE;2.29;2.70 +55997-1;Over refraction sphere;InvLen;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Over refraction sphere;R cont lens OR sphere;;ACTIVE;2.29;2.70 +55998-9;Over refraction cylinder;InvLen;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Over refraction cylinder;R cont lens OR cylinder;;ACTIVE;2.29;2.70 +55999-7;Over refraction axis;Angle;Pt;Contact lens.right;Qn;;EYE.CONTACT_LENS;2;Right contact lens Over refraction axis;R cont lens OR axis;;ACTIVE;2.29;2.70 +56000-3;Manufacturer name;ID;Pt;Contact lens.right;Nar;;EYE.CONTACT_LENS;2;Right contact lens Manufacturer name [Identifier];R cont lens Manufacturer name;;ACTIVE;2.29;2.68 +56001-1;Lenticulation;Arb;Pt;Contact lens.right;Ord;;EYE.CONTACT_LENS;2;Right contact lens Lenticulation;R cont lens Lenticulation;;ACTIVE;2.29;2.68 +5600-2;Boldenone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Boldenone [Mass/volume] in Urine;Boldenone Ur-mCnc;;ACTIVE;1.0;2.42 +56002-9;Platelet aggregation.adenosine diphosphate induced ATP secretion^5 umol/L;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ADP induced ATP secretion in Blood --5 umol/L;PA ADP ATP secr 5 umol/L Bld;;ACTIVE;2.29;2.73 +56003-7;Platelet aggregation.adenosine diphosphate induced ATP secretion^10 umol/L;PrThr;Pt;Bld;Ord;;COAG;1;Platelet aggregation ADP induced ATP secretion [Presence] in Blood --10 umol/L;PA ADP ATP secr 10 umol/L Bld Ql;;ACTIVE;2.29;2.56 +56004-5;Platelet aggregation.adenosine diphosphate induced ATP secretion^5 umol/L;PrThr;Pt;Bld;Ord;;COAG;1;Platelet aggregation ADP induced ATP secretion [Presence] in Blood --5 umol/L;PA ADP ATP secr 5 umol/L Bld Ql;;ACTIVE;2.29;2.56 +56005-2;Platelet aggregation.adenosine diphosphate induced^5 umol/L;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ADP induced in Blood --5 umol/L;PA ADP 5 umol/L Bld;;ACTIVE;2.29;2.73 +56006-0;Platelet aggregation.adenosine diphosphate induced^10 umol/L;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ADP induced in Blood --10 umol/L;PA ADP 10 umol/L Bld;;ACTIVE;2.29;2.73 +56007-8;Platelet aggregation.arachidonate induced^500 umol/L;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation arachidonate induced in Blood --500 umol/L;PA AA 500 umol/L Bld;;ACTIVE;2.29;2.73 +56008-6;Platelet aggregation.collagen induced^1 ug/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation collagen induced in Blood --1 ug/mL;PA Coll 1 ug/mL Bld;;ACTIVE;2.29;2.73 +56009-4;Platelet aggregation.collagen induced^5 ug/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation collagen induced in Blood --5 ug/mL;PA Coll 5 ug/mL Bld;;ACTIVE;2.29;2.73 +5601-0;Boldenone;MRat;24H;Urine;Qn;;DRUG/TOX;1;Boldenone [Mass/time] in 24 hour Urine;Boldenone 24h Ur-mRate;;ACTIVE;1.0;2.42 +56010-2;Platelet aggregation.ristocetin induced^250 ug/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ristocetin induced in Blood --250 ug/mL;PA Rist 250 ug/mL Bld;;ACTIVE;2.29;2.73 +56011-0;Platelet aggregation.adenosine diphosphate induced ATP secretion^10 umol/L;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ADP induced ATP secretion in Blood --10 umol/L;PA ADP ATP secr 10 umol/L Bld;;ACTIVE;2.29;2.73 +56012-8;Platelet aggregation.arachidonate induced ATP secretion^500 umol/L;PrThr;Pt;Bld;Ord;;COAG;1;Platelet aggregation arachidonate induced ATP secretion [Presence] in Blood --500 umol/L;PA AA ATP secr 500 umol/L Bld Ql;;ACTIVE;2.29;2.73 +56013-6;Platelet aggregation.arachidonate induced ATP secretion^500 umol/L;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation arachidonate induced ATP secretion in Blood --500 umol/L;PA AA ATP secr 500 umol/L Bld;;ACTIVE;2.29;2.73 +56014-4;Platelet aggregation.collagen induced ATP secretion^5 ug/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation collagen induced ATP secretion in Blood --5 ug/mL;PA Coll ATP secr 5 ug/mL Bld;;ACTIVE;2.29;2.73 +56015-1;Platelet aggregation.collagen induced ATP secretion^1 ug/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation collagen induced ATP secretion in Blood --1 ug/mL;PA Coll ATP secr 1 ug/mL Bld;;ACTIVE;2.29;2.73 +56016-9;Platelet aggregation.collagen induced ATP secretion^1 ug/mL;PrThr;Pt;Bld;Ord;;COAG;1;Platelet aggregation collagen induced ATP secretion [Presence] in Blood --1 ug/mL;PA Coll ATP secr 1 ug/mL Bld Ql;;ACTIVE;2.29;2.56 +56017-7;Platelet aggregation.collagen induced ATP secretion^5 ug/mL;PrThr;Pt;Bld;Ord;;COAG;1;Platelet aggregation collagen induced ATP secretion [Presence] in Blood --5 ug/mL;PA Coll ATP secr 5 ug/mL Bld Ql;;ACTIVE;2.29;2.56 +56018-5;Platelet aggregation.thrombin induced ATP secretion^5 U/mL;PrThr;Pt;Bld;Ord;;COAG;1;Platelet aggregation thrombin induced ATP secretion [Presence] in Blood --5 U/mL;PA Thromb ATP secr 5 U/mL Bld Ql;;ACTIVE;2.29;2.56 +56019-3;Platelet aggregation.thrombin induced ATP secretion^1 U/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation thrombin induced ATP secretion in Blood --1 U/mL;PA Thromb ATP secr 1 U/mL Bld;;ACTIVE;2.29;2.73 +56020-1;Platelet aggregation.thrombin induced ATP secretion^5 U/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation thrombin induced ATP secretion in Blood --5 U/mL;PA Thromb ATP secr 5 U/mL Bld;;ACTIVE;2.29;2.73 +56021-9;Platelet aggregation.thrombin induced ATP secretion^1 U/mL;PrThr;Pt;Bld;Ord;;COAG;1;Platelet aggregation thrombin induced ATP secretion [Presence] in Blood --1 U/mL;PA Thromb ATP secr 1 U/mL Bld Ql;;ACTIVE;2.29;2.73 +56022-7;ACE gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ACE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ACE gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +56023-5;Foot and mouth disease virus RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Foot and mouth disease virus RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;FMDV RNA Spec NAA+probe-aCnc;;ACTIVE;2.29;2.69 +56024-3;Influenza virus A N1 RNA;ACnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A N1 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection;FLUAV N1 RNA Spec NAA+probe-aCnc;;ACTIVE;2.29;2.69 +56025-0;Ethambutol 8.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ethambutol 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ethambutol 8 ug/mL Islt SlowMyco;;ACTIVE;2.29;2.32 +56026-8;Pyrazinamide 300.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Pyrazinamide 300 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;PZA 300 ug/mL Islt SlowMyco;;ACTIVE;2.29;2.32 +56027-6;Platelet aggregation.ristocetin induced^1.0 mg/mL;RelACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ristocetin induced in Blood --1.0 mg/mL;PA Rist 1.0 mg/mL Bld;;ACTIVE;2.29;2.73 +5602-8;Borate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Borate [Mass/volume] in Serum or Plasma;Borate SerPl-mCnc;;ACTIVE;1.0;2.73 +56028-4;Cells.CD3-CD56+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3-CD56+ cells/100 cells in Bone marrow;CD3-CD56+ Cells NFr Mar;;ACTIVE;2.29;2.40 +56029-2;Cells.CD3-CD56+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3-CD56+ cells/100 cells in Body fluid;CD3-CD56+ Cells NFr Fld;;ACTIVE;2.29;2.40 +560-3;Chlamydia sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Specimen by Organism specific culture;Chlamydia Spec Cult;;ACTIVE;1.0;2.73 +56030-0;Karyotype;Prid;Pt;Urine;Nar;FISH;MOLPATH;1;Karyotype [Identifier] in Urine by FISH Narrative;Karyotyp Ur FISH;;ACTIVE;2.29;2.73 +56031-8;Doripenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Doripenem [Susceptibility] by Minimum inhibitory concentration (MIC);Doripenem Islt MIC;;ACTIVE;2.29;2.73 +56032-6;Lithium;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Lithium [Moles/volume] in Gastric fluid;Lithium Gast-sCnc;;ACTIVE;2.29;2.42 +56033-4;Androstenediol;MRat;24H;Urine;Qn;;CHEM;1;Androstenediol [Mass/time] in 24 hour Urine;Androstenediol 24h Ur-mRate;;ACTIVE;2.29;2.70 +56034-2;Hydroxylysine;SCnc;Pt;Body fld;Qn;;CHEM;1;Hydroxylysine [Moles/volume] in Body fluid;OH-Lysine Fld-sCnc;;ACTIVE;2.29;2.70 +56035-9;Apolipoprotein A-I/Cholesterol.in HDL;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein A-I/Cholesterol in HDL [Mass Ratio] in Serum or Plasma;Apo A-I/HDLc SerPl;;ACTIVE;2.29;2.44 +5603-6;Borate;MRat;24H;Urine;Qn;;DRUG/TOX;1;Borate [Mass/time] in 24 hour Urine;Borate 24h Ur-mRate;;ACTIVE;1.0;2.73 +56036-7;Apolipoprotein B/Cholesterol.in LDL;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B/Cholesterol in LDL [Mass Ratio] in Serum or Plasma;Apo B/LDLc SerPl;;ACTIVE;2.29;2.44 +56037-5;Protein phosphatase 3;CCnc;Pt;WBC;Qn;;CHEM;1;Protein phosphatase 3 [Enzymatic activity/volume] in Leukocytes;Protein phosphatase 3 WBC-cCnc;;ACTIVE;2.29;2.29 +56038-3;Lysozyme;ARat;24H;Urine;Qn;;CHEM;1;Lysozyme [Units] in 24 hour Urine;Lysozyme 24h Ur;;ACTIVE;2.29;2.70 +56039-1;Lysozyme;ACnc;Pt;Urine;Qn;;CHEM;1;Lysozyme [Units/volume] in Urine;Lysozyme Ur-aCnc;;ACTIVE;2.29;2.70 +56040-9;Methemoglobin;SCnc;Pt;Bld;Qn;;CHEM;1;Methemoglobin [Moles/volume] in Blood;MetHgb Bld-sCnc;;ACTIVE;2.29;2.70 +56041-7;Beta defensin;MCnt;Pt;Stool.wet;Qn;;CHEM;1;Beta defensin [Mass/mass] in Stool.wet;Beta defensin Stool.wet-mCnt;;ACTIVE;2.29;2.70 +56042-5;Beta defensin;MCnt;Pt;Stool.dried;Qn;;CHEM;1;Beta defensin [Mass/mass] in Stool.dried;Beta defensin Stool.dried-mCnt;;ACTIVE;2.29;2.70 +56043-3;Horizontal adduction.passive range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Horizontal adduction Passive Range of Motion Quantitative;Should-R Horizontal adduction PROM Qn;;ACTIVE;2.29;2.70 +5604-4;Boron;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Boron [Mass/volume] in Blood;Boron Bld-mCnc;;ACTIVE;1.0;2.73 +56044-1;Horizontal adduction.active range of motion;Angle;Pt;Shoulder.right;Qn;;H&P.PX;2;Shoulder - right Horizontal adduction Active Range of Motion Quantitative;Should-R Horizontal adduction AROM Qn;;ACTIVE;2.29;2.70 +56045-8;Horizontal adduction.passive range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Horizontal adduction Passive Range of Motion Quantitative;Should-L Horizontal adduction PROM Qn;;ACTIVE;2.29;2.70 +56046-6;Horizontal adduction.passive range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Horizontal adduction Passive Range of Motion Quantitative;Should Horizontal adduction PROM Qn;;ACTIVE;2.29;2.70 +56047-4;Horizontal adduction.active range of motion;Angle;Pt;Shoulder;Qn;;H&P.PX;2;Shoulder Horizontal adduction Active Range of Motion Quantitative;Should Horizontal adduction AROM Qn;;ACTIVE;2.29;2.70 +56048-2;Horizontal adduction.active range of motion;Angle;Pt;Shoulder.left;Qn;;H&P.PX;2;Shoulder - left Horizontal adduction Active Range of Motion Quantitative;Should-L Horizontal adduction AROM Qn;;ACTIVE;2.29;2.70 +56049-0;PhenX measure - current age;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - current age;;;DEPRECATED;2.29;2.46 +56050-8;PhenX measure - ethnicity;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - ethnicity;;;DEPRECATED;2.29;2.46 +5605-1;Boron;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Boron [Mass/volume] in Body fluid;Boron Fld-mCnc;;ACTIVE;1.0;2.34 +56051-6;Hispanic or Latino;Find;Pt;^Patient;Ord;;ADMIN.PATIENT.DEMOG;2;Hispanic or Latino;Hispanic or Latino;;ACTIVE;2.29;2.73 +56052-4;PhenX measure - race;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - race;;;DEPRECATED;2.29;2.46 +56053-2;PhenX measure - gender;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - gender;;;DEPRECATED;2.29;2.46 +56054-0;PhenX measure - arm span;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - arm span;;;DEPRECATED;2.29;2.46 +56055-7;PhenX measure - birth weight;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - birth weight;;;DEPRECATED;2.29;2.46 +56056-5;Body weight^at birth;Mass;Pt;^Patient;Qn;Reported;BDYWGT.MOLEC;2;Birth weight - Reported;Birth weight Reported;;ACTIVE;2.29;2.73 +56057-3;Body weight more or less than 5.5 pounds (2500 g)^at birth;Find;Pt;^Patient;Ord;Reported;PHENX;2;Birth weight more or less than 5.5 pounds (2500 g) - Reported;Birth wt > or < 5.5 lbs Reported;;TRIAL;2.29;2.65 +56058-1;PhenX measure - child head circumference;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - child head circumference;;;DEPRECATED;2.29;2.46 +56059-9;PhenX measure - hand dominance;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - hand dominance;;;DEPRECATED;2.29;2.46 +56060-7;PhenX measure - height;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - height;;;DEPRECATED;2.29;2.46 +56061-5;Knee height;Len;Pt;^Patient;Qn;;PHENX;2;Knee height;Knee height;;TRIAL;2.29;2.65 +56062-3;PhenX measure - hip circumference;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - hip circumference;;;DEPRECATED;2.29;2.46 +56063-1;Circumference.at maximal protrusion of gluteus muscles;Len;Pt;Pelvis;Qn;;PHENX;2;Circumference.at maximal protrusion of gluteus muscles Pelvis;Circumf of gluteus muscles Pelvis;;TRIAL;2.29;2.65 +56064-9;PhenX measure - maximum adult height;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - maximum adult height;;;DEPRECATED;2.29;2.46 +56065-6;Self-Reported Maximum Adult Height;-;Pt;^Patient;-;;PANEL.PHENX;2;Self-Reported Maximum Adult Height;Self-Reported Maximum Adult Height;;TRIAL;2.29;2.68 +56066-4;Body height^at age 25;Len;Pt;^Patient;Qn;Stated;PHENX;2;Body height [Stated] --at age 25;Body height at age 25 Stated;;TRIAL;2.29;2.69 +56067-2;PhenX measure - maximum adult weight;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - maximum adult weight;;;DEPRECATED;2.29;2.46 +56068-0;Self-Reported Maximum Adult Weight;-;Pt;^Patient;-;;PANEL.PHENX;2;Self-Reported Maximum Adult Weight;Self-Reported Maximum Adult Weight;;TRIAL;2.29;2.68 +5606-9;Boron;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Boron [Mass/volume] in Red Blood Cells;Boron RBC-mCnc;;ACTIVE;1.0;2.42 +56069-8;Body weight.max;Mass;Pt;^Patient;Qn;Reported;PHENX;2;Body weight.max [Reported];Body weight.max Reported;;TRIAL;2.29;2.69 +56070-6;Age^at body weight.max;Time;Pt;^Patient;Qn;;PHENX;2;Age --at body weight.max;Age at body weight.max;;TRIAL;2.29;2.65 +56071-4;PhenX measure - mid upper arm circumference;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - mid-upper arm circumference;;;DEPRECATED;2.29;2.46 +56072-2;Circumference;Len;Pt;Upper arm.mid.right;Qn;;PHENX;2;Circumference Mid upper arm - right;Circumf Mid Upper arm-R;;TRIAL;2.29;2.65 +56073-0;PhenX measure - neck circumference;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - neck circumference;;;DEPRECATED;2.29;2.46 +56074-8;Circumference;Len;Pt;Neck;Qn;;PHENX;2;Circumference Neck;Circumf Neck;;TRIAL;2.29;2.73 +56075-5;PhenX measure - pregnancy weight gain;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - pregnancy weight gain;;;DEPRECATED;2.29;2.46 +56076-3;Pregnancy weight gain.current;-;Pt;^Patient;-;;PANEL.PHENX;2;Pregnancy weight gain.current;Pregnancy weight gain.current;;TRIAL;2.29;2.68 +5607-7;Boron;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Boron [Mass/volume] in Serum or Plasma;Boron SerPl-mCnc;;ACTIVE;1.0;2.73 +56077-1;Body weight^pre current pregnancy;Mass;Pt;^Patient;Qn;;PHENX;2;Body weight --pre current pregnancy;Weight pre current pregnancy;;TRIAL;2.29;2.69 +56078-9;Weight gain^during current pregnancy;Mass;Pt;^Patient;Qn;;PHENX;2;Weight gain [Mass] --during current pregnancy;Wt gain during current pregnancy;;TRIAL;2.29;2.65 +56079-7;Body weight^pre most recent pregnancy;Mass;Pt;^Patient;Qn;;PHENX;2;Body weight --pre most recent pregnancy;Weight pre most recent pregnancy;;TRIAL;2.29;2.69 +56080-5;Weight gain^during most recent pregnancy;Mass;Pt;^Patient;Qn;;PHENX;2;Weight gain [Mass] --during most recent pregnancy;Wt gain most recent preg;;TRIAL;2.29;2.65 +56081-3;Gestational age in W^at most recent delivery;Time;Pt;^Fetus;Qn;;PHENX;2;Fetal gestational age in weeks --at most recent delivery;GA (weeks)--at most recent delivery;;TRIAL;2.29;2.67 +56082-1;PhenX measure - weight loss or gain;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - weight loss or gain;;;DEPRECATED;2.29;2.46 +56083-9;Body weight^XXX time ago;Mass;Pt;^Patient;Qn;;PHENX;2;Body weight --XXX time ago;Weight XXX time ago;;TRIAL;2.29;2.69 +56084-7;PhenX measure - weight;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - weight;;;DEPRECATED;2.29;2.46 +5608-5;Bufotenine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bufotenine [Mass/volume] in Urine;Bufotenine Ur-mCnc;;ACTIVE;1.0;2.42 +56085-4;PhenX measure - waist circumference;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - waist circumference;;;DEPRECATED;2.29;2.46 +56086-2;Adult Waist Circumference Protocol;-;Pt;^Patient;-;;PANEL.PHENX;2;Adult Waist Circumference Protocol;Adult Waist Circumf;;TRIAL;2.29;2.65 +56087-0;Child Waist Circumference Protocol;-;Pt;^Patient;-;;PANEL.PHENX;2;Child Waist Circumference Protocol;Child Waist Circumf;;TRIAL;2.29;2.65 +56088-8;PhenX panel;-;Pt;^Patient;-;;PANEL.PHENX;2;Deprecated PhenX panel;Deprecated PhenX panel;;DEPRECATED;2.29;2.38 +56089-6;Pregnancy weight gain.most recent;-;Pt;^Patient;-;;PANEL.PHENX;2;Pregnancy weight gain.most recent;Pregnancy weight gain.most recent;;TRIAL;2.29;2.73 +56090-4;Hispanic origin;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Hispanic origin;Hispanic origin;;ACTIVE;2.29;2.68 +56091-2;Race;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Race [PhenX];Race PhenX;;TRIAL;2.29;2.65 +56092-0;Body weight^at birth;Mass;Pt;^Patient;Qn;GNWCH;BDYWGT.MOLEC;2;Birth weight GNWCH;Birth weight GNWCH;;ACTIVE;2.29;2.72 +5609-3;Cadmium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Blood;Cadmium Bld-mCnc;;ACTIVE;1.0;2.73 +56093-8;Body weight^at birth;Mass;Pt;^Patient;Qn;NVSS;BDYWGT.MOLEC;2;Birth weight NVSS;Birth weight NVSS;;ACTIVE;2.29;2.72 +56094-6;Body weight^at birth;-;Pt;^Patient;-;NHANES;PANEL.H&P;2;Birth weight [NHANES];Birth weight NHANES;;TRIAL;2.29;2.68 +56095-3;Body weight more or less than 9.0 pounds (4100 g)^at birth;Find;Pt;^Patient;Ord;Reported;PHENX;2;Birth weight more or less than 9.0 pounds (4100 g) - Reported;Birth wt > or < 9 lbs Reported;;TRIAL;2.29;2.65 +56096-1;Phenx - hand dominance - 42Mo and older protocol 020601;-;Pt;^Patient;-;ALSPAC;PANEL.PHENX;2;Phenx - hand dominance - 42 months and older protocol 020601 ALSPAC;Hand dom- 42Mo proto ALSPAC;;TRIAL;2.29;2.66 +56097-9;Hand dominance - drawing;Find;Pt;^Patient;Nom;ALSPAC;PHENX;2;Hand dominance - drawing [ALSPAC];Hand dom- drawing ALSPAC;;ACTIVE;2.29;2.65 +56098-7;Hand dominance - throwing a ball;Find;Pt;^Patient;Nom;ALSPAC;PHENX;2;Hand dominance - throwing a ball [ALSPAC];Hand dom- throwing a ball ALSPAC;;ACTIVE;2.29;2.65 +56099-5;Hand dominance - coloring;Find;Pt;^Patient;Nom;ALSPAC;PHENX;2;Hand dominance - coloring [ALSPAC];Hand dom- coloring ALSPAC;;ACTIVE;2.29;2.65 +56100-1;Hand dominance - holding a toothbrush;Find;Pt;^Patient;Nom;ALSPAC;PHENX;2;Hand dominance - holding a toothbrush [ALSPAC];Hand dom- holding a toothbrush ALSPAC;;ACTIVE;2.29;2.65 +5610-1;Cadmium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cadmium [Mass/mass] in Hair;Cadmium Hair-mCnt;;ACTIVE;1.0;2.73 +56101-9;PhenX - hand dominance - 12Y and older protocol 020602;-;Pt;^Patient;-;EHI;PANEL.PHENX;2;PhenX - hand dominance - 12 years and older protocol 020602 EHI;Hand dom- 12Y proto EHI;;TRIAL;2.29;2.66 +56102-7;Hand dominance - write;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - write [EHI];Hand dom- write EHI;;TRIAL;2.29;2.65 +56103-5;Hand dominance - draw;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - draw [EHI];Hand dom- draw EHI;;TRIAL;2.29;2.65 +56104-3;Hand dominance - throw;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - throw [EHI];Hand dom- throw EHI;;TRIAL;2.29;2.65 +56105-0;Hand dominance - hold a racquet;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - hold a racquet [EHI];Hand dom- hold a racquet EHI;;TRIAL;2.29;2.65 +56106-8;Hand dominance - clean teeth;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - clean teeth [EHI];Hand dom- clean teeth EHI;;TRIAL;2.29;2.65 +56107-6;Hand dominance - hammer;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - hammer [EHI];Hand dom- hammer EHI;;TRIAL;2.29;2.65 +56108-4;Hand dominance - strike a match;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - strike a match [EHI];Hand dom- strike a match EHI;;TRIAL;2.29;2.65 +56109-2;Hand dominance - use an eraser;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - use an eraser [EHI];Hand dom- use an eraser EHI;;TRIAL;2.29;2.65 +561-1;Chlamydia sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Specimen by Immunofluorescence;Chlamydia Ag Spec Ql IF;;ACTIVE;1.0;2.73 +56110-0;Hand dominance - deal cards;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - deal cards [EHI];Hand dom- deal cards EHI;;TRIAL;2.29;2.65 +56111-8;Hand dominance - thread a needle;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - thread a needle [EHI];Hand dom- thread a needle EHI;;TRIAL;2.29;2.65 +56112-6;Hand dominance - cut food with a knife;Find;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - cut food with a knife [EHI];Hand dom- cut food with a knife EHI;;TRIAL;2.29;2.65 +56113-4;Hand dominance - Total score;Score;Pt;^Patient;Qn;EHI;PHENX;2;Hand dominance - Total score [EHI];Hand dom- Total score EHI;;TRIAL;2.29;2.65 +56114-2;Circumference;Len;Pt;Abdomen.mid;Qn;NHANES;BDYCRC.MOLEC;2;Waist Circumference by NHANES;Circumf by NHANES;;ACTIVE;2.29;2.29 +56115-9;Circumference;Len;Pt;Abdomen.mid;Qn;NCFS;BDYCRC.MOLEC;2;Waist Circumference by NCFS;Circumf by NCFS;;ACTIVE;2.29;2.29 +56116-7;Width;Len;Pt;Arm span;Qn;;H&P.PX;2;Width Arm span;Width Arm span;;ACTIVE;2.29;2.66 +56117-5;Circumference;Len;Pt;Abdomen.mid;Qn;WHI;BDYCRC.MOLEC;2;Waist Circumference by WHI;Circumf by WHI;;ACTIVE;2.29;2.73 +56118-3;Proxy name;Pn;Pt;^Proxy;Nom;;PHENX;2;Proxy's name;Proxy's name;;ACTIVE;2.29;2.65 +5611-9;Cadmium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Urine;Cadmium Ur-mCnc;;ACTIVE;1.0;2.73 +56119-1;Cellular material;MCnt;Pt;Calculus;Qn;Estimated;SPEC;1;Cellular material [Mass/mass] of Stone by Estimated;Cell material Stone Est-mCnt;;ACTIVE;2.29;2.73 +56120-9;Amphetamine+Methamphetamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amphetamine+Methamphetamine [Mass/volume] in Urine;Amphet+Methamphet Ur-mCnc;;ACTIVE;2.29;2.73 +56121-7;IgA;MCnc;Pt;Urine;Qn;;CHEM;1;IgA [Mass/volume] in Urine;IgA Ur-mCnc;;ACTIVE;2.29;2.70 +56122-5;IgG;MCnc;Pt;BldCo;Qn;;CHEM;1;IgG [Mass/volume] in Cord blood;IgG BldCo-mCnc;;ACTIVE;2.29;2.70 +56123-3;IgM;MCnc;Pt;Urine;Qn;;CHEM;1;IgM [Mass/volume] in Urine;IgM Ur-mCnc;;ACTIVE;2.29;2.70 +56124-1;Glucose^1H post meal;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --1 hour post meal;Glucose 1h p meal Ur-mCnc;;ACTIVE;2.29;2.70 +56125-8;Immunoglobulin light chains.free;PrThr;Pt;Ser;Ord;;CHEM;1;Immunoglobulin light chains.free [Presence] in Serum;BJ Protein Free Ser Ql;;ACTIVE;2.29;2.56 +56126-6;Copper;MCnt;Pt;Liver;Qn;;CHEM;1;Copper [Mass/mass] in Liver;Copper Liver-mCnt;;ACTIVE;2.29;2.73 +5612-7;Cadmium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Cadmium [Mass/time] in 24 hour Urine;Cadmium 24h Ur-mRate;;ACTIVE;1.0;2.73 +56127-4;CD38 Ag;PrThr;Pt;Tiss;Ord;Immune stain;CELLMARK;1;CD38 Ag [Presence] in Tissue by Immune stain;CD38 Ag Tiss Ql ImStn;;ACTIVE;2.29;2.73 +56128-2;Chikungunya virus Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Chikungunya virus IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;CHIKV IgG Titr SerPl IF;;ACTIVE;2.29;2.73 +56129-0;Chikungunya virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Chikungunya virus IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;CHIKV IgG SerPl Ql IF;;ACTIVE;2.29;2.73 +56130-8;Chikungunya virus Ab.IgM;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Chikungunya virus IgM Ab [Titer] in Serum or Plasma by Immunofluorescence;CHIKV IgM Titr SerPl IF;;ACTIVE;2.29;2.73 +56131-6;Chikungunya virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Chikungunya virus IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;CHIKV IgM SerPl Ql IF;;ACTIVE;2.29;2.73 +56132-4;Cholesterol.in HDL 2a;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 2a [Moles/volume] in Serum or Plasma;HDLc 2a SerPl-sCnc;;ACTIVE;2.29;2.73 +56133-2;Cholesterol.in HDL 2b;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 2b [Moles/volume] in Serum or Plasma;HDLc 2b SerPl-sCnc;;ACTIVE;2.29;2.70 +56134-0;Cholesterol.in IDL 1;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in IDL 1 [Moles/volume] in Serum or Plasma;IDL1c SerPl-sCnc;;ACTIVE;2.29;2.70 +5613-5;Carbon disulfide;MCnc;Pt;Bld;Ord;;DRUG/TOX;1;Deprecated Carbon disulfide;Deprecated Carbon diS Bld Ql;;DEPRECATED;1.0;2.36 +56135-7;Cholesterol.in IDL 2;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in IDL 2 [Moles/volume] in Serum or Plasma;IDL2c SerPl-sCnc;;ACTIVE;2.29;2.70 +56136-5;LDL 1;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 1 [Moles/volume] in Serum or Plasma;LDL1 SerPl-sCnc;;DISCOURAGED;2.29;2.73 +56137-3;LDL 2;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 2 [Moles/volume] in Serum or Plasma;LDL2 SerPl-sCnc;;DISCOURAGED;2.29;2.73 +56138-1;LDL 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 3 [Moles/volume] in Serum or Plasma;LDL3 SerPl-sCnc;;DISCOURAGED;2.29;2.73 +56139-9;LDL 4;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 4 [Moles/volume] in Serum or Plasma;LDL4 SerPl-sCnc;;DISCOURAGED;2.29;2.73 +56140-7;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA;PrThr;Pt;Anal;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Anal by Probe with signal amplification;HPV I/H Risk 1 DNA Anal Ql Probe+sig amp;;ACTIVE;2.29;2.73 +56141-5;MPL gene.p.Ser505Asn;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MPL gene p.Ser505Asn [Presence] in Blood or Tissue by Molecular genetics method;MPL p.S505N Bld/T Ql;;ACTIVE;2.29;2.73 +56142-3;MPL gene.p.Trp515Leu+Trp515Lys;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MPL gene p.Trp515Leu+Trp515Lys [Presence] in Blood or Tissue by Molecular genetics method;MPL p.W515L+W515K Bld/T Ql;;ACTIVE;2.29;2.56 +5614-3;Cesium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cesium [Mass/volume] in Blood;Cesium Bld-mCnc;;ACTIVE;1.0;2.42 +56143-1;Potassium/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Potassium/Creatinine [Molar ratio] in 24 hour Urine;Potassium/Creat 24h Ur-sRto;;ACTIVE;2.29;2.73 +56144-9;CHIC2 gene 4q12 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.MUT;1;CHIC2 gene 4q12 deletion in Blood or Tissue by FISH;CHIC2 gene 4q12 Del Bld/T FISH;;ACTIVE;2.29;2.66 +56145-6;Erythrocytes+Granulocytes.CD55+CD59 deficient;Imp;Pt;Bld;Nar;;CELLMARK;1;CD55+CD59 deficient RBC+Granulocytes [Interpretation] in Blood Narrative;CD55+CD59 def RBC+Gran Bld-Imp;;ACTIVE;2.29;2.73 +56146-4;Fungal Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Fungal Ab panel - Serum;Fungal Ab Pnl Ser;;ACTIVE;2.29;2.73 +56147-2;Parietal cell Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Parietal cell Ab [Units/volume] in Serum by Immunoassay;PCA Ab Ser IA-aCnc;;ACTIVE;2.29;2.70 +56148-0;Smith extractable nuclear Ab & Ribonucleoprotein extractable nuclear Ab panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Smith extractable nuclear Ab and Ribonucleoprotein extractable nuclear Ab panel - Serum;ENA SM + RNP Ser;;ACTIVE;2.29;2.73 +56149-8;Beta 2 glycoprotein & Cardiolipin Ab & Phosphatidylserine panel;-;Pt;Ser;-;;PANEL.COAG;1;Beta 2 glycoprotein and Cardiolipin Ab and Phosphatidylserine panel - Serum;B2GPI+Cardiolipin Ab+PS Pnl Ser;;ACTIVE;2.29;2.73 +5615-0;Cesium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cesium [Mass/mass] in Hair;Cesium Hair-mCnt;;ACTIVE;1.0;2.42 +56150-6;Candida albicans Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Candida albicans IgM Ab [Units/volume] in Serum;C albicans IgM Ser-aCnc;;ACTIVE;2.29;2.73 +56151-4;Candida albicans Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Candida albicans IgA Ab [Units/volume] in Serum;C albicans IgA Ser-aCnc;;ACTIVE;2.29;2.73 +56152-2;Beta 2 glycoprotein 1 Ab.IgA & IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.COAG;1;Beta 2 glycoprotein 1 Ab IgA and IgG and IgM panel - Serum;B2 glycoprot 1 IgA+IgG+IgM Pnl Ser;;ACTIVE;2.29;2.73 +56153-0;Albumin.serum/Albumin.Periton fld;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Albumin in serum/Albumin in Peritoneal fluid;Albumin.Serum/Prt;;DISCOURAGED;2.29;2.42 +56154-8;Protein.abnormal band/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.abnormal band/Protein.total in Serum or Plasma by Electrophoresis;Abn Prot MFr SerPl Elph;;ACTIVE;2.29;2.70 +56155-5;Date referral lab test results received;TmStp;XXX;Referral lab test;Qn;;MISC;1;Date referral lab test results received in unspecified time Referral lab test;Date ref lab test received;;ACTIVE;2.29;2.73 +56156-3;Candida albicans Ab.IgA & IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Candida albicans IgA and IgG and IgM Ab panel - Serum;C albicans IgA+IgG+IgM Pnl Ser;;ACTIVE;2.29;2.73 +56157-1;HOXB13 gene/IL17BR gene;Ratio;Pt;Tiss;Qn;Molgen;MOLPATH;1;HOXB13 gene/IL17BR gene [Ratio] in Tissue by Molecular genetics method;HOXB13 gene/IL17BR gene Tiss-Rto;;ACTIVE;2.29;2.32 +56158-9;PCSK9 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PCSK9 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PCSK9 gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +56159-7;LDLR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LDLR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;LDLR gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +56160-5;Glucose^4H post peritoneal dialysis;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --4 hours post peritoneal dialysis;Glucose 4h p PD DiafP-mCnc;;ACTIVE;2.29;2.70 +56161-3;Calculus analysis with calculus photography;Imp;Pt;Calculus;Nom;;CHEM;1;Calculus analysis with calculus photography [Interpretation] in Stone;Stone Analysis+Photography-Imp;;ACTIVE;2.29;2.73 +56162-1;Hand dominance - 42Mo;Imp;Pt;^Patient;Nom;ALSPAC;PHENX;2;Hand dominance - 42 months [Interpretation] [ALSPAC];Hand dominance - 42Mo Imp ALSPAC;;ACTIVE;2.29;2.65 +56163-9;Hand dominance - 12Y;Imp;Pt;^Patient;Nom;EHI;PHENX;2;Hand dominance - 12 years [Interpretation] [EHI];Hand dominance - 12Y Imp EHI;;TRIAL;2.29;2.65 +56164-7;CYP2C9 gene allele 2;Prid;Pt;Bld;Nom;Molgen;MOLPATH.PHARMG;1;CYP2C9 gene allele 2 [Identifier] in Blood by Molecular genetics method Nominal;CYP2C9 allele 2 Bld;;ACTIVE;2.29;2.73 +56165-4;CYP2C9 gene allele 3;Prid;Pt;Bld;Nom;Molgen;MOLPATH.PHARMG;1;CYP2C9 gene allele 3 [Identifier] in Blood by Molecular genetics method Nominal;CYP2C9 allele 3 Bld;;ACTIVE;2.29;2.73 +56166-2;Gum arabic Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Gum arabic IgG4 Ab [Mass/volume] in Serum;Gum Arabic IgG4-mCnc;;ACTIVE;2.29;2.70 +56167-0;Corticotropin Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Corticotropin IgG4 Ab [Mass/volume] in Serum;ACTH IgG4-mCnc;;ACTIVE;2.29;2.70 +5616-8;Cesium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cesium [Mass/volume] in Serum or Plasma;Cesium SerPl-mCnc;;ACTIVE;1.0;2.42 +56168-8;Pimenta dioica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Allspice IgG4 Ab [Mass/volume] in Serum;Allspice IgG4-mCnc;;ACTIVE;2.29;2.73 +56169-6;Prunus dulcis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Almond IgG4 Ab [Mass/volume] in Serum;Almond IgG4-mCnc;;ACTIVE;2.29;2.73 +56170-4;Alternaria alternata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata IgG4 Ab [Mass/volume] in Serum;A alternata IgG4-mCnc;;ACTIVE;2.29;2.73 +56171-2;Fagus grandifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;American Beech IgG4 Ab [Mass/volume] in Serum;Amer Beech IgG4-mCnc;;ACTIVE;2.29;2.70 +56172-0;Cheese American Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;American Cheese IgG4 Ab [Mass/volume] in Serum;American Cheese IgG4-mCnc;;ACTIVE;2.29;2.73 +56173-8;Periplaneta americana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;American Cockroach IgG4 Ab [Mass/volume] in Serum;Amer Roach IgG4-mCnc;;ACTIVE;2.29;2.73 +56174-6;Ulmus americana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Elm IgG4 Ab [Mass/volume] in Serum;White Elm IgG4-mCnc;;ACTIVE;2.29;2.73 +56175-3;Platanus occidentalis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;American Sycamore IgG4 Ab [Mass/volume] in Serum;Amer Sycamore IgG4-mCnc;;ACTIVE;2.29;2.73 +5617-6;Cesium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Cesium [Mass/volume] in Red Blood Cells;Cesium RBC-mCnc;;ACTIVE;1.0;2.42 +56176-1;Malus sylvestris Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Apple IgG4 Ab [Mass/volume] in Serum;Apple IgG4-mCnc;;ACTIVE;2.29;2.73 +56177-9;Prunus armeniaca Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Apricot IgG4 Ab [Mass/volume] in Serum;Apricot IgG4-mCnc;;ACTIVE;2.29;2.73 +56178-7;Cynara scolymus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Artichoke IgG4 Ab [Mass/volume] in Serum;Artichoke IgG4-mCnc;;ACTIVE;2.29;2.70 +56179-5;Asparagus officinalis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Asparagus IgG4 Ab [Mass/volume] in Serum;Asparagus IgG4-mCnc;;ACTIVE;2.29;2.73 +56180-3;Aspergillus fumigatus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus IgG4 Ab [Mass/volume] in Serum;A fumigatus IgG4-mCnc;;ACTIVE;2.29;2.73 +56181-1;Aspergillus niger Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus niger IgG4 Ab [Mass/volume] in Serum;A niger IgG4-mCnc;;ACTIVE;2.29;2.73 +56182-9;Aspergillus versicolor Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus versicolor IgG4 Ab [Mass/volume] in Serum;A versicolor IgG4-mCnc;;ACTIVE;2.29;2.70 +56183-7;Casuarina equisetifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Australian pine IgG4 Ab [Mass/volume] in Serum;Australian pine IgG4-mCnc;;ACTIVE;2.29;2.73 +5618-4;Cesium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cesium [Mass/volume] in Urine;Cesium Ur-mCnc;;ACTIVE;1.0;2.42 +56184-5;Persea americana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Avocado IgG4 Ab [Mass/volume] in Serum;Avocado IgG4-mCnc;;ACTIVE;2.29;2.73 +56185-2;Paspalum notatum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bahia grass IgG4 Ab [Mass/volume] in Serum;Bahia grass IgG4-mCnc;;ACTIVE;2.29;2.73 +56186-0;Musa spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Banana IgG4 Ab [Mass/volume] in Serum;Banana IgG4-mCnc;;ACTIVE;2.29;2.73 +56187-8;Hordeum vulgare Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Barley IgG4 Ab [Mass/volume] in Serum;Barley IgG4-mCnc;;ACTIVE;2.29;2.73 +56188-6;Ocimum basilicum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Basil IgG4 Ab [Mass/volume] in Serum;Basil IgG4-mCnc;;ACTIVE;2.29;2.73 +56189-4;Laurus nobilis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bayleaf IgG4 Ab [Mass/volume] in Serum;Bayleaf IgG4-mCnc;;ACTIVE;2.29;2.73 +56190-2;Cynodon dactylon Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass IgG4 Ab [Mass/volume] in Serum;Bermuda grass IgG4-mCnc;;ACTIVE;2.29;2.70 +56191-0;Prunus avium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cherry IgG4 Ab [Mass/volume] in Serum;Cherry IgG4-mCnc;;ACTIVE;2.29;2.73 +5619-2;Chromium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Blood;Chromium Bld-mCnc;;ACTIVE;1.0;2.73 +56192-8;Micropterus salmoides Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bass, Black IgG4 Ab [Mass/volume] in Serum;Bass IgG4-mCnc;;ACTIVE;2.29;2.70 +56193-6;Salix nigra Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Black Willow IgG4 Ab [Mass/volume] in Serum;Black Willow IgG4-mCnc;;ACTIVE;2.29;2.70 +56194-4;Rubus fruticosus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blackberry IgG4 Ab [Mass/volume] in Serum;Blackberry IgG4-mCnc;;ACTIVE;2.29;2.73 +56195-1;Vigna sinensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Black-eye pea IgG4 Ab [Mass/volume] in Serum;Black-eye Pea IgG4-mCnc;;ACTIVE;2.29;2.70 +56196-9;Vaccinium myrtillus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blueberry IgG4 Ab [Mass/volume] in Serum;Blueberry IgG4-mCnc;;ACTIVE;2.29;2.73 +56197-7;Insulin bovine Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Insulin bovine IgG4 Ab [Mass/volume] in Serum;Insulin Bovine IgG4-mCnc;;ACTIVE;2.29;2.70 +56198-5;Bertholletia excelsa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Brazil Nut IgG4 Ab [Mass/volume] in Serum;Brazil Nut IgG4-mCnc;;ACTIVE;2.29;2.73 +56199-3;Yeast brewer's Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Brewer's yeast IgG4 Ab [Mass/volume] in Serum;Brewer's yeast IgG4-mCnc;;ACTIVE;2.29;2.73 +56-2;Capreomycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Capreomycin [Susceptibility] by Minimum inhibitory concentration (MIC);Capreomycin Islt MIC;;ACTIVE;1.0;2.19 +5620-0;Chromium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Chromium [Mass/mass] in Hair;Chromium Hair-mCnt;;ACTIVE;1.0;2.73 +56200-9;Brassica oleracea var italica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Broccoli IgG4 Ab [Mass/volume] in Serum;Broccoli IgG4-mCnc;;ACTIVE;2.29;2.73 +56201-7;Brassica oleracea var gemmifera Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Brussel Sprouts IgG4 Ab [Mass/volume] in Serum;Brussel Sprouts IgG4-mCnc;;ACTIVE;2.29;2.73 +56202-5;Fagopyrum esculentum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Buckwheat IgG4 Ab [Mass/volume] in Serum;Buckwheat IgG4-mCnc;;ACTIVE;2.29;2.73 +56203-3;Brassica oleracea var capitata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cabbage IgG4 Ab [Mass/volume] in Serum;Cabbage IgG4-mCnc;;ACTIVE;2.29;2.73 +56204-1;Candida albicans Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Candida albicans IgG4 Ab [Mass/volume] in Serum;C albicans IgG4-mCnc;;ACTIVE;2.29;2.73 +56205-8;Amaranthus palmeri Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Careless Weed IgG4 Ab [Mass/volume] in Serum;Careless Weed IgG4-mCnc;;ACTIVE;2.29;2.70 +56206-6;Daucus carota Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Carrot IgG4 Ab [Mass/volume] in Serum;Carrot IgG4-mCnc;;ACTIVE;2.29;2.73 +56207-4;Casein Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Casein IgG4 Ab [Mass/volume] in Serum;Casein IgG4-mCnc;;ACTIVE;2.29;2.73 +56208-2;Anacardium occidentale Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cashew nut IgG4 Ab [Mass/volume] in Serum;Cashew nut IgG4-mCnc;;ACTIVE;2.29;2.73 +56209-0;Ricinus communis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Castor Bean IgG4 Ab [Mass/volume] in Serum;Castor Bean IgG4-mCnc;;ACTIVE;2.29;2.70 +56210-8;Cat dander Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cat dander IgG4 Ab [Mass/volume] in Serum;Cat Dander IgG4-mCnc;;ACTIVE;2.29;2.73 +56211-6;Ictalurus punctatus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Catfish IgG4 Ab [Mass/volume] in Serum;Catfish IgG4-mCnc;;ACTIVE;2.29;2.70 +56212-4;Brassica oleracea var botrytis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cauliflower IgG4 Ab [Mass/volume] in Serum;Cauliflower IgG4-mCnc;;ACTIVE;2.29;2.73 +56213-2;Apium graveolens Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Celery IgG4 Ab [Mass/volume] in Serum;Celery IgG4-mCnc;;ACTIVE;2.29;2.73 +56214-0;Acremonium sp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Acremonium sp IgG4 Ab [Mass/volume] in Serum;Acremonium IgG4-mCnc;;ACTIVE;2.29;2.73 +56215-7;Cheese cheddar type Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cheese cheddar type IgG4 Ab [Mass/volume] in Serum;Cheddar IgG4-mCnc;;ACTIVE;2.29;2.73 +56216-5;Cheese mold type Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cheese mold type IgG4 Ab [Mass/volume] in Serum;Cheese Mold IgG4-mCnc;;ACTIVE;2.29;2.73 +56217-3;Cicer arietinus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chick Pea IgG4 Ab [Mass/volume] in Serum;Chick Pea IgG4-mCnc;;ACTIVE;2.29;2.73 +5621-8;Chromium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Red Blood Cells;Chromium RBC-mCnc;;ACTIVE;1.0;2.73 +56218-1;Chicken Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken IgG4 Ab [Mass/volume] in Serum;Chicken IgG4-mCnc;;ACTIVE;2.29;2.73 +56219-9;Cichorium intybus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicory IgG4 Ab [Mass/volume] in Serum;Chicory IgG4-mCnc;;ACTIVE;2.29;2.73 +56220-7;Capsicum frutescens Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chili Pepper IgG4 Ab [Mass/volume] in Serum;Chili Pepper IgG4-mCnc;;ACTIVE;2.29;2.73 +56221-5;Ulmus pumila Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chinese Elm IgG4 Ab [Mass/volume] in Serum;Chinese Elm IgG4-mCnc;;ACTIVE;2.29;2.70 +56222-3;Chocolate Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chocolate IgG4 Ab [Mass/volume] in Serum;Chocolate IgG4-mCnc;;ACTIVE;2.29;2.73 +56223-1;Cinnamomum spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cinnamon IgG4 Ab [Mass/volume] in Serum;Cinnamon IgG4-mCnc;;ACTIVE;2.29;2.73 +56224-9;Cladosporium herbarum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum IgG4 Ab [Mass/volume] in Serum;C herbarum IgG4-mCnc;;ACTIVE;2.29;2.73 +56225-6;Ruditapes spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Clam IgG4 Ab [Mass/volume] in Serum;Clam IgG4-mCnc;;ACTIVE;2.29;2.73 +5622-6;Chromium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Serum or Plasma;Chromium SerPl-mCnc;;ACTIVE;1.0;2.73 +56226-4;Xanthium commune Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cocklebur IgG4 Ab [Mass/volume] in Serum;Cocklebur IgG4-mCnc;;ACTIVE;2.29;2.73 +56227-2;Cocos nucifera Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Coconut IgG4 Ab [Mass/volume] in Serum;Coconut IgG4-mCnc;;ACTIVE;2.29;2.73 +56228-0;Gadus morhua Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Codfish IgG4 Ab [Mass/volume] in Serum;Codfish IgG4-mCnc;;ACTIVE;2.29;2.73 +56229-8;Coffea spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Coffee IgG4 Ab [Mass/volume] in Serum;Coffee IgG4-mCnc;;ACTIVE;2.29;2.73 +56230-6;Phragmites communis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common Reed IgG4 Ab [Mass/volume] in Serum;Common Reed IgG4-mCnc;;ACTIVE;2.29;2.70 +56231-4;Zea mays Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Corn IgG4 Ab [Mass/volume] in Serum;Corn IgG4-mCnc;;ACTIVE;2.29;2.73 +56232-2;Ustilago maydis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Corn smut IgG4 Ab [Mass/volume] in Serum;Corn smut IgG4-mCnc;;ACTIVE;2.29;2.70 +56233-0;Populus deltoides Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cottonwood IgG4 Ab [Mass/volume] in Serum;Cottonwood IgG4-mCnc;;ACTIVE;2.29;2.73 +5623-4;Chromium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Urine;Chromium Ur-mCnc;;ACTIVE;1.0;2.73 +56234-8;Cow milk Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cow milk IgG4 Ab [Mass/volume] in Serum;Cow Milk IgG4-mCnc;;ACTIVE;2.29;2.73 +56235-5;Cancer pagurus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Crab IgG4 Ab [Mass/volume] in Serum;Crab IgG4-mCnc;;ACTIVE;2.29;2.73 +56236-3;Vaccinium oxycoccos Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cranberry IgG4 Ab [Mass/volume] in Serum;Cranberry IgG4-mCnc;;ACTIVE;2.29;2.73 +56237-1;Astacus astacus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Crawfish IgG4 Ab [Mass/volume] in Serum;Crawfish IgG4-mCnc;;ACTIVE;2.29;2.73 +56238-9;Cucumis sativus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cucumber IgG4 Ab [Mass/volume] in Serum;Cucumber IgG4-mCnc;;ACTIVE;2.29;2.73 +56239-7;Curry Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Curry IgG4 Ab [Mass/volume] in Serum;Curry IgG4-mCnc;;ACTIVE;2.29;2.70 +56240-5;Loligo sp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Squid IgG4 Ab [Mass/volume] in Serum;Squid IgG4-mCnc;;ACTIVE;2.29;2.70 +56241-3;Dermatophagoides farinae Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite IgG4 Ab [Mass/volume] in Serum;D farinae IgG4-mCnc;;ACTIVE;2.29;2.73 +5624-2;Chromium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Chromium [Mass/time] in 24 hour Urine;Chromium 24h Ur-mRate;;ACTIVE;1.0;2.73 +56242-1;Dermatophagoides pteronyssinus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite IgG4 Ab [Mass/volume] in Serum;D pteronyss IgG4-mCnc;;ACTIVE;2.29;2.73 +56243-9;Taraxacum vulgare Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dandelion IgG4 Ab [Mass/volume] in Serum;Dandelion IgG4-mCnc;;ACTIVE;2.29;2.70 +56244-7;Phoenix dactylifera Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dates IgG4 Ab [Mass/volume] in Serum;Dates IgG4-mCnc;;ACTIVE;2.29;2.73 +56245-4;Chrysops flavidus (whole body) Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Deer Fly IgG4 Ab [Mass/volume] in Serum;Deer Fly IgG4-mCnc;;ACTIVE;2.29;2.70 +56246-2;Anethum graveolens Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dill IgG4 Ab [Mass/volume] in Serum;Dill IgG4-mCnc;;ACTIVE;2.29;2.70 +56247-0;Dog epithelium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dog epithelium IgG4 Ab [Mass/volume] in Serum;Dog Epith IgG4-mCnc;;ACTIVE;2.29;2.73 +56248-8;Dog dander Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dog dander IgG4 Ab [Mass/volume] in Serum;Dog Dander IgG4-mCnc;;ACTIVE;2.29;2.73 +56249-6;Pseudotsuga taxifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Douglas Fir IgG4 Ab [Mass/volume] in Serum;Douglas Fir IgG4-mCnc;;ACTIVE;2.29;2.70 +56250-4;Duck feather Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Duck feather IgG4 Ab [Mass/volume] in Serum;Duck Feather IgG4-mCnc;;ACTIVE;2.29;2.70 +56251-2;Duck meat Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Duck meat IgG4 Ab [Mass/volume] in Serum;Duck Meat IgG4-mCnc;;ACTIVE;2.29;2.70 +56252-0;Anguilla anguilla Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Eel IgG4 Ab [Mass/volume] in Serum;Eel IgG4-mCnc;;ACTIVE;2.29;2.70 +56253-8;Egg white Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Egg white IgG4 Ab [Mass/volume] in Serum;Egg White IgG4-mCnc;;ACTIVE;2.29;2.73 +56254-6;Egg yolk Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Egg yolk IgG4 Ab [Mass/volume] in Serum;Egg Yolk IgG4-mCnc;;ACTIVE;2.29;2.73 +56255-3;Egg whole Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Whole Egg IgG4 Ab [Mass/volume] in Serum;Whole Egg IgG4-mCnc;;ACTIVE;2.29;2.73 +56256-1;Solanum melongena Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Eggplant IgG4 Ab [Mass/volume] in Serum;Eggplant IgG4-mCnc;;ACTIVE;2.29;2.73 +56257-9;Plantago lanceolata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;English plantain IgG4 Ab [Mass/volume] in Serum;Engl plantain IgG4-mCnc;;ACTIVE;2.29;2.73 +56258-7;Eucalyptus spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Gum-Tree IgG4 Ab [Mass/volume] in Serum;Gum-Tree IgG4-mCnc;;ACTIVE;2.29;2.70 +5625-9;Cobalt;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Blood;Cobalt Bld-mCnc;;ACTIVE;1.0;2.73 +56259-5;(Chicken feather+Duck feather+Goose feather+Turkey feather) Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Epidermal Allergen Mix 71 (Chicken feather+Duck feather+Goose feather+Turkey feather) IgG4 Ab [Mass/volume] in Serum;Epid Allerg Mix71 IgG4-mCnc;;ACTIVE;2.29;2.70 +56260-3;Solenopsis invicta Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Imported Fire Ant IgG4 Ab [Mass/volume] in Serum;Red Imp Fire Ant IgG4-mCnc;;ACTIVE;2.29;2.73 +56261-1;Linum usitatissimum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Flax IgG4 Ab [Mass/volume] in Serum;Flax IgG4-mCnc;;ACTIVE;2.29;2.73 +56262-9;Ctenocephalides sp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Flea IgG4 Ab [Mass/volume] in Serum;Flea IgG4-mCnc;;ACTIVE;2.29;2.70 +56263-7;Flounder Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Flounder IgG4 Ab [Mass/volume] in Serum;Flounder IgG4-mCnc;;ACTIVE;2.29;2.73 +56264-5;Glycyphagus domesticus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Glycyphagus domesticus IgG4 Ab [Mass/volume] in Serum;G domesticus IgG4-mCnc;;ACTIVE;2.29;2.70 +56265-2;Allium sativum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Garlic IgG4 Ab [Mass/volume] in Serum;Garlic IgG4-mCnc;;ACTIVE;2.29;2.73 +56266-0;Blatella germanica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach IgG4 Ab [Mass/volume] in Serum;Roach IgG4-mCnc;;ACTIVE;2.29;2.73 +5626-7;Cobalt;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cobalt [Mass/mass] in Hair;Cobalt Hair-mCnt;;ACTIVE;1.0;2.19 +56267-8;Zingiber officinale Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Ginger IgG4 Ab [Mass/volume] in Serum;Ginger IgG4-mCnc;;ACTIVE;2.29;2.73 +56268-6;Gluten Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Gluten IgG4 Ab [Mass/volume] in Serum;Gluten IgG4-mCnc;;ACTIVE;2.29;2.73 +56269-4;Goat milk Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goat milk IgG4 Ab [Mass/volume] in Serum;Goat Milk IgG4-mCnc;;ACTIVE;2.29;2.73 +56270-2;Hamster epithelium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hamster epithelium IgG4 Ab [Mass/volume] in Serum;Hmtr Epith IgG4-mCnc;;ACTIVE;2.29;2.73 +56271-0;Solidago virgaurea Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goldenrod IgG4 Ab [Mass/volume] in Serum;Goldenrod IgG4-mCnc;;ACTIVE;2.29;2.70 +56272-8;Goose feather Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goose feather IgG4 Ab [Mass/volume] in Serum;Goose Feather IgG4-mCnc;;ACTIVE;2.29;2.70 +56273-6;Vitis vinifera Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grape IgG4 Ab [Mass/volume] in Serum;Grape IgG4-mCnc;;ACTIVE;2.29;2.73 +56274-4;Citrus paradisis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grapefruit IgG4 Ab [Mass/volume] in Serum;Grapefruit IgG4-mCnc;;ACTIVE;2.29;2.73 +5627-5;Cobalt;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Serum or Plasma;Cobalt SerPl-mCnc;;ACTIVE;1.0;2.73 +56275-1;Bean green Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Green Bean IgG4 Ab [Mass/volume] in Serum;Green Bean IgG4-mCnc;;ACTIVE;2.29;2.73 +56276-9;Olea europaea Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Olive IgG4 Ab [Mass/volume] in Serum;Olive IgG4-mCnc;;ACTIVE;2.29;2.73 +56277-7;Pisum sativum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pea IgG4 Ab [Mass/volume] in Serum;Pea IgG4-mCnc;;ACTIVE;2.29;2.73 +56278-5;Pepper green Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Green Pepper IgG4 Ab [Mass/volume] in Serum;Green Pepper IgG4-mCnc;;ACTIVE;2.29;2.73 +56279-3;Guinea pig epithelium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Guinea pig epithelium IgG4 Ab [Mass/volume] in Serum;Guinea Pig Epith IgG4-mCnc;;ACTIVE;2.29;2.70 +56280-1;Melanogrammus aeglefinus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Haddock IgG4 Ab [Mass/volume] in Serum;Haddock IgG4-mCnc;;ACTIVE;2.29;2.73 +56281-9;Hippoglossus hippoglossus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Halibut IgG4 Ab [Mass/volume] in Serum;Halibut IgG4-mCnc;;ACTIVE;2.29;2.73 +56282-7;Corylus avellana pollen Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut Pollen IgG4 Ab [Mass/volume] in Serum;Hazelnut Poln IgG4-mCnc;;ACTIVE;2.29;2.70 +5628-3;Cobalt;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Urine;Cobalt Ur-mCnc;;ACTIVE;1.0;2.73 +56283-5;Corylus avellana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut IgG4 Ab [Mass/volume] in Serum;Hazelnut IgG4-mCnc;;ACTIVE;2.29;2.73 +56284-3;Clupea harengus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Herring IgG4 Ab [Mass/volume] in Serum;Herring IgG4-mCnc;;ACTIVE;2.29;2.70 +56285-0;Honey Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honey IgG4 Ab [Mass/volume] in Serum;Honey IgG4-mCnc;;ACTIVE;2.29;2.73 +56286-8;Apis mellifera Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee IgG4 Ab [Mass/volume] in Serum;Honey bee IgG4-mCnc;;ACTIVE;2.29;2.73 +56287-6;Cucumis melo spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Melon IgG4 Ab [Mass/volume] in Serum;Deprecated Melon IgG4-mCnc;;DEPRECATED;2.29;2.70 +56288-4;Humulus lupus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hop IgG4 Ab [Mass/volume] in Serum;Hop IgG4-mCnc;;ACTIVE;2.29;2.73 +56289-2;Armoracia rusticana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horseradish IgG4 Ab [Mass/volume] in Serum;Horseradish IgG4-mCnc;;ACTIVE;2.29;2.73 +562-9;Clostridioides difficile;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Clostridioides difficile [Presence] in Stool by Organism specific culture;C diff Stl Ql Cult;;ACTIVE;1.0;2.73 +56290-0;House dust Greer Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;House dust Greer IgG4 Ab [Mass/volume] in Serum;House Dust Greer IgG4-mCnc;;ACTIVE;2.29;2.73 +5629-1;Copper;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Copper [Mass/mass] in Hair;Copper Hair-mCnt;;ACTIVE;1.0;2.73 +56291-8;(Blatella germanica+Dermatophagoides farinae+Dermatophagoides pteronyssinus+House dust Hollister Stier) Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dust Allergen Mix 2 (Cockroach+American house dust mite+European house dust mite+House dust Hollister Stier) IgG4 Ab [Mass/volume] in Serum;Dust Allerg Mix2 IgG4-mCnc;;ACTIVE;2.29;2.73 +56292-6;Insulin human Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Insulin human IgG4 Ab [Mass/volume] in Serum;Insulin Human IgG4-mCnc;;ACTIVE;2.29;2.70 +56293-4;Cupressus sempervirens Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Italian Cypress IgG4 Ab [Mass/volume] in Serum;Italian Cypress IgG4-mCnc;;ACTIVE;2.29;2.70 +56294-2;Sorghum halepense Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Johnson grass IgG4 Ab [Mass/volume] in Serum;Johnson grass IgG4-mCnc;;ACTIVE;2.29;2.73 +56295-9;Karaya gum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Karaya gum IgG4 Ab [Mass/volume] in Serum;Karaya Gum IgG4-mCnc;;ACTIVE;2.29;2.70 +56296-7;Poa pratensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Kentucky blue grass IgG4 Ab [Mass/volume] in Serum;Kent blue grass IgG4-mCnc;;ACTIVE;2.29;2.73 +56297-5;Bean kidney red Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Kidney Bean IgG4 Ab [Mass/volume] in Serum;Red Kidney Bean IgG4-mCnc;;ACTIVE;2.29;2.73 +56298-3;Actinidia chinensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Kiwifruit IgG4 Ab [Mass/volume] in Serum;Kiwifruit IgG4-mCnc;;ACTIVE;2.29;2.73 +56299-1;Kochia scoparia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Firebush IgG4 Ab [Mass/volume] in Serum;Firebush IgG4-mCnc;;ACTIVE;2.29;2.70 +56300-7;Lepidoglyphus destructor Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lepidoglyphus destructor IgG4 Ab [Mass/volume] in Serum;L destructor IgG4-mCnc;;ACTIVE;2.29;2.70 +56301-5;Lactalbumin alpha Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin alpha IgG4 Ab [Mass/volume] in Serum;A-Lactalb IgG4-mCnc;;ACTIVE;2.29;2.73 +56302-3;Beta lactoglobulin Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Beta lactoglobulin IgG4 Ab [Mass/volume] in Serum;B-Lactoglob IgG4-mCnc;;ACTIVE;2.29;2.73 +56303-1;Chenopodium album Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goosefoot IgG4 Ab [Mass/volume] in Serum;Goosefoot IgG4-mCnc;;ACTIVE;2.29;2.73 +56304-9;Citrus limon Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lemon IgG4 Ab [Mass/volume] in Serum;Lemon IgG4-mCnc;;ACTIVE;2.29;2.73 +56305-6;Atriplex lentiformis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lenscale IgG4 Ab [Mass/volume] in Serum;Lenscale IgG4-mCnc;;ACTIVE;2.29;2.73 +56306-4;Lens esculenta Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lentils IgG4 Ab [Mass/volume] in Serum;Lentils IgG4-mCnc;;ACTIVE;2.29;2.70 +56307-2;Lactuca sativa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lettuce IgG4 Ab [Mass/volume] in Serum;Lettuce IgG4-mCnc;;ACTIVE;2.29;2.73 +56308-0;Phaseolus limensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lima Bean IgG4 Ab [Mass/volume] in Serum;Lima Bean IgG4-mCnc;;ACTIVE;2.29;2.73 +5630-9;Copper;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Red Blood Cells;Copper RBC-mCnc;;ACTIVE;1.0;2.73 +56309-8;Citrus aurantifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lime IgG4 Ab [Mass/volume] in Serum;Lime IgG4-mCnc;;ACTIVE;2.29;2.73 +56310-6;Homarus gammarus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lobster IgG4 Ab [Mass/volume] in Serum;Lobster IgG4-mCnc;;ACTIVE;2.29;2.73 +56311-4;Locust tree Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Locust tree IgG4 Ab [Mass/volume] in Serum;Locust Tree IgG4-mCnc;;ACTIVE;2.29;2.73 +56312-2;Malt Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Malt IgG4 Ab [Mass/volume] in Serum;Malt IgG4-mCnc;;ACTIVE;2.29;2.73 +56313-0;Mangifera indica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mango IgG4 Ab [Mass/volume] in Serum;Mango IgG4-mCnc;;ACTIVE;2.29;2.73 +56314-8;Maple syrup Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Maple syrup IgG4 Ab [Mass/volume] in Serum;Maple Syrup IgG4-mCnc;;ACTIVE;2.29;2.70 +56315-5;Acer negundo Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Boxelder IgG4 Ab [Mass/volume] in Serum;Boxelder IgG4-mCnc;;ACTIVE;2.29;2.73 +56316-3;Iva ciliata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rough Marsh Elder IgG4 Ab [Mass/volume] in Serum;Marsh Elder IgG4-mCnc;;ACTIVE;2.29;2.73 +5631-7;Copper;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Serum or Plasma;Copper SerPl-mCnc;;ACTIVE;1.0;2.73 +56317-1;Festuca elatior Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Meadow Fescue IgG4 Ab [Mass/volume] in Serum;Meadow Fescue IgG4-mCnc;;ACTIVE;2.29;2.73 +56318-9;Alopercurus pratensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Meadow Foxtail IgG4 Ab [Mass/volume] in Serum;Meadow Foxtail IgG4-mCnc;;ACTIVE;2.29;2.70 +56319-7;Melaleuca leucadendron Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cajeput tree IgG4 Ab [Mass/volume] in Serum;Cajeput tree IgG4-mCnc;;ACTIVE;2.29;2.70 +56320-5;Prosopis juliflora Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mesquite IgG4 Ab [Mass/volume] in Serum;Mesquite IgG4-mCnc;;ACTIVE;2.29;2.70 +56321-3;Panicum milliaceum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common Millet IgG4 Ab [Mass/volume] in Serum;Common Millet IgG4-mCnc;;ACTIVE;2.29;2.73 +56322-1;Aedes communis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aedes mosquito IgG4 Ab [Mass/volume] in Serum;Aedes mosquito IgG4-mCnc;;ACTIVE;2.29;2.73 +56323-9;Juniperus sabinoides Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mountain Juniper IgG4 Ab [Mass/volume] in Serum;Mt Juniper IgG4-mCnc;;ACTIVE;2.29;2.70 +56324-7;Mucor racemosus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mucor racemosus IgG4 Ab [Mass/volume] in Serum;M racemosus IgG4-mCnc;;ACTIVE;2.29;2.70 +5632-5;Copper;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Urine;Copper Ur-mCnc;;ACTIVE;1.0;2.73 +56325-4;Artemisia vulgaris Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mugwort IgG4 Ab [Mass/volume] in Serum;Mugwort IgG4-mCnc;;ACTIVE;2.29;2.73 +56326-2;Agaricus hortensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mushroom IgG4 Ab [Mass/volume] in Serum;Mushroom IgG4-mCnc;;ACTIVE;2.29;2.73 +56327-0;Mytilus edulis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blue mussel IgG4 Ab [Mass/volume] in Serum;Blue mussel IgG4-mCnc;;ACTIVE;2.29;2.70 +56328-8;Mustard Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mustard IgG4 Ab [Mass/volume] in Serum;Mustard IgG4-mCnc;;ACTIVE;2.29;2.73 +56329-6;Prunus persica var nucipersica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Nectarine IgG4 Ab [Mass/volume] in Serum;Nectarine IgG4-mCnc;;ACTIVE;2.29;2.73 +56330-4;Urtica dioica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Nettle IgG4 Ab [Mass/volume] in Serum;Nettle IgG4-mCnc;;ACTIVE;2.29;2.70 +56331-2;(Anacardium occidentale+Carya illinoinensis+Castanea sativa+Juglans spp+Pistacia vera) Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Food Allergen Mix 46 (Cashew+Pecan or Hickory nut+Chestnut+Walnut+Pistachio) IgG4 Ab [Mass/volume] in Serum;Food Allerg Mix46 IgG4-mCnc;;ACTIVE;2.29;2.73 +56332-0;Nutmeg Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Nutmeg IgG4 Ab [Mass/volume] in Serum;Nutmeg IgG4-mCnc;;ACTIVE;2.29;2.73 +5633-3;Copper;MRat;24H;Urine;Qn;;DRUG/TOX;1;Copper [Mass/time] in 24 hour Urine;Copper 24h Ur-mRate;;ACTIVE;1.0;2.73 +56333-8;Avena sativa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oat IgG4 Ab [Mass/volume] in Serum;Oat IgG4-mCnc;;ACTIVE;2.29;2.73 +56334-6;Avena sativa cultivated Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oat pollen IgG4 Ab [Mass/volume] in Serum;Oat Poln IgG4-mCnc;;ACTIVE;2.29;2.73 +56335-3;Abelmoschus esculentus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Okra IgG4 Ab [Mass/volume] in Serum;Okra IgG4-mCnc;;ACTIVE;2.29;2.70 +56336-1;Olea europaea pollen Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Olive Pollen IgG4 Ab [Mass/volume] in Serum;Olive Poln IgG4-mCnc;;ACTIVE;2.29;2.70 +56337-9;Allium cepa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Onion IgG4 Ab [Mass/volume] in Serum;Onion IgG4-mCnc;;ACTIVE;2.29;2.73 +56338-7;Citrus sinensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Orange IgG4 Ab [Mass/volume] in Serum;Orange IgG4-mCnc;;ACTIVE;2.29;2.73 +56339-5;Dactylis glomerata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cocksfoot IgG4 Ab [Mass/volume] in Serum;Cocksfoot IgG4-mCnc;;ACTIVE;2.29;2.73 +56340-3;Origanum vulgare Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oregano IgG4 Ab [Mass/volume] in Serum;Oregano IgG4-mCnc;;ACTIVE;2.29;2.73 +5634-1;Cyanide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cyanide [Mass/volume] in Blood;Cyanide Bld-mCnc;;ACTIVE;1.0;2.73 +56341-1;Chrysanthemum leucanthemum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Ox-eye daisy IgG4 Ab [Mass/volume] in Serum;Ox-eye daisy IgG4-mCnc;;ACTIVE;2.29;2.70 +56342-9;Ostrea edulis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oyster IgG4 Ab [Mass/volume] in Serum;Oyster IgG4-mCnc;;ACTIVE;2.29;2.73 +56343-7;Carica papaya Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Papaya (Carica papaya) IgG4 Ab [Mass/volume] in Serum;Papaya IgG4-mCnc;;ACTIVE;2.29;2.73 +56344-5;Polistes spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp IgG4 Ab [Mass/volume] in Serum;Paper Wasp IgG4-mCnc;;ACTIVE;2.29;2.73 +56345-2;Capsicum annuum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paprika IgG4 Ab [Mass/volume] in Serum;Paprika IgG4-mCnc;;ACTIVE;2.29;2.73 +56346-0;Cheese parmesan Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parmesan Cheese IgG4 Ab [Mass/volume] in Serum;Parmesan IgG4-mCnc;;ACTIVE;2.29;2.70 +56347-8;Parrot feather Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parrot feather IgG4 Ab [Mass/volume] in Serum;Parrot Feather IgG4-mCnc;;ACTIVE;2.29;2.73 +56348-6;Petroselinum crispum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parsley IgG4 Ab [Mass/volume] in Serum;Parsley IgG4-mCnc;;ACTIVE;2.29;2.70 +56349-4;Pastinaca sativa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parsnip IgG4 Ab [Mass/volume] in Serum;Parsnip IgG4-mCnc;;ACTIVE;2.29;2.73 +56350-2;Prunus persica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peach IgG4 Ab [Mass/volume] in Serum;Peach IgG4-mCnc;;ACTIVE;2.29;2.73 +56351-0;Arachis hypogaea Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut IgG4 Ab [Mass/volume] in Serum;Peanut IgG4-mCnc;;ACTIVE;2.29;2.73 +56352-8;Pyrus communis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pear IgG4 Ab [Mass/volume] in Serum;Pear IgG4-mCnc;;ACTIVE;2.29;2.73 +56353-6;Carya illinoinensis nut Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Nut IgG4 Ab [Mass/volume] in Serum;Pecan/Hick Nut IgG4-mCnc;;ACTIVE;2.29;2.73 +56354-4;Carya illinoinensis tree Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Tree IgG4 Ab [Mass/volume] in Serum;Pecan/Hick Tree IgG4-mCnc;;ACTIVE;2.29;2.73 +56355-1;Penicillium notatum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium notatum IgG4 Ab [Mass/volume] in Serum;P notatum IgG4-mCnc;;ACTIVE;2.29;2.73 +56356-9;Perca spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Perch IgG4 Ab [Mass/volume] in Serum;Perch IgG4-mCnc;;ACTIVE;2.29;2.73 +56357-7;Lolium perenne Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Perennial rye grass IgG4 Ab [Mass/volume] in Serum;Per rye grass IgG4-mCnc;;ACTIVE;2.29;2.70 +5635-8;Cyanide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cyanide [Mass/volume] in Serum or Plasma;Cyanide SerPl-mCnc;;ACTIVE;1.0;2.42 +56358-5;Ananas comosus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pineapple IgG4 Ab [Mass/volume] in Serum;Pineapple IgG4-mCnc;;ACTIVE;2.29;2.73 +56359-3;Bean pinto Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pinto Bean IgG4 Ab [Mass/volume] in Serum;Pinto Bean IgG4-mCnc;;ACTIVE;2.29;2.73 +56360-1;Pistacia vera Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pistachio IgG4 Ab [Mass/volume] in Serum;Pistachio IgG4-mCnc;;ACTIVE;2.29;2.73 +56361-9;Prunus domestica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Plum IgG4 Ab [Mass/volume] in Serum;Plum IgG4-mCnc;;ACTIVE;2.29;2.73 +56362-7;Papaver somniferum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Poppy Seed IgG4 Ab [Mass/volume] in Serum;Poppy Seed IgG4-mCnc;;ACTIVE;2.29;2.70 +56363-5;Insulin porcine Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Insulin porcine IgG4 Ab [Mass/volume] in Serum;Insulin Porcine IgG4-mCnc;;ACTIVE;2.29;2.70 +56364-3;Iva axillaris Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Povertyweed IgG4 Ab [Mass/volume] in Serum;Povertyweed IgG4-mCnc;;ACTIVE;2.29;2.70 +56365-0;Syagrus romanzoffianum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Queen Palm IgG4 Ab [Mass/volume] in Serum;Queen Palm IgG4-mCnc;;ACTIVE;2.29;2.70 +5636-6;Cyanide;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Cyanide [Mass/mass] in Tissue;Cyanide Tiss-mCnt;;ACTIVE;1.0;2.42 +56366-8;Rabbit Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit IgG4 Ab [Mass/volume] in Serum;Rabbit IgG4-mCnc;;ACTIVE;2.29;2.70 +56367-6;Rabbit epithelium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit epithelium IgG4 Ab [Mass/volume] in Serum;Rabbit Epith IgG4-mCnc;;ACTIVE;2.29;2.70 +56368-4;Raphanus sativus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Radish IgG4 Ab [Mass/volume] in Serum;Radish IgG4-mCnc;;ACTIVE;2.29;2.70 +56369-2;Franseria acanthicarpa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;False ragweed IgG4 Ab [Mass/volume] in Serum;False ragweed IgG4-mCnc;;ACTIVE;2.29;2.70 +563-7;Clostridioides difficile;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Clostridioides difficile [Presence] in Specimen by Organism specific culture;C diff Spec Ql Cult;;ACTIVE;1.0;2.73 +56370-0;Ambrosia trifida Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Giant Ragweed IgG4 Ab [Mass/volume] in Serum;Giant Ragweed IgG4-mCnc;;ACTIVE;2.29;2.73 +56371-8;Ambrosia elatior Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common Ragweed IgG4 Ab [Mass/volume] in Serum;Common Ragweed IgG4-mCnc;;ACTIVE;2.29;2.73 +56372-6;Ambrosia psilostachya Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Western Ragweed IgG4 Ab [Mass/volume] in Serum;West Ragweed IgG4-mCnc;;ACTIVE;2.29;2.73 +56373-4;Rubus idaeus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Raspberry IgG4 Ab [Mass/volume] in Serum;Raspberry IgG4-mCnc;;ACTIVE;2.29;2.73 +5637-4;Cyanide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Cyanide [Mass/volume] in Urine;Cyanide Ur-mCnc;;ACTIVE;1.0;2.42 +56374-2;Rat epithelium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rat epithelium IgG4 Ab [Mass/volume] in Serum;Rat Epith IgG4-mCnc;;ACTIVE;2.29;2.70 +56375-9;Beet red Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Beet IgG4 Ab [Mass/volume] in Serum;Red Beet IgG4-mCnc;;ACTIVE;2.29;2.73 +56376-7;Snapper red Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Snapper IgG4 Ab [Mass/volume] in Serum;Red Snapper IgG4-mCnc;;ACTIVE;2.29;2.73 +56377-5;Agrostis stolonifera Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red top grass IgG4 Ab [Mass/volume] in Serum;Red top grass IgG4-mCnc;;ACTIVE;2.29;2.73 +56378-3;Rheum spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rhubarb IgG4 Ab [Mass/volume] in Serum;Rhubarb IgG4-mCnc;;ACTIVE;2.29;2.70 +56379-1;Oryza sativa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rice IgG4 Ab [Mass/volume] in Serum;Rice IgG4-mCnc;;ACTIVE;2.29;2.73 +56380-9;Salsola kali Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Saltwort IgG4 Ab [Mass/volume] in Serum;Saltwort IgG4-mCnc;;ACTIVE;2.29;2.73 +56381-7;Secale cereale pollen Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Rye IgG4 Ab [Mass/volume] in Serum;Cultivated Rye IgG4-mCnc;;ACTIVE;2.29;2.70 +5638-2;Diazinon;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Diazinon [Mass/volume] in Blood;Diazinon Bld-mCnc;;ACTIVE;1.0;2.73 +56382-5;Carthamus tinctorius Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Safflower IgG4 Ab [Mass/volume] in Serum;Safflower IgG4-mCnc;;ACTIVE;2.29;2.70 +56383-3;Salmo salar Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Salmon IgG4 Ab [Mass/volume] in Serum;Salmon IgG4-mCnc;;ACTIVE;2.29;2.73 +56384-1;Sardina pilchardus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sardine (pilchard) IgG4 Ab [Mass/volume] in Serum;Sardine (pilchard) IgG4-mCnc;;ACTIVE;2.29;2.73 +56385-8;Pecten spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Scallop IgG4 Ab [Mass/volume] in Serum;Scallop IgG4-mCnc;;ACTIVE;2.29;2.73 +56386-6;Sesamum indicum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sesame Seed IgG4 Ab [Mass/volume] in Serum;Sesame Seed IgG4-mCnc;;ACTIVE;2.29;2.73 +56387-4;Rumex acetosella Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sheep Sorrel IgG4 Ab [Mass/volume] in Serum;Sheep Sorrel IgG4-mCnc;;ACTIVE;2.29;2.73 +56388-2;Pandalus borealis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp IgG4 Ab [Mass/volume] in Serum;Shrimp IgG4-mCnc;;ACTIVE;2.29;2.73 +56389-0;Solea solea Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sole IgG4 Ab [Mass/volume] in Serum;Sole IgG4-mCnc;;ACTIVE;2.29;2.73 +5639-0;Ethanol;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Ethanol [Presence] in Blood;Ethanol Bld Ql;;ACTIVE;1.0;2.73 +56390-8;Glycine max Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Soybean IgG4 Ab [Mass/volume] in Serum;Soybean IgG4-mCnc;;ACTIVE;2.29;2.73 +56391-6;Spinacia oleracea Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Spinach IgG4 Ab [Mass/volume] in Serum;Spinach IgG4-mCnc;;ACTIVE;2.29;2.73 +56392-4;Pigweed spiny Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Spiny Pigweed IgG4 Ab [Mass/volume] in Serum;Spiny Pigweed IgG4-mCnc;;ACTIVE;2.29;2.70 +56393-2;Fragaria vesca Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Strawberry IgG4 Ab [Mass/volume] in Serum;Strawberry IgG4-mCnc;;ACTIVE;2.29;2.73 +56394-0;Saccharum officinarum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Cane IgG4 Ab [Mass/volume] in Serum;Sugar Cane IgG4-mCnc;;ACTIVE;2.29;2.73 +56395-7;Helianthus annuus seed Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sunflower Seed IgG4 Ab [Mass/volume] in Serum;Sunflower Seed IgG4-mCnc;;ACTIVE;2.29;2.73 +56396-5;Castanea sativa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chestnut IgG4 Ab [Mass/volume] in Serum;Chestnut IgG4-mCnc;;ACTIVE;2.29;2.73 +56397-3;Ipomoea batatas Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sweet potato IgG4 Ab [Mass/volume] in Serum;Sweet potato IgG4-mCnc;;ACTIVE;2.29;2.73 +56398-1;Anthoxanthum odoratum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sweet Vernal grass IgG4 Ab [Mass/volume] in Serum;Sw Vernal grass IgG4-mCnc;;ACTIVE;2.29;2.73 +56399-9;Cheese swiss Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Swiss Cheese IgG4 Ab [Mass/volume] in Serum;Swiss Cheese IgG4-mCnc;;ACTIVE;2.29;2.73 +56400-5;Citrus reticulata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mandarin IgG4 Ab [Mass/volume] in Serum;Mandarin IgG4-mCnc;;ACTIVE;2.29;2.73 +56401-3;Camellia sinensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tea IgG4 Ab [Mass/volume] in Serum;Tea IgG4-mCnc;;ACTIVE;2.29;2.73 +56402-1;Thymus vulgaris Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Thyme IgG4 Ab [Mass/volume] in Serum;Thyme IgG4-mCnc;;ACTIVE;2.29;2.73 +56403-9;Phleum pratense Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Timothy IgG4 Ab [Mass/volume] in Serum;Timothy IgG4-mCnc;;ACTIVE;2.29;2.73 +56404-7;Nicotiana tabacum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tobacco IgG4 Ab [Mass/volume] in Serum;Tobacco IgG4-mCnc;;ACTIVE;2.29;2.73 +56405-4;Lycopersicon lycopersicum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tomato IgG4 Ab [Mass/volume] in Serum;Tomato IgG4-mCnc;;ACTIVE;2.29;2.73 +56406-2;Trichoderma viride Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Trichoderma viride IgG4 Ab [Mass/volume] in Serum;T viride IgG4-mCnc;;ACTIVE;2.29;2.70 +56407-0;Oncorhynchus mykiss Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Trout IgG4 Ab [Mass/volume] in Serum;Trout IgG4-mCnc;;ACTIVE;2.29;2.73 +5640-8;Ethanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Blood;Ethanol Bld-mCnc;;ACTIVE;1.0;2.73 +56408-8;Thunnus albacares Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tuna IgG4 Ab [Mass/volume] in Serum;Tuna IgG4-mCnc;;ACTIVE;2.29;2.73 +56409-6;Turkey Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Turkey IgG4 Ab [Mass/volume] in Serum;Turkey IgG4-mCnc;;ACTIVE;2.29;2.73 +56410-4;Vanilla planifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Vanilla IgG4 Ab [Mass/volume] in Serum;Vanilla IgG4-mCnc;;ACTIVE;2.29;2.73 +56411-2;Holcus lanatus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Velvet grass IgG4 Ab [Mass/volume] in Serum;Velvet grass IgG4-mCnc;;ACTIVE;2.29;2.70 +56412-0;Venison Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Venison IgG4 Ab [Mass/volume] in Serum;Venison IgG4-mCnc;;ACTIVE;2.29;2.70 +56413-8;Quercus virginiana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Virginia Live Oak IgG4 Ab [Mass/volume] in Serum;Virg Live Oak IgG4-mCnc;;ACTIVE;2.29;2.70 +56414-6;Juglans spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Walnut IgG4 Ab [Mass/volume] in Serum;Walnut IgG4-mCnc;;ACTIVE;2.29;2.73 +56415-3;Citrullus lanatus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Watermelon IgG4 Ab [Mass/volume] in Serum;Watermelon IgG4-mCnc;;ACTIVE;2.29;2.73 +5641-6;Ethanol;MCnc;Pt;Exhl gas;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Exhaled gas;Ethanol ExG-mCnc;;ACTIVE;1.0;2.73 +56416-1;Acnida tamariscina Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Western Water Hemp IgG4 Ab [Mass/volume] in Serum;West Water Hemp IgG4-mCnc;;ACTIVE;2.29;2.73 +56417-9;Triticum aestivum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Wheat IgG4 Ab [Mass/volume] in Serum;Wheat IgG4-mCnc;;ACTIVE;2.29;2.73 +56418-7;Triticum aestivum pollen Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Wheat IgG4 Ab [Mass/volume] in Serum;Cultivated Wheat IgG4-mCnc;;ACTIVE;2.29;2.70 +56419-5;Cow whey Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cow whey IgG4 Ab [Mass/volume] in Serum;Cow Whey IgG4-mCnc;;ACTIVE;2.29;2.73 +56420-3;Fraxinus americana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Ash IgG4 Ab [Mass/volume] in Serum;White Ash IgG4-mCnc;;ACTIVE;2.29;2.73 +56421-1;Bean white Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Bean IgG4 Ab [Mass/volume] in Serum;White Bean IgG4-mCnc;;ACTIVE;2.29;2.73 +56422-9;Betula populifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Birch IgG4 Ab [Mass/volume] in Serum;White Birch IgG4-mCnc;;ACTIVE;2.29;2.70 +56423-7;Carya tomentosa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Hickory IgG4 Ab [Mass/volume] in Serum;White Hickory IgG4-mCnc;;ACTIVE;2.29;2.73 +5642-4;Ethanol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Ethanol [Presence] in Serum or Plasma;Ethanol SerPl Ql;;ACTIVE;1.0;2.73 +56424-5;Dolichovespula maculata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Whitefaced Hornet IgG4 Ab [Mass/volume] in Serum;Whitefaced Hornet IgG4-mCnc;;ACTIVE;2.29;2.73 +56425-2;Morus alba Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White mulberry IgG4 Ab [Mass/volume] in Serum;White mulberry IgG4-mCnc;;ACTIVE;2.29;2.70 +56426-0;Quercus alba Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Oak IgG4 Ab [Mass/volume] in Serum;White Oak IgG4-mCnc;;ACTIVE;2.29;2.73 +56427-8;Pinus strobus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Eastern White Pine IgG4 Ab [Mass/volume] in Serum;East White Pine IgG4-mCnc;;ACTIVE;2.29;2.73 +56428-6;Populus alba Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Poplar IgG4 Ab [Mass/volume] in Serum;White Poplar IgG4-mCnc;;ACTIVE;2.29;2.73 +56429-4;Solanum tuberosum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Potato IgG4 Ab [Mass/volume] in Serum;Potato IgG4-mCnc;;ACTIVE;2.29;2.73 +56430-2;Whitefish Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Whitefish IgG4 Ab [Mass/volume] in Serum;Whitefish IgG4-mCnc;;ACTIVE;2.29;2.73 +56431-0;Wine Vinegar Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Wine vinegar IgG4 Ab [Mass/volume] in Serum;Wine vinegar IgG4-mCnc;;ACTIVE;2.29;2.73 +5643-2;Ethanol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Serum or Plasma;Ethanol SerPl-mCnc;;ACTIVE;1.0;2.73 +56432-8;Artemisia absinthium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Wormwood IgG4 Ab [Mass/volume] in Serum;Wormwood IgG4-mCnc;;ACTIVE;2.29;2.70 +56433-6;Dolichovespula arenaria Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Hornet IgG4 Ab [Mass/volume] in Serum;Yellow Hornet IgG4-mCnc;;ACTIVE;2.29;2.73 +56434-4;Vespula spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Jacket IgG4 Ab [Mass/volume] in Serum;Yellow Jacket IgG4-mCnc;;ACTIVE;2.29;2.73 +56435-1;Yogurt Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yogurt IgG4 Ab [Mass/volume] in Serum;Yogurt IgG4-mCnc;;ACTIVE;2.29;2.73 +56436-9;Squash zucchini Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Zucchini IgG4 Ab [Mass/volume] in Serum;Zucchini IgG4-mCnc;;ACTIVE;2.29;2.73 +56437-7;Chicken feather Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken feather IgG4 Ab [Mass/volume] in Serum;Chicken Feather IgG4-mCnc;;ACTIVE;2.29;2.73 +56438-5;Beef Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Beef IgG4 Ab [Mass/volume] in Serum;Beef IgG4-mCnc;;ACTIVE;2.29;2.73 +56439-3;Scomber japonicus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chub Mackerel IgG4 Ab [Mass/volume] in Serum;Chub Mackerel IgG4-mCnc;;ACTIVE;2.29;2.70 +5644-0;Ethanol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethanol [Presence] in Urine;Ethanol Ur Ql;;ACTIVE;1.0;2.73 +56440-1;Syzygium aromaticum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Clove IgG4 Ab [Mass/volume] in Serum;Clove IgG4-mCnc;;ACTIVE;2.29;2.73 +56441-9;Latex Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Latex IgG4 Ab [Mass/volume] in Serum;Ltx IgG4-mCnc;;ACTIVE;2.29;2.70 +56442-7;Pork Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pork IgG4 Ab [Mass/volume] in Serum;Pork IgG4-mCnc;;ACTIVE;2.29;2.73 +56443-5;Secale cereale Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rye IgG4 Ab [Mass/volume] in Serum;Rye IgG4-mCnc;;ACTIVE;2.29;2.73 +56444-3;Healthcare communication;Find;Pt;^Patient;Doc;;DOC.MISC;2;Healthcare communication Document;Healthcare communication Doc;;ACTIVE;2.29;2.73 +56445-0;Medication summary;Find;Pt;^Patient;Doc;;DOC.MISC;2;Medication summary Document;Medication summary Doc;;ACTIVE;2.29;2.73 +56446-8;Appointment summary;Find;Pt;^Patient;Doc;;DOC.MISC;2;Appointment summary Document;Appointment summary Doc;;ACTIVE;2.29;2.73 +56447-6;Plan of care note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Deprecated Plan of care note;Deprecated Plan of care note;;DEPRECATED;2.29;2.73 +56448-4;Chloride;SCnc;Pt;Sweat;Qn;Screen;CHEM;1;Chloride [Moles/volume] in Sweat by Screen method;Chloride Sweat Scn-sCnc;;ACTIVE;2.29;2.73 +56449-2;Saccharomyces cerevisiae Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast IgG4 Ab [Mass/volume] in Serum;Baker's yeast IgG4-mCnc;;ACTIVE;2.29;2.73 +564-5;Colony count;Num;Pt;XXX;Qn;VC;MICRO;1;Colony count [#] in Specimen by Visual count;CC Spec VC;;ACTIVE;1.0;2.73 +56450-0;Piper nigrum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Black Pepper IgG4 Ab [Mass/volume] in Serum;Black Pepper IgG4-mCnc;;ACTIVE;2.29;2.73 +56451-8;Chymopapain Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chymopapain IgG4 Ab [Mass/volume] in Serum;Chymopapain IgG4-mCnc;;ACTIVE;2.29;2.70 +56452-6;Cottonseed Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cottonseed IgG4 Ab [Mass/volume] in Serum;Cottonseed IgG4-mCnc;;ACTIVE;2.29;2.73 +56453-4;Cow dander Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cow dander IgG4 Ab [Mass/volume] in Serum;Cow Dander IgG4-mCnc;;ACTIVE;2.29;2.73 +56454-2;Cuminum cyminum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cumin IgG4 Ab [Mass/volume] in Serum;Cumin IgG4-mCnc;;ACTIVE;2.29;2.73 +56455-9;Gelatin Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Gelatin IgG4 Ab [Mass/volume] in Serum;Gelatin IgG4-mCnc;;ACTIVE;2.29;2.73 +56456-7;Horse dander Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horse dander IgG4 Ab [Mass/volume] in Serum;Horse Dander IgG4-mCnc;;ACTIVE;2.29;2.73 +5645-7;Ethanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethanol [Mass/volume] in Urine;Ethanol Ur-mCnc;;ACTIVE;1.0;2.73 +56457-5;Lamb Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lamb IgG4 Ab [Mass/volume] in Serum;Lamb IgG4-mCnc;;ACTIVE;2.29;2.73 +56458-3;Acacia longifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Wattle IgG4 Ab [Mass/volume] in Serum;Wattle IgG4-mCnc;;ACTIVE;2.29;2.70 +56459-1;Ustilago avenae Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oat smut IgG4 Ab [Mass/volume] in Serum;Oat smut IgG4-mCnc;;ACTIVE;2.29;2.70 +56460-9;Schinus molle Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pepper tree IgG4 Ab [Mass/volume] in Serum;Pepper tree IgG4-mCnc;;ACTIVE;2.29;2.70 +56461-7;Alnus rubra Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Alder IgG4 Ab [Mass/volume] in Serum;Red Alder IgG4-mCnc;;ACTIVE;2.29;2.70 +56462-5;Pepper red Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Pepper IgG4 Ab [Mass/volume] in Serum;Red Pepper IgG4-mCnc;;ACTIVE;2.29;2.70 +56463-3;Pigweed rough Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rough Pigweed IgG4 Ab [Mass/volume] in Serum;Rough Pigweed IgG4-mCnc;;ACTIVE;2.29;2.70 +56464-1;Salvia officinalis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sage IgG4 Ab [Mass/volume] in Serum;Sage IgG4-mCnc;;ACTIVE;2.29;2.73 +5646-5;Ethylene glycol;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Ethylene glycol [Mass/volume] in Serum, Plasma or Blood;Ethylene Glycol SerPlBld-mCnc;;ACTIVE;1.0;2.73 +56465-8;Distichlis spicata Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Salt grass IgG4 Ab [Mass/volume] in Serum;Salt grass IgG4-mCnc;;ACTIVE;2.29;2.73 +56466-6;Xiphias gladius Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Swordfish IgG4 Ab [Mass/volume] in Serum;Swordfish IgG4-mCnc;;ACTIVE;2.29;2.70 +56467-4;Tabanus spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horse Fly IgG4 Ab [Mass/volume] in Serum;Horse Fly IgG4-mCnc;;ACTIVE;2.29;2.70 +56468-2;Cucurbita pepo Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pumpkin IgG4 Ab [Mass/volume] in Serum;Pumpkin IgG4-mCnc;;ACTIVE;2.29;2.73 +56469-0;Cardiac heart disease risk;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Cardiac heart disease risk [Ratio] in Serum or Plasma;CHD risk SerPl-Rto;;ACTIVE;2.29;2.73 +56470-8;Blasts;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Blasts [#] in Cerebral spinal fluid by Manual count;Blasts CSF Manual;;ACTIVE;2.29;2.69 +56471-6;Direct antiglobulin test.complement C3c specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.complement C3c specific reagent [Presence] on Red Blood Cells;DAT C3c-Sp Reag RBC Ql;;ACTIVE;2.29;2.56 +56472-4;Erythrocytes.nucleated;Num;Pt;XXX;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes [#] in Specimen by Manual count;nRBC Spec Manual;;ACTIVE;2.29;2.73 +5647-3;Ethylene glycol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethylene glycol [Mass/volume] in Urine;Ethylene Glycol Ur-mCnc;;ACTIVE;1.0;2.73 +56473-2;Metamyelocytes;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Metamyelocytes [#] in Cerebral spinal fluid by Manual count;Metamyelocytes CSF Manual;;ACTIVE;2.29;2.69 +56474-0;Salmonella sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Deprecated Salmonella sp identified in Isolate by Organism specific culture;Deprecated Salmonell Islt Cult;;DEPRECATED;2.29;2.32 +56475-7;Salmonella sp antigenic formula;ID;Pt;Isolate;Nom;Aggl;MICRO;1;Salmonella sp antigenic formula [Identifier] in Isolate by Agglutination;Salmonella sp Ag form Islt Aggl;;ACTIVE;2.29;2.29 +56476-5;Hemoglobin S/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;HEM/BC;1;Hemoglobin S/Hemoglobin.total in DBS;Hgb S MFr DBS;;ACTIVE;2.29;2.61 +56477-3;Thyroperoxidase Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Thyroperoxidase Ab [Units/volume] in Serum or Plasma by Immunoassay;Thyroperoxidase Ab SerPl IA-aCnc;;ACTIVE;2.29;2.73 +56478-1;Ethanol;MCnc;Pt;Bld;Qn;GC;DRUG/TOX;1;Ethanol [Mass/volume] in Blood by Gas chromatography;Ethanol Bld GC-mCnc;;ACTIVE;2.29;2.73 +56479-9;Superoxide dismutase;CCnt;Pt;RBC;Qn;;CHEM;1;Superoxide dismutase [Enzymatic activity/mass] in Red Blood Cells;SOD RBC-cCnt;;ACTIVE;2.29;2.70 +56480-7;Taenia solium larva Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Taenia solium larva Ab [Presence] in Cerebral spinal fluid by Immunoassay;T sol lar Ab CSF Ql IA;;ACTIVE;2.29;2.56 +5648-1;Fluoride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Fluoride [Mass/volume] in Blood;Fluoride Bld-mCnc;;ACTIVE;1.0;2.42 +56481-5;Immunoglobulin light chains.lambda.free;PrThr;Pt;Urine;Ord;Immunofixation;CHEM;1;Lambda light chains.free [Presence] in Urine by Immunofixation;Lambda LC Free Ur Ql IFE;;ACTIVE;2.29;2.63 +56482-3;Insulin^baseline;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --baseline;Insulin BS SerPl-aCnc;;ACTIVE;2.29;2.73 +56483-1;Porphobilinogen;MCnt;Pt;Stool;Qn;;CHEM;1;Porphobilinogen [Mass/mass] in Stool;PBG Stl-mCnt;;ACTIVE;2.29;2.70 +56484-9;Uroporphyrin;MCnt;Pt;Stool;Qn;;CHEM;1;Uroporphyrin [Mass/mass] in Stool;Uropor Stl-mCnt;;ACTIVE;2.29;2.70 +56485-6;Taenia solium Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Taenia solium IgG Ab [Presence] in Serum by Immunoassay;T sol IgG Ser Ql IA;;ACTIVE;2.29;2.73 +56486-4;Taenia solium Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Taenia solium IgG Ab [Units/volume] in Serum by Immunoassay;T sol IgG Ser IA-aCnc;;ACTIVE;2.29;2.69 +56487-2;Androsterone;MCnc;24H;Urine;Qn;;CHEM;1;Androsterone [Mass/volume] in 24 hour Urine;Androsterone 24h Ur-mCnc;;ACTIVE;2.29;2.42 +56488-0;Etiocholanolone;MCnc;24H;Urine;Qn;;CHEM;1;Etiocholanolone [Mass/volume] in 24 hour Urine;Etiocholanolone 24h Ur-mCnc;;ACTIVE;2.29;2.42 +56489-8;Acidity.titratable;SRat;24H;Urine;Qn;;CHEM;1;Acidity.titratable [Moles/time] in 24 hour Urine;Titratable Acidity 24h Ur-sRate;;ACTIVE;2.29;2.70 +56490-6;Hemoglobin.gastrointestinal.lower^2nd specimen;PrThr;Pt;Stool;Ord;IA;CHEM;1;Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay --2nd specimen;Hemoccult sp2 Stl Ql IA;;ACTIVE;2.29;2.73 +56491-4;Hemoglobin.gastrointestinal.lower^3rd specimen;PrThr;Pt;Stool;Ord;IA;CHEM;1;Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay --3rd specimen;Hemoccult sp3 Stl Ql IA;;ACTIVE;2.29;2.73 +56492-2;Insulin^6M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --6 minutes post XXX challenge;Insulin 6M p chal SerPl-aCnc;;ACTIVE;2.29;2.70 +56493-0;Lutropin^10M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --10 minutes post XXX challenge;LH 10M p chal SerPl-aCnc;;ACTIVE;2.29;2.70 +56494-8;Lutropin^2H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --2 hours post XXX challenge;LH 2h p chal SerPl-aCnc;;ACTIVE;2.29;2.73 +56495-5;Lutropin^3H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --3 hours post XXX challenge;LH 3h p chal SerPl-aCnc;;ACTIVE;2.29;2.73 +56496-3;Prolactin^2H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Units/volume] in Serum or Plasma --2 hours post XXX challenge;Prolactin 2h p chal SerPl-aCnc;;ACTIVE;2.29;2.70 +56497-1;Choriogonadotropin.beta subunit;ARat;24H;Urine;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Units] in 24 hour Urine;B-HCG 24h Ur;;ACTIVE;2.29;2.70 +56498-9;Androstenedione^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Androst 30M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +5649-9;Fluoride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fluoride [Mass/volume] in Serum or Plasma;Fluoride SerPl-mCnc;;ACTIVE;1.0;2.73 +56499-7;Somatotropin^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;GH 45M p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +56500-2;Somatotropin^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;GH 3h p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +56501-0;Somatotropin^6H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --6 hours post XXX challenge;GH 6h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56502-8;Somatotropin^7H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --7 hours post XXX challenge;GH 7h p chal SerPl-aCnc;;ACTIVE;2.29;2.40 +56503-6;Somatotropin^8H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --8 hours post XXX challenge;GH 8h p chal SerPl-aCnc;;ACTIVE;2.29;2.40 +56504-4;Corticotropin^15M post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --15 minutes post XXX challenge;ACTH 15M p chal Plas-mCnc;;ACTIVE;2.29;2.70 +56505-1;Corticotropin^45M post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --45 minutes post XXX challenge;ACTH 45M p chal Plas-mCnc;;ACTIVE;2.29;2.70 +56506-9;Corticotropin^2H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2 hours post XXX challenge;ACTH 2h p chal Plas-mCnc;;ACTIVE;2.29;2.40 +5650-7;Fluoride;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fluoride [Mass/volume] in Urine;Fluoride Ur-mCnc;;ACTIVE;1.0;2.73 +56507-7;Dehydroepiandrosterone sulfate^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;DHEA-S 30M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56508-5;Dehydroepiandrosterone sulfate^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;DHEA-S 1h p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56510-1;Dehydroepiandrosterone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;DHEA 1h p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +56511-9;Calcitonin^2M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --2 minutes post XXX challenge;Calcit 2M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56512-7;Porphyrins;MCnt;Pt;Stool;Qn;;CHEM;1;Porphyrins [Mass/mass] in Stool;Porphyrins Stl-mCnt;;ACTIVE;2.29;2.70 +56513-5;Hepatitis E virus Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis E virus IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;HEV IgG SerPl IA-aCnc;;ACTIVE;2.29;2.69 +56514-3;Legionella pneumophila Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Legionella pneumophila IgG Ab [Presence] in Serum by Immunofluorescence;L pneumo IgG Ser Ql IF;;ACTIVE;2.29;2.56 +5651-5;Fluoride;MRat;24H;Urine;Qn;;DRUG/TOX;1;Fluoride [Mass/time] in 24 hour Urine;Fluoride 24h Ur-mRate;;ACTIVE;1.0;2.42 +56515-0;Plasmodium falciparum Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Plasmodium falciparum IgG Ab [Presence] in Serum by Immunofluorescence;P falciparum IgG Ser Ql IF;;ACTIVE;2.29;2.56 +56516-8;C peptide^6M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --6 minutes post XXX challenge;C peptide 6M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56517-6;11-Deoxycortisol^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;11DC 2h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56518-4;11-Deoxycortisol^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;11DC 15M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56519-2;11-Deoxycortisol^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;11DC 30M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +565-2;Colony count;Num;Pt;XXX;Ord;VC;MICRO;1;Colony count [#] in Specimen Qualitative by Visual count;CC Spec Ql VC;;ACTIVE;1.0;2.69 +56520-0;11-Deoxycortisol^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;11DC 45M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56521-8;11-Deoxycortisol^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;11DC 1.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56522-6;17-Hydroxypregnenolone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;17OH-Preg 30M p chal SerPl-mCnc;;ACTIVE;2.32;2.73 +5652-3;Formaldehyde;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Formaldehyde [Mass/volume] in Blood;Formaldehyde Bld-mCnc;;ACTIVE;1.0;2.42 +56523-4;Insulin-like growth factor-I^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;IGF-I 15M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56524-2;Insulin-like growth factor-I^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;IGF-I 45M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56525-9;5-Hydroxytryptophan;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Mass/volume] in Urine;5OH-Tryptophan Ur-mCnc;;ACTIVE;2.29;2.70 +56526-7;Somatotropin^30M post exercise;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post exercise;GH 30M p Exc SerPl-mCnc;;ACTIVE;2.29;2.70 +56527-5;Vasopressin^1H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Mass/volume] in Plasma --1 hour post XXX challenge;Vasopressin 1h p chal Plas-mCnc;;ACTIVE;2.29;2.42 +56528-3;Androstenedione^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Androst 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56529-1;Ma+Ta Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Ma+Ta Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Ma+Ta Ab Titr CSF IF;;ACTIVE;2.29;2.32 +56530-9;CV2 Ab;Titr;Pt;CSF;Qn;IF;SERO;1;CV2 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CV2 Ab Titr CSF IF;;ACTIVE;2.29;2.32 +5653-1;Formaldehyde;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Formaldehyde [Mass/volume] in Urine;Formaldehyde Ur-mCnc;;ACTIVE;1.0;2.42 +56531-7;Amphiphysin Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Amphiphysin Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Amphiphysin Ab Titr CSF IF;;ACTIVE;2.29;2.73 +56532-5;Asialoglycoprotein receptor Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Asialoglycoprotein receptor Ab [Units/volume] in Serum by Immunoassay;ASGPR Ab Ser IA-aCnc;;ACTIVE;2.29;2.69 +56533-3;Insulin Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Insulin IgG Ab [Units/volume] in Serum;Insulin IgG Ser-aCnc;;ACTIVE;2.29;2.73 +56534-1;Calcitonin^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Calcit 15M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56535-8;8-Dehydrocholesterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;8-Dehydrocholesterol [Moles/volume] in Serum or Plasma;8-DHC SerPl-sCnc;;ACTIVE;2.29;2.70 +56536-6;Thyroglobulin Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Thyroglobulin Ab [Units/volume] in Serum or Plasma by Immunoassay;Thyroglob Ab SerPl IA-aCnc;;ACTIVE;2.29;2.73 +56537-4;Tissue transglutaminase Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Tissue transglutaminase IgG Ab [Units/volume] in Serum by Immunoassay;tTG IgG Ser IA-aCnc;;ACTIVE;2.29;2.73 +56538-2;Beta 2 glycoprotein 1 Ab;ACnc;Pt;Ser;Qn;IA;COAG;1;Beta 2 glycoprotein 1 Ab [Units/volume] in Serum by Immunoassay;B2 Glycoprot1 Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +56539-0;Intrinsic factor Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Intrinsic factor Ab [Units/volume] in Serum by Immunoassay;IF Ab Ser IA-aCnc;;ACTIVE;2.29;2.69 +56540-8;Glutamate decarboxylase 65 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay;GAD65 Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +56541-6;Ganglioside GD1b Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1b IgG Ab [Units/volume] in Serum by Immunoassay;GD1b Gangl IgG Ser IA-aCnc;;ACTIVE;2.29;2.73 +56542-4;Ganglioside GD1b Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1b IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GD1b Gangl IgM CSF IA-aCnc;;ACTIVE;2.29;2.68 +56543-2;Ganglioside GM2 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM2 IgG Ab [Units/volume] in Serum by Immunoassay;GM2 Gangl IgG Ser IA-aCnc;;ACTIVE;2.29;2.68 +56544-0;Ganglioside GM2 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM2 IgM Ab [Units/volume] in Serum by Immunoassay;GM2 Gangl IgM Ser IA-aCnc;;ACTIVE;2.29;2.68 +56545-7;Ganglioside GQ1b Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GQ1b IgM Ab [Units/volume] in Serum by Immunoassay;GQ1b Gangl IgM Ser IA-aCnc;;ACTIVE;2.29;2.73 +56546-5;Insulin Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Insulin Ab [Units/volume] in Serum by Immunoassay;Insulin Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +56547-3;Tubular basement membrane Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Tubular basement membrane IgG Ab [Titer] in Serum by Immunofluorescence;TBM IgG Titr Ser IF;;ACTIVE;2.29;2.32 +56548-1;U1 small nuclear ribonucleoprotein Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;U1 small nuclear ribonucleoprotein IgG Ab [Units/volume] in Serum by Immunoassay;U1 snRNP IgG Ser IA-aCnc;;ACTIVE;2.29;2.73 +5654-9;Gallium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Gallium [Mass/volume] in Urine;Gallium Ur-mCnc;;ACTIVE;1.0;2.73 +56549-9;Sjogrens syndrome-A extractable nuclear 52kD Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Units/volume] in Serum by Immunoassay;ENA SS-A 52kD Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +56550-7;Purkinje cell cytoplasmic type Tr Ab;Titr;Pt;Ser;Qn;IF;SERO;1;PCA-Tr Ab [Titer] in Serum by Immunofluorescence;PCA-Tr Ab Titr Ser IF;;ACTIVE;2.29;2.73 +56551-5;Purkinje cell cytoplasmic type Tr Ab;Titr;Pt;CSF;Qn;IF;SERO;1;PCA-Tr Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;PCA-Tr Ab Titr CSF IF;;ACTIVE;2.29;2.58 +56552-3;Dehydroepiandrosterone sulfate^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --baseline;DHEA-S BS SerPl-mCnc;;ACTIVE;2.29;2.73 +56553-1;Albumin;MRat;8H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/time] in 8 hour Urine;Microalbumin 8h Ur-mRate;;ACTIVE;2.29;2.30 +56554-9;Porphyrins;MRat;72H;Stool;Qn;;CHEM;1;Porphyrins [Mass/time] in 72 hour Stool;Porphyrins 72h Stl-mRate;;ACTIVE;2.29;2.42 +56555-6;11-Deoxycorticosterone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --baseline;11DOC BS SerPl-mCnc;;ACTIVE;2.29;2.73 +5655-6;Germanium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Germanium [Mass/volume] in Urine;Germanium Ur-mCnc;;ACTIVE;1.0;2.42 +56556-4;11-Deoxycorticosterone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;11DOC 30M p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56557-2;Renin^10M post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --10 minutes post XXX challenge;Renin 10M p chal Plas-cCnc;;ACTIVE;2.29;2.42 +56558-0;Aldosterone^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Aldost 10M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56559-8;Norepinephrine^pre/post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Norepinephrine [Mass/volume] in Serum or Plasma --pre/post XXX challenge;Deprecated Norepineph pre/p chal SerPl-m;;DEPRECATED;2.29;2.36 +56560-6;Somatotropin^4.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --4.5 hours post XXX challenge;GH 4.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56561-4;Somatotropin^5.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --5.5 hours post XXX challenge;GH 5.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56562-2;Somatotropin^6.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --6.5 hours post XXX challenge;GH 6.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56563-0;Somatotropin^7.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --7.5 hours post XXX challenge;GH 7.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +5656-4;Gold;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Gold [Mass/volume] in Blood;Gold Bld-mCnc;;ACTIVE;1.0;2.73 +56564-8;Somatotropin^8H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --8 hours post XXX challenge;GH 8h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56565-5;Somatotropin^9H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --9 hours post XXX challenge;GH 9h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56566-3;Somatotropin^9.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --9.5 hours post XXX challenge;GH 9.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56567-1;Somatotropin^10H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --10 hours post XXX challenge;GH 10h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56568-9;Somatotropin^10.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --10.5 hours post XXX challenge;GH 10.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56569-7;Somatotropin^11H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --11 hour post XXX challenge;GH 11h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56570-5;Somatotropin^11.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --11.5 hours post XXX challenge;GH 11.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56571-3;Somatotropin^post exercise;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --post exercise;GH p Exc SerPl-mCnc;;ACTIVE;2.29;2.40 +5657-2;Gold;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Gold [Mass/volume] in Cerebral spinal fluid;Gold CSF-mCnc;;ACTIVE;1.0;2.42 +56572-1;Somatotropin^20H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --20 hours post XXX challenge;GH 20H p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56573-9;Renin^30M post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --30 minutes post XXX challenge;Renin 30M p chal Plas-cCnc;;ACTIVE;2.29;2.42 +56574-7;Renin^1H post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --1 hour post XXX challenge;Renin 1h p chal Plas-cCnc;;ACTIVE;2.29;2.42 +56575-4;17-Hydroxyprogesterone^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;17OHP 15M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56576-2;17-Hydroxyprogesterone^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;17OHP 45M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56577-0;Renin^1.5H post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --1.5 hours post XXX challenge;Renin 1.5h p chal Plas-cCnc;;ACTIVE;2.29;2.42 +56578-8;Aldosterone^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Aldost 1.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56579-6;Aldosterone^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Aldost 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +5658-0;Gold;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Gold [Mass/mass] in Hair;Gold Hair-mCnt;;ACTIVE;1.0;2.42 +56580-4;Renin^20M post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --20 minutes post XXX challenge;Renin 20M p chal Plas-cCnc;;ACTIVE;2.29;2.42 +56581-2;Insulin^12M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --12 minutes post XXX challenge;Insulin 12M p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56582-0;C peptide^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;C peptide 10M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56583-8;C peptide^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;C peptide 45M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56584-6;C peptide^12M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --12 minutes post XXX challenge;C peptide 12M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56585-3;Cortisol^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;Cortis 45M p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +56586-1;Dehydroepiandrosterone^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;DHEA 15M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56587-9;Dehydroepiandrosterone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;DHEA 30M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56588-7;Dehydroepiandrosterone sulfate^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;DHEA-S 45M p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56589-5;Dehydroepiandrosterone^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;DHEA 1.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56590-3;Dehydroepiandrosterone^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;DHEA 2h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56591-1;Dehydroepiandrosterone sulfate^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;DHEA-S 3h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56592-9;Follitropin^10M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --10 minutes post XXX challenge;FSH 10M p chal SerPl-aCnc;;ACTIVE;2.29;2.38 +56593-7;Follitropin^3H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --3 hours post XXX challenge;FSH 3h p chal SerPl-aCnc;;ACTIVE;2.29;2.73 +56594-5;Thyrotropin^3H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --3 hours post XXX challenge;TSH 3h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56595-2;Latex recombinant (rHev b) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 3 IgE Ab [Units/volume] in Serum;Latex (rHev b) 3 IgE Qn;;ACTIVE;2.29;2.42 +56596-0;Latex recombinant (rHev b) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 5 IgE Ab [Units/volume] in Serum;Latex (rHev b) 5 IgE Qn;;ACTIVE;2.29;2.42 +56597-8;Latex recombinant (rHev b) 8 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 8 IgE Ab [Units/volume] in Serum;Latex (rHev b) 8 IgE Qn;;ACTIVE;2.29;2.42 +5659-8;Gold;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gold [Mass/volume] in Serum or Plasma;Gold SerPl-mCnc;;ACTIVE;1.0;2.73 +56598-6;Epstein Barr virus early Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus early IgM Ab [Units/volume] in Serum by Immunoassay;EBV EA IgM Ser IA-aCnc;;ACTIVE;2.29;2.73 +56599-4;Epstein Barr virus capsid Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Epstein Barr virus capsid IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;EBV VCA IgM CSF IA-aCnc;;ACTIVE;2.29;2.69 +566-0;Cryptosporidium sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Cryptosporidium sp Ag [Presence] in Specimen by Immunofluorescence;Cryptosp Ag Spec Ql IF;;ACTIVE;1.0;2.73 +56600-0;Vespa crabro Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;European Hornet IgG Ab [Mass/volume] in Serum;European Hornet IgG-mCnc;;ACTIVE;2.29;2.40 +56601-8;Hyaluronate;MCnc;Pt;Periton fld;Qn;;DRUG/TOX;1;Hyaluronate [Mass/volume] in Peritoneal fluid;Hyaluronate Prt-mCnc;;ACTIVE;2.29;2.42 +56602-6;11-Deoxycorticosterone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;11DOC sp1 p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +56603-4;11-Deoxycorticosterone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;11DOC sp2 p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +56604-2;11-Deoxycorticosterone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;11DOC sp3 p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56605-9;11-Deoxycorticosterone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;11DOC sp4 p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +5660-6;Gold;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Gold [Mass/volume] in Urine;Gold Ur-mCnc;;ACTIVE;1.0;2.73 +56606-7;11-Deoxycorticosterone^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --pre XXX challenge;11DOC pre chal SerPl-mCnc;;ACTIVE;2.32;2.40 +56608-3;11-Deoxycorticosterone^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;11DOC 15M p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56609-1;11-Deoxycorticosterone^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;11DOC 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56610-9;11-Deoxycorticosterone^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;11DOC 40M p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56611-7;11-Deoxycorticosterone^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;11DOC 1.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56612-5;11-Deoxycorticosterone^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;11DOC 2h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56613-3;11-Deoxycorticosterone^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;11DOC 2.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +5661-4;Gold;MRat;24H;Urine;Qn;;DRUG/TOX;1;Gold [Mass/time] in 24 hour Urine;Gold 24h Ur-mRate;;ACTIVE;1.0;2.42 +56614-1;17-Hydroxyprogesterone^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;17OHP 10M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56615-8;17-Hydroxyprogesterone^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;17OHP 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56616-6;17-Hydroxyprogesterone^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;17OHP 1.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56617-4;17-Hydroxyprogesterone^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;17OHP 2h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56618-2;Insulin-like growth factor-I^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;IGF-I 10M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56619-0;Insulin-like growth factor-I^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;IGF-I 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56620-8;Elastase Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Elastase Ab [Units/volume] in Serum by Immunoassay;Elastase Ab Ser IA-aCnc;;ACTIVE;2.29;2.69 +56621-6;Coxsackievirus A9 Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Coxsackievirus A9 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CV A9 IgG Titr CSF IF;;ACTIVE;2.29;2.32 +5662-2;Heavy metals;PrThr;Pt;Urine;Ord;Reinsch;DRUG/TOX;1;Heavy metals [Presence] in Urine by Reinsch;Heavy Metals Ur Ql Reinsch;;ACTIVE;1.0;2.73 +56622-4;Echovirus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Echovirus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;ECV IgG Titr CSF IF;;ACTIVE;2.29;2.32 +56623-2;Echovirus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Echovirus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;ECV IgM Titr CSF IF;;ACTIVE;2.29;2.32 +56624-0;Fructose;SCnc;Pt;Ser;Qn;;CHEM;1;Fructose [Moles/volume] in Serum;Fructose Ser-sCnc;;ACTIVE;2.29;2.42 +56625-7;Methylene chloride;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methylene chloride [Moles/volume] in Blood;DCM Bld-sCnc;;ACTIVE;2.29;2.42 +56626-5;Tetrachloroethylene;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tetrachloroethylene [Moles/volume] in Blood;TTCE Bld-sCnc;;ACTIVE;2.29;2.42 +56627-3;Procollagen type III;MCnc;Pt;Ser;Qn;;CHEM;1;Procollagen type III [Mass/volume] in Serum;Procollagen III Ser-mCnc;;ACTIVE;2.29;2.70 +56628-1;Amikacin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Moles/volume] in Serum or Plasma;Amikacin SerPl-sCnc;;ACTIVE;2.29;2.73 +56629-9;Myelin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Myelin Ab [Titer] in Serum by Immunofluorescence;Myelin Ab Titr Ser IF;;ACTIVE;2.29;2.73 +5663-0;Heavy metals positive;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Heavy metals positive [Identifier] in Urine by Screen method;Heavy Metals Pos Ur Scn;;ACTIVE;1.0;2.19 +56630-7;Brucella sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella sp IgG Ab [Units/volume] in Serum by Immunoassay;Brucella IgG Ser IA-aCnc;;ACTIVE;2.29;2.69 +56631-5;Brucella sp Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella sp IgM Ab [Units/volume] in Serum by Immunoassay;Brucella IgM Ser IA-aCnc;;ACTIVE;2.29;2.69 +56632-3;Mitochondria M2 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Mitochondria M2 IgG Ab [Titer] in Serum by Immunofluorescence;Mitochondria M2 IgG Titr Ser IF;;ACTIVE;2.29;2.32 +56633-1;Myocardium Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Myocardium IgG Ab [Titer] in Serum by Immunofluorescence;Myocardium IgG Titr Ser IF;;ACTIVE;2.29;2.73 +56634-9;Nuclear Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Nuclear IgG Ab [Titer] in Serum by Immunofluorescence;Nuclear IgG Titr Ser IF;;ACTIVE;2.29;2.73 +56635-6;Thyroglobulin Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Thyroglobulin IgG Ab [Units/volume] in Serum;Thyroglob IgG Ser-aCnc;;ACTIVE;2.29;2.73 +56636-4;Bordetella parapertussis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Bordetella parapertussis IgM Ab [Titer] in Serum by Immunofluorescence;B parapert IgM Titr Ser IF;;ACTIVE;2.29;2.32 +56637-2;Mi-2 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Mi-2 Ab [Units/volume] in Serum by Immunoassay;MI2 Ab Ser IA-aCnc;;ACTIVE;2.29;2.69 +56638-0;Rheumatoid arthritis nuclear Ab;Titr;Pt;Ser;Ord;IF;SERO;1;Deprecated Rheumatoid arthritis nuclear Ab [Titer] in Serum Qualitative by Immunofluorescence;Deprecated RA Nuc Ab Titr Ser Ql IF;;DEPRECATED;2.29;2.36 +56639-8;Methyl ethyl ketone;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyl ethyl ketone [Moles/volume] in Urine;MEK Ur-sCnc;;ACTIVE;2.29;2.42 +56640-6;Aspartate/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Aspartate/Creatinine [Ratio] in 24 hour Urine;Aspartate/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56641-4;Threonine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Threonine/Creatinine [Ratio] in 24 hour Urine;Threonine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56642-2;Serine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Serine/Creatinine [Ratio] in 24 hour Urine;Serine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56643-0;Asparagine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Asparagine/Creatinine [Ratio] in 24 hour Urine;Asparagine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56644-8;Glutamate/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Glutamate/Creatinine [Ratio] in 24 hour Urine;Glutamate/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56645-5;Vanillylmandelate/Creatine;Ratio;24H;Urine;Qn;;CHEM;1;Vanillylmandelate/Creatine [Ratio] in 24 hour Urine;VMA/Creatine 24h Ur-Rto;;ACTIVE;2.29;2.70 +56646-3;Trichloroacetate/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Trichloroacetate/Creatinine [Ratio] in Urine;TCA/Creat Ur-Rto;;ACTIVE;2.29;2.73 +56647-1;Phenol/Creatinine;Ratio;24H;Urine;Qn;;DRUG/TOX;1;Phenol/Creatinine [Ratio] in 24 hour Urine;Phenol/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +5664-8;Heavy metals negative;Prid;Pt;Urine;Nom;Screen;DRUG/TOX;1;Heavy metals negative [Identifier] in Urine by Screen method;Heavy Metals Neg Ur Scn;;ACTIVE;1.0;2.19 +56648-9;Phenylglyoxylate/Creatinine;Ratio;24H;Urine;Qn;;DRUG/TOX;1;Phenylglyoxylate/Creatinine [Ratio] in 24 hour Urine;Phenylglyoxylate/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56649-7;Hippurate/Creatinine;Ratio;24H;Urine;Qn;;DRUG/TOX;1;Hippurate/Creatinine [Ratio] in 24 hour Urine;Hippurate/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56650-5;Chromium/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Chromium/Creatinine [Ratio] in Urine;Chromium/Creat Ur-Rto;;ACTIVE;2.29;2.29 +56651-3;Cadmium/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Cadmium/Creatinine [Ratio] in Urine;Cadmium/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56652-1;Arsenic/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic/Creatinine [Ratio] in Urine;Arsenic/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56653-9;Mercury/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Mercury/Creatinine [Ratio] in Urine;Mercury/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56654-7;Nickel/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Nickel/Creatinine [Ratio] in Urine;Nickel/Creat Ur-Rto;;ACTIVE;2.29;2.70 +5665-5;Indium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Indium [Mass/volume] in Blood;Indium Bld-mCnc;;ACTIVE;1.0;2.42 +56655-4;Bromide/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Bromide/Creatinine [Ratio] in Urine;Bromide/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56656-2;Fluoride/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Fluoride/Creatinine [Ratio] in Urine;Fluoride/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56657-0;Tetrahydrocortisone;SRat;24H;Urine;Qn;;DRUG/TOX;1;Tetrahydrocortisone [Moles/time] in 24 hour Urine;THcortisone 24h Ur-sRate;;ACTIVE;2.29;2.70 +56658-8;Delta aminolevulinate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Delta aminolevulinate/Creatinine [Ratio] in Urine;D-ALA/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56659-6;Para aminophenol/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Para aminophenol/Creatinine [Ratio] in Urine;p-Aminophenol/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56660-4;Methyl formamide/Creatinine;Ratio;Pt;Urine;Qn;;DRUG/TOX;1;Methyl formamide/Creatinine [Ratio] in Urine;Mehyl Formamide/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56661-2;Myelin basic protein;MCnc;Pt;Ser;Qn;;CHEM;1;Myelin basic protein [Mass/volume] in Serum;MBP Ser-mCnc;;ACTIVE;2.29;2.70 +56662-0;Beta-2-Microglobulin;SRat;24H;Urine;Qn;;CHEM;1;Beta-2-Microglobulin [Moles/time] in 24 hour Urine;B2 Microglob 24h Ur-sRate;;ACTIVE;2.29;2.70 +5666-3;Indium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Indium [Mass/volume] in Urine;Indium Ur-mCnc;;ACTIVE;1.0;2.42 +56663-8;5-Hydroxytryptophan;SRat;24H;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Moles/time] in 24 hour Urine;5OH-Tryptophan 24h Ur-sRate;;ACTIVE;2.29;2.42 +56664-6;Methylmalonate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Methylmalonate/Creatinine [Ratio] in Urine;Methylmalonate/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56665-3;Taenia solium Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Taenia solium IgG Ab [Titer] in Serum by Immunofluorescence;T sol IgG Titr Ser IF;;ACTIVE;2.29;2.32 +56666-1;1-Methylhistidine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;1-Methylhistidine/Creatinine [Ratio] in 24 hour Urine;1Me-hist/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56667-9;3-Methylhistidine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;3-Methylhistidine/Creatinine [Ratio] in 24 hour Urine;3Me-histidine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56668-7;Alpha aminoadipate/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Alpha aminoadipate/Creatinine [Ratio] in 24 hour Urine;AAA/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56669-5;Carotene.alpha;MCnc;Pt;Ser;Qn;;CHEM;1;Carotene.alpha [Mass/volume] in Serum;A-Carotene Ser-mCnc;;ACTIVE;2.29;2.73 +56670-3;Adrenal cortex Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Adrenal cortex IgG Ab [Units/volume] in Serum;Adrenal cortex IgG Ser-aCnc;;ACTIVE;2.29;2.69 +5667-1;Isopropanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isopropanol [Mass/volume] in Blood;Isopropanol Bld-mCnc;;ACTIVE;1.0;2.73 +56671-1;Alanine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Alanine/Creatinine [Ratio] in 24 hour Urine;Alanine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56672-9;Arginine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Arginine/Creatinine [Ratio] in 24 hour Urine;Arginine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56673-7;Beta aminoisobutyrate/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Beta aminoisobutyrate/Creatinine [Ratio] in 24 hour Urine;B-AIB/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56674-5;Beta alanine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Beta alanine/Creatinine [Ratio] in 24 hour Urine;B-Alanine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56675-2;Carnosine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Carnosine/Creatinine [Ratio] in 24 hour Urine;Carnosine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56676-0;Citrulline/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Citrulline/Creatinine [Ratio] in 24 hour Urine;Citrulline/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56677-8;Cystine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Cystine/Creatinine [Ratio] in 24 hour Urine;Cystine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.73 +56678-6;Ethanolamine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Ethanolamine/Creatinine [Ratio] in 24 hour Urine;Ethanolamine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56679-4;Gamma aminobutyrate/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Gamma aminobutyrate/Creatinine [Ratio] in 24 hour Urine;GABA/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56680-2;Glutamine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Glutamine/Creatinine [Ratio] in 24 hour Urine;Glutamine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56681-0;Glycine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Glycine/Creatinine [Ratio] in 24 hour Urine;Glycine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56682-8;Homocystine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Homocystine/Creatinine [Ratio] in 24 hour Urine;(Hcys)2/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56683-6;Histidine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Histidine/Creatinine [Ratio] in 24 hour Urine;Histidine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56684-4;Hydroxylysine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Hydroxylysine/Creatinine [Ratio] in 24 hour Urine;OH-Lysine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56685-1;Hydroxyproline.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydroxyproline Free [Moles/volume] in Serum or Plasma;OH-Proline Free SerPl-sCnc;;ACTIVE;2.29;2.42 +56686-9;Hydroxyproline.free/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Hydroxyproline Free/Creatinine [Ratio] in 24 hour Urine;OH-Proline Free/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56687-7;Pancreatic islet cell Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Pancreatic islet cell IgG Ab [Titer] in Serum by Immunofluorescence;Panc Islet Cell IgG Titr Ser IF;;ACTIVE;2.29;2.73 +56688-5;IgD;ACnc;Pt;Ser;Qn;;CHEM;1;IgD [Units/volume] in Serum;IgD Ser-aCnc;;ACTIVE;2.29;2.70 +5668-9;Isopropanol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Isopropanol [Presence] in Serum or Plasma;Isopropanol SerPl Ql;;ACTIVE;1.0;2.56 +56689-3;Isoleucine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Isoleucine/Creatinine [Ratio] in 24 hour Urine;Isoleucine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56690-1;Insulin^16H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --16 hours post XXX challenge;Insulin 16h p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56691-9;Insulin^20H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --20 hours post XXX challenge;Insulin 20H p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56692-7;Insulin^1D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --1 day post XXX challenge;Insulin 1D p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +56693-5;SCL-70 extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA Scl70 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56694-3;Chicken droppings Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Chicken droppings Ab [Presence] in Serum by Immune diffusion (ID);Chicken Drop Ab Ql ID;;ACTIVE;2.29;2.56 +56695-0;Cephalexin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cephalexin IgE Ab [Units/volume] in Serum;Cephalexin IgE Qn;;ACTIVE;2.29;2.70 +56696-8;Cloxacillin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cloxacillin IgE Ab [Units/volume] in Serum;Cloxacillin IgE Qn;;ACTIVE;2.29;2.70 +5669-7;Isopropanol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Isopropanol [Mass/volume] in Serum or Plasma;Isopropanol SerPl-mCnc;;ACTIVE;1.0;2.73 +56697-6;Thiopental Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Thiopental IgE Ab [Units/volume] in Serum;Thiopental IgE Qn;;ACTIVE;2.29;2.70 +56698-4;Atropine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Atropine IgE Ab [Units/volume] in Serum;Atropine IgE Qn;;ACTIVE;2.29;2.70 +56699-2;Bupivacaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bupivacaine IgE Ab [Units/volume] in Serum;Bupivacaine IgE Qn;;ACTIVE;2.29;2.42 +56700-8;Naproxen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Naproxen IgE Ab [Units/volume] in Serum;Naproxen IgE Qn;;ACTIVE;2.29;2.42 +56701-6;Diclofenac Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Diclofenac IgE Ab [Units/volume] in Serum;Diclofenac IgE Qn;;ACTIVE;2.29;2.70 +56702-4;Ciprofloxacin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ciprofloxacin IgE Ab [Units/volume] in Serum;Ciprofloxacin IgE Qn;;ACTIVE;2.29;2.73 +56703-2;Piroxicam Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Piroxicam IgE Ab [Units/volume] in Serum;Piroxicam IgE Qn;;ACTIVE;2.29;2.42 +56704-0;Droperidol Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Droperidol IgE Ab [Units/volume] in Serum;Droperidol IgE Qn;;ACTIVE;2.29;2.70 +5670-5;Isopropanol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Isopropanol [Presence] in Urine;Isopropanol Ur Ql;;ACTIVE;1.0;2.73 +56705-7;Tobramycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tobramycin IgE Ab [Units/volume] in Serum;Tobramycin IgE Qn;;ACTIVE;2.29;2.70 +56706-5;Doxycycline Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Doxycycline IgE Ab [Units/volume] in Serum;Doxycycline IgE Qn;;ACTIVE;2.29;2.70 +56707-3;Spiramycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spiramycin IgE Ab [Units/volume] in Serum;Spiramycin IgE Qn;;ACTIVE;2.29;2.70 +56708-1;metroNIDAZOLE Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;metroNIDAZOLE IgE Ab [Units/volume] in Serum;metroNIDAZOLE IgE Qn;;ACTIVE;2.29;2.70 +56709-9;Tartrazine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tartrazine IgE Ab [Units/volume] in Serum;Tartrazine IgE Qn;;ACTIVE;2.29;2.70 +56710-7;Clarithromycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clarithromycin IgE Ab [Units/volume] in Serum;Clarithro IgE Qn;;ACTIVE;2.29;2.70 +56711-5;Sodium benzoate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sodium benzoate IgE Ab [Units/volume] in Serum;Sodium benzoate IgE Qn;;ACTIVE;2.29;2.70 +56712-3;Dexamethasone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dexamethasone IgE Ab [Units/volume] in Serum;Dexamethasone IgE Qn;;ACTIVE;2.29;2.70 +5671-3;Lead;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Blood;Lead Bld-mCnc;;DISCOURAGED;1.0;2.73 +56713-1;Dog dander+Dog epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog dander+Dog epithelium IgE Ab [Units/volume] in Serum;Dog Dander+Epith IgE Qn;;ACTIVE;2.29;2.73 +56714-9;Bacteria identified;Prid;Pt;Contact lens;Nom;Culture;MICRO;1;Bacteria identified in Contact lens by Culture;Bacteria Cont lens Cult;;ACTIVE;2.29;2.68 +56715-6;Bacteria identified;Prid;Pt;Pericard fld;Nom;Culture;MICRO;1;Bacteria identified in Pericardial fluid by Culture;Bacteria Pcar Cult;;ACTIVE;2.29;2.29 +56716-4;Nuclear pore protein gp210 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Nuclear pore protein gp210 Ab [Presence] in Serum by Immunoblot;Nuclear pore prot gp210 Ab Ser Ql IB;;ACTIVE;2.29;2.69 +56717-2;Histone Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Histone Ab [Presence] in Serum by Immunoblot;Histone Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56718-0;Islet cell 512 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Islet cell 512 Ab [Units/volume] in Serum by Immunoassay;Islet Cell512 Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +56719-8;Liver cytosol Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Liver cytosol Ab [Presence] in Serum by Immunoblot;Liver Cytosol Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56720-6;Ma+Ta Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Ma+Ta Ab [Presence] in Serum by Immunoblot;Ma+Ta Ab Ser Ql IB;;ACTIVE;2.29;2.73 +5672-1;Lead;MCnc;Pt;Bld;Ord;;DRUG/TOX;1;Deprecated Lead in blood;Deprecated Lead Bld Ql;;DEPRECATED;1.0;2.40 +56721-4;PM-SCL extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;PM-SCL extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA PM/SCL Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56722-2;Soluble liver Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Soluble liver Ab [Presence] in Serum by Immunoblot;Soluble liver Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56723-0;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA RNP Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56724-8;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA SS-A Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56725-5;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA SS-B Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56726-3;Lolium perenne recombinant profilin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Perennial rye grass recombinant profilin IgE Ab [Units/volume] in Serum;Per rye grass profilin IgE Qn;;ACTIVE;2.29;2.42 +56727-1;Olea europaea recombinant (rOle e) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive recombinant (rOle e) 2 IgE Ab [Units/volume] in Serum;Olive (rOle e) 2 IgE Qn;;ACTIVE;2.29;2.42 +56728-9;Thermoactinomyces vulgaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Thermoactinomyces vulgaris IgE Ab [Units/volume] in Serum;T vulgaris IgE Qn;;ACTIVE;2.29;2.73 +56729-7;Cladosporium cladosporioides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium cladosporioides IgE Ab [Units/volume] in Serum;C cladosporioides IgE Qn;;ACTIVE;2.29;2.70 +56730-5;Smith extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Smith extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA SM Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56731-3;Jo-1 extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA Jo1 Ab Ser Ql IB;;ACTIVE;2.29;2.73 +56732-1;Ribosomal P Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Ribosomal P Ab [Presence] in Serum by Immunoblot;Ribosomal P Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56733-9;PCNA extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;PCNA extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA PCNA Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56734-7;Centromere protein B Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Centromere protein B Ab [Presence] in Serum by Immunoblot;Centromere B Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56735-4;Mitochondria M2 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Mitochondria M2 Ab [Presence] in Serum by Immunoblot;Mitochondria M2 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56736-2;Purkinje cells Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Purkinje cells Ab [Presence] in Cerebral spinal fluid by Immunoblot;Purkinje Cells Ab CSF Ql IB;;ACTIVE;2.29;2.73 +56737-0;Ganglioside GM2 Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM2 IgG Ab [Presence] in Serum by Immunoblot;Deprecated GM2 Gangl IgG Ser Ql IB;;DEPRECATED;2.29;2.58 +56738-8;Ganglioside GM2 Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM2 IgM Ab [Presence] in Serum by Immunoblot;Deprecated GM2 Gangl IgM Ser Ql IB;;DEPRECATED;2.29;2.58 +5673-9;Lead;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Lead [Mass/mass] in Hair;Lead Hair-mCnt;;ACTIVE;1.0;2.73 +56739-6;Ganglioside GD1b Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Ganglioside GD1b IgG Ab [Presence] in Serum by Immunoblot;GD1b Gangl IgG Ser Ql IB;;ACTIVE;2.29;2.58 +56740-4;Ganglioside GD1b Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Ganglioside GD1b IgM Ab [Presence] in Serum by Immunoblot;GD1b Gangl IgM Ser Ql IB;;ACTIVE;2.29;2.58 +56741-2;Ganglioside GQ1b Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Ganglioside GQ1b IgG Ab [Presence] in Serum by Immunoblot;GQ1b Gangl IgG Ser Ql IB;;ACTIVE;2.29;2.58 +56742-0;Ganglioside GQ1b Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Ganglioside GQ1b IgM Ab [Presence] in Serum by Immunoblot;GQ1b Gangl IgM Ser Ql IB;;ACTIVE;2.29;2.58 +56743-8;Mi-2 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Mi-2 Ab [Presence] in Serum by Immunoblot;MI2 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56744-6;Pl-7 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;PL-7 Ab [Presence] in Serum by Immunoblot;PL7 Ab Ser Ql IB;;ACTIVE;2.29;2.73 +56745-3;Pl-12 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;PL-12 Ab [Presence] in Serum by Immunoblot;PL12 Ab Ser Ql IB;;ACTIVE;2.29;2.73 +56746-1;Allium ampeloprasum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Leeks IgE Ab [Units/volume] in Serum;Leeks IgE Qn;;ACTIVE;2.29;2.42 +5674-7;Lead;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Red Blood Cells;Lead RBC-mCnc;;ACTIVE;1.0;2.73 +56747-9;Azithromycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Azithromycin IgE Ab [Units/volume] in Serum;Azithromycin IgE Qn;;ACTIVE;2.29;2.42 +56748-7;Norovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Norovirus RNA [Presence] in Specimen by NAA with probe detection;Norovirus RNA Spec Ql NAA+probe;;ACTIVE;2.29;2.73 +56749-5;Estradiol^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Estradiol 30M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56750-3;Estradiol^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Estradiol 1h p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56751-1;Glucose^2.17H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.17 hours post XXX challenge;Glucose 2.17h p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +56752-9;APOB gene+LDLR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APOB gene+LDLR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;APOB+LDLR gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +56753-7;PML Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;PML Ab [Presence] in Serum by Immunoblot;PML Ab Ser Ql IB;;ACTIVE;2.29;2.58 +5675-4;Lead;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Lead [Presence] in Urine;Lead Ur Ql;;ACTIVE;1.0;2.56 +56754-5;sp100 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;sp100 Ab [Presence] in Serum by Immunoblot;sp100 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56755-2;Aldosterone^100M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --100 minutes post XXX challenge;Aldost 100M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56756-0;Aldosterone^70M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --70 minutes post XXX challenge;Aldost 70M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56757-8;Renin^100M post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --100 minutes post XXX challenge;Renin 100M p chal Plas-cCnc;;ACTIVE;2.29;2.42 +56758-6;Renin^70M post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --70 minutes post XXX challenge;Renin 70M p chal Plas-cCnc;;ACTIVE;2.29;2.42 +56759-4;Lactate dehydrogenase;CCnc;Pt;Semen;Qn;Reaction: lactate to pyruvate;CHEM;1;Deprecated Lactate dehydrogenase [Enzymatic activity/volume] in Semen by Lactate to pyruvate reaction;Deprecated LDH Smn L to P-cCnc;;DEPRECATED;2.29;2.36 +56760-2;Liver kidney microsomal Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Liver kidney microsomal Ab [Presence] in Serum by Immunoblot;LKM Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56761-0;Saccharomyces cerevisiae Ab;Titr;Pt;Ser;Qn;IF;ALLERGY;1;Baker's yeast Ab [Titer] in Serum by Immunofluorescence;Baker's yeast Ab Titr IF;;ACTIVE;2.29;2.32 +5676-2;Lead;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Urine;Lead Ur-mCnc;;ACTIVE;1.0;2.73 +56762-8;Protein fractions.oligoclonal bands.IgG;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Oligoclonal Bands IgG [Presence] in Serum or Plasma;Oligoclonal Bands IgG SerPl Ql;;ACTIVE;2.29;2.56 +56763-6;Protein fractions.oligoclonal bands.IgM;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Oligoclonal Bands IgM [Interpretation] in Serum or Plasma;Oligoclonal Bands IgM SerPl-Imp;;ACTIVE;2.29;2.54 +56764-4;Protein fractions.oligoclonal bands.IgG;PrThr;Pt;CSF;Ord;Isoelectric focusing;CHEM;1;Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing;Oligoclonal Bands IgG CSF Ql IEF;;ACTIVE;2.29;2.73 +56765-1;Protein fractions.oligoclonal bands.IgM;PrThr;Pt;CSF;Ord;Isoelectric focusing;CHEM;1;Oligoclonal Bands IgM [Presence] in Cerebral spinal fluid by Isoelectric focusing;Oligoclonal Bands IgM CSF Ql IEF;;ACTIVE;2.29;2.56 +56766-9;Protein.monoclonal band 1/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 1/Protein.total in Serum or Plasma by Electrophoresis;M Protein 1 MFr SerPl Elph;;ACTIVE;2.29;2.73 +56767-7;Protein.monoclonal.beta;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal.beta [Mass/volume] in Urine by Electrophoresis;M protein beta Ur Elph-mCnc;;ACTIVE;2.29;2.73 +56768-5;Protein.monoclonal.beta/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal.beta/Protein.total in Urine by Electrophoresis;M protein beta MFr Ur Elph;;ACTIVE;2.29;2.70 +56769-3;Lymphocytes/100 leukocytes;NFr;Pt;Bronchial;Qn;Flow cytometry;HEM/BC;1;Lymphocytes/100 leukocytes in Bronchial specimen by Flow cytometry (FC);Lymphocytes/leuk NFr Bronch FC;;ACTIVE;2.29;2.73 +5677-0;Lead;MRat;24H;Urine;Qn;;DRUG/TOX;1;Lead [Mass/time] in 24 hour Urine;Lead 24h Ur-mRate;;ACTIVE;1.0;2.73 +56770-1;Neutrophils/100 leukocytes;NFr;Pt;Bronchial;Qn;Flow cytometry;HEM/BC;1;Neutrophils/100 leukocytes in Bronchial specimen by Flow cytometry (FC);Neutrophils/leuk NFr Bronch FC;;ACTIVE;2.29;2.50 +56771-9;Eosinophils/100 leukocytes;NFr;Pt;Bronchial;Qn;Flow cytometry;HEM/BC;1;Eosinophils/100 leukocytes in Bronchial specimen by Flow cytometry (FC);Eosinophil/leuk NFr Bronch FC;;ACTIVE;2.29;2.50 +56772-7;Macrophages/100 leukocytes;NFr;Pt;Bronchial;Qn;Flow cytometry;HEM/BC;1;Macrophages/100 leukocytes in Bronchial specimen by Flow cytometry (FC);Macrophages/leuk NFr Bronch FC;;ACTIVE;2.29;2.50 +56773-5;Cells.CD1a/100 cells;NFr;Pt;Bronchial;Qn;;CELLMARK;1;CD1a cells/100 cells in Bronchial specimen;CD1a Cells NFr Bronch;;ACTIVE;2.29;2.73 +56774-3;Lymphocytes/100 leukocytes;NFr;Pt;Tiss;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Tissue;Lymphocytes/leuk NFr Tiss;;ACTIVE;2.29;2.50 +56775-0;Cells.CD3-CD16+CD56+;NCnc;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Tissue;CD3-CD16+CD56+ Cells # Tiss;;ACTIVE;2.29;2.42 +56776-8;Amylase.S3+S4/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S3+S4/Amylase.total in Serum or Plasma;Amylase S3+S4 CFr SerPl;;ACTIVE;2.29;2.42 +56777-6;Lipoprotein.pre-beta/Lipoprotein.beta;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.pre-beta/Lipoprotein.beta [Mass Ratio] in Serum or Plasma;VLDL/LDL SerPl;;ACTIVE;2.29;2.42 +56778-4;Articaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Articaine IgE Ab [Units/volume] in Serum;Articaine IgE Qn;;ACTIVE;2.29;2.42 +56779-2;Ascorbate;SCnc;Pt;Semen;Qn;;CHEM;1;Ascorbate [Moles/volume] in Semen;Vit C Smn-sCnc;;ACTIVE;2.29;2.42 +567-8;Diphtheria sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Diphtheria identified in Specimen by Organism specific culture;Diphtheria Spec Cult;;ACTIVE;1.0;2.73 +56780-0;CYP21A2 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CYP21A2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CYP21A2 Mut Tested Bld/T;;ACTIVE;2.29;2.68 +56781-8;(Canary feather+Parakeet feather+Parrot feather) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix C (Canary feather+Parakeet feather+Parrot feather) IgE Ab [Presence] in Serum by Multidisk;Epid Allerg MixC IgE Ql;;ACTIVE;2.29;2.56 +56782-6;Amylase.S4/Amylase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Amylase S4/Amylase.total in Serum or Plasma;Amylase S4 CFr SerPl;;ACTIVE;2.29;2.42 +56783-4;Trichloroethane;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichloroethane [Moles/volume] in Blood;TCE Bld-sCnc;;ACTIVE;2.29;2.42 +56784-2;Fibrinogen fragments;MCnc;Pt;Urine;Qn;;COAG;1;Fibrinogen fragments [Mass/volume] in Urine;Fibrinogen Frg Ur-mCnc;;ACTIVE;2.29;2.42 +56785-9;Saccharomyces cerevisiae Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast Ab [Units/volume] in Serum;Baker's yeast Ab Qn;;ACTIVE;2.29;2.69 +56786-7;Beta-2-Microglobulin.tumor marker;MCnc;Pt;Ser;Qn;;CHEM;1;Beta-2-Microglobulin.tumor marker [Mass/volume] in Serum;B2 Microglob tumor marker Ser-mCnc;;ACTIVE;2.29;2.73 +56787-5;Cytokeratin 19;ACnc;Pt;Urine;Qn;;CHEM;1;Cytokeratin 19 [Units/volume] in Urine;CK 19 Ur-aCnc;;ACTIVE;2.29;2.68 +5678-8;Lysergate diethylamide;MCnc;Pt;Ser/Plas;Qn;RIA;DRUG/TOX;1;Lysergate diethylamide [Mass/volume] in Serum or Plasma by Radioimmunoassay (RIA);LSD SerPl RIA-mCnc;;ACTIVE;1.0;2.73 +56788-3;Insulin^28H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --28 hours post XXX challenge;Insulin 28h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56789-1;Insulin^32H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --32 hours post XXX challenge;Insulin 32h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56790-9;Insulin^36H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --36 hours post XXX challenge;Insulin 36h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56791-7;Entecavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Entecavir [Susceptibility] by Genotype method;Entecavir Islt Genotyp;;ACTIVE;2.29;2.73 +56792-5;Telbivudine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Telbivudine [Susceptibility] by Genotype method;Telbivudine Islt Genotyp;;ACTIVE;2.29;2.73 +56793-3;Tenefovir;Susc;Pt;Isolate;OrdQn;Genotyping;ABXBACT;1;Deprecated Tenefovir [Susceptibility] by Genotype method;Deprecated Tenefovir Islt Genotyp;;DEPRECATED;2.29;2.36 +56794-1;Internal identifier;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Internal identifier;Internal ID;;ACTIVE;2.29;2.73 +56795-8;Account number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Account number [Identifier];Account #;;ACTIVE;2.29;2.66 +5679-6;Lysergate diethylamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lysergate diethylamide [Mass/volume] in Urine;LSD Ur-mCnc;;ACTIVE;1.0;2.73 +56796-6;Emergency contact information panel;-;Pt;^Emergency contact;-;;PANEL.ADMIN;2;Emergency contact information panel;Emergency contact info Pnl;;ACTIVE;2.29;2.67 +56797-4;Episode unique identifier;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Episode unique identifier;Episode unique ID;;ACTIVE;2.29;2.66 +56798-2;Alias;Pn;Pt;^Patient;Nom;;ED;2;Alias;Alias;;ACTIVE;2.29;2.29 +56799-0;Address;Addr;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Address;Address;;ACTIVE;2.29;2.73 +56800-6;Date and time ED consult request initiated;TmStp;Pt;^Patient;Qn;;ED;2;Date and time ED consult request initiated;Date+time ED consult request initiated;;ACTIVE;2.29;2.56 +56801-4;Date and time ED consult starts;TmStp;Pt;^Patient;Qn;;ED;2;Date and time ED consult starts;Date+time ED consult starts;;ACTIVE;2.29;2.56 +56802-2;Primary care provider;ID;Pt;Provider;Nom;;ADMIN.ID;2;Primary care provider [Identifier];Primary care provider;;ACTIVE;2.29;2.73 +56803-0;ED attending physician;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED attending physician [Identifier];ED attending physician;;ACTIVE;2.29;2.66 +5680-4;Malathion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Malathion [Mass/volume] in Serum or Plasma;Malathion SerPl-mCnc;;ACTIVE;1.0;2.73 +56804-8;ED nurse;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED nurse [Identifier] Provider;ED nurse Provider;;ACTIVE;2.29;2.66 +56805-5;ED accepting or admitting provider;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED accepting/admitting provider [Identifier];ED accepting/admitting provider;;ACTIVE;2.29;2.66 +56806-3;ED transferring provider;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED transferring provider [Identifier];ED transferring provider;;ACTIVE;2.29;2.66 +56807-1;ED transferring facility;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;ED transferring facility [Identifier];ED transferring facility;;ACTIVE;2.29;2.66 +56808-9;ED accepting or admitting facility;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;ED accepting or admitting facility [Identifier];ED accepting or admitting facility;;ACTIVE;2.29;2.66 +56809-7;ED tech;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED tech [Identifier] Provider;ED tech Provider;;ACTIVE;2.29;2.66 +56810-5;ED triage nurse;ID;Pt;Provider;Nom;;ADMIN.ID;2;ED triage nurse Provider;ED triage nurse Provider;;ACTIVE;2.29;2.66 +56811-3;Primary care clinic or system;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Primary care clinic or system [Identifier] Facility;Primary care clinic or system Facility;;ACTIVE;2.29;2.66 +5681-2;Manganese;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Blood;Manganese Bld-mCnc;;ACTIVE;1.0;2.73 +56812-1;Provider who accepted patient in transfer to another facility;ID;Pt;Provider;Nom;;ADMIN.ID;2;Provider who accepted patient in transfer to another facility [Identifier];Provider who accepted pt in transfer;;ACTIVE;2.29;2.66 +56813-9;Individuals accompanying patient to ED;Prid;Pt;^Patient;Nom;;ED;2;Individuals accompanying patient to ED;Individuals accompanying patient to ED;;ACTIVE;2.29;2.29 +56814-7;Prehospital care;Prid;Pt;^Patient;Nom;;ED;2;Prehospital care;Prehospital care;;ACTIVE;2.29;2.29 +56815-4;Time placed into treatment area;TmStp;Pt;^Patient;Qn;;ED;2;Time placed into treatment area;Time placed into treatment area;;ACTIVE;2.29;2.29 +56816-2;Patient location;Loc;Pt;^Patient;Nom;;ED;2;Patient location;Patient location;;ACTIVE;2.29;2.29 +56817-0;Presenting problem;Find;Pt;^Patient;Nom;;ED;2;Presenting problem;Presenting problem;;ACTIVE;2.29;2.29 +56818-8;Problem description;Prid;Pt;^Patient;Nom;;ED;2;Problem description [Identifier];Problem description;;ACTIVE;2.29;2.73 +56819-6;Problem prior evaluation;Find;Pt;^Patient;Nom;;ED;2;Problem prior evaluation;Problem prior evaluation;;ACTIVE;2.29;2.29 +5682-0;Manganese;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Red Blood Cells;Manganese RBC-mCnc;;ACTIVE;1.0;2.73 +56820-4;Problem context;Find;Pt;^Patient;Nom;;ED;2;Problem context;Problem context;;ACTIVE;2.29;2.29 +56821-2;Problem exacerbating factors;Find;Pt;^Patient;Nom;;ED;2;Problem exacerbating factors;Problem exacerbating factors;;ACTIVE;2.29;2.29 +56822-0;Problem response to therapy;Find;Pt;^Patient;Nom;;ED;2;Problem response to therapy;Problem response to therapy;;ACTIVE;2.29;2.29 +56823-8;Problem quality or description;Find;Pt;^Patient;Nom;;ED;2;Problem quality or description;Problem quality or description;;ACTIVE;2.29;2.29 +56824-6;Problem location;Anat;Pt;^Patient;Nom;;ED;2;Problem location;Problem location;;ACTIVE;2.29;2.29 +56825-3;Problem time course;TmStp;Pt;^Patient;Qn;;ED;2;Problem time course;Problem time course;;ACTIVE;2.29;2.29 +56826-1;Problem frequency;NRat;Pt;^Patient;Qn;;ED;2;Problem frequency;Problem frequency;;ACTIVE;2.29;2.50 +56827-9;Symptom duration during occurrences or episodes;Time;Pt;^Patient;Qn;;ED;2;Symptom duration during occurrences or episodes;Sym dur during occurrences or episodes;;ACTIVE;2.29;2.29 +56828-7;Time contractions became regular;TmStp;Pt;^Patient;Qn;;ED;2;Time contractions became regular;Time contractions became regular;;ACTIVE;2.29;2.29 +56829-5;Time membranes ruptured;TmStp;Pt;^Patient;Qn;;ED;2;Time membranes ruptured;Time membranes ruptured;;ACTIVE;2.29;2.29 +56830-3;Limitations in obtaining history;Find;Pt;^Patient;Nom;;ED;2;Limitations in obtaining history;Limitations in obtaining history;;ACTIVE;2.29;2.29 +56831-1;Problem associated signs and symptoms;Find;Pt;^Patient;Nom;;ED;2;Problem associated signs and symptoms;Problem associated signs+symptoms;;ACTIVE;2.29;2.73 +56832-9;Substance abused;Type;Pt;^Patient;Nom;;ED;2;Type of substance abused;Type of substance abused;;ACTIVE;2.29;2.66 +56833-7;Pregnancy related history;Find;Pt;^Patient;Nar;;H&P.HX;2;Pregnancy related history Narrative;Pregnancy related history;;ACTIVE;2.29;2.40 +56834-5;Movement;Find;Pt;^Fetus;Nar;;H&P.HX;2;Fetal Narrative Movement;Fet Movement;;ACTIVE;2.29;2.40 +56835-2;Viability of current pregnancy;Find;Pt;^Patient;Nar;;H&P.HX;2;Viability of current pregnancy Narrative;Viability of current pregnancy;;ACTIVE;2.29;2.40 +56836-0;Blood transfusion;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Blood transfusion Narrative;Hx of Blood transfusion;;ACTIVE;2.29;2.73 +56837-8;Neoplastic disease;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Neoplastic disease Narrative;Hx of Neoplastic disease;;ACTIVE;2.29;2.56 +5683-8;Manganese;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Serum or Plasma;Manganese SerPl-mCnc;;ACTIVE;1.0;2.73 +56838-6;Infectious disease;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Infectious disease Narrative;Hx of Infectious disease;;ACTIVE;2.29;2.63 +56839-4;Acuity assessment;Find;Pt;^Patient;Nar;;H&P.PX;2;Acuity assessment Narrative;Acuity assess;;ACTIVE;2.29;2.40 +56840-2;Pain severity verbal numeric scale;Score;Pt;^Patient;Qn;;H&P.HX;2;Pain severity verbal numeric scale [Score];Pain severity verbal numeric scale Score;;DISCOURAGED;2.29;2.50 +56841-0;Pain severity descriptive category;Arb;Pt;^Patient;Ord;;H&P.HX;2;Pain severity descriptive category;Pain severity descriptive category;;ACTIVE;2.29;2.29 +56842-8;Chronic pain assessment;Find;Pt;^Patient;Nar;;H&P.PX;2;Chronic pain assessment Narrative;Chronic pain assessment;;ACTIVE;2.29;2.40 +56843-6;Physical findings;Find;Pt;Nail bed;Nar;;H&P.PX;2;Physical findings of Nail bed Narrative;Phys find Nail Bed;;ACTIVE;2.29;2.40 +56844-4;Intraocular pressure;Pres;Pt;Eye;Qn;;H&P.PX;2;Intraocular pressure of Eye;IOP Eye;;ACTIVE;2.29;2.73 +56845-1;Pulse strength on exam;Find;Pt;^Patient;Nar;;H&P.PX;2;Pulse strength on exam Narrative;Pulse strength on exam;;ACTIVE;2.29;2.40 +5684-6;Manganese;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Urine;Manganese Ur-mCnc;;ACTIVE;1.0;2.73 +56846-9;Cardiac biomarkers;Cmplx;-;^Patient;Set;;ED;2;Cardiac biomarkers (set);Cardiac biomarkers;;ACTIVE;2.29;2.29 +56847-7;Calculated & derived values;Cmplx;-;^Patient;Set;;ED;2;Calculated and derived values (set);Calc and deriv values;;ACTIVE;2.29;2.73 +56848-5;Invasive hemodynamic monitoring;Cmplx;-;^Patient;Set;;ED;2;Invasive hemodynamic monitoring (set);Invasive hemodynamic monitoring;;ACTIVE;2.29;2.29 +56849-3;Cardiac rhythm monitoring;Cmplx;-;^Patient;Set;;ED;2;Cardiac rhythm monitoring (set);Cardiac rhythm monitoring;;ACTIVE;2.29;2.73 +56850-1;Interpretation and review of laboratory results;Imp;Pt;^Patient;Nom;;ED;2;Interpretation and review of laboratory results;Imp & review of lab results;;ACTIVE;2.29;2.73 +56851-9;Care process or plan;Prid;Pt;^Patient;Nom;;ED;2;Care process or plan;Care process or plan;;ACTIVE;2.29;2.29 +56852-7;Amount of ED discharge medication to be dispensed;Num;Pt;^Patient;Qn;;ED;2;Amount of ED discharge medication to be dispensed;Amount ED discharge meds to be dispensed;;ACTIVE;2.29;2.48 +5685-3;Mercury;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Blood;Mercury Bld-mCnc;;ACTIVE;1.0;2.73 +56853-5;ED outcome;Find;Pt;^Patient;Nom;;ED;2;ED outcome;ED outcome;;ACTIVE;2.29;2.29 +56854-3;Inpatient practitioner;Type;Pt;Provider;Nom;;ED;2;Inpatient practitioner;IP practitioner;;ACTIVE;2.29;2.29 +56855-0;Provider assuming ultimate responsibility for care for patient upon ED disposition;ID;Pt;Provider;Nom;;ADMIN.ID;2;Provider assuming ultimate responsibility for care for patient upon ED disposition [Identifier];Prov assuming resp for care;;ACTIVE;2.29;2.66 +56856-8;Provider assuming care for patient upon ED disposition;ID;Pt;Provider;Nom;;ADMIN.ID;2;Provider assuming care for patient upon ED disposition [Identifier];Prov assuming care uponED dispon;;ACTIVE;2.29;2.66 +56857-6;Time accepted for admission or transfer;TmStp;Pt;^Patient;Qn;;ED;2;Time accepted for admission or transfer;Time accepted for admission or transfer;;ACTIVE;2.29;2.29 +56858-4;Time received by accepting facility or unit;TmStp;Pt;^Patient;Qn;;ED;2;Time received by accepting facility or unit;Time received by accepting fac or unit;;ACTIVE;2.29;2.32 +56859-2;Date and time of ED departure;TmStp;Pt;^Patient;Qn;;ED;2;Date and time of ED departure;Date+time of ED departure;;ACTIVE;2.29;2.56 +568-6;Fungus identified;Prid;Pt;Asp;Nom;Culture;MICRO;1;Fungus identified in Aspirate by Culture;Fungus Aspirate Cult;;ACTIVE;1.0;2.17 +56860-0;ED follow-up care assistance;Type;Pt;^Patient;Nom;;ED;2;ED follow-up care assistance;ED follow-up care assistance;;ACTIVE;2.29;2.29 +5686-1;Mercury;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Mercury [Mass/mass] in Hair;Mercury Hair-mCnt;;ACTIVE;1.0;2.73 +56861-8;Name;Pn;Pt;^Emergency contact;Nom;;ED;2;Emergency contact Name;Emergency contact Name;;ACTIVE;2.29;2.66 +56862-6;Address;Addr;Pt;^Emergency contact;Nom;;ED;2;Emergency contact Address;Emergency contact Address;;ACTIVE;2.29;2.29 +56863-4;Phone number;Tele;Pt;^Emergency contact;Nom;;ADMIN;2;Emergency contact Phone number;Emergency contact Phone #;;ACTIVE;2.29;2.66 +56864-2;Relationship to patient;Type;Pt;^Emergency contact;Nom;;ED;2;Emergency contact Relationship to patient;Emergency contact Relationship to pt;;ACTIVE;2.29;2.34 +56865-9;Problem diagnostic considerations;Prid;Pt;^Patient;Nom;;ED;2;Problem diagnostic considerations;Problem diagnostic considerations;;ACTIVE;2.29;2.29 +56866-7;Onset of painful contractions;TmStp;Pt;^Patient;Qn;;ED;2;Onset of painful contractions;Onset of painful contractions;;ACTIVE;2.29;2.29 +56867-5;Physical findings;Find;Pt;Throat;Nar;Observed;H&P.PX;2;Physical findings of Throat Narrative;Phys find Throat;;ACTIVE;2.29;2.40 +56868-3;ED procedure indication;Imp;Pt;^Patient;Nom;;ED;2;ED procedure indication [Interpretation];ED procedure indication Imp;;ACTIVE;2.29;2.50 +56869-1;Continuous ST segment monitoring;Cmplx;-;^Patient;Set;;ED;2;Continuous ST segment monitoring (set);Continuous ST segment monitoring;;ACTIVE;2.29;2.29 +56870-9;ED facility ID;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;ED facility ID;ED facility ID;;ACTIVE;2.29;2.66 +56871-7;Symptoms & diseases;Hx;Pt;Gynecologic system;Nar;;H&P.HX;2;History of Gynecologic system disorders;Hx of Gynecologic system disorders;;ACTIVE;2.29;2.63 +56872-5;Constitutional symptoms;Find;Pt;^Patient;Nar;;H&P.HX;2;Constitutional symptoms Narrative;Constitutional symptoms;;ACTIVE;2.29;2.40 +56873-3;Physical findings;Find;Pt;Brain stem reflexes;Nar;;H&P.PX;2;Physical findings of Brain stem reflexes Narrative;Phys find Brain stem reflexes;;ACTIVE;2.29;2.40 +56874-1;Serology & blood bank studies;Cmplx;-;^Patient;Set;;ED;2;Serology and blood bank studies (set);Serology and blood bank studies;;ACTIVE;2.29;2.38 +56875-8;Mixed venous oxygen saturation monitoring;Cmplx;-;^Patient;Set;;ED;2;Mixed venous oxygen saturation monitoring (set);Mixed venous O2 sat monitoring;;ACTIVE;2.29;2.29 +56876-6;Physical findings;Find;Pt;Primitive reflexes;Nar;;H&P.PX;2;Physical findings of Primitive reflexes Narrative;Phys find Primitive reflexes;;ACTIVE;2.29;2.40 +56877-4;Mepivacaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mepivacaine IgE Ab [Units/volume] in Serum;Mepivacaine IgE Qn;;ACTIVE;2.29;2.42 +56878-2;Phenylbutazone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phenylbutazone IgE Ab [Units/volume] in Serum;Phenylbutazone IgE Qn;;ACTIVE;2.29;2.70 +5687-9;Mercury;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Serum or Plasma;Mercury SerPl-mCnc;;ACTIVE;1.0;2.73 +56879-0;Lactose Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactose IgE Ab [Units/volume] in Serum;Lactose IgE Qn;;ACTIVE;2.29;2.70 +56880-8;TCRB gene+TCRD gene+TCRG gene rearrangements;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.REARRANGE;1;TCRB gene+TCRD gene+TCRG gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method;TCRB gene+TCRD gene+TCRG gene Bld/T Ql;;ACTIVE;2.29;2.34 +56881-6;Rickettsia typhi Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rickettsia typhi IgG Ab [Presence] in Serum by Immunofluorescence;R typhi IgG Ser Ql IF;;ACTIVE;2.29;2.56 +56882-4;Parietaria judaica recombinant (rPar j) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pellitory (Parietaria judaica) recombinant (rPar j) 2 IgE Ab [Units/volume] in Serum;Pellitory (rPar j) 2 IgE Qn;;ACTIVE;2.29;2.56 +56883-2;BCHE gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BCHE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BCHE gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +56884-0;Somatotropin^160M post exercise;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --160 minutes post exercise;GH 160M p Exc SerPl-mCnc;;ACTIVE;2.29;2.40 +56885-7;Somatotropin^3H post exercise;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3 hours post exercise;GH 3h P Exc SerPl-mCnc;;ACTIVE;2.29;2.40 +56886-5;Indirect antiglobulin test.XXX reagent;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Indirect antiglobulin test.unspecified reagent [Titer] in Serum or Plasma;IAT Titr SerPl;;ACTIVE;2.29;2.73 +5688-7;Mercury;PrThr;Pt;Urine;Ord;Visual.Reinsch;DRUG/TOX;1;Mercury [Presence] in Urine by Visual.Reinsch;Mercury Ur Ql Visual.Reinsch;;ACTIVE;1.0;2.56 +56887-3;Myoglobin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Myoglobin [Moles/volume] in Serum or Plasma;Myoglobin SerPl-sCnc;;ACTIVE;2.29;2.70 +56888-1;HIV 1+2 Ab+HIV1 p24 Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;HIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay;HIV 1+2 Ab+HIV1 p24 Ag SerPl Ql IA;;ACTIVE;2.29;2.73 +56889-9;Cells.CD13+HLA-DR+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD13+HLA-DR+ cells/100 cells in Tissue;CD13+HLA-DR+ Cells NFr Tiss;;ACTIVE;2.29;2.40 +56890-7;Cells.CD13+HLA-DR+/100 cells;NFr;Pt;Asp;Qn;;CELLMARK;1;CD13+HLA-DR+ cells/100 cells in Aspirate;CD13+HLA-DR+ Cells NFr Aspirate;;ACTIVE;2.29;2.40 +56891-5;Cells.CD13+HLA-DR+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD13+HLA-DR+ cells/100 cells in Specimen;CD13+HLA-DR+ Cells NFr Spec;;ACTIVE;2.29;2.69 +56892-3;Cells.CD13+HLA-DR+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD13+HLA-DR+ cells/100 cells in Blood;CD13+HLA-DR+ Cells NFr Bld;;ACTIVE;2.29;2.34 +56893-1;Cells.CD13+HLA-DR+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD13+HLA-DR+ cells/100 cells in Body fluid;CD13+HLA-DR+ Cells NFr Fld;;ACTIVE;2.29;2.40 +56894-9;Cells.CD13+HLA-DR+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD13+HLA-DR+ cells/100 cells in Cerebral spinal fluid;CD13+HLA-DR+ Cells NFr CSF;;ACTIVE;2.29;2.40 +5689-5;Mercury;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Urine;Mercury Ur-mCnc;;ACTIVE;1.0;2.73 +56895-6;Cells.CD13+HLA-DR+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD13+HLA-DR+ cells/100 cells in Bone marrow;CD13+HLA-DR+ Cells NFr Mar;;ACTIVE;2.29;2.40 +56896-4;Cells.CD33+CD34+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD33+CD34+ cells/100 cells in Bone marrow;CD33+CD34+ Cells NFr Mar;;ACTIVE;2.29;2.40 +56897-2;Cells.CD3-CD56+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3-CD56+ cells/100 cells in Cerebral spinal fluid;CD3-CD56+ Cells NFr CSF;;ACTIVE;2.29;2.40 +56898-0;Cells.CD5+FMC7+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD5+FMC7+ cells/100 cells in Tissue;CD5+FMC7+ Cells NFr Tiss;;ACTIVE;2.29;2.40 +56899-8;Cells.CD5+FMC7+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD5+FMC7+ cells/100 cells in Bone marrow;CD5+FMC7+ Cells NFr Mar;;ACTIVE;2.29;2.40 +56900-4;Cells.terminal deoxyribonucleotidyl transferase/100 cells;NFr;Pt;CSF;Qn;Flow cytometry;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells/100 cells in Cerebral spinal fluid by Flow cytometry (FC);TdT Cells NFr CSF FC;;ACTIVE;2.29;2.40 +56901-2;Amino acid pattern;Imp;Pt;Body fld;Nom;;CHEM;1;Amino acid pattern [Interpretation] in Body fluid;Amino acid Pat Fld-Imp;;ACTIVE;2.29;2.32 +56902-0;Amylase/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Amylase/Creatinine [Ratio] in 24 hour Urine;Amylase/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +5690-3;Methanol;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Methanol [Presence] in Blood;Methanol Bld Ql;;ACTIVE;1.0;2.73 +56903-8;Anserine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Anserine/Creatinine [Ratio] in 24 hour Urine;Anserine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56904-6;APOE gene mutation analysis;Prid;Pt;Bld;Nom;Molgen;MOLPATH;1;Deprecated APOE gene mutations found [Identifier] in Blood by Molecular genetics method Nominal;Deprecated APOE gene Mut Anal Bld;;DEPRECATED;2.29;2.36 +56905-3;Bilirubin.glucuronidated+Bilirubin.albumin bound;MCnc;Pt;Plr fld;Qn;;CHEM;1;Bilirubin.direct [Mass/volume] in Pleural fluid;Bilirub Direct Plr-mCnc;;ACTIVE;2.29;2.34 +56906-1;Bilirubin.glucuronidated+Bilirubin.albumin bound;MCnc;Pt;Periton fld;Qn;;CHEM;1;Bilirubin.direct [Mass/volume] in Peritoneal fluid;Bilirub Direct Prt-mCnc;;ACTIVE;2.29;2.34 +56907-9;Cells.CD3+CD45+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD45+ cells/100 cells in Blood;CD3+CD45+ Cells NFr Bld;;ACTIVE;2.29;2.73 +56908-7;Cells.CD3+CD8+CD45+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD45+ cells/100 cells in Blood;CD3+CD8+CD45+ Cells NFr Bld;;DISCOURAGED;2.29;2.36 +56909-5;Chlamydia sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydia sp IgG Ab [Presence] in Serum by Immunoassay;Chlamydia IgG Ser Ql IA;;ACTIVE;2.29;2.56 +56910-3;Chlamydia sp Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;Chlamydia IgG sp1 Ser IA-aCnc;;ACTIVE;2.29;2.69 +5691-1;Methanol;PrThr;Pt;Exhl gas;Ord;;DRUG/TOX;1;Methanol [Presence] in Exhaled gas;Methanol ExG Ql;;ACTIVE;1.0;2.56 +56911-1;Chlamydia sp Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Chlamydia sp IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;Chlamydia IgG sp2 Ser IA-aCnc;;ACTIVE;2.29;2.69 +56912-9;Cholesterol;MCnc;Pt;Pericard fld;Qn;;CHEM;1;Cholesterol [Mass/volume] in Pericardial fluid;Cholest Pcar-mCnc;;ACTIVE;2.29;2.42 +56913-7;Corticotropin^morning specimen;MCnc;Pt;Plas;Qn;;CHEM;1;Corticotropin [Mass/volume] in Plasma --morning specimen;ACTH AM Plas-mCnc;;ACTIVE;2.29;2.42 +56914-5;Corticotropin^evening specimen;MCnc;Pt;Plas;Qn;;CHEM;1;Corticotropin [Mass/volume] in Plasma --evening specimen;ACTH evening Plas-mCnc;;ACTIVE;2.29;2.42 +56915-2;Coxiella burnetii Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii IgG Ab [Presence] in Serum by Immunofluorescence;C burnet IgG Ser Ql IF;;ACTIVE;2.29;2.56 +56916-0;Coxiella burnetii Ab.IgM^2nd specimen;ACnc;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii IgM Ab [Units/volume] in Serum by Immunofluorescence --2nd specimen;C burnet IgM sp2 Ser IF-aCnc;;ACTIVE;2.29;2.69 +56917-8;Coxiella burnetii Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii IgM Ab [Presence] in Serum by Immunofluorescence;C burnet IgM Ser Ql IF;;ACTIVE;2.29;2.56 +56918-6;Coxiella burnetii Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii IgM Ab [Titer] in Serum by Immunofluorescence --1st specimen;C burnet IgM sp1 Titr Ser IF;;ACTIVE;2.29;2.32 +56919-4;Coxiella burnetii Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii IgG Ab [Titer] in Serum by Immunofluorescence --2nd specimen;C burnet IgG sp2 Titr Ser IF;;ACTIVE;2.29;2.32 +56920-2;Coxiella burnetii Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxiella burnetii IgG Ab [Titer] in Serum by Immunofluorescence --1st specimen;C burnet IgG sp1 Titr Ser IF;;ACTIVE;2.29;2.32 +56921-0;Entamoeba histolytica Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Entamoeba histolytica Ab [Presence] in Serum by Immunofluorescence;E histolyt Ab Ser Ql IF;;ACTIVE;2.29;2.56 +56922-8;Entamoeba histolytica Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Entamoeba histolytica IgG Ab [Presence] in Serum by Immunoassay;E histolyt IgG Ser Ql IA;;ACTIVE;2.29;2.56 +56923-6;Fasciola hepatica Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Fasciola hepatica Ab [Presence] in Serum by Immunoassay;F hepatica Ab Ser Ql IA;;ACTIVE;2.29;2.56 +56924-4;Fasciola hepatica Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Fasciola hepatica Ab [Titer] in Serum by Hemagglutination;F hepatica Ab Titr Ser HA;;ACTIVE;2.29;2.32 +56925-1;Fractional excretion of phosphate;Ratio;24H;Urine+Ser/Plas;Qn;;CHEM;1;Fractional excretion of phosphate [Ratio] in 24 hour Urine and Serum or Plasma;Fract excret PO4 24h Ur+SerPl-Rto;;ACTIVE;2.29;2.38 +56926-9;Hepatitis C virus c1 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus c1 Ab [Presence] in Serum by Immunoblot;HCV c1 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56927-7;Hepatitis C virus c2 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus c2 Ab [Presence] in Serum by Immunoblot;HCV c2 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56928-5;Hepatitis C virus E2 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus E2 Ab [Presence] in Serum by Immunoblot;HCV E2 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +5692-9;Methanol;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methanol [Presence] in Serum or Plasma;Methanol SerPl Ql;;ACTIVE;1.0;2.56 +56929-3;Hepatitis C virus NS3 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus NS3 Ab [Presence] in Serum by Immunoblot;HCV NS3 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56930-1;Hepatitis C virus NS4 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus NS4 Ab [Presence] in Serum by Immunoblot;HCV NS4 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +56931-9;Hydrogen/Expired gas^pre dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --pre dose lactulose;Breath H2 pre Lac;;ACTIVE;2.29;2.42 +56932-7;Hydrogen/Expired gas^1H post dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose lactulose;Breath H2 1h p Lac;;ACTIVE;2.29;2.42 +56933-5;Hydrogen/Expired gas^2H post dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2 hour post dose lactulose;Breath H2 2h p Lac;;ACTIVE;2.29;2.42 +56934-3;Hydrogen/Expired gas^2.5H post dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.5 hour post dose lactulose;Breath H2 2.5h p Lac;;ACTIVE;2.29;2.42 +56935-0;Hydrogen/Expired gas^3.5H post dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3.5 hour post dose lactose;Breath H2 3.5h p Lac;;ACTIVE;2.29;2.42 +56936-8;Hydrogen/Expired gas^1.5H post dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.5 hour post dose lactulose;Breath H2 1.5h p Lac;;ACTIVE;2.29;2.42 +5693-7;Methanol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methanol [Mass/volume] in Serum or Plasma;Methanol SerPl-mCnc;;ACTIVE;1.0;2.73 +56937-6;Hydrogen/Expired gas^30M post dose glucose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose glucose;Breath H2 30M p Glc;;ACTIVE;2.29;2.42 +56938-4;Hydrogen/Expired gas^30M post dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose lactulose;Breath H2 30M p Lac;;ACTIVE;2.29;2.42 +56939-2;Hydroxyproline/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Hydroxyproline/Creatinine [Ratio] in 24 hour Urine;OH-Proline/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +569-4;Fungus identified;Prid;Pt;CSF;Nom;Culture;MICRO;1;Fungus identified in Cerebral spinal fluid by Culture;Fungus CSF Cult;;ACTIVE;1.0;2.73 +56940-0;Inhibin B;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Inhibin B [Mass/volume] in Serum or Plasma by Immunoassay;Inhibin B SerPl IA-mCnc;;ACTIVE;2.29;2.73 +56941-8;Insulin^8H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --8 hours post XXX challenge;Insulin 8h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56942-6;Insulin^64H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --64 hour post XXX challenge;Insulin 64h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56943-4;Insulin^68H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --68 hour post XXX challenge;Insulin 68h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56944-2;Insulin^3D post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3 days post XXX challenge;Insulin 3D p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +5694-5;Methanol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methanol [Presence] in Urine;Methanol Ur Ql;;ACTIVE;1.0;2.73 +56945-9;Insulin^56H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --56 hours post XXX challenge;Insulin 56h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56946-7;Insulin^2D post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2 days post XXX challenge;Insulin 2D p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56947-5;Insulin^60H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --60 hour post XXX challenge;Insulin 60H p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56948-3;Insulin^44H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --44 hour post XXX challenge;Insulin 44h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56949-1;Insulin^40H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --40 hours post XXX challenge;Insulin 40H p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +56950-9;Legionella pneumophila Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila IgG Ab [Titer] in Serum by Immunofluorescence --2nd specimen;L pneumo IgG sp2 Titr Ser IF;;ACTIVE;2.29;2.32 +56951-7;Leishmania sp Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Leishmania sp IgG Ab [Presence] in Serum by Immunofluorescence;Leishmania IgG Ser Ql IF;;ACTIVE;2.29;2.56 +5695-2;Methanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methanol [Mass/volume] in Urine;Methanol Ur-mCnc;;ACTIVE;1.0;2.73 +56952-5;Leptospira interrogans Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans Ab [Titer] in Serum by Agglutination;L inter Ab Titr Ser Aggl;;ACTIVE;2.29;2.32 +56953-3;Leptospira interrogans Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Leptospira interrogans IgM Ab [Presence] in Serum by Immunoassay;L inter IgM Ser Ql IA;;ACTIVE;2.29;2.56 +56954-1;Leucine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Leucine/Creatinine [Ratio] in 24 hour Urine;Leucine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56955-8;Lysine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Lysine/Creatinine [Ratio] in 24 hour Urine;Lysine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56956-6;Magnesium/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Magnesium/Creatinine [Ratio] in Urine;Magnesium/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56957-4;Methionine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Methionine/Creatinine [Ratio] in 24 hour Urine;Methionine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.70 +56958-2;Mycoplasma pneumoniae Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;M pneumo IgG sp1 Ser IA-aCnc;;ACTIVE;2.29;2.69 +56959-0;Neuronal nuclear type 2 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Hu2 Ab CSF Ql IF;;ACTIVE;2.29;2.73 +5696-0;Molybdenum;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Molybdenum [Mass/volume] in Blood;Molybdenum Bld-mCnc;;ACTIVE;1.0;2.73 +56960-8;Neutrophils.segmented/100 leukocytes;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Segmented neutrophils/100 leukocytes in Bone marrow by Manual count;Neuts Seg/leuk NFr Mar Manual;;ACTIVE;2.29;2.54 +56961-6;Nicotinamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nicotinamide [Mass/volume] in Serum or Plasma;Nicotinamide SerPl-mCnc;;ACTIVE;2.29;2.73 +56962-4;Ovary Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Ovary IgG Ab [Presence] in Serum by Immunofluorescence;Ovary IgG Ser Ql IF;;ACTIVE;2.29;2.73 +56963-2;pH;LsCnc;Pt;Saliva;Qn;;CHEM;1;pH of Saliva (oral fluid);pH Sal;;ACTIVE;2.29;2.42 +56964-0;Phosphate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Phosphate/Creatinine [Ratio] in Urine;Phosphate/Creat Ur-Rto;;ACTIVE;2.29;2.70 +56965-7;Phosphate/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Phosphate/Creatinine [Ratio] in 24 hour Urine;Phosphate/Creat 24h Ur-Rto;;ACTIVE;2.29;2.73 +56966-5;Phosphoethanolamine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Phosphoethanolamine/Creatinine [Ratio] in 24 hour Urine;PETN/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56967-3;Plasmodium falciparum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Plasmodium falciparum Ab [Presence] in Serum by Immunoassay;P falciparum Ab Ser Ql IA;;ACTIVE;2.29;2.56 +56968-1;Plasmodium sp Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Plasmodium sp Ab [Presence] in Serum by Immunofluorescence;Plasmodium Ab Ser Ql IF;;ACTIVE;2.29;2.56 +56969-9;Polistes spp Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp IgG4 Ab [Units/volume] in Serum;Paper Wasp IgG4 Qn;;ACTIVE;2.29;2.69 +56970-7;Porphyrins;MCnc;24H;Urine;Qn;;CHEM;1;Porphyrins [Mass/volume] in 24 hour Urine;Porphyrins 24h Ur-mCnc;;ACTIVE;2.29;2.63 +56971-5;Potassium/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Potassium/Creatinine [Ratio] in 24 hour Urine;Potassium/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56972-3;Prolactin^post precipitation;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin [Mass/volume] in Serum or Plasma --post precipitation;Prolactin post precipitation SerPl-mCnc;;ACTIVE;2.29;2.40 +56973-1;Proline/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Proline/Creatinine [Ratio] in 24 hour Urine;Proline/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56974-9;Protein fractions.oligoclonal bands;Imp;Pt;Ser/Plas;Nom;Isoelectric focusing;CHEM;1;Oligoclonal bands [Interpretation] in Serum or Plasma by Isoelectric focusing;Oligoclonal Bands SerPl IEF-Imp;;ACTIVE;2.29;2.73 +56975-6;Renin^upright+30M post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --upright+30 minutes post XXX challenge;Renin upr+30M p chal Plas-mCnc;;ACTIVE;2.29;2.42 +56976-4;Renin^upright+1H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --upright+1 hour post XXX challenge;Renin upr+1h p chal Plas-mCnc;;ACTIVE;2.29;2.42 +56977-2;Rheumatoid arthritis nuclear Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Rheumatoid arthritis nuclear Ab [Titer] in Serum by Immunofluorescence;RA Nuc Ab Titr Ser IF;;ACTIVE;2.29;2.73 +5697-8;Molybdenum;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Molybdenum [Mass/mass] in Hair;Molybdenum Hair-mCnt;;ACTIVE;1.0;2.19 +56978-0;Serotonin;MCnc;24H;Urine;Qn;;CHEM;1;Serotonin [Mass/volume] in 24 hour Urine;Serotonin 24h Ur-mCnc;;ACTIVE;2.29;2.42 +56979-8;Sodium;SCnc;Pt;Saliva;Qn;;CHEM;1;Sodium [Moles/volume] in Saliva (oral fluid);Sodium Sal-sCnc;;ACTIVE;2.29;2.42 +56980-6;Sodium/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Sodium/Creatinine [Ratio] in 24 hour Urine;Sodium/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56981-4;Somatotropin^30M post resting;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post resting;GH 30M p resting SerPl-mCnc;;ACTIVE;2.29;2.40 +56982-2;Somatotropin^90M post resting;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Mass/volume] in Serum or Plasma --90 minutes post resting;GH 90M p resting SerPl-mCnc;;ACTIVE;2.29;2.40 +56983-0;Somatotropin^1H post resting;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post resting;GH 1h p resting SerPl-mCnc;;ACTIVE;2.29;2.40 +56984-8;Taenia solium larva Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Taenia solium larva Ab [Presence] in Serum by Immunoassay;T sol lar Ab Ser Ql IA;;ACTIVE;2.29;2.56 +56985-5;Taurine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Taurine/Creatinine [Ratio] in 24 hour Urine;Taurine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +5698-6;Molybdenum;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Molybdenum [Mass/volume] in Serum or Plasma;Molybdenum SerPl-mCnc;;ACTIVE;1.0;2.73 +56986-3;Thyroxine.free^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;T4 Free 1h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56987-1;Thyroxine.free^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;T4 Free 40M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56988-9;Thyroxine.free^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;T4 Free 1.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56989-7;Thyroxine.free^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;T4 Free 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +56990-5;Toxoplasma gondii Ab.IgG avidity;Ratio;Pt;Ser;Qn;IA;MICRO;1;Toxoplasma gondii IgG Ab avidity [Ratio] in Serum by Immunoassay;T gondii IgG Avidity Ser IA-Rto;;ACTIVE;2.29;2.56 +56991-3;Toxoplasma gondii Ab.IgG avidity;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Toxoplasma gondii IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay;T gondii IgG Avidity SerPl Ql IA;;ACTIVE;2.29;2.73 +56992-1;Trichinella sp Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Trichinella sp IgG Ab [Presence] in Serum by Immunofluorescence;Trichinella IgG Ser Ql IF;;ACTIVE;2.29;2.56 +56993-9;Tryptophan/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Tryptophan/Creatinine [Ratio] in 24 hour Urine;Tryptophan/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +5699-4;Molybdenum;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Molybdenum [Mass/volume] in Urine;Molybdenum Ur-mCnc;;ACTIVE;1.0;2.73 +56994-7;Tyrosine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Tyrosine/Creatinine [Ratio] in 24 hour Urine;Tyrosine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56995-4;Urea;MCnc;Pt;Plr fld;Qn;;CHEM;1;Urea [Mass/volume] in Pleural fluid;Urea Plr-mCnc;;ACTIVE;2.29;2.42 +56996-2;Urea/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Urea/Creatinine [Mass Ratio] in 24 hour Urine;Urea/Creat 24h Ur;;ACTIVE;2.29;2.44 +56997-0;Urea/Creatinine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Urea/Creatinine [Mass Ratio] in Serum or Plasma;Urea/Creat SerPl;;ACTIVE;2.29;2.73 +56998-8;Valine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Valine/Creatinine [Ratio] in 24 hour Urine;Valine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +56999-6;Vespa crabro Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;European Hornet IgG4 Ab [Units/volume] in Serum;European Hornet IgG4 Qn;;ACTIVE;2.29;2.69 +57-0;Capreomycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Capreomycin [Susceptibility] by Disk diffusion (KB);Capreomycin Islt KB;;ACTIVE;1.0;2.19 +5700-0;Nickel;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Blood;Nickel Bld-mCnc;;ACTIVE;1.0;2.73 +57000-2;Vespula spp Ab.IgG4;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Jacket IgG4 Ab [Units/volume] in Serum;Yellow Jacket IgG4 Qn;;ACTIVE;2.29;2.69 +57001-0;Yersinia sp Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yersinia sp IgA Ab [Units/volume] in Serum by Immunoassay;Yersinia IgA Ser IA-aCnc;;ACTIVE;2.29;2.69 +57002-8;11-Deoxycortisol^4D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --4 days post XXX challenge;11DC 4D p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +57003-6;17-Hydroxyprogesterone^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;17OHP 4h p chal SerPl-mCnc;;ACTIVE;2.29;2.34 +57004-4;Glucose/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Glucose/Creatinine [Mass Ratio] in 24 hour Urine;Glucose/Creat 24h Ur;;ACTIVE;2.29;2.44 +57005-1;Glutathione;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutathione [Moles/volume] in Serum or Plasma;Glutathione SerPl-sCnc;;ACTIVE;2.29;2.40 +57006-9;Hepatitis C virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Hepatitis C virus IgG Ab [Units/volume] in Serum by Immunoassay;HCV IgG Ser IA-aCnc;;ACTIVE;2.29;2.69 +57007-7;Insulin^52H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --52 hours post XXX challenge;Insulin 52h p chal SerPl-aCnc;;ACTIVE;2.29;2.68 +57008-5;Legionella pneumophila Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila IgG Ab [Titer] in Serum by Immunofluorescence --1st specimen;L pneumo IgG sp1 Titr Ser IF;;ACTIVE;2.29;2.32 +57009-3;Mycoplasma pneumoniae Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;M pneumo IgG sp2 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57010-1;Nuclear Ab;PrThr;Pt;Plr fld;Ord;IA;SERO;1;Nuclear Ab [Presence] in Pleural fluid by Immunoassay;ANA Plr Ql IA;;ACTIVE;2.29;2.56 +57011-9;Ornithine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Ornithine/Creatinine [Ratio] in 24 hour Urine;Ornithine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +57012-7;Osteoblasts/100 cells;NFr;Pt;Bone mar;Qn;Manual;HEM/BC;1;Osteoblasts/100 cells in Bone marrow by Manual;Osteoblasts NFr Mar Manual;;ACTIVE;2.29;2.34 +57013-5;Phosphoserine/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Phosphoserine/Creatinine [Ratio] in 24 hour Urine;Phosphoserine/Creat 24h Ur-Rto;;ACTIVE;2.29;2.42 +57014-3;Iron/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Iron/Creatinine [Mass Ratio] in 24 hour Urine;Iron/Creat 24h Ur;;ACTIVE;2.29;2.42 +57015-0;Lactulose.PO;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Lactulose.PO [Mass] of Dose;Lac PO Dose;;ACTIVE;2.29;2.69 +57016-8;Privacy policy acknowledgment;Find;Pt;^Patient;Doc;;DOC.MISC;2;Privacy policy acknowledgment Document;Privacy policy acknowledgment Doc;;ACTIVE;2.29;2.73 +57017-6;Privacy policy;Find;Pt;Organization;Doc;;DOC.MISC;2;Privacy policy Organization Document;Privacy policy Organization Doc;;ACTIVE;2.29;2.73 +5701-8;Nickel;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Nickel [Mass/mass] in Hair;Nickel Hair-mCnt;;ACTIVE;1.0;2.73 +57018-4;Hydrogen/Expired gas^3H post dose lactulose;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3 hours post dose lactulose;Breath H2 3h p lactulose;;ACTIVE;2.29;2.42 +57019-2;Urinalysis dipstick W Reflex Culture panel;-;Pt;Urine;-;;PANEL.UA;1;Urinalysis dipstick W Reflex Culture panel - Urine;UA dipstick W Reflex Culture pnl Ur;;ACTIVE;2.29;2.73 +570-2;Fungus identified;Prid;Pt;Body fld;Nom;Culture;MICRO;1;Fungus identified in Body fluid by Culture;Fungus Fld Cult;;ACTIVE;1.0;2.73 +57020-0;Urinalysis dipstick W Reflex Microscopic panel;-;Pt;Urine;-;;PANEL.UA;1;Urinalysis dipstick W Reflex Microscopic panel - Urine;UA dipstick W Reflex Micro pnl Ur;;ACTIVE;2.29;2.73 +57021-8;Complete blood count W Auto Differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;CBC W Auto Differential panel - Blood;CBC W Auto Diff Bld;;ACTIVE;2.29;2.73 +57022-6;Complete blood count W Reflex Manual Differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;CBC W Reflex Manual Differential panel - Blood;CBC W Reflex Manual Diff Bld;;ACTIVE;2.29;2.73 +57023-4;Auto Differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Auto Differential panel - Blood;Auto Diff Pnl Bld;;DISCOURAGED;2.29;2.48 +57024-2;Health Quality Measure document;Find;Pt;^Patient;Doc;;PANEL.DOC;2;Health Quality Measure document;HQM document;;ACTIVE;2.29;2.63 +57025-9;Data criteria;Find;Pt;^Patient;Nar;;DOC.QUALITY;2;Data criteria Narrative;Data criteria;;ACTIVE;2.29;2.68 +5702-6;Nickel;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Serum or Plasma;Nickel SerPl-mCnc;;ACTIVE;1.0;2.73 +57026-7;Population criteria;Find;Pt;^Patient;Nar;;DOC.QUALITY;2;Population criteria Narrative;Population criteria;;ACTIVE;2.29;2.68 +57027-5;Measure observations;Find;Pt;^Patient;Nar;;DOC.QUALITY;2;Measure observations Narrative;Measure observations;;ACTIVE;2.29;2.68 +57028-3;Iron;MCnt;Pt;Liver;Qn;;CHEM;1;Iron [Mass/mass] in Liver;Iron Liver-mCnt;;ACTIVE;2.29;2.73 +57029-1;Fetal chromosome 13+18+21+X+Y aneuploidy;Find;Pt;Tiss^Fetus;Nom;Molgen;MOLPATH;1;Fetal chromosome 13+18+21+X+Y aneuploidy in Tissue by Molecular genetics method Nominal;Chr 13+18+21+X+Y aneup Tiss Fetus;;ACTIVE;2.29;2.66 +57030-9;Chromosome 13+18+21+X+Y aneuploidy;Find;Pt;Bld;Nom;Molgen;MOLPATH;1;Chromosome 13+18+21+X+Y aneuploidy in Blood by Molecular genetics method Nominal;Chr 13+18+21+X+Y aneup Bld;;ACTIVE;2.29;2.66 +57031-7;Herpesviruses 6 DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Herpesviruses 6 DNA panel - Specimen by NAA with probe detection;Herpesviruses 6 DNA pnl Spec NAA+probe;;ACTIVE;2.29;2.69 +57032-5;Treponema pallidum Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Treponema pallidum Ab [Presence] in Serum by Immunoblot;T pallidum Ab Ser Ql IB;;ACTIVE;2.29;2.58 +57033-3;Alternaria alternata Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Alternaria alternata Ab [Presence] in Serum by Immune diffusion (ID);A alternata Ab Ser Ql ID;;ACTIVE;2.29;2.56 +5703-4;Nickel;MRat;24H;Stool;Qn;;DRUG/TOX;1;Nickel [Mass/time] in 24 hour Stool;Nickel 24h Stl-mRate;;ACTIVE;1.0;2.42 +57034-1;Penicillium sp Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Penicillium sp Ab [Presence] in Serum by Immune diffusion (ID);Penicillium Ab Ser Ql ID;;ACTIVE;2.29;2.56 +57035-8;Cow milk Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Cow milk Ab [Presence] in Serum by Immune diffusion (ID);Cow Milk Ab Ql ID;;ACTIVE;2.29;2.56 +57036-6;Phadiatop inhalant allergen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phadiatop inhalant allergen IgE Ab [Units/volume] in Serum;Phadiatop inhalant allergen IgE Qn;;ACTIVE;2.29;2.73 +57037-4;Chromosome 13+18+21+X+Y aneuploidy;Find;Pt;Amnio fld;Nom;Molgen;MOLPATH;1;Chromosome 13+18+21+X+Y aneuploidy in Amniotic fluid by Molecular genetics method Nominal;Chr 13+18+21+X+Y aneup Amn;;ACTIVE;2.29;2.66 +57038-2;Chromosome 12 aneuploidy;Find;Pt;Amnio fld/CVS;Nom;FISH;MOLPATH;1;Chromosome 12 aneuploidy in Amniotic fluid or Chorionic villus sample by FISH Nominal;Chr 12 aneup Amn/CVS FISH;;ACTIVE;2.29;2.68 +57039-0;Outcome and assessment information set (OASIS) form - version C;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version C;;;DEPRECATED;2.29;2.73 +57040-8;Clinical record items;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Clinical Record Items [CMS Assessment];;;ACTIVE;2.29;2.67 +57041-6;Patient history and diagnoses;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Patient history and diagnoses;;;ACTIVE;2.29;2.73 +5704-2;Nickel;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nickel [Presence] in Urine;Nickel Ur Ql;;ACTIVE;1.0;2.56 +57042-4;Sensory status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Sensory status [CMS Assessment];;;ACTIVE;2.29;2.61 +57043-2;Living arrangements;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Living arrangements;;;ACTIVE;2.29;2.68 +57044-0;Integumentary status;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Integumentary status;;;ACTIVE;2.29;2.68 +57045-7;Cardiac status;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Cardiac status;;;ACTIVE;2.29;2.63 +57046-5;Elimination status;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Elimination status;;;ACTIVE;2.29;2.68 +57047-3;Neuro & emotional & behavioral status - start of care or resumption of care;-;-;^Patient;-;;PANEL.SURVEY.CMS;4;Neuro and emotional and behavioral status - SOC or ROC;;;ACTIVE;2.29;2.63 +57048-1;ADL & IADLs;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;ADL and IADLs;;;ACTIVE;2.29;2.68 +57049-9;Care management;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Care management [CMS Assessment];;;ACTIVE;2.29;2.61 +57050-7;Therapy need and plan of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Therapy need and plan of care [CMS Assessment];;;ACTIVE;2.29;2.61 +57051-5;Data items collected at inpatient facility admission or agency discharge only;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Data items collected at inpatient facility admission or agency discharge only;;;ACTIVE;2.29;2.68 +57052-3;Emergent care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Emergent care [CMS Assessment];;;ACTIVE;2.29;2.67 +57053-1;Note;Find;Pt;Emergency department;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Emergency department Note;Nurse ED Note;;ACTIVE;2.29;2.68 +57054-9;Triage+Care note;Find;Pt;Emergency department;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Emergency department Triage+care note;Nurse ED Triage+care note;;ACTIVE;2.29;2.67 +57055-6;Antepartum summary note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Antepartum summary note;Antepartum note;;ACTIVE;2.29;2.67 +57056-4;Labor and delivery admission history and physical note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Labor and delivery admission history and physical note;L&D admin H&P note;;ACTIVE;2.29;2.67 +57057-2;Labor and delivery summary note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Labor and delivery summary note;L&D summary note;;ACTIVE;2.29;2.67 +57058-0;Maternal discharge summary note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Deprecated Maternal discharge summary note;Deprecated Mat dischrg sum note;;DEPRECATED;2.29;2.73 +5705-9;Nickel;MRat;24H;Urine;Qn;;DRUG/TOX;1;Nickel [Mass/time] in 24 hour Urine;Nickel 24h Ur-mRate;;ACTIVE;1.0;2.73 +57059-8;Pregnancy visit summary note;Find;Pt;^Patient;Nar;;DOC.MISC;2;Pregnancy visit summary note Narrative;Pregnancy visit summary;;ACTIVE;2.29;2.73 +57060-6;Estimated date of delivery;Find;Pt;^Patient;Nar;;CLIN;2;Estimated date of delivery Narrative;Est date of delivery;;ACTIVE;2.29;2.73 +57061-4;Antepartum flowsheet panel;Find;Pt;^Patient;Nar;;CLIN;2;Antepartum flowsheet panel Narrative;Antepartum flowsheet Pnl;;ACTIVE;2.29;2.50 +57062-2;Births.stillborn;Num;Pt;^Patient;Qn;Reported;OB.US;2;[#] Births.stillborn;Births.stillborn;;ACTIVE;2.29;2.48 +57063-0;Delivery date;Date;Pt;^Patient;Qn;Estimated from quickening date;OB.US;2;Delivery date Estimated from quickening date;Deliv date Est from quickening date;;ACTIVE;2.29;2.50 +57064-8;Delivery date;Date;Pt;^Patient;Qn;Estimated from date fundal height reaches umb;OB.US;2;Delivery date Estimated from date fundal height reaches umb;Deliv date Est from date FH reaches umb;;ACTIVE;2.29;2.50 +57065-5;Quickening date;Date;Pt;^Patient;Qn;Reported;OB.US;2;Quickening date;Quickening date;;ACTIVE;2.29;2.50 +57066-3;Date fundal height reaches umbilicus;Date;Pt;^Patient;Qn;;OB.US;2;Date fundal height reaches umbilicus;Date fundal height reaches umbilicus;;ACTIVE;2.29;2.50 +5706-7;Opiates;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Opiates [Identifier] in Urine;Opiates Ur;;ACTIVE;1.0;2.73 +57067-1;Body weight;Mass;Pt;^Fetus;Qn;Estimated by palpation;OB.US;2;Fetal Body weight Estimated by palpation;Fet Weight Est by palpation;;ACTIVE;2.29;2.48 +57068-9;Heart rate;NRat;Pt;^Fetus;Qn;Auscultation;H&P.HX;2;Fetal Heart rate by Auscultation;Fet Heart rate Auscultation;;ACTIVE;2.29;2.54 +57069-7;Preterm labor symptoms;Find;Pt;^Patient;Nom;;H&P.HX;2;Preterm labor symptoms;Preterm labor symptoms;;ACTIVE;2.29;2.73 +57070-5;Date next clinic visit;Date;Pt;^Patient;Qn;;H&P.HX;2;Date next clinic visit;Date next clinic visit;;ACTIVE;2.29;2.50 +57071-3;Obstetric delivery method;Find;Pt;^Patient;Nom;;H&P.HX;2;Obstetric delivery method;Obstetric delivery method;;ACTIVE;2.29;2.29 +57072-1;Intravenous fluids administered;Find;Pt;^Patient;Nar;;H&P.PX;2;Intravenous fluids administered Narrative;IV fluids administered;;ACTIVE;2.29;2.63 +57073-9;Prenatal records;Find;Pt;^Patient;Doc;;H&P.PX;2;Prenatal records;Prenatal records;;ACTIVE;2.29;2.66 +57074-7;Labor and delivery process;Find;Pt;^Patient;Nar;;H&P.PX;2;Labor and delivery process Narrative;L&D process;;ACTIVE;2.29;2.63 +5707-5;Opiates;Prid;Pt;Urine;Nom;;DRUG/TOX;1;Deprecated Opiates [Identifier] in Urine;Deprecated Opiates Ur;;DEPRECATED;1.0;2.36 +57075-4;Newborn delivery information;Find;Pt;^Newborn;Doc;;H&P.PX;2;Newborn delivery information;NB delivery information;;ACTIVE;2.29;2.68 +57076-2;Postpartum hospitalization treatment;Find;Pt;^Patient;Nar;;H&P.PX;2;Postpartum hospitalization treatment Narrative;Postpartum hospitalization treatment;;ACTIVE;2.29;2.63 +57077-0;Newborn status at maternal discharge;Find;Pt;^Newborn;Nar;;H&P.PX;2;Newborn status at maternal discharge from Newborn Narrative;NB status at maternal discharge NB;;ACTIVE;2.29;2.63 +57078-8;Antenatal testing and surveillance;Find;Pt;^Patient;Nar;;H&P.PX;2;Antenatal testing and surveillance Narrative;Antenatal testing & surveillance;;ACTIVE;2.29;2.63 +57079-6;Birth plan;Find;Pt;^Patient;Nar;;H&P.PX;2;Birth plan Narrative;Birth plan;;ACTIVE;2.29;2.73 +57080-4;Implanted medical device;Find;Pt;^Patient;Nar;;H&P.PX;2;Implanted medical device Narrative;Implanted medical device;;ACTIVE;2.29;2.63 +57081-2;Anesthesia risk review of systems;Find;Pt;^Patient;Nar;;H&P.PX;2;Anesthesia risk review of systems Narrative;Anesthesia risk review of systems;;ACTIVE;2.29;2.63 +57082-0;Antepartum record panel;-;Pt;^Patient;-;;PANEL.DOC;2;Antepartum record panel;Antepartum record Pnl;;ACTIVE;2.29;2.50 +5708-3;Paraquat;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Paraquat [Mass/volume] in Blood;Paraquat Bld-mCnc;;ACTIVE;1.0;2.42 +57083-8;Labor and Delivery record panel;-;Pt;^Patient;-;;PANEL.DOC;2;Labor and Delivery record panel;Labor and Delivery record;;ACTIVE;2.29;2.29 +57084-6;Fatty acid oxidation newborn screen panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Fatty acid oxidation newborn screen panel;FA oxidation NB scn pnl DBS;;ACTIVE;2.29;2.73 +57085-3;Organic acid newborn screen panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Organic acid newborn screen panel;OA NB scn pnl DBS;;ACTIVE;2.29;2.40 +57086-1;Congenital adrenal hyperplasia newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Congenital adrenal hyperplasia newborn screening panel;CAH NB scn pnl DBS;;ACTIVE;2.29;2.40 +57087-9;Biotinidase newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Biotinidase newborn screening panel;BIO NB scn pnl DBS;;ACTIVE;2.29;2.40 +57088-7;Movement;Find;Pt;^Fetus;Ord;Reported;H&P.HX;2;Fetal Movement - Reported;Fet Movement Reported;;ACTIVE;2.29;2.29 +57089-5;Eosinophil cationic protein;MCnc;Pt;Nasal fluid;Qn;;ALLERGY;1;Eosinophil cationic protein (ECP) [Mass/volume] in Nasal fluid;ECP Nasal fluid-mCnc;;ACTIVE;2.29;2.42 +57090-3;HLA-DQA1*05:01;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQA1*05:01 [Presence];HLA-DQA1*05:01 Ql;;ACTIVE;2.29;2.73 +5709-1;Paraquat;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Paraquat [Mass/volume] in Serum or Plasma;Paraquat SerPl-mCnc;;ACTIVE;1.0;2.42 +57091-1;HLA-DQB1*02:01;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQB1*02:01 [Presence];HLA-DQB1*02:01 Ql;;ACTIVE;2.29;2.73 +57092-9;IgE;ACnc;Pt;Nasal fluid;Qn;;CHEM;1;IgE [Units/volume] in Nasal fluid;IgE Nasal fluid-aCnc;;ACTIVE;2.29;2.68 +57093-7;Cyclic citrullinated peptide Ab.IgA+IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Cyclic citrullinated peptide IgA+IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;cCP IgA+IgG SerPl IA-aCnc;;ACTIVE;2.29;2.73 +57094-5;Phenol^^adjusted to specific gravity 1.024;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenol [Mass/volume] adjusted to specific gravity 1.024 in Urine;Phenol adj SG 1.024 Ur-mCnc;;ACTIVE;2.29;2.73 +57095-2;Anidulafungin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Anidulafungin [Susceptibility];Anidulafungin Susc Islt;;ACTIVE;2.29;2.73 +57096-0;HPA 1a-1a+HPA 3a-3a;PrThr;Pt;Bld;Ord;;HPA;1;HPA 1a/1a+HPA 3a/3a [Presence] in Blood;HPA 1a/1a+HPA 3a-/3a Bld Ql;;ACTIVE;2.29;2.73 +57097-8;Follitropin^10M pre dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --10 minutes pre dose gonadotropin releasing hormone;FSH 10M pre GnRH SerPl-aCnc;;ACTIVE;2.29;2.70 +57098-6;Follitropin^1.5H post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1.5 hours post dose gonadotropin releasing hormone;FSH 1.5h p GnRH SerPl-aCnc;;ACTIVE;2.29;2.73 +57099-4;Follitropin^1H post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --1 hour post dose gonadotropin releasing hormone;FSH 1h p GnRH SerPl-aCnc;;ACTIVE;2.29;2.73 +571-0;Fungus identified;Prid;Pt;Hair;Nom;Culture;MICRO;1;Fungus identified in Hair by Culture;Fungus Hair Cult;;ACTIVE;1.0;2.19 +57100-0;Follitropin^30M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --30 minutes post dose gonadotropin releasing hormone;FSH 30M p GnRH SerPl-aCnc;;ACTIVE;2.29;2.73 +57101-8;Follitropin^20M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --20 minutes post dose gonadotropin releasing hormone;FSH 20M p GnRH SerPl-aCnc;;ACTIVE;2.29;2.70 +57102-6;Lutropin^2H post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --2 hours post dose gonadotropin releasing hormone;LH 2h p GnRH SerPl-aCnc;;ACTIVE;2.29;2.70 +57103-4;Lutropin^1.5H post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1.5 hours post dose gonadotropin releasing hormone;LH 1.5h p GnRH SerPl-aCnc;;ACTIVE;2.29;2.70 +57104-2;Lutropin^1H post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --1 hour post dose gonadotropin releasing hormone;LH 1h p GnRH SerPl-aCnc;;ACTIVE;2.29;2.70 +57105-9;Lutropin^30M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --30 minutes post dose gonadotropin releasing hormone;LH 30M p GnRH SerPl-aCnc;;ACTIVE;2.29;2.68 +57106-7;Lutropin^20M post dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --20 minutes post dose gonadotropin releasing hormone;LH 20M p GnRH SerPl-aCnc;;ACTIVE;2.29;2.70 +57107-5;Lutropin^10M pre dose gonadotropin releasing hormone;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --10 minutes pre dose gonadotropin releasing hormone;LH 10M pre GnRH SerPl-aCnc;;ACTIVE;2.29;2.70 +57108-3;Macular grid.center point thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.center point thickness by OCT;Macular grid.CP thickness OCT;;ACTIVE;2.29;2.70 +5710-9;Pentachlorophenol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pentachlorophenol [Mass/volume] in Serum or Plasma;Pentachlorophen SerPl-mCnc;;ACTIVE;1.0;2.42 +57109-1;Macular grid.center subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.center subfield thickness by OCT;Macular grid.CS thickness OCT;;ACTIVE;2.29;2.70 +57110-9;Macular grid.inner superior subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.inner superior subfield thickness by OCT;Macular grid.ISS thickness OCT;;ACTIVE;2.29;2.70 +57111-7;Macular grid.inner nasal subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.inner nasal subfield thickness by OCT;Macular grid.INS thickness OCT;;ACTIVE;2.29;2.70 +57112-5;Macular grid.inner inferior subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.inner inferior subfield thickness by OCT;Macular grid.IIS thickness OCT;;ACTIVE;2.29;2.70 +57113-3;Macular grid.inner temporal subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.inner temporal subfield thickness by OCT;Macular grid.ITS thickness OCT;;ACTIVE;2.29;2.70 +57114-1;Macular grid.outer superior subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.outer superior subfield thickness by OCT;Macular grid.OSS thickness OCT;;ACTIVE;2.29;2.70 +57115-8;Macular grid.outer nasal subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.outer nasal subfield thickness by OCT;Macular grid.ONS thickness OCT;;ACTIVE;2.29;2.70 +57116-6;Macular grid.outer inferior subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.outer inferior subfield thickness by OCT;Macular grid.OIS thickness OCT;;ACTIVE;2.29;2.70 +5711-7;Pentachlorophenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pentachlorophenol [Mass/volume] in Urine;Pentachlorophen Ur-mCnc;;ACTIVE;1.0;2.73 +57117-4;Macular grid.outer temporal subfield thickness;Len;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.outer temporal subfield thickness by OCT;Macular grid.OTS thickness OCT;;ACTIVE;2.29;2.70 +57118-2;Macular grid.total volume;Vol;Pt;Eye;Qn;OCT;EYE.OCT;2;Macular grid.total volume by OCT;Macular grid.total vol OCT;;ACTIVE;2.29;2.70 +57119-0;Optical coherence tomography panel;-;Pt;Eye;Qn;OCT;PANEL.EYE;2;Optical coherence tomography panel;Optical coherence tomography Pnl;;ACTIVE;2.29;2.72 +57120-8;Type of nursing provider;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Type of nursing provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.68 +57121-6;Type of client;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Type of client [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.50 +57122-4;Type of encounter;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Type of encounter [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.50 +57123-2;Hours designated;Time;Pt;{Nursing unit};Qn;Estimate;SURVEY.NMMDS;4;Hours designated [Estimate];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.70 +57124-0;Care capacity;Num;Pt;{Nursing unit};Qn;Estimate;SURVEY.NMMDS;4;Care capacity # [Estimate];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.52 +5712-5;Pentachlorophenol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Pentachlorophenol [Mass/volume] in Urine;Deprecated Pentachlorophen Ur-mCnc;;DEPRECATED;1.0;2.36 +57125-7;Care provided;Num;Pt;{Nursing unit};Qn;;SURVEY.NMMDS;4;Care provided #;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.52 +57126-5;Volume of nursing delivery unit or service panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Volume of nursing delivery unit or service panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.52 +57127-3;Method of care delivery;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Method of care delivery [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.29;2.50 +57128-1;Newborn Screening Report summary panel;-;Pt;^Patient;-;;PANEL.CHEM;1;Newborn Screening Report summary panel;NBS report summary pnl Patient;;ACTIVE;2.29;2.73 +57129-9;Full newborn screening summary report for display or printing;-;Pt;^Patient;Doc;;CHEM;1;Full newborn screening summary report for display or printing;Full NBS summary for display/printing;;ACTIVE;2.29;2.38 +57130-7;Newborn screening report - overall interpretation;Imp;Pt;^Patient;Nom;;CHEM;1;Newborn screening report - overall interpretation;NBS report - overall interp;;ACTIVE;2.29;2.73 +57131-5;Newborn conditions with positive markers;Prid;Pt;Bld.dot;Nom;;CHEM;1;Newborn conditions with positive markers [Identifier] in DBS;NB conditions positive DBS;;ACTIVE;2.29;2.73 +57132-3;CYP2C19 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP2C19 allele Geno Bld/T;;ACTIVE;2.29;2.73 +5713-3;Platinum;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Platinum [Mass/mass] in Hair;Platinum Hair-mCnt;;ACTIVE;1.0;2.40 +57133-1;Referral note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Referral note;Referral note;;ACTIVE;2.29;2.67 +57134-9;Referral note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Referral note;Dentistry Referral note;;ACTIVE;2.29;2.67 +57135-6;Referral note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Referral note;Dermatology Referral note;;ACTIVE;2.29;2.67 +57136-4;Referral note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Referral note;Diabetology Referral note;;ACTIVE;2.29;2.67 +57137-2;Referral note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Referral note;Endocrinology Referral note;;ACTIVE;2.29;2.67 +57138-0;Referral note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Referral note;Gastroenterology Referral note;;ACTIVE;2.29;2.67 +57139-8;Referral note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Referral note;General medicine Referral note;;ACTIVE;2.29;2.67 +57140-6;Referral note;Find;Pt;{Setting};Doc;General surgery;DOC.ONTOLOGY;2;Deprecated General surgery Referral note;Deprecated General surgery Referral note;;DEPRECATED;2.29;2.73 +5714-1;Platinum;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Platinum [Mass/volume] in Serum or Plasma;Platinum SerPl-mCnc;;ACTIVE;1.0;2.73 +57141-4;Referral note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Referral note;Infectious disease Referral note;;ACTIVE;2.29;2.67 +57142-2;Referral note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Referral note;Kinesiotherapy Referral note;;ACTIVE;2.29;2.67 +57143-0;Referral note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Referral note;Mental health Referral note;;ACTIVE;2.29;2.67 +57144-8;Referral note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Referral note;Nephrology Referral note;;ACTIVE;2.29;2.67 +57145-5;Referral note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Referral note;Neurology Referral note;;ACTIVE;2.29;2.67 +57146-3;Referral note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Referral note;Neuro surgery Referral note;;ACTIVE;2.29;2.67 +57147-1;Referral note;Find;Pt;{Setting};Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine Referral note;Occup med Referral note;;ACTIVE;2.29;2.67 +57148-9;Referral note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Referral note;OT Referral note;;ACTIVE;2.29;2.67 +57149-7;Referral note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Referral note;Oncology Referral note;;ACTIVE;2.29;2.67 +57150-5;Referral note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Referral note;Ophthalmol Referral note;;ACTIVE;2.29;2.67 +57151-3;Referral note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Referral note;Optometry Referral note;;ACTIVE;2.29;2.67 +57152-1;Referral note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Referral note;Pharmacology Referral note;;ACTIVE;2.29;2.67 +57153-9;Referral note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Referral note;PM+R Referral note;;ACTIVE;2.29;2.67 +57154-7;Referral note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Referral note;PT Referral note;;ACTIVE;2.29;2.67 +57155-4;Referral note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Referral note;Plastic surgery Referral note;;ACTIVE;2.29;2.67 +57156-2;Referral note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Referral note;Podiatry Referral note;;ACTIVE;2.29;2.67 +57157-0;Referral note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Referral note;Psychiatric Referral note;;ACTIVE;2.29;2.67 +5715-8;Platinum;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Platinum [Mass/volume] in Urine;Platinum Ur-mCnc;;ACTIVE;1.0;2.42 +57158-8;Referral note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Referral note;Psych Referral note;;ACTIVE;2.29;2.67 +57159-6;Referral note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Referral note;Radiation Onc Referral note;;ACTIVE;2.29;2.67 +57160-4;Referral note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Referral note;Rec therapy Referral note;;ACTIVE;2.29;2.67 +57161-2;Referral note;Find;Pt;{Setting};Doc;Rehabilitation;DOC.ONTOLOGY;2;Deprecated Rehabilitation Referral note;Deprecated Rehabilitation Referral note;;DEPRECATED;2.29;2.73 +57162-0;Referral note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Referral note;Resp therapy Referral note;;ACTIVE;2.29;2.67 +57163-8;Referral note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Referral note;Rheumatology Referral note;;ACTIVE;2.29;2.67 +57164-6;Referral note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Referral note;SW Referral note;;ACTIVE;2.29;2.67 +57165-3;Referral note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Referral note;Speech-lang path Referral note;;ACTIVE;2.29;2.67 +5716-6;Polychlorinated biphenyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Mass/volume] in Serum or Plasma;PCB SerPl-mCnc;;ACTIVE;1.0;2.73 +57166-1;Referral note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Referral note;Surgery Referral note;;ACTIVE;2.29;2.67 +57167-9;Referral note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Referral note;Cardiothor surg Referral note;;ACTIVE;2.29;2.67 +57168-7;Referral note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Referral note;Urology Referral note;;ACTIVE;2.29;2.67 +57169-5;Referral note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Referral note;Vascular surgery Referral note;;ACTIVE;2.29;2.67 +57170-3;Referral note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Referral note;Cardiology Referral note;;ACTIVE;2.29;2.67 +57171-1;Referral note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Referral note;Geri med Referral note;;ACTIVE;2.29;2.67 +57172-9;Referral note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Referral note;HemOnc Referral note;;ACTIVE;2.29;2.67 +57173-7;Referral note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Referral note;Nutr+diet Referral note;;ACTIVE;2.29;2.67 +5717-4;Polychlorinated biphenyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Mass/volume] in Urine;PCB Ur-mCnc;;ACTIVE;1.0;2.46 +57174-5;Referral note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Referral note;OMS Referral note;;ACTIVE;2.29;2.67 +57175-2;Referral note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Referral note;Orthopaedic surgery Referral note;;ACTIVE;2.29;2.67 +57176-0;Referral note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Referral note;Otolaryngology Referral note;;ACTIVE;2.29;2.67 +57177-8;Referral note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Referral note;Pulmonary disease Referral note;;ACTIVE;2.29;2.67 +57178-6;Referral note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Referral note;CCM Referral note;;ACTIVE;2.29;2.67 +57179-4;Referral note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Referral note;OBGYN Referral note;;DISCOURAGED;2.29;2.67 +57180-2;Neisseria gonorrhoeae DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Nasopharynx by NAA with probe detection;N gonorrhoea DNA Nph Ql NAA+probe;;ACTIVE;2.29;2.73 +57181-0;Lupus anticoagulant neutralization.dilute phospholipid/Lupus anticoagulant neutralization.high phospholipid;Ratio;Pt;PPP;Qn;Coag;COAG;1;Lupus anticoagulant neutralization dilute phospholipid/Lupus anticoagulant neutralization.high phospholipid [Ratio] in Platelet poor plasma by Coagulation assay;LA Nt dPL/LA Nt HPL PPP-Rto;;DISCOURAGED;2.29;2.73 +5718-2;Rubidium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Rubidium [Mass/volume] in Blood;Rubidium Bld-mCnc;;ACTIVE;1.0;2.42 +57182-8;HIV 1 RNA tropism;Prid;Pt;Plas;Nar;;ABXBACT;1;HIV 1 RNA tropism [Identifier] in Plasma Narrative;HIV1 RNA tropism Plas;;ACTIVE;2.29;2.73 +57183-6;Inpatient procedure relevant to plan of care;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Inpatient procedure relevant to plan of care;;;ACTIVE;2.29;2.68 +57184-4;Risk of developing pressure injuries;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Deprecated Risk of developing pressure injuries [OASIS];;;DEPRECATED;2.29;2.73 +57185-1;Current number of unhealed pressure ulcers;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Current number of unhealed pressure ulcers;;;ACTIVE;2.29;2.69 +57186-9;Number of pressure injuries at each stage;-;Pt;^Patient;Set;;PANEL.SURVEY.OASIS;4;Number of pressure injuries at each stage Set;;;ACTIVE;2.29;2.68 +57187-7;Number of pressure injuries present at admission;-;Pt;^Patient;Set;;PANEL.SURVEY.OASIS;4;Number of pressure injuries present at admission Set;;;ACTIVE;2.29;2.68 +57188-5;Stage 3 or 4 pressure injury with largest surface dimensions;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Stage 3 or 4 pressure injury with largest surface dimensions;;;ACTIVE;2.29;2.68 +57189-3;Medication follow-up;Find;Pt;^Patient;Ord;OASIS;SURVEY.OASIS;4;Deprecated Medication follow-up [OASIS];;;DEPRECATED;2.29;2.70 +5719-0;Rubidium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Rubidium [Mass/mass] in Hair;Rubidium Hair-mCnt;;ACTIVE;1.0;2.42 +57190-1;Outcome and assessment information set (OASIS) form - version C - Start of care;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version C - Start of care;;;DEPRECATED;2.29;2.73 +57191-9;Outcome and assessment information set (OASIS) form - version C - Resumption of Care;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version C - Resumption of Care;;;DEPRECATED;2.29;2.73 +57192-7;Outcome and assessment information set (OASIS) form - version C - Follow-Up;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version C - Follow-Up;;;DEPRECATED;2.29;2.73 +57193-5;Outcome and assessment information set (OASIS) form - version C - Transfer to facility;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version C - Transfer to facility;;;DEPRECATED;2.29;2.73 +57194-3;Outcome and assessment information set (OASIS) form - version C - Discharge from agency;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version C - Discharge from agency;;;DEPRECATED;2.29;2.73 +57195-0;Patient &or caregiver drug education intervention;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Patient/caregiver drug education intervention [CMS Assessment];;;ACTIVE;2.29;2.61 +57196-8;Prior medication management;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Prior medication management [CMS Assessment];;;ACTIVE;2.29;2.61 +57197-6;Plan of care synopsis;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Plan of care synopsis [CMS Assessment];;;ACTIVE;2.29;2.61 +57198-4;Intervention synopsis;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Intervention synopsis;;;ACTIVE;2.29;2.67 +57199-2;Current payment sources for home care;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Current payment sources for home care [CMS Assessment];;;ACTIVE;2.29;2.63 +57200-8;Reason for assessment;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Reason for assessment [CMS Assessment];;;ACTIVE;2.29;2.61 +57201-6;Date of Physician-ordered Start of Care (Resumption of Care);Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Date of Physician-ordered Start of Care (Resumption of Care) [CMS Assessment];;;ACTIVE;2.29;2.61 +57202-4;Date of Referral;Date;Pt;^Patient;Qn;;SURVEY.CMS;4;Date of Referral;;;ACTIVE;2.29;2.63 +57203-2;Episode Timing;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Episode Timing [CMS Assessment];;;ACTIVE;2.29;2.61 +57204-0;Inpatient discharge facility within the past 14D;Type;14D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Inpatient discharge facility within the past 14 days [CMS Assessment];;;ACTIVE;2.29;2.63 +57205-7;Inpatient stay within last 14D - ICD code;Prid;14D;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Inpatient stay within last 14 days - ICD code [OASIS-C];;;ACTIVE;2.29;2.54 +57206-5;Overall status;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Overall status [CMS Assessment];;;ACTIVE;2.29;2.61 +57207-3;Risk factors affecting health status and or outcome;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Risk factors affecting health status and or outcome [CMS Assessment];;;ACTIVE;2.29;2.73 +5720-8;Rubidium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Rubidium [Mass/volume] in Serum or Plasma;Rubidium SerPl-mCnc;;ACTIVE;1.0;2.42 +57208-1;Influenza virus vaccination received;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Influenza vaccination received in Reporting Period [CMS Assessment];;;ACTIVE;2.29;2.67 +57209-9;Reason influenza virus vaccine not received;Find;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Deprecated Reason influenza virus vaccine not received [OASIS-C];;;DEPRECATED;2.29;2.73 +57210-7;Pneumococcal vaccine;Find;Pt;^Patient;Ord;OASIS-C;SURVEY.OASIS;4;Pneumococcal vaccine [OASIS-C];;;ACTIVE;2.29;2.44 +57211-5;Reason pneumococcal vaccine not given;Find;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Reason pneumococcal vaccine not given [OASIS-C];;;ACTIVE;2.29;2.48 +57212-3;Patient lives alone;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Patient lives alone [CMS Assessment];;;ACTIVE;2.29;2.61 +57213-1;Patient lives with other person;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Patient lives with other person [CMS Assessment];;;ACTIVE;2.29;2.61 +57214-9;Patient lives in congregated situtation;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Patient lives in congregated situtation [CMS Assessment];;;ACTIVE;2.29;2.61 +57215-6;Vision;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Vision [CMS Assessment];;;ACTIVE;2.29;2.61 +5721-6;Rubidium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Rubidium [Mass/volume] in Urine;Rubidium Ur-mCnc;;ACTIVE;1.0;2.42 +57216-4;Ability to hear;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Ability to hear [CMS Assessment];;;ACTIVE;2.29;2.61 +57217-2;Understanding of verbal content;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Understanding of verbal content [CMS Assessment];;;ACTIVE;2.29;2.61 +57218-0;Speech and oral expression of language;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Speech and oral expression of language [CMS Assessment];;;ACTIVE;2.29;2.61 +57219-8;Formal pain assessment using standardized tool;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Formal pain assessment using standardized tool [CMS Assessment];;;ACTIVE;2.29;2.61 +57220-6;Frequency of pain interfering with activity or movement;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Frequency of pain interfering with activity or movement [CMS Assessment];;;ACTIVE;2.29;2.63 +57221-4;Pressure injury assessment was conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Pressure injury assessment was conducted [CMS Assessment];;;ACTIVE;2.29;2.63 +57222-2;Oldest non-epithelialized stage 2 pressure injury present at discharge;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Oldest non-epithelialized stage 2 pressure injury present at discharge [CMS Assessment];;;ACTIVE;2.29;2.63 +57223-0;Number of pressure ulcers - unstageable due to non-removable dressing or device;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers - unstageable due to non-removable dressing or device OASIS-C;;;DEPRECATED;2.29;2.36 +5722-4;Selenium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Blood;Selenium Bld-mCnc;;ACTIVE;1.0;2.73 +57224-8;Number of pressure ulcers - unstageable due to coverage of wound bed by slough and or eschar;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers - unstageable due to coverage of wound bed by slough and or eschar OASIS-C;;;DEPRECATED;2.29;2.36 +57225-5;Number of pressure ulcers - unstageable suspected deep tissue injury in evolution;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers - unstageable suspected deep tissue injury in evolution OASIS-C;;;DEPRECATED;2.29;2.36 +57226-3;Diameter.long;Len;Pt;Pressure injury.largest stage 3 or 4;Qn;OASIS-C;SURVEY.OASIS;4;Longitudinal diameter Pressure injury.largest stage 3 or 4 [OASIS-C];;;ACTIVE;2.29;2.63 +57227-1;Pressure ulcer width;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Pressure ulcer width OASIS-C;;;DEPRECATED;2.29;2.36 +57228-9;Depth;Len;Pt;Pressure injury.largest stage 3 or 4;Qn;CMS Assessment;SURVEY.CMS;4;Depth Pressure injury.largest stage 3 or 4 [CMS Assessment];;;ACTIVE;2.29;2.63 +57229-7;Status of most problematic pressure injury;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Status of most problematic pressure injury [CMS Assessment];;;ACTIVE;2.29;2.63 +57230-5;Current number of stage 1 pressure ulcers;Find;Pt;^Patient;Ord;OASIS-C;SURVEY.OASIS;4;Deprecated Current number of stage 1 pressure ulcers OASIS;;;DEPRECATED;2.29;2.36 +57231-3;Stage of most problematic pressure injury;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Stage of most problematic pressure injury [CMS Assessment];;;ACTIVE;2.29;2.67 +5723-2;Selenium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Red Blood Cells;Selenium RBC-mCnc;;ACTIVE;1.0;2.73 +57232-1;Stasis pressure injury;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Stasis ulcer [CMS Assessment];;;ACTIVE;2.29;2.73 +57233-9;Number of stasis ulcers;Num;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Number of stasis ulcers [CMS Assessment];;;ACTIVE;2.29;2.61 +57234-7;Status of most problematic stasis pressure injury;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Status of most problematic stasis pressure injury [CMS Assessment];;;ACTIVE;2.29;2.73 +57235-4;Surgical wound;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Surgical wound [CMS Assessment];;;ACTIVE;2.29;2.63 +57236-2;Status of most problematic surgical wound;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Status of most problematic surgical wound [CMS Assessment];;;ACTIVE;2.29;2.61 +57237-0;Exertion level causing shortness of breath;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Exertion level causing shortness of breath [CMS Assessment];;;ACTIVE;2.29;2.61 +57238-8;Respiratory treatments administered at home;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Respiratory treatments administered at home [CMS Assessment];;;ACTIVE;2.29;2.63 +57239-6;Symptoms in heart failure patients;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Symptoms in heart failure patients [CMS Assessment];;;ACTIVE;2.29;2.61 +5724-0;Selenium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Serum or Plasma;Selenium SerPl-mCnc;;ACTIVE;1.0;2.73 +57240-4;Heart failure follow-up;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Heart failure follow-up [CMS Assessment];;;ACTIVE;2.29;2.61 +57241-2;When urinary incontinence occurs;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;When urinary incontinence occurs [CMS Assessment];;;ACTIVE;2.29;2.61 +57242-0;Standardized depression screening was conducted;Find;Pt;^Patient;Nom;CMS Assessment;PANEL.SURVEY.CMS;4;Standardized depression screening was conducted [CMS Assessment];;;ACTIVE;2.29;2.68 +57243-8;Bathing - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bathing - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.29;2.70 +57244-6;Toilet transferring - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet transferring - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.29;2.70 +57245-3;Toileting hygiene - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toileting hygiene - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.29;2.72 +57246-1;Transferring - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Transferring - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.29;2.70 +57247-9;Locomotion - functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Locomotion - functional ability during assessment period [CMS Assessment];;;ACTIVE;2.29;2.70 +57248-7;Feeding - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Feeding - functional ability [CMS Assessment];;;ACTIVE;2.29;2.61 +57249-5;Prepare light meals - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Prepare light meals - functional ability [CMS Assessment];;;ACTIVE;2.29;2.61 +57250-3;Self-care;Find;Pt;^Patient;Ord;OASIS-C;SURVEY.OASIS;4;Self-care [OASIS-C];;;ACTIVE;2.29;2.44 +57251-1;Ambulation;Find;Pt;^Patient;Ord;OASIS-C;SURVEY.OASIS;4;Ambulation [OASIS-C];;;ACTIVE;2.29;2.44 +57252-9;Transfer;Find;Pt;^Patient;Ord;OASIS-C;SURVEY.OASIS;4;Transfer [OASIS-C];;;ACTIVE;2.29;2.44 +57253-7;Household tasks;Find;Pt;^Patient;Ord;OASIS-C;SURVEY.OASIS;4;Household tasks [OASIS-C];;;ACTIVE;2.29;2.44 +57254-5;Standardized fall risk assessment was conducted;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Standardized fall risk assessment was conducted [CMS Assessment];;;ACTIVE;2.29;2.61 +57255-2;Drug regimen review identified potential medication issues;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Drug regimen review identified potential medication issues [CMS Assessment];;;ACTIVE;2.29;2.61 +57256-0;Medication intervention since admission &or reentry;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication intervention since admission/reentry [CMS Assessment];;;ACTIVE;2.29;2.64 +5725-7;Selenium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Selenium [Mass/mass] in Tissue;Selenium Tiss-mCnt;;ACTIVE;1.0;2.40 +57257-8;Patient &or caregiver received high risk drug education;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Patient/caregiver received high risk drug education [CMS Assessment];;;ACTIVE;2.29;2.61 +57258-6;Oral medication management - prior ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Oral medication management - prior ability [CMS Assessment];;;ACTIVE;2.29;2.61 +57259-4;Injectable medication management - prior ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Injectable medication management - prior ability [CMS Assessment];;;ACTIVE;2.29;2.61 +57260-2;Non-agency caregiver ability and willingness to assist with ADL;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Non-agency caregiver ability and willingness to assist with ADL [CMS Assessment];;;ACTIVE;2.29;2.63 +57261-0;Non-agency caregiver ability and willingness to assist with IADL;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Non-agency caregiver ability and willingness to assist with IADL [CMS Assessment];;;ACTIVE;2.29;2.63 +57262-8;Non-agency caregiver ability and willingness to assist with medication administration;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Non-agency caregiver ability and willingness to assist with medication administration [CMS Assessment];;;ACTIVE;2.29;2.63 +57263-6;Non-agency caregiver ability and willingness to assist with medical procedures &or treatments;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Non-agency caregiver ability and willingness to assist with medical procedures/treatments [CMS Assessment];;;ACTIVE;2.29;2.64 +57264-4;Non-agency caregiver ability and willingness to assist with management of equipment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Non-agency caregiver ability and willingness to assist with management of equipment [CMS Assessment];;;ACTIVE;2.29;2.63 +5726-5;Selenium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Urine;Selenium Ur-mCnc;;ACTIVE;1.0;2.73 +57265-1;Non-agency caregiver ability and willingness to assist with supervision and safety;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Non-agency caregiver ability and willingness to assist with supervision and safety [CMS Assessment];;;ACTIVE;2.29;2.63 +57266-9;Non-agency caregiver ability and willingness to assist with advocacy or facilitation of patient participation;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Non-agency caregiver ability and willingness to assist with advocacy or facilitation of patient participation [CMS Assessment];;;ACTIVE;2.29;2.63 +57267-7;ADL or IADL assistance frequency from any caregiver;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;ADL or IADL assistance frequency from any caregiver [CMS Assessment];;;ACTIVE;2.29;2.63 +57268-5;Therapy need;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Therapy need # [CMS Assessment];;;ACTIVE;2.29;2.61 +57269-3;Plan of care includes patient-specific parameters for notifying physician of changes;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Plan of care includes patient-specific parameters for notifying physician of changes [CMS Assessment];;;ACTIVE;2.29;2.61 +57270-1;Plan of care includes diabetic foot care;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Plan of care includes diabetic foot care [CMS Assessment];;;ACTIVE;2.29;2.61 +57271-9;Plan of care includes fall prevention interventions;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Plan of care includes fall prevention interventions [CMS Assessment];;;ACTIVE;2.29;2.61 +57272-7;Plan of care includes depression intervention;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Plan of care includes depression intervention [CMS Assessment];;;ACTIVE;2.29;2.61 +5727-3;Selenium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Selenium [Mass/time] in 24 hour Urine;Selenium 24h Ur-mRate;;ACTIVE;1.0;2.73 +57273-5;Plan of care includes intervention to monitor and mitigate pain;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Plan of care includes intervention to monitor and mitigate pain [CMS Assessment];;;ACTIVE;2.29;2.61 +57274-3;Plan of care includes intervention to prevent pressure injuries;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Plan of care includes intervention to prevent pressure injuries [CMS Assessment];;;ACTIVE;2.29;2.63 +57275-0;Plan of care includes pressure injury treatment - moist healing;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Plan of care includes pressure injury treatment - moist healing [CMS Assessment];;;ACTIVE;2.29;2.63 +57276-8;Emergent care utilized;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Emergent care utilized [CMS Assessment];;;ACTIVE;2.29;2.61 +57277-6;Reason for emergent care;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Reason for emergent care [CMS Assessment];;;ACTIVE;2.29;2.63 +57278-4;Discharge disposition;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Deprecated Discharge disposition [CMS Assessment];;;DEPRECATED;2.29;2.70 +57279-2;Reason for hospitalization;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Reason for hospitalization [CMS Assessment];;;ACTIVE;2.29;2.61 +572-8;Fungus identified;Prid;Pt;Bone mar;Nom;Culture;MICRO;1;Fungus identified in Bone marrow by Culture;Fungus Mar Cult;;ACTIVE;1.0;2.19 +57280-0;Risk of developing pressure injuries;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Risk of developing pressure injuries [CMS Assessment];;;ACTIVE;2.29;2.63 +5728-1;Silicon;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Silicon [Mass/volume] in Blood;Silicon Bld-mCnc;;ACTIVE;1.0;2.34 +57281-8;Medication follow-up;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication follow-up [CMS Assessment];;;ACTIVE;2.29;2.61 +57282-6;Patient &or caregiver drug education intervention;Find;Pt;^Patient;Ord;OASIS-C;SURVEY.OASIS;4;Patient/caregiver drug education intervention [OASIS-C];;;ACTIVE;2.29;2.44 +57283-4;Cognitive functioning;Find;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Deprecated Cognitive functioning OASIS-C;;;DEPRECATED;2.29;2.36 +57284-2;Management of injectable medications - ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Management of injectable medications - ability [CMS Assessment];;;ACTIVE;2.29;2.61 +57285-9;Management of oral medications - ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Management of oral medications - ability [CMS Assessment];;;ACTIVE;2.29;2.61 +57286-7;Behaviors demonstrated at least once a week;Find;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Deprecated Behaviors demonstrated at least once a week OASIS-C;;;DEPRECATED;2.29;2.36 +57287-5;Chlamydia trachomatis rRNA;PrThr;Pt;Anal;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Anal by NAA with probe detection;C trach rRNA Anal Ql NAA+probe;;ACTIVE;2.29;2.73 +57288-3;Chlamydia trachomatis rRNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Nasopharynx by NAA with probe detection;C trach rRNA Nph Ql NAA+probe;;ACTIVE;2.29;2.73 +57289-1;Neisseria gonorrhoeae rRNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Nasopharynx by NAA with probe detection;N gonorrhoea rRNA Nph Ql NAA+probe;;ACTIVE;2.29;2.73 +57290-9;HLA-A;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-A [Type] by High resolution;HLA-A High Res;;ACTIVE;2.29;2.73 +57291-7;HLA-B;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-B [Type] by High resolution;HLA-B High Res;;ACTIVE;2.29;2.73 +57292-5;HLA-B57*01;ACnc;Pt;Bld;Ord;;HLA;1;Deprecated HLA-B57*01 [Presence];Deprecated HLA-B57*01 Ql;;DEPRECATED;2.29;2.36 +57293-3;HLA-DRB1;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB1 [Type] by High resolution;HLA-DRB1 High Res;;ACTIVE;2.29;2.73 +57294-1;HLA-DRB3;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB3 [Type] by High resolution;HLA-DRB3 High Res;;ACTIVE;2.29;2.73 +57295-8;HLA-DRB4;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB4 [Type] by High resolution;HLA-DRB4 High Res;;ACTIVE;2.29;2.73 +57296-6;HLA-DRB5;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB5 [Type] by High resolution;HLA-DRB5 High Res;;ACTIVE;2.29;2.73 +57297-4;HLA-Cw;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-Cw [Type] by High resolution;HLA-Cw High Res;;ACTIVE;2.29;2.73 +57298-2;HLA-DRB1;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DRB1 [Type];HLA-DRB1;;ACTIVE;2.29;2.73 +5729-9;Silicate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Silicate [Mass/volume] in Serum or Plasma;Silicate SerPl-mCnc;;ACTIVE;1.0;2.34 +57299-0;HLA-DQB1;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DQB1 [Type] by High resolution;HLA-DQB1 High Res;;ACTIVE;2.29;2.73 +57300-6;6-Monoacetylmorphine;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Saliva (oral fluid);6MAM Sal-mCnc;;ACTIVE;2.29;2.73 +57301-4;Benzoylecgonine;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Saliva (oral fluid);BZE Sal-mCnc;;ACTIVE;2.29;2.73 +57302-2;Temazepam;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Saliva (oral fluid);Temazepam Sal-mCnc;;ACTIVE;2.29;2.73 +57303-0;7-Aminonitrazepam;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;7-Aminonitrazepam [Mass/volume] in Saliva (oral fluid);7Aminonitrazepam Sal-mCnc;;ACTIVE;2.29;2.42 +57304-8;Codeine;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Codeine [Mass/volume] in Saliva (oral fluid);Codeine Sal-mCnc;;ACTIVE;2.29;2.73 +57305-5;Tropomyosin Ab.IgE;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tropomyosin IgE Ab [Mass/volume] in Serum;Tropomyosin IgE-mCnc;;ACTIVE;2.29;2.42 +57306-3;Types and sources of assistance;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Types and sources of assistance [CMS Assessment];;;ACTIVE;2.29;2.61 +5730-7;Silicate;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Silicate [Mass/mass] in Tissue;Silicate Tiss-mCnt;;ACTIVE;1.0;2.22 +57307-1;Unhealed pressure injury at Stage 2 or higher or designated as unstageable;Find;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Unhealed pressure injury at stage 2 or higher or designated as unstageable [OASIS-C];;;ACTIVE;2.29;2.64 +57308-9;CYP11B1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CYP11B1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CYP11B1 gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +57309-7;PRNP gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PRNP gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PRNP gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +57310-5;SRY gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SRY gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SRY gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +57311-3;CYP11B1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CYP11B1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;CYP11B1 gene Mut Tested Bld/T;;ACTIVE;2.29;2.29 +57312-1;PRNP gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PRNP gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;PRNP gene Mut Tested Bld/T;;ACTIVE;2.29;2.29 +57313-9;Pyrazole Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pyrazole IgE Ab [Units/volume] in Serum;Pyrazole IgE Qn;;ACTIVE;2.29;2.42 +57314-7;SRY gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SRY gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;SRY gene Mut Tested Bld/T;;ACTIVE;2.29;2.29 +5731-5;Silicate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Silicate [Mass/volume] in Urine;Silicate Ur-mCnc;;ACTIVE;1.0;2.34 +57315-4;Sulphonamide Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sulphonamide IgE Ab [Units/volume] in Serum;Sulphonamide IgE Qn;;ACTIVE;2.29;2.54 +57316-2;Tropomyosin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tropomyosin IgE Ab [Units/volume] in Serum;Tropomyosin IgE Qn;;ACTIVE;2.29;2.42 +57317-0;Chromosome 13+18+21+X+Y aneuploidy;Find;Pt;Amnio fld/CVS;Nom;FISH;MOLPATH;1;Chromosome 13+18+21+X+Y aneuploidy in Amniotic fluid or Chorionic villus sample by FISH Nominal;Chr 13+18+21+X+Y aneup Amn/CVS FISH;;ACTIVE;2.29;2.73 +57318-8;Chromosome 13+18+21+X+Y aneuploidy;Find;Pt;Bld/Tiss;Nom;FISH;MOLPATH;1;Chromosome 13+18+21+X+Y aneuploidy in Blood or Tissue by FISH Nominal;Chr 13+18+21+X+Y aneup Bld/T FISH;;ACTIVE;2.29;2.73 +57319-6;Risk for hospitalization;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Risk for hospitalization [CMS Assessment];;;ACTIVE;2.29;2.61 +57320-4;Trypanosoma cruzi Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Trypanosoma cruzi Ab [Presence] in Serum or Plasma by Immunoassay;T cruzi Ab SerPl Ql IA;;ACTIVE;2.29;2.73 +57321-2;Herpes simplex virus 2 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;HSV2 IgG sp2 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57322-0;Varicella zoster virus Ab.IgM^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Varicella zoster virus IgM Ab [Units/volume] in Serum by Immunoassay --1st specimen;VZV IgM sp1 Ser IA-aCnc;;ACTIVE;2.29;2.69 +5732-3;Silver;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Blood;Silver Bld-mCnc;;ACTIVE;1.0;2.73 +57323-8;Varicella zoster virus Ab.IgM^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Varicella zoster virus IgM Ab [Units/volume] in Serum by Immunoassay --2nd specimen;VZV IgM sp2 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57324-6;Influenza virus A Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A IgG Ab [Units/volume] in Serum by Immunoassay --1st specimen;FLUAV IgG sp1 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57325-3;Influenza virus A Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A IgG Ab [Units/volume] in Serum by Immunoassay --2nd specimen;FLUAV IgG sp2 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57326-1;Influenza virus A Ab.IgM^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A IgM Ab [Units/volume] in Serum by Immunoassay --1st specimen;FLUAV IgM sp1 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57327-9;Influenza virus A Ab.IgM^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A IgM Ab [Units/volume] in Serum by Immunoassay --2nd specimen;FLUAV IgM sp2 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57328-7;Influenza virus B Ab.IgM^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus B IgM Ab [Units/volume] in Serum by Immunoassay --1st specimen;FLUBV IgM sp1 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57329-5;Influenza virus B Ab.IgM^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus B IgM Ab [Units/volume] in Serum by Immunoassay --2nd specimen;FLUBV IgM sp2 Ser IA-aCnc;;ACTIVE;2.29;2.69 +57330-3;Corticotropin^40M post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --40 minutes post XXX challenge;ACTH 40M p chal Plas-mCnc;;ACTIVE;2.29;2.70 +5733-1;Silver;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Silver [Mass/mass] in Hair;Silver Hair-mCnt;;ACTIVE;1.0;2.19 +57332-9;Urate;MCnc;12H;Urine;Qn;;CHEM;1;Urate [Mass/volume] in 12 hour Urine;Urate 12h Ur-mCnc;;ACTIVE;2.29;2.70 +57333-7;Calcium.ionized^^adjusted to pH 7.4;MCnc;Pt;Ser/Plas;Qn;ISE;CHEM;1;Calcium.ionized [Mass/volume] adjusted to pH 7.4 in Serum or Plasma by Ion-selective membrane electrode (ISE);Ca-I adj pH7.4 SerPl ISE-mCnc;;ACTIVE;2.29;2.73 +57334-5;Calcium;MCnc;2H;Urine;Qn;;CHEM;1;Calcium [Mass/volume] in 2 hour Urine;Calcium 2h Ur-mCnc;;ACTIVE;2.29;2.70 +57335-2;Calcium;MCnc;12H;Urine;Qn;;CHEM;1;Calcium [Mass/volume] in 12 hour Urine;Calcium 12h Ur-mCnc;;ACTIVE;2.29;2.70 +57336-0;Beta hydroxybutyrate^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Beta hydroxybutyrate [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;B-OH-Butyr 1h p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57337-8;Citrate;MCnc;12H;Urine;Qn;;CHEM;1;Citrate [Mass/volume] in 12 hour Urine;Citrate 12h Ur-mCnc;;ACTIVE;2.29;2.70 +57338-6;Citrate;MCnc;2H;Urine;Qn;;CHEM;1;Citrate [Mass/volume] in 2 hour Urine;Citrate 2h Ur-mCnc;;ACTIVE;2.29;2.70 +57339-4;Citrate;MRat;12H;Urine;Qn;;CHEM;1;Citrate [Mass/time] in 12 hour Urine;Citrate 12h Ur-mRate;;ACTIVE;2.29;2.70 +57340-2;Chloride;SCnc;12H;Urine;Qn;;CHEM;1;Chloride [Moles/volume] in 12 hour Urine;Chloride 12h Ur-sCnc;;ACTIVE;2.29;2.70 +57341-0;Chloride;SCnc;2H;Urine;Qn;;CHEM;1;Chloride [Moles/volume] in 2 hour Urine;Chloride 2h Ur-sCnc;;ACTIVE;2.29;2.70 +57342-8;Chloride;SRat;12H;Urine;Qn;;CHEM;1;Chloride [Moles/time] in 12 hour Urine;Chloride 12h Ur-sRate;;ACTIVE;2.29;2.70 +57344-4;Creatinine;MCnc;2H;Urine;Qn;;CHEM;1;Creatinine [Mass/volume] in 2 hour Urine;Creat 2h Ur-mCnc;;ACTIVE;2.29;2.70 +57345-1;Creatinine^overnight;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in Peritoneal dialysis fluid --overnight;Creat Overnight DiafP-mCnc;;ACTIVE;2.29;2.70 +57346-9;Creatinine;MCnc;12H;Urine;Qn;;CHEM;1;Creatinine [Mass/volume] in 12 hour Urine;Creat 12h Ur-mCnc;;ACTIVE;2.29;2.73 +57347-7;Copper;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Dialysis fluid;Copper Dial fld-mCnc;;ACTIVE;2.29;2.70 +57348-5;Phosphate;MCnc;12H;Urine;Qn;;CHEM;1;Phosphate [Mass/volume] in 12 hour Urine;Phosphate 12h Ur-mCnc;;ACTIVE;2.29;2.70 +5734-9;Silver;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Serum or Plasma;Silver SerPl-mCnc;;ACTIVE;1.0;2.73 +57349-3;Phosphate;MCnc;2H;Urine;Qn;;CHEM;1;Phosphate [Mass/volume] in 2 hour Urine;Phosphate 2h Ur-mCnc;;ACTIVE;2.29;2.70 +57350-1;Glucose^1M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 minute post XXX challenge;Glucose 1M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57353-5;Insulin^5M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --5 minutes post XXX challenge;Insulin 5M p chal SerPl-aCnc;;ACTIVE;2.29;2.70 +57355-0;Potassium;SCnc;12H;Urine;Qn;;CHEM;1;Potassium [Moles/volume] in 12 hour Urine;Potassium 12h Ur-sCnc;;ACTIVE;2.29;2.70 +5735-6;Silver;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Urine;Silver Ur-mCnc;;ACTIVE;1.0;2.73 +57356-8;Lactate^1M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --1 minute post XXX challenge;Lactate 1M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57357-6;Lactate^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;Lactate 10M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57358-4;Lactate^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Lactate 2h p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +57359-2;Lactate^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Lactate 3h p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +573-6;Fungus identified;Prid;Pt;Nail;Nom;Culture;MICRO;1;Fungus identified in Nail by Culture;Fungus Nail Cult;;ACTIVE;1.0;2.73 +57360-0;Lactate^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Lactate 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57361-8;Lactate^3M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --3 minutes post XXX challenge;Lactate 3M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57362-6;Lactate^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Lactate 30M p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +57363-4;Lactate^5M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --5 minutes post XXX challenge;Lactate 5M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +5736-4;Strontium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Strontium [Mass/volume] in Serum or Plasma;Strontium SerPl-mCnc;;ACTIVE;1.0;2.73 +57364-2;Lactate^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Lactate 1h p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +57365-9;Lactate^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Lactate 1.5h p chal SerPl-mCnc;;ACTIVE;2.29;2.73 +57366-7;Lactate^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --pre XXX challenge;Lactate pre chal SerPl-mCnc;;ACTIVE;2.32;2.70 +57367-5;Magnesium;MCnc;12H;Urine;Qn;;CHEM;1;Magnesium [Mass/volume] in 12 hour Urine;Magnesium 12h Ur-mCnc;;ACTIVE;2.29;2.70 +57368-3;Magnesium;MRat;12H;Urine;Qn;;CHEM;1;Magnesium [Mass/time] in 12 hour Urine;Magnesium 12h Ur-mRate;;ACTIVE;2.29;2.70 +57369-1;Albumin;MCnc;12H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/volume] in 12 hour Urine;Microalbumin 12h Ur-mCnc;;ACTIVE;2.29;2.73 +57370-9;Sodium;SCnc;12H;Urine;Qn;;CHEM;1;Sodium [Moles/volume] in 12 hour Urine;Sodium 12h Ur-sCnc;;ACTIVE;2.29;2.70 +57371-7;Enolase.neuron specific;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Enolase.neuron specific [Mass/volume] in Serum or Plasma by Immunoassay;NSE SerPl IA-mCnc;;ACTIVE;2.29;2.73 +5737-2;Strychnine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Strychnine [Presence] in Serum or Plasma;Strychnine SerPl Ql;;ACTIVE;1.0;2.56 +57372-5;Osmolality;Osmol;12H;Urine;Qn;;CHEM;1;Osmolality of 12 hour Urine;Osmolality 12h Ur;;ACTIVE;2.29;2.70 +57373-3;Oxalate;MCnc;12H;Urine;Qn;;CHEM;1;Oxalate [Mass/volume] in 12 hour Urine;Oxalate 12h Ur-mCnc;;ACTIVE;2.29;2.70 +57374-1;Oxalate;MCnc;2H;Urine;Qn;;CHEM;1;Oxalate [Mass/volume] in 2 hour Urine;Oxalate 2h Ur-mCnc;;ACTIVE;2.29;2.70 +57375-8;Oxalate;MRat;12H;Urine;Qn;;CHEM;1;Oxalate [Mass/time] in 12 hour Urine;Oxalate 12h Ur-mRate;;ACTIVE;2.29;2.70 +57376-6;C peptide^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --baseline;C peptide BS SerPl-mCnc;;ACTIVE;2.29;2.73 +57377-4;Pyruvate^5M post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --5 minutes post XXX challenge;Pyruvate 5M p chal Bld-mCnc;;ACTIVE;2.29;2.70 +57378-2;Porphyrins/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Porphyrins/Creatinine [Molar ratio] in Urine;Porphyrins/Creat Ur-sRto;;ACTIVE;2.29;2.73 +57379-0;Potassium;SCnc;2H;Urine;Qn;;CHEM;1;Potassium [Moles/volume] in 2 hour Urine;Potassium 2h Ur-sCnc;;ACTIVE;2.29;2.73 +5738-0;Strychnine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Strychnine [Mass/volume] in Serum or Plasma;Strychnine SerPl-mCnc;;ACTIVE;1.0;2.73 +57380-8;Potassium;SRat;12H;Urine;Qn;;CHEM;1;Potassium [Moles/time] in 12 hour Urine;Potassium 12h Ur-sRate;;ACTIVE;2.29;2.70 +57382-4;Sodium;SCnc;2H;Urine;Qn;;CHEM;1;Sodium [Moles/volume] in 2 hour Urine;Sodium 2h Ur-sCnc;;ACTIVE;2.29;2.70 +57383-2;Tipranavir;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Tipranavir [Mass/volume] in Serum;Tipranavir Ser-mCnc;;ACTIVE;2.29;2.70 +57385-7;Urea;MRat;12H;Urine;Qn;;CHEM;1;Urea [Mass/time] in 12 hour Urine;Urea 12h Ur-mRate;;ACTIVE;2.29;2.70 +57386-5;Urate;MCnc;2H;Urine;Qn;;CHEM;1;Urate [Mass/volume] in 2 hour Urine;Urate 2h Ur-mCnc;;ACTIVE;2.29;2.70 +57387-3;Urate;MRat;12H;Urine;Qn;;CHEM;1;Urate [Mass/time] in 12 hour Urine;Urate 12h Ur-mRate;;ACTIVE;2.29;2.70 +57388-1;Urea;MCnc;24H;Dial fld prt;Qn;;CHEM;1;Urea [Mass/volume] in 24 hour Peritoneal dialysis fluid;Urea 24h DiafP-mCnc;;ACTIVE;2.29;2.70 +57389-9;Urea;MCnc;12H;Urine;Qn;;CHEM;1;Urea [Mass/volume] in 12 hour Urine;Urea 12h Ur-mCnc;;ACTIVE;2.29;2.70 +57390-7;Specimen volume;VRat;12H;Urine;Qn;;SPEC;1;Volume [Flow] of 12 hour Urine;Specimen vol 12h Ur-vRate;;ACTIVE;2.29;2.70 +57391-5;Eosinophils/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Synovial fluid by Manual count;Eosinophil/leuk NFr Snv Manual;;ACTIVE;2.29;2.73 +57392-3;Urea;MCnc;Pt;Body fld;Qn;;CHEM;1;Urea [Mass/volume] in Body fluid;Urea Fld-mCnc;;ACTIVE;2.29;2.70 +57393-1;Cells.CD11a/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD11a cells/100 cells in Body fluid;CD11a Cells NFr Fld;;ACTIVE;2.29;2.70 +57394-9;Cells.CD19+CD34+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD34+ cells/100 cells in Body fluid;CD19+CD34+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57395-6;Cells.CD19+CD38+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD38+ cells/100 cells in Body fluid;CD19+CD38+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57396-4;Cells.CD19+CD56+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD56+ cells/100 cells in Body fluid;CD19+CD56+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57397-2;Cells.CD19+CD20+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD20+ cells/100 cells in Body fluid;CD19+CD20+ Cells NFr Fld;;ACTIVE;2.29;2.70 +5739-8;Strychnine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Strychnine [Presence] in Urine;Strychnine Ur Ql;;ACTIVE;1.0;2.56 +57398-0;Cells.CD22+CD19+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD22+CD19+ cells/100 cells in Body fluid;CD22+CD19+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57399-8;Cells.CD19+CD23+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+CD23+ cells/100 cells in Body fluid;CD19+CD23+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57400-4;Cells.CD34/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD34 cells/100 cells in Bone marrow;CD34 Cells NFr Mar;;ACTIVE;2.29;2.73 +57401-2;Cells.CD4+CD8+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD4+CD8+ cells/100 cells in Body fluid;CD4+CD8+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57402-0;Cells.CD42a/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD42a cells/100 cells in Body fluid;CD42a Cells NFr Fld;;ACTIVE;2.29;2.70 +57403-8;Cells.CD45RA/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD45RA cells/100 cells in Body fluid;CD45RA Cells NFr Fld;;ACTIVE;2.29;2.70 +57404-6;Cells.CD45RO/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD45RO cells/100 cells in Body fluid;CD45RO Cells NFr Fld;;ACTIVE;2.29;2.70 +57405-3;Cells.CD8+CD56+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD8+CD56+ cells/100 cells in Body fluid;CD8+CD56+ Cells NFr Fld;;ACTIVE;2.29;2.70 +5740-6;Strychnine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Strychnine [Mass/volume] in Urine;Strychnine Ur-mCnc;;ACTIVE;1.0;2.73 +57406-1;Cells.CD8+CD57+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD8+CD57+ cells/100 cells in Body fluid;CD8+CD57+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57407-9;Cells.CD8+CD45RA+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD8+CD45RA+ cells/100 cells in Body fluid;CD8+CD45RA+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57408-7;Cells.CD8+CD45RO+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD8+CD45RO+ cells/100 cells in Body fluid;CD8+CD45RO+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57409-5;Cells.CD3+TCR alpha beta+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+TCR alpha beta+ cells/100 cells in Body fluid;CD3+TCR A-B+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57410-3;Actin.filamentous Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Actin.filamentous Ab [Units/volume] in Serum or Plasma by Immunoassay;F-actin Ab SerPl IA-aCnc;;ACTIVE;2.29;2.70 +57411-1;Desmoglein 1 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Desmoglein 1 Ab [Units/volume] in Serum by Immunoassay;Desmoglein 1 Ab Ser IA-aCnc;;ACTIVE;2.29;2.70 +57412-9;Desmoglein 3 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Desmoglein 3 Ab [Units/volume] in Serum by Immunoassay;Desmoglein 3 Ab Ser IA-aCnc;;ACTIVE;2.29;2.70 +57413-7;Mitochondria Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Mitochondria Ab [Presence] in Serum by Immunoblot;Mitochondria Ab Ser Ql IB;;ACTIVE;2.29;2.58 +5741-4;Strychnine;MRat;24H;Urine;Qn;;DRUG/TOX;1;Strychnine [Mass/time] in 24 hour Urine;Strychnine 24h Ur-mRate;;ACTIVE;1.0;2.42 +57414-5;Reticulin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Reticulin Ab [Presence] in Serum by Immunofluorescence;Reticulin Ab Ser Ql IF;;ACTIVE;2.29;2.73 +57415-2;Saccharomyces cerevisiae Ab.IgA;PrThr;Pt;Ser;Ord;IA;ALLERGY;1;Baker's yeast IgA Ab [Presence] in Serum by Immunoassay;Baker's yeast IgA Ql IA;;ACTIVE;2.29;2.73 +57416-0;Thyrotropin receptor Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Thyrotropin receptor Ab [Units/volume] in Serum by Immunoassay;TSH Recep Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +57417-8;Cells.CD18/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD18 cells/100 cells in Body fluid;CD18 Cells NFr Fld;;ACTIVE;2.29;2.70 +57418-6;Cells.CD20/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD20 cells/100 cells in Body fluid;CD20 Cells NFr Fld;;ACTIVE;2.29;2.70 +57419-4;Cells.CD21/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD21 cells/100 cells in Body fluid;CD21 Cells NFr Fld;;ACTIVE;2.29;2.70 +57420-2;Cells.CD27/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD27 cells/100 cells in Body fluid;CD27 Cells NFr Fld;;ACTIVE;2.29;2.70 +57421-0;Cells.CD34/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD34 cells/100 cells in Body fluid;CD34 Cells NFr Fld;;ACTIVE;2.29;2.70 +5742-2;Tellurium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tellurium [Mass/volume] in Urine;Tellurium Ur-mCnc;;ACTIVE;1.0;2.73 +57422-8;Cells.CD40/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD40 cells/100 cells in Body fluid;CD40 Cells NFr Fld;;ACTIVE;2.29;2.70 +57423-6;Cells.CD5/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD5 cells/100 cells in Body fluid;CD5 Cells NFr Fld;;ACTIVE;2.29;2.70 +57424-4;Cells.CD56/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD56 cells/100 cells in Body fluid;CD56 Cells NFr Fld;;ACTIVE;2.29;2.70 +57425-1;Cells.CD7/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD7 cells/100 cells in Body fluid;CD7 Cells NFr Fld;;ACTIVE;2.29;2.70 +57426-9;Cells.CD71/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD71 cells/100 cells in Body fluid;CD71 Cells NFr Fld;;ACTIVE;2.29;2.70 +57427-7;Cells.CD10+FMC7+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD10+FMC7+ cells/100 cells in Body fluid;CD10+FMC7+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57428-5;Cells.FMC7/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;FMC7 cells/100 cells in Body fluid;FMC7 Cells NFr Fld;;ACTIVE;2.29;2.70 +57429-3;Cells.CD3+TCR gamma delta+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+TCR gamma delta+ cells/100 cells in Body fluid;CD3+TCR G-D+ Cells NFr Fld;;ACTIVE;2.29;2.70 +5743-0;Thallium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in Blood;Thallium Bld-mCnc;;ACTIVE;1.0;2.73 +57430-1;Cells.CD235a/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD235a cells/100 cells in Body fluid;CD235a Cells NFr Fld;;ACTIVE;2.29;2.70 +57431-9;Extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Extractable nuclear Ab [Presence] in Serum by Immunoblot;ENA Ab Ser Ql IB;;ACTIVE;2.29;2.58 +57432-7;Cells.CD19+Kappa+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+Kappa+ cells/100 cells in Body fluid;CD19+Kappa+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57433-5;Cells.CD19+Lambda+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD19+Lambda+ cells/100 cells in Body fluid;CD19+Lambda+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57434-3;Liver kidney microsomal 1 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Liver kidney microsomal 1 Ab [Titer] in Serum by Immunofluorescence;LKM-1 Ab Titr Ser IF;;ACTIVE;2.29;2.73 +57435-0;Cells.myeloperoxidase;PrThr;Pt;Body fld;Ord;;CELLMARK;1;Myeloperoxidase cells [Presence] in Body fluid;Myeloperoxidase Cells Fld Ql;;ACTIVE;2.29;2.56 +57436-8;Muscle specific receptor tyrosine kinase Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Muscle specific receptor tyrosine kinase Ab [Units/volume] in Serum by Immunoassay;MuSK Ab Ser IA-aCnc;;ACTIVE;2.29;2.70 +57437-6;Cells.CD56+CD138+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD56+CD138+ cells/100 cells in Body fluid;CD56+CD138+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57438-4;Cells.CD56-CD138+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD56-CD138+ cells/100 cells in Body fluid;CD56-CD138+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57439-2;Cells.terminal deoxyribonucleotidyl transferase;PrThr;Pt;Body fld;Ord;;CELLMARK;1;Terminal deoxyribonucleotidyl transferase cells [Presence] in Body fluid;TdT Cells Fld Ql;;ACTIVE;2.29;2.56 +574-4;Fungus identified;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Fungus identified in Peritoneal fluid by Culture;Fungus Prt Cult;;ACTIVE;1.0;2.19 +57440-0;Platelet Ab;PrThr;Pt;Ser;Ord;IF;COAG;1;Platelet Ab [Presence] in Serum by Immunofluorescence;Platelet Ab Ser Ql IF;;ACTIVE;2.29;2.56 +57441-8;Toxoplasma gondii DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Body fluid by NAA with probe detection;T gondii DNA Fld Ql NAA+probe;;ACTIVE;2.29;2.63 +57442-6;Specimen volume^post concentration;Vol;Pt;Semen;Qn;;FERT;1;Volume of Semen--post concentration;Specimen vol p conc Smn;;ACTIVE;2.29;2.70 +57443-4;Spermatozoa.progressive.grade 3/100 spermatozoa^post concentration;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 3/100 spermatozoa in Semen --post concentration;Sperm Prog 3 p conc NFr Smn;;ACTIVE;2.29;2.70 +57444-2;Spermatozoa.progressive.grade 2/100 spermatozoa^post concentration;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 2/100 spermatozoa in Semen --post concentration;Sperm Prog 2 p conc NFr Smn;;ACTIVE;2.29;2.70 +57445-9;Spermatozoa.progressive.grade 1/100 spermatozoa^post concentration;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 1/100 spermatozoa in Semen --post concentration;Sperm Prog 1 p conc NFr Smn;;ACTIVE;2.29;2.70 +57446-7;Spermatozoa.immotile/100 spermatozoa^post concentration;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Immotile/100 spermatozoa in Semen --post concentration;Sperm Immotile p conc NFr Smn;;ACTIVE;2.29;2.70 +57447-5;Nuclear Ab;Titr;Pt;Synv fld;Qn;IF;SERO;1;Deprecated Nuclear Ab [Titer] in Synovial fluid by Immunofluorescence;Deprecated ANA Titr Snv IF;;DEPRECATED;2.29;2.36 +5744-8;Thallium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in Serum or Plasma;Thallium SerPl-mCnc;;ACTIVE;1.0;2.73 +57448-3;Nuclear Ab pattern;Imp;Pt;Synv fld;Nom;IF;SERO;1;Nuclear Ab pattern [Interpretation] in Synovial fluid by Immunofluorescence;ANA Pat Snv IF-Imp;;ACTIVE;2.29;2.29 +57449-1;Tubular basement membrane Ab;ACnc;Pt;Ser;Qn;;SERO;1;Tubular basement membrane Ab [Units/volume] in Serum;TBM Ab Ser-aCnc;;ACTIVE;2.29;2.69 +57450-9;Soluble liver Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Deprecated Soluble liver Ab [Presence] in Serum by Immunoassay;Deprecated Soluble liver Ab Ser Ql IA;;DEPRECATED;2.29;2.58 +57451-7;CV2 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;CV2 Ab [Presence] in Cerebral spinal fluid by Immunoblot;CV2 Ab CSF Ql IB;;ACTIVE;2.29;2.58 +57452-5;Ma+Ta Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Ma+Ta Ab [Presence] in Cerebral spinal fluid by Immunoblot;Ma+Ta Ab CSF Ql IB;;ACTIVE;2.29;2.58 +57453-3;Chromosome 18 aneuploidy;Find;Pt;Amnio fld/CVS;Nom;FISH;MOLPATH;1;Chromosome 18 aneuploidy in Amniotic fluid or Chorionic villus sample by FISH Nominal;Chr 18 aneup Amn/CVS FISH;;ACTIVE;2.29;2.68 +57454-1;Chromosome 13 aneuploidy;Find;Pt;Amnio fld/CVS;Nom;FISH;MOLPATH;1;Chromosome 13 aneuploidy in Amniotic fluid or Chorionic villus sample by FISH Nominal;Chr 13 aneup Amn/CVS FISH;;ACTIVE;2.29;2.68 +5745-5;Thallium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in Urine;Thallium Ur-mCnc;;ACTIVE;1.0;2.73 +57455-8;Taenia solium Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Taenia solium IgG Ab [Units/volume] in Serum;T sol IgG Ser-aCnc;;ACTIVE;2.29;2.69 +57456-6;Spermatozoa.progressive^post concentration;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive [#/volume] in Semen --post concentration;Sperm Prog p conc # Smn;;ACTIVE;2.29;2.42 +57457-4;Interpretation;Imp;24H;Urine;Nom;Immunoelectrophoresis;CHEM;1;Immunoelectrophoresis for 24 hour Urine;Interpretation 24h Ur IEP-Imp;;ACTIVE;2.29;2.54 +57458-2;Neisseria gonorrhoeae rRNA;PrThr;Pt;Anal;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Anal by NAA with probe detection;N gonorrhoea rRNA Anal Ql NAA+probe;;ACTIVE;2.29;2.73 +57459-0;Outcome and assessment information set (OASIS) form - version C - Death at home;-;Pt;^Patient;-;;PANEL.SURVEY.OASIS;4;Deprecated Outcome and assessment information set (OASIS) form - version C - Death at home;;;DEPRECATED;2.29;2.73 +57460-8;Lymphocytes.activated T cells/100 lymphocytes.small;NFr;Pt;BAL;Qn;;CELLMARK;1;Activated T cells lymphocytes/100 lymphocytes.small in Bronchoalveolar lavage;Activ T Lymphs NFr BAL;;ACTIVE;2.29;2.40 +57461-6;Lymphocytes.activated T cells/100 lymphocytes.small;NFr;Pt;Bronchial;Qn;;CELLMARK;1;Activated T cells lymphocytes/100 lymphocytes.small in Bronchial specimen;Activ T Lymphs NFr Bronch;;ACTIVE;2.29;2.70 +57462-4;Normetanephrine.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Normetanephrine Free [Mass/volume] in Serum or Plasma;Normetaneph Free SerPl-mCnc;;ACTIVE;2.29;2.73 +5746-3;Thallium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Thallium [Mass/time] in 24 hour Urine;Thallium 24h Ur-mRate;;ACTIVE;1.0;2.73 +57463-2;Cortisol^12th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma --12th specimen;Cortis sp12 SerPl-mCnc;;ACTIVE;2.29;2.40 +57464-0;Cortisol^11th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma --11th specimen;Cortis sp11 SerPl-mCnc;;ACTIVE;2.29;2.40 +57465-7;Cortisol^10th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma --10th specimen;Cortis sp10 SerPl-mCnc;;ACTIVE;2.29;2.40 +57466-5;Cortisol^9th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma --9th specimen;Cortis sp9 SerPl-mCnc;;ACTIVE;2.29;2.40 +57467-3;Calcitriol^pre dose calcium;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Mass/volume] in Serum or Plasma --pre dose calcium;1,25(OH)2D3 pre Ca SerPl-mCnc;;ACTIVE;2.29;2.70 +57468-1;Calcitriol^pre dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Moles/volume] in Serum or Plasma --pre dose calcium;1,25(OH)2D3 pre Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +57469-9;Calcitriol^2H post dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Moles/volume] in Serum or Plasma --2 hours post dose calcium;1,25(OH)2D3 2h p Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +57470-7;Calcitriol^2H post dose calcium;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Mass/volume] in Serum or Plasma --2 hours post dose calcium;1,25(OH)2D3 2h p Ca SerPl-mCnc;;ACTIVE;2.29;2.70 +5747-1;Tin;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tin [Mass/volume] in Blood;Tin Bld-mCnc;;ACTIVE;1.0;2.73 +57471-5;Calcitriol^3H post dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Moles/volume] in Serum or Plasma --3 hours post dose calcium;1,25(OH)2D3 3h p Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +57472-3;Calcitriol^3H post dose calcium;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Mass/volume] in Serum or Plasma --3 hours post dose calcium;1,25(OH)2D3 3h p Ca SerPl-mCnc;;ACTIVE;2.29;2.70 +57473-1;Calcitriol^1H post dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Moles/volume] in Serum or Plasma --1 hour post dose calcium;1,25(OH)2D3 1h p Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +57474-9;Calcitriol^1H post dose calcium;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitriol [Mass/volume] in Serum or Plasma --1 hour post dose calcium;1,25(OH)2D3 1h p Ca SerPl-mCnc;;ACTIVE;2.29;2.70 +57475-6;11-Ketoandrosterone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;11Ketoandros pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57476-4;11-Ketoandrosterone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/time] in 24 hour Urine --pre high dose dexamethasone;11Ketoandros pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57477-2;11-Ketoandrosterone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;11Ketoandros 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57478-0;11-Ketoandrosterone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;11Ketoandros 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57479-8;11-Ketoandrosterone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/volume] in 24 hour Urine --pre dose dexamethasone;11Ketoandros Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57480-6;11-Ketoandrosterone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/time] in 24 hour Urine --pre dose dexamethasone;11Ketoandros Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57481-4;11-Ketoandrosterone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;11Ketoandros 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57482-2;11-Ketoandrosterone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoandrosterone [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;11Ketoandros 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57483-0;11-Ketoetiocholanolone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;11Ketoetioch pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57484-8;11-Ketoetiocholanolone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/time] in 24 hour Urine --pre high dose dexamethasone;11Ketoetioch pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57485-5;11-Ketoetiocholanolone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;11Ketoetioch 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57486-3;11-Ketoetiocholanolone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;11Ketoetioch 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57487-1;11-Ketoetiocholanolone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/volume] in 24 hour Urine --pre dose dexamethasone;11Ketoetioch Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57488-9;11-Ketoetiocholanolone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/time] in 24 hour Urine --pre dose dexamethasone;11Ketoetioch Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +5748-9;Tin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tin [Mass/volume] in Serum or Plasma;Tin SerPl-mCnc;;ACTIVE;1.0;2.73 +57489-7;11-Ketoetiocholanolone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;11Ketoetioch 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57490-5;11-Ketoetiocholanolone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Ketoetiocholanolone [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;11Ketoetioch 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57491-3;11-Deoxycorticosterone^pre 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin;11DOC pre 250 ug ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57492-1;11-Deoxycorticosterone^30M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;11DOC 30M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57493-9;11-Deoxycorticosterone^1H post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;11DOC 1h p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57494-7;11-Deoxycortisol^pre dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --pre dose dexamethasone;11DC Pre Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57495-4;11-Deoxycortisol^pre dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --pre dose dexamethasone;11DC Pre Dex SerPl-mCnc;;ACTIVE;2.29;2.70 +57496-2;11-Deoxycortisol^1D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --1 day post dose dexamethasone;11DC 1D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +5749-7;Titanium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Titanium [Mass/volume] in Urine;Titanium Ur-mCnc;;ACTIVE;1.0;2.73 +57497-0;11-Deoxycortisol^1D post dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --1 day post dose dexamethasone;11DC 1D p Dex SerPl-mCnc;;ACTIVE;2.29;2.70 +57498-8;11-Deoxycortisol^2D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --2 days post dose dexamethasone;11DC 2D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57499-6;11-Deoxycortisol^2D post dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --2 days post dose dexamethasone;11DC 2D p Dex SerPl-mCnc;;ACTIVE;2.29;2.70 +57500-1;11-Deoxycortisol^pre dose metyraPONE;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --pre dose metyraPONE;11DC pre MTP SerPl-sCnc;;ACTIVE;2.29;2.70 +57501-9;11-Deoxycortisol^pre dose metyraPONE;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --pre dose metyraPONE;11DC pre MTP SerPl-mCnc;;ACTIVE;2.29;2.70 +57502-7;11-Deoxycortisol^1D post dose metyraPONE;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --1 day post dose metyraPONE;11DC 1D p MTP SerPl-sCnc;;ACTIVE;2.29;2.70 +57503-5;11-Deoxycortisol^1D post dose metyraPONE;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --1 day post dose metyraPONE;11DC 1D p MTP SerPl-mCnc;;ACTIVE;2.29;2.70 +57504-3;11-Deoxycortisol^2D post dose metyraPONE;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Moles/volume] in Serum or Plasma --2 days post dose metyraPONE;11DC 2D p MTP SerPl-sCnc;;ACTIVE;2.29;2.70 +5750-5;Toluene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Toluene [Mass/volume] in Serum or Plasma;Toluene SerPl-mCnc;;ACTIVE;1.0;2.73 +57505-0;11-Deoxycortisol^2D post dose metyraPONE;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --2 days post dose metyraPONE;11DC 2D p MTP SerPl-mCnc;;ACTIVE;2.29;2.70 +57506-8;11-Deoxycortisol^pre 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin;11DC pre 250 ug ACTH SerPl-mCnc;;ACTIVE;2.29;2.70 +57507-6;11-Deoxycortisol^45M post 250 ug corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --45 minutes post 250 ug corticotropin;11DC 45M p 250 ug ACTH SerPl-mCnc;;ACTIVE;2.29;2.70 +57508-4;11-Hydroxyandrosterone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;11OH-Androst pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57509-2;11-Hydroxyandrosterone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/time] in 24 hour Urine --pre high dose dexamethasone;11OH-Androst pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +575-1;Fungus identified;Prid;Pt;Skin;Nom;Culture;MICRO;1;Fungus identified in Skin by Culture;Fungus Skin Cult;;ACTIVE;1.0;2.73 +57510-0;11-Hydroxyandrosterone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;11OH-Androst 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57511-8;11-Hydroxyandrosterone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;11OH-Androst 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57512-6;11-Hydroxyandrosterone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/volume] in 24 hour Urine --pre dose dexamethasone;11OH-Androst Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5751-3;Uranium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Uranium [Mass/volume] in Blood;Uranium Bld-mCnc;;ACTIVE;1.0;2.42 +57513-4;11-Hydroxyandrosterone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/time] in 24 hour Urine --pre dose dexamethasone;11OH-Androst Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57514-2;11-Hydroxyandrosterone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;11OH-Androst 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57515-9;11-Hydroxyandrosterone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyandrosterone [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;11OH-Androst 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57516-7;11-Hydroxyetiocholanolone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;11OH-Etioch pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57517-5;11-Hydroxyetiocholanolone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/time] in 24 hour Urine --pre high dose dexamethasone;11OH-Etioch pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57518-3;11-Hydroxyetiocholanolone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;11OH-Etioch 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57519-1;11-Hydroxyetiocholanolone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;11OH-Etioch 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57520-9;11-Hydroxyetiocholanolone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/volume] in 24 hour Urine --pre dose dexamethasone;11OH-Etioch Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5752-1;Uranium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Uranium [Mass/volume] in Urine;Uranium Ur-mCnc;;ACTIVE;1.0;2.73 +57521-7;11-Hydroxyetiocholanolone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/time] in 24 hour Urine --pre dose dexamethasone;11OH-Etioch Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57522-5;11-Hydroxyetiocholanolone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;11OH-Etioch 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57523-3;11-Hydroxyetiocholanolone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;11-Hydroxyetiocholanolone [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;11OH-Etioch 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57524-1;17-Ketogenic steroids^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/volume] in 24 hour Urine --pre dose dexamethasone;17KGS Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57525-8;17-Ketogenic steroids^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Ketogenic steroids [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;17KGS 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57526-6;17-Hydroxycorticosteroids^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;17OHCS pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57527-4;17-Hydroxycorticosteroids^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;17OHCS 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57528-2;17-Hydroxycorticosteroids^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/volume] in 24 hour Urine --pre dose dexamethasone;17OHCS Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57529-0;17-Hydroxycorticosteroids^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;17-Hydroxycorticosteroids [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;17OHCS 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57530-8;17-Hydroxypregnenolone^pre dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Moles/volume] in Serum or Plasma --pre dose dexamethasone;17OH-Preg Pre Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57531-6;17-Hydroxypregnenolone^1D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Moles/volume] in Serum or Plasma --1 day post dose dexamethasone;17OH-Preg 1D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57532-4;17-Hydroxypregnenolone^2D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxypregnenolone [Moles/volume] in Serum or Plasma --2 days post dose dexamethasone;17OH-Preg 2D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57533-2;17-Hydroxyprogesterone^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;17OHP sp10 p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57534-0;17-Hydroxyprogesterone^11th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --11th specimen post XXX challenge;17OHP sp11 p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57535-7;17-Hydroxyprogesterone^12th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --12th specimen post XXX challenge;17OHP sp12 p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57536-5;17-Hydroxyprogesterone^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;17OHP sp8 p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57537-3;17-Hydroxyprogesterone^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;17OHP sp9 p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57538-1;17-Hydroxyprogesterone^1st specimen post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1st specimen post dose gonadotropin releasing hormone;17OHP sp1 p GnRH SerPl-mCnc;;ACTIVE;2.29;2.70 +5753-9;Vanadium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Vanadium [Mass/volume] in Blood;Vanadium Bld-mCnc;;ACTIVE;1.0;2.73 +57539-9;17-Hydroxyprogesterone^2nd specimen post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --2nd specimen post dose gonadotropin releasing hormone;17OHP sp2 p GnRH SerPl-mCnc;;ACTIVE;2.29;2.70 +57540-7;17-Hydroxyprogesterone^3rd specimen post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --3rd specimen post dose gonadotropin releasing hormone;17OHP sp3 p GnRH SerPl-mCnc;;ACTIVE;2.29;2.70 +57541-5;17-Hydroxyprogesterone^4th specimen post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --4th specimen post dose gonadotropin releasing hormone;17OHP sp4 p GnRH SerPl-mCnc;;ACTIVE;2.29;2.70 +57542-3;17-Hydroxyprogesterone^5th specimen post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --5th specimen post dose gonadotropin releasing hormone;17OHP sp5 p GnRH SerPl-mCnc;;ACTIVE;2.29;2.70 +57543-1;17-Hydroxyprogesterone^6th specimen post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --6th specimen post dose gonadotropin releasing hormone;17OHP sp6 p GnRH SerPl-mCnc;;ACTIVE;2.29;2.70 +57544-9;17-Hydroxyprogesterone^7th specimen post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --7th specimen post dose gonadotropin releasing hormone;17OHP sp7 p GnRH SerPl-mCnc;;ACTIVE;2.29;2.70 +57545-6;17-Hydroxyprogesterone^pre dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --pre dose dexamethasone;17OHP Pre Dex SerPl-mCnc;;ACTIVE;2.29;2.70 +57546-4;17-Hydroxyprogesterone^pre dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --pre dose dexamethasone;17OHP Pre Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +5754-7;Vanadium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Vanadium [Mass/mass] in Hair;Vanadium Hair-mCnt;;ACTIVE;1.0;2.19 +57547-2;17-Hydroxyprogesterone^1D post dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1 day post dose dexamethasone;17OHP 1D p Dex SerPl-mCnc;;ACTIVE;2.29;2.70 +57548-0;17-Hydroxyprogesterone^1D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --1 day post dose dexamethasone;17OHP 1D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57549-8;17-Hydroxyprogesterone^2D post dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --2 days post dose dexamethasone;17OHP 2D p Dex SerPl-mCnc;;ACTIVE;2.29;2.70 +57550-6;17-Hydroxyprogesterone^2D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --2 days post dose dexamethasone;17OHP 2D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57551-4;18-Hydroxydeoxycorticosterone^pre dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxydeoxycorticosterone [Moles/volume] in Serum or Plasma --pre dose corticotropin;18OH-DOC Pre ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57552-2;18-Hydroxydeoxycorticosterone^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxydeoxycorticosterone [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;18OH-DOC 30M p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57553-0;18-Hydroxydeoxycorticosterone^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxydeoxycorticosterone [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;18OH-DOC 1h p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +5755-4;Vanadium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Vanadium [Mass/volume] in Red Blood Cells;Vanadium RBC-mCnc;;ACTIVE;1.0;2.73 +57554-8;18-Hydroxycorticosterone^pre dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxycorticosterone [Moles/volume] in Serum or Plasma --pre dose corticotropin;18OHB Pre ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57555-5;18-Hydroxycorticosterone^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxycorticosterone [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;18OHB 30M p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57556-3;18-Hydroxycorticosterone^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxycorticosterone [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;18OHB 1h p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57557-1;18-Hydroxycortisol^pre dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxycortisol [Moles/volume] in Serum or Plasma --pre dose corticotropin;18OH-Cortis Pre ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57558-9;18-Hydroxycortisol^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxycortisol [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;18OH-Cortis 30M p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57559-7;18-Hydroxycortisol^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;18-Hydroxycortisol [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;18OH-Cortis 1h p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57560-5;21-Deoxycorticosterone^pre dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycorticosterone [Moles/volume] in Serum or Plasma --pre dose corticotropin;21DOC Pre ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57561-3;21-Deoxycorticosterone^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycorticosterone [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;21DOC 30M p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +5756-2;Vanadium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vanadium [Mass/volume] in Serum or Plasma;Vanadium SerPl-mCnc;;ACTIVE;1.0;2.73 +57562-1;21-Deoxycorticosterone^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycorticosterone [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;21DOC 1h p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57563-9;21-Deoxycortisol^pre dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma --pre dose dexamethasone;21DC Pre Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57564-7;21-Deoxycortisol^1D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma --1 day post dose dexamethasone;21DC 1D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57565-4;21-Deoxycortisol^2D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;21-Deoxycortisol [Moles/volume] in Serum or Plasma --2 days post dose dexamethasone;21DC 2D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57566-2;Calcidiol^pre dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;25-hydroxyvitamin D3 [Moles/volume] in Serum or Plasma --pre dose calcium;25(OH)D3 pre Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +57567-0;Calcidiol^2H post dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;25-hydroxyvitamin D3 [Moles/volume] in Serum or Plasma --2 hours post dose calcium;25(OH)D3 2h p Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +57568-8;Calcidiol^3H post dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;25-hydroxyvitamin D3 [Moles/volume] in Serum or Plasma --3 hours post dose calcium;25(OH)D3 3h p Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +57569-6;Calcidiol^1H post dose calcium;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;25-hydroxyvitamin D3 [Moles/volume] in Serum or Plasma --1 hour post dose calcium;25(OH)D3 1h p Ca SerPl-sCnc;;ACTIVE;2.29;2.70 +5757-0;Vanadium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Vanadium [Mass/volume] in Urine;Vanadium Ur-mCnc;;ACTIVE;1.0;2.73 +57570-4;3-Alpha-Androstanediol glucuronide^pre dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Serum or Plasma --pre dose dexamethasone;3A-diol G Pre Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57571-2;3-Alpha-Androstanediol glucuronide^1D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Serum or Plasma --1 day post dose dexamethasone;3A-diol G 1D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57572-0;3-Alpha-Androstanediol glucuronide^2D post dose dexamethasone;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Serum or Plasma --2 days post dose dexamethasone;3A-diol G 2D p Dex SerPl-sCnc;;ACTIVE;2.29;2.70 +57573-8;3-Alpha-Androstanediol glucuronide^pre dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Serum or Plasma --pre dose corticotropin;3A-diol G Pre ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57574-6;3-Alpha-Androstanediol glucuronide^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;3A-diol G 30M p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57575-3;3-Alpha-Androstanediol glucuronide^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;3-Alpha-Androstanediol glucuronide [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;3A-diol G 1h p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57576-1;Androstanolone^pre dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Moles/volume] in Serum or Plasma --pre dose corticotropin;Androstanolone Pre ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57577-9;Androstanolone^30M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Moles/volume] in Serum or Plasma --30 minutes post dose corticotropin;Androstanolone 30M p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57578-7;Androstanolone^1H post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Moles/volume] in Serum or Plasma --1 hour post dose corticotropin;Androstanolone 1h p ACTH SerPl-sCnc;;ACTIVE;2.29;2.70 +57579-5;Aldosterone^post 25 mg captopril PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --post 25 mg captopril PO;Aldost p 25 mg Cpl PO SerPl-mCnc;;ACTIVE;2.29;2.70 +57580-3;Aldosterone^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --post XXX challenge;Aldost p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57581-1;Aldosterone^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --pre XXX challenge;Aldost pre chal SerPl-mCnc;;ACTIVE;2.32;2.70 +57582-9;Aldosterone^pre 25 mg captopril PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --pre 25 mg captopril PO;Aldost pre 25 mg Cpl PO SerPl-mCnc;;ACTIVE;2.29;2.70 +57583-7;Aldosterone^2H post 25 mg captopril PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --2 hours post 25 mg captopril PO;Aldost 2h p 25 mg Cpl PO SerPl-sCnc;;ACTIVE;2.29;2.70 +57584-5;Aldosterone^3H post 25 mg captopril PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --3 hours post 25 mg captopril PO;Aldost 3h p 25 mg Cpl PO SerPl-sCnc;;ACTIVE;2.29;2.70 +57585-2;Aldosterone^3H post 25 mg captopril PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --3 hours post 25 mg captopril PO;Aldost 3h p 25 mg Cpl PO SerPl-mCnc;;ACTIVE;2.29;2.70 +57586-0;Aldosterone^1H post 25 mg captopril PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --1 hour post 25 mg captopril PO;Aldost 1h p 25 mg Cpl PO SerPl-sCnc;;ACTIVE;2.29;2.70 +57587-8;Aldosterone^2H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --2 hours post XXX challenge;Aldost 2h p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +5758-8;Dimethylbenzene;MCnc;Pt;Bld;Ord;;DRUG/TOX;1;Deprecated Dimethylbenzene;Deprecated DMB Bld Ql;;DEPRECATED;1.0;2.36 +57588-6;Aldosterone^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;Aldost 15M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57589-4;Aldosterone^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;Aldost 15M p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +57590-2;Aldosterone^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;Aldost 3h p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57591-0;Aldosterone^3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --3 hours post XXX challenge;Aldost 3h p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +57592-8;Aldosterone^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Aldost 30M p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +57593-6;Aldosterone^30M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --30 minutes pre XXX challenge;Aldost 30M pre chal SerPl-mCnc;;ACTIVE;2.36;2.70 +57594-4;Aldosterone^30M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --30 minutes pre XXX challenge;Aldost 30M pre chal SerPl-sCnc;;ACTIVE;2.36;2.70 +57595-1;Aldosterone^1H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --1 hour post XXX challenge;Aldost 1h p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +5759-6;Dimethylbenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dimethylbenzene [Mass/volume] in Serum or Plasma;DMB SerPl-mCnc;;ACTIVE;1.0;2.73 +57596-9;Aldosterone^pre 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM;Aldost pre 250 ug ACTH IM SerPl-mCnc;;ACTIVE;2.29;2.70 +57597-7;6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;6A-OH-THS pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57598-5;6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/time] in 24 hour Urine --pre high dose dexamethasone;6A-OH-THS pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57599-3;6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;6A-OH-THS 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57600-9;6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;6A-OH-THS 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57601-7;6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/volume] in 24 hour Urine --pre dose dexamethasone;6A-OH-THS Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57602-5;6-Alpha hydroxytetrahydro-11-Deoxycortisol^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/time] in 24 hour Urine --pre dose dexamethasone;6A-OH-THS Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57603-3;6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;6A-OH-THS 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5760-4;Zinc;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Dialysis fluid;Zinc Dial fld-mCnc;;ACTIVE;1.0;2.42 +57604-1;6-Alpha hydroxytetrahydro-11-Deoxycortisol^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-Alpha hydroxytetrahydro-11-Deoxycortisol [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;6A-OH-THS 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57605-8;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;6A-OH-THA pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57606-6;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/time] in 24 hour Urine --pre high dose dexamethasone;6A-OH-THA pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57607-4;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;6A-OH-THA 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57608-2;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;6A-OH-THA 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57609-0;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/volume] in 24 hour Urine --pre dose dexamethasone;6A-OH-THA Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57610-8;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/time] in 24 hour Urine --pre dose dexamethasone;6A-OH-THA Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57611-6;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;6A-OH-THA 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5761-2;Zinc;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Red Blood Cells;Zinc RBC-mCnc;;ACTIVE;1.0;2.73 +57612-4;6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;6A-OH-THA 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57613-2;5-Alpha tetrahydrocortisol^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;5-A THF pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57614-0;5-Alpha tetrahydrocortisol^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/time] in 24 hour Urine --pre high dose dexamethasone;5-A THF pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57615-7;5-Alpha tetrahydrocortisol^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;5-A THF 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57616-5;5-Alpha tetrahydrocortisol^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;5-A THF 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57617-3;5-Alpha tetrahydrocortisol^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/volume] in 24 hour Urine --pre dose dexamethasone;5-A THF Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57618-1;5-Alpha tetrahydrocortisol^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/time] in 24 hour Urine --pre dose dexamethasone;5-A THF Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57619-9;5-Alpha tetrahydrocortisol^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;5-A THF 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5762-0;Zinc;MCnc;Pt;Semen;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Semen;Zinc Smn-mCnc;;ACTIVE;1.0;2.42 +57620-7;5-Alpha tetrahydrocortisol^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;5-Alpha tetrahydrocortisol [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;5-A THF 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57621-5;Alpha cortol^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;A-Cortol pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57622-3;Alpha cortol^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/time] in 24 hour Urine --pre high dose dexamethasone;A-Cortol pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57623-1;Alpha cortol^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;A-Cortol 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57624-9;Alpha cortol^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;A-Cortol 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57625-6;Alpha cortol^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/volume] in 24 hour Urine --pre dose dexamethasone;A-Cortol Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57626-4;Alpha cortol^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/time] in 24 hour Urine --pre dose dexamethasone;A-Cortol Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57627-2;Alpha cortol^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;A-Cortol 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57628-0;Alpha cortol^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortol [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;A-Cortol 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57629-8;Alpha cortolone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;A-cortolone pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57630-6;Alpha cortolone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/time] in 24 hour Urine --pre high dose dexamethasone;A-cortolone pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57631-4;Alpha cortolone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;A-cortolone 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57632-2;Alpha cortolone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;A-cortolone 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57633-0;Alpha cortolone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/volume] in 24 hour Urine --pre dose dexamethasone;A-cortolone Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57634-8;Alpha cortolone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/time] in 24 hour Urine --pre dose dexamethasone;A-cortolone Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57635-5;Alpha cortolone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;A-cortolone 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57636-3;Alpha cortolone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Alpha cortolone [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;A-cortolone 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57637-1;Androsterone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;Androsterone pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5763-8;Zinc;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Serum or Plasma;Zinc SerPl-mCnc;;ACTIVE;1.0;2.73 +57638-9;Androsterone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/time] in 24 hour Urine --pre high dose dexamethasone;Androsterone pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57639-7;Androsterone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;Androsterone 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57640-5;Androsterone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;Androsterone 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57641-3;Androsterone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/volume] in 24 hour Urine --pre dose dexamethasone;Androsterone Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57642-1;Androsterone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/time] in 24 hour Urine --pre dose dexamethasone;Androsterone Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57643-9;Androsterone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;Androsterone 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57644-7;Androsterone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Androsterone [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;Androsterone 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57645-4;C peptide^10M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --10 minutes pre XXX challenge;C peptide 10M pre chal SerPl-sCnc;;ACTIVE;2.36;2.70 +5764-6;Zinc;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Urine;Zinc Ur-mCnc;;ACTIVE;1.0;2.73 +57646-2;C peptide^190M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --190 minutes post XXX challenge;C peptide 190M p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +57647-0;C peptide^3.3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --3.3 hours post XXX challenge;C peptide 3.3h p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +57648-8;C peptide^5M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5 minutes pre XXX challenge;C peptide 5M pre chal SerPl-sCnc;;ACTIVE;2.36;2.70 +57649-6;C peptide^1H pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1 hour pre XXX challenge;C peptide 1h pre chal SerPl-sCnc;;ACTIVE;2.36;2.70 +57650-4;C peptide^70M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --70 minutes pre XXX challenge;C peptide 70M pre chal SerPl-sCnc;;ACTIVE;2.36;2.70 +57651-2;C peptide^1.3H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --1.3 hours post XXX challenge;C peptide 1.3h p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +57652-0;Humidifier heated wire temperature differential setting;Temp;Pt;Ventilator airway circuit;Qn;;PULM;2;Humidifier heated wire temperature differential setting Ventilator airway circuit;Humid wire TempDiff Vent airway circuit;;ACTIVE;2.29;2.70 +5765-3;Zinc;MRat;24H;Urine;Qn;;DRUG/TOX;1;Zinc [Mass/time] in 24 hour Urine;Zinc 24h Ur-mRate;;ACTIVE;1.0;2.73 +57653-8;Tidal volume.spontaneous min setting;Vol;Pt;Ventilator.alarm;Qn;;PULM;2;Tidal volume.spontaneous minimum setting Ventilator alarm;VT.spontaneous min setting Vent alarm;;ACTIVE;2.29;2.48 +57654-6;Tidal volume.inspired max setting;Vol;Pt;Ventilator.alarm;Qn;;PULM;2;Tidal volume.inspired maximum setting Ventilator alarm;VT.inspired max setting Vent alarm;;ACTIVE;2.29;2.48 +57655-3;Tidal volume.exhaled max setting;Vol;Pt;Ventilator.alarm;Qn;;PULM;2;Tidal volume.exhaled maximum setting Ventilator alarm;VT.exhaled max Vent alarm;;ACTIVE;2.29;2.48 +57656-1;Flow trigger setting;VRat;Pt;Ventilator;Qn;;PULM;2;Flow trigger setting Ventilator;Flow trigger setting Vent;;ACTIVE;2.29;2.70 +57657-9;Disconnect sensitivity setting;VFr;Pt;Ventilator.alarm;Qn;;PULM;2;Disconnect sensitivity setting Ventilator alarm;Disconnect sensitivity VFr Vent alarm;;ACTIVE;2.29;2.70 +57658-7;Rise time setting;TRto;Pt;Ventilator;Qn;;PULM;2;Rise time setting Ventilator;Rise time Vent;;ACTIVE;2.29;2.70 +57660-3;Ganglioside GQ1b Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GQ1b IgG Ab [Units/volume] in Serum by Immunoassay;GQ1b Gangl IgG Ser IA-aCnc;;ACTIVE;2.29;2.73 +5766-1;Ammonium urate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Ammonium urate crystals [Presence] in Urine sediment by Light microscopy;Amm Urate Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57661-1;Tubular basement membrane Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Tubular basement membrane Ab [Titer] in Serum by Immunofluorescence;TBM Ab Titr Ser IF;;ACTIVE;2.29;2.70 +57662-9;U1 small nuclear ribonucleoprotein Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;U1 small nuclear ribonucleoprotein Ab [Units/volume] in Serum by Immunoassay;U1 snRNP Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +57663-7;Norepinephrine^post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Norepinephrine [Mass/volume] in Plasma --post XXX challenge;Norepineph p chal Plas-mCnc;;ACTIVE;2.29;2.42 +57664-5;Lactate dehydrogenase;CCnc;Pt;Semen;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Semen;LDH Smn-cCnc;;ACTIVE;2.29;2.70 +57665-2;Protein fractions.oligoclonal bands.IgG;PrThr;Pt;Ser/Plas;Ord;Isoelectric focusing;CHEM;1;Oligoclonal Bands IgG [Presence] in Serum or Plasma by Isoelectric focusing;Oligoclonal Bands IgG SerPl Ql IEF;;ACTIVE;2.29;2.56 +57666-0;Protein fractions.oligoclonal bands.IgM;PrThr;Pt;Ser/Plas;Ord;Isoelectric focusing;CHEM;1;Oligoclonal Bands IgM [Presence] in Serum or Plasma by Isoelectric focusing;Oligoclonal Bands IgM SerPl Ql IEF;;ACTIVE;2.29;2.56 +57667-8;Protein.monoclonal.beta;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Deprecated Protein.monoclonal.beta [Mass/volume] in Urine by Electrophoresis;Deprecated M protein beta Ur Elph-mCnc;;DEPRECATED;2.29;2.70 +57668-6;Insulin-like growth factor binding protein 3^10M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge;IGF BP3 10M p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +57669-4;Insulin-like growth factor binding protein 3^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;IGF BP3 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +57670-2;Brucella melitensis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella melitensis IgG Ab [Units/volume] in Serum by Immunoassay;B melitensis IgG Ser IA-aCnc;;ACTIVE;2.29;2.69 +57671-0;Brucella melitensis Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella melitensis IgM Ab [Units/volume] in Serum by Immunoassay;B melitensis IgM Ser IA-aCnc;;ACTIVE;2.29;2.69 +57672-8;11-Deoxycortisol^2D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --2 days post XXX challenge;11DC 2D p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57673-6;Coxiella burnetii Ab.IgM^1st specimen;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii IgM Ab [Presence] in Serum by Immunofluorescence --1st specimen;C burnet IgM sp1 Ser Ql IF;;ACTIVE;2.29;2.56 +57674-4;Coxiella burnetii Ab.IgM^2nd specimen;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii IgM Ab [Presence] in Serum by Immunofluorescence --2nd specimen;C burnet IgM sp2 Ser Ql IF;;ACTIVE;2.29;2.56 +57675-1;Legionella pneumophila Ab.IgG^1st specimen;PrThr;Pt;Ser;Ord;IF;MICRO;1;Legionella pneumophila IgG Ab [Presence] in Serum by Immunofluorescence --1st specimen;L pneumo IgG sp1 Ser Ql IF;;ACTIVE;2.29;2.56 +57676-9;Legionella pneumophila Ab.IgG^2nd specimen;PrThr;Pt;Ser;Ord;IF;MICRO;1;Legionella pneumophila IgG Ab [Presence] in Serum by Immunofluorescence --2nd specimen;L pneumo IgG sp2 Ser Ql IF;;ACTIVE;2.29;2.56 +57677-7;Mycoplasma pneumoniae Ab.IgG^1st specimen;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma pneumoniae IgG Ab [Presence] in Serum by Immunoassay --1st specimen;M pneumo IgG sp1 Ser Ql IA;;ACTIVE;2.29;2.56 +57678-5;Mycoplasma pneumoniae Ab.IgG^2nd specimen;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mycoplasma pneumoniae IgG Ab [Presence] in Serum by Immunoassay --2nd specimen;M pneumo IgG sp2 Ser Ql IA;;ACTIVE;2.29;2.56 +5767-9;Appearance;Aper;Pt;Urine;Nom;;SPEC;1;Appearance of Urine;Appearance Ur;;ACTIVE;1.0;2.73 +57679-3;Chlamydia sp Ab.IgG^1st specimen;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydia sp IgG Ab [Presence] in Serum by Immunoassay --1st specimen;Chlamydia IgG sp1 Ser Ql IA;;ACTIVE;2.29;2.56 +57680-1;Chlamydia sp Ab.IgG^2nd specimen;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydia sp IgG Ab [Presence] in Serum by Immunoassay --2nd specimen;Chlamydia IgG sp2 Ser Ql IA;;ACTIVE;2.29;2.56 +57681-9;Coxiella burnetii Ab.IgG^1st specimen;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii IgG Ab [Presence] in Serum by Immunofluorescence --1st specimen;C burnet IgG sp1 Ser Ql IF;;ACTIVE;2.29;2.56 +57682-7;Coxiella burnetii Ab.IgG^2nd specimen;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii IgG Ab [Presence] in Serum by Immunofluorescence --2nd specimen;C burnet IgG sp2 Ser Ql IF;;ACTIVE;2.29;2.56 +57683-5;Plasmodium falciparum Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Plasmodium falciparum IgM Ab [Presence] in Serum by Immunoassay;P falciparum IgM Ser Ql IA;;ACTIVE;2.29;2.56 +57684-3;Cortisol^11th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --11th specimen;Cortis sp11 Sal-mCnc;;ACTIVE;2.29;2.73 +57685-0;Cortisol^2nd specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --2nd specimen;Cortis sp2 Sal-mCnc;;ACTIVE;2.29;2.73 +57686-8;Cortisol^12th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --12th specimen;Cortis sp12 Sal-mCnc;;ACTIVE;2.29;2.73 +5768-7;Ascorbate;MCnc;Pt;Urine;Qn;Test strip;UA;1;Ascorbate [Mass/volume] in Urine by Test strip;Vit C Ur Strip-mCnc;;ACTIVE;1.0;2.73 +57687-6;Cortisol^1st specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --1st specimen;Cortis sp1 Sal-mCnc;;ACTIVE;2.29;2.73 +57688-4;Cortisol^3rd specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --3rd specimen;Cortis sp3 Sal-mCnc;;ACTIVE;2.29;2.73 +57689-2;Cortisol^4th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --4th specimen;Cortis sp4 Sal-mCnc;;ACTIVE;2.29;2.73 +576-9;Fungus identified;Prid;Pt;Synv fld;Nom;Culture;MICRO;1;Fungus identified in Synovial fluid by Culture;Fungus Snv Cult;;ACTIVE;1.0;2.73 +57690-0;Cortisol^10th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --10th specimen;Cortis sp10 Sal-mCnc;;ACTIVE;2.29;2.73 +57691-8;Cortisol^9th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --9th specimen;Cortis sp9 Sal-mCnc;;ACTIVE;2.29;2.73 +57692-6;Cortisol^5th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --5th specimen;Cortis sp5 Sal-mCnc;;ACTIVE;2.29;2.73 +57693-4;Cortisol^6th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --6th specimen;Cortis sp6 Sal-mCnc;;ACTIVE;2.29;2.73 +57694-2;Cortisol^7th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --7th specimen;Cortis sp7 Sal-mCnc;;ACTIVE;2.29;2.73 +5769-5;Bacteria;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Bacteria [#/area] in Urine sediment by Microscopy high power field;Bacteria #/area UrnS HPF;;ACTIVE;1.0;2.73 +57695-9;Cortisol^8th specimen;MCnc;Pt;Saliva;Qn;;CHEM;1;Cortisol [Mass/volume] in Saliva (oral fluid) --8th specimen;Cortis sp8 Sal-mCnc;;ACTIVE;2.29;2.73 +57696-7;Pain severity;Find;Pt;^Patient;Ord;Reported.FPS-R;H&P.HX;2;Pain severity FPS-R;Pain severity FPS-R;Copyright © 2011 International Association for the Study of Pain (IASP). Used with permission. Before translating text into a language other than found on the Pediatric Pain Sourcebook (www.painsourcebook.ca), please contact IASP to gain permission.;ACTIVE;2.29;2.50 +57697-5;Protein Z Ag;MCnc;Pt;Plas;Qn;IA;CHEM;1;Protein Z Ag [Mass/volume] in Plasma by Immunoassay;Protein Z Ag Plas IA-mCnc;;ACTIVE;2.29;2.73 +57698-3;Lipid panel with direct LDL;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Lipid panel with direct LDL - Serum or Plasma;Lipid pnl with direct LDL SerPl;;ACTIVE;2.29;2.73 +57699-1;Biotinidase deficiency newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Biotinidase deficiency newborn screening comment-discussion;BIOT NBS comment;;ACTIVE;2.29;2.73 +57700-7;Hearing loss newborn screening comment-discussion;Txt;Pt;Ear;Nar;;H&P.HX.LAB;1;Hearing loss newborn screening comment/discussion;Hearing loss NBS comment/discussion;;ACTIVE;2.29;2.46 +57701-5;Infectious diseases newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Infectious diseases newborn screening comment-discussion;Infectious diseases NBS comment;;ACTIVE;2.29;2.42 +57702-3;Infectious diseases;Imp;Pt;Bld.dot;Nom;;CHEM;1;Infectious diseases newborn screen interpretation;Infectious diseases DBS-Imp;;ACTIVE;2.29;2.56 +5770-3;Bilirubin;PrThr;Pt;Urine;Ord;Test strip;UA;1;Bilirubin.total [Presence] in Urine by Test strip;Bilirub Ur Ql Strip;;ACTIVE;1.0;2.73 +57703-1;Hemoglobin disorders newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Hemoglobin disorders newborn screening comment-discussion;Hemoglobin disorders NBS comment;;ACTIVE;2.29;2.73 +57704-9;Galactosemias newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Galactosemias newborn screening comment-discussion;Galactosemias NBS comment;;ACTIVE;2.29;2.73 +57705-6;Congenital hypothyroidism newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Congenital hypothyroidism newborn screening comment-discussion;CH NBS comment;;ACTIVE;2.29;2.73 +57706-4;Congenital adrenal hyperplasia newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Congenital adrenal hyperplasia newborn screening comment-discussion;CAH NBS comment;;ACTIVE;2.29;2.73 +57707-2;Cystic fibrosis newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Cystic fibrosis newborn screening comment-discussion;CF NBS comment;;ACTIVE;2.29;2.73 +57708-0;Organic acidemias defects newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Organic acidemias defects newborn screening comment-discussion;OA defects NBS comment;;ACTIVE;2.29;2.42 +57709-8;Fatty acid oxidation defects newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Fatty acid oxidation defects newborn screening comment-discussion;FOD NBS comment;;ACTIVE;2.29;2.42 +57710-6;Amino acidemias newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Amino acidemias newborn screening comment-discussion;Amino acidemias NBS comment;;ACTIVE;2.29;2.73 +5771-1;Bilirubin crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Bilirubin crystals [Presence] in Urine sediment by Light microscopy;Bilirub Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57711-4;Unique bar code number;ID;Pt;Initial sample;Nom;;SPEC;1;Unique bar code number of Initial sample;Unique bar code # Initial sample;;ACTIVE;2.29;2.36 +57712-2;Highest level of education;Hx;Pt;^Mother;Ord;;H&P.HX;2;Highest level of education Mother;Highest level of education Mother;;ACTIVE;2.29;2.63 +57713-0;Infant factors that affect newborn screening interpretation;Find;Pt;^Patient;Nom;;H&P.HX;2;Infant factors that affect newborn screening interpretation;Inf factors affecting NBS imp;;ACTIVE;2.29;2.73 +57714-8;Obstetric estimation of gestational age;Time;Pt;^Patient;Qn;;H&P.HX;2;Obstetric estimation of gestational age;OB est of GA;;ACTIVE;2.29;2.73 +57715-5;Birth time;ClockTime;Pt;^Patient;Qn;;H&P.HX;2;Birth time;Birth time;;ACTIVE;2.29;2.73 +57716-3;State printed on filter paper card;ID;Pt;NBS card;Nom;;CHEM;1;State printed on filter paper card [Identifier] in NBS card;State printed on card NBS card;;ACTIVE;2.29;2.73 +57717-1;Newborn screen card data panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Newborn screen card data panel;NBS card data pnl;;ACTIVE;2.29;2.40 +57718-9;Sample condition;Type;Pt;Bld.dot;Nom;;SPEC;1;Sample quality of Dried blood spot;Sample quality of DBS;;ACTIVE;2.29;2.73 +57719-7;Conditions tested for in this newborn screening study;ID;Pt;Bld.dot;Nom;;CHEM;1;Conditions tested for in this newborn screening study [Identifier] in DBS;Conditions tested for in NBS study DBS;;ACTIVE;2.29;2.73 +57720-5;Newborn conditions with equivocal markers;Prid;Pt;Bld.dot;Nom;;CHEM;1;Newborn conditions with equivocal markers [Identifier] in DBS;NB conditions with equivocal markers;;ACTIVE;2.29;2.73 +57721-3;Reason for lab test;Type;Pt;Bld.dot;Nom;;MISC;1;Reason for lab test in Dried blood spot;Reason for lab test DBS;;ACTIVE;2.29;2.73 +57722-1;Birth plurality;Num;Pt;Pregnancy;Ord;;H&P.PX;2;Birth plurality of Pregnancy;Birth plurality;;ACTIVE;2.29;2.73 +57723-9;Unique bar code number;ID;Pt;Current sample;Nom;;SPEC;1;Unique bar code number of Current sample;Unique bar code # Current sample;;ACTIVE;2.29;2.73 +57724-7;Newborn screening short narrative summary;Txt;Pt;^Patient;Nar;;CHEM;1;Newborn screening short narrative summary;NBS short summary;;ACTIVE;2.29;2.73 +57725-4;Corticotropin^20M post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --20 minutes post XXX challenge;ACTH 20M p chal Plas-mCnc;;ACTIVE;2.29;2.70 +57726-2;Creatinine;MCnc;24H;Dial fld prt;Qn;;CHEM;1;Creatinine [Mass/volume] in 24 hour Peritoneal dialysis fluid;Creat 24h DiafP-mCnc;;ACTIVE;2.29;2.73 +57727-0;Norolanzapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norolanzapine [Mass/volume] in Serum or Plasma;Norolanzapine SerPl-mCnc;;ACTIVE;2.29;2.70 +57728-8;Lactate^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;Lactate 40M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +5772-9;Calcium carbonate crystals;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Calcium carbonate crystals [Presence] in Synovial fluid by Light microscopy;Ca Carbonate Cry Snv Ql Micro;;ACTIVE;1.0;2.56 +57729-6;Lactate^6M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Mass/volume] in Serum or Plasma --6 minutes post XXX challenge;Lactate 6M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57731-2;Osmolality^2nd specimen;Osmol;Pt;Urine;Qn;;CHEM;1;Osmolality of Urine--2nd specimen;Osmolality sp2 Ur;;ACTIVE;2.29;2.70 +57732-0;Osmolality^3rd specimen;Osmol;Pt;Urine;Qn;;CHEM;1;Osmolality of Urine--3rd specimen;Osmolality sp3 Ur;;ACTIVE;2.29;2.70 +57733-8;Beta-trace protein;MCnc;Pt;Body fld;Qn;;CHEM;1;Beta-trace protein [Mass/volume] in Body fluid;Beta-trace protein Fld-mCnc;;ACTIVE;2.29;2.70 +57734-6;Ketones;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Ketones [Presence] in Urine by Automated test strip;Ketones Ur Ql Strip.auto;;ACTIVE;2.29;2.73 +57735-3;Protein;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Protein [Presence] in Urine by Automated test strip;Prot Ur Ql Strip.auto;;ACTIVE;2.29;2.73 +57736-1;Cells.CD154/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD154 cells/100 cells in Body fluid;CD154 cells NFr Fld;;ACTIVE;2.29;2.70 +5773-7;Calcium carbonate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Calcium carbonate crystals [Presence] in Urine sediment by Light microscopy;Ca Carbonate Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57737-9;Basement membrane Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Basement membrane Ab [Titer] in Serum by Immunofluorescence;BM Ab Titr Ser IF;;ACTIVE;2.29;2.73 +57738-7;Basement membrane zone BP180 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay;BMZ BP180 Ab Ser IA-aCnc;;ACTIVE;2.29;2.73 +57739-5;Centromere Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Centromere Ab [Presence] in Serum by Immunoblot;Centromere Ab Ser Ql IB;;ACTIVE;2.29;2.58 +57740-3;Cells.CD3+HLA-DR+/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD3+HLA-DR+ cells/100 cells in Body fluid;CD3+HLA-DR+ Cells NFr Fld;;ACTIVE;2.29;2.70 +57741-1;Lymphocyte proliferation.OKT3 stimulation;NRat;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by OKT3 in Blood;LPT OKT3 Bld-nRate;;ACTIVE;2.29;2.73 +57742-9;Phadiatop Infant Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phadiatop infant IgE Ab [Units/volume] in Serum;Phadiatop infant IgE Qn;;ACTIVE;2.29;2.42 +57743-7;ABO group;Type;Pt;Bld;Nom;Confirm;BLDBK;1;ABO group [Type] in Blood by Confirmatory method;ABO Group Bld Cfm;;ACTIVE;2.29;2.73 +57744-5;Striated muscle Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Striated muscle Ab [Presence] in Serum by Immunofluorescence;Stria Mus Ab Ser Ql IF;;ACTIVE;2.29;2.73 +5774-5;Calcium oxalate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Calcium oxalate crystals [Presence] in Urine sediment by Light microscopy;CaOx Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57745-2;Adrenal Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Adrenal Ab [Presence] in Serum by Immunofluorescence;Adrenal Ab Ser Ql IF;;ACTIVE;2.29;2.73 +57746-0;Gamma hydroxybutyrate;PrThr;Pt;Urine;Ord;Confirm;CHEM;1;Gamma hydroxybutyrate [Presence] in Urine by Confirmatory method;G-OH-Butyr Ur Ql Cfm;;ACTIVE;2.29;2.56 +57747-8;Erythrocytes;NCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Erythrocytes [#/volume] in Urine by Automated test strip;RBC # Ur Strip.auto;;ACTIVE;2.29;2.73 +57748-6;Liver cytosol Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Liver cytosol Ab [Presence] in Serum by Immunoassay;Liver Cytosol Ab Ser Ql IA;;ACTIVE;2.29;2.56 +57749-4;Amphiphysin Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Amphiphysin Ab [Presence] in Serum by Immunoblot;Amphiphysin Ab Ser Ql IB;;ACTIVE;2.29;2.73 +57750-2;Amphiphysin Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Amphiphysin Ab [Presence] in Cerebral spinal fluid by Immunoblot;Amphiphysin Ab CSF Ql IB;;ACTIVE;2.29;2.58 +57751-0;Hemoglobin;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Hemoglobin [Presence] in Urine by Automated test strip;Hgb Ur Ql Strip.auto;;ACTIVE;2.29;2.73 +5775-2;Calcium phosphate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Calcium phosphate crystals [Presence] in Urine sediment by Light microscopy;Ca Phos Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57752-8;Urea^overnight;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea [Mass/volume] in Peritoneal dialysis fluid --overnight;Urea Overnight DiafP-mCnc;;ACTIVE;2.29;2.70 +57753-6;IKBKG gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;IKBKG gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;IKBKG gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +57754-4;TNFRSF13B gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TNFRSF13B gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;TNFRSF13B gene Mut Tested Bld/T;;ACTIVE;2.29;2.29 +57755-1;WAS gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;WAS gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;WAS gene Mut Tested Bld/T;;ACTIVE;2.29;2.29 +57756-9;Procollagen type III.N-terminal propeptide;ACnc;Pt;Ser;Qn;;CHEM;1;Procollagen type III.N-terminal propeptide [Units/volume] in Serum;Procollagen III.N-term propep Ser-aCnc;;ACTIVE;2.29;2.70 +57757-7;IKBKG gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;IKBKG gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;IKBKG gene Mut Tested Bld/T;;ACTIVE;2.29;2.29 +57758-5;TNFRSF13B gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TNFRSF13B gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TNFRSF13B gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +57759-3;WAS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;WAS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;WAS gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +5776-0;Calcium sulfate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Calcium sulfate crystals [Presence] in Urine sediment by Light microscopy;Ca Sulfate Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57760-1;Coagulation factor XIII inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor XIII inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact XIII Inhib PPP Ql;;ACTIVE;2.29;2.73 +57761-9;Platelet factor 4 heparin complex induced Ab;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Heparin induced platelet Ab [Presence] in Serum or Plasma by Immunoassay;PF4 heparin cmplx Ab SerPl Ql IA;;ACTIVE;2.29;2.73 +57762-7;Cells.CD55+CD59;PrThr;Pt;Bld;Ord;Aggl;CELLMARK;1;CD55+CD59 cells [Presence] in Blood by Agglutination;CD55+CD59 cells Bld Ql Aggl;;ACTIVE;2.29;2.56 +57763-5;Coagulation surface induced.factor substitution^immediately after addition of normal plasma/Coagulation surface induced;TRto;Pt;PPP;Qn;Coag;COAG;1;Activated partial thromboplastin time (aPTT).factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma/pre addition of normal plasma;aPTT imm NP/pre NP PPP;;ACTIVE;2.29;2.73 +57764-3;Microscopic exam;Imp;Pt;Bone mar;Nom;Cytology;CYTO;1;Microscopic exam [Interpretation] of Bone marrow by Cytology;Microscopic Mar-Imp;;ACTIVE;2.29;2.29 +57765-0;Disaccharidases panel;-;Pt;Tsmi;Qn;;PANEL.CHEM;1;Disaccharidases panel - Small intestine Tissue;Disaccharidases pnl TSMI;;ACTIVE;2.29;2.73 +57766-8;Histoplasma capsulatum Ag;MCnc;Pt;Body fld;Qn;;MICRO;1;Histoplasma capsulatum Ag [Mass/volume] in Body fluid;H capsul Ag Fld-mCnc;;ACTIVE;2.29;2.70 +57767-6;Trimipramine & Nortrimipramine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Trimipramine and Nortrimipramine panel - Serum or Plasma;Trimipram + Nor pnl SerPl;;ACTIVE;2.29;2.42 +57768-4;Campylobacter jejuni+Campylobacter coli Ag;PrThr;Pt;Stool;Ord;;MICRO;1;Campylobacter jejuni+Campylobacter coli Ag [Presence] in Stool;C jejuni+C coli Ag Stl Ql;;ACTIVE;2.29;2.73 +57769-2;Salmonella typhi O Vi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Salmonella typhi O Vi Ab [Presence] in Serum;S Typhi O Vi Ab Ser Ql;;ACTIVE;2.29;2.73 +577-7;Fungus identified;Prid;Pt;Sputum;Nom;Culture;MICRO;1;Fungus identified in Sputum by Culture;Fungus Spt Cult;;ACTIVE;1.0;2.73 +57770-0;Toxoplasma gondii Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Toxoplasma gondii IgG and IgM panel - Serum;T gondii IgG+IgM pnl Ser;;ACTIVE;2.29;2.42 +57771-8;Paraneoplastic Ab;Imp;Pt;Ser;Nar;;SERO;1;Paraneoplastic Ab [Interpretation] in Serum Narrative;Paraneoplastic Ab Ser-Imp;;ACTIVE;2.29;2.73 +57772-6;Metanephrine.free & Normetanephrine.free panel;SCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Metanephrine.free and Normetanephrine.free panel [Moles/volume] - Serum or Plasma;Metaneph+Normetaneph free Pnl SerPl-sCnc;;ACTIVE;2.29;2.73 +57773-4;Colorado tick fever virus Ab.IgG & IgM;Imp;Pt;Ser;Nar;;MICRO;1;Colorado tick fever virus IgG and IgM [Interpretation] in Serum Narrative;CTFV IgG+IgM Ser-Imp;;ACTIVE;2.29;2.73 +57774-2;Colorado tick fever virus Ab.IgG & IgM panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Colorado tick fever virus IgG and IgM panel [Titer] - Serum;CTFV IgG+IgM Pnl Titr Ser;;ACTIVE;2.29;2.42 +57775-9;Valproate.free & Valproate panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Valproate.free and Valproate panel - Serum or Plasma;Valproate.free + Valproate pnl SerPl;;ACTIVE;2.29;2.73 +57776-7;Gliadin peptide Ab.IgA & IgG panel;-;Pt;Ser;-;;PANEL.SERO;1;Gliadin peptide IgA and IgG panel - Serum;Gliadin peptide IgA & IgG pnl Ser;;ACTIVE;2.29;2.73 +57777-5;Myeloperoxidase Ab & Proteinase 3 panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Myeloperoxidase Ab and Proteinase 3 panel - Serum;MPO Ab + PR3 pnl Ser;;ACTIVE;2.29;2.73 +5777-8;Cholesterol crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Cholesterol crystals [Presence] in Urine sediment by Light microscopy;Cholest Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57778-3;Immunoglobulin light chains.free panel;-;Pt;Ser;Qn;;PANEL.CHEM;1;Immunoglobulin light chains.free panel - Serum;Immunoglobulin LC free Pnl Ser;;ACTIVE;2.29;2.73 +57779-1;Disaccharidases;Imp;Pt;Tsmi;Nar;;CHEM;1;Disaccharidases [Interpretation] in Small intestine Tissue Narrative;Disaccharidases TSMI-Imp;;ACTIVE;2.29;2.73 +57780-9;Thyroglobulin & Thyroglobulin Ab panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Thyroglobulin and Thyroglobulin Ab panel - Serum or Plasma;Thyroglob + Thyroglob Ab pnl SerPl;;ACTIVE;2.29;2.73 +57781-7;Chromosome breakage;Prid;Pt;Bld;Nar;Diepoxybutane;MOLPATH;1;Chromosome breakage [Identifier] in Blood by Diepoxybutane Narrative;Chrom Break Bld DEB;;ACTIVE;2.29;2.73 +57782-5;Complete blood count W Ordered Manual Differential panel;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;CBC W Ordered Manual Differential panel - Blood;CBC W ordered manual diff Bld;;ACTIVE;2.29;2.73 +57783-3;Dehydroepiandrosterone^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;DHEA pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57784-1;Dehydroepiandrosterone^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/time] in 24 hour Urine --pre high dose dexamethasone;DHEA pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57785-8;Dehydroepiandrosterone^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;DHEA 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5778-6;Color;Type;Pt;Urine;Nom;;SPEC;1;Color of Urine;Color Ur;;ACTIVE;1.0;2.73 +57786-6;Dehydroepiandrosterone^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;DHEA 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57787-4;Dehydroepiandrosterone^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in 24 hour Urine --pre dose dexamethasone;DHEA Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57788-2;Dehydroepiandrosterone^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/time] in 24 hour Urine --pre dose dexamethasone;DHEA Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57789-0;Dehydroepiandrosterone^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;DHEA 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57790-8;Dehydroepiandrosterone^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;DHEA 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57791-6;Organic acidemia conditions suspected;Prid;Pt;Bld.dot;Nom;;CHEM;1;Organic acidemia conditions suspected [Identifier] in DBS;OA conditions suspected DBS;;ACTIVE;2.29;2.61 +57792-4;Fatty acid oxidation conditions suspected;Prid;Pt;Bld.dot;Nom;;CHEM;1;Fatty acid oxidation conditions suspected [Identifier] in DBS;FA oxidation conditions suspected DBS;;ACTIVE;2.29;2.61 +57793-2;Amino acidemia disorder suspected;Prid;Pt;Bld.dot;Nom;;CHEM;1;Amino acidemia disorder suspected [Identifier] in DBS;Amino acidemia disorder suspected DBS;;ACTIVE;2.29;2.73 +5779-4;Crystals;Prid;Pt;Bil fld;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Bile fluid by Light microscopy;Crystals Bifl Micro;;ACTIVE;1.0;2.73 +57794-0;Newborn screening test results panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Newborn screening test results panel - DBS;NBS test results pnl DBS;;ACTIVE;2.29;2.67 +57795-7;Fecal hydrolysis panel;-;Pt;Stool;-;;PANEL.CHEM;1;Fecal hydrolysis panel - Stool;Fecal hydrolysis pnl Stl;;ACTIVE;2.36;2.42 +57796-5;Reducing substances;PrThr;Pt;Stool;Ord;Post hydrolysis;CHEM;1;Reducing substances [Presence] in Stool by Post hydrolysis;Reducing Subs Stl Ql Post hydrolysis;;ACTIVE;2.29;2.73 +57797-3;Glucose;MCnc;Pt;Stool;Qn;Post hydrolysis;CHEM;1;Glucose [Mass/volume] in Stool by Post hydrolysis;Glucose Stl Post hydrolysis-mCnc;;ACTIVE;2.29;2.70 +57798-1;Progesterone^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Progesterone [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;Progest 20M p chal SerPl-mCnc;;ACTIVE;2.29;2.70 +57800-5;Oxygen content;VFr;Pt;Bld;Qn;Calculated;CHEM;1;Oxygen content in Blood by calculation;O2 Ct VFr Bld Calc;;ACTIVE;2.29;2.73 +57801-3;Oximetry site;Anat;Pt;Bld;Nom;;PULM;2;Oximetry site Blood;Oximetry site Bld;;ACTIVE;2.29;2.73 +5780-2;Crystals;Prid;Pt;Duod fld;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Duodenal fluid by Light microscopy;Crystals Duod fl Micro;;ACTIVE;1.0;2.26 +57802-1;Chromosome analysis.interphase;Imp;Pt;Bld/Bone mar;Nar;FISH;MOLPATH;1;Chromosome analysis.interphase [Interpretation] in Blood or Marrow by FISH Narrative;Chrom analy interphase Bld/Mar FISH-Imp;;ACTIVE;2.29;2.73 +57803-9;Occult blood panel;-;Pt;Stool;-;IA;PANEL.CHEM;1;Occult blood panel - Stool by Immunoassay;OB Pnl Stl IA;;ACTIVE;2.29;2.73 +57804-7;Number of occult blood specimens recommended by testing kit protocol;Num;Pt;Stool;Qn;;CHEM;1;Number of occult blood specimens recommended by testing kit protocol [#] in Stool;# Occ bld spec recommended Stl;;ACTIVE;2.29;2.73 +57805-4;HEDIS 2010 Tests used in early prenatal care - ABO & Rh (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Tests used in early prenatal care - ABO and Rh (PPC-C);HEDIS 2010 PPC-C ABO+Rh;;DISCOURAGED;2.29;2.67 +57806-2;HEDIS 2010-2013 Tests used in early prenatal care - Rubella (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010-2013 Tests used in early prenatal care - Rubella (PPC-C);HEDIS 2010-13 PPC-C RUBV;;DISCOURAGED;2.29;2.67 +57807-0;HEDIS 2010 Tests used in early prenatal care (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Tests used in early prenatal care (PPC-C);HEDIS 2010 PPC-C;;DISCOURAGED;2.29;2.67 +57808-8;HEDIS 2010-2013 Codes to identify anticonvulsant serum concentration monitoring tests - carBAMazepine (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010-2013 Codes to identify anticonvulsant serum concentration monitoring tests - carBAMazepine (MPM-E);HEDIS 2010-13 MPM-E carBAMazepine;;DISCOURAGED;2.29;2.67 +57809-6;HEDIS 2010, 2011 Codes to identify anticonvulsant serum concentration monitoring tests (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010, 2011 Codes to identify anticonvulsant serum concentration monitoring tests (MPM-E);HEDIS 2010-11 MPM-E;;DISCOURAGED;2.29;2.67 +5781-0;Crystals;Prid;Pt;Synv fld;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Synovial fluid by Light microscopy;Crystals Snv Micro;;ACTIVE;1.0;2.73 +57810-4;HEDIS 2010, 2011 Codes to identify physiologic monitoring tests - Blood urea nitrogen (BUN) (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010, 2011 Codes to identify physiologic monitoring tests - Blood urea nitrogen (BUN) (MPM-A);HEDIS 2010-11 MPM-A BUN;;DISCOURAGED;2.29;2.67 +57811-2;HEDIS 2010,2011 Codes to identify physiologic monitoring tests - Serum creatinine (SCr) (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010,2011 Codes to identify physiologic monitoring tests - Serum creatinine (SCr) (MPM-A);HEDIS 2010-11 MPM-A SCr;;DISCOURAGED;2.29;2.67 +57812-0;HEDIS 2010 Codes to identify physiologic monitoring tests (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify physiologic monitoring tests (MPM-A);HEDIS 2010 MPM-A;;DISCOURAGED;2.29;2.67 +57813-8;HEDIS 2010 Codes to identify evidence of nephropathy (CDC-K);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify evidence of nephropathy (CDC-K);HEDIS 2010 CDC-K;;DISCOURAGED;2.29;2.67 +57814-6;HEDIS 2010 Codes to identify nephropathy screening tests (CDC-J);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify nephropathy screening tests (CDC-J);HEDIS 2010 CDC-J;;DISCOURAGED;2.29;2.67 +57815-3;HEDIS 2010 Codes to identify LDLc screening (CDC-H);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify LDLc screening (CDC-H);HEDIS 2010 CDC-H;;DISCOURAGED;2.29;2.67 +57816-1;HEDIS 2010 Codes to identify LDLc screening (CMC-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify LDLc screening (CMC-D);HEDIS 2010 CMC-D;;DISCOURAGED;2.29;2.67 +57817-9;HEDIS 2010-2013 Codes to identify Chlamydia screening (CHL-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010-2013 Codes to identify Chlamydia screening (CHL-C);HEDIS 2010-13 CHL-C;;DISCOURAGED;2.29;2.73 +57818-7;HEDIS 2010 Codes to identify sexually active women (CHL-B);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify sexually active women (CHL-B);HEDIS 2010 CHL-B;;DISCOURAGED;2.29;2.67 +57819-5;HEDIS 2010 Codes to identify colorectal cancer screening (COL-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify colorectal cancer screening (COL-A);HEDIS 2010 COL-A;;DISCOURAGED;2.29;2.67 +57820-3;HEDIS 2010 panel;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 panel;HEDIS 2010 panel;;DISCOURAGED;2.29;2.67 +57821-1;HEDIS 2010 Codes to identify physiologic monitoring tests - Serum potassium (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Codes to identify physiologic monitoring tests - Serum potassium (MPM-A);HEDIS 2010 MPM-A K;;DISCOURAGED;2.29;2.67 +57822-9;Multisection^W radionuclide IV;Find;Pt;Chest>Lung;Doc;PT;RAD;2;PT Lung;PT Lung W RNC IV;;ACTIVE;2.29;2.61 +57823-7;Multisection^W radionuclide IV;Find;Pt;Chest>Esophagus;Doc;PT;RAD;2;PT Esophagus;PT Esophagus W RNC IV;;ACTIVE;2.29;2.61 +57824-5;Cortisol.free^AM peak specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol Free [Mass/volume] in Serum or Plasma --AM peak specimen;Cortis F AM peak SerPl-mCnc;;ACTIVE;2.29;2.73 +57825-2;Cortisol.free^PM trough specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol Free [Mass/volume] in Serum or Plasma --PM trough specimen;Cortis F PM SerPl-mCnc;;ACTIVE;2.29;2.73 +57826-0;Co-payment amount;Find;Pt;^Patient;Nar;;DOC.MISC;2;Co-payment amount Narrative;Co-payment amount;;ACTIVE;2.29;2.73 +57827-8;Reason for co-payment exemption;Find;Pt;^Patient;Doc;;DOC.MISC;2;Reason for co-payment exemption Document;Reason for co-payment exemption Doc;;ACTIVE;2.29;2.73 +5782-8;Crystals;Prid;Pt;Urine sed;Nom;Microscopy.light;UA;1;Crystals [type] in Urine sediment by Light microscopy;Crystals UrnS Micro;;ACTIVE;1.0;2.73 +57828-6;Prescription list;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Prescription list;Prescriptions;;ACTIVE;2.29;2.67 +57829-4;Prescription for medical equipment or product;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Prescription for medical equipment or product;Rx for medical equipment or product;;ACTIVE;2.29;2.67 +57830-2;Admission request;Find;Pt;^Patient;Doc;;DOC.MISC;2;Admission request Document;Admission request Doc;;ACTIVE;2.29;2.73 +57831-0;Prescription for rehabilitation;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Prescription for rehabilitation;Rx for rehabilitation;;ACTIVE;2.29;2.67 +57832-8;Prescription for diagnostic or specialist care;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Prescription for diagnostic or specialist care;Rx for Dx or specialist care;;ACTIVE;2.29;2.67 +57833-6;Prescription for medication;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Prescription for medication;Rx for medication;;ACTIVE;2.29;2.67 +57834-4;Patient transportation request;Find;Pt;^Patient;Doc;;DOC.MISC;2;Patient transportation request Document;Patient transportation request Doc;;ACTIVE;2.29;2.73 +57835-1;Appearance;Aper;Pt;Dial fld;Nom;;SPEC;1;Appearance of Dialysis fluid;Appearance Dial fld;;ACTIVE;2.29;2.29 +5783-6;Crystals.unidentified;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Unidentified crystals [Presence] in Urine sediment by Light microscopy;Unident Crys UrnS Ql Micro;;ACTIVE;1.0;2.73 +57836-9;Basophils/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Synovial fluid by Manual count;Basophils/leuk NFr Snv Manual;;ACTIVE;2.36;2.73 +57837-7;Beta-1 transferrin;PrThr;Pt;Body fld;Ord;;CHEM;1;Beta-1 transferrin [Presence] in Body fluid;Beta-1 transferrin Fld Ql;;ACTIVE;2.29;2.56 +57838-5;Coagulation dilute Russell viper venom induced.excess phospholipid;Time;Pt;PPP;Qn;;COAG;1;dRVVT W excess phospholipid (LA confirm);Confirm dRVVT;;ACTIVE;2.29;2.73 +57839-3;Activated clotting time.kaolin induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Activated clotting time.kaolin induced of Platelet poor plasma from Control;ACT Kaolin Ind Cont PPP;;ACTIVE;2.29;2.70 +57840-1;Eosinophils/100 leukocytes;NFr;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Dialysis fluid by Manual count;Eosinophil/leuk NFr Dial fld Manual;;ACTIVE;2.36;2.50 +57841-9;Erythrocytes;NCnc;Pt;Dial fld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Dialysis fluid by Automated count;RBC # Dial fld Auto;;ACTIVE;2.29;2.70 +57842-7;Erythrocytes;NCnc;Pt;Pericard fld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Pericardial fluid by Automated count;RBC # Pcar Auto;;ACTIVE;2.29;2.70 +57843-5;Erythrocytes;NCnc;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Peritoneal fluid by Automated count;RBC # Prt Auto;;ACTIVE;2.29;2.70 +5784-4;Cystine crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Cystine crystals [Presence] in Urine sediment by Light microscopy;Cystine Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57844-3;Imatinib mesylate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imatinib mesylate [Mass/volume] in Serum or Plasma;Imatinib mesylate SerPl-mCnc;;ACTIVE;2.29;2.70 +57845-0;Leukocytes;NCnc;Pt;Body fld;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Body fluid by Automated count;WBC # Fld Auto;;ACTIVE;2.29;2.73 +57846-8;Leukocytes;NCnc;Pt;Pericard fld;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Pericardial fluid by Automated count;WBC # Pcar Auto;;ACTIVE;2.29;2.70 +57847-6;Leukocytes;NCnc;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Dialysis fluid by Manual count;WBC # Dial fld Manual;;ACTIVE;2.29;2.70 +57848-4;Maltose;PrThr;Pt;Urine;Ord;;CHEM;1;Maltose [Presence] in Urine;Maltose Ur Ql;;ACTIVE;2.29;2.56 +57849-2;Medication allergy;Hx;Pt;^Patient;Nar;Reported;H&P.HX;2;Medication allergy Narrative - Reported;Medication allergy Reported;;ACTIVE;2.29;2.40 +578-5;Fungus identified;Prid;Pt;Tiss;Nom;Culture;MICRO;1;Fungus identified in Tissue by Culture;Fungus Tiss Cult;;ACTIVE;1.0;2.73 +57850-0;Mesothelial cells/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 leukocytes in Synovial fluid by Manual count;Mesothl Cell/leuk NFr Snv Manual;;ACTIVE;2.36;2.50 +5785-1;Eosinophils;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Eosinophils [#/area] in Urine sediment by Microscopy high power field;Eosinophil #/area UrnS HPF;;ACTIVE;1.0;2.73 +57851-8;Microscopic observation;Prid;Pt;Urethra;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Urethra by Wet preparation;Wet Prep Urth;;ACTIVE;2.29;2.29 +57852-6;Problem list;Find;Pt;^Patient;Nar;Reported;H&P.HX;2;Problem list Narrative - Reported;Problem list Reported;;ACTIVE;2.29;2.40 +57853-4;Snowshoe hare virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Snowshoe hare virus IgG Ab [Presence] in Serum by Immunoassay;SSHV IgG Ser Ql IA;;ACTIVE;2.29;2.56 +57854-2;Thyrotropin^5M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --5 minutes post XXX challenge;TSH 5M p chal SerPl-aCnc;;ACTIVE;2.29;2.70 +57855-9;Atenolol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Atenolol [Moles/volume] in Specimen;Atenolol Spec-sCnc;;ACTIVE;2.29;2.69 +57856-7;Carisoprodol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Carisoprodol [Moles/volume] in Specimen;Carisoprodol Spec-sCnc;;ACTIVE;2.29;2.69 +57857-5;Chlorpheniramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Chlorpheniramine [Moles/volume] in Specimen;Chlorphenir Spec-sCnc;;ACTIVE;2.29;2.69 +57858-3;Normaprotiline;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Normaprotiline [Moles/volume] in Specimen;Normaprotiline Spec-sCnc;;ACTIVE;2.29;2.69 +57859-1;Dextromethorphan;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Dextromethorphan [Moles/volume] in Specimen;D-methorphan Spec-sCnc;;ACTIVE;2.29;2.69 +57860-9;Diethylamine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Diethylamine [Moles/volume] in Specimen;Diethylamine Spec-sCnc;;ACTIVE;2.29;2.69 +57861-7;HYDROcodone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;HYDROcodone [Moles/volume] in Specimen;HYDROcodone Spec-sCnc;;ACTIVE;2.29;2.69 +57862-5;Hydrocortisone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Hydrocortisone [Moles/volume] in Specimen;Hydrocortisone Spec-sCnc;;ACTIVE;2.29;2.69 +57863-3;HYDROmorphone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;HYDROmorphone [Moles/volume] in Specimen;HYDROmorphone Spec-sCnc;;ACTIVE;2.29;2.69 +57864-1;Meperidine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Meperidine [Moles/volume] in Specimen;Meperidine Spec-sCnc;;ACTIVE;2.29;2.69 +57865-8;oxyCODONE;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;oxyCODONE [Moles/volume] in Specimen;oxyCODONE Spec-sCnc;;ACTIVE;2.29;2.69 +57866-6;PENTobarbital;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;PENTobarbital [Moles/volume] in Specimen;Pentobarb Spec-sCnc;;ACTIVE;2.29;2.69 +57867-4;Pericyazine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Pericyazine [Moles/volume] in Specimen;Pericyazine Spec-sCnc;;ACTIVE;2.29;2.69 +57868-2;Perphenazine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Perphenazine [Moles/volume] in Specimen;Perphenazine Spec-sCnc;;ACTIVE;2.29;2.69 +5786-9;Epithelial casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Epithelial casts [#/area] in Urine sediment by Microscopy low power field;Epith Casts #/area UrnS LPF;;ACTIVE;1.0;2.73 +57869-0;Phencyclidine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Phencyclidine [Moles/volume] in Specimen;PCP Spec-sCnc;;ACTIVE;2.29;2.69 +57870-8;Phenylpropanolamine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Phenylpropanolamine [Moles/volume] in Specimen;PPA Spec-sCnc;;ACTIVE;2.29;2.69 +57871-6;quiNINE;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;quiNINE [Moles/volume] in Specimen;quiNINE Spec-sCnc;;ACTIVE;2.29;2.69 +57872-4;Strychnine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Strychnine [Moles/volume] in Specimen;Strychnine Spec-sCnc;;ACTIVE;2.29;2.69 +57873-2;Thiothixene;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Thiothixene [Moles/volume] in Specimen;Thiothixene Spec-sCnc;;ACTIVE;2.29;2.69 +57874-0;Cucumis melo cantalupensis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cantaloupe triggered histamine release [Units/volume] in Blood;Cantaloupe BasoBnd Ab Qn;;ACTIVE;2.29;2.69 +57875-7;Cucumis melo cantalupensis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cantaloupe IgG4 Ab [Mass/volume] in Serum;Cantaloupe IgG4-mCnc;;ACTIVE;2.29;2.73 +57876-5;Cucumis melo spp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honeydew melon IgG4 Ab [Mass/volume] in Serum;Melon IgG4-mCnc;;ACTIVE;2.29;2.73 +5787-7;Epithelial cells;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Epithelial cells [#/area] in Urine sediment by Microscopy high power field;Epi Cells #/area UrnS HPF;;ACTIVE;1.0;2.73 +57877-3;Cucumis melo cantalupensis Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cantaloupe IgG Ab RAST class [Presence] in Serum;Cantaloupe IgG RAST Ql;;ACTIVE;2.29;2.67 +57878-1;Cucumis melo spp Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honeydew melon IgG Ab RAST class [Presence] in Serum;Melon IgG RAST Ql;;ACTIVE;2.29;2.58 +57879-9;Cucumis melo cantalupensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cantaloupe IgG Ab [Units/volume] in Serum;Cantaloupe IgG Qn;;ACTIVE;2.29;2.69 +57880-7;Cucumis melo spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honeydew melon IgG Ab [Units/volume] in Serum;Melon IgG Qn;;ACTIVE;2.29;2.69 +57881-5;Cucumis melo cantalupensis Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cantaloupe IgE Ab RAST class [Presence] in Serum;Cantaloupe IgE RAST Ql;;ACTIVE;2.29;2.73 +57882-3;Cucumis melo spp Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honeydew melon IgE Ab RAST class [Presence] in Serum;Melon IgE RAST Ql;;ACTIVE;2.29;2.73 +57883-1;Cucumis melo cantalupensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cantaloupe IgE Ab [Units/volume] in Serum;Cantaloupe IgE Qn;;ACTIVE;2.29;2.73 +57884-9;Cucumis melo spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honeydew melon IgE Ab [Units/volume] in Serum;Melon IgE Qn;;ACTIVE;2.29;2.73 +5788-5;Oval fat bodies (globules);Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Oval fat bodies (globules) [#/area] in Urine sediment by Microscopy high power field;Oval fat bodies #/area UrnS HPF;;ACTIVE;1.0;2.73 +57885-6;Cucumis melo spp basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Honeydew melon triggered histamine release [Units/volume] in Blood;Melon BasoBnd Ab Qn;;ACTIVE;2.29;2.69 +57886-4;Pregnanediol^pre high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/volume] in 24 hour Urine --pre high dose dexamethasone;Pregnanediol pre hi Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57887-2;Pregnanediol^pre high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/time] in 24 hour Urine --pre high dose dexamethasone;Pregnanediol pre hi Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57888-0;Pregnanediol^2D post high dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/volume] in 24 hour Urine --2 days post high dose dexamethasone;Pregnanediol 2D p high Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57889-8;Pregnanediol^2D post high dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/time] in 24 hour Urine --2 days post high dose dexamethasone;Pregnanediol 2D p high Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57890-6;Pregnanediol^pre dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/volume] in 24 hour Urine --pre dose dexamethasone;Pregnanediol Pre Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57891-4;Pregnanediol^pre dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/time] in 24 hour Urine --pre dose dexamethasone;Pregnanediol Pre Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57892-2;Pregnanediol^2D post dose dexamethasone;MCnc;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/volume] in 24 hour Urine --2 days post dose dexamethasone;Pregnanediol 2D p Dex 24h Ur-mCnc;;ACTIVE;2.29;2.70 +5789-3;Fatty casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Fatty casts [#/area] in Urine sediment by Microscopy low power field;Fatty Casts #/area UrnS LPF;;ACTIVE;1.0;2.73 +57893-0;Pregnanediol^2D post dose dexamethasone;MRat;24H;Urine;Qn;;CHAL;1;Pregnanediol [Mass/time] in 24 hour Urine --2 days post dose dexamethasone;Pregnanediol 2D p Dex 24h Ur-mRate;;ACTIVE;2.29;2.70 +57894-8;C peptide^100M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --100 minutes post XXX challenge;C peptide 100M p chal SerPl-sCnc;;ACTIVE;2.29;2.70 +57895-5;Influenza virus A H1.neuraminidase inhibitor resistance;Susc;Pt;XXX;Ord;Genotyping;ABXBACT;1;Influenza virus A H1.neuraminidase inhibitor resistance [Susceptibility] in Specimen by Genotype method;FLUAV H1 NI resis Spec Genotyp;;ACTIVE;2.29;2.69 +57896-3;Influenza virus A 2009 H1N1v.neuraminidase inhibitor resistance;Susc;Pt;XXX;Ord;Genotyping;ABXBACT;1;Influenza virus A 2009 H1N1v.neuraminidase inhibitor resistance [Susceptibility] in Specimen by Genotype method;FLUAV 2009H1N1v NI resis Spec Genotyp;;ACTIVE;2.29;2.73 +57897-1;Influenza virus A+B.neuraminidase inhibitor resistance;Susc;Pt;XXX;Ord;Genotyping;ABXBACT;1;Influenza virus A+B.neuraminidase inhibitor resistance [Susceptibility] in Specimen by Genotype method;FLUAV+FLUBV NI resis Spec Genotyp;;ACTIVE;2.29;2.69 +57898-9;Cocaine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cocaine [Moles/volume] in Specimen;Cocaine Spec-sCnc;;ACTIVE;2.29;2.69 +57899-7;Triiodothyronine/Triiodothyronine.reverse;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3)/Triiodothyronine (T3).reverse [Ratio] in Serum or Plasma;T3/T3Reverse SerPl-Rto;;ACTIVE;2.29;2.73 +57900-3;Specimen age;Time;Pt;XXX;Qn;;SPEC;1;Age of Specimen;Age of specimen;;ACTIVE;2.29;2.73 +5790-1;Fungi.filamentous;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Fungi.filamentous [#/area] in Urine sediment by Microscopy high power field;Filament Fungi #/area UrnS HPF;;ACTIVE;1.0;2.40 +57901-1;Clostridioides difficile glutamate dehydrogenase;PrThr;Pt;Stool;Ord;;MICRO;1;Clostridioides difficile glutamate dehydrogenase [Presence] in Stool;C diff GDH Stl Ql;;ACTIVE;2.29;2.73 +57902-9;B little g super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Bg sup(a) Ab [Presence] in Serum or Plasma;Bg sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +57903-7;B little g super little a Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;Bg sup(a) Ab [Titer] in Serum or Plasma;Bg sup(a) Ab Titr SerPl;;ACTIVE;2.29;2.42 +57904-5;B little g super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Bg sup(a) Ag [Presence] on Red Blood Cells;Bg sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +57905-2;Hemoglobin.gastrointestinal.lower^1st specimen;PrThr;Pt;Stool;Ord;IA;CHEM;1;Hemoglobin.gastrointestinal.lower [Presence] in Stool by Immunoassay --1st specimen;Hemoccult sp1 Stl Ql IA;;ACTIVE;2.29;2.73 +57906-0;9p21 chromosome deletion;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;9p21 chromosome deletion [Identifier] in Blood or Tissue by FISH Nominal;9p21 chrom Del Bld/T FISH;;ACTIVE;2.34;2.73 +57907-8;Atazanavir+Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Atazanavir+Ritonavir [Susceptibility] by Phenotype method;Atazanavir+Ritonavir Islt Phenotyp;;ACTIVE;2.29;2.73 +57908-6;AIRE gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;AIRE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;AIRE gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +57909-4;ADNFLE gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ADNFLE gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ADNFLE gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +57910-2;Bartonella quintana DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bartonella quintana DNA [Presence] in Specimen by NAA with probe detection;B quintana DNA Spec Ql NAA+probe;;ACTIVE;2.29;2.73 +57911-0;Basement membrane zone BP230 Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Basement membrane zone BP230 Ab [Units/volume] in Serum or Plasma;BMZ BP230 Ab SerPl-aCnc;;ACTIVE;2.29;2.73 +57912-8;Bean green Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Green Bean IgE Ab/IgE total in Serum;Green Bean IgE/IgE total %;;ACTIVE;2.32;2.70 +57913-6;Bean white Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;White Bean IgE Ab/IgE total in Serum;White Bean IgE/IgE total %;;ACTIVE;2.32;2.70 +57914-4;Beta lactoglobulin Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Beta lactoglobulin IgE Ab/IgE total in Serum;B-Lactoglob IgE/IgE total %;;ACTIVE;2.32;2.70 +57915-1;Bombus terrestris Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Bumble Bee IgE Ab/IgE total in Serum;Bumble Bee IgE/IgE total %;;ACTIVE;2.32;2.70 +57916-9;Borrelia burgdorferi C6 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia burgdorferi C6 Ab [Presence] in Serum;B burgdor C6 Ab Ser Ql;;ACTIVE;2.29;2.73 +57917-7;Budgerigar droppings Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Budgerigar droppings IgG Ab [Units/volume] in Serum;Budgie Drop IgG Qn;;ACTIVE;2.29;2.69 +57918-5;CACNA1S+SCN4A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CACNA1S+SCN4A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CACNA1S+SCN4A gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +5791-9;Fungi.yeastlike;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Fungi.yeastlike [#/area] in Urine sediment by Microscopy high power field;Yeast Like Fungi #/area UrnS HPF;;ACTIVE;1.0;2.73 +57919-3;Calcium;MCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Calcium [Mass/volume] in Nonbiological fluid;Calcium Fld.NB-mCnc;;ACTIVE;2.29;2.70 +57920-1;Carbon dioxide;SCnc;Pt;BldMV;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Mixed venous blood by calculation;CO2 BldMV Calc-sCnc;;ACTIVE;2.29;2.73 +57921-9;Carbon dioxide;SCnc;Pt;BldCoA;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Arterial cord blood by calculation;CO2 BldCoA Calc-sCnc;;ACTIVE;2.29;2.73 +57922-7;Carbon dioxide;SCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Serum or Plasma by calculation;CO2 SerPl Calc-sCnc;;ACTIVE;2.29;2.70 +57923-5;Carbon dioxide;SCnc;Pt;BldCoV;Qn;Calculated;CHEM;1;Carbon dioxide, total [Moles/volume] in Venous cord blood by calculation;CO2 BldCoV Calc-sCnc;;ACTIVE;2.29;2.73 +57924-3;Carboxy tetrahydrocannabinol;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Meconium;CarboxyTHC Mec Ql;;ACTIVE;2.29;2.56 +57925-0;Castanea sativa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Chestnut IgE Ab/IgE total in Serum;Chestnut IgE/IgE total %;;ACTIVE;2.32;2.70 +5792-7;Glucose;MCnc;Pt;Urine;Qn;Test strip;UA;1;Glucose [Mass/volume] in Urine by Test strip;Glucose Ur Strip-mCnc;;ACTIVE;1.0;2.73 +57927-6;CDKN2A+CDK4 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CDKN2A+CDK4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CDKN2A+CDK4 gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +579-3;Fungus identified;Prid;Pt;Wound;Nom;Culture;MICRO;1;Fungus identified in Wound by Culture;Fungus Wnd Cult;;ACTIVE;1.0;2.73 +57930-0;CFTR gene.p.Asp1152His;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene p.Asp1152His [Presence] in Blood or Tissue by Molecular genetics method;CFTR p.D1152H Bld/T Ql;;ACTIVE;2.29;2.73 +57931-8;CFTR+PRSS1+SPINK1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CFTR+PRSS1+SPINK1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CFTR+PRSS1+SPINK1 gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +57932-6;Cheese cheddar type Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cheese cheddar type IgE Ab/IgE total in Serum;Cheddar IgE/IgE total %;;ACTIVE;2.32;2.70 +57933-4;Cheese mold type Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cheese mold type IgE Ab/IgE total in Serum;Cheese Mold IgE/IgE total %;;ACTIVE;2.32;2.70 +57934-2;Chikungunya virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Chikungunya virus IgM Ab [Presence] in Serum or Plasma;CHIKV IgM SerPl Ql;;ACTIVE;2.29;2.73 +5793-5;Granular casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Granular casts [#/area] in Urine sediment by Microscopy low power field;Gran Casts #/area UrnS LPF;;ACTIVE;1.0;2.73 +57935-9;Chocolate Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Chocolate IgE Ab/IgE total in Serum;Chocolate IgE/IgE total %;;ACTIVE;2.32;2.70 +57936-7;Cholesterol.in HDL 2a;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 2a [Mass/volume] in Serum or Plasma;HDLc 2a SerPl-mCnc;;ACTIVE;2.29;2.34 +57937-5;Cholesterol.in HDL 3a;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 3a [Mass/volume] in Serum or Plasma;HDLc 3a SerPl-mCnc;;ACTIVE;2.29;2.34 +57938-3;LDL 5;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;LDL 5 [Mass/volume] in Serum or Plasma;LDL5 SerPl-mCnc;;DISCOURAGED;2.29;2.73 +57939-1;Chromium;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Cerebral spinal fluid;Chromium CSF-mCnc;;ACTIVE;2.29;2.70 +57940-9;Citrullus lanatus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Watermelon IgE Ab/IgE total in Serum;Watermelon IgE/IgE total %;;ACTIVE;2.32;2.70 +57941-7;Citrus aurantifolia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lime IgE Ab/IgE total in Serum;Lime IgE/IgE total %;;ACTIVE;2.32;2.70 +57942-5;Cladosporium sp Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium sp IgG4 Ab [Mass/volume] in Serum;Cladosporium IgG4-mCnc;;ACTIVE;2.29;2.70 +5794-3;Hemoglobin;PrThr;Pt;Urine;Ord;Test strip;UA;1;Hemoglobin [Presence] in Urine by Test strip;Hgb Ur Ql Strip;;ACTIVE;1.0;2.73 +57943-3;Clenbuterol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Clenbuterol [Presence] in Urine;Clenbuterol Ur Ql;;ACTIVE;2.29;2.73 +57944-1;Cobalt;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Cerebral spinal fluid;Cobalt CSF-mCnc;;ACTIVE;2.29;2.70 +57945-8;Cocaethylene;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Cocaethylene [Presence] in Meconium;Cocaethylene Mec Ql;;ACTIVE;2.29;2.56 +57946-6;Coccidioides immitis Ab.IgG;PrThr;Pt;CSF;Ord;Comp fix;MICRO;1;Coccidioides immitis IgG Ab [Presence] in Cerebral spinal fluid by Complement fixation;C immitis IgG CSF Ql CF;;ACTIVE;2.29;2.56 +57947-4;Coffee bean Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Coffee bean IgE Ab RAST class [Presence] in Serum;Coffee Bean IgE RAST Ql;;ACTIVE;2.32;2.58 +57948-2;Collagen crosslinked C-telopeptide;MCnc;24H;Urine;Qn;;CHEM;1;Collagen crosslinked C-telopeptide [Mass/volume] in 24 hour Urine;Collagen CTx 24h Ur-mCnc;;ACTIVE;2.29;2.70 +57949-0;Complement C4c;MCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4c [Mass/volume] in Serum or Plasma;Complement C4c SerPl-mCnc;;ACTIVE;2.29;2.70 +5795-0;Hippurate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Hippurate crystals [Presence] in Urine sediment by Light microscopy;Hippurate Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57950-8;Cow whey Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cow whey IgE Ab/IgE total in Serum;Cow Whey IgE/IgE total %;;ACTIVE;2.32;2.70 +57951-6;CPVT1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CPVT1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CPVT1 gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +57952-4;Cucumis melo spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Honeydew melon IgE Ab/IgE total in Serum;Melon IgE/IgE total %;;ACTIVE;2.32;2.70 +57953-2;Ethisterone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Ethisterone [Presence] in Urine;Ethisterone Ur Ql;;ACTIVE;2.29;2.73 +57954-0;Darunavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Darunavir [Mass/volume] in Serum or Plasma;Darunavir SerPl-mCnc;;ACTIVE;2.29;2.42 +57955-7;Darunavir+Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Darunavir+Ritonavir [Susceptibility] by Phenotype method;Darunavir+Ritonavir Islt Phenotyp;;ACTIVE;2.29;2.73 +57956-5;Desoxymethyltestosterone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Desoxymethyltestosterone [Presence] in Urine;Desoxy MeT Ur Ql;;ACTIVE;2.29;2.69 +57957-3;Difenacoum;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Difenacoum [Mass/volume] in Serum or Plasma;Difenacoum SerPl-mCnc;;ACTIVE;2.29;2.70 +57958-1;DPYD2A gene targeted mutation analysis;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;DPYD2A gene targeted mutation analysis [Presence] in Blood or Tissue by Molecular genetics method;DPYD2A gene Mut Anl Bld/T Ql;;ACTIVE;2.29;2.63 +57959-9;Drostanolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Drostanolone [Presence] in Urine;Drostanolone Ur Ql;;ACTIVE;2.29;2.73 +57960-7;Erythrocytes;Morph;Pt;Body fld;Nom;Microscopy.light;HEM/BC;1;Erythrocytes [Morphology] in Body fluid by Light microscopy;RBC Fld Micro;;ACTIVE;2.29;2.73 +57961-5;Etravirine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Etravirine [Mass/volume] in Serum or Plasma;Etravirine SerPl-mCnc;;ACTIVE;2.29;2.34 +57962-3;FECH gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FECH gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FECH gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +57963-1;FLCN gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FLCN gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FLCN gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +57964-9;Formebolone metabolite;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Formebolone metabolite [Presence] in Urine;Formebolone metab Ur Ql;;ACTIVE;2.29;2.56 +57965-6;Fosamprenavir+Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Fosamprenavir+Ritonavir [Susceptibility] by Phenotype method;Fosamprenavir+Ritonavir Islt Phenotyp;;ACTIVE;2.29;2.73 +57966-4;Furazabol metabolite;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Furazabol metabolite [Presence] in Urine;Furazabol metab Ur Ql;;ACTIVE;2.29;2.56 +57967-2;Galactitol;PrThr;Pt;Urine;Ord;;CHEM;1;Galactitol [Presence] in Urine;Galactitol Ur Ql;;ACTIVE;2.29;2.56 +5796-8;Hyaline casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Hyaline casts [#/area] in Urine sediment by Microscopy low power field;Hyaline Casts #/area UrnS LPF;;ACTIVE;1.0;2.73 +57968-0;Ganglioside GD1a Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GD1a IgG Ab [Presence] in Serum;GD1a Gangl IgG Ser Ql;;ACTIVE;2.29;2.56 +57969-8;Ganglioside GD1a Ab.IgM;PrThr;Pt;Ser;Ord;;SERO;1;Ganglioside GD1a IgM Ab [Presence] in Serum;GD1a Gangl IgM Ser Ql;;ACTIVE;2.29;2.56 +57970-6;Glucose^3H post 75 g glucose PO;MCnc;Pt;Urine;Qn;;CHAL;1;Glucose [Mass/volume] in Urine --3 hours post 75 g glucose PO;Glucose 3h p 75 g Glc PO Ur-mCnc;;ACTIVE;2.29;2.73 +57971-4;Glucose^4th specimen post dose lactose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4th specimen post lactose;Glucose 4sp p Lact SerPl-mCnc;;ACTIVE;2.29;2.70 +57972-2;Glucose^5th specimen post dose lactose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5th specimen post lactose;Glucose 5sp p Lact SerPl-mCnc;;ACTIVE;2.29;2.70 +57973-0;Histoplasma capsulatum Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Histoplasma capsulatum IgM Ab [Presence] in Cerebral spinal fluid;H capsul IgM CSF Ql;;ACTIVE;2.29;2.56 +57974-8;HIV 1 Ab;PrThr;Pt;CSF;Ord;IB;MICRO;1;HIV 1 Ab [Presence] in Cerebral spinal fluid by Immunoblot;HIV1 Ab CSF Ql IB;;ACTIVE;2.29;2.58 +57975-5;HIV 1+O+2 Ab;PrThr;Pt;Body fld;Ord;;MICRO;1;HIV 1+O+2 Ab [Presence] in Body fluid;HIV 1+O+2 Ab Fld Ql;;ACTIVE;2.29;2.56 +5797-6;Ketones;MCnc;Pt;Urine;Qn;Test strip;UA;1;Ketones [Mass/volume] in Urine by Test strip;Ketones Ur Strip-mCnc;;ACTIVE;1.0;2.73 +57976-3;HIV 2 gp140 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 gp140 Ab [Presence] in Serum by Immunoblot;HIV 2 gp140 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +57977-1;HIV 2 p16 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p16 Ab [Presence] in Serum by Immunoblot;HIV 2 p16 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +57978-9;HIV 2 p34 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p34 Ab [Presence] in Serum by Immunoblot;HIV 2 p34 Ab Ser Ql IB;;ACTIVE;2.29;2.58 +57979-7;HLA-B*15:02;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-B*15:02 [Presence];HLA-B*15:02 Ql;;ACTIVE;2.29;2.73 +57980-5;HLA-B51;ACnc;Pt;Bld/Tiss;Ord;;HLA;1;Deprecated HLA-B51 [Presence];Deprecated HLA-B51 Ql;;DEPRECATED;2.29;2.54 +57981-3;HYDROcodone;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;HYDROcodone [Presence] in Meconium;HYDROcodone Mec Ql;;ACTIVE;2.29;2.56 +57982-1;HYDROmorphone;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;HYDROmorphone [Presence] in Meconium;HYDROmorphone Mec Ql;;ACTIVE;2.29;2.56 +57983-9;IDUA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;IDUA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;IDUA gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +5798-4;Leucine crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Leucine crystals [Presence] in Urine sediment by Light microscopy;Leucine Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +57984-7;Indinavir+Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Indinavir+Ritonavir [Susceptibility] by Phenotype method;Indinavir+Ritonavir Islt Phenotyp;;ACTIVE;2.29;2.73 +57985-4;Influenza virus A H2 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H2 RNA [Presence] in Specimen by NAA with probe detection;FLUAV H2 RNA Spec Ql NAA+probe;;ACTIVE;2.29;2.69 +57986-2;Insulin-like growth factor^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;IGF sp1 p chal SerPl-mCnc;;ACTIVE;2.29;2.40 +57987-0;Ipomoea batatas Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sweet potato IgE Ab/IgE total in Serum;Sweet potato IgE/IgE total %;;ACTIVE;2.32;2.70 +57988-8;Iron;MCnc;Pt;CSF;Qn;;CHEM;1;Iron [Mass/volume] in Cerebral spinal fluid;Iron CSF-mCnc;;ACTIVE;2.29;2.70 +57990-4;KRIT1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KRIT1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KRIT1 gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +57991-2;Lactalbumin Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin IgE Ab/IgE total in Serum;Lactalb IgE/IgE total %;;ACTIVE;2.32;2.70 +5799-2;Leukocyte esterase;PrThr;Pt;Urine;Ord;Test strip;UA;1;Leukocyte esterase [Presence] in Urine by Test strip;Leukocyte esterase Ur Ql Strip;;ACTIVE;1.0;2.73 +57992-0;Legionella pneumophila 1+3+4+5+6+8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila 1+3+4+5+6+8 Ab [Presence] in Serum;L pneumo 1+3+4+5+6+8 Ab Ser Ql;;ACTIVE;2.29;2.56 +57993-8;Lepidoglyphus destructor Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lepidoglyphus destructor IgE Ab/IgE total in Serum;L destructor IgE/IgE total %;;ACTIVE;2.32;2.70 +57994-6;Leucine/Alanine;MRto;Pt;Bld.dot;Qn;;CHEM;1;Leucine/Alanine [Mass Ratio] in DBS;Leucine/Alanine DBS;;ACTIVE;2.29;2.61 +57995-3;Leucine/Phenylalanine;MRto;Pt;Bld.dot;Qn;;CHEM;1;Leucine/Phenylalanine [Mass Ratio] in DBS;Leucine/Phe DBS;;ACTIVE;2.29;2.61 +57996-1;Leucine+Isoleucine;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Leucine+Isoleucine [Mass/volume] in DBS;Leu+Ile DBS-mCnc;;ACTIVE;2.29;2.70 +57997-9;Lopinavir+Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Lopinavir+Ritonavir [Susceptibility] by Phenotype method;Lopinavir+Ritonavir Islt Phenotyp;;ACTIVE;2.29;2.29 +57998-7;Magnesium;MCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Magnesium [Mass/volume] in Nonbiological fluid;Magnesium Fld.NB-mCnc;;ACTIVE;2.29;2.70 +57999-5;Manganese;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Cerebral spinal fluid;Manganese CSF-mCnc;;ACTIVE;2.29;2.70 +58000-1;Maple sugar Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Maple sugar IgE Ab/IgE total in Serum;Maple sugar IgE/IgE total %;;ACTIVE;2.32;2.70 +58001-9;Matrix metallopeptidase 9;MCnc;Pt;Bld;Qn;;CHEM;1;Matrix metallopeptidase 9 [Mass/volume] in Blood;MMP9 Bld-mCnc;;ACTIVE;2.29;2.70 +58002-7;Mestanolone metabolite;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mestanolone metabolite [Presence] in Urine;Mestanolone metab Ur Ql;;ACTIVE;2.29;2.56 +58003-5;Methylandrostenediol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methylandrostenediol [Presence] in Urine;Methylandrostenediol Ur Ql;;ACTIVE;2.29;2.73 +58004-3;Methasterone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methasterone [Presence] in Urine;Methasterone Ur Ql;;ACTIVE;2.29;2.56 +58005-0;Methylnortestosterone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methylnortestosterone [Presence] in Urine;Methylnortestosterone Ur Ql;;ACTIVE;2.29;2.56 +58006-8;Mibolerone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mibolerone [Presence] in Urine;Mibolerone Ur Ql;;ACTIVE;2.29;2.56 +5800-8;Lipids;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Lipids [#/area] in Urine sediment by Microscopy high power field;Lipids #/area UrnS HPF;;ACTIVE;1.0;2.40 +58008-4;Morus alba Ab.IgG.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;White mulberry IgG Ab RAST class [Presence] in Serum;White mulberry IgG RAST Ql;;ACTIVE;2.29;2.58 +58009-2;MPL gene.p.Trp515;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MPL gene p.Trp515 [Presence] in Blood or Tissue by Molecular genetics method;MPL p.W515 Bld/T Ql;;ACTIVE;2.29;2.73 +580-1;Fungus identified;Prid;Pt;XXX;Nom;Culture;MICRO;1;Fungus identified in Specimen by Culture;Fungus Spec Cult;;ACTIVE;1.0;2.73 +58010-0;MSH2 gene+MLH1 gene+MSH6 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MSH2 gene+MLH1 gene+MSH6 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MSH2+MLH1+MSH6 gene Mut Anl Bld/T;;ACTIVE;2.29;2.73 +58011-8;Myelin Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Myelin IgG Ab [Presence] in Serum by Immunofluorescence;Myelin IgG Ser Ql IF;;ACTIVE;2.29;2.56 +58012-6;Natalizumab Ab;PrThr;Pt;Ser;Ord;;SERO;1;Natalizumab Ab [Presence] in Serum;Natalizumab Ab Ser Ql;;ACTIVE;2.29;2.73 +58013-4;Norclomipramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norclomipramine [Presence] in Urine;Norclomipramine Ur Ql;;ACTIVE;2.29;2.73 +58014-2;Nordoxepin;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nordoxepin [Presence] in Urine;Nordoxepin Ur Ql;;ACTIVE;2.29;2.73 +58015-9;Nortrimipramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nortrimipramine [Presence] in Urine;Nortrimipramine Ur Ql;;ACTIVE;2.29;2.56 +5801-6;Magnesium ammonium phosphate crystals;ACnc;Pt;Urine sed;Ord;Microscopy.light;UA;1;Deprecated Magnesium ammonium phosphate crystals [Presence] in Urine sediment by Light microscopy;Deprecated MAP Cry UrnS Ql Micro;;DEPRECATED;1.0;2.36 +58016-7;Octreotide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Octreotide [Mass/volume] in Serum or Plasma;Octreotide SerPl-mCnc;;ACTIVE;2.29;2.70 +58017-5;Olea europaea pollen Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Olive Pollen IgE Ab/IgE total in Serum;Olive Poln IgE/IgE total %;;ACTIVE;2.32;2.70 +58018-3;Oxabolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Oxabolone [Presence] in Urine;Oxabolone Ur Ql;;ACTIVE;2.29;2.56 +58019-1;Phosphate;MCnc;Pt;Flu.nonbiological;Qn;;CHEM;1;Phosphate [Mass/volume] in Nonbiological fluid;Phosphate Fld.NB-mCnc;;ACTIVE;2.29;2.70 +58020-9;PKD2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PKD2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PKD2 gene Mut Anl Bld/T;;ACTIVE;2.29;2.66 +58021-7;Populus deltoides Ab.IgG.RAST class;PrThr;Pt;Ser/Plas;Ord;;ALLERGY;1;Cottonwood IgG Ab RAST class [Presence] in Serum or Plasma;Cottonwood IgG RAST Ql;;ACTIVE;2.29;2.58 +58022-5;Prostanozol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Prostanozol [Presence] in Urine;Prostanozol Ur Ql;;ACTIVE;2.29;2.56 +58023-3;Rabies virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rabies virus IgG Ab [Units/volume] in Serum;RABV IgG Ser-aCnc;;ACTIVE;2.29;2.73 +5802-4;Nitrite;PrThr;Pt;Urine;Ord;Test strip;UA;1;Nitrite [Presence] in Urine by Test strip;Nitrite Ur Ql Strip;;ACTIVE;1.0;2.73 +58024-1;Saquinavir+Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Saquinavir+Ritonavir [Susceptibility] by Phenotype method;Saquinavir+Ritonavir Islt Phenotyp;;ACTIVE;2.29;2.73 +58025-8;Secale cereale pollen Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cultivated Rye IgE Ab/IgE total in Serum;Cultivated Rye IgE/IgE total %;;ACTIVE;2.32;2.70 +58026-6;Selenium;MCnc;Pt;Flu.nonbiological;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Nonbiological fluid;Selenium Fld.NB-mCnc;;ACTIVE;2.29;2.70 +58027-4;Testolactone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Testolactone [Presence] in Urine;Testolactone Ur Ql;;ACTIVE;2.29;2.56 +58028-2;Tetrahydrogestrinone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tetrahydrogestrinone [Presence] in Urine;Tetrahydrogestrinone Ur Ql;;ACTIVE;2.29;2.56 +58029-0;Tipranavir+Ritonavir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Tipranavir+Ritonavir [Susceptibility] by Phenotype method;Tipranavir+Ritonavir Islt Phenotyp;;ACTIVE;2.29;2.73 +58030-8;Tranylcypromine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Tranylcypromine [Presence] in Urine;Tranylcypromine Ur Ql;;ACTIVE;2.29;2.56 +58031-6;Treponema pallidum Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Treponema pallidum IgG Ab [Presence] in Cerebral spinal fluid;T pallidum IgG CSF Ql;;ACTIVE;2.29;2.56 +5803-2;pH;LsCnc;Pt;Urine;Qn;Test strip;UA;1;pH of Urine by Test strip;pH Ur Strip;;ACTIVE;1.0;2.73 +58032-4;Ulmus americana Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Elm IgG Ab [Mass/volume] in Serum;White Elm IgG-mCnc;;ACTIVE;2.29;2.73 +58033-2;Urtica dioica Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Nettle IgE Ab/IgE total in Serum;Nettle IgE/IgE total %;;ACTIVE;2.32;2.70 +58034-0;Ustilago cynodontis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass smut IgE Ab/IgE total in Serum;Bermuda grass smut IgE/IgE total %;;ACTIVE;2.32;2.70 +58035-7;Vaccinium myrtillus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blueberry IgG Ab [Mass/volume] in Serum;Blueberry IgG-mCnc;;ACTIVE;2.29;2.73 +58036-5;Xanthine/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Xanthine/Total in Stone;Xanthine MFr Stone;;ACTIVE;2.29;2.44 +58037-3;Zinc;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Cerebral spinal fluid;Zinc CSF-mCnc;;ACTIVE;2.29;2.42 +58038-1;Gestrinone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Gestrinone [Presence] in Urine;Gestrinone Ur Ql;;ACTIVE;2.29;2.56 +58039-9;HLA-B SBT;Type;Pt;Bone mar;Nom;High resolution;HLA;1;HLA-B SBT [Type] in Bone marrow by High resolution;HLA-B SBT Mar High Res;;ACTIVE;2.29;2.29 +5804-0;Protein;MCnc;Pt;Urine;Qn;Test strip;UA;1;Protein [Mass/volume] in Urine by Test strip;Prot Ur Strip-mCnc;;ACTIVE;1.0;2.73 +58041-5;Norclostebol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norclostebol [Presence] in Urine;Norclostebol Ur Ql;;ACTIVE;2.29;2.56 +58042-3;Phencyclidine;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Blood by Confirmatory method;PCP Bld Ql Cfm;;ACTIVE;2.29;2.56 +58043-1;Platanus occidentalis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;American Sycamore IgE Ab/IgE total in Serum;Amer Sycamore IgE/IgE total %;;ACTIVE;2.32;2.70 +58044-9;RYR1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;RYR1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;RYR1 gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +58045-6;SCN4A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SCN4A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SCN4A gene Mut Anl Bld/T;;ACTIVE;2.29;2.63 +58046-4;Strongyloides stercoralis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Strongyloides stercoralis Ab [Titer] in Serum;S stercoralis Ab Titr Ser;;ACTIVE;2.29;2.32 +58047-2;Tetrahydrocannabinol;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Blood by Confirmatory method;THC Bld Ql Cfm;;ACTIVE;2.29;2.73 +58050-6;Inpatient procedure relevant to plan of care;Type;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Inpatient procedure relevant to plan of care [OASIS-C];;;ACTIVE;2.29;2.44 +58051-4;Payment diagnosis;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Payment diagnosis [OASIS-C];;;ACTIVE;2.29;2.68 +58052-2;Date pressure injury first identified;Date;Pt;Pressure injury.oldest non-epithelialized stage 2;Qn;CMS Assessment;SURVEY.CMS;4;Date pressure injury.oldest non-epithelialized stage 2 first identified [CMS Assessment];;;ACTIVE;2.29;2.63 +58053-0;C little h super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Ch sup(a) Ag [Presence] on Red Blood Cells;Ch sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +58054-8;C little h super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ch sup(a) Ab [Presence] in Serum or Plasma;Ch sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58055-5;C little o super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Co sup(a) Ag [Presence] on Red Blood Cells;Co sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +58056-3;C little o super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Co sup(b) Ag [Presence] on Red Blood Cells;Co sup(b) Ag RBC Ql;;ACTIVE;2.29;2.56 +5805-7;Pyrophosphate crystals;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Pyrophosphate crystals [Presence] in Synovial fluid by Light microscopy;Pyrophos Cry Snv Ql Micro;;ACTIVE;1.0;2.73 +58057-1;C little s super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Cs sup(a) Ab [Presence] in Serum or Plasma;Cs sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58058-9;C little s super little a Ag;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Cs sup(a) Ag [Presence] in Serum or Plasma;Cs sup(a) Ag SerPl Ql;;ACTIVE;2.29;2.56 +58059-7;D little o super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Do sup(b) Ab [Presence] in Serum or Plasma;Do sup(b) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58060-5;D little o super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Do sup(b) Ag [Presence] on Red Blood Cells;Do sup(b) Ag RBC Ql;;ACTIVE;2.29;2.56 +58061-3;G little o super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Go sup(a) Ab [Presence] in Serum or Plasma;Go sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58062-1;I little n super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;In sup (b) Ag [Presence] on Red Blood Cells;In sup (b) Ag RBC Ql;;ACTIVE;2.29;2.56 +58063-9;I little n super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;In sup (b) Ab [Presence] in Serum or Plasma;In sup (b) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58064-7;J little r super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Jr sup(a) Ag [Presence] on Red Blood Cells;Jr sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +5806-5;Pyrophosphate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Pyrophosphate crystals [Presence] in Urine sediment by Light microscopy;Pyrophos Cry UrnS Ql Micro;;ACTIVE;1.0;2.56 +58065-4;J little r super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Jr sup(a) Ab [Presence] in Serum or Plasma;Jr sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58066-2;K little n super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Kn sup(a) Ag [Presence] on Red Blood Cells;Kn sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +58067-0;K little n super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Kn sup(a) Ab [Presence] in Serum or Plasma;Kn sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58068-8;K little n super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Kn sup (b) Ab [Presence] in Serum or Plasma;Kn sup (b) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58069-6;K little n super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Kn sup (b) Ag [Presence] on Red Blood Cells;Kn sup (b) Ag RBC Ql;;ACTIVE;2.29;2.56 +58070-4;M little c C super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;McC sup(a) Ab [Presence] in Serum or Plasma;McC sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58071-2;R little g super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Rg sup(a) Ag [Presence] on Red Blood Cells;Rg sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +58072-0;R little g super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Rg sup(a) Ab [Presence] in Serum or Plasma;Rg sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +5807-3;Erythrocyte casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;RBC casts [#/area] in Urine sediment by Microscopy low power field;RBC Casts #/area UrnS LPF;;ACTIVE;1.0;2.73 +58073-8;W little r super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Wr sup(a) Ag [Presence] on Red Blood Cells;Wr sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +58074-6;W little r super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Wr sup(a) Ab [Presence] in Serum or Plasma;Wr sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58075-3;Y little k super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Yk sup(a) Ag [Presence] on Red Blood Cells;Yk sup(a) Ag RBC Ql;;ACTIVE;2.29;2.56 +58076-1;Y little k super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Yk sup(a) Ab [Presence] in Serum or Plasma;Yk sup(a) Ab SerPl Ql;;ACTIVE;2.29;2.56 +58077-9;Urinalysis complete W Reflex Culture panel;-;Pt;Urine;-;;PANEL.UA;1;Urinalysis complete W Reflex Culture panel - Urine;UA complete W Reflex Culture pnl Ur;;ACTIVE;2.29;2.73 +58078-7;IH Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;IH Ab [Presence] in Serum or Plasma;IH Ab SerPl Ql;;ACTIVE;2.29;2.56 +58079-5;JMH Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;JMH Ab [Presence] in Serum or Plasma;JMH Ab SerPl Ql;;ACTIVE;2.29;2.56 +58080-3;Penicillin.parenteral;Susc;Pt;Isolate.meningitis;OrdQn;;ABXBACT;1;Penicillin Parenteral [Susceptibility] for meningitis;Penicillin Parenteral Susc Islt.mening;;ACTIVE;2.29;2.73 +5808-1;Erythrocytes;NCnc;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Erythrocytes [#/volume] in Urine sediment by Microscopy high power field;RBC # UrnS HPF;;ACTIVE;1.0;2.73 +58081-1;Vel Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Vel Ab [Presence] in Serum or Plasma;Vel Ab SerPl Ql;;ACTIVE;2.29;2.56 +58082-9;Vel Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Vel Ag [Presence] on Red Blood Cells;Vel Ag RBC Ql;;ACTIVE;2.29;2.56 +58083-7;Vw Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Vw Ag [Presence] on Red Blood Cells;Vw Ag RBC Ql;;ACTIVE;2.29;2.56 +58084-5;Vw Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Vw Ab [Presence] in Serum or Plasma;Vw Ab SerPl Ql;;ACTIVE;2.29;2.56 +58085-2;Penicillin.parenteral;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Penicillin Parenteral [Susceptibility];Penicillin Parenteral Susc Islt;;ACTIVE;2.29;2.73 +58086-0;NOS Ab;PrThr;Pt;Ser/Plas;Ord;Warm absorption;BLDBK;1;Deprecated Not otherwise specified Ab [Presence] in Serum or Plasma by Warm absorption;Deprecated Other Ab SerPl Ql Warm Abs;;DEPRECATED;2.29;2.65 +58087-8;NOS Ab;PrThr;Pt;Ser/Plas;Ord;Cold absorption;BLDBK;1;Deprecated Not otherwise specified Ab [Presence] in Serum or Plasma by Cold absorption;Deprecated Other Ab SerPl Ql Cold Abs;;DEPRECATED;2.29;2.65 +58088-6;Acylcarnitine;Imp;Pt;Bld.dot;Nar;;CHEM;1;Acylcarnitine newborn screen interpretation;Acylcarnitine DBS-Imp;;ACTIVE;2.29;2.73 +58089-4;Glucose-6-Phosphate dehydrogenase;Imp;Pt;Bld.dot;Nar;;CHEM;1;Glucose-6-Phosphate dehydrogenase newborn screen interpretation;G6PD DBS-Imp;;ACTIVE;2.29;2.56 +58090-2;Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion;G6PD NBS comment;;ACTIVE;2.29;2.42 +58091-0;Glucose-6-Phosphate dehydrogenase newborn screen panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Glucose-6-Phosphate dehydrogenase newborn screen panel;G6PD NBS pnl DBS;;ACTIVE;2.29;2.42 +58092-8;Acylcarnitine newborn screen panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Acylcarnitine newborn screen panel;Acylcarnitine NBS pnl DBS;;ACTIVE;2.29;2.73 +58093-6;Acylcarnitine newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Acylcarnitine newborn screening comment-discussion;Acylcarnitine NBS comment;;ACTIVE;2.29;2.73 +58094-4;Number of pressure ulcers at assessment - stage 3;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers at assessment - stage 3 OASIS-C;;;DEPRECATED;2.29;2.36 +58095-1;Number of pressure ulcers at assessment - stage 4;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers at assessment - stage 4 OASIS-C;;;DEPRECATED;2.29;2.36 +58096-9;Number of pressure ulcers present upon admission &or reentry - stage 2;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers present upon admission/reentry - stage 2 OASIS-C;;;DEPRECATED;2.29;2.36 +58097-7;Number of pressure ulcers present upon admission &or reentry - stage 3;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers present upon admission/reentry - stage 3 OASIS-C;;;DEPRECATED;2.29;2.36 +58098-5;Number of pressure ulcers present upon admission &or reentry - stage 4;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers present upon admission/reentry - stage 4 OASIS-C;;;DEPRECATED;2.29;2.36 +5809-9;Reducing substances;PrThr;Pt;Urine;Ord;;UA;1;Reducing substances [Presence] in Urine;Reducing Subs Ur Ql;;ACTIVE;1.0;2.73 +58099-3;Number of pressure ulcers present upon admission &or reentry - unstageable due to non-removable dressing;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Number of pressure ulcers present upon admission/reentry - unstageable due to non-removable dressing [OASIS-C];;;DISCOURAGED;2.29;2.63 +58100-9;Number of pressure ulcers present upon admission &or reentry - unstageable due to coverage of wound bed by slough &or eschar;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Number of pressure ulcers present upon admission/reentry - unstageable due to coverage of wound bed by slough/eschar [OASIS-C];;;DISCOURAGED;2.29;2.63 +58101-7;Number of pressure ulcers present upon admission &or reentry - unstageable with suspected deep tissue injury in evolution;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Number of pressure ulcers present upon admission/reentry - unstageable with suspected deep tissue injury in evolution [OASIS-C];;;DISCOURAGED;2.29;2.63 +58102-5;Current number of unhealed (non-epithelialized) pressure injuries at each stage;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Current number of unhealed (non-epithelialized) pressure injuries at each stage [OASIS-C];;;ACTIVE;2.29;2.68 +58103-3;Number of pressure ulcers at assessment - stage 2;Num;Pt;^Patient;Qn;OASIS-C;SURVEY.OASIS;4;Deprecated Number of pressure ulcers at assessment - stage 2 OASIS-C;;;DEPRECATED;2.29;2.36 +58104-1;When confused within the last 14D;Find;14D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;When confused within the last 14 days [CMS Assessment];;;ACTIVE;2.29;2.61 +58105-8;Current payment sources for home care.other specified;Find;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Current payment sources for home care.other specified [OASIS-C];;;ACTIVE;2.29;2.44 +58106-6;Inpatient discharge facility.other specified;Type;Pt;^Patient;Nom;OASIS-C;SURVEY.OASIS;4;Inpatient discharge facility.other specified [OASIS-C];;;ACTIVE;2.29;2.44 +5810-7;Specific gravity;Rden;Pt;Urine;Qn;Refractometry;UA;1;Specific gravity of Urine by Refractometry;Sp Gr Ur Refractometry;;ACTIVE;1.0;2.73 +58107-4;Swing bed clinical change assessment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Swing bed clinical change assessment [CMS Assessment];;;ACTIVE;2.29;2.63 +58108-2;Entry &or discharge reporting;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Entry/discharge reporting [CMS Assessment];;;ACTIVE;2.29;2.63 +58109-0;Multidrug-resistant organism (MDRO) in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Multidrug-resistant organism (MDRO) in last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58110-8;Wound infection (other than foot) in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Wound infection (other than foot) in last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58111-6;Neurogenic bladder in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Neurogenic bladder in last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58112-4;Obstructive uropathy in the last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Obstructive uropathy in the last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58113-2;Huntington's disease in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Huntington's disease Multiple sclerosis in last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58114-0;Tourette's syndrome in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Tourette's syndrome in last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +5811-5;Specific gravity;Rden;Pt;Urine;Qn;Test strip;UA;1;Specific gravity of Urine by Test strip;Sp Gr Ur Strip;;ACTIVE;1.0;2.73 +58115-7;Psychotic disorder (other than schizophrenia) in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Psychotic disorder (other than schizophrenia) in last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58116-5;Respiratory failure in last 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Respiratory failure in last 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58117-3;Staff pain assessment interview should be conducted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Staff pain assessment interview should be conducted [CMS Assessment];;;ACTIVE;2.29;2.63 +58118-1;Frequency of indicator of pain or possible pain;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Frequency of indicator of pain or possible pain during assessment period [CMS Assessment];;;ACTIVE;2.29;2.70 +58119-9;Unable to examine oral or dental status;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Unable to examine oral or dental status [MDSv3];;;ACTIVE;2.29;2.44 +58120-7;Patient health questionnaire 2 item;-;2W;^Patient;-;PHQ.CMS;PANEL.SURVEY.CMS;4;Patient Health Questionnaire 2 item (PHQ-2) [PHQ.CMS];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.29;2.68 +58121-5;Prior Functioning ADL and IADL;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Prior Functioning ADL/IADL [CMS Assessment];;;ACTIVE;2.29;2.61 +58122-3;Resident has one or more unhealed pressure injuries at stage 1 or higher;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Resident has one or more unhealed pressure injuries at stage 1 or higher [MDSv3];;;ACTIVE;2.29;2.64 +5812-3;Sulfonamide crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Sulfonamide crystals [Presence] in Urine sediment by Light microscopy;Sulfonamide cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +58123-1;Date of oldest stage 2 pressure injury;Date;Pt;Pressure injury.oldest non-epithelialized stage 2;Qn;CMS Assessment;SURVEY.CMS;4;Date of Pressure injury.oldest non-epithelialized stage 2 [CMS Assessment];;;ACTIVE;2.29;2.63 +58124-9;Diabetic foot ulcers;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Diabetic foot ulcers [MDSv3];;;ACTIVE;2.29;2.44 +58125-6;Other open lesion(s) on the foot;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Other open lesion(s) on the foot [MDSv3];;;ACTIVE;2.29;2.44 +58126-4;Number of D injection of any type were received in last 5D or since admission &or reentry if less than 7D;Num;7D;^Patient;Qn;MDSv3;SURVEY.MDS;4;Number of days injection of any type were received in last 5 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58127-2;Number of D insulin injections were received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days insulin injections were received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58128-0;Number of D the physician changed the resident's insulin orders in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days the physician changed the resident's insulin orders in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58129-8;Antibiotic received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Antibiotic received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.29;2.54 +58130-6;Diuretic received in last 7D or since admission &or reentry if less than 7D;Find;7D;^Patient;Ord;MDSv3;SURVEY.MDS;4;Diuretic received in last 7 days or since admission/reentry if less than 7 days [MDSv3];;;ACTIVE;2.29;2.54 +5813-1;Trichomonas vaginalis;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Trichomonas vaginalis [Presence] in Urine sediment by Light microscopy;T vaginalis UrnS Ql Micro;;ACTIVE;1.0;2.73 +58131-4;Date of influenza vaccination;Date;Pt;^Patient;Qn;;CLIN;2;Date of influenza vaccination;Flu vaccine date;;ACTIVE;2.29;2.63 +58132-2;Speech-language pathology and audiology services;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Speech-language pathology and audiology services [MDSv3];;;ACTIVE;2.29;2.68 +58133-0;Speech-language pathology and audiology services - concurrent minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - concurrent minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58134-8;Speech-language pathology and audiology services - group minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - group minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58135-5;Occupational therapy;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Occupational therapy [MDSv3];;;ACTIVE;2.29;2.68 +58136-3;Occupational therapy - concurrent minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - concurrent minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58137-1;Occupational therapy - group minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - group minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58138-9;Physical therapy;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Physical therapy [MDSv3];;;ACTIVE;2.29;2.68 +58139-7;Physical therapy - concurrent minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - concurrent minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58140-5;Physical therapy - group minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - group minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58141-3;Respiratory therapy;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Respiratory therapy [CMS Assessment];;;ACTIVE;2.29;2.74 +58142-1;Psychological therapy;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Psychological therapy [CMS Assessment];;;ACTIVE;2.29;2.74 +58143-9;Recreational therapy;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Recreational therapy [CMS Assessment];;;ACTIVE;2.29;2.74 +58144-7;Resident's overall goal established during assessment process;Find;Pt;^Patient;Nom;MDSv3;SURVEY.MDS;4;Resident's overall goal established during assessment process [MDSv3];;;ACTIVE;2.29;2.44 +58145-4;Information source for overall goal;Find;Pt;^Patient;Nom;MDSv3;SURVEY.MDS;4;Information source for overall goal [MDSv3];;;ACTIVE;2.29;2.44 +58146-2;Active discharge planning in place for resident return to community;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Active discharge planning in place for resident return to community [CMS Assessment];;;ACTIVE;2.29;2.63 +58147-0;Determination made by resident and core planning team regarding discharge to community;Find;Pt;^Patient;Nom;MDSv3;SURVEY.MDS;4;Determination made by resident and core planning team regarding discharge to community [MDSv3];;;ACTIVE;2.29;2.44 +58148-8;Resident has been asked about returning to the community;Find;Pt;^Patient;Nom;MDSv3;SURVEY.MDS;4;Resident has been asked about returning to the community [MDSv3];;;ACTIVE;2.29;2.44 +5814-9;Triple phosphate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Triple phosphate crystals [Presence] in Urine sediment by Light microscopy;Tri-Phos Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +58149-6;Wants to talk to someone about the possibility of returning to the community;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wants to talk to someone about the possibility of returning to the community [CMS Assessment];;;ACTIVE;2.29;2.63 +58150-4;Referral has been made to the local contact agency;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Referral has been made to the local contact agency [CMS Assessment];;;ACTIVE;2.29;2.67 +58151-2;Prior assessment brief interview for mental status summary score;Score;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Prior assessment Brief Interview for Mental Status (BIMS) summary score [MDSv3];;;ACTIVE;2.29;2.50 +58152-0;Prior assessment resident mood interview (PHQ-9) total severity score;Score;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Prior assessment resident mood interview (PHQ-9) total severity score [MDSv3];;;ACTIVE;2.29;2.50 +58153-8;Prior assessment staff assessment of resident mood interview (PHQ-9) total severity score;Score;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Prior assessment staff assessment of resident mood interview (PHQ-9) total severity score [MDSv3];;;ACTIVE;2.29;2.50 +58154-6;Care Area Assessment (CAA) Summary;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Care Area Assessment (CAA) Summary [MDSv3];;;ACTIVE;2.29;2.68 +58155-3;Care Area Assessment (CAA) and care planning;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Care Area Assessment (CAA) and care planning [MDSv3];;;ACTIVE;2.29;2.68 +5815-6;Tyrosine crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Tyrosine crystals [Presence] in Urine sediment by Light microscopy;Tyrosine Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +58156-1;Care Area Assessment (CAA) results;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Care Area Assessment (CAA) results [MDSv3];;;ACTIVE;2.29;2.68 +58157-9;Delirium - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Delirium - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58158-7;Delirium - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Delirium - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58159-5;Cognitive loss &or dementia - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cognitive loss/dementia - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58160-3;Cognitive loss &or dementia - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Cognitive loss/dementia - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58161-1;Communication - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Communication - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58162-9;Communication - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Communication - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58163-7;ADL functional &or rehabilitation potential - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;ADL functional/rehabilitation potential - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +5816-4;Urate crystals;PrThr;Pt;Synv fld;Ord;Microscopy.light;HEM/BC;1;Urate crystals [Presence] in Synovial fluid by Light microscopy;Urate Cry Snv Ql Micro;;ACTIVE;1.0;2.73 +58164-5;ADL functional &or rehabilitation potential - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;ADL functional/rehabilitation potential - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58165-2;Urinary incontinence and indwelling catheter - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Urinary incontinence and indwelling catheter - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58166-0;Urinary incontinence and indwelling catheter - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Urinary incontinence and indwelling catheter - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58167-8;Psychosocial well being - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Psychosocial well-being - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58168-6;Psychosocial well being - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Psychosocial well-being - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58169-4;Mood state - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Mood state - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58170-2;Mood state - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Mood state - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58171-0;Behavioral symptoms - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Behavioral symptoms - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +5817-2;Urate crystals;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Urate crystals [Presence] in Urine sediment by Light microscopy;Urate Cry UrnS Ql Micro;;ACTIVE;1.0;2.73 +58172-8;Behavioral symptoms - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Behavioral symptoms - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58173-6;Activities - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Activities - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58174-4;Activities - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Activities - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58175-1;Falls - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Falls - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58176-9;Falls - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Falls - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58177-7;Nutritional status - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Nutritional status - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58178-5;Nutritional status - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Nutritional status - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58179-3;Feeding tube - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Feeding tube - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +5818-0;Urobilinogen;PrThr;Pt;Urine;Ord;Test strip;CHEM;1;Urobilinogen [Presence] in Urine by Test strip;Urobilinogen Ur Ql Strip;;ACTIVE;1.0;2.73 +58180-1;Feeding tube - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Feeding tube - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58181-9;Dehydration &or fluid maintenance - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dehydration/fluid maintenance - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58182-7;Dehydration &or fluid maintenance - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dehydration/fluid maintenance - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58183-5;Dental care - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dental care - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58184-3;Dental care - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Dental care - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58185-0;Pressure injury - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure injury - care area triggered [MDSv3];;;ACTIVE;2.29;2.64 +58186-8;Pressure injury - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pressure injury - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.64 +58187-6;Psychotropic drug use - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Psychotropic drug use - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58188-4;Psychotropic drug use - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Psychotropic drug use - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58189-2;Physical restraints - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +581-9;Streptococcus agalactiae;PrThr;Pt;Cvx;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Cervix by Organism specific culture;Gp B Strep Cvx Ql Cult;;ACTIVE;1.0;2.58 +58190-0;Physical restraints - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Physical restraints - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58191-8;Pain - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pain - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58192-6;Pain - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Pain - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58193-4;Return to community referral - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Return to community referral - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58194-2;Return to community referral - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Return to community referral - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58195-9;Date of Care Area Assessment (CAA) information;Date;Pt;^Patient;Qn;MDSv3;SURVEY.MDS;4;Date of Care Area Assessment (CAA) information [MDSv3];;;ACTIVE;2.29;2.50 +58196-7;Location of Care Area Assessment (CAA) information;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Location of Care Area Assessment (CAA) information [MDSv3];;;ACTIVE;2.29;2.44 +58197-5;Correction request;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Correction request [MDSv3];;;ACTIVE;2.29;2.69 +5819-8;Waxy casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Waxy casts [#/area] in Urine sediment by Microscopy low power field;Waxy Casts #/area UrnS LPF;;ACTIVE;1.0;2.73 +58198-3;Type of record;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Type of record [CMS Assessment];;;ACTIVE;2.29;2.63 +58199-1;Reasons for modification;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Reasons for modification [MDSv3];;;ACTIVE;2.29;2.68 +58200-7;Correction number;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Correction number [CMS Assessment];;;ACTIVE;2.29;2.63 +58201-5;Transcription error;Type;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Transcription error [MDSv3];;;ACTIVE;2.29;2.44 +58202-3;Data entry error;Type;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Data entry error [MDSv3];;;ACTIVE;2.29;2.44 +58203-1;Item coding error;Type;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Item coding error [MDSv3];;;ACTIVE;2.29;2.44 +58204-9;Other error requiring modification;Type;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Other error requiring modification [MDSv3];;;ACTIVE;2.29;2.44 +58205-6;Other error requiring modification.other specified;Type;Pt;^Patient;Nom;MDSv3;SURVEY.MDS;4;Other error requiring modification.other specified [MDSv3];;;ACTIVE;2.29;2.44 +5820-6;Leukocyte casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;WBC casts [#/area] in Urine sediment by Microscopy low power field;WBC Casts #/area UrnS LPF;;ACTIVE;1.0;2.73 +58206-4;Reasons for inactivation;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Reasons for inactivation [MDSv3];;;ACTIVE;2.29;2.68 +58207-2;Reasons for inactivation - event did not occur;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Reasons for inactivation - event did not occur [MDSv3];;;ACTIVE;2.29;2.44 +58208-0;Other error requiring error requiring inactivation;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Other error requiring error requiring inactivation [MDSv3];;;ACTIVE;2.29;2.44 +58209-8;Other error requiring error requiring inactivation.other specified;Find;Pt;^Patient;Nom;MDSv3;SURVEY.MDS;4;Other error requiring error requiring inactivation.other specified [MDSv3];;;ACTIVE;2.29;2.44 +58210-6;Medicare non-therapy Part A HIPPS code;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Medicare non-therapy Part A HIPPS code [CMS Assessment];;;ACTIVE;2.29;2.63 +58211-4;Medicare non-therapy Part A - RUG version code;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Medicare non-therapy Part A - RUG version code [CMS Assessment];;;ACTIVE;2.29;2.63 +58212-2;Alternate state Medicaid billing - RUG group;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Alternate state Medicaid billing - RUG group [CMS Assessment];;;ACTIVE;2.29;2.63 +58213-0;Alternate state Medicaid billing - RUG version code;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Alternate state Medicaid billing - RUG version code [CMS Assessment];;;ACTIVE;2.29;2.63 +5821-4;Leukocytes;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Leukocytes [#/area] in Urine sediment by Microscopy high power field;WBC #/area UrnS HPF;;ACTIVE;1.0;2.73 +58214-8;One or more unhealed pressure injuries stage 1 or higher;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;One or more unhealed pressure injuries stage 1 or higher [CMS Assessment];;;ACTIVE;2.29;2.63 +58215-5;Stage 1;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Stage 1 [MDSv3];;;ACTIVE;2.29;2.68 +58216-3;Depth;Len;Pt;Ulcer.largest stage 3 or 4;Qn;MDSv3;SURVEY.MDS;4;Deprecated Depth Ulcer.largest stage 3 or 4 MDSv3;;;DEPRECATED;2.29;2.36 +58217-1;Insulin;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Insulin [CMS Assessment];;;ACTIVE;2.29;2.74 +58218-9;Speech-language pathology and audiology services - individual minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - individual minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58219-7;Occupational therapy - individual minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - individual minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58220-5;Physical therapy - individual minutes in the last 7D;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - individual minutes in the last 7 days [CMS Assessment];;;ACTIVE;2.29;2.63 +58221-3;Participation in assessment;Find;Pt;^Guardian or legally authorized representative;Nom;CMS Assessment;SURVEY.CMS;4;Participation in assessment Guardian or legally authorized representative [CMS Assessment];;;ACTIVE;2.29;2.67 +5822-2;Yeast;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Yeast [#/area] in Urine sediment by Microscopy high power field;Yeast #/area UrnS HPF;;ACTIVE;1.0;2.73 +58222-1;Discharge plan;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Discharge plan;;;ACTIVE;2.29;2.68 +58223-9;Return to community;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Return to community;;;ACTIVE;2.29;2.68 +58224-7;Items from most recent prior OBRA or scheduled PPS assessment;-;Pt;^Patient;-;;PANEL.SURVEY.MDS;4;Items from most recent prior OBRA or scheduled PPS assessment;;;ACTIVE;2.29;2.68 +58225-4;Visual function - addressed in care plan;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Visual function - addressed in care plan [MDSv3];;;ACTIVE;2.29;2.44 +58226-2;Visual function - care area triggered;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Visual function - care area triggered [MDSv3];;;ACTIVE;2.29;2.44 +58227-0;Software product error;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Software product error [MDSv3];;;ACTIVE;2.29;2.44 +58228-8;Infection of the foot;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Infection of the foot [MDSv3];;;ACTIVE;2.29;2.44 +58229-6;Body weight^when specimen taken;Mass;Pt;^Patient;Qn;Measured;CLIN;2;Body weight Measured --when specimen taken;Weight when spec taken Measured;;ACTIVE;2.30;2.70 +5823-0;Adenovirus Ag;PrThr;Pt;Cnjt;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Conjunctival specimen by Immunoassay;HAdV Ag Conjunct Ql IA;;ACTIVE;1.0;2.56 +58230-4;Maple syrup urine disease newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Maple syrup urine disease newborn screening comment-discussion;MSUD NBS comment;;ACTIVE;2.30;2.42 +58231-2;Phenylketonuria and variants &or biopterin defects newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Phenylketonuria and variants/Biopterin defects newborn screening comment-discussion;PKU+Var/BIOPT Defects NBS comment;;ACTIVE;2.30;2.73 +58232-0;Hearing loss risk indicators;Prid;Pt;^Patient;Nom;;H&P.HX;2;Hearing loss risk indicators [Identifier];Hearing loss risk indicators;;ACTIVE;2.30;2.56 +58233-8;Age when the first heart attack occurred;Find;Pt;^Brother;Ord;;PHENX;2;Age when the first heart attack occurred Brother;Age 1st heart attack occurred Brother;;TRIAL;2.30;2.65 +58234-6;Date of trauma or procedure;Date;Pt;^Patient;Qn;;PHENX;2;Date of trauma or procedure;Date of trauma or procedure;;TRIAL;2.30;2.65 +58235-3;Type of trauma or procedure;Type;Pt;^Patient;Nom;;PHENX;2;Type of trauma or procedure;Type of trauma or procedure;;TRIAL;2.30;2.65 +58236-1;Date of myocardial infarction;Date;Pt;^Patient;Qn;;PHENX;2;Date of myocardial infarction;Date of myocardial infarction;;TRIAL;2.30;2.65 +58237-9;Name;ID;Pt;Hospital;Nom;;PHENX;2;Hospital Name;Hospital Name;;TRIAL;2.30;2.64 +58238-7;PhenX measure - family history of heart attack;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - family history of heart attack;;;DEPRECATED;2.30;2.46 +58239-5;PhenX measure - lipid profile;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - lipid profile;;;DEPRECATED;2.30;2.46 +58240-3;PhenX measure - blood pressure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - blood pressure;;;DEPRECATED;2.30;2.46 +58241-1;PhenX measure - high blood pressure during pregnancy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - high blood pressure during pregnancy;;;DEPRECATED;2.30;2.46 +58242-9;PhenX measure - heart valve function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - heart valve function;;;DEPRECATED;2.30;2.46 +58243-7;PhenX measure - angina;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - angina;;;DEPRECATED;2.30;2.46 +58244-5;PhenX measure - sudden cardiac arrest;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - sudden cardiac arrest;;;DEPRECATED;2.30;2.46 +58245-2;PhenX measure - myocardial infarction;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - myocardial infarction;;;DEPRECATED;2.30;2.46 +58246-0;PhenX measure - peripheral arterial disease;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - peripheral arterial disease;;;DEPRECATED;2.30;2.46 +58247-8;PhenX measure - abdominal aortic aneurysm;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - abdominal aortic aneurysm;;;DEPRECATED;2.30;2.46 +5824-8;Adenovirus Ag;PrThr;Pt;Cnjt;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Conjunctival specimen by Immunofluorescence;HAdV Ag Conjunct Ql IF;;ACTIVE;1.0;2.56 +58248-6;PhenX measure - arrhythmia;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - arrhythmia;;;DEPRECATED;2.30;2.46 +58249-4;PhenX measure - deep venous thrombosis;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - deep venous thrombosis;;;DEPRECATED;2.30;2.46 +58250-2;PhenX measure - pulmonary embolism;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - pulmonary embolism;;;DEPRECATED;2.30;2.46 +58251-0;PhenX measure - rheumatic fever;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - rheumatic fever;;;DEPRECATED;2.30;2.46 +58252-8;Discomfort or pain diagnosed as having a non-cardiac origin;Find;Pt;^Patient;Ord;;PHENX;2;Discomfort or pain diagnosed as having a non-cardiac origin;Non-cardiac origin discomfort/pain dx;;TRIAL;2.30;2.65 +58253-6;Electrocardiograms recorded;Find;Pt;^Patient;Ord;;PHENX;2;Electrocardiograms recorded;Electrocardiograms recorded;;TRIAL;2.30;2.65 +58254-4;Cardiac enzyme measurements performed during this admission;Find;Pt;^Patient;Nom;;PHENX;2;Cardiac enzyme measurements performed during this admission;Cardiac enzyme tests done during adm;;TRIAL;2.30;2.65 +5825-5;Adenovirus Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Stool by Immunoassay;HAdV Ag Stl Ql IA;;ACTIVE;1.0;2.73 +58255-1;Participant had active liver disease;Find;Pt;^Patient;Nom;;PHENX;2;Participant had active liver disease;Participant had active liver disease;;TRIAL;2.30;2.65 +58256-9;Evidence of hemolytic disease during this hospitalization;Find;Pt;^Patient;Nom;;PHENX;2;Evidence of hemolytic disease during this hospitalization;Evid hem disease during hospit;;TRIAL;2.30;2.65 +58257-7;Mention of the participant having either trauma, a surgical procedure, or rhabdomyolysis within 1W prior to the cardiac enzymes measurement;Find;Pt;^Patient;Ord;;PHENX;2;Mention of the participant having either trauma, a surgical procedure, or rhabdomyolysis within 1 week prior to the cardiac enzymes measurement;Trauma/surgical proc/rhabdomyolysis;;TRIAL;2.30;2.66 +58258-5;Myocardial infarction;Find;Pt;^Patient;Ord;;PHENX;2;Myocardial infarction;Myocardial infarction;;TRIAL;2.30;2.65 +58259-3;Chest pain;Find;Pt;^Patient;Ord;;PHENX;2;Chest pain;Chest pain;;TRIAL;2.30;2.73 +58260-1;Cardiac enzymes;Find;Pt;^Patient;Ord;;PHENX;2;Cardiac enzymes;Cardiac enzymes;;TRIAL;2.30;2.73 +58261-9;Electrocardiogram serial reading;Find;Pt;^Patient;Nom;;PHENX;2;Electrocardiogram serial reading;Electrocardiogram serial reading;;TRIAL;2.30;2.65 +58262-7;Ever told by doctor that you had claudication or peripheral arterial disease;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor that you had claudication or peripheral arterial disease;Claudication or PAD;;TRIAL;2.30;2.65 +5826-3;Adenovirus Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Stool by Immunofluorescence;HAdV Ag Stl Ql IF;;ACTIVE;1.0;2.56 +58263-5;Ever had angiography for claudication or peripheral arterial disease;Find;Pt;^Patient;Ord;;PHENX;2;Ever had angiography for claudication or peripheral arterial disease;Angiography for claudication or PAF;;TRIAL;2.30;2.65 +58264-3;Ever had angioplasty for claudication or peripheral arterial disease;Find;Pt;^Patient;Ord;;PHENX;2;Ever had angioplasty for claudication or peripheral arterial disease;Angioplasty for claudication or PAD;;TRIAL;2.30;2.65 +58265-0;Ever had surgery to improve blood flow in legs for claudication or peripheral arterial disease;Find;Pt;^Patient;Ord;;PHENX;2;Ever had surgery to improve blood flow in legs for claudication or peripheral arterial disease;Surgery to improve blood flow legs;;TRIAL;2.30;2.65 +58266-8;Ever diagnosed by a doctor as having an abdominal aortic aneurysm;Find;Pt;^Patient;Nom;;PHENX;2;Ever diagnosed by a doctor as having an abdominal aortic aneurysm;Abdominal aortic aneurysm;;TRIAL;2.30;2.73 +58267-6;Surgery or other repair for aneurysm;Find;Pt;^Patient;Nom;;PHENX;2;Surgery or other repair for aneurysm;Surgery or other repair for aneurysm;;TRIAL;2.30;2.65 +58268-4;Ever told you have or had atrial fibrillation;Find;Pt;^Patient;Ord;;PHENX;2;Ever told you have or had atrial fibrillation;Atrial fibrillation;;TRIAL;2.30;2.73 +58269-2;Date of first episode of atrial fibrillation;Date;Pt;^Patient;Qn;;PHENX;2;Date of first episode of atrial fibrillation;Date of 1st episode atrial fibrillation;;TRIAL;2.30;2.65 +582-7;Streptococcus agalactiae;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Genital specimen by Organism specific culture;Gp B Strep Genital Ql Cult;;ACTIVE;1.0;2.73 +58270-0;Emergency room visit or hospitalized or saw doctor for atrial fibrillation;Find;Pt;^Patient;Ord;;PHENX;2;Emergency room visit or hospitalized or saw doctor for atrial fibrillation;ER visit/hospital/saw doctor for AF;;TRIAL;2.30;2.65 +5827-1;Adenovirus Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Throat by Immunoassay;HAdV Ag Throat Ql IA;;ACTIVE;1.0;2.56 +58271-8;Permanent pacemaker insertion;Find;Pt;^Patient;Ord;;PHENX;2;Permanent pacemaker insertion;Permanent pacemaker insertion;;TRIAL;2.30;2.65 +58272-6;Y permanent pacemaker inserted;Date;Pt;^Patient;Qn;;PHENX;2;Year permanent pacemaker inserted;Y perm pacemaker inserted;;TRIAL;2.30;2.65 +58273-4;Taking any anticoagulants for treatment of atrial fibrillation;Find;Pt;^Patient;Ord;;PHENX;2;Taking any anticoagulants for treatment of atrial fibrillation;Anticoagulants for treatment of AF;;TRIAL;2.30;2.65 +58274-2;Taking any antiarrhythmics for treatment of atrial fibrillation;Find;Pt;^Patient;Ord;;PHENX;2;Taking any antiarrhythmics for treatment of atrial fibrillation;Antiarrhythmics for treatment of AF;;TRIAL;2.30;2.65 +58275-9;Ever told by doctor that you had deep venous thrombosis;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor that you had deep venous thrombosis;DVT;;TRIAL;2.30;2.73 +58276-7;Ever had outpatient test(s) performed for deep vein thrombosis;TmStp;Pt;^Patient;Qn;;PHENX;2;Ever had outpatient test(s) performed for deep vein thrombosis [Date and time];OP test(s) for DVT;;TRIAL;2.30;2.65 +58277-5;Deep vein thrombosis diagnosis;Find;Pt;^Patient;Ord;;PHENX;2;Deep vein thrombosis diagnosis;DVT Dx;;TRIAL;2.30;2.65 +58278-3;Date of deep vein thrombosis diagnosis;Date;Pt;^Patient;Qn;;PHENX;2;Date of deep vein thrombosis diagnosis;Date of deep vein thrombosis Dx;;TRIAL;2.30;2.65 +58279-1;Pulmonary embolism diagnosis category;Find;Pt;^Patient;Nom;;PHENX;2;Pulmonary embolism diagnosis category;PE dix category;;TRIAL;2.30;2.65 +58280-9;Source of evidence for deep vein thrombosis diagnosis;Find;Pt;^Patient;Nom;;PHENX;2;Source of evidence for deep vein thrombosis diagnosis;Source of evidence DVT Dx;;TRIAL;2.30;2.65 +58281-7;Deep vein thrombosis diagnosis reporting source;Find;Pt;^Patient;Nom;;PHENX;2;Deep vein thrombosis diagnosis reporting source;DVT Dx reporting source;;TRIAL;2.30;2.65 +58282-5;Ever told by doctor that you had pulmonary embolus;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor that you had pulmonary embolus;PE;;TRIAL;2.30;2.65 +58283-3;Pulmonary embolism requiring hospitalization;Find;Pt;^Patient;Nom;;PHENX;2;Pulmonary embolism requiring hospitalization;PE requiring hospitalization;;TRIAL;2.30;2.65 +58284-1;Date of pulmonary embolus diagnosis;Date;Pt;^Patient;Qn;;PHENX;2;Date of pulmonary embolus diagnosis;Date of pulmonary embolus Dx;;TRIAL;2.30;2.65 +58285-8;Deep vein thrombosis diagnosis category;Find;Pt;^Patient;Nom;;PHENX;2;Deep vein thrombosis diagnosis category;DVT Dx category;;TRIAL;2.30;2.65 +58286-6;Source of evidence for pulmonary embolism diagnosis;Find;Pt;^Patient;Nom;;PHENX;2;Source of evidence for pulmonary embolism diagnosis;Source of evidence PE Dx;;TRIAL;2.30;2.65 +58287-4;Ever told by doctor that you had rheumatic fever;Find;Pt;^Patient;Nom;;PHENX;2;Ever told by doctor that you had rheumatic fever;Rheumatic fever;;TRIAL;2.30;2.65 +58288-2;Rheumatic fever in the past 12Mo;Find;12Mo;^Patient;Ord;;PHENX;2;Rheumatic fever in the past 12 months;Rheumatic fever in the past 12 months;;TRIAL;2.30;2.65 +5828-9;Adenovirus Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Throat by Immunofluorescence;HAdV Ag Throat Ql IF;;ACTIVE;1.0;2.56 +58289-0;Taking medication for rheumatic fever;Find;Pt;^Patient;Nom;;PHENX;2;Taking medication for rheumatic fever;Taking medication for rheumatic fever;;TRIAL;2.30;2.65 +58290-8;Name of medication for rheumatic fever;Find;Pt;^Patient;Nom;;PHENX;2;Name of medication for rheumatic fever;Name of medication for rheumatic fever;;TRIAL;2.30;2.65 +58291-6;Mother, father, full-blooded sisters, full-blooded brothers, daughters, or sons ever have a heart attack or myocardial infarction;Find;Pt;^Patient;Ord;;PHENX;2;Mother, father, full-blooded sisters, full-blooded brothers, daughters, or sons ever have a heart attack or myocardial infarction;Family ever have a heart attack/MI;;TRIAL;2.30;2.65 +58292-4;Ever told by doctor or nurse that you have high blood cholesterol;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor or nurse that you have high blood cholesterol;Hgh blood cholesterol;;TRIAL;2.30;2.65 +58293-2;Taken medication for high blood cholesterol;Find;Pt;^Patient;Ord;;PHENX;2;Taken medication for high blood cholesterol;High cholest med;;TRIAL;2.30;2.65 +58294-0;Age began taking high blood pressure medication;Time;Pt;^Patient;Qn;;PHENX;2;Age began taking high blood pressure medication;Age began taking BP med;;TRIAL;2.30;2.65 +58295-7;Ever told by doctor or nurse that you have high blood pressure;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor or nurse that you have high blood pressure;High blood pressure;;TRIAL;2.30;2.65 +58296-5;Age when told have high blood pressure;Time;Pt;^Patient;Qn;;PHENX;2;Age when told have high blood pressure;Age when told have high BP;;TRIAL;2.30;2.65 +5829-7;Adenovirus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Tissue by Immunoassay;HAdV Ag Tiss Ql IA;;ACTIVE;1.0;2.56 +58297-3;Diagnosis of high blood pressure during pregnancy only;Find;Pt;^Patient;Ord;;PHENX;2;Diagnosis of high blood pressure during pregnancy only;Dx high BP- pregnancy only;;TRIAL;2.30;2.65 +58298-1;Medication taken for high blood pressure;Find;Pt;^Patient;Ord;;PHENX;2;Medication taken for high blood pressure;Medication taken for high BP;;ACTIVE;2.30;2.70 +58299-9;Age began taking high blood cholesterol medication;Time;Pt;^Patient;Qn;;PHENX;2;Age began taking high blood cholesterol medication;Age began taking cholest med;;TRIAL;2.30;2.65 +58300-5;Toxemia including high blood pressure, albumin in urine and swelling of ankles during this pregnancy;Find;Pt;^Patient;Ord;;PHENX;2;Toxemia including high blood pressure, albumin in urine and swelling of ankles during this pregnancy;Toxemia during preg;;TRIAL;2.30;2.65 +58301-3;High blood pressure without toxemia during this pregnancy;Find;Pt;^Patient;Ord;;PHENX;2;High blood pressure without toxemia during this pregnancy;High BP WO toxemia during pregnancy;;TRIAL;2.30;2.65 +58302-1;Ever told by doctor that you had rheumatic heart or heart valve problems;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor that you had rheumatic heart or heart valve problems;Rheumatic heart or heart valve problems;;TRIAL;2.30;2.65 +58303-9;Ever told by doctor that you had angina;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor that you had angina;Angina;;TRIAL;2.30;2.65 +58304-7;Chest discomfort ever or since last exam or medical history update;TmStp;Pt;^Patient;Ord;;PHENX;2;Chest discomfort ever or since last exam or medical history update;Chest discomfort ever/since last exam;;TRIAL;2.30;2.65 +5830-5;Adenovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Tissue by Immunofluorescence;HAdV Ag Tiss Ql IF;;ACTIVE;1.0;2.73 +58305-4;Chest discomfort with exertion or excitement;Find;Pt;^Patient;Ord;;PHENX;2;Chest discomfort with exertion or excitement;Chest discomf W exertion/excitement;;TRIAL;2.30;2.65 +58306-2;Chest discomfort when quiet or resting;Find;Pt;^Patient;Ord;;PHENX;2;Chest discomfort when quiet or resting;Chest discomfort when quiet or resting;;TRIAL;2.30;2.65 +58307-0;Date of onset of chest discomfort;Date;Pt;^Patient;Qn;;PHENX;2;Date of onset of chest discomfort;Date of onset of chest discomfort;;TRIAL;2.30;2.65 +58308-8;Usual duration of chest discomfort;Time;Pt;^Patient;Qn;;PHENX;2;Usual duration of chest discomfort;Usual duration of chest discomfort;;TRIAL;2.30;2.65 +58309-6;Longest duration of chest discomfort;Time;Pt;^Patient;Qn;;PHENX;2;Longest duration of chest discomfort;Longest duration of chest discomfort;;TRIAL;2.30;2.65 +58310-4;Location of chest discomfort;Anat;Pt;^Patient;Nom;;PHENX;2;Location of chest discomfort [Anatomy];Location of chest discomfort;;TRIAL;2.30;2.65 +58311-2;Radiation of chest discomfort;Anat;Pt;^Patient;Ord;;PHENX;2;Radiation of chest discomfort;Radiation of chest discomfort;;TRIAL;2.30;2.65 +58312-0;Frequency (number in past Mo) of chest discomfort;NRat;Pt;^Patient;Qn;;PHENX;2;Frequency (number in past month) of chest discomfort;Freq (past Mo) of chest discomf;;TRIAL;2.30;2.65 +5831-3;Adenovirus Ag;PrThr;Pt;Urine;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Urine by Immunoassay;HAdV Ag Ur Ql IA;;ACTIVE;1.0;2.56 +58313-8;Frequency (number in past year) of chest discomfort;NRat;Pt;^Patient;Qn;;PHENX;2;Frequency (number in past year) of chest discomfort;Freq (past year) of chest discomf;;TRIAL;2.30;2.65 +58314-6;Type of chest discomfort;Type;Pt;^Patient;Nom;;PHENX;2;Type of chest discomfort;Type of chest discomfort;;TRIAL;2.30;2.65 +58315-3;Relief of chest discomfort by nitroglycerine in <15 minutes;Find;Pt;^Patient;Ord;;PHENX;2;Relief of chest discomfort by nitroglycerine in <15 minutes;Chest discomfort relief by NTG;;TRIAL;2.30;2.65 +58316-1;Relief of chest discomfort by rest in <15 minutes;Find;Pt;^Patient;Ord;;PHENX;2;Relief of chest discomfort by rest in <15 minutes;Chest discomfort relief by rest;;TRIAL;2.30;2.65 +58317-9;Relief of chest discomfort spontaneously in <15 minutes;Find;Pt;^Patient;Ord;;PHENX;2;Relief of chest discomfort spontaneously in <15 minutes;Chest discomfort relief spontaneous;;TRIAL;2.30;2.65 +58318-7;Relief of chest discomfort by other cause in <15 minutes;Find;Pt;^Patient;Ord;;PHENX;2;Relief of chest discomfort by other cause in <15 minutes;Chest discomfort relief by other;;TRIAL;2.30;2.65 +58319-5;Since your last exam told by a doctor you had a heart attack;Find;Pt;^Patient;Ord;;PHENX;2;Since your last exam told by a doctor you had a heart attack;Told by a doctor had heart attack;;TRIAL;2.30;2.65 +58320-3;Angina pectoris in interim;Find;Pt;^Patient;Ord;;PHENX;2;Angina pectoris in interim;Angina pectoris in interim;;TRIAL;2.30;2.65 +5832-1;Adenovirus Ag;PrThr;Pt;Urine;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Urine by Immunofluorescence;HAdV Ag Ur Ql IF;;ACTIVE;1.0;2.56 +58321-1;Angina pectoris since revascularization procedure;Find;Pt;^Patient;Ord;;PHENX;2;Angina pectoris since revascularization procedure;AP since revascularization proc;;TRIAL;2.30;2.65 +58322-9;Coronary insufficiency in interim;Find;Pt;^Patient;Ord;;PHENX;2;Coronary insufficiency in interim;Coronary insufficiency in interim;;TRIAL;2.30;2.65 +58323-7;Myocardial infarction in interim;Find;Pt;^Patient;Ord;;PHENX;2;Myocardial infarction in interim;Myocardial infarction in interim;;TRIAL;2.30;2.65 +58324-5;Provider familiar with the events surrounding the decedent's death;Find;Pt;^Patient;Nom;;PHENX;2;Provider familiar with the events surrounding the decedent's death;Provid familiar W death events;;TRIAL;2.30;2.65 +58325-2;Provider witnessed decedent's death;Find;Pt;^Patient;Nom;;PHENX;2;Provider witnessed decedent's death;Provider witnessed decedent's death;;TRIAL;2.30;2.65 +58326-0;Pain in the chest, left arm or shoulder or jaw within 72H of death;Find;Pt;^Patient;Ord;;PHENX;2;Pain in the chest, left arm or shoulder or jaw within 72 hours of death;Chest/L-arm/shoulder/jaw pain<3D death;;TRIAL;2.30;2.65 +58327-8;Pain included chest;Find;Pt;^Patient;Ord;;PHENX;2;Pain included chest;Pain included chest;;TRIAL;2.30;2.65 +58328-6;Pain was of a cardiac origin;Find;Pt;^Patient;Ord;;PHENX;2;Pain was of a cardiac origin;Pain was of a cardiac origin;;TRIAL;2.30;2.65 +58329-4;Cardiopulmonary resuscitation &or cardioversion performed within 24H of death;Find;Pt;^Patient;Ord;;PHENX;2;Cardiopulmonary resuscitation/Cardioversion performed within 24 hours of death;CPR/CV within 24H of death;;TRIAL;2.30;2.65 +58330-2;Time between onset of acute symptoms to death;Time;Pt;^Patient;Ord;;PHENX;2;Time between onset of acute symptoms to death;Time onset acute symptoms to death;;TRIAL;2.30;2.65 +58331-0;Decedent's cause of death due to coronary heart disease;Find;Pt;^Patient;Ord;;PHENX;2;Decedent's cause of death due to coronary heart disease;Decedent's CoD due to CHD;;TRIAL;2.30;2.65 +58332-8;Location of death;Loc;Pt;^Patient;Nom;;PHENX;2;Location of death;Location of death;;TRIAL;2.30;2.65 +58333-6;Death witnessed;Find;Pt;^Patient;Nom;;PHENX;2;Death witnessed;Death witnessed;;TRIAL;2.30;2.65 +58334-4;Multi-Ethnic Study of Atherosclerosis (MESA) classification of underlying cause of death;Type;Pt;^Patient;Nom;;PHENX;2;Multi-Ethnic Study of Atherosclerosis (MESA) classification of underlying cause of death;MESA class of underlying cause of death;;TRIAL;2.30;2.65 +58335-1;Type of fatal coronary heart disease;Type;Pt;^Patient;Nom;;PHENX;2;Type of fatal coronary heart disease;Type of fatal coronary heart disease;;TRIAL;2.30;2.65 +58336-9;Estimated time between onset of acute cardiac symptoms and death;Time;Pt;^Patient;Ord;;PHENX;2;Estimated time between onset of acute cardiac symptoms and death;Est time acute cardiac sympt+death;;TRIAL;2.30;2.65 +58337-7;Mechanism of death in patient's dying of cardiovascular causes;Type;Pt;^Patient;Nom;;PHENX;2;Mechanism of death in patient's dying of cardiovascular causes;Death due to CV causes;;TRIAL;2.30;2.65 +58338-5;Ever told by doctor that you had a myocardial infarction or heart attack;Find;Pt;^Patient;Ord;;PHENX;2;Ever told by doctor that you had a myocardial infarction or heart attack;Myocardial infarction or heart attack;;TRIAL;2.30;2.65 +5833-9;Adenovirus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Specimen by Immunoassay;HAdV Ag Spec Ql IA;;ACTIVE;1.0;2.69 +58339-3;Outpatient or day surgery procedure to unblock blocked or narrowed blood vessels of the heart;Find;Pt;^Patient;Ord;;PHENX;2;Outpatient or day surgery procedure to unblock blocked or narrowed blood vessels of the heart;OP proced to unblock heart vessels;;TRIAL;2.30;2.65 +58340-1;Acute episode of pain, discomfort or tightness in the chest, left arm or jaw within 72H of the hospitalization or in-hospital event;Find;Pt;^Patient;Ord;;PHENX;2;Acute episode of pain, discomfort or tightness in the chest, left arm or jaw within 72 hours of the hospitalization or in-hospital event;Acute episode within 72h of hosp;;TRIAL;2.30;2.65 +58341-9;Ever treated by a doctor or a nurse with shots at home or as an outpatient for deep vein thrombosis;Find;Pt;^Patient;Ord;;PHENX;2;Ever treated by a doctor or a nurse with shots at home or as an outpatient for deep vein thrombosis;Shots at home/OP for DVT;;TRIAL;2.30;2.65 +58342-7;Age when the first heart attack occurred;Find;Pt;^Sister;Ord;;PHENX;2;Age when the first heart attack occurred Sister;Age 1st heart attack occurred Sister;;TRIAL;2.30;2.65 +58343-5;PhenX domain - Cardiovascular;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Cardiovascular;Domain - Cardiovascular;;TRIAL;2.30;2.68 +58344-3;Age when the first heart attack occurred;Find;Pt;^Daughter;Ord;;PHENX;2;Age when the first heart attack occurred Daughter;Age 1st heart attack occurred Daughter;;TRIAL;2.30;2.65 +58345-0;Age when the first heart attack occurred;Find;Pt;^Son;Ord;;PHENX;2;Age when the first heart attack occurred Son;Age 1st heart attack occurred Son;;TRIAL;2.30;2.65 +58346-8;Age when the first heart attack occurred;Find;Pt;^Father;Ord;;PHENX;2;Age when the first heart attack occurred Father;Age 1st heart attack occurred Father;;TRIAL;2.30;2.65 +5834-7;Adenovirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Specimen by Immunofluorescence;HAdV Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58347-6;Age when the first heart attack occurred;Find;Pt;^Mother;Ord;;PHENX;2;Age when the first heart attack occurred Mother;Age 1st heart attack occurred Mother;;TRIAL;2.30;2.65 +58348-4;MethylePHEDrine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;MethylePHEDrine [Mass/volume] in Serum or Plasma by Confirmatory method;Me-ePHEDrine SerPl Cfm-mCnc;;ACTIVE;2.30;2.73 +58349-2;Procedure-related;Find;Pt;^Patient;Ord;;PHENX;2;Procedure-related;Procedure-related;;TRIAL;2.30;2.65 +583-5;Streptococcus agalactiae;PrThr;Pt;Genital loc;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Genital lochia by Organism specific culture;Gp B Strep Gen lochia Ql Cult;;ACTIVE;1.0;2.56 +58350-0;Plasma cells.immature/100 cells;NFr;Pt;Bld;Qn;;HEM/BC;1;Plasma cells immature/100 cells in Blood;Imm Plasma Cells NFr Bld;;ACTIVE;2.30;2.70 +58351-8;Connective tissue growth factor;MCnc;Pt;Urine;Qn;;CHEM;1;Connective tissue growth factor [Mass/volume] in Urine;Connective tissue GF Ur-mCnc;;ACTIVE;2.32;2.70 +58352-6;Connective tissue growth factor;SCnc;Pt;Urine;Qn;;CHEM;1;Connective tissue growth factor [Moles/volume] in Urine;Connective tissue GF Ur-sCnc;;ACTIVE;2.32;2.70 +58353-4;Human antihuman Ab;MCnc;Pt;Plas;Qn;;CHEM;1;Human antihuman Ab [Mass/volume] in Plasma;HAHA Ab Plas-mCnc;;ACTIVE;2.34;2.70 +5835-4;Cytomegalovirus;PrThr;Pt;Bld;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Blood by Organism specific culture;CMV Bld Ql Cult;;ACTIVE;1.0;2.73 +58354-2;Human antihuman Ab;SCnc;Pt;Plas;Qn;;CHEM;1;Human antihuman Ab [Moles/volume] in Plasma;HAHA Ab Plas-sCnc;;ACTIVE;2.34;2.70 +58355-9;Plasma cells.immature;NCnc;Pt;Bld;Qn;;HEM/BC;1;Plasma cells immature [#/volume] in Blood;Imm Plasma Cells # Bld;;ACTIVE;2.30;2.40 +58356-7;Ethanol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Ethanol/Creatinine [Mass Ratio] in Urine;Ethanol/Creat Ur;;ACTIVE;2.30;2.73 +58357-5;Amphetamine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Amphetamine/Creatinine [Mass Ratio] in Urine;Amphet/Creat Ur;;ACTIVE;2.30;2.73 +58358-3;Methamphetamine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methamphetamine/Creatinine [Mass Ratio] in Urine;Methamphet/Creat Ur;;ACTIVE;2.30;2.73 +58359-1;Buprenorphine+Norbuprenorphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Buprenorphine+Norbuprenorphine [Presence] in Urine by Screen method;Buprenorphine+Nor Ur Ql Scn;;ACTIVE;2.30;2.73 +58360-9;Buprenorphine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Buprenorphine/Creatinine [Mass Ratio] in Urine;Buprenorphine/Creat Ur;;ACTIVE;2.30;2.73 +58361-7;Norbuprenorphine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Norbuprenorphine/Creatinine [Mass Ratio] in Urine;Norbuprenorphine/Creat Ur;;ACTIVE;2.30;2.73 +5836-2;Cytomegalovirus;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Tissue by Organism specific culture;CMV Tiss Ql Cult;;ACTIVE;1.0;2.56 +58362-5;Norbuprenorphine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Norbuprenorphine [Presence] in Urine by Confirmatory method;Norbuprenorphine Ur Ql Cfm;;ACTIVE;2.30;2.73 +58363-3;Alpha hydroxyalprazolam/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam/Creatinine [Mass Ratio] in Urine;A-OH Alpraz/Creat Ur;;ACTIVE;2.30;2.73 +58364-1;7-Aminoclonazepam/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;7-Aminoclonazepam/Creatinine [Mass Ratio] in Urine;7Aminoclonazepam/Creat Ur;;ACTIVE;2.30;2.73 +58365-8;7-Aminoclonazepam;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Urine by Confirmatory method;7Aminoclonazepam Ur Ql Cfm;;ACTIVE;2.30;2.73 +58366-6;LORazepam/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;LORazepam/Creatinine [Mass Ratio] in Urine;LORazepam/Creat Ur;;ACTIVE;2.30;2.73 +58367-4;Nordiazepam/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Nordiazepam/Creatinine [Mass Ratio] in Urine;Nordiazepam/Creat Ur;;ACTIVE;2.30;2.73 +58368-2;Oxazepam/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Oxazepam/Creatinine [Mass Ratio] in Urine;Oxazepam/Creat Ur;;ACTIVE;2.30;2.73 +58369-0;Temazepam/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Temazepam/Creatinine [Mass Ratio] in Urine;Temazepam/Creat Ur;;ACTIVE;2.30;2.73 +5837-0;Cytomegalovirus;PrThr;Pt;Urine;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Urine by Organism specific culture;CMV Ur Ql Cult;;ACTIVE;1.0;2.73 +58370-8;Carisoprodol+Meprobamate;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Carisoprodol+Meprobamate [Presence] in Urine by Screen method;Carisoprodol+Meprob Ur Ql Scn;;ACTIVE;2.30;2.73 +58371-6;Carisoprodol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Carisoprodol/Creatinine [Mass Ratio] in Urine;Carisoprodol/Creat Ur;;ACTIVE;2.30;2.73 +58372-4;Meprobamate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Meprobamate/Creatinine [Mass Ratio] in Urine;Meprobamate/Creat Ur;;ACTIVE;2.30;2.73 +58373-2;Meprobamate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Meprobamate [Presence] in Urine by Confirmatory method;Meprobamate Ur Ql Cfm;;ACTIVE;2.30;2.73 +58374-0;Meprobamate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Meprobamate [Mass/volume] in Urine by Confirmatory method;Meprobamate Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58375-7;Ethyl glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Ethyl glucuronide [Presence] in Urine by Screen method;Ethyl glucuronide Ur Ql Scn;;ACTIVE;2.30;2.73 +58376-5;Ethyl glucuronide/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Ethyl glucuronide/Creatinine [Mass Ratio] in Urine;Ethyl glucuronide/Creat Ur;;ACTIVE;2.30;2.73 +58377-3;Ethyl glucuronide;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ethyl glucuronide [Presence] in Urine by Confirmatory method;Ethyl glucuronide Ur Ql Cfm;;ACTIVE;2.30;2.73 +58378-1;Ethyl glucuronide;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethyl glucuronide [Mass/volume] in Urine by Confirmatory method;Ethyl glucuronide Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58379-9;Fentanyl+Norfentanyl;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;fentaNYL+Norfentanyl [Presence] in Urine by Screen method;fentaNYL+Norfentanyl Ur Ql Scn;;ACTIVE;2.30;2.73 +58380-7;fentaNYL/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;fentaNYL/Creatinine [Mass Ratio] in Urine;fentaNYL/Creat Ur;;ACTIVE;2.30;2.73 +58381-5;fentaNYL;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;fentaNYL [Mass/volume] in Urine by Confirmatory method;fentaNYL Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58382-3;Norfentanyl/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Norfentanyl/Creatinine [Mass Ratio] in Urine;Norfentanyl/Creat Ur;;ACTIVE;2.30;2.73 +58383-1;Norfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norfentanyl [Mass/volume] in Urine by Confirmatory method;Norfentanyl Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58384-9;6-Monoacetylmorphine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM)/Creatinine [Mass Ratio] in Urine;6MAM/Creat Ur;;ACTIVE;2.30;2.73 +58385-6;Meperidine+Normeperidine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Meperidine+Normeperidine [Presence] in Urine by Screen method;Meperidine+Nor Ur Ql Scn;;ACTIVE;2.30;2.73 +58386-4;Meperidine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Meperidine/Creatinine [Mass Ratio] in Urine;Meperidine/Creat Ur;;ACTIVE;2.30;2.73 +58387-2;Normeperidine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Normeperidine/Creatinine [Mass Ratio] in Urine;Normeperidine/Creat Ur;;ACTIVE;2.30;2.73 +5838-8;Cytomegalovirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Specimen by Organism specific culture;CMV Spec Ql Cult;;ACTIVE;1.0;2.73 +58388-0;Normeperidine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Normeperidine [Presence] in Urine by Confirmatory method;Normeperidine Ur Ql Cfm;;ACTIVE;2.30;2.73 +58389-8;Normeperidine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Normeperidine [Mass/volume] in Urine by Confirmatory method;Normeperidine Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58390-6;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP)/Creatinine [Mass Ratio] in Urine;EDDP/Creat Ur;;ACTIVE;2.30;2.73 +58391-4;Codeine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Codeine/Creatinine [Mass Ratio] in Urine;Codeine/Creat Ur;;ACTIVE;2.30;2.73 +58392-2;Morphine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Morphine/Creatinine [Mass Ratio] in Urine;Morphine/Creat Ur;;ACTIVE;2.30;2.73 +58393-0;HYDROcodone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;HYDROcodone/Creatinine [Mass Ratio] in Urine;HYDROcodone/Creat Ur;;ACTIVE;2.30;2.73 +58394-8;HYDROmorphone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;HYDROmorphone/Creatinine [Mass Ratio] in Urine;HYDROmorphone/Creat Ur;;ACTIVE;2.30;2.73 +58395-5;oxyCODONE/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;oxyCODONE/Creatinine [Mass Ratio] in Urine;oxyCODONE/Creat Ur;;ACTIVE;2.30;2.73 +5839-6;Enterovirus identified;Prid;Pt;CSF;Nom;Organism specific culture;MICRO;1;Enterovirus identified in Cerebral spinal fluid by Organism specific culture;EV CSF Cult;;ACTIVE;1.0;1.0ma +58396-3;oxyMORphone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;oxyMORphone/Creatinine [Mass Ratio] in Urine;oxyMORphone/Creat Ur;;ACTIVE;2.30;2.73 +58397-1;Phencyclidine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Phencyclidine/Creatinine [Mass Ratio] in Urine;PCP/Creat Ur;;ACTIVE;2.30;2.73 +58398-9;Propoxyphene/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Propoxyphene/Creatinine [Mass Ratio] in Urine;Propoxyph/Creat Ur;;ACTIVE;2.30;2.73 +58399-7;Norpropoxyphene/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Norpropoxyphene/Creatinine [Mass Ratio] in Urine;Norpropoxyph/Creat Ur;;ACTIVE;2.30;2.73 +58400-3;Specimen pH acceptable;Arb;Pt;Urine;Ord;;SPEC;1;Specimen pH acceptable of Urine;Specimen pH acceptable Ur;;ACTIVE;2.30;2.73 +58401-1;Tapentadol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Tapentadol [Presence] in Urine by Confirmatory method;Tapentadol Ur Ql Cfm;;ACTIVE;2.30;2.73 +58402-9;Tapentadol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Tapentadol [Mass/volume] in Urine by Confirmatory method;Tapentadol Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58403-7;Tricyclic antidepressants/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Tricyclic antidepressants/Creatinine [Mass Ratio] in Urine;Tricyclics/Creat Ur;;ACTIVE;2.30;2.70 +5840-4;Enterovirus identified;Prid;Pt;Isolate;Nom;IF;MICRO;1;Enterovirus identified in Isolate by Immunofluorescence;EV Islt IF;;ACTIVE;1.0;2.19 +58404-5;traMADol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;traMADol/Creatinine [Mass Ratio] in Urine;traMADol/Creat Ur;;ACTIVE;2.30;2.73 +58405-2;Hepatitis B virus surface Ab Signal/Cutoff;RelACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus surface Ab Signal/Cutoff in Serum;HBV surface Ab s/co Ser;;ACTIVE;2.30;2.40 +58406-0;Platelet morphology panel;-;Pt;Bld;-;;PANEL.HEM/BC;1;Platelet morphology panel - Blood;Platelet morphology pnl Bld;;DISCOURAGED;2.30;2.73 +58407-8;Leukocyte morphology panel;-;Pt;Bld;-;;PANEL.HEM/BC;1;Leukocyte morphology panel - Blood;WBC morphology pnl Bld;;DISCOURAGED;2.30;2.73 +58408-6;Erythrocyte morphology panel;-;Pt;Bld;-;;PANEL.HEM/BC;1;Erythrocyte morphology panel - Blood;RBC morphology pnl Bld;;ACTIVE;2.30;2.73 +58409-4;Other cells/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Other cells/100 leukocytes in Blood by Automated count;Other cells/leuk NFr Bld Auto;;ACTIVE;2.30;2.50 +58410-2;Complete blood count panel;-;Pt;Bld;-;Automated count;PANEL.HEM/BC;1;CBC panel - Blood by Automated count;CBC Pnl Bld Auto;;ACTIVE;2.30;2.73 +58411-0;Clinical research drug XXX;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Clinical research drug XXX [Mass/volume] in Plasma;Clinical research drug Plas-mCnc;;ACTIVE;2.30;2.70 +5841-2;Enterovirus identified;Prid;Pt;Isolate;Nom;Neut;MICRO;1;Enterovirus identified in Isolate by Neutralization test;EV Islt Nt;;ACTIVE;1.0;2.19 +58412-8;Cefepime;Susc;Pt;Isolate.meningitis;OrdQn;Agar diffusion;ABXBACT;1;Cefepime [Susceptibility] for meningitis by Disk diffusion (KB);Cefepime Islt.mening KB;;ACTIVE;2.30;2.58 +58413-6;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Bld;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Blood by Automated count;nRBC/100 WBC Bld Auto-Rto;;ACTIVE;2.30;2.73 +58414-4;Herpes simplex virus 1+2 DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [Presence] in Amniotic fluid by NAA with probe detection;HSV1+2 DNA Amn Ql NAA+probe;;ACTIVE;2.30;2.73 +58415-1;BRAF gene.p.Val600Glu;PrThr;Pt;Tiss;Ord;Molgen;MOLPATH.MUT;1;BRAF gene p.Val600Glu [Presence] in Tissue by Molecular genetics method;BRAF p.V600E Tiss Ql;;ACTIVE;2.30;2.73 +58416-9;MLH1 gene methylation;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;MLH1 gene methylation [Presence] in Blood or Tissue by Molecular genetics method;MLH1 gene methylation Bld/T Ql;;ACTIVE;2.30;2.73 +58417-7;dilTIAZem;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;dilTIAZem [Presence] in Urine;dilTIAZem Ur Ql;;ACTIVE;2.30;2.73 +58418-5;Micafungin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Micafungin [Mass/volume] in Serum or Plasma;Micafungin SerPl-mCnc;;ACTIVE;2.30;2.70 +58419-3;Caspofungin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Caspofungin [Mass/volume] in Serum or Plasma;Caspofungin SerPl-mCnc;;ACTIVE;2.30;2.70 +5842-0;Enterovirus identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Enterovirus identified in Stool by Organism specific culture;EV Stl Cult;;ACTIVE;1.0;2.19 +58420-1;Anidulafungin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Anidulafungin [Mass/volume] in Serum or Plasma;Anidulafungin SerPl-mCnc;;ACTIVE;2.30;2.70 +58421-9;Medicare short stay assessment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medicare short stay assessment [CMS Assessment];;;ACTIVE;2.30;2.63 +58422-7;Alternate state Medicaid billing;-;Pt;^Patient;-;;PANEL.SURVEY.CMS;4;Alternate state Medicaid billing;;;ACTIVE;2.30;2.63 +58423-5;Ethyl sulfate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Ethyl sulfate/Creatinine [Mass Ratio] in Urine;Ethyl sulfate/Creat Ur;;ACTIVE;2.30;2.73 +58424-3;Ethyl sulfate;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Ethyl sulfate [Presence] in Urine by Screen method;Ethyl sulfate Ur Ql Scn;;ACTIVE;2.30;2.73 +58425-0;Ethyl sulfate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethyl sulfate [Mass/volume] in Urine by Confirmatory method;Ethyl sulfate Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58426-8;Carisoprodol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Carisoprodol [Presence] in Urine by Confirmatory method;Carisoprodol Ur Ql Cfm;;ACTIVE;2.30;2.73 +58427-6;Carisoprodol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Carisoprodol [Mass/volume] in Urine by Confirmatory method;Carisoprodol Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +58428-4;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Urine by Confirmatory method;EDDP Ur Ql Cfm;;ACTIVE;2.30;2.73 +58429-2;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Mass/volume] in Urine by Confirmatory method;EDDP Ur Cfm-mCnc;;ACTIVE;2.30;2.73 +584-3;Streptococcus agalactiae;PrThr;Pt;Vag;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture;Gp B Strep Vag Ql Cult;;ACTIVE;1.0;2.73 +58430-0;oxyCODONE+Oxymorphone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Urine by Screen method;oxyCODONE+oxyMORphone Ur Ql Scn;;ACTIVE;2.30;2.73 +58431-8;Microalbumin panel;-;24H;Urine;-;;PANEL.CHEM;1;Microalbumin panel - 24 hour Urine;Microalbumin panel 24h Ur;;ACTIVE;2.30;2.73 +58432-6;Casts panel;-;Pt;Urine sed;Qn;;PANEL.UA;1;Casts panel - Urine sediment;Casts Pnl UrnS;;DISCOURAGED;2.30;2.61 +58433-4;Crystals panel;-;Pt;Urine sed;Qn;;PANEL.UA;1;Crystals panel - Urine sediment;Crystals Pnl UrnS;;DISCOURAGED;2.30;2.61 +58434-2;Cells panel;-;Pt;Urine sed;-;;PANEL.UA;1;Cells panel - Urine sediment;Cells Pnl UrnS;;DISCOURAGED;2.30;2.61 +58435-9;Microorganisms panel;-;Pt;Urine sed;-;;PANEL.UA;1;Microorganisms panel - Urine sediment;Microrganisms Pnl UrnS;;DISCOURAGED;2.30;2.61 +58436-7;Casts;Type;Pt;Urine sed;Nom;Microscopy.light;UA;1;Casts [Type] in Urine sediment by Light microscopy;Casts UrnS Micro;;ACTIVE;2.30;2.73 +58437-5;Microorganisms seen;Type;Pt;Urine sed;Nom;Microscopy.light;UA;1;Microorganisms seen [Type] in Urine sediment by Light microscopy;Microorganisms UrnS Micro;;ACTIVE;2.30;2.30 +5843-8;Enterovirus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Enterovirus identified in Specimen by Organism specific culture;EV Spec Cult;;ACTIVE;1.0;2.73 +58438-3;Cells;Type;Pt;Urine sed;Nom;Microscopy.light;UA;1;Cells [Type] in Urine sediment by Light microscopy;Cells UrnS Micro;;ACTIVE;2.30;2.30 +58439-1;Clinical research drug XXX;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Clinical research drug XXX [Mass/volume] in Urine;Clinical research drug Ur-mCnc;;ACTIVE;2.30;2.42 +58440-9;Classical swine fever virus E2 Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Classical swine fever virus E2 Ab [Units/volume] in Serum by Immunoassay;CSFV E2 Ab Ser IA-aCnc;;ACTIVE;2.30;2.69 +58441-7;Other elements;-;Pt;Urine sed;-;;PANEL.UA;1;Other elements in Urine sediment;Other elements UrnS;;DISCOURAGED;2.30;2.32 +58442-5;Other elements;Prid;Pt;Urine sed;Nom;Microscopy.light;UA;1;Other elements [Identifier] in Urine sediment by Light microscopy;Other elements UrnS Micro;;ACTIVE;2.30;2.73 +58443-3;Other cells;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Other cells [#/volume] in Blood by Automated count;Other cells # Bld Auto;;ACTIVE;2.30;2.73 +58444-1;Erythrocytes.dysmorphic;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Erythrocytes.dysmorphic [Presence] in Urine sediment by Light microscopy;Dysmorphic RBC UrnS Ql Micro;;ACTIVE;2.30;2.73 +58445-8;Manual differential comment;Imp;Pt;Bld;Nar;;HEM/BC;1;Manual differential comment [Interpretation] in Blood Narrative;Manual dif comment Bld-Imp;;ACTIVE;2.30;2.73 +5844-6;Herpes simplex virus 1 Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Genital specimen by Immunofluorescence;HSV1 Ag Genital Ql IF;;ACTIVE;1.0;2.56 +58446-6;Creatinine renal clearance adjusted for body surface area panel;-;24H;Urine+Ser/Plas;Qn;;PANEL.CHEM;1;Creatinine 24H renal clearance adjusted for body surface area panel;Creat 24H Cl BSA adj Pnl Ur+SerPl;;ACTIVE;2.30;2.73 +58447-4;Microalbumin/Creatinine ratio panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Microalbumin/Creatinine panel in 24H Urine;Microalbumin/creat Pnl 24H Ur;;ACTIVE;2.30;2.73 +58448-2;Albumin ug/min;MRat;24H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin ug/min [Mass/time] in 24 hour Urine;Microalbumin ug/min 24H Ur-mRate;;ACTIVE;2.30;2.73 +58449-0;Erythrocyte clumps;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Erythrocyte clumps [#/area] in Urine sediment by Microscopy high power field;RBC clumps #/area UrnS HPF;;ACTIVE;2.30;2.73 +58450-8;Bilirubin;PrThr;Pt;Urine;Ord;Confirm;UA;1;Bilirubin [Presence] in Urine by Confirmatory method;Bilirub Ur Ql Cfm;;ACTIVE;2.30;2.73 +58451-6;Glutamate decarboxylase 65 Ab;MCnc;Pt;Ser;Qn;;SERO;1;Glutamate decarboxylase 65 Ab [Mass/volume] in Serum;GAD65 Ab Ser-mCnc;;ACTIVE;2.32;2.70 +58452-4;Hepatitis B virus surface Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis B virus surface Ag [Units/volume] in Serum;HBV surface Ag Ser-aCnc;;ACTIVE;2.32;2.73 +5845-3;Herpes simplex virus 1 Ag;PrThr;Pt;Skin;Ord;IF;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Skin by Immunofluorescence;HSV1 Ag Skin Ql IF;;ACTIVE;1.0;2.56 +58453-2;Hemoglobin.gastrointestinal.lower;MCnc;Pt;Stool;Qn;IA;CHEM;1;Hemoglobin.gastrointestinal.lower [Mass/volume] in Stool by Immunoassay;Hemoccult Stl IA-mCnc;;ACTIVE;2.32;2.73 +58454-0;Subtelomere analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;Subtelomere analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal;Subtelomere analysis Bld/T;;ACTIVE;2.32;2.32 +58455-7;Taenia solium Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Taenia solium Ab [Presence] in Cerebral spinal fluid by Immunoassay;T sol Ab CSF Ql IA;;ACTIVE;2.32;2.56 +58456-5;Bladder cells;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Bladder cells [Presence] in Urine sediment by Light microscopy;Bladder Cells UrnS Ql Micro;;ACTIVE;2.32;2.56 +58457-3;Sulfites;PrThr;Pt;Urine;Ord;Test strip;CHEM;1;Sulfites [Presence] in Urine by Test strip;Sulfites Ur Ql Strip;;ACTIVE;2.32;2.56 +58458-1;Mitochondria Ab pattern;Imp;Pt;Ser;Nom;IF;SERO;1;Mitochondria Ab pattern [Interpretation] in Serum by Immunofluorescence;Mitochondria Ab pattern Ser IF-Imp;;ACTIVE;2.32;2.73 +58459-9;Ganglioside GT1b Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Ganglioside GT1b Ab [Presence] in Serum by Immunofluorescence;GT1b Ganlg Ab Ser Ql IF;;ACTIVE;2.32;2.56 +58460-7;Endothelial cell Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Endothelial cell Ab [Titer] in Serum or Plasma;Endothelial cell Ab Titr SerPl;;ACTIVE;2.32;2.32 +5846-1;Herpes simplex virus 1 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Specimen by Immunofluorescence;HSV1 Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58461-5;Intestinal goblet cell Ab;Titr;Pt;Ser;Qn;;SERO;1;Intestinal goblet cell Ab [Titer] in Serum;Intestinal goblet cell Ab Titr Ser;;ACTIVE;2.32;2.32 +58462-3;Complement functional activity;ACnc;Pt;Ser/Plas;Qn;IA;HEM/BC;1;Complement functional activity [Units/volume] in Serum or Plasma by Immunoassay;Comp functional activity SerPl IA-aCnc;;ACTIVE;2.32;2.73 +58463-1;Tau protein/Protein.total;MFr;Pt;CSF;Qn;;CHEM;1;Tau protein/Protein.total in Cerebral spinal fluid;Tau Prot MFr CSF;;ACTIVE;2.32;2.73 +58464-9;Campesterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Campesterol [Moles/volume] in Serum or Plasma;Campesterol SerPl-sCnc;;ACTIVE;2.32;2.70 +58465-6;DNA double strand Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;DNA double strand IgG Ab [Presence] in Serum by Immunoassay;dsDNA IgG Ser Ql IA;;ACTIVE;2.32;2.73 +58466-4;DNA double strand Ab.IgG;Titr;Pt;Ser;Qn;Crithidia luciliae IF;SERO;1;DNA double strand IgG Ab [Titer] in Serum by Immunofluorescence (IF) Crithidia luciliae;dsDNA IgG Titr Ser CLIF;;ACTIVE;2.32;2.73 +58467-2;Gasterophilus intestinalis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horse Bot Fly IgG4 Ab [Mass/volume] in Serum;Horse Bot Fly IgG4-mCnc;;ACTIVE;2.32;2.70 +58468-0;Pimpinella anisum Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Anise IgG4 Ab [Mass/volume] in Serum;Anise IgG4-mCnc;;ACTIVE;2.32;2.70 +58469-8;Cells;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Cells [#/volume] in Body fluid;Cells # Fld;;ACTIVE;2.42;2.73 +58470-6;Nucleated cells;NCnc;Pt;CSF;Qn;;HEM/BC;1;Nucleated cells [#/volume] in Cerebral spinal fluid;Nuc cell # CSF;;ACTIVE;2.32;2.73 +58471-4;Erythrocytes.pitted/Erythrocytes.total;NFr;Pt;RBC;Qn;;HEM/BC;1;Erythrocytes.pitted/Erythrocytes.total in Red Blood Cells;RBC.pitted/RBC.total NFr RBC;;ACTIVE;2.32;2.48 +58472-2;Other cells;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Other cells [#] in Body fluid by Manual count;Other cells Fld Manual;;ACTIVE;2.36;2.73 +58473-0;Haemophilus influenzae serotype DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Haemophilus influenzae serotype DNA [Identifier] in Specimen by NAA with probe detection;Haem influ serotyp DNA Spec NAA+probe;;ACTIVE;2.32;2.72 +58474-8;Cosmetic;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Cosmetic;FDA label Cosmetic;;ACTIVE;2.32;2.34 +58475-5;Medical food;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Medical food;FDA label Medical food;;ACTIVE;2.32;2.34 +58476-3;Dietary supplement;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Dietary supplement;FDA label Dietary supplement;;ACTIVE;2.32;2.34 +58477-1;Pulmonary function study;Find;Pt;^Patient;Doc;Pulmonary function;PULM;2;Pulmonary function study;Pulmonary function study;;ACTIVE;2.32;2.72 +58478-9;Bombus sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bombus sp IgG Ab [Mass/volume] in Serum;Bombus sp IgG-mCnc;;ACTIVE;2.32;2.73 +5847-9;Herpes simplex virus 2 Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Genital specimen by Immunofluorescence;HSV2 Ag Genital Ql IF;;ACTIVE;1.0;2.56 +58479-7;Fatty acids.nonesterified^7th specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --7th specimen fasting;NEFA sp7 p fast SerPl-sCnc;;ACTIVE;2.32;2.70 +58480-5;Fatty acids.nonesterified^6th specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --6th specimen fasting;NEFA sp6 p fast SerPl-sCnc;;ACTIVE;2.32;2.70 +58481-3;Protein C Ag/Coagulation factor IX Ag;MRto;Pt;PPP;Qn;IA;COAG;1;Protein C Ag/Coagulation factor IX Ag [Mass Ratio] in Platelet poor plasma by Immunoassay;Prot C Ag/Fact IX Ag PPP IA;;ACTIVE;2.32;2.73 +58482-1;Protein S Ag/Coagulation factor IX Ag;MRto;Pt;PPP;Qn;IA;COAG;1;Protein S Ag/Coagulation factor IX Ag [Mass Ratio] in Platelet poor plasma by Immunoassay;Prot S Ag/Fact IX Ag PPP IA;;ACTIVE;2.32;2.73 +58483-9;BRAF gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BRAF gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BRAF gene Mut Anl Bld/T;;ACTIVE;2.32;2.73 +58484-7;Estradiol^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --8th specimen post XXX challenge;Estradiol sp8 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.70 +58485-4;Estradiol^baseline;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --baseline;Estradiol BS SerPl HS-mCnc;;ACTIVE;2.32;2.73 +58486-2;Estradiol^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --7th specimen post XXX challenge;Estradiol sp7 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.70 +5848-7;Herpes simplex virus 2 Ag;PrThr;Pt;Skin;Ord;IF;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Skin by Immunofluorescence;HSV2 Ag Skin Ql IF;;ACTIVE;1.0;2.56 +58487-0;Estradiol^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --6th specimen post XXX challenge;Estradiol sp6 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.70 +58488-8;Estradiol^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --5th specimen post XXX challenge;Estradiol sp5 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.70 +58489-6;Estradiol^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --4th specimen post XXX challenge;Estradiol sp4 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.73 +58490-4;Estradiol^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --3rd specimen post XXX challenge;Estradiol sp3 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.73 +58491-2;Estradiol^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --2nd specimen post XXX challenge;Estradiol sp2 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.73 +58492-0;Estradiol^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by High sensitivity method --1st specimen post XXX challenge;Estradiol sp1 p chal SerPl HS-mCnc;;ACTIVE;2.32;2.73 +58493-8;Coagulation factor VIII Ab;PrThr;Pt;PPP;Ord;IA;COAG;1;Coagulation factor VIII Ab [Presence] in Platelet poor plasma by Immunoassay;Fact VIII Ab PPP Ql IA;;ACTIVE;2.32;2.73 +58494-6;C peptide^1.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --1.5 hours post dose glucose;C peptide 1.5h p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +5849-5;Herpes simplex virus 2 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Specimen by Immunofluorescence;HSV2 Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58495-3;C peptide^10M post 1 mg glucagon IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --10 minutes post 1 mg glucagon IV;C peptide 10M p 1 mg Gc IV SerPl-sCnc;;ACTIVE;2.32;2.70 +58496-1;C peptide^10th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge;C peptide sp10 p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58497-9;C peptide^11th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --11th specimen post XXX challenge;C peptide sp11 p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58498-7;C peptide^12th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --12th specimen post XXX challenge;C peptide sp12 p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58499-5;C peptide^15M post 1 mg glucagon IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --15 minutes post 1 mg glucagon IV;C peptide 15M p 1 mg Gc PO SerPl-sCnc;;ACTIVE;2.32;2.70 +585-0;Streptococcus agalactiae;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Throat by Organism specific culture;Gp B Strep Throat Ql Cult;;ACTIVE;1.0;2.73 +58500-0;C peptide^15M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --15 minutes post dose glucose;C peptide 15M p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58501-8;C peptide^15M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --15 minutes pre XXX challenge;C peptide 15M pre chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58502-6;C peptide^15M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --15 minutes pre XXX challenge;C peptide 15M pre chal SerPl-sCnc;;ACTIVE;2.32;2.70 +5850-3;Herpes simplex virus Ag;PrThr;Pt;Genital;Ord;IA;MICRO;1;Herpes simplex virus Ag [Presence] in Genital specimen by Immunoassay;HSV Ag Genital Ql IA;;ACTIVE;1.0;2.56 +58503-4;C peptide^1H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --1 hour post dose glucose;C peptide 1h p Glc SerPl-mCnc;;ACTIVE;2.32;2.73 +58504-2;C peptide^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;C peptide sp1 p chal SerPl-mCnc;;ACTIVE;2.32;2.73 +58505-9;C peptide^2.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2.5 hours post dose glucose;C peptide 2.5h p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58506-7;C peptide^2.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --2.5 hours post dose glucose;C peptide 2.5h p Glc SerPl-sCnc;;ACTIVE;2.32;2.70 +58507-5;C peptide^2M post 1 mg glucagon IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --2 minutes post 1 mg glucagon IV;C peptide 2M p 1 mg Glc IV SerPl-sCnc;;ACTIVE;2.32;2.70 +58508-3;C peptide^3.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --3.5 hours post dose glucose;C peptide 3.5h p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58509-1;C peptide^3.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --3.5 hours post dose glucose;C peptide 3.5h p Glc SerPl-sCnc;;ACTIVE;2.32;2.70 +58510-9;C peptide^30M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --30 minutes post dose glucose;C peptide 30M p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +5851-1;Herpes simplex virus Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Genital specimen by Immunofluorescence;HSV Ag Genital Ql IF;;ACTIVE;1.0;2.56 +58511-7;C peptide^3H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --3 hours post dose glucose;C peptide 3h p Glc SerPl-mCnc;;ACTIVE;2.32;2.73 +58512-5;C peptide^4.5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --4.5 hours post dose glucose;C peptide 4.5h p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58513-3;C peptide^4.5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --4.5 hours post dose glucose;C peptide 4.5h p Glc SerPl-sCnc;;ACTIVE;2.32;2.70 +58514-1;C peptide^45M post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --45 minutes post dose glucose;C peptide 45M p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58515-8;C peptide^45M post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --45 minutes post dose glucose;C peptide 45M p Glc SerPl-sCnc;;ACTIVE;2.32;2.70 +58516-6;C peptide^4H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --4 hours post dose glucose;C peptide 4h p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58517-4;C peptide^4H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --4 hours post dose glucose;C peptide 4h p Glc SerPl-sCnc;;ACTIVE;2.32;2.70 +58518-2;C peptide^5H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --5 hours post dose glucose;C peptide 5h p Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58519-0;C peptide^5H post dose glucose;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5 hours post dose glucose;C peptide 5h p Glc SerPl-sCnc;;ACTIVE;2.32;2.70 +58520-8;C peptide^5M post 1 mg glucagon IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5 minutes post 1 mg glucagon IV;C peptide 5M p 1 mg Gc IV SerPl-sCnc;;ACTIVE;2.32;2.70 +58521-6;C peptide^9th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge;C peptide sp9 p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58522-4;C peptide^pre dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --pre dose glucose;C peptide pre Glc SerPl-mCnc;;ACTIVE;2.32;2.70 +58523-2;Corticosterone^30M post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Corticosterone [Moles/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin;Corticoster 30M p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.32;2.70 +58524-0;Corticosterone^1H post 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Corticosterone [Moles/volume] in Serum or Plasma --1 hour post 250 ug corticotropin;Corticoster 1h p 250 ug ACTH SerPl-sCnc;;ACTIVE;2.32;2.70 +58525-7;Corticosterone^pre 250 ug corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Corticosterone [Moles/volume] in Serum or Plasma --pre 250 ug corticotropin;Corticoster pre 250 ug ACTH SerPl-sCnc;;ACTIVE;2.32;2.70 +58526-5;Corticotropin^1.5H post dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1.5 hours post dose glucagon;ACTH 1.5h p Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58527-3;Corticotropin^1.5H post dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1.5 hours post dose glucagon;ACTH 1.5h p Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58528-1;Corticotropin^1.5H post dose glucose;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1.5 hours post dose glucose;ACTH 1.5h p Glc Plas-mCnc;;ACTIVE;2.32;2.70 +5852-9;Herpes simplex virus Ag;PrThr;Pt;Skin;Ord;IA;MICRO;1;Herpes simplex virus Ag [Presence] in Skin by Immunoassay;HSV Ag Skin Ql IA;;ACTIVE;1.0;2.56 +58529-9;Corticotropin^1.5H post dose glucose;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1.5 hours post dose glucose;ACTH 1.5h p Glc Plas-sCnc;;ACTIVE;2.32;2.70 +58530-7;Corticotropin^1.5H post 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1.5 hours post 1 ug/kg CRH IV;ACTH 1.5h p 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58531-5;Corticotropin^1.5H post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1.5 hours post dose insulin IV;ACTH 1.5h p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58532-3;Corticotropin^10 AM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --10 AM specimen;ACTH 10 AM Plas-mCnc;;ACTIVE;2.32;2.70 +58533-1;Corticotropin^10 AM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --10 AM specimen;ACTH 10 AM Plas-sCnc;;ACTIVE;2.32;2.70 +58534-9;Corticotropin^10 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --10 PM specimen;ACTH 10 PM Plas-mCnc;;ACTIVE;2.32;2.70 +58535-6;Corticotropin^10 PM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --10 PM specimen;ACTH 10 PM Plas-sCnc;;ACTIVE;2.32;2.70 +58536-4;Corticotropin^105M post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --105 minutes post dose insulin IV;ACTH 105M p Ins IV Plas-mCnc;;ACTIVE;2.32;2.70 +5853-7;Herpes simplex virus Ag;PrThr;Pt;Skin;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Skin by Immunofluorescence;HSV Ag Skin Ql IF;;ACTIVE;1.0;2.56 +58537-2;Corticotropin^105M post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --105 minutes post dose insulin IV;ACTH 105M p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58538-0;Corticotropin^10th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --10th specimen post XXX challenge;ACTH sp10 p chal Plas-mCnc;;ACTIVE;2.32;2.70 +58539-8;Corticotropin^10th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --10th specimen post XXX challenge;ACTH sp10 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58540-6;Corticotropin^11th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --11th specimen post XXX challenge;ACTH sp11 p chal Plas-mCnc;;ACTIVE;2.32;2.70 +58541-4;Corticotropin^11th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --11th specimen post XXX challenge;ACTH sp11 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58542-2;Corticotropin^12 AM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --12 AM specimen;ACTH 12 AM Plas-sCnc;;ACTIVE;2.32;2.70 +58543-0;Corticotropin^12 PM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --12 PM specimen;ACTH 12 PM Plas-sCnc;;ACTIVE;2.32;2.70 +58544-8;Corticotropin^12th specimen post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --12th specimen post XXX challenge;ACTH sp12 p chal Plas-mCnc;;ACTIVE;2.32;2.70 +5854-5;Herpes simplex virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Herpes simplex virus Ag [Presence] in Specimen by Immunoassay;HSV Ag Spec Ql IA;;ACTIVE;1.0;2.73 +58545-5;Corticotropin^12th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --12th specimen post XXX challenge;ACTH sp12 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58546-3;Corticotropin^15M post 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --15 minutes post 1 ug/kg CRH IV;ACTH 15M p 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58547-1;Corticotropin^15M post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --15 minutes post dose insulin IV;ACTH 15M p Ins IV Plas-mCnc;;ACTIVE;2.32;2.70 +58548-9;Corticotropin^15M post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --15 minutes post dose insulin IV;ACTH 15M p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58549-7;Corticotropin^15M post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --15 minutes post XXX challenge;ACTH 15M p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58550-5;Corticotropin^15M pre 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --15 minutes pre 1 ug/kg CRH IV;ACTH 15M pre 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58551-3;Corticotropin^15M pre dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --15 minutes pre dose insulin IV;ACTH 15M pre Ins IV Plas-mCnc;;ACTIVE;2.32;2.70 +5855-2;Herpes simplex virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Specimen by Immunofluorescence;HSV Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58552-1;Corticotropin^15M pre dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --15 minutes pre dose insulin IV;ACTH 15M pre Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58553-9;Corticotropin^1H post 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1 hour post 1 ug/kg CRH IV;ACTH 1h p 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58554-7;Corticotropin^1H post dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 hour post dose glucagon;ACTH 1h p Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58555-4;Corticotropin^1H post dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1 hour post dose glucagon;ACTH 1h p Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58556-2;Corticotropin^1H post dose glucose;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 hour post dose glucose;ACTH 1h p Glc Plas-mCnc;;ACTIVE;2.32;2.70 +58557-0;Corticotropin^1H post dose glucose;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1 hour post dose glucose;ACTH 1h p Glc Plas-sCnc;;ACTIVE;2.32;2.70 +58558-8;Corticotropin^1H post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1 hour post dose insulin IV;ACTH 1h p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58559-6;Corticotropin^1H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1 hour post XXX challenge;ACTH 1h p chal Plas-sCnc;;ACTIVE;2.32;2.70 +5856-0;Herpes simplex virus identified;Prid;Pt;Genital;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Genital specimen by Organism specific culture;HSV Genital Cult;;ACTIVE;1.0;2.21 +58560-4;Corticotropin^1st specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1st specimen post XXX challenge;ACTH sp1 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58561-2;Corticotropin^2 PM specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2 PM specimen;ACTH 2 PM Plas-mCnc;;ACTIVE;2.32;2.70 +58562-0;Corticotropin^2 PM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2 PM specimen;ACTH 2 PM Plas-sCnc;;ACTIVE;2.32;2.70 +58563-8;Corticotropin^2.5H post dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2.5 hours post dose glucagon;ACTH 2.5h p Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58564-6;Corticotropin^2.5H post dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2.5 hours post dose glucagon;ACTH 2.5h p Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58565-3;Corticotropin^2.5H post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2.5 hours post dose insulin IV;ACTH 2.5h p Ins IV Plas-mCnc;;ACTIVE;2.32;2.70 +58566-1;Corticotropin^2.5H post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2.5 hours post dose insulin IV;ACTH 2.5h p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58567-9;Corticotropin^2.5H post dose glucose;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2.5 hours post dose glucose;ACTH 2.5h p Glc Plas-mCnc;;ACTIVE;2.32;2.70 +58568-7;Corticotropin^2.5H post dose glucose;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2.5 hours post dose glucose;ACTH 2.5h p Glc Plas-sCnc;;ACTIVE;2.32;2.70 +58569-5;Corticotropin^1D post dose metyraPONE;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 day post dose metyraPONE;ACTH 1D p MTP Plas-mCnc;;ACTIVE;2.32;2.70 +58570-3;Corticotropin^1D post dose metyraPONE;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1 day post dose metyraPONE;ACTH 1D p MTP Plas-sCnc;;ACTIVE;2.32;2.70 +58571-1;Corticotropin^2H post 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2 hours post 1 ug/kg CRH IV;ACTH 2h p 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58572-9;Corticotropin^2H post dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2 hours post dose glucagon;ACTH 2h p Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58573-7;Corticotropin^2H post dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2 hours post dose glucagon;ACTH 2h p Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58574-5;Corticotropin^2H post dose glucose;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2 hours post dose glucose;ACTH 2h p Glc Plas-mCnc;;ACTIVE;2.32;2.70 +58575-2;Corticotropin^2H post dose glucose;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2 hours post dose glucose;ACTH 2h p Glc Plas-sCnc;;ACTIVE;2.32;2.70 +58576-0;Corticotropin^2H post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2 hours post dose insulin IV;ACTH 2h p Ins IV Plas-mCnc;;ACTIVE;2.32;2.70 +58577-8;Corticotropin^2H post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2 hours post dose insulin IV;ACTH 2h p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +5857-8;Herpes simplex virus identified;Prid;Pt;Isolate;Nom;IF;MICRO;1;Herpes simplex virus identified in Isolate by Immunofluorescence;HSV Islt IF;;ACTIVE;1.0;2.73 +58578-6;Corticotropin^2H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2 hours post XXX challenge;ACTH 2h p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58579-4;Corticotropin^2nd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2nd specimen post XXX challenge;ACTH sp2 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58580-2;Corticotropin^30M post 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes post 1 ug/kg CRH IV;ACTH 30M p 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58581-0;Corticotropin^30M post dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes post dose glucagon;ACTH 30M p Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58582-8;Corticotropin^30M post dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes post dose glucagon;ACTH 30M p Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58583-6;Corticotropin^30M post dose glucose;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes post dose glucose;ACTH 30M p Glc Plas-mCnc;;ACTIVE;2.32;2.70 +58584-4;Corticotropin^30M post dose glucose;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes post dose glucose;ACTH 30M p Glc Plas-sCnc;;ACTIVE;2.32;2.70 +58585-1;Corticotropin^30M post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes post dose insulin IV;ACTH 30M p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +5858-6;Herpes simplex virus identified;Prid;Pt;Skin;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Skin by Organism specific culture;HSV Skin Cult;;ACTIVE;1.0;2.73 +58586-9;Corticotropin^30M post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes post XXX challenge;ACTH 30M p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58587-7;Corticotropin^30M pre 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes pre 1 ug/kg CRH IV;ACTH 30M pre 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.32;2.70 +58588-5;Corticotropin^30M pre 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes pre 1 ug/kg CRH IV;ACTH 30M pre 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58589-3;Corticotropin^30M pre dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes pre dose glucagon;ACTH 30M pre Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58590-1;Corticotropin^30M pre dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes pre dose glucagon;ACTH 30M pre Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58591-9;Corticotropin^30M pre dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes pre dose insulin IV;ACTH 30M pre Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58592-7;Corticotropin^30M pre XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --30 minutes pre XXX challenge;ACTH 30M pre chal Plas-mCnc;;ACTIVE;2.32;2.70 +58593-5;Corticotropin^30M pre XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --30 minutes pre XXX challenge;ACTH 30M pre chal Plas-sCnc;;ACTIVE;2.32;2.70 +5859-4;Herpes simplex virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Specimen by Organism specific culture;HSV Spec Cult;;ACTIVE;1.0;2.73 +58594-3;Corticotropin^3H post dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3 hours post dose glucagon;ACTH 3h p Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58595-0;Corticotropin^3H post dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --3 hours post dose glucagon;ACTH 3h p Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58596-8;Corticotropin^3H post dose glucose;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3 hours post dose glucose;ACTH 3h p Glc Plas-mCnc;;ACTIVE;2.32;2.70 +58597-6;Corticotropin^3H post dose glucose;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --3 hours post dose glucose;ACTH 3h p Glc Plas-sCnc;;ACTIVE;2.32;2.70 +58598-4;Corticotropin^3H post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3 hours post dose insulin IV;ACTH 3h p Ins IV Plas-mCnc;;ACTIVE;2.32;2.70 +58599-2;Corticotropin^3H post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --3 hours post dose insulin IV;ACTH 3h p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58600-8;Corticotropin^3H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --3 hours post XXX challenge;ACTH 3h p chal Plas-mCnc;;ACTIVE;2.32;2.70 +58601-6;Corticotropin^3H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --3 hours post XXX challenge;ACTH 3h p chal Plas-sCnc;;ACTIVE;2.32;2.70 +5860-2;Influenza virus A Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Influenza virus A Ag [Presence] in Throat by Immunoassay;FLUAV Ag Throat Ql IA;;ACTIVE;1.0;2.73 +58602-4;Corticotropin^3rd specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --3rd specimen post XXX challenge;ACTH sp3 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58603-2;Corticotropin^4 AM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --4 AM specimen;ACTH 4 AM specimen Plas-sCnc;;ACTIVE;2.32;2.70 +58604-0;Corticotropin^4 PM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --4 PM specimen;ACTH 4 PM Plas-sCnc;;ACTIVE;2.32;2.70 +58605-7;Corticotropin^45M post 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --45 minutes post 1 ug/kg CRH IV;ACTH 45M p 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58606-5;Corticotropin^45M post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --45 minutes post dose insulin IV;ACTH 45M p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58607-3;Corticotropin^2D post dose metyraPONE;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --2 days post dose metyraPONE;ACTH 2D p MTP Plas-sCnc;;ACTIVE;2.32;2.70 +58608-1;Corticotropin^4th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --4th specimen post XXX challenge;ACTH sp4 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58609-9;Corticotropin^5th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --5th specimen post XXX challenge;ACTH sp5 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +5861-0;Influenza virus A Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Throat by Immunofluorescence;FLUAV Ag Throat Ql IF;;ACTIVE;1.0;2.56 +58610-7;Corticotropin^6 PM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --6 PM specimen;ACTH 6 PM Plas-sCnc;;ACTIVE;2.32;2.70 +58611-5;Corticotropin^6th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --6th specimen post XXX challenge;ACTH sp6 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58612-3;Corticotropin^75M post dose insulin IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --75 minutes post dose insulin IV;ACTH 75M p Ins IV Plas-mCnc;;ACTIVE;2.32;2.70 +58613-1;Corticotropin^75M post dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --75 minutes post dose insulin IV;ACTH 75M p Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58614-9;Corticotropin^7th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --7th specimen post XXX challenge;ACTH sp7 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58615-6;Corticotropin^8 AM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --8 AM specimen;ACTH 8 AM Plas-sCnc;;ACTIVE;2.32;2.70 +58616-4;Corticotropin^8 PM specimen;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --8 PM specimen;ACTH 8 PM Plas-sCnc;;ACTIVE;2.32;2.70 +58617-2;Corticotropin^8th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --8th specimen post XXX challenge;ACTH sp8 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58618-0;Corticotropin^post dose dexamethasone;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --post dose dexamethasone;ACTH p Dex Plas-sCnc;;ACTIVE;2.32;2.70 +58619-8;Corticotropin^pre 1 ug/kg CRH IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre 1 ug/kg CRH IV;ACTH pre 1 ug/kg CRH IV Plas-sCnc;;ACTIVE;2.32;2.70 +58620-6;Corticotropin^pre dose dexamethasone;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre dose dexamethasone;ACTH Pre Dex Plas-mCnc;;ACTIVE;2.32;2.70 +58621-4;Corticotropin^pre dose dexamethasone;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre dose dexamethasone;ACTH Pre Dex Plas-sCnc;;ACTIVE;2.32;2.70 +58622-2;Corticotropin^pre dose glucagon;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre dose glucagon;ACTH pre Gc Plas-mCnc;;ACTIVE;2.32;2.70 +58623-0;Corticotropin^pre dose glucagon;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre dose glucagon;ACTH pre Gc Plas-sCnc;;ACTIVE;2.32;2.70 +58624-8;Corticotropin^pre dose glucose;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre dose glucose;ACTH pre Glc Plas-mCnc;;ACTIVE;2.32;2.70 +58625-5;Corticotropin^pre dose glucose;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre dose glucose;ACTH pre Glc Plas-sCnc;;ACTIVE;2.32;2.70 +58626-3;Corticotropin^pre dose insulin IV;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre dose insulin IV;ACTH pre Ins IV Plas-sCnc;;ACTIVE;2.32;2.70 +58627-1;Corticotropin^pre dose metyraPONE;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre dose metyraPONE;ACTH pre MTP Plas-mCnc;;ACTIVE;2.32;2.70 +5862-8;Influenza virus A Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Influenza virus A Ag [Presence] in Specimen by Immunoassay;FLUAV Ag Spec Ql IA;;ACTIVE;1.0;2.73 +58628-9;Corticotropin^pre dose metyraPONE;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre dose metyraPONE;ACTH pre MTP Plas-sCnc;;ACTIVE;2.32;2.70 +58629-7;Corticotropin^pre XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --pre XXX challenge;ACTH pre chal Plas-mCnc;;ACTIVE;2.32;2.70 +58630-5;Corticotropin^pre XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --pre XXX challenge;ACTH pre chal Plas-sCnc;;ACTIVE;2.32;2.70 +58631-3;Cortisol^1.5H post 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --1.5 hours post 1 ug/kg CRH IV;Cortis 1.5h p 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +58632-1;Cortisol^1.5H post 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --1.5 hours post 1 ug/kg CRH IV;Cortis 1.5h p 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +58633-9;Cortisol^10 AM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --10 AM specimen;Cortis 10 AM SerPl-mCnc;;ACTIVE;2.32;2.73 +58634-7;Cortisol^10 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --10 AM specimen;Cortis 10 AM SerPl-sCnc;;ACTIVE;2.32;2.70 +58635-4;Cortisol^10 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --10 PM specimen;Cortis 10 PM SerPl-mCnc;;ACTIVE;2.32;2.70 +5863-6;Influenza virus A Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Specimen by Immunofluorescence;FLUAV Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58636-2;Cortisol^10 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --10 PM specimen;Cortis 10 PM SerPl-sCnc;;ACTIVE;2.32;2.70 +58637-0;Cortisol^10th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --10th specimen post XXX challenge;Cortis sp10 p chal Sal-mCnc;;ACTIVE;2.32;2.70 +58638-8;Cortisol^10th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --10th specimen post XXX challenge;Cortis sp10 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58639-6;Cortisol^10th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge;Cortis sp10 p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +58640-4;Cortisol^11th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --11th specimen post XXX challenge;Cortis sp11 p chal Sal-mCnc;;ACTIVE;2.32;2.70 +58641-2;Cortisol^11th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --11th specimen post XXX challenge;Cortis sp11 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58642-0;Cortisol^12 AM specimen;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --12 AM specimen;Cortis 12 AM Sal-mCnc;;ACTIVE;2.32;2.70 +58643-8;Cortisol^12 AM specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --12 AM specimen;Cortis 12 AM Sal-sCnc;;ACTIVE;2.32;2.70 +5864-4;Influenza virus B Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Influenza virus B Ag [Presence] in Throat by Immunoassay;FLUBV Ag Throat Ql IA;;ACTIVE;1.0;2.73 +58644-6;Cortisol^12 PM specimen;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --12 PM specimen;Cortis 12 PM Sal-mCnc;;ACTIVE;2.32;2.70 +58645-3;Cortisol^12 PM specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --12 PM specimen;Cortis 12 PM Sal-sCnc;;ACTIVE;2.32;2.70 +58646-1;Cortisol^12th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --12th specimen post XXX challenge;Cortis sp12 p chal Sal-mCnc;;ACTIVE;2.32;2.70 +58647-9;Cortisol^12th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --12th specimen post XXX challenge;Cortis sp12 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58648-7;Cortisol^15M post 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --15 minutes post 1 ug/kg CRH IV;Cortis 15M p 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +58649-5;Cortisol^15M post 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --15 minutes post 1 ug/kg CRH IV;Cortis 15M p 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +58650-3;Cortisol^15M pre 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --15 minutes pre 1 ug/kg CRH IV;Cortis 15M pre 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +5865-1;Influenza virus B Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Throat by Immunofluorescence;FLUBV Ag Throat Ql IF;;ACTIVE;1.0;2.73 +58651-1;Cortisol^15M pre 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --15 minutes pre 1 ug/kg CRH IV;Cortis 15M pre 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +58652-9;Cortisol^1H post 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --1 hour post 1 ug/kg CRH IV;Cortis 1h p 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +58653-7;Cortisol^1H post 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --1 hour post 1 ug/kg CRH IV;Cortis 1h p 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +58654-5;Cortisol^1st specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --1st specimen post XXX challenge;Cortis sp1 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58655-2;Cortisol^2 PM specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2 PM specimen;Cortis 2 PM SerPl-mCnc;;ACTIVE;2.32;2.70 +58656-0;Cortisol^2 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --2 PM specimen;Cortis 2 PM SerPl-sCnc;;ACTIVE;2.32;2.70 +58657-8;Cortisol^2H post 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --2 hours post 1 ug/kg CRH IV;Cortis 2h p 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +58658-6;Cortisol^2H post 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --2 hours post 1 ug/kg CRH IV;Cortis 2h p 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +58659-4;Cortisol^2H post 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --2 hours post 1 ug/kg CRH IV;Cortis 2h p 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.32;2.70 +58660-2;Cortisol^2nd specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --2nd specimen post XXX challenge;Cortis sp2 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58661-0;Cortisol^30M pre 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --30 minutes pre 1 ug/kg CRH IV;Cortis 30M pre 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +58662-8;Cortisol^30M pre 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --30 minutes pre 1 ug/kg CRH IV;Cortis 30M pre 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +58663-6;Cortisol^30M pre 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --30 minutes pre 1 ug/kg CRH IV;Cortis 30M pre 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.32;2.73 +58664-4;Cortisol^30M pre 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --30 minutes pre 1 ug/kg CRH IV;Cortis 30M pre 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.32;2.70 +58665-1;Cortisol^3rd specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --3rd specimen post XXX challenge;Cortis sp3 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58666-9;Cortisol^4 AM specimen;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --4 AM specimen;Cortis 4 AM specimen Sal-mCnc;;ACTIVE;2.32;2.70 +58667-7;Cortisol^4 AM specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --4 AM specimen;Cortis 4 AM specimen Sal-sCnc;;ACTIVE;2.32;2.70 +58668-5;Cortisol^4 PM specimen;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --4 PM specimen;Cortis 4 PM Sal-mCnc;;ACTIVE;2.32;2.70 +5866-9;Influenza virus B Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Influenza virus B Ag [Presence] in Specimen by Immunoassay;FLUBV Ag Spec Ql IA;;ACTIVE;1.0;2.73 +58669-3;Cortisol^4 PM specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --4 PM specimen;Cortis 4 PM Sal-sCnc;;ACTIVE;2.32;2.70 +58670-1;Cortisol^45M post 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --45 minutes post 1 ug/kg CRH IV;Cortis 45M p 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +58671-9;Cortisol^45M post 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --45 minutes post 1 ug/kg CRH IV;Cortis 45M p 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +58672-7;Cortisol^45M post 1 ug/kg CRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --45 minutes post 1 ug/kg CRH IV;Cortis 45M p 1 ug/kg CRH IV SerPl-sCnc;;ACTIVE;2.32;2.70 +58673-5;Cortisol^4th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --4th specimen post XXX challenge;Cortis sp4 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58674-3;Cortisol^8 AM specimen;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --8 AM specimen;Cortis 8 AM Sal-mCnc;;ACTIVE;2.32;2.70 +58675-0;Cortisol^8 AM specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --8 AM specimen;Cortis 8 AM Sal-sCnc;;ACTIVE;2.32;2.70 +58676-8;Cortisol^8 PM specimen;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --8 PM specimen;Cortis 8 PM Sal-mCnc;;ACTIVE;2.32;2.70 +5867-7;Influenza virus B Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Specimen by Immunofluorescence;FLUBV Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58677-6;Cortisol^8 PM specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --8 PM specimen;Cortis 8 PM Sal-sCnc;;ACTIVE;2.32;2.70 +58678-4;Cortisol^pre 1 ug/kg CRH IV;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --pre 1 ug/kg CRH IV;Cortis pre 1 ug/kg CRH IV Sal-mCnc;;ACTIVE;2.32;2.70 +58679-2;Cortisol^pre 1 ug/kg CRH IV;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --pre 1 ug/kg CRH IV;Cortis pre 1 ug/kg CRH IV Sal-sCnc;;ACTIVE;2.32;2.70 +586-8;Streptococcus agalactiae;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Specimen by Organism specific culture;Gp B Strep Spec Ql Cult;;ACTIVE;1.0;2.73 +58680-0;Cortisol^pre 2 mg dexamethasone PO 2.5 day high dose q6h;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --pre 2 mg dexamethasone PO 2.5 day high dose q6h;Cortis pre 2 mg Dex high SerPl-sCnc;;ACTIVE;2.32;2.70 +58681-8;Temperature;Temp;Pt;Urine;Qn;;SPEC;1;Temperature of Urine;Temp Ur;;ACTIVE;2.32;2.73 +58682-6;Sulfatides;MCnc;Pt;Urine;Qn;;CHEM;1;Sulfatides [Mass/volume] in Urine;Sulfatides Ur-mCnc;;ACTIVE;2.32;2.70 +58683-4;Complement C5;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;Complement C5 [Presence] in Serum or Plasma;C5 SerPl Ql;;ACTIVE;2.32;2.56 +58684-2;Uroporphyrin 1 isomer/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Uroporphyrin 1 isomer/Creatinine [Molar ratio] in Urine;Uropor1/Creat Ur-sRto;;ACTIVE;2.32;2.70 +5868-5;Parainfluenza virus 1 Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Throat by Immunofluorescence;HPIV1 Ag Throat Ql IF;;ACTIVE;1.0;2.56 +58685-9;Beta hydroxybutyrate;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Beta hydroxybutyrate [Moles/volume] in Vitreous fluid;B-OH-Butyr Vitf-sCnc;;ACTIVE;2.32;2.70 +58686-7;C peptide^2H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2 hours post dose glucose;C peptide 2h p Glc SerPl-mCnc;;ACTIVE;2.32;2.73 +58687-5;Corticotropin^9th specimen post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --9th specimen post XXX challenge;ACTH sp9 p chal Plas-sCnc;;ACTIVE;2.32;2.70 +58688-3;Cortisol^11th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --11th specimen post XXX challenge;Cortis sp11 p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58689-1;Cortisol^11th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --11th specimen post XXX challenge;Cortis sp11 p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +58690-9;Cortisol^12th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --12th specimen post XXX challenge;Cortis sp12 p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58691-7;Cortisol^12th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --12th specimen post XXX challenge;Cortis sp12 p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +58692-5;Cortisol^5th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --5th specimen post XXX challenge;Cortis sp5 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +5869-3;Parainfluenza virus 1 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Specimen by Immunofluorescence;HPIV1 Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58693-3;Cortisol^6th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --6th specimen post XXX challenge;Cortis sp6 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58694-1;Cortisol^7th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --7th specimen post XXX challenge;Cortis sp7 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58695-8;Cortisol^8th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --8th specimen post XXX challenge;Cortis sp8 p chal Sal-mCnc;;ACTIVE;2.32;2.70 +58696-6;Cortisol^8th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --8th specimen post XXX challenge;Cortis sp8 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +58697-4;Cortisol^9th specimen post XXX challenge;MCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Mass/volume] in Saliva (oral fluid) --9th specimen post XXX challenge;Cortis sp9 p chal Sal-mCnc;;ACTIVE;2.32;2.70 +58698-2;Cortisol^9th specimen post XXX challenge;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisol [Moles/volume] in Saliva (oral fluid) --9th specimen post XXX challenge;Cortis sp9 p chal Sal-sCnc;;ACTIVE;2.32;2.70 +5870-1;Parainfluenza virus 2 Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Parainfluenza virus 2 Ag [Presence] in Throat by Immunofluorescence;HPIV2 Ag Throat Ql IF;;ACTIVE;1.0;2.56 +58705-5;cefTAZidime;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cefTAZidime [Susceptibility] by Method for Slow-growing mycobacteria;cefTAZidime Islt SlowMyco;;ACTIVE;2.32;2.32 +58706-3;OmpC Ab.IgA;PrThr;Pt;Ser;Ord;IA;SERO;1;OmpC IgA Ab [Presence] in Serum by Immunoassay;OmpC IgA Ser Ql IA;;ACTIVE;2.32;2.70 +58707-1;Ephedrine+Pseudoephedrine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ePHEDrine+Pseudoephedrine [Mass/volume] in Urine by Confirmatory method;Ephedrin+Pseudo Ur Cfm-mCnc;;ACTIVE;2.32;2.73 +58708-9;Mycoplasma pneumoniae Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunofluorescence;M pneumo IgM Ser Ql IF;;ACTIVE;2.32;2.73 +58709-7;Gliadin peptide Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Gliadin peptide IgA Ab [Units/volume] in Serum;Gliadin peptide IgA Ser-aCnc;;ACTIVE;2.32;2.73 +58710-5;Gliadin peptide Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Gliadin peptide IgG Ab [Units/volume] in Serum;Gliadin peptide IgG Ser-aCnc;;ACTIVE;2.32;2.73 +58711-3;Doripenem;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Doripenem [Susceptibility] by Gradient strip;Doripenem Islt Grad strip;;ACTIVE;2.32;2.56 +58712-1;Quinupristin+Dalfopristin;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Quinupristin+Dalfopristin [Susceptibility] by Method for Slow-growing mycobacteria;Quinupristin+Dalfoprist Islt SlowMyco;;ACTIVE;2.32;2.32 +58713-9;DNAse B Ab.Streptococcal & Streptolysin O Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Streptococcal DNAse B and ASO antibodies panel - Serum;Strep DNAse B+ ASO Ab pnl Ser;;ACTIVE;2.32;2.73 +58714-7;Oxidants;PrThr;Pt;Urine;Ord;;UA;1;Oxidants [Presence] in Urine;Oxidants Ur Ql;;ACTIVE;2.32;2.73 +58715-4;Adulterants panel;-;Pt;Urine;-;;PANEL.CHEM;1;Adulterants panel - Urine;Adulterants Pnl Ur;;ACTIVE;2.32;2.73 +58716-2;Testosterone.free+weakly bound & total panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Testosterone.free+weakly bound and total panel - Serum or Plasma;Testost free+WB + Total pnl SerPl;;ACTIVE;2.32;2.73 +58717-0;Lymphocyte proliferation.concanavalin A stimulation;Imp;Pt;Bld;Nom;;SERO;1;Lymphocyte proliferation stimulated by concanavalin A [Interpretation] in Blood;LPT CA Bld-Imp;;ACTIVE;2.32;2.32 +58718-8;Lymphocyte proliferation. 10 ug concanavalin A stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 10 ug concanavalin A actual/normal in Blood;LPT 10 ug CA Act/Nor Bld;;ACTIVE;2.32;2.70 +5871-9;Parainfluenza virus 2 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Parainfluenza virus 2 Ag [Presence] in Specimen by Immunofluorescence;HPIV2 Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58719-6;Lymphocyte proliferation. 5 ug concanavalin A stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 5 ug concanavalin A actual/normal in Blood;LPT 5 ug CA Act/Nor Bld;;ACTIVE;2.32;2.70 +58720-4;Lymphocyte proliferation. 2.0 ug concanavalin A stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 2.0 ug concanavalin A actual/normal in Blood;LPT 2 ug CA Act/Nor Bld;;ACTIVE;2.32;2.70 +58721-2;Lymphocyte proliferation. 0.5 ug concanavalin A stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.5 ug concanavalin A actual/normal in Blood;LPT .5 ug CA Act/Nor Bld;;ACTIVE;2.32;2.70 +58722-0;Lymphocyte proliferation.pokeweed mitogen stimulation;Imp;Pt;Bld;Nom;;SERO;1;Lymphocyte proliferation stimulated by pokeweed mitogen [Interpretation] in Blood;LPT PW Bld-Imp;;ACTIVE;2.32;2.73 +58723-8;Lymphocyte proliferation. 10 ug pokeweed mitogen stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 10 ug pokeweed mitogen actual/normal in Blood;LPT 10 ug PW Act/Nor Bld;;ACTIVE;2.32;2.70 +58724-6;Lymphocyte proliferation. 5 ug pokeweed mitogen stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 5 ug pokeweed mitogen actual/normal in Blood;LPT 5 ug PW Act/Nor Bld;;ACTIVE;2.32;2.70 +58725-3;Lymphocyte proliferation. 1.0 ug pokeweed mitogen stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 1.0 ug pokeweed mitogen actual/normal in Blood;LPT 1.0 ug PW Act/Nor Bld;;ACTIVE;2.32;2.70 +58726-1;Lymphocyte proliferation. 0.50 ug pokeweed mitogen stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.50 ug pokeweed mitogen actual/normal in Blood;LPT 0.50 ug PW Act/Nor Bld;;ACTIVE;2.32;2.70 +5872-7;Parainfluenza virus 3 Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Parainfluenza virus 3 Ag [Presence] in Throat by Immunofluorescence;HPIV3 Ag Throat Ql IF;;ACTIVE;1.0;2.56 +58727-9;Lymphocyte proliferation.phytohemagglutinin stimulation;Imp;Pt;Bld;Nar;;SERO;1;Lymphocyte proliferation stimulated by phytohemagglutinin [Interpretation] in Blood Narrative;LPT PHA Bld-Imp;;ACTIVE;2.32;2.32 +58728-7;Lymphocyte proliferation. 5 ug phytohemagglutinin stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 5 ug phytohemagglutin actual/normal in Blood;LPT 5 ug PHA Act/Nor Bld;;ACTIVE;2.32;2.70 +58729-5;Lymphocyte proliferation. 2.5 ug phytohemagglutinin stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 2.5 ug phytohemagglutin actual/normal in Blood;LPT 2.5 ug PHA Act/Nor Bld;;ACTIVE;2.32;2.70 +58730-3;Lymphocyte proliferation. 1.0 ug phytohemagglutinin stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 1.0 ug phytohemagglutinin actual/normal in Blood;LPT 1.0 ug PHA Act/Nor Bld;;ACTIVE;2.32;2.70 +58731-1;Lymphocyte proliferation. 0.5 ug phytohemagglutinin stimulation actual/Normal;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.5 ug phytohemagglutinin actual/normal in Blood;LPT 0.5 ug PHA Act/Nor Bld;;ACTIVE;2.32;2.70 +58732-9;Porphyrin fractions panel;MCnc;Pt;Ser/Plas;-;;PANEL.CHEM;1;Porphyrin fractions panel [Mass/volume] - Serum or Plasma;Porphyrin Fract Pnl SerPl-mCnc;;ACTIVE;2.32;2.52 +58733-7;Mycoplasma pneumoniae Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Mycoplasma pneumoniae IgG and IgM panel - Serum;M pneumo IgG+IgM pnl Ser;;ACTIVE;2.32;2.73 +58734-5;Collection date;TmStp;Pt;Amnio fld;Qn;;SPEC;1;Collection date of Amniotic fluid;Collect Date Amn;;ACTIVE;2.32;2.32 +5873-5;Parainfluenza virus 3 Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Parainfluenza virus 3 Ag [Presence] in Specimen by Immunofluorescence;HPIV3 Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58735-2;Alpha-1-fetoprotein panel;-;Pt;Amnio fld;-;;PANEL.CHEM;1;Alpha-1-Fetoprotein panel - Amniotic fluid;AFP Pnl Amn;;ACTIVE;2.32;2.73 +58736-0;Manganese panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Manganese panel - Urine;Manganese pnl Ur;;ACTIVE;2.32;2.46 +58737-8;Parvovirus B19 Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Parvovirus B19 IgG and IgM [Interpretation] in Serum;B19V IgG+IgM Ser-Imp;;ACTIVE;2.32;2.73 +58738-6;Drugs of abuse;Imp;Pt;Meconium;Nom;;DRUG/TOX;1;Drugs of abuse [Interpretation] in Meconium;Drugs of abuse Mec-Imp;;ACTIVE;2.32;2.73 +58739-4;Haemophilus influenzae serotype;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Haemophilus influenzae serotype [Identifier] in Isolate by Agglutination;Haem influ Sertyp Islt Aggl;;ACTIVE;2.32;2.32 +58740-2;Guidance for endoscopy^WO contrast;Find;Pt;Abdomen>Liver+Biliary ducts+Pancreas;Doc;MR;RAD;2;MRCP Abdomen WO contrast;MRCP Abd WO contr;;ACTIVE;2.32;2.73 +58741-0;Multisection^W radionuclide IV;Find;Pt;Whole body>Skull base to mid-thigh;Doc;PT;RAD;2;PT Skull base to mid-thigh;PT Skull to thigh W RNC IV;;ACTIVE;2.32;2.73 +58742-8;Multisection^W radionuclide IV;Find;Pt;Head+Neck;Doc;PT;RAD;2;PT Head and Neck;PT Head+Neck W RNC IV;;ACTIVE;2.32;2.61 +5874-3;Respiratory syncytial virus Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Respiratory syncytial virus Ag [Presence] in Throat by Immunoassay;RSV Ag Throat Ql IA;;ACTIVE;1.0;2.73 +58743-6;Guidance for ablation of tissue;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for ablation of tissue of Unspecified body region;US Guided Ablation;;ACTIVE;2.32;2.64 +58744-4;Multisection;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart;CT Hrt;;ACTIVE;2.32;2.73 +58745-1;Multisection & 3D reconstruction^W contrast IV;Find;Pt;Chest>Coronary arteries;Doc;CT.angio;RAD;2;Deprecated Chest>Coronary arteries CT angiogram and 3D reconstruction W contrast IV;Deprecated Chest>CA CT.Angio +3DR W cont;;DEPRECATED;2.32;2.58 +58746-9;Views^W contrast IV;Find;Pt;XXX>AV fistula;Doc;RF.angio;RAD;2;RFA AV fistula Views W contrast IV;RFA AVF Views W contr IV;;ACTIVE;2.32;2.64 +58747-7;Guidance for ablation of tissue;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for ablation of tissue of Unspecified body region;CT Guided Ablation;;ACTIVE;2.32;2.64 +58748-5;Multisection;Find;Pt;Head>Brain;Doc;MR.functional;RAD;2;Functional MR Brain;fMR Brain;;ACTIVE;2.32;2.61 +58749-3;Multisection^W stress+WO & W contrast IV;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart W stress and WO and W contrast IV;MR Hrt W stress+WO+W contr IV;;ACTIVE;2.32;2.61 +5875-0;Respiratory syncytial virus Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Respiratory syncytial virus Ag [Presence] in Throat by Immunofluorescence;RSV Ag Throat Ql IF;;ACTIVE;1.0;2.73 +58750-1;Multisection^W stress;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart W stress;MR Hrt W Stress;;ACTIVE;2.32;2.61 +58751-9;Treponema pallidum Ab.IgG;PrThr;Pt;CSF;Ord;IF;MICRO;1;Treponema pallidum IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;T pallidum IgG CSF Ql IF;;ACTIVE;2.32;2.73 +58752-7;Triticum aestivum recombinant (rTri a) 19 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat recombinant (rTri a) 19 IgE Ab [Units/volume] in Serum;Wheat (rTri a) 19 IgE Qn;;ACTIVE;2.32;2.70 +58753-5;Corylus avellana recombinant (rCor a) 8 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut recombinant (rCor a) 8 IgE Ab [Units/volume] in Serum;Hazelnut (rCor a) 8 IgE Qn;;ACTIVE;2.32;2.73 +58754-3;Olea europaea native (nOle e) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive pollen native (nOle e) 1 IgE Ab [Units/volume] in Serum;Olive (nOle e) 1 IgE Qn;;ACTIVE;2.32;2.70 +58755-0;Varicella zoster virus Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;VZV IgG CSF IA-aCnc;;ACTIVE;2.32;2.73 +58756-8;Parvovirus B19 Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B19V IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +58757-6;Parvovirus B19 Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B19V IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58758-4;Chlamydophila pneumoniae Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Chlamydophila pneumoniae IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;C pneum IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58759-2;Echovirus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Echovirus Ab [Titer] in Cerebral spinal fluid by Complement fixation;ECV Ab Titr CSF CF;;ACTIVE;2.32;2.70 +587-6;Helicobacter pylori;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Helicobacter pylori [Presence] in Specimen by Organism specific culture;H pylori Spec Ql Cult;;ACTIVE;1.0;2.73 +58760-0;Epstein Barr virus capsid Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;EBV VCA IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58761-8;Coxiella burnetii phase 2 Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;C burnet Ph2 IgG Titr CSF IF;;ACTIVE;2.32;2.70 +58762-6;Coxiella burnetii phase 2 Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;C burnet Ph2 IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58763-4;IgA;MRat;24H;Urine;Qn;;CHEM;1;IgA [Mass/time] in 24 hour Urine;IgA 24h Ur-mRate;;ACTIVE;2.32;2.70 +58764-2;IgM;MRat;24H;Urine;Qn;;CHEM;1;IgM [Mass/time] in 24 hour Urine;IgM 24h Ur-mRate;;ACTIVE;2.32;2.70 +58765-9;Histone Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Histone Ab [Presence] in Serum by Immunoassay;Histone Ab Ser Ql IA;;ACTIVE;2.32;2.73 +58766-7;Epithelial cells;Naric;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Epithelial cells [#/area] in Semen by Microscopy high power field;Epi Cells #/area Smn HPF;;ACTIVE;2.34;2.73 +58767-5;Erythrocytes;Naric;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Erythrocytes [#/area] in Semen by Microscopy high power field;RBC #/area Smn HPF;;ACTIVE;2.34;2.73 +5876-8;Respiratory syncytial virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Respiratory syncytial virus Ag [Presence] in Specimen by Immunoassay;RSV Ag Spec Ql IA;;ACTIVE;1.0;2.73 +58768-3;Gamma glutamyl transferase;CRat;24H;Urine;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/time] in 24 hour Urine;GGT 24h Ur-cRate;;ACTIVE;2.32;2.70 +58769-1;Fetal trisomy 13 risk;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Trisomy 13 risk [Likelihood] in Fetus;Ts 13 risk Fetus;;ACTIVE;2.32;2.73 +58770-9;Clostridium tetani toxoid Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Clostridium tetani toxoid IgG Ab [Units/volume] in Serum by Immunofluorescence;C tetani Toxoid IgG Ser IF-aCnc;;ACTIVE;2.32;2.70 +58771-7;Bactericidal permeability increasing protein Ab;ACnc;Pt;Ser;Qn;;SERO;1;Bactericidal permeability increasing protein Ab [Units/volume] in Serum;BPI Ab Ser-aCnc;;ACTIVE;2.32;2.70 +58772-5;Dog recombinant (rCan f) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog recombinant (rCan f) 2 IgE Ab [Units/volume] in Serum;Dog (rCan f) 2 IgE Qn;;ACTIVE;2.32;2.70 +58773-3;Dog recombinant (rCan f) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog recombinant (rCan f) 1 IgE Ab [Units/volume] in Serum;Dog (rCan f) 1 IgE Qn;;ACTIVE;2.32;2.70 +58774-1;Alternaria alternata recombinant (rAlt a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata recombinant (rAlt a) 1 IgE Ab [Units/volume] in Serum;A alternata (rAlt a) 1 IgE Qn;;ACTIVE;2.32;2.70 +58775-8;Prunus persica recombinant (rPru p) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peach recombinant (rPru p) 4 IgE Ab [Units/volume] in Serum;Peach (rPru p) 4 IgE Qn;;ACTIVE;2.32;2.70 +5877-6;Respiratory syncytial virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Respiratory syncytial virus Ag [Presence] in Specimen by Immunofluorescence;RSV Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58776-6;Prunus persica recombinant (rPru p) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peach recombinant (rPru p) 1 IgE Ab [Units/volume] in Serum;Peach (rPru p) 1 IgE Qn;;ACTIVE;2.32;2.70 +58777-4;Arachis hypogaea recombinant (rAra h) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 3 IgE Ab [Units/volume] in Serum;Peanut (rAra h) 3 IgE Qn;;ACTIVE;2.32;2.73 +58778-2;Arachis hypogaea recombinant (rAra h) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 2 IgE Ab [Units/volume] in Serum;Peanut (rAra h) 2 IgE Qn;;ACTIVE;2.32;2.73 +58779-0;Arachis hypogaea recombinant (rAra h) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 1 IgE Ab [Units/volume] in Serum;Peanut (rAra h) 1 IgE Qn;;ACTIVE;2.32;2.73 +58780-8;Coxsackievirus B Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B IgG Ab [Titer] in Serum;CV B IgG Titr Ser;;ACTIVE;2.32;2.70 +58781-6;Calcium;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Calcium [Mass/volume] in Peritoneal dialysis fluid;Calcium DiafP-mCnc;;ACTIVE;2.32;2.70 +58782-4;Mycoplasma pneumoniae Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Mycoplasma pneumoniae IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;M pneumo IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +58783-2;Herpes simplex virus 2 Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Herpes simplex virus 2 IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;HSV2 IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +5878-4;Rickettsia sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Rickettsia sp identified in Blood by Organism specific culture;Rickettsia Bld Cult;;ACTIVE;1.0;1.0ma +58784-0;Herpes simplex virus 1 Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Herpes simplex virus 1 IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;HSV1 IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +58785-7;Herpes simplex virus 2 Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;HSV2 IgG CSF IA-aCnc;;ACTIVE;2.32;2.73 +58786-5;Herpes simplex virus 1 Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Herpes simplex virus 1 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;HSV1 IgG CSF IA-aCnc;;ACTIVE;2.32;2.73 +58787-3;Corynebacterium diphtheriae Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Corynebacterium diphtheriae IgG Ab [Units/volume] in Serum by Immunoassay;C diphtheriae IgG Ser IA-aCnc;;ACTIVE;2.32;2.73 +58788-1;Campylobacter jejuni Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Campylobacter jejuni IgM Ab [Titer] in Serum by Immunofluorescence;C jejuni IgM Titr Ser IF;;ACTIVE;2.32;2.70 +58789-9;Campylobacter jejuni Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Campylobacter jejuni IgG Ab [Titer] in Serum by Immunofluorescence;C jejuni IgG Titr Ser IF;;ACTIVE;2.32;2.70 +58790-7;Coxsackievirus B Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus B IgM Ab [Titer] in Serum by Immunofluorescence;CV B IgM Titr Ser IF;;ACTIVE;2.32;2.70 +58791-5;Coxsackievirus A9 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A9 IgM Ab [Titer] in Serum by Immunofluorescence;CV A9 IgM Titr Ser IF;;ACTIVE;2.32;2.73 +5879-2;Rotavirus Ag;PrThr;Pt;Stool;Ord;Aggl;MICRO;1;Rotavirus Ag [Presence] in Stool by Agglutination;RV Ag Stl Ql Aggl;;ACTIVE;1.0;2.73 +58792-3;Coxsackievirus A9 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A9 IgG Ab [Titer] in Serum by Immunofluorescence;CV A9 IgG Titr Ser IF;;ACTIVE;2.32;2.73 +58793-1;Phytonadione;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phytonadione [Moles/volume] in Serum or Plasma;Phytonadione SerPl-sCnc;;ACTIVE;2.32;2.73 +58794-9;5-Hydroxytryptophan;MCnc;24H;Urine;Qn;;DRUG/TOX;1;5-Hydroxytryptophan [Mass/volume] in 24 hour Urine;5OH-Tryptophan 24h Ur-mCnc;;ACTIVE;2.32;2.70 +58795-6;Glomerular basement membrane Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Glomerular basement membrane IgG Ab [Titer] in Serum by Immunofluorescence;GBM IgG Titr Ser IF;;ACTIVE;2.32;2.70 +58796-4;Glomerular basement membrane Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Glomerular basement membrane IgG Ab [Presence] in Serum by Immunofluorescence;GBM IgG Ser Ql IF;;ACTIVE;2.32;2.56 +58797-2;Yersinia enterocolitica Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Yersinia enterocolitica Ab [Titer] in Serum by Complement fixation;Y enterocol Ab Titr Ser CF;;ACTIVE;2.32;2.70 +58798-0;Legionella pneumophila 2 Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Legionella pneumophila 2 IgM Ab [Units/volume] in Serum by Immunoassay;L pneumo2 IgM Ser IA-aCnc;;ACTIVE;2.32;2.70 +58799-8;Legionella pneumophila 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Legionella pneumophila 1 IgG Ab [Units/volume] in Serum by Immunoassay;L pneumo1 IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +58-8;Capreomycin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Capreomycin [Susceptibility] by Serum bactericidal titer;Capreomycin Titr SBT;;ACTIVE;1.0;2.32 +5880-0;Rotavirus Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Rotavirus Ag [Presence] in Stool by Immunoassay;RV Ag Stl Ql IA;;ACTIVE;1.0;2.73 +58800-4;Protein fractions.oligoclonal bands;Imp;24H;Urine;Nom;Isoelectric focusing;CHEM;1;Oligoclonal bands [Interpretation] in 24 hour Urine by Isoelectric focusing;Oligoclonal Bands 24h Ur IEF-Imp;;ACTIVE;2.32;2.54 +58801-2;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Dial fld prt;Qn;;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Peritoneal dialysis fluid;Polys/leuk NFr DiafP;;ACTIVE;2.32;2.73 +58802-0;Mononuclear cells/100 leukocytes;NFr;Pt;Dial fld prt;Qn;;HEM/BC;1;Mononuclear cells/100 leukocytes in Peritoneal dialysis fluid;Mononuc Cells/leuk NFr DiafP;;ACTIVE;2.32;2.73 +58803-8;Acetone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Acetone/Creatinine [Mass Ratio] in Urine;Acetone/Creat Ur;;ACTIVE;2.32;2.70 +58804-6;Polistes dominulus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European paper wasp IgE Ab [Units/volume] in Serum;European paper wasp IgE Qn;;ACTIVE;2.32;2.73 +58805-3;Leukocytes;NCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Leukocytes [#/volume] in Urine by Automated test strip;WBC # Ur Strip.auto;;ACTIVE;2.32;2.73 +58806-1;Brucella sp Ab;Titr;Pt;CSF;Qn;Aggl;MICRO;1;Brucella sp Ab [Titer] in Cerebral spinal fluid by Agglutination;Brucella Ab Titr CSF Aggl;;ACTIVE;2.32;2.70 +58807-9;Conalbumin native (nGal d) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Conalbumin native (nGal d) 3 IgE Ab [Units/volume] in Serum;Conalb (nGal d) 3 IgE Qn;;ACTIVE;2.32;2.70 +58808-7;Aspergillus sp Ab;Titr;Pt;Ser;Qn;HA;MICRO;1;Aspergillus sp Ab [Titer] in Serum by Hemagglutination;Aspergillus Ab Titr Ser HA;;ACTIVE;2.32;2.70 +58809-5;Rickettsia conorii Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Rickettsia conorii IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;R conorii IgG Titr CSF IF;;ACTIVE;2.32;2.70 +58810-3;Testosterone^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --2nd specimen;Testost sp2 SerPl-mCnc;;ACTIVE;2.32;2.73 +58811-1;Renin^post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --post XXX challenge;Renin p chal Plas-mCnc;;ACTIVE;2.32;2.70 +58812-9;Renin^3rd specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --3rd specimen;Renin sp3 Plas-mCnc;;ACTIVE;2.32;2.70 +58813-7;Renin^2nd specimen;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --2nd specimen;Renin sp2 Plas-mCnc;;ACTIVE;2.32;2.70 +58814-5;17-Hydroxyprogesterone^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --3rd specimen;17OHP sp3 SerPl-mCnc;;ACTIVE;2.32;2.70 +58815-2;17-Hydroxyprogesterone^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --2nd specimen;17OHP sp2 SerPl-mCnc;;ACTIVE;2.32;2.70 +58816-0;C peptide^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2nd specimen;C peptide sp2 SerPl-mCnc;;ACTIVE;2.32;2.70 +58817-8;Estradiol^3rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --3rd specimen;Estradiol sp3 SerPl-mCnc;;ACTIVE;2.32;2.70 +5881-8;Varicella zoster virus Ag;PrThr;Pt;Skin;Ord;IF;MICRO;1;Varicella zoster virus Ag [Presence] in Skin by Immunofluorescence;VZV Ag Skin Ql IF;;ACTIVE;1.0;2.73 +58818-6;Estrogen^2nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estrogen [Mass/volume] in Serum or Plasma --2nd specimen;Estrogen sp2 SerPl-mCnc;;ACTIVE;2.32;2.70 +58819-4;Cortisol^21st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --21st specimen;Cortis sp21 SerPl-mCnc;;ACTIVE;2.32;2.70 +58820-2;Cortisol^24th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --24th specimen;Cortis sp24 SerPl-mCnc;;ACTIVE;2.32;2.70 +58821-0;Cortisol^23rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --23rd specimen;Cortis sp23 SerPl-mCnc;;ACTIVE;2.32;2.70 +58822-8;Cortisol^22nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --22nd specimen;Cortis sp22 SerPl-mCnc;;ACTIVE;2.32;2.70 +58823-6;Cortisol^20th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --20th specimen;Cortis sp20 SerPl-mCnc;;ACTIVE;2.32;2.70 +58824-4;Cortisol^19th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --19th specimen;Cortis sp19 SerPl-mCnc;;ACTIVE;2.32;2.70 +58825-1;Cortisol^18th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --18th specimen;Cortis sp18 SerPl-mCnc;;ACTIVE;2.32;2.70 +5882-6;Varicella zoster virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Varicella zoster virus Ag [Presence] in Specimen by Immunofluorescence;VZV Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58826-9;Cortisol^17th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --17th specimen;Cortis sp17 SerPl-mCnc;;ACTIVE;2.32;2.70 +58827-7;Cortisol^16th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --16th specimen;Cortis sp16 SerPl-mCnc;;ACTIVE;2.32;2.70 +58828-5;Cortisol^14th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --14th specimen;Cortis sp14 SerPl-mCnc;;ACTIVE;2.32;2.70 +58829-3;Cortisol^15th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --15th specimen;Cortis sp15 SerPl-mCnc;;ACTIVE;2.32;2.70 +58830-1;Cortisol^13th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --13th specimen;Cortis sp13 SerPl-mCnc;;ACTIVE;2.32;2.70 +58831-9;Urea;SCnc;Pt;CSF;Qn;;CHEM;1;Urea [Moles/volume] in Cerebral spinal fluid;Urea CSF-sCnc;;ACTIVE;2.32;2.70 +58832-7;Insulin-like growth factor binding protein 3^45M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge;IGF BP3 45M p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58833-5;Thyrotropin^20M pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Mass/volume] in Serum or Plasma --20 minutes pre XXX challenge;TSH 20M pre chal SerPl-mCnc;;DISCOURAGED;2.32;2.70 +5883-4;Virus identified;Prid;Pt;Bld;Nom;Culture;MICRO;1;Virus identified in Blood by Culture;Virus Bld Cult;;ACTIVE;1.0;2.73 +58834-3;Thyrotropin^15M pre XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --15 minutes pre XXX challenge;TSH 15M pre chal SerPl-aCnc;;ACTIVE;2.32;2.70 +58835-0;Testosterone^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --baseline;Testost BS SerPl-mCnc;;ACTIVE;2.32;2.73 +58836-8;Thyroxine.free^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;T4 Free 3h p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58837-6;Thyroxine.free^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;T4 Free 2h p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58838-4;Thyroxine.free^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma --baseline;T4 Free BS SerPl-mCnc;;ACTIVE;2.32;2.70 +58839-2;Triiodothyronine.free^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;T3Free 3h p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +588-4;Legionella pneumophila Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Legionella pneumophila Ag [Presence] in Specimen by Immunofluorescence;L pneumo Ag Spec Ql IF;;ACTIVE;1.0;2.73 +58840-0;Triiodothyronine.free^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma --baseline;T3Free BS SerPl-mCnc;;ACTIVE;2.32;2.70 +58841-8;C peptide^5M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --5 minutes post XXX challenge;C peptide 5M p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +5884-2;Virus identified;Prid;Pt;CSF;Nom;Culture;MICRO;1;Virus identified in Cerebral spinal fluid by Culture;Virus CSF Cult;;ACTIVE;1.0;2.17 +58842-6;Somatotropin^25th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --25th specimen;GH sp25 SerPl-mCnc;;ACTIVE;2.32;2.70 +58843-4;Somatotropin^24th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --24th specimen;GH sp24 SerPl-mCnc;;ACTIVE;2.32;2.70 +58844-2;Somatotropin^20th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --20th specimen;GH sp20 SerPl-mCnc;;ACTIVE;2.32;2.70 +58845-9;Somatotropin^19th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --19th specimen;GH sp19 SerPl-mCnc;;ACTIVE;2.32;2.70 +58846-7;Somatotropin^18th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --18th specimen;GH sp18 SerPl-mCnc;;ACTIVE;2.32;2.70 +58847-5;Somatotropin^17th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --17th specimen;GH sp17 SerPl-mCnc;;ACTIVE;2.32;2.70 +58848-3;Somatotropin^16th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --16th specimen;GH sp16 SerPl-mCnc;;ACTIVE;2.32;2.70 +58849-1;Somatotropin^15th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15th specimen;GH sp15 SerPl-mCnc;;ACTIVE;2.32;2.70 +58850-9;Somatotropin^14th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --14th specimen;GH sp14 SerPl-mCnc;;ACTIVE;2.32;2.70 +58851-7;Testosterone^3D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --3 days post XXX challenge;Testost 3D p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58852-5;Osmolality^post 1.5H FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--1.5 hours post fluid fast;Osmolality p 1.5h FFST Ur;;ACTIVE;2.32;2.70 +58853-3;Osmolality^post 30M FFst;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--30 minutes post fluid fast;Osmolality p 30M FFST Ur;;ACTIVE;2.32;2.70 +58854-1;Estradiol^4D post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --4 days post XXX challenge;Estradiol 4D p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58855-8;Somatotropin^13th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --13th specimen;GH sp13 SerPl-mCnc;;ACTIVE;2.32;2.70 +58856-6;Somatotropin^10th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --10th specimen;GH sp10 SerPl-mCnc;;ACTIVE;2.32;2.73 +58857-4;Somatotropin^9th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --9th specimen;GH sp9 SerPl-mCnc;;ACTIVE;2.32;2.73 +58858-2;Parathyrin.intact^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Parathyrin.intact [Mass/volume] in Serum or Plasma --post XXX challenge;PTH-Intact p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +5885-9;Virus identified;Prid;Pt;Skin;Nom;Culture;MICRO;1;Virus identified in Skin by Culture;Virus Skin Cult;;ACTIVE;1.0;2.73 +58859-0;Homocyst(e)ine^post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Homocyst(e)ine [Moles/volume] in Serum or Plasma --post XXX challenge;Hcys p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +58860-8;Somatotropin^48th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --48th specimen;GH sp48 SerPl-mCnc;;ACTIVE;2.32;2.70 +58861-6;Somatotropin^47th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --47th specimen;GH sp47 SerPl-mCnc;;ACTIVE;2.32;2.70 +58862-4;Somatotropin^46th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --46th specimen;GH sp46 SerPl-mCnc;;ACTIVE;2.32;2.70 +58863-2;Somatotropin^45th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --45th specimen;GH sp45 SerPl-mCnc;;ACTIVE;2.32;2.70 +58864-0;Somatotropin^44th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --44th specimen;GH sp44 SerPl-mCnc;;ACTIVE;2.32;2.70 +58865-7;Somatotropin^43rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --43rd specimen;GH sp43 SerPl-mCnc;;ACTIVE;2.32;2.70 +58866-5;Somatotropin^42nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --42nd specimen;GH sp42 SerPl-mCnc;;ACTIVE;2.32;2.70 +5886-7;Virus identified;Prid;Pt;Stool;Nom;Culture;MICRO;1;Virus identified in Stool by Culture;Virus Stl Cult;;ACTIVE;1.0;2.19 +58867-3;Somatotropin^41st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --41st specimen;GH sp41 SerPl-mCnc;;ACTIVE;2.32;2.70 +58868-1;Somatotropin^40th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --40th specimen;GH sp40 SerPl-mCnc;;ACTIVE;2.32;2.70 +58869-9;Somatotropin^39th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --39th specimen;GH sp39 SerPl-mCnc;;ACTIVE;2.32;2.70 +58870-7;Somatotropin^38th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --38th specimen;GH sp38 SerPl-mCnc;;ACTIVE;2.32;2.70 +58871-5;Somatotropin^37th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --37th specimen;GH sp37 SerPl-mCnc;;ACTIVE;2.32;2.70 +58872-3;Somatotropin^36th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --36th specimen;GH sp36 SerPl-mCnc;;ACTIVE;2.32;2.70 +58873-1;Somatotropin^35th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --35th specimen;GH sp35 SerPl-mCnc;;ACTIVE;2.32;2.70 +58874-9;Somatotropin^33rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --33rd specimen;GH sp33 SerPl-mCnc;;ACTIVE;2.32;2.70 +5887-5;Virus identified;Prid;Pt;Thrt;Nom;Culture;MICRO;1;Virus identified in Throat by Culture;Virus Throat Cult;;ACTIVE;1.0;2.17 +58875-6;Somatotropin^32nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --32nd specimen;GH sp32 SerPl-mCnc;;ACTIVE;2.32;2.70 +58876-4;Somatotropin^31st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --31st specimen;GH sp31 SerPl-mCnc;;ACTIVE;2.32;2.70 +58877-2;Somatotropin^30th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30th specimen;GH sp30 SerPl-mCnc;;ACTIVE;2.32;2.73 +58878-0;Somatotropin^29th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --29th specimen;GH sp29 SerPl-mCnc;;ACTIVE;2.32;2.70 +58879-8;Somatotropin^28th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --28th specimen;GH sp28 SerPl-mCnc;;ACTIVE;2.32;2.70 +58880-6;Somatotropin^27th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --27th specimen;GH sp27 SerPl-mCnc;;ACTIVE;2.32;2.70 +58881-4;Somatotropin^26th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --26th specimen;GH sp26 SerPl-mCnc;;ACTIVE;2.32;2.70 +58882-2;Somatotropin^23rd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --23rd specimen;GH sp23 SerPl-mCnc;;ACTIVE;2.32;2.70 +5888-3;Virus identified;Prid;Pt;Tiss;Nom;Culture;MICRO;1;Virus identified in Tissue by Culture;Virus Tiss Cult;;ACTIVE;1.0;2.73 +58883-0;Somatotropin^22nd specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --22nd specimen;GH sp22 SerPl-mCnc;;ACTIVE;2.32;2.70 +58884-8;Somatotropin^21st specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --21st specimen;GH sp21 SerPl-mCnc;;ACTIVE;2.32;2.70 +58885-5;Urea;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea [Mass/volume] in Peritoneal dialysis fluid;Urea DiafP-mCnc;;ACTIVE;2.32;2.70 +58886-3;Pyruvate^30M post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --30 minutes post XXX challenge;Pyruvate 30M p chal Bld-mCnc;;ACTIVE;2.32;2.70 +58887-1;Pyruvate^15M post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --15 minutes post XXX challenge;Pyruvate 15M p chal Bld-mCnc;;ACTIVE;2.32;2.70 +58888-9;Pyruvate^10M post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --10 minutes post XXX challenge;Pyruvate 10M p chal Bld-mCnc;;ACTIVE;2.32;2.70 +58889-7;Pyruvate^3M post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --3 minutes post XXX challenge;Pyruvate 3M p chal Bld-mCnc;;ACTIVE;2.32;2.70 +58890-5;Pyruvate^1M post XXX challenge;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --1 minute post XXX challenge;Pyruvate 1M p chal Bld-mCnc;;ACTIVE;2.32;2.70 +5889-1;Protein S.free;ACnc;Pt;PPP;Qn;Coag;COAG;1;Protein S Free [Units/volume] in Platelet poor plasma by Coagulation assay;Prot S Free PPP-aCnc;;DISCOURAGED;1.0;2.73 +58891-3;Calcitonin^1M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Mass/volume] in Serum or Plasma --1 minute post XXX challenge;Calcit 1M p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58892-1;Calcitonin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcitonin [Mass/volume] in Serum or Plasma --baseline;Calcit BS SerPl-mCnc;;ACTIVE;2.32;2.73 +58893-9;Vasopressin^1.5H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Mass/volume] in Plasma --1.5 hours post XXX challenge;Vasopressin 1.5h p chal Plas-mCnc;;ACTIVE;2.32;2.70 +58894-7;Vasopressin^baseline;MCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Mass/volume] in Plasma --baseline;Vasopressin BS Plas-mCnc;;ACTIVE;2.32;2.70 +58895-4;Pyruvate^post exercise;MCnc;Pt;Bld;Qn;;CHAL;1;Pyruvate [Mass/volume] in Blood --post exercise;Pyruvate p Exc Bld-mCnc;;ACTIVE;2.32;2.70 +58896-2;C peptide^post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --post XXX challenge;C peptide p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58897-0;Methyl ethyl ketone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methyl ethyl ketone/Creatinine [Mass Ratio] in Urine;MEK/Creat Ur;;ACTIVE;2.32;2.70 +58898-8;Renin^4H post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --4 hours post XXX challenge;Renin 4h p chal Plas-cCnc;;ACTIVE;2.32;2.70 +58899-6;Aldosterone^4H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Mass/volume] in Serum or Plasma --4 hours post XXX challenge;Aldost 4h p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58900-2;HIV 1+2 Ab+HIV1 p24 Ag;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HIV 1+2 Ab+HIV1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay;HIV 1+2 Ab+HIV1 p24 Ag SerPl IA-aCnc;;ACTIVE;2.32;2.73 +58901-0;Spermatozoa.progressive;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive [#/volume] in Semen;Sperm Prog # Smn;;ACTIVE;2.32;2.73 +58902-8;F12 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F12 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;F12 gene Mut Tested Bld/T;;ACTIVE;2.32;2.32 +58903-6;Neomycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Neomycin IgE Ab [Units/volume] in Serum;Neomycin IgE Qn;;ACTIVE;2.32;2.70 +58904-4;Nucleated cells;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Pleural fluid by Manual count;Nuc cell # Plr Manual;;ACTIVE;2.36;2.70 +58905-1;Nucleated cells;NCnc;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Pericardial fluid by Manual count;Nuc cell # Pcar Manual;;ACTIVE;2.36;2.70 +58906-9;Nucleated cells;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Cerebral spinal fluid by Manual count;Nuc cell # CSF Manual;;ACTIVE;2.36;2.73 +58907-7;Liver kidney microsomal 1 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Liver kidney microsomal 1 Ab [Presence] in Serum by Immunofluorescence;LKM-1 Ab Ser Ql IF;;ACTIVE;2.32;2.56 +58908-5;11-Deoxycortisol^40M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge;11DC 40M p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +5890-9;Protein S+Acarboxy.free Ag;ACnc;Pt;PPP;Qn;IA;CHAL;1;Protein S+Acarboxy Free Ag [Units/volume] in Platelet poor plasma by Immunoassay;Prot S+ACA Free Ag PPP IA-aCnc;;ACTIVE;1.0;2.73 +58909-3;11-Deoxycortisol^20M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge;11DC 20M p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58910-1;11-Deoxycortisol^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;11DC 2.5h p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58911-9;Chicken droppings Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken droppings IgG Ab [Mass/volume] in Serum;Chicken Drop IgG-mCnc;;ACTIVE;2.32;2.70 +58912-7;Pigeon feather Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon feather IgG Ab [Mass/volume] in Serum;Pigeon Feather IgG-mCnc;;ACTIVE;2.32;2.70 +58913-5;Parrot feather Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parrot feather IgG Ab [Mass/volume] in Serum;Parrot Feather IgG-mCnc;;ACTIVE;2.32;2.70 +58914-3;Aspergillus niger Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Aspergillus niger IgG Ab [Mass/volume] in Serum;A niger IgG Ser-mCnc;;ACTIVE;2.32;2.73 +58915-0;Parakeet feather Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parakeet feather IgG Ab [Mass/volume] in Serum;Parakeet Feather IgG-mCnc;;ACTIVE;2.32;2.70 +58916-8;Canary feather Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Canary feather IgG Ab [Mass/volume] in Serum;Canary Feather IgG-mCnc;;ACTIVE;2.32;2.70 +5891-7;Protein S+Acarboxy Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Protein S+Acarboxy Ag [Units/volume] in Platelet poor plasma by Immunoassay;Prot S+ACA Ag PPP IA-aCnc;;ACTIVE;1.0;2.69 +58917-6;Androstanolone^1H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge;Androstanolone 1h p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58918-4;Androstanolone^30M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge;Androstanolone 30M p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58919-2;Androstenedione^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Androst 1.5h p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +589-2;Legionella sp identified;Prid;Pt;Bronchial;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Bronchial specimen by Organism specific culture;Legionella Bronch Cult;;ACTIVE;1.0;2.19 +58920-0;Cells.CD4+CD45RO+/Cells.CD3+CD4+;NRto;Pt;Bld;Qn;;CELLMARK;1;CD4+CD45RO+ cells/CD3+CD4+ (T4 helper) cells [# Ratio] in Blood;CD4+CD45RO+ Cells/CD3+CD4+ Cells Bld;;ACTIVE;2.32;2.70 +58921-8;Glutamine+Histidine;SCnc;Pt;CSF;Qn;;CHEM;1;Glutamine+Histidine [Moles/volume] in Cerebral spinal fluid;Glutamine+Histidine CSF-sCnc;;ACTIVE;2.32;2.70 +58922-6;Vasopressin^2H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Vasopressin [Mass/volume] in Plasma --2 hours post XXX challenge;Vasopressin 2h p chal Plas-mCnc;;ACTIVE;2.32;2.70 +58923-4;Lolium perenne Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Perennial rye grass IgG Ab [Mass/volume] in Serum;Per rye grass IgG-mCnc;;ACTIVE;2.32;2.73 +58924-2;LCT gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LCT gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;LCT gene Mut Tested Bld/T;;ACTIVE;2.32;2.32 +5892-5;Protein S;ACnc;Pt;PPP;Qn;Coag;COAG;1;Protein S [Units/volume] in Platelet poor plasma by Coagulation assay;Prot S PPP-aCnc;;ACTIVE;1.0;2.73 +58925-9;Dextromethamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Dextromethamphetamine [Presence] in Urine;D-methamphet Ur Ql;;ACTIVE;2.32;2.73 +58927-5;Glutamine+Histidine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Glutamine+Histidine/Creatinine [Ratio] in Urine;Glutamine+Histidine/Creat Ur-Rto;;ACTIVE;2.32;2.70 +58928-3;HLA-DQA1*03:01;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQA1*03:01 [Presence];HLA-DQA1*03:01 Ql;;ACTIVE;2.32;2.56 +58929-1;HLA-DQB1*03:02;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQB1*03:02 [Presence];HLA-DQB1*03:02 Ql;;ACTIVE;2.32;2.73 +58930-9;Glutamine+Histidine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamine+Histidine [Moles/volume] in Serum or Plasma;Glutamine+Histidine SerPl-sCnc;;ACTIVE;2.32;2.70 +58931-7;Mycobacterium tuberculosis DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Body fluid by NAA with probe detection;M tb DNA Fld Ql NAA+probe;;ACTIVE;2.32;2.73 +58932-5;Protoporphyrin;MCnt;Pt;Stool;Qn;;CHEM;1;Protoporphyrin [Mass/mass] in Stool;Protopor Stl-mCnt;;ACTIVE;2.32;2.70 +5893-3;Protein S;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Protein S [Units/volume] in Platelet poor plasma by Chromogenic method;Prot S PPP Chro-aCnc;;ACTIVE;1.0;2.73 +58933-3;Endothelial cell Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Endothelial cell Ab [Presence] in Serum or Plasma by Immunofluorescence;Endothelial cell Ab SerPl Ql IF;;ACTIVE;2.32;2.56 +58934-1;Fat;MCnt;72H;Stool;Qn;;CHEM;1;Fat [Mass/mass] in 72 hour Stool;Fat 72h Stl-mCnt;;ACTIVE;2.32;2.70 +58935-8;Yersinia pseudotuberculosis Ab;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Yersinia pseudotuberculosis Ab [Presence] in Serum by Agglutination;Y pseudoTB Ab Ser Ql Aggl;;ACTIVE;2.32;2.56 +58936-6;Hepatitis E virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Hepatitis E virus Ab [Presence] in Serum by Immunoassay;HEV Ab Ser Ql IA;;ACTIVE;2.32;2.56 +58937-4;F12 gene targeted mutation analysis;Type;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F12 gene mutations found [Type] in Blood or Tissue by Molecular genetics method;F12 gene Mut Anl Bld/T;;ACTIVE;2.32;2.63 +58938-2;LCT gene targeted mutation analysis;Type;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;LCT gene mutations found [Type] in Blood or Tissue by Molecular genetics method;LCT gene Mut Anl Bld/T;;ACTIVE;2.32;2.63 +58939-0;Cells.CD34;NCnc;Pt;Body fld;Qn;;CELLMARK;1;CD34 cells [#/volume] in Body fluid;CD34 Cells # Fld;;ACTIVE;2.32;2.70 +58940-8;Bacteria identified;Prid;Pt;TPN;Nom;Culture;MICRO;1;Bacteria identified in Total parental nutrition by Culture;Bacteria TPN Cult;;ACTIVE;2.32;2.32 +5894-1;Coagulation tissue factor induced actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) actual/Normal;Prothrombin time/nomal;;ACTIVE;1.0;2.73 +58941-6;Bilirubin;MCnc;Pt;Skin;Qn;Transcutaneous meter;CHEM;1;Bilirubin [Mass/volume] in Skin;Bilirub Skin-mCnc;;ACTIVE;2.32;2.73 +58942-4;Microscopic observation;Prid;Pt;Plr fld;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Pleural fluid by Acid fast stain.Ziehl-Neelsen;ZN Stn Plr;;ACTIVE;2.32;2.32 +58943-2;Microscopic observation;Prid;Pt;CSF;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by Acid fast stain.Ziehl-Neelsen;ZN Stn CSF;;ACTIVE;2.32;2.32 +58944-0;Microscopic observation;Prid;Pt;Body fld;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Body fluid by Acid fast stain.Ziehl-Neelsen;ZN Stn Fld;;ACTIVE;2.32;2.32 +58945-7;Microscopic observation;Prid;Pt;Periton fld;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Peritoneal fluid by Acid fast stain.Ziehl-Neelsen;ZN Stn Prt;;ACTIVE;2.32;2.32 +58946-5;Lutropin^pre XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Lutropin [Units/volume] in Serum or Plasma --pre XXX challenge;LH pre chal SerPl-aCnc;;ACTIVE;2.32;2.70 +58947-3;Follitropin^pre XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --pre XXX challenge;FSH pre chal SerPl-aCnc;;ACTIVE;2.32;2.70 +58948-1;Somatotropin^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --pre XXX challenge;GH pre chal SerPl-mCnc;;ACTIVE;2.32;2.73 +58949-9;Somatotropin^12th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Mass/volume] in Serum or Plasma --12th specimen;GH sp12 SerPl-mCnc;;ACTIVE;2.32;2.70 +58950-7;Somatotropin^11th specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Somatotropin [Mass/volume] in Serum or Plasma --11th specimen;GH sp11 SerPl-mCnc;;ACTIVE;2.32;2.70 +58951-5;Creatinine^2nd specimen;MCnc;Pt;Urine;Qn;;CHAL;1;Creatinine [Mass/volume] in Urine --2nd specimen;Creat sp2 Ur-mCnc;;ACTIVE;2.32;2.70 +58952-3;Testosterone free & total panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Testosterone free and total panel [Mass/volume] - Serum or Plasma;Testost free+total panel SerPl-mCnc;;ACTIVE;2.32;2.73 +58953-1;Meperidine & Normeperidine panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Meperidine and Normeperidine panel - Urine;Meperidine + Normeperidine Pnl Ur;;ACTIVE;2.32;2.73 +58954-9;Deoxypyridinoline/Pyridinoline;SRto;Pt;Urine;Qn;;CHEM;1;Deoxypyridinoline/Pyridinoline [Molar ratio] in Urine;DPD/PYD Ur-sRto;;ACTIVE;2.32;2.73 +58955-6;Pyridinoline & Deoxypyridinoline;Imp;Pt;Urine;Nom;;CHEM;1;Pyridinoline and Deoxypyridinoline [Interpretation] in Urine;Pyridinoline + Deoxypyridinoline Ur-Imp;;ACTIVE;2.32;2.56 +58956-4;Direct antiglobulin test.complement C3b+C4d specific reagent;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.complement C3b+C4d specific reagent [Presence] on Red Blood Cells;DAT C3b+C4d Comp-Sp Reag RBC Ql;;ACTIVE;2.32;2.56 +5895-7;Coagulation tissue factor induced.INR;TRto;Pt;Plas;Qn;Coag;COAG;1;Deprecated INR in Platelet poor plasma by Coagulation assay;Deprecated INR Plas;;DEPRECATED;1.0;2.36 +58957-2;Heparin given;Type;Pt;^Patient;Nom;;DRUGDOSE;1;Heparin given [Type];Heparin Gvn;;ACTIVE;2.32;2.73 +58958-0;Fusarium oxysporum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium oxysporum IgG Ab [Mass/volume] in Serum;F oxysporum IgG-mCnc;;ACTIVE;2.32;2.73 +58959-8;BIPAP &or CPAP setting;Find;Pt;Ventilator;Ord;;PULM;2;BIPAP AndOr CPAP setting Ventilator;BIPAP AndOr CPAP setting Vent;;ACTIVE;2.32;2.73 +58960-6;Pressure.bilevel positive airway;Pres;Pt;Ventilator;Qn;;PULM;2;Pressure.bilevel positive airway Ventilator;BPAP Vent;;ACTIVE;2.32;2.73 +58961-4;Ganglioside GT1b Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GT1b IgM Ab [Units/volume] in Serum by Immunoassay;GT1b Ganlg IgM Ser IA-aCnc;;ACTIVE;2.32;2.70 +58962-2;Ganglioside GT1b Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GT1b IgG Ab [Units/volume] in Serum by Immunoassay;GT1b Ganlg IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +58963-0;Ganglioside GT1a Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GT1a IgM Ab [Units/volume] in Serum by Immunoassay;GT1a Gangl IgM Ser IA-aCnc;;ACTIVE;2.32;2.70 +58964-8;Ganglioside GT1a Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GT1a IgG Ab [Units/volume] in Serum by Immunoassay;GT1a Gangl IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +5896-5;Coagulation tissue factor induced.normal/Actual;TRto;Pt;Plas;Qn;Coag-inverse ratio;COAG;1;Deprecated reverse INR in Platelet poor plasma by Coagulation assay;Deprecated PT Inv Ratio Plas;;DEPRECATED;1.0;2.36 +58965-5;Ganglioside GM4 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM4 IgM Ab [Units/volume] in Serum by Immunoassay;GM4 IgM Ser IA-aCnc;;ACTIVE;2.32;2.70 +58966-3;Ganglioside GM4 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM4 IgG Ab [Units/volume] in Serum by Immunoassay;GM4 IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +58967-1;Ganglioside GM3 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM3 IgM Ab [Units/volume] in Serum by Immunoassay;GM3 IgM Ser IA-aCnc;;ACTIVE;2.32;2.70 +58968-9;Asialoganglioside GM1 Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Asialoganglioside GM1 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM1 Asialo IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58969-7;Ganglioside GD1a Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1a IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GD1a Gangl IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58970-5;Ganglioside GD1a Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1a IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GD1a Gangl IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +58971-3;Ganglioside GD1b Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD1b IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GD1b Gangl IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58972-1;Ganglioside GM1 Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM1 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM1 Gangl IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +5897-3;Coagulation dilute Russell viper venom induced;Time;Pt;Plas;Qn;Coag;COAG;1;Deprecated Dilute Russell viper venom time (dRVVT) in Platelet poor plasma by Coagulation assay;Deprecated dRVV Tme Plas Qn;;DEPRECATED;1.0;2.36 +58973-9;Ganglioside GM2 Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM2 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM2 Gangl IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58974-7;Ganglioside GM2 Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM2 IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM2 Gangl IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +58975-4;Ganglioside GQ1b Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GQ1b IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GQ1b Gangl IgG CSF IA-aCnc;;ACTIVE;2.32;2.70 +58976-2;Ganglioside GQ1b Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GQ1b IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GQ1b Gangl IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +58977-0;Ganglioside GD1b Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1b IgM Ab [Units/volume] in Serum by Immunoassay;GD1b Gangl IgM Ser IA-aCnc;;ACTIVE;2.32;2.73 +58978-8;Ganglioside GD3 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD3 IgM Ab [Units/volume] in Serum by Immunoassay;GD3 Gangl IgM Ser IA-aCnc;;ACTIVE;2.32;2.70 +58979-6;Ganglioside GD3 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD3 IgG Ab [Units/volume] in Serum by Immunoassay;GD3 Gangl IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +58980-4;Ganglioside GD2 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD2 IgM Ab [Units/volume] in Serum by Immunoassay;GD2 Gangl IgM Ser IA-aCnc;;ACTIVE;2.32;2.70 +58981-2;Phleum pratense recombinant (rPhl p) 5b Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 5b IgE Ab [Units/volume] in Serum;Timothy (rPhl p) 5b IgE Qn;;ACTIVE;2.32;2.70 +5898-2;Coagulation surface induced;Time;Pt;Plas;Qn;Coag;COAG;1;Deprecated Activated partial thrombplastin time (aPTT) in Blood by Coagulation assay;Deprecated aPTT Plas Qn;;DEPRECATED;1.0;2.36 +58982-0;Quercus ilex Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Holm oak IgE Ab [Units/volume] in Serum;Holm oak IgE Qn;;ACTIVE;2.32;2.70 +58983-8;Apis mellifera phospholipase A2 native (nApi m) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee phospholipase A2 native (nApi m) 1 IgE Ab [Units/volume] in Serum;PLA2 nApi m 1 IgE Qn;;ACTIVE;2.32;2.70 +58984-6;Bromelin MUXF3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bromelin MUXF3 IgE Ab [Units/volume] in Serum;Bromelin MUXF3 IgE Qn;;ACTIVE;2.32;2.70 +58985-3;11-Deoxycortisol^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycortisol [Mass/volume] in Serum or Plasma --pre XXX challenge;11DC pre chal SerPl-mCnc;;ACTIVE;2.32;2.70 +58986-1;Penaeus aztecus tropomyosin recombinant (rPen a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp tropomyosin recombinant (rPen a) 1 IgE Ab [Units/volume] in Serum;Shrimp tm (rPen a) 1 IgE Qn;;ACTIVE;2.32;2.70 +58987-9;ITGB3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ITGB3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ITGB3 Mut Anl Bld/T;;ACTIVE;2.32;2.63 +58988-7;FGB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FGB Mut Anl Bld/T;;ACTIVE;2.32;2.63 +58989-5;Specimen volume;Vol;18H;Urine;Qn;;SPEC;1;Volume of 18 hour Urine;Specimen vol 18h Ur;;ACTIVE;2.32;2.70 +5899-0;Coagulation surface induced normal/Actual;RelTime;Pt;PPP;Qn;Coag;COAG;1;aPTT normal/actual in Platelet poor plasma by Coagulation assay;aPTT Inv Ratio PPP;;ACTIVE;1.0;2.73 +58990-3;Urate;MRat;18H;Urine;Qn;;CHEM;1;Urate [Mass/time] in 18 hour Urine;Urate 18h Ur-mRate;;ACTIVE;2.32;2.70 +58991-1;Urea;MRat;18H;Urine;Qn;;CHEM;1;Urea [Mass/time] in 18 hour Urine;Urea 18h Ur-mRate;;ACTIVE;2.32;2.70 +58992-9;Protein;MRat;18H;Urine;Qn;;CHEM;1;Protein [Mass/time] in 18 hour Urine;Prot 18h Ur-mRate;;ACTIVE;2.32;2.73 +58993-7;Phosphate;MRat;18H;Urine;Qn;;CHEM;1;Phosphate [Mass/time] in 18 hour Urine;Phosphate 18h Ur-mRate;;ACTIVE;2.32;2.70 +58994-5;Sodium;SRat;18H;Urine;Qn;;CHEM;1;Sodium [Moles/time] in 18 hour Urine;Sodium 18h Ur-sRate;;ACTIVE;2.32;2.70 +58995-2;Magnesium;MRat;18H;Urine;Qn;;CHEM;1;Magnesium [Mass/time] in 18 hour Urine;Magnesium 18h Ur-mRate;;ACTIVE;2.32;2.70 +58996-0;Potassium;SRat;18H;Urine;Qn;;CHEM;1;Potassium [Moles/time] in 18 hour Urine;Potassium 18h Ur-sRate;;ACTIVE;2.32;2.70 +58997-8;Glucose;MRat;18H;Urine;Qn;;CHEM;1;Glucose [Mass/time] in 18 hour Urine;Glucose 18h Ur-mRate;;ACTIVE;2.32;2.70 +58998-6;Creatinine;MRat;18H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 18 hour Urine;Creat 18h Ur-mRate;;ACTIVE;2.32;2.70 +58999-4;Chloride;SRat;18H;Urine;Qn;;CHEM;1;Chloride [Moles/time] in 18 hour Urine;Chloride 18h Ur-sRate;;ACTIVE;2.32;2.70 +5-9;Almecillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Almecillin [Susceptibility] by Serum bactericidal titer;Almecillin Titr SBT;;ACTIVE;1.0;2.32 +590-0;Legionella sp identified;Prid;Pt;Sputum;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Sputum by Organism specific culture;Legionella Spt Cult;;ACTIVE;1.0;2.73 +59000-0;Calcium;MRat;18H;Urine;Qn;;CHEM;1;Calcium [Mass/time] in 18 hour Urine;Calcium 18h Ur-mRate;;ACTIVE;2.32;2.70 +59001-8;Amylase;CRat;18H;Urine;Qn;;CHEM;1;Amylase [Enzymatic activity/time] in 18 hour Urine;Amylase 18h Ur-cRate;;ACTIVE;2.32;2.70 +59002-6;Paliperidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Paliperidone [Mass/volume] in Serum or Plasma;Deprecated Paliperidone SerPl-mCnc;;DEPRECATED;2.32;2.70 +59003-4;Lactoferrin Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Lactoferrin Ab [Units/volume] in Serum by Immunoassay;Lactoferrin Ab Ser IA-aCnc;;ACTIVE;2.32;2.70 +59004-2;Lactate^baseline;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --baseline;Lactate BS SerPl-sCnc;;ACTIVE;2.32;2.70 +59005-9;Lactate^1M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --1 minute post XXX challenge;Lactate 1M p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +5900-6;Prothrombin fragment 1+2;ACnc;Pt;Ser/Plas;Qn;;COAG;1;Prothrombin Fragment 1.2 [Units/volume] in Serum or Plasma;Pro Frg1+2 SerPl-aCnc;;ACTIVE;1.0;2.73 +59006-7;Lactate^3M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --3 minutes post XXX challenge;Lactate 3M p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +59007-5;Lactate^5M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge;Lactate 5M p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +59008-3;Insulin-like growth factor binding protein 3^15M post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge;IGF BP3 15M p chal SerPl-mCnc;;ACTIVE;2.32;2.70 +59009-1;Fractional excretion of urea;Ratio;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Fractional excretion of urea [Ratio] in Urine and Serum or Plasma collected for unspecified duration;Fract excret urea ?Tm Ur+SerPl-Rto;;ACTIVE;2.32;2.70 +59010-9;Fractional excretion of potassium;Ratio;XXX;Urine+Ser/Plas;Qn;;CHEM;1;Fractional excretion of potassium [Ratio] in Urine and Serum or Plasma collected for unspecified duration;Fract excret K ?Tm Ur+SerPl-Rto;;ACTIVE;2.32;2.70 +59011-7;Lactate^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;Lactate 10M p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +59012-5;Lactate^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;Lactate 15M p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +59013-3;Lactate^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Lactate 30M p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +5901-4;Coagulation tissue factor induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) in Control Platelet poor plasma by Coagulation assay;PT Cont PPP;;ACTIVE;1.0;2.73 +59014-1;Sjogrens syndrome-A extractable nuclear 60kD Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Sjogrens syndrome-A extractable nuclear 60kD Ab [Presence] in Serum by Immunoblot;ENA SS-a 60kD Ab Ser Ql IB;;ACTIVE;2.32;2.58 +59015-8;Carbohydrates;MCnt;Pt;Stool;Qn;Infrared spectroscopy;CHEM;1;Carbohydrates [Mass/mass] in Stool by Infrared spectroscopy;Carbohydrates Stl IR-mCnt;;ACTIVE;2.34;2.70 +59016-6;Water;MCnt;Pt;Stool;Qn;Infrared spectroscopy;CHEM;1;Water [Mass/mass] in Stool by Infrared spectroscopy;Water Stl IR-mCnt;;ACTIVE;2.34;2.70 +59017-4;HLA-DPB1;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DPB1 [Type] by High resolution;HLA-DPB1 High Res;;ACTIVE;2.32;2.73 +59018-2;HLA-DPA1;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DPA1 [Type] by High resolution;HLA-DPA1 High Res;;ACTIVE;2.32;2.73 +59019-0;HLA-DQA1;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DQA1 [Type] by High resolution;HLA-DQA1 High Res;;ACTIVE;2.32;2.73 +59020-8;HLA-DRB5;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DRB5 [Type];HLA-DRB5;;ACTIVE;2.32;2.73 +59021-6;HLA-DRB4;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DRB4 [Type];HLA-DRB4;;ACTIVE;2.32;2.73 +5902-2;Coagulation tissue factor induced;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT);Prothrombin time;;ACTIVE;1.0;2.73 +59022-4;HLA-DRB3;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DRB3 [Type];HLA-DRB3;;ACTIVE;2.32;2.73 +59023-2;Adenosine deaminase;CCnc;Pt;Dial fld prt;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Peritoneal dialysis fluid;Adenosine deaminase DiafP-cCnc;;ACTIVE;2.34;2.70 +59024-0;Renin^supine+30M post XXX challenge;CCnc;Pt;Plas;Qn;;CHAL;1;Renin [Enzymatic activity/volume] in Plasma --supine+30 minutes post XXX challenge;Renin sup+30M p chal Plas-cCnc;;ACTIVE;2.32;2.70 +59025-7;Neutrophil Ab;ACnc;Pt;Ser;Qn;Flow cytometry;SERO;1;Neutrophil Ab [Units/volume] in Serum by Flow cytometry (FC);Neutrophil Ab Ser FC-aCnc;;ACTIVE;2.32;2.70 +59026-5;U1 small nuclear ribonucleoprotein 70kD Ab;ACnc;Pt;Ser;Qn;;SERO;1;U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum;U1 snRNP70 Ab Ser-aCnc;;ACTIVE;2.32;2.73 +59027-3;Asialoganglioside GM1 Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;Asialoganglioside GM1 IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM1 Asialo IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +59028-1;Ganglioside GM1 Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM1 IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM1 Gangl IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +59029-9;HLA-DRB1*15:01;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DRB1*15:01 [Presence];HLA-DRB1*15:01 Ql;;ACTIVE;2.32;2.56 +5903-0;Coagulation Russell viper venom induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Russell viper venom time in Control Platelet poor plasma by Coagulation assay;RVV time Cont PPP;;ACTIVE;1.0;2.44 +59030-7;Cells.CD45+CD103+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD45+CD103+ Cells/100 cells in Tissue;CD45+CD103+ Cells NFr Tiss;;ACTIVE;2.32;2.70 +59031-5;Cells.CD25+C69+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25+C69+ cells/100 cells in Blood;CD25+C69+ Cells NFr Bld;;ACTIVE;2.32;2.70 +59032-3;Lactate;MCnc;Pt;Bld;Qn;;CHEM;1;Lactate [Mass/volume] in Blood;Lactate Bld-mCnc;;ACTIVE;2.32;2.73 +59033-1;Ganglioside GM3 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM3 IgG Ab [Units/volume] in Serum by Immunoassay;GM3 IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +59034-9;Ganglioside GD2 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD2 IgG Ab [Units/volume] in Serum by Immunoassay;GD2 Gangl IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +59035-6;Cells.CD54/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;CD54 cells/100 cells in Body fluid;CD54 Cells NFr Fld;;ACTIVE;2.32;2.70 +59036-4;Triglyceride;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Triglyceride [Mass/volume] in Peritoneal dialysis fluid;Trigl DiafP-mCnc;;ACTIVE;2.32;2.70 +59037-2;Phosphate;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Phosphate [Mass/volume] in Peritoneal dialysis fluid;Phosphate DiafP-mCnc;;ACTIVE;2.32;2.70 +59038-0;Cholesterol;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Cholesterol [Mass/volume] in Peritoneal dialysis fluid;Cholest DiafP-mCnc;;ACTIVE;2.32;2.73 +59039-8;Amylase;CCnc;Pt;Dial fld prt;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Peritoneal dialysis fluid;Amylase DiafP-cCnc;;ACTIVE;2.32;2.70 +59040-6;Cancer Ag 125;ACnc;Pt;Dial fld prt;Qn;;CHEM;1;Cancer Ag 125 [Units/volume] in Peritoneal dialysis fluid;Cancer Ag125 DiafP-aCnc;;ACTIVE;2.32;2.70 +59041-4;BRCA1+BRCA2 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BRCA1+BRCA2 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;BRCA1+BRCA2 Mut Tested Bld/T;;ACTIVE;2.32;2.73 +59042-2;Cells.TCR gamma delta/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;TCR gamma delta cells/100 cells in Tissue;TCR G-D Cells NFr Tiss;;ACTIVE;2.32;2.70 +59043-0;Somatotropin^34th specimen;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --34th specimen;GH sp34 SerPl-mCnc;;ACTIVE;2.32;2.70 +59044-8;ACE gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ACE gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;ACE gene Mut Tested Bld/T;;ACTIVE;2.32;2.32 +59045-5;ITGB3 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ITGB3 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;ITGB3 Mut Tested Bld/T;;ACTIVE;2.32;2.32 +59046-3;FGB gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FGB gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;FGB Mut Tested Bld/T;;ACTIVE;2.32;2.32 +59047-1;F5 gene.p.His1299Arg;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;F5 gene p.His1299Arg [Presence] in Blood or Tissue by Molecular genetics method;F5 p.H1299R Bld/T Ql;;ACTIVE;2.32;2.56 +5904-8;Coagulation Russell viper venom induced;Time;Pt;PPP;Qn;Coag;COAG;1;Russell viper venom time in Platelet poor plasma by Coagulation assay;RVV time PPP;;ACTIVE;1.0;2.73 +59048-9;Lactate/Pyruvate;MRto;Pt;Bld;Qn;;CHEM;1;Lactate/Pyruvate [Mass Ratio] in Blood;Lactate/Pyruvate Bld;;ACTIVE;2.32;2.73 +59049-7;Coccidioides sp Ab.IgG & IgM panel;-;Pt;XXX;-;;PANEL.MICRO;1;Coccidioides sp IgG and IgM panel - Specimen;Coccidioides Ab.IgG + IgM Pnl Spec;;ACTIVE;2.32;2.73 +59050-5;Chromosome analysis.interphase;Imp;Pt;XXX;Nar;FISH;MOLPATH;1;Chromosome analysis.interphase [Interpretation] in Specimen by FISH Narrative;Chrom analy interphase Spec FISH-Imp;;ACTIVE;2.32;2.73 +59051-3;Bacteria identified^^^4;Prid;Pt;Tiss;Nom;Anaerobic culture;MICRO;1;Bacteria # 4 identified in Tissue by Anaerobe culture;Bacteria Tiss Anaerobe Cult org #4;;ACTIVE;2.32;2.32 +59052-1;HIV 1+Hepatitis C virus RNA+Hepatitis B virus DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;HIV 1+Hepatitis C virus RNA+Hepatitis B virus DNA [Presence] in Serum or Plasma by NAA with probe detection;HIV 1+HCV RNA+HBV DNA SerPl Ql NAA+probe;;ACTIVE;2.32;2.73 +59053-9;Glucagon^5th specimen post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --5th specimen fasting;Glucagon sp5 p fast SerPl-mCnc;;ACTIVE;2.32;2.70 +59054-7;Glucagon^4th specimen post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --4th specimen fasting;Glucagon sp4 p fast SerPl-mCnc;;ACTIVE;2.32;2.73 +5905-5;Monocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Monocytes/100 leukocytes in Blood by Automated count;Monocytes/leuk NFr Bld Auto;;ACTIVE;1.0;2.73 +59055-4;Glucagon^3rd specimen post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --3rd specimen fasting;Glucagon sp3 p fast SerPl-mCnc;;ACTIVE;2.32;2.73 +59056-2;Glucagon^2nd specimen post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --2nd specimen fasting;Glucagon sp2 p fast SerPl-mCnc;;ACTIVE;2.32;2.73 +59057-0;Glucagon^1st specimen post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --1st specimen fasting;Glucagon sp1 p fast SerPl-mCnc;;ACTIVE;2.32;2.73 +59058-8;Cow whey Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cow whey IgG Ab [Mass/volume] in Serum;Cow Whey IgG-mCnc;;ACTIVE;2.32;2.73 +59059-6;Inflammatory bowel disease Ab 7 panel;-;Pt;Ser;-;;PANEL.SERO;1;Inflammatory bowel disease Ab 7 panel - Serum;IBD Ab 7 pnl Ser;;ACTIVE;2.32;2.42 +59060-4;Inflammatory bowel disease Ab 7;Imp;Pt;Ser;Nom;;SERO;1;Inflammatory bowel disease Ab 7 [Interpretation] in Serum;IBD Ab 7 Ser-Imp;;ACTIVE;2.32;2.73 +59061-2;Adulterants;Imp;Pt;Urine;Nom;;CHEM;1;Adulterants [Interpretation] in Urine;Adulterants Ur-Imp;;ACTIVE;2.32;2.73 +59062-0;Lipoprofile panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Lipoprofile panel - Serum or Plasma;Lipoprofile pnl SerPl;;ACTIVE;2.32;2.73 +5906-3;Neutrophils;NCnc;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Neutrophils [#/volume] in Synovial fluid by Automated count;Neutrophils # Snv Auto;;ACTIVE;1.0a;2.73 +59063-8;Lymphocyte proliferation panel;-;Pt;Bld;-;;PANEL.SERO;1;Lymphocyte proliferation panel - Blood;Lymphocyte prolif pnl Bld;;ACTIVE;2.32;2.73 +59064-6;PAX6 gene targeted mutation analysis;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PAX6 gene targeted mutation analysis [Presence] in Blood or Tissue by Molecular genetics method;PAX6 gene Mut Anl Bld/T Ql;;ACTIVE;2.32;2.63 +59065-3;Chlamydophila psittaci;PrThr;Pt;Bronchial brush;Ord;Organism specific culture;MICRO;1;Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture;C psittaci Bro Brush Ql Cult;;ACTIVE;2.32;2.56 +59066-1;sp100 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;sp100 Ab [Presence] in Serum by Immunoassay;sp100 Ab Ser Ql IA;;ACTIVE;2.32;2.56 +59067-9;ALAS2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ALAS2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ALAS2 gene Mut Anl Bld/T;;ACTIVE;2.32;2.63 +59068-7;RPS19 gene targeted mutation analysis;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;RPS19 gene targeted mutation analysis [Presence] in Blood or Tissue by Molecular genetics method;RPS19 gene Mut Anl Bld/T Ql;;ACTIVE;2.32;2.63 +59069-5;Nuclear Ab;PrThr;Pt;Ser;Ord;Hep2 substrate;SERO;1;Nuclear Ab [Presence] in Serum by Hep2 substrate;ANA Ser Ql HEp2 subst;;ACTIVE;2.32;2.73 +59070-3;Paraquat;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Paraquat [Presence] in Serum or Plasma;Paraquat SerPl Ql;;ACTIVE;2.32;2.56 +5907-1;Platelets;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Platelets [#/volume] in Blood by Automated count;Deprecated Platelet # Bld Auto;;DEPRECATED;1.0b;2.40 +59071-1;Tropheryma whipplei Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Tropheryma whipplei Ab [Presence] in Serum;T whipplei Ab Ser Ql;;ACTIVE;2.32;2.70 +59072-9;Liver kidney microsomal 1 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Liver kidney microsomal 1 Ab [Presence] in Serum by Immunoblot;LKM-1 Ab Ser Ql IB;;ACTIVE;2.32;2.58 +59073-7;Circumference.transverse;Len;Pt;Heart;Qn;US;CARD.US;2;Heart Circumference, transverse by US;Hrt Circumf.transverse US;;ACTIVE;2.32;2.48 +59074-5;Circumference.transverse.heart/Circumference.thorax;LenRto;Pt;Heart;Qn;US;CARD.US;2;Heart circumference, transverse/Thorax circumference by US;Hrt CC.transverse/TC US;;ACTIVE;2.32;2.48 +59075-2;Cross section.transverse;Area;Pt;Heart;Qn;US;CARD.US;2;Heart Cross-sectional, transverse [Area] by US;Hrt Xsection.transverse Area US;;ACTIVE;2.32;2.48 +59076-0;Cross section.transverse.heart/Transverse.thorax;AreaRto;Pt;Heart;Qn;US;CARD.US;2;Heart cross-sectional, transverse/Thorax, transverse by US;Hrt Xsection.transverse.heart/thorax US;;ACTIVE;2.32;2.69 +59077-8;Diameter.foramen ovale/Diameter.aorta root;LenRto;Pt;Heart;Qn;US;CARD.US;2;Heart Foramen ovale diameter/Aortic root diameter by US;Hrt Diam FO/OA root US;;ACTIVE;2.32;2.48 +59078-6;Diameter.left ventricle/Diameter.right ventricle;LenRto;Pt;Heart;Qn;US;CARD.US;2;Heart Left ventricular diameter/Right ventricular diameter by US;Hrt LV diam/RV diam US;;ACTIVE;2.32;2.48 +59079-4;Blood flow.reverse.max^during atrial contraction;Vel;Pt;Pulmonary vein;Qn;US;CARD.US;2;Pulmonary vein Peak reversal velocity by US --during atrial contraction;Pulm v PRV AC US;;ACTIVE;2.32;2.32 +59080-2;E wave.max;Vel;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Peak E wave by US;Valve Peak E-wave US;;ACTIVE;2.32;2.54 +59081-0;A wave.max;Vel;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Peak A wave by US;Valve Peak A-wave US;;ACTIVE;2.32;2.54 +59082-8;Closure to opening;Time;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Closure to opening [Time] by US;Valve Closure to opening Time US;;ACTIVE;2.32;2.54 +59083-6;Isovolumic relaxation time;Time;Pt;Heart;Qn;US;CARD.US;2;Heart Isovolumic relaxation time by US;Hrt Isovolumic relaxation time US;;ACTIVE;2.32;2.54 +59084-4;Isovolumic contraction time;Time;Pt;Heart;Qn;US;CARD.US;2;Heart Isovolumic contraction time by US;Hrt Isovolumic contraction time US;;ACTIVE;2.32;2.54 +59085-1;Pre ejection time;Time;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Pre ejection time by US;Valve Pre eject time US;;ACTIVE;2.32;2.54 +59086-9;Ejection time^^corrected for heart rate;Time;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Ejection time heart rate-corrected by US;LV Ejection time HR cor US;;ACTIVE;2.32;2.54 +59087-7;Pre ejection time^^corrected for heart rate;Time;Pt;Heart.ventricle.XXX;Qn;US;CARD.US;2;Ventricular Pre ejection time heart rate-corrected by US;Hrt ventr Pre eject time HR cor US;;ACTIVE;2.32;2.54 +59088-5;Pre ejection time/Ejection time;TRto;Pt;Heart.ventricle.XXX;Qn;US;CARD.US;2;Ventricular Pre ejection time/Ejection time by US;Hrt ventr Pre eject time/Eject time US;;ACTIVE;2.32;2.69 +5908-9;Platelets.giant;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Giant platelets [Presence] in Blood by Light microscopy;Giant Platelets Bld Ql Smear;;ACTIVE;1.0b;2.73 +59089-3;Thickness;Len;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Thickness by US;ROI Thickness US;;ACTIVE;2.32;2.48 +59090-1;Internal Dimension;Len;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Internal dimension by US;ROI Internal dim US;;ACTIVE;2.32;2.48 +59091-9;D-E excursion;Len;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve D-E excursion [Length] by US;Valve D-E excursion US;;ACTIVE;2.32;2.48 +59092-7;Thickening;LenFr;Pt;Region of interest.XXX;Qn;US;CARD.US;2;Region of interest Thickening by US;ROI Thickening LenFr US;;ACTIVE;2.32;2.48 +59093-5;Epicardial area;Area;Pt;Heart;Qn;US;CARD.US;2;Epicardial area by US;Epicardial area US;;ACTIVE;2.32;2.48 +59094-3;Endocardial area;Area;Pt;Heart;Qn;US;CARD.US;2;Endocardial area by US;Endocardial area US;;ACTIVE;2.32;2.48 +59095-0;QRS to S wave.max;Time;Pt;Heart.ventricle;Qn;US;CARD.US;2;Ventricular QRS to S wave peak [Time] by US;Hrt ventr QRS to S wave peak Time US;;ACTIVE;2.32;2.54 +59096-8;QRS to E wave.max;Time;Pt;Heart.ventricle;Qn;US;CARD.US;2;Ventricular QRS to E wave peak [Time] by US;Hrt ventr QRS to E wave peak Time US;;ACTIVE;2.32;2.54 +5909-7;Blood smear finding;Prid;Pt;Bld;Nom;Microscopy.light;HEM/BC;1;Blood smear finding [Identifier] in Blood by Light microscopy;Bld Smear Interp;;ACTIVE;1.0b;2.73 +59097-6;Meridional wall stress;Pres;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Meridional wall stress [Pressure] by US;LV Meridional wall stress US;;ACTIVE;2.32;2.70 +59098-4;E wave to septal separation;Len;Pt;Mitral valve;Qn;US;CARD.US;2;Mitral valve E-septal separation [Length] by US;MV E-septal separation US;;ACTIVE;2.32;2.48 +59099-2;Myocardial performance index;TRto;Pt;Heart.ventricle.XXX;Qn;US;CARD.US;2;Ventricular Myocardial performance index (Tei) by US;Hrt ventr MPI US;;ACTIVE;2.32;2.69 +59100-8;A wave amplitude;Len;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve A-wave amplitude [Length] by US;Valve A-wave amp US;;ACTIVE;2.32;2.54 +59101-6;Pressure;Pres;Pt;Pulmonary artery;Qn;US.derived;CARD.US;2;Pulmonary artery Pressure by derived by US;PA Press der US;;ACTIVE;2.32;2.68 +59102-4;Flow radius;Len;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Flow radius by US;Flow radius US;;ACTIVE;2.32;2.48 +59103-2;A-C duration;Time;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve A-C interval by US;Valve A-C interval US;;ACTIVE;2.32;2.48 +59104-0;E wave.max/A wave.max;VelRto;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Peak E wave/Peak A wave by US;Valve Peak E-wave/Peak A wave US;;ACTIVE;2.32;2.54 +5910-5;Lactate dehydrogenase isoenzymes;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Lactate dehydrogenase isoenzymes [Interpretation] in Serum or Plasma;LDH Isos SerPl-Imp;;ACTIVE;1.0b;2.73 +59105-7;A wave duration;Time;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;A-wave duration by US;A-wave duration US;;ACTIVE;2.32;2.54 +59106-5;Pressure gradient.max^at stenosis;PressDiff;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Peak pressure gradient by US --at stenosis;Peak press grad @ stenosis US;;ACTIVE;2.32;2.67 +59107-3;Velocity.max^at stenosis;Vel;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Peak velocity by US --at stenosis;Peak velocity @ stenosis US;;ACTIVE;2.32;2.32 +59108-1;Measure duration;Time;Pt;XXX;Qn;US;CARD.US;2;Body region Envelope duration by US;Body reg Envelope duration US;;ACTIVE;2.32;2.69 +59109-9;Leaflet separation;Len;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Leaflet separation [Length] by US;Valve Leaflet separation US;;ACTIVE;2.32;2.48 +59110-7;Leaflet thickness;Len;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Leaflet thickness by US;Valve Leaflet thickness US;;ACTIVE;2.32;2.48 +59111-5;Blood flow velocity E wave/Annulus velocity E wave;VelRto;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve E velocity/Annulus E wave by US;Valve E-wave/Annulus E wave US;;ACTIVE;2.32;2.69 +59112-3;A wave duration.pulmonary vein/A wave duration.mitral valve;TRto;Pt;Circulatory system;Qn;US;CARD.US;2;Circulatory system Pulmonary vein A duration/Mitral vave A duration by US;Circ sys Pulm v A dur/MV A dur US;;ACTIVE;2.32;2.69 +5911-3;Lipoprotein pattern;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Lipoprotein fractions [Interpretation] in Serum or Plasma;LP SerPl-Imp;;ACTIVE;1.0b;2.73 +59113-1;Velocity-time integral.pulmonary vein A wave/Velocity-time integral.mitral valve A wave;LenRto;Pt;Pulmonary vein+Mitral valve;Qn;US;CARD.US;2;Pulmonary vein+Mitral valve Pulmonary vein A VTI/Mitral valve VTI by US;PV+MV Pulm v A VTI/MV VTI US;;ACTIVE;2.32;2.67 +59114-9;A wave duration.pulmonary vein - A wave duration.mitral valve;TimeDif;Pt;Pulmonary vein;Qn;US;CARD.US;2;Pulmonary vein A duration to Mitral valve A duration difference by US;Pulm v A dur - MV A dur US;;ACTIVE;2.32;2.48 +59115-6;Flow propagation velocity;Vel;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Flow propagation velocity by US;Valve Flow propagation velocity US;;ACTIVE;2.32;2.67 +59116-4;Diameter.aortic sinotubular junction/Diameter.aorta root;LenRto;Pt;Aorta;Qn;US;CARD.US;2;Aortic sinotubular junction diameter/Aortic root diameter by US;Diam AO STJ/OA root US;;ACTIVE;2.32;2.48 +59117-2;Circumferential fiber shortening.mean;Vel;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Mean circumferential fiber shortening [Velocity] by US;LV Mean VcFv US;;ACTIVE;2.32;2.68 +59118-0;Circumferential fiber shortening.mean^^corrected for heart rate;Vel;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Mean circumferential fiber shortening [Velocity] heart rate-corrected by US;LV Mean VcFv HR cor US;;ACTIVE;2.32;2.48 +59119-8;Filling period.diastole;Time;Pt;Heart.ventricle.XXX;Qn;US;CARD.US;2;Ventricular Diastolic filling period by US;Hrt ventr Dias fill period US;;ACTIVE;2.32;2.48 +59120-6;dP/dt;PresRat;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;dP/dt [Pressure rate] by US;dP/dt US;;ACTIVE;2.32;2.73 +5912-1;Creatine kinase isoenzymes;Imp;Pt;Ser/Plas;Nom;;CHEM;1;Creatine kinase isoenzymes [Interpretation] in Serum or Plasma;CK Isos SerPl-Imp;;ACTIVE;1.0b;2.73 +59121-4;Time to peak;Time;Pt;Circulatory system.XXX;Qn;US;CARD.US;2;Time to peak by US;Time to peak US;;ACTIVE;2.32;2.32 +59122-2;C-E excursion;Len;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve C-E distance [Length] by US;Valve C-E distance US;;ACTIVE;2.32;2.48 +59123-0;Cross section.jet;Area;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve Jet cross-section [Area] by US;Valve Jet Xsection Area US;;ACTIVE;2.32;2.48 +59124-8;Blood velocity-time integral.E wave;Len;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Velocity-time integral (VTI) for the area under E wave by US;LV VTI E-wave US;;ACTIVE;2.32;2.58 +59125-5;Blood velocity-time integral.A wave;Len;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Velocity-time integral (VTI) for the area under A wave by US;LV VTI A-wave US;;ACTIVE;2.32;2.58 +59126-3;B-C slope;Vel;Pt;Pulmonic valve;Qn;US;CARD.US;2;Pulmonic valve B-C slope [Velocity] by US;PV B-C slope US;;ACTIVE;2.32;2.67 +59127-1;D-E slope;Vel;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve D-E slope [Velocity] by US;Valve D-E slope US;;ACTIVE;2.32;2.32 +59128-9;E-F slope;Vel;Pt;Heart.valve.XXX;Qn;US;CARD.US;2;Heart valve E-F slope [Velocity] by US;Valve E-F slope US;;ACTIVE;2.32;2.68 +59129-7;E wave/A wave;VelRto;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular E-wave/A-wave by US;LV E-wave/A-wave US;;ACTIVE;2.32;2.54 +59130-5;Alias velocity;Vel;Pt;Equipment;Qn;US;CARD.US;2;Equipment Alias velocity by US;Equip Alias vel US;;ACTIVE;2.32;2.63 +59131-3;Volume.atrium.left/Volume.atrium.right;VRto;Pt;Heart.atria;Qn;US;CARD.US;2;Atrium Left atrium volume/Right atrium volume by US;Hrt.atria LA vol/RA vol US;;ACTIVE;2.32;2.73 +59132-1;Fractional shortening;LenFr;Pt;Heart.XXX;Qn;US;CARD.US;2;Heart.XXX Fractional shortening by US;Heart.XXX FS US;;ACTIVE;2.32;2.48 +59133-9;Tissue velocity;Vel;Pt;Heart.XXX;Qn;US;CARD.US;2;Heart.XXX Tissue velocity by US;Heart.XXX Tissue velocity US;;ACTIVE;2.32;2.32 +59134-7;ePHEDrine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ePHEDrine [Mass/volume] in Urine by Confirmatory method;Ephedrin Ur Cfm-mCnc;;ACTIVE;2.32;2.70 +59135-4;Benzylpiperazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Benzylpiperazine [Mass/volume] in Urine by Confirmatory method;Benzylpiperazine Ur Cfm-mCnc;;ACTIVE;2.32;2.70 +59136-2;Cells.CD11c+CD103+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD11c+CD103+ cells/100 cells in Bone marrow;CD11c+CD103+ Cells NFr Mar;;ACTIVE;2.32;2.40 +59137-0;Cells.CD5+CD23+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD5+CD23+ cells/100 cells in Bone marrow;CD5+CD23+ Cells NFr Mar;;ACTIVE;2.32;2.40 +59138-8;Cells.CD7+CD34+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD7+CD34+ cells/100 cells in Bone marrow;CD7+CD34+ Cells NFr Mar;;ACTIVE;2.32;2.40 +5913-9;Hemoglobin F/Hemoglobin.total;MFr;Pt;Amnio fld;Qn;;HEM/BC;1;Hemoglobin F/Hemoglobin.total in Amniotic fluid;Hgb F MFr Amn;;ACTIVE;1.0b;2.73 +59139-6;Cells.CD19+CD34+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19+CD34+ cells/100 cells in Bone marrow;CD19+CD34+ Cells NFr Mar;;ACTIVE;2.32;2.40 +59140-4;Cells.CD13+CD34+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD13+CD34+ cells/100 cells in Bone marrow;CD13+CD34+ Cells NFr Mar;;ACTIVE;2.32;2.40 +59141-2;Cells.CD11c-CD103+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11c-CD103+ cells/100 cells in Blood;CD11c-CD103+ Cells NFr Bld;;ACTIVE;2.32;2.40 +59142-0;Cells.CD11c-CD25+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11c-CD25+ cells/100 cells in Blood;CD11c-CD25+ Cells NFr Bld;;ACTIVE;2.32;2.40 +59143-8;Cells.CD19+CD38+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19+CD38+ cells/100 cells in Blood;CD19+CD38+ Cells NFr Bld;;ACTIVE;2.32;2.40 +59144-6;Cells.CD5+CD23+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5+CD23+ cells/100 cells in Blood;CD5+CD23+ Cells NFr Bld;;ACTIVE;2.32;2.40 +59145-3;Cells.CD11c+CD103+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD11c+CD103+ cells [#/volume] in Blood;CD11c+CD103+ Cells # Bld;;ACTIVE;2.32;2.70 +59146-1;Cells.CD11c+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD11c+CD25+ cells [#/volume] in Blood;CD11c+CD25+ Cells # Bld;;ACTIVE;2.32;2.70 +5914-7;Glucose;PrThr;Pt;Bld;Ord;Test strip;CHEM;1;Glucose [Presence] in Blood by Test strip;Glucose Bld Ql Strip;;DISCOURAGED;1.0b;2.56 +59147-9;Cells.CD19+CD38+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD38+ cells [#/volume] in Blood;CD19+CD38+ Cells # Bld;;ACTIVE;2.32;2.70 +59148-7;Calcium^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcium [Moles/volume] in Serum or Plasma --post dialysis;Calcium p dialysis SerPl-sCnc;;ACTIVE;2.32;2.70 +59149-5;Creatine kinase.macromolecular;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Creatine kinase.macromolecular [Presence] in Serum or Plasma;CK Macro SerPl Ql;;ACTIVE;2.32;2.73 +59150-3;Enterococcus species.vancomycin resistant;PrThr;Pt;Anal;Ord;Organism specific culture;MICRO;1;Vancomycin resistant enterococcus [Presence] in Anal by Organism specific culture;VRE Anal Ql Cult;;ACTIVE;2.32;2.73 +59151-1;Enterococcus species.vancomycin resistant;PrThr;Pt;Urine;Ord;Organism specific culture;MICRO;1;Vancomycin resistant enterococcus [Presence] in Urine by Organism specific culture;VRE Ur Ql Cult;;ACTIVE;2.32;2.56 +59152-9;Enterococcus species.vancomycin resistant DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Vancomycin resistant enterococcus DNA [Presence] in Specimen by NAA with probe detection;VRE DNA Spec Ql NAA+probe;;DISCOURAGED;2.32;2.73 +59153-7;Cortisol^5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --5 hours post XXX challenge;Cortis 5h p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +59154-5;Base deficit;SCnc;Pt;BldCo;Qn;;CHEM;1;Base deficit in Cord blood;Base deficit BldCo-sCnc;;ACTIVE;2.32;2.73 +59155-2;17-Hydroxyprogesterone^20M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge;17OHP 20M p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +59156-0;Glucose;SCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Glucose [Moles/volume] in Urine by Automated test strip;Glucose Ur Strip.auto-sCnc;;ACTIVE;2.32;2.73 +59157-8;Glucose^pre dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre dose lactose PO;Glucose pre Lac PO SerPl-sCnc;;ACTIVE;2.32;2.70 +59158-6;Ketones;SCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Ketones [Moles/volume] in Urine by Automated test strip;Ketones Ur Strip.auto-sCnc;;ACTIVE;2.32;2.73 +59159-4;Albumin/Creatinine;Ratio;24H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin/Creatinine [Ratio] in 24 hour Urine;Microalbumin/Creat 24h Ur-Rto;;ACTIVE;2.32;2.73 +59160-2;Cannabinoids;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Cannabinoids [Mass/mass] in Hair;Cannabinoids Hair-mCnt;;ACTIVE;2.32;2.70 +59161-0;Phosphate;SCnc;Pt;Stool;Qn;;CHEM;1;Phosphate [Moles/volume] in Stool;Phosphate Stl-sCnc;;ACTIVE;2.32;2.70 +59162-8;Potassium;SCnc;24H;Stool;Qn;;CHEM;1;Potassium [Moles/volume] in 24 hour Stool;Potassium 24h Stl-sCnc;;ACTIVE;2.32;2.70 +59163-6;Sodium;SCnc;24H;Stool;Qn;;CHEM;1;Sodium [Moles/volume] in 24 hour Stool;Sodium 24h Stl-sCnc;;ACTIVE;2.32;2.70 +59164-4;Alkaline phosphatase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Dialysis fluid;ALP Dial fld-cCnc;;ACTIVE;2.32;2.70 +59165-1;Carbon dioxide;PPres;Pt;Dial fld;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Dialysis fluid;pCO2 Dial fld;;ACTIVE;2.32;2.70 +59166-9;Bilirubin;SRat;24H;Stool;Qn;;CHEM;1;Bilirubin.total [Moles/time] in 24 hour Stool;Bilirub 24h Stl-sRate;;ACTIVE;2.32;2.70 +59167-7;Phosphate;SRat;24H;Stool;Qn;;CHEM;1;Phosphate [Moles/time] in 24 hour Stool;Phosphate 24h Stl-sRate;;ACTIVE;2.32;2.70 +59168-5;Urea;SRat;24H;Stool;Qn;;CHEM;1;Urea [Moles/time] in 24 hour Stool;Urea 24h Stl-sRate;;ACTIVE;2.32;2.70 +59169-3;buPROPion;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;buPROPion [Presence] in Urine;buPROPion Ur Ql;;ACTIVE;2.32;2.73 +5917-0;???lead;MCnc;Pt;Dial fld;Qn;;CHEM;1;Deprecated lead in dialysis fluid;Deprecated ? Dial fld-mCnc;;DEPRECATED;1.0b;2.40 +59170-1;Citalopram;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Citalopram [Presence] in Urine;Citalopram Ur Ql;;ACTIVE;2.32;2.73 +59171-9;Norclozapine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norclozapine [Presence] in Urine;Norclozapine Ur Ql;;ACTIVE;2.32;2.73 +59172-7;Methotrimeprazine metabolite;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methotrimeprazine metabolite [Presence] in Urine;Methotrimeprazine metabolite Ur Ql;;ACTIVE;2.32;2.56 +59174-3;QUEtiapine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;QUEtiapine [Presence] in Urine;QUEtiapine Ur Ql;;ACTIVE;2.32;2.73 +59175-0;QUEtiapine metabolite;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;QUEtiapine metabolite [Presence] in Urine;QUEtiapine metabolite Ur Ql;;ACTIVE;2.32;2.56 +59176-8;Zopiclone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Zopiclone [Presence] in Urine;Zopiclone Ur Ql;;ACTIVE;2.32;2.73 +59177-6;Beta-2-Microglobulin/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Beta-2-Microglobulin/Creatinine [Ratio] in Urine;B2 Microglob/Creat Ur-Rto;;ACTIVE;2.32;2.70 +59178-4;Chloride;SCnc;Pt;Gast fld;Qn;;CHEM;1;Chloride [Moles/volume] in Gastric fluid;Chloride Gast-sCnc;;ACTIVE;2.32;2.70 +59179-2;Insulin^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --fasting;Insulin p fast SerPl-sCnc;;ACTIVE;2.32;2.73 +591-8;Legionella sp;Prid;Pt;Sptc;Nom;Organism specific culture;MICRO;1;Deprecated Legionella sp identified in Sputum (cough) by Organism specific culture;Deprecated Legionella Cult;;DEPRECATED;1.0;2.40 +59180-0;Monoethylglycinexylidide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Monoethylglycinexylidide [Presence] in Urine;MEGX Ur Ql;;ACTIVE;2.32;2.56 +59181-8;Interferon.beta given;Type;Pt;^Patient;Nom;;DRUGDOSE;1;Interferon beta given [Type];IFN-B Gvn;;ACTIVE;2.32;2.40 +59182-6;C reactive protein;MCnc;Pt;CSF;Qn;High sensitivity;CHEM;1;C reactive protein [Mass/volume] in Cerebral spinal fluid by High sensitivity method;CRP CSF HS-mCnc;;ACTIVE;2.32;2.70 +59183-4;Epstein Barr virus early diffuse Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus early diffuse IgG Ab [Presence] in Serum;EBV EA-D IgG Ser Ql;;ACTIVE;2.32;2.73 +59185-9;Hemoglobin H inclusion bodies;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin H inclusion bodies [Presence] in Blood;Hgb H inclusion bodies Bld Ql;;ACTIVE;2.32;2.56 +59186-7;Cyanide;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cyanide [Moles/volume] in Blood;Cyanide Bld-sCnc;;ACTIVE;2.32;2.70 +59187-5;Urea renal clearance/1.73 sq M;ArVRat;24H;Urine+Ser/Plas;Qn;;CHEM;1;Urea renal clearance/1.73 sq M in 24 hour Urine and Serum or Plasma;Urea Cl/1.73 sq M 24h Ur+SerPl-ArVRat;;ACTIVE;2.32;2.70 +5918-8;Urea nitrogen;MCnc;Pt;Dial fld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Dialysis fluid;Urea nit Dial fld-mCnc;;ACTIVE;1.0b;2.73 +59188-3;Alkaline phosphatase.placental;CCnc;Pt;CSF;Qn;;CHEM;1;Alkaline phosphatase.placental [Enzymatic activity/volume] in Cerebral spinal fluid;ALP Plac CSF-cCnc;;ACTIVE;2.32;2.70 +59189-1;Methyl ethyl ketone/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Methyl ethyl ketone/Creatinine [Molar ratio] in Urine;MEK/Creat Ur-sRto;;ACTIVE;2.32;2.70 +59190-9;2-Hydroxycaproate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Hydroxycaproate/Creatinine [Molar ratio] in Urine;2-Hydroxycaproate/Creat Ur-sRto;;ACTIVE;2.32;2.70 +59191-7;2-Ketobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Ketobutyrate/Creatinine [Molar ratio] in Urine;2-Ketobutyrate/Creat Ur-sRto;;ACTIVE;2.32;2.70 +59192-5;3-Methyl crotonate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methyl crotonate/Creatinine [Molar ratio] in Urine;3Me crotonate/Creat Ur-sRto;;ACTIVE;2.32;2.70 +59193-3;Deoxyuridine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deoxyuridine/Creatinine [Molar ratio] in Urine;Deoxyuridine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59194-1;Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1) [Molar ratio] in Serum or Plasma;Tdecenoylcarn/C12:1 SerPl-sRto;;ACTIVE;2.32;2.70 +59195-8;3-Hydroxydodecenoylcarnitine (C12:1-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydodecenoylcarnitine (C12:1-OH) [Moles/volume] in Serum or Plasma;3-OH-dodecenoylcarn SerPl-sCnc;;ACTIVE;2.32;2.70 +5919-6;Creatinine;MCnc;Pt;Dial fld;Qn;;CHEM;1;Creatinine [Mass/volume] in Dialysis fluid;Creat Dial fld-mCnc;;ACTIVE;1.0b;2.73 +59196-6;3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16);SRto;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16) [Molar ratio] in Serum or Plasma;3OH-Palmitoylcarn/C16 SerPl-sRto;;ACTIVE;2.32;2.70 +59197-4;Propionylcarnitine (C3)/Palmitoylcarnitine (C16);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Propionylcarnitine (C3)/Palmitoylcarnitine (C16) [Molar ratio] in Serum or Plasma;Propionylcarn/C16 SerPl-sRto;;ACTIVE;2.32;2.70 +59198-2;Propionylcarnitine (C3)/Acetylcarnitine (C2);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Propionylcarnitine (C3)/Acetylcarnitine (C2) [Molar ratio] in Serum or Plasma;Propionylcarn/C2 SerPl-sRto;;ACTIVE;2.32;2.70 +59199-0;Deoxyadenosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deoxyadenosine/Creatinine [Molar ratio] in Urine;Deoxyadenosine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59200-6;Octanoylcarnitine (C8)/Acetylcarnitine (C2);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Octanoylcarnitine (C8)/Acetylcarnitine (C2) [Molar ratio] in Serum or Plasma;Octanoylcarn/C2 SerPl-sRto;;ACTIVE;2.32;2.70 +59201-4;Deoxyguanosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deoxyguanosine/Creatinine [Molar ratio] in Urine;Deoxyguanosine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59202-2;Deoxyinosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Deoxyinosine/Creatinine [Molar ratio] in Urine;Deoxyinosine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59203-0;Adenine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adenine/Creatinine [Molar ratio] in Urine;Adenine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +5920-4;Protein;MCnc;Pt;Dial fld;Qn;;CHEM;1;Protein [Mass/volume] in Dialysis fluid;Prot Dial fld-mCnc;;ACTIVE;1.0b;2.34 +59204-8;Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)/Acetylcarnitine (C2);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)/Acetylcarnitine (C2) [Molar ratio] in Serum or Plasma;Palmitoyl+Oleoylcarn/C2 SerPl-sRto;;ACTIVE;2.34;2.70 +59205-5;Gamma tocopherol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma tocopherol [Moles/volume] in Serum or Plasma;Gamma tocopherol SerPl-sCnc;;ACTIVE;2.32;2.70 +59206-3;Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Carnitine free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18) [Molar ratio] in Serum or Plasma;Carnitine Free/C16+C18 SerPl-sRto;;ACTIVE;2.32;2.70 +59207-1;Dicarboxyoleylcarnitine (C18:1-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxyoleylcarnitine (C18:1-DC) [Moles/volume] in Serum or Plasma;Dicarboxyoleylcarn SerPl-sCnc;;ACTIVE;2.32;2.73 +59208-9;Octanoylcarnitine (C8)/Decanoylcarnitine (C10);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Octanoylcarnitine (C8)/Decanoylcarnitine (C10) [Molar ratio] in Serum or Plasma;Octanoylcarn/C10 SerPl-sRto;;ACTIVE;2.32;2.70 +59209-7;Gamma hydroxybutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma hydroxybutyrate [Moles/volume] in Serum or Plasma;G-OH-Butyr SerPl-sCnc;;ACTIVE;2.32;2.70 +59210-5;Inosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Inosine/Creatinine [Molar ratio] in Urine;Inosine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59211-3;Transcobalamin I+Transcobalamin III;SCnc;Pt;Ser;Qn;;CHEM;1;Transcobalamin I+Transcobalamin III [Moles/volume] in Serum;Transcobalamin I+III Ser-sCnc;;ACTIVE;2.32;2.70 +5921-2;Lactate dehydrogenase;CCnc;Pt;Dial fld;Qn;;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Dialysis fluid;LDH Dial fld-cCnc;;ACTIVE;1.0b;2.68 +59212-1;Alloisoleucine;SCnc;Pt;Urine;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in Urine;Alloisoleucine Ur-sCnc;;ACTIVE;2.32;2.70 +59213-9;Alloisoleucine;SRat;XXX;Urine;Qn;;CHEM;1;Alloisoleucine [Moles/time] in Urine collected for unspecified duration;Alloisoleucine ?Tm Ur-sRate;;ACTIVE;2.32;2.70 +59214-7;Succinyladenosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Succinyladenosine/Creatinine [Molar ratio] in Urine;Succinyladenosine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59215-4;Thymidine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Thymidine/Creatinine [Molar ratio] in Urine;Thymidine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59216-2;Uridine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Uridine/Creatinine [Molar ratio] in Urine;Uridine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59217-0;Beta-2-Microglobulin;MCnc;Pt;Periton fld;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Peritoneal fluid;B2 Microglob Prt-mCnc;;ACTIVE;2.32;2.70 +59218-8;Beta-2-Microglobulin;MCnc;Pt;Plr fld;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Pleural fluid;B2 Microglob Plr-mCnc;;ACTIVE;2.32;2.70 +59219-6;Testosterone;SCnc;Pt;Plr fld;Qn;;CHEM;1;Testosterone [Moles/volume] in Pleural fluid;Testost Plr-sCnc;;ACTIVE;2.32;2.70 +5922-0;Gastric acid;SCnc;Pt;Gast fld;Qn;;CHEM;1;Gastric acid [Moles/volume] in Gastric fluid;Gastric Ac Gast-sCnc;;ACTIVE;1.0b;2.73 +59220-4;Chromogranin A;ACnc;Pt;Plr fld;Qn;;CHEM;1;Chromogranin A [Units/volume] in Pleural fluid;CgA Plr-aCnc;;ACTIVE;2.32;2.70 +59221-2;Prostate specific Ag;MCnc;Pt;Plr fld;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in Pleural fluid;PSA Plr-mCnc;;ACTIVE;2.32;2.70 +59222-0;Squamous cell carcinoma Ag;MCnc;Pt;Plr fld;Qn;;CHEM;1;Squamous cell carcinoma Ag [Mass/volume] in Pleural fluid;SCC Ag Plr-mCnc;;ACTIVE;2.32;2.70 +59223-8;Prostate specific Ag;MCnc;Pt;Periton fld;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in Peritoneal fluid;PSA Prt-mCnc;;ACTIVE;2.32;2.73 +59224-6;Prostate specific Ag.free;MCnc;Pt;Periton fld;Qn;;CHEM;1;Prostate Specific Ag Free [Mass/volume] in Peritoneal fluid;PSA Free Prt-mCnc;;ACTIVE;2.32;2.70 +59225-3;Squamous cell carcinoma Ag;MCnc;Pt;Periton fld;Qn;;CHEM;1;Squamous cell carcinoma Ag [Mass/volume] in Peritoneal fluid;SCC Ag Prt-mCnc;;ACTIVE;2.32;2.70 +59226-1;Chromogranin A;ACnc;Pt;Periton fld;Qn;;CHEM;1;Chromogranin A [Units/volume] in Peritoneal fluid;CgA Prt-aCnc;;ACTIVE;2.32;2.70 +59227-9;Chromogranin A;ACnc;Pt;CSF;Qn;;CHEM;1;Chromogranin A [Units/volume] in Cerebral spinal fluid;CgA CSF-aCnc;;ACTIVE;2.32;2.70 +59228-7;Squamous cell carcinoma Ag;MCnc;Pt;CSF;Qn;;CHEM;1;Squamous cell carcinoma Ag [Mass/volume] in Cerebral spinal fluid;SCC Ag CSF-mCnc;;ACTIVE;2.32;2.70 +59229-5;Testosterone;SCnc;Pt;Periton fld;Qn;;CHEM;1;Testosterone [Moles/volume] in Peritoneal fluid;Testost Prt-sCnc;;ACTIVE;2.32;2.70 +59230-3;Prostate specific Ag;MCnc;Pt;CSF;Qn;;CHEM;1;Prostate specific Ag [Mass/volume] in Cerebral spinal fluid;PSA CSF-mCnc;;ACTIVE;2.32;2.70 +59231-1;Prostate specific Ag.free;MCnc;Pt;CSF;Qn;;CHEM;1;Prostate Specific Ag Free [Mass/volume] in Cerebral spinal fluid;PSA Free CSF-mCnc;;ACTIVE;2.32;2.70 +59232-9;Prostate specific Ag.free;MCnc;Pt;Plr fld;Qn;;CHEM;1;Prostate Specific Ag Free [Mass/volume] in Pleural fluid;PSA Free Plr-mCnc;;ACTIVE;2.32;2.70 +59233-7;Testosterone;SCnc;Pt;CSF;Qn;;CHEM;1;Testosterone [Moles/volume] in Cerebral spinal fluid;Testost CSF-sCnc;;ACTIVE;2.32;2.70 +59234-5;Reducing substances;SCnc;Pt;Urine;Qn;;CHEM;1;Reducing substances [Moles/volume] in Urine;Reducing Subs Ur-sCnc;;ACTIVE;2.32;2.70 +59235-2;Prostate specific Ag.free/Prostate specific Ag.total;MFr;Pt;CSF;Qn;;CHEM;1;Prostate Specific Ag Free/Prostate specific Ag.total in Cerebral spinal fluid;PSA Free MFr CSF;;ACTIVE;2.32;2.40 +59236-0;Prostate specific Ag.free/Prostate specific Ag.total;MFr;Pt;Periton fld;Qn;;CHEM;1;Prostate Specific Ag Free/Prostate specific Ag.total in Peritoneal fluid;PSA Free MFr Prt;;ACTIVE;2.32;2.40 +59237-8;Prostate specific Ag.free/Prostate specific Ag.total;MFr;Pt;Plr fld;Qn;;CHEM;1;Prostate Specific Ag Free/Prostate specific Ag.total in Pleural fluid;PSA Free MFr Plr;;ACTIVE;2.32;2.40 +5923-8;Gastric acid.free;SCnc;Pt;Gast fld;Qn;;CHEM;1;Gastric acid free [Moles/volume] in Gastric fluid;Gastric Ac free Gast-sCnc;;ACTIVE;1.0b;2.73 +59238-6;Prostate specific Ag.free/Prostate specific Ag.total;MFr;Pt;Body fld;Qn;;CHEM;1;Prostate Specific Ag Free/Prostate specific Ag.total in Body fluid;PSA Free MFr Fld;;ACTIVE;2.32;2.73 +59239-4;Prostate specific Ag.free;MCnc;Pt;Body fld;Qn;;CHEM;1;Prostate Specific Ag Free [Mass/volume] in Body fluid;PSA Free Fld-mCnc;;ACTIVE;2.32;2.70 +59240-2;Testosterone;SCnc;Pt;Body fld;Qn;;CHEM;1;Testosterone [Moles/volume] in Body fluid;Testost Fld-sCnc;;ACTIVE;2.32;2.70 +59241-0;Chromogranin A;ACnc;Pt;Body fld;Qn;;CHEM;1;Chromogranin A [Units/volume] in Body fluid;CgA Fld-aCnc;;ACTIVE;2.32;2.70 +59242-8;Reducing substances;SCnc;Pt;Stool;Qn;;CHEM;1;Reducing substances [Moles/volume] in Stool;Reducing Subs Stl-sCnc;;ACTIVE;2.32;2.70 +59243-6;Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)/Acetylcarnitine (C2) [Molar ratio] in DBS;Palmitoyl+Oleoylcarn/C2 DBS-sRto;;ACTIVE;2.34;2.70 +59244-4;Arylsulfatase C;CCnt;Pt;WBC;Qn;;CHEM;1;Arylsulfatase C [Enzymatic activity/mass] in Leukocytes;Arylsulfatase C WBC-cCnt;;ACTIVE;2.32;2.70 +59245-1;Alanine glyoxylate aminotransferase;CCnt;Pt;Tiss;Qn;;CHEM;1;Alanine glyoxylate aminotransferase [Enzymatic activity/mass] in Tissue;AGT Tiss-cCnt;;ACTIVE;2.32;2.70 +5924-6;pH;LsCnc;Pt;Gast fld;Qn;;CHEM;1;Deprecated pH of Gastric fluid;Deprecated pH Gast-LsCnc;;DEPRECATED;1.0b;2.36 +59246-9;Palmitoyl protein thioesterase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Palmitoyl protein thioesterase [Enzymatic activity/volume] in DBS;PPT DBS-cCnc;;ACTIVE;2.36;2.70 +59247-7;Tetrahydrobiopterin;SCnc;Pt;CSF;Qn;;CHEM;1;Tetrahydrobiopterin [Moles/volume] in Cerebral spinal fluid;Biopterin H4 CSF-sCnc;;ACTIVE;2.32;2.70 +59248-5;Cholesterol esterase;CCnt;Pt;Tiss;Qn;;CHEM;1;Cholesterol esterase [Enzymatic activity/mass] in Tissue;Cholest Est Tiss-cCnt;;ACTIVE;2.32;2.70 +59249-3;Acylcarnitine/Acylcarnitine+Carnitine Free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Acylcarnitine/Acylcarnitine+Carnitine Free (C0) [Molar ratio] in DBS;Acylcarnitine/Acyl+C0 DBS-sRto;;ACTIVE;2.32;2.70 +59250-1;Tocopherols/Cholesterol;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Tocopherols/Cholesterol [Molar ratio] in Serum or Plasma;Tocopherols/Cholest SerPl-sRto;;ACTIVE;2.32;2.70 +59251-9;N-carbamoyl beta alanine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N-carbamoyl beta alanine/Creatinine [Molar ratio] in Urine;N-carbamoyl B-alanine/Creat Ur-sRto;;ACTIVE;2.32;2.73 +59252-7;Homocysteine cysteine disulfide;SCnc;Pt;CSF;Qn;;CHEM;1;Homocysteine cysteine disulfide [Moles/volume] in Cerebral spinal fluid;Hycs-Cys diS CSF-sCnc;;ACTIVE;2.32;2.70 +5925-3;Gastric acid;Vol;Pt;Gast fld;Qn;;CHEM;1;Gastric acid [Volume] in Gastric fluid;Gastric Ac Vol Gast;;ACTIVE;1.0b;2.21 +59253-5;Homocysteine cysteine disulfide;SCnc;Pt;Urine;Qn;;CHEM;1;Homocysteine cysteine disulfide [Moles/volume] in Urine;Hycs-Cys diS Ur-sCnc;;ACTIVE;2.32;2.70 +59254-3;Acylcarnitine/Acylcarnitine+Carnitine Free (C0);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Acylcarnitine/Acylcarnitine+Carnitine Free (C0) [Molar ratio] in Serum or Plasma;Acylcarnitine/Acyl+C0 SerPl-sRto;;ACTIVE;2.32;2.70 +59255-0;Multisection & 3D reconstruction^W contrast IV;Find;Pt;Chest>Heart.atrium.left+Pulmonary veins;Doc;CT.angio;RAD;2;Deprecated Chest>Heart.atrium.left+Pulmonary veins CT angiogram and 3D reconstruction W contrast IV;Deprecated Cht>Ht.LA+Pul v CT.Angio +3DR;;DEPRECATED;2.32;2.58 +59256-8;Cytologist;ID;Pt;XXX;Nom;Cyto stain;CYTO;1;Cytologist who read Cyto stain of Specimen;Cytologist Spec Cyto;;ACTIVE;2.32;2.73 +59257-6;Cell count & Differential panel;-;Pt;Pericard fld;Qn;;PANEL.HEM/BC;1;Cell count and Differential panel - Pericardial fluid;Cell Cnt + Diff Pnl Pcar;;ACTIVE;2.32;2.42 +59258-4;Discharge summary note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Discharge summary;ED D/C sum;;ACTIVE;2.32;2.73 +59259-2;Discharge summary note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Discharge summary;Psychiatric D/C sum;;ACTIVE;2.32;2.73 +592-6;Legionella sp;Prid;Pt;Sptt;Nom;Organism specific culture;MICRO;1;Deprecated Legionella sp identified in Sputum (trach) by Organism specific culture;Deprecated Legionella Sputum trach asp C;;DEPRECATED;1.0;2.40 +59260-0;Hemoglobin;SCnc;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin [Moles/volume] in Blood;Hgb Bld-sCnc;;ACTIVE;2.32;2.73 +5926-1;Sodium;SCnc;Pt;Dial fld;Qn;;CHEM;1;Deprecated Sodium [Molecules/volume] in Dialysis fluid;Deprecated Sodium Dial fld-sCnc;;DEPRECATED;1.0b;2.36 +59261-8;Hemoglobin A1c/Hemoglobin.total;SFr;Pt;Bld;Qn;IFCC;CHEM;1;Hemoglobin A1c/Hemoglobin.total in Blood by IFCC protocol;HbA1c SFr Bld IFCC;;ACTIVE;2.32;2.73 +59262-6;Leukocyte esterase;PrThr;Pt;CSF;Ord;Test strip;UA;1;Leukocyte esterase [Presence] in Cerebral spinal fluid by Test strip;Leukocyte esterase CSF Ql Strip;;ACTIVE;2.32;2.70 +59263-4;Human papilloma virus 16 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 16 DNA [Presence] in Cervix by Probe with signal amplification;HPV16 DNA Cvx Ql Probe+sig amp;;ACTIVE;2.32;2.73 +59264-2;Human papilloma virus 18 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 18 DNA [Presence] in Cervix by Probe with signal amplification;HPV18 DNA Cvx Ql Probe+sig amp;;ACTIVE;2.32;2.73 +59265-9;8-Hydroxydeoxyguanosine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;8-Hydroxydeoxyguanosine/Creatinine [Mass Ratio] in Urine;8OH-deoxyguanosine/Creat Ur;;ACTIVE;2.32;2.70 +59266-7;Maternal cell contamination;Prid;Pt;XXX;Nom;;MOLPATH;1;Maternal cell contamination [Identifier] in Specimen Nominal;Maternal Cell Contam Spec;;ACTIVE;2.32;2.73 +59267-5;Karyotype;Prid;Pt;Bld/Tiss;Nar;FISH;MOLPATH;1;Karyotype [Identifier] in Blood or Tissue by FISH Narrative;Karyotyp Bld/T FISH;;ACTIVE;2.32;2.73 +59268-3;Neonatal care report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Neonatal care report;Neonatal care report;;ACTIVE;2.32;2.73 +59269-1;Respiratory severity score;Pres;Pt;Respiratory system.airway+Inhl Gas;Qn;;PULM;2;Respiratory severity score;Respiratory severity score;;ACTIVE;2.32;2.50 +59270-9;Surgical operative note panel;-;Pt;^Patient;-;;PANEL.DOC;2;Surgical operative note panel;Surgical operative note pnl;;ACTIVE;2.32;2.32 +59271-7;Hospital discharge summary panel;-;Pt;^Patient;-;;PANEL.DOC;2;Hospital discharge summary panel;Hospital discharge summary pnl;;ACTIVE;2.32;2.32 +59272-5;Power setting;Arb;Pt;Ventilator;Ord;;PULM;2;Power setting Ventilator;Power setting Vent;;ACTIVE;2.32;2.70 +59273-3;Cortisol^post 6 mg dexamethasone PO overnight;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --post 6 mg dexamethasone PO overnight;Cortis p 6 mg Dex SerPl-mCnc;;ACTIVE;2.34;2.70 +59274-1;Oxygen content;VFr;Pt;BldA;Qn;Calculated;CHEM;1;Oxygen content in Arterial blood by calculation;O2 Ct VFr BldA Calc;;ACTIVE;2.32;2.73 +59275-8;Oxygen capacity;VFr;Pt;BldA;Qn;;CHEM;1;Oxygen capacity [Volume Fraction] in Arterial blood;O2 Cap VFr BldA;;ACTIVE;2.32;2.73 +59276-6;Calcium hydrogen phosphate dihydrate crystals;PrThr;Pt;Calculus;Ord;XR diffraction;CHEM;1;Calcium hydrogen phosphate dihydrate crystals [Presence] in Stone by X-ray diffraction;Ca H2 Phos dihyd Cry Stone Ql XR diff;;ACTIVE;2.32;2.56 +59277-4;Cystine crystals;PrThr;Pt;Calculus;Ord;XR diffraction;CHEM;1;Cystine crystals [Presence] in Stone by X-ray diffraction;Cystine Cry Stone Ql XR diff;;ACTIVE;2.32;2.56 +59278-2;Calcium oxalate dihydrate crystals;PrThr;Pt;Calculus;Ord;XR diffraction;CHEM;1;Calcium oxalate dihydrate crystals [Presence] in Stone by X-ray diffraction;COD Cry Stone Ql XR diff;;ACTIVE;2.32;2.56 +5927-9;Potassium;SCnc;Pt;Dial fld;Qn;;CHEM;1;Deprecated Potassium [Molecules/volume] in Dialysis fluid;Deprecated Potassium Dial fld-sCnc;;DEPRECATED;1.0b;2.36 +59279-0;Urate crystals;PrThr;Pt;Calculus;Ord;XR diffraction;CHEM;1;Urate crystals [Presence] in Stone by X-ray diffraction;Urate Cry Stone Ql XR diff;;ACTIVE;2.32;2.56 +59280-8;Urate dihydrate crystals;PrThr;Pt;Calculus;Ord;XR diffraction;CHEM;1;Urate dihydrate crystals [Presence] in Stone by X-ray diffraction;Urate dihyd Cry Stone Ql XR diff;;ACTIVE;2.32;2.56 +5928-1;Chloride;SCnc;Pt;Dial fld;Qn;;CHEM;1;Deprecated Chloride [Molecules/volume] in Dialysis fluid;Deprecated Chloride Dial fld-sCnc;;DEPRECATED;1.0b;2.36 +59281-6;Multisection transthoracic;Find;Pt;Chest>Heart;Doc;US;CARD.US;2;US Heart Transthoracic;US Heart Transthoracic;;ACTIVE;2.32;2.64 +59282-4;Cardiac stress echo study;Find;Pt;Heart;Doc;US;CARD.US;2;Cardiac stress echo study;Stress cardiac echo study;;ACTIVE;2.32;2.72 +59283-2;Well child visit note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Well child visit note;Well child visit note;;ACTIVE;2.32;2.67 +59284-0;Consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Consent Document;Consent;;ACTIVE;2.32;2.65 +59285-7;Benzylpiperazine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Benzylpiperazine [Mass/volume] in Blood;Benzylpiperazine Bld-mCnc;;ACTIVE;2.32;2.70 +59286-5;Benzylpiperazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benzylpiperazine [Mass/volume] in Serum or Plasma;Benzylpiperazine SerPl-mCnc;;ACTIVE;2.32;2.70 +59287-3;Benzylpiperazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzylpiperazine [Mass/volume] in Urine;Benzylpiperazine Ur-mCnc;;ACTIVE;2.32;2.70 +59288-1;Bisphenol A;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bisphenol A [Mass/volume] in Urine;Bisphenol A Ur-mCnc;;ACTIVE;2.32;2.73 +59289-9;Iloperidone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Iloperidone [Mass/volume] in Blood;Iloperidone Bld-mCnc;;ACTIVE;2.32;2.70 +59290-7;Iloperidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Iloperidone [Mass/volume] in Serum or Plasma;Iloperidone SerPl-mCnc;;ACTIVE;2.32;2.70 +59291-5;Levamisole;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Levamisole [Mass/volume] in Blood;Levamisole Bld-mCnc;;ACTIVE;2.32;2.70 +59292-3;Levamisole;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Levamisole [Mass/volume] in Body fluid;Levamisole Fld-mCnc;;ACTIVE;2.32;2.70 +59293-1;Levamisole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Levamisole [Mass/volume] in Serum or Plasma;Levamisole SerPl-mCnc;;ACTIVE;2.32;2.70 +59294-9;Levamisole;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Levamisole [Mass/mass] in Tissue;Levamisole Tiss-mCnt;;ACTIVE;2.32;2.70 +5929-5;Candida albicans reaction wheal^3D post 50 ug Candida albicans ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Candida albicans reaction wheal [Diameter] --3 days post 50 ug Candida albicans intradermal;Wheal 3D p 50ug C albicans Diam;;ACTIVE;1.0b;2.42 +59295-6;Levamisole;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Levamisole [Mass/volume] in Urine;Levamisole Ur-mCnc;;ACTIVE;2.32;2.70 +59296-4;Lacosamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Lacosamide [Mass/volume] in Blood;Lacosamide Bld-mCnc;;ACTIVE;2.32;2.73 +59297-2;Lacosamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lacosamide [Mass/volume] in Serum or Plasma;Lacosamide SerPl-mCnc;;ACTIVE;2.32;2.73 +59298-0;Lacosamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Lacosamide [Mass/volume] in Urine;Lacosamide Ur-mCnc;;ACTIVE;2.32;2.70 +59299-8;Desloratadine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Desloratadine [Mass/volume] in Blood;Desloratadine Bld-mCnc;;ACTIVE;2.32;2.70 +59300-4;Desloratadine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desloratadine [Mass/volume] in Serum or Plasma;Desloratadine SerPl-mCnc;;ACTIVE;2.32;2.70 +59301-2;Desloratadine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Desloratadine [Mass/volume] in Urine;Desloratadine Ur-mCnc;;ACTIVE;2.32;2.70 +59302-0;Memantine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Memantine [Mass/volume] in Blood;Memantine Bld-mCnc;;ACTIVE;2.32;2.70 +5930-3;Mumps reaction wheal^3D post 0.1 mL mumps ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Mumps reaction wheal [Diameter] --3 days post 0.1 mL mumps intradermal;Wheal 3D p .1mL Mumps Diam;;ACTIVE;1.0c;2.26 +59303-8;Memantine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Memantine [Mass/volume] in Body fluid;Memantine Fld-mCnc;;ACTIVE;2.32;2.70 +59304-6;Memantine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Memantine [Mass/volume] in Serum or Plasma;Memantine SerPl-mCnc;;ACTIVE;2.32;2.70 +59305-3;Memantine;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Memantine [Mass/mass] in Tissue;Memantine Tiss-mCnt;;ACTIVE;2.32;2.70 +59306-1;Memantine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Memantine [Mass/volume] in Urine;Memantine Ur-mCnc;;ACTIVE;2.32;2.70 +59307-9;Metaxalone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Metaxalone [Mass/volume] in Blood;Metaxalone Bld-mCnc;;ACTIVE;2.32;2.70 +59308-7;Metaxalone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metaxalone [Mass/volume] in Serum or Plasma;Metaxalone SerPl-mCnc;;ACTIVE;2.32;2.70 +59309-5;Metaxalone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Metaxalone [Mass/volume] in Urine;Metaxalone Ur-mCnc;;ACTIVE;2.32;2.70 +59310-3;Milnacipran;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Milnacipran [Mass/volume] in Blood;Milnacipran Bld-mCnc;;ACTIVE;2.32;2.70 +5931-1;Trichophyton reaction wheal^3D post 50 ug trichophyton ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Trichophyton reaction wheal [Diameter] --3 days post 50 ug trichophyton intradermal;Wheal 3D p 50ug Trichophyt Diam;;ACTIVE;1.0c;2.42 +59311-1;Milnacipran;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Milnacipran [Mass/volume] in Serum or Plasma;Milnacipran SerPl-mCnc;;ACTIVE;2.32;2.70 +59312-9;Milnacipran;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Milnacipran [Mass/volume] in Urine;Milnacipran Ur-mCnc;;ACTIVE;2.32;2.70 +59313-7;Ramelteon M-II;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ramelteon M-II [Mass/volume] in Blood;Ramelteon M-II Bld-mCnc;;ACTIVE;2.32;2.70 +59314-5;Ramelteon;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ramelteon [Mass/volume] in Blood;Ramelteon Bld-mCnc;;ACTIVE;2.32;2.70 +59315-2;Ramelteon M-II;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Ramelteon M-II [Mass/volume] in Body fluid;Ramelteon M-II Fld-mCnc;;ACTIVE;2.32;2.70 +59316-0;Ramelteon;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Ramelteon [Mass/volume] in Body fluid;Ramelteon Fld-mCnc;;ACTIVE;2.32;2.70 +59317-8;Ramelteon M-II;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ramelteon M-II [Mass/volume] in Serum or Plasma;Ramelteon M-II SerPl-mCnc;;ACTIVE;2.32;2.70 +59318-6;Ramelteon;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ramelteon [Mass/volume] in Serum or Plasma;Ramelteon SerPl-mCnc;;ACTIVE;2.32;2.70 +59319-4;Ramelteon M-II;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Ramelteon M-II [Mass/mass] in Tissue;Ramelteon M-II Tiss-mCnt;;ACTIVE;2.32;2.70 +59320-2;Ramelteon;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Ramelteon [Mass/mass] in Tissue;Ramelteon Tiss-mCnt;;ACTIVE;2.32;2.70 +59321-0;Ramelteon M-II;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ramelteon M-II [Mass/volume] in Urine;Ramelteon M-II Ur-mCnc;;ACTIVE;2.32;2.70 +59322-8;Ramelteon;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ramelteon [Mass/volume] in Urine;Ramelteon Ur-mCnc;;ACTIVE;2.32;2.70 +59323-6;Rufinamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Rufinamide [Mass/volume] in Serum or Plasma;Rufinamide SerPl-mCnc;;ACTIVE;2.32;2.73 +59324-4;Salvinorin A;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Salvinorin A [Mass/volume] in Blood;Salvinorin A Bld-mCnc;;ACTIVE;2.32;2.70 +59325-1;Salvinorin B;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Salvinorin B [Mass/volume] in Blood;Salvinorin B Bld-mCnc;;ACTIVE;2.32;2.70 +59326-9;Salvinorin A;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salvinorin A [Mass/volume] in Serum or Plasma;Salvinorin A SerPl-mCnc;;ACTIVE;2.32;2.70 +59327-7;Salvinorin B;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salvinorin B [Mass/volume] in Serum or Plasma;Salvinorin B SerPl-mCnc;;ACTIVE;2.32;2.70 +59328-5;Salvinorin A;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Salvinorin A [Mass/volume] in Urine;Salvinorin A Ur-mCnc;;ACTIVE;2.32;2.73 +5932-9;Cholesterol;PrThr;Pt;Bld;Ord;Test strip;CHEM;1;Cholesterol [Presence] in Blood by Test strip;Cholest Bld Ql Strip;;ACTIVE;1.0d;2.73 +59329-3;Salvinorin B;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Salvinorin B [Mass/volume] in Urine;Salvinorin B Ur-mCnc;;ACTIVE;2.32;2.73 +59330-1;Norsibutramine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Norsibutramine [Mass/volume] in Blood;Norsibutramine Bld-mCnc;;ACTIVE;2.32;2.70 +59331-9;Dinorsibutramine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dinorsibutramine [Mass/volume] in Blood;Dinorsibutramine Bld-mCnc;;ACTIVE;2.32;2.70 +59332-7;Sibutramine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Sibutramine [Mass/volume] in Blood;Sibutramine Bld-mCnc;;ACTIVE;2.32;2.70 +59333-5;Norsibutramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norsibutramine [Mass/volume] in Serum or Plasma;Norsibutramine SerPl-mCnc;;ACTIVE;2.32;2.70 +59334-3;Dinorsibutramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dinorsibutramine [Mass/volume] in Serum or Plasma;Dinorsibutramine SerPl-mCnc;;ACTIVE;2.32;2.70 +59335-0;Sibutramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sibutramine [Mass/volume] in Serum or Plasma;Sibutramine SerPl-mCnc;;ACTIVE;2.32;2.70 +59336-8;Norsibutramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norsibutramine [Mass/volume] in Urine;Norsibutramine Ur-mCnc;;ACTIVE;2.32;2.70 +5933-7;Lead;MCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Dialysis fluid;Lead Dial fld-mCnc;;ACTIVE;1.0d;2.34 +59337-6;Dinorsibutramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dinorsibutramine [Mass/volume] in Urine;Dinorsibutramine Ur-mCnc;;ACTIVE;2.32;2.70 +59338-4;Sibutramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sibutramine [Mass/volume] in Urine;Sibutramine Ur-mCnc;;ACTIVE;2.32;2.70 +59339-2;Stiripentol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Stiripentol [Mass/volume] in Blood;Stiripentol Bld-mCnc;;ACTIVE;2.32;2.70 +593-4;Legionella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Specimen by Organism specific culture;Legionella Spec Cult;;ACTIVE;1.0;2.73 +59340-0;Stiripentol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Stiripentol [Mass/volume] in Serum or Plasma;Stiripentol SerPl-mCnc;;ACTIVE;2.32;2.70 +59341-8;Stiripentol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Stiripentol [Mass/volume] in Urine;Stiripentol Ur-mCnc;;ACTIVE;2.32;2.70 +59342-6;Tadalafil;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tadalafil [Mass/volume] in Blood;Tadalafil Bld-mCnc;;ACTIVE;2.32;2.70 +59343-4;Tadalafil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tadalafil [Mass/volume] in Serum or Plasma;Tadalafil SerPl-mCnc;;ACTIVE;2.32;2.70 +59344-2;Tadalafil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tadalafil [Mass/volume] in Urine;Tadalafil Ur-mCnc;;ACTIVE;2.32;2.70 +5934-5;Blood group antigens absent;Prid;Pt;BBL;Nom;;BLDBK;1;Deprecated Blood group antigens absent [Identifier] in Blood product unit;Deprecated Antigens Absent BBL;;DEPRECATED;1.0d;2.36 +59345-9;Endoxifen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Endoxifen [Mass/volume] in Blood;Endoxifen Bld-mCnc;;ACTIVE;2.32;2.70 +59346-7;4-Hydroxy-Tamoxifen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;4-Hydroxy-Tamoxifen [Mass/volume] in Blood;4OHTamoxifen Bld-mCnc;;ACTIVE;2.32;2.70 +59347-5;Tamoxifen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tamoxifen [Mass/volume] in Blood;Tamoxifen Bld-mCnc;;ACTIVE;2.32;2.70 +59348-3;Nortamoxifen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Nortamoxifen [Mass/volume] in Blood;Nortamoxifen Bld-mCnc;;ACTIVE;2.32;2.70 +59349-1;Endoxifen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Endoxifen [Mass/volume] in Serum or Plasma;Endoxifen SerPl-mCnc;;ACTIVE;2.32;2.73 +59350-9;4-Hydroxy-Tamoxifen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;4-Hydroxy-Tamoxifen [Mass/volume] in Serum or Plasma;4OHTamoxifen SerPl-mCnc;;ACTIVE;2.32;2.73 +59351-7;Nortamoxifen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortamoxifen [Mass/volume] in Serum or Plasma;Nortamoxifen SerPl-mCnc;;ACTIVE;2.32;2.73 +5935-2;Benzoylecgonine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Benzoylecgonine [Mass/volume] in Urine;Deprecated BZE Ur-mCnc;;DEPRECATED;1.0d;2.36 +59352-5;Tapentadol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tapentadol [Mass/volume] in Blood;Tapentadol Bld-mCnc;;ACTIVE;2.32;2.73 +59353-3;Tapentadol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Tapentadol [Mass/volume] in Body fluid;Tapentadol Fld-mCnc;;ACTIVE;2.32;2.70 +59354-1;Tapentadol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tapentadol [Mass/volume] in Serum or Plasma;Tapentadol SerPl-mCnc;;ACTIVE;2.32;2.73 +59355-8;Tapentadol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Tapentadol [Mass/mass] in Tissue;Tapentadol Tiss-mCnt;;ACTIVE;2.32;2.70 +59356-6;Desethylvardenafil;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Desethylvardenafil [Mass/volume] in Blood;Desethylvardenafil Bld-mCnc;;ACTIVE;2.32;2.70 +59357-4;Vardenafil;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Vardenafil [Mass/volume] in Blood;Vardenafil Bld-mCnc;;ACTIVE;2.32;2.70 +59358-2;Desethylvardenafil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desethylvardenafil [Mass/volume] in Serum or Plasma;Desethylvardenafil SerPl-mCnc;;ACTIVE;2.32;2.70 +59359-0;Vardenafil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vardenafil [Mass/volume] in Serum or Plasma;Vardenafil SerPl-mCnc;;ACTIVE;2.32;2.70 +5936-0;Benzoylecgonine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/mass] in Hair;BZE Hair-mCnt;;ACTIVE;1.0d;2.73 +59360-8;Desethylvardenafil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Desethylvardenafil [Mass/volume] in Urine;Desethylvardenafil Ur-mCnc;;ACTIVE;2.32;2.70 +59361-6;Vardenafil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Vardenafil [Mass/volume] in Urine;Vardenafil Ur-mCnc;;ACTIVE;2.32;2.70 +59362-4;Race or ethnicity;Type;Pt;^Patient;Nom;OMB.1997;CLIN;2;Race or ethnicity OMB.1997;Race or ethnicity OMB.1997;;ACTIVE;2.32;2.63 +59363-2;Leptospira interrogans serovar Manhao Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Manhao Ab [Titer] in Serum by Agglutination;L inter Manhao Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59364-0;Leptospira interrogans serovar Pyrogenes Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Pyrogenes Ab [Titer] in Serum by Agglutination;L inter Pyrogenes Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59365-7;Leptospira interrogans serovar Mini Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Mini Ab [Titer] in Serum by Agglutination;L inter Mini Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59366-5;Leptospira interrogans serovar Sejroe Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Sejroe Ab [Titer] in Serum by Agglutination;L inter Sejroe Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59367-3;Leptospira interrogans serovar Tarassovi Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Tarassovi Ab [Titer] in Serum by Agglutination;L inter Tarassovi Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59368-1;Leptospira interrogans serovar Bataviae Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Bataviae Ab [Titer] in Serum by Agglutination;L inter Batav Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59369-9;Leptospira interrogans serovar Hebdomadis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Hebdomadis Ab [Titer] in Serum by Agglutination;L inter Hebdo Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59370-7;Leptospira interrogans serovar Australis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Australis Ab [Titer] in Serum by Agglutination;L inter Austral Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59371-5;Leptospira interrogans serovar Autumnalis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Autumnalis Ab [Titer] in Serum by Agglutination;L inter Autum Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59372-3;Leptospira interrogans serovar Ballum Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Ballum Ab [Titer] in Serum by Agglutination;L inter Ballum Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59373-1;Special treatments &or programs - none of above - while a resident;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Special treatments andor programs - none of above - while a resident [MDSv3];;;ACTIVE;2.32;2.44 +59374-9;Special treatments &or programs - none of above - while NOT a resident;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Special treatments andor programs - none of above - while NOT a resident [MDSv3];;;ACTIVE;2.32;2.44 +59375-6;Medicare non-therapy Part A billing;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Medicare non-therapy Part A billing [CMS Assessment];;;ACTIVE;2.32;2.63 +59376-4;3-Keto, 2-Methylvalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Keto, 2-Methylvalerate/Creatinine [Molar ratio] in Urine;3-Keto, 2-Methylvalerate/Creat Ur-sRto;;ACTIVE;2.32;2.70 +59377-2;2-Methylacetoacetate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methylacetoacetate/Creatinine [Molar ratio] in Urine;2-Methylacetoacetate/Creat Ur-sRto;;ACTIVE;2.32;2.73 +5937-8;Cocaine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Cocaine [Mass/volume] in Urine;Deprecated Cocaine Ur-mCnc;;DEPRECATED;1.0d;2.40 +59378-0;Amikacin^post dialysis;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin [Mass/volume] in Serum or Plasma --post dialysis;Amikacin p dialysis SerPl-mCnc;;ACTIVE;2.32;2.70 +59379-8;Gentamicin^post dialysis;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Mass/volume] in Serum or Plasma --post dialysis;Gentamicin p dialysis SerPl-mCnc;;ACTIVE;2.32;2.70 +59380-6;Tobramycin^post dialysis;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin [Mass/volume] in Serum or Plasma --post dialysis;Tobramycin p dialysis SerPl-mCnc;;ACTIVE;2.32;2.70 +59381-4;Vancomycin^post dialysis;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Serum or Plasma --post dialysis;Vancomycin p dialysis SerPl-mCnc;;ACTIVE;2.32;2.70 +59382-2;Aspergillus versicolor Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus versicolor IgG Ab [Mass/volume] in Serum;A versicolor IgG-mCnc;;ACTIVE;2.32;2.73 +59383-0;Hydroxyproline/Creatinine;MRto;2H;Urine;Qn;;CHEM;1;Hydroxyproline/Creatinine [Mass Ratio] in 2 hour Urine;OH-Proline/Creat 2h Ur;;ACTIVE;2.32;2.70 +59384-8;Acetaminophen;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Acetaminophen [Presence] in Urine by Screen method;APAP Ur Ql Scn;;ACTIVE;2.32;2.73 +59385-5;Nitrogen;MCnt;Pt;Stool;Qn;Infrared spectroscopy;CHEM;1;Nitrogen [Mass/mass] in Stool by Infrared spectroscopy;N2 Stl IR-mCnt;;ACTIVE;2.34;2.70 +5938-6;Benzoylecgonine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Benzoylecgonine [Presence] in Hair;BZE Hair Ql;;ACTIVE;1.0d;2.56 +59386-3;Starch;MCnt;Pt;Stool;Qn;Infrared spectroscopy;CHEM;1;Starch [Mass/mass] in Stool by Infrared spectroscopy;Starch Stl IR-mCnt;;ACTIVE;2.34;2.70 +59387-1;Trypanosoma cruzi Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Trypanosoma cruzi IgG Ab [Units/volume] in Serum by Immunoassay;T cruzi IgG Ser IA-aCnc;;ACTIVE;2.32;2.73 +59388-9;Taenia solium larva DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Taenia solium larva DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;T sol lar DNA CSF Ql NAA+probe;;ACTIVE;2.32;2.63 +59389-7;Androstanolone^1.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge;Androstanolone 1.5h p chal SerPl-mCnc;;ACTIVE;2.32;2.34 +59390-5;Neuronal nuclear Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear Ab [Titer] in Serum by Immunofluorescence;Hu Ab Titr Ser IF;;ACTIVE;2.32;2.73 +59391-3;Prunus persica recombinant (rPru p) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peach recombinant (rPru p) 3 IgE Ab [Units/volume] in Serum;Peach (rPru p) 3 IgE Qn;;ACTIVE;2.32;2.70 +59392-1;Hydroxyproline;MCnc;24H;Urine;Qn;;CHEM;1;Hydroxyproline [Mass/volume] in 24 hour Urine;OH-Proline 24h Ur-mCnc;;ACTIVE;2.32;2.34 +59393-9;Trypanosoma cruzi Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Trypanosoma cruzi IgG Ab [Titer] in Serum by Immunofluorescence;T cruzi IgG Titr Ser IF;;ACTIVE;2.32;2.32 +5939-4;Benzoylecgonine;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Benzoylecgonine [Presence] in Urine;Deprecated BZE Ur Ql;;DEPRECATED;1.0d;2.36 +59394-7;Glomerular basement membrane Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Glomerular basement membrane Ab [Units/volume] in Serum by Immunoassay;GBM Ab Ser IA-aCnc;;ACTIVE;2.32;2.73 +59395-4;Latex recombinant (rHev b) 9 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 9 IgE Ab [Units/volume] in Serum;Latex (rHev b) 9 IgE Qn;;ACTIVE;2.32;2.70 +59396-2;Echovirus Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Echovirus IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ECV IgM CSF IA-aCnc;;ACTIVE;2.32;2.70 +59397-0;Echovirus Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Echovirus IgG Ab [Units/volume] in Cerebral spinal fluid;ECV IgG CSF-aCnc;;ACTIVE;2.32;2.70 +59398-8;Ascorbate;MCnc;Pt;Semen;Qn;;CHEM;1;Ascorbate [Mass/volume] in Semen;Vit C Smn-mCnc;;ACTIVE;2.32;2.34 +59399-6;PM-1 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;PM-1 Ab [Titer] in Serum by Immunofluorescence;PM1 Ab Titr Ser IF;;ACTIVE;2.32;2.32 +59400-2;RNA Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;RNA Ab [Units/volume] in Serum by Immunoassay;RNA Ab Ser IA-aCnc;;ACTIVE;2.32;2.70 +59401-0;Echovirus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echovirus IgG Ab [Units/volume] in Serum by Immunoassay;ECV IgG Ser IA-aCnc;;ACTIVE;2.32;2.70 +5940-2;Cocaine;ACnc;Pt;Ser;Ord;;DRUG/TOX;1;Deprecated Cocaine [Presence] in Serum or Plasma;Deprecated Cocaine Ser Ql;;DEPRECATED;1.0d;2.36 +59402-8;Mi-1+Mi-2 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Mi-1+Mi-2 Ab [Titer] in Serum by Immunofluorescence;Mi-1+Mi-2 Ab Titr Ser IF;;ACTIVE;2.32;2.32 +59403-6;Ku Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Ku Ab [Titer] in Serum by Immunofluorescence;Ku Ab Titr Ser IF;;ACTIVE;2.32;2.73 +59404-4;Oxygen capacity;SCnc;Pt;BldA;Qn;;CHEM;1;Oxygen capacity [Moles/volume] in Arterial blood;O2 Cap BldA-sCnc;;ACTIVE;2.32;2.73 +59405-1;Oxygen saturation;MFr;8H^max;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation (8 hour maximum) in Arterial blood Pulse oximetry;SaO2 8h Max % BldA PulseOx;;ACTIVE;2.32;2.70 +59406-9;Oxygen saturation;MFr;8H^min;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation (8 hour minimum) in Arterial blood Pulse oximetry;SaO2 8h Min % BldA PulseOx;;ACTIVE;2.32;2.70 +59407-7;Oxygen saturation;MFr;Pt;Bld.preductal;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Blood Preductal by Pulse oximetry;SaO2 % Bld Preductal PulseOx;;ACTIVE;2.32;2.73 +59408-5;Oxygen saturation;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry;SaO2 % BldA PulseOx;;ACTIVE;2.32;2.73 +59409-3;Oxygen saturation^during treatment;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --during treatment;SaO2 during Tx % BldA PulseOx;;ACTIVE;2.32;2.70 +5941-0;Cocaine;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Cocaine [Mass/volume] in Serum or Plasma;Deprecated Cocaine Ser-mCnc;;DEPRECATED;1.0d;2.36 +59410-1;Oxygen saturation^on room air;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --on room air;SaO2 room air % BldA PulseOx;;ACTIVE;2.32;2.70 +59411-9;Oxygen saturation^post bronchodilation;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --post bronchodilation;SaO2 p BD % BldA PulseOx;;ACTIVE;2.32;2.70 +59412-7;Oxygen saturation^post exercise;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --post exercise;SaO2 p Exc % BldA PulseOx;;ACTIVE;2.32;2.73 +59413-5;Oxygen saturation^post treatment;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --post treatment;SaO2 p Tx % BldA PulseOx;;ACTIVE;2.32;2.70 +59414-3;Oxygen saturation^pre bronchodilation;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --pre bronchodilation;SaO2 pre BD % BldA PulseOx;;ACTIVE;2.32;2.70 +59415-0;Oxygen saturation^pre physiotherapy;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --pre physiotherapy;SaO2 pre PT % BldA PulseOx;;ACTIVE;2.32;2.70 +59416-8;Oxygen saturation^pre treatment;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --pre treatment;SaO2 pre Tx % BldA PulseOx;;ACTIVE;2.32;2.70 +59417-6;Oxygen saturation^resting;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Arterial blood by Pulse oximetry --resting;SaO2 Resting % BldA PulseOx;;ACTIVE;2.32;2.73 +59418-4;Oxygen saturation;MFr;Pt;Bld.postductal;Qn;Pulse oximetry;PULM;2;Oxygen saturation in Blood Postductal by Pulse oximetry;SaO2 % Bld Postductal PulseOx;;ACTIVE;2.32;2.73 +59419-2;HIV 1 RNA;NCnc;Pt;Plas;Qn;Probe.amp.sig;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Plasma by Probe with signal amplification;HIV1 RNA # Plas Probe+sig amp;;ACTIVE;2.32;2.73 +594-2;Leptospira sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Leptospira sp identified in Specimen by Organism specific culture;Leptospira Spec Cult;;ACTIVE;1.0;2.73 +59420-0;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Cervix by Probe with signal amplification;HPV I/H Risk 4 DNA Cvx Ql Probe+sig amp;;ACTIVE;2.32;2.73 +59421-8;Neisseria meningitidis serogroups A+B+C+w135+Y Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroups A+B+C+w135+Y Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg A+B+C+W135+Y Ag CSF Ql LA;;ACTIVE;2.32;2.64 +59422-6;Leptospira interrogans serovar Javanica Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Javanica Ab [Titer] in Serum by Agglutination;L inter Javani Ab Titr Ser Aggl;;ACTIVE;2.32;2.32 +59423-4;Influenza virus A hemagglutinin type RNA;ID;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Influenza virus A hemagglutinin type RNA [Identifier] in Specimen by NAA with probe detection;FLUAV HA RNA Spec NAA+probe;;ACTIVE;2.32;2.69 +59424-2;Influenza virus A hemagglutinin type RNA;ID;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Influenza virus A hemagglutinin type RNA [Identifier] in Isolate by NAA with probe detection;FLUAV HA RNA Islt NAA+probe;;ACTIVE;2.32;2.63 +5942-8;Coagulation reptilase induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Reptilase time in Control Platelet poor plasma by Coagulation assay;Reptilase time Cont PPP;;ACTIVE;1.0d;2.73 +5943-6;Coagulation reptilase induced;Time;Pt;PPP^Control;Qn;Tilt tube;COAG;1;Deprecated Reptilase time in Platelet poor plasma from control by Coagulation assay;Deprecated Reptilase PPP Cont Qn;;DEPRECATED;1.0d;2.36 +5944-4;Coagulation Russell viper venom induced;Time;Pt;PPP^Control;Qn;Tilt tube;COAG;1;Deprecated Russell viper venom time in Platelet poor plasma from control by Coagulation assay;Deprecated Coag RVV Ind PPP Cont Qn;;DEPRECATED;1.0d;2.36 +5945-1;Coagulation Russell viper venom induced;Time;Pt;PPP;Qn;Tilt tube;COAG;1;Deprecated Russell viper venom time in Platelet poor plasma by Coagulation assay;Deprecated Coag RVV Ind PPP Qn;;DEPRECATED;1.0d;2.36 +59453-1;Morse Fall Scale panel;Find;Pt;^Patient;Ord;;PANEL.SURVEY.MFS;4;Morse Fall Scale panel;;;ACTIVE;2.32;2.32 +59454-9;"History of falling; immediate or within 3Mo";Find;Pt;^Patient;Ord;Morse Fall Scale;SURVEY.MFS;4;"History of falling; immediate or within 3 months [Morse Fall Scale]";;;ACTIVE;2.32;2.44 +59455-6;Secondary diagnosis is present;Find;Pt;^Patient;Ord;;SURVEY.MFS;4;Secondary diagnosis is present;;;ACTIVE;2.32;2.68 +59456-4;Ambulatory aid;Find;Pt;^Patient;Ord;Morse Fall Scale;SURVEY.MFS;4;Ambulatory aid [Morse Fall Scale];;;ACTIVE;2.32;2.44 +59457-2;Intravenous apparatus;Find;Pt;^Patient;Ord;Morse Fall Scale;SURVEY.MFS;4;Intravenous apparatus [Morse Fall Scale];;;ACTIVE;2.32;2.44 +59458-0;Gait;Find;Pt;^Patient;Ord;Morse Fall Scale;SURVEY.MFS;4;Gait [Morse Fall Scale];;;ACTIVE;2.32;2.44 +59459-8;Mental status;Find;Pt;^Patient;Ord;Morse Fall Scale;SURVEY.MFS;4;Mental status [Morse Fall Scale];;;ACTIVE;2.32;2.44 +59460-6;Fall risk total;Score;Pt;^Patient;Qn;Morse Fall Scale;SURVEY.MFS;4;Fall risk total [Morse Fall Scale];;;ACTIVE;2.32;2.73 +59461-4;Fall risk level;Find;Pt;^Patient;Ord;Morse Fall Scale;SURVEY.MFS;4;Fall risk level [Morse Fall Scale];;;ACTIVE;2.32;2.56 +59462-2;Clinical biochemist review;Imp;Pt;XXX;Nar;;CHEM;1;Clinical biochemist review of results;Clinical biochemist review;;ACTIVE;2.32;2.73 +59463-0;Lymphocytes/100 leukocytes;NFr;Pt;Dial fld;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Dialysis fluid;Lymphocytes/leuk NFr Dial fld;;ACTIVE;2.32;2.50 +59464-8;Microbiologist review;Imp;Pt;XXX;Nar;;MICRO;1;Microbiologist review of results;Microbiologist review;;ACTIVE;2.32;2.73 +59465-5;Pathologist review;Imp;Pt;XXX;Nar;;PATH;1;Pathologist review of results;Path Rev;;ACTIVE;2.32;2.73 +59466-3;Hematologist review;Imp;Pt;XXX;Nar;;HEM/BC;1;Hematologist review of results;Hematologist review;;ACTIVE;2.32;2.73 +59467-1;Erythrocyte mean corpuscular hemoglobin concentration;SCnc;Pt;RBC;Qn;;HEM/BC;1;MCHC [Moles/volume];MCHC RBC-sCnc;;ACTIVE;2.32;2.73 +59468-9;Erythrocyte mean corpuscular hemoglobin;EntSub;Pt;RBC;Qn;;HEM/BC;1;MCH [Entitic substance];MCH EntSub RBC;;ACTIVE;2.32;2.70 +5946-9;Coagulation surface induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;aPTT imm NP PPP;;ACTIVE;1.0d;2.73 +59470-5;Calcium.ionized;MCnc;Pt;BldA;Qn;;CHEM;1;Calcium.ionized [Mass/volume] in Arterial blood;Ca-I BldA-mCnc;;ACTIVE;2.34;2.73 +59471-3;Calcium.ionized;MCnc;Pt;BldV;Qn;;CHEM;1;Calcium.ionized [Mass/volume] in Venous blood;Ca-I BldV-mCnc;;ACTIVE;2.34;2.73 +59472-1;Calcium.ionized^^adjusted to pH 7.4;MCnc;Pt;BldA;Qn;ISE;CHEM;1;Calcium.ionized [Mass/volume] adjusted to pH 7.4 in Arterial blood by Ion-selective membrane electrode (ISE);Ca-I adj pH7.4 BldA ISE-mCnc;;ACTIVE;2.34;2.73 +59473-9;Calcium.ionized^^adjusted to pH 7.4;MCnc;Pt;BldV;Qn;ISE;CHEM;1;Calcium.ionized [Mass/volume] adjusted to pH 7.4 in Venous blood by Ion-selective membrane electrode (ISE);Ca-I adj pH7.4 BldV ISE-mCnc;;ACTIVE;2.34;2.70 +59474-7;Microscopic observation;Prid;Pt;CSF;Nom;Acridine orange stain;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by Acridine orange stain;AO Stn CSF;;ACTIVE;2.32;2.32 +59475-4;Collaborative staging metastasis at diagnosis - bone involvement;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging metastasis at diagnosis - bone involvement Cancer;CS mets at Dx - bone Cancer;;ACTIVE;2.34;2.34 +59476-2;Collaborative staging metastasis at diagnosis - brain involvement;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging metastasis at diagnosis - brain involvement Cancer;CS mets at Dx - brain Cancer;;ACTIVE;2.34;2.34 +5947-7;Coagulation surface induced.factor substitution^20M post incubation after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma;aPTT 20M NP Cont PPP;;ACTIVE;1.0d;2.52 +59477-0;Collaborative staging metastasis at diagnosis - liver involvement;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging metastasis at diagnosis - liver involvement Cancer;CS mets at Dx - liver Cancer;;ACTIVE;2.34;2.34 +59478-8;Collaborative staging metastasis at diagnosis - lung involvement;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging metastasis at diagnosis - lung involvement Cancer;CS mets at Dx - lung Cancer;;ACTIVE;2.34;2.34 +59479-6;Collaborative staging post treatment extension;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging post treatment extension Cancer;CS post Rx ext Cancer;;ACTIVE;2.34;2.34 +59480-4;Collaborative staging post treatment lymph nodes;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging post treatment lymph nodes Cancer;CS post Rx LN Cancer;;ACTIVE;2.34;2.34 +59481-2;Collaborative staging post treatment metastasis at diagnosis;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging post treatment metastasis at diagnosis Cancer;CS post Rx mets at Dx Cancer;;ACTIVE;2.34;2.34 +59482-0;Collaborative staging post treatment tumor size;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging post treatment tumor size Cancer;CS post Rx tumor size Cancer;;ACTIVE;2.34;2.34 +59483-8;Collaborative staging pre treatment lymph nodes;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging pre treatment lymph nodes Cancer;CS pre Rx LN Cancer;;ACTIVE;2.34;2.34 +59484-6;Collaborative staging pre treatment metastasis at diagnosis;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging pre treatment metastasis at diagnosis Cancer;CS pre Rx mets at Dx Cancer;;ACTIVE;2.34;2.34 +5948-5;Coagulation surface induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Deprecated Activated partial thrombplastin time (aPTT).factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;Deprecated aPTT imm NP PPP Qn;;DEPRECATED;1.0d;2.40 +59485-3;Collaborative staging pre treatment metastasis evaluation;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging pre treatment metastasis evaluation Cancer;CS pre Rx mets eval Cancer;;ACTIVE;2.34;2.34 +59486-1;Collaborative staging pre treatment regional nodes evaluation;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging pre treatment regional nodes evaluation Cancer;CS pre Rx reg nodes eval Cancer;;ACTIVE;2.34;2.34 +59487-9;Collaborative staging pre treatment tumor size and extension evaluation;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging pre treatment tumor size and extension evaluation Cancer;CS pre Rx tumor size/ext eval Cancer;;ACTIVE;2.34;2.34 +59488-7;Collaborative staging pre treatment tumor size;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging pre treatment tumor size Cancer;CS pre Rx tumor size Cancer;;ACTIVE;2.34;2.34 +59489-5;Collaborative staging site-specific factor 7;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 7 Cancer;CS site-specific factor 7 Cancer;;ACTIVE;2.34;2.34 +59490-3;Collaborative staging site-specific factor 8;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 8 Cancer;CS site-specific factor 8 Cancer;;ACTIVE;2.34;2.34 +59491-1;Collaborative staging site-specific factor 9;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 9 Cancer;CS site-specific factor 9 Cancer;;ACTIVE;2.34;2.34 +59492-9;Collaborative staging site-specific factor 10;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 10 Cancer;CS site-specific factor 10 Cancer;;ACTIVE;2.34;2.34 +5949-3;Coagulation surface induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;aPTT.factor substitution in Control Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;aPTT imm NP Cont PPP;;ACTIVE;1.0d;2.73 +59493-7;Collaborative staging site-specific factor 11;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 11 Cancer;CS site-specific factor 11 Cancer;;ACTIVE;2.34;2.34 +59494-5;Collaborative staging site-specific factor 12;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 12 Cancer;CS site-specific factor 12 Cancer;;ACTIVE;2.34;2.34 +59495-2;Collaborative staging site-specific factor 13;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 13 Cancer;CS site-specific factor 13 Cancer;;ACTIVE;2.34;2.34 +59496-0;Collaborative staging site-specific factor 14;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 14 Cancer;CS site-specific factor 14 Cancer;;ACTIVE;2.34;2.34 +59497-8;Collaborative staging site-specific factor 15;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 15 Cancer;CS site-specific factor 15 Cancer;;ACTIVE;2.34;2.34 +59498-6;Collaborative staging site-specific factor 16;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 16 Cancer;CS site-specific factor 16 Cancer;;ACTIVE;2.34;2.34 +59499-4;Collaborative staging site-specific factor 17;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 17 Cancer;CS site-specific factor 17 Cancer;;ACTIVE;2.34;2.34 +59500-9;Collaborative staging site-specific factor 18;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 18 Cancer;CS site-specific factor 18 Cancer;;ACTIVE;2.34;2.34 +5950-1;Coagulation surface induced.factor substitution^20M post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma;aPTT 20M NP PPP;;ACTIVE;1.0d;2.73 +59501-7;Collaborative staging site-specific factor 19;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 19 Cancer;CS site-specific factor 19 Cancer;;ACTIVE;2.34;2.34 +59502-5;Collaborative staging site-specific factor 20;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 20 Cancer;CS site-specific factor 20 Cancer;;ACTIVE;2.34;2.34 +59503-3;Collaborative staging site-specific factor 21;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 21 Cancer;CS site-specific factor 21 Cancer;;ACTIVE;2.34;2.34 +59504-1;Collaborative staging site-specific factor 22;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 22 Cancer;CS site-specific factor 22 Cancer;;ACTIVE;2.34;2.34 +59505-8;Collaborative staging site-specific factor 23;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 23 Cancer;CS site-specific factor 23 Cancer;;ACTIVE;2.34;2.34 +59506-6;Collaborative staging site-specific factor 24;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 24 Cancer;CS site-specific factor 24 Cancer;;ACTIVE;2.34;2.34 +59507-4;Collaborative staging site-specific factor 25;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging site-specific factor 25 Cancer;CS site-specific factor 25 Cancer;;ACTIVE;2.34;2.34 +59508-2;Collaborative staging version.current;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging version.current Cancer;CS version current Cancer;;ACTIVE;2.34;2.34 +59509-0;Date case completed.COC;Date;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date case completed.COC Cancer case;Date case completed.COC Cancer case;;ACTIVE;2.34;2.50 +59510-8;Date case initiated;Date;Pt;Cancer case.XXX;Qn;;TUMRRGT;2;Date case initiated Cancer case;Date case initiated Cancer case;;ACTIVE;2.34;2.50 +59511-6;Flag for Date of conclusive diagnosis not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date of conclusive diagnosis not populated Cancer;Flag for Date of conclusive Dx Cancer;;ACTIVE;2.34;2.34 +59512-4;Flag for Hospital admission.first contact not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Hospital admission.first contact not populated Cancer;Flag for 1st contact Cancer;;ACTIVE;2.34;2.34 +59513-2;Flag for Date 1st cancer Rx (any).COC not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st cancer treatment (any).COC not populated;Flag for Date 1st cancer Rx (any).COC;;ACTIVE;2.34;2.34 +59514-0;Flag for Date of birth not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date of birth not populated;Flag for Date of birth;;ACTIVE;2.34;2.34 +59515-7;Flag for Date of death - Canada not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date of death - Canada not populated;Flag for Date of death - Canada;;ACTIVE;2.34;2.34 +59516-5;Flag for Date first Dx not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date first Dx not populated Cancer;Flag for Date first Dx Cancer;;ACTIVE;2.34;2.66 +59517-3;Flag for Date 1st cancer Rx (any).SEERS not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st cancer treatment (any).SEERS not populated;Flag for Date 1st cancer Rx (any).SEERS;;ACTIVE;2.34;2.34 +59518-1;Flag for Date of inpatient admission not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date of inpatient admission not populated Cancer;Flag for Date of inpt adm Cancer;;ACTIVE;2.34;2.34 +5951-9;Coagulation surface induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP^Control;Qn;Tilt tube;COAG;1;Deprecated Activated partial thrombplastin time (aPTT).factor substitution in Platelet poor plasma from control by Coagulation assay --immediately after addition of normal plasma;Deprecated aPTT imm NP PPP Cont Qn;;DEPRECATED;1.0d;2.36 +59519-9;Flag for Date of inpatient discharge not populated;-;Pt;Cancer.XXX;-;;TUMRRGT;2;Flag for Date of inpatient discharge not populated Cancer;Flag for Date of inpt disch Cancer;;ACTIVE;2.34;2.34 +59520-7;Flag for Date last contact not populated;-;Pt;Cancer.XXX;-;;TUMRRGT;2;Flag for Date last contact not populated;Flag for Date last contact;;ACTIVE;2.34;2.34 +59521-5;Flag for Date of diagnosis of multiple tumors not populated;-;Pt;Cancer.XXX;-;;TUMRRGT;2;Flag for Date of diagnosis of multiple tumors not populated Cancer;Flag for Date Dx multiple tumors Cancer;;ACTIVE;2.34;2.34 +59522-3;Derived American Joint Committee on Cancer-7 M;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer-7 M;Derived AJCC-7 M Cancer;;ACTIVE;2.34;2.34 +59523-1;Derived American Joint Committee on Cancer-7 M descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer-7 M descriptor;Derived AJCC-7 M descript Cancer;;ACTIVE;2.34;2.34 +59524-9;Derived American Joint Committee on Cancer-7 N;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer-7 N;Derived AJCC-7 N Cancer;;ACTIVE;2.34;2.34 +59525-6;Derived American Joint Committee on Cancer-7 N descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer-7 N descriptor;Derived AJCC-7 N descript Cancer;;ACTIVE;2.34;2.34 +59526-4;Derived American Joint Committee on Cancer-7 stage group;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer-7 stage group;Derived AJCC-7 stg grp Cancer;;ACTIVE;2.34;2.34 +5952-7;Coagulation surface induced.factor substitution^20M post incubation.37 deg c after addition of normal plasma;Time;Pt;PPP;Qn;Tilt tube;COAG;1;Deprecated Activated partial thrombplastin time (aPTT).factor substitution in Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma;Deprecated aPTT PPP Qn;;DEPRECATED;1.0d;2.46 +59527-2;Derived American Joint Committee on Cancer-7 T;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer-7 T;Derived AJCC-7 T Cancer;;ACTIVE;2.34;2.34 +59528-0;Derived American Joint Committee on Cancer-7 T descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived American Joint Committee on Cancer-7 T descriptor;Derived AJCC-7 T descript Cancer;;ACTIVE;2.34;2.34 +59529-8;Flag for Derived neoadjuvant therapy not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Derived neoadjuvant therapy not populated Cancer;Flag for Derived neoadjuv Rx Cancer;;ACTIVE;2.34;2.34 +59530-6;Derived post treatment-7 M;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived post treatment-7 M Cancer;Derived post Rx-7 M Cancer;;ACTIVE;2.34;2.34 +59531-4;Derived post treatment-7 N;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived post treatment-7 N Cancer;Derived post Rx-7 N Cancer;;ACTIVE;2.34;2.34 +59532-2;Derived post treatment-7 stage group;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived post treatment-7 stage group Cancer;Derived post Rx-7 stg grp Cancer;;ACTIVE;2.34;2.34 +59533-0;Derived post treatment-7 T;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived post treatment-7 T Cancer;Derived post Rx-7 T Cancer;;ACTIVE;2.34;2.34 +59534-8;Derived pre treatment-7 M;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived pre treatment-7 M Cancer;Derived pre Rx-7 M Cancer;;ACTIVE;2.34;2.34 +5953-5;Coagulation surface induced.factor substitution^20M post incubation.37 deg c after addition of normal plasma;Time;Pt;PPP^Control;Qn;Tilt tube;COAG;1;Deprecated Activated partial thrombplastin time (aPTT).factor substitution in Platelet poor plasma from control by Coagulation assay --20M post incubation with normal plasma;Deprecated aPTT PPP Cont Qn;;DEPRECATED;1.0d;2.36 +59535-5;Derived pre treatment-7 M descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived pre treatment-7 M descriptor Cancer;Derived pre Rx-7 M descript Cancer;;ACTIVE;2.34;2.34 +59536-3;Derived pre treatment-7 N;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived pre treatment-7 N Cancer;Derived pre Rx-7 N Cancer;;ACTIVE;2.34;2.34 +59537-1;Derived pre treatment-7 N descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived pre treatment-7 N descriptor Cancer;Derived pre Rx-7 N descript Cancer;;ACTIVE;2.34;2.34 +59538-9;Derived pre treatment-7 stage group;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived pre treatment-7 stage group Cancer;Derived pre Rx-7 stg grp Cancer;;ACTIVE;2.34;2.34 +59539-7;Derived pre treatment-7 T;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived pre treatment-7 T Cancer;Derived pre Rx-7 T Cancer;;ACTIVE;2.34;2.34 +59540-5;Derived pre treatment-7 T descriptor;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Derived pre treatment-7 T descriptor Cancer;Derived pre Rx-7 T descript Cancer;;ACTIVE;2.34;2.34 +59541-3;Grade pathology system;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Grade pathology system Cancer;Grade pathology system Cancer;;ACTIVE;2.34;2.34 +59542-1;Grade pathology value;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Grade pathology value Cancer;Grade pathology value Cancer;;ACTIVE;2.34;2.34 +5954-3;Coagulation thrombin induced;Time;Pt;PPP;Qn;Tilt tube;COAG;1;Deprecated Thrombin time in Platelet poor plasma by Coagulation assay;Deprecated TT PPP Qn;;DEPRECATED;1.0d;2.40 +59543-9;Inpatient status;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Inpatient status Cancer;Inpatient status Cancer;;ACTIVE;2.34;2.34 +59544-7;Lymph-vascular invasion;Prid;Pt;Cancer specimen;Nom;;TUMRRGT;2;Lymph-vascular invasion Cancer specimen;Lymph-vascular invasion Ca spec;;ACTIVE;2.34;2.61 +59545-4;Flag for Recurrence date not populated;Prid;Episode^frst;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Recurrence date not populated first episode Cancer;Flag for Recur date 1st episode Cancer;;ACTIVE;2.34;2.34 +59546-2;Flag for Date 1st most definitive surgery Rx for not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st most definitive surgery Rx for not populated Cancer;Flag for Date 1st mst defn srg Cancer;;ACTIVE;2.34;2.34 +59547-0;Flag for Date radiation ended not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date radiation ended not populated Cancer;Flag for Date rad ended Cancer;;ACTIVE;2.34;2.34 +59548-8;Flag for Date of surgical discharge not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date of surgical discharge not populated Cancer;Flag for Date of surg disch Cancer;;ACTIVE;2.34;2.34 +59549-6;Flag for Date 1st systemic treatment not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st systemic treatment not populated Cancer;Flag for Date 1st systemic Cancer;;ACTIVE;2.34;2.34 +5955-0;Coagulation thrombin induced;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Thrombin time in Control Platelet poor plasma by Coagulation assay;TT Cont PPP;;ACTIVE;1.0d;2.73 +59550-4;Flag for Date 1st immunotherapy treatment not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st immunotherapy treatment not populated Cancer;Flag for Date 1st BRM Cancer;;ACTIVE;2.34;2.34 +59551-2;Flag for Date 1st chemotherapy treatment not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st chemotherapy treatment not populated Cancer;Flag for Date 1st chemo Cancer;;ACTIVE;2.34;2.34 +59552-0;Flag for Date non cancer directed surgery Rx as part of 1st cancer not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date non cancer directed surgery treatment as part of 1st cancer not populated;Flag for Date Dx/Stg proc;;ACTIVE;2.34;2.34 +59553-8;Flag for Date 1st hormone treatment not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st hormone treatment not populated Cancer;Flag for Date 1st hormone Cancer;;ACTIVE;2.34;2.34 +59554-6;Flag for Date 1st other treatment not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st other treatment not populated Cancer;Flag for Date 1st other Tx Cancer;;ACTIVE;2.34;2.34 +59555-3;Flag for Date 1st radiation treatment not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st radiation treatment not populated Cancer;Flag for Date 1st radiation Cancer;;ACTIVE;2.34;2.34 +59556-1;Flag for Date 1st surgery treatment not populated;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Flag for Date 1st surgery treatment not populated Cancer;Flag for Date 1st surgery Cancer;;ACTIVE;2.34;2.34 +59557-9;Treatment status;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Treatment status Cancer;Tx status Cancer;;ACTIVE;2.34;2.34 +59558-7;Flag for 2nd course treatment start date not populated;Prid;Pt;Subsequent cancer Rx;Nom;;TUMRRGT;2;Flag for 2nd course treatment start date not populated Cancer Rx;Flag for 2nd crs Tx start date Cancer Rx;;ACTIVE;2.34;2.34 +59559-5;Collaborative staging pre treatment extension;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Collaborative staging pre treatment extension Cancer;CS pre Rx ex Cancer;;ACTIVE;2.34;2.34 +59560-3;Surgical approach at facility.YYY 2010;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Surgical approach at facility.YYY 2010 Cancer;Surg app at facility 2010 Cancer;;ACTIVE;2.34;2.34 +59561-1;Propofol glucuronide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propofol glucuronide [Mass/volume] in Urine;Propofol glucuronide Ur-mCnc;;ACTIVE;2.32;2.73 +59562-9;DNA index;AreaRto;Pt;Cells.XXX;Qn;Automated image cytometry;MOLPATH;1;DNA index by Automated image cytometry;DNA Index Auto cyto;;ACTIVE;2.32;2.73 +59563-7;Protein.monoclonal band 4;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 4 [Mass/volume] in Urine by Electrophoresis;M Protein 4 Ur Elph-mCnc;;ACTIVE;2.32;2.73 +59564-5;Alpha-1-Fetoprotein;ACnc;Pt;CSF;Qn;;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Cerebral spinal fluid;AFP CSF-aCnc;;ACTIVE;2.32;2.70 +59565-2;Netilmicin^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Netilmicin [Moles/volume] in Serum or Plasma --trough;Netilmicin Trough SerPl-sCnc;;ACTIVE;2.32;2.70 +59566-0;Netilmicin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Netilmicin [Moles/volume] in Serum or Plasma;Netilmicin SerPl-sCnc;;ACTIVE;2.32;2.70 +59567-8;Netilmicin^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Netilmicin [Moles/volume] in Serum or Plasma --peak;Netilmicin Peak SerPl-sCnc;;ACTIVE;2.32;2.70 +5956-8;Coagulation tissue factor induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;PT imm NP Cont PPP;;ACTIVE;1.0d;2.73 +59568-6;Orotate;SRat;24H;Urine;Qn;;CHEM;1;Orotate [Moles/time] in 24 hour Urine;Orotate 24h Ur-sRate;;ACTIVE;2.32;2.70 +59569-4;Calcitonin^post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Moles/volume] in Serum or Plasma --post XXX challenge;Calcit p chal SerPl-sCnc;;ACTIVE;2.32;2.70 +59570-2;Urea nitrogen;SCnc;Pt;Bld;Qn;;CHEM;1;Urea nitrogen [Moles/volume] in Blood;BUN Bld-sCnc;;ACTIVE;2.32;2.73 +59571-0;Triglyceride;SRat;24H;Urine;Qn;;CHEM;1;Triglyceride [Moles/time] in 24 hour Urine;Trigl 24h Ur-sRate;;ACTIVE;2.32;2.70 +59572-8;Triglyceride;SCnc;Pt;Urine;Qn;;CHEM;1;Triglyceride [Moles/volume] in Urine;Trigl Ur-sCnc;;ACTIVE;2.32;2.70 +59573-6;Cannabinoids;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Cannabinoids [Presence] in Gastric fluid;Cannabinoids Gast Ql;;ACTIVE;2.32;2.56 +59574-4;Body mass index;Prctl;Pt;^Patient;Qn;;BDYWGT.MOLEC;2;Body mass index (BMI) [Percentile];BMI Prctl;;ACTIVE;2.32;2.73 +59575-1;Body mass index;Prctl;Pt;^Patient;Qn;Per age;BDYWGT.MOLEC;2;Body mass index (BMI) [Percentile] Per age;BMI Prctl Per Age;;ACTIVE;2.32;2.48 +5957-6;Coagulation tissue factor induced.factor substitution^20M post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma;PT 20M NP PPP;;ACTIVE;1.0d;2.44 +59576-9;Body mass index;Prctl;Pt;^Patient;Qn;Per age and sex;BDYWGT.MOLEC;2;Body mass index (BMI) [Percentile] Per age and sex;BMI Prctl Per age+sex;;ACTIVE;2.32;2.66 +59577-7;Glucagon^7th specimen post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --7th specimen fasting;Glucagon sp7 p fast SerPl-mCnc;;ACTIVE;2.32;2.70 +59578-5;Glucagon^6th specimen post CFst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --6th specimen fasting;Glucagon sp6 p fast SerPl-mCnc;;ACTIVE;2.32;2.70 +59579-3;Coxsackievirus A24 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A24 IgM Ab [Titer] in Serum by Immunofluorescence;CV A24 IgM Titr Ser IF;;ACTIVE;2.32;2.73 +59580-1;Coxsackievirus A16 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A16 IgM Ab [Titer] in Serum by Immunofluorescence;CV A16 IgM Titr Ser IF;;ACTIVE;2.32;2.73 +59581-9;Coxsackievirus A7 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A7 IgM Ab [Titer] in Serum by Immunofluorescence;CV A7 IgM Titr Ser IF;;ACTIVE;2.32;2.73 +59582-7;Coxsackievirus A24 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A24 IgG Ab [Titer] in Serum by Immunofluorescence;CV A24 IgG Titr Ser IF;;ACTIVE;2.32;2.73 +59583-5;Coxsackievirus A16 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A16 IgG Ab [Titer] in Serum by Immunofluorescence;CV A16 IgG Titr Ser IF;;ACTIVE;2.32;2.73 +5958-4;Coagulation tissue factor induced.factor substitution^20M post incubation after addition of normal plasma;Time;Pt;PPP^Control;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma;PT 20M NP Cont PPP;;ACTIVE;1.0d;2.44 +59584-3;Coxsackievirus A7 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Coxsackievirus A7 IgG Ab [Titer] in Serum by Immunofluorescence;CV A7 IgG Titr Ser IF;;ACTIVE;2.32;2.73 +59585-0;GSTP1 gene+APC gene methylation;Arb;Pt;Tiss;Ord;Molgen;MOLPATH;1;GSTP1 gene+APC gene methylation [Presence] in Tissue by Molecular genetics method;GSTP1+APC gene methylation Tiss Ql;;ACTIVE;2.32;2.73 +59586-8;HLA Ab.IgG;PrThr;Pt;Ser;Ord;IF;HLA;1;HLA IgG Ab [Presence] in Serum by Immunofluorescence;HLA IgG Ser Ql IF;;ACTIVE;2.36;2.56 +59587-6;Homovanillate;MCnc;XXX;Urine;Qn;;CHEM;1;Homovanillate [Mass/volume] in Urine collected for unspecified duration;HVA ?Tm Ur-mCnc;;ACTIVE;2.32;2.73 +59588-4;1-Hydroxymidazolam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;1-Hydroxymidazolam [Mass/mass] in Meconium;1OH-midazolam Mec-mCnt;;ACTIVE;2.32;2.70 +59589-2;1-Hydroxymidazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;1-Hydroxymidazolam [Mass/volume] in Urine;1OH-midazolam Ur-mCnc;;ACTIVE;2.32;2.73 +595-9;Bacteria identified;Prid;Pt;Abscess;Nom;Aerobic culture;MICRO;1;Bacteria identified in Abscess by Aerobe culture;Bacteria Absc Aerobe Cult;;ACTIVE;1.0;2.73 +59590-0;1-Hydroxymidazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;1-Hydroxymidazolam [Mass/volume] in Urine by Confirmatory method;1OH-midazolam Ur Cfm-mCnc;;ACTIVE;2.32;2.73 +59591-8;7-Aminoclonazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Blood;7Aminoclonazepam Bld-mCnc;;ACTIVE;2.32;2.70 +5959-2;Coagulation tissue factor induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;PT imm NP PPP;;ACTIVE;1.0d;2.73 +59592-6;7-Aminoclonazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Blood by Confirmatory method;7Aminoclonazepam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59593-4;7-Aminoclonazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Body fluid;7Aminoclonazepam Fld-mCnc;;ACTIVE;2.32;2.70 +59594-2;7-Aminoclonazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Body fluid by Confirmatory method;7Aminoclonazepam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59595-9;7-Aminoclonazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Mass/volume] in Serum or Plasma by Confirmatory method;7Aminoclonazepam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59596-7;7-Aminoclonazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;7-Aminoclonazepam [Mass/mass] in Tissue;7Aminoclonazepam Tiss-mCnt;;ACTIVE;2.32;2.70 +59597-5;7-Aminoclonazepam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Mass/mass] in Tissue by Confirmatory method;7Aminoclonazepam Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59598-3;acetaZOLAMIDE;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acetazolamide [Mass/volume] in Blood;acetaZOLAMIDE Bld-mCnc;;ACTIVE;2.32;2.70 +59599-1;Alpha hydroxyalprazolam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Blood;A-OH Alpraz Bld-mCnc;;ACTIVE;2.32;2.70 +59-6;Carbenicillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Carbenicillin [Susceptibility] by Minimum lethal concentration (MLC);Carbenicillin Islt MLC;;ACTIVE;1.0;2.19 +5960-0;Coagulation tissue factor induced.factor substitution^20M post incubation.37 deg c after addition of normal plasma;Time;Pt;PPP^Control;Qn;Tilt tube;COAG;1;Deprecated Prothrombin time (PT) factor substitution in Platelet poor plasma from control by Coagulation assay --20M post incubation with normal plasma;Deprecated PT PPP Cont Qn;;DEPRECATED;1.0d;2.36 +59600-7;Alpha hydroxyalprazolam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Blood by Confirmatory method;A-OH Alpraz Bld Cfm-mCnc;;ACTIVE;2.32;2.70 +59601-5;Alpha hydroxyalprazolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Body fluid;A-OH Alpraz Fld-mCnc;;ACTIVE;2.32;2.70 +59602-3;Alpha hydroxyalprazolam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Body fluid by Confirmatory method;A-OH Alpraz Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59603-1;Alpha hydroxyalprazolam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/mass] in Meconium by Confirmatory method;A-OH Alpraz Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59604-9;Alpha hydroxyalprazolam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/volume] in Serum or Plasma by Confirmatory method;A-OH Alpraz SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59605-6;Alpha hydroxyalprazolam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/mass] in Tissue;A-OH Alpraz Tiss-mCnt;;ACTIVE;2.32;2.70 +59606-4;Alpha hydroxyalprazolam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam [Mass/mass] in Tissue by Confirmatory method;A-OH Alpraz Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59607-2;ALPRAZolam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Blood by Confirmatory method;Alpraz Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59608-0;ALPRAZolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Body fluid;Alpraz Fld-mCnc;;ACTIVE;2.32;2.70 +59609-8;ALPRAZolam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Body fluid by Confirmatory method;Alpraz Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59610-6;ALPRAZolam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/mass] in Meconium by Confirmatory method;Alpraz Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59611-4;ALPRAZolam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Serum or Plasma by Confirmatory method;Alpraz SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59612-2;ALPRAZolam;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/mass] in Stool by Confirmatory method;Alpraz Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59613-0;ALPRAZolam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/mass] in Tissue;Alpraz Tiss-mCnt;;ACTIVE;2.32;2.73 +59614-8;ALPRAZolam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/mass] in Tissue by Confirmatory method;Alpraz Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59615-5;ALPRAZolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Urine by Confirmatory method;Alpraz Ur Cfm-mCnc;;ACTIVE;2.32;2.73 +59616-3;Benzoylecgonine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Serum or Plasma by Confirmatory method;BZE SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59617-1;chlordiazePOXIDE;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Blood;Chlordiazep Bld-mCnc;;ACTIVE;2.32;2.70 +5961-8;Coagulation tissue factor induced.factor substitution^20M post incubation.37 deg c after addition of normal plasma;Time;Pt;PPP;Qn;Tilt tube;COAG;1;Deprecated Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma;Deprecated PT PPP Qn;;DEPRECATED;1.0d;2.36 +59618-9;chlordiazePOXIDE;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Blood by Confirmatory method;Chlordiazep Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59619-7;chlordiazePOXIDE;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Body fluid;Chlordiazep Fld-mCnc;;ACTIVE;2.32;2.70 +59620-5;chlordiazePOXIDE;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Body fluid by Confirmatory method;Chlordiazep Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59621-3;chlordiazePOXIDE;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/mass] in Meconium by Confirmatory method;Chlordiazep Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59622-1;chlordiazePOXIDE;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Serum or Plasma by Confirmatory method;Chlordiazep SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59623-9;chlordiazePOXIDE;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/mass] in Stool by Confirmatory method;Chlordiazep Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59624-7;chlordiazePOXIDE;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Mass/mass] in Tissue;Chlordiazep Tiss-mCnt;;ACTIVE;2.32;2.70 +59625-4;chlordiazePOXIDE;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/mass] in Tissue by Confirmatory method;Chlordiazep Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +5962-6;Coagulation tissue factor induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Tilt tube;COAG;1;Deprecated Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;Deprecated PT imm NP PPP Qn;;DEPRECATED;1.0d;2.36 +59626-2;cloBAZam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cloBAZam [Mass/volume] in Blood;cloBAZam Bld-mCnc;;ACTIVE;2.32;2.70 +59627-0;cloBAZam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;cloBAZam [Mass/volume] in Blood by Confirmatory method;cloBAZam Bld Cfm-mCnc;;ACTIVE;2.32;2.70 +59628-8;cloBAZam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;cloBAZam [Mass/volume] in Body fluid;cloBAZam Fld-mCnc;;ACTIVE;2.32;2.70 +59629-6;cloBAZam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;cloBAZam [Mass/volume] in Body fluid by Confirmatory method;cloBAZam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59630-4;cloBAZam;MCnt;Pt;Meconium;Qn;;DRUG/TOX;1;cloBAZam [Mass/mass] in Meconium;cloBAZam Mec-mCnt;;ACTIVE;2.32;2.70 +59631-2;cloBAZam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;cloBAZam [Mass/mass] in Meconium by Confirmatory method;cloBAZam Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59632-0;cloBAZam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;cloBAZam [Mass/volume] in Serum or Plasma by Confirmatory method;cloBAZam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59633-8;cloBAZam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;cloBAZam [Mass/mass] in Tissue;cloBAZam Tiss-mCnt;;ACTIVE;2.32;2.70 +5963-4;Coagulation tissue factor induced.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP^Control;Qn;Tilt tube;COAG;1;Deprecated Prothrombin time (PT) factor substitution in Platelet poor plasma from control by Coagulation assay --immediately after addition of normal plasma;Deprecated PT imm NP PPP Cont Qn;;DEPRECATED;1.0d;2.36 +59634-6;cloBAZam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;cloBAZam [Mass/mass] in Tissue by Confirmatory method;cloBAZam Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59635-3;cloBAZam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;cloBAZam [Mass/volume] in Urine by Confirmatory method;cloBAZam Ur Cfm-mCnc;;ACTIVE;2.32;2.70 +59636-1;clonazePAM;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;clonazePAM [Mass/volume] in Blood;clonazePAM Bld-mCnc;;ACTIVE;2.32;2.70 +59637-9;clonazePAM;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;clonazePAM [Mass/volume] in Blood by Confirmatory method;clonazePAM Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59638-7;clonazePAM;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;clonazePAM [Mass/volume] in Body fluid;clonazePAM Fld-mCnc;;ACTIVE;2.32;2.70 +59639-5;clonazePAM;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;clonazePAM [Mass/volume] in Body fluid by Confirmatory method;clonazePAM Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59640-3;clonazePAM;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;clonazePAM [Mass/volume] in Serum or Plasma by Confirmatory method;clonazePAM SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59641-1;clonazePAM;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;clonazePAM [Mass/mass] in Tissue;clonazePAM Tiss-mCnt;;ACTIVE;2.32;2.70 +5964-2;Coagulation tissue factor induced;Time;Pt;Bld;Qn;Coag;COAG;1;Prothrombin time (PT) in Blood by Coagulation assay;PT Bld;;ACTIVE;1.0d;2.73 +59642-9;clonazePAM;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;clonazePAM [Mass/mass] in Tissue by Confirmatory method;clonazePAM Tiss Cfm-mCnt;;ACTIVE;2.32;2.73 +59643-7;Cocaethylene;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Cocaethylene [Mass/volume] in Serum or Plasma by Confirmatory method;Cocaethylene SerPl Cfm-mCnc;;ACTIVE;2.32;2.70 +59644-5;Cocaine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Cocaine [Mass/volume] in Serum or Plasma by Confirmatory method;Cocaine SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59645-2;Cotinine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Cotinine [Presence] in Serum or Plasma by Screen method;Cotinine SerPl Ql Scn;;ACTIVE;2.32;2.73 +59646-0;Cotinine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Cotinine [Presence] in Urine by Screen method;Cotinine Ur Ql Scn;;ACTIVE;2.32;2.73 +59647-8;N-desalkylflurazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Blood;Desalkylfluraz Bld-mCnc;;ACTIVE;2.32;2.70 +59648-6;N-desalkylflurazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Body fluid;Desalkylfluraz Fld-mCnc;;ACTIVE;2.32;2.70 +59649-4;N-desalkylflurazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Body fluid by Confirmatory method;Desalkylfluraz Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59650-2;N-desalkylflurazepam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Mass/mass] in Meconium by Confirmatory method;Desalkylfluraz Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59651-0;N-desalkylflurazepam;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Mass/mass] in Stool by Confirmatory method;Desalkylfluraz Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59652-8;N-desalkylflurazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/mass] in Tissue;Desalkylfluraz Tiss-mCnt;;ACTIVE;2.32;2.73 +59653-6;N-desalkylflurazepam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Mass/mass] in Tissue by Confirmatory method;Desalkylfluraz Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59654-4;diazePAM;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Blood;diazePAM Bld-mCnc;;ACTIVE;2.32;2.70 +59655-1;diazePAM;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/volume] in Blood by Confirmatory method;diazePAM Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59656-9;diazePAM;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;diazePAM [Mass/volume] in Body fluid;diazePAM Fld-mCnc;;ACTIVE;2.32;2.70 +59657-7;diazePAM;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/volume] in Body fluid by Confirmatory method;diazePAM Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59658-5;diazePAM;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/mass] in Meconium by Confirmatory method;diazePAM Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +5965-9;Plasmin inhibitor;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Plasmin inhibitor [Units/volume] in Platelet poor plasma by Chromogenic method;Plasm Inhib PPP Chro-aCnc;;ACTIVE;1.0d;2.73 +59659-3;diazePAM;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/mass] in Stool by Confirmatory method;diazePAM Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59660-1;diazePAM;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;diazePAM [Mass/mass] in Tissue;diazePAM Tiss-mCnt;;ACTIVE;2.32;2.70 +59661-9;diazePAM;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/mass] in Tissue by Confirmatory method;diazePAM Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59662-7;Diclofenac;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Diclofenac [Mass/volume] in Blood;Diclofenac Bld-mCnc;;ACTIVE;2.32;2.70 +59663-5;Diclofenac;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Diclofenac [Mass/volume] in Urine;Diclofenac Ur-mCnc;;ACTIVE;2.32;2.73 +59664-3;Estazolam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Estazolam [Mass/volume] in Blood;Estazolam Bld-mCnc;;ACTIVE;2.32;2.70 +59665-0;Estazolam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Estazolam [Mass/volume] in Blood by Confirmatory method;Estazolam Bld Cfm-mCnc;;ACTIVE;2.32;2.70 +59666-8;Estazolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Estazolam [Mass/volume] in Body fluid;Estazolam Fld-mCnc;;ACTIVE;2.32;2.70 +5966-7;Plasmin inhibitor Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasmin inhibitor Ag [Mass/volume] in Platelet poor plasma by Immunoassay;Plasm Inhib Ag PPP IA-mCnc;;ACTIVE;1.0d;2.73 +59667-6;Estazolam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Estazolam [Mass/volume] in Body fluid by Confirmatory method;Estazolam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59668-4;Estazolam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Estazolam [Mass/volume] in Serum or Plasma by Confirmatory method;Estazolam SerPl Cfm-mCnc;;ACTIVE;2.32;2.70 +59669-2;Estazolam;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;Estazolam [Mass/mass] in Stool by Confirmatory method;Estazolam Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +596-7;Bacteria identified;Prid;Pt;Amnio fld;Nom;Culture;MICRO;1;Bacteria identified in Amniotic fluid by Culture;Bacteria Amn Cult;;ACTIVE;1.0;2.19 +59670-0;Estazolam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Estazolam [Mass/mass] in Tissue;Estazolam Tiss-mCnt;;ACTIVE;2.32;2.70 +59671-8;Estazolam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;Estazolam [Mass/mass] in Tissue by Confirmatory method;Estazolam Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59672-6;Estazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Estazolam [Mass/volume] in Urine by Confirmatory method;Estazolam Ur Cfm-mCnc;;ACTIVE;2.32;2.73 +59673-4;fentaNYL;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;fentaNYL [Presence] in Urine by Screen method;fentaNYL Ur Ql Scn;;ACTIVE;2.32;2.73 +59674-2;Flurazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Flurazepam [Mass/volume] in Blood;Flurazepam Bld-mCnc;;ACTIVE;2.32;2.73 +5967-5;Plasmin inhibitor Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Plasmin inhibitor Ag [Units/volume] in Platelet poor plasma by Immunoassay;Plasm Inhib Ag PPP IA-aCnc;;ACTIVE;1.0d;2.69 +59675-9;Flurazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Flurazepam [Mass/volume] in Blood by Confirmatory method;Flurazepam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59676-7;Flurazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Flurazepam [Mass/volume] in Body fluid;Flurazepam Fld-mCnc;;ACTIVE;2.32;2.70 +59677-5;Flurazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Flurazepam [Mass/volume] in Body fluid by Confirmatory method;Flurazepam Fld Cfm-mCnc;;ACTIVE;2.32;2.73 +59678-3;Flurazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Flurazepam [Mass/mass] in Tissue;Flurazepam Tiss-mCnt;;ACTIVE;2.32;2.70 +59679-1;Flurazepam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;Flurazepam [Mass/mass] in Tissue by Confirmatory method;Flurazepam Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59680-9;Gabapentin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Gabapentin [Mass/volume] in Urine;Gabapentin Ur-mCnc;;ACTIVE;2.32;2.73 +59681-7;Gamma hydroxybutyrate;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Gamma hydroxybutyrate [Presence] in Serum or Plasma by Screen method;G-OH-Butyr SerPl Ql Scn;;ACTIVE;2.32;2.73 +59682-5;Hydroxyethylflurazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Blood;OH-Ethylfluraz Bld-mCnc;;ACTIVE;2.32;2.70 +5968-3;Plasminogen activator tissue type^20M post venistasis;MCnc;Pt;PPP;Qn;Enzy;COAG;1;Deprecated Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --20 minutes post venistasis;Deprecated tPA 20M PPP-mCnc;;DEPRECATED;1.0d;2.36 +59683-3;Hydroxyethylflurazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Blood by Confirmatory method;OH-Ethylfluraz Bld Cfm-mCnc;;ACTIVE;2.32;2.70 +59684-1;Hydroxyethylflurazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Body fluid;OH-Ethylfluraz Fld-mCnc;;ACTIVE;2.32;2.70 +59685-8;Hydroxyethylflurazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/volume] in Body fluid by Confirmatory method;OH-Ethylfluraz Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59686-6;Hydroxyethylflurazepam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/mass] in Meconium by Confirmatory method;OH-Ethylfluraz Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59687-4;Hydroxyethylflurazepam;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/mass] in Stool by Confirmatory method;OH-Ethylfluraz Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59688-2;Hydroxyethylflurazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/mass] in Tissue;OH-Ethylfluraz Tiss-mCnt;;ACTIVE;2.32;2.70 +59689-0;Hydroxyethylflurazepam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;Hydroxyethylflurazepam [Mass/mass] in Tissue by Confirmatory method;OH-Ethylfluraz Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59690-8;Hydroxytriazolam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Blood;OH-Triazolam Bld-mCnc;;ACTIVE;2.32;2.73 +5969-1;Plasmin-plasmin inhibitor complex;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasmin-plasmin inhibitor complex [Mass/volume] in Platelet poor plasma by Immunoassay;PAP PPP IA-mCnc;;ACTIVE;1.0d;2.58 +59691-6;Hydroxytriazolam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Blood by Confirmatory method;OH-Triazolam Bld Cfm-mCnc;;ACTIVE;2.32;2.70 +59692-4;Hydroxytriazolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Body fluid;OH-Triazolam Fld-mCnc;;ACTIVE;2.32;2.70 +59693-2;Hydroxytriazolam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Hydroxytriazolam [Mass/volume] in Body fluid by Confirmatory method;OH-Triazolam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59694-0;Hydroxytriazolam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Hydroxytriazolam [Mass/mass] in Meconium by Confirmatory method;OH-Triazolam Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59695-7;Hydroxytriazolam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Hydroxytriazolam [Mass/mass] in Tissue;OH-Triazolam Tiss-mCnt;;ACTIVE;2.32;2.70 +59696-5;Hydroxytriazolam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;Hydroxytriazolam [Mass/mass] in Tissue by Confirmatory method;OH-Triazolam Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59697-3;Iodide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Iodide [Mass/volume] in Serum or Plasma;Iodide SerPl-mCnc;;ACTIVE;2.34;2.73 +59699-9;LORazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Blood;LORazepam Bld-mCnc;;ACTIVE;2.32;2.70 +59700-5;LORazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;LORazepam [Mass/volume] in Blood by Confirmatory method;LORazepam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59701-3;LORazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Body fluid;LORazepam Fld-mCnc;;ACTIVE;2.32;2.70 +59702-1;LORazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;LORazepam [Mass/volume] in Body fluid by Confirmatory method;LORazepam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59703-9;LORazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;LORazepam [Mass/volume] in Serum or Plasma by Confirmatory method;LORazepam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59704-7;LORazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;LORazepam [Mass/mass] in Tissue;LORazepam Tiss-mCnt;;ACTIVE;2.32;2.70 +59705-4;Methadone;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Methadone [Presence] in Serum or Plasma by Screen method;Methadone SerPl Ql Scn;;ACTIVE;2.32;2.73 +59706-2;MethylePHEDrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;MethylePHEDrine [Mass/volume] in Serum or Plasma;Me-ePHEDrine SerPl-mCnc;;ACTIVE;2.32;2.70 +59707-0;Midazolam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Midazolam [Mass/volume] in Blood;Midazolam Bld-mCnc;;ACTIVE;2.32;2.70 +59708-8;Midazolam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Midazolam [Mass/volume] in Blood by Confirmatory method;Midazolam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +5970-9;Plasminogen;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen [Units/volume] in Platelet poor plasma by Chromogenic method;PLG PPP Chro-aCnc;;ACTIVE;1.0d;2.73 +59709-6;Midazolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Midazolam [Mass/volume] in Body fluid;Midazolam Fld-mCnc;;ACTIVE;2.32;2.70 +59710-4;Midazolam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Midazolam [Mass/volume] in Body fluid by Confirmatory method;Midazolam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59711-2;Midazolam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Midazolam [Mass/volume] in Serum or Plasma by Confirmatory method;Midazolam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59712-0;Midazolam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Midazolam [Mass/mass] in Tissue;Midazolam Tiss-mCnt;;ACTIVE;2.32;2.73 +59713-8;Midazolam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;Midazolam [Mass/mass] in Tissue by Confirmatory method;Midazolam Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59714-6;Nitrous oxide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Nitrous oxide [Mass/volume] in Blood;N2O Bld-mCnc;;ACTIVE;2.32;2.70 +59715-3;Nitrous oxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitrous oxide [Mass/volume] in Serum or Plasma;N2O SerPl-mCnc;;ACTIVE;2.32;2.70 +59716-1;Nordiazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Blood;Nordiazepam Bld-mCnc;;ACTIVE;2.32;2.70 +5971-7;Plasminogen activator tissue type Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay;tPA Ag PPP IA-mCnc;;ACTIVE;1.0d;2.73 +59717-9;Nordiazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Mass/volume] in Blood by Confirmatory method;Nordiazepam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59718-7;Nordiazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Body fluid;Nordiazepam Fld-mCnc;;ACTIVE;2.32;2.70 +59719-5;Nordiazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Mass/volume] in Body fluid by Confirmatory method;Nordiazepam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59720-3;Nordiazepam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Mass/mass] in Meconium by Confirmatory method;Nordiazepam Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59721-1;Nordiazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Mass/volume] in Serum or Plasma by Confirmatory method;Nordiazepam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59722-9;Nordiazepam;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Mass/mass] in Stool by Confirmatory method;Nordiazepam Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59723-7;Nordiazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Nordiazepam [Mass/mass] in Tissue;Nordiazepam Tiss-mCnt;;ACTIVE;2.32;2.70 +59724-5;Cathine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cathine [Mass/volume] in Serum or Plasma;Cathine SerPl-mCnc;;ACTIVE;2.32;2.73 +5972-5;Plasminogen activator tissue type Ag^20M post venistasis;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --20 minutes post venistasis;tPA Ag 20M PPP IA-mCnc;;ACTIVE;1.0d;2.58 +59725-2;Oxazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Blood;Oxazepam Bld-mCnc;;ACTIVE;2.32;2.70 +59726-0;Oxazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Oxazepam [Mass/volume] in Blood by Confirmatory method;Oxazepam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59727-8;Oxazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Body fluid;Oxazepam Fld-mCnc;;ACTIVE;2.32;2.70 +59728-6;Oxazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Oxazepam [Mass/volume] in Body fluid by Confirmatory method;Oxazepam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59729-4;Oxazepam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Oxazepam [Mass/mass] in Meconium by Confirmatory method;Oxazepam Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +59730-2;Oxazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Oxazepam [Mass/volume] in Serum or Plasma by Confirmatory method;Oxazepam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59731-0;Oxazepam;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;Oxazepam [Mass/mass] in Stool by Confirmatory method;Oxazepam Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59732-8;Oxazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Oxazepam [Mass/mass] in Tissue;Oxazepam Tiss-mCnt;;ACTIVE;2.32;2.70 +5973-3;Plasminogen activator tissue type Ag^10M post venistasis;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --10 minutes post venistasis;tPA Ag 10M PPP IA-mCnc;;ACTIVE;1.0d;2.73 +59733-6;Potassium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Potassium [Mass/mass] in Tissue;Potassium Tiss-mCnt;;ACTIVE;2.32;2.70 +59734-4;Propoxyphene;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Propoxyphene [Presence] in Serum or Plasma by Screen method;Propoxyph SerPl Ql Scn;;ACTIVE;2.32;2.73 +59735-1;Salicylamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Salicylamide [Mass/volume] in Blood;Salicylamide Bld-mCnc;;ACTIVE;2.32;2.70 +59736-9;Salicylamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Salicylamide [Mass/volume] in Urine;Salicylamide Ur-mCnc;;ACTIVE;2.32;2.70 +59737-7;Selenium;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Selenium [Mass/mass] in Nail;Selenium Nail-mCnt;;ACTIVE;2.32;2.70 +59738-5;Silver;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Body fluid;Silver Fld-mCnc;;ACTIVE;2.32;2.70 +59739-3;Silver;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Silver [Mass/mass] in Nail;Silver Nail-mCnt;;ACTIVE;2.32;2.70 +59740-1;Silver;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Red Blood Cells;Silver RBC-mCnc;;ACTIVE;2.32;2.70 +5974-1;Plasminogen activator inhibitor 1;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator inhibitor 1 [Units/volume] in Platelet poor plasma by Chromogenic method;PAI1 PPP Chro-aCnc;;ACTIVE;1.0d;2.73 +59741-9;Silver;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Silver [Mass/mass] in Tissue;Silver Tiss-mCnt;;ACTIVE;2.32;2.70 +59742-7;sulfADIAZINE;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;sulfADIAZINE [Mass/volume] in Blood;sulfADIAZINE Bld-mCnc;;ACTIVE;2.32;2.70 +59743-5;SUMAtriptan;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;SUMAtriptan [Mass/volume] in Blood;SUMAtriptan Bld-mCnc;;ACTIVE;2.32;2.70 +59744-3;SUMAtriptan;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;SUMAtriptan [Mass/volume] in Urine;SUMAtriptan Ur-mCnc;;ACTIVE;2.32;2.70 +59745-0;Temazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Blood;Temazepam Bld-mCnc;;ACTIVE;2.32;2.73 +59746-8;Temazepam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Temazepam [Mass/volume] in Blood by Confirmatory method;Temazepam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59747-6;Temazepam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Temazepam [Mass/volume] in Body fluid;Temazepam Fld-mCnc;;ACTIVE;2.32;2.70 +59748-4;Temazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Temazepam [Mass/volume] in Body fluid by Confirmatory method;Temazepam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59749-2;Temazepam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Temazepam [Mass/mass] in Meconium by Confirmatory method;Temazepam Mec Cfm-mCnt;;ACTIVE;2.32;2.70 +597-5;Bacteria identified;Prid;Pt;Asp;Nom;Aerobic culture;MICRO;1;Bacteria identified in Aspirate by Aerobe culture;Bacteria Aspirate Aerobe Cult;;ACTIVE;1.0;2.73 +59750-0;Temazepam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Temazepam [Mass/volume] in Serum or Plasma by Confirmatory method;Temazepam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59751-8;Temazepam;MCnt;Pt;Stool;Qn;Confirm;DRUG/TOX;1;Temazepam [Mass/mass] in Stool by Confirmatory method;Temazepam Stl Cfm-mCnt;;ACTIVE;2.32;2.70 +59752-6;Temazepam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Temazepam [Mass/mass] in Tissue;Temazepam Tiss-mCnt;;ACTIVE;2.32;2.70 +59753-4;Titanium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Titanium [Mass/volume] in Blood;Titanium Bld-mCnc;;ACTIVE;2.32;2.73 +59754-2;Titanium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Titanium [Mass/mass] in Hair;Titanium Hair-mCnt;;ACTIVE;2.32;2.70 +59755-9;Titanium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Titanium [Mass/volume] in Red Blood Cells;Titanium RBC-mCnc;;ACTIVE;2.32;2.70 +59756-7;Titanium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Titanium [Mass/mass] in Tissue;Titanium Tiss-mCnt;;ACTIVE;2.32;2.70 +59757-5;tiZANidine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;tiZANidine [Mass/volume] in Blood;tiZANidine Bld-mCnc;;ACTIVE;2.32;2.70 +5975-8;Plasminogen activator inhibitor 1 Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator inhibitor 1 Ag [Units/volume] in Platelet poor plasma by Immunoassay;PAI1 Ag PPP IA-aCnc;;ACTIVE;1.0d;2.73 +59758-3;Triazolam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Triazolam [Mass/volume] in Blood;Triazolam Bld-mCnc;;ACTIVE;2.32;2.70 +59759-1;Triazolam;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Triazolam [Mass/volume] in Blood by Confirmatory method;Triazolam Bld Cfm-mCnc;;ACTIVE;2.32;2.73 +59760-9;Triazolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Triazolam [Mass/volume] in Body fluid;Triazolam Fld-mCnc;;ACTIVE;2.32;2.70 +59761-7;Triazolam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Triazolam [Mass/volume] in Body fluid by Confirmatory method;Triazolam Fld Cfm-mCnc;;ACTIVE;2.32;2.70 +59762-5;Triazolam;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Triazolam [Mass/volume] in Serum or Plasma by Confirmatory method;Triazolam SerPl Cfm-mCnc;;ACTIVE;2.32;2.73 +59763-3;Triazolam;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Triazolam [Mass/mass] in Tissue;Triazolam Tiss-mCnt;;ACTIVE;2.32;2.73 +59764-1;Triazolam;MCnt;Pt;Tiss;Qn;Confirm;DRUG/TOX;1;Triazolam [Mass/mass] in Tissue by Confirmatory method;Triazolam Tiss Cfm-mCnt;;ACTIVE;2.32;2.70 +59765-8;Tungsten;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tungsten [Mass/volume] in Blood;Tungsten Bld-mCnc;;ACTIVE;2.32;2.70 +5976-6;Plasminogen activator inhibitor 1;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator inhibitor 1 [Mass/volume] in Platelet poor plasma by Chromogenic method;PAI1 PPP Chro-mCnc;;ACTIVE;1.0d;2.73 +59766-6;Tungsten;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Tungsten [Mass/volume] in Red Blood Cells;Tungsten RBC-mCnc;;ACTIVE;2.32;2.70 +59767-4;Ziprasidone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ziprasidone [Mass/volume] in Blood;Ziprasidone Bld-mCnc;;ACTIVE;2.32;2.70 +59768-2;Procedure indications;Imp;Pt;^Patient;Nar;;DOC.MISC;2;Procedure indications [Interpretation] Narrative;Procedure indications Imp;;ACTIVE;2.32;2.73 +59769-0;Postprocedure diagnosis;Imp;Pt;^Patient;Nar;;DOC.MISC;2;Postprocedure diagnosis Narrative;Postprocedure Dx;;ACTIVE;2.32;2.73 +59770-8;Procedure estimated blood loss;Find;Pt;^Patient;Nar;;DOC.MISC;2;Procedure estimated blood loss Narrative;Estimated blood loss;;ACTIVE;2.32;2.73 +59771-6;Procedure implants;Find;Pt;^Patient;Nar;;DOC.MISC;2;Procedure implants Narrative;Implants;;ACTIVE;2.32;2.73 +59772-4;Planned procedure;Find;Pt;^Patient;Nar;;DOC.MISC;2;Planned procedure Narrative;Planned procedure;;ACTIVE;2.32;2.73 +59773-2;Procedure specimens taken;Find;Pt;^Patient;Nar;;DOC.MISC;2;Procedure specimens taken Narrative;Specimens taken;;ACTIVE;2.32;2.73 +5977-4;Plasminogen activator inhibitor 2 Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator inhibitor 2 Ag [Mass/volume] in Platelet poor plasma by Immunoassay;PAI2 Ag PPP IA-mCnc;;ACTIVE;1.0d;2.58 +59774-0;Procedure anesthesia;Find;Pt;^Patient;Nar;;DOC.MISC;2;Procedure anesthesia Narrative;Anesthesia;;ACTIVE;2.32;2.73 +59775-7;Procedure disposition;Find;Pt;^Patient;Nar;;DOC.MISC;2;Procedure disposition Narrative;Disposition;;ACTIVE;2.32;2.73 +59776-5;Procedure findings;Find;Pt;^Patient;Nar;;DOC.MISC;2;Procedure findings Narrative;Findings;;ACTIVE;2.32;2.73 +59777-3;Latest date to give immunization;Date;Pt;^Patient;Qn;;VACCIN;2;Latest date to give immunization;Latest date to give immunization;;ACTIVE;2.32;2.68 +59778-1;Date when overdue for immunization;Date;Pt;^Patient;Qn;;VACCIN;2;Date when overdue for immunization;Date when overdue for immunization;;ACTIVE;2.32;2.68 +59779-9;Immunization schedule used;Find;Pt;^Patient;Nom;;VACCIN;2;Immunization schedule used;Immunization schedule used;;ACTIVE;2.32;2.68 +59780-7;Immunization series;Find;Pt;^Patient;Nom;;VACCIN;2;Immunization series;Immunization series;;ACTIVE;2.32;2.68 +59781-5;Dose validity;Find;Pt;^Patient;Nom;;VACCIN;2;Dose validity;Dose validity;;ACTIVE;2.32;2.68 +5978-2;Plasminogen activator inhibitor 2;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator inhibitor 2 [Units/volume] in Platelet poor plasma by Chromogenic method;PAI2 PPP Chro-aCnc;;ACTIVE;1.0d;2.69 +59782-3;Number of doses in primary immunization series;Num;Pt;^Patient;Qn;;VACCIN;2;Number of doses in primary immunization series;# doses primary immunization series;;ACTIVE;2.32;2.68 +59783-1;Status in immunization series;Find;Pt;^Patient;Nom;;VACCIN;2;Status in immunization series;Status in immunization series;;ACTIVE;2.32;2.68 +59784-9;Disease with presumed immunity;Find;Pt;^Patient;Nom;;VACCIN;2;Disease with presumed immunity;Disease with presumed immunity;;ACTIVE;2.32;2.73 +59785-6;Indication for Immunization;Find;Pt;^Patient;Nom;;VACCIN;2;Indication for Immunization;Indication for Immunization;;ACTIVE;2.32;2.68 +59786-4;Urea/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Urea/Creatinine [Molar ratio] in Urine;Urea/Creat Ur-sRto;;ACTIVE;2.32;2.70 +59787-2;Catecholamines;SCnc;Pt;Plas;Qn;;CHEM;1;Catecholamines [Moles/volume] in Plasma;Catechols Plas-sCnc;;ACTIVE;2.32;2.73 +59788-0;Coagulation dilute Russell viper venom induced.factor substitution^1H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with normal plasma;dRVVT 1h NP PPP;;DISCOURAGED;2.32;2.73 +59789-8;Coagulation dilute Russell viper venom induced.factor substitution^2H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with normal plasma;dRVVT 2h NP PPP;;DISCOURAGED;2.32;2.70 +5979-0;Plasminogen activator inhibitor 2 Ag;ACnc;Pt;PPP;Qn;Imm;COAG;1;Deprecated Plasminogen activator inhibitor 2 Ag [Units/volume] in Platelet poor plasma by Immunologic method;Deprecated PAI2 Ag PPP Imm-aCnc;;DEPRECATED;1.0d;2.69 +59790-6;Hexacarboxylporphyrin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexacarboxylporphyrin [Moles/volume] in Serum or Plasma;Hexa-CP SerPl-sCnc;;ACTIVE;2.32;2.70 +59791-4;Glucose^30M post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Molar concentration difference] in Serum or Plasma --30 minutes post XXX challenge;Glucose 30M p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59792-2;Glucose^1H post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Molar concentration difference] in Serum or Plasma --1 hour post XXX challenge;Glucose 1h p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59793-0;Glucose^1.5H post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Molar concentration difference] in Serum or Plasma --1.5 hours post XXX challenge;Glucose 1.5h p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59794-8;Glucose^2H post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Molar concentration difference] in Serum or Plasma --2 hours post XXX challenge;Glucose 2h p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59795-5;Glucose^3H post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Molar concentration difference] in Serum or Plasma --3 hours post XXX challenge;Glucose 3h p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59796-3;Glucose^4H post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Molar concentration difference] in Serum or Plasma --4 hours post XXX challenge;Glucose 4h p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59797-1;Glucose^5H post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Molar concentration difference] in Serum or Plasma --5 hours post XXX challenge;Glucose 5h p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59798-9;Ganciclovir^peak;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Ganciclovir [Mass/volume] in Plasma --peak;Ganciclovir Peak Plas-mCnc;;ACTIVE;2.32;2.70 +59799-7;Ganciclovir^trough;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Ganciclovir [Mass/volume] in Plasma --trough;Ganciclovir Trough Plas-mCnc;;ACTIVE;2.32;2.70 +59800-3;Protein.monoclonal band 2/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 2/Protein.total in Urine by Electrophoresis;M Protein 2 MFr Ur Elph;;ACTIVE;2.32;2.73 +59801-1;Protein.monoclonal band 3/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 3/Protein.total in Urine by Electrophoresis;M Protein 3 MFr Ur Elph;;ACTIVE;2.32;2.73 +59802-9;Protein.monoclonal band 4/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 4/Protein.total in Urine by Electrophoresis;M Protein 4 MFr Ur Elph;;ACTIVE;2.32;2.73 +59803-7;Cortisol^30M post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Molar concentration difference] in Serum or Plasma --30 minutes post XXX challenge;Cortis 30M p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59804-5;Cortisol^1H post XXX challenge;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Molar concentration difference] in Serum or Plasma --1 hour post XXX challenge;Cortis 1h p chal SerPl-SCDiff;;ACTIVE;2.32;2.70 +59805-2;Epstein Barr virus DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Body fluid by NAA with probe detection;EBV DNA Fld Ql NAA+probe;;ACTIVE;2.32;2.63 +59806-0;Coagulation surface induced.lupus sensitive.factor substitution^2H post incubation after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with normal plasma;aPTT-LA 2h NP PPP;;DISCOURAGED;2.32;2.73 +59807-8;Phosphatidylglycerol;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylglycerol [Moles/volume] in Amniotic fluid;PG Amn-sCnc;;ACTIVE;2.32;2.70 +5980-8;Plasminogen activator inhibitor Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator inhibitor Ag [Mass/volume] in Platelet poor plasma by Immunoassay;PAI Ag PPP IA-mCnc;;ACTIVE;1.0d;2.73 +59808-6;Lymphocytes.large granular;PrThr;Pt;Bld;Ord;;HEM/BC;1;Large granular lymphocytes [Presence] in Blood;Lg Gran Lymphs Bld Ql;;ACTIVE;2.32;2.73 +59809-4;Lymphoma cells;PrThr;Pt;Bld;Ord;;HEM/BC;1;Lymphoma cells [Presence] in Blood;Lymphoma Cells Bld Ql;;ACTIVE;2.32;2.56 +59810-2;Caffeine^trough;SCnc;Pt;Ser;Qn;;DRUG/TOX;1;Caffeine [Moles/volume] in Serum --trough;Caffeine Trough Ser-sCnc;;ACTIVE;2.34;2.70 +59811-0;Caffeine^peak;SCnc;Pt;Ser;Qn;;DRUG/TOX;1;Caffeine [Moles/volume] in Serum --peak;Caffeine Peak Ser-sCnc;;ACTIVE;2.34;2.70 +59812-8;Glucose^11 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --11 AM specimen;Glucose 11 AM SerPl-sCnc;;ACTIVE;2.32;2.70 +59813-6;Glucose^7 AM specimen;SCnc;Pt;BldC;Qn;Glucometer;CHAL;1;Glucose [Moles/volume] in Capillary blood by Glucometer --7 AM specimen;Glucose 7 AM BldC Glucomtr-sCnc;;ACTIVE;2.32;2.70 +59814-4;Glucose^7 AM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --7 AM specimen;Glucose 7 AM SerPl-sCnc;;ACTIVE;2.32;2.70 +59815-1;Glucose^3 PM specimen;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --3 PM specimen;Glucose 3 PM SerPl-sCnc;;ACTIVE;2.32;2.70 +5981-6;Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay;tPA-PAI1 PPP IA-mCnc;;ACTIVE;1.0d;2.58 +59816-9;Neutrophils.immature/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Neutrophils.immature/100 leukocytes in Body fluid;Neutrophils.immature/leuk NFr Fld;;ACTIVE;2.32;2.50 +59817-7;Uroporphyrin 1 isomer/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Uroporphyrin 1 isomer/Creatinine [Molar ratio] in 24 hour Urine;Uropor1/Creat 24h Ur-sRto;;ACTIVE;2.32;2.70 +59818-5;Uroporphyrin 3 isomer/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Uroporphyrin 3 isomer/Creatinine [Molar ratio] in 24 hour Urine;Uropor3/Creat 24h Ur-sRto;;ACTIVE;2.32;2.70 +59819-3;Pentacarboxylporphyrins/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins/Creatinine [Molar ratio] in 24 hour Urine;Penta-CP/Creat 24h Ur-sRto;;ACTIVE;2.32;2.70 +59820-1;Coproporphyrin 1/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Coproporphyrin 1/Creatinine [Molar ratio] in 24 hour Urine;Copro1/Creat 24h Ur-sRto;;ACTIVE;2.32;2.70 +59821-9;Coproporphyrin 3/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Coproporphyrin 3/Creatinine [Molar ratio] in 24 hour Urine;Copro3/Creat 24h Ur-sRto;;ACTIVE;2.32;2.70 +59822-7;Tacrolimus^4H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Serum or Plasma --4 hours post dose;Tacrolimus 4h p SerPl-mCnc;;ACTIVE;2.32;2.70 +59823-5;Tacrolimus^2H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Serum or Plasma --2 hours post dose;Tacrolimus 2h p SerPl-mCnc;;ACTIVE;2.32;2.70 +5982-4;Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex^20M post venistasis;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay --20 minutes post venistasis;tPA-PAI1 20M PPP IA-mCnc;;ACTIVE;1.0d;2.58 +59824-3;Cyanide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Cyanide [Presence] in Urine;Cyanide Ur Ql;;ACTIVE;2.32;2.56 +59825-0;Phenols;PrThr;Pt;Urine;Ord;;UA;1;Phenols [Presence] in Urine;Phenols Ur Ql;;ACTIVE;2.32;2.56 +59826-8;Creatinine;SCnc;Pt;Bld;Qn;;CHEM;1;Creatinine [Moles/volume] in Blood;Creat Bld-sCnc;;ACTIVE;2.32;2.73 +59827-6;Bilirubin;MCnc;Pt;BldA;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Arterial blood;Bilirub BldA-mCnc;;ACTIVE;2.32;2.70 +59828-4;Bilirubin;MCnc;Pt;BldV;Qn;;CHEM;1;Bilirubin.total [Mass/volume] in Venous blood;Bilirub BldV-mCnc;;ACTIVE;2.32;2.70 +59829-2;Leukocytes;NRat;3H;Urine sed;Qn;Microscopy.light;UA;1;Leukocytes in 3 hour Urine sediment by Light microscopy;WBC 3h UrnS Micro-nRate;;ACTIVE;2.32;2.70 +598-3;Bacteria identified;Prid;Pt;Asp;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Aspirate by Anaerobe culture;Bacteria Aspirate Anaerobe Cult;;ACTIVE;1.0;2.21 +59830-0;Erythrocytes;NRat;3H;Urine sed;Qn;Microscopy.light;UA;1;Erythrocytes in 3 hour Urine sediment by Light microscopy;RBC 3h UrnS Micro-nRate;;ACTIVE;2.32;2.70 +59831-8;Gastrin^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --baseline;Gastrin BS SerPl-mCnc;;ACTIVE;2.32;2.73 +5983-2;Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex^10M post venistasis;MCnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay --10 minutes post venistasis;tPA-PAI1 10M PPP IA-mCnc;;ACTIVE;1.0d;2.58 +59832-6;Gastrin^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Gastrin sp1 p chal SerPl-mCnc;;ACTIVE;2.32;2.73 +59833-4;Antibiotic XXX;Susc;Pt;Isolate;OrdQn;MLC;ABXBACT;1;Other Antibiotic [Susceptibility] by Minimum lethal concentration (MLC);Other Antibiotic Islt MLC;;ACTIVE;2.32;2.32 +59834-2;Creatinine reduction ratio;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine reduction ratio in Serum or Plasma;Creatinine reduction ratio MFr SerPl;;ACTIVE;2.32;2.70 +59835-9;Parathyrin.intact;MCnc;Pt;Body fld;Qn;;CHEM;1;Parathyrin.intact [Mass/volume] in Body fluid;PTH-Intact Fld-mCnc;;ACTIVE;2.32;2.73 +59836-7;Mycoplasma sp+Ureaplasma urealyticum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma sp+Ureaplasma urealyticum DNA [Presence] in Specimen by NAA with probe detection;Mycoplas+U urealyt DNA Spec Ql NAA+probe;;ACTIVE;2.32;2.73 +59837-5;Methylenedioxyamphetamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Serum or Plasma;MDA SerPl-mCnc;;ACTIVE;2.32;2.73 +59838-3;Cytomegalovirus Ab;PrThr;Pt;Ser/Plas;Ord;LA;MICRO;1;Cytomegalovirus Ab [Presence] in Serum or Plasma by Latex agglutination;CMV Ab SerPl Ql LA;;ACTIVE;2.32;2.56 +59839-1;Urate crystals;PrThr;Pt;Tiss;Ord;Microscopy.light;PATH;1;Urate crystals [Presence] in Tissue by Light microscopy;Urate Cry Tiss Ql Micro;;ACTIVE;2.32;2.73 +5984-0;Plasminogen activator urokinase type;ACnc;Pt;Urine;Qn;;COAG;1;Plasminogen activator urokinase type [Units/volume] in Urine;uPA Ur-aCnc;;ACTIVE;1.0d;2.69 +59840-9;Dehydroepiandrosterone^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone (DHEA) [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;DHEA sp8 p chal SerPl-mCnc;;ACTIVE;2.32;2.73 +59841-7;Vendor name;ID;Pt;XXX;Nom;;CHEM;1;Vendor name [Identifier] in Specimen;Vendor name Spec;;ACTIVE;2.32;2.73 +59842-5;Apnea interval;Time;Pt;Ventilator.alarm;Qn;;PULM;2;Apnea interval Ventilator alarm;Apnea interval Vent alarm;;ACTIVE;2.32;2.70 +59843-3;Procedure note - recommended C-CDA R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Procedure note - recommended C-CDA R1.1 sections;Proced Nte C-CDA R1.1 Sections;;ACTIVE;2.32;2.56 +59844-1;Methylenedioxyethylamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Urine by Screen method;MDEA Ur Ql Scn;;ACTIVE;2.32;2.73 +59845-8;Instructions for use section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Instructions for use section;FDA insert Instructions for use;;ACTIVE;2.34;2.34 +59846-6;Salmonella sp identified;Type;Pt;Isolate;Nom;;MICRO;1;Salmonella sp identified [Type] in Isolate;Salmonella Islt;;ACTIVE;2.34;2.34 +59847-4;Histology and Behavior ICD-O-3;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Histology and Behavior ICD-O-3 Cancer;Histology and Behavior ICD-O-3 Cancer;;ACTIVE;2.34;2.34 +59848-2;Morphology.ICD-O-3;Prid;Pt;Cancer.XXX;Nom;;TUMRRGT;2;Morphology.ICD-O-3 Cancer;Morphology.ICD-O-3 Cancer;;ACTIVE;2.34;2.34 +59849-0;Lactate^post exercise;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactate [Moles/volume] in Serum or Plasma --post exercise;Lactate p Exc SerPl-sCnc;;ACTIVE;2.34;2.70 +59850-8;Wuchereria bancrofti Ag;ACnc;Pt;Ser;Qn;IA;MICRO;1;Wuchereria bancrofti Ag [Units/volume] in Serum by Immunoassay;W bancr Ag Ser IA-aCnc;;ACTIVE;2.34;2.70 +59852-4;North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panel;-;Pt;^Patient;-;;PANEL.TUMRRGT;2;North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panel;NAACCR v 12 Pnl;;ACTIVE;2.34;2.34 +59853-2;Pathology specimen collection date 1;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Pathology specimen collection date 1 Cancer;Path spec coll date 1 Cancer;;ACTIVE;2.34;2.34 +59854-0;Pathology specimen collection date 2;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Pathology specimen collection date 2 Cancer;Path spec coll date 2 Cancer;;ACTIVE;2.34;2.34 +59855-7;Pathology specimen collection date 3;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Pathology specimen collection date 3 Cancer;Path spec coll date 3 Cancer;;ACTIVE;2.34;2.34 +59856-5;Pathology specimen collection date 4;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Pathology specimen collection date 4 Cancer;Path spec coll date 4 Cancer;;ACTIVE;2.34;2.34 +5985-7;Plasminogen activator urokinase type;ACnc;Pt;PPP;Qn;;COAG;1;Plasminogen activator urokinase type [Units/volume] in Platelet poor plasma;uPA PPP-aCnc;;ACTIVE;1.0d;2.69 +59857-3;Pathology specimen collection date 5;TmStp;Pt;Cancer.XXX;Qn;;TUMRRGT;2;Pathology specimen collection date 5 Cancer;Path spec coll date 5 Cancer;;ACTIVE;2.34;2.34 +59858-1;SEER site-specific fact 1;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;SEER site-specific fact 1 [Identifier] Cancer;SEER site-specific fact 1 Cancer;;ACTIVE;2.34;2.34 +59859-9;SEER site-specific fact 2;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;SEER site-specific fact 2 [Identifier] Cancer;SEER site-specific fact 2 Cancer;;ACTIVE;2.34;2.34 +59860-7;SEER site-specific fact 3;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;SEER site-specific fact 3 [Identifier] Cancer;SEER site-specific fact 3 Cancer;;ACTIVE;2.34;2.34 +59861-5;SEER site-specific fact 4;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;SEER site-specific fact 4 [Identifier] Cancer;SEER site-specific fact 4 Cancer;;ACTIVE;2.34;2.34 +59862-3;SEER site-specific fact 5;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;SEER site-specific fact 5 [Identifier] Cancer;SEER site-specific fact 5 Cancer;;ACTIVE;2.34;2.34 +59863-1;SEER site-specific fact 6;ID;Pt;Cancer.XXX;Nom;;TUMRRGT;2;SEER site-specific fact 6 [Identifier] Cancer;SEER site-specific fact 6 Cancer;;ACTIVE;2.34;2.34 +59864-9;Acetone;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Acetone [Moles/volume] in Gastric fluid;Acetone Gast-sCnc;;ACTIVE;2.34;2.70 +5986-5;Plasminogen activator tissue type;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method;tPA PPP Chro-aCnc;;ACTIVE;1.0d;2.73 +59865-6;Amobarbital;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amobarbital [Moles/volume] in Urine;Amobarbital Ur-sCnc;;ACTIVE;2.34;2.70 +59866-4;Amobarbital;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Amobarbital [Moles/volume] in Gastric fluid;Amobarbital Gast-sCnc;;ACTIVE;2.34;2.70 +59867-2;Amoxapine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amoxapine [Moles/volume] in Urine;Amoxapine Ur-sCnc;;ACTIVE;2.34;2.70 +59868-0;Amoxapine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Amoxapine [Moles/volume] in Gastric fluid;Amoxapine Gast-sCnc;;ACTIVE;2.34;2.70 +59869-8;Benztropine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benztropine [Moles/volume] in Serum or Plasma;Benztropine SerPl-sCnc;;ACTIVE;2.34;2.70 +59870-6;Benztropine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benztropine [Moles/volume] in Urine;Benztropine Ur-sCnc;;ACTIVE;2.34;2.70 +59871-4;Benztropine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Benztropine [Moles/volume] in Gastric fluid;Benztropine Gast-sCnc;;ACTIVE;2.34;2.70 +59872-2;Bromazepam;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Bromazepam [Moles/volume] in Urine;Bromazepam Ur-sCnc;;ACTIVE;2.34;2.70 +5987-3;Plasminogen activator tissue type;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator tissue type [Mass/volume] in Platelet poor plasma by Chromogenic method;tPA PPP Chro-mCnc;;ACTIVE;1.0d;2.73 +59873-0;Bromazepam;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Bromazepam [Moles/volume] in Gastric fluid;Bromazepam Gast-sCnc;;ACTIVE;2.34;2.70 +59874-8;Brompheniramine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Brompheniramine [Moles/volume] in Urine;Brompheniramine Ur-sCnc;;ACTIVE;2.34;2.70 +59875-5;Brompheniramine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Brompheniramine [Moles/volume] in Gastric fluid;Brompheniramine Gast-sCnc;;ACTIVE;2.34;2.70 +59876-3;carBAMazepine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;carBAMazepine [Presence] in Gastric fluid;carBAMazepine Gast Ql;;ACTIVE;2.34;2.56 +59877-1;Chloral hydrate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chloral hydrate [Moles/volume] in Urine;Chloral Hydrate Ur-sCnc;;ACTIVE;2.34;2.70 +59878-9;Chloral hydrate;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Chloral hydrate [Moles/volume] in Gastric fluid;Chloral Hydrate Gast-sCnc;;ACTIVE;2.34;2.70 +59879-7;chlordiazePOXIDE;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Moles/volume] in Urine;Chlordiazep Ur-sCnc;;ACTIVE;2.34;2.70 +59880-5;chlordiazePOXIDE;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Moles/volume] in Gastric fluid;Chlordiazep Gast-sCnc;;ACTIVE;2.34;2.70 +5988-1;Plasminogen activator tissue type^10M post venistasis;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator tissue type [Mass/volume] in Platelet poor plasma by Chromogenic method --10 minutes post venistasis;tPA 10M PPP Chro-mCnc;;ACTIVE;1.0d;2.34 +59881-3;Chlorpheniramine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorpheniramine [Moles/volume] in Serum or Plasma;Chlorphenir SerPl-sCnc;;ACTIVE;2.34;2.70 +59882-1;Chlorpheniramine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorpheniramine [Moles/volume] in Urine;Chlorphenir Ur-sCnc;;ACTIVE;2.34;2.70 +59883-9;Chlorpheniramine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Chlorpheniramine [Moles/volume] in Gastric fluid;Chlorphenir Gast-sCnc;;ACTIVE;2.34;2.70 +59884-7;chlorproMAZINE;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;chlorproMAZINE [Moles/volume] in Urine;chlorproMAZINE Ur-sCnc;;ACTIVE;2.34;2.70 +59885-4;chlorproMAZINE;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;chlorproMAZINE [Moles/volume] in Gastric fluid;chlorproMAZINE Gast-sCnc;;ACTIVE;2.34;2.70 +59886-2;Citalopram;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Citalopram [Moles/volume] in Urine;Citalopram Ur-sCnc;;ACTIVE;2.34;2.70 +59887-0;Citalopram;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Citalopram [Moles/volume] in Gastric fluid;Citalopram Gast-sCnc;;ACTIVE;2.34;2.70 +59888-8;cloBAZam;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;cloBAZam [Moles/volume] in Urine;cloBAZam Ur-sCnc;;ACTIVE;2.34;2.70 +59889-6;clomiPRAMINE;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;clomiPRAMINE [Moles/volume] in Gastric fluid;clomiPRAMINE Gast-sCnc;;ACTIVE;2.34;2.70 +59890-4;cloZAPine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;cloZAPine [Moles/volume] in Gastric fluid;cloZAPine Gast-sCnc;;ACTIVE;2.34;2.70 +59891-2;Cotinine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cotinine [Moles/volume] in Serum or Plasma;Cotinine SerPl-sCnc;;ACTIVE;2.34;2.70 +59892-0;Cotinine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Cotinine [Moles/volume] in Gastric fluid;Cotinine Gast-sCnc;;ACTIVE;2.34;2.70 +59893-8;Desipramine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Desipramine [Moles/volume] in Gastric fluid;Desipramine Gast-sCnc;;ACTIVE;2.34;2.70 +59894-6;Dextromethorphan;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dextromethorphan [Moles/volume] in Serum or Plasma;D-methorphan SerPl-sCnc;;ACTIVE;2.34;2.70 +59895-3;Dextromethorphan;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dextromethorphan [Moles/volume] in Urine;D-methorphan Ur-sCnc;;ACTIVE;2.34;2.70 +59896-1;Dextromethorphan;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Dextromethorphan [Moles/volume] in Gastric fluid;D-methorphan Gast-sCnc;;ACTIVE;2.34;2.70 +59897-9;Disopyramide;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Disopyramide [Moles/volume] in Urine;Disopyramide Ur-sCnc;;ACTIVE;2.34;2.70 +59898-7;Disopyramide;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Disopyramide [Moles/volume] in Gastric fluid;Disopyramide Gast-sCnc;;ACTIVE;2.34;2.70 +5989-9;Plasminogen activator tissue type^10M post venistasis;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --10 minutes post venistasis;tPA 10M PPP Chro-aCnc;;ACTIVE;1.0d;2.69 +59899-5;Ethylene glycol;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Ethylene glycol [Moles/volume] in Gastric fluid;Ethylene Glycol Gast-sCnc;;ACTIVE;2.34;2.70 +59900-1;Fenoprofen;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fenoprofen [Moles/volume] in Urine;Fenoprofen Ur-sCnc;;ACTIVE;2.34;2.70 +59901-9;Fenoprofen;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Fenoprofen [Moles/volume] in Gastric fluid;Fenoprofen Gast-sCnc;;ACTIVE;2.34;2.70 +59902-7;FLUoxetine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;FLUoxetine [Moles/volume] in Urine;FLUoxetine Ur-sCnc;;ACTIVE;2.34;2.70 +59903-5;FLUoxetine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;FLUoxetine [Moles/volume] in Gastric fluid;FLUoxetine Gast-sCnc;;ACTIVE;2.34;2.70 +59904-3;fluPHENAZine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;fluPHENAZine [Moles/volume] in Urine;fluPHENAZine Ur-sCnc;;ACTIVE;2.34;2.70 +59905-0;fluPHENAZine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;fluPHENAZine [Moles/volume] in Gastric fluid;fluPHENAZine Gast-sCnc;;ACTIVE;2.34;2.70 +59906-8;fluvoxaMINE;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;fluvoxaMINE [Moles/volume] in Urine;fluvoxaMINE Ur-sCnc;;ACTIVE;2.34;2.70 +5990-7;Plasminogen activator tissue type^20M post venistasis;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --20 minutes post venistasis;tPA 20M PPP Chro-aCnc;;ACTIVE;1.0d;2.73 +59907-6;fluvoxaMINE;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;fluvoxaMINE [Moles/volume] in Gastric fluid;fluvoxaMINE Gast-sCnc;;ACTIVE;2.34;2.70 +59908-4;hydrOXYzine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;hydrOXYzine [Moles/volume] in Urine;hydrOXYzine Ur-sCnc;;ACTIVE;2.34;2.70 +59909-2;hydrOXYzine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;hydrOXYzine [Moles/volume] in Gastric fluid;hydrOXYzine Gast-sCnc;;ACTIVE;2.34;2.70 +599-1;Bacteria identified;Prid;Pt;^BPU;Nom;Aerobic culture;MICRO;1;Bacteria identified in Blood product unit by Aerobe culture;Bacteria BPU Aerobe Cult;;ACTIVE;1.0;2.73 +59910-0;Ibuprofen;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ibuprofen [Moles/volume] in Urine;Ibuprofen Ur-sCnc;;ACTIVE;2.34;2.70 +59911-8;Ibuprofen;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Ibuprofen [Moles/volume] in Gastric fluid;Ibuprofen Gast-sCnc;;ACTIVE;2.34;2.70 +59912-6;Imipramine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Imipramine [Moles/volume] in Urine;Imipramine Ur-sCnc;;ACTIVE;2.34;2.70 +59913-4;Imipramine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Imipramine [Moles/volume] in Gastric fluid;Imipramine Gast-sCnc;;ACTIVE;2.34;2.70 +59914-2;Indomethacin;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Indomethacin [Moles/volume] in Urine;Indomethacin Ur-sCnc;;ACTIVE;2.34;2.70 +5991-5;Plasminogen Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Plasminogen Ag [Units/volume] in Platelet poor plasma by Immunoassay;PLG Ag PPP IA-aCnc;;ACTIVE;1.0d;2.73 +59915-9;Indomethacin;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Indomethacin [Moles/volume] in Gastric fluid;Indomethacin Gast-sCnc;;ACTIVE;2.34;2.70 +59916-7;Isopropanol;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Isopropanol [Moles/volume] in Gastric fluid;Isopropanol Gast-sCnc;;ACTIVE;2.34;2.70 +59917-5;Ketoprofen;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ketoprofen [Moles/volume] in Urine;Ketoprofen Ur-sCnc;;ACTIVE;2.34;2.70 +59918-3;Ketoprofen;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Ketoprofen [Moles/volume] in Gastric fluid;Ketoprofen Gast-sCnc;;ACTIVE;2.34;2.70 +59919-1;lamoTRIgine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;lamoTRIgine [Moles/volume] in Urine;lamoTRIgine Ur-sCnc;;ACTIVE;2.34;2.70 +59920-9;lamoTRIgine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;lamoTRIgine [Moles/volume] in Gastric fluid;lamoTRIgine Gast-sCnc;;ACTIVE;2.34;2.70 +59921-7;Mefenamate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mefenamate [Moles/volume] in Serum or Plasma;Mefenamate SerPl-sCnc;;ACTIVE;2.34;2.70 +59922-5;Mefenamate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mefenamate [Moles/volume] in Urine;Mefenamate Ur-sCnc;;ACTIVE;2.34;2.70 +5992-3;Platelet aggregation.adenosine diphosphate induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma;PA ADP PRP;;ACTIVE;1.0d;2.73 +59923-3;Mefenamate;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Mefenamate [Moles/volume] in Gastric fluid;Mefenamate Gast-sCnc;;ACTIVE;2.34;2.70 +59924-1;Meperidine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Meperidine [Moles/volume] in Serum or Plasma;Meperidine SerPl-sCnc;;ACTIVE;2.34;2.70 +59925-8;Mesoridazine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mesoridazine [Moles/volume] in Urine;Mesoridazine Ur-sCnc;;ACTIVE;2.34;2.70 +59926-6;Mesoridazine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Mesoridazine [Moles/volume] in Gastric fluid;Mesoridazine Gast-sCnc;;ACTIVE;2.34;2.70 +59927-4;Methanol;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methanol [Moles/volume] in Gastric fluid;Methanol Gast-sCnc;;ACTIVE;2.34;2.70 +59928-2;Methaqualone;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methaqualone [Moles/volume] in Urine;Methaqualone Ur-sCnc;;ACTIVE;2.34;2.70 +59929-0;Methaqualone;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methaqualone [Moles/volume] in Gastric fluid;Methaqualone Gast-sCnc;;ACTIVE;2.34;2.70 +59930-8;Methotrimeprazine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methotrimeprazine [Moles/volume] in Urine;Methotrimeprazine Ur-sCnc;;ACTIVE;2.34;2.70 +5993-1;Platelet aggregation.arachidonate induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation arachidonate induced in Platelet rich plasma;PA AA PRP;;ACTIVE;1.0d;2.73 +59931-6;Methotrimeprazine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Methotrimeprazine [Moles/volume] in Gastric fluid;Methotrimeprazine Gast-sCnc;;ACTIVE;2.34;2.70 +59932-4;Mexiletine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mexiletine [Moles/volume] in Urine;Mexiletine Ur-sCnc;;ACTIVE;2.34;2.70 +59933-2;Mexiletine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Mexiletine [Moles/volume] in Gastric fluid;Mexiletine Gast-sCnc;;ACTIVE;2.34;2.70 +59934-0;Naproxen;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Naproxen [Moles/volume] in Urine;Naproxen Ur-sCnc;;ACTIVE;2.34;2.70 +59935-7;Naproxen;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Naproxen [Moles/volume] in Gastric fluid;Naproxen Gast-sCnc;;ACTIVE;2.34;2.70 +59936-5;Nicotine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nicotine [Moles/volume] in Urine;Nicotine Ur-sCnc;;ACTIVE;2.34;2.70 +59937-3;Nicotine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Nicotine [Moles/volume] in Gastric fluid;Nicotine Gast-sCnc;;ACTIVE;2.34;2.70 +59938-1;Norclobazam;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norclobazam [Moles/volume] in Urine;Norclobazam Ur-sCnc;;ACTIVE;2.34;2.70 +59939-9;Norclobazam;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Norclobazam [Moles/volume] in Gastric fluid;Norclobazam Gast-sCnc;;ACTIVE;2.34;2.70 +59940-7;Norclomipramine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norclomipramine [Moles/volume] in Urine;Norclomipramine Ur-sCnc;;ACTIVE;2.34;2.70 +59941-5;Norclomipramine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Norclomipramine [Moles/volume] in Gastric fluid;Norclomipramine Gast-sCnc;;ACTIVE;2.34;2.70 +59942-3;Nordoxepin;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nordoxepin [Moles/volume] in Urine;Nordoxepin Ur-sCnc;;ACTIVE;2.34;2.70 +59943-1;Nordoxepin;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Nordoxepin [Moles/volume] in Gastric fluid;Nordoxepin Gast-sCnc;;ACTIVE;2.34;2.70 +59944-9;Normeperidine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Normeperidine [Moles/volume] in Serum or Plasma;Normeperidine SerPl-sCnc;;ACTIVE;2.34;2.70 +59945-6;Nortriptyline;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Nortriptyline [Moles/volume] in Gastric fluid;Nortrip Gast-sCnc;;ACTIVE;2.34;2.70 +59946-4;OLANZapine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;OLANZapine [Moles/volume] in Gastric fluid;OLANZapine Gast-sCnc;;ACTIVE;2.34;2.70 +59947-2;OXcarbazepine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;OXcarbazepine [Moles/volume] in Urine;OXcarbazepine Ur-sCnc;;ACTIVE;2.34;2.70 +59948-0;OXcarbazepine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;OXcarbazepine [Moles/volume] in Gastric fluid;OXcarbazepine Gast-sCnc;;ACTIVE;2.34;2.70 +5994-9;Platelet aggregation.calcium ionophore induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation calcium ionophore induced in Platelet rich plasma;PA Ca Ionoph PRP;;ACTIVE;1.0d;2.54 +59949-8;PARoxetine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;PARoxetine [Moles/volume] in Urine;PARoxetine Ur-sCnc;;ACTIVE;2.34;2.70 +59950-6;PARoxetine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;PARoxetine [Moles/volume] in Gastric fluid;PARoxetine Gast-sCnc;;ACTIVE;2.34;2.70 +59951-4;Pentazocine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pentazocine [Moles/volume] in Urine;Pentazocine Ur-sCnc;;ACTIVE;2.34;2.70 +59952-2;Pentazocine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Pentazocine [Moles/volume] in Gastric fluid;Pentazocine Gast-sCnc;;ACTIVE;2.34;2.70 +59953-0;Perphenazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Perphenazine [Moles/volume] in Serum or Plasma;Perphenazine SerPl-sCnc;;ACTIVE;2.34;2.70 +59954-8;Perphenazine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Perphenazine [Moles/volume] in Urine;Perphenazine Ur-sCnc;;ACTIVE;2.34;2.70 +59955-5;Perphenazine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Perphenazine [Moles/volume] in Gastric fluid;Perphenazine Gast-sCnc;;ACTIVE;2.34;2.70 +5995-6;Platelet aggregation.collagen induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation collagen induced in Platelet rich plasma;PA Coll PRP;;ACTIVE;1.0d;2.73 +59956-3;Phencyclidine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phencyclidine [Moles/volume] in Serum or Plasma;PCP SerPl-sCnc;;ACTIVE;2.34;2.70 +59957-1;Promazine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Promazine [Moles/volume] in Serum or Plasma;Promazine SerPl-sCnc;;ACTIVE;2.34;2.70 +59958-9;Promazine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Promazine [Moles/volume] in Urine;Promazine Ur-sCnc;;ACTIVE;2.34;2.70 +59959-7;Promazine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Promazine [Moles/volume] in Gastric fluid;Promazine Gast-sCnc;;ACTIVE;2.34;2.70 +59960-5;Propoxyphene;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propoxyphene [Moles/volume] in Urine;Propoxyph Ur-sCnc;;ACTIVE;2.34;2.73 +59961-3;Propoxyphene;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Propoxyphene [Moles/volume] in Gastric fluid;Propoxyph Gast-sCnc;;ACTIVE;2.34;2.70 +59962-1;Propranolol;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Propranolol [Moles/volume] in Gastric fluid;Propranolol Gast-sCnc;;ACTIVE;2.34;2.70 +59963-9;QUEtiapine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;QUEtiapine [Moles/volume] in Urine;QUEtiapine Ur-sCnc;;ACTIVE;2.34;2.70 +5996-4;Platelet aggregation.EPINEPHrine induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma;PA Epineph PRP;;ACTIVE;1.0d;2.73 +59964-7;QUEtiapine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;QUEtiapine [Moles/volume] in Gastric fluid;QUEtiapine Gast-sCnc;;ACTIVE;2.34;2.70 +59965-4;quiNINE;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNINE [Moles/volume] in Serum or Plasma;quiNINE SerPl-sCnc;;ACTIVE;2.34;2.70 +59966-2;quiNINE;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;quiNINE [Moles/volume] in Urine;quiNINE Ur-sCnc;;ACTIVE;2.34;2.70 +59967-0;quiNINE;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;quiNINE [Moles/volume] in Gastric fluid;quiNINE Gast-sCnc;;ACTIVE;2.34;2.70 +59968-8;Strychnine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Strychnine [Moles/volume] in Serum or Plasma;Strychnine SerPl-sCnc;;ACTIVE;2.34;2.70 +59969-6;Strychnine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Strychnine [Moles/volume] in Urine;Strychnine Ur-sCnc;;ACTIVE;2.34;2.70 +59970-4;Strychnine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Strychnine [Moles/volume] in Gastric fluid;Strychnine Gast-sCnc;;ACTIVE;2.34;2.70 +59971-2;Sulfamethoxazole;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sulfamethoxazole [Moles/volume] in Urine;Sulfamethoxazole Ur-sCnc;;ACTIVE;2.34;2.70 +5997-2;Platelet aggregation.norepinephrine induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation norepinephrine induced in Platelet rich plasma;PA Norepineph PRP;;ACTIVE;1.0d;2.54 +59972-0;Sulfamethoxazole;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Sulfamethoxazole [Moles/volume] in Gastric fluid;Sulfamethoxazole Gast-sCnc;;ACTIVE;2.34;2.70 +59973-8;Thiocyanate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiocyanate [Moles/volume] in Urine;Thiocyanate Ur-sCnc;;ACTIVE;2.34;2.70 +59974-6;Thiocyanate;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Thiocyanate [Moles/volume] in Gastric fluid;Thiocyanate Gast-sCnc;;ACTIVE;2.34;2.70 +59975-3;traZODone;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;traZODone [Moles/volume] in Urine;traZODone Ur-sCnc;;ACTIVE;2.34;2.70 +59976-1;traZODone;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;traZODone [Moles/volume] in Gastric fluid;traZODone Gast-sCnc;;ACTIVE;2.34;2.70 +59977-9;Venlafaxine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Venlafaxine [Moles/volume] in Urine;Venlafaxine Ur-sCnc;;ACTIVE;2.34;2.70 +59978-7;Venlafaxine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Venlafaxine [Moles/volume] in Gastric fluid;Venlafaxine Gast-sCnc;;ACTIVE;2.34;2.70 +59979-5;Warfarin;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Warfarin [Moles/volume] in Urine;Warfarin Ur-sCnc;;ACTIVE;2.34;2.70 +5998-0;Platelet aggregation.ristocetin induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma;PA Rist PRP;;ACTIVE;1.0d;2.73 +59980-3;Warfarin;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Warfarin [Moles/volume] in Gastric fluid;Warfarin Gast-sCnc;;ACTIVE;2.34;2.70 +59981-1;Zopiclone;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zopiclone [Moles/volume] in Urine;Zopiclone Ur-sCnc;;ACTIVE;2.34;2.70 +59982-9;Zopiclone;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Zopiclone [Moles/volume] in Gastric fluid;Zopiclone Gast-sCnc;;ACTIVE;2.34;2.70 +59983-7;Dehydroepiandrosterone sulfate^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Dehydroepiandrosterone sulfate (DHEA-S) [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;DHEA-S sp1 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +59984-5;11-Deoxycorticosterone^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;11DOC sp8 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59985-2;11-Deoxycorticosterone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;11DOC sp7 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59986-0;11-Deoxycorticosterone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;11DOC sp6 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59987-8;11-Deoxycorticosterone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;11-Deoxycorticosterone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;11DOC sp5 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59988-6;Testosterone^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Testost sp8 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59989-4;Testosterone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Testost sp7 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +59990-2;Testosterone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Testost sp6 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59991-0;Testosterone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Testost sp5 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59992-8;Testosterone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Testost sp4 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +59993-6;Testosterone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Testost sp3 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +59994-4;Testosterone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Testost sp2 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +59995-1;Testosterone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Testost sp1 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59996-9;Insulin-like growth factor binding protein 3^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;IGF BP3 sp8 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59997-7;Insulin-like growth factor binding protein 3^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;IGF BP3 sp7 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +5999-8;Platelet aggregation.serotonin induced;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation serotonin induced in Platelet rich plasma;PA Serotonin PRP;;ACTIVE;1.0d;2.73 +59998-5;Insulin-like growth factor binding protein 3^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;IGF BP3 sp6 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +59999-3;Insulin-like growth factor binding protein 3^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;IGF BP3 sp5 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60000-7;Insulin-like growth factor binding protein 3^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;IGF BP3 sp4 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60001-5;Insulin-like growth factor binding protein 3^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;IGF BP3 sp3 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60002-3;Insulin-like growth factor binding protein 3^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;IGF BP3 sp2 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60003-1;Insulin-like growth factor binding protein 3^baseline;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --baseline;IGF BP3 BS SerPl-mCnc;;ACTIVE;2.34;2.70 +6000-4;Platelet aggregation.thrombin induced;ThrACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation thrombin induced [Units threshold] in Platelet rich plasma;PA Thrombin PRP;;ACTIVE;1.0d;2.29 +60004-9;Insulin-like growth factor binding protein 3^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor binding protein 3 [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;IGF BP3 sp1 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60005-6;Insulin-like growth factor-I^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;IGF-I sp8 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60006-4;Insulin-like growth factor-I^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;IGF-I sp7 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60007-2;Insulin-like growth factor-I^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;IGF-I sp6 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60008-0;Insulin-like growth factor-I^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;IGF-I sp5 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60009-8;Insulin-like growth factor-I^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;IGF-I sp4 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60010-6;Insulin-like growth factor-I^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;IGF-I sp3 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60011-4;Insulin-like growth factor-I^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;IGF-I sp2 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +6001-2;Platelet factor 3;ACnc;Pt;PPP;Qn;;COAG;1;Platelet factor 3 [Units/volume] in Platelet poor plasma;PF3 PPP-aCnc;;ACTIVE;1.0d;2.69 +60012-2;Insulin-like growth factor-I^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;IGF-I sp1 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60013-0;Cortisol^40M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --40 minutes post XXX challenge;Cortis 40M p chal SerPl-sCnc;;ACTIVE;2.34;2.70 +60014-8;Corticotropin^baseline;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --baseline;ACTH BS Plas-sCnc;;ACTIVE;2.34;2.70 +60015-5;Corticotropin^5M post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --5 minutes post XXX challenge;ACTH 5M p chal Plas-sCnc;;ACTIVE;2.34;2.70 +60016-3;Corticotropin^1.5H post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --1.5 hours post XXX challenge;ACTH 1.5h p chal Plas-sCnc;;ACTIVE;2.34;2.70 +60017-1;Lactate dehydrogenase;CCnc;Pt;Body fld;Qn;Reaction: pyruvate to lactate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Body fluid by Pyruvate to lactate reaction;LDH Fld P to L-cCnc;;ACTIVE;2.34;2.73 +60018-9;Lactate dehydrogenase;CCnc;Pt;Pericard fld;Qn;Reaction: pyruvate to lactate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Pericardial fluid by Pyruvate to lactate reaction;LDH Pcar P to L-cCnc;;ACTIVE;2.34;2.70 +60019-7;Lactate dehydrogenase;CCnc;Pt;Pericard fld;Qn;Reaction: lactate to pyruvate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Pericardial fluid by Lactate to pyruvate reaction;LDH Pcar L to P-cCnc;;ACTIVE;2.34;2.73 +6002-0;Platelet factor 4;ACnc;Pt;PPP;Qn;;COAG;1;Platelet factor 4 [Units/volume] in Platelet poor plasma;PF4 PPP-aCnc;;ACTIVE;1.0d;2.73 +60020-5;Lactate dehydrogenase;CCnc;Pt;Periton fld;Qn;Reaction: pyruvate to lactate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Peritoneal fluid by Pyruvate to lactate reaction;LDH Prt P to L-cCnc;;ACTIVE;2.34;2.73 +60021-3;Lactate dehydrogenase;CCnc;Pt;Plr fld;Qn;Reaction: pyruvate to lactate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid by Pyruvate to lactate reaction;LDH Plr P to L-cCnc;;ACTIVE;2.34;2.73 +60022-1;Lactate dehydrogenase;CCnc;Pt;Plr fld;Qn;Reaction: lactate to pyruvate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid by Lactate to pyruvate reaction;LDH Plr L to P-cCnc;;ACTIVE;2.34;2.73 +60023-9;Lactate dehydrogenase;CCnc;Pt;CSF;Qn;Reaction: pyruvate to lactate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Cerebral spinal fluid by Pyruvate to lactate reaction;LDH CSF P to L-cCnc;;ACTIVE;2.34;2.70 +60024-7;Lactate dehydrogenase;CCnc;Pt;CSF;Qn;Reaction: lactate to pyruvate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Cerebral spinal fluid by Lactate to pyruvate reaction;LDH CSF L to P-cCnc;;ACTIVE;2.34;2.73 +60025-4;Urobilinogen;SCnc;Pt;Urine;Qn;Test strip.automated;UA;1;Urobilinogen [Moles/volume] in Urine by Automated test strip;Urobilinogen Ur Strip.auto-sCnc;;ACTIVE;2.34;2.73 +60026-2;Leukocyte esterase;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Leukocyte esterase [Presence] in Urine by Automated test strip;Leukocyte esterase Ur Ql Strip.auto;;ACTIVE;2.34;2.73 +60027-0;Specific gravity;Rden;Pt;Pericard fld;Qn;;CHEM;1;Specific gravity of Pericardial fluid;Sp Gr Pcar;;ACTIVE;2.34;2.34 +60028-8;West Nile Virus Ab.IgG avidity;PrThr;Pt;Ser;Ord;IA;MICRO;1;West Nile virus IgG Ab avidity [Presence] in Serum by Immunoassay;WNV IgG Avidity Ser Ql IA;;ACTIVE;2.34;2.56 +60029-6;West Nile Virus Ab.IgG avidity;PrThr;Pt;Ser;Ord;IF;MICRO;1;West Nile virus IgG Ab avidity [Presence] in Serum by Immunofluorescence;WNV IgG Avidity Ser Ql IF;;ACTIVE;2.34;2.56 +60030-4;West Nile virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;West Nile virus IgG Ab [Presence] in Serum by Immunofluorescence;WNV IgG Ser Ql IF;;ACTIVE;2.34;2.56 +60032-0;Bacteria identified;Prid;Pt;Dial fld prt;Nom;Culture;MICRO;1;Bacteria identified in Peritoneal dialysis fluid by Culture;Bacteria DiafP Cult;;ACTIVE;2.34;2.73 +60033-8;PIK3CA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PIK3CA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PIK3CA gene Mut Anl Bld/T;;ACTIVE;2.34;2.73 +60034-6;PIK3CA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PIK3CA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PIK3CA gene Mut Anl Bld/T;;ACTIVE;2.34;2.73 +60035-3;10-Hydroxycarbazepine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;10-Hydroxycarbazepine [Mass/volume] in Blood;10OH-Carbazepine Bld-mCnc;;ACTIVE;2.34;2.70 +60036-1;1-Naphthol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1-Naphthol [Mass/volume] in Blood;1Naphthol Bld-mCnc;;ACTIVE;2.34;2.70 +60037-9;1-Naphthol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;1-Naphthol [Mass/volume] in Body fluid;1Naphthol Fld-mCnc;;ACTIVE;2.34;2.70 +6003-8;Platelet factor 4 Ag;MCnc;Pt;PPP;Qn;IA;COAG;1;Platelet factor 4 Ag [Mass/volume] in Platelet poor plasma by Immunoassay;PF4 Ag PPP IA-mCnc;;ACTIVE;1.0d;2.73 +60038-7;1-Naphthol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;1-Naphthol [Mass/mass] in Tissue;1Naphthol Tiss-mCnt;;ACTIVE;2.34;2.70 +60039-5;Acebutolol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acebutolol [Mass/volume] in Blood;Acebutolol Bld-mCnc;;ACTIVE;2.34;2.70 +60040-3;Acebutolol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acebutolol [Mass/volume] in Serum or Plasma;Acebutolol SerPl-mCnc;;ACTIVE;2.34;2.70 +60041-1;Acebutolol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Acebutolol [Mass/mass] in Tissue;Acebutolol Tiss-mCnt;;ACTIVE;2.34;2.70 +60042-9;N-acetylprocainamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;N-acetylprocainamide [Mass/volume] in Blood;NAPA Bld-mCnc;;ACTIVE;2.34;2.70 +60043-7;Acepromazine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acepromazine [Mass/volume] in Blood;Acepromazine Bld-mCnc;;ACTIVE;2.34;2.70 +60044-5;Acepromazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acepromazine [Mass/volume] in Urine;Acepromazine Ur-mCnc;;ACTIVE;2.34;2.70 +60045-2;Acetaldehyde;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acetaldehyde [Mass/volume] in Body fluid;Acetaldehyde Fld-mCnc;;ACTIVE;2.34;2.70 +6004-6;Prekallikrein;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Prekallikrein (Fletcher Factor) [Mass/volume] in Platelet poor plasma by Chromogenic method;PK PPP Chro-mCnc;;ACTIVE;1.0d;2.34 +60046-0;Acetaldehyde;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Acetaldehyde [Mass/volume] in Red Blood Cells;Acetaldehyde RBC-mCnc;;ACTIVE;2.34;2.70 +60047-8;Acetaldehyde;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Acetaldehyde [Mass/mass] in Tissue;Acetaldehyde Tiss-mCnt;;ACTIVE;2.34;2.70 +60048-6;Acetaminophen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acetaminophen [Mass/volume] in Blood;APAP Bld-mCnc;;ACTIVE;2.34;2.73 +60049-4;Acetaminophen;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acetaminophen [Mass/volume] in Body fluid;APAP Fld-mCnc;;ACTIVE;2.34;2.70 +60050-2;Acetaminophen;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Acetaminophen [Mass/mass] in Tissue;APAP Tiss-mCnt;;ACTIVE;2.34;2.70 +60051-0;Acetophenazine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acetophenazine [Mass/volume] in Blood;Acetophenazine Bld-mCnc;;ACTIVE;2.34;2.70 +60052-8;Alphapinene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Alphapinene [Mass/volume] in Blood;Alphapinene Bld-mCnc;;ACTIVE;2.34;2.70 +6005-3;Prekallikrein;ACnc;Pt;PPP;Qn;;COAG;1;Prekallikrein (Fletcher Factor) [Units/volume] in Platelet poor plasma;PK PPP-aCnc;;ACTIVE;1.0d;2.73 +60053-6;aMILoride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;aMILoride [Mass/volume] in Blood;aMILoride Bld-mCnc;;ACTIVE;2.34;2.70 +60054-4;Amiodarone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Amiodarone [Mass/volume] in Blood;Amiodarone Bld-mCnc;;ACTIVE;2.34;2.70 +60055-1;Astemizole;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Astemizole [Mass/volume] in Body fluid;Astemizole Fld-mCnc;;ACTIVE;2.34;2.70 +60056-9;Astemizole;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Astemizole [Mass/mass] in Tissue;Astemizole Tiss-mCnt;;ACTIVE;2.34;2.70 +60057-7;Bismuth;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Bismuth [Mass/mass] in Hair;Bismuth Hair-mCnt;;ACTIVE;2.34;2.70 +60058-5;Bismuth;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Bismuth [Mass/volume] in Red Blood Cells;Bismuth RBC-mCnc;;ACTIVE;2.34;2.70 +60059-3;Bismuth;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Bismuth [Mass/mass] in Tissue;Bismuth Tiss-mCnt;;ACTIVE;2.34;2.70 +60060-1;Boron;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Boron [Mass/mass] in Tissue;Boron Tiss-mCnt;;ACTIVE;2.34;2.70 +6006-1;Protein C;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Protein C [Units/volume] in Platelet poor plasma by Chromogenic method;Prot C PPP Chro-aCnc;;ACTIVE;1.0d;2.73 +60061-9;buPROPion;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;buPROPion [Mass/volume] in Blood;buPROPion Bld-mCnc;;ACTIVE;2.34;2.73 +60062-7;buPROPion;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;buPROPion [Mass/volume] in Body fluid;buPROPion Fld-mCnc;;ACTIVE;2.34;2.70 +60063-5;buPROPion;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;buPROPion [Mass/mass] in Tissue;buPROPion Tiss-mCnt;;ACTIVE;2.34;2.70 +60064-3;buPROPion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;buPROPion [Mass/volume] in Urine;buPROPion Ur-mCnc;;ACTIVE;2.34;2.73 +60065-0;Cobalt;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Cobalt [Mass/mass] in Nail;Cobalt Nail-mCnt;;ACTIVE;2.34;2.70 +60066-8;Cobalt;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Red Blood Cells;Cobalt RBC-mCnc;;ACTIVE;2.34;2.73 +60067-6;Cobalt;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Cobalt [Mass/mass] in Tissue;Cobalt Tiss-mCnt;;ACTIVE;2.34;2.70 +60068-4;Colchicine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Colchicine [Mass/volume] in Blood;Colchicine Bld-mCnc;;ACTIVE;2.34;2.70 +60069-2;Dantrolene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dantrolene [Mass/volume] in Blood;Dantrolene Bld-mCnc;;ACTIVE;2.34;2.70 +600-7;Bacteria identified;Prid;Pt;Bld;Nom;Culture;MICRO;1;Bacteria identified in Blood by Culture;Bacteria Bld Cult;;ACTIVE;1.0;2.73 +60070-0;Dichlorvos;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Dichlorvos [Mass/volume] in Blood;Dichlorvos Bld-mCnc;;ACTIVE;2.34;2.70 +60071-8;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Mass/volume] in Serum or Plasma;EDDP SerPl-mCnc;;ACTIVE;2.34;2.73 +60072-6;Fexofenadine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Fexofenadine [Mass/volume] in Blood;Fexofenadine Bld-mCnc;;ACTIVE;2.34;2.70 +60073-4;Fexofenadine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fexofenadine [Mass/volume] in Serum or Plasma;Fexofenadine SerPl-mCnc;;ACTIVE;2.34;2.70 +60074-2;Fexofenadine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Fexofenadine [Mass/volume] in Urine;Fexofenadine Ur-mCnc;;ACTIVE;2.34;2.70 +60075-9;Finasteride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Finasteride [Mass/volume] in Serum or Plasma;Finasteride SerPl-mCnc;;ACTIVE;2.34;2.70 +60076-7;Gallium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Gallium [Mass/volume] in Red Blood Cells;Gallium RBC-mCnc;;ACTIVE;2.34;2.70 +60077-5;Ganciclovir;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ganciclovir [Mass/volume] in Blood;Ganciclovir Bld-mCnc;;ACTIVE;2.34;2.70 +60078-3;Ganciclovir;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ganciclovir [Mass/volume] in Urine;Ganciclovir Ur-mCnc;;ACTIVE;2.34;2.70 +6007-9;Protein C;ACnc;Pt;PPP;Qn;Coag;COAG;1;Protein C [Units/volume] in Platelet poor plasma by Coagulation assay;Prot C PPP-aCnc;;ACTIVE;1.0d;2.73 +60079-1;Germanium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Germanium [Mass/volume] in Blood;Germanium Bld-mCnc;;ACTIVE;2.34;2.70 +60080-9;Germanium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Germanium [Mass/volume] in Red Blood Cells;Germanium RBC-mCnc;;ACTIVE;2.34;2.70 +60081-7;Germanium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Germanium [Mass/volume] in Serum or Plasma;Germanium SerPl-mCnc;;ACTIVE;2.34;2.70 +60082-5;Gold;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Gold [Mass/volume] in Red Blood Cells;Gold RBC-mCnc;;ACTIVE;2.34;2.70 +60083-3;Hydroxybupropion;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hydroxybupropion [Mass/volume] in Blood;OH-bupropion Bld-mCnc;;ACTIVE;2.34;2.73 +60084-1;Hydroxybupropion;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Hydroxybupropion [Mass/volume] in Body fluid;OH-bupropion Fld-mCnc;;ACTIVE;2.34;2.70 +60085-8;Hydroxybupropion;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Hydroxybupropion [Mass/mass] in Tissue;OH-bupropion Tiss-mCnt;;ACTIVE;2.34;2.70 +60086-6;Hydroxybupropion;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hydroxybupropion [Mass/volume] in Urine;OH-bupropion Ur-mCnc;;ACTIVE;2.34;2.73 +6008-7;Protein C+Acarboxy Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Protein C+Acarboxy Ag [Units/volume] in Platelet poor plasma by Immunoassay;Prot C+ACA Ag PPP IA-aCnc;;ACTIVE;1.0d;2.69 +60087-4;Hyoscyamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hyoscyamine [Mass/volume] in Blood;Hyoscyamine Bld-mCnc;;ACTIVE;2.34;2.70 +60088-2;Hyoscyamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hyoscyamine [Mass/volume] in Urine;Hyoscyamine Ur-mCnc;;ACTIVE;2.34;2.70 +60089-0;Indium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Indium [Mass/volume] in Red Blood Cells;Indium RBC-mCnc;;ACTIVE;2.34;2.70 +60090-8;Indium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Indium [Mass/volume] in Serum or Plasma;Indium SerPl-mCnc;;ACTIVE;2.34;2.70 +60091-6;Ketoconazole;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ketoconazole [Mass/volume] in Blood;Ketoconazole Bld-mCnc;;ACTIVE;2.34;2.70 +60092-4;Ketoconazole;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ketoconazole [Mass/volume] in Urine;Ketoconazole Ur-mCnc;;ACTIVE;2.34;2.70 +60093-2;Ketoprofen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ketoprofen [Mass/volume] in Blood;Ketoprofen Bld-mCnc;;ACTIVE;2.34;2.70 +60094-0;Ketoprofen;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ketoprofen [Mass/volume] in Urine;Ketoprofen Ur-mCnc;;ACTIVE;2.34;2.73 +6009-5;Protein C Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Protein C Ag [Units/volume] in Platelet poor plasma by Immunoassay;Prot C Ag PPP IA-aCnc;;ACTIVE;1.0d;2.73 +60095-7;Loperamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Loperamide [Mass/volume] in Blood;Loperamide Bld-mCnc;;ACTIVE;2.34;2.70 +60096-5;Loperamide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Loperamide [Mass/volume] in Urine;Loperamide Ur-mCnc;;ACTIVE;2.34;2.70 +60097-3;Loratadine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Loratadine [Mass/volume] in Blood;Loratadine Bld-mCnc;;ACTIVE;2.34;2.70 +60098-1;Loratadine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Loratadine [Mass/volume] in Urine;Loratadine Ur-mCnc;;ACTIVE;2.34;2.70 +60099-9;Loxapine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Loxapine [Mass/volume] in Blood;Loxapine Bld-mCnc;;ACTIVE;2.34;2.70 +60100-5;Loxapine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Loxapine [Mass/volume] in Urine;Loxapine Ur-mCnc;;ACTIVE;2.34;2.70 +60101-3;Molybdenum;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Molybdenum [Mass/mass] in Nail;Molybdenum Nail-mCnt;;ACTIVE;2.34;2.70 +60102-1;O-desmethylvenlafaxine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;O-desmethylvenlafaxine [Mass/volume] in Blood;ODV Bld-mCnc;;ACTIVE;2.34;2.70 +6010-3;Protein C inhibitor;MCnc;Pt;PPP;Qn;IA;COAG;1;Protein C inhibitor [Mass/volume] in Platelet poor plasma by Immunoassay;Prot C Inhib PPP IA-mCnc;;ACTIVE;1.0d;2.73 +60103-9;O-desmethylvenlafaxine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;O-desmethylvenlafaxine [Mass/volume] in Body fluid;ODV Fld-mCnc;;ACTIVE;2.34;2.70 +60104-7;O-desmethylvenlafaxine;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;O-desmethylvenlafaxine [Mass/mass] in Tissue;ODV Tiss-mCnt;;ACTIVE;2.34;2.70 +60105-4;OLANZapine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;OLANZapine [Mass/volume] in Blood;OLANZapine Bld-mCnc;;ACTIVE;2.34;2.70 +60106-2;OLANZapine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;OLANZapine [Mass/volume] in Body fluid;OLANZapine Fld-mCnc;;ACTIVE;2.34;2.70 +60107-0;OLANZapine;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;OLANZapine [Mass/mass] in Tissue;OLANZapine Tiss-mCnt;;ACTIVE;2.34;2.70 +60108-8;Oxychlordane;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Oxychlordane [Mass/volume] in Body fluid;Oxychlordane Fld-mCnc;;ACTIVE;2.34;2.70 +60109-6;Oxychlordane;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Oxychlordane [Mass/mass] in Tissue;Oxychlordane Tiss-mCnt;;ACTIVE;2.34;2.70 +60110-4;Oxyphenbutazone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Oxyphenbutazone [Mass/volume] in Blood;Oxyphenbutazone Bld-mCnc;;ACTIVE;2.34;2.70 +6011-1;Protein C cofactor;ACnc;Pt;PPP;Qn;;COAG;1;Protein C cofactor [Units/volume] in Platelet poor plasma;Prot C CF PPP-aCnc;;ACTIVE;1.0d;2.69 +60111-2;Oxyphenbutazone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxyphenbutazone [Mass/volume] in Urine;Oxyphenbutazone Ur-mCnc;;ACTIVE;2.34;2.70 +60112-0;Oxipurinol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Oxipurinol [Mass/volume] in Blood;Oxipurinol Bld-mCnc;;ACTIVE;2.34;2.70 +60113-8;Oxypurinol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Oxypurinole;Deprecated Oxypurinole;;DEPRECATED;2.34;2.70 +60114-6;PACLitaxel;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PACLitaxel [Mass/volume] in Serum or Plasma;PACLitaxel SerPl-mCnc;;ACTIVE;2.34;2.70 +60115-3;9-Hydroxyrisperidone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;9-Hydroxyrisperidone [Mass/volume] in Blood;9OH-risperidone Bld-mCnc;;ACTIVE;2.34;2.70 +60116-1;9-Hydroxyrisperidone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;9-Hydroxyrisperidone [Mass/volume] in Urine;9OH-risperidone Ur-mCnc;;ACTIVE;2.34;2.73 +60117-9;Palladium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Palladium [Mass/volume] in Blood;Palladium Bld-mCnc;;ACTIVE;2.34;2.70 +60118-7;Palladium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Palladium [Mass/volume] in Red Blood Cells;Palladium RBC-mCnc;;ACTIVE;2.34;2.70 +60119-5;Palladium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Palladium [Mass/volume] in Serum or Plasma;Palladium SerPl-mCnc;;ACTIVE;2.34;2.70 +60120-3;Palladium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Palladium [Mass/volume] in Urine;Palladium Ur-mCnc;;ACTIVE;2.34;2.70 +60121-1;Pancuronium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pancuronium [Mass/volume] in Blood;Pancuronium Bld-mCnc;;ACTIVE;2.34;2.70 +60122-9;Pancuronium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pancuronium [Mass/volume] in Serum or Plasma;Pancuronium SerPl-mCnc;;ACTIVE;2.34;2.70 +60123-7;Pancuronium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Pancuronium [Mass/mass] in Tissue;Pancuronium Tiss-mCnt;;ACTIVE;2.34;2.70 +60124-5;Pancuronium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pancuronium [Mass/volume] in Urine;Pancuronium Ur-mCnc;;ACTIVE;2.34;2.70 +60125-2;Papaverine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Papaverine [Mass/volume] in Blood;Papaverine Bld-mCnc;;ACTIVE;2.34;2.70 +60126-0;Papaverine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Papaverine [Mass/volume] in Urine;Papaverine Ur-mCnc;;ACTIVE;2.34;2.70 +60127-8;Paramethadione;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Paramethadione [Mass/volume] in Blood;PMO Bld-mCnc;;ACTIVE;2.34;2.70 +60128-6;Paramethadione;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Paramethadione [Mass/volume] in Urine;PMO Ur-mCnc;;ACTIVE;2.34;2.70 +6012-9;von Willebrand factor Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf) Ag [Units/volume] in Platelet poor plasma by Immunoassay;vWF Ag PPP IA-aCnc;;ACTIVE;1.0d;2.73 +60129-4;Paraoxon;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Paraoxon [Mass/volume] in Blood;Paraoxon Bld-mCnc;;ACTIVE;2.34;2.70 +60130-2;Paraoxon;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Paraoxon [Mass/volume] in Body fluid;Paraoxon Fld-mCnc;;ACTIVE;2.34;2.70 +60131-0;Paraoxon;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Paraoxon [Mass/mass] in Tissue;Paraoxon Tiss-mCnt;;ACTIVE;2.34;2.70 +60132-8;Parathion;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Parathion [Mass/volume] in Blood;Parathion Bld-mCnc;;ACTIVE;2.34;2.70 +60133-6;Parathion;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Parathion [Mass/volume] in Body fluid;Parathion Fld-mCnc;;ACTIVE;2.34;2.70 +60134-4;Parathion;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Parathion [Mass/mass] in Tissue;Parathion Tiss-mCnt;;ACTIVE;2.34;2.70 +60135-1;Pargyline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pargyline [Mass/volume] in Serum or Plasma;Pargyline SerPl-mCnc;;ACTIVE;2.34;2.70 +60136-9;PARoxetine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;PARoxetine [Mass/volume] in Blood;PARoxetine Bld-mCnc;;ACTIVE;2.34;2.70 +6013-7;von Willebrand factor multimers;Prid;Pt;PPP;Nom;IB;COAG;1;von Willebrand factor (vWf) multimers in Platelet poor plasma by Immunoblot;vWF multimers PPP IB;;ACTIVE;1.0d;2.73 +60137-7;PARoxetine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;PARoxetine [Mass/volume] in Body fluid;PARoxetine Fld-mCnc;;ACTIVE;2.34;2.70 +60138-5;PARoxetine;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;PARoxetine [Mass/mass] in Tissue;PARoxetine Tiss-mCnt;;ACTIVE;2.34;2.70 +60139-3;Pemoline;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pemoline [Mass/volume] in Blood;Pemoline Bld-mCnc;;ACTIVE;2.34;2.70 +60140-1;Penciclovir;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Penciclovir [Mass/volume] in Blood;Penciclovir Bld-mCnc;;ACTIVE;2.34;2.70 +60141-9;Penciclovir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Penciclovir [Mass/volume] in Serum or Plasma;Penciclovir SerPl-mCnc;;ACTIVE;2.34;2.70 +60142-7;Pendimethalin;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pendimethalin [Mass/volume] in Blood;Pendimethalin Bld-mCnc;;ACTIVE;2.34;2.70 +60143-5;Pendimethalin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pendimethalin [Mass/volume] in Serum or Plasma;Pendimethalin SerPl-mCnc;;ACTIVE;2.34;2.70 +60144-3;Pendimethalin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pendimethalin [Mass/volume] in Urine;Pendimethalin Ur-mCnc;;ACTIVE;2.34;2.70 +6014-5;von Willebrand factor.ristocetin cofactor activity actual/Normal;RelTime;Pt;PPP;Qn;Platelet aggr;COAG;1;von Willebrand factor (vWf) ristocetin cofactor actual/normal in Platelet poor plasma by Platelet aggregation;vWf:RCo Act/Nor PPP Pl Agg;;ACTIVE;1.0d;2.73 +60145-0;Pentane;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Pentane [Mass/volume] in Body fluid;Pentane Fld-mCnc;;ACTIVE;2.34;2.70 +60146-8;Pentane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pentane [Mass/volume] in Serum or Plasma;Pentane SerPl-mCnc;;ACTIVE;2.34;2.70 +60147-6;Pentane;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Pentane [Mass/mass] in Tissue;Pentane Tiss-mCnt;;ACTIVE;2.34;2.70 +60148-4;Pentane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pentane [Mass/volume] in Urine;Pentane Ur-mCnc;;ACTIVE;2.34;2.70 +60149-2;Pentazocine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pentazocine [Mass/volume] in Blood;Pentazocine Bld-mCnc;;ACTIVE;2.34;2.70 +601-5;Fungus identified;Prid;Pt;Bld;Nom;Culture;MICRO;1;Fungus identified in Blood by Culture;Fungus Bld Cult;;ACTIVE;1.0;2.73 +60150-0;Pentazocine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Pentazocine [Mass/volume] in Body fluid;Pentazocine Fld-mCnc;;ACTIVE;2.34;2.70 +60151-8;PENTobarbital;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;PENTobarbital [Mass/volume] in Blood;Pentobarb Bld-mCnc;;ACTIVE;2.34;2.73 +6015-2;Acacia longifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wattle IgE Ab [Units/volume] in Serum;Wattle IgE Qn;;ACTIVE;1.0d;2.73 +60152-6;PENTobarbital;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;PENTobarbital [Mass/volume] in Body fluid;Pentobarb Fld-mCnc;;ACTIVE;2.34;2.70 +60153-4;PENTobarbital;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;PENTobarbital [Mass/mass] in Tissue;Pentobarb Tiss-mCnt;;ACTIVE;2.34;2.70 +60154-2;Pentoxifylline;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pentoxifylline [Mass/volume] in Blood;Pentoxifylline Bld-mCnc;;ACTIVE;2.34;2.70 +60155-9;Pentoxifylline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pentoxifylline [Mass/volume] in Urine;Pentoxifylline Ur-mCnc;;ACTIVE;2.34;2.70 +60156-7;Perfluorooctanoate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Perfluorooctanoate [Mass/volume] in Blood;Perfluorooctanoate Bld-mCnc;;ACTIVE;2.34;2.73 +60157-5;Perfluorooctanoate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Perfluorooctanoate [Mass/volume] in Serum or Plasma;Perfluorooctanoate SerPl-mCnc;;ACTIVE;2.34;2.73 +60158-3;Pergolide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Pergolide [Mass/volume] in Blood;Pergolide Bld-mCnc;;ACTIVE;2.34;2.70 +60159-1;Pergolide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Pergolide [Mass/volume] in Urine;Pergolide Ur-mCnc;;ACTIVE;2.34;2.70 +6016-0;Corticotropin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Corticotropin IgE Ab [Units/volume] in Serum;ACTH IgE Qn;;ACTIVE;1.0d;2.73 +60160-9;Perphenazine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Perphenazine [Mass/volume] in Blood;Perphenazine Bld-mCnc;;ACTIVE;2.34;2.70 +60161-7;Phenacemide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phenacemide [Mass/volume] in Blood;Phenacemide Bld-mCnc;;ACTIVE;2.34;2.70 +60162-5;Phenacemide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phenacemide [Mass/volume] in Urine;Phenacemide Ur-mCnc;;ACTIVE;2.34;2.70 +60163-3;Phenolphthalein;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenolphthalein [Mass/volume] in Serum or Plasma;Phenolphthalein SerPl-mCnc;;ACTIVE;2.34;2.70 +60164-1;Phensuximide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phensuximide [Mass/volume] in Blood;Phensuximide Bld-mCnc;;ACTIVE;2.34;2.70 +60165-8;Phensuximide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Phensuximide [Mass/volume] in Urine;Phensuximide Ur-mCnc;;ACTIVE;2.34;2.70 +60166-6;Platinum;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Platinum [Mass/mass] in Nail;Platinum Nail-mCnt;;ACTIVE;2.34;2.70 +60167-4;Platinum;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Platinum [Mass/volume] in Red Blood Cells;Platinum RBC-mCnc;;ACTIVE;2.34;2.70 +60168-2;Platinum;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Platinum [Mass/mass] in Tissue;Platinum Tiss-mCnt;;ACTIVE;2.34;2.70 +60169-0;Rubidium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Rubidium [Mass/volume] in Red Blood Cells;Rubidium RBC-mCnc;;ACTIVE;2.34;2.70 +60170-8;Silicon;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Silicon [Mass/volume] in Body fluid;Silicon Fld-mCnc;;ACTIVE;2.34;2.70 +60171-6;Silicon;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Silicon [Mass/volume] in Red Blood Cells;Silicon RBC-mCnc;;ACTIVE;2.34;2.70 +60172-4;Strontium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Strontium [Mass/volume] in Blood;Strontium Bld-mCnc;;ACTIVE;2.34;2.73 +60173-2;Strontium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Strontium [Mass/volume] in Red Blood Cells;Strontium RBC-mCnc;;ACTIVE;2.34;2.70 +60174-0;Strontium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Strontium [Mass/mass] in Tissue;Strontium Tiss-mCnt;;ACTIVE;2.34;2.70 +60175-7;Sulfamethizole;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Sulfamethizole [Mass/volume] in Blood;Sulfamethizole Bld-mCnc;;ACTIVE;2.34;2.70 +60176-5;Sulfamethizole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfamethizole [Mass/volume] in Serum or Plasma;Sulfamethizole SerPl-mCnc;;ACTIVE;2.34;2.70 +60177-3;Sulfamethizole;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sulfamethizole [Mass/volume] in Urine;Sulfamethizole Ur-mCnc;;ACTIVE;2.34;2.70 +6017-8;Alder Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Alder Ab.IgE;Deprecated Alder IgE Qn;;DEPRECATED;1.0d;2.70 +60178-1;Tellurium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Tellurium [Mass/mass] in Hair;Tellurium Hair-mCnt;;ACTIVE;2.34;2.70 +60179-9;Tellurium;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Tellurium [Mass/mass] in Nail;Tellurium Nail-mCnt;;ACTIVE;2.34;2.70 +60180-7;Tellurium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Tellurium [Mass/volume] in Red Blood Cells;Tellurium RBC-mCnc;;ACTIVE;2.34;2.70 +60181-5;Tellurium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Tellurium [Mass/mass] in Tissue;Tellurium Tiss-mCnt;;ACTIVE;2.34;2.70 +60182-3;Temephos;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Temephos [Mass/volume] in Urine;Temephos Ur-mCnc;;ACTIVE;2.34;2.70 +60183-1;Terazosin;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Terazosin [Mass/volume] in Blood;Terazosin Bld-mCnc;;ACTIVE;2.34;2.70 +60184-9;Terazosin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Terazosin [Mass/volume] in Serum or Plasma;Terazosin SerPl-mCnc;;ACTIVE;2.34;2.70 +60185-6;Thallium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Thallium [Mass/volume] in Red Blood Cells;Thallium RBC-mCnc;;ACTIVE;2.34;2.70 +6018-6;House dust Allergopharma Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Allergopharma IgE Ab [Units/volume] in Serum;House Dust Allergo IgE Qn;;ACTIVE;1.0d;2.70 +60186-4;Thiethylperazine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Thiethylperazine [Mass/volume] in Blood;Thiethylperazine Bld-mCnc;;ACTIVE;2.34;2.70 +60187-2;Thiethylperazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thiethylperazine [Mass/volume] in Serum or Plasma;Thiethylperazine SerPl-mCnc;;ACTIVE;2.34;2.70 +60188-0;Thiethylperazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Thiethylperazine [Mass/volume] in Urine;Thiethylperazine Ur-mCnc;;ACTIVE;2.34;2.70 +60189-8;Tin;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Tin [Mass/mass] in Nail;Tin Nail-mCnt;;ACTIVE;2.34;2.70 +60190-6;Tin;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Tin [Mass/volume] in Red Blood Cells;Tin RBC-mCnc;;ACTIVE;2.34;2.70 +60191-4;Tin;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Tin [Mass/mass] in Tissue;Tin Tiss-mCnt;;ACTIVE;2.34;2.70 +60192-2;Topiramate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Topiramate [Mass/volume] in Blood;Topiramate Bld-mCnc;;ACTIVE;2.34;2.73 +60193-0;Topiramate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Topiramate [Mass/volume] in Urine;Topiramate Ur-mCnc;;ACTIVE;2.34;2.73 +6019-4;Prunus dulcis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Almond IgE Ab [Units/volume] in Serum;Almond IgE Qn;;ACTIVE;1.0d;2.73 +60194-8;Triamterene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Triamterene [Mass/volume] in Blood;Triamterene Bld-mCnc;;ACTIVE;2.34;2.70 +60195-5;Trichlormethiazide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichlormethiazide [Mass/volume] in Blood;TCM Bld-mCnc;;ACTIVE;2.34;2.70 +60196-3;Trichlormethiazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trichlormethiazide [Mass/volume] in Serum or Plasma;TCM SerPl-mCnc;;ACTIVE;2.34;2.70 +60197-1;Triclopyr;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Triclopyr [Mass/volume] in Serum or Plasma;Triclopyr SerPl-mCnc;;ACTIVE;2.34;2.73 +60198-9;Trifluralin;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trifluralin [Mass/volume] in Blood;Trifluralin Bld-mCnc;;ACTIVE;2.34;2.70 +60199-7;Trifluralin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trifluralin [Mass/volume] in Serum or Plasma;Trifluralin SerPl-mCnc;;ACTIVE;2.34;2.70 +60200-3;Trifluralin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trifluralin [Mass/volume] in Urine;Trifluralin Ur-mCnc;;ACTIVE;2.34;2.70 +60201-1;Salicylates;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Salicylates [Mass/volume] in Blood;Salicylates Bld-mCnc;;ACTIVE;2.34;2.73 +6020-2;Alternaria alternata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata IgE Ab [Units/volume] in Serum;A alternata IgE Qn;;ACTIVE;1.0d;2.73 +60204-5;Trimethadione;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trimethadione [Mass/volume] in Blood;TMO Bld-mCnc;;ACTIVE;2.34;2.70 +60205-2;Trimethadione;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trimethadione [Mass/volume] in Urine;TMO Ur-mCnc;;ACTIVE;2.34;2.70 +60206-0;Tripelennamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tripelennamine [Mass/volume] in Blood;Tripelennamine Bld-mCnc;;ACTIVE;2.34;2.70 +60207-8;Vanadium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Vanadium [Mass/mass] in Tissue;Vanadium Tiss-mCnt;;ACTIVE;2.34;2.70 +60208-6;Venlafaxine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Venlafaxine [Mass/volume] in Blood;Venlafaxine Bld-mCnc;;ACTIVE;2.34;2.70 +60209-4;Venlafaxine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Venlafaxine [Mass/volume] in Body fluid;Venlafaxine Fld-mCnc;;ACTIVE;2.34;2.70 +6021-0;Malus sylvestris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apple IgE Ab [Units/volume] in Serum;Apple IgE Qn;;ACTIVE;1.0d;2.73 +60210-2;Venlafaxine;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Venlafaxine [Mass/mass] in Tissue;Venlafaxine Tiss-mCnt;;ACTIVE;2.34;2.70 +60211-0;Zolazepam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Zolazepam [Mass/volume] in Blood;Zolazepam Bld-mCnc;;ACTIVE;2.34;2.70 +60212-8;Zolazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zolazepam [Mass/volume] in Serum or Plasma;Zolazepam SerPl-mCnc;;ACTIVE;2.34;2.70 +60213-6;Zolazepam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zolazepam [Mass/volume] in Urine;Zolazepam Ur-mCnc;;ACTIVE;2.34;2.70 +60214-4;ZOLMitriptan;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;ZOLMitriptan [Mass/volume] in Blood;ZOLMitriptan Bld-mCnc;;ACTIVE;2.34;2.70 +60215-1;ZOLMitriptan;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;ZOLMitriptan [Mass/volume] in Urine;ZOLMitriptan Ur-mCnc;;ACTIVE;2.34;2.70 +60216-9;Zomepirac;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Zomepirac [Mass/volume] in Blood;Zomepirac Bld-mCnc;;ACTIVE;2.34;2.70 +60217-7;Chloride;SCnc;Pt;Mmlk;Qn;;CHEM;1;Chloride [Moles/volume] in Mother's milk;Chloride Mother Milk-sCnc;;ACTIVE;2.34;2.70 +60218-5;Potassium;SCnc;Pt;Mmlk;Qn;;CHEM;1;Potassium [Moles/volume] in Mother's milk;Potassium Mother Milk-sCnc;;ACTIVE;2.34;2.70 +60219-3;Ubiquinone 10/Protein;SRto;Pt;Tiss;Qn;;CHEM;1;Coenzyme Q10/Protein [Molar ratio] in Tissue;Ubiquinone10/Prot Tiss-sRto;;ACTIVE;2.34;2.70 +60220-1;Sodium;SCnc;Pt;Mmlk;Qn;;CHEM;1;Sodium [Moles/volume] in Mother's milk;Sodium Mother Milk-sCnc;;ACTIVE;2.34;2.70 +60221-9;Intrinsic factor Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Intrinsic factor IgG Ab [Units/volume] in Serum;IF IgG Ser-aCnc;;ACTIVE;2.34;2.70 +60224-3;Beta-trace protein;MCnc;Pt;Nasal fluid;Qn;;CHEM;1;Beta-trace protein [Mass/volume] in Nasal fluid;Beta-trace protein Nasal fluid-mCnc;;ACTIVE;2.34;2.70 +60225-0;Hydrogen/Expired gas^3H post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3 hours post dose fructose PO;Breath H2 3h p fructose PO;;ACTIVE;2.34;2.70 +60226-8;Hydrogen/Expired gas^2.5H post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.5 hours post dose fructose PO;Breath H2 2.5h p fructose PO;;ACTIVE;2.34;2.70 +60227-6;Hydrogen/Expired gas^2H post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose fructose PO;Breath H2 2h p fructose PO;;ACTIVE;2.34;2.70 +6022-8;Ascaris sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ascaris sp IgE Ab [Units/volume] in Serum;Ascaris IgE Qn;;ACTIVE;1.0d;2.73 +60228-4;Hydrogen/Expired gas^1.5H post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose fructose PO;Breath H2 1.5h p fructose PO;;ACTIVE;2.34;2.70 +60229-2;Hydrogen/Expired gas^1H post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose fructose PO;Breath H2 1h p fructose PO;;ACTIVE;2.34;2.70 +602-3;Bacteria identified;Prid;Pt;Bone;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bone by Aerobe culture;Bacteria Bone Aerobe Cult;;ACTIVE;1.0;2.73 +60230-0;Hydrogen/Expired gas^30M post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose fructose PO;Breath H2 30M p fructose PO;;ACTIVE;2.34;2.70 +60231-8;Hydrogen/Expired gas^pre dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --pre dose fructose PO;Breath H2 Pre fructose PO;;ACTIVE;2.34;2.70 +60232-6;Hydrogen/Expired gas^2.75H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.75 hours post dose lactose PO;Breath H2 2.75h p Lac PO;;ACTIVE;2.34;2.70 +60233-4;Hydrogen/Expired gas^2.25H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.25 hours post dose lactose PO;Breath H2 2.25h p Lac PO;;ACTIVE;2.34;2.70 +60234-2;Hydrogen/Expired gas^1.75H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.75 hours post dose lactose PO;Breath H2 1.75h p Lac PO;;ACTIVE;2.34;2.70 +60235-9;Hydrogen/Expired gas^1.25H post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.25 hours post dose lactose PO;Breath H2 1.25h p Lac PO;;ACTIVE;2.34;2.70 +6023-6;Aspergillus amstelodami Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus amstelodami IgE Ab [Units/volume] in Serum;A amstelodami IgE Qn;;ACTIVE;1.0d;2.73 +60236-7;Penaeus aztecus tropomyosin recombinant (rPen a) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Shrimp tropomyosin recombinant (rPen a) 1 IgE Ab RAST class [Presence] in Serum;Shrimp tm (rPen a) 1 IgE RAST Ql;;ACTIVE;2.34;2.58 +60237-5;Fraxinus excelsior Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European Ash IgE Ab RAST class [Presence] in Serum;European Ash IgE RAST Ql;;ACTIVE;2.34;2.70 +60238-3;Fraxinus excelsior Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European Ash IgE Ab [Units/volume] in Serum;European Ash IgE Qn;;ACTIVE;2.34;2.70 +60239-1;Vespula vulgaris recombinant (rVes v) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common wasp recombinant (rVes v) 5 IgE Ab RAST class [Presence] in Serum;Common wasp (rVes v) 5 IgE RAST Ql;;ACTIVE;2.34;2.70 +60240-9;Vespula vulgaris recombinant (rVes v) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common wasp recombinant (rVes v) 5 IgE Ab [Units/volume] in Serum;Common wasp (rVes v) 5 IgE Qn;;ACTIVE;2.34;2.70 +60241-7;Apis mellifera phospholipase A2 recombinant (rApi m) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee phospholipase A2 recombinant (rApi m) 1 IgE Ab RAST class [Presence] in Serum;PLA2 rApi m 1 IgE RAST Ql;;ACTIVE;2.34;2.58 +60242-5;Coagulation ecarin induced;Time;Pt;PPP;Qn;Coag;COAG;1;Ecarin clotting time (ECT) in Platelet poor plasma by Coagulation assay;ECT PPP;;ACTIVE;2.34;2.73 +60243-3;Matrix metallopeptidase 9;MCnc;Pt;Ser;Qn;;CHEM;1;Matrix metallopeptidase 9 [Mass/volume] in Serum;MMP9 Ser-mCnc;;ACTIVE;2.34;2.73 +6024-4;Aspergillus flavus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus flavus IgE Ab [Units/volume] in Serum;A flavus IgE Qn;;ACTIVE;1.0d;2.73 +60244-1;Androstanolone^8th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge;Androstanolone sp8 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60245-8;Androstanolone^7th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge;Androstanolone sp7 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60246-6;Androstanolone^6th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge;Androstanolone sp6 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60247-4;Androstanolone^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Androstanolone sp5 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60248-2;Androstanolone^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Androstanolone sp4 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60249-0;Androstanolone^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Androstanolone sp3 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +60250-8;Androstanolone^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Androstanolone sp2 p chal SerPl-mCnc;;ACTIVE;2.34;2.70 +6025-1;Aspergillus fumigatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus IgE Ab [Units/volume] in Serum;A fumigatus IgE Qn;;ACTIVE;1.0d;2.73 +60251-6;Androstanolone^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstanolone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Androstanolone sp1 p chal SerPl-mCnc;;ACTIVE;2.34;2.73 +60252-4;MGMT gene methylation;Arb;Pt;Tiss;Ord;Molgen;MOLPATH.MUT;1;MGMT gene methylation [Presence] in Tissue by Molecular genetics method;MGMT gene methylation Tiss Ql;;ACTIVE;2.34;2.73 +60253-2;DNA index 4;ACnc;Pt;XXX;Qn;Flow cytometry;MOLPATH;1;DNA index 4 in Specimen by Flow cytometry (FC);DNA index 4 Spec FC-aCnc;;ACTIVE;2.34;2.70 +60254-0;Parainfluenza virus 1+2+3 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1+2+3 RNA [Presence] in Specimen by NAA with probe detection;HPIV1+2+3 RNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +60255-7;Neisseria gonorrhoeae rRNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Throat by NAA with probe detection;N gonorrhoea rRNA Throat Ql NAA+probe;;ACTIVE;2.34;2.73 +60256-5;Neisseria gonorrhoeae rRNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Urine by NAA with probe detection;N gonorrhoea rRNA Ur Ql NAA+probe;;ACTIVE;2.34;2.73 +60257-3;Bacteria identified;Prid;Pt;Crn;Nom;Culture;MICRO;1;Bacteria identified in Cornea by Culture;Bacteria Crn Cult;;ACTIVE;2.34;2.73 +60258-1;Bacteria identified;Prid;Pt;Bone mar;Nom;Culture;MICRO;1;Bacteria identified in Bone marrow by Culture;Bacteria Mar Cult;;ACTIVE;2.34;2.73 +60259-9;Adenovirus DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Isolate by NAA with probe detection;HAdV DNA Islt Ql NAA+probe;;ACTIVE;2.34;2.63 +60260-7;Chikungunya virus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus RNA [Presence] in Serum or Plasma by NAA with probe detection;CHIKV RNA SerPl Ql NAA+probe;;ACTIVE;2.34;2.73 +60261-5;Coxiella burnetii DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Coxiella burnetii DNA [Presence] in Serum or Plasma by NAA with probe detection;C burnet DNA SerPl Ql NAA+probe;;ACTIVE;2.34;2.63 +60262-3;Dengue virus 1 RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1 RNA [Presence] in Serum by NAA with probe detection;DENV1 RNA Ser Ql NAA+probe;;ACTIVE;2.34;2.73 +60263-1;Enterovirus RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Isolate by NAA with probe detection;EV RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.63 +60264-9;Hantavirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Hantavirus Ab [Titer] in Serum;Hantavirus Ab Titr Ser;;ACTIVE;2.34;2.70 +60265-6;Human coronavirus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Human coronavirus RNA [Presence] in Serum or Plasma by NAA with probe detection;HCoV RNA SerPl Ql NAA+probe;;ACTIVE;2.34;2.63 +60266-4;Human metapneumovirus RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Isolate by NAA with probe detection;hMPV RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +60267-2;Influenza virus C RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus C RNA [Presence] in Isolate by NAA with probe detection;FLUCV RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.63 +60268-0;Orientia tsutsugamushi DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Orientia tsutsugamushi DNA [Presence] in Serum or Plasma by NAA with probe detection;O tsut DNA SerPl Ql NAA+probe;;ACTIVE;2.34;2.63 +6026-9;Aspergillus terreus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus terreus IgE Ab [Units/volume] in Serum;A terreus IgE Qn;;ACTIVE;1.0d;2.73 +60269-8;Parainfluenza virus 1 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Isolate by NAA with probe detection;HPIV1 RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +60270-6;Rabies virus RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Rabies virus RNA [Presence] in Isolate by NAA with probe detection;RABV RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.63 +60271-4;Respiratory syncytial virus RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Isolate by NAA with probe detection;RSV RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +60272-2;Rickettsia typhus group DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Rickettsia typhus group DNA [Presence] in Serum or Plasma by NAA with probe detection;Rick Typhus DNA SerPl Ql NAA+probe;;ACTIVE;2.34;2.63 +60273-0;Rotavirus RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Rotavirus RNA [Presence] in Isolate by NAA with probe detection;RV RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +60274-8;Rubella virus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Rubella virus RNA [Presence] in Serum or Plasma by NAA with probe detection;RUBV RNA SerPl Ql NAA+probe;;ACTIVE;2.34;2.63 +60275-5;SARS coronavirus RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus RNA [Presence] in Isolate by NAA with probe detection;SARS-CoV RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.68 +60276-3;oxyCODONE+Oxymorphone cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;oxyCODONE+oxyMORphone cutoff [Mass/volume] in Urine for Screen method;oxyCODONE+oxyMORphone CtO Ur Scn-mCnc;;ACTIVE;2.34;2.73 +6027-7;Aspergillus versicolor Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus versicolor IgE Ab [Units/volume] in Serum;A versicolor IgE Qn;;ACTIVE;1.0d;2.73 +60277-1;Complement C3 Ag;PrThr;Pt;Tiss;Ord;IF;HEM/BC;1;Complement C3 Ag [Presence] in Tissue by Immunofluorescence;C3 Ag Tiss Ql IF;;ACTIVE;2.34;2.73 +60278-9;Fibrinogen Ag;PrThr;Pt;Tiss;Ord;IF;COAG;1;Fibrinogen Ag [Presence] in Tissue by Immunofluorescence;Fibrinogen Ag Tiss Ql IF;;ACTIVE;2.34;2.73 +60279-7;IL28B gene associated variant rs12979860;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;IL28B gene associated variant rs12979860 [Presence] in Blood or Tissue by Molecular genetics method;IL28B rs12979860 Bld/T Ql;;ACTIVE;2.34;2.73 +60280-5;Discharge instructions;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Discharge instructions;ED Discharge instruct;;ACTIVE;2.34;2.67 +60281-3;Discharge instructions;Find;Pt;Inpatient hospital;Doc;{Provider};DOC.ONTOLOGY;2;Deprecated Inpatient hospital Discharge instructions;Deprecated IP hospital Discharge instruc;;DEPRECATED;2.34;2.73 +60282-1;ALPRAZolam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;ALPRAZolam [Moles/volume] in Specimen;Alpraz Spec-sCnc;;ACTIVE;2.34;2.70 +6028-3;Parrot australian droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Australian parrot droppings IgE Ab [Units/volume] in Serum;Deprecated Aust Parrot Drop IgE Qn;;DEPRECATED;1.0d;2.70 +60283-9;Amitriptyline;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Amitriptyline [Moles/volume] in Specimen;Amitrip Spec-sCnc;;ACTIVE;2.34;2.70 +60284-7;Amobarbital;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Amobarbital [Moles/volume] in Specimen;Amobarbital Spec-sCnc;;ACTIVE;2.34;2.70 +6028-5;Aureobasidium pullulans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Aureobasidium pullulans IgE Ab [Units/volume] in Serum;Deprecated A pullulans IgE Qn;;DEPRECATED;1.0d;2.70 +60285-4;Amoxapine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Amoxapine [Moles/volume] in Specimen;Amoxapine Spec-sCnc;;ACTIVE;2.34;2.70 +60286-2;Ascorbate;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ascorbate [Moles/volume] in Specimen;Vit C Spec-sCnc;;ACTIVE;2.34;2.70 +60287-0;Benztropine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Benztropine [Moles/volume] in Specimen;Benztropine Spec-sCnc;;ACTIVE;2.34;2.70 +60288-8;Bromazepam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Bromazepam [Moles/volume] in Specimen;Bromazepam Spec-sCnc;;ACTIVE;2.34;2.70 +60289-6;Brompheniramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Brompheniramine [Moles/volume] in Specimen;Brompheniramine Spec-sCnc;;ACTIVE;2.34;2.70 +60290-4;Caffeine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Caffeine [Moles/volume] in Specimen;Caffeine Spec-sCnc;;ACTIVE;2.34;2.70 +60291-2;carBAMazepine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;carBAMazepine [Presence] in Specimen;carBAMazepine Spec Ql;;ACTIVE;2.34;2.69 +60292-0;Chloral hydrate;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Chloral hydrate [Moles/volume] in Specimen;Chloral Hydrate Spec-sCnc;;ACTIVE;2.34;2.70 +6029-3;Aureobasidium pullulans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aureobasidium pullulans IgE Ab [Units/volume] in Serum;A pullulans IgE Qn;;ACTIVE;1.0d;2.73 +60293-8;chlordiazePOXIDE;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;chlordiazePOXIDE [Moles/volume] in Specimen;Chlordiazep Spec-sCnc;;ACTIVE;2.34;2.70 +60294-6;chlorproMAZINE;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;chlorproMAZINE [Moles/volume] in Specimen;chlorproMAZINE Spec-sCnc;;ACTIVE;2.34;2.70 +60295-3;Citalopram;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Citalopram [Moles/volume] in Specimen;Citalopram Spec-sCnc;;ACTIVE;2.34;2.70 +60296-1;cloBAZam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;cloBAZam [Moles/volume] in Specimen;cloBAZam Spec-sCnc;;ACTIVE;2.34;2.70 +60297-9;clomiPRAMINE;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;clomiPRAMINE [Moles/volume] in Specimen;clomiPRAMINE Spec-sCnc;;ACTIVE;2.34;2.70 +60298-7;cloZAPine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;cloZAPine [Moles/volume] in Specimen;cloZAPine Spec-sCnc;;ACTIVE;2.34;2.70 +60299-5;Cotinine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cotinine [Moles/volume] in Specimen;Cotinine Spec-sCnc;;ACTIVE;2.34;2.70 +60300-1;Desipramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Desipramine [Moles/volume] in Specimen;Desipramine Spec-sCnc;;ACTIVE;2.34;2.70 +6030-1;Budgerigar feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Budgerigar feather IgE Ab [Units/volume] in Serum;Budgie Feather IgE Qn;;ACTIVE;1.0d;2.73 +60301-9;Disopyramide;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Disopyramide [Moles/volume] in Specimen;Disopyramide Spec-sCnc;;ACTIVE;2.34;2.70 +60302-7;Doxepin;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Doxepin [Moles/volume] in Specimen;Doxepin Spec-sCnc;;ACTIVE;2.34;2.70 +60303-5;Fenoprofen;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Fenoprofen [Moles/volume] in Specimen;Fenoprofen Spec-sCnc;;ACTIVE;2.34;2.70 +60304-3;FLUoxetine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;FLUoxetine [Moles/volume] in Specimen;FLUoxetine Spec-sCnc;;ACTIVE;2.34;2.70 +60305-0;fluPHENAZine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;fluPHENAZine [Moles/volume] in Specimen;fluPHENAZine Spec-sCnc;;ACTIVE;2.34;2.70 +60306-8;fluvoxaMINE;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;fluvoxaMINE [Moles/volume] in Specimen;fluvoxaMINE Spec-sCnc;;ACTIVE;2.34;2.70 +60307-6;hydrOXYzine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;hydrOXYzine [Moles/volume] in Specimen;hydrOXYzine Spec-sCnc;;ACTIVE;2.34;2.70 +60308-4;Ibuprofen;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ibuprofen [Moles/volume] in Specimen;Ibuprofen Spec-sCnc;;ACTIVE;2.34;2.70 +60309-2;Imipramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Imipramine [Moles/volume] in Specimen;Imipramine Spec-sCnc;;ACTIVE;2.34;2.70 +603-1;Bacteria identified;Prid;Pt;Burn;Nom;Culture;MICRO;1;Bacteria identified in Burn by Culture;Bacteria Burn Cult;;ACTIVE;1.0;2.73 +60310-0;Indomethacin;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Indomethacin [Moles/volume] in Specimen;Indomethacin Spec-sCnc;;ACTIVE;2.34;2.70 +60311-8;Ketoprofen;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Ketoprofen [Moles/volume] in Specimen;Ketoprofen Spec-sCnc;;ACTIVE;2.34;2.70 +60312-6;lamoTRIgine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;lamoTRIgine [Moles/volume] in Specimen;lamoTRIgine Spec-sCnc;;ACTIVE;2.34;2.70 +60313-4;Maprotiline;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Maprotiline [Moles/volume] in Specimen;Maprotiline Spec-sCnc;;ACTIVE;2.34;2.70 +60314-2;Mefenamate;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Mefenamate [Moles/volume] in Specimen;Mefenamate Spec-sCnc;;ACTIVE;2.34;2.70 +60315-9;Mesoridazine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Mesoridazine [Moles/volume] in Specimen;Mesoridazine Spec-sCnc;;ACTIVE;2.34;2.70 +60316-7;Methaqualone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Methaqualone [Moles/volume] in Specimen;Methaqualone Spec-sCnc;;ACTIVE;2.34;2.70 +60317-5;Methotrimeprazine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Methotrimeprazine [Moles/volume] in Specimen;Methotrimeprazine Spec-sCnc;;ACTIVE;2.34;2.70 +60318-3;Mexiletine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Mexiletine [Moles/volume] in Specimen;Mexiletine Spec-sCnc;;ACTIVE;2.34;2.70 +6031-9;Budgerigar serum proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Budgerigar serum proteins IgE Ab [Units/volume] in Serum;Budgie Serum Prot IgE Qn;;ACTIVE;1.0d;2.73 +60319-1;Naproxen;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Naproxen [Moles/volume] in Specimen;Naproxen Spec-sCnc;;ACTIVE;2.34;2.70 +60320-9;Nicotine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nicotine [Moles/volume] in Specimen;Nicotine Spec-sCnc;;ACTIVE;2.34;2.70 +60321-7;Norclobazam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Norclobazam [Moles/volume] in Specimen;Norclobazam Spec-sCnc;;ACTIVE;2.34;2.70 +60322-5;Norclomipramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Norclomipramine [Moles/volume] in Specimen;Norclomipramine Spec-sCnc;;ACTIVE;2.34;2.70 +60323-3;Nordoxepin;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nordoxepin [Moles/volume] in Specimen;Nordoxepin Spec-sCnc;;ACTIVE;2.34;2.70 +60324-1;Nortriptyline;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nortriptyline [Moles/volume] in Specimen;Nortrip Spec-sCnc;;ACTIVE;2.34;2.70 +60325-8;OLANZapine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;OLANZapine [Moles/volume] in Specimen;OLANZapine Spec-sCnc;;ACTIVE;2.34;2.70 +60326-6;OXcarbazepine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;OXcarbazepine [Moles/volume] in Specimen;OXcarbazepine Spec-sCnc;;ACTIVE;2.34;2.73 +6032-7;Casuarina equisetifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Australian pine IgE Ab [Units/volume] in Serum;Australian pine IgE Qn;;ACTIVE;1.0d;2.73 +60327-4;PARoxetine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;PARoxetine [Moles/volume] in Specimen;PARoxetine Spec-sCnc;;ACTIVE;2.34;2.70 +60328-2;Pentazocine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Pentazocine [Moles/volume] in Specimen;Pentazocine Spec-sCnc;;ACTIVE;2.34;2.70 +60329-0;Promazine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Promazine [Moles/volume] in Specimen;Promazine Spec-sCnc;;ACTIVE;2.34;2.70 +60330-8;Propoxyphene;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Propoxyphene [Moles/volume] in Specimen;Propoxyph Spec-sCnc;;ACTIVE;2.34;2.70 +60331-6;Propranolol;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Propranolol [Moles/volume] in Specimen;Propranolol Spec-sCnc;;ACTIVE;2.34;2.70 +60332-4;QUEtiapine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;QUEtiapine [Moles/volume] in Specimen;QUEtiapine Spec-sCnc;;ACTIVE;2.34;2.70 +60333-2;Sulfamethoxazole;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Sulfamethoxazole [Moles/volume] in Specimen;Sulfamethoxazole Spec-sCnc;;ACTIVE;2.34;2.70 +60334-0;Thiocyanate;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Thiocyanate [Moles/volume] in Specimen;Thiocyanate Spec-sCnc;;ACTIVE;2.34;2.70 +6033-5;Persea americana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Avocado IgE Ab [Units/volume] in Serum;Avocado IgE Qn;;ACTIVE;1.0d;2.73 +60335-7;traZODone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;traZODone [Moles/volume] in Specimen;traZODone Spec-sCnc;;ACTIVE;2.34;2.73 +60336-5;Trimipramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Trimipramine [Moles/volume] in Specimen;Trimipramine Spec-sCnc;;ACTIVE;2.34;2.70 +60337-3;Venlafaxine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Venlafaxine [Moles/volume] in Specimen;Venlafaxine Spec-sCnc;;ACTIVE;2.34;2.70 +60338-1;Warfarin;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Warfarin [Moles/volume] in Specimen;Warfarin Spec-sCnc;;ACTIVE;2.34;2.70 +60339-9;Zopiclone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Zopiclone [Moles/volume] in Specimen;Zopiclone Spec-sCnc;;ACTIVE;2.34;2.70 +60340-7;Crystals.amorphous;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Crystals.amorphous [Presence] in Urine sediment by Light microscopy;Amorph Cry UrnS Ql Micro;;ACTIVE;2.34;2.73 +60341-5;Sodium urate crystals;ACnc;Pt;Urine sed;Ord;Microscopy.light;UA;1;Deprecated Sodium urate crystals [Presence] in Urine sediment by Light microscopy;Deprecated Na Urate Cry UrnS Ql Micro;;DEPRECATED;2.34;2.38 +60342-3;Borrelia burgdorferi Ab.IgG bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Borrelia burgdorferi IgG bands panel - Serum by Immunoblot;B burgdor IgG bands pnl Ser IB;;ACTIVE;2.34;2.71 +6034-3;Paspalum notatum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bahia grass IgE Ab [Units/volume] in Serum;Bahia grass IgE Qn;;ACTIVE;1.0d;2.73 +60343-1;Borrelia burgdorferi Ab.IgM bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Borrelia burgdorferi IgM bands panel - Serum by Immunoblot;B burgdor IgM bands pnl Ser IB;;ACTIVE;2.34;2.71 +60344-9;Lipoprotein (little a)/Lipoprotein.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein a/total Lipoprotein in Serum or Plasma;LPa MFr SerPl;;ACTIVE;2.34;2.73 +60345-6;Viable CD34 cells/100 cells;NFr;Pt;Body fld;Qn;;CELLMARK;1;Viable CD34 cells/100 cells in Body fluid;Viable CD34 cells NFr Fld;;ACTIVE;2.34;2.56 +60346-4;Viable CD34 cells/100 cells.CD34;NFr;Pt;Body fld;Qn;;CELLMARK;1;Viable CD34 cells/100 CD34 cells in Body fluid;Viable CD34 cells/100 CD34 NFr Fld;;ACTIVE;2.34;2.56 +60347-2;Viable CD34 cells;NCnc;Pt;Body fld;Qn;;CELLMARK;1;Viable CD34 cells [#/volume] in Body fluid;Viable CD34 cells # Fld;;ACTIVE;2.34;2.70 +60348-0;Prunus dulcis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Almond IgG Ab [Mass/volume] in Serum;Almond IgG-mCnc;;ACTIVE;2.34;2.73 +60349-8;Malus sylvestris Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Apple IgG Ab [Mass/volume] in Serum;Apple IgG-mCnc;;ACTIVE;2.34;2.73 +6035-0;Musa spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Banana IgE Ab [Units/volume] in Serum;Banana IgE Qn;;ACTIVE;1.0d;2.73 +60350-6;Prunus armeniaca Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Apricot IgG Ab [Mass/volume] in Serum;Apricot IgG-mCnc;;ACTIVE;2.34;2.73 +60351-4;Cynara scolymus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Artichoke IgG Ab [Mass/volume] in Serum;Artichoke IgG-mCnc;;ACTIVE;2.34;2.73 +60352-2;Musa spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Banana IgG Ab [Mass/volume] in Serum;Banana IgG-mCnc;;ACTIVE;2.34;2.73 +60353-0;Bean green Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Green Bean IgG Ab [Mass/volume] in Serum;Green Bean IgG-mCnc;;ACTIVE;2.34;2.73 +60354-8;Bean kidney red Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Kidney Bean IgG Ab [Mass/volume] in Serum;Red Kidney Bean IgG-mCnc;;ACTIVE;2.34;2.73 +60355-5;Bean pinto Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pinto Bean IgG Ab [Mass/volume] in Serum;Pinto Bean IgG-mCnc;;ACTIVE;2.34;2.73 +60356-3;Brassica oleracea var italica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Broccoli IgG Ab [Mass/volume] in Serum;Broccoli IgG-mCnc;;ACTIVE;2.34;2.73 +60357-1;Brassica oleracea var gemmifera Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Brussel Sprouts IgG Ab [Mass/volume] in Serum;Brussel Sprouts IgG-mCnc;;ACTIVE;2.34;2.73 +60358-9;Brassica oleracea var capitata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cabbage IgG Ab [Mass/volume] in Serum;Cabbage IgG-mCnc;;ACTIVE;2.34;2.73 +60359-7;Cucumis melo cantalupensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cantaloupe IgG Ab [Mass/volume] in Serum;Cantaloupe IgG-mCnc;;ACTIVE;2.34;2.73 +60360-5;Daucus carota Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Carrot IgG Ab [Mass/volume] in Serum;Carrot IgG-mCnc;;ACTIVE;2.34;2.73 +60361-3;Brassica oleracea var botrytis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cauliflower IgG Ab [Mass/volume] in Serum;Cauliflower IgG-mCnc;;ACTIVE;2.34;2.73 +60362-1;Asparagus officinalis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Asparagus IgG Ab [Mass/volume] in Serum;Asparagus IgG-mCnc;;ACTIVE;2.34;2.73 +60363-9;Apium graveolens Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Celery IgG Ab [Mass/volume] in Serum;Celery IgG-mCnc;;ACTIVE;2.34;2.73 +60364-7;Cheese mold type Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cheese mold type IgG Ab [Mass/volume] in Serum;Cheese Mold IgG-mCnc;;ACTIVE;2.34;2.73 +60365-4;Prunus avium Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cherry IgG Ab [Mass/volume] in Serum;Cherry IgG-mCnc;;ACTIVE;2.34;2.73 +60366-2;Capsicum frutescens Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chili Pepper IgG Ab [Mass/volume] in Serum;Chili Pepper IgG-mCnc;;ACTIVE;2.34;2.73 +60367-0;Cinnamomum spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cinnamon IgG Ab [Mass/volume] in Serum;Cinnamon IgG-mCnc;;ACTIVE;2.34;2.73 +6036-8;Hordeum vulgare Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Barley IgE Ab [Units/volume] in Serum;Deprecated Barley IgE Qn;;DEPRECATED;1.0d;2.70 +60368-8;Ruditapes spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Clam IgG Ab [Mass/volume] in Serum;Clam IgG-mCnc;;ACTIVE;2.34;2.73 +60369-6;Syzygium aromaticum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Clove IgG Ab [Mass/volume] in Serum;Clove IgG-mCnc;;ACTIVE;2.34;2.73 +60370-4;Cancer pagurus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Crab IgG Ab [Mass/volume] in Serum;Crab IgG-mCnc;;ACTIVE;2.34;2.73 +60371-2;Cucumis sativus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cucumber IgG Ab [Mass/volume] in Serum;Cucumber IgG-mCnc;;ACTIVE;2.34;2.73 +60372-0;Solanum melongena Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Eggplant IgG Ab [Mass/volume] in Serum;Eggplant IgG-mCnc;;ACTIVE;2.34;2.73 +60373-8;Flounder Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Flounder IgG Ab [Mass/volume] in Serum;Flounder IgG-mCnc;;ACTIVE;2.34;2.73 +60374-6;Allium sativum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Garlic IgG Ab [Mass/volume] in Serum;Garlic IgG-mCnc;;ACTIVE;2.34;2.73 +60375-3;Zingiber officinale Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Ginger IgG Ab [Mass/volume] in Serum;Ginger IgG-mCnc;;ACTIVE;2.34;2.73 +6037-6;Hordeum vulgare Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Barley IgE Ab [Units/volume] in Serum;Barley IgE Qn;;ACTIVE;1.0d;2.73 +60376-1;Vitis vinifera Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grape IgG Ab [Mass/volume] in Serum;Grape IgG-mCnc;;ACTIVE;2.34;2.73 +60377-9;Citrus paradisis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grapefruit IgG Ab [Mass/volume] in Serum;Grapefruit IgG-mCnc;;ACTIVE;2.34;2.73 +60378-7;Melanogrammus aeglefinus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Haddock IgG Ab [Mass/volume] in Serum;Haddock IgG-mCnc;;ACTIVE;2.34;2.73 +60379-5;Hippoglossus hippoglossus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Halibut IgG Ab [Mass/volume] in Serum;Halibut IgG-mCnc;;ACTIVE;2.34;2.73 +60380-3;Lamb Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lamb IgG Ab [Mass/volume] in Serum;Lamb IgG-mCnc;;ACTIVE;2.34;2.73 +60381-1;Citrus limon Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lemon IgG Ab [Mass/volume] in Serum;Lemon IgG-mCnc;;ACTIVE;2.34;2.73 +60382-9;Citrus aurantifolia Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lime IgG Ab [Mass/volume] in Serum;Lime IgG-mCnc;;ACTIVE;2.34;2.73 +60383-7;Homarus gammarus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lobster IgG Ab [Mass/volume] in Serum;Lobster IgG-mCnc;;ACTIVE;2.34;2.73 +6038-4;Fagus grandifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American Beech IgE Ab [Units/volume] in Serum;Amer Beech IgE Qn;;ACTIVE;1.0d;2.73 +60384-5;Mustard Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mustard IgG Ab [Mass/volume] in Serum;Mustard IgG-mCnc;;ACTIVE;2.34;2.73 +60385-2;Nutmeg Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Nutmeg IgG Ab [Mass/volume] in Serum;Nutmeg IgG-mCnc;;ACTIVE;2.34;2.73 +60386-0;Olive green Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Green Olive IgG Ab [Mass/volume] in Serum;Deprecated Green Olive IgG-mCnc;;DEPRECATED;2.34;2.70 +60387-8;Origanum vulgare Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oregano IgG Ab [Mass/volume] in Serum;Oregano IgG-mCnc;;ACTIVE;2.34;2.73 +60388-6;Ostrea edulis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oyster IgG Ab [Mass/volume] in Serum;Oyster IgG-mCnc;;ACTIVE;2.34;2.73 +60389-4;Pisum sativum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pea IgG Ab [Mass/volume] in Serum;Pea IgG-mCnc;;ACTIVE;2.34;2.73 +60390-2;Prunus persica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peach IgG Ab [Mass/volume] in Serum;Peach IgG-mCnc;;ACTIVE;2.34;2.73 +60391-0;Pyrus communis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pear IgG Ab [Mass/volume] in Serum;Pear IgG-mCnc;;ACTIVE;2.34;2.73 +6039-2;Beef Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beef IgE Ab [Units/volume] in Serum;Beef IgE Qn;;ACTIVE;1.0d;2.73 +60392-8;Piper nigrum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Black Pepper IgG Ab [Mass/volume] in Serum;Black Pepper IgG-mCnc;;ACTIVE;2.34;2.73 +60393-6;Pepper green Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Green Pepper IgG Ab [Mass/volume] in Serum;Green Pepper IgG-mCnc;;ACTIVE;2.34;2.73 +60394-4;Ananas comosus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pineapple IgG Ab [Mass/volume] in Serum;Pineapple IgG-mCnc;;ACTIVE;2.34;2.73 +60395-1;Prunus domestica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Plum IgG Ab [Mass/volume] in Serum;Plum IgG-mCnc;;ACTIVE;2.34;2.73 +60396-9;Ipomoea batatas Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sweet potato IgG Ab [Mass/volume] in Serum;Sweet potato IgG-mCnc;;ACTIVE;2.34;2.73 +60397-7;Raphanus sativus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Radish IgG Ab [Mass/volume] in Serum;Radish IgG-mCnc;;ACTIVE;2.34;2.73 +60398-5;Persea americana Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Avocado IgG Ab [Mass/volume] in Serum;Avocado IgG-mCnc;;ACTIVE;2.34;2.73 +60399-3;Salvia officinalis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sage IgG Ab [Mass/volume] in Serum;Sage IgG-mCnc;;ACTIVE;2.34;2.73 +60-4;Carbenicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Carbenicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Carbenicillin Islt MIC;;ACTIVE;1.0;2.19 +6040-0;House dust Bencard Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Bencard IgE Ab [Units/volume] in Serum;House Dust Bencard IgE Qn;;ACTIVE;1.0d;2.70 +60400-9;Salmo salar Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Salmon IgG Ab [Mass/volume] in Serum;Salmon IgG-mCnc;;ACTIVE;2.34;2.73 +60401-7;Pecten spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Scallop IgG Ab [Mass/volume] in Serum;Scallop IgG-mCnc;;ACTIVE;2.34;2.73 +60402-5;Sesamum indicum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sesame Seed IgG Ab [Mass/volume] in Serum;Sesame Seed IgG-mCnc;;ACTIVE;2.34;2.73 +60403-3;Pandalus borealis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp IgG Ab [Mass/volume] in Serum;Shrimp IgG-mCnc;;ACTIVE;2.34;2.73 +60404-1;Snapper red Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Snapper IgG Ab [Mass/volume] in Serum;Red Snapper IgG-mCnc;;ACTIVE;2.34;2.73 +60405-8;Solea solea Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sole IgG Ab [Mass/volume] in Serum;Sole IgG-mCnc;;ACTIVE;2.34;2.73 +60406-6;Spinacia oleracea Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Spinach IgG Ab [Mass/volume] in Serum;Spinach IgG-mCnc;;ACTIVE;2.34;2.73 +60407-4;Helianthus annuus seed Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sunflower Seed IgG Ab [Mass/volume] in Serum;Sunflower Seed IgG-mCnc;;ACTIVE;2.34;2.73 +60408-2;Citrus reticulata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mandarin IgG Ab [Mass/volume] in Serum;Mandarin IgG-mCnc;;ACTIVE;2.34;2.73 +60409-0;Oncorhynchus mykiss Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Trout IgG Ab [Mass/volume] in Serum;Trout IgG-mCnc;;ACTIVE;2.34;2.73 +60410-8;Thunnus albacares Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tuna IgG Ab [Mass/volume] in Serum;Tuna IgG-mCnc;;ACTIVE;2.34;2.73 +60411-6;Turkey Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Turkey IgG Ab [Mass/volume] in Serum;Turkey IgG-mCnc;;ACTIVE;2.34;2.73 +60412-4;Vanilla planifolia Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Vanilla IgG Ab [Mass/volume] in Serum;Vanilla IgG-mCnc;;ACTIVE;2.34;2.73 +60413-2;Yeast brewer's Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Brewer's yeast IgG Ab [Mass/volume] in Serum;Brewer's yeast IgG-mCnc;;ACTIVE;2.34;2.73 +60414-0;Squash zucchini Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Zucchini IgG Ab [Mass/volume] in Serum;Zucchini IgG-mCnc;;ACTIVE;2.34;2.73 +60415-7;Parainfluenza virus 4 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Isolate by NAA with probe detection;HPIV4 RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +60416-5;Parainfluenza virus 3 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Isolate by NAA with probe detection;HPIV3 RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +60417-3;Parainfluenza virus 2 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Isolate by NAA with probe detection;HPIV2 RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +6041-8;Cynodon dactylon Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass IgE Ab [Units/volume] in Serum;Bermuda grass IgE Qn;;ACTIVE;1.0d;2.73 +60418-1;Dengue virus 4 RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 4 RNA [Presence] in Serum by NAA with probe detection;DENV4 RNA Ser Ql NAA+probe;;ACTIVE;2.34;2.73 +60419-9;Dengue virus 3 RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 3 RNA [Presence] in Serum by NAA with probe detection;DENV3 RNA Ser Ql NAA+probe;;ACTIVE;2.34;2.73 +60420-7;Dengue virus 2 RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 2 RNA [Presence] in Serum by NAA with probe detection;DENV2 RNA Ser Ql NAA+probe;;ACTIVE;2.34;2.73 +60421-5;Apis mellifera phospholipase A2 recombinant (rApi m) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee phospholipase A2 recombinant (rApi m) 1 IgE Ab [Units/volume] in Serum;PLA2 rApi m 1 IgE Qn;;ACTIVE;2.34;2.70 +60422-3;Measles virus genotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Measles virus genotype [Identifier] in Specimen by NAA with probe detection;MeV Gentyp Spec NAA+probe;;ACTIVE;2.34;2.72 +60423-1;Measles virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Deprecated Measles virus identified in Unspecified specimen by Organism specific culture;Deprecated MeV XXX Cult;;DEPRECATED;2.34;2.69 +60424-9;Parainfluenza virus 4 Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Parainfluenza virus 4 Ag [Presence] in Specimen;HPIV4 Ag Spec Ql;;ACTIVE;2.34;2.69 +60425-6;Human metapneumovirus Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Human metapneumovirus Ag [Presence] in Specimen;hMPV Ag Spec Ql;;ACTIVE;2.34;2.73 +6042-6;Beta lactoglobulin MF77 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beta lactoglobulin MF77 IgE Ab [Units/volume] in Serum;B-Lactoglob MF77 IgE Qn;;ACTIVE;1.0d;2.73 +60426-4;SARS coronavirus Ab;Titr;Pt;Ser;Qn;;MICRO;1;SARS coronavirus Ab [Titer] in Serum;SARS-CoV Ab Titr Ser;;ACTIVE;2.34;2.70 +60427-2;Norovirus RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Norovirus RNA [Presence] in Isolate by NAA with probe detection;Norovirus RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.73 +60428-0;Toxoplasma gondii Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgA Ab [Titer] in Serum;T gondii IgA Titr Ser;;ACTIVE;2.34;2.70 +60429-8;Enterovirus 71 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Enterovirus 71 RNA [Presence] in Isolate by NAA with probe detection;EV 71 RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.63 +60430-6;Hepatitis E virus genotype;Prid;Pt;Bld;Nom;Probe.amp.tar;MICRO;1;Hepatitis E virus genotype [Identifier] in Blood by NAA with probe detection;HEV Gentyp Bld NAA+probe;;ACTIVE;2.34;2.72 +60431-4;Date of previous biopsy;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of previous biopsy;Date previous bx;;ACTIVE;2.34;2.73 +60432-2;Date of previous PAP smear;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of previous PAP smear;Date of previous PAP;;ACTIVE;2.34;2.73 +60433-0;Leukocytes;NRat;XXX;Urine sed;Qn;Microscopy.light;UA;1;Leukocytes by Light microscopy in Urine sediment collected for unspecified duration;WBC ?Tm UrnS Micro-nRate;;ACTIVE;2.34;2.70 +6043-4;Birch Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Birch Ab.IgE;Deprecated Birch IgE Qn;;DEPRECATED;1.0d;2.70 +60434-8;Cells.CD19+CD103+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD103+ cells [#/volume] in Blood;CD19+CD103+ Cells # Bld;;ACTIVE;2.34;2.70 +60435-5;Cells.CD10+CD19+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD10+CD19+ cells [#/volume] in Blood;CD10+CD19+ Cells # Bld;;ACTIVE;2.34;2.70 +60436-3;Cells.CD19+CD25+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD25+ cells [#/volume] in Blood;CD19+CD25+ cells # Bld;;ACTIVE;2.34;2.70 +60437-1;Cells.CD5+CD23+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD5+CD23+ cells [#/volume] in Blood;CD5+CD23+ Cells # Bld;;ACTIVE;2.34;2.70 +60438-9;Diamine oxidase;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Diamine oxidase [Units/volume] in Serum or Plasma;Diamine oxidase SerPl-aCnc;;ACTIVE;2.34;2.70 +60439-7;Lymphocytes.large granular/100 leukocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Large granular lymphocytes/100 leukocytes in Blood by Flow cytometry (FC);Lg Gran Lymphs/leuk NFr Bld FC;;ACTIVE;2.34;2.70 +60440-5;Oseltamivir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Oseltamivir [Susceptibility] by Genotype method;Oseltamivir Islt Genotyp;;ACTIVE;2.34;2.68 +60441-3;Oseltamivir+Zanamivir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Oseltamivir+Zanamivir [Susceptibility] by Genotype method;Oseltamivir+Zanamivir Islt Genotyp;;ACTIVE;2.34;2.68 +6044-2;Monomorium minimum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Ant IgE Ab [Units/volume] in Serum;Black Ant IgE Qn;;ACTIVE;1.0d;2.73 +60442-1;HEDIS 2011 panel;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 panel;HEDIS 2011 panel;;DISCOURAGED;2.34;2.67 +60443-9;HEDIS 2011 Codes to identify colorectal cancer screening (COL-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 Codes to identify colorectal cancer screening (COL-A);HEDIS 2011 COL-A;;DISCOURAGED;2.34;2.67 +60444-7;HEDIS 2011 Codes to identify sexually active women (CHL-B);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 Codes to identify sexually active women (CHL-B);HEDIS 2011 CHL-B;;DISCOURAGED;2.34;2.67 +60445-4;HEDIS 2011 Codes to identify exclusions (CHL-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 Codes to identify exclusions (CHL-D);HEDIS 2011 CHL-D;;DISCOURAGED;2.34;2.67 +60446-2;HEDIS 2011 Codes to identify nephropathy screening tests (CDC-J);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 Codes to identify nephropathy screening tests (CDC-J);HEDIS 2011 CDC-J;;DISCOURAGED;2.34;2.67 +60447-0;HEDIS 2011-2013 Codes to identify evidence of nephropathy (CDC-K);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011-2013 Codes to identify evidence of nephropathy (CDC-K);HEDIS 2011-12 CDC-K;;DISCOURAGED;2.34;2.67 +60448-8;HEDIS 2011 Codes to identify physiologic monitoring tests (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 Codes to identify physiologic monitoring tests (MPM-A);HEDIS 2011 MPM-A;;DISCOURAGED;2.34;2.67 +60449-6;HEDIS 2011-2013 Codes to identify physiologic monitoring tests - Serum potassium (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011-2013 Codes to identify physiologic monitoring tests - Serum potassium (MPM-A);HEDIS 2011-12 MPM-A K;;DISCOURAGED;2.34;2.67 +60450-4;HEDIS 2011 Tests used in early prenatal care (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 Tests used in early prenatal care (PPC-C);HEDIS 2011 PPC-C;;DISCOURAGED;2.34;2.67 +60451-2;HEDIS 2011-2013 Tests used in early prenatal care - Herpes simplex (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011-2013 Tests used in early prenatal care - Herpes simplex (PPC-C);HEDIS 2011-12 PPC-C HSV;;DISCOURAGED;2.34;2.67 +60452-0;HEDIS 2011-2013 Tests used in early prenatal care - Toxoplasma (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011-2013 Tests used in early prenatal care - Toxoplasma (PPC-C);HEDIS 2011-12 PPC-C Toxo;;DISCOURAGED;2.34;2.67 +60453-8;HEDIS 2011 Tests used in early prenatal care - ABO & Rh (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011 Tests used in early prenatal care - ABO and Rh (PPC-C);HEDIS 2011 PPC-C ABO+Rh;;DISCOURAGED;2.34;2.67 +60454-6;Bixa orellana seed Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Annatto seed IgE Ab RAST class [Presence] in Serum;Annatto seed IgE RAST Ql;;ACTIVE;2.34;2.73 +60455-3;Bizarre platelets;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Bizarre platelets [Presence] in Blood by Light microscopy;Bizarre platelets Bld Ql Smear;;ACTIVE;2.34;2.73 +60456-1;Cells.CD3+CD8+CD57+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD57+ cells/100 cells in Blood;CD3+CD8+CD57+ Cells NFr Bld;;ACTIVE;2.34;2.73 +60457-9;Cells.CD4+CD26-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+ CD26- Cells [#/volume] in Blood;CD4+CD26- Cells # Bld;;ACTIVE;2.34;2.70 +60458-7;Collection time^6th specimen;TmStp;Pt;Bld;Qn;;SPEC;1;Collection time of Blood--6th specimen;Collect Tme sp6 Bld;;ACTIVE;2.34;2.70 +6045-9;Piper nigrum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Pepper IgE Ab [Units/volume] in Serum;Black Pepper IgE Qn;;ACTIVE;1.0d;2.73 +60459-5;Complement C6.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C6.functional [Units/volume] in Serum or Plasma;C6.functional SerPl-aCnc;;ACTIVE;2.34;2.73 +60461-1;Herpes simplex virus 1 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HSV1 DNA # Spec NAA+probe;;ACTIVE;2.34;2.73 +60462-9;Herpes simplex virus 2 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HSV2 DNA # Spec NAA+probe;;ACTIVE;2.34;2.73 +60463-7;Insulin Ab;SCnc;Pt;Ser;Qn;;SERO;1;Insulin Ab [Moles/volume] in Serum;Insulin Ab Ser-sCnc;;ACTIVE;2.34;2.73 +60464-5;Monosodium glutamate Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Monosodium glutamate (MSG) IgE Ab RAST class [Presence] in Serum;MSG IgE RAST Ql;;ACTIVE;2.34;2.73 +60465-2;Neisseria meningitidis serogroup w135 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Neisseria meningitidis serogroup w135 IgG Ab [Mass/volume] in Serum by Immunoassay;N men sg W135 IgG Ser IA-mCnc;;ACTIVE;2.34;2.73 +60466-0;Neisseria meningitidis serogroup Y Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Neisseria meningitidis serogroup Y IgG Ab [Mass/volume] in Serum by Immunoassay;N men sg Y IgG Ser IA-mCnc;;ACTIVE;2.34;2.73 +6046-7;Juglans nigra pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Walnut Pollen IgE Ab [Units/volume] in Serum;Black Walnut Poln IgE Qn;;ACTIVE;1.0d;2.73 +60467-8;oxyMORphone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;oxyMORphone [Mass/volume] in Serum or Plasma;oxyMORphone SerPl-mCnc;;ACTIVE;2.34;2.73 +60468-6;PHENobarbital;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;PHENobarbital [Mass/volume] in Serum or Plasma by Confirmatory method;Phenobarb SerPl Cfm-mCnc;;ACTIVE;2.34;2.73 +60469-4;Urate;MCnc;Pt;Plr fld;Qn;;CHEM;1;Urate [Mass/volume] in Pleural fluid;Urate Plr-mCnc;;ACTIVE;2.34;2.70 +60470-2;Toxocara canis Ab;ACnc;Pt;Body fld;Qn;;MICRO;1;Toxocara canis Ab [Units/volume] in Body fluid;T canis Ab Fld-aCnc;;ACTIVE;2.34;2.70 +60471-0;busPIRone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;busPIRone [Mass/volume] in Urine;busPIRone Ur-mCnc;;ACTIVE;2.34;2.70 +60472-8;Complement C5.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C5.functional [Units/volume] in Serum or Plasma;C5.functional SerPl-aCnc;;ACTIVE;2.34;2.73 +60473-6;Lymphocytes.vacuolated;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Lymphocytes.vacuolated [Presence] in Blood by Light microscopy;Lymphs Vac Bld Ql Smear;;ACTIVE;2.34;2.56 +60474-4;Reticulocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Reticulocytes [#/volume] in Blood by Automated count;Retics # Auto;;ACTIVE;2.34;2.73 +6047-5;Chironomus thummi Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bloodworm IgE Ab [Units/volume] in Serum;Bloodworm IgE Qn;;ACTIVE;1.0d;2.73 +60475-1;Serotonin release 0.2 IU/mL heparin.low molecular weight;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 0.2 IU/mL heparin.low molecular weight [Units/volume] in Serum;SRA .2 IU/mL LMW heparin Ser-aCnc;;DISCOURAGED;2.34;2.73 +60476-9;Stage;Type;Pt;^Tick;Nom;;MICRO;1;Stage [Type] in Tick;Stage Tick;;ACTIVE;2.34;2.34 +60477-7;Thickness^^adjusted for maternal weight;MoM;Pt;Nuchal fold^Fetus;Qn;;OB.US;2;Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight;Fet Nuchal fold MoM Thickness wt adj;;ACTIVE;2.34;2.70 +60478-5;Sex;Type;Pt;^Tick;Nom;;MICRO;1;Sex of Tick;Sex of Tick;;ACTIVE;2.34;2.66 +60479-3;HEDIS 2011-2013 Codes to identify LDLc screening (CMC-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011-2013 Codes to identify LDLc screening (CMC-D);HEDIS 2011-12 CMC-D;;DISCOURAGED;2.34;2.67 +60480-1;HEDIS 2010-11 Codes to identify group A Streptococcus tests (CWP-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010-11 Codes to identify group A Streptococcus tests (CWP-D);HEDIS 2010-11 CWP-D;;DISCOURAGED;2.34;2.67 +60481-9;HEDIS 2011-2013 Codes to identify LDLc screening (CDC-H);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011-2013 Codes to identify LDLc screening (CDC-H);HEDIS 2011-12 CDC-H;;DISCOURAGED;2.34;2.67 +60482-7;HEDIS 2011-2013 Codes to identify anticonvulsant serum concentration monitoring tests - Phenytoin (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2011-2013 Codes to identify anticonvulsant serum concentration monitoring tests - Phenytoin (MPM-E);HEDIS 2011-12 MPM-E Phenytoin;;DISCOURAGED;2.34;2.67 +6048-3;Mytilus edulis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blue mussel IgE Ab [Units/volume] in Serum;Blue mussel IgE Qn;;ACTIVE;1.0d;2.73 +60483-5;HEDIS 2010 Tests used in early prenatal care - Toxoplasma (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2010 Tests used in early prenatal care - Toxoplasma (PPC-C);HEDIS 2010 PPC-C Toxo;;DISCOURAGED;2.34;2.67 +60484-3;CDC Immunization panel;-;Pt;^Patient;-;;PANEL.VACCIN;2;CDC Immunization panel;CDC Immunization pnl;;ACTIVE;2.34;2.34 +60485-0;Interferon.gamma;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Interferon gamma [Mass/volume] in Body fluid;IGNF Fld-mCnc;;ACTIVE;2.34;2.70 +60486-8;MED12 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MED12 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MED12 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +60487-6;NPHP1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NPHP1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NPHP1 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +60488-4;NPHS2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NPHS2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NPHS2 gene Mut Anl Bld/T;;ACTIVE;2.34;2.73 +60489-2;Streptococcus pyogenes DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Presence] in Throat by NAA with probe detection;S pyo DNA Throat Ql NAA+probe;;ACTIVE;2.34;2.73 +604-9;Bacteria identified;Prid;Pt;Bronchial;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bronchial specimen by Aerobe culture;Bacteria Bronch Aerobe Cult;;ACTIVE;1.0;2.73 +60490-0;UMOD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;UMOD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;UMOD gene Mut Anl Bld/T;;ACTIVE;2.34;2.68 +6049-1;Botrytis cinerea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Botrytis cinerea IgE Ab [Units/volume] in Serum;B cinerea IgE Qn;;ACTIVE;1.0d;2.73 +60491-8;LCA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LCA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LCA gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +60492-6;Hypertrophic cardiomyopathy gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Hypertrophic cardiomyopathy gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HCM Mut Anl Bld/T;;ACTIVE;2.34;2.68 +60493-4;Calcidiol+Calciferol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Calcidiol+Calciferol [Moles/volume] in Serum or Plasma;Calcidiol+Calciferol SerPl-sCnc;;ACTIVE;2.34;2.70 +60494-2;Influenza virus A H1 2009 pandemic & Influenza virus A swine origin RNA;Imp;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic and Influenza virus A swine origin RNA [Interpretation] in Specimen Qualitative by NAA with probe detection;FLUAV H1 2009 RNA Spec NAA+probe-Imp;;ACTIVE;2.34;2.73 +60495-9;MAP2K1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MAP2K1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MAP2K1 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +60496-7;MAP2K2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MAP2K2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MAP2K2 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +60497-5;SLC22A5 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC22A5 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC22A5 gene Mut Anl Bld/T;;ACTIVE;2.34;2.73 +60498-3;Cancer identification section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Cancer identification section Set NAACCR v.12;Cancer ID section NAACCR v.12;;ACTIVE;2.34;2.61 +60499-1;Demographic section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Demographic section Set NAACCR v.12;Demographic section NAACCR v.12;;ACTIVE;2.34;2.61 +60500-6;Edit overrides &or Conversion history &or System admin section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Edit overrides/Conversion history/System admin section Set NAACCR v.12;Edit ovrds/Conv Hx/Sys admin NAACCR v.12;;ACTIVE;2.34;2.61 +60501-4;Follow-up &or Recurrence &or Death section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Follow-up/Recurrence/Death section Set NAACCR v.12;Follow-up/Recur/Death sec NAACCR v.12;;ACTIVE;2.34;2.61 +60502-2;Hospital-confidential section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Hospital-confidential section Set NAACCR v.12;Hosp-confidential section NAACCR v.12;;ACTIVE;2.34;2.61 +60503-0;Hospital-specific section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Hospital-specific section Set NAACCR v.12;Hosp-specific section NAACCR v.12;;ACTIVE;2.34;2.61 +60504-8;Other-confidential section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Other-confidential section Set NAACCR v.12;Other-confidential sec NAACCR v.12;;ACTIVE;2.34;2.61 +60505-5;Patient-confidential section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Patient-confidential section Set NAACCR v.12;Patient-confidential section NAACCR v.12;;ACTIVE;2.34;2.61 +60506-3;Record ID section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Record ID section Set NAACCR v.12;Record ID section NAACCR v.12;;ACTIVE;2.34;2.61 +60507-1;Special use section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Special use section Set NAACCR v.12;Special use section NAACCR v.12;;ACTIVE;2.34;2.61 +60508-9;Stage &or prognostic factors section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Stage/prognostic factors section Set NAACCR v.12;Stage/prognost fact section NAACCR v.12;;ACTIVE;2.34;2.61 +6050-9;Bertholletia excelsa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brazil Nut IgE Ab [Units/volume] in Serum;Brazil Nut IgE Qn;;ACTIVE;1.0d;2.73 +60509-7;Text-diagnosis section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Text-diagnosis section Set NAACCR v.12;Text-Dx section NAACCR v.12;;ACTIVE;2.34;2.61 +60510-5;Text-miscellaneous section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Text-miscellaneous section Set NAACCR v.12;Text-miscellaneous section NAACCR v.12;;ACTIVE;2.34;2.61 +60511-3;Text-treatment section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Text-treatment section Set NAACCR v.12;Text-Tx section NAACCR v.12;;ACTIVE;2.34;2.61 +60512-1;Treatment-1st course section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Treatment-1st course section Set NAACCR v.12;Tx-1st course section NAACCR v.12;;ACTIVE;2.34;2.61 +60513-9;Treatment-subsequent & other section;-;Pt;^Patient;Set;NAACCR v.12;TUMRRGT;2;Treatment-subsequent and other section Set NAACCR v.12;Tx-subseq + other section NAACCR v.12;;ACTIVE;2.34;2.61 +60514-7;6-Acetylcodeine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;6-Acetylcodeine [Mass/volume] in Urine by Confirmatory method;6-Acetylcodeine Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +60515-4;Multisection^W air contrast PR;Find;Pt;Abdomen+Pelvis>Colon+Rectum;Doc;CT;RAD;2;CT Colon and Rectum W air contrast PR;CT Colon+Rect W Air contr PR;;ACTIVE;2.34;2.61 +60516-2;Hormone Rx;Type;Pt;^Patient;Nom;;CLIN;2;Hormone treatment;Hormone Rx;;ACTIVE;2.34;2.34 +6051-7;Yeast brewer's Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brewer's yeast IgE Ab [Units/volume] in Serum;Brewer's yeast IgE Qn;;ACTIVE;1.0d;2.73 +60517-0;Iron/Transferrin;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Iron/Transferrin [Ratio] in Serum or Plasma;Iron/Transferrin SerPl-Rto;;ACTIVE;2.34;2.73 +60518-8;Creatinine;SRat;24H;Stool;Qn;;CHEM;1;Creatinine [Moles/time] in 24 hour Stool;Creat 24h Stl-sRate;;ACTIVE;2.34;2.70 +60519-6;Fatty acids.ethyl esters;SCnt;Pt;Meconium;Qn;;CHEM;1;Fatty acids.ethyl esters [Moles/mass] in Meconium;Fatty acids.ethyl esters Mec-sCnt;;ACTIVE;2.36;2.70 +60520-4;Eosinophils;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Eosinophils [Presence] in Body fluid by Light microscopy;Eosinophil Fld Ql Micro;;ACTIVE;2.34;2.73 +60521-2;Babesia microti Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Babesia microti IgG+IgM Ab [Presence] in Serum;B microti IgG+IgM Ser Ql;;ACTIVE;2.34;2.64 +60522-0;Borrelia hermsii Ab.IgG+IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Borrelia hermsii IgG+IgM Ab [Presence] in Serum;B hermsii IgG+IgM Ser Ql;;ACTIVE;2.34;2.73 +60523-8;Carbromal;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbromal [Mass/volume] in Serum or Plasma;Carbromal SerPl-mCnc;;ACTIVE;2.34;2.70 +60524-6;Helicobacter pylori Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Helicobacter pylori IgG Ab [Presence] in Serum by Immunoblot;H pylori IgG Ser Ql IB;;ACTIVE;2.34;2.73 +6052-5;Brassica oleracea var italica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Broccoli IgE Ab [Units/volume] in Serum;Broccoli IgE Qn;;ACTIVE;1.0d;2.73 +60525-3;Parechovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parechovirus RNA [Presence] in Specimen by NAA with probe detection;PeV RNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +60526-1;Pseudo Pelger Huet cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Pseudo Pelger Huet cells [Presence] in Blood by Light microscopy;Pseudo Pelger Huet cells Bld Ql Smear;;ACTIVE;2.34;2.73 +60527-9;Views+views uptake^W I-123 PO;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views and Views uptake W I-123 PO;NM Thyroid Views+views uptake W I-123 PO;;ACTIVE;2.34;2.64 +60528-7;Enterovirus subtype;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Enterovirus subtype in Specimen by NAA with probe detection;EV subtype Spec NAA+probe;;ACTIVE;2.34;2.73 +60529-5;Influenza virus A H1 2009 pandemic Ab;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A H1 2009 pandemic Ab [Titer] in Serum;FLUAV H1 2009 pand Ab Titr Ser;;ACTIVE;2.34;2.70 +60530-3;Influenza virus A H9 RNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H9 RNA [Presence] in Isolate by NAA with probe detection;FLUAV H9 RNA Islt Ql NAA+probe;;ACTIVE;2.34;2.63 +60531-1;Japanese encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Japanese encephalitis virus IgM Ab [Titer] in Serum;JEV IgM Titr Ser;;ACTIVE;2.34;2.70 +60532-9;Japanese encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;;MICRO;1;Japanese encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid;JEV IgM Titr CSF;;ACTIVE;2.34;2.70 +6053-3;Bromus inermis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brome IgE Ab [Units/volume] in Serum;Brome IgE Qn;;ACTIVE;1.0d;2.73 +60533-7;Mycoplasma pneumoniae Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum by Latex agglutination;M pneumo Ab Titr Ser LA;;ACTIVE;2.34;2.70 +60534-5;SARS coronavirus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;SARS coronavirus RNA [Presence] in Serum or Plasma by NAA with probe detection;SARS-CoV RNA SerPl Ql NAA+probe;;ACTIVE;2.34;2.68 +60535-2;Doripenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Doripenem [Susceptibility];Doripenem Susc Islt;;ACTIVE;2.34;2.73 +60536-0;HLA-DQ beta;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DQ beta [Type];HLA-DQ beta;;ACTIVE;2.34;2.73 +60537-8;CLCN5 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CLCN5 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CLCN5 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +60538-6;Influenza virus A H1+H3+B RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1+H3+B RNA [Presence] in Specimen by NAA with probe detection;FLUAV H1+H3+FLUBV RNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +60539-4;Tryptase.beta;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tryptase.beta [Mass/volume] in Serum or Plasma;Tryptase.beta SerPl-mCnc;;ACTIVE;2.34;2.70 +60540-2;HBA2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HBA2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HBA2 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +6054-1;Fagopyrum esculentum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Buckwheat IgE Ab [Units/volume] in Serum;Buckwheat IgE Qn;;ACTIVE;1.0d;2.73 +60541-0;Cytomegalovirus early Ag;PrThr;Pt;XXX;Ord;;MICRO;1;Cytomegalovirus early Ag [Presence] in Specimen;CMV EA Ag Spec Ql;;ACTIVE;2.34;2.73 +60542-8;Mupirocin 5 ug;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Mupirocin 5 ug [Susceptibility] by Disk diffusion (KB);Mupirocin 5 ug Islt KB;;ACTIVE;2.34;2.34 +60543-6;Mupirocin 200 ug;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Mupirocin 200 ug [Susceptibility] by Disk diffusion (KB);Mupirocin 200 ug Islt KB;;ACTIVE;2.34;2.34 +60544-4;Giardia lamblia DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Giardia lamblia DNA [Presence] in Specimen by NAA with probe detection;G lamblia DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +60545-1;Cryptosporidium sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cryptosporidium sp DNA [Presence] in Specimen by NAA with probe detection;Cryptosp DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +60546-9;Polio virus identified;Type;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Polio virus identified [Type] in Isolate by Organism specific culture;PV Islt Cult;;ACTIVE;2.34;2.34 +60547-7;11-Oxo-Androsterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;11-Oxo-Androsterone/Creatinine [Mass Ratio] in Urine;11oxoAndrost/Creat Ur;;ACTIVE;2.34;2.73 +60548-5;11-Oxo-Etiocholanolone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;11-Oxo-Etiocholanolone/Creatinine [Mass Ratio] in Urine;11oxoEtioch/Creat Ur;;ACTIVE;2.34;2.73 +60549-3;8-Estriol;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated 8-Estriol [Mass/volume] in Urine;Deprecated 8-Estriol Ur-mCnc;;DEPRECATED;2.34;2.70 +60550-1;Fascin;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Fascin [Presence] in Tissue by Immune stain;Fascin Tiss Ql ImStn;;ACTIVE;2.34;2.73 +60551-9;Interferon.beta 1a Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Interferon.beta 1a Ab [Titer] in Serum or Plasma;INF-B1a Ab Titr SerPl;;ACTIVE;2.34;2.73 +60552-7;Interferon.beta 1b Ab;Titr;Pt;Ser/Plas;Qn;;SERO;1;Interferon.beta 1b Ab [Titer] in Serum or Plasma;INF-B1b Ab Titr SerPl;;ACTIVE;2.34;2.73 +60553-5;Trypanosoma cruzi Ab;PrThr;Pt;Ser^Donor;Ord;;MICRO;1;Trypanosoma cruzi Ab [Presence] in Serum from Donor;T cruzi Ab Ser Donr Ql;;ACTIVE;2.34;2.73 +60554-3;Monocytes.CD59 deficient/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD59 deficient monocytes/100 cells in Blood;CD59 deficient Monocytes NFr Bld;;ACTIVE;2.34;2.73 +60555-0;Accessories;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Accessories;FDA insert Accessories;;ACTIVE;2.34;2.34 +60556-8;Assembly or installation instructions;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Assembly or installation instructions;FDA insert Assembly/install inst;;ACTIVE;2.34;2.34 +60557-6;Calibration instructions;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Calibration instructions;FDA insert Calibration instructions;;ACTIVE;2.34;2.34 +6055-8;Budgerigar feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Budgerigar feather IgE Ab [Units/volume] in Serum;Deprecated Budgie Feather IgE Qn;;DEPRECATED;1.0d;2.70 +60558-4;Cleaning, disinfecting, and sterilization instructions;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Cleaning, disinfecting, and sterilization instructions;FDA insert Clean/disinfect/ster inst;;ACTIVE;2.34;2.34 +60559-2;Components;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Components;FDA insert Components;;ACTIVE;2.34;2.34 +605-6;Bacteria identified;Prid;Pt;Cnl;Nom;Aerobic culture;MICRO;1;Bacteria identified in Cannula specimen by Aerobe culture;Bacteria Cannula Aerobe Cult;;ACTIVE;1.0;2.21 +60560-0;Intended Use of the Device;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Intended use of the device;FDA insert Intended use of device;;ACTIVE;2.34;2.34 +60561-8;Other safety information;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Other safety information;FDA insert Other safety info;;ACTIVE;2.34;2.34 +60562-6;Route, method and frequency of administration;-;-;^FDA package insert;Nar;;DOCUMENT.REGULATORY;2;FDA package insert Route, method and frequency of administration;FDA insert Route/method/freq;;ACTIVE;2.34;2.34 +60563-4;Summary of safety and effectiveness;-;-;^FDA package insert;Nar;;DOCUMENT.REGULATORY;2;FDA package insert Summary of safety and effectiveness;FDA insert Summ of safety/effect;;ACTIVE;2.34;2.34 +60564-2;Amikacin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 1 ug/mL Islt SlowMyco;;ACTIVE;2.34;2.40 +60565-9;Amikacin 4.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Amikacin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Amikacin 4 ug/mL Islt SlowMyco;;ACTIVE;2.34;2.40 +6056-6;Bombus terrestris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bumble Bee IgE Ab [Units/volume] in Serum;Bumble Bee IgE Qn;;ACTIVE;1.0d;2.73 +60566-7;Respiratory pathogens DNA & RNA 12b panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA 12b panel - Specimen by NAA with probe detection;Resp path 12b Pnl Spec NAA+probe;;ACTIVE;2.34;2.73 +60567-5;Comprehensive pathology report panel;-;Pt;^Patient;-;;PANEL.DOC;2;Comprehensive pathology report panel;Comprehensive path report pnl;;ACTIVE;2.34;2.63 +60568-3;Synoptic report;Find;Pt;^Patient;Doc;Pathology;PATH;1;Pathology Synoptic report;Pathology Synoptic report;;ACTIVE;2.34;2.73 +60569-1;Report addendum.synoptic;Find;Pt;^Patient;Doc;Pathology;PATH;1;Pathology Report addendum.synoptic Document;Path Report addendum.synoptic Doc;;ACTIVE;2.34;2.61 +60570-9;Consultation note;Find;Pt;{Setting};Doc;Pathology;DOC.ONTOLOGY;2;Pathology Consult note;Pathology Consult note;;ACTIVE;2.34;2.73 +60571-7;Consultation note.synoptic;Find;Pt;{Setting};Doc;Pathology;PATH;1;Pathology Consult note.synoptic;Pathology Consult note.synoptic;;ACTIVE;2.34;2.61 +60572-5;Report template ID;ID;Pt;Report;Nom;;DOC.MISC;2;Report template ID;Report template ID;;ACTIVE;2.34;2.73 +60573-3;Report template source;ID;Pt;Report;Nom;;DOC.REF;2;Report template source;Report template source;;ACTIVE;2.34;2.34 +6057-4;Matricaria chamomilla Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chamomile IgE Ab [Units/volume] in Serum;Chamomile IgE Qn;;ACTIVE;1.0d;2.73 +60574-1;Report template version ID;ID;Pt;Report;Nom;;DOC.MISC;2;Report template version ID;Report template version ID;;ACTIVE;2.34;2.73 +60575-8;Immunoglobulin heavy chain gene rearrangements;Arb;Pt;Bone mar;Ord;Molgen;MOLPATH.REARRANGE;1;HC gene rearrangements [Presence] in Bone marrow by Molecular genetics method;HC gene Rear Mar Ql;;ACTIVE;2.34;2.34 +60576-6;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points";Arb;Pt;CSF;Ord;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points [Presence] in Cerebral spinal fluid by Molecular genetics method";"t(14;18)(IGH,BCL2) Major CSF Ql";;ACTIVE;2.38;2.50 +60577-4;SERPINE1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SERPINE1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SERPINE1 gene Mut Anl Bld/T;;ACTIVE;2.34;2.73 +60578-2;TCRG gene rearrangements;Arb;Pt;Body fld;Ord;Molgen;MOLPATH.REARRANGE;1;TCRG gene rearrangements [Presence] in Body fluid by Molecular genetics method;TCRG gene Rear Fld Ql;;ACTIVE;2.34;2.34 +60579-0;TCRG gene rearrangements;Arb;Pt;CSF;Ord;Molgen;MOLPATH.REARRANGE;1;TCRG gene rearrangements [Presence] in Cerebral spinal fluid by Molecular genetics method;TCRG gene Rear CSF Ql;;ACTIVE;2.34;2.73 +60580-8;TCRG gene rearrangements;Arb;Pt;Bone mar;Ord;Molgen;MOLPATH.REARRANGE;1;TCRG gene rearrangements [Presence] in Bone marrow by Molecular genetics method;TCRG gene Rear Mar Ql;;ACTIVE;2.34;2.34 +60581-6;TCRB gene rearrangements;Arb;Pt;Body fld;Ord;Molgen;MOLPATH.REARRANGE;1;TCRB gene rearrangements [Presence] in Body fluid by Molecular genetics method;TCRB gene Rear Fld Ql;;ACTIVE;2.34;2.34 +6058-2;Phalaris arundinacea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Canary grass IgE Ab [Units/volume] in Serum;Canary grass IgE Qn;;ACTIVE;1.0d;2.73 +60582-4;TCRB gene rearrangements;Arb;Pt;CSF;Ord;Molgen;MOLPATH.REARRANGE;1;TCRB gene rearrangements [Presence] in Cerebral spinal fluid by Molecular genetics method;TCRB gene Rear CSF Ql;;ACTIVE;2.34;2.73 +60583-2;TCRB gene rearrangements;Arb;Pt;Bone mar;Ord;Molgen;MOLPATH.REARRANGE;1;TCRB gene rearrangements [Presence] in Bone marrow by Molecular genetics method;TCRB gene Rear Mar Ql;;ACTIVE;2.34;2.34 +60584-0;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points";Arb;Pt;CSF;Ord;Molgen;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points [Presence] in Cerebral spinal fluid by Molecular genetics method";"t(14;18)(IGH,BCL2) Minor CSF Ql";;ACTIVE;2.38;2.50 +60585-7;Ganglioside GT1b Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GT1b IgG Ab [Presence] in Serum by Immunoblot;Deprecated GT1b Ganlg IgG Ser Ql IB;;DEPRECATED;2.34;2.58 +60586-5;Ganglioside GM3 Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM3 IgG Ab [Presence] in Serum by Immunoblot;Deprecated GM3 IgG Ser Ql IB;;DEPRECATED;2.34;2.58 +60587-3;Cell count & Differential panel;-;Pt;Dial fld prt;Qn;;PANEL.HEM/BC;1;Cell count and Differential panel - Peritoneal dialysis fluid;Cell Cnt + Diff Pnl DiafP;;ACTIVE;2.34;2.42 +60588-1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr2 fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr2 fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(15;17) BCR2 Bld/T Ql";;ACTIVE;2.36;2.40 +60589-9;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr1 fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr1 fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(15;17) BCR1 Bld/T Ql";;ACTIVE;2.36;2.40 +6059-0;Candida albicans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Candida albicans IgE Ab [Units/volume] in Serum;C albicans IgE Qn;;ACTIVE;1.0d;2.73 +60590-7;Medication dispensed.brief;Find;Pt;^Patient;Doc;;DOC.EPSOS;2;Medication dispensed.brief Document;Medication dispensed.brief Doc;;ACTIVE;2.34;2.34 +60591-5;Patient summary;Find;Pt;^Patient;Doc;;DOC.EPSOS;2;Patient summary Document;Patient summary Doc;;ACTIVE;2.34;2.34 +60592-3;Patient summary.unexpected contact;Find;Pt;^Patient;Doc;;DOC.EPSOS;2;Patient summary.unexpected contact Document;Patient summary.unexpected contact Doc;;ACTIVE;2.34;2.68 +60593-1;Medication dispensed.extended;Find;Pt;^Patient;Doc;;DOC.EPSOS;2;Medication dispensed.extended Document;Medication dispensed.extended Doc;;ACTIVE;2.34;2.73 +60594-9;Face low/Face all;LenRto;Pt;Skull;Qn;XR.measured;DENTAL;2;Face low/Face all Skull X-ray measured;Sn-Me'/Face all Skull XR;;ACTIVE;2.34;2.48 +60595-6;Face mid/Face all;LenRto;Pt;Skull;Qn;XR.measured;DENTAL;2;Face mid/Face all Skull X-ray measured;Gl'-Sn/Face all Skull XR;;ACTIVE;2.34;2.48 +60596-4;Face lower incisor to chin/Face mid;LenRto;Pt;Skull;Qn;XR.measured;DENTAL;2;Face lower incisor to chin/Face mid Skull X-ray measured;Face L1 to chin/Face mid Skull XR;;ACTIVE;2.34;2.48 +60597-2;Face upper/Face all;LenRto;Pt;Skull;Qn;XR.measured;DENTAL;2;Face upper/Face all Skull X-ray measured;Face upper/Face all Skull XR;;ACTIVE;2.34;2.48 +60598-0;Face all;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Face all [Length] Skull X-ray measured;Face all Skull XR;;ACTIVE;2.34;2.34 +60599-8;Face lower incisor to chin;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Face lower incisor to chin [Length] Skull X-ray measured;Face L1 to chin Skull XR;;ACTIVE;2.34;2.34 +60600-4;Face upper;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Face upper [Length] Skull X-ray measured;Face upper Skull XR;;ACTIVE;2.34;2.34 +60601-2;Lower incisor to A point-pogonion line;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Lower incisor to A point-pogonion line [Length] Skull X-ray measured;1L-APg Skull XR;;ACTIVE;2.34;2.34 +60602-0;Upper molar position;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Upper molar position [Length] Skull X-ray measured;U6_PTV Skull XR;;ACTIVE;2.34;2.34 +60603-8;Molar relationship;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Molar relationship [Length] Skull X-ray measured;Molar rel Skull XR;;ACTIVE;2.34;2.34 +60604-6;Lower incisal edge perpendicular to nasion-B point line;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Lower incisal edge perpendicular to nasion-B point line [Length] Skull X-ray measured;1L-NB Skull XR;;ACTIVE;2.34;2.34 +60605-3;Overjet;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Overjet [Length] Skull X-ray measured;Overjet Skull XR;;ACTIVE;2.34;2.34 +60606-1;Incisor mandibular plane angle using menton;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Incisor mandibular plane angle using menton Skull X-ray measured;IMPA (1L-GOME) Skull XR;;ACTIVE;2.34;2.40 +60607-9;Incisor mandibular plane angle using constructed Gonion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Incisor mandibular plane angle using constructed Gonion Skull X-ray measured;IMPA (1L-GoMe) (constructed) Skull XR;;ACTIVE;2.34;2.40 +6060-8;Amaranthus palmeri Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Careless Weed IgE Ab [Units/volume] in Serum;Careless Weed IgE Qn;;ACTIVE;1.0d;2.73 +60608-7;Lower incisor to nasion-B point line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Lower incisor to nasion-B point line [Angle] Skull X-ray measured;1L-NB Angle Skull XR;;ACTIVE;2.34;2.40 +60609-5;Upper incisor to nasion-A point line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Upper incisor to nasion-A point line [Angle] Skull X-ray measured;1U-Na Angle Skull XR;;ACTIVE;2.34;2.40 +60610-3;Upper incisor to palatal plane;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Upper incisor to palatal plane [Angle] Skull X-ray measured;1U-ANSPNS Angle Skull XR;;ACTIVE;2.34;2.40 +60611-1;Upper central incisor to sella-nasion line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Upper central incisor to sella-nasion line [Angle] Skull X-ray measured;1U-SeNa Angle Skull XR;;ACTIVE;2.34;2.40 +60612-9;Incisor mandibular plane angle using Gnathion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Incisor mandibular plane angle using gnathion Skull X-ray measured;IMPA (1L-GoGn) Skull XR;;ACTIVE;2.34;2.40 +60613-7;Inter incisal angle;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Inter incisal angle Skull X-ray measured;U1-L1 Skull XR;;ACTIVE;2.34;2.40 +60614-5;Condylion to gnathion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Condylion to gnathion [Length] Skull X-ray measured;Cd-Gn Skull XR;;ACTIVE;2.34;2.34 +60615-2;Condylion to anterior nasal spine;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Condylion to anterior nasal spine [Length] Skull X-ray measured;Cd-ANS Skull XR;;ACTIVE;2.34;2.34 +6061-6;Daucus carota Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Carrot IgE Ab [Units/volume] in Serum;Carrot IgE Qn;;ACTIVE;1.0d;2.73 +60616-0;Condylion to A-point;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Condylion to A-point [Length] Skull X-ray measured;Cd-A Skull XR;;ACTIVE;2.34;2.34 +60617-8;Infradentale to A-point;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Infradentale to A-point [Length] Skull X-ray measured;UIE-A FH Skull XR;;ACTIVE;2.34;2.34 +60618-6;Facial taper;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Facial taper [Angle] Skull X-ray measured;Go-Gn-A Angle Skull XR;;ACTIVE;2.34;2.40 +60619-4;Angle of convexity;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Angle of convexity Skull X-ray measured;NAP Skull XR;;ACTIVE;2.34;2.40 +60620-2;Upper central incisor to stomion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Upper central incisor to stomion [Length] Skull X-ray measured;1U-St Skull XR;;ACTIVE;2.34;2.34 +60621-0;Chin thickness;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Chin thickness Skull X-ray measured;Pg-Pg' Skull XR;;ACTIVE;2.34;2.34 +60622-8;Subnasal sulcus;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Subnasal sulcus [Length] Skull X-ray measured;Pg'Ls-Sls Skull XR;;ACTIVE;2.34;2.34 +60623-6;Naso-labial angle;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Naso-labial angle Skull X-ray measured;Lnt-Sn-Ls Skull XR;;ACTIVE;2.34;2.40 +6062-4;Casein Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Casein IgE Ab [Units/volume] in Serum;Casein IgE Qn;;ACTIVE;1.0d;2.73 +60624-4;Holdaway angle;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Holdaway angle Skull X-ray measured;Na'-Pg'-Ls Skull XR;;ACTIVE;2.34;2.40 +60625-1;Nasion to Frankfort horizontal plane;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Nasion to Frankfort horizontal plane [Length] Skull X-ray measured;Na-FH Skull XR;;ACTIVE;2.34;2.34 +60626-9;Facial axis;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Facial axis Skull X-ray measured;BaNa-CC Skull XR;;ACTIVE;2.34;2.40 +60627-7;Facial axis using constructed Gnathion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Facial axis using constructed Gnathion Skull X-ray measured;BaNa-CC (constructed) Skull XR;;ACTIVE;2.34;2.40 +60628-5;Y axis to Frankfort horizontal plane;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Y axis to Frankfort horizontal plane Skull X-ray measured;FH-SeGn Skull XR;;ACTIVE;2.34;2.40 +60629-3;Y axis to Frankfort horizontal plane using constructed Gnathion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Y axis to Frankfort horizontal plane using constructed Gnathion Skull X-ray measured;FH-SeGn (constructed) Skull XR;;ACTIVE;2.34;2.40 +60630-1;Y axis to sella-nasion plane;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Y axis to sella-nasion plane Skull X-ray measured;SeNa-SeGn Skull XR;;ACTIVE;2.34;2.40 +60631-9;Posterior facial height;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Posterior facial height Skull X-ray measured;Se-Go Skull XR;;ACTIVE;2.34;2.34 +6063-2;Ricinus communis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Castor Bean IgE Ab [Units/volume] in Serum;Castor Bean IgE Qn;;ACTIVE;1.0d;2.73 +60632-7;Ramus height;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Ramus height Skull X-ray measured;Ar-Go Skull XR;;ACTIVE;2.34;2.34 +60633-5;Ramus height using constructed Gonion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Ramus height using constructed Gonion Skull X-ray measured;Ar-Go (constructed) Skull XR;;ACTIVE;2.34;2.34 +60634-3;Anterior nasal spine to menton;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Anterior nasal spine to menton [Length] Skull X-ray measured;ANS-Me Skull XR;;ACTIVE;2.34;2.34 +60635-0;Gonial angle;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Gonial angle Skull X-ray measured;Ar-Go-Me Skull XR;;ACTIVE;2.34;2.40 +60636-8;Gonial angle using constructed Gonion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Gonial angle using constructed Gonion Skull X-ray measured;Ar-Go-Me (constructed) Skull XR;;ACTIVE;2.34;2.40 +60637-6;Frankfort horizontal plane to mandibular plane using constructed Gonion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Frankfort horizontal plane to mandibular plane using constructed Gonion [Angle] Skull X-ray measured;FMA (constructed) Angle Skull XR;;ACTIVE;2.34;2.40 +60638-4;Posterior facial height using CF point;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Posterior facial height using CF point Skull X-ray measured;CF-Go Skull XR;;ACTIVE;2.34;2.34 +60639-2;Face low;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Face low [Length] Skull X-ray measured;Sn-Me' Skull XR;;ACTIVE;2.34;2.34 +606-4;Bacteria identified;Prid;Pt;CSF;Nom;Culture;MICRO;1;Bacteria identified in Cerebral spinal fluid by Culture;Bacteria CSF Cult;;ACTIVE;1.0;2.73 +6064-0;Cat epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cat epithelium IgE Ab [Units/volume] in Serum;Deprecated Cat Epith IgE Qn;;DEPRECATED;1.0d;2.70 +60640-0;Lower lip to pogonion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Lower lip to pogonion [Length] Skull X-ray measured;Li-Pg' Skull XR;;ACTIVE;2.34;2.34 +60641-8;Stomion to menton;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Stomion to menton [Length] Skull X-ray measured;Sti-Me' Skull XR;;ACTIVE;2.34;2.34 +60642-6;Upper lip to pogonion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Upper lip to pogonion [Length] Skull X-ray measured;Ls-Pg' Skull XR;;ACTIVE;2.34;2.34 +60643-4;Anterior facial height;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Anterior facial height Skull X-ray measured;Na-Me Skull XR;;ACTIVE;2.34;2.34 +60644-2;Subnasale to pogonion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Subnasale to pogonion [Length] Skull X-ray measured;Sn-Pg' Skull XR;;ACTIVE;2.34;2.34 +60645-9;Subnasale to lower lip;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Subnasale to lower lip [Length] Skull X-ray measured;Sn-Li Skull XR;;ACTIVE;2.34;2.34 +60646-7;Subnasale to stomion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Subnasale to stomion [Length] Skull X-ray measured;St-Sn Skull XR;;ACTIVE;2.34;2.34 +60647-5;Anterior nasal spine to pogonion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Anterior nasal spine to pogonion [Length] Skull X-ray measured;ANS-Pg Skull XR;;ACTIVE;2.34;2.34 +60648-3;Adenoid width;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Adenoid width Skull X-ray measured;Adenoid Skull XR;;ACTIVE;2.34;2.34 +60649-1;Tonsilar width;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Tonsilar width Skull X-ray measured;Tonsil Skull XR;;ACTIVE;2.34;2.34 +60650-9;Wits analysis;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Wits analysis [Length] Skull X-ray measured;AO-BO Skull XR;;ACTIVE;2.34;2.34 +60651-7;Mandibular arc;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Mandibular arc [Angle] Skull X-ray measured;Cd-Xi-Pm Angle Skull XR;;ACTIVE;2.34;2.40 +60652-5;Lower facial height angle;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Lower facial height angle Skull X-ray measured;ANS-Xi-Pm Skull XR;;ACTIVE;2.34;2.40 +60653-3;Lower lip to menton;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Lower lip to menton [Length] Skull X-ray measured;Li-Me' Skull XR;;ACTIVE;2.34;2.34 +60654-1;Posterior cranial base;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Posterior cranial base [Length] Skull X-ray measured;Se-Ar Skull XR;;ACTIVE;2.34;2.34 +60655-8;Anterior cranial;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Anterior cranial [Length] Skull X-ray measured;CC-Na Skull XR;;ACTIVE;2.34;2.34 +60656-6;Condylion to gonion;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Condylion to gonion [Length] Skull X-ray measured;Cd-Go Skull XR;;ACTIVE;2.34;2.34 +6065-7;Apium graveolens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Celery IgE Ab [Units/volume] in Serum;Celery IgE Qn;;ACTIVE;1.0d;2.73 +60657-4;Subnasale to upper lip;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Subnasale to upper lip [Length] Skull X-ray measured;Sn-Ls Skull XR;;ACTIVE;2.34;2.34 +60658-2;Face lower incisor to chin/Face low;LenRto;Pt;Skull;Qn;XR.measured;DENTAL;2;Face lower incisor to chin/Face low Skull X-ray measured;Face L1 to chin/Face low Skull XR;;ACTIVE;2.34;2.48 +60659-0;Face mid/Face low;LenRto;Pt;Skull;Qn;XR.measured;DENTAL;2;Face mid/Face low Skull X-ray measured;GL'-SN/Face low Skull XR;;ACTIVE;2.34;2.48 +60660-8;Face lower incisor to chin/Face all;LenRto;Pt;Skull;Qn;XR.measured;DENTAL;2;Face lower incisor to chin/Face all Skull X-ray measured;Face L1 to chin/Face all Skull XR;;ACTIVE;2.34;2.48 +60661-6;Maxillary mandibular planes angle using menton;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Maxillary mandibular planes angle using menton Skull X-ray measured;ANSPNS-GoMe Skull XR;;ACTIVE;2.34;2.40 +60662-4;Maxillary mandibular planes angle using menton and constructed gonion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Maxillary mandibular planes angle using menton and constructed gonion Skull X-ray measured;ANSPNS-GoMe (constructed) Skull XR;;ACTIVE;2.34;2.40 +60663-2;Sella-nasion plane to mandibular plane using menton;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Sella-nasion plane to mandibular plane using menton [Angle] Skull X-ray measured;SENA-GoMe Angle Skull XR;;ACTIVE;2.34;2.40 +60664-0;Sella-nasion plane to mandibular plane using menton and constructed gonion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Sella-nasion plane to mandibular plane using menton and constructed gonion [Angle] Skull X-ray measured;SENA-GoMe (constructed) Angle Skull XR;;ACTIVE;2.34;2.40 +6066-5;Acremonium sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Acremonium sp IgE Ab [Units/volume] in Serum;Acremonium IgE Qn;;ACTIVE;1.0d;2.73 +60665-7;Face mid;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Face mid [Length] Skull X-ray measured;Gl'-Sn Skull XR;;ACTIVE;2.34;2.34 +60666-5;Sella-nasion plane to palatal plane;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Sella-nasion plane to palatal plane [Angle] Skull X-ray measured;SeNa-ANSPNS Angle Skull XR;;ACTIVE;2.34;2.40 +60667-3;Palatal plane to mandibular plane;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Palatal plane to mandibular plane [Angle] Skull X-ray measured;ANSPNS-GoGn Angle Skull XR;;ACTIVE;2.34;2.40 +60668-1;Palatal plane to mandibular plane constructed Gonion;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Palatal plane to mandibular plane constructed Gonion [Angle] Skull X-ray measured;ANSPNS-GoGn (constructed) Angle Skull XR;;ACTIVE;2.34;2.40 +60669-9;Glabella to subnasale;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Glabella to subnasale [Length] Skull X-ray measured;Gl-Sn Skull XR;;ACTIVE;2.34;2.34 +60670-7;Subnasale to menton;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Subnasale to menton [Length] Skull X-ray measured;Sn-Me Skull XR;;ACTIVE;2.34;2.34 +60671-5;Sella-nasion plane to nasion-pogonion line;Angle;Pt;Skull;Qn;XR.measured;DENTAL;2;Sella-nasion plane to nasion-pogonion line [Angle] Skull X-ray measured;SeNa-NaPg Angle Skull XR;;ACTIVE;2.34;2.40 +60672-3;Upper lip thickness;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Upper lip thickness Skull X-ray measured;Ls-Sd Skull XR;;ACTIVE;2.34;2.34 +6067-3;Cheese cheddar type Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cheese cheddar type IgE Ab [Units/volume] in Serum;Cheddar IgE Qn;;ACTIVE;1.0d;2.73 +60673-1;Soft tissue thickness at A-point;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Soft tissue thickness at A-point Skull X-ray measured;A-A' Skull XR;;ACTIVE;2.34;2.34 +60674-9;Nasion to A-point;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Nasion to A-point [Length] Skull X-ray measured;Na-A Skull XR;;ACTIVE;2.34;2.34 +60675-6;Mandibular body length;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Mandibular body length Skull X-ray measured;Go-Me Skull XR;;ACTIVE;2.34;2.34 +60676-4;Ethyl sulfate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethyl sulfate [Mass/volume] in Urine;Ethyl sulfate Ur-mCnc;;ACTIVE;2.34;2.73 +60677-2;Alpha hydroxytriazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alpha hydroxytriazolam [Mass/volume] in Urine;A-OH-triazolam Ur-mCnc;;ACTIVE;2.34;2.73 +60678-0;Protein/Creatinine;MRto;12H;Urine;Qn;;CHEM;1;Protein/Creatinine [Mass Ratio] in 12 hour Urine;Prot/Creat 12h Ur;;ACTIVE;2.36;2.73 +60680-6;Cortisol.free^30M post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol Free [Mass/volume] in Serum or Plasma --30 minutes post dose corticotropin;Cortis F 30M p ACTH SerPl-mCnc;;ACTIVE;2.34;2.73 +6068-1;Cheese mold type Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cheese mold type IgE Ab [Units/volume] in Serum;Cheese Mold IgE Qn;;ACTIVE;1.0d;2.73 +60681-4;Cortisol.free^1H post dose corticotropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol Free [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin;Cortis F 1h p ACTH SerPl-mCnc;;ACTIVE;2.34;2.73 +60682-2;Standardized allergenic;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Standardized allergenic;FDA label Standardized allergenic;;ACTIVE;2.34;2.34 +60683-0;Plasma derivative;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Plasma derivative;FDA label Plasma derivative;;ACTIVE;2.34;2.34 +60684-8;Cellular therapy;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Cellular therapy;FDA label Cellular therapy;;ACTIVE;2.34;2.34 +60685-5;Indexing - pharmacologic class;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indexing - pharmacologic class;FDA insert Index - pharm class;;ACTIVE;2.34;2.34 +60686-3;Overbite;Len;Pt;Skull;Qn;XR.measured;DENTAL;2;Overbite [Length] Skull X-ray measured;Overbite Skull XR;;ACTIVE;2.34;2.34 +60687-1;Test of Infant Motor Performance Version 5.1;-;Pt;^Patient;-;;PANEL.TIMP;4;Test of Infant Motor Performance Version 5.1;;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60688-9;TIMP cover;-;Pt;^Patient;-;;PANEL.TIMP;4;TIMP cover;;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.68 +60689-7;Observed items;-;Pt;^Patient;-;TIMP;PANEL.TIMP;4;Observed items [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.68 +60690-5;Elicited items;-;Pt;^Patient;-;TIMP;PANEL.TIMP;4;Elicited items [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.68 +60691-3;Head in midline;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head in midline [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60692-1;Individual right finger movement;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Individual right finger movement [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60693-9;Individual left finger movement;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Individual left finger movement [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60694-7;Fingers objects or surfaces on right;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Fingers objects or surfaces on right [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60695-4;Fingers objects or surfaces on left;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Fingers objects or surfaces on left [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60696-2;Bilateral hip and knee flexion;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Bilateral hip and knee flexion [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60697-0;Isolated right ankle movement;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Isolated right ankle movement [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60698-8;Isolated left ankle movement;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Isolated left ankle movement [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +6069-9;Castanea sativa pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chestnut Pollen IgE Ab [Units/volume] in Serum;Chestnut Poln IgE Qn;;ACTIVE;1.0d;2.73 +60699-6;Fidgety movements;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Fidgety movements [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60700-2;Ballistic movements of the arms or legs (swipes or swats);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Ballistic movements of the arms or legs (swipes or swats) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60701-0;Oscillation of arm or leg during movement;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Oscillation of arm or leg during movement [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60702-8;Reaches for person or object;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Reaches for person or object [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60703-6;Total observed item score;Score;Pt;^Patient;Qn;TIMP;TIMP;4;Total observed item score [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60704-4;Head rotation side to side;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head rotation side to side [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60705-1;Head control - supported sitting;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head control - supported sitting [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60706-9;Head control - posterior neck muscles;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head control - posterior neck muscles [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +6070-7;Chicken feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicken feather IgE Ab [Units/volume] in Serum;Chicken Feather IgE Qn;;ACTIVE;1.0d;2.73 +60707-7;Head control - anterior neck muscles;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head control - anterior neck muscles [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60708-5;Head control - lowered from sitting;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head control - lowered from sitting [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60709-3;Inhibition of neonatal neck righting (right side);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Inhibition of neonatal neck righting (right side) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60710-1;Inhibition of neonatal neck righting (left side);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Inhibition of neonatal neck righting (left side) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60711-9;Head in midline without visual stimulation;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head in midline without visual stimulation [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60712-7;Head held in midline with visual stimulation;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head held in midline with visual stimulation [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60713-5;Supine neck rotation (right);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Supine neck rotation (right) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60714-3;Supine neck rotation (left);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Supine neck rotation (left) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +6071-5;Chicken meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicken meat IgE Ab [Units/volume] in Serum;Chicken Meat IgE Qn;;ACTIVE;1.0d;2.73 +60715-0;Defensive Reaction - Head and Neck Response;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Defensive Reaction - Head and Neck Response [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60716-8;Defensive reaction - arm movements;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Defensive reaction - arm movements [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60717-6;Hip and knee flexion;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Hip and knee flexion [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60718-4;Rolling - elicited from the legs (right);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Rolling - elicited from the legs (right) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.54 +60719-2;Rolling - elicited from the legs (left);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Rolling - elicited from the legs (left) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.54 +607-2;Bacteria identified;Prid;Pt;Drain;Nom;Aerobic culture;MICRO;1;Bacteria identified in Drain by Aerobe culture;Bacteria Drain Aerobe Cult;;ACTIVE;1.0;2.73 +60720-0;Rolling - elicited from the arms (right);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Rolling - elicited from the arms (right) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.54 +60721-8;Rolling - elicited from the arms (left);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Rolling - elicited from the arms (left) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.54 +60722-6;Pull to sit;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Pull to sit [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +6072-3;Chloramin T Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chloramin T IgE Ab [Units/volume] in Serum;Chloramin T IgE Qn;;ACTIVE;1.0d;2.73 +60723-4;Lateral straightening of the head and body with arm support;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Lateral straightening of the head and body with arm support [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60724-2;Lateral hip abduction reaction;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Lateral hip abduction reaction [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60725-9;Prone suspension;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Prone suspension [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60726-7;Head lift in prone;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head lift in prone [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60727-5;Crawling;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Crawling [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60728-3;Head turn in prone to sound (right);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head turn in prone to sound (right) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60729-1;Head turn in prone to sound (left);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Head turn in prone to sound (left) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60730-9;Standing;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Standing [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +6073-1;Chocolate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chocolate IgE Ab [Units/volume] in Serum;Chocolate IgE Qn;;ACTIVE;1.0d;2.73 +60731-7;Lateral head righting (right);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Lateral head righting (right) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60732-5;Lateral head righting (left);Find;Pt;^Patient;Ord;TIMP;TIMP;4;Lateral head righting (left) [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60733-3;Notes;Find;Pt;^Patient;Nar;TIMP;TIMP;4;Notes [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60734-1;Total elicited items score;Score;Pt;^Patient;Qn;TIMP;TIMP;4;Total elicited items score [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60735-8;Total score;Score;Pt;^Patient;Qn;TIMP;TIMP;4;Total score [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60736-6;Reciprocal kicking;Find;Pt;^Patient;Ord;TIMP;TIMP;4;Reciprocal kicking [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +60738-2;Intraluminal;Pres;Pt;Esophagus;Qn;;GI;2;Intraluminal [Pressure] Esophagus;Intraluminal Esoph;;ACTIVE;2.54;2.70 +60739-0;Expiration;Time;Pt;Respiratory system;Qn;;PULM;2;Expiration [Time] Respiratory system;Exp time;;ACTIVE;2.54;2.70 +60740-8;Inspiration;Time;Pt;Respiratory system;Qn;;PULM;2;Inspiration [Time] Respiratory system;Insp time;;ACTIVE;2.54;2.70 +60741-6;Desflurane target^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Desflurane target [VFr/PPres] Airway adaptor --at end expiration;Desfl target end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60744-0;Desflurane setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Desflurane setting [VFr/PPres];Des set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60746-5;Desflurane^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Desflurane [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Des during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.70 +60747-3;Desflurane^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Desflurane [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Des during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.70 +60748-1;Desflurane gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Desflurane gas delivered during case [Volume] from Gas delivery system;Desfl gas del dur case Vol Gas DS;;ACTIVE;2.56;2.70 +6074-9;Chymopapain Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chymopapain IgE Ab [Units/volume] in Serum;Chymopapain IgE Qn;;ACTIVE;1.0d;2.73 +60749-9;Enflurane target^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Target enflurane [VFr/PPres] Airway adaptor --at end expiration;Target enfl end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60752-3;Enflurane setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Enflurane setting [VFr/PPres];Enf set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60754-9;Enflurane^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Enflurane [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Enf during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.70 +60755-6;Enflurane gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Enflurane gas delivered during case [Volume] from Gas delivery system;Enfl gas del dur case Vol Gas DS;;ACTIVE;2.56;2.70 +6075-6;Cladosporium herbarum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum IgE Ab [Units/volume] in Serum;C herbarum IgE Qn;;ACTIVE;1.0d;2.73 +60756-4;Halothane target^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Target halothane [VFr/PPres] Airway adaptor --at end expiration;Target halo end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60759-8;Halothane setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Halothane setting [VFr/PPres];Hal set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60761-4;Halothane^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Halothane [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Hal during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.70 +60762-2;Halothane gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Halothane gas delivered during case [Volume] from Gas delivery system;Halo gas del dur case Vol Gas DS;;ACTIVE;2.56;2.70 +60763-0;Isoflurane target^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Target isoflurane [VFr/PPres] Airway adaptor --at end expiration;Target isofl end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +6076-4;Ruditapes spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clam IgE Ab [Units/volume] in Serum;Clam IgE Qn;;ACTIVE;1.0d;2.73 +60766-3;Isoflurane setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Isoflurane setting [VFr/PPres];Isof set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60768-9;Isoflurane^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Isoflurane [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Isofl during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.70 +60769-7;Isoflurane gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Isoflurane gas delivered during case [Volume] from Gas delivery system;Isofl gas del dur case Vol Gas DS;;ACTIVE;2.56;2.70 +6077-2;Xanthium commune Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cocklebur IgE Ab [Units/volume] in Serum;Cocklebur IgE Qn;;ACTIVE;1.0d;2.73 +60773-9;Nitrous oxide setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Nitrous oxide setting [VFr/PPres];N2O set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60775-4;Nitrous oxide gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Nitrous oxide gas delivered during case [Volume] from Gas delivery system;N2O gas del dur case Vol Gas DS;;ACTIVE;2.54;2.70 +60776-2;Sevoflurane target^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Target sevoflurane [VFr/PPres] Airway adaptor --at end expiration;Target sevo end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60779-6;Sevoflurane setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Sevoflurane setting [VFr/PPres];Sevo set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +6078-0;Blatella germanica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach IgE Ab [Units/volume] in Serum;Roach IgE Qn;;ACTIVE;1.0d;2.73 +60781-2;Sevoflurane;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Sevoflurane [VFr/PPres] Gas delivery system;Sevofl VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60782-0;Sevoflurane gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Sevoflurane gas delivered during case [Volume] from Gas delivery system;Sevo gas del dur case Vol Gas DS;;ACTIVE;2.56;2.70 +60786-1;Carbon dioxide setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Carbon dioxide setting [VFr/PPres];CO2 set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60789-5;Carbon dioxide gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Carbon dioxide gas delivered during case [Volume] from Gas delivery system;CO2 gas del dur case Vol Gas DS;;ACTIVE;2.54;2.70 +60790-3;Carbon dioxide gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Carbon dioxide gas delivered.total [Volume] in Reporting period from Gas delivery system;CO2 gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.54;2.70 +60791-1;Gas flow^on ventilator;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Gas flow Respiratory system airway --on ventilator;Gas flow on vent Airway;;ACTIVE;2.54;2.70 +60792-9;Expiratory gas flow^on ventilator;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Expiratory gas flow Respiratory system airway --on ventilator;Expiratory gas flow on vent Airway;;ACTIVE;2.54;2.70 +60793-7;Expiratory gas flow.max^on ventilator;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow Respiratory system airway --on ventilator;PEF on vent Airway;;ACTIVE;2.54;2.70 +60794-5;Inspiratory gas flow^on ventilator;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Inspiratory gas flow Respiratory system airway --on ventilator;Insp gas flow on vent Airway;;ACTIVE;2.54;2.70 +60795-2;Inspiratory gas flow.max^on ventilator;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Inspiratory gas flow.max Respiratory system airway --on ventilator;Insp gas flow.max on vent Airway;;ACTIVE;2.54;2.70 +60796-0;Oxygen target^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Target oxygen [VFr/PPres] Airway adaptor --at end expiration;Target O2 end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +6079-8;Blatella germanica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cockroach IgE Ab [Units/volume] in Serum;Deprecated Roach IgE Qn;;DEPRECATED;1.0d;2.70 +60799-4;Oxygen setting^during inspiration;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system inspiratory Oxygen setting [VFr/PPres];O2 set during insp VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +608-0;Bacteria identified;Prid;Pt;Ear;Nom;Aerobic culture;MICRO;1;Bacteria identified in Ear by Aerobe culture;Bacteria Ear Aerobe Cult;;ACTIVE;1.0;2.73 +60801-8;Volume.trapped^at end expiration;Vol;Pt;Lung;Qn;;PULM;2;Trapped lung volume --at end expiration;Trapped lung vol at end exp;;ACTIVE;2.54;2.70 +60802-6;Pressure.plateau dynamic;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Dynamic plateau pressure;Plateau dynamic Airway;;ACTIVE;2.54;2.70 +60804-2;Minimum alveolar concentration for anesthesia.XXX;VFr;Pt;Anesthetic agent.XXX;Qn;;PULM;2;Minimum alveolar concentration (MAC) for anesthesia.XXX Anesthetic agent.XXX;MAC for anesthesia VFr Anesthetic;;ACTIVE;2.54;2.70 +60805-9;Desflurane^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Desflurane [VFr/PPres] Airway adaptor --during inspiration;Des during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6080-6;Theobroma cacao Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cocoa IgE Ab [Units/volume] in Serum;Cocoa IgE Qn;;ACTIVE;1.0d;2.73 +60807-5;Sevoflurane^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Sevoflurane [VFr/PPres] Airway adaptor --during expiration;Sevofl during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60808-3;Carbon dioxide^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Carbon dioxide [VFr/PPres] in Airway adaptor --at end expiration;CO2 end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60809-1;Carbon dioxide^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Carbon dioxide [VFr/PPres] in Airway adaptor --during expiration;CO2 during expir VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60812-5;Helium^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Helium [VFr/PPres] Airway adaptor --at end expiration;Helium end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60813-3;Helium^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Helium [VFr/PPres] Airway adaptor --during expiration;Helium during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +6081-4;Cocos nucifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coconut IgE Ab [Units/volume] in Serum;Coconut IgE Qn;;ACTIVE;1.0d;2.73 +60815-8;Minimum alveolar concentration sum;VFr;Pt;Anesthetic agent.XXX+Nitrous oxide;Qn;;PULM;2;Minimum alveolar concentration (MAC) sum Anesthetic agent.XXX+Nitrous oxide;MAC sum VFr Anesthetic+N2O;;ACTIVE;2.54;2.70 +60816-6;Minimum alveolar concentration sum^^corrected for age;VFr;Pt;Anesthetic agent.XXX+Nitrous oxide;Qn;;PULM;2;Minimum alveolar concentration (MAC) sum corrected for age Anesthetic agent.XXX+Nitrous oxide;MAC sum age correct VFr Anesthetic+N2O;;ACTIVE;2.54;2.70 +60817-4;Carbon dioxide.gastric-Carbon dioxide.BldA;PPresDiff;Pt;Stomach+BldA;Qn;Gastric tonometry;GI;2;Gastric-arterial pCO2 gap;Gastric-art pCO2 gap;;ACTIVE;2.54;2.70 +60818-2;Carbon dioxide.gastric-Carbon dioxide.airway^end of expiration;PPresDiff;Pt;Stomach+Airway;Qn;Gastric tonometry;GI;2;Gastric-end tidal pCO2 gap;Gastric-ET pCO2 gap;;ACTIVE;2.54;2.70 +60819-0;Carbon dioxide;PPres;Pt;Stomach;Qn;Gastric tonometry;GI;2;Gastric mucosal pCO2;Gastric pCO2;;ACTIVE;2.54;2.70 +60821-6;Apnea duration;Time;Pt;Respiratory system;Qn;;PULM;2;Apnea duration;Apnea duration;;ACTIVE;2.54;2.70 +6082-2;Gadus morhua Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Codfish IgE Ab [Units/volume] in Serum;Codfish IgE Qn;;ACTIVE;1.0d;2.73 +60822-4;Shunt fraction;NFr;Pt;Pulmonary circulation;Qn;Estimated;PULM;2;Estimated pulmonary Shunt fraction;Shunt fract Pulmonary circulation Est;;ACTIVE;2.54;2.70 +60823-2;Oxygen consumption/Body surface area;ArVRat;Pt;^Patient;Qn;;PULM;2;Oxygen consumption (VO2)/Body surface area [Volume Rate/Area];O2 consumption/BSA ArVRat;;ACTIVE;2.58;2.70 +60824-0;Oxygen delivery/Body surface area;ArVRat;Pt;^Patient;Qn;;PULM;2;Oxygen delivery (VO2)/Body surface area [Volume Rate/Area];O2 delivery/BSA ArVRat;;ACTIVE;2.65;2.70 +60825-7;Carbon dioxide production;VRat;Pt;Respiratory system;Qn;;PULM;2;Carbon dioxide production (VCO2) in Respiratory system;CO2 production Respiratory;;ACTIVE;2.54;2.70 +60826-5;Compliance;Compli;Pt;Lung;Qn;;PULM;2;Lung compliance;Compliance Lung;;ACTIVE;2.54;2.70 +60827-3;Compliance.dynamic;Compli;Pt;Lung;Qn;;PULM;2;Dynamic lung compliance;Compliance.dynamic Lung;;ACTIVE;2.54;2.70 +60828-1;Compliance.static;Compli;Pt;Lung;Qn;;PULM;2;Compliance.static Lung;Compliance.static Lung;;ACTIVE;2.54;2.70 +60829-9;Pressure.plateau;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure.plateau Respiratory system airway;Plateau pressure;;ACTIVE;2.63;2.70 +6083-0;Coffea spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coffee IgE Ab [Units/volume] in Serum;Coffee IgE Qn;;ACTIVE;1.0d;2.73 +60830-7;Body temperature;Temp;Pt;Finger;Qn;;BDYTMP.MOLEC;2;Finger temperature;Finger temp;;ACTIVE;2.54;2.70 +60832-3;Temperature.ambient;Temp;Pt;Room;Qn;;PULM;2;Room temperature;Room temp;;ACTIVE;2.36;2.70 +60833-1;Body temperature;Temp;Pt;Toe;Qn;;BDYTMP.MOLEC;2;Toe temperature;Toe temp;;ACTIVE;2.54;2.70 +60834-9;Body temperature;Temp;Pt;Bld;Qn;;BDYTMP.MOLEC;2;Blood temperature;Blood temp;;ACTIVE;2.54;2.70 +60835-6;Body temperature;Temp;Pt;Arterial system;Qn;;BDYTMP.MOLEC;2;Arterial blood temperature;Arterial blood temp;;ACTIVE;2.54;2.70 +60836-4;Body temperature;Temp;Pt;Esophagus;Qn;;BDYTMP.MOLEC;2;Esophageal temperature;Esoph temp;;ACTIVE;2.54;2.73 +60837-2;Temperature;Temp;Pt;Injectate;Qn;;CARDIO-PULM;2;Injectate temperature;Injectate temp;;ACTIVE;2.54;2.70 +60838-0;Body temperature;Temp;Pt;Nasopharynx;Qn;;BDYTMP.MOLEC;2;Nasopharyngeal temperature;Nasoph temp;;ACTIVE;2.54;2.70 +60839-8;Body temperature^in microenvironment;Temp;Pt;Skin;Qn;;NEONAT;2;Skin temperature --in microenvironment;Skin temp in microenvt;;ACTIVE;2.54;2.70 +60840-6;Base excess;SCnc;Pt;Extracellular fld;Qn;Calculated;CHEM;1;Base excess in Extracellular fluid by calculation;Base excess Extracellular fld Calc-sCnc;;ACTIVE;2.54;2.70 +60841-4;Oxygen content;VFr;Pt;BldV;Qn;Calculated;CHEM;1;Oxygen content in Venous blood by calculation;O2 Ct VFr BldV Calc;;ACTIVE;2.36;2.73 +60842-2;Oxygen consumption;VRat;Pt;^Patient;Qn;;PULM;2;Oxygen consumption (VO2);O2 consumption;;ACTIVE;2.54;2.70 +60843-0;Power spectrum.mean dominant frequency;Freq;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Mean dominant power frequency on EEG;Mean dominant freq EEG;;ACTIVE;2.54;2.70 +60844-8;Power spectrum.median frequency;Freq;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Median power frequency on EEG;Median power frequency EEG;;ACTIVE;2.54;2.70 +60845-5;Power spectrum.peak frequency;Freq;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Peak power frequency on EEG;Peak power frequency EEG;;ACTIVE;2.54;2.70 +60846-3;Burst count;Num;Pt;Cerebral cortex;Qn;EEG;IEEE Rosetta;2;Burst count Cerebral cortex Electroencephalogram (EEG);Burst count Ctx EEG;;ACTIVE;2.58;2.70 +60847-1;Seizure count;Num;Procedure dur;Cerebral cortex;Qn;EEG;NEURO;2;Seizure count Cerebral cortex Electroencephalogram (EEG);Seizure count Ctx EEG;;ACTIVE;2.54;2.70 +6084-8;Colza Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Colza IgE Ab [Units/volume] in Serum;Colza IgE Qn;;ACTIVE;1.0d;2.70 +60848-9;Power spectrum.alpha frequency/Power spectrum.total;EngRatFr;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Alpha frequency relative power on EEG;Alpha freq rel power EEG;;ACTIVE;2.54;2.70 +60849-7;Power spectrum.beta frequency/Power spectrum.total;EngRatFr;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Beta frequency relative power on EEG;Beta freq rel power EEG;;ACTIVE;2.54;2.70 +60850-5;Power spectrum.delta frequency/Power spectrum.total;EngRatFr;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Delta frequency relative power on EEG;Delta freq rel power EEG;;ACTIVE;2.54;2.70 +60851-3;Power spectrum.theta frequency/Power spectrum.total;EngRatFr;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Theta frequency relative power on EEG;Theta freq rel power EEG;;ACTIVE;2.54;2.70 +60852-1;Electrical potential;Elpot;Pt;Muscle;Qn;EMG;NEURO;2;Electrical potential Muscle on EMG;Electrical potential Muscle EMG;;ACTIVE;2.54;2.70 +60853-9;Desflurane;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Desflurane [VFr/PPres] Gas delivery system;Des VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60854-7;Enflurane;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Enflurane [VFr/PPres] Gas delivery system;Enf VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +6085-5;Ambrosia elatior Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common Ragweed IgE Ab [Units/volume] in Serum;Common Ragweed IgE Qn;;ACTIVE;1.0d;2.73 +60855-4;Enflurane^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Enflurane [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Enf during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.70 +60856-2;Halothane;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Halothane [VFr/PPres] Gas delivery system;Hal VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60857-0;Halothane^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Halothane [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Hal during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.70 +60858-8;Isoflurane;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Isoflurane [VFr/PPres] Gas delivery system;Isofl VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60859-6;Isoflurane^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Isoflurane [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Isofl during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.70 +60860-4;Nitrous oxide;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Nitrous oxide [VFr/PPres] Gas delivery system;N2O VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +60861-2;Nitrous oxide^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Nitrous oxide [VFr/PPres] Gas delivery system.expiratory limb --during expiration;N2O during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.70 +60862-0;Nitrous oxide^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Nitrous oxide [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;N2O during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.70 +6086-3;Ambrosia elatior Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Ragweed Common IgE Ab [Units/volume] in Serum;Deprecated Common Ragweed IgE Qn;;DEPRECATED;1.0d;2.70 +60863-8;Sevoflurane;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Sevoflurane [VFr/PPres] Airway adaptor;Sevofl VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60864-6;Sevoflurane^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Sevoflurane [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Sevofl during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.70 +60866-1;Oxygen;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Oxygen [VFr/PPres] Airway adaptor;O2 VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60867-9;Oxygen^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Oxygen [VFr/PPres] Airway adaptor --during expiration;O2 during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60869-5;Physiological dead space^on ventilator;Vol;Pt;Respiratory system;Qn;;PULM;2;Physiological dead space [Volume] Respiratory system --on ventilator;Phys dead space on vent Vol Respiratory;;ACTIVE;2.54;2.70 +60870-3;Physiological dead space/Tidal volume^on ventilator;VRto;Pt;Respiratory system;Qn;;PULM;2;Physiological dead space/Tidal volume Respiratory system --on ventilator;Phys dead space/TV on vent Respiratory;;ACTIVE;2.54;2.70 +6087-1;Zea mays Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Corn IgE Ab [Units/volume] in Serum;Corn IgE Qn;;ACTIVE;1.0d;2.73 +60873-7;Anesthetic agent.XXX^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Anesthetic agent.XXX Airway adaptor --at end expiration;Anesthetic end exp Away adap;;ACTIVE;2.54;2.70 +60874-5;Anesthetic agent.XXX^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Anesthetic agent.XXX Airway adaptor --during inspiration;Anesthetic during insp Away adap;;ACTIVE;2.54;2.70 +60876-0;Desflurane;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Desflurane [VFr/PPres] Airway adaptor;Des VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60877-8;Desflurane^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Desflurane [VFr/PPres] Airway adaptor --at end expiration;Des end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60884-4;Enflurane^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Enflurane [VFr/PPres] Airway adaptor --at end expiration;Enf end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60885-1;Enflurane^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Enflurane [VFr/PPres] Airway adaptor --during inspiration;Enf during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6088-9;Cotton cultivated Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Cotton IgE Ab [Units/volume] in Serum;Cultivated Cotton IgE Qn;;ACTIVE;1.0d;2.73 +60889-3;Halothane^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Halothane [VFr/PPres] Airway adaptor --at end expiration;Hal end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60895-0;Isoflurane^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Isoflurane [VFr/PPres] Airway adaptor --at end expiration;Isofl end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6089-7;Cottonseed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cottonseed IgE Ab [Units/volume] in Serum;Cottonseed IgE Qn;;ACTIVE;1.0d;2.73 +60901-6;Nitrous oxide^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrous oxide [VFr/PPres] Airway adaptor --at end expiration;N2O end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6090-5;Populus deltoides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cottonwood IgE Ab [Units/volume] in Serum;Cottonwood IgE Qn;;ACTIVE;1.0d;2.73 +60907-3;Sevoflurane^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Sevoflurane [VFr/PPres] Airway adaptor --during inspiration;Sevofl during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60908-1;Sevoflurane^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Sevoflurane [VFr/PPres] Airway adaptor --at end expiration;Sevofl end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6091-3;Cow dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow dander IgE Ab [Units/volume] in Serum;Cow Dander IgE Qn;;ACTIVE;1.0d;2.73 +60914-9;Argon;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Argon [VFr/PPres] Airway adaptor;Argon VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60915-6;Argon^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Argon [VFr/PPres] Airway adaptor --during expiration;Argon during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60916-4;Argon^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Argon [VFr/PPres] Airway adaptor --during inspiration;Argon during insp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60918-0;Argon^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Argon [VFr/PPres] Airway adaptor --at end expiration;Argon end exp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60919-8;Nitrogen;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen [VFr/PPres] Airway adaptor;N2 VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60920-6;Nitrogen^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen [VFr/PPres] Airway adaptor --at end expiration;N2 end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6092-1;Cancer pagurus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Crab IgE Ab [Units/volume] in Serum;Crab IgE Qn;;ACTIVE;1.0d;2.73 +60921-4;Nitrogen^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen [VFr/PPres] Airway adaptor --during inspiration;N2 during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60924-8;Carbon dioxide^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Carbon dioxide [VFr/PPres] in Airway adaptor --during inspiration;CO2 during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60926-3;Carbon dioxide;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Carbon dioxide [VFr/PPres] in Airway adaptor;CO2 VFr/PPres Away adap;;ACTIVE;2.54;2.70 +60932-1;Helium;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Helium [VFr/PPres] Airway adaptor;Helium VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60934-7;Helium^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Helium [VFr/PPres] Airway adaptor --during inspiration;Helium during insp VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60935-4;Nitrogen^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen [VFr/PPres] Airway adaptor --during expiration;N2 during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +6093-9;Avena sativa cultivated Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oat pollen IgE Ab [Units/volume] in Serum;Oat Poln IgE Qn;;ACTIVE;1.0d;2.73 +60939-6;Nitrous oxide^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrous oxide [VFr/PPres] Airway adaptor --during expiration;N2O during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +60943-8;Oxygen^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Oxygen [VFr/PPres] Airway adaptor --at end expiration;O2 end exp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6094-7;Curvularia lunata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Curvularia lunata IgE Ab [Units/volume] in Serum;C lunata IgE Qn;;ACTIVE;1.0d;2.73 +60947-9;Peak expiratory flow;VRat;Pt;Airway;Qn;;PULM;2;Deprecated Peak expiratory flow Airway;Deprecated Peak expiratory flow Airway;;DEPRECATED;2.38;2.70 +60948-7;Peak inspiratory flow;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Peak inspiratory flow Respiratory system airway;Pmax Airway;;ACTIVE;2.54;2.70 +60949-5;Pressure.mean;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Mean airway pressure;Mean Pres Airway;;ACTIVE;2.58;2.70 +60951-1;Pressure max^during inspiration;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure max Respiratory system airway --during inspiration;Pressure max during insp Airway;;ACTIVE;2.54;2.73 +60952-9;Pressure mean^during inspiration;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Mean airway pressure --during inspiration;Pressure mean during insp Airway;;ACTIVE;2.54;2.70 +6095-4;Dermatophagoides farinae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite IgE Ab [Units/volume] in Serum;D farinae IgE Qn;;ACTIVE;1.0d;2.73 +60955-2;Body temperature;Temp;Pt;Respiratory system.airway;Qn;;BDYTMP.MOLEC;2;Airway temperature;Airway temp;;ACTIVE;2.54;2.70 +60956-0;Intracranial;Pres;Pt;Skull;Qn;;NEURO;2;Intracranial pressure (ICP);ICP;;ACTIVE;2.54;2.70 +60957-8;Intracranial diastolic;Pres;Pt;Skull;Qn;;NEURO;2;Intracranial pressure (ICP) Diastolic;ICP diastolic;;ACTIVE;2.54;2.70 +60958-6;Intracranial mean;Pres;Pt;Skull;Qn;;NEURO;2;Intracranial pressure (ICP) Mean;ICP mean;;ACTIVE;2.54;2.70 +60959-4;Intracranial systolic;Pres;Pt;Skull;Qn;;NEURO;2;Intracranial pressure (ICP) Systolic;ICP systolic;;ACTIVE;2.54;2.70 +60960-2;ST amplitude.lead AI;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead AI;ST Amp L-AI;;ACTIVE;2.54;2.70 +60961-0;ST amplitude.lead AS;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead AS;ST Amp L-AS;;ACTIVE;2.54;2.70 +6096-2;Dermatophagoides pteronyssinus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite IgE Ab [Units/volume] in Serum;D pteronyss IgE Qn;;ACTIVE;1.0d;2.73 +60962-8;ST amplitude.derived lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.derived lead V1;ST Amp dL-V1;;ACTIVE;2.54;2.70 +60963-6;ST amplitude.derived lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.derived lead V2;ST Amp dL-V2;;ACTIVE;2.54;2.70 +60964-4;ST amplitude.derived lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.derived lead V3;ST Amp dL-V3;;ACTIVE;2.54;2.70 +60965-1;ST amplitude.derived lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.derived lead V4;ST Amp dL-V4;;ACTIVE;2.54;2.70 +60966-9;ST amplitude.derived lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.derived lead V5;ST Amp dL-V5;;ACTIVE;2.54;2.70 +60967-7;ST amplitude.derived lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.derived lead V6;ST Amp dL-V6;;ACTIVE;2.54;2.70 +60968-5;ST amplitude.lead ES;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead ES;ST Amp L-ES;;ACTIVE;2.54;2.70 +60969-3;ST amplitude.lead MCL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead MCL;ST Amp L-MCL;;ACTIVE;2.54;2.70 +6097-0;Taraxacum vulgare Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dandelion IgE Ab [Units/volume] in Serum;Dandelion IgE Qn;;ACTIVE;1.0d;2.73 +60970-1;ST amplitude.lead MCL1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead MCL1;ST Amp L-MCL1;;ACTIVE;2.54;2.70 +60971-9;ST amplitude.lead MCL6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead MCL6;ST Amp L-MCL6;;ACTIVE;2.54;2.70 +60972-7;ST amplitude.precordial lead;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.precordial lead;ST amp.precordial lead;;ACTIVE;2.54;2.70 +60973-5;Pre ejection time;Time;Pt;Heart.ventricle.left;Qn;NI-ICG;CARDIO-PULM;2;Left ventricular Pre ejection Time;LV Pre eject Time;;ACTIVE;2.54;2.70 +60974-3;Ejection time;Time;Pt;Heart.ventricle.left;Qn;NI-ICG;HEMODYN.MOLEC;2;Left ventricular Ejection Time;LV Eject Time;;ACTIVE;2.54;2.70 +60975-0;Hemodynamic resistance;Resis;Pt;Circulatory system;Qn;;CARDIO-PULM;2;Vascular resistance;Res Circ sys;;ACTIVE;2.54;2.70 +60976-8;Work;Enrg;Pt;Heart.ventricle.right;Qn;;HEMODYN.MOLEC;2;Right ventricular Work [Energy];RV Work;;ACTIVE;2.54;2.70 +60977-6;Work;Enrg;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventricular Work [Energy];LV Work;;ACTIVE;2.54;2.70 +60978-4;Heart rate;NRat;Pt;Intra arterial line;Qn;Invasive;HRTRATE.MOLEC;2;Heart rate Intra arterial line by Invasive;Heart rate Intra arterial line Invasive;;ACTIVE;2.54;2.70 +609-8;Bacteria identified;Prid;Pt;Eye;Nom;Aerobic culture;MICRO;1;Bacteria identified in Eye by Aerobe culture;Bacteria Eye Aerobe Cult;;ACTIVE;1.0;2.73 +60981-8;Intravascular;Pres;Pt;Aorta;Qn;;BP.CENT.MOLEC;2;Aorta blood pressure;Aorta BP;;ACTIVE;2.54;2.70 +60982-6;Intravascular diastolic;Pres;Pt;Aorta;Qn;;BP.CENT.MOLEC;2;Aorta Diastolic blood pressure;Aorta BP dias;;ACTIVE;2.54;2.70 +60983-4;Intravascular mean;Pres;Pt;Aorta;Qn;;BP.CENT.MOLEC;2;Aorta Mean blood pressure;Aorta BP mean;;ACTIVE;2.54;2.70 +60984-2;Intravascular systolic;Pres;Pt;Aorta;Qn;;BP.CENT.MOLEC;2;Aorta Systolic blood pressure;Aorta BP sys;;ACTIVE;2.54;2.70 +60985-9;Intravascular;Pres;Pt;Central venous catheter (CVP);Qn;;BP.CENT.MOLEC;2;Central venous pressure (CVP);CVP;;ACTIVE;2.54;2.73 +60986-7;Intravascular diastolic;Pres;Pt;Central venous catheter (CVP);Qn;;BP.CENT.MOLEC;2;Central venous pressure (CVP) Diastolic;CVP dias;;ACTIVE;2.54;2.70 +60987-5;Intravascular systolic;Pres;Pt;Central venous catheter (CVP);Qn;;BP.CENT.MOLEC;2;Central venous pressure (CVP) Systolic;CVP sys;;ACTIVE;2.54;2.70 +6098-8;Dog dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog dander IgE Ab [Units/volume] in Serum;Dog Dander IgE Qn;;ACTIVE;1.0d;2.73 +60988-3;Intrachamber;Pres;Pt;Heart.atrium.left;Qn;;BP.CENT.MOLEC;2;Left atrial pressure;LA pressure;;ACTIVE;2.54;2.70 +60989-1;Intrachamber systolic;Pres;Pt;Heart.atrium.left;Qn;;BP.CENT.MOLEC;2;Left atrial pressure Systolic;LA pressure sys;;ACTIVE;2.54;2.70 +60994-1;Intravascular diastolic;Pres;Pt;Pulmonary artery.wedge;Qn;;BP.CENT.MOLEC;2;Pulmonary artery wedge Diastolic blood pressure;PAW pressure dias;;ACTIVE;2.58;2.70 +60995-8;Intravascular systolic;Pres;Pt;Pulmonary artery.wedge;Qn;;BP.CENT.MOLEC;2;Pulmonary artery wedge Systolic blood pressure;PAW pressure sys;;ACTIVE;2.58;2.70 +6099-6;Dog epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog epithelium IgE Ab [Units/volume] in Serum;Dog Epith IgE Qn;;ACTIVE;1.0d;2.73 +60996-6;Intrachamber;Pres;Pt;Heart.atrium.right;Qn;;BP.CENT.MOLEC;2;Right atrial pressure;RA pressure;;ACTIVE;2.54;2.73 +60997-4;Intrachamber diastolic;Pres;Pt;Heart.atrium.right;Qn;;BP.CENT.MOLEC;2;Right atrial pressure Diastolic;RA pressure dias;;ACTIVE;2.54;2.70 +60998-2;Intrachamber systolic;Pres;Pt;Heart.atrium.right;Qn;;BP.CENT.MOLEC;2;Right atrial pressure Systolic;RA pressure sys;;ACTIVE;2.54;2.70 +6100-2;Duck feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Duck feather IgE Ab [Units/volume] in Serum;Duck Feather IgE Qn;;ACTIVE;1.0d;2.73 +61002-2;Intravascular;Pres;Pt;Umbilical artery;Qn;;BP.CENT.MOLEC;2;Umbilical artery blood pressure;Umb artery BP;;ACTIVE;2.54;2.70 +61003-0;Intravascular diastolic;Pres;Pt;Umbilical vein;Qn;;BP.CENT.MOLEC;2;Umbilical vein Diastolic blood pressure;Umb vein BP dias;;ACTIVE;2.54;2.70 +61004-8;Intravascular mean;Pres;Pt;Umbilical vein;Qn;;BP.CENT.MOLEC;2;Umbilical vein Mean blood pressure;Umb vein BP mean;;ACTIVE;2.54;2.70 +61005-5;Intravascular systolic;Pres;Pt;Umbilical vein;Qn;;BP.CENT.MOLEC;2;Umbilical vein Systolic blood pressure;Umb vein BP sys;;ACTIVE;2.54;2.70 +61006-3;Perfusion index;VelRto;Pt;Tiss;Qn;Pulse oximetry;PULM;2;Perfusion index Tissue by Pulse oximetry;Perfusion index Tiss PulseOx;;ACTIVE;2.42;2.70 +61007-1;Oxygen.BldA-Oxygen.BldV;VFrDiff;Pt;BldA+BldV;Qn;Estimated;PULM;2;Oxygen arterial - venous [Volume Fraction Difference] in Blood arterial + Blood venous by Estimated;O2 BldA-BldV VFrDiff BldA+BldV Est;;ACTIVE;2.54;2.70 +61008-9;Body temperature;Temp;Pt;Surface;Qn;;BDYTMP.MOLEC;2;Body surface temperature;Body surf temp;;ACTIVE;2.54;2.73 +61009-7;Body temperature;Temp;Pt;Myocardium;Qn;;BDYTMP.MOLEC;2;Myocardial temperature;Myocard temp;;ACTIVE;2.54;2.70 +6101-0;Duck meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Duck meat IgE Ab [Units/volume] in Serum;Duck Meat IgE Qn;;ACTIVE;1.0d;2.73 +61010-5;Burst suppression ratio;Ratio;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Burst suppression ratio [Ratio] Cerebral cortex Electroencephalogram (EEG);Burst supp rto Ctx EEG;;ACTIVE;2.54;2.70 +61011-3;Intravascular;Pres;Pt;Umbilical vein;Qn;;BP.CENT.MOLEC;2;Umbilical vein blood pressure;Umb vein BP;;ACTIVE;2.54;2.70 +61012-1;Breaths;NRat;Pt;BldC;Qn;;PULM;2;Breath rate Capillary blood;Breaths BldC;;ACTIVE;2.42;2.70 +61014-7;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;Intermitent measure;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Intermitent measure;LV Output Intermitent;;ACTIVE;2.54;2.70 +61017-0;Perfusion;Pres;Pt;Cerebrum;Qn;;NEURO;2;Cerebral perfusion pressure;Cerebral perf pres;;ACTIVE;2.54;2.70 +61018-8;Oxygen;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Oxygen [VFr/PPres] Gas delivery system;O2 VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +61019-6;Enflurane^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Enflurane [VFr/PPres] Airway adaptor --during expiration;Enf during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +61020-4;Halothane^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Halothane [VFr/PPres] Airway adaptor --during expiration;Hal during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +61021-2;Halothane^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Halothane [VFr/PPres] Airway adaptor --during inspiration;Hal during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +61022-0;Desflurane gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Desflurane gas delivered.total [Volume] in Reporting period from Gas delivery system;Desfl gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.56;2.70 +61023-8;Enflurane gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Enflurane gas delivered.total [Volume] in Reporting period from Gas delivery system;Enfl gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.56;2.70 +61024-6;Halothane gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Halothane gas delivered.total [Volume] in Reporting period from Gas delivery system;Halo gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.56;2.70 +61025-3;Isoflurane gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Isoflurane gas delivered.total [Volume] in Reporting period from Gas delivery system;Isofl gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.56;2.70 +61026-1;Nitrous oxide gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Nitrous oxide gas delivered.total [Volume] in Reporting period from Gas delivery system;N2O gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.54;2.70 +61027-9;Sevoflurane gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Sevoflurane gas delivered.total [Volume] in Reporting period from Gas delivery system;Sevo gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.56;2.70 +6102-8;Dust profile Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Dust profile Ab.IgE;Deprecated Dust IgE Qn;;DEPRECATED;1.0d;2.70 +61028-7;Pressure.min;Pres;Pt;Respiratory system.airway;Qn;;IEEE Rosetta;2;Pressure.min Respiratory system airway;Press.min Airway;;ACTIVE;2.63;2.70 +61029-5;7-Aminoclonazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Serum or Plasma;7Aminoclonazepam SerPl Ql;;ACTIVE;2.34;2.73 +61030-3;7-Aminoclonazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Urine;7Aminoclonazepam Ur Ql;;ACTIVE;2.34;2.73 +61031-1;7-Aminoclonazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Specimen;7Aminoclonazepam Spec Ql;;ACTIVE;2.34;2.73 +61032-9;7-Aminoflunitrazepam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;7-Aminoflunitrazepam [Presence] in Serum or Plasma;7Aminoflunitrazepam SerPl Ql;;ACTIVE;2.34;2.73 +61033-7;7-Aminoflunitrazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;7-Aminoflunitrazepam [Presence] in Urine;7Aminoflunitrazepam Ur Ql;;ACTIVE;2.34;2.56 +61034-5;7-Aminoflunitrazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;7-Aminoflunitrazepam [Presence] in Specimen;7Aminoflunitrazepam Spec Ql;;ACTIVE;2.34;2.73 +61035-2;Alpha hydroxyalprazolam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Alpha hydroxyalprazolam [Presence] in Serum or Plasma;A-OH Alpraz SerPl Ql;;ACTIVE;2.34;2.73 +6103-6;Echinococcus sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Echinococcus sp IgE Ab [Units/volume] in Serum;Echinococcus IgE Qn;;ACTIVE;1.0d;2.73 +61036-0;Alpha hydroxyalprazolam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Alpha hydroxyalprazolam [Presence] in Urine;A-OH Alpraz Ur Ql;;ACTIVE;2.34;2.73 +61037-8;Alpha hydroxyalprazolam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Alpha hydroxyalprazolam [Presence] in Specimen;A-OH Alpraz Spec Ql;;ACTIVE;2.34;2.73 +61038-6;ALPRAZolam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;ALPRAZolam [Presence] in Specimen;Alpraz Spec Ql;;ACTIVE;2.34;2.73 +61039-4;clonazePAM;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;clonazePAM [Presence] in Specimen;clonazePAM Spec Ql;;ACTIVE;2.34;2.73 +61040-2;N-desalkylflurazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Urine;Desalkylfluraz Ur Ql;;ACTIVE;2.34;2.56 +61041-0;N-desalkylflurazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Specimen;Desalkylfluraz Spec Ql;;ACTIVE;2.34;2.69 +61042-8;fentaNYL;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;fentaNYL [Presence] in Specimen;fentaNYL Spec Ql;;ACTIVE;2.34;2.73 +61043-6;Ketamine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Ketamine [Presence] in Specimen;Ketamine Spec Ql;;ACTIVE;2.34;2.69 +6104-4;Echinococcus sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Echinococcus sp IgE Ab [Units/volume] in Serum;Deprecated Echinococcus IgE Qn;;DEPRECATED;1.0d;2.70 +61044-4;LORazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;LORazepam [Presence] in Specimen;LORazepam Spec Ql;;ACTIVE;2.34;2.73 +61045-1;Methylenedioxyamphetamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Serum or Plasma;MDA SerPl Ql;;ACTIVE;2.34;2.73 +61046-9;Methylenedioxyamphetamine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Specimen;MDA Spec Ql;;ACTIVE;2.34;2.73 +61047-7;Methylenedioxyethylamphetamine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Serum or Plasma;MDEA SerPl Ql;;ACTIVE;2.34;2.73 +61048-5;Methylenedioxyethylamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Urine;MDEA Ur Ql;;ACTIVE;2.34;2.73 +61049-3;Methylenedioxyethylamphetamine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Specimen;MDEA Spec Ql;;ACTIVE;2.34;2.73 +61050-1;Methylphenidate;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Methylphenidate [Presence] in Specimen;Me-phenidate Spec Ql;;ACTIVE;2.34;2.69 +6105-1;Anguilla anguilla Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Eel IgE Ab [Units/volume] in Serum;Eel IgE Qn;;ACTIVE;1.0d;2.73 +61051-9;Nordiazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Nordiazepam [Presence] in Specimen;Nordiazepam Spec Ql;;ACTIVE;2.34;2.73 +61052-7;Norfentanyl;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Norfentanyl [Presence] in Serum or Plasma;Norfentanyl SerPl Ql;;ACTIVE;2.34;2.73 +61053-5;Norfentanyl;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Norfentanyl [Presence] in Specimen;Norfentanyl Spec Ql;;ACTIVE;2.34;2.69 +61054-3;Normeperidine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Normeperidine [Presence] in Specimen;Normeperidine Spec Ql;;ACTIVE;2.34;2.69 +61055-0;Oxazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Oxazepam [Presence] in Specimen;Oxazepam Spec Ql;;ACTIVE;2.34;2.73 +61056-8;Pseudoephedrine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Pseudoephedrine [Presence] in Serum or Plasma;Pseudoephedrine SerPl Ql;;ACTIVE;2.34;2.56 +61057-6;Pseudoephedrine;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Pseudoephedrine [Presence] in Specimen;Pseudoephedrine Spec Ql;;ACTIVE;2.34;2.69 +61058-4;Alpha-Phenyl-2-Piperidine acetate;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate [Presence] in Urine;PPAA Ur Ql;;ACTIVE;2.34;2.73 +61059-2;Alpha-Phenyl-2-Piperidine acetate;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate [Presence] in Specimen;PPAA Spec Ql;;ACTIVE;2.34;2.73 +610-6;Bacteria identified;Prid;Pt;Body fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Body fluid by Aerobe culture;Bacteria Fld Aerobe Cult;;ACTIVE;1.0;2.73 +61060-0;Temazepam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Temazepam [Presence] in Urine;Temazepam Ur Ql;;ACTIVE;2.34;2.73 +61061-8;Temazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Temazepam [Presence] in Specimen;Temazepam Spec Ql;;ACTIVE;2.34;2.73 +61062-6;Carboxy tetrahydrocannabinol;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Gastric fluid;CarboxyTHC Gast Ql;;ACTIVE;2.34;2.56 +61063-4;Carboxy tetrahydrocannabinol;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Specimen;CarboxyTHC Spec Ql;;ACTIVE;2.34;2.73 +61064-2;Triazolam;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Triazolam [Presence] in Serum or Plasma;Triazolam SerPl Ql;;ACTIVE;2.34;2.73 +61065-9;Lysergate diethylamide;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Lysergate diethylamide [Presence] in Specimen;LSD Spec Ql;;ACTIVE;2.34;2.69 +61066-7;Ethanol;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Ethanol [Presence] in Specimen by Screen method;Ethanol Spec Ql Scn;;ACTIVE;2.34;2.73 +61067-5;Barbiturates;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Specimen by Screen method;Barbiturates Spec Ql Scn;;ACTIVE;2.34;2.69 +6106-9;Egg white Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Egg white IgE Ab [Units/volume] in Serum;Egg White IgE Qn;;ACTIVE;1.0d;2.73 +61070-9;7-Aminoclonazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Gastric fluid;7Aminoclonazepam Gast Ql;;ACTIVE;2.34;2.56 +61071-7;7-Aminoflunitrazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;7-Aminoflunitrazepam [Presence] in Gastric fluid;7Aminoflunitrazepam Gast Ql;;ACTIVE;2.34;2.56 +61072-5;Alpha hydroxyalprazolam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Alpha hydroxyalprazolam [Presence] in Gastric fluid;A-OH Alpraz Gast Ql;;ACTIVE;2.34;2.56 +61073-3;ALPRAZolam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;ALPRAZolam [Presence] in Gastric fluid;Alpraz Gast Ql;;ACTIVE;2.34;2.56 +61074-1;diazePAM;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;diazePAM [Presence] in Specimen;diazePAM Spec Ql;;ACTIVE;2.34;2.73 +61075-8;diphenhydrAMINE;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;diphenhydrAMINE [Presence] in Gastric fluid;Diphenhy Gast Ql;;ACTIVE;2.34;2.56 +61076-6;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Gastric fluid;EDDP Gast Ql;;ACTIVE;2.34;2.56 +6107-7;Egg yolk Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Egg yolk IgE Ab [Units/volume] in Serum;Egg Yolk IgE Qn;;ACTIVE;1.0d;2.73 +61077-4;fentaNYL;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;fentaNYL [Presence] in Gastric fluid;fentaNYL Gast Ql;;ACTIVE;2.34;2.56 +61078-2;Flunitrazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Flunitrazepam [Presence] in Gastric fluid;Flunitrazepam Gast Ql;;ACTIVE;2.34;2.56 +61079-0;Flunitrazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Flunitrazepam [Presence] in Specimen;Flunitrazepam Spec Ql;;ACTIVE;2.34;2.73 +61080-8;Flurazepam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Flurazepam [Presence] in Specimen;Flurazepam Spec Ql;;ACTIVE;2.34;2.73 +61081-6;Ketamine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Ketamine [Presence] in Gastric fluid;Ketamine Gast Ql;;ACTIVE;2.34;2.56 +61082-4;Methylenedioxyethylamphetamine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Gastric fluid;MDEA Gast Ql;;ACTIVE;2.34;2.56 +61083-2;Methylenedioxymethamphetamine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Gastric fluid;MDMA Gast Ql;;ACTIVE;2.34;2.56 +61084-0;Methylphenidate;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Methylphenidate [Presence] in Gastric fluid;Me-phenidate Gast Ql;;ACTIVE;2.34;2.56 +6108-5;Sambucus nigra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Elder IgE Ab [Units/volume] in Serum;Elder IgE Qn;;ACTIVE;1.0d;2.73 +61085-7;Nordiazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Nordiazepam [Presence] in Gastric fluid;Nordiazepam Gast Ql;;ACTIVE;2.34;2.56 +61086-5;Norfentanyl;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Norfentanyl [Presence] in Gastric fluid;Norfentanyl Gast Ql;;ACTIVE;2.34;2.56 +61087-3;Normeperidine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Normeperidine [Presence] in Gastric fluid;Normeperidine Gast Ql;;ACTIVE;2.34;2.56 +61088-1;Oxazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Oxazepam [Presence] in Gastric fluid;Oxazepam Gast Ql;;ACTIVE;2.34;2.56 +61089-9;Pseudoephedrine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Pseudoephedrine [Presence] in Gastric fluid;Pseudoephedrine Gast Ql;;ACTIVE;2.34;2.56 +61090-7;Alpha-Phenyl-2-Piperidine acetate;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate [Presence] in Gastric fluid;PPAA Gast Ql;;ACTIVE;2.34;2.56 +61091-5;Temazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Temazepam [Presence] in Gastric fluid;Temazepam Gast Ql;;ACTIVE;2.34;2.56 +61092-3;Triazolam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Triazolam [Presence] in Gastric fluid;Triazolam Gast Ql;;ACTIVE;2.34;2.56 +6109-3;Ulmus americana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Elm IgE Ab [Units/volume] in Serum;White Elm IgE Qn;;ACTIVE;1.0d;2.73 +61093-1;Triazolam;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Triazolam [Presence] in Specimen;Triazolam Spec Ql;;ACTIVE;2.34;2.73 +61094-9;Lysergate diethylamide;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Lysergate diethylamide [Presence] in Gastric fluid;LSD Gast Ql;;ACTIVE;2.34;2.56 +61095-6;Ethanol;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Ethanol [Presence] in Gastric fluid by Screen method;Ethanol Gast Ql Scn;;ACTIVE;2.34;2.56 +61096-4;Barbiturates;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Gastric fluid by Screen method;Barbiturates Gast Ql Scn;;ACTIVE;2.34;2.56 +61098-0;N-desalkylflurazepam;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Gastric fluid;Desalkylfluraz Gast Ql;;ACTIVE;2.34;2.56 +61099-8;Collection date^3rd specimen;TmStp;Pt;Stool;Qn;;SPEC;1;Collection date of Stool--3rd specimen;Collect Date sp3 Stl;;ACTIVE;2.38;2.73 +61100-4;Collection date^2nd specimen;TmStp;Pt;Stool;Qn;;SPEC;1;Collection date of Stool--2nd specimen;Collect Date sp2 Stl;;ACTIVE;2.38;2.73 +6110-1;Plantago lanceolata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English plantain IgE Ab [Units/volume] in Serum;Engl plantain IgE Qn;;ACTIVE;1.0d;2.73 +61101-2;Influenza virus A neuraminidase RNA;Type;Pt;XXX;Nom;Sequencing;MICRO;1;Influenza virus A neuraminidase RNA [Type] in Specimen by Sequencing;FLUAV NA RNA Spec Seq;;ACTIVE;2.34;2.69 +61102-0;Influenza virus A & B Ag;Prid;Pt;XXX;Nom;IF;MICRO;1;Influenza virus A and B Ag [Identifier] in Specimen by Immunofluorescence;FLUAV + FLUBV Ag Spec IF;;ACTIVE;2.34;2.73 +61103-8;Prochlorperazine;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Prochlorperazine [Moles/volume] in Urine;Prochlorperazine Ur-sCnc;;ACTIVE;2.34;2.70 +61104-6;Prochlorperazine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Prochlorperazine [Moles/volume] in Specimen;Prochlorperazine Spec-sCnc;;ACTIVE;2.34;2.70 +61105-3;Prochlorperazine;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Prochlorperazine [Moles/volume] in Gastric fluid;Prochlorperazine Gast-sCnc;;ACTIVE;2.34;2.70 +61106-1;16p11.2 chromosome region deletion+duplication;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;16p11.2 chromosome region deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal;16p11.2 chrom Del+Dup Bld/T;;ACTIVE;2.34;2.50 +61107-9;SLC25A13 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC25A13 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC25A13 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +61108-7;Mitochondria DNA complex I targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondria DNA complex I targeted mutation analysis in Blood or Tissue by Molecular genetics method;mtDNA I Mut Anl Bld/T;;ACTIVE;2.34;2.68 +61109-5;Mitochondria DNA complex V targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondria DNA complex V targeted mutation analysis in Blood or Tissue by Molecular genetics method;mtDNA V Mut Anl Bld/T;;ACTIVE;2.34;2.68 +61110-3;ACSL4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACSL4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ACSL4 gene Mut Anl Bld/T;;ACTIVE;2.34;2.66 +61111-1;Mitochondria tRNA targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondria tRNA targeted mutation analysis in Blood or Tissue by Molecular genetics method;Mt tRNA Mut Anl Bld/T;;ACTIVE;2.34;2.66 +61112-9;HTLV;Type;Pt;Ser/Plas;Nom;;MICRO;1;HTLV [Type] in Serum or Plasma;HTLV SerPl;;ACTIVE;2.34;2.73 +61113-7;Immunoglobulin gene rearrangements;Find;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.REARRANGE;1;Immunoglobulin gene rearrangements in Blood or Tissue by Molecular genetics method Narrative;Ig gene Rear Bld/T;;ACTIVE;2.34;2.34 +61114-5;Mitochondria DNA complex III targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondria DNA complex III targeted mutation analysis in Blood or Tissue by Molecular genetics method;mtDNA III Mut Anl Bld/T;;ACTIVE;2.34;2.66 +61115-2;Mitochondria DNA complex IV targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondria DNA complex IV targeted mutation analysis in Blood or Tissue by Molecular genetics method;mtDNA IV Mut Anl Bld/T;;ACTIVE;2.34;2.68 +61116-0;Mitochondria rRNA targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Mitochondria rRNA targeted mutation analysis in Blood or Tissue by Molecular genetics method;MT rRNA Mut Anl Bld/T;;ACTIVE;2.34;2.68 +61117-8;Aquaporin 4 water channel Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Immune stain;SERO;1;Aquaporin 4 water channel IgG Ab [Presence] in Serum or Plasma by Immune stain;AQP4 H2O channel IgG SerPl Ql ImStn;;ACTIVE;2.34;2.67 +61118-6;Lymphocytes.cytoplasmic IgG/100 lymphocytes;NFr;Pt;Body fld;Qn;;CELLMARK;1;Lymphocytes.cytoplasmic IgG/100 lymphocytes in Body fluid;Lymphocytes.cyIgG/lymph NFr Fld;;ACTIVE;2.34;2.70 +6111-9;Epicoccum purpurascens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Epicoccum purpurascens IgE Ab [Units/volume] in Serum;E purpurascens IgE Qn;;ACTIVE;1.0d;2.73 +61119-4;Lymphocytes.cytoplasmic IgM/100 lymphocytes;NFr;Pt;Body fld;Qn;;CELLMARK;1;Lymphocytes.cytoplasmic IgM/100 lymphocytes in Body fluid;Lymphocytes.cyIgM/lymph NFr Fld;;ACTIVE;2.34;2.70 +61120-2;PM-SCL-100 Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;PM-SCL-100 IgG Ab [Units/volume] in Serum;PM/SCL-100 IgG Ser-aCnc;;ACTIVE;2.34;2.73 +61121-0;Cells.CD8-CD57+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8-CD57+ cells/100 cells in Blood;CD8-CD57+ Cells NFr Bld;;ACTIVE;2.34;2.73 +61122-8;Cells.CD8-CD57+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8-CD57+ cells [#/volume] in Blood;CD8-CD57+ Cells # Bld;;ACTIVE;2.34;2.73 +61123-6;Lymphocytes/100 leukocytes;NFr;Pt;XXX;Qn;Flow cytometry;CELLMARK;1;Lymphocytes/100 leukocytes in Specimen by Flow cytometry (FC);Lymphocytes/leuk NFr Spec FC;;ACTIVE;2.34;2.70 +61124-4;Granulocytes/100 leukocytes;NFr;Pt;XXX;Qn;Flow cytometry;CELLMARK;1;Granulocytes/100 leukocytes in Specimen by Flow cytometry (FC);Granulocytes/leuk NFr Spec FC;;ACTIVE;2.34;2.73 +61125-1;Monocytes/100 leukocytes;NFr;Pt;XXX;Qn;Flow cytometry;CELLMARK;1;Monocytes/100 leukocytes in Specimen by Flow cytometry (FC);Monocytes/leuk NFr Spec FC;;ACTIVE;2.34;2.70 +61126-9;Blasts/100 cells;NFr;Pt;XXX;Qn;Flow cytometry;CELLMARK;1;Blasts/100 cells in Specimen by Flow cytometry (FC);Blasts NFr Spec FC;;ACTIVE;2.34;2.70 +6112-7;Ethylene oxide Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ethylene oxide IgE Ab [Units/volume] in Serum;Ethylene Oxide IgE Qn;;ACTIVE;1.0d;2.73 +61127-7;Whitefish Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Whitefish IgG Ab [Mass/volume] in Serum;Whitefish IgG-mCnc;;ACTIVE;2.34;2.73 +61128-5;Cotinine;PrThr;Pt;Ser/Plas;Ord;;DRUG/TOX;1;Cotinine [Presence] in Serum or Plasma;Cotinine SerPl Ql;;ACTIVE;2.34;2.73 +61129-3;PhenX domain - Demographics;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Demographics;Domain - Demographics;;TRIAL;2.34;2.68 +61130-1;PhenX domain - Anthropometrics;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Anthropometrics;Domain - Anthropometrics;;TRIAL;2.34;2.68 +61131-9;Preterm time;Time;Pt;^Patient;Qn;;TIMP;4;Preterm time;;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +61132-7;Gestation adjusted age;Time;Pt;^Patient;Qn;;TIMP;4;Gestation adjusted age;;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.73 +61133-5;Clinical impression;Imp;Pt;^Patient;Ord;TIMP;TIMP;4;Clinical impression [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +61134-3;Environment;Find;Pt;^Patient;Nom;TIMP;PANEL.TIMP;4;Environment [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.68 +6113-5;Eucalyptus spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gum-Tree IgE Ab [Units/volume] in Serum;Gum-Tree IgE Qn;;ACTIVE;1.0d;2.73 +61135-0;Environment.other specified;Find;Pt;^Patient;Nar;TIMP;TIMP;4;Environment.other specified [TIMP];;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +61136-8;Start time;TmStp;Pt;Study;Qn;;TIMP;4;Start time Study;;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +61137-6;End time;TmStp;Pt;Study;Qn;;TIMP;4;End time Study;;Copyright © 2001 IMPS, LLC. Authors: Suzann K. Campbell, Gay L. Girolami, Thubi, H. A. Kolobe, Elizabeth T. Osten, Maureen C. Lenke. All rights reserved. Used with permission.;ACTIVE;2.34;2.50 +61138-4;Principal result interpreter;Pn;Pt;Study;Nom;;TIMP;4;Principal result interpreter Study;;;ACTIVE;2.34;2.70 +61139-2;Toluene diisocyanate (TDI) Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate TDI IgG Ab [Mass/volume] in Serum;Isocyanate TDI IgG-mCnc;;ACTIVE;2.34;2.73 +611-4;Bacteria identified;Prid;Pt;Body fld;Nom;Culture;MICRO;1;Bacteria identified in Body fluid by Culture;Bacteria Fld Cult;;ACTIVE;1.0;2.73 +61140-0;Diphenylmethane diisocyanate (MDI) Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate MDI IgG Ab [Mass/volume] in Serum;Isocyanate MDI IgG-mCnc;;ACTIVE;2.34;2.73 +61141-8;Hexamethylene diisocyanate (HDI) Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate HDI IgG Ab [Mass/volume] in Serum;Isocyanate HDI IgG-mCnc;;ACTIVE;2.34;2.73 +61142-6;Trimellitic anhydride Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Trimellitic anhydride (TMA) IgG Ab [Mass/volume] in Serum;TMA IgG-mCnc;;ACTIVE;2.34;2.73 +6114-3;Euroglyphus maynei Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Euroglyphus maynei IgE Ab [Units/volume] in Serum;E maynei IgE Qn;;ACTIVE;1.0d;2.73 +61143-4;Summary note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Summary note;Nurse Summary note;;ACTIVE;2.34;2.67 +61144-2;Diet and nutrition;Find;Pt;^Patient;Nar;;H&P.HX;2;Diet and nutrition Narrative;Diet+nutrition;;ACTIVE;2.34;2.63 +61145-9;Patient plan of care;Find;Pt;^Patient;Doc;;DOC.MISC;2;Deprecated Patient plan of care Document;Deprecated Plan of care Doc;;DEPRECATED;2.34;2.73 +61146-7;Goals;Find;Pt;^Patient;Nar;;DOC.MISC;2;Goals Narrative;Goals;;ACTIVE;2.34;2.73 +61147-5;Expected outcomes;Find;Pt;^Patient;Nar;;DOC.MISC;2;Expected outcomes Narrative;Expected outcomes;;ACTIVE;2.34;2.73 +61148-3;Fluid management note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Fluid management note;Fluid management note;;ACTIVE;2.34;2.67 +61149-1;Objective;Find;Pt;^Patient;Nar;;DOC.MISC;2;Objective Narrative;Objective;;ACTIVE;2.34;2.73 +6115-0;Franseria acanthicarpa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;False ragweed IgE Ab [Units/volume] in Serum;False ragweed IgE Qn;;ACTIVE;1.0d;2.73 +61150-9;Subjective;Find;Pt;^Patient;Nar;;DOC.MISC;2;Subjective Narrative;Subjective;;ACTIVE;2.34;2.73 +61151-7;Albumin;MCnc;Pt;Ser/Plas;Qn;BCG;CHEM;1;Albumin [Mass/volume] in Serum or Plasma by Bromocresol green (BCG) dye binding method;Albumin SerPl BCG-mCnc;;ACTIVE;2.34;2.73 +61152-5;Albumin;MCnc;Pt;Ser/Plas;Qn;BCP;CHEM;1;Albumin [Mass/volume] in Serum or Plasma by Bromocresol purple (BCP) dye binding method;Albumin SerPl BCP-mCnc;;ACTIVE;2.34;2.73 +61153-3;Glucose^baseline;MCnc;Pt;Dial fld prt;Qn;;CHAL;1;Glucose [Mass/volume] in Peritoneal dialysis fluid --baseline;Glucose BS DiafP-mCnc;;ACTIVE;2.34;2.70 +61154-1;Hepatitis B virus codon L180M;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon L180M [Presence] by Genotype method;HBV L180M Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61155-8;Hepatitis B virus codon L80V;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon L80V [Presence] by Genotype method;HBV L80V Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61156-6;Hepatitis B virus codon V173L;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon V173L [Presence] by Genotype method;HBV V173L Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61157-4;Hepatitis B virus codon M204V;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon M204V [Presence] by Genotype method;HBV M204V Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61158-2;Hepatitis B virus codon M204I;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon M204I [Presence] by Genotype method;HBV M204I Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61159-0;Hepatitis B virus codon M204S;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon M204S [Presence] by Genotype method;HBV M204S Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61160-8;Hepatitis B virus codon A181V;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon A181V [Presence] by Genotype method;HBV A181V Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61161-6;Hepatitis B virus codon A181T;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon A181T [Presence] by Genotype method;HBV A181T Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61162-4;Hepatitis B virus codon N236T;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon N236T [Presence] by Genotype method;HBV N236T Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61163-2;Hepatitis B virus codon A194T;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon A194T [Presence] by Genotype method;HBV A194T Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61164-0;Hepatitis B virus codon T184S;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon T184S [Presence] by Genotype method;HBV T184S Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61165-7;Hepatitis B virus codon T184I;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon T184I [Presence] by Genotype method;HBV T184I Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61166-5;Hepatitis B virus codon S202G;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon S202G [Presence] by Genotype method;HBV S202G Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61167-3;Hepatitis B virus codon S202C;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon S202C [Presence] by Genotype method;HBV S202C Islt Ql Genotyp;;ACTIVE;2.36;2.56 +6116-8;Ficus sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ficus sp IgE Ab [Units/volume] in Serum;Ficus IgE Qn;;ACTIVE;1.0d;2.73 +61168-1;Hepatitis B virus codon S202I;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon S202I [Presence] by Genotype method;HBV S202I Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61169-9;Hepatitis B virus codon I233V;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon I233V [Presence] by Genotype method;HBV I233V Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61170-7;Hepatitis B virus codon M250V;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon M250V [Presence] by Genotype method;HBV M250V Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61171-5;Hepatitis B virus codon M250I;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon M250I [Presence] by Genotype method;HBV M250I Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61172-3;Hepatitis B virus codon M250L;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon M250L [Presence] by Genotype method;HBV M250L Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61173-1;Hepatitis B virus codon L80I;PrThr;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Hepatitis B virus codon L80I [Presence] by Genotype method;HBV L80I Islt Ql Genotyp;;ACTIVE;2.36;2.56 +61174-9;17-Hydroxyprogesterone^20M pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --20 minutes pre XXX challenge;17OHP 20M pre chal SerPl-sCnc;;ACTIVE;2.34;2.70 +61175-6;Polychlorinated biphenyl.Aroclor 1242;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Polychlorinated biphenyl.Aroclor 1242 [Mass/volume] in Serum or Plasma;PCB Aroclor1242 SerPl-mCnc;;ACTIVE;2.34;2.70 +6117-6;Solenopsis invicta Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Imported Fire Ant IgE Ab [Units/volume] in Serum;Red Imp Fire Ant IgE Qn;;ACTIVE;1.0d;2.73 +61176-4;Polychlorinated biphenyl.Aroclor 1248;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Polychlorinated biphenyl.Aroclor 1248 [Mass/volume] in Serum or Plasma;PCB Aroclor1248 SerPl-mCnc;;ACTIVE;2.34;2.70 +61177-2;Paraneoplastic Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Paraneoplastic Ab [Presence] in Serum by Immunofluorescence;Paraneoplastic Ab Ser Ql IF;;ACTIVE;2.34;2.73 +61178-0;Cells.CD79/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD79 cells/100 cells in Specimen;CD79 cells NFr Spec;;ACTIVE;2.34;2.70 +61179-8;Leukocyte morphology finding;Prid;Pt;Bld^Fetus;Nom;;HEM/BC;1;Leukocyte morphology finding [Identifier] in Blood from Fetus;WBC morph Bld Fetus;;ACTIVE;2.34;2.34 +61180-6;Hemoglobin;MCnc;Pt;Bld^Fetus;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Blood from Fetus;Hgb Bld Fetus-mCnc;;ACTIVE;2.34;2.70 +61181-4;Cells counted.total;Num;Pt;Bld^Fetus;Qn;;HEM/BC;1;Cells Counted Total [#] in Blood from Fetus;Total Cells Counted Bld Fetus;;ACTIVE;2.34;2.73 +61182-2;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;Bld^Fetus;Qn;;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Blood from Fetus;WBC nRBC cor # Bld Fetus;;ACTIVE;2.34;2.70 +61183-0;Cells.myeloperoxidase/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Myeloperoxidase cells/100 cells in Blood;Myeloperoxidase Cells NFr Bld;;ACTIVE;2.34;2.73 +6118-4;Kochia scoparia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Firebush IgE Ab [Units/volume] in Serum;Firebush IgE Qn;;ACTIVE;1.0d;2.73 +61184-8;Spermatozoa.broken tail/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa broken tail/100 spermatozoa in Semen;Sperm broken tail NFr Smn;;ACTIVE;2.34;2.70 +61185-5;Spermatozoa.thick midpiece/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa thick midpiece/100 spermatozoa in Semen;Sperm thick midpiece NFr Smn;;ACTIVE;2.34;2.70 +61186-3;Spermatozoa.thin midpiece/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa thin midpiece/100 spermatozoa in Semen;Sperm thin midpiece NFr Smn;;ACTIVE;2.34;2.70 +61187-1;Spermatozoa.bent midpiece/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa bent midpiece/100 spermatozoa in Semen;Sperm bent midpiece NFr Smn;;ACTIVE;2.34;2.70 +61188-9;Clindamycin.induced;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Clindamycin.induced [Susceptibility];Clindamycin.induced Susc Islt;;ACTIVE;2.36;2.73 +61189-7;Coagulation tissue factor induced.INR;RelTime;Pt;PPP^Fetus;Qn;Coag;COAG;1;INR in Platelet poor plasma from Fetus by Coagulation assay;INR PPP Fetus;;ACTIVE;2.34;2.69 +61190-5;Coagulation tissue factor induced;Time;Pt;PPP^Fetus;Qn;Coag;COAG;1;Prothrombin time (PT) in Platelet poor plasma from Fetus by Coagulation assay;PT PPP Fetus;;ACTIVE;2.34;2.70 +61191-3;Coagulation surface induced;Time;Pt;PPP^Fetus;Qn;Coag;COAG;1;aPTT in Platelet poor plasma from Fetus by Coagulation assay;aPTT PPP Fetus;;ACTIVE;2.34;2.70 +6119-2;Formaldehyde Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Formaldehyde IgE Ab [Units/volume] in Serum;Formaldehyde IgE Qn;;ACTIVE;1.0d;2.73 +61192-1;Color;Type;Pt;Plr fld^Fetus;Nom;;SPEC;1;Color of Pleural fluid from Fetus;Color Plr Fetus;;ACTIVE;2.34;2.34 +61193-9;Clarity;Type;Pt;Plr fld^Fetus;Nom;;SPEC;1;Clarity of Pleural fluid from Fetus;Clarity Plr Fetus;;ACTIVE;2.34;2.34 +61194-7;Cells counted.total;Num;Pt;Plr fld^Fetus;Qn;;HEM/BC;1;Cells Counted Total [#] in Pleural fluid from Fetus;Total Cells Counted Plr Fetus;;ACTIVE;2.34;2.69 +61195-4;Albumin;MCnc;Pt;Ser/Plas^Fetus;Qn;;CHEM;1;Albumin [Mass/volume] in Serum or Plasma from Fetus;Albumin SerPl Fetus-mCnc;;ACTIVE;2.34;2.70 +61196-2;Albumin;MCnc;Pt;Urine^Fetus;Qn;;CHEM;1;Albumin [Mass/volume] in Urine from Fetus;Albumin Ur Fetus-mCnc;;ACTIVE;2.34;2.70 +61197-0;oxyCODONE+Oxymorphone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Urine by Confirmatory method;oxyCODONE+oxyMORphone Ur Ql Cfm;;ACTIVE;2.34;2.73 +61198-8;Raltegravir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Raltegravir [Susceptibility] by Phenotype method;Raltegravir Islt Phenotyp;;ACTIVE;2.34;2.73 +61199-6;HIV 1 integrase gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;HIV 1 integrase gene mutations detected [Identifier];HIV1 integrase gene Mut Det Islt;;ACTIVE;2.34;2.73 +61-2;Carbenicillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Carbenicillin [Susceptibility] by Disk diffusion (KB);Carbenicillin Islt KB;;ACTIVE;1.0;2.73 +6120-0;Fusarium culmorum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium culmorum IgE Ab [Units/volume] in Serum;F culmorum IgE Qn;;ACTIVE;1.0d;2.73 +61200-2;Colorado tick fever virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Colorado tick fever virus IgG Ab [Titer] in Serum by Immunofluorescence;CTFV IgG Titr Ser IF;;ACTIVE;2.34;2.70 +61201-0;(Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;Multidisk;ALLERGY;1;Mold Allergen Mix 1 (Alternaria alternata+Aspergillus fumigatus+Cladosporium herbarum+Penicillium notatum) IgE Ab/IgE total in Serum by Multidisk;Mold Allerg Mix1 IgE/IgE total %;;ACTIVE;2.34;2.70 +61202-8;(Ambrosia elatior+Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Salsola kali) Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 1 (Common ragweed+Mugwort+Goosefoot or Lambs quarters+English plantain+Saltwort) IgE Ab/IgE total in Serum by Multidisk;Weed Allerg Mix1 IgE/IgE total %;;ACTIVE;2.34;2.70 +61203-6;(Chicken feather+Duck feather+Goose feather+Turkey feather) Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 71 (Chicken feather+Duck feather+Goose feather+Turkey feather) IgE Ab/IgE total in Serum by Multidisk;Epid Allerg Mix71 IgE/IgE total %;;ACTIVE;2.34;2.70 +61204-4;(Cynodon dactylon+Lolium perenne+Phleum pratense+Poa pratensis+Sorghum halepense+Paspalum notatum) Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 2 (Bermuda grass+Perennial rye grass+Timothy+Kentucky blue grass+Johnson grass+Bahia grass) IgE Ab/IgE total in Serum by Multidisk;Grass Allerg Mix2 IgE/IgE total %;;ACTIVE;2.34;2.70 +61205-1;Acer macrophyllum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Coastal Maple IgE Ab/IgE total in Serum;Coastal Maple IgE/IgE total %;;ACTIVE;2.34;2.70 +61206-9;Acer negundo Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Boxelder IgE Ab/IgE total in Serum;Boxelder IgE/IgE total %;;ACTIVE;2.34;2.73 +61207-7;Acremonium sp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Acremonium sp IgE Ab/IgE total in Serum;Acremonium IgE/IgE total %;;ACTIVE;2.34;2.70 +61208-5;Aedes communis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Aedes mosquito IgE Ab/IgE total in Serum;Aedes mosquito IgE/IgE total %;;ACTIVE;2.34;2.70 +61209-3;Agaricus hortensis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Mushroom IgE Ab/IgE total in Serum;Mushroom IgE/IgE total %;;ACTIVE;2.34;2.70 +61210-1;Allium cepa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Onion IgE Ab/IgE total in Serum;Onion IgE/IgE total %;;ACTIVE;2.34;2.70 +61211-9;Allium sativum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Garlic IgE Ab/IgE total in Serum;Garlic IgE/IgE total %;;ACTIVE;2.34;2.70 +61212-7;Alnus incana Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Grey Alder IgE Ab/IgE total in Serum;Grey Alder IgE/IgE total %;;ACTIVE;2.34;2.70 +61213-5;Lactalbumin alpha Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin alpha IgE Ab/IgE total in Serum;A-Lactalb IgE/IgE total %;;ACTIVE;2.34;2.70 +61214-3;Ambrosia elatior Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Common Ragweed IgE Ab/IgE total in Serum;Common Ragweed IgE/IgE total %;;ACTIVE;2.34;2.73 +61215-0;Ambrosia trifida Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Giant Ragweed IgE Ab/IgE total in Serum;Giant Ragweed IgE/IgE total %;;ACTIVE;2.34;2.70 +61216-8;Ananas comosus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pineapple IgE Ab/IgE total in Serum;Pineapple IgE/IgE total %;;ACTIVE;2.34;2.70 +61217-6;Anthoxanthum odoratum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sweet Vernal grass IgE Ab/IgE total in Serum;Sw Vernal grass IgE/IgE total %;;ACTIVE;2.34;2.70 +6121-8;Fusarium moniliforme Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium moniliforme IgE Ab [Units/volume] in Serum;F moniliforme IgE Qn;;ACTIVE;1.0d;2.73 +61218-4;Apium graveolens Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Celery IgE Ab/IgE total in Serum;Celery IgE/IgE total %;;ACTIVE;2.34;2.70 +61219-2;Arachis hypogaea Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Peanut IgE Ab/IgE total in Serum;Peanut IgE/IgE total %;;ACTIVE;2.34;2.70 +612-2;Bacterial strain;Type;Pt;Isolate;Nom;Bacterial subtyping;MICRO;1;Bacterial strain [Type] in Isolate by Bacteria subtyping;Bacteria Islt Subtyping;;ACTIVE;1.0;2.73 +61220-0;Ascaris sp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Ascaris sp IgE Ab/IgE total in Serum;Ascaris IgE/IgE total %;;ACTIVE;2.34;2.70 +61221-8;Aspergillus niger Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Aspergillus niger IgE Ab/IgE total in Serum;A niger IgE/IgE total %;;ACTIVE;2.34;2.70 +61222-6;Aspergillus sp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Aspergillus sp IgE Ab/IgE total in Serum;Aspergillus IgE/IgE total %;;ACTIVE;2.34;2.70 +61223-4;Astacus astacus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Crawfish IgE Ab/IgE total in Serum;Crawfish IgE/IgE total %;;ACTIVE;2.34;2.70 +61224-2;Atriplex lentiformis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lenscale IgE Ab/IgE total in Serum;Lenscale IgE/IgE total %;;ACTIVE;2.34;2.73 +61225-9;Aureobasidium pullulans Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Aureobasidium pullulans IgE Ab/IgE total in Serum;A pullulans IgE/IgE total %;;ACTIVE;2.34;2.70 +6122-6;Allium sativum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Garlic IgE Ab [Units/volume] in Serum;Garlic IgE Qn;;ACTIVE;1.0d;2.73 +61226-7;Avena sativa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Oat IgE Ab/IgE total in Serum;Oat IgE/IgE total %;;ACTIVE;2.34;2.70 +61227-5;Betula populifolia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;White Birch IgE Ab/IgE total in Serum;White Birch IgE/IgE total %;;ACTIVE;2.34;2.70 +61228-3;Betula verrucosa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Silver Birch IgE Ab/IgE total in Serum;Silver Birch IgE/IgE total %;;ACTIVE;2.34;2.70 +61229-1;Betula verrucosa recombinant (rBet v) 1 Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 1 IgE Ab/IgE total in Serum;Silver Birch (rBet v) 1 IgE/IgE total %;;ACTIVE;2.34;2.70 +61230-9;Blatella germanica Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cockroach IgE Ab/IgE total in Serum;Roach IgE/IgE total %;;ACTIVE;2.34;2.70 +61231-7;Botrytis cinerea Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Botrytis cinerea IgE Ab/IgE total in Serum;B cinerea IgE/IgE total %;;ACTIVE;2.34;2.70 +61232-5;Brassica oleracea var botrytis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cauliflower IgE Ab/IgE total in Serum;Cauliflower IgE/IgE total %;;ACTIVE;2.34;2.70 +61233-3;Brassica oleracea var capitata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cabbage IgE Ab/IgE total in Serum;Cabbage IgE/IgE total %;;ACTIVE;2.34;2.70 +6123-4;Pelargonium sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Geranium IgE Ab [Units/volume] in Serum;Geranium IgE Qn;;ACTIVE;1.0d;2.73 +61234-1;Brassica oleracea var italica Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Broccoli IgE Ab/IgE total in Serum;Broccoli IgE/IgE total %;;ACTIVE;2.34;2.70 +61235-8;Bromus inermis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Brome IgE Ab/IgE total in Serum;Brome IgE/IgE total %;;ACTIVE;2.34;2.70 +61236-6;Budgerigar droppings Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Budgerigar droppings IgE Ab/IgE total in Serum;Budgie Drop IgE/IgE total %;;ACTIVE;2.34;2.70 +61237-4;Budgerigar feather Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Budgerigar feather IgE Ab/IgE total in Serum;Budgie Feather IgE/IgE total %;;ACTIVE;2.34;2.70 +61238-2;Candida albicans Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Candida albicans IgE Ab/IgE total in Serum;C albicans IgE/IgE total %;;ACTIVE;2.34;2.73 +61239-0;Capsicum annuum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Paprika IgE Ab/IgE total in Serum;Paprika IgE/IgE total %;;ACTIVE;2.34;2.70 +61240-8;Carya illinoinensis tree Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Tree IgE Ab/IgE total in Serum;Pecan/Hick Tree IgE/IgE total %;;ACTIVE;2.34;2.70 +61241-6;Casein Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Casein IgE Ab/IgE total in Serum;Casein IgE/IgE total %;;ACTIVE;2.34;2.70 +6124-2;Ambrosia trifida Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Giant Ragweed IgE Ab [Units/volume] in Serum;Giant Ragweed IgE Qn;;ACTIVE;1.0d;2.73 +61242-4;Chaetomium globosum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Chaetomium globosum IgE Ab/IgE total in Serum;C globosum IgE/IgE total %;;ACTIVE;2.34;2.70 +61243-2;Chenopodium album Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Goosefoot IgE Ab/IgE total in Serum;Goosefoot IgE/IgE total %;;ACTIVE;2.34;2.73 +61244-0;Cicer arietinus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Chick Pea IgE Ab/IgE total in Serum;Chick Pea IgE/IgE total %;;ACTIVE;2.34;2.70 +61245-7;Cinnamomum spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cinnamon IgE Ab/IgE total in Serum;Cinnamon IgE/IgE total %;;ACTIVE;2.34;2.70 +61246-5;Citrus limon Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lemon IgE Ab/IgE total in Serum;Lemon IgE/IgE total %;;ACTIVE;2.34;2.70 +61247-3;Citrus paradisis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Grapefruit IgE Ab/IgE total in Serum;Grapefruit IgE/IgE total %;;ACTIVE;2.34;2.70 +61248-1;Citrus sinensis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Orange IgE Ab/IgE total in Serum;Orange IgE/IgE total %;;ACTIVE;2.34;2.70 +61249-9;Cladosporium herbarum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum IgE Ab/IgE total in Serum;C herbarum IgE/IgE total %;;ACTIVE;2.34;2.70 +61250-7;Coffea spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Coffee IgE Ab/IgE total in Serum;Coffee IgE/IgE total %;;ACTIVE;2.34;2.70 +61251-5;Cryptomeria japonica Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Japanese Cedar IgE Ab/IgE total in Serum;Japanese Cedar IgE/IgE total %;;ACTIVE;2.34;2.70 +61252-3;Cucurbita pepo seed Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pumpkin Seed IgE Ab/IgE total in Serum;Pumpkin Seed IgE/IgE total %;;ACTIVE;2.34;2.70 +61253-1;Cupressus arizonica Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Arizona Cypress IgE Ab/IgE total in Serum;Arizona Cypress IgE/IgE total %;;ACTIVE;2.34;2.70 +61254-9;Cupressus sempervirens Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Italian Cypress IgE Ab/IgE total in Serum;Italian Cypress IgE/IgE total %;;ACTIVE;2.34;2.70 +61255-6;Cynodon dactylon Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass IgE Ab/IgE total in Serum;Bermuda grass IgE/IgE total %;;ACTIVE;2.34;2.73 +61256-4;Dactylis glomerata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cocksfoot IgE Ab/IgE total in Serum;Cocksfoot IgE/IgE total %;;ACTIVE;2.34;2.70 +61257-2;Dermatophagoides microceras Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides microceras IgE Ab/IgE total in Serum;D microceras IgE/IgE total %;;ACTIVE;2.34;2.70 +61258-0;Dermatophagoides pteronyssinus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;European house dust mite IgE Ab/IgE total in Serum;D pteronyss IgE/IgE total %;;ACTIVE;2.34;2.73 +6125-9;Gluten Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gluten IgE Ab [Units/volume] in Serum;Gluten IgE Qn;;ACTIVE;1.0d;2.73 +61259-8;Dolichovespula maculata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Whitefaced Hornet IgE Ab/IgE total in Serum;Whitefaced Hornet IgE/IgE total %;;ACTIVE;2.34;2.70 +61260-6;Erythromycin Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Erythromycin IgE Ab/IgE total in Serum;Erythromycin IgE/IgE total %;;ACTIVE;2.34;2.70 +61261-4;Eucalyptus spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Gum-Tree IgE Ab/IgE total in Serum;Gum-Tree IgE/IgE total %;;ACTIVE;2.34;2.70 +61262-2;Fagopyrum esculentum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Buckwheat IgE Ab/IgE total in Serum;Buckwheat IgE/IgE total %;;ACTIVE;2.34;2.70 +61263-0;Fagus grandifolia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;American Beech IgE Ab/IgE total in Serum;Amer Beech IgE/IgE total %;;ACTIVE;2.34;2.70 +61264-8;Festuca elatior Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Meadow Fescue IgE Ab/IgE total in Serum;Meadow Fescue IgE/IgE total %;;ACTIVE;2.34;2.73 +61265-5;Foeniculum vulgare seed Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Fennel Seed IgE Ab/IgE total in Serum;Fennel Seed IgE/IgE total %;;ACTIVE;2.34;2.70 +61266-3;Fragaria vesca Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Strawberry IgE Ab/IgE total in Serum;Strawberry IgE/IgE total %;;ACTIVE;2.34;2.70 +6126-7;Glycyphagus domesticus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Glycyphagus domesticus IgE Ab [Units/volume] in Serum;G domesticus IgE Qn;;ACTIVE;1.0d;2.73 +61267-1;Franseria acanthicarpa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;False ragweed IgE Ab/IgE total in Serum;False ragweed IgE/IgE total %;;ACTIVE;2.34;2.70 +61268-9;Gadus morhua Ab.IgG/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Codfish IgG Ab/IgE total in Serum;Codfish IgG/IgE total %;;ACTIVE;2.34;2.70 +61269-7;Gelatin Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Gelatin IgE Ab/IgE total in Serum;Gelatin IgE/IgE total %;;ACTIVE;2.34;2.70 +61270-5;Gluten Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Gluten IgE Ab/IgE total in Serum;Gluten IgE/IgE total %;;ACTIVE;2.34;2.70 +61271-3;Glycine max Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Soybean IgE Ab/IgE total in Serum;Soybean IgE/IgE total %;;ACTIVE;2.34;2.70 +61272-1;Helianthus annuus seed Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sunflower Seed IgE Ab/IgE total in Serum;Sunflower Seed IgE/IgE total %;;ACTIVE;2.34;2.70 +61273-9;Hordeum vulgare Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Barley IgE Ab/IgE total in Serum;Barley IgE/IgE total %;;ACTIVE;2.34;2.70 +61274-7;House dust Greer Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;House dust Greer IgE Ab/IgE total in Serum;House Dust Greer IgE/IgE total %;;ACTIVE;2.34;2.70 +6127-5;Goat epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goat epithelium IgE Ab [Units/volume] in Serum;Goat Epith IgE Qn;;ACTIVE;1.0d;2.73 +61275-4;Humulus lupus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Hop IgE Ab/IgE total in Serum;Hop IgE/IgE total %;;ACTIVE;2.34;2.70 +61276-2;Insulin porcine Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Insulin porcine IgE Ab/IgE total in Serum;Insulin Porcine IgE/IgE total %;;ACTIVE;2.34;2.70 +61277-0;Hexamethylene diisocyanate (HDI) Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Isocyanate HDI IgE Ab/IgE total in Serum;Isocyanate HDI IgE/IgE total %;;ACTIVE;2.34;2.70 +61278-8;Toluene diisocyanate (TDI) Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Isocyanate TDI IgE Ab/IgE total in Serum;Isocyanate TDI IgE/IgE total %;;ACTIVE;2.34;2.70 +61279-6;Juglans regia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;English Walnut IgE Ab/IgE total in Serum;English Walnut IgE/IgE total %;;ACTIVE;2.34;2.70 +61280-4;Lactuca sativa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Lettuce IgE Ab/IgE total in Serum;Lettuce IgE/IgE total %;;ACTIVE;2.34;2.70 +61281-2;Loligo sp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Squid IgE Ab/IgE total in Serum;Squid IgE/IgE total %;;ACTIVE;2.34;2.73 +61282-0;Lolium perenne Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Perennial rye grass IgE Ab/IgE total in Serum;Per rye grass IgE/IgE total %;;ACTIVE;2.34;2.73 +6128-3;Solidago virgaurea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goldenrod IgE Ab [Units/volume] in Serum;Goldenrod IgE Qn;;ACTIVE;1.0d;2.73 +61283-8;Macadamia spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Macadamia IgE Ab/IgE total in Serum;Macadamia IgE/IgE total %;;ACTIVE;2.34;2.70 +61284-6;Melaleuca leucadendron Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cajeput tree IgE Ab/IgE total in Serum;Cajeput tree IgE/IgE total %;;ACTIVE;2.34;2.70 +61285-3;Micropterus salmoides Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Bass, Black IgE Ab/IgE total in Serum;Bass IgE/IgE total %;;ACTIVE;2.34;2.70 +61286-1;Morus alba Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;White mulberry IgE Ab/IgE total in Serum;White mulberry IgE/IgE total %;;ACTIVE;2.34;2.70 +61287-9;Musa spp Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Banana IgE Ab/IgE total in Serum;Banana IgE/IgE total %;;ACTIVE;2.34;2.70 +61288-7;Ocimum basilicum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Basil IgE Ab/IgE total in Serum;Basil IgE/IgE total %;;ACTIVE;2.34;2.70 +61289-5;Oncorhynchus mykiss Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Trout IgE Ab/IgE total in Serum;Trout IgE/IgE total %;;ACTIVE;2.34;2.70 +61290-3;Origanum vulgare Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Oregano IgE Ab/IgE total in Serum;Oregano IgE/IgE total %;;ACTIVE;2.34;2.70 +6129-1;Goose feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goose feather IgE Ab [Units/volume] in Serum;Goose Feather IgE Qn;;ACTIVE;1.0d;2.73 +61291-1;Oryza sativa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Rice IgE Ab/IgE total in Serum;Rice IgE/IgE total %;;ACTIVE;2.34;2.73 +61292-9;Ostrea edulis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Oyster IgE Ab/IgE total in Serum;Oyster IgE/IgE total %;;ACTIVE;2.34;2.70 +61293-7;Passiflora edulis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Passion fruit IgE Ab/IgE total in Serum;Passion fruit IgE/IgE total %;;ACTIVE;2.34;2.70 +61294-5;Persea americana Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Avocado IgE Ab/IgE total in Serum;Avocado IgE/IgE total %;;ACTIVE;2.34;2.70 +61295-2;Petroselinum crispum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Parsley IgE Ab/IgE total in Serum;Parsley IgE/IgE total %;;ACTIVE;2.34;2.70 +61296-0;Phleum pratense Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Timothy IgE Ab/IgE total in Serum;Timothy IgE/IgE total %;;ACTIVE;2.34;2.73 +61297-8;Phthalic anhydride Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Phthalic anhydride IgE Ab/IgE total in Serum;PAN IgE/IgE total %;;ACTIVE;2.34;2.70 +61298-6;Picea excelsa Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Spruce IgE Ab/IgE total in Serum;Spruce IgE/IgE total %;;ACTIVE;2.34;2.70 +61299-4;Pinus strobus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Eastern White Pine IgE Ab/IgE total in Serum;East White Pine IgE/IgE total %;;ACTIVE;2.34;2.70 +613-0;Fungal strain;Type;Pt;Isolate;Nom;Fungal subtyping;MICRO;1;Fungal strain [Type] in Isolate by Fungus subtyping;Fungal strain Islt Fungus subtyping;;ACTIVE;1.0;2.73 +61300-0;Pisum sativum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pea IgE Ab/IgE total in Serum;Pea IgE/IgE total %;;ACTIVE;2.34;2.70 +61301-8;Plantago lanceolata Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;English plantain IgE Ab/IgE total in Serum;Engl plantain IgE/IgE total %;;ACTIVE;2.34;2.73 +61302-6;Platanus acerifolia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;London Plane IgE Ab/IgE total in Serum;London Plane IgE/IgE total %;;ACTIVE;2.34;2.73 +61303-4;Poa pratensis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Kentucky blue grass IgE Ab/IgE total in Serum;Kent blue grass IgE/IgE total %;;ACTIVE;2.34;2.70 +61304-2;Populus deltoides Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cottonwood IgE Ab/IgE total in Serum;Cottonwood IgE/IgE total %;;ACTIVE;2.34;2.70 +61305-9;Prosopis juliflora Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Mesquite IgE Ab/IgE total in Serum;Mesquite IgE/IgE total %;;ACTIVE;2.34;2.70 +61306-7;Prunus avium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cherry IgE Ab/IgE total in Serum;Cherry IgE/IgE total %;;ACTIVE;2.34;2.70 +61307-5;Pyrus communis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pear IgE Ab/IgE total in Serum;Pear IgE/IgE total %;;ACTIVE;2.34;2.70 +61308-3;Rhizopus nigricans Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Rhizopus nigricans IgE Ab/IgE total in Serum;R nigricans IgE/IgE total %;;ACTIVE;2.34;2.70 +6130-9;Goose meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goose meat IgE Ab [Units/volume] in Serum;Goose Meat IgE Qn;;ACTIVE;1.0d;2.73 +61309-1;Rumex acetosella Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sheep Sorrel IgE Ab/IgE total in Serum;Sheep Sorrel IgE/IgE total %;;ACTIVE;2.34;2.70 +61310-9;Salix caprea Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Willow IgE Ab/IgE total in Serum;Willow IgE/IgE total %;;ACTIVE;2.34;2.70 +61311-7;Salsola kali Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Saltwort IgE Ab/IgE total in Serum;Saltwort IgE/IgE total %;;ACTIVE;2.34;2.70 +61312-5;Secale cereale Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Rye IgE Ab/IgE total in Serum;Rye IgE/IgE total %;;ACTIVE;2.34;2.70 +61313-3;Sesamum indicum Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sesame Seed IgE Ab/IgE total in Serum;Sesame Seed IgE/IgE total %;;ACTIVE;2.34;2.70 +61314-1;Sheep wool Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sheep wool IgE Ab/IgE total in Serum;Sheep Wool IgE/IgE total %;;ACTIVE;2.34;2.70 +61315-8;Solenopsis invicta Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Red Imported Fire Ant IgE Ab/IgE total in Serum;Red Imp Fire Ant IgE/IgE total %;;ACTIVE;2.34;2.70 +61316-6;Solidago virgaurea Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Goldenrod IgE Ab/IgE total in Serum;Goldenrod IgE/IgE total %;;ACTIVE;2.34;2.73 +6131-7;Citrus paradisis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grapefruit IgE Ab [Units/volume] in Serum;Grapefruit IgE Qn;;ACTIVE;1.0d;2.73 +61317-4;Spinacia oleracea Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Spinach IgE Ab/IgE total in Serum;Spinach IgE/IgE total %;;ACTIVE;2.34;2.70 +61318-2;Taraxacum vulgare Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Dandelion IgE Ab/IgE total in Serum;Dandelion IgE/IgE total %;;ACTIVE;2.34;2.70 +61319-0;Theobroma cacao Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cocoa IgE Ab/IgE total in Serum;Cocoa IgE/IgE total %;;ACTIVE;2.34;2.70 +61320-8;Trachurus japonicus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Scad IgE Ab/IgE total in Serum;Scad IgE/IgE total %;;ACTIVE;2.34;2.70 +61321-6;Trimellitic anhydride Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Trimellitic anhydride (TMA) IgE Ab/IgE total in Serum;TMA IgE/IgE total %;;ACTIVE;2.34;2.70 +61322-4;Ulmus americana Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;White Elm IgE Ab/IgE total in Serum;White Elm IgE/IgE total %;;ACTIVE;2.34;2.73 +61323-2;Vaccinium oxycoccos Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cranberry IgE Ab/IgE total in Serum;Cranberry IgE/IgE total %;;ACTIVE;2.34;2.70 +61324-0;Vanilla planifolia Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Vanilla IgE Ab/IgE total in Serum;Vanilla IgE/IgE total %;;ACTIVE;2.34;2.70 +6132-5;Coffee bean green Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Green Coffee Bean IgE Ab [Units/volume] in Serum;Green Coffee Bean IgE Qn;;ACTIVE;1.0d;2.73 +61325-7;Vespa crabro Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;European Hornet IgE Ab/IgE total in Serum;European Hornet IgE/IgE total %;;ACTIVE;2.34;2.70 +61326-5;Xanthium commune Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cocklebur IgE Ab/IgE total in Serum;Cocklebur IgE/IgE total %;;ACTIVE;2.34;2.70 +61327-3;Zea mays Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Corn IgE Ab/IgE total in Serum;Corn IgE/IgE total %;;ACTIVE;2.34;2.70 +61328-1;Zingiber officinale Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Ginger IgE Ab/IgE total in Serum;Ginger IgE/IgE total %;;ACTIVE;2.34;2.70 +61329-9;Cucumis sativus Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cucumber IgE Ab/IgE total in Serum;Cucumber IgE/IgE total %;;ACTIVE;2.34;2.70 +61330-7;Pinus edulis Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pine Nut IgE Ab/IgE total in Serum;Pine Nut IgE/IgE total %;;ACTIVE;2.34;2.70 +61331-5;Beef Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Beef IgE Ab/IgE total in Serum;Beef IgE/IgE total %;;ACTIVE;2.34;2.73 +61332-3;Cow milk Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cow milk IgE Ab/IgE total in Serum;Cow Milk IgE/IgE total %;;ACTIVE;2.34;2.70 +6133-3;Cladotanytarsus lewisi Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Green Nimitti IgE Ab [Units/volume] in Serum;Green Nimitti IgE Qn;;ACTIVE;1.0d;2.73 +61333-1;Dog dander Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Dog dander IgE Ab/IgE total in Serum;Dog Dander IgE/IgE total %;;ACTIVE;2.34;2.73 +61334-9;Dog epithelium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Dog epithelium IgE Ab/IgE total in Serum;Dog Epith IgE/IgE total %;;ACTIVE;2.34;2.70 +61335-6;Goat milk Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Goat milk IgE Ab/IgE total in Serum;Goat Milk IgE/IgE total %;;ACTIVE;2.34;2.70 +61336-4;Cochineal extract Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cochineal extract IgE Ab/IgE total in Serum;Chocineal IgE/IgE total %;;ACTIVE;2.34;2.70 +61337-2;Chicken feather Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Chicken feather IgE Ab/IgE total in Serum;Chicken Feather IgE/IgE total %;;ACTIVE;2.34;2.70 +61338-0;Egg white Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Egg white IgE Ab/IgE total in Serum;Egg White IgE/IgE total %;;ACTIVE;2.34;2.70 +61339-8;Egg yolk Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Egg yolk IgE Ab/IgE total in Serum;Egg Yolk IgE/IgE total %;;ACTIVE;2.34;2.70 +61340-6;Cottonseed Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cottonseed IgE Ab/IgE total in Serum;Cottonseed IgE/IgE total %;;ACTIVE;2.34;2.70 +6134-1;Guinea pig epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Guinea pig epithelium IgE Ab [Units/volume] in Serum;Guinea Pig Epith IgE Qn;;ACTIVE;1.0d;2.73 +61341-4;Gerbil epithelium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Gerbil epithelium IgE Ab/IgE total in Serum;Gerbil Epith IgE/IgE total %;;ACTIVE;2.34;2.70 +61342-2;Mouse urine proteins Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Mouse urine proteins IgE Ab/IgE total in Serum;Mouse Urine Prot IgE/IgE total %;;ACTIVE;2.34;2.70 +61343-0;Ferret epithelium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Ferret epithelium IgE Ab/IgE total in Serum;Ferret Epith IgE/IgE total %;;ACTIVE;2.34;2.70 +61344-8;Sheep epithelium Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Sheep epithelium IgE Ab/IgE total in Serum;Sheep Epith IgE/IgE total %;;ACTIVE;2.34;2.70 +61345-5;Flounder Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Flounder IgE Ab/IgE total in Serum;Flounder IgE/IgE total %;;ACTIVE;2.34;2.70 +61346-3;Rat urine proteins Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Rat urine proteins IgE Ab/IgE total in Serum;Rat Urine Prot IgE/IgE total %;;ACTIVE;2.34;2.70 +61347-1;Pork Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Pork IgE Ab/IgE total in Serum;Pork IgE/IgE total %;;ACTIVE;2.34;2.70 +61348-9;Cockatiel droppings Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cockatiel droppings IgE Ab/IgE total in Serum;Cockatiel Drop IgE/IgE total %;;ACTIVE;2.34;2.70 +61349-7;Cockatiel feather Ab.IgE/IgE.total;AFr;Pt;Ser;Qn;;ALLERGY;1;Cockatiel feather IgE Ab/IgE total in Serum;Cockatiel Feather IgE/IgE total %;;ACTIVE;2.34;2.70 +61350-5;Lymphocyte proliferation. 2.5 ug concanavalin A stimulation;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 2.5 ug concanavalin A in Blood;LPT 2.5 ug CA Bld;;ACTIVE;2.34;2.70 +61351-3;Lymphocyte proliferation. 0.6 ug pokeweed mitogen stimulation;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 0.6 ug pokeweed mitogen in Blood;LPT 0.6 ug PW Bld;;ACTIVE;2.34;2.70 +61352-1;Lymphocyte proliferation. 2.5 ug pokeweed mitogen stimulation;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 2.5 ug pokeweed mitogen in Blood;LPT 2.5 ug PW Bld;;ACTIVE;2.34;2.70 +61353-9;Lymphocyte proliferation. 10 ug phytohemagglutinin stimulation;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 10 ug phytohemagglutinin in Blood;LPT 10 ug PHA Bld;;ACTIVE;2.34;2.70 +61354-7;Lymphocyte proliferation. 40 ug phytohemagglutinin stimulation;RelRto;Pt;Bld;Qn;;SERO;1;Lymphocyte proliferation stimulated by 40 ug phytohemagglutinin in Blood;LPT 40 ug PHA Bld;;ACTIVE;2.34;2.70 +61355-4;Capreomycin 5.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Capreomycin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Capreomycin 5 ug/mL Islt SlowMyco;;ACTIVE;2.34;2.34 +61356-2;Medication pharmaceutical advice.extended;Find;Pt;^Patient;Doc;;DOC.MISC;2;Medication pharmaceutical advice.extended Document;Medication pharm advice.extended Doc;;ACTIVE;2.34;2.73 +61357-0;Medication pharmaceutical advice.brief;Find;Pt;^Patient;Doc;;DOC.MISC;2;Medication pharmaceutical advice.brief Document;Medication pharm advice.brief Doc;;ACTIVE;2.34;2.73 +6135-8;Hamster epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hamster epithelium IgE Ab [Units/volume] in Serum;Hmtr Epith IgE Qn;;ACTIVE;1.0d;2.73 +61358-8;Surgical operation consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Surgical operation consent Document;Operative consent;;ACTIVE;2.34;2.65 +61359-6;Anesthesia consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Anesthesia consent Document;Anesthesia consent;;ACTIVE;2.34;2.65 +61360-4;Acinetobacter baumannii DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Acinetobacter baumannii DNA [Presence] in Specimen by NAA with probe detection;A baumannii DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61361-2;Klebsiella aerogenes DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [Presence] in Specimen by NAA with probe detection;K. aerogenes DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61362-0;Enterococcus faecalis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecalis DNA [Presence] in Specimen by NAA with probe detection;E faecalis DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61363-8;Adenovirus 3+4+7+21 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus 3+4+7+21 DNA [Presence] in Specimen by NAA with probe detection;AdV 3+4+7+21 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61364-6;Echovirus+Coxsackievirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Echovirus+Coxsackievirus RNA [Presence] in Specimen by NAA with probe detection;ECV+CV RNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61365-3;Parainfluenza virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection;HPIV RNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +6136-6;Corylus avellana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut IgE Ab [Units/volume] in Serum;Hazelnut IgE Qn;;ACTIVE;1.0d;2.73 +61366-1;Haemophilus influenzae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] in Specimen by NAA with probe detection;Haem influ DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61367-9;Clostridioides difficile DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridioides difficile DNA [Presence] in Specimen by NAA with probe detection;C diff DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61368-7;Campylobacter jejuni DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Campylobacter jejuni DNA [Presence] in Specimen by NAA with probe detection;C jejuni DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61369-5;Listeria monocytogenes DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Listeria monocytogenes DNA [Presence] in Specimen by NAA with probe detection;L monocytog DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61370-3;Salmonella enterica DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Salmonella enterica DNA [Presence] in Specimen by NAA with probe detection;S enterica DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61371-1;Vibrio cholerae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Vibrio cholerae DNA [Presence] in Specimen by NAA with probe detection;V cholerae DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61372-9;Human papilloma virus 16 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16 DNA [Presence] in Specimen by NAA with probe detection;HPV16 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61373-7;Human papilloma virus 18 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 18 DNA [Presence] in Specimen by NAA with probe detection;HPV18 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +6137-4;Corylus avellana pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut Pollen IgE Ab [Units/volume] in Serum;Hazelnut Poln IgE Qn;;ACTIVE;1.0d;2.73 +61374-5;Human papilloma virus 26 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 26 DNA [Presence] in Specimen by NAA with probe detection;HPV26 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61375-2;Human papilloma virus 31 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 31 DNA [Presence] in Specimen by NAA with probe detection;HPV31 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61376-0;Human papilloma virus 33 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 33 DNA [Presence] in Specimen by NAA with probe detection;HPV33 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61377-8;Human papilloma virus 35 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 35 DNA [Presence] in Specimen by NAA with probe detection;HPV35 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61378-6;Human papilloma virus 39 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 39 DNA [Presence] in Specimen by NAA with probe detection;HPV39 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61379-4;Human papilloma virus 44 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 44 DNA [Presence] in Specimen by NAA with probe detection;HPV44 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61380-2;Human papilloma virus 45 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 45 DNA [Presence] in Specimen by NAA with probe detection;HPV45 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61381-0;Human papilloma virus 51 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 51 DNA [Presence] in Specimen by NAA with probe detection;HPV51 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +6138-2;Setomelanomma rostrata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Setomelanomma rostrata IgE Ab [Units/volume] in Serum;S rostrata IgE Qn;;ACTIVE;1.0d;2.73 +61382-8;Human papilloma virus 52 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 52 DNA [Presence] in Specimen by NAA with probe detection;HPV52 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61383-6;Human papilloma virus 53 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 53 DNA [Presence] in Specimen by NAA with probe detection;HPV53 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61384-4;Human papilloma virus 58 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 58 DNA [Presence] in Specimen by NAA with probe detection;HPV58 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61385-1;Human papilloma virus 59 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 59 DNA [Presence] in Specimen by NAA with probe detection;HPV59 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61386-9;Human papilloma virus 66 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 66 DNA [Presence] in Specimen by NAA with probe detection;HPV66 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61387-7;Human papilloma virus 67 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 67 DNA [Presence] in Specimen by NAA with probe detection;HPV67 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61388-5;Human papilloma virus 68 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 68 DNA [Presence] in Specimen by NAA with probe detection;HPV68 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61389-3;Human papilloma virus 69 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 69 DNA [Presence] in Specimen by NAA with probe detection;HPV69 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +6139-0;Clupea harengus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Herring IgE Ab [Units/volume] in Serum;Herring IgE Qn;;ACTIVE;1.0d;2.73 +61390-1;Human papilloma virus 70 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 70 DNA [Presence] in Specimen by NAA with probe detection;HPV70 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61391-9;Human papilloma virus 73 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 73 DNA [Presence] in Specimen by NAA with probe detection;HPV73 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61392-7;Human papilloma virus 82 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 82 DNA [Presence] in Specimen by NAA with probe detection;HPV82 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61393-5;Human papilloma virus 6 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 6 DNA [Presence] in Specimen by NAA with probe detection;HPV6 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61394-3;Human papilloma virus 11 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 11 DNA [Presence] in Specimen by NAA with probe detection;HPV11 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61395-0;Human papilloma virus 42 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 42 DNA [Presence] in Specimen by NAA with probe detection;HPV42 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61396-8;Human papilloma virus 56 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 56 DNA [Presence] in Specimen by NAA with probe detection;HPV56 DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61397-6;Enterococcus faecium DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecium DNA [Presence] in Specimen by NAA with probe detection;E faecium DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61398-4;Escherichia coli DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Escherichia coli DNA [Presence] in Specimen by NAA with probe detection;E coli DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61399-2;Klebsiella pneumoniae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Klebsiella pneumoniae DNA [Presence] in Specimen by NAA with probe detection;K pneumon DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61400-8;Proteus mirabilis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Proteus mirabilis DNA [Presence] in Specimen by NAA with probe detection;P mirabilis DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61401-6;Pseudomonas aeruginosa DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [Presence] in Specimen by NAA with probe detection;P aeruginosa DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61402-4;Serratia marcescens DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Serratia marcescens DNA [Presence] in Specimen by NAA with probe detection;S marcescens DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61403-2;Stenotrophomonas maltophilia DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Stenotrophomonas maltophilia DNA [Presence] in Specimen by NAA with probe detection;S maltophilia DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61404-0;Staphylococcus aureus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [Presence] in Specimen by NAA with probe detection;S aureus DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.73 +61405-7;Staphylococcus epidermidis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus epidermidis DNA [Presence] in Specimen by NAA with probe detection;S epidermidis DNA Spec Ql NAA+probe;;ACTIVE;2.34;2.69 +61406-5;XXX blood group Ab;Titr;Pt;Ser/Plas;Qn;;BLDBK;1;XXX blood group Ab [Titer] in Serum or Plasma;XXX blood group Ab Titr SerPl;;ACTIVE;2.34;2.73 +61407-3;Amitriptyline/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Amitriptyline/Creatinine [Mass Ratio] in Urine;Amitrip/Creat Ur;;ACTIVE;2.36;2.73 +6140-8;Hickory Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Hickory Ab.IgE;Deprecated Hickory IgE Qn;;DEPRECATED;1.0d;2.70 +61408-1;Cyclobenzaprine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Cyclobenzaprine/Creatinine [Mass Ratio] in Urine;Cyclobenzaprine/Creat Ur;;ACTIVE;2.36;2.73 +61409-9;Cyclobenzaprine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cyclobenzaprine [Presence] in Urine by Confirmatory method;Cyclobenzaprine Ur Ql Cfm;;ACTIVE;2.34;2.73 +61410-7;Cyclobenzaprine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cyclobenzaprine [Mass/volume] in Urine by Confirmatory method;Cyclobenzaprine Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +61411-5;Desipramine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Desipramine/Creatinine [Mass Ratio] in Urine;Desipramine/Creat Ur;;ACTIVE;2.36;2.73 +61412-3;Desipramine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Desipramine [Presence] in Urine by Confirmatory method;Desipramine Ur Ql Cfm;;ACTIVE;2.34;2.73 +61413-1;Desipramine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Desipramine [Mass/volume] in Urine by Confirmatory method;Desipramine Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +61414-9;Doxepin/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Doxepin/Creatinine [Mass Ratio] in Urine;Doxepin/Creat Ur;;ACTIVE;2.36;2.70 +61415-6;Doxepin;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Doxepin [Presence] in Urine by Confirmatory method;Doxepin Ur Ql Cfm;;ACTIVE;2.34;2.73 +6141-6;Humulus lupus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hop IgE Ab [Units/volume] in Serum;Hop IgE Qn;;ACTIVE;1.0d;2.73 +61416-4;Doxepin;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Doxepin [Mass/volume] in Urine by Confirmatory method;Doxepin Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +61417-2;Imipramine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Imipramine/Creatinine [Mass Ratio] in Urine;Imipramine/Creat Ur;;ACTIVE;2.36;2.73 +61418-0;Imipramine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Imipramine [Presence] in Urine by Confirmatory method;Imipramine Ur Ql Cfm;;ACTIVE;2.34;2.73 +61419-8;Imipramine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Imipramine [Mass/volume] in Urine by Confirmatory method;Imipramine Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +61420-6;Norhydrocodone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Norhydrocodone/Creatinine [Mass Ratio] in Urine;Norhydrocodone/Creat Ur;;ACTIVE;2.36;2.73 +61421-4;Norhydrocodone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Norhydrocodone [Presence] in Urine by Confirmatory method;Norhydrocodone Ur Ql Cfm;;ACTIVE;2.34;2.73 +61422-2;Norhydrocodone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norhydrocodone [Mass/volume] in Urine by Confirmatory method;Norhydrocodone Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +61423-0;Noroxycodone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Noroxycodone/Creatinine [Mass Ratio] in Urine;Noroxycodone/Creat Ur;;ACTIVE;2.36;2.73 +6142-4;Hornet venom Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hornet venom IgE Ab [Units/volume] in Serum;Hornet Venom IgE Qn;;ACTIVE;1.0d;2.73 +61424-8;Noroxycodone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Noroxycodone [Presence] in Urine by Confirmatory method;Noroxycodone Ur Ql Cfm;;ACTIVE;2.34;2.73 +61425-5;Noroxycodone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Noroxycodone [Mass/volume] in Urine by Confirmatory method;Noroxycodone Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +61426-3;Nortriptyline/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Nortriptyline/Creatinine [Mass Ratio] in Urine;Nortrip/Creat Ur;;ACTIVE;2.36;2.73 +61427-1;Nortriptyline;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Nortriptyline [Presence] in Urine by Confirmatory method;Nortrip Ur Ql Cfm;;ACTIVE;2.34;2.73 +61428-9;Nortriptyline;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nortriptyline [Mass/volume] in Urine by Confirmatory method;Nortrip Ur Cfm-mCnc;;ACTIVE;2.34;2.73 +61429-7;Tapentadol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Tapentadol/Creatinine [Mass Ratio] in Urine;Tapentadol/Creat Ur;;ACTIVE;2.36;2.73 +61430-5;Aquaporin 4 water channel Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Aquaporin 4 water channel Ab [Units/volume] in Serum or Plasma by Immunoassay;AQP4 H2O channel Ab SerPl IA-aCnc;;ACTIVE;2.34;2.73 +61431-3;PhenX measure - breastfeeding;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - breastfeeding;;;DEPRECATED;2.34;2.46 +6143-2;Horse dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse dander IgE Ab [Units/volume] in Serum;Horse Dander IgE Qn;;ACTIVE;1.0d;2.73 +61432-1;How old was sample person when he or she was first fed something other than breast milk or water;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old was sample person when he or she was first fed something other than breast milk or water [PhenX];Age fed other than breastmlk PhenX;;TRIAL;2.34;2.65 +61433-9;How old was sample person when he or she completely stopped breastfeeding or being fed breast milk;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old was sample person when he or she completely stopped breastfeeding or being fed breast milk [PhenX];Age stopped breastfeed breast milk PhenX;;TRIAL;2.34;2.65 +61434-7;Was sample person ever breastfed or fed breast milk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was sample person ever breastfed or fed breast milk [PhenX];Ever fed breast milk PhenX;;TRIAL;2.34;2.65 +61435-4;Calcium Intake (Daily) Protocols;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated Deprecated Calcium Intake (Daily) Protocols PhenX;Deprecated Calcium Intake (Da;;DEPRECATED;2.34;2.38 +61436-2;PhenX - calcium intake - pediatric protocol 050201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - calcium intake - pediatric protocol 050201;PhenX calcium intake ped proto;;TRIAL;2.34;2.66 +61437-0;How often did you eat bread, toast or dinner rolls, including bread as part of a sandwich in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat bread, toast or dinner rolls, including bread as part of a sandwich in past 30 days [PhenX];Bread in 30D PhenX;;TRIAL;2.34;2.65 +61438-8;Each time you ate bread, toast or dinner rolls, how much did you usually eat in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you ate bread, toast or dinner rolls, how much did you usually eat in the past 30 days [PhenX];How much bread in 30D PhenX;;TRIAL;2.34;2.65 +61439-6;How often did you eat cold cereal in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat cold cereal in the past 30 days [PhenX];Cold cereal in 30D PhenX;;TRIAL;2.34;2.65 +6144-0;Tabanus spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse Fly IgE Ab [Units/volume] in Serum;Horse Fly IgE Qn;;ACTIVE;1.0d;2.73 +61440-4;When you ate cold cereal, how much did you usually eat in the past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated When you ate cold cereal, how much did you usually eat in the past 30 days PhenX;Deprecated When you ate cold cereal, how;;DEPRECATED;2.34;2.38 +61441-2;How often did you eat cheese in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat cheese in the past 30 days [PhenX];Cheese in 30D PhenX;;TRIAL;2.34;2.65 +61442-0;Each time you ate cheese, how much did you usually eat in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you ate cheese, how much did you usually eat in the past 30 days [PhenX];How much cheese in 30D PhenX;;TRIAL;2.34;2.65 +61443-8;How often did you eat ice cream, ice cream bars, milk shakes, or frozen yogurt in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat ice cream, ice cream bars, milk shakes, or frozen yogurt in the past 30 days [PhenX];Freq ice crm froz yogurt in 30D PhenX;;TRIAL;2.34;2.65 +61444-6;Each time you ate ice cream, ice cream bars, milkshakes, or frozen yogurt, how much did you usually eat in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you ate ice cream, ice cream bars, milkshakes, or frozen yogurt, how much did you usually eat in the past 30 days [PhenX];Amt ice crm froz yogurt in 30D PhenX;;TRIAL;2.34;2.65 +61445-3;How often did you eat macaroni and cheese in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat macaroni and cheese in the past 30 days [PhenX];Macaroni cheese in 30D PhenX;;TRIAL;2.34;2.65 +61446-1;Each time you ate macaroni and cheese, how much did you usually eat in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you ate macaroni and cheese, how much did you usually eat in the past 30 days [PhenX];How much macaroni cheese in 30D PhenX;;TRIAL;2.34;2.65 +61447-9;How often did you eat mexican foods such as tacos, tostados, burritos, tamales, fajitas, enchiladas, quesadillas, or chimichangas in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat Mexican foods such as tacos, tostados, burritos, tamales, fajitas, enchiladas, quesadillas, or chimichangas in the past 30 days [PhenX];Mexican foods in 30D PhenX;;TRIAL;2.34;2.65 +61448-7;Each time you ate mexican foods, how much did you usually eat in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you ate Mexican foods, how much did you usually eat in the past 30 days [PhenX];How much mexican food in 30D PhenX;;TRIAL;2.34;2.65 +61449-5;How often did you drink milk as a beverage in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you drink milk as a beverage in the past 30 days [PhenX];Milk in 30D PhenX;;TRIAL;2.34;2.65 +61450-3;Each time you drank milk, how much did you usually drink in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you drank milk, how much did you usually drink in the past 30 days [PhenX];How much milk in 30D PhenX;;TRIAL;2.34;2.65 +61451-1;What kind of milk did you usually drink in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;What kind of milk did you usually drink in the past 30 days [PhenX];Kind of milk drink in the past 30D PhenX;;TRIAL;2.34;2.65 +61452-9;How often was the orange juice you drank calcium fortified in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often was the orange juice you drank calcium fortified in the past 30 days [PhenX];OJ calcium fortified in 30D PhenX;;TRIAL;2.34;2.65 +61453-7;How often did you drink 100 percent orange juice in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you drink 100% orange juice in the past 30 days [PhenX];100 % OJ in 30D PhenX;;TRIAL;2.34;2.65 +61454-5;Each time you drank orange juice, how much did you usually drink in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you drank orange juice, how much did you usually drink in the past 30 days [PhenX];How much orange juice in 30D PhenX;;TRIAL;2.34;2.65 +61455-2;How often did you eat pizza in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat pizza in the past 30 days [PhenX];Pizza in 30D PhenX;;TRIAL;2.34;2.65 +61456-0;Each time you ate pizza, how much did you usually eat in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you ate pizza, how much did you usually eat in past 30 days [PhenX];How much pizza in 30D PhenX;;TRIAL;2.34;2.65 +6145-7;House dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust IgE Ab [Units/volume] in Serum;House Dust IgE Qn;;ACTIVE;1.0d;2.73 +61457-8;How often did you eat yogurt in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat yogurt in past 30 days [PhenX];Yogurt in 30D PhenX;;TRIAL;2.34;2.65 +61458-6;PhenX measure - calcium intake;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - calcium intake;;;DEPRECATED;2.34;2.46 +61459-4;How often did you eat cooked dried beans, such as refried beans, baked beans, bean soup, and pork and beans in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat cooked dried beans, such as refried beans, baked beans, bean soup, and pork and beans in past 30 days [PhenX];Freq cooked dried beans in 30D PhenX;;TRIAL;2.34;2.65 +61460-2;How often did you eat hot or cold cereals in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat hot or cold cereals in past 30 days [PhenX];Hot cold cereals in 30D PhenX;;TRIAL;2.34;2.65 +61461-0;When you ate cereal, which kinds did you usually eat in past 30D;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Deprecated When you ate cereal, which kinds did you usually eat in past 30D;Deprecated When you ate cereal,;;DEPRECATED;2.34;2.40 +61462-8;How often did you eat any kind of cheese in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat any kind of cheese in past 30 days [PhenX];Any cheese in 30D PhenX;;TRIAL;2.34;2.65 +61463-6;How often did you eat cookies, cake, pie, or brownies in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat cookies, cake, pie, or brownies in past 30 days [PhenX];Cookies cake pie in 30D PhenX;;TRIAL;2.34;2.65 +61464-4;How often did you eat DOUGHNUTS, sweet rolls, Danish, muffins, or pop-tarts in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you eat DOUGHNUTS, sweet rolls, Danish, muffins, or pop-tarts in past 30 days PhenX;Deprecated How often did you eat DOUGHNU;;DEPRECATED;2.34;2.40 +6146-5;House dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated House dust IgE Ab [Units/volume] in Serum;Deprecated House Dust IgE Qn;;DEPRECATED;1.0d;2.70 +61465-1;How often did you eat french fries, home fries, or hash brown potatoes in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat french fries, home fries, or hash brown potatoes in past 30 days [PhenX];Fries hash browns in 30D PhenX;;TRIAL;2.34;2.65 +61466-9;How often did you drink fruit flavored drinks with sugar (such as kool aid, hi C, lemonade, or cranberry cocktail) in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you drink FRUIT-FLAVORED DRINKS with sugar (such as Kool-aid, Hi-C, lemonade, or cranberry cocktail) in past 30 days PhenX;Deprecated How often did you drink FRUIT;;DEPRECATED;2.34;2.40 +61467-7;How often did you eat FRUIT in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you eat FRUIT in past 30 days PhenX;Deprecated How often did you eat FRUIT i;;DEPRECATED;2.34;2.40 +61468-5;How often did you drink 100 percent fruit juice, such as orange, mango, apple, and grape juices in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you drink 100 % fruit juice, such as orange, mango, apple, and grape juices in past 30 days [PhenX];100 % juice 30D PhenX;;TRIAL;2.34;2.65 +61469-3;Each time you ate cold cereal, how much did you usually eat in the past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Each time you ate cold cereal, how much did you usually eat in the past 30 days [PhenX];How much cold cereal in 30D PhenX;;TRIAL;2.34;2.65 +61470-1;Not counting lettuce salads, white potatoes, cooked dried beans, and not counting rice, how often did you eat OTHER VEGETABLES in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated Not counting lettuce salads, white potatoes, cooked dried beans, and not counting rice, how often did you eat OTHER VEGETABLES in past 30 days PhenX;Deprecated Not counting lettuce salads,;;DEPRECATED;2.34;2.40 +61471-9;How often did you eat a green leafy or lettuce SALAD, with or without other vegetables, in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you eat a green leafy or lettuce SALAD, with or without other vegetables, in past 30 days PhenX;Deprecated How often did you eat a green;;DEPRECATED;2.34;2.40 +61472-7;How often did you have salsa in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you have salsa in past 30 days [PhenX];Salsa in 30D PhenX;;TRIAL;2.34;2.65 +6147-3;Insulin bovine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Insulin bovine IgE Ab [Units/volume] in Serum;Insulin Bovine IgE Qn;;ACTIVE;1.0d;2.73 +61473-5;How often did you drink regular, carbonated soda or soft drinks that contain sugar in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you drink regular, carbonated soda or soft drinks that contain sugar in past 30 days [PhenX];Carb soda w sugar in 30D PhenX;;TRIAL;2.34;2.65 +61474-3;How often did you have tomato sauces such as spaghetti sauce or pizza with tomato sauce in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you have tomato sauces such as spaghetti sauce or pizza with tomato sauce in past 30 days [PhenX];Tomato sauces in 30D PhenX;;TRIAL;2.34;2.65 +61475-0;How often did you eat other WHITE POTATOES in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you eat other WHITE POTATOES in past 30 days PhenX;Deprecated How often did you eat other W;;DEPRECATED;2.34;2.40 +61476-8;How often did you eat whole grain bread including toast, rolls and in sandwiches in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat whole grain bread including toast, rolls and in sandwiches in past 30 days [PhenX];Whole grain bread in 30D PhenX;;TRIAL;2.34;2.65 +61477-6;PhenX measure - caffeine intake;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - caffeine intake;;;DEPRECATED;2.34;2.46 +61478-4;How often did you drink black tea such as lipton, or earl grey;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink black tea such as Lipton, or Earl Grey [PhenX];Black tea PhenX;;TRIAL;2.34;2.65 +61479-2;What is your serving size for black tea such as lipton, or earl grey;Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for black tea such as Lipton, or Earl Grey [PhenX];Size for black tea PhenX;;TRIAL;2.34;2.65 +614-8;Mycobacterial strain;Type;Pt;Isolate;Nom;Mycobacterial subtyping;MICRO;1;Mycobacterial strain [Type] in Isolate by Mycobacterial subtyping;Mycobacterial strain by Subtyping;;ACTIVE;1.0;2.73 +61480-0;How often did you drink brewed coffee, not decaffeinated;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink brewed coffee, not decaffeinated [PhenX];Brewed coffee not decaf PhenX;;TRIAL;2.34;2.65 +6148-1;Insulin human Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Insulin human IgE Ab [Units/volume] in Serum;Insulin Human IgE Qn;;ACTIVE;1.0d;2.73 +61481-8;What is your serving size for brewed coffee, not decaffeinated;Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for brewed coffee, not decaffeinated [PhenX];Size brewed coffee, not decaf PhenX;;TRIAL;2.34;2.65 +61482-6;How often did you drink decaffeinated coffee (instant & brewed);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink decaffeinated coffee (instant and brewed) [PhenX];Drink decaf coffee PhenX;;TRIAL;2.34;2.65 +61483-4;What is your serving size for decaffeinated coffee (instant & brewed);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for decaffeinated coffee (instant and brewed) [PhenX];Size for decaf coffee PhenX;;TRIAL;2.34;2.65 +61484-2;How often did you drink decaffeinated espresso and espresso drinks (latte, mocha, americano);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink decaffeinated espresso and espresso drinks (latte, mocha, Americano) [PhenX];Decaf espresso PhenX;;TRIAL;2.34;2.65 +61485-9;What is your serving size for decaffeinated espresso and espresso drinks;Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for decaffeinated espresso and espresso drinks [PhenX];Size decaf espresso PhenX;;TRIAL;2.34;2.65 +61486-7;How often did you drink herbal or decaffeinated tea (instant, bottled, and brewed);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink herbal or decaffeinated tea (instant, bottled, and brewed) [PhenX];Herbal decaf tea PhenX;;TRIAL;2.34;2.65 +61487-5;What is your serving size for herbal or decaffeinated tea (instant, bottled, and brewed);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for herbal or decaffeinated tea (instant, bottled, and brewed) [PhenX];Size herbal decaf tea PhenX;;TRIAL;2.34;2.65 +61488-3;How often did you drink diet colas and diet root beer (caffeine free);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink diet colas and diet root beer (caffeine free) [PhenX];Diet cola no caffeine PhenX;;TRIAL;2.34;2.65 +61489-1;What is your serving size for diet colas and diet root beer (caffeine free);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for diet colas and diet root beer (caffeine free) [PhenX];Size diet colas caffeine free PhenX;;TRIAL;2.34;2.65 +61490-9;How often did you drink diet colas and diet root beer (with caffeine);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink diet colas and diet root beer (with caffeine) [PhenX];Diet cola w caffeine PhenX;;TRIAL;2.34;2.65 +61491-7;What is your serving size for diet colas and diet root beer (with caffeine);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for diet colas and diet root beer (with caffeine) [PhenX];Size diet colas w caffeine PhenX;;TRIAL;2.34;2.65 +61492-5;How often did you drink espresso and espresso drinks, not decaffeinated (latte, mocha, americano);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink espresso and espresso drinks, not decaffeinated (latte, mocha, Americano) [PhenX];Espresso not decaf PhenX;;TRIAL;2.34;2.65 +61493-3;What is your serving size for espresso and espresso drinks, not decaffeinated (latte, mocha, americano);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for espresso and espresso drinks, not decaffeinated (latte, mocha, Americano) [PhenX];Size espresso not decaf PhenX;;TRIAL;2.34;2.65 +61494-1;How often did you drink green tea;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink green tea [PhenX];Green tea PhenX;;TRIAL;2.34;2.65 +61495-8;What is your serving size for green tea;Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for green tea [PhenX];Size for green tea PhenX;;TRIAL;2.34;2.65 +61496-6;How often did you drink jolt, surge, mountain dew, red bull and other highly caffeinated sodas;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink Jolt, Surge, Mountain Dew, Red Bull and other highly caffeinated sodas [PhenX];Highly caffeinated soda PhenX;;TRIAL;2.34;2.65 +61497-4;What is your serving size for jolt, surge, mountain dew, red bull and other highly caffeinated sodas;Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for Jolt, Surge, Mountain Dew, Red Bull and other highly caffeinated sodas [PhenX];Size high caffeinated soda PhenX;;TRIAL;2.34;2.65 +61498-2;How often did you drink instant coffee, not decaffeinated (including flavored types);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink instant coffee, not decaffeinated (including flavored types) [PhenX];Instant coffee not decaf PhenX;;TRIAL;2.34;2.65 +6149-9;Insulin porcine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Insulin porcine IgE Ab [Units/volume] in Serum;Insulin Porcine IgE Qn;;ACTIVE;1.0d;2.73 +61499-0;What is your serving size for instant coffee, not decaffeinated (including flavored types);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for instant coffee, not decaffeinated (including flavored types) [PhenX];Size instant coffee not decaf PhenX;;TRIAL;2.34;2.65 +61500-5;How often did you drink regular colas and root beer (caffeine free, not diet);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink regular colas and root beer (caffeine free, not diet) [PhenX];Reg cola caffeine free PhenX;;TRIAL;2.34;2.65 +61501-3;What is your serving size for regular colas and root beer (caffeine free, not diet);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for regular colas and root beer (caffeine free, not diet) [PhenX];Size reg cola caffeine free PhenX;;TRIAL;2.34;2.65 +61502-1;How often did you drink regular colas and root beer (with caffeine, not diet);Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you drink regular colas and root beer (with caffeine, not diet) [PhenX];Regular cola w caffeine PhenX;;TRIAL;2.34;2.65 +61503-9;What is your serving size for regular colas and root beer (with caffeine, not diet);Find;Pt;^Patient;Ord;PhenX;PHENX;2;What is your serving size for regular colas and root beer (with caffeine, not diet) [PhenX];Size reg cola w caffeine PhenX;;TRIAL;2.34;2.65 +61504-7;PhenX measure - dairy food intake;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - dairy food intake;;;DEPRECATED;2.34;2.46 +61505-4;How many Y did you take zinc;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Zinc [PhenX];Years zinc PhenX;;TRIAL;2.34;2.65 +61506-2;How often did you eat whole grain bread in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you eat whole grain bread in past 30 days PhenX;Deprecated How often whole grain bread i;;DEPRECATED;2.34;2.40 +6150-7;Ispaghula laxative Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ispaghula laxative IgE Ab [Units/volume] in Serum;Ispaghula IgE Qn;;ACTIVE;1.0d;2.73 +61507-0;Not counting lettuce salads, white potatoes, cooked dried beans, and not counting rice, how often did you eat other vegetables in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;Not counting lettuce salads, white potatoes, cooked dried beans, and not counting rice, how often did you eat other vegetables in past 30 days [PhenX];How often other vegetables in 30D PhenX;;TRIAL;2.34;2.65 +61508-8;How often did you have MILK, either to drink or on cereal in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you have MILK, either to drink or on cereal in past 30 days PhenX;Deprecated How often did you have MILK,;;DEPRECATED;2.34;2.40 +61509-6;PhenX measure - dietary supplements;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - dietary supplements;;;DEPRECATED;2.34;2.46 +61510-4;How often did you take B complex or stress tab type multiple vitamins;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take B-complex or Stress-tab type multiple vitamins [PhenX];Bcomplex stress vit PhenX;;TRIAL;2.34;2.65 +61511-2;How many Y did you take B complex or stress tab type multiple vitamins;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take B complex or stress tab type multiple vitamins [PhenX];Years Bcomplex stress multiple vit PhenX;;TRIAL;2.34;2.65 +61512-0;How often did you take calcium, alone or combined with something else such as in a bone health supplement or in an antacid;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Calcium, alone or combined with something else such as in a bone health supplement OR in an antacid [PhenX];Calcium PhenX;;TRIAL;2.34;2.65 +61513-8;How many Y did you take calcium, alone or combined with something else such as in a bone health supplement or in an antacid;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take calcium, alone or combined with something else such as in a bone health supplement or in an antacid [PhenX];Y calcium alone or combined PhenX;;TRIAL;2.34;2.65 +61514-6;Did you take any dietary supplements during the past Y, at least once a W;Find;1Y;^Patient;Ord;PhenX;PHENX;2;Did you take any dietary supp during the past year, at least once a week [PhenX];DS in 12Mo once W PhenX;;TRIAL;2.34;2.65 +6151-5;Cupressus sempervirens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Italian Cypress IgE Ab [Units/volume] in Serum;Italian Cypress IgE Qn;;ACTIVE;1.0d;2.73 +61515-3;How often did you take flaxseed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take flaxseed [PhenX];Flaxseed PhenX;;TRIAL;2.34;2.65 +61516-1;How many Y did you take flaxseed;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take flaxseed [PhenX];Years flaxseed PhenX;;TRIAL;2.34;2.65 +61517-9;How often did you take folic acid, folate;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Folic acid, Folate [PhenX];Folic acid folate PhenX;;TRIAL;2.34;2.65 +61518-7;How often did you take garlic, as a pill, tablet, or capsule;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take garlic, as a pill, tablet, or capsule [PhenX];Garlic pill capsule PhenX;;TRIAL;2.34;2.65 +61519-5;How many Y did you take garlic, as a pill, tablet, or capsule;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take garlic, as a pill, tablet, or capsule [PhenX];Years garlic pill capsule PhenX;;TRIAL;2.34;2.65 +61520-3;How often did you take glucosamine, alone or combined with something else;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take glucosamine, alone or combined with something else [PhenX];Glucosamine PhenX;;TRIAL;2.34;2.65 +61521-1;How many Y did you take glucosamine, alone or combined with something else;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take glucosamine, alone or combined with something else [PhenX];Years glucosamine PhenX;;TRIAL;2.34;2.65 +61522-9;How often did you take iron;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take iron [PhenX];Iron PhenX;;TRIAL;2.34;2.65 +6152-3;Sorghum halepense Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Johnson grass IgE Ab [Units/volume] in Serum;Johnson grass IgE Qn;;ACTIVE;1.0d;2.73 +61523-7;How many Y did you take iron;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take iron [PhenX];Years iron PhenX;;TRIAL;2.34;2.65 +61524-5;How often did you take fish oil or omega 3 fatty acids;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take fish oil or omega - 3 fatty acids [PhenX];How oft fish oil omega3 fat acid PhenX;;TRIAL;2.34;2.65 +61525-2;How many Y did you take fish oil or omega 3 fatty acids;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take fish oil or omega-3 fatty acids [PhenX];Years fish oil omega 3 acids PhenX;;TRIAL;2.34;2.65 +61526-0;How often did you take regular one a day type, centrum or thera type multiple vitamins;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take regular One-a-day type, Centrum or Thera-type multiple vitamins [PhenX];Regular multiple vit PhenX;;TRIAL;2.34;2.65 +61527-8;How many Y did you take regular one a day type, centrum or thera type multiple vitamins;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Regular One-a-Day type, Centrum or Thera-type multiple vitamins [PhenX];Years regular multiple vit PhenX;;TRIAL;2.34;2.65 +61528-6;How often did you take coenzyme Q 10;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Coenzyme Q-10 [PhenX];Coenzyme Q10 PhenX;;TRIAL;2.34;2.65 +61529-4;How many Y did you take coenzyme Q 10;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Coenzyme Q-10 [PhenX];Years coenzyme Q10 PhenX;;TRIAL;2.34;2.65 +61530-2;How often did you take saw palmetto;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Saw Palmetto [PhenX];Saw palmetto PhenX;;TRIAL;2.34;2.65 +6153-1;Poa pratensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kentucky blue grass IgE Ab [Units/volume] in Serum;Kent blue grass IgE Qn;;ACTIVE;1.0d;2.73 +61531-0;How many Y did you take saw palmetto;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Saw Palmetto [PhenX];Years saw palmetto PhenX;;TRIAL;2.34;2.65 +61532-8;How often did you take selenium;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Selenium [PhenX];Selenium PhenX;;TRIAL;2.34;2.65 +61533-6;How many Y did you take selenium;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Selenium [PhenX];Years selenium PhenX;;TRIAL;2.34;2.65 +61534-4;How often did you take vitamin B 12;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Vitamin B-12 [PhenX];Vit B12 PhenX;;TRIAL;2.34;2.65 +61535-1;How many Y did you take vitamin B 12;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Vitamin B-12 [PhenX];Years vit B12 PhenX;;TRIAL;2.34;2.65 +61536-9;How often did you take vitamin B 6;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Vitamin B-6 [PhenX];Vit B6 PhenX;;TRIAL;2.34;2.65 +61537-7;How many Y did you take vitamin B 6;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Vitamin B-6 [PhenX];Years vit B6 PhenX;;TRIAL;2.34;2.65 +61538-5;How often did you take vitamin C;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Vitamin C [PhenX];Vit C PhenX;;TRIAL;2.34;2.65 +61539-3;When you took vitamin C, how much did you usually take;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you took Vitamin C, how much did you usually take [PhenX];How much vitamin C PhenX;;TRIAL;2.34;2.65 +61540-1;How many Y did you take vitamin C;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Vitamin C [PhenX];Years vit C PhenX;;TRIAL;2.34;2.65 +61541-9;How often did you take vitamin D, alone;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Vitamin D, alone [PhenX];Vit D alone PhenX;;TRIAL;2.34;2.65 +61542-7;How many Y did you take vitamin D, alone;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Vitamin D, alone [PhenX];Years vit D alone PhenX;;TRIAL;2.34;2.65 +61543-5;How often did you take vitamin E;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Vitamin E [PhenX];Vit E PhenX;;TRIAL;2.34;2.65 +61544-3;When you took vitamin E, how much did you usually take;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you took Vitamin E, how much did you usually take [PhenX];How much vitamin E PhenX;;TRIAL;2.34;2.65 +61545-0;How many Y did you take vitamin E;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Vitamin E [PhenX];Years vit E PhenX;;TRIAL;2.34;2.65 +61546-8;How many Y did you take folic acid, folate;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many years did you take Folic acid, Folate [PhenX];Years folic acid folate PhenX;;TRIAL;2.34;2.65 +61547-6;How often did you take zinc;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you take Zinc [PhenX];Zinc PhenX;;TRIAL;2.34;2.65 +61548-4;PhenX measure - fiber intake;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - fiber intake;;;DEPRECATED;2.34;2.46 +6154-9;Actinidia chinensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kiwifruit IgE Ab [Units/volume] in Serum;Kiwifruit IgE Qn;;ACTIVE;1.0d;2.73 +61549-2;How often did you have milk, either to drink or on cereal in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you have milk, either to drink or on cereal in past 30 days [PhenX];Have milk drink or cereal in 30D PhenX;;TRIAL;2.34;2.65 +615-5;Viral strain;Type;Pt;Isolate;Nom;Viral subtyping;MICRO;1;Viral strain [Type] in Isolate by Viral subtyping;Viral strain Islt Viral Subtyping;;ACTIVE;1.0;2.73 +61550-0;How often did you drink fruit flavored drinks with sugar (such as kool aid, hi C, lemonade, or cranberry cocktail) in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you drink fruit flavored drinks with sugar (such as Kool-Aid, Hi-C, lemonade, or cranberry cocktail) in past 30 days [PhenX];How oft fruit flav w sugar in 30D PhenX;;TRIAL;2.34;2.65 +61551-8;How often did you eat fruit in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat fruit in past 30 days [PhenX];Fruit in 30D PhenX;;TRIAL;2.34;2.65 +61552-6;How often did you eat a green leafy or lettuce salad, with or without other vegetables in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat a green leafy or lettuce salad, with or without other vegetables in past 30 days [PhenX];Green salad in 30D PhenX;;TRIAL;2.34;2.65 +61553-4;How often did you eat other white potatoes in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat other white potatoes in past 30 days [PhenX];White potatoes in 30D PhenX;;TRIAL;2.34;2.65 +61554-2;How often did you eat doughnuts, sweet rolls, danish, muffins, or pop-tarts in past 30D;Find;30D;^Patient;Ord;PhenX;PHENX;2;How often did you eat doughnuts, sweet rolls, danish, muffins, or pop-tarts in past 30 days [PhenX];Doughnut poptart in 30D PhenX;;TRIAL;2.34;2.65 +61555-9;How often did you eat COOKIES, CAKE, PIE, or BROWNIES in past 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated How often did you eat COOKIES, CAKE, PIE, or BROWNIES in past 30 days PhenX;Deprecated;;DEPRECATED;2.34;2.40 +6155-6;Lamb Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lamb IgE Ab [Units/volume] in Serum;Lamb IgE Qn;;ACTIVE;1.0d;2.73 +61556-7;PhenX measure - fruits and vegetables intake;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - fruits and vegetables intake;;;DEPRECATED;2.34;2.46 +61557-5;PhenX measure - percent energy from fat;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - percent energy from fat;;;DEPRECATED;2.34;2.46 +61558-3;How often did you eat cold cereal in the past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;How often did you eat cold cereal in the past 12 months [PhenX];Cold cereal in 12Mo PhenX;;TRIAL;2.34;2.65 +61559-1;About how often did you drink skim milk, on cereal or to drink in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you drink skim milk, on cereal or to drink in past 12 months [PhenX];How often skim milk in 12Mo PhenX;;TRIAL;2.34;2.65 +61560-9;About how often did you eat eggs, fried or scrambled in margarine, butter, or oil in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat eggs, fried or scrambled in margarine, butter, or oil in past 12 months [PhenX];How often egg w butter oil in 12Mo PhenX;;TRIAL;2.34;2.65 +61561-7;About how often did you eat sausage or bacon, regular fat, in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat sausage or bacon, regular-fat, in past 12 months [PhenX];How often sausage bacon in 12Mo PhenX;;TRIAL;2.34;2.65 +61562-5;About how often did you eat margarine or butter on bread, rolls, pancakes in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat margarine or butter on bread, rolls, pancakes in past 12 months [PhenX];How often butter on bread in 12Mo PhenX;;TRIAL;2.34;2.65 +61563-3;About how often did you drink orange juice or grapefruit juice in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you drink orange juice or grapefruit juice in past 12 months [PhenX];How often orange juice in 12Mo PhenX;;TRIAL;2.34;2.65 +6156-4;Chenopodium album Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goosefoot IgE Ab [Units/volume] in Serum;Goosefoot IgE Qn;;ACTIVE;1.0d;2.73 +61564-1;About how often did you eat fruit (not juices) in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat fruit (not juices) in past 12 months [PhenX];How often fruit not juice in 12Mo PhenX;;TRIAL;2.34;2.65 +61565-8;About how often did you eat beef or pork hot dogs, regular fat, in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat beef or pork hot dogs, regular-fat, in past 12 months [PhenX];Freq beef pork hot dog in 12Mo PhenX;;TRIAL;2.34;2.65 +61566-6;About how often did you eat cheese or cheese spread, regular fat, in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat cheese or cheese spread, regular fat, in past 12 months [PhenX];How often cheese reg fat in 12Mo PhenX;;TRIAL;2.34;2.65 +61567-4;About how often did you eat french fries, home fries, or hash brown potatoes in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat french fries, home fries, or hash brown potatoes in past 12 months [PhenX];How often fries hash brown in 12Mo PhenX;;TRIAL;2.34;2.65 +61568-2;About how often did you eat margarine or butter on vegetables, including potatoes in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat margarine or butter on vegetables, including potatoes in past 12 months [PhenX];How often butter on veg in 12Mo PhenX;;TRIAL;2.34;2.65 +61569-0;About how often did you eat mayonnaise, regular fat, in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat mayonnaise, regular-fat, in past 12 months [PhenX];How often mayo reg fat 12Mo PhenX;;TRIAL;2.34;2.65 +61570-8;About how often did you eat salad dressings, regular fat, in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat salad dressings, regular-fat, in past 12 months [PhenX];Freq salad drsing reg fat in 12Mo PhenX;;TRIAL;2.34;2.65 +61571-6;About how often did you eat rice in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat rice in past 12 months [PhenX];About how often rice in 12Mo PhenX;;TRIAL;2.34;2.65 +6157-2;Mutton Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Mutton IgE Ab [Units/volume] in Serum;Deprecated Mutton IgE Qn;;DEPRECATED;1.0d;2.70 +61572-4;About how often did you eat margarine, butter, or oil on rice or pasta in past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;About how often did you eat margarine, butter, or oil on rice or pasta in past 12 months [PhenX];Freq butter w rice pasta in 12Mo PhenX;;TRIAL;2.34;2.65 +61573-2;When you prepared foods with margarine or ate margarine in past 12Mo, how often did you use reduced fat margarine;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;When you prepared foods with margarine or ate margarine in past 12 months, how often did you use reduced-fat margarine [PhenX];Freq reduced fat margarine 12Mo PhenX;;TRIAL;2.34;2.65 +61574-0;Overall, when you think about the foods you ate over the past 12Mo, would you say your diet was high, medium, or low in fat;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Overall, when you think about the foods you ate over the past 12 months, would you say your diet was high, medium, or low in fat [PhenX];Diet high med lo in fat in 12Mo PhenX;;TRIAL;2.34;2.65 +61575-7;When you ate cereal, which kinds did you usually eat in past 30D;Find;30D;^Patient;Nom;PhenX;PHENX;2;When you ate cereal, which kinds did you usually eat in past 30 days [PhenX];Kinds of cereal usu eat in 30D PhenX;;TRIAL;2.34;2.65 +61576-5;PROMIS short form - global - version 1.1;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - global - version 1.1;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +61577-3;In general, would you say your health is;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;In general, would you say your health is;;;ACTIVE;2.34;2.71 +61578-1;In general, would you say your quality of life is;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;In general, would you say your quality of life is [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61579-9;In general, how would you rate your physical health;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;In general, how would you rate your physical health [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6158-0;Latex Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex IgE Ab [Units/volume] in Serum;Ltx IgE Qn;;ACTIVE;1.0d;2.73 +61580-7;In general, how would you rate your mental health, including your mood and your ability to think;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;In general, how would you rate your mental health, including your mood and your ability to think [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.68 +61581-5;In general, how would you rate your satisfaction with you social activities and relationships;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;In general, how would you rate your satisfaction with you social activities and relationships [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61582-3;To what extent are you able to carry out your everyday physical activities such as walking, climbing stairs, carrying groceries, or moving a chair;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what extent are you able to carry out your everyday physical activities such as walking, climbing stairs, carrying groceries, or moving a chair [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61583-1;How would you rate your pain on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How would you rate your pain on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61584-9;How would you rate your fatigue on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How would you rate your fatigue on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61585-6;In general, please rate how well you carry out your usual social activities and roles;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;In general, please rate how well you carry out your usual social activities and roles [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61586-4;How often have you been bothered by emotional problems such as feeling anxious, depressed or irritable in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often have you been bothered by emotional problems such as feeling anxious, depressed or irritable in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.73 +61587-2;PROMIS item bank - physical function - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - physical function - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +61588-0;Does your health now limit you in doing vigorous activities, such as running, lifting heavy objects, participating in strenuous sports;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing vigorous activities, such as running, lifting heavy objects, participating in strenuous sports [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61589-8;Does your health now limit you in bending, kneeling, or stooping;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in bending, kneeling, or stooping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61590-6;Does your health now limit you in doing heavy work around the house like scrubbing floors, or lifting or moving heavy furniture;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing heavy work around the house like scrubbing floors, or lifting or moving heavy furniture [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61591-4;Does your health now limit you in lifting or carrying groceries;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in lifting or carrying groceries [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61592-2;Does your health now limit you in bathing or dressing yourself;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in bathing or dressing yourself [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61593-0;How much do physical health problems now limit your usual physical activities (such as walking or climbing stairs);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much do physical health problems now limit your usual physical activities (such as walking or climbing stairs) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61594-8;Are you able to move a chair from one room to another;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to move a chair from one room to another [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61595-5;Are you able to bend down and pick up clothing from the floor;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to bend down and pick up clothing from the floor [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61596-3;Are you able to stand for one hour;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand for one hour [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61597-1;Are you able to do chores such as vacuuming or yard work;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do chores such as vacuuming or yard work [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6159-8;Citrus limon Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lemon IgE Ab [Units/volume] in Serum;Lemon IgE Qn;;ACTIVE;1.0d;2.73 +61598-9;Are you able to push open a heavy door;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to push open a heavy door [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61599-7;Are you able to exercise for an hour;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to exercise for an hour [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61600-3;Are you able to carry a heavy object (over 10 pounds);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a heavy object (over 10 pounds) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DISCOURAGED;2.34;2.65 +61601-1;Are you able to stand up from an armless straight chair;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand up from an armless straight chair [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61602-9;Are you able to dress yourself, including tying shoelaces and doing buttons;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dress yourself, including tying shoelaces and doing buttons [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61603-7;Are you able to reach into a high cupboard;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to reach into a high cupboard [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61604-5;Are you able to use a hammer to pound a nail;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to use a hammer to pound a nail [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61605-2;Are you able to run or jog for two miles;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run or jog for two miles [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6160-6;Lepidoglyphus destructor Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lepidoglyphus destructor IgE Ab [Units/volume] in Serum;L destructor IgE Qn;;ACTIVE;1.0d;2.73 +61606-0;Are you able to cut your food using eating utensils;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to cut your food using eating utensils [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61607-8;Are you able to go up and down stairs at a normal pace;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to go up and down stairs at a normal pace [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61608-6;Are you able to open previously opened jars;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to open previously opened jars [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61609-4;Are you able to go for a walk of at least 15 minutes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to go for a walk of at least 15 minutes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61610-2;Are you able to do yard work like raking leaves, weeding, or pushing a lawn mower;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do yard work like raking leaves, weeding, or pushing a lawn mower [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61611-0;Are you able to open a can with a hand can opener;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to open a can with a hand can opener [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61612-8;Are you able to pull heavy objects (10 pounds) towards yourself;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pull heavy objects (10 pounds) towards yourself [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61613-6;Are you able to step up and down curbs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to step up and down curbs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6161-4;Lactuca sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lettuce IgE Ab [Units/volume] in Serum;Lettuce IgE Qn;;ACTIVE;1.0d;2.73 +61614-4;Are you able to get up off the floor from lying on your back without help;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get up off the floor from lying on your back without help [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61615-1;Are you able to stand with your knees straight;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand with your knees straight [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61616-9;Are you able to exercise hard for half an hour;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to exercise hard for half an hour [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61617-7;Are you able to wash your back;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to wash your back [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61618-5;Are you able to open and close a zipper;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to open and close a zipper [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61619-3;Are you able to put on and take off a coat or jacket;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to put on and take off a coat or jacket [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61620-1;Are you able to stand for short periods of time;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand for short periods of time [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61621-9;Are you able to dry your back with a towel;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dry your back with a towel [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6162-2;Syringa vulgaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lilac IgE Ab [Units/volume] in Serum;Lilac IgE Qn;;ACTIVE;1.0d;2.73 +61622-7;Are you able to run at a fast pace for two miles;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run at a fast pace for two miles [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61623-5;Are you able to turn a key in a lock;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to turn a key in a lock [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61624-3;Are you able to squat and get up;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to squat and get up [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61625-0;Are you able to carry a laundry basket up a flight of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a laundry basket up a flight of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61626-8;Are you able to write with a pen or pencil;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to write with a pen or pencil [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61627-6;Are you able to put on a shirt or blouse;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to put on a shirt or blouse [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61628-4;Are you able to get out of bed into a chair;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get out of bed into a chair [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61629-2;Are you able to pull on trousers;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pull on trousers [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +616-3;Bacteria identified;Prid;Pt;Line;Nom;Intravascular line culture;MICRO;1;Bacteria identified in Line specimen by IV Line culture;Bacteria Line IV Ln Cult;;ACTIVE;1.0;2.21 +6163-0;Citrus aurantifolia tree Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lime Tree (Citrus aurantifolia tree) IgE Ab [Units/volume] in Serum;Lime Tree IgE Qn;;ACTIVE;1.0d;2.70 +61630-0;Are you able to peel fruit;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to peel fruit [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61631-8;Are you able to bend or twist your back;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to bend or twist your back [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61632-6;Are you able to brush your teeth;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to brush your teeth [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61633-4;Are you able to sit on the edge of a bed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to sit on the edge of a bed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61634-2;Are you able to tie your shoelaces;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to tie your shoelaces [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61635-9;Are you able to run errands and shop;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run errands and shop [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61636-7;Are you able to button your shirt;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to button your shirt [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61637-5;Are you able to wash and dry your body;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to wash and dry your body [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61638-3;Are you able to get in and out of a car;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get in and out of a car [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61639-1;Does your health now limit you in doing moderate work around the house like vacuuming, sweeping floors or carrying in groceries;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing moderate work around the house like vacuuming, sweeping floors or carrying in groceries [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61640-9;Does your health now limit you in putting a trash bag outside;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in putting a trash bag outside [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61641-7;Does your health now limit you in hiking a couple of miles on uneven surfaces, including hills;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in hiking a couple of miles on uneven surfaces, including hills [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61642-5;Does your health now limit you in doing strenuous activities such as backpacking, skiing, playing tennis, bicycling or jogging;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing strenuous activities such as backpacking, skiing, playing tennis, bicycling or jogging [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61643-3;Are you able to carry two bags filled with groceries 100 yards;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry two bags filled with groceries 100 yards [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61644-1;Are you able to jump up and down;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to jump up and down [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61645-8;Are you able to climb up five steps;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to climb up five steps [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61646-6;Are you able to wash dishes, pots, and utensils by hand while standing at a sink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to wash dishes, pots, and utensils by hand while standing at a sink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61647-4;Are you able to make a bed, including spreading and tucking in bed sheets;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to make a bed, including spreading and tucking in bed sheets [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6164-8;Quercus virginiana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Virginia Live Oak IgE Ab [Units/volume] in Serum;Virg Live Oak IgE Qn;;ACTIVE;1.0d;2.73 +61648-2;Are you able to carry a shopping bag or briefcase;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a shopping bag or briefcase [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61649-0;Are you able to take a tub bath;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to take a tub bath [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61650-8;Are you able to change the bulb in a table lamp;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to change the bulb in a table lamp [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61651-6;Are you able to press with your index finger (for example ringing a doorbell);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to press with your index finger (for example ringing a doorbell) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61652-4;Are you able to put on and take off your socks;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to put on and take off your socks [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61653-2;Are you able to shave your face or apply makeup;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to shave your face or apply makeup [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61654-0;Are you able to squeeze a new tube of toothpaste;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to squeeze a new tube of toothpaste [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6165-5;Homarus gammarus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lobster IgE Ab [Units/volume] in Serum;Lobster IgE Qn;;ACTIVE;1.0d;2.73 +61655-7;Are you able to cut a piece of paper with scissors;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to cut a piece of paper with scissors [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61656-5;Are you able to pick up coins from a table top;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pick up coins from a table top [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61657-3;Are you able to hold a plate full of food;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to hold a plate full of food [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61658-1;Are you able to pour liquid from a bottle into a glass;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pour liquid from a bottle into a glass [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61659-9;Are you able to run a short distance, such as to catch a bus;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run a short distance, such as to catch a bus [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61660-7;Are you able to push open a door after turning the knob;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to push open a door after turning the knob [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61661-5;Are you able to shampoo your hair;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to shampoo your hair [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61662-3;Are you able to tie a knot or a bow;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to tie a knot or a bow [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6166-3;Malt Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Malt IgE Ab [Units/volume] in Serum;Malt IgE Qn;;ACTIVE;1.0d;2.73 +61663-1;Are you able to lift 10 pounds above your shoulder;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift 10 pounds above your shoulder [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61664-9;Are you able to lift a full cup or glass to your mouth;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift a full cup or glass to your mouth [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61665-6;Are you able to open a new milk carton;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to open a new milk carton [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61666-4;Are you able to open car doors;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to open car doors [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61667-2;Are you able to stand unsupported for 10 minutes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand unsupported for 10 minutes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61668-0;Are you able to remove something from your back pocket;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to remove something from your back pocket [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61669-8;Are you able to change a light bulb overhead;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to change a light bulb overhead [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61670-6;Are you able to put on a pullover sweater;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to put on a pullover sweater [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6167-1;Mangifera indica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mango IgE Ab [Units/volume] in Serum;Mango IgE Qn;;ACTIVE;1.0d;2.73 +61671-4;Are you able to turn faucets on and off;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to turn faucets on and off [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61672-2;Are you able to reach and get down a 5 pound object from above your head;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to reach and get down a 5 pound object from above your head [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61673-0;Are you able to stand up on tiptoes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand up on tiptoes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61674-8;Are you able to trim your fingernails;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to trim your fingernails [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61675-5;Are you able to stand unsupported for 30 minutes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand unsupported for 30 minutes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61676-3;Does your health now limit you in taking care of your personal needs (dress, comb hair, toilet, eat, bathe);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in taking care of your personal needs (dress, comb hair, toilet, eat, bathe) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61677-1;Does your health now limit you in doing moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61678-9;Does your health now limit you in taking a shower;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in taking a shower [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61679-7;Does your health now limit you in going for a short walk (less than 15 minutes);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in going for a short walk (less than 15 minutes) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61680-5;How much difficulty do you have doing your daily physical activities, because of your health;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you have doing your daily physical activities, because of your health [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61681-3;Does your health now limit you in participating in active sports such as swimming, tennis, or basketball;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in participating in active sports such as swimming, tennis, or basketball [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61682-1;Does your health now limit you in going outside the home, for example to shop or visit a doctor's office;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in going outside the home, for example to shop or visit a doctor's office [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61683-9;Are you able to lift one pound (a full pint container) to shoulder level without bending your elbow;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift one pound (a full pint container) to shoulder level without bending your elbow [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61684-7;Physical Function - Pediatric Protocol;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;Deprecated Deprecated Physical Function - Pediatric Protocol PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.70 +61685-4;Are you able to walk a block on flat ground;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk a block on flat ground [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61686-2;Are you able to run five miles;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run five miles [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61687-0;Does your health now limit you in climbing several flights of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in climbing several flights of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +61688-8;Does your health now limit you in doing 2H of physical labor;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing two hours of physical labor [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +6168-9;Maple Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Maple IgE Ab [Units/volume] in Serum;Maple IgE Qn;;ACTIVE;1.0d;2.73 +61689-6;Are you able to run 100 yards;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run 100 yards [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61690-4;Does your health now limit you in walking one hundred yards;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in walking one hundred yards [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +61691-2;Are you able to walk up and down two steps;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk up and down two steps [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61692-0;Are you able to reach into a low cupboard;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to reach into a low cupboard [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61693-8;Are you able to climb up 5 flights of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to climb up 5 flights of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61694-6;Are you able to run ten miles;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run ten miles [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61695-3;Does your health now limit you in walking several hundred yards;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in walking several hundred yards [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +61696-1;Does your health now limit you in doing 8H of physical labor;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing eight hours of physical labor [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +6169-7;Festuca elatior Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Meadow Fescue IgE Ab [Units/volume] in Serum;Meadow Fescue IgE Qn;;ACTIVE;1.0d;2.73 +61697-9;Does your health now limit you in walking more than a mile;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in walking more than a mile [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +61698-7;Does your health now limit you in climbing one flight of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in climbing one flight of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +61699-5;Are you able to walk at a normal speed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk at a normal speed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61700-1;Are you able to stand without losing your balance for several minutes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand without losing your balance for several minutes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61701-9;Are you able to kneel on the floor;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to kneel on the floor [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61702-7;Are you able to sit down in and stand up from a low, soft couch;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to sit down in and stand up from a low, soft couch [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61703-5;Are you able to use your hands, such as for turning faucets, using kitchen gadgets, or sewing;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to use your hands, such as for turning faucets, using kitchen gadgets, or sewing [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61704-3;Are you able to get on and off the toilet;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get on and off the toilet [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6170-5;Alopercurus pratensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Meadow Foxtail IgE Ab [Units/volume] in Serum;Meadow Foxtail IgE Qn;;ACTIVE;1.0d;2.73 +61705-0;Are you able to transfer from a bed to a chair and back;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to transfer from a bed to a chair and back [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61706-8;Are you able to be out of bed most of the day;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to be out of bed most of the day [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61707-6;Are you able to water a house plant;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to water a house plant [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61708-4;Are you able to wipe yourself after using the toilet;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to wipe yourself after using the toilet [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61709-2;Are you able to turn from side to side in bed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to turn from side to side in bed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +617-1;Bacteria identified;Prid;Pt;Placenta;Nom;Aerobic culture;MICRO;1;Bacteria identified in Placenta by Aerobe culture;Bacteria Placenta Aerobe Cult;;ACTIVE;1.0;2.73 +61710-0;Are you able to get in and out of bed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get in and out of bed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61711-8;Does your health now limit you in getting in and out of the bathtub;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in getting in and out of the bathtub [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +61712-6;Does your health now limit you in walking about the house;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in walking about the house [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.66 +6171-3;Melaleuca leucadendron Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cajeput tree IgE Ab [Units/volume] in Serum;Cajeput tree IgE Qn;;ACTIVE;1.0d;2.73 +61713-4;Pain Protocols;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;Deprecated Deprecated Pain Protocols PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.70 +61714-2;When I was in pain I became irritable in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I became irritable in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61715-9;When I was in pain I grimaced in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I grimaced in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61716-7;When I was in pain I would lie down in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I would lie down in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61717-5;When I was in pain I moved extremely slowly in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I moved extremely slowly in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61718-3;When I was in pain I became angry in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I became angry in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61719-1;When I was in pain I clenched my teeth in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I clenched my teeth in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61720-9;When I was in pain I tried to stay very still in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I tried to stay very still in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6172-1;Cucumis melo spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Melon IgE Ab [Units/volume] in Serum;Deprecated Melon IgE Qn;;DEPRECATED;1.0d;2.70 +61721-7;When I was in pain I appeared upset or sad in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I appeared upset or sad in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61722-5;When I was in pain I gasped in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I gasped in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61723-3;When I was in pain I asked for help doing things that needed to be done in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked for help doing things that needed to be done in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61724-1;When I was in pain it showed on my face (squinching eyes, opening eyes wide, frowning) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain it showed on my face (squinching eyes, opening eyes wide, frowning) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61725-8;Pain caused me to bend over while walking in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Pain caused me to bend over while walking in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61726-6;When I was in pain I asked one or more people to leave me alone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked one or more people to leave me alone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61727-4;When I was in pain I moved stiffly in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I moved stiffly in the past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.67 +61728-2;When I was in pain I called out for someone to help me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I called out for someone to help me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61729-0;Pain caused me to curl up in a ball in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Pain caused me to curl up in a ball in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61730-8;I had pain so bad it made me cry in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had pain so bad it made me cry in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61731-6;When I was in pain I squirmed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I squirmed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61732-4;When I was in pain I used a cane or something else for support in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I used a cane or something else for support in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61733-2;I limped because of pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I limped because of pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61734-0;When I was in pain I became quiet and withdrawn in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I became quiet and withdrawn in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61735-7;When I was in pain I frowned in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I frowned in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61736-5;When I was in pain I asked for help when walking or changing positions in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked for help when walking or changing positions in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61737-3;When I was in pain I groaned in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I groaned in the past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.67 +61738-1;When I was in pain I isolated myself from others in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I isolated myself from others in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6173-9;Prosopis juliflora Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mesquite IgE Ab [Units/volume] in Serum;Mesquite IgE Qn;;ACTIVE;1.0d;2.73 +61739-9;When I was in pain I drew my knees up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I drew my knees up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61740-7;When I was in pain I moaned, whined or whimpered in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I moaned, whined or whimpered in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61741-5;When I was in pain I flung my arms or limbs around in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I flung my arms or limbs around in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61742-3;When I was in pain I screamed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I screamed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61743-1;When I was in pain my upper body would tense up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain my upper body would tense up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61744-9;When I was in pain I walked carefully in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I walked carefully in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61745-6;When I was in pain I bit or pursed my lips in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I bit or pursed my lips in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61746-4;When I was in pain I thrashed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I thrashed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6174-7;Milk Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Milk IgE Ab [Units/volume] in Serum;Milk IgE Qn;;ACTIVE;1.0d;2.73 +61747-2;When I was in pain I protected the part of my body that hurt in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I protected the part of my body that hurt in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61748-0;When I was in pain my body became stiff in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain my body became stiff in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61749-8;When I was in pain I clenched my jaw or gritted my teeth in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I clenched my jaw or gritted my teeth in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61750-6;When I was in pain I winced in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I winced in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61751-4;When I was in pain I moved my limbs protectively in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I moved my limbs protectively in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61752-2;When I was in pain I avoided physical contact with others in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I avoided physical contact with others in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61753-0;PROMIS item bank - pain interference - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - pain interference - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +6175-4;Panicum milliaceum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common Millet IgE Ab [Units/volume] in Serum;Common Millet IgE Qn;;ACTIVE;1.0d;2.73 +61754-8;How difficult was it for you to take in new information because of pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How difficult was it for you to take in new information because of pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61755-5;How much did pain interfere with your ability to participate in leisure activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to participate in leisure activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61756-3;How much did pain interfere with your close personal relationships in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your close personal relationships in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61757-1;How much did pain interfere with your ability to concentrate in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to concentrate in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61758-9;How much did pain interfere with your day to day activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your day to day activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61759-7;How much did pain interfere with your enjoyment of recreational activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your enjoyment of recreational activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61760-5;How often did you feel emotionally tense because of your pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you feel emotionally tense because of your pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61761-3;How much did pain interfere with the things you usually do for fun in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with the things you usually do for fun in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6176-2;Mimosa spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mimosa IgE Ab [Units/volume] in Serum;Mimosa IgE Qn;;ACTIVE;1.0d;2.70 +61762-1;How much did pain interfere with your family life in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your family life in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61763-9;How much did pain interfere with doing your tasks away from home (e.g., getting groceries, running errands) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with doing your tasks away from home (e.g., getting groceries, running errands) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61764-7;How often did pain make you feel depressed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain make you feel depressed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61765-4;How much did pain interfere with your relationships with other people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your relationships with other people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61766-2;How much did pain interfere with your ability to work (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to work (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61767-0;How much did pain make it difficult to fall asleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain make it difficult to fall asleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61768-8;How much did pain feel like a burden to you in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain feel like a burden to you in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61769-6;How much did pain interfere with work around the home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with work around the home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6177-0;Aedes communis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aedes mosquito IgE Ab [Units/volume] in Serum;Aedes mosquito IgE Qn;;ACTIVE;1.0d;2.73 +61770-4;How often was pain distressing to you in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often was pain distressing to you in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61771-2;How often did pain keep you from socializing with others in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain keep you from socializing with others in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61772-0;How often was your pain so severe you could think of nothing else in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often was your pain so severe you could think of nothing else in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61773-8;How much did pain interfere with your ability to participate in social activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to participate in social activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61774-6;How often did pain make you feel discouraged in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain make you feel discouraged in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61775-3;How much did pain interfere with your household chores in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your household chores in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61776-1;How much did pain interfere with your ability to make trips from home that kept you gone for more than 2H in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to make trips from home that kept you gone for more than 2 hours in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61777-9;How much did pain interfere with your enjoyment of social activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your enjoyment of social activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61778-7;How often did pain make you feel anxious in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain make you feel anxious in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61779-5;How often did you avoid social activities because it might make you hurt more in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you avoid social activities because it might make you hurt more in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61780-3;How often did pain make simple tasks hard to complete in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain make simple tasks hard to complete in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61781-1;How often did pain prevent you from walking more than 1 mile in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain prevent you from walking more than 1 mile in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61782-9;How often did pain prevent you from standing for more than one hour in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain prevent you from standing for more than one hour in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61783-7;How often did pain make it difficult for you to plan social activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain make it difficult for you to plan social activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61784-5;How often did pain prevent you from standing for more than 30 minutes in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain prevent you from standing for more than 30 minutes in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61785-2;How much did pain interfere with your ability to do household chores in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to do household chores in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61786-0;How much did pain interfere with your ability to remember things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to remember things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61787-8;How often did pain prevent you from sitting for more than 30 minutes in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain prevent you from sitting for more than 30 minutes in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6178-8;Juniperus sabinoides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mountain Juniper IgE Ab [Units/volume] in Serum;Mt Juniper IgE Qn;;ACTIVE;1.0d;2.73 +61788-6;How often did pain prevent you from sitting for more than 10 minutes in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain prevent you from sitting for more than 10 minutes in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61789-4;How often was it hard to plan social activities because you didn't know if you would be in pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often was it hard to plan social activities because you didn't know if you would be in pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61790-2;How often did pain restrict your social life to your home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain restrict your social life to your home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61791-0;How often did pain keep you from getting into a standing position in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain keep you from getting into a standing position in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61792-8;How often did pain prevent you from sitting for more than one hour in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain prevent you from sitting for more than one hour in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61793-6;How irritable did you feel because of pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How irritable did you feel because of pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61794-4;How much did pain interfere with your enjoyment of life in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your enjoyment of life in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61795-1;PROMIS item bank - fatigue - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - fatigue - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +6179-6;Mouse epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse epithelium IgE Ab [Units/volume] in Serum;Mouse Epith IgE Qn;;ACTIVE;1.0d;2.73 +61796-9;To what degree did you have to push yourself to get things done because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did you have to push yourself to get things done because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61797-7;To what degree did your fatigue make you feel slowed down in your thinking in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue make you feel slowed down in your thinking in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61798-5;How often did you have to push yourself to get things done because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have to push yourself to get things done because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61799-3;How often did your fatigue interfere with your social activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue interfere with your social activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61800-9;How often are you less effective at work due to your fatigue (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often are you less effective at work due to your fatigue (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61801-7;How often did your fatigue make you feel slowed down in your thinking in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make you feel slowed down in your thinking in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61802-5;How often were you too tired to watch television in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to watch television in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61803-3;How often did your fatigue make it difficult to plan activities ahead of time in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make it difficult to plan activities ahead of time in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6180-4;Mouse serum proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse serum proteins IgE Ab [Units/volume] in Serum;Mouse Serum Prot IgE Qn;;ACTIVE;1.0d;2.73 +61804-1;How often did your fatigue make it difficult to start anything new in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make it difficult to start anything new in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61805-8;How often did your fatigue make you more forgetful in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make you more forgetful in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61806-6;How often were you too tired to do errands in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to do errands in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61807-4;How often did your fatigue make it difficult to organize your thoughts when doing things at work (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make it difficult to organize your thoughts when doing things at work (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.73 +61808-2;How often did your fatigue interfere with your ability to engage in recreational activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue interfere with your ability to engage in recreational activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61809-0;How often did you have trouble finishing things because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have trouble finishing things because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61810-8;How often did your fatigue make it difficult to make decisions in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make it difficult to make decisions in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61811-6;How often did you have to limit your social activities because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have to limit your social activities because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6181-2;Mouse urine proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse urine proteins IgE Ab [Units/volume] in Serum;Mouse Urine Prot IgE Qn;;ACTIVE;1.0d;2.73 +61812-4;How often were you too tired to do your household chores in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to do your household chores in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61813-2;How often did your fatigue make you feel less alert in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make you feel less alert in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61814-0;How often were you too tired to take a bath or shower in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to take a bath or shower in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61815-7;How often did your fatigue make it difficult to organize your thoughts when doing things at home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue make it difficult to organize your thoughts when doing things at home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61816-5;How often did you have trouble starting things because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have trouble starting things because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61817-3;How often was it an effort to carry on a conversation because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often was it an effort to carry on a conversation because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61818-1;How often were you too tired to socialize with your family in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to socialize with your family in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61819-9;To what degree did you have trouble starting things because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did you have trouble starting things because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6182-0;Mucor racemosus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mucor racemosus IgE Ab [Units/volume] in Serum;M racemosus IgE Qn;;ACTIVE;1.0d;2.73 +61820-7;How hard was it for you to carry on a conversation because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How hard was it for you to carry on a conversation because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61821-5;How often were you too tired to leave the house in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to leave the house in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61822-3;How often were you too tired to think clearly in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to think clearly in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61823-1;How often did your fatigue limit you at work (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did your fatigue limit you at work (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61824-9;To what degree did you have to limit your social activities because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did you have to limit your social activities because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61825-6;To what degree did your fatigue make it difficult to organize your thoughts when doing things at home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue make it difficult to organize your thoughts when doing things at home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61826-4;To what degree did your fatigue make it difficult to start anything new in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue make it difficult to start anything new in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61827-2;Due to your fatigue were you less effective at work (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Due to your fatigue were you less effective at work (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61828-0;To what degree did your fatigue make it difficult to make decisions in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue make it difficult to make decisions in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61829-8;How often did you have enough energy to exercise strenuously in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have enough energy to exercise strenuously in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61830-6;How often were you less effective at home due to your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you less effective at home due to your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61831-4;To what degree did your fatigue make it difficult to organize your thoughts when doing things at work (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue make it difficult to organize your thoughts when doing things at work (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61832-2;To what degree did your fatigue make you more forgetful in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue make you more forgetful in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61833-0;To what degree did your fatigue interfere with your ability to engage in recreational activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue interfere with your ability to engage in recreational activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61834-8;To what degree did you have to force yourself to get up and do things because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did you have to force yourself to get up and do things because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61835-5;To what degree did your fatigue interfere with your social activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue interfere with your social activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61836-3;To what degree did your fatigue interfere with your physical functioning in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue interfere with your physical functioning in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61837-1;Did fatigue make you less effective at home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Did fatigue make you less effective at home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6183-8;Artemisia vulgaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mugwort IgE Ab [Units/volume] in Serum;Mugwort IgE Qn;;ACTIVE;1.0d;2.73 +61838-9;To what degree did you have trouble finishing things because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did you have trouble finishing things because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61839-7;To what degree did your fatigue make you feel less alert in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did your fatigue make you feel less alert in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61840-5;How often were you too tired to take a short walk in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to take a short walk in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61841-3;How often did you have to force yourself to get up and do things because of your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have to force yourself to get up and do things because of your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61842-1;How often were you too tired to socialize with your friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to socialize with your friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61843-9;How often did you feel run-down in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you feel run-down in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61844-7;How often did you experience extreme exhaustion in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you experience extreme exhaustion in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61845-4;How often did you feel tired even when you hadn't done anything in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you feel tired even when you hadn't done anything in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6184-6;Mussel Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Blue mussel IgE Ab [Units/volume] in Serum;Deprecated Mussel IgE Qn;;DEPRECATED;1.0d;2.70 +61846-2;How often did you feel your fatigue was beyond your control in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you feel your fatigue was beyond your control in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61847-0;To what degree did you feel tired even when you hadn't done anything in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;To what degree did you feel tired even when you hadn't done anything in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61848-8;How bushed were you on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How bushed were you on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61849-6;How often were you sluggish in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you sluggish in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61850-4;How often did you run out of energy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you run out of energy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61851-2;How often were you physically drained in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you physically drained in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61852-0;How often did you feel tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you feel tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6185-3;Mustard Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mustard IgE Ab [Units/volume] in Serum;Mustard IgE Qn;;ACTIVE;1.0d;2.73 +61853-8;How fatigued were you when your fatigue was at its worst in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How fatigued were you when your fatigue was at its worst in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61854-6;How often were you bothered by your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you bothered by your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61855-3;How often did you have enough energy to enjoy the things you do for fun in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have enough energy to enjoy the things you do for fun in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61856-1;How often were you too tired to enjoy life in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to enjoy life in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61857-9;How often were you too tired to feel happy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you too tired to feel happy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61858-7;How often did you feel totally drained in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you feel totally drained in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61859-5;How often were you energetic in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often were you energetic in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61860-3;How tired did you feel on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How tired did you feel on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6186-1;Urtica dioica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nettle IgE Ab [Units/volume] in Serum;Nettle IgE Qn;;ACTIVE;1.0d;2.73 +61861-1;How much were you bothered by your fatigue on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much were you bothered by your fatigue on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61862-9;How exhausted were you on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How exhausted were you on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61863-7;How fatigued were you on the day you felt most fatigued in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How fatigued were you on the day you felt most fatigued in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61864-5;How fatigued were you on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How fatigued were you on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61865-2;How run-down did you feel on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How run-down did you feel on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61866-0;How much mental energy did you have on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much mental energy did you have on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61867-8;How physically drained were you on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How physically drained were you on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61868-6;How energetic were you on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How energetic were you on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61869-4;How sluggish were you on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How sluggish were you on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61870-2;On how many D was your fatigue worse in the morning in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;On how many days was your fatigue worse in the morning in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61871-0;How often did you find yourself getting tired easily in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you find yourself getting tired easily in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61872-8;How often did you think about your fatigue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you think about your fatigue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61873-6;How fatigued were you on the day you felt least fatigued in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How fatigued were you on the day you felt least fatigued in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61874-4;How easily did you find yourself getting tired on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How easily did you find yourself getting tired on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61875-1;How wiped out were you on average in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How wiped out were you on average in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61876-9;How often did you have physical energy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did you have physical energy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61877-7;What was the level of your fatigue on most D in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;What was the level of your fatigue on most days in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61878-5;I feel fatigued during the past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel fatigued during the past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6187-9;Neurospora sitophila Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Neurospora sitophila IgE Ab [Units/volume] in Serum;N sitophila IgE Qn;;ACTIVE;1.0d;2.73 +61879-3;I felt weak all over in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt weak all over in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61880-1;I felt listless (washed out) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt listless (washed out) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61881-9;I felt tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61882-7;I had trouble starting things because I was tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble starting things because I was tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61883-5;I had trouble finishing things because I was tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble finishing things because I was tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61884-3;I needed to sleep during the day in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I needed to sleep during the day in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61885-0;I was too tired to eat in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to eat in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61886-8;I needed help doing my usual activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I needed help doing my usual activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6188-7;Nutmeg Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nutmeg IgE Ab [Units/volume] in Serum;Nutmeg IgE Qn;;ACTIVE;1.0d;2.73 +61887-6;I was frustrated by being too tired to do the things I want to do in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was frustrated by being too tired to do the things I want to do in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61888-4;I had to limit my social activity because I was tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had to limit my social activity because I was tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61889-2;I had energy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had energy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +618-9;Bacteria identified;Prid;Pt;Plr fld;Nom;Culture;MICRO;1;Bacteria identified in Pleural fluid by Culture;Bacteria Plr Cult;;ACTIVE;1.0;2.73 +61890-0;I am able to do my usual activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am able to do my usual activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.54 +61891-8;Emotional Distress Protocols;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;Deprecated Deprecated Emotional Distress Protocols PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.70 +61892-6;PROMIS item bank - emotional distress - anger - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - emotional distress - anger - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +61893-4;When I was frustrated, I let it show in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was frustrated, I let it show in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61894-2;I was irritated more than people knew in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was irritated more than people knew in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6189-5;Quercus alba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Oak IgE Ab [Units/volume] in Serum;White Oak IgE Qn;;ACTIVE;1.0d;2.73 +61895-9;I felt envious of others in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt envious of others in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61896-7;I disagreed with people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I disagreed with people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61897-5;I made myself angry about something just by thinking about it in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I made myself angry about something just by thinking about it in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61898-3;I tried to get even when I was angry with someone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I tried to get even when I was angry with someone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61899-1;I felt angry in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt angry in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61900-7;When I was mad at someone, I gave them the silent treatment in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was mad at someone, I gave them the silent treatment in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61901-5;I felt like breaking things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like breaking things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61902-3;I felt like I was ready to explode in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like I was ready to explode in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6190-3;Avena sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oat IgE Ab [Units/volume] in Serum;Oat IgE Qn;;ACTIVE;1.0d;2.73 +61903-1;When I was angry, I sulked in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was angry, I sulked in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61904-9;I felt resentful when I didn't get my way in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt resentful when I didn't get my way in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61905-6;I felt guilty about my anger in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt guilty about my anger in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61906-4;I felt bitter about things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt bitter about things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61907-2;I felt people are trying to anger me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt people are trying to anger me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61908-0;I stayed angry for hours in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I stayed angry for hours in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61909-8;I held grudges towards others in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I held grudges towards others in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61910-6;I felt angrier than I thought I should in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt angrier than I thought I should in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6191-1;Avena sativa cultivated Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Oat pollen IgE Ab [Units/volume] in Serum;Deprecated Oat Poln IgE Qn;;DEPRECATED;1.0d;2.70 +61911-4;I was grouchy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was grouchy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61912-2;I was stubborn with others in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was stubborn with others in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61913-0;I felt annoyed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt annoyed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61914-8;I had a bad temper in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a bad temper in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61915-5;I had trouble controlling my temper in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble controlling my temper in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61916-3;I was angry when I was delayed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was angry when I was delayed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61917-1;Even when I expressed my anger, I had trouble forgetting about it in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Even when I expressed my anger, I had trouble forgetting about it in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61918-9;I felt like I needed help for my anger in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like I needed help for my anger in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61919-7;I was angry when something blocked my plans in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was angry when something blocked my plans in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61920-5;I felt like yelling at someone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like yelling at someone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61921-3;Just being around people irritated me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Just being around people irritated me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61922-1;PROMIS item bank - emotional distress - anxiety - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - emotional distress - anxiety - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +61923-9;I felt fearful in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt fearful in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61924-7;I felt frightened in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt frightened in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61925-4;It scared me when I felt nervous in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It scared me when I felt nervous in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61926-2;I felt anxious in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt anxious in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61927-0;I felt like I needed help for my anxiety in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like I needed help for my anxiety in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61928-8;I was concerned about my mental health in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was concerned about my mental health in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6192-9;Olea europaea pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive Pollen IgE Ab [Units/volume] in Serum;Olive Poln IgE Qn;;ACTIVE;1.0d;2.73 +61929-6;I felt upset in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt upset in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61930-4;I had a racing or pounding heart in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a racing or pounding heart in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61931-2;I was anxious if my normal routine was disturbed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was anxious if my normal routine was disturbed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61932-0;I had sudden feelings of panic in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had sudden feelings of panic in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61933-8;Easily startled in past 7D;Find;7D;^Patient;Ord;;SURVEY.GNHLTH;4;Easily startled in past 7 days;;;ACTIVE;2.34;2.73 +61934-6;I had trouble paying attention in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble paying attention in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61935-3;I avoided public places or activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I avoided public places or activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61936-1;I felt fidgety in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt fidgety in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6193-7;Allium cepa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Onion IgE Ab [Units/volume] in Serum;Onion IgE Qn;;ACTIVE;1.0d;2.73 +61937-9;I felt something awful would happen in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt something awful would happen in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61938-7;I felt worried in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt worried in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61939-5;I felt terrified in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt terrified in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61940-3;I worried about other people's reactions to me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried about other people's reactions to me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61941-1;I found it hard to focus on anything other than my anxiety in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I found it hard to focus on anything other than my anxiety in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61942-9;My worries overwhelmed me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My worries overwhelmed me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61943-7;I had twitching or trembling muscles in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had twitching or trembling muscles in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61944-5;I felt nervous in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt nervous in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6194-5;Citrus sinensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Orange IgE Ab [Units/volume] in Serum;Orange IgE Qn;;ACTIVE;1.0d;2.73 +61945-2;I felt indecisive in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt indecisive in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61946-0;Many situations made me worry in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Many situations made me worry in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61947-8;I had difficulty sleeping in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had difficulty sleeping in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61948-6;I had trouble relaxing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble relaxing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61949-4;I felt uneasy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt uneasy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61950-2;I felt tense in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt tense in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61951-0;I had difficulty calming down in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had difficulty calming down in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6195-2;Dactylis glomerata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cocksfoot IgE Ab [Units/volume] in Serum;Cocksfoot IgE Qn;;ACTIVE;1.0d;2.73 +61952-8;PROMIS item bank - emotional distress - depression - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - emotional distress - depression - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +61953-6;I felt worthless in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt worthless in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61954-4;I felt that I had nothing to look forward to in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that I had nothing to look forward to in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61955-1;I felt helpless in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt helpless in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61956-9;I withdrew from other people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I withdrew from other people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61957-7;I felt that nothing could cheer me up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that nothing could cheer me up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61958-5;I felt that I was not as good as other people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that I was not as good as other people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61959-3;I felt sad in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt sad in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6196-0;Chrysanthemum leucanthemum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ox-eye daisy IgE Ab [Units/volume] in Serum;Ox-eye daisy IgE Qn;;ACTIVE;1.0d;2.73 +61960-1;I felt that I wanted to give up on everything in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that I wanted to give up on everything in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61961-9;I felt that I was to blame for things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that I was to blame for things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61962-7;I felt like a failure in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like a failure in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61963-5;I had trouble feeling close to people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble feeling close to people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61964-3;I felt disappointed in myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt disappointed in myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61965-0;I felt that I was not needed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that I was not needed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61966-8;I felt lonely in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt lonely in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61967-6;I felt depressed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt depressed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61968-4;I had trouble making decisions in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble making decisions in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61969-2;I felt discouraged about the future in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt discouraged about the future in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +619-7;Bacteria identified;Prid;Pt;Periton fld;Nom;Culture;MICRO;1;Bacteria identified in Peritoneal fluid by Culture;Bacteria Prt Cult;;ACTIVE;1.0;2.73 +61970-0;I found that things in my life were overwhelming in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I found that things in my life were overwhelming in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61971-8;I felt unhappy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt unhappy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61972-6;I felt I had no reason for living in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt I had no reason for living in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61973-4;I felt hopeless in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt hopeless in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61974-2;I felt ignored by people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt ignored by people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61975-9;I felt upset for no reason in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt upset for no reason in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61976-7;I felt that nothing was interesting in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that nothing was interesting in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61977-5;I felt pessimistic in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt pessimistic in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6197-8;Paecilomyces sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paecilomyces sp IgE Ab [Units/volume] in Serum;Paecilomyces IgE Qn;;ACTIVE;1.0d;2.73 +61978-3;I felt that my life was empty in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that my life was empty in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61979-1;I felt guilty in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt guilty in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61980-9;I felt emotionally exhausted in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt emotionally exhausted in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61981-7;Sleep Protocols;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;Deprecated Deprecated Sleep Protocols PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.70 +61982-5;PROMIS item bank - sleep disturbance - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - sleep disturbance - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +61983-3;My sleep was restful in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My sleep was restful in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61984-1;My sleep was deep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My sleep was deep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61985-8;I was satisfied with my sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6198-6;Polistes spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp IgE Ab [Units/volume] in Serum;Paper Wasp IgE Qn;;ACTIVE;1.0d;2.73 +61986-6;My sleep was refreshing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My sleep was refreshing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61987-4;My sleep quality was...in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My sleep quality was...in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61988-2;I got enough sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I got enough sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61989-0;It was easy for me to fall asleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was easy for me to fall asleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61990-8;I laid in bed for hours waiting to fall asleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I laid in bed for hours waiting to fall asleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61991-6;I woke up too early and could not fall back asleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I woke up too early and could not fall back asleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61992-4;Trouble staying asleep in past 7D;Find;7D;^Patient;Ord;;H&P.HX;2;Trouble staying asleep in past 7 days;Trouble staying asleep past 7D;;ACTIVE;2.34;2.73 +61993-2;I had trouble sleeping in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble sleeping in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6199-4;Parietaria judaica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pellitory (Parietaria judaica) IgE Ab [Units/volume] in Serum;Pellitory (judaic) IgE Qn;;ACTIVE;1.0d;2.70 +61994-0;I woke up and had trouble falling back to sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I woke up and had trouble falling back to sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61995-7;My sleep was light in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My sleep was light in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61996-5;My sleep was restless in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My sleep was restless in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61997-3;I felt lousy when I woke up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt lousy when I woke up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61998-1;I had a problem with my sleep 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a problem with my sleep 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +61999-9;I had difficulty falling asleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had difficulty falling asleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62-0;Carbenicillin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Carbenicillin [Susceptibility] by Serum bactericidal titer;Carbenicillin Titr SBT;;ACTIVE;1.0;2.32 +6200-0;Parietaria officinalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pellitory (Parietaria officinalis) IgE Ab [Units/volume] in Serum;Pellitory (offic) IgE Qn;;ACTIVE;1.0d;2.73 +62000-5;I felt physically tense at bedtime in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt physically tense at bedtime in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62001-3;I worried about not being able to fall asleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried about not being able to fall asleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62002-1;I felt worried at bedtime in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt worried at bedtime in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62003-9;I had trouble stopping my thoughts at bedtime in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble stopping my thoughts at bedtime in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62004-7;I felt sad at bedtime in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt sad at bedtime in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62005-4;I had trouble getting into a comfortable position to sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble getting into a comfortable position to sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62006-2;I tried hard to get to sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I tried hard to get to sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62007-0;Stress disturbed my sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Stress disturbed my sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62008-8;I tossed and turned at night in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I tossed and turned at night in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62009-6;I was afraid I would not get back to sleep after waking up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was afraid I would not get back to sleep after waking up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62010-4;PROMIS item bank - sleep related impairment - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - sleep related impairment - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +62011-2;I tried to sleep whenever I could in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I tried to sleep whenever I could in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62012-0;My daytime activities are disturbed by poor sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My daytime activities are disturbed by poor sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62013-8;I was sleepy during the daytime in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was sleepy during the daytime in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62014-6;I had trouble staying awake during the day in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble staying awake during the day in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62015-3;I had a hard time getting things done because I was sleepy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a hard time getting things done because I was sleepy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62016-1;I had a hard time concentrating because I was sleepy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a hard time concentrating because I was sleepy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62017-9;I had problems during the day because of poor sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had problems during the day because of poor sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6201-8;Parrot droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parrot droppings IgE Ab [Units/volume] in Serum;Parrot Drop IgE Qn;;ACTIVE;1.0d;2.70 +62018-7;I had a hard time concentrating because of poor sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a hard time concentrating because of poor sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62019-5;I felt irritable because of poor sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt irritable because of poor sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62020-3;I had a hard time controlling my emotions because of poor sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a hard time controlling my emotions because of poor sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62021-1;I had difficulty waking up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had difficulty waking up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62022-9;I still felt sleepy when I woke up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I still felt sleepy when I woke up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62023-7;I had enough energy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had enough energy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62024-5;I felt alert when I woke up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt alert when I woke up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62025-2;When I woke up I felt ready to start the day in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I woke up I felt ready to start the day in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6202-6;Parrot feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parrot feather IgE Ab [Units/volume] in Serum;Parrot Feather IgE Qn;;ACTIVE;1.0d;2.73 +62026-0;PROMIS item bank - satisfaction with participation in DSA - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - satisfaction with participation in DSA - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +62027-8;I was satisfied with the amount of time I spend doing leisure activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with the amount of time I spend doing leisure activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62028-6;I was satisfied with my current level of social activity in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my current level of social activity in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62029-4;I was satisfied with my ability to do all of the community activities that Are really important to me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do all of the community activities that are really important to me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62030-2;I was satisfied with my ability to do things for my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do things for my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62031-0;I was satisfied with my ability to do leisure activities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do leisure activities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62032-8;I was satisfied with my current level of activities with my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my current level of activities with my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62033-6;I was satisfied with my ability to do things for fun outside my home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do things for fun outside my home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6203-4;Petroselinum crispum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parsley IgE Ab [Units/volume] in Serum;Parsley IgE Qn;;ACTIVE;1.0d;2.73 +62034-4;I felt good about my ability to do things for my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt good about my ability to do things for my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62035-1;I was happy with how much I do for my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was happy with how much I do for my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62036-9;I was satisfied with the amount of time I spend visiting friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with the amount of time I spend visiting friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62037-7;I was satisfied with my ability to do things for fun at home (like reading, listening to music, etc.) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do things for fun at home (like reading, listening to music, etc.) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62038-5;I was satisfied with my ability to do all of the leisure activities that are really important to me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do all of the leisure activities that Are really important to me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62039-3;PROMIS item bank - satisfaction with participation in roles - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - satisfaction with participation in roles - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +62040-1;I was satisfied with my ability to do things for my family in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do things for my family in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62041-9;I was satisfied with how much work I can do (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with how much work I can do (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6204-2;Pisum sativum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pea IgE Ab [Units/volume] in Serum;Pea IgE Qn;;ACTIVE;1.0d;2.73 +62042-7;I feel good about my ability to do things for my family in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel good about my ability to do things for my family in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62043-5;I was satisfied with my ability to do the work that is really important to me (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do the work that is really important to me (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62044-3;I was satisfied with the amount of time I spend doing work (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with the amount of time I spend doing work (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62045-0;I was happy with how much I do for my family in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was happy with how much I do for my family in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62046-8;I was satisfied with my ability to work (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to work (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62047-6;The quality of my work is as good as I want it to be (include work at home) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;The quality of my work is as good as I want it to be (include work at home) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62048-4;I was satisfied with the amount of time I spend performing my daily routines in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with the amount of time I spend performing my daily routines in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62049-2;I was satisfied with my ability to do household chores and tasks in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do household chores and tasks in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +620-5;Bacteria identified;Prid;Pt;Skin;Nom;Aerobic culture;MICRO;1;Bacteria identified in Skin by Aerobe culture;Bacteria Skin Aerobe Cult;;ACTIVE;1.0;2.73 +62050-0;I was satisfied with my ability to do regular personal and household responsibilities in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to do regular personal and household responsibilities in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62051-8;I was satisfied with my ability to perform my daily routines in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to perform my daily routines in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62052-6;I was satisfied with my ability to meet the needs of those who depend on me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to meet the needs of those who depend on me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62053-4;I was satisfied with my ability to run errands in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was satisfied with my ability to run errands in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62054-2;PROMIS pediatric item bank - emotional distress - anxiety - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - emotional distress - anxiety - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62055-9;I felt like something awful might happen in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like something awful might happen in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62056-7;I got scared really easy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I got scared really easy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62057-5;I felt scared in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt scared in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62058-3;I worried about what could happen to me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried about what could happen to me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6205-9;Prunus persica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peach IgE Ab [Units/volume] in Serum;Peach IgE Qn;;ACTIVE;1.0d;2.73 +62059-1;I was worried I might die in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was worried I might die in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62060-9;I woke up at night scared in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I woke up at night scared in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62061-7;I worried when I went to bed at night in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried when I went to bed at night in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62062-5;I worried when I was away from home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried when I was away from home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62063-3;I worried when I was at home in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried when I was at home in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62064-1;I thought about scary things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I thought about scary things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62065-8;I was afraid that I would make mistakes in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was afraid that I would make mistakes in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62066-6;I was afraid of going to school in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was afraid of going to school in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6206-7;Arachis hypogaea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut IgE Ab [Units/volume] in Serum;Peanut IgE Qn;;ACTIVE;1.0d;2.73 +62067-4;It was hard for me to relax in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to relax in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62068-2;PROMIS pediatric item bank - asthma - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - asthma - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62069-0;I felt scared that I might have trouble breathing because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt scared that I might have trouble breathing because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62070-8;My chest felt tight because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My chest felt tight because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62071-6;I felt wheezy because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt wheezy because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62072-4;I had trouble sleeping at night because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble sleeping at night because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62073-2;It was hard for me to play sports or exercise because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to play sports or exercise because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62074-0;It was hard to take a deep breath because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard to take a deep breath because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6207-5;Pyrus communis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pear IgE Ab [Units/volume] in Serum;Pear IgE Qn;;ACTIVE;1.0d;2.73 +62075-7;My asthma bothered me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My asthma bothered me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62076-5;I coughed because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I coughed because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62077-3;I got tired easily because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I got tired easily because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62078-1;I had asthma attacks in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had asthma attacks in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62079-9;I had trouble walking because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble walking because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62080-7;I missed school because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I missed school because of asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62081-5;I was bothered by the amount of time I spent wheezing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was bothered by the amount of time I spent wheezing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62082-3;It was hard for me to play with pets because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to play with pets because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6208-3;Carya illinoinensis nut Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Nut IgE Ab [Units/volume] in Serum;Pecan/Hick Nut IgE Qn;;ACTIVE;1.0d;2.73 +62083-1;My asthma bothered me when I was with my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My asthma bothered me when I was with my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62084-9;My body felt bad when I was out of breath in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My body felt bad when I was out of breath in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62085-6;PROMIS pediatric short form - depressive symptoms - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - depressive symptoms - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62086-4;I felt too sad to eat in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt too sad to eat in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62087-2;I didn't care about anything in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I didn't care about anything in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62088-0;I wanted to be by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I wanted to be by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62089-8;I thought that my life was bad in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I thought that my life was bad in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62090-6;It was hard for me to have fun in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to have fun in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6209-1;Carya illinoinensis tree Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Tree IgE Ab [Units/volume] in Serum;Pecan/Hick Tree IgE Qn;;ACTIVE;1.0d;2.73 +62091-4;I felt alone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt alone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62092-2;I could not stop feeling sad in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could not stop feeling sad in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62093-0;I felt like I couldn't do anything right in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like I couldn't do anything right in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62094-8;I felt everything in my life went wrong in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt everything in my life went wrong in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62095-5;I felt stressed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt stressed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62096-3;Being sad made it hard for me to do things with my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Being sad made it hard for me to do things with my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62097-1;PROMIS pediatric item bank - fatigue - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - fatigue - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62098-9;Being tired kept me from having fun in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Being tired kept me from having fun in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62099-7;Being tired made it hard for me to keep up with my schoolwork in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Being tired made it hard for me to keep up with my schoolwork in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62100-3;Being tired made it hard for me to play or go out with my friends as much as I'd like in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Being tired made it hard for me to play or go out with my friends as much as I'd like in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62101-1;I felt more tired than usual when I woke up in the morning in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt more tired than usual when I woke up in the morning in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62102-9;I felt too tired to spend time with my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt too tired to spend time with my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62103-7;I felt weak in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt weak in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62104-5;I got tired easily in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I got tired easily in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62105-2;I had trouble finishing things because I was too tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble finishing things because I was too tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62106-0;I had trouble starting things because I was too tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble starting things because I was too tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62107-8;I was so tired it was hard for me to focus on my work in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was so tired it was hard for me to focus on my work in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62108-6;I was so tired it was hard for me to pay attention in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was so tired it was hard for me to pay attention in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6210-9;Penicillin V Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillin V IgE Ab [Units/volume] in Serum;Penicillin V IgE Qn;;ACTIVE;1.0d;2.73 +62109-4;I was too tired to do sports or exercise in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to do sports or exercise in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62110-2;I was too tired to do things outside in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to do things outside in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62111-0;I was too tired to enjoy the things I like to do in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to enjoy the things I like to do in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62112-8;I was too tired to go out with my family in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to go out with my family in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62113-6;I was too tired to go up and down a lot of stairs in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to go up and down a lot of stairs in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62114-4;I was too tired to read in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to read in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62115-1;I was too tired to take a bath or shower in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to take a bath or shower in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62116-9;I was too tired to watch television in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was too tired to watch television in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6211-7;Penicillium brevicompactum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium brevicompactum IgE Ab [Units/volume] in Serum;P brevicompactum IgE Qn;;ACTIVE;1.0d;2.73 +62117-7;PROMIS pediatric item bank - physical function - mobility - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - physical function - mobility - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62118-5;I could ride a bike in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could ride a bike in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62119-3;I could get in and out of a car in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could get in and out of a car in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62120-1;I could walk more than one block in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could walk more than one block in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62121-9;I could do sports and exercise that other kids my age could do in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could do sports and exercise that other kids my age could do in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62122-7;I could keep up when I played with other kids in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could keep up when I played with other kids in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62123-5;I could get out of bed by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could get out of bed by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62124-3;I could get into bed by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could get into bed by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6212-5;Penicillium notatum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium notatum IgE Ab [Units/volume] in Serum;P notatum IgE Qn;;ACTIVE;1.0d;2.73 +62125-0;I could stand up by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could stand up by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62126-8;I could get down on my knees without holding on to something in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could get down on my knees without holding on to something in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62127-6;I could walk up stairs without holding on to anything in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could walk up stairs without holding on to anything in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62128-4;I used a wheelchair to get around in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I used a wheelchair to get around in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62129-2;I used a walker, cane or crutches to get around in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I used a walker, cane or crutches to get around in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +621-3;Bacteria identified;Prid;Pt;Synv fld;Nom;Culture;MICRO;1;Bacteria identified in Synovial fluid by Culture;Bacteria Snv Cult;;ACTIVE;1.0;2.73 +62130-0;I could carry my books in my backpack in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could carry my books in my backpack in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62131-8;I could move my legs in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could move my legs in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62132-6;I could get up from a regular toilet in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could get up from a regular toilet in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6213-3;Schinus molle Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pepper tree IgE Ab [Units/volume] in Serum;Pepper tree IgE Qn;;ACTIVE;1.0d;2.73 +62133-4;I could get up from the floor in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could get up from the floor in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62134-2;I could go up one step in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could go up one step in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62135-9;I could stand up on my tiptoes in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could stand up on my tiptoes in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62136-7;I could turn my head all the way to the side in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could turn my head all the way to the side in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62137-5;I have been physically able to do the activities I enjoy most in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been physically able to do the activities I enjoy most in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62138-3;I could run a mile in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could run a mile in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62139-1;I could bend over to pick something up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could bend over to pick something up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62140-9;I could walk across the room in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could walk across the room in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6214-1;Perca spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Perch IgE Ab [Units/volume] in Serum;Perch IgE Qn;;ACTIVE;1.0d;2.73 +62141-7;PROMIS pediatric item bank - pain interference - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - pain interference - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62142-5;I felt angry when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt angry when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62143-3;I had trouble doing schoolwork when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble doing schoolwork when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62144-1;I had trouble sleeping when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble sleeping when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62145-8;I hurt a lot in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I hurt a lot in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62146-6;It was hard for me to remember things when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to remember things when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62147-4;I hurt all over my body in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I hurt all over my body in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62148-2;It was hard for me to run when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to run when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62149-0;It was hard for me to walk one block when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to walk one block when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62150-8;I missed school when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I missed school when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62151-6;It was hard to get along with other people when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard to get along with other people when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62152-4;It was hard to have fun when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard to have fun when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62153-2;It was hard to stay standing when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard to stay standing when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62154-0;It was hard for me to pay attention when I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to pay attention when I had pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62155-7;PROMIS pediatric item bank - peer relationships - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - peer relationships - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62156-5;I felt accepted by other kids my age in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt accepted by other kids my age in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62157-3;I felt good about my friendships in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt good about my friendships in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6215-8;Lolium perenne Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Perennial rye grass IgE Ab [Units/volume] in Serum;Deprecated Per rye grass IgE Qn;;DEPRECATED;1.0d;2.70 +62158-1;I liked being around other kids my age in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I liked being around other kids my age in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62159-9;I played alone and kept to myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I played alone and kept to myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62160-7;I shared with other kids (food, games, pens, etc) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I shared with other kids (food, games, pens, etc) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62161-5;I spent time with my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I spent time with my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62162-3;I was a good friend in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was a good friend in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62163-1;I was able to count on my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was able to count on my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62164-9;I was able to have fun with my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was able to have fun with my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62165-6;I was able to talk about everything with my friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was able to talk about everything with my friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6216-6;Phoma betae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phoma betae IgE Ab [Units/volume] in Serum;P betae IgE Qn;;ACTIVE;1.0d;2.73 +62166-4;I was good at making friends in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was good at making friends in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62167-2;My friends and I helped each other out in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My friends and I helped each other out in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62168-0;Other kids wanted to be my friend in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Other kids wanted to be my friend in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62169-8;Other kids wanted to be with me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Other kids wanted to be with me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62170-6;Other kids wanted to talk to me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Other kids wanted to talk to me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62171-4;PROMIS pediatric item bank - physical function - upper extremity - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - physical function - upper extremity - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62172-2;I could button my shirt or pants in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could button my shirt or pants in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62173-0;I could open a jar by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could open a jar by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6217-4;Pigeon droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon droppings IgE Ab [Units/volume] in Serum;Pigeon Drop IgE Qn;;ACTIVE;1.0d;2.73 +62174-8;I could open the rings in school binders in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could open the rings in school binders in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62175-5;I could pour a drink from a full pitcher in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could pour a drink from a full pitcher in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62176-3;I could pull a shirt on over my head by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could pull a shirt on over my head by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62177-1;I could pull open heavy doors in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could pull open heavy doors in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62178-9;I could put on my shoes by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could put on my shoes by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62179-7;I could use a key to unlock a door in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could use a key to unlock a door in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62180-5;PROMIS pediatric short form - emotional distress - anger - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - emotional distress - anger - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62181-3;I felt fed up in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt fed up in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6218-2;Ananas comosus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pineapple IgE Ab [Units/volume] in Serum;Pineapple IgE Qn;;ACTIVE;1.0d;2.73 +62182-1;I felt mad in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt mad in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62183-9;I was so angry I felt like throwing something in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was so angry I felt like throwing something in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62184-7;I was so angry I felt like yelling at somebody in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was so angry I felt like yelling at somebody in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62185-4;When I got mad, I stayed mad in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I got mad, I stayed mad in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62186-2;PROMIS pediatric short form - emotional distress - anxiety 8a - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - emotional distress - anxiety - 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62187-0;I felt scared n past 7D;Find;1W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Deprecated I felt scared n past 7 days PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.52 +62188-8;I was afraid that I would make mistakes in past 7D;Find;1W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Deprecated I was afraid that I would make mistakes in past 7 days PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.70 +62189-6;PROMIS short form - emotional distress - anger 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional distress - anger 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.54 +6219-0;Pork Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pork IgE Ab [Units/volume] in Serum;Pork IgE Qn;;ACTIVE;1.0d;2.73 +62190-4;PROMIS short form - emotional distress - anxiety 7a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional distress - anxiety 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.54 +62191-2;PROMIS short form - emotional distress - depression 8b - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional distress - depression 8b - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.54 +62192-0;PROMIS short form - fatigue 7a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - fatigue 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62193-8;PROMIS short form - pain interference 6b - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - pain interference 6b - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62194-6;PROMIS short form - pain behavior 7a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - pain behavior 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62195-3;PROMIS short form - satisfaction with participation in DSA 7a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in DSA 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62196-1;PROMIS short form - satisfaction with participation in social roles 7a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in social roles 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62197-9;PROMIS short form - sleep disturbance 8b - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - sleep disturbance 8b - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62198-7;PROMIS short form - sleep impairment 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - sleep impairment 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62199-5;PROMIS short form - physical function 10a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function 10a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62200-1;Short Forms;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;Deprecated Deprecated Short Forms PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.70 +62201-9;XXX microorganism DNA;Prid;Pt;Ser/Plas;Nom;Probe.amp.tar;MICRO;1;XXX microorganism DNA [Identifier] in Serum or Plasma by NAA with probe detection;Other microorg DNA SerPl NAA+probe;;ACTIVE;2.38;2.63 +62202-7;XXX microorganism DNA;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;XXX microorganism DNA [Identifier] in Isolate by NAA with probe detection;Other microorg DNA Islt NAA+probe;;ACTIVE;2.38;2.63 +62203-5;"t(10;11)(p12;q23)(MLLT10,MLL) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(10;11)(p12;q23)(MLLT10,MLL) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(10;11)(MLLT10,MLL) Bld/T Ql";;ACTIVE;2.34;2.52 +62204-3;It was hard for me to get out of bed in the morning because I was too tired in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was hard for me to get out of bed in the morning because I was too tired in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62205-0;I needed help with a bath in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I needed help with a bath in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62206-8;PROMIS pediatric short form - physical function - mobility 8a - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - physical function - mobility 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62207-6;PROMIS pediatric short form - physical function - upper extremity 8a - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - physical function - upper extremity 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +6220-8;Solanum tuberosum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Potato IgE Ab [Units/volume] in Serum;Potato IgE Qn;;ACTIVE;1.0d;2.73 +62208-4;PROMIS pediatric short form - asthma 8a - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - asthma 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62209-2;PROMIS pediatric short form - peer relationships 8a - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - peer relationships 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +622-1;Bacteria identified;Prid;Pt;Sputum;Nom;Aerobic culture;MICRO;1;Bacteria identified in Sputum by Aerobe culture;Bacteria Spt Aerobe Cult;;ACTIVE;1.0;2.73 +62210-0;PROMIS pediatric short form - fatigue 10a - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - fatigue 10a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62211-8;PROMIS pediatric short form - pain interference 8a - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - pain interference 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.52 +62212-6;PROMIS item bank - pain behavior - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - pain behavior - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +62213-4;I had trouble breathing because of my asthma in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble breathing because of my asthma in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62214-2;I could put on my socks by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could put on my socks by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62215-9;I could write with a pen or pencil in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could write with a pen or pencil in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6221-6;Primrose Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Primrose IgE Ab [Units/volume] in Serum;Primrose IgE Qn;;ACTIVE;1.0d;2.70 +62216-7;I could put toothpaste on my toothbrush by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could put toothpaste on my toothbrush by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62217-5;I could lift a cup to drink in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could lift a cup to drink in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62218-3;I could zip up my clothes in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could zip up my clothes in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62219-1;I could pull on and fasten my seatbelt in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could pull on and fasten my seatbelt in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62220-9;I could open my clothing drawers in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could open my clothing drawers in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62221-7;I could dial a phone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could dial a phone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62222-5;I could cut paper with scissors in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could cut paper with scissors in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62223-3;I could dry my back with a towel in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could dry my back with a towel in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6222-4;Syagrus romanzoffianum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Queen Palm IgE Ab [Units/volume] in Serum;Queen Palm IgE Qn;;ACTIVE;1.0d;2.73 +62224-1;I could wash my face with a cloth in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could wash my face with a cloth in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62225-8;I used a pencil with a special grip to write in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I used a pencil with a special grip to write in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62226-6;I could move my hands or fingers in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could move my hands or fingers in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62227-4;I could tie shoelaces by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could tie shoelaces by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62228-2;I could put on my clothes by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could put on my clothes by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62229-0;I could turn door handles by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could turn door handles by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62230-8;I could use a mouse or touch pad for the computer in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could use a mouse or touch pad for the computer in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62231-6;I could hold a full cup in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could hold a full cup in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +6223-2;Rabbit epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit epithelium IgE Ab [Units/volume] in Serum;Rabbit Epith IgE Qn;;ACTIVE;1.0d;2.73 +62232-4;I could hold an empty cup in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could hold an empty cup in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62233-2;I could brush my teeth by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could brush my teeth by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62234-0;Albumin;SCnc;Pt;Ser/Plas;Qn;BCP;CHEM;1;Albumin [Moles/volume] in Serum or Plasma by Bromocresol purple (BCP) dye binding method;Albumin SerPl BCP-sCnc;;ACTIVE;2.34;2.42 +62235-7;Albumin;SCnc;Pt;Ser/Plas;Qn;BCG;CHEM;1;Albumin [Moles/volume] in Serum or Plasma by Bromocresol green (BCG) dye binding method;Albumin SerPl BCG-sCnc;;ACTIVE;2.34;2.36 +62236-5;Pyridoxal phosphate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyridoxal phosphate [Moles/volume] in Serum or Plasma;Pyridoxal Phos SerPl-sCnc;;ACTIVE;2.34;2.73 +62237-3;Carbapenem;Susc;Pt;Isolate;Ord;;ABXBACT;1;Deprecated Carbapenem [Susceptibility] in Isolate Qualitative;Deprecated Carbapenem Islt Ql;;DEPRECATED;2.34;2.64 +62238-1;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (CKD-EPI);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI);GFR/BSA.pred SerPlBld CKD-EPI-ArVRat;;ACTIVE;2.34;2.73 +62239-9;Leukocytes;NCnc;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Blood from Fetus by Automated count;WBC # Bld Fetus Auto;;ACTIVE;2.34;2.70 +6224-0;Rat epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rat epithelium IgE Ab [Units/volume] in Serum;Rat Epith IgE Qn;;ACTIVE;1.0d;2.73 +62240-7;Erythrocytes;NCnc;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Blood from Fetus by Automated count;RBC # Bld Fetus Auto;;ACTIVE;2.34;2.70 +62241-5;Hematocrit;VFr;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Hematocrit [Volume Fraction] of Blood from Fetus by Automated count;Hct VFr Bld Fetus Auto;;ACTIVE;2.34;2.70 +62242-3;Erythrocyte mean corpuscular volume;EntVol;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;MCV [Entitic volume] in Blood from Fetus by Automated count;MCV Bld Fetus Auto;;ACTIVE;2.34;2.73 +62243-1;Erythrocyte mean corpuscular hemoglobin;EntMass;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;MCH [Entitic mass] in Blood from Fetus by Automated count;MCH Bld Fetus Qn Auto;;ACTIVE;2.34;2.70 +62244-9;Platelets;NCnc;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Platelets [#/volume] in Blood from Fetus by Automated count;Platelet # Bld Fetus Auto;;ACTIVE;2.34;2.70 +62245-6;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Blood from Fetus by Automated count;nRBC/100 WBC Bld Fetus Auto-Rto;;ACTIVE;2.34;2.73 +62246-4;Erythrocyte mean corpuscular hemoglobin concentration;MCnc;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;MCHC [Mass/volume] in Blood from Fetus by Automated count;MCHC Bld Fetus Auto-mCnc;;ACTIVE;2.34;2.70 +62247-2;Erythrocyte distribution width;Ratio;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Erythrocyte distribution width [Ratio] in Blood from Fetus by Automated count;RDW Bld Fetus Auto-Rto;;ACTIVE;2.34;2.70 +62248-0;Erythrocytes.nucleated;NCnc;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Blood from Fetus by Automated count;nRBC # Bld Fetus Auto;;ACTIVE;2.34;2.70 +62249-8;Reticulocytes;NCnc;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Reticulocytes [#/volume] in Blood from Fetus by Automated count;Retics # Fetus Auto;;ACTIVE;2.34;2.70 +62250-6;Reticulocytes.immature/Reticulocytes.total;NFr;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Immature reticulocytes/Reticulocytes.total in Blood from Fetus by Automated count;Imm Retics NFr Fetus Auto;;ACTIVE;2.34;2.73 +62251-4;Leukocytes;NCnc;Pt;Plr fld^Fetus;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Pleural fluid from Fetus by Automated count;WBC # Plr Fetus Auto;;ACTIVE;2.34;2.70 +62252-2;Cells.CD79/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD79 cells/100 cells in Blood;CD79 cells NFr Bld;;ACTIVE;2.34;2.70 +62253-0;Lipoprotein.alpha;EntLen;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.alpha [Entitic length] in Serum or Plasma;HDL SerPl Qn;;ACTIVE;2.34;2.73 +62254-8;Lipoprotein.pre-beta;EntLen;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein.pre-beta [Entitic length] in Serum or Plasma;VLDL SerPl Qn;;ACTIVE;2.34;2.73 +62255-5;Lipoprotein insulin resistance score;Score;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein insulin resistance score in Serum or Plasma;LP-IR score SerPl;;ACTIVE;2.34;2.73 +62256-3;Bacterial aminoglycoside resistance aacA gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Aminoglycoside resistance aacA gene [Presence] by Molecular method;aacA Islt/Spm Ql;;ACTIVE;2.34;2.65 +6225-7;Rat serum proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rat serum proteins IgE Ab [Units/volume] in Serum;Rat Serum Prot IgE Qn;;ACTIVE;1.0d;2.73 +62257-1;Cephalosporin resistance gene;ACnc;Pt;XXX;Ord;Probe.amp.tar;ABXBACT;1;Deprecated Cephalosporin resistance gene [Presence] by Probe & target amplification method;Deprecated Cephalosporin resis XXX Ql PC;;DEPRECATED;2.34;2.69 +62258-9;Bacterial erythromyin+clindamycin resistance ermA+ermC genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Erythromyin+clindamycin resistance ermA + ermC genes [Presence] by Molecular method;ermA+ermC Islt/Spm Ql;;ACTIVE;2.34;2.65 +62259-7;Methicillin resistance gene;ACnc;Pt;XXX;Ord;Probe.amp.tar;ABXBACT;1;Deprecated Methicillin resistance gene [Presence] by Probe & target amplification method;Deprecated Methicillin resis XXX Ql PCR;;DEPRECATED;2.34;2.69 +62260-5;Bacterial tetracycline resistance tetK+tetM genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Tetracycline resistance tetK + tetM genes [Presence] by Molecular method;tetK+tetM Islt/Spm Ql;;ACTIVE;2.34;2.65 +62261-3;Bacterial vancomycin resistance vanA+vanB genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Vancomycin resistance vanA + vanB genes [Presence] by Molecular method;vanA+vanB Islt/Spm Ql;;ACTIVE;2.34;2.73 +62262-1;PhenX measure - sugar intake;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - sugar intake;;;DEPRECATED;2.34;2.46 +62263-9;PhenX domain - Nutrition and dietary supplements;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Nutrition and dietary supplements;Domain - Nutrition DS;;TRIAL;2.34;2.68 +62264-7;Carbon dioxide;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Carbon dioxide [VFr/PPres] in Gas delivery system;CO2 VFr/PPres Gas DS;;ACTIVE;2.56;2.70 +6226-5;Rat urine proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rat urine proteins IgE Ab [Units/volume] in Serum;Rat Urine Prot IgE Qn;;ACTIVE;1.0d;2.73 +62265-4;Desflurane^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Desflurane [VFr/PPres] Airway adaptor --during expiration;Des during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +62266-2;Enflurane;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Enflurane [VFr/PPres] Airway adaptor;Enf VFr/PPres Away adap;;ACTIVE;2.54;2.70 +62267-0;Halothane;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Halothane [VFr/PPres] Airway adaptor;Hal VFr/PPres Away adap;;ACTIVE;2.54;2.70 +62268-8;Isoflurane;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Isoflurane [VFr/PPres] Airway adaptor;Isofl VFr/PPres Away adap;;ACTIVE;2.54;2.70 +62269-6;Isoflurane^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Isoflurane [VFr/PPres] Airway adaptor --during expiration;Isofl during expir VFr/PPres Away adap;;ACTIVE;2.56;2.70 +62270-4;Isoflurane^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Isoflurane [VFr/PPres] Airway adaptor --during inspiration;Isofl during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +62271-2;Nitrous oxide;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrous oxide [VFr/PPres] Airway adaptor;N2O VFr/PPres Away adap;;ACTIVE;2.54;2.70 +62272-0;Nitrous oxide^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrous oxide [VFr/PPres] Airway adaptor --during inspiration;N2O during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +6227-3;Pepper red Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Pepper IgE Ab [Units/volume] in Serum;Red Pepper IgE Qn;;ACTIVE;1.0d;2.73 +62274-6;Oxygen^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Oxygen [VFr/PPres] Airway adaptor --during inspiration;O2 during insp VFr/PPres Away adap;;ACTIVE;2.54;2.70 +62277-9;PhenX measure - vitamin D;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - vitamin D;;;DEPRECATED;2.34;2.46 +62278-7;PhenX measure - selenium;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - selenium;;;DEPRECATED;2.34;2.46 +62279-5;PhenX - breastfeeding protocol 050101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - breastfeeding protocol 050101;PhenX - breastfeeding protocol;;TRIAL;2.34;2.66 +62280-3;PhenX - caffeine protocol 050301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - caffeine protocol 050301;PhenX - caffeine protocol;;TRIAL;2.34;2.66 +6228-1;Agrostis stolonifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red top grass IgE Ab [Units/volume] in Serum;Red top grass IgE Qn;;ACTIVE;1.0d;2.73 +62281-1;PhenX - dairy food protocol 050401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - dairy food protocol 050401;PhenX - dairy food protocol;;TRIAL;2.34;2.66 +62282-9;PhenX - dietary supplements protocol 050501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - dietary supplements protocol 050501;PhenX - diet supplement proto;;TRIAL;2.34;2.66 +62283-7;PhenX - fiber protocol 050601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - fiber protocol 050601;PhenX - fiber protocol;;TRIAL;2.34;2.66 +62284-5;PhenX - fruits and veg protocol 050701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - fruits and veg protocol 050701;PhenX - fruits and veg protocol;;TRIAL;2.34;2.66 +62285-2;PhenX - energy from fat protocol 050801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - energy from fat protocol 050801;PhenX - energy from fat protocol;;TRIAL;2.34;2.66 +62286-0;PhenX - sugar protocol 051001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - sugar protocol 051001;PhenX - sugar protocol;;TRIAL;2.34;2.66 +62287-8;PhenX - selenium protocol 050901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - selenium protocol 050901;PhenX - selenium protocol;;TRIAL;2.34;2.66 +62288-6;PhenX - vitamin D protocol 051101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - vitamin D protocol 051101;PhenX - vitamin D protocol;;TRIAL;2.34;2.66 +62289-4;PhenX - calcium intake - adult protocol 050202;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - calcium intake - adult protocol 050202;PhenX - calcium intake - adult protocol;;TRIAL;2.34;2.66 +62290-2;1,25-Dihydroxyvitamin D;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;1,25-Dihydroxyvitamin D [Mass/volume] in Serum or Plasma;1,25(OH)2D SerPl-mCnc;;ACTIVE;2.34;2.73 +62291-0;1,25-Dihydroxyvitamin D2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;1,25-Dihydroxyvitamin D2 [Mass/volume] in Serum or Plasma;1,25(OH)2D2 SerPl-mCnc;;ACTIVE;2.34;2.73 +62292-8;Calcidiol+ercalcidiol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma;25(OH)D3+25(OH)D2 SerPl-mCnc;;ACTIVE;2.34;2.73 +62293-6;PhenX - current age protocol 010101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - current age protocol 010101;Current age proto;;ACTIVE;2.34;2.67 +62294-4;PhenX - standing height protocol 020703;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - standing height protocol 020703;PhenX - standing height;;TRIAL;2.34;2.66 +62295-1;PhenX - recumbent length protocol 020702;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - recumbent length protocol 020702;Recumbent length proto;;TRIAL;2.34;2.66 +62296-9;PhenX - self reported height protocol 020704;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - self reported height protocol 020704;Self reported height proto;;TRIAL;2.34;2.66 +62297-7;PhenX - weight - measured weight protocol 021501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - weight - measured weight protocol 021501;Measured weight proto;;TRIAL;2.34;2.66 +62298-5;PhenX - weight - self reported weight protocol 021502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - weight - self reported weight protocol 021502;Self reported weight proto;;TRIAL;2.34;2.66 +6229-9;Rhizopus nigricans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rhizopus nigricans IgE Ab [Units/volume] in Serum;R nigricans IgE Qn;;ACTIVE;1.0d;2.73 +62299-3;PhenX - ethnicity protocol 010501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - ethnicity protocol 010501;PhenX - ethnicity protocol;;DISCOURAGED;2.34;2.68 +62300-9;Lysosomal storage disorders newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Lysosomal storage disorders newborn screening panel;LSD NBS pnl DBS;;ACTIVE;2.34;2.40 +62301-7;Lysosomal storage disorders;Imp;Pt;Bld.dot;Nom;;CHEM;1;Lysosomal storage disorders newborn screen interpretation;LSD DBS-Imp;;ACTIVE;2.34;2.71 +62302-5;Lysosomal storage disorders suspected;Prid;Pt;Bld.dot;Nom;;CHEM;1;Lysosomal storage disorders suspected [Identifier] in DBS;LSD suspected DBS;;ACTIVE;2.34;2.61 +62303-3;Lysosomal storage disorders newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Lysosomal storage disorders newborn screening comment-discussion;LSD NBS comment;;ACTIVE;2.34;2.42 +62304-1;Fabry disease newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Fabry disease newborn screening panel;Fabry disease NBS pnl DBS;;ACTIVE;2.34;2.40 +62305-8;Fabry disease;Imp;Pt;Bld.dot;Nom;;CHEM;1;Fabry disease newborn screen interpretation;Fabry disease DBS-Imp;;ACTIVE;2.34;2.56 +62306-6;Fabry disease newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Fabry disease newborn screening comment-discussion;Fabry disease NBS comment;;ACTIVE;2.34;2.42 +6230-7;Oryza sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rice IgE Ab [Units/volume] in Serum;Rice IgE Qn;;ACTIVE;1.0d;2.73 +62307-4;Krabbe disease newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Krabbe disease newborn screening panel;Krabbe disease NBS pnl DBS;;ACTIVE;2.34;2.40 +62308-2;Krabbe disease;Imp;Pt;Bld.dot;Nom;;CHEM;1;Krabbe disease newborn screen interpretation;Krabbe disease DBS-Imp;;ACTIVE;2.34;2.56 +62309-0;Krabbe disease newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Krabbe disease newborn screening comment-discussion;Krabbe disease NBS comment;;ACTIVE;2.34;2.42 +62310-8;Galactosylceramidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Galactosylceramidase [Enzymatic activity/volume] in DBS;GALC DBS-cCnc;;ACTIVE;2.34;2.61 +62311-6;Gaucher disease newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Gaucher disease newborn screening panel;Gaucher disease NBS pnl DBS;;ACTIVE;2.34;2.40 +62312-4;Gaucher disease;Imp;Pt;Bld.dot;Nom;;CHEM;1;Gaucher disease newborn screen interpretation;Gaucher disease DBS-Imp;;ACTIVE;2.34;2.56 +62313-2;Gaucher disease newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Gaucher disease newborn screening comment-discussion;Gaucher disease NBS comment;;ACTIVE;2.34;2.42 +6231-5;Rosa spp hip Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rose Hip IgE Ab [Units/volume] in Serum;Rose Hip IgE Qn;;ACTIVE;1.0d;2.73 +62315-7;Niemann Pick disease A+B newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Niemann Pick disease A/B newborn screening panel;Niemann Pick disease A/B NBS pnl DBS;;ACTIVE;2.34;2.40 +62316-5;Acid sphingomyelinase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Acid sphingomyelinase [Enzymatic activity/volume] in DBS;Acid sphingomyelinase DBS-cCnc;;ACTIVE;2.34;2.61 +62317-3;Date of last blood product transfusion;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Date of last blood product transfusion;Date last blood product transfusion;;ACTIVE;2.34;2.36 +62318-1;Niemann Pick disease A+B;Imp;Pt;Bld.dot;Nom;;CHEM;1;Niemann Pick disease A/B newborn screen interpretation;Niemann Pick disease A/B DBS-Imp;;ACTIVE;2.34;2.56 +62319-9;Niemann Pick disease A+B newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Niemann Pick disease A/B newborn screening comment-discussion;Niemann Pick disease A/B NBS comment;;ACTIVE;2.34;2.42 +62320-7;T-cell receptor excision circle;NCnc;Pt;Bld.dot;Qn;Probe.amp.tar;CHEM;1;T-cell receptor excision circle [#/volume] in DBS by NAA with probe detection;TREC # DBS NAA+probe;;ACTIVE;2.34;2.73 +62321-5;Severe combined immunodeficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Severe combined immunodeficiency newborn screen interpretation;SCID DBS-Imp;;ACTIVE;2.34;2.73 +62322-3;Severe combined immunodeficiency newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Severe combined immunodeficiency newborn screening comment-discussion;SCID NBS comment;;ACTIVE;2.34;2.73 +6232-3;Iva ciliata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rough Marsh Elder IgE Ab [Units/volume] in Serum;Marsh Elder IgE Qn;;ACTIVE;1.0d;2.73 +62323-1;Post-discharge provider ID;ID;Pt;Provider;Nom;;CHEM;1;Post-discharge provider ID [Identifier];Post-discharge provider ID;;ACTIVE;2.56;2.56 +62324-9;Post-discharge provider name;Pn;Pt;Provider;Nom;;CHEM;1;Post-discharge provider name in Provider;Post-discharge provider name Provider;;ACTIVE;2.56;2.56 +62325-6;Post-discharge provider practice ID;ID;Pt;Provider;Nom;;CHEM;1;Post-discharge provider practice ID;Post-discharge provider practice ID;;ACTIVE;2.56;2.56 +62326-4;Post-discharge provider practice name;ID;Pt;Provider;Nom;;CHEM;1;Post-discharge provider practice name;Post-discharge provider practice name;;ACTIVE;2.56;2.56 +62327-2;Post-discharge provider practice address;Addr;Pt;Provider;Nom;;CHEM;1;Post-discharge provider practice address;Post-disch prov practice address;;ACTIVE;2.56;2.56 +62328-0;Post-discharge provider practice phone number;Tele;Pt;Provider;Nom;;ADMIN;2;Post-discharge provider practice phone number;Post-disch prov practice phone #;;ACTIVE;2.56;2.66 +62329-8;Birth hospital facility ID;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Birth hospital facility ID;Birth hospital ID;;ACTIVE;2.34;2.67 +62330-6;Birth hospital facility name;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Birth hospital facility name;Birth hospital name;;ACTIVE;2.34;2.67 +6233-1;Pigweed rough Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rough Pigweed IgE Ab [Units/volume] in Serum;Rough Pigweed IgE Qn;;ACTIVE;1.0d;2.73 +62331-4;Birth hospital facility address;Addr;Pt;Facility;Nom;;ADMIN.FACILITY;2;Birth hospital facility address;Birth hospital address;;ACTIVE;2.34;2.67 +62332-2;Birth hospital facility phone number;Tele;Pt;Facility;Nom;;ADMIN.FACILITY;2;Birth hospital facility phone number;Birth hospital phone #;;ACTIVE;2.34;2.66 +62333-0;Severe combined immunodeficiency (SCID) newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Severe combined immunodeficiency (SCID) newborn screening panel;SCID NBS pnl DBS;;ACTIVE;2.34;2.73 +62334-8;PROMIS domain - Item banks and short forms - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;Deprecated Deprecated PROMIS domain - Item banks and short forms - version 1.0 PROMIS;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.34;2.70 +62335-5;PhenX - knee height protocol 020701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - knee height protocol 020701;PhenX - knee height protocol;;TRIAL;2.34;2.66 +62336-3;PROMIS item bank - 43 profile;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - 43 profile;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +62337-1;PROMIS item bank - 29 profile;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - 29 profile;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +62338-9;PROMIS item bank - 57 profile;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - 57 profile;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.50 +62339-7;I felt sad in the past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt sad in the past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62340-5;I felt tired in the past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt tired in the past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.34;2.65 +62341-3;Borrelia burgdorferi Ab.IgG+IgM with reflex to immune blot panel;-;Pt;Ser;-;;PANEL.MICRO;1;Borrelia burgdorferi IgG+IgM with reflex to immune blot panel - Serum;B burgdor IgG+IgM W reflex to IB pnl Ser;;ACTIVE;2.34;2.73 +62342-1;Borrelia burgdorferi Ab.IgG & IgM;Imp;Pt;Ser;Nom;IB;MICRO;1;Borrelia burgdorferi IgG and IgM [Interpretation] in Serum by Immunoblot;B burgdor IgG+IgM Ser IB-Imp;;ACTIVE;2.34;2.58 +62343-9;Chromosome analysis copy number change panel;-;Pt;Bld/Tiss;-;Microarray;PANEL.HL7.CYTOGEN;1;Chromosome analysis copy number change panel by Microarray;CMA # change pnl Microarray;;ACTIVE;2.34;2.73 +62344-7;Chromosome analysis.metaphase panel;-;Pt;Bld;-;FISH;PANEL.HL7.CYTOGEN;1;Chromosome analysis.metaphase panel - Blood by FISH;Chrom analy metaphase pnl Bld FISH;;ACTIVE;2.34;2.61 +62345-4;Chromosome analysis.interphase panel;-;Pt;Bld;-;FISH;PANEL.HL7.CYTOGEN;1;Chromosome analysis.interphase panel - Blood by FISH;Chrom analy interphase pnl Bld FISH;;ACTIVE;2.34;2.61 +62346-2;Chromosome analysis.interphase panel;-;Pt;Amnio fld;-;FISH;PANEL.HL7.CYTOGEN;1;Chromosome analysis.interphase panel - Amniotic fluid by FISH;Chrom analy interphase pnl Amn FISH;;ACTIVE;2.34;2.61 +62347-0;Chromosome analysis.prenatal panel;-;Pt;Bld/Tiss;-;FISH;PANEL.HL7.CYTOGEN;1;Chromosome analysis.prenatal panel by FISH;Chrom analy prenatal pnl FISH;;ACTIVE;2.34;2.73 +62348-8;Chromosome analysis panel;-;Pt;Bld;-;G-banded;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel - Blood by G-banded;Chrom analy pnl Bld G-banded;;ACTIVE;2.34;2.73 +6234-9;Salsola kali Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saltwort IgE Ab [Units/volume] in Serum;Saltwort IgE Qn;;ACTIVE;1.0d;2.73 +62349-6;Chromosome analysis panel;-;Pt;Bld^Fetus;-;G-banded;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel - Blood from Fetus by G-banded;Chrom analy pnl Bld Fetus G-banded;;ACTIVE;2.34;2.61 +62350-4;Chromosome analysis panel;-;Pt;CVS;-;G-banded;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel - Chorionic villus sample by G-banded;Chrom analy pnl CVS G-banded;;ACTIVE;2.34;2.73 +62351-2;Chromosome analysis panel;-;Pt;Amnio fld;-;G-banded;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel - Amniotic fluid by G-banded;Chrom analy pnl Amn G-banded;;ACTIVE;2.34;2.73 +62352-0;Chromosome analysis panel;-;Pt;POC;-;G-banded;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel - Products of Conception by G-banded;Chrom analy pnl POC G-banded;;ACTIVE;2.34;2.73 +62353-8;Chromosome analysis panel;-;Pt;Skin;-;G-banded;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel - Skin by G-banded;Chrom analy pnl Skin G-banded;;ACTIVE;2.34;2.61 +62354-6;Chromosome analysis.metaphase panel;-;Pt;Amnio fld;-;FISH;PANEL.HL7.CYTOGEN;1;Chromosome analysis.metaphase panel - Amniotic fluid by FISH;Chrom analy metaphase pnl Amn FISH;;ACTIVE;2.34;2.61 +62355-3;Chromosome analysis panel;-;Pt;Bld/Tiss;-;Banding;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel by Banding;Chrom analy pnl Banding;;ACTIVE;2.34;2.61 +6235-6;Secale cereale Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Secale cereale Ab.IgE;Deprecated Rye IgE Qn;;DEPRECATED;1.0d;2.70 +62356-1;Chromosome analysis result in ISCN expression;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Chromosome analysis result in ISCN expression;Chrom analy result (ISCN);;ACTIVE;2.34;2.73 +62357-9;Chromosome analysis overall interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;HL7.CYTOGEN;1;Chromosome analysis overall interpretation Qualitative;Chrom analy overall interp-Imp;;ACTIVE;2.34;2.73 +62358-7;ISCN band level;Num;Pt;Bld/Tiss;Ord;Molgen;HL7.CYTOGEN;1;ISCN band level [#] Qualitative;ISCN band level Ql;;ACTIVE;2.34;2.73 +62359-5;Chromosome banding method;Type;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Chromosome banding method -;Chrom banding method;;ACTIVE;2.34;2.73 +62360-3;Cells analyzed;Num;Pt;Bld/Tiss;Qn;Molgen;HL7.CYTOGEN;1;Cells analyzed [#];Cells analyzed;;ACTIVE;2.34;2.73 +62361-1;Cells counted;Num;Pt;Bld/Tiss;Qn;Molgen;HL7.CYTOGEN;1;Cells counted [#];Cells counted;;ACTIVE;2.34;2.73 +62362-9;Colonies counted;Num;Pt;Bld/Tiss;Qn;Molgen;HL7.CYTOGEN;1;Colonies counted [#];Colonies counted;;ACTIVE;2.34;2.73 +62363-7;Mosaicism detected;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Mosaicism detected;Mosaicism detected;;ACTIVE;2.34;2.73 +6236-4;Secale cereale pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Rye IgE Ab [Units/volume] in Serum;Cultivated Rye IgE Qn;;ACTIVE;1.0d;2.73 +62364-5;Test performance information;Find;Pt;XXX;Nar;;HL7.CYTOGEN;1;Test performance information in Specimen Narrative;Test performance info Spec;;ACTIVE;2.34;2.73 +62365-2;Diagnostic impression;Imp;Pt;XXX;Nar;Molgen;HL7.CYTOGEN;1;Diagnostic impression [Interpretation] in Specimen Narrative;Diagnostic imp Spec-Imp;;ACTIVE;2.34;2.73 +62366-0;Recommended follow-up;Prid;Pt;^Patient;Nom;;HL7.CYTOGEN;1;Recommended follow-up [Identifier];Recom F/U Patient;;ACTIVE;2.34;2.73 +62367-8;Chromosome analysis panel;-;Pt;Bld/Tiss;-;FISH;PANEL.HL7.CYTOGEN;1;Chromosome analysis panel by FISH;Chrom analy pnl FISH;;ACTIVE;2.34;2.73 +62368-6;Cell phase;Type;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Cell phase [Type];Cell phase;;ACTIVE;2.34;2.68 +62369-4;FISH probe name panel;-;Pt;Laboratory device;-;;PANEL.HL7.CYTOGEN;1;FISH probe name panel - Laboratory device;FISH probe name pnl Lab Device;;ACTIVE;2.34;2.73 +62370-2;FISH probe gene name;ID;Pt;Laboratory device;Nom;;MOLPATH;1;FISH probe gene name [Identifier] in Laboratory device;FISH probe gene name Lab Device;;ACTIVE;2.34;2.73 +62371-0;FISH probe locus;ID;Pt;Laboratory device;Nom;;MOLPATH;1;FISH probe locus [Identifier] in Laboratory device;FISH probe locus Lab Device;;ACTIVE;2.34;2.73 +6237-2;Salmo salar Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Salmon IgE Ab [Units/volume] in Serum;Salmon IgE Qn;;ACTIVE;1.0d;2.73 +62372-8;FISH probe vendor;ID;Pt;Laboratory device;Nom;;MOLPATH;1;FISH probe vendor [Identifier] in Laboratory device;FISH probe vendor Lab Device;;ACTIVE;2.34;2.67 +62373-6;Human reference assembly release, UCSC version;ID;Pt;Bld/Tiss;Nom;;HL7.CYTOGEN;1;Human reference assembly release, UCSC version [Identifier];Hum RefSeq ass release UCSC ver;;ACTIVE;2.34;2.68 +62374-4;Human reference sequence assembly release number;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Human reference sequence assembly version;Human ref seq assembly+build;;ACTIVE;2.34;2.64 +62375-1;Microarray platform;ID;Pt;Bld/Tiss;Nar;Molgen;HL7.CYTOGEN;1;Microarray platform [Identifier] Narrative;Microarray platform;;ACTIVE;2.34;2.73 +62376-9;Microarray platform version number;ID;Pt;Bld/Tiss;Nar;Molgen;HL7.CYTOGEN;1;Microarray platform version number Narrative;Microarray platform version;;ACTIVE;2.34;2.56 +62377-7;Chromosome copy number change panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.CYTOGEN;1;Chromosome copy number change panel;Chrom copy # change pnl;;ACTIVE;2.34;2.61 +62378-5;Chromosome copy number change;Type;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Chromosome copy number change [Type];Chrom copy # change;;ACTIVE;2.34;2.73 +62379-3;Chromosome band involved start;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Chromosome band involved start;Chrom band involved start;;ACTIVE;2.34;2.56 +6238-0;Distichlis spicata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Salt grass IgE Ab [Units/volume] in Serum;Salt grass IgE Qn;;ACTIVE;1.0d;2.73 +62380-1;Chromosome band involved end;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Chromosome band involved end;Chrom band involved end;;ACTIVE;2.34;2.68 +62381-9;Base pair start coordinate;Num;Pt;Bld/Tiss;Qn;Molgen;HL7.CYTOGEN;1;Base pair start coordinate [#];Base pair start coordinate;;ACTIVE;2.34;2.70 +62382-7;Base pair end coordinate;Num;Pt;Bld/Tiss;Qn;Molgen;HL7.CYTOGEN;1;Base pair end coordinate [#];Base pair end coordinate;;ACTIVE;2.34;2.70 +62383-5;Flanking normal region before start;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Flanking normal region before start;Flanking norm reg before start;;ACTIVE;2.34;2.56 +62384-3;Flanking normal region after end;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.CYTOGEN;1;Flanking normal region after end;Flanking norm reg after end;;ACTIVE;2.34;2.56 +62385-0;Recommendation;Imp;Pt;^Patient;Doc;;HL7.CYTOGEN;1;Recommendation [Interpretation] Document;Recommendation Patient Doc-Imp;;ACTIVE;2.34;2.73 +62386-8;Chromosome analysis summary panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HL7.CYTOGEN;1;Chromosome analysis summary panel;Chrom anl summary pnl;;ACTIVE;2.34;2.63 +62387-6;Interventions;Find;Pt;^Patient;Nar;;DOC.MISC;2;Interventions Narrative;Interventions;;ACTIVE;2.34;2.73 +62388-4;Hemoglobin A1c/Hemoglobin.total;MFr;Pt;Bld;Qn;JDS/JSCC;CHEM;1;Hemoglobin A1c/Hemoglobin.total in Blood by JDS/JSCC protocol;HbA1c MFr Bld JDS/JSCC;;ACTIVE;2.34;2.70 +62389-2;Chromosome analysis master panel;-;Pt;Bld/Tiss;-;;PANEL.HL7.CYTOGEN;1;Chromosome analysis master panel;Chromosome analysis master panel;;ACTIVE;2.34;2.73 +623-9;Bacteria identified;Prid;Pt;Sputum;Nom;Cystic fibrosis respiratory culture;MICRO;1;Bacteria identified in Sputum by Cystic fibrosis respiratory culture;Bacteria Spt CF Resp Cult;;ACTIVE;1.0;2.73 +62390-0;PhenX - family history heart attack protocol 040101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - family history heart attack protocol 040101;Fam hx heart attack proto;;TRIAL;2.36;2.66 +62391-8;PhenX - lipid profile protocol 040201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - lipid profile protocol 040201;Lipid profile proto;;TRIAL;2.36;2.73 +62392-6;PhenX - blood pressure protocol 040301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - blood pressure protocol 040301;Blood pressure proto;;TRIAL;2.36;2.66 +62393-4;PhenX - preg high blood pressure protocol 040401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - preg high blood pressure protocol 040401;Preg high blood pressure proto;;TRIAL;2.36;2.66 +62394-2;PhenX - heart valve func protocol 040501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - heart valve func protocol 040501;PhenX - heart valve func protocol;;TRIAL;2.36;2.66 +62395-9;PhenX - angina protocol 040601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - angina protocol 040601;PhenX - angina protocol;;TRIAL;2.36;2.66 +62396-7;PhenX - sudden cardiac arrest protocol 040701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - sudden cardiac arrest protocol 040701;Sudden cardiac arrest proto;;TRIAL;2.36;2.66 +62397-5;PhenX - myocardial infarct protocol 040801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - myocardial infarct protocol 040801;Myocardial infarct proto;;TRIAL;2.36;2.66 +6239-8;Atriplex lentiformis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lenscale IgE Ab [Units/volume] in Serum;Lenscale IgE Qn;;ACTIVE;1.0d;2.73 +62398-3;PhenX - periph arterial disease protocol 040901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - periph arterial disease protocol 040901;Periph arterial disease proto;;TRIAL;2.36;2.66 +62399-1;PhenX - abd aortic aneurysm protocol 041001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - abd aortic aneurysm protocol 041001;Abdominal aortic aneurysm proto;;TRIAL;2.36;2.66 +62400-7;PhenX - arrhythmia protocol 041101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - arrhythmia protocol 041101;PhenX - arrhythmia protocol;;TRIAL;2.36;2.66 +62401-5;PhenX - deep venous thrombosis protocol 041201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - deep venous thrombosis protocol 041201;Deep venous thrombosis proto;;TRIAL;2.36;2.66 +62402-3;PhenX - pulmonary embolus protocol 041301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - pulmonary embolus protocol 041301;PhenX - pulmonary embolus protocol;;TRIAL;2.36;2.66 +62403-1;PhenX - rheumatic fever protocol 041401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - rheumatic fever protocol 041401;Rheumatic fever proto;;TRIAL;2.36;2.66 +62404-9;PhenX - arm span protocol 020101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - arm span protocol 020101;PhenX - arm span protocol;;TRIAL;2.36;2.66 +62405-6;PhenX - birth weight protocol 020201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - birth weight protocol 020201;PhenX - birth weight protocol;;TRIAL;2.36;2.66 +6240-6;Seminal fluid Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Seminal fluid IgE Ab [Units/volume] in Serum;Seminal Fld IgE Qn;;ACTIVE;1.0d;2.73 +62406-4;PhenX - child head circum protocol 020501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - child head circum protocol 020501;PhenX - child head circum protocol;;TRIAL;2.36;2.66 +62409-8;PhenX - hip circumference protocol 020801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - hip circumference protocol 020801;PhenX - hip circumference protocol;;TRIAL;2.36;2.73 +62410-6;PhenX - max adult ht protocol 020901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - max adult ht protocol 020901;PhenX - max adult ht protocol;;TRIAL;2.36;2.66 +62411-4;PhenX - max adult wt protocol 021001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - max adult wt protocol 021001;Max adult wt proto;;TRIAL;2.36;2.66 +62412-2;PhenX - upper arm circ protocol 021101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - upper arm circ protocol 021101;PhenX - upper arm circ protocol;;TRIAL;2.36;2.66 +62413-0;PhenX - neck circ protocol 021201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - neck circ protocol 021201;Neck circumference proto;;TRIAL;2.36;2.66 +6241-4;Serpula lacrymans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dry-rot Fungus IgE Ab [Units/volume] in Serum;S lacrymans IgE Qn;;ACTIVE;1.0d;2.73 +62414-8;PhenX - pregnancy wt gain protocol 021301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - pregnancy wt gain protocol 021301;Pregnancy wt gain proto;;TRIAL;2.36;2.66 +62415-5;PhenX - wt loss - gain protocol 021401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - wt loss - gain protocol 021401;PhenX - wt loss - gain protocol;;TRIAL;2.36;2.66 +62418-9;Glucose/Insulin;Ratio;Pt;Ser/Plas;Qn;;CHEM;1;Glucose/Insulin [Ratio] in Serum or Plasma;Glucose/Insulin SerPl-Rto;;ACTIVE;2.36;2.73 +62419-7;Galectin 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Galectin 3 [Mass/volume] in Serum or Plasma;Galectin 3 SerPl-mCnc;;ACTIVE;2.36;2.73 +62420-5;Fatty acids.nonesterified^8th specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --8th specimen fasting;NEFA sp8 p fast SerPl-sCnc;;ACTIVE;2.36;2.70 +62421-3;Fatty acids.nonesterified^9th specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --9th specimen fasting;NEFA sp9 p fast SerPl-sCnc;;ACTIVE;2.36;2.70 +6242-2;Sesamum indicum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sesame Seed IgE Ab [Units/volume] in Serum;Sesame Seed IgE Qn;;ACTIVE;1.0d;2.73 +62422-1;Fatty acids.nonesterified^10th specimen post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Fatty acids.nonesterified [Moles/volume] in Serum or Plasma --10th specimen fasting;NEFA sp10 p fast SerPl-sCnc;;ACTIVE;2.36;2.70 +62423-9;Human coronavirus HKU1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Specimen by NAA with probe detection;HCoV HKU1 RNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +62424-7;Human bocavirus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human bocavirus DNA [Presence] in Specimen by NAA with probe detection;HBoV DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +62425-4;Creatinine^post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Moles/volume] in Serum or Plasma --post XXX challenge;Creat p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +62426-2;Bordetella sp DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Bordetella sp DNA panel - Specimen by NAA with probe detection;Bordetella DNA pnl Spec NAA+probe;;ACTIVE;2.36;2.69 +62427-0;Bordetella holmesii DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bordetella holmesii DNA [Presence] in Specimen by NAA with probe detection;B holmseii DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +62428-8;Bordetella sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Bordetella sp DNA [Identifier] in Specimen by NAA with probe detection;Bordetella DNA Spec NAA+probe;;ACTIVE;2.36;2.73 +62429-6;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;Body fld;Ord;IF;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Body fluid by Immunofluorescence;EEEV IgM Fld Ql IF;;ACTIVE;2.36;2.56 +6243-0;Sheep epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep epithelium IgE Ab [Units/volume] in Serum;Sheep Epith IgE Qn;;ACTIVE;1.0d;2.73 +62430-4;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Body fluid by Immunoassay;EEEV IgM Fld Ql IA;;ACTIVE;2.36;2.56 +62431-2;Eastern equine encephalitis virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Eastern equine encephalitis virus IgG Ab [Presence] in Body fluid by Immunoassay;EEEV IgG Fld Ql IA;;ACTIVE;2.36;2.56 +62432-0;La Crosse virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;La Crosse virus IgM Ab [Presence] in Body fluid by Immunoassay;LACV IgM Fld Ql IA;;ACTIVE;2.36;2.56 +62433-8;La Crosse virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;La Crosse virus IgG Ab [Presence] in Body fluid by Immunoassay;LACV IgG Fld Ql IA;;ACTIVE;2.36;2.56 +62434-6;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;Body fld;Ord;IF;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Body fluid by Immunofluorescence;SLEV IgM Fld Ql IF;;ACTIVE;2.36;2.56 +62435-3;Saint Louis encephalitis virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgG Ab [Presence] in Body fluid by Immunoassay;SLEV IgG Fld Ql IA;;ACTIVE;2.36;2.56 +62436-1;West Nile virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;West Nile virus IgM Ab [Presence] in Body fluid by Immunoassay;WNV IgM Fld Ql IA;;ACTIVE;2.36;2.56 +62437-9;Erythrocytes.nucleated;NCnc;Pt;CSF;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Cerebral spinal fluid by Automated count;nRBC # CSF Auto;;ACTIVE;2.36;2.70 +62438-7;Erythrocytes.nucleated;NCnc;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Synovial fluid by Automated count;nRBC # Snv Auto;;ACTIVE;2.36;2.70 +62439-5;Erythrocytes.nucleated;NCnc;Pt;Body fld;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Body fluid by Automated count;nRBC # Fld Auto;;ACTIVE;2.36;2.70 +62440-3;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Body fld;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Body fluid by Automated count;nRBC/100 WBC Fld Auto-Rto;;ACTIVE;2.36;2.70 +62441-1;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;CSF;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Cerebral spinal fluid by Automated count;nRBC/100 WBC CSF Auto-Rto;;ACTIVE;2.36;2.70 +62442-9;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Synovial fluid by Automated count;nRBC/100 WBC Snv Auto-Rto;;ACTIVE;2.36;2.70 +62443-7;View;Find;Pt;Teeth;Doc;XR;DENTAL;2;Single view Teeth Document XR;1V Teeth Doc XR;;ACTIVE;2.36;2.64 +62444-5;Views;Find;Pt;Teeth.partial;Doc;XR;DENTAL;2;Views Teeth.partial Document XR;Views Teeth.partial Doc XR;;ACTIVE;2.36;2.64 +62445-2;Views;Find;Pt;Teeth;Doc;XR;DENTAL;2;Views Teeth Document XR;Views Teeth Doc XR;;ACTIVE;2.36;2.64 +62446-0;Views^W contrast IA;Find;Pt;Abdomen>Renal artery.left;Doc;RF.angio;RAD;2;RFA Renal artery - left Views W contrast IA;RFA Renal a-L Views W contr IA;;ACTIVE;2.36;2.64 +62447-8;Views^W contrast IA;Find;Pt;Abdomen>Renal artery.right;Doc;RF.angio;RAD;2;RFA Renal artery - right Views W contrast IA;RFA Renal a-R Views W contr IA;;ACTIVE;2.36;2.64 +6244-8;Rumex acetosella Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep Sorrel IgE Ab [Units/volume] in Serum;Sheep Sorrel IgE Qn;;ACTIVE;1.0d;2.73 +62448-6;Views^W contrast IA;Find;Pt;Head>Head artery.left & Neck>Neck artery.left;Doc;RF.angio;RAD;2;RFA Head artery - left and Neck artery - left Views W contrast IA;RFA Head a+Neck a-L Views W contr IA;;ACTIVE;2.36;2.64 +62449-4;Views^W contrast IA;Find;Pt;Head>Head artery.right & Neck>Neck artery.right;Doc;RF.angio;RAD;2;RFA Head artery - right and Neck artery - right Views W contrast IA;RFA Head a+Neck a-L-R Views W contr IA;;ACTIVE;2.36;2.64 +62450-2;Guidance for placement of catheter;Find;Pt;Abdomen>Peritoneum;Doc;RF;RAD;2;RF Guidance for placement of catheter in Peritoneum;RF Guided Peritoneum Cath place;;ACTIVE;2.36;2.64 +62451-0;Multisection limited;Find;Pt;Extremity.left;Doc;US;RAD;2;US Extremity - left limited;US Extr-L Ltd;;ACTIVE;2.36;2.61 +62452-8;Multisection limited;Find;Pt;Extremity.right;Doc;US;RAD;2;US Extremity - right limited;US Extr-R Ltd;;ACTIVE;2.36;2.61 +62453-6;Fatty acids.ethyl esters;SCnt;Pt;Hair;Qn;;CHEM;1;Fatty acids.ethyl esters [Moles/mass] in Hair;Fatty acids.ethyl esters Hair-sCnt;;ACTIVE;2.36;2.70 +62454-4;Herpes simplex virus & Varicella zoster virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Herpes simplex virus and Varicella zoster virus identified in Specimen by Organism specific culture;HSV+VZV Spec Cult;;ACTIVE;2.36;2.73 +6245-5;Sheep wool Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep wool IgE Ab [Units/volume] in Serum;Sheep Wool IgE Qn;;ACTIVE;1.0d;2.73 +62455-1;Coccidioides sp F Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Coccidioides sp F Ab [Presence] in Serum by Immune diffusion (ID);C immitis F Ab Ser Ql ID;;ACTIVE;2.36;2.73 +62456-9;HIV 2 p15 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 2 p15 Ab [Presence] in Serum by Immunoblot;HIV2 p15 Ab Ser Ql IB;;ACTIVE;2.36;2.58 +62457-7;Coccidioides sp TP Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Coccidioides sp TP Ab [Presence] in Serum by Immune diffusion (ID);Coccidioides TP Ab Ser Ql ID;;ACTIVE;2.36;2.73 +62458-5;Coccidioides immitis Ab.IgM;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Coccidioides immitis IgM Ab [Presence] in Serum by Immune diffusion (ID);C immitis IgM Ser Ql ID;;ACTIVE;2.36;2.73 +62459-3;Coccidioides immitis Ab.IgG;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Coccidioides immitis IgG Ab [Presence] in Serum by Immune diffusion (ID);C immitis IgG Ser Ql ID;;ACTIVE;2.36;2.73 +62460-1;Candida sp DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida sp DNA [Presence] in Vaginal fluid by NAA with probe detection;Candida DNA Vag Ql NAA+probe;;ACTIVE;2.36;2.73 +62461-9;Trichomonas vaginalis DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis DNA [Presence] in Vaginal fluid by NAA with probe detection;T vaginalis DNA Vag Ql NAA+probe;;ACTIVE;2.36;2.73 +62462-7;Influenza virus A+B RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A+B RNA [Presence] in Specimen by NAA with probe detection;FLUAV+FLUBV RNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +6246-3;Pandalus borealis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp IgE Ab [Units/volume] in Serum;Shrimp IgE Qn;;ACTIVE;1.0d;2.73 +62463-5;Enterovirus RNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Enterovirus RNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;EV RNA # CSF NAA+probe;;ACTIVE;2.36;2.70 +62464-3;Enterovirus RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Enterovirus RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;EV RNA # SerPl NAA+probe;;ACTIVE;2.36;2.70 +62465-0;Toxoplasma gondii DNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [#/volume] in Cerebral spinal fluid by NAA with probe detection;T gondii DNA # CSF NAA+probe;;ACTIVE;2.36;2.73 +62466-8;BK virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;BK virus IgG Ab [Presence] in Serum or Plasma;BKV IgG SerPl Ql;;ACTIVE;2.36;2.56 +62467-6;Galactomannan Ag;ACnc;Pt;XXX;Qn;IA;MICRO;1;Galactomannan Ag [Units/volume] in Specimen by Immunoassay;Galactomannan Ag Spec IA-aCnc;;ACTIVE;2.36;2.73 +62468-4;1,3 beta glucan;MCnc;Pt;XXX;Qn;;MICRO;1;1,3 beta glucan [Mass/volume] in Specimen;1,3 beta glucan Spec-mCnc;;ACTIVE;2.36;2.73 +62469-2;HIV 1 RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HIV1 RNA SerPl NAA+probe-aCnc;;ACTIVE;2.36;2.73 +624-7;Bacteria identified;Prid;Pt;Sputum;Nom;Respiratory culture;MICRO;1;Bacteria identified in Sputum by Respiratory culture;Bacteria Spt Resp Cult;;ACTIVE;1.0;2.73 +62470-0;Herpes simplex virus 1 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HSV1 DNA # Mar NAA+probe;;ACTIVE;2.36;2.70 +6247-1;Silk Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silk IgE Ab [Units/volume] in Serum;Silk IgE Qn;;ACTIVE;1.0d;2.73 +62471-8;Herpes simplex virus 1 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HSV1 DNA # Tiss NAA+probe;;ACTIVE;2.36;2.73 +62472-6;Herpes simplex virus 1 DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Amniotic fluid by NAA with probe detection;HSV1 DNA # Amn NAA+probe;;ACTIVE;2.36;2.70 +62473-4;Herpes simplex virus 1 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;HSV1 DNA # BAL NAA+probe;;ACTIVE;2.36;2.73 +62474-2;Herpes simplex virus 2 DNA;NCnc;Pt;Bone mar;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection;HSV2 DNA # Mar NAA+probe;;ACTIVE;2.36;2.70 +62475-9;Herpes simplex virus 2 DNA;NCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Tissue by NAA with probe detection;HSV2 DNA # Tiss NAA+probe;;ACTIVE;2.36;2.73 +62476-7;Herpes simplex virus 2 DNA;NCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Amniotic fluid by NAA with probe detection;HSV2 DNA # Amn NAA+probe;;ACTIVE;2.36;2.70 +62477-5;Herpes simplex virus 2 DNA;NCnc;Pt;BAL;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection;HSV2 DNA # BAL NAA+probe;;ACTIVE;2.36;2.73 +62478-3;Aspergillus fumigatus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Aspergillus fumigatus DNA [Presence] in Specimen by NAA with probe detection;A fumigatus DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +62479-1;Aspergillus terreus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Aspergillus terreus DNA [Presence] in Specimen by NAA with probe detection;A terreus DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +62480-9;Adenovirus DNA;PrThr;Pt;BAL;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Bronchoalveolar lavage by NAA with probe detection;HAdV DNA BAL Ql NAA+probe;;ACTIVE;2.36;2.63 +62481-7;Herpes virus 6A DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6A DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HHV 6A DNA CSF Ql NAA+probe;;ACTIVE;2.36;2.63 +62482-5;Herpes virus 6B DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6B DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HHV 6B DNA CSF Ql NAA+probe;;ACTIVE;2.36;2.63 +62483-3;Herpes virus 6A DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6A DNA [Presence] in Serum or Plasma by NAA with probe detection;HHV 6A DNA SerPl Ql NAA+probe;;ACTIVE;2.36;2.63 +62484-1;Herpes virus 6B DNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6B DNA [Presence] in Serum or Plasma by NAA with probe detection;HHV 6B DNA SerPl Ql NAA+probe;;ACTIVE;2.36;2.63 +62485-8;Herpes virus 6A DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6A DNA [Presence] in Specimen by NAA with probe detection;HHV 6A DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.69 +62486-6;Herpes virus 6B DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6B DNA [Presence] in Specimen by NAA with probe detection;HHV 6B DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.69 +62487-4;Urobilinogen;PrThr;Pt;Urine;Ord;Test strip.automated;UA;1;Urobilinogen [Presence] in Urine by Automated test strip;Urobilinogen Ur Ql Strip.auto;;ACTIVE;2.36;2.73 +62488-2;Ova1 test;PrThr;Pt;Ser;Ord;;CHEM;1;Ova1 test [Presence] in Serum;Ova1 Ser Ql;;ACTIVE;2.36;2.73 +6248-9;Glycine max Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Soybean IgE Ab [Units/volume] in Serum;Soybean IgE Qn;;ACTIVE;1.0d;2.73 +62489-0;Sulfate.inorganic;SRat;24H;Urine;Qn;;CHEM;1;Sulfate.inorganic [Moles/time] in 24 hour Urine;Inorg Sulfate 24h Ur-sRate;;ACTIVE;2.36;2.40 +62491-6;Guidance for placement of prosthesis^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.left;Doc;RF.angio;RAD;2;RFA Guidance for placement of prosthesis in Iliac artery - left-- W contrast IA;RFA Guided Iliac a-L Prosth pl--W cont IA;;ACTIVE;2.36;2.64 +62492-4;Guidance for placement of prosthesis^W contrast IA;Find;Pt;Abdomen+Pelvis>Iliac artery.right;Doc;RF.angio;RAD;2;RFA Guidance for placement of prosthesis in Iliac artery - right-- W contrast IA;RFA Guided Iliac a-R Prosth pl--W cont IA;;ACTIVE;2.36;2.64 +62493-2;Streptococcus pneumoniae DNA & Haemophilus influenza DNA & Streptococcus agalactiae DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA and Haemophilus influenza DNA and Streptococcus agalactiae DNA [Identifier] in Unspecified specimen by NAA with probe detection;S pn+HFLU+S agal DNA XXX NAA+pr;;ACTIVE;2.36;2.69 +62494-0;Guidance for percutaneous drainage+placement of drainage catheter;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for percutaneous drainage and placement of drainage catheter of Unspecified body region;US Guided PC drn+cath place;;ACTIVE;2.36;2.66 +62495-7;PhenX - tobacco - age of initiation of use - adult protocol 030702;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - age of initiation of use - adult protocol 030702;Tobac age init use adult proto;;DISCOURAGED;2.36;2.68 +62496-5;PhenX measure - tobacco - 30D quantity and frequency;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - tobacco - 30 days quantity and frequency;;;DEPRECATED;2.36;2.46 +6249-7;Palinurus spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spiny lobster IgE Ab [Units/volume] in Serum;Spiny lobster IgE Qn;;ACTIVE;1.0d;2.73 +62497-3;PhenX - tobacco - 30D quantity and frequency - adolescent protocol 030801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - 30D quantity and frequency - adolescent protocol 030801;Tobacco 30D quant freq adoles proto;;TRIAL;2.36;2.66 +62498-1;PhenX - tobacco - 30D quantity and frequency - adult protocol 030802;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - 30D quantity and frequency - adult protocol 030802;Tobacco 30D quant freq adult proto;;TRIAL;2.36;2.66 +62499-9;PhenX measure - tobacco - age of offset use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - tobacco - age of offset use;;;DEPRECATED;2.36;2.46 +62500-4;PhenX - tobacco - age of offset use - adolescent protocol 030901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - age of offset use - adolescent protocol 030901;Tobac age offset adoles proto;;TRIAL;2.36;2.66 +62501-2;PhenX - tobacco - age of offset use - adult protocol 030902;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - age of offset use - adult protocol 030902;Tobac age offset adult proto;;TRIAL;2.36;2.66 +62502-0;PhenX measure - tobacco - nicotine dependence;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - tobacco - nicotine dependence;;;DEPRECATED;2.36;2.46 +62503-8;PhenX - tobacco - nicotine dependence protocol 031001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - nicotine dependence protocol 031001;Tobac nicotine depend proto;;TRIAL;2.36;2.66 +62504-6;PhenX measure - substance - lifetime use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - substance - lifetime use;;;DEPRECATED;2.36;2.46 +6250-5;Pigweed spiny Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spiny Pigweed IgE Ab [Units/volume] in Serum;Spiny Pigweed IgE Qn;;ACTIVE;1.0d;2.73 +62505-3;PhenX - substance - lifetime use protocol 031101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - substance - lifetime use protocol 031101;Substance - lifetime use proto;;TRIAL;2.36;2.66 +62506-1;PhenX measure - substance - age of first use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - substance - age of first use;;;DEPRECATED;2.36;2.46 +62507-9;PhenX - substance - age of first use protocol 031201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - substance - age of first use protocol 031201;Substance age first use proto;;TRIAL;2.36;2.66 +62508-7;PhenX measure - substance - 30D frequency;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - substance - 30 days frequency;;;DEPRECATED;2.36;2.46 +62509-5;PhenX - substance - 30D frequency protocol 031301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - substance - 30D frequency protocol 031301;Substance - 30D frequency proto;;TRIAL;2.36;2.66 +62510-3;PhenX measure - substance - lifetime abuse and dependence;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - substance - lifetime abuse and dependence;;;DEPRECATED;2.36;2.46 +62511-1;PhenX - substance - lifetime abuse and dependence protocol 031401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - substance - lifetime abuse and dependence protocol 031401;Substance lifetime abuse proto;;TRIAL;2.36;2.66 +62512-9;PhenX domain - Environmental exposures;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Environmental exposures;Domain - Environmental exposures;;TRIAL;2.36;2.65 +6251-3;Sporobolomyces roseus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sporobolomyces roseus IgE Ab [Units/volume] in Serum;S roseus IgE Qn;;ACTIVE;1.0d;2.73 +62513-7;PhenX measure - environmental exposures - characteristics of current residence;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - characteristics of current residence;;;DEPRECATED;2.36;2.46 +62514-5;PhenX - environmental exposures - characteristics of current residence protocol 060101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - characteristics of current residence protocol 060101;Environ exp current residence proto;;TRIAL;2.36;2.66 +62515-2;PhenX measure - environmental exposures - water source;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - water source;;;DEPRECATED;2.36;2.46 +62516-0;PhenX - environmental exposures - water source protocol 060201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - water source protocol 060201;Environ exp water source proto;;TRIAL;2.36;2.66 +62517-8;PhenX measure - environmental exposures - residential history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - residential history;;;DEPRECATED;2.36;2.46 +62518-6;PhenX - environmental exposures - residential history protocol 060301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - residential history protocol 060301;Environ exp residential hx proto;;TRIAL;2.36;2.66 +62519-4;PhenX measure - environmental exposures - exposure at work and daily life;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - exposure at work and daily life;;;DEPRECATED;2.36;2.46 +62520-2;PhenX - environmental exposures - exposure at work and daily life protocol 060401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - exposure at work and daily life protocol 060401;Environ exp work daily life proto;;TRIAL;2.36;2.66 +6252-1;Stemphylium botryosum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Stemphylium botryosum IgE Ab [Units/volume] in Serum;S botryosum IgE Qn;;ACTIVE;1.0d;2.73 +62521-0;PhenX measure - environmental exposures - occupation - occupation history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - occupation - occupation history;;;DEPRECATED;2.36;2.46 +62522-8;PhenX - environmental exposures - occupation - occupation history protocol 060501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - occupation - occupation history protocol 060501;Environ exp occupation hx proto;;TRIAL;2.36;2.66 +62523-6;PhenX measure - environmental exposures - exposures from hobbies;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - exposures from hobbies;;;DEPRECATED;2.36;2.46 +62524-4;PhenX - environmental exposures - exposures from hobbies protocol 060601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - exposures from hobbies protocol 060601;Environ exp hobbies proto;;TRIAL;2.36;2.66 +62525-1;PhenX measure - environmental exposures - current environmental tobacco smoke exposure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - current environmental tobacco smoke exposure;;;DEPRECATED;2.36;2.46 +62526-9;PhenX - environmental exposures - current environmental tobacco smoke exposure protocol 060701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - current environmental tobacco smoke exposure protocol 060701;Environ exp tobacco smoke proto;;TRIAL;2.36;2.66 +62527-7;PhenX measure - environmental exposures - sibship - birth order;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - sibship - birth order;;;DEPRECATED;2.36;2.46 +62528-5;PhenX - environmental exposures - sibship - birth order protocol 060801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - sibship - birth order protocol 060801;Environ exp sibship birth order proto;;TRIAL;2.36;2.66 +62529-3;PhenX measure - environmental exposures - day care - pre-school attendance;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - day care - pre-school attendance;;;DEPRECATED;2.36;2.46 +62530-1;PhenX - environmental exposures - day care - pre-school attendance protocol 060901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - day care - pre-school attendance protocol 060901;Environ exp day care preschool proto;;TRIAL;2.36;2.66 +62531-9;PhenX measure - environmental exposures - history of being breast fed;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - history of being breast fed;;;DEPRECATED;2.36;2.46 +62532-7;PhenX - environmental exposures - history of being breast fed protocol 061001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - history of being breast fed protocol 061001;Environ exp hx breast fed proto;;TRIAL;2.36;2.66 +62533-5;PhenX measure - environmental exposures - air contaminants in the home environment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - air contaminants in the home environment;;;DEPRECATED;2.36;2.46 +62534-3;PhenX - environmental exposures - air contaminants in the home environment protocol 061101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - air contaminants in the home environment protocol 061101;Environ exp air contaminants proto;;TRIAL;2.36;2.66 +62535-0;PhenX measure - environmental exposures - dust collection - vacuum bag;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - dust collection - vacuum bag;;;DEPRECATED;2.36;2.46 +62536-8;PhenX - environmental exposures - dust collection - vacuum bag protocol 061201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - dust collection - vacuum bag protocol 061201;Environ expo dust vacuum proto;;TRIAL;2.36;2.66 +62537-6;PhenX measure - environmental exposures - ultraviolet light exposure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - ultraviolet light exposure;;;DEPRECATED;2.36;2.46 +62538-4;PhenX - environmental exposures - ultraviolet light exposure protocol 061301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - ultraviolet light exposure protocol 061301;Environ exp UV light proto;;TRIAL;2.36;2.66 +6253-9;Midge stinging Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Midge stinging IgE Ab [Units/volume] in Serum;Midge Stinging IgE Qn;;ACTIVE;1.0d;2.73 +62539-2;PhenX measure - environmental exposures - plastic exposures at work and home;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - environmental exposures - plastic exposures at work and home;;;DEPRECATED;2.36;2.46 +625-4;Bacteria identified;Prid;Pt;Stool;Nom;Culture;MICRO;1;Bacteria identified in Stool by Culture;Bacteria Stl Cult;;ACTIVE;1.0;2.73 +62540-0;PhenX - environmental exposures - plastic exposures at work and home protocol 061401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - environmental exposures - plastic exposures at work and home protocol 061401;Environ expo plastic work home proto;;TRIAL;2.36;2.66 +62541-8;PhenX domain - Alcohol, tobacco & other substances;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Alcohol, tobacco and other substances;Domain Alcohol tobac substances;;TRIAL;2.36;2.65 +62542-6;PhenX measure - alcohol - lifetime use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - alcohol - lifetime use;;;DEPRECATED;2.36;2.46 +62543-4;PhenX - alcohol - lifetime use protocol 030101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - alcohol - lifetime use protocol 030101;Alcohol lifetime use proto;;TRIAL;2.36;2.66 +62544-2;PhenX measure - alcohol - age of first use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - alcohol - age of first use;;;DEPRECATED;2.36;2.46 +62545-9;PhenX - alcohol - age of first use protocol 030201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - alcohol - age of first use protocol 030201;Alcohol age first use proto;;TRIAL;2.36;2.66 +62546-7;PhenX measure - alcohol - 30D quantity - frequency;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - alcohol - 30 days quantity - frequency;;;DEPRECATED;2.36;2.46 +6254-7;Acarus siro Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Acarus siro IgE Ab [Units/volume] in Serum;A siro IgE Qn;;ACTIVE;1.0d;2.73 +62547-5;PhenX - alcohol - 30D quantity - frequency protocol 030301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - alcohol - 30D quantity - frequency protocol 030301;Alcohol 30D quantity frequency proto;;TRIAL;2.36;2.66 +62548-3;PhenX measure - alcohol - maximum drinks in 24H;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - alcohol - maximum drinks in 24 hours;;;DEPRECATED;2.36;2.46 +62549-1;PhenX - alcohol - maximum drinks in 24H protocol 030401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - alcohol - maximum drinks in 24H protocol 030401;Alcohol max drinks 24h proto;;TRIAL;2.36;2.66 +62550-9;PhenX measure - alcohol - lifetime abuse and dependence;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - alcohol - lifetime abuse and dependence;;;DEPRECATED;2.36;2.46 +62551-7;PhenX - alcohol - lifetime abuse and dependence protocol 030501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - alcohol - lifetime abuse and dependence protocol 030501;Alcohol lifetime abuse proto;;TRIAL;2.36;2.66 +62552-5;PhenX measure - tobacco - smoking status;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - tobacco - smoking status;;;DEPRECATED;2.36;2.46 +62553-3;PhenX - tobacco - smoking status - adolescent protocol 030601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - smoking status - adolescent protocol 030601;Tobac smok status adoles proto;;TRIAL;2.36;2.66 +6255-4;Lepidoglyphus destructor Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Lepidoglyphus destructor IgE Ab [Units/volume] in Serum;Deprecated L destructor IgE Qn;;DEPRECATED;1.0d;2.70 +62554-1;PhenX - tobacco - smoking status - adult protocol 030602;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - smoking status - adult protocol 030602;Tobac smok status adult proto;;TRIAL;2.36;2.73 +62555-8;PhenX measure - tobacco - age of initiation of use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - tobacco - age of initiation of use;;;DEPRECATED;2.36;2.46 +62556-6;PhenX - tobacco - age of initiation of use - adolescent protocol 030701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tobacco - age of initiation of use - adolescent protocol 030701;Tobac age init use adoles proto;;TRIAL;2.36;2.66 +62557-4;PhenX domain - Cancer;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Cancer;Domain - Cancer;;TRIAL;2.36;2.65 +62558-2;PhenX measure - cumulative lifetime alcohol exposure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - cumulative lifetime alcohol exposure;;;DEPRECATED;2.36;2.46 +62559-0;PhenX - lifetime alcohol exposure protocol 070101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - lifetime alcohol exposure protocol 070101;Lifetime alcohol exp proto;;TRIAL;2.36;2.66 +62560-8;PhenX measure - cumulative lifetime physical activity;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - cumulative lifetime physical activity;;;DEPRECATED;2.36;2.46 +62561-6;PhenX - lifetime physical activity protocol 070201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - lifetime physical activity protocol 070201;Lifetime phys act proto;;TRIAL;2.36;2.66 +6256-2;Tyrophagus putrescentiae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tyrophagus putrescentiae IgE Ab [Units/volume] in Serum;T putrescentiae IgE Qn;;ACTIVE;1.0d;2.73 +62562-4;PhenX measure - passive smoke exposure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - passive smoke exposure;;;DEPRECATED;2.36;2.46 +62563-2;PhenX - passive smoke exposure protocol 070301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - passive smoke exposure protocol 070301;Passive smoke exposure proto;;TRIAL;2.36;2.66 +62564-0;PhenX measure - exogenous female hormone use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - exogenous female hormone use;;;DEPRECATED;2.36;2.46 +62565-7;PhenX - exogenous female hormone use protocol 070401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - exogenous female hormone use protocol 070401;Exogenous female hormone proto;;TRIAL;2.36;2.66 +62566-5;PhenX measure - ovulation history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - ovulation history;;;DEPRECATED;2.36;2.46 +62567-3;PhenX - ovulation history protocol 070501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - ovulation history protocol 070501;Ovulation hx proto;;TRIAL;2.36;2.66 +62568-1;PhenX measure - cancer - personal and family history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - cancer - personal and family history;;;DEPRECATED;2.36;2.46 +62569-9;PhenX - cancer - personal and family history protocol 070601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - cancer - personal and family history protocol 070601;Cancer pers family hx proto;;TRIAL;2.36;2.66 +6257-0;Fragaria vesca Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Strawberry IgE Ab [Units/volume] in Serum;Strawberry IgE Qn;;ACTIVE;1.0d;2.73 +62570-7;PhenX measure - personal perception and knowledge of smoking-related cancer risk;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal perception and knowledge of smoking-related cancer risk;;;DEPRECATED;2.36;2.46 +62571-5;PhenX - knowledge of smoking-related cancer risk protocol 070701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - knowledge of smoking-related cancer risk protocol 070701;Knowl smok cancer risk proto;;TRIAL;2.36;2.66 +62572-3;PhenX measure - pre-existing conditions associated with cancer;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - pre-existing conditions associated with cancer;;;DEPRECATED;2.36;2.46 +62573-1;PhenX - pre-existing cancer conditions protocol 070801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - pre-existing cancer conditions protocol 070801;Pre-existing cancer conditions proto;;TRIAL;2.36;2.66 +62574-9;PhenX measure - cancer screenings;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - cancer screenings;;;DEPRECATED;2.36;2.46 +62575-6;PhenX - cancer screenings protocol 070901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - cancer screenings protocol 070901;Cancer screenings proto;;TRIAL;2.36;2.66 +62576-4;PhenX domain - Oral health;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Oral health;Domain - Oral health;;TRIAL;2.36;2.65 +62577-2;PhenX measure - oral health - breast or bottle feeding patterns;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - breast or bottle feeding patterns;;;DEPRECATED;2.36;2.46 +62578-0;PhenX - oral health - breast or bottle feeding patterns protocol 080101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - breast or bottle feeding patterns protocol 080101;Oral breast bottle feeding proto;;TRIAL;2.36;2.66 +62579-8;PhenX measure - oral health - consumption of sweet beverages;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - consumption of sweet beverages;;;DEPRECATED;2.36;2.46 +62580-6;PhenX - oral health - consumption of sweet beverages protocol 080201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - consumption of sweet beverages protocol 080201;Oral consumption sweet bev proto;;TRIAL;2.36;2.66 +62581-4;PhenX measure - oral health - dental caries experience - prevalence;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - dental caries experience - prevalence;;;DEPRECATED;2.36;2.46 +62582-2;PhenX - oral health - dental caries experience - prevalence protocol 080301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - dental caries experience - prevalence protocol 080301;Oral dental caries proto;;TRIAL;2.36;2.66 +62583-0;PhenX measure - oral health - dry mouth;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - dry mouth;;;DEPRECATED;2.36;2.46 +62584-8;PhenX - oral health - dry mouth protocol 080401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - dry mouth protocol 080401;Oral dry mouth proto;;TRIAL;2.36;2.66 +62585-5;PhenX measure - oral health - existence of cleft lip or palate;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - existence of cleft lip or palate;;;DEPRECATED;2.36;2.46 +62586-3;PhenX - oral health - existence of cleft lip or palate protocol 080501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - existence of cleft lip or palate protocol 080501;Oral cleft lip or palate proto;;TRIAL;2.36;2.66 +62587-1;PhenX measure - oral health - fluoride use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - fluoride use;;;DEPRECATED;2.36;2.46 +6258-8;Helianthus annuus seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sunflower Seed IgE Ab [Units/volume] in Serum;Sunflower Seed IgE Qn;;ACTIVE;1.0d;2.73 +62588-9;PhenX - oral health - fluoride use protocol 080601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - fluoride use protocol 080601;Oral fluoride use proto;;TRIAL;2.36;2.66 +62589-7;PhenX measure - oral health - malocclusion;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - malocclusion;;;DEPRECATED;2.36;2.46 +62590-5;PhenX - oral health - malocclusion protocol 080701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - malocclusion protocol 080701;Oral malocclusion proto;;TRIAL;2.36;2.66 +62591-3;PhenX measure - oral health - number of natural teeth;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - number of natural teeth;;;DEPRECATED;2.36;2.46 +62592-1;PhenX - oral health - number of natural teeth protocol 080801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - number of natural teeth protocol 080801;Oral num natural teeth proto;;TRIAL;2.36;2.66 +62593-9;PhenX measure - oral health - oral hygiene - personal care;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - oral hygiene - personal care;;;DEPRECATED;2.36;2.46 +62594-7;PhenX - oral health - oral hygiene - personal care protocol 080901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - oral hygiene - personal care protocol 080901;Oral hygiene proto;;TRIAL;2.36;2.66 +62595-4;PhenX measure - oral health - oral mucosal lesions;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - oral mucosal lesions;;;DEPRECATED;2.36;2.46 +6259-6;Castanea sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chestnut IgE Ab [Units/volume] in Serum;Chestnut IgE Qn;;ACTIVE;1.0d;2.73 +62596-2;PhenX - oral health - oral mucosal lesions protocol 081001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - oral mucosal lesions protocol 081001;Oral mucosal lesions proto;;TRIAL;2.36;2.66 +62597-0;PhenX measure - oral health - periodontal disease - prevalence;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - periodontal disease - prevalence;;;DEPRECATED;2.36;2.46 +62598-8;PhenX - oral health - periodontal disease - prevalence protocol 081101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - periodontal disease - prevalence protocol 081101;Oral periodontal dis proto;;TRIAL;2.36;2.66 +62599-6;PhenX measure - oral health - presence of dental fluorosis;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - presence of dental fluorosis;;;DEPRECATED;2.36;2.46 +62600-2;PhenX - oral health - presence of dental fluorosis protocol 081201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - presence of dental fluorosis protocol 081201;Oral dental fluorosis proto;;TRIAL;2.36;2.66 +62601-0;PhenX measure - oral health - professional dental care;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - professional dental care;;;DEPRECATED;2.36;2.46 +62602-8;PhenX - oral health - professional dental care protocol 081301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - professional dental care protocol 081301;Oral profess dental care proto;;TRIAL;2.36;2.66 +62603-6;PhenX measure - oral health - tobacco non-cigarette - product use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - tobacco non-cigarette - product use;;;DEPRECATED;2.36;2.46 +6260-4;Liquidambar styraciflua Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sweet gum IgE Ab [Units/volume] in Serum;Sweet gum IgE Qn;;ACTIVE;1.0d;2.73 +62604-4;PhenX - oral health - tobacco non-cigarette - product use protocol 081401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - tobacco non-cigarette - product use protocol 081401;Oral tobac non-cigarette proto;;TRIAL;2.36;2.66 +62605-1;PhenX measure - oral health - toothache and orofacial pain;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral health - toothache and orofacial pain;;;DEPRECATED;2.36;2.46 +62606-9;PhenX - oral health - toothache and orofacial pain protocol 081501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral health - toothache and orofacial pain protocol 081501;Oral toothache orofacial pain proto;;TRIAL;2.36;2.66 +62607-7;PhenX measure - smoking quit attempts;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - smoking quit attempts;;;DEPRECATED;2.36;2.46 +62608-5;PhenX - smoking quit attempts protocol 071001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - smoking quit attempts protocol 071001;Smoking quit attempts proto;;TRIAL;2.36;2.66 +62609-3;PhenX measure - cancer treatment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - cancer treatment;;;DEPRECATED;2.36;2.46 +62610-1;PhenX - cancer treatment protocol 071101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - cancer treatment protocol 071101;Cancer treatment proto;;TRIAL;2.36;2.66 +62611-9;PhenX domain - Respiratory;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Respiratory;Domain - Respiratory;;TRIAL;2.36;2.65 +6261-2;Anthoxanthum odoratum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sweet Vernal grass IgE Ab [Units/volume] in Serum;Sw Vernal grass IgE Qn;;ACTIVE;1.0d;2.73 +62612-7;PhenX measure - respiratory - arterial blood gas - ABG;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - arterial blood gas - ABG;;;DEPRECATED;2.36;2.46 +62613-5;PhenX - respiratory - arterial blood gas - ABG protocol 090201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - arterial blood gas - ABG protocol 090201;Resp arterial blood gas proto;;TRIAL;2.36;2.66 +62614-3;PhenX measure - respiratory - bronchodilator responsiveness - BDR;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - bronchodilator responsiveness - BDR;;;DEPRECATED;2.36;2.46 +62615-0;PhenX - respiratory - bronchodilator responsiveness - BDR protocol 090301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - bronchodilator responsiveness - BDR protocol 090301;Resp bronchodil respons proto;;TRIAL;2.36;2.66 +62616-8;PhenX measure - respiratory - chest computed tomography - CT;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - chest computed tomography - CT;;;DEPRECATED;2.36;2.46 +62617-6;PhenX - respiratory - chest computed tomography - CT protocol 090401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - chest computed tomography - CT protocol 090401;Resp chest CT proto;;TRIAL;2.36;2.66 +62618-4;PhenX measure - respiratory - exercise capacity - 6M walk test;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - exercise capacity - 6 minute walk test;;;DEPRECATED;2.36;2.46 +62619-2;PhenX - respiratory - exercise capacity - 6M walk test protocol 090601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - exercise capacity - 6 minute walk test protocol 090601;Resp exercise 6M walk proto;;TRIAL;2.36;2.66 +626-2;Bacteria identified;Prid;Pt;Thrt;Nom;Culture;MICRO;1;Bacteria identified in Throat by Culture;Bacteria Throat Cult;;ACTIVE;1.0;2.73 +6262-0;Swine epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swine epithelium IgE Ab [Units/volume] in Serum;Swine Epith IgE Qn;;ACTIVE;1.0d;2.73 +62620-0;PhenX measure - respiratory - immunoglobulin E - total and specific;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - immunoglobulin E - total and specific;;;DEPRECATED;2.36;2.46 +62621-8;PhenX - respiratory - immunoglobulin E - total and specific protocol 090701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - immunoglobulin E - total and specific protocol 090701;Resp immunoglobulin E proto;;TRIAL;2.36;2.66 +62622-6;PhenX measure - respiratory - peak expiratory flow rate - PEFR;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - peak expiratory flow rate - PEFR;;;DEPRECATED;2.36;2.46 +62623-4;PhenX - respiratory - peak expiratory flow rate - PEFR protocol 090801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - peak expiratory flow rate - PEFR protocol 090801;Resp peak expiratory flow rate proto;;TRIAL;2.36;2.66 +62624-2;PhenX measure - respiratory - personal - family hx of respiratory symptoms - diseases;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - personal - family hx of respiratory symptoms - diseases;;;DEPRECATED;2.36;2.46 +62625-9;PhenX - respiratory - personal - family hx of respiratory symptoms - diseases - adult protocol 090901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - personal - family hx of respiratory symptoms - diseases - adult protocol 090901;Resp fam hx resp sympt adult proto;;TRIAL;2.36;2.66 +62626-7;PhenX - respiratory - personal - family hx of respiratory symptoms - diseases - child protocol 090902;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - personal - family hx of respiratory symptoms - diseases - child protocol 090902;Resp fam hx resp sympt child proto;;TRIAL;2.36;2.66 +62627-5;PhenX measure - respiratory - pulse oximetry - exercise;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - pulse oximetry - exercise;;;DEPRECATED;2.36;2.46 +62628-3;PhenX - respiratory - pulse oximetry - exercise protocol 091001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - pulse oximetry - exercise protocol 091001;Resp pulse ox exercise proto;;TRIAL;2.36;2.66 +62629-1;PhenX measure - respiratory - quality of life;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - quality of life;;;DEPRECATED;2.36;2.46 +62630-9;PhenX - respiratory - quality of life protocol 091301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - quality of life protocol 091301;Resp quality of life proto;;TRIAL;2.36;2.66 +62631-7;PhenX measure - respiratory - respiratory rate;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - respiratory rate;;;DEPRECATED;2.36;2.46 +62632-5;PhenX - respiratory - respiratory rate - infant protocol 091401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - respiratory rate - infant protocol 091401;Resp rate infant proto;;TRIAL;2.36;2.66 +62633-3;PhenX - respiratory - respiratory rate - child protocol 091402;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - respiratory rate - child protocol 091402;Resp rate child proto;;TRIAL;2.36;2.66 +62634-1;PhenX - respiratory - respiratory rate - adult protocol 091403;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - respiratory rate - adult protocol 091403;Resp rate adult proto;;TRIAL;2.36;2.66 +62635-8;PhenX measure - respiratory - sleep apnea;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - sleep apnea;;;DEPRECATED;2.36;2.46 +62636-6;PhenX - respiratory - sleep apnea - adult protocol 091501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - sleep apnea - adult protocol 091501;Resp sleep apnea adult proto;;TRIAL;2.36;2.66 +62637-4;PhenX - respiratory - sleep apnea - child protocol 091502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - sleep apnea - child protocol 091502;Resp sleep apnea child proto;;TRIAL;2.36;2.66 +6263-8;Platanus occidentalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American Sycamore IgE Ab [Units/volume] in Serum;Amer Sycamore IgE Qn;;ACTIVE;1.0d;2.73 +62638-2;PhenX measure - respiratory - spirometry;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - spirometry;;;DEPRECATED;2.36;2.46 +62639-0;PhenX - respiratory - spirometry protocol 091601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - spirometry protocol 091601;Resp spirometry proto;;TRIAL;2.36;2.66 +62640-8;PhenX measure - respiratory - urine assay for tobacco smoke exposure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - urine assay for tobacco smoke exposure;;;DEPRECATED;2.36;2.46 +62641-6;PhenX - respiratory - urine assay for tobacco smoke exposure protocol 091701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - urine assay for tobacco smoke exposure protocol 091701;Resp urine assay smoke exp proto;;TRIAL;2.36;2.66 +62642-4;PhenX domain - Reproductive health;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Reproductive health;Domain - Reproductive health;;TRIAL;2.36;2.65 +62643-2;PhenX measure - assessment of pubertal development;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assessment of pubertal development;;;DEPRECATED;2.36;2.46 +62644-0;PhenX - assessment of pubertal development - female protocol 100101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assessment of pubertal development - female protocol 100101;Assess pubertal dev female proto;;TRIAL;2.36;2.66 +62645-7;PhenX - assessment of pubertal development - male protocol 100102;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assessment of pubertal development - male protocol 100102;Assess pubertal dev male proto;;TRIAL;2.36;2.66 +6264-6;Camellia sinensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tea IgE Ab [Units/volume] in Serum;Tea IgE Qn;;ACTIVE;1.0d;2.73 +62646-5;PhenX measure - causes and treatments of known infertility;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - causes and treatments of known infertility;;;DEPRECATED;2.36;2.46 +62647-3;PhenX - causes and treatments of known infertility - male protocol 100201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - causes and treatments of known infertility - male protocol 100201;Cause treat infertility male proto;;TRIAL;2.36;2.66 +62648-1;PhenX - causes and treatments of known infertility - female protocol 100202;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - causes and treatments of known infertility - female protocol 100202;Cause treat infertility female proto;;TRIAL;2.36;2.66 +62649-9;PhenX measure - contraceptive methods;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - contraceptive methods;;;DEPRECATED;2.36;2.46 +62650-7;PhenX - contraceptive methods - female protocol 100301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - contraceptive methods - female protocol 100301;Contraceptive methods female proto;;TRIAL;2.36;2.66 +62651-5;PhenX - contraceptive methods - male protocol 100302;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - contraceptive methods - male protocol 100302;Contraceptive methods male proto;;TRIAL;2.36;2.66 +62652-3;PhenX measure - difficulty in conceiving;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - difficulty in conceiving;;;DEPRECATED;2.36;2.46 +6265-3;Phleum pratense Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Timothy IgE Ab [Units/volume] in Serum;Timothy IgE Qn;;ACTIVE;1.0d;2.73 +62653-1;PhenX - difficulty in conceiving protocol 100401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - difficulty in conceiving protocol 100401;Difficulty conceiving proto;;TRIAL;2.36;2.66 +62654-9;PhenX measure - female reproductive organ surgical procedures;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - female reproductive organ surgical procedures;;;DEPRECATED;2.36;2.46 +62655-6;PhenX - female reproductive organ surgical procedures protocol 100501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - female reproductive organ surgical procedures protocol 100501;Fem reproduct surg proc proto;;TRIAL;2.36;2.66 +62656-4;PhenX measure - history of prepubertal development;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - history of prepubertal development;;;DEPRECATED;2.36;2.46 +62657-2;PhenX - history of prepubertal development - female protocol 100601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - history of prepubertal development - female protocol 100601;Hx prepubertal devel female proto;;TRIAL;2.36;2.66 +62658-0;PhenX - history of prepubertal development - male protocol 100602;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - history of prepubertal development - male protocol 100602;Hx prepubertal devel male proto;;TRIAL;2.36;2.66 +62659-8;PhenX measure - hormonal therapy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - hormonal therapy;;;DEPRECATED;2.36;2.46 +62660-6;PhenX - hormonal therapy protocol 100701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - hormonal therapy protocol 100701;Hormonal therapy proto;;TRIAL;2.36;2.66 +6266-1;Lycopersicon lycopersicum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tomato IgE Ab [Units/volume] in Serum;Tomato IgE Qn;;ACTIVE;1.0d;2.73 +62661-4;PhenX measure - human papillomavirus vaccine use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - human papillomavirus vaccine use;;;DEPRECATED;2.36;2.46 +62662-2;PhenX - human papillomavirus vaccine use protocol 100801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - human papillomavirus vaccine use protocol 100801;HPV vaccine use proto;;TRIAL;2.36;2.66 +62663-0;PhenX measure - male reproductive tract birth defects;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - male reproductive tract birth defects;;;DEPRECATED;2.36;2.46 +62664-8;PhenX - male reproductive tract birth defects protocol 100901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - male reproductive tract birth defects protocol 100901;Male reproductive birth defects proto;;TRIAL;2.36;2.66 +62665-5;PhenX measure - male sexual function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - male sexual function;;;DEPRECATED;2.36;2.46 +62666-3;PhenX - male sexual function protocol 101001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - male sexual function protocol 101001;Male sexual func proto;;TRIAL;2.36;2.66 +62667-1;PhenX measure - menstrual history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - menstrual history;;;DEPRECATED;2.36;2.46 +62668-9;PhenX - menstrual history protocol 101101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - menstrual history protocol 101101;Menstrual hx proto;;TRIAL;2.36;2.66 +62669-7;PhenX measure - prostate health;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - prostate health;;;DEPRECATED;2.36;2.46 +62670-5;PhenX - prostate health protocol 101201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - prostate health protocol 101201;Prostate health proto;;TRIAL;2.36;2.73 +62671-3;PhenX measure - reproductive history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - reproductive history;;;DEPRECATED;2.36;2.46 +62672-1;PhenX - reproductive history - female protocol 101301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - reproductive history - female protocol 101301;Reproductive history female proto;;TRIAL;2.36;2.66 +62673-9;PhenX measure - sexual history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - sexual history;;;DEPRECATED;2.36;2.46 +62674-7;PhenX - sexual history protocol 101401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - sexual history protocol 101401;Sexual history proto;;TRIAL;2.36;2.66 +62675-4;PhenX measure - testes development;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - testes development;;;DEPRECATED;2.36;2.46 +62676-2;PhenX - testes development protocol 101501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - testes development protocol 101501;Testes development proto;;TRIAL;2.36;2.66 +62677-0;PhenX domain - Ocular;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Ocular;Domain - Ocular;;TRIAL;2.36;2.65 +62678-8;PhenX measure - contact biometry;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - contact biometry;;;DEPRECATED;2.36;2.46 +6267-9;Trichoderma viride Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trichoderma viride IgE Ab [Units/volume] in Serum;T viride IgE Qn;;ACTIVE;1.0d;2.73 +62679-6;PhenX - contact biometry protocol 110101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - contact biometry protocol 110101;Contact biometry proto;;TRIAL;2.36;2.66 +62680-4;PhenX measure - color vision;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - color vision;;;DEPRECATED;2.36;2.46 +62681-2;PhenX - color vision protocol 110201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - color vision protocol 110201;Color vision proto;;TRIAL;2.36;2.66 +62682-0;PhenX measure - dry eye syndrome;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - dry eye syndrome;;;DEPRECATED;2.36;2.46 +62683-8;PhenX - dry eye syndrome protocol 110301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - dry eye syndrome protocol 110301;PhenX - dry eye syndrome protocol;;TRIAL;2.36;2.66 +62684-6;PhenX measure - eye diseases - treatment in young children;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - eye diseases - treatment in young children;;;DEPRECATED;2.36;2.46 +62685-3;PhenX - eye diseases - treatment in young children protocol 110401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - eye diseases - treatment in young children protocol 110401;Eye diseases young children proto;;TRIAL;2.36;2.66 +62686-1;PhenX measure - eye drop use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - eye drop use;;;DEPRECATED;2.36;2.46 +6268-7;Oncorhynchus mykiss Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trout IgE Ab [Units/volume] in Serum;Trout IgE Qn;;ACTIVE;1.0d;2.73 +62687-9;PhenX - eye drop use protocol 110501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - eye drop use protocol 110501;Eye drop use proto;;TRIAL;2.36;2.66 +62688-7;PhenX measure - eye patching;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - eye patching;;;DEPRECATED;2.36;2.46 +62689-5;PhenX - eye patching protocol 110601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - eye patching protocol 110601;Eye patching proto;;TRIAL;2.36;2.66 +62690-3;PhenX measure - intraocular pressure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - intraocular pressure;;;DEPRECATED;2.36;2.46 +62691-1;PhenX - intraocular pressure protocol 110701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - intraocular pressure protocol 110701;Intraocular pressure proto;;TRIAL;2.36;2.66 +62692-9;PhenX measure - ocular exposure to ultraviolet light;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - ocular exposure to ultraviolet light;;;DEPRECATED;2.36;2.46 +62693-7;PhenX - ocular exposure to ultraviolet light protocol 110801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - ocular exposure to ultraviolet light protocol 110801;Ocular exposure UV light protocol;;TRIAL;2.36;2.66 +62694-5;PhenX measure - personal and family history of eye disease and treatments;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal and family history of eye disease and treatments;;;DEPRECATED;2.36;2.46 +6269-5;Tulipa spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tulip IgE Ab [Units/volume] in Serum;Tulip IgE Qn;;ACTIVE;1.0d;2.70 +62695-2;PhenX measure - personal - family history of strabismus;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal - family history of strabismus;;;DEPRECATED;2.36;2.46 +62696-0;PhenX - personal - family history of strabismus protocol 111001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal - family history of strabismus protocol 111001;Pers fam hx strabismus proto;;TRIAL;2.36;2.66 +62697-8;PhenX measure - visual acuity;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - visual acuity;;;DEPRECATED;2.36;2.46 +62698-6;PhenX - visual acuity protocol 111101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - visual acuity protocol 111101;Visual acuity proto;;TRIAL;2.36;2.66 +62699-4;PhenX measure - visual function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - visual function;;;DEPRECATED;2.36;2.46 +627-0;Bacteria identified;Prid;Pt;Tiss;Nom;Aerobic culture;MICRO;1;Bacteria identified in Tissue by Aerobe culture;Bacteria Tiss Aerobe Cult;;ACTIVE;1.0;2.73 +62700-0;PhenX - visual function protocol 111201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - visual function protocol 111201;Visual function proto;;TRIAL;2.36;2.66 +62701-8;PhenX measure - corrective lens use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - corrective lens use;;;DEPRECATED;2.36;2.46 +62702-6;PhenX - contact lens use - adult protocol 111301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - contact lens use - adult protocol 111301;Contact lens use adult proto;;TRIAL;2.36;2.66 +6270-3;Thunnus albacares Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tuna IgE Ab [Units/volume] in Serum;Tuna IgE Qn;;ACTIVE;1.0d;2.73 +62704-2;PhenX - use of eye glasses - adult protocol 111303;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - use of eye glasses - adult protocol 111303;Use of eye glasses adult proto;;TRIAL;2.36;2.66 +62705-9;PhenX measure - refractive error measurement;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - refractive error measurement;;;DEPRECATED;2.36;2.46 +62706-7;PhenX - refractive error - adult protocol 111401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - refractive error - adult protocol 111401;Refractive error adult proto;;TRIAL;2.36;2.66 +62707-5;PhenX - refractive error - child protocol 111402;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - refractive error - child protocol 111402;Refractive error child proto;;TRIAL;2.36;2.66 +62708-3;PhenX measure - retinal digital photography;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - retinal digital photography;;;DEPRECATED;2.36;2.46 +62709-1;PhenX - retinal digital photography protocol 111501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - retinal digital photography protocol 111501;Retinal digital photography proto;;TRIAL;2.36;2.66 +62710-9;PhenX domain - Psychiatric;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Psychiatric;Domain - Psychiatric;;TRIAL;2.36;2.65 +6271-1;Turkey meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Turkey meat IgE Ab [Units/volume] in Serum;Turkey Meat IgE Qn;;ACTIVE;1.0d;2.73 +62711-7;PhenX measure - general psychiatric assessment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - general psychiatric assessment;;;DEPRECATED;2.36;2.46 +62712-5;PhenX - general psychiatric assessment - adult protocol 120101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - general psychiatric assessment - adult protocol 120101;Gen psych assess adult proto;;TRIAL;2.36;2.66 +62713-3;PhenX - general psychiatric assessment - child protocol 120102;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - general psychiatric assessment - child protocol 120102;Gen psych assess child protocol;;TRIAL;2.36;2.66 +62714-1;PhenX measure - anxiety disorders screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - anxiety disorders screener;;;DEPRECATED;2.36;2.46 +62715-8;PhenX - anxiety disorders screener - child protocol 120201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - anxiety disorders screener - child protocol 120201;Anx disorders screener child proto;;TRIAL;2.36;2.66 +62716-6;PhenX - anxiety disorders screener - adult protocol 120202;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - anxiety disorders screener - adult protocol 120202;Anx disorders screener adult proto;;TRIAL;2.36;2.66 +62717-4;PhenX measure - compulsive disorder screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - compulsive disorder screener;;;DEPRECATED;2.36;2.46 +62718-2;PhenX - obsessive compulsive disorder screener protocol 120301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - obsessive compulsive disorder screener protocol 120301;Obs - Compuls screener proto;;TRIAL;2.36;2.66 +62719-0;PhenX measure - hypomania - mania symptoms;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - hypomania - mania symptoms;;;DEPRECATED;2.36;2.46 +62720-8;PhenX - hypomania - mania symptoms - child protocol 120401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - hypomania - mania symptoms - child protocol 120401;Hypomania mania sympts child proto;;TRIAL;2.36;2.66 +62721-6;PhenX - hypomania - mania symptoms - adult protocol 120402;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - hypomania - mania symptoms - adult protocol 120402;Hypomania mania sympts adult proto;;TRIAL;2.36;2.66 +62722-4;PhenX measure - depression;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - depression;;;DEPRECATED;2.36;2.46 +62723-2;PhenX - depression - child protocol 120501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - depression - child protocol 120501;Depression child proto;;TRIAL;2.36;2.66 +62724-0;PhenX - depression - adult protocol 120502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - depression - adult protocol 120502;Depression adult proto;;TRIAL;2.36;2.66 +62725-7;PhenX measure - eating disorders screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - eating disorders screener;;;DEPRECATED;2.36;2.46 +62726-5;PhenX - eating disorders screener protocol 120601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - eating disorders screener protocol 120601;Eating disorders screener proto;;TRIAL;2.36;2.66 +62727-3;PhenX - personal and family history of eye disease and treatments protocol 110901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal and family history of eye disease and treatments protocol 110901;Pers fam hx eye disease proto;;TRIAL;2.36;2.66 +62728-1;PhenX - use of glasses - contact lenses as child protocol 111302;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - use of glasses - contact lenses as child protocol 111302;Glasses contact lenses child proto;;TRIAL;2.36;2.66 +6272-9;Holcus lanatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Velvet grass IgE Ab [Units/volume] in Serum;Velvet grass IgE Qn;;ACTIVE;1.0d;2.73 +62731-5;PhenX measure - medications - pain relievers, statins, steroids;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - medications - pain relievers, statins, steroids;;;DEPRECATED;2.36;2.46 +62732-3;PhenX - medications - pain relievers, statins, steroids protocol 071201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - medications - pain relievers, statins, steroids protocol 071201;Meds pain statins steroids proto;;TRIAL;2.36;2.66 +62733-1;PhenX - respiratory - pulse oximetry - rest protocol 091101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - respiratory - pulse oximetry - rest protocol 091101;Resp pulse ox rest proto;;TRIAL;2.36;2.66 +62734-9;PhenX measure - respiratory - pulse oximetry - rest;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - respiratory - pulse oximetry - rest;;;DEPRECATED;2.36;2.46 +62736-4;PhenX - schizophrenia protocol 120701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - schizophrenia protocol 120701;Schizophrenia proto;;TRIAL;2.36;2.66 +6273-7;Juglans spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Walnut IgE Ab [Units/volume] in Serum;Walnut IgE Qn;;ACTIVE;1.0d;2.73 +62737-2;PhenX measure - symptoms of autism spectrum disorders;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - symptoms of autism spectrum disorders;;;DEPRECATED;2.36;2.61 +62738-0;PhenX - symptoms of autism spectrum disorders - adult protocol 120901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - symptoms of autism spectrum disorders - adult protocol 120901;Autism disorders adult proto;;TRIAL;2.36;2.66 +62739-8;PhenX - symptoms of autism spectrum disorders - adolescent protocol 120902;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - symptoms of autism spectrum disorders - adolescent protocol 120902;Autism disorders adoles proto;;TRIAL;2.36;2.66 +62740-6;PhenX - symptoms of autism spectrum disorders - child protocol 120903;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - symptoms of autism spectrum disorders - child protocol 120903;Autism disorders child proto;;TRIAL;2.36;2.66 +62741-4;PhenX measure - sleep disorders screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - sleep disorders screener;;;DEPRECATED;2.36;2.46 +62742-2;PhenX - sleep disorders screener protocol 121001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - sleep disorders screener protocol 121001;Sleep disorders screener proto;;TRIAL;2.36;2.66 +62743-0;PhenX measure - personality traits;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personality traits;;;DEPRECATED;2.36;2.46 +62744-8;PhenX - personality traits protocol 121101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personality traits protocol 121101;Personality traits proto;;TRIAL;2.36;2.66 +6274-5;Juglans california Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;California Walnut IgE Ab [Units/volume] in Serum;Calif Walnut IgE Qn;;ACTIVE;1.0d;2.73 +62745-5;PhenX measure - general distress screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - general distress screener;;;DEPRECATED;2.36;2.46 +62746-3;PhenX - general distress screener protocol 121301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - general distress screener protocol 121301;General distress screener proto;;TRIAL;2.36;2.66 +62747-1;PhenX measure - posttraumatic stress disorder (PTSD);-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - posttraumatic stress disorder (PTSD);;;DEPRECATED;2.36;2.46 +62748-9;PhenX - posttraumatic stress disorder (PTSD) protocol 121401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - posttraumatic stress disorder (PTSD) protocol 121401;Posttraumatic stress disorder proto;;TRIAL;2.36;2.66 +62749-7;PhenX measure - attention-deficit - hyperactivity disorder symptoms;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - attention-deficit - hyperactivity disorder symptoms;;;DEPRECATED;2.36;2.46 +62750-5;PhenX - attention-deficit - hyperactivity disorder symptoms protocol - adult 121501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - attention-deficit - hyperactivity disorder symptoms protocol - adult 121501;Attention deficit hyperac adult proto;;TRIAL;2.36;2.66 +62751-3;PhenX - attention-deficit - hyperactivity disorder symptoms protocol - child 121502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - attention-deficit - hyperactivity disorder symptoms protocol - child 121502;Attention deficit hyperac child proto;;TRIAL;2.36;2.66 +6275-2;Ambrosia psilostachya Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Western Ragweed IgE Ab [Units/volume] in Serum;West Ragweed IgE Qn;;ACTIVE;1.0d;2.73 +62752-1;PhenX measure - psychopathy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - psychopathy;;;DEPRECATED;2.36;2.46 +62753-9;PhenX - psychopathy protocol 121601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - psychopathy protocol 121601;Psychopathy proto;;TRIAL;2.36;2.66 +62754-7;PhenX measure - schizophrenia;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - schizophrenia;;;DEPRECATED;2.36;2.46 +62755-4;PhenX domain - Neurology;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Neurology;Domain - Neurology;;TRIAL;2.36;2.65 +62756-2;PhenX measure - parkinsonian symptoms;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - parkinsonian symptoms;;;DEPRECATED;2.36;2.46 +62757-0;PhenX - parkinsonian protocol 130101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - parkinsonian protocol 130101;Parkinsonian proto;;TRIAL;2.36;2.66 +62758-8;PhenX measure - clinical neuropathy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - clinical neuropathy;;;DEPRECATED;2.36;2.46 +62759-6;PhenX - clinical neuropathy protocol 130201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - clinical neuropathy protocol 130201;Clinical neuropathy proto;;TRIAL;2.36;2.66 +6276-0;Triticum aestivum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat IgE Ab [Units/volume] in Serum;Wheat IgE Qn;;ACTIVE;1.0d;2.73 +62760-4;PhenX measure - history of stroke - ischemic infarct - hemorrhage;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - history of stroke - ischemic infarct - hemorrhage;;;DEPRECATED;2.36;2.46 +62761-2;PhenX - history of stroke protocol 130301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - history of stroke protocol 130301;Hx stroke proto;;TRIAL;2.36;2.66 +62762-0;PhenX measure - epilepsy screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - epilepsy screener;;;DEPRECATED;2.36;2.46 +62763-8;PhenX - epilepsy screener protocol 130401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - epilepsy screener protocol 130401;Epilepsy screener proto;;TRIAL;2.36;2.66 +62764-6;PhenX measure - migraine;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - migraine;;;DEPRECATED;2.36;2.46 +62765-3;PhenX - migraine protocol 130501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - migraine protocol 130501;Migraine proto;;TRIAL;2.36;2.66 +62766-1;PhenX measure - history of head trauma;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - history of head trauma;;;DEPRECATED;2.36;2.46 +62767-9;PhenX - head trauma protocol 130601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - head trauma protocol 130601;Head trauma proto;;TRIAL;2.36;2.66 +62768-7;PhenX measure - global mental status screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - global mental status screener;;;DEPRECATED;2.36;2.46 +62769-5;PhenX - global mental status - adult protocol 130701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - global mental status - adult protocol 130701;Global mental status adult proto;;TRIAL;2.36;2.66 +62770-3;PhenX - global mental status - child protocol 130702;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - global mental status - child protocol 130702;Global mental status child proto;;TRIAL;2.36;2.66 +62771-1;PhenX measure - verbal memory;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - verbal memory;;;DEPRECATED;2.36;2.46 +62772-9;PhenX - verbal memory protocol 130801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - verbal memory protocol 130801;Verbal memory proto;;TRIAL;2.36;2.66 +62773-7;PhenX measure - visual memory;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - visual memory;;;DEPRECATED;2.36;2.46 +62774-5;PhenX - visual memory protocol 130901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - visual memory protocol 130901;Visual memory proto;;TRIAL;2.36;2.66 +62775-2;PhenX measure - working memory;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - working memory;;;DEPRECATED;2.36;2.46 +62776-0;PhenX - working memory protocol 131001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - working memory protocol 131001;Working memory proto;;TRIAL;2.36;2.66 +62777-8;PhenX measure - executive function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - executive function;;;DEPRECATED;2.36;2.46 +6277-8;Triticum aestivum pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Wheat IgE Ab [Units/volume] in Serum;Cultivated Wheat IgE Qn;;ACTIVE;1.0d;2.73 +62778-6;PhenX - executive function protocol 131101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - executive function protocol 131101;Executive function proto;;TRIAL;2.36;2.66 +62779-4;PhenX measure - gross motor function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - gross motor function;;;DEPRECATED;2.36;2.46 +62780-2;PhenX - gross motor function - 2-4Y protocol 131201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - gross motor function - 2-4Y protocol 131201;Gross motor func 2-4Y proto;;TRIAL;2.36;2.66 +62781-0;PhenX - gross motor function - 4-6Y protocol 131202;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - gross motor function - 4-6Y protocol 131202;Gross motor func 4-6Y proto;;TRIAL;2.36;2.66 +62782-8;PhenX - gross motor function - 6-12Y protocol 131203;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - gross motor function - 6-12 years protocol 131203;Gross motor func 6-12Y proto;;TRIAL;2.36;2.66 +62783-6;PhenX measure - signs of essential tremor;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - signs of essential tremor;;;DEPRECATED;2.36;2.46 +62784-4;PhenX - signs of essential tremor protocol 131301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - signs of essential tremor protocol 131301;Signs of essential tremor proto;;TRIAL;2.36;2.66 +62785-1;PhenX measure - symptoms of restless legs syndrome;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - symptoms of restless legs syndrome;;;DEPRECATED;2.36;2.46 +6278-6;Fraxinus americana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Ash IgE Ab [Units/volume] in Serum;White Ash IgE Qn;;ACTIVE;1.0d;2.73 +62786-9;PhenX - restless legs syndrome protocol 131401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - restless legs syndrome protocol 131401;Restless legs syndrome proto;;TRIAL;2.36;2.66 +62787-7;PhenX domain - Diabetes;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Diabetes;Domain - Diabetes;;TRIAL;2.36;2.67 +62788-5;PhenX measure - autoimmune diseases related to type 1 diabetes;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - autoimmune diseases related to type 1 diabetes;;;DEPRECATED;2.36;2.46 +62789-3;PhenX - autoimmune diseases related to type 1 diabetes protocol 140101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - autoimmune diseases related to type 1 diabetes protocol 140101;Autoimmune dis type 1 diabetes proto;;TRIAL;2.36;2.66 +62790-1;PhenX measure - family history of diabetes;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - family history of diabetes;;;DEPRECATED;2.36;2.46 +62791-9;PhenX - family history of diabetes protocol 140201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - family history of diabetes protocol 140201;Fam hx diabetes proto;;TRIAL;2.36;2.66 +62792-7;PhenX measure - medication inventory;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - medication inventory;;;DEPRECATED;2.36;2.46 +62793-5;PhenX - medication inventory protocol 140301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - medication inventory protocol 140301;Medication inventory proto;;TRIAL;2.36;2.66 +6279-4;Bean white Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Bean IgE Ab [Units/volume] in Serum;White Bean IgE Qn;;ACTIVE;1.0d;2.73 +62794-3;PhenX measure - diabetic peripheral neuropathy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - diabetic peripheral neuropathy;;;DEPRECATED;2.36;2.46 +62795-0;PhenX - diabetic peripheral neuropathy protocol 140401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - diabetic peripheral neuropathy protocol 140401;Diabetic peripheral neuropathy proto;;TRIAL;2.36;2.66 +62796-8;PhenX measure - personal history of type 1- type 2 diabetes;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal history of type 1- type 2 diabetes;;;DEPRECATED;2.36;2.46 +62797-6;PhenX - personal history of type 1 - type 2 diabetes protocol 140501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal history of type 1 - type 2 diabetes protocol 140501;Pers hx type 1-2 diabetes proto;;TRIAL;2.36;2.66 +62798-4;PhenX measure - personal history of kidney failure;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal history of kidney failure;;;DEPRECATED;2.36;2.46 +62799-2;PhenX - personal history of kidney failure protocol 140601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal history of kidney failure protocol 140601;Pers hx kidney failure proto;;TRIAL;2.36;2.66 +62800-8;PhenX measure - diabetic retinopathy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - diabetic retinopathy;;;DEPRECATED;2.36;2.46 +62801-6;PhenX - diabetic retinopathy protocol 140701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - diabetic retinopathy protocol 140701;Diabetic retinopathy proto;;TRIAL;2.36;2.66 +6280-2;Dolichovespula maculata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whitefaced Hornet IgE Ab [Units/volume] in Serum;Whitefaced Hornet IgE Qn;;ACTIVE;1.0d;2.73 +62802-4;PhenX measure - fasting C-peptide assay for residual beta cell function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - fasting C-peptide assay for residual beta cell function;;;DEPRECATED;2.36;2.46 +62803-2;PhenX - fasting C-peptide assay for residual beta cell function protocol 141201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - fasting C-peptide assay for residual beta cell function protocol 141201;Fasting C-peptide proto;;TRIAL;2.36;2.66 +62804-0;PhenX measure - fasting serum insulin;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - fasting serum insulin;;;DEPRECATED;2.36;2.46 +62805-7;PhenX - fasting serum insulin protocol 141301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - fasting serum insulin protocol 141301;Fasting serum insulin proto;;TRIAL;2.36;2.66 +62806-5;PhenX measure - serum creatinine assay for kidney function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - serum creatinine assay for kidney function;;;DEPRECATED;2.36;2.46 +62807-3;PhenX - serum creatinine assay for kidney function protocol 141401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - serum creatinine assay for kidney function protocol 141401;Serum creatinine assay proto;;TRIAL;2.36;2.66 +62808-1;PhenX measure - urinary microalbumin assay for kidney function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - urinary microalbumin assay for kidney function;;;DEPRECATED;2.36;2.46 +62809-9;PhenX - urinary microalbumin assay for kidney function protocol 141501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - urinary microalbumin assay for kidney function protocol 141501;Urinary microalbumin assay proto;;TRIAL;2.36;2.67 +6281-0;Morus alba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White mulberry IgE Ab [Units/volume] in Serum;White mulberry IgE Qn;;ACTIVE;1.0d;2.73 +62810-7;PhenX measure - urinary creatinine assay for kidney function;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - urinary creatinine assay for kidney function;;;DEPRECATED;2.36;2.46 +62811-5;PhenX - urinary creatinine assay for kidney function protocol 141601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - urinary creatinine assay for kidney function protocol 141601;Urinary creatinine assay proto;;TRIAL;2.36;2.73 +62812-3;PhenX domain - Physical activity and physical fitness;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Physical activity and physical fitness;Domain Physical act physical fit;;TRIAL;2.36;2.65 +62813-1;PhenX measure - cardiorespiratory fitness - exercise;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - cardiorespiratory fitness - exercise;;;DEPRECATED;2.36;2.46 +62814-9;PhenX - cardiorespiratory fitness - 1 mile walk protocol 150101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - cardiorespiratory fitness - 1 mile walk protocol 150101;Cardioresp fitness 1 mi walk proto;;TRIAL;2.36;2.66 +62815-6;PhenX - cardiorespiratory fitness - treadmill protocol 150102;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - cardiorespiratory fitness - treadmill protocol 150102;Cardioresp fitness treadmill proto;;TRIAL;2.36;2.66 +62816-4;PhenX measure - integrated fitness;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - integrated fitness;;;DEPRECATED;2.36;2.46 +62817-2;PhenX - integrated fitness - adult protocol 150201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - integrated fitness - adult protocol 150201;Integrated fitness adult proto;;TRIAL;2.36;2.66 +62818-0;PhenX - integrated fitness - older adult protocol 150202;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - integrated fitness - older adult protocol 150202;Integrated fitness older adult proto;;TRIAL;2.36;2.66 +62819-8;PhenX - integrated fitness - child protocol 150203;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - integrated fitness - child protocol 150203;Integrated fitness child proto;;TRIAL;2.36;2.66 +62820-6;PhenX measure - muscle strength;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - muscle strength;;;DEPRECATED;2.36;2.46 +62821-4;PhenX - muscle strength protocol 150301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - muscle strength protocol 150301;Muscle strength proto;;TRIAL;2.36;2.66 +62822-2;PhenX measure - physical activity - readiness;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - physical activity readiness;;;DEPRECATED;2.36;2.46 +62823-0;PhenX - physical activity - readiness protocol 150401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - physical activity - readiness protocol 150401;Phys act readiness proto;;TRIAL;2.36;2.66 +62824-8;PhenX measure - physical functioning - objective;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - physical functioning - objective;;;DEPRECATED;2.36;2.46 +62825-5;PhenX - physical functioning - objective protocol 150501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - physical functioning - objective protocol 150501;Phys func objective proto;;TRIAL;2.36;2.66 +62826-3;PhenX measure - sitting - sedentary behavior;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - sitting - sedentary behavior;;;DEPRECATED;2.36;2.46 +62827-1;PhenX - sitting - sedentary behavior - adult protocol 150601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - sitting - sedentary behavior - adult protocol 150601;Sit sedentary behav adult proto;;TRIAL;2.36;2.66 +6282-8;Pinus strobus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Eastern White Pine IgE Ab [Units/volume] in Serum;East White Pine IgE Qn;;ACTIVE;1.0d;2.73 +62828-9;PhenX - sitting - sedentary behavior - adolescent protocol 150602;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - sitting - sedentary behavior - adolescent protocol 150602;Sit sedentary behav adoles proto;;TRIAL;2.36;2.66 +62829-7;PhenX measure - total physical activity - comprehensive;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - total physical activity - comprehensive;;;DEPRECATED;2.36;2.46 +62830-5;PhenX - total physical activity - comprehensive - adolescent protocol 150701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - total physical activity - comprehensive - adolescent protocol 150701;Tot phys act comp adoles proto;;TRIAL;2.36;2.66 +62831-3;PhenX - total physical activity - comprehensive - adult protocol 150702;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - total physical activity - comprehensive - adult protocol 150702;Tot phys act comp adult proto;;TRIAL;2.36;2.66 +62832-1;PhenX - total physical activity - comprehensive - older adult protocol 150703;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - total physical activity - comprehensive - older adult protocol 150703;Tot phys activity comp old adult proto;;TRIAL;2.36;2.66 +62833-9;PhenX measure - total physical activity - objective;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - total physical activity - objective;;;DEPRECATED;2.36;2.46 +62834-7;PhenX - total physical activity - objective protocol 150801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - total physical activity - objective protocol 150801;Total phys activity objective proto;;TRIAL;2.36;2.66 +62835-4;PhenX measure - total physical activity - screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - total physical activity - screener;;;DEPRECATED;2.36;2.46 +6283-6;Elymus triticoides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Wild rye grass IgE Ab [Units/volume] in Serum;Deprecated Wild rye grass IgE Qn;;DEPRECATED;1.0d;2.70 +62836-2;PhenX - total physical activity - screener protocol 150901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - total physical activity - screener protocol 150901;Total phys activity screener proto;;TRIAL;2.36;2.66 +62837-0;PhenX measure - walking - ambulation objective;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - walking - ambulation objective;;;DEPRECATED;2.36;2.46 +62838-8;PhenX - walking - ambulation objective protocol 151001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - walking - ambulation objective protocol 151001;Walking ambulation objective proto;;TRIAL;2.36;2.66 +62839-6;PhenX measure - physical functioning - subjective;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - physical functioning - subjective;;;DEPRECATED;2.36;2.46 +62840-4;PhenX - physical functioning - subjective protocol 151101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - physical functioning - subjective protocol 151101;Phys func subj proto;;TRIAL;2.36;2.66 +62841-2;PhenX measure - physical activity - neighborhood environment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - physical activity - neighborhood environment;;;DEPRECATED;2.36;2.46 +62842-0;PhenX - physical activity - neighborhood environment protocol 151201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - physical activity - neighborhood environment protocol 151201;Phys act neighbor environ proto;;TRIAL;2.36;2.66 +62843-8;PhenX measure - physical activity - self efficacy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - physical activity - self efficacy;;;DEPRECATED;2.36;2.46 +6284-4;Silk wild Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wild Silk IgE Ab [Units/volume] in Serum;Wild Silk IgE Qn;;ACTIVE;1.0d;2.73 +62844-6;PhenX - physical activity - self efficacy - adolescent protocol 151301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - physical activity - self efficacy - adolescent protocol 151301;Phys act self efficacy adoles proto;;TRIAL;2.36;2.66 +62845-3;PhenX - physical activity - self efficacy - adult protocol 151302;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - physical activity - self efficacy - adult protocol 151302;Phys act self efficacy adult proto;;TRIAL;2.36;2.66 +62846-1;PhenX measure - cardiorespiratory fitness - non-exercise;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - cardiorespiratory fitness - non-exercise;;;DEPRECATED;2.36;2.46 +62847-9;PhenX - cardiorespiratory fitness - non-exercise protocol 151401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - cardiorespiratory fitness - non-exercise protocol 151401;Cardioresp non-exercise proto;;TRIAL;2.36;2.66 +62848-7;Mirtazapine+Normirtazapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mirtazapine+Normirtazapine [Mass/volume] in Serum or Plasma;Mirtazapine+Normirtazapine SerPl-mCnc;;ACTIVE;2.36;2.70 +62849-5;Venlafaxine+O-desmethylvenlafaxine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Venlafaxine+O-desmethylvenlafaxine [Mass/volume] in Serum or Plasma;Vnlfxn+ODV SerPl-mCnc;;ACTIVE;2.36;2.73 +62850-3;PhenX measure - fasting plasma glucose for diabetes screening - blood draw;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - fasting plasma glucose for diabetes screening - blood draw;;;DEPRECATED;2.36;2.46 +6285-1;Salix caprea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Willow IgE Ab [Units/volume] in Serum;Willow IgE Qn;;ACTIVE;1.0d;2.73 +62851-1;PhenX - fasting plasma glucose for diabetes screening - blood draw protocol 140801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - fasting plasma glucose for diabetes screening - blood draw protocol 140801;Fast plasma gluc blood draw proto;;TRIAL;2.36;2.67 +62852-9;PhenX - fasting plasma glucose for diabetes screening - glucometer protocol 140802;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - fasting plasma glucose for diabetes screening - glucometer protocol 140802;Fast plasma gluc glucometer proto;;TRIAL;2.36;2.67 +62853-7;PhenX measure - glycosylated hemoglobin assay that reflects long-term glucose concentration;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - glycosylated hemoglobin assay that reflects long-term glucose concentration;;;DEPRECATED;2.36;2.46 +62854-5;PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol 140901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol 140901;Glycosylated hemoglobin assay;;TRIAL;2.36;2.67 +62855-2;PhenX measure - oral glucose tolerance test;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - oral glucose tolerance test;;;DEPRECATED;2.36;2.46 +62856-0;PhenX - oral glucose tolerance test protocol 141001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - oral glucose tolerance test protocol 141001;Oral glucose tolerance test proto;;TRIAL;2.36;2.67 +62857-8;Micromegakaryocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Micromegakaryocytes [#/volume] in Blood by Manual count;Micromegakaryocytes # Bld Manual;;ACTIVE;2.36;2.70 +62858-6;Micromegakaryocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Micromegakaryocytes/100 leukocytes in Blood by Manual count;Micromegakaryocytes/leuk NFr Bld Manual;;ACTIVE;2.36;2.73 +62859-4;Rotavirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rotavirus RNA [Presence] in Specimen by NAA with probe detection;RV RNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +62860-2;Influenza virus C RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus C RNA [Presence] in Specimen by NAA with probe detection;FLUCV RNA Spec Ql NAA+probe;;ACTIVE;2.36;2.69 +62861-0;Enterovirus 71 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterovirus 71 RNA [Presence] in Specimen by NAA with probe detection;EV 71 RNA Spec Ql NAA+probe;;ACTIVE;2.36;2.69 +62862-8;Microsatellite instability;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Microsatellite instability [Presence] in Tissue by Immune stain;MSI Tiss Ql ImStn;;ACTIVE;2.36;2.73 +62863-6;PhenX domain - Infectious diseases and immunity;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Infectious diseases and immunity;Domain - Infectious diseases immunity;;TRIAL;2.36;2.67 +62864-4;PhenX measure - assay for chlamydia - gonorrhea;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assay for chlamydia - gonorrhea;;;DEPRECATED;2.36;2.46 +62865-1;PhenX - assay for chlamydia - gonorrhea protocol 160101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assay for chlamydia - gonorrhea protocol 160101;Assay for chlamydia gonorrhea proto;;TRIAL;2.36;2.67 +62866-9;PhenX measure - assay for cytokine panel 12;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assay for cytokine panel 12;;;DEPRECATED;2.36;2.46 +62867-7;PhenX - assay for cytokine panel 12 protocol 160201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assay for cytokine panel 12 protocol 160201;Assay for cytokine panel 12 proto;;TRIAL;2.36;2.67 +62868-5;PhenX measure - assay for hepatitis C;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assay for hepatitis C;;;DEPRECATED;2.36;2.46 +6286-9;Artemisia absinthium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wormwood IgE Ab [Units/volume] in Serum;Wormwood IgE Qn;;ACTIVE;1.0d;2.73 +62869-3;PhenX - assay for hepatitis C protocol 160301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assay for hepatitis C protocol 160301;Assay for hepatitis C proto;;TRIAL;2.36;2.67 +62870-1;PhenX measure - assay for hepatitis B;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assay for hepatitis B;;;DEPRECATED;2.36;2.46 +62871-9;PhenX - assay for hepatitis B protocol 160401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assay for hepatitis B protocol 160401;Assay for hepatitis B proto;;TRIAL;2.36;2.67 +62872-7;PhenX measure - assay herpes simplex virus types 1 - 2;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assay herpes simplex virus types 1 - 2;;;DEPRECATED;2.36;2.46 +62873-5;PhenX - assay herpes simplex virus types 1 - 2 protocol 160501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assay herpes simplex virus types 1 - 2 protocol 160501;Assay herpes simplex 1-2 proto;;TRIAL;2.36;2.67 +62874-3;PhenX measure - assay for human leukocyte antigen (HLA) genotyping;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assay for human leukocyte antigen (HLA) genotyping;;;DEPRECATED;2.36;2.46 +62875-0;PhenX - assay for human leukocyte antigen (HLA) genotyping protocol 160601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assay for human leukocyte antigen (HLA) genotyping protocol 160601;Assay human leukocyte antg (HLA) proto;;TRIAL;2.36;2.67 +62876-8;PhenX measure - assay for syphilis;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assay for syphilis;;;DEPRECATED;2.36;2.46 +6287-7;Saccharomyces cerevisiae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast IgE Ab [Units/volume] in Serum;Baker's yeast IgE Qn;;ACTIVE;1.0d;2.73 +62877-6;PhenX - assay for syphilis protocol 160701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assay for syphilis protocol 160701;Assay for syphilis proto;;TRIAL;2.36;2.67 +62878-4;PhenX measure - conditions relevant to immune response - screener;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - conditions relevant to immune response - screener;;;DEPRECATED;2.36;2.46 +62879-2;PhenX - conditions relevant to immune response - screener - adult protocol 160801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - conditions relevant to immune response - screener - adult protocol 160801;Immune response - adult proto;;TRIAL;2.36;2.66 +628-8;Bacteria identified;Prid;Pt;Tiss;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Tissue by Anaerobe culture;Bacteria Tiss Anaerobe Cult;;ACTIVE;1.0;2.73 +62880-0;PhenX - conditions relevant to immune response - screener - child protocol 160802;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - conditions relevant to immune response - screener - child protocol 160802;Immune response - child proto;;TRIAL;2.36;2.66 +62881-8;PhenX measure - human immunodeficiency virus (HIV);-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - human immunodeficiency virus (HIV);;;DEPRECATED;2.36;2.46 +62882-6;PhenX - human immunodeficiency virus (HIV) protocol 160901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - human immunodeficiency virus (HIV) protocol 160901;HIV proto;;TRIAL;2.36;2.67 +62883-4;PhenX measure - immunizations;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - immunizations;;;DEPRECATED;2.36;2.46 +62884-2;PhenX - immunizations protocol 161001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - immunizations protocol 161001;Immunizations proto;;TRIAL;2.36;2.66 +6288-5;Dolichovespula arenaria Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Hornet IgE Ab [Units/volume] in Serum;Yellow Hornet IgE Qn;;ACTIVE;1.0d;2.73 +62885-9;PhenX measure - injection drug use;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - injection drug use;;;DEPRECATED;2.36;2.46 +62886-7;PhenX - injection drug use protocol 161101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - injection drug use protocol 161101;Injection drug use proto;;TRIAL;2.36;2.66 +62887-5;PhenX measure - international travel history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - international travel history;;;DEPRECATED;2.36;2.46 +62888-3;PhenX - international travel history protocol 161201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - international travel history protocol 161201;International travel hx proto;;TRIAL;2.36;2.67 +62889-1;PhenX measure - medical history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - medical history;;;DEPRECATED;2.36;2.46 +62890-9;PhenX - medical history protocol 161301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - medical history protocol 161301;Medical history proto;;TRIAL;2.36;2.66 +62891-7;PhenX measure - personal - family history of autoimmune - inflammatory disorders;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal - family history of autoimmune - inflammatory disorders;;;DEPRECATED;2.36;2.46 +62892-5;PhenX - personal - family history of autoimmune - inflammatory disorders protocol 161401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal - family history of autoimmune - inflammatory disorders protocol 161401;Pers fam hx autoimm inflamm proto;;TRIAL;2.36;2.66 +6289-3;Lysozyme;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lysozyme [Moles/volume] in Serum or Plasma;Lysozyme SerPl-sCnc;;ACTIVE;1.0d;2.73 +62893-3;PhenX measure - personal medical history of allergies, infectious diseases, and immunizations;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal medical history of allergies, infectious diseases, and immunizations;;;DEPRECATED;2.36;2.46 +62894-1;PhenX - personal medical history of allergies, infectious diseases, and immunizations - child protocol 161601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal medical history of allergies, infectious diseases, and immunizations - child protocol 161601;Hx allerg infect immun child proto;;TRIAL;2.36;2.66 +62895-8;PhenX - personal medical history of allergies, infectious diseases, and immunizations - adult protocol 161602;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal medical history of allergies, infectious diseases, and immunizations - adult protocol 161602;Hx allerg infect immun adult proto;;TRIAL;2.36;2.68 +62896-6;PhenX domain - Skin, bone, muscle and joint;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Skin, bone, muscle and joint;Domain - Skin, bone, muscle and joint;;TRIAL;2.36;2.67 +62897-4;PhenX measure - alkaline phosphatase;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - alkaline phosphatase;;;DEPRECATED;2.36;2.46 +62898-2;PhenX - alkaline phosphatase protocol 170101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - alkaline phosphatase protocol 170101;Alkaline phosphatase proto;;TRIAL;2.36;2.67 +62899-0;PhenX measure - arthritis - osteoarthritis;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - arthritis - osteoarthritis;;;DEPRECATED;2.36;2.46 +62900-6;PhenX - arthritis - osteoarthritis protocol 170201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - arthritis - osteoarthritis protocol 170201;Arthritis osteoarthritis proto;;TRIAL;2.36;2.66 +6290-1;Complement membrane C3b-C4b cofactor protein;PrThr;Pt;WBC;Ord;;HEM/BC;1;Complement membrane C3b-C4b cofactor protein [Presence] in Leukocytes;MCP C3b-C4b WBC Ql;;ACTIVE;1.0d;2.56 +62901-4;PhenX measure - eczema;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - eczema;;;DEPRECATED;2.36;2.46 +62902-2;PhenX - eczema protocol 170301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - eczema protocol 170301;Eczema proto;;TRIAL;2.36;2.66 +62903-0;PhenX measure - pain;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - pain;;;DEPRECATED;2.36;2.46 +62904-8;PhenX - pain protocol 170401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - pain protocol 170401;Pain proto;;TRIAL;2.36;2.73 +62905-5;PhenX measure - personal and family history of psoriasis;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal and family history of psoriasis;;;DEPRECATED;2.36;2.46 +62906-3;PhenX - personal and family history of psoriasis protocol 170501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal and family history of psoriasis protocol 170501;Pers fam hx psoriasis proto;;TRIAL;2.36;2.66 +62907-1;PhenX measure - skin cancer;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - skin cancer;;;DEPRECATED;2.36;2.46 +62908-9;PhenX - skin cancer protocol 170601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - skin cancer protocol 170601;Skin cancer proto;;TRIAL;2.36;2.66 +62909-7;PhenX measure - spine - femur bone density by dual-energy x-ray absorptiometry;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - spine - femur bone density by dual-energy x-ray absorptiometry;;;DEPRECATED;2.36;2.46 +62910-5;PhenX - spine - femur bone density by dual-energy x-ray absorptiometry protocol 170701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - spine - femur bone density by dual-energy x-ray absorptiometry protocol 170701;Spine - femur bone density DXA proto;;TRIAL;2.36;2.66 +62911-3;PhenX domain - Psychosocial;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Psychosocial;Domain - Psychosocial;;TRIAL;2.36;2.65 +62912-1;PhenX measure - acculturation;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - acculturation;;;DEPRECATED;2.36;2.46 +62913-9;PhenX - acculturation protocol 180101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - acculturation protocol 180101;Acculturation proto;;TRIAL;2.36;2.66 +62914-7;PhenX measure - coping styles;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - coping styles;;;DEPRECATED;2.36;2.46 +62915-4;PhenX - coping styles - adolescent protocol 180201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - coping styles - adolescent protocol 180201;Coping styles adolescent proto;;TRIAL;2.36;2.66 +62916-2;PhenX - coping styles - adult protocol 180202;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - coping styles - adult protocol 180202;Coping styles adult proto;;TRIAL;2.36;2.66 +62917-0;PhenX measure - current quality of life;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - current quality of life;;;DEPRECATED;2.36;2.46 +62918-8;PhenX - current quality of life protocol 180301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - current quality of life protocol 180301;Current quality of life proto;;TRIAL;2.36;2.66 +6291-9;Complement iC3b receptors;PrThr;Pt;WBC;Ord;;HEM/BC;1;Complement iC3b receptors [Presence] in Leukocytes;iC3b Recep WBC Ql;;ACTIVE;1.0d;2.56 +62919-6;PhenX measure - disinhibiting behaviors - impulsivity;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - disinhibiting behaviors - impulsivity;;;DEPRECATED;2.36;2.46 +62920-4;PhenX - disinhibiting behaviors - impulsivity - adult protocol 180401;-;Pt;^Patient;-;UPPS-P;PANEL.PHENX;2;PhenX - disinhibiting behaviors - impulsivity - adult protocol 180401 UPPS-P;Disinhibit behav - impuls adult UPPS-P;;TRIAL;2.36;2.66 +62921-2;PhenX - disinhibiting behaviors - impulsivity - child protocol 180402;-;Pt;^Patient;-;UPPS-R-C;PANEL.PHENX;2;PhenX - disinhibiting behaviors - impulsivity - child protocol 180402 UPPS-R-Child;Disinhibit behav/impuls -child UPPS-R-C;;TRIAL;2.36;2.66 +62922-0;PhenX measure - emotional state;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - emotional state;;;DEPRECATED;2.36;2.46 +62923-8;PhenX - emotional state - adult protocol 180501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - emotional state - adult protocol 180501;Emotional state - adult proto;;TRIAL;2.36;2.66 +62924-6;PhenX - emotional state - child protocol 180502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - emotional state - child protocol 180502;Emotional state - child proto;;TRIAL;2.36;2.66 +62925-3;PhenX measure - general self-efficacy;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - general self-efficacy;;;DEPRECATED;2.36;2.46 +62926-1;PhenX - general self-efficacy - adult protocol 180601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - general self-efficacy - adult protocol 180601;Gen self-efficacy - adult proto;;TRIAL;2.36;2.66 +6292-7;Complement decay accelerating factor;PrThr;Pt;RBC;Ord;;HEM/BC;1;Complement decay accelerating factor [Presence] in Red Blood Cells;Comp DAF RBC Ql;;ACTIVE;1.0d;2.56 +62927-9;PhenX - general self-efficacy - child protocol 180602;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - general self-efficacy - child protocol 180602;Gen self-efficacy - child proto;;TRIAL;2.36;2.66 +62928-7;PhenX measure - perceived social support - conflict;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - perceived social support - conflict;;;DEPRECATED;2.36;2.46 +62929-5;PhenX - perceived social support - conflict protocol 180701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - perceived social support - conflict protocol 180701;Social support - conflict proto;;TRIAL;2.36;2.66 +62930-3;PhenX measure - self-esteem;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - self-esteem;;;DEPRECATED;2.36;2.46 +62931-1;PhenX - self-esteem protocol 180901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - self-esteem protocol 180901;Self-esteem proto;;TRIAL;2.36;2.66 +62932-9;PhenX measure - social isolation;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - social isolation;;;DEPRECATED;2.36;2.46 +62933-7;PhenX - social isolation protocol 181001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - social isolation protocol 181001;Social isolation proto;;TRIAL;2.36;2.66 +62934-5;PhenX measure - temperament;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - temperament;;;DEPRECATED;2.36;2.46 +6293-5;Complement C4d;PrThr;Pt;RBC;Ord;;HEM/BC;1;Complement C4d [Presence] in Red Blood Cells;C4d RBC Ql;;ACTIVE;1.0d;2.56 +62935-2;PhenX - temperament - child protocol 181101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - temperament - child protocol 181101;Temperament - child proto;;TRIAL;2.36;2.66 +62936-0;PhenX - temperament - early child protocol 181102;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - temperament - early child protocol 181102;Temperament - early child proto;;TRIAL;2.36;2.66 +62937-8;PhenX - temperament - infant protocol 181103;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - temperament - infant protocol 181103;Temperament - infant proto;;TRIAL;2.36;2.66 +62938-6;PhenX measure - crime and delinquency;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - crime and delinquency;;;DEPRECATED;2.36;2.46 +62939-4;PhenX - crime and delinquency - adolescent protocol 181201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - crime and delinquency - adolescent protocol 181201;Crime delinquency adolescent proto;;TRIAL;2.36;2.66 +62940-2;PhenX - crime and delinquency - adult protocol 181202;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - crime and delinquency - adult protocol 181202;Crime delinquency adult proto;;TRIAL;2.36;2.66 +62941-0;PhenX measure - chronic stress;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - chronic stress;;;DEPRECATED;2.36;2.46 +62942-8;PhenX - chronic stress protocol 181301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - chronic stress protocol 181301;Chronic stress proto;;TRIAL;2.36;2.66 +6294-3;Complement C3d-C3d+Gg-IC3b receptors;EntNum;Pt;WBC;Qn;;HEM/BC;1;Deprecated Complement C3d-C3d+Gg-IC3b receptors [Entitic number] in Leukocytes;Deprecated C3d-C3d+Gg-iC3b Recep EntNum WBC;;DEPRECATED;1.0d;2.65 +62943-6;PhenX measure - exposures to violence;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - exposures to violence;;;DEPRECATED;2.36;2.46 +62944-4;PhenX - exposures to violence - adult protocol 181401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - exposures to violence - adult protocol 181401;Exposures to violence - adult proto;;TRIAL;2.36;2.66 +62945-1;PhenX - exposures to violence - child protocol 181402;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - exposures to violence - child protocol 181402;Exposures to violence - child proto;;TRIAL;2.36;2.66 +62946-9;Jamestown canyon virus Ab.IgM;Titr;Pt;Body fld;Qn;IF;MICRO;1;Jamestown canyon virus IgM Ab [Titer] in Body fluid by Immunofluorescence;JCV IgM Titr Fld IF;;ACTIVE;2.36;2.42 +62947-7;MPL gene.p.Trp515Leu+Trp515Lys+Ser505Asn;Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MPL gene p.Trp515Leu+Trp515Lys+Ser505Asn [Presence] in Blood or Tissue by Molecular genetics method;MPL p.W515L+W515K+S505N Bld/T Ql;;ACTIVE;2.36;2.73 +62948-5;MPL gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MPL gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MPL gene Mut Tested Bld/T;;ACTIVE;2.36;2.73 +62949-3;PhenX domain - Gastrointestinal;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Gastrointestinal;Domain - Gastrointestinal;;TRIAL;2.36;2.67 +6295-0;Complement C3d;PrThr;Pt;RBC;Ord;;HEM/BC;1;Complement C3d [Presence] in Red Blood Cells;C3d RBC Ql;;ACTIVE;1.0d;2.56 +62950-1;PhenX measure - assessment of functional gastrointestinal disorders;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assessment of functional gastrointestinal disorders;;;DEPRECATED;2.36;2.46 +62951-9;PhenX - assessment of functional gastrointestinal disorders - adult protocol 190101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assessment of functional gastrointestinal disorders - adult protocol 190101;Assess func GI disorders adult proto;;TRIAL;2.36;2.66 +62952-7;PhenX - assessment of functional gastrointestinal disorders - adolescent protocol 190102;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assessment of functional gastrointestinal disorders - adolescent protocol 190102;Assess func GI disorders adoles proto;;TRIAL;2.36;2.66 +62953-5;PhenX - assessment of functional gastrointestinal disorders - child protocol 190103;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assessment of functional gastrointestinal disorders - child protocol 190103;Assess func GI disorders child proto;;TRIAL;2.36;2.66 +62954-3;PhenX measure - assessment of gallbladder disease and related conditions;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - assessment of gallbladder disease and related conditions;;;DEPRECATED;2.36;2.46 +62955-0;PhenX - assessment of gallbladder disease and related conditions protocol 190201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - assessment of gallbladder disease and related conditions protocol 190201;Assessment gallbladder disease proto;;TRIAL;2.36;2.66 +62956-8;PhenX measure - celiac sprue assay;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - celiac sprue assay;;;DEPRECATED;2.36;2.46 +62957-6;PhenX - celiac sprue assay protocol 190301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - celiac sprue assay protocol 190301;Celiac sprue assay proto;;TRIAL;2.36;2.67 +62958-4;PhenX measure - colorectal procedures and outcomes;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - colorectal procedures and outcomes;;;DEPRECATED;2.36;2.46 +62959-2;PhenX - colorectal procedures and outcomes protocol 190401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - colorectal procedures and outcomes protocol 190401;Colorectal procedure outcomes proto;;TRIAL;2.36;2.66 +629-6;Bacteria identified;Prid;Pt;Ulc;Nom;Aerobic culture;MICRO;1;Deprecated Bacteria identified in Ulcer by Aerobe culture;Deprecated Bacteria Ulcer Aerobe Cult;;DEPRECATED;1.0;2.63 +62960-0;PhenX measure - computed tomography (CT) of the abdominal organs;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - computed tomography (CT) of the abdominal organs;;;DEPRECATED;2.36;2.46 +62961-8;PhenX - computed tomography (CT) of the abdominal organs protocol 190501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - computed tomography (CT) of the abdominal organs protocol 190501;CTabdominal organs proto;;TRIAL;2.36;2.66 +62962-6;PhenX measure - emotional distress;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - emotional distress;;;DEPRECATED;2.36;2.46 +62963-4;PhenX - emotional distress protocol 190601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - emotional distress protocol 190601;Emotional distress proto;;TRIAL;2.36;2.66 +62964-2;PhenX measure - health impact of inflammatory bowel disease;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - health impact of inflammatory bowel disease;;;DEPRECATED;2.36;2.46 +62965-9;PhenX - health impact of inflammatory bowel disease protocol 190701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - health impact of inflammatory bowel disease protocol 190701;Health impact of inflamm bowel proto;;TRIAL;2.36;2.66 +62966-7;PhenX measure - liver function assay;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - liver function assay;;;DEPRECATED;2.36;2.46 +62967-5;PhenX - liver function assay protocol 190801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - liver function assay protocol 190801;Liver func assay proto;;TRIAL;2.36;2.67 +6296-8;Complement C3b-C4b receptor;PrThr;Pt;RBC;Ord;;HEM/BC;1;Complement C3b-C4b receptor [Presence] in Red Blood Cells;C3b-C4b Recep RBC Ql;;ACTIVE;1.0d;2.56 +62968-3;PhenX measure - pain, abdominal - type and intensity;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - pain, abdominal - type and intensity;;;DEPRECATED;2.36;2.46 +62969-1;PhenX - pain, abdominal - type and intensity protocol 190901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - pain, abdominal - type and intensity protocol 190901;Pain abd - type intensity proto;;TRIAL;2.36;2.66 +62970-9;PhenX measure - personal history of gastrointestinal conditions;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal history of gastrointestinal conditions;;;DEPRECATED;2.36;2.46 +62971-7;PhenX - personal history of gastrointestinal conditions protocol 191001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal history of gastrointestinal conditions protocol 191001;Pers hx GI conditions proto;;TRIAL;2.36;2.66 +62972-5;PhenX measure - gastroesophageal reflux disease (GERD) symptoms;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - gastroesophageal reflux disease (GERD) symptoms;;;DEPRECATED;2.36;2.46 +62973-3;PhenX - gastroesophageal reflux disease (GERD) symptoms protocol 191101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - gastroesophageal reflux disease (GERD) symptoms protocol 191101;GERD symptoms proto;;TRIAL;2.36;2.66 +62974-1;PhenX measure - physical, social, and mental health functioning - SF-36v2;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - physical, social, and mental health functioning - SF-36v2;;;DEPRECATED;2.36;2.46 +62975-8;PhenX - physical, social, and mental health functioning - SF-36v2 protocol 191201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - physical, social, and mental health functioning - SF-36v2 protocol 191201;Phys soc mntl hlth func SF-36v2 proto;;TRIAL;2.36;2.66 +6297-6;Complement C1q Ag;ACnc;Pt;Ser;Qn;;HEM/BC;1;Complement C1q Ag [Units/volume] in Serum;C1q Ag Ser-aCnc;;ACTIVE;1.0e;2.73 +62976-6;PhenX measure - audiogram hearing test;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - audiogram hearing test;;;DEPRECATED;2.36;2.46 +62977-4;PhenX - audiogram hearing test protocol 200101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - audiogram hearing test protocol 200101;Audiogram hearing test proto;;TRIAL;2.36;2.73 +62978-2;PhenX measure - ear infections - otitis media;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - ear infections - otitis media;;;DEPRECATED;2.36;2.46 +62979-0;PhenX - ear infections - otitis media protocol 200201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - ear infections - otitis media protocol 200201;Ear infections - otitis media proto;;TRIAL;2.36;2.66 +62980-8;PhenX measure - early childhood speech and language assessment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - early childhood speech and language assessment;;;DEPRECATED;2.36;2.46 +62981-6;PhenX - early childhood speech and language assessment protocol - ages - stages questionnaire 200301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - early childhood speech and language assessment protocol - ages - stages questionnaire 200301;Child speech age stages proto;;TRIAL;2.36;2.66 +62982-4;PhenX - early childhood speech and language assessment protocol - speech and language assessment scale 200302;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - early childhood speech and language assessment protocol - speech and language assessment scale 200302;Child speech lang assess scale proto;;TRIAL;2.36;2.66 +62983-2;PhenX measure - family history of speech and language impairment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - family history of speech and language impairment;;;DEPRECATED;2.36;2.46 +6298-4;Potassium;SCnc;Pt;Bld;Qn;;CHEM;1;Potassium [Moles/volume] in Blood;Potassium Bld-sCnc;;ACTIVE;1.0f;2.73 +62984-0;PhenX - family history of speech and language impairment protocol 200401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - family history of speech and language impairment protocol 200401;Fam hx speech lang impair proto;;TRIAL;2.36;2.66 +62985-7;PhenX measure - grammatical impairments;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - grammatical impairments;;;DEPRECATED;2.36;2.46 +62986-5;PhenX - grammatical impairments - clinical evaluation of language fundamentals protocol 200501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - grammatical impairments - clinical evaluation of language fundamentals protocol 200501;Grammat impair - eval lang proto;;TRIAL;2.36;2.66 +62987-3;PhenX - grammatical impairments - test of early grammatical impairment protocol 200502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - grammatical impairments - test of early grammatical impairment protocol 200502;Grammat impairment proto;;TRIAL;2.36;2.66 +62988-1;PhenX - grammatical impairments - grammaticality judgment task protocol 200503;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - grammatical impairments - grammaticality judgment task protocol 200503;Grammat impair judgment proto;;TRIAL;2.36;2.66 +62989-9;PhenX measure - non-word repetition;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - non-word repetition;;;DEPRECATED;2.36;2.46 +62990-7;PhenX - non-word repetition protocol 200601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - non-word repetition protocol 200601;Non-word repetition proto;;TRIAL;2.36;2.66 +62991-5;PhenX measure - phonemic inventory;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - phonemic inventory;;;DEPRECATED;2.36;2.46 +6299-2;Urea nitrogen;MCnc;Pt;Bld;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Blood;BUN Bld-mCnc;;ACTIVE;1.0f;2.73 +62992-3;PhenX - phonemic inventory protocol 200701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - phonemic inventory protocol 200701;Phonemic inventory proto;;TRIAL;2.36;2.66 +62993-1;PhenX measure - reading comprehension;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - reading comprehension;;;DEPRECATED;2.36;2.46 +62994-9;PhenX - reading comprehension protocol 200801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - reading comprehension protocol 200801;Reading comprehension proto;;TRIAL;2.36;2.66 +62995-6;PhenX measure - stuttering;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - stuttering;;;DEPRECATED;2.36;2.46 +62996-4;PhenX - stuttering protocol 200901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - stuttering protocol 200901;Stuttering proto;;TRIAL;2.36;2.66 +62997-2;PhenX measure - tinnitus;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - tinnitus;;;DEPRECATED;2.36;2.46 +62998-0;PhenX - tinnitus protocol 201001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - tinnitus protocol 201001;Tinnitus proto;;TRIAL;2.36;2.66 +62999-8;PhenX measure - vertigo;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - vertigo;;;DEPRECATED;2.36;2.46 +63000-4;PhenX - vertigo protocol 201101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - vertigo protocol 201101;Vertigo proto;;TRIAL;2.36;2.66 +63001-2;PhenX measure - vocabulary assessment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - vocabulary assessment;;;DEPRECATED;2.36;2.46 +63002-0;PhenX - vocabulary assessment protocol 201201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - vocabulary assessment protocol 201201;Vocabulary assessment proto;;TRIAL;2.36;2.66 +63003-8;PhenX measure - voice impairments;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - voice impairments;;;DEPRECATED;2.36;2.46 +63004-6;PhenX - voice impairments protocol 201301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - voice impairments protocol 201301;Voice impairments proto;;TRIAL;2.36;2.66 +63005-3;PhenX measure - word decoding;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - word decoding;;;DEPRECATED;2.36;2.46 +63006-1;PhenX - word decoding protocol 201401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - word decoding protocol 201401;Word decoding proto;;TRIAL;2.36;2.66 +63007-9;PhenX measure - personal and family history of hearing loss;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - personal and family history of hearing loss;;;DEPRECATED;2.36;2.46 +6300-8;Glucose;MCnc;Pt;Amnio fld;Qn;;CHEM;1;Glucose [Mass/volume] in Amniotic fluid;Glucose Amn-mCnc;;ACTIVE;1.0f;2.73 +63008-7;PhenX - personal and family history of hearing loss protocol 201501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - personal and family history of hearing loss protocol 201501;Pers fam hx hearing loss proto;;TRIAL;2.36;2.66 +63009-5;PhenX domain - Social environments;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Social environments;Domain - Social environments;;TRIAL;2.36;2.65 +63010-3;PhenX measure - childhood maltreatment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - childhood maltreatment;;;DEPRECATED;2.36;2.46 +63011-1;PhenX - childhood maltreatment protocol 210101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - childhood maltreatment protocol 210101;Childhood maltreatment proto;;TRIAL;2.36;2.66 +63012-9;PhenX measure - child-reported parental education attainment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - child-reported parental education attainment;;;DEPRECATED;2.36;2.46 +63013-7;PhenX - child-reported parental education attainment protocol 210201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - child-reported parental education attainment protocol 210201;Child report parent educ attain proto;;TRIAL;2.36;2.66 +63014-5;PhenX measure - discrimination;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - discrimination;;;DEPRECATED;2.36;2.46 +63015-2;PhenX - discrimination protocol 210301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - discrimination protocol 210301;Discrimination proto;;TRIAL;2.36;2.66 +6301-6;Coagulation tissue factor induced.INR;RelTime;Pt;PPP;Qn;Coag;COAG;1;INR in Platelet poor plasma by Coagulation assay;INR PPP;;ACTIVE;1.0f;2.73 +63016-0;PhenX measure - family conflict;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - family conflict;;;DEPRECATED;2.36;2.46 +63017-8;PhenX - family conflict - intimate-relationship protocol 210401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - family conflict - intimate-relationship protocol 210401;Fam conflict intimate-relat proto;;TRIAL;2.36;2.66 +63018-6;PhenX - family conflict - parent - child protocol 210402;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - family conflict - parent - child protocol 210402;Fam conflict parent child proto;;TRIAL;2.36;2.66 +63019-4;PhenX measure - family control and organization;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - family control and organization;;;DEPRECATED;2.36;2.46 +63020-2;PhenX - family control and organization protocol 210501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - family control and organization protocol 210501;Fam control org proto;;TRIAL;2.36;2.66 +63021-0;PhenX measure - family interpersonal relationships;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - family interpersonal relationships;;;DEPRECATED;2.36;2.46 +63022-8;PhenX - family interpersonal relationships protocol 210601;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - family interpersonal relationships protocol 210601;Fam interpersonal relat proto;;TRIAL;2.36;2.66 +63023-6;PhenX measure - healthy food environments;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - healthy food environments;;;DEPRECATED;2.36;2.46 +6302-4;Coagulation tissue factor induced.normal/Actual;RelTime;Pt;PPP;Qn;Coag inverse ratio;COAG;1;Prothrombin index in Platelet poor plasma by Coagulation assay;PT index PPP;;ACTIVE;1.0f;2.73 +63024-4;PhenX - healthy food environments protocol 210701;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - healthy food environments protocol 210701;Healthy food environments proto;;TRIAL;2.36;2.66 +63025-1;PhenX measure - neighborhood collective efficacy - community cohesion and informal social control;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - neighborhood collective efficacy - community cohesion and informal social control;;;DEPRECATED;2.36;2.46 +63026-9;PhenX - neighborhood collective efficacy - community cohesion and informal social control protocol 210801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - neighborhood collective efficacy - community cohesion and informal social control protocol 210801;Neighborhood - comm cohesion proto;;TRIAL;2.36;2.66 +63027-7;PhenX measure - neighborhood safety;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - neighborhood safety;;;DEPRECATED;2.36;2.46 +63028-5;PhenX - neighborhood safety protocol 210901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - neighborhood safety protocol 210901;Neighborhood safety proto;;TRIAL;2.36;2.66 +63029-3;PhenX measure - school social environment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - school social environment;;;DEPRECATED;2.36;2.46 +63030-1;PhenX - school social environment protocol 211001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - school social environment protocol 211001;School social environ proto;;TRIAL;2.36;2.66 +63031-9;PhenX measure - social networks;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - social networks;;;DEPRECATED;2.36;2.46 +6303-2;Coagulation dilute Russell viper venom induced;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT (LA screen);Screen dRVVT;;ACTIVE;1.0f;2.73 +63032-7;PhenX - social networks protocol 211101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - social networks protocol 211101;Social networks proto;;TRIAL;2.36;2.66 +63033-5;PhenX measure - job strain;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - job strain;;;DEPRECATED;2.36;2.46 +63034-3;PhenX - job strain protocol 211201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - job strain protocol 211201;Job strain proto;;TRIAL;2.36;2.66 +63035-0;PhenX measure - neighborhood concentrated disadvantage;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - neighborhood concentrated disadvantage;;;DEPRECATED;2.36;2.46 +63036-8;PhenX - neighborhood concentrated disadvantage protocol 211301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - neighborhood concentrated disadvantage protocol 211301;Neighborhood disadvantage proto;;TRIAL;2.36;2.66 +63037-6;PhenX measure - race - ethnic residential segregation;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - race - ethnic residential segregation;;;DEPRECATED;2.36;2.46 +63038-4;PhenX - race - ethnic residential segregation protocol 211401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - race - ethnic residential segregation protocol 211401;Race - ethnic resid segregation proto;;TRIAL;2.36;2.66 +63039-2;PhenX measure - life events;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - life events;;;DEPRECATED;2.36;2.46 +630-4;Bacteria identified;Prid;Pt;Urine;Nom;Culture;MICRO;1;Bacteria identified in Urine by Culture;Bacteria Ur Cult;;ACTIVE;1.0;2.73 +6304-0;Budgerigar droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Budgerigar droppings IgE Ab [Units/volume] in Serum;Budgie Drop IgE Qn;;ACTIVE;1.0f;2.73 +63040-0;PhenX - life events - child protocol 211501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - life events - child protocol 211501;Life events child proto;;TRIAL;2.36;2.66 +63041-8;PhenX - life events - adult protocol 211502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - life events - adult protocol 211502;Life events adult proto;;TRIAL;2.36;2.66 +63042-6;17-Hydroxyprogesterone/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone/Creatinine [Mass Ratio] in Urine;17OHP/Creat Ur;;ACTIVE;2.36;2.73 +63043-4;Nuclei scored;Num;Pt;Tiss;Qn;;MOLPATH;1;Nuclei scored in Tissue;Nuclei scored Tiss;;ACTIVE;2.36;2.73 +63044-2;Cotinine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Cotinine [Presence] in Saliva (oral fluid) by Screen method;Cotinine Sal Ql Scn;;ACTIVE;2.36;2.73 +63045-9;PhenX measure - birthplace;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - birthplace;;;DEPRECATED;2.36;2.46 +63046-7;PhenX - birthplace protocol 010201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - birthplace protocol 010201;Birthplace proto;;ACTIVE;2.36;2.67 +63047-5;PhenX measure - birthplace of parents;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - birthplace of parents;;;DEPRECATED;2.36;2.46 +63048-3;PhenX - birthplace of parents protocol 010301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - birthplace of parents protocol 010301;Birthplace of parents proto;;TRIAL;2.36;2.66 +63049-1;PhenX measure - birthplace of grandparents;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - birthplace of grandparents;;;DEPRECATED;2.36;2.46 +63050-9;PhenX - birthplace of grandparents protocol 010401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - birthplace of grandparents protocol 010401;Birthplace grandparents proto;;TRIAL;2.36;2.66 +63051-7;PhenX measure - current address;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - current address;;;DEPRECATED;2.36;2.46 +63052-5;PhenX - current address protocol 010801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - current address protocol 010801;Current address proto;;TRIAL;2.36;2.66 +63053-3;PhenX measure - current marital status;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - current marital status;;;DEPRECATED;2.36;2.46 +63054-1;PhenX - current marital status protocol 010901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - current marital status protocol 010901;Current marital status proto;;TRIAL;2.36;2.66 +63055-8;PhenX measure - current educational attainment;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - current educational attainment;;;DEPRECATED;2.36;2.46 +63056-6;PhenX - current educational attainment protocol 011001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - current educational attainment protocol 011001;Current educ attainment proto;;TRIAL;2.36;2.66 +6305-7;Plasmodium malariae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Plasmodium malariae Ab [Units/volume] in Serum;P malariae Ab Ser-aCnc;;ACTIVE;1.0f;2.69 +63057-4;PhenX measure - annual family income;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - annual family income;;;DEPRECATED;2.36;2.46 +63058-2;PhenX - annual family income protocol 011101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - annual family income protocol 011101;Annual family income proto;;TRIAL;2.36;2.66 +63059-0;PhenX measure - years living in the U.S.;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - years living in the U.S.;;;DEPRECATED;2.36;2.46 +63060-8;PhenX - years living in the U.S. protocol 011201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - years living in the U.S. protocol 011201;Years in US proto;;TRIAL;2.36;2.66 +63061-6;PhenX measure - current employment status;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - current employment status;;;DEPRECATED;2.36;2.46 +63062-4;PhenX - current employment status protocol 011301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - current employment status protocol 011301;Current employment proto;;TRIAL;2.36;2.66 +63063-2;PhenX measure - household roster-relationships;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - household roster-relationships;;;DEPRECATED;2.36;2.46 +63064-0;PhenX - household roster-relationships protocol 011401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - household roster-relationships protocol 011401;Household relat proto;;TRIAL;2.36;2.66 +6306-5;Adenovirus 40+41 Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Adenovirus 40+41 Ag [Presence] in Stool by Immunoassay;AdV 40+41 Ag Stl Ql IA;;ACTIVE;1.0f;2.73 +63065-7;PhenX measure - health insurance coverage;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - health insurance coverage;;;DEPRECATED;2.36;2.46 +63066-5;PhenX - health insurance coverage protocol 011501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - health insurance coverage protocol 011501;Health ins coverage proto;;TRIAL;2.36;2.66 +63067-3;PhenX domain - Speech and hearing;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX domain - Speech and hearing;Domain - Speech and hearing;;TRIAL;2.36;2.65 +63068-1;TOP2A gene copy number/Chromosome 17 copy number;NRto;Pt;Tiss;Qn;FISH;MOLPATH;1;TOP2A gene copy number/Chromosome 17 copy number in Tissue by FISH;TOP2A copy num/Chr 17 copy num Tiss FISH;;ACTIVE;2.36;2.66 +63069-9;TOP2A gene;Imp;Pt;Tiss;Nar;;MOLPATH;1;TOP2A gene [Interpretation] in Tissue Narrative;TOP2A gene Tiss-Imp;;ACTIVE;2.36;2.36 +63070-7;TOP2A gene 17q21-22 deletion+duplication;PrThr;Pt;Tiss;Ord;FISH;MOLPATH;1;TOP2A gene 17q21-22 deletion and duplication mutation analysis [Presence] in Tissue by FISH;TOP2A 17q21-22 Del+Dup Tiss Ql FISH;;ACTIVE;2.36;2.61 +63071-5;PhenX - reproductive history - male protocol 101302;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - reproductive history - male protocol 101302;Reproductive history male proto;;TRIAL;2.36;2.66 +63072-3;Mycobacterium tuberculosis inhA gene isoniazid low level resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis inhA gene isoniazid low level resistance mutation [Presence] by Molecular method;MTB inhA INH low res mut Islt/Spm Ql;;ACTIVE;2.36;2.65 +6307-3;Adenovirus rRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Adenovirus rRNA [Presence] in Tissue by Probe;HAdV rRNA Tiss Ql Probe;;ACTIVE;1.0f;2.63 +63073-1;PhenX measure - total dietary intake;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - total dietary intake;;;DEPRECATED;2.36;2.46 +63074-9;PhenX - total dietary intake protocol 051201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - total dietary intake protocol 051201;Total dietary intake proto;;TRIAL;2.36;2.66 +63075-6;Dermatophagoides farinae Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite IgG Ab [Mass/volume] in Serum;D farinae IgG-mCnc;;ACTIVE;2.36;2.73 +63076-4;Cat dander Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cat dander IgG Ab [Mass/volume] in Serum;Cat Dander IgG-mCnc;;ACTIVE;2.36;2.73 +63077-2;Dog dander Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dog dander IgG Ab [Mass/volume] in Serum;Dog Dander IgG-mCnc;;ACTIVE;2.36;2.73 +63078-0;Fagopyrum esculentum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Buckwheat IgG Ab [Mass/volume] in Serum;Buckwheat IgG-mCnc;;ACTIVE;2.36;2.73 +63079-8;Bean white Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Bean IgG Ab [Mass/volume] in Serum;White Bean IgG-mCnc;;ACTIVE;2.36;2.73 +63080-6;Corylus avellana Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut IgG Ab [Mass/volume] in Serum;Hazelnut IgG-mCnc;;ACTIVE;2.36;2.73 +6308-1;Adenovirus rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Adenovirus rRNA [Presence] in Specimen by Probe;HAdV rRNA Spec Ql Probe;;ACTIVE;1.0f;2.73 +63081-4;Bertholletia excelsa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Brazil Nut IgG Ab [Mass/volume] in Serum;Brazil Nut IgG-mCnc;;ACTIVE;2.36;2.73 +63082-2;Pepper cayenne Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cayenne IgG Ab [Mass/volume] in Serum;Cayenne IgG-mCnc;;ACTIVE;2.36;2.73 +63083-0;Rubus idaeus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Raspberry IgG Ab [Mass/volume] in Serum;Raspberry IgG-mCnc;;ACTIVE;2.36;2.73 +63084-8;Cocos nucifera Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Coconut IgG Ab [Mass/volume] in Serum;Coconut IgG-mCnc;;ACTIVE;2.36;2.73 +63085-5;Mytilus edulis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blue mussel IgG Ab [Mass/volume] in Serum;Blue mussel IgG-mCnc;;ACTIVE;2.36;2.73 +63086-3;Scomber japonicus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chub Mackerel IgG Ab [Mass/volume] in Serum;Chub Mackerel IgG-mCnc;;ACTIVE;2.36;2.73 +63087-1;Panicum milliaceum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common Millet IgG Ab [Mass/volume] in Serum;Common Millet IgG-mCnc;;ACTIVE;2.36;2.73 +63088-9;Perca spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Perch IgG Ab [Mass/volume] in Serum;Perch IgG-mCnc;;ACTIVE;2.36;2.73 +63089-7;Cheese parmesan Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parmesan Cheese IgG Ab [Mass/volume] in Serum;Parmesan IgG-mCnc;;ACTIVE;2.36;2.73 +63090-5;Beta lactoglobulin Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Beta lactoglobulin IgG Ab [Mass/volume] in Serum;B-Lactoglob IgG-mCnc;;ACTIVE;2.36;2.73 +63091-3;Gluten Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Gluten IgG Ab [Mass/volume] in Serum;Gluten IgG-mCnc;;ACTIVE;2.36;2.73 +63092-1;Cheese cheddar type Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cheese cheddar type IgG Ab [Mass/volume] in Serum;Cheddar IgG-mCnc;;ACTIVE;2.36;2.73 +63093-9;Actinidia chinensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Kiwifruit IgG Ab [Mass/volume] in Serum;Kiwifruit IgG-mCnc;;ACTIVE;2.36;2.73 +63094-7;Petroselinum crispum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parsley IgG Ab [Mass/volume] in Serum;Parsley IgG-mCnc;;ACTIVE;2.36;2.73 +63095-4;Cucumis melo spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honeydew melon IgG Ab [Mass/volume] in Serum;Melon IgG-mCnc;;ACTIVE;2.36;2.73 +63096-2;Mangifera indica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mango IgG Ab [Mass/volume] in Serum;Mango IgG-mCnc;;ACTIVE;2.36;2.73 +63097-0;Cottonseed Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cottonseed IgG Ab [Mass/volume] in Serum;Cottonseed IgG-mCnc;;ACTIVE;2.36;2.73 +63098-8;Venison Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Venison IgG Ab [Mass/volume] in Serum;Venison IgG-mCnc;;ACTIVE;2.36;2.73 +6309-9;Arbovirus identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Arbovirus identified in Blood by Organism specific culture;Arbovirus Bld Cult;;ACTIVE;1.0f;1.0ma +63099-6;Cheese American Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;American Cheese IgG Ab [Mass/volume] in Serum;American Cheese IgG-mCnc;;ACTIVE;2.36;2.73 +63100-2;Vigna sinensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Black-eye pea IgG Ab [Mass/volume] in Serum;Black-eye Pea IgG-mCnc;;ACTIVE;2.36;2.73 +63101-0;Duck meat Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Duck meat IgG Ab [Mass/volume] in Serum;Duck Meat IgG-mCnc;;ACTIVE;2.36;2.73 +63102-8;Prunus persica var nucipersica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Nectarine IgG Ab [Mass/volume] in Serum;Nectarine IgG-mCnc;;ACTIVE;2.36;2.73 +63103-6;Cheese swiss Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Swiss Cheese IgG Ab [Mass/volume] in Serum;Swiss Cheese IgG-mCnc;;ACTIVE;2.36;2.73 +63104-4;Vaccinium oxycoccos Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cranberry IgG Ab [Mass/volume] in Serum;Cranberry IgG-mCnc;;ACTIVE;2.36;2.73 +63105-1;Rheum spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rhubarb IgG Ab [Mass/volume] in Serum;Rhubarb IgG-mCnc;;ACTIVE;2.36;2.73 +63106-9;Phaseolus limensis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lima Bean IgG Ab [Mass/volume] in Serum;Lima Bean IgG-mCnc;;ACTIVE;2.36;2.73 +6310-7;Arbovirus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Arbovirus identified in Specimen by Organism specific culture;Arbovirus Spec Cult;;ACTIVE;1.0f;2.69 +63107-7;Linum usitatissimum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Flax IgG Ab [Mass/volume] in Serum;Flax IgG-mCnc;;ACTIVE;2.36;2.73 +63108-5;Carya illinoinensis nut Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Nut IgG Ab [Mass/volume] in Serum;Pecan/Hick Nut IgG-mCnc;;ACTIVE;2.36;2.73 +63109-3;Anacardium occidentale Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cashew nut IgG Ab [Mass/volume] in Serum;Cashew nut IgG-mCnc;;ACTIVE;2.36;2.73 +63110-1;Pistacia vera Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pistachio IgG Ab [Mass/volume] in Serum;Pistachio IgG-mCnc;;ACTIVE;2.36;2.73 +63111-9;Clupea harengus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Herring IgG Ab [Mass/volume] in Serum;Herring IgG-mCnc;;ACTIVE;2.36;2.73 +63112-7;Rubus fruticosus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blackberry IgG Ab [Mass/volume] in Serum;Blackberry IgG-mCnc;;ACTIVE;2.36;2.73 +63113-5;Rabbit Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit IgG Ab [Mass/volume] in Serum;Rabbit IgG-mCnc;;ACTIVE;2.36;2.73 +63114-3;Capsicum annuum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paprika IgG Ab [Mass/volume] in Serum;Paprika IgG-mCnc;;ACTIVE;2.36;2.73 +6311-5;Babesia microti Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Babesia microti Ab [Units/volume] in Serum by Immunoassay;B microti Ab Ser IA-aCnc;;ACTIVE;1.0f;2.69 +63115-0;Papaver somniferum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Poppy Seed IgG Ab [Mass/volume] in Serum;Poppy Seed IgG-mCnc;;ACTIVE;2.36;2.73 +63116-8;Cucurbita pepo Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pumpkin IgG Ab [Mass/volume] in Serum;Pumpkin IgG-mCnc;;ACTIVE;2.36;2.73 +63117-6;Carthamus tinctorius Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Safflower IgG Ab [Mass/volume] in Serum;Safflower IgG-mCnc;;ACTIVE;2.36;2.73 +63118-4;Lens esculenta Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lentils IgG Ab [Mass/volume] in Serum;Lentils IgG-mCnc;;ACTIVE;2.36;2.73 +63119-2;Honey Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honey IgG Ab [Mass/volume] in Serum;Honey IgG-mCnc;;ACTIVE;2.36;2.73 +631-2;Bacteria identified;Prid;Pt;Unk sub;Nom;Aerobic culture;MICRO;1;Bacteria identified in Unknown substance by Aerobe culture;Bacteria Usub Aerobe Cult;;ACTIVE;1.0;2.73 +63120-0;Juglans spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Walnut IgG Ab [Mass/volume] in Serum;Walnut IgG-mCnc;;ACTIVE;2.36;2.73 +63121-8;Loligo sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Squid IgG Ab [Mass/volume] in Serum;Squid IgG-mCnc;;ACTIVE;2.36;2.73 +63122-6;Anguilla anguilla Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Eel IgG Ab [Mass/volume] in Serum;Eel IgG-mCnc;;ACTIVE;2.36;2.73 +6312-3;Bartonella henselae Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bartonella henselae IgM Ab [Units/volume] in Serum by Immunoassay;B henselae IgM Ser IA-aCnc;;ACTIVE;1.0f;2.69 +63123-4;Cuminum cyminum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cumin IgG Ab [Mass/volume] in Serum;Cumin IgG-mCnc;;ACTIVE;2.36;2.73 +63124-2;Ocimum basilicum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Basil IgG Ab [Mass/volume] in Serum;Basil IgG-mCnc;;ACTIVE;2.36;2.73 +63125-9;Thymus vulgaris Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Thyme IgG Ab [Mass/volume] in Serum;Thyme IgG-mCnc;;ACTIVE;2.36;2.73 +63126-7;Foeniculum vulgare fresh Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Fennel Fresh IgG Ab [Mass/volume] in Serum;Fennel Fresh IgG-mCnc;;ACTIVE;2.36;2.73 +63127-5;Anethum graveolens Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dill IgG Ab [Mass/volume] in Serum;Dill IgG-mCnc;;ACTIVE;2.36;2.73 +63128-3;Laurus nobilis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bayleaf IgG Ab [Mass/volume] in Serum;Bayleaf IgG-mCnc;;ACTIVE;2.36;2.73 +63129-1;Curry Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Curry IgG Ab [Mass/volume] in Serum;Curry IgG-mCnc;;ACTIVE;2.36;2.73 +63130-9;Phoenix dactylifera Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dates IgG Ab [Mass/volume] in Serum;Dates IgG-mCnc;;ACTIVE;2.36;2.73 +6313-1;Blastomyces dermatitidis Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Blastomyces dermatitidis Ag [Presence] in Serum by Immunoassay;B dermat Ag Ser Ql IA;;ACTIVE;1.0f;2.73 +63131-7;Carica papaya Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Papaya (Carica papaya) IgG Ab [Mass/volume] in Serum;Papaya IgG-mCnc;;ACTIVE;2.36;2.73 +63132-5;Castanea sativa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chestnut IgG Ab [Mass/volume] in Serum;Chestnut IgG-mCnc;;ACTIVE;2.36;2.73 +63133-3;Goat milk Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goat milk IgG Ab [Mass/volume] in Serum;Goat Milk IgG-mCnc;;ACTIVE;2.36;2.73 +63134-1;Sardina pilchardus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sardine (pilchard) IgG Ab [Mass/volume] in Serum;Sardine (pilchard) IgG-mCnc;;ACTIVE;2.36;2.73 +63135-8;Cicer arietinus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chick Pea IgG Ab [Mass/volume] in Serum;Chick Pea IgG-mCnc;;ACTIVE;2.36;2.73 +63136-6;Pimenta dioica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Allspice IgG Ab [Mass/volume] in Serum;Allspice IgG-mCnc;;ACTIVE;2.36;2.73 +63137-4;Astacus astacus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Crawfish IgG Ab [Mass/volume] in Serum;Crawfish IgG-mCnc;;ACTIVE;2.36;2.73 +63138-2;Humulus lupus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hop IgG Ab [Mass/volume] in Serum;Hop IgG-mCnc;;ACTIVE;2.36;2.73 +63139-0;Wine Vinegar Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Wine vinegar IgG Ab [Mass/volume] in Serum;Wine vinegar IgG-mCnc;;ACTIVE;2.36;2.73 +63140-8;Gelatin Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Gelatin IgG Ab [Mass/volume] in Serum;Gelatin IgG-mCnc;;ACTIVE;2.36;2.73 +63141-6;Yogurt Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yogurt IgG Ab [Mass/volume] in Serum;Yogurt IgG-mCnc;;ACTIVE;2.36;2.73 +63142-4;Micropterus salmoides Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bass, Black IgG Ab [Mass/volume] in Serum;Bass IgG-mCnc;;ACTIVE;2.36;2.70 +63143-2;Ictalurus punctatus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Catfish IgG Ab [Mass/volume] in Serum;Catfish IgG-mCnc;;ACTIVE;2.36;2.73 +63144-0;Cichorium intybus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicory IgG Ab [Mass/volume] in Serum;Chicory IgG-mCnc;;ACTIVE;2.36;2.73 +63145-7;Gum arabic Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Gum arabic IgG Ab [Mass/volume] in Serum;Gum Arabic IgG-mCnc;;ACTIVE;2.36;2.73 +63146-5;Karaya gum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Karaya gum IgG Ab [Mass/volume] in Serum;Karaya Gum IgG-mCnc;;ACTIVE;2.36;2.70 +63147-3;Armoracia rusticana Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horseradish IgG Ab [Mass/volume] in Serum;Horseradish IgG-mCnc;;ACTIVE;2.36;2.73 +63148-1;Maple syrup Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Maple syrup IgG Ab [Mass/volume] in Serum;Maple Syrup IgG-mCnc;;ACTIVE;2.36;2.73 +6314-9;Bordetella pertussis Ab;Titr;Pt;XXX;Qn;IF;MICRO;1;Bordetella pertussis Ab [Titer] in Specimen by Immunofluorescence;B pert Ab Titr Spec IF;;ACTIVE;1.0f;2.70 +63149-9;Abelmoschus esculentus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Okra IgG Ab [Mass/volume] in Serum;Okra IgG-mCnc;;ACTIVE;2.36;2.73 +63150-7;Pastinaca sativa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parsnip IgG Ab [Mass/volume] in Serum;Parsnip IgG-mCnc;;ACTIVE;2.36;2.73 +63151-5;(Anacardium occidentale+Carya illinoinensis+Castanea sativa+Juglans spp+Pistacia vera) Ab.IgG;MCnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 46 (Cashew+Pecan or Hickory nut+Chestnut+Walnut+Pistachio) IgG Ab [Mass/volume] in Serum by Multidisk;Food Allerg Mix46 IgG-mCnc;;ACTIVE;2.36;2.73 +63152-3;Cynodon dactylon Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass IgG Ab [Mass/volume] in Serum;Bermuda grass IgG-mCnc;;ACTIVE;2.36;2.73 +63153-1;Sorghum halepense Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Johnson grass IgG Ab [Mass/volume] in Serum;Johnson grass IgG-mCnc;;ACTIVE;2.36;2.73 +63154-9;Secale cereale pollen Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Rye IgG Ab [Mass/volume] in Serum;Cultivated Rye IgG-mCnc;;ACTIVE;2.36;2.73 +63155-6;Triticum aestivum pollen Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Wheat IgG Ab [Mass/volume] in Serum;Cultivated Wheat IgG-mCnc;;ACTIVE;2.36;2.73 +6315-6;Bordetella pertussis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Bordetella pertussis Ab [Titer] in Serum by Agglutination;B pert Ab Titr Ser Aggl;;ACTIVE;1.0f;2.73 +63156-4;Paspalum notatum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bahia grass IgG Ab [Mass/volume] in Serum;Bahia grass IgG-mCnc;;ACTIVE;2.36;2.73 +63157-2;House dust Greer Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;House dust Greer IgG Ab [Mass/volume] in Serum;House Dust Greer IgG-mCnc;;ACTIVE;2.36;2.73 +63158-0;House dust Hollister Stier Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;House dust Hollister Stier IgG Ab [Mass/volume] in Serum;House Dust HS IgG-mCnc;;ACTIVE;2.36;2.73 +63159-8;Ctenocephalides sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Flea IgG Ab [Mass/volume] in Serum;Flea IgG-mCnc;;ACTIVE;2.36;2.70 +63160-6;Ricinus communis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Castor Bean IgG Ab [Mass/volume] in Serum;Castor Bean IgG-mCnc;;ACTIVE;2.36;2.73 +63161-4;Latex Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Latex IgG Ab [Mass/volume] in Serum;Ltx IgG-mCnc;;ACTIVE;2.36;2.73 +63162-2;Curvularia lunata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Curvularia lunata IgG Ab [Mass/volume] in Serum;C lunata IgG-mCnc;;ACTIVE;2.36;2.73 +63163-0;Paecilomyces sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paecilomyces sp IgG Ab [Mass/volume] in Serum;Paecilomyces IgG-mCnc;;ACTIVE;2.36;2.73 +6316-4;Bordetella pertussis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Bordetella pertussis Ab [Titer] in Serum by Complement fixation;B pert Ab Titr Ser CF;;ACTIVE;1.0f;2.70 +63164-8;Penicillium brevicompactum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium brevicompactum IgG Ab [Mass/volume] in Serum;P brevicompactum IgG-mCnc;;ACTIVE;2.36;2.73 +63165-5;Serpula lacrymans Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dry-rot Fungus IgG Ab [Mass/volume] in Serum;S lacrymans IgG-mCnc;;ACTIVE;2.36;2.73 +63166-3;Aspergillus terreus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus terreus IgG Ab [Mass/volume] in Serum;A terreus IgG-mCnc;;ACTIVE;2.36;2.73 +63167-1;Trichophyton mentagrophytes Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Trichophyton mentagrophytes IgG Ab [Mass/volume] in Serum;T ment IgG-mCnc;;ACTIVE;2.36;2.73 +63168-9;Aspergillus amstelodami Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus amstelodami IgG Ab [Mass/volume] in Serum;A amstelodami IgG-mCnc;;ACTIVE;2.36;2.73 +63169-7;Aspergillus nidulans Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus nidulans IgG Ab [Mass/volume] in Serum;A nidulans IgG-mCnc;;ACTIVE;2.36;2.73 +63170-5;Helminthosporium interseminatum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Helminthosporium interseminatum IgG Ab [Mass/volume] in Serum;H interseminatum IgG-mCnc;;ACTIVE;2.36;2.73 +63171-3;Neurospora sitophila Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Neurospora sitophila IgG Ab [Mass/volume] in Serum;N sitophila IgG-mCnc;;ACTIVE;2.36;2.73 +6317-2;Bordetella sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Bordetella sp identified in Specimen by Organism specific culture;Bordetella Spec Cult;;ACTIVE;1.0f;2.73 +63172-1;Mucor plumbeus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mucor plumbeus IgG Ab [Mass/volume] in Serum;M plumbeus IgG-mCnc;;ACTIVE;2.36;2.73 +63173-9;Mycogone perniciosa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mycogone perniciosa IgG Ab [Mass/volume] in Serum;M perniciosa IgG-mCnc;;ACTIVE;2.36;2.73 +63174-7;Spondylocladium sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Spondylocladium sp IgG Ab [Mass/volume] in Serum;Spondylocladium IgG-mCnc;;ACTIVE;2.36;2.73 +63175-4;Epidermophyton floccosum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Epidermophyton floccosum IgG Ab [Mass/volume] in Serum;E floccosum IgG-mCnc;;ACTIVE;2.36;2.73 +63176-2;Algae Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Algae IgG Ab [Mass/volume] in Serum;Algae IgG-mCnc;;ACTIVE;2.36;2.73 +63177-0;Acremonium sp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Acremonium sp IgG Ab [Mass/volume] in Serum;Acremonium IgG-mCnc;;ACTIVE;2.36;2.73 +63178-8;Chaetomium globosum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chaetomium globosum IgG Ab [Mass/volume] in Serum;C globosum IgG-mCnc;;ACTIVE;2.36;2.73 +63179-6;Sphacelotheca cruenta Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Johnson grass smut IgG Ab [Mass/volume] in Serum;Johnson grass smut IgG-mCnc;;ACTIVE;2.36;2.73 +6318-0;Borrelia burgdorferi Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B burgdor Ab CSF IA-aCnc;;ACTIVE;1.0f;2.73 +63180-4;Nicotiana tabacum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tobacco IgG Ab [Mass/volume] in Serum;Tobacco IgG-mCnc;;ACTIVE;2.36;2.73 +63181-2;Juniperus sabinoides Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mountain Juniper IgG Ab [Mass/volume] in Serum;Mt Juniper IgG-mCnc;;ACTIVE;2.36;2.73 +63182-0;Quercus alba Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Oak IgG Ab [Mass/volume] in Serum;White Oak IgG-mCnc;;ACTIVE;2.36;2.73 +63183-8;Populus deltoides Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cottonwood IgG Ab [Mass/volume] in Serum;Cottonwood IgG-mCnc;;ACTIVE;2.36;2.73 +63184-6;Fraxinus americana Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;White Ash IgG Ab [Mass/volume] in Serum;White Ash IgG-mCnc;;ACTIVE;2.36;2.73 +63185-3;Prosopis juliflora Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mesquite IgG Ab [Mass/volume] in Serum;Mesquite IgG-mCnc;;ACTIVE;2.36;2.73 +63186-1;Chenopodium album Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goosefoot IgG Ab [Mass/volume] in Serum;Goosefoot IgG-mCnc;;ACTIVE;2.36;2.73 +63187-9;Salsola kali Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Saltwort IgG Ab [Mass/volume] in Serum;Saltwort IgG-mCnc;;ACTIVE;2.36;2.73 +63188-7;Xanthium commune Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cocklebur IgG Ab [Mass/volume] in Serum;Cocklebur IgG-mCnc;;ACTIVE;2.36;2.73 +63189-5;Pigweed rough Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rough Pigweed IgG Ab [Mass/volume] in Serum;Rough Pigweed IgG-mCnc;;ACTIVE;2.36;2.73 +63190-3;Iva ciliata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rough Marsh Elder IgG Ab [Mass/volume] in Serum;Marsh Elder IgG-mCnc;;ACTIVE;2.36;2.73 +63191-1;Urtica dioica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Nettle IgG Ab [Mass/volume] in Serum;Nettle IgG-mCnc;;ACTIVE;2.36;2.73 +63192-9;Rumex crispus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Dock IgG Ab [Mass/volume] in Serum;Yellow Dock IgG-mCnc;;ACTIVE;2.36;2.73 +63193-7;Artemisia tridentata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common Sagebrush IgG Ab [Mass/volume] in Serum;Sagbrsh IgG-mCnc;;ACTIVE;2.36;2.73 +63194-5;Medicago sativa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Alfalfa IgG Ab [Mass/volume] in Serum;Alfalfa IgG-mCnc;;ACTIVE;2.36;2.73 +63195-2;Helianthus annuus pollen Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sunflower Pollen IgG Ab [Mass/volume] in Serum;Sunflower Poln IgG-mCnc;;ACTIVE;2.36;2.73 +63196-0;(Alternaria alternata+Dermatophagoides farinae) Ab.IgG;MCnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Alternaria alternata+American house dust mite IgG Ab [Mass/volume] in Serum by Multidisk;A alternata+D farinae IgG-mCnc;;ACTIVE;2.36;2.70 +63197-8;(Ambrosia elatior+Artemisia vulgaris+Chrysanthemum leucathemum+Taraxacum vulgare+Solidago virgaurea) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 5 (Common ragweed+Mugwort+Ox-eye daisy+Dandelion+Goldenrod) IgE Ab [Units/volume] in Serum by Multidisk;Weed Allerg Mix5 IgE Qn;;ACTIVE;2.36;2.73 +6319-8;Borrelia burgdorferi Ab;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Borrelia burgdorferi Ab [Units/volume] in Body fluid by Immunoassay;B burgdor Ab Fld IA-aCnc;;ACTIVE;1.0f;2.73 +63198-6;(Plantago lanceolata+Chenopodium album+Salsola kali+Rumex acetosella) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 6 (English plantain+Goosefoot or Lambs quarters+Saltwort+Sheep sorrel) IgE Ab [Units/volume] in Serum by Multidisk;Weed Allerg Mix6 IgE Qn;;ACTIVE;2.36;2.73 +63199-4;(Anacardium occidentale+Carya illinoinensis+Castanea sativa+Juglans spp+Pistacia vera) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 46 (Cashew+Pecan or Hickory nut+Chestnut+Walnut+Pistachio) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix46 IgE Qn;;ACTIVE;2.36;2.73 +632-0;Bacteria identified;Prid;Pt;Wound;Nom;Aerobic culture;MICRO;1;Bacteria identified in Wound by Aerobe culture;Bacteria Wnd Aerobe Cult;;ACTIVE;1.0;2.73 +63200-0;Solidago virgaurea Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goldenrod IgG Ab [Mass/volume] in Serum;Goldenrod IgG-mCnc;;ACTIVE;2.36;2.73 +63201-8;Beet red Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Beet IgG Ab [Mass/volume] in Serum;Red Beet IgG-mCnc;;ACTIVE;2.36;2.73 +63202-6;Morus alba Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;White mulberry IgG Ab [Mass/volume] in Serum;White mulberry IgG-mCnc;;ACTIVE;2.36;2.73 +63203-4;Alnus rugosa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Smooth Alder IgG Ab [Mass/volume] in Serum;Smooth Alder IgG-mCnc;;ACTIVE;2.36;2.70 +63204-2;Ligustrum vulgare Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Privet IgG Ab [Mass/volume] in Serum;Privet IgG-mCnc;;ACTIVE;2.36;2.73 +63205-9;Populus tremula Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Aspen IgG Ab [Mass/volume] in Serum;Aspen IgG-mCnc;;ACTIVE;2.36;2.73 +6320-6;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Serum by Immunoblot;B burgdor IgG Ser Ql IB;;ACTIVE;1.0f;2.73 +63206-7;Ambrosia elatior Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common Ragweed IgG Ab [Mass/volume] in Serum;Common Ragweed IgG-mCnc;;ACTIVE;2.36;2.73 +63207-5;Franseria acanthicarpa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;False ragweed IgG Ab [Mass/volume] in Serum;False ragweed IgG-mCnc;;ACTIVE;2.36;2.73 +63208-3;Artemisia vulgaris Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Mugwort IgG Ab [Mass/volume] in Serum;Mugwort IgG-mCnc;;ACTIVE;2.36;2.73 +63209-1;Plantago lanceolata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;English plantain IgG Ab [Mass/volume] in Serum;Engl plantain IgG-mCnc;;ACTIVE;2.36;2.73 +63210-9;Actin.smooth muscle Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Actin smooth muscle Ab [Presence] in Serum by Immunoassay;SMA Ab Ser Ql IA;;ACTIVE;2.36;2.73 +63211-7;Actin.smooth muscle Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Actin smooth muscle Ab [Presence] in Serum by Immunofluorescence;SMA Ab Ser Ql IF;;ACTIVE;2.36;2.73 +63212-5;Asialoganglioside GM1 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Asialoganglioside GM1 IgG Ab [Presence] in Serum by Immunoassay;GM1 Asialo IgG Ser Ql IA;;ACTIVE;2.36;2.56 +63213-3;Bactericidal permeability increasing protein Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Bactericidal permeability increasing protein Ab [Units/volume] in Serum by Immunoassay;BPI Ab Ser IA-aCnc;;ACTIVE;2.36;2.56 +6321-4;Borrelia burgdorferi Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Serum by Immunoblot;B burgdor IgM Ser Ql IB;;ACTIVE;1.0f;2.73 +63214-1;Bactericidal permeability increasing protein Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Bactericidal permeability increasing protein Ab [Presence] in Body fluid by Immunoassay;BPI Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63215-8;Cathepsin G Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Cathepsin G Ab [Units/volume] in Serum by Immunoassay;Cathepsin G Ab Ser IA-aCnc;;ACTIVE;2.36;2.69 +63216-6;CV2 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;CV2 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;CV2 Ab CSF Ql IF;;ACTIVE;2.36;2.73 +63217-4;Cyclic citrullinated peptide Ab.IgG;ACnc;Pt;Body fld;Qn;IA;SERO;1;Cyclic citrullinated peptide IgG Ab [Units/volume] in Body fluid by Immunoassay;cCP IgG Fld IA-aCnc;;ACTIVE;2.36;2.73 +63218-2;Desmoglein 1 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Desmoglein 1 Ab [Presence] in Serum by Immunoassay;Desmoglein 1 Ab Ser Ql IA;;ACTIVE;2.36;2.56 +63219-0;Desmoglein 3 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Desmoglein 3 Ab [Presence] in Serum by Immunoassay;Desmoglein 3 Ab Ser Ql IA;;ACTIVE;2.36;2.56 +63220-8;DNA double strand Ab;Titr;Pt;CSF;Qn;IF;SERO;1;DNA double strand Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;dsDNA Ab Titr CSF IF;;ACTIVE;2.36;2.36 +63221-6;DNA double strand Ab;PrThr;Pt;Plr fld;Ord;IF;SERO;1;DNA double strand Ab [Presence] in Pleural fluid by Immunofluorescence;dsDNA Ab Plr Ql IF;;ACTIVE;2.36;2.56 +6322-2;Borrelia burgdorferi Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi Ag [Units/volume] in Serum;B burgdor Ag Ser-aCnc;;ACTIVE;1.0f;2.73 +63222-4;DNA double strand Ab;ACnc;Pt;Plr fld;Qn;IA;SERO;1;DNA double strand Ab [Units/volume] in Pleural fluid by Immunoassay;dsDNA Ab Plr IA-aCnc;;ACTIVE;2.36;2.70 +63223-2;DNA double strand Ab;Titr;Pt;Plr fld;Qn;IF;SERO;1;DNA double strand Ab [Titer] in Pleural fluid by Immunofluorescence;dsDNA Ab Titr Plr IF;;ACTIVE;2.36;2.36 +63224-0;DNA double strand Ab.IgG;PrThr;Pt;Body fld;Ord;IA;SERO;1;DNA double strand IgG Ab [Presence] in Body fluid by Immunoassay;dsDNA IgG Fld Ql IA;;ACTIVE;2.36;2.56 +63225-7;DNA double strand Ab.IgG;PrThr;Pt;Body fld;Ord;IF;SERO;1;DNA double strand IgG Ab [Presence] in Body fluid by Immunofluorescence;dsDNA IgG Fld Ql IF;;ACTIVE;2.36;2.56 +63226-5;DNA double strand Ab.IgG;ACnc;Pt;Body fld;Qn;IA;SERO;1;DNA double strand IgG Ab [Units/volume] in Body fluid by Immunoassay;dsDNA IgG Fld IA-aCnc;;ACTIVE;2.36;2.70 +63227-3;DNA double strand Ab.IgG;Titr;Pt;Body fld;Qn;IF;SERO;1;DNA double strand IgG Ab [Titer] in Body fluid by Immunofluorescence;dsDNA IgG Titr Fld IF;;ACTIVE;2.36;2.36 +63228-1;DNA double strand Ab.IgG;PrThr;Pt;CSF;Ord;IA;SERO;1;DNA double strand IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;dsDNA IgG CSF Ql IA;;ACTIVE;2.36;2.56 +63229-9;DNA double strand Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;DNA double strand IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;dsDNA IgG CSF IA-aCnc;;ACTIVE;2.36;2.70 +6323-0;Borrelia sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Borrelia sp identified in Specimen by Organism specific culture;Borrelia Spec Cult;;ACTIVE;1.0f;2.69 +63230-7;DNA double strand Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;DNA double strand IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;dsDNA IgG Titr CSF IF;;ACTIVE;2.36;2.36 +63231-5;DNA double strand Ab.IgG;ACnc;Pt;Plr fld;Qn;IA;SERO;1;DNA double strand IgG Ab [Units/volume] in Pleural fluid by Immunoassay;dsDNA IgG Plr IA-aCnc;;ACTIVE;2.36;2.70 +63232-3;DNA double strand Ab.IgM;PrThr;Pt;Body fld;Ord;IF;SERO;1;DNA double strand IgM Ab [Presence] in Body fluid by Immunofluorescence;dsDNA IgM Fld Ql IF;;ACTIVE;2.36;2.56 +63233-1;DNA double strand Ab.IgM;ACnc;Pt;Body fld;Qn;IA;SERO;1;DNA double strand IgM Ab [Units/volume] in Body fluid by Immunoassay;dsDNA IgM Fld IA-aCnc;;ACTIVE;2.36;2.70 +63234-9;DNA double strand Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;DNA double strand IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;dsDNA IgM CSF IA-aCnc;;ACTIVE;2.36;2.70 +63235-6;DNA double strand Ab.IgM;ACnc;Pt;Plr fld;Qn;IA;SERO;1;DNA double strand IgM Ab [Units/volume] in Pleural fluid by Immunoassay;dsDNA IgM Plr IA-aCnc;;ACTIVE;2.36;2.70 +63236-4;DNA double strand Ab.IgM;PrThr;Pt;Ser;Ord;IF;SERO;1;DNA double strand IgM Ab [Presence] in Serum by Immunofluorescence;dsDNA IgM Ser Ql IF;;ACTIVE;2.36;2.56 +63237-2;DNA double strand Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;DNA double strand IgM Ab [Units/volume] in Serum by Immunoassay;dsDNA IgM Ser IA-aCnc;;ACTIVE;2.36;2.70 +63238-0;Extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63239-8;Extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63240-6;Ganglioside GD3 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GD3 IgG+IgM Ab [Presence] in Serum by Immunoassay;GD3 Gangl IgG+IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63241-4;Ganglioside GM1 Ab.IgG;PrThr;Pt;Body fld;Ord;IA;SERO;1;Ganglioside GM1 IgG Ab [Presence] in Body fluid by Immunoassay;GM1 Gangl IgG Fld Ql IA;;ACTIVE;2.36;2.56 +63242-2;Ganglioside GM1 Ab.IgG;PrThr;Pt;CSF;Ord;IA;SERO;1;Ganglioside GM1 IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;GM1 Gangl IgG CSF Ql IA;;ACTIVE;2.36;2.56 +63243-0;Ganglioside GM1 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM1 IgG Ab [Presence] in Serum by Immunoassay;GM1 Gangl IgG Ser Ql IA;;ACTIVE;2.36;2.56 +63244-8;Ganglioside GM1 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM1 IgG+IgM Ab [Presence] in Serum by Immunoassay;GM1 Gangl IgG+IgM Ser Ql IA;;ACTIVE;2.36;2.73 +63245-5;Ganglioside GM1 Ab.IgM;PrThr;Pt;Body fld;Ord;IA;SERO;1;Ganglioside GM1 IgM Ab [Presence] in Body fluid by Immunoassay;GM1 Gangl IgM Fld Ql IA;;ACTIVE;2.36;2.56 +63246-3;Ganglioside GM1 Ab.IgM;PrThr;Pt;CSF;Ord;IA;SERO;1;Ganglioside GM1 IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;GM1 Gangl IgM CSF Ql IA;;ACTIVE;2.36;2.56 +63247-1;Ganglioside GM1 Ab.IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM1 IgM Ab [Presence] in Serum by Immunoassay;GM1 Gangl IgM Ser Ql IA;;ACTIVE;2.36;2.56 +6324-8;Brucella abortus Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Brucella abortus Ab [Titer] in Serum by Agglutination;B abortus Ab Titr Ser Aggl;;ACTIVE;1.0f;2.73 +63248-9;Ganglioside GM2 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM2 IgG Ab [Presence] in Serum by Immunoassay;GM2 Gangl IgG Ser Ql IA;;ACTIVE;2.36;2.56 +63249-7;Ganglioside GM2 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM2 IgG+IgM Ab [Presence] in Serum by Immunoassay;GM2 Gangl IgG+IgM Ser Ql IA;;ACTIVE;2.36;2.73 +63250-5;Ganglioside GM2 Ab.IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM2 IgM Ab [Presence] in Serum by Immunoassay;GM2 Gangl IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63251-3;Ganglioside GM3 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM3 IgG Ab [Presence] in Serum by Immunoassay;GM3 IgG Ser Ql IA;;ACTIVE;2.36;2.56 +63252-1;Ganglioside GM3 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM3 IgG+IgM Ab [Presence] in Serum by Immunoassay;GM3 IgG+IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63253-9;Ganglioside GM3 Ab.IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GM3 IgM Ab [Presence] in Serum by Immunoassay;GM3 IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63254-7;Ganglioside GQ1b Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GQ1b IgG Ab [Presence] in Serum by Immunoassay;GQ1b Gangl IgG Ser Ql IA;;ACTIVE;2.36;2.56 +6325-5;Brucella abortus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Brucella abortus Ab [Titer] in Serum by Complement fixation;B abortus Ab Titr Ser CF;;ACTIVE;1.0f;2.70 +63255-4;Ganglioside GQ1b Ab.IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GQ1b IgM Ab [Presence] in Serum by Immunoassay;GQ1b Gangl IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63256-2;Ganglioside GT1a Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GT1a IgG+IgM Ab [Presence] in Serum by Immunoassay;GT1a Gangl IgG+IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63257-0;Ganglioside GT1b Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GT1b IgG Ab [Presence] in Serum by Immunoassay;GT1b Ganlg IgG Ser Ql IA;;ACTIVE;2.36;2.56 +63258-8;Ganglioside GT1b Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GT1b IgG+IgM Ab [Presence] in Serum by Immunoassay;GT1b Ganlg IgG+IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63259-6;Ganglioside GT1b Ab.IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GT1b IgM Ab [Presence] in Serum by Immunoassay;GT1b Ganlg IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63260-4;Gliadin Ab.IgA;Titr;Pt;CSF;Qn;IA;SERO;1;Gliadin IgA Ab [Titer] in Cerebral spinal fluid by Immunoassay;Gliadin IgA Titr CSF IA;;ACTIVE;2.36;2.56 +63261-2;Gliadin Ab.IgG;Titr;Pt;CSF;Qn;IA;SERO;1;Gliadin IgG Ab [Titer] in Cerebral spinal fluid by Immunoassay;Gliadin IgG Titr CSF IA;;ACTIVE;2.36;2.56 +63262-0;Glomerular basement membrane Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Glomerular basement membrane Ab [Presence] in Serum by Immunoassay;GBM Ab Ser Ql IA;;ACTIVE;2.36;2.73 +6326-3;Brucella abortus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella abortus IgM Ab [Units/volume] in Serum by Immunoassay;B abortus IgM Ser IA-aCnc;;ACTIVE;1.0f;2.73 +63263-8;Histone Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Histone Ab [Presence] in Body fluid by Immunoassay;Histone Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63264-6;Histone Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Histone Ab [Presence] in Cerebral spinal fluid by Immunoassay;Histone Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63265-3;Jo-1 extractable nuclear Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Body fluid by Immune diffusion (ID);ENA Jo1 Ab Fld Ql ID;;ACTIVE;2.36;2.56 +63266-1;Jo-1 extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA Jo1 Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63267-9;Jo-1 extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA Jo1 Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63268-7;Keratin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Keratin Ab [Presence] in Serum by Immunofluorescence;Keratin Ab Ser Ql IF;;ACTIVE;2.36;2.56 +63269-5;Ku Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Ku Ab [Presence] in Body fluid by Immunoassay;Ku Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63270-3;Liver kidney microsomal 1 Ab;PrThr;Pt;Body fld;Ord;IF;SERO;1;Liver kidney microsomal 1 Ab [Presence] in Body fluid by Immunofluorescence;LKM-1 Ab Fld Ql IF;;ACTIVE;2.36;2.56 +6327-1;Brucella canis Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella canis Ab [Units/volume] in Serum by Immunoassay;B canis Ab Ser IA-aCnc;;ACTIVE;1.0f;2.69 +63271-1;Liver kidney microsomal 1 Ab;Titr;Pt;Body fld;Qn;IF;SERO;1;Liver kidney microsomal 1 Ab [Titer] in Body fluid by Immunofluorescence;LKM-1 Ab Titr Fld IF;;ACTIVE;2.36;2.40 +63272-9;Liver kidney microsomal 1 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Liver kidney microsomal 1 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;LKM-1 Ab CSF Ql IF;;ACTIVE;2.36;2.56 +63273-7;Liver kidney microsomal 1 Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Liver kidney microsomal 1 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;LKM-1 Ab Titr CSF IF;;ACTIVE;2.36;2.40 +63274-5;Liver kidney microsomal 2 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Liver kidney microsomal 2 Ab [Presence] in Serum by Immunofluorescence;LKM-2 Ab Ser Ql IF;;ACTIVE;2.36;2.56 +63275-2;Liver kidney microsomal 2 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Liver kidney microsomal 2 Ab [Titer] in Serum by Immunofluorescence;LKM-2 Ab Titr Ser IF;;ACTIVE;2.36;2.40 +63276-0;Mi-2 Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Mi-2 Ab [Presence] in Body fluid by Immunoassay;MI2 Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63277-8;Mitochondria Ab;PrThr;Pt;Body fld;Ord;IF;SERO;1;Mitochondria Ab [Presence] in Body fluid by Immunofluorescence;Mitochondria Ab Fld Ql IF;;ACTIVE;2.36;2.56 +63278-6;Mitochondria Ab;Titr;Pt;Body fld;Qn;IF;SERO;1;Mitochondria Ab [Titer] in Body fluid by Immunofluorescence;Mitochondria Ab Titr Fld IF;;ACTIVE;2.36;2.36 +63279-4;Mitochondria Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Mitochondria Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Mitochondria Ab CSF Ql IF;;ACTIVE;2.36;2.56 +63280-2;Mitochondria Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Mitochondria Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Mitochondria Ab Titr CSF IF;;ACTIVE;2.36;2.36 +63281-0;Mitochondria M2 Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Mitochondria M2 Ab [Presence] in Body fluid by Immunoassay;Mitochondria M2 Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63282-8;Mitochondria M2 Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Mitochondria M2 Ab [Presence] in Cerebral spinal fluid by Immunoassay;Mitochondria M2 Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63283-6;Mitochondria M2 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Mitochondria M2 Ab [Presence] in Serum by Immunoassay;Mitochondria M2 Ab Ser Ql IA;;ACTIVE;2.36;2.73 +63284-4;Mitochondria M5 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Mitochondria M5 Ab [Presence] in Serum by Immunofluorescence;Mitochondria M5 Ab Ser Ql IF;;ACTIVE;2.36;2.56 +63285-1;Mitochondria M5 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Mitochondria M5 Ab [Titer] in Serum by Immunofluorescence;Mitochondria M5 Ab Titr Ser IF;;ACTIVE;2.36;2.36 +63286-9;Myelin Ab;PrThr;Pt;Body fld;Ord;IF;SERO;1;Myelin Ab [Presence] in Body fluid by Immunofluorescence;Myelin Ab Fld Ql IF;;ACTIVE;2.36;2.56 +63287-7;Myelin Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Myelin Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Myelin Ab CSF Ql IF;;ACTIVE;2.36;2.73 +63288-5;Myelin associated glycoprotein Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Myelin associated glycoprotein Ab [Presence] in Body fluid by Immunoassay;MAG Ab Fld Ql IA;;ACTIVE;2.36;2.56 +6328-9;Brucella sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Brucella sp Ab [Titer] in Serum by Immunofluorescence;Brucella Ab Titr Ser IF;;ACTIVE;1.0f;2.70 +63289-3;Myelin associated glycoprotein Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Myelin associated glycoprotein Ab [Units/volume] in Body fluid by Immunoassay;MAG Ab Fld IA-aCnc;;ACTIVE;2.36;2.70 +63290-1;Myelin associated glycoprotein Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Myelin associated glycoprotein Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;MAG Ab CSF IA-aCnc;;ACTIVE;2.36;2.70 +63291-9;Neuronal nuclear type 2 Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Cerebral spinal fluid by Immunoassay;Hu2 Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63292-7;Neutrophil cytoplasmic Ab;Titr;Pt;Body fld;Qn;IF;SERO;1;Neutrophil cytoplasmic Ab [Titer] in Body fluid by Immunofluorescence;ANCA Ab Titr Fld IF;;ACTIVE;2.36;2.73 +63293-5;Neutrophil cytoplasmic Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Neutrophil cytoplasmic Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;ANCA Ab Titr CSF IF;;ACTIVE;2.36;2.36 +63294-3;Nuclear Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Nuclear Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;ANA CSF Ql IF;;ACTIVE;2.36;2.56 +63295-0;Nuclear Ab;PrThr;Pt;CSF;Ord;Hep2 substrate;SERO;1;Nuclear Ab [Presence] in Cerebral spinal fluid by Hep2 substrate;ANA CSF Ql HEp2 subst;;ACTIVE;2.36;2.56 +63296-8;Nuclear Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Nuclear Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA Titr CSF IF;;ACTIVE;2.36;2.36 +6329-7;Campylobacter coli rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Campylobacter coli rRNA [Presence] in Specimen by Probe;C coli rRNA Spec Ql Probe;;ACTIVE;1.0f;2.69 +63297-6;Nuclear Ab;Titr;Pt;CSF;Qn;Hep2 substrate;SERO;1;Nuclear Ab [Titer] in Cerebral spinal fluid by Hep2 substrate;ANA Titr CSF HEp2 subst;;ACTIVE;2.36;2.36 +63298-4;Nucleosome Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Nucleosome Ab [Presence] in Body fluid by Immunoassay;Nucleosome Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63299-2;Nucleosome Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Nucleosome Ab [Presence] in Cerebral spinal fluid by Immunoassay;Nucleosome Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63300-8;Nucleosome Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Nucleosome Ab [Presence] in Serum by Immunoassay;Nucleosome Ab Ser Ql IA;;ACTIVE;2.36;2.56 +63301-6;Parathyrin Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Parathyrin Ab [Presence] in Serum by Immunofluorescence;PTH Ab Ser Ql IF;;ACTIVE;2.36;2.56 +63302-4;Parathyrin Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Parathyrin Ab [Titer] in Serum by Immunofluorescence;PTH Ab Titr Ser IF;;ACTIVE;2.36;2.36 +63303-2;Parietal cell Ab;PrThr;Pt;Gast fld;Ord;IF;SERO;1;Parietal cell Ab [Presence] in Gastric fluid by Immunofluorescence;PCA Ab Gast Ql IF;;ACTIVE;2.36;2.56 +63304-0;Parietal cell Ab;Titr;Pt;Gast fld;Qn;IF;SERO;1;Parietal cell Ab [Titer] in Gastric fluid by Immunofluorescence;PCA Ab Titr Gast IF;;ACTIVE;2.36;2.36 +6330-5;Campylobacter sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Campylobacter sp identified in Blood by Organism specific culture;Campylobacter Bld Cult;;ACTIVE;1.0f;1.0ma +63305-7;PCNA extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;PCNA extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA PCNA Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63306-5;PCNA extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;PCNA extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA PCNA Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63307-3;PM-SCL extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;PM-SCL extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA PM/SCL Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63308-1;PM-SCL extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;PM-SCL extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA PM/SCL Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63309-9;Proteinase 3 Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Proteinase 3 Ab [Presence] in Body fluid by Immunoassay;Proteinase3 Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63310-7;Proteinase 3 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Proteinase 3 Ab [Presence] in Serum by Immunoassay;Proteinase3 Ab Ser Ql IA;;ACTIVE;2.36;2.73 +63311-5;Proteinase 3 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Proteinase 3 Ab [Presence] in Serum by Immunofluorescence;Proteinase3 Ab Ser Ql IF;;ACTIVE;2.36;2.73 +63312-3;Purkinje cells Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Purkinje cells Ab [Presence] in Cerebral spinal fluid by Immunoassay;Purkinje Cells Ab CSF Ql IA;;ACTIVE;2.36;2.56 +6331-3;Campylobacter sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Campylobacter sp identified in Stool by Organism specific culture;Campylobacter Stl Cult;;ACTIVE;1.0f;2.73 +63313-1;Rheumatoid factor;ACnc;Pt;Body fld;Qn;Sheep cell aggl;SERO;1;Rheumatoid factor [Units/volume] in Body fluid by Sheep Cell Agglutination;Rheumatoid fact Fld Shp Aggl-aCnc;;ACTIVE;2.36;2.70 +63314-9;Rheumatoid factor.IgA;ACnc;Pt;Body fld;Qn;IA;SERO;1;Rheumatoid factor IgA [Units/volume] in Body fluid by Immunoassay;RF IgA Fld IA-aCnc;;ACTIVE;2.36;2.70 +63315-6;Rheumatoid factor.IgM;ACnc;Pt;Body fld;Qn;IA;SERO;1;Rheumatoid factor IgM [Units/volume] in Body fluid by Immunoassay;RF IgM Fld IA-aCnc;;ACTIVE;2.36;2.70 +63316-4;U1 small nuclear ribonucleoprotein 70kD Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum by Immunoassay;U1 snRNP70 Ab Ser IA-aCnc;;ACTIVE;2.36;2.73 +63317-2;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Body fluid by Immune diffusion (ID);ENA RNP Ab Fld Ql ID;;ACTIVE;2.36;2.56 +63318-0;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA RNP Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63319-8;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA RNP Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63320-6;Ribosomal Ab;PrThr;Pt;Body fld;Ord;IF;SERO;1;Ribosomal Ab [Presence] in Body fluid by Immunofluorescence;Ribosomal Ab Fld Ql IF;;ACTIVE;2.36;2.56 +6332-1;Campylobacter sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Campylobacter sp identified in Specimen by Organism specific culture;Campylobacter Spec Cult;;ACTIVE;1.0f;2.73 +63321-4;Ribosomal Ab;Titr;Pt;Body fld;Qn;IF;SERO;1;Ribosomal Ab [Titer] in Body fluid by Immunofluorescence;Ribosomal Ab Titr Fld IF;;ACTIVE;2.36;2.36 +63322-2;Ribosomal Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Ribosomal Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Ribosomal Ab CSF Ql IF;;ACTIVE;2.36;2.56 +63323-0;Ribosomal Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Ribosomal Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Ribosomal Ab Titr CSF IF;;ACTIVE;2.36;2.36 +63324-8;Ribosomal Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Ribosomal IgG Ab [Presence] in Serum by Immunoassay;Ribosomal IgG Ser Ql IA;;ACTIVE;2.36;2.56 +63325-5;Ribosomal Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Ribosomal IgG Ab [Titer] in Serum by Immunoassay;Ribosomal IgG Titr Ser IA;;ACTIVE;2.36;2.56 +63326-3;Ribosomal P Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Ribosomal P Ab [Presence] in Body fluid by Immunoassay;Ribosomal P Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63327-1;Ribosomal P Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Ribosomal P Ab [Presence] in Cerebral spinal fluid by Immunoassay;Ribosomal P Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63328-9;RNA polymerase III Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;RNA polymerase III Ab [Presence] in Serum by Immunoassay;RNAp III Ab Ser Ql IA;;ACTIVE;2.36;2.73 +63329-7;RNA polymerase III Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;RNA polymerase III Ab [Units/volume] in Serum by Immunoassay;RNAp III Ab Ser IA-aCnc;;ACTIVE;2.36;2.73 +63330-5;Saccharomyces cerevisiae Ab.IgA;ACnc;Pt;Body fld;Qn;IA;ALLERGY;1;Baker's yeast IgA Ab [Units/volume] in Body fluid by Immunoassay;Baker's yeast IgA Fld Qn IA;;ACTIVE;2.36;2.70 +63331-3;Saccharomyces cerevisiae Ab.IgA;PrThr;Pt;Ser;Ord;IF;ALLERGY;1;Baker's yeast IgA Ab [Presence] in Serum by Immunofluorescence;Baker's yeast IgA Ql IF;;ACTIVE;2.36;2.56 +63332-1;Saccharomyces cerevisiae Ab.IgG;ACnc;Pt;Body fld;Qn;IA;ALLERGY;1;Baker's yeast IgG Ab [Units/volume] in Body fluid by Immunoassay;Baker's yeast IgG Fld Qn IA;;ACTIVE;2.36;2.70 +63333-9;Saccharomyces cerevisiae Ab.IgG;PrThr;Pt;Ser;Ord;IF;ALLERGY;1;Baker's yeast IgG Ab [Presence] in Serum by Immunofluorescence;Baker's yeast IgG Ql IF;;ACTIVE;2.36;2.56 +63334-7;SCL-70 extractable nuclear Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Body fluid by Immune diffusion (ID);ENA Scl70 Ab Fld Ql ID;;ACTIVE;2.36;2.56 +63335-4;SCL-70 extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA Scl70 Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63336-2;SCL-70 extractable nuclear Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;SCL-70 extractable nuclear Ab [Units/volume] in Body fluid by Immunoassay;ENA Scl70 Ab Fld IA-aCnc;;ACTIVE;2.36;2.73 +63337-0;SCL-70 extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA Scl70 Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63338-8;SCL-70 extractable nuclear Ab;Titr;Pt;Ser;Qn;IA;SERO;1;SCL-70 extractable nuclear Ab [Titer] in Serum by Immunoassay;ENA Scl70 Ab Titr Ser IA;;ACTIVE;2.36;2.56 +6333-9;Campylobacter jejuni rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Campylobacter jejuni rRNA [Presence] in Specimen by Probe;C jejuni rRNA Spec Ql Probe;;ACTIVE;1.0f;2.69 +63339-6;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Body fluid by Immunoassay;ENA SS-A 52kD Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63340-4;Sjogrens syndrome-A extractable nuclear 52kD Ab;Titr;Pt;Body fld;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Titer] in Body fluid by Immunoassay;ENA SS-A 52kD Ab Titr Fld IA;;ACTIVE;2.36;2.56 +63341-2;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA SS-A 52kD Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63342-0;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Serum by Immunoassay;ENA SS-A 52kD Ab Ser Ql IA;;ACTIVE;2.36;2.56 +63343-8;Sjogrens syndrome-A extractable nuclear 60kD Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 60kD Ab [Presence] in Body fluid by Immunoassay;ENA SS-a 60kD Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63344-6;Sjogrens syndrome-A extractable nuclear 60kD Ab;Titr;Pt;Body fld;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 60kD Ab [Titer] in Body fluid by Immunoassay;ENA SS-a 60kD Ab Titr Fld IA;;ACTIVE;2.36;2.56 +63345-3;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Body fld;Ord;Flow cytometry;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Body fluid by Flow cytometry (FC);ENA SS-A Ab Fld Ql FC;;ACTIVE;2.36;2.56 +63346-1;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Body fluid by Immune diffusion (ID);ENA SS-A Ab Fld Ql ID;;ACTIVE;2.36;2.56 +6334-7;Campylobacter lari rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Campylobacter lari rRNA [Presence] in Specimen by Probe;C lari rRNA Spec Ql Probe;;ACTIVE;1.0f;2.69 +63347-9;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA SS-A Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63348-7;Sjogrens syndrome-A extractable nuclear Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Units/volume] in Body fluid by Immunoassay;ENA SS-A Ab Fld IA-aCnc;;ACTIVE;2.36;2.70 +63349-5;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Body fluid by Immune diffusion (ID);ENA SS-B Ab Fld Ql ID;;ACTIVE;2.36;2.56 +63350-3;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA SS-B Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63351-1;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA SS-B Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63352-9;Smith extractable nuclear Ab;PrThr;Pt;Body fld;Ord;Immune diffusion;SERO;1;Smith extractable nuclear Ab [Presence] in Body fluid by Immune diffusion (ID);ENA SM Ab Fld Ql ID;;ACTIVE;2.36;2.56 +63353-7;Smith extractable nuclear Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Smith extractable nuclear Ab [Presence] in Body fluid by Immunoassay;ENA SM Ab Fld Ql IA;;ACTIVE;2.36;2.56 +6335-4;Campylobacter sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Deprecated Campylobacter sp identified in Unspecified specimen by Organism specific culture;Deprecated Campylobacter XXX Cult;;DEPRECATED;1.0f;2.69 +63354-5;Smith extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Smith extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA SM Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63355-2;Smooth muscle Ab;PrThr;Pt;Body fld;Ord;IF;SERO;1;Smooth muscle Ab [Presence] in Body fluid by Immunofluorescence;Smooth muscle Ab Fld Ql IF;;ACTIVE;2.36;2.56 +63356-0;Smooth muscle Ab;Titr;Pt;Body fld;Qn;IF;SERO;1;Smooth muscle Ab [Titer] in Body fluid by Immunofluorescence;Smooth muscle Ab Titr Fld IF;;ACTIVE;2.36;2.36 +63357-8;Smooth muscle Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Smooth muscle Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Smooth muscle Ab CSF Ql IF;;ACTIVE;2.36;2.56 +63358-6;Smooth muscle Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Smooth muscle Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Smooth muscle Ab Titr CSF IF;;ACTIVE;2.36;2.36 +63359-4;Thyroglobulin Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Thyroglobulin Ab [Units/volume] in Body fluid by Immunoassay;Thyroglob Ab Fld IA-aCnc;;ACTIVE;2.36;2.70 +63360-2;Thyroglobulin Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Thyroglobulin Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Thyroglob Ab CSF IA-aCnc;;ACTIVE;2.36;2.70 +63361-0;Thyroperoxidase Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Thyroperoxidase Ab [Units/volume] in Body fluid by Immunoassay;Thyroperoxidase Ab Fld IA-aCnc;;ACTIVE;2.36;2.70 +6336-2;Candida albicans Ab;ACnc;Pt;Ser;Qn;ID;MICRO;1;Deprecated Candida albicans Ab [Presence] in Serum by Immune diffusion (ID);Deprecated C albicans Ab Ser-aCnc;;DEPRECATED;1.0f;2.69 +63362-8;Thyroperoxidase Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Thyroperoxidase Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Thyroperoxidase Ab CSF IA-aCnc;;ACTIVE;2.36;2.70 +63363-6;Thyrotropin receptor Ab;ACnc;Pt;Bld^Fetus;Qn;;SERO;1;Thyrotropin receptor Ab [Units/volume] in Blood from Fetus;TSH Recep Ab Bld Fetus-aCnc;;ACTIVE;2.36;2.70 +63364-4;Thyrotropin receptor Ab;ACnc;Pt;BldCo;Qn;;SERO;1;Thyrotropin receptor Ab [Units/volume] in Cord blood;TSH Recep Ab BldCo-aCnc;;ACTIVE;2.36;2.70 +63365-1;Thyrotropin receptor Ab;ACnc;Pt;Body fld;Qn;;SERO;1;Thyrotropin receptor Ab [Units/volume] in Body fluid;TSH Recep Ab Fld-aCnc;;ACTIVE;2.36;2.70 +63366-9;Thyrotropin receptor Ab;ACnc;Pt;CSF;Qn;;SERO;1;Thyrotropin receptor Ab [Units/volume] in Cerebral spinal fluid;TSH Recep Ab CSF-aCnc;;ACTIVE;2.36;2.70 +63367-7;U1 small nuclear ribonucleoprotein Ab;Titr;Pt;Ser;Qn;IA;SERO;1;U1 small nuclear ribonucleoprotein Ab [Titer] in Serum by Immunoassay;U1 snRNP Ab Titr Ser IA;;ACTIVE;2.36;2.56 +63368-5;Carbapenem resistance genes;Prid;Pt;Isolate;Nom;Probe.amp.tar;ABXBACT;1;Carbapenem resistance genes [Identifier] by NAA with probe detection;CPR genes Islt NAA+probe;;ACTIVE;2.36;2.66 +63369-3;Chronic urticaria index;ACnc;Pt;Ser;Qn;;SERO;1;Chronic urticaria index in Serum;Chronic urticaria index Ser-aCnc;;ACTIVE;2.36;2.73 +6337-0;Candida albicans Ag;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Candida albicans Ag [Presence] in Serum by Immune diffusion (ID);C albicans Ag Ser Ql ID;;ACTIVE;1.0f;2.73 +63370-1;Gamma tocopherol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma tocopherol [Mass/volume] in Serum or Plasma;Gamma tocopherol SerPl-mCnc;;ACTIVE;2.36;2.73 +63371-9;Ketones^1H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Ketones [Presence] in Urine by Test strip --1 hour post dose glucose;Ketones 1h p Glc Ur Ql Strip;;ACTIVE;2.36;2.56 +63372-7;Ketones^3H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Ketones [Presence] in Urine by Test strip --3 hours post dose glucose;Ketones 3h p Glc Ur Ql Strip;;ACTIVE;2.36;2.56 +63373-5;Ketones^4H post dose glucose;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Ketones [Presence] in Urine by Test strip --4 hours post dose glucose;Ketones 4h p Glc Ur Ql Strip;;ACTIVE;2.36;2.56 +63374-3;Fusarium roseum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium roseum IgE Ab [Units/volume] in Serum;F roseum IgE Qn;;ACTIVE;2.36;2.70 +63375-0;Cyclic citrullinated peptide Ab.IgA+IgG;PrThr;Pt;Ser;Ord;;SERO;1;Cyclic citrullinated peptide IgA+IgG Ab [Presence] in Serum;cCP IgA+IgG Ser Ql;;ACTIVE;2.36;2.73 +63376-8;Lactoferrin;PrThr;Pt;Stool;Ord;;CHEM;1;Lactoferrin [Presence] in Stool;Lactoferrin Stl Ql;;ACTIVE;2.36;2.73 +63378-4;Erythrocyte clumps;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Erythrocyte clumps [Presence] in Urine sediment by Light microscopy;RBC clumps UrnS Ql Micro;;ACTIVE;2.36;2.73 +63379-2;DNA double strand Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;DNA double strand IgG Ab [Presence] in Serum;dsDNA IgG Ser Ql;;ACTIVE;2.36;2.73 +633-8;Bacteria identified;Prid;Pt;Wound;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Wound by Anaerobe culture;Bacteria Wnd Anaerobe Cult;;ACTIVE;1.0;2.73 +63380-0;Methionine;PrThr;Pt;Bld.dot;Ord;;CHEM;1;Methionine [Presence] in DBS;Methionine DBS Ql;;ACTIVE;2.36;2.61 +63381-8;DNA double strand Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;DNA double strand IgG Ab [Titer] in Serum;dsDNA IgG Titr Ser;;ACTIVE;2.36;2.73 +63382-6;Glucose^post CFst;MCnc;Pt;Urine;Qn;;CHAL;1;Fasting glucose [Mass/volume] in Urine;Glucose p fast Ur-mCnc;;ACTIVE;2.36;2.73 +63383-4;Amphiphysin Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Amphiphysin Ab [Presence] in Cerebral spinal fluid by Immunoassay;Amphiphysin Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63384-2;Asialoganglioside GM1 Ab.IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Asialoganglioside GM1 IgM Ab [Presence] in Serum by Immunoassay;GM1 Asialo IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63385-9;DNA double strand Ab.IgG;ACnc;Pt;Body fld;Qn;Flow cytometry;SERO;1;DNA double strand IgG Ab [Units/volume] in Body fluid by Flow cytometry (FC);dsDNA IgG Fld FC-aCnc;;ACTIVE;2.36;2.70 +63386-7;DNA double strand Ab.IgG;ACnc;Pt;Plr fld;Qn;Flow cytometry;SERO;1;DNA double strand IgG Ab [Units/volume] in Pleural fluid by Flow cytometry (FC);dsDNA IgG Plr FC-aCnc;;ACTIVE;2.36;2.70 +63387-5;Elastase Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Elastase Ab [Presence] in Body fluid by Immunoassay;Elastase Ab Fld Ql IA;;ACTIVE;2.36;2.56 +6338-8;Chlamydophila psittaci Ag;PrThr;Pt;Genital;Ord;IA;MICRO;1;Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay;C psittaci Ag Genital Ql IA;;ACTIVE;1.0f;2.56 +63388-3;Extractable nuclear Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Extractable nuclear Ab [Units/volume] in Body fluid by Immunoassay;ENA Ab Fld IA-aCnc;;ACTIVE;2.36;2.68 +63389-1;Extractable nuclear Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Extractable nuclear Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ENA Ab CSF IA-aCnc;;ACTIVE;2.36;2.68 +63390-9;Extractable nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID);ENA Ab Ser Ql ID;;ACTIVE;2.36;2.56 +63391-7;Extractable nuclear Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Extractable nuclear Ab [Presence] in Serum by Immunoassay;ENA Ab Ser Ql IA;;ACTIVE;2.36;2.73 +63392-5;Herpes gestationis Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Herpes gestationis Ab [Titer] in Serum by Immunofluorescence;HG Ab Titr Ser IF;;ACTIVE;2.36;2.36 +63393-3;Jo-1 extractable nuclear Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Jo-1 extractable nuclear Ab [Units/volume] in Body fluid by Immunoassay;ENA Jo1 Ab Fld IA-aCnc;;ACTIVE;2.36;2.73 +63394-1;Jo-1 extractable nuclear Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Jo-1 extractable nuclear Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ENA Jo1 Ab CSF IA-aCnc;;ACTIVE;2.36;2.73 +63395-8;Liver cytosol Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Liver cytosol Ab [Titer] in Serum by Immunofluorescence;Liver Cytosol Ab Titr Ser IF;;ACTIVE;2.36;2.73 +6339-6;Chlamydophila psittaci Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence;C psittaci Ag Genital Ql IF;;ACTIVE;1.0f;2.56 +63396-6;Myelin associated glycoprotein Ab;PrThr;Pt;Body fld;Ord;IB;SERO;1;Myelin associated glycoprotein Ab [Presence] in Body fluid by Immunoblot;MAG Ab Fld Ql IB;;ACTIVE;2.36;2.58 +63397-4;Myeloperoxidase Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Myeloperoxidase Ab [Presence] in Body fluid by Immunoassay;Myeloperoxidase Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63398-2;Ribonucleoprotein extractable nuclear Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Ribonucleoprotein extractable nuclear Ab [Units/volume] in Body fluid by Immunoassay;ENA RNP Ab Fld IA-aCnc;;ACTIVE;2.36;2.69 +63399-0;Ribonucleoprotein extractable nuclear Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Ribonucleoprotein extractable nuclear Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ENA RNP Ab CSF IA-aCnc;;ACTIVE;2.36;2.69 +63400-6;SCL-70 extractable nuclear Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;SCL-70 extractable nuclear Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ENA Scl70 Ab CSF IA-aCnc;;ACTIVE;2.36;2.69 +63401-4;Sjogrens syndrome-A extractable nuclear Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ENA SS-A Ab CSF IA-aCnc;;ACTIVE;2.36;2.69 +63402-2;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoassay;ENA SS-A Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63403-0;Sjogrens syndrome-B extractable nuclear Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Body fluid by Immunoassay;ENA SS-B Ab Fld IA-aCnc;;ACTIVE;2.36;2.69 +6340-4;Chlamydophila psittaci Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay;C psittaci Ag Spec Ql IA;;ACTIVE;1.0f;2.73 +63404-8;Sjogrens syndrome-B extractable nuclear Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ENA SS-B Ab CSF IA-aCnc;;ACTIVE;2.36;2.69 +63405-5;Smith extractable nuclear Ab;ACnc;Pt;Body fld;Qn;IA;SERO;1;Smith extractable nuclear Ab [Units/volume] in Body fluid by Immunoassay;ENA SM Ab Fld IA-aCnc;;ACTIVE;2.36;2.69 +63406-3;Smith extractable nuclear Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;Smith extractable nuclear Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ENA SM Ab CSF IA-aCnc;;ACTIVE;2.36;2.69 +63407-1;Thyroid colloidal Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Thyroid colloidal Ab [Presence] in Serum by Immunofluorescence;Thyroid Colloidal Ab Ser Ql IF;;ACTIVE;2.36;2.56 +63408-9;DNA double strand Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;DNA double strand Ab [Presence] in Cerebral spinal fluid by Immunoassay;dsDNA Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63409-7;DNA double strand Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;DNA double strand Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;dsDNA Ab CSF Ql IF;;ACTIVE;2.36;2.56 +63410-5;DNA double strand Ab;ACnc;Pt;CSF;Qn;IA;SERO;1;DNA double strand Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;dsDNA Ab CSF IA-aCnc;;ACTIVE;2.36;2.70 +63411-3;Sjogrens syndrome-A extractable nuclear 60kD Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 60kD Ab [Presence] in Serum by Immunoassay;ENA SS-a 60kD Ab Ser Ql IA;;ACTIVE;2.36;2.73 +6341-2;Chlamydophila psittaci Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence;C psittaci Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +63412-1;Thyroid colloidal Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Thyroid colloidal Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Thyroid Colloidal Ab CSF Ql IF;;ACTIVE;2.36;2.56 +63413-9;Thyroid colloidal Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Thyroid colloidal Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Thyroid Colloidal Ab Titr CSF IF;;ACTIVE;2.36;2.36 +63414-7;Pompe disease newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Pompe disease newborn screening panel;Pompe disease NBS pnl DBS;;ACTIVE;2.36;2.42 +63415-4;Pompe disease;Imp;Pt;Bld.dot;Nom;;CHEM;1;Pompe disease newborn screen interpretation;Pompe disease DBS-Imp;;ACTIVE;2.36;2.56 +63416-2;Pompe disease newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Pompe disease newborn screening comment-discussion;Pompe disease NBS comment;;ACTIVE;2.36;2.42 +63417-0;Indexing - Indication;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Indexing - Indication;FDA label Indexing - Indication;;ACTIVE;2.36;2.36 +63418-8;Lactalbumin alpha Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin alpha IgG Ab [Mass/volume] in Serum;A-Lactalb IgG-mCnc;;ACTIVE;2.36;2.73 +63419-6;PIK3CA gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PIK3CA gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;PIK3CA gene Mut Tested Bld/T;;ACTIVE;2.36;2.73 +6342-0;Chlamydia sp Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Deprecated Chlamydia sp Ab [Titer] in Serum by Complement fixation;Deprecated Chlamydia Ab Titr Ser CF;;DEPRECATED;1.0f;2.36 +63420-4;Gliadin peptide+Tissue transglutaminase Ab.IgA+IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Gliadin peptide+tissue transglutaminase IgA+IgG Ab [Presence] in Serum by Immunoassay;Gliadin peptide+tTG IgA+IgG Ser Ql IA;;ACTIVE;2.36;2.73 +63421-2;JAK2 gene exon 12 mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;JAK2 gene exon 12 mutations tested for in Blood or Tissue by Molecular genetics method Nominal;JAK2 exon 12 Mut Tested Bld/T;;ACTIVE;2.36;2.73 +63422-0;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2+e1a2 fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2+e1a2 fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)p210+p190 Bld/T Ql;;ACTIVE;2.36;2.73 +63423-8;Escherichia coli eaeA gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Escherichia coli eaeA gene [Presence] in Specimen by NAA with probe detection;EC eaeA gene Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +63424-6;Bacterial enterohemolysin (ehlyA) gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bacterial enterohemolysin ehlyA gene [Presence] in Specimen by NAA with probe detection;ehlyA Spec QA PCR NAA+probe;;ACTIVE;2.36;2.69 +63425-3;Bacterial heat-labile enterotoxin LT gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bacterial heat-labile enterotoxin LT gene [Presence] in Specimen by NAA with probe detection;LT Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +63426-1;Bacterial heat-stable enterotoxin ST gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bacterial heat-stable enterotoxin ST gene [Presence] in Specimen by NAA with probe detection;ST Spec Ql NAA+probe;;ACTIVE;2.36;2.69 +63427-9;Escherichia coli Stx1 toxin stx1 gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx1 toxin stx1 gene [Presence] in Specimen by NAA with probe detection;EC stx1 Spec QI NAA+probe;;ACTIVE;2.36;2.73 +63428-7;Escherichia coli Stx2 toxin stx2 gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx2 toxin stx2 gene [Presence] in Specimen by NAA with probe detection;EC stx2 Spec QI NAA+probe;;ACTIVE;2.36;2.73 +63429-5;Bacterial beta-glucuronidase (uidA) gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bacterial beta-glucuronidase uidA gene [Presence] in Specimen by NAA with probe detection;uidA gene Spec Ql NAA+probe;;ACTIVE;2.36;2.69 +63430-3;Human coronavirus RNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Human coronavirus RNA panel - Specimen by NAA with probe detection;HCoV pnl Spec NAA+probe;;ACTIVE;2.36;2.73 +63431-1;Bordetella sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bordetella sp DNA [Presence] in Specimen by NAA with probe detection;Bordetella DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.69 +63432-9;Herpes simplex virus 1+2 Ab.IgM;ACnc;Pt;CSF;Qn;;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Units/volume] in Cerebral spinal fluid;HSV1+2 IgM CSF-aCnc;;ACTIVE;2.36;2.73 +63433-7;Microscopic observation;Prid;Pt;Synv fld;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Synovial fluid by Acid fast stain.Ziehl-Neelsen;ZN Stn Snv;;ACTIVE;2.36;2.36 +63434-5;Coxsackievirus A Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus A Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV A Ab Titr CSF CF;;ACTIVE;2.36;2.70 +63435-2;Brucella abortus Ab;Titr;Pt;CSF;Qn;Antihuman globulin;MICRO;1;Brucella abortus Ab [Titer] in Cerebral spinal fluid by Antihuman globulin;B abortus Ab Titr CSF AHG;;ACTIVE;2.36;2.70 +63436-0;Polistes spp recombinant (rPol d) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp recombinant (rPol d) 5 IgE Ab [Units/volume] in Serum;Paper wasp (rPol d) 5 IgE Qn;;ACTIVE;2.36;2.70 +63437-8;Brucella abortus Ab;Titr;Pt;Ser;Qn;Antihuman globulin;MICRO;1;Brucella abortus Ab [Titer] in Serum by Antihuman globulin;B abortus Ab Titr Ser AHG;;ACTIVE;2.36;2.70 +6343-8;Chlamydia sp Ag;PrThr;Pt;Cnjt;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Conjunctival specimen by Immunoassay;Chlamydia Ag Conjunct Ql IA;;ACTIVE;1.0f;2.56 +63438-6;MAPT gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MAPT gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;MAPT gene Mut Tested Bld/T;;ACTIVE;2.36;2.36 +63439-4;Aquaporin 4 water channel Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Aquaporin 4 water channel IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;AQP4 H2O channel IgG SerPl Ql IF;;ACTIVE;2.36;2.73 +63440-2;Purkinje cell cytoplasmic type Tr Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;PCA-Tr Ab [Presence] in Serum by Immunoblot;PCA-Tr Ab Ser Ql IB;;ACTIVE;2.36;2.73 +63441-0;Tissue polypeptide Ag;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Tissue polypeptide Ag [Units/volume] in Serum or Plasma;Tiss Polypept Ag SerPl-aCnc;;ACTIVE;2.36;2.70 +63443-6;Fasciola hepatica Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Fasciola hepatica Ab [Presence] in Serum by Hemagglutination;F hepatica Ab Ser Ql HA;;ACTIVE;2.36;2.56 +63444-4;Somatotropin^7H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --7 hours post XXX challenge;GH 7h p chal SerPl-mCnc;;ACTIVE;2.36;2.70 +63445-1;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Serum by Immunoblot;ENA SS-A 52kD Ab Ser Ql IB;;ACTIVE;2.36;2.58 +6344-6;Chlamydia sp Ag;PrThr;Pt;Cnjt;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Conjunctival specimen by Immunofluorescence;Chlamydia Ag Conjunct Ql IF;;ACTIVE;1.0f;2.56 +63446-9;Cells.CD3+CD5-/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD5- cells/100 cells in Cerebral spinal fluid;CD3+CD5- cells NFr CSF;;ACTIVE;2.36;2.70 +63447-7;Cells.CD3+CD5-;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD3+CD5- cells [#/volume] in Cerebral spinal fluid;CD3+CD5- cells # CSF;;ACTIVE;2.36;2.70 +63448-5;Cells.CD3+CD5+/100 cells;NFr;Pt;CSF;Qn;;CELLMARK;1;CD3+CD5+ cells/100 cells in Cerebral spinal fluid;CD3+CD5+ cells NFr CSF;;ACTIVE;2.36;2.70 +63449-3;Cells.CD3;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD3 cells [#/volume] in Cerebral spinal fluid;CD3 Cells # CSF;;ACTIVE;2.36;2.70 +63450-1;Cells.CD3+CD4+;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells [#/volume] in Cerebral spinal fluid;CD3+CD4+ Cells # CSF;;ACTIVE;2.36;2.70 +63451-9;Cells.CD3+CD8+;NCnc;Pt;CSF;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells [#/volume] in Cerebral spinal fluid;CD3+CD8+ Cells # CSF;;ACTIVE;2.36;2.72 +63452-7;Cells.CD3-CD7+/100 cells;NFr;Pt;Tiss;Qn;;CELLMARK;1;CD3-CD7+cells/100 cells in Tissue;CD3-CD7+ Cells NFr Tiss;;ACTIVE;2.36;2.70 +6345-3;Chlamydia sp Ag;PrThr;Pt;Genital;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Genital specimen by Immunoassay;Chlamydia Ag Genital Ql IA;;ACTIVE;1.0f;2.73 +63453-5;Gliadin peptide Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay;Gliadin peptide IgA Ser IA-aCnc;;ACTIVE;2.36;2.73 +63454-3;TPMT gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;TPMT gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;TPMT gene Mut Tested Bld/T;;ACTIVE;2.36;2.73 +63455-0;Coxiella burnetii phase 1 Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Presence] in Serum by Immunofluorescence;C burnet Ph1 IgM Ser Ql IF;;ACTIVE;2.36;2.73 +63456-8;Dermatophagoides pteronyssinus native (nDer p) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite native (nDer p) 1 IgE Ab [Units/volume] in Serum;D pteronyss (nDer p) 1 IgE Qn;;ACTIVE;2.36;2.70 +63457-6;Dermatophagoides pteronyssinus recombinant (rDer p) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite recombinant (rDer p) 2 IgE Ab [Units/volume] in Serum;D pteronyss (rDer p) 2 IgE Qn;;ACTIVE;2.36;2.70 +63458-4;Artemisia vulgaris native (nArt v) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mugwort native (nArt v) 1 IgE Ab [Units/volume] in Serum;Mugwort (nArt v) 1 IgE Qn;;ACTIVE;2.36;2.70 +63459-2;Gliadin peptide Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay;Gliadin peptide IgG Ser IA-aCnc;;ACTIVE;2.36;2.73 +634-6;Bacteria identified;Prid;Pt;XXX;Nom;Aerobic culture;MICRO;1;Bacteria identified in Specimen by Aerobe culture;Bacteria Spec Aerobe Cult;;ACTIVE;1.0;2.73 +63460-0;HTLV I+II Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;HTLV I+II Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;HTLV I+II Ab CSF IA-aCnc;;ACTIVE;2.36;2.70 +6346-1;Chlamydia sp Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Chlamydia sp Ag [Presence] in Genital specimen by Immunofluorescence;Chlamydia Ag Genital Ql IF;;ACTIVE;1.0f;2.73 +63461-8;Ganglioside GM1 Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM1 IgG Ab [Presence] in Serum by Immunoblot;Deprecated GM1 Gangl IgG Ser Ql IB;;DEPRECATED;2.36;2.58 +63462-6;Rubella virus Ab.IgG;PrThr;Pt;Ser;Ord;LA;MICRO;1;Rubella virus IgG Ab [Presence] in Serum by Latex agglutination;RUBV IgG Ser Ql LA;;ACTIVE;2.36;2.56 +63463-4;Dermatophagoides pteronyssinus recombinant (rDer p) 10 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite recombinant (rDer p) 10 IgE Ab [Units/volume] in Serum;D pteronyss (rDer p) 10 IgE Qn;;ACTIVE;2.36;2.70 +63464-2;Treponema pallidum Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Treponema pallidum Ab [Units/volume] in Serum by Immunoassay;T pallidum Ab Ser IA-aCnc;;ACTIVE;2.36;2.73 +63465-9;Brucella sp DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Brucella sp DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Brucella DNA CSF Ql NAA+probe;;ACTIVE;2.36;2.63 +63466-7;Ganglioside GM3 Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM3 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM3 IgG CSF IA-aCnc;;ACTIVE;2.36;2.70 +63467-5;Ganglioside GM3 Ab.IgM;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM3 IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM3 IgM CSF IA-aCnc;;ACTIVE;2.36;2.70 +63468-3;Ganglioside GT1a Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GT1a IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GT1a Gangl IgG CSF IA-aCnc;;ACTIVE;2.36;2.70 +63469-1;Ganglioside GT1b Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GT1b IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GT1b Ganlg IgG CSF IA-aCnc;;ACTIVE;2.36;2.70 +63470-9;Ganglioside GM4 Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GM4 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GM4 IgG CSF IA-aCnc;;ACTIVE;2.36;2.70 +63471-7;Ganglioside GD2 Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD2 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GD2 Gangl IgG CSF IA-aCnc;;ACTIVE;2.36;2.70 +63472-5;Ganglioside GD3 Ab.IgG;ACnc;Pt;CSF;Qn;IA;SERO;1;Ganglioside GD3 IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;GD3 Gangl IgG CSF IA-aCnc;;ACTIVE;2.36;2.70 +63473-3;Gadus morhua recombinant (rGad c) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Codfish recombinant (rGad c) 1 IgE Ab [Units/volume] in Serum;Codfish (rGad c) 1 IgE Qn;;ACTIVE;2.36;2.70 +63474-1;Albumin;MRat;18H;Urine;Qn;Detection limit <= 20 mg/L;CHEM;1;Microalbumin [Mass/time] in 18 hour Urine;Microalbumin 18h Ur-mRate;;ACTIVE;2.36;2.73 +63475-8;BK virus DNA;PrThr;Pt;Bld;Ord;;MICRO;1;BK virus DNA [Presence] in Blood;BKV DNA Bld Ql;;ACTIVE;2.36;2.73 +63476-6;Glycine max recombinant (rGly m) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Soybean recombinant (rGly m) 4 IgE Ab [Units/volume] in Serum;Soybean (rGly m) 4 IgE Qn;;ACTIVE;2.36;2.70 +63477-4;Arachis hypogaea recombinant (rAra h) 8 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 8 IgE Ab [Units/volume] in Serum;Peanut (rAra h) 8 IgE Qn;;ACTIVE;2.36;2.73 +63478-2;Platelet glycoprotein Ib-Ix Ab;PrThr;Pt;Bld;Ord;IA;SERO;1;Platelet glycoprotein Ib/Ix Ab [Presence] in Blood by Immunoassay;Plat Gp Ib/Ix Ab Bld Ql IA;;ACTIVE;2.36;2.73 +6347-9;Chlamydia sp Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Chlamydia sp Ag [Presence] in Specimen by Immunoassay;Chlamydia Ag Spec Ql IA;;ACTIVE;1.0f;2.73 +63479-0;Platelet glycoprotein Ia-IIa Ab;PrThr;Pt;Bld;Ord;IA;SERO;1;Platelet glycoprotein Ia/IIa Ab [Presence] in Blood by Immunoassay;Plat Gp Ia/IIa Ab Bld Ql IA;;ACTIVE;2.36;2.73 +63480-8;Pseudomonas aeruginosa.multidrug resistant isolate;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Pseudomonas aeruginosa.multidrug resistant isolate [Presence] in Specimen by Organism specific culture;P aerug.MRI Spec Ql Cult;;ACTIVE;2.36;2.69 +63481-6;Urea;MCnc;24H;Urine;Qn;;CHEM;1;Urea [Mass/volume] in 24 hour Urine;Urea 24h Ur-mCnc;;ACTIVE;2.36;2.70 +63482-4;Methotrimeprazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrimeprazine [Mass/volume] in Serum or Plasma;Methotrimeprazine SerPl-mCnc;;ACTIVE;2.36;2.70 +63483-2;Penicillium notatum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;MICRO;1;Penicillium notatum Ab [Presence] in Serum by Immune diffusion (ID);P notatum Ab Ser Ql ID;;ACTIVE;2.36;2.56 +63484-0;Actin.filamentous Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Actin.filamentous Ab [Presence] in Serum or Plasma by Immunofluorescence;F-actin Ab SerPl Ql IF;;ACTIVE;2.36;2.56 +63485-7;Computer generated recommendation;Find;Pt;^Patient;Doc;;DOC.MISC;2;Computer generated recommendation Document;Computer generated recommendation Doc;;ACTIVE;2.36;2.73 +63486-5;Nut allergen panel;-;Pt;Ser;-;;PANEL.ALLERGY;1;Nut allergen panel - Serum;Nut allergen pnl Ser;;ACTIVE;2.36;2.70 +6348-7;Chlamydia sp identified;Prid;Pt;Sputum;Nom;Organism specific culture;MICRO;1;Chlamydia sp identified in Sputum by Organism specific culture;Chlamydia Spt Cult;;ACTIVE;1.0f;2.19 +63487-3;Epithelial cells.squamous;PrThr;Pt;BAL;Ord;;HEM/BC;1;Epithelial cells.squamous [Presence] in Bronchoalveolar lavage;Squamous BAL Ql;;ACTIVE;2.36;2.56 +63488-1;Epithelial cells.ciliated;PrThr;Pt;BAL;Ord;;HEM/BC;1;Epithelial cells.ciliated [Presence] in Bronchoalveolar lavage;Ciliated BAL Ql;;ACTIVE;2.36;2.56 +63490-7;Where were you born;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Deprecated Birthplace [PhenX];Deprecated Birthplace PhenX;;DEPRECATED;2.36;2.67 +63492-3;Birthplace;Loc;Pt;^Father;Nom;;ADMIN.DEMOG;2;Father birthplace;Father birthplace;;ACTIVE;2.36;2.67 +63493-1;Where was your mother's mother born;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Maternal grandmother birthplace [PhenX];Maternal grandmother birthplace;;TRIAL;2.36;2.65 +63494-9;Where was your mother's father born;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Maternal grandfather birthplace [PhenX];Maternal grandfather birthplace;;TRIAL;2.36;2.65 +6349-5;Chlamydia trachomatis;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Specimen by Organism specific culture;C trach Spec Ql Cult;;ACTIVE;1.0f;2.73 +63495-6;Where was your father's mother born;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Paternal grandmother birthplace [PhenX];Paternal grandmother birthplace;;TRIAL;2.36;2.65 +63496-4;Where was your father's father born;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Paternal grandfather birthplace [PhenX];Paternal grandfather birthplace;;TRIAL;2.36;2.65 +63497-2;Current street number;Loc;Pt;^Patient;Nom;PhenX;PHENX;2;Current street number [Location] [PhenX];Current street number;;TRIAL;2.36;2.65 +63498-0;Current street name;Loc;Pt;^Patient;Nom;PhenX;PHENX;2;Current street name [Location] [PhenX];Current street name;;TRIAL;2.36;2.65 +63499-8;Current apartment number;Loc;Pt;^Patient;Nom;PhenX;PHENX;2;Current apartment number [Location] [PhenX];Current apartment number;;TRIAL;2.36;2.65 +63500-3;Current city;Loc;Pt;^Patient;Nom;PhenX;PHENX;2;Current city [PhenX];Current city;;TRIAL;2.36;2.65 +63501-1;Current state;Loc;Pt;^Patient;Nom;PhenX;PHENX;2;Current state [PhenX];Current state;;TRIAL;2.36;2.65 +63502-9;Current zip code;Loc;Pt;^Patient;Nom;PhenX;PHENX;2;Deprecated Current zip code [Location] [PhenX];Deprecated Zip code;;DEPRECATED;2.36;2.66 +6350-3;Chlamydia trachomatis Ag;PrThr;Pt;Cnjt;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Conjunctival specimen by Immunoassay;C trach Ag Conjunct Ql IA;;ACTIVE;1.0f;2.56 +63503-7;Marital status;Find;Pt;^Patient;Nom;NHANES;PHENX;2;Marital status [NHANES];Current marital status [NHANES];;ACTIVE;2.36;2.73 +63504-5;What is the highest grade or level of school you have completed or the highest degree you have received;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What is the highest grade or level of school you have completed or the highest degree you have received [NHANES];Current educational attainment;;ACTIVE;2.36;2.66 +63506-0;Was your total family income from all sources less than 50,000 dollars or 50,000 dollars or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your total family income from all sources less than 50,000 dollars or 50,000 dollars or more [PhenX];Annual family income 50K;;TRIAL;2.36;2.65 +63507-8;Was your total family income from all sources less than 35,000 dollars or 35,000 dollars or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your total family income from all sources less than 35,000 dollars or 35,000 dollars or more [PhenX];Annual family income 35K;;TRIAL;2.36;2.65 +63508-6;Was your total family income from all sources less than poverty threshold or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your total family income from all sources less than poverty threshold or more [PhenX];Annual family income poverty threshold;;TRIAL;2.36;2.65 +63509-4;Was your total family income from all sources less than 100,000 dollars or 100,000 dollars or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your total family income from all sources less than 100,000 dollars or 100,000 dollars or more [PhenX];Annual family income 100K;;TRIAL;2.36;2.65 +63510-2;Was your total family income from all sources less than 75,000 dollars or 75,000 dollars or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your total family income from all sources less than 75,000 dollars or 75,000 dollars or more [PhenX];Annual family income 75K;;TRIAL;2.36;2.65 +6351-1;Chlamydia trachomatis Ag;PrThr;Pt;Cnjt;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Conjunctival specimen by Immunofluorescence;C trach Ag Conjunct Ql IF;;ACTIVE;1.0f;2.73 +63511-0;Are you working now, looking for work, retired, keeping house, a student, or what;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Are you working now, looking for work, retired, keeping house, a student, or what [PhenX];Current employment status;;TRIAL;2.36;2.65 +63512-8;How many people are living or staying at this address;Num;Pt;^Patient;Qn;;PHENX;2;How many people are living or staying at this address [#];No people this address;;TRIAL;2.36;2.66 +63513-6;Are you covered by health insurance or some other kind of health care plan;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you covered by health insurance or some other kind of health care plan [PhenX];Health insurance coverage;;TRIAL;2.36;2.65 +63514-4;What kind of health insurance or health care coverage do you have;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What kind of health insurance or health care coverage do you have [PhenX];Health insurance coverage type;;TRIAL;2.36;2.73 +63515-1;Where was your biological mother born;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Mother birthplace [PhenX];Mother birthplace PhenX;;TRIAL;2.36;2.65 +63516-9;What are person initials;Find;Pt;^Patient;Nom;;H&P.HX;2;What are person initials;Person initials;;TRIAL;2.36;2.65 +63517-7;Relationship to patient;Type;Pt;^Household member;Nom;;ADMIN;2;Household member Relationship to patient;Household member Relationship to pt;;ACTIVE;2.36;2.67 +63518-5;DXA instrument make and model name;Find;Pt;{Device};Nom;;DEVICES;2;DXA instrument make and model name;DXA Instrument Make Model;;ACTIVE;2.36;2.72 +63519-3;PhenX measure - body composition;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - body composition;;;DEPRECATED;2.36;2.46 +63520-1;PhenX - body composition by dual-energy x-ray absorptiometry protocol 020301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - body composition by dual-energy x-ray absorptiometry protocol 020301;DXA proto;;TRIAL;2.36;2.72 +63521-9;PhenX measure - body image;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - body image;;;DEPRECATED;2.36;2.46 +63522-7;PhenX - body image protocol 020401;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - body image protocol 020401;Body image proto;;TRIAL;2.36;2.66 +63523-5;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldCoA;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Arterial cord blood;COHgb MFr BldCoA;;ACTIVE;2.36;2.73 +63524-3;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldCoV;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Venous cord blood;COHgb MFr BldCoV;;ACTIVE;2.36;2.73 +63526-8;Centromere Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Centromere Ab [Presence] in Body fluid;Centromere Ab Fld Ql;;ACTIVE;2.36;2.56 +63527-6;Centromere Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Centromere Ab [Presence] in Body fluid by Immunoassay;Centromere Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63528-4;Centromere Ab;PrThr;Pt;Body fld;Ord;IF;SERO;1;Centromere Ab [Presence] in Body fluid by Immunofluorescence;Centromere Ab Fld Ql IF;;ACTIVE;2.36;2.56 +6352-9;Chlamydia trachomatis Ag;PrThr;Pt;Stool;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Stool by Immunofluorescence;C trach Ag Stl Ql IF;;ACTIVE;1.0f;2.56 +63529-2;Centromere Ab;Titr;Pt;Body fld;Qn;IF;SERO;1;Centromere Ab [Titer] in Body fluid by Immunofluorescence;Centromere Ab Titr Fld IF;;ACTIVE;2.36;2.36 +635-3;Bacteria identified;Prid;Pt;XXX;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Specimen by Anaerobe culture;Bacteria Spec Anaerobe Cult;;ACTIVE;1.0;2.73 +63530-0;Centromere Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Centromere Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Centromere Ab CSF Ql IF;;ACTIVE;2.36;2.56 +63531-8;Centromere Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Centromere Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Centromere Ab Titr CSF IF;;ACTIVE;2.36;2.36 +63532-6;Centromere protein B Ab;PrThr;Pt;Body fld;Ord;IA;SERO;1;Centromere protein B Ab [Presence] in Body fluid by Immunoassay;Centromere B Ab Fld Ql IA;;ACTIVE;2.36;2.56 +63533-4;Centromere protein B Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Centromere protein B Ab [Presence] in Cerebral spinal fluid by Immunoassay;Centromere B Ab CSF Ql IA;;ACTIVE;2.36;2.56 +63534-2;DNA double strand Ab.IgG;ACnc;Pt;Body fld;Qn;;SERO;1;DNA double strand IgG Ab [Units/volume] in Body fluid;dsDNA IgG Fld-aCnc;;ACTIVE;2.36;2.70 +63535-9;DNA double strand Ab.IgG;ACnc;Pt;CSF;Qn;;SERO;1;DNA double strand IgG Ab [Units/volume] in Cerebral spinal fluid;dsDNA IgG CSF-aCnc;;ACTIVE;2.36;2.70 +63536-7;Jo-1 extractable nuclear Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Body fluid;ENA Jo1 Ab Fld Ql;;ACTIVE;2.36;2.56 +6353-7;Chlamydia trachomatis Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Tissue by Immunofluorescence;C trach Ag Tiss Ql IF;;ACTIVE;1.0f;2.56 +63537-5;Muscle specific receptor tyrosine kinase Ab.IgG;MCnc;Pt;Ser;Qn;IA;SERO;1;Muscle specific receptor tyrosine kinase IgG Ab [Mass/volume] in Serum by Immunoassay;MuSK IgG Ser IA-mCnc;;ACTIVE;2.36;2.70 +63538-3;Myeloperoxidase Ab;ACnc;Pt;Body fld;Qn;;SERO;1;Myeloperoxidase Ab [Units/volume] in Body fluid;Myeloperoxidase Ab Fld-aCnc;;ACTIVE;2.36;2.70 +63539-1;Proteinase 3 Ab;ACnc;Pt;Body fld;Qn;;SERO;1;Proteinase 3 Ab [Units/volume] in Body fluid;Proteinase3 Ab Fld-aCnc;;ACTIVE;2.36;2.70 +63540-9;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Body fluid;ENA RNP Ab Fld Ql;;ACTIVE;2.36;2.56 +63541-7;Ribosomal P Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Ribosomal P Ab [Presence] in Body fluid;Ribosomal P Ab Fld Ql;;ACTIVE;2.36;2.56 +63542-5;SCL-70 extractable nuclear Ab;PrThr;Pt;Body fld;Ord;;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Body fluid;ENA Scl70 Ab Fld Ql;;ACTIVE;2.36;2.56 +63543-3;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Body fluid;ENA SS-A 52kD Ab Fld Ql;;ACTIVE;2.36;2.56 +63544-1;Sjogrens syndrome-A extractable nuclear 60kD Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Sjogrens syndrome-A extractable nuclear 60kD Ab [Presence] in Body fluid;ENA SS-a 60kD Ab Fld Ql;;ACTIVE;2.36;2.56 +6354-5;Chlamydia trachomatis Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Specimen by Immunoassay;C trach Ag Spec Ql IA;;ACTIVE;1.0f;2.69 +63545-8;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Body fluid;ENA SS-B Ab Fld Ql;;ACTIVE;2.36;2.56 +63546-6;Smith extractable nuclear Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Smith extractable nuclear Ab [Presence] in Body fluid;ENA SM Ab Fld Ql;;ACTIVE;2.36;2.56 +63547-4;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Body fld;Ord;;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Presence] in Body fluid;ENA SM+RNP Ab Fld Ql;;ACTIVE;2.36;2.56 +63548-2;Smith extractable nuclear B Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Smith extractable nuclear B Ab [Units/volume] in Serum by Immunoassay;ENA SM-B Ab Ser IA-aCnc;;ACTIVE;2.36;2.70 +63549-0;Albumin.serum-Albumin.periton fld;MCncDiff;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Albumin in serum - albumin in peritoneal fluid [Mass concentration difference];Albumin ser-prt fld-MCDiff;;ACTIVE;2.36;2.70 +63550-8;Calcium magnesium phosphate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium magnesium phosphate/Total in Stone;Calcium magnesium phosphate MFr Stone;;ACTIVE;2.38;2.70 +63551-6;Pituitary Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Pituitary Ab [Titer] in Serum by Immunofluorescence;Pituitary Ab Titr Ser IF;;ACTIVE;2.36;2.70 +6355-2;Chlamydia trachomatis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Specimen by Immunofluorescence;C trach Ag Spec Ql IF;;ACTIVE;1.0f;2.73 +63552-4;Macrophages/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Macrophages/100 cells in Bone marrow by Manual count;Macrophages NFr Mar Manual;;ACTIVE;2.36;2.70 +63553-2;Succinylaminoimidazole carboxamide riboside;PrThr;Pt;Urine;Ord;;CHEM;1;Succinylaminoimidazole carboxamide riboside [Presence] in Urine;SAICAR Ur Ql;;ACTIVE;2.36;2.56 +63554-0;Leukocytes;NRat;24H;Urine sed;Qn;Microscopy;UA;1;Leukocytes in 24 hour Urine sediment by Microscopy;WBC 24h UrnS Micro-nRate;;ACTIVE;2.36;2.70 +63555-7;Leukocytes;NCnc;XXX;Urine sed;Qn;Microscopy.light.HPF;UA;1;Leukocytes [#/volume] by Microscopy high power field in Urine sediment collected for unspecified duration;WBC ?Tm # UrnS HPF;;ACTIVE;2.36;2.73 +63556-5;Fat;MCnt;Pt;Stool;Qn;;CHEM;1;Fat [Mass/mass] in Stool;Fat Stl-mCnt;;ACTIVE;2.36;2.73 +63557-3;Hepatitis B virus surface Ag;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis B virus surface Ag [Units/volume] in Serum or Plasma by Immunoassay;HBV surface Ag SerPl IA-aCnc;;ACTIVE;2.36;2.73 +63558-1;HLA-DQB1*06:02;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQB1*06:02 [Presence];HLA-DQB1*06:02 Ql;;ACTIVE;2.36;2.73 +63559-9;Signal recognition particle Ab;PrThr;Pt;Ser/Plas;Ord;IB;SERO;1;Signal Recognition Particle (SRP) Ab [Presence] in Serum or Plasma by Immunoblot;SRP Ab SerPl Ql IB;;ACTIVE;2.36;2.73 +6356-0;Chlamydia trachomatis DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Genital specimen by NAA with probe detection;C trach DNA Genital Ql NAA+probe;;ACTIVE;1.0f;2.73 +63560-7;Somatotropin^8.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --8.5 hours post XXX challenge;GH 8.5h p chal SerPl-mCnc;;ACTIVE;2.36;2.70 +63561-5;Coagulation surface induced actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;aPTT actual/normal in Platelet poor plasma by Coagulation assay;aPTT Act/Nor PPP;;ACTIVE;2.36;2.73 +63562-3;Japanese encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Japanese encephalitis virus IgM Ab [Presence] in Serum by Immunoassay;JEV IgM Ser Ql IA;;ACTIVE;2.36;2.56 +63563-1;Japanese encephalitis virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Japanese encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;JEV IgM CSF Ql IA;;ACTIVE;2.36;2.56 +63564-9;Giardia lamblia Ag & Cryptosporidium parvum Ag & Entamoeba histolytica or dispar Ag;Prid;Pt;Stool;Nom;;MICRO;1;Giardia lamblia Ag and Cryptosporidium parvum Ag and Entamoeba histolytica/dispar Ag [Identifier] in Stool;G lambl+C par+E hist/dis Ag Stl;;ACTIVE;2.36;2.36 +63565-6;Prothionamide;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Prothionamide [Susceptibility] by Method for Slow-growing mycobacteria;Prothionamide Islt SlowMyco;;ACTIVE;2.36;2.36 +63566-4;Basement membrane Ab pattern;Imp;Pt;Ser;Nom;IF;SERO;1;Basement membrane Ab pattern [Interpretation] in Serum by Immunofluorescence;BM Ab pattern Ser IF-Imp;;ACTIVE;2.36;2.36 +63567-2;Neutrophil cytoplasmic Ab pattern;Imp;Pt;Body fld;Nom;IF;SERO;1;Neutrophil cytoplasmic Ab pattern [Interpretation] in Body fluid by Immunofluorescence;ANCA Ab pattern Fld IF-Imp;;ACTIVE;2.36;2.36 +63568-0;Neutrophil cytoplasmic Ab pattern;Imp;Pt;CSF;Nom;IF;SERO;1;Neutrophil cytoplasmic Ab pattern [Interpretation] in Cerebral spinal fluid by Immunofluorescence;ANCA Ab pattern CSF IF-Imp;;ACTIVE;2.36;2.36 +63569-8;Nuclear Ab pattern;Imp;Pt;CSF;Nom;IF;SERO;1;Nuclear Ab pattern [Interpretation] in Cerebral spinal fluid by Immunofluorescence;ANA Pat CSF IF-Imp;;ACTIVE;2.36;2.36 +63570-6;Nuclear Ab pattern;Imp;Pt;Plr fld;Nom;IF;SERO;1;Nuclear Ab pattern [Interpretation] in Pleural fluid by Immunofluorescence;ANA Pat Plr IF-Imp;;ACTIVE;2.36;2.36 +63571-4;Pancreatic islet cell Ab pattern;Imp;Pt;Ser;Nom;IF;SERO;1;Pancreatic islet cell Ab pattern [Interpretation] in Serum by Immunofluorescence;Panc Islet Cell Ab pattern Ser IF-Imp;;ACTIVE;2.36;2.36 +63572-2;Time received in laboratory;TmStp;Pt;Specimen;Qn;;SPEC;1;Time received in laboratory of Specimen;Time received in lab Spec;;ACTIVE;2.36;2.73 +63574-8;Staphylococcus sp.coagulase negative DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Staphylococcus sp.coagulase negative DNA [Presence] in Isolate by NAA with probe detection;Coag neg Staph DNA Islt Ql NAA+probe;;ACTIVE;2.36;2.63 +63575-5;Was there ever a time when two or more of these problems occurred together;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Was there ever a time when two or more of these problems occurred together [SSAGA II];Alc withdraw multiple symptoms SSAGA II;;ACTIVE;2.36;2.65 +63576-3;At what age did you begin to drink regularly - that is, drinking at least once a month for 6Mo or more;Time;Pt;^Patient;Qn;SSAGA II;PHENX;2;At what age did you begin to drink regularly - that is, drinking at least once a month for 6 months or more [SSAGA II];Regular drinking age SSAGA II;;ACTIVE;2.36;2.65 +63577-1;How old were you the first time you got drunk, that is, your speech was slurred or you were unsteady on your feet;Time;Pt;^Patient;Qn;SSAGA II;PHENX;2;How old were you the first time you got drunk, that is, your speech was slurred or you were unsteady on your feet [SSAGA II];First drunk age SSAGA II;;ACTIVE;2.36;2.65 +6357-8;Chlamydia trachomatis DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection;C trach DNA Ur Ql NAA+probe;;ACTIVE;1.0f;2.73 +63578-9;In your lifetime, what is the largest number of drinks you have ever had in a 24H period, including all types of alcohol;Num;Pt;^Patient;Qn;SSAGA II;PHENX;2;In your lifetime, what is the largest number of drinks you have ever had in a 24 hour period, including all types of alcohol [SSAGA II];Largest drinking 24h SSAGA II;;ACTIVE;2.36;2.65 +63579-7;Have you ever taken a drink to keep from having any of these problems, or to make them go away;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever taken a drink to keep from having any of these problems, or to make them go away [SSAGA II];Drink alleviate symptoms SSAGA II;;ACTIVE;2.36;2.65 +63580-5;Have you ever smoked part or all of a cigarette;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever smoked part or all of a cigarette [PhenX];Cigarette smoking PhenX;;ACTIVE;2.36;2.65 +63581-3;Smoked at least 100 cigarettes in entire life;Find;Pt;^Patient;Ord;;H&P.HX;2;Smoked at least 100 cigarettes in entire life;Smoked 100 Cigs entire life;;ACTIVE;2.36;2.68 +63582-1;Do you now smoke cigarettes every D, some D, or not at all;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you now smoke cigarettes every day, some days, or not at all [PhenX];Cigarette smoking current PhenX;;ACTIVE;2.36;2.73 +63583-9;Has there ever been a period in your life when you smoked cigarettes every day for at least 30D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has there ever been a period in your life when you smoked cigarettes every day for at least 30 days [PhenX];Cigarette everday 30D PhenX;;ACTIVE;2.36;2.65 +63584-7;Has there ever been a period in your life when you smoked cigarettes every day for at least 6Mo;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has there ever been a period in your life when you smoked cigarettes every day for at least 6 months [PhenX];Former smoker 6Mo PhenX;;TRIAL;2.36;2.65 +63585-4;About how long have you been in the United States;Time;Pt;^Patient;Qn;PhenX;PHENX;2;About how long have you been in the United States [PhenX];Years living in US PhenX;;TRIAL;2.36;2.65 +6358-6;Chlamydia trachomatis rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Chlamydia trachomatis rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated C trach rRNA XXX Ql Prb;;DEPRECATED;1.0f;2.69 +63586-2;What was your best estimate of the total income of all family members from all sources, before taxes, in last Y;NRat;1Y;^Patient;Qn;PhenX;PHENX;2;What was your best estimate of the total income of all family members from all sources, before taxes, in last year [PhenX];Annual family income nRate PhenX;;TRIAL;2.36;2.65 +63587-0;Whole body scan image name;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Body scan image name [PhenX];Whole body scan image name PhenX;;TRIAL;2.36;2.65 +63588-8;Subject of body image assessment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Subject of body image assessment [PhenX];Body image subject PhenX;;TRIAL;2.36;2.65 +63589-6;Scale used for body image assessment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Scale used for body image assessment [PhenX];Body image scale PhenX;;TRIAL;2.36;2.65 +63590-4;Choose the picture that most closely resembles your, or your childs, body shape;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Choose the picture that most closely resembles your, or your childs, body shape [PhenX];Choose picture body shape PhenX;;TRIAL;2.36;2.65 +63591-2;What was the largest number of drinks that you ever drank in a single day;NRat;Pt;^Patient;Qn;AUDADIS-IV;PHENX;2;What was the largest number of drinks that you ever drank in a single day [AUDADIS-IV];Alcohol max drinks 1D nRate AUDADIS-IV;;ACTIVE;2.36;2.68 +63592-0;Did your tolerance to alcohol increase 50 percent or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did your tolerance to alcohol increase 50 percent or more [SSAGA II];Alc half increase same effect SSAGA II;;ACTIVE;2.36;2.65 +63593-8;Did the need to drink a lot more before you got drunk increase 50 percent or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did the need to drink a lot more before you got drunk increase 50 percent or more [SSAGA II];Alcohol half increase drunk SSAGA II;;ACTIVE;2.36;2.65 +6359-4;Clostridioides difficile toxin A;ACnc;Pt;Stool;Qn;IA;MICRO;1;Clostridioides difficile toxin A [Units/volume] in Stool by Immunoassay;C diff Tox A Stl IA-aCnc;;ACTIVE;1.0f;2.73 +63594-6;Were you unable to stop or cut down drinking 3 or more times;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Were you unable to stop or cut down drinking 3 or more times [SSAGA II];Not stop cut down 3X SSAGA II;;ACTIVE;2.36;2.65 +63595-3;Did you ever start drinking and become drunk when you didn't want to 3 or more times;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you ever start drinking and become drunk when you didn't want to 3 or more times [SSAGA II];Drunk not intended 3X SSAGA II;;ACTIVE;2.36;2.65 +63596-1;Did giving up or greatly reduced important activities while drinking happen 3 or more times or for a month or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did giving up or greatly reduced important activities while drinking happen 3 or more times or for a month or more [SSAGA II];Alcohol interfere activity 3X SSAGA II;;ACTIVE;2.36;2.65 +63597-9;During the past 30D, on how many D did you drink one or more drinks of an alcoholic beverage;NRat;30D;^Patient;Qn;PhenX;PHENX;2;During the past 30 days, on how many days did you drink one or more drinks of an alcoholic beverage [PhenX];Alcohol 30D freq PhenX;;ACTIVE;2.36;2.65 +63598-7;On the D that you drank during the past 30D, how many drinks did you usually have each D;Find;30D;^Patient;Nom;PhenX;PHENX;2;On the days that you drank during the past 30 days, how many drinks did you usually have each day [PhenX];Alcohol 30D quantity PhenX;;ACTIVE;2.36;2.65 +63599-5;Did you ever become tolerant to alcohol, that is, you drank a great deal more in order to get an effect, or found you could no longer get high on the amount you used to drink;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you ever become tolerant to alcohol, that is, you drank a great deal more in order to get an effect, or found you could no longer get high on the amount you used to drink [SSAGA II];Alcohol tolerant SSAGA II;;ACTIVE;2.36;2.65 +63600-1;Have you ever started drinking at times you promised yourself that you wouldn't, or have you ever drunk more than you intended, for example, when you decided to drink 2 drinks and ended up drinking 4 or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever started drinking at times you promised yourself that you wouldn't, or have you ever drunk more than you intended, for example, when you decided to drink 2 drinks and ended up drinking 4 or more [SSAGA II];Alcohol more than intended SSAGA II;;ACTIVE;2.36;2.65 +63601-9;Have you ever given up or greatly reduced important activities while drinking - like sports, work, or associating with friends or relatives;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever given up or greatly reduced important activities while drinking - like sports, work, or associating with friends or relatives [SSAGA II];Alcohol interfere activity SSAGA II;;ACTIVE;2.36;2.65 +6360-2;Clostridioides difficile toxin A;ACnc;Pt;XXX;Qn;IA;MICRO;1;Clostridioides difficile toxin A [Units/volume] in Specimen by Immunoassay;C diff Tox A Spec IA-aCnc;;ACTIVE;1.0f;2.69 +63602-7;Has there ever been a period of several D or more when you spent so much time drinking or recovering from the effects of alcohol that you had little time for anything else;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Has there ever been a period of several days or more when you spent so much time drinking or recovering from the effects of alcohol that you had little time for anything else [SSAGA II];Alcohol interfere life SSAGA II;;ACTIVE;2.36;2.65 +63604-3;Did spending so much time drinking or recovering from the effects of alcohol that you had little time for anything else happen 3 or more times or for a month or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did spending so much time drinking or recovering from the effects of alcohol that you had little time for anything else happen 3 or more times or for a month or more [SSAGA II];Alcohol interfere life 3X SSAGA II;;ACTIVE;2.36;2.65 +63605-0;Health problem resulting from long stretches of drinking;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Health problem resulting from long stretches of drinking [SSAGA II];Health prob long drinking SSAGA II;;ACTIVE;2.36;2.65 +63606-8;Which of these problems occurred together;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Which of these problems occurred together [SSAGA II];Alc withdraw multiple problems SSAGA II;;ACTIVE;2.36;2.65 +63607-6;Did taking a drink to keep from having any of these problems, or to make them go away, happen 3 times or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did taking a drink to keep from having any of these problems, or to make them go away, happen 3 times or more [SSAGA II];Drink alleviate symptoms 3X SSAGA II;;ACTIVE;2.36;2.65 +63608-4;Age when first smoked part or all of a cigarette;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first smoked part or all of a cigarette;Age first smoked part/all cig;;ACTIVE;2.36;2.68 +63609-2;How old were you when you first started smoking cigarettes every day;Time;Pt;^Patient;Qn;TUS-CPS;PHENX;2;How old were you when you first started smoking cigarettes every day [TUS-CPS];First smoking every day age TUS-CPS;;ACTIVE;2.36;2.65 +636-1;Bacteria identified;Prid;Pt;XXX;Nom;Sterile body fluid culture;MICRO;1;Bacteria identified in Specimen by Sterile body fluid culture;Bacteria Spec BFld Cult;;ACTIVE;1.0;2.73 +6361-0;Clostridioides difficile toxin A+B;ACnc;Pt;Ser;Qn;IA;MICRO;1;Clostridioides difficile toxin A+B [Units/volume] in Serum by Immunoassay;C diff Tox A+B Ser IA-aCnc;;ACTIVE;1.0f;2.69 +63610-0;Age when first started smoking cigarettes fairly regularly;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first started smoking cigarettes fairly regularly;First smoking regularly age;;ACTIVE;2.36;2.68 +63611-8;During the past 30D, have you smoked part or all of a cigarette;Find;30D;^Patient;Ord;PhenX;PHENX;2;During the past 30 days, have you smoked part or all of a cigarette [PhenX];30Dcigarette smoking PhenX;;TRIAL;2.36;2.65 +63612-6;During the past 30D, on how many D did you smoke part or all of a cigarette;NRat;30D;^Patient;Qn;PhenX;PHENX;2;During the past 30 days, on how many days did you smoke part or all of a cigarette [PhenX];Smoke 30D freq nRate PhenX;;TRIAL;2.36;2.65 +63613-4;What is your best estimate of the number of D you smoked part or all of a cigarette during the past 30D;NRat;30D;^Patient;Qn;PhenX;PHENX;2;What is your best estimate of the number of days you smoked part or all of a cigarette during the past 30 days [PhenX];30D freq estimate nRate PhenX;;TRIAL;2.36;2.65 +63614-2;Did you ever find you could drink a lot more before you got drunk;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you ever find you could drink a lot more before you got drunk [SSAGA II];Alcohol more get drunk SSAGA II;;ACTIVE;2.36;2.65 +63615-9;Have you wanted to stop or cut down on drinking 3 or more times;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you wanted to stop or cut down on drinking 3 or more times [SSAGA II];Alcohol withdrawal 3X SSAGA II;;ACTIVE;2.36;2.65 +63616-7;Have you ever tried to stop or cut down on drinking;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever tried to stop or cut down on drinking [SSAGA II];Alcohol cessation SSAGA II;;ACTIVE;2.36;2.65 +63617-5;How many times were you unable to stop or cut down on drinking;Num;Pt;^Patient;Qn;SSAGA II;PHENX;2;How many times were you unable to stop or cut down on drinking [SSAGA II];Alc withdraw failure times SSAGA II;;ACTIVE;2.36;2.65 +63618-3;Have you ever started drinking and become drunk when you didn't want to;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever started drinking and become drunk when you didn't want to [SSAGA II];Drunk not intended SSAGA II;;ACTIVE;2.36;2.65 +63619-1;Did drinking ever cause you to have any other physical health problems;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did drinking ever cause you to have any other physical health problems [SSAGA II];Drinking other health probs SSAGA II;;ACTIVE;2.36;2.65 +63620-9;Did you continue to drink knowing that drinking caused you to have health problems;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you continue to drink knowing that drinking caused you to have health problems [SSAGA II];Alc continue health problems SSAGA II;;ACTIVE;2.36;2.65 +63621-7;Have you ever continued to drink when you knew you had any other serious physical illness or condition that might be made worse by drinking;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever continued to drink when you knew you had any other serious physical illness or condition that might be made worse by drinking [SSAGA II];Alc continue worse problems SSAGA II;;ACTIVE;2.36;2.65 +63622-5;Did you continue to drink after you knew it caused you any of these emotional or psychological problems;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you continue to drink after you knew it caused you any of these problems [SSAGA II];Alc continue use emot problems SSAGA II;;ACTIVE;2.36;2.65 +63623-3;Other physical health problems from drinking;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Other physical health problems from drinking [SSAGA II];Drinking other problems SSAGA II;;ACTIVE;2.36;2.65 +63624-1;Did long stretches of drinking cause you to have this health problem;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did long stretches of drinking cause you to have this health problem [SSAGA II];Alcohol use problems SSAGA II;;ACTIVE;2.36;2.65 +63625-8;Emotional or psychological problem related to drinking;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Emotional or psychological problem related to drinking [SSAGA II];Emot psych problem re drinking SSAGA II;;ACTIVE;2.36;2.65 +63626-6;Has drinking ever caused you this emotional or psychological problem for more than 24H to the point that it interfered with your functioning or relationships;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Has drinking ever caused you this emotional or psychological problem for more than 24 hours to the point that it interfered with your functioning or relationships [SSAGA II];Alc use emotional problems SSAGA II;;ACTIVE;2.36;2.65 +63627-4;When you stopped, cut down or went without drinking, did you ever experience this problem for most of the day for 2D or longer;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;When you stopped, cut down or went without drinking, did you ever experience this problem for most of the day for 2 days or longer [SSAGA II];Alcohol withdraw problems SSAGA II;;ACTIVE;2.36;2.65 +6362-8;Clostridioides difficile toxin A+B;PrThr;Pt;Stool;Ord;Cytotoxin tissue culture assay;MICRO;1;Clostridioides difficile toxin A+B [Presence] in Stool by Cytotoxin tissue culture assay;C diff Tox A+B Stl Ql CT Tiss Cult;;ACTIVE;1.0f;2.73 +63628-2;Problem after cutting down or going without drinking;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Problem after cutting down or going without drinking [SSAGA II];Alc withdraw problem type SSAGA II;;ACTIVE;2.36;2.65 +63629-0;On the number of D you reported you smoked cigarettes during the past 30D, how many cigarettes did you smoke per D, on average;Find;30D;^Patient;Ord;PhenX;PHENX;2;On the number of days you reported you smoked cigarettes during the past 30 days, how many cigarettes did you smoke per day, on average [PhenX];30Dquantity PhenX;;TRIAL;2.36;2.65 +63630-8;How long has it been since you last smoked part or all of a cigarette;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long has it been since you last smoked part or all of a cigarette [PhenX];Smoking cessation time PhenX;;ACTIVE;2.36;2.65 +63631-6;How old were you the last time you smoked part or all of a cigarette;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you the last time you smoked part or all of a cigarette [PhenX];Smoking cessation age PhenX;;ACTIVE;2.36;2.65 +63632-4;About how long has it been since you completely quit smoking cigarettes;Time;Pt;^Patient;Qn;TUS-CPS;PHENX;2;About how long has it been since you completely quit smoking cigarettes [TUS-CPS];Smoke cessation time number TUS-CPS;;ACTIVE;2.36;2.65 +63633-2;In your entire life, have you had at least 1 drink of any kind of alcohol, not counting small tastes or sips;Find;Pt;^Patient;Ord;AUDADIS-IV;PHENX;2;In your entire life, have you had at least 1 drink of any kind of alcohol, not counting small tastes or sips [AUDADIS-IV];Lifetime use AUDADIS-IV;;ACTIVE;2.36;2.65 +63634-0;About how old were you when you first started drinking, not counting small tastes or sips of alcohol;Time;Pt;^Patient;Qn;PhenX;PHENX;2;About how old were you when you first started drinking, not counting small tastes or sips of alcohol [PhenX];Alc first use age PhenX;;ACTIVE;2.36;2.65 +63635-7;Did drinking when you promised yourself that you wouldn't, or being drunk more than you intended happen 3 times or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did drinking when you promised yourself that you wouldn't, or being drunk more than you intended happen 3 times or more [SSAGA II];Alc more than intended 3X SSAGA II;;ACTIVE;2.36;2.65 +6363-6;Clostridioides difficile toxin A+B;ACnc;Pt;Stool;Qn;IA;MICRO;1;Clostridioides difficile toxin A+B [Units/volume] in Stool by Immunoassay;C diff Tox A+B Stl IA-aCnc;;ACTIVE;1.0f;2.73 +63636-5;How soon after you wake up do, or did, you smoke your first cigarette;Find;Pt;^Patient;Ord;FTND;PHENX;2;How soon after you wake up do, or did, you smoke your first cigarette [FTND];First smoke time FTND;;ACTIVE;2.36;2.65 +63637-3;Do, or did, you find it difficult to refrain from smoking in places where it is forbidden, such as in church, at the library, in a cinema, etc;Find;Pt;^Patient;Ord;FTND;PHENX;2;Do, or did, you find it difficult to refrain from smoking in places where it is forbidden, such as in church, at the library, in a cinema, etc [FTND];Smoke difficult refrain FTND;;ACTIVE;2.36;2.65 +63638-1;Smoking status;Find;Pt;^Patient;Nom;FTND;PHENX;2;Smoking status [FTND];Smoking status FTND;;ACTIVE;2.36;2.73 +63639-9;Which cigarette would, or did, you hate most to give up;Find;Pt;^Patient;Ord;FTND;PHENX;2;Which cigarette would, or did, you hate most to give up [FTND];Smoke first give up FTND;;ACTIVE;2.36;2.65 +63640-7;How many cigarettes per day do, or did, you smoke;Find;Pt;^Patient;Nom;;PHENX;2;How many cigarettes per day do, or did, you smoke;Smoke quant 1D;;ACTIVE;2.36;2.73 +63641-5;Do, or did, you smoke more frequently during the first Hs after waking than during the rest of the day;Find;Pt;^Patient;Ord;FTND;PHENX;2;Do, or did, you smoke more frequently during the first hours after waking than during the rest of the day [FTND];Smoke more 1st Hs FTND;;ACTIVE;2.36;2.65 +63642-3;Do, or did, you smoke if you are so ill that you are in bed most of the day;Find;Pt;^Patient;Ord;FTND;PHENX;2;Do, or did, you smoke if you are so ill that you are in bed most of the day [FTND];Smoke during illness FTND;;ACTIVE;2.36;2.65 +63643-1;Drug type used in your lifetime;Type;Lifetime;^Patient;Nom;;H&P.HX;2;Drug type used in your lifetime;Lifetime drug med use;;ACTIVE;2.36;2.69 +6364-4;Clostridioides difficile toxin A+B;ACnc;Pt;XXX;Qn;IA;MICRO;1;Clostridioides difficile toxin A+B [Units/volume] in Specimen by Immunoassay;C diff Tox A+B Spec IA-aCnc;;ACTIVE;1.0f;2.73 +63644-9;Have you ever used any of these medicines or drugs;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever used any of these medicines or drugs [SSAGA II];Meds drugs ever SSAGA II;;ACTIVE;2.36;2.65 +63645-6;How old were you when you first used this drug;Time;Pt;^Patient;Qn;AUDADIS-IV;PHENX;2;How old were you when you first used this drug [AUDADIS-IV];Drug first use age AUDADIS-IV;;ACTIVE;2.36;2.65 +63646-4;During the past 30D, on how many D did you use drugs;NRat;30D;^Patient;Qn;PhenX;PHENX;2;During the past 30 days, on how many days did you use drugs [PhenX];Durg 30D freq nRate PhenX;;ACTIVE;2.36;2.65 +63647-2;Did you ever use marijuana at least 21 times in a single Y;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you ever use marijuana at least 21 times in a single year [SSAGA II];Marijuana 21 times a Y SSAGA II;;ACTIVE;2.36;2.65 +63648-0;Has there ever been a period of a Mo or more when a great deal of your time was spent using marijuana, getting marijuana, or getting over its effects;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Has there ever been a period of a month or more when a great deal of your time was spent using marijuana, getting marijuana, or getting over its effects [SSAGA II];Marijuana use or get over SSAGA II;;ACTIVE;2.36;2.65 +63649-8;Problem, related to marijuana use, that occurred for more than 24H to the point that it interfered with functioning or relationships;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Problem, related to marijuana use, that occurred for more than 24 hours to the point that it interfered with functioning or relationships [SSAGA II];Problem marijuana > 24h SSAGA II;;ACTIVE;2.36;2.65 +6365-1;Clostridioides difficile toxin B;ACnc;Pt;Stool;Qn;IA;MICRO;1;Clostridioides difficile toxin B [Units/volume] in Stool by Immunoassay;C diff Tox B Stl IA-aCnc;;ACTIVE;1.0f;2.73 +63651-4;Did you continue to use marijuana after you knew it caused this problem;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you continue to use marijuana after you knew it caused this problem [SSAGA II];Continue marijuana depressed SSAGA II;;ACTIVE;2.36;2.65 +63652-2;Have you often wanted to stop or cut down on marijuana;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you often wanted to stop or cut down on marijuana [SSAGA II];Marijuana want stop SSAGA II;;ACTIVE;2.36;2.65 +63653-0;Have you ever tried to stop or cut down on marijuana but found you couldn't;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever tried to stop or cut down on marijuana but found you couldn't [SSAGA II];Marijuana could not stop SSAGA II;;ACTIVE;2.36;2.65 +63654-8;Were you unable to stop or cut down on marijuana 3 or more times;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Were you unable to stop or cut down on marijuana 3 or more times [SSAGA II];Marijuana unable stop 3X SSAGA II;;ACTIVE;2.36;2.65 +63655-5;Have you often used marijuana more frequently or in larger amounts than you intended to;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you often used marijuana more frequently or in larger amounts than you intended to [SSAGA II];Marijuana more than intended SSAGA II;;ACTIVE;2.36;2.65 +63656-3;Did you ever need larger amounts of marijuana to get an effect, or did you ever find that you could no longer get high on the amount you used to use;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you ever need larger amounts of marijuana to get an effect, or did you ever find that you could no longer get high on the amount you used to use [SSAGA II];Marijuana need more for effect SSAGA II;;ACTIVE;2.36;2.65 +63657-1;When you stopped, cut down, or went without marijuana, did you ever experience any of these problems for most of the day for 2D or longer;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;When you stopped, cut down, or went without marijuana, did you ever experience any of these problems for most of the day for 2 days or longer [SSAGA II];Marijuana withdrawal SSAGA II;;ACTIVE;2.36;2.65 +63658-9;Have you ever used marijuana to keep from having any of these problems or to make them go away;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever used marijuana to keep from having any of these problems or to make them go away [SSAGA II];Marijuana prevent withdrawal SSAGA II;;ACTIVE;2.36;2.65 +63659-7;Did using marijuana, to keep from having any of these problems, happen 3 or more times;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did using marijuana, to keep from having any of these problems, happen 3 or more times [SSAGA II];Marijuana prevent withdrawal 3X SSAGA II;;ACTIVE;2.36;2.65 +63660-5;Did these problems, related to using marijuana, ever occur together;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did these problems, related to using marijuana, ever occur together [SSAGA II];Marijuana withdraw sympts combo SSAGA II;;ACTIVE;2.36;2.65 +63661-3;Did giving up, or greatly reducing important activities while using marijuana happen 3 or more times or last for a month or longer;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did giving up, or greatly reducing important activities while using marijuana happen 3 or more times or last for a month or longer [SSAGA II];Marijuana prevent act length 3X SSAGA II;;ACTIVE;2.36;2.65 +63662-1;Medicine or drug used to feel good or high, or to feel more active or alert;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Medicine or drug used to feel good or high, or to feel more active or alert [SSAGA II];Medicine drug lifetime use SSAGA II;;ACTIVE;2.36;2.65 +63663-9;Have you ever used any of these medicines or drugs to feel good or high, or to feel more active or alert - or did you use any prescription drugs when they were not prescribed, or more than prescribed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever used any of these medicines or drugs to feel good or high, or to feel more active or alert - or did you use any prescription drugs when they were not prescribed, or more than prescribed [PhenX];Meds drugs feel high PhenX;;TRIAL;2.36;2.65 +63664-7;How many times in your life have you used this medicine or drug;Num;Pt;^Patient;Qn;SSAGA II;PHENX;2;How many times in your life have you used this medicine or drug [SSAGA II];Drug lifetime times used SSAGA II;;ACTIVE;2.36;2.65 +63665-4;Was there ever a period of a Mo or more when a great deal of your time was spent getting over this drug or its effects;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Was there ever a period of a month or more when a great deal of your time was spent getting over this drug or its effects [SSAGA II];Drug 30D use get over SSAGA II;;ACTIVE;2.36;2.65 +63666-2;Have you often wanted to stop or cut down on this drug;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you often wanted to stop or cut down on this drug [SSAGA II];Drug wanted to stop SSAGA II;;ACTIVE;2.36;2.65 +63667-0;Have you ever tried to stop or cut down on this drug but found that you couldn't;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever tried to stop or cut down on this drug but found that you couldn't [SSAGA II];Drug tried to stop SSAGA II;;ACTIVE;2.36;2.65 +63668-8;Were you unable to stop or cut down 3 or more times on this drug;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Were you unable to stop or cut down 3 or more times on this drug [SSAGA II];Drug tried to stop 3X SSAGA II;;ACTIVE;2.36;2.65 +6366-9;Clostridioides difficile toxin B;ACnc;Pt;XXX;Qn;IA;MICRO;1;Clostridioides difficile toxin B [Units/volume] in Specimen by Immunoassay;C diff Tox B Spec IA-aCnc;;ACTIVE;1.0f;2.69 +63669-6;Did you ever need larger amounts of this drug to get an effect or find that you could no longer get high on the amount you used to use;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you ever need larger amounts of this drug to get an effect or find that you could no longer get high on the amount you used to use [SSAGA II];Drug need more for effect SSAGA II;;ACTIVE;2.36;2.65 +63670-4;Have you ever given up or greatly reduced important activities like sports, work, or associating with friends or relatives while using this drug;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever given up or greatly reduced important activities like sports, work, or associating with friends or relatives while using this drug [SSAGA II];Drug reduced activity SSAGA II;;ACTIVE;2.36;2.65 +63671-2;Drug type used steadily, for a month or more;Type;Pt;^Patient;Nom;SSAGA II;PHENX;2;Drug type used steadily, for a month or more [SSAGA II];Drug type >30D SSAGA II;;ACTIVE;2.36;2.65 +63672-0;Did giving up or greatly reducing important activities while using this drug, happen 3 or more times or more or for a month or more;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did giving up or greatly reducing important activities while using this drug, happen 3 or more times or more or for a month or more [SSAGA II];Reduced activity 3X SSAGA II;;ACTIVE;2.36;2.65 +63673-8;Have you often used this drug, used steadily, more D or in larger amounts than you intended to;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you often used this drug, used steadily, more days or in larger amounts than you intended to [SSAGA II];Drug more than intended SSAGA II;;ACTIVE;2.36;2.65 +63674-6;Problem when you stopped, cut down, or went without drugs after using drugs steadily;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Problem when you stopped, cut down, or went without drugs after using drugs steadily [SSAGA II];Drug withdrawal problem SSAGA II;;ACTIVE;2.36;2.65 +63675-3;When you stopped, cut down, or went without drugs after using drugs steadily, did you ever experience this problem;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;When you stopped, cut down, or went without drugs after using drugs steadily, did you ever experience this problem [SSAGA II];Drug withdraw prob experience SSAGA II;;ACTIVE;2.36;2.65 +63676-1;Was there ever a time, because of stopping, cutting down on, or going without this drug, after using it steadily, when 2 or more of these problems occurred together;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Was there ever a time, because of stopping, cutting down on, or going without this drug, after using it steadily, when 2 or more of these problems occurred together [SSAGA II];Drug withdraw multiple symptoms SSAGA II;;ACTIVE;2.36;2.65 +6367-7;Clostridium tetani Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Clostridium tetani IgG Ab [Units/volume] in Serum by Immunoassay;C tetani IgG Ser IA-aCnc;;DISCOURAGED;1.0f;2.73 +63677-9;Have you ever used this drug to keep from having any of these problems or make them go away;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you ever used this drug to keep from having any of these problems or make them go away [SSAGA II];Drug ease withdrawal SSAGA II;;ACTIVE;2.36;2.65 +63678-7;Did you have to use this drug to make problems go away 3 or more times;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you have to use this drug to make problems go away 3 or more times [SSAGA II];Use ease withdrawal 3X SSAGA II;;ACTIVE;2.36;2.65 +63679-5;Did using this drug cause you to have any other problems, like an overdose that required medical treatment;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did using this drug cause you to have any other problems, like an overdose that required medical treatment [SSAGA II];Drug use overdose SSAGA II;;ACTIVE;2.36;2.65 +63680-3;Did an overdose of this drug that required medical treatment, happen 3 or more times;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did an overdose of this drug that required medical treatment, happen 3 or more times [SSAGA II];Drug use overdose 3X SSAGA II;;ACTIVE;2.36;2.65 +63681-1;Did using this drug cause you to have any other problems, like hepatitis;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did using this drug cause you to have any other problems, like hepatitis [SSAGA II];Drug use hepatitis SSAGA II;;ACTIVE;2.36;2.65 +63682-9;Did you continue to use this drug knowing it caused hepatitis;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you continue to use this drug knowing it caused hepatitis [SSAGA II];Drug continue cause hepatitis SSAGA II;;ACTIVE;2.36;2.65 +63683-7;Did using this drug cause you to have any other serious health problems;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did using this drug cause you to have any other serious health problems [SSAGA II];Drug use other health probs SSAGA II;;ACTIVE;2.36;2.65 +63684-5;Did you continue to use this drug knowing it caused other serious health problems;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you continue to use this drug knowing it caused other serious health problems [SSAGA II];Drug use serious hlth probs SSAGA II;;ACTIVE;2.36;2.65 +6368-5;Coccidioides immitis Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Coccidioides immitis Ab [Titer] in Serum by Latex agglutination;C immitis Ab Titr Ser LA;;ACTIVE;1.0f;2.73 +63685-2;Has use of this drug ever caused you emotional or psychological problems for more than 24H to the point that it interfered with your functioning or relationships;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Has use of this drug ever caused you emotional or psychological problems for more than 24 hours to the point that it interfered with your functioning or relationships [SSAGA II];Drug emot_psych probs > 24h SSAGA II;;ACTIVE;2.36;2.65 +63686-0;Did you continue to use drug after you knew it caused any of these emotional or psychological problems;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Did you continue to use drug after you knew it caused any of these emotional or psychological problems [SSAGA II];Cont drug use othr hlth probs SSAGA II;;ACTIVE;2.36;2.65 +63687-8;Which specific drug of this type did you use;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Which specific drug of this type did you use [SSAGA II];Drug type specific drug SSAGA II;;ACTIVE;2.36;2.65 +63688-6;Emotional or psychological problem related to drug use;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Emotional or psychological problem related to drug use [SSAGA II];Emot psych problem re drugs SSAGA II;;ACTIVE;2.36;2.65 +63689-4;Drug used in past 30D;Find;30D;^Patient;Nom;PhenX;PHENX;2;Drug used in past 30 days [PhenX];30D freq drug type PhenX;;ACTIVE;2.36;2.65 +63690-2;Have you given up or greatly reduced important activities like sports, work, or associating with friends or relatives while using marijuana;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;Have you given up or greatly reduced important activities like sports, work, or associating with friends or relatives while using marijuana [SSAGA II];Marijuana interfere activity SSAGA II;;ACTIVE;2.36;2.65 +63691-0;Problem when you stopped, cut down or went without marijuana for 2D or longer;Find;Pt;^Patient;Nom;SSAGA II;PHENX;2;Problem when you stopped, cut down or went without marijuana for 2 days or longer [SSAGA II];Marijuana withdraw problem SSAGA II;;ACTIVE;2.36;2.66 +63692-8;What is type of dwelling;Type;Pt;^Patient;Nom;Inner City Asthma Survey;PHENX;2;What is type of dwelling [ICAS];Dwelling type ICAS;;ACTIVE;2.36;2.65 +6369-3;Cryptococcus neoformans Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Cryptococcus neoformans Ab [Titer] in Serum by Agglutination;C neoform Ab Titr Ser Aggl;;ACTIVE;1.0f;2.73 +63693-6;Type of dwelling if other;Type;Pt;^Patient;Nom;Inner City Asthma Survey;PHENX;2;Type of dwelling if other [ICAS];Dwelling type other ICAS;;ACTIVE;2.36;2.65 +63694-4;Is property actively used as a farm or ranch;Find;Pt;^Patient;Ord;NHEXAS;PHENX;2;Is property actively used as a farm or ranch [NHEXAS];House farm use NHEXAS;;ACTIVE;2.36;2.65 +63695-1;What is the approximate age of your building;Time;Pt;^Patient;Qn;MESA Air Pollution;PHENX;2;What is the approximate age of your building [MESA];Building age MESA;;ACTIVE;2.36;2.65 +63696-9;What Y was building built;Date;Pt;^Patient;Qn;LIBCSP;PHENX;2;What year was building built [LIBCSP];What Y was building built LIBCSP;;ACTIVE;2.36;2.65 +63697-7;What Mo did you start living there;Find;Pt;^Patient;Nom;LIBCSP;PHENX;2;What month did you start living there [LIBCSP];Bldg residence Mo LIBCSP;;ACTIVE;2.36;2.65 +63698-5;What Y did you start living there;Date;Pt;^Patient;Qn;LIBCSP;PHENX;2;What year did you start living there [LIBCSP];What Y did you start living there LIBCSP;;ACTIVE;2.36;2.65 +63699-3;At what age did you start living there;Time;Pt;^Patient;Qn;NHEXAS;PHENX;2;At what age did you start living there [NHEXAS];Bldg residence age NHEXAS;;ACTIVE;2.36;2.65 +63700-9;What Mo did you move from there;Find;Pt;^Patient;Nom;NHEXAS;PHENX;2;What month did you move from there [NHEXAS];Residence move Mo NHEXAS;;ACTIVE;2.36;2.65 +6370-1;Cryptococcus sp Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Cryptococcus sp Ab [Presence] in Serum by Immunofluorescence;Cryptoc Ab Ser Ql IF;;ACTIVE;1.0f;2.73 +63701-7;What Y did you move from there;Date;Pt;^Patient;Qn;NHEXAS;PHENX;2;What year did you move from there [NHEXAS];Residence move Y NHEXAS;;ACTIVE;2.36;2.65 +63702-5;What age did you move from there;Time;Pt;^Patient;Qn;NHEXAS;PHENX;2;What age did you move from there [NHEXAS];Residence move age NHEXAS;;ACTIVE;2.36;2.65 +63703-3;How many Ys have or did you live there;Time;Pt;^Patient;Qn;NHEXAS;PHENX;2;How many years have or did you live there [NHEXAS];Ys at address NHEXAS;;ACTIVE;2.36;2.65 +63704-1;Is there an enclosed garage attached to this house or apartment;Find;Pt;^Patient;Ord;NHEXAS;PHENX;2;Is there an enclosed garage attached to this house or apartment [NHEXAS];House garage attached NHEXAS;;ACTIVE;2.36;2.65 +63705-8;Are automobiles, vans, trucks or other motor vehicles parked in this attached garage;Find;Pt;^Patient;Ord;NHEXAS;PHENX;2;Are automobiles, vans, trucks or other motor vehicles parked in this attached garage [NHEXAS];Garage vehicle parked NHEXAS;;ACTIVE;2.36;2.65 +63706-6;Are any gas powered devices stored in any room, basement, or attached garage in this house or apartment;Find;Pt;^Patient;Ord;NHEXAS;PHENX;2;Are any gas powered devices stored in any room, basement, or attached garage in this house or apartment [NHEXAS];Gas powered device storage NHEXAS;;ACTIVE;2.36;2.65 +63707-4;During the past 12Mo, has there been water or dampness in your home from broken pipes, leaks, heavy rain, or floods;Find;12Mo;^Patient;Ord;NSLAH;PHENX;2;During the past 12 months, has there been water or dampness in your home from broken pipes, leaks, heavy rain, or floods [NSLAH];House water dampness NSLAH;;ACTIVE;2.36;2.65 +63708-2;Does your home frequently have a mildew odor or musty smell;Find;Pt;^Patient;Ord;NSLAH;PHENX;2;Does your home frequently have a mildew odor or musty smell [NSLAH];House mildew odor NSLAH;;ACTIVE;2.36;2.65 +63709-0;Is air conditioning, refrigeration, used to cool this house or apartment;Find;Pt;^Patient;Ord;NHEXAS;PHENX;2;Is air conditioning, refrigeration, used to cool this house or apartment [NHEXAS];House air conditioning NHEXAS;;ACTIVE;2.36;2.65 +63710-8;Which types of air conditioning units do you use;Type;Pt;^Patient;Nom;NHEXAS;PHENX;2;Which types of air conditioning units do you use [NHEXAS];House air conditioning type NHEXAS;;ACTIVE;2.36;2.65 +63711-6;During which Mo do you usually start using air conditioning to cool this house or apartment;Find;Pt;^Patient;Nom;NHEXAS;PHENX;2;During which month do you usually start using air conditioning to cool this house or apartment [NHEXAS];Air conditioning start month NHEXAS;;ACTIVE;2.36;2.65 +63712-4;During which Mo do you usually stop using air conditioning;Find;Pt;^Patient;Nom;NHEXAS;PHENX;2;During which month do you usually stop using air conditioning [NHEXAS];Air conditioning stop month NHEXAS;;ACTIVE;2.36;2.65 +63713-2;Which fuels are used for heating this house or apartment;Find;Pt;^Patient;Nom;NHEXAS;PHENX;2;Which fuels are used for heating this house or apartment [NHEXAS];House heating fuel NHEXAS;;ACTIVE;2.36;2.65 +63714-0;Does this house or apartment have a central heating system with ducts that blow air into most rooms;Find;Pt;^Patient;Ord;NHEXAS;PHENX;2;Does this house or apartment have a central heating system with ducts that blow air into most rooms [NHEXAS];House central heating NHEXAS;;ACTIVE;2.36;2.65 +63715-7;During which Mo do you usually start using heating devices;Find;Pt;^Patient;Nom;NHEXAS;PHENX;2;During which month do you usually start using heating devices [NHEXAS];House heating start month NHEXAS;;ACTIVE;2.36;2.65 +63716-5;During which Mo do you usually stop using heating devices;Find;Pt;^Patient;Nom;NHEXAS;PHENX;2;During which month do you usually stop using heating devices [NHEXAS];House heating stop month NHEXAS;;ACTIVE;2.36;2.65 +63717-3;In the last 12Mo, did any dogs, cats or other small furry animals, such as a rabbit, guinea pig or hamster, live or spend time inside your home;Find;12Mo;^Patient;Ord;NHANES;PHENX;2;In the last 12 months, did any dogs, cats or other small furry animals, such as a rabbit, guinea pig or hamster, live or spend time inside your home [NHANES];House pet NHANES;;ACTIVE;2.36;2.65 +63718-1;What kind of pet lived or spent time inside your home;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What kind of pet lived or spent time inside your home [NHANES];House pet type NHANES;;ACTIVE;2.36;2.65 +6371-9;Cryptosporidium sp Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Cryptosporidium sp Ag [Presence] in Stool by Immunoassay;Cryptosp Ag Stl Ql IA;;ACTIVE;1.0f;2.73 +63719-9;What was the primary source of drinking water at your home;Find;Pt;^Patient;Nom;Next-of-kin;PHENX;2;What was the primary source of drinking water at your home [Next-of-kin];Drinking water source Next-of-kin;;ACTIVE;2.36;2.65 +63720-7;What was the primary source of drinking water at your home if other;Find;Pt;^Patient;Nom;Next-of-kin;PHENX;2;What was the primary source of drinking water at your home if other [Next-of-kin];Drinking water source other Next-of-kin;;ACTIVE;2.36;2.65 +63721-5;What was the depth of the private well;Find;Pt;^Patient;Ord;Next-of-kin;PHENX;2;What was the depth of the private well [Next-of-kin];Well depth Next-of-kin;;ACTIVE;2.36;2.65 +63722-3;Was the private well cased;Find;Pt;^Patient;Nom;Next-of-kin;PHENX;2;Was the private well cased [Next-of-kin];Well cased Next-of-kin;;ACTIVE;2.36;2.65 +63723-1;Are any of the water treatment devices listed on this card used in your home;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are any of the water treatment devices listed on this card used in your home [PhenX];Water treatment usage PhenX;;TRIAL;2.36;2.65 +63724-9;Which of these water treatment devices are now used in your home;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which of these water treatment devices are now used in your home [PhenX];Water treatment current PhenX;;TRIAL;2.36;2.65 +63725-6;Residence;Find;Pt;^Patient;Nom;PEG Study;PHENX;2;Residence [PEG];Residence PEG;;ACTIVE;2.36;2.65 +63726-4;From what date did you live in the residence;Date;Pt;^Patient;Qn;;ADMIN.PATIENT;2;From what date did you live in the residence;Residence date lived from;;ACTIVE;2.36;2.67 +6372-7;Cryptosporidium sp Ag;Titr;Pt;Stool;Qn;IF;MICRO;1;Cryptosporidium sp Ag [Titer] in Stool by Immunofluorescence;Cryptosp Ag Titr Stl IF;;ACTIVE;1.0f;2.73 +63727-2;To what date did you live in the residence;Date;Pt;^Patient;Qn;;ADMIN.PATIENT;2;To what date did you live in the residence;Resid date lived to;;ACTIVE;2.36;2.67 +63728-0;What is the residence address, street - crosstreets, city, state or landmark;Find;Pt;^Patient;Nom;PEG Study;PHENX;2;What is the residence address, street - crosstreets, city, state or landmark [PEG];Residence address PEG;;ACTIVE;2.36;2.65 +63729-8;Was this on a farm;Find;Pt;^Patient;Nom;PEG Study;PHENX;2;Was this on a farm [PEG];Was this on a farm PEG;;ACTIVE;2.36;2.65 +63730-6;What was your water supply;Find;Pt;^Patient;Nom;PEG Study;PHENX;2;What was your water supply [PEG];Residence water supply PEG;;ACTIVE;2.36;2.65 +63731-4;What was your water supply if other;Find;Pt;^Patient;Nom;PEG Study;PHENX;2;What was your water supply if other [PEG];Residence water supply other PEG;;ACTIVE;2.36;2.65 +63732-2;Near fields or orchards;Find;Pt;^Patient;Ord;PEG Study;PHENX;2;Near fields or orchards [PEG];Near fields or orchards PEG;;ACTIVE;2.36;2.65 +63733-0;Did you live close to the center or margin of town;Find;Pt;^Patient;Nom;PEG Study;PHENX;2;Did you live close to the center or margin of town [PEG];Residence near town PEG;;ACTIVE;2.36;2.65 +63734-8;Were geocoordinates verified;Find;Pt;^Patient;Ord;PEG Study;PHENX;2;Were geocoordinates verified [PEG];Geocoordinates verified PEG;;ACTIVE;2.36;2.65 +6373-5;Taenia solium larva Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Taenia solium larva IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;T sol lar IgG CSF Ql IB;;ACTIVE;1.0f;2.73 +63735-5;How were the geocoordinates verified;Find;Pt;^Patient;Nom;PEG Study;PHENX;2;How were the geocoordinates verified [PEG];Resid geocoord verified how PEG;;ACTIVE;2.36;2.65 +63736-3;Materials to which you were exposed in your work or daily life;Find;Pt;^Patient;Nom;ACSCP Study II;PHENX;2;Materials to which you were exposed in your work or daily life [ACSCP-II];Exposure to materials ACSCP-II;;ACTIVE;2.36;2.65 +63737-1;In your work or daily life, were you regularly exposed to this material;Find;Pt;^Patient;Ord;ACSCP Study II;PHENX;2;In your work or daily life, were you regularly exposed to this material [ACSCP-II];Exposure work and life ACSCP-II;;ACTIVE;2.36;2.65 +63738-9;How many Y were you regularly exposed to this material;Time;Pt;^Patient;Qn;ACSCP Study II;PHENX;2;How many years were you regularly exposed to this material [ACSCP-II];Exposure Ys ACSCP-II;;ACTIVE;2.36;2.65 +63739-7;How many H did you work last W at all jobs or businesses;Time;1W;^Patient;Qn;NHANES;PHENX;2;How many hours did you work last week at all jobs or businesses in the past week [NHANES];Working H last W NHANES;;ACTIVE;2.36;2.65 +63740-5;Do you usually work 35H or more per W in total at all jobs or businesses;Find;Pt;^Patient;Ord;NHANES;PHENX;2;Do you usually work 35 hours or more per week in total at all jobs or businesses [NHANES];Job 35h/W NHANES;;ACTIVE;2.36;2.65 +63741-3;For whom did you work for at your main job or business;Find;Pt;^Patient;Nom;NHANES;PHENX;2;For whom did you work for at your main job or business [NHANES];Job employer NHANES;;ACTIVE;2.36;2.65 +63742-1;What kind of business or industry is this;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What kind of business or industry is this [NHANES];Job business industry NHANES;;ACTIVE;2.36;2.65 +6374-3;Taenia solium larva Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva IgG Ab [Presence] in Serum by Immunoblot;T sol lar IgG Ser Ql IB;;ACTIVE;1.0f;2.73 +63743-9;What kind of work were you doing;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What kind of work were you doing [NHANES];Job occupation NHANES;;ACTIVE;2.36;2.65 +63744-7;What were your most important activities on this job;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What were your most important activities on this job [NHANES];Job duties NHANES;;ACTIVE;2.36;2.65 +63745-4;Which of the following best describes the H you usually work at you main job or business;Find;Pt;^Patient;Nom;NHANES;PHENX;2;Which of the following best describes the hours you usually work at you main job or business [NHANES];Job shift schedule NHANES;;ACTIVE;2.36;2.65 +63746-2;About how long have you worked for your employer in your occupation;Time;Pt;^Patient;Qn;NHANES;PHENX;2;About how long have you worked for your employer in your occupation [NHANES];Job duration NHANES;;ACTIVE;2.36;2.58 +63748-8;What kind of work were you doing the longest;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What kind of work were you doing the longest [NHANES];Longest job occupation NHANES;;ACTIVE;2.36;2.65 +63749-6;What kind of business or industry did you work in for the longest period of time;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What kind of business or industry did you work in for the longest period of time [NHANES];Longest job industry NHANES;;ACTIVE;2.36;2.65 +6375-0;Cytomegalovirus Ag;ACnc;Pt;Bld;OrdQn;EMIA;MICRO;1;Deprecated Cytomegalovirus Ag in blood;Deprecated CMV Ag Bld EMIA;;DEPRECATED;1.0f;2.40 +63750-4;What were your most important activities on this job or business;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What were your most important activities on this job or business [NHANES];Longest job duties NHANES;;ACTIVE;2.36;2.65 +63751-2;About how long did you work at that job or business;Time;Pt;^Patient;Qn;;PHENX;2;About how long did you work at that job or business;Longest job duration;;ACTIVE;2.36;2.65 +63752-0;Since the age 16, did you ever work for 6Mo or more;Find;Pt;^Patient;Ord;NHANES;PHENX;2;Since the age 16, did you ever work for 6 months or more [NHANES];Job hx since age 16 NHANES;;ACTIVE;2.36;2.65 +63753-8;Job number;Find;Pt;^Patient;Nom;NHANES;PHENX;2;Job number [NHANES];Job number NHANES;;ACTIVE;2.36;2.65 +63754-6;What was the name of the company where you first or next worked, for 6Mo or longer;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What was the name of the company where you first or next worked, for 6 months or longer [NHANES];Job hx employer NHANES;;ACTIVE;2.36;2.65 +63755-3;What was the job title of the first or next job you held at this company;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What was the job title of the first or next job you held at this company [NHANES];Job hx title NHANES;;ACTIVE;2.36;2.65 +63756-1;In what Y did you start working at this job;Date;Pt;^Patient;Qn;NHANES;PHENX;2;In what year did you start working at this job [NHANES];Job hx Y start NHANES;;ACTIVE;2.36;2.65 +63757-9;In what Y did you stop working at this job;Date;Pt;^Patient;Qn;NHANES;PHENX;2;In what year did you stop working at this job [NHANES];Job hx stop Y NHANES;;ACTIVE;2.36;2.65 +63758-7;What was the location of this company;Addr;Pt;^Patient;Nom;NHANES;PHENX;2;What was the location of this company [Address] [NHANES];Job hx company address Addr NHANES;;ACTIVE;2.36;2.65 +63759-5;Was this a full-time or part-time job;Find;Pt;^Patient;Nom;NHANES;PHENX;2;Was this a full-time or part-time job [NHANES];Job hx full time NHANES;;ACTIVE;2.36;2.65 +63760-3;What did they make, or what service did they provide - what type of business was it;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What did they make, or what service did they provide - what type of business was it [NHANES];Job hx business industry NHANES;;ACTIVE;2.36;2.65 +63761-1;What were your main activities or duties for this job;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What were your main activities or duties for this job [NHANES];Job hx duties NHANES;;ACTIVE;2.36;2.65 +63762-9;What kinds of chemicals or materials did you handle in that job;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What kinds of chemicals or materials did you handle in that job [NHANES];Job hx chemical material NHANES;;ACTIVE;2.36;2.65 +63763-7;What kinds of tools and equipment did you use;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What kinds of tools and equipment did you use [NHANES];Job hx tool equipment NHANES;;ACTIVE;2.36;2.65 +63764-5;Hobby;Find;Pt;^Patient;Nom;LIBCSP;PHENX;2;Hobby [LIBCSP];Hobby LIBCSP;;ACTIVE;2.36;2.65 +63765-2;Have you participated for 6Mo or longer in this hobby;Find;Pt;^Patient;Ord;LIBCSP;PHENX;2;Have you participated for 6 months or longer in this hobby [LIBCSP];Hobby participated LIBCSP;;ACTIVE;2.36;2.65 +63766-0;In what Y were you first involved in this hobby;Date;Pt;^Patient;Qn;LIBCSP;PHENX;2;In what year were you first involved in this hobby [LIBCSP];Hobby first Y LIBCSP;;ACTIVE;2.36;2.65 +63767-8;In what Y were you last involved in in this hobby;Date;Pt;^Patient;Qn;LIBCSP;PHENX;2;In what year were you last involved in in this hobby [LIBCSP];Hobby last Y LIBCSP;;ACTIVE;2.36;2.65 +6376-8;Cytomegalovirus Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Cytomegalovirus Ag [Presence] in Serum or Plasma by Immunoassay;CMV Ag SerPl Ql IA;;ACTIVE;1.0f;2.64 +63768-6;Overall, for how many Y were you involved in this hobby;Time;Pt;^Patient;Qn;LIBCSP;PHENX;2;Overall, for how many years were you involved in this hobby [LIBCSP];Hobby total Ys LIBCSP;;ACTIVE;2.36;2.65 +63769-4;On average, about how many hours per W, Mo, or Y have you participated in this hobby;Time;Pt;^Patient;Qn;LIBCSP;PHENX;2;On average, about how many hours per week, month, or year have you participated in this hobby [LIBCSP];Hobby Hs quantity LIBCSP;;ACTIVE;2.36;2.65 +63770-2;Other activities involving use of chemicals;Find;Pt;^Patient;Nom;LIBCSP;PHENX;2;Other activities involving use of chemicals [LIBCSP];Hobby chemicals specify LIBCSP;;ACTIVE;2.36;2.65 +63771-0;Does anyone who lives here smoke cigarettes, cigars, or pipes anywhere inside this home;Find;Pt;^Patient;Nom;NHANES;PHENX;2;Does anyone who lives here smoke cigarettes, cigars, or pipes anywhere inside this home [NHANES];Smoking at home NHANES;;ACTIVE;2.36;2.68 +63772-8;Who smokes;Find;Pt;^Patient;Nom;NHANES;PHENX;2;Who smokes [NHANES];Who smokes NHANES;;ACTIVE;2.36;2.65 +63773-6;How many cigarettes per D do you usually smoke anywhere inside the home;NRat;Pt;^Patient;Qn;NHANES;PHENX;2;How many cigarettes per day do you usually smoke anywhere inside the home [NHANES];Smoking cigarette quantity nRate NHANES;;ACTIVE;2.36;2.65 +63774-4;At this job or business, that is at your employer, in your occupation, how many H per D can you smell the smoke from other peoples cigarettes, cigars, or pipes;Time;Pt;^Patient;Qn;NHANES;PHENX;2;At this job or business, that is at your employer, in your occupation, how many hours per day can you smell the smoke from other peoples cigarettes, cigars, or pipes [NHANES];Hs smell smoke at work NHANES;;ACTIVE;2.36;2.65 +63775-1;How many full brothers do you have;Num;Pt;^Patient;Qn;Carolina Breast Cancer Study;PHENX;2;How many full brothers do you have [#] [CBCS];Full brothers CBCS;;ACTIVE;2.36;2.65 +6377-6;Cytomegalovirus Ag;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Cytomegalovirus Ag [Presence] in Serum or Plasma by Immunofluorescence;CMV Ag SerPl Ql IF;;ACTIVE;1.0f;2.64 +63776-9;How many full sisters do you have;Num;Pt;^Patient;Qn;Carolina Breast Cancer Study;PHENX;2;How many full sisters do you have [#] [CBCS];Full sisters CBCS;;ACTIVE;2.36;2.65 +63777-7;Do you have a twin brother or sister;Find;Pt;^Patient;Ord;Carolina Breast Cancer Study;PHENX;2;Do you have a twin brother or sister [CBCS];Twin brother sister CBCS;;ACTIVE;2.36;2.65 +63778-5;Are you and your twin identical or not identical;Find;Pt;^Patient;Nom;Carolina Breast Cancer Study;PHENX;2;Are you and your twin identical or not identical [CBCS];Identical twin CBCS;;ACTIVE;2.36;2.65 +63779-3;Sibling;Find;Pt;^Patient;Nom;Carolina Breast Cancer Study;PHENX;2;Sibling [CBCS];Sibling CBCS;;ACTIVE;2.36;2.65 +63780-1;Who is the oldest or what is the first name of your next brother or sister;Find;Pt;^Patient;Nom;Carolina Breast Cancer Study;PHENX;2;Who is the oldest or what is the first name of your next brother or sister [CBCS];Sibling name CBCS;;ACTIVE;2.36;2.65 +63781-9;Sex;Find;Pt;^Sibling;Nom;;ADMIN.DEMOG;2;Sex of Sibling;Sex of Sibling;;ACTIVE;2.36;2.66 +63782-7;Is this brother or sister still living;Find;Pt;^Patient;Ord;Carolina Breast Cancer Study;PHENX;2;Is this brother or sister still living [CBCS];Sibling still living CBCS;;ACTIVE;2.36;2.65 +63783-5;How old is this brother or sister now or how old was brother or sister when he or she died;Time;Pt;^Patient;Qn;Carolina Breast Cancer Study;PHENX;2;How old is this brother or sister now or how old was brother or sister when he or she died [CBCS];Sibling age CBCS;;ACTIVE;2.36;2.65 +6378-4;Cytomegalovirus Ag;ACnc;Pt;Urine;OrdQn;EMIA;MICRO;1;Deprecated Cytomegalovirus Ag in urine;Deprecated CMV Ag Ur EMIA;;DEPRECATED;1.0f;2.40 +63784-3;Day care or preschool category;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Day care or preschool category [PhenX];Day care preschool PhenX;;TRIAL;2.36;2.65 +63785-0;In what Mo and Y did child begin the first or next attendance at day care or preschool outside the home;Date;Pt;^Patient;Qn;PhenX;PHENX;2;In what month and year did child begin the first or next attendance at day care or preschool outside the home [PhenX];Day care begin Mo PhenX;;TRIAL;2.36;2.65 +63786-8;In what Mo and Y did child end the first or next attendance of day care or preschool;Date;Pt;^Patient;Qn;PhenX;PHENX;2;In what month and year did child end the first or next attendance of day care or preschool [PhenX];Day care end Mo PhenX;;TRIAL;2.36;2.65 +63787-6;About how many H per W did or does child attend day care or preschool outside the home;Time;Pt;^Patient;Qn;PhenX;PHENX;2;About how many hours per week did or does child attend day care or preschool outside the home [PhenX];Day care Hs per W PhenX;;TRIAL;2.36;2.65 +63788-4;Childs age at reference date;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Childs age at reference date [PhenX];Childs age at reference date PhenX;;TRIAL;2.36;2.65 +63789-2;Did your mother breastfeed you;Find;Pt;^Patient;Ord;LIBCSP;PHENX;2;Did your mother breastfeed you [LIBCSP];Did your mother breastfeed you LIBCSP;;ACTIVE;2.36;2.65 +637-9;Plasmodium sp identified;Prid;Pt;Bld;Nom;Thick film;MICRO;1;Plasmodium sp identified in Blood by Thick film;Plasmodium Bld Thick Film;;ACTIVE;1.0;2.73 +63790-0;In the past Y has there been a major renovation to this house or apartment, such as adding a room, putting up or taking down a wall, replacing windows, or refinishing floors;Find;1Y;^Patient;Ord;RIOPA;PHENX;2;In the past year has there been a major renovation to this house or apartment, such as adding a room, putting up or taking down a wall, replacing windows, or refinishing floors [RIOPA];House renovation RIOPA;;ACTIVE;2.36;2.65 +63791-8;What type of renovation;Type;Pt;^Patient;Nom;RIOPA;PHENX;2;What type of renovation [RIOPA];Renovation type RIOPA;;ACTIVE;2.36;2.65 +6379-2;Cytomegalovirus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Cytomegalovirus Ag [Presence] in Specimen by Immunoassay;CMV Ag Spec Ql IA;;ACTIVE;1.0f;2.73 +63792-6;When was the last renovation;Time;Pt;^Patient;Qn;RIOPA;PHENX;2;When was the last renovation [RIOPA];Renovation date RIOPA;;ACTIVE;2.36;2.65 +63793-4;Within the last 6Mo were rugs, drapes or furniture professionally cleaned;Find;6Mo;^Patient;Ord;RIOPA;PHENX;2;Within the last 6 months were rugs, drapes or furniture professionally cleaned [RIOPA];Rugs, drapes furniture cleaned RIOPA;;ACTIVE;2.36;2.65 +63794-2;Were they cleaned inside the house;Find;Pt;^Patient;Nom;RIOPA;PHENX;2;Were they cleaned inside the house [RIOPA];Rugs drapes cleaned inside RIOPA;;ACTIVE;2.36;2.65 +63795-9;When were they cleaned;Find;Pt;^Patient;Nom;RIOPA;PHENX;2;When were they cleaned [RIOPA];When were they cleaned RIOPA;;ACTIVE;2.36;2.65 +63796-7;What items were cleaned;Find;Pt;^Patient;Nom;RIOPA;PHENX;2;What items were cleaned [RIOPA];What items were cleaned RIOPA;;ACTIVE;2.36;2.65 +63797-5;In the past Y, was the inside of this house or apartment painted;Find;1Y;^Patient;Ord;RIOPA;PHENX;2;In the past year, was the inside of this house or apartment painted [RIOPA];House apartment painted RIOPA;;ACTIVE;2.36;2.65 +63798-3;When was the last time the inside of this house or apartment was painted;Find;Pt;^Patient;Nom;RIOPA;PHENX;2;When was the last time the inside of this house or apartment was painted [RIOPA];Painting date RIOPA;;ACTIVE;2.36;2.65 +63799-1;How many rooms of the inside of this house or apartment were painted;Num;Pt;^Patient;Qn;RIOPA;PHENX;2;How many rooms of the inside of this house or apartment were painted [#] [RIOPA];Painting room quantity RIOPA;;ACTIVE;2.36;2.65 +63-8;Cefadroxil;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefadroxil [Susceptibility] by Minimum lethal concentration (MLC);Cefadroxil Islt MLC;;ACTIVE;1.0;2.19 +6380-0;Cytomegalovirus Ag;ACnc;Pt;XXX;OrdQn;EMIA;MICRO;1;Deprecated Cytomegalovirus Ag in unspecified specimen;Deprecated CMV Ag XXX EMIA;;DEPRECATED;1.0f;2.69 +63800-7;Did you go to the dry cleaners during the past W;Find;1W;^Patient;Ord;RIOPA;PHENX;2;Did you go to the dry cleaners during the past week [PhenX];Dry cleaner visit RIOPA;;ACTIVE;2.36;2.65 +63801-5;Did you bring home any items from the cleaners that were dry-cleaned during the past W;Find;1W;^Patient;Ord;RIOPA;PHENX;2;Did you bring home any items from the cleaners that were dry-cleaned during the past week [PhenX];Dry-cleaned items past W RIOPA;;ACTIVE;2.36;2.65 +63802-3;Air contaminant in the home;Find;Pt;^Patient;Nom;RIOPA;PHENX;2;Specify air contaminant in the home [RIOPA];Air contaminant home RIOPA;;ACTIVE;2.36;2.65 +63803-1;Have you, or has someone near you, used this air contaminant in the last 48H;Find;48H;^Patient;Ord;RIOPA;PHENX;2;Have you, or has someone near you, used this air contaminant in the last 48 hours [RIOPA];Exposure RIOPA;;ACTIVE;2.36;2.65 +63804-9;Did you handle this air contaminant yourself;Find;Pt;^Patient;Ord;RIOPA;PHENX;2;Did you handle this air contaminant yourself [RIOPA];Exposure self RIOPA;;ACTIVE;2.36;2.65 +63805-6;How long did you handle this air contaminant yourself;Time;Pt;^Patient;Qn;RIOPA;PHENX;2;How long did you handle this air contaminant yourself [RIOPA];Exposure self Hs RIOPA;;ACTIVE;2.36;2.65 +63806-4;Were you near somebody who handled this air contaminant;Find;Pt;^Patient;Ord;RIOPA;PHENX;2;Were you near somebody who handled this air contaminant [RIOPA];Exposure nearby RIOPA;;ACTIVE;2.36;2.65 +63807-2;How long were you near somebody else who handled this air contaminant;Time;Pt;^Patient;Qn;RIOPA;PHENX;2;How long were you near somebody else who handled this air contaminant [RIOPA];Exposure nearby Hs RIOPA;;ACTIVE;2.36;2.65 +63808-0;Which cleaning solutions;Find;Pt;^Patient;Nom;RIOPA;PHENX;2;Which cleaning solutions [RIOPA];Which cleaning solutions RIOPA;;ACTIVE;2.36;2.65 +63809-8;During the last 48H, the study period, did you or anyone else park a car or other motor vehicle in;Find;48H;^Patient;Nom;RIOPA;PHENX;2;During the last 48 hours, the study period, did you or anyone else park a car or other motor vehicle in [RIOPA];Park car garage carport RIOPA;;ACTIVE;2.36;2.65 +63810-6;During the last 48H, the study period, did you or anyone else start a car or other motor vehicle in;Find;48H;^Patient;Nom;RIOPA;PHENX;2;During the last 48 hours, the study period, did you or anyone else start a car or other motor vehicle in [RIOPA];Start car garage carport RIOPA;;ACTIVE;2.36;2.65 +63811-4;During the last 48H, the study period, was there any diesel vehicles parked around the house;Find;48H;^Patient;Ord;RIOPA;PHENX;2;During the last 48 hours, the study period, was there any diesel vehicles parked around the house [RIOPA];Park diesel vehicle RIOPA;;ACTIVE;2.36;2.65 +63812-2;During the last 48H, the study period, have you operated or been near diesel engines, e.g. bus terminal, truck stop;Find;48H;^Patient;Ord;RIOPA;PHENX;2;During the last 48 hours, the study period, have you operated or been near diesel engines, e.g. bus terminal, truck stop [RIOPA];Operate near diesel vehicle RIOPA;;ACTIVE;2.36;2.65 +63813-0;Time vacuum bag was emptied;ClockTime;Pt;^Patient;Nom;PhenX;PHENX;2;Time vacuum bag was emptied [PhenX];Vacuum bag emptied time Clock time PhenX;;TRIAL;2.36;2.65 +63814-8;Vacuum dust collection contaminant;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Vacuum dust collection contaminant [PhenX];Vacuum dust contaminant PhenX;;TRIAL;2.36;2.65 +63815-5;Name of vacuum dust collection contaminant;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Name of vacuum dust collection contaminant [PhenX];Vacuum dust contaminant name PhenX;;TRIAL;2.36;2.65 +63816-3;Concentration of vacuum dust collection contaminant;MCnc;Pt;^Patient;Qn;PhenX;PHENX;2;Concentration of vacuum dust collection contaminant [Mass/volume] [PhenX];Vacuum dust concentration mCnc PhenX;;TRIAL;2.36;2.65 +63817-1;If you spent an hour in the mid-day sun for the first time without sunscreen, which of these reactions best describes what would happen to your skin;Find;Pt;^Patient;Nom;NHL;PHENX;2;If you spent an hour in the mid-day sun for the first time without sunscreen, which of these reactions best describes what would happen to your skin [NHL];Skin reaction NHL;;ACTIVE;2.36;2.65 +6381-8;Cytomegalovirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Cytomegalovirus Ag [Presence] in Specimen by Immunofluorescence;CMV Ag Spec Ql IF;;ACTIVE;1.0f;2.73 +63818-9;Who provided most of the responses in this section;Find;Pt;^Patient;Nom;NHANES;PHENX;2;Who provided most of the responses in this section [NHANES];Job provided most responses NHANES;;ACTIVE;2.36;2.65 +63819-7;On 3 or more different occasions have you taken a drink to keep from having fits, seizures, or convulsions or to make them go away;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;On 3 or more different occasions have you taken a drink to keep from having fits, seizures, or convulsions or to make them go away [SSAGA II];Drink allev withdraw SZ 3X SSAGA II;;ACTIVE;2.36;2.65 +63820-5;When you stopped, cut down, or went without drinking, did you ever have the DTs, that is, where you were very confused, extremely shaky, felt very frightened or nervous, or saw things that weren't really there;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;When you stopped, cut down, or went without drinking, did you ever have the DTs, that is, where you were very confused, extremely shaky, felt very frightened or nervous, or saw things that weren't really there [SSAGA II];Alc withdraw DT SSAGA II;;ACTIVE;2.36;2.65 +63821-3;On 3 or more different occasions have you taken a drink to keep from having the DTs or to make them go away;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;On 3 or more different occasions have you taken a drink to keep from having the DTs or to make them go away [SSAGA II];Drink allev withdraw DT 3X SSAGA II;;ACTIVE;2.36;2.65 +63822-1;When you stopped, cut down, or went without drinking, did you ever have fits, seizures, or convulsions, where you lost consciousness, fell to the floor, and had difficulty remembering what happened;Find;Pt;^Patient;Ord;SSAGA II;PHENX;2;When you stopped, cut down, or went without drinking, did you ever have fits, seizures, or convulsions, where you lost consciousness, fell to the floor, and had difficulty remembering what happened [SSAGA II];Alc withdraw seizure SSAGA II;;ACTIVE;2.36;2.65 +63823-9;Did you ever get a blistering sunburn;Find;Pt;^Patient;Ord;NHL;PHENX;2;Did you ever get a blistering sunburn [NHL];Blistering sunburn ever NHL;;ACTIVE;2.36;2.65 +63824-7;Did you ever get a skin rash from sun exposure;Find;Pt;^Patient;Ord;NHL;PHENX;2;Did you ever get a skin rash from sun exposure [NHL];Skin rash ever NHL;;ACTIVE;2.36;2.65 +63825-4;Have you ever used a sunlamp;Find;Pt;^Patient;Ord;NHL;PHENX;2;Have you ever used a sunlamp [NHL];Sunlamp ever NHL;;ACTIVE;2.36;2.65 +6382-6;Dengue virus Ab;ACnc;Pt;Ser;OrdQn;;MICRO;1;Deprecated Dengue virus Ab in serum;Deprecated DENV Ab Ser;;DEPRECATED;1.0f;2.40 +63826-2;Have you ever used a tanning booth;Find;Pt;^Patient;Ord;NHL;PHENX;2;Have you ever used a tanning booth [NHL];Tanning booth ever NHL;;ACTIVE;2.36;2.65 +63827-0;Ultraviolet light exposure;Find;Pt;^Patient;Nom;NHL;PHENX;2;Ultraviolet light exposure [NHL];UV light exposure NHL;;ACTIVE;2.36;2.65 +63828-8;Age group for ultraviolet light exposure;Find;Pt;^Patient;Nom;NHL;PHENX;2;Age group for ultraviolet light exposure [NHL];Age group UV light exposure NHL;;ACTIVE;2.36;2.65 +63829-6;On a typical weekday in the summer, about how many H did you generally spend in the mid-day sun;NRat;Pt;^Patient;Qn;NHL;PHENX;2;On a typical weekday in the summer, about how many hours did you generally spend in the mid-day sun [NHL];Weekday sun Hs nRate NHL;;ACTIVE;2.36;2.65 +63830-4;On a typical weekend D in the summer, about how many H did you generally spend in the mid-day sun;NRat;Pt;^Patient;Qn;NHL;PHENX;2;On a typical weekend day in the summer, about how many hours did you generally spend in the mid-day sun [NHL];Weekend day sun Hs nRate NHL;;ACTIVE;2.36;2.65 +63831-2;Has there been renovation or repairs in your workspace because of moisture damage;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Has there been renovation or repairs in your workspace because of moisture damage [FEAS];Workspace renovation moisture FEAS;;ACTIVE;2.36;2.65 +63832-0;What is the floor material in your workspace;Find;Pt;^Patient;Nom;FEAS;PHENX;2;What is the floor material in your workspace [FEAS];Workspace floor material FEAS;;ACTIVE;2.36;2.65 +63833-8;Floor material in your workspace if other;Find;Pt;^Patient;Nom;FEAS;PHENX;2;Floor material in your workspace if other [FEAS];Workspace floor material other FEAS;;ACTIVE;2.36;2.65 +6383-4;Dengue virus Ab;ACnc;Pt;XXX;OrdQn;;MICRO;1;Deprecated Dengue virus Ab in unspecified specimen;Deprecated DENV Ab XXX;;DEPRECATED;1.0f;2.69 +63834-6;Is the wall material of your work space textile, cloth, jute, etc;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Is the wall material of your work space textile, cloth, jute, etc [FEAS];Textile wall material FEAS;;ACTIVE;2.36;2.65 +63835-3;Is the wall material of your work space plastic;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Is the wall material of your work space plastic [FEAS];Plastic wall material FEAS;;ACTIVE;2.36;2.65 +63836-1;Has there been renovation or repairs in your home due to moisture damage;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Has there been renovation or repairs in your home due to moisture damage [FEAS];Home renovation moisture FEAS;;ACTIVE;2.36;2.65 +63837-9;Has there been renovation in your home during the past 12Mo;Find;12Mo;^Patient;Ord;FEAS;PHENX;2;Has there been renovation in your home during the past 12 months [FEAS];Home renovation FEAS;;ACTIVE;2.36;2.65 +63838-7;Which of the following repairs was done in your home during the past 12Mo;Find;12Mo;^Patient;Ord;FEAS;PHENX;2;Which of the following repairs was done in your home during the past 12 months [FEAS];Home repairs enumerated FEAS;;ACTIVE;2.36;2.65 +63839-5;Do you have wall-to-wall carpeting in your home;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Do you have wall-to-wall carpeting in your home [FEAS];Wall to wall carpeting FEAS;;ACTIVE;2.36;2.65 +63840-3;Is the floor material in your home plastic or vinyl;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Is the floor material in your home plastic or vinyl [FEAS];Vinyl plastic floor FEAS;;ACTIVE;2.36;2.65 +63841-1;Is the wall material in your home textile, cloth, jute, etc;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Is the wall material in your home textile, cloth, jute, etc [FEAS];Textile wall material home FEAS;;ACTIVE;2.36;2.65 +6384-2;Dengue virus Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Dengue virus Ag [Presence] in Serum by Immunofluorescence;DENV Ag Ser Ql IF;;ACTIVE;1.0f;2.56 +63842-9;Is the wall material in your home plastic;Find;Pt;^Patient;Ord;FEAS;PHENX;2;Is the wall material in your home plastic [FEAS];Plastic wall material home FEAS;;ACTIVE;2.36;2.65 +63843-7;Has child attended day care outside the home;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has child attended day care outside the home [PhenX];Child attended day care PhenX;;TRIAL;2.36;2.65 +63844-5;Has child attended preschool;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has child attended preschool [PhenX];Child attended preschool PhenX;;TRIAL;2.36;2.65 +63845-2;In the past Y were new carpets or rugs installed;Find;1Y;^Patient;Ord;RIOPA;PHENX;2;In the past year were new carpets or rugs installed [RIOPA];Carpet rug installed RIOPA;;ACTIVE;2.36;2.65 +63846-0;When was the installation;Time;Pt;^Patient;Qn;RIOPA;PHENX;2;When was the installation [RIOPA];Carpet rug date RIOPA;;ACTIVE;2.36;2.65 +63847-8;On how many rooms were new carpets or rugs installed;Num;Pt;^Patient;Qn;RIOPA;PHENX;2;On how many rooms were new carpets or rugs installed [#] [RIOPA];Carpet rug room quantity RIOPA;;ACTIVE;2.36;2.65 +63849-4;Number of D vacuum has been used since changing bag or emptying the collection chamber;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Number of days vacuum has been used since changing bag or emptying the collection chamber [PhenX];Number Ds vacuum used PhenX;;TRIAL;2.36;2.65 +63850-2;Weight of dust collected;Mass;Pt;^Patient;Qn;PhenX;PHENX;2;Weight of dust collected [Mass] [PhenX];Weight of dust collected PhenX;;TRIAL;2.36;2.65 +63851-0;How old were you the first time you got this exposure;Time;Pt;^Patient;Qn;NHL;PHENX;2;How old were you the first time you got this exposure [NHL];First exposure age exact NHL;;ACTIVE;2.36;2.65 +63852-8;About how old were you the first time you got this exposure;Time;Pt;^Patient;Qn;NHL;PHENX;2;About how old were you the first time you got this exposure [NHL];First exposure age estimate NHL;;ACTIVE;2.36;2.65 +63853-6;How old were you the last time you got this exposure;Time;Pt;^Patient;Qn;NHL;PHENX;2;How old were you the last time you got this exposure [NHL];Last exposure age exact NHL;;ACTIVE;2.36;2.65 +63854-4;About how old were you the last time you got this exposure;Time;Pt;^Patient;Qn;NHL;PHENX;2;About how old were you the last time you got this exposure [NHL];Last exposure age estimate NHL;;ACTIVE;2.36;2.65 +63855-1;How many of these ultraviolet light exposures have you gotten in your life;Num;Pt;^Patient;Qn;NHL;PHENX;2;How many of these ultraviolet light exposures have you gotten in your life [#] [NHL];UV exposure times exact NHL;;ACTIVE;2.36;2.65 +63856-9;About how many of these ultraviolet light exposures have you gotten in your life;Find;Pt;^Patient;Ord;NHL;PHENX;2;About how many of these ultraviolet light exposures have you gotten in your life [NHL];UV exposures times estimate NHL;;ACTIVE;2.36;2.65 +63857-7;How many Mo a Y did you usually have a tan;NRat;Pt;^Patient;Qn;NHL;PHENX;2;How many months a year did you usually have a tan [NHL];Tan Mos nRate NHL;;ACTIVE;2.36;2.65 +63858-5;On the average, when you smoke, or on the last day you smoked every day, about how many cigarettes do, or did, you smoke;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;On the average, when you smoke, or on the last day you smoked every day, about how many cigarettes do, or did, you smoke [PhenX];Cigarettes per D PhenX;;TRIAL;2.36;2.65 +6385-9;Dengue virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Dengue virus Ag [Presence] in Specimen by Immunofluorescence;DENV Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +63859-3;Have you ever consumed alcoholic beverages, such as beer, wine, or liquor at least once a W for 6Mo or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever consumed alcoholic beverages, such as beer, wine, or liquor at least once a week for 6 months or more [PhenX];Drinking ever PhenX;;TRIAL;2.36;2.65 +63860-1;In this age range, did you drink alcoholic beverages at least once a W for 6Mo or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;In this age range, did you drink alcoholic beverages at least once a week for 6 months or more [PhenX];Drinking weekly PhenX;;TRIAL;2.36;2.65 +63861-9;For how many Y did you drink alcoholic beverages at least once a W for 6Mo or more;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how many years did you drink alcoholic beverages at least once a week for 6 months or more [PhenX];Drinking Ys PhenX;;TRIAL;2.36;2.65 +63862-7;Age range for exercise;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Age range for exercise [CA Teachers];Age range exercise CTS;;ACTIVE;2.36;2.65 +63863-5;Average H per W you participated in strenuous exercise activities or sports like swimming laps, aerobics, calisthenics, running, jogging, basketball, cycling on hills, racquetball during this age range;NRat;Pt;^Patient;Qn;California Teachers Study;PHENX;2;Average hours per week you participated in strenuous exercise activities or sports like swimming laps, aerobics, calisthenics, running, jogging, basketball, cycling on hills, racquetball during this age range [CA Teachers];Strenuous exercise Hs CTS;;ACTIVE;2.36;2.65 +63864-3;Average Mo per Y you participated in strenuous exercise activities or sports like swimming laps, aerobics, calisthenics, running, jogging, basketball, cycling on hills, racquetball during this age range;NRat;Pt;^Patient;Qn;California Teachers Study;PHENX;2;Average months per year you participated in strenuous exercise activities or sports like swimming laps, aerobics, calisthenics, running, jogging, basketball, cycling on hills, racquetball during this age range [CA Teachers];Strenuous exercise Mo CTS;;ACTIVE;2.36;2.65 +63865-0;Average H per W you participated in moderate exercise activities or sports like brisk walking, golf, volleyball, cycling on level streets, recreational tennis, or softball during this age range;NRat;Pt;^Patient;Qn;California Teachers Study;PHENX;2;Average hours per week you participated in moderate exercise activities or sports like brisk walking, golf, volleyball, cycling on level streets, recreational tennis, or softball during this age range [CA Teachers];Moderate exercise Hs CTS;;ACTIVE;2.36;2.65 +63866-8;Average Mo per Y you participated in moderate exercise activities or sports like brisk walking, golf, volleyball, cycling on level streets, recreational tennis, or softball during this age range;NRat;Pt;^Patient;Qn;California Teachers Study;PHENX;2;Average months per year you participated in moderate exercise activities or sports like brisk walking, golf, volleyball, cycling on level streets, recreational tennis, or softball during this age range [CA Teachers];Moderate exercise Mo CTS;;ACTIVE;2.36;2.65 +6386-7;Dengue virus DNA;PrThr;Pt;Ser;Ord;Probe;MICRO;1;Dengue virus DNA [Presence] in Serum by Probe;DENV DNA Ser Ql Probe;;ACTIVE;1.0f;2.63 +63867-6;Physical activity in past Y;Find;1Y;^Patient;Nom;California Teachers Study;PHENX;2;Physical activity in past year [CA Teachers];Physical activity in past Y CTS;;ACTIVE;2.36;2.65 +63868-4;Average H per D did you spend doing this activity;NRat;Pt;^Patient;Qn;California Teachers Study;PHENX;2;Average hours per day did you spend doing this activity [CA Teachers];Activity H per D CTS;;ACTIVE;2.36;2.65 +63869-2;Average D per W did you spend doing this activity;NRat;Pt;^Patient;Qn;California Teachers Study;PHENX;2;Average days per week did you spend doing this activity [CA Teachers];Activity D per W CTS;;ACTIVE;2.36;2.65 +638-7;Microscopic observation;Prid;Pt;CSF;Nom;India ink preparation;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by India ink prep;India Ink Prep CSF;;ACTIVE;1.0;2.73 +63870-0;For how many H per D were you exposed to smoke from other peoples cigarettes or tobacco products during this time at this location;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;For how many hours per day were you exposed to smoke from other peoples cigarettes or tobacco products during this time at this location [PhenX];Exposure smoke Hs nRate PhenX;;TRIAL;2.36;2.65 +63871-8;For how many Y were you exposed to smoke from other peoples cigarettes or tobacco products during this time at this location;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how many years were you exposed to smoke from other peoples cigarettes or tobacco products during this time at this location [PhenX];Smoke exposure Ys PhenX;;TRIAL;2.36;2.65 +63872-6;At the present time, how many H per D are you exposed to the smoke of others;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At the present time, how many hours per day are you exposed to the smoke of others [PhenX];Exposure smoke present_Hs PhenX;;TRIAL;2.36;2.65 +63873-4;Have you ever taken estrogen, female hormones, for symptoms of menopause, the change of life, or for other reasons;Find;Pt;^Patient;Ord;California Teachers Study;PHENX;2;Have you ever taken estrogen, female hormones, for symptoms of menopause, the change of life, or for other reasons [CA Teachers];Ever estrogen CTS;;ACTIVE;2.36;2.65 +63874-2;Have you ever taken premarin by mouth as pills;Find;Pt;^Patient;Ord;California Teachers Study;PHENX;2;Have you ever taken premarin by mouth as pills [CA Teachers];Ever premarin CTS;;ACTIVE;2.36;2.65 +6387-5;Dengue virus DNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Dengue virus DNA [Presence] in Specimen by Probe;DENV DNA Spec Ql Probe;;ACTIVE;1.0f;2.73 +63875-9;At what age did you first take premarin;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;At what age did you first take premarin [CA Teachers];Premarin age first CTS;;ACTIVE;2.36;2.65 +63876-7;At what age did you last take premarin;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;At what age did you last take premarin [CA Teachers];Premarin age last CTS;;ACTIVE;2.36;2.65 +63877-5;How many Y in total did you take premarin - exclude those periods when you temporarily stopped;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;How many years in total did you take premarin - exclude those periods when you temporarily stopped [CA Teachers];Premarin Ys CTS;;ACTIVE;2.36;2.65 +63878-3;Which premarin pill did you use the longest;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Which premarin pill did you use the longest [CA Teachers];Premarin pill use longest CTS;;ACTIVE;2.36;2.65 +63879-1;At what age did you first use estrogens other than premarin pills;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;At what age did you first use estrogens other than premarin pills [CA Teachers];Estrogen age first CTS;;ACTIVE;2.36;2.65 +63880-9;At what age did you last use estrogens other than premarin pills;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;At what age did you last use estrogens other than premarin pills [CA Teachers];Estrogen age last CTS;;ACTIVE;2.36;2.65 +63881-7;How many Y in total did you take estrogens other than premarin pills - exclude any time when you temporarily stopped;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;How many years in total did you take estrogens other than premarin pills - exclude any time when you temporarily stopped [CA Teachers];Estrogen Ys CTS;;ACTIVE;2.36;2.65 +63882-5;Have you ever used progesterone or a progestin;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Have you ever used progesterone or a progestin [CA Teachers];Ever progesterone progestin CTS;;ACTIVE;2.36;2.65 +6388-3;Eastern equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Serum by Immunoassay;EEEV Ag Ser Ql IA;;ACTIVE;1.0f;2.56 +63883-3;At what age did you first take progesterone or a progestin;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;At what age did you first take progesterone or a progestin [CA Teachers];Progesterone age first CTS;;ACTIVE;2.36;2.65 +63884-1;At what age did you last take progesterone or a progestin;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;At what age did you last take progesterone or a progestin [CA Teachers];Progesterone age last CTS;;ACTIVE;2.36;2.65 +63885-8;How many Y in total did you take progesterone or a progestin - excluding any time when you temporarily stopped;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;How many years in total did you take progesterone or a progestin - excluding any time when you temporarily stopped [CA Teachers];Progestin Ys CTS;;ACTIVE;2.36;2.65 +63886-6;If you used provera, what was your usual dose;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;If you used provera, what was your usual dose [CA Teachers];Provera dose CTS;;ACTIVE;2.36;2.65 +63887-4;When using progestin or progesterone, for how many D each Mo would you usually take it;Time;Pt;^Patient;Qn;California Teachers Study;PHENX;2;When using progestin or progesterone, for how many day each month would you usually take it [CA Teachers];Progesterone Ds CTS;;ACTIVE;2.36;2.65 +63888-2;Age at first menstrual period;Time;Pt;^Patient;Qn;;PHENX;2;Age at first menstrual period;Age at first menstrual period;;ACTIVE;2.36;2.52 +63889-0;Have you had a menstrual period within the last year;Find;1Y;^Patient;Ord;PhenX;PHENX;2;Have you had a menstrual period within the last year [PhenX];Menstrual period in last year PhenX;;TRIAL;2.36;2.65 +63890-8;Age at last menstrual period;Time;Pt;^Patient;Qn;;PHENX;2;Age at last menstrual period;Age at last menstrual period;;ACTIVE;2.36;2.52 +6389-1;Eastern equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Eastern equine encephalitis virus Ag [Presence] in Serum by Immunofluorescence;EEEV Ag Ser Ql IF;;ACTIVE;1.0f;2.56 +63891-6;Cause of menopause;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Cause of menopause [PhenX];Cause of menopause PhenX;;TRIAL;2.36;2.65 +63892-4;Have you ever been pregnant;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been pregnant [PhenX];Have you ever been pregnant PhenX;;TRIAL;2.36;2.65 +63893-2;Outcome of pregnancy;Find;Pt;^Patient;Nom;;H&P.HX;2;Outcome of pregnancy;Outcome of pregnancy;;ACTIVE;2.36;2.64 +63894-0;Number of birth;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Number of birth [PhenX];#birth PhenX;;TRIAL;2.36;2.65 +63895-7;Breastfeeding status;Find;Pt;^Patient;Nom;;PHENX;2;Breastfeeding status;Breastfeeding status;;ACTIVE;2.36;2.64 +63896-5;Months of breast feeding;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Months of breast feeding [PhenX];Months of breast feeding PhenX;;TRIAL;2.36;2.65 +63897-3;Relative;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Relative [CA Teachers];Relative;;ACTIVE;2.36;2.65 +63898-1;Sex of relative;Type;Pt;^Family member;Nom;California Teachers Study;PHENX;2;Deprecated Sex of relative Family member [CA Teachers];Deprecated Cancer relative gender;;DEPRECATED;2.36;2.66 +63899-9;Is relative alive;Find;Pt;^Patient;Ord;California Teachers Study;PHENX;2;Is relative alive [CA Teachers];Relative alive CTS;;ACTIVE;2.36;2.65 +63900-5;Current age or age at death;Time;Pt;^Patient;Qn;;PHENX;2;Current age or age at death;Current age or death age;;ACTIVE;2.36;2.66 +63901-3;Relative never had cancer;Find;Pt;^Patient;Ord;California Teachers Study;PHENX;2;Relative never had cancer [CA Teachers];Relative never had cancer CTS;;ACTIVE;2.36;2.65 +63902-1;First cancer diagnosis;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;First cancer diagnosis [CA Teachers];First cancer Dx CTS;;ACTIVE;2.36;2.65 +63903-9;Age at first cancer diagnosis;Time;Pt;^Patient;Qn;;H&P.HX;2;Age at first cancer diagnosis;First cancer Dx age;;ACTIVE;2.36;2.65 +63904-7;Second or other cancer diagnoses;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Second or other cancer diagnoses [CA Teachers];Second cancer diagnosis CTS;;ACTIVE;2.36;2.65 +63905-4;How often do you worry about getting lung cancer;Find;Pt;^Patient;Ord;PLCO;PHENX;2;How often do you worry about getting lung cancer [PLCO];Lung cancer worry PLCO;;ACTIVE;2.36;2.65 +63906-2;Compared to others your age who currently smoke, what do you think are your chances of being diagnosed with lung cancer during your lifetime;Find;Pt;^Patient;Ord;PLCO;PHENX;2;Compared to others your age who currently smoke, what do you think are your chances of being diagnosed with lung cancer during your lifetime [PLCO];Lung cancer risk assess PLCO;;ACTIVE;2.36;2.65 +63907-0;Clinician-diagnosed illness;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Clinician-diagnosed illness [PhenX];Clinician-diagnosed illness PhenX;;TRIAL;2.36;2.65 +63908-8;Have you had this clinician-diagnosed illness;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had this clinician-diagnosed illness [PhenX];Pre-existing condition hx PhenX;;TRIAL;2.36;2.65 +6390-9;Echinococcus sp Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Echinococcus sp Ab [Units/volume] in Serum by Complement fixation;Echinococcus Ab Ser CF-aCnc;;ACTIVE;1.0f;2.69 +63909-6;Y of diagnosis of clinician-diagnosed illness;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Year of diagnosis of clinician-diagnosed illness [PhenX];Pre-existing condition Y PhenX;;TRIAL;2.36;2.65 +63910-4;Angina pectoris confirmed angiography;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Angina pectoris confirmed angiography [PhenX];Angina pectoris by angiography PhenX;;TRIAL;2.36;2.65 +63911-2;Fibrocystic or other benign breast disease confirmed by breast biopsy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Fibrocystic or other benign breast disease confirmed by breast biopsy [PhenX];Fibrocystic by breast biopsy PhenX;;TRIAL;2.36;2.65 +63912-0;Fibrocystic or other benign breast disease confirmed by aspiration;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Fibrocystic or other benign breast disease confirmed by aspiration [PhenX];Fibrocystic by aspiration PhenX;;TRIAL;2.36;2.65 +63913-8;Site of other cancer;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Site of other cancer [PhenX];Site of other cancer PhenX;;TRIAL;2.36;2.65 +63914-6;Did you have symptoms of gallstones;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you have symptoms of gallstones [PhenX];Gallstones symptoms PhenX;;TRIAL;2.36;2.65 +63915-3;How were gallstones diagnosed;Find;Pt;^Patient;Nom;PhenX;PHENX;2;How were gallstones diagnosed [PhenX];How were gallstones diagnosed PhenX;;TRIAL;2.36;2.65 +63916-1;Was endometriosis confirmed by laparoscopy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was endometriosis confirmed by laparoscopy [PhenX];Endometriosis by laparoscopy PhenX;;TRIAL;2.36;2.65 +6391-7;Echinococcus sp Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echinococcus sp Ab [Units/volume] in Serum by Immunoassay;Echinococcus Ab Ser IA-aCnc;;ACTIVE;1.0f;2.73 +63917-9;Were uterine fibroids confirmed by pelvic exam;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were uterine fibroids confirmed by pelvic exam [PhenX];Uterine fibroids by pelvic exam PhenX;;TRIAL;2.36;2.65 +63918-7;Were uterine fibroids confirmed by ultrasound or hysterectomy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were uterine fibroids confirmed by ultrasound or hysterectomy [PhenX];Uterine fibroids by ultrasound PhenX;;TRIAL;2.36;2.65 +63920-3;During the past 3Y, have you had this cancer screening test;Find;3Y;^Patient;Ord;PLCO;PHENX;2;During the past 3Y, have you had this cancer screening test 3 years [PLCO];Cancer screening test 3Y 3Y PLCO;;ACTIVE;2.36;2.65 +63921-1;Cancer screening;Find;Pt;^Patient;Nom;PLCO;PHENX;2;Cancer screening [PLCO];Cancer screening PLCO;;ACTIVE;2.36;2.65 +63922-9;Are you considering quitting smoking during the next 6Mo;Find;Pt;^Patient;Ord;PLCO;PHENX;2;Are you considering quitting smoking during the next 6 months [PLCO];Quit smoking consider PLCO;;ACTIVE;2.36;2.73 +63923-7;In the past, have you ever made a serious attempt to quit smoking That is, have you stopped smoking for at least one day or longer because you were trying to quit;Find;Pt;^Patient;Ord;PLCO;PHENX;2;In the past, have you ever made a serious attempt to quit smoking That is, have you stopped smoking for at least one day or longer because you were trying to quit [PLCO];Quit smoking attempt PLCO;;ACTIVE;2.36;2.65 +63924-5;What was the longest length of time you stopped smoking because you were trying to quit;Time;Pt;^Patient;Qn;PLCO;PHENX;2;What was the longest length of time you stopped smoking because you were trying to quit [PLCO];Quit smoking longest time PLCO;;ACTIVE;2.36;2.65 +6392-5;Echovirus 30 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 30 Ab [Titer] in Serum by Complement fixation;ECV30 Ab Titr Ser CF;;ACTIVE;1.0f;2.73 +63925-2;How old were you when you most recently quit smoking;Time;Pt;^Patient;Qn;PLCO;PHENX;2;How old were you when you most recently quit smoking [PLCO];Quit smoking age PLCO;;ACTIVE;2.36;2.65 +63926-0;Thinking of the most recent time you quit smoking, did you use any of the following products;Find;Pt;^Patient;Nom;PLCO;PHENX;2;Thinking of the most recent time you quit smoking, did you use any of the following products [PLCO];Quit smoking products PLCO;;ACTIVE;2.36;2.65 +63927-8;During the past 12Mo, did any doctor, dentist, nurse, or any other health professional advise you to quit smoking;Find;12Mo;^Patient;Ord;PLCO;PHENX;2;During the past 12 months, did any doctor, dentist, nurse, or any other health professional advise you to quit smoking [PLCO];Quit smoking profess advise PLCO;;ACTIVE;2.36;2.65 +63928-6;Have you ever had cancer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had cancer [PhenX];Have you ever had cancer PhenX;;TRIAL;2.36;2.65 +63929-4;Cancer site - type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Cancer site - type [PhenX];Cancer site - type PhenX;;TRIAL;2.36;2.73 +63930-2;Laterality;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Laterality [PhenX];Laterality PhenX;;TRIAL;2.36;2.65 +63931-0;Date of diagnosis;Date;Pt;^Patient;Qn;;PHENX;2;Date of diagnosis;Date of Dx;;ACTIVE;2.36;2.66 +63932-8;Age at diagnosis;Time;Pt;^Patient;Qn;;PHENX;2;Age at diagnosis;Age at Dx;;ACTIVE;2.36;2.54 +6393-3;Echovirus 30 Ab.Neut;ACnc;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 30 neutralizing antibody [Units/volume] in Serum by Neutralization test;ECV30 NAb Ser Nt-aCnc;;ACTIVE;1.0f;2.73 +63933-6;Cancer treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Cancer treatment [PhenX];Cancer treatment PhenX;;TRIAL;2.36;2.65 +63934-4;Did you have this treatment or therapy for cancer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you have this treatment or therapy for cancer [PhenX];Cancer treatment therapy PhenX;;TRIAL;2.36;2.65 +63935-1;Name of surgical procedure;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Name of surgical procedure [PhenX];Surgical procedure name PhenX;;TRIAL;2.36;2.65 +63936-9;Start date of treatment or therapy;Date;Pt;^Patient;Qn;;H&P.HX;2;Start date of treatment or therapy;Start date treatment or therapy;;ACTIVE;2.36;2.66 +63937-7;Treatment hospital;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Treatment hospital [PhenX];Treatment hospital PhenX;;TRIAL;2.36;2.65 +63938-5;Type of chemotherapy;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Type of chemotherapy [PhenX];Type of chemotherapy PhenX;;TRIAL;2.36;2.65 +63939-3;End date of treatment or therapy;Date;Pt;^Patient;Qn;;H&P.HX;2;End date of treatment or therapy;End date treatment or therapy;;ACTIVE;2.36;2.66 +63940-1;Hormone treatment for cancer;Type;Pt;^Patient;Nom;;H&P.HX;2;Hormone treatment for cancer;Hormone Rx for cancer;;ACTIVE;2.36;2.66 +6394-1;Echovirus 40 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 40 Ab [Titer] in Serum by Complement fixation;ECV40 Ab Titr Ser CF;;ACTIVE;1.0f;2.70 +63941-9;Did you receive any other types of therapy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you receive any other types of therapy [PhenX];Cancer other therapy PhenX;;TRIAL;2.36;2.65 +63942-7;Name of other cancer therapy;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Name of other cancer therapy [PhenX];Other cancer therapy PhenX;;TRIAL;2.36;2.65 +63943-5;Have you had a recurrence with this cancer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had a recurrence with this cancer [PhenX];Cancer recurrence PhenX;;TRIAL;2.36;2.65 +63944-3;Date of cancer recurrence;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date of cancer recurrence [PhenX];Date of cancer recurrence PhenX;;TRIAL;2.36;2.65 +63945-0;Where did this cancer recur - example lung, breast, liver;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Where did this cancer recur - example lung, breast, liver [PhenX];Cancer recur location PhenX;;TRIAL;2.36;2.65 +63946-8;Pain-relieving medication;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Pain-relieving medication [CA Teachers];Pain-relieving medication CTS;;ACTIVE;2.36;2.65 +63947-6;Do you currently take this pain-relieving medication at least once a week;Find;Pt;^Patient;Ord;California Teachers Study;PHENX;2;Do you currently take this pain-relieving medication at least once a week [CA Teachers];Pain-relieving med once a W CTS;;ACTIVE;2.36;2.65 +63948-4;How many total tablets per W of pain-relieving medication;NRat;Pt;^Patient;Qn;California Teachers Study;PHENX;2;How many total tablets per week of pain-relieving medication [CA Teachers];Total tablets per W pain med nRate CTS;;ACTIVE;2.36;2.65 +63949-2;Did you stop the regular use of pain-relieving medication during past 3Y;Find;3Y;^Patient;Ord;California Teachers Study;PHENX;2;Did you stop the regular use of pain-relieving medication during past 3Y 3 years [CA Teachers];Stop regular use pain med past 3Y 3Y CTS;;ACTIVE;2.36;2.65 +639-5;Microscopic observation;Prid;Pt;CSF;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by KOH preparation;KOH Prep CSF;;DISCOURAGED;1.0;2.58 +63950-0;Why did you stop regular use of pain-relieving medication;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Why did you stop regular use of pain-relieving medication [CA Teachers];Stop reg use pain med past 3Y why CTS;;ACTIVE;2.36;2.65 +63951-8;In the past 3Y have you taken statins, lovastatin - mevacor, atorvastatin - lipitor, rosuvastain - crestor, pravastatin - pravachol, simvastatin - zocor, fluvastatin - lescol;Find;3Y;^Patient;Ord;California Teachers Study;PHENX;2;ln the past 3Y have you taken statins, lovastatin - mevacor, atorvastatin - lipitor, rosuvastain - crestor, pravastatin - pravachol, simvastatin - zocor, fluvastatin - lescol 3 years [CA Teachers];Statins past 3Y 3Y CTS;;ACTIVE;2.36;2.65 +63952-6;In the past 3Y have you taken steroids, predniSONE, dexamethasone - decadron, solumedrol - medrol dose-pack;Find;3Y;^Patient;Ord;California Teachers Study;PHENX;2;In the past 3Y have you taken steroids, prednisone, dexamethasone - decadron, solumedrol - medrol dose-pac 3 years [CA Teachers];Steroids past 3Y 3Y CTS;;ACTIVE;2.36;2.65 +63953-4;Age range for lifetime alcohol exposure;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Specify age range for lifetime alcohol exposure [PhenX];Age range lifetime alcohol exp PhenX;;TRIAL;2.36;2.65 +63954-2;How many drinks per D, W, Mo, or Y did you usually have;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How many drinks per day, week, month, or year did you usually have [PhenX];Drinks per D, W, Mo, Y PhenX;;TRIAL;2.36;2.65 +63955-9;Time and location of passive smoke exposure;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Time and location of passive smoke exposure [PhenX];Time loc passive smoke exp PhenX;;TRIAL;2.36;2.65 +63956-7;Were you exposed to smoke from other peoples cigarettes or tobacco products during this time at this location;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were you exposed to smoke from other peoples cigarettes or tobacco products during this time at this location [PhenX];Exposed smoke others cigarettes PhenX;;TRIAL;2.36;2.65 +63957-5;Premarin pill;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Premarin pill [CA Teachers];Premarin pill CTS;;ACTIVE;2.36;2.65 +6395-8;Echovirus 40 Ab.Neut;ACnc;Pt;Ser;Qn;Neut;MICRO;1;Echovirus 40 neutralizing antibody [Units/volume] in Serum by Neutralization test;ECV40 NAb Ser Nt-aCnc;;ACTIVE;1.0f;2.72 +63958-3;Have you ever used this premarin pill;Find;Pt;^Patient;Ord;California Teachers Study;PHENX;2;Have you ever used this premarin pill [CA Teachers];Premarin pill use CTS;;ACTIVE;2.36;2.65 +63959-1;Estrogen administration method;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Estrogen administration method [CA Teachers];Estrogen admin method CTS;;ACTIVE;2.36;2.65 +63960-9;Have you ever used this estrogen administration method;Find;Pt;^Patient;Ord;California Teachers Study;PHENX;2;Have you ever used this estrogen administration method [CA Teachers];Estrogen admin method use CTS;;ACTIVE;2.36;2.65 +63961-7;Cause of menopause if other;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Cause of menopause if other [PhenX];Cause of menopause if other PhenX;;TRIAL;2.36;2.65 +63962-5;Pregnancy number;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Pregnancy number [PhenX];Pregnancy number PhenX;;TRIAL;2.36;2.65 +63963-3;Date of end of pregnancy;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date of end of pregnancy [PhenX];Date of end of pregnancy PhenX;;TRIAL;2.36;2.65 +63964-1;Cancer diagnosis if other;Find;Pt;^Patient;Nom;California Teachers Study;PHENX;2;Cancer diagnosis if other [CA Teachers];Cancer Dx other CTS;;ACTIVE;2.36;2.65 +6396-6;Entamoeba histolytica DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Entamoeba histolytica DNA [Presence] in Specimen by NAA with probe detection;E histolyt DNA Spec Ql NAA+probe;;ACTIVE;1.0f;2.73 +63968-2;Date of major illness or surgery;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date of major illness or surgery [PhenX];Maj illness surgery date PhenX;;TRIAL;2.36;2.65 +63969-0;How often was your baby put to bed with a bottle of formula, breast milk, juice drink, or any other kind of milk in past 2W;Find;2W;^Patient;Nom;IFPS-II;PHENX;2;How often was your baby put to bed with a bottle of formula, breast milk, juice drink, or any other kind of milk in past 2 weeks [IFPS-II];Baby to bed w bottle 2W times IFPS-II;;TRIAL;2.36;2.58 +63970-8;Did you give your baby a bottle in the past 2W;Find;2W;^Patient;Ord;IFPS-II;PHENX;2;Did you give your baby a bottle in the past 2 weeks [IFPS-II];Give baby bottle past 2W IFPS-II;;TRIAL;2.36;2.58 +63971-6;How often have you added this item to babys bottle or breast milk in past 2W;Find;2W;^Patient;Ord;IFPS-II;PHENX;2;How often have you added this item to babys bottle or breast milk in past 2 weeks [IFPS-II];Freq add to bottle/milk in p 2W IFPS-II;;TRIAL;2.36;2.58 +63972-4;Items added to babys bottle or breast milk;Find;Pt;^Patient;Nom;IFPS-II;PHENX;2;Items added to babys bottle or breast milk [IFPS-II];Items added babys milk IFPS-II;;TRIAL;2.36;2.52 +63973-2;Items added to babys bottle or breast milk if other;Find;Pt;^Patient;Nom;IFPS-II;PHENX;2;Items added to babys bottle or breast milk if other [IFPS-II];Items added babys milk other IFPS-II;;TRIAL;2.36;2.52 +6397-4;Entamoeba histolytica Ag;ACnc;Pt;Ser;Qn;IA;MICRO;1;Entamoeba histolytica Ag [Units/volume] in Serum by Immunoassay;E histolyt Ag Ser IA-aCnc;;ACTIVE;1.0f;2.73 +63974-0;Beverage consumed;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Beverage consumed [PhenX];Beverage consumed PhenX;;TRIAL;2.36;2.65 +63975-7;Did your child consume this beverage during the past W;Find;1W;^Patient;Ord;PhenX;PHENX;2;Did your child consume this beverage during the past week [PhenX];Child consume beverage past W PhenX;;TRIAL;2.36;2.65 +63976-5;How many servings of this beverage per D did your child drink;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How many servings of this beverage per day did your child drink [PhenX];Child beverage per D amount PhenX;;TRIAL;2.36;2.65 +63977-3;What type of container does your child most often use for beverages;Type;Pt;^Patient;Nom;PhenX;PHENX;2;What type of container does your child most often use for beverages [PhenX];Container child use for beverages PhenX;;TRIAL;2.36;2.65 +63978-1;What beverage does your child most often consume at meals;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What beverage does your child most often consume at meals [PhenX];Beverage child consume at meals PhenX;;TRIAL;2.36;2.65 +63979-9;What beverage does your child most often consume between meals;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What beverage does your child most often consume between meals [PhenX];Beverage most between meals PhenX;;TRIAL;2.36;2.65 +63980-7;Which statement best describes your child's nighttime feedings;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which statement best describes your child's nighttime feedings [PhenX];Nighttime feedings PhenX;;TRIAL;2.36;2.65 +63981-5;Does your mouth frequently feel dry;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your mouth frequently feel dry [PhenX];Mouth frequently dry PhenX;;TRIAL;2.36;2.65 +6398-2;Entamoeba histolytica Ag;ACnc;Pt;Stool;Qn;IA;MICRO;1;Entamoeba histolytica Ag [Units/volume] in Stool by Immunoassay;E histolyt Ag Stl IA-aCnc;;ACTIVE;1.0f;2.73 +63982-3;Does your mouth feel dry when eating;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your mouth feel dry when eating [PhenX];Mouth dry when eating PhenX;;TRIAL;2.36;2.65 +63983-1;Does the amount of saliva in your mouth seem to be;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does the amount of saliva in your mouth seem to be [PhenX];Amount saliva in mouth PhenX;;TRIAL;2.36;2.65 +63984-9;Do you sip liquids frequently during the day to keep your mouth moist;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you sip liquids frequently during the day to keep your mouth moist [PhenX];Liquids freq mouth moist PhenX;;TRIAL;2.36;2.65 +63985-6;Do you have difficulties swallowing food if you eat without additional fluids;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have difficulties swallowing food if you eat without additional fluids [PhenX];Difficulties swallowing W/O fluids PhenX;;TRIAL;2.36;2.65 +63986-4;Have you been diagnosed with a cleft lip or palate;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Have you been diagnosed with a cleft lip or palate [PhenX];Diagnosed cleft lip palate PhenX;;TRIAL;2.36;2.65 +63987-2;Defect location of cleft lip or palate;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Defect location of cleft lip or palate [PhenX];Defect loc cleft lip palate PhenX;;TRIAL;2.36;2.65 +63988-0;Code for cleft lip or palate defect;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Code for cleft lip or palate defect [PhenX];Code cleft lip palate defect PhenX;;TRIAL;2.36;2.65 +63989-8;Does anyone in the family use toothpaste with fluoride;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does anyone in the family use toothpaste with fluoride [PhenX];Fam use toothpaste fluoride PhenX;;TRIAL;2.36;2.65 +6399-0;Entamoeba histolytica Ag;ACnc;Pt;XXX;Qn;IA;MICRO;1;Entamoeba histolytica Ag [Units/volume] in Specimen by Immunoassay;E histolyt Ag Spec IA-aCnc;;ACTIVE;1.0f;2.69 +63990-6;Who in the family uses toothpaste with fluoride;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Who in the family uses toothpaste with fluoride [PhenX];Family use toothpaste fluoride PhenX;;TRIAL;2.36;2.65 +63991-4;Does anyone else in the family use toothpaste with fluoride;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does anyone else in the family use toothpaste with fluoride [PhenX];More fam use toothpaste fluoride PhenX;;TRIAL;2.36;2.65 +63992-2;Does your child now take vitamins with fluoride in them or any other kind of fluoride tablets, drops or supplements;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child now take vitamins with fluoride in them or any other kind of flouride tablets, drops or supplements [PhenX];Child vitamins W fluoride PhenX;;TRIAL;2.36;2.65 +63993-0;Have you ever had any orthodontic treatment;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any orthodontic treatment [PhenX];Had orthodontic treatment PhenX;;TRIAL;2.36;2.65 +63994-8;How long did you wear fixed braces on your teeth;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long did you wear fixed braces on your teeth [PhenX];Fixed braces on teeth duration PhenX;;TRIAL;2.36;2.65 +63995-5;How many natural teeth do you have;Num;Pt;^Patient;Ord;PhenX;PHENX;2;How many natural teeth do you have [PhenX];Natural teeth amount PhenX;;TRIAL;2.36;2.65 +63996-3;How many natural teeth does your child have;Num;Pt;^Patient;Ord;PhenX;PHENX;2;How many natural teeth does your child have [PhenX];Natural teeth your child amount PhenX;;TRIAL;2.36;2.65 +63997-1;How many teeth does your baby have now;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many teeth does your baby have now [#] [PhenX];Teeth baby has now amount PhenX;;TRIAL;2.36;2.65 +63998-9;How often do you brush your teeth;Find;Pt;^Patient;Nom;PhenX;PHENX;2;How often do you brush your teeth [PhenX];Brush your teeth times PhenX;;TRIAL;2.36;2.65 +63999-7;Do you use dental floss;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you use dental floss [PhenX];Use dental floss PhenX;;TRIAL;2.36;2.65 +64000-3;Did you have painful sores or irritations around the lips or on the tongue, cheeks, or gums more than once in past 6Mo;Find;6Mo;^Patient;Ord;PhenX;PHENX;2;Did you have painful sores or irritations around the lips or on the tongue, cheeks, or gums more than once in past 6 months [PhenX];Sores lips tongue cheeks >1 in 6Mo PhenX;;TRIAL;2.36;2.65 +64001-1;Did you first have the sores or irritations more than 6Mo ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you first have the sores or irritations more than 6 months ago [PhenX];Sores irritations > 6Mo ago PhenX;;TRIAL;2.36;2.65 +64002-9;About how long has it been since you last visited a dentist;Time;Pt;^Patient;Qn;PhenX;PHENX;2;About how long has it been since you last visited a dentist [PhenX];Last visited dentist PhenX;;TRIAL;2.36;2.65 +64003-7;What was the main reason you last visited the dentist;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What was the main reason you last visited the dentist [PhenX];Reason last visited dentist PhenX;;TRIAL;2.36;2.65 +64004-5;Tobacco product;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Tobacco product [PhenX];Tobacco prod PhenX;;ACTIVE;2.36;2.65 +64005-2;In your entire life, have you ever smoked or used this type of tobacco;Find;Pt;^Patient;Ord;PhenX;PHENX;2;In your entire life, have you ever smoked or used this type of tobacco [PhenX];Entire life tobacco type PhenX;;TRIAL;2.36;2.67 +6400-6;Ehrlichia canis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ehrlichia canis Ab [Presence] in Serum by Immunoassay;E canis Ab Ser Ql IA;;ACTIVE;1.0f;2.56 +64006-0;Pain or toothache;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Pain or toothache [PhenX];Pain or toothache PhenX;;TRIAL;2.36;2.65 +64007-8;Did you have this pain or toothache more than once, in past 6Mo;Find;6Mo;^Patient;Ord;PhenX;PHENX;2;Did you have this pain or toothache more than once, in past 6 months [PhenX];Pain toothache >1 past 6Mo PhenX;;TRIAL;2.36;2.65 +64008-6;Pain severity;Score;Pt;^Patient;Qn;PhenX;PHENX;2;Pain severity [Score] [PhenX];Pain severity Score PhenX;;TRIAL;2.36;2.65 +64009-4;When you have this pain, does it come and go or is it continuous and uninterrupted;Find;Pt;^Patient;Nom;PhenX;PHENX;2;When you have this pain, does it come and go or is it continuous and uninterrupted [PhenX];Pain come go contin uninterrupt PhenX;;TRIAL;2.36;2.65 +64010-2;Latitude for the residence;Angle;Pt;^Patient;Qn;PEG Study;PHENX;2;Latitude for the residence [PEG];Latitude residence PEG;;ACTIVE;2.36;2.65 +64011-0;Longitude for the residence;Angle;Pt;^Patient;Qn;PEG Study;PHENX;2;Longitude for the residence [PEG];Longitude residence PEG;;ACTIVE;2.36;2.65 +64012-8;CEBPA gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CEBPA gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CEBPA gene Mut Anl Bld/T;;ACTIVE;2.36;2.73 +64013-6;Escherichia coli shiga-like toxin 1 & 2;Prid;Pt;Stool;Nom;IA;MICRO;1;Escherichia coli shiga-like toxin 1 and 2 [Identifier] in Stool by Immunoassay;E coli SXT1+2 Stl IA;;ACTIVE;2.36;2.73 +6401-4;Ehrlichia chaffeensis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ehrlichia chaffeensis IgG Ab [Presence] in Serum by Immunoassay;E chaffeensis IgG Ser Ql IA;;ACTIVE;1.0f;2.56 +64014-4;If your baby was breastfed or fed breast milk in past 7D, about how long did an average breastfeeding session last;NRat;7D;^Patient;Ord;IFPS-II;PHENX;2;If your baby was breastfed or fed breast milk in past 7 days, about how long did an average breastfeeding session last [IFPS-II];Baby fed breast milk session len IFPS-II;;TRIAL;2.36;2.58 +64015-1;How many times in the past 7D was your baby fed pumped breast milk to drink;NRat;1W;^Patient;Qn;IFPS-II;PHENX;2;How many times in the past 7 days was your baby fed pumped breast milk to drink [IFPS-II];Baby fed breast milk 7D 1W nRate IFPS-II;;TRIAL;2.36;2.52 +64016-9;The amount of this beverage per serving during the past W;Vol;1W;^Patient;Qn;PhenX;PHENX;2;The amount of this beverage per serving during the pastweek in the past week [PhenX];Beverage serving past W amount PhenX;;TRIAL;2.36;2.65 +64017-7;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Specimen by NAA with probe detection;C trach+GC pnl Spec NAA+probe;;ACTIVE;2.36;2.73 +64018-5;Has any relative in your family been diagnosed with a cleft lip or palate;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has any relative in your family been diagnosed with a cleft lip or palate [PhenX];Relative cleft lip palate PhenX;;TRIAL;2.36;2.65 +64019-3;Details on who has cleft lip or palate;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Details on who has cleft lip or palate [PhenX];Relative cleft lip palate details PhenX;;TRIAL;2.36;2.65 +64020-1;If your child drinks cows milk, what type of cows milk does your child usually drink;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If your child drinks cows milk, what type of cows milk does your child usually drink [PhenX];Cow milk type PhenX;;TRIAL;2.36;2.65 +64021-9;How many servings of this beverage per W did your child drink;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How many servings of this beverage per week did your child drink [PhenX];Beverage per W amount PhenX;;TRIAL;2.36;2.65 +6402-2;Ehrlichia chaffeensis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ehrlichia chaffeensis IgM Ab [Presence] in Serum by Immunoassay;E chaffeensis IgM Ser Ql IA;;ACTIVE;1.0f;2.56 +64022-7;Patients activity level;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Patients activity level [PhenX];Patients activity level PhenX;;TRIAL;2.36;2.65 +64023-5;Mode of supported ventilation;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Mode of supported ventilation [PhenX];Supported ventilation mode PhenX;;TRIAL;2.36;2.73 +64024-3;Spirometry contraindicated;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Spirometry contraindicated [PhenX];Spirometry contraindicated PhenX;;TRIAL;2.36;2.65 +64025-0;Reason for contraindication;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Reason for contraindication [PhenX];Reason contraindication PhenX;;TRIAL;2.36;2.65 +64026-8;Pre-bronchodilator forced expiratory volume in 1 second attempt;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Pre-bronchodilator forced expiratory volume in 1 second (FEV1) attempt [PhenX];Pre-bronch FEV1 attempt PhenX;;TRIAL;2.36;2.65 +64027-6;Pre-bronchodilator forced vital capacity attempt;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Pre-bronchodilator forced vital capacity (FVC) attempt [PhenX];Pre-bronch FVC attempt PhenX;;TRIAL;2.36;2.65 +64028-4;Post-bronchodilator forced expiratory volume in 1 second attempt;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Post-bronchodilator forced expiratory volume in 1 second (FEV1) attempt [PhenX];Post-bronch FEV1 attempt PhenX;;TRIAL;2.36;2.65 +64029-2;Post-bronchodilator forced vital capacity attempt;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Post-bronchodilator forced vital capacity (FVC) attempt [PhenX];Post-bronch FVC attempt PhenX;;TRIAL;2.36;2.73 +640-3;Microscopic observation;Prid;Pt;Gast fld;Nom;Acid fast stain.Kinyoun;MICRO;1;Microscopic observation [Identifier] in Gastric fluid by Acid fast stain.Kinyoun;Acid fast Kiny Stn Gast;;ACTIVE;1.0;2.21 +6403-0;Anaplasma phagocytophilum Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Anaplasma phagocytophilum Ab [Presence] in Serum by Immunoassay;A phagocytoph Ab Ser Ql IA;;ACTIVE;1.0f;2.56 +64030-0;Percent of baseline forced expiratory volume in 1 second;SFr;Pt;^Patient;Qn;PhenX;PHENX;2;Percent of baseline forced expiratory volume in 1 second [PhenX];FEV1 % baseline SFr PhenX;;TRIAL;2.36;2.65 +64031-8;Absolute volume;Vol;Pt;^Patient;Qn;PhenX;PHENX;2;Absolute volume [PhenX];Absolute volume PhenX;;TRIAL;2.36;2.65 +64032-6;Conditions that might affect ability to comply with breathing instructions;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Conditions that might affect ability to comply with breathing instructions [PhenX];Conditions affecting breathing PhenX;;TRIAL;2.36;2.65 +64033-4;Supine inspiratory CT image ID;Imp;Pt;^Patient;Nom;PhenX;PHENX;2;Supine inspiratory CT image ID [PhenX];Inspiratory CT image ID PhenX;;TRIAL;2.36;2.65 +64034-2;Supine expiratory CT image ID;Imp;Pt;^Patient;Nom;PhenX;PHENX;2;Supine expiratory CT image ID [PhenX];Expiratory CT image ID PhenX;;TRIAL;2.36;2.65 +64035-9;Repair done in your home during the past 12Mo if other;Find;12Mo;^Patient;Nom;FEAS;PHENX;2;Repair done in your home during the past 12 months if other [FEAS];Home repairs enumerated other FEAS;;ACTIVE;2.36;2.65 +64036-7;What did they make, or what service did they provide;Find;Pt;^Patient;Nom;NHANES;PHENX;2;What did they make, or what service did they provide [NHANES];Job hx business industry verbatim NHANES;;ACTIVE;2.36;2.65 +64037-5;Gadus morhua recombinant (rGad c) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Codfish recombinant (rGad c) 1 IgE Ab RAST class [Presence] in Serum;Codfish (rGad c) 1 IgE RAST Ql;;ACTIVE;2.36;2.70 +64038-3;Adenovirus DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HAdV DNA Spec NAA+probe-Log#;;ACTIVE;2.36;2.73 +64039-1;Decayed tooth surfaces + filled tooth surfaces;Find;Pt;Tooth;Nom;PhenX;PHENX;2;Decayed tooth surfaces + filled tooth surfaces Tooth [PhenX];Decayed filled tooth Tooth PhenX;;TRIAL;2.36;2.65 +64040-9;Tooth site - periodontal;Find;Pt;Tooth;Nom;PhenX;PHENX;2;Tooth site - periodontal Tooth [PhenX];Tooth site - periodontal Tooth PhenX;;TRIAL;2.36;2.65 +64041-7;Tooth code - caries - periodontal;Find;Pt;Tooth;Nom;PhenX;PHENX;2;Tooth code - caries - periodontal Tooth [PhenX];Tooth code caries periodon Tooth PhenX;;TRIAL;2.36;2.65 +64042-5;Distance from the free gingival margin, FGM, to the sulcus base, SB;Len;Pt;Tooth;Qn;PhenX;PHENX;2;Distance from the free gingival margin, FGM, to the sulcus base, SB Tooth [PhenX];Distance FGM to SB Tooth PhenX;;TRIAL;2.36;2.65 +64043-3;Distance from the free gingival margin, FGM, to the cement-enamel junction, CEJ;Len;Pt;Tooth;Qn;PhenX;PHENX;2;Distance from the free gingival margin, FGM, to the cement-enamel junction, CEJ Tooth [PhenX];Distance FGM to CEJ Tooth PhenX;;TRIAL;2.36;2.65 +64044-1;Clinical observation of the presence of blood, bleeding on probing, BOP;Find;Pt;Tooth;Nom;PhenX;PHENX;2;Clinical observation of the presence of blood, bleeding on probing, BOP Tooth [PhenX];Blood, bleeding on probing Tooth PhenX;;TRIAL;2.36;2.65 +64045-8;Tooth position - fluorosis;Find;Pt;Tooth;Ord;PhenX;PHENX;2;Tooth position - fluorosis Tooth [PhenX];Tooth position - fluorosis Tooth PhenX;;TRIAL;2.36;2.65 +64046-6;Tooth code - fluorosis;Find;Pt;Tooth;Nom;PhenX;PHENX;2;Tooth code - fluorosis Tooth [PhenX];Tooth code - fluorosis Tooth PhenX;;TRIAL;2.36;2.65 +64047-4;Tooth surface index of fluorosis - TSIF;Find;Pt;Tooth.aspect;Ord;PhenX;PHENX;2;Tooth surface index of fluorosis - TSIF Tooth.aspect [PhenX];TSIF Tooth.aspect PhenX;;TRIAL;2.36;2.65 +6404-8;Anaplasma phagocytophilum Ab;ACnc;Pt;Ser;Ord;EIA;MICRO;1;Deprecated Anaplasma phagocytophilum Ab [Presence] in Serum by Immunoassay;Deprecated A phagocytoph Ab Ser Ql EIA;;DEPRECATED;1.0f;2.36 +64048-2;Missing teeth;Find;Pt;Tooth;Nom;PhenX;PHENX;2;Missing teeth Tooth [PhenX];Missing teeth Tooth PhenX;;TRIAL;2.36;2.65 +64049-0;Tooth aspect - fluorosis;Find;Pt;Tooth;Nom;;PHENX;2;Tooth aspect - fluorosis Tooth;Tooth aspect fluorosis Tooth;;TRIAL;2.36;2.65 +64051-6;Views^W radionuclide intra lymphatic;Find;Pt;Breast.left>Lymphatic vessels;Doc;NM;RAD;2;NM Breast lymphatic vessels - left Views W radionuclide intra lymphatic;NM Breast lymph ves-L Vs W RNC IL;;ACTIVE;2.36;2.64 +64052-4;Views^W radionuclide intra lymphatic;Find;Pt;Breast.right>Lymphatic vessels;Doc;NM;RAD;2;NM Breast lymphatic vessels - right Views W radionuclide intra lymphatic;NM Breast lymph ves-R Vs W RNC IL;;ACTIVE;2.36;2.64 +64053-2;Admission evaluation note;Find;Pt;Hospital;Doc;General medicine;DOC.ONTOLOGY;2;General medicine Hospital Admission evaluation note;General medicine Hosp Admit eval note;;ACTIVE;2.36;2.67 +64054-0;Admission evaluation note;Find;Pt;Hospital;Doc;General medicine.medical student;DOC.ONTOLOGY;2;General medicine Medical student Hospital Admission evaluation note;Gen med MS Hosp Admit eval note;;ACTIVE;2.36;2.67 +6405-5;Ehrlichia sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ehrlichia sp Ab [Presence] in Serum by Immunoassay;Ehrlichia Ab Ser Ql IA;;ACTIVE;1.0f;2.56 +64055-7;Progress note;Find;Pt;Hospital;Doc;General medicine.medical student;DOC.ONTOLOGY;2;General medicine Medical student Hospital Progress note;Gen med MS Hosp Prog note;;ACTIVE;2.36;2.73 +64056-5;Consultation note;Find;Pt;Hospital;Doc;General medicine.medical student;DOC.ONTOLOGY;2;General medicine Medical student Hospital Consult note;Gen med MS Hosp Consult note;;ACTIVE;2.36;2.67 +64057-3;Progress note;Find;Pt;Hospital;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Hospital Progress note;Surgery Hosp Prog note;;ACTIVE;2.36;2.73 +64058-1;Admission evaluation note;Find;Pt;Hospital;Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Hospital Admission evaluation note;CCM Hosp Admit eval note;;ACTIVE;2.36;2.67 +64059-9;Progress note;Find;Pt;Hospital;Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Hospital Progress note;CCM Hosp Prog note;;ACTIVE;2.36;2.73 +64060-7;Admission evaluation note;Find;Pt;Hospital;Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Hospital Admission evaluation note;Cardiothor surg Hosp Admit eval note;;ACTIVE;2.36;2.67 +64061-5;Progress note;Find;Pt;Hospital;Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Hospital Progress note;Cardiothor surg Hosp Prog note;;ACTIVE;2.36;2.73 +64062-3;Admission evaluation note;Find;Pt;Hospital;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Hospital Admission evaluation note;Pulmonary disease Hosp Admit eval note;;ACTIVE;2.36;2.67 +6406-3;Flavivirus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Flavivirus identified in Specimen by Organism specific culture;Flavivirus Spec Cult;;ACTIVE;1.0f;2.69 +64063-1;Progress note;Find;Pt;Hospital;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Hospital Progress note;Pulmonary disease Hosp Prog note;;ACTIVE;2.36;2.73 +64064-9;Evaluation note;Find;Pt;Hospital;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Hospital Evaluation note;Pastoral Care Hosp Eval note;;ACTIVE;2.36;2.73 +64065-6;Initial evaluation note;Find;Pt;Hospital;Doc;Case manager;DOC.ONTOLOGY;2;Case manager Hospital Initial evaluation note;Case Manager Hosp Initial eval note;;ACTIVE;2.36;2.67 +64066-4;Admission evaluation note;Find;Pt;Hospital;Doc;Surgery.medical student;DOC.ONTOLOGY;2;Surgery Medical student Hospital Admission evaluation note;Surg Med stdnt Hosp Admit eval note;;ACTIVE;2.36;2.67 +64067-2;Progress note;Find;Pt;Hospital;Doc;Surgery.medical student;DOC.ONTOLOGY;2;Surgery Medical student Hospital Progress note;Surg Med stdnt Hosp Prog note;;ACTIVE;2.36;2.73 +64068-0;Consultation note;Find;Pt;Hospital;Doc;Surgery.medical student;DOC.ONTOLOGY;2;Surgery Medical student Hospital Consult note;Surg Med stdnt Hosp Consult note;;ACTIVE;2.36;2.67 +64069-8;Note;Find;Pt;Hospital;Doc;Critical care medicine.attending;DOC.ONTOLOGY;2;Critical care medicine Attending Hospital Note;CCM Attend Hosp Note;;ACTIVE;2.36;2.67 +64070-6;Admission evaluation note;Find;Pt;Hospital;Doc;Critical care medicine.medical student;DOC.ONTOLOGY;2;Critical care medicine Medical student Hospital Admission evaluation note;CCM MS Hosp Admit eval note;;ACTIVE;2.36;2.67 +6407-1;Francisella tularensis Ab.IgM;PrThr;Pt;Ser;Ord;LA;MICRO;1;Francisella tularensis IgM Ab [Presence] in Serum by Latex agglutination;F tular IgM Ser Ql LA;;ACTIVE;1.0f;2.56 +64071-4;Progress note;Find;Pt;Hospital;Doc;Critical care medicine.medical student;DOC.ONTOLOGY;2;Critical care medicine Medical student Hospital Progress note;CCM MS Hosp Prog note;;ACTIVE;2.36;2.73 +64072-2;Consultation note;Find;Pt;Hospital;Doc;Critical care medicine.medical student;DOC.ONTOLOGY;2;Critical care medicine Medical student Hospital Consult note;CCM MS Hosp Consult note;;ACTIVE;2.36;2.67 +64073-0;Note;Find;Pt;Hospital;Doc;Thoracic and cardiac surgery.attending;DOC.ONTOLOGY;2;Cardiothoracic surgery Attending Hospital Note;Cardiothor surg Attend Hosp Note;;ACTIVE;2.36;2.67 +64074-8;Admission evaluation note;Find;Pt;Hospital;Doc;Thoracic and cardiac surgery.medical student;DOC.ONTOLOGY;2;Cardiothoracic surgery Medical student Hospital Admission evaluation note;Cardiothor surg MS Hosp Admit eval note;;ACTIVE;2.36;2.67 +64075-5;Progress note;Find;Pt;Hospital;Doc;Thoracic and cardiac surgery.medical student;DOC.ONTOLOGY;2;Cardiothoracic surgery Medical student Hospital Progress note;Cardiothor surg MS Hosp Prog note;;ACTIVE;2.36;2.73 +64076-3;Consultation note;Find;Pt;Hospital;Doc;Thoracic and cardiac surgery.medical student;DOC.ONTOLOGY;2;Cardiothoracic surgery Medical student Hospital Consult note;Cardiothor surg MS Hosp Consult note;;ACTIVE;2.36;2.67 +64077-1;Note;Find;Pt;Hospital;Doc;Pulmonary disease.attending;DOC.ONTOLOGY;2;Pulmonary Attending Hospital Note;Pulmonary Attend Hosp Note;;ACTIVE;2.36;2.67 +64078-9;Admission evaluation note;Find;Pt;Hospital;Doc;Pulmonary disease.medical student;DOC.ONTOLOGY;2;Pulmonary Medical student Hospital Admission evaluation note;Pulmonary MS Hosp Admit eval note;;ACTIVE;2.36;2.67 +64079-7;Progress note;Find;Pt;Hospital;Doc;Pulmonary disease.medical student;DOC.ONTOLOGY;2;Pulmonary Medical student Hospital Progress note;Pulmonary MS Hosp Prog note;;ACTIVE;2.36;2.73 +64080-5;Consultation note;Find;Pt;Hospital;Doc;Pulmonary disease.medical student;DOC.ONTOLOGY;2;Pulmonary Medical student Hospital Consult note;Pulmonary MS Hosp Consult note;;ACTIVE;2.36;2.67 +64081-3;Cells.FMRP/100 lymphocytes;NFr;Pt;Bld;Qn;Immune stain;PATH;1;FMRP cells/100 lymphocytes in Blood by Immune stain;FMRP cells/lymph NFr Bld ImStn;;ACTIVE;2.36;2.73 +64082-1;Bilirubin.non-glucuronidated;MCnc;Pt;BldCo;Qn;;CHEM;1;Bilirubin.indirect [Mass/volume] in Cord blood;Bilirub Indirect BldCo-mCnc;;ACTIVE;2.36;2.70 +64083-9;MGMT gene methylation score;Ratio;Pt;Tiss;Qn;Molgen;MOLPATH;1;MGMT gene methylation score in Tissue by Molecular genetics method;MGMT methylation score Tiss;;ACTIVE;2.36;2.73 +64084-7;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells^^corrected for background;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood;M TB IFN-g CD4+ bckgrnd cor Bld-aCnc;;ACTIVE;2.36;2.73 +64085-4;Cells karyotyped.total;Num;Pt;CVS;Qn;;MOLPATH;1;Cells karyotyped.total [#] in Chorionic villus sample;Cells karyotyped.total CVS;;ACTIVE;2.36;2.73 +64086-2;Cells analyzed;Num;Pt;CVS;Qn;Molgen;MOLPATH;1;Cells analyzed [#] in Chorionic villus sample by Molecular genetics method;Cells analyzed CVS;;ACTIVE;2.36;2.73 +64087-0;ISCN band level;Num;Pt;CVS;Ord;Molgen;MOLPATH;1;ISCN band level [#] in Chorionic villus sample Qualitative by Molecular genetics method;ISCN band level CVS Ql;;ACTIVE;2.36;2.73 +64088-8;Karyotype;Prid;Pt;CVS;Nar;;MOLPATH;1;Karyotype [Identifier] in Chorionic villus sample Narrative;Karyotyp CVS;;ACTIVE;2.36;2.73 +6408-9;Francisella tularensis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Francisella tularensis Ag [Presence] in Specimen by Immunofluorescence;F tular Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +64089-6;Cells counted;Num;Pt;CVS;Qn;Molgen;MOLPATH;1;Cells counted [#] in Chorionic villus sample by Molecular genetics method;Cells counted CVS;;ACTIVE;2.36;2.73 +64090-4;Chromosome analysis overall interpretation;Imp;Pt;XXX;Ord;Molgen;MOLPATH;1;Chromosome analysis overall interpretation in Specimen Qualitative by Molecular genetics method;Chrom analy overall interp Spec-Imp;;ACTIVE;2.36;2.73 +64091-2;Cells karyotyped.total;Num;Pt;Amnio fld;Qn;;MOLPATH;1;Cells karyotyped.total [#] in Amniotic fluid;Cells karyotyped.total Amn;;ACTIVE;2.36;2.73 +64092-0;Cells analyzed;Num;Pt;Amnio fld;Qn;Molgen;MOLPATH;1;Cells analyzed [#] in Amniotic fluid by Molecular genetics method;Cells analyzed Amn;;ACTIVE;2.36;2.73 +64093-8;ISCN band level;Num;Pt;Amnio fld;Ord;Molgen;MOLPATH;1;ISCN band level [#] in Amniotic fluid Qualitative by Molecular genetics method;ISCN band level Amn Ql;;ACTIVE;2.36;2.73 +64094-6;Karyotype;Prid;Pt;Amnio fld;Nar;;MOLPATH;1;Karyotype [Identifier] in Amniotic fluid Narrative;Karyotyp Amn;;ACTIVE;2.36;2.73 +64095-3;Cells counted;Num;Pt;Amnio fld;Qn;Molgen;MOLPATH;1;Cells counted [#] in Amniotic fluid by Molecular genetics method;Cells counted Amn;;ACTIVE;2.36;2.73 +64096-1;Colonies counted;Num;Pt;Amnio fld;Qn;Molgen;MOLPATH;1;Colonies counted [#] in Amniotic fluid by Molecular genetics method;Colonies counted Amn;;ACTIVE;2.36;2.73 +6409-7;Fungus identified;Prid;Pt;Sptt;Nom;Culture;MICRO;1;Fungus identified in Sputum tracheal aspirate by Culture;Fungus Sputum trach asp Cult;;ACTIVE;1.0f;2.17 +64097-9;Fatigue^post exercise;Find;Pt;^Patient;Ord;;PHENX;2;Fatigue --post exercise;Fatigue post exercise;;TRIAL;2.36;2.65 +64098-7;Walking distance;Len;6M;^Patient;Qn;;CLIN;2;Six minute walk test;Walk distance 6M;;ACTIVE;2.36;2.72 +64099-5;Peak expiratory flow attempt;Find;Pt;^Patient;Nom;;PHENX;2;Peak expiratory flow attempt;Peak expiratory flow attempt;;TRIAL;2.36;2.65 +64100-1;Contraindication;Find;Pt;^Patient;Nom;;PHENX;2;Contraindication;Contraindication;;TRIAL;2.36;2.65 +64101-9;Fatigue^resting;Find;Pt;^Patient;Ord;;PHENX;2;Fatigue --resting;Fatigue resting;;TRIAL;2.36;2.65 +64102-7;Oxygen therapy type during walk test;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Oxygen therapy type [PhenX];O2 therapy type PhenX;;TRIAL;2.36;2.73 +64103-5;Baseline time;ClockTime;Pt;^Patient;Qn;;PHENX;2;Baseline time;Baseline time;;TRIAL;2.36;2.65 +64104-3;Stopped or paused before 6M;Find;Pt;^Patient;Ord;;PHENX;2;Stopped or paused before 6 minutes;Stopped before 6M;;TRIAL;2.36;2.65 +6410-5;Gardnerella vaginalis rRNA;PrThr;Pt;Genital;Ord;Probe;MICRO;1;Gardnerella vaginalis rRNA [Presence] in Genital specimen by Probe;G vaginalis rRNA Genital Ql Probe;;ACTIVE;1.0f;2.73 +64105-0;Reason stopped or paused before 6M;Find;Pt;^Patient;Nom;;PHENX;2;Reason stopped or paused before 6 minutes;Reason stopped before 6M;;TRIAL;2.36;2.65 +64106-8;Other symptoms at end of exercise;Find;Pt;^Patient;Nom;;PHENX;2;Other symptoms at end of exercise;Other sympts exercise end;;TRIAL;2.36;2.65 +64107-6;Number of laps;Num;Pt;^Patient;Qn;;PHENX;2;Number of laps;#laps;;TRIAL;2.36;2.73 +64108-4;Final partial lap distance;Len;Pt;^Patient;Qn;;PHENX;2;Final partial lap distance;Final partial lap distance;;TRIAL;2.36;2.65 +641-1;Microscopic observation;Prid;Pt;Gast fld;Nom;Acid fast stain.Kinyoun modified;MICRO;1;Microscopic observation [Identifier] in Gastric fluid by Acid fast stain.Kinyoun modified;Acid fast Mod Kiny Stn Gast;;ACTIVE;1.0;2.21 +64110-0;Interpretation;Imp;Pt;^Patient;Nom;;PHENX;2;Interpretation;Interpretation;;TRIAL;2.36;2.73 +64111-8;Time at blood draw;ClockTime;Pt;^Patient;Qn;;PHENX;2;Time at blood draw;Blood draw time Clock time;;TRIAL;2.36;2.65 +64112-6;Dyspnea^post exercise;Find;Pt;Respiratory system;Ord;;PHENX;2;Dyspnea Respiratory system --post exercise;Dyspnea p Exc Respiratory;;TRIAL;2.36;2.65 +6411-3;Giardia lamblia Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Giardia lamblia IgG Ab [Titer] in Serum by Immunofluorescence;G lamblia IgG Titr Ser IF;;ACTIVE;1.0f;2.73 +64113-4;Dyspnea^resting;Find;Pt;Respiratory system;Ord;;PHENX;2;Dyspnea Respiratory system --resting;Dyspnea Resting Respiratory;;TRIAL;2.36;2.65 +64114-2;End of test time;ClockTime;Pt;^Patient;Qn;;PHENX;2;End of test time;Test time end Clock time;;TRIAL;2.36;2.65 +64116-7;Hemoglobin observations newborn screening panel;-;Pt;Bld.dot;-;;PANEL.HEM/BC;1;Hemoglobin observations newborn screening panel;Hb observations NBS pnl DBS;;ACTIVE;2.36;2.73 +64117-5;Most predominant hemoglobin;Find;Pt;Bld.dot;Nom;;HEM/BC;1;Most predominant hemoglobin in DBS;Most predominant Hb DBS;;ACTIVE;2.36;2.73 +64118-3;Second most predominant hemoglobin;Find;Pt;Bld.dot;Nom;;HEM/BC;1;Second most predominant hemoglobin in DBS;2nd most predominant Hb DBS;;ACTIVE;2.36;2.73 +64119-1;Third most predominant hemoglobin;Find;Pt;Bld.dot;Nom;;HEM/BC;1;Third most predominant hemoglobin in DBS;3rd most predominant Hb DBS;;ACTIVE;2.36;2.73 +64120-9;Fourth most predominant hemoglobin;Find;Pt;Bld.dot;Nom;;HEM/BC;1;Fourth most predominant hemoglobin in DBS;4th most predominant Hb DBS;;ACTIVE;2.36;2.73 +6412-1;Giardia lamblia Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Giardia lamblia Ag [Presence] in Stool by Immunoassay;G lamblia Ag Stl Ql IA;;ACTIVE;1.0f;2.73 +64121-7;Fifth most predominant hemoglobin;Find;Pt;Bld.dot;Nom;;HEM/BC;1;Fifth most predominant hemoglobin in DBS;5th most predominant Hb DBS;;ACTIVE;2.36;2.73 +64122-5;Hemoglobins that can be presumptively identified based on available controls;Find;Pt;Bld.dot;Nom;;HEM/BC;1;Hemoglobins that can be presumptively identified based on available controls in DBS;Hb pres ID based on avail contr DBS;;ACTIVE;2.36;2.73 +64123-3;Indexing - adverse reaction;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indexing - adverse reaction;FDA insert Indexing - adverse rx;;ACTIVE;2.36;2.36 +64124-1;Indexing - substance;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indexing - substance;FDA insert Indexing - substance;;ACTIVE;2.36;2.36 +64125-8;Pregabalin;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pregabalin [Mass/volume] in Urine by Confirmatory method;Pregabalin Ur Cfm-mCnc;;ACTIVE;2.36;2.73 +64126-6;Drugs identified;Prid;Pt;Meconium;Nom;Confirm;DRUG/TOX;1;Drugs identified in Meconium by Confirmatory method;Drugs Mec Cfm;;ACTIVE;2.36;2.38 +64127-4;Methylenedioxyethylamphetamine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine/Creatinine [Mass Ratio] in Urine;MDEA/Creat Ur;;ACTIVE;2.36;2.73 +64128-2;Amobarbital/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Amobarbital/Creatinine [Mass Ratio] in Urine;Amobarbital/Creat Ur;;ACTIVE;2.36;2.73 +64129-0;N-desalkylflurazepam/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;N-desalkylflurazepam/Creatinine [Mass Ratio] in Urine;Desalkylfluraz/Creat Ur;;ACTIVE;2.36;2.73 +64130-8;diazePAM/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;diazePAM/Creatinine [Mass Ratio] in Urine;diazePAM/Creat Ur;;ACTIVE;2.36;2.73 +64131-6;Dihydrocodeine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Dihydrocodeine/Creatinine [Mass Ratio] in Urine;DHC/Creat Ur;;ACTIVE;2.36;2.73 +64132-4;PENTobarbital/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;PENTobarbital/Creatinine [Mass Ratio] in Urine;Pentobarb/Creat Ur;;ACTIVE;2.36;2.70 +64133-2;PHENobarbital/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;PHENobarbital/Creatinine [Mass Ratio] in Urine;Phenobarb/Creat Ur;;ACTIVE;2.36;2.73 +64134-0;Phentermine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Phentermine/Creatinine [Mass Ratio] in Urine;Phentermine/Creat Ur;;ACTIVE;2.36;2.70 +64135-7;Secobarbital/Creatinine;MRto;Pt;Urine;Qn;;DRUGDOSE;1;Secobarbital/Creatinine [Mass Ratio] of Urine;Secobarbital/Creat Ur;;ACTIVE;2.36;2.73 +64136-5;Pregabalin/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Pregabalin/Creatinine [Mass Ratio] in Urine;Pregabalin/Creat Ur;;ACTIVE;2.36;2.73 +64137-3;Pregabalin;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Pregabalin [Presence] in Urine by Screen method;Pregabalin Ur Ql Scn;;ACTIVE;2.36;2.73 +64138-1;Methylenedioxyamphetamine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine/Creatinine [Mass Ratio] in Urine;MDA/Creat Ur;;ACTIVE;2.36;2.73 +6413-9;Giardia lamblia Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Giardia lamblia Ag [Presence] in Specimen by Immunoassay;G lamblia Ag Spec Ql IA;;ACTIVE;1.0f;2.73 +64139-9;Butalbital/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Butalbital/Creatinine [Mass Ratio] in Urine;Butalbital/Creat Ur;;ACTIVE;2.36;2.73 +64140-7;Views^W contrast;Find;Pt;Abdomen>Renal vessels.left;Doc;RF.angio;RAD;2;RFA Renal vessels - left Views W contrast;RFA Renal ves-L Views W contr;;ACTIVE;2.36;2.64 +64141-5;Views^W contrast;Find;Pt;Abdomen>Renal vessels.right;Doc;RF.angio;RAD;2;RFA Renal vessels - right Views W contrast;RFA Renal ves-R Views W contr;;ACTIVE;2.36;2.64 +64142-3;Evaluation and management of smoking cessation note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Evaluation and management of smoking cessation note;Hosp E/M smoke cess note;;ACTIVE;2.36;2.58 +64145-6;Do you usually have a cough;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually have a cough [PhenX];Cough hx PhenX;;TRIAL;2.36;2.65 +64146-4;Do you usually cough as much as 4 to 6 times a D, 4 or more D out of the W;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually cough as much as 4 to 6 times a day, 4 or more day out of the week [PhenX];Cough frequently PhenX;;TRIAL;2.36;2.65 +6414-7;Haemophilus influenzae A Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Haemophilus influenzae A Ag [Presence] in Specimen by Immunofluorescence;Haem influ A Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +64147-2;Do you usually cough at all on getting up, or first thing in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually cough at all on getting up, or first thing in the morning [PhenX];Cough morning PhenX;;TRIAL;2.36;2.65 +64148-0;Do you usually cough at all during the rest of the day or at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually cough at all during the rest of the day or at night [PhenX];Cough D night PhenX;;TRIAL;2.36;2.65 +64149-8;Do you usually cough like this on most days for 3 consecutive Mo or more during the Y;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually cough like this on most days for 3 consecutive Mos or more during the year [PhenX];Cough consecutive M PhenX;;TRIAL;2.36;2.65 +64150-6;For how many Y have you had this cough;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how many years have you had this cough [PhenX];Cough Ys PhenX;;TRIAL;2.36;2.65 +64151-4;Do you usually bring up phlegm from your chest;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually bring up phlegm from your chest [PhenX];Phlegm hx PhenX;;TRIAL;2.36;2.65 +64152-2;Do you usually bring up phlegm like this as much as twice a D, 4 or more D of the W;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually bring up phlegm like this as much as twice a day, 4 or more days of the week [PhenX];Phlegm frequently PhenX;;TRIAL;2.36;2.65 +64153-0;Do you usually bring up phlegm at all on getting up or first thing in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually bring up phlegm at all on getting up or first thing in the morning [PhenX];Phlegm morning PhenX;;TRIAL;2.36;2.65 +64154-8;Do you usually bring up phlegm at all during the rest of the D or at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually bring up phlegm at all during the rest of the day or at night [PhenX];Phlegm D night PhenX;;TRIAL;2.36;2.65 +6415-5;Haemophilus influenzae C Ag;ACnc;Pt;XXX;Ord;IF;MICRO;1;Deprecated Haemophilus influenzae C Ag [Presence] in Unspecified specimen by Immunofluorescence;Deprecated Haem influ C Ag XXX Ql IF;;DEPRECATED;1.0f;2.69 +64155-5;Do you bring up phlegm like this on most D for 3 consecutive Mo or more during the Y;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you bring up phlegm like this on most days for 3 consecutive months or more during the year [PhenX];Phlegm consecutive Mo PhenX;;TRIAL;2.36;2.65 +64156-3;For how many Y have you had trouble with phlegm;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how many years have you had trouble with phlegm [PhenX];Phlegm Ys PhenX;;TRIAL;2.36;2.65 +64157-1;Have you had periods or episodes of increased cough and phlegm lasting for 3W or more each Y;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had periods or episodes of increased cough and phlegm lasting for 3 weeks or more each year [PhenX];Cough phlegm period episode PhenX;;TRIAL;2.36;2.65 +64158-9;For how long have you had at least 1 cough and phlegm episode per Y;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how long have you had at least 1 cough and phlegm episode per year [PhenX];Cough phlegm lasting time PhenX;;TRIAL;2.36;2.65 +64159-7;Does your chest ever sound wheezy or whistling when you have a cold;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your chest ever sound wheezy or whistling when you have a cold [PhenX];Wheezing with cold PhenX;;TRIAL;2.36;2.65 +64160-5;Does your chest ever sound wheezy or whistling occasionally apart from colds;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your chest ever sound wheezy or whistling occasionally apart from colds [PhenX];Wheezing apart from colds PhenX;;TRIAL;2.36;2.65 +64161-3;Does your chest ever sound wheezy or whistling most Ds or nights;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your chest ever sound wheezy or whistling most days or nights [PhenX];Wheezying day/night PhenX;;TRIAL;2.36;2.65 +6416-2;Haemophilus influenzae D Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Haemophilus influenzae D Ag [Presence] in Specimen by Immunofluorescence;Haem influ D Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +64162-1;For how many Y has this wheezing been present;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how many years has this wheezing been present [PhenX];Wheezing Ys PhenX;;TRIAL;2.36;2.65 +64163-9;Have you ever had an attack of wheezing that has made you feel short of breath;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had an attack of wheezing that has made you feel short of breath [PhenX];Wheezing attack ever PhenX;;TRIAL;2.36;2.65 +64164-7;How old were you when you had your first wheezing attack leaving you short of breath;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you had your first wheezing attack leaving you short of breath [PhenX];Wheezing first age PhenX;;TRIAL;2.36;2.65 +64165-4;Have you had 2 or more such episodes of wheezing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had 2 or more such episodes of wheezing [PhenX];Wheezing mult episodes PhenX;;TRIAL;2.36;2.65 +64166-2;Have you ever required medicine or treatment for these wheezing attacks;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever required medicine or treatment for these wheezing attacks [PhenX];Wheezing meds ever PhenX;;TRIAL;2.36;2.65 +64167-0;If disabled from walking by any condition other than heart or lung disease, please describe nature of conditions;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If disabled from walking by any condition other than heart or lung disease, please describe nature of conditions [PhenX];Breathless conditon nature PhenX;;TRIAL;2.36;2.65 +64168-8;Are you troubled by shortness of breath when hurrying on level ground or walking up a slight hill;Find;Pt;^Patient;Ord;Rose Dyspnea Scale;PHENX;2;Are you troubled by shortness of breath when hurrying on level ground or walking up a slight hill [Rose Dyspnea Scale];SOB hurry slight hill Rose Dyspnea Scale;;ACTIVE;2.36;2.64 +64169-6;Do you have to walk slower than people of your age on the level because of breathlessness;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have to walk slower than people of your age on the level because of breathlessness [PhenX];Breath need walk slower PhenX;;TRIAL;2.36;2.65 +6417-0;Haemophilus influenzae E Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Haemophilus influenzae E Ag [Presence] in Specimen by Immunofluorescence;Haem influ E Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +64170-4;Do you ever have to stop for breath when walking at your own pace on the level;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever have to stop for breath when walking at your own pace on the level [PhenX];Breath stop own pace PhenX;;TRIAL;2.36;2.65 +64171-2;Do you ever have to stop for breath after walking about 100 yards, or after a few Ms, on the level;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever have to stop for breath after walking about 100 yards, or after a few Ms, on the level [PhenX];Breath stop 100 yards PhenX;;TRIAL;2.36;2.65 +64172-0;Are you too breathless to leave the house or breathless on dressing or undressing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you too breathless to leave the house or breathless on dressing or undressing [PhenX];Breathless leave house dressing PhenX;;TRIAL;2.36;2.65 +64173-8;If you get a cold, does it usually go to your chest;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If you get a cold, does it usually go to your chest [PhenX];Cold to chest PhenX;;TRIAL;2.36;2.65 +64174-6;During the past 3Y, have you had any chest illnesses that have kept you off work, indoors at home, or in bed;Find;3Y;^Patient;Ord;PhenX;PHENX;2;During the past 3Y, have you had any chest illnesses that have kept you off work, indoors at home, or in bed 3 years [PhenX];Chest illness home bed 3Y PhenX;;TRIAL;2.36;2.65 +64175-3;Did you produce phlegm with any of these chest illnesses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you produce phlegm with any of these chest illnesses [PhenX];Chest illness phlegm PhenX;;TRIAL;2.36;2.65 +64176-1;In the last 3Y, how many such illnesses, with increased phlegm, did you have which lasted a W or more;NRat;3Y;^Patient;Qn;PhenX;PHENX;2;In the last 3 years, how many such illnesses, with increased phlegm, did you have which lasted a week or more 3 years [PhenX];Chest illness phlegm > W 3Y nRate PhenX;;TRIAL;2.36;2.66 +64177-9;Did you have any lung trouble before the age of 16;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you have any lung trouble before the age of 16 [PhenX];Lung trouble < 16 PhenX;;TRIAL;2.36;2.65 +64178-7;Have you ever had attacks of bronchitis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had attacks of bronchitis [PhenX];Bronch attack ever PhenX;;TRIAL;2.36;2.65 +64179-5;Was bronchitis confirmed by a doctor;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was bronchitis confirmed by a doctor [PhenX];Bronchitis Dr confirmed PhenX;;TRIAL;2.36;2.65 +64180-3;At what age was your first attack of bronchitis;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age was your first attack of bronchitis [PhenX];Bronchitis attack first age PhenX;;TRIAL;2.36;2.65 +64181-1;Have you ever had pneumonia, include bronchopneumonia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had pneumonia, include bronchopneumonia [PhenX];Pneumonia ever PhenX;;TRIAL;2.36;2.65 +64182-9;Was pneumonia confirmed by a doctor;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was pneumonia confirmed by a doctor [PhenX];Pneumonia Dr confirmed PhenX;;TRIAL;2.36;2.65 +64183-7;At what age did you first have pneumonia;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did you first have pneumonia [PhenX];Pneumonia first age PhenX;;TRIAL;2.36;2.65 +64184-5;Have you ever had hay fever;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had hay fever [PhenX];Hay fever ever PhenX;;TRIAL;2.36;2.65 +64185-2;Was hay fever confirmed by a doctor;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was hay fever confirmed by a doctor [PhenX];Hay fever Dr confirmed PhenX;;TRIAL;2.36;2.65 +64186-0;At what age did hay fever start;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did hay fever start [PhenX];Hay fever start age PhenX;;TRIAL;2.36;2.65 +64187-8;Have you ever had chronic bronchitis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had chronic bronchitis [PhenX];Chronic bronch ever PhenX;;TRIAL;2.36;2.65 +6418-8;Haemophilus influenzae F Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Haemophilus influenzae F Ag [Presence] in Specimen by Immunofluorescence;Haem influ F Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +64188-6;Was chronic bronchitis confirmed by a doctor;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was chronic bronchitis confirmed by a doctor [PhenX];Chronic bronch Dr comfirmed PhenX;;TRIAL;2.36;2.65 +64189-4;Do you still have chronic bronchitis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you still have chronic bronchitis [PhenX];Chronic bronch still have PhenX;;TRIAL;2.36;2.65 +64190-2;At what age did chronic bronchitis start;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did chronic bronchitis start [PhenX];Chronic bronch start age PhenX;;TRIAL;2.36;2.65 +64191-0;Have you ever had emphysema;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had emphysema [PhenX];Emphysema ever PhenX;;TRIAL;2.36;2.65 +64192-8;Do you still have emphysema;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you still have emphysema [PhenX];Emphysema still have PhenX;;TRIAL;2.36;2.65 +64193-6;Was emphysema confirmed by a doctor;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was emphysema confirmed by a doctor [PhenX];Emphysema Dr confirmed PhenX;;TRIAL;2.36;2.65 +64194-4;At what age did emphysema start;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did emphysema start [PhenX];Emphysema start age PhenX;;TRIAL;2.36;2.65 +64195-1;Have you ever had asthma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had asthma [PhenX];Asthma ever PhenX;;TRIAL;2.36;2.65 +6419-6;Helicobacter pylori Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Helicobacter pylori Ab [Presence] in Serum by Immunofluorescence;H pylori Ab Ser Ql IF;;ACTIVE;1.0f;2.73 +64196-9;Do you still have asthma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you still have asthma [PhenX];Asthma still have PhenX;;TRIAL;2.36;2.65 +64197-7;Was asthma confirmed by a doctor;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was asthma confirmed by a doctor [PhenX];Asthma Dr confirmed PhenX;;TRIAL;2.36;2.65 +64198-5;At what age did asthma start;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did asthma start [PhenX];Asthma start age PhenX;;TRIAL;2.36;2.65 +64199-3;If you no longer have asthma, at what age did it stop;Time;Pt;^Patient;Qn;PhenX;PHENX;2;If you no longer have asthma, at what age did it stop [PhenX];Asthma stop age PhenX;;TRIAL;2.36;2.65 +64200-9;Have you ever had any other chest illnesses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any other chest illnesses [PhenX];Other chest illness ever PhenX;;TRIAL;2.36;2.65 +64201-7;Other chest illnesses you had;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other chest illnesses you had [PhenX];Other chest illness specify PhenX;;TRIAL;2.36;2.65 +64202-5;Have you ever had any chest injuries;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any chest injuries [PhenX];Chest injury ever PhenX;;TRIAL;2.36;2.65 +64203-3;Chest injuries you had;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Chest injuries you had [PhenX];Chest injury specify PhenX;;TRIAL;2.36;2.65 +6420-4;Helicobacter pylori Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Helicobacter pylori IgA Ab [Units/volume] in Serum by Immunoassay;H pylori IgA Ser IA-aCnc;;ACTIVE;1.0f;2.73 +64204-1;Has doctor ever told you that you had heart trouble;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has doctor ever told you that you had heart trouble [PhenX];Heart trouble ever PhenX;;TRIAL;2.36;2.65 +64205-8;Have you ever had treatment for heart trouble in the past 10Y;Find;10Y;^Patient;Ord;PhenX;PHENX;2;Have you ever had treatment for heart trouble in the past 10Y [PhenX];Heart trouble tx ever PhenX;;TRIAL;2.36;2.65 +64206-6;Have you had any treatment for high blood pressure, hypertension, in the past 10Y;Find;10Y;^Patient;Ord;PhenX;PHENX;2;Have you had any treatment for high blood pressure, hypertension, in the past 10Y [PhenX];High blood press tx ever PhenX;;TRIAL;2.36;2.65 +64207-4;Have you ever worked full time, 30H per W or more, for 6Mo or more;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever worked full time, 30 hours per week or more, for 6 months or more [PhenX];Full time ever PhenX;;TRIAL;2.36;2.65 +64208-2;Have you ever worked for a Y or more in any dusty job;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever worked for a year or more in any dusty job [PhenX];Dusty job ever PhenX;;TRIAL;2.36;2.65 +64209-0;Job or industry of dusty job;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Job or industry of dusty job [PhenX];Dusty job specify PhenX;;TRIAL;2.36;2.65 +64210-8;Was dusty job exposure;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was dusty job exposure [PhenX];Dusty job exp degree PhenX;;TRIAL;2.36;2.65 +64211-6;Have you ever been exposed to gas or chemical fumes in your work;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been exposed to gas or chemical fumes in your work [PhenX];Gas chem fumes ever PhenX;;TRIAL;2.36;2.65 +6421-2;Hepatitis B virus rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Hepatitis B virus rRNA [Presence] in Specimen by Probe;HBV rRNA Spec Ql Probe;;ACTIVE;1.0f;2.73 +64212-4;Job or industry with gas or chemical fumes;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Job or industry with gas or chemical fumes [PhenX];Job/industry with fumes PhenX;;TRIAL;2.36;2.65 +64213-2;Total Y worked in job or industry with gas or chemical fume;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Total years worked in job or industry with gas or chemical fume [PhenX];Gas chem fumes tot Ys PhenX;;TRIAL;2.36;2.65 +64214-0;Was gas or chemical fumes exposure;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was gas or chemical fumes exposure [PhenX];Chem fumes exp degree PhenX;;TRIAL;2.36;2.65 +64216-5;Have you ever smoked cigarettes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever smoked cigarettes [PhenX];Smoke cigarettes ever PhenX;;TRIAL;2.36;2.65 +64217-3;Do you now smoke cigarettes, as of 1Mo ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you now smoke cigarettes, as of 1 month ago [PhenX];Smoke cigarettes now PhenX;;TRIAL;2.36;2.73 +64218-1;How many cigarettes do you smoke per D now;NRat;Pt;^Patient;Qn;;PHENX;2;How many cigarettes do you smoke per day now [PhenX];Cigarettes quant D now nRate PhenX;;ACTIVE;2.36;2.73 +64219-9;On the average of the entire time you smoked, how many cigarettes did you smoke per D;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;On the average of the entire time you smoked, how many cigarettes did you smoke per day [PhenX];Cigarettes quant D PhenX;;TRIAL;2.36;2.73 +6422-0;Hepatitis C virus rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Hepatitis C virus rRNA;Deprecated HCV rRNA XXX Ql Prb;;DEPRECATED;1.0f;2.69 +64220-7;Do or did you inhale the cigarette smoke;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Do or did you inhale the cigarette smoke [PhenX];Smoke cigarettes inhale PhenX;;TRIAL;2.36;2.65 +64221-5;Have you ever smoked a pipe regularly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever smoked a pipe regularly [PhenX];Smoke pipe ever PhenX;;TRIAL;2.36;2.65 +64222-3;How old were you when you started to smoke a pipe regularly;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you started to smoke a pipe regularly [PhenX];Smoke pipe first age PhenX;;TRIAL;2.36;2.65 +64223-1;Age when stopped smoking a pipe completely;Time;Pt;^Patient;Qn;;H&P.HX;2;If you have stopped smoking a pipe completely, how old were you when you stopped [PhenX];Smoke pipe stop age PhenX;;ACTIVE;2.36;2.66 +64224-9;On the average over the entire time you smoked a pipe, how much pipe tobacco did you smoke per W;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;On the average over the entire time you smoked a pipe, how much pipe tobacco did you smoke per week [PhenX];Pipe tobacco quant W PhenX;;TRIAL;2.36;2.65 +64225-6;How much pipe tobacco are you smoking now;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How much pipe tobacco are you smoking now [PhenX];Pipe tobacco quant now nRate PhenX;;TRIAL;2.36;2.65 +64226-4;Do or did you inhale the pipe smoke;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do or did you inhale the pipe smoke [PhenX];Smoke pipe inhale PhenX;;TRIAL;2.36;2.65 +64227-2;Have you ever smoked cigars regularly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever smoked cigars regularly [PhenX];Smoke cigars ever PhenX;;TRIAL;2.36;2.65 +64228-0;How old were you when you started smoking cigars regularly;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you started smoking cigars regularly [PhenX];Smoke cigars first age PhenX;;TRIAL;2.36;2.65 +64229-8;Age when stopped smoking cigars completely;Time;Pt;^Patient;Qn;;H&P.HX;2;If you have stopped smoking cigars completely, how old were you when you stopped [PhenX];Smoke cigars stop age PhenX;;ACTIVE;2.36;2.66 +64230-6;On the average over the entire time you smoked cigars, how many cigars did you smoke per W;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;On the average over the entire time you smoked cigars, how many cigars did you smoke per week [PhenX];Cigars quant W PhenX;;TRIAL;2.36;2.65 +64231-4;How many cigars are you smoking per W now;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How many cigars are you smoking per week now [PhenX];Cigars quant W now nRate PhenX;;TRIAL;2.36;2.65 +64232-2;Do or did you inhale the cigar smoke;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do or did you inhale the cigar smoke [PhenX];Smoke cigars inhale PhenX;;TRIAL;2.36;2.65 +64233-0;Benzylpiperazine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Benzylpiperazine [Presence] in Urine by Confirmatory method;Benzylpiperazine Ur Ql Cfm;;ACTIVE;2.36;2.56 +64234-8;Current smoker;Find;Pt;^Patient;Ord;;H&P.HX;2;Current smoker;Current smoker;;ACTIVE;2.36;2.73 +64235-5;Total Y worked in dusty job;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Total years worked in dusty job [PhenX];Dusty job tot Ys PhenX;;TRIAL;2.36;2.65 +64236-3;Have you ever had any chest operations;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any chest operations [PhenX];Chest operations ever PhenX;;TRIAL;2.36;2.65 +64237-1;Chest operations you had;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Chest operations you had [PhenX];Chest operations had PhenX;;TRIAL;2.36;2.65 +6423-8;Herpes simplex virus Ag;ACnc;Pt;Genital;Ord;EIA;MICRO;1;Deprecated Herpes simplex virus Ag [Presence] in Genital specimen by Immunoassay;Deprecated HSV Ag Genital Ql EIA;;DEPRECATED;1.0f;2.36 +64238-9;Natural parent;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Natural parent [PhenX];Natural parent PhenX;;TRIAL;2.36;2.65 +64239-7;Was your parent ever told by a doctor that he or she had chronic bronchitis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your parent ever told by a doctor that he or she had chronic bronchitis [PhenX];Hx parent chronic bronchitis PhenX;;TRIAL;2.36;2.65 +64240-5;Was your parent ever told by a doctor that he or she had emphysema;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your parent ever told by a doctor that he or she had emphysema [PhenX];Hx parent emphysema PhenX;;TRIAL;2.36;2.65 +64241-3;Was your parent ever told by a doctor that he or she had asthma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your parent ever told by a doctor that he or she had asthma [PhenX];Hx parent asthma PhenX;;TRIAL;2.36;2.65 +64242-1;Was your parent ever told by a doctor that he or she had lung cancer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your parent ever told by a doctor that he or she had lung cancer [PhenX];Hx parent lung cancer PhenX;;TRIAL;2.36;2.65 +64243-9;Was your parent ever told by a doctor that he or she had other chest conditions;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your parent ever told by a doctor that he or she had other chest conditions [PhenX];Hx parent other chest conditions PhenX;;TRIAL;2.36;2.65 +64244-7;Have you ever had wheezing or whistling in your chest;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had wheezing or whistling in your chest [PhenX];Wheezing whistling chest ever PhenX;;TRIAL;2.36;2.65 +64245-4;About how old were you when you first had wheezing or whistling in your chest;Time;Pt;^Patient;Qn;PhenX;PHENX;2;About how old were you when you first had wheezing or whistling in your chest [PhenX];Wheezing whistling chest first age PhenX;;TRIAL;2.36;2.65 +6424-6;Heterophile Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Heterophile Ab [Titer] in Serum by Agglutination;Heteroph Ab Titr Ser Aggl;;ACTIVE;1.0f;2.73 +64246-2;In the last 12Mo, have you had wheezing or whistling in your chest at any time;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, have you had wheezing or whistling in your chest at any time [PhenX];Hx wheezing whistling chest PhenX;;TRIAL;2.36;2.65 +64247-0;In the last 12Mo, does your chest ever sound wheezy or whistling when you have a cold;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, does your chest ever sound wheezy or whistling when you have a cold [PhenX];Hx wheezy whistling chest cold PhenX;;TRIAL;2.36;2.65 +64248-8;In the last 12Mo, does your chest ever sound wheezy or whistling more than once a W;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, does your chest ever sound wheezy or whistling more than once a week [PhenX];Hx wheezy whistling chest multiple PhenX;;TRIAL;2.36;2.65 +64249-6;In the last 12Mo, does your chest ever sound wheezy or whistling most Ds and nights;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, does your chest ever sound wheezy or whistling most days and nights [PhenX];Hx wheezy whistling chest D night PhenX;;TRIAL;2.36;2.65 +64250-4;In the last 12Mo, have you been awakened from sleep by coughing, apart from a cough associated with a cold or chest infection;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, have you been awakened from sleep by coughing, apart from a cough associated with a cold or chest infection [PhenX];Hx awake coughing PhenX;;TRIAL;2.36;2.65 +64251-2;In the last 12Mo, have you been awakened from sleep by shortness of breath or a feeling of tightness in your chest;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, have you been awakened from sleep by shortness of breath or a feeling of tightness in your chest [PhenX];Hx awake breath chest tightness I PhenX;;TRIAL;2.36;2.65 +64252-0;In the past 12Mo, have you been bothered by sneezing or a runny or blocked nose when you did not have a cold or the flu;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, have you been bothered by sneezing or a runny or blocked nose when you did not have a cold or the flu [PhenX];Sneezing runny nose 12Mo 13 PhenX;;TRIAL;2.36;2.65 +6425-3;Heterophile Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Heterophile Ab [Presence] in Serum or Plasma by Immunoassay;Heteroph Ab SerPl Ql IA;;ACTIVE;1.0f;2.73 +64253-8;In the past 12Mo, have you been bothered by watery, itchy, or burning eyes when you did not have a cold or the flu;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, have you been bothered by watery, itchy, or burning eyes when you did not have a cold or the flu [PhenX];Hx watery itchy burning eyes PhenX;;TRIAL;2.36;2.65 +64254-6;In the past 12Mo, have you had periods or episodes of cough with phlegm that lasted 1 W or more;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, have you had periods or episodes of cough with phlegm that lasted 1 week or more [PhenX];Hx cough phlegm > 1W PhenX;;TRIAL;2.36;2.65 +64255-3;For how many Y have you had at least one such episode of cough with phlegm that lasted 1 W or more per Y;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how many years have you had at least one such episode of cough with phlegm that lasted 1 week or more per year [PhenX];Cough phlegm >1 W Ys PhenX;;TRIAL;2.36;2.65 +64256-1;About how many such episodes of cough with phlegm that lasted 1 W or more have you had in the past 12Mo;NRat;12Mo;^Patient;Qn;PhenX;PHENX;2;About how many such episodes of cough with phlegm that lasted 1 week or more have you had in the past 12 months [PhenX];How many times cough phlegm > 1W PhenX;;TRIAL;2.36;2.65 +64257-9;In the past Y, have you been to the emergency room or hospitalized for lung problems;Find;1Y;^Patient;Ord;PhenX;PHENX;2;In the past year, have you been to the emergency room or hospitalized for lung problems [PhenX];Hx ER hospitalized lung problems PhenX;;TRIAL;2.36;2.65 +64258-7;How many times have you been to the emergency room or hospitalized for lung problems;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many times have you been to the emergency room or hospitalized for lung problems [PhenX];Hx ER lung problems PhenX;;TRIAL;2.36;2.65 +64259-5;In the past Y, have you been treated with antibiotics for a chest illness;Find;1Y;^Patient;Ord;PhenX;PHENX;2;In the past year, have you been treated with antibiotics for a chest illness [PhenX];Hx antibiotics tx chest last Y PhenX;;TRIAL;2.36;2.65 +64260-3;How many times have you had to be treated with antibiotics for a chest illness;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many times have you had to be treated with antibiotics for a chest illness [PhenX];Hx antibiotics tx chest PhenX;;TRIAL;2.36;2.65 +6426-1;Histoplasma capsulatum Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Histoplasma capsulatum Ab [Units/volume] in Serum by Immunoassay;H capsul Ab Ser IA-aCnc;;ACTIVE;1.0f;2.73 +64261-1;In the past Y, have you been treated with steroid pills or injections, such as predniSONE or solumedrol, for a chest illness;Find;1Y;^Patient;Ord;PhenX;PHENX;2;In the past year, have you been treated with steroid pills or injections, such as prednisone or solumedrol, for a chest illness [PhenX];Hx steroid tx chest last Y PhenX;;TRIAL;2.36;2.65 +64262-9;How many times have you been treated with steroid pills or injections, such as predniSONE or solumedrol, for a chest illness;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many times have you been treated with steroid pills or injections, such as prednisone or solumedrol, for a chest illness [PhenX];Hx steroid tx chest PhenX;;TRIAL;2.36;2.65 +64263-7;Have you ever had wheezing or whistling in the chest at any time in the past;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had wheezing or whistling in the chest at any time in the past [PhenX];Wheezing whistling chest past PhenX;;TRIAL;2.36;2.65 +64264-5;Have you had wheezing or whistling in the chest in the last 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Have you had wheezing or whistling in the chest in the last 12 months [PhenX];Wheezing whistling chest last 12Mo PhenX;;TRIAL;2.36;2.65 +64265-2;How many attacks of wheezing have you had in the last 12Mo;NRat;12Mo;^Patient;Ord;PhenX;PHENX;2;How many attacks of wheezing have you had in the last 12 months [PhenX];Wheezing times 12Mo PhenX;;TRIAL;2.36;2.65 +64266-0;In the last 12Mo, how often, on average, has your sleep been disturbed due to wheezing;NRat;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, how often, on average, has your sleep been disturbed due to wheezing [PhenX];Wheezing sleep disturb 12Mo PhenX;;TRIAL;2.36;2.65 +64267-8;In the last 12Mo, has wheezing ever been severe enough to limit your speech to only one or two words at a time between breaths;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, has wheezing ever been severe enough to limit your speech to only one or two words at a time between breaths [PhenX];Wheezing limit speech 12Mo PhenX;;TRIAL;2.36;2.65 +64268-6;In the last 12Mo, has your chest sounded wheezy during or after exercise;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, has your chest sounded wheezy during or after exercise [PhenX];Wheezy chest exercise 12Mo PhenX;;TRIAL;2.36;2.65 +64269-4;In the last 12Mo, have you had a dry cough at night, apart from a cough associated with a cold or chest infection;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, have you had a dry cough at night, apart from a cough associated with a cold or chest infection [PhenX];Dry cough night 12Mo PhenX;;TRIAL;2.36;2.65 +64270-2;Have you ever had a problem with sneezing, or a runny or blocked nose, when you did not have a cold or the flu;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had a problem with sneezing, or a runny or blocked nose, when you did not have a cold or the flu [PhenX];Hx sneezing blocked runny nose PhenX;;TRIAL;2.36;2.65 +64271-0;In the past 12Mo, have you had a problem with sneezing, or a runny or blocked nose, when you did not have a cold or the flu;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, have you had a problem with sneezing, or a runny or blocked nose, when you did not have a cold or the flu [PhenX];Hx sneezing runny blocked nose PhenX;;TRIAL;2.36;2.65 +64272-8;In the past 12Mo, has this nose problem been accompanied by itchy or watery eyes;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, has this nose problem been accompanied by itchy or watery eyes [PhenX];Nose itchy eyes 12Mo 13 PhenX;;TRIAL;2.36;2.65 +64273-6;In which of the past 12Mo did this nose problem occur;Find;12Mo;^Patient;Nom;PhenX;PHENX;2;In which of the past 12 months did this nose problem occur [PhenX];Nose problem occur Mos 13 PhenX;;TRIAL;2.36;2.65 +64274-4;In the past 12Mo, how much did this nose problem interfere with your daily activities;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, how much did this nose problem interfere with your daily activities [PhenX];Nose interfere activities 12Mo 13 PhenX;;TRIAL;2.36;2.65 +64275-1;Have you ever had an itchy rash which was coming and going for at least 6Mo;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had an itchy rash which was coming and going for at least 6 months [PhenX];Itchy rash ever PhenX;;TRIAL;2.36;2.65 +64276-9;Have you had this itchy rash at any time in the last 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Have you had this itchy rash at any time in the last 12 months [PhenX];Itchy rash last 12Mo PhenX;;TRIAL;2.36;2.65 +64277-7;Has this itchy rash at any time affected any of the following places - the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears, or eyes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has this itchy rash at any time affected any of the following places - the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears, or eyes [PhenX];Itchy rash places PhenX;;TRIAL;2.36;2.65 +64278-5;Has this itchy rash cleared completely at any time during the last 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Has this itchy rash cleared completely at any time during the last 12 months [PhenX];Itchy rash cleared completely PhenX;;TRIAL;2.36;2.65 +6427-9;Histoplasma capsulatum Ab;PrThr;Pt;Ser;Ord;LA;MICRO;1;Histoplasma capsulatum Ab [Presence] in Serum by Latex agglutination;H capsul Ab Ser Ql LA;;ACTIVE;1.0f;2.56 +64279-3;In the last 12Mo, how often, on average, have you been kept awake at night by this itchy rash;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, how often, on average, have you been kept awake at night by this itchy rash [PhenX];Itchy rash awake night 13 PhenX;;TRIAL;2.36;2.65 +64280-1;Have you ever had eczema;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had eczema [PhenX];Eczema ever PhenX;;TRIAL;2.36;2.65 +64281-9;Has your child ever had wheezing or whistling in the chest at any time in the past;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had wheezing or whistling in the chest at any time in the past [PhenX];Child wheezing chest ever PhenX;;TRIAL;2.36;2.65 +64282-7;Has your child had wheezing or whistling in the chest in the last 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Has your child had wheezing or whistling in the chest in the last 12 months [PhenX];Child wheezing last 12Mo PhenX;;TRIAL;2.36;2.65 +64283-5;How many attacks of wheezing has your child had in the last 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;How many attacks of wheezing has your child had in the last 12 months [PhenX];Child wheezing times 12Mo PhenX;;TRIAL;2.36;2.65 +64284-3;Readiness for military duty assessment note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Readiness for duty assessment;Readiness for duty assessment;;ACTIVE;2.36;2.67 +64285-0;Medical history screening form;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Medical history screening form;Medical Hx screening form;;ACTIVE;2.36;2.67 +64286-8;Diagnostic imaging order;Find;Pt;{Setting};Doc;{Provider};DOC.MISC;2;Deprecated Diagnostic imaging order;Deprecated Diagnostic imaging order;;DEPRECATED;2.36;2.73 +6428-7;Histoplasma capsulatum Ag;ACnc;Pt;Ser;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Units/volume] in Serum by Immunoassay;H capsul Ag Ser IA-aCnc;;ACTIVE;1.0f;2.73 +64287-6;Prescription;Find;Pt;^Patient;Doc;;DOC.MISC;2;Deprecated Prescription;Deprecated Prescription;;DEPRECATED;2.36;2.73 +64288-4;Prescription for eyewear;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Prescription for eyewear;Prescription for eyewear;;ACTIVE;2.36;2.67 +64289-2;Health record cover sheet;Find;Pt;{Setting};Doc;;DOC.MISC;2;Health record cover sheet;Health record cover sheet;;ACTIVE;2.36;2.73 +642-9;Microscopic observation;Prid;Pt;Gast fld;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Gastric fluid by Acid fast stain.Ziehl-Neelsen;ZN Stn Gast;;ACTIVE;1.0;2.21 +64290-0;Health insurance card;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Health insurance card;Health insurance card;;ACTIVE;2.36;2.67 +64291-8;Health insurance-related form;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Health insurance-related form;Health insurance-related form;;ACTIVE;2.36;2.67 +64292-6;Release of information consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Release of information consent Document;Release of information consent;;ACTIVE;2.36;2.65 +64293-4;Procedure consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Procedure consent Document;Procedure consent;;ACTIVE;2.36;2.65 +64294-2;Readiness for military duty assessment letter;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Readiness for duty letter;Readiness for duty letter;;ACTIVE;2.36;2.68 +6429-5;HIV identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;HIV identified in Blood by Organism specific culture;HIV Bld Cult;;ACTIVE;1.0f;1.0ma +64295-9;Plan of care note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Plan of care note;Nurse Plan of care note;;ACTIVE;2.36;2.67 +64296-7;Personal health monitoring report;Find;Pt;{Setting};Doc;Automated;DOC.MISC;2;Personal health monitoring report Automated;PH monitoring report Auto;;ACTIVE;2.36;2.73 +64297-5;Death certificate;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Death certificate;Death certificate;;ACTIVE;2.36;2.67 +64298-3;Power of attorney;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Power of attorney;Power of attorney;;ACTIVE;2.36;2.68 +64299-1;Legal document;Find;Pt;{Setting};Doc;;DOC.ONTOLOGY;2;Legal document;Legal document;;ACTIVE;2.36;2.67 +64300-7;Organ donation consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Organ donation consent Document;Organ donation consent;;ACTIVE;2.36;2.65 +64301-5;Full time dietitian staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time dietitian staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64302-3;Full time social worker staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time social worker staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +6430-3;HIV identified;Prid;Pt;Semen;Nom;Organism specific culture;MICRO;1;HIV identified in Semen by Organism specific culture;HIV Smn Cult;;ACTIVE;1.0f;2.19 +64303-1;Part time registered nurse staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time registered nurse staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64304-9;Part time licensed practical nurse and licensed vocational nurse staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time licensed practical nurse and licensed vocational nurse staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64305-6;Part time patient care technician staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time patient care technician staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64306-4;Part time advance practice nurse staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time advance practice nurse staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64307-2;Part time dietitian staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time dietitian staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64308-0;Part time social worker staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time social worker staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64309-8;Full time registered nurse staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time registered nurse staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64310-6;Full time licensed practical nurse and licensed vocational nurse staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time licensed practical nurse and licensed vocational nurse staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +6431-1;HIV identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;HIV identified in Specimen by Organism specific culture;HIV Spec Cult;;ACTIVE;1.0f;2.73 +64311-4;Full time patient care technician staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time patient care technician staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64312-2;Full time advanced practice nurse staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time advance practiced nurse staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64313-0;Full time dietitian staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time dietitian staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64314-8;Full time social worker staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time social worker staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64315-5;Part time registered nurse staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time registered nurse staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64316-3;Part time licensed practical nurse and licensed vocational nurse staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time licensed practical nurse and licensed vocational nurse staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64317-1;Part time patient care technician staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time patient care technician staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64318-9;Part time advance practice nurse staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time advance practice nurse staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64319-7;Part time dietitian staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time dietitian staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64320-5;Part time social worker staff positions vacant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Part time social worker staff positions vacant at end of period Population #;;;ACTIVE;2.36;2.48 +64321-3;Kidney transplant center patients who received at least one kidney transplant;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant Population #;;;ACTIVE;2.36;2.52 +64322-1;Kidney transplant center patients who received at least one kidney transplant and enrolled in Medicare;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant and enrolled in Medicare Population #;;;ACTIVE;2.36;2.52 +64323-9;End stage renal disease facility survey - OMB CMS form 2744;-;Pt;Facility;-;;PANEL.SURVEY.ESRD;4;End Stage Renal Disease (ESRD) Facility Survey - OMB CMS form 2744;;;ACTIVE;2.36;2.50 +64324-7;Dialysis stations;Num;Pt;Facility;Qn;;SURVEY.ESRD;4;Dialysis stations Facility #;;;ACTIVE;2.36;2.48 +64325-4;Incenter dialysis patients at beginning of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter dialysis patients at beginning of reporting period Population #;;;ACTIVE;2.36;2.48 +64326-2;Home dialysis patients at beginning of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Home dialysis patients at beginning of reporting period Population #;;;ACTIVE;2.36;2.48 +64327-0;Total dialysis patients at beginning of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Total dialysis patients at beginning of reporting period Population #;;;ACTIVE;2.36;2.48 +64328-8;Incenter patients starting dialysis for first time ever;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter patients starting dialysis for first time ever Population #;;;ACTIVE;2.36;2.52 +6432-9;HTLV I Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HTLV I Ab [Presence] in Serum by Immunoblot;HTLV I Ab Ser Ql IB;;ACTIVE;1.0f;2.73 +64329-6;Home patients starting dialysis for first time ever;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home patients starting dialysis for first time ever Population #;;;ACTIVE;2.36;2.52 +64330-4;Incenter patients restarting dialysis;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter patients restarting dialysis Population #;;;ACTIVE;2.36;2.52 +64331-2;Home patients restarting dialysis;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home patients restarting dialysis Population #;;;ACTIVE;2.36;2.52 +64332-0;Incenter patients transferred from other dialysis unit;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter patients transferred from other dialysis unit Population #;;;ACTIVE;2.36;2.52 +64333-8;Home patients transferred from other dialysis unit;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home patients transferred from other dialysis unit Population #;;;ACTIVE;2.36;2.52 +64334-6;Incenter patients restarting dialysis after failed transplantation;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter patients restarting dialysis after failed transplantation Population #;;;ACTIVE;2.36;2.52 +64335-3;Home patients restarting dialysis after failed transplantation;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home patients restarting dialysis after failed transplantation Population #;;;ACTIVE;2.36;2.52 +64336-1;Incenter dialysis patients who died;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter dialysis patients who died Population #;;;ACTIVE;2.36;2.52 +6433-7;HTLV I Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;HTLV I IgG Ab [Presence] in Serum by Immunoassay;HTLV I IgG Ser Ql IA;;ACTIVE;1.0f;2.56 +64337-9;Home dialysis patients who died;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home dialysis patients who died Population #;;;ACTIVE;2.36;2.52 +64338-7;Incenter dialysis patients who recovered kidney function;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter dialysis patients who recovered kidney function Population #;;;ACTIVE;2.36;2.52 +64339-5;Home dialysis patients who recovered kidney function;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home dialysis patients who recovered kidney function Population #;;;ACTIVE;2.36;2.52 +64340-3;Incenter dialysis patients who received transplant;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter dialysis patients who received transplant Population #;;;ACTIVE;2.36;2.52 +64341-1;Home dialysis patients who received transplant;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home dialysis patients who received transplant Population #;;;ACTIVE;2.36;2.52 +64342-9;Incenter patients who transferred to other dialysis unit;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter patients who transferred to other dialysis unit Population #;;;ACTIVE;2.36;2.52 +64343-7;Home patients who transferred to other dialysis unit;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home patients who transferred to other dialysis unit Population #;;;ACTIVE;2.36;2.52 +64344-5;Incenter patients who discontinued dialysis;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter patients who discontinued dialysis Population #;;;ACTIVE;2.36;2.52 +6434-5;Influenza virus A+B Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Influenza virus A+B Ab [Titer] in Serum by Immunofluorescence;FLUAV+FLUBV Ab Titr Ser IF;;ACTIVE;1.0f;2.70 +64345-2;Home patients who discontinued dialysis;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home patients who discontinued dialysis Population #;;;ACTIVE;2.36;2.52 +64346-0;Incenter dialysis patients lost to follow up;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter dialysis patients lost to follow up Population #;;;ACTIVE;2.36;2.52 +64347-8;Home dialysis patients lost to follow up;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Home dialysis patients lost to follow up Population #;;;ACTIVE;2.36;2.52 +64348-6;Incenter patients receiving hemodialysis at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients receiving hemodialysis at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64349-4;Incenter patients receiving dialysis other than hemodialysis at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients receiving dialysis other than hemodialysis at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64350-2;Incenter patients in self-dialysis hemodialysis training at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients in self-dialysis hemodialysis training at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64351-0;Incenter patients in self-dialysis Continuous Ambulatory Peritoneal Dialysis (CAPD) training at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients in self-dialysis Continuous Ambulatory Peritoneal Dialysis (CAPD) training at end of reporting period Population #;;;ACTIVE;2.36;2.48 +6435-2;Influenza virus A+B Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Influenza virus A+B Ag [Presence] in Throat by Immunoassay;FLUAV+FLUBV Ag Throat Ql IA;;ACTIVE;1.0f;2.56 +64352-8;Incenter patients in self-dialysis Continuous Cyclic Peritoneal Dialysis (CCPD) training at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients in self-dialysis Continuous Cyclic Peritoneal Dialysis (CCPD) training at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64353-6;Incenter patients in self-dialysis training other than hemodialysis, CAPD or CCPD at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients in self-dialysis training other than hemodialysis, CAPD or CCPD at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64354-4;Total incenter dialysis patients at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Total incenter dialysis patients at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64355-1;Home patients hemodialyzing at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Home patients hemodialyzing at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64356-9;Home patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Home patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64357-7;Home patients on Continuous Cyclic Peritoneal Dialysis (CCPD) at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Home patients on Continuous Cyclic Peritoneal Dialysis (CCPD) at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64358-5;Home patients who received dialysis other than hemodialysis, CAPD or CCPD at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Home patients who received dialysis other than hemodialysis, CAPD or CCPD at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64359-3;Total home dialysis patients at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Total home dialysis patients at end of reporting period Population #;;;ACTIVE;2.36;2.48 +6436-0;Influenza virus A+B Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Influenza virus A+B Ag [Presence] in Throat by Immunofluorescence;FLUAV+FLUBV Ag Throat Ql IF;;ACTIVE;1.0f;2.56 +64360-1;Total dialysis patients receiving services at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Total dialysis patients receiving services at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64361-9;Dialysis patients enrolled in Medicare at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Dialysis patients enrolled in Medicare at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64362-7;Dialysis patients who have pending enrollment in Medicare at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Dialysis patients who have pending enrollment in Medicare at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64363-5;Dialysis patients not enrolled or pending enrollment in Medicare at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Dialysis patients not enrolled or pending enrollment in Medicare at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64364-3;Incenter patients dialyzing during the day and more than 4 times per week at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients dialyzing during the day and more than 4 times per week at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64365-0;Home patients dialyzing during the day and more than 4 times per week at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Home patients dialyzing during the day and more than 4 times per week at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64366-8;Incenter patients dialyzing nocturnally and more than 4 times per week at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Incenter patients dialyzing nocturnally and more than 4 times per week at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64367-6;Home patients dialyzing nocturnally and more than 4 times per week at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Home patients dialyzing nocturnally and more than 4 times per week at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64368-4;Total patients age 18-54 Y dialysing at facility at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Total patients age 18-54 years dialysing at facility at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64369-2;Dialysis patients who have received or are receiving vocational rehabilitation services;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Dialysis patients who have received or are receiving vocational rehabilitation services Population #;;;ACTIVE;2.36;2.52 +643-7;Microscopic observation;Prid;Pt;Pus;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Pus by Gram stain;Gram Stn Pus;;ACTIVE;1.0;2.21 +64370-0;Dialysis patients age 18 to 54 Y employed full-time or part-time at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Dialysis patients age 18 to 54 years employed full-time or part-time at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64371-8;Dialysis patients age 18 to 54 Y attending school full-time or part-time at end of reporting period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Dialysis patients age 18 to 54 years attending school full-time or part-time at end of reporting period Population #;;;ACTIVE;2.36;2.48 +64372-6;Incenter hemodialysis patients receiving treatments including training treatments;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Incenter hemodialysis patients receiving treatments including training treatments Population #;;;ACTIVE;2.36;2.52 +64373-4;Incenter dialysis patients receiving treatments other than hemodialysis including training treatments;Num;RptPeriod;^Population;Qn;Reported;SURVEY.ESRD;4;Incenter dialysis patients receiving treatments other than hemodialysis including training treatments Population # [Reported];;;ACTIVE;2.36;2.52 +64374-2;Full time registered nurse staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time registered nurse staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64375-9;Full time licensed practical nurse and licensed vocational nurse staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time licensed practical nurse and licensed vocational nurse staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64376-7;Full time patient care technician staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time patient care technician staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +64377-5;Full time advanced practice nurse staff positions filled at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Full time advanced practice nurse staff positions filled at end of period Population #;;;ACTIVE;2.36;2.48 +6437-8;Influenza virus A+B Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Influenza virus A+B Ag [Presence] in Specimen by Immunoassay;FLUAV+FLUBV Ag Spec Ql IA;;ACTIVE;1.0f;2.73 +64378-3;Kidney transplant center patients who received at least one kidney transplant with pending enrollment in Medicare at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant with pending enrollment in Medicare at end of period Population #;;;ACTIVE;2.36;2.48 +64379-1;Kidney transplant center patients who received at least one kidney transplant, who is US citizen or a foreign national US resident, and not eligible for enrollment in Medicare at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant, who is US citizen or a foreign national US resident, and not eligible for enrollment in Medicare at end of period Population #;;;ACTIVE;2.36;2.48 +64380-9;Kidney transplant center patients who received at least one kidney transplant who is neither a US citizen nor a foreign national US resident and not eligible for enrollment in Medicare at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant who is neither a US citizen nor a foreign national US resident and not eligible for enrollment in Medicare at end of period Population #;;;ACTIVE;2.36;2.48 +64381-7;Kidney transplant center patients who received at least one kidney transplant from a living related donor;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant from a living related donor Population #;;;ACTIVE;2.36;2.52 +64382-5;Kidney transplant center patients who received at least one kidney transplant from a living unrelated donor;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant from a living unrelated donor Population #;;;ACTIVE;2.36;2.52 +64383-3;Kidney transplant center patients who received at least one kidney transplant from a deceased donor;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center patients who received at least one kidney transplant from a deceased donor Population #;;;ACTIVE;2.36;2.52 +64384-1;Total kidney transplant center patients who received at least one kidney transplant;Num;RptPeriod;^Population;Qn;;SURVEY.ESRD;4;Total kidney transplant center patients who received at least one kidney transplant Population #;;;ACTIVE;2.36;2.52 +64385-8;Kidney transplant center dialysis patients who are awaiting a kidney transplant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center dialysis patients who are awaiting a kidney transplant at end of period Population #;;;ACTIVE;2.36;2.48 +6438-6;Influenza virus A+B Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Influenza virus A+B Ag [Presence] in Specimen by Immunofluorescence;FLUAV+FLUBV Ag Spec Ql IF;;ACTIVE;1.0f;2.73 +64386-6;Kidney transplant center non-dialysis patients who are awaiting a kidney transplant at end of period;Num;Pt;^Population;Qn;;SURVEY.ESRD;4;Kidney transplant center non-dialysis patients who are awaiting a kidney transplant at end of period Population #;;;ACTIVE;2.36;2.48 +64387-4;PhenX measure - balance;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - balance;;;DEPRECATED;2.36;2.46 +64388-2;PhenX - balance protocol 170801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - balance protocol 170801;Balance proto;;TRIAL;2.36;2.66 +64389-0;PhenX measure - fracture history;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - fracture history;;;DEPRECATED;2.36;2.46 +64390-8;PhenX - fracture history protocol 170901;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - fracture history protocol 170901;Fracture hx proto;;TRIAL;2.36;2.66 +64391-6;PhenX measure - systemic lupus erythematosus;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated Phenx measure - systemic lupus erythematosus;;;DEPRECATED;2.36;2.46 +64392-4;PhenX - systemic lupus erythematosus protocol 171001;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - systemic lupus erythematosus protocol 171001;Lupus SLE proto;;TRIAL;2.36;2.66 +64393-2;PhenX measure - perceived stress;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - perceived stress;;;DEPRECATED;2.36;2.46 +6439-4;Influenza virus A+B+C Ag;PrThr;Pt;Thrt;Ord;IA;MICRO;1;Influenza virus A+B+C Ag [Presence] in Throat by Immunoassay;FLUAV+FLUBV+FLUCV Ag Throat Ql IA;;ACTIVE;1.0f;2.56 +64394-0;PhenX - perceived stress protocol 180801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - perceived stress protocol 180801;Perceived stress proto;;TRIAL;2.36;2.66 +64395-7;PhenX measure - social capitol;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Deprecated PhenX measure - social capitol;;;DEPRECATED;2.36;2.46 +64396-5;PhenX - social capitol protocol 181501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - social capitol protocol 181501;Social capitol proto;;TRIAL;2.36;2.66 +64397-3;In the last 12Mo, how often, on average, has your childs sleep been disturbed due to wheezing;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, how often, on average, has your childs sleep been disturbed due to wheezing [PhenX];Child wheeze sleep disturb 12Mo PhenX;;TRIAL;2.36;2.65 +64398-1;In the last 12Mo, has wheezing ever been severe enough to limit your childs speech to only one or two words at a time between breaths;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, has wheezing ever been severe enough to limit your childs speech to only one or two words at a time between breaths [PhenX];Child wheeze limit speech 12Mo PhenX;;TRIAL;2.36;2.65 +64399-9;Has your child ever had asthma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had asthma [PhenX];Asthma ever 6 PhenX;;TRIAL;2.36;2.65 +64400-5;In the last 12Mo, has your childs chest sounded wheezy during or after exercise;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, has your childs chest sounded wheezy during or after exercise [PhenX];Child wheeze exercise 12Mo PhenX;;TRIAL;2.36;2.65 +64401-3;In the last 12Mo, has your child had a dry cough at night, apart from a cough associated with a cold or chest infection;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, has your child had a dry cough at night, apart from a cough associated with a cold or chest infection [PhenX];Dry cough night 12Mo child PhenX;;TRIAL;2.36;2.65 +6440-2;Influenza virus A+B+C Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Influenza virus A+B+C Ag [Presence] in Throat by Immunofluorescence;FLUAV+FLUBV+FLUCV Ag Throat Ql IF;;ACTIVE;1.0f;2.56 +64402-1;Has your child ever had a problem with sneezing, or a runny or blocked nose, when he or she did not have a cold or the flu;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had a problem with sneezing, or a runny or blocked nose, when he or she did not have a cold or the flu [PhenX];Sneeze runny nose ever 6 PhenX;;TRIAL;2.36;2.65 +64403-9;In the past 12Mo, has your child had a problem with sneezing, or a runny or blocked nose, when he or she did not have a cold or the flu;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, has your child had a problem with sneezing, or a runny or blocked nose, when he or she did not have a cold or the flu [PhenX];Sneeze runny nose 12Mo 6 PhenX;;TRIAL;2.36;2.65 +64404-7;In the past 12Mo, has this nose problem been accompanied by itchy, watery eyes;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, has this nose problem been accompanied by itchy, watery eyes [PhenX];Nose itchy eyes 12Mo 6 PhenX;;TRIAL;2.36;2.65 +64405-4;In the past 12Mo, how much did this nose problem interfere with your childs daily activities;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the past 12 months, how much did this nose problem interfere with your childs daily activities [PhenX];Nose interfere activities 12Mo 6 PhenX;;TRIAL;2.36;2.65 +64406-2;Has your child ever had hay fever;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had hay fever [PhenX];Hay fever ever 6 PhenX;;TRIAL;2.36;2.65 +64407-0;Has your child ever had an itchy rash that was coming and going for at least 6Mo;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had an itchy rash that was coming and going for at least 6 months [PhenX];Itchy rash ever 6Mo PhenX;;TRIAL;2.36;2.65 +64408-8;Has your child had this itchy rash at any time in the last 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Has your child had this itchy rash at any time in the last 12 months [PhenX];Itchy rash 12Mo PhenX;;TRIAL;2.36;2.65 +64409-6;At what age did this itchy rash first occur;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did this itchy rash first occur [PhenX];Itchy rash first age 6 PhenX;;TRIAL;2.36;2.65 +6441-0;Influenza virus A+B+C Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Influenza virus A+B+C Ag [Presence] in Specimen by Immunoassay;FLUAV+FLUBV+FLUCV Ag Spec Ql IA;;ACTIVE;1.0f;2.69 +64410-4;In the last 12Mo, how often, on average, has your child been kept awake at night by this itchy rash;NRat;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, how often, on average, has your child been kept awake at night by this itchy rash [PhenX];Itchy rash awake 12Mo 6 PhenX;;TRIAL;2.36;2.65 +64411-2;Has your child ever had eczema;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had eczema [PhenX];Eczema ever 6 PhenX;;TRIAL;2.36;2.65 +64412-0;Mycobacterium sp;PrThr;Pt;Bld;Ord;Organism specific culture;MICRO;1;Mycobacterium sp [Presence] in Blood by Organism specific culture;Mycobacterium Bld Ql Cult;;ACTIVE;2.36;2.73 +64413-8;KIR gene allele 2DL1;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DL1 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DL1 Bld/T Ql;;ACTIVE;2.36;2.73 +64414-6;KIR gene allele 2DL2;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DL2 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DL2 Bld/T Ql;;ACTIVE;2.36;2.73 +64415-3;KIR gene allele 2DL3;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DL3 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DL3 Bld/T Ql;;ACTIVE;2.36;2.73 +64416-1;KIR gene allele 2DL4;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DL4 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DL4 Bld/T Ql;;ACTIVE;2.36;2.73 +64417-9;Fragile X protein (FMRP);Imp;Pt;Bld;Nom;;PATH;1;Fragile X protein (FMRP) [Interpretation] in Blood;Fragile X protein (FMRP) Bld-Imp;;ACTIVE;2.36;2.73 +64418-7;KIR genotyping panel;-;Pt;Bld/Tiss;-;;PANEL.MOLPATH;1;KIR genotyping panel - Blood or Tissue;KIR pnl Bld/T;;ACTIVE;2.36;2.42 +64419-5;KIR gene allele 2DL5;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DL5 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DL5 Bld/T Ql;;ACTIVE;2.36;2.73 +64420-3;KIR gene allele 2DS1;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DS1 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DS1 Bld/T Ql;;ACTIVE;2.36;2.73 +64421-1;KIR gene allele 2DS2;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DS2 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DS2 Bld/T Ql;;ACTIVE;2.36;2.73 +64422-9;KIR gene allele 2DS3;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DS3 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DS3 Bld/T Ql;;ACTIVE;2.36;2.73 +64423-7;KIR2DS4 gene full variant;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR2DS4 gene full variant [Presence] in Blood or Tissue by Molecular genetics method;KIR2DS4 full variant Bld/T Ql;;ACTIVE;2.36;2.73 +64424-5;KIR2DS4 gene deletion variant;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR2DS4 gene deletion variant [Presence] in Blood or Tissue by Molecular genetics method;KIR2DS4 del variant Bld/T Ql;;ACTIVE;2.36;2.73 +64425-2;KIR gene allele 2DS5;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DS5 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DS5 Bld/T Ql;;ACTIVE;2.36;2.73 +64426-0;KIR gene allele 3DL1;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 3DL1 [Presence] in Blood or Tissue by Molecular genetics method;KIR 3DL1 Bld/T Ql;;ACTIVE;2.36;2.73 +64427-8;KIR gene allele 3DL2;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 3DL2 [Presence] in Blood or Tissue by Molecular genetics method;KIR 3DL2 Bld/T Ql;;ACTIVE;2.36;2.73 +6442-8;Influenza virus A+B+C Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Influenza virus A+B+C Ag [Presence] in Specimen by Immunofluorescence;FLUAV+FLUBV+FLUCV Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +64428-6;KIR gene allele 3DL3;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 3DL3 [Presence] in Blood or Tissue by Molecular genetics method;KIR 3DL3 Bld/T Ql;;ACTIVE;2.36;2.73 +64429-4;KIR gene allele 3DS1;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 3DS1 [Presence] in Blood or Tissue by Molecular genetics method;KIR 3DS1 Bld/T Ql;;ACTIVE;2.36;2.73 +64430-2;KIR gene allele 2DP1;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR gene allele 2DP1 [Presence] in Blood or Tissue by Molecular genetics method;KIR 2DP1 Bld/T Ql;;ACTIVE;2.36;2.73 +64431-0;KIR3DP1 gene full variant;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR3DP1 gene full variant [Presence] in Blood or Tissue by Molecular genetics method;KIR3DP1 full variant Bld/T Ql;;ACTIVE;2.36;2.73 +64432-8;KIR3DP1 gene deletion variant;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;KIR3DP1 gene deletion variant [Presence] in Blood or Tissue by Molecular genetics method;KIR3DP1 del variant Bld/T Ql;;ACTIVE;2.36;2.73 +64433-6;Fragile X protein (FMRP) panel;-;Pt;Bld;-;;PANEL.PATH;1;Fragile X protein (FMRP) panel - Blood;Fragile X protein (FMRP) pnl Bld;;ACTIVE;2.36;2.42 +64434-4;Medication;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Medication [PhenX];Medication oximetry;;TRIAL;2.36;2.65 +64435-1;Medication time and date^pre exercise;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;Medication time and date [PhenX] --Pre excercise;Medication time date pre Exc PhenX;;TRIAL;2.36;2.65 +6443-6;Lactoferrin;PrThr;Pt;Stool;Ord;LA;CHEM;1;Lactoferrin [Presence] in Stool by Latex agglutination;Lactoferrin Stl Ql LA;;ACTIVE;1.0f;2.73 +64436-9;Clinical or research indication for test;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Clinical or research indication for test [PhenX];Indication for test PhenX;;TRIAL;2.36;2.73 +64437-7;Contraindications for test;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Contraindications for test [PhenX];Contraindications for test PhenX;;TRIAL;2.36;2.65 +64438-5;How do you describe your current health;Find;Pt;^Patient;Ord;;PHENX;2;How do you describe your current health;Health self assess;;TRIAL;2.36;2.65 +64439-3;Over the past 3Mo, I have coughed;Find;3Mo;^Patient;Ord;PhenX;PHENX;2;Over the past 3 months, I have coughed [PhenX];Freq 3Mo cough PhenX;;TRIAL;2.36;2.65 +64440-1;Over the past 3Mo, I have brought up phlegm - sputum;Find;3Mo;^Patient;Ord;PhenX;PHENX;2;Over the past 3 months, I have brought up phlegm - sputum [PhenX];Freq 3Mo phlegm - sputum PhenX;;TRIAL;2.36;2.65 +64441-9;Over the past 3Mo, I have had shortness of breath;Find;3Mo;^Patient;Ord;PhenX;PHENX;2;Over the past 3 months, I have had shortness of breath [PhenX];Freq 3Mo breath shortness PhenX;;TRIAL;2.36;2.65 +64442-7;Over the past 3Mo, I have had attacks of wheezing;Find;3Mo;^Patient;Ord;PhenX;PHENX;2;Over the past 3 months, I have had attacks of wheezing [PhenX];Freq 3Mo wheezing PhenX;;TRIAL;2.36;2.65 +64443-5;During the past 3Mo, how many severe or very unpleasant attacks of chest trouble have you had;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;During the past 3 months, how many severe or very unpleasant attacks of chest trouble have you had [PhenX];3Mo chest attacks times nRate PhenX;;TRIAL;2.36;2.65 +6444-4;Lactoferrin;PrThr;Pt;XXX;Ord;LA;CHEM;1;Lactoferrin [Presence] in Specimen by Latex agglutination;Lactoferrin Spec Ql LA;;ACTIVE;1.0f;2.69 +64444-3;How long did the worst attack of chest trouble last;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long did the worst attack of chest trouble last [PhenX];Worst chest attack last PhenX;;TRIAL;2.36;2.65 +64445-0;Over the past 3Mo, in an average W, how many good Ds, with little chest trouble, have you had;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;Over the past 3 months, in an average week, how many good days, with little chest trouble, have you had [PhenX];Good Ds in W PhenX;;TRIAL;2.36;2.65 +64446-8;If you have a wheeze, is it worse in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If you have a wheeze, is it worse in the morning [PhenX];Wheeze worse in morning PhenX;;TRIAL;2.36;2.65 +64447-6;How would you describe your chest condition;Find;Pt;^Patient;Nom;PhenX;PHENX;2;How would you describe your chest condition [PhenX];Chest self assess PhenX;;TRIAL;2.36;2.65 +64448-4;If you have ever had paid employment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If you have ever had paid employment [PhenX];Chest trouble affect employ PhenX;;TRIAL;2.36;2.65 +64449-2;My cough hurts;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My cough hurts [PhenX];My cough hurts PhenX;;TRIAL;2.36;2.65 +644-5;Microscopic observation;Prid;Pt;Skin;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Skin by KOH preparation;KOH Prep Skin;;ACTIVE;1.0;2.73 +64450-0;My cough makes me tired;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My cough makes me tired [PhenX];Cough breathless tired PhenX;;TRIAL;2.36;2.65 +6445-1;Legionella pneumophila Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Legionella pneumophila Ag [Presence] in Sputum by Immunofluorescence;L pneumo Ag Spt Ql IF;;ACTIVE;1.0f;2.56 +64451-8;I am breathless when I talk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am breathless when I talk [PhenX];Cough breathless talk PhenX;;TRIAL;2.36;2.65 +64452-6;I am breathless when I bend over;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am breathless when I bend over [PhenX];Cough breathless bend over PhenX;;TRIAL;2.36;2.65 +64453-4;My cough or breathing disturbs my sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My cough or breathing disturbs my sleep [PhenX];Cough breathless disturb sleep PhenX;;TRIAL;2.36;2.65 +64454-2;I get exhausted easily;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I get exhausted easily [PhenX];Get exhausted easily PhenX;;TRIAL;2.36;2.65 +64455-9;My cough or breathing is embarrassing in public;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My cough or breathing is embarrassing in public [PhenX];Chest effect embarrassing PhenX;;TRIAL;2.36;2.65 +64456-7;My chest trouble is a nuisance to my family, friends or neighbors;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My chest trouble is a nuisance to my family, friends or neighbors [PhenX];Chest effect nuisance PhenX;;TRIAL;2.36;2.65 +64457-5;I get afraid or panic when I cannot get my breath;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I get afraid or panic when I cannot get my breath [PhenX];Chest effect afraid panic PhenX;;TRIAL;2.36;2.65 +64458-3;I feel that I am not in control of my chest problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel that I am not in control of my chest problem [PhenX];Chest effect no control PhenX;;TRIAL;2.36;2.65 +64459-1;I do not expect my chest to get any better;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I do not expect my chest to get any better [PhenX];Chest effect not get better PhenX;;TRIAL;2.36;2.65 +64460-9;I have become frail or an invalid because of my chest;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have become frail or an invalid because of my chest [PhenX];Chest effect frail invalid PhenX;;TRIAL;2.36;2.65 +64461-7;Exercise is not safe for me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Exercise is not safe for me [PhenX];Exercise not safe PhenX;;TRIAL;2.36;2.65 +64462-5;Everything seems too much of an effort;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Everything seems too much of an effort [PhenX];Chest effect everything effort PhenX;;TRIAL;2.36;2.65 +64463-3;My medication does not help me very much;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My medication does not help me very much [PhenX];Medication not help PhenX;;TRIAL;2.36;2.65 +64464-1;I get embarrassed using my medication in public;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I get embarrassed using my medication in public [PhenX];Medication embarrassing PhenX;;TRIAL;2.36;2.65 +64465-8;I have unpleasant side effects from my medication;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have unpleasant side effects from my medication [PhenX];Medication unpleasant effects PhenX;;TRIAL;2.36;2.65 +64466-6;My medication interferes with my life a lot;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My medication interferes with my life a lot [PhenX];Medication interfere life PhenX;;TRIAL;2.36;2.65 +64467-4;I take a long time to get washed or dressed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I take a long time to get washed or dressed [PhenX];Activities affect washed dressed PhenX;;TRIAL;2.36;2.65 +64468-2;I cannot take a bath or shower, or I take a long time;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I cannot take a bath or shower, or I take a long time [PhenX];Activities affect bath shower PhenX;;TRIAL;2.36;2.65 +6446-9;Legionella pneumophila Ag;PrThr;Pt;Sputum;Ord;LA;MICRO;1;Legionella pneumophila Ag [Presence] in Sputum by Latex agglutination;L pneumo Ag Spt Ql LA;;ACTIVE;1.0f;2.56 +64469-0;I walk slower than other people, or I stop for rests;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I walk slower than other people, or I stop for rests [PhenX];Activities affect walk stop PhenX;;TRIAL;2.36;2.65 +64470-8;Jobs such as housework take a long time, or I have to stop for rests;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Jobs such as housework take a long time, or I have to stop for rests [PhenX];Activities affect housework stop PhenX;;TRIAL;2.36;2.65 +64471-6;If I walk up one flight of stairs, I have to go slowly or stop;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If I walk up one flight of stairs, I have to go slowly or stop [PhenX];Activities affect upstairs stop PhenX;;TRIAL;2.36;2.65 +64472-4;If I hurry or walk fast, I have to stop or slow down;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If I hurry or walk fast, I have to stop or slow down [PhenX];Activities affect hurry fast stop PhenX;;TRIAL;2.36;2.65 +64473-2;My breathing makes it difficult to do things such as walk up hills, carrying things up stairs, light gardening such as weeding, dance, play bowls or play golf;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My breathing makes it difficult to do things such as walk up hills, carrying things up stairs, light gardening such as weeding, dance, play bowls or play golf [PhenX];Breathing diff activ light PhenX;;TRIAL;2.36;2.65 +64474-0;My breathing makes it difficult to do things such as carry heavy loads, dig the garden or shovel snow, jog or walk at 5 miles per H, play tennis or swim;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My breathing makes it difficult to do things such as carry heavy loads, dig the garden or shovel snow, jog or walk at 5 miles per H, play tennis or swim [PhenX];Breathing diff activ heavy PhenX;;TRIAL;2.36;2.65 +64475-7;My breathing makes it difficult to do things such as very heavy manual work, run, cycle, swim fast or play competitive sport;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My breathing makes it difficult to do things such as very heavy manual work, run, cycle, swim fast or play competitive sport [PhenX];Breathing diff activ very heavy PhenX;;TRIAL;2.36;2.65 +64476-5;I cannot play sports or games;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I cannot play sports or games [PhenX];Daily no sports games PhenX;;TRIAL;2.36;2.65 +6447-7;Legionella pneumophila Ag;PrThr;Pt;Urine;Ord;IA;MICRO;1;Legionella pneumophila Ag [Presence] in Urine by Immunoassay;L pneumo Ag Ur Ql IA;;ACTIVE;1.0f;2.73 +64477-3;I cannot go out for entertainment or recreation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I cannot go out for entertainment or recreation [PhenX];Daily no entertainment recreation PhenX;;TRIAL;2.36;2.65 +64478-1;I cannot go out of the house to do the shopping;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I cannot go out of the house to do the shopping [PhenX];Daily no shopping PhenX;;TRIAL;2.36;2.65 +64479-9;I cannot do housework;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I cannot do housework [PhenX];Daily no housework PhenX;;TRIAL;2.36;2.65 +64480-7;I cannot move far from my bed or chair;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I cannot move far from my bed or chair [PhenX];Daily no move bed chair PhenX;;TRIAL;2.36;2.65 +64481-5;Write in any other important activities that your chest trouble may stop you doing;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Write in any other important activities that your chest trouble may stop you doing [PhenX];Chest affect daily specify PhenX;;TRIAL;2.36;2.65 +64482-3;Which do you think best describes how your chest affects you;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which do you think best describes how your chest affects you [PhenX];Chest affects description PhenX;;TRIAL;2.36;2.65 +64483-1;Infant awake;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Infant awake [PhenX];Infant awake PhenX;;TRIAL;2.36;2.65 +64484-9;Respiratory depth comments;Imp;Pt;^Patient;Nom;;PHENX;2;Deprecated Respiratory depth comments;Deprecated Resp depth comment Imp;;DEPRECATED;2.36;2.44 +6448-5;Legionella pneumophila Ag;PrThr;Pt;Urine;Ord;RIA;MICRO;1;Legionella pneumophila Ag [Presence] in Urine by Radioimmunoassay (RIA);L pneumo Ag Ur Ql RIA;;ACTIVE;1.0f;2.73 +64487-2;Do you snore;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you snore [PhenX];Do you snore PhenX;;TRIAL;2.36;2.65 +64488-0;Your snoring is;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Your snoring is [PhenX];Your snoring is PhenX;;TRIAL;2.36;2.65 +64489-8;How often do you snore;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often do you snore [PhenX];Sleep apnea snore freq PhenX;;TRIAL;2.36;2.65 +64490-6;Has your snoring ever bothered other people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your snoring ever bothered other people [PhenX];Sleep apnea snore bother other PhenX;;TRIAL;2.36;2.65 +64491-4;Has anyone noticed that you quit breathing during your sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has anyone noticed that you quit breathing during your sleep [PhenX];Sleep apnea quit breathing PhenX;;TRIAL;2.36;2.65 +64492-2;How often do you feel tired or fatigued after your sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often do you feel tired or fatigued after your sleep [PhenX];Sleep apnea tired fatigued waking PhenX;;TRIAL;2.36;2.65 +6449-3;Legionella pneumophila Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Legionella pneumophila Ag [Presence] in Specimen by Latex agglutination;L pneumo Ag Spec Ql LA;;ACTIVE;1.0f;2.69 +64493-0;During your waking time, do you feel tired, fatigued, or not up to par;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During your waking time, do you feel tired, fatigued, or not up to par [PhenX];Sleep apnea tired waking PhenX;;TRIAL;2.36;2.65 +64494-8;Have you ever nodded off or fallen asleep while driving a vehicle;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever nodded off or fallen asleep while driving a vehicle [PhenX];Sleep apnea asleep driving PhenX;;TRIAL;2.36;2.65 +64495-5;How often does this nodding off or falling alseep while driving occur;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often does this nodding off or falling alseep while driving occur [PhenX];Sleep apnea sleep drive freq PhenX;;TRIAL;2.36;2.65 +64496-3;Do you have high blood pressure;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have high blood pressure [PhenX];Sleep apnea high B/P PhenX;;TRIAL;2.36;2.73 +64497-1;Where are you completing this questionnaire;Loc;Pt;^Patient;Nom;;ADMIN;2;Where are you completing this questionnaire [Location];Interview location;;ACTIVE;2.36;2.72 +64498-9;Medication dose^pre exercise;Find;Pt;^Patient;Nar;PhenX;PHENX;2;Medication dose Narrative [PhenX] --Pre excercise;Medication dose pre Exc PhenX;;TRIAL;2.36;2.65 +64499-7;Medication^pre exercise;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Medication [PhenX] --Pre excercise;Medication pre Exc PhenX;;TRIAL;2.36;2.65 +64500-2;While sleeping, does your child ever snore;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While sleeping, does your child ever snore [PhenX];Child snore ever PhenX;;TRIAL;2.36;2.65 +6450-1;Legionella sp Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella sp Ab [Titer] in Serum by Immunofluorescence;Legionella Ab Titr Ser IF;;ACTIVE;1.0f;2.73 +64501-0;While sleeping, does your child ever snore more than half the time;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While sleeping, does your child ever snore more than half the time [PhenX];Child snore > half time PhenX;;TRIAL;2.36;2.65 +64502-8;While sleeping, does your child always snore;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While sleeping, does your child always snore [PhenX];Child always snore PhenX;;TRIAL;2.36;2.65 +64503-6;While sleeping, does your child snore loudly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While sleeping, does your child snore loudly [PhenX];Child snore loudly PhenX;;TRIAL;2.36;2.65 +64504-4;While sleeping, does your child have heavy or loud breathing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While sleeping, does your child have heavy or loud breathing [PhenX];Child heavy loud breathing PhenX;;TRIAL;2.36;2.65 +64505-1;While sleeping, does your child have trouble breathing, or struggle to breathe;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While sleeping, does your child have trouble breathing, or struggle to breathe [PhenX];Child struggle breathing PhenX;;TRIAL;2.36;2.65 +64506-9;Have you ever seen your child stop breathing during the night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever seen your child stop breathing during the night [PhenX];Child stop breathing ever PhenX;;TRIAL;2.36;2.65 +64507-7;Have you ever been concerned about your childs breathing during sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been concerned about your childs breathing during sleep [PhenX];Concern child breathing ever PhenX;;TRIAL;2.36;2.65 +64508-5;Have you ever had to shake your sleeping child to get him or her to breathe, or wake up and breathe;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had to shake your sleeping child to get him or her to breathe, or wake up and breathe [PhenX];Shake wake sleeping child PhenX;;TRIAL;2.36;2.65 +64509-3;Have you ever seen your child wake up with a snorting sound;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever seen your child wake up with a snorting sound [PhenX];Child wake snorting PhenX;;TRIAL;2.36;2.65 +64510-1;Does your child have restless sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have restless sleep [PhenX];Child restless sleep PhenX;;TRIAL;2.36;2.65 +64511-9;Does your child describe restlessness of the legs when in bed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Child restless legs bed [PhenX];Child describe restless legs bed PhenX;;TRIAL;2.36;2.65 +64512-7;Does your child have growing pains - unexplained leg pains;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have growing pains - unexplained leg pains [PhenX];Child growing leg pains PhenX;;TRIAL;2.36;2.65 +64513-5;Does your child have growing pains that are worst in bed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have growing pains that are worst in bed [PhenX];Child growing pains worst bed PhenX;;TRIAL;2.36;2.65 +64514-3;While your child sleeps, have you seen brief kicks of one leg or both legs;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While your child sleeps, have you seen brief kicks of one leg or both legs [PhenX];Child legs brief kicks PhenX;;TRIAL;2.36;2.65 +64515-0;While your child sleeps, have you seen repeated kicks or jerks of the legs at regular intervals - about every 20 to 40S;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While your child sleeps, have you seen repeated kicks or jerks of the legs at regular intervals - about every 20 to 40S [PhenX];Child legs repeated kicks PhenX;;TRIAL;2.36;2.65 +64516-8;At night, does your child usually become sweaty, or do the pajamas usually become wet with perspiration;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At night, does your child usually become sweaty, or do the pajamas usually become wet with perspiration [PhenX];Child night sweat PhenX;;TRIAL;2.36;2.65 +64517-6;At night, does your child usually get out of bed for any reason;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At night, does your child usually get out of bed for any reason [PhenX];Child night out of bed PhenX;;TRIAL;2.36;2.65 +64518-4;At night, does your child usually get out of bed to urinate;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At night, does your child usually get out of bed to urinate [PhenX];Child night urinate PhenX;;TRIAL;2.36;2.65 +6451-9;Legionella sp rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Legionella sp rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated Legionella rRNA XXX Ql Prb;;DEPRECATED;1.0f;2.69 +64519-2;If your child usually gets out of bed to urinate, how many times each night, on average;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;If your child usually gets out of bed to urinate, how many times each night, on average [PhenX];Child night urinate times PhenX;;TRIAL;2.36;2.65 +645-2;Microscopic observation;Prid;Pt;Sputum;Nom;Acid fast stain.Kinyoun;MICRO;1;Microscopic observation [Identifier] in Sputum by Acid fast stain.Kinyoun;Acid fast Kiny Stn Spt;;ACTIVE;1.0;2.73 +64520-0;Does your child usually sleep with the mouth open;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child usually sleep with the mouth open [PhenX];Child sleep mouth open PhenX;;TRIAL;2.36;2.65 +64521-8;Is your child's nose usually congested or stuffed at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is your child's nose usually congested or stuffed at night [PhenX];Child night congested nose PhenX;;TRIAL;2.36;2.65 +64522-6;Do any allergies affect your childs ability to breathe through the nose;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do any allergies affect your childs ability to breathe through the nose [PhenX];Child allergy affect breathe nose PhenX;;TRIAL;2.36;2.65 +64523-4;Does your child tend to breathe through the mouth during the day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child tend to breathe through the mouth during the day [PhenX];Child breathe through mouth day PhenX;;TRIAL;2.36;2.65 +64524-2;Does your child have a dry mouth on waking up in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have a dry mouth on waking up in the morning [PhenX];Child dry mouth waking PhenX;;TRIAL;2.36;2.65 +64525-9;Does your child complain of an upset stomach at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child complain of an upset stomach at night [PhenX];Child upset stomach night PhenX;;TRIAL;2.36;2.65 +64526-7;Does your child get a burning feeling in the throat at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child get a burning feeling in the throat at night [PhenX];Child burning feeling throat night PhenX;;TRIAL;2.36;2.65 +6452-7;Leptospira interrogans Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Leptospira interrogans Ag [Presence] in Specimen by Immunofluorescence;L inter Ag Spec Ql IF;;ACTIVE;1.0f;2.69 +64527-5;Does your child grind his or her teeth at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child grind his or her teeth at night [PhenX];Child grind teeth night PhenX;;TRIAL;2.36;2.65 +64528-3;Does your child occasionally wet the bed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child occasionally wet the bed [PhenX];Child wet bed PhenX;;TRIAL;2.36;2.65 +64529-1;Has your child ever walked during sleep - sleep walking;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever walked during sleep - sleep walking [PhenX];Child sleep walking PhenX;;TRIAL;2.36;2.65 +64530-9;Have you ever heard your child talk during sleep - sleep talking;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever heard your child talk during sleep - sleep talking [PhenX];Child sleep talking PhenX;;TRIAL;2.36;2.65 +64531-7;Does your child have nightmares once a W or more on average;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have nightmares once a week or more on average [PhenX];Child nightmare PhenX;;TRIAL;2.36;2.65 +64532-5;Has your child ever woken up screaming during the night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever woken up screaming during the night [PhenX];Child wake screaming night PhenX;;TRIAL;2.36;2.65 +64533-3;Has your child ever been moving or behaving, at night, in a way that made you think your child was neither completely awake nor asleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever been moving or behaving, at night, in a way that made you think your child was neither completely awake nor asleep [PhenX];Child neither awake asleep PhenX;;TRIAL;2.36;2.65 +64534-1;Does your child have difficulty falling asleep at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have difficulty falling asleep at night [PhenX];Child diff falling asleep night PhenX;;TRIAL;2.36;2.65 +6453-5;Leptospira sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Leptospira sp identified in Blood by Organism specific culture;Leptospira Bld Cult;;ACTIVE;1.0f;1.0ma +64535-8;How long does it take your child to fall asleep at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How long does it take your child to fall asleep at night [PhenX];Child time fall asleep PhenX;;TRIAL;2.36;2.65 +64536-6;At bedtime does your child usually have difficult routines or rituals, argue a lot, or otherwise behave badly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At bedtime does your child usually have difficult routines or rituals, argue a lot, or otherwise behave badly [PhenX];Child difficult bed routines PhenX;;TRIAL;2.36;2.65 +64537-4;Does your child bang his or her head or rock his or her body when going to sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child bang his or her head or rock his or her body when going to sleep [PhenX];Child bang head rock body PhenX;;TRIAL;2.36;2.65 +64538-2;Does your child wake up more than twice a night on average;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child wake up more than twice a night on average [PhenX];Child wake multiple times PhenX;;TRIAL;2.36;2.65 +64539-0;Does your child have trouble falling back asleep if he or she wakes up at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have trouble falling back asleep if he or she wakes up at night [PhenX];Child trouble back asleep PhenX;;TRIAL;2.36;2.65 +64540-8;Does your child wake up early in the morning and have difficulty going back to sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child wake up early in the morning and have difficulty going back to sleep [PhenX];Child trouble back sleep morn PhenX;;TRIAL;2.36;2.65 +64541-6;Does the time at which your child goes to bed change a lot from day to day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does the time at which your child goes to bed change a lot from day to day [PhenX];Child bedtime change a lot PhenX;;TRIAL;2.36;2.65 +64542-4;Does the time at which your child gets up from bed change a lot from day to day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does the time at which your child gets up from bed change a lot from day to day [PhenX];Child get up change a lot PhenX;;TRIAL;2.36;2.65 +6454-3;Leptospira sp identified;Prid;Pt;CSF;Nom;Organism specific culture;MICRO;1;Leptospira sp identified in Cerebral spinal fluid by Organism specific culture;Leptospira CSF Cult;;ACTIVE;1.0f;1.0ma +64543-2;What time does your child usually go to bed during the week;ClockTime;Pt;^Patient;Qn;PhenX;PHENX;2;What time does your child usually go to bed during the week [PhenX];Time child bed weekday Clock time PhenX;;TRIAL;2.36;2.65 +64544-0;What time does your child usually go to bed on the weekend or vacation;ClockTime;Pt;^Patient;Qn;PhenX;PHENX;2;What time does your child usually go to bed on the weekend or vacation [PhenX];Time child bed weekend Clock time PhenX;;TRIAL;2.36;2.65 +64545-7;What time does your child usually get out of bed on weekday mornings;ClockTime;Pt;^Patient;Qn;PhenX;PHENX;2;What time does your child usually get out of bed on weekday mornings [PhenX];Time child up weekday Clock time PhenX;;TRIAL;2.36;2.65 +64546-5;What time does your child usually get out of bed on weekend or vacation mornings;ClockTime;Pt;^Patient;Qn;PhenX;PHENX;2;What time does your child usually get out of bed on weekend or vacation mornings [PhenX];Time child up weekend Clock time PhenX;;TRIAL;2.36;2.65 +64547-3;Does your child wake up feeling unrefreshed in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child wake up feeling unrefreshed in the morning [PhenX];Child wake up unrefreshed PhenX;;TRIAL;2.36;2.65 +64548-1;Does your child have a problem with sleepiness during the day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have a problem with sleepiness during the day [PhenX];Child sleepy problem day PhenX;;TRIAL;2.36;2.65 +64549-9;Does your child complain that he or she feels sleepy during the day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child complain that he or she feels sleepy during the day [PhenX];Child feel sleepy day PhenX;;TRIAL;2.36;2.65 +6455-0;Leptospira sp identified;Prid;Pt;Urine;Nom;Organism specific culture;MICRO;1;Leptospira sp identified in Urine by Organism specific culture;Leptospira Ur Cult;;ACTIVE;1.0f;2.19 +64550-7;Has a teacher or other supervisor commented that your child appears sleepy during the day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a teacher or other supervisor commented that your child appears sleepy during the day [PhenX];Child appear sleepy day PhenX;;TRIAL;2.36;2.65 +64551-5;Does your child usually take a nap during the day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child usually take a nap during the day [PhenX];Child usually nap day PhenX;;TRIAL;2.36;2.65 +64552-3;Is it hard to wake your child up in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is it hard to wake your child up in the morning [PhenX];Child hard wake up morn PhenX;;TRIAL;2.36;2.65 +64553-1;Does your child wake up with headaches in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child wake up with headaches in the morning [PhenX];Child wake up headache morn PhenX;;TRIAL;2.36;2.65 +64554-9;Does your child get a headache at least once a Mo, on average;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child get a headache at least once a Mo, on average [PhenX];Child headache once Mo PhenX;;TRIAL;2.36;2.65 +64555-6;Did your child stop growing at a normal rate at any time since birth;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did your child stop growing at a normal rate at any time since birth [PhenX];Child stop growing normal rate PhenX;;TRIAL;2.36;2.65 +64556-4;Does your child still have tonsils;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child still have tonsils [PhenX];Child tonsils removed PhenX;;TRIAL;2.36;2.65 +64557-2;When were your childs tonsils removed;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When were your childs tonsils removed [Date and time] [PhenX];Childs tonsil removed date PhenX;;TRIAL;2.36;2.65 +64558-0;Why were your childs tonsils removed;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Why were your childs tonsils removed [PhenX];Childs tonsils removed reason PhenX;;TRIAL;2.36;2.65 +64559-8;Has your child ever had a condition causing difficulty with breathing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had a condition causing difficulty with breathing [PhenX];Child difficulty breathing ever PhenX;;TRIAL;2.36;2.65 +64560-6;Has your child ever had surgery;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever had surgery [PhenX];Child surgery ever PhenX;;TRIAL;2.36;2.65 +64561-4;Did any difficulties with breathing occur before, during, or after surgery;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did any difficulties with breathing occur before, during, or after surgery [PhenX];Child difficulty breathing surgery PhenX;;TRIAL;2.36;2.65 +64562-2;Has your child ever become suddenly weak in the legs, or anywhere else, after laughing or being surprised by something;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever become suddenly weak in the legs, or anywhere else, after laughing or being surprised by something [PhenX];Child sudden weak legs ever PhenX;;TRIAL;2.36;2.65 +64563-0;Has your child ever felt unable to move for a short period, in bed, though awake and able to look around;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever felt unable to move for a short period, in bed, though awake and able to look around [PhenX];Child unable move able ever PhenX;;TRIAL;2.36;2.65 +64564-8;Has your child felt an irresistible urge to take a nap at times, forcing him or her to stop what he or she is doing in order to sleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child felt an irresistible urge to take a nap at times, forcing him or her to stop what he or she is doing in order to sleep [PhenX];Child irresistible urge nap PhenX;;TRIAL;2.36;2.65 +64565-5;Has your child ever sensed that he or she was dreaming, seeing images or hearing sounds, while still awake;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever sensed that he or she was dreaming, seeing images or hearing sounds, while still awake [PhenX];Child sense dreaming awake ever PhenX;;TRIAL;2.36;2.65 +64566-3;Does your child drink caffeinated beverages on a typical D - cola, tea, coffee;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child drink caffeinated beverages on a typical day - cola, tea, coffee [PhenX];Child caffeinated beverage PhenX;;TRIAL;2.36;2.65 +64567-1;How many cups or cans of caffeinated beverages per D;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How many cups or cans of caffeinated beverages per day [PhenX];Child caffeinated beverage quant PhenX;;TRIAL;2.36;2.65 +6456-8;Listeria monocytogenes Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Listeria monocytogenes Ab [Titer] in Serum by Complement fixation;L monocytog Ab Titr Ser CF;;ACTIVE;1.0f;2.73 +64568-9;Does your child use any recreational drugs;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child use any recreational drugs [PhenX];Child recreational drug PhenX;;TRIAL;2.36;2.65 +64569-7;Which recreational drugs does your child use;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which recreational drugs does your child use [PhenX];Child recreational drug list PhenX;;TRIAL;2.36;2.65 +64570-5;Does your child use cigarettes, smokeless tobacco, snuff, or other tobacco products;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child use cigarettes, smokeless tobacco, snuff, or other tobacco products [PhenX];Child use cigarette tobacco PhenX;;TRIAL;2.36;2.65 +64571-3;Which tobacco products does your child use;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which tobacco products does your child use [PhenX];Child use cigarette tobacco list PhenX;;TRIAL;2.36;2.65 +64572-1;How often does your child use cigarettes, smokeless tobacco, snuff, or other tobacco products;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How often does your child use cigarettes, smokeless tobacco, snuff, or other tobacco products [PhenX];Child cigarette tobacco freq nRate PhenX;;TRIAL;2.36;2.65 +64573-9;Is your child overweight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is your child overweight [PhenX];Child overweight PhenX;;TRIAL;2.36;2.65 +64574-7;At what age did this first develop;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did this first develop [PhenX];Child overweight first age PhenX;;TRIAL;2.36;2.65 +64575-4;Has a doctor ever told you that your child has a high-arched palate, roof of the mouth;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that your child has a high-arched palate, roof of the mouth [PhenX];Child high-arched palate mouth PhenX;;TRIAL;2.36;2.65 +6457-6;DNA double strand Ab;PrThr;Pt;Ser;Ord;Crithidia luciliae IF;SERO;1;DNA double strand Ab [Presence] in Serum by Immunofluorescence (IF) Crithidia luciliae;dsDNA Ab Ser Ql CLIF;;ACTIVE;1.0f;2.73 +64576-2;Has your child ever taken Ritalin, methylphenidate, for behavioral problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever taken Ritalin, methylphenidate, for behavioral problems [PhenX];Child Ritalin ever PhenX;;TRIAL;2.36;2.65 +64577-0;Has a health professional ever said that your child has attention-deficit disorder, ADD, or attention-deficit-hyperactivity disorder, ADHD;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a health professional ever said that your child has attention-deficit disorder, ADD, or attention-deficit-hyperactivity disorder, ADHD [PhenX];Child ADD ADHD ever PhenX;;TRIAL;2.36;2.65 +64578-8;If you are currently at a clinic with your child to see a physician, what is the problem that brought you;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If you are currently at a clinic with your child to see a physician, what is the problem that brought you [PhenX];Child medical problem PhenX;;TRIAL;2.36;2.65 +64579-6;If your child has long-term medical problems, please list the three you think are most significant;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If your child has long-term medical problems, please list the three you think are most significant [PhenX];Child long term medical problem PhenX;;TRIAL;2.36;2.65 +64581-2;Please list the size, mg, or amount per dose of medication your child currently takes;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Please list the size, mg, or amount per dose of medication your child currently takes [PhenX];Child current medication dose PhenX;;TRIAL;2.36;2.65 +64582-0;How often does your child take this medication;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How often does your child take this medication [PhenX];Child current med freq nRate PhenX;;TRIAL;2.36;2.65 +64583-8;Date your child has taken this medication;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date your child has taken this medication [PhenX];Child current medication date PhenX;;TRIAL;2.36;2.65 +6458-4;Lymphocytic choriomeningitis virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Lymphocytic choriomeningitis virus Ab [Titer] in Serum by Immunofluorescence;LCMV Ab Titr Ser IF;;ACTIVE;1.0f;2.70 +64584-6;Effect this medication has on your child;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Effect this medication has on your child [PhenX];Child current medication effect PhenX;;TRIAL;2.36;2.65 +64585-3;Sleep disorders diagnosed or suspected by a physician in your child;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Sleep disorders diagnosed or suspected by a physician in your child [PhenX];Child sleep disorder dx PhenX;;TRIAL;2.36;2.65 +64586-1;Date the sleep disorder started;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date the sleep disorder started [PhenX];Child sleep disorder start date PhenX;;TRIAL;2.36;2.65 +64587-9;Is the sleep disorder still present;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is the sleep disorder still present [PhenX];Child sleep disorder still present PhenX;;TRIAL;2.36;2.65 +64588-7;Psychological, psychiatric, emotional, or behavioral problems diagnosed or suspected by a physician in your child;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Psychological, psychiatric, emotional, or behavioral problems diagnosed or suspected by a physician in your child [PhenX];Child psych behav dx PhenX;;TRIAL;2.36;2.65 +64589-5;Date the psychological, psychiatric, emotional, or behavioral problem started;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date the psychological, psychiatric, emotional, or behavioral problem started [PhenX];Child psych behav start date PhenX;;TRIAL;2.36;2.65 +64590-3;How often does your child use recreational drugs;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How often does your child use recreational drugs [PhenX];Child recreat drug freq nRate PhenX;;TRIAL;2.36;2.65 +64591-1;Data type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Data type [PhenX];Data type PhenX;;TRIAL;2.36;2.65 +6459-2;Bacteria identified;Prid;Pt;Food;Nom;Culture;MICRO;1;Bacteria identified in Food by Culture;Bacteria Food Cult;;ACTIVE;1.0f;2.17 +64592-9;FVC quality attribute;Find;Pt;Respiratory system;Nom;PhenX;PHENX;2;FVC quality attribute Respiratory system [PhenX];FVCQA Respiratory PhenX;;TRIAL;2.36;2.65 +64593-7;FEV1 quality attribute;Find;Pt;Respiratory system;Nom;PhenX;PHENX;2;FEV1 quality attribute Respiratory system [PhenX];FEV1QA Respiratory PhenX;;TRIAL;2.36;2.65 +64594-5;Effort attribute;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Effort attribute [PhenX];Effort attribute PhenX;;TRIAL;2.36;2.65 +64595-2;Deleted maneuver;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deleted maneuver [PhenX];Deleted maneuver PhenX;;TRIAL;2.36;2.65 +64596-0;Acceptable maneuver;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Acceptable maneuver [PhenX];Acceptable maneuver PhenX;;TRIAL;2.36;2.65 +64597-8;Technician quality control code;ID;Pt;^Patient;Nom;PhenX;PHENX;2;Technician quality control code [PhenX];Technician quality control code PhenX;;TRIAL;2.36;2.65 +64598-6;Computer quality code;ID;Pt;^Patient;Nom;PhenX;PHENX;2;Computer quality code [PhenX];Computer quality code PhenX;;TRIAL;2.36;2.65 +64599-4;Plateau achieved;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Plateau achieved [PhenX];Plateau achieved PhenX;;TRIAL;2.36;2.65 +64-6;Cefadroxil;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefadroxil [Susceptibility] by Minimum inhibitory concentration (MIC);Cefadroxil Islt MIC;;ACTIVE;1.0;2.19 +646-0;Microscopic observation;Prid;Pt;Sputum;Nom;Acid fast stain.Kinyoun modified;MICRO;1;Microscopic observation [Identifier] in Sputum by Acid fast stain.Kinyoun modified;Acid fast Mod Kiny Stn Spt;;ACTIVE;1.0;2.73 +6460-0;Bacteria identified;Prid;Pt;Sputum;Nom;Culture;MICRO;1;Bacteria identified in Sputum by Culture;Bacteria Spt Cult;;ACTIVE;1.0f;2.73 +64600-0;Review status;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Review status [PhenX];Review status PhenX;;TRIAL;2.36;2.65 +64601-8;Date of review;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date of review [PhenX];Date of review PhenX;;TRIAL;2.36;2.65 +64603-4;Calibration result;Find;Pt;^Patient;Ord;;PHENX;2;Calibration result;Calibration result;;TRIAL;2.36;2.65 +64604-2;Technician ID;ID;Pt;^Patient;Nom;;ADMIN;2;Technician [Identifier];Technician ID;;ACTIVE;2.36;2.66 +64605-9;Maneuver number;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Maneuver number [PhenX];Maneuver number PhenX;;TRIAL;2.36;2.65 +64606-7;Race - 2 character code;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Race - 2 character code [PhenX];Race - 2 character code PhenX;;TRIAL;2.36;2.65 +64607-5;Reference values source;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Reference values source [PhenX];Ref values source PhenX;;TRIAL;2.36;2.65 +64608-3;Testing position;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Testing position [PhenX];Testing position spirometry;;TRIAL;2.36;2.65 +64609-1;Current breast stage;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Current breast stage [PhenX];Current breast stage PhenX;;TRIAL;2.36;2.65 +64610-9;Current pubic hair stage;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Current pubic hair stage [PhenX];Current pubic hair stage PhenX;;TRIAL;2.36;2.65 +64611-7;Current stage of genital development;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Current stage of genital development [PhenX];Current stage of genital dev PhenX;;TRIAL;2.36;2.65 +64612-5;Current stage of physical development;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Current stage of physical development [PhenX];Current stage of physical dev PhenX;;TRIAL;2.36;2.65 +64613-3;Did you or your partner ever go to a doctor or other medical care provider to talk about ways to help you have a baby together;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you or your partner ever go to a doctor or other medical care provider to talk about ways to help you have a baby together [PhenX];Help have baby Dr. PhenX;;TRIAL;2.36;2.65 +64614-1;Which of the services did you or your partner have to help you have a baby together;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which of the services did you or your partner have to help you have a baby together [PhenX];Help have baby services PhenX;;TRIAL;2.36;2.65 +64615-8;When you and your partner went for medical help to have a baby together, were you ever told that you had any of the following male infertility problems;Find;Pt;^Patient;Nom;PhenX;PHENX;2;When you and your partner went for medical help to have a baby together, were you ever told that you had any of the following male infertility problems [PhenX];Help have baby infertility male PhenX;;TRIAL;2.36;2.65 +64616-6;Has a doctor or other medical care provider ever told you you had fibroid tumors or myomas in your uterus;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor or other medical care provider ever told you you had fibroid tumors or myomas in your uterus [PhenX];Had uterus fibroid tumor PhenX;;TRIAL;2.36;2.65 +64617-4;Has a doctor or other medical care provider ever told you you had endometriosis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor or other medical care provider ever told you you had endometriosis [PhenX];Had endometriosis PhenX;;TRIAL;2.36;2.65 +6461-8;Bacteria identified;Prid;Pt;Stool;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Stool by Anaerobe culture;Bacteria Stl Anaerobe Cult;;ACTIVE;1.0f;2.73 +64618-2;Have you ever had both of your tubes tied, cut, or removed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had both of your tubes tied, cut, or removed [PhenX];Tubal ligation steriliz PhenX;;TRIAL;2.36;2.65 +64619-0;Have you ever had any other operation that makes it impossible for you to have a baby;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any other operation that makes it impossible for you to have a baby [PhenX];Other sterilization operation PhenX;;TRIAL;2.36;2.65 +64620-8;As far as you know, are you completely sterile from this operation, that is, does it make it impossible for you to have a baby in the future;Find;Pt;^Patient;Ord;PhenX;PHENX;2;As far as you know, are you completely sterile from this operation, that is, does it make it impossible for you to have a baby in the future [PhenX];Completely sterile female PhenX;;TRIAL;2.36;2.65 +64621-6;Has your husband or partner ever had a vasectomy or any other operation that would make it impossible for him to father a baby in the future;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your husband or partner ever had a vasectomy or any other operation that would make it impossible for him to father a baby in the future [PhenX];Vasectomy operation PhenX;;TRIAL;2.36;2.65 +64622-4;What type of operation did husband or partner have;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What type of operation did husband or partner have [PhenX];Vasectomy operation type PhenX;;TRIAL;2.36;2.65 +64623-2;As far as you know, is he completely sterile from this operation, that is, does it make it impossible for him to father a baby in the future;Find;Pt;^Patient;Ord;PhenX;PHENX;2;As far as you know, is he completely sterile from this operation, that is, does it make it impossible for him to father a baby in the future [PhenX];Completely sterile male PhenX;;TRIAL;2.36;2.65 +64624-0;How old were you when you began using oral contraceptives;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you began using oral contraceptives [PhenX];Oral contraceptive first age PhenX;;TRIAL;2.36;2.65 +64625-7;For how long in total have you used oral contraceptives;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how long in total have you used oral contraceptives [PhenX];Oral contraceptive total Ys PhenX;;TRIAL;2.36;2.65 +6462-6;Bacteria identified;Prid;Pt;Wound;Nom;Culture;MICRO;1;Bacteria identified in Wound by Culture;Bacteria Wnd Cult;;ACTIVE;1.0f;2.73 +64626-5;Have you used any other methods of contraception;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you used any other methods of contraception [PhenX];Birth control other method PhenX;;TRIAL;2.36;2.65 +64627-3;Other method of contraception;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other method of contraception [PhenX];Other method contraception PhenX;;TRIAL;2.36;2.65 +64628-1;Are you currently using any method of birth control;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you currently using any method of birth control [PhenX];Current use method birth control PhenX;;TRIAL;2.36;2.65 +64629-9;Mark methods of birth control you are currently using;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Mark methods of birth control you are currently using [PhenX];Current birth control list PhenX;;TRIAL;2.36;2.65 +64630-7;Including any methods you may have already told me about and methods you may have used only once, during the last 12Mo, which of these methods did you and she use to prevent pregnancy or sexually transmitted diseases;Find;12Mo;^Patient;Nom;PhenX;PHENX;2;Including any methods you may have already told me about and methods you may have used only once, during the last 12 months, which of these methods did you and she use to prevent pregnancy or sexually transmitted diseases [PhenX];Prevent pregnancy STD method list PhenX;;TRIAL;2.36;2.65 +64631-5;Are you and your partner currently trying to get pregnant;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you and your partner currently trying to get pregnant [PhenX];Try pregnancy currently PhenX;;TRIAL;2.36;2.65 +64632-3;How long, how many Mo, have you and your partner been trying to get pregnant;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long, how many Mos, have you and your partner been trying to get pregnant [PhenX];Try pregnancy Mos PhenX;;TRIAL;2.36;2.65 +64633-1;Have you had a hysterectomy - womb removed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had a hysterectomy - womb removed [PhenX];Hysterectomy womb removed PhenX;;TRIAL;2.36;2.65 +6463-4;Bacteria identified;Prid;Pt;XXX;Nom;Culture;MICRO;1;Bacteria identified in Specimen by Culture;Bacteria Spec Cult;;ACTIVE;1.0f;2.73 +64634-9;How old were you when your menstrual periods began;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when your menstrual periods began [PhenX];Menstrual period began first age PhenX;;TRIAL;2.36;2.65 +64635-6;At about what age did you reach your full height;Time;Pt;^Patient;Ord;PhenX;PHENX;2;At about what age did you reach your full height [PhenX];Full height age PhenX;;TRIAL;2.36;2.65 +64636-4;Your voice changed Compared to your friends this was;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your voice changed Compared to your friends this was [PhenX];Voice changed peer comparison PhenX;;TRIAL;2.36;2.65 +64637-2;What is your age when your voice changed;Time;Pt;^Patient;Qn;PhenX;PHENX;2;What is your age when your voice changed [PhenX];Voice changed age PhenX;;TRIAL;2.36;2.65 +64638-0;Your penis started increasing in size Compared to your friends this was;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your penis started increasing in size Compared to your friends this was [PhenX];Penis size increase peer compar PhenX;;TRIAL;2.36;2.65 +64639-8;What is your age when your penis started increasing in size;Time;Pt;^Patient;Qn;PhenX;PHENX;2;What is your age when your penis started increasing in size [PhenX];Penis size increase age PhenX;;TRIAL;2.36;2.65 +64640-6;What is your age when your testicles started increasing in size;Time;Pt;^Patient;Qn;PhenX;PHENX;2;What is your age when your testicles started increasing in size [PhenX];Testicle size increase age PhenX;;TRIAL;2.36;2.65 +64641-4;You developed pubic hair Compared to your friends this was;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You developed pubic hair Compared to your friends this was [PhenX];Pubic hair peer comparison PhenX;;TRIAL;2.36;2.65 +6464-2;Microscopic observation;Prid;Pt;Cvx;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Cervix by Gram stain;Gram Stn Cvx;;ACTIVE;1.0f;2.58 +64642-2;What is your age when you developed pubic hair;Time;Pt;^Patient;Qn;PhenX;PHENX;2;What is your age when you developed pubic hair [PhenX];Pubic hair age PhenX;;TRIAL;2.36;2.65 +64643-0;Would you say these physical changes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Would you say these physical changes [PhenX];Puberty reach PhenX;;TRIAL;2.36;2.65 +64644-8;How old were you when you entered puberty, that is, when these changes began;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you entered puberty, that is, when these changes began [PhenX];Puberty began first age PhenX;;TRIAL;2.36;2.65 +64645-5;Have you used evista - raloxifene or nolvadex - tamoxifen;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you used evista - raloxifene or nolvadex - tamoxifen [PhenX];Evista Nolvadex used PhenX;;TRIAL;2.36;2.65 +64646-3;How many Mo have you used evista;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many Mos have you used evista [PhenX];Evista used Mos PhenX;;TRIAL;2.36;2.65 +64647-1;How many Mo have you used nolvadex;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many Mos have you used nolvadex [PhenX];Nolvadex used Mos PhenX;;TRIAL;2.36;2.65 +64648-9;Are you currently using evista or nolvadex;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you currently using evista or nolvadex [PhenX];Evista Nolvadex currently PhenX;;TRIAL;2.36;2.65 +64649-7;Are you currently using any over-the-counter - herbal, natural, or soy-based - preparations for hormone replacement or to treat post-menopausal symptoms;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you currently using any over-the-counter - herbal, natural, or soy-based - preparations for hormone replacement or to treat post-menopausal symptoms [PhenX];Herb natural soy ERT current PhenX;;TRIAL;2.36;2.65 +64650-5;What types of over-the-counter - herbal, natural, or soy-based - preparations for hormone;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What types of over-the-counter - herbal, natural, or soy-based - preparations for hormone [PhenX];Herbal natural soy ERT type PhenX;;TRIAL;2.36;2.65 +64651-3;Have you used prescription female hormones;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you used prescription female hormones [PhenX];Female hormone prescript used PhenX;;TRIAL;2.36;2.65 +64652-1;How many Mo did you use prescription hormones;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many months did you use prescription hormones [PhenX];Female hormone prescript Mos PhenX;;TRIAL;2.36;2.65 +64653-9;Are you currently using them - within the last Mo;Find;1Mo;^Patient;Ord;PhenX;PHENX;2;Are you currently using them - within the last month [PhenX];Female hormone currently using PhenX;;TRIAL;2.36;2.65 +64654-7;Combined hormone treatment;Type;Pt;^Patient;Nom;;H&P.HX;2;Combined hormone treatment;Combined hormone Rx;;ACTIVE;2.36;2.66 +64655-4;Estrogen hormone treatment;Type;Pt;^Patient;Nom;;H&P.HX;2;Estrogen hormone treatment;Estrogen hormone Rx;;ACTIVE;2.36;2.66 +64656-2;Other estrogen you are currently using;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other estrogen you are currently using [PhenX];Current use estrogen other PhenX;;TRIAL;2.36;2.65 +64657-0;Progesterone-progestin hormone treatment;Type;Pt;^Patient;Nom;;H&P.HX;2;Progesterone-progestin hormone treatment;Progesterone-progestin hormone Rx;;ACTIVE;2.36;2.66 +64658-8;Other progresterone you are currently using;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other progresterone you are currently using [PhenX];Current other progesterone PhenX;;TRIAL;2.36;2.65 +6465-9;Microscopic observation;Prid;Pt;Duod fld;Nom;Trichrome stain;MICRO;1;Microscopic observation [Identifier] in Duodenal fluid by Trichrome stain;Tri Stn Duod fl;;ACTIVE;1.0f;2.73 +64659-6;Other hormones currently used such as tri-est;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other hormones currently used such as tri-est [PhenX];Current use hormones other PhenX;;TRIAL;2.36;2.65 +64660-4;If you used oral conjugated estrogen, premarin, what dose did you usually take;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If you used oral conjugated estrogen, premarin, what dose did you usually take [PhenX];Oral conjugated estrogen dose PhenX;;TRIAL;2.36;2.65 +64661-2;What was your D per Mo pattern of oral or patch estrogen use;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;What was your day per month pattern of oral or patch estrogen use [PhenX];Estrogen pattern use PhenX;;TRIAL;2.36;2.65 +64662-0;What was your D per Mo pattern of progesterone use;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;What was your day per month pattern of progesterone use [PhenX];Progesterone pattern use PhenX;;TRIAL;2.36;2.65 +64663-8;Have you ever had the HPV vaccination;Find;Pt;^Patient;Ord;;VACCIN;2;Have you ever had the HPV vaccination;HPV vaccination ever;;ACTIVE;2.36;2.68 +64664-6;Age when received human papillomavirus vaccination;Time;Pt;^Patient;Qn;;VACCIN;2;Age when received human papillomavirus vaccination;Age when received HPV vaccine;;ACTIVE;2.36;2.68 +64665-3;Number of human papillomavirus vaccine doses received;Num;Pt;^Patient;Qn;;VACCIN;2;Number of HPV doses received;HPV vaccine doses received;;ACTIVE;2.36;2.68 +64666-1;Were you born with one or both of your testicles undescended - not completely down in the scrotum;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were you born with one or both of your testicles undescended - not completely down in the scrotum [PhenX];Undescended testicle born PhenX;;TRIAL;2.36;2.65 +6466-7;Microscopic observation;Prid;Pt;Duod fld;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Duodenal fluid by Wet preparation;Wet Prep Duod fl;;ACTIVE;1.0f;2.21 +64667-9;Which testicle was this;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which testicle was this [PhenX];Which testicle PhenX;;TRIAL;2.36;2.65 +64668-7;Did the testicle go down to the scrotum by itself;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did the testicle go down to the scrotum by itself [PhenX];Undescended testicle down itself PhenX;;TRIAL;2.36;2.65 +64669-5;Did you receive treatment;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you receive treatment [PhenX];Did you receive treatment PhenX;;TRIAL;2.36;2.65 +64670-3;What treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What treatment [PhenX];What treatment PhenX;;TRIAL;2.36;2.65 +64671-1;Other treatment for undescended testicle;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other treatment for undescended testicle [PhenX];Undescended testicle tx other PhenX;;TRIAL;2.36;2.71 +64672-9;Has your doctor or another health care provider ever told you that you had other diseases of the penis, testicles, urinary tract or scrotum;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your doctor or another health care provider ever told you that you had other diseases of the penis, testicles, urinary tract or scrotum [PhenX];Other penis testicles disease PhenX;;TRIAL;2.36;2.65 +64673-7;Disease of the penis, testicles, urinary tract or scrotum;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Disease of the penis, testicles, urinary tract or scrotum [PhenX];Penis testicles scrotum diseas PhenX;;TRIAL;2.36;2.65 +64674-5;Has your doctor or another health care provider ever told you that you had hypospadius;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your doctor or another health care provider ever told you that you had hypospadius [PhenX];Hypospadius ever PhenX;;TRIAL;2.36;2.65 +6467-5;Microscopic observation;Prid;Pt;Genital fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Genital fluid by Gram stain;Gram Stn Genital fl;;ACTIVE;1.0f;2.21 +64675-2;What was your most recent treatment or medication, if any;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What was your most recent treatment or medication, if any [PhenX];Most treatment medication PhenX;;TRIAL;2.36;2.65 +64676-0;What Y was your most recent treatment or medication, if any;Date;Pt;^Patient;Qn;PhenX;PHENX;2;What year was your most recent treatment or medication, if any [PhenX];Most treatment Y PhenX;;TRIAL;2.36;2.65 +64677-8;How often did you have difficulty with achieving an erection;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you have difficulty with achieving an erection [PhenX];Difficulty achieve erection PhenX;;TRIAL;2.36;2.65 +64678-6;How often did you have difficulty with ejaculating too early;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you have difficulty with ejaculating too early [PhenX];Difficult ejaculating early PhenX;;TRIAL;2.36;2.65 +64679-4;How often did you have difficulty ejaculating;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you have difficulty ejaculating [PhenX];Difficult ejaculating freq PhenX;;TRIAL;2.36;2.65 +64680-2;How often did you have difficulty with lack of interest in sex;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you have difficulty with lack of interest in sex [PhenX];Lack interest sex freq PhenX;;TRIAL;2.36;2.65 +64681-0;Over the past 4W how often were you able to get an erection during sexual activity;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how often were you able to get an erection during sexual activity [PhenX];Erection during sex PhenX;;TRIAL;2.36;2.65 +64682-8;Over the past 4W when you had erections with sexual stimulation, how often were your erections hard enough for penetration;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks when you had erections with sexual stimulation, how often were your erections hard enough for penetration [PhenX];Erections hard penetration PhenX;;TRIAL;2.36;2.65 +6468-3;Microscopic observation;Prid;Pt;Sputum;Nom;Calcofluor white preparation;MICRO;1;Microscopic observation [Identifier] in Sputum by Calcofluor white;Calcofluor white Spt;;ACTIVE;1.0f;2.19 +64683-6;Over the past 4W when you attempted sexual intercourse, how often were you able to penetrate - enter your partner;Find;4W;^Patient;Nom;PhenX;PHENX;2;Over the past 4 weeks when you attempted sexual intercourse, how often were you able to penetrate - enter your partner [PhenX];Penetrate sexual intercourse PhenX;;TRIAL;2.36;2.65 +64684-4;Over the past 4W during sexual intercourse, how often were you able to maintain your erection after you had penetrated - entered your partner;Find;4W;^Patient;Nom;PhenX;PHENX;2;Over the past 4 weeks during sexual intercourse, how often were you able to maintain your erection after you had penetrated - entered your partner [PhenX];Maintain erection after penetrate PhenX;;TRIAL;2.36;2.65 +64685-1;Over the past 4W during sexual intercourse, how difficult was it to maintain your erection to completion of intercourse;Find;4W;^Patient;Nom;PhenX;PHENX;2;Over the past 4 weeks during sexual intercourse, how difficult was it to maintain your erection to completion of intercourse [PhenX];Maint erection complete penetrate PhenX;;TRIAL;2.36;2.65 +64686-9;Over the past 4W how many times have you attempted sexual intercourse;NRat;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how many times have you attempted sexual intercourse [PhenX];Attempt sexual intercourse times PhenX;;TRIAL;2.36;2.65 +64687-7;Over the past 4W when you attempted sexual intercourse, how often was it satisfactory for you;Find;4W;^Patient;Nom;PhenX;PHENX;2;Over the past 4 weeks when you attempted sexual intercourse, how often was it satisfactory for you [PhenX];Attempt sex intercourse satisfac PhenX;;TRIAL;2.36;2.65 +64688-5;Over the past 4W how much have you enjoyed sexual intercourse;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how much have you enjoyed sexual intercourse [PhenX];Enjoy sexual intercourse PhenX;;TRIAL;2.36;2.65 +64689-3;Over the past 4W when you had sexual stimulation or intercourse, how often did you ejaculate;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks when you had sexual stimulation or intercourse, how often did you ejaculate [PhenX];Sex stimul intercourse ejaculate PhenX;;TRIAL;2.36;2.65 +64690-1;Over the past 4W when you had sexual stimulation or intercourse, how often did you have the feeling of orgasm or climax;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks when you had sexual stimulation or intercourse, how often did you have the feeling of orgasm or climax [PhenX];Sex stimulation intercourse orgasm PhenX;;TRIAL;2.36;2.65 +6469-1;Microscopic observation;Prid;Pt;Stool;Nom;Trichrome stain;MICRO;1;Microscopic observation [Identifier] in Stool by Trichrome stain;Tri Stn Stl;;ACTIVE;1.0f;2.73 +64691-9;Over the past 4W how often have you felt sexual desire;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how often have you felt sexual desire [PhenX];Sexual desire felt PhenX;;TRIAL;2.36;2.65 +64692-7;Over the past 4W how would you rate your level of sexual desire;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how would you rate your level of sexual desire [PhenX];Sexual desire level rate PhenX;;TRIAL;2.36;2.65 +64693-5;Over the past 4W how satisfied have you been with your overall sex life;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how satisfied have you been with your overall sex life [PhenX];Overall sex life satisfac PhenX;;TRIAL;2.36;2.65 +64694-3;Over the past 4W how satisfied have you been with your sexual relationship with your partner;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how satisfied have you been with your sexual relationship with your partner [PhenX];Sexual relationship satisfac PhenX;;TRIAL;2.36;2.65 +64695-0;Over the past 4W how do you rate your confidence that you could get and keep an erection;Find;4W;^Patient;Ord;PhenX;PHENX;2;Over the past 4 weeks how do you rate your confidence that you could get and keep an erection [PhenX];Confidence get keep erection PhenX;;TRIAL;2.36;2.65 +64696-8;Since the age of 18, have you ever experienced a time interval of 3 or more Mo when you did not have a menstrual period;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since the age of 18, have you ever experienced a time interval of 3 or months when you did not have a menstrual period [PhenX];No menstrual period 3 or more Mos PhenX;;TRIAL;2.36;2.65 +64697-6;Were you breastfeeding at the time;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were you breastfeeding at the time [PhenX];No menstrual period breastfeeding PhenX;;TRIAL;2.36;2.65 +64698-4;Were you breastfeeding or pregnant every time this happened;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were you breastfeeding or pregnant every time this happened [PhenX];No period breastfeed preg always PhenX;;TRIAL;2.36;2.65 +64699-2;During ages 18-22 what was the pattern of your menstrual cycles, excluding time around pregnancies;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During ages 18-22 what was the pattern of your menstrual cycles, excluding time around pregnancies [PhenX];Menstrual cycle pattern age 18-22 PhenX;;TRIAL;2.36;2.65 +64700-8;On average, during the last Y, how many D were there in a typical menstrual cycle, that is, from the beginning of bleeding of one menstrual period to the beginning of bleeding of the next period;NRat;1Y;^Patient;Ord;PhenX;PHENX;2;On average, during the last year, how many day were there in a typical menstrual cycle, that is, from the beginning of bleeding of one menstrual period to the beginning of bleeding of the next period [PhenX];Menstrual cycle typical days PhenX;;TRIAL;2.36;2.65 +64701-6;Have your menstrual periods stopped permanently;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have your menstrual periods stopped permanently [PhenX];Menstrual period stop permanent PhenX;;TRIAL;2.36;2.73 +64702-4;How old were you when your periods stopped;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when your periods stopped [PhenX];Menstrual period stopped age PhenX;;TRIAL;2.36;2.65 +64703-2;How many times a night do you usually get up to urinate, pass water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How many times a night do you usually get up to urinate, pass water [PhenX];Get up urinate night times PhenX;;TRIAL;2.36;2.65 +64704-0;When you urinate, pass water, do you usually feel like you have not completely emptied your bladder;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you urinate, pass water, do you usually feel like you have not completely emptied your bladder [PhenX];Urinate feel bladder not empty PhenX;;TRIAL;2.36;2.65 +64705-7;Do you usually have trouble starting to urinate, pass water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually have trouble starting to urinate, pass water [PhenX];Trouble starting urinate PhenX;;TRIAL;2.36;2.65 +64706-5;Has the force of your urinary stream or water decreased over the Y;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has the force of your urinary stream or water decreased over the years [PhenX];Urinary stream force decrease PhenX;;TRIAL;2.36;2.65 +64707-3;Have you ever had surgery for your prostate not related to cancer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had surgery for your prostate not related to cancer [PhenX];Prostate surgery not cancer PhenX;;TRIAL;2.36;2.65 +64708-1;Including live births, stillbirths, miscarriages, abortions, and tubal and other ectopic pregnancies, how many times have you been pregnant;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Including live births, stillbirths, miscarriages, abortions, and tubal and other ectopic pregnancies, how many times have you been pregnant [PhenX];Number pregnancy PhenX;;TRIAL;2.36;2.65 +6470-9;Microscopic observation;Prid;Pt;Stool;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Stool by Wet preparation;Wet Prep Stl;;ACTIVE;1.0f;2.73 +64709-9;Pregnancy sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Pregnancy sequence [PhenX];Pregnancy sequence PhenX;;TRIAL;2.36;2.65 +64710-7;Was your pregnancy a live birth, stillbirth, miscarriage, abortion, or ectopic pregnancy;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Was your pregnancy a live birth, stillbirth, miscarriage, abortion, or ectopic pregnancy [PhenX];Pregnancy outcome PhenX;;TRIAL;2.36;2.65 +64711-5;How many W or Mo did that pregnancy last;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many weeks or months did that pregnancy last [#] [PhenX];Pregnancy last W Mo PhenX;;TRIAL;2.36;2.65 +64712-3;On what date did that pregnancy end;Date;Pt;^Patient;Qn;PhenX;PHENX;2;On what date did that pregnancy end [PhenX];Pregnancy end date PhenX;;TRIAL;2.36;2.65 +64713-1;In which Mos of the pregnancy did you have frequent nausea or vomiting;Find;Pt;^Patient;Nom;PhenX;PHENX;2;In which months of the pregnancy did you have frequent nausea or vomiting [PhenX];Frequent nausea vomiting Mos PhenX;;TRIAL;2.36;2.65 +64714-9;Was the baby a boy or a girl;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Was the baby a boy or a girl [PhenX];Baby boy girl PhenX;;TRIAL;2.36;2.65 +64715-6;During the 3Mo before you got pregnant, how many times did you drink 4 alcoholic drinks or more in one sitting;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;During the 3 months before you got pregnant, how many times did you drink 4 alcoholic drinks or more in one sitting [PhenX];Heavy alcohol before preg nRate PhenX;;TRIAL;2.36;2.65 +64716-4;During the last 3Mo of your pregnancy, how many alcoholic drinks did you have in an average W;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;During the last 3 months of your pregnancy, how many alcoholic drinks did you have in an average week [PhenX];Alcohol last 3Mo pregnancy PhenX;;TRIAL;2.36;2.65 +6471-7;Microscopic observation;Prid;Pt;Tiss;Nom;XXX stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Other stain;Other Stn Tiss;;ACTIVE;1.0f;2.73 +64717-2;During the last 3Mo of your pregnancy, how many times did you drink 4 alcoholic drinks or more in one sitting;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;During the last 3 months of your pregnancy, how many times did you drink 4 alcoholic drinks or more in one sitting [PhenX];Heavy alc last 3Mo preg nRate PhenX;;TRIAL;2.36;2.65 +64718-0;During this pregnancy, did you receive help with an alcohol or drug problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During this pregnancy, did you receive help with an alcohol or drug problem [PhenX];Receive help alcohol drug prob PhenX;;TRIAL;2.36;2.65 +64719-8;Have you ever fathered a pregnancy, regardless of outcome;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever fathered a pregnancy, regardless of outcome [PhenX];Father pregnancy ever PhenX;;TRIAL;2.36;2.65 +64720-6;How many times have you fathered a pregnancy, regardless of outcome;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many times have you fathered a pregnancy, regardless of outcome [PhenX];Father pregnancy times PhenX;;TRIAL;2.36;2.65 +64721-4;How old were you when you fathered this pregnancy;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you fathered this pregnancy [PhenX];Father pregnancy age PhenX;;TRIAL;2.36;2.65 +64722-2;Was this a planned pregnancy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was this a planned pregnancy [PhenX];Planned pregnancy PhenX;;TRIAL;2.36;2.65 +64723-0;How many Mo did it take for your partner to achieve pregnancy;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many months did it take for your partner to achieve pregnancy [PhenX];Planned pregnancy Mos achieve PhenX;;TRIAL;2.36;2.65 +64724-8;Was this a multiple pregnancy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was this a multiple pregnancy [PhenX];Multiple pregnancy PhenX;;TRIAL;2.36;2.65 +6472-5;Microscopic observation;Prid;Pt;Tiss;Nom;Calcofluor white preparation;MICRO;1;Microscopic observation [Identifier] in Tissue by Calcofluor white;Calcofluor white Tiss;;ACTIVE;1.0f;2.22 +64726-3;What was the outcome of this pregnancy;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What was the outcome of this pregnancy [PhenX];This pregnancy outcome PhenX;;TRIAL;2.36;2.65 +64727-1;Date of birth or loss;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;Date of birth or loss [PhenX];Birth loss date PhenX;;TRIAL;2.36;2.65 +64728-9;Have you ever had vaginal intercourse;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had vaginal intercourse [PhenX];Had vaginal intercourse PhenX;;TRIAL;2.36;2.65 +64729-7;How old were you the first time you had vaginal intercourse;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you the first time you had vaginal intercourse [PhenX];Vaginal intercourse first age PhenX;;TRIAL;2.36;2.65 +64730-5;With how many partners have you ever had vaginal intercourse, even if only once;Num;Pt;^Patient;Qn;PhenX;PHENX;2;With how many partners have you ever had vaginal intercourse, even if only once [#] [PhenX];Num vag intercourse partners PhenX;;TRIAL;2.36;2.65 +64731-3;With how many different partners have you had vaginal intercourse in the past 12Mo;NRat;12Mo;^Patient;Qn;PhenX;PHENX;2;With how many different partners have you had vaginal intercourse in the past 12 months [PhenX];Vag intercrse partners 12Mo nRate PhenX;;TRIAL;2.36;2.65 +64732-1;How many times have you had vaginal intercourse in the past 12Mo;NRat;12Mo;^Patient;Qn;PhenX;PHENX;2;How many times have you had vaginal intercourse in the past 12 months [PhenX];# vaginal intercourse 12Mo nRate PhenX;;TRIAL;2.36;2.65 +6473-3;Microscopic observation;Prid;Pt;Tiss;Nom;Trichrome stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Trichrome stain;Tri Stn Tiss;;ACTIVE;1.0f;2.73 +64733-9;On how many of these occasions did you or your partner use a condom in the past 12Mo;NRat;12Mo;^Patient;Qn;PhenX;PHENX;2;On how many of these occasions did you or your partner use a condom in the past 12 months [PhenX];Condom use count 12Mo nRate PhenX;;TRIAL;2.36;2.65 +64734-7;To whom have you felt sexually attracted, even if you did not take any action based on feeling attracted;Find;Pt;^Patient;Ord;PhenX;PHENX;2;To whom have you felt sexually attracted, even if you did not take any action based on feeling attracted [PhenX];Sexual attraction level PhenX;;TRIAL;2.36;2.65 +64735-4;Have you ever had any kind of sexual experience or sexual contact with a female, for women, or male, for men;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any kind of sexual experience or sexual contact with a female, for women, or male, for men [PhenX];Same gender sexual contact exper PhenX;;TRIAL;2.36;2.65 +64736-2;For females - have you ever had sex with a woman involving genital area or vaginal contact. For males - have you ever had sex with a man involving genital area or penis contact;Find;Pt;^Patient;Ord;PhenX;PHENX;2;For females - have you ever had sex with a woman involving genital area or vaginal contact. For males - have you ever had sex with a man involving genital area or penis contact [PhenX];Same gender genital contact ever PhenX;;TRIAL;2.36;2.65 +64737-0;When was the last occasion;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When was the last occasion [PhenX];When was last occasion PhenX;;TRIAL;2.36;2.65 +64738-8;Number of the largest bead that is at least as large as the right testis;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Number of the largest bead that is at least as large as the right testis [PhenX];# of largest bead - R testis PhenX;;TRIAL;2.36;2.65 +64739-6;Number of the largest bead that is at least as large as the left testis;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Number of the largest bead that is at least as large as the left testis [PhenX];# of largest bead - L testis PhenX;;TRIAL;2.36;2.65 +64740-4;Contact biometry instrument model;ID;Pt;Eye;Nom;PhenX;DEVICES;2;Eye Contact biometry instrument model PhenX;Eye Contact biometry instru mod PhenX;;TRIAL;2.36;2.65 +6474-1;Microscopic observation;Prid;Pt;Urethra;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Urethra by Gram stain;Gram Stn Urth;;ACTIVE;1.0f;2.73 +64741-2;Eye;Find;Pt;Eye;Nom;PhenX;PHENX;2;Eye [PhenX];Eye PhenX;;TRIAL;2.36;2.65 +64742-0;Axial length;Len;Pt;Eye.right;Qn;;EYE.PX;2;Right eye Axial length;R eye Axial length;;ACTIVE;2.36;2.68 +64744-6;Cornea thickness;Len;Pt;Eye.right;Qn;;PHENX;2;Cornea thickness Right eye;Cornea thickness R eye;;ACTIVE;2.36;2.72 +64745-3;Eye problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Eye problem [PhenX];Eye problem PhenX;;TRIAL;2.36;2.65 +64746-1;In the last 12Mo, have you noticed this eye problem;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;In the last 12 months, have you noticed this eye problem [PhenX];Eye problem last 12Mo PhenX;;TRIAL;2.36;2.71 +64747-9;Which eye;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which eye [PhenX];Which eye PhenX;;TRIAL;2.36;2.65 +64748-7;Symptom duration;Time;Pt;^Patient;Qn;;PHENX;2;Symptoms duration;Symptoms duration;;ACTIVE;2.36;2.70 +64749-5;Is it still ongoing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is it still ongoing [PhenX];Eye problem ongoing PhenX;;TRIAL;2.36;2.65 +64750-3;Severity of symptoms;Find;Pt;^Patient;Ord;;PHENX;2;Severity of symptoms;Symptom severity;;ACTIVE;2.36;2.68 +64751-1;During the last 12Mo have you noticed your child frequently squinting;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;During the last 12 months have you noticed your child frequently squinting [PhenX];Frequently squinting PhenX;;TRIAL;2.36;2.65 +64752-9;During the last 12Mo has your child had difficulty drawing or coloring;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;During the last 12 months has your child had difficulty drawing or coloring [PhenX];Difficulty drawing coloring PhenX;;TRIAL;2.36;2.65 +64753-7;During the last 12Mo has your child appeared to have difficulty seeing;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;During the last 12 months has your child appeared to have difficulty seeing [PhenX];Difficulty seeing PhenX;;TRIAL;2.36;2.65 +64754-5;Does your child close one eye when he or she is in bright sun light;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child close one eye when he or she is in bright sun light [PhenX];Close one eye bright light PhenX;;TRIAL;2.36;2.65 +64755-2;Does your child close or cover one eye when he or she is concentrating;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child close or cover one eye when he or she is concentrating [PhenX];Close one eye concentrating PhenX;;TRIAL;2.36;2.65 +64756-0;When was your childs last complete eye examination, one that included dilating of pupils where the doctor used bright lights to look in the back of his or her eyes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When was your childs last complete eye examination, one that included dilating of pupils where the doctor used bright lights to look in the back of his or her eyes [PhenX];Eye exam dilating pupils PhenX;;TRIAL;2.36;2.65 +64757-8;Child vision problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Child vision problem [PhenX];Child vision problem PhenX;;TRIAL;2.36;2.65 +6475-8;Mobiluncus sp rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mobiluncus sp rRNA [Presence] in Specimen by Probe;Mobiluncus rRNA Spec Ql Probe;;ACTIVE;1.0f;2.73 +64758-6;Has a doctor ever told you that your child had this vision problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that your child had this vision problem [PhenX];Vision problem Dr. told PhenX;;TRIAL;2.36;2.65 +64759-4;Has the child ever been treated in the past for this vision problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has the child ever been treated in the past for this vision problem [PhenX];Vision problem treatment PhenX;;TRIAL;2.36;2.65 +64760-2;Do or did any of his or her relatives have this vision problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do or did any of his or her relatives have this vision problem [PhenX];Vision problem relatives PhenX;;TRIAL;2.36;2.65 +64761-0;Which relatives have vision problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which relatives have vision problem [PhenX];Which relatives vison problem PhenX;;TRIAL;2.36;2.65 +64762-8;Other relative;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other relative [PhenX];Other relative PhenX;;TRIAL;2.36;2.65 +64763-6;How many of his or her sisters have, had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of his or her sisters have, had, or were suspected of having this eye problem [#] [PhenX];Eye problem sisters PhenX;;TRIAL;2.36;2.65 +64764-4;How many of his or her brothers have, had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of his or her brothers have, had, or were suspected of having this eye problem [#] [PhenX];Eye problem brothers PhenX;;TRIAL;2.36;2.65 +64765-1;How many of his or her grandparents have, had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of his or her grandparents have, had, or were suspected of having this eye problem [#] [PhenX];Eye problem grandparents PhenX;;TRIAL;2.36;2.73 +6476-6;Mumps virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mumps virus IgG Ab [Presence] in Serum by Immunoassay;MuV IgG Ser Ql IA;;ACTIVE;1.0f;2.73 +64766-9;How many of his or her other relatives have, had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of his or her other relatives have, had, or were suspected of having this eye problem [#] [PhenX];Eye problem other relatives PhenX;;TRIAL;2.36;2.65 +64767-7;Does your child have strabismus - that is one or both eyes are turned in, or turned out, or up or down, or crossed or wall eyes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have strabismus - that is one or both eyes are turned in, or turned out, or up or down, or crossed or wall eyes [PhenX];Child strabismus eye PhenX;;TRIAL;2.36;2.65 +64768-5;What treatment for strabismus did your child receive;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What treatment for strabismus did your child receive [PhenX];Child strabismus treatment PhenX;;TRIAL;2.36;2.65 +64769-3;Other strabismus treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other strabismus treatment [PhenX];Other strabismus treatment PhenX;;TRIAL;2.36;2.65 +64770-1;What treatment for myopia did your child receive;Find;Pt;^Patient;Ord;PhenX;PHENX;2;What treatment for myopia did your child receive [PhenX];Myopia treatment PhenX;;TRIAL;2.36;2.65 +64771-9;Other myopia treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other myopia treatment [PhenX];Other myopia treatment PhenX;;TRIAL;2.36;2.65 +64772-7;In the past 12Mo, how many times has he or she seen an eye doctor for his or her myopia, nearsightedness;NRat;12Mo;^Patient;Qn;PhenX;PHENX;2;In the past 12 months, how many times has he or she seen an eye doctor for his or her myopia, nearsightedness [PhenX];Myopia Dr. times last 12Mo nRate PhenX;;TRIAL;2.36;2.65 +64773-5;When did your child receive this treatment for other eye or vision problems;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did your child receive this treatment for other eye or vision problems [Date and time] [PhenX];Other eye vision problem tx date PhenX;;TRIAL;2.36;2.65 +6477-4;Mumps virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Mumps virus IgG Ab [Titer] in Serum by Immunofluorescence;MuV IgG Titr Ser IF;;ACTIVE;1.0f;2.73 +64774-3;Does your child have or had any other eye or vision problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your child have or had any other eye or vision problems [PhenX];Other eye vision problems PhenX;;TRIAL;2.36;2.65 +64775-0;What treatment did your child receive for other eye or vision problems;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What treatment did your child receive for other eye or vision problems [PhenX];Other eye vision problem tx PhenX;;TRIAL;2.36;2.65 +64776-8;Is the participant currently taking drops for glaucoma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is the participant currently taking drops for glaucoma [PhenX];Glaucoma drops currently PhenX;;TRIAL;2.36;2.65 +64777-6;What is the name of the glaucoma drops you are using;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What is the name of the glaucoma drops you are using [PhenX];Gaucoma drops name PhenX;;TRIAL;2.36;2.65 +64778-4;Other glaucoma drops you are using;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other glaucoma drops you are using [PhenX];Other glaucoma drops PhenX;;TRIAL;2.36;2.65 +64779-2;For the past 3Mo or longer, have you had dry eyes, foreign body sensation with itching and burning, sandy feeling, not related to allergy;Find;3Mo;^Patient;Nom;PhenX;PHENX;2;For the past 3 months or longer, have you had dry eyes, foreign body sensation with itching and burning, sandy feeling, not related to allergy [PhenX];Dry eyes past 3Mo PhenX;;TRIAL;2.36;2.65 +647-8;Microscopic observation;Prid;Pt;Sputum;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Sputum by Acid fast stain.Ziehl-Neelsen;ZN Stn Spt;;ACTIVE;1.0;2.21 +64780-0;Do you currently use artificial tears or prescription medication for dry eyes regularly for 3Mo or longer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you currently use artificial tears or prescription medication for dry eyes regularly for 3 months or longer [PhenX];Dry eye medication currently PhenX;;TRIAL;2.36;2.65 +64781-8;Are you currently using steroid eye drops;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you currently using steroid eye drops [PhenX];Steroid eye drops currently PhenX;;TRIAL;2.36;2.65 +6478-2;Mumps virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Mumps virus IgM Ab [Presence] in Serum by Immunoassay;MuV IgM Ser Ql IA;;ACTIVE;1.0f;2.73 +64782-6;Was your child born with any health problems, either physical or mental;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was your child born with any health problems, either physical or mental [PhenX];Child born health problems PhenX;;TRIAL;2.36;2.65 +64783-4;Health problem child was born with;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Health problem child was born with [PhenX];Child health problem specify PhenX;;TRIAL;2.36;2.65 +64784-2;During the past 12Mo, if child less than 12Mo, the childs age in Mos, has your child appeared to have any difficulty seeing;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;During the past 12 months, if child less than 12 months, the childs age in Mos, has your child appeared to have any difficulty seeing [PhenX];Child difficulty seeing 12Mo PhenX;;TRIAL;2.36;2.65 +64785-9;Has your child ever been diagnosed with an eye problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child ever been diagnosed with an eye problem [PhenX];Child eye problem diagnosis PhenX;;TRIAL;2.36;2.65 +64786-7;When was your child first diagnosed as having an eye problem;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When was your child first diagnosed as having an eye problem [Date and time] [PhenX];Child eye problem dx date PhenX;;TRIAL;2.36;2.65 +64787-5;When was your child first diagnosed as having amblyopia;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When was your child first diagnosed as having amblyopia [Date and time] [PhenX];Child amblyopia dx date PhenX;;TRIAL;2.36;2.65 +64788-3;When was your child first diagnosed as having strabismus;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When was your child first diagnosed as having strabismus [Date and time] [PhenX];Child strabismus dx date PhenX;;TRIAL;2.36;2.65 +64789-1;Did he or she ever have an operation to straighten his or her eyes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did he or she ever have an operation to straighten his or her eyes [PhenX];Operation straighten eyes ever PhenX;;TRIAL;2.36;2.65 +6479-0;Mumps virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Mumps virus IgM Ab [Titer] in Serum by Immunofluorescence;MuV IgM Titr Ser IF;;ACTIVE;1.0f;2.73 +64790-9;When did your child first have this type of operation;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;What month and year did your child first have this type of operation [Date and time] [PhenX];Operation straighten eyes date PhenX;;TRIAL;2.36;2.65 +64791-7;When did your child first start wearing an eye patch;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;What month and year did your child first start wearing an eye patch [Date and time] [PhenX];Child eye patch date PhenX;;TRIAL;2.36;2.65 +64792-5;In general, your childs overall health is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;In general, your childs overall health is [PhenX];Child overall health PhenX;;TRIAL;2.36;2.65 +64793-3;At the present time, childs eyesight, using both eyes, is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At the present time, childs eyesight, using both eyes, is [PhenX];Childs eyesight now PhenX;;TRIAL;2.36;2.65 +64794-1;In the 3Mo before you got pregnant, how many cigarettes did you smoke on an average D;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;In the 3 months before you got pregnant, how many cigarettes did you smoke on an average day [PhenX];Cigarettes before preg per D PhenX;;TRIAL;2.36;2.65 +64795-8;In the last 3Mo of your pregnancy, how many cigarettes did you smoke on an average D;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;In the last 3 months of your pregnancy, how many cigarettes did you smoke on an average day [PhenX];Cigarettes per D last 3Mo preg PhenX;;TRIAL;2.36;2.65 +64796-6;During the 3Mo before you got pregnant, how many alcoholic drinks did you have in an average W;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;During the 3 months before you got pregnant, how many alcoholic drinks did you have in an average week [PhenX];Alc drinks per W 3Mo before preg PhenX;;TRIAL;2.36;2.65 +64797-4;Oxygen content;VFr;Pt;BldCoV;Qn;Calculated;CHEM;1;Oxygen content in Venous cord blood by calculation;O2 Ct VFr BldCoV Calc;;ACTIVE;2.36;2.70 +64798-2;Oxygen content;VFr;Pt;BldMV;Qn;Calculated;CHEM;1;Oxygen content in Mixed venous blood by calculation;O2 Ct VFr BldMV Calc;;ACTIVE;2.36;2.73 +64799-0;Oxygen content;VFr;Pt;BldC;Qn;Calculated;CHEM;1;Oxygen content in Capillary blood by calculation;O2 Ct VFr BldC Calc;;ACTIVE;2.36;2.70 +64800-6;Oxygen content;VFr;Pt;BldCoA;Qn;Calculated;CHEM;1;Oxygen content in Arterial cord blood by calculation;O2 Ct VFr BldCoA Calc;;ACTIVE;2.36;2.73 +64803-0;What Y did you move from that city or town;Date;Pt;^Patient;Qn;PhenX;PHENX;2;What year did you move from that city or town [PhenX];City town Y end PhenX;;TRIAL;2.36;2.65 +64804-8;What was your main daytime activity or job when you turned 18;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What was your main daytime activity or job when you turned 18 [PhenX];Daytime activity job 18 PhenX;;TRIAL;2.36;2.65 +64805-5;What was your new daytime activity or job;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What was your new daytime activity or job [PhenX];Daytime activity job 2 PhenX;;TRIAL;2.36;2.65 +64806-3;What Y did your sunlight exposure change;Date;Pt;^Patient;Qn;PhenX;PHENX;2;What year did your sunlight exposure change [PhenX];Y sunlight exposure chng PhenX;;TRIAL;2.36;2.65 +64807-1;When you were living in your city or town in your occupation, how many H each D during a typical 5D work week in April through September did you spend outside in direct sunlight between 10 AM and 4 PM;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;When you were living in your city or town in your occupation, how many hours each day during a typical 5 day work week in April through September did you spend outside in direct sunlight between 10 AM and 4 PM [PhenX];Workday sunlight exposure H nRate PhenX;;TRIAL;2.36;2.65 +6480-8;Mumps virus Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Mumps virus Ag [Presence] in Serum by Immunofluorescence;MuV Ag Ser Ql IF;;ACTIVE;1.0f;2.56 +64808-9;Sunlight protection;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Sunlight protection [PhenX];Sunlight protection PhenX;;TRIAL;2.36;2.65 +64809-7;During your work time, when you were outside in direct sunlight, how often did you wear this sunlight protection;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During your work time, when you were outside in direct sunlight, how often did you wear this sunlight protection [PhenX];Workday sunlight protection freq PhenX;;TRIAL;2.36;2.65 +64810-5;How often did you wear this sunlight protection when you were outside in direct sunlight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you wear this sunlight protection when you were outside in direct sunlight [PhenX];Outside sunlight protection freq PhenX;;TRIAL;2.36;2.65 +64811-3;During the Mos of April through September, how many H each D of this leisure time did you spend outside in direct sunlight between 10 AM and 4 PM;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;During the months of April through September, how many hours each day of this leisure time did you spend outside in direct sunlight between 10 AM and 4 PM [PhenX];Leisure sunlight exposure H nRate PhenX;;TRIAL;2.36;2.65 +64812-1;Did your main daytime activities during your leisure time have you over water for a total of three or more H a D, for example sailing, fishing or swimming;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did your main daytime activities during your leisure time have you over water for a total of three or more hours a day, for example sailing, fishing or swimming [PhenX];Leisure over water >3H PhenX;;TRIAL;2.36;2.65 +64813-9;During your leisure time, when you were outside in direct sunlight, how often did you wear this sunlight protection;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During your leisure time, when you were outside in direct sunlight, how often did you wear this sunlight protection [PhenX];Leisure sunlight protection freq PhenX;;TRIAL;2.36;2.65 +64814-7;At the present time, would you say your eyesight using both eyes, with glasses or contact lenses, if you wear them, is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At the present time, would you say your eyesight using both eyes, with glasses or contact lenses, if you wear them, is [PhenX];Both eyes eyesight PhenX;;TRIAL;2.36;2.65 +64815-4;Adult eye problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Adult eye problem [PhenX];Adult eye problem PhenX;;TRIAL;2.36;2.65 +6481-6;Mycoplasma pneumoniae Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Mycoplasma pneumoniae IgG Ab [Titer] in Serum by Immunofluorescence;M pneumo IgG Titr Ser IF;;ACTIVE;1.0f;2.73 +64816-2;Has a doctor ever told you that you had this eye problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that you had this eye problem [PhenX];Eye problem ever PhenX;;TRIAL;2.36;2.65 +64817-0;Did you ever have cataract surgery;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you ever have cataract surgery [PhenX];Cataract surgery ever PhenX;;TRIAL;2.36;2.65 +64818-8;Do or did his or her relative have this eye problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do or did his or her relative have this eye problem [PhenX];Eye problem relative PhenX;;TRIAL;2.36;2.65 +64819-6;Have you ever been treated for your glaucoma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been treated for your glaucoma [PhenX];Glaucoma tx ever PhenX;;TRIAL;2.36;2.65 +64820-4;Has a medical doctor ever told you that diabetes has affected blood vessels in your eyes or that you had diabetic retinopathy or diabetic eye disease;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a medical doctor ever told you that diabetes has affected blood vessels in your eyes or that you had diabetic retinopathy or diabetic eye disease [PhenX];Diabetic retinopathy ever PhenX;;TRIAL;2.36;2.65 +64821-2;Did you ever have laser treatment or surgery for your diabetic eye disease;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you ever have laser treatment or surgery for your diabetic eye disease [PhenX];Diabetic retinopathy surgery ever PhenX;;TRIAL;2.36;2.65 +64822-0;How many different times have you had laser treatment or surgery for diabetic eye disease;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many different times have you had laser treatment or surgery for diabetic eye disease [PhenX];Diabet retinop laser surg times PhenX;;TRIAL;2.36;2.65 +64823-8;Have you ever had a crossed or wandering eye, amblyopia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had a crossed or wandering eye, amblyopia [PhenX];Amblyopia ever PhenX;;TRIAL;2.36;2.65 +6482-4;Mycoplasma pneumoniae rRNA;PrThr;Pt;Sputum;Ord;Probe;MICRO;1;Mycoplasma pneumoniae rRNA [Presence] in Sputum by Probe;M pneumo rRNA Spt Ql Probe;;ACTIVE;1.0f;2.63 +64824-6;Have you ever had double vision;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had double vision [PhenX];Double vision ever PhenX;;TRIAL;2.36;2.65 +64825-3;Do you ever tilt your head when looking straight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever tilt your head when looking straight [PhenX];Tilt head look straight ever PhenX;;TRIAL;2.36;2.65 +64826-1;Have you ever undergone eye muscle surgery;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever undergone eye muscle surgery [PhenX];Eye muscle surgery PhenX;;TRIAL;2.36;2.65 +64827-9;Have you ever worn a patch or used eye drops, atropine penalization for eye correction;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever worn a patch or used eye drops, atropine penalization for eye correction [PhenX];Patch eye drops correction ever PhenX;;TRIAL;2.36;2.65 +64828-7;Have you ever worn glasses or contacts;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever worn glasses or contacts [PhenX];Glasses contacts ever PhenX;;TRIAL;2.36;2.65 +64829-5;Details for glasses or contacts;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Details for glasses or contacts [PhenX];Details glasses contacts PhenX;;TRIAL;2.36;2.65 +64830-3;Do you have a coloboma, absence or defect of ocular tissue ranging from a small pit in the optic disk to extensive defects in the iris, ciliary body, choroid, retina, or optic disk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have a coloboma, absence or defect of ocular tissue ranging from a small pit in the optic disk to extensive defects in the iris, ciliary body, choroid, retina, or optic disk [PhenX];Coloboma absence ocular tiss PhenX;;TRIAL;2.36;2.65 +64831-1;Do you have microphthalmia, abnormally small eye;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have microphthalmia, abnormally small eye [PhenX];Microphthalmia small eye PhenX;;TRIAL;2.36;2.65 +6483-2;Mycoplasma pneumoniae rRNA;PrThr;Pt;XXX;Ord;Probe;MICRO;1;Mycoplasma pneumoniae rRNA [Presence] in Specimen by Probe;M pneumo rRNA Spec Ql Probe;;ACTIVE;1.0f;2.73 +64832-9;Do you have epibulbar dermoid, eye tumors that are not recurrent or progressive;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have epibulbar dermoid, eye tumors that are not recurrent or progressive [PhenX];Epibulbar dermoid eye tumors PhenX;;TRIAL;2.36;2.65 +64833-7;Do you have any abnormal ocular features;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any abnormal ocular features [PhenX];Abnormal ocular features PhenX;;TRIAL;2.36;2.65 +64834-5;Do you have any retinal defects, retinal tears, detachments, etc;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any retinal defects, retinal tears, detachments, etc [PhenX];Retinal defects tears detachments PhenX;;TRIAL;2.36;2.65 +64835-2;Do you have any visual impairment other than previously noted;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any visual impairment other than previously noted [PhenX];Other visual impairment PhenX;;TRIAL;2.36;2.65 +64836-0;Describe other visual impairment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Describe other visual impairment [PhenX];Describe other visual impair PhenX;;TRIAL;2.36;2.65 +64837-8;Relative with strabismus;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Relative with strabismus [PhenX];Relative with strabismus PhenX;;TRIAL;2.36;2.65 +64838-6;Treatment related to strabismus;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Treatment related to strabismus [PhenX];Strabismus treatment PhenX;;TRIAL;2.36;2.65 +64839-4;Did this relative have this strabismus treatment;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did this relative have this strabismus treatment [PhenX];Strabismus treatment relative PhenX;;TRIAL;2.36;2.71 +6484-0;Mycoplasma pneumoniae rRNA;ACnc;Pt;Sputum;Ord;Probe;MICRO;1;Deprecated Mycoplasma pneumoniae rRNA [Presence] in Sputum by DNA probe;Deprecated M pneumo rRNA Spt Ql Prb;;DEPRECATED;1.0f;2.36 +64840-2;Other relative with strabismus;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other relative with strabismus [PhenX];Other relative strabismus PhenX;;TRIAL;2.36;2.65 +64841-0;Line in the ETDRS visual acuity chart read by patient;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Line in the ETDRS visual acuity chart read by patient [PhenX];ETDRS Visual Acuity Chart line PhenX;;TRIAL;2.36;2.65 +64842-8;Distance from the patients eyes to the ETDRS visual acuity chart;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Distance from the patients eyes to the ETDRS visual acuity chart [PhenX];Visual acuity test distance PhenX;;TRIAL;2.36;2.65 +64843-6;Letter on line read by the patient;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Letter on line read by the patient [PhenX];Visual acuity letter line PhenX;;TRIAL;2.36;2.65 +64844-4;Equivalent visual acuity from table based on number of letters read correctly;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Equivalent visual acuity from table based on number of letters read correctly [PhenX];Equivalent visual acuity PhenX;;TRIAL;2.36;2.65 +64845-1;In general, would you say your overall health is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;In general, would you say your overall health is [PhenX];Overall health PhenX;;TRIAL;2.36;2.65 +64846-9;At the present time, how is your eyesight, using both eyes with glasses or contact lenses, if you wear them;Find;Pt;^Patient;Ord;;EYE.HX.NEI;2;At the present time, how is your eyesight, using both eyes with glasses or contact lenses, if you wear them;Eyesight both eyes;;ACTIVE;2.36;2.71 +64847-7;How much of the time do you worry about your eyesight;Find;Pt;^Patient;Ord;;EYE.HX;2;How much of the time do you worry about your eyesight;Time worry eyesight;;ACTIVE;2.36;2.71 +64848-5;How much pain or discomfort have you had in and around your eyes, for example, burning, itching, or aching;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much pain or discomfort have you had in and around your eyes, for example, burning, itching, or aching [PhenX];Pain discomfort around eyes PhenX;;TRIAL;2.36;2.65 +64849-3;Currently driving, at least once in a while;Find;Pt;^Patient;Ord;;PHENX;2;Currently driving, at least once in a while;Currently driving;;ACTIVE;2.36;2.72 +64850-1;Have you never driven a car or have you given up driving;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Have you never driven a car or have you given up driving [PhenX];Never or given up driving PhenX;;TRIAL;2.36;2.65 +64851-9;If you gave up driving, was that mainly because of your vision, mainly for some other reason, or because of both your vision and other reasons;Find;Pt;^Patient;Nom;;PHENX;2;If you gave up driving, was that mainly because of your vision, mainly for some other reason, or because of both your vision and other reasons;Reason gave up driving;;ACTIVE;2.36;2.72 +64852-7;How much difficulty do you have driving during the daytime in familiar places;Find;Pt;^Patient;Ord;;PHENX;2;How much difficulty do you have driving during the daytime in familiar places;Diff driving day familiar places;;ACTIVE;2.36;2.71 +64853-5;How much difficulty do you have driving at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have driving at night [PhenX];Diff driving night PhenX;;TRIAL;2.36;2.65 +64854-3;How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic;Find;Pt;^Patient;Ord;;PHENX;2;How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic;Difficult driving diff conditions;;ACTIVE;2.36;2.71 +64855-0;Do you accomplish less than you would like because of your vision;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you accomplish less than you would like because of your vision [PhenX];Accomplish less due to vision PhenX;;TRIAL;2.36;2.65 +64856-8;Are you limited in how long you can work or do other activities because of your vision;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you limited in how long you can work or do other activities because of your vision [PhenX];Limited work due to vision PhenX;;TRIAL;2.36;2.65 +6485-7;Mycoplasma pneumoniae rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Mycoplasma pneumoniae rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated M pneumo rRNA XXX Ql Prb;;DEPRECATED;1.0f;2.69 +64857-6;How much does pain or discomfort in or around your eyes, for example, burning, itching, or aching, keep you from doing what you'd like to be doing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much does pain or discomfort in or around your eyes, for example, burning, itching, or aching, keep you from doing what you'd like to be doing [PhenX];Eye pain discomfort limit doing PhenX;;TRIAL;2.36;2.65 +64858-4;How would you rate your overall health;Num;Pt;^Patient;Ord;PhenX;PHENX;2;How would you rate your overall health [PhenX];Rate overall health PhenX;;TRIAL;2.36;2.65 +64859-2;How would you rate your eyesight now, with glasses or contact lens on, if you wear them;Num;Pt;^Patient;Ord;PhenX;PHENX;2;How would you rate your eyesight now, with glasses or contact lens on, if you wear them [PhenX];Rate eyesight now PhenX;;TRIAL;2.36;2.65 +648-6;Microscopic observation;Prid;Pt;Sputum;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Sputum by Gram stain;Gram Stn Spt;;ACTIVE;1.0;2.73 +64860-0;Do you currently wear contact lenses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you currently wear contact lenses [PhenX];Contact lense currently PhenX;;TRIAL;2.36;2.65 +64861-8;Have you ever worn contact lenses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever worn contact lenses [PhenX];Contact lense ever PhenX;;TRIAL;2.36;2.65 +64862-6;Are you considering wearing contact lenses in the next year;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you considering wearing contact lenses in the next year [PhenX];Contact lense next year PhenX;;TRIAL;2.36;2.65 +64863-4;What type of contact lenses do you wear;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What type of contact lenses do you wear [PhenX];Contact lense type PhenX;;TRIAL;2.36;2.65 +64864-2;Measurement sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Measurement sequence [PhenX];Measurement sequence PhenX;;TRIAL;2.36;2.73 +6486-5;Mycoplasma sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Mycoplasma sp identified in Specimen by Organism specific culture;Mycoplasma Spec Cult;;ACTIVE;1.0f;2.73 +64866-7;In what city or town were you living when you were 18;Find;Pt;^Patient;Nom;PhenX;PHENX;2;In what city or town were you living when you were 18 [PhenX];City town 18 PhenX;;TRIAL;2.36;2.65 +64867-5;To what city or town did you move to next;Find;Pt;^Patient;Nom;PhenX;PHENX;2;To what city or town did you move to next [PhenX];Next city town PhenX;;TRIAL;2.36;2.65 +64868-3;What Y did you turn 18;Date;Pt;^Patient;Qn;PhenX;PHENX;2;What year did you turn 18 [PhenX];Y turn 18 PhenX;;TRIAL;2.36;2.65 +64869-1;City;Find;Pt;^Patient;Nom;PhenX;PHENX;2;City [PhenX];City PhenX;;TRIAL;2.36;2.65 +64870-9;Do you sleep with your contact lenses in;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you sleep with your contact lenses in [PhenX];Contact lense sleep PhenX;;TRIAL;2.36;2.65 +64871-7;Does your child currently wear glasses or contact lenses to correct, or partially correct, his or her eyesight;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Does your child currently wear glasses or contact lenses to correct, or partially correct, his or her eyesight [PhenX];Child glasses contacts currently PhenX;;TRIAL;2.36;2.65 +64872-5;How often are the glasses or contact lenses worn;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often are the glasses or contact lenses worn [PhenX];Glasses contact lense freq PhenX;;TRIAL;2.36;2.65 +6487-3;Neisseria gonorrhoeae Ag;PrThr;Pt;Genital;Ord;IA;MICRO;1;Neisseria gonorrhoeae Ag [Presence] in Genital specimen by Immunoassay;N gonorrhoea Ag Genital Ql IA;;DISCOURAGED;1.0f;2.56 +64873-3;Were the glasses or contact lenses prescribed for astigmatism;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were the glasses or contact lenses prescribed for astigmatism [PhenX];Glasses contact lense astigmatism PhenX;;TRIAL;2.36;2.65 +64874-1;Were the glasses or contact lenses prescribed for short-sightedness or myopia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were the glasses or contact lenses prescribed for short-sightedness or myopia [PhenX];Glasses contact lense myopia PhenX;;TRIAL;2.36;2.65 +64875-8;Were the glasses or contact lenses prescribed for long-sightedness or hyperopia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were the glasses or contact lenses prescribed for long-sightedness or hyperopia [PhenX];Glasses contact lense hyperopia PhenX;;TRIAL;2.36;2.65 +64876-6;Were the glasses or contact lenses prescribed for other;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were the glasses or contact lenses prescribed for other [PhenX];Glasses contact lense other PhenX;;TRIAL;2.36;2.65 +64877-4;Other glasses or contact lenses prescribed;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other glasses or contact lenses prescribed [PhenX];Other glasses contact lense PhenX;;TRIAL;2.36;2.65 +64878-2;Has your child worn glasses or contact lenses in the past, but no longer needs to wear them;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your child worn glasses or contact lenses in the past, but no longer needs to wear them [PhenX];Glasses no longer need PhenX;;TRIAL;2.36;2.65 +64879-0;Date when first prescribed;Date;Pt;Glasses prescription;Qn;PhenX;PHENX;2;Date when first prescribed Glasses lens prescription [PhenX];Glasses first date Glasses Rx PhenX;;TRIAL;2.36;2.68 +64880-8;Age when first prescribed;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Age when first prescribed [PhenX];Glasses first age PhenX;;TRIAL;2.36;2.65 +6488-1;Neisseria gonorrhoeae Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Neisseria gonorrhoeae Ag [Presence] in Genital specimen by Immunofluorescence;N gonorrhoea Ag Genital Ql IF;;DISCOURAGED;1.0f;2.56 +64881-6;Date stopped;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date stopped [PhenX];Date stopped PhenX;;TRIAL;2.36;2.65 +64882-4;Reason stopped;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Reason stopped [PhenX];Reason stopped PhenX;;TRIAL;2.36;2.65 +64883-2;How often did your child wear their glasses - contact lenses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often did your child wear their glasses - contact lenses [PhenX];Glasses freq PhenX;;TRIAL;2.36;2.65 +64884-0;Do you wear glasses of any kind;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you wear glasses of any kind [PhenX];Wear glasses PhenX;;TRIAL;2.36;2.65 +64885-7;Glasses type;Type;Pt;^Patient;Ord;PhenX;PHENX;2;Glasses type [PhenX];Glasses type PhenX;;TRIAL;2.36;2.65 +64886-5;How old were you when you first needed to wear glasses to see clearly in the distance;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you first needed to wear glasses to see clearly in the distance [PhenX];Distance glasses age PhenX;;TRIAL;2.36;2.65 +64887-3;How old were you when you first needed reading glasses, bifocals or multifocals;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you first needed reading glasses, bifocals or multifocals [PhenX];Reading glasses age PhenX;;TRIAL;2.36;2.65 +64888-1;How long have you had your current glasses;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long have you had your current glasses [PhenX];Current glasses age PhenX;;TRIAL;2.36;2.65 +64889-9;When did you last have the strength of your glasses checked;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did you last have the strength of your glasses checked [Date and time] [PhenX];Glasses strength checked last PhenX;;TRIAL;2.36;2.65 +64890-7;Can you read the ordinary print in the newspaper reasonably well, with or without glasses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Can you read the ordinary print in the newspaper reasonably well, with or without glasses [PhenX];Newspaper print read well PhenX;;TRIAL;2.36;2.65 +64891-5;When were you last able to do this;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When were you last able to do this [Date and time] [PhenX];Newspaper print read well last PhenX;;TRIAL;2.36;2.65 +64892-3;Do you use a magnifier to read;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you use a magnifier to read [PhenX];Use magnifier read PhenX;;TRIAL;2.36;2.65 +64893-1;I am so scared of a harmless animal that I do not dare to touch it;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am so scared of a harmless animal that I do not dare to touch it [SCARED-R];Anxiety animal SCARED-R;;ACTIVE;2.36;2.65 +64894-9;I worry about things working out for me;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about things working out for me [SCARED-R];Anxiety working out SCARED-R;;ACTIVE;2.36;2.65 +64895-6;I doubt whether I really did something;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I doubt whether I really did something [SCARED-R];Anxiety doubt did something SCARED-R;;ACTIVE;2.36;2.65 +64896-4;When frightened, I sweat a lot;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, I sweat a lot [SCARED-R];Anxiety sweat SCARED-R;;ACTIVE;2.36;2.65 +64897-2;I am a worrier;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am a worrier [SCARED-R];I am a worrier SCARED-R;;ACTIVE;2.36;2.65 +64898-0;I feel scared when I watch an operation;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I feel scared when I watch an operation [SCARED-R];Anxiety operation SCARED-R;;ACTIVE;2.36;2.65 +6489-9;Neisseria gonorrhoeae Ag;PrThr;Pt;Genital;Ord;LA;MICRO;1;Neisseria gonorrhoeae Ag [Presence] in Genital specimen by Latex agglutination;N gonorrhoea Ag Genital Ql LA;;DISCOURAGED;1.0f;2.56 +64899-8;I try not to think about a very aversive event I once experienced;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I try not to think about a very aversive event I once experienced [SCARED-R];Anxiety aversive event SCARED-R;;ACTIVE;2.36;2.65 +64900-4;I get really frightened for no reason;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I get really frightened for no reason [SCARED-R];Anxiety frightened no reason SCARED-R;;ACTIVE;2.36;2.65 +64901-2;I am afraid to be alone at home;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid to be alone at home [SCARED-R];Anxiety home alone SCARED-R;;ACTIVE;2.36;2.65 +64902-0;I get scared when I think back of a very aversive event I once experienced;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I get scared when I think back of a very aversive event I once experienced [SCARED-R];Scared think aversive event SCARED-R;;ACTIVE;2.36;2.65 +64903-8;I find it hard to talk with people I don't know;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I find it hard to talk with people I don't know [SCARED-R];Anxiety talk strangers SCARED-R;;ACTIVE;2.36;2.65 +64904-6;When frightened, I feel like I am choking;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, I feel like I am choking [SCARED-R];Anxiety frightened choking SCARED-R;;ACTIVE;2.36;2.65 +64905-3;People tell me I worry too much;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;People tell me I worry too much [SCARED-R];Anxiety told worry too much SCARED-R;;ACTIVE;2.36;2.65 +64906-1;I don't like being away from my family;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I don't like being away from my family [SCARED-R];Anxiety away from family SCARED-R;;ACTIVE;2.36;2.65 +6490-7;Neisseria gonorrhoeae Ag;PrThr;Pt;Urethra;Ord;;MICRO;1;Neisseria gonorrhoeae Ag [Presence] in Urethra;N gonorrhoea Ag Urth Ql;;DISCOURAGED;1.0f;2.73 +64907-9;I worry about others not liking me;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about others not liking me [SCARED-R];Anxiety don't like me SCARED-R;;ACTIVE;2.36;2.65 +64908-7;When frightened, I feel like passing out;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, I feel like passing out [SCARED-R];Anxiety pass out SCARED-R;;ACTIVE;2.36;2.65 +64909-5;I think that I will be contaminated with a serious disease;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I think that I will be contaminated with a serious disease [SCARED-R];Anxiety contamination SCARED-R;;ACTIVE;2.36;2.65 +64910-3;I am nervous;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am nervous [SCARED-R];I am nervous SCARED-R;;ACTIVE;2.36;2.65 +64911-1;I follow my parents wherever they go;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I follow my parents wherever they go [SCARED-R];Anxiety follow parents SCARED-R;;ACTIVE;2.36;2.65 +64912-9;I have thoughts that frighten me;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I have thoughts that frighten me [SCARED-R];Anxiety frightening thoughts SCARED-R;;ACTIVE;2.36;2.65 +64913-7;People tell me that I look nervous;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;People tell me that I look nervous [SCARED-R];Anxiety look nervous SCARED-R;;ACTIVE;2.36;2.65 +64914-5;I feel nervous with people I don't know well;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I feel nervous with people I don't know well [SCARED-R];Anxiety nervous with strangers SCARED-R;;ACTIVE;2.36;2.65 +6491-5;Neisseria gonorrhoeae rRNA;ACnc;Pt;XXX;Ord;Probe;MICRO;1;Deprecated Neisseria gonorrhoeae rRNA [Presence] in Unspecified specimen by DNA probe;Deprecated N gonorrhoea rRNA XXX Ql Prb;;DEPRECATED;1.0f;2.69 +64915-2;I am afraid to visit the doctor;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid to visit the doctor [SCARED-R];Anxiety afraid doctor SCARED-R;;ACTIVE;2.36;2.65 +64916-0;I don't like going to school;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I don't like going to school [SCARED-R];Anxiety school SCARED-R;;ACTIVE;2.36;2.65 +64917-8;When frightened, I feel like going crazy;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, I feel like going crazy [SCARED-R];Anxiety frightened crazy SCARED-R;;ACTIVE;2.36;2.65 +64918-6;I worry about sleeping alone;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about sleeping alone [SCARED-R];Anxiety sleep alone SCARED-R;;ACTIVE;2.36;2.65 +64919-4;I am afraid to visit the dentist;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid to visit the dentist [SCARED-R];Anxiety dentist SCARED-R;;ACTIVE;2.36;2.65 +64920-2;I worry about being as good as other kids;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about being as good as other kids [SCARED-R];Anxiety good others SCARED-R;;ACTIVE;2.36;2.65 +64921-0;I am afraid of an animal that is not really dangerous;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid of an animal that is not really dangerous [SCARED-R];Anxiety not dangerous animal SCARED-R;;ACTIVE;2.36;2.65 +64922-8;I get scared when there is thunder in the air;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I get scared when there is thunder in the air [SCARED-R];Anxiety thunder SCARED-R;;ACTIVE;2.36;2.65 +6492-3;Neisseria meningitidis Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Neisseria meningitidis Ag [Presence] in Specimen by Immunofluorescence;N men Ag Spec Ql IF;;ACTIVE;1.0g;2.69 +64923-6;I do things more than twice in order to check whether I did it right;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I do things more than twice in order to check whether I did it right [SCARED-R];Anxiety do things twice SCARED-R;;ACTIVE;2.36;2.65 +64924-4;I have frightening dreams about a very aversive event I once experienced;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I have frightening dreams about a very aversive event I once experienced [SCARED-R];Anxiety frightening dreams SCARED-R;;ACTIVE;2.36;2.65 +64925-1;I want things to be clean and tidy;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I want things to be clean and tidy [SCARED-R];Anxiety clean tidy SCARED-R;;ACTIVE;2.36;2.65 +64926-9;When frightened, I feel that things are not real;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, I feel that things are not real [SCARED-R];Anxiety things unreal SCARED-R;;ACTIVE;2.36;2.65 +64927-7;I feel scared when I have to fly in an airplane;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I feel scared when I have to fly in an airplane [SCARED-R];Anxiety flying SCARED-R;;ACTIVE;2.36;2.65 +64928-5;I have nightmares about my parents;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I have nightmares about my parents [SCARED-R];Anxiety nightmares parents SCARED-R;;ACTIVE;2.36;2.65 +64929-3;I worry about going to school;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about going to school [SCARED-R];Anxiety going to school SCARED-R;;ACTIVE;2.36;2.65 +64930-1;I do things to get less scared of my thoughts;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I do things to get less scared of my thoughts [SCARED-R];Anxiety scared of thoughts SCARED-R;;ACTIVE;2.36;2.65 +6493-1;Neisseria meningitidis serogroup A Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Cerebral spinal fluid by Immunoassay;N men sg A Ag CSF Ql IA;;ACTIVE;1.0g;2.64 +64931-9;When frightened, my heart beats fast;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, my heart beats fast [SCARED-R];Anxiety heart race SCARED-R;;ACTIVE;2.36;2.65 +64932-7;I am scared when I get an injection;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am scared when I get an injection [SCARED-R];Anxiety injection SCARED-R;;ACTIVE;2.36;2.65 +64933-5;I am afraid to get a serious disease;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid to get a serious disease [SCARED-R];Anxiety serious disease SCARED-R;;ACTIVE;2.36;2.65 +64934-3;I feel weak and shaky;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I feel weak and shaky [SCARED-R];Anxiety shaky SCARED-R;;ACTIVE;2.36;2.65 +64935-0;I have nightmares about bad things happening to me;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I have nightmares about bad things happening to me [SCARED-R];Anxiety nightmares bad things SCARED-R;;ACTIVE;2.36;2.65 +64936-8;I am afraid of having anxiety attacks;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid of having anxiety attacks [SCARED-R];Anxiety afraid of attacks SCARED-R;;ACTIVE;2.36;2.65 +64937-6;I worry that bad happens to my parents;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry that bad happens to my parents [SCARED-R];Anxiety bad things parents SCARED-R;;ACTIVE;2.36;2.65 +64938-4;I am shy with people I don't know well;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am shy with people I don't know well [SCARED-R];Anxiety shy strangers SCARED-R;;ACTIVE;2.36;2.65 +64939-2;I fantasize about hurting other people;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I fantasize about hurting other people [SCARED-R];Fantasize hurting others SCARED-R;;ACTIVE;2.36;2.65 +649-4;Microscopic observation;Prid;Pt;Stool;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Stool by Gram stain;Gram Stn Stl;;ACTIVE;1.0;2.73 +64940-0;I worry about the future;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about the future [SCARED-R];Anxiety worry future SCARED-R;;ACTIVE;2.36;2.65 +64941-8;When frightened, I feel like throwing up;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, I feel like throwing up [SCARED-R];Anxiety frightened throw up SCARED-R;;ACTIVE;2.36;2.65 +64942-6;I worry about how well I do things;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about how well I do things [SCARED-R];Anxiety performance SCARED-R;;ACTIVE;2.36;2.65 +64943-4;I am scared to go to school;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am scared to go to school [SCARED-R];Anxiety scared school SCARED-R;;ACTIVE;2.36;2.65 +64944-2;I worry about things that happened in the past;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I worry about things that happened in the past [SCARED-R];Anxiety past events SCARED-R;;ACTIVE;2.36;2.65 +64945-9;When frightened, I feel dizzy;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, I feel dizzy [SCARED-R];Anxiety frightened dizzy SCARED-R;;ACTIVE;2.36;2.65 +64947-5;I have thoughts that I prefer not to have;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I have thoughts that I prefer not to have [SCARED-R];Anxiety unwanted thoughts SCARED-R;;ACTIVE;2.36;2.65 +64948-3;I am afraid of the dark;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid of the dark [SCARED-R];Anxiety afraid dark SCARED-R;;ACTIVE;2.36;2.65 +6494-9;Neisseria meningitidis serogroup A Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg A Ag CSF Ql LA;;ACTIVE;1.0g;2.73 +64949-1;I have unbidden thoughts about a very aversive event I once experienced;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I have unbidden thoughts about a very aversive event I once experienced [SCARED-R];Anxiety thoughts bad events SCARED-R;;ACTIVE;2.36;2.65 +64950-9;I am afraid of an animal that most children do not fear;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid of an animal that most children do not fear [SCARED-R];Anxiety animal others no fear SCARED-R;;ACTIVE;2.36;2.65 +64951-7;I don't like being in a hospital;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I don't like being in a hospital [SCARED-R];Anxiety hospital SCARED-R;;ACTIVE;2.36;2.65 +64952-5;When frightened, it is hard to breathe;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When frightened, it is hard to breathe [SCARED-R];Anxiety hard to breathe SCARED-R;;ACTIVE;2.36;2.65 +64953-3;I am afraid of heights;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I am afraid of heights [SCARED-R];Anxiety heights SCARED-R;;ACTIVE;2.36;2.65 +64954-1;I get headaches or stomach aches when I am at school;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I get headaches or stomach aches when I am at school [SCARED-R];Anxiety head stomachache school SCARED-R;;ACTIVE;2.36;2.65 +64955-8;I don't like to be with people I don't know;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I don't like to be with people I don't know [SCARED-R];Anxiety people don't know SCARED-R;;ACTIVE;2.36;2.65 +6495-6;Neisseria meningitidis serogroup A Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Neisseria meningitidis serogroup A Ag [Presence] in Specimen by Immunofluorescence;N men sg A Ag Spec Ql IF;;ACTIVE;1.0g;2.69 +64956-6;When I see blood, I get dizzy;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;When I see blood, I get dizzy [SCARED-R];Anxiety blood SCARED-R;;ACTIVE;2.36;2.65 +64957-4;I want that things are in a fixed order;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I want that things are in a fixed order [SCARED-R];Anxiety fixed order SCARED-R;;ACTIVE;2.36;2.65 +64958-2;I get scared when I sleep away from home;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I get scared when I sleep away from home [SCARED-R];Anxiety homesick SCARED-R;;ACTIVE;2.36;2.65 +64959-0;Actinidia deliciosa recombinant (rAct d) 8 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kiwi recombinant (rAct d) 8 IgE Ab [Units/volume] in Serum;Kiwi (rAct d) 8 IgE Qn;;ACTIVE;2.36;2.70 +64960-8;Apium graveolens recombinant (rApi g) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Celery recombinant (rApi g) 1 IgE Ab [Units/volume] in Serum;Celery (rApi g) 1 IgE Qn;;ACTIVE;2.36;2.70 +64961-6;Malus domestica recombinant (rMal d) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apple recombinant (rMal d) 1 IgE Ab [Units/volume] in Serum;Apple (rMal d) 1 IgE Qn;;ACTIVE;2.36;2.73 +64962-4;Anacardium occidentale recombinant (rAna o) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cashew nut recombinant (rAna o) 2 IgE Ab [Units/volume] in Serum;Cashew nut (rAna o) 2 IgE Qn;;ACTIVE;2.36;2.70 +64963-2;Bertholletia excelsa recombinant (rBer e) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brazil Nut recombinant (rBer e) 1 IgE Ab [Units/volume] in Serum;Brazil Nut (rBer e) 1 IgE Qn;;ACTIVE;2.36;2.73 +6496-4;Neisseria meningitidis serogroup B Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Cerebral spinal fluid by Immunoassay;N men sg B Ag CSF Ql IA;;ACTIVE;1.0g;2.64 +64964-0;Corylus avellana recombinant (rCor a) 1.0401 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut recombinant (rCor a) 1.0401 IgE Ab [Units/volume] in Serum;Hazelnut (rCor a) 1.0401 IgE Qn;;ACTIVE;2.36;2.70 +64965-7;Arachis hypogaea recombinant (rAra h) 9 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 9 IgE Ab [Units/volume] in Serum;Peanut (rAra h) 9 IgE Qn;;ACTIVE;2.36;2.73 +64966-5;Triticum aestivum recombinant (rTri a) 14 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat recombinant (rTri a) 14 IgE Ab [Units/volume] in Serum;Wheat (rTri a) 14 IgE Qn;;ACTIVE;2.36;2.70 +64967-3;Alnus glutinosa recombinant (rAln g) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Alder recombinant (rAln g) 1 IgE Ab [Units/volume] in Serum;Black Alder (rAln g) 1 IgE Qn;;ACTIVE;2.36;2.70 +64968-1;Corylus avellana recombinant (rCor a) 1.0101 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut recombinant (rCor a) 1.0101 IgE Ab [Units/volume] in Serum;Hazelnut (rCor a) 1.0101 IgE Qn;;ACTIVE;2.36;2.70 +64969-9;Platanus acerifolia recombinant (rPla a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;London Plane recombinant (rPla a) 1 IgE Ab [Units/volume] in Serum;London Plane (rPla a) 1 IgE Qn;;ACTIVE;2.36;2.70 +64970-7;Platanus acerifolia recombinant (rPla a) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;London Plane recombinant (rPla a) 3 IgE Ab [Units/volume] in Serum;London Plane (rPla a) 3 IgE Qn;;ACTIVE;2.36;2.70 +64971-5;Chenopodium album recombinant (rChe a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goosefoot recombinant (rChe a) 1 IgE Ab [Units/volume] in Serum;Goosefoot (rChe a) 1 IgE Qn;;ACTIVE;2.36;2.70 +6497-2;Neisseria meningitidis serogroup B Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;N men sg B Ag CSF Ql IF;;ACTIVE;1.0g;2.64 +64972-3;Plantago lanceolata recombinant (rPla l) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English plantain recombinant (rPla l) 1 IgE Ab [Units/volume] in Serum;English plantain (rPla l) 1 IgE Qn;;ACTIVE;2.36;2.70 +64973-1;Dog recombinant (rCan f) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog recombinant 5 IgE Ab [Units/volume] in Serum;Dog (rCan f) 5 IgE Qn;;ACTIVE;2.36;2.70 +64974-9;Horse recombinant (rEqu c) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse recombinant (rEqu c) 1 IgE Ab [Units/volume] in Serum;Horse (rEqu c) 1 IgE Qn;;ACTIVE;2.36;2.70 +64975-6;Cat recombinant (rFel d) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cat recombinant (rFel d) 1 IgE Ab [Units/volume] in Serum;Cat (rFel d) 1 IgE Qn;;ACTIVE;2.36;2.70 +64976-4;Cat recombinant (rFel d) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cat recombinant (rFel d) 4 IgE Ab [Units/volume] in Serum;Cat (rFel d) 4 IgE Qn;;ACTIVE;2.36;2.70 +64977-2;Alternaria alternata recombinant (rAlt a) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata recombinant (rAlt a) 6 IgE Ab [Units/volume] in Serum;A alternata (rAlt a) 6 IgE Qn;;ACTIVE;2.36;2.70 +64978-0;Cladosporium herbarum recombinant (rCla h) 8 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum recombinant (rCla h) 8 IgE Ab [Units/volume] in Serum;C herbarum (rCla h) 8 IgE Qn;;ACTIVE;2.36;2.70 +64979-8;Blomia tropicalis recombinant (rBlo t) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blomia tropicalis recombinant (rBlo t) 5 IgE Ab [Units/volume] in Serum;B tropicalis (rBlo t) 5 IgE Qn;;ACTIVE;2.36;2.70 +6498-0;Neisseria meningitidis serogroup B Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroup B Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg B Ag CSF Ql LA;;ACTIVE;1.0g;2.64 +64980-6;Dermatophagoides farinae recombinant (rDer f) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite recombinant (rDer f) 2 IgE Ab [Units/volume] in Serum;Am house dust mite (rDer f) 2 IgE Qn;;ACTIVE;2.36;2.70 +64981-4;Lepidoglyphus destructor recombinant (rLep d) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lepidoglyphus destructor recombinant (rLep d) 2 IgE Ab [Units/volume] in Serum;L destructor (rLep d) 2 IgE Qn;;ACTIVE;2.36;2.70 +64982-2;Blatella germanica recombinant (rBla g) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach recombinant (rBla g) 1 IgE Ab [Units/volume] in Serum;Roach (rBla g) 1 IgE Qn;;ACTIVE;2.36;2.70 +64983-0;Blatella germanica recombinant (rBla g) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach recombinant (rBla g) 2 IgE Ab [Units/volume] in Serum;Roach (rBla g) 2 IgE Qn;;ACTIVE;2.36;2.70 +64984-8;Blatella germanica recombinant (rBla g) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach recombinant (rBla g) 5 IgE Ab [Units/volume] in Serum;Roach (rBla g) 5 IgE Qn;;ACTIVE;2.36;2.70 +64985-5;Anisakis simplex recombinant (rAni s) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Anisakis recombinant (rAni s) 1 IgE Ab [Units/volume] in Serum;Anisakis (rAni s) 1 IgE Qn;;ACTIVE;2.36;2.70 +64986-3;Anisakis simplex recombinant (rAni s) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Anisakis recombinant (rAni s) 3 IgE Ab [Units/volume] in Serum;Anisakis (rAni s) 3 IgE Qn;;ACTIVE;2.36;2.70 +64987-1;Race or ethnicity;Type;Pt;^Family member;Nom;PhenX;PHENX;2;Race or ethnicity Family member [PhenX];Race or ethnicity Fam Mem PhenX;;TRIAL;2.36;2.65 +64988-9;Has a doctor ever told you that your child ever had other eye or vision problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that your child ever had other eye or vision problems [PhenX];Child other eye vision problems PhenX;;TRIAL;2.36;2.65 +64989-7;Other doctor reported eye or vision treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other doctor reported eye or vision treatment [PhenX];Other Dr. reported eye vision tx PhenX;;TRIAL;2.36;2.65 +64990-5;Grade in school, if applicable;Hx;Pt;^Patient;Nom;;PHENX;2;Grade in school, if applicable;School grade;;ACTIVE;2.36;2.71 +64991-3;Date of observation;Date;Pt;^Patient;Qn;;PHENX;2;Date of observation;Observation date;;TRIAL;2.38;2.50 +64993-9;Guidance for placement of needle;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for placement of needle in Unspecified body region;US Guided Needle place;;ACTIVE;2.36;2.64 +64994-7;Vaccine funding program eligibility category;Find;Pt;^Patient;Nom;;VACCIN;2;Vaccine funding program eligibility category;Vaccine fund pgm elig cat;;ACTIVE;2.36;2.73 +64995-4;Views^W contrast IA;Find;Pt;Chest>Internal thoracic artery.left;Doc;RF.angio;RAD;2;RFA Internal thoracic artery - left Views W contrast IA;RFA IT a-L Views W contr IA;;ACTIVE;2.36;2.64 +64996-2;Views^W contrast intrabronchial;Find;Pt;Chest>Lung.left;Doc;XR;RAD;2;XR Lung - left Views W contrast intrabronchial;XR Lung-L Views W contr IB;;ACTIVE;2.36;2.64 +64997-0;Views^W contrast intrabronchial;Find;Pt;Chest>Lung.right;Doc;XR;RAD;2;XR Lung - right Views W contrast intrabronchial;XR Lung-R Views W contr IB;;ACTIVE;2.36;2.64 +6499-8;Neisseria meningitidis serogroup C Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Cerebral spinal fluid by Immunoassay;N men sg C Ag CSF Ql IA;;ACTIVE;1.0g;2.64 +64998-8;Guidance for placement of catheter^transcervical;Find;Pt;Pelvis>Fallopian tube.left;Doc;RF;RAD;2;RF Guidance for placement of catheter in Fallopian tube - left-- transcervical;RF Guided FT-L Cath place--transcervical;;ACTIVE;2.36;2.64 +64999-6;Guidance for placement of catheter^transcervical;Find;Pt;Pelvis>Fallopian tube.right;Doc;RF;RAD;2;RF Guidance for placement of catheter in Fallopian tube - right-- transcervical;RF Guided FR-R Cath place--transcervical;;ACTIVE;2.36;2.64 +65000-2;Views^W contrast IA;Find;Pt;Chest>Internal thoracic artery.right;Doc;RF.angio;RAD;2;RFA Internal thoracic artery - right Views W contrast IA;RFA IT a-R Views W contr IA;;ACTIVE;2.36;2.64 +65001-0;I prefer to do things with others rather than on my own;Find;Pt;^Patient;Ord;AQ;PHENX;2;I prefer to do things with others rather than on my own [AQ];Prefer do things with others AQ;;ACTIVE;2.36;2.65 +65002-8;I prefer to do things the same way over and over again;Find;Pt;^Patient;Ord;AQ;PHENX;2;I prefer to do things the same way over and over again [AQ];Prefer do things same way AQ;;ACTIVE;2.36;2.65 +6500-3;Neisseria meningitidis serogroup C Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg C Ag CSF Ql LA;;ACTIVE;1.0g;2.64 +65003-6;If I try to imagine something I find it very easy to create a picture in my mind;Find;Pt;^Patient;Ord;AQ;PHENX;2;If I try to imagine something I find it very easy to create a picture in my mind [AQ];Easy create picture in mind AQ;;ACTIVE;2.36;2.65 +65004-4;I frequently get so strongly absorbed in one thing that I lose sight of other things;Find;Pt;^Patient;Ord;AQ;PHENX;2;I frequently get so strongly absorbed in one thing that I lose sight of other things [AQ];Strongly absorbed AQ;;ACTIVE;2.36;2.65 +65005-1;I often notice small sounds when others do not;Find;Pt;^Patient;Ord;AQ;PHENX;2;I often notice small sounds when others do not [AQ];Notice small sounds AQ;;ACTIVE;2.36;2.65 +65006-9;I usually notice car number plates or similar strings of information;Find;Pt;^Patient;Ord;AQ;PHENX;2;I usually notice car number plates or similar strings of information [AQ];Notice license plates AQ;;ACTIVE;2.36;2.65 +65007-7;Other people frequently tell me that what I've said is impolite even though I think it is polite;Find;Pt;^Patient;Ord;AQ;PHENX;2;Other people frequently tell me that what I've said is impolite even though I think it is polite [AQ];People call me impolite AQ;;ACTIVE;2.36;2.65 +65008-5;When I'm reading a story I can easily imagine what the characters might look like;Find;Pt;^Patient;Ord;AQ;PHENX;2;When I'm reading a story I can easily imagine what the characters might look like [AQ];Easily imagine story characters AQ;;ACTIVE;2.36;2.65 +65009-3;I am fascinated by dates;Find;Pt;^Patient;Ord;AQ;PHENX;2;Fascinated dates [AQ];I am fascinated by dates AQ;;ACTIVE;2.36;2.65 +65010-1;In a social group I can easily keep track of several different people's conversations;Find;Pt;^Patient;Ord;AQ;PHENX;2;In a social group I can easily keep track of several different people's conversations [AQ];Keep track different conversations AQ;;ACTIVE;2.36;2.68 +6501-1;Neisseria meningitidis serogroup C Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Neisseria meningitidis serogroup C Ag [Presence] in Specimen by Immunofluorescence;N men sg C Ag Spec Ql IF;;ACTIVE;1.0g;2.69 +65011-9;I find social situations easy;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find social situations easy [AQ];Social situations easy AQ;;ACTIVE;2.36;2.65 +65012-7;I tend to notice details that others do not;Find;Pt;^Patient;Ord;AQ;PHENX;2;I tend to notice details that others do not [AQ];Notice details AQ;;ACTIVE;2.36;2.65 +65013-5;I would rather go to a library than a party;Find;Pt;^Patient;Ord;AQ;PHENX;2;I would rather go to a library than a party [AQ];Library over party AQ;;ACTIVE;2.36;2.65 +65014-3;I find making up stories easy;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find making up stories easy [AQ];Make up stories easy AQ;;ACTIVE;2.36;2.65 +65015-0;I find myself drawn more strongly to people than to things;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find myself drawn more strongly to people than to things [AQ];Drawn to people AQ;;ACTIVE;2.36;2.65 +65016-8;I tend to have very strong interests which I get upset about if I can't pursue;Find;Pt;^Patient;Ord;AQ;PHENX;2;I tend to have very strong interests which I get upset about if I can't pursue [AQ];Strong interests AQ;;ACTIVE;2.36;2.65 +65017-6;I enjoy social chit-chat;Find;Pt;^Patient;Ord;AQ;PHENX;2;I enjoy social chit-chat [AQ];Enjoy chit-chat AQ;;ACTIVE;2.36;2.65 +65018-4;When I talk, it isn't always easy for others to get a word in edgeways;Find;Pt;^Patient;Ord;AQ;PHENX;2;When I talk, it isn't always easy for others to get a word in edgeways [AQ];Dominate conversation AQ;;ACTIVE;2.36;2.65 +65019-2;I am fascinated by numbers;Find;Pt;^Patient;Ord;AQ;PHENX;2;I am fascinated by numbers [AQ];Fascinated by numbers AQ;;ACTIVE;2.36;2.65 +650-2;Microscopic observation;Prid;Pt;Urine;Nom;Acid fast stain.Kinyoun;MICRO;1;Microscopic observation [Identifier] in Urine by Acid fast stain.Kinyoun;Acid fast Kiny Stn Ur;;ACTIVE;1.0;2.21 +65020-0;When I'm reading a story I find it difficult to work out the characters intentions;Find;Pt;^Patient;Ord;AQ;PHENX;2;When I'm reading a story I find it difficult to work out the characters intentions [AQ];Diff understanding characters AQ;;ACTIVE;2.36;2.65 +65021-8;I don't particularly enjoy reading fiction;Find;Pt;^Patient;Ord;AQ;PHENX;2;I don't particularly enjoy reading fiction [AQ];Don't enjoy fiction AQ;;ACTIVE;2.36;2.65 +65022-6;I find it hard to make new friends;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find it hard to make new friends [AQ];Difficulty making friends AQ;;ACTIVE;2.36;2.65 +65023-4;I notice patterns in things all the time;Find;Pt;^Patient;Ord;AQ;PHENX;2;I notice patterns in things all the time [AQ];Notice patterns AQ;;ACTIVE;2.36;2.65 +65024-2;I would rather go to the theatre than a museum;Find;Pt;^Patient;Ord;AQ;PHENX;2;I would rather go to the theatre than a museum [AQ];Theatre over museum AQ;;ACTIVE;2.36;2.65 +65025-9;It does not upset me if my daily routine is disturbed;Find;Pt;^Patient;Ord;AQ;PHENX;2;It does not upset me if my daily routine is disturbed [AQ];Daily routine AQ;;ACTIVE;2.36;2.65 +65026-7;I frequently find that I don't know how to keep a conversation going;Find;Pt;^Patient;Ord;AQ;PHENX;2;I frequently find that I don't know how to keep a conversation going [AQ];Difficulty with conversation AQ;;ACTIVE;2.36;2.65 +65027-5;I find it easy to read between the lines when someone is talking to me;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find it easy to read between the lines when someone is talking to me [AQ];Read between conversation lines AQ;;ACTIVE;2.36;2.65 +65028-3;I usually concentrate more on the whole picture rather than the small details;Find;Pt;^Patient;Ord;AQ;PHENX;2;I usually concentrate more on the whole picture rather than the small details [AQ];Whole picture over details AQ;;ACTIVE;2.36;2.65 +6502-9;Neisseria meningitidis serogroup Y Ab;Titr;Pt;XXX;Qn;IF;MICRO;1;Neisseria meningitidis serogroup Y Ab [Titer] in Specimen by Immunofluorescence;N men sg Y Ab Titr Spec IF;;ACTIVE;1.0g;2.70 +65029-1;I am not very good at remembering phone numbers;Find;Pt;^Patient;Ord;AQ;PHENX;2;I am not very good at remembering phone numbers [AQ];Diff remembering phone numbers AQ;;ACTIVE;2.36;2.65 +65030-9;I don't usually notice small changes in a situation or a person's appearance;Find;Pt;^Patient;Ord;AQ;PHENX;2;I don't usually notice small changes in a situation or a person's appearance [AQ];Notice small changes AQ;;ACTIVE;2.36;2.65 +65031-7;I know how to tell if someone listening to me is getting bored;Find;Pt;^Patient;Ord;AQ;PHENX;2;I know how to tell if someone listening to me is getting bored [AQ];Tell if boring others AQ;;ACTIVE;2.36;2.65 +65032-5;I find it easy to do more than one thing at once;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find it easy to do more than one thing at once [AQ];Easy to multi-task AQ;;ACTIVE;2.36;2.65 +65033-3;When I talk on the phone I'm not sure when its my turn to speak;Find;Pt;^Patient;Ord;AQ;PHENX;2;When I talk on the phone I'm not sure when its my turn to speak [AQ];Difficulty phone conversations AQ;;ACTIVE;2.36;2.65 +65034-1;I enjoy doing things spontaneously;Find;Pt;^Patient;Ord;AQ;PHENX;2;I enjoy doing things spontaneously [AQ];Enjoy spontaneity AQ;;ACTIVE;2.36;2.65 +65035-8;I am often the last to understand the point of a joke;Find;Pt;^Patient;Ord;AQ;PHENX;2;I am often the last to understand the point of a joke [AQ];Difficulty understanding jokes AQ;;ACTIVE;2.36;2.65 +65036-6;I find it easy to work out what someone is thinking or feeling just by looking at their face;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find it easy to work out what someone is thinking or feeling just by looking at their face [AQ];Easy to read facial expressions AQ;;ACTIVE;2.36;2.65 +6503-7;Neisseria meningitidis serogroup Y Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Neisseria meningitidis serogroup Y Ag [Presence] in Cerebral spinal fluid by Immunoassay;N men sg Y Ag CSF Ql IA;;ACTIVE;1.0g;2.64 +65037-4;If there is an interruption I can switch back to what I was doing very quickly;Find;Pt;^Patient;Ord;AQ;PHENX;2;If there is an interruption I can switch back to what I was doing very quickly [AQ];Easy to switch after interruption AQ;;ACTIVE;2.36;2.65 +65038-2;I am good at social chit-chat;Find;Pt;^Patient;Ord;AQ;PHENX;2;I am good at social chit-chat [AQ];Good at chit-chat AQ;;ACTIVE;2.36;2.65 +65039-0;People often tell me that I keep going on and on about the same thing;Find;Pt;^Patient;Ord;AQ;PHENX;2;People often tell me that I keep going on and on about the same thing [AQ];Go on about one thing AQ;;ACTIVE;2.36;2.65 +65040-8;When I was young I used to enjoy playing games involving pretending with other children;Find;Pt;^Patient;Ord;AQ;PHENX;2;When I was young I used to enjoy playing games involving pretending with other children [AQ];Pretend with other children AQ;;ACTIVE;2.36;2.65 +65041-6;I like to collect information about categories of things - types of car, types of bird, types of train, types of plant, etc;Find;Pt;^Patient;Ord;AQ;PHENX;2;I like to collect information about categories of things - types of car, types of bird, types of train, types of plant, etc [AQ];Collect categories AQ;;ACTIVE;2.36;2.65 +65042-4;I find it difficult to imagine what it would be like to be someone else;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find it difficult to imagine what it would be like to be someone else [AQ];Difficulty imagine be someone else AQ;;ACTIVE;2.36;2.65 +65043-2;I like to plan any activities I participate in carefully;Find;Pt;^Patient;Ord;AQ;PHENX;2;I like to plan any activities I participate in carefully [AQ];Enjoy planning activities AQ;;ACTIVE;2.36;2.65 +65044-0;I enjoy social occasions;Find;Pt;^Patient;Ord;AQ;PHENX;2;I enjoy social occasions [AQ];Enjoy social occasions AQ;;ACTIVE;2.36;2.65 +6504-5;Neisseria meningitidis serogroup Y Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Neisseria meningitidis serogroup Y Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;N men sg Y Ag CSF Ql IF;;ACTIVE;1.0g;2.64 +65045-7;I find it difficult to work out peoples intentions;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find it difficult to work out peoples intentions [AQ];Difficult working out intentions AQ;;ACTIVE;2.36;2.65 +65046-5;New situations make me anxious;Find;Pt;^Patient;Ord;AQ;PHENX;2;New situations make me anxious [AQ];Anxious new situations AQ;;ACTIVE;2.36;2.65 +65047-3;I enjoy meeting new people;Find;Pt;^Patient;Ord;AQ;PHENX;2;I enjoy meeting new people [AQ];Enjoy meeting new people AQ;;ACTIVE;2.36;2.65 +65048-1;I am a good diplomat;Find;Pt;^Patient;Ord;AQ;PHENX;2;I am a good diplomat [AQ];Good diplomat AQ;;ACTIVE;2.36;2.65 +65049-9;I am not very good at remembering peoples date of birth;Find;Pt;^Patient;Ord;AQ;PHENX;2;I am not very good at remembering peoples date of birth [AQ];Difficulty remember birth dates AQ;;ACTIVE;2.36;2.65 +65050-7;I find it very easy to play games with children that involve pretending;Find;Pt;^Patient;Ord;AQ;PHENX;2;I find it very easy to play games with children that involve pretending [AQ];Easy playing pretend games AQ;;ACTIVE;2.36;2.65 +65051-5;Your child prefers to do things with others rather than on his or her own;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child prefers to do things with others rather than on his or her own [AQ Adolescent];Child prefer things with others AQ Adol;;ACTIVE;2.36;2.65 +6505-2;Neisseria meningitidis serogroup Y Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroup Y Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg Y Ag CSF Ql LA;;ACTIVE;1.0g;2.64 +65052-3;Your child prefers to do things the same way over and over again;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child prefers to do things the same way over and over again [AQ Adolescent];Child prefer do things same way AQ Adol;;ACTIVE;2.36;2.65 +65053-1;If your child tries to imagine something, your child finds it very easy to create a picture in his or her mind;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;If your child tries to imagine something, your child finds it very easy to create a picture in his or her mind [AQ Adolescent];Child easy create picture mind AQ Adol;;ACTIVE;2.36;2.65 +65054-9;Your child frequently gets so strongly absorbed in one thing that your child loses sight of other things;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child frequently gets so strongly absorbed in one thing that your child loses sight of other things [AQ Adolescent];Child strongly absorbed AQ Adol;;ACTIVE;2.36;2.65 +65055-6;Your child often notices small sounds when others do not;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child often notices small sounds when others do not [AQ Adolescent];Child notices small sounds AQ Adol;;ACTIVE;2.36;2.65 +65056-4;Your child usually notices car number plates or similar strings of information;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child usually notices car number plates or similar strings of information [AQ Adolescent];Child notices licwnse plates AQ Adol;;ACTIVE;2.36;2.65 +65057-2;Other people frequently tell him or her that what your child has said is impolite, even though your child thinks it is polite;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Other people frequently tell him or her that what your child has said is impolite, even though your child thinks it is polite [AQ Adolescent];People call child impolite AQ Adol;;ACTIVE;2.36;2.65 +65058-0;When your child is reading a story, your child can easily imagine what the characters might look like;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;When your child is reading a story, your child can easily imagine what the characters might look like [AQ Adolescent];Child imagine story characters AQ Adol;;ACTIVE;2.36;2.65 +65059-8;Your child is fascinated by dates;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child is fascinated by dates [AQ Adolescent];Child fascinated dates AQ Adol;;ACTIVE;2.36;2.65 +6506-0;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;N men sg W135 Ag CSF Ql IF;;ACTIVE;1.0g;2.64 +65060-6;In a social group, your child can easily keep track of several different peoples conversations;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;In a social group, your child can easily keep track of several different peoples conversations [AQ Adolescent];Child track diff conversations AQ Adol;;ACTIVE;2.36;2.65 +65061-4;Your child finds social situations easy;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds social situations easy [AQ Adolescent];Child social situations easy AQ Adol;;ACTIVE;2.36;2.65 +65062-2;Your child tends to notice details that others do not;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child tends to notice details that others do not [AQ Adolescent];Child notice details AQ Adol;;ACTIVE;2.36;2.65 +65063-0;Your child would rather go to a library than a party;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child would rather go to a library than a party [AQ Adolescent];Child library over party AQ Adol;;ACTIVE;2.36;2.65 +65064-8;Your child finds making up stories easy;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds making up stories easy [AQ Adolescent];Child make up stories easy AQ Adol;;ACTIVE;2.36;2.65 +65065-5;Your child finds him or herself drawn more strongly to people than to things;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds him or herself drawn more strongly to people than to things [AQ Adolescent];Child drawn to people AQ Adol;;ACTIVE;2.36;2.65 +65066-3;Your child tends to have very strong interests, which your child gets upset about if your child can't pursue;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child tends to have very strong interests, which your child gets upset about if your child can't pursue [AQ Adolescent];Child strong interests AQ Adol;;ACTIVE;2.36;2.65 +65067-1;Your child enjoys social chit-chat;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child enjoys social chit-chat [AQ Adolescent];Child enjoy chit-chat AQ Adol;;ACTIVE;2.36;2.65 +65068-9;When your child talks, it isn't always easy for others to get a word in edgeways;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;When your child talks, it isn't always easy for others to get a word in edgeways [AQ Adolescent];Child dominate conversation AQ Adol;;ACTIVE;2.36;2.65 +65069-7;Your child is fascinated by numbers;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child is fascinated by numbers [AQ Adolescent];Child fascinated numbers AQ Adol;;ACTIVE;2.36;2.65 +65070-5;When your child is reading a story, your child finds it difficult to work out the characters' intentions;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;When your child is reading a story, your child finds it difficult to work out the characters' intentions [AQ Adolescent];Child diff understand characters AQ Adol;;ACTIVE;2.36;2.65 +65071-3;Your child doesn't particularly enjoy reading fiction;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child doesn't particularly enjoy reading fiction [AQ Adolescent];Child not enjoy reading AQ Adol;;ACTIVE;2.36;2.65 +65072-1;Your child finds it hard to make new friends;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds it hard to make new friends [AQ Adolescent];Child hard make friends AQ Adol;;ACTIVE;2.36;2.65 +65073-9;Your child notices patterns in things all the time;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child notices patterns in things all the time [AQ Adolescent];Child notices patterns AQ Adol;;ACTIVE;2.36;2.65 +65074-7;Your child would rather go to the theatre than a museum;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child would rather go to the theatre than a museum [AQ Adolescent];Child theatre over museum AQ Adol;;ACTIVE;2.36;2.65 +65075-4;It does not upset your child if the daily routine is disturbed;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;It does not upset your child if the daily routine is disturbed [AQ Adolescent];Child daily routine AQ Adol;;ACTIVE;2.36;2.65 +65076-2;Your child frequently finds that he or she doesn't know how to keep a conversation going;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child frequently finds that he or she doesn't know how to keep a conversation going [AQ Adolescent];Child difficulty conversation AQ Adol;;ACTIVE;2.36;2.65 +65077-0;Your child finds it easy to read between the lines when someone is talking to her or him;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds it easy to read between the lines when someone is talking to her or him [AQ Adolescent];Child read between lines AQ Adol;;ACTIVE;2.36;2.65 +6507-8;Neisseria meningitidis serogroup w135 Ag;PrThr;Pt;CSF;Ord;LA;MICRO;1;Neisseria meningitidis serogroup w135 Ag [Presence] in Cerebral spinal fluid by Latex agglutination;N men sg W135 Ag CSF Ql LA;;ACTIVE;1.0g;2.64 +65078-8;Your child usually concentrates more on the whole picture, rather than the small details;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child usually concentrates more on the whole picture, rather than the small details [AQ Adolescent];Child whole picture over details AQ Adol;;ACTIVE;2.36;2.65 +65079-6;Your child is not very good at remembering phone numbers;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child is not very good at remembering phone numbers [AQ Adolescent];Child not remember phone numbers AQ Adol;;ACTIVE;2.36;2.65 +65080-4;Your child doesn't usually notice small changes in a situation, or a person's appearance;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child doesn't usually notice small changes in a situation, or a person's appearance [AQ Adolescent];Child notice small changes AQ Adol;;ACTIVE;2.36;2.65 +65081-2;Your child knows how to tell if someone listening to them is getting bored;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child knows how to tell if someone listening to them is getting bored [AQ Adolescent];Child tell if boring others AQ Adol;;ACTIVE;2.36;2.65 +65082-0;Your child finds it easy to do more than one thing at once;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds it easy to do more than one thing at once [AQ Adolescent];Child easy to multi-task AQ Adol;;ACTIVE;2.36;2.65 +65083-8;When your child talks on the phone, he or she is not sure when its their turn to speak;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;When your child talks on the phone, he or she is not sure when its their turn to speak [AQ Adolescent];Child diff phone conversation AQ Adol;;ACTIVE;2.36;2.65 +65084-6;Your child enjoys doing things spontaneously;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child enjoys doing things spontaneously [AQ Adolescent];Child enjoy spontaneity AQ Adol;;ACTIVE;2.36;2.65 +65085-3;Your child is often the last to understand the point of a joke;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child is often the last to understand the point of a joke [AQ Adolescent];Child diff understand joke AQ Adol;;ACTIVE;2.36;2.65 +6508-6;Neisseria meningitidis Ag;PrThr;Pt;CSF;Ord;;MICRO;1;Neisseria meningitidis Ag [Presence] in Cerebral spinal fluid;N men Ag CSF Ql;;ACTIVE;1.0g;2.73 +65086-1;Your child finds it easy to work out what someone is thinking or feeling just by looking at their face;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds it easy to work out what someone is thinking or feeling just by looking at their face [AQ Adolescent];Child easy to read face AQ Adol;;ACTIVE;2.36;2.65 +65087-9;If there is an interruption, your child can switch back to what he or she was doing very quickly;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;If there is an interruption, your child can switch back to what he or she was doing very quickly [AQ Adolescent];Child switch after interrupt AQ Adol;;ACTIVE;2.36;2.65 +65088-7;Your child is good at social chit-chat;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child is good at social chit-chat [AQ Adolescent];Child good social chit-chat AQ Adol;;ACTIVE;2.36;2.65 +65089-5;People often tell them that your child keeps going on and on about the same thing;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;People often tell them that your child keeps going on and on about the same thing [AQ Adolescent];Child go on one thing AQ Adol;;ACTIVE;2.36;2.65 +65090-3;When your child was younger, he or she used to enjoy playing games involving pretending with other children;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;When your child was younger, he or she used to enjoy playing games involving pretending with other children [AQ Adolescent];Child pretend w other children AQ Adol;;ACTIVE;2.36;2.65 +65091-1;Your child likes to collect information about categories of things, types of car, types of bird, types of train, types of plant, etc;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child likes to collect information about categories of things, types of car, types of bird, types of train, types of plant, etc [AQ Adolescent];Child collect categories AQ Adol;;ACTIVE;2.36;2.65 +65092-9;Your child finds it difficult to imagine what it would be like to be someone else;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds it difficult to imagine what it would be like to be someone else [AQ Adolescent];Child diff imagine someone else AQ Adol;;ACTIVE;2.36;2.65 +65093-7;Your child likes to plan any activities he or she participates in carefully;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child likes to plan any activities he or she participates in carefully [AQ Adolescent];Child enjoy planning activities AQ Adol;;ACTIVE;2.36;2.65 +6509-4;Neisseria meningitidis rRNA;PrThr;Pt;CSF;Ord;Probe;MICRO;1;Neisseria meningitidis rRNA [Presence] in Cerebral spinal fluid by Probe;N men rRNA CSF Ql Probe;;ACTIVE;1.0g;2.63 +65094-5;Your child enjoys social occasions;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child enjoys social occasions [AQ Adolescent];Child enjoys social occasions AQ Adol;;ACTIVE;2.36;2.65 +65095-2;Your child finds it difficult to work out peoples intentions;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child finds it difficult to work out peoples intentions [AQ Adolescent];Child diff work out intentions AQ Adol;;ACTIVE;2.36;2.65 +65096-0;New situations make your child anxious;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;New situations make your child anxious [AQ Adolescent];Child anxious new situations AQ Adol;;ACTIVE;2.36;2.65 +65097-8;Your child enjoys meeting new people;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child enjoys meeting new people [AQ Adolescent];Child enjoys meeting new people AQ Adol;;ACTIVE;2.36;2.65 +65098-6;Your child is a good diplomat;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child is a good diplomat [AQ Adolescent];Child good diplomat AQ Adol;;ACTIVE;2.36;2.65 +65099-4;Your child is not very good at remembering peoples date of birth;Find;Pt;^Patient;Ord;AQ Adolescent;PHENX;2;Your child is not very good at remembering peoples date of birth [AQ Adolescent];Child diff remember birth dates AQ Adol;;ACTIVE;2.36;2.65 +651-0;Microscopic observation;Prid;Pt;Urine;Nom;Acid fast stain.Kinyoun modified;MICRO;1;Microscopic observation [Identifier] in Urine by Acid fast stain.Kinyoun modified;Acid fast Mod Kiny Stn Ur;;ACTIVE;1.0;2.21 +65100-0;Does your child join in playing games with other children easily;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child join in playing games with other children easily [CAST];Join games CAST;;ACTIVE;2.36;2.65 +65101-8;Does your child come up to you spontaneously for a chat;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child come up to you spontaneously for a chat [CAST];Chat spontaneously CAST;;ACTIVE;2.36;2.65 +6510-2;Human papilloma virus Ab;PrThr;Pt;Genital;Ord;IA;MICRO;1;Human papilloma virus Ab [Presence] in Genital specimen by Immunoassay;HPV Ab Genital Ql IA;;ACTIVE;1.0g;2.73 +65102-6;Was your child speaking by 2Y old;Find;Pt;^Patient;Ord;CAST;PHENX;2;Was your child speaking by 2 years old [CAST];Speaking by 2 CAST;;ACTIVE;2.36;2.65 +65103-4;Does your child enjoy sports;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child enjoy sports [CAST];Enjoy sports CAST;;ACTIVE;2.36;2.65 +65104-2;Is it important to your child to fit in with the peer group;Find;Pt;^Patient;Ord;CAST;PHENX;2;Is it important to your child to fit in with the peer group [CAST];Important to fit in CAST;;ACTIVE;2.36;2.65 +65105-9;Does your child appear to notice unusual details that others miss;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child appear to notice unusual details that others miss [CAST];Does child notice details CAST;;ACTIVE;2.36;2.65 +65106-7;Does your child tend to take things literally;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child tend to take things literally [CAST];Take things literally CAST;;ACTIVE;2.36;2.65 +65107-5;When your child was 3Y old, did your child spend a lot of time pretending, play-acting being a superhero, or holding teddy's tea parties;Find;Pt;^Patient;Ord;CAST;PHENX;2;When your child was 3Y old, did your child spend a lot of time pretending, play-acting being a superhero, or holding teddy's tea parties [CAST];Pretending at age 3 CAST;;ACTIVE;2.36;2.65 +65108-3;Does your child like to do things over and over again, in the same way all the time;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child like to do things over and over again, in the same way all the time [CAST];Enjoy repetition CAST;;ACTIVE;2.36;2.65 +65109-1;Does your child find it easy to interact with other children;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child find it easy to interact with other children [CAST];Easy interact other children CAST;;ACTIVE;2.36;2.65 +6511-0;Human papilloma virus Ab;PrThr;Pt;Genital;Ord;IB;MICRO;1;Human papilloma virus Ab [Presence] in Genital specimen by Immunoblot;HPV Ab Genital Ql IB;;ACTIVE;1.0g;2.58 +65110-9;Can your child keep a two-way conversation going;Find;Pt;^Patient;Ord;CAST;PHENX;2;Can your child keep a two-way conversation going [CAST];Keep conversation going CAST;;ACTIVE;2.36;2.65 +65111-7;Can your child read appropriately for his or her age;Find;Pt;^Patient;Ord;CAST;PHENX;2;Can your child read appropriately for his or her age [CAST];Read at age level CAST;;ACTIVE;2.36;2.65 +65112-5;Does your child mostly have the same interests as his or her peers;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child mostly have the same interests as his or her peers [CAST];Same interests as peers CAST;;ACTIVE;2.36;2.65 +65113-3;Does your child have an interest which takes up so much time that he or she does little else;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child have an interest which takes up so much time that he or she does little else [CAST];Dominating interest CAST;;ACTIVE;2.36;2.65 +65114-1;Does your child have friends, rather than just acquaintances;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child have friends, rather than just acquaintances [CAST];Friends or acquaintances CAST;;ACTIVE;2.36;2.65 +65115-8;Does your child often bring you things he or she is interested in to show you;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child often bring you things he or she is interested in to show you [CAST];Share things CAST;;ACTIVE;2.36;2.65 +65116-6;Does your child enjoy joking around;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child enjoy joking around [CAST];Enjoy joking around CAST;;ACTIVE;2.36;2.65 +65117-4;Does your child have difficulty understanding the rules for polite behavior;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child have difficulty understanding the rules for polite behavior [CAST];Difficulty polite behavior CAST;;ACTIVE;2.36;2.65 +65118-2;Does your child appear to have an unusual memory for details;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child appear to have an unusual memory for details [CAST];Unusual memory for details CAST;;ACTIVE;2.36;2.65 +65119-0;Is your childs voice unusual, overly adult, flat, or very monotonous;Find;Pt;^Patient;Ord;CAST;PHENX;2;Is your childs voice unusual, overly adult, flat, or very monotonous [CAST];Unusual voice CAST;;ACTIVE;2.36;2.65 +65120-8;Are people important to your child;Find;Pt;^Patient;Ord;CAST;PHENX;2;Are people important to your child [CAST];People are important CAST;;ACTIVE;2.36;2.65 +65121-6;Can your child dress him or herself;Find;Pt;^Patient;Ord;CAST;PHENX;2;Can your child dress him or herself [CAST];Get dressed CAST;;ACTIVE;2.36;2.65 +65122-4;Is your child good at turn-taking in conversation;Find;Pt;^Patient;Ord;CAST;PHENX;2;Is your child good at turn-taking in conversation [CAST];Conversation turn-taking CAST;;ACTIVE;2.36;2.65 +65123-2;Does your child play imaginatively with other children, and engage in role-play;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child play imaginatively with other children, and engage in role-play [CAST];Engage in role-play CAST;;ACTIVE;2.36;2.65 +65124-0;Does your child often do or say things that are tactless or socially inappropriate;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child often do or say things that are tactless or socially inappropriate [CAST];Socially inappropriate behavior CAST;;ACTIVE;2.36;2.65 +65125-7;Can your child count to 50 without leaving out any numbers;Find;Pt;^Patient;Ord;CAST;PHENX;2;Can your child count to 50 without leaving out any numbers [CAST];Count to 50 CAST;;ACTIVE;2.36;2.65 +65126-5;Does your child make normal eye-contact;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child make normal eye-contact [CAST];Make eye-contact CAST;;ACTIVE;2.36;2.65 +65127-3;Does your child have any unusual and repetitive movements;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child have any unusual and repetitive movements [CAST];Repetitive movements CAST;;ACTIVE;2.36;2.65 +6512-8;Human papilloma virus Ab;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Human papilloma virus Ab [Presence] in Tissue by Immunoassay;HPV Ab Tiss Ql IA;;ACTIVE;1.0g;2.56 +65128-1;Is your childs social behavior very one-sided and always on your childs own terms;Find;Pt;^Patient;Ord;CAST;PHENX;2;Is your childs social behavior very one-sided and always on your childs own terms [CAST];One-sided social behavior CAST;;ACTIVE;2.36;2.65 +65129-9;Does your child sometimes say you or your child when he or she means I;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child sometimes say you or your child when he or she means I [CAST];You or I CAST;;ACTIVE;2.36;2.65 +65130-7;Does your child prefer imaginative activities such as play-acting or story-telling, rather than numbers or lists of facts;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child prefer imaginative activities such as play-acting or story-telling, rather than numbers or lists of facts [CAST];Imagination or facts CAST;;ACTIVE;2.36;2.65 +65131-5;Does your child sometimes lose the listener because of not explaining what your child is talking about;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child sometimes lose the listener because of not explaining what your child is talking about [CAST];Does not explain topic CAST;;ACTIVE;2.36;2.65 +65132-3;Can your child ride a bicycle, even if with stabilizers;Find;Pt;^Patient;Ord;CAST;PHENX;2;Can your child ride a bicycle, even if with stabilizers [CAST];Ride bicycle CAST;;ACTIVE;2.36;2.65 +65133-1;Does your child try to impose routines on him or herself, or on others, in such a way that it causes problems;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child try to impose routines on him or herself, or on others, in such a way that it causes problems [CAST];Self imposed routine CAST;;ACTIVE;2.36;2.65 +65134-9;Does your child care how he or she is perceived by the rest of the group;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child care how he or she is perceived by the rest of the group [CAST];Care how perceived CAST;;ACTIVE;2.36;2.65 +65135-6;Does your child often turn conversations to his or her favorite subject rather than following what the other person wants to talk about;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child often turn conversations to his or her favorite subject rather than following what the other person wants to talk about [CAST];Redirects conversation CAST;;ACTIVE;2.36;2.65 +6513-6;Human papilloma virus Ab;PrThr;Pt;Tiss;Ord;IB;MICRO;1;Human papilloma virus Ab [Presence] in Tissue by Immunoblot;HPV Ab Tiss Ql IB;;ACTIVE;1.0g;2.58 +65136-4;Does your child have odd or unusual phrases;Find;Pt;^Patient;Ord;CAST;PHENX;2;Does your child have odd or unusual phrases [CAST];Unusual phrases CAST;;ACTIVE;2.36;2.65 +65137-2;Have teachers or health visitors ever expressed any concerns about your childs development;Find;Pt;^Patient;Ord;CAST;PHENX;2;Have teachers or health visitors ever expressed any concerns about your childs development [CAST];Teachers concerns CAST;;ACTIVE;2.36;2.65 +65139-8;Teachers or health visitors concerns about your child development;Find;Pt;^Patient;Nom;CAST;PHENX;2;Teachers or health visitors concerns about your child development [CAST];Teachers concerns specify CAST;;ACTIVE;2.36;2.65 +65140-6;Has your child ever been diagnosed with language delay;Find;Pt;^Patient;Ord;CAST;PHENX;2;Has your child ever been diagnosed with language delay [CAST];Diagnosed language delay CAST;;ACTIVE;2.36;2.65 +65141-4;Has your child ever been diagnosed with hyperactivity - attention deficit disorder, ADHD;Find;Pt;^Patient;Ord;CAST;PHENX;2;Has your child ever been diagnosed with hyperactivity - attention deficit disorder, ADHD [CAST];Diagnosed ADHD CAST;;ACTIVE;2.36;2.65 +65142-2;Has your child ever been diagnosed with hearing or visual difficulties;Find;Pt;^Patient;Ord;CAST;PHENX;2;Has your child ever been diagnosed with hearing or visual difficulties [CAST];Dx hearing visual diff child CAST;;ACTIVE;2.36;2.65 +65143-0;Has your child ever been diagnosed with autism spectrum condition, including aspergers syndrome;Find;Pt;^Patient;Ord;CAST;PHENX;2;Has your child ever been diagnosed with autism spectrum condition, including aspergers syndrome [CAST];Diagnosed autism spectrum CAST;;ACTIVE;2.36;2.65 +6514-4;Human papilloma virus rRNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus rRNA [Presence] in Genital specimen by NAA with probe detection;HPV rRNA Genital Ql NAA+probe;;ACTIVE;1.0g;2.73 +65144-8;Has your child ever been diagnosed with a physical disability;Find;Pt;^Patient;Ord;CAST;PHENX;2;Has your child ever been diagnosed with a physical disability [CAST];Diagnosed physical disability CAST;;ACTIVE;2.36;2.65 +65145-5;I see myself as someone who is talkative;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is talkative [BFI];Talkative BFI;;ACTIVE;2.36;2.65 +65146-3;I see myself as someone who tends to find fault with others;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who tends to find fault with others [BFI];Finds fault BFI;;ACTIVE;2.36;2.65 +65147-1;I see myself as someone who does a thorough job;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who does a thorough job [BFI];Thorough job BFI;;ACTIVE;2.36;2.65 +65148-9;I see myself as someone who is depressed, blue;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is depressed, blue [BFI];Depressed BFI;;ACTIVE;2.36;2.65 +65149-7;I see myself as someone who is original, comes up with new ideas;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is original, comes up with new ideas [BFI];Original BFI;;ACTIVE;2.36;2.65 +65150-5;I see myself as someone who is reserved;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is reserved [BFI];Reserved BFI;;ACTIVE;2.36;2.65 +6515-1;Human papilloma virus rRNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus rRNA [Presence] in Tissue by NAA with probe detection;HPV rRNA Tiss Ql NAA+probe;;ACTIVE;1.0g;2.73 +65151-3;I see myself as someone who is helpful and unselfish with others;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is helpful and unselfish with others [BFI];Helpful BFI;;ACTIVE;2.36;2.65 +65152-1;I see myself as someone who can be somewhat careless;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who can be somewhat careless [BFI];Somewhat careless BFI;;ACTIVE;2.36;2.65 +65153-9;I see myself as someone who is relaxed, handles stress well;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is relaxed, handles stress well [BFI];Relaxed BFI;;ACTIVE;2.36;2.65 +65154-7;I see myself as someone who is curious about many different things;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is curious about many different things [BFI];Curious BFI;;ACTIVE;2.36;2.65 +65155-4;I see myself as someone who is full of energy;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is full of energy [BFI];Energetic BFI;;ACTIVE;2.36;2.65 +65156-2;I see myself as someone who starts quarrels with others;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who starts quarrels with others [BFI];Starts quarrels BFI;;ACTIVE;2.36;2.65 +65157-0;I see myself as someone who is a reliable worker;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is a reliable worker [BFI];Reliable worker BFI;;ACTIVE;2.36;2.65 +65158-8;I see myself as someone who can be tense;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who can be tense [BFI];Tense BFI;;ACTIVE;2.36;2.65 +65159-6;I see myself as someone who is ingenious, a deep thinker;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is ingenious, a deep thinker [BFI];Ingenious BFI;;ACTIVE;2.36;2.65 +65160-4;I see myself as someone who generates a lot of enthusiasm;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who generates a lot of enthusiasm [BFI];Generates enthusiasm BFI;;ACTIVE;2.36;2.65 +65161-2;I see myself as someone who has a forgiving nature;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who has a forgiving nature [BFI];Forgiving BFI;;ACTIVE;2.36;2.65 +65162-0;I see myself as someone who tends to be disorganized;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who tends to be disorganized [BFI];Disorganized BFI;;ACTIVE;2.36;2.65 +65163-8;I see myself as someone who worries a lot;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who worries a lot [BFI];Worries BFI;;ACTIVE;2.36;2.65 +65164-6;I see myself as someone who has an active imagination;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who has an active imagination [BFI];Active imagination BFI;;ACTIVE;2.36;2.65 +65165-3;I see myself as someone who tends to be quiet;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who tends to be quiet [BFI];Myself quiet BFI;;ACTIVE;2.36;2.65 +65166-1;I see myself as someone who is generally trusting;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is generally trusting [BFI];Trusting BFI;;ACTIVE;2.36;2.65 +65167-9;I see myself as someone who tends to be lazy;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who tends to be lazy [BFI];Lazy BFI;;ACTIVE;2.36;2.65 +65168-7;I see myself as someone who is emotionally stable, not easily upset;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is emotionally stable, not easily upset [BFI];Emotionally stable BFI;;ACTIVE;2.36;2.65 +6516-9;Human papilloma virus rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus rRNA [Presence] in Specimen by NAA with probe detection;HPV rRNA Spec Ql NAA+probe;;ACTIVE;1.0g;2.73 +65169-5;I see myself as someone who is inventive;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is inventive [BFI];Inventive BFI;;ACTIVE;2.36;2.65 +65170-3;I see myself as someone who has an assertive personality;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who has an assertive personality [BFI];Assertive BFI;;ACTIVE;2.36;2.65 +65171-1;I see myself as someone who can be cold and aloof;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who can be cold and aloof [BFI];Aloof BFI;;ACTIVE;2.36;2.65 +65172-9;I see myself as someone who perseveres until the task is finished;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who perseveres until the task is finished [BFI];Persevere BFI;;ACTIVE;2.36;2.65 +65173-7;I see myself as someone who can be moody;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who can be moody [BFI];Moody BFI;;ACTIVE;2.36;2.65 +65174-5;I see myself as someone who values artistic, aesthetic experiences;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who values artistic, aesthetic experiences [BFI];Artistic experiences BFI;;ACTIVE;2.36;2.65 +65175-2;I see myself as someone who is sometimes shy, inhibited;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is sometimes shy, inhibited [BFI];Shy - inhibited BFI;;ACTIVE;2.36;2.65 +65176-0;I see myself as someone who is considerate, kind to almost everyone;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is considerate, kind to almost everyone [BFI];Considerate BFI;;ACTIVE;2.36;2.65 +6517-7;Parvovirus B19 Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Parvovirus B19 IgM Ab [Presence] in Serum by Immunoblot;B19V IgM Ser Ql IB;;ACTIVE;1.0g;2.58 +65177-8;I see myself as someone who does things efficiently;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who does things efficiently [BFI];Efficientl BFI;;ACTIVE;2.36;2.65 +65178-6;I see myself as someone who remains calm in tense situations;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who remains calm in tense situations [BFI];Remains calm BFI;;ACTIVE;2.36;2.65 +65179-4;I see myself as someone who prefers work that is routine;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who prefers work that is routine [BFI];Prefers routine BFI;;ACTIVE;2.36;2.65 +65180-2;I see myself as someone who is outgoing, sociable;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is outgoing, sociable [BFI];Outgoing BFI;;ACTIVE;2.36;2.65 +65181-0;I see myself as someone who is sometimes rude to others;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is sometimes rude to others [BFI];Rude to others BFI;;ACTIVE;2.36;2.65 +65182-8;I see myself as someone who makes plans and follows through on them;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who makes plans and follows through on them [BFI];Follows through on plans BFI;;ACTIVE;2.36;2.65 +65183-6;I see myself as someone who gets nervous easily;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who gets nervous easily [BFI];Gets nervous BFI;;ACTIVE;2.36;2.65 +65184-4;I see myself as someone who likes to reflect, play with ideas;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who likes to reflect, play with ideas [BFI];Reflective BFI;;ACTIVE;2.36;2.65 +6518-5;Pneumocystis jiroveci Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Serum by Immunofluorescence;P jiroveci Ag Ser Ql IF;;ACTIVE;1.0g;2.56 +65185-1;I see myself as someone who has few artistic interests;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who has few artistic interests [BFI];Few artistic interests BFI;;ACTIVE;2.36;2.65 +65186-9;I see myself as someone who likes to cooperate with others;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who likes to cooperate with others [BFI];Cooperates with others BFI;;ACTIVE;2.36;2.65 +65187-7;I see myself as someone who is easily distracted;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is easily distracted [BFI];Easily distracted BFI;;ACTIVE;2.36;2.65 +65188-5;I see myself as someone who is sophisticated in art, music or literature;Find;Pt;^Patient;Ord;BFI;PHENX;2;I see myself as someone who is sophisticated in art, music or literature [BFI];Sophisticated art music literature BFI;;ACTIVE;2.36;2.65 +65189-3;During the past 30D, about how often did you feel nervous;Find;30D;^Patient;Ord;Kessler 6 Distress;PHENX;2;During the past 30 days, about how often did you feel nervous [Kessler 6 Distress];Nervous 30D K6;;ACTIVE;2.36;2.65 +65190-1;During the past 30D, about how often did you feel hopeless;Find;30D;^Patient;Ord;Kessler 6 Distress;PHENX;2;During the past 30 days, about how often did you feel hopeless [Kessler 6 Distress];Hopeless 30D K6;;ACTIVE;2.36;2.65 +65191-9;During the past 30D, about how often did you feel restless or fidgety;Find;30D;^Patient;Ord;Kessler 6 Distress;SURVEY.MTLHLTH;4;During the past 30 days, about how often did you feel restless or fidgety [Kessler 6 Distress];;;ACTIVE;2.36;2.61 +65192-7;During the past 30D, about how often did you feel so depressed that nothing could cheer you up;Find;30D;^Patient;Ord;Kessler 6 Distress;PHENX;2;During the past 30 days, about how often did you feel so depressed that nothing could cheer you up [Kessler 6 Distress];Depressed 30D K6;;ACTIVE;2.36;2.65 +6519-3;Pneumocystis jiroveci Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Sputum by Immunofluorescence;P jiroveci Ag Spt Ql IF;;ACTIVE;1.0g;2.56 +65193-5;Taking them altogether, did these feelings occur more often in the past 30D than is usual for you, about the same as usual, or less often than usual;Find;30D;^Patient;Ord;Kessler 6 Distress;PHENX;2;Taking them altogether, did these feelings occur more often in the past 30 days than is usual for you, about the same as usual, or less often than usual [Kessler 6 Distress];Feelings last 30D K6;;ACTIVE;2.36;2.65 +65194-3;During the past 30D, how many Ds out of 30 were you totally unable to work or carry out your normal activities because of these feelings;NRat;30D;^Patient;Qn;Kessler 6 Distress;PHENX;2;During the past 30 days, how many days out of 30 were you totally unable to work or carry out your normal activities because of these feelings [Kessler 6 Distress];Number Ds of 30D worked nRate K6;;ACTIVE;2.36;2.65 +65195-0;Not counting the D you reported in response to 3, how many D in the past 30 were you able to do only half or less of what you would normally have been able to do, because of these feelings;NRat;30D;^Patient;Qn;Kessler 6 Distress;PHENX;2;Not counting the days you reported in response to 3, how many days in the past 30 were you able to do only half or less of what you would normally have been able to do, because of these feelings [Kessler 6 Distress];Ds do only half 30D nRate K6;;ACTIVE;2.36;2.65 +65196-8;During the past 30D, about how often did you feel that everything was an effort;Find;30D;^Patient;Ord;Kessler 6 Distress;PHENX;2;During the past 30 days, about how often did you feel that everything was an effort [Kessler 6 Distress];Everything an effort 30D K6;;ACTIVE;2.36;2.65 +65197-6;During the past 30D, how many times did you see a doctor or other health professional about these feelings;NRat;30D;^Patient;Qn;Kessler 6 Distress;PHENX;2;During the past 30 days, how many times did you see a doctor or other health professional about these feelings [Kessler 6 Distress];Number times see doctor 30D nRate K6;;ACTIVE;2.36;2.65 +65198-4;During the past 30D, about how often did you feel worthless;Find;30D;^Patient;Ord;Kessler 6 Distress;PHENX;2;During the past 30 days, about how often did you feel worthless [Kessler 6 Distress];Worthless 30D K6;;ACTIVE;2.36;2.65 +65199-2;During the past 30D, how often have physical health problems been the main cause of these feelings;Find;30D;^Patient;Ord;Kessler 6 Distress;PHENX;2;During the past 30 days, how often have physical health problems been the main cause of these feelings [Kessler 6 Distress];Physical health cause problems 30D K6;;ACTIVE;2.36;2.65 +65200-8;Have you ever experienced, witnessed, or otherwise been involved in any events that could have brought serious harm or even death to you or someone else;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever experienced, witnessed, or otherwise been involved in any events that could have brought serious harm or even death to you or someone else [PhenX];Experienced harmful events PhenX;;TRIAL;2.36;2.65 +6520-1;Pneumocystis carinii Ag;ACnc;Pt;XXX;Ord;IF;MICRO;1;Deprecated Pneumocystis jiroveci Ag [Presence] in Unspecified specimen by Immunofluorescence;Deprecated P carinii Ag XXX Ql IF;;DEPRECATED;1.0g;2.69 +65201-6;Specify, in general, what you have you ever experienced, witnessed, or otherwise been involved in any events that could have brought serious harm or even death to you or someone else;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Specify, in general, what you have you ever experienced, witnessed, or otherwise been involved in any events that could have brought serious harm or even death to you or someone else [PhenX];Specify harmful events PhenX;;TRIAL;2.36;2.65 +65202-4;Did this event cause you to have intense feelings of fear, helplessness, or horror;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did this event cause you to have intense feelings of fear, helplessness, or horror [PhenX];Event caused horror PhenX;;TRIAL;2.36;2.65 +65203-2;If this event caused you to have intense feelings of fear, helplessness, or horror, specify;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If this event caused you to have intense feelings of fear, helplessness, or horror, specify [PhenX];Event caused horror specify PhenX;;TRIAL;2.36;2.65 +65204-0;Have you ever been bothered by unwanted thoughts, or dreams, or images that kept coming back to you, about a traumatic event that you experienced or witnessed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been bothered by unwanted thoughts, or dreams, or images that kept coming back to you, about a traumatic event that you experienced or witnessed [PhenX];Bothered by event thoughts PhenX;;TRIAL;2.36;2.65 +65205-7;Have you ever felt as if you were reliving some traumatic event that you experienced or witnessed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever felt as if you were reliving some traumatic event that you experienced or witnessed [PhenX];Reliving event PhenX;;TRIAL;2.36;2.65 +65206-5;Have you ever been intensely distressed or extremely anxious when you were reminded in some way about a traumatic event that you experienced or witnessed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been intensely distressed or extremely anxious when you were reminded in some way about a traumatic event that you experienced or witnessed [PhenX];Anxious about event PhenX;;TRIAL;2.36;2.65 +65207-3;Have you tried in general to avoid thinking or talking about the event;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you tried in general to avoid thinking or talking about the event [PhenX];Avoid thinking of event PhenX;;TRIAL;2.36;2.65 +65208-1;Have you tried in general to avoid activities, places, or people that remind you of the event;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you tried in general to avoid activities, places, or people that remind you of the event [PhenX];Avoid activities PhenX;;TRIAL;2.36;2.65 +65209-9;Are you unable to recall important parts of the event;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you unable to recall important parts of the event [PhenX];Unable to remember PhenX;;TRIAL;2.36;2.65 +65210-7;Since the event, do you tend to feel detached from other people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since the event, do you tend to feel detached from other people [PhenX];Detached since event PhenX;;TRIAL;2.36;2.65 +65211-5;Since the event, have you been unable to experience a full range of feelings;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since the event, have you been unable to experience a full range of feelings [PhenX];Full range of feelings PhenX;;TRIAL;2.36;2.65 +65212-3;Since the event, have you found yourself unable to see a future for yourself;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since the event, have you found yourself unable to see a future for yourself [PhenX];Unable to see a future PhenX;;TRIAL;2.36;2.65 +65213-1;Since this event happened, have you had problems with difficulty falling asleep or staying asleep, apart from depression or mania;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since this event happened, have you had problems with difficulty falling asleep or staying asleep, apart from depression or mania [PhenX];Difficulty falling asleep PhenX;;TRIAL;2.36;2.65 +65214-9;Since this event happened, have you had problems with irritability or angry outbursts, apart from depression or mania;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since this event happened, have you had problems with irritability or angry outbursts, apart from depression or mania [PhenX];Irritable since event PhenX;;TRIAL;2.36;2.65 +65215-6;Since this event happened, have you had problems with difficulty concentrating, apart from depression or mania;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since this event happened, have you had problems with difficulty concentrating, apart from depression or mania [PhenX];Diff concentrating since event PhenX;;TRIAL;2.36;2.65 +65216-4;Since this event happened, have you had problems with being too much on alert;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since this event happened, have you had problems with being too much on alert [PhenX];On alert since event PhenX;;TRIAL;2.36;2.65 +65217-2;Since this event happened, have you had problems with being too easily startled;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Since this event happened, have you had problems with being too easily startled [PhenX];Easily startled since event PhenX;;TRIAL;2.36;2.65 +65218-0;Have you been very upset about having these symptoms;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you been very upset about having these symptoms [PhenX];Upset by symptoms PhenX;;TRIAL;2.36;2.65 +6521-9;Pneumocystis jiroveci DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection;P jiroveci DNA Spec Ql NAA+probe;;ACTIVE;1.0g;2.73 +65219-8;Have these symptoms interfered with your ability to work, to be with others, or to function in other areas of life;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have these symptoms interfered with your ability to work, to be with others, or to function in other areas of life [PhenX];Symptoms interfere with work PhenX;;TRIAL;2.36;2.65 +65220-6;How long did these symptoms last;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long did these symptoms last [PhenX];Symptoms last PhenX;;TRIAL;2.36;2.65 +65221-4;When did the traumatic event occur - if several, ask about the most closely associated with symptoms;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did the traumatic event occur - if several, ask about the most closely associated with symptoms [Date and time] [PhenX];When did event occur PhenX;;TRIAL;2.36;2.65 +65222-2;Symptom onset;TmStp;Pt;^Patient;Qn;;H&P.PX;2;Date and time of symptom onset;Date+time symptom onset;;ACTIVE;2.36;2.72 +65223-0;Age of onset of symptoms;Time;Pt;^Patient;Qn;;H&P.HX;2;Age of onset of symptoms;Age of onset;;ACTIVE;2.36;2.65 +65224-8;How often do you have trouble wrapping up the final details of a project, once the challenging parts have been done;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you have trouble wrapping up the final details of a project, once the challenging parts have been done [ASRS];Trouble wrapping up project ASRS;;ACTIVE;2.36;2.65 +65225-5;How often do you have difficulty getting things in order when you have to do a task that requires organization;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you have difficulty getting things in order when you have to do a task that requires organization [ASRS];Difficulty getting organized ASRS;;ACTIVE;2.36;2.65 +65226-3;How often do you have problems remembering appointments or obligations;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you have problems remembering appointments or obligations [ASRS];Diff remembering appointments ASRS;;ACTIVE;2.36;2.65 +6522-7;Rabies virus Ab;ACnc;Pt;CSF;Qn;;MICRO;1;Rabies virus Ab [Units/volume] in Cerebral spinal fluid;RABV Ab CSF-aCnc;;ACTIVE;1.0g;2.69 +65227-1;When you have a task that requires a lot of thought, how often do you avoid or delay getting started;Find;Pt;^Patient;Ord;ASRS;PHENX;2;When you have a task that requires a lot of thought, how often do you avoid or delay getting started [ASRS];Procrastinate tasks ASRS;;ACTIVE;2.36;2.65 +65228-9;How often do you fidget or squirm with your hands or feet when you have to sit down for a long time;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you fidget or squirm with your hands or feet when you have to sit down for a long time [ASRS];Fidget while sitting ASRS;;ACTIVE;2.36;2.65 +65229-7;How often do you feel overly active and compelled to do things, like you were driven by a motor;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you feel overly active and compelled to do things, like you were driven by a motor [ASRS];Feet driven by motor ASRS;;ACTIVE;2.36;2.65 +65230-5;How often do you make careless mistakes when you have to work on a boring or difficult project;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you make careless mistakes when you have to work on a boring or difficult project [ASRS];Careless mistakes tedious task ASRS;;ACTIVE;2.36;2.65 +65231-3;How often do you have difficulty keeping your attention when you are doing boring or repetitive work;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you have difficulty keeping your attention when you are doing boring or repetitive work [ASRS];Diff attention repetitive task ASRS;;ACTIVE;2.36;2.65 +65232-1;How often do you have difficulty concentrating on what people say to you, even when they are speaking to you directly;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you have difficulty concentrating on what people say to you, even when they are speaking to you directly [ASRS];Diff concentrating on conversation ASRS;;ACTIVE;2.36;2.65 +65233-9;How often do you misplace or have difficulty finding things at home or at work;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you misplace or have difficulty finding things at home or at work [ASRS];Misplace items home work ASRS;;ACTIVE;2.36;2.65 +65234-7;How often are you distracted by activity or noise around you;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often are you distracted by activity or noise around you [ASRS];Freq distracted by noise ASRS;;ACTIVE;2.36;2.65 +6523-5;Rabies virus Ab.Neut;ACnc;Pt;CSF;Qn;Neut;MICRO;1;Rabies virus neutralizing antibody [Units/volume] in Cerebral spinal fluid by Neutralization test;RABV NAb CSF Nt-aCnc;;ACTIVE;1.0g;2.72 +65235-4;How often do you leave your seat in meetings or other situations in which you are expected to remain seated;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you leave your seat in meetings or other situations in which you are expected to remain seated [ASRS];Freq leave seat at meetings ASRS;;ACTIVE;2.36;2.65 +65236-2;How often do you feel restless or fidgety;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you feel restless or fidgety [ASRS];Restless fidgety ASRS;;ACTIVE;2.36;2.65 +65237-0;How often do you have difficulty unwinding and relaxing when you have time to yourself;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you have difficulty unwinding and relaxing when you have time to yourself [ASRS];Difficulty unwinding ASRS;;ACTIVE;2.36;2.65 +65238-8;How often do you find yourself talking too much when you are in social situations;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you find yourself talking too much when you are in social situations [ASRS];Freq talk too much ASRS;;ACTIVE;2.36;2.65 +65239-6;When you're in a conversation, how often do you find yourself finishing the sentences of the people you are talking to, before they can finish them themselves;Find;Pt;^Patient;Ord;ASRS;PHENX;2;When you're in a conversation, how often do you find yourself finishing the sentences of the people you are talking to, before they can finish them themselves [ASRS];Finish others sentences ASRS;;ACTIVE;2.36;2.65 +65240-4;How often do you have difficulty waiting your turn in situations when turn taking is required;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you have difficulty waiting your turn in situations when turn taking is required [ASRS];Difficulty waiting turn ASRS;;ACTIVE;2.36;2.65 +65241-2;How often do you interrupt others when they are busy;Find;Pt;^Patient;Ord;ASRS;PHENX;2;How often do you interrupt others when they are busy [ASRS];Interrupt others when busy ASRS;;ACTIVE;2.36;2.65 +65242-0;Compared to other children, does this child give close attention to detail and avoid careless mistakes;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child give close attention to detail and avoid careless mistakes [SWAN];Close attention to detail SWAN;;ACTIVE;2.36;2.65 +6524-3;Rabies virus Ab.Neut;ACnc;Pt;Ser;Qn;Neut;MICRO;1;Rabies virus neutralizing antibody [Units/volume] in Serum by Neutralization test;RABV NAb Ser Nt-aCnc;;ACTIVE;1.0g;2.73 +65243-8;Compared to other children, does this child sustain attention on tasks or play activities;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child sustain attention on tasks or play activities [SWAN];Sustain attention SWAN;;ACTIVE;2.36;2.65 +65244-6;Compared to other children, does this child listen when spoken to directly;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child listen when spoken to directly [SWAN];Listen when spoken to SWAN;;ACTIVE;2.36;2.65 +65245-3;Compared to other children, does this child follow through on instructions and finish school work or chores;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child follow through on instructions and finish school work or chores [SWAN];Follow through chores SWAN;;ACTIVE;2.36;2.65 +65246-1;Compared to other children, does this child organize tasks and activities;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child organize tasks and activities [SWAN];Organize tasks activities SWAN;;ACTIVE;2.36;2.65 +65247-9;Compared to other children, does this child engage in tasks that require sustained mental effort;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child engage in tasks that require sustained mental effort [SWAN];Engage mental effort SWAN;;ACTIVE;2.36;2.65 +65248-7;Compared to other children, does this child keep track of things necessary for activities;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child keep track of things necessary for activities [SWAN];Keep track activity items SWAN;;ACTIVE;2.36;2.65 +65249-5;Compared to other children, does this child ignore extraneous stimuli;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child ignore extraneous stimuli [SWAN];Ignore extraneous stimuli SWAN;;ACTIVE;2.36;2.65 +6525-0;Rabies virus Ab.Neut;ACnc;Pt;Tiss;Qn;Neut;MICRO;1;Rabies virus neutralizing antibody [Units/volume] in Tissue by Neutralization test;RABV NAb Tiss Nt-aCnc;;ACTIVE;1.0g;2.72 +65250-3;Compared to other children, does this child remember daily activities;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child remember daily activities [SWAN];Remember daily activities SWAN;;ACTIVE;2.36;2.65 +65251-1;Compared to other children, does this child sit still, control movement of hands or feet or control squirming;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child sit still, control movement of hands or feet or control squirming [SWAN];Sit still SWAN;;ACTIVE;2.36;2.65 +65252-9;Compared to other children, does this child stay seated, when required by class rules or social conventions;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child stay seated, when required by class rules or social conventions [SWAN];Stay seated SWAN;;ACTIVE;2.36;2.65 +65253-7;Compared to other children, does this child modulate motor activity, inhibit inappropriate running or climbing;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child modulate motor activity, inhibit inappropriate running or climbing [SWAN];Modulate motor activity SWAN;;ACTIVE;2.36;2.65 +65254-5;Compared to other children, does this child play quietly, keep noise level reasonable;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child play quietly, keep noise level reasonable [SWAN];Play quietly SWAN;;ACTIVE;2.36;2.65 +65255-2;Compared to other children, does this child settle down and rest, control constant activity;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child settle down and rest, control constant activity [SWAN];Settle down SWAN;;ACTIVE;2.36;2.65 +65256-0;Compared to other children, does this child modulate verbal activity, control excess talking;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child modulate verbal activity, control excess talking [SWAN];Control excess talking SWAN;;ACTIVE;2.36;2.65 +65257-8;Compared to other children, does this child reflect on questions, control blurting out answers;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child reflect on questions, control blurting out answers [SWAN];Control blurting out SWAN;;ACTIVE;2.36;2.65 +65258-6;Compared to other children, does this child await turn, stand in line and take turns;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child await turn, stand in line and take turns [SWAN];Await turns SWAN;;ACTIVE;2.36;2.65 +65259-4;Compared to other children, does this child enter into conversation and games, control interrupting or intruding;Find;Pt;^Patient;Ord;SWAN ADHD;PHENX;2;Compared to other children, does this child enter into conversation and games, control interrupting or intruding [SWAN];Control interrupting SWAN;;ACTIVE;2.36;2.65 +65260-2;I'm optimistic more often than not;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I'm optimistic more often than not [PhenX];Optimistic PhenX;;TRIAL;2.36;2.65 +65261-0;How other people feel is important to me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How other people feel is important to me [PhenX];Other people feelings PhenX;;TRIAL;2.36;2.65 +65262-8;I often act on immediate needs;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I often act on immediate needs [PhenX];Act on immediate needs PhenX;;TRIAL;2.36;2.65 +65263-6;I have no strong desire to parachute out of an airplane;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have no strong desire to parachute out of an airplane [PhenX];Parachute PhenX;;TRIAL;2.36;2.65 +65264-4;I've often missed things I promised to attend;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I've often missed things I promised to attend [PhenX];Missed events PhenX;;TRIAL;2.36;2.65 +65265-1;I would enjoy being in a high-speed chase;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I would enjoy being in a high-speed chase [PhenX];High-speed chase PhenX;;TRIAL;2.36;2.65 +65266-9;I am well-equipped to deal with stress;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am well-equipped to deal with stress [PhenX];Deal with stress PhenX;;TRIAL;2.36;2.65 +65267-7;I don't mind if someone I dislike gets hurt;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I don't mind if someone I dislike gets hurt [PhenX];Someone I dislike gets hurt PhenX;;TRIAL;2.36;2.65 +6526-8;Rabies virus Ab;ACnc;Pt;XXX;Qn;;MICRO;1;Rabies virus Ab [Units/volume] in Specimen;RABV Ab Spec-aCnc;;ACTIVE;1.0g;2.73 +65268-5;My impulsive decisions have caused problems with loved ones;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My impulsive decisions have caused problems with loved ones [PhenX];Impulsive decisions PhenX;;TRIAL;2.36;2.65 +65269-3;I get scared easily;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I get scared easily [PhenX];Easily scared PhenX;;TRIAL;2.36;2.65 +65270-1;I sympathize with others problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I sympathize with others problems [PhenX];Sympathize with others PhenX;;TRIAL;2.36;2.65 +65271-9;I have missed work without bothering to call in;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have missed work without bothering to call in [PhenX];Missed work W/O calling PhenX;;TRIAL;2.36;2.65 +65272-7;I'm a born leader;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I'm a born leader [PhenX];Born leader PhenX;;TRIAL;2.36;2.65 +65273-5;I enjoy a good physical fight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I enjoy a good physical fight [PhenX];Enjoy physical fight PhenX;;TRIAL;2.36;2.65 +65274-3;I jump into things without thinking;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I jump into things without thinking [PhenX];Jump W/O thinking PhenX;;TRIAL;2.36;2.65 +65275-0;I have a hard time making things turn out the way I want;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have a hard time making things turn out the way I want [PhenX];Things turn out my way PhenX;;TRIAL;2.36;2.65 +6527-6;Rabies virus Ab.Neut;ACnc;Pt;XXX;Qn;Neut;MICRO;1;Rabies virus neutralizing antibody [Units/volume] in Specimen by Neutralization test;RABV NAb Spec Nt-aCnc;;ACTIVE;1.0g;2.73 +65276-8;I return insults;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I return insults [PhenX];Return insults PhenX;;TRIAL;2.36;2.65 +65277-6;I've gotten in trouble because I missed too much school;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I've gotten in trouble because I missed too much school [PhenX];Missed too much school PhenX;;TRIAL;2.36;2.65 +65278-4;I have a knack for influencing people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have a knack for influencing people [PhenX];Influence people PhenX;;TRIAL;2.36;2.65 +65279-2;It doesn't bother me to see someone else in pain;Find;Pt;^Patient;Ord;PhenX;PHENX;2;It doesn't bother me to see someone else in pain [PhenX];Other peoples pain PhenX;;TRIAL;2.36;2.65 +652-8;Microscopic observation;Prid;Pt;Urine;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Urine by Acid fast stain.Ziehl-Neelsen;ZN Stn Ur;;ACTIVE;1.0;2.21 +65280-0;I have good control over myself;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have good control over myself [PhenX];Good self control PhenX;;TRIAL;2.36;2.65 +65281-8;I function well in new situations, even when unprepared;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I function well in new situations, even when unprepared [PhenX];New situations PhenX;;TRIAL;2.36;2.65 +65282-6;I enjoy pushing people around sometimes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I enjoy pushing people around sometimes [PhenX];Enjoy pushing people around PhenX;;TRIAL;2.36;2.65 +65283-4;I have taken money from someone's purse or wallet without asking;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have taken money from someone's purse or wallet without asking [PhenX];Take money from wallet PhenX;;TRIAL;2.36;2.65 +6528-4;Rabies virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Rabies virus Ag [Presence] in Tissue by Immunofluorescence;RABV Ag Tiss Ql IF;;ACTIVE;1.0g;2.56 +65284-2;I don't think of myself as talented;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I don't think of myself as talented [PhenX];Not talented PhenX;;TRIAL;2.36;2.65 +65285-9;I taunt people just to stir things up;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I taunt people just to stir things up [PhenX];Taunt others PhenX;;TRIAL;2.36;2.65 +65286-7;People often abuse my trust;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People often abuse my trust [PhenX];Abuse trust PhenX;;TRIAL;2.36;2.65 +65287-5;I'm afraid of far fewer things than most people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I'm afraid of far fewer things than most people [PhenX];Less fear than others PhenX;;TRIAL;2.36;2.65 +65288-3;I don't see any point in worrying if what I do hurts someone else;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I don't see any point in worrying if what I do hurts someone else [PhenX];Not worried hurting others PhenX;;TRIAL;2.36;2.65 +65289-1;I keep appointments I make;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I keep appointments I make [PhenX];Keep appointments PhenX;;TRIAL;2.36;2.65 +65290-9;I often get bored quickly and lose interest;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I often get bored quickly and lose interest [PhenX];Bore quickly PhenX;;TRIAL;2.36;2.65 +65291-7;I can get over things that would traumatize others;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can get over things that would traumatize others [PhenX];Not traumatized like others PhenX;;TRIAL;2.36;2.65 +6529-2;Rabies virus Ag;ACnc;Pt;Tiss;Qn;IF;MICRO;1;Rabies virus Ag [Units/volume] in Tissue by Immunofluorescence;RABV Ag Tiss IF-aCnc;;DISCOURAGED;1.0g;2.69 +65292-5;I am sensitive to the feelings of others;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am sensitive to the feelings of others [PhenX];Sensitive to others feelings PhenX;;TRIAL;2.36;2.65 +65293-3;I have conned people to get money from them;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have conned people to get money from them [PhenX];Conned people for money PhenX;;TRIAL;2.36;2.65 +65294-1;It worries me to go into an unfamiliar situation without knowing all the details;Find;Pt;^Patient;Ord;PhenX;PHENX;2;It worries me to go into an unfamiliar situation without knowing all the details [PhenX];Worried about unfamiliar situation PhenX;;TRIAL;2.36;2.65 +65295-8;I don't have much sympathy for people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I don't have much sympathy for people [PhenX];No sympathy for others PhenX;;TRIAL;2.36;2.65 +65296-6;I get in trouble for not considering the consequences of my actions;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I get in trouble for not considering the consequences of my actions [PhenX];Trouble not consider consequences PhenX;;TRIAL;2.36;2.65 +65297-4;I can convince people to do what I want;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can convince people to do what I want [PhenX];Convince others PhenX;;TRIAL;2.36;2.65 +65298-2;For me, honesty really is the best policy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;For me, honesty really is the best policy [PhenX];Honesty best policy PhenX;;TRIAL;2.36;2.65 +65299-0;I've injured people to see them in pain;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I've injured people to see them in pain [PhenX];Injured to see pain PhenX;;TRIAL;2.36;2.65 +65-3;Cefadroxil;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefadroxil [Susceptibility] by Disk diffusion (KB);Cefadroxil Islt KB;;ACTIVE;1.0;2.19 +6530-0;Rabies virus Ag;ACnc;Pt;Tiss;Qn;IF;MICRO;1;Deprecated Rabies virus Ag [Units/volume] in Tissue by Immunofluorescence;Deprecated RABV Ag Tiss IF-aCnc;;DEPRECATED;1.0g;2.69 +65300-6;I don't like to take the lead in groups;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I don't like to take the lead in groups [PhenX];Don't like lead groups PhenX;;TRIAL;2.36;2.65 +65301-4;I sometimes insult people on purpose to get a reaction from them;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I sometimes insult people on purpose to get a reaction from them [PhenX];Insult to get reaction PhenX;;TRIAL;2.36;2.65 +65302-2;I have taken items from a store without paying for them;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have taken items from a store without paying for them [PhenX];Stolen from store PhenX;;TRIAL;2.36;2.65 +65303-0;It's easy to embarrass me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;It's easy to embarrass me [PhenX];Easily embarrassed PhenX;;TRIAL;2.36;2.65 +65304-8;Things are more fun if a little danger is involved;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Things are more fun if a little danger is involved [PhenX];Enjoy danger PhenX;;TRIAL;2.36;2.65 +65305-5;I have a hard time waiting patiently for things I want;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have a hard time waiting patiently for things I want [PhenX];Hard to wait PhenX;;TRIAL;2.36;2.65 +65306-3;I stay away from physical danger as much as I can;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I stay away from physical danger as much as I can [PhenX];Avoid physical danger PhenX;;TRIAL;2.36;2.65 +65307-1;I don't care much if what I do hurts others;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I don't care much if what I do hurts others [PhenX];Don't mind hurting others PhenX;;TRIAL;2.36;2.65 +65308-9;I have lost a friend because of irresponsible things I've done;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have lost a friend because of irresponsible things I've done [PhenX];Actions lost friends PhenX;;TRIAL;2.36;2.65 +65309-7;I don't stack up well against most others;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I don't stack up well against most others [PhenX];Stack up to others PhenX;;TRIAL;2.36;2.65 +65310-5;Others have told me they are concerned about my lack of self-control;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Others have told me they are concerned about my lack of self-control [PhenX];Concerned lack self-control PhenX;;TRIAL;2.36;2.65 +65311-3;It's easy for me to relate to other people's emotions;Find;Pt;^Patient;Ord;PhenX;PHENX;2;It's easy for me to relate to other people's emotions [PhenX];Relate to people's emotions PhenX;;TRIAL;2.36;2.65 +65312-1;I have robbed someone;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have robbed someone [PhenX];Robbed someone PhenX;;TRIAL;2.36;2.65 +65313-9;I never worry about making a fool of myself with others;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I never worry about making a fool of myself with others [PhenX];No worred about looking foolish PhenX;;TRIAL;2.36;2.65 +65314-7;It doesn't bother me when people around me are hurting;Find;Pt;^Patient;Ord;PhenX;PHENX;2;It doesn't bother me when people around me are hurting [PhenX];Not bothered people hurting PhenX;;TRIAL;2.36;2.65 +65315-4;I have had problems at work because I was irresponsible;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have had problems at work because I was irresponsible [PhenX];Work problems irresponsible PhenX;;TRIAL;2.36;2.65 +65316-2;I'm not very good at influencing people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I'm not very good at influencing people [PhenX];Not good influencing others PhenX;;TRIAL;2.36;2.65 +65317-0;I have stolen something out of a vehicle;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have stolen something out of a vehicle [PhenX];Stolen from vehicle PhenX;;TRIAL;2.36;2.65 +6531-8;Rabies virus Ag;ACnc;Pt;Tiss;Qn;IF;MICRO;1;Deprecated Rabies virus Ag [Units/volume] in Tissue by Immunofluorescence;Deprecated RABV Ag Tiss IF-aCnc;;DEPRECATED;1.0g;2.69 +65318-8;A little t super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;At sup(a) Ab [Presence] in Serum or Plasma;At sup(a) Ab SerPl Ql;;ACTIVE;2.36;2.56 +65319-6;D little u super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Deprecated Du sup(a) Ab [Presence] in Serum or Plasma;Deprecated Du sup(a) Ab SerPl Ql;;DEPRECATED;2.36;2.70 +65320-4;F little y3 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Fy3 Ab [Presence] in Serum or Plasma;Fy3 Ab SerPl Ql;;ACTIVE;2.36;2.56 +65321-2;G little e Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ge Ab [Presence] in Serum or Plasma;Ge Ab SerPl Ql;;ACTIVE;2.36;2.56 +65322-0;G little y super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Gy sup(a) Ab [Presence] in Serum or Plasma;Gy sup(a) Ab SerPl Ql;;ACTIVE;2.36;2.56 +65323-8;H little e Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;He Ab [Presence] in Serum or Plasma;He Ab SerPl Ql;;ACTIVE;2.36;2.56 +65324-6;J little k3 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Jk3 Ab [Presence] in Serum or Plasma;Jk3 Ab SerPl Ql;;ACTIVE;2.36;2.56 +65325-3;K little u Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ku Ab [Presence] in Serum or Plasma;Ku Ab SerPl Ql;;ACTIVE;2.36;2.56 +6532-6;Rabies virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Rabies virus Ag [Presence] in Specimen by Immunofluorescence;RABV Ag Spec Ql IF;;ACTIVE;1.0g;2.69 +65326-1;LAN Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;LAN Ab [Presence] in Serum or Plasma;LAN Ab SerPl Ql;;ACTIVE;2.36;2.56 +65327-9;L little u 14 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Lu 14 Ab [Presence] in Serum or Plasma;Lu 14 Ab SerPl Ql;;ACTIVE;2.36;2.56 +65328-7;LW super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;LW sup(a) Ab [Presence] in Serum or Plasma;LW sup(a) Ab SerPl Ql;;ACTIVE;2.36;2.56 +65329-5;M little c C super little c Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;McC sup(c) Ab [Presence] in Serum or Plasma;McC sup(c) Ab SerPl Ql;;ACTIVE;2.36;2.56 +65330-3;MER Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;MER Ab [Presence] in Serum or Plasma;MER Ab SerPl Ql;;ACTIVE;2.36;2.56 +65331-1;little c E Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;little cE Ab [Presence] in Serum or Plasma;little cE Ab SerPl Ql;;ACTIVE;2.36;2.56 +65332-9;Rh32 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Rh32 Ab [Presence] in Serum or Plasma;Rh32 Ab SerPl Ql;;ACTIVE;2.36;2.56 +65333-7;S little c 1 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Sc1 Ab [Presence] in Serum or Plasma;Sc1 Ab SerPl Ql;;ACTIVE;2.36;2.69 +6533-4;Rabies virus Ag;ACnc;Pt;XXX;Qn;IF;MICRO;1;Rabies virus Ag [Units/volume] in Specimen by Immunofluorescence;RABV Ag Spec IF-aCnc;;DISCOURAGED;1.0g;2.69 +65334-5;S little c 2 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Sc2 Ab [Presence] in Serum or Plasma;Sc2 Ab SerPl Ql;;ACTIVE;2.36;2.69 +65335-2;S little w super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Sw sup(a) Ab [Presence] in Serum or Plasma;Sw sup(a) Ab SerPl Ql;;ACTIVE;2.36;2.56 +65336-0;T little m Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Tm Ab [Presence] in Serum or Plasma;Tm Ab SerPl Ql;;ACTIVE;2.36;2.56 +65337-8;T little r super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Tr sup(a) Ab [Presence] in Serum or Plasma;Tr sup(a) Ab SerPl Ql;;ACTIVE;2.36;2.73 +65338-6;WES super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;WES sup(b) Ab [Presence] in Serum or Plasma;WES sup(b) Ab SerPl Ql;;ACTIVE;2.36;2.56 +65339-4;W little r super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Wr sup(b) Ab [Presence] in Serum or Plasma;Wr sup(b) Ab SerPl Ql;;ACTIVE;2.36;2.56 +65340-2;Micafungin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Micafungin [Susceptibility];Micafungin Susc Islt;;ACTIVE;2.36;2.36 +6534-2;Rabies virus Ag;ACnc;Pt;XXX;Qn;IF;MICRO;1;Deprecated Rabies virus Ag [Units/volume] in Unspecified specimen by Immunofluorescence;Deprecated RABV Ag XXX IF-aCnc;;DEPRECATED;1.0g;2.69 +65343-6;Oxygen^^saturation adjusted to 0.5;PPres;Pt;Bld;Qn;;CHEM;1;Oxygen [Partial pressure] saturation adjusted to 0.5 in Blood;pO2 satn adj to 0.5 Bld;;ACTIVE;2.36;2.73 +65344-4;Glucagon^pre XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --pre XXX challenge;Glucagon pre chal SerPl-mCnc;;ACTIVE;2.36;2.70 +65345-1;Glucagon^1st specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge;Glucagon sp1 p chal SerPl-mCnc;;ACTIVE;2.36;2.70 +65346-9;Glucagon^2nd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge;Glucagon sp2 p chal SerPl-mCnc;;ACTIVE;2.36;2.70 +65347-7;Glucagon^3rd specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge;Glucagon sp3 p chal SerPl-mCnc;;ACTIVE;2.36;2.70 +65348-5;Glucagon^4th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge;Glucagon sp4 p chal SerPl-mCnc;;ACTIVE;2.36;2.70 +65349-3;Glucagon^5th specimen post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge;Glucagon sp5 p chal SerPl-mCnc;;ACTIVE;2.36;2.70 +65350-1;Follitropin^pre or post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Follitropin [Units/volume] in Serum or Plasma --pre or post XXX challenge;FSH pre/p chal SerPl-aCnc;;ACTIVE;2.36;2.70 +65351-9;Triiodothyronine.free^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --pre or post XXX challenge;T3Free pre/p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +65352-7;Proinsulin^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;Proinsulin sp1 p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +65353-5;Proinsulin^2nd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge;Proinsulin sp2 p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +65354-3;Proinsulin^3rd specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge;Proinsulin sp3 p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +65355-0;Proinsulin^4th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge;Proinsulin sp4 p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +65356-8;Proinsulin^5th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge;Proinsulin sp5 p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +65357-6;Proinsulin^6th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge;Proinsulin sp6 p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +65358-4;Proinsulin^7th specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Proinsulin [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge;Proinsulin sp7 p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +6535-9;Rabies virus Ag;ACnc;Pt;XXX;Qn;IF;MICRO;1;Deprecated Rabies virus Ag [Units/volume] in Unspecified specimen by Immunofluorescence;Deprecated RABV Ag XXX IF-aCnc;;DEPRECATED;1.0g;2.69 +65359-2;Sex hormone binding globulin^pre or post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Sex hormone binding globulin [Moles/volume] in Serum or Plasma --pre or post XXX challenge;SHBG pre/p chal SerPl-sCnc;;ACTIVE;2.36;2.70 +653-6;Microscopic observation;Prid;Pt;Urine;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Urine by Gram stain;Gram Stn Ur;;ACTIVE;1.0;2.73 +65360-0;Thyrotropin^pre or post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --pre or post XXX challenge;TSH pre/p chal SerPl-aCnc;;ACTIVE;2.36;2.70 +65361-8;Phenytoin^^corrected for albumin;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin [Moles/volume] corrected for albumin in Serum or Plasma;Phenytoin Album cor SerPl-sCnc;;ACTIVE;2.36;2.70 +65362-6;Magnesium^^corrected for albumin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Magnesium [Moles/volume] corrected for albumin in Serum or Plasma;Magnesium Album cor SerPl-sCnc;;ACTIVE;2.36;2.70 +65363-4;Glutathione;SCnc;Pt;Bld;Qn;;CHEM;1;Glutathione [Moles/volume] in Blood;Glutathione Bld-sCnc;;ACTIVE;2.36;2.73 +65364-2;Cortisol.free/Cortisol.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol Free/Cortisol.total in Serum or Plasma;Cortis F/Total MFr SerPl;;ACTIVE;2.36;2.73 +65365-9;Did anyone ever tell you that you had a seizure or convulsion caused by a high fever when you were a child;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did anyone ever tell you that you had a seizure or convulsion caused by a high fever when you were a child [PhenX];Seizure or convulsion PhenX;;TRIAL;2.36;2.65 +65366-7;Have you ever had, or has anyone ever told you that you had, a seizure disorder or epilepsy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had, or has anyone ever told you that you had, a seizure disorder or epilepsy [PhenX];Seizure disorder or epilepsy PhenX;;TRIAL;2.36;2.65 +6536-7;Rabies virus identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Rabies virus identified in Tissue by Organism specific culture;RABV Tiss Cult;;ACTIVE;1.0g;2.40 +65367-5;Have you ever had, or has anyone ever told you that you had, a seizure, convulsion, fit or spell under any circumstances;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had, or has anyone ever told you that you had, a seizure, convulsion, fit or spell under any circumstances [PhenX];Other seizure PhenX;;TRIAL;2.36;2.65 +65368-3;Have you ever had, or has anyone ever told you that you had, uncontrolled movements of part or all of your body such as twitching, jerking, shaking or going limp;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had, or has anyone ever told you that you had, uncontrolled movements of part or all of your body such as twitching, jerking, shaking or going limp [PhenX];Uncontrolled movements PhenX;;TRIAL;2.36;2.65 +65369-1;Have you ever had, or has anyone ever told you that you had, an unexplained change in your mental state or level of awareness, or an episode of spacing out that you could not control;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had, or has anyone ever told you that you had, an unexplained change in your mental state or level of awareness, or an episode of spacing out that you could not control [PhenX];Unexplained mental change PhenX;;TRIAL;2.36;2.65 +65370-9;Did anyone ever tell you that when you were a small child, you would daydream or stare into space more than other children;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did anyone ever tell you that when you were a small child, you would daydream or stare into space more than other children [PhenX];Daydream or stare into space PhenX;;TRIAL;2.36;2.65 +65371-7;Have you ever noticed any unusual body movements or feelings when exposed to strobe lights, video games, flickering lights, or sun glare;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever noticed any unusual body movements or feelings when exposed to strobe lights, video games, flickering lights, or sun glare [PhenX];Strobe lights response PhenX;;TRIAL;2.36;2.65 +65372-5;Shortly after waking up, either in the morning or after a nap, have you ever noticed uncontrollable jerking or clumsiness, such as dropping things or things suddenly flying from your hands;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Shortly after waking up, either in the morning or after a nap, have you ever noticed uncontrollable jerking or clumsiness, such as dropping things or things suddenly flying from your hands [PhenX];Uncontrollable jerking clumsiness PhenX;;TRIAL;2.36;2.65 +65373-3;Have you ever had any other type of repeated unusual spells;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any other type of repeated unusual spells [PhenX];Other repeated unusual spells PhenX;;TRIAL;2.36;2.65 +65374-1;Over the past Y, have you suffered from severe headaches;Find;1Y;^Patient;Ord;PhenX;PHENX;2;Over the past Y, have you suffered from severe headaches [PhenX];Severe headaches past Y PhenX;;TRIAL;2.36;2.65 +6537-5;Rabies virus identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Deprecated Rabies virus strain identified in Tissue by Organism specific culture;Deprecated RABV Tiss Cult;;DEPRECATED;1.0g;2.66 +65375-8;When you have a severe headache, do you experience any of the following;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you have a severe headache, do you experience any of the following [PhenX];Headache complications PhenX;;TRIAL;2.36;2.65 +65376-6;About how often do your severe headaches occur;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;About how often do your severe headaches occur [PhenX];Severe headaches avg freq nRate PhenX;;TRIAL;2.36;2.65 +65377-4;Which statement best describes the pain of your severe headaches;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Which statement best describes the pain of your severe headaches [PhenX];Severe headache pain type PhenX;;TRIAL;2.36;2.65 +65378-2;Which best describes how you are usually affected by severe headaches;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Which best describes how you are usually affected by severe headaches [PhenX];How affected by headaches PhenX;;TRIAL;2.36;2.65 +65379-0;Each time you have a severe headache, how long are you unable to work or undertake normal activities;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Each time you have a severe headache, how long are you unable to work or undertake normal activities [PhenX];How long unable to work PhenX;;TRIAL;2.36;2.65 +65380-8;On how many Ds in the last 3Mo did you have a headache, if headache lasted more than 1D, count each D;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;On how many days in the last 3 months did you have a headache, if headache lasted more than 1 day, count each day [PhenX];Headache freq last 3Mo nRate PhenX;;TRIAL;2.36;2.65 +65381-6;Because of your headaches on how many Ds in the last 3Mo did you miss work or school;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;Because of your headaches on how many days in the last 3 months did you miss work or school [PhenX];# Ds miss school nRate PhenX;;TRIAL;2.36;2.65 +65382-4;Because of your headaches on how many Ds in the last 3Mo was your productivity at work or school reduced by half or more;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;Because of your headaches on how many days in the last 3 months was your productivity at work or school reduced by half or more [PhenX];# Ds reduced productiv nRate PhenX;;TRIAL;2.36;2.65 +6538-3;Rabies virus identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Deprecated Rabies virus strain identified in Tissue by Organism specific culture;Deprecated RABV Tiss Cult;;DEPRECATED;1.0g;2.36 +65383-2;Because of your headaches on how many Ds in the last 3Mo did you not do household work;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;Because of your headaches on how many days in the last 3 months did you not do household work [PhenX];# Ds no housework nRate PhenX;;TRIAL;2.36;2.65 +65384-0;Because of your headaches on how many Ds in the last 3Mo was your productivity in house-hold work reduced by half or more;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;Because of your headaches on how many days in the last 3 months was your productivity in house-hold work reduced by half or more [PhenX];Num Ds housework reduced 1/2 nRate PhenX;;TRIAL;2.36;2.65 +65385-7;Because of your headaches on how many Ds in the last 3Mo did you miss family, social, or leisure activities;NRat;3Mo;^Patient;Qn;PhenX;PHENX;2;Because of your headaches on how many days in the last 3 months did you miss family, social, or leisure activities [PhenX];Number Ds missed activities nRate PhenX;;TRIAL;2.36;2.65 +65386-5;At what age did you begin having severe headaches;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did you begin having severe headaches [PhenX];Age headaches began PhenX;;TRIAL;2.36;2.65 +65387-3;Have you ever gone to the hospital emergency room or to an urgent care clinic because of your severe headaches;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever gone to the hospital emergency room or to an urgent care clinic because of your severe headaches [PhenX];Hospital for headaches PhenX;;TRIAL;2.36;2.65 +65388-1;Which best describes the way you usually treat severe headaches;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Which best describes the way you usually treat severe headaches [PhenX];Usual headache treatment PhenX;;TRIAL;2.36;2.65 +65389-9;Have you ever taken prescription medication for headache on a daily basis, whether or not you have a headache, to help prevent a severe headache from happening in the first place;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever taken prescription medication for headache on a daily basis, whether or not you have a headache, to help prevent a severe headache from happening in the first place [PhenX];Headache prescription med daily PhenX;;TRIAL;2.36;2.65 +65390-7;Are you currently taking any other medication on a daily basis;Find;Pt;^Patient;Ord;;PHENX;2;Are you currently taking any other medication on a daily basis [PhenX];Any other med daily PhenX;;ACTIVE;2.36;2.73 +6539-1;Rabies virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Rabies virus identified in Specimen by Organism specific culture;RABV Spec Cult;;ACTIVE;1.0g;2.69 +65391-5;When did you last take prescription medication for headache on a daily basis to help prevent a severe headache from happening in the first place;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When did you last take prescription medication for headache on a daily basis to help prevent a severe headache from happening in the first place [PhenX];Last took daily med PhenX;;TRIAL;2.36;2.65 +65392-3;Do you consider your severe headaches to be migraines;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you consider your severe headaches to be migraines [PhenX];Consider headaches migraines PhenX;;TRIAL;2.36;2.65 +65393-1;Have you ever been diagnosed by a physician or other health professional as suffering from;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been diagnosed by a physician or other health professional as suffering from [PhenX];Diagnosed with headache type PhenX;;TRIAL;2.36;2.65 +65394-9;If diagnosed with migraines, at what age were you first diagnosed with migraines;Time;Pt;^Patient;Qn;PhenX;PHENX;2;If diagnosed with migraines, at what age were you first diagnosed with migraines [PhenX];Age diagnosed migraines PhenX;;TRIAL;2.36;2.65 +65395-6;Have you ever been hospitalized or treated in an emergency room following an injury to your head or neck;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been hospitalized or treated in an emergency room following an injury to your head or neck [PhenX];Hospitalized head injury PhenX;;TRIAL;2.36;2.65 +65396-4;Have you ever injured your head or neck in a car accident or from some other moving vehicle accident, motorcycle, ATV;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever injured your head or neck in a car accident or from some other moving vehicle accident, motorcycle, ATV [PhenX];Moving vehicle head injury PhenX;;TRIAL;2.36;2.65 +65397-2;If no, were you dazed or did you have a gap in your memory from the injury;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If no, were you dazed or did you have a gap in your memory from the injury [PhenX];Head injury memory gap PhenX;;TRIAL;2.36;2.65 +65398-0;Have you ever injured your head or neck in a fall or from being hit by something, falling from a bike, horse, or rollerblades, falling on ice, being hit by a rock or have you ever injured your head or neck playing sports or on the playground;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever injured your head or neck in a fall or from being hit by something, falling from a bike, horse, or rollerblades, falling on ice, being hit by a rock or have you ever injured your head or neck playing sports or on the playground [PhenX];Head injury fall hit sports PhenX;;TRIAL;2.36;2.65 +65399-8;Have you ever injured your head or neck in a fight, from being hit by someone, or from being shaken violently or have you ever been shot in the head;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever injured your head or neck in a fight, from being hit by someone, or from being shaken violently or have you ever been shot in the head [PhenX];Head injury fight PhenX;;TRIAL;2.36;2.65 +65400-4;Have you ever been nearby when an explosion or a blast occurred;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been nearby when an explosion or a blast occurred [PhenX];Explosion head injury PhenX;;TRIAL;2.36;2.65 +65401-2;How many more injuries with LOC;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many more injuries with LOC [#] [PhenX];Num other injuries LOC PhenX;;TRIAL;2.36;2.65 +65402-0;If more injuries with LOC, longest knocked out;Time;Pt;^Patient;Qn;PhenX;PHENX;2;If more injuries with LOC, longest knocked out [PhenX];Other injuries LOC longest PhenX;;TRIAL;2.36;2.65 +65403-8;If more injuries with LOC, how many longer than 30M;Num;Pt;^Patient;Qn;PhenX;PHENX;2;If more injuries with LOC, how many longer than 30 minutes [#] [PhenX];Other injuries LOC >30M PhenX;;TRIAL;2.36;2.65 +65404-6;If more injuries with LOC, youngest age;Time;Pt;^Patient;Qn;PhenX;PHENX;2;If more injuries with LOC, youngest age [PhenX];Other injuries LOC age PhenX;;TRIAL;2.36;2.65 +65405-3;Have you ever lost consciousness from a drug overdose;Num;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever lost consciousness from a drug overdose [PhenX];LOC drug overdose PhenX;;TRIAL;2.36;2.65 +65406-1;Have you ever lost consciousness from being choked;Num;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever lost consciousness from being choked [PhenX];LOC choked PhenX;;TRIAL;2.36;2.65 +65407-9;Hands resting in lap for 15S;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Hands resting in lap for 15 seconds [PhenX];Hands resting lap PhenX;;TRIAL;2.36;2.65 +65408-7;Arms held at 90 degrees for 15S - arm sustention;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Arms held at 90 degrees for 15 seconds - arm sustention [PhenX];Arm sustention PhenX;;TRIAL;2.36;2.65 +6540-9;Rabies virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Deprecated Rabies virus strain identified in Unspecified specimen by Organism specific culture;Deprecated RABV XXX Cult;;DEPRECATED;1.0g;2.69 +65409-5;Arms held in wing position for 15S;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Arms held in wing position for 15 seconds [PhenX];Arms wing position PhenX;;TRIAL;2.36;2.65 +65410-3;Pouring water from one cup to another;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Pouring water from one cup to another [PhenX];Pouring water PhenX;;TRIAL;2.36;2.65 +65411-1;Bring a spoon of water from lap level up to mouth and back again - repeat 7 additional times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Bring a spoon of water from lap level up to mouth and back again - repeat 7 additional times [PhenX];Drink from spoon PhenX;;TRIAL;2.36;2.65 +65412-9;Drinking water from a full glass - repeat 7 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Drinking water from a full glass - repeat 7 times [PhenX];Drinking water PhenX;;TRIAL;2.36;2.65 +65413-7;Side;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Side [PhenX];Side PhenX;;TRIAL;2.38;2.65 +65414-5;Finger-nose-finger on right - 8 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Finger-nose-finger on right - 8 times [PhenX];Finger-nose-finger PhenX;;TRIAL;2.36;2.65 +65415-2;Open and close right hand - 10 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Open and close right hand - 10 times [PhenX];Open close hand PhenX;;TRIAL;2.36;2.65 +65416-0;Alternatively pronate and supinate right hand - 10 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Alternatively pronate and supinate right hand - 10 times [PhenX];Pronate supinate hand PhenX;;TRIAL;2.36;2.65 +6541-7;Rabies virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Deprecated Rabies virus strain identified in Unspecified specimen by Organism specific culture;Deprecated RABV XXX Cult;;DEPRECATED;1.0g;2.69 +65417-8;Tap right foot - 10 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Tap right foot - 10 times [PhenX];Tap foot PhenX;;TRIAL;2.36;2.65 +65418-6;Jaw at rest for 5S;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Jaw at rest for 5 seconds [PhenX];Jaw at rest PhenX;;TRIAL;2.36;2.65 +65419-4;Mouth open for 5S;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Mouth open for 5 seconds [PhenX];Mouth open PhenX;;TRIAL;2.36;2.65 +65420-2;Sustained phonation - first AAA for 10 s, then EEE;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Sustained phonation - first AAA for 10 s, then EEE [PhenX];Sustained phonation PhenX;;TRIAL;2.36;2.65 +65421-0;Head while patient is seated for 10S;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Head while patient is seated for 10 seconds [PhenX];Head while seated PhenX;;TRIAL;2.36;2.65 +65423-6;Drawing 2 archimedes spirals with each hand, subject should make at least 6 full circular motions;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Drawing 2 archimedes spirals with each hand, subject should make at least 6 full circular motions [PhenX];Archimedes spirals PhenX;;TRIAL;2.36;2.65 +65424-4;Is your fear unreasonable - that is, much stronger than it should be;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Is your fear unreasonable - that is, much stronger than it should be [CIDI-SF];Social unreasonable CIDI-SF;;ACTIVE;2.36;2.65 +6542-5;Rickettsia prowazekii Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Rickettsia prowazekii Ab [Units/volume] in Serum by Complement fixation;R prowazek Ab Ser CF-aCnc;;ACTIVE;1.0g;2.69 +65425-1;Is your fear much stronger than in other people;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Is your fear much stronger than in other people [CIDI-SF];Social fear stronger others CIDI-SF;;ACTIVE;2.36;2.65 +65426-9;Were you ever afraid that you might faint, lose control, or embarrass yourself in other ways;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Were you ever afraid that you might faint, lose control, or embarrass yourself in other ways [CIDI-SF];Agoraphobia faint embarrass CIDI-SF;;ACTIVE;2.36;2.65 +65427-7;Do you worry that you might be trapped without any way to escape;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Do you worry that you might be trapped without any way to escape [CIDI-SF];Agoraphobia trapped CIDI-SF;;ACTIVE;2.36;2.65 +65428-5;Did any of these attacks occur when you were in a life-threatening situation;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did any of these attacks occur when you were in a life-threatening situation [CIDI-SF];Panic life-threatening situation CIDI-SF;;ACTIVE;2.36;2.65 +65429-3;Do you worry that help might not be available if you needed it;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Do you worry that help might not be available if you needed it [CIDI-SF];Agoraphobia no help CIDI-SF;;ACTIVE;2.36;2.65 +65430-1;Did any of these attacks occur when you were not in a life-threatening situation;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did any of these attacks occur when you were not in a life-threatening situation [CIDI-SF];Panic not life-threatening situa CIDI-SF;;ACTIVE;2.36;2.65 +65431-9;About how many attacks have you had in your life;Num;Pt;^Patient;Qn;CIDI-SF;PHENX;2;About how many attacks have you had in your life [#] [CIDI-SF];Panic number attacks CIDI-SF;;ACTIVE;2.36;2.65 +65432-7;Did you ever have a spell or an attack when all of a sudden you felt frightened, anxious, or very uneasy;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you ever have a spell or an attack when all of a sudden you felt frightened, anxious, or very uneasy [CIDI-SF];Panic attack CIDI-SF;;ACTIVE;2.36;2.65 +6543-3;Rickettsia rickettsii Ag;Prid;Pt;Tiss;Nom;IF;MICRO;1;Rickettsia rickettsii Ag [Identifier] in Tissue by Immunofluorescence;R rickettsi Ag Tiss IF;;ACTIVE;1.0g;2.22 +65433-5;Did you ever have an attack when you were not in a situation that usually causes you to have unreasonably strong fears;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you ever have an attack when you were not in a situation that usually causes you to have unreasonably strong fears [CIDI-SF];Panic attack random CIDI-SF;;ACTIVE;2.36;2.65 +65435-0;Have you ever been bothered by having certain unpleasant thoughts of your own that kept entering your mind against your wishes;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Have you ever been bothered by having certain unpleasant thoughts of your own that kept entering your mind against your wishes [CIDI-SF];OCD unpleasant thoughts germs CIDI-SF;;ACTIVE;2.36;2.65 +65436-8;Have you ever had any unpleasant and persistent thoughts like that;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Have you ever had any unpleasant and persistent thoughts like that [CIDI-SF];OCD thoughts harm ashamed CIDI-SF;;ACTIVE;2.36;2.65 +65437-6;Did some of these thoughts seem to you to be unreasonable;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did some of these thoughts seem to you to be unreasonable [CIDI-SF];OCD thoughts unreasonable CIDI-SF;;ACTIVE;2.36;2.65 +65438-4;Did these thoughts keep coming back again and again into your mind no matter how hard you tried to resist, ignore, or get rid of them;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did these thoughts keep coming back again and again into your mind no matter how hard you tried to resist, ignore, or get rid of them [CIDI-SF];OCD thoughts coming back CIDI-SF;;ACTIVE;2.36;2.65 +65439-2;Did you ever tell a doctor about these thoughts;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you ever tell a doctor about these thoughts [CIDI-SF];OCD tell professional thoughts CIDI-SF;;ACTIVE;2.36;2.65 +654-4;Microscopic observation;Prid;Pt;XXX;Nom;Acid fast stain.Kinyoun;MICRO;1;Microscopic observation [Identifier] in Specimen by Acid fast stain.Kinyoun;Acid fast Kiny Stn Spec;;ACTIVE;1.0;2.73 +65440-0;Did thinking about these ideas interfere with your life or work, or cause you difficulty with your relatives or friends, or upset you a great deal;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did thinking about these ideas interfere with your life or work, or cause you difficulty with your relatives or friends, or upset you a great deal [CIDI-SF];OCD interfere w activities CIDI-SF;;ACTIVE;2.36;2.65 +6544-1;Rickettsia sp identified;Prid;Pt;Genital;Nom;Organism specific culture;MICRO;1;Rickettsia sp identified in Genital specimen by Organism specific culture;Rickettsia Genital Cult;;ACTIVE;1.0g;2.21 +65441-8;Have you ever had to do something like that over and over;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Have you ever had to do something like that over and over [CIDI-SF];OCD repeat actions CIDI-SF;;ACTIVE;2.36;2.65 +65442-6;Was there a time when you felt you had to do something in a certain order, like getting dressed perhaps, and had to start all over again if you did it in the wrong order;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Was there a time when you felt you had to do something in a certain order, like getting dressed perhaps, and had to start all over again if you did it in the wrong order [CIDI-SF];OCD certain order CIDI-SF;;ACTIVE;2.36;2.65 +65443-4;Has there been a period of several Ws when you felt you had to count something, like the squares in a tile floor, and couldn't resist doing it even when you tried to;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Has there been a period of several weeks when you felt you had to count something, like the squares in a tile floor, and couldn't resist doing it even when you tried to [CIDI-SF];OCD counting CIDI-SF;;ACTIVE;2.36;2.65 +65444-2;Did you have a period when you had to say certain words over and over, either aloud or to yourself;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you have a period when you had to say certain words over and over, either aloud or to yourself [CIDI-SF];OCD repeat words CIDI-SF;;ACTIVE;2.36;2.65 +65445-9;Did you think that these actions were unnecessary or that you overdid it;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you think that these actions were unnecessary or that you overdid it [CIDI-SF];OCD think actions unnecessary CIDI-SF;;ACTIVE;2.36;2.65 +65446-7;Did you tell a doctor about having to do these things;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you tell a doctor about having to do these things [CIDI-SF];OCD tell doctor about things CIDI-SF;;ACTIVE;2.36;2.65 +65447-5;Did having to do these things interfere with your life or work, or cause you difficulty with your relatives or friends, or upset you a great deal;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did having to do these things interfere with your life or work, or cause you difficulty with your relatives or friends, or upset you a great deal [CIDI-SF];OCD actions interfere activities CIDI-SF;;ACTIVE;2.36;2.65 +65448-3;Has your child experienced periods of several Ds or more when he or she was unable to sit still, and had to keep moving or jumping from one activity to another;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Has your child experienced periods of several days or more when he or she was unable to sit still, and had to keep moving or jumping from one activity to another [P-GBI];Mania intense energy several Ds P-GBI;;ACTIVE;2.36;2.65 +65449-1;Have there been periods of several Ds or more when your childs friends or other family members told you that your child seemed unusually happy or high;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Have there been periods of several days or more when your childs friends or other family members told you that your child seemed unusually happy or high [P-GBI];Mania others say child happy P-GBI;;ACTIVE;2.36;2.65 +65450-9;Has your childs mood or energy shifted rapidly back and forth from happy to sad or high to low;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Has your childs mood or energy shifted rapidly back and forth from happy to sad or high to low [P-GBI];Mania mood changes rapidly P-GBI;;ACTIVE;2.36;2.65 +65451-7;Has your child had periods of extreme happiness and intense energy lasting several Ds or more when he or she also felt much more anxious;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Has your child had periods of extreme happiness and intense energy lasting several days or more when he or she also felt much more anxious [P-GBI];Mania intense energy and anxious P-GBI;;ACTIVE;2.36;2.65 +65452-5;Have there been times of several Ds or more when, although your child was feeling unusually happy and intensely energetic, he or she also had to struggle very hard to control rage;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Have there been times of several days or more when, although your child was feeling unusually happy and intensely energetic, he or she also had to struggle very hard to control rage [P-GBI];Mania intense energy and rage P-GBI;;ACTIVE;2.36;2.65 +65453-3;Has your child had periods of extreme happiness and intense energy, when it took him or her over an H to get to sleep at night;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Has your child had periods of extreme happiness and intense energy, when it took him or her over an hour to get to sleep at night [P-GBI];Mania intense energy sleeplessness P-GBI;;ACTIVE;2.36;2.65 +65454-1;Have you found that your childs feelings or energy are generally up or down, but rarely in the middle;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Have you found that your childs feelings or energy are generally up or down, but rarely in the middle [P-GBI];Mania feelings always extreme P-GBI;;ACTIVE;2.36;2.65 +65455-8;Has your child had periods lasting several Ds or more when he or she felt depressed or irritable, and then other periods when he or she felt extremely high, elated, and overflowing with energy;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Has your child had periods lasting several days or more when he or she felt depressed or irritable, and then other periods when he or she felt extremely high, elated, and overflowing with energy [P-GBI];Mania alternating irritable elated P-GBI;;ACTIVE;2.36;2.65 +65456-6;Have there been periods when, although your child was feeling unusually happy and intensely energetic, almost everything got on his or her nerves and made him or her irritable or angry;Find;Pt;^Patient;Ord;P-GBI;PHENX;2;Have there been periods when, although your child was feeling unusually happy and intensely energetic, almost everything got on his or her nerves and made him or her irritable or angry [P-GBI];Mania intense energy and irritable P-GBI;;ACTIVE;2.36;2.65 +65457-4;How are you feeling today compared to your usual state;Find;Pt;^Patient;Nom;HCL-32;PHENX;2;How are you feeling today compared to your usual state [HCL-32];Mania feeling today HCL-32;;ACTIVE;2.36;2.65 +6545-8;Rickettsia sp identified;Prid;Pt;Sputum;Nom;Organism specific culture;MICRO;1;Rickettsia sp identified in Sputum by Organism specific culture;Rickettsia Spt Cult;;ACTIVE;1.0g;2.19 +65458-2;Compared to other people my level of activity, energy and mood;Find;Pt;^Patient;Ord;HCL-32;PHENX;2;Compared to other people my level of activity, energy and mood [HCL-32];Mania compared to others HCL-32;;ACTIVE;2.36;2.65 +65459-0;How did people close to you react to or comment on your highs;Find;Pt;^Patient;Ord;HCL-32;PHENX;2;How did people close to you react to or comment on your highs [HCL-32];Mania other people reaction HCL-32;;ACTIVE;2.36;2.65 +65460-8;Length of your highs as a rule, on the average;Time;Pt;^Patient;Qn;HCL-32;PHENX;2;Length of your highs as a rule, on the average [HCL-32];Mania length of highs HCL-32;;ACTIVE;2.36;2.65 +65461-6;Have you experienced such highs in the past 12Mo;Find;12Mo;^Patient;Ord;HCL-32;PHENX;2;Have you experienced such highs in the past 12 months [HCL-32];Highs last Y HCL-32;;ACTIVE;2.36;2.65 +65462-4;If yes, please estimate how many D you spent in highs during the last 12Mo;NRat;12Mo;^Patient;Qn;HCL-32;PHENX;2;If yes, please estimate how many day you spent in highs during the last 12 months [HCL-32];Mania number Ds highs nRate HCL-32;;ACTIVE;2.36;2.65 +65463-2;I was bothered by things that usually don't bother me;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I was bothered by things that usually don't bother me [CES-DC];Bothered CES-DC;;ACTIVE;2.36;2.65 +65464-0;I did not feel like eating, I wasn't very hungry;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I did not feel like eating, I wasn't very hungry [CES-DC];Not hungry CES-DC;;ACTIVE;2.36;2.65 +65465-7;I wasn't able to feel happy, even when my family or friends tried to help me feel better;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I wasn't able to feel happy, even when my family or friends tried to help me feel better [CES-DC];Not happy CES-DC;;ACTIVE;2.36;2.65 +6546-6;Rickettsia sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Rickettsia sp identified in Specimen by Organism specific culture;Rickettsia Spec Cult;;ACTIVE;1.0g;2.69 +65466-5;I felt like I was just as good as other kids;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt like I was just as good as other kids [CES-DC];Good as other kids CES-DC;;ACTIVE;2.36;2.65 +65467-3;I felt like I couldn't pay attention to what I was doing;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt like I couldn't pay attention to what I was doing [CES-DC];Not pay attention CES-DC;;ACTIVE;2.36;2.65 +65468-1;I felt down and unhappy;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt down and unhappy [CES-DC];Felt unhappy CES-DC;;ACTIVE;2.36;2.65 +65469-9;I felt like I was too tired to do things;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt like I was too tired to do things [CES-DC];Too tired CES-DC;;ACTIVE;2.36;2.65 +65470-7;I felt like something good was going to happen;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt like something good was going to happen [CES-DC];Something good happen CES-DC;;ACTIVE;2.36;2.65 +65471-5;I felt like things I did before didn't work out right;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt like things I did before didn't work out right [CES-DC];Things not work out right CES-DC;;ACTIVE;2.36;2.65 +65472-3;I felt scared;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt scared [CES-DC];Scared CES-DC;;ACTIVE;2.36;2.65 +65473-1;I didn't sleep as well as I usually sleep;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I didn't sleep as well as I usually sleep [CES-DC];Not sleep well CES-DC;;ACTIVE;2.36;2.65 +6547-4;Rotavirus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Rotavirus identified in Specimen by Organism specific culture;RV Spec Cult;;ACTIVE;1.0g;2.69 +65474-9;I was happy;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I was happy [CES-DC];Happy CES-DC;;ACTIVE;2.36;2.65 +65475-6;I was more quiet than usual;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I was more quiet than usual [CES-DC];Quiet CES-DC;;ACTIVE;2.36;2.65 +65476-4;I felt lonely, like I didn't have any friends;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt lonely, like I didn't have any friends [CES-DC];Felt lonely CES-DC;;ACTIVE;2.36;2.65 +65477-2;I felt like kids I know were not friendly or that they didn't want to be with me;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt like kids I know were not friendly or that they didn't want to be with me [CES-DC];Kids not friendly CES-DC;;ACTIVE;2.36;2.65 +65478-0;I had a good time;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I had a good time [CES-DC];Had good time CES-DC;;ACTIVE;2.36;2.65 +65479-8;I felt like crying;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt like crying [CES-DC];Felt like crying CES-DC;;ACTIVE;2.36;2.65 +65480-6;I felt sad;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt sad [CES-DC];Felt sad CES-DC;;ACTIVE;2.36;2.65 +65481-4;I felt people didn't like me;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;I felt people didn't like me [CES-DC];People didn't like me CES-DC;;ACTIVE;2.36;2.65 +6548-2;Rubella virus identified;Prid;Pt;Ser;Nom;Organism specific culture;MICRO;1;Rubella virus identified in Serum by Organism specific culture;RUBV Ser Cult;;ACTIVE;1.0g;1.0ma +65482-2;It was hard to get started doing things;Find;Pt;^Patient;Ord;CES-DC;PHENX;2;It was hard to get started doing things [CES-DC];Hard to get started CES-DC;;ACTIVE;2.36;2.65 +65483-0;Have you ever had a time in your life when you felt sad, blue, or depressed for 2W or more in a row;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Have you ever had a time in your life when you felt sad, blue, or depressed for 2 weeks or more in a row [CIDI-SF];Depression 2W lifetime CIDI-SF;;ACTIVE;2.36;2.65 +65484-8;Have you ever had a time in your life lasting 2W or more when you lost interest in most things like hobbies, work, or activities that usually give you pleasure;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Have you ever had a time in your life lasting 2 weeks or more when you lost interest in most things like hobbies, work, or activities that usually give you pleasure [CIDI-SF];Depression lost interest CIDI-SF;;ACTIVE;2.36;2.65 +65485-5;How much of the D did these feelings usually last;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How much of the day did these feelings usually last [CIDI-SF];Depression D length CIDI-SF;;ACTIVE;2.36;2.65 +65486-3;How often did you feel this way;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How often did you feel this way [CIDI-SF];Depression how often CIDI-SF;;ACTIVE;2.36;2.65 +65487-1;Did you feel more tired out or low on energy than is usual for you;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you feel more tired out or low on energy than is usual for you [CIDI-SF];Depression tired CIDI-SF;;ACTIVE;2.36;2.65 +65488-9;Did you gain or lose weight without trying, or did you stay about the same weight;Find;Pt;^Patient;Nom;CIDI-SF;PHENX;2;Did you gain or lose weight without trying, or did you stay about the same weight [CIDI-SF];Depression weight gain loss CIDI-SF;;ACTIVE;2.36;2.65 +65489-7;About how much weight did you gain;Mass;Pt;^Patient;Qn;CIDI-SF;PHENX;2;About how much weight did you gain [Mass] [CIDI-SF];Weight gain CIDI-SF;;ACTIVE;2.36;2.65 +6549-0;Saint Louis encephalitis virus Ag;ACnc;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus Ag [Units/volume] in Serum;SLEV Ag Ser-aCnc;;ACTIVE;1.0g;2.69 +65490-5;About how much weight did you lose;Mass;Pt;^Patient;Qn;CIDI-SF;PHENX;2;About how much weight did you lose [Mass] [CIDI-SF];Weight loss amount CIDI-SF;;ACTIVE;2.36;2.65 +65491-3;Did you have more trouble falling asleep than you usually do;Find;Pt;^Patient;Ord;QIDS;PHENX;2;Did you have more trouble falling asleep than you usually do [QIDS];Depression trouble sleeping QIDS;;ACTIVE;2.36;2.65 +65492-1;Did you have a lot more trouble concentrating than usual;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you have a lot more trouble concentrating than usual [CIDI-SF];Depression trouble concentrating CIDI-SF;;ACTIVE;2.36;2.65 +65493-9;People sometimes feel down on themselves, no good, or worthless - did you feel this way;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;People sometimes feel down on themselves, no good, or worthless - did you feel this way [CIDI-SF];Depression feel worthless CIDI-SF;;ACTIVE;2.36;2.65 +65494-7;Did you think a lot about death - either your own, someone elses, or death in general;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you think a lot about death - either your own, someone elses, or death in general [CIDI-SF];Depression thoughts of death CIDI-SF;;ACTIVE;2.36;2.65 +65495-4;About how many Ws altogether did you feel this way - the total period of depression or loss of interest was;Time;Pt;^Patient;Qn;CIDI-SF;PHENX;2;About how many weeks altogether did you feel this way - the total period of depression or loss of interest was [CIDI-SF];Depression number Ws CIDI-SF;;ACTIVE;2.36;2.65 +65496-2;How many periods like this did you have in your life, lasting 2 or more Ws;Num;Pt;^Patient;Qn;CIDI-SF;PHENX;2;How many periods like this did you have in your life, lasting 2 or more weeks [CIDI-SF];Depression number >2Ws CIDI-SF;;ACTIVE;2.36;2.65 +65497-0;About how old were you the first time you had a period of 2Ws like this;Time;Pt;^Patient;Qn;CIDI-SF;PHENX;2;About how old were you the first time you had a period of 2 weeks like this [CIDI-SF];Depression age onset CIDI-SF;;ACTIVE;2.36;2.65 +65498-8;About how old were you the last time you had a period of 2Ws like this;Time;Pt;^Patient;Qn;CIDI-SF;PHENX;2;About how old were you the last time you had a period of 2 weeks like this [CIDI-SF];Depression age last occurrence CIDI-SF;;ACTIVE;2.36;2.65 +65499-6;Did you ever tell a professional about these problems - medical doctor, psychologist, social worker, counselor, nurse, clergy, or other helping professional;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you ever tell a professional about these problems - medical doctor, psychologist, social worker, counselor, nurse, clergy, or other helping professional [CIDI-SF];Depression tell professional CIDI-SF;;ACTIVE;2.36;2.65 +65500-1;Did you take medication or use drugs or alcohol more than once for these problems;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you take medication or use drugs or alcohol more than once for these problems [CIDI-SF];Depression medication CIDI-SF;;ACTIVE;2.36;2.65 +65501-9;How much did these problems interfere with your life or activities;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How much did these problems interfere with your life or activities [CIDI-SF];Depression interfere activities CIDI-SF;;ACTIVE;2.36;2.65 +65502-7;Falling asleep in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Falling asleep in past 7 days [QIDS];Falling asleep QIDS;;ACTIVE;2.36;2.65 +65503-5;Sleep during the night in past 7D;Find;7D;^Patient;Nom;QIDS;PHENX;2;Sleep during the night in past 7 days [QIDS];Sleep during night QIDS;;ACTIVE;2.36;2.65 +65504-3;Waking up too early in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Waking up too early in past 7 days [QIDS];Waking too early QIDS;;ACTIVE;2.36;2.65 +65505-0;Sleeping too much in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Sleeping too much in past 7 days [QIDS];Sleeping too much QIDS;;ACTIVE;2.36;2.65 +65506-8;Feeling sad in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Feeling sad in past 7 days [QIDS];Feeling sad QIDS;;ACTIVE;2.36;2.65 +65507-6;Decreased appetite in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Decreased appetite in past 7 days [QIDS];Decreased appetite past 7D QIDS;;ACTIVE;2.36;2.65 +6550-8;Staphylococcus aureus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Staphylococcus aureus Ab [Units/volume] in Serum;S aureus Ab Ser-aCnc;;ACTIVE;1.0g;2.69 +65508-4;Increased appetite in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Increased appetite in past 7 days [QIDS];Increased appetite past 7D QIDS;;ACTIVE;2.36;2.65 +65509-2;Decreased weight within the last 2W;Find;2W;^Patient;Ord;QIDS;PHENX;2;Decreased weight within the last 2 weeks [QIDS];Decreased weight 2W [QIDS];;ACTIVE;2.36;2.65 +655-1;Microscopic observation;Prid;Pt;XXX;Nom;Acid fast stain.Kinyoun modified;MICRO;1;Microscopic observation [Identifier] in Specimen by Acid fast stain.Kinyoun modified;Acid fast Mod Kiny Stn Spec;;ACTIVE;1.0;2.73 +65510-0;Increased weight within the last 2W;Find;2W;^Patient;Ord;QIDS;PHENX;2;Increased weight within the last 2 weeks [QIDS];Increased weight 2W [QIDS];;ACTIVE;2.36;2.65 +65511-8;Concentration or decision making in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Concentration or decision making in past 7 days [QIDS];Concentration decision making QIDS;;ACTIVE;2.36;2.65 +65512-6;View of myself in past 7D;Find;7D;^Patient;Nom;QIDS;PHENX;2;View of myself in past 7 days [QIDS];View of myself QIDS;;ACTIVE;2.36;2.65 +65513-4;Thoughts of death or suicide in past 7D;Find;7D;^Patient;Nom;QIDS;PHENX;2;Thoughts of death or suicide in past 7 days [QIDS];Thoughts of death QIDS;;ACTIVE;2.36;2.65 +65514-2;General interest in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;General interest in past 7 days [QIDS];General interest QIDS;;ACTIVE;2.36;2.65 +65515-9;Energy level in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Energy level in past 7 days [QIDS];Energy level QIDS;;ACTIVE;2.36;2.65 +6551-6;Streptococcus agalactiae Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Streptococcus agalactiae Ag [Presence] in Throat by Immunofluorescence;Gp B Strep Ag Throat Ql IF;;ACTIVE;1.0g;2.73 +65516-7;Feeling slowed down in past 7D;Find;7D;^Patient;Ord;QIDS;PHENX;2;Feeling slowed down in past 7 days [QIDS];Feeling slowed down QIDS;;ACTIVE;2.36;2.65 +65517-5;Feeling restless in past 7D;Find;7D;^Patient;Nom;QIDS;PHENX;2;Feeling restless in past 7 days [QIDS];Feeling restless QIDS;;ACTIVE;2.36;2.65 +65518-3;Have you felt fat;Find;Pt;^Patient;Ord;EDDS;PHENX;2;Have you felt fat [EDDS];Felt fat EDDS;;ACTIVE;2.36;2.65 +65519-1;Have you had a definite fear that you might gain weight or become fat;Find;Pt;^Patient;Ord;EDDS;PHENX;2;Have you had a definite fear that you might gain weight or become fat [EDDS];Fear gain weight EDDS;;ACTIVE;2.36;2.65 +65520-9;Has your weight influenced how you think about or judge yourself as a person;Find;Pt;^Patient;Ord;EDDS;PHENX;2;Has your weight influenced how you think about or judge yourself as a person [EDDS];Weight self esteem EDDS;;ACTIVE;2.36;2.65 +65521-7;Has your shape influenced how you think about or judge yourself as a person;Find;Pt;^Patient;Ord;EDDS;PHENX;2;Has your shape influenced how you think about or judge yourself as a person [EDDS];Shape self esteem EDDS;;ACTIVE;2.36;2.65 +65522-5;During the past 6Mo have there been times when you felt you have eaten what other people would regard as an unusually large amount of food - a quart of ice cream - given the circumstances;Find;6Mo;^Patient;Ord;EDDS;PHENX;2;During the past 6 months have there been times when you felt you have eaten what other people would regard as an unusually large amount of food - a quart of ice cream - given the circumstances [EDDS];Eaten large amt food EDDS;;ACTIVE;2.36;2.65 +65523-3;During the times when you ate an unusually large amount of food, did you experience a loss of control - feel you couldn't stop eating or control what or how much you were eating;Find;Pt;^Patient;Ord;EDDS;PHENX;2;During the times when you ate an unusually large amount of food, did you experience a loss of control - feel you couldn't stop eating or control what or how much you were eating [EDDS];Couldn't stop eating EDDS;;ACTIVE;2.36;2.65 +6552-4;Streptococcus pneumoniae Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Streptococcus pneumoniae Ab [Presence] in Serum by Immunoassay;S pneum Ab Ser Ql IA;;ACTIVE;1.0g;2.56 +65524-1;How many D per W on average over the past 6Mo have you eaten an unusually large amount of food and experienced a loss of control;NRat;6Mo;^Patient;Qn;EDDS;PHENX;2;How many days per week on average over the past 6 months have you eaten an unusually large amount of food and experienced a loss of control [EDDS];6Mo D control loss EDDS;;ACTIVE;2.36;2.65 +65525-8;How many times per W on average over the past 3Mo have you eaten an unusually large amount of food and experienced a loss of control;NRat;3Mo;^Patient;Qn;EDDS;PHENX;2;How many times per week on average over the past 3 months have you eaten an unusually large amount of food and experienced a loss of control [EDDS];3Mo D control loss EDDS;;ACTIVE;2.36;2.65 +65526-6;How long have you had any of these fears;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How long have you had any of these fears [CIDI-SF];Specific how long fears CIDI-SF;;ACTIVE;2.36;2.65 +65527-4;Are you limited in the kinds of things you can do because of your vision;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you limited in the kinds of things you can do because of your vision [PhenX];Limited do things because vision PhenX;;TRIAL;2.36;2.65 +65528-2;Do you have more help from others because of your vision;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have more help from others because of your vision [PhenX];More help because vision PhenX;;TRIAL;2.36;2.65 +65529-0;Corneal vertex distance measured by retinomax;Len;Pt;Eye;Qn;PhenX;PHENX;2;Corneal vertex distance measured by retinomax Eye [PhenX];Corneal vertex Eye PhenX;;TRIAL;2.36;2.65 +65530-8;What is the longest period of time that this kind of worrying has ever continued;Time;Pt;^Patient;Qn;CIDI-SF;PHENX;2;What is the longest period of time that this kind of worrying has ever continued [CIDI-SF];GAD longest time worried CIDI-SF;;ACTIVE;2.36;2.65 +65531-6;During that period, was your worry stronger than in other people;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;During that period, was your worry stronger than in other people [CIDI-SF];GADstronger worry than others CIDI-SF;;ACTIVE;2.36;2.65 +6553-2;Streptococcus pneumoniae Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;S pneum Ag CSF Ql IF;;ACTIVE;1.0g;2.56 +65532-4;Did you worry most D;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you worry most days [CIDI-SF];GAD worry most Ds CIDI-SF;;ACTIVE;2.36;2.65 +65533-2;Did you usually worry about one particular thing, such as your job security or the failing health of a loved one, or more than one thing;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you usually worry about one particular thing, such as your job security or the failing health of a loved one, or more than one thing [CIDI-SF];GAD worry one particular thing CIDI-SF;;ACTIVE;2.36;2.65 +65534-0;Did you find it difficult to stop worrying;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you find it difficult to stop worrying [CIDI-SF];GAD difficult to stop worry CIDI-SF;;ACTIVE;2.36;2.65 +65535-7;Did you ever have different worries on your mind at the same time;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you ever have different worries on your mind at the same time [CIDI-SF];GAD different worries same time CIDI-SF;;ACTIVE;2.36;2.65 +65536-5;How often was your worry so strong that you couldn't put it out of your mind no matter how hard you tried;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How often was your worry so strong that you couldn't put it out of your mind no matter how hard you tried [CIDI-SF];GAD worry always on mind CIDI-SF;;ACTIVE;2.36;2.65 +65537-3;How often did you find it difficult to control your worry;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How often did you find it difficult to control your worry [CIDI-SF];GAD difficult control worry CIDI-SF;;ACTIVE;2.36;2.65 +65538-1;Did you take medication or use drugs or alcohol more than once for the worry or the problems it was causing;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you take medication or use drugs or alcohol more than once for the worry or the problems it was causing [CIDI-SF];GAD take medication CIDI-SF;;ACTIVE;2.36;2.65 +65539-9;How much did the worry or anxiety interfere with your life or activities;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How much did the worry or anxiety interfere with your life or activities [CIDI-SF];GAD interfere activities CIDI-SF;;ACTIVE;2.36;2.65 +6554-0;Streptococcus pneumoniae Ag;PrThr;Pt;Sputum;Ord;IF;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Sputum by Immunofluorescence;S pneum Ag Spt Ql IF;;ACTIVE;1.0g;2.56 +65540-7;How often do you get upset when you are in that situation;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How often do you get upset when you are in that situation [CIDI-SF];Specific upset with self CIDI-SF;;ACTIVE;2.36;2.65 +65541-5;How many Mo have you had any of these fears;Time;Pt;^Patient;Qn;CIDI-SF;PHENX;2;How many Mos have you had any of these fears [CIDI-SF];How long fears Mo CIDI-SF;;ACTIVE;2.36;2.68 +65542-3;How much have any of these fears ever interfered with your life or activities;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;How much have any of these fears ever interfered with your life or activities [CIDI-SF];Specific interfere activities CIDI-SF;;ACTIVE;2.36;2.65 +65543-1;Have you ever been very upset with yourself for having any of these fears;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Have you ever been very upset with yourself for having any of these fears [CIDI-SF];Upset with self ever CIDI-SF;;ACTIVE;2.36;2.65 +65544-9;Do you or your child have any of the following diseases;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Do you or your child have any of the following diseases [PhenX];Have autoimmune diseases PhenX;;TRIAL;2.36;2.65 +65545-6;Relation with diabetes-related problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Relation with diabetes-related problem [PhenX];Diabetes problem relative PhenX;;TRIAL;2.36;2.65 +65546-4;Problem related to diabetes;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Problem related to diabetes [PhenX];Diabetes problem PhenX;;TRIAL;2.36;2.65 +65547-2;Do you normally work or attend school during the D and sleep at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you normally work or attend school during the day and sleep at night [PhenX];Work during D PhenX;;TRIAL;2.36;2.65 +65548-0;What is your normal work or school and sleep schedule;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What is your normal work or school and sleep schedule [PhenX];Normal schedule PhenX;;TRIAL;2.36;2.65 +65549-8;If your normal work or school and sleep schedule is other, describe;Find;Pt;^Patient;Nom;PhenX;PHENX;2;If your normal work or school and sleep schedule is other, describe [PhenX];Normal schedule other PhenX;;TRIAL;2.36;2.65 +65550-6;What shift schedule do you most often work;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What shift schedule do you most often work [PhenX];What shift PhenX;;TRIAL;2.36;2.65 +65551-4;At what time do you usually go to bed;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;At what time do you usually go to bed [PhenX];Bedtime PhenX;;TRIAL;2.36;2.65 +65552-2;About how many M does it usually take for you to fall asleep;Time;Pt;^Patient;Qn;PhenX;PHENX;2;About how many minutes does it usually take for you to fall asleep [PhenX];Fall asleep PhenX;;TRIAL;2.36;2.65 +65553-0;At what time do you usually wake up;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;At what time do you usually wake up [PhenX];Wake up school work day PhenX;;TRIAL;2.36;2.65 +65554-8;How many H and M does it take for you to become fully awake from regular sleep, after first opening your eyes in the morning;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many hours and minutes does it take for you to become fully awake from regular sleep, after first opening your eyes in the morning [PhenX];Time to wake up PhenX;;TRIAL;2.36;2.65 +65555-5;Do you use an alarm clock to wake up in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you use an alarm clock to wake up in the morning [PhenX];Alarm clock PhenX;;TRIAL;2.36;2.65 +65556-3;Do you have great difficulty waking up in the morning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have great difficulty waking up in the morning [PhenX];Difficulty waking up PhenX;;TRIAL;2.36;2.65 +6555-7;Streptococcus pneumoniae Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Specimen by Immunofluorescence;S pneum Ag Spec Ql IF;;ACTIVE;1.0g;2.73 +65557-1;Do you often have so much trouble waking up that an alarm clock won't wake you and you have to use other methods to wake up;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you often have so much trouble waking up that an alarm clock won't wake you and you have to use other methods to wake up [PhenX];Methods besides alarm PhenX;;TRIAL;2.36;2.65 +65558-9;Describe other methods used to wake up;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Describe other methods used to wake up [PhenX];Methods besides alarm other PhenX;;TRIAL;2.36;2.65 +65559-7;When you wake up in the morning or from a nap, do you feel out of it and confused;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you wake up in the morning or from a nap, do you feel out of it and confused [PhenX];Waking up confused PhenX;;TRIAL;2.36;2.65 +65560-5;How many Hs and Ms does it take for you to fully awaken from a nap;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many hours and minutes does it take for you to fully awaken from a nap [PhenX];Fully awaken nap PhenX;;TRIAL;2.36;2.65 +65561-3;How much sleep do you usually get on a typical night;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How much sleep do you usually get on a typical night [PhenX];Amount sleep night nRate PhenX;;TRIAL;2.36;2.65 +65562-1;Do you usually follow the same sleep schedule, that is, no more than a 1H difference in sleep and wake times, on both work or school and non-work or school D;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you usually follow the same sleep schedule, that is, no more than a 1 hour difference in sleep and wake times, on both work or school and non-work or school days [PhenX];Follow same sleep schedule PhenX;;TRIAL;2.36;2.65 +65563-9;How many Hs of sleep per night do you think you need to feel fully rested the next day;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How many hours of sleep per night do you think you need to feel fully rested the next day [PhenX];Hs sleep needed nRate PhenX;;TRIAL;2.36;2.65 +65564-7;Do you feel awake and refreshed after sleeping;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel awake and refreshed after sleeping [PhenX];Feel refreshed PhenX;;TRIAL;2.36;2.65 +6556-5;Streptococcus pyogenes Ag;Pr;Pt;Thrt;Ord;EIA;MICRO;1;Deprecated Streptococcus pyogenes Ag [Presence] in Throat by Immunoassay;Deprecated S pyo Ag Throat Ql EIA;;DEPRECATED;1.0g;2.54 +65565-4;How often do you remember your dreams - that is, dreams that occur during your regular sleep and not while napping;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;How often do you remember your dreams - that is, dreams that occur during your regular sleep and not while napping [PhenX];Remember dreams PhenX;;TRIAL;2.36;2.65 +65566-2;How often do you take naps;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;How often do you take naps [PhenX];Naps PhenX;;TRIAL;2.36;2.65 +65567-0;At what time of the D do you usually take naps;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;At what time of the day do you usually take naps [PhenX];Naptime PhenX;;TRIAL;2.36;2.65 +65568-8;How many H and Ms of sleep do you usually get when you take a nap;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many hours and minutes of sleep do you usually get when you take a nap [PhenX];Amount sleep naptime PhenX;;TRIAL;2.36;2.65 +65569-6;Do you have great difficulty waking up from naps;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have great difficulty waking up from naps [PhenX];Difficulty waking naps PhenX;;TRIAL;2.36;2.65 +65570-4;How often do you dream when you nap;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;How often do you dream when you nap [PhenX];Dream nap PhenX;;TRIAL;2.36;2.65 +65571-2;Are these dreams very intense, detailed and vivid, like watching a movie;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are these dreams very intense, detailed and vivid, like watching a movie [PhenX];Nap dreams intense PhenX;;TRIAL;2.36;2.65 +65572-0;How difficult is it for you to adapt to a sleep loss of 3H or more - sleeping 3 or more H less than you normally do the night before;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How difficult is it for you to adapt to a sleep loss of 3 hours or more - sleeping 3 or more hours less than you normally do the night before [PhenX];Adapt sleep loss 3h PhenX;;TRIAL;2.36;2.65 +6557-3;Streptococcus pyogenes Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Streptococcus pyogenes Ag [Presence] in Throat by Immunofluorescence;S pyo Ag Throat Ql IF;;ACTIVE;1.0g;2.73 +65573-8;Does this loss of sleep affect you the next day with respect to your mood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does this loss of sleep affect you the next day with respect to your mood [PhenX];Loss of sleep affect mood PhenX;;TRIAL;2.36;2.65 +65574-6;How quickly after this loss of sleep, do you return to your usual self if you are allowed to sleep as much as you like;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How quickly after this loss of sleep, do you return to your usual self if you are allowed to sleep as much as you like [PhenX];Loss of sleep recovery PhenX;;TRIAL;2.36;2.65 +65575-3;Do you prefer to keep a regular sleep schedule - one that does not change much from one night to the next;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you prefer to keep a regular sleep schedule - one that does not change much from one night to the next [PhenX];Prefer regular sleep schedule PhenX;;TRIAL;2.36;2.65 +65576-1;If you do not keep your regular sleep schedule, how much do you feel off - not your regular self, the next day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If you do not keep your regular sleep schedule, how much do you feel off - not your regular self, the next day [PhenX];No sleep schedule feel off PhenX;;TRIAL;2.36;2.65 +65577-9;When you are traveling east by air and you cross over several time zones, how quickly do you return to your usual sleeping pattern;Time;Pt;^Patient;Qn;PhenX;PHENX;2;When you are traveling east by air and you cross over several time zones, how quickly do you return to your usual sleeping pattern [PhenX];Jet lag west PhenX;;TRIAL;2.36;2.65 +65578-7;How does this loss of sleep affect you the next D with respect to your mood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How does this loss of sleep affect you the next day with respect to your mood [PhenX];Sleep loss affect mood how PhenX;;TRIAL;2.36;2.65 +65579-5;What about when you are traveling west by air over several time zones;Time;Pt;^Patient;Qn;PhenX;PHENX;2;What about when you are traveling west by air over several time zones [PhenX];Jet lag east PhenX;;TRIAL;2.36;2.65 +65580-3;Do you consider yourself to be a morning person - early bird, an evening person - night owl, or neither;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Do you consider yourself to be a morning person - early bird, an evening person - night owl, or neither [PhenX];Morning or evening person PhenX;;TRIAL;2.36;2.65 +6558-1;Streptococcus pyogenes Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Streptococcus pyogenes Ag [Presence] in Specimen by Immunoassay;S pyo Ag Spec Ql IA;;ACTIVE;1.0g;2.73 +65581-1;How strong is your preference;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How strong is your preference [PhenX];Morning evening person PhenX;;TRIAL;2.36;2.65 +65582-9;Does respondent consistently fall asleep very late - 12 a.m. or later, at night and characterize him or herself as a night owl with a strong preference;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does respondent consistently fall asleep very late - 12 a.m. or later, at night and characterize him or herself as a night owl with a strong preference [PhenX];Morning evening preference PhenX;;TRIAL;2.36;2.65 +65583-7;At what time do you usually go to sleep - feel sleepy and ready to go to bed;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;At what time do you usually go to sleep - feel sleepy and ready to go to bed [PhenX];Sleep time vacation PhenX;;TRIAL;2.36;2.65 +65585-2;Are these usual sleep and wake times always about the same - each day during a week of vacation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are these usual sleep and wake times always about the same - each day during a week of vacation [PhenX];Similar sleep wake time vacation PhenX;;TRIAL;2.36;2.65 +65586-0;Do you wake up on your own, without an alarm or other assistance;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you wake up on your own, without an alarm or other assistance [PhenX];Wake on own vacation PhenX;;TRIAL;2.36;2.65 +65587-8;Have you ever tried to force yourself to fall asleep at an earlier time than your usual bedtime;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever tried to force yourself to fall asleep at an earlier time than your usual bedtime [PhenX];Force self asleep early PhenX;;TRIAL;2.36;2.65 +65589-4;When you tried to shift your sleep schedule to an earlier bedtime, at least 1 to 2H earlier, did you have difficulty falling asleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you tried to shift your sleep schedule to an earlier bedtime, at least 1 to 2 hours earlier, did you have difficulty falling asleep [PhenX];Force self asleep early difficult PhenX;;TRIAL;2.36;2.65 +65590-2;Do attempts to change your sleep or wake schedule tend to make your sleeping difficulties worse;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do attempts to change your sleep or wake schedule tend to make your sleeping difficulties worse [PhenX];Change sleep schedule difficulty PhenX;;TRIAL;2.36;2.65 +65591-0;During the past Y, what was the longest period of time that you had these sleeping problems on most nights;Time;1Y;^Patient;Qn;PhenX;PHENX;2;During the past Y, what was the longest period of time that you had these sleeping problems on most nights [PhenX];Last Y longest period PhenX;;TRIAL;2.36;2.65 +65592-8;How old were you when you first began going to sleep very late without being able to adjust your schedule when you tried;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you first began going to sleep very late without being able to adjust your schedule when you tried [PhenX];Age sleep W/O adjust schedule PhenX;;TRIAL;2.36;2.65 +65593-6;How old were you the last time you experienced these problems;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you the last time you experienced these problems [PhenX];Age last episode PhenX;;TRIAL;2.36;2.65 +65594-4;Do you currently experience these problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you currently experience these problems [PhenX];Currently experience problems PhenX;;TRIAL;2.36;2.65 +65595-1;Have you ever had frequent problems getting to sleep at the beginning of the night which has negatively affected how you function during the following day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had frequent problems getting to sleep at the beginning of the night which has negatively affected how you function during the following day [PhenX];Getting to sleep work problems PhenX;;TRIAL;2.36;2.65 +65596-9;Have you ever had frequent problems staying asleep at night which has negatively affected how you function during the following day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had frequent problems staying asleep at night which has negatively affected how you function during the following day [PhenX];Staying asleep work problems PhenX;;TRIAL;2.36;2.65 +65597-7;Have you ever had frequent problems falling back to sleep after waking in the middle of the night which has negatively affected how you function during the following day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had frequent problems falling back to sleep after waking in the middle of the night which has negatively affected how you function during the following day [PhenX];Back sleep work problems PhenX;;TRIAL;2.36;2.65 +65598-5;In the past Y, have you had difficulty getting to sleep;Find;1Y;^Patient;Ord;PhenX;PHENX;2;In the past year, have you had difficulty getting to sleep [PhenX];Past Y sleep difficulty PhenX;;TRIAL;2.36;2.65 +6559-9;Streptococcus pyogenes Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Streptococcus pyogenes Ag [Presence] in Specimen by Immunofluorescence;S pyo Ag Spec Ql IF;;ACTIVE;1.0g;2.73 +65599-3;In the past Y, have you awakened during the night and had a hard time getting back to sleep;Find;1Y;^Patient;Ord;PhenX;PHENX;2;In the past year, have you awakened during the night and had a hard time getting back to sleep [PhenX];Past Y awake night PhenX;;TRIAL;2.36;2.65 +65600-9;In the past Y, have you awakened too early in the morning and couldn't get back to sleep;Find;1Y;^Patient;Ord;PhenX;PHENX;2;In the past year, have you awakened too early in the morning and couldn't get back to sleep [PhenX];Past Y awake too early PhenX;;TRIAL;2.36;2.65 +65601-7;Do you look at the clock frequently to see how long you have not been able to fall asleep during the night when you cannot fall asleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you look at the clock frequently to see how long you have not been able to fall asleep during the night when you cannot fall asleep [PhenX];Look at clock PhenX;;TRIAL;2.36;2.65 +65602-5;When you are not sleeping in your usual bed, in a hotel room while on vacation, or on your couch watching television, do you still have problems initially getting to sleep, staying asleep, or falling back to sleep after waking up during the night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you are not sleeping in your usual bed, in a hotel room while on vacation, or on your couch watching television, do you still have problems initially getting to sleep, staying asleep, or falling back to sleep after waking up during the night [PhenX];Unusual bed difficult PhenX;;TRIAL;2.36;2.73 +65603-3;Do you ever have trouble falling asleep or staying asleep, when there seems to be no cause or explanation for it;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever have trouble falling asleep or staying asleep, when there seems to be no cause or explanation for it [PhenX];No explanation PhenX;;TRIAL;2.36;2.65 +65604-1;Has your difficulty with sleeping occurred or worsened during pregnancy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your difficulty with sleeping occurred or worsened during pregnancy [PhenX];Pregnancy sleep difficulty PhenX;;TRIAL;2.36;2.65 +65605-8;Has your difficulty with sleeping occurred or worsened during menopause;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your difficulty with sleeping occurred or worsened during menopause [PhenX];Menopause sleep difficulty PhenX;;TRIAL;2.36;2.65 +65606-6;Has your difficulty with sleeping occurred or worsened during a few Ds before menstruation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your difficulty with sleeping occurred or worsened during a few days before menstruation [PhenX];Before menstruation diff sleep PhenX;;TRIAL;2.36;2.65 +6560-7;Plasmodium ovale Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Plasmodium ovale Ab [Units/volume] in Serum;P ovale Ab Ser-aCnc;;ACTIVE;1.0g;2.69 +65607-4;Has your difficulty with sleeping occurred or worsened during menstruation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your difficulty with sleeping occurred or worsened during menstruation [PhenX];During menstruation diff sleep PhenX;;TRIAL;2.36;2.65 +65608-2;How many separate times in your life have you had difficulty getting to sleep, staying asleep or falling back to sleep after waking up during the night, for at least 1Mo;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many separate times in your life have you had difficulty getting to sleep, staying asleep or falling back to sleep after waking up during the night, for at least 1 month [PhenX];# times sleep difficulty PhenX;;TRIAL;2.36;2.65 +65609-0;How old were you when you first experienced this kind of difficulty with sleeping, for at least 1Mo;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you first experienced this kind of difficulty with sleeping, for at least 1 month [PhenX];Age first sleep difficulty PhenX;;TRIAL;2.36;2.65 +65610-8;How old were you the last time you experienced this insomnia, for at least 1Mo;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you the last time you experienced this insomnia, for at least 1 month [PhenX];Age last sleep difficulty PhenX;;TRIAL;2.36;2.65 +65611-6;Do you currently experience insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you currently experience insomnia [PhenX];Current insomnia PhenX;;TRIAL;2.36;2.65 +65612-4;How frequently do you experience insomnia;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How frequently do you experience insomnia [PhenX];Insomnia freq nRate PhenX;;TRIAL;2.36;2.65 +65613-2;Do you feel so sleepy during the D that it interrupts your normal activities, such as driving, reading, or concentrating at work or school, even when you have had enough sleep the night before;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel so sleepy during the day that it interrupts your normal activities, such as driving, reading, or concentrating at work or school, even when you have had enough sleep the night before [PhenX];Sleepy interrupt D PhenX;;TRIAL;2.36;2.65 +65614-0;How often do you feel so sleepy during the D that it interrupts your normal activities;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How often do you feel so sleepy during the day that it interrupts your normal activities [PhenX];Sleepy interrupt activ times nRate PhenX;;TRIAL;2.36;2.65 +6561-5;Treponema pallidum Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Treponema pallidum IgG Ab [Presence] in Serum;T pallidum IgG Ser Ql;;ACTIVE;1.0g;2.73 +65615-7;What is the longest period of time that you have felt so sleepy during the D that it interrupts your normal activities on most Ds;Time;Pt;^Patient;Qn;PhenX;PHENX;2;What is the longest period of time that you have felt so sleepy during the day that it interrupts your normal activities on most days [PhenX];Longest period interrupt activ PhenX;;TRIAL;2.36;2.65 +65616-5;How often does this overwhelming desire to go to sleep occur;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How often does this overwhelming desire to go to sleep occur [PhenX];Freq desire to sleep PhenX;;TRIAL;2.36;2.69 +65617-3;During the daytime, do you experience an overwhelming desire to go to sleep - so overwhelming that you cannot resist;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During the daytime, do you experience an overwhelming desire to go to sleep - so overwhelming that you cannot resist [PhenX];Daytime desire to sleep PhenX;;TRIAL;2.36;2.65 +65618-1;What is the longest period of time that you have felt this overwhelming desire to go to sleep, on most Ds;Time;Pt;^Patient;Qn;PhenX;PHENX;2;What is the longest period of time that you have felt this overwhelming desire to go to sleep, on most days [PhenX];Longest period desire to sleep PhenX;;TRIAL;2.36;2.65 +65619-9;When you do doze off during the D and take a nap, do you find this sleep refreshing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you do doze off during the day and take a nap, do you find this sleep refreshing [PhenX];Nap refreshing PhenX;;TRIAL;2.36;2.65 +65620-7;Describe refreshing sleep;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Describe refreshing sleep [PhenX];Nap refreshing describe PhenX;;TRIAL;2.36;2.65 +65621-5;Do you feel that you are sleepier than other people your age;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel that you are sleepier than other people your age [PhenX];Sleepier than others PhenX;;TRIAL;2.36;2.65 +65622-3;Do you ever experience periods of muscle weakness, loss of muscle strength or limp muscles in any part of your body, such as the legs or face, when you laugh;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever experience periods of muscle weakness, loss of muscle strength or limp muscles in any part of your body, such as the legs or face, when you laugh [PhenX];Muscle weakness laugh PhenX;;TRIAL;2.36;2.65 +6562-3;Treponema pallidum Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Treponema pallidum IgM Ab [Presence] in Serum;T pallidum IgM Ser Ql;;ACTIVE;1.0g;2.73 +65623-1;Do you ever experience periods of muscle weakness, loss of muscle strength or limp muscles in any part of your body, such as the legs or face, when you are angry;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever experience periods of muscle weakness, loss of muscle strength or limp muscles in any part of your body, such as the legs or face, when you are angry [PhenX];Muscle weakness angry PhenX;;TRIAL;2.36;2.65 +65624-9;Do you ever experience periods of muscle weakness, loss of muscle strength or limp muscles in any part of your body, such as the legs or face, when you hear or tell a joke;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever experience periods of muscle weakness, loss of muscle strength or limp muscles in any part of your body, such as the legs or face, when you hear or tell a joke [PhenX];Muscle weakness joke PhenX;;TRIAL;2.36;2.65 +65625-6;Have you ever been told that you act out your dreams;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been told that you act out your dreams [PhenX];Act out dreams PhenX;;TRIAL;2.36;2.65 +65626-4;How often does acting out your dreams happen;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How often does acting out your dreams happen [PhenX];Act out dreams freq nRate PhenX;;TRIAL;2.36;2.65 +65627-2;Do you ever move so much during your sleep that you accidentally hit your bed partner, if any, or hurt yourself?;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever move so much during your sleep that you accidentally hit your bed partner, if any, or hurt yourself? [PhenX];Move in sleep PhenX;;TRIAL;2.36;2.65 +65628-0;Do you have any memory of these events;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any memory of these events [PhenX];Memory move in sleep PhenX;;TRIAL;2.36;2.65 +65629-8;Does moving at night disrupt your sleep, wake you up at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does moving at night disrupt your sleep, wake you up at night [PhenX];Moving disrupt sleep PhenX;;TRIAL;2.36;2.65 +65630-6;During what part of the night do these events most often occur;Find;Pt;^Patient;Nom;PhenX;PHENX;2;During what part of the night do these events most often occur [PhenX];Move which part night PhenX;;TRIAL;2.36;2.65 +6563-1;Trichinella spiralis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trichinella spiralis IgG Ab [Presence] in Serum by Immunoassay;T spiralis IgG Ser Ql IA;;ACTIVE;1.0g;2.73 +65631-4;Does this loss of sleep affect you the next day with respect to your tendency to be irritable;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does this loss of sleep affect you the next day with respect to your tendency to be irritable [PhenX];Sleep loss affect irritable PhenX;;TRIAL;2.36;2.65 +65632-2;Clozapine & Norclozapine panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;cloZAPine and Norclozapine panel - Serum or Plasma;cloZAPine+Nor pnl SerPl;;ACTIVE;2.36;2.42 +65633-0;Hepatitis B virus surface Ag;PrThr;Pt;Ser/Plas;Ord;Confirm;MICRO;1;Hepatitis B virus surface Ag [Presence] in Serum or Plasma by Confirmatory method;HBV surface Ag SerPl Ql Cfm;;ACTIVE;2.36;2.73 +65634-8;Creatinine 24 hour urine panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Creatinine 24 hour urine panel - 24 hour Urine;Creatinine 24H UR pnl 24h Ur;;DISCOURAGED;2.36;2.73 +65635-5;When you have sudden anxiety attacks, do they usually occur in specific situations that cause you unreasonably strong fear;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;When you have sudden anxiety attacks, do they usually occur in specific situations that cause you unreasonably strong fear [CIDI-SF];Panic specific situations CIDI-SF;;ACTIVE;2.36;2.65 +65637-1;Finger-nose-finger on left - 8 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Finger-nose-finger on left - 8 times [PhenX];Finger-nose-finger left PhenX;;TRIAL;2.36;2.65 +65638-9;Open and close left hand - 10 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Open and close left hand - 10 times [PhenX];Open close left hand PhenX;;TRIAL;2.36;2.65 +65639-7;Alternatively pronate and supinate left hand - 10 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Alternatively pronate and supinate left hand - 10 times [PhenX];Pronate supinate left hand PhenX;;TRIAL;2.36;2.65 +65640-5;Tap left foot - 10 times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Tap left foot - 10 times [PhenX];Tap left foot PhenX;;TRIAL;2.36;2.65 +65641-3;Activity that usually makes you feel breathless these days;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Activity that usually makes you feel breathless these days [PhenX];Activity makes breathless PhenX;;TRIAL;2.36;2.65 +65642-1;This activity usually makes you feel breathless these days;Find;Pt;^Patient;Ord;PhenX;PHENX;2;This activity usually makes you feel breathless these days [PhenX];Activity makes breathless ever PhenX;;TRIAL;2.36;2.65 +65643-9;Relative humidity;RelMCnc;Pt;Air;Qn;;PHENX;2;Relative humidity;Relative humidity;;TRIAL;2.36;2.65 +65644-7;BTPS factor;Ratio;Pt;^Patient;Qn;PhenX;PHENX;2;BTPS factor [Ratio] [PhenX];BTPS factor PhenX;;TRIAL;2.36;2.65 +65645-4;Reviewer initials;ID;Pt;XXX;Nom;;ADMIN;2;Reviewer initials;Reviewer initials;;TRIAL;2.36;2.69 +65646-2;Manufacturer name;ID;Pt;Oxygen saturation device;Nom;;DEVICES;2;Manufacturer name Oxygen saturation device;SaO2% Device Manufacturer name;;TRIAL;2.36;2.66 +65647-0;City;Loc;Pt;Facility;Nom;;ADMIN.FACILITY;2;City Facility;City Facility;;ACTIVE;2.36;2.66 +65648-8;Zip - post code;Loc;Pt;Facility;Nom;;PHENX;2;Deprecated Zip - post code Facility;Deprecated Zip-post code Facility;;DEPRECATED;2.36;2.66 +6564-9;Trichomonas vaginalis;PrThr;Pt;Genital;Ord;Comp fix;MICRO;1;Trichomonas vaginalis [Presence] in Genital specimen by Complement fixation;T vaginalis Genital Ql CF;;ACTIVE;1.0g;2.73 +65649-6;Country;Loc;Pt;Facility;Nom;;ADMIN.FACILITY;2;Country Facility;Country Facility;;ACTIVE;2.36;2.66 +65650-4;Email address;EmailAddr;Pt;Facility;Nom;;ADMIN.FACILITY;2;Email address Facility;Email address Facility;;ACTIVE;2.36;2.66 +65651-2;Phone number;Tele;Pt;Facility;Nom;;ADMIN.FACILITY;2;Phone number Facility;Facility Phone #;;ACTIVE;2.36;2.73 +65652-0;Testing facility name;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Testing facility name;Testing facility name;;ACTIVE;2.36;2.73 +65653-8;Test challenge type;Type;Pt;Respiratory system;Nom;;PHENX;2;Test challenge type Respiratory system;Test challenge type Respiratory;;ACTIVE;2.36;2.65 +65654-6;Extrapolated volume;Vol;Pt;Respiratory system;Qn;;PHENX;2;Extrapolated volume Respiratory system;Extrapolated volume Respiratory;;ACTIVE;2.36;2.65 +65655-3;Volume expired during 6.0 s of forced expiration;Vol;Pt;Respiratory system;Qn;;PULM;2;FEV6;FEV6;;TRIAL;2.36;2.65 +6565-6;Trichomonas vaginalis;PrThr;Pt;Genital;Ord;Wet preparation;MICRO;1;Trichomonas vaginalis [Presence] in Genital specimen by Wet preparation;T vaginalis Genital Ql Wet Prep;;ACTIVE;1.0g;2.73 +65656-1;Volume expired during 6.0 s of forced expiration;Vol;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV6 Predicted;FEV6 Predicted;;TRIAL;2.36;2.65 +65657-9;Volume expired during 1.0 s of forced expiration/Forced vital capacity.predicted;VRto;Pt;Respiratory system;Qn;;PULM;2;Deprecated FEV1/predicted;Deprecated FEV1/predicted FVC;;DEPRECATED;2.36;2.40 +65658-7;Volume expired during 1.0 s of forced expiration/Volume expired during 6.0 s of forced expiration;VRto;Pt;Respiratory system;Qn;Predicted;PULM;2;FEV1/FEV6 Predicted;FEV1/FEV6 Predicted;;ACTIVE;2.36;2.65 +65660-3;Original sampling interval;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Original sampling interval [PhenX];Original sampling interval PhenX;;TRIAL;2.36;2.65 +65661-1;Data points;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Data points [#] [PhenX];Data points PhenX;;TRIAL;2.36;2.65 +65662-9;Flow time data point;Num;Pt;^Patient;Nom;PhenX;PHENX;2;Flow time data point [PhenX];Flow time data point PhenX;;TRIAL;2.36;2.65 +65663-7;Have you ever had sex with a partner who had a vasectomy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had sex with a partner who had a vasectomy [PhenX];Sex partner with vasectomy PhenX;;TRIAL;2.36;2.65 +6566-4;Trichomonas vaginalis Ag;PrThr;Pt;Genital;Ord;IA;MICRO;1;Trichomonas vaginalis Ag [Presence] in Genital specimen by Immunoassay;T vaginalis Ag Genital Ql IA;;ACTIVE;1.0g;2.73 +65664-5;Have you ever had sex with a partner who used withdrawal or pulling out;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had sex with a partner who used withdrawal or pulling out [PhenX];Sex partner withdrawal PhenX;;TRIAL;2.36;2.65 +65665-2;Doctor reported child vision problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Doctor reported child vision problem [PhenX];Doctor reported child vision prob PhenX;;TRIAL;2.36;2.65 +65666-0;What treatment did your child receive for this doctor reported vision problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What treatment did your child receive for this doctor reported vision problem [PhenX];Tx child receive Dr. reported PhenX;;TRIAL;2.36;2.65 +65667-8;When did your child receive this treatment for doctor reported vision problem;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did your child receive this treatment for doctor reported vision problem [Date and time] [PhenX];Tx child receive Dr. reported date PhenX;;TRIAL;2.36;2.65 +65668-6;Has a doctor ever told you that your child ever had this vision problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that your child ever had this vision problem [PhenX];Dr. told child vision prob ever PhenX;;TRIAL;2.36;2.65 +65669-4;What Mo and Y did child first begin wearing glasses or contact lenses;Date;Pt;^Patient;Qn;PhenX;PHENX;2;What month and year did child first begin wearing glasses or contact lenses [PhenX];Begin glasses contact lenses date PhenX;;TRIAL;2.36;2.65 +65670-2;Blood relative with eye problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Blood relative with eye problem [PhenX];Blood relative eye problem PhenX;;TRIAL;2.36;2.65 +65671-0;Other treatment or treatments you are receiving or you received for your eye problem;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other treatment or treatments you are receiving or you received for your eye problem [PhenX];Other treatment eye problem PhenX;;TRIAL;2.36;2.65 +6567-2;Trichomonas vaginalis Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Trichomonas vaginalis Ag [Presence] in Genital specimen by Immunofluorescence;T vaginalis Ag Genital Ql IF;;ACTIVE;1.0g;2.73 +65672-8;Did you receive this treatment for your glaucoma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you receive this treatment for your glaucoma [PhenX];Receive glaucoma tx PhenX;;TRIAL;2.36;2.65 +65673-6;Do or did any of your relatives have this eye problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do or did any of your relatives have this eye problem [PhenX];Relatives have eye problem PhenX;;TRIAL;2.36;2.65 +65674-4;How does this loss of sleep affect you the next day with respect to your tendency to be irritable;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How does this loss of sleep affect you the next day with respect to your tendency to be irritable [PhenX];Sleep loss affect irritable how PhenX;;TRIAL;2.36;2.65 +65675-1;Does this loss of sleep affect you the next day with respect to your ability to get your work done;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does this loss of sleep affect you the next day with respect to your ability to get your work done [PhenX];Sleep loss affect work done PhenX;;TRIAL;2.36;2.65 +65676-9;How does this loss of sleep affect you the next day with respect to your ability to get your work done;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How does this loss of sleep affect you the next day with respect to your ability to get your work done [PhenX];Sleep loss affect work how PhenX;;TRIAL;2.36;2.65 +65677-7;Does this loss of sleep affect you the next day with respect to how much you eat;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does this loss of sleep affect you the next day with respect to how much you eat [PhenX];Sleep loss affect eating PhenX;;TRIAL;2.36;2.65 +65678-5;How does this loss of sleep affect you the next day with respect to how much you eat;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How does this loss of sleep affect you the next day with respect to how much you eat [PhenX];Sleep loss affect eating how PhenX;;TRIAL;2.36;2.65 +65679-3;Does this loss of sleep affect you the next day with respect to your desire for chocolate or sweets;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does this loss of sleep affect you the next day with respect to your desire for chocolate or sweets [PhenX];Sleep loss affect desire sweets PhenX;;TRIAL;2.36;2.65 +6568-0;Trichomonas vaginalis rRNA;PrThr;Pt;Genital;Ord;Probe;MICRO;1;Trichomonas vaginalis rRNA [Presence] in Genital specimen by Probe;T vaginalis rRNA Genital Ql Probe;;ACTIVE;1.0g;2.73 +65680-1;How does this loss of sleep affect you the next day with respect to your desire for chocolate or sweets;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How does this loss of sleep affect you the next day with respect to your desire for chocolate or sweets [PhenX];Sleep loss affect sweets how PhenX;;TRIAL;2.36;2.65 +65681-9;Treatment for your glaucoma;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Treatment for your glaucoma [PhenX];Treatment glaucoma PhenX;;TRIAL;2.36;2.65 +65682-7;Things experienced during the daytime due to difficulties falling asleep or staying asleep at night;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things experienced during the daytime due to difficulties falling asleep or staying asleep at night [PhenX];Things diff falling asleep PhenX;;TRIAL;2.36;2.65 +65683-5;Do you experience any of these things during the daytime due to your difficulties falling asleep or staying asleep at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you experience any of these things during the daytime due to your difficulties falling asleep or staying asleep at night [PhenX];Diff d/t falling asleep ever PhenX;;TRIAL;2.36;2.65 +65684-3;Do you experience frustration, tension or anxiety over not being able to go to sleep during the night when you cannot fall asleep;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you experience frustration, tension or anxiety over not being able to go to sleep during the night when you cannot fall asleep [PhenX];Difficulty anxiety PhenX;;TRIAL;2.36;2.65 +65685-0;Events or conditions occurring at the same time as difficulty with insomnia;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Events or conditions occurring at the same time as difficulty with insomnia [PhenX];Events with insomnia PhenX;;TRIAL;2.36;2.65 +65686-8;Does your difficulty with insomnia occur at the same time as any of these events or conditions;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your difficulty with insomnia occur at the same time as any of these events or conditions [PhenX];Events with insomnia ever PhenX;;TRIAL;2.36;2.65 +65687-6;Other drugs or medications occurring with insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Other drugs or medications occurring with insomnia [PhenX];Other meds with insomnia PhenX;;TRIAL;2.36;2.65 +65688-4;Changing schedule occurring with insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Changing schedule occurring with insomnia [PhenX];Changing schedule with insomnia PhenX;;TRIAL;2.36;2.65 +65689-2;Noisy or uncomfortable surroundings occurring with insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Noisy or uncomfortable surroundings occurring with insomnia [PhenX];Noisy surroundings with insomnia PhenX;;TRIAL;2.36;2.65 +656-9;Microscopic observation;Prid;Pt;XXX;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Specimen by Acid fast stain.Ziehl-Neelsen;ZN Stn Spec;;ACTIVE;1.0;2.73 +65690-0;Stress or major life event occurring with insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Stress or major life event occurring with insomnia [PhenX];Stress with insomnia PhenX;;TRIAL;2.36;2.65 +65691-8;Other disturbances occurring with insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Other disturbances occurring with insomnia [PhenX];Other disturbances with insomnia PhenX;;TRIAL;2.36;2.65 +65692-6;Emotional or mental condition occurring with insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Emotional or mental condition occurring with insomnia [PhenX];Emotional condition with insomnia PhenX;;TRIAL;2.36;2.65 +65693-4;Other medical condition occurring with insomnia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Other medical condition occurring with insomnia [PhenX];Other med condition with insomnia PhenX;;TRIAL;2.36;2.65 +65695-9;Finger taps - right;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Finger taps - right [UPDRS];Finger taps - right UPDRS;;ACTIVE;2.36;2.71 +65696-7;Finger taps - left;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Finger taps - left [UPDRS];Finger taps - left UPDRS;;ACTIVE;2.36;2.71 +65697-5;Hand movements - right;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Hand movements - right [UPDRS];Hand movements - right UPDRS;;ACTIVE;2.36;2.71 +6569-8;Varicella zoster virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Varicella zoster virus IgG Ab [Titer] in Serum by Immunofluorescence;VZV IgG Titr Ser IF;;ACTIVE;1.0g;2.73 +65698-3;Hand movements - left;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Hand movements - left [UPDRS];Hand movements - left UPDRS;;ACTIVE;2.36;2.71 +65699-1;Rapid alternating hand movements - right;Find;Pt;^Patient;Ord;;NEURO;2;Rapid alternating hand movements - right;Rapid alt hand move - R;;ACTIVE;2.36;2.66 +65700-7;Rapid alternating hand movements - left;Find;Pt;^Patient;Ord;;NEURO;2;Rapid alternating hand movements - left;Rapid alt hand move - L;;ACTIVE;2.36;2.66 +65701-5;Leg agility - right;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Leg agility - right [UPDRS];Leg agility - right UPDRS;;ACTIVE;2.36;2.71 +65702-3;Leg agility - left;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Leg agility - left [UPDRS];Leg agility - left UPDRS;;ACTIVE;2.36;2.71 +65703-1;Arising from chair;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Arising from chair [UPDRS];Arising from chair UPDRS;;ACTIVE;2.36;2.71 +65704-9;Posture;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Posture [UPDRS];Posture UPDRS;;ACTIVE;2.36;2.71 +65705-6;Gait - parkinsons;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Gait - parkinsons [UPDRS];Gait - parkinsons UPDRS;;ACTIVE;2.36;2.71 +6570-6;Varicella zoster virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Varicella zoster virus IgM Ab [Titer] in Serum by Immunofluorescence;VZV IgM Titr Ser IF;;ACTIVE;1.0g;2.73 +65706-4;Postural stability - retropulsion test;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Postural stability - retropulsion test [UPDRS];Postural stability UPDRS;;ACTIVE;2.36;2.71 +65707-2;Extent of lower extremity sensory symptoms;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Extent of lower extremity sensory symptoms [PhenX];Ext LE symp PhenX;;TRIAL;2.36;2.69 +65708-0;Motor symptoms - legs;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Motor symptoms - legs [PhenX];Motor symptoms - legs PhenX;;TRIAL;2.36;2.65 +65709-8;Motor symptoms - arms;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Motor symptoms - arms [PhenX];Motor symptoms - arms PhenX;;TRIAL;2.36;2.65 +65710-6;Pin sensibility;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Pin sensibility [PhenX];Pin sensibility PhenX;;TRIAL;2.36;2.65 +65711-4;Vibration;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Vibration [PhenX];Vibration PhenX;;TRIAL;2.36;2.65 +65712-2;Strength - legs;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Strength - legs [PhenX];Strength - legs PhenX;;TRIAL;2.36;2.65 +65713-0;Strength - arms;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Strength - arms [PhenX];Strength - arms PhenX;;TRIAL;2.36;2.65 +6571-4;Venezuelan equine encephalitis virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Venezuelan equine encephalitis virus Ab [Units/volume] in Serum;VEEV Ab Ser-aCnc;;ACTIVE;1.0g;2.69 +65714-8;Ulnar compound muscle action potential - CMAP;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Ulnar compound muscle action potential - CMAP [PhenX];Ulnar CMAP PhenX;;TRIAL;2.36;2.65 +65715-5;Ulnar compound muscle action potential - CMAP - median;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Ulnar compound muscle action potential - CMAP - median [PhenX];Ulnar CMAP median PhenX;;TRIAL;2.36;2.65 +65716-3;Ulnar sensory nerve action potential - SNAP;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Ulnar sensory nerve action potential - SNAP [PhenX];Ulnar SNAP PhenX;;TRIAL;2.36;2.65 +65717-1;Ulnar sensory nerve action potential - SNAP - median;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Ulnar sensory nerve action potential - SNAP - median [PhenX];Ulnar SNAP median PhenX;;TRIAL;2.36;2.65 +65718-9;Have you ever been told by a physician that you had a stroke;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been told by a physician that you had a stroke [PhenX];Physician dx stroke PhenX;;TRIAL;2.36;2.65 +65719-7;When did the first stroke occur;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did the first stroke occur [Date and time] [PhenX];Date stroke occurred PhenX;;TRIAL;2.36;2.65 +65720-5;Have you ever had any sudden loss or changes in speech lasting 24 H or longer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any sudden loss or changes in speech lasting 24 hours or longer [PhenX];Sudden loss of speech PhenX;;TRIAL;2.36;2.65 +65721-3;Did the episode come on suddenly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did the episode come on suddenly [PhenX];Episode occur suddenly PhenX;;TRIAL;2.36;2.65 +6572-2;Venezuelan equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Serum by Immunoassay;VEEV Ag Ser Ql IA;;ACTIVE;1.0g;2.56 +65722-1;Do any of the following describe your change in speech;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do any of the following describe your change in speech [PhenX];Speech change PhenX;;TRIAL;2.36;2.65 +65723-9;Which of these most closely describes the problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Which of these most closely describes the problem [PhenX];Describe speech change PhenX;;TRIAL;2.36;2.65 +65724-7;Things occurring with episode of change in speech;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things occurring with episode of change in speech [PhenX];Things with change in speech PhenX;;TRIAL;2.36;2.65 +65725-4;While you were having your episode of change in speech, did any of these things occur;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While you were having your episode of change in speech, did any of these things occur [PhenX];Things with change speech occur PhenX;;TRIAL;2.36;2.65 +65726-2;Side affected;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Side affected [PhenX];Side affected PhenX;;TRIAL;2.36;2.65 +65727-0;Visual disturbance description;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Visual disturbance description [PhenX];Visual disturbance description PhenX;;TRIAL;2.36;2.65 +65728-8;Have you ever had any sudden loss of vision, or blurring, lasting 24 H or longer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any sudden loss of vision, or blurring, lasting 24 hours or longer [PhenX];Sudden vision loss blurring PhenX;;TRIAL;2.36;2.65 +65729-6;Things occurring with loss of vision;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things occurring with loss of vision [PhenX];Things with vision loss blurring PhenX;;TRIAL;2.36;2.65 +6573-0;Venezuelan equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Venezuelan equine encephalitis virus Ag [Presence] in Serum by Immunofluorescence;VEEV Ag Ser Ql IF;;ACTIVE;1.0g;2.56 +65730-4;While you were having your loss of vision, did any of these things occur;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While you were having your loss of vision, did any of these things occur [PhenX];Things vision loss occur PhenX;;TRIAL;2.36;2.65 +65731-2;Have you ever had a sudden spell of double vision, which lasted 24 H or longer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had a sudden spell of double vision, which lasted 24 hours or longer [PhenX];Double vision PhenX;;TRIAL;2.36;2.65 +65732-0;If you closed one eye, did the double vision go away;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If you closed one eye, did the double vision go away [PhenX];Double vision 1 eye PhenX;;TRIAL;2.36;2.65 +65733-8;Things occurring with double vision;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things occurring with double vision [PhenX];Things with double vision PhenX;;TRIAL;2.36;2.65 +65734-6;While you were having your double vision, did any of these things occur;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While you were having your double vision, did any of these things occur [PhenX];Things with double vision occur PhenX;;TRIAL;2.36;2.65 +65735-3;Have you ever had sudden numbness, tingling, or loss of feeling on one side of your body, including your face, arm, or leg which lasted 24H or longer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had sudden numbness, tingling, or loss of feeling on one side of your body, including your face, arm, or leg which lasted 24 hours or longer [PhenX];Sudden numbness tingling PhenX;;TRIAL;2.36;2.65 +65736-1;Feeling of numbness or tingling occur only when kept your arms or legs in a certain position;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Feeling of numbness or tingling occur only when kept your arms or legs in a certain position [PhenX];Numbness tingling certain position PhenX;;TRIAL;2.36;2.65 +65737-9;Body part;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Body part [PhenX];Body part PhenX;;TRIAL;2.36;2.65 +65738-7;Was this part of your body affected;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was this part of your body affected [PhenX];Body part affected PhenX;;TRIAL;2.36;2.65 +65739-5;During this episode, did the abnormal sensation start in one part of your body and spread to another, or did it stay in the same place;Find;Pt;^Patient;Nom;PhenX;PHENX;2;During this episode, did the abnormal sensation start in one part of your body and spread to another, or did it stay in the same place [PhenX];Sensation spread PhenX;;TRIAL;2.36;2.65 +65740-3;Things occurring with tingling and loss of sensation;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things occurring with tingling and loss of sensation [PhenX];Things with tingling PhenX;;TRIAL;2.36;2.65 +65741-1;While you were having numbness, tingling and loss of sensation, did any of these things occur;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While you were having numbness, tingling and loss of sensation, did any of these things occur [PhenX];Things with tingling occur PhenX;;TRIAL;2.36;2.65 +65742-9;Have you ever had any sudden episode of paralysis or weakness on one side of your body, including your face, arm, or leg which lasted at least 24 H;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had any sudden episode of paralysis or weakness on one side of your body, including your face, arm, or leg which lasted at least 24 hours [PhenX];Paralysis or weakness PhenX;;TRIAL;2.36;2.65 +65743-7;Things occurring with paralysis or weakness;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things occurring with paralysis or weakness [PhenX];Things with paralysis weakness PhenX;;TRIAL;2.36;2.65 +65744-5;While you were having paralysis or weakness did any of these things occur;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While you were having paralysis or weakness did any of these things occur [PhenX];Things paralysis weakness occur PhenX;;TRIAL;2.36;2.65 +65745-2;Have you had any sudden spells of dizziness, loss of balance, or sensation of spinning which lasted 24H or longer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had any sudden spells of dizziness, loss of balance, or sensation of spinning which lasted 24 hours or longer [PhenX];Sudden Dizzi Loss bal Spin PhenX;;TRIAL;2.36;2.65 +65746-0;Dizziness, loss of balance or spinning sensation occur only when changing the position of your head or body;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Dizziness, loss of balance or spinning sensation occur only when changing the position of your head or body [PhenX];Dizziness change position only PhenX;;TRIAL;2.36;2.65 +65747-8;Things occurring with dizziness, loss of balance or spinning sensation;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things occurring with dizziness, loss of balance or spinning sensation [PhenX];Things with dizziness loss balance PhenX;;TRIAL;2.36;2.65 +6574-8;Escherichia coli verotoxin 1;PrThr;Pt;Stool;Ord;;MICRO;1;Escherichia coli verotoxin 1 [Presence] in Stool;E coli VTN1 Stl Ql;;ACTIVE;1.0g;2.56 +65748-6;While you were having sudden spells of dizziness, loss of balance or spinning sensation, did any of these things occur;Find;Pt;^Patient;Ord;PhenX;PHENX;2;While you were having sudden spells of dizziness, loss of balance or spinning sensation, did any of these things occur [PhenX];Things dizziness balance occur PhenX;;TRIAL;2.36;2.65 +65749-4;Did you have trouble seeing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you have trouble seeing [PhenX];Trouble seeing PhenX;;TRIAL;2.36;2.65 +65750-2;Drugs of abuse 5 panel;-;Pt;Urine;-;Screen;PANEL.DRUG/TOX;1;Drugs of abuse 5 panel - Urine by Screen method;Drugs of Abuse 5 Pnl Ur Scn;;ACTIVE;2.36;2.42 +65751-0;Pathology biopsy report;Find;Pt;Muscle;Nar;;PATH;1;Muscle Pathology biopsy report;Muscle Path Bx report;;ACTIVE;2.36;2.73 +65752-8;Pathology biopsy report;Find;Pt;Liver;Nar;;PATH;1;Liver Pathology biopsy report;Liver Path Bx report;;ACTIVE;2.36;2.73 +65753-6;Pathology biopsy report;Find;Pt;Cervix;Nar;;PATH;1;Cervix Pathology biopsy report;Cervix Path Bx report;;ACTIVE;2.36;2.73 +65754-4;Pathology biopsy report;Find;Pt;Skin;Nar;;PATH;1;Skin Pathology biopsy report;Skin Path Bx report;;ACTIVE;2.36;2.73 +6575-5;Escherichia coli verotoxin 1 Ab.Neut;Titr;Pt;Stool;Qn;Neut;MICRO;1;Escherichia coli verotoxin 1 neutralizing antibody [Titer] in Stool by Neutralization test;E coli VTN1 NAb Titr Stl Nt;;ACTIVE;1.0g;2.72 +65755-1;Pathology biopsy report;Find;Pt;Rectum;Nar;;PATH;1;Rectum Pathology biopsy report;Rectum Path Bx report;;ACTIVE;2.36;2.36 +65756-9;Salmonella sp serovar;Type;Pt;Isolate;Nom;;MICRO;1;Salmonella sp serovar [Type] in Isolate;Salmonella serovar Islt;;ACTIVE;2.38;2.38 +65757-7;Pathology biopsy report;Find;Pt;Kidney;Nar;;PATH;1;Kidney Pathology biopsy report;Kidney Path Bx report;;ACTIVE;2.36;2.73 +65758-5;T-cell helper (CD4) subset panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;T-cell helper (CD4) subset panel - Blood;T-cell CD4 subset pnl Bld;;ACTIVE;2.36;2.73 +65759-3;T-cell subsets CD4 & CD8 panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;T-cell subsets CD4 and CD8 panel - Blood;T-cell subsets CD4+CD8 pnl Bld;;ACTIVE;2.36;2.73 +65761-9;Lymphocyte subset interpretation;Imp;Pt;Bld;Nom;Flow cytometry;CELLMARK;1;Lymphocyte subset interpretation in Blood by Flow cytometry (FC);Lymph subset interp Bld FC-Imp;;ACTIVE;2.36;2.73 +65762-7;Hantavirus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Hantavirus Ag [Presence] in Tissue by Immune stain;Hantavirus Ag Tiss Ql ImStn;;ACTIVE;2.36;2.68 +6576-3;Escherichia coli verotoxin 2;PrThr;Pt;Stool;Ord;;MICRO;1;Escherichia coli verotoxin 2 [Presence] in Stool;E coli VTN2 Stl Ql;;ACTIVE;1.0g;2.56 +65763-5;Neisseria meningitidis Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Neisseria meningitidis Ag [Presence] in Tissue by Immune stain;N men Ag Tiss Ql ImStn;;ACTIVE;2.36;2.68 +65764-3;Actinidia deliciosa native (nAct d) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kiwi native (nAct d) 5 IgE Ab [Units/volume] in Serum;Kiwi (nAct d) 5 IgE Qn;;ACTIVE;2.36;2.70 +65765-0;Corylus avellana native (nCor a) 9 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut native (nCor a) 9 IgE Ab [Units/volume] in Serum;Hazelnut (nCor a) 9 IgE Qn;;ACTIVE;2.36;2.73 +65766-8;Juglans regia native (nJug r) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English Walnut native (nJug r) 1 IgE Ab [Units/volume] in Serum;English Walnut (nJug r) 1 IgE Qn;;ACTIVE;2.36;2.70 +65767-6;Juglans regia native (nJug r) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English Walnut native (nJug r) 2 IgE Ab [Units/volume] in Serum;English Walnut (nJug r) 2 IgE Qn;;ACTIVE;2.36;2.70 +65768-4;Juglans regia native (nJug r) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English Walnut native (nJug r) 3 IgE Ab [Units/volume] in Serum;English Walnut (nJug r) 3 IgE Qn;;ACTIVE;2.36;2.70 +65769-2;Arachis hypogaea native (nAra h) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut native (nAra h) 1 IgE Ab [Units/volume] in Serum;Peanut (nAra h) 1 IgE Qn;;ACTIVE;2.36;2.73 +657-7;Microscopic observation;Prid;Pt;XXX;Nom;Acridine orange stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Acridine orange stain;AO Stn Spec;;ACTIVE;1.0;2.73 +65770-0;Arachis hypogaea native (nAra h) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut native (nAra h) 2 IgE Ab [Units/volume] in Serum;Peanut (nAra h) 2 IgE Qn;;ACTIVE;2.36;2.73 +6577-1;Escherichia coli verotoxin 2 Ab.Neut;Titr;Pt;Stool;Qn;Neut;MICRO;1;Escherichia coli verotoxin 2 neutralizing antibody [Titer] in Stool by Neutralization test;E coli VTN2 NAb Titr Stl Nt;;ACTIVE;1.0g;2.72 +65771-8;Arachis hypogaea native (nAra h) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut native (nAra h) 3 IgE Ab [Units/volume] in Serum;Peanut (nAra h) 3 IgE Qn;;ACTIVE;2.36;2.73 +65772-6;Glycine max native (nGly m) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Soybean native (nGly m) 6 IgE Ab [Units/volume] in Serum;Soybean (nGly m) 6 IgE Qn;;ACTIVE;2.36;2.70 +65773-4;Fagopyrum esculentum native (nFag e) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Buckwheat native (nFag e) 2 IgE Ab [Units/volume] in Serum;Buckwheat (nFag e) 2 IgE Qn;;ACTIVE;2.36;2.70 +65774-2;Triticum aestivum native (nTri a) aA_TI Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat native (nTri a) aA/TI IgE Ab [Units/volume] in Serum;Wheat (nTri a) aA/TI IgE Qn;;ACTIVE;2.36;2.70 +65775-9;Cynodon dactylon native (nCyn d) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass native (nCyn d) 1 IgE Ab [Units/volume] in Serum;Bermuda grass (nCyn d) 1 IgE Qn;;ACTIVE;2.36;2.70 +65776-7;Betula verrucosa native (nBet v) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver birch native (nBet v) 1 IgE Ab [Units/volume] in Serum;Silver birch (nBet v) 1 IgE Qn;;ACTIVE;2.36;2.70 +65777-5;Cryptomeria japonica native (nCry j) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Japanese Cedar native (nCry j) 1 IgE Ab [Units/volume] in Serum;Japanese Cedar (nCry j) 1 IgE Qn;;ACTIVE;2.36;2.70 +65778-3;Cupressus arizonica native (nCup a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Arizona Cypress native (nCup a) 1 IgE Ab [Units/volume] in Serum;Arizona Cypress (nCup a) 1 IgE Qn;;ACTIVE;2.36;2.70 +65779-1;Olea europaea native (nOle e) 7 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive pollen native (nOle e) 7 IgE Ab [Units/volume] in Serum;Olive (nOle e) 7 IgE Qn;;ACTIVE;2.36;2.70 +65780-9;Olea europaea recombinant (rOle e) 9 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive pollen recombinant (rOle e) 9 IgE Ab [Units/volume] in Serum;Olive (rOle e) 9 IgE Qn;;ACTIVE;2.36;2.70 +65781-7;Platanus acerifolia native (nPla a) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;London Plane native (nPla a) 2 IgE Ab [Units/volume] in Serum;London Plane (nPla a) 2 IgE Qn;;ACTIVE;2.36;2.70 +65782-5;Ambrosia artemisiifolia native (nAmb a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common ragweed native (nAmb a) 1 IgE Ab [Units/volume] in Serum;Common ragweed (nAmb a) 1 IgE Qn;;ACTIVE;2.36;2.70 +65783-3;Artemisia vulgaris native (nArt v) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mugwort native (nArt v) 3 IgE Ab [Units/volume] in Serum;Mugwort (nArt v) 3 IgE Qn;;ACTIVE;2.36;2.70 +65784-1;Salsola kali native (nSal k) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saltwort native (nSal k) 1 IgE Ab [Units/volume] in Serum;Saltwort (nSal k) 1 IgE Qn;;ACTIVE;2.36;2.70 +65785-8;Chicken CSA (livetin) serum albumin native (nGal d) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicken CSA serum albumin native (nGal d) 5 IgE Ab [Units/volume] in Serum;Chicken CSA (nGal d) 5 IgE Qn;;ACTIVE;2.36;2.70 +65786-6;Penaeus monodon native (nPen m) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp native (nPen m) 2 IgE Ab [Units/volume] in Serum;Shrimp (nPen m) 2 IgE Qn;;ACTIVE;2.36;2.70 +65787-4;Penaeus monodon native (nPen m) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp native (nPen m) 4 IgE Ab [Units/volume] in Serum;Shrimp (nPen m) 4 IgE Qn;;ACTIVE;2.36;2.70 +65788-2;Horse serum albumin native (nEqu c) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse serum albumin native (nEqu c) 3 IgE Ab [Units/volume] in Serum;Horse serum albumin (nEqu c) 3 IgE Qn;;ACTIVE;2.36;2.70 +6578-9;Vibrio sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Vibrio sp identified in Blood by Organism specific culture;Vibrio Bld Cult;;ACTIVE;1.0g;1.0ma +65789-0;Mouse lipocain native (nMus m) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse lipocain native (nMus m) 1 IgE Ab [Units/volume] in Serum;Mouse lipocain (nMus m) 1 IgE Qn;;ACTIVE;2.36;2.70 +65790-8;Dermatophagoides farinae native (nDer f) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite native (nDer f) 1 IgE Ab [Units/volume] in Serum;D farinae (nDer f) 1 IgE Qn;;ACTIVE;2.36;2.70 +65791-6;Apis mellifera native (nApi m) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee native (nApi m) 4 IgE Ab [Units/volume] in Serum;Honey bee (nApi m) 4 IgE Qn;;ACTIVE;2.36;2.70 +65792-4;Armoracia rusticana native (nArm r) HRP Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horseradish native (nArm r) HRP IgE Ab [Units/volume] in Serum;Horseradish (nArm r) HRP IgE Qn;;ACTIVE;2.36;2.70 +65793-2;Blatella germanica native (nBla g) 7 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach native (nBla g) 7 IgE Ab [Units/volume] in Serum;Cockroach (nBla g) 7 IgE Qn;;ACTIVE;2.36;2.73 +65794-0;Penaeus monodon native (nPen m) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp native (nPen m) 1 IgE Ab [Units/volume] in Serum;Shrimp (nPen m) 1 IgE Qn;;ACTIVE;2.36;2.70 +65795-7;Actinidia deliciosa native (nAct d) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kiwi native (nAct d) 1 IgE Ab [Units/volume] in Serum;Kiwi (nAct d) 1 IgE Qn;;ACTIVE;2.36;2.73 +65796-5;Actinidia deliciosa native (nAct d) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kiwi native (nAct d) 2 IgE Ab [Units/volume] in Serum;Kiwi (nAct d) 2 IgE Qn;;ACTIVE;2.36;2.70 +6579-7;Vibrio sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Vibrio sp identified in Stool by Organism specific culture;Vibrio Stl Cult;;ACTIVE;1.0g;2.73 +65797-3;Guidance for placement of stent;Find;Pt;XXX>Artery.left;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Artery - left;RFA Guided Artery-L Stent place;;ACTIVE;2.36;2.64 +65798-1;Guidance for placement of stent;Find;Pt;XXX>Artery.right;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Artery - right;RFA Guided Artery.-R Stent place;;ACTIVE;2.36;2.64 +65799-9;View for cyst;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Kidney - bilateral Single view for cyst;RF Kdny-Bl 1V for cyst;;ACTIVE;2.36;2.64 +65800-5;View for cyst;Find;Pt;Abdomen>Kidney.left;Doc;RF;RAD;2;RF Kidney - left Single view for cyst;RF Kidney-L 1V for cyst;;ACTIVE;2.36;2.64 +65801-3;View for cyst;Find;Pt;Abdomen>Kidney.right;Doc;RF;RAD;2;RF Kidney - right Single view for cyst;RF Kidney-R 1V for cyst;;ACTIVE;2.36;2.64 +65802-1;Views^W contrast IV;Find;Pt;Sagittal sinus vein.left+Jugular vein.left;Doc;XR.fluor.angio;RAD;2;Deprecated Sagittal sinus and Jugular veins - left Fluoroscopic angiogram W contrast IV;Deprecated SS v+Jugular v-L XRA W contr;;DEPRECATED;2.36;2.58 +65803-9;Views^W contrast IV;Find;Pt;Sagittal sinus vein.left;Doc;XR.fluor.angio;RAD;2;Deprecated Sagittal sinus vein - left Fluoroscopic angiogram W contrast IV;Deprecated SS v-L XRA W contr IV;;DEPRECATED;2.36;2.58 +65804-7;Views^W contrast IV;Find;Pt;Sagittal sinus vein.right;Doc;XR.fluor.angio;RAD;2;Deprecated Sagittal sinus vein - right Fluoroscopic angiogram W contrast IV;Deprecated SS v-R XRA W contr IV;;DEPRECATED;2.36;2.58 +6580-5;Vibrio sp identified;Prid;Pt;Water;Nom;Organism specific culture;MICRO;1;Vibrio sp identified in Water by Organism specific culture;Vibrio Wat Cult;;ACTIVE;1.0g;2.19 +65805-4;Views^W contrast IV;Find;Pt;Sagittal sinus vein.right+Jugular vein.right;Doc;XR.fluor.angio;RAD;2;Deprecated Sagittal sinus and Jugular veins - right Fluoroscopic angiogram W contrast IV;Deprecated SS v+Jugular v-R XRA W contr;;DEPRECATED;2.36;2.58 +65806-2;Inhalation challenge test report^W methacholine inhaled;Find;Pt;^Patient;Doc;;PULM;2;Inhalation challenge test report Document --W methacholine inhaled;Inhal chal W MECH IH Doc;;ACTIVE;2.36;2.38 +6580-7;Treponema identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Deprecated Treponema identified;Deprecated Treponema XXX Cult;;DEPRECATED;1.0g;2.69 +65807-0;Tapentadol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tapentadol [Mass/volume] in Urine;Tapentadol Ur-mCnc;;ACTIVE;2.36;2.73 +65808-8;Nortapentadol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nortapentadol [Mass/volume] in Urine;Nortapentadol Ur-mCnc;;ACTIVE;2.36;2.73 +65809-6;Kingella kingae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Kingella kingae DNA [Presence] in Specimen by NAA with probe detection;K kingae DNA Spec Ql NAA+probe;;ACTIVE;2.36;2.73 +65810-4;SEPT9 gene methylation;PrThr;Pt;Plas;Ord;Molgen;MOLPATH;1;SEPT9 gene methylation [Presence] in Plasma by Molecular genetics method;SEPT9 gene methylation Plas Ql;;ACTIVE;2.36;2.73 +65811-2;Body bradykinesia - hypokinesia;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Body bradykinesia - hypokinesia [UPDRS];Body bradykinesia - hypokinesia UPDRS;;ACTIVE;2.36;2.71 +65812-0;During the episode, which of the following parts of your vision were affected;Find;Pt;^Patient;Nom;PhenX;PHENX;2;During the episode, which of the following parts of your vision were affected [PhenX];Parts of vision affected PhenX;;TRIAL;2.36;2.65 +6581-3;Vibrio sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Vibrio sp identified in Specimen by Organism specific culture;Vibrio Spec Cult;;ACTIVE;1.0g;2.73 +65814-6;How many girls did you have;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many girls did you have [#] [PhenX];Girls number PhenX;;TRIAL;2.36;2.65 +65815-3;How many boys did you have;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many boys did you have [#] [PhenX];Boys number PhenX;;TRIAL;2.36;2.65 +65816-1;When you were living in your city or town, did your exposure to direct sunlight in April through September stay pretty much the same for all your daytime activities between the hours of 10 AM and 4 PM.;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you were living in your city or town, did your exposure to direct sunlight in April through September stay pretty much the same for all your daytime activities between the hours of 10 AM and 4 PM. [PhenX];Day activity sun exposure PhenX;;TRIAL;2.36;2.65 +65817-9;Reference values correction factor;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Reference values correction factor PhenX;Ref values correction factor PhenX;;TRIAL;2.36;2.73 +65818-7;Medication XXX;MCnc;Pt;Dose;Qn;;DRUGDOSE;1;Medication [Mass/volume] Dose;Medication Dose-mCnc;;ACTIVE;2.36;2.73 +65819-5;Forced expiratory time;Time;Pt;^Patient;Qn;;PULM;2;Forced expiratory time;Forced expiratory time;;ACTIVE;2.36;2.73 +65820-3;Time to expiratory gas flow.max;Time;Pt;^Patient;Qn;;PULM;2;Time to expiratory gas flow.max;Time to PEF;;TRIAL;2.36;2.65 +6582-1;Microscopic observation;Find;Pt;XXX;Nom;Tzanck smear;MICRO;1;Deprecated Microscopic observation [Identifier] in Unspecified specimen by Tzanck smear;Deprecated Vir Incl Bod XXX Tzanck Smear;;DEPRECATED;1.0g;2.69 +65821-1;Gas flow at 25% of forced expiration;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Gas flow FEV 25%;Gas flow FEV 25%;;TRIAL;2.36;2.65 +65822-9;Gas flow at 50% of forced expiration;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Gas flow FEV 50%;Gas flow FEV 50%;;TRIAL;2.36;2.65 +65823-7;Gas flow at 75% of forced expiration;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Gas flow FEV 75%;Gas flow FEV 75%;;TRIAL;2.36;2.65 +65824-5;Gas flow at 90% of forced expiration;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Gas flow FEV 90%;Gas flow FEV 90%;;TRIAL;2.36;2.65 +65825-2;How much have your late bedtime and inability to adjust your schedule upset or distressed you;Num;Pt;^Patient;Ord;PhenX;PHENX;2;How much have your late bedtime and inability to adjust your schedule upset or distressed you [PhenX];Distressed scale PhenX;;TRIAL;2.36;2.65 +65826-0;What number describes how much this eveningness tendency has affected your social life or relationships with your friends;Num;Pt;^Patient;Ord;PhenX;PHENX;2;What number describes how much this eveningness tendency has affected your social life or relationships with your friends [PhenX];Social distress scale PhenX;;TRIAL;2.36;2.65 +65827-8;What number describes how much this eveningness tendency has affected your relationships with family members;Num;Pt;^Patient;Ord;PhenX;PHENX;2;What number describes how much this eveningness tendency has affected your relationships with family members [PhenX];Relationship distress scale PhenX;;TRIAL;2.36;2.65 +65828-6;What number describes how much this eveningness tendency has affected your performance in school or work or your relationships with your co-workers, employers, teachers or classmates;Num;Pt;^Patient;Ord;PhenX;PHENX;2;What number describes how much this eveningness tendency has affected your performance in school or work or your relationships with your co-workers, employers, teachers or classmates [PhenX];Work distress scale PhenX;;TRIAL;2.36;2.65 +65829-4;Were you knocked out or did you lose consciousness;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Were you knocked out or did you lose consciousness [PhenX];LOC PhenX;;TRIAL;2.36;2.65 +65830-2;How long were you knocked out - lost consciousness;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long were you knocked out - lost consciousness [PhenX];LOC time PhenX;;TRIAL;2.36;2.65 +65831-0;How long ago did you have the most recent attack;Time;Pt;^Patient;Qn;CIDI-SF;PHENX;2;How long ago did you have the most recent attack [CIDI-SF];Panic most recent attack CIDI-SF;;ACTIVE;2.36;2.65 +65832-8;Did some of your attacks happen in a situation when you were not in danger or not the center of attention;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did some of your attacks happen in a situation when you were not in danger or not the center of attention [CIDI-SF];Panic not center of attention CIDI-SF;;ACTIVE;2.36;2.65 +65833-6;Address;Addr;Pt;Facility;Nom;;SURVEY.ESRD;4;Facility Address;;;ACTIVE;2.36;2.64 +65834-4;Facility ownership;Type;Pt;Facility;Nom;;SURVEY.ESRD;4;Facility ownership;;;ACTIVE;2.36;2.36 +65835-1;Facility affiliation information;Find;Pt;Facility;Nar;;SURVEY.ESRD;4;Facility affiliation information;;;ACTIVE;2.36;2.36 +65836-9;Dialysis services offered;Type;Pt;Facility;Nom;;SURVEY.ESRD;4;Dialysis services offered Facility;;;ACTIVE;2.36;2.36 +65837-7;Facility offers dialysis shift starting at 5:00 pm;Arb;Pt;Facility;Ord;;SURVEY.ESRD;4;Facility offers dialysis shift starting at 5:00 pm;;;ACTIVE;2.36;2.36 +65838-5;Date submitted;Date;Pt;Form;Qn;;SURVEY.ESRD;4;Date submitted;;;ACTIVE;2.36;2.50 +6583-9;Virus identified;Prid;Pt;Semen;Nom;Culture;MICRO;1;Virus identified in Semen by Culture;Virus Smn Cult;;ACTIVE;1.0g;2.19 +65839-3;Principal result interpreter title;Type;Pt;Study;Nom;;SURVEY.ESRD;4;Principal result interpreter title Study;;;ACTIVE;2.36;2.70 +65840-1;Principal result interpreter phone number;Tele;Pt;Form;Nom;;SURVEY.ESRD;4;Principal result interpreter phone number;;;ACTIVE;2.36;2.70 +65841-9;Form status;Type;Pt;Form;Nom;;SURVEY.ESRD;4;Form status;;;ACTIVE;2.36;2.36 +65842-7;Acceptance status;Type;Pt;Form;Nom;;SURVEY.ESRD;4;Acceptance status;;;ACTIVE;2.36;2.48 +65843-5;Responsible observer;ID;Pt;XXX;Nom;;SURVEY.ESRD;4;Responsible observer;;;ACTIVE;2.36;2.36 +65844-3;Date of observation;Date;Pt;XXX;Qn;;MISC;1;Date of observation (non-patient);Observation date Spec;;ACTIVE;2.36;2.73 +65845-0;Is the psychological, psychiatric, emotional, or behavioral problem still present;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is the psychological, psychiatric, emotional, or behavioral problem still present [PhenX];Child psych behavior still present PhenX;;TRIAL;2.36;2.65 +65846-8;Relative with sleep or behavior disorders diagnosed or suspected;Find;Pt;^Family member;Nom;PhenX;PHENX;2;Relative with sleep or behavior disorders diagnosed or suspected Family member [PhenX];Behavior disorders relatives Family;;TRIAL;2.36;2.65 +6584-7;Virus identified;Prid;Pt;XXX;Nom;Culture;MICRO;1;Virus identified in Specimen by Culture;Virus Spec Cult;;ACTIVE;1.0g;2.73 +65847-6;Sleep or behavior disorders diagnosed or suspected in your child's brothers, sisters, or parents;Find;Pt;^Family member;Nom;PhenX;PHENX;2;Please list any sleep or behavior disorders diagnosed or suspected in your child's brothers, sisters, or parents Condition Family member [PhenX];Behavior disorders conditions Family;;TRIAL;2.36;2.65 +65849-2;This child often does not seem to listen when spoken to directly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;This child often does not seem to listen when spoken to directly [PhenX];Child not seem listen PhenX;;TRIAL;2.36;2.65 +658-5;Microscopic observation;Prid;Pt;XXX;Nom;Calcofluor white preparation;MICRO;1;Microscopic observation [Identifier] in Specimen by Calcofluor white;Calcofluor white Spec;;ACTIVE;1.0;2.73 +65850-0;Hard coronary heart disease 10Y risk;Num;Pt;^Patient;Qn;Framingham.The Adult Treatment Panel III 2001;CARD.RISK;2;Hard coronary heart disease 10Y risk [#] Framingham.The Adult Treatment Panel III 2001;Hard CHD10Y risk;;ACTIVE;2.36;2.42 +65851-8;Coronary heart disease 10Y risk;Num;Pt;^Patient;Qn;Framingham.Wilson 1998;CARD.RISK;2;Coronary heart disease 10Y risk [#] Framingham.Wilson 1998;CHD 10Y risk;;ACTIVE;2.36;2.42 +65852-6;Coronary heart disease 2Y risk;Num;Pt;^Patient;Qn;Framingham.D'Agostino 2000;CARD.RISK;2;Coronary heart disease 2Y risk [#] Framingham.D'Agostino 2000;CHD 2Y risk;;ACTIVE;2.36;2.42 +65853-4;General cardiovascular disease 10Y risk;Num;Pt;^Patient;Qn;Framingham.D'Agostino;CARD.RISK;2;General cardiovascular disease 10Y risk [#] Framingham.D'Agostino;General CVD 10Y risk;;ACTIVE;2.36;2.44 +6585-4;Western equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Western equine encephalitis virus Ag [Presence] in Serum by Immunoassay;WEEV Ag Ser Ql IA;;ACTIVE;1.0g;2.56 +65854-2;Intermittent claudication 4Y risk;Num;Pt;^Patient;Qn;Framingham.Murabito 1997;CARD.RISK;2;Intermittent claudication 4Y risk [#] Framingham.Murabito 1997;IC 4Y risk;;ACTIVE;2.36;2.42 +65855-9;Stroke 10Y risk;Num;Pt;^Patient;Qn;Framingham.D'Agostino 1994;CARD.RISK;2;Stroke 10Y risk [#] Framingham.D'Agostino 1994;Stroke 10Y risk;;ACTIVE;2.36;2.42 +65856-7;Atrial fibrillation 10Y risk;Num;Pt;^Patient;Qn;Framingham.Schnabel 2009;CARD.RISK;2;Atrial fibrillation 10Y risk [#] Framingham.Schnabel 2009;Afib 10Y risk;;ACTIVE;2.36;2.42 +65857-5;Coronary heart disease 10Y risk;Num;Pt;^Patient;Qn;Reynolds.Ridker 2007;CARD.RISK;2;Coronary heart disease 10Y risk [#] Reynolds.Ridker 2007;CHD 10Y risk Reynolds.Ridker 2007;;ACTIVE;2.36;2.73 +65858-3;Coronary event 10Y risk;Num;Pt;^Patient;Qn;PROCAM.QuickCheck.Cullen 1997;CARD.RISK;2;Coronary event 10Y risk [#] PROCAM.QuickCheck.Cullen 1997;CE10Y rsk PROCAM.QuickCheck.Cullen97;;ACTIVE;2.36;2.42 +65859-1;Coronary event 10Y risk;Num;Pt;^Patient;Qn;PROCAM.HealthCheck.Cullen 1997;CARD.RISK;2;Coronary event 10Y risk [#] PROCAM.HealthCheck.Cullen 1997;CE10Y rsk PROCAM.HealthCheck.Cullen97;;ACTIVE;2.36;2.42 +65860-9;Cardiovascular disease 10Y risk;Num;Pt;^Patient;Qn;SCORE.PC.Conroy 2003;CARD.RISK;2;Cardiovascular disease 10Y risk [#] SCORE.PC.Conroy 2003;CVD 10Y risk SCORE.PC.Conroy 2003;;ACTIVE;2.36;2.48 +65861-7;Cardiovascular disease 10Y risk;Num;Pt;^Patient;Qn;SCORE.Quick.Conroy 2003;CARD.RISK;2;Cardiovascular disease 10Y risk [#] SCORE.Quick.Conroy 2003;CVD 10Y risk SCORE.Quick.Conroy 2003;;ACTIVE;2.36;2.42 +6586-2;Western equine encephalitis virus Ag;PrThr;Pt;Ser;Ord;IF;MICRO;1;Western equine encephalitis virus Ag [Presence] in Serum by Immunofluorescence;WEEV Ag Ser Ql IF;;ACTIVE;1.0g;2.56 +65862-5;Recurring coronary heart disease 2Y risk;Num;Pt;^Patient;Qn;Framingham.D'Agostino 2000;CARD.RISK;2;Recurring coronary heart disease 2Y risk [#] Framingham.D'Agostino 2000;Recurring CHD 2Y risk;;ACTIVE;2.36;2.42 +65863-3;Heart failure 4Y risk;Num;Pt;^Patient;Qn;Framingham.Kannel 1999;CARD.RISK;2;Heart failure 4Y risk [#] Framingham.Kannel 1999;HF 4Y risk;;ACTIVE;2.36;2.42 +65864-1;Stroke after atrial fibrillation 5Y risk;Num;Pt;^Patient;Qn;Framingham.Wang 2003;CARD.RISK;2;Stroke after atrial fibrillation 5 year risk [#] Framingham.Wang 2003;Stroke post Afib 5Y risk;;ACTIVE;2.36;2.66 +65865-8;Stroke or death after atrial fibrillation 5Y risk;Num;Pt;^Patient;Qn;Framingham.Wang 2003;CARD.RISK;2;Stroke or death after atrial fibrillation 5 year risk [#] Framingham.Wang 2003;Stroke death post Afib 5Y risk;;ACTIVE;2.36;2.66 +65866-6;Methacholine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Methacholine [Mass] of Dose;Methacholine Dose;;ACTIVE;2.36;2.69 +65867-4;How many different times have you used emergency contraception;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many different times have you used emergency contraception [PhenX];Emerg contraception times PhenX;;TRIAL;2.36;2.65 +65868-2;Your testicles started increasing in size Compared to your friends was this;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your testicles started increasing in size Compared to your friends was this [PhenX];Testicle size peer compare PhenX;;TRIAL;2.36;2.65 +65869-0;Pregnancy complication;Find;Pt;^Patient;Nom;;H&P.HX;2;Pregnancy complication;Preg complication;;ACTIVE;2.36;2.66 +6587-0;Yellow fever virus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Yellow fever virus Ab [Titer] in Serum by Complement fixation;YFV Ab Titr Ser CF;;DISCOURAGED;1.0g;2.70 +65870-8;During that pregnancy, did you ever develop any of these things;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During that pregnancy, did you ever develop any of these things [PhenX];Things during pregnancy ever PhenX;;TRIAL;2.36;2.65 +65871-6;Has a doctor ever told you that your child needs to wear glasses or contact lenses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that your child needs to wear glasses or contact lenses [PhenX];Child need glasses contacts PhenX;;TRIAL;2.36;2.65 +65873-2;Has a doctor ever told you that your child had amblyopia, that is, poor vision that cannot be corrected with glasses or contact lenses;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that your child had amblyopia, that is, poor vision that cannot be corrected with glasses or contact lenses [PhenX];Child amblyopia PhenX;;TRIAL;2.36;2.65 +65874-0;Did he or she ever have to wear an eye patch to improve his or her vision;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did he or she ever have to wear an eye patch to improve his or her vision [PhenX];Child eye patch ever PhenX;;TRIAL;2.36;2.65 +65875-7;Vendor device model code;ID;Pt;Intraocular pressure device;Nom;PhenX;DEVICES;2;Intraocular pressure device Vendor model code PhenX;IOP device Model Cd PhenX;;TRIAL;2.36;2.65 +65876-5;Statistical reliability level measured;Num;Pt;Measurement;Qn;PhenX;EYE.TONOMETRY;2;Statistical reliability level measured PhenX;Statistical reliability level PhenX;;TRIAL;2.36;2.68 +65877-3;Did your main daytime activities during a typical work W have you on water for a total of three or more H a D, for example working on a boat;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did your main daytime activities during a typical work week have you on water for a total of three or more hours a day, for example working on a boat [PhenX];Work day over water >3H PhenX;;TRIAL;2.36;2.65 +65878-1;Do or did any of his or her other relatives have this eye problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do or did any of his or her other relatives have this eye problem [PhenX];His her other relatives eye prob PhenX;;TRIAL;2.36;2.65 +65879-9;Condition causing difficulty with breathing;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Condition causing difficulty with breathing [PhenX];Condition difficulty breathing PhenX;;TRIAL;2.36;2.65 +65880-7;What happened if child stopped growing at a normal rate at any time since birth;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What happened if child stopped growing at a normal rate at any time since birth [PhenX];Child stop grow normal rate spec PhenX;;TRIAL;2.36;2.65 +65881-5;In the past 12Mo, how many times have you seen an eye doctor for your glaucoma;NRat;12Mo;^Patient;Qn;PhenX;PHENX;2;In the past 12 months, how many times have you seen an eye doctor for your glaucoma [PhenX];Dr. glaucoma past 12Mo nRate PhenX;;TRIAL;2.36;2.65 +65882-3;Vendor model number;ID;Pt;Refractive error device;Nom;;DEVICES;2;Refractive error device Vendor model number;Refractive error device Model #;;TRIAL;2.36;2.65 +65883-1;Vendor model number;ID;Pt;Retinal digital photog device;Nom;;DEVICES;2;Retinal digital photog device Vendor model number;Retinal digi photog model Model #;;TRIAL;2.36;2.65 +65884-9;Photographer ID;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Photographer ID;Photographer ID;;TRIAL;2.36;2.66 +65885-6;I get scared in small, closed places;Find;Pt;^Patient;Ord;SCARED-R;PHENX;2;I get scared in small, closed places [SCARED-R];Anxiety small closed place SCARED-R;;ACTIVE;2.36;2.65 +65886-4;Have you ever had a period lasting one Mo or longer when most of the time you felt worried, tense, or anxious;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Have you ever had a period lasting one month or longer when most of the time you felt worried, tense, or anxious [CIDI-SF];GAD worried >1Mo CIDI-SF;;ACTIVE;2.36;2.65 +65887-2;Did you ever have a time when you worried a lot more than most people would in your situation;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Did you ever have a time when you worried a lot more than most people would in your situation [CIDI-SF];GAD worried more than others CIDI-SF;;ACTIVE;2.36;2.65 +6588-8;Yellow fever virus Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Yellow fever virus Ab [Units/volume] in Serum by Hemagglutination inhibition;YFV Ab Ser HAI-aCnc;;DISCOURAGED;1.0g;2.69 +65888-0;Things accompanying a panic attack;Find;Pt;^Patient;Nom;CIDI-SF;PHENX;2;Things accompanying a panic attack [CIDI-SF];Things with panic attack CIDI-SF;;ACTIVE;2.36;2.65 +65889-8;When you have panic attacks do you experience this thing;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;When you have panic attacks do you experience this thing [CIDI-SF];Panic attack things CIDI-SF;;ACTIVE;2.36;2.65 +65890-6;Spherical power;InvLen;Pt;Eye.right;Qn;;PHENX;2;Spherical power [Inverse Length] Right eye;Spherical power InvLen R eye;;TRIAL;2.36;2.70 +65891-4;Cylinder axis;Angle;Pt;Eye.right;Qn;;PHENX;2;Cylinder axis Right eye;Cylinder axis R eye;;TRIAL;2.36;2.68 +65892-2;Cylindrical power;InvLen;Pt;Eye.right;Qn;;PHENX;2;Cylindrical power [Inverse Length] Right eye;Cylindrical power InvLen R eye;;TRIAL;2.36;2.70 +65893-0;Visual acuity^best corrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION;2;Visual acuity best corrected Right eye;R eye VA--corr;;ACTIVE;2.36;2.73 +65894-8;Spherical power;InvLen;Pt;Eye.left;Qn;;PHENX;2;Spherical power [Inverse Length] Left eye;Spherical power InvLen L eye;;TRIAL;2.36;2.70 +65895-5;Cylinder axis;Angle;Pt;Eye.left;Qn;;PHENX;2;Cylinder axis Left eye;Cylinder axis L eye;;TRIAL;2.36;2.68 +6589-6;Yellow fever virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Yellow fever virus Ab [Titer] in Serum by Immunofluorescence;YFV Ab Titr Ser IF;;ACTIVE;1.0g;2.70 +65896-3;Cylindrical power;InvLen;Pt;Eye.left;Qn;;PHENX;2;Cylindrical power [Inverse Length] Left eye;Cylindrical power InvLen L eye;;TRIAL;2.36;2.70 +65897-1;Visual acuity^best corrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION;2;Visual acuity best corrected Left eye;L eye VA--corr;;ACTIVE;2.36;2.73 +65898-9;Eye fields photographed in the retinal digital photography;Find;Pt;Eye.right;Nom;Retinal digital photography;PHENX;2;Eye fields photographed in the retinal digital photography Right eye [Retinal digital photography];Eye fields photo R eye Ret dig photog;;TRIAL;2.36;2.68 +65899-7;Other eye field;Find;Pt;Eye.right;Nom;Retinal digital photography;PHENX;2;Other eye field Right eye [Retinal digital photography];Oth eye field R eye Ret dig photog;;TRIAL;2.36;2.68 +65900-3;Flash setting in the retinal digital photography;Find;Pt;Retinal digital photog device;Nom;Retinal digital photography;DEVICES;2;Retinal digital photog device Flash setting in the retinal digital photography Retinal digital photography;Retinal digital photog flash setting;;TRIAL;2.36;2.65 +65901-1;Images captured in the retinal digital photography;Num;Pt;Retinal digital photog device;Qn;Retinal digital photography;DEVICES;2;Number Images captured in the retinal digital photography;# Images retinal photo;;TRIAL;2.36;2.65 +65902-9;Estimated diameter of pupil;Len;Pt;Eye.right;Qn;Retinal digital photography;PHENX;2;Estimated diameter of pupil Right eye [Retinal digital photography];Diam pupil est R eye Ret dig photog;;TRIAL;2.36;2.68 +65903-7;Problems or unusual findings;Find;Pt;Eye.right;Nom;;PHENX;2;Problems or unusual findings Right eye;Problems unusual findings R eye;;TRIAL;2.36;2.68 +6590-4;Yellow fever virus Ab;Titr;Pt;Ser;Qn;LA;MICRO;1;Yellow fever virus Ab [Titer] in Serum by Latex agglutination;YFV Ab Titr Ser LA;;DISCOURAGED;1.0g;2.70 +65904-5;Eye fields photographed in the retinal digital photography;Find;Pt;Eye.left;Nom;Retinal digital photography;PHENX;2;Eye fields photographed in the retinal digital photography Left eye [Retinal digital photography];Eye fields photo L eye Ret dig photog;;TRIAL;2.36;2.68 +65905-2;Other eye field;Find;Pt;Eye.left;Nom;Retinal digital photography;PHENX;2;Other eye field Left eye [Retinal digital photography];Oth eye field L eye Ret dig photog;;TRIAL;2.36;2.68 +65906-0;Estimated diameter of pupil;Len;Pt;Eye.left;Qn;Retinal digital photography;PHENX;2;Estimated diameter of pupil Left eye [Retinal digital photography];Diam pupil est L eye Ret dig photog;;TRIAL;2.36;2.68 +65907-8;Problems or unusual findings;Find;Pt;Eye.left;Nom;;PHENX;2;Problems or unusual findings Left eye;Problems unusual findings L eye;;TRIAL;2.36;2.68 +65908-6;Other things occurring while worried or anxious;Find;Pt;^Patient;Nom;CIDI-SF;PHENX;2;Other things occurring while worried or anxious [CIDI-SF];Things while worried anxious CIDI-SF;;ACTIVE;2.36;2.65 +65909-4;When you were worried or anxious did this thing also occur;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;When you were worried or anxious did this thing also occur [CIDI-SF];Worried anxious things ever CIDI-SF;;ACTIVE;2.36;2.65 +65910-2;Specific things you have an unreasonable fear about or avoid;Find;Pt;^Patient;Nom;CIDI-SF;PHENX;2;Specific things you have an unreasonable fear about or avoid [CIDI-SF];Specific phobias CIDI-SF;;ACTIVE;2.36;2.65 +65911-0;Do you have an unreasonably strong fear or avoid this specific thing;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Do you have an unreasonably strong fear or avoid this specific thing [CIDI-SF];Specific phobias ever CIDI-SF;;ACTIVE;2.36;2.65 +6591-2;Yellow fever virus Ab.Neut;ACnc;Pt;Ser;Qn;Neut;MICRO;1;Yellow fever virus neutralizing antibody [Units/volume] in Serum by Neutralization test;YFV NAb Ser Nt-aCnc;;ACTIVE;1.0g;2.72 +65912-8;Agoraphobias;Find;Pt;^Patient;Nom;CIDI-SF;PHENX;2;Agoraphobias [CIDI-SF];Agoraphobias CIDI-SF;;ACTIVE;2.36;2.65 +65913-6;Do you have an unreasonably strong fear for or avoid this situation;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Do you have an unreasonably strong fear for or avoid this situation [CIDI-SF];Have agoraphobia ever CIDI-SF;;ACTIVE;2.36;2.65 +65914-4;Social phobias;Find;Pt;^Patient;Nom;CIDI-SF;PHENX;2;Social phobias [CIDI-SF];Social phobias CIDI-SF;;ACTIVE;2.36;2.65 +65915-1;Do you have an unreasonably strong fear or avoid this social situation;Find;Pt;^Patient;Ord;CIDI-SF;PHENX;2;Do you have an unreasonably strong fear or avoid this social situation [CIDI-SF];Have social phobia ever CIDI-SF;;ACTIVE;2.36;2.65 +65916-9;Aspects of your life;Find;Pt;^Patient;Nom;HCL-32;PHENX;2;Aspects of your life [HCL-32];Life aspects HCL-32;;ACTIVE;2.36;2.65 +65917-7;Impact of your highs on this aspect of your life;Find;Pt;^Patient;Ord;HCL-32;PHENX;2;Impact of your highs on this aspect of your life [HCL-32];Life aspects highs impact HCL-32;;ACTIVE;2.36;2.65 +65918-5;High state behavior or feelings;Find;Pt;^Patient;Nom;HCL-32;PHENX;2;High state behavior or feelings [HCL-32];Mania behavior HCL-32;;ACTIVE;2.36;2.65 +65919-3;In a high state I have this behavior or feeling;Find;Pt;^Patient;Ord;HCL-32;PHENX;2;In a high state I have this behavior or feeling [HCL-32];Mania behavior ever HCL-32;;ACTIVE;2.36;2.65 +6592-0;Yellow fever virus Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yellow fever virus IgG Ab [Units/volume] in Serum by Immunoassay;YFV IgG Ser IA-aCnc;;ACTIVE;1.0g;2.69 +65920-1;During these episodes of overeating and loss of control did you eat much more rapidly than normal;Find;Pt;^Patient;Ord;EDDS;PHENX;2;During these episodes of overeating and loss of control did you eat much more rapidly than normal [EDDS];Eat more rapidly EDDS;;ACTIVE;2.36;2.65 +65921-9;During these episodes of overeating and loss of control did you eat until you felt uncomfortably full;Find;Pt;^Patient;Ord;EDDS;PHENX;2;During these episodes of overeating and loss of control did you eat until you felt uncomfortably full [EDDS];Eat until uncomfortably full EDDS;;ACTIVE;2.36;2.65 +65922-7;During these episodes of overeating and loss of control did you eat large amounts of food when you didn't feel physically hungry;Find;Pt;^Patient;Ord;EDDS;PHENX;2;During these episodes of overeating and loss of control did you eat large amounts of food when you didn't feel physically hungry [EDDS];Eat when not hungry EDDS;;ACTIVE;2.36;2.65 +65923-5;During these episodes of overeating and loss of control did you eat alone because you were embarrassed by how much you were eating;Find;Pt;^Patient;Ord;EDDS;PHENX;2;During these episodes of overeating and loss of control did you eat alone because you were embarrassed by how much you were eating [EDDS];Eat alone EDDS;;ACTIVE;2.36;2.65 +65924-3;During these episodes of overeating and loss of control did you feel disgusted with yourself, depressed or very guilty after overeating;Find;Pt;^Patient;Ord;EDDS;PHENX;2;During these episodes of overeating and loss of control did you feel disgusted with yourself, depressed or very guilty after overeating [EDDS];Feel disgusted EDDS;;ACTIVE;2.36;2.65 +65925-0;During these episodes of overeating and loss of control did you feel very upset about your uncontrollable overeating or resulting weight gain;Find;Pt;^Patient;Ord;EDDS;PHENX;2;During these episodes of overeating and loss of control did you feel very upset about your uncontrollable overeating or resulting weight gain [EDDS];Feel very upset EDDS;;ACTIVE;2.36;2.65 +65926-8;How many times per W on average over the past 3Mo have you made yourself vomit to prevent weight gain or counteract the effects of eating;NRat;3Mo;^Patient;Qn;EDDS;PHENX;2;How many times per week on average over the past 3 months have you made yourself vomit to prevent weight gain or counteract the effects of eating [EDDS];Made yourself vomit last 3Mo EDDS;;ACTIVE;2.36;2.65 +65927-6;How many times per W on average over the past 3Mo have you used laxatives or diuretics to prevent weight gain or counteract the effects of eating;NRat;3Mo;^Patient;Qn;EDDS;PHENX;2;How many times per week on average over the past 3 months have you used laxatives or diuretics to prevent weight gain or counteract the effects of eating [EDDS];Laxative times / W EDDS;;ACTIVE;2.36;2.65 +65928-4;How many times per W on average over the past 3Mo have you fasted - skipped at least 2 meals in a row - to prevent weight gain or counteract the effects of eating;NRat;3Mo;^Patient;Qn;EDDS;PHENX;2;How many times per week on average over the past 3 months have you fasted - skipped at least 2 meals in a row - to prevent weight gain or counteract the effects of eating [EDDS];Fasted - times / W EDDS;;ACTIVE;2.36;2.65 +65929-2;How many times per W on average over the past 3Mo have you engaged in excessive exercise specifically to counteract the effects of overeating episodes;NRat;3Mo;^Patient;Qn;EDDS;PHENX;2;How many times per week on average over the past 3 months have you engaged in excessive exercise specifically to counteract the effects of overeating episodes [EDDS];Exercised times / W EDDS;;ACTIVE;2.36;2.65 +659-3;Microscopic observation;Prid;Pt;XXX;Nom;Carbol-fuchsin stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Carbol-fuchsin stain;CF Stn Spec;;ACTIVE;1.0;2.69 +65930-0;Over the past 3Mo, how many menstrual periods have you missed;NRat;3Mo;^Patient;Qn;EDDS;PHENX;2;Over the past 3 months, how many menstrual periods have you missed [EDDS];Missed menstrual periods EDDS;;ACTIVE;2.36;2.65 +65931-8;Have you been taking birth control pills during the past 3Mo;Find;3Mo;^Patient;Ord;EDDS;PHENX;2;Have you been taking birth control pills during the past 3 months [EDDS];Birth control pills past 3Mo EDDS;;ACTIVE;2.36;2.65 +65932-6;Source of rating;Find;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Source of rating [DI-PAD];Source of rating DI-PAD;;ACTIVE;2.36;2.65 +65933-4;Day;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Day [PhenX];Day PhenX;;TRIAL;2.36;2.65 +65934-2;Age of first psychiatric problems;Time;Pt;^Patient;Qn;DI-PAD CGP V 1.4;PHENX;2;Age of first psychiatric problems [DI-PAD];Age of onset psych problems DI-PAD;;ACTIVE;2.36;2.65 +65935-9;Onset psychiatric illness;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Onset psychiatric illness [DI-PAD];Mode onset psych illness DI-PAD;;ACTIVE;2.36;2.65 +65936-7;Age and mode of onset notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Age and mode of onset notes [DI-PAD];Mode onset notes DI-PAD;;ACTIVE;2.36;2.65 +65937-5;Psychological stressor prior to onset of first episode;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Psychological stressor prior to onset of first episode [DI-PAD];Psychological stressors DI-PAD;;ACTIVE;2.36;2.65 +6593-8;Yellow fever virus Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yellow fever virus IgM Ab [Units/volume] in Serum by Immunoassay;YFV IgM Ser IA-aCnc;;ACTIVE;1.0g;2.69 +65938-3;Psychological stressor notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Psychological stressor notes [Text] [DI-PAD];Psychological stressor notes DI-PAD;;ACTIVE;2.36;2.65 +65939-1;Employment status at onset of illness;Find;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Employment status at onset of illness [DI-PAD];Employment status onset illness DI-PAD;;ACTIVE;2.36;2.65 +65940-9;Premorbid work adjustment;Find;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Premorbid work adjustment [DI-PAD];Premorbid work adjustment DI-PAD;;ACTIVE;2.36;2.65 +65941-7;Premorbid social adjustment;Find;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Premorbid social adjustment [DI-PAD];Premorbid social adjustment DI-PAD;;ACTIVE;2.36;2.65 +65942-5;Premorbid adjustment notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Premorbid adjustment notes [Text] [DI-PAD];Premorbid adjustment notes DI-PAD;;ACTIVE;2.36;2.65 +65943-3;Coarse brain disorder prior to onset;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Coarse brain disorder prior to onset [DI-PAD];Coarse brain disorder DI-PAD;;ACTIVE;2.36;2.65 +65944-1;Coarse brain disorder notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Coarse brain disorder notes [Text] [DI-PAD];Coarse brain disorder notes DI-PAD;;ACTIVE;2.36;2.65 +65945-8;Schizophrenia;Hx;Pt;^Family member;Ord;DI-PAD CGP V 1.4;PHENX;2;Family history of Schizophrenia [DI-PAD];Family hx of SCZ DI-PAD;;ACTIVE;2.36;2.65 +6594-6;Amoeba identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Amoeba identified in Specimen by Organism specific culture;Amoeba Spec Cult;;ACTIVE;1.0g;2.73 +65946-6;Other psychiatric disorders;Hx;Pt;^Family member;Ord;DI-PAD CGP V 1.4;PHENX;2;Family history of Other psychiatric disorders [DI-PAD];Family hx of Other psyc disorders DI-PAD;;ACTIVE;2.36;2.65 +65947-4;Family history notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Family history notes [Text] [DI-PAD];Family hx notes DI-PAD;;ACTIVE;2.36;2.65 +65948-2;Dysphoria - depression;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Dysphoria - depression [DI-PAD];Dysphoria - depression DI-PAD;;ACTIVE;2.36;2.65 +65949-0;Dysphoria - irritable impatient;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Dysphoria - irritable impatient [DI-PAD];Dysphoria - irritable DI-PAD;;ACTIVE;2.36;2.65 +65950-8;Dysphoria notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Dysphoria notes [Text] [DI-PAD];Dysphoria notes DI-PAD;;ACTIVE;2.36;2.65 +65951-6;Anhedonia;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Anhedonia [DI-PAD];Anhedonia DI-PAD;;ACTIVE;2.36;2.65 +65952-4;Anhedonia notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Anhedonia notes [Text] [DI-PAD];Anhedonia notes DI-PAD;;ACTIVE;2.36;2.65 +6595-3;Klebsiella granulomatis;PrThr;Pt;Isolate;Ord;Organism specific culture;MICRO;1;Klebsiella granulomatis [Presence] in Isolate by Organism specific culture;K granulomatis Islt Ql Cult;;ACTIVE;1.0g;2.56 +65953-2;Loss of energy or fatigue;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Loss of energy or fatigue [DI-PAD];Loss energy fatigue DI-PAD;;ACTIVE;2.36;2.65 +65954-0;Slowed activity;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Slowed activity [DI-PAD];Slowed activity DI-PAD;;ACTIVE;2.36;2.65 +65955-7;Impaired concentration;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Impaired concentration [DI-PAD];Impaired concentration DI-PAD;;ACTIVE;2.36;2.65 +65956-5;Altered libido;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Altered libido [DI-PAD];Altered libido DI-PAD;;ACTIVE;2.36;2.65 +65957-3;Excessive self reproach;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Excessive self reproach [DI-PAD];Excessive self reproach DI-PAD;;ACTIVE;2.36;2.65 +65958-1;Depressive symptom notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Depressive symptom notes [Text] [DI-PAD];Depressive symptom notes DI-PAD;;ACTIVE;2.36;2.65 +65959-9;Suicidality;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Suicidality [DI-PAD];Suicidality DI-PAD;;ACTIVE;2.36;2.65 +65960-7;Suicidality notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Suicidality notes [Text] [DI-PAD];Suicidality notes DI-PAD;;ACTIVE;2.36;2.65 +6596-1;Diphtheria sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Diphtheria identified in Isolate by Organism specific culture;Diphtheria Islt Cult;;ACTIVE;1.0g;2.19 +65961-5;Decreased appetite;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Decreased appetite [DI-PAD];Decreased appetite DI-PAD;;ACTIVE;2.36;2.65 +65962-3;Weight loss;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Weight loss [DI-PAD];Weight loss DI-PAD;;ACTIVE;2.36;2.65 +65963-1;Increased appetite;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Increased appetite [DI-PAD];Increased appetite DI-PAD;;ACTIVE;2.36;2.65 +65964-9;Weight gain;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Weight gain [DI-PAD];Wt gain DI-PAD;;ACTIVE;2.36;2.65 +65965-6;Initial insomnia;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Initial insomnia [DI-PAD];Initial insomnia DI-PAD;;ACTIVE;2.36;2.65 +65966-4;Middle insomnia;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Middle insomnia [DI-PAD];Middle insomnia DI-PAD;;ACTIVE;2.36;2.65 +65967-2;Terminal insomnia;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Terminal insomnia [DI-PAD];Terminal insomnia DI-PAD;;ACTIVE;2.36;2.65 +65968-0;How many Hs do you normally sleep;Time;Pt;^Patient;Qn;DI-PAD CGP V 1.4;PHENX;2;How many hours do you normally sleep [DI-PAD];Hs normal sleep DI-PAD;;ACTIVE;2.36;2.73 +65969-8;How many Hs were you sleeping then;Time;Pt;^Patient;Qn;DI-PAD CGP V 1.4;PHENX;2;How many hours were you sleeping then [DI-PAD];Hs sleeping then DI-PAD;;ACTIVE;2.36;2.65 +65970-6;Excessive sleep;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Excessive sleep [DI-PAD];Excessive sleep DI-PAD;;ACTIVE;2.36;2.65 +65971-4;Diurnal variation of depression;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Diurnal variation of depression [DI-PAD];Diurnal variation depression DI-PAD;;ACTIVE;2.36;2.65 +65972-2;Appetite or sleep change notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Appetite or sleep change notes [Text] [DI-PAD];Appetite sleep chg notes DI-PAD;;ACTIVE;2.36;2.65 +65973-0;Elevated mood;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Elevated mood [DI-PAD];Elevated mood DI-PAD;;ACTIVE;2.36;2.65 +65974-8;Irritable mood;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Irritable mood [DI-PAD];Irritable mood DI-PAD;;ACTIVE;2.36;2.65 +65975-5;Elevated or irritable mood notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Elevated or irritable mood notes [Text] [DI-PAD];Elevated irritable mood notes DI-PAD;;ACTIVE;2.36;2.65 +65976-3;Pressured speech;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Pressured speech [DI-PAD];Pressured speech DI-PAD;;ACTIVE;2.36;2.65 +65977-1;Racing thoughts;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Racing thoughts [DI-PAD];Racing thoughts DI-PAD;;ACTIVE;2.36;2.65 +65978-9;Distractibility;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Distractibility [DI-PAD];Distractibility DI-PAD;;ACTIVE;2.36;2.65 +6597-9;Troponin T.cardiac;MCnc;Pt;BldV;Qn;;CHEM;1;Troponin T.cardiac [Mass/volume] in Venous blood;Troponin T BldV-mCnc;;ACTIVE;1.0g;2.73 +65979-7;Reduced need for sleep;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Reduced need for sleep [DI-PAD];Reduced need sleep DI-PAD;;ACTIVE;2.36;2.65 +65980-5;Excessive activity;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Excessive activity [DI-PAD];Excessive activity DI-PAD;;ACTIVE;2.36;2.65 +65981-3;Reckless activity;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Reckless activity [DI-PAD];Reckless activity DI-PAD;;ACTIVE;2.36;2.65 +65982-1;Increased sociability;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Increased sociability [DI-PAD];Increased sociability DI-PAD;;ACTIVE;2.36;2.65 +65983-9;Increased self-esteem;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Increased self-esteem [DI-PAD];Increased self-esteem DI-PAD;;ACTIVE;2.36;2.65 +65984-7;Hypomanic or manic symptom notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Hypomanic or manic symptom notes [Text] [DI-PAD];Hypomanic manic notes DI-PAD;;ACTIVE;2.36;2.65 +65985-4;Hallucinations in any modality;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Hallucinations in any modality [DI-PAD];Hallucinations any DI-PAD;;ACTIVE;2.36;2.65 +65986-2;Any modality hallucinations notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Any modality hallucinations notes [Text] [DI-PAD];Any hallucination notes DI-PAD;;ACTIVE;2.36;2.65 +6598-7;Troponin T.cardiac;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Troponin T.cardiac [Mass/volume] in Serum or Plasma;Troponin T SerPl-mCnc;;ACTIVE;1.0g;2.73 +65987-0;Neutral voices or non-verbal hallucinations;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Neutral voices or non-verbal hallucinations [DI-PAD];Voices non-verbal hallucinations DI-PAD;;ACTIVE;2.36;2.65 +65988-8;Command, accusatory, abusive or persecusatory voices;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Command, accusatory, abusive or persecusatory voices [DI-PAD];Command accusatory voices DI-PAD;;ACTIVE;2.36;2.65 +65989-6;Running commentary;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Running commentary [DI-PAD];Running commentary DI-PAD;;ACTIVE;2.36;2.65 +65990-4;Third person auditory hallucinations;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Third person auditory hallucinations [DI-PAD];3rd person auditory hallucination DI-PAD;;ACTIVE;2.36;2.65 +65991-2;Hallucination notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Hallucination notes [Text] [DI-PAD];Hallucination notes DI-PAD;;ACTIVE;2.36;2.65 +65992-0;Thought insertion;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Thought insertion [DI-PAD];Thought insertion DI-PAD;;ACTIVE;2.36;2.65 +65993-8;Thought broadcast;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Thought broadcast [DI-PAD];Thought broadcast DI-PAD;;ACTIVE;2.36;2.65 +65994-6;Thought withdrawal;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Thought withdrawal [DI-PAD];Thought withdrawal DI-PAD;;ACTIVE;2.36;2.65 +6599-5;Haemophilus influenzae B Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Haemophilus influenzae B Ag [Presence] in Specimen by Immunofluorescence;Haem influ B Ag Spec Ql IF;;ACTIVE;1.0g;2.73 +65995-3;Thought echo;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Thought echo [DI-PAD];Thought echo DI-PAD;;ACTIVE;2.36;2.65 +65996-1;Subjective thought disturbance notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Subjective thought disturbance notes [Text] [DI-PAD];Subj thought disturb notes DI-PAD;;ACTIVE;2.36;2.65 +65997-9;Delusion screen;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Delusion screen [DI-PAD];Delusion screen DI-PAD;;ACTIVE;2.36;2.65 +65998-7;Delusions of guilt;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Delusions of guilt [DI-PAD];Delusions guilt DI-PAD;;ACTIVE;2.36;2.65 +65999-5;Delusions of poverty;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Delusions of poverty [DI-PAD];Delusions poverty DI-PAD;;ACTIVE;2.36;2.65 +66000-1;Nihilistic delusions;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Nihilistic delusions [DI-PAD];Nihilistic delusion DI-PAD;;ACTIVE;2.36;2.65 +6600-1;Haemophilus sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Haemophilus sp identified in Specimen by Organism specific culture;Haemphilus Spec Cult;;ACTIVE;1.0g;2.73 +66001-9;Delusions of passivity;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Delusions of passivity [DI-PAD];Delusions passivity DI-PAD;;ACTIVE;2.36;2.65 +66002-7;Delusions of influence;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Delusions of influence [DI-PAD];Delusions influence DI-PAD;;ACTIVE;2.36;2.65 +66003-5;Persecutory delusions;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Persecutory delusions [DI-PAD];Persecutory delusion DI-PAD;;ACTIVE;2.36;2.65 +66004-3;Grandiose delusions;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Grandiose delusions [DI-PAD];Grandiose delusion DI-PAD;;ACTIVE;2.36;2.65 +66005-0;Delusional moods;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Delusional moods [DI-PAD];Delusional mood DI-PAD;;ACTIVE;2.36;2.65 +66006-8;Primary delusional ideas;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Primary delusional ideas [DI-PAD];Primary delusional idea DI-PAD;;ACTIVE;2.36;2.65 +66007-6;Bizarre delusions;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Bizarre delusions [DI-PAD];Bizarre delusion DI-PAD;;ACTIVE;2.36;2.65 +66008-4;Delusion notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Delusion notes [Text] [DI-PAD];Delusion notes DI-PAD;;ACTIVE;2.36;2.65 +66009-2;Insight into illness;Find;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Insight into illness [DI-PAD];Insight into illness DI-PAD;;ACTIVE;2.36;2.65 +660-1;Microscopic observation;Prid;Pt;XXX;Nom;Dark field examination;MICRO;1;Microscopic observation [Identifier] in Specimen by Dark field examination;Dark Field Spec;;ACTIVE;1.0;2.69 +66010-0;Relationship between psychotic and affective symptoms;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Relationship between psychotic and affective symptoms [DI-PAD];Relat psych affective sympts DI-PAD;;ACTIVE;2.36;2.65 +66011-8;Insight or relationship between psychotic and affective symptom notes;Txt;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Insight or relationship between psychotic and affective symptom notes [Text] [DI-PAD];Relation psych affect sympts DI-PAD;;ACTIVE;2.36;2.65 +66012-6;Psychotic symptoms respond to antipsychotic medications;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Psychotic symptoms respond to antipsychotic medications [DI-PAD];Response antipsychotic meds DI-PAD;;ACTIVE;2.36;2.65 +66013-4;Well organized delusions;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Well organized delusions [DI-PAD];Well organized delusion DI-PAD;;ACTIVE;2.36;2.65 +66014-2;Widespread delusions;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Widespread delusions [DI-PAD];Widespread delusion DI-PAD;;ACTIVE;2.36;2.65 +66015-9;Delusions and hallucinations last for one W;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Delusions and hallucinations last for one week [DI-PAD];Delusions hallucinations one W DI-PAD;;ACTIVE;2.36;2.65 +66016-7;Persecutory or jealous delusions and hallucinations;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Persecutory or jealous delusions and hallucinations [DI-PAD];Persecutory delusion halluc DI-PAD;;ACTIVE;2.36;2.65 +66017-5;Illness duration;Time;Pt;^Patient;Qn;DI-PAD CGP V 1.4;PHENX;2;Illness duration [DI-PAD];Illness duration DI-PAD;;ACTIVE;2.36;2.65 +66018-3;Impairment or incapacity;Find;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Impairment or incapacity [DI-PAD];Impairment incapacity DI-PAD;;ACTIVE;2.36;2.65 +6601-9;Influenza virus identified;Prid;Pt;Sputum;Nom;Organism specific culture;MICRO;1;Influenza virus identified in Sputum by Organism specific culture;FLUV Spt Cult;;ACTIVE;1.0g;2.21 +66019-1;Deterioration from premorbid level of functioning;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Deterioration from premorbid level of functioning [DI-PAD];Deterioration fr premorbid level DI-PAD;;ACTIVE;2.36;2.65 +66020-9;Course of disorder;Find;Pt;^Patient;Nom;;CLIN;2;Course of disorder;Course of disorder;;ACTIVE;2.36;2.65 +66021-7;Rapport;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Rapport [DI-PAD];Rapport DI-PAD;;ACTIVE;2.36;2.65 +66022-5;Credibility of information;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Credibility of information [DI-PAD];Credibility information DI-PAD;;ACTIVE;2.36;2.65 +66023-3;Catatonia;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Catatonia [DI-PAD];Catatonia DI-PAD;;ACTIVE;2.36;2.65 +66024-1;Bizarre behavior;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Bizarre behavior [DI-PAD];Bizarre behavior DI-PAD;;ACTIVE;2.36;2.65 +66025-8;Agitated activity;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Agitated activity [DI-PAD];Agitated activity DI-PAD;;ACTIVE;2.36;2.65 +66026-6;Restricted affect;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Restricted affect [DI-PAD];Restricted affect DI-PAD;;ACTIVE;2.36;2.65 +6602-7;Influenza virus identified;Prid;Pt;Sptt;Nom;Organism specific culture;MICRO;1;Influenza virus identified in Sputum tracheal aspirate by Organism specific culture;FLUV Sputum trach asp Cult;;ACTIVE;1.0g;2.21 +66027-4;Blunted affect;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Blunted affect [DI-PAD];Blunted affect DI-PAD;;ACTIVE;2.36;2.65 +66028-2;Inappropriate affect;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Inappropriate affect [DI-PAD];Inappropriate affect DI-PAD;;ACTIVE;2.36;2.65 +66029-0;Speech difficult to understand;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Speech difficult to understand [DI-PAD];Speech difficult understand DI-PAD;;ACTIVE;2.36;2.65 +66030-8;Speech incoherent;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Speech incoherent [DI-PAD];Speech incoherent DI-PAD;;ACTIVE;2.36;2.65 +66031-6;Positive formal thought disorder;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Positive formal thought disorder [DI-PAD];Pos formal thought disorder DI-PAD;;ACTIVE;2.36;2.65 +66032-4;Negative formal thought disorder;Find;Pt;^Patient;Ord;DI-PAD CGP V 1.4;PHENX;2;Negative formal thought disorder [DI-PAD];Neg formal thought disorder DI-PAD;;ACTIVE;2.36;2.65 +66033-2;Marital status;Find;Pt;^Patient;Nom;DI-PAD CGP V 1.4;PHENX;2;Marital status PhenX;Marital status PhenX;;ACTIVE;2.36;2.65 +6603-5;Influenza virus identified;Prid;Pt;Thrt;Nom;Organism specific culture;MICRO;1;Influenza virus identified in Throat by Organism specific culture;FLUV Throat Cult;;ACTIVE;1.0g;2.21 +66035-7;Tremor at rest;Find;Pt;Upper extremity.right;Ord;UPDRS;UPDRS;2;Tremor at rest Upper extremity - right [UPDRS];Tremor at rest UE-R UPDRS;;ACTIVE;2.36;2.71 +66036-5;Postural tremor;Find;Pt;Upper extremity.right;Ord;UPDRS;UPDRS;2;Postural tremor Upper extremity - right [UPDRS];Postural tremor UE-R UPDRS;;ACTIVE;2.36;2.71 +66037-3;Rigidity;Find;Pt;Neck;Ord;UPDRS;UPDRS;2;Rigidity Neck [UPDRS];Rigidity Neck UPDRS;;ACTIVE;2.36;2.71 +66038-1;Speech;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Speech [UPDRS];Speech - Parkinson's;;ACTIVE;2.36;2.71 +66039-9;Facial expression;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Facial expression [UPDRS];Facial expression UPDRS;;ACTIVE;2.36;2.71 +66040-7;Tremor at rest;Find;Pt;Face;Ord;UPDRS;UPDRS;2;Tremor at rest Face [UPDRS];Tremor at rest Face UPDRS;;ACTIVE;2.36;2.71 +66041-5;Cause of injury;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Cause of injury [PhenX];Cause of injury PhenX;;TRIAL;2.36;2.65 +66042-3;Dominant hand;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Dominant hand [PhenX];Dominant hand PhenX;;TRIAL;2.36;2.65 +6604-3;Influenza virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Influenza virus identified in Specimen by Organism specific culture;FLUV Spec Cult;;ACTIVE;1.0g;2.73 +66043-1;Hands hanging at sides for 10S;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Hands hanging at sides for 10 seconds [PhenX];Hands hanging at sides PhenX;;TRIAL;2.36;2.65 +66044-9;Walking 20 ft and turning;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Walking 20 ft and turning [PhenX];Walking 20 ft turn PhenX;;TRIAL;2.36;2.65 +66045-6;Tandem gait for 10 steps;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Tandem gait for 10 steps [PhenX];Tandem gait PhenX;;TRIAL;2.36;2.65 +66047-2;Do or did you have this diabetes-related problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do or did you have this diabetes-related problem [PhenX];Diabetes-related problem ever PhenX;;TRIAL;2.36;2.65 +66048-0;Age diabetes-related problem occurred;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Age diabetes-related problem occurred [PhenX];Diabetes-related problem age PhenX;;TRIAL;2.36;2.65 +66049-8;I stay home most of the time because of my eyesight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I stay home most of the time because of my eyesight [PhenX];Stay home because eyesight PhenX;;TRIAL;2.36;2.65 +6605-0;Leptospira interrogans Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Leptospira interrogans Ag [Presence] in Tissue by Immunofluorescence;L inter Ag Tiss Ql IF;;ACTIVE;1.0g;2.56 +66050-6;I feel frustrated a lot of the time because of my eyesight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel frustrated a lot of the time because of my eyesight [PhenX];Frustrated because eyesight PhenX;;TRIAL;2.36;2.65 +66051-4;I have much less control over what I do, because of my eyesight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have much less control over what I do, because of my eyesight [PhenX];Less control because eyesight PhenX;;TRIAL;2.36;2.65 +66052-2;Because of my eyesight, I have to rely too much on what other people tell me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of my eyesight, I have to rely too much on what other people tell me [PhenX];Rely others because eyesight PhenX;;TRIAL;2.36;2.65 +66053-0;I need a lot of help from others because of my eyesight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I need a lot of help from others because of my eyesight [PhenX];Need help because eyesight PhenX;;TRIAL;2.36;2.65 +66054-8;I worry about doing things that will embarrass myself or others, because of my eyesight;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I worry about doing things that will embarrass myself or others, because of my eyesight [PhenX];Worry embarrass because eyesight PhenX;;TRIAL;2.36;2.65 +66055-5;Because of your eyesight, how much difficulty do you have figuring out whether bills you receive are accurate;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have figuring out whether bills you receive are accurate [PhenX];Difficulty accurate bills PhenX;;TRIAL;2.36;2.65 +66056-3;Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair, or putting on makeup;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair, or putting on makeup [PhenX];Difficulty shaving makeup PhenX;;TRIAL;2.36;2.65 +66057-1;Because of your eyesight, how much difficulty do you have recognizing people you know from across a room;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have recognizing people you know from across a room [PhenX];Difficulty recognize people PhenX;;TRIAL;2.36;2.65 +66058-9;Because of your eyesight, how much difficulty do you have taking part in active sports or other outdoor activities that you enjoy, like golf, bowling, jogging, or walking;Find;Pt;^Patient;Ord;;PHENX;2;Because of your eyesight, how much difficulty do you have taking part in active sports or other outdoor activities that you enjoy, like golf, bowling, jogging, or walking;Diff sports outdoor activities;;ACTIVE;2.36;2.71 +66059-7;Because of your eyesight, how much difficulty do you have seeing and enjoying programs on TV;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have seeing and enjoying programs on TV [PhenX];Difficulty TV programs PhenX;;TRIAL;2.36;2.65 +66060-5;Because of your eyesight, how much difficulty do you have entertaining friends and family in your home;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have entertaining friends and family in your home [PhenX];Difficulty entertaining PhenX;;TRIAL;2.36;2.65 +66061-3;My child - 2-4Y;Find;Pt;^Patient;Nom;PhenX;PHENX;2;My child - 2-4Y [PhenX];My child - 2-4Y PhenX;;TRIAL;2.36;2.65 +66062-1;My child - 4-6Y;Find;Pt;^Patient;Nom;PhenX;PHENX;2;My child - 4-6Y [PhenX];My child - 4-6Y PhenX;;TRIAL;2.36;2.65 +66063-9;My child - 6-12Y;Find;Pt;^Patient;Nom;PhenX;PHENX;2;My child - 6-12 years [PhenX];My child - 6-12Y PhenX;;TRIAL;2.36;2.66 +66064-7;Methods to prevent pregnancy;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Methods to prevent pregnancy [PhenX];Prevent pregnancy methods PhenX;;TRIAL;2.36;2.65 +66065-4;Have you ever used this method to prevent pregnancy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever used this method to prevent pregnancy [PhenX];Prevent pregnancy methods ever PhenX;;TRIAL;2.36;2.65 +66066-2;Have you ever used oral contraceptives for 2Mo or more for any reason - contraception, acne, menstrual irregularity, etc;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever used oral contraceptives for two months or more for any reason - contraception, acne, menstrual irregularity, etc [PhenX];Oral contraceptives 2Mo PhenX;;TRIAL;2.36;2.65 +66067-0;Axial length;Len;Pt;Eye.left;Qn;;EYE.PX.NEI;2;Left eye Axial length;L eye Axial length;;ACTIVE;2.36;2.68 +6606-8;Brugia malayi Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brugia malayi Ab [Presence] in Serum by Immunoassay;B malayi Ab Ser Ql IA;;ACTIVE;1.0g;2.56 +66068-8;Cornea thickness;Len;Pt;Eye.left;Qn;;PHENX;2;Cornea thickness Left eye;Cornea thickness L eye;;ACTIVE;2.36;2.72 +66069-6;How many of your sisters have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your sisters have had, or were suspected of having this eye problem [#] [PhenX];Sisters eye problem PhenX;;TRIAL;2.36;2.65 +66070-4;How many of your brothers have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your brothers have had, or were suspected of having this eye problem [#] [PhenX];Brothers eye problem PhenX;;TRIAL;2.36;2.65 +66071-2;How many of your daughters have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your daughters have had, or were suspected of having this eye problem [#] [PhenX];Daughters eye problem PhenX;;TRIAL;2.36;2.65 +66072-0;How many of your sons have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your sons have had, or were suspected of having this eye problem [#] [PhenX];Sons have eye problem PhenX;;TRIAL;2.36;2.65 +66073-8;How many of your mother's sisters have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your mother's sisters have had, or were suspected of having this eye problem [#] [PhenX];Mother's sisters eye problem PhenX;;TRIAL;2.36;2.65 +66074-6;How many of your mother's brothers have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your mother's brothers have had, or were suspected of having this eye problem [#] [PhenX];Mothers brothers eye problem PhenX;;TRIAL;2.36;2.65 +66075-3;How many of your father's sisters have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your father's sisters have had, or were suspected of having this eye problem [#] [PhenX];Fathers sisters eye problem PhenX;;TRIAL;2.36;2.65 +6607-6;Microscopic observation;Prid;Pt;Tiss;Nom;Dark field examination;MICRO;1;Microscopic observation [Identifier] in Tissue by Dark field examination;Dark Field Tiss;;ACTIVE;1.0g;2.22 +66076-1;How many of your father's brothers have had, or were suspected of having this eye problem;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your father's brothers have had, or were suspected of having this eye problem [#] [PhenX];Fathers brothers eye problem PhenX;;TRIAL;2.36;2.65 +66077-9;How much difficulty do you have reading ordinary print in newspapers;Find;Pt;^Patient;Ord;;PHENX;2;How much difficulty do you have reading ordinary print in newspapers;Difficulty read newspapers;;ACTIVE;2.36;2.72 +66078-7;How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing things around the house, or using hand tools;Find;Pt;^Patient;Ord;;PHENX;2;How much difficulty do you have doing work or hobbies that require you to see well up close;Difficulty see close;;ACTIVE;2.36;2.72 +66079-5;Because of your eyesight, how much difficulty do you have finding something on a crowded shelf;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have finding something on a crowded shelf [PhenX];Difficulty find something shelf PhenX;;TRIAL;2.36;2.65 +66080-3;How much difficulty do you have reading street signs or the names of stores;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have reading street signs or the names of stores [PhenX];Difficulty read signs PhenX;;TRIAL;2.36;2.65 +66081-1;Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night [PhenX];Difficulty stairs dim light PhenX;;TRIAL;2.36;2.65 +66082-9;Level of difficulty seeing objects off to the side;Find;Pt;^Patient;Ord;;H&P.HX;2;Level of difficulty seeing objects off to the side;Diff notice objects off to side PhenX;;ACTIVE;2.36;2.72 +66083-7;Because of your eyesight, how much difficulty do you have seeing how people react to things you say;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have seeing how people react to things you say [PhenX];Difficulty see people react PhenX;;TRIAL;2.36;2.65 +6608-4;Virus identified;Prid;Pt;Isolate;Nom;Culture;MICRO;1;Virus identified in Isolate by Culture;Virus Islt Cult;;ACTIVE;1.0g;2.73 +66084-5;Because of your eyesight, how much difficulty do you have picking out and matching your own clothes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have picking out and matching your own clothes [PhenX];Difficulty matching clothes PhenX;;TRIAL;2.36;2.65 +66085-2;Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants [PhenX];Difficulty visit people PhenX;;TRIAL;2.36;2.65 +66086-0;Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events [PhenX];Difficulty go out PhenX;;TRIAL;2.36;2.65 +66087-8;Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on a medicine bottle, or on legal forms;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on a medicine bottle, or on legal forms [PhenX];Difficulty small print PhenX;;TRIAL;2.36;2.65 +66088-6;How often did having trouble falling asleep happen;Find;Pt;^Patient;Ord;QIDS;PHENX;2;How often did having trouble falling asleep happen [QIDS];Depression trouble sleeping freq QIDS;;ACTIVE;2.36;2.65 +66089-4;Have you brought this bag with you and are these all the medications that you have taken in the past 2W;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you brought this bag with you and are these all the medications that you have taken in the past 2 weeks [PhenX];Brought medications PhenX;;TRIAL;2.36;2.65 +66090-2;Are your legs or feet numb;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are your legs or feet numb [PhenX];Legs feet numb PhenX;;TRIAL;2.36;2.65 +66091-0;Do you ever have any burning pain in your legs or feet;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever have any burning pain in your legs or feet [PhenX];Burning pain PhenX;;TRIAL;2.36;2.65 +6609-2;Listeria sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Listeria sp identified in Specimen by Organism specific culture;Listeria Spec Cult;;ACTIVE;1.0g;2.69 +66092-8;Are your feet too sensitive to touch;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are your feet too sensitive to touch [PhenX];Feet too sensitive to touch PhenX;;TRIAL;2.36;2.65 +66093-6;Do you get muscle cramps in your legs or feet;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you get muscle cramps in your legs or feet [PhenX];Muscle cramps PhenX;;TRIAL;2.36;2.65 +66094-4;Do you ever have any prickling feelings in your legs or feet;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever have any prickling feelings in your legs or feet [PhenX];Prickling feelings PhenX;;TRIAL;2.36;2.65 +66095-1;Does it hurt when the bed covers touch your skin;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does it hurt when the bed covers touch your skin [PhenX];Bed covers hurt PhenX;;TRIAL;2.36;2.65 +66096-9;When you get into the tub or shower, are you able to tell the hot water from the cold water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When you get into the tub or shower, are you able to tell the hot water from the cold water [PhenX];Tell hot water from cold PhenX;;TRIAL;2.36;2.65 +66097-7;Have you ever had an open sore on your foot;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had an open sore on your foot [PhenX];Open sore PhenX;;TRIAL;2.36;2.65 +66098-5;Has your doctor ever told you that you have diabetic neuropathy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your doctor ever told you that you have diabetic neuropathy [PhenX];Diagnosed diabetic neuropathy PhenX;;TRIAL;2.36;2.65 +66099-3;Do you feel weak all over most of the time;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel weak all over most of the time [PhenX];Weak all over PhenX;;TRIAL;2.36;2.65 +66-1;Cefadroxil;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefadroxil [Susceptibility] by Serum bactericidal titer;Cefadroxil Titr SBT;;ACTIVE;1.0;2.32 +6610-0;Haemophilus influenzae A Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Haemophilus influenzae A Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;Haem influ A Ag CSF Ql IF;;ACTIVE;1.0g;2.56 +66100-9;Are your symptoms worse at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are your symptoms worse at night [PhenX];Symptoms worse at night PhenX;;TRIAL;2.36;2.65 +66101-7;Do your legs hurt when you walk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do your legs hurt when you walk [PhenX];Legs hurt when walk PhenX;;TRIAL;2.36;2.65 +66102-5;Are you able to sense your feet when you walk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you able to sense your feet when you walk [PhenX];Sense feet when walking PhenX;;TRIAL;2.36;2.65 +66103-3;Is the skin on your feet so dry that it cracks open;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is the skin on your feet so dry that it cracks open [PhenX];Skin cracks open PhenX;;TRIAL;2.36;2.65 +66104-1;Have you ever had an amputation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had an amputation [PhenX];Amputation ever PhenX;;TRIAL;2.36;2.65 +66105-8;Lot distribution data;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Lot distribution data;FDA insert Lot distribution data;;ACTIVE;2.38;2.38 +66106-6;Pharmacogenomics section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Pharmacogenomics section;FDA insert Pharmacogenomics;;ACTIVE;2.38;2.38 +66107-4;Pathology biopsy report;Find;Pt;Lung;Nar;;PATH;1;Lung Pathology biopsy report;Lung Path Bx report;;ACTIVE;2.38;2.52 +66108-2;Pathology biopsy report;Find;Pt;Bone;Nar;;PATH;1;Bone Pathology biopsy report;Bone Path Bx report;;ACTIVE;2.38;2.52 +66109-0;Pathology biopsy report;Find;Pt;Brain;Nar;;PATH;1;Brain Pathology biopsy report;Brain Path Bx report;;ACTIVE;2.38;2.52 +66110-8;Pathology biopsy report;Find;Pt;Breast;Nar;;PATH;1;Breast Pathology biopsy report;Brst Path Bx report;;ACTIVE;2.38;2.52 +66111-6;Pathology biopsy report;Find;Pt;Peritoneum;Nar;;PATH;1;Peritoneum Pathology biopsy report;Peritoneum Path Bx report;;ACTIVE;2.38;2.52 +66112-4;Pathology biopsy report;Find;Pt;Lymph node;Nar;;PATH;1;Lymph node Pathology biopsy report;LN Path Bx report;;ACTIVE;2.38;2.52 +66113-2;Pathology biopsy report;Find;Pt;Uterus;Nar;;PATH;1;Uterus Pathology biopsy report;Uterus Path Bx report;;ACTIVE;2.38;2.52 +66114-0;Pathology biopsy report;Find;Pt;Stomach;Nar;;PATH;1;Stomach Pathology biopsy report;Stom Path Bx report;;ACTIVE;2.38;2.52 +66115-7;Pathology biopsy report;Find;Pt;Pancreas;Nar;;PATH;1;Pancreas Pathology biopsy report;Pancreas Path Bx report;;ACTIVE;2.38;2.52 +66116-5;Pathology biopsy report;Find;Pt;Ovary;Nar;;PATH;1;Ovary Pathology biopsy report;Ovary Path Bx report;;ACTIVE;2.38;2.52 +66117-3;Pathology biopsy report;Find;Pt;Prostate;Nar;;PATH;1;Prostate Pathology biopsy report;Prostate Path Bx report;;ACTIVE;2.38;2.73 +6611-8;Haemophilus influenzae B Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Haemophilus influenzae B Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;Haem influ B Ag CSF Ql IF;;ACTIVE;1.0g;2.56 +66118-1;Pathology biopsy report;Find;Pt;Spleen;Nar;;PATH;1;Spleen Pathology biopsy report;Spleen Path Bx report;;ACTIVE;2.38;2.52 +66119-9;Pathology biopsy report;Find;Pt;Bone mar;Nar;;PATH;1;Bone marrow Pathology biopsy report Narrative;Mar Path Bx report;;ACTIVE;2.38;2.73 +66120-7;Pathology biopsy report;Find;Pt;Thyroid;Nar;;PATH;1;Thyroid Pathology biopsy report;Thyroid Path Bx report;;ACTIVE;2.38;2.52 +66121-5;Pathology biopsy report;Find;Pt;Tiss;Nar;;PATH;1;Tissue Pathology biopsy report;Tiss Path Bx report;;ACTIVE;2.38;2.73 +66122-3;Pathology biopsy report;Find;Pt;Adrenal gland;Nar;;PATH;1;Adrenal gland Pathology biopsy report;Adrenal Path Bx report;;ACTIVE;2.38;2.52 +66123-1;Pathology biopsy report;Find;Pt;Pleura;Nar;;PATH;1;Pleura Pathology biopsy report;Pleura Path Bx report;;ACTIVE;2.38;2.52 +66124-9;Pathology biopsy report;Find;Pt;Testis;Nar;;PATH;1;Testis Pathology biopsy report;Testis Path Bx report;;ACTIVE;2.38;2.52 +66125-6;Pathology biopsy report;Find;Pt;Urinary bladder;Nar;;PATH;1;Urinary bladder Pathology biopsy report;Bladder Path Bx report;;ACTIVE;2.38;2.52 +6612-6;Haemophilus influenzae C Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Haemophilus influenzae C Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;Haem influ C Ag CSF Ql IF;;ACTIVE;1.0g;2.56 +66126-4;Cholesterol.in VLDL;SCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Cholesterol in VLDL [Moles/volume] in Serum or Plasma by calculation;VLDLc SerPl Calc-sCnc;;ACTIVE;2.38;2.73 +66127-2;Amphetamine;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Amphetamine [Presence] in Serum or Plasma by Confirmatory method;Amphet SerPl Ql Cfm;;ACTIVE;2.38;2.73 +66128-0;chlordiazePOXIDE/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;chlordiazePOXIDE/Creatinine [Mass Ratio] in Urine;Chlordiazep/Creat Ur;;ACTIVE;2.38;2.73 +66129-8;Fentanyl+Norfentanyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;fentaNYL+Norfentanyl [Presence] in Urine by Confirmatory method;fentaNYL+Norfentanyl Ur Ql Cfm;;ACTIVE;2.38;2.73 +66130-6;Fentanyl+Norfentanyl;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;fentaNYL+Norfentanyl [Presence] in Serum or Plasma by Confirmatory method;fentaNYL+Norfentanyl SerPl Ql Cfm;;ACTIVE;2.38;2.56 +66131-4;Norbuprenorphine;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Norbuprenorphine [Presence] in Serum or Plasma by Confirmatory method;Norbuprenorphine SerPl Ql Cfm;;ACTIVE;2.38;2.73 +66132-2;Mononuclear+Mesothelial cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Mononuclear+Mesothelial cells/100 leukocytes in Body fluid by Manual count;Mono+Meso/leuk NFr Fld Manual;;ACTIVE;2.38;2.73 +66133-0;Mononuclear cells.atypical/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Mononuclear cells atypical/100 leukocytes in Body fluid by Manual count;Atypical Mononuc/leuk NFr Fld Manual;;ACTIVE;2.38;2.73 +6613-4;Haemophilus influenzae D Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Haemophilus influenzae D Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;Haem influ D Ag CSF Ql IF;;ACTIVE;1.0g;2.56 +66134-8;Blasts;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Blasts [#/volume] in Blood from Fetus by Manual count;Blasts # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66135-5;Promyelocytes;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Promyelocytes [#/volume] in Blood from Fetus by Manual count;Promyelocytes # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66136-3;Myelocytes;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Myelocytes [#/volume] in Blood from Fetus by Manual count;Myelocytes # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66137-1;Metamyelocytes;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Metamyelocytes [#/volume] in Blood from Fetus by Manual count;Metamyelocytes # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66138-9;Neutrophils.band form;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Band form neutrophils [#/volume] in Blood from Fetus by Manual count;Neuts Band # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66139-7;Neutrophils;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Blood from Fetus by Manual count;Neutrophils # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66140-5;Lymphocytes;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Lymphocytes [#/volume] in Blood from Fetus by Manual count;Lymphocytes # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66141-3;Eosinophils;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Eosinophils [#/volume] in Blood from Fetus by Manual count;Eosinophil # Bld Fetus Manual;;ACTIVE;2.38;2.70 +6614-2;Haemophilus influenzae E Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Haemophilus influenzae E Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;Haem influ E Ag CSF Ql IF;;ACTIVE;1.0g;2.56 +66142-1;Basophils;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Basophils [#/volume] in Blood from Fetus by Manual count;Basophils # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66143-9;Monocytes;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Monocytes [#/volume] in Blood from Fetus by Manual count;Monocytes # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66144-7;Lymphocytes.variant;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Variant lymphocytes [#/volume] in Blood from Fetus by Manual count;Variant Lymphs # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66145-4;Leukocytes other;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Leukocytes other [#/volume] in Blood from Fetus by Manual count;WBC Other # Bld Fetus Manual;;ACTIVE;2.38;2.70 +66146-2;Reticulocytes;NCnc;Pt;Bld^Fetus;Qn;Manual count;HEM/BC;1;Reticulocytes [#/volume] in Blood from Fetus by Manual count;Retics # Fetus Manual;;ACTIVE;2.38;2.70 +66147-0;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Plr fld^Fetus;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Pleural fluid from Fetus by Manual count;Polys/leuk NFr Plr Fetus Manual;;ACTIVE;2.38;2.70 +66148-8;Mononuclear cells/100 leukocytes;NFr;Pt;Plr fld^Fetus;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Pleural fluid from Fetus by Manual count;Mononuc Cells/leuk NFr Plr Fetus Manual;;ACTIVE;2.38;2.70 +66149-6;Prescribed medications;-;Pt;^Patient;-;;PANEL.PHENX;2;Prescribed medications;Prescribed medications;;TRIAL;2.36;2.73 +66150-4;Over the counter medications;-;Pt;^Patient;-;;PANEL.PHENX;2;Over the counter medications;Over the counter medications;;TRIAL;2.36;2.65 +66151-2;On the average during the last 2W, how many of these pills, or medication items, did you take a D, W, or Mo;NRat;2W;^Patient;Qn;PhenX;PHENX;2;On the average during the last 2 weeks, how many of these pills, or medication items, did you take a day, week, or month [PhenX];Avg number pills prescription PhenX;;TRIAL;2.36;2.65 +66152-0;Doctor or health care professional ever told you that you have diabetes;Find;Pt;^Patient;Ord;;PHENX;2;Doctor or health care professional ever told you that you have diabetes;HCP told you that you have diabetes;;ACTIVE;2.36;2.65 +66153-8;Are you taking medicine for diabetes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you taking medicine for diabetes [PhenX];Diabetes medicine PhenX;;TRIAL;2.36;2.65 +66154-6;What medication are you taking for diabetes;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What medication are you taking for diabetes [PhenX];Diabetes medicine type PhenX;;TRIAL;2.36;2.65 +66155-3;At what age was diabetes first treated;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age was diabetes first treated [PhenX];Diabetes age PhenX;;TRIAL;2.36;2.65 +66156-1;Was insulin your first diabetes medicine;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was insulin your first diabetes medicine [PhenX];Diabetes insulin PhenX;;TRIAL;2.36;2.65 +66157-9;Did diabetes occur only during pregnancy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did diabetes occur only during pregnancy [PhenX];Diabetes women pregnancy PhenX;;TRIAL;2.36;2.65 +66158-7;Has a medical person ever told you that you had kidney failure;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a medical person ever told you that you had kidney failure [PhenX];Kidney failure PhenX;;TRIAL;2.36;2.65 +6615-9;Haemophilus influenzae F Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Haemophilus influenzae F Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;Haem influ F Ag CSF Ql IF;;ACTIVE;1.0g;2.56 +66159-5;If yes, are one or both working well now;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If yes, are one or both working well now [PhenX];Kidneys working now PhenX;;TRIAL;2.36;2.65 +66160-3;How old were you when you were first told by a medical person that you had kidney failure;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you were first told by a medical person that you had kidney failure [PhenX];Kidney failure age PhenX;;TRIAL;2.36;2.65 +66161-1;Are you currently on renal dialysis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you currently on renal dialysis [PhenX];Dialysis PhenX;;TRIAL;2.36;2.65 +66162-9;Have you ever had a kidney transplant;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had a kidney transplant [PhenX];Kidney transplant PhenX;;TRIAL;2.36;2.65 +66164-5;Did you eat or drink anything other than plain water after 11:30 last night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you eat or drink anything other than plain water after 11:30 last night [PhenX];Eat or drink PhenX;;TRIAL;2.36;2.65 +66165-2;Last ate or drank anything other than plain water;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Last ate or drank anything other than plain water [Date and time];Last ate or drank D/T;;ACTIVE;2.36;2.68 +66166-0;Have you had coffee or tea with cream and sugar since eating or drinking anything but plain water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had coffee or tea with cream and sugar since eating or drinking anything but plain water [PhenX];Coffee tea PhenX;;TRIAL;2.36;2.65 +6616-7;Visual acuity log MAR.right;Cmplx;Pt;Eye.right;Qn;;EYE;2;Visual acuity log MAR Eye - right;R eye Visual acuity log MAR;;ACTIVE;1.0g;2.68 +66167-8;When did you have coffee or tea with cream and sugar;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did you have coffee or tea with cream and sugar [Date and time] [PhenX];Coffee tea time PhenX;;TRIAL;2.36;2.65 +66168-6;Have you had alcohol, such as beer, wine, or liquor since eating or drinking anything but plain water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had alcohol, such as beer, wine, or liquor since eating or drinking anything but plain water [PhenX];Alcohol PhenX;;TRIAL;2.36;2.65 +66169-4;When did you have alcohol, such as beer, wine, or liquor;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did you have alcohol, such as beer, wine, or liquor [Date and time] [PhenX];Alcohol time PhenX;;TRIAL;2.36;2.65 +66170-2;Have you had gum, breath mints, lozenges, or cough drops, or other cough or cold remedies since eating or drinking anything but plain water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had gum, breath mints, lozenges, or cough drops, or other cough or cold remedies since eating or drinking anything but plain water [PhenX];Gum PhenX;;TRIAL;2.36;2.65 +66171-0;When did you have gum, breath mints, lozenges, or cough drops, or other cough or cold remedies;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did you have gum, breath mints, lozenges, or cough drops, or other cough or cold remedies [Date and time] [PhenX];Gum time PhenX;;TRIAL;2.36;2.65 +66172-8;Have you had antacids, laxatives, or anti-diarrheals since eating or drinking anything but plain water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had antacids, laxatives, or anti-diarrheals since eating or drinking anything but plain water [PhenX];Antacids PhenX;;TRIAL;2.36;2.65 +66173-6;When did you have antacids, laxatives, or anti-diarrheals;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did you have antacids, laxatives, or anti-diarrheals [Date and time] [PhenX];Antacids time PhenX;;TRIAL;2.36;2.65 +66174-4;Are you currently pregnant;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you currently pregnant [PhenX];Pregnant currently PhenX;;TRIAL;2.36;2.73 +6617-5;Visual acuity log MAR.left;Cmplx;Pt;Eye.left;Qn;;EYE;2;Visual acuity log MAR Eye - left;L eye Visual acuity log MAR;;ACTIVE;1.0g;2.68 +66175-1;Are you now taking insulin;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you now taking insulin [PhenX];Taking insulin PhenX;;TRIAL;2.36;2.73 +66176-9;Are you now taking diabetic pills to lower your blood sugar;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you now taking diabetic pills to lower your blood sugar [PhenX];Diabetic pills PhenX;;TRIAL;2.36;2.65 +66177-7;Hemophilia;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Hemophilia;Hx of Hemophilia;;ACTIVE;2.36;2.67 +66178-5;Cancer chemotherapy received in the past 4W or will be received in the next 4W;Find;Pt;^Patient;Ord;;ONCOLOGY;2;Cancer chemotherapy received in the past 4W or will be received in the next 4W;Chemotherapy rcvd past 4W or next 4W;;ACTIVE;2.36;2.68 +66179-3;Exclusion criteria for fasting plasma glucose;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Exclusion criteria for fasting plasma glucose [PhenX];Exclusion criteria glucose PhenX;;TRIAL;2.36;2.65 +66180-1;Was blood drawn;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was blood drawn [PhenX];Blood draw done PhenX;;TRIAL;2.36;2.65 +66181-9;Was full sample obtained;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was full sample obtained [PhenX];Blood draw sample PhenX;;TRIAL;2.36;2.65 +66182-7;Have you had dietary supplements such as vitamins and minerals since eating or drinking anything but plain water;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had dietary supplements such as vitamins and minerals since eating or drinking anything but plain water [PhenX];DS PhenX;;TRIAL;2.36;2.65 +6618-3;Acanthamoeba sp Ab;PrThr;Pt;Crn;Ord;IF;MICRO;1;Acanthamoeba sp Ab [Presence] in Cornea by Immunofluorescence;Acanthamoeba Ab Crn Ql IF;;ACTIVE;1.0g;2.73 +66183-5;When did you have dietary supplements such as vitamins and minerals;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;When did you have dietary supplements such as vitamins and minerals [Date and time] [PhenX];DS time PhenX;;TRIAL;2.36;2.73 +66184-3;How much does your insomnia, sleep difficulties, upset or distress you;Num;Pt;^Patient;Ord;PhenX;PHENX;2;How much does your insomnia, sleep difficulties, upset or distress you [PhenX];Insomnia distress scale PhenX;;TRIAL;2.36;2.65 +66185-0;What number describes how much your insomnia has affected your social life or relationships with your friends;Num;Pt;^Patient;Ord;PhenX;PHENX;2;What number describes how much your insomnia has affected your social life or relationships with your friends [PhenX];Insomnia social impairment scale PhenX;;TRIAL;2.36;2.65 +66186-8;What number describes how much your insomnia has affected your relationships with family members;Num;Pt;^Patient;Ord;PhenX;PHENX;2;What number describes how much your insomnia has affected your relationships with family members [PhenX];Insomnia family impairment scale PhenX;;TRIAL;2.36;2.65 +66187-6;What number describes how much your insomnia has affected your performance in school or work or your relationships with your co-workers, employers, teachers or classmates;Num;Pt;^Patient;Ord;PhenX;PHENX;2;What number describes how much your insomnia has affected your performance in school or work or your relationships with your co-workers, employers, teachers or classmates [PhenX];Insomnia work impairment scale PhenX;;TRIAL;2.36;2.65 +66189-2;Tremor at rest;Find;Pt;Upper extremity.left;Ord;UPDRS;UPDRS;2;Tremor at rest Upper extremity - left [UPDRS];Tremor at rest UE-L UPDRS;;ACTIVE;2.36;2.71 +661-9;Microscopic observation;Prid;Pt;XXX;Nom;Dry mount;MICRO;1;Microscopic observation [Identifier] in Specimen by Dry mount;Dry Mount Spec;;ACTIVE;1.0;2.69 +66190-0;Tremor at rest;Find;Pt;Lower extremity.right;Ord;UPDRS;UPDRS;2;Tremor at rest Lower extremity - right [UPDRS];Tremor at rest LE-R UPDRS;;ACTIVE;2.36;2.71 +6619-1;Acanthamoeba sp Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Acanthamoeba sp Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Acanthamoeba Ab CSF Ql IF;;ACTIVE;1.0g;2.56 +66191-8;Tremor at rest;Find;Pt;Lower extremity.left;Ord;UPDRS;UPDRS;2;Tremor at rest Lower extremity - left [UPDRS];Tremor at rest LE-L UPDRS;;ACTIVE;2.36;2.71 +66192-6;Rigidity;Find;Pt;Upper extremity.right;Ord;UPDRS;UPDRS;2;Rigidity Upper extremity - right [UPDRS];Rigidity - Parkinson's UE-R;;ACTIVE;2.36;2.71 +66193-4;Rigidity;Find;Pt;Upper extremity.left;Ord;UPDRS;UPDRS;2;Rigidity Upper extremity - left [UPDRS];Rigidity - Parkinson's UE-L;;ACTIVE;2.36;2.71 +66194-2;Rigidity;Find;Pt;Lower extremity.right;Ord;UPDRS;UPDRS;2;Rigidity Lower extremity - right [UPDRS];Rigidity - Parkinson's LE-R;;ACTIVE;2.36;2.71 +66195-9;Rigidity;Find;Pt;Lower extremity.left;Ord;UPDRS;UPDRS;2;Rigidity Lower extremity - left [UPDRS];Rigidity - Parkinson's LE-L;;ACTIVE;2.36;2.71 +66196-7;Postural tremor;Find;Pt;Upper extremity.left;Ord;UPDRS;UPDRS;2;Postural tremor Upper extremity - left [UPDRS];Postural tremor UE-L UPDRS;;ACTIVE;2.36;2.71 +66197-5;Injury sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Injury sequence [PhenX];Injury sequence PhenX;;TRIAL;2.36;2.65 +66200-7;Repeatability of the assay;Ratio;Pt;^Patient;Qn;PhenX;PHENX;2;Repeatability of the assay [Ratio] [PhenX];Assay repeatability PhenX;;TRIAL;2.36;2.65 +66201-5;Coefficient of variation for the assay;Ratio;Pt;^Patient;Qn;;DEVICES;2;Coefficient of variation for the assay;Coefficient of variation;;TRIAL;2.36;2.72 +66202-3;Was the participant fasting;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was the participant fasting [PhenX];Participant fasting PhenX;;TRIAL;2.36;2.65 +66203-1;Amount of dextrose solution administered;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Amount of dextrose solution administered [#] [PhenX];Amount of dextrose solution PhenX;;TRIAL;2.36;2.65 +66204-9;Amount of dextrose solution the participant drank;Num;Pt;^Patient;Ord;PhenX;PHENX;2;Amount of dextrose solution the participant drank [PhenX];Amount of dextrose consumed PhenX;;TRIAL;2.36;2.65 +66205-6;Was all of the solution was consumed in 10M;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was all of the solution was consumed in 10 minutes [PhenX];All solution consumed 10M PhenX;;TRIAL;2.36;2.65 +66206-4;Time between consuming dextrose solution and administering the second blood draw;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time between consuming dextrose solution and administering the second blood draw [PhenX];Ms between dextrose blood draw PhenX;;TRIAL;2.36;2.65 +66208-0;Make of the equipment used;ID;Pt;^Patient;Nom;PhenX;DEVICES;2;Make of the equipment used [Identifier] [PhenX];Make of equipment used PhenX;;TRIAL;2.36;2.66 +6620-9;Acanthamoeba sp Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Acanthamoeba sp Ab [Presence] in Cerebral spinal fluid by Immunoassay;Acanthamoeba Ab CSF Ql IA;;ACTIVE;1.0g;2.56 +66209-8;Manufacturer of the equipment used;ID;Pt;^Patient;Nom;PhenX;DEVICES;2;Deprecated Manufacturer of the equipment used PhenX [Identifier] [PhenX];Deprecated Manufacturer of equipment used PhenX;;DEPRECATED;2.36;2.67 +66210-6;Time to complete entire 1 mile walk;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time to complete entire 1 mile walk [PhenX];Time to complete walk PhenX;;TRIAL;2.38;2.65 +66211-4;Treadmill speed during warm up;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;Treadmill speed during warm up [PhenX];Treadmill speed nRate PhenX;;TRIAL;2.38;2.65 +66212-2;Push-ups;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Push-ups [#] [PhenX];Push-ups PhenX;;TRIAL;2.38;2.65 +66213-0;Sit and reach stretch distance;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Sit and reach stretch distance [PhenX];Location fingertips stretch PhenX;;TRIAL;2.38;2.65 +66214-8;Trial attempt;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Trial attempt [PhenX];Trial attempt PhenX;;TRIAL;2.38;2.65 +66215-5;Inches person is short of reaching the toe, a minus score, or reaches beyond the toe, a plus score;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Inches person is short of reaching the toe, a minus score, or reaches beyond the toe, a plus score [PhenX];Chair reach distance PhenX;;TRIAL;2.38;2.65 +66216-3;Distance of overlap or distance between the tips of the middle fingers;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Distance of overlap or distance between the tips of the middle fingers [PhenX];Back scratch distance PhenX;;TRIAL;2.38;2.65 +6621-7;Leishmania sp Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Leishmania sp Ab [Presence] in Serum by Immunofluorescence;Leishmania Ab Ser Ql IF;;ACTIVE;1.0g;2.56 +66217-1;Time to rise from chair, walk 8 feet and back, and return to sitting;Time;Pt;^Patient;Qn;8UG;H&P.PX;2;Time to rise from chair, walk 8 feet and back, and return to sitting 8UG;Time rise, walk 8ft, return sitting 8UG;;ACTIVE;2.38;2.67 +66218-9;Length of laps;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Length of laps [PhenX];Length of laps PhenX;;TRIAL;2.38;2.65 +66219-7;Time to complete entire 1 mile run;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time to complete entire 1 mile run [PhenX];Time complete run PhenX;;TRIAL;2.38;2.65 +66220-5;Curl-ups;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Curl-ups [#] [PhenX];Curl-ups PhenX;;TRIAL;2.38;2.65 +66221-3;Floor to the childs chin;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Floor to the childs chin [Length] [PhenX];Distance to chin PhenX;;TRIAL;2.38;2.65 +66222-1;Time child retains position;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time child retains position [PhenX];Flexed arm hang PhenX;;TRIAL;2.38;2.65 +66223-9;Modified pull-ups;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Modified pull-ups [#] [PhenX];Modified pull-ups PhenX;;TRIAL;2.38;2.65 +66224-7;Distance reached;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Distance reached [PhenX];Distance reached PhenX;;TRIAL;2.38;2.65 +6622-5;Leishmania sp Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Leishmania sp Ab [Presence] in Serum by Hemagglutination;Leishmania Ab Ser Ql HA;;ACTIVE;1.0g;2.56 +66225-4;Fingertips touch with left arm behind the back and right arm behind the head;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Fingertips touch with left arm behind the back and right arm behind the head [PhenX];Shoulder stretch - left PhenX;;TRIAL;2.38;2.65 +66226-2;Which hand;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Which hand [PhenX];Which hand PhenX;;TRIAL;2.38;2.65 +66227-0;Has any pain or arthritis in your hand gotten worse recently;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has any pain or arthritis in your hand gotten worse recently [PhenX];Pain hand worse PhenX;;TRIAL;2.38;2.65 +66228-8;Will the pain keep you from squeezing as hard as you can;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Will the pain keep you from squeezing as hard as you can [PhenX];Pain prevent squeeze PhenX;;TRIAL;2.38;2.65 +66229-6;Have you had any surgery on your hands or wrists in the past 3Mo;Find;3Mo;^Patient;Ord;PhenX;PHENX;2;Have you had any surgery on your hands or wrists in the past 3 months [PhenX];Surgery hand past 3Mo PhenX;;TRIAL;2.38;2.65 +66230-4;Hand trial;Force;Pt;Hand.right;Qn;PhenX;PHENX;2;Hand trial Hand - right [PhenX];Hand trial Hand-R PhenX;;TRIAL;2.38;2.65 +66231-2;Reason did not squeeze;Find;Pt;Hand.right;Nom;PhenX;PHENX;2;Reason did not squeeze Hand - right [PhenX];Reason not squeeze Hand-R PhenX;;TRIAL;2.38;2.65 +66232-0;Reason did not squeeze;Find;Pt;Hand.left;Nom;PhenX;PHENX;2;Reason did not squeeze Hand - left [PhenX];Reason not squeeze Hand-L PhenX;;TRIAL;2.38;2.65 +6623-3;Leishmania sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Leishmania sp Ab [Presence] in Serum by Complement fixation;Leishmania Ab Ser Ql CF;;ACTIVE;1.0g;2.56 +66233-8;Has your doctor ever said that you have a heart condition and that you should only do physical activity recommended by a doctor;Find;Pt;^Patient;Ord;rPARQ;PHENX;2;Has your doctor ever said that you have a heart condition and that you should only do physical activity recommended by a doctor [Revised PARQ];Heart condition rPARQ;;ACTIVE;2.38;2.61 +66234-6;Do you feel pain in your chest when you do physical activity;Find;Pt;^Patient;Ord;rPARQ;PHENX;2;Do you feel pain in your chest when you do physical activity [Revised PARQ];Chest pain physical activity rPARQ;;ACTIVE;2.38;2.61 +66235-3;In the past Mo, have you had chest pain when you were not doing physical activity;Find;1Mo;^Patient;Ord;rPARQ;PHENX;2;In the past Mo, have you had chest pain when you were not doing physical activity [Revised PARQ];Chest pain past Mo rPARQ;;ACTIVE;2.38;2.61 +66236-1;Do you lose your balance because of dizziness or do you ever lose consciousness;Find;Pt;^Patient;Ord;rPARQ;PHENX;2;Do you lose your balance because of dizziness or do you ever lose consciousness [Revised PARQ];Lose balance rPARQ;;ACTIVE;2.38;2.61 +66237-9;Do you have a bone or joint problem, for example, back, knee or hip, that could be made worse by a change in your physical activity;Find;Pt;^Patient;Ord;rPARQ;PHENX;2;Do you have a bone or joint problem, for example, back, knee or hip, that could be made worse by a change in your physical activity [Revised PARQ];Bone joint problem rPARQ;;ACTIVE;2.38;2.61 +66238-7;Is your doctor currently prescribing drugs, for example, water pills, for your blood pressure or heart condition;Find;Pt;^Patient;Ord;rPARQ;PHENX;2;Is your doctor currently prescribing drugs, for example, water pills, for your blood pressure or heart condition [Revised PARQ];Prescribed drugs rPARQ;;ACTIVE;2.38;2.61 +66239-5;Do you know of any other reason why you should not do physical activity;Find;Pt;^Patient;Ord;rPARQ;PHENX;2;Do you know of any other reason why you should not do physical activity [Revised PARQ];Other reason no physical activity rPARQ;;ACTIVE;2.38;2.61 +66240-3;Blood draw;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Blood draw [PhenX];Blood draw PhenX;;TRIAL;2.36;2.65 +6624-1;Naegleria fowleri Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Naegleria fowleri Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;N fowleri Ab CSF Ql IF;;ACTIVE;1.0g;2.56 +66241-1;Stretch attempt;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Stretch attempt [PhenX];Stretch attempt PhenX;;TRIAL;2.38;2.65 +66242-9;Half sit-ups;NRat;30S;^Patient;Qn;PhenX;PHENX;2;Half sit-ups 30 seconds [PhenX];Half sit-ups 30S nRate PhenX;;TRIAL;2.38;2.65 +66243-7;Fingertips touch with right arm behind the back and left arm behind the head;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Fingertips touch with right arm behind the back and left arm behind the head [PhenX];Shoulder Stretch - right PhenX;;TRIAL;2.38;2.65 +66245-2;Yards walked;NRat;6M;^Patient;Qn;PhenX;PHENX;2;Yards walked 6 minutes [PhenX];Yards walked 6M nRate PhenX;;TRIAL;2.38;2.65 +66246-0;Reaches the minimum height;Num;2M;Knee.right;Qn;PhenX;PHENX;2;Reaches the minimum height [#] 2 minutes Knee - right [PhenX];Knee reach minimum ht 2M Knee-R PhenX;;TRIAL;2.38;2.65 +66247-8;Sit to stand;NRat;30S;^Patient;Qn;;H&P.PX;2;Sit to stand frequency in 30 seconds;Sit to stand # in 30s;;ACTIVE;2.38;2.67 +66248-6;Balance test;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Balance test [PhenX];Balance test PhenX;;TRIAL;2.38;2.65 +66249-4;Balance test score;Score;Pt;^Patient;Ord;PhenX;PHENX;2;Balance test score [PhenX];Balance test score PhenX;;TRIAL;2.38;2.65 +66250-2;Why participant did not attempt test or failed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Why participant did not attempt test or failed [PhenX];Why not attempt test failed PhenX;;TRIAL;2.38;2.65 +66251-0;Other reason not attempt test or failed;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other reason not attempt test or failed [PhenX];Reason not attempt test PhenX;;TRIAL;2.38;2.65 +66252-8;Seconds held, if less than 10S;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Seconds held, if less than 10 seconds [PhenX];Seconds held PhenX;;TRIAL;2.38;2.65 +66253-6;Total balance tests score;Score;Pt;^Patient;Qn;PhenX;PHENX;2;Total balance tests score [PhenX];Total balance tests score PhenX;;TRIAL;2.38;2.65 +66254-4;Walk test course;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Walk test course [Length] [PhenX];Walk test course PhenX;;TRIAL;2.38;2.65 +66255-1;Time for 3 or 4 meters;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time for 3 or 4 meters [PhenX];3 or 4 meters time PhenX;;TRIAL;2.38;2.65 +66256-9;Aids for the walk;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Aids for the walk [PhenX];Aids for walk PhenX;;TRIAL;2.38;2.65 +66257-7;Shorter of the two times;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Shorter of the two times [PhenX];Shorter of two times PhenX;;TRIAL;2.38;2.65 +6625-8;Naegleria fowleri Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Naegleria fowleri Ab [Presence] in Cerebral spinal fluid by Immunoassay;N fowleri Ab CSF Ql IA;;ACTIVE;1.0g;2.56 +66258-5;Points for 4-meter walk;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Points for 4-meter walk [#] [PhenX];4 meter walk points PhenX;;TRIAL;2.38;2.65 +66259-3;Points for 3-meter walk;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Points for 3-meter walk [#] [PhenX];3-meter walk points PhenX;;TRIAL;2.38;2.65 +66260-1;Safe to stand without help;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Safe to stand without help [PhenX];Safe to stand PhenX;;TRIAL;2.38;2.65 +66261-9;Stood without using arms;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Stood without using arms [PhenX];Stood W/O using arms PhenX;;TRIAL;2.38;2.65 +66262-7;Used arms to stand;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Used arms to stand [PhenX];Used arms to stand PhenX;;TRIAL;2.38;2.65 +66263-5;Test not completed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Test not completed [PhenX];Test not completed PhenX;;TRIAL;2.38;2.65 +66264-3;Safe to stand five times;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Safe to stand five times [PhenX];Safe to stand 5x PhenX;;TRIAL;2.38;2.65 +66265-0;Sedentary adolescent activity;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Sedentary adolescent activity [PhenX];Sedentary adoles activity PhenX;;TRIAL;2.38;2.65 +6626-6;Schistosoma japonicum Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Schistosoma japonicum Ab [Titer] in Serum by Complement fixation;S japonicum Ab Titr Ser CF;;ACTIVE;1.0g;2.70 +66266-8;How long you spend doing this activity on this D;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How long you spend doing this activity on this day [PhenX];This activity time nRate PhenX;;TRIAL;2.38;2.65 +66267-6;Time period;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time period [PhenX];Time period PhenX;;TRIAL;2.38;2.65 +66268-4;Adolescent activity;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Adolescent activity [PhenX];Adolescent activity PhenX;;TRIAL;2.38;2.65 +66269-2;Number that corresponds to the main activity you actually performed during that particular time period;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Number that corresponds to the main activity you actually performed during that particular time period [PhenX];#main activity PhenX;;TRIAL;2.38;2.65 +662-7;Microscopic observation;Prid;Pt;XXX;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Giemsa stain;Gie Stn Spec;;ACTIVE;1.0;2.73 +66270-0;Activity intensity;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Activity intensity [PhenX];Activity intensity PhenX;;TRIAL;2.38;2.65 +66271-8;Were you employed in the last 7D;Find;7D;^Patient;Ord;PhenX;PHENX;2;Were you employed in the last 7 days [PhenX];Employed in last 7D PhenX;;TRIAL;2.38;2.65 +66272-6;If yes, which Ds;Type;Pt;^Patient;Nom;PhenX;PHENX;2;If yes, which days [PhenX];Which Ds PhenX;;TRIAL;2.38;2.65 +66273-4;What two Ds do you consider your weekend Ds;Type;Pt;^Patient;Nom;PhenX;PHENX;2;What two days do you consider your weekend days [PhenX];What Ds weekend PhenX;;TRIAL;2.38;2.65 +6627-4;Schistosoma mansoni Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Schistosoma mansoni Ab [Presence] in Serum by Immunoassay;S mansoni Ab Ser Ql IA;;ACTIVE;1.0g;2.56 +66274-2;Adult activity;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Adult activity [PhenX];Adult activity PhenX;;TRIAL;2.38;2.65 +66275-9;Day sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Day sequence [PhenX];Day sequence PhenX;;TRIAL;2.38;2.65 +66276-7;Day name;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Day name [PhenX];Day name PhenX;;TRIAL;2.38;2.65 +66277-5;Time adult activity starts;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time adult activity starts [PhenX];Adult activity start PhenX;;TRIAL;2.38;2.65 +66278-3;Time adult activity ends;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time adult activity ends [PhenX];Adult activity end PhenX;;TRIAL;2.38;2.65 +66279-1;Total time of adult activity;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;Total time of adult activity [PhenX];Adult activity total time nRate PhenX;;TRIAL;2.38;2.65 +66280-9;Name;ID;Pt;School;Nom;;ADMIN.FACILITY;2;School Name;School Name;;ACTIVE;2.38;2.66 +66281-7;Compared to your physical activity over the past 3Mo, was last week's physical activity more, less, or about the same;Find;3Mo;^Patient;Ord;PhenX;PHENX;2;Compared to your physical activity over the past 3 months, was last week's physical activity more, less, or about the same [PhenX];Physical activity comparison PhenX;;TRIAL;2.38;2.65 +6628-2;Schistosoma sp Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Schistosoma sp Ab [Presence] in Serum by Immunofluorescence;Schistosoma Ab Ser Ql IF;;ACTIVE;1.0g;2.56 +66282-5;Day segment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Day segment [PhenX];Day segment PhenX;;TRIAL;2.38;2.65 +66283-3;Older adult activity;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Older adult activity [PhenX];Older adult activity PhenX;;TRIAL;2.38;2.65 +66284-1;In a typical W, during the past 4W, did you do this activity;Find;4W;^Patient;Ord;PhenX;PHENX;2;In a typical week, during the past 4 weeks, did you do this activity [PhenX];Activity done past 4W PhenX;;TRIAL;2.38;2.65 +66285-8;How many total Hs a W did you usually do it;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;How many total hours a week did you usually do it [PhenX];Activity total Hs nRate PhenX;;TRIAL;2.38;2.65 +66286-6;Other type of physical activity;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other type of physical activity [PhenX];Other physical activity PhenX;;TRIAL;2.38;2.65 +66287-4;Problems with the 7D PAR interview;Find;Pt;^Observer;Ord;PhenX;PHENX;2;Problems with the 7 days PAR interview Observer [PhenX];Problems with 7D PAR Observer PhenX;;TRIAL;2.38;2.65 +66288-2;Problem with 7D interview;Txt;Pt;^Observer;Nom;PhenX;PHENX;2;Problem with 7 days interview [Text] Observer [PhenX];Problem 7D specify Observer PhenX;;TRIAL;2.38;2.65 +66289-0;Do you think this was a valid 7D PAR interview;Find;Pt;^Observer;Ord;PhenX;PHENX;2;Do you think this was a valid 7 days PAR interview Observer [PhenX];Valid 7D PAR Observer PhenX;;TRIAL;2.38;2.65 +6629-0;Schistosoma sp Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Schistosoma sp Ab [Presence] in Serum by Immunoassay;Schistosoma Ab Ser Ql IA;;ACTIVE;1.0g;2.73 +66290-8;Reason not a valid 7D PAR interview;Txt;Pt;^Observer;Nom;PhenX;PHENX;2;Reason not a valid 7 days PAR interview [Text] Observer [PhenX];Not valid 7D PAR Observer PhenX;;TRIAL;2.38;2.65 +66293-2;Situations you spend sitting;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Situations you spend sitting [PhenX];Situations sitting PhenX;;TRIAL;2.38;2.65 +66294-0;H sitting each D in this situation;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;Hours sitting each day in this situation [PhenX];Sitting H per D nRate PhenX;;TRIAL;2.38;2.65 +66295-7;Did the participant receive an actigraph;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did the participant receive an actigraph [PhenX];Received AG PhenX;;TRIAL;2.38;2.65 +66296-5;Last four digits of actigraph serial number;ID;Pt;^Patient;Nom;PhenX;PHENX;2;Last four digits of actigraph serial number [PhenX];Last 4 digits of AG serial number PhenX;;TRIAL;2.38;2.65 +66297-3;Why didnt the participant receive an actigraph;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Why didnt the participant receive an actigraph [PhenX];Why didnt receive AG PhenX;;TRIAL;2.38;2.65 +66299-9;Other physical or medical problem;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Other physical or medical problem [PhenX];Other physical or medical problem PhenX;;TRIAL;2.38;2.65 +66300-5;Actigraph is connected to USB cable;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Actigraph is connected to USB cable [PhenX];AG is connected to USB cable PhenX;;TRIAL;2.38;2.65 +66301-3;Actigraph set up for free-living;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Actigraph set up for free-living [PhenX];AG set up for free-living PhenX;;TRIAL;2.38;2.65 +66302-1;Participant ID;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Participant [Identifier];Participant ID;;ACTIVE;2.38;2.66 +66303-9;Actigraph disconnected from USB cable and OK clicked;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Actigraph disconnected from USB cable and OK clicked [PhenX];AG disconnected from USB cable PhenX;;TRIAL;2.38;2.65 +66304-7;Participant instructed about how to wear actigraph;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Participant instructed about how to wear actigraph [PhenX];AG wear instructions PhenX;;TRIAL;2.38;2.65 +66305-4;Actigraph placed as close to iliac crest as possible;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Actigraph placed as close to iliac crest as possible [PhenX];AG placed close to IC PhenX;;TRIAL;2.38;2.65 +66306-2;Procedure for completing 7D activity diary explained to participant;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Procedure for completing 7 days activity diary explained to participant [PhenX];QA distribution 7D activity diary PhenX;;TRIAL;2.38;2.65 +66307-0;Procedure for returning actigraph explained to participant;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Procedure for returning actigraph explained to participant [PhenX];AG return procedure explained PhenX;;TRIAL;2.38;2.65 +6630-8;Schistosoma sp Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Schistosoma sp Ab [Presence] in Serum by Hemagglutination;Schistosoma Ab Ser Ql HA;;ACTIVE;1.0g;2.56 +66308-8;Participant asked if they have any questions;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Participant asked if they have any questions [PhenX];QA distribution questions PhenX;;TRIAL;2.38;2.65 +66309-6;Fills out actigraph distribution form;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Fills out actigraph distribution form [PhenX];AG distribution form PhenX;;TRIAL;2.38;2.65 +66310-4;Reviews form for completeness;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Reviews form for completeness [PhenX];QA actigraph review form PhenX;;TRIAL;2.38;2.65 +66311-2;Date participant returned actigraph to clinic;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date participant returned actigraph to clinic [PhenX];Date AG returned PhenX;;TRIAL;2.38;2.65 +66312-0;Returned actigraph;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Returned actigraph [PhenX];Returned AG PhenX;;TRIAL;2.38;2.65 +66313-8;How many Ds was actigraph worn;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many days was actigraph worn [#] [PhenX];# D AG worn PhenX;;TRIAL;2.38;2.65 +66314-6;How many of the Ds that the actiGraph was worn were valid;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of the days that the actiGraph was worn were valid [#] [PhenX];# D AG worn valid PhenX;;TRIAL;2.38;2.65 +66315-3;Activity collected and recorded on the actigraph;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Activity collected and recorded on the actigraph [PhenX];Activity collected/recorded on AG PhenX;;TRIAL;2.38;2.65 +6631-6;Schistosoma sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Schistosoma sp Ab [Presence] in Serum by Complement fixation;Schistosoma Ab Ser Ql CF;;ACTIVE;1.0g;2.56 +66316-1;Reason no activity collected and recorded on the actigraph;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Reason no activity collected and recorded on the actigraph [PhenX];Reason no record on AG PhenX;;TRIAL;2.38;2.65 +66317-9;Other reason no activity collected and recorded on actigraph;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other reason no activity collected and recorded on actigraph [PhenX];Othr reason no record on AG PhenX;;TRIAL;2.38;2.65 +66318-7;Diary completed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Diary completed [PhenX];Diary completed PhenX;;TRIAL;2.38;2.65 +66319-5;Actigraph properly connected to USB cable;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Actigraph properly connected to USB cable [PhenX];AG properly connected to USB cable PhenX;;TRIAL;2.38;2.65 +66320-3;Download button clicked on actiweb client software;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Download button clicked on actiweb client software [PhenX];QA return download button PhenX;;TRIAL;2.38;2.65 +66321-1;Data saved properly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Data saved properly [PhenX];Data saved properly PhenX;;TRIAL;2.38;2.65 +66322-9;Reviews activity diary to see if completely filled out, partially filled out, or not filled out at all;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Reviews activity diary to see if completely filled out, partially filled out, or not filled out at all [PhenX];QA return review diary PhenX;;TRIAL;2.38;2.65 +66323-7;Correctly enters activities on computer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Correctly enters activities on computer [PhenX];QA return enter activity computer PhenX;;TRIAL;2.38;2.65 +6632-4;Strongyloides stercoralis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Strongyloides stercoralis IgG Ab [Presence] in Serum by Immunoassay;S stercoralis IgG Ser Ql IA;;ACTIVE;1.0g;2.73 +66324-5;Records how many Ds the actigraph was worn on actigraph return and reading form;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Records how many days the actigraph was worn on actigraph return and reading form [PhenX];# D AG was worn on PhenX;;TRIAL;2.38;2.65 +66325-2;Records how many valid Ds the actigraph was worn on actigraph return and reading form;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Records how many valid days the actigraph was worn on actigraph return and reading form [PhenX];# valid D AG was worn PhenX;;TRIAL;2.38;2.65 +66326-0;Records whether diary was completed partially, fully, or not at all on the actiGraph return and reading form;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Records whether diary was completed partially, fully, or not at all on the actiGraph return and reading form [PhenX];Diary completed on form PhenX;;TRIAL;2.38;2.65 +66327-8;Took monitor off;ClockTime;Pt;^Patient;Qn;PhenX;PHENX;2;Took monitor off [Clock time] [PhenX];Took monitor off Clock time PhenX;;TRIAL;2.38;2.65 +66328-6;Activity while not wearing monitor;Txt;Pt;^Patient;Nom;PhenX;PHENX;2;Activity while not wearing monitor [Text] [PhenX];Diary time off activity PhenX;;TRIAL;2.38;2.65 +66329-4;Monitor put back on;ClockTime;Pt;^Patient;Qn;PhenX;PHENX;2;Monitor put back on [Clock time] [PhenX];Monitor put back on Clock time PhenX;;TRIAL;2.38;2.65 +66330-2;About how much weight did you gain and lose;Mass;Pt;^Patient;Qn;QIDS;PHENX;2;About how much weight did you gain and lose [Mass] [QIDS];Depression wt gain loss QIDS;;ACTIVE;2.38;2.65 +66331-0;Hand trial;Force;Pt;Hand.left;Qn;PhenX;PHENX;2;Hand trial Hand - left [PhenX];Hand trial Hand-L PhenX;;TRIAL;2.38;2.65 +6633-2;Wuchereria bancrofti Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Wuchereria bancrofti Ab [Presence] in Serum by Immunoassay;W bancr Ab Ser Ql IA;;ACTIVE;1.0g;2.56 +66332-8;End time - right before going to sleep;ClockTime;Pt;^Patient;Qn;PhenX;PHENX;2;End time - right before going to sleep [PhenX];Diary end time Clock time PhenX;;TRIAL;2.38;2.65 +66333-6;Kinds of physical activity you usually performed while on the job this last Y;Find;1Y;^Patient;Nom;PhenX;PHENX;2;Kinds of physical activity you usually performed while on the job this last year [PhenX];On job activity PhenX;;TRIAL;2.38;2.65 +66334-4;Steps taken;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Steps taken [#] [PhenX];Steps taken PhenX;;TRIAL;2.38;2.65 +66336-9;Framingham Risk Assessments;-;Pt;^Patient;-;Framingham;PANEL.CV;2;Framingham Risk Assessments Framingham;Framingham Risk Assess;;ACTIVE;2.36;2.73 +66337-7;Kinds of physical activity you usually performed during leisure time this last Y;Find;1Y;^Patient;Nom;PhenX;PHENX;2;Kinds of physical activity you usually performed during leisure time this last year [PhenX];Leisure activities PhenX;;TRIAL;2.38;2.58 +66338-5;How much difficulty do you have managing your money, such as keeping track of your expenses or paying bills;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have managing your money, such as keeping track of your expenses or paying bills [PhenX];Managing money PhenX;;TRIAL;2.38;2.65 +66339-3;How much difficulty do you have walking for a quarter of a mile, that is about 2 or 3 blocks;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have walking for a quarter of a mile, that is about 2 or 3 blocks [PhenX];Walking quarter mile PhenX;;TRIAL;2.38;2.72 +6634-0;Influenza virus A Hong Kong Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Hong Kong Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV HK Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66340-1;How much difficulty do you have walking up 10 steps without resting;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have walking up 10 steps without resting [PhenX];Walking up 10 steps PhenX;;TRIAL;2.38;2.65 +66341-9;How much difficulty do you have stooping, crouching, or kneeling;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have stooping, crouching, or kneeling [PhenX];Stooping PhenX;;TRIAL;2.38;2.65 +66342-7;How much difficulty do you have lifting or carrying something as heavy as 10 pounds, like a sack of potatoes or rice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have lifting or carrying something as heavy as 10 pounds, like a sack of potatoes or rice [PhenX];Lifting 10 pounds PhenX;;TRIAL;2.38;2.65 +66343-5;How much difficulty do you have doing chores around the house, like vacuuming, sweeping, dusting or straightening up;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have doing chores around the house, like vacuuming, sweeping, dusting or straightening up [PhenX];Doing house chores PhenX;;TRIAL;2.38;2.65 +66344-3;How much difficulty do you have preparing your own meals;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have preparing your own meals [PhenX];Preparing meals PhenX;;TRIAL;2.38;2.65 +66345-0;How much difficulty do you have standing up from an armless straight chair;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have standing up from an armless straight chair [PhenX];Standing armless chair PhenX;;TRIAL;2.38;2.65 +66346-8;How much difficulty do you have getting in or out of bed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have getting in or out of bed [PhenX];Getting out of bed PhenX;;TRIAL;2.38;2.65 +66347-6;How much difficulty do you have eating, like holding a fork, cutting food or drinking from a glass;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have eating, like holding a fork, cutting food or drinking from a glass [PhenX];Eating PhenX;;TRIAL;2.38;2.65 +66348-4;How much difficulty do you have dressing yourself, including tying shoes, working zippers, and doing buttons;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have dressing yourself, including tying shoes, working zippers, and doing buttons [PhenX];Dressing PhenX;;TRIAL;2.38;2.65 +66349-2;How much difficulty do you have sitting for about 2H;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have sitting for about 2 hours [PhenX];Sitting 2h PhenX;;TRIAL;2.38;2.65 +663-5;Microscopic observation;Prid;Pt;XXX;Nom;Gimenez stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Gimenez stain;Gimenez Stn Spec;;ACTIVE;1.0;2.69 +66350-0;How much difficulty do you have reaching up over your head;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have reaching up over your head [PhenX];Reaching over head PhenX;;TRIAL;2.38;2.65 +66351-8;How much difficulty do you have using your fingers to grasp or handle small objects;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have using your fingers to grasp or handle small objects [PhenX];Using fingers small objects PhenX;;TRIAL;2.38;2.65 +66352-6;How much difficulty do you have going out to things like shopping, movies, or sporting events;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have going out to things like shopping, movies, or sporting events [PhenX];Going out PhenX;;TRIAL;2.38;2.73 +66353-4;How much difficulty do you have participating in social activities, visiting friends, attending clubs or meetings or going to parties;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have participating in social activities, visiting friends, attending clubs or meetings or going to parties [PhenX];Social activities PhenX;;TRIAL;2.38;2.65 +66354-2;How much difficulty do you have doing things to relax at home or for leisure, reading, watching TV, sewing, listening to music;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have doing things to relax at home or for leisure, reading, watching TV, sewing, listening to music [PhenX];Leisure PhenX;;TRIAL;2.38;2.65 +66355-9;How much difficulty do you have pushing or pulling large objects like a living room chair;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have pushing or pulling large objects like a living room chair [PhenX];Pushing pulling large objects PhenX;;TRIAL;2.38;2.65 +66356-7;What is the main type of housing in your neighborhood;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What is the main type of housing in your neighborhood [PhenX];Neighborhood housing main type PhenX;;TRIAL;2.38;2.65 +6635-7;Influenza virus A England Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A England Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Eng Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66357-5;Many shops, stores, markets, or other places to buy things I need are within easy walking distance of my home;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Many shops, stores, markets, or other places to buy things I need are within easy walking distance of my home [PhenX];Shops walking distance PhenX;;TRIAL;2.38;2.65 +66358-3;It is within a 10-15M walk to a transit stop, such as bus, train, trolley, or tram, from my home;Find;Pt;^Patient;Ord;PhenX;PHENX;2;It is within a 10-15 minute walk to a transit stop, such as bus, train, trolley, or tram, from my home [PhenX];Transit stop PhenX;;TRIAL;2.38;2.65 +66359-1;There are sidewalks on most of the streets in my neighborhood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;There are sidewalks on most of the streets in my neighborhood [PhenX];Sidewalks PhenX;;TRIAL;2.38;2.65 +66360-9;There are facilities to bicycle in or near my neighborhood, such as special lanes, separate paths or trails, shared use paths for cycles and pedestrians;Find;Pt;^Patient;Ord;PhenX;PHENX;2;There are facilities to bicycle in or near my neighborhood, such as special lanes, separate paths or trails, shared use paths for cycles and pedestrians [PhenX];Bike pedestrian paths PhenX;;TRIAL;2.38;2.65 +66361-7;My neighborhood has several free or low-cost recreation facilities, such as parks, walking trails, bike paths, recreation centers, playgrounds, public swimming pools, etc;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My neighborhood has several free or low-cost recreation facilities, such as parks, walking trails, bike paths, recreation centers, playgrounds, public swimming pools, etc [PhenX];Recreation facilities PhenX;;TRIAL;2.38;2.65 +66362-5;The crime rate in my neighborhood makes it unsafe to go on walks at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The crime rate in my neighborhood makes it unsafe to go on walks at night [PhenX];Crime rate PhenX;;TRIAL;2.38;2.65 +66363-3;I can be physically active during my free time on most Ds;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can be physically active during my free time on most days [PhenX];Physically active free time PhenX;;TRIAL;2.38;2.65 +66364-1;I can ask my parent or other adult to do physically active things with me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can ask my parent or other adult to do physically active things with me [PhenX];Adult physical activity partner PhenX;;TRIAL;2.38;2.65 +6636-5;Influenza virus A Port Chalmers Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Port Chalmers Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Pt Chal Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66365-8;I can be physically active during my free time on most Ds even if I could watch TV or play video games instead;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can be physically active during my free time on most days even if I could watch TV or play video games instead [PhenX];Physically active TV PhenX;;TRIAL;2.38;2.65 +66366-6;I can be physically active during my free time on most Ds even if it is very hot or cold outside;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can be physically active during my free time on most days even if it is very hot or cold outside [PhenX];Physically active weather PhenX;;TRIAL;2.38;2.65 +66367-4;I can ask my best friend to be physically active with me during my free time on most Ds;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can ask my best friend to be physically active with me during my free time on most days [PhenX];Physically active best friend PhenX;;TRIAL;2.38;2.65 +66368-2;I can be physically active during my free time on most Ds even if I have a lot of homework;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can be physically active during my free time on most days even if I have a lot of homework [PhenX];Physically active homework PhenX;;TRIAL;2.38;2.65 +66369-0;I have the coordination I need to be physically active during my free time on most Ds;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I have the coordination I need to be physically active during my free time on most days [PhenX];Physically active coordination PhenX;;TRIAL;2.38;2.65 +66370-8;I can be physically active during my free time on most Ds no matter how busy my D is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I can be physically active during my free time on most days no matter how busy my day is [PhenX];Physically active busy PhenX;;TRIAL;2.38;2.65 +66371-6;Circumstances in which you could exercise 3 time per W in the next 3Mos;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Circumstances in which you could exercise 3 time per week in the next 3 months [PhenX];Exercise circumstances PhenX;;TRIAL;2.38;2.65 +66372-4;Degree of confidence for exercising 3 times per W in the next 3Mo;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Degree of confidence for exercising 3 times per week in the next 3 months [PhenX];Exercise degree of confidence PhenX;;TRIAL;2.38;2.65 +6637-3;Influenza virus A Victoria Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Victoria Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Vic Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66373-2;Are you sick today;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you sick today [PhenX];Sick today PhenX;;TRIAL;2.38;2.65 +66374-0;Do you have allergies to medications, food, or any vaccine;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have allergies to medications, food, or any vaccine [PhenX];Allergies PhenX;;TRIAL;2.38;2.65 +66375-7;Have you ever had a serious reaction after receiving a vaccination;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had a serious reaction after receiving a vaccination [PhenX];Reaction to vaccine PhenX;;TRIAL;2.38;2.65 +66376-5;Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease, diabetes, anemia, or other blood disorder;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease, diabetes, anemia, or other blood disorder [PhenX];Long-term health problem PhenX;;TRIAL;2.38;2.65 +66377-3;Do you have cancer, leukemia, AIDS, or any other immune system problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have cancer, leukemia, AIDS, or any other immune system problem [PhenX];Immune system problem PhenX;;TRIAL;2.38;2.65 +66378-1;Do you take cortisone, predniSONE, other steroids, or anticancer drugs, or have you had radiation treatments;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you take cortisone, prednisone, other steroids, or anticancer drugs, or have you had radiation treatments [PhenX];Steroids anti-CA drugs radiation PhenX;;TRIAL;2.38;2.65 +66379-9;Have you had a seizure, brain, or other nervous system problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had a seizure, brain, or other nervous system problem [PhenX];Nervous system problem PhenX;;TRIAL;2.38;2.65 +66380-7;During the past Y, have you received a transfusion of blood or blood products, or have you been given immune gamma globulin or an antiviral drug;Find;1Y;^Patient;Ord;PhenX;PHENX;2;During the past Y, have you received a transfusion of blood or blood products, or have you been given immune gamma globulin or an antiviral drug [PhenX];Transfus immune globulin antiviral PhenX;;TRIAL;2.38;2.65 +6638-1;Influenza virus A Texas Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Texas Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Tex Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66381-5;Are you pregnant, or is there a chance you could become pregnant during the next Mo;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you pregnant, or is there a chance you could become pregnant during the next month [PhenX];Pregnant PhenX;;TRIAL;2.38;2.65 +66382-3;Have you received any vaccinations in the past 4W;Find;4W;^Patient;Ord;PhenX;PHENX;2;Have you received any vaccinations in the past 4 weeks [PhenX];Vaccinations PhenX;;TRIAL;2.38;2.65 +66383-1;Is the child sick today;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is the child sick today [PhenX];Child sick today PhenX;;TRIAL;2.38;2.65 +66384-9;Does the child have allergies to medications, food, or any vaccine;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does the child have allergies to medications, food, or any vaccine [PhenX];Child allergies PhenX;;TRIAL;2.38;2.65 +66385-6;Has the child had a serious reaction to a vaccine in the past;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has the child had a serious reaction to a vaccine in the past [PhenX];Child vaccine reaction PhenX;;TRIAL;2.38;2.65 +66386-4;Has the child had a seizure or a brain problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has the child had a seizure or a brain problem [PhenX];Child seizure brain problem PhenX;;TRIAL;2.38;2.65 +66387-2;Does the child have cancer, leukemia, AIDS, or any other immune system problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does the child have cancer, leukemia, AIDS, or any other immune system problem [PhenX];Child immune system problem PhenX;;TRIAL;2.38;2.65 +66388-0;Has the child take cortisone, predniSONE, other steroids, or anticancer drugs or had x-ray treatments in the past 3Mo;Find;3Mo;^Patient;Ord;PhenX;PHENX;2;Has the child take cortisone, prednisone, other steroids, or anticancer drugs or had x-ray treatments in the past 3 months [PhenX];Child steroids anti-CA drugs PhenX;;TRIAL;2.38;2.65 +66389-8;Has the child received a transfusion of blood or blood products or been given a medicine called immune gamma globulin in the past Y;Find;1Y;^Patient;Ord;PhenX;PHENX;2;Has the child received a transfusion of blood or blood products or been given a medicine called immune gamma globulin in the past year [PhenX];Child transfusion immune globulin PhenX;;TRIAL;2.38;2.65 +66390-6;Is the child or teen pregnant, or is there a chance she could become pregnant during the next Mo;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is the child or teen pregnant, or is there a chance she could become pregnant during the next month [PhenX];Child pregnant PhenX;;TRIAL;2.38;2.65 +66391-4;Has the child received vaccinations in the past 4W;Find;4W;^Patient;Ord;PhenX;PHENX;2;Has the child received vaccinations in the past 4 weeks [PhenX];Child vaccinations PhenX;;TRIAL;2.38;2.65 +66392-2;Booster sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Booster sequence [PhenX];Booster sequence PhenX;;TRIAL;2.38;2.65 +66393-0;Booster type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Booster type [PhenX];Booster type PhenX;;TRIAL;2.38;2.65 +66394-8;Booster age;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Booster age [PhenX];Booster age PhenX;;TRIAL;2.38;2.65 +66395-5;Booster date;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Booster date [PhenX];Booster date PhenX;;TRIAL;2.38;2.65 +66396-3;Trip number;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Trip number [PhenX];Trip number PhenX;;TRIAL;2.38;2.65 +66397-1;Country number;Find;Pt;^Patient;Nom;;PHENX;2;Country number;Country number;;ACTIVE;2.38;2.52 +66398-9;Trip start;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;Trip start [Date and time] [PhenX];Trip start PhenX;;TRIAL;2.38;2.65 +6639-9;Influenza virus A Bangkok Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Bangkok Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Bang Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66399-7;Trip end;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;Trip end [Date and time] [PhenX];Trip end PhenX;;TRIAL;2.38;2.65 +66400-3;Travelled to country this Y;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Travelled to country this year [PhenX];Travelled this Y PhenX;;TRIAL;2.38;2.65 +66401-1;Travelled to country last Y;Find;1Y;^Patient;Ord;PhenX;PHENX;2;Travelled to country last year [PhenX];Travelled last Y PhenX;;TRIAL;2.38;2.65 +66402-9;Travelled to country 2Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Travelled to country 2 years ago [PhenX];Travelled 2Ys ago PhenX;;TRIAL;2.38;2.65 +66403-7;Travelled to country 3Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Travelled to country 3 years ago [PhenX];Travelled 3Ys ago PhenX;;TRIAL;2.38;2.65 +66404-5;Travelled to country 4Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Travelled to country 4 years ago [PhenX];Travelled 4Ys ago PhenX;;TRIAL;2.38;2.65 +66405-2;Travelled to country 5Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Travelled to country 5 years ago [PhenX];Travelled 5Ys ago PhenX;;TRIAL;2.38;2.65 +66406-0;Stay was longer than 30 consecutive Ds this Y;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Stay was longer than 30 consecutive days this year [PhenX];Stay 30Ds this Y PhenX;;TRIAL;2.38;2.65 +6640-7;Influenza virus A Phillipines Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Phillipines Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Phill Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66407-8;Stay was longer than 30 consecutive Ds last Y;Find;1Y;^Patient;Ord;PhenX;PHENX;2;Stay was longer than 30 consecutive days last year [PhenX];Stay 30Ds last Y PhenX;;TRIAL;2.38;2.65 +66408-6;Stay was longer than 30 consecutive Ds 2Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Stay was longer than 30 consecutive days 2 years ago [PhenX];Stay 30Ds 2Ys ago PhenX;;TRIAL;2.38;2.65 +66409-4;Stay was longer than 30 consecutive Ds 3Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Stay was longer than 30 consecutive days 3 years ago [PhenX];Stay 30Ds 3Ys ago PhenX;;TRIAL;2.38;2.65 +66410-2;Stay was longer than 30 consecutive Ds 4Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Stay was longer than 30 consecutive days 4 years ago [PhenX];Stay 30Ds 4Ys ago PhenX;;TRIAL;2.38;2.65 +66411-0;Stay was longer than 30 consecutive Ds 5Ys ago;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Stay was longer than 30 consecutive days 5 years ago [PhenX];Stay 30Ds 5Ys ago PhenX;;TRIAL;2.38;2.65 +66412-8;Country of exposure - other;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Country of exposure - other [PhenX];Other country exposure PhenX;;TRIAL;2.38;2.65 +66413-6;Country of exposure sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Country of exposure sequence [PhenX];Country exposure sequence PhenX;;TRIAL;2.38;2.65 +66414-4;More specific place of exposure;Find;Pt;^Patient;Nom;PhenX;PHENX;2;More specific place of exposure [PhenX];Specific place exposure PhenX;;TRIAL;2.38;2.65 +6641-5;Influenza virus A Mississippi Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Mississippi Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Miss Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66415-1;Reason for travel related to current illness;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Reason for travel related to current illness [PhenX];Reason for travel PhenX;;TRIAL;2.38;2.65 +66416-9;Risk level qualifier;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Risk level qualifier [PhenX];Risk level qualifier PhenX;;TRIAL;2.38;2.65 +66417-7;Clinical setting;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Clinical setting [PhenX];Clinical setting PhenX;;TRIAL;2.38;2.65 +66418-5;Patient type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Patient type [PhenX];Patient type PhenX;;TRIAL;2.38;2.73 +66419-3;Did the patient have a pre-travel encounter with a health care provider;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did the patient have a pre-travel encounter with a health care provider [PhenX];Pre-travel health provider PhenX;;TRIAL;2.38;2.65 +66420-1;Abnormal lab test;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Abnormal lab test [PhenX];Abnormal lab test PhenX;;TRIAL;2.38;2.65 +66421-9;Asymptomatic screening;Find;Pt;^Patient;Ord;;PHENX;2;Asymptomatic screening;Asymptomatic screening;;TRIAL;2.38;2.71 +66422-7;Main presenting symptom;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Main presenting symptom [PhenX];Main presenting symptom PhenX;;TRIAL;2.38;2.65 +6642-3;Influenza virus A Leningrad Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Influenza virus A Leningrad Ab [Units/volume] in Serum by Hemagglutination inhibition;FLUAV Lenin Ab Ser HAI-aCnc;;ACTIVE;1.0g;2.69 +66423-5;Medications;Find;Pt;Medication.current;Nom;;PHENX;2;Medications Current medication;Medications Medication.current;;ACTIVE;2.36;2.74 +66424-3;Medication strength;Dosage;Pt;Medication.current;Qn;PhenX;PHENX;2;Medication strength [Dosage] Current medication [PhenX];Med strength Medication.current PhenX;;TRIAL;2.36;2.65 +66425-0;Number of medication items prescribed;Num;Pt;Medication.current;Qn;PhenX;PHENX;2;Number of medication items prescribed Current medication [PhenX];# meds Medication.current PhenX;;TRIAL;2.36;2.65 +66426-8;PRN medicine;Find;Pt;Medication.current;Ord;PhenX;PHENX;2;PRN medicine Current medication [PhenX];PRN medicine Medication.current PhenX;;TRIAL;2.36;2.65 +66427-6;Main presenting symptom, if other;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Main presenting symptom, if other [PhenX];Presenting symptom other PhenX;;TRIAL;2.38;2.65 +66428-4;Working diagnosis number;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Working diagnosis number [PhenX];Working Dx number PhenX;;TRIAL;2.38;2.65 +66429-2;Working diagnosis status;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Working diagnosis status [PhenX];Working Dx status PhenX;;TRIAL;2.38;2.65 +664-3;Microscopic observation;Prid;Pt;XXX;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Gram stain;Gram Stn Spec;;ACTIVE;1.0;2.73 +66430-0;Infection or disease not travel related;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Infection or disease not travel related [PhenX];Disease not travel related PhenX;;TRIAL;2.38;2.65 +6643-1;Cefepime;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefepime [Susceptibility] by Minimum lethal concentration (MLC);Cefepime Islt MLC;;ACTIVE;1.0g;2.19 +66431-8;Symptoms & diseases;Hx;Pt;XXX;Nar;;PHENX;2;History of disorders;Hx of disorders;;ACTIVE;2.38;2.69 +66432-6;Date first Dx;Date;Pt;XXX;Qn;;PHENX;2;Date first Dx;Date first Dx;;TRIAL;2.38;2.69 +66433-4;How much difficulty do you have standing or being on your feet for about 2Hs;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much difficulty do you have standing or being on your feet for about 2 hourss [PhenX];Standing 2hs PhenX;;TRIAL;2.38;2.65 +66434-2;Inflammatory disorder;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Inflammatory disorder [PhenX];Inflammatory disorder PhenX;;TRIAL;2.38;2.65 +66435-9;Autoimmune disease;Find;Pt;^Family member;Nom;PhenX;PHENX;2;Autoimmune disease Family member [PhenX];Autoimmune disease Fam Mem PhenX;;TRIAL;2.38;2.65 +66436-7;Health problem sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Health problem sequence [PhenX];Health problem sequence PhenX;;TRIAL;2.38;2.65 +66440-9;Heart rate;NRat;10M^mean;XXX;Qn;Palpation;PHENX;2;Heart rate 10 minutes mean [palpation];Heart rate 10M Mean Palpation;;ACTIVE;2.38;2.44 +66441-7;Beta hydroxybutyrate;SCnc;Pt;Bld;Qn;Test strip;CHEM;1;Beta hydroxybutyrate [Moles/volume] in Blood by Test strip;B-OH-Butyr Bld Strip-sCnc;;ACTIVE;2.38;2.73 +66444-1;Blatella germanica recombinant (rBla g) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach recombinant (rBla g) 4 IgE Ab [Units/volume] in Serum;Roach (rBla g) 4 IgE Qn;;ACTIVE;2.38;2.70 +66445-8;Cyprinus carpio recombinant (rCyp c) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cyprinus carpio recombinant (rCyp c) 1 IgE Ab [Units/volume] in Serum;Carp (rCyp c) 1 IgE Qn;;ACTIVE;2.38;2.72 +66446-6;Daucus carota recombinant (rDau c) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Carrot recombinant (rDau c) 1 IgE Ab [Units/volume] in Serum;Carrot (rDau c) 1 Ab.IgE IgE Qn;;ACTIVE;2.38;2.70 +66447-4;Euroglyphus maynei recombinant (rEur m) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Euroglyphus maynei recombinant (rEur m) 2 IgE Ab [Units/volume] in Serum;E maynei (rEur m) 2 IgE Qn;;ACTIVE;2.38;2.70 +66448-2;Latex recombinant (rHev b) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 6 IgE Ab [Units/volume] in Serum;Latex (rHev b) 6 IgE Qn;;ACTIVE;2.38;2.70 +6644-9;Cefepime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefepime [Susceptibility] by Minimum inhibitory concentration (MIC);Cefepime Islt MIC;;ACTIVE;1.0g;2.73 +66449-0;Mercurialis annua recombinant (rMer a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Annual mercury recombinant (rMer a) 1 IgE Ab [Units/volume] in Serum;Annual mercury (rMer a) 1 IgE Qn;;ACTIVE;2.38;2.70 +66450-8;Olea europaea native (nOle e) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive native (nOle e) 2 IgE Ab [Units/volume] in Serum;Olive (nOle e) 2 IgE Qn;;ACTIVE;2.38;2.70 +66451-6;Penaeus indicus native (nPen i) 11 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp native (nPen i) 11 IgE Ab [Units/volume] in Serum;Shrimp (nPen i) 11 IgE Qn;;ACTIVE;2.38;2.70 +66452-4;Triticum aestivum native (nTri a) 18 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat native (nTri a) 18 IgE Ab [Units/volume] in Serum;Wheat (nTri a) 18 IgE Qn;;ACTIVE;2.38;2.70 +66453-2;M little c D super little d Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;McD sup(d) Ab [Presence] in Serum or Plasma;McD sup(d) Ab SerPl Ql;;ACTIVE;2.38;2.56 +66454-0;Infectious disease;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Infectious disease [PhenX];Infectious disease PhenX;;TRIAL;2.38;2.65 +66455-7;Condition status;Find;Pt;^Patient;Nom;;H&P.HX;2;Condition status;Condition status;;ACTIVE;2.38;2.72 +66456-5;Doctor visit sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Doctor visit sequence [PhenX];Doctor visit sequence PhenX;;TRIAL;2.38;2.65 +6645-7;Cefepime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Deprecated Cefepime [Susceptibility] by Disk diffusion (KB);Deprecated Cefepime Islt KB;;DEPRECATED;1.0g;2.36 +66457-3;Hospitalization type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Hospitalization type [PhenX];Hospitalization type PhenX;;TRIAL;2.38;2.65 +66459-9;Surgery sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Surgery sequence [PhenX];Surgery sequence PhenX;;TRIAL;2.38;2.65 +66460-7;Lab or imaging sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Lab or imaging sequence [PhenX];Lab or imaging sequence PhenX;;TRIAL;2.38;2.65 +66464-9;Medical device type;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Medical device type [PhenX];Medical device type PhenX;;TRIAL;2.38;2.65 +6646-5;Cefepime;Susc;Pt;Isolate+Ser;Ord;SBT;ABXBACT;1;Deprecated Cefepime [Susceptibility] by Serum bactericidal titer;Deprecated Cefepime SBT;;DEPRECATED;1.0g;2.36 +66465-6;Physical &or occupational therapy sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Physical/Occupational therapy sequence [PhenX];PT/OT sequence PhenX;;TRIAL;2.38;2.65 +66466-4;Physical &or occupational therapy type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Physical/Occupational therapy type [PhenX];PT/OT type PhenX;;TRIAL;2.38;2.65 +66467-2;Have you ever, even once, used a needle to inject a drug not prescribed by a doctor;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever, even once, used a needle to inject a drug not prescribed by a doctor [PhenX];Needle to inject drugs PhenX;;TRIAL;2.38;2.65 +66468-0;Which of the following drugs have you injected using a needle;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which of the following drugs have you injected using a needle [PhenX];Which drugs injected PhenX;;TRIAL;2.38;2.65 +66469-8;How old were you when you first used a needle to inject any drug not prescribed by a doctor;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you first used a needle to inject any drug not prescribed by a doctor [PhenX];Age first used needle PhenX;;TRIAL;2.38;2.65 +66470-6;How long ago has it been since you last used a needle to inject a drug not prescribed by a doctor;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long ago has it been since you last used a needle to inject a drug not prescribed by a doctor [PhenX];How long since last injected PhenX;;TRIAL;2.38;2.65 +66472-2;During your life, altogether how many times have you injected drugs not prescribed by a doctor;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;During your life, altogether how many times have you injected drugs not prescribed by a doctor [PhenX];How many times injected nRate PhenX;;TRIAL;2.38;2.65 +6647-3;Cefpirome;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Deprecated Cefpirome [Susceptibility] by Minimum lethal concentration (MLC);Deprecated Cefpirome Islt MLC;;DEPRECATED;1.0g;2.36 +66473-0;Think about the period of your life when you injected drugs the most often. How often did you inject then;NRat;Pt;^Patient;Qn;PhenX;PHENX;2;Think about the period of your life when you injected drugs the most often. How often did you inject then [PhenX];How often injected PhenX;;TRIAL;2.38;2.65 +66474-8;Have you ever been in a drug treatment or drug rehabilitation program;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been in a drug treatment or drug rehabilitation program [PhenX];Drug treatment program PhenX;;TRIAL;2.38;2.65 +66475-5;Primary country of residency before age 10;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Primary country of residency before age 10 [PhenX];Primary country before 10 PhenX;;TRIAL;2.38;2.65 +66476-3;Country of citizenship;Find;Pt;^Patient;Nom;;PHENX;2;Country of citizenship;Country of citizenship;;ACTIVE;2.38;2.52 +66477-1;Country of current residence;Find;Pt;^Patient;Nom;;PHENX;2;Country of current residence;Country of current residence;;ACTIVE;2.38;2.52 +66478-9;Immigrant;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Immigrant [PhenX];Immigrant PhenX;;TRIAL;2.38;2.65 +66479-7;If you were not born in USA, indicate as closely as possible the date you first arrived here;Date;Pt;^Patient;Qn;PhenX;PHENX;2;If you were not born in USA, indicate as closely as possible the date you first arrived here [PhenX];Date arrived USA PhenX;;TRIAL;2.38;2.65 +66480-5;Medical history;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Medical history [PhenX];Medical history PhenX;;TRIAL;2.38;2.65 +6648-1;Cefpirome;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Deprecated Cefpirome [Susceptibility] by Minimum inhibitory concentration (MIC);Deprecated Cefpirome Islt MIC;;DEPRECATED;1.0g;2.36 +66481-3;Protein.monoclonal band 2;MRat;XXX;Urine;Qn;;CHEM;1;Protein.monoclonal band 2 [Mass/time] in Urine collected for unspecified duration;M Protein 2 ?Tm Ur-mRate;;ACTIVE;2.38;2.73 +66482-1;OmpC Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;OmpC IgA Ab [Units/volume] in Serum by Immunoassay;OmpC IgA Ser IA-aCnc;;ACTIVE;2.38;2.73 +66483-9;Heparin.unfractionated;ACnc;Pt;PPP;Qn;;COAG;1;Heparin unfractionated [Units/volume] in Platelet poor plasma;UFH PPP-aCnc;;ACTIVE;2.38;2.73 +66484-7;DNA single strand Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;DNA single strand Ab [Units/volume] in Serum by Immunoassay;ssDNA Ab Ser IA-aCnc;;ACTIVE;2.38;2.73 +66485-4;Brucella sp Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Brucella sp IgG and IgM [Interpretation] in Serum;Brucella IgG+IgM Ser-Imp;;ACTIVE;2.38;2.73 +66488-8;Serotonin release.heparin.unfractionated interpretation;Imp;Pt;Ser;Nar;;SERO;1;Serotonin release.heparin.unfractionated in Serum Narrative;SRA UFH Ser-Imp;;ACTIVE;2.38;2.73 +66489-6;CYP2C19 gene targeted mutation analysis;Find;Pt;Bld;Doc;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene targeted mutation analysis in Blood by Molecular genetics method;CYP2C19 Mut Anl Bld;;ACTIVE;2.38;2.73 +66491-2;Urease^2nd specimen;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --2nd specimen;Urease sp2 Tiss Ql;;ACTIVE;2.38;2.56 +66492-0;Urease^3rd specimen;PrThr;Pt;Tiss;Ord;;MICRO;1;Urease [Presence] in Tissue --3rd specimen;Urease sp3 Tiss Ql;;ACTIVE;2.38;2.56 +66493-8;Epstein Barr virus nuclear 1 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus nuclear 1 IgG Ab [Units/volume] in Serum;EBV NA 1 IgG Ser-aCnc;;ACTIVE;2.38;2.73 +66494-6;Spermatozoa.acrosome defects/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Acrosome defects/100 spermatozoa in Semen;Sperm acrosome defects NFr Smn;;ACTIVE;2.38;2.73 +66495-3;Spermatozoa.abnormal head shape/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Abnormal head shape/100 spermatozoa in Semen;Sperm abnorm head shape NFr Smn;;ACTIVE;2.38;2.73 +66496-1;Spermatozoa.abnormal head size/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Abnormal head size/100 spermatozoa in Semen;Sperm abnorm head size NFr Smn;;ACTIVE;2.38;2.73 +66497-9;Spermatozoa.double forms/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Double forms/100 spermatozoa in Semen;Sperm double forms NFr Smn;;ACTIVE;2.38;2.73 +66498-7;Spermatozoa.multiple defects/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Multiple defects/100 spermatozoa in Semen;Sperm multiple defects NFr Smn;;ACTIVE;2.38;2.73 +6649-9;Cefpirome;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Deprecated Cefpirome [Susceptibility] by Disk diffusion (KB);Deprecated Cefpirome Islt KB;;DEPRECATED;1.0g;2.36 +66499-5;Cholesterol.in VLDL.beta;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL.beta [Mass/volume] in Serum or Plasma;VLDLc beta SerPl-mCnc;;ACTIVE;2.38;2.73 +665-0;Microscopic observation;Prid;Pt;XXX;Nom;Hematoxylin and eosin stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Hematoxylin and eosin stain;H+E Stn Spec;;ACTIVE;1.0;2.69 +66500-0;Do you have this disorder;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Do you have this disorder [PhenX];Autoimmune disorder ever PhenX;;TRIAL;2.38;2.65 +66501-8;Noninfectious major illness;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Noninfectious major illness [PhenX];Noninfectious major illness PhenX;;TRIAL;2.38;2.65 +66502-6;HBA1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HBA1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HBA1 gene Mut Anl Bld/T;;ACTIVE;2.38;2.73 +66503-4;APC gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;APC gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;APC gene Fam Mut Anl Bld/T;;ACTIVE;2.38;2.66 +66504-2;Exclusion criteria present;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Exclusion criteria present [PhenX];Exclusion criteria present PhenX;;TRIAL;2.38;2.65 +66505-9;Exclusion criteria for fasting serum insulin;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Exclusion criteria for fasting serum insulin [PhenX];Exclusion criteria serum insulin PhenX;;TRIAL;2.38;2.65 +6650-6;Cefpirome;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefpirome [Susceptibility] by Serum bactericidal titer;Cefpirome Titr SBT;;ACTIVE;1.0g;2.32 +66506-7;Image name;ID;Pt;Hand;Nom;PhenX;PHENX;2;Image name Hand [PhenX];Image name Hand PhenX;;TRIAL;2.38;2.65 +66507-5;Hand scanned;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Hand scanned [PhenX];Hand scanned PhenX;;TRIAL;2.38;2.65 +66508-3;Kellgren-Lawrence score;Score;Pt;Hand;Ord;PhenX;PHENX;2;Kellgren-Lawrence score Hand [PhenX];Kellgren-Lawrence score Hand PhenX;;TRIAL;2.38;2.65 +66509-1;Image name;ID;Pt;Knee;Nom;PhenX;PHENX;2;Image name Knee [PhenX];Image name Knee PhenX;;TRIAL;2.38;2.65 +66510-9;Knee scanned;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Knee scanned [PhenX];Knee scanned PhenX;;TRIAL;2.38;2.65 +66511-7;Kellgren-Lawrence score;Score;Pt;Knee;Ord;PhenX;PHENX;2;Kellgren-Lawrence score Knee [PhenX];Kellgren-Lawrence score Knee PhenX;;TRIAL;2.38;2.65 +66512-5;Image name;ID;Pt;Hip;Nom;PhenX;PHENX;2;Image name Hip [PhenX];Image name Hip PhenX;;TRIAL;2.38;2.65 +66513-3;Hip scanned;Find;Pt;Hip;Nom;PhenX;PHENX;2;Hip scanned Hip [PhenX];Hip scanned Hip PhenX;;TRIAL;2.38;2.65 +6651-4;Meropenem;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Meropenem [Susceptibility] by Minimum lethal concentration (MLC);Meropenem Islt MLC;;ACTIVE;1.0g;2.19 +66514-1;Kellgren-Lawrence score;Score;Pt;Hip;Ord;PhenX;PHENX;2;Kellgren-Lawrence score Hip [PhenX];Kellgren-Lawrence score Hip PhenX;;TRIAL;2.38;2.65 +66515-8;Redness score;Score;Pt;Head+Neck;Qn;PhenX;PHENX;2;Redness score Head and Neck [PhenX];Redness score Head+Neck PhenX;;TRIAL;2.38;2.65 +66516-6;Thickness score;Score;Pt;Head+Neck;Qn;PhenX;PHENX;2;Thickness score Head and Neck [PhenX];Thickness score Head+Neck PhenX;;TRIAL;2.38;2.65 +66517-4;Scratching score;Score;Pt;Head+Neck;Qn;PhenX;PHENX;2;Scratching score Head and Neck [PhenX];Scratching score Head+Neck PhenX;;TRIAL;2.38;2.65 +66518-2;Lichenification score;Score;Pt;Head+Neck;Qn;PhenX;PHENX;2;Lichenification score Head and Neck [PhenX];Lichenification score Head+Neck PhenX;;TRIAL;2.38;2.65 +66519-0;Percentage area affected by eczema;NRat;Pt;Head+Neck;Qn;PhenX;PHENX;2;Percentage area affected by eczema Head and Neck [PhenX];Area affected by eczema Head+Neck PhenX;;TRIAL;2.38;2.65 +66520-8;Redness score;Score;Pt;Upper extremity.bilateral;Qn;PhenX;PHENX;2;Redness score Upper extremity - bilateral [PhenX];Redness score UE-Bl PhenX;;TRIAL;2.38;2.65 +66521-6;Thickness score;Score;Pt;Upper extremity.bilateral;Qn;PhenX;PHENX;2;Thickness score Upper extremity - bilateral [PhenX];Thickness score UE-Bl PhenX;;TRIAL;2.38;2.65 +6652-2;Meropenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Meropenem [Susceptibility] by Minimum inhibitory concentration (MIC);Meropenem Islt MIC;;ACTIVE;1.0g;2.73 +66522-4;Scratching score;Score;Pt;Upper extremity.bilateral;Qn;PhenX;PHENX;2;Scratching score Upper extremity - bilateral [PhenX];Scratching score UE-Bl PhenX;;TRIAL;2.38;2.65 +66523-2;Lichenification score;Score;Pt;Upper extremity.bilateral;Qn;PhenX;PHENX;2;Lichenification score Upper extremity - bilateral [PhenX];Lichenification score UE-Bl PhenX;;TRIAL;2.38;2.65 +66524-0;Percentage area affected by eczema;NRat;Pt;Upper extremity.bilateral;Qn;PhenX;PHENX;2;Percentage area affected by eczema Upper extremity - bilateral [PhenX];Area affected by eczema UE-Bl PhenX;;TRIAL;2.38;2.65 +66525-7;Redness score;Score;Pt;Trunk;Qn;PhenX;PHENX;2;Redness score Trunk [PhenX];Redness score Trunk PhenX;;TRIAL;2.38;2.65 +66526-5;Thickness score;Score;Pt;Trunk;Qn;PhenX;PHENX;2;Thickness score Trunk [PhenX];Thickness score Trunk PhenX;;TRIAL;2.38;2.65 +66527-3;Scratching score;Score;Pt;Trunk;Qn;PhenX;PHENX;2;Scratching score Trunk [PhenX];Scratching score Trunk PhenX;;TRIAL;2.38;2.65 +66528-1;Lichenification score;Score;Pt;Trunk;Qn;PhenX;PHENX;2;Lichenification score Trunk [PhenX];Lichenification score Trunk PhenX;;TRIAL;2.38;2.65 +66529-9;Percentage area affected by eczema;NRat;Pt;Trunk;Qn;PhenX;PHENX;2;Percentage area affected by eczema Trunk [PhenX];Area affected by eczema Trunk PhenX;;TRIAL;2.38;2.65 +6653-0;Meropenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Meropenem [Susceptibility] by Disk diffusion (KB);Meropenem Islt KB;;ACTIVE;1.0g;2.73 +66530-7;Redness score;Score;Pt;Lower extremity.bilateral;Qn;PhenX;PHENX;2;Redness score Lower extremity - bilateral [PhenX];Redness score LE-Bl PhenX;;TRIAL;2.38;2.65 +66531-5;Thickness score;Score;Pt;Lower extremity.bilateral;Qn;PhenX;PHENX;2;Thickness score Lower extremity - bilateral [PhenX];Thickness score LE-Bl PhenX;;TRIAL;2.38;2.65 +66532-3;Scratching score;Score;Pt;Lower extremity.bilateral;Qn;PhenX;PHENX;2;Scratching score Lower extremity - bilateral [PhenX];Scratching score LE-Bl PhenX;;TRIAL;2.38;2.65 +66533-1;Lichenification score;Score;Pt;Lower extremity.bilateral;Qn;PhenX;PHENX;2;Lichenification score Lower extremity - bilateral [PhenX];Lichenification score LE-Bl PhenX;;TRIAL;2.38;2.65 +66534-9;Percentage area affected by eczema;NRat;Pt;Lower extremity.bilateral;Qn;PhenX;PHENX;2;Percentage area affected by eczema Lower extremity - bilateral [PhenX];Area affected by eczema LE-Bl PhenX;;TRIAL;2.38;2.65 +66535-6;Is the physician who diagnosed you a dermatologist;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Is the physician who diagnosed you a dermatologist [PhenX];Psoriasis physician dermatologist PhenX;;TRIAL;2.38;2.65 +66536-4;Have you been told by a rheumatologist that you have psoriatic arthritis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you been told by a rheumatologist that you have psoriatic arthritis [PhenX];Arthritis dx. Rheumatologist PhenX;;TRIAL;2.38;2.65 +66537-2;Have you been diagnosed with crohn's disease or another inflammatory bowel disorder;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you been diagnosed with crohn's disease or another inflammatory bowel disorder [PhenX];Dx Crohn's disease PhenX;;TRIAL;2.38;2.65 +66538-0;Have you been diagnosed with any type of autoimmune disease - lupus, scleroderma, etc;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you been diagnosed with any type of autoimmune disease - lupus, scleroderma, etc [PhenX];Dx autoimmune disease PhenX;;TRIAL;2.38;2.65 +66539-8;Do you have any blood relatives affected with psoriasis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any blood relatives affected with psoriasis [PhenX];Psoriasis family hx PhenX;;TRIAL;2.38;2.65 +66540-6;Do you have any blood relatives with inflammatory bowel disease;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any blood relatives with inflammatory bowel disease [PhenX];Inflammatory bowel disease fam hx PhenX;;TRIAL;2.38;2.65 +66541-4;Do you have any blood relatives with any type of autoimmune disease;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any blood relatives with any type of autoimmune disease [PhenX];Autoimmune disease family hx PhenX;;TRIAL;2.38;2.65 +66542-2;What color is an average spot of your psoriasis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;What color is an average spot of your psoriasis [PhenX];Psoriasis spot color PhenX;;TRIAL;2.38;2.65 +66543-0;How thick is an average spot of your psoriasis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How thick is an average spot of your psoriasis [PhenX];Psoriasis spot thickness PhenX;;TRIAL;2.38;2.65 +66544-8;How scaly is an average spot of your psoriasis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How scaly is an average spot of your psoriasis [PhenX];Psoriasis spot scaly PhenX;;TRIAL;2.38;2.65 +66545-5;Do you have nail psoriasis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have nail psoriasis [PhenX];Nail psoriasis PhenX;;TRIAL;2.38;2.65 +66546-3;Has a dermatologist told you that you have pustular psoriasis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a dermatologist told you that you have pustular psoriasis [PhenX];Derm dx psoriasis PhenX;;TRIAL;2.38;2.65 +66547-1;Things to smoke;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Things to smoke [PhenX];Things to smoke PhenX;;TRIAL;2.38;2.65 +6654-8;Meropenem;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Meropenem [Susceptibility] by Serum bactericidal titer;Meropenem Titr SBT;;ACTIVE;1.0g;2.32 +66548-9;How many of these do you smoke per D;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of these do you smoke per day [#] [PhenX];Smoke number per D PhenX;;TRIAL;2.38;2.65 +66549-7;Psoriasis treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Psoriasis treatment [PhenX];Psoriasis treatment PhenX;;TRIAL;2.38;2.65 +66550-5;Psoriasis treatment duration;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;Psoriasis treatment duration [PhenX];Psoriasis treatment duration PhenX;;TRIAL;2.38;2.65 +66551-3;Psoriasis treatment effectiveness;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Psoriasis treatment effectiveness [PhenX];Psoriasis treatment effectiveness PhenX;;TRIAL;2.38;2.65 +66552-1;Other biologicals - injected;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other biologicals - injected [PhenX];Other biologicals PhenX;;TRIAL;2.38;2.65 +66553-9;Other systemics;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other systemics [PhenX];Other systemics PhenX;;TRIAL;2.38;2.65 +66554-7;Other topicals;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other topicals [PhenX];Other topicals PhenX;;TRIAL;2.38;2.65 +6655-5;Microscopic observation;Prid;Pt;Tiss;Nom;Acid fast stain.Kinyoun;MICRO;1;Microscopic observation [Identifier] in Tissue by Acid fast stain.Kinyoun;Acid fast Kiny Stn Tiss;;ACTIVE;1.0g;2.22 +66555-4;Skin type;Type;Pt;^Patient;Nom;Fitzpatrick Classification Scale;PHENX;2;Skin type [Fitzpatrick Classification Scale];Skin type Fitzpatrick;;ACTIVE;2.38;2.65 +66556-2;Freckles;Find;Pt;^Patient;Ord;;H&P.PX;2;Freckles;Freckles;;ACTIVE;2.38;2.68 +66557-0;How many moles do you approximately have on the whole body;Find;Pt;^Patient;Nom;PhenX;PHENX;2;How many moles do you approximately have on the whole body [PhenX];Moles PhenX;;TRIAL;2.38;2.65 +66558-8;Did you have one or more severe blistering sunburns as a child or teenager;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you have one or more severe blistering sunburns as a child or teenager [PhenX];Sunburn PhenX;;TRIAL;2.38;2.65 +66559-6;Did you live for more than 1Y in a country where sunshine is high - africa, french west indies, south of united states, australia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you live for more than 1 year in a country where sunshine is high - africa, french west indies, south of united states, australia [PhenX];Country high sunshine PhenX;;TRIAL;2.38;2.66 +66560-4;Have you been diagnosed with melanoma in the past - skin cancer, arising in melanocytes, skin cells that make skin pigment;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you been diagnosed with melanoma in the past - skin cancer, arising in melanocytes, skin cells that make skin pigment [PhenX];Melanoma PhenX;;TRIAL;2.38;2.65 +66561-2;Has any of your first degree relatives, parents, children, brother or sister, ever had melanoma;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has any of your first degree relatives, parents, children, brother or sister, ever had melanoma [PhenX];Melanoma family hx PhenX;;TRIAL;2.38;2.65 +66562-0;Pregnancy test required;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Pregnancy test required [PhenX];Pregnancy test required PhenX;;TRIAL;2.38;2.65 +6656-3;Microscopic observation;Prid;Pt;Tiss;Nom;Acid fast stain.Kinyoun modified;MICRO;1;Microscopic observation [Identifier] in Tissue by Acid fast stain.Kinyoun modified;Acid fast Mod Kiny Stn Tiss;;ACTIVE;1.0g;2.73 +66563-8;Pregnancy test result;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Pregnancy test result [PhenX];Pregnancy test result PhenX;;TRIAL;2.38;2.65 +66564-6;Have you had sexual intercourse in the past 7Ds;Find;7D;^Patient;Ord;PhenX;PHENX;2;Have you had sexual intercourse in the past 7 days [PhenX];Intercourse in last W PhenX;;TRIAL;2.38;2.65 +66565-3;Did you use one of the following forms of birth control each time you had sexual intercourse in the past 7D;Find;7D;^Patient;Ord;PhenX;PHENX;2;Did you use one of the following forms of birth control each time you had sexual intercourse in the past 7 days [PhenX];Birth control in last W PhenX;;TRIAL;2.38;2.65 +66566-1;Image name;ID;Pt;Femur;Nom;PhenX;PHENX;2;Image name Femur [PhenX];Image name Femur PhenX;;TRIAL;2.38;2.65 +66567-9;Image name;ID;Pt;Spine;Nom;PhenX;PHENX;2;Image name Spine [PhenX];Image name Spine PhenX;;TRIAL;2.38;2.65 +66568-7;Leg stand attempt;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Leg stand attempt [PhenX];Leg stand attempt PhenX;;TRIAL;2.38;2.65 +66569-5;Time participant holds position during first one leg stand;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Time participant holds position during first one leg stand [PhenX];Leg stand time PhenX;;TRIAL;2.38;2.65 +66570-3;Has a doctor ever said that you had a broken or fractured bone;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever said that you had a broken or fractured bone [PhenX];Doctor dx fractured bone PhenX;;TRIAL;2.38;2.65 +6657-1;Microscopic observation;Prid;Pt;Tiss;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Tissue by Acid fast stain.Ziehl-Neelsen;ZN Stn Tiss;;ACTIVE;1.0g;2.22 +66571-1;Broken bone;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Broken bone [PhenX];Broken bone PhenX;;TRIAL;2.38;2.65 +66572-9;Age when broken;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Age when broken [PhenX];Age when broken PhenX;;TRIAL;2.38;2.65 +66573-7;What language do you speak with most of your family;Find;Pt;^Patient;Nom;NLAAS;PHENX;2;What language do you speak with most of your family [NLAAS];Language speak with family NLAAS;;ACTIVE;2.38;2.65 +66574-5;In what language do you think;Find;Pt;^Patient;Nom;NLAAS;PHENX;2;In what language do you think [NLAAS];Language think in NLAAS;;ACTIVE;2.38;2.65 +66575-2;Other language;Find;Pt;^Patient;Nom;NLAAS;PHENX;2;Other language [NLAAS];Other language NLAAS;;ACTIVE;2.38;2.65 +66576-0;Would you say that in general your health is;Find;Pt;^Patient;Ord;HRQOL;PHENX;2;Would you say that in general your health is [HRQOL];General health HRQOL;;ACTIVE;2.38;2.65 +66577-8;Now thinking about your physical health, which includes physical illness and injury, for how many Ds during the past 30D was your physical health not good;NRat;30D;^Patient;Qn;HRQOL;PHENX;2;Now thinking about your physical health, which includes physical illness and injury, for how many days during the past 30 days was your physical health not good [HRQOL];Poor phys health last 30D nRate HRQOL;;ACTIVE;2.38;2.65 +66578-6;Now thinking about your mental health, which includes stress, depression, and problems with emotions, for how many Ds during the past 30D was your mental health not good;NRat;30D;^Patient;Qn;HRQOL;PHENX;2;Now thinking about your mental health, which includes stress, depression, and problems with emotions, for how many days during the past 30 days was your mental health not good [HRQOL];Poor mental health last 30D nRate HRQOL;;ACTIVE;2.38;2.65 +66579-4;During the past 30D, for about how many Ds did poor physical or mental health keep you from doing your usual activities, such as self-care, work, or recreation;NRat;30D;^Patient;Qn;HRQOL;PHENX;2;During the past 30 days, for about how many days did poor physical or mental health keep you from doing your usual activities, such as self-care, work, or recreation [HRQOL];Poor health prevent activ nRate HRQOL;;ACTIVE;2.38;2.65 +66580-2;I have a reserved and cautious attitude toward life;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I have a reserved and cautious attitude toward life [UPPS-P];Cautious attitude toward life UPPS-P;;ACTIVE;2.38;2.65 +66581-0;I have trouble controlling my impulses;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I have trouble controlling my impulses [UPPS-P];Trouble controlling impulses UPPS-P;;ACTIVE;2.38;2.65 +66582-8;I generally seek new and exciting experiences and sensations;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I generally seek new and exciting experiences and sensations [UPPS-P];Seek new exciting experiences UPPS-P;;ACTIVE;2.38;2.65 +66583-6;I generally like to see things through to the end;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I generally like to see things through to the end [UPPS-P];See things through UPPS-P;;ACTIVE;2.38;2.65 +66584-4;When I am very happy, I can't seem to stop myself from doing things that can have bad consequences;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I am very happy, I can't seem to stop myself from doing things that can have bad consequences [UPPS-P];Happy do things bad consequences UPPS-P;;ACTIVE;2.38;2.65 +66585-1;My thinking is usually careful and purposeful;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;My thinking is usually careful and purposeful [UPPS-P];Thinking careful and purposeful UPPS-P;;ACTIVE;2.38;2.65 +66586-9;I have trouble resisting my cravings for food, cigarettes, etc;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I have trouble resisting my cravings for food, cigarettes, etc [UPPS-P];Trouble resisting cravings UPPS-P;;ACTIVE;2.38;2.65 +66587-7;I'll try anything once;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I'll try anything once [UPPS-P];Try anything once UPPS-P;;ACTIVE;2.38;2.65 +66588-5;I tend to give up easily;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I tend to give up easily [UPPS-P];Give up easily UPPS-P;;ACTIVE;2.38;2.65 +6658-9;Microscopic observation;Prid;Pt;Tiss;Nom;Acridine orange stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Acridine orange stain;AO Stn Tiss;;ACTIVE;1.0g;2.22 +66589-3;When I am in a great mood, I tend to get into situations that could cause me problems;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I am in a great mood, I tend to get into situations that could cause me problems [UPPS-P];Great mood problem situations UPPS-P;;ACTIVE;2.38;2.65 +66590-1;I am not one of those people who blurt out things without thinking;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I am not one of those people who blurt out things without thinking [UPPS-P];Not blurt things W/O thinking UPPS-P;;ACTIVE;2.38;2.65 +66591-9;I often get involved in things I later wish I could get out of;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I often get involved in things I later wish I could get out of [UPPS-P];Later wish I could get out of UPPS-P;;ACTIVE;2.38;2.65 +66592-7;I like sports and games in which you have to choose your next move very quickly;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I like sports and games in which you have to choose your next move very quickly [UPPS-P];Like games choose quickly UPPS-P;;ACTIVE;2.38;2.65 +66593-5;Unfinished tasks really bother me;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Unfinished tasks really bother me [UPPS-P];Unfinished tasks really bother UPPS-P;;ACTIVE;2.38;2.65 +66594-3;When I am very happy, I tend to do things that may cause problems in my life;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I am very happy, I tend to do things that may cause problems in my life [UPPS-R-Child];Do things that cause problems UPPS-R-C;;ACTIVE;2.38;2.65 +66595-0;I like to stop and think things over before I do them;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I like to stop and think things over before I do them [UPPS-P];Stop think things over UPPS-P;;ACTIVE;2.38;2.65 +66596-8;When I feel bad, I will often do things I later regret in order to make myself feel better now;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I feel bad, I will often do things I later regret in order to make myself feel better now [UPPS-P];Regret actions to feel better UPPS-P;;ACTIVE;2.38;2.65 +6659-7;Microscopic observation;Prid;Pt;Tiss;Nom;Carbol-fuchsin stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Carbol-fuchsin stain;CF Stn Tiss;;ACTIVE;1.0g;2.22 +66597-6;I would enjoy water skiing;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I would enjoy water skiing [UPPS-P];Would enjoy water skiing UPPS-P;;ACTIVE;2.38;2.65 +66598-4;Once I get going on something I hate to stop;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Once I get going on something I hate to stop [UPPS-P];Hate to stop UPPS-P;;ACTIVE;2.38;2.65 +66599-2;I tend to lose control when I am in a great mood;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I tend to lose control when I am in a great mood [UPPS-P];Lose control UPPS-P;;ACTIVE;2.38;2.65 +66600-8;I don't like to start a project until I know exactly how to proceed;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I don't like to start a project until I know exactly how to proceed [UPPS-P];Exactly how to proceed UPPS-P;;ACTIVE;2.38;2.65 +66601-6;Sometimes when I feel bad, I can't seem to stop what I am doing even though it is making me feel worse;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Sometimes when I feel bad, I can't seem to stop what I am doing even though it is making me feel worse [UPPS-P];Can't stop hurtful actions UPPS-P;;ACTIVE;2.38;2.65 +66602-4;I quite enjoy taking risks;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I quite enjoy taking risks [UPPS-P];Enjoy taking risks UPPS-P;;ACTIVE;2.38;2.65 +66603-2;I concentrate easily;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I concentrate easily [UPPS-P];Concentrate easily UPPS-P;;ACTIVE;2.38;2.65 +66604-0;When I am really ecstatic, I tend to get out of control;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I am really ecstatic, I tend to get out of control [UPPS-P];Out of control when ecstatic UPPS-P;;ACTIVE;2.38;2.65 +6660-5;Microscopic observation;Prid;Pt;Tiss;Nom;Dark field examination;MICRO;1;Deprecated Microscopic observation [Identifier] in Tissue by Dark field examination;Deprecated Dark Field Tiss;;DEPRECATED;1.0g;2.36 +66605-7;Source of fracture confirmation;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Source of fracture confirmation [PhenX];Fracture confirmation PhenX;;TRIAL;2.38;2.65 +66606-5;Was this the source of fracture confirmation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was this the source of fracture confirmation [PhenX];Fracture confirmation type PhenX;;TRIAL;2.38;2.65 +66607-3;Other source of fracture confirmation;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other source of fracture confirmation [PhenX];Other fracture confirmation PhenX;;TRIAL;2.38;2.65 +66608-1;Cataract;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Cataract [Reported];Cataract Reported;;TRIAL;2.38;2.65 +66609-9;Retinal change or optic atrophy;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Retinal change or optic atrophy [Reported];Retinal change Reported;;TRIAL;2.38;2.65 +66610-7;Cognitive impairment;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Cognitive impairment [Reported];Cognitive impairment Reported;;TRIAL;2.38;2.65 +66611-5;Seizures requiring therapy for 6Mo;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Seizures requiring therapy for 6 months [Reported];Neuropsychiatric seizures Reported;;TRIAL;2.38;2.65 +66612-3;Cerebrovascular accident;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Cerebrovascular accident [Reported];CVA Reported;;TRIAL;2.38;2.65 +6661-3;Microscopic observation;Prid;Pt;Tiss;Nom;Dry mount;MICRO;1;Microscopic observation [Identifier] in Tissue by Dry mount;Dry Mount Tiss;;ACTIVE;1.0g;2.22 +66613-1;Cranial or peripheral neuropathy;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Cranial or peripheral neuropathy [Reported];Cranial peripheral neuropathy Reported;;TRIAL;2.38;2.65 +66614-9;Transverse myelitis;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Transverse myelitis [Reported];Transverse myelitis Reported;;TRIAL;2.38;2.65 +66615-6;Estimated or measured glomerular filtration rate less than 50 percent;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Estimated or measured glomerular filtration rate less than 50 percent [Reported];Renal GFR <50% Reported;;TRIAL;2.38;2.65 +66616-4;Proteinuria greater than or equal to 3.5 gm in 24H;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Proteinuria greater than or equal to 3.5 gm in 24 hours [Reported];Renal proteinuria Reported;;TRIAL;2.38;2.65 +66617-2;End-stage renal disease;Hx;Pt;^Patient;Ord;Reported;PHENX;2;End-stage renal disease [Reported];End-stage renal disease Reported;;TRIAL;2.38;2.65 +66618-0;Pulmonary hypertension;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Pulmonary hypertension [Reported];Pulmonary hypertension Reported;;TRIAL;2.38;2.65 +66619-8;Pulmonary fibrosis;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Pulmonary fibrosis [Reported];Pulmonary fibrosis Reported;;TRIAL;2.38;2.65 +66620-6;Shrinking lung;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Shrinking lung [Reported];Shrinking lung Reported;;TRIAL;2.38;2.65 +6662-1;Microscopic observation;Prid;Pt;Tiss;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Giemsa stain;Gie Stn Tiss;;ACTIVE;1.0g;2.22 +66621-4;Pleural fibrosis;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Pleural fibrosis [Reported];Pleural fibrosis Reported;;TRIAL;2.38;2.65 +66622-2;Pulmonary infarction;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Pulmonary infarction [Reported];Pulmonary infarction Reported;;TRIAL;2.38;2.65 +66623-0;Angina or coronary artery bypass;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Angina or coronary artery bypass [Reported];Angina or coronary bypass Reported;;TRIAL;2.38;2.65 +66624-8;Myocardial infarction;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Myocardial infarction [Reported];Myocardial infarction Reported;;TRIAL;2.38;2.65 +66625-5;Cardiomyopathy;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Cardiomyopathy [Reported];Cardiomyopathy Reported;;TRIAL;2.38;2.65 +66626-3;Valvular disease;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Valvular disease [Reported];Valvular disease Reported;;TRIAL;2.38;2.65 +66627-1;Pericarditis for 6Mo, or pericardiectomy;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Pericarditis for 6 months, or pericardiectomy [Reported];Pericarditis Reported;;TRIAL;2.38;2.65 +66628-9;Claudication for 6Mo;Hx;Pt;^Patient;Ord;Reported;PHENX;2;Claudication for 6 months [Reported];Claudication Reported;;TRIAL;2.38;2.65 +66629-7;I would enjoy parachute jumping;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I would enjoy parachute jumping [UPPS-P];Would enjoy parachute jumping UPPS-P;;ACTIVE;2.38;2.65 +66630-5;I finish what I start;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I finish what I start [UPPS-P];Finish what I start UPPS-P;;ACTIVE;2.38;2.65 +66631-3;I tend to value and follow a rational, sensible approach to things;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I tend to value and follow a rational, sensible approach to things [UPPS-P];Rational approach to things UPPS-P;;ACTIVE;2.38;2.65 +66632-1;When I am upset I often act without thinking;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I am upset I often act without thinking [UPPS-P];Act W/O thinking when upset UPPS-P;;ACTIVE;2.38;2.65 +66633-9;Others would say I make bad choices when I am extremely happy about something;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Others would say I make bad choices when I am extremely happy about something [UPPS-P];Others say make bad choices UPPS-P;;ACTIVE;2.38;2.65 +66634-7;I welcome new and exciting experiences and sensations, even if they are a little frightening and unconventional;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I welcome new and exciting experiences and sensations, even if they are a little frightening and unconventional [UPPS-P];Welcome new exciting experiences UPPS-P;;ACTIVE;2.38;2.65 +66635-4;I am able to pace myself so as to get things done on time;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I am able to pace myself so as to get things done on time [UPPS-P];Able to pace myself UPPS-P;;ACTIVE;2.38;2.65 +66636-2;I usually make up my mind through careful reasoning;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I usually make up my mind through careful reasoning [UPPS-P];Careful reasoning UPPS-P;;ACTIVE;2.38;2.65 +66637-0;When I feel rejected, I will often say things I regret later;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I feel rejected, I will often say things I regret later [UPPS-P];Say things regret when rejected UPPS-P;;ACTIVE;2.38;2.65 +66638-8;Others are shocked or worried about the things I do when I am feeling very excited;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Others are shocked or worried about the things I do when I am feeling very excited [UPPS-P];Others shocked about things I do UPPS-P;;ACTIVE;2.38;2.65 +6663-9;Microscopic observation;Prid;Pt;Tiss;Nom;Gimenez stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Gimenez stain;Gimenez Stn Tiss;;ACTIVE;1.0g;2.22 +66639-6;I would like to learn to fly an airplane;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I would like to learn to fly an airplane [UPPS-P];Would like fly airplane UPPS-P;;ACTIVE;2.38;2.65 +66640-4;I am a person who always gets the job done;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I am a person who always gets the job done [UPPS-P];Gets job done UPPS-P;;ACTIVE;2.38;2.65 +66641-2;I am a cautious person;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I am a cautious person [UPPS-P];Cautious person UPPS-P;;ACTIVE;2.38;2.65 +66642-0;It is hard for me to resist acting on my feelings;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;It is hard for me to resist acting on my feelings [UPPS-P];Hard to resist feelings UPPS-P;;ACTIVE;2.38;2.65 +66643-8;When I get really happy about something, I tend to do things that can have bad consequences;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I get really happy about something, I tend to do things that can have bad consequences [UPPS-P];Do things with bad consequences UPPS-P;;ACTIVE;2.38;2.65 +66644-6;I sometimes like doing things that are a bit frightening;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I sometimes like doing things that are a bit frightening [UPPS-P];Like doing frightening things UPPS-P;;ACTIVE;2.38;2.65 +66645-3;I almost always finish projects that I start;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I almost always finish projects that I start [UPPS-P];Almost always finish projects UPPS-P;;ACTIVE;2.38;2.65 +66646-1;Before I get into a new situation I like to find out what to expect from it;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Before I get into a new situation I like to find out what to expect from it [UPPS-P];Cautious about new situation UPPS-P;;ACTIVE;2.38;2.65 +6664-7;Microscopic observation;Prid;Pt;Tiss;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Gram stain;Gram Stn Tiss;;ACTIVE;1.0g;2.73 +66647-9;I often make matters worse because I act without thinking when I am upset;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I often make matters worse because I act without thinking when I am upset [UPPS-P];Matters worse act w/o thinking UPPS-P;;ACTIVE;2.38;2.65 +66648-7;When overjoyed, I feel like I can't stop myself from going overboard;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When overjoyed, I feel like I can't stop myself from going overboard [UPPS-P];Can't stop going overboard UPPS-P;;ACTIVE;2.38;2.65 +66649-5;I would enjoy the sensation of skiing very fast down a high mountain slope;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I would enjoy the sensation of skiing very fast down a high mountain slope [UPPS-P];Would enjoy sensation skiing UPPS-P;;ACTIVE;2.38;2.65 +66650-3;Sometimes there are so many little things to be done that I just ignore them all;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Sometimes there are so many little things to be done that I just ignore them all [UPPS-P];Ignore little things UPPS-P;;ACTIVE;2.38;2.65 +66651-1;I usually think carefully before doing anything;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I usually think carefully before doing anything [UPPS-P];Think carefully before doing UPPS-P;;ACTIVE;2.38;2.65 +66652-9;When I am really excited, I tend not to think of the consequences of my actions;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I am really excited, I tend not to think of the consequences of my actions [UPPS-P];Don't think about consequences UPPS-P;;ACTIVE;2.38;2.65 +66653-7;In the heat of an argument, I will often say things that I later regret;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;In the heat of an argument, I will often say things that I later regret [UPPS-P];Say things regret later UPPS-P;;ACTIVE;2.38;2.65 +6665-4;Microscopic observation;Prid;Pt;Tiss;Nom;Hematoxylin and eosin stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Hematoxylin and eosin stain;H+E Stn Tiss;;ACTIVE;1.0g;2.73 +66654-5;I would like to go scuba diving;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I would like to go scuba diving [UPPS-P];Would scuba diving UPPS-P;;ACTIVE;2.38;2.65 +66655-2;I tend to act without thinking when I am really excited;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I tend to act without thinking when I am really excited [UPPS-P];Act W/O thinking when excited UPPS-P;;ACTIVE;2.38;2.65 +66656-0;I always keep my feelings under control;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I always keep my feelings under control [UPPS-P];Keep my feelings under control UPPS-P;;ACTIVE;2.38;2.65 +66657-8;When I am really happy, I often find myself in situations that I normally wouldn't be comfortable with;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I am really happy, I often find myself in situations that I normally wouldn't be comfortable with [UPPS-P];Uncomfort situations when happy UPPS-P;;ACTIVE;2.38;2.65 +66658-6;Before making up my mind, I consider all the advantages and disadvantages;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Before making up my mind, I consider all the advantages and disadvantages [UPPS-P];Consider all advant disadvant UPPS-P;;ACTIVE;2.38;2.65 +66659-4;I would enjoy fast driving;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I would enjoy fast driving [UPPS-P];Would enjoy fast driving UPPS-P;;ACTIVE;2.38;2.65 +66660-2;When I am very happy, I feel like it is ok to give in to cravings or overindulge;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;When I am very happy, I feel like it is ok to give in to cravings or overindulge [UPPS-P];Give in to cravings when happy UPPS-P;;ACTIVE;2.38;2.65 +66661-0;Sometimes I do impulsive things that I later regret;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;Sometimes I do impulsive things that I later regret [UPPS-P];Do impulsive things later regret UPPS-P;;ACTIVE;2.38;2.65 +6666-2;Microscopic observation;Prid;Pt;Tiss;Nom;India ink preparation;MICRO;1;Microscopic observation [Identifier] in Tissue by India ink prep;India Ink Prep Tiss;;ACTIVE;1.0g;2.22 +66662-8;Minor tissue loss;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Minor tissue loss [PhenX];Minor tissue loss PhenX;;TRIAL;2.38;2.65 +66663-6;Significant tissue loss;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Significant tissue loss [PhenX];Significant tissue loss PhenX;;TRIAL;2.38;2.65 +66664-4;Venous thrombosis with swelling, ulceration, or venous stasis;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Venous thrombosis with swelling, ulceration, or venous stasis [PhenX];Venous thrombosis PhenX;;TRIAL;2.38;2.65 +66665-1;Gastrointestinal Infarction or resection of bowel below duodenum, spleen, liver, or gall bladder;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Gastrointestinal infarction or resection of bowel below duodenum, spleen, liver, or gall bladder [PhenX];Gastrointestinal infarction PhenX;;TRIAL;2.38;2.65 +66666-9;Mesenteric insufficiency;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Mesenteric insufficiency [PhenX];Mesenteric insufficiency PhenX;;TRIAL;2.38;2.65 +66667-7;Chronic peritonitis;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Chronic peritonitis [PhenX];Chronic peritonitis PhenX;;TRIAL;2.38;2.65 +66668-5;Stricture or upper gastrointestinal tract surgery;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Stricture or upper gastrointestinal tract surgery [PhenX];Stricture upper GI surgery PhenX;;TRIAL;2.38;2.65 +66669-3;Muscle atrophy or weakness;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Muscle atrophy or weakness [PhenX];Muscle atrophy weakness PhenX;;TRIAL;2.38;2.65 +6667-0;Microscopic observation;Prid;Pt;Tiss;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Tissue by KOH preparation;KOH Prep Tiss;;ACTIVE;1.0g;2.58 +66670-1;Deforming or erosive arthritis;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Deforming or erosive arthritis [PhenX];Deforming erosive arthritis PhenX;;TRIAL;2.38;2.65 +66671-9;Osteoporosis with fracture or vertebral collapse;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Osteoporosis with fracture or vertebral collapse [PhenX];Osteoporosis with fracture PhenX;;TRIAL;2.38;2.65 +66672-7;Avascular necrosis;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Avascular necrosis [PhenX];Avascular necrosis PhenX;;TRIAL;2.38;2.65 +66673-5;Osteomyelitis;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Osteomyelitis [PhenX];Osteomyelitis PhenX;;TRIAL;2.38;2.65 +66674-3;Scarring chronic alopecia;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Scarring chronic alopecia [PhenX];Scarring chronic alopecia PhenX;;TRIAL;2.38;2.65 +66675-0;Extensive scarring or panniculum other than scalp and pulp space;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Extensive scarring or panniculum other than scalp and pulp space [PhenX];Skin scarring panniculum PhenX;;TRIAL;2.38;2.65 +66676-8;Skin ulceration for >6Mo;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Skin ulceration for >6 months [PhenX];Skin ulceration PhenX;;TRIAL;2.38;2.65 +66677-6;Premature gonadal failure;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Premature gonadal failure [PhenX];Premature gonadal failure PhenX;;TRIAL;2.38;2.65 +66678-4;Diabetes;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Diabetes [PhenX];Diabetes PhenX;;TRIAL;2.38;2.65 +66679-2;Malignancy;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Malignancy [PhenX];Malignancy PhenX;;TRIAL;2.38;2.65 +666-8;Microscopic observation;Prid;Pt;XXX;Nom;India ink preparation;MICRO;1;Microscopic observation [Identifier] in Specimen by India ink prep;India Ink Prep Spec;;ACTIVE;1.0;2.73 +66680-0;How well do you speak english;Find;Pt;^Patient;Ord;NLAAS;PHENX;2;How well do you speak English [NLAAS];How well speak English NLAAS;;ACTIVE;2.38;2.65 +66681-8;How well do you read english;Find;Pt;^Patient;Ord;NLAAS;PHENX;2;How well do you read english [NLAAS];How well read english NLAAS;;ACTIVE;2.38;2.65 +66682-6;How well do you write in english;Find;Pt;^Patient;Ord;NLAAS;PHENX;2;How well do you write in english [NLAAS];How well write in english NLAAS;;ACTIVE;2.38;2.65 +66683-4;What language do you speak with most of your friends;Find;Pt;^Patient;Nom;NLAAS;PHENX;2;What language do you speak with most of your friends [NLAAS];Language speak with friends NLAAS;;ACTIVE;2.38;2.65 +66684-2;I am surprised at the things I do while in a great mood;Find;Pt;^Patient;Ord;UPPS-P;PHENX;2;I am surprised at the things I do while in a great mood [UPPS-P];Surpris actions great mood UPPS-P;;ACTIVE;2.38;2.65 +66685-9;If I feel like doing something, I tend to do it, even if it's bad;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;If I feel like doing something, I tend to do it, even if it's bad [UPPS-R-Child];Do what I feel like UPPS-R-C;;ACTIVE;2.38;2.65 +66686-7;I like new, thrilling things to happen;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I like new, thrilling things to happen [UPPS-R-Child];Like thrilling things UPPS-R-C;;ACTIVE;2.38;2.65 +66687-5;I like to see things through to the end;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I like to see things through to the end [UPPS-R-Child];See things through UPPS-R-C;;ACTIVE;2.38;2.65 +6668-8;Microscopic observation;Prid;Pt;Tiss;Nom;M'Fadyean stain;MICRO;1;Microscopic observation [Identifier] in Tissue by M'Fadyean stain;M'Fadyean Stn Tiss;;ACTIVE;1.0g;2.22 +66688-3;I tend to blurt out things without thinking;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I tend to blurt out things without thinking [UPPS-R-Child];Blurt out things W/O thinking UPPS-R-C;;ACTIVE;2.38;2.65 +66689-1;I am upset when I am not finished with things;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I am upset when I am not finished with things [UPPS-R-Child];Upset when not finished UPPS-R-C;;ACTIVE;2.38;2.65 +66690-9;I like to stop and think about something before I do it;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I like to stop and think about something before I do it [UPPS-R-Child];Stop and think UPPS-R-C;;ACTIVE;2.38;2.65 +66691-7;When I feel bad, I often do things I later regret in order to make myself feel better now;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I feel bad, I often do things I later regret in order to make myself feel better now [UPPS-R-Child];Do things I later regret UPPS-R-C;;ACTIVE;2.38;2.65 +66692-5;I would like water skiing;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I would like water skiing [UPPS-R-Child];Would like water skiing UPPS-R-C;;ACTIVE;2.38;2.65 +66693-3;I like to know just what to do before I start a project;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I like to know just what to do before I start a project [UPPS-R-Child];Like to know what to do UPPS-R-C;;ACTIVE;2.38;2.65 +66694-1;Sometimes when I feel bad, I keep doing something even though it is making me feel worse;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;Sometimes when I feel bad, I keep doing something even though it is making me feel worse [UPPS-R-Child];Keep doing even feel worse UPPS-R-C;;ACTIVE;2.38;2.65 +66695-8;I enjoy taking risks;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I enjoy taking risks [UPPS-R-Child];Enjoy taking risks UPPS-R-C;;ACTIVE;2.38;2.65 +6669-6;Microscopic observation;Prid;Pt;Tiss;Nom;Macchiavello stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Macchiavello stain;Macchiavello Stn Tiss;;ACTIVE;1.0g;2.22 +66696-6;It is easy for me to think hard;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;It is easy for me to think hard [UPPS-R-Child];Easy to think hard UPPS-R-C;;ACTIVE;2.38;2.65 +66697-4;I would like parachute jumping;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I would like parachute jumping [UPPS-R-Child];Would like parachute jumping UPPS-R-C;;ACTIVE;2.38;2.65 +66698-2;I try to take a careful approach to things;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I try to take a careful approach to things [UPPS-R-Child];Take a careful approach UPPS-R-C;;ACTIVE;2.38;2.65 +66699-0;I like new, thrilling things, even if they are a little scary;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I like new, thrilling things, even if they are a little scary [UPPS-R-Child];Like new thrilling things UPPS-R-C;;ACTIVE;2.38;2.65 +66700-6;I tend to get things done on time;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I tend to get things done on time [UPPS-R-Child];Tend to get things done UPPS-R-C;;ACTIVE;2.38;2.65 +66701-4;When I feel rejected, I often say things that I later regret;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I feel rejected, I often say things that I later regret [UPPS-R-Child];Say things regret when rejected UPPS-R-C;;ACTIVE;2.38;2.65 +66702-2;I am very careful;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I am very careful [UPPS-R-Child];Very careful UPPS-R-C;;ACTIVE;2.38;2.65 +66703-0;I like to know what to expect, before doing something new;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I like to know what to expect, before doing something new [UPPS-R-Child];Like to know what to expect UPPS-R-C;;ACTIVE;2.38;2.65 +6670-4;Microscopic observation;Prid;Pt;Tiss;Nom;Malaria smear;MICRO;1;Microscopic observation [Identifier] in Tissue by Malaria smear;Malaria Smear Tiss;;ACTIVE;1.0g;2.22 +66704-8;I would like to ski very fast down a high mountain slope;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I would like to ski very fast down a high mountain slope [UPPS-R-Child];Like to ski fast UPPS-R-C;;ACTIVE;2.38;2.65 +66705-5;I tend to stop and think before doing things;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I tend to stop and think before doing things [UPPS-R-Child];Stop think before doing things UPPS-R-C;;ACTIVE;2.38;2.65 +66706-3;Before making a choice, I tend to think about both the good things and the bad things about the choice;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;Before making a choice, I tend to think about both the good things and the bad things about the choice [UPPS-R-Child];Consider good and bad UPPS-R-C;;ACTIVE;2.38;2.65 +66707-1;When I am mad, I sometimes say things that I later regret;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I am mad, I sometimes say things that I later regret [UPPS-R-Child];Say things regret when mad UPPS-R-C;;ACTIVE;2.38;2.65 +66708-9;When I am very happy, I can't stop myself from going overboard;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I am very happy, I can't stop myself from going overboard [UPPS-R-Child];Can't stop going overboard UPPS-R-C;;ACTIVE;2.38;2.65 +66709-7;When I am really thrilled, I tend not to think about the results of my actions;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I am really thrilled, I tend not to think about the results of my actions [UPPS-R-Child];Don't think action results UPPS-R-C;;ACTIVE;2.38;2.65 +66710-5;When I am in a great mood, I tend to do things that could cause me problems;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I am in a great mood, I tend to do things that could cause me problems [UPPS-R-Child];Do things cause problems UPPS-R-C;;ACTIVE;2.38;2.65 +66711-3;I tend to act without thinking when I am very, very happy;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I tend to act without thinking when I am very, very happy [UPPS-R-Child];Act W/O thinking when happy UPPS-R-C;;ACTIVE;2.38;2.65 +6671-2;Microscopic observation;Prid;Pt;Tiss;Nom;Methenamine silver nitrate stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Methenamine silver nitrate stain;MS Nitrate Stn Tiss;;ACTIVE;1.0g;2.22 +66712-1;When I get really happy about something, I tend to do things that can lead to trouble;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I get really happy about something, I tend to do things that can lead to trouble [UPPS-R-Child];Actions lead to trouble UPPS-R-C;;ACTIVE;2.38;2.65 +66713-9;When I am really happy, I tend to get out of control;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;When I am really happy, I tend to get out of control [UPPS-R-Child];Out of control when happy UPPS-R-C;;ACTIVE;2.38;2.65 +66714-7;Vespula vulgaris recombinant (rVes v) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common wasp recombinant (rVes v) 1 IgE Ab [Units/volume] in Serum;Common wasp (rVes v) 1 IgE Qn;;ACTIVE;2.38;2.70 +66715-4;Vespula vulgaris recombinant (rVes v) 1 Ab.IgE.RAST Class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common wasp recombinant (rVes v) 1 IgE Ab RAST class [Presence] in Serum;Common wasp (rVes v) 1 IgE RAST Ql;;ACTIVE;2.38;2.70 +66716-2;Chlorhexidine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chlorhexidine IgE Ab RAST class [Presence] in Serum;Chlorhexidine IgE RAST Ql;;ACTIVE;2.38;2.70 +66717-0;Chlorhexidine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chlorhexidine IgE Ab [Units/volume] in Serum;Chlorhexidine IgE Qn;;ACTIVE;2.38;2.70 +66718-8;Rickettsia typhi & Rickettsia spotted fever group Ab.IgG & IgM;Imp;Pt;XXX;Nom;;MICRO;1;Rickettsia typhi and Rickettsia spotted fever group IgG and IgM [Interpretation] in Specimen;R typhi and SF IgG+IgM Spec-Imp;;ACTIVE;2.38;2.69 +66719-6;Adenovirus DNA;LnCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Urine by NAA with probe detection;HAdV DNA Ur NAA+probe-Log#;;ACTIVE;2.38;2.70 +6672-0;Microscopic observation;Prid;Pt;Tiss;Nom;Methylene blue stain.Loeffler;MICRO;1;Microscopic observation [Identifier] in Tissue by Methylene blue stain.Loeffler;Loeffler MB Stn Tiss;;ACTIVE;1.0g;2.22 +66720-4;Adenovirus DNA;LnCnc;Pt;Body fld;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Body fluid by NAA with probe detection;HAdV DNA Fld NAA+probe-Log#;;ACTIVE;2.38;2.70 +66721-2;Adenovirus DNA;NCnc;Pt;Body fld;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Body fluid by NAA with probe detection;HAdV DNA # Fld NAA+probe;;ACTIVE;2.38;2.70 +66722-0;Adenovirus DNA;LnCnc;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Tissue by NAA with probe detection;HAdV DNA Tiss NAA+probe-Log#;;ACTIVE;2.38;2.70 +66723-8;Adenovirus DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HAdV DNA SerPl NAA+probe-Log#;;ACTIVE;2.38;2.73 +66724-6;Adenovirus DNA;LnCnc;Pt;Stool;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Stool by NAA with probe detection;HAdV DNA Stl NAA+probe-Log#;;ACTIVE;2.38;2.70 +66725-3;Adenovirus DNA;LnCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection;HAdV DNA Bld NAA+probe-Log#;;ACTIVE;2.38;2.70 +66726-1;Adenovirus DNA;LnCnc;Pt;Genital;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Genital specimen by NAA with probe detection;HAdV DNA Genital NAA+probe-Log#;;ACTIVE;2.38;2.70 +66727-9;Adenovirus DNA;NCnc;Pt;Genital;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Genital specimen by NAA with probe detection;HAdV DNA # Genital NAA+probe;;ACTIVE;2.38;2.70 +66728-7;Adenovirus DNA;LnCnc;Pt;Skin;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Skin by NAA with probe detection;HAdV DNA Skin NAA+probe-Log#;;ACTIVE;2.38;2.70 +66729-5;Adenovirus DNA;NCnc;Pt;Skin;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Skin by NAA with probe detection;HAdV DNA # Skin NAA+probe;;ACTIVE;2.38;2.70 +66730-3;Adenovirus DNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HAdV DNA CSF NAA+probe-Log#;;ACTIVE;2.38;2.70 +66731-1;Adenovirus DNA;LnCnc;Pt;Sputum/Bronchial;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Sputum or Bronchial by NAA with probe detection;HAdV DNA Spt/Bro NAA+probe-Log#;;ACTIVE;2.38;2.70 +66732-9;Corticotropin;MSCnc;Pt;Plas;Qn;;CHEM;1;Corticotropin [Mass or Moles/volume] in Plasma;ACTH Plas-msCnc;;DISCOURAGED;2.38;2.70 +66733-7;Cortisol^afternoon specimen;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass or Moles/volume] in Serum or Plasma --afternoon specimen;Cortis afternoon SerPl-msCnc;;DISCOURAGED;2.38;2.70 +66734-5;Glucagon;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucagon [Mass or Moles/volume] in Serum or Plasma;Glucagon SerPl-msCnc;;DISCOURAGED;2.38;2.70 +66735-2;Cortisol^AM peak specimen;MSCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass or Moles/volume] in Serum or Plasma --AM peak specimen;Cortis AM peak SerPl-msCnc;;DISCOURAGED;2.38;2.70 +66736-0;Normalized silica clotting time;Ratio;Pt;PPP;Qn;;COAG;1;Normalized silica clotting time of Platelet poor plasma;Normalized SCT PPP-Rto;;ACTIVE;2.38;2.73 +66737-8;CYP2C19 gene.c.1A>G(*4);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene c.1A>G(*4) [Presence] in Blood or Tissue by Molecular genetics method;CYP2C19 c.1A>G(*4) Bld/T Ql;;ACTIVE;2.38;2.67 +6673-8;Microscopic observation;Prid;Pt;Tiss;Nom;Neisser stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Neisser stain;Neisser Stn Tiss;;ACTIVE;1.0g;2.22 +66738-6;CYP2C19 gene.c.358T>C(*8);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene c.358T>C(*8) [Presence] in Blood or Tissue by Molecular genetics method;CYP2C19 c.358T>C(*8) Bld/T Ql;;ACTIVE;2.38;2.67 +66739-4;CYP2C19 gene.c.395G>A(*6);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene c.395G>A(*6) [Presence] in Blood or Tissue by Molecular genetics method;CYP2C19 c.G395G>A(*6) Bld/T Ql;;ACTIVE;2.38;2.67 +66740-2;CYP2C19 gene.c.636G>A(*3);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene c.636G>A(*3) [Presence] in Blood or Tissue by Molecular genetics method;CYP2C19 c.636G>A(*3) Bld/T Ql;;ACTIVE;2.38;2.73 +66741-0;CYP2C19 gene.c.681G>A(*2);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene c.681G>A(*2) [Presence] in Blood or Tissue by Molecular genetics method;CYP2C19 c.681G>A(*2) Bld/T Ql;;ACTIVE;2.38;2.73 +66742-8;CYP2C19 gene.c.806C>T(*17);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene c.806C>T(*17) [Presence] in Blood or Tissue by Molecular genetics method;CYP2C19 c.806C>T(*17) Bld/T Ql;;ACTIVE;2.38;2.73 +66743-6;CYP2C19 gene.c.IVS5+2T>A(*7);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene c.IVS5+2T>A(*7) [Presence] in Blood or Tissue by Molecular genetics method;CYP2C19 c.IVS5+2T>A(*7) Bld/T Ql;;ACTIVE;2.38;2.67 +66744-4;Heparin/body weight;MCnt;Pt;Bld;Qn;;COAG;1;Heparin/Body weight [Mass/mass] in Blood;Heparin/BW Bld-mCnt;;ACTIVE;2.38;2.73 +66745-1;Coagulum lysis^30M post maximum clot amplitude;LenFr;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot Lysis [Length fraction] in Blood by Thromboelastography --30 minutes post maximum clot amplitude;Clot Lysis 30M p MA LenFr Bld TEG;;ACTIVE;2.38;2.73 +6674-6;Ova & parasites identified;Prid;Pt;Tiss;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Tissue by Light microscopy;O+P Tiss Micro;;ACTIVE;1.0g;2.38 +66746-9;Specimen type;Type;Pt;Specimen;Nom;;SPEC;1;Specimen type;Specimen type;;ACTIVE;2.38;2.73 +66747-7;Clotting time;Time;Pt;Bld;Qn;Heparin protamine titration;COAG;1;Clotting time of Blood by Heparin protamine titration;Clotting time Bld HPT;;ACTIVE;2.38;2.73 +66748-5;Clot angle;Angle;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot angle in Blood by Thromboelastography;Clot angle Bld TEG;;ACTIVE;2.38;2.73 +66749-3;Circulatory assist status;Prid;Pt;^Patient;Nom;;COAG;1;Circulatory assist status [Identifier];Circ assist status Patient;;ACTIVE;2.38;2.38 +66750-1;Clot angle^after addition of heparinase;Angle;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot angle in Blood by Thromboelastography --after addition of heparinase;Clot angle P Hpase Bld TEG;;ACTIVE;2.38;2.73 +66751-9;Clot strength;ArEnrg;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot strength in Blood by Thromboelastography;Clot strength Bld TEG;;ACTIVE;2.38;2.73 +66752-7;Clot strength^after addition of heparinase;ArEnrg;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot strength in Blood by Thromboelastography --after addition of heparinase;Clot strength P Hpase Bld TEG;;ACTIVE;2.38;2.73 +6675-3;Microscopic observation;Prid;Pt;Tiss;Nom;Periodic acid-Schiff stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Periodic acid-Schiff stain;PAS Stn Tiss;;ACTIVE;1.0g;2.22 +66753-5;Clot formation^after addition of heparinase;Time;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot formation [Time] in Blood by Thromboelastography --after addition of heparinase;CFT P Hpase Bld TEG;;ACTIVE;2.38;2.73 +66754-3;Clot firmness^30M after maximum clot amplitude after addition of heparinase;LenFr;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot firmness [Length fraction] in Blood by Thromboelastography --30 min p max clot amplitude + heparinase;CF 30M p MA p hepase LenFr Bld TEG;;ACTIVE;2.38;2.73 +66755-0;Maximum clot firmness^after addition of heparinase;Len;Pt;Bld;Qn;Thromboelastography;COAG;1;Maximum clot firmness [Length] in Blood by Thromboelastography --after addition of heparinase;MCF P Hpase Bld TEG;;ACTIVE;2.38;2.73 +66756-8;Clot initiation^after addition of heparinase;Time;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot initiation [Time] in Blood by Thromboelastography --after addition of heparinase;Clot init P Hpase Bld TEG;;ACTIVE;2.38;2.73 +66757-6;Clot lysis estimate;Prctl;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot lysis estimate [Percentile] by Thromboelastography;Clot lysis estimate Prctl Bld TEG;;ACTIVE;2.38;2.70 +66758-4;Clot firmness reduction^60M post maximum clot amplitude;LenFr;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot firmness reduction [Length fraction] in Blood by Thromboelastography --60M post maximum clot amplitude;CF reduc 60M p MA LenFr Bld TEG;;ACTIVE;2.38;2.70 +66759-2;Heparin neutralization;PrThr;Pt;Bld;Ord;Thromboelastography;COAG;1;Heparin neutralization [Presence] in Blood by Thromboelastography;Heparin Nt Bld Ql TEG;;ACTIVE;2.38;2.73 +667-6;Microscopic observation;Prid;Pt;XXX;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Specimen by KOH preparation;KOH Prep Spec;;ACTIVE;1.0;2.73 +66760-0;Coagulation index;ACnc;Pt;Bld;Qn;Thromboelastography;COAG;1;Coagulation index in Blood by Thromboelastography;CI Bld TEG-aCnc;;ACTIVE;2.38;2.73 +6676-1;Enterobius vermicularis;PrThr;Pt;Anal;Ord;Pinworm examination;MICRO;1;Enterobius vermicularis [Presence] in Anal by Pinworm exam;E vermicularis Anal Ql Pinworm Exam;;ACTIVE;1.0g;2.73 +66761-8;Lymphocytes/100 leukocytes;NFr;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Dialysis fluid by Manual count;Lymphocytes/leuk NFr Dial fld Manual;;ACTIVE;2.38;2.70 +66762-6;Choriogonadotropin.beta subunit;ACnc;Pt;Plr fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Units/volume] in Pleural fluid;B-HCG Plr-aCnc;;ACTIVE;2.40;2.70 +66763-4;Choriogonadotropin.beta subunit;ACnc;Pt;Periton fld;Qn;;CHEM;1;Choriogonadotropin.beta subunit [Units/volume] in Peritoneal fluid;B-HCG Prt-aCnc;;ACTIVE;2.40;2.70 +66764-2;Erythrocytes.nucleated/100 leukocytes;Ratio;Pt;BldCo;Qn;;HEM/BC;1;Nucleated erythrocytes/100 leukocytes [Ratio] in Cord blood;nRBC/100 WBC BldCo-Rto;;ACTIVE;2.38;2.70 +66765-9;Albumin.pericard fld/Albumin.SerPl;RelRto;Pt;Pericard fld+Ser/Plas;Qn;;CHEM;1;Albumin in pericardial fld/Albumin in Serum or Plasma;Alb Pcar/SerPl;;ACTIVE;2.38;2.70 +66766-7;Albumin.periton fld/Albumin.SerPl;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Albumin in peritoneal fluid/Albumin in Serum or Plasma;Alb Prt/SerPl;;ACTIVE;2.38;2.70 +66767-5;Vanillylmandelate/body weight;RelSRat;24H;Urine;Qn;;CHEM;1;Vanillylmandelate/Body weight [Moles/kg/time] in 24 hour Urine;VMA/BW 24h Ur-RelSRat;;ACTIVE;2.38;2.70 +66768-3;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Cord blood;WBC nRBC cor # BldCo;;ACTIVE;2.38;2.70 +66769-1;Triglyceride;SCnc;Pt;Periton fld;Qn;;CHEM;1;Triglyceride [Moles/volume] in Peritoneal fluid;Trigl Prt-sCnc;;ACTIVE;2.38;2.70 +66773-3;Feelings and emotions;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Feelings and emotions [PhenX];Feelings and emotions PhenX;;TRIAL;2.38;2.65 +66774-1;How much have you felt this way during the past few Ws;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much have you felt this way during the past few Ws [PhenX];Felt this way past few Ws PhenX;;TRIAL;2.38;2.65 +66775-8;I can always manage to solve difficult problems if I try hard enough;Find;Pt;^Patient;Ord;GSE;PHENX;2;I can always manage to solve difficult problems if I try hard enough [GSE];Can solve difficult problems GSE;;ACTIVE;2.38;2.65 +66776-6;If someone opposes me, I can find the means and ways to get what I want;Find;Pt;^Patient;Ord;GSE;PHENX;2;If someone opposes me, I can find the means and ways to get what I want [GSE];Can get what I want GSE;;ACTIVE;2.38;2.65 +66777-4;It is easy for me to stick to my aims and accomplish my goals;Find;Pt;^Patient;Ord;GSE;PHENX;2;It is easy for me to stick to my aims and accomplish my goals [GSE];Easy to accomplish my goals GSE;;ACTIVE;2.38;2.65 +66778-2;I am confident that I could deal efficiently with unexpected events;Find;Pt;^Patient;Ord;GSE;PHENX;2;I am confident that I could deal efficiently with unexpected events [GSE];Deal with unexpected events GSE;;ACTIVE;2.38;2.65 +6677-9;Microscopic observation;Prid;Pt;Tiss;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Tiss;;ACTIVE;1.0g;2.22 +66779-0;Thanks to my resourcefulness, I know how to handle unforeseen situations;Find;Pt;^Patient;Ord;GSE;PHENX;2;Thanks to my resourcefulness, I know how to handle unforeseen situations [GSE];Handle unforeseen situations GSE;;ACTIVE;2.38;2.65 +66780-8;I can solve most problems if I invest the necessary effort;Find;Pt;^Patient;Ord;GSE;PHENX;2;I can solve most problems if I invest the necessary effort [GSE];Can solve most problems GSE;;ACTIVE;2.38;2.65 +66781-6;I can remain calm when facing difficulties because I can rely on my coping abilities;Find;Pt;^Patient;Ord;GSE;PHENX;2;I can remain calm when facing difficulties because I can rely on my coping abilities [GSE];Can remain calm GSE;;ACTIVE;2.38;2.65 +66782-4;When I am confronted with a problem, I can usually find several solutions;Find;Pt;^Patient;Ord;GSE;PHENX;2;When I am confronted with a problem, I can usually find several solutions [GSE];Can find several solutions GSE;;ACTIVE;2.38;2.65 +66783-2;If I am in trouble, I can usually think of a solution;Find;Pt;^Patient;Ord;GSE;PHENX;2;If I am in trouble, I can usually think of a solution [GSE];Can think of solution GSE;;ACTIVE;2.38;2.65 +66784-0;I can usually handle whatever comes my way;Find;Pt;^Patient;Ord;GSE;PHENX;2;I can usually handle whatever comes my way [GSE];Handle whatever comes GSE;;ACTIVE;2.38;2.65 +66785-7;How well can you get teachers to help you when you get stuck on schoolwork;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you get teachers to help you when you get stuck on schoolwork [SEQ-C];Can get teachers to help SEQ-C;;ACTIVE;2.38;2.65 +66786-5;How well can you express your opinions when other classmates disagree with you;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you express your opinions when other classmates disagree with you [SEQ-C];Express opinions SEQ-C;;ACTIVE;2.38;2.65 +6678-7;Microscopic observation;Prid;Pt;Tiss;Nom;Toluidine blue O stain;PATH;1;Microscopic observation [Identifier] in Tissue by Toluidine blue O stain;TBO Stn Tiss;;ACTIVE;1.0g;2.22 +66787-3;How well do you succeed in cheering yourself up when an unpleasant event has happened;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in cheering yourself up when an unpleasant event has happened [SEQ-C];Cheering self up SEQ-C;;ACTIVE;2.38;2.65 +66788-1;How well can you study when there are other interesting things to do;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you study when there are other interesting things to do [SEQ-C];How well can study SEQ-C;;ACTIVE;2.38;2.65 +66789-9;How well do you succeed in becoming calm again when you are very scared;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in becoming calm again when you are very scared [SEQ-C];Calm again when scared SEQ-C;;ACTIVE;2.38;2.65 +66790-7;How well can you become friends with other children;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you become friends with other children [SEQ-C];Become friends with children SEQ-C;;ACTIVE;2.38;2.65 +66791-5;How well can you study a chapter for a test;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you study a chapter for a test [SEQ-C];Study chapter for test SEQ-C;;ACTIVE;2.38;2.65 +66792-3;How well can you have a chat with an unfamiliar person;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you have a chat with an unfamiliar person [SEQ-C];Chat with unfamiliar person SEQ-C;;ACTIVE;2.38;2.65 +66793-1;How well can you prevent becoming nervous;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you prevent becoming nervous [SEQ-C];Prevent becoming nervous SEQ-C;;ACTIVE;2.38;2.65 +66794-9;How well do you succeed in finishing all your homework every day;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in finishing all your homework every day [SEQ-C];Finish homework every day SEQ-C;;ACTIVE;2.38;2.65 +6679-5;Microscopic observation;Prid;Pt;Tiss;Nom;Warthin-Starry stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Warthin-Starry stain;WS Stn Tiss;;ACTIVE;1.0g;2.22 +66795-6;How well can you work in harmony with your classmates;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you work in harmony with your classmates [SEQ-C];Harmony with classmates SEQ-C;;ACTIVE;2.38;2.65 +66796-4;How well can you control your feelings;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you control your feelings [SEQ-C];Control your feelings SEQ-C;;ACTIVE;2.38;2.65 +66797-2;How well can you pay attention during every class;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you pay attention during every class [SEQ-C];Pay attention during class SEQ-C;;ACTIVE;2.38;2.65 +66798-0;How well can you tell other children that they are doing something that you don't like;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you tell other children that they are doing something that you don't like [SEQ-C];Tell other children SEQ-C;;ACTIVE;2.38;2.65 +66799-8;How well can you give yourself a pep talk when you feel low;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you give yourself a pep talk when you feel low [SEQ-C];Give self pep talk SEQ-C;;ACTIVE;2.38;2.65 +66800-4;How well do you succeed in understanding all subjects in school;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in understanding all subjects in school [SEQ-C];Understand subjects in school SEQ-C;;ACTIVE;2.38;2.65 +66801-2;How well can you tell a funny event to a group of children;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you tell a funny event to a group of children [SEQ-C];Tell funny event SEQ-C;;ACTIVE;2.38;2.65 +66802-0;How well can you tell a friend that you don't feel well;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well can you tell a friend that you don't feel well [SEQ-C];Tell friend don't feel well SEQ-C;;ACTIVE;2.38;2.65 +6680-3;Microscopic observation;Prid;Pt;Tiss;Nom;Wet preparation;MICRO;1;Microscopic observation [Identifier] in Tissue by Wet preparation;Wet Prep Tiss;;ACTIVE;1.0g;2.22 +66803-8;How well do you succeed in satisfying your parents with your schoolwork;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in satisfying your parents with your schoolwork [SEQ-C];Satisfy parents with schoolwork SEQ-C;;ACTIVE;2.38;2.65 +66804-6;How well do you succeed in staying friends with other children;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in staying friends with other children [SEQ-C];Stay friends SEQ-C;;ACTIVE;2.38;2.65 +66805-3;How well do you succeed in suppressing unpleasant thoughts;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in suppressing unpleasant thoughts [SEQ-C];Suppress unpleasant thoughts SEQ-C;;ACTIVE;2.38;2.65 +66806-1;How well do you succeed in passing a test;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in passing a test [SEQ-C];Pass test SEQ-C;;ACTIVE;2.38;2.65 +66807-9;How well do you succeed in preventing quarrels with other children;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in preventing quarrels with other children [SEQ-C];Prevent quarrels with children SEQ-C;;ACTIVE;2.38;2.65 +66808-7;How well do you succeed in not worrying about things that might happen;Find;Pt;^Patient;Nom;SEQ-C;PHENX;2;How well do you succeed in not worrying about things that might happen [SEQ-C];Worry things might happen SEQ-C;;ACTIVE;2.38;2.65 +66809-5;How much does your spouse or partner really care about you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much does your spouse or partner really care about you [MIDUS II];Spouse care about you MIDUS II;;ACTIVE;2.38;2.65 +66810-3;How much does he or she understand the way you feel about things;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much does he or she understand the way you feel about things [MIDUS II];Spouse understand way you feel MIDUS II;;ACTIVE;2.38;2.65 +6681-1;Microscopic observation;Prid;Pt;Tiss;Nom;Wright stain;MICRO;1;Microscopic observation [Identifier] in Tissue by Wright stain;Wright Stn Tiss;;ACTIVE;1.0g;2.22 +66811-1;How much does he or she appreciate you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much does he or she appreciate you [MIDUS II];Spouse appreciate you MIDUS II;;ACTIVE;2.38;2.65 +66812-9;How much can you rely on him or her for help if you have a serious problem;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much can you rely on him or her for help if you have a serious problem [MIDUS II];Rely on spouse MIDUS II;;ACTIVE;2.38;2.65 +66813-7;How much can you open up to him or her if you need to talk about your worries;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much can you open up to him or her if you need to talk about your worries [MIDUS II];Open up to spouse MIDUS II;;ACTIVE;2.38;2.65 +66814-5;How much can you relax and be yourself around him or her;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much can you relax and be yourself around him or her [MIDUS II];Relax around spouse MIDUS II;;ACTIVE;2.38;2.65 +66815-2;How often does your spouse or partner make too many demands on you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often does your spouse or partner make too many demands on you [MIDUS II];Spouse too many demands MIDUS II;;ACTIVE;2.38;2.65 +66816-0;How often does he or she make you feel tense;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often does he or she make you feel tense [MIDUS II];Spouse make feel tense MIDUS II;;ACTIVE;2.38;2.65 +66817-8;How often does he or she argue with you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often does he or she argue with you [MIDUS II];Spouse argue with you MIDUS II;;ACTIVE;2.38;2.65 +66818-6;How often does he or she criticize you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often does he or she criticize you [MIDUS II];Spouse criticize you MIDUS II;;ACTIVE;2.38;2.65 +66819-4;How often does he or she let you down when you are counting on him or her;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often does he or she let you down when you are counting on him or her [MIDUS II];Spouse let you down MIDUS II;;ACTIVE;2.38;2.65 +66820-2;How often does he or she get on your nerves;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often does he or she get on your nerves [MIDUS II];Spouse get on nerves MIDUS II;;ACTIVE;2.38;2.65 +66821-0;In the last Mo, how often have you been upset because of something that happened unexpectedly;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you been upset because of something that happened unexpectedly [PSS-10];Upset because of unexpected PSS-10;;ACTIVE;2.38;2.65 +66822-8;In the last Mo, how often have you felt that you were unable to control the important things in your life;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you felt that you were unable to control the important things in your life [PSS-10];Unable control important things PSS-10;;ACTIVE;2.38;2.65 +66823-6;In the last Mo, how often have you felt nervous and stressed;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you felt nervous and stressed [PSS-10];Felt nervous stressed PSS-10;;ACTIVE;2.38;2.65 +66824-4;In the last Mo, how often have you felt confident about your ability to handle your personal problems;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you felt confident about your ability to handle your personal problems [PSS-10];Confident handle personal prob PSS-10;;ACTIVE;2.38;2.65 +66825-1;In the last Mo, how often have you felt that things were going your way;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you felt that things were going your way [PSS-10];Felt things going your way PSS-10;;ACTIVE;2.38;2.65 +66826-9;In the last Mo, how often have you found that you could not cope with all the things that you had to do;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you found that you could not cope with all the things that you had to do [PSS-10];Not cope with all things PSS-10;;ACTIVE;2.38;2.65 +66827-7;In the last Mo, how often have you been able to control irritations in your life;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you been able to control irritations in your life [PSS-10];Able to control irritations PSS-10;;ACTIVE;2.38;2.65 +66828-5;In the last Mo, how often have you felt that you were on top of things;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you felt that you were on top of things [PSS-10];Felt on top of things PSS-10;;ACTIVE;2.38;2.65 +6682-9;Microscopic observation;Prid;Pt;Tiss;Nom;Wright Giemsa stain;PATH;1;Microscopic observation [Identifier] in Tissue by Wright Giemsa stain;Wright Gie Stn Tiss;;ACTIVE;1.0g;2.22 +66829-3;In the last Mo, how often have you been angered because of things that were outside of your control;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you been angered because of things that were outside of your control [PSS-10];Angered things outside control PSS-10;;ACTIVE;2.38;2.65 +66830-1;In the last Mo, how often have you felt difficulties were piling up so high that you could not overcome them;Find;1Mo;^Patient;Ord;Perceived Stress Scale-10;PHENX;2;In the last month, how often have you felt difficulties were piling up so high that you could not overcome them [PSS-10];Difficulties piling up PSS-10;;ACTIVE;2.38;2.65 +66831-9;Not including your spouse or partner, how much do members of your family really care about you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;Not including your spouse or partner, how much do members of your family really care about you [MIDUS II];Family really care about you MIDUS II;;ACTIVE;2.38;2.65 +66832-7;How much do they understand the way you feel about things;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much do they understand the way you feel about things [MIDUS II];Family understand way you feel MIDUS II;;ACTIVE;2.38;2.65 +66833-5;How much can you rely on them for help if you have a serious problem;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much can you rely on them for help if you have a serious problem [MIDUS II];Rely on family for help MIDUS II;;ACTIVE;2.38;2.65 +66834-3;How much can you open up to them if you need to talk about your worries;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much can you open up to them if you need to talk about your worries [MIDUS II];Open up to family MIDUS II;;ACTIVE;2.38;2.65 +66835-0;How much do you really care about the members of your family, not including your partner or spouse;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much do you really care about the members of your family, not including your partner or spouse [MIDUS II];Really care family MIDUS II;;ACTIVE;2.38;2.65 +66836-8;How much do you understand the way they feel about things;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much do you understand the way they feel about things [MIDUS II];You understand family MIDUS II;;ACTIVE;2.38;2.65 +6683-7;Coagulation reptilase induced;Time;Pt;PPP;Qn;Coag;COAG;1;Reptilase time;Reptilase time;;ACTIVE;1.0g;2.73 +66837-6;Not including your spouse or partner, how often do members of your family make too many demands on you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;Not including your spouse or partner, how often do members of your family make too many demands on you [MIDUS II];Family make demands MIDUS II;;ACTIVE;2.38;2.65 +66838-4;How often do they criticize you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often do they criticize you [MIDUS II];Family/friends criticize you MIDUS II;;ACTIVE;2.38;2.65 +66839-2;How often do they let you down when you are counting on them;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often do they let you down when you are counting on them [MIDUS II];Family/friends let you down MIDUS II;;ACTIVE;2.38;2.65 +668-4;Microscopic observation;Prid;Pt;XXX;Nom;M'Fadyean stain;MICRO;1;Microscopic observation [Identifier] in Specimen by M'Fadyean stain;M'Fadyean Stn Spec;;ACTIVE;1.0;2.69 +66840-0;How often do they get on your nerves;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often do they get on your nerves [MIDUS II];Family/friends get on nerves MIDUS II;;ACTIVE;2.38;2.65 +66841-8;How much do your friends really care about you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How much do your friends really care about you [MIDUS II];Friends care about you MIDUS II;;ACTIVE;2.38;2.65 +66842-6;How often do your friends make too many demands on you;Find;Pt;^Patient;Ord;MIDUS II;PHENX;2;How often do your friends make too many demands on you [MIDUS II];Friends make demands MIDUS II;;ACTIVE;2.38;2.65 +66843-4;I feel that I'm a person of worth, at least on an equal plane with others;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;I feel that I'm a person of worth, at least on an equal plane with others [Rosenberg];Person of worth Rosenberg;;ACTIVE;2.38;2.65 +66844-2;I feel that I have a number of good qualities;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;I feel that I have a number of good qualities [Rosenberg];Number good qualities Rosenberg;;ACTIVE;2.38;2.65 +6684-5;Coagulation reptilase induced;Time;Pt;PPP;Qn;Tilt tube;COAG;1;Deprecated Reptilase time in Platelet poor plasma by Coagulation assay;Deprecated Reptilase PPP Qn;;DEPRECATED;1.0g;2.36 +66845-9;All in all, I am inclined to feel that I am a failure;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;All in all, I am inclined to feel that I am a failure [Rosenberg];Inclined to feel failure Rosenberg;;ACTIVE;2.38;2.65 +66846-7;I am able to do things as well as most other people;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;I am able to do things as well as most other people [Rosenberg];Do as well as others Rosenberg;;ACTIVE;2.38;2.65 +66847-5;I feel I do not have much to be proud of;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;I feel I do not have much to be proud of [Rosenberg];Not much to be proud of Rosenberg;;ACTIVE;2.38;2.65 +66848-3;I take a positive attitude toward myself;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;I take a positive attitude toward myself [Rosenberg];Positive self attitude Rosenberg;;ACTIVE;2.38;2.65 +66849-1;On the whole, I am satisfied with myself;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;On the whole, I am satisfied with myself [Rosenberg];Satisfied with myself Rosenberg;;ACTIVE;2.38;2.65 +66850-9;I wish I could have more respect for myself;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;I wish I could have more respect for myself [Rosenberg];Wish have self respect Rosenberg;;ACTIVE;2.38;2.65 +66851-7;I certainly feel useless at times;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;I certainly feel useless at times [Rosenberg];Feel useless at times Rosenberg;;ACTIVE;2.38;2.65 +6685-2;Apolipoprotein B/Apolipoprotein A-I;MCrto;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Apolipoprotein B/Apolipoprotein A-I [Mass ratio] in Serum or Plasma;Deprecated Apo B/Apo A-I SerPl-mRto;;DEPRECATED;1.0g;2.36 +66852-5;At times I think I am no good at all;Find;Pt;^Patient;Ord;Rosenberg;PHENX;2;At times I think I am no good at all [Rosenberg];Times think no good Rosenberg;;ACTIVE;2.38;2.65 +66853-3;Myeloperoxidase;SCnc;Pt;Plas;Qn;;CHEM;1;Myeloperoxidase [Moles/volume] in Plasma;Myeloperoxidase Plas-sCnc;;ACTIVE;2.38;2.73 +66854-1;How often do you feel that you are in tune with the people around you;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that you are in tune with the people around you [UCLA Loneliness v3];In tune with people UCLA Lone v3;;ACTIVE;2.38;2.65 +66855-8;How often do you feel that you lack companionship;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that you lack companionship [UCLA Loneliness v3];Lack companionship UCLA Lone v3;;ACTIVE;2.38;2.65 +66856-6;How often do you feel that there is no one you can turn to;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that there is no one you can turn to [UCLA Loneliness v3];No one can turn to UCLA Lone v3;;ACTIVE;2.38;2.65 +66857-4;How often do you feel alone;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel alone [UCLA Loneliness v3];Feel alone UCLA Lone v3;;ACTIVE;2.38;2.65 +66858-2;How often do you feel part of a group of friends;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel part of a group of friends [UCLA Loneliness v3];Part of group of friends UCLA Lone v3;;ACTIVE;2.38;2.65 +66859-0;How often do you feel that you have a lot in common with the people around you;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that you have a lot in common with the people around you [UCLA Loneliness v3];Lot in common with people UCLA Lone v3;;ACTIVE;2.38;2.65 +6686-0;Ascorbate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Ascorbate [Mass/volume] in Blood;Deprecated Vit C SerPl-mCnc;;DEPRECATED;1.0g;2.36 +66860-8;How often do you feel that you are no longer close to anyone;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that you are no longer close to anyone [UCLA Loneliness v3];Not close to anyone UCLA Lone v3;;ACTIVE;2.38;2.65 +66861-6;How often do you feel that your interests and ideas are not shared by those around you;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that your interests and ideas are not shared by those around you [UCLA Loneliness v3];Interests not shared UCLA Lone v3;;ACTIVE;2.38;2.65 +66862-4;How often do you feel outgoing and friendly;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel outgoing and friendly [UCLA Loneliness v3];Outgoing and friendly UCLA Lone v3;;ACTIVE;2.38;2.65 +66863-2;How often do you feel close to people;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel close to people [UCLA Loneliness v3];Close to people UCLA Lone v3;;ACTIVE;2.38;2.65 +66864-0;How often do you feel left out;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel left out [UCLA Loneliness v3];Feel left out UCLA Lone v3;;ACTIVE;2.38;2.65 +66865-7;How often do you feel that your relationships with others are not meaningful;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that your relationships with others are not meaningful [UCLA Loneliness v3];Relationship not meaningful UCLA Lone v3;;ACTIVE;2.38;2.65 +66866-5;How often do you feel that no one really knows you well;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that no one really knows you well [UCLA Loneliness v3];No one knows UCLA Lone v3;;ACTIVE;2.38;2.65 +66867-3;How often do you feel isolated from others;Find;Pt;^Patient;Ord;;PHENX;2;How often do you feel isolated from others;Isolated from others;;ACTIVE;2.38;2.70 +66868-1;How often do you feel you can find companionship when you want it;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel you can find companionship when you want it [UCLA Loneliness v3];Companionship when want it UCLA Lone v3;;ACTIVE;2.38;2.65 +66869-9;How often do you feel that there are people who really understand you;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that there are people who really understand you [UCLA Loneliness v3];People understand you UCLA Lone v3;;ACTIVE;2.38;2.65 +66870-7;How often do you feel shy;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel shy [UCLA Loneliness v3];Feel shy UCLA Lone v3;;ACTIVE;2.38;2.65 +66871-5;How often do you feel that people are around you but not with you;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that people are around you but not with you [UCLA Loneliness v3];People not with you UCLA Lone v3;;ACTIVE;2.38;2.65 +66872-3;How often do you feel that there are people you can talk to;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that there are people you can talk to [UCLA Loneliness v3];People you can talk to UCLA Lone v3;;ACTIVE;2.38;2.65 +66874-9;FMR1 gene activation;NFr;Pt;Bld;Qn;Molgen;MOLPATH.MUT;1;FMR1 gene activation in Blood by Molecular genetics method;FMR1 activation NFr Bld;;ACTIVE;2.38;2.70 +66875-6;FMR1 gene methylation/methylated+unmethylated;NFr;Pt;Bld;Qn;Molgen;MOLPATH.MUT;1;FMR1 gene methylation/methylated+unmethylated in Blood by Molecular genetics method;FMR1 methylation NFr Bld;;ACTIVE;2.38;2.70 +66876-4;FMR1 gene premutation/premutation+full mutation;NFr;Pt;Bld;Qn;Molgen;MOLPATH.MUT;1;FMR1 gene premutation/premutation+full mutation in Blood by Molecular genetics method;FMR1 premutation NFr Bld;;ACTIVE;2.38;2.70 +66877-2;Skin Ab pattern;Imp;Pt;Ser;Nom;;SERO;1;Skin Ab pattern [Interpretation] in Serum;Skin Ab pattern Ser-Imp;;ACTIVE;2.38;2.38 +6687-8;Citrate;MRat;24H;Urine;Qn;;CHEM;1;Citrate [Mass/time] in 24 hour Urine;Citrate 24h Ur-mRate;;ACTIVE;1.0g;2.73 +66878-0;Skin Ab;Titr;Pt;Ser;Qn;;SERO;1;Skin Ab [Titer] in Serum;Skin Ab Titr Ser;;ACTIVE;2.38;2.70 +66879-8;Skin Ab.IgG;Titr;Pt;Ser;Qn;Guinea pig esophagus substrate;SERO;1;Skin IgG Ab [Titer] in Serum by Guinea pig esophagus substrate;Skin IgG Titr Ser GP esoph;;ACTIVE;2.38;2.70 +66880-6;Skin Ab.IgG pattern;Imp;Pt;Ser;Nom;Monkey esophagus substrate;SERO;1;Skin Ab.IgG pattern [Interpretation] in Serum by Monkey esophagus substrate;Skin Ab.IgG pattern Ser Monkey esoph-Imp;;ACTIVE;2.38;2.38 +66881-4;Skin Ab.IgG;PrThr;Pt;Ser;Ord;Monkey esophagus substrate;SERO;1;Skin IgG Ab [Presence] in Serum by Monkey esophagus substrate;Skin IgG Ser Ql Monkey esoph;;ACTIVE;2.38;2.73 +66882-2;Skin Ab.IgG;PrThr;Pt;Ser;Ord;Guinea pig esophagus substrate;SERO;1;Skin IgG Ab [Presence] in Serum by Guinea pig esophagus substrate;Skin IgG Ser Ql GP esoph;;ACTIVE;2.38;2.56 +66883-0;Skin Ab.IgG;Titr;Pt;Ser;Qn;Monkey esophagus substrate;SERO;1;Skin IgG Ab [Titer] in Serum by Monkey esophagus substrate;Skin IgG Titr Ser Monkey esoph;;ACTIVE;2.38;2.70 +66884-8;Skin Ab.IgG pattern;Imp;Pt;Ser;Nom;Guinea pig esophagus substrate;SERO;1;Skin Ab.IgG pattern [Interpretation] in Serum by Guinea pig esophagus substrate;Skin Ab.IgG pattern Ser GP esoph-Imp;;ACTIVE;2.38;2.38 +66885-5;Bacteria identified based on 16S rRNA gene;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing;Bacteria identified 16S rRNA Spec Seq;;ACTIVE;2.38;2.73 +6688-6;Coxsackievirus A16 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A16 Ab [Titer] in Serum by Complement fixation;CV A16 Ab Titr Ser CF;;ACTIVE;1.0g;2.73 +66886-3;Have you ever been involved in a natural disaster, such as a tornado, hurricane, flood, or earthquake;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been involved in a natural disaster, such as a tornado, hurricane, flood, or earthquake [LTVH];Natural disaster LTVH;;ACTIVE;2.38;2.65 +66887-1;How old were you the first time it happened;Time;Pt;^Patient;Qn;LTVH;PHENX;2;How old were you the first time it happened [LTVH];Exposure to violence age LTVH;;ACTIVE;2.38;2.65 +66888-9;Were you in danger of death or serious injury;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Were you in danger of death or serious injury [LTVH];Exposure to violence injury LTVH;;ACTIVE;2.38;2.65 +66889-7;Did you feel intense fear, helplessness, or horror;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Did you feel intense fear, helplessness, or horror [LTVH];Exposure to violence fear LTVH;;ACTIVE;2.38;2.65 +66890-5;Was there another time this happened;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Was there another time this happened [LTVH];Exposure to violence other LTVH;;ACTIVE;2.38;2.65 +66891-3;Have you ever been involved in a man-made disaster, such as a fire, train crash, car accident, or building collapse;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been involved in a man-made disaster, such as a fire, train crash, car accident, or building collapse [LTVH];Man-made disaster LTVH;;ACTIVE;2.38;2.65 +66892-1;Have you ever been involved in direct combat experience in a war;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been involved in direct combat experience in a war [LTVH];Combat experience LTVH;;ACTIVE;2.38;2.65 +66893-9;Have you ever lived in a war zone such as the Persian Gulf or Bosnia;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever lived in a war zone such as the Persian Gulf or Bosnia [LTVH];Lived war zone LTVH;;ACTIVE;2.38;2.65 +6689-4;Glucose^2H post meal;MCnc;Pt;Bld;Qn;;CHAL;1;Glucose [Mass/volume] in Blood --2 hours post meal;Glucose 2h p meal Bld-mCnc;;ACTIVE;1.0g;2.73 +66894-7;Have you ever had a serious accident at home, at work, or somewhere else;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever had a serious accident at home, at work, or somewhere else [LTVH];Serious accident LTVH;;ACTIVE;2.38;2.65 +66895-4;Have you ever been exposed to dangerous chemicals or radioactivity;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been exposed to dangerous chemicals or radioactivity [LTVH];Chemicals radiation LTVH;;ACTIVE;2.38;2.65 +66896-2;Have you ever been shot at, stabbed, struck, kicked, beaten, punched, slapped around, or otherwise physically harmed;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been shot at, stabbed, struck, kicked, beaten, punched, slapped around, or otherwise physically harmed [LTVH];Physically harmed LTVH;;ACTIVE;2.38;2.65 +66897-0;How many times did this happen;Num;Pt;^Patient;Qn;LTVH;PHENX;2;How many times did this happen [LTVH];Exposure to violence times LTVH;;ACTIVE;2.38;2.65 +66898-8;How old were you the last time this happened;Time;Pt;^Patient;Qn;LTVH;PHENX;2;How old were you the last time this happened [LTVH];Exposure to violence last time age LTVH;;ACTIVE;2.38;2.65 +66899-6;Have you ever been threatened with any kind of a weapon, like a knife, gun, baseball bat, frying pan, scissors, stick, rock or bottle;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been threatened with any kind of a weapon, like a knife, gun, baseball bat, frying pan, scissors, stick, rock or bottle [LTVH];Threatened LTVH;;ACTIVE;2.38;2.65 +66900-2;Has anyone ever threatened you in a face-to-face confrontation;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever threatened you in a face-to-face confrontation [LTVH];Threatened confrontation LTVH;;ACTIVE;2.38;2.65 +66901-0;Have you ever been actually assaulted with any kind of a weapon, like a knife, gun, baseball bat, frying pan, scissors, stick, rock, or bottle;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been actually assaulted with any kind of a weapon, like a knife, gun, baseball bat, frying pan, scissors, stick, rock, or bottle [LTVH];Assaulted weapon LTVH;;ACTIVE;2.38;2.65 +6690-2;Leukocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Blood by Automated count;WBC # Bld Auto;;ACTIVE;1.0g;2.73 +66902-8;When you were a child - that is, when you were in elementary or middle school, before about age 12 - were you ever struck, kicked, beaten, punched, slapped around, or otherwise physically harmed;Find;Pt;^Patient;Ord;LTVH;PHENX;2;When you were a child - that is, when you were in elementary or middle school, before about age 12 - were you ever struck, kicked, beaten, punched, slapped around, or otherwise physically harmed [LTVH];Physically harmed before 12 LTVH;;ACTIVE;2.38;2.65 +66904-4;When you were a child - that is, when you were in elementary or middle school, before about age 12 - were you ever physically abused;Find;Pt;^Patient;Ord;LTVH;PHENX;2;When you were a child - that is, when you were in elementary or middle school, before about age 12 - were you ever physically abused [LTVH];Physically abused before 12 LTVH;;ACTIVE;2.38;2.65 +66905-1;Has anyone, male or female, ever forced or coerced you to engage in unwanted sexual activity;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone, male or female, ever forced or coerced you to engage in unwanted sexual activity [LTVH];Forced sexual activity LTVH;;ACTIVE;2.38;2.65 +66906-9;Other than what we just talked about, did anyone, male or female ever attempt to, but not actually, force you to engage in unwanted sexual activity;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Other than what we just talked about, did anyone, male or female ever attempt to, but not actually, force you to engage in unwanted sexual activity [LTVH];Attempted sexual activity LTVH;;ACTIVE;2.38;2.65 +66909-3;Have you ever had an immediate family member, romantic partner, or very close friend who was murdered;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever had an immediate family member, romantic partner, or very close friend who was murdered [LTVH];Known someone murdered LTVH;;ACTIVE;2.38;2.65 +6691-0;Loxapine+8-Hydroxyamoxapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Loxapine+8-Hydroxyamoxapine [Mass/volume] in Serum or Plasma;Loxapine+8OH-Amox SerPl-mCnc;;ACTIVE;1.0g;2.40 +66910-1;Have you ever seen or been present when someone was murdered or seriously injured;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen or been present when someone was murdered or seriously injured [LTVH];Witness murder LTVH;;ACTIVE;2.38;2.65 +66911-9;Have you ever had an immediate family member, romantic partner, or very close friend commit suicide;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever had an immediate family member, romantic partner, or very close friend commit suicide [LTVH];Known someone suicide LTVH;;ACTIVE;2.38;2.65 +66912-7;Have you ever seen a dead or mutilated body, other than at a funeral, in the movies or newspaper;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen a dead or mutilated body, other than at a funeral, in the movies or newspaper [LTVH];Dead body LTVH;;ACTIVE;2.38;2.65 +66913-5;Have you ever seen or been present when another person was shot at, stabbed, struck, kicked, beaten, slapped around, or otherwise physically harmed;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen or been present when another person was shot at, stabbed, struck, kicked, beaten, slapped around, or otherwise physically harmed [LTVH];Other person physically harmed LTVH;;ACTIVE;2.38;2.65 +66914-3;Have you ever seen or been present when another person was raped, sexually attacked, or made to engage in unwanted sexual activity;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen or been present when another person was raped, sexually attacked, or made to engage in unwanted sexual activity [LTVH];Witnessed sexual attack LTVH;;ACTIVE;2.38;2.65 +66915-0;Has anyone ever intentionally damaged or destroyed property owned by you or by someone in your household;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever intentionally damaged or destroyed property owned by you or by someone in your household [LTVH];Destroyed property LTVH;;ACTIVE;2.38;2.65 +66916-8;Has anyone ever stolen something from you by using force or the threat of force like in a stick-up, mugging, or car-jacking;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever stolen something from you by using force or the threat of force like in a stick-up, mugging, or car-jacking [LTVH];Stolen property LTVH;;ACTIVE;2.38;2.65 +66917-6;Has anyone ever tried to, but not actually, steal something from you by using force or the threat of force like in a stick-up, mugging, or car-jacking;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever tried to, but not actually, steal something from you by using force or the threat of force like in a stick-up, mugging, or car-jacking [LTVH];Tried to steal LTVH;;ACTIVE;2.38;2.65 +66918-4;Has anyone ever tried to or actually broken in to your house, garage, shed, or storage room when you were not there;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever tried to or actually broken in to your house, garage, shed, or storage room when you were not there [LTVH];Break in LTVH;;ACTIVE;2.38;2.65 +66919-2;Has anyone ever tried to or actually broken in to your house, garage, shed, or storage room when you were there;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever tried to or actually broken in to your house, garage, shed, or storage room when you were there [LTVH];Break in while there LTVH;;ACTIVE;2.38;2.65 +669-2;Microscopic observation;Prid;Pt;XXX;Nom;Macchiavello stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Macchiavello stain;Macchiavello Stn Spec;;ACTIVE;1.0;2.69 +66920-0;Has anyone ever stolen something directly from you without the threat or use of force - purse-snatching or pick-pocket;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever stolen something directly from you without the threat or use of force - purse-snatching or pick-pocket [LTVH];Stolen W/O threat LTVH;;ACTIVE;2.38;2.65 +66922-6;Have you ever been kidnapped or held captive;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been kidnapped or held captive [LTVH];Kidnapped LTVH;;ACTIVE;2.38;2.65 +66923-4;Have you ever been stalked by anyone - has anyone ever followed or spied on you;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been stalked by anyone - has anyone ever followed or spied on you [LTVH];Stalked LTVH;;ACTIVE;2.38;2.65 +66924-2;Have you ever been in any other situation in which you were in danger of death or serious physical injury, or in which you felt intense fear, helplessness, or horror;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been in any other situation in which you were in danger of death or serious physical injury, or in which you felt intense fear, helplessness, or horror [LTVH];Other situation LTVH;;ACTIVE;2.38;2.65 +66925-9;Situation in which you were in danger of death or serious physical injury, or in which you felt intense fear, helplessness, or horror;Find;Pt;^Patient;Nom;LTVH;PHENX;2;Situation in which you were in danger of death or serious physical injury, or in which you felt intense fear, helplessness, or horror [LTVH];Situation describe LTVH;;ACTIVE;2.38;2.65 +66926-7;Were you afraid that you might die or get hurt really badly;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Were you afraid that you might die or get hurt really badly [LTVH];Exposure to violence might die LTVH;;ACTIVE;2.38;2.65 +66927-5;Were you very scared;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Were you very scared [LTVH];Were you very scared LTVH;;ACTIVE;2.38;2.65 +6692-8;Lutropin;SRat;24H;Urine;Qn;;CHEM;1;Lutropin [Moles/time] in 24 hour Urine;LH 24h Ur-sRate;;DISCOURAGED;1.0g;2.29 +66928-3;Did you feel like there was nothing you could do to stop what was happening;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Did you feel like there was nothing you could do to stop what was happening [LTVH];Could not stop LTVH;;ACTIVE;2.38;2.65 +66929-1;Before you turned 12Y old (when you were in grade school), did anyone ever hit you, kick you, beat you, punch you, slap you around, or hurt your body in some other way;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Before you turned 12 years old (when you were in grade school), did anyone ever hit you, kick you, beat you, punch you, slap you around, or hurt your body in some other way [LTVH];Hurt bef 12Y LTVH;;ACTIVE;2.38;2.65 +66930-9;Did anyone else ever do this to you;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Did anyone else ever do this to you [LTVH];Anyone else do this to you LTVH;;ACTIVE;2.38;2.65 +66932-5;Was there any other time when anyone, male or female, tried to force or bully you into doing something sexual that you didn't want to do, but it didn't end up happening;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Was there any other time when anyone, male or female, tried to force or bully you into doing something sexual that you didn't want to do, but it didn't end up happening [LTVH];Sexual attempt other LTVH;;ACTIVE;2.38;2.65 +66933-3;"Have you ever known someone who was murdered; that is, a parent, a brother, a sister, a very close friend, a boyfriend or girlfriend, or someone who lived with you";Find;Pt;^Patient;Ord;LTVH;PHENX;2;"Have you ever known someone who was murdered; that is, a parent, a brother, a sister, a very close friend, a boyfriend or girlfriend, or someone who lived with you [LTVH]";Child known someone murdered LTVH;;ACTIVE;2.38;2.65 +66934-1;Has anyone ever stolen something from you without your knowing it;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever stolen something from you without your knowing it [LTVH];Child stolen something LTVH;;ACTIVE;2.38;2.65 +66935-8;Have you ever been in any other situation in which you were afraid you might die or get really badly hurt, or when you were very scared or felt like there was nothing you could do to stop what was happening;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever been in any other situation in which you were afraid you might die or get really badly hurt, or when you were very scared or felt like there was nothing you could do to stop what was happening [LTVH];Child could not stop LTVH;;ACTIVE;2.38;2.65 +6693-6;Mercury;MRat;24H;Urine;Qn;;DRUG/TOX;1;Mercury [Mass/time] in 24 hour Urine;Mercury 24h Ur-mRate;;ACTIVE;1.0g;2.73 +66936-6;Hip fracture location;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Hip fracture location [PhenX];Hip fracture location PhenX;;TRIAL;2.38;2.65 +66937-4;Other fracture location;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other fracture location [PhenX];Other fracture location PhenX;;TRIAL;2.38;2.65 +66938-2;Fracture treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Fracture treatment [PhenX];Fracture treatment PhenX;;TRIAL;2.38;2.65 +66939-0;Other fracture treatment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other fracture treatment [PhenX];Other fracture treatment PhenX;;TRIAL;2.38;2.65 +66940-8;Other fractures occurred at the same time;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other fractures occurred at the same time [PhenX];Other fractures occur same time PhenX;;TRIAL;2.38;2.65 +66941-6;Location of fall or trauma;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Location of fall or trauma [PhenX];Location fall trauma PhenX;;TRIAL;2.38;2.65 +66942-4;Other location of fall or trauma;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other location of fall or trauma [PhenX];Other location fall trauma PhenX;;TRIAL;2.38;2.65 +66943-2;Time fracture occurred;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Time fracture occurred [PhenX];Fracture occur time PhenX;;TRIAL;2.38;2.65 +6694-4;quiNIDine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNIDine [Mass/volume] in Serum or Plasma;quiNIDine SerPl-mCnc;;ACTIVE;1.0g;2.73 +66944-0;Death occurred during hospitalization;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Death occurred during hospitalization [PhenX];Death during hospital PhenX;;TRIAL;2.38;2.65 +66945-7;Detailed circumstances of fracture;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Detailed circumstances of fracture [PhenX];Detailed circumstances fracture PhenX;;TRIAL;2.38;2.65 +66946-5;Data retrieval completed;TmStp;Pt;^Patient;Qn;PhenX;PHENX;2;Data retrieval completed [Date and time] [PhenX];Data retrieval complete PhenX;;TRIAL;2.38;2.65 +66947-3;Date last reaction;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date last reaction [PhenX];Date last reaction PhenX;;TRIAL;2.38;2.65 +66948-1;What primary non-english language or dialect do you speak or understand;Find;Pt;^Patient;Nom;NLAAS;PHENX;2;What primary non-english language or dialect do you speak or understand [NLAAS];List of languages NLAAS;;ACTIVE;2.38;2.65 +66949-9;How often do you feel that there are people you can turn to;Find;Pt;^Patient;Ord;UCLA Loneliness Scale v3;PHENX;2;How often do you feel that there are people you can turn to [UCLA Loneliness v3];People you can turn to UCLA Lone v3;;ACTIVE;2.38;2.65 +66950-7;MALT1 18q21 gene rearrangements;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.REARRANGE;1;MALT1 18q21 gene rearrangements in Blood or Tissue by FISH;MALT1 18q21 Rear Bld/T FISH;;ACTIVE;2.38;2.73 +6695-1;Riboflavin;MCnc;Pt;Bld;Qn;;CHEM;1;Riboflavin [Mass/volume] in Blood;Vit B2 Bld-mCnc;;ACTIVE;1.0g;2.73 +66951-5;Complement C1.functional;ACnc;Pt;Ser;Qn;;HEM/BC;1;Complement C1.functional [Units/volume] in Serum;C1.functional Ser-aCnc;;ACTIVE;2.44;2.70 +66952-3;Circumstances of fracture;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Circumstances of fracture [PhenX];Circumstances of fracture PhenX;;TRIAL;2.38;2.65 +66953-1;Detailed fracture location;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Detailed fracture location [PhenX];Detailed fracture location PhenX;;TRIAL;2.38;2.65 +66954-9;How many times in the last Y have you purposely damaged or destroyed property that did not belong to you;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you purposely damaged or destroyed property that did not belong to you [Denver Youth Survey];Destroyed property last Y DYS;;ACTIVE;2.38;2.65 +66955-6;How many times in the last Y have you purposely set fire to a house, building, car, or other property or tried to do so;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you purposely set fire to a house, building, car, or other property or tried to do so [Denver Youth Survey];Set fire nRate DYS;;ACTIVE;2.38;2.65 +66956-4;How many times in the last Y have you broken city curfew laws;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you broken city curfew laws [Denver Youth Survey];Broken city curfew laws nRate DYS;;ACTIVE;2.38;2.65 +66957-2;How many times in the last Y have you avoided paying for things such as movies, bus or subway rides, and food or computer services;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you avoided paying for things such as movies, bus or subway rides, and food or computer services [Denver Youth Survey];Avoided paying nRate DYS;;ACTIVE;2.38;2.65 +66958-0;How many times in the last Y have you gone into or tried to go into a building to steal something;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you gone into or tried to go into a building to steal something [Denver Youth Survey];Steal from building nRate DYS;;ACTIVE;2.38;2.65 +66959-8;How many times in the last Y have you stolen or tried to steal money or things worth 5 dollars or less;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you stolen or tried to steal money or things worth 5 dollars or less [Denver Youth Survey];Steal $5 nRate DYS;;ACTIVE;2.38;2.65 +66960-6;How many times in the last Y have you stolen or tried to steal money or things worth between 5 and 50 dollars;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you stolen or tried to steal money or things worth between 5 and 50 dollars [Denver Youth Survey];Steal $50 nRate DYS;;ACTIVE;2.38;2.65 +66961-4;How many times in the last Y have you stolen or tried to steal money or things worth more than 50 but less than 100 dollars;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you stolen or tried to steal money or things worth more than 50 but less than 100 dollars [Denver Youth Survey];Steal $100 nRate DYS;;ACTIVE;2.38;2.65 +66962-2;How many times in the last Y have you stolen or tried to steal money or things worth 100 dollars or more;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you stolen or tried to steal money or things worth 100 dollars or more [Denver Youth Survey];Steal > $100 nRate DYS;;ACTIVE;2.38;2.65 +66963-0;How many times in the last Y have you taken something from a store without paying for it;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you taken something from a store without paying for it [Denver Youth Survey];Shoplift nRate DYS;;ACTIVE;2.38;2.65 +66964-8;How many times in the last Y have you snatched someone's purse or wallet or picked someones pocket;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you snatched someone's purse or wallet or picked someones pocket [Denver Youth Survey];Stolen purse wallet nRate DYS;;ACTIVE;2.38;2.65 +66965-5;How many times in the last Y have you taken something from a car that did not belong to you;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you taken something from a car that did not belong to you [Denver Youth Survey];Steal from car nRate DYS;;ACTIVE;2.38;2.65 +66966-3;How many times in the last Y have you knowingly bought, sold or held stolen goods or tried to do any of these things;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you knowingly bought, sold or held stolen goods or tried to do any of these things [Denver Youth Survey];Stolen goods nRate DYS;;ACTIVE;2.38;2.65 +66967-1;How many times in the last Y have you gone joyriding;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you gone joyriding [Denver Youth Survey];Joyriding nRate DYS;;ACTIVE;2.38;2.65 +66968-9;How many times in the last Y have you stolen or tried to steal a motor vehicle such as a car or motorcycle;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you stolen or tried to steal a motor vehicle such as a car or motorcycle [Denver Youth Survey];Steal car nRate DYS;;ACTIVE;2.38;2.65 +6696-9;Thiothixene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Thiothixene [Mass/volume] in Serum or Plasma;Thiothixene SerPl-mCnc;;ACTIVE;1.0g;2.73 +66969-7;How many times in the last Y have you used checks illegally or used a slug or fake money to pay for something;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you used checks illegally or used a slug or fake money to pay for something [Denver Youth Survey];Fake money nRate DYS;;ACTIVE;2.38;2.65 +66970-5;How many times in the last Y have you used or tried to use a credit or bank cards without the owners permission;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you used or tried to use a credit or bank cards without the owners permission [Denver Youth Survey];Bank cards nRate DYS;;ACTIVE;2.38;2.65 +66971-3;How many times in the last Y have you tried to cheat someone by selling them something that was worthless or not what you said it was;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you tried to cheat someone by selling them something that was worthless or not what you said it was [Denver Youth Survey];Cheat someone nRate DYS;;ACTIVE;2.38;2.65 +66972-1;How many times in the last Y have you attacked someone with a weapon or with the idea of seriously hurting or killing them;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you attacked someone with a weapon or with the idea of seriously hurting or killing them [Denver Youth Survey];Attacked someone nRate DYS;;ACTIVE;2.38;2.65 +66973-9;How many times in the last Y have you hit someone with the idea of hurting them, other than the events just mentioned;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you hit someone with the idea of hurting them, other than the events just mentioned [Denver Youth Survey];Hit someone nRate DYS;;ACTIVE;2.38;2.65 +66974-7;How many times in the last Y have you used a weapon, force, or strong-arm methods to get money or things from people;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you used a weapon, force, or strong-arm methods to get money or things from people [Denver Youth Survey];Strongarm money nRate DYS;;ACTIVE;2.38;2.65 +66975-4;How many times in the last Y have you thrown objects such as rocks or bottles at people, other than events you have already mentioned;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you thrown objects such as rocks or bottles at people, other than events you have already mentioned [Denver Youth Survey];Thrown objects nRate DYS;;ACTIVE;2.38;2.65 +66976-2;How many times in the last Y have you been involved in gang fights;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been involved in gang fights [Denver Youth Survey];Gang fights nRate DYS;;ACTIVE;2.38;2.65 +6697-7;Amylase;CCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Amylase [Enzymatic activity/volume] in Serum;Deprecated Amylase Ser-cCnc;;DEPRECATED;1.0g;2.36 +66977-0;How many times in the last Y have you been paid for having sexual relations with someone;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been paid for having sexual relations with someone [Denver Youth Survey];Paid for sex nRate DYS;;ACTIVE;2.38;2.65 +66978-8;How many times in the last Y have you physically hurt or threatened to hurt someone to get them to have sex with you;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you physically hurt or threatened to hurt someone to get them to have sex with you [Denver Youth Survey];Forced sex nRate DYS;;ACTIVE;2.38;2.68 +66979-6;How many times in the last Y have you had or tried to have sexual relations with someone against their will, other than events you just mentioned;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you had or tried to have sexual relations with someone against their will, other than events you just mentioned [Denver Youth Survey];Other forced sex nRate DYS;;ACTIVE;2.38;2.65 +66980-4;How many times in the last Y have you sold marijuana or hashish, pot, grass, hash;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you sold marijuana or hashish, pot, grass, hash [Denver Youth Survey];Sold marijuana nRate DYS;;ACTIVE;2.38;2.65 +66981-2;How many times in the last Y have you sold hard drugs such as heroin, cocaine, and LSD;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you sold hard drugs such as heroin, cocaine, and LSD [Denver Youth Survey];Sold hard drugs nRate DYS;;ACTIVE;2.38;2.65 +66982-0;Have you done anything else in the past year that could have gotten you in trouble with the police;Find;Pt;^Patient;Ord;Denver Youth Survey;PHENX;2;Have you done anything else in the past year that could have gotten you in trouble with the police [Denver Youth Survey];Trouble with police DYS;;ACTIVE;2.38;2.65 +66983-8;What kind of things did you do;Find;Pt;^Patient;Nom;Denver Youth Survey;PHENX;2;What kind of things did you do [Denver Youth Survey];Trouble with police specify DYS;;ACTIVE;2.38;2.65 +66984-6;How many times in the past Y;Num;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the past year [Denver Youth Survey];Trouble with police freq DYS;;ACTIVE;2.38;2.65 +6698-5;Aldolase;CCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Aldolase [Enzymatic activity/volume] in Serum;Deprecated Aldolase Ser-cCnc;;DEPRECATED;1.0g;2.36 +66985-3;How many times in the last Y have you run away from home;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you run away from home [Denver Youth Survey];Run away from home nRate DYS;;ACTIVE;2.38;2.65 +66986-1;How many times in the last Y have you skipped classes or school without an excuse;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you skipped classes or school without an excuse [Denver Youth Survey];Skipped classes school nRate DYS;;ACTIVE;2.38;2.65 +66987-9;How many times in the last Y have you been suspended or sent home from school for bad behavior;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been suspended or sent home from school for bad behavior [Denver Youth Survey];Suspended sent home nRate DYS;;ACTIVE;2.38;2.65 +66988-7;How many times in the last Y have you lied about your age to get into some place or to buy something;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you lied about your age to get into some place or to buy something [Denver Youth Survey];Lied about age DYS;;ACTIVE;2.38;2.65 +66989-5;How many times in the last Y have you cheated on school tests;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you cheated on school tests [Denver Youth Survey];Cheated on tests nRate DYS;;ACTIVE;2.38;2.65 +66990-3;How many times in the last Y have you hitchhiked where it was illegal to do so;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you hitchhiked where it was illegal to do so [Denver Youth Survey];Hitchhiked nRate DYS;;ACTIVE;2.38;2.65 +66991-1;How many times in the last Y have you carried a hidden weapon;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you carried a hidden weapon [Denver Youth Survey];Carried hidden weapon nRate DYS;;ACTIVE;2.38;2.65 +66992-9;How many times in the last Y have you been loud, rowdy, or unruly in a public place so that people complained about it or you got in trouble;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been loud, rowdy, or unruly in a public place so that people complained about it or you got in trouble [Denver Youth Survey];Loud rowdy unruly nRate DYS;;ACTIVE;2.38;2.65 +6699-3;Delta 5-Pregnanetriol;MRat;24H;Urine;Qn;;CHEM;1;Delta 5-Pregnanetriol [Mass/time] in 24 hour Urine;D5Pregnanetriol 24h Ur-mRate;;ACTIVE;1.0g;2.42 +66993-7;How many times in the last Y have you begged for money or things from strangers;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you begged for money or things from strangers [Denver Youth Survey];Begged for money nRate DYS;;ACTIVE;2.38;2.65 +66994-5;How many times in the last Y have you made obscene telephone calls such as calling someone and saying dirty things;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you made obscene telephone calls such as calling someone and saying dirty things [Denver Youth Survey];Obscene phone calls nRate DYS;;ACTIVE;2.38;2.65 +66995-2;How many times in the last Y have you been drunk in a public place;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been drunk in a public place [Denver Youth Survey];Publicly drunk nRate DYS;;ACTIVE;2.38;2.65 +66996-0;How many times in the last Y did you run away from your home and stay away overnight;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you run away from your home and stay away overnight [Denver Youth Survey];Run away from home overnight nRate DYS;;ACTIVE;2.38;2.65 +6-7;Amantadine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Amantadine [Susceptibility];Amantadine Susc Islt;;ACTIVE;1.0;2.19 +670-0;Microscopic observation;Prid;Pt;XXX;Nom;Methenamine silver nitrate stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Methenamine silver nitrate stain;MS Nitrate Stn Spec;;ACTIVE;1.0;2.73 +67001-8;How many times in the last Y did you break into, or try to break into a building, to steal something;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you break into, or try to break into a building, to steal something [Denver Youth Survey];Break into a building nRate DYS;;ACTIVE;2.38;2.65 +67003-4;How many times in the last Y did you steal, or try to steal, money or things worth between 5 and 100 dollars;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you steal, or try to steal, money or things worth between 5 and 100 dollars [Denver Youth Survey];Stolen $5 - 100 nRate DYS;;ACTIVE;2.38;2.65 +67004-2;How many times in the last Y did you steal, or try to steal, money or things worth between 100 and 500 dollars;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you steal, or try to steal, money or things worth between 100 and 500 dollars [Denver Youth Survey];Stolen $100 - 500 nRate DYS;;ACTIVE;2.38;2.65 +67005-9;How many times in the last Y did you steal, or try to steal, money or things worth over 500 dollars;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you steal, or try to steal, money or things worth over 500 dollars [Denver Youth Survey];Stolen > $500 nRate DYS;;ACTIVE;2.38;2.65 +67008-3;How many times in the last Y have you converted a vehicle, that is, taken a motor vehicle such as a car or motorcycle for a ride or drive without the owner's permission, when you didn't mean to keep or sell it;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you converted a vehicle, that is, taken a motor vehicle such as a car or motorcycle for a ride or drive without the owner's permission, when you didn't mean to keep or sell it [Denver Youth Survey];Converted motor vehicle nRate DYS;;ACTIVE;2.38;2.65 +6700-9;11-Hydroxyetiocholanolone;MRat;24H;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone [Mass/time] in 24 hour Urine;11OH-Etioch 24h Ur-mRate;;ACTIVE;1.0g;2.73 +67009-1;How many times in the last Y have you stolen, or tried to steal, a motor vehicle such as a car or motorcycle to keep or sell;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you stolen, or tried to steal, a motor vehicle such as a car or motorcycle to keep or sell [Denver Youth Survey];Stolen motor vehicle nRate DYS;;ACTIVE;2.38;2.65 +67010-9;How many times in the last Y have you used worthless checks or fake money to pay for something;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you used worthless checks or fake money to pay for something [Denver Youth Survey];Worthless checks nRate DYS;;ACTIVE;2.38;2.65 +67013-3;How many times in the last Y have you been so angry with a child that you attacked them with a weapon, or with the idea of seriously hurting them;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been so angry with a child that you attacked them with a weapon, or with the idea of seriously hurting them [Denver Youth Survey];Attacked child nRate DYS;;ACTIVE;2.38;2.65 +67014-1;How many times in the last Y have you been so angry with a child that you hit them;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been so angry with a child that you hit them [Denver Youth Survey];Attacked child other nRate DYS;;ACTIVE;2.38;2.65 +67015-8;How many times in the last Y have you attacked an adult with a weapon or with the idea of seriously hurting or killing them;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you attacked an adult with a weapon or with the idea of seriously hurting or killing them [Denver Youth Survey];Attacked adult with weapon nRate DYS;;ACTIVE;2.38;2.65 +67016-6;How many times in the last Y have you hit an adult with the idea of hurting them;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you hit an adult with the idea of hurting them [Denver Youth Survey];Hit an adult nRate DYS;;ACTIVE;2.38;2.65 +6701-7;11-Hydroxyandrosterone;MRat;24H;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone [Mass/time] in 24 hour Urine;11OH-Androst 24h Ur-mRate;;ACTIVE;1.0g;2.73 +67017-4;How many times in the last Y have you used a weapon, force or strong arm methods to rob a person, shop, bank, or other business;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you used a weapon, force or strong arm methods to rob a person, shop, bank, or other business [Denver Youth Survey];Strong arm methods nRate DYS;;ACTIVE;2.38;2.65 +67019-0;How many times in the last Y have you committed a serious driving offense, such as driving while drunk, driving recklessly, or speeding 50 km per hour over the posted speed limit;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you committed a serious driving offense, such as driving while drunk, driving recklessly, or speeding 50 km per hour over the posted speed limit [Denver Youth Survey];Serious driving offense nRate DYS;;ACTIVE;2.38;2.65 +67020-8;How many times in the last Y have you embezzled money - that means used money entrusted to your care for some purpose not intended;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you embezzled money - that means used money entrusted to your care for some purpose not intended [Denver Youth Survey];Embezzled money nRate DYS;;ACTIVE;2.38;2.65 +67021-6;How many times in the last Y have you lied about your age;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you lied about your age [Denver Youth Survey];Lied about your age DYS;;ACTIVE;2.38;2.65 +67022-4;How many times in the last Y have you made obscene telephone calls, such as calling someone and saying rude things;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you made obscene telephone calls, such as calling someone and saying rude things [Denver Youth Survey];Made obscene telephone calls nRate DYS;;ACTIVE;2.38;2.65 +67024-0;How many times in the last Y did you give false information on a tax form, an insurance claim, or on applications for a loan or bank account;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you give false information on a tax form, an insurance claim, or on applications for a loan or bank account [Denver Youth Survey];Gave false information nRate DYS;;ACTIVE;2.38;2.65 +6702-5;11-Ketoandrosterone;MRat;24H;Urine;Qn;;CHEM;1;11-Ketoandrosterone [Mass/time] in 24 hour Urine;11Ketoandros 24h Ur-mRate;;ACTIVE;1.0g;2.73 +67025-7;How many times in the last Y did you use a false name or alias so you couldn't be identified;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you use a false name or alias so you couldn't be identified [Denver Youth Survey];Used false name;;ACTIVE;2.38;2.65 +67026-5;How many times in the last Y did you move away from a flat or house without paying the final bills or rent;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you move away from a flat or house without paying the final bills or rent [Denver Youth Survey];Moved W/O paying nRate DYS;;ACTIVE;2.38;2.65 +67027-3;How many times in the last Y have you made illegal copies of computer software or video files;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you made illegal copies of computer software or video files [Denver Youth Survey];Made illegal copies nRate DYS;;ACTIVE;2.38;2.65 +67028-1;How many times in the last Y did you buy something on credit and then never made the payments;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you buy something on credit and then never made the payments [Denver Youth Survey];Never made payments nRate DYS;;ACTIVE;2.38;2.65 +67029-9;How many times in the last Y did you interfere with the work of the law by trying to get away from police, by hiding someone that the police were looking for, or by telling a lie to a police officer or judge;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you interfere with the work of the law by trying to get away from police, by hiding someone that the police were looking for, or by telling a lie to a police officer or judge [Denver Youth Survey];Interfered with police nRate DYS;;ACTIVE;2.38;2.65 +67030-7;How many times in the last Y have you driven a vehicle when you did not have a driver's license or after your license had been suspended or disqualified;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you driven a vehicle when you did not have a driver's license or after your license had been suspended or disqualified [Denver Youth Survey];Suspended license nRate DYS;;ACTIVE;2.38;2.65 +6703-3;11-Ketoetiocholanolone;MRat;24H;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone [Mass/time] in 24 hour Urine;11Ketoetioch 24h Ur-mRate;;ACTIVE;1.0g;2.73 +67033-1;How many times in the last Y have you used marijuana;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you used marijuana [Denver Youth Survey];Used marijuana nRate DYS;;ACTIVE;2.38;2.65 +67034-9;How many times in the last Y have you used a harder drug, such as heroin, cocaine or LSD;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you used a harder drug, such as heroin, cocaine or LSD [Denver Youth Survey];Used harder drug nRate DYS;;ACTIVE;2.38;2.65 +67035-6;How many times in the last Y have you paid someone to have sex with you;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you paid someone to have sex with you [Denver Youth Survey];Paid someone for sex nRate DYS;;ACTIVE;2.38;2.65 +67036-4;How many times in the last Y have you been paid, or received other favors for having sex with someone;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you been paid, or received other favors for having sex with someone [Denver Youth Survey];Paid for having sex nRate DYS;;ACTIVE;2.38;2.65 +67037-2;How many times in the last Y did you threaten or hurt someone to get them to have sex with you;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year did you threaten or hurt someone to get them to have sex with you [Denver Youth Survey];Force to have sex nRate DYS;;ACTIVE;2.38;2.65 +67038-0;How many times in the last Y have you contributed to the delinquency of a person under age 17;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you contributed to the delinquency of a person under age 17 [Denver Youth Survey];Contributed to delinquency DYS;;ACTIVE;2.38;2.65 +67039-8;How many times in the last Y have you failed to obey the courts;NRat;1Y;^Patient;Qn;Denver Youth Survey;PHENX;2;How many times in the last year have you failed to obey the courts [Denver Youth Survey];Failed to obey courts nRate DYS;;ACTIVE;2.38;2.65 +67040-6;Your rent or mortgage is too much;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your rent or mortgage is too much [PhenX];Rent mortgage too much PhenX;;TRIAL;2.38;2.65 +6704-1;11-Ketopregnanetriol;MRat;24H;Urine;Qn;;CHEM;1;11-Ketopregnanetriol [Mass/time] in 24 hour Urine;11Ketopregnanet 24h Ur-mRate;;ACTIVE;1.0g;2.42 +67041-4;You don't have enough money to take vacations;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't have enough money to take vacations [PhenX];Not enough money vacations PhenX;;TRIAL;2.38;2.65 +67042-2;You don't have enough money to make a down payment on a home;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't have enough money to make a down payment on a home [PhenX];Not enough money down payment PhenX;;TRIAL;2.38;2.65 +67043-0;You have more work to do than most people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have more work to do than most people [PhenX];More work than most PhenX;;TRIAL;2.38;2.65 +67044-8;Your supervisor is always monitoring what you do at work;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your supervisor is always monitoring what you do at work [PhenX];Supervisor always monitoring PhenX;;TRIAL;2.38;2.65 +67045-5;You want to change jobs or career but don't feel you can;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You want to change jobs or career but don't feel you can [PhenX];Don't feel change job PhenX;;TRIAL;2.38;2.65 +67046-3;Your job often leaves you feeling both mentally and physically tired;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your job often leaves you feeling both mentally and physically tired [PhenX];Job leaves you tired PhenX;;TRIAL;2.38;2.65 +67047-1;You want to achieve more at work but things get in the way;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You want to achieve more at work but things get in the way [PhenX];Want achieve more at work PhenX;;TRIAL;2.38;2.65 +67048-9;You don't get paid enough for what you do;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't get paid enough for what you do [PhenX];Don't get paid enough PhenX;;TRIAL;2.38;2.65 +67049-7;Your work is boring and repetitive;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your work is boring and repetitive [PhenX];Work boring repetitive PhenX;;TRIAL;2.38;2.65 +67050-5;You are looking for a job and can't find the one you want;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You are looking for a job and can't find the one you want [PhenX];Can't find job you want PhenX;;TRIAL;2.38;2.65 +67051-3;You have a lot of conflict with your partner;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have a lot of conflict with your partner [PhenX];Conflict with partner PhenX;;TRIAL;2.38;2.65 +67052-1;Your relationship restricts your freedom;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your relationship restricts your freedom [PhenX];Relationship restricts freedom PhenX;;TRIAL;2.38;2.65 +67053-9;Your partner doesn't understand you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your partner doesn't understand you [PhenX];Partner not understand you PhenX;;TRIAL;2.38;2.65 +67054-7;Your partner expects too much of you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your partner expects too much of you [PhenX];Partner expects too much PhenX;;TRIAL;2.38;2.65 +67055-4;You don't get what you deserve out of your relationship;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't get what you deserve out of your relationship [PhenX];Don't get needs from relationship PhenX;;TRIAL;2.38;2.65 +67056-2;Your partner doesn't show enough affection;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your partner doesn't show enough affection [PhenX];Partner not show enough affection PhenX;;TRIAL;2.38;2.65 +67057-0;Your partner is not committed enough to your relationship;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your partner is not committed enough to your relationship [PhenX];Partner not committed enough PhenX;;TRIAL;2.38;2.65 +6705-8;Androsterone;MRat;24H;Urine;Qn;;CHEM;1;Androsterone [Mass/time] in 24 hour Urine;Androsterone 24h Ur-mRate;;ACTIVE;1.0g;2.73 +67058-8;Your sexual needs are not fulfilled by this relationship;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your sexual needs are not fulfilled by this relationship [PhenX];SWexual needs not fulfilled PhenX;;TRIAL;2.38;2.65 +67059-6;Your partner is always threatening to leave or end the relationship;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your partner is always threatening to leave or end the relationship [PhenX];Partner threatens to leave PhenX;;TRIAL;2.38;2.65 +67060-4;You wonder whether you will ever get married;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You wonder whether you will ever get married [PhenX];Wonder if ever get married PhenX;;TRIAL;2.38;2.65 +67061-2;You find it is too difficult to find someone compatible with you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You find it is too difficult to find someone compatible with you [PhenX];Hard to find someone compatible PhenX;;TRIAL;2.38;2.65 +67062-0;You have a lot of conflict with your ex-spouse;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have a lot of conflict with your ex-spouse [PhenX];Conflict with your ex-spouse PhenX;;TRIAL;2.38;2.65 +67063-8;You don't see your children from a former marriage as much as you would like;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't see your children from a former marriage as much as you would like [PhenX];Don't see children from marriage PhenX;;TRIAL;2.38;2.65 +67064-6;You are alone too much;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You are alone too much [PhenX];Alone too much PhenX;;TRIAL;2.38;2.65 +67065-3;You wish you could have children but you cannot;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You wish you could have children but you cannot [PhenX];Cannot have children PhenX;;TRIAL;2.38;2.65 +6706-6;buPROPion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;buPROPion [Mass/volume] in Serum or Plasma;buPROPion SerPl-mCnc;;ACTIVE;1.0g;2.73 +67066-1;One of your children seems very unhappy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;One of your children seems very unhappy [PhenX];One child seems unhappy PhenX;;TRIAL;2.38;2.65 +67067-9;You feel your children don't listen to you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You feel your children don't listen to you [PhenX];Children don't listen PhenX;;TRIAL;2.38;2.65 +67068-7;A childs behavior is a source of serious concern to you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;A childs behavior is a source of serious concern to you [PhenX];Childs behavior concerning PhenX;;TRIAL;2.38;2.65 +67069-5;One or more children do not do well enough at school or work;Find;Pt;^Patient;Ord;PhenX;PHENX;2;One or more children do not do well enough at school or work [PhenX];Children don't do well school PhenX;;TRIAL;2.38;2.65 +67070-3;Your children don't help around the house;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your children don't help around the house [PhenX];Children don't help PhenX;;TRIAL;2.38;2.65 +67071-1;One of your children spends too much time away from the house;Find;Pt;^Patient;Ord;PhenX;PHENX;2;One of your children spends too much time away from the house [PhenX];Children spend much time away PhenX;;TRIAL;2.38;2.65 +67072-9;You feel like being a housewife is not appreciated;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You feel like being a housewife is not appreciated [PhenX];Housewife not appreciated PhenX;;TRIAL;2.38;2.65 +67073-7;You have to go to social events alone and you don't want to;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have to go to social events alone and you don't want to [PhenX];Go to social events alone PhenX;;TRIAL;2.38;2.65 +6707-4;CD16-CD57+;ACnc;Pt;WBC;Qn;;CELLMARK;1;Deprecated CD16-CD57+;Deprecated CD16-CD57+ WBC-aCnc;;DEPRECATED;1.0g;2.69 +67074-5;Your friends are a bad influence;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your friends are a bad influence [PhenX];Friends bad influence PhenX;;TRIAL;2.38;2.65 +67075-2;You don't have enough friends;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't have enough friends [PhenX];Don't have enough friends PhenX;;TRIAL;2.38;2.65 +67076-0;You don't have time for your favorite leisure time activities;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't have time for your favorite leisure time activities [PhenX];No time leisure activities PhenX;;TRIAL;2.38;2.65 +67077-8;You want to live farther away from your family;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You want to live farther away from your family [PhenX];Want to live farther from family PhenX;;TRIAL;2.38;2.65 +67078-6;You would like to move but you cannot;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You would like to move but you cannot [PhenX];Like to move but cannot PhenX;;TRIAL;2.38;2.65 +67079-4;The place you live is too noisy or too polluted;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The place you live is too noisy or too polluted [PhenX];Living place noisy polluted PhenX;;TRIAL;2.38;2.65 +67080-2;Your family lives too far away;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Your family lives too far away [PhenX];Family too far away PhenX;;TRIAL;2.38;2.65 +67081-0;Someone in your family or a close friend has a long-term illness or handicap;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Someone in your family or a close friend has a long-term illness or handicap [PhenX];Family long-term illness PhenX;;TRIAL;2.38;2.65 +6708-2;Echovirus 11 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 11 Ab [Titer] in Serum by Complement fixation;ECV11 Ab Titr Ser CF;;ACTIVE;1.0g;2.73 +67082-8;You have a parent, a child, or a spouse or partner who is in very bad health and may die;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have a parent, a child, or a spouse or partner who is in very bad health and may die [PhenX];Family member may die PhenX;;TRIAL;2.38;2.65 +67083-6;Someone in your family has an alcohol or drug problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Someone in your family has an alcohol or drug problem [PhenX];Family has alcohol drug problem PhenX;;TRIAL;2.38;2.65 +67084-4;A long- term health problem prevents you from doing the things you like to do;Find;Pt;^Patient;Ord;PhenX;PHENX;2;A long- term health problem prevents you from doing the things you like to do [PhenX];Health problem prevents activities PhenX;;TRIAL;2.38;2.65 +67085-1;You take care of an aging parent almost every day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You take care of an aging parent almost every day [PhenX];Take care aging parent PhenX;;TRIAL;2.38;2.65 +67086-9;You're trying to take on too many things at once;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You're trying to take on too many things at once [PhenX];Too many things at once PhenX;;TRIAL;2.38;2.65 +67087-7;There is too much pressure on you to be like other people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;There is too much pressure on you to be like other people [PhenX];Pressure to be like others PhenX;;TRIAL;2.38;2.65 +67088-5;Too much is expected of you by others;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Too much is expected of you by others [PhenX];Too much expected by others PhenX;;TRIAL;2.38;2.65 +67089-3;You don't have enough money to buy the things you or your kids need;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You don't have enough money to buy the things you or your kids need [PhenX];Not enough money for needs PhenX;;TRIAL;2.38;2.65 +6709-0;Hippurate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hippurate [Mass/volume] in Urine;Hippurate Ur-mCnc;;ACTIVE;1.0g;2.73 +67090-1;You have a long-term debt or loan;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have a long-term debt or loan [PhenX];Long-term debt loan PhenX;;TRIAL;2.38;2.65 +67091-9;How long were you held or not allowed to leave;Time;Pt;^Patient;Qn;LTVH;PHENX;2;How long were you held or not allowed to leave [LTVH];Kidnapped how long LTVH;;ACTIVE;2.38;2.65 +67092-7;Career position;Find;Pt;^Patient;Nom;The Position Generator;PHENX;2;Career position [The Position Generator];Career position Pos Gen;;ACTIVE;2.38;2.65 +67093-5;Is there anyone you know who has this career;Find;Pt;^Patient;Ord;The Position Generator;PHENX;2;Is there anyone you know who has this career [The Position Generator];Career position acquaintance Pos Gen;;ACTIVE;2.38;2.65 +67094-3;Did you get to know them through your spouse or partner;Find;Pt;^Patient;Ord;The Position Generator;PHENX;2;Did you get to know them through your spouse or partner [The Position Generator];Know through spouse partner Pos Gen;;ACTIVE;2.38;2.65 +67095-0;How long have you known each other;Time;Pt;^Patient;Qn;The Position Generator;PHENX;2;How long have you known each other [The Position Generator];How long known Pos Gen;;ACTIVE;2.38;2.65 +67096-8;How close are you to them;Find;Pt;^Patient;Ord;The Position Generator;PHENX;2;How close are you to them [The Position Generator];How close to Pos Gen;;ACTIVE;2.38;2.65 +67097-6;Coagulation surface induced.lupus sensitive.factor substitution^immediately after addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma;aPTT-LA imm NP PPP;;DISCOURAGED;2.40;2.73 +67098-4;Reason for test or procedure;Find;Pt;^Patient;Nom;;PHENX;2;Reason for test or procedure;Reason for test procedure;;ACTIVE;2.38;2.73 +67099-2;Vendor device name;ID;Pt;{Device};Nom;;DEVICES;2;Deprecated Vendor device name;Deprecated Vendor device name;;DEPRECATED;2.38;2.68 +67100-8;Therapist name;Pn;Pt;Provider;Nom;;PHENX;2;Therapist name Provider;Therapist name Provider;;TRIAL;2.38;2.65 +67101-6;Dermatologist name;Pn;Pt;Provider;Nom;;PHENX;2;Dermatologist name Provider;Dermatologist name Provider;;TRIAL;2.38;2.65 +67102-4;Diagnosing provider;Pn;Pt;Provider;Nom;;PHENX;2;Diagnosing provider;Diagnosing provider;;TRIAL;2.38;2.65 +67103-2;Body location affected by psoriasis now;Anat;Pt;^Patient;Nom;PhenX;PHENX;2;Body location affected by psoriasis now [Anatomy] [PhenX];Body psoriasis now PhenX;;TRIAL;2.38;2.65 +67104-0;Body location affected by psoriasis when it was the worst;Anat;Pt;^Patient;Nom;PhenX;PHENX;2;Body location affected by psoriasis when it was the worst [Anatomy] [PhenX];Body psoriasis worst PhenX;;TRIAL;2.38;2.65 +67105-7;Have you had a hysterectomy - removal of the uterus, or tubal ligation - tubes tied;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had a hysterectomy - removal of the uterus, or tubal ligation - tubes tied [PhenX];Women <55 hyster tubal ligation PhenX;;TRIAL;2.38;2.65 +67106-5;Other than what we just talked about, has anyone ever actually touched private parts of your body or made you touch theirs against your wishes;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Other than what we just talked about, has anyone ever actually touched private parts of your body or made you touch theirs against your wishes [LTVH];Private parts LTVH;;ACTIVE;2.38;2.65 +67107-3;Have you ever fought in a war;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever fought in a war [LTVH];Child war LTVH;;ACTIVE;2.38;2.65 +6710-8;Hydroxyproline;MRat;24H;Urine;Qn;;CHEM;1;Deprecated Hydroxyproline [Mass/time] in 24 hour Urine;Deprecated OH-Proline 24H Ur-mRate;;DEPRECATED;1.0g;2.36 +67108-1;Have you ever had a serious accident at home, at school, or somewhere else;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever had a serious accident at home, at school, or somewhere else [LTVH];Child serious accident LTVH;;ACTIVE;2.38;2.65 +67109-9;Has anyone ever shot at you, stabbed you, hit you, kicked you, beaten you, punched you, slapped you around, or hurt your body in some other way;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever shot at you, stabbed you, hit you, kicked you, beaten you, punched you, slapped you around, or hurt your body in some other way [LTVH];Child shot stabbed LTVH;;ACTIVE;2.38;2.65 +67110-7;Has anyone ever threatened to hurt you with any kind of a weapon, like a knife, a gun, a baseball bat, a frying pan, scissors, a stick, a rock or a bottle;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever threatened to hurt you with any kind of a weapon, like a knife, a gun, a baseball bat, a frying pan, scissors, a stick, a rock or a bottle [LTVH];Child threatened LTVH;;ACTIVE;2.38;2.65 +67111-5;Has anyone ever threatened to hurt you when they were standing right in front of you;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever threatened to hurt you when they were standing right in front of you [LTVH];Child threatened in front of you LTVH;;ACTIVE;2.38;2.65 +67112-3;Has anyone ever actually hurt you with any kind of a weapon, like a knife, a gun, a baseball bat, a frying pan, scissors, a stick, a rock, or a bottle;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever actually hurt you with any kind of a weapon, like a knife, a gun, a baseball bat, a frying pan, scissors, a stick, a rock, or a bottle [LTVH];Child hurt by weapon LTVH;;ACTIVE;2.38;2.65 +67113-1;Before you turned 12Y old (when you were in grade school), were you ever physically abused;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Before you turned 12 years old (when you were in grade school), were you ever physically abused [LTVH];Physically abused before 12Y LTVH;;ACTIVE;2.38;2.65 +67114-9;Has anyone, male or female, ever forced or pressured you into doing something sexual that you didn't want to do;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone, male or female, ever forced or pressured you into doing something sexual that you didn't want to do [LTVH];Child something sexual LTVH;;ACTIVE;2.38;2.65 +67115-6;Have there been any other times when anyone, male or female, ever tried to force or bully you into doing something sexual that you didn't want to do, but it didn't end up happening - you stopped them or someone else;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have there been any other times when anyone, male or female, ever tried to force or bully you into doing something sexual that you didn't want to do, but it didn't end up happening - you stopped them or someone else [LTVH];Child something sexual stopped LTVH;;ACTIVE;2.38;2.65 +6711-6;Acetaminophen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Acetaminophen IgE Ab [Units/volume] in Serum;APAP IgE Qn;;ACTIVE;1.0g;2.44 +67116-4;Was anyone murdered who was a parent, a brother, a sister, a very close friend, a boyfriend or girlfriend, or someone who lived with you;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Was anyone murdered who was a parent, a brother, a sister, a very close friend, a boyfriend or girlfriend, or someone who lived with you [LTVH];Child anyone murdered LTVH;;ACTIVE;2.38;2.65 +67117-2;Have you ever seen or been present when someone was murdered or hurt very badly;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen or been present when someone was murdered or hurt very badly [LTVH];Child witnessed murder LTVH;;ACTIVE;2.38;2.65 +67118-0;"Have you ever known someone who committed suicide or killed themselves; that is, a parent, a sister, a brother, a very close friend, a boyfriend or girlfriend, or someone who lived with you";Find;Pt;^Patient;Ord;LTVH;PHENX;2;"Have you ever known someone who committed suicide or killed themselves; that is, a parent, a sister, a brother, a very close friend, a boyfriend or girlfriend, or someone who lived with you [LTVH]";Child suicide LTVH;;ACTIVE;2.38;2.65 +67119-8;Have you ever seen a dead body;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen a dead body [LTVH];Child dead body LTVH;;ACTIVE;2.38;2.65 +67120-6;Have you ever seen or heard another person be threatened with a weapon - a gun or a knife;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen or heard another person be threatened with a weapon - a gun or a knife [LTVH];Child witnessed threats LTVH;;ACTIVE;2.38;2.65 +67121-4;Have you ever seen or heard another person be raped, sexually attacked, or made to do something sexual that they didn't want to do;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Have you ever seen or heard another person be raped, sexually attacked, or made to do something sexual that they didn't want to do [LTVH];Child witnessed sexual attack LTVH;;ACTIVE;2.38;2.65 +67122-2;Has anyone ever damaged or destroyed something on purpose that belonged to you or to someone who you lived with;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever damaged or destroyed something on purpose that belonged to you or to someone who you lived with [LTVH];Child destroyed property LTVH;;ACTIVE;2.38;2.65 +67123-0;Has anyone ever stolen something from you by using force or threatening to hurt you, like in a stick-up, a mugging, or a car-jacking;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever stolen something from you by using force or threatening to hurt you, like in a stick-up, a mugging, or a car-jacking [LTVH];Child stolen property LTVH;;ACTIVE;2.38;2.65 +6712-4;Ampicillin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ampicillin IgE Ab [Units/volume] in Serum;Ampicillin IgE Qn;;ACTIVE;1.0h(2);2.73 +67124-8;Has anyone ever tried to steal something from you by using force or threatening to hurt you;Find;Pt;^Patient;Ord;LTVH;PHENX;2;Has anyone ever tried to steal something from you by using force or threatening to hurt you [LTVH];Child tried to steal LTVH;;ACTIVE;2.38;2.65 +67125-5;Situation in which you were afraid you might die or get really badly hurt, or when you were very scared or felt like there was nothing you could do to stop what was happening;Find;Pt;^Patient;Nom;LTVH;PHENX;2;Situation in which you were afraid you might die or get really badly hurt, or when you were very scared or felt like there was nothing you could do to stop what was happening [LTVH];Other situation afraid LTVH;;ACTIVE;2.38;2.65 +67126-3;Cannabinoids.synthetic;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cannabinoids synthetic [Presence] in Urine by Confirmatory method;Cannabinoids synthetic Ur Ql Cfm;;ACTIVE;2.38;2.73 +67127-1;Cellularity assessment;Imp;Pt;XXX;Nar;Flow cytometry;CELLMARK;1;Cellularity assessment [Interpretation] in Specimen by Flow cytometry (FC) Narrative;Cellularity assessment Spec FC-Imp;;ACTIVE;2.38;2.73 +67128-9;Leukocytes.abnormal/100 leukocytes;NFr;Pt;XXX;Qn;Flow cytometry;CELLMARK;1;Abnormal leukocytes/100 leukocytes in Specimen by Flow cytometry (FC);Abnormal WBC/leuk NFr Spec FC;;ACTIVE;2.38;2.73 +67129-7;Heart rate^resting;NRat;Pt;Peripheral artery;Qn;Palpation;HRTRATE.MOLEC;2;Heart rate Peripheral artery by palpation --resting;Heart rate Resting Periph a Palpation;;ACTIVE;2.38;2.65 +67131-3;Age range for gallbladder disease;Time;Pt;^Patient;Qn;PhenX;PHENX;2;Age range for gallbladder disease [PhenX];Age range gallbladder PhenX;;TRIAL;2.38;2.65 +6713-2;Saccharomyces cerevisiae Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Baker's yeast IgG Ab [Units/volume] in Serum;Baker's yeast IgG Qn;;ACTIVE;1.0h(2);2.73 +67132-1;Area of gallbladder pain;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Area of gallbladder pain [PhenX];Gallbladder pain area PhenX;;TRIAL;2.38;2.65 +67133-9;Has pain that has been most uncomfortable in this area the past 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Has pain that has been most uncomfortable in this area the past 12 months [PhenX];Gallbladder pain worst PhenX;;TRIAL;2.38;2.65 +67134-7;During the past 12Mo, what is the longest time that one episode of this pain has lasted;Time;12Mo;^Patient;Qn;PhenX;PHENX;2;During the past 12 months, what is the longest time that one episode of this pain has lasted [PhenX];Longest time pain PhenX;;TRIAL;2.38;2.65 +67135-4;On how many Ds in the past 12Mo have you had this pain;NRat;12Mo;^Patient;Qn;PhenX;PHENX;2;On how many days in the past 12 months have you had this pain [PhenX];# Ds pain nRate PhenX;;TRIAL;2.38;2.65 +67136-2;When you had the pain, if you moved around, did you hurt more, less, or was there no difference;Find;Pt;^Patient;Nom;PhenX;PHENX;2;When you had the pain, if you moved around, did you hurt more, less, or was there no difference [PhenX];Moving helped pain PhenX;;TRIAL;2.38;2.65 +67137-0;Have you ever seen a doctor about this pain;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever seen a doctor about this pain [PhenX];Seen doctor for pain PhenX;;TRIAL;2.38;2.65 +67138-8;What did the doctor say caused the pain;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What did the doctor say caused the pain [PhenX];Doctor cause of pain PhenX;;TRIAL;2.38;2.65 +67139-6;Other cause of pain;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other cause of pain [PhenX];Other cause pain PhenX;;TRIAL;2.38;2.65 +6714-0;Beef Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beef IgG Ab [Units/volume] in Serum;Beef IgG Qn;;ACTIVE;1.0h(2);2.73 +67140-4;Has a doctor ever told you that you had gallstones;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has a doctor ever told you that you had gallstones [PhenX];Doctor dx gallstones PhenX;;TRIAL;2.38;2.65 +67141-2;What was the reason you visited the doctor the time that he told you that you had gallstones;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What was the reason you visited the doctor the time that he told you that you had gallstones [PhenX];Reason for doctor visit PhenX;;TRIAL;2.38;2.65 +67142-0;Other reason you visited the doctor the time that he told you that you had gallstones;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other reason you visited the doctor the time that he told you that you had gallstones [PhenX];Other reason for doctor visit PhenX;;TRIAL;2.38;2.65 +67143-8;Have you ever had medical treatment to dissolve or remove gallstones;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had medical treatment to dissolve or remove gallstones [PhenX];Tx dissolve remove gallstones PhenX;;TRIAL;2.38;2.65 +67144-6;Have you ever had gallbladder surgery;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had gallbladder surgery [PhenX];Had gallbladder surgery PhenX;;TRIAL;2.38;2.65 +67145-3;How old were you when you had your gallbladder surgery;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How old were you when you had your gallbladder surgery [PhenX];Age gallbladder surgery PhenX;;TRIAL;2.38;2.65 +67146-1;During the past 12Mo, have you had pain in the area shaded on the diagram;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;During the past 12 months, have you had pain in the area shaded on the diagram [PhenX];Pain diagram PhenX;;TRIAL;2.38;2.65 +67147-9;Did the pain that caused you to visit the doctor continue after your gallbladder surgery;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did the pain that caused you to visit the doctor continue after your gallbladder surgery [PhenX];Pain continue after surgery PhenX;;TRIAL;2.38;2.65 +67148-7;Adjudication date by MD fracture coordinator;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Adjudication date by MD fracture coordinator [PhenX];Date adjudication PhenX;;TRIAL;2.38;2.65 +67149-5;Final adjudication;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Final adjudication [PhenX];Final adjudication PhenX;;TRIAL;2.38;2.65 +67151-1;Troponin T.cardiac;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;Troponin T.cardiac [Mass/volume] in Serum or Plasma by High sensitivity method;Troponin T SerPl HS-mCnc;;ACTIVE;2.38;2.73 +67152-9;Date abstracted;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Date abstracted [PhenX];Date abstracted PhenX;;TRIAL;2.38;2.65 +67153-7;Abstractor ID;ID;Pt;^Observer;Nom;;ADMIN.ID;2;Abstractor [Identifier];Abstractor ID;;ACTIVE;2.38;2.66 +67154-5;Nosologist ID;ID;Pt;^Observer;Nom;;ADMIN.ID;2;Nosologist [Identifier];Nosologist ID;;ACTIVE;2.38;2.66 +67155-2;Study year;Time;Pt;Study;Qn;PhenX;PHENX;2;Study year Study [PhenX];Study year Study PhenX;;TRIAL;2.38;2.65 +67156-0;Purpose of abstract;Find;Pt;Study;Nom;PhenX;PHENX;2;Purpose of abstract Study [PhenX];Purpose of abstract Study PhenX;;TRIAL;2.38;2.65 +6715-7;Yeast brewer's Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brewer's yeast IgG Ab [Units/volume] in Serum;Brewer's yeast IgG Qn;;ACTIVE;1.0h(2);2.73 +67157-8;Multiple primary cancer number;Num;Pt;Study;Qn;PhenX;PHENX;2;Multiple primary cancer number Study [PhenX];Multiple primary cancer Study PhenX;;TRIAL;2.38;2.65 +67158-6;Form receipted into SMS;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Form receipted into SMS [PhenX];Form receipted SMS PhenX;;TRIAL;2.38;2.65 +67159-4;Manual review completed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Manual review completed [PhenX];Manual review completed PhenX;;TRIAL;2.38;2.65 +67160-2;Data entry of non-scannable items;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Data entry of non-scannable items [PhenX];Use non-scannable items PhenX;;TRIAL;2.38;2.65 +67161-0;Data retrieval;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Data retrieval [PhenX];Data retrieval PhenX;;TRIAL;2.38;2.65 +67162-8;Disposition;Find;Pt;^Patient;Nom;;CLIN;2;Patient Disposition;Patient Disposition;;ACTIVE;2.38;2.66 +67163-6;Diagnostic procedures performed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Diagnostic procedures performed [PhenX];Diagnostic procedures performed PhenX;;TRIAL;2.38;2.65 +67164-4;Reason for initial visit for clinical assessment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Reason for initial visit for clinical assessment [PhenX];Initial visit reason PhenX;;TRIAL;2.38;2.65 +6716-5;Cardiolipin Ab.IgG;ACnc;Pt;Ser;Qn;EIA;COAG;1;Deprecated Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated Cardiolipin IgG Ser EIA-aCnc;;DEPRECATED;1.0h(2);2.69 +67165-1;Other reason for initial visit for clinical assessment;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other reason for initial visit for clinical assessment [PhenX];Initial visit reason other PhenX;;TRIAL;2.38;2.65 +67166-9;Sigmoidoscopy or colonoscopy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Sigmoidoscopy or colonoscopy [PhenX];Sigmoidoscopy colonoscopy PhenX;;TRIAL;2.38;2.73 +67168-5;Cecum visualization;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Cecum visualization [PhenX];Cecum visualization PhenX;;TRIAL;2.38;2.65 +67169-3;Bowel preparation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Bowel preparation [PhenX];Bowel preparation PhenX;;TRIAL;2.38;2.65 +67170-1;Hyperplastic polyps;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Hyperplastic polyps [PhenX];Hyperplastic polyps PhenX;;TRIAL;2.38;2.65 +67171-9;Procedure type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Procedure type [PhenX];Procedure type PhenX;;TRIAL;2.38;2.65 +67172-7;Adenomas on sigmoidoscopy or colonoscopy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Adenomas on sigmoidoscopy or colonoscopy [PhenX];Adenomas colonoscopy PhenX;;TRIAL;2.38;2.65 +6717-3;Cardiolipin Ab.IgM;ACnc;Pt;Ser;Qn;EIA;COAG;1;Deprecated Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay;Deprecated Cardiolipin IgM Ser EIA-aCnc;;DEPRECATED;1.0h(2);2.69 +67173-5;Multiple polyps in specimen jar;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Multiple polyps in specimen jar [PhenX];Multiple polyps PhenX;;TRIAL;2.38;2.65 +67174-3;Adenoma distance;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Adenoma distance [PhenX];Adenoma distance PhenX;;TRIAL;2.38;2.65 +67175-0;Longest adenoma dimension;Len;Pt;^Patient;Qn;PhenX;PHENX;2;Longest adenoma dimension [PhenX];Adenoma dimension PhenX;;TRIAL;2.38;2.65 +67176-8;Adenoma description;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Adenoma description [PhenX];Adenoma description PhenX;;TRIAL;2.38;2.65 +67177-6;Adenoma histology;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Adenoma histology [PhenX];Adenoma histology PhenX;;TRIAL;2.38;2.65 +67178-4;Adenoma dysplasia;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Adenoma dysplasia [PhenX];Adenoma dysplasia PhenX;;TRIAL;2.38;2.65 +67179-2;Non-advanced adenomas;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Non-advanced adenomas [#] [PhenX];Non-advanced adenomas PhenX;;TRIAL;2.38;2.65 +671-8;Microscopic observation;Prid;Pt;XXX;Nom;Methylene blue stain.Loeffler;MICRO;1;Microscopic observation [Identifier] in Specimen by Methylene blue stain.Loeffler;Loeffler MB Stn Spec;;ACTIVE;1.0;2.69 +67180-0;Advanced adenomas;Num;Pt;^Patient;Qn;PhenX;PHENX;2;Advanced adenomas [#] [PhenX];Advanced adenomas PhenX;;TRIAL;2.38;2.65 +6718-1;Anacardium occidentale Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cashew nut IgE Ab [Units/volume] in Serum;Cashew nut IgE Qn;;ACTIVE;1.0h(2);2.73 +67181-8;Can exact number of adenomas be determined;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Can exact number of adenomas be determined [PhenX];Exact number adenomas determined PhenX;;TRIAL;2.38;2.65 +67182-6;Other diagnostic or staging procedures done;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Other diagnostic or staging procedures done [PhenX];Other diagnos staging proced done PhenX;;TRIAL;2.38;2.65 +67183-4;Diagnostic or staging procedure;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Diagnostic or staging procedure [PhenX];Diagnostic staging procedure PhenX;;TRIAL;2.38;2.65 +67184-2;Other diagnostic or staging procedure;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Other diagnostic or staging procedure [PhenX];Other diagnostic staging proced PhenX;;TRIAL;2.38;2.65 +67185-9;Diagnostic_staging procedures supplement form completed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Diagnostic_staging procedures supplement form completed [PhenX];Proced supplem form completed PhenX;;TRIAL;2.38;2.65 +67186-7;Medical complications of diagnostic evaluation and staging;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Medical complications of diagnostic evaluation and staging [PhenX];Medical complications PhenX;;TRIAL;2.38;2.65 +67187-5;Type of complication;Type;Pt;^Patient;Nom;;PHENX;2;Type of complication;Complication type;;ACTIVE;2.38;2.65 +67188-3;Infection;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Infection [PhenX];Infection PhenX;;TRIAL;2.38;2.65 +67189-1;Diagnostic evaluation for colorectal cancer;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Diagnostic evaluation for colorectal cancer [PhenX];Diag eval colorectal CA PhenX;;TRIAL;2.38;2.65 +67190-9;Other cancer diagnosis;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Other cancer diagnosis [PhenX];Other cancer Dx PhenX;;TRIAL;2.38;2.65 +67191-7;Description of colorectal carcinoma;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Description of colorectal carcinoma [PhenX];Colorectal carcinoma descript PhenX;;TRIAL;2.38;2.65 +67192-5;Procedure for primary diagnosis of colorectal carcinoma;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Procedure for primary diagnosis of colorectal carcinoma [PhenX];Primary Dx procedure PhenX;;TRIAL;2.38;2.65 +67193-3;Gross morphology;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Gross morphology [PhenX];Gross morphology PhenX;;TRIAL;2.38;2.65 +67194-1;Verbatim description of primary colorectal cancer diagnosis;Hx;Pt;^Patient;Nar;PhenX;PHENX;2;Verbatim description of primary colorectal cancer diagnosis Narrative [PhenX];Colorectal cancer Dx descript PhenX;;TRIAL;2.38;2.65 +67195-8;ICD-O-2 cancer classification - topography;Num;Pt;^Patient;Qn;PhenX;PHENX;2;ICD-O-2 cancer classification - topography [#] [PhenX];ICDO2 cancer - topography PhenX;;TRIAL;2.38;2.65 +67196-6;ICD-O-2 cancer classification - morphology;Num;Pt;^Patient;Qn;PhenX;PHENX;2;ICD-O-2 cancer classification - morphology [#] [PhenX];ICDO2 cancer - morphology PhenX;;TRIAL;2.38;2.65 +67197-4;ICD-O-2 cancer classification - behavior;Num;Pt;^Patient;Qn;PhenX;PHENX;2;ICD-O-2 cancer classification - behavior [#] [PhenX];ICDO2 cancer - behavior PhenX;;TRIAL;2.38;2.65 +67198-2;ICD-O-2 cancer classification - grade;Num;Pt;^Patient;Ord;PhenX;PHENX;2;ICD-O-2 cancer classification - grade [PhenX];ICD-O-2 cancer - grade PhenX;;TRIAL;2.38;2.65 +6719-9;Prunus avium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cherry IgE Ab [Units/volume] in Serum;Cherry IgE Qn;;ACTIVE;1.0h(2);2.73 +67199-0;Photocopy of report confirming primary colorectal cancer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Photocopy of report confirming primary colorectal cancer [PhenX];Primary cancer report photocopy PhenX;;TRIAL;2.38;2.65 +67200-6;Histopathologic type for primary colorectal cancer;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Histopathologic type for primary colorectal cancer [PhenX];Primary CA histopath type PhenX;;TRIAL;2.38;2.65 +67201-4;Other histopathologic type for primary colorectal cancer;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Other histopathologic type for primary colorectal cancer [PhenX];Other histopathologic type PhenX;;TRIAL;2.38;2.65 +67202-2;Histopathologic grade for primary colorectal cancer;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Histopathologic grade for primary colorectal cancer [PhenX];Primary CA histopath grade PhenX;;TRIAL;2.38;2.65 +67203-0;AJCC cancer staging manual;Find;Pt;^Patient;Nom;PhenX;PHENX;2;AJCC cancer staging manual [PhenX];AJCC cancer staging manual PhenX;;TRIAL;2.38;2.65 +67204-8;TNM clinical staging;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM clinical staging [PhenX];Deprecated TNM clinical staging PhenX;;DEPRECATED;2.38;2.61 +67205-5;TNM clinical staging - primary tumor - T;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM clinical staging - primary tumor - T [PhenX];Deprecated TNM clin-T PhenX;;DEPRECATED;2.38;2.61 +67206-3;TNM clinical staging - nodal involvement - N;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM clinical staging - nodal involvement - N [PhenX];Deprecated TNM clin-N PhenX;;DEPRECATED;2.38;2.61 +6720-7;Chocolate Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chocolate IgG Ab [Units/volume] in Serum;Chocolate IgG Qn;;ACTIVE;1.0h(2);2.73 +67207-1;TNM clinical staging - distant metastases - M;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM clinical staging - distant metastases - M [PhenX];Deprecated TNM clin-M PhenX;;DEPRECATED;2.38;2.61 +67208-9;TNM pathologic staging;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM pathologic staging [PhenX];Deprecated TNM path staging PhenX;;DEPRECATED;2.38;2.61 +67209-7;TNM pathologic staging - primary tumor - T;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM pathologic staging - primary tumor - T [PhenX];Deprecated TNM path-T PhenX;;DEPRECATED;2.38;2.61 +67210-5;TNM pathologic staging - nodal involvement - N;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM pathologic staging - nodal involvement - N [PhenX];Deprecated TNM path-N PhenX;;DEPRECATED;2.38;2.61 +67211-3;TNM pathologic staging - distant metastases - M;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Deprecated TNM pathologic staging - distant metastases - M [PhenX];Deprecated TNM path-M PhenX;;DEPRECATED;2.38;2.61 +67212-1;Record stage;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Record stage [PhenX];Record stage PhenX;;TRIAL;2.38;2.65 +67213-9;Disease stage;Find;Pt;^Patient;Ord;;CLIN;2;Disease stage;Disease stg;;ACTIVE;2.38;2.68 +67214-7;Dukes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Dukes [PhenX];Dukes PhenX;;TRIAL;2.38;2.65 +6721-5;Gadus morhua Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Codfish IgG Ab [Units/volume] in Serum;Codfish IgG Qn;;ACTIVE;1.0h(2);2.73 +67215-4;Modified dukes - astler-coller;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Modified dukes - astler-coller [PhenX];Modified dukes - astler-coller PhenX;;TRIAL;2.38;2.65 +67216-2;Summary staging;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Summary staging [PhenX];Summary staging PhenX;;TRIAL;2.38;2.65 +67217-0;Adenomas procedure;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Adenomas procedure [PhenX];Adenomas procedure PhenX;;TRIAL;2.38;2.65 +67218-8;Location of polyps;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Location of polyps [PhenX];Location of polyps PhenX;;TRIAL;2.38;2.65 +67219-6;In the past 2Y, have you had upper endoscopy, esophagus or stomach;Find;2Y;^Patient;Ord;PhenX;PHENX;2;In the past 2Y, have you had upper endoscopy, esophagus or stomach [PhenX];Upper endoscopy PhenX;;TRIAL;2.38;2.65 +67220-4;In the past 2Y, have you had a virtual CT colonoscopy;Find;2Y;^Patient;Ord;PhenX;PHENX;2;In the past 2Y, have you had a virtual CT colonoscopy [PhenX];Virtual CT colonoscopy PhenX;;TRIAL;2.38;2.65 +67221-2;In the past 2Y have you had a colonoscopy;Find;2Y;^Patient;Ord;PhenX;PHENX;2;In the past 2Y have you had a colonoscopy [PhenX];Colonoscopy PhenX;;TRIAL;2.38;2.65 +67222-0;In the past 2Y, have you had a sigmoidoscopy;Find;2Y;^Patient;Ord;PhenX;PHENX;2;In the past 2Y, have you had a sigmoidoscopy [PhenX];Sigmoidoscopy PhenX;;TRIAL;2.38;2.65 +6722-3;Coffea spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coffee IgG Ab [Units/volume] in Serum;Coffee IgG Qn;;ACTIVE;1.0h(2);2.73 +67223-8;Initial reasons you had a colonoscopy or sigmoidoscopy;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Initial reasons you had a colonoscopy or sigmoidoscopy [PhenX];Reasons had colon sigmoidoscopy PhenX;;TRIAL;2.38;2.65 +67224-6;Clinician diagnosed gastrointestinal conditions;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Clinician diagnosed gastrointestinal conditions [PhenX];Gastrointestinal conditions PhenX;;TRIAL;2.38;2.65 +67225-3;Have you had this clinician diagnosed condition;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had this clinician diagnosed condition [PhenX];Clinician diagnosed condition ever PhenX;;TRIAL;2.38;2.65 +67226-1;Site of the bleeding;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Site of the bleeding [PhenX];Site of bleeding PhenX;;TRIAL;2.38;2.65 +67227-9;Was this the site of the bleeding;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was this the site of the bleeding [PhenX];Bleeding site PhenX;;TRIAL;2.38;2.65 +67228-7;What Ys did this happen;DateRange;Pt;^Patient;Qn;PhenX;PHENX;2;What years did this happen [DateRange] [PhenX];What Ys happened DateRange PhenX;;TRIAL;2.38;2.65 +67229-5;How often did you have a burning feeling behind your breastbone - heartburn;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;How often did you have a burning feeling behind your breastbone - heartburn [PhenX];Heartburn freq PhenX;;TRIAL;2.38;2.65 +67230-3;How often did you have stomach contents - liquid or food moving upwards to your throat or mouth - regurgitation in the past 7D;NRat;7D;^Patient;Ord;PhenX;PHENX;2;How often did you have stomach contents - liquid or food moving upwards to your throat or mouth - regurgitation in the past 7 days [PhenX];Regurgitation freq PhenX;;TRIAL;2.38;2.65 +6723-1;Zea mays Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Corn IgG Ab [Units/volume] in Serum;Corn IgG Qn;;ACTIVE;1.0h(2);2.73 +67231-1;How often did you have pain in the center of the upper stomach in the past 7D;NRat;7D;^Patient;Ord;PhenX;PHENX;2;How often did you have pain in the center of the upper stomach in the past 7 days [PhenX];Stomach pain freq PhenX;;TRIAL;2.38;2.65 +67232-9;How often did you have nausea in the past 7D;NRat;7D;^Patient;Ord;PhenX;PHENX;2;How often did you have nausea in the past 7 days [PhenX];Nausea freq PhenX;;TRIAL;2.38;2.65 +67233-7;How often did you have difficulty getting a good night's sleep because of your heartburn or regurgitation in the past 7D;NRat;7D;^Patient;Ord;PhenX;PHENX;2;How often did you have difficulty getting a good night's sleep because of your heartburn or regurgitation in the past 7 days [PhenX];Difficulty sleeping freq PhenX;;TRIAL;2.38;2.65 +67234-5;How often did you take additional medications for your heartburn or regurgitation other than what your physician told you to take, such as tums, rolaids, maalox in the past 7D;NRat;7D;^Patient;Ord;PhenX;PHENX;2;How often did you take additional medications for your heartburn or regurgitation other than what your physician told you to take, such as tums, rolaids, maalox in the past 7 days [PhenX];Additional medications freq PhenX;;TRIAL;2.38;2.65 +67235-2;Does the examinee have hearing aids that cannot be removed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does the examinee have hearing aids that cannot be removed [PhenX];Hearing aids PhenX;;TRIAL;2.38;2.65 +67236-0;Do you now have a tube in your right or left ear;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you now have a tube in your right or left ear [PhenX];Ear tubes PhenX;;TRIAL;2.38;2.65 +67238-6;Have you had a cold, sinus problem or earache in the last 24H;Find;24H;^Patient;Ord;PhenX;PHENX;2;Have you had a cold, sinus problem or earache in the last 24 hours 24 hour [PhenX];Cold sinus problem 24h PhenX;;TRIAL;2.38;2.65 +67239-4;Which have you had;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which have you had [PhenX];Which have you had PhenX;;TRIAL;2.38;2.65 +67240-2;Have you been exposed to loud noise or listened to music with headphone in the past 24H;Find;24H;^Patient;Ord;PhenX;PHENX;2;Have you been exposed to loud noise or listened to music with headphone in the past 24 hours 24 hour [PhenX];Loud noise exposure 24h PhenX;;TRIAL;2.38;2.65 +67241-0;How many Hs ago did the noise or music end;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many hours ago did the noise or music end [PhenX];Loud noise when PhenX;;TRIAL;2.38;2.65 +67242-8;Do you hear better in one ear than the other;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you hear better in one ear than the other [PhenX];Hear better in one ear PhenX;;TRIAL;2.38;2.65 +67243-6;Comment to describe the ear;Find;Pt;Ear.left;Ord;PhenX;PHENX;2;Comment to describe the ear Ear - left [PhenX];Ear comment Ear-L PhenX;;TRIAL;2.38;2.65 +67244-4;Comment to describe the ear;Find;Pt;Ear.right;Ord;PhenX;PHENX;2;Comment to describe the ear Ear - right [PhenX];Ear comment Ear-R PhenX;;TRIAL;2.38;2.65 +67245-1;Acoustic immittance;Pres;Pt;Ear.right;Qn;PhenX;PHENX;2;Acoustic immittance [Pressure] Ear - right [PhenX];Acoustic immittance Ear-R PhenX;;TRIAL;2.38;2.65 +67246-9;Tympanogram ID;ID;Pt;Ear.right;Nom;PhenX;PHENX;2;Tympanogram ID Ear - right [PhenX];Tympanogram ID Ear-R PhenX;;TRIAL;2.38;2.65 +67247-7;Acoustic immittance;Pres;Pt;Ear.left;Qn;PhenX;PHENX;2;Acoustic immittance [Pressure] Ear - left [PhenX];Acoustic immittance Ear-L PhenX;;TRIAL;2.38;2.65 +67248-5;Tympanogram ID;ID;Pt;Ear.left;Nom;PhenX;PHENX;2;Tympanogram ID Ear - left [PhenX];Tympanogram ID Ear-L PhenX;;TRIAL;2.38;2.65 +6724-9;Cucumis sativus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cucumber IgE Ab [Units/volume] in Serum;Cucumber IgE Qn;;ACTIVE;1.0h(2);2.73 +67249-3;Ear tested first;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Ear tested first [PhenX];Ear tested first PhenX;;TRIAL;2.38;2.65 +67250-1;Headphones used, original test;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Headphones used, original test [PhenX];Headphones used original test PhenX;;TRIAL;2.38;2.65 +67251-9;Test mode;Find;Pt;Ear.right;Nom;PhenX;PHENX;2;Test mode Ear - right [PhenX];Test mode Ear-R PhenX;;TRIAL;2.38;2.65 +67252-7;Hz when switched to manual mode;Num;Pt;Ear.right;Qn;PhenX;PHENX;2;Hz when switched to manual mode [#] Ear - right [PhenX];Hz switched manual Ear-R PhenX;;TRIAL;2.38;2.73 +67253-5;Frequencies;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Frequencies [PhenX];Frequencies PhenX;;TRIAL;2.38;2.65 +67254-3;Threshold;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Threshold [PhenX];Threshold PhenX;;TRIAL;2.38;2.65 +6725-6;Egg white Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Egg white IgG Ab [Units/volume] in Serum;Egg White IgG Qn;;ACTIVE;1.0h(2);2.73 +67256-8;Right or left ear;Find;Pt;Ear;Nom;PhenX;PHENX;2;Right or left ear Ear [PhenX];Right or left ear Ear PhenX;;TRIAL;2.38;2.65 +67257-6;Test mode;Find;Pt;Ear.left;Nom;PhenX;PHENX;2;Test mode Ear - left [PhenX];Test mode Ear-L PhenX;;TRIAL;2.38;2.65 +67258-4;Hz when switched to manual mode;Num;Pt;Ear.left;Qn;PhenX;PHENX;2;Hz when switched to manual mode [#] Ear - left [PhenX];Hz switched manual Ear-L PhenX;;TRIAL;2.38;2.73 +67259-2;Have you ever had 3 or more ear infections;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had 3 or more ear infections [PhenX];>3 ear infections PhenX;;TRIAL;2.38;2.65 +672-6;Microscopic observation;Prid;Pt;XXX;Nom;Neisser stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Neisser stain;Neisser Stn Spec;;ACTIVE;1.0;2.69 +67260-0;Have you ever had a tube placed in your ear to drain the fluid from your ear;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had a tube placed in your ear to drain the fluid from your ear [PhenX];Tubes in ears PhenX;;TRIAL;2.38;2.65 +67261-8;My child's ability to ask questions properly is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to ask questions properly is [PhenX];Ability ask questions PhenX;;TRIAL;2.38;2.65 +67262-6;My child's ability to answer questions properly is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to answer questions properly is [PhenX];Answer questions PhenX;;TRIAL;2.38;2.65 +67263-4;My child's ability to understand what others say to him or her is-;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to understand what others say to him or her is - [PhenX];Ability understand others PhenX;;TRIAL;2.38;2.65 +6726-4;Arrhenatherum elatius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;False oat grass IgE Ab [Units/volume] in Serum;False oat grass IgE Qn;;ACTIVE;1.0h(2);2.73 +67264-2;My child's ability to say sentences clearly enough to be understood by strangers is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to say sentences clearly enough to be understood by strangers is [PhenX];Ability say sentences clearly PhenX;;TRIAL;2.38;2.65 +67265-9;The number of words my child knows is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The number of words my child knows is [PhenX];Number words known PhenX;;TRIAL;2.38;2.65 +67266-7;My child's ability to use his or her words correctly is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to use his or her words correctly is [PhenX];Ability use words correctly PhenX;;TRIAL;2.38;2.65 +67267-5;My child's ability to get his or her messages across to others when talking is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to get his or her messages across to others when talking is [PhenX];Ability get message across PhenX;;TRIAL;2.38;2.65 +67268-3;My child's ability to understand directions spoken to him or her is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to understand directions spoken to him or her is [PhenX];Ability understand directions PhenX;;TRIAL;2.38;2.65 +67269-1;My child's ability to follow directions spoken to him or her is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to follow directions spoken to him or her is [PhenX];Ability follow spoken directions PhenX;;TRIAL;2.38;2.65 +67270-9;My child's ability to use the proper words when talking to others is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to use the proper words when talking to others is [PhenX];Ability use proper words PhenX;;TRIAL;2.38;2.65 +67271-7;My child's ability to get what he or she wants by talking is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to get what he or she wants by talking is [PhenX];Ability get talking PhenX;;TRIAL;2.38;2.65 +6727-2;Apis mellifera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee IgG Ab [Units/volume] in Serum;Honey bee IgG Qn;;ACTIVE;1.0h(2);2.73 +67272-5;My child's ability to start a conversation, or start talking with other children is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to start a conversation, or start talking with other children is [PhenX];Ability start conversation PhenX;;TRIAL;2.38;2.65 +67273-3;My child's ability to keep a conversation going with other children is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to keep a conversation going with other children is [PhenX];Ability keep conversation going PhenX;;TRIAL;2.38;2.65 +67274-1;The length of this child's sentences is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The length of this child's sentences is [PhenX];Length of sentences PhenX;;TRIAL;2.38;2.65 +67275-8;My child's ability to make grown up sentences is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to make grown up sentences is [PhenX];Ability make grown up sentences PhenX;;TRIAL;2.38;2.65 +67276-6;My child's ability to correctly say the sounds in individual words is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's ability to correctly say the sounds in individual words is [PhenX];Ability correctly say sounds PhenX;;TRIAL;2.38;2.65 +67277-4;My child's awareness of differences in the way people act, speak, dress, etc is;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child's awareness of differences in the way people act, speak, dress, etc is [PhenX];Child awareness PhenX;;TRIAL;2.38;2.65 +67278-2;My child usually speaks - volume;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child usually speaks - volume [PhenX];Speaking volume PhenX;;TRIAL;2.38;2.65 +67279-0;My child usually speaks - frequency;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My child usually speaks - frequency [PhenX];Speaking frequency PhenX;;TRIAL;2.38;2.65 +6728-0;Latex glove extract Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex glove extract IgE Ab [Units/volume] in Serum;Ltx Glv Ext IgE Qn;;ACTIVE;1.0h(2);2.73 +67280-8;I tend to lose control when I am in a great mood;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I tend to lose control when I am in a great mood [UPPS-R-Child];Lose control UPPS-R-C;;ACTIVE;2.38;2.65 +67281-6;I would like to learn to fly an airplane;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I would like to learn to fly an airplane [UPPS-R-Child];Would like fly airplane UPPS-R-C;;ACTIVE;2.38;2.65 +67282-4;I am a person who always gets the job done;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I am a person who always gets the job done [UPPS-R-Child];Gets job done UPPS-R-C;;ACTIVE;2.38;2.65 +67283-2;I almost always finish projects that I start;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I almost always finish projects that I start [UPPS-R-Child];Almost always finish projects UPPS-R-C;;ACTIVE;2.38;2.65 +67284-0;I often make matters worse because I act without thinking when I am upset;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I often make matters worse because I act without thinking when I am upset [UPPS-R-Child];Matters worse act w/o thinking UPPS-R-C;;ACTIVE;2.38;2.65 +67285-7;I would enjoy fast driving;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I would enjoy fast driving [UPPS-R-Child];Would enjoy fast driving UPPS-R-C;;ACTIVE;2.38;2.65 +67286-5;Relationship to you;Find;Pt;^Patient;Nom;The Position Generator;PHENX;2;Relationship to you [The Position Generator];Relationship Pos Gen;;ACTIVE;2.38;2.65 +67287-3;I finish what I start;Find;Pt;^Patient;Ord;UPPS-R-C;PHENX;2;I finish what I start [UPPS-R-Child];Finish what I start UPPS-R-C;;ACTIVE;2.38;2.65 +67288-1;Race or ethnicity;Type;Pt;^Patient;Nom;The Position Generator;ADMIN.PATIENT.DEMOG;2;Race or ethnicity [The Position Generator];Race or ethnicity Pos Gen;;ACTIVE;2.38;2.66 +67289-9;When you had this pain, was it continuous, or did it tend to come and go;Find;Pt;^Patient;Nom;PhenX;PHENX;2;When you had this pain, was it continuous, or did it tend to come and go [PhenX];Pain continuous PhenX;;TRIAL;2.38;2.65 +67290-7;Date of complication;Date;Pt;^Patient;Qn;;PHENX;2;Date of complication;Date of complication;;TRIAL;2.38;2.65 +67291-5;Other biopsy;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Other biopsy [PhenX];Other biopsy PhenX;;TRIAL;2.38;2.65 +67292-3;Other CT scan;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Other CT scan [PhenX];Other CT scan PhenX;;TRIAL;2.38;2.65 +67293-1;Other MRI scan;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Other MRI scan [PhenX];Other MRI scan PhenX;;TRIAL;2.38;2.65 +67294-9;Other resection;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Other resection [PhenX];Other resection PhenX;;TRIAL;2.38;2.65 +67295-6;Other radiograph;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Other radiograph [PhenX];Other radiograph PhenX;;TRIAL;2.38;2.65 +67296-4;Other ultrasound;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Other ultrasound [PhenX];Other ultrasound PhenX;;TRIAL;2.38;2.65 +67297-2;By age 2, was your child talking in short phrases or sentences;Find;Pt;^Patient;Ord;PhenX;PHENX;2;By age 2, was your child talking in short phrases or sentences [PhenX];Talking short sentences PhenX;;TRIAL;2.38;2.65 +6729-8;Cow milk Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow milk IgG Ab [Units/volume] in Serum;Cow Milk IgG Qn;;ACTIVE;1.0h(2);2.73 +67298-0;When your child was 2Ys old, were you concerned that they were having difficulty learning to talk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;When your child was 2Ys old, were you concerned that they were having difficulty learning to talk [PhenX];Difficulty learning to talk PhenX;;TRIAL;2.38;2.65 +67299-8;At this time, do people frequently have trouble understanding your child;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At this time, do people frequently have trouble understanding your child [PhenX];Trouble understanding child PhenX;;TRIAL;2.38;2.65 +67300-4;Has anyone in your child's family had speech or language therapy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has anyone in your child's family had speech or language therapy [PhenX];Family hx speech language therapy PhenX;;TRIAL;2.38;2.65 +67301-2;What did anyone in your child's family have speech or language therapy for;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What did anyone in your child's family have speech or language therapy for [PhenX];Fam hx speech therapy PhenX;;TRIAL;2.38;2.65 +67302-0;Has anyone in your child's family had difficulty learning to read or had problems with school work;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has anyone in your child's family had difficulty learning to read or had problems with school work [PhenX];Child's family diff learn read PhenX;;TRIAL;2.38;2.65 +67304-6;Details of family having difficulty reading or problems with school work;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Details of family having difficulty reading or problems with school work [PhenX];Diff learning read details PhenX;;TRIAL;2.38;2.65 +67305-3;Has anyone in your child's family been diagnosed with an intellectual disability;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has anyone in your child's family been diagnosed with an intellectual disability [PhenX];Family hx int disability PhenX;;TRIAL;2.38;2.65 +6730-6;Citrus sinensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Orange IgG Ab [Units/volume] in Serum;Orange IgG Qn;;ACTIVE;1.0h(2);2.73 +67306-1;Does anyone in your child's family have a hearing difficulty;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does anyone in your child's family have a hearing difficulty [PhenX];Family hx hearing difficulty PhenX;;TRIAL;2.38;2.65 +67307-9;Has anyone in your child's family been slow in learning to talk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has anyone in your child's family been slow in learning to talk [PhenX];Family hx slow to talk PhenX;;TRIAL;2.38;2.65 +67308-7;Has anyone in your child's family had stuttering;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has anyone in your child's family had stuttering [PhenX];Family hx stuttering PhenX;;TRIAL;2.38;2.65 +67309-5;Anyone in your child's family less talkative;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family less talkative [PhenX];Family hx less talkative PhenX;;TRIAL;2.38;2.65 +67310-3;Has anyone in your child's family had a hard time carrying on a conversation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has anyone in your child's family had a hard time carrying on a conversation [PhenX];Family hx carrying conversation PhenX;;TRIAL;2.38;2.65 +67311-1;Anyone in your child's family that doesn't like to read;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that doesn't like to read [PhenX];Family hx doesn't like to read PhenX;;TRIAL;2.38;2.65 +67312-9;Anyone in your child's family that doesn't read well;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that doesn't read well [PhenX];Family hx doesn't read well PhenX;;TRIAL;2.38;2.65 +67313-7;Anyone in your child's family that has difficulty thinking of words they want to say when talking;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that has difficulty thinking of words they want to say when talking [PhenX];Family hx thinking of words PhenX;;TRIAL;2.38;2.65 +6731-4;Polistes spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp IgG Ab [Units/volume] in Serum;Paper Wasp IgG Qn;;ACTIVE;1.0h(2);2.73 +67314-5;Anyone in your child's family that has a poorer vocabulary than other family members;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that has a poorer vocabulary than other family members [PhenX];Family hx poor vocabulary PhenX;;TRIAL;2.38;2.65 +67315-2;Anyone in your child's family that is a poor speller;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that is a poor speller [PhenX];Family hx poor speller PhenX;;TRIAL;2.38;2.65 +67316-0;Anyone in your child's family that has awkward sentence structures when writing or talking;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that has awkward sentence structures when writing or talking [PhenX];Family hx awkward sentences PhenX;;TRIAL;2.38;2.65 +67317-8;Anyone in your child's family that mispronounces long words;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that mispronounces long words [PhenX];Family hx mispronounces words PhenX;;TRIAL;2.38;2.65 +67318-6;Anyone in your child's family that is hard to follow when they tell you something, such as a personal experience;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that is hard to follow when they tell you something, such as a personal experience [PhenX];Family hx hard to follow PhenX;;TRIAL;2.38;2.65 +67319-4;Anyone in your child's family that has difficulty explaining things;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Anyone in your child's family that has difficulty explaining things [PhenX];Family hx difficulty explaining PhenX;;TRIAL;2.38;2.65 +67320-2;Because of your tinnitus is it difficult to concentrate;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus is it difficult to concentrate [PhenX];Difficult to concentrate-tinnitis PhenX;;TRIAL;2.38;2.65 +67321-0;Does the loudness of your tinnitus make it difficult for you to hear people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does the loudness of your tinnitus make it difficult for you to hear people [PhenX];Difficult to hear people PhenX;;TRIAL;2.38;2.65 +6732-2;Arachis hypogaea Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut IgG Ab [Units/volume] in Serum;Peanut IgG Qn;;ACTIVE;1.0h(2);2.73 +67322-8;Does your tinnitus make you angry;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus make you angry [PhenX];Tinnitus angry PhenX;;TRIAL;2.38;2.65 +67323-6;Does your tinnitus make you feel confused;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus make you feel confused [PhenX];Tinnitus confused PhenX;;TRIAL;2.38;2.65 +67324-4;Because of your tinnitus do you feel desperate;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus do you feel desperate [PhenX];Tinnitus desperate PhenX;;TRIAL;2.38;2.65 +67325-1;Do you complain a great deal about your tinnitus;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you complain a great deal about your tinnitus [PhenX];Tinnitus complain PhenX;;TRIAL;2.38;2.65 +67326-9;Because of your tinnitus do you have trouble falling to sleep at night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus do you have trouble falling to sleep at night [PhenX];Tinnitus sleeplessness PhenX;;TRIAL;2.38;2.65 +67327-7;Do you feel that you cannot escape your tinnitus;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel that you cannot escape your tinnitus [PhenX];Tinnitus cannot escape PhenX;;TRIAL;2.38;2.65 +67328-5;Does your tinnitus interfere with your ability to enjoy social activities;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus interfere with your ability to enjoy social activities [PhenX];Tinnitus interfere social activ PhenX;;TRIAL;2.38;2.65 +67329-3;Because of your tinnitus do you feel frustrated;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus do you feel frustrated [PhenX];Tinnitus frustrated PhenX;;TRIAL;2.38;2.65 +6733-0;Pigeon serum Ab;PrThr;Pt;Ser;Ord;Immune diffusion;ALLERGY;1;Pigeon serum Ab [Presence] in Serum by Immune diffusion (ID);Pigeon Serum Ab Ql ID;;ACTIVE;1.0h(2);2.73 +67330-1;Because of your tinnitus do you feel that you have a terrible disease;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus do you feel that you have a terrible disease [PhenX];Tinnitus terrible disease PhenX;;TRIAL;2.38;2.65 +67331-9;Does your tinnitus make it difficult for you to enjoy life;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus make it difficult for you to enjoy life [PhenX];Tinnitus difficult enjoy life PhenX;;TRIAL;2.38;2.65 +67332-7;Does your tinnitus interfere with your job or household duties;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus interfere with your job or household duties [PhenX];Tinnitus interfere household PhenX;;TRIAL;2.38;2.65 +67333-5;Because of your tinnitus do you find that you are often irritable;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus do you find that you are often irritable [PhenX];Tinnitus irritable PhenX;;TRIAL;2.38;2.65 +67334-3;Because of your tinnitus is it difficult for you to read;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus is it difficult for you to read [PhenX];Tinnitus difficult to read PhenX;;TRIAL;2.38;2.65 +67335-0;Does your tinnitus make you upset;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus make you upset [PhenX];Tinnitus upset PhenX;;TRIAL;2.38;2.65 +67336-8;Do you feel that your tinnitus problem has placed stress on your relationship with members of your family and friends;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel that your tinnitus problem has placed stress on your relationship with members of your family and friends [PhenX];Tinnitus stressed relationships PhenX;;TRIAL;2.38;2.65 +67337-6;Do you find it difficult to focus your attention away from your tinnitus and on other things;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you find it difficult to focus your attention away from your tinnitus and on other things [PhenX];Tinnitus difficult focus PhenX;;TRIAL;2.38;2.65 +67338-4;Do you feel that you have no control over your tinnitus;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel that you have no control over your tinnitus [PhenX];Tinnitus no control PhenX;;TRIAL;2.38;2.65 +67339-2;Because of your tinnitus do you often feel tired;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus do you often feel tired [PhenX];Tinnitus tired PhenX;;TRIAL;2.38;2.65 +673-4;Ova & parasites identified;Prid;Pt;XXX;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Specimen by Light microscopy;O+P Spec Micro;;ACTIVE;1.0;2.73 +67340-0;Because of your tinnitus do you feel depressed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your tinnitus do you feel depressed [PhenX];Tinnitus depressed PhenX;;TRIAL;2.38;2.65 +67341-8;Does your tinnitus make you feel anxious;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus make you feel anxious [PhenX];Tinnitus anxious PhenX;;TRIAL;2.38;2.65 +67342-6;Do you feel that you can no longer cope with your tinnitus;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel that you can no longer cope with your tinnitus [PhenX];Tinnitus no longer cope PhenX;;TRIAL;2.38;2.65 +67343-4;Does your tinnitus get worse when are you are under stress;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus get worse when are you are under stress [PhenX];Tinnitus worse under stress PhenX;;TRIAL;2.38;2.65 +67344-2;Does your tinnitus make you feel insecure;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your tinnitus make you feel insecure [PhenX];Tinnitus insecure PhenX;;TRIAL;2.38;2.65 +67345-9;Does looking up increase your problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does looking up increase your problem [PhenX];Looking up increase problem PhenX;;TRIAL;2.38;2.65 +67346-7;Because of your problem, do you feel frustrated;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, do you feel frustrated [PhenX];Feel frustrated PhenX;;TRIAL;2.38;2.65 +67347-5;Because of your problem, do you restrict your travel for business or recreation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, do you restrict your travel for business or recreation [PhenX];Restrict travel PhenX;;TRIAL;2.38;2.65 +6734-8;Pork Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pork IgG Ab [Units/volume] in Serum;Pork IgG Qn;;ACTIVE;1.0h(2);2.73 +67348-3;Does walking down the aisle of a supermarket increase your problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does walking down the aisle of a supermarket increase your problem [PhenX];Walking aisle increase problem PhenX;;TRIAL;2.38;2.65 +67349-1;Because of your problem, do you have difficulty getting into or out of bed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, do you have difficulty getting into or out of bed [PhenX];Difficulty get out bed PhenX;;TRIAL;2.38;2.65 +67350-9;Does your problem significantly restrict your participation in social activities such as going out to dinner, the movies, dancing or to parties;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your problem significantly restrict your participation in social activities such as going out to dinner, the movies, dancing or to parties [PhenX];Restricts social participation PhenX;;TRIAL;2.38;2.65 +67351-7;Because of your problem, do you have difficulty reading;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, do you have difficulty reading [PhenX];Difficulty reading PhenX;;TRIAL;2.38;2.65 +67352-5;Does performing more ambitious activities such as sports or dancing or household chores such as sweeping or putting dishes away increase your problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does performing more ambitious activities such as sports or dancing or household chores such as sweeping or putting dishes away increase your problem [PhenX];Sports dancing chores more problem PhenX;;TRIAL;2.38;2.65 +67353-3;Because of your problem, are your afraid to leave your home without having someone accompany you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, are your afraid to leave your home without having someone accompany you [PhenX];Afraid to leave unaccompanied PhenX;;TRIAL;2.38;2.65 +67354-1;Because of your problem, are you embarrassed in front of others;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, are you embarrassed in front of others [PhenX];Embarrassed in front of others PhenX;;TRIAL;2.38;2.65 +6735-5;Glycine max Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Soybean IgG Ab [Units/volume] in Serum;Soybean IgG Qn;;ACTIVE;1.0h(2);2.73 +67355-8;Do quick movements of your head increase your problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do quick movements of your head increase your problem [PhenX];Quick head moves increase problem PhenX;;TRIAL;2.38;2.65 +67356-6;Because of your problem, do you avoid heights;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, do you avoid heights [PhenX];Avoid heights PhenX;;TRIAL;2.38;2.65 +67357-4;Does turning over in bed increase your problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does turning over in bed increase your problem [PhenX];Turning in bed increase problem PhenX;;TRIAL;2.38;2.65 +67358-2;Because of your problem, is it difficult for you to do strenuous housework or yard work;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, is it difficult for you to do strenuous housework or yard work [PhenX];Difficulty house yard work PhenX;;TRIAL;2.38;2.65 +67359-0;Because of your problem, are you afraid people may think you are intoxicated;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, are you afraid people may think you are intoxicated [PhenX];People think intoxicated PhenX;;TRIAL;2.38;2.65 +67360-8;Because of your problem, is it difficult for you to walk by yourself;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, is it difficult for you to walk by yourself [PhenX];Difficult walk alone PhenX;;TRIAL;2.38;2.65 +67361-6;Does walking down a sidewalk increase your problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does walking down a sidewalk increase your problem [PhenX];Sidewalk increase problem PhenX;;TRIAL;2.38;2.65 +67362-4;Because of your problem, is it difficult for you to concentrate;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, is it difficult for you to concentrate [PhenX];Difficult to concentrate PhenX;;TRIAL;2.38;2.65 +6736-3;Lycopersicon lycopersicum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tomato IgG Ab [Units/volume] in Serum;Tomato IgG Qn;;ACTIVE;1.0h(2);2.73 +67363-2;Because of your problem, is it difficult for you to walk around the house in the dark;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, is it difficult for you to walk around the house in the dark [PhenX];Difficult walk in dark PhenX;;TRIAL;2.38;2.65 +67364-0;Because of your problem, are you afraid to stay at home alone;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, are you afraid to stay at home alone [PhenX];Afraid stay home alone PhenX;;TRIAL;2.38;2.65 +67365-7;Because of your problem, do you feel handicapped;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, do you feel handicapped [PhenX];Feel handicapped PhenX;;TRIAL;2.38;2.65 +67366-5;Has your problem placed stress on your relationship with members of your family or friends;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Has your problem placed stress on your relationship with members of your family or friends [PhenX];Relationship stress PhenX;;TRIAL;2.38;2.65 +67367-3;Because of your problem, are you depressed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Because of your problem, are you depressed [PhenX];Problem cause depression PhenX;;TRIAL;2.38;2.65 +67368-1;Does your problem interfere with your job or household responsibilities;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your problem interfere with your job or household responsibilities [PhenX];Problem interfere with job PhenX;;TRIAL;2.38;2.65 +67369-9;Does bending over increase your problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does bending over increase your problem [PhenX];Bend over increase problem PhenX;;TRIAL;2.38;2.65 +67370-7;My voice makes it difficult for people to hear me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice makes it difficult for people to hear me [PhenX];Difficult people to hear me PhenX;;TRIAL;2.38;2.65 +6737-1;Triticum aestivum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat IgG Ab [Units/volume] in Serum;Wheat IgG Qn;;ACTIVE;1.0h(2);2.73 +67371-5;I run out of air when I talk;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I run out of air when I talk [PhenX];Run out of air PhenX;;TRIAL;2.38;2.65 +67372-3;People have difficulty understanding me in a noisy room;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People have difficulty understanding me in a noisy room [PhenX];Diff understand me noisy room PhenX;;TRIAL;2.38;2.65 +67373-1;The sound of my voice varies throughout the day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The sound of my voice varies throughout the day [PhenX];Sound of voice varies PhenX;;TRIAL;2.38;2.65 +67374-9;My family has difficulty hearing me when I call them throughout the house;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My family has difficulty hearing me when I call them throughout the house [PhenX];Family difficulty hearing me PhenX;;TRIAL;2.38;2.65 +67375-6;I use the phone less often than I would like;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I use the phone less often than I would like [PhenX];Use phone less often PhenX;;TRIAL;2.38;2.65 +67376-4;I'm tense when talking with others because of my voice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I'm tense when talking with others because of my voice [PhenX];Tense when talking PhenX;;TRIAL;2.38;2.65 +67377-2;I tend to avoid groups of people because of my voice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I tend to avoid groups of people because of my voice [PhenX];Avoid groups because of voice PhenX;;TRIAL;2.38;2.65 +67378-0;People seem irritated with my voice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People seem irritated with my voice [PhenX];People irritated with voice PhenX;;TRIAL;2.38;2.65 +67379-8;People ask, what's wrong with your voice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People ask, what's wrong with your voice [PhenX];People ask about voice PhenX;;TRIAL;2.38;2.65 +67380-6;I speak with friends, neighbors, or relatives less often because of my voice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I speak with friends, neighbors, or relatives less often because of my voice [PhenX];Speak less often with friends PhenX;;TRIAL;2.38;2.65 +67381-4;People ask me to repeat myself when speaking face-to-face;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People ask me to repeat myself when speaking face-to-face [PhenX];People ask me to repeat PhenX;;TRIAL;2.38;2.65 +67382-2;My voice sounds creaky and dry;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice sounds creaky and dry [PhenX];Voice creaky dry PhenX;;TRIAL;2.38;2.65 +67383-0;I feel as though I have to strain to produce voice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel as though I have to strain to produce voice [PhenX];Strain to produce voice PhenX;;TRIAL;2.38;2.65 +67384-8;I find other people don't understand my voice problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I find other people don't understand my voice problem [PhenX];People don't understand voice prob PhenX;;TRIAL;2.38;2.65 +67385-5;My voice difficulties restrict my personal and social life;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice difficulties restrict my personal and social life [PhenX];Voice restricts social life PhenX;;TRIAL;2.38;2.65 +67386-3;The clarity of my voice is unpredictable;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The clarity of my voice is unpredictable [PhenX];Voice clarity unpredictable PhenX;;TRIAL;2.38;2.65 +67387-1;I try to change my voice to sound different;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I try to change my voice to sound different [PhenX];Change voice sound different PhenX;;TRIAL;2.38;2.65 +67388-9;I feel left out of conversations because of my voice;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel left out of conversations because of my voice [PhenX];Left out of conversations PhenX;;TRIAL;2.38;2.65 +6738-9;Rumex crispus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Dock IgE Ab [Units/volume] in Serum;Yellow Dock IgE Qn;;ACTIVE;1.0h(2);2.73 +67389-7;I use a great deal of effort to speak;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I use a great deal of effort to speak [PhenX];Great effort to speak PhenX;;TRIAL;2.38;2.65 +67390-5;My voice is worse in the evening;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice is worse in the evening [PhenX];Voice worse evening PhenX;;TRIAL;2.38;2.65 +67391-3;My voice problem causes me to lose income;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice problem causes me to lose income [PhenX];Voice causes lost income PhenX;;TRIAL;2.38;2.65 +67392-1;My voice problem upsets me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice problem upsets me [PhenX];Voice upsets me PhenX;;TRIAL;2.38;2.65 +67393-9;I am less outgoing because of my voice problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am less outgoing because of my voice problem [PhenX];Less outgoing because voice PhenX;;TRIAL;2.38;2.65 +67394-7;My voice makes me feel handicapped;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice makes me feel handicapped [PhenX];Voice makes feel handicapped PhenX;;TRIAL;2.38;2.65 +67395-4;My voice gives out on me in the middle of speaking;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice gives out on me in the middle of speaking [PhenX];Voice gives out PhenX;;TRIAL;2.38;2.65 +67396-2;I feel annoyed when people ask me to repeat;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel annoyed when people ask me to repeat [PhenX];Annoyed when asked to repeat PhenX;;TRIAL;2.38;2.65 +6739-7;Dolichovespula arenaria Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Hornet IgG Ab [Units/volume] in Serum;Yellow Hornet IgG Qn;;ACTIVE;1.0h(2);2.73 +67397-0;I feel embarrassed when people ask me to repeat;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel embarrassed when people ask me to repeat [PhenX];Embarrassed when repeat PhenX;;TRIAL;2.38;2.65 +67398-8;My voice makes me feel incompetent;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My voice makes me feel incompetent [PhenX];Voice makes feel incompetent PhenX;;TRIAL;2.38;2.65 +67399-6;I'm ashamed of my voice problem;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I'm ashamed of my voice problem [PhenX];Ashamed of voice problem PhenX;;TRIAL;2.38;2.65 +67400-2;Do you have any difficulty with your hearing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any difficulty with your hearing [PhenX];Difficulty hearing PhenX;;TRIAL;2.38;2.65 +67401-0;How quickly did your hearing difficulty develop;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How quickly did your hearing difficulty develop [PhenX];How quickly difficulty develop PhenX;;TRIAL;2.38;2.65 +67402-8;Do you know the reason for your hearing difficulty;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you know the reason for your hearing difficulty [PhenX];Reason hearing difficulty known PhenX;;TRIAL;2.38;2.65 +67403-6;Does your hearing vary from day to day;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your hearing vary from day to day [PhenX];Hearing vary day to day PhenX;;TRIAL;2.38;2.65 +67404-4;Do you find it very difficult to follow a conversation if there is background noise;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you find it very difficult to follow a conversation if there is background noise [PhenX];Background noise PhenX;;TRIAL;2.38;2.65 +6740-5;Vespula spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Jacket IgE Ab [Units/volume] in Serum;Yellow Jacket IgE Qn;;ACTIVE;1.0h(2);2.73 +67405-1;Are you particularly sensitive to loud sounds;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you particularly sensitive to loud sounds [PhenX];Sensitive loud sounds PhenX;;TRIAL;2.38;2.65 +67406-9;Do you sometimes feel a fullness or blockage in your ears;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you sometimes feel a fullness or blockage in your ears [PhenX];Fullness in ears PhenX;;TRIAL;2.38;2.65 +67407-7;Do you ever get noises in your head or ears, tinnitus, which usually last longer than 5M;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you ever get noises in your head or ears, tinnitus, which usually last longer than 5 minutes [PhenX];Tinnitus PhenX;;TRIAL;2.38;2.65 +67408-5;Have you ever had an ear disease that has caused your hearing to get worse;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had an ear disease that has caused your hearing to get worse [PhenX];Disease caused hearing get worse PhenX;;TRIAL;2.38;2.65 +67409-3;Have you ever had discharge of blood or pus, or smelly discharge, not wax, from either ear;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Have you ever had discharge of blood or pus, or smelly discharge, not wax, from either ear [PhenX];Ear discharge PhenX;;TRIAL;2.38;2.65 +67410-1;Have you ever had an ear operation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had an ear operation [PhenX];Ear operation PhenX;;TRIAL;2.38;2.65 +67411-9;Have you ever suffered from attacks of dizziness in which things seem to spin around you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever suffered from attacks of dizziness in which things seem to spin around you [PhenX];Dizziness attack PhenX;;TRIAL;2.38;2.65 +67412-7;Do you feel unsteady when walking in the dark;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you feel unsteady when walking in the dark [PhenX];Unsteady in dark PhenX;;TRIAL;2.38;2.65 +6741-3;Erythrocytes;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Body fluid by Manual count;RBC # Fld Manual;;ACTIVE;1.0h(2);2.73 +67413-5;Country of origin;Find;Pt;^Family member;Nom;PhenX;PHENX;2;Country of origin Family member [PhenX];Country of origin Fam Mem PhenX;;TRIAL;2.38;2.65 +67414-3;Region of origin;Find;Pt;^Patient;Nom;PhenX;ADMIN.PATIENT.DEMOG;2;Region of origin [PhenX];Region of origin PhenX;;ACTIVE;2.38;2.66 +67415-0;Does your parent have or had hearing problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does your parent have or had hearing problems [PhenX];Parents hearing problems PhenX;;TRIAL;2.38;2.65 +67416-8;Do you have any brothers or sisters with normal hearing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any brothers or sisters with normal hearing [PhenX];Siblings normal hearing PhenX;;TRIAL;2.38;2.65 +67417-6;How many of your brothers or sisters have normal hearing;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your brothers or sisters have normal hearing [#] [PhenX];Number siblings normal hearing PhenX;;TRIAL;2.38;2.65 +67418-4;Do you have any children with normal hearing;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any children with normal hearing [PhenX];Children with normal hearing PhenX;;TRIAL;2.38;2.65 +67419-2;How many of your children have normal hearing;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your children have normal hearing [#] [PhenX];Number children w/ normal hearing PhenX;;TRIAL;2.38;2.65 +674-2;Microscopic observation;Prid;Pt;XXX;Nom;Periodic acid-Schiff stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Periodic acid-Schiff stain;PAS Stn Spec;;ACTIVE;1.0;2.69 +67420-0;Do you have uncles, aunts, cousins, nephews, or nieces with hearing difficulties;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have uncles, aunts, cousins, nephews, or nieces with hearing difficulties [PhenX];Relatives w/ hearing difficulties PhenX;;TRIAL;2.38;2.65 +6742-1;Erythrocyte morphology finding;Prid;Pt;Bld;Nom;;HEM/BC;1;Erythrocyte morphology finding [Identifier] in Blood;RBC morph Bld;;ACTIVE;1.0h(2);2.73 +67421-8;Do you know if any of your relatives have already participated in this investigation;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Do you know if any of your relatives have already participated in this investigation [PhenX];Other relatives participated PhenX;;TRIAL;2.38;2.65 +67422-6;Name of your relative that have already participated in this investigation;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Name of your relative that have already participated in this investigation [PhenX];Other relative name PhenX;;TRIAL;2.38;2.65 +67423-4;Do you suffer from migraine;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Do you suffer from migraine [PhenX];Migraine hx PhenX;;TRIAL;2.38;2.65 +67424-2;How often do you generally have attacks;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;How often do you generally have attacks [PhenX];Migraine freq PhenX;;TRIAL;2.38;2.65 +67425-9;Have you ever suffered a hearing loss from meningitis or encephalitis;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever suffered a hearing loss from meningitis or encephalitis [PhenX];Hearing loss meningitis enceph PhenX;;TRIAL;2.38;2.65 +67426-7;Have you ever had a whiplash injury;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had a whiplash injury [PhenX];Whiplash injury PhenX;;TRIAL;2.38;2.65 +67427-5;Have you ever been knocked unconscious, in a traffic accident, contact sport, a fight or after a fall;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been knocked unconscious, in a traffic accident, contact sport, a fight or after a fall [PhenX];Knocked unconscious PhenX;;TRIAL;2.38;2.65 +67428-3;Have you ever had heart surgery;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had heart surgery [PhenX];Heart surgery PhenX;;TRIAL;2.38;2.65 +67429-1;Have you ever had coronary artery catheterization;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had coronary artery catheterization [PhenX];Coronary artery catheterization PhenX;;TRIAL;2.38;2.65 +67430-9;Type of intervention, stent, balloon dilatation;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Type of intervention, stent, balloon dilatation [PhenX];Coronary cath intervention PhenX;;TRIAL;2.38;2.65 +67431-7;Have you ever had an operation on your carotid artery;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had an operation on your carotid artery [PhenX];Carotid artery operation PhenX;;TRIAL;2.38;2.65 +67432-5;Do you suffer from intermittent claudication;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Do you suffer from intermittent claudication [PhenX];Intermittent claudication PhenX;;TRIAL;2.38;2.65 +67433-3;Do you have other problems with your heart or circulation;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have other problems with your heart or circulation [PhenX];Heart problems PhenX;;TRIAL;2.38;2.65 +67434-1;Problems with your heart or circulation;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Problems with your heart or circulation [PhenX];Other heart problems PhenX;;TRIAL;2.38;2.65 +67435-8;Do you suffer from diabetes;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Do you suffer from diabetes [PhenX];You have diabetes PhenX;;TRIAL;2.38;2.65 +67436-6;Do you need insulin;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Do you need insulin [PhenX];Need insulin PhenX;;TRIAL;2.38;2.65 +67437-4;Disease history;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Disease history [PhenX];Disease history PhenX;;TRIAL;2.38;2.65 +67438-2;Disease description;Hx;Pt;^Patient;Nar;PhenX;PHENX;2;Disease description Narrative [PhenX];Disease description PhenX;;TRIAL;2.38;2.65 +6743-9;Leukocytes;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Body fluid by Manual count;WBC # Fld Manual;;ACTIVE;1.0h(2);2.73 +67439-0;Autoimmune diseases;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Autoimmune diseases [PhenX];Autoimmune diseases PhenX;;TRIAL;2.38;2.65 +67440-8;Do you have other serious health problems that are not covered by the previous questions;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have other serious health problems that are not covered by the previous questions [PhenX];Other serious health problems PhenX;;TRIAL;2.38;2.65 +67441-6;Serious health problems;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Serious health problems [PhenX];Serious health problems PhenX;;TRIAL;2.38;2.65 +67442-4;Have you ever been treated for a serious infection with an antibiotic, other than penicillin, which was administered by injection or drip for a W or more;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been treated for a serious infection with an antibiotic, other than penicillin, which was administered by injection or drip for a week or more [PhenX];Antibiotic drip PhenX;;TRIAL;2.38;2.65 +67443-2;Infections for which you received these antibiotics;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Infections for which you received these antibiotics [PhenX];Antibiotic drip infection PhenX;;TRIAL;2.38;2.65 +67444-0;Have you had cancer or leukemia;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you had cancer or leukemia [PhenX];Cancer or leukemia PhenX;;TRIAL;2.38;2.65 +67446-5;Have you been treated with chemotherapy or other medication for this condition;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you been treated with chemotherapy or other medication for this condition [PhenX];Cancer chemotherapy med PhenX;;TRIAL;2.38;2.65 +6744-7;Lymphocytes;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Lymphocytes [#/volume] in Body fluid by Manual count;Lymphocytes # Fld Manual;;ACTIVE;1.0h(2);2.73 +67447-3;Have you ever received radiotherapy to your head or neck for a tumor;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever received radiotherapy to your head or neck for a tumor [PhenX];Radiotherapy tumor PhenX;;TRIAL;2.38;2.65 +67448-1;Tumor type treated with radiotherapy;Type;Pt;^Patient;Nom;;ONCOLOGY;2;Kind of tumor [PhenX];Radiotherapy tumor type;;ACTIVE;2.38;2.67 +67449-9;On average how often do you take painkillers;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;On average how often do you take painkillers [PhenX];Painkiller freq PhenX;;TRIAL;2.38;2.65 +67450-7;Do you take aspirin on a daily basis for your heart or to dilute your blood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you take aspirin on a daily basis for your heart or to dilute your blood [PhenX];Daily aspirin PhenX;;TRIAL;2.38;2.65 +67451-5;How long have you been taking aspirin;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How long have you been taking aspirin [PhenX];Aspirin how long PhenX;;TRIAL;2.38;2.65 +67452-3;Medical reason why you had or have to take this medication;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Medical reason why you had or have to take this medication [PhenX];Regular med reason PhenX;;TRIAL;2.38;2.65 +67453-1;Treatment duration;Time;Pt;^Patient;Qn;;CLIN;2;Treatment duration;Treatment duration;;ACTIVE;2.38;2.65 +6745-4;Neutrophils.segmented;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Segmented neutrophils [#/volume] in Body fluid by Manual count;Neuts Seg # Fld Manual;;ACTIVE;1.0h(2);2.73 +67454-9;Have you ever fired a gun;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever fired a gun [PhenX];Ever fired gun PhenX;;TRIAL;2.38;2.65 +67455-6;Weapon type;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Weapon type [PhenX];Weapon type PhenX;;TRIAL;2.38;2.65 +67456-4;Shots fired;Num;Pt;^Patient;Ord;PhenX;PHENX;2;Shots fired [PhenX];Shots fired PhenX;;TRIAL;2.38;2.65 +67457-2;Did you use ear protection;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Did you use ear protection [PhenX];Ear protection PhenX;;TRIAL;2.38;2.65 +67458-0;Type of ear protection;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Type of ear protection [PhenX];Ear protection type PhenX;;TRIAL;2.38;2.65 +67459-8;During your leisure time, have you been regularly, more than once a W, exposed to loud sound or noise, so that you have to shout to make yourself heard by someone who was more than 1 meter away from you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;During your leisure time, have you been regularly, more than once a W, exposed to loud sound or noise, so that you have to shout to make yourself heard by someone who was more than 1 meter away from you [PhenX];Leisure time loud sound PhenX;;TRIAL;2.38;2.65 +67460-6;What kind of loud sound;Type;Pt;^Patient;Nom;PhenX;PHENX;2;What kind of loud sound [PhenX];What kind of loud sound PhenX;;TRIAL;2.38;2.65 +67461-4;For how many Y have you been exposed to this loud sound;Time;Pt;^Patient;Qn;PhenX;PHENX;2;For how many years have you been exposed to this loud sound [PhenX];Leisure time loud sound Ys PhenX;;TRIAL;2.38;2.65 +6746-2;Prolymphocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Prolymphocytes/100 leukocytes in Blood by Manual count;Prolymphocytes/leuk NFr Bld Manual;;ACTIVE;1.0h(2);2.73 +67462-2;How many H per W have you been exposed;Time;Pt;^Patient;Qn;PhenX;PHENX;2;How many hours per week have you been exposed [PhenX];Exposure Hs/W PhenX;;TRIAL;2.38;2.65 +67463-0;Do you have any brothers or sisters with hearing difficulties;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any brothers or sisters with hearing difficulties [PhenX];Siblings with hearing difficulties PhenX;;TRIAL;2.38;2.65 +67464-8;How many of your brothers or sisters have hearing difficulties;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your brothers or sisters have hearing difficulties [#] [PhenX];Number sibs w hearing diff PhenX;;TRIAL;2.38;2.65 +67465-5;Do you have any children with hearing difficulties;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you have any children with hearing difficulties [PhenX];Children with hearing difficulties PhenX;;TRIAL;2.38;2.65 +67466-3;How many of your children have hearing difficulties;Num;Pt;^Patient;Qn;PhenX;PHENX;2;How many of your children have hearing difficulties [#] [PhenX];No. children w hear diff PhenX;;TRIAL;2.38;2.65 +67467-1;Ear with hearing difficulty;Find;Pt;Ear;Nom;PhenX;PHENX;2;Ear with hearing difficulty Ear [PhenX];Ear w hearing difficulty Ear PhenX;;TRIAL;2.38;2.65 +67468-9;At what age did you first notice a hearing difficulty;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At what age did you first notice a hearing difficulty [PhenX];Hearing difficulty age PhenX;;TRIAL;2.38;2.65 +67469-7;Chemotherapy or other medication for this condition;Hx;Pt;^Patient;Nom;PhenX;PHENX;2;Chemotherapy or other medication for this condition [PhenX];Chemotherapy other med PhenX;;TRIAL;2.38;2.65 +6747-0;Glucose^1H post 50 g lactose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --1 hour post 50 g lactose PO;Glucose 1h p 50 g Lac PO Ur Ql Strip;;ACTIVE;1.0h(2);2.56 +67470-5;Which solvents;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Which solvents [PhenX];Solvent type PhenX;;TRIAL;2.38;2.65 +67471-3;Pregnancy;Hx;Pt;^Patient;Ord;;NEMSIS;2;History of Pregnancy;Hx of Pregnancy;;ACTIVE;2.40;2.56 +67480-4;Dispatch delay;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Dispatch delay NEMSIS;Dispatch delay NEMSIS;;ACTIVE;2.38;2.50 +67481-2;First EMS unit on scene;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;First EMS unit on scene NEMSIS;First EMS unit on scene NEMSIS;;ACTIVE;2.38;2.50 +67482-0;Response mode to scene;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Response mode to scene NEMSIS;Response mode to scene NEMSIS;;ACTIVE;2.38;2.50 +67483-8;EMS unit primary role;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Deprecated EMS unit primary role NEMSIS;Deprecated EMS unit primary role NEMSIS;;DEPRECATED;2.38;2.40 +67484-6;Counter or odometer reading^beginning of call;Num;Pt;^Vehicle;Qn;;NEMSIS;2;Vehicle Counter or odometer reading --beginning of call;Odometer beginning of call Vehicle;;ACTIVE;2.38;2.64 +67485-3;Counter or odometer reading^patient arrival;Num;Pt;^Vehicle;Qn;;NEMSIS;2;Vehicle Counter or odometer reading --patient arrival;Odometer reading arrive;;ACTIVE;2.38;2.64 +67486-1;Counter or odometer reading^patient destination;Num;Pt;^Vehicle;Qn;;NEMSIS;2;Vehicle Counter or odometer reading --patient destination;Odometer reading dest;;ACTIVE;2.38;2.64 +67487-9;Counter or odometer reading^end of call;Num;Pt;^Vehicle;Qn;;NEMSIS;2;Vehicle Counter or odometer reading --end of call;Odometer end of call Vehicle;;ACTIVE;2.38;2.64 +6748-8;Glucose^1H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --1 hour post 75 g glucose PO;Glucose 1h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67488-7;Emergency medical dispatch performed;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Emergency medical dispatch performed NEMSIS;EMD performed NEMSIS;;ACTIVE;2.38;2.50 +67489-5;Total patients at the scene;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Total patients at the scene NEMSIS;Total pts at scene NEMSIS;;ACTIVE;2.38;2.50 +67490-3;Mass casualty incident;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Mass casualty incident NEMSIS;Mass casualty incident NEMSIS;;ACTIVE;2.38;2.50 +67491-1;Chief complaint duration;Time;Pt;^Patient;Qn;;NEMSIS;2;Chief complaint duration;Chief complaint duration;;ACTIVE;2.38;2.64 +67492-9;Primary problem;Imp;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Primary problem [Interpretation] NEMSIS;Primary problem Imp NEMSIS;;ACTIVE;2.38;2.50 +67493-7;Initial patient acuity;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Initial patient acuity NEMSIS;Initial patient acuity NEMSIS;;ACTIVE;2.38;2.50 +67494-5;General mechanism of the forces which caused the injury;Find;Pt;^Patient;Nom;;TRAUMA;2;General mechanism of the forces which caused the injury;Mechanism of injury;;ACTIVE;2.38;2.63 +67495-2;CDC field triage criteria;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;CDC field triage criteria NEMSIS;CDC field triage criteria NEMSIS;;ACTIVE;2.38;2.72 +6749-6;Glucose^2.5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.5 hours post 75 g glucose PO;Glucose 2.5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +67496-0;Other injury risk factors;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Other injury risk factors NEMSIS;Other inj risk factors NEMSIS;;ACTIVE;2.38;2.72 +67497-8;Location of impact on the vehicle;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Location of impact on the vehicle NEMSIS;Impact on vehicle NEMSIS;;ACTIVE;2.38;2.50 +67498-6;Location of patient in vehicle;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Location of patient in vehicle NEMSIS;Loc pt in vehicle NEMSIS;;ACTIVE;2.38;2.50 +67499-4;Safety equipment;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Safety equipment NEMSIS;Safety equipment NEMSIS;;ACTIVE;2.38;2.50 +67500-9;Airbag deployment;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Airbag deployment NEMSIS;Airbag deployment NEMSIS;;ACTIVE;2.38;2.50 +67501-7;Height of fall;Len;Pt;^Patient;Qn;;NEMSIS;2;Height of fall;Height of fall;;ACTIVE;2.38;2.64 +67502-5;Cardiac arrest;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Cardiac arrest NEMSIS;Cardiac arrest NEMSIS;;ACTIVE;2.38;2.50 +67503-3;Cardiac arrest cause;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Cardiac arrest cause NEMSIS;Cardiac arrest cause NEMSIS;;ACTIVE;2.38;2.50 +6750-4;Glucose^2H post 50 g lactose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --2 hours post 50 g lactose PO;Glucose 2h p 50 g Lac PO Ur Ql Strip;;ACTIVE;1.0h(2);2.56 +67504-1;Reason resuscitation not attempted;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Reason resuscitation not attempted NEMSIS;Reason resusc not attempted NEMSIS;;ACTIVE;2.38;2.50 +67505-8;Cardiac arrest witness;Pn;Pt;^Observer;Nom;NEMSIS;NEMSIS;2;Cardiac arrest witness Observer NEMSIS;Cardiac arrest witness Observer NEMSIS;;ACTIVE;2.38;2.50 +67506-6;CPR prior to EMS arrival;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Deprecated CPR prior to EMS arrival NEMSIS;Deprecated CPR prior to EMS arrival NEMSIS;;DEPRECATED;2.38;2.72 +67507-4;Provider of CPR prior to EMS arrival;Find;Pt;^Patient;Nom;;TRAUMA;2;Provider of CPR prior to EMS arrival;Provider of CPR prior to EMS;;ACTIVE;2.38;2.72 +67508-2;AED use prior to EMS arrival;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;AED use prior to EMS arrival NEMSIS;AED prior to EMS arrival NEMSIS;;ACTIVE;2.38;2.50 +67509-0;Provider of AED use prior to EMS arrival;Pn;Pt;^Patient;Nom;;TRAUMA;2;Provider of AED use prior to EMS arrival;Provider of AED prior EMS;;ACTIVE;2.38;2.72 +67510-8;Cardiopulmonary resuscitation technique;Type;Pt;^Patient;Nom;;TRAUMA;2;CPR technique;CPR technique;;ACTIVE;2.38;2.70 +67511-6;EMS therapeutic hypothermia;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;EMS therapeutic hypothermia NEMSIS;EMS therapeutic hypothermia NEMSIS;;ACTIVE;2.38;2.50 +6751-2;Glucose^2H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --2 hours post 75 g glucose PO;Glucose 2h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67512-4;First monitored rhythm;Type;Pt;^Patient;Nom;;NEMSIS;2;First monitored rhythm;First monitored rhythm;;ACTIVE;2.38;2.63 +67513-2;Return of spontaneous circulation;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Deprecated Return of spontaneous circulation NEMSIS;Deprecated Return of circulation NEMSIS;;DEPRECATED;2.38;2.64 +67514-0;Cardiac rhythm on arrival at destination;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Cardiac rhythm on arrival at destination NEMSIS;Cardiac rhythm on arrival NEMSIS;;ACTIVE;2.38;2.50 +67515-7;Barriers to patient care;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Barriers to patient care NEMSIS;Barriers to patient care NEMSIS;;ACTIVE;2.38;2.50 +67516-5;Advance directive;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Advance directive NEMSIS;Advance directive NEMSIS;;ACTIVE;2.38;2.50 +67517-3;Last oral intake;TmStp;Pt;^Patient;Qn;;NEMSIS;2;Last oral intake [Date and time];Last oral intake;;ACTIVE;2.38;2.64 +67518-1;Obtained prior to units EMS care;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Obtained prior to units EMS care NEMSIS;Obtained prior to EMS NEMSIS;;ACTIVE;2.38;2.50 +67519-9;Cardiac rhythm;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Cardiac rhythm NEMSIS;Cardiac rhythm NEMSIS;;ACTIVE;2.38;2.50 +6752-0;Glucose^3.5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3.5 hours post 75 g glucose PO;Glucose 3.5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +67520-7;Stroke scale overall interpretation;Imp;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Stroke scale overall interpretation NEMSIS;Stroke scale interpretation NEMSIS;;ACTIVE;2.38;2.50 +67521-5;Stroke scale type;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Stroke scale type NEMSIS;Stroke scale type NEMSIS;;ACTIVE;2.38;2.50 +67522-3;Other stroke scale type;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Other stroke scale type NEMSIS;Other stroke scale type NEMSIS;;ACTIVE;2.38;2.50 +67523-1;Contraindication for thrombolytic use;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Contraindication for thrombolytic use NEMSIS;Contra for thrombolytic NEMSIS;;ACTIVE;2.38;2.50 +67524-9;Physical findings;Find;Pt;Skin;Nom;NEMSIS;NEMSIS;2;Physical findings of Skin NEMSIS;Phys find Skin NEMSIS;;ACTIVE;2.38;2.50 +67525-6;Physical findings;Find;Pt;Head;Nom;NEMSIS;NEMSIS;2;Physical findings of Head NEMSIS;Phys find Head NEMSIS;;ACTIVE;2.38;2.50 +67526-4;Physical findings;Find;Pt;Face;Nom;NEMSIS;NEMSIS;2;Physical findings of Face NEMSIS;Phys find Face NEMSIS;;ACTIVE;2.38;2.50 +67527-2;Physical findings;Find;Pt;Neck;Nom;NEMSIS;NEMSIS;2;Physical findings of Neck NEMSIS;Phys find Neck NEMSIS;;ACTIVE;2.38;2.50 +67528-0;Physical findings;Find;Pt;Chest+Lungs;Nom;;H&P.PX;2;Physical findings of Chest+Lungs;Phys find Chest+Lungs;;ACTIVE;2.38;2.72 +67529-8;Physical findings;Find;Pt;Heart;Nom;NEMSIS;NEMSIS;2;Physical findings of Heart NEMSIS;Phys find Hrt NEMSIS;;ACTIVE;2.38;2.50 +67530-6;Physical findings;Find;Pt;Abdomen;Nom;NEMSIS;NEMSIS;2;Physical findings of Abdomen NEMSIS;Phys find Abd NEMSIS;;ACTIVE;2.38;2.50 +67531-4;Physical findings;Find;Pt;Pelvis+Genitourinary;Nom;NEMSIS;NEMSIS;2;Physical findings of Pelvis+Genitourinary NEMSIS;Phys find Pelvis+Genitourinary NEMSIS;;ACTIVE;2.38;2.50 +67532-2;Physical findings;Find;Pt;Back+Spine;Nom;NEMSIS;NEMSIS;2;Physical findings of Back+Spine NEMSIS;Phys find Back+Spine NEMSIS;;ACTIVE;2.38;2.50 +67533-0;Physical findings;Find;Pt;Extremity;Nom;NEMSIS;NEMSIS;2;Physical findings of Extremity NEMSIS;Phys find Extr NEMSIS;;ACTIVE;2.38;2.50 +67534-8;Physical findings;Find;Pt;Eye;Nom;NEMSIS;NEMSIS;2;Physical findings of Eye NEMSIS;Phys find Eye NEMSIS;;ACTIVE;2.38;2.50 +67535-5;Mental status assessment;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Mental status assessment NEMSIS;Mental status assessment NEMSIS;;ACTIVE;2.38;2.50 +67536-3;Neurological assessment;Find;Pt;Neurologic system;Nom;NEMSIS;NEMSIS;2;Neurological assessment Nervous system NEMSIS;Neuro assessment Neurologic NEMSIS;;ACTIVE;2.38;2.50 +67537-1;Protocol used;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Protocol used NEMSIS;Protocol used NEMSIS;;ACTIVE;2.38;2.50 +6753-8;Glucose^30M post 50 g lactose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --30 minutes post 50 g lactose PO;Glucose 30M p 50 g Lac PO Ur Ql Strip;;ACTIVE;1.0h(2);2.56 +67538-9;Protocol age category;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Protocol age category NEMSIS;Protocol age category NEMSIS;;ACTIVE;2.38;2.50 +67539-7;Medication administered prior to this unit's EMS care;Find;Pt;^Patient;Ord;;NEMSIS;2;Medication administered prior to this unit's EMS care;Med administered prior to EMS care;;ACTIVE;2.38;2.64 +67540-5;Response to medication;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Response to medication NEMSIS;Response to med NEMSIS;;ACTIVE;2.38;2.50 +67541-3;Medication complication;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Medication complication NEMSIS;Med complication NEMSIS;;ACTIVE;2.38;2.50 +67542-1;Procedure performed prior to this units EMS care;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Procedure performed prior to this units EMS care NEMSIS;Procedure performed prior NEMSIS;;ACTIVE;2.38;2.50 +67543-9;Procedure attempts;Num;Pt;^Patient;Qn;;NEMSIS;2;Procedure attempts [#];Procedure attempts;;ACTIVE;2.38;2.73 +67544-7;Procedure successful;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Procedure successful NEMSIS;Procedure successful NEMSIS;;ACTIVE;2.38;2.50 +67545-4;Procedure complication;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Procedure complication NEMSIS;Procedure complication NEMSIS;;ACTIVE;2.38;2.73 +6754-6;Glucose^30M post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --30 minutes post 75 g glucose PO;Glucose 30M p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67546-2;Response to procedure;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Response to procedure NEMSIS;Response to procedure NEMSIS;;ACTIVE;2.38;2.50 +67547-0;Patients transported in EMS unit;Num;Pt;^Patient;Qn;;NEMSIS;2;Patients transported in EMS unit [#];Patients transported EMS unit;;ACTIVE;2.38;2.64 +67548-8;Incident - patient disposition;Type;Pt;^Patient;Nom;;TRAUMA;2;Incident - patient disposition;Incident - patient disposition;;ACTIVE;2.38;2.72 +67549-6;Transport method;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Transport method NEMSIS;Transport method NEMSIS;;ACTIVE;2.38;2.50 +67550-4;Transport mode from scene;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Transport mode from scene NEMSIS;Transport mode from scene NEMSIS;;ACTIVE;2.38;2.50 +67551-2;Condition of patient at destination;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Deprecated Condition of patient at destination NEMSIS;Deprecated;;DEPRECATED;2.38;2.52 +67552-0;Reason for choosing destination;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Reason for choosing destination NEMSIS;Reason choosing destination NEMSIS;;ACTIVE;2.38;2.50 +6755-3;Glucose^3H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --3 hours post 75 g glucose PO;Glucose 3h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67553-8;Condition indicating eligibility for illness or injury registry;Find;Pt;^Patient;Nom;;H&P.HX;2;Condition indicating eligibility for illness or injury registry;Condition illness injury reg;;ACTIVE;2.38;2.70 +67554-6;Work related exposure, injury, or death;Find;Pt;Provider;Ord;NEMSIS;NEMSIS;2;Work related exposure, injury, or death Provider NEMSIS;Work expos/inj/death Provider NEMSIS;;ACTIVE;2.38;2.50 +67555-3;Work related exposure, injury, or death;Type;Pt;Provider;Nom;NEMSIS;NEMSIS;2;Work related exposure, injury, or death Provider NEMSIS type;Work expos/inj/death Provider NEMSIS typ;;ACTIVE;2.38;2.50 +67556-1;EMS condition code;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;EMS condition code NEMSIS;EMS condition code NEMSIS;;ACTIVE;2.38;2.50 +67557-9;Response delay;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Response delay NEMSIS;Response delay NEMSIS;;ACTIVE;2.38;2.50 +67558-7;Scene delay;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Scene delay NEMSIS;Scene delay NEMSIS;;ACTIVE;2.38;2.50 +67559-5;Transport delay;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Transport delay NEMSIS;Transport delay NEMSIS;;ACTIVE;2.38;2.50 +67560-3;Turn-around delay;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Turn-around delay NEMSIS;Turn-around delay NEMSIS;;ACTIVE;2.38;2.50 +6756-1;Glucose^4.5H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4.5 hours post 75 g glucose PO;Glucose 4.5h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +67561-1;Corynebacterium diphtheriae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Corynebacterium diphtheriae DNA [Presence] in Specimen by NAA with probe detection;C diphtheriae DNA Spec Ql NAA+probe;;ACTIVE;2.38;2.69 +67562-9;Achromobacter sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Achromobacter sp DNA [Presence] in Specimen by NAA with probe detection;Achromobacter sp DNA Spec Ql NAA+probe;;ACTIVE;2.38;2.69 +67563-7;Legionella micdadei DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Legionella micdadei DNA [Presence] in Specimen by NAA with probe detection;L micdadei DNA Spec Ql NAA+probe;;ACTIVE;2.38;2.69 +67566-0;Coagulation surface induced.factor substitution^after addition of normal plasma 2H post incubation separate tubes;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --with normal plasma 2H post incubation separate tubes;aPTT NP 2h separate PPP;;ACTIVE;2.38;2.70 +67568-6;Circulating tumor cells.breast;NCnc;Pt;Bld;Qn;;CHEM;1;Circulating tumor cells.breast [#/volume] in Blood;CTC.breast # Bld;;ACTIVE;2.38;2.73 +67569-4;Streptococcus pyogenes M protein (emm) gene;Type;Pt;Isolate;Nom;Sequencing;MICRO;1;Streptococcus pyogenes M protein emm gene [Type] in Isolate by Sequencing;St pyo emm gene Islt Seq;;ACTIVE;2.38;2.65 +67570-2;Chief complaint per dispatch;Find;Pt;^Patient;Nom;Reported.dispatch;NEMSIS;2;Chief complaint per dispatch Reported.dispatch;Cplaint per dispatch Reported.dispatch;;ACTIVE;2.40;2.50 +67571-0;Contraindication for thrombolytic use;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Deprecated Contraindication for thrombolytic use NEMSIS;Deprecated;;DEPRECATED;2.38;2.40 +67572-8;Condition indicating eligibility for illness or injury registry;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Deprecated Condition indicating eligibility for illness or injury registry;Deprecated Deprecated;;DEPRECATED;2.38;2.40 +67573-6;Exposure to blood or body fluids;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Deprecated Exposure to blood or body fluids;Deprecated Deprecated;;DEPRECATED;2.38;2.40 +67574-4;Reason CPR resuscitation discontinued;Find;Pt;^Patient;Nom;;TRAUMA;2;Reason CPR resuscitation discontinued;Reason CPR discontinued;;ACTIVE;2.38;2.70 +67575-1;Are you susceptible to sunburn;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Are you susceptible to sunburn [PhenX];Susceptible to sunburn PhenX;;TRIAL;2.38;2.65 +67576-9;Color;Type;Pt;Eyes;Nom;;H&P.PX;2;Color of Eyes;Color Eyes;;TRIAL;2.38;2.68 +67577-7;How far in school did she go;Find;Pt;^Mother;Nom;PhenX;PHENX;2;Deprecated How far in school did she go Mother [PhenX];Deprecated Mother's education PhenX;;DEPRECATED;2.38;2.64 +67578-5;How far in school did he go;Find;Pt;^Father;Nom;PhenX;PHENX;2;Deprecated How far in school did he go Father [PhenX];Deprecated Father's education PhenX;;DEPRECATED;2.38;2.64 +6757-9;Glucose^4H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --4 hours post 75 g glucose PO;Glucose 4h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67579-3;At any time in your life, have you ever been unfairly fired;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At any time in your life, have you ever been unfairly fired [PhenX];Unfairly fired PhenX;;TRIAL;2.38;2.65 +67580-1;What do you think was the main reason for this experience;Find;Pt;^Patient;Nom;PhenX;PHENX;2;What do you think was the main reason for this experience [PhenX];Reason for this experience PhenX;;TRIAL;2.38;2.65 +67581-9;For unfair reasons, have you ever not been hired for a job;Find;Pt;^Patient;Ord;PhenX;PHENX;2;For unfair reasons, have you ever not been hired for a job [PhenX];Unfairly not hired PhenX;;TRIAL;2.38;2.65 +67582-7;Have you ever been unfairly denied a promotion;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been unfairly denied a promotion [PhenX];Unfairly denied promotion PhenX;;TRIAL;2.38;2.65 +67583-5;Have you ever been unfairly stopped, searched, questioned, physically threatened or abused by the police;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been unfairly stopped, searched, questioned, physically threatened or abused by the police [PhenX];Unfairly treated by police PhenX;;TRIAL;2.38;2.65 +67584-3;Have you ever been unfairly denied a bank loan;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been unfairly denied a bank loan [PhenX];Unfairly denied loan PhenX;;TRIAL;2.38;2.65 +67585-0;Have you ever received service from someone such as a plumber or car mechanic that was worse than what other people get;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever received service from someone such as a plumber or car mechanic that was worse than what other people get [PhenX];Worse service PhenX;;TRIAL;2.38;2.65 +67586-8;You have been treated with less courtesy than other people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have been treated with less courtesy than other people [PhenX];Treated with less courtesy PhenX;;TRIAL;2.38;2.65 +6758-7;Glucose^5H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --5 hours post 75 g glucose PO;Glucose 5h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67587-6;You have been treated with less respect than other people;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have been treated with less respect than other people [PhenX];Treated with less respect PhenX;;TRIAL;2.38;2.65 +67588-4;You have received poorer service than other people at restaurants or stores;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have received poorer service than other people at restaurants or stores [PhenX];Received poorer service PhenX;;TRIAL;2.38;2.65 +67589-2;People have acted as if they think you are not smart;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People have acted as if they think you are not smart [PhenX];People think not smart PhenX;;TRIAL;2.38;2.65 +675-9;Enterobius vermicularis;PrThr;Pt;XXX;Ord;Pinworm examination;MICRO;1;Enterobius vermicularis [Presence] in Specimen by Pinworm exam;E vermicularis Spec Ql Pinworm Exam;;ACTIVE;1.0;2.73 +67590-0;People have acted as if they are afraid of you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People have acted as if they are afraid of you [PhenX];People act afraid PhenX;;TRIAL;2.38;2.65 +67591-8;People have acted as if they think you are dishonest;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People have acted as if they think you are dishonest [PhenX];People think dishonest PhenX;;TRIAL;2.38;2.65 +67592-6;People have acted as if they're better than you are;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People have acted as if they're better than you are [PhenX];People act superior PhenX;;TRIAL;2.38;2.65 +67593-4;You have been called names or insulted;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have been called names or insulted [PhenX];Called names insulted PhenX;;TRIAL;2.38;2.65 +67594-2;You have been threatened or harassed;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have been threatened or harassed [PhenX];Threatened harassed PhenX;;TRIAL;2.38;2.65 +6759-5;Glucose^6H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --6 hours post 75 g glucose PO;Glucose 6h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67595-9;You have been followed around in stores;Find;Pt;^Patient;Ord;PhenX;PHENX;2;You have been followed around in stores [PhenX];Followed in stores PhenX;;TRIAL;2.38;2.65 +67596-7;The fresh fruits and vegetables in my neighborhood are of high quality;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The fresh fruits and vegetables in my neighborhood are of high quality [PhenX];Quality fresh fruits vegetables PhenX;;TRIAL;2.38;2.65 +67597-5;A large selection of fresh fruits and vegetables is available in my neighborhood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;A large selection of fresh fruits and vegetables is available in my neighborhood [PhenX];Large selection fruits vegetables PhenX;;TRIAL;2.38;2.65 +67598-3;A large selection of low-fat products is available in my neighborhood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;A large selection of low-fat products is available in my neighborhood [PhenX];Large selection low-fat products PhenX;;TRIAL;2.38;2.65 +67601-5;This is a close-knit neighborhood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;This is a close-knit neighborhood [PhenX];Close-knit neighborhood PhenX;;TRIAL;2.38;2.65 +67602-3;People around here are willing to help their neighbors;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People around here are willing to help their neighbors [PhenX];People help neighbors PhenX;;TRIAL;2.38;2.65 +6760-3;Glucose^6H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --6 hours post 75 g glucose PO;Glucose 6h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +67603-1;People in this neighborhood generally don't get along with each other;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People in this neighborhood generally don't get along with each other [PhenX];People don't get along PhenX;;TRIAL;2.38;2.65 +67604-9;People in this neighborhood do not share the same values;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People in this neighborhood do not share the same values [PhenX];People do not share same values PhenX;;TRIAL;2.38;2.65 +67605-6;People in this neighborhood can be trusted;Find;Pt;^Patient;Ord;PhenX;PHENX;2;People in this neighborhood can be trusted [PhenX];People can be trusted PhenX;;TRIAL;2.38;2.65 +67606-4;If a group of neighborhood children were skipping school and hanging out on a street corner, how likely is that your neighbors would do something about it;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If a group of neighborhood children were skipping school and hanging out on a street corner, how likely is that your neighbors would do something about it [PhenX];Neighbors report children PhenX;;TRIAL;2.38;2.65 +67607-2;If some children were spray-painting graffiti on a local building, how likely is it that your neighbors would do something about it;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If some children were spray-painting graffiti on a local building, how likely is it that your neighbors would do something about it [PhenX];Neighbors report children graffiti PhenX;;TRIAL;2.38;2.65 +67608-0;If a child was showing disrespect to an adult, how likely is it that people in your neighborhood would scold that child;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If a child was showing disrespect to an adult, how likely is it that people in your neighborhood would scold that child [PhenX];Neighbors scold children PhenX;;TRIAL;2.38;2.65 +67609-8;If there was a fight in front of your house and someone was being beaten or threatened, how likely is it that your neighbors would break it up;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If there was a fight in front of your house and someone was being beaten or threatened, how likely is it that your neighbors would break it up [PhenX];Neighbors break up fight PhenX;;TRIAL;2.38;2.65 +67610-6;Suppose that because of budget cuts the fire station closest to your home was going to be closed down by the city. How likely is it that neighborhood residents would organize to try to do something to keep the fire station open;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Suppose that because of budget cuts the fire station closest to your home was going to be closed down by the city. How likely is it that neighborhood residents would organize to try to do something to keep the fire station open [PhenX];Neighbors keep station open PhenX;;TRIAL;2.38;2.65 +6761-1;Glucose^1.5H post 50 g lactose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --1.5 hours post 50 g lactose PO;Glucose 1.5h p 50 g Lac PO Ur Ql Strip;;ACTIVE;1.0h(2);2.56 +67611-4;I feel safe walking in my neighborhood, day or night;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel safe walking in my neighborhood, day or night [PhenX];Safe walking neighborhood PhenX;;TRIAL;2.38;2.65 +67612-2;Violence is not a problem in my neighborhood;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Violence is not a problem in my neighborhood [PhenX];Neighborhood violence PhenX;;TRIAL;2.38;2.65 +67613-0;My neighborhood is safe from crime;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My neighborhood is safe from crime [PhenX];Neighborhood safe from crime PhenX;;TRIAL;2.38;2.65 +67614-8;Teachers understand my problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Teachers understand my problems [PhenX];Teachers understands problems PhenX;;TRIAL;2.38;2.65 +67615-5;Teachers and staff seem to take a real interest in my future;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Teachers and staff seem to take a real interest in my future [PhenX];Teacher interested in future PhenX;;TRIAL;2.38;2.65 +67616-3;Teachers are available when I need to talk with them;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Teachers are available when I need to talk with them [PhenX];Teachers available to talk PhenX;;TRIAL;2.38;2.65 +67617-1;It is easy to talk with teachers;Find;Pt;^Patient;Ord;PhenX;PHENX;2;It is easy to talk with teachers [PhenX];Easy to talk with teachers PhenX;;TRIAL;2.38;2.65 +67618-9;Students get along well with teachers;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Students get along well with teachers [PhenX];Students get along with teachers PhenX;;TRIAL;2.38;2.65 +67619-7;At my school, there is a teacher or some other adult who notices when I'm not there;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At my school, there is a teacher or some other adult who notices when I'm not there [PhenX];Teacher notices truancy PhenX;;TRIAL;2.38;2.65 +67620-5;Teachers at my school help us children with our problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Teachers at my school help us children with our problems [PhenX];Teachers help with problems PhenX;;TRIAL;2.38;2.65 +67621-3;My teachers care about me;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My teachers care about me [PhenX];Teachers care PhenX;;TRIAL;2.38;2.65 +67622-1;My teacher makes me feel good about myself;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My teacher makes me feel good about myself [PhenX];Teacher feel good PhenX;;TRIAL;2.38;2.65 +67623-9;My schoolwork is exciting;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My schoolwork is exciting [PhenX];Exciting schoolwork PhenX;;TRIAL;2.38;2.65 +67624-7;Students can make suggestions on courses that are offered;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Students can make suggestions on courses that are offered [PhenX];Students influence courses PhenX;;TRIAL;2.38;2.65 +67625-4;Students are publicly recognized for their outstanding performances in speech, drama, art, music, etc;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Students are publicly recognized for their outstanding performances in speech, drama, art, music, etc [PhenX];Students recognized for arts PhenX;;TRIAL;2.38;2.65 +67626-2;If this school had an extra period during the day, I would take an additional academic class;Find;Pt;^Patient;Ord;PhenX;PHENX;2;If this school had an extra period during the day, I would take an additional academic class [PhenX];Take additional classes PhenX;;TRIAL;2.38;2.65 +67627-0;This school makes students enthusiastic about learning;Find;Pt;^Patient;Ord;PhenX;PHENX;2;This school makes students enthusiastic about learning [PhenX];School makes students enthusiastic PhenX;;TRIAL;2.38;2.65 +67628-8;Students are frequently rewarded or praised by faculty and staff for following school rules;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Students are frequently rewarded or praised by faculty and staff for following school rules [PhenX];Students recog following rules PhenX;;TRIAL;2.38;2.65 +6762-9;Glucose^1.5H post 50 g lactose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 50 g lactose PO;Glucose 1.5h p 50 g Lac PO SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +67629-6;I usually understand my homework assignments;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I usually understand my homework assignments [PhenX];Understand homework PhenX;;TRIAL;2.38;2.65 +67630-4;Teachers make it clear what work needs to be done to get the grade I want;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Teachers make it clear what work needs to be done to get the grade I want [PhenX];Clear expectations for grades PhenX;;TRIAL;2.38;2.65 +67631-2;I believe that teachers expect all students to learn;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I believe that teachers expect all students to learn [PhenX];Teachers expect students to learn PhenX;;TRIAL;2.38;2.65 +67632-0;I feel that I can do well in this school;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I feel that I can do well in this school [PhenX];Do well in school PhenX;;TRIAL;2.38;2.65 +67633-8;My teachers believe that I can do well in my school work;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My teachers believe that I can do well in my school work [PhenX];Teachers believe student ability PhenX;;TRIAL;2.38;2.65 +67634-6;I try hard to succeed in my classes;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I try hard to succeed in my classes [PhenX];Try to succeed PhenX;;TRIAL;2.38;2.65 +67635-3;Classroom rules are applied equally;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Classroom rules are applied equally [PhenX];Classroom rules applied equally PhenX;;TRIAL;2.38;2.65 +67636-1;Problems in this school are solved by students and staff;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Problems in this school are solved by students and staff [PhenX];Problems solved by students staff PhenX;;TRIAL;2.38;2.65 +6763-7;Glucose^1.5H post 75 g glucose PO;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Glucose [Presence] in Urine by Test strip --1.5 hours post 75 g glucose PO;Glucose 1.5h p 75 g Glc PO Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67637-9;Students get in trouble if they do not follow school rules;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Students get in trouble if they do not follow school rules [PhenX];Students punished not follow rules PhenX;;TRIAL;2.38;2.65 +67638-7;The rules of the school are fair;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The rules of the school are fair [PhenX];School rules fair PhenX;;TRIAL;2.38;2.65 +67639-5;School rules are enforced consistently and fairly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;School rules are enforced consistently and fairly [PhenX];School rules enforced consistently PhenX;;TRIAL;2.38;2.65 +67640-3;My teachers make it clear to me when I have misbehaved in class;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My teachers make it clear to me when I have misbehaved in class [PhenX];Teachers call out misbehavior PhenX;;TRIAL;2.38;2.65 +67641-1;Discipline is fair;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Discipline is fair [PhenX];Discipline is fair PhenX;;TRIAL;2.38;2.65 +67642-9;The school grounds are kept clean;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The school grounds are kept clean [PhenX];School grounds kept clean PhenX;;TRIAL;2.38;2.65 +67643-7;My school is neat and clean;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My school is neat and clean [PhenX];School neat clean PhenX;;TRIAL;2.38;2.65 +67644-5;My school buildings are generally pleasant and well maintained;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My school buildings are generally pleasant and well maintained [PhenX];School bldgs pleasant maintained PhenX;;TRIAL;2.38;2.65 +6764-5;Glucose^post CFst;PrThr;Pt;Urine;Ord;Test strip;CHAL;1;Fasting glucose [Presence] in Urine by Test strip;Glucose p fast Ur Ql Strip;;ACTIVE;1.0h(2);2.73 +67645-2;My school is usually clean and tidy;Find;Pt;^Patient;Ord;PhenX;PHENX;2;My school is usually clean and tidy [PhenX];School usually clean tidy PhenX;;TRIAL;2.38;2.65 +67646-0;I am happy with kinds of students who go to my school;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am happy with kinds of students who go to my school [PhenX];Happy with schoolmates PhenX;;TRIAL;2.38;2.65 +67647-8;I am happy, in general, with the other students who go to my school;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am happy, in general, with the other students who go to my school [PhenX];Happy with other students PhenX;;TRIAL;2.38;2.65 +67648-6;At my school, the same person always gets to help the teacher;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At my school, the same person always gets to help the teacher [PhenX];Same person helps teacher PhenX;;TRIAL;2.38;2.65 +67649-4;At my school, the same kids get chosen every time to take part in after-school or special activities;Find;Pt;^Patient;Ord;PhenX;PHENX;2;At my school, the same kids get chosen every time to take part in after-school or special activities [PhenX];Same kids get special activ PhenX;;TRIAL;2.38;2.65 +67650-2;The same kids always get to use things, like a computer, a ball or a piano, when we play;Find;Pt;^Patient;Ord;PhenX;PHENX;2;The same kids always get to use things, like a computer, a ball or a piano, when we play [PhenX];Same kids use resources PhenX;;TRIAL;2.38;2.65 +67651-0;I am happy about the number of tests I have;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am happy about the number of tests I have [PhenX];Happy about number tests PhenX;;TRIAL;2.38;2.65 +6765-2;17-Hydroxypregnenolone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma;17OH-Preg SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +67652-8;I am happy about the amount of homework I have;Find;Pt;^Patient;Ord;PhenX;PHENX;2;I am happy about the amount of homework I have [PhenX];Happy about amt homework PhenX;;TRIAL;2.38;2.65 +67653-6;How close are you to this person;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How close are you to this person [PhenX];Person how close PhenX;;TRIAL;2.38;2.65 +67654-4;How often do you see or talk to the person;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How often do you see or talk to the person [PhenX];Person contact frequency PhenX;;TRIAL;2.38;2.65 +67655-1;Do they trust doctors to take care of people's problems;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do they trust doctors to take care of people's problems [PhenX];Person trust doctors PhenX;;TRIAL;2.38;2.65 +67656-9;Has this person done any of the following for you or helped you out;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Has this person done any of the following for you or helped you out [PhenX];Person function PhenX;;TRIAL;2.38;2.65 +67657-7;Does this person hassle you, cause you problems, or make your life difficult;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Does this person hassle you, cause you problems, or make your life difficult [PhenX];Person cause problems PhenX;;TRIAL;2.38;2.65 +67658-5;EMS exposures or injuries of EMS personnel;-;Pt;Provider;Nar;NEMSIS;PANEL.NEMSIS;2;EMS exposures or injuries of EMS personnel Provider Narrative NEMSIS;Expos inj EMS person Provider NEMSIS;;ACTIVE;2.38;2.50 +67659-3;EMS billing;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS billing Narrative NEMSIS;EMS billing NEMSIS;;ACTIVE;2.38;2.50 +6766-0;17-Ketosteroids;MRat;24H;Urine;Qn;;CHEM;1;17-Ketosteroids [Mass/time] in 24 hour Urine;17KS 24h Ur-mRate;;ACTIVE;1.0h(2);2.73 +67660-1;EMS dispatch;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS dispatch Narrative NEMSIS;EMS dispatch NEMSIS;;ACTIVE;2.38;2.50 +67661-9;EMS disposition;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS disposition Narrative NEMSIS;EMS disposition NEMSIS;;ACTIVE;2.38;2.50 +67663-5;EMS protocol;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS protocol Narrative NEMSIS;EMS protocol NEMSIS;;ACTIVE;2.38;2.50 +67664-3;EMS response;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS response Narrative NEMSIS;EMS response NEMSIS;;ACTIVE;2.38;2.50 +67665-0;EMS scene;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS scene Narrative NEMSIS;EMS scene NEMSIS;;ACTIVE;2.38;2.50 +67666-8;EMS situation;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS situation Narrative NEMSIS;EMS situation NEMSIS;;ACTIVE;2.38;2.50 +67667-6;EMS times;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS times Narrative NEMSIS;EMS times NEMSIS;;ACTIVE;2.38;2.50 +67668-4;EMS physical assessment;-;Pt;^Patient;Nar;NEMSIS;PANEL.NEMSIS;2;EMS physical assessment Narrative NEMSIS;EMS physical assessment NEMSIS;;ACTIVE;2.38;2.50 +67669-2;Alcohol - drug use;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Alcohol - drug use NEMSIS;Alcohol - drug use NEMSIS;;ACTIVE;2.38;2.50 +676-7;Microscopic observation;Prid;Pt;XXX;Nom;Rhodamine-auramine fluorochrome stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Rhodamine-auramine fluorochrome stain;Rhodamine-auramine Stn Spec;;ACTIVE;1.0;2.73 +67670-0;Length-based tape measure category;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Length-based tape measure category NEMSIS;Length-based tape NEMSIS;;ACTIVE;2.38;2.50 +67671-8;Have you ever been unfairly discouraged by a teacher or advisor from continuing your education;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been unfairly discouraged by a teacher or advisor from continuing your education [PhenX];Unfairly discouraged education PhenX;;TRIAL;2.38;2.65 +67672-6;Have you ever been unfairly prevented from moving into a neighborhood because the landlord or a realtor refused to sell or rent you a house or apartment;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever been unfairly prevented from moving into a neighborhood because the landlord or a realtor refused to sell or rent you a house or apartment [PhenX];Unfairly not sold rented PhenX;;TRIAL;2.38;2.65 +67673-4;Have you ever moved into a neighborhood where neighbors made life difficult for you or your family;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever moved into a neighborhood where neighbors made life difficult for you or your family [PhenX];Unfairly treated by neighbors PhenX;;TRIAL;2.38;2.65 +67674-2;Someone in family died;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Someone in family died [PhenX];Family member died PhenX;;TRIAL;2.38;2.65 +67675-9;Was this a good or bad experience;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Was this a good or bad experience [PhenX];Good bad experience PhenX;;TRIAL;2.38;2.65 +67676-7;How much did the event affect you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;How much did the event affect you [PhenX];Event affect PhenX;;TRIAL;2.38;2.65 +67677-5;Family member was seriously injured;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Family member was seriously injured [PhenX];Family member injured PhenX;;TRIAL;2.38;2.65 +6767-8;18-Hydroxycorticosteroids;MCnc;Pt;Ser;Qn;;CHEM;1;18-Hydroxycorticosteroids [Mass/volume] in Serum;18OH-CS Ser-mCnc;;ACTIVE;1.0h(2);2.42 +67678-3;Saw crime - accident;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Saw crime - accident [PhenX];Saw crime - accident PhenX;;TRIAL;2.38;2.65 +67679-1;Lost a close friend;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Lost a close friend [PhenX];Lost close friend PhenX;;TRIAL;2.38;2.65 +67680-9;Close friend was seriously sick - injured;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Close friend was seriously sick - injured [PhenX];Close friend sick - injured PhenX;;TRIAL;2.38;2.65 +67681-7;Negative change in parent's financial situation;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Negative change in parent's financial situation [PhenX];Parent's financial situation PhenX;;TRIAL;2.38;2.65 +67682-5;Drug - alcohol problem;Hx;Pt;^Family member;Ord;PhenX;PHENX;2;Family history of Drug - alcohol problem [PhenX];Family hx of Drug - alcohol PhenX;;TRIAL;2.38;2.65 +67683-3;Got seriously sick or injured;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Got seriously sick or injured [PhenX];Sick injured PhenX;;TRIAL;2.38;2.65 +67684-1;Parents argued more than previously;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Parents argued more than previously [PhenX];Parents argued PhenX;;TRIAL;2.38;2.65 +67685-8;Mother or father figure lost job;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Mother or father figure lost job [PhenX];Mother father lost job PhenX;;TRIAL;2.38;2.65 +6768-6;Alkaline phosphatase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma;ALP SerPl-cCnc;;ACTIVE;1.0h(2);2.73 +67686-6;One parent was away from home more often;Find;Pt;^Patient;Ord;PhenX;PHENX;2;One parent was away from home more often [PhenX];Parent away from home PhenX;;TRIAL;2.38;2.65 +67687-4;Someone in the family was arrested;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Someone in the family was arrested [PhenX];Family member arrested PhenX;;TRIAL;2.38;2.65 +67688-2;Close friend died;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Close friend died [PhenX];Close friend died PhenX;;TRIAL;2.38;2.65 +67689-0;Mental - emotional problem;Hx;Pt;^Family member;Ord;PhenX;PHENX;2;Family history of Mental - emotional problem [PhenX];Family hx of Mental - emotional PhenX;;TRIAL;2.38;2.65 +67690-8;Brother or sister left home;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Brother or sister left home [PhenX];Sibling left home PhenX;;TRIAL;2.38;2.65 +67691-6;Being a victim of crime - violence - assault;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Being a victim of crime - violence - assault [PhenX];Victim crime - violence - assault PhenX;;TRIAL;2.38;2.65 +67692-4;Parents separated in last 12Mo;Find;12Mo;^Patient;Ord;PhenX;PHENX;2;Parents separated in last 12 months [PhenX];Parents separated last 12Mo PhenX;;TRIAL;2.38;2.65 +67693-2;Parents got into trouble with the law;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Parents got into trouble with the law [PhenX];Parents trouble with law PhenX;;TRIAL;2.38;2.65 +6769-4;Alkaline phosphatase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma;Deprecated ALP SerPl-cCnc;;DEPRECATED;1.0h(2);2.36 +67694-0;Attended a new school;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Attended a new school [PhenX];Attended new school PhenX;;TRIAL;2.38;2.65 +67695-7;Family moved;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Family moved [PhenX];Family moved PhenX;;TRIAL;2.38;2.65 +67696-5;Parents got divorced;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Parents got divorced [PhenX];Parents got divorced PhenX;;TRIAL;2.38;2.65 +67697-3;One of the parents went to jail;Find;Pt;^Patient;Ord;PhenX;PHENX;2;One of the parents went to jail [PhenX];Parent went to jail PhenX;;TRIAL;2.38;2.65 +67698-1;Got new stepmother or stepfather;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Got new stepmother or stepfather [PhenX];New stepparent PhenX;;TRIAL;2.38;2.65 +67699-9;Parent got a new job;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Parent got a new job [PhenX];Parent got new job PhenX;;TRIAL;2.38;2.65 +67700-5;Got new brother or sister;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Got new brother or sister [PhenX];New sibling PhenX;;TRIAL;2.38;2.65 +67701-3;Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Palmitoylcarnitine (C16);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS;Glut+3OHhexanoylcarn/C16 DBS-sRto;;ACTIVE;2.38;2.73 +6770-2;Alpha 1 antitrypsin phenotype;Prid;Pt;Ser/Plas;Nom;Immunofixation;CHEM;1;Alpha 1 antitrypsin phenotype [Identifier] in Serum or Plasma by Immunofixation;A1AT Phenotyp SerPl IFE;;ACTIVE;1.0h(2);2.73 +67703-9;Other infant factors that affect newborn screening interpretation;Find;Pt;^Patient;Nar;;H&P.HX;2;Other infant factors that affect newborn screening interpretation Narrative;Other Inf factors affecting NBS imp;;ACTIVE;2.38;2.58 +67704-7;Feeding types;Find;Pt;^Patient;Nom;;H&P.HX;2;Feeding types;Feeding types;;ACTIVE;2.38;2.73 +67705-4;Other feeding types;Find;Pt;^Patient;Nar;;H&P.HX;2;Other feeding types Narrative;Other feeding types;;ACTIVE;2.38;2.40 +67706-2;Maternal factors that affect newborn screening interpretation;Find;Pt;^Mother;Nom;;H&P.HX;2;Maternal factors that affect newborn screening interpretation;Mat factors affecting NBS imp;;ACTIVE;2.38;2.56 +67707-0;Other maternal factors that affect newborn screening interpretation;Find;Pt;^Mother;Nar;;H&P.HX;2;Other maternal factors that affect newborn screening interpretation Narrative;Other mat factors affecting NBS imp;;ACTIVE;2.38;2.48 +67708-8;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in DBS;Malonyl+3OHbutyrylcarn DBS-sCnc;;ACTIVE;2.38;2.73 +67709-6;Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in DBS;C4-DC+C5-OH DBS-sCnc;;ACTIVE;2.38;2.73 +6771-0;Alpha 1 antitrypsin;MCnc;Pt;Ser/Plas;Qn;Nephelometry;CHEM;1;Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephelometry;A1AT SerPl Neph-mCnc;;ACTIVE;1.0h(2);2.73 +67710-4;Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in DBS;Glut+3OHhexanoylcarn DBS-sCnc;;ACTIVE;2.38;2.73 +67711-2;Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Octanoylcarnitine (C8);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS;Glut+3OHhexanoylcarn/C8 DBS-sRto;;ACTIVE;2.38;2.73 +67712-0;Center - CTR - ID number;ID;Pt;Facility;Nom;PhenX;PHENX;2;Center - CTR - ID number Facility [PhenX];CTR ID number Facility PhenX;;TRIAL;2.38;2.65 +67713-8;Diagnosing provider;Addr;Pt;Provider;Nom;;CLIN;2;Diagnosing provider [Address];Diagnosing provider Addr;;ACTIVE;2.38;2.40 +67714-6;Diagnosing provider phone number;Tele;Pt;Provider;Nom;;CLIN;2;Diagnosing provider phone number;Diagnosing provider phone #;;ACTIVE;2.38;2.66 +67715-3;Vendor device model type;Type;Pt;{Device};Nom;;DEVICES;2;Vendor device model type;Vendor device model type;;ACTIVE;2.38;2.58 +67716-1;Vendor device model;ID;Pt;{Device};Nom;;DEVICES;2;Vendor device model;Vendor device model;;ACTIVE;2.38;2.58 +67717-9;Image ID;ID;Pt;XXX;Nom;;RAD;2;Unspecified body region Image ID;Image ID;;ACTIVE;2.38;2.64 +67718-7;Reason for your hearing difficulty;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Reason for your hearing difficulty [PhenX];Reason your hearing difficulty PhenX;;TRIAL;2.38;2.65 +67719-5;Which ear;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Which ear [PhenX];Which ear PhenX;;TRIAL;2.38;2.65 +67720-3;Occupation;Find;Pt;^Family member;Nom;PhenX;PHENX;2;Occupation Family member [PhenX];Occupation Fam Mem PhenX;;TRIAL;2.38;2.65 +67721-1;Age of onset of health-related event;Time;Pt;^Family member;Qn;;CLIN;2;Age of onset of health-related event Family member;Age onset health event Fam Mem;;ACTIVE;2.38;2.46 +67722-9;Cause of hearing problem;Find;Pt;^Family member;Ord;PhenX;PHENX;2;Cause of hearing problem Family member [PhenX];Cause hearing prob Fam Mem PhenX;;TRIAL;2.38;2.65 +67723-7;Date of health-related event;Date;Pt;^Patient;Qn;;CLIN;2;Date of health-related event;Date of health event;;ACTIVE;2.38;2.66 +67724-5;Length-based tape measure category;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Deprecated Length-based tape measure category NEMSIS;Deprecated Length-based tape NEMSIS;;DEPRECATED;2.38;2.38 +67725-2;Mycobacterium sp identified;Prid;Pt;Isolate;Nom;HPLC;MICRO;1;Mycobacterium sp identified in Isolate by HPLC;Mycobacterium Islt HPLC;;ACTIVE;2.38;2.38 +67726-0;Rickettsia sp DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Rickettsia sp DNA [Identifier] in Specimen by NAA with probe detection;Rickettsia DNA Spec NAA+probe;;ACTIVE;2.38;2.69 +67727-8;Heart surgery operation;Type;Pt;^Patient;Nom;PhenX;PHENX;2;Heart surgery operation [PhenX];Heart surgery operation PhenX;;TRIAL;2.38;2.65 +6772-8;Apolipoprotein B;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Apolipoprotein B [Mass/volume] in Serum or Plasma;Deprecated Apo B SerPl-mCnc;;DEPRECATED;1.0h(2);2.36 +67728-6;Have you been exposed to solvents such as thrichloroethylene, toluene, evaporations from paints or lacquers, for more than one Y in one of your jobs;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you been exposed to solvents such as thrichloroethylene, toluene, evaporations from paints or lacquers, for more than one year in one of your jobs [PhenX];Occ exposure to solvents PhenX;;TRIAL;2.38;2.65 +67730-2;Y exposure started;Date;Pt;^Patient;Qn;PhenX;PHENX;2;Year exposure started [PhenX];Y exposure started PhenX;;TRIAL;2.38;2.65 +67732-8;Do you suffer from white finger syndrome or raynaud's syndrome caused by excessive vibration from pneumatic hammers or drills;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you suffer from white finger syndrome or raynaud's syndrome caused by excessive vibration from pneumatic hammers or drills [PhenX];White finger syndrome PhenX;;TRIAL;2.38;2.65 +67733-6;Have you ever worked for more than 1Y in a place where you had to raise your voice to make yourself heard by someone standing 1 mile away from you;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever worked for more than 1 year in a place where you had to raise your voice to make yourself heard by someone standing 1 mile away from you [PhenX];Loud working environment PhenX;;TRIAL;2.38;2.66 +67734-4;Most important noise sources;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Most important noise sources [PhenX];Most important noise sources PhenX;;TRIAL;2.38;2.65 +67735-1;Noise level;Ratio;Pt;^Patient;Qn;PhenX;PHENX;2;Noise level [Ratio] [PhenX];Noise level PhenX;;TRIAL;2.38;2.65 +6773-6;Creatine kinase.MB;CCnc;Pt;Ser/Plas;Qn;EIA;CHEM;1;Deprecated Creatine kinase.MB;Deprecated CK MB SerPl EIA-cCnc;;DEPRECATED;1.0h(2);2.70 +67736-9;Noise dose;Ratio;Pt;^Patient;Qn;PhenX;PHENX;2;Noise dose [Ratio] [PhenX];Noise dose PhenX;;TRIAL;2.38;2.65 +67737-7;How many Hs per D were you exposed;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;How many hours per day were you exposed [PhenX];Exposed Hs/D PhenX;;TRIAL;2.38;2.65 +67738-5;Was this a constant loud noise or an impulse noise;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Was this a constant loud noise or an impulse noise [PhenX];Constant or impulse noise PhenX;;TRIAL;2.38;2.65 +67739-3;Have you ever smoked regularly;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever smoked regularly [PhenX];Smoked regularly PhenX;;TRIAL;2.38;2.65 +67740-1;At which age did you start smoking;Time;Pt;^Patient;Qn;PhenX;PHENX;2;At which age did you start smoking [PhenX];Age started smoking PhenX;;TRIAL;2.38;2.65 +67741-9;Smoking tobacco use duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Smoking tobacco use duration;Smoking tobacco;;TRIAL;2.38;2.73 +67742-7;How many drinks do you have on average;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;How many drinks do you have on average [PhenX];Average num drinks PhenX;;TRIAL;2.38;2.65 +67743-5;Do you drink alcohol regularly, every W;Find;Pt;^Patient;Ord;PhenX;PHENX;2;Do you drink alcohol regularly, every week [PhenX];Drink alcohol regularly PhenX;;TRIAL;2.38;2.65 +6774-4;Desethylamiodarone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desethylamiodarone [Mass/volume] in Serum or Plasma;Desethylamiodarone SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +67744-3;Approximately how many cigarettes did you smoke on average;NRat;Pt;^Patient;Ord;PhenX;PHENX;2;Approximately how many cigarettes did you smoke on average [PhenX];Average cigarettes smoked PhenX;;TRIAL;2.38;2.65 +67745-0;Name generator;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Name generator [PhenX];Name generator PhenX;;TRIAL;2.38;2.65 +67746-8;Person;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Person [PhenX];Person PhenX;;TRIAL;2.38;2.65 +67747-6;Section generator;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Section generator [PhenX];Section generator PhenX;;TRIAL;2.38;2.65 +67748-4;Total population;Num;Pt;^Census tract;Qn;;PHENX;2;Total population [#] Census tract;Total population Census tract;;TRIAL;2.38;2.65 +67749-2;Not hispanic or latino;Num;Pt;^Census tract;Qn;;PHENX;2;Not hispanic or latino [#] Census tract;Not hispanic or latino Census tract;;TRIAL;2.38;2.65 +677-5;Microscopic observation;Prid;Pt;XXX;Nom;Toluidine blue O stain;MICRO;1;Microscopic observation [Identifier] in Specimen by Toluidine blue O stain;TBO Stn Spec;;ACTIVE;1.0;2.69 +67750-0;White alone;Num;Pt;^Census tract;Qn;;PHENX;2;White alone [#] Census tract;White alone Census tract;;TRIAL;2.38;2.65 +6775-1;Androstanolone;MCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Androstanolone [Mass/volume] in Serum;Deprecated Androstanolone Ser-mCnc;;DEPRECATED;1.0h(2);2.36 +67751-8;Black or african american alone;Num;Pt;^Census tract;Qn;;PHENX;2;Black or african american alone [#] Census tract;Black african amer alone Census tract;;TRIAL;2.38;2.65 +67752-6;American indian and alaska native alone;Num;Pt;^Census tract;Qn;;PHENX;2;American indian and alaska native alone [#] Census tract;Amer indian alaska native Census tract;;TRIAL;2.38;2.65 +67753-4;Asian alone;Num;Pt;^Census tract;Qn;;PHENX;2;Asian alone [#] Census tract;Asian alone Census tract;;TRIAL;2.38;2.65 +67754-2;Native hawaiian and other pacific islander alone;Num;Pt;^Census tract;Qn;;PHENX;2;Native hawaiian and other pacific islander alone [#] Census tract;NH+PI alone Census tract;;TRIAL;2.38;2.65 +67755-9;Some other race alone;Num;Pt;^Census tract;Qn;;PHENX;2;Some other race alone [#] Census tract;Other race alone Census tract;;TRIAL;2.38;2.65 +67756-7;Two or more races alone;Num;Pt;^Census tract;Qn;;PHENX;2;Two or more races alone [#] Census tract;Two races alone Census tract;;TRIAL;2.38;2.65 +67757-5;HEDIS 2012, 2013 Codes to identify colorectal cancer screening (COL-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify colorectal cancer screening (COL-A);HEDIS 2012-13-13 COL-A;;DISCOURAGED;2.38;2.67 +67758-3;HEDIS 2012, 2013 Codes to identify anticonvulsant serum concentration monitoring tests - PHENobarbital (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify anticonvulsant serum concentration monitoring tests - PHENobarbital (MPM-E);HEDIS 2012-13 MPM-E PHENobarbital;;DISCOURAGED;2.38;2.67 +67759-1;HEDIS 2012, 2013 Codes to identify anticonvulsant serum concentration monitoring tests (MPM-E);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify anticonvulsant serum concentration monitoring tests (MPM-E);HEDIS 2012-13 MPM-E;;DISCOURAGED;2.38;2.67 +67760-9;HEDIS 2012 Codes to identify group A Streptococcus tests (CWP-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012 Codes to identify group A Streptococcus tests (CWP-D);HEDIS 2012 CWP-D;;DISCOURAGED;2.38;2.67 +67761-7;HEDIS 2012, 2013 Codes to identify HbA1c tests (CDC-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify HbA1c tests (CDC-D);HEDIS 2012-13 CDC-D;;DISCOURAGED;2.38;2.67 +67762-5;HEDIS 2012, 2013 Codes to identify nephropathy screening tests (CDC-J);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify nephropathy screening tests (CDC-J);HEDIS 2012-13 CDC-J;;DISCOURAGED;2.38;2.67 +67763-3;HEDIS 2012, 2013 Codes to identify physiologic monitoring tests - Blood urea nitrogen (BUN) (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify physiologic monitoring tests - Blood urea nitrogen (BUN) (MPM-A);HEDIS 2012-13 MPM-A BUN;;DISCOURAGED;2.38;2.67 +67764-1;HEDIS 2012, 2013 Codes to identify physiologic monitoring tests - Serum creatinine (SCr) (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify physiologic monitoring tests - Serum creatinine (SCr) (MPM-A);HEDIS 2012-13 MPM-A SCr;;DISCOURAGED;2.38;2.67 +67765-8;HEDIS 2012, 2013 Codes to identify physiologic monitoring tests (MPM-A);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Codes to identify physiologic monitoring tests (MPM-A);HEDIS 2012-13 MPM-A;;DISCOURAGED;2.38;2.67 +67766-6;HEDIS 2012 Codes to identify sexually active women (CHL-B);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012 Codes to identify sexually active women (CHL-B);HEDIS 2012 CHL-B;;DISCOURAGED;2.38;2.67 +67767-4;HEDIS 2012 panel;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012 panel;HEDIS 2012 panel;;DISCOURAGED;2.38;2.67 +67768-2;HEDIS 2012, 2013 Tests used in early prenatal care - ABO & Rh (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Tests used in early prenatal care - ABO and Rh (PPC-C);HEDIS 2012-13 PPC-C ABO+Rh;;DISCOURAGED;2.38;2.67 +6776-9;Estrone;MRat;24H;Urine;Qn;;CHEM;1;Estrone (E1) [Mass/time] in 24 hour Urine;Estrone 24h Ur-mRate;;ACTIVE;1.0h(2);2.42 +67769-0;HEDIS 2012, 2013 Tests used in early prenatal care - Cytomegalovirus (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Tests used in early prenatal care - Cytomegalovirus (PPC-C);HEDIS 2012-13 PPC-C CMV;;DISCOURAGED;2.38;2.67 +67770-8;HEDIS 2012, 2013 Tests used in early prenatal care (PPC-C);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2012, 2013 Tests used in early prenatal care (PPC-C);HEDIS 2012-13 PPC-C;;DISCOURAGED;2.38;2.67 +67771-6;Nature of health problem;Find;Pt;^Patient;Nar;PhenX;PHENX;2;Nature of health problem Narrative [PhenX];Nature of health problem PhenX;;TRIAL;2.38;2.65 +67772-4;Hospitalization sequence;Find;Pt;^Patient;Nom;PhenX;PHENX;2;Hospitalization sequence [PhenX];Hospitalization sequence PhenX;;TRIAL;2.38;2.65 +67774-0;Primary sign and symptom;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Primary sign and symptom NEMSIS;Primary sign symptom NEMSIS;;ACTIVE;2.38;2.50 +67775-7;Level of responsiveness;Find;Pt;^Patient;Ord;;TRAUMA;2;Level of responsiveness;Level of responsiveness;;ACTIVE;2.38;2.70 +67776-5;Other symptoms;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Other symptoms NEMSIS;Other symptoms NEMSIS;;ACTIVE;2.38;2.50 +6777-7;Glucose;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deprecated Glucose [Mass/volume] in Serum or Plasma;Deprecated Glucose SerPl-mCnc;;DEPRECATED;1.0h(2);2.36 +67781-5;Summarization of encounter note;Hx;Pt;{Setting};Nar;{Role};NEMSIS;2;Summarization of encounter note Narrative;Summ of encounter note;;ACTIVE;2.40;2.54 +67782-3;Surgical operation date;Date;Pt;^Patient;Qn;;PHENX;2;Surgical operation date;Surgical operation date;;ACTIVE;2.38;2.56 +67783-1;Have you ever had other operations not covered by the previous questions;Hx;Pt;^Patient;Ord;PhenX;PHENX;2;Have you ever had other operations not covered by the previous questions [PhenX];Other operations PhenX;;TRIAL;2.38;2.65 +67784-9;Individuals below poverty line;NFr;Pt;^Neighborhood;Qn;PhenX;PHENX;2;Individuals below poverty line Neighborhood [PhenX];% Aortic arch;Doc;RF.angio;RAD;2;RFA Aortic arch Views W contrast IA;RFA Ao arch Views W contr IA;;ACTIVE;2.38;2.64 +69055-2;Views^WO weight;Find;Pt;Upper extremity.bilateral>Acromioclavicular joint;Doc;XR;RAD;2;XR Acromioclavicular joint - bilateral Views WO weight;XR AC joint-Bl Views WO Wt;;ACTIVE;2.38;2.64 +69056-0;Views + obliques;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral Views and Obliques;XR Elbow-Bl Views+Obls;;ACTIVE;2.38;2.64 +69057-8;Views AP + lateral + oblique;Find;Pt;Upper extremity.bilateral>Hand;Doc;XR;RAD;2;XR Hand - bilateral AP and Lateral and oblique;XR Hand-Bl AP+Lat+Obl;;ACTIVE;2.38;2.61 +69058-6;Views 2;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral 2 Views;XR Hip-Bl 2V;;ACTIVE;2.38;2.61 +69059-4;Views + lateral crosstable;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral Views and Lateral crosstable;XR Hip-Bl Views+Lat Xtable;;ACTIVE;2.38;2.64 +69060-2;Views 2 + Sunrise;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 2 Views and Sunrise;XR Knee-Bl 2V+Sunrise;;ACTIVE;2.38;2.61 +69061-0;Views 2 + tunnel;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 2 Views and Tunnel;XR Knee-Bl 2V+Tunnel;;ACTIVE;2.38;2.61 +6906-2;Sertraline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sertraline [Mass/volume] in Serum or Plasma;Sertraline SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +69062-8;Views 4^W standing;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 4 Views W standing;XR Knee-Bl 4V W Stand;;ACTIVE;2.38;2.61 +69063-6;Views 4 + Sunrise + tunnel;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral 4 Views and Sunrise and Tunnel;XR Knee-Bl 4V+Sunrise+Tunnel;;ACTIVE;2.38;2.61 +69064-4;(View Sunrise) + (views^W standing);Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Sunrise and (Views W standing);XR Knee-Bl Sunrise+views Stand;;ACTIVE;2.38;2.61 +69065-1;Views AP + lateral crosstable;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen AP and Lateral crosstable;XR Abd AP+Lat Xtable;;ACTIVE;2.38;2.61 +69066-9;Views^W contrast IV;Find;Pt;Abdomen>Abdominal vessels;Doc;RF.angio;RAD;2;RFA Abdominal vessels Views W contrast IV;RFA Abd ves Views W contr IV;;ACTIVE;2.38;2.64 +69067-7;Guidance for angioplasty^W contrast;Find;Pt;XXX;Doc;RF.angio;RAD;2;RFA Guidance for angioplasty of Unspecified body region-- W contrast;RFA Guided Angio--W contr;;ACTIVE;2.38;2.64 +69068-5;Guidance for needle localization;Find;Pt;Breast.bilateral;Doc;MG;RAD;2;MG Guidance for needle localization of Breast - bilateral;MG Guided Brst-Bl Needle loc;;ACTIVE;2.38;2.64 +69069-3;View Sunrise;Find;Pt;Lower extremity.bilateral>Patella;Doc;XR;RAD;2;XR Patella - bilateral Sunrise;XR Patella-Bl Sunrise;;ACTIVE;2.38;2.61 +6907-0;sulfADIAZINE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;sulfADIAZINE [Mass/volume] in Serum or Plasma;sulfADIAZINE SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +69070-1;Views anterior + lateral;Find;Pt;Chest>Ribs.bilateral;Doc;XR;RAD;2;XR Ribs - bilateral Anterior and Lateral;XR Ribs-Bl Ant+Lat;;ACTIVE;2.38;2.61 +69071-9;Views;Find;Pt;Chest>Ribs.bilateral & Chest;Doc;XR;RAD;2;XR Ribs - bilateral and Chest Views;XR Ribs-Bl + Chest Views;;ACTIVE;2.38;2.64 +69072-7;Views ulnar deviation + radial deviation;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Ulnar deviation and Radial deviation;XR Wrist-Bl Ulnar+Radial Deviation;;ACTIVE;2.38;2.61 +69073-5;Guidance for biopsy.core needle;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for core needle biopsy of Unspecified body region;RF Guided CN Bx;;ACTIVE;2.38;2.64 +69074-3;Guidance for percutaneous biopsy;Find;Pt;Pelvis;Doc;RF;RAD;2;RF Guidance for biopsy of Pelvis;RF Guided Pelvis Bx;;ACTIVE;2.38;2.64 +69075-0;Guidance for percutaneous biopsy;Find;Pt;Head>Salivary gland;Doc;RF;RAD;2;RF Guidance for biopsy of Salivary gland;RF Guided Salivary gland Bx;;ACTIVE;2.38;2.64 +69076-8;Guidance for percutaneous biopsy;Find;Pt;XXX>Bone;Doc;RF;RAD;2;RF guidance for percutaneous biopsy of Bone;RF Bone PC Bx;;ACTIVE;2.38;2.63 +69077-6;Views^W contrast IA;Find;Pt;Chest>Brachiocephalic artery;Doc;RF.angio;RAD;2;RFA Brachiocephalic artery Views W contrast IA;RFA BrachCeph a Views W contr IA;;ACTIVE;2.38;2.64 +69078-4;Guidance for drainage+placement of drainage catheter;Find;Pt;Chest;Doc;RF;RAD;2;RF Guidance for drainage and placement of drainage catheter of Chest;RF Guided Chest Drain+cath place;;ACTIVE;2.38;2.66 +69079-2;View 45 degree cephalic angle;Find;Pt;Chest>Clavicle;Doc;XR;RAD;2;XR Clavicle 45 degree cephalic angle;XR Clavicle 45 deg ceph angle;;ACTIVE;2.38;2.61 +690-8;Neisseria gonorrhoeae;PrThr;Pt;Endomet;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Endometrium by Organism specific culture;N gonorrhoea Endometrium Ql Cult;;ACTIVE;1.0;2.56 +69080-0;Views 5^W flexion + W extension;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 5 Views W flexion and W extension;XR C-spine 5V W FE;;ACTIVE;2.38;2.61 +69081-8;Views 5 + Swimmers;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 5 Views and Swimmers;XR C-spine 5V+Swimmers;;ACTIVE;2.38;2.61 +69082-6;Multisection & 3D reconstruction^WO contrast;Find;Pt;Head;Doc;CT;RAD;2;Deprecated Head CT and 3D reconstruction WO contrast;Deprecated Head CT +3DR WO contr;;DEPRECATED;2.38;2.58 +69083-4;Guidance for percutaneous biopsy^WO contrast;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for biopsy of Abdomen-- WO contrast;CT Guided Abd Bx--WO contr;;ACTIVE;2.38;2.64 +69084-2;Multisection^WO contrast;Find;Pt;Chest>Chest vessels;Doc;CT.angio;RAD;2;CTA Chest vessels WO contrast;CTA Chest ves WO contr;;ACTIVE;2.38;2.61 +69085-9;Multisection^WO & W contrast;Find;Pt;Abdomen>Renal vessels;Doc;CT.angio;RAD;2;Deprecated Abdomen>Renal vessels CT angiogram WO and W contrast;Deprecated Abd>Renal vls CT.Angio WO+W c;;DEPRECATED;2.38;2.58 +69086-7;Multisection^WO & W contrast;Find;Pt;Chest+Abdomen>Aorta;Doc;CT;RAD;2;Deprecated Chest+Abdomen>Aorta CT WO and W contrast;Deprecated Chest+Abd>Aorta CT WO+W contr;;DEPRECATED;2.38;2.58 +69087-5;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Ankle;Doc;CT;RAD;2;CT Ankle - bilateral WO contrast;CT Ankle-Bl WO contr;;ACTIVE;2.38;2.61 +6908-8;Complement C4;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Complement C4 [Mass/volume] in Body fluid;C4 Fld-mCnc;;ACTIVE;1.0h(2);2.73 +69088-3;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Knee;Doc;CT;RAD;2;CT Knee - bilateral W contrast IV;CT Knee-Bl W contr IV;;ACTIVE;2.38;2.61 +69089-1;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Knee;Doc;CT;RAD;2;CT Knee - bilateral WO contrast;CT Knee-Bl WO contr;;ACTIVE;2.38;2.61 +69090-9;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;CT;RAD;2;CT Shoulder - bilateral WO contrast;CT Shoulder-Bl WO contr;;ACTIVE;2.38;2.61 +69091-7;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Wrist;Doc;CT;RAD;2;CT Wrist - bilateral W contrast IV;CT Wrist-Bl W contr IV;;ACTIVE;2.38;2.61 +69092-5;Guidance for percutaneous biopsy^WO contrast;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;CT Guidance for biopsy of Liver-- WO contrast;CT Guided Liver Bx--WO contr;;ACTIVE;2.38;2.64 +69093-3;Guidance for percutaneous biopsy^W contrast IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for biopsy of Pelvis-- W contrast IV;CT Guided Pelvis Bx--W contr IV;;ACTIVE;2.38;2.64 +69094-1;Guidance for percutaneous biopsy^WO contrast;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for biopsy of Pelvis-- WO contrast;CT Guided Pelvis Bx--WO contr;;ACTIVE;2.38;2.64 +69095-8;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis>Urinary bladder;Doc;CT;RAD;2;CT Urinary bladder W contrast IV;CT Bladder W contr IV;;ACTIVE;2.38;2.61 +6909-6;Mucin clot;Aper;Pt;Synv fld;Ord;;HEM/BC;1;Mucin clot [Appearance] in Synovial fluid Qualitative;Mucin Clot Snv Ql;;ACTIVE;1.0h(2);2.73 +69096-6;Multisection limited^W contrast IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest limited W contrast IV;CT Chest Ltd W contr IV;;ACTIVE;2.38;2.61 +69097-4;Guidance for biopsy.needle;Find;Pt;Abdomen>Liver;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Liver;Deprecated CT Liver Bx needle guide;;DEPRECATED;2.38;2.63 +69098-2;Guidance for biopsy.needle;Find;Pt;XXX>Muscle;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Muscle;Deprecated CT Muscle Bx needle guide;;DEPRECATED;2.38;2.63 +69099-0;Guidance for biopsy.needle;Find;Pt;Chest>Pleura;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Chest Pleura;Deprecated CT Chest Pleura Bx needle guide;;DEPRECATED;2.38;2.63 +69100-6;Guidance for biopsy.needle;Find;Pt;Head>Salivary gland;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Salivary gland;Deprecated CT Salivary gland Bx needle guide;;DEPRECATED;2.38;2.63 +69101-4;Guidance for biopsy.needle;Find;Pt;Neck>Thyroid gland;Doc;CT;RAD;2;Deprecated CT Guidance for needle biopsy of Thyroid gland;Deprecated CT Thyroid Bx needle guide;;DEPRECATED;2.38;2.63 +69102-2;Multisection^W contrast IS;Find;Pt;Lower extremity.left>Ankle;Doc;CT;RAD;2;CT Ankle - left Arthrogram;CT Ankle-L W contr IS;;ACTIVE;2.38;2.61 +69103-0;Multisection^W contrast IS;Find;Pt;Upper extremity.left>Elbow;Doc;CT;RAD;2;CT Elbow - left Arthrogram;CT Elbow-L W contr IS;;ACTIVE;2.38;2.61 +6910-4;Brucella abortus Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella abortus IgA Ab [Units/volume] in Serum;B abortus IgA Ser-aCnc;;ACTIVE;1.0h(2);2.69 +69104-8;Multisection^WO contrast;Find;Pt;Extremity.left;Doc;CT;RAD;2;CT Extremity - left WO contrast;CT Extr-L WO contr;;ACTIVE;2.38;2.61 +69105-5;Multisection^W contrast IS;Find;Pt;Lower extremity.left>Hip;Doc;CT;RAD;2;CT Hip - left Arthrogram;CT Hip-L W contr IS;;ACTIVE;2.38;2.61 +69106-3;Multisection^W contrast IS;Find;Pt;Lower extremity.left>Knee;Doc;CT;RAD;2;CT Knee - left Arthrogram;CT Knee-L W contr IS;;ACTIVE;2.38;2.61 +69107-1;Multisection^W contrast IS;Find;Pt;Upper extremity.left>Wrist;Doc;CT;RAD;2;CT Wrist - left Arthrogram;CT Wrist-L W contr IS;;ACTIVE;2.38;2.61 +69108-9;Multisection^WO & W contrast;Find;Pt;Pulmonary vessels;Doc;CT.angio;RAD;2;Deprecated Pulmonary vessels CT angiogram WO and W contrast;Deprecated Pulm ves CT.Angio WO+W contr;;DEPRECATED;2.38;2.58 +69109-7;Multisection^W contrast IS;Find;Pt;Lower extremity.right>Ankle;Doc;CT;RAD;2;CT Ankle - right Arthrogram;CT Ankle-R W contr IS;;ACTIVE;2.38;2.61 +69110-5;Multisection^W contrast IS;Find;Pt;Upper extremity.right>Elbow;Doc;CT;RAD;2;CT Elbow - right Arthrogram;CT Elbow-R W contr IS;;ACTIVE;2.38;2.61 +69111-3;Multisection^WO contrast;Find;Pt;Extremity.right;Doc;CT;RAD;2;CT Extremity - right WO contrast;CT Extr-R WO contr;;ACTIVE;2.38;2.61 +6911-2;Brucella abortus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Brucella abortus IgG Ab [Units/volume] in Serum;B abortus IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +69112-1;Multisection^W contrast IS;Find;Pt;Lower extremity.right>Hip;Doc;CT;RAD;2;CT Hip - right Arthrogram;CT Hip-R W contr IS;;ACTIVE;2.38;2.61 +69113-9;Multisection;Find;Pt;Abdomen>Kidney.right;Doc;CT;RAD;2;CT Kidney - right;CT Kidney-R;;ACTIVE;2.38;2.61 +69114-7;Multisection^W contrast IS;Find;Pt;Lower extremity.right>Knee;Doc;CT;RAD;2;CT Knee - right Arthrogram;CT Knee-R W contr IS;;ACTIVE;2.38;2.73 +69115-4;Multisection^W contrast IS;Find;Pt;Upper extremity.right>Wrist;Doc;CT;RAD;2;CT Wrist - right Arthrogram;CT Wrist-R W contr IS;;ACTIVE;2.38;2.61 +69116-2;Multisection;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;CT;RAD;2;CT Sacrum and Coccyx;CT Sacrum+Coccyx;;ACTIVE;2.38;2.61 +69117-0;Multisection;Find;Pt;Chest>Scapula;Doc;CT;RAD;2;CT Scapula;CT Scapula;;ACTIVE;2.38;2.61 +69118-8;Multisection^WO contrast;Find;Pt;Chest>Scapula;Doc;CT;RAD;2;CT Scapula WO contrast;CT Scapula WO contr;;ACTIVE;2.38;2.61 +69119-6;Multisection^WO contrast;Find;Pt;Chest>Aorta.thoracic;Doc;CT.angio;RAD;2;CTA Thoracic Aorta WO contrast;CTA TA WO contr;;ACTIVE;2.38;2.61 +6912-0;Chlamydophila pneumoniae Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila pneumoniae IgA Ab [Titer] in Serum by Immunofluorescence;C pneum IgA Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69120-4;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Neck;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of drainage catheter of Neck;RF Guided Neck Absc drain+cath place;;ACTIVE;2.38;2.66 +69121-2;Guidance for percutaneous aspiration of cyst;Find;Pt;Pelvis>Ovary;Doc;RF;RAD;2;RF Guidance for aspiration of cyst of Ovary;RF Guided Ovary Cyst asp;;ACTIVE;2.38;2.64 +69122-0;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Pancreas;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of drainage catheter of Pancreas;RF Guided Pancreas Absc drain+cath place;;ACTIVE;2.38;2.66 +69123-8;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of chest tube of Pleural space;RF Guided Pl space Absc drn+CT place;;ACTIVE;2.38;2.66 +69124-6;Guidance for superficial aspiration.fine needle;Find;Pt;XXX>Tissue;Doc;RF;RAD;2;RF Guidance for superficial aspiration.fine needle of Tissue;RF Guided Tiss Sup FNA;;ACTIVE;2.38;2.64 +69125-3;Guidance for biopsy.needle;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;Deprecated RF Guidance for needle biopsy of Liver;Deprecated RF Liver Bx needle guide;;DEPRECATED;2.38;2.63 +69126-1;Guidance for biopsy.needle;Find;Pt;Abdomen>Pancreas;Doc;RF;RAD;2;Deprecated RF Guidance for needle biopsy of Pancreas;Deprecated RF Pancreas Bx needle guide;;DEPRECATED;2.38;2.63 +69127-9;Guidance for biopsy;Find;Pt;Chest>Pleura;Doc;RF;RAD;2;RF Guidance for biopsy of Chest Pleura;RF Guided Chest Pleura Bx;;ACTIVE;2.38;2.64 +69128-7;Guidance for biopsy.needle;Find;Pt;Head>Salivary gland;Doc;RF;RAD;2;Deprecated RF Guidance for needle biopsy of Salivary gland;Deprecated RF Salivary gland Bx needle guide;;DEPRECATED;2.38;2.63 +69129-5;Guidance for percutaneous biopsy;Find;Pt;Neck>Thyroid gland;Doc;RF;RAD;2;RF Guidance for biopsy of Thyroid gland;RF Guided Thyroid Bx;;ACTIVE;2.38;2.64 +69130-3;Views AP + lateral;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand AP and Lateral;XR Hand AP+Lat;;ACTIVE;2.38;2.61 +69131-1;Views + Danelius Miller;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Views and Danelius Miller;XR Hip Views+Danelius Miller;;ACTIVE;2.38;2.64 +69132-9;View Danelius Miller;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip Danelius Miller;XR Hip Danelius Miller;;ACTIVE;2.38;2.61 +69133-7;Guidance for drainage+placement of drainage catheter;Find;Pt;Lower extremity>Hip;Doc;RF;RAD;2;RF Guidance for drainage and placement of drainage catheter of Hip;RF Guided Hip Drain+cath place;;ACTIVE;2.38;2.66 +69134-5;Guidance for placement of stent;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;RF.angio;RAD;2;RFA Guidance for placement of stent in Iliac artery;RFA Guided Iliac a Stent place;;ACTIVE;2.38;2.64 +69135-2;Guidance for atherectomy^W contrast;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Iliac artery-- W contrast;RFA Guided Iliac a Atherect--W contr;;ACTIVE;2.38;2.64 +69136-0;Views Sunrise + tunnel;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee Sunrise and Tunnel;XR Knee Sunrise+Tunnel;;ACTIVE;2.38;2.61 +69137-8;Views AP + lateral + oblique^W standing;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left AP and Lateral and oblique W standing;XR Ankle-L AP+Lat+Obl W Stand;;ACTIVE;2.38;2.61 +6913-8;Chlamydophila pneumoniae Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila pneumoniae IgG Ab [Titer] in Serum by Immunofluorescence;C pneum IgG Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69138-6;Views 3^W standing;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left 3 Views W standing;XR Ankle-L 3V W Stand;;ACTIVE;2.38;2.61 +69139-4;Views + lateral crosstable;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Views and Lateral crosstable;XR Hip-L Views+Lat Xtable;;ACTIVE;2.38;2.64 +69140-2;Views + Danelius Miller;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Views and Danelius Miller;XR Hip-L Views+Danelius Miller;;ACTIVE;2.38;2.64 +69141-0;View Danelius Miller;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Danelius Miller;XR Hip-L Danelius Miller;;ACTIVE;2.38;2.61 +69142-8;Views 2 + Sunrise;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 2 Views and Sunrise;XR Knee-L 2V+Sunrise;;ACTIVE;2.38;2.61 +69143-6;(Views 2) + (view tunnel^W standing);Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 2 views and (Tunnel W standing);XR Knee-L 2V+tunnel Stand;;ACTIVE;2.38;2.61 +69144-4;(Views 4) + (view AP^W standing);Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 4 views and (AP W standing);XR Knee-L 4V+AP Stand;;ACTIVE;2.38;2.61 +69145-1;Views 4 + tunnel;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left 4 views and Tunnel;XR Knee-L 4V+Tunnel;;ACTIVE;2.38;2.61 +6914-6;Chlamydophila pneumoniae Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila pneumoniae IgM Ab [Titer] in Serum by Immunofluorescence;C pneum IgM Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69146-9;Views AP + lateral crosstable;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral crosstable;XR Knee-L AP+Lat Xtable;;ACTIVE;2.38;2.61 +69147-7;Views AP + lateral + R-oblique + L-oblique;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP and Lateral and Right oblique and Left oblique;XR Knee-L AP+Lat+R-Obl+L-Obl;;ACTIVE;2.38;2.61 +69148-5;Views + tunnel;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Views and Tunnel;XR Knee-L Views+Tunnel;;ACTIVE;2.38;2.64 +69149-3;(View Sunrise) + (views^W standing);Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left Sunrise and (Views W standing);XR Knee-L Sunrise+views Stand;;ACTIVE;2.38;2.61 +69150-1;Views diagnostic for implant;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Diagnostic for implant;MG Brst-L Dx for implant;;ACTIVE;2.38;2.61 +69151-9;Views 3 scaphoid;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left 3 Scaphoid Views;XR Wrist-L 3V Scaphoid;;ACTIVE;2.38;2.64 +69152-7;View;Find;Pt;Lower extremity.left>Patella;Doc;XR;RAD;2;XR Patella - left Single view;XR Patella-L 1V;;ACTIVE;2.38;2.64 +6915-3;Chlamydophila psittaci Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence;C psittaci IgA Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69153-5;Views AP + Grashey + axillary;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP and Grashey and Axillary;XR Should-L AP+Grashey+Ax;;ACTIVE;2.38;2.61 +69154-3;Views 3 + axillary;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 3 Views and Axillary;XR Should-L 3V+Ax;;ACTIVE;2.38;2.61 +69155-0;Views 3 + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left 3 Views and Y;XR Should-L 3V+Y;;ACTIVE;2.38;2.61 +69156-8;Views Grashey + Y;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Grashey and Y;XR Should-L Grashey+Y;;ACTIVE;2.38;2.61 +69157-6;Views lateral^W flexion + W extension;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Lateral Views W flexion and W extension;XR Wrist-L Views Lat W FE;;ACTIVE;2.38;2.64 +69158-4;Views diagnostic for implant;Find;Pt;Breast;Doc;XR;RAD;2;XR Breast Diagnostic for implant;XR Brst Dx for implant;;ACTIVE;2.38;2.61 +69159-2;Views screening for implant;Find;Pt;Breast;Doc;XR;RAD;2;XR Breast Screening for implant;XR Brst screening for implant;;ACTIVE;2.38;2.61 +691-6;Neisseria gonorrhoeae;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Genital specimen by Organism specific culture;N gonorrhoea Genital Ql Cult;;ACTIVE;1.0;2.73 +69160-0;Guidance for percutaneous aspiration.fine needle &or biopsy.core needle;Find;Pt;Breast;Doc;MG.stereotactic;RAD;2;Deprecated MG stereo Guidance for percutaneous aspiration.fine needle AndOr biopsy.core needle of Breast;Deprecated MG.stereo Brst PC Asp FN +or Bx CN guide;;DEPRECATED;2.38;2.63 +6916-1;Chlamydophila psittaci Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence;C psittaci IgG Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69161-8;Multisection^WO & W contrast IV;Find;Pt;Head+Neck>Circle of Willis;Doc;MR.angio;RAD;2;MRA Circle of Willis WO and W contrast IV;MRA Circle of Willis WO+W contr IV;;ACTIVE;2.38;2.61 +69162-6;Multisection^W contrast IA;Find;Pt;Chest>Pulmonary arteries.bilateral;Doc;MR.angio;RAD;2;MRA Pulmonary artery - bilateral W contrast IA;MRA PA-Bl W contr IA;;ACTIVE;2.38;2.61 +69163-4;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Ankle;Doc;MR;RAD;2;MR Ankle - bilateral W contrast IV;MR Ankle-Bl W contr IV;;ACTIVE;2.38;2.61 +69164-2;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Ankle;Doc;MR;RAD;2;MR Ankle - bilateral WO contrast;MR Ankle-Bl WO contr;;ACTIVE;2.38;2.61 +69165-9;Multisection for implant;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral for implant;MR Brst-Bl for Implant;;ACTIVE;2.38;2.61 +69166-7;Multisection for implant^WO & W contrast IV;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral for implant WO and W contrast IV;MR Brst-Bl for Implant WO+W contr IV;;ACTIVE;2.38;2.61 +69167-5;Multisection for implant^W contrast IV;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral for implant W contrast IV;MR Brst-Bl for Implant W contr IV;;ACTIVE;2.38;2.61 +69168-3;Multisection for implant^WO contrast;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Breast - bilateral for implant WO contrast;MR Brst-Bl for Implant WO contr;;ACTIVE;2.38;2.61 +69169-1;Guidance for percutaneous biopsy;Find;Pt;Breast.bilateral;Doc;MR;RAD;2;MR Guidance for biopsy of Breast - bilateral;MR Guided Brst-Bl Bx;;ACTIVE;2.38;2.64 +69170-9;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Elbow;Doc;MR;RAD;2;MR Elbow - bilateral W contrast IV;MR Elbow-Bl W contr IV;;ACTIVE;2.38;2.61 +69171-7;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Elbow;Doc;MR;RAD;2;MR Elbow - bilateral WO contrast;MR Elbow-Bl WO contr;;ACTIVE;2.38;2.61 +69172-5;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Femur;Doc;MR;RAD;2;MR Femur - bilateral W contrast IV;MR Femur-Bl W contr IV;;ACTIVE;2.38;2.61 +69173-3;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Femur;Doc;MR;RAD;2;MR Femur - bilateral WO contrast;MR Femur-Bl WO contr;;ACTIVE;2.38;2.61 +69174-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral>Forearm;Doc;MR;RAD;2;MR Forearm - bilateral WO and W contrast IV;MR Forearm-Bl WO+W contr IV;;ACTIVE;2.38;2.61 +69175-8;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Forearm;Doc;MR;RAD;2;MR Forearm - bilateral W contrast IV;MR Forearm-Bl W contr IV;;ACTIVE;2.38;2.61 +69176-6;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Forearm;Doc;MR;RAD;2;MR Forearm - bilateral WO contrast;MR Forearm-Bl WO contr;;ACTIVE;2.38;2.61 +69177-4;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral>Hand;Doc;MR;RAD;2;MR Hand - bilateral WO and W contrast IV;MR Hand-Bl WO+W contr IV;;ACTIVE;2.38;2.61 +69178-2;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Hand;Doc;MR;RAD;2;MR Hand - bilateral W contrast IV;MR Hand-Bl W contr IV;;ACTIVE;2.38;2.61 +6917-9;Chlamydophila psittaci Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence;C psittaci IgM Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69179-0;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Hand;Doc;MR;RAD;2;MR Hand - bilateral WO contrast;MR Hand-Bl WO contr;;ACTIVE;2.38;2.61 +69180-8;Multisection;Find;Pt;Upper extremity.bilateral>Upper arm;Doc;MR;RAD;2;MR Upper arm - bilateral;MR Upper arm-Bl;;ACTIVE;2.38;2.61 +69181-6;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral>Upper arm;Doc;MR;RAD;2;MR Upper arm - bilateral WO and W contrast IV;MR Upper arm-Bl WO+W contr IV;;ACTIVE;2.38;2.61 +69182-4;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Upper arm;Doc;MR;RAD;2;MR Upper arm - bilateral W contrast IV;MR Upper arm-Bl W contr IV;;ACTIVE;2.38;2.61 +69183-2;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Upper arm;Doc;MR;RAD;2;MR Upper arm - bilateral WO contrast;MR Upper arm-Bl WO contr;;ACTIVE;2.38;2.61 +69184-0;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;MR;RAD;2;MR Shoulder - bilateral W contrast IV;MR Shoulder-Bl W contr IV;;ACTIVE;2.38;2.61 +69185-7;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Lower leg;Doc;MR;RAD;2;MR Lower leg - bilateral WO contrast;MR Lower leg-Bl WO contr;;ACTIVE;2.38;2.61 +69186-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral;Doc;MR;RAD;2;MR Upper extremity - bilateral WO and W contrast IV;MR UE-Bl WO+W contr IV;;ACTIVE;2.38;2.61 +6918-7;Chlamydia trachomatis Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis IgA Ab [Titer] in Serum by Immunofluorescence;C trach IgA Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69187-3;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral;Doc;MR;RAD;2;MR Upper extremity - bilateral W contrast IV;MR UE-Bl W contr IV;;ACTIVE;2.38;2.61 +69188-1;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral;Doc;MR;RAD;2;MR Upper extremity - bilateral WO contrast;MR UE-Bl WO contr;;ACTIVE;2.38;2.61 +69189-9;Multisection for implant^WO & W contrast IV;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast for implant WO and W contrast IV;MR Brst for Implant WO+W contr IV;;ACTIVE;2.38;2.61 +69190-7;Multisection for implant^W contrast IV;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast for implant W contrast IV;MR Brst for Implant W contr IV;;ACTIVE;2.38;2.61 +69191-5;Multisection for implant^WO contrast;Find;Pt;Breast;Doc;MR;RAD;2;MR Breast for implant WO contrast;MR Brst for Implant WO contr;;ACTIVE;2.38;2.61 +69192-3;Guidance for percutaneous aspiration of cyst;Find;Pt;Breast;Doc;MR;RAD;2;MR Guidance for aspiration of cyst of Breast;MR Guided Brst Cyst asp;;ACTIVE;2.38;2.64 +69193-1;Multisection;Find;Pt;Extremity;Doc;MR;RAD;2;MR Extremity;MR Extr;;ACTIVE;2.38;2.61 +69194-9;Multisection^WO & W contrast IV;Find;Pt;Upper extremity>Finger;Doc;MR;RAD;2;MR Finger WO and W contrast IV;MR Finger WO+W contr IV;;ACTIVE;2.38;2.61 +6919-5;Chlamydia trachomatis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis IgG Ab [Titer] in Serum by Immunofluorescence;C trach IgG Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69195-6;Multisection^W contrast IV;Find;Pt;Upper extremity>Finger;Doc;MR;RAD;2;MR Finger W contrast IV;MR Finger W contr IV;;ACTIVE;2.38;2.61 +69196-4;Multisection^WO contrast;Find;Pt;Upper extremity>Finger;Doc;MR;RAD;2;MR Finger WO contrast;MR Finger WO contr;;ACTIVE;2.38;2.61 +69197-2;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Liver;Doc;MR;RAD;2;MR Guidance for biopsy of Liver;MR Guided Liver Bx;;ACTIVE;2.38;2.64 +69198-0;Guidance for percutaneous biopsy;Find;Pt;XXX>Muscle;Doc;MR;RAD;2;MR Guidance for biopsy of Muscle;MR Guided Muscle Bx;;ACTIVE;2.38;2.64 +69199-8;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Pancreas;Doc;MR;RAD;2;MR Guidance for biopsy of Pancreas;MR Guided Pancreas Bx;;ACTIVE;2.38;2.64 +69200-4;Guidance for biopsy;Find;Pt;Chest>Pleura;Doc;MR;RAD;2;MR Guidance for biopsy of Chest Pleura;MR Guided Chest Pleura Bx;;ACTIVE;2.38;2.64 +69201-2;Guidance for biopsy;Find;Pt;Head>Salivary gland;Doc;MR;RAD;2;MR Guidance for biopsy of Salivary gland;MR Guided Salivary gland Bx;;ACTIVE;2.38;2.64 +69202-0;Guidance for percutaneous biopsy;Find;Pt;Neck>Thyroid gland;Doc;MR;RAD;2;MR Guidance for biopsy of Thyroid gland;MR Guided Thyroid Bx;;ACTIVE;2.38;2.64 +6920-3;Chlamydia trachomatis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Chlamydia trachomatis IgM Ab [Titer] in Serum by Immunofluorescence;C trach IgM Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69203-8;Guidance for percutaneous biopsy;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Guidance for biopsy of Breast - left;MR Guided Brst-L Bx;;ACTIVE;2.38;2.64 +69204-6;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.left>Finger;Doc;MR;RAD;2;MR Finger - left WO and W contrast IV;MR Finger-L WO+W contr IV;;ACTIVE;2.38;2.61 +69205-3;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Finger;Doc;MR;RAD;2;MR Finger - left W contrast IV;MR Finger-L W contr IV;;ACTIVE;2.38;2.61 +69206-1;Multisection^WO contrast;Find;Pt;Upper extremity.left>Finger;Doc;MR;RAD;2;MR Finger - left WO contrast;MR Finger-L WO contr;;ACTIVE;2.38;2.61 +69207-9;Multisection^WO & W contrast IS;Find;Pt;Lower extremity.left>Hip;Doc;MR;RAD;2;MR Hip - left Arthrogram WO and W contrast;MR Hip-L WO+W contr IS;;ACTIVE;2.38;2.61 +69208-7;Multisection^WO & W contrast IS;Find;Pt;Upper extremity.left>Shoulder;Doc;MR;RAD;2;MR Shoulder - left Arthrogram WO and W contrast;MR Should-L WO+W contr IS;;ACTIVE;2.38;2.61 +69209-5;Multisection;Find;Pt;Upper extremity.left>Wrist+Hand;Doc;MR;RAD;2;MR Wrist - left and Hand - left;MR Wrist+Hand-L;;ACTIVE;2.38;2.61 +69210-3;Multisection^W contrast IS;Find;Pt;Lower extremity>Lower extremity joint;Doc;MR;RAD;2;MR Lower Extremity Joint Arthrogram;MR LE joint W contr IS;;ACTIVE;2.38;2.65 +6921-1;Cytomegalovirus Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;CMV IgG CSF IA-aCnc;;ACTIVE;1.0h(2);2.73 +69211-1;Multisection;Find;Pt;Head>Nasal bones;Doc;MR;RAD;2;MR Nasal bones;MR Nasal bones;;ACTIVE;2.38;2.61 +69212-9;Multisection limited;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis limited;MR Pelvis Ltd;;ACTIVE;2.38;2.61 +69213-7;Guidance for percutaneous biopsy;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Guidance for biopsy of Breast - right;MR Guided Brst-R Bx;;ACTIVE;2.38;2.64 +69214-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.right>Finger;Doc;MR;RAD;2;MR Finger - right WO and W contrast IV;MR Finger-R WO+W contr IV;;ACTIVE;2.38;2.61 +69215-2;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Finger;Doc;MR;RAD;2;MR Finger - right W contrast IV;MR Finger-R W contr IV;;ACTIVE;2.38;2.61 +69216-0;Multisection^WO contrast;Find;Pt;Upper extremity.right>Finger;Doc;MR;RAD;2;MR Finger - right WO contrast;MR Finger-R WO contr;;ACTIVE;2.38;2.61 +69217-8;Multisection^WO & W contrast IS;Find;Pt;Lower extremity.right>Hip;Doc;MR;RAD;2;MR Hip - right Arthrogram WO and W contrast;MR Hip-R WO+W contr IS;;ACTIVE;2.38;2.61 +69218-6;Multisection^WO & W contrast IS;Find;Pt;Upper extremity.right>Shoulder;Doc;MR;RAD;2;MR Shoulder - right Arthrogram WO and W contrast;MR Should-R WO+W contr IS;;ACTIVE;2.38;2.61 +69219-4;Multisection;Find;Pt;Upper extremity.right>Wrist+Hand;Doc;MR;RAD;2;MR Wrist - right and Hand - right;MR Wrist+Hand-R;;ACTIVE;2.38;2.61 +69220-2;Multisection^WO & W contrast IV;Find;Pt;Head>Skull.base;Doc;MR;RAD;2;MR Skull base WO and W contrast IV;MR Skull.base WO+W contr IV;;ACTIVE;2.38;2.61 +69221-0;Multisection^W contrast IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;MR;RAD;2;MR Scrotum and testicle W contrast IV;MR Scrotum+Test W contr IV;;ACTIVE;2.38;2.61 +69222-8;Multisection;Find;Pt;Chest+Abdomen>Vena cava.superior &or Vena cava.inferior;Doc;MR;RAD;2;MR Vena cava;MR Vena cava;;ACTIVE;2.38;2.61 +69223-6;Multisection^WO contrast;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region WO contrast;MR WO contr;;ACTIVE;2.38;2.69 +69224-4;Guidance for biopsy.needle;Find;Pt;Abdomen;Doc;RF;RAD;2;Deprecated RF Guidance for needle biopsy of Abdomen;Deprecated RF Abd Bx needle guide;;DEPRECATED;2.38;2.63 +69225-1;Guidance for biopsy.needle;Find;Pt;Chest;Doc;RF;RAD;2;Deprecated RF Guidance for needle biopsy of Chest;Deprecated RF Chest Bx needle guide;;DEPRECATED;2.38;2.63 +69226-9;Guidance for percutaneous biopsy;Find;Pt;XXX>Muscle;Doc;RF;RAD;2;RF Guidance for biopsy of Muscle;RF Guided Muscle Bx;;ACTIVE;2.38;2.64 +69227-7;Guidance for biopsy.needle;Find;Pt;Pleura;Doc;XR.fluor;RAD;2;Deprecated Fluoroscopy Guidance for needle biopsy of Pleura;Deprecated;;DEPRECATED;2.38;2.58 +69228-5;Guidance for biopsy.needle;Find;Pt;Pelvis>Prostate;Doc;RF;RAD;2;Deprecated RF Guidance for needle biopsy of Prostate;Deprecated RF Prostate Bx needle guide;;DEPRECATED;2.38;2.63 +6922-9;Echovirus 7 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 7 Ab [Titer] in Serum by Complement fixation;ECV7 Ab Titr Ser CF;;ACTIVE;1.0h(2);2.73 +69229-3;Multisection^W Tc-99m SC IV;Find;Pt;Abdomen>Liver;Doc;NM.SPECT;RAD;2;SPECT Liver W Tc-99m SC IV;SPECT Liver W Tc99mSC IV;;ACTIVE;2.38;2.61 +69230-1;Views^W Tc-99m SC IV;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views W Tc-99m SC IV;NM Liver Views W Tc99mSC IV;;ACTIVE;2.38;2.64 +69231-9;Views^W stress+W Tc-99m IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W stress and W Tc-99m IV;NM Hrt Views W Stress+W Tc-99m IV;;ACTIVE;2.38;2.64 +69232-7;Views^W stress+W Tc-99m Sestamibi IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Views W stress and W Tc-99m Sestamibi IV;NM Hrt Views W Stress+W Tc99mMIBI IV;;ACTIVE;2.38;2.64 +69233-5;Views^W Tc-99m pertechnetate IV;Find;Pt;Neck>Parotid gland;Doc;NM;RAD;2;NM Parotid gland Views W Tc-99m pertechnetate IV;NM Parotid gland Views W Tc99mP IV;;ACTIVE;2.38;2.64 +69234-3;Multisection^W Tc-99m tagged RBC IV;Find;Pt;Abdomen>Spleen;Doc;NM.SPECT;RAD;2;SPECT Spleen W Tc-99m tagged RBC IV;SPECT Spleen W Tc99m RBC IV;;ACTIVE;2.38;2.63 +69235-0;Multisection for blood flow^W radionuclide IV;Find;Pt;Pelvis>Scrotum+Testicle;Doc;NM.SPECT;RAD;2;SPECT Scrotum and testicle for blood flow;SPECT Scrotum+Test bld flow W RNC IV;;ACTIVE;2.38;2.61 +69236-8;Views+views uptake^W I-131 PO;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views and Views uptake W I-131 PO;NM Thyroid Views+views uptake W I-131 PO;;ACTIVE;2.38;2.64 +6923-7;Adrenal cortex Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Adrenal cortex Ab [Units/volume] in Serum by Immunofluorescence;Adrenal cortex Ab Ser IF-aCnc;;ACTIVE;1.0h(2);2.69 +69237-6;Multisection for tumor^W radionuclide IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body for tumor;SPECT Whole body for Tumor W RNC IV;;ACTIVE;2.38;2.61 +69238-4;Multisection^W contrast intra bladder+during voiding;Find;Pt;Pelvis>Urinary bladder+Urethra;Doc;NM.SPECT;RAD;2;SPECT Urinary bladder and Urethra W contrast intra bladder during voiding;SPECT Bladder+Urethra W contr IB void;;ACTIVE;2.38;2.64 +69239-2;View Sunrise;Find;Pt;Lower extremity>Patella;Doc;XR;RAD;2;XR Patella Sunrise;XR Patella Sunrise;;ACTIVE;2.38;2.61 +692-4;Neisseria gonorrhoeae;PrThr;Pt;Genital loc;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Genital lochia by Organism specific culture;N gonorrhoea Gen lochia Ql Cult;;ACTIVE;1.0;2.56 +69240-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen;Doc;RF;RAD;2;Deprecated RF guidance for percutaneous biopsy of Abdomen;Deprecated RF Abd PC bx;;DEPRECATED;2.38;2.63 +69241-8;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Abdomen;RF Guided Abd PC Absc drn+cath place;;ACTIVE;2.38;2.66 +69242-6;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen+Pelvis>Appendix;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Appendix;RF Guided Appendix PC Absc drn+cath plc;;ACTIVE;2.38;2.66 +69243-4;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;Chest>Lung;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Lung;RF Guided Lung PC Absc drn+cath place;;ACTIVE;2.38;2.66 +69244-2;Guidance for percutaneous drainage of abscess+placement of drainage catheter;Find;Pt;Pelvis;Doc;RF;RAD;2;RF Guidance for percutaneous drainage of abscess and placement of drainage catheter of Pelvis;RF Guided Pelvis PC Absc drn+cath place;;ACTIVE;2.38;2.66 +6924-5;Gliadin Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Gliadin IgA Ab [Units/volume] in Serum;Gliadin IgA Ser-aCnc;;ACTIVE;1.0h(2);2.73 +69245-9;Guidance for percutaneous biopsy.needle;Find;Pt;Abdomen>Kidney;Doc;RF;RAD;2;Deprecated RF Guidance for percutaneous biopsy.needle of Kidney;Deprecated RF Kidney PC Bx needle guide;;DEPRECATED;2.38;2.63 +69246-7;Guidance for percutaneous biopsy.needle;Find;Pt;Abdomen>Liver;Doc;RF;RAD;2;Deprecated RF Guidance for percutaneous biopsy.needle of Liver;Deprecated RF Liver PC Bx needle guide;;DEPRECATED;2.38;2.63 +69247-5;Guidance for percutaneous biopsy.needle;Find;Pt;Head>Salivary gland;Doc;RF;RAD;2;Deprecated RF Guidance for percutaneous biopsy.needle of Salivary gland;Deprecated RF Salivary gland PC Bx needle guide;;DEPRECATED;2.38;2.63 +69248-3;Guidance for percutaneous transluminal angioplasty^W contrast IA;Find;Pt;Abdomen>Renal artery;Doc;RF.angio;RAD;2;RFA Guidance for percutaneous transluminal angioplasty of Renal artery-- W contrast IA;RFA Guided Renal a PTA--W contr IA;;ACTIVE;2.38;2.64 +69249-1;Views^W contrast IA;Find;Pt;Lower extremity>Popliteal artery;Doc;RF.angio;RAD;2;RFA Popliteal artery Views W contrast IA;RFA Pop a Views W contr IA;;ACTIVE;2.38;2.64 +69250-9;Views^W contrast IV;Find;Pt;Abdomen>Portal vein;Doc;RF.angio;RAD;2;RFA Portal vein Views W contrast IV;RFA Portal v Views W contr IV;;ACTIVE;2.38;2.64 +69251-7;Views^post wire placement;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Views Post Wire Placement;MG Brst Views p wire place;;ACTIVE;2.38;2.64 +6925-2;Ganglioside GM1 Ab.IgG;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 IgG Ab [Titer] in Serum;GM1 Gangl IgG Titr Ser;;ACTIVE;1.0h(2);2.73 +69252-5;Guidance for percutaneous transluminal angioplasty^W contrast IA;Find;Pt;Chest>Pulmonary arteries;Doc;RF.angio;RAD;2;RFA Guidance for percutaneous transluminal angioplasty of Pulmonary arteries-- W contrast IA;RFA Guided PA PTA--W contr IA;;ACTIVE;2.38;2.64 +69253-3;Guidance for atherectomy^W contrast;Find;Pt;Abdomen>Renal vessels;Doc;RF.angio;RAD;2;RFA Guidance for atherectomy of Renal vessels-- W contrast;RFA Guided Renal ves Atherect--W contr;;ACTIVE;2.38;2.64 +69254-1;Views 3^W standing;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right 3 Views W standing;XR Ankle-R 3V W Stand;;ACTIVE;2.38;2.61 +69255-8;(View Sunrise) + (View tunnel^W standing);Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Sunrise and (Tunnel W standing);XR Knee-R Sunrise+tunnel Stand;;ACTIVE;2.38;2.61 +69256-6;View Sunrise;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right Sunrise;XR Knee-R Sunrise;;ACTIVE;2.38;2.61 +69257-4;Views 2;Find;Pt;Lower extremity.right;Doc;XR;RAD;2;XR Lower extremity - right 2 Views;XR LE-R 2V;;ACTIVE;2.38;2.61 +69258-2;Views AP + lateral;Find;Pt;Lower extremity.right;Doc;XR;RAD;2;XR Lower extremity - right AP and Lateral;XR LE-R AP+Lat;;ACTIVE;2.38;2.61 +69259-0;Views diagnostic for implant;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Diagnostic for implant;MG Brst-R Dx for implant;;ACTIVE;2.38;2.61 +6926-0;Ganglioside GM1 Ab.IgM;Titr;Pt;Ser;Qn;;SERO;1;Ganglioside GM1 IgM Ab [Titer] in Serum;GM1 Gangl IgM Titr Ser;;ACTIVE;1.0h(2);2.73 +69260-8;View;Find;Pt;Lower extremity.right>Patella;Doc;XR;RAD;2;XR Patella - right Single view;XR Patella-R 1V;;ACTIVE;2.38;2.64 +69261-6;Views 3;Find;Pt;Lower extremity.right>Patella;Doc;XR;RAD;2;XR Patella - right 3 Views;XR Patella-R 3V;;ACTIVE;2.38;2.61 +69262-4;Views AP + Grashey + axillary;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP and Grashey and Axillary;XR Should-R AP+Grashey+Ax;;ACTIVE;2.38;2.61 +69263-2;View PA^W clenched fist;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right PA W clenched fist;XR Wrist-R PA W clenched fist;;ACTIVE;2.38;2.61 +69264-0;Views^W standing;Find;Pt;Pelvis>Sacrum;Doc;XR;RAD;2;XR Sacrum Views W standing;XR Sacrum Views W Stand;;ACTIVE;2.38;2.64 +69265-7;Views 4;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder 4 Views;XR Should 4V;;ACTIVE;2.38;2.61 +69266-5;Views AP + Y;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP and Y;XR Should AP+Y;;ACTIVE;2.38;2.61 +69267-3;Views Grashey + axillary + Y;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder Grashey and Axillary and Y;XR Should Grashey+Ax+Y;;ACTIVE;2.38;2.61 +69268-1;View^W contrast intra duct;Find;Pt;Breast>Breast duct;Doc;MG;RAD;2;MG Breast duct Single view W contrast intra duct;MG Brst duct 1V W contr intra Dct;;ACTIVE;2.38;2.64 +69269-9;View AP;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull AP;XR Skull AP;;ACTIVE;2.38;2.61 +69270-7;View PA;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull PA;XR Skull PA;;ACTIVE;2.38;2.61 +69271-5;Views PA + lateral + Waters + Towne;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull PA and Lateral and Waters and Towne;XR Skull PA+lateral+Waters+Towne;;ACTIVE;2.38;2.61 +69272-3;Views^W contrast via ileostomy;Find;Pt;Abdomen>Small bowel;Doc;RF;RAD;2;RF Small bowel Views W contrast via ileostomy;RF SB Views W cntr via ileostomy;;ACTIVE;2.38;2.64 +69273-1;Views 2;Find;Pt;Chest+Abdomen>Spine.thoracolumbar junction;Doc;XR;RAD;2;XR Spine thoracolumbar junction 2 Views;XR TLJ 2V;;ACTIVE;2.38;2.61 +69274-9;Views 2^W standing;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine 2 Views W standing;XR T-spine 2V W Stand;;ACTIVE;2.38;2.61 +69275-6;Views^W standing;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Views W standing;XR T-spine Views W Stand;;ACTIVE;2.38;2.64 +69276-4;Multisection;Find;Pt;Abdomen>Aorta.abdominal;Doc;US;RAD;2;US Abdominal Aorta;US Abd Aorta;;ACTIVE;2.38;2.73 +69277-2;Multisection;Find;Pt;Abdomen>Adrenal gland;Doc;US;RAD;2;US Adrenal gland;US Adrenal;;ACTIVE;2.38;2.73 +6927-8;Platelet Ab.IgG;PrThr;Pt;Ser;Ord;Flow cytometry;SERO;1;Platelet IgG Ab [Presence] in Serum by Flow cytometry (FC);Platelet IgG Ser Ql FC;;ACTIVE;1.0h(2);2.73 +69278-0;Guidance for percutaneous aspiration of fluid;Find;Pt;Breast.bilateral;Doc;US;RAD;2;US Guidance for fluid aspiration of Breast - bilateral;US Guided Brst-Bl PC fluid asp;;ACTIVE;2.38;2.64 +69279-8;Guidance for biopsy.core needle;Find;Pt;XXX>Lymph node;Doc;US;RAD;2;US Guidance for core needle biopsy of Lymph node;US Guided LN CN Bx;;ACTIVE;2.38;2.64 +69280-6;Multisection limited;Find;Pt;Pelvis>Urinary bladder;Doc;US;RAD;2;US Urinary bladder limited;US Bladder Ltd;;ACTIVE;2.38;2.61 +69281-4;Multisection limited;Find;Pt;Chest;Doc;US;RAD;2;US Chest limited;US Chest Ltd;;ACTIVE;2.38;2.61 +69282-2;Multisection limited;Find;Pt;XXX;Doc;US.doppler;RAD;2;US.doppler Unspecified body region limited;DOP Ltd Unsp region;;ACTIVE;2.38;2.64 +69283-0;Multisection;Find;Pt;Extremity.bilateral>Extremity veins;Doc;US.doppler;RAD;2;US.doppler Extremity veins - bilateral;DOP Extr vv-Bl;;ACTIVE;2.38;2.61 +69284-8;Multisection;Find;Pt;Abdomen>Portal vein+Hepatic vein;Doc;US.doppler;RAD;2;US.doppler Portal vein and Hepatic vein;DOP Portal v+Hepatic v;;ACTIVE;2.38;2.61 +69285-5;Multisection;Find;Pt;Umbilical artery^Fetus;Doc;US.doppler;RAD;2;US.doppler Umbilical artery Fetal;DOP Umb a Fet;;ACTIVE;2.38;2.61 +6928-6;Rheumatoid factor;ACnc;Pt;Ser;Qn;IA;SERO;1;Rheumatoid factor [Units/volume] in Serum by Immunoassay;Rheumatoid fact Ser IA-aCnc;;ACTIVE;1.0h(2);2.73 +69286-3;Multisection limited;Find;Pt;Head>Eye;Doc;US;RAD;2;US Eye limited;US Eye Ltd;;ACTIVE;2.38;2.61 +69287-1;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Lymph node;Doc;US;RAD;2;US Guidance for fluid aspiration of Lymph node;US Guided LN PC fluid asp;;ACTIVE;2.38;2.64 +69288-9;Guidance for biopsy.needle;Find;Pt;XXX>Muscle;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Muscle;Deprecated US Muscle Bx needle guide;;DEPRECATED;2.38;2.63 +69289-7;Guidance for biopsy.needle;Find;Pt;Abdomen>Pancreas;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Pancreas;Deprecated US Pancreas Bx needle guide;;DEPRECATED;2.38;2.63 +69290-5;Guidance for biopsy.needle;Find;Pt;Breast.right;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Breast - right;Deprecated US Brst-R Bx needle guide;;DEPRECATED;2.38;2.63 +69291-3;Guidance for biopsy.needle;Find;Pt;Head>Salivary gland;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Salivary gland;Deprecated US Salivary gland Bx needle guide;;DEPRECATED;2.38;2.63 +69292-1;Guidance for percutaneous aspiration of fluid;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for fluid aspiration of Breast - left;US Guided Brst-L PC fluid asp;;ACTIVE;2.38;2.64 +69293-9;Multisection;Find;Pt;Extremity.left>Extremity artery;Doc;US;RAD;2;US Extremity artery - left;US Extr a-L;;ACTIVE;2.38;2.61 +6929-4;Aluminum;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in 24 hour Urine;Aluminum 24h Ur-mCnc;;ACTIVE;1.0h(2);2.73 +69294-7;Multisection;Find;Pt;Abdomen>Renal artery;Doc;US;RAD;2;US Renal artery;US Renal a;;ACTIVE;2.38;2.73 +69295-4;Multisection;Find;Pt;Abdomen>Renal vessels;Doc;US;RAD;2;US Renal vessels;US Renal ves;;ACTIVE;2.38;2.73 +69296-2;Guidance for percutaneous aspiration of fluid;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for fluid aspiration of Breast - right;US Guided Brst-R PC fluid asp;;ACTIVE;2.38;2.64 +69297-0;Multisection;Find;Pt;Extremity.right>Extremity artery;Doc;US;RAD;2;US Extremity artery - right;US Extr a-R;;ACTIVE;2.38;2.61 +69298-8;Multisection;Find;Pt;Head>Salivary gland;Doc;US;RAD;2;US Salivary gland;US Salivary gland;;ACTIVE;2.38;2.61 +69299-6;Multisection limited;Find;Pt;Pelvis>Scrotum+Testicle;Doc;US;RAD;2;US Scrotum and testicle limited;US Scrotum+Test Ltd;;ACTIVE;2.38;2.61 +69300-2;Multisection limited for transplanted kidney;Find;Pt;Pelvis;Doc;US;RAD;2;US for transplanted kidney limited;US for transplanted kidney Ltd;;ACTIVE;2.38;2.64 +69301-0;Guidance for percutaneous transluminal angioplasty^W contrast IV;Find;Pt;Upper extremity>Upper extremity vein;Doc;RF.angio;RAD;2;RFA Guidance for percutaneous transluminal angioplasty of Upper extremity vein-- W contrast IV;RFA Guided UE v PTA--W contr IV;;ACTIVE;2.38;2.64 +6930-2;Psilocybin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Psilocybin [Mass/volume] in Urine;Psilocybin Ur-mCnc;;ACTIVE;1.0h(2);2.42 +69302-8;View^W clenched fist;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Single view W clenched fist;XR Wrist 1V W clenched fist;;ACTIVE;2.38;2.64 +69303-6;Views ulnar deviation + radial deviation;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Ulnar deviation and Radial deviation;XR Wrist Ulnar+Radial Deviation;;ACTIVE;2.38;2.61 +69304-4;Views ulnar deviation;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist Ulnar deviation Views;XR Wrist Views ulnar dev;;ACTIVE;2.38;2.73 +69305-1;Views 2;Find;Pt;Head>Zygomatic arch;Doc;XR;RAD;2;XR Zygomatic arch 2 Views;XR Zygomatic arch 2V;;ACTIVE;2.38;2.61 +69306-9;Guidance for percutaneous aspiration of cyst;Find;Pt;XXX>Bone;Doc;RF;RAD;2;RF Guidance for aspiration of cyst of Bone;RF Guided Bone Cyst asp;;ACTIVE;2.38;2.64 +69307-7;View;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Single view;XR Ankle-L 1V;;ACTIVE;2.38;2.64 +69308-5;View;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left Single view;XR Elbow-L 1V;;ACTIVE;2.38;2.64 +69309-3;View;Find;Pt;Lower extremity.left>Foot;Doc;XR;RAD;2;XR Foot - left Single view;XR Foot-L 1V;;ACTIVE;2.38;2.64 +6931-0;Silver;MRat;24H;Urine;Qn;;DRUG/TOX;1;Silver [Mass/time] in 24 hour Urine;Silver 24h Ur-mRate;;ACTIVE;1.0h(2);2.73 +69310-1;View;Find;Pt;Upper extremity.left>Hand;Doc;XR;RAD;2;XR Hand - left Single view;XR Hand-L 1V;;ACTIVE;2.38;2.64 +69311-9;View;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Single view;XR Heel-L 1V;;ACTIVE;2.38;2.64 +69312-7;View;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left Single view;XR Humerus-L 1V;;ACTIVE;2.38;2.64 +69313-5;View;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left Single view;XR Tib+Fib-L 1V;;ACTIVE;2.38;2.64 +69314-3;View;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Single view;XR Ankle-R 1V;;ACTIVE;2.38;2.64 +69315-0;View;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Single view;XR Elbow-R 1V;;ACTIVE;2.38;2.64 +69316-8;View;Find;Pt;Lower extremity.right>Foot;Doc;XR;RAD;2;XR Foot - right Single view;XR Foot-R 1V;;ACTIVE;2.38;2.64 +69317-6;View;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right Single view;XR Radius+Ulna-R 1V;;ACTIVE;2.38;2.64 +69318-4;View;Find;Pt;Upper extremity.right>Hand;Doc;XR;RAD;2;XR Hand - right Single view;XR Hand-R 1V;;ACTIVE;2.38;2.64 +69319-2;View;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Single view;XR Heel-R 1V;;ACTIVE;2.38;2.64 +693-2;Neisseria gonorrhoeae;PrThr;Pt;Vag;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Vaginal fluid by Organism specific culture;N gonorrhoea Vag Ql Cult;;ACTIVE;1.0;2.73 +69320-0;View;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right Single view;XR Humerus-R 1V;;ACTIVE;2.38;2.64 +69321-8;View;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right Single view;XR Tib+Fib-R 1V;;ACTIVE;2.38;2.64 +69322-6;Health insurance plan benefits comment;Find;Pt;^Patient;Nar;;MISC;1;Health insurance plan benefits comment;Health insurance plan benefits comment;;ACTIVE;2.38;2.38 +69323-4;Changed medical regimen diagnoses - OASIS - B1;-;Pt;^Patient;-;OASIS;PANEL.SURVEY.OASIS;4;Changed medical regimen diagnoses - OASIS - B1 [OASIS];;;ACTIVE;2.38;2.44 +69324-2;Patient history and diagnosis - start of care, resumption of care;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Deprecated Patient history and diagnosis - start of care, resumption of care [OASIS-C];;;DEPRECATED;2.38;2.73 +69325-9;Diagnosis and severity index - OASIS B1;-;Pt;^Patient;-;OASIS;PANEL.SURVEY.OASIS;4;Diagnosis and severity index - OASIS B1 [OASIS];;;ACTIVE;2.38;2.73 +69326-7;Patient information - acute;-;Pt;^Patient;-;CARE;PANEL.SURVEY.OASIS;4;Patient information - acute [CARE];;;DISCOURAGED;2.38;2.67 +69327-5;Patient history and diagnosis - follow-up;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Deprecated Patient history and diagnosis - follow-up [OASIS-C];;;DEPRECATED;2.38;2.73 +6932-8;Penicillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Penicillin [Susceptibility] by Minimum inhibitory concentration (MIC);Penicillin Islt MIC;;ACTIVE;1.0h(2);2.73 +69328-3;Patient history and diagnosis - transfer to facility, discharge from agency;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Deprecated Patient history and diagnosis - transfer to facility, discharge from agency [OASIS-C];;;DEPRECATED;2.38;2.73 +69329-1;Data items collected at inpatient facility admission or agency discharge only - death at home;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Data items collected at inpatient facility admission or agency discharge only - death at home [OASIS-C];;;DISCOURAGED;2.38;2.73 +69330-9;Data items collected at inpatient facility admission or agency discharge only - transfer to facility;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Data items collected at inpatient facility admission or agency discharge only - OASIS-C - transfer to facility [OASIS-C];;;ACTIVE;2.38;2.44 +69331-7;Data items collected at inpatient facility admission or agency discharge only - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Data items collected at inpatient facility admission or agency discharge only - discharge from agency [CMS Assessment];;;ACTIVE;2.38;2.61 +69332-5;Neuro & emotional & behavioral status - discharge from agency;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Neuro and emotional and behavioral status - discharge from agency [CMS Assessment];;;ACTIVE;2.38;2.67 +69333-3;Neuro & emotional & behavioral status - resumption of care;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Neuro and emotional and behavioral status - resumption of care [OASIS-C];;;ACTIVE;2.38;2.44 +69334-1;Neuro & emotional & behavioral status - start of care;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Neuro and emotional and behavioral status - start of care [OASIS-C];;;ACTIVE;2.38;2.44 +69335-8;Therapy need and plan of care - follow-up;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;Deprecated Therapy need and plan of care - follow-up [OASIS-C];;;DEPRECATED;2.38;2.73 +6933-6;Streptomycin.high potency;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Streptomycin.high potency [Susceptibility] by Minimum inhibitory concentration (MIC);Streptomycin High Pot Islt MIC;;ACTIVE;1.0h(2);2.73 +69336-6;ADL and IADLs - follow-up;-;Pt;^Patient;-;OASIS-C;PANEL.SURVEY.OASIS;4;ADL and IADLs - follow-up [OASIS-C];;;ACTIVE;2.38;2.61 +69337-4;ADL and IADLs - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;ADL and IADLs - discharge [CMS Assessment];;;ACTIVE;2.38;2.61 +69338-2;One or more unhealed pressure ulcer(s) at stage 2 or higher - interim, post acute care discharge;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;One or more unhealed pressure ulcer(s) at stage 2 or higher - CARE - interim, PAC discharge [CARE];;;DISCOURAGED;2.38;2.64 +69339-0;Influenza vaccine;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Influenza vaccine [CMS Assessment];;;ACTIVE;2.38;2.74 +69340-8;Administrative items - interim, discharge;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Administrative items - interim, discharge [CARE];;;DISCOURAGED;2.38;2.73 +69341-6;Administrative items - expired;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Administrative items - expired [CARE];;;DISCOURAGED;2.38;2.73 +69342-4;Patient information - expired;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Patient information - expired [CARE];;;DISCOURAGED;2.38;2.64 +69343-2;Patient information - interim, discharge;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Patient information - interim, discharge [CARE];;;DISCOURAGED;2.38;2.64 +6934-4;RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;RAST class [Presence] in Serum;RAST class Ql;;ACTIVE;1.0h(2);2.73 +69344-0;Laboratory - acute;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Laboratory - acute [CARE];;;DISCOURAGED;2.38;2.64 +69345-7;Physical findings - DEEDS 1.0;Find;Pt;Genitalia;Nar;;ED;2;Physical findings - DEEDS 1.0 Genitalia Narrative;Physical findings - DEEDS 1.0 Genitalia;;ACTIVE;2.38;2.4 +69346-5;Endotracheal tube activity;Find;Pt;^Patient;Ord;;SURVEY.CERNER;4;Endotracheal tube activity;;;TRIAL;2.38;2.4 +69347-3;Artificial airway;Type;Pt;^Patient;Ord;;SURVEY.CERNER;4;Artificial airway;;;TRIAL;2.38;2.4 +69348-1;Respiratory assist status;Find;Pt;^Patient;Ord;;PULM;2;Respiratory assist status;Respiratory assist status;;ACTIVE;2.38;2.7 +69349-9;Presence of pressure ulcers - acute;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Presence of pressure ulcers - acute [CARE];;;DISCOURAGED;2.38;2.64 +69350-7;Temporal orientation &or mental status - acute;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Temporal orientation and/or mental status - acute [CARE];;;DISCOURAGED;2.38;2.64 +6935-1;Alpha aminoadipate;MRat;24H;Urine;Qn;;CHEM;1;Alpha aminoadipate [Mass/time] in 24 hour Urine;AAA 24h Ur-mRate;;DISCOURAGED;1.0h(2);2.73 +69351-5;Medical coding information - admission, home health;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Medical coding information - admission, home health [CARE];;;DISCOURAGED;2.38;2.73 +69352-3;Admission information - home health;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Admission information - home health [CARE];;;DISCOURAGED;2.38;2.64 +69353-1;HIV 2 RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;HIV 2 RNA [Presence] in Serum or Plasma by NAA with probe detection;HIV 2 RNA SerPl Ql NAA+probe;;ACTIVE;2.38;2.63 +69354-9;HIV 2 RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;HIV 2 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HIV 2 RNA SerPl NAA+probe-aCnc;;ACTIVE;2.38;2.7 +69355-6;Parvovirus B19 DNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;B19V DNA SerPl NAA+probe-Log#;;ACTIVE;2.38;2.73 +69356-4;oxyCODONE;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;oxyCODONE [Presence] in Saliva (oral fluid) by Screen method;oxyCODONE Sal Ql Scn;;ACTIVE;2.38;2.73 +69357-2;Amylase^post CFst;CCnc;Pt;Ser/Plas;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Serum or Plasma --fasting;Amylase p fast SerPl-cCnc;;ACTIVE;2.38;2.7 +69358-0;Cells.HPV E6+E7 mRNA/cells;PrThr;Pt;Cvx;Ord;Flow cytometry;MICRO;1;HPV E6+E7 mRNA cells/cells [Presence] in Cervix by Flow cytometry (FC);HPV E6+E7 mRNA cells/cells Cvx Ql FC;;ACTIVE;2.38;2.73 +69359-8;Amylase^2nd specimen post XXX challenge;CCnc;Pt;Ser/Plas;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Serum or Plasma --2nd specimen post XXX challenge;Amylase sp2 p chal SerPl-cCnc;;ACTIVE;2.38;2.7 +69360-6;Amylase^1st specimen post XXX challenge;CCnc;Pt;Ser/Plas;Qn;;CHAL;1;Amylase [Enzymatic activity/volume] in Serum or Plasma --1st specimen post XXX challenge;Amylase sp1 p chal SerPl-cCnc;;ACTIVE;2.38;2.7 +69361-4;PCA3 score;NRto;Pt;Urine;Qn;Molgen;MOLPATH;1;PCA3 score in Urine by Molecular genetics method;PCA3 score Ur;;ACTIVE;2.38;2.73 +69362-2;PCA3 score;Imp;Pt;Urine;Ord;Molgen;MOLPATH;1;PCA3 score in Urine Qualitative by Molecular genetics method;PCA3 score Ur;;ACTIVE;2.38;2.73 +69363-0;SERPINA10 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SERPINA10 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SERPINA10 gene Mut Anl Bld/T;;ACTIVE;2.38;2.63 +69364-8;ATP1A2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ATP1A2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ATP1A2 gene Mut Anl Bld/T;;ACTIVE;2.38;2.63 +69365-5;Inpatient facility diagnoses - OASIS B1;-;Pt;^Patient;-;OASIS;PANEL.SURVEY.OASIS;4;Inpatient facility diagnoses - OASIS B1 [OASIS];;;ACTIVE;2.38;2.44 +69366-3;Bordetella pertussis Ab.IgA;PrThr;Pt;Ser;Ord;IB;MICRO;1;Bordetella pertussis IgA Ab [Presence] in Serum by Immunoblot;B pert IgA Ser Ql IB;;ACTIVE;2.38;2.73 +69367-1;Bordetella pertussis Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Bordetella pertussis IgG Ab [Presence] in Serum by Immunoblot;B pert IgG Ser Ql IB;;ACTIVE;2.38;2.73 +69368-9;Bordetella pertussis Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Bordetella pertussis IgM Ab [Presence] in Serum by Immunoblot;B pert IgM Ser Ql IB;;ACTIVE;2.38;2.73 +6936-9;Deoxypyridinoline;MRat;2H;Urine;Qn;;CHEM;1;Deoxypyridinoline [Mass/time] in 2 hour Urine;DPD 2h Ur-mRate;;DISCOURAGED;1.0h(2);2.44 +69369-7;Blood group antibody screen;PrThr;Pt;BldCo;Ord;;BLDBK;1;Blood group antibody screen [Presence] in Cord blood;Bld gp Ab Scn BldCo Ql;;ACTIVE;2.38;2.73 +69370-5;A1 Ab;PrThr;Pt;BldCo;Ord;;BLDBK;1;A1 Ab [Presence] in Cord blood;A1 Ab BldCo Ql;;ACTIVE;2.38;2.73 +69371-3;B Ab;PrThr;Pt;BldCo;Ord;;BLDBK;1;B Ab [Presence] in Cord blood;B Ab BldCo Ql;;ACTIVE;2.38;2.73 +69372-1;What is the highest level of school this patient has completed;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;What is the highest level of school this patient has completed [CARE];;;DISCOURAGED;2.38;2.64 +69373-9;Passive D Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Passive D Ab [Presence] in Serum or Plasma;Passive D Ab SerPl Ql;;ACTIVE;2.38;2.73 +69374-7;Cognitive status, mood, pain - discharge;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Cognitive status, mood, pain - discharge [CARE];;;DISCOURAGED;2.38;2.64 +69375-4;Cognitive status, mood, pain - acute;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Cognitive status, mood, pain - acute [CARE];;;DISCOURAGED;2.38;2.64 +69376-2;Current medical information - interim;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Current medical information - interim [CARE];;;DISCOURAGED;2.38;2.64 +6937-7;Deoxypyridinoline;MRat;24H;Urine;Qn;;CHEM;1;Deoxypyridinoline [Mass/time] in 24 hour Urine;DPD 24h Ur-mRate;;DISCOURAGED;1.0h(2);2.44 +69377-0;Current medical information - admission, home health;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Current medical information - admission, home health [CARE];;;DISCOURAGED;2.38;2.64 +69378-8;Current medical information - expired;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Current medical information - expired [CARE];;;DISCOURAGED;2.38;2.64 +69379-6;Bacterial vancomycin resistance vanA & vanB & vanC1 & vanC2 genes;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Vancomycin resistance vanA and vanB and vanC1 and vanC2 genes [Identifier] by Molecular method;van(A+B+C1+C2) genes Islt/Spm;;ACTIVE;2.38;2.65 +69380-4;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript (International Scale)";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript (International Scale) [# Ratio] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)p210/Control (IS) Bld/T;;ACTIVE;2.38;2.73 +69381-2;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 fusion transcript/control transcript (International Scale)";RelRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 fusion transcript/control transcript (International Scale) in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)b2a2/Control (IS) Bld/T;;ACTIVE;2.38;2.7 +69382-0;"t(9;22)(q34.1;q11)(ABL1,BCR) b3a2 fusion transcript/control transcript (International Scale)";RelRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b3a2 fusion transcript/control transcript (International Scale) in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)b3a2/Control (IS) Bld/T;;ACTIVE;2.38;2.7 +69383-8;AGXT gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AGXT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;AGXT gene Mut Anl Bld/T;;ACTIVE;2.38;2.73 +69384-6;AGXT gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AGXT gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;AGXT gene Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +6938-5;IgA;MCnc;Pt;Saliva;Qn;;CHEM;1;IgA [Mass/volume] in Saliva (oral fluid);IgA Sal-mCnc;;ACTIVE;1.0h(2);2.73 +69385-3;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity veins;Doc;US;RAD;2;US Lower extremity veins - bilateral;US LE vv-Bl;;ACTIVE;2.38;2.61 +69387-9;Guidance for percutaneous biopsy;Find;Pt;Pelvis>Epididymis;Doc;US;RAD;2;US Guidance for biopsy of Epididymis;US Guided Epid Bx;;ACTIVE;2.38;2.64 +69388-7;Multisection^post void;Find;Pt;Pelvis>Urinary bladder;Doc;US;RAD;2;US Urinary bladder post void;US Bladder p vdg;;ACTIVE;2.38;2.61 +69389-5;Multisection;Find;Pt;Lower extremity>Femoral artery+Popliteal artery;Doc;US;RAD;2;US Femoral artery and Popliteal artery;US Fem a+Pop a;;ACTIVE;2.38;2.73 +69390-3;Multisection;Find;Pt;Pelvis>Ovary;Doc;US;RAD;2;US Ovary;US Ovary;;ACTIVE;2.38;2.73 +69391-1;Guidance for percutaneous aspiration of fluid;Find;Pt;Umbilical cord^Fetus;Doc;US;RAD;2;US Guidance for cordocentesis;US Guided Cordocentesis;;ACTIVE;2.38;2.67 +69392-9;Multisection;Find;Pt;Lower extremity.left>Lower extremity veins;Doc;US;RAD;2;US Lower extremity veins - left;US LE vv-L;;ACTIVE;2.38;2.61 +6939-3;IgA subclass 2;MCnc;Pt;Ser;Qn;;CHEM;1;IgA subclass 2 [Mass/volume] in Serum;IgA2 Ser-mCnc;;ACTIVE;1.0h(2);2.73 +69393-7;Multisection;Find;Pt;Abdomen>Spine.lumbar;Doc;US;RAD;2;US Lumbar spine;US L-spine;;ACTIVE;2.38;2.61 +69394-5;Multisection;Find;Pt;Abdomen>Mesenteric arteries;Doc;US;RAD;2;US Mesenteric arteries;US Mesenteric aa;;ACTIVE;2.38;2.73 +69395-2;Multisection;Find;Pt;Upper extremity>Upper extremity veins;Doc;US;RAD;2;US Upper extremity veins;US UE vv;;ACTIVE;2.38;2.61 +69396-0;Guidance for percutaneous biopsy;Find;Pt;XXX>Spinal cord;Doc;US;RAD;2;US Guidance for biopsy of Spinal cord;US Guided Spinal cord Bx;;ACTIVE;2.38;2.64 +69397-8;Multisection;Find;Pt;Breast>Breast vessels;Doc;US.doppler;RAD;2;US.doppler Breast vessels;DOP Breast ves;;ACTIVE;2.38;2.61 +69398-6;Multisection;Find;Pt;Extremity.left>Extremity vessels;Doc;US.doppler;RAD;2;US.doppler Extremity vessels - left;DOP Extremity ves-L;;ACTIVE;2.38;2.61 +69399-4;Multisection;Find;Pt;Lower extremity>Femoral vein+Popliteal vein;Doc;US;RAD;2;US Femoral vein and Popliteal vein;US Fem v+Polliteal a;;ACTIVE;2.38;2.61 +694-0;Neisseria gonorrhoeae;PrThr;Pt;Semen;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Semen by Organism specific culture;N gonorrhoea Smn Ql Cult;;ACTIVE;1.0;2.56 +69400-0;Guidance for tissue sampling of chorionic villus;Find;Pt;Pelvis>Placenta;Doc;US;RAD;2;US Guidance for chorionic villus sampling;US CVS Guid;;ACTIVE;2.38;2.58 +6940-1;Potassium;SRat;XXX;Stool;Qn;;CHEM;1;Potassium [Moles/time] in unspecified time Stool;Potassium ?Tm Stl-sRate;;ACTIVE;1.0h(2);2.73 +69401-8;Guidance for biopsy.needle;Find;Pt;XXX>Spinal cord;Doc;US;RAD;2;Deprecated US Guidance for needle biopsy of Spinal cord;Deprecated US Spinal cord Bx needle guide;;DEPRECATED;2.38;2.63 +69402-6;Multisection;Find;Pt;Abdomen>Kidney.bilateral & Pelvis>Urinary bladder;Doc;US;RAD;2;US Kidney - bilateral and Urinary bladder;US Kid-Bl+Blad;;ACTIVE;2.38;2.73 +69403-4;OTC medical device label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label OTC medical device label;FDA label OTC medical device;;ACTIVE;2.40;2.4 +69404-2;Prescription medical device label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Prescription medical device label;FDA label Prescription medical device;;ACTIVE;2.40;2.4 +69405-9;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood;GFR/BSA.pred SerPlBld-ArVRat;;ACTIVE;2.38;2.73 +69406-7;Adult GFR method;Type;Pt;Ser/Plas;Nom;;SURVEY.ESRD;4;Adult GFR method;;;TRIAL;2.38;2.73 +69407-5;Pediatric GFR method;Type;Pt;Ser/Plas;Nom;;SURVEY.ESRD;4;Pediatric GFR method;;;TRIAL;2.38;2.42 +69408-3;Orthostatic heart rate;RatDiff;Pt;Arterial system;Qn;;HRTRATE.PSTN.MOLEC;2;Orthostatic heart rate [Difference in rate];Orthostatic heart rate RatDiff;;ACTIVE;2.38;2.4 +69409-1;U.S. standard certificate of death - 2003 revision;-;Pt;^Patient;Doc;;PANEL.SURVEY.CDC;4;U.S. standard certificate of death - 2003 revision;;;ACTIVE;2.38;2.61 +69410-9;Haemophilus influenzae;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Haemophilus influenzae [Identifier] in Specimen by Organism specific culture;Haem influ Spec Cult;;ACTIVE;2.40;2.69 +69411-7;Medical services received in past 2Mo - Long term care hospital;Find;2Mo;^Patient;Nom;CARE;SURVEY.CARE;4;Medical services received in past 2 months - Long term care hospital [CARE];;;DISCOURAGED;2.38;2.64 +69412-5;Continuity assessment record and evaluation tool - long term care hospital - version 1.0;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Long term care hospital (LTCH) - version 1.0;;;DISCOURAGED;2.38;2.73 +69413-3;Continuity assessment record and evaluation tool - Long term care hospital - Planned discharge - version 1.0;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity Assessment Record and Evaluation (CARE) tool - Long term care hospital (LTCH) - Planned discharge - version 1.0;;;DISCOURAGED;2.38;2.73 +69414-1;Continuity assessment record and evaluation tool - Long term care hospital - Unplanned discharge - version 1.0;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity assessment record and evaluation (CARE) tool - Long term care hospital (LTCH) - Unplanned discharge - version 1.0;;;DISCOURAGED;2.38;2.73 +69415-8;Continuity assessment record and evaluation tool - Long term care hospital - Expired - version 1.0;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity assessment record and evaluation (CARE) tool - Long term care hospital (LTCH) - Expired - version 1.0;;;DISCOURAGED;2.38;2.73 +69416-6;Continuity assessment record and evaluation tool - Long term care hospital - Admission - version 1.0;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Continuity assessment record and evaluation (CARE) tool - Long term care hospital (LTCH) - Admission - version 1.0;;;DISCOURAGED;2.38;2.73 +69417-4;CMS certification number;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;CMS certification number (CCN) for Facility;CMS certification # Facility;;ACTIVE;2.38;2.66 +69418-2;Reason for assessment - Long term care hospital - version 1.0;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Reason for assessment - Long term care hospital - version 1.0 [CARE];;;DISCOURAGED;2.38;2.64 +6941-9;Albumin;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Albumin [Mass/time] in 24 hour Urine by Electrophoresis;Albumin 24h Ur Elph-mRate;;ACTIVE;1.0h(2);2.73 +69419-0;Cholesterol.in LDL;SCnc;Pt;Ser/Plas;Qn;Direct assay;CHEM;1;Cholesterol in LDL [Moles/volume] in Serum or Plasma by Direct assay;LDLc SerPl Direct Assay-sCnc;;ACTIVE;2.40;2.73 +69420-8;Heterophile Ab;PrThr;Pt;Bld;Ord;IA;MICRO;1;Heterophile Ab [Presence] in Blood by Immunoassay;Heteroph Ab Bld Ql IA;;ACTIVE;2.40;2.73 +69421-6;Corylus avellana recombinant (rCor a) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut recombinant (rCor a) 1 IgE Ab [Units/volume] in Serum;Hazelnut (rCor a) 1 IgE Qn;;ACTIVE;2.40;2.73 +69422-4;Carnitine.free (C0);SCnc;Pt;Semen;Qn;;FERT;1;Carnitine free (C0) [Moles/volume] in Semen;Carnitine Free Smn-sCnc;;ACTIVE;2.40;2.7 +69423-2;Rosner index;RelTime;Pt;PPP;Qn;Coag;COAG;1;Rosner index in Platelet poor plasma by Coagulation assay;Rosner index PPP;;ACTIVE;2.40;2.7 +69424-0;Nitrogen;MRat;72H;Stool;Qn;;CHEM;1;Nitrogen [Mass/time] in 72 hour Stool;N2 72h Stl-mRate;;ACTIVE;2.40;2.7 +69425-7;Calcium;MCnc;Pt;Semen;Qn;;FERT;1;Calcium [Mass/volume] in Semen;Calcium Smn-mCnc;;ACTIVE;2.40;2.7 +69426-5;Medical director review;Imp;Pt;XXX;Nar;;MISC;1;Medical director review of results;Medical director review;;ACTIVE;2.40;2.73 +6942-7;Albumin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Albumin [Mass/volume] in Urine by Electrophoresis;Albumin Ur Elph-mCnc;;ACTIVE;1.0h(2);2.73 +69427-3;Supervisor review;Imp;Pt;XXX;Nom;;MISC;1;Supervisor review of results;Supervisor review;;ACTIVE;2.40;2.73 +69428-1;Jugular vein distension;Find;Pt;^Patient;Ord;;H&P.PX;2;Jugular vein distension;Jugular vein distension;;ACTIVE;2.38;2.4 +69429-9;Metabolic rate^resting;EngRat;Pt;^Patient;Qn;;MISC;1;Metabolic rate --resting;Metabolic rate Resting Patient;;ACTIVE;2.38;2.73 +69430-7;Expected self-care dialysis;Loc;Pt;^Patient;Nom;;SURVEY.ESRD;4;Expected self-care dialysis;;;TRIAL;2.38;2.4 +69431-5;Medicare enrollment status;Find;Pt;^Patient;Nom;;SURVEY.ESRD;4;Medicare enrollment status;;;ACTIVE;2.38;2.64 +69432-3;Dialysis time period;Find;Pt;^Patient;Nom;;SURVEY.ESRD;4;Dialysis time period;;;TRIAL;2.38;2.4 +69433-1;Citizenship status;Find;Pt;^Patient;Nom;;SURVEY.ESRD;4;Citizenship status;;;TRIAL;2.38;2.4 +69434-9;Location of death name;ID;Pt;Facility;Nom;;SURVEY.CDC;4;Location of death name Facility;;;ACTIVE;2.38;2.42 +6943-5;acetoHEXAMIDE;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Acetohexamide [Mass/volume] in Specimen;acetoHEXAMIDE Spec-mCnc;;ACTIVE;1.0h(2);2.73 +69435-6;Street address where death occurred if not facility;Addr;Pt;Facility;Nom;;SURVEY.CDC;4;Street address where death occurred if not facility;;;ACTIVE;2.38;2.44 +69436-4;Autopsy results available;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Autopsy results available;;;ACTIVE;2.38;2.44 +69437-2;Death certifier;Type;Pt;Provider;Nom;;SURVEY.CDC;4;Death certifier [Type];;;ACTIVE;2.38;2.63 +69438-0;Referral note;Find;Pt;{Setting};Doc;Forensic medicine;DOC.ONTOLOGY;2;Forensic medicine Referral note;Forensic medicine Referral note;;ACTIVE;2.38;2.67 +69439-8;Death certifier;Addr;Pt;Provider;Nom;;SURVEY.CDC;4;Death certifier Address;;;ACTIVE;2.38;2.63 +69440-6;Disease onset to death interval;Find;Pt;^Patient;Nar;;SURVEY.CDC;4;Disease onset to death interval;;;ACTIVE;2.38;2.44 +69441-4;Other significant causes or conditions of death;Hx;Pt;^Patient;Nar;;SURVEY.CDC;4;Other significant causes or conditions of death;;;ACTIVE;2.38;2.66 +69442-2;Timing of recent pregnancy in relation to death;Hx;Pt;^Patient;Ord;;SURVEY.CDC;4;Timing of recent pregnancy in relation to death;;;ACTIVE;2.38;2.44 +6944-3;glipiZIDE;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;glipiZIDE [Mass/volume] in Specimen;glipiZIDE Spec-mCnc;;ACTIVE;1.0h(2);2.73 +69443-0;Did tobacco use contribute to death;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Did tobacco use contribute to death;;;ACTIVE;2.38;2.44 +69444-8;Did death result from injury at work;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Did death result from injury at work;;;ACTIVE;2.38;2.44 +69445-5;Injury date;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Injury date;;;ACTIVE;2.38;2.5 +69446-3;Injury date comment;Txt;Pt;^Patient;Nar;;SURVEY.CDC;4;Injury date comment;;;ACTIVE;2.38;2.44 +69447-1;Injury location;Addr;Pt;^Patient;Nar;;SURVEY.CDC;4;Injury location Narrative;;;ACTIVE;2.38;2.44 +69448-9;Injury leading to death associated with transportation event;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Injury leading to death associated with transportation event;;;ACTIVE;2.38;2.44 +69449-7;Manner of death;Type;Pt;^Patient;Nom;;SURVEY.CDC;4;Manner of death;;;ACTIVE;2.38;2.64 +6945-0;glyBURIDE;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;glyBURIDE [Mass/volume] in Specimen;glyBURIDE Spec-mCnc;;ACTIVE;1.0h(2);2.73 +69450-5;Place of injury;Type;Pt;Facility;Nar;;SURVEY.CDC;4;Place of injury Facility;;;ACTIVE;2.38;2.42 +69451-3;Transportation role of decedent;Find;Pt;^Patient;Nom;;SURVEY.CDC;4;Transportation role of decedent;;;ACTIVE;2.38;2.44 +69452-1;Coroner - medical examiner case number;Find;Pt;^Patient;Nom;;SURVEY.CDC;4;Coroner - medical examiner case number;;;ACTIVE;2.38;2.44 +69453-9;Cause of death;Find;Pt;^Patient;Nom;US standard certificate of death;SURVEY.CDC;4;Cause of death [US Standard Certificate of Death];;;ACTIVE;2.38;2.54 +69454-7;Death date comment;Find;Pt;^Patient;Nar;;SURVEY.CDC;4;Death date comment;;;ACTIVE;2.38;2.44 +69455-4;Major treatments - expired;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Major treatments - expired [CARE];;;DISCOURAGED;2.38;2.64 +69456-2;Major treatments - interim;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Major treatments - interim [CARE];;;DISCOURAGED;2.38;2.64 +69457-0;Major treatments - discharge;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Major treatments - discharge [CARE];;;DISCOURAGED;2.38;2.64 +69458-8;Cardiology monitoring;-;Pt;^Patient;-;;PANEL.ED;2;Cardiology monitoring;Cardiology monitoring;;ACTIVE;2.38;2.38 +69459-6;Care record summary panel;-;Pt;^Patient;-;;PANEL.DOC;2;Care record summary panel;CRS Pnl;;ACTIVE;2.38;2.5 +69460-4;Body weight^pre current pregnancy;Mass;Pt;^Mother;Qn;;BDYWGT.MOLEC;2;Body weight Mother --pre current pregnancy;Weight pre current pregnancy Mother;;ACTIVE;2.38;2.69 +69461-2;Body weight^at delivery;Mass;Pt;^Mother;Qn;;BDYWGT.MOLEC;2;Mother's body weight --at delivery;Weight at delivery Mother;;ACTIVE;2.38;2.73 +69462-0;Activation of the destination healthcare facility team;Find;Pt;^Patient;Ord;;TRAUMA;2;Activation of the destination healthcare facility team;Activation dest healthcare team;;ACTIVE;2.38;2.7 +69463-8;Suspected intentional or unintentional disaster;Type;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Suspected intentional or unintentional disaster NEMSIS;Suspected disaster NEMSIS;;ACTIVE;2.38;2.5 +69464-6;Centers for medicare - medicaid, CMS, service level;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Centers for medicare - medicaid, CMS, service level NEMSIS;CMS service level NEMSIS;;ACTIVE;2.38;2.5 +69465-3;EMS unit GPS longitude^at dispatch;Angle;Pt;^Vehicle;Qn;;NEMSIS;2;EMS unit GPS longitude Vehicle --at dispatch;EMS unit GPS coordinates at dispatch;;ACTIVE;2.38;2.64 +69466-1;Vehicle location^at dispatch;Loc;Pt;^Vehicle;Ord;NEMSIS;NEMSIS;2;Vehicle location Vehicle NEMSIS --at dispatch;Facility or geographic location;;ACTIVE;2.38;2.5 +69467-9;Possible injury;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Possible injury NEMSIS;Possible injury NEMSIS;;ACTIVE;2.38;2.5 +6946-8;Imipramine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Imipramine [Mass/volume] in Specimen;Imipramine Spec-mCnc;;ACTIVE;1.0h(2);2.69 +69468-7;Primary anatomic organ system of chief complaint;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Primary anatomic organ system of chief complaint NEMSIS;CC Anat organ system NEMSIS;;ACTIVE;2.38;2.5 +69469-5;911 call to public safety answering point or other designated entity requesting EMS services;TmStp;Pt;Facility;Qn;;NEMSIS;2;911 call to public safety answering point or other designated entity requesting EMS services [Date and time] Facility;911 call time Facility;;ACTIVE;2.38;2.64 +69470-3;Dispatch was notified by the 911 call taker;TmStp;Pt;Facility;Qn;;NEMSIS;2;Dispatch was notified by the 911 call taker [Date and time] Facility;Time dispatch notified by 911;;ACTIVE;2.38;2.64 +69471-1;Responding unit was notified by dispatch;TmStp;Pt;^Vehicle;Qn;;NEMSIS;2;Responding unit was notified by dispatch [Date and time] Vehicle;Time respond unit notified by dispatch;;ACTIVE;2.38;2.64 +69472-9;Unit responded;TmStp;Pt;^Vehicle;Qn;;NEMSIS;2;Unit responded [Date and time] Vehicle;Time unit responded;;ACTIVE;2.38;2.64 +69473-7;Responding unit arrived on the scene;TmStp;Pt;^Vehicle;Qn;;NEMSIS;2;Responding unit arrived on the scene [Date and time] Vehicle;Time respond unit arrived on scene;;ACTIVE;2.38;2.64 +69474-5;Responding unit arrived at the patient's side;TmStp;Pt;^Vehicle;Qn;;NEMSIS;2;Responding unit arrived at the patient's side [Date and time] Vehicle;Time respond unit at pt's side;;ACTIVE;2.38;2.64 +69475-2;Responding unit left the scene with a patient;TmStp;Pt;^Vehicle;Qn;;NEMSIS;2;Responding unit left the scene with a patient [Date and time] Vehicle;Time respond unit left scene;;ACTIVE;2.38;2.64 +6947-6;ISOtretinoin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ISOtretinoin [Mass/volume] in Serum or Plasma;ISOtretinoin SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +69476-0;Responding unit arrived with the patient at the destination or transfer point;TmStp;Pt;^Vehicle;Qn;;NEMSIS;2;Responding unit arrived with the patient at the destination or transfer point [Date and time] Vehicle;Time respond unit arrived;;ACTIVE;2.38;2.64 +69477-8;Unit was back in service and available for response;TmStp;Pt;^Vehicle;Qn;;NEMSIS;2;Unit was back in service and available for response [Date and time] Vehicle;Time unit back in service;;ACTIVE;2.38;2.64 +69478-6;AGXT gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.MUT;1;AGXT gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;AGXT gene Del+Dup Bld/T MLPA;;ACTIVE;2.40;2.66 +69479-4;BTK gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BTK gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;BTK gene Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +69480-2;CFTR gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.MUT;1;CFTR gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;CFTR Del+Dup Bld/T MLPA;;ACTIVE;2.40;2.73 +69481-0;ACVRL1 gene+ENG gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.MUT;1;ACVRL1 gene+ENG gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;ACVRL1+ENG gene Del+Dup Bld/T MLPA;;ACTIVE;2.40;2.66 +69482-8;ENG gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ENG gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ENG Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +69483-6;F9 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;F9 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;F9 gene Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +6948-4;lamoTRIgine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;lamoTRIgine [Mass/volume] in Serum or Plasma;lamoTRIgine SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +69484-4;FBN1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FBN1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;FBN1 gene Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +69485-1;LDLR gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LDLR gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;LDLR gene Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +69486-9;LDLR gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.MUT;1;LDLR gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;LDLR gene Del+Dup Bld/T MLPA;;ACTIVE;2.40;2.66 +69487-7;TNFRSF13B gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;TNFRSF13B gene full mutation analysis in Blood or Tissue by Sequencing;TNFRSF13B gene Full Mut Anl Bld/T Seq;;ACTIVE;2.40;2.66 +69488-5;TNFRSF13B gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TNFRSF13B gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;TNFRSF13B gene Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +69489-3;VHL gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;VHL gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;VHL gene Fam Mut Anl Bld/T;;ACTIVE;2.40;2.66 +69490-1;Ethnicity;Type;Pt;^Patient;Nom;OMB.1997;CLIN;2;Ethnicity OMB.1997;Ethnicity OMB.1997;;ACTIVE;2.38;2.73 +69491-9;Mobility aids;Find;Pt;^Patient;Nom;OPTIMAL;SURVEY.OPTIMAL;4;Mobility aids [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6949-2;Metaproterenol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metaproterenol [Mass/volume] in Serum or Plasma;Metaproterenol SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +69492-7;Outpatient physical therapy improvement in movement assessment log;-;Pt;^Patient;-;OPTIMAL;PANEL.SURVEY.OPTIMAL;4;Outpatient physical therapy improvement in movement assessment log [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69493-5;OPTIMAL difficulty - baseline;-;Pt;^Patient;-;OPTIMAL;PANEL.SURVEY.OPTIMAL;4;OPTIMAL difficulty - baseline;;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69494-3;OPTIMAL confidence - baseline;-;Pt;^Patient;-;OPTIMAL;PANEL.SURVEY.OPTIMAL;4;OPTIMAL confidence - baseline;;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69495-0;OPTIMAL difficulty - follow up;-;Pt;^Patient;-;OPTIMAL;PANEL.SURVEY.OPTIMAL;4;OPTIMAL difficulty - follow up;;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69496-8;OPTIMAL confidence - follow up;-;Pt;^Patient;-;OPTIMAL;PANEL.SURVEY.OPTIMAL;4;OPTIMAL confidence - follow up;;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69497-6;Lying flat - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Lying flat - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69498-4;Rolling over - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Rolling over - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69499-2;Moving - lying to sitting - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Moving - lying to sitting - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69-5;Cefamandole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefamandole [Susceptibility] by Disk diffusion (KB);Cefamandole Islt KB;;ACTIVE;1.0;2.21 +6950-0;raNITIdine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;raNITIdine [Mass/volume] in Serum or Plasma;raNITIdine SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +69500-7;Sitting - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Sitting - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69501-5;Squatting - difficulty;Find;Pt;^Patient;Ord;;SURVEY.OPTIMAL;4;Squatting - difficulty;;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.72 +69502-3;Bending - stooping - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Bending - stooping - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69503-1;Balancing - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Balancing - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69504-9;Kneeling - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Kneeling - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69505-6;Walking - short distance - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Walking - short distance - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69506-4;Walking - long distance - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Walking - long distance - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69507-2;Walking - outdoors - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Walking - outdoors - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69508-0;Climbing stairs - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Climbing stairs - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69509-8;Hopping - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Hopping - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69510-6;Jumping - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Jumping - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69511-4;Running - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Running - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69512-2;Pushing - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Pushing - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69513-0;Pulling - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Pulling - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69514-8;Reaching - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Reaching - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69515-5;Grasping - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Grasping - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69516-3;Lifting - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Lifting - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69517-1;Carrying - difficulty;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Carrying - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6951-8;TOLAZamide;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;TOLAZamide [Mass/volume] in Specimen;TOLAZamide Spec-mCnc;;ACTIVE;1.0h(2);2.73 +69518-9;Choose the number of the activity you would most like to be able to do without any difficulty;Find;Pt;^Patient;Nom;OPTIMAL;SURVEY.OPTIMAL;4;Choose the number of the activity you would most like to be able to do without any difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69519-7;Overall level of difficulty with these activities today;Find;Pt;^Patient;Nar;OPTIMAL;SURVEY.OPTIMAL;4;Overall level of difficulty with these activities today [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69520-5;Lying flat - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Lying flat - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69521-3;Rolling over - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Rolling over - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69522-1;Moving - lying to sitting - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Moving - lying to sitting - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69523-9;Sitting - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Sitting - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69524-7;Squatting - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Squatting - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69525-4;Bending - stooping - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Bending - stooping - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6952-6;TOLBUTamide;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;TOLBUTamide [Mass/volume] in Specimen;TOLBUTamide Spec-mCnc;;ACTIVE;1.0h(2);2.73 +69526-2;Balancing - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Balancing - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69527-0;Kneeling - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Kneeling - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69528-8;Walking - short distance - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Walking - short distance - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69529-6;Walking - long distance - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Walking - long distance - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69530-4;Walking - outdoors - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Walking - outdoors - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69531-2;Climbing stairs - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Climbing stairs - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69532-0;Hopping - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Hopping - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69533-8;Jumping - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Jumping - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6953-4;Zolpidem;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zolpidem [Mass/volume] in Serum or Plasma;Zolpidem SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +69534-6;Running - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Running - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69535-3;Pushing - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Pushing - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69536-1;Pulling - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Pulling - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69537-9;Reaching - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Reaching - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69538-7;Grasping - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Grasping - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69539-5;Lifting - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Lifting - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69540-3;Carrying - confidence;Find;Pt;^Patient;Ord;OPTIMAL;SURVEY.OPTIMAL;4;Carrying - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69541-1;Overall level of confidence with these activities today;Find;Pt;^Patient;Nom;OPTIMAL;SURVEY.OPTIMAL;4;Overall level of confidence with these activities today [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6954-2;Bartonella henselae Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella henselae IgG Ab [Titer] in Serum by Immunofluorescence;B henselae IgG Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69542-9;Secondary problem;Imp;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Secondary problem [Interpretation] NEMSIS;Secondary problem Imp NEMSIS;;ACTIVE;2.38;2.5 +69543-7;Cause of injury;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Cause of injury NEMSIS;Cause of injury NEMSIS;;ACTIVE;2.38;2.5 +69544-5;Chief complaint - ICD code;Prid;Pt;^Patient;Nom;;NEMSIS;2;Chief complaint - ICD code [Identifier];Chief complaint - ICD code;;ACTIVE;2.38;2.61 +69545-2;DNA region of interest start;Prid;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;DNA region of interest start [Identifier];DNA ROI start;;ACTIVE;2.38;2.56 +69546-0;DNA region of interest stop;Prid;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;DNA region of interest stop [Identifier];DNA ROI stop;;ACTIVE;2.38;2.56 +69547-8;Reference nucleotide;Prid;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genomic ref allele [ID];Ref nucleotide;;ACTIVE;2.38;2.58 +69548-6;Genetic variant assessment;Find;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genetic variant assessment;Genetic var assess;;ACTIVE;2.38;2.73 +69549-4;Genetic knowledge reference;ID;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genetic knowledge reference [Identifier];Gen knwldge ref ID;;ACTIVE;2.38;2.73 +69550-2;Genetic knowledge reference;Type;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genetic knowledge reference [Type];Gen knwldge ref Type;;ACTIVE;2.38;2.56 +69551-0;Variable nucleotide;Prid;Pt;Bld/Tiss;Nom;Molgen;HL7.GENETICS;1;Genomic alt allele [ID];Alt allele;;ACTIVE;2.38;2.58 +69552-8;Thromboelastography after addtion of heparinase panel;-;Pt;Bld;-;;PANEL.COAG;1;Thromboelastography after addtion of heparinase panel - Blood;TEG after heparinase pnl Bld;;ACTIVE;2.40;2.73 +69553-6;Lactose tolerance;Imp;Pt;Ser/Plas;Nar;;CHAL;1;Lactose tolerance [Interpretation] in Serum or Plasma Narrative;Lactose tolerance SerPl-Imp;;ACTIVE;2.40;2.73 +69554-4;Lactose tolerance panel^dosage unspecified;SCnc;Pt;Ser/Plas;-;;PANEL.CHAL;1;Lactose tolerance panel [Moles/volume] in Serum or Plasma;Lactose tolerance pnl SerPl-sCnc;;ACTIVE;2.40;2.4 +69555-1;Lactose tolerance panel^dosage unspecified;MCnc;Pt;Ser/Plas;-;;PANEL.CHAL;1;Lactose tolerance panel [Mass/volume] in Serum or Plasma;Lactose tolerance pnl SerPl-mCnc;;ACTIVE;2.40;2.73 +69556-9;Ku Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Ku Ab [Presence] in Serum by Immunoblot;Ku Ab Ser Ql IB;;ACTIVE;2.40;2.58 +69557-7;OJ Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;OJ Ab [Presence] in Serum by Immunoblot;OJ Ab Ser Ql IB;;ACTIVE;2.40;2.73 +69558-5;Ma1 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Ma1 Ab [Presence] in Serum by Immunoblot;Ma1 Ab Ser Ql IB;;ACTIVE;2.40;2.58 +6955-9;Bartonella henselae Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Bartonella henselae IgM Ab [Titer] in Serum by Immunofluorescence;B henselae IgM Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69559-3;Ma1 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Ma1 Ab [Presence] in Cerebral spinal fluid by Immunoblot;Ma1 Ab CSF Ql IB;;ACTIVE;2.40;2.58 +69560-1;Enolase.neuron specific;MCnc;Pt;Periton fld;Qn;;CHEM;1;Enolase.neuron specific [Mass/volume] in Peritoneal fluid;NSE Prt-mCnc;;ACTIVE;2.40;2.7 +69561-9;Thyrotropin;ACnc;Pt;BldCo;Qn;;CHEM;1;Thyrotropin [Units/volume] in Cord blood;TSH BldCo-aCnc;;ACTIVE;2.40;2.7 +69562-7;Candida albicans DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida albicans DNA [Presence] in Vaginal fluid by NAA with probe detection;C albicans DNA Vag Ql NAA+probe;;ACTIVE;2.40;2.73 +69563-5;Candida glabrata DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida glabrata DNA [Presence] in Vaginal fluid by NAA with probe detection;C glabrata DNA Vag Ql NAA+probe;;ACTIVE;2.40;2.73 +69564-3;Bacterial vaginosis score;Score;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Bacterial vaginosis score in Vaginal fluid Qualitative by NAA with probe detection;BV score Vag Ql NAA+probe;;ACTIVE;2.40;2.73 +69565-0;Atopobium vaginae DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Atopobium vaginae DNA [Presence] in Vaginal fluid by NAA with probe detection;A vaginae DNA Vag Ql NAA+probe;;ACTIVE;2.40;2.73 +69566-8;Bacterial vaginosis associated bacterium 2 DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Bacterial vaginosis associated bacterium 2 DNA [Presence] in Vaginal fluid by NAA with probe detection;BVAB2 DNA Vag Ql NAA+probe;;ACTIVE;2.40;2.73 +6956-7;Coxsackievirus A21 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A21 Ab [Titer] in Serum by Complement fixation;CV A21 Ab Titr Ser CF;;ACTIVE;1.0h(2);2.73 +69567-6;Megasphaera sp type 1 DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Megasphaera sp type 1 DNA [Presence] in Vaginal fluid by NAA with probe detection;Mega1 DNA Vag Ql NAA+probe;;ACTIVE;2.40;2.73 +69568-4;Bacterial vaginosis;Imp;Pt;Vag;Ord;;MICRO;1;Bacterial vaginosis [Interpretation] in Vaginal fluid Qualitative;Bacterial vaginosis Vag-Imp;;ACTIVE;2.40;2.73 +69569-2;Risk of ovarian malignancy algorithm score^premenopausal;Score;Pt;Ser/Plas;Qn;;CHEM;1;Risk of ovarian malignancy algorithm score in Serum or Plasma --premenopausal;ROMA score premen SerPl;;ACTIVE;2.40;2.73 +695-7;Neisseria gonorrhoeae;PrThr;Pt;Synv fld;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Synovial fluid by Organism specific culture;N gonorrhoea Snv Ql Cult;;ACTIVE;1.0;2.56 +69570-0;Risk of ovarian malignancy algorithm score^postmenopausal;Score;Pt;Ser/Plas;Qn;;CHEM;1;Risk of ovarian malignancy algorithm score in Serum or Plasma --postmenopausal;ROMA score postmen SerPl;;ACTIVE;2.40;2.73 +69571-8;Bacterial vaginosis DNA & score panel;-;Pt;Vag;-;Probe.amp.tar;PANEL.MICRO;1;Bacterial vaginosis DNA and score panel - Vaginal fluid by NAA with probe detection;BV DNA + score Pnl Vag NAA+probe;;ACTIVE;2.40;2.73 +69572-6;ERCC1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;ERCC1 Ag [Presence] in Tissue by Immune stain;ERCC1 Ag Tiss Ql ImStn;;ACTIVE;2.40;2.73 +69573-4;Tiglylcarnitine+methylcrotonylcarnitine (C5:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tiglylcarnitine+methylcrotonylcarnitine (C5:1) [Moles/volume] in Serum or Plasma;Tgly+Mthyl (C5:1) SerPl-sCnc;;ACTIVE;2.40;2.73 +69574-2;Furazolidone;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Furazolidone [Susceptibility];Furazolidone Susc Islt;;ACTIVE;2.40;2.4 +6957-5;Western equine encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Western equine encephalitis virus IgG Ab [Titer] in Serum by Immunofluorescence;WEEV IgG Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69575-9;Campylobacter jejuni Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Campylobacter jejuni Ab [Presence] in Serum by Complement fixation;C jejuni Ab Ser Ql CF;;ACTIVE;2.40;2.56 +69576-7;Campylobacter fetus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Campylobacter fetus Ab [Presence] in Serum;C fetus Ab Ser Ql;;ACTIVE;2.40;2.56 +69577-5;Hepatitis E virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Hepatitis E virus RNA [Presence] in Blood by NAA with probe detection;HEV RNA Bld Ql NAA+probe;;ACTIVE;2.40;2.63 +69578-3;Diffusion capacity.carbon monoxide/Alveolar volume^^adjusted for hemoglobin;Inverse VI;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity.carbon monoxide/Alveolar volume adjusted for hemoglobin;Diff cap.CO/Alv vol Hgb adj;;ACTIVE;2.40;2.7 +69579-1;Local PFGE event description;ID;Pt;Isolate;Nom;;MICRO;1;Local PFGE event description in Isolate;Local PFGE event Islt;;ACTIVE;2.40;2.4 +69580-9;Local assigning authority;ID;Pt;Isolate;Nom;;MICRO;1;Local assigning authority [Identifier] in Isolate;Local assigning authority Islt;;ACTIVE;2.40;2.4 +69581-7;National (USA) PFGE cluster code or CDC cluster;ID;Pt;Isolate;Nom;;MICRO;1;National (USA) PFGE cluster code or CDC cluster [Identifier] in Isolate;Nat PFGE cluster/CDC cluster Islt;;ACTIVE;2.40;2.4 +69582-5;PFGE restriction enzyme;ID;Pt;Isolate;Nom;;MICRO;1;PFGE restriction enzyme [Identifier] in Isolate;PFGE restriction enzyme Islt;;ACTIVE;2.40;2.4 +6958-3;Western equine encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Western equine encephalitis virus IgM Ab [Titer] in Serum by Immunofluorescence;WEEV IgM Titr Ser IF;;ACTIVE;1.0h(2);2.73 +69586-6;Carrying - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Carrying - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69587-4;Lifting - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Lifting - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69588-2;Grasping - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Grasping - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69589-0;Reaching - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Reaching - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69590-8;Pulling - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Pulling - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6959-1;Yersinia enterocolitica O:3 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:3 Ab [Titer] in Serum;Y entero O:3 Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +69591-6;Pushing - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Pushing - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69592-4;Running - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Running - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69593-2;Jumping - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Jumping - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69594-0;Hopping - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Hopping - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69595-7;Climbing stairs - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Climbing stairs - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69596-5;Walking - outdoors - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Walking - outdoors - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69597-3;Walking - long distance - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Walking - long distance - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69598-1;Walking - short distance - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Walking - short distance - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69599-9;Kneeling - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Kneeling - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69600-5;Balancing - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Balancing - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69601-3;Bending - stooping - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Bending - stooping - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69602-1;Squatting - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Squatting - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69603-9;Sitting - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Sitting - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69604-7;Moving - lying to sitting - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Moving - lying to sitting - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69605-4;Rolling over - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Rolling over - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69606-2;Lying flat - confidence - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Lying flat - confidence - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69607-0;Carrying - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Carrying - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69608-8;Lifting - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Lifting - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6960-9;Yersinia enterocolitica O:5 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:5 Ab [Titer] in Serum;Y entero O:5 Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +69609-6;Grasping - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Grasping - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69610-4;Reaching - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Reaching - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69611-2;Pulling - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Pulling - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69612-0;Pushing - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Pushing - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69613-8;Running - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Running - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69614-6;Jumping - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Jumping - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69615-3;Hopping - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Hopping - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69616-1;Climbing stairs - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Climbing stairs - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6961-7;Yersinia enterocolitica O:8 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:8 Ab [Titer] in Serum;Y entero O:8 Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +69617-9;Walking - outdoors - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Walking - outdoors - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69618-7;Walking - long distance - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Walking - long distance - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69619-5;Walking - short distance - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Walking - short distance - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69620-3;Kneeling - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Kneeling - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69621-1;Balancing - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Balancing - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69622-9;Bending - stooping - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Bending - stooping - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69623-7;Squatting - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Squatting - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69624-5;Sitting - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Sitting - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6962-5;Yersinia enterocolitica O:9 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica O:9 Ab [Titer] in Serum;Y entero O:9 Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +69625-2;Moving - lying to sitting - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Moving - lying to sitting - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69626-0;Rolling over - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Rolling over - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69627-8;Lying flat - difficulty - score change;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Lying flat - difficulty - score change [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69631-0;Total change score - difficulty;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Total change score - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69632-8;Total difficulty score - baseline;Score;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Total difficulty score - baseline [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6963-3;Yersinia enterocolitica Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia enterocolitica Ab [Titer] in Serum;Y enterocol Ab Titr Ser;;ACTIVE;1.0h(2);2.7 +69633-6;Total difficulty score - follow-up;Score;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Total difficulty score - follow-up [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6964-1;Yersinia enterocolitica Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yersinia enterocolitica IgA Ab [Units/volume] in Serum by Immunoassay;Y enterocol IgA Ser IA-aCnc;;ACTIVE;1.0h(2);2.73 +696-5;Neisseria gonorrhoeae;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Throat by Organism specific culture;N gonorrhoea Throat Ql Cult;;ACTIVE;1.0;2.73 +69652-6;Total change score - confidence;ScoreDiff;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Total change score - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69653-4;Total confidence score - baseline;Score;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Total confidence score - baseline [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69654-2;Total confidence score - follow-up;Score;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Total confidence score - follow-up [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +6965-8;Yersinia enterocolitica Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yersinia enterocolitica IgG Ab [Units/volume] in Serum by Immunoassay;Y enterocol IgG Ser IA-aCnc;;ACTIVE;1.0h(2);2.73 +6966-6;Yersinia enterocolitica Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Yersinia enterocolitica IgM Ab [Units/volume] in Serum by Immunoassay;Y enterocol IgM Ser IA-aCnc;;ACTIVE;1.0h(2);2.69 +69667-4;Bowel continence;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Bowel continence [CARE];;;DISCOURAGED;2.40;2.64 +69668-2;HIV 1 & 2 Ab;Prid;Pt;Ser/Plas;Nom;IA.rapid;MICRO;1;HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay;HIV 1 & 2 Ab SerPl IA.rapid;;ACTIVE;2.40;2.73 +69669-0;Population stratification description;Find;Pt;^Patient;Nar;;DOC.QUALITY;2;Population stratification description Narrative;Population stratification description;;ACTIVE;2.38;2.4 +69670-8;Health quality measure supplemental data;Find;Pt;^Patient;Nar;;DOC.QUALITY;2;Health quality measure supplemental data Narrative;Health quality measure supplemental data;;ACTIVE;2.38;2.4 +69671-6;Bothered by stomach pain in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by stomach pain in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69672-4;Bothered by back pain in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by back pain in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69673-2;Bothered by pain in your arms, legs, or joints - knees, hips, etc - in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by pain in your arms, legs, or joints - knees, hips, etc - in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +6967-4;Yersinia pseudotuberculosis Ab;Titr;Pt;Ser;Qn;;MICRO;1;Yersinia pseudotuberculosis Ab [Titer] in Serum;Y pseudoTB Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +69674-0;Bothered by menstrual cramps or other problems with your period in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by menstrual cramps or other problems with your period in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69675-7;Bothered by headaches in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by headaches in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69676-5;Bothered by chest pain in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by chest pain in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69677-3;Bothered by dizziness in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by dizziness in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69678-1;Bothered by fainting spells in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by fainting spells in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69679-9;Bothered by feeling your heart pound or race in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by feeling your heart pound or race in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69680-7;Bothered by shortness of breath in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by shortness of breath in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69681-5;Bothered by constipation, loose stools, or diarrhea in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by constipation, loose stools, or diarrhea in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +6968-2;Proteinase 3 Ab;ACnc;Pt;Ser;Qn;;SERO;1;Proteinase 3 Ab [Units/volume] in Serum;Proteinase3 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +69682-3;Bothered by nausea, gas, or indigestion in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by nausea, gas, or indigestion in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69683-1;Feeling nervous, anxious, on edge, or worrying a lot about different things in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Feeling nervous, anxious, on edge, or worrying a lot about different things in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69684-9;Feeling restless so that it is hard to sit still in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Feeling restless so that it is hard to sit still in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69685-6;Getting tired very easily in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Getting tired very easily in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69686-4;Muscle tension, aches, or soreness in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Muscle tension, aches, or soreness in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69687-2;Trouble falling asleep or staying asleep in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Trouble falling asleep or staying asleep in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69688-0;Trouble concentrating on things, such as reading a book or watching TV in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Trouble concentrating on things, such as reading a book or watching TV in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69689-8;Becoming easily annoyed or irritable in last 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Becoming easily annoyed or irritable in last 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +6969-0;Myeloperoxidase Ab;ACnc;Pt;Ser;Qn;;SERO;1;Myeloperoxidase Ab [Units/volume] in Serum;Myeloperoxidase Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +69690-6;Do you often feel that you can't control what or how much you eat;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Do you often feel that you can't control what or how much you eat [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.5 +69691-4;Do you often eat, within any 2H period, what most people would regard as an unusually large amount of food;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Do you often eat, within any 2 hour period, what most people would regard as an unusually large amount of food [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.5 +69692-2;Has this been as often, on average, as twice a W for the last 3Mo;Find;3Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Has this been as often, on average, as twice a week for the last 3 months [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69693-0;Made yourself vomit often in last 3Mo in order to avoid gaining weight;Find;3Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Made yourself vomit often in last 3 months in order to avoid gaining weight [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69694-8;Took more than twice the recommended dose of laxatives often in last 3Mo in order to avoid gaining weight;Find;3Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Took more than twice the recommended dose of laxatives often in last 3 months in order to avoid gaining weight [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69695-5;Fasted - not eaten anything at all for at least 24H - often in last 3Mo in order to avoid gaining weight;Find;3Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Fasted - not eaten anything at all for at least 24 hours - often in last 3 months in order to avoid gaining weight [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69696-3;Exercised for more than an hour specifically to avoid gaining weight after binge eating often in last 3Mo in order to avoid gaining weight;Find;3Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Exercised for more than an hour specifically to avoid gaining weight after binge eating often in last 3 months in order to avoid gaining weight [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69697-1;You drank alcohol, even though a doctor suggested that you stop drinking because of a problem with your health, more than once in last 6Mo;Find;6Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;You drank alcohol, even though a doctor suggested that you stop drinking because of a problem with your health, more than once in last 6 months [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69698-9;You drank alcohol, were high from alcohol, or hung over while you were working, going to school, or taking care of children or other responsibilities more than once in last 6Mo;Find;6Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;You drank alcohol, were high from alcohol, or hung over while you were working, going to school, or taking care of children or other responsibilities more than once in last 6 months [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69699-7;You missed or were late for work, school, or other activities because you were drinking or hung over, more than once in last 6Mo;Find;6Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;You missed or were late for work, school, or other activities because you were drinking or hung over, more than once in last 6 months [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69700-3;You had a problem getting along with other people while you were drinking more than once in last 6Mo;Find;6Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;You had a problem getting along with other people while you were drinking more than once in last 6 months [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69701-1;You drove a car after having several drinks or after drinking too much more than once in last 6Mo;Find;6Mo;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;You drove a car after having several drinks or after drinking too much more than once in last 6 months [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.61 +69702-9;Has this ever happened before;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Has this ever happened before [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69703-7;Do some of these attacks come suddenly out of the blue - that is, in situations where you don't expect to be nervous or uncomfortable;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Do some of these attacks come suddenly out of the blue - that is, in situations where you don't expect to be nervous or uncomfortable [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.5 +69704-5;Do these attacks bother you a lot or are you worried about having another attack;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Do these attacks bother you a lot or are you worried about having another attack [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.5 +69705-2;Were you short of breath;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Were you short of breath [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69706-0;Did your heart race, pound, or skip;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did your heart race, pound, or skip [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69707-8;Did you have chest pain or pressure;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you have chest pain or pressure [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +6970-8;Purkinje cells Ab;Titr;Pt;Ser;Qn;;SERO;1;Purkinje cells Ab [Titer] in Serum;Purkinje Cells Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +69708-6;Did you sweat;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you sweat [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69709-4;Did you feel as if you were choking;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you feel as if you were choking [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69710-2;Did you have hot flashes or chills;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you have hot flashes or chills [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69711-0;Did you have nausea or an upset stomach, or the feeling that you were going to have diarrhea;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you have nausea or an upset stomach, or the feeling that you were going to have diarrhea [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69712-8;Did you feel dizzy, unsteady, or faint;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you feel dizzy, unsteady, or faint [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69713-6;Did you have tingling or numbness in parts of your body;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you have tingling or numbness in parts of your body [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69714-4;Did you tremble or shake;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Did you tremble or shake [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69715-1;Were you afraid you were dying;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Were you afraid you were dying [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +6971-6;2,4 toluenediamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2,4 toluenediamine [Mass/volume] in Urine;2,4Toluenediam Ur-mCnc;;ACTIVE;1.0h(2);2.42 +69716-9;In the last 4W, have you had an anxiety attack - suddenly feeling fear or panic;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;In the last 4 weeks, have you had an anxiety attack - suddenly feeling fear or panic [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69717-7;Bothered by pain or problems during sexual intercourse;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Bothered by pain or problems during sexual intercourse [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69718-5;Statement of identity section;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Statement of identity section;FDA label Statement of identity;;ACTIVE;2.40;2.4 +69719-3;Health claim section;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Health claim section;FDA label Health claim;;ACTIVE;2.40;2.4 +69720-1;If you checked yes to any of these ways of avoiding gaining weight, were any as often, on average, as twice a W;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;If you checked yes to any of these ways of avoiding gaining weight, were any as often, on average, as twice a week [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69721-9;Do you ever drink alcohol - including beer or wine;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Do you ever drink alcohol - including beer or wine [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.44 +69722-7;How difficult have these made it for you to do your work, take care of things at home, or get along with other people;Find;Pt;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;How difficult have these made it for you to do your work, take care of things at home, or get along with other people [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.58 +69723-5;Patient health questionnaire;-;Pt;^Patient;-;Reported.PHQ;PANEL.SURVEY.PHQ;4;Patient Health Questionnaire (PHQ) [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.48 +6972-4;2,6 toluenediamine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2,6 toluenediamine [Mass/volume] in Urine;2,6Toluenediam Ur-mCnc;;ACTIVE;1.0h(2);2.42 +69724-3;Patient health questionnaire 4 item;-;Pt;^Patient;-;Reported.PHQ;PANEL.SURVEY.PHQ;4;Patient Health Questionnaire 4 item (PHQ-4) [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.48 +69725-0;Feeling nervous, anxious or on edge in last 2W;Find;2W;^Patient;Ord;;SURVEY.PHQ;4;Feeling nervous, anxious or on edge in last 2 weeks;;;ACTIVE;2.38;2.72 +69726-8;Tissue transglutaminase Ab.IgA+gliadin peptides Ab.IgA & IgG panel;-;Pt;Ser;-;;PANEL.SERO;1;Tissue transglutaminase IgA + Gliadin peptides IgA and IgG panel - Serum;tTG IgA+DGP IgA+IgG pnl Ser;;ACTIVE;2.40;2.73 +69727-6;Tissue transglutaminase Ab.IgA+gliadin peptides Ab.IgA & IgG;Imp;Pt;Ser;Nar;;SERO;1;Tissue transglutaminase IgA + Gliadin peptides IgA and IgG [Interpretation] in Serum Narrative;tTG IgA+DGP IgA+IgG Ser-Imp;;ACTIVE;2.40;2.73 +69728-4;Patient health questionnaire 15 item;-;Pt;^Patient;-;Reported.PHQ;PANEL.SURVEY.PHQ;4;Patient Health Questionnaire 15 item (PHQ-15) [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.48 +69729-2;Patient Health Questionnaire-somatic, anxiety, and depressive symptoms;-;Pt;^Patient;-;Reported.PHQ;PANEL.SURVEY.PHQ;4;Patient Health Questionnaire - Somatic, Anxiety, and Depressive Symptoms (PHQ-SADS) [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.48 +697-3;Neisseria gonorrhoeae;PrThr;Pt;Urethra;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Urethra by Organism specific culture;N gonorrhoea Urth Ql Cult;;ACTIVE;1.0;2.73 +69730-0;Instructions;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Instructions;Instructions;;ACTIVE;2.38;2.73 +69731-8;Feeling tired or having low energy level in past 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Feeling tired or having low energy level in past 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +6973-2;Zinc;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Deprecated Zinc [Mass/volume] in Serum or Plasma;Deprecated Zinc Plas-mCnc;;DEPRECATED;1.0h(2);2.36 +69732-6;Trouble sleeping in past 4W;Find;4W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Trouble sleeping in past 4 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69733-4;Worrying too much about different things in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Worrying too much about different things in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69734-2;Trouble relaxing in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Trouble relaxing in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69735-9;Being so restless that it is hard to sit still in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Being so restless that it is hard to sit still in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69736-7;Feeling afraid as if something awful might happen in last 2W;Find;2W;^Patient;Ord;Reported.PHQ;SURVEY.PHQ;4;Feeling afraid as if something awful might happen in last 2 weeks [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.54 +69737-5;Generalized anxiety disorder 7 item;-;Pt;^Patient;-;;PANEL.SURVEY.PHQ;4;Generalized anxiety disorder 7 item (GAD-7);;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.38;2.4 +69738-3;Differential panel, method unspecified;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;Differential panel, method unspecified - Blood;Diff pnl,unspecified Bld;;ACTIVE;2.40;2.42 +69739-1;Drugs of abuse panel;-;Pt;Urine;-;Screen;PANEL.DRUG/TOX;1;Drugs of abuse panel - Urine by Screen method;Drugs of abuse Pnl Ur Scn;;ACTIVE;2.40;2.73 +6974-0;Zirconium;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Zirconium [Mass/volume] in Specimen;Zirconium Spec-mCnc;;ACTIVE;1.0h(2);2.69 +69740-9;Cell count panel;-;Pt;Pericard fld;Qn;;PANEL.HEM/BC;1;Cell count panel - Pericardial fluid;Cell Cnt Pnl Pcar;;ACTIVE;2.40;2.42 +69741-7;Differential panel;-;Pt;Pericard fld;-;;PANEL.HEM/BC;1;Differential panel - Pericardial fluid;Diff Pnl Pcar;;ACTIVE;2.40;2.42 +69742-5;Complete blood count W Differential panel, method unspecified;-;Pt;Bld;Qn;;PANEL.HEM/BC;1;CBC W Differential panel, method unspecified - Blood;CBC W Diff pnl,unspecified Bld;;ACTIVE;2.40;2.68 +69747-4;Does the patient have any environmental allergies;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Does the patient have any environmental allergies NEMSIS;Any environmental allergies NEMSIS;;ACTIVE;2.38;2.5 +69748-2;Known allergies to food or environmental agents;Find;Pt;^Patient;Nar;NEMSIS;NEMSIS;2;Deprecated Known allergies to food or environmental agents Narrative NEMSIS;Deprecated Allergies to food environment;;DEPRECATED;2.38;2.54 +69749-0;Is the patient on anticoagulants;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Is the patient on anticoagulants NEMSIS;Pt on anticoagulants NEMSIS;;ACTIVE;2.38;2.5 +69750-8;EMS unit GPS latitude^at dispatch;Angle;Pt;^Vehicle;Qn;;NEMSIS;2;EMS unit GPS latitude Vehicle --at dispatch;EMS unit lat at dispatch Vehicle;;ACTIVE;2.38;2.64 +69751-6;OPTIMAL change scores - difficulty;-;Pt;^Patient;-;OPTIMAL;PANEL.SURVEY.OPTIMAL;4;OPTIMAL change scores - difficulty;;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69752-4;OPTIMAL change scores - confidence;-;Pt;^Patient;-;OPTIMAL;PANEL.SURVEY.OPTIMAL;4;OPTIMAL change scores - confidence;;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.38;2.67 +69753-2;Bordetella pertussis+Bordetella parapertussis.filamentous hemagglutinin Ab.IgA;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Bordetella pertussis+Bordetella parapertussis filamentous hemagglutinin IgA Ab [Presence] in Serum by Line blot;B pert+para.FHA IgA Ser Ql Line blot;;ACTIVE;2.56;2.64 +69754-0;Bordetella pertussis+Bordetella parapertussis.filamentous hemagglutinin Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Bordetella pertussis+Bordetella parapertussis filamentous hemagglutinin IgG Ab [Presence] in Serum by Line blot;B pert+para.FHA IgG Ser Ql Line blot;;ACTIVE;2.56;2.64 +69755-7;Bordetella pertussis.pertussis toxin Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Bordetella pertussis.pertussis toxin IgG Ab [Presence] in Serum by Line blot;B pert.PT IgG Ser Ql Line blot;;ACTIVE;2.56;2.64 +69756-5;Bordetella sp filamentous hemagglutinin & pertussis toxin Ab.IgA & IgG panel;-;Pt;Ser;-;Line blot;PANEL.MICRO;1;Bordetella sp filamentous hemagglutinin and pertussis toxin Ab.IgA and IgG panel - Serum by Line blot;Bord sp FHA + PT IgA+IgG pnl Ser Ln blot;;ACTIVE;2.56;2.64 +6975-7;Amikacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Amikacin [Susceptibility] by Gradient strip;Amikacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69757-3;Indications of drug or alcohol use by the patient;Find;Pt;^Patient;Ord;NEMSIS;NEMSIS;2;Indications of drug or alcohol use by the patient NEMSIS;Indications drug alcohol by pt NEMSIS;;ACTIVE;2.38;2.5 +69758-1;Diagram of device;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Diagram of device;FDA insert Diagram of device;;ACTIVE;2.40;2.4 +69759-9;Risks;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Risks;FDA insert Risks;;ACTIVE;2.40;2.4 +69760-7;Compatible accessories;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Compatible accessories;FDA insert Compatible accessories;;ACTIVE;2.40;2.4 +69761-5;Alarms;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Alarms;FDA insert Alarms;;ACTIVE;2.40;2.4 +69762-3;Troubleshooting;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Troubleshooting;FDA insert Troubleshooting;;ACTIVE;2.40;2.4 +69763-1;Disposal and waste handling;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Disposal and waste handling;FDA insert Disposal/Waste handling;;ACTIVE;2.40;2.4 +69764-9;Document type identifier;ID;Pt;Form;Nom;;DOC.MISC;2;Document type ID;Document type ID;;ACTIVE;2.40;2.73 +6976-5;Amoxicillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Amoxicillin [Susceptibility] by Gradient strip;Amoxicillin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69765-6;Rubella virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Rubella virus IgM Ab [Presence] in Body fluid by Immunoassay;RUBV IgM Fld Ql IA;;ACTIVE;2.40;2.68 +69766-4;Mumps virus Ab.IgM;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Mumps virus IgM Ab [Presence] in Body fluid by Immunoassay;MuV IgM Fld Ql IA;;ACTIVE;2.40;2.68 +69767-2;La Crosse virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;La Crosse virus RNA [Presence] in Specimen by NAA with probe detection;LACV RNA Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +69768-0;2-Oxoadipate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Oxoadipate [Moles/volume] in Serum or Plasma;2-Oxoadipate SerPl-sCnc;;ACTIVE;2.40;2.7 +69769-8;Dicarboxyoleylcarnitine (C18:1-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dicarboxyoleylcarnitine (C18:1-DC)/Creatinine [Molar ratio] in Urine;Dicarboxyoleylcarn/Creat Ur-sRto;;ACTIVE;2.40;2.7 +69770-6;Dicarboxyoleylcarnitine (C18:1-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Dicarboxyoleylcarnitine (C18:1-DC) [Moles/volume] in Cerebral spinal fluid;Dicarboxyoleylcarn CSF-sCnc;;ACTIVE;2.40;2.7 +69771-4;Dicarboxyoleylcarnitine (C18:1-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dicarboxyoleylcarnitine (C18:1-DC) [Moles/volume] in Amniotic fluid;Dicarboxyoleylcarn Amn-sCnc;;ACTIVE;2.40;2.7 +69772-2;Orotate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Orotate [Moles/volume] in Serum or Plasma;Orotate SerPl-sCnc;;ACTIVE;2.40;2.7 +6977-3;Amoxicillin+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Amoxicillin+Clavulanate [Susceptibility] by Gradient strip;Amoxicillin+Clav Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69773-0;Dicarboxyoleylcarnitine (C18:1-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Dicarboxyoleylcarnitine (C18:1-DC) [Moles/volume] in Urine;Dicarboxyoleylcarn Ur-sCnc;;ACTIVE;2.40;2.7 +69774-8;Propionylcarnitine (C3);SCnc;Pt;Urine;Qn;;CHEM;1;Propionylcarnitine (C3) [Moles/volume] in Urine;Propionylcarn Ur-sCnc;;ACTIVE;2.40;2.7 +69775-5;Stearoylcarnitine (C18);SCnc;Pt;Urine;Qn;;CHEM;1;Stearoylcarnitine (C18) [Moles/volume] in Urine;Stearoylcarn Ur-sCnc;;ACTIVE;2.40;2.7 +69776-3;Suberylcarnitine (C8-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Suberylcarnitine (C8-DC)/Creatinine [Molar ratio] in Urine;Suberylcarn/Creat Ur-sRto;;ACTIVE;2.40;2.7 +69777-1;Suberylcarnitine (C8-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Suberylcarnitine (C8-DC) [Moles/volume] in Cerebral spinal fluid;Suberylcarn CSF-sCnc;;ACTIVE;2.40;2.7 +69778-9;Suberylcarnitine (C8-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Suberylcarnitine (C8-DC) [Moles/volume] in Amniotic fluid;Suberylcarn Amn-sCnc;;ACTIVE;2.40;2.7 +69779-7;Suberylcarnitine (C8-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Suberylcarnitine (C8-DC) [Moles/volume] in Urine;Suberylcarn Ur-sCnc;;ACTIVE;2.40;2.7 +69780-5;2-Hydroxyisovalerate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Hydroxyisovalerate [Moles/volume] in Cerebral spinal fluid;2OH-isovalerate CSF-sCnc;;ACTIVE;2.40;2.7 +6978-1;Amphotericin B;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Amphotericin B [Susceptibility] by Gradient strip;Amphotericin B Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69781-3;2-Hydroxyisovalerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxyisovalerate [Moles/volume] in Serum or Plasma;2OH-isovalerate SerPl-sCnc;;ACTIVE;2.40;2.7 +69782-1;2-Hydroxyphenylacetate;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;2-Hydroxyphenylacetate [Moles/volume] in Cerebral spinal fluid;2OH-phenylacetate CSF-sCnc;;ACTIVE;2.40;2.7 +69783-9;2-Hydroxyphenylacetate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;2-Hydroxyphenylacetate [Moles/volume] in Serum or Plasma;2OH-phenylacetate SerPl-sCnc;;ACTIVE;2.40;2.7 +69784-7;2-Hydroxysebacate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Hydroxysebacate [Moles/volume] in Cerebral spinal fluid;2OH-sebacate CSF-sCnc;;ACTIVE;2.40;2.7 +69785-4;2-Hydroxysebacate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxysebacate [Moles/volume] in Serum or Plasma;2OH-sebacate SerPl-sCnc;;ACTIVE;2.40;2.7 +69786-2;2-Methylacetoacetate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Methylacetoacetate [Moles/volume] in Cerebral spinal fluid;2-Methylacetoacetate CSF-sCnc;;ACTIVE;2.40;2.7 +69787-0;2-Methylacetoacetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Methylacetoacetate [Moles/volume] in Serum or Plasma;2-Methylacetoacetate SerPl-sCnc;;ACTIVE;2.40;2.7 +69788-8;2-Methyl-3-Hydroxybutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;2-methyl-3-hydroxybutyrate (C5-OH) [Moles/volume] in Cerebral spinal fluid;2Me3OH-butyrate CSF-sCnc;;ACTIVE;2.40;2.7 +69789-6;2-Methyl-3-Hydroxybutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-methyl-3-hydroxybutyrate (C5-OH) [Moles/volume] in Serum or Plasma;2Me3OH-butyrate SerPl-sCnc;;ACTIVE;2.40;2.7 +69790-4;2-Methylbutyrylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Methylbutyrylglycine [Moles/volume] in Serum or Plasma;2Me-butyrylglycine SerPl-sCnc;;ACTIVE;2.40;2.7 +69791-2;Tetradecadienoylcarnitine (C14:2)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2)/Creatinine [Molar ratio] in Urine;Tdecadienoylcarn/Creat Ur-sRto;;ACTIVE;2.40;2.7 +69792-0;Tetradecadienoylcarnitine (C14:2);SCnc;Pt;CSF;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2) [Moles/volume] in Cerebral spinal fluid;Tdecadienoylcarn CSF-sCnc;;ACTIVE;2.40;2.7 +69793-8;Tetradecadienoylcarnitine (C14:2);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2) [Moles/volume] in Amniotic fluid;Tdecadienoylcarn Amn-sCnc;;ACTIVE;2.40;2.7 +69794-6;Tetradecadienoylcarnitine (C14:2);SCnc;Pt;Urine;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2) [Moles/volume] in Urine;Tdecadienoylcarn Ur-sCnc;;ACTIVE;2.40;2.7 +69795-3;Dicarboxytetradecenoylcarnitine (C14:1-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dicarboxytetradecenoylcarnitine (C14:1-DC)/Creatinine [Molar ratio] in Urine;Dicarboxytetradecenoylcarn/Creat Ur-sRto;;ACTIVE;2.40;2.7 +69796-1;17-Hydroxyprogesterone;SCnc;Pt;Amnio fld;Qn;;CHEM;1;17-Hydroxyprogesterone [Moles/volume] in Amniotic fluid;17OHP Amn-sCnc;;ACTIVE;2.40;2.7 +69797-9;1-Hydroxymidazolam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1-Hydroxymidazolam [Mass/volume] in Serum or Plasma;1OH-midazolam SerPl-mCnc;;ACTIVE;2.40;2.73 +69798-7;2,5-dimethoxy-4-bromoamphetamine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;2,5-dimethoxy-4-bromoamphetamine [Presence] in Urine;2,5-DOB Ur Ql;;ACTIVE;2.40;2.56 +6979-9;Ampicillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ampicillin [Susceptibility] by Gradient strip;Ampicillin Islt Grad strip;;ACTIVE;1.0h(2);2.73 +69799-5;21-Deoxycorticosterone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;21-Deoxycorticosterone [Moles/volume] in Serum or Plasma;21DOC SerPl-sCnc;;ACTIVE;2.40;2.7 +69800-1;Methyl ethyl ketone;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Methyl ethyl ketone [Mass/volume] in Body fluid;MEK Fld-mCnc;;ACTIVE;2.40;2.7 +69801-9;2-Oxoadipate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Oxoadipate [Moles/volume] in Cerebral spinal fluid;2-Oxoadipate CSF-sCnc;;ACTIVE;2.40;2.7 +69802-7;Alpha ketoglutarate;SCnc;Pt;CSF;Qn;;CHEM;1;Alpha ketoglutarate [Moles/volume] in Cerebral spinal fluid;A-Ketoglut CSF-sCnc;;ACTIVE;2.40;2.7 +69803-5;Alpha ketoglutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha ketoglutarate [Moles/volume] in Serum or Plasma;A-Ketoglut SerPl-sCnc;;ACTIVE;2.40;2.7 +69804-3;2-Oxoisocaproate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Oxoisocaproate [Moles/volume] in Cerebral spinal fluid;2Oxoisocaproate CSF-sCnc;;ACTIVE;2.40;2.7 +69805-0;2-Dechloroethylifosfamide^12H post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --12 hours post dose ifosfamide;2-DCE-IF 12H p IFF Bld-mCnc;;ACTIVE;2.40;2.7 +69806-8;2-Dechloroethylifosfamide^post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --post dose ifosfamide;2-DCE-IF p IFF Bld-mCnc;;ACTIVE;2.40;2.7 +6980-7;Ampicillin+Sulbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ampicillin+Sulbactam [Susceptibility] by Gradient strip;Ampicillin+Sulbac Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69807-6;2-Dechloroethylifosfamide^pre dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --pre dose ifosfamide;2-DCE-IF pre IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +69808-4;2-Dechloroethylifosfamide^pre dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --pre dose ifosfamide;2-DCE-IF pre IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +69809-2;2-Dechloroethylifosfamide^1D post dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --1 day post dose ifosfamide;2-DCE-IF 1D p IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +698-1;Neisseria gonorrhoeae;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Specimen by Organism specific culture;N gonorrhoea Spec Ql Cult;;ACTIVE;1.0;2.73 +69810-0;2-Dechloroethylifosfamide^1D post dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --1 day post dose ifosfamide;2-DCE-IF 1D p IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +69811-8;2-Dechloroethylifosfamide^2D post dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --2 days post dose ifosfamide;2-DCE-IF 2D p IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +69812-6;2-Dechloroethylifosfamide^2D post dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --2 days post dose ifosfamide;2-DCE-IF 2D p IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +69813-4;2-Dechloroethylifosfamide^3D post dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --3 days post dose ifosfamide;2-DCE-IF 3D p IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +69814-2;2-Dechloroethylifosfamide^3D post dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --3 days post dose ifosfamide;2-DCE-IF 3D p IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +6981-5;Azithromycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Azithromycin [Susceptibility] by Gradient strip;Azithromycin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69815-9;2-Dechloroethylifosfamide^4D post dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --4 days post dose ifosfamide;2-DCE-IF 4D p IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +69816-7;2-Dechloroethylifosfamide^4D post dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --4 days post dose ifosfamide;2-DCE-IF 4D p IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +69817-5;2-Dechloroethylifosfamide^5D post dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --5 days post dose ifosfamide;2-DCE-IF 5D p IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +69818-3;2-Dechloroethylifosfamide^5D post dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --5 days post dose ifosfamide;2-DCE-IF 5D p IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +69819-1;2-Dechloroethylifosfamide^6D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --6 days post dose ifosfamide;2-DCE-IF 6D p IFF Bld-mCnc;;ACTIVE;2.40;2.7 +69820-9;2-Dechloroethylifosfamide^6D post dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --6 days post dose ifosfamide;2-DCE-IF 6D p IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +69821-7;2-Dechloroethylifosfamide^6D post dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --6 days post dose ifosfamide;2-DCE-IF 6D p IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +69822-5;2-Dechloroethylifosfamide^7D post dose ifosfamide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in Blood --7 days post dose ifosfamide;2-DCE-IF 7D p IFF Bld-mCnc;;ACTIVE;2.40;2.7 +6982-3;Aztreonam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Aztreonam [Susceptibility] by Gradient strip;Aztreonam Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69823-3;2-Dechloroethylifosfamide^7D post dose ifosfamide;MRat;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/time] in 24 hour Urine --7 days post dose ifosfamide;2-DCE-IF 7D p IFF 24h Ur-mRate;;ACTIVE;2.40;2.7 +69824-1;2-Dechloroethylifosfamide^7D post dose ifosfamide;MCnc;24H;Urine;Qn;;DRUG/TOX;1;2-Dechloroethylifosfamide [Mass/volume] in 24 hour Urine --7 days post dose ifosfamide;2-DCE-IF 7D p IFF 24h Ur-mCnc;;ACTIVE;2.40;2.7 +69825-8;2-Ethylhydracrylate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Ethylhydracrylate [Moles/volume] in Cerebral spinal fluid;2-ethylhydracrylate CSF-sCnc;;ACTIVE;2.40;2.7 +69826-6;2-Ethylhydracrylate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Ethylhydracrylate [Moles/volume] in Serum or Plasma;2-ethylhydracrylate SerPl-sCnc;;ACTIVE;2.40;2.7 +69827-4;2-Methylglutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Methylglutarate [Moles/volume] in Serum or Plasma;2Me-glutarate SerPl-sCnc;;ACTIVE;2.40;2.7 +69828-2;Methylsuccinate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Methylsuccinate [Moles/volume] in Amniotic fluid;Me-succinate Amn-sCnc;;ACTIVE;2.40;2.7 +69829-0;Methylsuccinate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylsuccinate [Moles/volume] in Serum or Plasma;Me-succinate SerPl-sCnc;;ACTIVE;2.40;2.73 +69830-8;3,4-Dihydroxyphenylacetate;SCnc;24H;Urine;Qn;;DRUG/TOX;1;3,4-Dihydroxyphenylacetate [Moles/volume] in 24 hour Urine;3,4-DiOH-phenylacetate 24h Ur-sCnc;;ACTIVE;2.40;2.7 +6983-1;Bacitracin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Bacitracin [Susceptibility] by Gradient strip;Bacitracin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69831-6;3,4-Dihydroxyphenylacetate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;3,4-Dihydroxyphenylacetate/Creatinine [Molar ratio] in Urine;3,4-DiOH-phenylacetate/Creat Ur-sRto;;ACTIVE;2.40;2.7 +69832-4;3-Hydroxy,3-Methylglutarate;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;3-Hydroxy,3-Methylglutarate [Moles/volume] in Cerebral spinal fluid;3OH3Me-glutarate CSF-sCnc;;ACTIVE;2.40;2.7 +69833-2;3-Hydroxy,3-Methylglutarate;SCnc;Pt;Amnio fld;Qn;;DRUG/TOX;1;3-Hydroxy,3-Methylglutarate [Moles/volume] in Amniotic fluid;3OH3Me-glutarate Amn-sCnc;;ACTIVE;2.40;2.7 +69834-0;3-Hydroxy,3-Methylglutarate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;3-Hydroxy,3-Methylglutarate [Moles/volume] in Serum or Plasma;3OH3Me-glutarate SerPl-sCnc;;ACTIVE;2.40;2.7 +69835-7;3-Hydroxyadipate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxyadipate [Moles/volume] in Cerebral spinal fluid;3OH-Adipate CSF-sCnc;;ACTIVE;2.40;2.7 +69836-5;3-Hydroxyadipate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyadipate [Moles/volume] in Serum or Plasma;3OH-Adipate SerPl-sCnc;;ACTIVE;2.40;2.7 +69837-3;3-Hydroxyglutarate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxyglutarate [Moles/volume] in Cerebral spinal fluid;3OH-Glutarate CSF-sCnc;;ACTIVE;2.40;2.7 +69838-1;2-Hydroxy-3-Methylvalerate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Hydroxy-3-Methylvalerate [Moles/volume] in Cerebral spinal fluid;2OH3Me-valerate CSF-sCnc;;ACTIVE;2.40;2.7 +69839-9;2-Hydroxy-3-Methylvalerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxy-3-Methylvalerate [Moles/volume] in Serum or Plasma;2OH3Me-valerate SerPl-sCnc;;ACTIVE;2.40;2.7 +69840-7;2-Hydroxyadipate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Hydroxyadipate [Moles/volume] in Cerebral spinal fluid;2OH-adipate CSF-sCnc;;ACTIVE;2.40;2.7 +69841-5;2-Hydroxyadipate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxyadipate [Moles/volume] in Serum or Plasma;2OH-adipate SerPl-sCnc;;ACTIVE;2.40;2.7 +69842-3;Alpha hydroxybutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;Alpha hydroxybutyrate [Moles/volume] in Cerebral spinal fluid;A-OH-Butyr CSF-sCnc;;ACTIVE;2.40;2.7 +69843-1;Alpha hydroxybutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha hydroxybutyrate [Moles/volume] in Serum or Plasma;A-OH-Butyr SerPl-sCnc;;ACTIVE;2.40;2.7 +69844-9;2-Hydroxyglutarate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Hydroxyglutarate [Moles/volume] in Cerebral spinal fluid;2OH-gluterate CSF-sCnc;;ACTIVE;2.40;2.7 +69845-6;2-Hydroxyglutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxyglutarate [Moles/volume] in Serum or Plasma;2OH-gluterate SerPl-sCnc;;ACTIVE;2.40;2.73 +69846-4;2-Hydroxyisobutyrate;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;2-Hydroxyisobutyrate [Moles/volume] in Cerebral spinal fluid;2OH-isobutyrate CSF-sCnc;;ACTIVE;2.40;2.7 +69847-2;2-Hydroxyisobutyrate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;2-Hydroxyisobutyrate [Moles/volume] in Serum or Plasma;2OH-isobutyrate SerPl-sCnc;;ACTIVE;2.40;2.7 +69848-0;2-Hydroxyisocaproate;SCnc;Pt;CSF;Qn;;CHEM;1;2-Hydroxyisocaproate [Moles/volume] in Cerebral spinal fluid;2OH-isocaproate CSF-sCnc;;ACTIVE;2.40;2.7 +6984-9;Beta lactamase.extended spectrum;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Beta lactamase.extended spectrum [Susceptibility];B-Lactamase Extended Susc Islt;;ACTIVE;1.0h(2);2.73 +69849-8;2-Hydroxyisocaproate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Hydroxyisocaproate [Moles/volume] in Serum or Plasma;2OH-isocaproate SerPl-sCnc;;ACTIVE;2.40;2.7 +69850-6;3-Hydroxyglutarate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Hydroxyglutarate [Moles/volume] in Amniotic fluid;3OH-Glutarate Amn-sCnc;;ACTIVE;2.40;2.7 +69851-4;3-Hydroxyglutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyglutarate [Moles/volume] in Serum or Plasma;3OH-Glutarate SerPl-sCnc;;ACTIVE;2.40;2.73 +69852-2;3-Hydroxyisobutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxyisobutyrate [Moles/volume] in Cerebral spinal fluid;3OH-Isobutyrate CSF-sCnc;;ACTIVE;2.40;2.7 +69853-0;3-Hydroxyisobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyisobutyrate [Moles/volume] in Serum or Plasma;3OH-Isobutyrate SerPl-sCnc;;ACTIVE;2.40;2.7 +69854-8;Hispanic, latino-a, or spanish origin;Find;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Hispanic, latino-a, or spanish origin;Hispanic, latino-a, or spanish;;ACTIVE;2.40;2.68 +69855-5;Race;Type;Pt;^Patient;Nom;HHS.ACA Section 4302;SURVEY.HHS;4;Race [HHS.ACA Section 4302];;;ACTIVE;2.40;2.67 +6985-6;Beta lactamase.usual;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Beta lactamase.usual [Susceptibility];B-Lactamase Usual Susc Islt;;ACTIVE;1.0h(2);2.73 +69856-3;Are you deaf, or do you have serious difficulty hearing;Find;Pt;^Patient;Ord;;SURVEY.HHS;4;Are you deaf, or do you have serious difficulty hearing;;;ACTIVE;2.40;2.71 +69857-1;Are you blind, or do you have serious difficulty seeing, even when wearing glasses;Find;Pt;^Patient;Ord;;SURVEY.HHS;4;Are you blind, or do you have serious difficulty seeing, even when wearing glasses;;;ACTIVE;2.40;2.71 +69858-9;Because of a physical, mental, or emotional condition, do you have serious difficulty concentrating, remembering, or making decisions;Find;Pt;^Patient;Ord;;SURVEY.HHS;4;Because of a physical, mental, or emotional condition, do you have serious difficulty concentrating, remembering, or making decisions;;;ACTIVE;2.40;2.71 +69859-7;Do you have serious difficulty walking or climbing stairs;Find;Pt;^Patient;Ord;;SURVEY.HHS;4;Do you have serious difficulty walking or climbing stairs;;;ACTIVE;2.40;2.71 +69860-5;Do you have difficulty dressing or bathing;Find;Pt;^Patient;Ord;;SURVEY.HHS;4;Do you have difficulty dressing or bathing;;;ACTIVE;2.40;2.71 +69861-3;Because of a physical, mental, or emotional condition, do you have difficulty doing errands alone such as visiting a physician's office or shopping;Find;Pt;^Patient;Ord;;SURVEY.HHS;4;Because of a physical, mental, or emotional condition, do you have difficulty doing errands alone such as visiting a physician's office or shopping;;;ACTIVE;2.40;2.71 +69862-1;Exclusion criteria - assays;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Exclusion criteria - assays PhenX;Exclusion criteria - assays PhenX;;TRIAL;2.40;2.4 +69863-9;Process variables for assays;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Process variables for assays PhenX;Process variables assays PhenX;;TRIAL;2.40;2.4 +6986-4;Cefaclor;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefaclor [Susceptibility] by Gradient strip;Cefaclor Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69864-7;Manufacturer variables for assays;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Manufacturer variables for assays PhenX;Manufacturer variables assays PhenX;;TRIAL;2.40;2.67 +69865-4;Process variables for assays - gonorrhea-chlamydia;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Process variables for assays - gonorrhea-chlamydia PhenX;Process for assays-GC/Chlamydia PhenX;;TRIAL;2.40;2.4 +69866-2;Process variables for assays - human leukocyte antigen - HLA;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Process variables for assays - human leukocyte antigen - HLA PhenX;Process for assays-HLA PhenX;;TRIAL;2.40;2.4 +69867-0;Active diagnoses based on review of patient records;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Active diagnoses based on review of patient records [CARE];;;DISCOURAGED;2.40;2.64 +69868-8;Service comment 41;Imp;Pt;XXX;Nom;;MISC;1;Service comment 41;Service Cmnt 41-Imp;;ACTIVE;2.40;2.73 +69869-6;Service comment 42;Imp;Pt;XXX;Nom;;MISC;1;Service comment 42;Service Cmnt 42-Imp;;ACTIVE;2.40;2.73 +69870-4;Service comment 43;Imp;Pt;XXX;Nom;;MISC;1;Service comment 43;Service Cmnt 43-Imp;;ACTIVE;2.40;2.69 +69871-2;Service comment 44;Imp;Pt;XXX;Nom;;MISC;1;Service comment 44;Service Cmnt 44-Imp;;ACTIVE;2.40;2.69 +6987-2;Cefepime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefepime [Susceptibility] by Gradient strip;Cefepime Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69872-0;Service comment 45;Imp;Pt;XXX;Nom;;MISC;1;Service comment 45;Service Cmnt 45-Imp;;ACTIVE;2.40;2.73 +69873-8;Service comment 46;Imp;Pt;XXX;Nom;;MISC;1;Service comment 46;Service Cmnt 46-Imp;;ACTIVE;2.40;2.69 +69874-6;Service comment 47;Imp;Pt;XXX;Nom;;MISC;1;Service comment 47;Service Cmnt 47-Imp;;ACTIVE;2.40;2.73 +69875-3;Service comment 48;Imp;Pt;XXX;Nom;;MISC;1;Service comment 48;Service Cmnt 48-Imp;;ACTIVE;2.40;2.69 +69876-1;Service comment 49;Imp;Pt;XXX;Nom;;MISC;1;Service comment 49;Service Cmnt 49-Imp;;ACTIVE;2.40;2.73 +69877-9;Service comment 50;Imp;Pt;XXX;Nom;;MISC;1;Service comment 50;Service Cmnt 50-Imp;;ACTIVE;2.40;2.69 +69878-7;Service comment 51;Imp;Pt;XXX;Nom;;MISC;1;Service comment 51;Service Cmnt 51-Imp;;ACTIVE;2.40;2.69 +69879-5;Service comment 52;Imp;Pt;XXX;Nom;;MISC;1;Service comment 52;Service Cmnt 52-Imp;;ACTIVE;2.40;2.69 +6988-0;Cefodizime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefodizime [Susceptibility] by Gradient strip;Cefodizime Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69880-3;Service comment 53;Imp;Pt;XXX;Nom;;MISC;1;Service comment 53;Service Cmnt 53-Imp;;ACTIVE;2.40;2.69 +69881-1;Service comment 54;Imp;Pt;XXX;Nom;;MISC;1;Service comment 54;Service Cmnt 54-Imp;;ACTIVE;2.40;2.69 +69882-9;Service comment 55;Imp;Pt;XXX;Nom;;MISC;1;Service comment 55;Service Cmnt 55-Imp;;ACTIVE;2.40;2.69 +69883-7;Service comment 56;Imp;Pt;XXX;Nom;;MISC;1;Service comment 56;Service Cmnt 56-Imp;;ACTIVE;2.40;2.69 +69884-5;Service comment 57;Imp;Pt;XXX;Nom;;MISC;1;Service comment 57;Service Cmnt 57-Imp;;ACTIVE;2.40;2.69 +69885-2;Service comment 58;Imp;Pt;XXX;Nom;;MISC;1;Service comment 58;Service Cmnt 58-Imp;;ACTIVE;2.40;2.69 +69886-0;Service comment 59;Imp;Pt;XXX;Nom;;MISC;1;Service comment 59;Service Cmnt 59-Imp;;ACTIVE;2.40;2.69 +69887-8;Service comment 60;Imp;Pt;XXX;Nom;;MISC;1;Service comment 60;Service Cmnt 60-Imp;;ACTIVE;2.40;2.69 +69888-6;Service comment 61;Imp;Pt;XXX;Nom;;MISC;1;Service comment 61;Service Cmnt 61-Imp;;ACTIVE;2.40;2.69 +69889-4;Service comment 62;Imp;Pt;XXX;Nom;;MISC;1;Service comment 62;Service Cmnt 62-Imp;;ACTIVE;2.40;2.69 +69890-2;Service comment 63;Imp;Pt;XXX;Nom;;MISC;1;Service comment 63;Service Cmnt 63-Imp;;ACTIVE;2.40;2.69 +69891-0;Service comment 64;Imp;Pt;XXX;Nom;;MISC;1;Service comment 64;Service Cmnt 64-Imp;;ACTIVE;2.40;2.69 +69892-8;Service comment 65;Imp;Pt;XXX;Nom;;MISC;1;Service comment 65;Service Cmnt 65-Imp;;ACTIVE;2.40;2.69 +69893-6;Service comment 66;Imp;Pt;XXX;Nom;;MISC;1;Service comment 66;Service Cmnt 66-Imp;;ACTIVE;2.40;2.69 +69894-4;Service comment 67;Imp;Pt;XXX;Nom;;MISC;1;Service comment 67;Service Cmnt 67-Imp;;ACTIVE;2.40;2.69 +69895-1;Service comment 68;Imp;Pt;XXX;Nom;;MISC;1;Service comment 68;Service Cmnt 68-Imp;;ACTIVE;2.40;2.69 +69896-9;Service comment 69;Imp;Pt;XXX;Nom;;MISC;1;Service comment 69;Service Cmnt 69-Imp;;ACTIVE;2.40;2.69 +69897-7;Service comment 70;Imp;Pt;XXX;Nom;;MISC;1;Service comment 70;Service Cmnt 70-Imp;;ACTIVE;2.40;2.69 +6989-8;Cefotaxime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefotaxime [Susceptibility] by Gradient strip;Cefotaxime Islt Grad strip;;ACTIVE;1.0h(2);2.73 +69898-5;Service comment 71;Imp;Pt;XXX;Nom;;MISC;1;Service comment 71;Service Cmnt 71-Imp;;ACTIVE;2.40;2.69 +69899-3;Service comment 72;Imp;Pt;XXX;Nom;;MISC;1;Service comment 72;Service Cmnt 72-Imp;;ACTIVE;2.40;2.69 +69900-9;Service comment 73;Imp;Pt;XXX;Nom;;MISC;1;Service comment 73;Service Cmnt 73-Imp;;ACTIVE;2.40;2.73 +69901-7;Service comment 74;Imp;Pt;XXX;Nom;;MISC;1;Service comment 74;Service Cmnt 74-Imp;;ACTIVE;2.40;2.69 +69902-5;Service comment 75;Imp;Pt;XXX;Nom;;MISC;1;Service comment 75;Service Cmnt 75-Imp;;ACTIVE;2.40;2.69 +69903-3;Service comment 76;Imp;Pt;XXX;Nom;;MISC;1;Service comment 76;Service Cmnt 76-Imp;;ACTIVE;2.40;2.69 +69904-1;Service comment 77;Imp;Pt;XXX;Nom;;MISC;1;Service comment 77;Service Cmnt 77-Imp;;ACTIVE;2.40;2.69 +69905-8;Service comment 78;Imp;Pt;XXX;Nom;;MISC;1;Service comment 78;Service Cmnt 78-Imp;;ACTIVE;2.40;2.69 +6990-6;cefoTEtan;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefoTEtan [Susceptibility] by Gradient strip;cefoTEtan Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69906-6;Service comment 79;Imp;Pt;XXX;Nom;;MISC;1;Service comment 79;Service Cmnt 79-Imp;;ACTIVE;2.40;2.69 +69907-4;Service comment 80;Imp;Pt;XXX;Nom;;MISC;1;Service comment 80;Service Cmnt 80-Imp;;ACTIVE;2.40;2.69 +69908-2;Multisection^W contrast IV;Find;Pt;Abdomen>Abdominal vessels & Pelvis>Pelvis vessels;Doc;CT.angio;RAD;2;CTA Abdominal vessels and Pelvis vessels W contrast IV;CTA Abd ves+Pelvis ves W contr IV;;ACTIVE;2.40;2.68 +69910-8;Basophils+Mast cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Basophils+Mast cells/100 leukocytes in Body fluid;Basophils/Masts/leuk NFr Fld;;ACTIVE;2.40;2.73 +69913-2;Basophils+Mast cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Basophils+Mast cells/100 leukocytes in Cerebral spinal fluid;Basophils/Masts/leuk NFr CSF;;ACTIVE;2.40;2.73 +6991-4;cefOXitin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefOXitin [Susceptibility] by Gradient strip;cefOXitin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69916-5;Basophils+Mast cells/100 leukocytes;NFr;Pt;Synv fld;Qn;;HEM/BC;1;Basophils+Mast cells/100 leukocytes in Synovial fluid;Basophils/Masts/leuk NFr Snv;;ACTIVE;2.40;2.73 +69918-1;Coagulation thrombin induced.high dose;Time;Pt;PPP;Qn;Coag;COAG;1;Thrombin time.high dose in Platelet poor plasma by Coagulation assay;HiTT PPP;;ACTIVE;2.40;2.73 +69919-9;Race, ethnicity, sex, primary language, disability - Health & Human Services (HHS) panel;-;Pt;^Patient;-;HHS.ACA Section 4302;PANEL.SURVEY.HHS;4;Race, ethnicity, sex, primary language, disability - Health and Human Services (HHS) panel [HHS.ACA Section 4302];;;TRIAL;2.40;2.44 +69920-7;Adenovirus Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Adenovirus IgA Ab [Presence] in Serum by Immunoassay;HAdV IgA Ser Ql IA;;ACTIVE;2.40;2.56 +69921-5;Herpes simplex virus 1 Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Herpes simplex virus 1 IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;HSV1 IgM CSF Ql IA;;ACTIVE;2.40;2.56 +6992-2;Cefpirome;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefpirome [Susceptibility] by Gradient strip;Cefpirome Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69922-3;(Beef+Chicken+Pork) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix fx73 (Beef+Chicken+Pork) IgE Ab [Units/volume] in Serum by Multidisk;Food Allergen Mix fx73 IgE Qn;;ACTIVE;2.40;2.7 +69923-1;European tick borne encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;European tick borne encephalitis virus IgM Ab [Presence] in Serum by Immunoassay;TBEV IgM Ser Ql IA;;ACTIVE;2.40;2.68 +69924-9;European tick borne encephalitis virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;European tick borne encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;TBEV IgM CSF Ql IA;;ACTIVE;2.40;2.68 +69925-6;European tick borne encephalitis virus Ab.IgM index;ACnc;Pt;Ser+CSF;Qn;IA;MICRO;1;European tick borne encephalitis virus IgM Ab index [Units/volume] in Serum and CSF by Immunoassay;TBEV IgM Index Ser+CSF IA-aCnc;;ACTIVE;2.40;2.7 +69926-4;European tick borne encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;European tick borne encephalitis virus IgG Ab [Presence] in Serum by Immunoassay;TBEV IgG Ser Ql IA;;ACTIVE;2.40;2.68 +69927-2;European tick borne encephalitis virus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;European tick borne encephalitis virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;TBEV IgG CSF Ql IA;;ACTIVE;2.40;2.68 +69928-0;European tick borne encephalitis virus Ab.IgG index;ACnc;Pt;Ser+CSF;Qn;IA;MICRO;1;European tick borne encephalitis virus IgG Ab index [Units/volume] in Serum and CSF by Immunoassay;TBEV IgG Index Ser+CSF IA-aCnc;;ACTIVE;2.40;2.7 +69929-8;Respiratory syncytial virus Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Respiratory syncytial virus IgA Ab [Presence] in Serum by Immunoassay;RSV IgA Ser Ql IA;;ACTIVE;2.40;2.68 +6993-0;Cefpodoxime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefpodoxime [Susceptibility] by Gradient strip;Cefpodoxime Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69930-6;Varicella zoster virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Varicella zoster virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;VZV IgM CSF Ql IA;;ACTIVE;2.40;2.68 +69931-4;(Daucus carota+Phaseolus vulgaris+Pisum sativum+Solanum tuberosum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 13 (Carrot+White bean+Peas+Potato) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix13 IgE Qn;;ACTIVE;2.40;2.7 +69933-0;Ureaplasma parvum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ureaplasma parvum DNA [Presence] in Specimen by NAA with probe detection;U parvum DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +69934-8;Ureaplasma urealyticum+Ureaplasma parvum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ureaplasma urealyticum+Ureaplasma parvum DNA [Presence] in Specimen by NAA with probe detection;U urealyt+U parvum DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.72 +69935-5;Mycoplasma genitalium DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Specimen by NAA with probe detection;M genitalium DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +69936-3;Gardnerella vaginalis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Gardnerella vaginalis DNA [Presence] in Specimen by NAA with probe detection;G vaginalis DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +69937-1;Trichomonas vaginalis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis DNA [Presence] in Specimen by NAA with probe detection;T vaginalis DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +69938-9;Astrovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Astrovirus RNA [Presence] in Specimen by NAA with probe detection;HAstV RNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +69939-7;Trichophyton rubrum DNA;PrThr;Pt;Nail;Ord;Probe.amp.tar;MICRO;1;Trichophyton rubrum DNA [Presence] in Nail by NAA with probe detection;T rubrum DNA Nail Ql NAA+probe;;ACTIVE;2.40;2.68 +69941-3;Glucose^20M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20 minutes post dose lactose PO;Glucose 20M p Lac PO SerPl-sCnc;;ACTIVE;2.40;2.7 +69942-1;Glucose^40M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --40 minutes post dose lactose PO;Glucose 40M p Lac PO SerPl-sCnc;;ACTIVE;2.40;2.7 +69943-9;Glucose^20M post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --20 minutes post 50 g lactose PO;Glucose 20M p 50 g lac PO SerPl-sCnc;;ACTIVE;2.40;2.7 +69944-7;Glucose^40M post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --40 minutes post 50 g lactose PO;Glucose 40M p 50 g lac PO SerPl-sCnc;;ACTIVE;2.40;2.7 +69945-4;Insulin-like growth factor binding protein 1;PrThr;Pt;Vag;Ord;;CHEM;1;Insulin-like growth factor binding protein 1 [Presence] in Vaginal fluid;IGF BP1 Vag Ql;;ACTIVE;2.40;2.73 +69946-2;Treponema pallidum Ab.IgM;PrThr;Pt;CSF;Ord;IB;MICRO;1;Treponema pallidum IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;T pallidum IgM CSF Ql IB;;ACTIVE;2.40;2.68 +69947-0;Triglyceride;SCnc;Pt;Pericard fld;Qn;;CHEM;1;Triglyceride [Moles/volume] in Pericardial fluid;Trigl Pcar-sCnc;;ACTIVE;2.40;2.7 +6994-8;Cefprozil;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefprozil [Susceptibility] by Gradient strip;Cefprozil Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69948-8;Bordetella parapertussis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bordetella parapertussis IgG Ab [Presence] in Serum by Immunoassay;B parapert IgG Ser Ql IA;;ACTIVE;2.40;2.68 +69949-6;Epstein Barr virus capsid Ab.IgG avidity;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epstein Barr virus capsid IgG Ab avidity [Presence] in Serum by Immunoassay;EBV VCA IgG Avidity Ser Ql IA;;ACTIVE;2.40;2.68 +69950-4;Hemoglobin;MCnc;Pt;Pericard fld;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Pericardial fluid;Hgb Pcar-mCnc;;ACTIVE;2.40;2.7 +69951-2;Amylase.pancreatic/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Amylase.pancreatic/Creatinine [Ratio] in Urine;Amylase P/Creat Ur-Rto;;ACTIVE;2.40;2.7 +69952-0;Liver kidney microsomal 1 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Liver kidney microsomal 1 IgG Ab [Presence] in Serum by Immunoassay;LKM-1 IgG Ser Ql IA;;ACTIVE;2.40;2.68 +69953-8;Purkinje cell cytoplasmic type 1 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;PCA-1 IgG Ab [Presence] in Serum by Immunoassay;PCA-1 IgG Ser Ql IA;;ACTIVE;2.40;2.68 +69954-6;Neuronal nuclear type 2 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Neuronal nuclear type 2 IgG Ab [Presence] in Serum by Immunoassay;Hu2 IgG Ser Ql IA;;ACTIVE;2.40;2.68 +6995-5;cefTAZidime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefTAZidime [Susceptibility] by Gradient strip;cefTAZidime Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69955-3;Intestinal goblet cell Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Intestinal goblet cell Ab [Presence] in Serum by Immunoassay;Intestinal goblet cell Ab Ser Ql IA;;ACTIVE;2.40;2.68 +69956-1;Human upstream binding factor Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Human upstream binding factor IgG Ab [Presence] in Serum by Immunoassay;hUBF IgG Ser Ql IA;;ACTIVE;2.40;2.68 +69957-9;Proteinase 3 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Proteinase 3 IgG Ab [Presence] in Serum by Immunoassay;Proteinase3 IgG Ser Ql IA;;ACTIVE;2.40;2.68 +69958-7;(Citrus sinensis+Malus sylvestris+Musa spp+Prunus persica) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 15 (Orange+Apple+Banana+Peach) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix15 IgE Qn;;ACTIVE;2.40;2.7 +69959-5;(Alnus incana+Corylus avellana+Ulmus americana+Salix caprea+Populus deltoides) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 5 (Grey alder+Hazelnut+White elm+Willow+Cottonwood) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix5 IgE Qn;;ACTIVE;2.40;2.73 +69960-3;(Anthoxanthum odoratum+Holcus lanatus+Lolium perenne+Phragmites communis+Secale cereale) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 4 (Sweet vernal grass+Velvet grass+Perennial rye grass+Common reed+Rye) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allerg Mix4 IgE Qn;;ACTIVE;2.40;2.7 +69961-1;Hepatitis E virus RNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis E virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HEV RNA SerPl NAA+probe-aCnc;;ACTIVE;2.40;2.73 +69962-9;Respiratory syncytial virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Respiratory syncytial virus IgM Ab [Presence] in Serum by Immunoassay;RSV IgM Ser Ql IA;;ACTIVE;2.40;2.68 +6996-3;Ceftibuten;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ceftibuten [Susceptibility] by Gradient strip;Ceftibuten Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69963-7;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";t(ABL1,BCR)e1a2/control Mar;;ACTIVE;2.40;2.7 +69964-5;Bicarbonate^^standard;SCnc;Pt;Plas;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Plasma;HCO3 std Plas-sCnc;;ACTIVE;2.40;2.7 +69965-2;Clinical cytogeneticist review;Imp;Pt;XXX;Nar;;MOLPATH;1;Clinical cytogeneticist review of results;Clinical cytogeneticist review;;ACTIVE;2.40;2.73 +69966-0;Brief interview for mental status;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Brief interview for mental status (BIMS) [CARE];;;DISCOURAGED;2.40;2.64 +69967-8;Procedure ICD code;Find;Pt;^Patient;Nom;;SURVEY.CARE;4;Procedure ICD code;;;ACTIVE;2.40;2.42 +69968-6;NDC labeler code inactivation;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label NDC labeler code inactivation;FDA label NDC labeler code inactivation;;ACTIVE;2.40;2.4 +69969-4;Newborn screening report overall laboratory comment;Txt;Pt;^Patient;Nar;;CHEM;1;Newborn screening report overall laboratory comment;NBS report overall lab comment;;ACTIVE;2.40;2.73 +69970-2;Volume expired during 1.0 s of forced expiration/Forced vital capacity^post bronchodilation;VRto;Pt;Respiratory system;Qn;;PULM;2;FEV1/FVC --post bronchodilation;FEV1/FVC p BD;;ACTIVE;2.40;2.73 +6997-1;Ceftizoxime;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ceftizoxime [Susceptibility] by Gradient strip;Ceftizoxime Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69971-0;Gas flow at 25-75% of forced expiration;VRat;Pt;Respiratory system;Qn;Predicted;PULM;2;FEF 25-75% Predicted;FEF 25-75% Predicted;;ACTIVE;2.40;2.73 +69972-8;Gas flow at 25-75% of forced expiration^pre bronchodilation;VRat;Pt;Respiratory system;Qn;;PULM;2;FEF 25-75% --pre bronchodilation;FEF 25-75% pre BD;;ACTIVE;2.40;2.73 +69973-6;Gas flow at 25-75% of forced expiration^post bronchodilation;VRat;Pt;Respiratory system;Qn;;PULM;2;FEF 25-75% --post bronchodilation;FEF 25-75% p BD;;ACTIVE;2.40;2.73 +69974-4;Expiratory gas flow.max;VRat;Pt;Respiratory system.airway;Qn;Predicted;PULM;2;Maximum expiratory gas flow Respiratory system airway Predicted;PEF Airway Predicted;;ACTIVE;2.40;2.73 +69975-1;Expiratory gas flow.max^pre bronchodilation;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow Respiratory system airway --pre bronchodilation;PEF pre BD Airway;;ACTIVE;2.40;2.73 +69976-9;Expiratory gas flow.max^post bronchodilation;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow Respiratory system airway --post bronchodilation;PEF p BD Airway;;ACTIVE;2.40;2.7 +69977-7;Expiratory gas flow.max/Expiratory gas flow.max.predicted^pre bronchodilation;RelVRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow/Predicted maximum expiratory gas flow Respiratory system airway --pre bronchodilation;PEF/Predicted pre BD Airway;;ACTIVE;2.40;2.73 +69978-5;Expiratory gas flow.max/Expiratory gas flow.max.predicted^post bronchodilation;RelVRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow/Predicted maximum expiratory gas flow Respiratory system airway --post bronchodilation;PEF/Predicted p BD Airway;;ACTIVE;2.40;2.7 +69979-3;Gas flow at 50% of forced expiration/Gas flow at 50% of forced inspiration^pre bronchodilation;RelVRat;Pt;Respiratory system;Qn;;PULM;2;FEF 50%/FIV 50% --pre bronchodilation;FEF 50%/FIV 50% pre BD;;ACTIVE;2.40;2.48 +69980-1;Gas flow at 50% of forced expiration/Gas flow at 50% of forced inspiration^post bronchodilation;RelVRat;Pt;Respiratory system;Qn;;PULM;2;FEF 50%/FIV 50% --post bronchodilation;FEF 50%/FIV 50% p BD;;ACTIVE;2.40;2.48 +69981-9;Asthma action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Asthma action plan;Asthma action plan;;ACTIVE;2.40;2.73 +69982-7;Forced vital capacity percent change;VRtoPctDiff;Pt;Respiratory system;Qn;;PULM;2;FVC percent change Respiratory system;FVC % change Respiratory;;ACTIVE;2.40;2.73 +69983-5;Volume expired during 1.0 s of forced expiration percent change;VPctDiff;Pt;Respiratory system;Qn;;PULM;2;FEV1 percent change;FEV1 % change;;ACTIVE;2.40;2.73 +69984-3;Volume expired during 1.0 s of forced expiration/Forced vital capacity percent change;VPctDiff;Pt;Respiratory system;Qn;;PULM;2;FEV1/FVC percent change;FEV1/FVC % change;;ACTIVE;2.40;2.73 +69985-0;Pressure.continuous positive airway;Pres;24H^mean;Respiratory system;Qn;;PULM;2;Continuous positive airway pressure 24 hour mean Respiratory system;CPAP 24h Mean Respiratory;;ACTIVE;2.40;2.7 +69986-8;Pressure.continuous positive airway.95%;Pres;24H^max;Respiratory system;Qn;;PULM;2;Pressure.continuous positive airway.95% 24 hour maximum Respiratory system;PAP.95% 24h Max Respiratory;;ACTIVE;2.40;2.7 +69987-6;Pressure.continuous positive airway;Pres;24H^max;Respiratory system;Qn;;PULM;2;Continuous positive airway pressure 24 hour maximum Respiratory system;CPAP 24h Max Respiratory;;ACTIVE;2.40;2.7 +69988-4;Positive airway pressure device usage;Time;24H;^Patient;Qn;;PULM;2;Positive airway pressure device usage 24 hour;PAP device usage 24h;;ACTIVE;2.40;2.7 +6998-9;cefTRIAXone;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefTRIAXone [Susceptibility] by Gradient strip;cefTRIAXone Islt Grad strip;;ACTIVE;1.0h(2);2.73 +69989-2;Positive airway pressure device usage;Time;1Mo^mean;^Patient;Qn;;PULM;2;Positive airway pressure device usage 1 month mean;PAP device usage 1MO Mean;;ACTIVE;2.40;2.7 +699-9;Organism count;NCnc;Pt;XXX;Qn;Microscopic count;MICRO;1;Organism count [#/volume] in Specimen by Microscopic count;Organism # Spec Microscopic Cnt;;ACTIVE;1.0;2.73 +69990-0;Apnea hypopnea index;NRat;24H;^Patient;Qn;;PULM;2;Apnea hypopnea index 24 hour;Apnea hypopnea index 24h nRate;;ACTIVE;2.40;2.73 +69991-8;Vendor device model code;ID;Pt;Positive airway pressure device;Nom;;PULM;2;Vendor model code Positive airway pressure device;Model Cd PAP device;;ACTIVE;2.40;2.4 +69992-6;Vendor device name;ID;Pt;Positive airway pressure device;Nom;;DEVICES;2;Positive airway pressure device Vendor name;PAP device Vendor name;;ACTIVE;2.40;2.68 +69993-4;Vendor serial number;ID;Pt;Positive airway pressure device;Nom;;DEVICES;2;Positive airway pressure device Vendor serial number;PAP device Serial #;;ACTIVE;2.40;2.68 +69994-2;Vendor software version;ID;Pt;Positive airway pressure device;Nom;;DEVICES;2;Positive airway pressure device Vendor software version;PAP device Software vers;;ACTIVE;2.40;2.68 +69995-9;Class;Type;Pt;Positive airway pressure device;Nom;;DEVICES;2;Type of Positive airway pressure device;PAP device Class;;ACTIVE;2.40;2.4 +69996-7;Leak;VRat;24H^mean;Positive airway pressure device;Qn;;PULM;2;Leak 24 hour mean Positive airway pressure device;Leak 24h Mean PAP device;;ACTIVE;2.40;2.7 +6999-7;Cefuroxime.parenteral;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cefuroxime Parenteral [Susceptibility] by Gradient strip;Cefuroxime Parenter Islt Grad strip;;ACTIVE;1.0h(2);2.56 +69997-5;Leak.95%;VRat;24H^max;Positive airway pressure device;Qn;;PULM;2;Leak.95% 24 hour maximum Positive airway pressure device;Leak.95% 24h Max PAP device;;ACTIVE;2.40;2.7 +69998-3;Leak;VRat;24H^max;Positive airway pressure device;Qn;;DEVICES;2;Positive airway pressure device Leak;PAP device Leak;;ACTIVE;2.40;2.7 +69999-1;Positive airway pressure panel;-;Pt;^Patient;-;;PANEL.PULM;2;Positive airway pressure panel;PAP pnl;;ACTIVE;2.40;2.4 +70000-5;Pressure.continuous positive airway;Pres;24H^median;Respiratory system;Qn;;PULM;2;Continuous positive airway pressure 24 hour median Respiratory system;CPAP 24h median Respiratory;;ACTIVE;2.40;2.7 +70001-3;Leak;VRat;24H^median;Positive airway pressure device;Qn;;PULM;2;Leak 24 hour median Positive airway pressure device;Leak 24h median PAP device;;ACTIVE;2.40;2.7 +70002-1;Obstructive apnea index;NRat;24H;^Patient;Qn;;PULM;2;Obstructive apnea index 24 hour;Obstructive apnea index 24h nRate;;ACTIVE;2.40;2.7 +7000-3;Cephalothin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Cephalothin [Susceptibility] by Gradient strip;Cephalothin Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70003-9;Central apnea index;NRat;24H;^Patient;Qn;;PULM;2;Central apnea index 24 hour;Central apnea index 24h nRate;;ACTIVE;2.40;2.7 +70004-7;Diagnostic study note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Diagnostic study note;Diag study note;;ACTIVE;2.40;2.54 +70005-4;Evaluation and management of smoking cessation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation and management of smoking cessation note;E/M smoke cess note;;ACTIVE;2.40;2.58 +70006-2;Medication management note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Medication management note;Med mgmt note;;ACTIVE;2.40;2.54 +70007-0;Restraint note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Restraint note;Restraint note;;ACTIVE;2.40;2.54 +70008-8;Enterovirus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Enterovirus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;EV IgM CSF Ql IA;;ACTIVE;2.40;2.56 +70009-6;Enterovirus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Enterovirus IgM Ab [Presence] in Serum or Plasma by Immunoassay;EV IgM SerPl Ql IA;;ACTIVE;2.40;2.56 +70010-4;Enterovirus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Enterovirus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;EV IgG CSF Ql IA;;ACTIVE;2.40;2.56 +7001-1;Chloramphenicol;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Chloramphenicol [Susceptibility] by Gradient strip;Chloramphen Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70011-2;Enterovirus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Enterovirus IgG Ab [Presence] in Serum or Plasma by Immunoassay;EV IgG SerPl Ql IA;;ACTIVE;2.40;2.56 +70012-0;Coxsackievirus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Coxsackievirus IgM Ab [Presence] in Serum or Plasma by Immunoassay;CV IgM SerPl Ql IA;;ACTIVE;2.40;2.56 +70013-8;Coxsackievirus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Coxsackievirus IgG Ab [Presence] in Serum or Plasma by Immunoassay;CV IgG SerPl Ql IA;;ACTIVE;2.40;2.56 +70014-6;Parainfluenza virus 1+2+3+4 Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 1+2+3+4 IgA Ab [Presence] in Serum by Immunoassay;HPIV 1+2+3+4 IgA Ser Ql IA;;ACTIVE;2.40;2.68 +70015-3;Streptococcus sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Streptococcus sp DNA [Presence] in Blood by NAA with probe detection;Streptococcus DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70016-1;Staphylococcus sp.coagulase negative DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Staphylococcus sp.coagulase negative DNA [Presence] in Blood by NAA with probe detection;Coag neg Staph DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70017-9;Parainfluenza virus 1+2+3+4 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 1+2+3+4 IgM Ab [Presence] in Serum by Immunoassay;HPIV 1+2+3+4 IgM Ser Ql IA;;ACTIVE;2.40;2.73 +70018-7;Staphylococcus haemolyticus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Staphylococcus haemolyticus DNA [Presence] in Blood by NAA with probe detection;S haemolyticus DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.68 +70019-5;Klebsiella oxytoca DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [Presence] in Blood by NAA with probe detection;K oxytoca DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70020-3;Bacteroides fragilis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Bacteroides fragilis DNA [Presence] in Blood by NAA with probe detection;B fragilis DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70021-1;Salmonella typhi DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Salmonella typhi DNA [Presence] in Blood by NAA with probe detection;S Typhi DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.68 +70022-9;Candida albicans DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Candida albicans DNA [Presence] in Blood by NAA with probe detection;C albicans DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70023-7;Candida tropicalis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Candida tropicalis DNA [Presence] in Blood by NAA with probe detection;C tropicls DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70024-5;Candida parapsilosis DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Candida parapsilosis DNA [Presence] in Blood by NAA with probe detection;C parap DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70025-2;Candida krusei DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Candida krusei DNA [Presence] in Blood by NAA with probe detection;C krusei DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70026-0;Candida glabrata DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Candida glabrata DNA [Presence] in Blood by NAA with probe detection;C glabrata DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70027-8;Dermatophytes chitin synthase 1 (chs1) gene;PrThr;Pt;Nail;Ord;Probe.amp.tar;MICRO;1;Dermatophytes chitin synthase 1 chs1 gene [Presence] in Nail by NAA with probe detection;Dermatophytes chs1 Nail Ql NAA+probe;;ACTIVE;2.40;2.68 +70028-6;Megakaryocytic nuclei/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Megakaryocytic nuclei/100 leukocytes in Blood by Manual count;Megakar nuclei/leuk NFr Bld Manual;;ACTIVE;2.40;2.7 +7002-9;Ciprofloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ciprofloxacin [Susceptibility] by Gradient strip;Ciprofloxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70032-8;Platelets.reticulated/platelets.total;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Platelets reticulated in Blood by Automated count;Deprecated Platelets.reticulated NFr Bld;;DEPRECATED;2.40;2.7 +70033-6;Ragocytes/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Ragocytes/100 leukocytes in Synovial fluid by Manual count;Ragocytes/leuk NFr Snv Manual;;ACTIVE;2.40;2.7 +70034-4;Lipophages/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Lipophages/100 leukocytes in Cerebral spinal fluid by Manual count;Lipophages/leuk NFr CSF Manual;;ACTIVE;2.40;2.7 +70035-1;Siderophages/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Siderophages/100 leukocytes in Cerebral spinal fluid by Manual count;Siderophages/leuk NFr CSF Manual;;ACTIVE;2.40;2.7 +70036-9;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Pericardial fluid by Automated count;Polys/leuk NFr Pcar Auto;;ACTIVE;2.40;2.7 +7003-7;Clarithromycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Clarithromycin [Susceptibility] by Gradient strip;Clarithro Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70037-7;Mononuclear cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;Automated count;HEM/BC;1;Mononuclear cells/100 leukocytes in Pericardial fluid by Automated count;Mononuc Cells/leuk NFr Pcar Auto;;ACTIVE;2.40;2.7 +70038-5;Mononuclear cells/100 leukocytes;NFr;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Mononuclear cells/100 leukocytes in Peritoneal fluid by Automated count;Mononuc Cells/leuk NFr Prt Auto;;ACTIVE;2.40;2.7 +70039-3;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Peritoneal fluid by Automated count;Polys/leuk NFr Prt Auto;;ACTIVE;2.40;2.7 +70040-1;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Synovial fluid by Automated count;Polys/leuk NFr Snv Auto;;ACTIVE;2.40;2.7 +70041-9;FSHB gene.c.-211G>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;FSHB gene c.-211G>T [Presence] in Blood or Tissue by Molecular genetics method;FSHB c.-211G>T Bld/T Ql;;ACTIVE;2.40;2.68 +70042-7;Mononuclear cells/100 leukocytes;NFr;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Mononuclear cells/100 leukocytes in Synovial fluid by Automated count;Mononuc Cells/leuk NFr Snv Auto;;ACTIVE;2.40;2.7 +70043-5;Mononuclear cells;NCnc;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Mononuclear cells [#/volume] in Pleural fluid by Automated count;Mononuc Cells # Plr Auto;;ACTIVE;2.40;2.7 +70044-3;Polymorphonuclear cells;NCnc;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells [#/volume] in Pleural fluid by Automated count;Polys # Plr Auto;;ACTIVE;2.40;2.7 +7004-5;Clinafloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Clinafloxacin [Susceptibility] by Gradient strip;Clinafloxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70045-0;Polymorphonuclear cells;NCnc;Pt;Pericard fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells [#/volume] in Pericardial fluid by Automated count;Polys # Pcar Auto;;ACTIVE;2.40;2.7 +70046-8;Mononuclear cells;NCnc;Pt;Pericard fld;Qn;Automated count;HEM/BC;1;Mononuclear cells [#/volume] in Pericardial fluid by Automated count;Mononuc Cells # Pcar Auto;;ACTIVE;2.40;2.7 +70047-6;Mononuclear cells;NCnc;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Mononuclear cells [#/volume] in Peritoneal fluid by Automated count;Mononuc Cells # Prt Auto;;ACTIVE;2.40;2.7 +70048-4;Polymorphonuclear cells;NCnc;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells [#/volume] in Peritoneal fluid by Automated count;Polys # Prt Auto;;ACTIVE;2.40;2.7 +70049-2;Polymorphonuclear cells;NCnc;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells [#/volume] in Synovial fluid by Automated count;Polys # Snv Auto;;ACTIVE;2.40;2.7 +700-5;Pneumocystis jiroveci Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Specimen by Immunofluorescence;P jiroveci Ag Spec Ql IF;;ACTIVE;1.0;2.73 +70050-0;Mononuclear cells;NCnc;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Mononuclear cells [#/volume] in Synovial fluid by Automated count;Mononuc Cells # Snv Auto;;ACTIVE;2.40;2.7 +70051-8;Multiple inhalant allergen Ab.IgE;PrThr;Pt;Ser;Ord;IA;ALLERGY;1;Multiple inhalant allergen IgE Ab [Presence] in Serum by Immunoassay;MIA IgE Ql IA;;ACTIVE;2.40;2.68 +7005-2;Clindamycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Clindamycin [Susceptibility] by Gradient strip;Clindamycin Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70052-6;Hantavirus hantaan Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus hantaan IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;HTNV IgG SerPl Ql IF;;ACTIVE;2.40;2.68 +70053-4;Hantavirus hantaan Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus hantaan IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;HTNV IgM SerPl Ql IF;;ACTIVE;2.40;2.68 +70054-2;Hantavirus dobrova Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus dobrova IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;H dobrova IgM SerPl Ql IF;;ACTIVE;2.40;2.68 +70055-9;Hantavirus dobrova Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus dobrova IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;H dobrova IgG SerPl Ql IF;;ACTIVE;2.40;2.68 +70056-7;Hantavirus saaremaa Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus saaremaa IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;H saaremaa IgG SerPl Ql IF;;ACTIVE;2.40;2.68 +70057-5;Hantavirus saaremaa Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus saaremaa IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;H saaremaa IgM SerPl Ql IF;;ACTIVE;2.40;2.68 +70058-3;Hantavirus puumala Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;PUUV IgM SerPl Ql IF;;ACTIVE;2.40;2.68 +70059-1;Hantavirus puumala Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus puumala IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;PUUV IgG SerPl Ql IF;;ACTIVE;2.40;2.68 +7006-0;Demeclocycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Demeclocycline [Susceptibility] by Gradient strip;Demeclocycline Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70060-9;Hantavirus seoul Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus seoul IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;H seoul IgG SerPl Ql IF;;ACTIVE;2.40;2.68 +70061-7;Human papilloma virus 16 & 18 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16 and 18 DNA [Presence] in Specimen by NAA with probe detection;HPV16 and 18 DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +70065-8;Enterovirus Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Enterovirus Ag [Presence] in Stool by Immunoassay;EV Ag Stl Ql IA;;ACTIVE;2.40;2.56 +70066-6;Mononuclear cells/100 leukocytes;NFr;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Mononuclear cells/100 leukocytes in Pleural fluid by Automated count;Mononuc Cells/leuk NFr Plr Auto;;ACTIVE;2.40;2.7 +70067-4;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Pleural fluid by Automated count;Polys/leuk NFr Plr Auto;;ACTIVE;2.40;2.7 +70068-2;Streptococcus dysgalactiae subspecies equisimilis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptococcus dysgalactiae subspecies equisimilis DNA [Presence] in Specimen by NAA with probe detection;S dysgal eqsmls DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +70069-0;Streptococcus intermedius DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptococcus intermedius DNA [Presence] in Specimen by NAA with probe detection;S intermedius DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +70070-8;Streptococcus anginosus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptococcus anginosus DNA [Presence] in Specimen by NAA with probe detection;S anginosus DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +70071-6;Streptococcus constellatus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptococcus constellatus DNA [Presence] in Specimen by NAA with probe detection;S constellatus DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +70072-4;Amyloid beta 40 peptide;MCnc;Pt;CSF;Qn;;CHEM;1;Amyloid beta 40 peptide [Mass/volume] in Cerebral spinal fluid;AL beta40 CSF-mCnc;;ACTIVE;2.40;2.73 +70073-2;Amyloid beta 40 peptide;MCnc;Pt;Plas;Qn;;CHEM;1;Amyloid beta 40 peptide [Mass/volume] in Plasma;AL beta40 Plas-mCnc;;ACTIVE;2.40;2.7 +70074-0;Angiotensin II^supine;MCnc;Pt;Plas;Qn;;CHAL;1;Angiotensin II [Mass/volume] in Plasma --supine;Angiotensin II sup Plas-mCnc;;ACTIVE;2.40;2.7 +70075-7;Interleukin 1 alpha;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 1 alpha [Mass/volume] in Cerebral spinal fluid;Il1Alpha CSF-mCnc;;ACTIVE;2.40;2.7 +70076-5;Interleukin 1 alpha;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 1 alpha [Mass/volume] in Body fluid;Il1Alpha Fld-mCnc;;ACTIVE;2.40;2.7 +70077-3;Interleukin 2;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 2 [Mass/volume] in Cerebral spinal fluid;Il2 CSF-mCnc;;ACTIVE;2.40;2.7 +7007-8;Dirithromycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Dirithromycin [Susceptibility] by Gradient strip;Dirithromycin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70078-1;Interleukin 2;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 2 [Mass/volume] in Body fluid;Il2 Fld-mCnc;;ACTIVE;2.40;2.7 +70079-9;Interleukin 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 3 [Mass/volume] in Serum or Plasma;Il3 SerPl-mCnc;;ACTIVE;2.40;2.7 +70080-7;Interleukin 3;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 3 [Mass/volume] in Cerebral spinal fluid;Il3 CSF-mCnc;;ACTIVE;2.40;2.7 +70081-5;Interleukin 3;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 3 [Mass/volume] in Body fluid;Il3 Fld-mCnc;;ACTIVE;2.40;2.7 +70082-3;Interleukin 4;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 4 [Mass/volume] in Body fluid;Il4 Fld-mCnc;;ACTIVE;2.40;2.7 +70083-1;Interleukin 4;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 4 [Mass/volume] in Cerebral spinal fluid;Il4 CSF-mCnc;;ACTIVE;2.40;2.7 +70084-9;Interleukin 5;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 5 [Mass/volume] in Cerebral spinal fluid;Il5 CSF-mCnc;;ACTIVE;2.40;2.7 +70085-6;Interleukin 5;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 5 [Mass/volume] in Body fluid;Il5 Fld-mCnc;;ACTIVE;2.40;2.7 +7008-6;Doxycycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Doxycycline [Susceptibility] by Gradient strip;Doxycycline Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70086-4;Interleukin 7;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 7 [Mass/volume] in Serum or Plasma;Il7 SerPl-mCnc;;ACTIVE;2.40;2.7 +70087-2;Interleukin 7;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 7 [Mass/volume] in Cerebral spinal fluid;Il7 CSF-mCnc;;ACTIVE;2.40;2.7 +70088-0;Interleukin 7;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 7 [Mass/volume] in Body fluid;Il7 Fld-mCnc;;ACTIVE;2.40;2.7 +70089-8;Interleukin 13;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 13 [Mass/volume] in Cerebral spinal fluid;Il13 CSF-mCnc;;ACTIVE;2.40;2.7 +70090-6;Interleukin 13;MCnc;Pt;Body fld;Qn;;CHEM;1;Interleukin 13 [Mass/volume] in Body fluid;Il13 Fld-mCnc;;ACTIVE;2.40;2.7 +70091-4;Prostaglandin E2;MCnc;Pt;CSF;Qn;;CHEM;1;Prostaglandin E2 [Mass/volume] in Cerebral spinal fluid;Prostaglandin E2 CSF-mCnc;;ACTIVE;2.40;2.7 +70092-2;Prostaglandin E1;MCnc;Pt;Body fld;Qn;;CHEM;1;Prostaglandin E1 [Mass/volume] in Body fluid;Prostaglandin E1 Fld-mCnc;;ACTIVE;2.40;2.7 +70093-0;Prostaglandin E1;MCnc;Pt;CSF;Qn;;CHEM;1;Prostaglandin E1 [Mass/volume] in Cerebral spinal fluid;Prostaglandin E1 CSF-mCnc;;ACTIVE;2.40;2.7 +7009-4;Erythromycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Erythromycin [Susceptibility] by Gradient strip;Erythromycin Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70094-8;Prostaglandin F2 alpha;MCnc;Pt;CSF;Qn;;CHEM;1;Prostaglandin F2 alpha [Mass/volume] in Cerebral spinal fluid;Prostaglandin F2A CSF-mCnc;;ACTIVE;2.40;2.7 +70095-5;Prostaglandin F2 alpha;MCnc;Pt;Body fld;Qn;;CHEM;1;Prostaglandin F2 alpha [Mass/volume] in Body fluid;Prostaglandin F2A Fld-mCnc;;ACTIVE;2.40;2.7 +70096-3;Thyrotropin releasing hormone;MCnc;Pt;Urine;Qn;;CHEM;1;Thyrotropin releasing hormone [Mass/volume] in Urine;Thyrotropin releasing horm Ur-mCnc;;ACTIVE;2.40;2.7 +70097-1;Establishment de-registration;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Establishment de-registration;FDA label Establishment de-registration;;ACTIVE;2.40;2.4 +70098-9;Methotrexate^10th specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --10th specimen;MTX sp10 SerPl-sCnc;;ACTIVE;2.40;2.7 +70099-7;Methotrexate^2nd specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --2nd specimen;MTX sp2 SerPl-sCnc;;ACTIVE;2.40;2.7 +70100-3;Methotrexate^3rd specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --3rd specimen;MTX sp3 SerPl-sCnc;;ACTIVE;2.40;2.7 +70101-1;Methotrexate^4th specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --4th specimen;MTX sp4 SerPl-sCnc;;ACTIVE;2.40;2.7 +7010-2;Ethambutol;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ethambutol [Susceptibility] by Gradient strip;Ethambutol Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70102-9;Methotrexate^5th specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --5th specimen;MTX sp5 SerPl-sCnc;;ACTIVE;2.40;2.7 +70103-7;Methotrexate^6th specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --6th specimen;MTX sp6 SerPl-sCnc;;ACTIVE;2.40;2.7 +70104-5;Methotrexate^7th specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --7th specimen;MTX sp7 SerPl-sCnc;;ACTIVE;2.40;2.7 +70105-2;Methotrexate^8th specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --8th specimen;MTX sp8 SerPl-sCnc;;ACTIVE;2.40;2.7 +70106-0;Methotrexate^9th specimen;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --9th specimen;MTX sp9 SerPl-sCnc;;ACTIVE;2.40;2.7 +70107-8;SERPINC1 gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SERPINC1 gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;SERPINC1 gene Mut Tested Bld/T;;ACTIVE;2.40;2.4 +70108-6;Glutathione S-transferase T1 Ab;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Glutathione S-transferase T1 Ab [Titer] in Serum or Plasma by Immunofluorescence;GSTT1 Ab Titr SerPl IF;;ACTIVE;2.40;2.7 +70109-4;Number of chromosome 13 present;Num;Pt;Amnio fld;Qn;Probe.amp.tar;MOLPATH;1;Number of chromosome 13 present [#] in Amniotic fluid by NAA with probe detection;# chromosome 13 Amn NAA+probe;;ACTIVE;2.40;2.7 +7011-0;Ethionamide;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ethionamide [Susceptibility] by Gradient strip;Ethionamide Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70110-2;Number of chromosome 18 present;Num;Pt;Amnio fld;Qn;Probe.amp.tar;MOLPATH;1;Number of chromosome 18 present [#] in Amniotic fluid by NAA with probe detection;# chromosome 18 Amn NAA+probe;;ACTIVE;2.40;2.7 +70111-0;Number of chromosome 21 present;Num;Pt;Amnio fld;Qn;Probe.amp.tar;MOLPATH;1;Number of chromosome 21 present [#] in Amniotic fluid by NAA with probe detection;# chromosome 21 Amn NAA+probe;;ACTIVE;2.40;2.7 +70112-8;Skin conditions - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Skin conditions - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70113-6;Current number of unhealed (non-epithelialized) pressure ulcers at each stage - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Current number of unhealed (non-epithelialized) pressure ulcers at each stage - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70114-4;Functional status - usual performance - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Functional status - usual performance - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70115-1;Swallowing - nutritional status - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Swallowing - nutritional status - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70116-9;Bowel and bladder - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Bowel and bladder - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70117-7;Administrative information - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Administrative information - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70118-5;Hearing, speech, vision - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Hearing, speech, vision - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70119-3;Healed pressure ulcers - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Healed pressure ulcers - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70120-1;Assessment administration - Long term care hospital;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Assessment administration - Long term care hospital [CARE];;;DISCOURAGED;2.40;2.64 +70121-9;Francisella tularensis Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Francisella tularensis IgG Ab [Units/volume] in Serum or Plasma;F tular IgG SerPl-aCnc;;ACTIVE;2.40;2.73 +70122-7;Epithelial cells.squamous;PrThr;Pt;Body fld;Ord;;HEM/BC;1;Epithelial cells.squamous [Presence] in Body fluid;Squamous Fld Ql;;ACTIVE;2.40;2.73 +70123-5;Epithelial cells.ciliated;PrThr;Pt;Body fld;Ord;;HEM/BC;1;Epithelial cells.ciliated [Presence] in Body fluid;Ciliated Fld Ql;;ACTIVE;2.40;2.73 +70124-3;Erythrocytes;PrThr;Pt;XXX;Ord;Wet preparation;HEM/BC;1;Erythrocytes [Presence] in Specimen by Wet preparation;RBC Spec Ql Wet Prep;;ACTIVE;2.40;2.73 +70125-0;Yeast.hyphae;PrThr;Pt;XXX;Ord;KOH preparation;MICRO;1;Yeast.hyphae [Presence] in Specimen by KOH preparation;Yeast Hyphae Spec Ql KOH Prep;;ACTIVE;2.40;2.73 +70126-8;Leukocytes^^corrected for nucleated erythrocytes;NCnc;Pt;Plr fld;Qn;;HEM/BC;1;Leukocytes [#/volume] corrected for nucleated erythrocytes in Pleural fluid;WBC nRBC cor # Plr;;ACTIVE;2.40;2.7 +70127-6;Signature verifying assessment completion;Pn;Pt;^Patient;Nom;;SURVEY.CMS;4;Signature verifying assessment completion;;;ACTIVE;2.40;2.63 +7012-8;Fleroxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Fleroxacin [Susceptibility] by Gradient strip;Fleroxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70128-4;Discharge return;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Discharge return [CARE];;;DISCOURAGED;2.40;2.64 +70129-2;Within this acute care hospital stay, on what other units has the patient been treated prior to coming to this unit;Find;Pt;^Patient;Ord;CARE;SURVEY.CARE;4;Within this acute care hospital stay, on what other units has the patient been treated prior to coming to this unit [CARE];;;DISCOURAGED;2.40;2.64 +701-3;Yersinia sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Yersinia sp identified in Specimen by Organism specific culture;Yersinia Spec Cult;;ACTIVE;1.0;2.73 +70130-0;Rickettsia typhus group & Rickettsia spotted fever group acute & convalescent Ab.IgG & IgM panel;-;-;Ser;-;IF;PANEL.MICRO;1;Rickettsia typhus group and Rickettsia spotted fever group acute and convalescent IgG and IgM panel - Serum by Immunofluorescence;Rickettsia TG+SFG IgG+IgM pnl Ser IF;;ACTIVE;2.40;2.7 +70131-8;Rickettsia typhus group Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhus group IgG Ab [Titer] in Serum by Immunofluorescence --1st specimen;Rick Typhus IgG sp1 Titr Ser IF;;ACTIVE;2.40;2.7 +70132-6;Rickettsia typhus group Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhus group IgG Ab [Titer] in Serum by Immunofluorescence --2nd specimen;Rick Typhus IgG sp2 Titr Ser IF;;ACTIVE;2.40;2.7 +70133-4;Rickettsia typhus group Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhus group IgM Ab [Titer] in Serum by Immunofluorescence --1st specimen;Rick Typhus IgM sp1 Titr Ser IF;;ACTIVE;2.40;2.7 +70134-2;Rickettsia typhus group Ab.IgM^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia typhus group IgM Ab [Titer] in Serum by Immunofluorescence --2nd specimen;Rick Typhus IgM sp2 Titr Ser IF;;ACTIVE;2.40;2.7 +70135-9;Rickettsia spotted fever group Ab.IgM^1st specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia spotted fever group IgM Ab [Titer] in Serum by Immunofluorescence --1st specimen;Rick SF IgM sp1 Titr Ser IF;;ACTIVE;2.40;2.7 +7013-6;Fluconazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Fluconazole [Susceptibility] by Gradient strip;Fluconazole Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70136-7;Rickettsia spotted fever group Ab.IgM^2nd specimen;Titr;Pt;Ser;Qn;IF;MICRO;1;Rickettsia spotted fever group IgM Ab [Titer] in Serum by Immunofluorescence --2nd specimen;Rick SF IgM sp2 Titr Ser IF;;ACTIVE;2.40;2.7 +70137-5;Sample icteric;PrThr;Pt;CSF;Ord;Spectrophotometry;SPEC;1;Sample icteric [Presence] of Cerebral spinal fluid Qualitative by Spectrophotometry;Sample Icteric CSF Ql Spect;;ACTIVE;2.44;2.56 +70138-3;Amphetamines;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Amphetamines [Mass/volume] in Urine by Screen method;Amphetamines Ur Scn-mCnc;;ACTIVE;2.40;2.73 +70139-1;Barbiturates;PrThr;Pt;Urine;Ord;Screen>300 ng/mL;DRUG/TOX;1;Barbiturates [Presence] in Urine by Screen method >300 ng/mL;Barbiturates Ur Ql Scn>300 ng/mL;;ACTIVE;2.40;2.73 +70140-9;Benzodiazepines;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Urine by Screen method;Benzodiaz Ur Scn-mCnc;;ACTIVE;2.40;2.73 +70141-7;Benzodiazepines;PrThr;Pt;Urine;Ord;Screen>200 ng/mL;DRUG/TOX;1;Benzodiazepines [Presence] in Urine by Screen method >200 ng/mL;Benzodiaz Ur Ql Scn>200 ng/mL;;ACTIVE;2.40;2.73 +70142-5;Benzodiazepines;PrThr;Pt;Urine;Ord;Screen>300 ng/mL;DRUG/TOX;1;Benzodiazepines [Presence] in Urine by Screen method >300 ng/mL;Benzodiaz Ur Ql Scn>300 ng/mL;;ACTIVE;2.40;2.73 +70143-3;Cannabinoids;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Cannabinoids [Mass/volume] in Urine by Screen method;Cannabinoids Ur Scn-mCnc;;ACTIVE;2.40;2.73 +7014-4;5-Fluorocytosine;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;5-Fluorocytosine [Susceptibility] by Gradient strip;5-fluorocytosine Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70144-1;Cannabinoids;PrThr;Pt;Urine;Ord;Screen>20 ng/mL;DRUG/TOX;1;Cannabinoids [Presence] in Urine by Screen method >20 ng/mL;Cannabinoids Ur Ql Scn>20 ng/mL;;ACTIVE;2.40;2.73 +70145-8;Cannabinoids;PrThr;Pt;Urine;Ord;Screen>50 ng/mL;DRUG/TOX;1;Cannabinoids [Presence] in Urine by Screen method >50 ng/mL;Cannabinoids Ur Ql Scn>50 ng/mL;;ACTIVE;2.44;2.73 +70146-6;Benzoylecgonine;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Urine by Screen method;BZE Ur Scn-mCnc;;ACTIVE;2.44;2.73 +70147-4;Methadone;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Methadone [Mass/volume] in Urine by Screen method;Methadone Ur Scn-mCnc;;ACTIVE;2.44;2.73 +70148-2;Methadone;PrThr;Pt;Urine;Ord;Screen>150 ng/mL;DRUG/TOX;1;Methadone [Presence] in Urine by Screen method >150 ng/mL;Methadone Ur Ql Scn>150 ng/mL;;ACTIVE;2.44;2.7 +70149-0;Methadone;PrThr;Pt;Urine;Ord;Screen>300 ng/mL;DRUG/TOX;1;Methadone [Presence] in Urine by Screen method >300 ng/mL;Methadone Ur Ql Scn>300 ng/mL;;ACTIVE;2.40;2.73 +70150-8;Opiates;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Opiates [Mass/volume] in Urine by Screen method;Opiates Ur Scn-mCnc;;ACTIVE;2.44;2.73 +7015-1;Fusidate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Fusidate [Susceptibility] by Gradient strip;Fusidate Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70151-6;Opiates;PrThr;Pt;Urine;Ord;Screen>300 ng/mL;DRUG/TOX;1;Opiates [Presence] in Urine by Screen method >300 ng/mL;Opiates Ur Ql Scn>300 ng/mL;;ACTIVE;2.44;2.73 +70152-4;Triiodothyronine/Thyroxine;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Triiodothyronine (T3)/Thyroxine (T4) [Mass Ratio] in Serum or Plasma;T3/T4 SerPl;;ACTIVE;2.44;2.44 +70153-2;Sample hemolyzed;PrThr;Pt;CSF;Ord;;SPEC;1;Sample hemolyzed [Presence] of Cerebral spinal fluid Qualitative;Sample Hemolyzed CSF Ql;;ACTIVE;2.44;2.56 +70154-0;Hepatitis B virus surface Ag;AFr;Pt;Ser/Plas;Qn;Confirm;MICRO;1;Hepatitis B virus surface Ag in Serum or Plasma by Confirmatory method;HBV surface Ag SerPl Cfm-%;;ACTIVE;2.40;2.73 +70155-7;Barbiturates;PrThr;Pt;Urine;Ord;Screen>200 ng/mL;DRUG/TOX;1;Barbiturates [Presence] in Urine by Screen method >200 ng/mL;Barbiturates Ur Ql Scn>200 ng/mL;;ACTIVE;2.40;2.73 +70156-5;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript/control transcript";LnRto;Pt;Bld/Tiss;Qn;;MOLPATH.TRNLOC;1;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript/control transcript [Log Number Ratio] in Blood or Tissue";"inv(16)(p13;q22)/control Bld/T-LnRto";;ACTIVE;2.40;2.7 +70157-3;Form sections completed;Type;Pt;Provider;Nom;;SURVEY.CMS;4;Form sections completed Provider;;;ACTIVE;2.40;2.63 +70158-1;Date sections completed;TmStp;Pt;Provider;Qn;;SURVEY.CMS;4;Date sections completed Provider;;;ACTIVE;2.40;2.63 +70159-9;Tetradecenoylcarnitine (C14:1)/Tetradecanoylcarnitine (C14);SRto;Pt;Bld.dot;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Tetradecanoylcarnitine (C14) [Molar ratio] in DBS;Tdecenoylcarn/C14 DBS-sRto;;ACTIVE;2.40;2.73 +70160-7;Reason for assessment - acute;Find;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Reason for assessment - acute [CARE];;;DISCOURAGED;2.40;2.64 +70161-5;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;Urine;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Urine by NAA with probe detection;C trach+GC pnl Ur NAA+probe;;ACTIVE;2.40;2.73 +70162-3;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;Urethra;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Urethra by NAA with probe detection;C trach+GC pnl Urth NAA+probe;;ACTIVE;2.40;2.63 +70163-1;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;Cvx;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Cervix by NAA with probe detection;C trach+GC pnl Cvx NAA+probe;;ACTIVE;2.40;2.73 +70164-9;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;Vag;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Vaginal fluid by NAA with probe detection;C trach+GC pnl Vag NAA+probe;;ACTIVE;2.40;2.73 +70165-6;Trichomonas vaginalis rRNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis rRNA [Presence] in Vaginal fluid by NAA with probe detection;T vaginalis rRNA Vag Ql NAA+probe;;ACTIVE;2.40;2.73 +70166-4;Trichomonas vaginalis rRNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis rRNA [Presence] in Cervix by NAA with probe detection;T vaginalis rRNA Cvx Ql NAA+probe;;ACTIVE;2.40;2.73 +70167-2;Trichomonas vaginalis rRNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis rRNA [Presence] in Urine by NAA with probe detection;T vaginalis rRNA Ur Ql NAA+probe;;ACTIVE;2.40;2.73 +70168-0;Hematocrit;VFr;Pt;Synv fld;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Synovial fluid;Hct VFr Snv;;ACTIVE;2.40;2.7 +7016-9;Gentamicin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Gentamicin [Susceptibility] by Gradient strip;Gentamicin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70169-8;Hematocrit;VFr;Pt;Plr fld;Qn;;HEM/BC;1;Hematocrit [Volume Fraction] of Pleural fluid;Hct VFr Plr;;ACTIVE;2.40;2.7 +70170-6;Erythrocytes.nucleated/100 cells;NFr;Pt;Plr fld;Qn;;HEM/BC;1;Nucleated erythrocytes/100 cells in Pleural fluid;nRBC/total cells NFr Plr;;ACTIVE;2.40;2.7 +70171-4;Erythrocytes.nucleated/100 cells;NFr;Pt;Periton fld;Qn;;HEM/BC;1;Nucleated erythrocytes/100 cells in Peritoneal fluid;nRBC/total cells NFr Prt;;ACTIVE;2.40;2.7 +70172-2;Neisseria meningitidis serogroup;Prid;Pt;XXX;Nom;;MICRO;1;Neisseria meningitidis serogroup [Identifier] in Specimen;N men serogroup Spec;;ACTIVE;2.40;2.69 +70173-0;JC virus Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;JC virus Ab [Presence] in Serum or Plasma by Immunoassay;JCPyV Ab SerPl Ql IA;;ACTIVE;2.40;2.73 +70174-8;Dicarboxytetradecenoylcarnitine (C14:1-DC);SCnc;Pt;CSF;Qn;;CHEM;1;Dicarboxytetradecenoylcarnitine (C14:1-DC) [Moles/volume] in Cerebral spinal fluid;Dicarboxytetradecenoylcarn CSF-sCnc;;ACTIVE;2.40;2.7 +70175-5;Dicarboxytetradecenoylcarnitine (C14:1-DC);SCnc;Pt;Amnio fld;Qn;;CHEM;1;Dicarboxytetradecenoylcarnitine (C14:1-DC) [Moles/volume] in Amniotic fluid;Dicarboxytetradecenoylcarn Amn-sCnc;;ACTIVE;2.40;2.7 +70176-3;Dicarboxytetradecenoylcarnitine (C14:1-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxytetradecenoylcarnitine (C14:1-DC) [Moles/volume] in Serum or Plasma;Dicarboxytetradecenoylcarn SerPl-sCnc;;ACTIVE;2.40;2.7 +7017-7;Gentamicin.high potency;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Gentamicin.high potency [Susceptibility] by Disk diffusion (KB);Gentamicin Synergy Islt KB;;ACTIVE;1.0h(2);2.73 +70177-1;Dicarboxytetradecenoylcarnitine (C14:1-DC);SCnc;Pt;Urine;Qn;;CHEM;1;Dicarboxytetradecenoylcarnitine (C14:1-DC) [Moles/volume] in Urine;Dicarboxytetradecenoylcarn Ur-sCnc;;ACTIVE;2.40;2.7 +70178-9;11-Hydroxy delta-9 tetrahydrocannabinol;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Blood;11OH-THC Bld Ql;;ACTIVE;2.40;2.56 +70179-7;1-Methylhistidine;SCnc;Pt;Ser/Plas^Fetus;Qn;;CHEM;1;1-Methylhistidine [Moles/volume] in Serum or Plasma from Fetus;1Me-hist SerPl Fetus-sCnc;;ACTIVE;2.40;2.7 +70180-5;Alpha aminoadipate;SCnc;Pt;Ser/Plas^Fetus;Qn;;CHEM;1;Alpha aminoadipate [Moles/volume] in Serum or Plasma from Fetus;AAA SerPl Fetus-sCnc;;ACTIVE;2.40;2.7 +70181-3;Alpha aminobutyrate;SCnc;Pt;Ser/Plas^Fetus;Qn;;CHEM;1;Alpha aminobutyrate [Moles/volume] in Serum or Plasma from Fetus;A-Aminobutyr SerPl Fetus-sCnc;;ACTIVE;2.40;2.7 +70182-1;NIH stroke scale;-;Pt;^Patient;-;NIHSS;PANEL.SURVEY.NEURO;4;NIH Stroke Scale;;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.40;2.61 +70183-9;NIH stroke scale interval;Find;Pt;^Patient;Nom;NIHSS;SURVEY.NEURO;4;NIH stroke scale interval [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70184-7;Level of consciousness;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Level of consciousness [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +7018-5;Gentamicin.high potency;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Gentamicin.high potency [Susceptibility] by Minimum inhibitory concentration (MIC);Gentamicin Synergy Islt MIC;;ACTIVE;1.0h(2);2.73 +70185-4;LOC questions;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;LOC questions [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70186-2;LOC commands;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;LOC commands [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70187-0;Best gaze;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Best gaze [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70188-8;Visual;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Visual [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70189-6;Facial palsy;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Facial palsy [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70190-4;Motor arm;Find;Pt;Arm.left;Ord;NIHSS;SURVEY.NEURO;4;Motor arm Left arm [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70191-2;Motor leg;Find;Pt;Leg.left;Ord;NIHSS;SURVEY.NEURO;4;Motor leg Leg - left [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70192-0;Limb ataxia;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Limb ataxia [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +7019-3;Imipenem;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Imipenem [Susceptibility] by Gradient strip;Imipenem Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70193-8;Sensory;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Sensory [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70194-6;Best language;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Best language [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70195-3;Dysarthria;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Dysarthria [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70196-1;Extinction and inattention;Find;Pt;^Patient;Ord;NIHSS;SURVEY.NEURO;4;Extinction and inattention [NIH Stroke Scale];;;ACTIVE;2.40;2.44 +70197-9;6-Monoacetylmorphine;SCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Moles/volume] in Urine by Confirmatory method;6MAM Ur Cfm-sCnc;;ACTIVE;2.40;2.73 +70198-7;Acetaminophen;SCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Acetaminophen [Moles/volume] in Serum or Plasma by Screen method;APAP SerPl Scn-sCnc;;ACTIVE;2.40;2.73 +70199-5;Bilirubin;SCnc;Pt;Urine;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Urine;Bilirub Ur-sCnc;;ACTIVE;2.40;2.73 +70200-1;Cholesterol.in HDL/Cholesterol.total;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma;HDLc SerPl-sRto;;ACTIVE;2.40;2.73 +7020-1;Isoniazid;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Isoniazid [Susceptibility] by Gradient strip;Isoniazid Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70201-9;Cholesterol.in IDL;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in IDL [Moles/volume] in Serum or Plasma;IDLc SerPl-sCnc;;ACTIVE;2.40;2.73 +70202-7;Cholesterol.in IDL+Cholesterol.in VLDL 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in IDL+Cholesterol in VLDL 3 [Moles/volume] in Serum or Plasma;IDLc+VLDL3c SerPl-sCnc;;ACTIVE;2.40;2.73 +70203-5;Cholesterol.in VLDL 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in VLDL 3 [Moles/volume] in Serum or Plasma;VLDL3c SerPl-sCnc;;ACTIVE;2.40;2.73 +70204-3;Cholesterol.non HDL;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol non HDL [Moles/volume] in Serum or Plasma;NonHDLc SerPl-sCnc;;ACTIVE;2.40;2.73 +70205-0;clonazePAM;SCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;clonazePAM [Moles/volume] in Serum or Plasma by Screen method;clonazePAM SerPl Scn-sCnc;;ACTIVE;2.40;2.73 +70206-8;Codeine;SCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Codeine [Moles/volume] in Urine by Confirmatory method;Codeine Ur Cfm-sCnc;;ACTIVE;2.40;2.73 +70207-6;Estrogen;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Estrogen [Moles/volume] in Serum or Plasma;Estrogen SerPl-sCnc;;ACTIVE;2.40;2.73 +70208-4;Glucose^pre 100 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --pre 100 g glucose PO;Glucose pre 100 g Glc PO SerPl-sCnc;;ACTIVE;2.40;2.73 +70209-2;Haptoglobin;SCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Haptoglobin [Moles/volume] in Serum or Plasma;Haptoglob SerPl-sCnc;;ACTIVE;2.40;2.73 +702-1;Anisocytosis;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Anisocytosis [Presence] in Blood by Light microscopy;Anisocytosis Bld Ql Smear;;ACTIVE;1.0;2.73 +70210-0;Morphine;SCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Morphine [Moles/volume] in Urine by Confirmatory method;Morphine Ur Cfm-sCnc;;ACTIVE;2.40;2.73 +70211-8;Mycophenolate;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mycophenolate [Moles/volume] in Serum or Plasma;Mycophenolate SerPl-sCnc;;ACTIVE;2.40;2.73 +70212-6;Nordiazepam;SCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Nordiazepam [Moles/volume] in Serum or Plasma by Screen method;Nordiazepam SerPl Scn-sCnc;;ACTIVE;2.40;2.73 +70213-4;Nordiazepam;SCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Moles/volume] in Urine by Confirmatory method;Nordiazepam Ur Cfm-sCnc;;ACTIVE;2.40;2.73 +70214-2;Oxazepam;SCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Oxazepam [Moles/volume] in Urine by Confirmatory method;Oxazepam Ur Cfm-sCnc;;ACTIVE;2.40;2.73 +70215-9;oxyCODONE;SCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;oxyCODONE [Moles/volume] in Urine by Confirmatory method;oxyCODONE Ur Cfm-sCnc;;ACTIVE;2.40;2.73 +70216-7;Salicylates;SCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Salicylates [Moles/volume] in Serum or Plasma by Screen method;Salicylates SerPl Scn-sCnc;;ACTIVE;2.40;2.73 +70217-5;Thyroxine.free;SCnc;Pt;Ser/Plas;Qn;Dialysis;CHEM;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma by Dialysis;T4 Free SerPl Dialy-sCnc;;ACTIVE;2.40;2.73 +70218-3;Triglyceride;SCnc;Pt;Bld;Qn;;CHEM;1;Triglyceride [Moles/volume] in Blood;Trigl Bld-sCnc;;ACTIVE;2.40;2.73 +7021-9;Itraconazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Itraconazole [Susceptibility] by Gradient strip;Itraconaz Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70219-1;Basic metabolic 2008 panel with ionized calcium;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Basic metabolic 2008 panel with ionized calcium - Serum or Plasma;Bas Metab 2000 Pnl W Ca-I SerPl;;ACTIVE;2.40;2.73 +70220-9;Repeated disturbing memories, thoughts, or images of a stressful experience from the past in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Repeated disturbing memories, thoughts, or images of a stressful experience from the past in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70221-7;Post traumatic stress disorder checklist - civilian version;-;Pt;^Patient;-;PCL-C;PANEL.SURVEY.MTLHLTH;4;Post traumatic stress disorder (PTSD) checklist - civilian version [PCL-C];;;ACTIVE;2.40;2.44 +70222-5;Repeated disturbing dreams of a stressful experience from the past in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Repeated disturbing dreams of a stressful experience from the past in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70223-3;Suddenly acting or feeling as if a stressful experience were happening again - as if you were reliving it - in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Suddenly acting or feeling as if a stressful experience were happening again - as if you were reliving it - in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70224-1;Feeling very upset when something reminded you of a stressful experience from the past in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Feeling very upset when something reminded you of a stressful experience from the past in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70225-8;Having physical reactions, heart pounding, trouble breathing or sweating, when something reminded you of a stressful experience from the past in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Having physical reactions, heart pounding, trouble breathing or sweating, when something reminded you of a stressful experience from the past in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70226-6;Avoid thinking about or talking about a stressful experience from the past or avoid having feelings related to it in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Avoid thinking about or talking about a stressful experience from the past or avoid having feelings related to it in the last month [PCL-C];;;ACTIVE;2.40;2.54 +7022-7;Kanamycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Kanamycin [Susceptibility] by Gradient strip;Kanamycin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70227-4;Avoid activites or situations because they remind you of a stressful experience from the past in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;[PCL-C];;;ACTIVE;2.40;2.68 +70228-2;Trouble remembering important parts of a stressful experience from the past in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Trouble remembering important parts of a stressful experience from the past in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70229-0;Loss of interest in things that you used to enjoy in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Loss of interest in things that you used to enjoy in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70230-8;Feeling distant or cut off from other people in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Feeling distant or cut off from other people in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70231-6;Feeling emotionally numb or being unable to have loving feelings for those close to you in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Feeling emotionally numb or being unable to have loving feelings for those close to you in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70232-4;Feeling as if your future will somehow be cut short in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Feeling as if your future will somehow be cut short in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70233-2;Trouble falling or staying asleep in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Trouble falling or staying asleep in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70234-0;Feeling irritable or having angry outbursts in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Feeling irritable or having angry outbursts in the last month [PCL-C];;;ACTIVE;2.40;2.54 +7023-5;Kanamycin.high potency;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Kanamycin.high potency [Susceptibility] by Disk diffusion (KB);Kanamycin High Pot Islt KB;;ACTIVE;1.0h(2);2.19 +70235-7;Having difficulty concentrating in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Having difficulty concentrating in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70236-5;Being super alert or watchful on guard in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Being super alert or watchful on guard in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70237-3;Feeling jumpy or easily startled in the last Mo;Find;1Mo;^Patient;Ord;PCL-C;SURVEY.MTLHLTH;4;Feeling jumpy or easily startled in the last month [PCL-C];;;ACTIVE;2.40;2.54 +70238-1;Progress note;Find;Pt;Hospital;Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Hospital Progress note;Transpl surg Hosp Prog note;;ACTIVE;2.40;2.73 +70239-9;Testosterone;SCnc;Pt;Ser/Plas;Qn;Detection limit <= 3.47 pmol/L;CHEM;1;Testosterone [Moles/volume] in Serum or Plasma by Detection limit <= 3.47 pmol/L;Testost SerPl DL<= 3.47 pmol/L-sCnc;;ACTIVE;2.40;2.73 +70240-7;Testosterone.free;SCnc;Pt;Ser/Plas;Qn;Detection limit <= 3.47 pmol/L;CHEM;1;Testosterone Free [Moles/volume] in Serum or Plasma by Detection limit <= 3.47 pmol/L;Testost Free SerPl DL<= 3.47 pmol/L-sCnc;;ACTIVE;2.40;2.73 +70241-5;HIV 1 RNA;NCnc;Pt;Plas;Qn;Probe.amp.tar detection limit = 20 copies/mL;MICRO;1;HIV 1 RNA [#/volume] (viral load) in Plasma by Probe and target amplification method detection limit = 20 copies/mL;HIV1 RNA # Plas NAA DL=20;;ACTIVE;2.40;2.73 +70242-3;Shigella species+EIEC invasion plasmid antigen H (ipaH) gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection;Shigella sp+EIEC ipaH Stl Ql NAA+probe;;ACTIVE;2.40;2.73 +7024-3;Kanamycin.high potency;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Kanamycin.high potency [Susceptibility] by Minimum inhibitory concentration (MIC);Kanamycin High Pot Islt MIC;;ACTIVE;1.0h(2);2.19 +70243-1;CLN3 gene exon 7+8 deletion;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CLN3 gene exon 7+8 deletion [Presence] in Blood or Tissue by Molecular genetics method;CLN3 exon 7+8 Del Bld/T Ql;;ACTIVE;2.40;2.73 +70244-9;CFTR gene.c.394delTT;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CFTR gene c.394delTT [Presence] in Blood or Tissue by Molecular genetics method;CFTR c.394delTT Bld/T Ql;;ACTIVE;2.40;2.73 +70245-6;PAH gene.p.Arg408Trp;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PAH gene.p.Arg408Trp [Presence] in Blood or Tissue by Molecular genetics method;PAH p.R408W Bld/T Ql;;ACTIVE;2.40;2.68 +70246-4;CCR2 gene.p.Val64Ile;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CCR2 gene p.Val64Ile [Presence] in Blood or Tissue by Molecular genetics method;CCR2 p.V64I Bld/T Ql;;ACTIVE;2.40;2.68 +70247-2;CCR5 gene.c.794_825del;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CCR5 gene c.794_825del [Presence] in Blood or Tissue by Molecular genetics method;CCR5 c.794_825del Bld/T Ql;;ACTIVE;2.40;2.68 +70248-0;GALT gene.p.Gln188Arg;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;GALT gene p.Gln188Arg [Presence] in Blood or Tissue by Molecular genetics method;GALT p.Q188R Bld/T Ql;;ACTIVE;2.40;2.68 +7025-0;Ketoconazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ketoconazole [Susceptibility] by Gradient strip;Ketoconazole Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70251-4;Pyruvate dehydrogenase Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Pyruvate dehydrogenase IgG Ab [Units/volume] in Serum by Immunoassay;PDH IgG Ser IA-aCnc;;ACTIVE;2.40;2.7 +70252-2;Islet cell 512 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Islet cell 512 IgG Ab [Presence] in Serum or Plasma by Immunoassay;Islet Cell512 IgG SerPl Ql IA;;ACTIVE;2.40;2.56 +70253-0;Islet cell 512 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Islet cell 512 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Islet Cell512 IgG SerPl IA-aCnc;;ACTIVE;2.40;2.7 +70254-8;Follitropin Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Follitropin IgG Ab [Units/volume] in Serum by Immunoassay;FSH IgG Ser IA-aCnc;;ACTIVE;2.40;2.7 +70255-5;Follitropin Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Follitropin IgA Ab [Units/volume] in Serum by Immunoassay;FSH IgA Ser IA-aCnc;;ACTIVE;2.40;2.7 +70256-3;Nuclear Ab.IgG;Ratio;Pt;Ser;Qn;IA;SERO;1;Nuclear IgG Ab [Ratio] in Serum by Immunoassay;Nuclear IgG Ser IA-Rto;;ACTIVE;2.40;2.7 +70257-1;Sjogrens syndrome-A extractable nuclear 52kD Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD IgG Ab [Units/volume] in Serum by Immunoassay;ENA SS-A 52kD IgG Ser IA-aCnc;;ACTIVE;2.40;2.73 +70258-9;Amylase.pancreatic;CCnc;Pt;Periton fld;Qn;;CHEM;1;Amylase.pancreatic [Enzymatic activity/volume] in Peritoneal fluid;Amylase P Prt-cCnc;;ACTIVE;2.40;2.7 +70259-7;Triglyceride.pericard fld/Triglyceride.serum;RelRto;Pt;Pericard fld+Ser/Plas;Qn;;CHEM;1;Triglyceride in pericardial fluid/Triglyceride in serum;Trigl Pcar/Ser;;ACTIVE;2.40;2.44 +70260-5;Triglyceride.periton fld/Triglyceride.serum;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Triglyceride in peritoneal fluid/Triglyceride in serum;Trigl Prt/Ser;;ACTIVE;2.40;2.44 +70261-3;Cholesterol.periton fld/Cholesterol.serum;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Cholesterol in peritoneal fluid/Cholesterol in serum;Chol Prt/Ser;;ACTIVE;2.40;2.44 +70262-1;Amylase.periton fld/Amylase.serum;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Amylase in peritoneal fluid/Amylase in serum;Amylase.prt fld/SerPl;;ACTIVE;2.40;2.44 +70263-9;Cholesterol.pericard fld/Cholesterol.serum;RelRto;Pt;Pericard fld+Ser/Plas;Qn;;CHEM;1;Cholesterol in pericardial fluid/Cholesterol in serum;Chol Pcar/Ser;;ACTIVE;2.40;2.44 +70264-7;Creatinine.plr fld/Creatinine.serum;RelRto;Pt;Ser/Plas+Plr fld;Qn;;CHEM;1;Creatinine in pleural fluid/Creatinine in serum;Creat Plr/Ser;;ACTIVE;2.40;2.44 +70265-4;Protein.pericard fld/Protein.serum;RelRto;Pt;Pericard fld+Ser/Plas;Qn;;CHEM;1;Protein in pericardial fluid/Protein in serum;Prot Pcar/SerPl;;ACTIVE;2.40;2.44 +70266-2;Creatinine.periton fld/Creatinine.serum;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Creatinine in peritoneal fluid/Creatinine in serum;Creat Prt/Ser;;ACTIVE;2.40;2.44 +70267-0;Protein.periton fld/Protein.serum;RelRto;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Protein in peritoneal fluid/Protein in serum;Prot Prt/SerPl;;ACTIVE;2.40;2.44 +7026-8;levoFLOXacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;levoFLOXacin [Susceptibility] by Gradient strip;levoFLOXacin Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70268-8;Cholesterol.plr fld/Cholesterol.serum;RelRto;Pt;Ser/Plas+Plr fld;Qn;;CHEM;1;Cholesterol in pleural fluid/Cholesterol in serum;Chol Plr/Ser;;ACTIVE;2.40;2.44 +70269-6;Triglyceride.plr fld/Triglyceride.serum;RelRto;Pt;Ser/Plas+Plr fld;Qn;;CHEM;1;Triglyceride in pleural fluid/Triglyceride in serum;Trigl Plr fld/Ser;;ACTIVE;2.40;2.44 +70270-4;Amylase.pancreatic;CCnc;Pt;Plr fld;Qn;;CHEM;1;Amylase.pancreatic [Enzymatic activity/volume] in Pleural fluid;Amylase P Plr-cCnc;;ACTIVE;2.40;2.7 +70271-2;Patient health questionnaire-somatic, anxiety, and depressive symptoms total score;Score;Pt;^Patient;Qn;Reported.PHQ;SURVEY.PHQ;4;Patient Health Questionnaire - Somatic, Anxiety, and Depressive Symptoms (PHQ-SADS) total score [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.40;2.5 +70272-0;Patient health questionnaire 4 item total score;Score;Pt;^Patient;Qn;Reported.PHQ;SURVEY.PHQ;4;Patient Health Questionnaire 4 item (PHQ-4) total score [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.40;2.5 +70273-8;Patient health questionnaire 15 item total score;Score;Pt;^Patient;Qn;Reported.PHQ;SURVEY.PHQ;4;Patient Health Questionnaire 15 item (PHQ-15) total score [Reported];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.40;2.5 +70274-6;Generalized anxiety disorder 7 item total score;Score;Pt;^Patient;Qn;Reported.PHQ;SURVEY.PHQ;4;Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.40;2.73 +70275-3;"t(X;11)(q13.1;q23)(FOXO4,MLL) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(X;11)(q13.1;q23)(FOXO4,MLL) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(X;11)(FOXO4,MLL) Bld/T Ql";;ACTIVE;2.40;2.4 +7027-6;Loracarbef;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Loracarbef [Susceptibility] by Gradient strip;Loracarbef Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70276-1;"t(1;11)(p32;q23)(EPS15,MLL) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(1;11)(p32;q23)(EPS15,MLL) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(1;11)(EPS15,MLL) Bld/T Ql";;ACTIVE;2.40;2.4 +70277-9;"t(3;5)(q25.1;q35.1)(MLF1,NPM1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(3;5)(q25.1;q35.1)(MLF1,NPM1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(3;5)(MLF1,NPM1) Bld/T Ql";;ACTIVE;2.40;2.4 +70278-7;"t(3;21)(q26;q22.3)(MECOM,RUNX1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(3;21)(q26;q22.3)(MECOM,RUNX1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(3;21)(MECOM,RUNX1) Bld/T Ql";;ACTIVE;2.40;2.4 +70279-5;"t(5;17)(q25.1;q21.1)(NPM1,RARA) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(5;17)(q25.1;q21.1)(NPM1,RARA) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(5;17)(NPM1,RARA) Bld/T Ql";;ACTIVE;2.40;2.4 +70280-3;"t(6;11)(q27;q23)(MLLT4,MLL) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(6;11)(q27;q23)(MLLT4,MLL) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(6;11)(MLLT4,MLL) Bld/T Ql";;ACTIVE;2.40;2.4 +70281-1;"t(9;9)(q34;q34)(NUP214,SET) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;9)(q34;q34)(NUP214,SET) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(9;9)(NUP214,SET) Bld/T Ql";;ACTIVE;2.40;2.4 +70282-9;"t(9;12)(q34.1;p13)(ABL1,ETV6) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;12)(q34.1;p13)(ABL1,ETV6) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(9;12)(ABL1,ETV6) Bld/T Ql";;ACTIVE;2.40;2.4 +70283-7;"t(11;17)(q23;q21)(MLL,MLLT6) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;17)(q23;q21)(MLL,MLLT6) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(11;17)(MLL,MLLT6) Bld/T Ql";;ACTIVE;2.40;2.4 +7028-4;Amdinocillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Amdinocillin [Susceptibility] by Gradient strip;Amdinocillin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70284-5;"t(11;17)(q23;q21.1)(ZBTB16,RARA) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;17)(q23;q21.1)(ZBTB16,RARA) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(11;17)(ZBTB16,RARA) Bld/T Ql";;ACTIVE;2.40;2.4 +70285-2;"t(11;19)(q23;p13.1)(MLL,ELL) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;19)(q23;p13.1)(MLL,ELL) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(11;19)(MLL,ELL) Bld/T Ql";;ACTIVE;2.40;2.4 +70286-0;"t(12;22)(p13;q12.1)(ETV6,MN1) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(12;22)(p13;q12.1)(ETV6,MN1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(12;22)(ETV6,MN1) Bld/T Ql";;ACTIVE;2.40;2.4 +70287-8;"t(16;21)(p11.2;q22.3)(FUS,ERG) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(16;21)(p11.2;q22.3)(FUS,ERG) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(16;21)(FUS,ERG) Bld/T Ql";;ACTIVE;2.40;2.4 +70288-6;"t(17;19)(q22;p13.3)(HLF,TCF3) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(17;19)(q22;p13.3)(HLF,TCF3) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"t(17;19)(HLF,TCF3) Bld/T Ql";;ACTIVE;2.40;2.4 +70289-4;Del(1)(p32p32)(STIL,TAL1) fusion transcript;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.DEL;1;Del(1)(p32p32)(STIL,TAL1) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method;Del(1p32)(STIL,TAL1) Bld/T Ql;;ACTIVE;2.40;2.56 +70291-0;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript";Arb;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.INV;1;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";"inv(16)(p13;q22) Bld/T Ql";;ACTIVE;2.40;2.73 +7029-2;Meropenem;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Meropenem [Susceptibility] by Gradient strip;Meropenem Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70292-8;Blastocystis hominis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Blastocystis hominis DNA [Presence] in Stool by NAA with probe detection;B hominis DNA Stl Ql NAA+probe;;ACTIVE;2.40;2.73 +70293-6;Entamoeba histolytica+Entamoeba dispar+Entamoeba ecuadoriensis+Entamoeba nuttalli DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Entamoeba histolytica+Entamoeba dispar+Entamoeba ecuadoriensis+Entamoeba nuttalli DNA [Presence] in Specimen by NAA with probe detection;E his+dis+ecua+nutt DNA Spec Ql NAA+prb;;ACTIVE;2.40;2.69 +70294-4;Entamoeba sp DNA;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Entamoeba sp DNA [Identifier] in Specimen by Sequencing;Entamoeba DNA Spec Seq;;ACTIVE;2.40;2.69 +70295-1;Dientamoeba fragilis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Dientamoeba fragilis DNA [Presence] in Stool by NAA with probe detection;D fragilis DNA Stl Ql NAA+probe;;ACTIVE;2.40;2.73 +70296-9;Plesiomonas shigelloides DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Plesiomonas shigelloides DNA [Presence] in Stool by NAA with probe detection;P shigelloides DNA Stl Ql NAA+probe;;ACTIVE;2.40;2.73 +70297-7;Patient information panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;ESRD patient information panel;;;TRIAL;2.40;2.42 +70298-5;Mineral metabolism panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;ESRD mineral metabolism panel;;;TRIAL;2.40;2.42 +70299-3;Anemia management panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;ESRD anemia management panel;;;TRIAL;2.40;2.42 +70-3;Cefamandole;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefamandole [Susceptibility] by Serum bactericidal titer;Cefamandole Titr SBT;;ACTIVE;1.0;2.32 +7030-0;Methicillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Methicillin [Susceptibility] by Gradient strip;Methicillin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70300-9;Dialysis adequacy panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;ESRD dialysis adequacy panel;;;TRIAL;2.40;2.42 +70301-7;I have pain in my stomach area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my stomach area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70302-5;I get headaches in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get headaches in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70303-3;I need help doing my usual activities in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I need help doing my usual activities in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70304-1;I feel tired in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel tired in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70305-8;I have been short of breath in the past 7D;Find;7D;^Patient;Ord;;SURVEY.GNHLTH;4;I have been short of breath in the past 7 days;;;ACTIVE;2.40;2.72 +70306-6;I am self-conscious about the way I dress in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am self-conscious about the way I dress in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70307-4;One or more of my arms are swollen or tender in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;One or more of my arms are swollen or tender in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70308-2;I feel sexually attractive in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel sexually attractive in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70309-0;I am bothered by hair loss in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by hair loss in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70310-8;I worry that other members of my family might someday get the same illness I have in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that other members of my family might someday get the same illness I have in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70311-6;I worry about the effect of stress on my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about the effect of stress on my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70312-4;I am bothered by a change in weight in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by a change in weight in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70313-2;I am able to feel like a woman in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to feel like a woman in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70314-0;I have trouble controlling my urine in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble controlling my urine in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70315-7;I urinate more frequently than usual in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I urinate more frequently than usual in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70316-5;It burns when I urinate in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;It burns when I urinate in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70317-3;I am interested in sex in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am interested in sex in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7031-8;metroNIDAZOLE;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;metroNIDAZOLE [Susceptibility] by Gradient strip;metroNIDAZOLE Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70318-1;For men only - I am able to have and maintain an erection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;For men only - I am able to have and maintain an erection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70319-9;I have emotional ups and downs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have emotional ups and downs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70320-7;I am able to get around by myself in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to get around by myself in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70321-5;I have concerns about my ability to have children in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have concerns about my ability to have children in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70322-3;I have bone pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have bone pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70323-1;I am able to concentrate in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to concentrate in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70324-9;I am bothered by the change in my personality in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by the change in my personality in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70325-6;I am able to make decisions and take responsibility in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to make decisions and take responsibility in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7032-6;Minocycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Minocycline [Susceptibility] by Gradient strip;Minocycline Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70326-4;I am bothered by the drop in my contribution to the family in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by the drop in my contribution to the family in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70327-2;I am able to put my thoughts together in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to put my thoughts together in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70328-0;I need help caring for myself - bathing, dressing, eating, etc in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I need help caring for myself - bathing, dressing, eating, etc in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70329-8;I am able to put my thoughts into action in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to put my thoughts into action in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70330-6;I am able to read like I used to in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to read like I used to in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70331-4;I am able to write like I used to in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to write like I used to in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70332-2;I am able to drive a vehicle - my car, truck, etc - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to drive a vehicle - my car, truck, etc - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70333-0;I have trouble feeling sensation in my arms, hands or legs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble feeling sensation in my arms, hands or legs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7033-4;Mupirocin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Mupirocin [Susceptibility] by Gradient strip;Mupirocin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70334-8;I have had seizures - convulsions - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had seizures - convulsions - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70335-5;I have weakness in my arms or legs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have weakness in my arms or legs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70336-3;I have trouble with coordination in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble with coordination in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70337-1;I can remember new things in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I can remember new things in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70338-9;I get frustrated that I cannot do the things I used to in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get frustrated that I cannot do the things I used to in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70339-7;I am afraid of having a seizure - convulsion - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am afraid of having a seizure - convulsion - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70340-5;I have trouble with my eyesight in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble with my eyesight in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70341-3;I feel independent in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel independent in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7034-2;Nalidixate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Nalidixate [Susceptibility] by Gradient strip;Nalidixate Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70342-1;I am able to find the right words to say what I mean in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to find the right words to say what I mean in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70343-9;I have difficulty expressing my thoughts in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty expressing my thoughts in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70344-7;I am bothered by fevers - episodes of high body temperature - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by fevers - episodes of high body temperature - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70345-4;I have swelling or cramps in my stomach area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have swelling or cramps in my stomach area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70346-2;I am losing weight in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am losing weight in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70347-0;I have control of my bowels in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have control of my bowels in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70348-8;I can digest my food well in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I can digest my food well in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70349-6;I have diarrhea in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have diarrhea in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70350-4;I have a good appetite in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have a good appetite in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70351-2;I like the appearance of my body in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I like the appearance of my body in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70352-0;I am embarrassed by my ostomy appliance in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am embarrassed by my ostomy appliance in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70353-8;Caring for my ostomy appliance is difficult in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Caring for my ostomy appliance is difficult in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70354-6;I am able to maintain my balance in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to maintain my balance in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70355-3;I am able to walk in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to walk in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70356-1;I have strength in my arms in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have strength in my arms in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70357-9;I have strength in my legs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have strength in my legs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70358-7;I have numbness in my legs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have numbness in my legs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7035-9;Netilmicin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Netilmicin [Susceptibility] by Gradient strip;Netilmicin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70359-5;I have pain in my back in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my back in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70360-3;I am bothered by discharge or bleeding from my vagina in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by discharge or bleeding from my vagina in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70361-1;I am bothered by odor coming from my vagina in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by odor coming from my vagina in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70362-9;I am afraid to have sex in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am afraid to have sex in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70363-7;My vagina feels too narrow or short in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My vagina feels too narrow or short in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70364-5;I am afraid the treatment will harm my body in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am afraid the treatment will harm my body in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70365-2;I am bothered by constipation in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by constipation in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70366-0;I have discomfort when I urinate in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have discomfort when I urinate in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7036-7;Nitrofurantoin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Nitrofurantoin [Susceptibility] by Gradient strip;Nitrofurantoin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70367-8;I have difficulty swallowing solid foods in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty swallowing solid foods in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70368-6;I have difficulty swallowing soft or mashed foods in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty swallowing soft or mashed foods in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70369-4;I have difficulty swallowing liquids in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty swallowing liquids in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70370-2;I have a pain in my chest when I swallow in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have a pain in my chest when I swallow in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70371-0;I choke when I swallow in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I choke when I swallow in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70372-8;I am able to enjoy meals with family or friends in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to enjoy meals with family or friends in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70373-6;I wake at night because of coughing in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I wake at night because of coughing in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70374-4;I have trouble digesting food in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble digesting food in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7037-5;Norfloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Norfloxacin [Susceptibility] by Gradient strip;Norfloxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70375-1;I have discomfort or pain in my pelvic area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have discomfort or pain in my pelvic area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70376-9;I have hot flashes in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have hot flashes in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70377-7;I have gained weight in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have gained weight in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70378-5;I have cold sweats in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have cold sweats in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70379-3;I have night sweats in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have night sweats in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70380-1;I have vaginal discharge in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have vaginal discharge in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70381-9;I have vaginal bleeding or spotting in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have vaginal bleeding or spotting in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70382-7;I have pain or discomfort with intercourse in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain or discomfort with intercourse in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7038-3;Ofloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ofloxacin [Susceptibility] by Gradient strip;Ofloxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70383-5;I have a loss of appetite in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have a loss of appetite in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70384-3;My digestive problems interfere with my usual activities in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My digestive problems interfere with my usual activities in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70385-0;I have trouble swallowing food in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble swallowing food in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70386-8;I am bothered by gas - flatulence - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by gas - flatulence - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70387-6;I am bothered by reflux or heartburn in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by reflux or heartburn in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70388-4;I am bothered by a change in my eating habits in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by a change in my eating habits in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70389-2;I have discomfort or pain when I eat in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have discomfort or pain when I eat in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +703-9;Basophilic stippling;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Basophilic stippling [Presence] in Blood by Light microscopy;Baso Stipl Bld Ql Smear;;ACTIVE;1.0;2.73 +70390-0;I have stomach problems that worry me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have stomach problems that worry me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7039-1;Oxacillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Oxacillin [Susceptibility] by Gradient strip;Oxacillin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70391-8;I avoid going out to eat because of my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I avoid going out to eat because of my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70392-6;I feel sad in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel sad in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70393-4;I am satisfied with how I am coping with my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am satisfied with how I am coping with my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70394-2;I am losing hope in the fight against my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am losing hope in the fight against my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70395-9;I feel nervous in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel nervous in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70396-7;I worry about dying in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about dying in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70397-5;I worry that my condition will get worse in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that my condition will get worse in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70398-3;I am able to work - include work at home - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to work - include work at home - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70399-1;My work - include work at home - is fulfilling in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My work - include work at home - is fulfilling in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70400-7;I am able to enjoy life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to enjoy life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70401-5;I have accepted my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have accepted my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70402-3;I am sleeping well in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am sleeping well in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70403-1;I am enjoying the things I usually do for fun in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am enjoying the things I usually do for fun in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70404-9;I am content with the quality of my life right now in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am content with the quality of my life right now in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70405-6;I have a lack of energy in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have a lack of energy in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70406-4;I have nausea in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have nausea in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70407-2;Because of my physical condition, I have trouble meeting the needs of my family in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Because of my physical condition, I have trouble meeting the needs of my family in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70408-0;I have pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7040-9;Pefloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Pefloxacin [Susceptibility] by Gradient strip;Pefloxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70409-8;I am bothered by side effects of treatment in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by side effects of treatment in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70410-6;I feel ill in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel ill in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70411-4;I am forced to spend time in bed in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am forced to spend time in bed in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70412-2;I feel close to my friends in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel close to my friends in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70413-0;I get emotional support from my family in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get emotional support from my family in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70414-8;I get support from my friends in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get support from my friends in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70415-5;My family has accepted my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My family has accepted my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70416-3;I am satisfied with family communication about my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am satisfied with family communication about my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7041-7;Penicillin G;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Penicillin G [Susceptibility] by Gradient strip;Penicillin G Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70417-1;I feel close to my partner, or the person who is my main support, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel close to my partner, or the person who is my main support, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70418-9;I am satisfied with my sex life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am satisfied with my sex life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70419-7;I am unhappy about a change in my appearance in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am unhappy about a change in my appearance in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70420-5;I am bothered by jaundice or yellow color to my skin in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by jaundice or yellow color to my skin in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70421-3;I have had fevers - episodes of high body temperature - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had fevers - episodes of high body temperature - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70422-1;I have had a change in the way food tastes in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had a change in the way food tastes in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70423-9;I have had chills in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had chills in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70424-7;I have discomfort or pain in my stomach area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have discomfort or pain in my stomach area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7042-5;Penicillin V;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Penicillin V [Susceptibility] by Gradient strip;Penicillin V Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70425-4;I feel weak all over in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel weak all over in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70426-2;I feel fatigued in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel fatigued in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70427-0;I am able to eat the foods that I like in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to eat the foods that I like in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70428-8;I am able to communicate with others in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to communicate with others in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70429-6;I can eat solid foods in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I can eat solid foods in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70430-4;I have pain in my mouth, throat or neck in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my mouth, throat or neck in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70431-2;My mouth is dry in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My mouth is dry in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70432-0;I have trouble breathing in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble breathing in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7043-3;Piperacillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Piperacillin [Susceptibility] by Gradient strip;Piperacillin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70433-8;My voice has its usual quality and strength in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My voice has its usual quality and strength in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70434-6;I am able to eat as much food as I want in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to eat as much food as I want in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70435-3;I am unhappy with how my face and neck look in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am unhappy with how my face and neck look in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70436-1;I can swallow naturally and easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I can swallow naturally and easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70437-9;I smoke cigarettes or other tobacco products in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I smoke cigarettes or other tobacco products in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70438-7;I drink alcohol - beer, wine, etc - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I drink alcohol - beer, wine, etc - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70439-5;I have to limit my social activity because of my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my social activity because of my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70440-3;I have to limit my physical activity because of my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my physical activity because of my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7044-1;Piperacillin+Tazobactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Piperacillin+Tazobactam [Susceptibility] by Gradient strip;Pip+Tazo Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70441-1;My thinking is clear in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My thinking is clear in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70442-9;I have been coughing in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been coughing in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70443-7;I feel tightness in my chest in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel tightness in my chest in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70444-5;Breathing is easy for me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Breathing is easy for me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70445-2;I regret my smoking in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I regret my smoking in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70446-0;I am bothered by lumps or swelling in certain part of my body - neck, armpits, or groin - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by lumps or swelling in certain part of my body - neck, armpits, or groin - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70447-8;Because of my illness, I have difficulty planning for the future in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Because of my illness, I have difficulty planning for the future in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70448-6;I feel uncertain about my future health in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel uncertain about my future health in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70449-4;I worry that I might get new symptoms of my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that I might get new symptoms of my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70450-2;I feel isolated from others because of my illness or treatment in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel isolated from others because of my illness or treatment in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70451-0;I am bothered by itching in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by itching in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70452-8;I have trouble sleeping at night in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble sleeping at night in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70453-6;I have pain at my melanoma site or surgical site in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain at my melanoma site or surgical site in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70454-4;I have swelling at my melanoma site in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have swelling at my melanoma site in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70455-1;I have swelling as a result of surgery in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have swelling as a result of surgery in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70456-9;I am bothered by the amount of swelling in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by the amount of swelling in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70457-7;Movement of my swollen area is painful in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Movement of my swollen area is painful in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7045-8;rifAMPin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;rifAMPin [Susceptibility] by Gradient strip;rifAMPin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70458-5;Swelling keeps me from doing the things I want to do in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Swelling keeps me from doing the things I want to do in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70459-3;Swelling keeps me from wearing clothes or shoes I want to wear in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Swelling keeps me from wearing clothes or shoes I want to wear in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70460-1;I feel numbness at my surgical site in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel numbness at my surgical site in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70461-9;I have good range of movement in my arm or leg in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have good range of movement in my arm or leg in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70462-7;I have noticed new changes in my skin - lumps, bumps, color in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have noticed new changes in my skin - lumps, bumps, color in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70463-5;I worry about the appearance of surgical scars in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about the appearance of surgical scars in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70464-3;I have aches and pains in my bones in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have aches and pains in my bones in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70465-0;I have noticed blood in my stool in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have noticed blood in my stool in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7046-6;Roxithromycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Roxithromycin [Susceptibility] by Gradient strip;Roxithromycin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70466-8;I isolate myself from others because of my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I isolate myself from others because of my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70467-6;I have difficulty thinking clearly - remembering, concentrating - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty thinking clearly - remembering, concentrating - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70468-4;I have trouble walking because of the pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble walking because of the pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70469-2;I feel overwhelmed by my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel overwhelmed by my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +704-7;Basophils;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Basophils [#/volume] in Blood by Automated count;Basophils # Bld Auto;;ACTIVE;1.0;2.73 +70470-0;I worry about getting infections in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about getting infections in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70471-8;I have difficulty moving my neck and shoulders because of stiffness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty moving my neck and shoulders because of stiffness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70472-6;I am bothered by ringing in my ears in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by ringing in my ears in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70473-4;I am bothered by worsening eyesight in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by worsening eyesight in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7047-4;Sparfloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Sparfloxacin [Susceptibility] by Gradient strip;Sparfloxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70474-2;I have trouble smelling the in past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble smelling the in past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70475-9;I can enjoy the taste of food in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I can enjoy the taste of food in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70476-7;I am bothered by having a blocked nose in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by having a blocked nose in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70477-5;I have trouble hearing in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble hearing in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70478-3;I have swelling in my stomach area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have swelling in my stomach area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70479-1;I have been vomiting in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been vomiting in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70480-9;I have cramps in my stomach area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have cramps in my stomach area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70481-7;I have certain parts of my body where I experience pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have certain parts of my body where I experience pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7048-2;Streptomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Streptomycin [Susceptibility] by Gradient strip;Streptomycin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70482-5;Do you have an ostomy appliance;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Do you have an ostomy appliance [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70483-3;Have you ever smoked;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Have you ever smoked [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70484-1;I bleed easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I bleed easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70485-8;I bruise easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I bruise easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70486-6;I am bothered by discharge or bleeding from my vulva in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by discharge or bleeding from my vulva in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70487-4;I am bothered by odor coming from my vulva in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by odor coming from my vulva in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70488-2;I am bothered by swelling, fluid in my legs, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by swelling, fluid in my legs, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70489-0;I am bothered by discomfort in my groin or legs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by discomfort in my groin or legs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7049-0;Streptomycin.high potency;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Streptomycin.high potency [Susceptibility] by Disk diffusion (KB);Streptomycin High Pot Islt KB;;ACTIVE;1.0h(2);2.73 +70490-8;I am bothered by itching - burning in my vulva area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by itching - burning in my vulva area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70491-6;I am bothered by pain or numbness in my vulva area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by pain or numbness in my vulva area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70492-4;I have trouble bending in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble bending in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70493-2;I have discomfort when I'm sitting in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have discomfort when I'm sitting in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70494-0;I am bothered by wearing compression stockings in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by wearing compression stockings in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70495-7;Functional assessment of cancer therapy - general questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - General Questionnaire - version 4 (FACT-G) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70496-5;Functional assessment of cancer therapy for patients with breast cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with breast cancer questionnaire - version 4 (FACT-B) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70497-3;Functional assessment of cancer therapy for patients with bladder cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with bladder cancer questionnaire - version 4 (FACT-Bl) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70498-1;Physical well being;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Physical well-being [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70499-9;Social - family well being;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social - family well-being [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70500-4;Emotional well being;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well being [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70501-2;Functional well being;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional well-being [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70502-0;Additional concerns;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70503-8;Functional assessment of cancer therapy for patients with brain cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with brain cancer questionnaire - version 4 (FACT-Br) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70504-6;Functional assessment of chronic illness therapy - general measures panel;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy (FACIT) - General Measures Panel;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70505-3;Functional assessment of chronic illness therapy - cancer specific measures panel;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy (FACIT) - Cancer Specific Measures Panel;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70506-1;Functional assessment of chronic illness therapy - cancer specific symptom indexes panel;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy (FACIT) - Cancer Specific Symptom Indexes Panel;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70507-9;Functional assessment of cancer therapy for patients with colorectal cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with colorectal cancer questionnaire - version 4 (FACT-C) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7050-8;sulfADIAZINE;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;sulfADIAZINE [Susceptibility] by Gradient strip;sulfADIAZINE Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70508-7;Functional assessment of cancer therapy for patients with cancer in the central nervous system questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with cancer in the central nervous system questionnaire - version 4 (FACT-CNS) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70509-5;Functional assessment of cancer therapy for patients with cancer of the cervix questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with cancer of the cervix questionnaire - version 4 (FACT-Cx) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70510-3;Functional assessment of cancer therapy for patients with esophageal cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with esophageal cancer questionnaire - version 4 (FACT-E) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70511-1;Functional assessment of cancer therapy for patients with endometrial cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with endometrial cancer questionnaire - version 4 (FACT-En) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70512-9;Functional assessment of cancer therapy for patients with gastric cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with gastric cancer questionnaire - version 4 (FACT-Ga) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70513-7;Functional assessment of cancer therapy for patients with head and neck cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with head and neck cancer questionnaire - version 4 (FACT H and N) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70514-5;Functional assessment of cancer therapy for patients with hepatobiliary cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with hepatobiliary cancer - version 4 (FACT-Hep) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70515-2;Functional assessment of cancer therapy for patients with lung cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with lung cancer questionnaire - version 4 (FACT-L) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7051-6;Teicoplanin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Teicoplanin [Susceptibility] by Gradient strip;Teicoplanin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70516-0;Functional assessment of cancer therapy for patients with leukemia questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with leukemia questionnaire - version 4 (FACT-Leu) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70517-8;Functional assessment of cancer therapy for patients with non-hodgkins lymphoma questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with non-Hodgkins lymphoma questionnaire - version 4 (FACT-Lym) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70518-6;Functional assessment of cancer therapy for patients with melanoma questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with melanoma questionnaire - version 4 (FACT-M) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70519-4;Functional assessment of cancer therapy for patient with multiple myeloma questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patient with multiple myeloma questionnaire - version 4 (FACT-MM) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70520-2;Functional assessment of cancer therapy for patients with nasopharyngeal cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with nasopharyngeal cancer questionnaire - version 4 (FACT-NP) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70521-0;Functional assessment of cancer therapy for patients with ovarian cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with ovarian cancer questionnaire - version 4 (FACT-O) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70522-8;Functional assessment of cancer therapy for patients with vulva cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with vulva cancer questionnaire - version 4 (FACT-V) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70523-6;Functional assessment of cancer therapy - general population questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - General Population Questionnaire - version 4 (FACT-GP) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7052-4;Tetracycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Tetracycline [Susceptibility] by Gradient strip;Tetracycline Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70524-4;Functional assessment of non-life threatening conditions questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Non-Life Threatening Conditions Questionnaire - version 4 (FANLTC) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70525-1;I have a feeling of fullness or heaviness in my stomach area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have a feeling of fullness or heaviness in my stomach area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70526-9;I have had itching in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had itching in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70527-7;I am bothered by the chills in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by the chills in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70528-5;I get tired easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get tired easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70530-1;I have trouble concentrating in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble concentrating in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70531-9;I feel discouraged about my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel discouraged about my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7053-2;Ticarcillin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ticarcillin [Susceptibility] by Gradient strip;Ticarcillin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70532-7;Functional assessment of cancer therapy - prostate symptom index questionnaire - 8 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Prostate Symptom Index Questionnaire - 8 items (FAPSI-8) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70533-5;Functional assessment of cancer therapy - bladder symptom index questionnaire - 7 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Bladder Symptom Index Questionnaire - 7 items (FBlSI) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70534-3;National comprehensive cancer network - bladder symptom index questionnaire - 18 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Bladder Symptom Index Questionnaire - 18 items (NCCN-FBlSI-18) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70535-0;Functional assessment of cancer therapy - brain symptom index questionnaire - 15 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Brain Symptom Index Questionnaire - 15 items [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70536-8;National comprehensive cancer network - brain symptom index questionnaire - 24 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National comprehensive cancer network - Brain Symptom Index Questionnaire - 24 items (NCCN-FACT - FBrSI-24) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70537-6;Functional assessment of cancer therapy - breast symptom index questionnaire - 8 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Breast Symptom Index Questionnaire - 8 items (FBSI-8) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70538-4;National comprehensive cancer network - breast symptom index questionnaire - 16 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Breast Symptom Index Questionnaire - 16 items (NCCN-FBSI-16) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70539-2;Functional assessment of cancer therapy - colorectal symptom index questionnaire - 9 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Colorectal Symptom Index Questionnaire - 9 items (FCSI-9) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +705-4;Basophils;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Basophils [#/volume] in Blood by Manual count;Basophils # Bld Manual;;ACTIVE;1.0;2.73 +7054-0;Ticarcillin+Clavulanate;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ticarcillin+Clavulanate [Susceptibility] by Gradient strip;Ticarcillin+Clav Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70540-0;National comprehensive cancer network - colorectal symptom index questionnaire - 19 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Colorectal Symptom Index Questionnaire - 19 items (NCCN - FCSI-19) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70541-8;Functional assessment of cancer therapy - head and neck symptom index questionnaire - 10 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Head and Neck Symptom Index Questionnaire - 10 items (FACIT - FHNSI) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70542-6;National comprehensive cancer network - head and neck symptom index questionnaire - 22 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Head and Neck Symptom Index Questionnaire - 22 items (NCCN-FACT - FHNSI-22) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70543-4;Functional assessment of cancer therapy - hepatibiliary symptom index questionnaire - 8 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Hepatibiliary Symptom Index Questionnaire - 8 items (FACIT - FHSI-8) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70544-2;National comprehensive cancer network - hepatibiliary symptom index questionnaire - 18 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Hepatibiliary Symptom Index Questionnaire - 18 items (NCCN-FACT - FHSI-18) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70545-9;Functional assessment of chronic illness therapy for patients with kidney cancer questionnaire - 15 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy for patients with kidney cancer questionnaire -15 items (FACIT - FKSI-15);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70546-7;Functional assessment of chronic illness therapy for patients with kidney cancer questionnaire - 10 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy for patients with kidney cancer questionnaire -10 items (FACIT - FKSI-10);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70547-5;Functional assessment of chronic illness therapy for patients with kidney cancer - disease related symptoms questionnaire - 9 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy for patients with kidney cancer - Disease Related Symptoms Questionnaire - 9 items (FACIT - FKSI-DRS 9);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70548-3;National comprehensive cancer network - kidney symptom index questionnaire - 19 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Kidney Symptom Index Questionnaire - 19 items (NCCN-FACT - FKSI-19) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70549-1;Functional assessment of cancer therapy - lung symptom index questionnaire - 6 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Lung Symptom Index Questionnaire - 6 items - version 4 (FACT - FLSI 6) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70550-9;Functional assessment of cancer therapy - lung symptom index questionnaire - 12 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Lung Symptom Index Questionnaire - 12 items - version 4 (FACIT - FLSI-12) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70551-7;Functional assessment of cancer therapy - lung symptom index questionnaire - 7 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Lung Symptom Index Questionnaire - 7 items - version 4 (FACIT - FACT-LCS) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70552-5;National comprehensive cancer network - lung symptom index questionnaire - 17 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Lung Symptom Index Questionnaire - 17 items (NCCN-FACT - FLSI-17) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70553-3;National comprehensive cancer network - lymphoma symptom index questionnaire - 18 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Lymphoma Symptom Index Questionnaire - 18 items (NCCN-FACT - FLymSI-18) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70554-1;Functional assessment of cancer therapy - ovarian symptom index questionnaire - 8 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Ovarian Symptom Index Questionnaire - 8 items (FACIT-FOSI 8) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70555-8;National comprehensive cancer network - ovarian symptom index questionnaire - 18 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Ovarian Symptom Index Questionnaire - 18 items (NCCN_FACT - FOSI 18) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70556-6;Functional assessment of cancer therapy - prostate symptom index questionnaire - 8 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Deprecated Deprecated Functional Assessment of Cancer Therapy - Prostate Symptom Index Questionnaire - 8 items (FAPSI-8)-FACIT;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;DEPRECATED;2.40;2.68 +7055-7;Tobramycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Tobramycin [Susceptibility] by Gradient strip;Tobramycin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70557-4;National comprehensive cancer network - prostate symptom index questionnaire - 17 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;National Comprehensive Cancer Network - Prostate Symptom Index Questionnaire - 17 items (NCCN-FACT-FPSI 17) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70558-2;My pain keeps me from doing things I want to do in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My pain keeps me from doing things I want to do in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70559-0;My problems with urinating limit my activities in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My problems with urinating limit my activities in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70560-8;I feel light-headed, dizzy in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel light-headed, dizzy in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70561-6;I have mouth sores in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have mouth sores in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70562-4;I have numbness or tingling in my hands in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have numbness or tingling in my hands in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70563-2;I have pain in my hands or feet when I am exposed to cold temperatures in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my hands or feet when I am exposed to cold temperatures in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70564-0;I have had blood in my urine in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had blood in my urine in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7056-5;Trimethoprim;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Trimethoprim [Susceptibility] by Gradient strip;Trimethoprim Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70565-7;I am bothered by skin problems in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by skin problems in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70566-5;I have difficulty urinating in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty urinating in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70567-3;I have trouble moving my bowels in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble moving my bowels in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70568-1;Plasmodium knowlesi DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Plasmodium knowlesi DNA [Presence] in Blood by NAA with probe detection;P knowlesi DNA Bld Ql NAA+probe;;ACTIVE;2.40;2.73 +70569-9;Plasmodium sp Ag;Prid;Pt;Bld;Nom;IA.rapid;MICRO;1;Plasmodium sp Ag [Identifier] in Blood by Rapid immunoassay;Plasmodium Ag Bld IA.rapid;;ACTIVE;2.40;2.73 +70570-7;I have weakness in my legs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have weakness in my legs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70571-5;Functional assessment of chronic illness therapy - bone treatment convenience and satisfaction questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Bone treatment convenience and satisfaction questionnaire - version 1 (FACIT-TS-BTCSQ);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70572-3;I believe that treatment for bone disease will take up my time;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that treatment for bone disease will take up my time [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7057-3;Trimethoprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Trimethoprim+Sulfamethoxazole [Susceptibility] by Gradient strip;TMP SMX Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70573-1;I believe that my treatment for bone disease will take up my family's time;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that my treatment for bone disease will take up my family's time [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70574-9;I worry about side effects from treatment for bone disease;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about side effects from treatment for bone disease [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70575-6;I believe that my treatment for bone disease will cause me physical pain;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that my treatment for bone disease will cause me physical pain [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70576-4;I believe that receiving treatment for bone disease will be inconvenient;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that receiving treatment for bone disease will be inconvenient [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70577-2;I worry that my treatment for bone disease will not be effective;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that my treatment for bone disease will not be effective [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70578-0;I believe that treatment for bone disease will be harmful to me;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that treatment for bone disease will be harmful to me [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70579-8;I believe that my treatment schedule for bone disease will be stressful to me;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that my treatment schedule for bone disease will be stressful to me [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70580-6;I believe that my treatment schedule for bone disease will be stressful to my family;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that my treatment schedule for bone disease will be stressful to my family [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7058-1;Trovafloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Trovafloxacin [Susceptibility] by Gradient strip;Trovafloxacin Islt Grad strip;;ACTIVE;1.0h(2);2.56 +70581-4;I believe that I will be bothered by side effects of treatment for bone disease;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that I will be bothered by side effects of treatment for bone disease [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70582-2;I believe that waiting up to 60M before eating breakfast in the morning will be inconvenient;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that waiting up to 60 minutes before eating breakfast in the morning will be inconvenient [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70583-0;I believe that an infusion for my bone treatment will cause me physical pain;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that an infusion for my bone treatment will cause me physical pain [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70584-8;I believe that having my blood drawn will be inconvenient;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I believe that having my blood drawn will be inconvenient [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70585-5;Functional assessment of cancer therapy for patients receiving enteral feeding questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients receiving enteral feeding questionnaire - version 1 (FACT-EF) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70586-3;I experience a pleasant feeling of fullness during or after my tube feeding in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I experience a pleasant feeling of fullness during or after my tube feeding in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70587-1;I feel uncomfortably full during or after my tube feeding in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel uncomfortably full during or after my tube feeding in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70588-9;I have constipation during or after my tube feeding in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have constipation during or after my tube feeding in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70589-7;I experience vomiting during or after my tube feeding in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I experience vomiting during or after my tube feeding in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70590-5;Tube feeding limits what I can do inside the house - for example housework, watching TV or reading - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Tube feeding limits what I can do inside the house - for example housework, watching TV or reading - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70591-3;Tube feeding limits what I can do outside of the house - for example shopping, driving or yard work - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Tube feeding limits what I can do outside of the house - for example shopping, driving or yard work - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70592-1;Tube feeding limits my activities with my friends in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Tube feeding limits my activities with my friends in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70593-9;During the use of tube feeding, I can eat and drink by mouth in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;During the use of tube feeding, I can eat and drink by mouth in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70594-7;I miss being able to take more food or drink by mouth now that I have a feeding tube in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I miss being able to take more food or drink by mouth now that I have a feeding tube in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70595-4;I have the desire to eat in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have the desire to eat in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70596-2;I worry that having a feeding tube means my health is worse in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that having a feeding tube means my health is worse in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70597-0;I worry about the tube coming out by accident in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about the tube coming out by accident in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70598-8;I worry about the tube getting plugged or blocked in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about the tube getting plugged or blocked in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7059-9;Vancomycin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Vancomycin [Susceptibility] by Gradient strip;Vancomycin Islt Grad strip;;ACTIVE;1.0h(2);2.73 +70599-6;I worry about getting an infection from the feeding tube in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about getting an infection from the feeding tube in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70600-2;I worry about losing weight because I have a feeding tube in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about losing weight because I have a feeding tube in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70601-0;I feel that I have lost control of my food choices because I have a feeding tube in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel that I have lost control of my food choices because I have a feeding tube in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70602-8;I feel dependent on others because I have a feeding tube in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel dependent on others because I have a feeding tube in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70603-6;I feel left out when others are eating in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel left out when others are eating in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70604-4;I am more confident about my nutrition because of my feeding tube in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am more confident about my nutrition because of my feeding tube in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70605-1;Getting a feeding tube was the right decision for me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Getting a feeding tube was the right decision for me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70606-9;Functional assessment of cancer therapy for patients with EGFRI inhibitors questionnaire - 18 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with EGFRI inhibitors questionnaire - 18 items (FACT-EGFRI-18) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7060-7;Haliotis spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Abalone IgE Ab [Units/volume] in Serum;Abalone IgE Qn;;ACTIVE;1.0h(2);2.73 +70607-7;My skin or scalp feels irritated in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My skin or scalp feels irritated in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70608-5;My skin or scalp is dry or flaky in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My skin or scalp is dry or flaky in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70609-3;My skin or scalp itches in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My skin or scalp itches in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70610-1;My skin bleeds easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My skin bleeds easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70611-9;I am bothered by a change in my skins sensitivity to the sun in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by a change in my skins sensitivity to the sun in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70612-7;My skin condition interferes with my ability to sleep in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My skin condition interferes with my ability to sleep in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70613-5;My skin condition affects my mood in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My skin condition affects my mood in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70614-3;My skin condition interferes with my social life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My skin condition interferes with my social life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7061-5;Alder Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Alder Ab.IgG;Deprecated Alder IgG Qn;;DEPRECATED;1.0h(2);2.69 +70615-0;I am embarrassed by my skin condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am embarrassed by my skin condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70616-8;I avoid going out in public because of how my skin looks in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I avoid going out in public because of how my skin looks in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70617-6;I feel unattractive because of how my skin looks in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel unattractive because of how my skin looks in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70618-4;Changes in my skin condition make daily life difficult in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Changes in my skin condition make daily life difficult in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70619-2;The skin side effects from treatment have interfered with household tasks in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The skin side effects from treatment have interfered with household tasks in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +706-2;Basophils/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Basophils/100 leukocytes in Blood by Automated count;Basophils/leuk NFr Bld Auto;;ACTIVE;1.0;2.73 +70620-0;My eyes are dry in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My eyes are dry in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70621-8;I am bothered by sensitivity around my fingernails or toenails in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by sensitivity around my fingernails or toenails in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70622-6;Sensitivity around my fingernails makes it difficult to perform household tasks in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Sensitivity around my fingernails makes it difficult to perform household tasks in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7062-3;Alnus rubra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Alder IgE Ab [Units/volume] in Serum;Red Alder IgE Qn;;ACTIVE;1.0h(2);2.73 +70623-4;I am bothered by increased facial hair in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by increased facial hair in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70624-2;Functional assessment of cancer therapy for patients with neurotoxicity questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with neurotoxicity questionnaire - version 4 (FACT-GOG-NTX) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70625-9;I have numbness or tingling in my feet in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have numbness or tingling in my feet in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70626-7;I feel discomfort in my hands in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel discomfort in my hands in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70627-5;I feel discomfort in my feet in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel discomfort in my feet in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70628-3;I have joint pain or muscle cramps in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have joint pain or muscle cramps in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70629-1;I get a ringing or buzzing in my ears in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get a ringing or buzzing in my ears in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70630-9;I have trouble buttoning buttons in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble buttoning buttons in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7063-1;Alnus rugosa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Smooth Alder IgE Ab [Units/volume] in Serum;Smooth Alder IgE Qn;;ACTIVE;1.0h(2);2.73 +70631-7;I have trouble feeling the shape of small objects when they are in my hand in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble feeling the shape of small objects when they are in my hand in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70632-5;I have trouble walking in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble walking in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70633-3;Functional assessment of cancer therapy for patients with neurotoxicity questionnaire - 12 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with neurotoxicity questionnaire - 12 items - version 4 (FACT-GOG-NTX 12) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.68 +70634-1;I have difficulty breathing when I am exposed to cold temperatures in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty breathing when I am exposed to cold temperatures in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70635-8;Functional assessment of cancer therapy for patients with neurotoxicity questionnaire - 13 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with neurotoxicity questionnaire - 13 items - version 4 (FACT-GOG-NTX 13) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70636-6;Functional assessment of cancer therapy for patients with neurotoxicity questionnaire - 4 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with neurotoxicity questionnaire - 4 items - version 4 (FACT-GOG-NTX-4) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70637-4;Functional assessment of cancer therapy for patients undergoing bone marrow transplantation questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients undergoing bone marrow transplantation questionnaire - version 4 (FACT-BMT) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70638-2;I am concerned about keeping my job - include work at home - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am concerned about keeping my job - include work at home - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70639-0;I feel distant from other people in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel distant from other people in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70640-8;I worry that the transplant will not work in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that the transplant will not work in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70641-6;The effects of treatment are worse than I had imagined in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The effects of treatment are worse than I had imagined in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70642-4;I have confidence in my nurse-s in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have confidence in my nurse-s in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70643-2;I regret having the bone marrow transplant in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I regret having the bone marrow transplant in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70644-0;I have frequent colds-infections in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have frequent colds-infections in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70645-7;My eyesight is blurry in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My eyesight is blurry in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70646-5;I have tremors in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have tremors in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70647-3;My illness is a personal hardship for my close family members in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My illness is a personal hardship for my close family members in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70648-1;The cost of my treatment is a burden on me or my family in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The cost of my treatment is a burden on me or my family in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7064-9;Alnus rhombifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Alder IgE Ab [Units/volume] in Serum;White Alder IgE Qn;;ACTIVE;1.0h(2);2.73 +70649-9;Functional assessment of cancer therapy for patients receiving biologic response modifiers questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients receiving biologic response modifiers questionnaire - version 4 (FACT-BRM) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70650-7;I am bothered by sweating in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by sweating in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70651-5;I have trouble remembering things in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble remembering things in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70652-3;I get depressed easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get depressed easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70653-1;I get annoyed easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get annoyed easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70654-9;I feel motivated to do things in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel motivated to do things in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70655-6;Functional assessment of cancer therapy - taxane questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy - Taxane Questionnaire - version 4 (FACT-Taxane) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7065-6;Medicago sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alfalfa IgE Ab [Units/volume] in Serum;Alfalfa IgE Qn;;ACTIVE;1.0h(2);2.73 +70656-4;I feel bloated in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel bloated in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70657-2;My hands are swollen in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My hands are swollen in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70658-0;My legs or feet are swollen in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My legs or feet are swollen in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70659-8;I have pain in my fingertips in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my fingertips in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70660-6;I am bothered by the way my hands or nails look in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by the way my hands or nails look in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70663-0;I can remember things in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I can remember things in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7066-4;Medicago sativa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alfalfa IgG Ab [Units/volume] in Serum;Alfalfa IgG Qn;;ACTIVE;1.0h(2);2.69 +70664-8;Parathyrin.intact intraoperative percent change;MCPctDiff;Pt;Ser/Plas;Qn;;CHEM;1;Parathyrin.intact intraoperative percent change in Serum or Plasma;PTH-Intact IO % Dif SerPl;;ACTIVE;2.40;2.73 +70665-5;Cold agglutinin;PrThr;Pt;Ser;Ord;18 deg C incubation;SERO;1;Cold agglutinin [Presence] in Serum by 18 degree C incubation;CA Ser Ql 18 deg C inc;;ACTIVE;2.40;2.56 +70666-3;Cold agglutinin;PrThr;Pt;Ser;Ord;22 deg C incubation;SERO;1;Cold agglutinin [Presence] in Serum by 22 degree C incubation;CA Ser Ql 22 deg C inc;;ACTIVE;2.40;2.56 +70667-1;Cold agglutinin;PrThr;Pt;Ser;Ord;28 deg C incubation;SERO;1;Cold agglutinin [Presence] in Serum by 28 degree C incubation;CA Ser Ql 28 deg C inc;;ACTIVE;2.40;2.56 +70668-9;I am bothered by a change in the way food tastes in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by a change in the way food tastes in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70669-7;I have trouble with my bowels in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble with my bowels in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70670-5;I have pain in my joints in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my joints in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70671-3;Mycobacterium avium subspecies paratuberculosis Ab;PrThr;Pt;Milk;Ord;IA;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Presence] in Milk by Immunoassay;M avium paraTB Ab Mlk Ql IA;;ACTIVE;2.40;2.56 +7067-2;Medicago sativa pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alfalfa Pollen IgE Ab [Units/volume] in Serum;Alfalfa Poln IgE Qn;;ACTIVE;1.0h(2);2.73 +70672-1;Functional assessment of chronic illness therapy - treatment specific measures panel;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy (FACIT) - Treatment Specific Measures Panel;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70673-9;Functional assessment of chronic illness therapy - non cancer specific measures panel;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy (FACIT) - Non cancer Specific Measures Panel;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70674-7;Functional assessment of chronic illness therapy - symptom specific measures panel;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy (FACIT) - Symptom Specific Measures Panel;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70675-4;Functional assessment of chronic illness therapy - pediatric measures panel;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy (FACIT) - Pediatric Measures Panel;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.73 +70676-2;Functional assessment of anorexia-cachexia treatment questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Anorexia-Cachexia Treatment Questionnaire - version 4 (FAACT) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70677-0;The amount I eat is sufficient to meet my needs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The amount I eat is sufficient to meet my needs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70678-8;I am worried about my weight in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am worried about my weight in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70679-6;Most food tastes unpleasant to me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Most food tastes unpleasant to me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7068-0;Algae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Algae IgE Ab [Units/volume] in Serum;Algae IgE Qn;;ACTIVE;1.0h(2);2.73 +70680-4;I am concerned about how thin I look in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am concerned about how thin I look in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70681-2;My interest in food drops as soon as I try to eat in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My interest in food drops as soon as I try to eat in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70682-0;I have difficulty eating rich or heavy foods in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have difficulty eating rich or heavy foods in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70683-8;My family or friends are pressuring me to eat in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My family or friends are pressuring me to eat in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70684-6;When I eat, I seem to get full quickly in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When I eat, I seem to get full quickly in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70685-3;My general health is improving in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My general health is improving in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70686-1;Functional assessment of chronic illness therapy for patients with abdominal symptoms questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy for patients with abdominal symptoms questionnaire - version 4 (FACIT-AD);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70687-9;Stomach pain interferes with my daily functioning in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Stomach pain interferes with my daily functioning in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70688-7;Functional assessment of chronic illness therapy for patients with ascites questionnaire;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy for patients with ascites questionnaire (FACIT-AI);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70689-5;I have been emotionally distressed in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been emotionally distressed in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70690-3;Functional assessment of chronic illness therapy for patients with cervical dysplasia questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy for patients with cervical dysplasia questionnaire - version 4 (FACIT-CD);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70691-1;Treatment satisfaction;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Treatment satisfaction [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70692-9;General perceptions;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;General perceptions [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70693-7;Relationships;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Relationships [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70694-5;I have to limit my sexual activity because of the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my sexual activity because of the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70695-2;I worry about spreading the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about spreading the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70696-0;I am hopeful about the future in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am hopeful about the future in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70697-8;I find comfort in my faith or spiritual beliefs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I find comfort in my faith or spiritual beliefs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7069-8;Pimenta dioica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Allspice IgE Ab [Units/volume] in Serum;Allspice IgE Qn;;ACTIVE;1.0h(2);2.73 +70698-6;I feel that I can manage things that come up around this infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel that I can manage things that come up around this infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70699-4;I have accepted that I have this infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have accepted that I have this infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +707-0;Basophils/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Blood by Manual count;Basophils/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +70700-0;I worry that the infection will get worse in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that the infection will get worse in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70701-8;I have hidden this problem so others will not notice in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have hidden this problem so others will not notice in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70702-6;I have concerns about my ability to become pregnant in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have concerns about my ability to become pregnant in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70703-4;I worry about other peoples attitudes towards me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about other peoples attitudes towards me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70704-2;I feel embarrassed about the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel embarrassed about the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70705-9;I tend to blame myself for the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I tend to blame myself for the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7070-6;Prunus dulcis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Almond IgG Ab [Units/volume] in Serum;Almond IgG Qn;;ACTIVE;1.0h(2);2.73 +70706-7;I was careful who I told about the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I was careful who I told about the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70707-5;I have had difficulty telling my partner - spouse about the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had difficulty telling my partner - spouse about the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70708-3;I am frustrated by the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am frustrated by the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70709-1;I am depressed about the infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am depressed about the infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70710-9;I have told my partner - spouse about my infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have told my partner - spouse about my infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.54 +70711-7;I get emotional support from my partner - spouse in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get emotional support from my partner - spouse in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70712-5;I have told family members about my infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have told family members about my infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.54 +70713-3;I get emotional support from family members in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get emotional support from family members in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7071-4;Prunus dulcis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Almond triggered histamine release [Units/volume] in Blood;Almond BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +70714-1;I have people to help me if I need it in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have people to help me if I need it in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70715-8;Functional assessment of chronic illness therapy - diarrhea questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy-Diarrhea Questionnaire - version 4 (FACIT-D);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70716-6;I move my bowels more frequently than usual in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I move my bowels more frequently than usual in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70717-4;I am afraid to be far from a toilet in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am afraid to be far from a toilet in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70718-2;I have to limit my social activity because of diarrhea in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my social activity because of diarrhea in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70719-0;I have to limit my physical activity because of diarrhea in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my physical activity because of diarrhea in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70720-8;I have to limit my sexual activity because of diarrhea in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my sexual activity because of diarrhea in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70721-6;I am embarrassed by having diarrhea in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am embarrassed by having diarrhea in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7072-2;Prunus dulcis tree Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Almond Tree IgE Ab [Units/volume] in Serum;Almond Tree IgE Qn;;ACTIVE;1.0h(2);2.73 +70722-4;I have abdominal cramps or discomfort due to my diarrhea in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have abdominal cramps or discomfort due to my diarrhea in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70723-2;My problem with diarrhea keeps - wakes - me up at night in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My problem with diarrhea keeps - wakes - me up at night in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70724-0;I must move my bowels frequently to avoid accidents in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I must move my bowels frequently to avoid accidents in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70725-7;I wear protection for soiling of stool in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I wear protection for soiling of stool in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70726-5;Functional assessment of chronic illness therapy - fatigue questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire - version 4 (FACIT-F);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70727-3;I feel listless - washed out - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel listless - washed out - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70728-1;I have trouble starting things because I am tired in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble starting things because I am tired in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70729-9;I have trouble finishing things because I am tired in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble finishing things because I am tired in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7073-0;Amylase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Amylase IgE Ab [Units/volume] in Serum;Amylase IgE Qn;;ACTIVE;1.0h(2);2.73 +70730-7;I have energy in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have energy in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70731-5;I need to sleep during the day in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I need to sleep during the day in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70732-3;I am too tired to eat in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am too tired to eat in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70733-1;I am frustrated by being too tired to do the things I want to do in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am frustrated by being too tired to do the things I want to do in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70734-9;I have to limit my social activity because I am tired in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my social activity because I am tired in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70735-6;Functional assessment of chronic illness therapy - fatigue questionnaire -13 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire -13 items - version 4 (FACIT - fatigue 13);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70736-4;Functional assessment of cancer therapy for patients with anemia - fatigue questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with anemia - fatigue questionnaire - version 4 (FACT-An) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70737-2;I have pain in my chest in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my chest in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70738-0;I am motivated to do my usual activities in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am motivated to do my usual activities in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70739-8;Functional assessment of cancer therapy for patients with lymphedema questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for Patients with lymphedema questionnaire - version 4 (FACT-B + 4) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70740-6;On which side was your breast operation;Find;Pt;^Patient;Nom;FACIT;SURVEY.GNHLTH;4;On which side was your breast operation [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.52 +70741-4;Movement of my arm on this side is painful in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Movement of my arm on this side is painful in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70742-2;I have a poor range of arm movements on this side in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have a poor range of arm movements on this side in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70743-0;My arm on this side feels numb in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My arm on this side feels numb in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70744-8;I have stiffness of my arm on this side in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have stiffness of my arm on this side in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70745-5;Functional assessment of cancer therapy for patients with bone pain questionnaire;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with bone pain questionnaire (FACT-BP) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70746-3;In how many places in your body have you felt bone pain;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;In how many places in your body have you felt bone pain [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70747-1;It hurts when I put weight or pressure on the place where I have bone pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;It hurts when I put weight or pressure on the place where I have bone pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7074-8;Alternaria sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria sp IgE Ab [Units/volume] in Serum;Alternaria IgE Qn;;ACTIVE;1.0h(2);2.42 +70748-9;I have bone pain even when I sit or lie still in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have bone pain even when I sit or lie still in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70749-7;I need help doing my usual activities because of bone pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I need help doing my usual activities because of bone pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70750-5;I am forced to rest during the day because of bone pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am forced to rest during the day because of bone pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70751-3;I have trouble walking because of bone pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble walking because of bone pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70752-1;Bone pain interferes with my ability to care for myself - bathing, dressing, eating, etc - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Bone pain interferes with my ability to care for myself - bathing, dressing, eating, etc - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70753-9;Bone pain interferes with my social activities in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Bone pain interferes with my social activities in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70754-7;Bone pain wakes me up at night in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Bone pain wakes me up at night in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7075-5;Alternaria sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria sp IgG Ab [Units/volume] in Serum;Alternaria IgG Qn;;ACTIVE;1.0h(2);2.69 +70755-4;I am frustrated by my bone pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am frustrated by my bone pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70756-2;I feel depressed about my bone pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel depressed about my bone pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70757-0;I worry that my bone pain will get worse in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that my bone pain will get worse in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70758-8;My family has trouble understanding when my bone pain interferes with my activity in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My family has trouble understanding when my bone pain interferes with my activity in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70759-6;Functional assessment of cancer therapy for patients with cognitive function issues questionnaire - version 3;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with cognitive function issues questionnaire - version 3 (FACT-Cog) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70760-4;I have had trouble forming thoughts in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble forming thoughts in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70761-2;My thinking has been slow in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My thinking has been slow in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70762-0;I have had trouble concentrating in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble concentrating in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7076-3;Alternaria alternata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alternaria alternata IgG Ab [Units/volume] in Serum;A alternata IgG Qn;;ACTIVE;1.0h(2);2.73 +70763-8;I have had trouble finding my way to a familiar place in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble finding my way to a familiar place in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70764-6;I have had trouble remembering where I put things, like my keys or my wallet in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble remembering where I put things, like my keys or my wallet in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70765-3;I have had trouble remembering new information, like phone numbers or simple instructions in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble remembering new information, like phone numbers or simple instructions in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70766-1;I have had trouble recalling the name of an object while talking to someone in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble recalling the name of an object while talking to someone in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70767-9;I have had trouble finding the right words to express myself in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble finding the right words to express myself in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70768-7;I have used the wrong word when I referred to an object in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have used the wrong word when I referred to an object in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70769-5;I have had trouble saying what I mean in conversations with others in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had trouble saying what I mean in conversations with others in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70770-3;I have walked into a room and forgotten what I meant to get or do there in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have walked into a room and forgotten what I meant to get or do there in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7077-1;Alternaria alternata basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Alternaria alternata triggered histamine release [Units/volume] in Blood;A alternata BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +70771-1;I have had to work really hard to pay attention or I would make a mistake in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had to work really hard to pay attention or I would make a mistake in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70772-9;I have forgotten names of people soon after being introduced in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have forgotten names of people soon after being introduced in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70773-7;My reactions in everyday situations have been slow in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My reactions in everyday situations have been slow in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70774-5;Comments from others;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Comments from others [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70775-2;Other people have told me I seemed to have trouble remembering information in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people have told me I seemed to have trouble remembering information in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70776-0;I have had to work harder than usual to keep track of what I was doing in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had to work harder than usual to keep track of what I was doing in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70777-8;My thinking has been slower than usual in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My thinking has been slower than usual in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70778-6;I have had to work harder than usual to express myself clearly in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had to work harder than usual to express myself clearly in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70779-4;I have had to use written lists more often than usual so I would not forget things in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have had to use written lists more often than usual so I would not forget things in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70780-2;I have trouble keeping track of what I am doing if I am interrupted in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble keeping track of what I am doing if I am interrupted in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70781-0;I have trouble shifting back and forth between different activities that require thinking in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble shifting back and forth between different activities that require thinking in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70782-8;Other people have told me I seemed to have trouble speaking clearly in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people have told me I seemed to have trouble speaking clearly in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70783-6;Other people have told me I seemed to have trouble thinking clearly in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people have told me I seemed to have trouble thinking clearly in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70784-4;Other people have told me I seemed confused in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people have told me I seemed confused in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70785-1;Perceived cognitive abilities;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Perceived cognitive abilities [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70786-9;I have been able to concentrate in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been able to concentrate in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70787-7;I have been able to bring to mind words that I wanted to use while talking to someone in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been able to bring to mind words that I wanted to use while talking to someone in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70788-5;I have been able to remember things, like where I left my keys or wallet, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been able to remember things, like where I left my keys or wallet, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7078-9;Ampicillin Ab.IgM;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ampicillin IgM Ab [Units/volume] in Serum;Ampicillin IgM Qn;;ACTIVE;1.0h(2);2.69 +70789-3;I have been able to remember to do things, like take medicine or buy something I needed, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been able to remember to do things, like take medicine or buy something I needed, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70790-1;I am able to pay attention and keep track of what I am doing without extra effort in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to pay attention and keep track of what I am doing without extra effort in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70791-9;My mind is as sharp as it has always been in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My mind is as sharp as it has always been in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70792-7;My memory is as good as it has always been in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My memory is as good as it has always been in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70793-5;I am able to shift back and forth between two activities that require thinking in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to shift back and forth between two activities that require thinking in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70794-3;I am able to keep track of what I am doing, even if I am interrupted in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to keep track of what I am doing, even if I am interrupted in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70795-0;Impact on quality of life;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Impact on quality of life [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.69 +70796-8;I have been upset about these problems in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been upset about these problems in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7079-7;Engraulis encrasicolus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Anchovy IgE Ab [Units/volume] in Serum;Anchovy IgE Qn;;ACTIVE;1.0h(2);2.73 +70797-6;These problems have interfered with my ability to work in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;These problems have interfered with my ability to work in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70798-4;These problems have interfered with my ability to do things I enjoy in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;These problems have interfered with my ability to do things I enjoy in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70799-2;These problems have interfered with the quality of my life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;These problems have interfered with the quality of my life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70800-8;Functional assessment of cancer therapy for patients with endocrine symptoms questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with endocrine symptoms questionnaire - version 4 (FACT-ES) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70801-6;I have vaginal itching - irritation - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have vaginal itching - irritation - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70802-4;I have vaginal dryness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have vaginal dryness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70803-2;I have lost interest in sex in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have lost interest in sex in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70804-0;I have breast sensitivity - tenderness - in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have breast sensitivity - tenderness - in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7080-5;Engraulis encrasicolus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Anchovy IgG Ab [Units/volume] in Serum;Anchovy IgG Qn;;ACTIVE;1.0h(2);2.69 +70805-7;I have mood swings in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have mood swings in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70806-5;I am irritable in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am irritable in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70807-3;Functional assessment of cancer therapy for patients with neutropenia questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional assessment of cancer therapy for patients with neutropenia questionnaire - version 4 (FACT-N) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70808-1;I worry about getting sick due to low blood counts in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about getting sick due to low blood counts in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70809-9;I avoid public places for fear of getting an infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I avoid public places for fear of getting an infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70810-7;I get aches and pains that bother me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get aches and pains that bother me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70811-5;I worry my condition will not improve if my treatment is delayed in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry my condition will not improve if my treatment is delayed in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70812-3;My partner worries about me when my blood counts are low in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My partner worries about me when my blood counts are low in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7081-3;Pimpinella anisum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Anise IgE Ab [Units/volume] in Serum;Anise IgE Qn;;ACTIVE;1.0h(2);2.73 +70813-1;My low blood counts interfere with my intimate relationships in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My low blood counts interfere with my intimate relationships in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70814-9;I am bothered by headaches in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by headaches in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70815-6;I need to rest during the day in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I need to rest during the day in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70816-4;Functional assessment of cancer therapy for patients with thrombocytopenia questionnaire - 11 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with thrombocytopenia questionnaire -11 items - version 4 (FACT-Th11) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70817-2;I worry about problems with bruising or bleeding in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about problems with bruising or bleeding in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70818-0;I am bothered by nosebleeds in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by nosebleeds in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70819-8;I am bothered by pinpoint bruising beneath my skin in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by pinpoint bruising beneath my skin in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70820-6;I am bothered by blood in my urine or stool in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by blood in my urine or stool in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7082-1;Monomorium minimum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Ant IgG Ab [Units/volume] in Serum;Black Ant IgG Qn;;ACTIVE;1.0h(2);2.69 +70821-4;I avoid or limit physical activity, because of concern with bleeding or bruising, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I avoid or limit physical activity, because of concern with bleeding or bruising, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70822-2;I am frustrated by not being able to do my usual activities in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am frustrated by not being able to do my usual activities in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70823-0;I worry that my treatment will be delayed, because of low blood counts, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that my treatment will be delayed, because of low blood counts, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70824-8;Functional assessment of cancer therapy for patients with thrombocytopenia questionnaire - 18 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with thrombocytopenia questionnaire -18 items - version 4 (FACT-Th18) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70825-5;I worry about the possibility of serious bleeding in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about the possibility of serious bleeding in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70826-3;I am bothered by bleeding in my gums or mouth in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by bleeding in my gums or mouth in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70827-1;I am inconvenienced by platelet transfusions in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am inconvenienced by platelet transfusions in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70828-9;I avoid or limit social activity, because of concern with bleeding or bruising, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I avoid or limit social activity, because of concern with bleeding or bruising, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70829-7;I worry that my treatment dose will be reduced, because of low blood counts, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry that my treatment dose will be reduced, because of low blood counts, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70830-5;For women only - I am bothered by vaginal bleeding in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;For women only - I am bothered by vaginal bleeding in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70831-3;Functional assessment of incontinence therapy - fecal questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Incontinence Therapy - Fecal Questionnaire - version 4 ( [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70832-1;I am comfortable discussing my condition with friends in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am comfortable discussing my condition with friends in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70833-9;I have to limit my sexual activity because of my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to limit my sexual activity because of my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70834-7;I am embarrassed by my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am embarrassed by my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70835-4;My condition wakes or keeps me up at night in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My condition wakes or keeps me up at night in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70836-2;I can be far from home - work without fearing soilage in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I can be far from home - work without fearing soilage in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70837-0;Functional assessment of incontinence therapy - urinary questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Incontinence Therapy - Urinary Questionnaire - version 4 (FAIT-U) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70838-8;My condition wakes me up at night in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My condition wakes me up at night in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7083-9;Monomorium minimum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Black Ant triggered histamine release [Units/volume] in Blood;Black Ant BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +70839-6;I must urinate frequently to avoid leaking in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I must urinate frequently to avoid leaking in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70840-4;I wear protection for leakage of urine in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I wear protection for leakage of urine in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70841-2;I have discomfort in my pelvic area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have discomfort in my pelvic area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70842-0;I have pain in my pelvic area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my pelvic area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70843-8;I have cramping in my pelvic area in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have cramping in my pelvic area in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70844-6;Are you sexually active or would you like to be sexually active;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Are you sexually active or would you like to be sexually active [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70845-3;I have confidence in my doctors in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have confidence in my doctors in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70846-1;I feel that I received the treatment that was right for me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel that I received the treatment that was right for me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +7084-7;Solenopsis geminata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fire Ant IgG Ab [Units/volume] in Serum;Fire Ant IgG Qn;;ACTIVE;1.0h(2);2.69 +70847-9;My doctor gave me explanations that I could understand in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My doctor gave me explanations that I could understand in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70848-7;My doctor explained the possible benefits of my treatment in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My doctor explained the possible benefits of my treatment in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.66 +70849-5;Perceived cognitive impairments;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Perceived cognitive impairments [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70850-3;Burkholderia mallei;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Burkholderia mallei [Presence] in Specimen by Organism specific culture;B mallei Spec Ql Cult;;ACTIVE;2.40;2.69 +70851-1;Burkholderia pseudomallei;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Burkholderia pseudomallei [Presence] in Specimen by Organism specific culture;B pseudomal Spec Ql Cult;;ACTIVE;2.40;2.69 +70852-9;Burkholderia pseudomallei DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Burkholderia pseudomallei DNA [Presence] in Specimen by NAA with probe detection;B pseudomal DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +70853-7;Burkholderia mallei DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Burkholderia mallei DNA [Presence] in Specimen by NAA with probe detection;B mallei DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +7085-4;Solenopsis invicta Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Red Imported Fire Ant IgE Ab [Units/volume] in Serum;Deprecated Red Imp Fire Ant IgE Qn;;DEPRECATED;1.0h(2);2.69 +70854-5;Burkholderia mallei Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Burkholderia mallei Ag [Presence] in Specimen by Immunofluorescence;B mallei Ag Spec Ql IF;;ACTIVE;2.40;2.69 +70855-2;Burkholderia pseudomallei Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Burkholderia pseudomallei Ag [Presence] in Specimen by Immunofluorescence;B pseudomal Ag Spec Ql IF;;ACTIVE;2.40;2.69 +70856-0;Rabies virus Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Rabies virus Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;RABV Ab CSF IA-aCnc;;ACTIVE;2.40;2.7 +70857-8;Rabies virus Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Rabies virus Ab [Presence] in Cerebral spinal fluid by Immunoassay;RABV Ab CSF Ql IA;;ACTIVE;2.40;2.56 +70858-6;Rabies virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Rabies virus neutralizing antibody [Presence] in Serum by Neutralization test;RABV NAb Ser Ql Nt;;ACTIVE;2.40;2.72 +70859-4;Rabies virus Ab.Neut;PrThr;Pt;CSF;Ord;Neut;MICRO;1;Rabies virus neutralizing antibody [Presence] in Cerebral spinal fluid by Neutralization test;RABV NAb CSF Ql Nt;;ACTIVE;2.40;2.72 +70860-2;Rabies virus Ab.IgG;ACnc;Pt;CSF;Qn;IF;MICRO;1;Rabies virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence;RABV IgG CSF IF-aCnc;;ACTIVE;2.40;2.7 +70861-0;Rabies virus Ab.IgG;PrThr;Pt;CSF;Ord;IF;MICRO;1;Rabies virus IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;RABV IgG CSF Ql IF;;ACTIVE;2.40;2.56 +7086-2;Solenopsis richteri Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Imported Fire Ant IgE Ab [Units/volume] in Serum;Black Imp Fire Ant IgE Qn;;ACTIVE;1.0h(2);2.42 +70862-8;Rabies virus Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;Rabies virus IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;RABV IgM CSF Ql IF;;ACTIVE;2.40;2.56 +70863-6;Rabies virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rabies virus IgM Ab [Presence] in Serum by Immunofluorescence;RABV IgM Ser Ql IF;;ACTIVE;2.40;2.56 +70864-4;Rabies virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Rabies virus IgM Ab [Titer] in Serum by Immunofluorescence;RABV IgM Titr Ser IF;;ACTIVE;2.40;2.7 +70865-1;Rabies virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Rabies virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;RABV IgM Titr CSF IF;;ACTIVE;2.40;2.7 +70866-9;Rabies virus strain identified;Prid;Pt;XXX;Nom;IF;MICRO;1;Rabies virus strain identified in Specimen by Immunofluorescence;RABV strain Spec IF;;ACTIVE;2.40;2.69 +70867-7;Rabies virus strain identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Rabies virus strain identified in Specimen by Sequencing;RABV strain Spec Seq;;ACTIVE;2.40;2.69 +70868-5;Additional concerns - FACT-B;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-B [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70869-3;Additional concerns - FACT-Bl;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Bl [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7087-0;Pogonomyrmex barbatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Ant IgE Ab [Units/volume] in Serum;Red Ant IgE Qn;;ACTIVE;1.0h(2);2.73 +70870-1;Additional concerns - FACT-Br;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Br [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70871-9;Additional concerns - FACT-C;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-C [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70872-7;Additional concerns - FACT-CNS;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-CNS [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70873-5;Additional concerns - FACT-Cx;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Cx [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70874-3;Additional concerns - FACT-E;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-E [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70875-0;Additional concerns - FACT-En;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-En [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70876-8;Additional concerns - FACT-Ga;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Ga [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70877-6;Additional concerns - FACT-Hep;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Hep [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70878-4;Additional concerns - FACT-H&N;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-H and N [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70879-2;Additional concerns - FACT-L;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-L [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +708-8;Blasts;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Blasts [#/volume] in Blood by Manual count;Blasts # Bld Manual;;ACTIVE;1.0;2.73 +70880-0;Additional concerns - FACT-Leu;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Leu [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70881-8;Additional concerns - FACT-Lym;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Lym [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70882-6;Additional concerns - FACT-M;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-M [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70883-4;Additional concerns - FACT-MM;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-MM [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70884-2;Additional concerns - FACT-NP;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-NP [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70885-9;Additional concerns - FACT-O;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-O [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70886-7;Additional concerns - FACT-V;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-V [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70887-5;Additional concerns - FACT-GOG-NTX;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-GOG-NTX [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7088-8;Malus sylvestris Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apple IgG Ab [Units/volume] in Serum;Apple IgG Qn;;ACTIVE;1.0h(2);2.73 +70888-3;Additional concerns - FACT-GOG-NTX-12;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-GOG-NTX-12 [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70889-1;Additional concerns - FACT-GOG-NTX-13;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-GOG-NTX-13 [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70890-9;Additional concerns - FACT-BMT;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-BMT [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70891-7;Additional concerns - FACT-BRM;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-BRM [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70892-5;Additional concerns - FACT-Taxane;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Taxane [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70893-3;Additional concerns - FAACT;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FAACT [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70894-1;Additional concerns - FACIT-D;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACIT-D [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70895-8;Additional concerns - FACIT-F;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACIT-F [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7089-6;Malus sylvestris basophil bound Ab;ACnc;Pt;Ser;Qn;LHR;ALLERGY;1;Apple triggered histamine release [Units/volume] in Serum;Apple BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +70896-6;Additional concerns - FACT-An;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-An [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70897-4;Additional concerns - FACT-B+4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-B+4 [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70898-2;Additional concerns - FACT-ES;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-ES [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70899-0;Additional concerns - FACT-N;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-N [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70900-6;Additional concerns - FACT-Th11;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Th11 [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70901-4;Additional concerns - FACT-Th18;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Th18 [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70902-2;Additional concerns - FAIT-F;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FAIT-F [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70903-0;Additional concerns - FAIT-U;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FAIT-U [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7090-4;Malus sylvestris tree Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apple Tree IgE Ab [Units/volume] in Serum;Apple Tree IgE Qn;;ACTIVE;1.0h(2);2.73 +70904-8;Additional concerns - FACIT-AD;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACIT-AD [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70905-5;Physical well being - FACIT-CD;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Physical well-being - FACIT-CD [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70906-3;Emotional well being - FACIT-CD;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well being - FACIT-CD [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70907-1;Cryptococcus sp rRNA gene;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Cryptococcus sp rRNA gene [Identifier] in Specimen by Sequencing;Crypt sp rRNA gene Spec Seq;;ACTIVE;2.40;2.69 +70908-9;Cryptococcus sp Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Cryptococcus sp Ag [Presence] in Tissue by Immunofluorescence;Cryptoc Ag Tiss Ql IF;;ACTIVE;2.40;2.56 +70909-7;Cryptococcus sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Cryptococcus sp Ag [Presence] in Tissue by Immune stain;Cryptoc Ag Tiss Ql ImStn;;ACTIVE;2.40;2.56 +70910-5;Cryptococcus sp Ag;PrThr;Pt;Ser;Ord;IA.rapid;MICRO;1;Cryptococcus sp Ag [Presence] in Serum by Rapid immunoassay;Cryptoc Ag Ser Ql IA.rapid;;ACTIVE;2.40;2.73 +70911-3;Cryptococcus sp Ag;PrThr;Pt;CSF;Ord;IA.rapid;MICRO;1;Cryptococcus sp Ag [Presence] in Cerebral spinal fluid by Rapid immunoassay;Cryptoc Ag CSF Ql IA.rapid;;ACTIVE;2.40;2.73 +7091-2;Prunus armeniaca Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apricot IgE Ab [Units/volume] in Serum;Apricot IgE Qn;;ACTIVE;1.0h(2);2.73 +70912-1;Additional concerns - physical;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - physical [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70913-9;Additional concerns - mental;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - mental [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70914-7;Would you like to answer the question referring to your sex life;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Would you like to answer the question referring to your sex life [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70915-4;Guidance for aspiration of CSF;Find;Pt;Neck>Spine.cervical;Doc;US;RAD;2;US Guidance for aspiration of CSF of Cervical spine;US Guided C-spine CSF asp;;ACTIVE;2.40;2.64 +70916-2;Guidance for aspiration of CSF;Find;Pt;Abdomen>Spine.lumbar;Doc;US;RAD;2;US Guidance for aspiration of CSF of Lumbar spine;US Guided L-spine CSF asp;;ACTIVE;2.40;2.64 +70917-0;Guidance for aspiration of CSF;Find;Pt;Chest>Spine.thoracic;Doc;US;RAD;2;US Guidance for aspiration of CSF of Thoracic spine;US Guided T-spine CSF asp;;ACTIVE;2.40;2.64 +70918-8;Guidance for injection;Find;Pt;Neck>Spine.cervical;Doc;RF;RAD;2;RF Guidance for injection of Cervical spine;RF Guided C-spine Inj;;ACTIVE;2.40;2.64 +70919-6;Guidance for injection;Find;Pt;Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Guidance for injection of Lumbar spine;RF Guided L-spine Inj;;ACTIVE;2.40;2.64 +7092-0;Prunus armeniaca Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apricot IgG Ab [Units/volume] in Serum;Apricot IgG Qn;;ACTIVE;1.0h(2);2.73 +70920-4;Guidance for injection;Find;Pt;Chest>Spine.thoracic;Doc;RF;RAD;2;RF Guidance for injection of Thoracic spine;RF Guided T-spine Inj;;ACTIVE;2.40;2.64 +70921-2;Guidance for nerve block;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Guidance for nerve block of Cervical spine;CT Guided C-spine Nerve block;;ACTIVE;2.40;2.64 +70922-0;Guidance for nerve block;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Guidance for nerve block of Thoracic spine;CT Guided T-spine Nerve block;;ACTIVE;2.40;2.64 +70923-8;Guidance for percutaneous vertebroplasty;Find;Pt;Neck>Spine.cervical;Doc;RF;RAD;2;RF Guidance for percutaneous vertebroplasty of Cervical spine;RF Guided C-spine PC Vertebroplasty;;ACTIVE;2.40;2.64 +70924-6;Guidance for percutaneous vertebroplasty;Find;Pt;Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Guidance for percutaneous vertebroplasty of Lumbar spine;RF Guided L-spine PC Vertebroplasty;;ACTIVE;2.40;2.64 +70925-3;Guidance for percutaneous vertebroplasty;Find;Pt;Chest>Spine.thoracic;Doc;RF;RAD;2;RF Guidance for percutaneous vertebroplasty of Thoracic spine;RF Guided T-spine PC Vertebroplasty;;ACTIVE;2.40;2.64 +70926-1;Multisection;Find;Pt;Neck>Spine.cervical;Doc;US;RAD;2;US Cervical spine;US C-spine;;ACTIVE;2.40;2.73 +70927-9;Multisection;Find;Pt;Chest>Spine.thoracic;Doc;US;RAD;2;US Thoracic spine;US T-spine;;ACTIVE;2.40;2.73 +70928-7;Multisection stereotactic;Find;Pt;Spine.lumbar;Doc;CT;RAD;2;Deprecated Spine Lumbar CT stereotactic;Deprecated L-spine CT Stereo;;DEPRECATED;2.40;2.58 +70929-5;Multisection stereotactic;Find;Pt;Spine.cervical;Doc;CT;RAD;2;Deprecated Spine Cervical CT stereotactic;Deprecated C-spine CT Stereo;;DEPRECATED;2.40;2.58 +70930-3;Multisection stereotactic;Find;Pt;Spine.thoracic;Doc;CT;RAD;2;Deprecated Spine Thoracic CT stereotactic;Deprecated T-spine CT Stereo;;DEPRECATED;2.40;2.58 +70931-1;Multisection^W contrast intradisc;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine W contrast intradisc;CT T-spine W contr ID;;ACTIVE;2.40;2.61 +70932-9;View;Find;Pt;Chest>Spine.thoracic;Doc;XR.portable;RAD;2;Portable XR Thoracic spine Single view;XR port T-spine 1V;;ACTIVE;2.40;2.64 +70933-7;Views^W contrast intradisc;Find;Pt;Chest>Spine.thoracic;Doc;RF;RAD;2;RF Thoracic spine Views W contrast intradisc;RF T-spine Views W contr ID;;ACTIVE;2.40;2.64 +70934-5;Ocular history;Find;Pt;^Patient;Nar;;DOC.MISC;2;Ocular history Narrative;Ocular history;;ACTIVE;2.40;2.73 +70935-2;Ophthalmic medications;Find;Pt;^Patient;Nar;;DOC.MISC;2;Ophthalmic medications Narrative;Ophthalmic medications;;ACTIVE;2.40;2.73 +70936-0;Vision testing;Find;Pt;^Patient;Nar;;DOC.MISC;2;Vision testing Narrative;Vision testing;;ACTIVE;2.40;2.73 +70937-8;Visual acuity;Find;Pt;^Patient;Nar;;DOC.MISC;2;Deprecated Visual acuity Narrative;Deprecated Visual acuity;;DEPRECATED;2.40;2.73 +7093-8;Maranta arundinacea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Arrowroot IgE Ab [Units/volume] in Serum;Arrowroot IgE Qn;;ACTIVE;1.0h(2);2.42 +70938-6;Refractive measurements;Find;Pt;^Patient;Nar;;DOC.MISC;2;Refractive measurements Narrative;Refractive measurements;;ACTIVE;2.40;2.73 +70939-4;Lensometry measurements;Find;Pt;^Patient;Nar;;DOC.MISC;2;Lensometry measurements Narrative;Lensometry measurements;;ACTIVE;2.40;2.73 +70940-2;Confrontation visual field;Find;Pt;^Patient;Nar;;DOC.MISC;2;Confrontation visual field Narrative;Confrontation visual field;;ACTIVE;2.40;2.73 +70941-0;Eye external;Find;Pt;^Patient;Nar;;DOC.MISC;2;Eye external Narrative;Eye external;;ACTIVE;2.40;2.73 +70942-8;Ocular alignment and motility;Find;Pt;^Patient;Nar;;DOC.MISC;2;Ocular alignment and motility Narrative;Ocular alignment and motility;;ACTIVE;2.40;2.73 +70943-6;Eye anterior segment;Find;Pt;^Patient;Nar;;DOC.MISC;2;Eye anterior segment Narrative;Eye anterior segment;;ACTIVE;2.40;2.73 +70944-4;Eye posterior segment;Find;Pt;^Patient;Nar;;DOC.MISC;2;Eye posterior segment Narrative;Eye posterior segment;;ACTIVE;2.40;2.73 +70945-1;Lacrimal;Find;Pt;^Patient;Nar;;DOC.MISC;2;Lacrimal Narrative;Lacrimal;;ACTIVE;2.40;2.73 +7094-6;Cynara scolymus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Artichoke IgE Ab [Units/volume] in Serum;Artichoke IgE Qn;;ACTIVE;1.0h(2);2.73 +70946-9;Ancillary eye tests;Find;Pt;^Patient;Nar;;DOC.MISC;2;Ancillary eye tests Narrative;Ancillary eye tests;;ACTIVE;2.40;2.73 +70947-7;General eye evaluation;-;Pt;^Patient;-;;PANEL.DOC;2;General eye evaluation;General eye evaluation;;ACTIVE;2.40;2.4 +70948-5;Ocular physical exam;Find;Pt;^Patient;Nar;;DOC.MISC;2;Ocular physical exam Narrative;Ocular physical exam;;ACTIVE;2.40;2.73 +70949-3;Pathology report.section heading;-;Pt;XXX;Nom;;DOC.MISC;2;Pathology report.section heading;Pathology report.section heading;;ACTIVE;2.40;2.73 +70950-1;Residual renal function testing performed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Residual renal function testing performed [ESRD];;;TRIAL;2.40;2.67 +70951-9;Interdialytic time;TmStp;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Interdialytic time [ESRD];;;TRIAL;2.40;2.67 +70952-7;Date of peritoneal dialysis adequacy measurement;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date of peritoneal dialysis adequacy measurement [ESRD];;;TRIAL;2.40;2.67 +7095-3;Fraxinus velutina Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Arizona Ash IgE Ab [Units/volume] in Serum;Arizona Ash IgE Qn;;ACTIVE;1.0h(2);2.73 +70953-5;Body surface area measurement method;Type;Pt;^Patient;Nom;;SURVEY.ESRD;4;Body surface area measurement method;;;TRIAL;2.40;2.42 +70954-3;Standard process followed for residual renal function assessed in calculating Kt/V;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Standard process followed for residual renal function assessed in calculating Kt/V [ESRD];;;TRIAL;2.40;2.67 +70955-0;Prescription changed following the peritoneal dialysis adequacy measurement;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Prescription changed following the peritoneal dialysis adequacy measurement [ESRD];;;TRIAL;2.40;2.67 +70956-8;Minutes of hemodialysis completed when BUN drawn;Time;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Minutes of hemodialysis completed when BUN drawn [ESRD];;;TRIAL;2.40;2.67 +70957-6;Creatinine clearance corrected for body surface area using standard methods;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Creatinine clearance corrected for body surface area using standard methods [ESRD];;;TRIAL;2.40;2.67 +70958-4;Dialysis method;Type;Pt;XXX;Nom;ESRD;SURVEY.ESRD;4;Dialysis method [ESRD];;;TRIAL;2.40;2.67 +70959-2;Protein catabolic rate^^adjusted for body weight;MRat;XXX;Ser/Plas;Qn;Calculated;SURVEY.ESRD;4;Protein catabolic rate adjusted for body weight based on Serum or Plasma [Calculated];;;ACTIVE;2.40;2.68 +709-6;Blasts/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Blasts/100 leukocytes in Blood by Manual count;Blasts/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +70960-0;Kt/V.Peritoneal Dialysis;Ratio;Pt;^Patient;Qn;;SURVEY.ESRD;4;Kt/V.Peritoneal Dialysis;;;TRIAL;2.40;2.7 +70961-8;Kt/V.Hemodialysis;Ratio;Pt;^Patient;Qn;;SURVEY.ESRD;4;Kt/V.Hemodialysis;;;TRIAL;2.40;2.48 +70962-6;Body weight^at peritoneal dialysis adequacy measurement;Mass;Pt;^Patient;Qn;Measured;SURVEY.ESRD;4;Body weight Measured --at peritoneal dialysis adequacy measurement;;;TRIAL;2.40;2.69 +70963-4;Kt/V.Peritoneal Dialysis;Ratio;Pt;^Patient;Qn;Hume;SURVEY.ESRD;4;Kt/V.Peritoneal Dialysis [Hume];;;TRIAL;2.40;2.67 +70964-2;Kt/V.Peritoneal Dialysis;Ratio;Pt;^Patient;Qn;Watson;SURVEY.ESRD;4;Kt/V.Peritoneal Dialysis [Watson];;;TRIAL;2.40;2.67 +70965-9;Kt/V.Hemodialysis;Ratio;Pt;^Patient;Qn;Daugirdas II;SURVEY.ESRD;4;Kt/V.Hemodialysis [Daugirdas II];;;TRIAL;2.40;2.67 +70966-7;Kt/V.Hemodialysis;Ratio;Pt;^Patient;Qn;UKM;SURVEY.ESRD;4;Kt/V.Hemodialysis [UKM];;;TRIAL;2.40;2.67 +70967-5;Motor arm;Find;Pt;Arm.right;Ord;NIHSS;SURVEY.NEURO;4;Motor arm Right arm [NIH Stroke Scale];;;ACTIVE;2.40;2.67 +70968-3;Motor leg;Find;Pt;Leg.right;Ord;NIHSS;SURVEY.NEURO;4;Motor leg Leg - right [NIH Stroke Scale];;;ACTIVE;2.40;2.67 +70969-1;Glomerular filtration rate/1.73 sq M.predicted.male;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (MDRD);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among males [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD);GFR/BSA pred.male SerPlBld MDRD-ArVRat;;ACTIVE;2.40;2.73 +70970-9;Cryoglobulin;PrThr;Pt;Ser;Ord;Hypotonic dilution;SERO;1;Cryoglobulin [Presence] in Serum by Hypotonic dilution;Cryoglob Ser Ql Hypotonic dilution;;ACTIVE;2.40;2.56 +70971-7;How short of breath did you get dressing yourself without help in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get dressing yourself without help in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70972-5;How short of breath did you get walking 50 steps-paces on flat ground at a normal speed without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking 50 steps-paces on flat ground at a normal speed without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70973-3;How short of breath did you get walking up 20 stairs - 2 flights - without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking up 20 stairs - 2 flights - without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70974-1;How short of breath did you get preparing meals in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get preparing meals in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70975-8;How short of breath did you get washing dishes in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get washing dishes in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70976-6;How short of breath did you get sweeping or mopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get sweeping or mopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70977-4;How short of breath did you get making a bed in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get making a bed in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70978-2;How short of breath did you get lifting something weighing 10-20 lbs, about 4.5-9kg , like a large bag of groceries, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get lifting something weighing 10-20 lbs, about 4.5-9kg , like a large bag of groceries, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7097-9;Ash Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Ash Ab.IgG;Deprecated Ash IgG Qn;;DEPRECATED;1.0h(2);2.69 +70979-0;How short of breath did you get carrying something weighing 10-20 lbs, about 4.5-9kg, like a large bag of groceries, from one room to another in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get carrying something weighing 10-20 lbs, about 4.5-9kg, like a large bag of groceries, from one room to another in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70980-8;How short of breath did you get walking faster than your usual speed for half a mile, almost 1 km, without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking faster than your usual speed for half a mile, almost 1 km, without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70981-6;Why you did not do this in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Why you did not do this in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70982-4;Functional assessment of chronic illness therapy - dyspnea questionnaire - 10 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Dyspnea Questionnaire - 10 items (FACIT-Dyspnea - 10);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70983-2;Functional assessment of chronic illness therapy - dyspnea questionnaire - 33 items;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Dyspnea Questionnaire - 33 items (FACIT-Dyspnea - 33);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +70984-0;How short of breath did you get taking a bath without help in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get taking a bath without help in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70985-7;How short of breath did you get taking a shower in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get taking a shower in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70986-5;How short of breath did you get putting on socks or stockings in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get putting on socks or stockings in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7098-7;Fraxinus americana basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;White Ash triggered histamine release [Units/volume] in Blood;White Ash BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +70987-3;How short of breath did you get standing for at least 5M in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get standing for at least 5 minutes in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70988-1;How short of breath did you get walking 10 steps - paces on flat ground at a normal speed without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking 10 steps - paces on flat ground at a normal speed without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70989-9;How short of breath did you get walking half a mile, almost 1 km, on flat ground at a normal speed, without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking half a mile, almost 1 km, on flat ground at a normal speed, without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70990-7;How short of breath did you get walking up 5 stairs without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking up 5 stairs without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70991-5;How short of breath did you get walking up 10 stairs, 1 flight, without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking up 10 stairs, 1 flight, without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70992-3;How short of breath did you get walking up 30 stairs, 3 flights, without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking up 30 stairs, 3 flights, without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70993-1;How short of breath did you get lifting something weighing less than 5 lbs, about 2 kg, like a houseplant, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get lifting something weighing less than 5 lbs, about 2 kg, like a houseplant, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70994-9;How short of breath did you get lifting something weighing 5-10 lbs, about 2-4.5 kg, like a basket of clothes in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get lifting something weighing 5-10 lbs, about 2-4.5 kg, like a basket of clothes in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7099-5;Asparagus officinalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Asparagus IgE Ab [Units/volume] in Serum;Asparagus IgE Qn;;ACTIVE;1.0h(2);2.73 +70995-6;How short of breath did you get lifting something weighing more than 20 lbs, about 9 kg, like a medium-sized suitcase in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get lifting something weighing more than 20 lbs, about 9 kg, like a medium-sized suitcase in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70996-4;How short of breath did you get carrying something weighing less than 5 lbs, about 2 kg, like a houseplant, from one room to another in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get carrying something weighing less than 5 lbs, about 2 kg, like a houseplant, from one room to another in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70997-2;How short of breath did you get carrying something weighing 5-10 lbs, about 2-4.5 kg, like a basket of clothes, from one room to another in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get carrying something weighing 5-10 lbs, about 2-4.5 kg, like a basket of clothes, from one room to another in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70998-0;How short of breath did you get getting in or out of a car in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get getting in or out of a car in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +70999-8;How short of breath did you get dining out in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get dining out in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71000-4;How short of breath did you get low-intensity leisure activity - gardening, etc, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get low-intensity leisure activity - gardening, etc, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7100-1;Asparagus officinalis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Asparagus IgG Ab [Units/volume] in Serum;Asparagus IgG Qn;;ACTIVE;1.0h(2);2.73 +71001-2;How short of breath did you get moderate-intensity leisure activity - bicycling on level terrain, etc, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get moderate-intensity leisure activity - bicycling on level terrain, etc, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71002-0;How short of breath did you get walking, faster than your usual speed, for 50 steps without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking, faster than your usual speed, for 50 steps without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71003-8;How short of breath did you get walking, faster than your usual speed, for at least 1 mile, a little more than 1.5 km, without stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get walking, faster than your usual speed, for at least 1 mile, a little more than 1.5 km, without stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71004-6;How short of breath did you get singing or humming in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get singing or humming in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71005-3;How short of breath did you get talking while walking in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get talking while walking in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71006-1;How short of breath did you get scrubbing the floor or counter in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How short of breath did you get scrubbing the floor or counter in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71007-9;Functional assessment of chronic illness therapy - palliative care questionnaire;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Palliative Care Questionnaire (FACIT-Pal);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71008-7;Additional concerns - FACIT-Pal;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACIT-Pal [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71009-5;I maintain contact with my friends in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I maintain contact with my friends in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71010-3;I have family members who will take on my responsibilities in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have family members who will take on my responsibilities in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71011-1;I feel that my family appreciates me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel that my family appreciates me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71012-9;I feel like a burden to my family in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel like a burden to my family in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71013-7;I am constipated in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am constipated in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71014-5;I have swelling in parts of my body in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have swelling in parts of my body in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71015-2;My mouth and throat are dry in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My mouth and throat are dry in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71016-0;I feel useful in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel useful in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71017-8;I make each day count in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I make each day count in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71018-6;I have peace of mind in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have peace of mind in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7101-9;Populus tremula Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspen IgE Ab [Units/volume] in Serum;Aspen IgE Qn;;ACTIVE;1.0h(2);2.73 +71019-4;I feel hopeful in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel hopeful in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71020-2;I am able to make decisions in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to make decisions in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71021-0;I have been able to reconcile, make peace, with other people in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been able to reconcile, make peace, with other people in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71022-8;I am able to openly discuss my concerns with the people closest to me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to openly discuss my concerns with the people closest to me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71023-6;Functional assessment of chronic illness therapy - spiritual well being questionnaire - 12 items - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Spiritual well-being Questionnaire - 12 items - version 4 (FACIT-Sp-12);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71024-4;I feel peaceful in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel peaceful in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71025-1;I have a reason for living in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have a reason for living in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71026-9;My life has been productive in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My life has been productive in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7102-7;Populus tremula Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspen IgG Ab [Units/volume] in Serum;Aspen IgG Qn;;ACTIVE;1.0h(2);2.69 +71027-7;I have trouble feeling peace of mind in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble feeling peace of mind in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71028-5;I feel a sense of purpose in my life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel a sense of purpose in my life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71029-3;I am able to reach down deep into myself for comfort in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to reach down deep into myself for comfort in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71030-1;I feel a sense of harmony within myself in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel a sense of harmony within myself in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71031-9;My life lacks meaning and purpose in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My life lacks meaning and purpose in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71032-7;I find strength in my faith or spiritual beliefs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I find strength in my faith or spiritual beliefs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71033-5;My illness has strengthened my faith or spiritual beliefs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My illness has strengthened my faith or spiritual beliefs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71034-3;I know that whatever happens with my illness things will be okay in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I know that whatever happens with my illness things will be okay in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7103-5;Aspergillus fumigatus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus fumigatus IgG Ab [Units/volume] in Serum;A fumigatus IgG Qn;;ACTIVE;1.0h(2);2.73 +71035-0;Functional assessment of chronic illness therapy - spiritual well being, expanded version questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Spiritual well-being, expanded version questionnaire - version 4 (FACIT-Sp-Ex);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71036-8;I feel connected to a higher power, or God, in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel connected to a higher power, or God, in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71037-6;I feel connected to other people in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel connected to other people in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71038-4;I feel loved in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel loved in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71039-2;I feel love for others in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel love for others in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +710-4;Blood smear finding positive;Prid;Pt;Bld;Nom;Microscopy.light;HEM/BC;1;Blood smear finding positive [Identifier] in Blood by Light microscopy;Bld smear finding positive Interp;;ACTIVE;1.0;2.73 +71040-0;I am able to forgive others for any harm they have ever caused me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to forgive others for any harm they have ever caused me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71041-8;I feel forgiven for any harm I may have ever caused in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel forgiven for any harm I may have ever caused in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71042-6;Throughout the course of my day, I feel a sense of thankfulness for my life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Throughout the course of my day, I feel a sense of thankfulness for my life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7104-3;Aspergillus fumigatus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Aspergillus fumigatus triggered histamine release [Units/volume] in Blood;A fumigatus BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71043-4;Throughout the course of my day, I feel a sense of thankfulness for what others bring to my life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Throughout the course of my day, I feel a sense of thankfulness for what others bring to my life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71044-2;I feel a sense of appreciation for the beauty of nature in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel a sense of appreciation for the beauty of nature in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71045-9;I feel compassion for others in the difficulties they are facing in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel compassion for others in the difficulties they are facing in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71046-7;Functional assessment of chronic illness therapy - spiritual well being - non-illness questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Spiritual well-being - non-illness questionnaire - version 4 (FACIT-Sp - non-illness);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71047-5;Functional assessment of chronic illness therapy - satisfaction with pharmacist scale - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Satisfaction with Pharmacist Scale - version 4 (FACIT - SWiP);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71048-3;My pharmacist advises me on the proper use of my medicines in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My pharmacist advises me on the proper use of my medicines in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71049-1;My pharmacist advises me on the adverse - side - effects of my medicines in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My pharmacist advises me on the adverse - side - effects of my medicines in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7105-0;Aspergillus nidulans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus nidulans IgE Ab [Units/volume] in Serum;A nidulans IgE Qn;;ACTIVE;1.0h(2);2.73 +71050-9;I have confidence in my pharmacist-s in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have confidence in my pharmacist-s in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71051-7;My pharmacist is available to answer my questions in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My pharmacist is available to answer my questions in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71052-5;My pharmacist helps with the arrangements necessary to obtain my medicines in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My pharmacist helps with the arrangements necessary to obtain my medicines in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71053-3;My pharmacist is aware of my treatment-related needs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My pharmacist is aware of my treatment-related needs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71054-1;My pharmacist responds to my treatment-related needs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My pharmacist responds to my treatment-related needs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71055-8;Functional assessment of chronic illness therapy - treatment satisfaction - general questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy - Treatment satisfaction - General Questionnaire - version 1 (FACIT-TS-G);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71056-6;Compared to what you expected, how do you rate the effectiveness of the treatment so far;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Compared to what you expected, how do you rate the effectiveness of the treatment so far [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71057-4;Compared to what you expected, how do you rate the side effects of treatment so far;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Compared to what you expected, how do you rate the side effects of treatment so far [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71058-2;Did your doctor-s help you evaluate the effects of your treatment so far;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s help you evaluate the effects of your treatment so far [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71059-0;Do you feel you received the treatment that was right for you;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Do you feel you received the treatment that was right for you [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71060-8;Are you satisfied with the effects of this treatment so far;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Are you satisfied with the effects of this treatment so far [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71061-6;Would you recommend this treatment to others with your illness;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Would you recommend this treatment to others with your illness [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71062-4;Would you choose this treatment again;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Would you choose this treatment again;;;ACTIVE;2.40;2.72 +71063-2;How do you rate this treatment overall;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How do you rate this treatment overall [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71064-0;Name of treatment;Find;Pt;^Patient;Nom;FACIT;SURVEY.GNHLTH;4;Name of treatment [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71065-7;Functional assessment of chronic illness therapy - treatment satisfaction - patient satisfaction questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness therapy - Treatment satisfaction - patient satisfaction questionnaire - version 1 (FACIT-TS-PS);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71066-5;Visits you would like to rate;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Visits you would like to rate [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71067-3;Explanations;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Explanations [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7106-8;Aspergillus sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus sp IgE Ab [Units/volume] in Serum;Aspergillus IgE Qn;;ACTIVE;1.0h(2);2.73 +71068-1;Did your doctor-s give explanations that you could understand;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s give explanations that you could understand [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71069-9;Did your doctor-s explain the possible benefits of your treatment;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s explain the possible benefits of your treatment [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71070-7;Did your doctor-s explain the possible side effects or risks of your treatment;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s explain the possible side effects or risks of your treatment [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71071-5;Did you have an opportunity to ask questions;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you have an opportunity to ask questions [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71072-3;Interpersonal;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Interpersonal [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71073-1;Did you get to say the things that were important to you;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you get to say the things that were important to you [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71074-9;Did your doctor-s seem to understand what was important to you;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s seem to understand what was important to you [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71075-6;Did your doctor-s show genuine concern for you;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s show genuine concern for you [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7107-6;Aspergillus sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus sp IgG Ab [Units/volume] in Serum;Aspergillus IgG Qn;;ACTIVE;1.0h(2);2.73 +71076-4;Comprehensive care;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Comprehensive care [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71077-2;Did your doctor-s seem to understand your needs;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s seem to understand your needs [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71078-0;Did you feel that the treatment staff worked together towards the same goal;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you feel that the treatment staff worked together towards the same goal [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71079-8;Were you able to talk to your doctor-s when you needed to;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Were you able to talk to your doctor-s when you needed to [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71080-6;Did the treatment staff discuss how your health and treatment may affect your normal work - including housework;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did the treatment staff discuss how your health and treatment may affect your normal work - including housework [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71081-4;Did the treatment staff discuss how your health and treatment may affect your normal daily activities;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did the treatment staff discuss how your health and treatment may affect your normal daily activities [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71082-2;Did the treatment staff discuss how your health and treatment may affect your personal relationships;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did the treatment staff discuss how your health and treatment may affect your personal relationships [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71083-0;Did the treatment staff discuss how your health and treatment may affect you emotionally;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did the treatment staff discuss how your health and treatment may affect you emotionally [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7108-4;Acetylsalicylate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Acetylsalicylate IgE Ab [Units/volume] in Serum;Acetylsalicylate IgE Qn;;ACTIVE;1.0h(2);2.73 +71084-8;Technical quality;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Technical quality [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71085-5;Did you feel your doctors had experience treating your illness;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you feel your doctors had experience treating your illness [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71086-3;Did you feel your doctor-s knew about the latest medical developments for your illness;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you feel your doctor-s knew about the latest medical developments for your illness [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71087-1;Was the treatment staff thorough in examining and treating you;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Was the treatment staff thorough in examining and treating you [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71088-9;Decision-making;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Decision-making [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71089-7;Did your doctor-s discuss other treatments, example, alternative medicine or new for treatments;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s discuss other treatments, example, alternative medicine or new for treatments [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71090-5;Were you encouraged to participate in decisions about your health care;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Were you encouraged to participate in decisions about your health care [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71091-3;Did you have enough time to make decisions about your health care;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you have enough time to make decisions about your health care [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7109-2;Persea americana Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Avocado IgG Ab [Units/volume] in Serum;Avocado IgG Qn;;ACTIVE;1.0h(2);2.73 +71092-1;Did you have enough information to make decisions about your health care;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you have enough information to make decisions about your health care [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71093-9;Did your doctor-s seem to respect your opinions;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your doctor-s seem to respect your opinions [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71094-7;Nurses;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Nurses [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71095-4;Did your nurses give explanations that you could understand;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your nurses give explanations that you could understand [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71096-2;Did your nurses show genuine concern for you;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your nurses show genuine concern for you [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71097-0;Did your nurse-s seem to understand your needs;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did your nurse-s seem to understand your needs [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71098-8;Trust;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Trust [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71099-6;Did you feel that the treatment staff answered your questions honestly;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you feel that the treatment staff answered your questions honestly [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71-1;Cefatrizine;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefatrizine [Susceptibility] by Minimum lethal concentration (MLC);Cefatrizine Islt MLC;;ACTIVE;1.0;2.19 +7110-0;Baccharis spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Groundsel Tree IgE Ab [Units/volume] in Serum;Groundsel Tree IgE Qn;;ACTIVE;1.0h(2);2.73 +71100-2;Did the treatment staff respect your privacy;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did the treatment staff respect your privacy [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71101-0;Did you have confidence in your doctor-s;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you have confidence in your doctor-s [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71102-8;Did you trust your doctor-s suggestions for treatment;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Did you trust your doctor-s suggestions for treatment [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71103-6;Overall;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Overall [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71104-4;Would you recommend this clinic or office to others;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Would you recommend this clinic or office to others [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71105-1;Would you choose this clinic or office again;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Would you choose this clinic or office again [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71106-9;How do you rate the care you received;Find;Pt;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;How do you rate the care you received [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71107-7;Functional assessment of multiple sclerosis questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of multiple sclerosis questionnaire - version 4 (FAMS) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71108-5;Mobility;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Mobility [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71109-3;I have trouble getting around in public places in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble getting around in public places in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71110-1;I have to take my condition into account when making plans in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to take my condition into account when making plans in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71111-9;I am bothered by muscle pains in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by muscle pains in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71112-7;Emotional well being - FAMS;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well-being - FAMS [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71113-5;I feel trapped by my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel trapped by my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71114-3;I am depressed about my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am depressed about my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71115-0;I feel useless in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel useless in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71116-8;General contentment;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;General contentment [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71117-6;I am frustrated by my condition in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am frustrated by my condition in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7111-8;Paspalum notatum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Bahia grass triggered histamine release [Units/volume] in Blood;Bahia grass BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71118-4;Thinking and fatigue;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Thinking and fatigue [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71119-2;My family has trouble understanding when my condition gets worse in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My family has trouble understanding when my condition gets worse in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +711-2;Eosinophils;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Eosinophils [#/volume] in Blood by Automated count;Eosinophil # Bld Auto;;ACTIVE;1.0;2.73 +71120-0;I feel left out of things in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel left out of things in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71121-8;Additional concerns - FAMS;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FAMS [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71122-6;Heat worsens my symptoms in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Heat worsens my symptoms in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71123-4;I am bothered by muscle spasms in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by muscle spasms in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71124-2;Difficult times have strengthened my faith or spiritual beliefs in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Difficult times have strengthened my faith or spiritual beliefs in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71125-9;Even during difficult times, I know that things will be okay in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Even during difficult times, I know that things will be okay in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7112-6;Musa spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Banana IgG Ab [Units/volume] in Serum;Banana IgG Qn;;ACTIVE;1.0h(2);2.73 +71126-7;Physical well being - FAHI;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Physical well-being - FAHI [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71127-5;Emotional well being - living with HIV;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well-being - living with HIV [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71128-3;Functional and global well being;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional and global well-being [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71129-1;Social well being;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social well-being [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71130-9;Cognitive functioning;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Cognitive functioning [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71131-7;Additional concerns - FACIT-Sp;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACIT-Sp [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71132-5;Additional concerns - FACIT-Sp-NI;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACIT-Sp-NI [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71133-3;Functional assessment of HIV infection questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of HIV Infection Questionnaire - version 4 (FAHI) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7113-4;Musa spp basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Banana triggered histamine release [Units/volume] in Blood;Banana BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71134-1;I am unhappy with my appearance in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am unhappy with my appearance in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71135-8;It is hard to tell other people about my infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;It is hard to tell other people about my infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71136-6;I worry about spreading my infection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about spreading my infection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71137-4;I am concerned about what the future holds for me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am concerned about what the future holds for me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71138-2;I am embarrassed by my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am embarrassed by my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71139-0;My thinking is slower than before in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My thinking is slower than before in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71140-8;I have trouble learning new tasks or directions in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble learning new tasks or directions in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71141-6;Social - family well being - FAMS;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social - family well-being - FAMS [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7114-2;Hordeum vulgare Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Barley IgG Ab [Units/volume] in Serum;Barley IgG Qn;;ACTIVE;1.0h(2);2.73 +71142-4;Pediatric - functional assessment of anorexia cachexia - adolescent questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Functional Assessment of Anorexia Cachexia - Adolescent Questionnaire - version 1 (Peds-FAACT - adoles) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.73 +71143-2;Pediatric - functional assessment of anorexia cachexia - child questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Functional Assessment of Anorexia Cachexia - Child Questionnaire - version 1 (Peds-FAACT - child) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71144-0;Pediatric - functional assessment of anorexia cachexia - parent_adolescent questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Functional Assessment of Anorexia Cachexia - Parent_adolescent Questionniare - version 1 (Peds-FAACT - adoles) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71145-7;Pediatric - functional assessment of anorexia cachexia - parent_child questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Functional Assessment of Anorexia Cachexia - Parent_child Questionnaire - version 1 (Peds-FAACT - parent_child) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71146-5;Pediatric - functional assessment of anorexia cachexia questionnaire - 10 items - version 2;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Functional Assessment of Anorexia Cachexia Questionnaire - 10 items - version 2 (Peds-FAACT- 10 - v2) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71147-3;Pediatric - patients with brain cancer - adolescent questionnaire - version 2;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - patients with brain cancer - Adolescent Questionnaire - version 2 (Peds-FACT-Br - adoles) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71148-1;Pediatric - patients with brain cancer - child questionnaire - version 2;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - patients with brain cancer - Child Questionnaire - version 2 (Peds-FACT-Br - child) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71149-9;Pediatric - patients with brain cancer - parent_adolescent questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Patients with brain cancer - Parent_adolescent Questionnaire - version 1 (Peds-FACT-Br - parent_adoles) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71150-7;Pediatric - patients with brain cancer - parent_child questionnaire - version 1;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Patients with brain cancer - Parent_child Questionnaire - version 1 (Peds-FACT-Br - parent_child) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71151-5;Pediatric - functional assessment of chronic illness therapy - fatigue questionnaire;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Pediatric - Functional Assessment of Chronic Illness Therapy - Fatigue Questionnaire (Peds-FACIT-Fatigue);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71152-3;I eat as much as I want in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I eat as much as I want in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71153-1;I eat enough food for me to do whatever I need to do in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I eat enough food for me to do whatever I need to do in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71154-9;Most food tastes bad to me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Most food tastes bad to me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71155-6;As soon as I start eating, I feel like stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;As soon as I start eating, I feel like stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71156-4;I am afraid to eat because it may make me sick in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am afraid to eat because it may make me sick in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71157-2;My family or friends try to get me to eat more in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My family or friends try to get me to eat more in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71158-0;I have been throwing up in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have been throwing up in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7115-9;Hordeum vulgare basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Barley triggered histamine release [Units/volume] in Blood;Barley BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71159-8;I have pain in my stomach in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have pain in my stomach in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71160-6;I feel like I am getting better in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel like I am getting better in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71161-4;I have energy or strength in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have energy or strength in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71162-2;I could do my usual things at home in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I could do my usual things at home in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71163-0;I lose balance or fall down easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I lose balance or fall down easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71164-8;I have trouble getting myself dressed in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble getting myself dressed in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71165-5;I have trouble running like other people in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble running like other people in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71166-3;My arms or legs feel weak in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My arms or legs feel weak in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7116-7;Hordeum vulgare pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Barley Pollen IgE Ab [Units/volume] in Serum;Barley Poln IgE Qn;;ACTIVE;1.0h(2);2.73 +71167-1;I get ill easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get ill easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71168-9;I have trouble writing with a pen or pencil in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble writing with a pen or pencil in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71169-7;I feel happy in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel happy in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71170-5;When I try to do something, I usually believe I will do it well in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When I try to do something, I usually believe I will do it well in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71171-3;The cancer-tumor experience makes me a stronger person in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The cancer-tumor experience makes me a stronger person in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71172-1;The cancer-tumor experience has taught me to appreciate life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The cancer-tumor experience has taught me to appreciate life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71173-9;I often feel that other people are better than me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I often feel that other people are better than me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71174-7;I worry about getting another cancer-tumor in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about getting another cancer-tumor in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7117-5;(Avena sativa+Hordeum vulgare) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oat+Barley IgE Ab [Units/volume] in Serum;Oat+Barley IgE Qn;;ACTIVE;1.0h(2);2.42 +71175-4;I often switch from good moods to bad moods in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I often switch from good moods to bad moods in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71176-2;I worry when I go back to the hospital or clinic in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry when I go back to the hospital or clinic in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71177-0;I get nervous - frightened easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get nervous - frightened easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71178-8;I worry about having a good life in the future in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about having a good life in the future in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71179-6;I worry about being able to have a girlfriend or boyfriend because of my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about being able to have a girlfriend or boyfriend because of my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71180-4;I worry about being able to go to college because of my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about being able to go to college because of my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71181-2;I worry about getting a job because of my illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about getting a job because of my illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71182-0;Other people pick on - tease me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people pick on - tease me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7118-3;Ocimum basilicum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Basil IgE Ab [Units/volume] in Serum;Basil IgE Qn;;ACTIVE;1.0h(2);2.73 +71183-8;I think I have fewer friends than others in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I think I have fewer friends than others in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71184-6;Other people avoid hanging out with me because I am different in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people avoid hanging out with me because I am different in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71185-3;I feel lonely in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel lonely in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71186-1;I would rather do something by myself than with other people in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I would rather do something by myself than with other people in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71187-9;My parents worry too much about me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My parents worry too much about me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71188-7;My parents spoil me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My parents spoil me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71189-5;I am worried about how thin I am in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am worried about how thin I am in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71190-3;What would be important about how you feel about eating, food, and how food affects your life in the past 7D;Find;7D;^Patient;Nar;FACIT;SURVEY.GNHLTH;4;What would be important about how you feel about eating, food, and how food affects your life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7119-1;Ocimum basilicum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Basil IgG Ab [Units/volume] in Serum;Basil IgG Qn;;ACTIVE;1.0h(2);2.69 +71191-1;I often feel that other children are better than me in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I often feel that other children are better than me in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71192-9;I think I have fewer friends than other children in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I think I have fewer friends than other children in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71193-7;Other children avoid playing with me because I am different in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other children avoid playing with me because I am different in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71194-5;I would rather play alone than with other children in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I would rather play alone than with other children in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71195-2;My child loses balance or falls down easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child loses balance or falls down easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71196-0;My child has trouble getting dressed on his-her own in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has trouble getting dressed on his-her own in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71197-8;My child has trouble running like other people in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has trouble running like other people in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71198-6;My child gets tired easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child gets tired easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71199-4;My child's arms or legs seem weak in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child's arms or legs seem weak in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +712-0;Eosinophils;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Eosinophils [#/volume] in Blood by Manual count;Eosinophil # Bld Manual;;ACTIVE;1.0;2.73 +71200-0;My child gets ill easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child gets ill easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71201-8;My child has trouble writing with a pen or pencil in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has trouble writing with a pen or pencil in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71202-6;My child has pain in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has pain in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71203-4;My child seems happy in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child seems happy in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71204-2;When my child tries to do something, s-he usually believes s-he will do it well in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When my child tries to do something, s-he usually believes s-he will do it well in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71205-9;The cancer-tumor experience makes my child a stronger person in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The cancer-tumor experience makes my child a stronger person in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71206-7;The cancer-tumor experience has taught my child to appreciate life in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The cancer-tumor experience has taught my child to appreciate life in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71207-5;My child often feels inferior to other people in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child often feels inferior to other people in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71208-3;My child worries about getting another cancer-tumor in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about getting another cancer-tumor in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7120-9;Micropterus salmoides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bass, Black IgE Ab [Units/volume] in Serum;Bass IgE Qn;;ACTIVE;1.0h(2);2.73 +71209-1;My child is moody or irritable in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is moody or irritable in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71210-9;My child worries when we go back to the hospital or clinic in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries when we go back to the hospital or clinic in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71211-7;My child gets nervous - frightened easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child gets nervous - frightened easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71212-5;My child worries about having a good life in the future in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about having a good life in the future in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71213-3;My child worries about being able to have a girlfriend or boyfriend because of his-her illness in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about being able to have a girlfriend or boyfriend because of his-her illness in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71214-1;My child worries about being able to go to college because of his-her illness in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about being able to go to college because of his-her illness in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71215-8;My child worries about getting a job because of his-her illness in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about getting a job because of his-her illness in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71216-6;Physical well being - FACIT-peds;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Physical well-being - FACIT-peds [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7121-7;Bassiai Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bassiai IgE Ab [Units/volume] in Serum;Bassiai IgE Qn;;ACTIVE;1.0h(2);2.42 +71217-4;Emotional well being and illness experience - FAACT-peds-adoles;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well-being and illness experience FACIT;;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71218-2;Social - family well being - FAACT-peds;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social - family well-being - FAACT-peds [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.73 +71219-0;Other people pick on - tease my child in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people pick on - tease my child in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71220-8;My child has fewer friends than others in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has fewer friends than others in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71221-6;Other people avoid hanging out with my child because s-he is different in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people avoid hanging out with my child because s-he is different in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71222-4;My child seems lonely in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child seems lonely in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71223-2;My child prefers to do something alone in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child prefers to do something alone in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71224-0;My child thinks I worry too much about him-her in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child thinks I worry too much about him-her in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7122-5;Tilia americana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Basswood IgE Ab [Units/volume] in Serum;Basswood IgE Qn;;ACTIVE;1.0h(2);2.42 +71225-7;My child thinks I spoil him-her in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child thinks I spoil him-her in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71226-5;Additional concerns - FAACT-child_adoles;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FAACT-child_adoles [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71228-1;Additional concerns - FACT-Br-peds;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Br-peds [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71229-9;Additional concerns - FACT-Br-parent;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-Br-parent [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71230-7;Birth certificate;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Birth certificate;Birth certificate;;ACTIVE;2.40;2.54 +71231-5;The illness experience has taught my child to appreciate life in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The illness experience has taught my child to appreciate life in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71232-3;The illness experience makes my child a stronger person in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The illness experience makes my child a stronger person in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7123-3;Myrica spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bayberry IgE Ab [Units/volume] in Serum;Bayberry IgE Qn;;ACTIVE;1.0h(2);2.73 +71233-1;I often feel that other children are better than me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I often feel that other children are better than me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71234-9;Physical well being - FAACT-peds - parent;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Physical well being - FAACT-peds - parent [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71235-6;Emotional well being - FAACT-peds - parent_adoles;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well being - FAACT-peds - parent_adoles [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71236-4;My child seems happy in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child seems happy in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71237-2;When my child tries to do something, s-he usually believes s-he will do it well in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When my child tries to do something, s-he usually believes s-he will do it well in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71238-0;My child often feels inferior to other people in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child often feels inferior to other people in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71239-8;My child worries about getting another cancer-tumor in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about getting another cancer-tumor in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71240-6;My child is moody or irritable in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is moody or irritable in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7124-1;Myrica spp pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bayberry Pollen IgE Ab [Units/volume] in Serum;Bayberry Poln IgE Qn;;ACTIVE;1.0h(2);2.73 +71241-4;My child worries when we go back to the hospital or clinic in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries when we go back to the hospital or clinic in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71242-2;My child gets nervous - frightened easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child gets nervous - frightened easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71243-0;My child worries about having a good life in the future in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about having a good life in the future in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71244-8;My child worries about being able to have a girlfriend or boyfriend because of his-her illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about being able to have a girlfriend or boyfriend because of his-her illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71245-5;My child worries about being able to go to college because of his-her illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about being able to go to college because of his-her illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71246-3;My child worries about getting a job because of his-her illness in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child worries about getting a job because of his-her illness in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71247-1;My child has fewer friends than others in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has fewer friends than others in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71248-9;Other people avoid hanging out with my child because s-he is different in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people avoid hanging out with my child because s-he is different in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71249-7;My child seems lonely in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child seems lonely in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71250-5;My child prefers to do something alone in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child prefers to do something alone in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71251-3;Additional concerns - FAACT-parent;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FAACT-parent [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71252-1;My child eats as much as s-he wants in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child eats as much as s-he wants in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71253-9;My child eats enough to do whatever s-he needs to do in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child eats enough to do whatever s-he needs to do in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71254-7;My child is worried about his-her weight in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is worried about his-her weight in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71255-4;Most food tastes bad to my child in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Most food tastes bad to my child in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71256-2;My child is worried about how thin s-he is in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is worried about how thin s-he is in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71257-0;As soon as my child starts eating, s-he feels like stopping in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;As soon as my child starts eating, s-he feels like stopping in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7125-8;Laurus nobilis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bayleaf IgE Ab [Units/volume] in Serum;Bayleaf IgE Qn;;ACTIVE;1.0h(2);2.73 +71258-8;My child is afraid to eat because it may make her-him sick in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is afraid to eat because it may make her-him sick in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71260-4;My child has been throwing up in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has been throwing up in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71261-2;When my child eats, s-he seems to get full quickly in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When my child eats, s-he seems to get full quickly in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71262-0;My child has pain in his-her stomach in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has pain in his-her stomach in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71263-8;My child feels like s-he is getting better in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child feels like s-he is getting better in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71264-6;Social - family well being - FAACT-parent_adoles;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social - family well-being - FAACT-parent_adoles [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71265-3;My child loses balance or falls down easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child loses balance or falls down easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7126-6;Laurus nobilis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bayleaf IgG Ab [Units/volume] in Serum;Bayleaf IgG Qn;;ACTIVE;1.0h(2);2.69 +71266-1;My child has trouble getting dressed on his-her own in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has trouble getting dressed on his-her own in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71267-9;My child has trouble running like other people in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has trouble running like other people in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71268-7;My child gets tired easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child gets tired easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71269-5;My child's arms or legs seem weak in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child's arms or legs seem weak in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71270-3;My child gets ill easily in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child gets ill easily in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71271-1;My child has trouble writing with a pen or pencil in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has trouble writing with a pen or pencil in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71272-9;Other people pick on - tease my child in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people pick on - tease my child in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71273-7;Family or friends try to get my child to eat more in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Family or friends try to get my child to eat more in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7127-4;Bean green Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Green Bean IgG Ab [Units/volume] in Serum;Green Bean IgG Qn;;ACTIVE;1.0h(2);2.73 +71274-5;Emotional well being - FAACT-peds - parent_child;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well being - FAACT-peds - parent_child [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71275-2;Social well being - FAACT-peds - parent_child;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social well being - FAACT-peds - parent_child [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71276-0;Other children avoid playing with my child because s-he is different in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other children avoid playing with my child because s-he is different in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71277-8;My child prefers to play alone in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child prefers to play alone in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71278-6;I lose my balance or fall down easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I lose my balance or fall down easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71279-4;I have trouble getting myself dressed in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble getting myself dressed in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71280-2;I have trouble running like other people in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble running like other people in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71281-0;I get tired easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get tired easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7128-2;Bean green basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Green Bean triggered histamine release [Units/volume] in Blood;Green Bean BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71282-8;My arms or legs are weak in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My arms or legs are weak in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71283-6;I get ill easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get ill easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71284-4;I have trouble writing with a pen or pencil in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have trouble writing with a pen or pencil in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71285-1;I feel happy in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel happy in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71286-9;When I try to do something, I usually believe I will do it well in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When I try to do something, I usually believe I will do it well in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71287-7;The illness experience makes me a stronger person in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The illness experience makes me a stronger person in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71288-5;The illness experience has taught me to appreciate life in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;The illness experience has taught me to appreciate life in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71289-3;I often feel that other people are better than me in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I often feel that other people are better than me in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7129-0;Bean kidney red Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Kidney Bean IgE Ab [Units/volume] in Serum;Red Kidney Bean IgE Qn;;ACTIVE;1.0h(2);2.73 +71290-1;I worry about being sick again in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about being sick again in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71291-9;I often switch from good moods to bad moods in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I often switch from good moods to bad moods in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71292-7;I worry when I go back to the hospital or clinic in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry when I go back to the hospital or clinic in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71293-5;I get nervous - frightened easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I get nervous - frightened easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71294-3;I worry about having a good life in the future in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about having a good life in the future in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71295-0;I worry about being able to date because of my illness history in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about being able to date because of my illness history in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71296-8;I worry about being able to go to college because of my illness history in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about being able to go to college because of my illness history in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71297-6;I worry about getting a job to support myself because of my illness history in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I worry about getting a job to support myself because of my illness history in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71298-4;Other people pick on - tease me in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people pick on - tease me in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71299-2;I think I have fewer friends than others in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I think I have fewer friends than others in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71300-8;Other people avoid hanging out with me because of my illness history in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Other people avoid hanging out with me because of my illness history in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71301-6;I feel lonely in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel lonely in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71302-4;I would rather do something by myself than with other people in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I would rather do something by myself than with other people in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71303-2;I am bothered by being shorter than other people in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by being shorter than other people in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71304-0;I am bothered by being unable to see well in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by being unable to see well in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71305-7;I am bothered by being unable to hear well in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by being unable to hear well in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71306-5;I am bothered by headaches in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am bothered by headaches in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71307-3;When I speak, people have trouble understanding me in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When I speak, people have trouble understanding me in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7130-8;Bean kidney red Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Kidney Bean IgG Ab [Units/volume] in Serum;Red Kidney Bean IgG Qn;;ACTIVE;1.0h(2);2.73 +71308-1;I need to work harder than other people to get my school work done in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I need to work harder than other people to get my school work done in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71309-9;My grades are worse than they were before I was sick in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My grades are worse than they were before I was sick in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71310-7;I forget things easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I forget things easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71311-5;It is hard for me to concentrate in school in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;It is hard for me to concentrate in school in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71312-3;I have to read things several times so I can understand them in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have to read things several times so I can understand them in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71313-1;When I play games or sports, I react more slowly than most people my age in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When I play games or sports, I react more slowly than most people my age in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71314-9;It is hard for me to find the right words to say what I mean in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;It is hard for me to find the right words to say what I mean in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71315-6;Emotional well being and illness experience - FACT-Br -peds-adoles;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well-being and illness experience - FACT-Br -peds-adoles [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +7131-6;Phaseolus limensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lima Bean IgE Ab [Units/volume] in Serum;Lima Bean IgE Qn;;ACTIVE;1.0h(2);2.73 +71316-4;Emotional well being and illness experience - FACT-Br -peds-child;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well-being and illness experience - FACT-Br -peds-child [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71317-2;Social - family well being - FACT-Br-peds;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social - family well-being - FACT-Br-peds [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71318-0;Physical well being - FACT-Br -peds-parent;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Physical well-being - FACT-Br -peds-parent [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71319-8;Emotional well being - FACT-Br -peds-parent_adoles;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well being - FACT-Br -peds-parent_adoles [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71320-6;Emotional well being - FACT-Br -peds-parent_child;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well-being - FACT-Br -peds-parent_child [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71321-4;Social and family well being - FACT-Br -peds-parent_child;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social and family well-being - FACT-Br -peds-parent_child [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71322-2;Social and family well being - FACT-Br -peds-parent_adoles;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social and family well-being - FACT-Br -peds-parent_adoles [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71323-0;My child is bothered by being shorter than his-her peers in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is bothered by being shorter than his-her peers in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7132-4;Phaseolus limensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lima Bean IgG Ab [Units/volume] in Serum;Lima Bean IgG Qn;;ACTIVE;1.0h(2);2.73 +71324-8;My child is bothered by poor vision in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is bothered by poor vision in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71325-5;My child is bothered by poor hearing in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is bothered by poor hearing in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71326-3;My child is bothered by headaches in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child is bothered by headaches in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71327-1;My child's speech is hard for others to understand in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child's speech is hard for others to understand in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71328-9;My child needs to work harder than his-her peers to get school work done in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child needs to work harder than his-her peers to get school work done in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71329-7;My child's school performance is worse than it was before s-he was diagnosed in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child's school performance is worse than it was before s-he was diagnosed in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71330-5;My child forgets things easily in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child forgets things easily in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71331-3;It is hard for my child to concentrate in school in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;It is hard for my child to concentrate in school in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7133-2;Vigna radiata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mung Bean IgE Ab [Units/volume] in Serum;Mung Bean IgE Qn;;ACTIVE;1.0h(2);2.73 +71332-1;My child has to read things several times so s-he can understand them in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has to read things several times so s-he can understand them in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71333-9;When my child plays games or sports, s-he reacts more slowly than his-her peers in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;When my child plays games or sports, s-he reacts more slowly than his-her peers in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71334-7;My child has difficulty using the right words in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child has difficulty using the right words in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71335-4;My child often feels inferior to other children in the past 4W;Find;4W;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;My child often feels inferior to other children in the past 4 weeks [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71336-2;I feel weak in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I feel weak in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71337-0;Being tired made me sad in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Being tired made me sad in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71338-8;Being tired made me mad-angry in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Being tired made me mad-angry in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71339-6;Urea renal clearance/1.73 sq M^hemodialysis;ArVRat;Pt;Urine+Ser/Plas;Qn;ESRD;SURVEY.ESRD;4;Urea renal clearance/1.73 sq M--hemodialysis Urine and Serum or Plasma [ESRD];;;TRIAL;2.40;2.67 +7134-0;Vigna radiata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mung Bean IgG Ab [Units/volume] in Serum;Mung Bean IgG Qn;;ACTIVE;1.0h(2);2.69 +71340-4;Time between hemodialysis sessons;Time;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Deprecated Time between hemodialysis sessons [ESRD];;;DEPRECATED;2.40;2.7 +71341-2;Kt/V.Peritoneal Dialysis;Ratio;Pt;^Patient;Qn;Percent of body weight;SURVEY.ESRD;4;Kt/V.Peritoneal Dialysis [Percent of body weight];;;TRIAL;2.40;2.67 +71342-0;Kt/V.Hemodialysis;Ratio;Pt;^Patient;Qn;Derived;SURVEY.ESRD;4;Kt/V.Hemodialysis [Derived];;;TRIAL;2.40;2.67 +71343-8;Emotional well being and illness experience - FAACT-peds-child;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well-being and illness experience - FAACT-peds-child [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71344-6;I have been able to laugh and see the funny side of things in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have been able to laugh and see the funny side of things in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71345-3;I have looked forward with enjoyment to things in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have looked forward with enjoyment to things in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71346-1;I have blamed myself unnecessarily when things went wrong in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have blamed myself unnecessarily when things went wrong in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71347-9;I have been anxious or worried for no good reason in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have been anxious or worried for no good reason in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71348-7;I have felt scared or panicky for no very good reason in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have felt scared or panicky for no very good reason in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71349-5;Things have been getting on top of me in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;Things have been getting on top of me in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71350-3;I have been so unhappy that I have had difficulty sleeping in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have been so unhappy that I have had difficulty sleeping in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71351-1;I have felt sad or miserable in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have felt sad or miserable in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71352-9;I have been so unhappy that I have been crying in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;I have been so unhappy that I have been crying in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71353-7;The thought of harming myself has occurred to me in the past 7D;Find;7D;^Patient;Ord;EPDS;SURVEY.EPDS;4;The thought of harming myself has occurred to me in the past 7 days [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.67 +71354-5;Edinburgh Postnatal Depression Scale;-;Pt;^Patient;-;EPDS;PANEL.SURVEY.EPDS;4;Edinburgh Postnatal Depression Scale [EPDS];;Copyright © The Royal College of Psychiatrists The Edinburgh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782-786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium).;ACTIVE;2.40;2.72 +71355-2;SLC26A5 gene.c.-53-2A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;SLC26A5 gene c.-53-2A>G [Presence] in Blood or Tissue by Molecular genetics method;SLC26A5 c.-53-2A>G Bld/T Ql;;ACTIVE;2.40;2.56 +71356-0;TPMT gene.c.238G>C+460G>A+719A>G;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.PHARMG;1;TPMT gene c.238G>C+460G>A+719A>G [Identifier] in Blood or Tissue by Molecular genetics method Narrative;TPMT c.238G>C+460G>A+719A>G Bld/T;;ACTIVE;2.40;2.67 +7135-7;Bean pinto Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pinto Bean IgE Ab [Units/volume] in Serum;Pinto Bean IgE Qn;;ACTIVE;1.0h(2);2.73 +71357-8;PDGFRA gene exon 18 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;PDGFRA gene exon 18 targeted mutation analysis in Blood or Tissue by Sequencing;PDGFRA exon 18 Mut Anl Bld/T Seq;;ACTIVE;2.40;2.66 +71358-6;GJB3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GJB3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GJB3 gene Mut Anl Bld/T;;ACTIVE;2.40;2.66 +71359-4;Y chromosome AZFa region deletion;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.DEL;1;Y chromosome AZFa region deletion [Identifier] in Blood or Tissue by Molecular genetics method Narrative;Y chr AZFa region Del Bld/T;;ACTIVE;2.40;2.4 +71360-2;Y chromosome AZFb region deletion;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.DEL;1;Y chromosome AZFb region deletion [Identifier] in Blood or Tissue by Molecular genetics method Narrative;Y chr AZFb region Del Bld/T;;ACTIVE;2.40;2.4 +71361-0;Y chromosome AZFc region deletion;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.DEL;1;Y chromosome AZFc region deletion [Identifier] in Blood or Tissue by Molecular genetics method Narrative;Y chr AZFc region Del Bld/T;;ACTIVE;2.40;2.4 +71363-6;Alkaline phosphatase.placental 2/Alkaline phosphatase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.placental 2/Alkaline phosphatase.total in Serum or Plasma;ALP Plac 2 CFr SerPl;;ACTIVE;2.40;2.7 +7136-5;Bean pinto Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pinto Bean IgG Ab [Units/volume] in Serum;Pinto Bean IgG Qn;;ACTIVE;1.0h(2);2.73 +71365-1;Alkaline phosphatase.intestinal 2;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.intestinal 2 [Enzymatic activity/volume] in Serum or Plasma;ALP Intest 2 SerPl-cCnc;;ACTIVE;2.40;2.7 +71366-9;Alkaline phosphatase.intestinal 3;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.intestinal 3 [Enzymatic activity/volume] in Serum or Plasma;ALP Intest 3 SerPl-cCnc;;ACTIVE;2.40;2.7 +71367-7;Alkaline phosphatase.placental 2;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.placental 2 [Enzymatic activity/volume] in Serum or Plasma;ALP Plac 2 SerPl-cCnc;;ACTIVE;2.40;2.7 +71368-5;Desmosome Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Desmosome IgG Ab [Titer] in Serum by Immunofluorescence;Desmosome IgG Titr Ser IF;;ACTIVE;2.40;2.7 +71369-3;Neutrophils.dysplastic;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Neutrophils.dysplastic [Presence] in Blood by Light microscopy;Neutrophils.dysplastic Bld Ql Smear;;ACTIVE;2.40;2.73 +71370-1;(Guinea pig epithelium+Hamster epithelium+Mouse+Rabbit epithelium+Rat) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 70 (Guinea pig epithelium+Hamster epithelium+Mouse+Rabbit epithelium+Rat) IgE Ab [Units/volume] in Serum by Multidisk;Epidermal Mix 70 IgE Qn;;ACTIVE;2.40;2.7 +71371-9;(Alnus incana+Betula verrucosa+Corylus avellana+Quercus alba+Salix caprea) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 9 (Grey alder+Silver birch+Hazelnut+White oak+Willow) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix 9 IgE Qn;;ACTIVE;2.40;2.7 +7137-3;Glycine max basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Soybean triggered histamine release [Units/volume] in Blood;Soybean BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71373-5;(Artemisia vulgaris+Betula verrucosa+Cat dander+Cladosporium herbarum+Dermatophagoides pteronyssinus+Dog dander+Phleum pratense+Secale cereale) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Inhalant Allergen Mix 8 (Mugwort+Common silver birch+Cat dander+C herbarum+Dermatophagoides pteronyssinus+Dog dander+Timothy grass+Rye) IgE Ab [Units/volume] in Serum by Multidisk;Inhalant Allerg Mix 8 IgE Qn;;ACTIVE;2.40;2.7 +71374-3;(Daucus carota+Lycopersicon lycopersicum+Mustard+Solanum tuberosum+Allium sativum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 51 (Carrot+Tomato+Mustard+Potato+Garlic) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix 51 IgE Qn;;ACTIVE;2.40;2.7 +71375-0;(Alternaria tenuis+Artemisia vulgaris+Betula verrucosa+Cladosporium herbarum+Phleum pratense) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Inhalant Allergen Mix 6 (Alternaria tenuis+Mugwort+Silver birch+Cladosporium herbarum+Timothy grass) IgE Ab [Units/volume] in Serum by Multidisk;Inhalant Allerg Mix 6 IgE Qn;;ACTIVE;2.40;2.7 +71376-8;(Dermatophagoides pteronyssinus+Cat dander+Cat epithelium+Horse dander+Dog dander+Rabbit epithelium) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Inhalant Allergen Mix 7 (Dermatophagoides pteronyssinus+Cat dander+Cat epithelium+Horse dander+Dog dander+Rabbit epithelium) IgE Ab [Units/volume] in Serum by Multidisk;Inhalant Allerg Mix 7 IgE Qn;;ACTIVE;2.40;2.7 +71377-6;Legionella sp;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Legionella sp [Identifier] in Isolate by Agglutination;Legionella Islt Aggl;;ACTIVE;2.40;2.4 +71378-4;Leptospira sp;Prid;Pt;Isolate;Nom;Aggl;MICRO;1;Leptospira sp [Identifier] in Isolate by Agglutination;Leptospira Islt Aggl;;ACTIVE;2.40;2.4 +71379-2;I had trouble starting things because I was too tired in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I had trouble starting things because I was too tired in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +713-8;Eosinophils/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Eosinophils/100 leukocytes in Blood by Automated count;Eosinophil/leuk NFr Bld Auto;;ACTIVE;1.0;2.73 +71380-0;I had trouble finishing things because I was too tired in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I had trouble finishing things because I was too tired in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +7138-1;Glycine max dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Soybean dust IgE Ab [Units/volume] in Serum;Soybean dust IgE Qn;;ACTIVE;1.0h(2);2.42 +71381-8;I needed to sleep during the day in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I needed to sleep during the day in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71382-6;I got upset by being too tired to do things I wanted to do in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I got upset by being too tired to do things I wanted to do in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71383-4;Being tired made it hard for me to play or go out with my friends as much as I'd like in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;Being tired made it hard for me to play or go out with my friends as much as I'd like in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71384-2;I was too tired to eat in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I was too tired to eat in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71385-9;I needed help doing my usual things at home in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I needed help doing my usual things at home in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71386-7;Hepcidin 25 peptide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hepcidin 25 amino acid peptide [Moles/volume] in Serum or Plasma;Hepcidin-25 SerPl-sCnc;;ACTIVE;2.40;2.7 +71387-5;Spermatozoa.motile^post ejaculate;Num;Pt;Semen;Qn;;FERT;1;Spermatozoa Motile [#] in Semen --post ejaculate;Sperm Motile post ejac Smn;;ACTIVE;2.40;2.73 +71388-3;CMS - physical exam panel;-;Pt;^Patient;Doc;;PANEL.SURVEY.CMS;4;CMS - physical exam panel;;;TRIAL;2.40;2.4 +71389-1;CMS - constitutional exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - constitutional exam panel;;;TRIAL;2.40;2.4 +71390-9;CMS - head & face exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - head and face exam panel;;;TRIAL;2.40;2.4 +71391-7;CMS - eye exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - eye exam panel;;;TRIAL;2.40;2.4 +71392-5;CMS - ear-nose-mouth-throat exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - ear-nose-mouth-throat exam panel;;;TRIAL;2.40;2.4 +71393-3;CMS - neck exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - neck exam panel;;;TRIAL;2.40;2.4 +71394-1;CMS - respiratory exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - respiratory exam panel;;;TRIAL;2.40;2.4 +71395-8;CMS - cardiovascular exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - cardiovascular exam panel;;;TRIAL;2.40;2.4 +71396-6;CMS - breast exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - breast exam panel;;;TRIAL;2.40;2.4 +71397-4;CMS - gastrointestinal - abdomen - exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - gastrointestinal - abdomen - exam panel;;;TRIAL;2.40;2.4 +71398-2;CMS - genitourinary exam - male panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - genitourinary exam - male panel;;;TRIAL;2.40;2.4 +7139-9;Bean string Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bean string IgG Ab [Units/volume] in Serum;Bean string IgG Qn;;ACTIVE;1.0h(2);2.73 +71399-0;CMS - genitourinary exam - female panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - genitourinary exam - female panel;;;TRIAL;2.40;2.4 +71400-6;CMS - lymphatic exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - lymphatic exam panel;;;TRIAL;2.40;2.4 +71401-4;CMS - extremities exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - extremities exam panel;;;TRIAL;2.40;2.4 +71402-2;CMS - musculoskeletal exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - musculoskeletal exam panel;;;TRIAL;2.40;2.4 +71403-0;CMS - skin exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - skin exam panel;;;TRIAL;2.40;2.4 +71404-8;CMS - neurologic exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - neurologic exam panel;;;TRIAL;2.40;2.4 +71405-5;CMS - psychiatric exam panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - psychiatric exam panel;;;TRIAL;2.40;2.4 +71406-3;CMS - review of systems panel;-;Pt;^Patient;Doc;;PANEL.SURVEY.CMS;4;CMS - review of systems panel;;;TRIAL;2.40;2.4 +7140-7;Bean wax Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wax Bean IgE Ab [Units/volume] in Serum;Wax Bean IgE Qn;;ACTIVE;1.0h(2);2.73 +71407-1;CMS - constitutional symptoms panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - constitutional symptoms panel;;;TRIAL;2.40;2.4 +71408-9;CMS - eye panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - eye panel;;;TRIAL;2.40;2.4 +71409-7;CMS - ear-nose-mouth-throat panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - ear-nose-mouth-throat panel;;;TRIAL;2.40;2.4 +71410-5;CMS - cardiovascular panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - cardiovascular panel;;;TRIAL;2.40;2.4 +71411-3;CMS - respiratory panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - respiratory panel;;;TRIAL;2.40;2.4 +71412-1;CMS - gastrointestinal panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - gastrointestinal panel;;;TRIAL;2.40;2.4 +71413-9;CMS - genitourinary panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - genitourinary panel;;;TRIAL;2.40;2.4 +71414-7;CMS - musculoskeletal panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - musculoskeletal panel;;;TRIAL;2.40;2.4 +7141-5;Bean white Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Bean IgG Ab [Units/volume] in Serum;White Bean IgG Qn;;ACTIVE;1.0h(2);2.73 +71415-4;CMS - integumentary panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - integumentary panel;;;TRIAL;2.40;2.4 +71416-2;CMS - neurological panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - neurological panel;;;TRIAL;2.40;2.4 +71417-0;CMS - psychiatric panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - psychiatric panel;;;TRIAL;2.40;2.4 +71418-8;CMS - endocrine panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - endocrine panel;;;TRIAL;2.40;2.4 +71419-6;CMS - hematologic - lymphatic panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - hematologic - lymphatic panel;;;TRIAL;2.40;2.4 +71420-4;CMS - allergic - immunologic panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - allergic - immunologic panel;;;TRIAL;2.40;2.4 +71421-2;CMS - past family - social history panel;-;Pt;^Patient;Doc;;PANEL.SURVEY.CMS;4;CMS - past family - social history panel;;;TRIAL;2.40;2.4 +71422-0;CMS - social history panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - social history panel;;;TRIAL;2.40;2.4 +7142-3;Bean yellow Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Bean IgG Ab [Units/volume] in Serum;Yellow Bean IgG Qn;;ACTIVE;1.0h(2);2.54 +71423-8;CMS - family history panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - family history panel;;;TRIAL;2.40;2.4 +71424-6;CMS - past medical - surgical history panel;-;Pt;^Patient;Nar;;PANEL.SURVEY.CMS;4;CMS - past medical - surgical history panel;;;TRIAL;2.40;2.4 +71425-3;Natriuretic peptide.B prohormone N-Terminal;MCnc;Pt;Bld;Qn;IA;CHEM;1;Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Blood by Immunoassay;NT-proBNP Bld IA-mCnc;;ACTIVE;2.40;2.73 +71426-1;C reactive protein;MCnc;Pt;Bld;Qn;High sensitivity;CHEM;1;C reactive protein [Mass/volume] in Blood by High sensitivity method;CRP Bld HS-mCnc;;ACTIVE;2.40;2.73 +71427-9;Fibrin D-dimer FEU;MCnc;Pt;Bld;Qn;IA;COAG;1;Fibrin D-dimer FEU [Mass/volume] in Blood by Immunoassay;D dimer FEU Bld IA-mCnc;;ACTIVE;2.40;2.73 +71428-7;CMS - history of present illness panel;-;Pt;^Patient;Doc;;PANEL.SURVEY.CMS;4;CMS - history of present illness panel;;;TRIAL;2.40;2.4 +71429-5;Campylobacter sp DNA.diarrheagenic;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter sp DNA.diarrheagenic [Presence] in Stool by NAA with probe detection;Campy sp DNA.diarrhea Stl Ql NAA+probe;;ACTIVE;2.40;2.73 +71430-3;oxyCODONE+Oxymorphone;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Saliva (oral fluid) by Screen method;oxyCODONE+oxyMORphone Sal Ql Scn;;ACTIVE;2.40;2.73 +7143-1;Beef basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Beef triggered histamine release [Units/volume] in Blood;Beef BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.73 +71431-1;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Cervix by NAA with probe detection;HPV HR 12 DNA Cvx Ql NAA+probe;;ACTIVE;2.40;2.73 +71432-9;Human papilloma virus 16 & 18 & 31+33+35+39+45+51+52+56+58+59+66+68 DNA panel;-;Pt;Cvx;-;;PANEL.MICRO;1;Human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 DNA - Cervix;HPV16+18+H Risk 12 DNA Pnl Cvx;;ACTIVE;2.40;2.73 +71433-7;Functional assessment of cancer therapy for patients with prostate cancer questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Cancer Therapy for patients with prostate cancer questionnaire - version 4 (FACT-P) [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71434-5;Additional concerns - FACT-P;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Additional concerns - FACT-P [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71435-2;I have aches and pains that bother me in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I have aches and pains that bother me in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71436-0;I am satisfied with my present level of comfort in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am satisfied with my present level of comfort in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71437-8;I am able to feel like a man in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to feel like a man in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71438-6;I am able to have and maintain an erection in the past 7D;Find;7D;^Patient;Ord;FACIT;SURVEY.GNHLTH;4;I am able to have and maintain an erection in the past 7 days [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.67 +71439-4;Functional assessment of chronic illness therapy - spiritual well being questionnaire - version 4;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional Assessment of Chronic Illness Therapy Spiritual Well-being Questionnaire - version 4 (FACIT-Sp);;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.40;2.5 +71440-2;Discharge;Type;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Discharge type [CMS Assessment];;;ACTIVE;2.40;2.63 +71441-0;Level II Preadmission Screening and Resident Review (PASRR);Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Level II Preadmission Screening and Resident Review (PASRR) [CMS Assessment];;;ACTIVE;2.40;2.63 +71442-8;Weight gain;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Weight gain [MDSv3];;;ACTIVE;2.40;2.67 +71443-6;Preference to avoid asking Q0500B again;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Preference to avoid asking Q0500B again [MDSv3];;;ACTIVE;2.40;2.67 +71444-4;Nutritional approaches during last 7D - while not a resident;Find;7D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Nutritional approaches during last 7 days - while not a resident [CMS Assessment];;;ACTIVE;2.40;2.7 +71445-1;Nutritional approaches during last 7D - while a resident;Find;7D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Nutritional approaches during last 7 days - while a resident [CMS Assessment];;;ACTIVE;2.40;2.63 +71446-9;Indexing - billing unit;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indexing - billing unit;FDA insert Indexing - billing;;ACTIVE;2.40;2.44 +71447-7;Received scheduled pain medication regimen;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Received scheduled pain medication regimen during assessment period [CMS Assessment];;;ACTIVE;2.40;2.7 +71448-5;Received PRN pain medications or was offered and declined;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Received PRN pain medications or was offered and declined during assessment period [CMS Assessment];;;ACTIVE;2.40;2.7 +7144-9;Liver beef basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Liver beef triggered histamine release [Units/volume] in Blood;Liver Beef BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71449-3;Received non-medication intervention for pain;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Received non-medication intervention for pain during assessment period [CMS Assessment];;;ACTIVE;2.40;2.7 +71450-1;Skin tear(s);Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Skin tear(s) [MDSv3];;;ACTIVE;2.40;2.67 +71451-9;Moisture associated skin damage (MASD);Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Moisture associated skin damage (MASD) [MDSv3];;;ACTIVE;2.40;2.67 +71452-7;Intellectual disability and developmental disability with organic condition;Find;Pt;^Patient;Ord;MDSv3;PANEL.SURVEY.MDS;4;Intellectual disability and developmental disability with organic condition [MDSv3];;;ACTIVE;2.40;2.68 +71453-5;Intellectual disability and developmental disability with no organic condition;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Intellectual disability and developmental disability with no organic condition [MDSv3];;;ACTIVE;2.40;2.67 +71454-3;Conditions related to intellectual disability and developmental disability status;-;Pt;^Patient;-;MDSv3;PANEL.SURVEY.MDS;4;Conditions related to intellectual disability and developmental disability status [MDSv3];;;ACTIVE;2.40;2.44 +71455-0;Other organic condition related to intellectual disability and developmental disability status;Find;Pt;^Patient;Ord;MDSv3;SURVEY.MDS;4;Other organic condition related to intellectual disability and developmental disability status [MDSv3];;;ACTIVE;2.40;2.67 +7145-6;Beet Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Beet IgG Ab [Units/volume] in Serum;Beet IgG Qn;;ACTIVE;1.0h(2);2.73 +71456-8;Nitrofural;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Deprecated Nitrofural [Susceptibility];Deprecated Nitrofural Susc Islt;;DEPRECATED;2.40;2.5 +71457-6;Erythropoiesis-stimulating agent panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Erythropoiesis-stimulating agent panel [ESRD];;;TRIAL;2.40;2.44 +71458-4;Was erythropoiesis-stimulating agent prescribed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Was erythropoiesis-stimulating agent prescribed [ESRD];;;TRIAL;2.40;2.67 +71459-2;Infection panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Infection panel [ESRD];;;TRIAL;2.40;2.44 +714-6;Eosinophils/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Blood by Manual count;Eosinophil/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +71460-0;Outpatient antibiotics prescribed in past Mo;Find;1Mo;^Patient;Ord;ESRD;SURVEY.ESRD;4;Outpatient antibiotics prescribed in past month [ESRD];;;TRIAL;2.40;2.67 +71461-8;Vascular infection source;Type;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Vascular infection source [ESRD];;;TRIAL;2.40;2.67 +71462-6;Method of identifying vascular access infection;Find;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Method of identifying vascular access infection [ESRD];;;TRIAL;2.40;2.67 +71463-4;Date of infection onset;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date of infection onset [ESRD];;;TRIAL;2.40;2.67 +7146-4;Beet red Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Beet IgE Ab [Units/volume] in Serum;Red Beet IgE Qn;;ACTIVE;1.0h(2);2.73 +71464-2;Date first prescribed;TmStp;Pt;Medication;Qn;;SURVEY.ESRD;4;Date first prescribed Medication;;;TRIAL;2.40;2.67 +71465-9;Date prescription changed;TmStp;Pt;Medication;Qn;;SURVEY.ESRD;4;Date prescription changed Medication;;;TRIAL;2.40;2.67 +71466-7;Date prescription stopped;TmStp;Pt;Medication;Qn;;SURVEY.ESRD;4;Date prescription stopped Medication;;;TRIAL;2.40;2.67 +71467-5;Erythropoiesis-stimulating agent prescribed;Find;Pt;Medication;Nom;;SURVEY.ESRD;4;Erythropoiesis-stimulating agent prescribed Medication;;;TRIAL;2.40;2.67 +71468-3;Route;Find;Pt;Medication;Nom;;SURVEY.ESRD;4;Route Medication;;;ACTIVE;2.40;2.67 +71469-1;Medication frequency;Find;Pt;Medication;Ord;ESRD;SURVEY.ESRD;4;Medication frequency Medication [ESRD];;;TRIAL;2.40;2.67 +71470-9;Antibiotic panel;-;Pt;Medication;-;ESRD;PANEL.SURVEY.ESRD;4;ESRD antibiotic panel;;;TRIAL;2.40;2.44 +71471-7;Antibiotic administered;Type;Pt;Medication;Nom;;SURVEY.ESRD;4;Antibiotic administered Medication;;;ACTIVE;2.40;2.67 +7147-2;Beta vulgaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Beet IgE Ab [Units/volume] in Serum;Sugar Beet IgE Qn;;ACTIVE;1.0h(2);2.73 +71472-5;Date of blood culture;TmStp;Pt;^Patient;Qn;;SURVEY.ESRD;4;Date of blood culture;;;TRIAL;2.40;2.67 +71473-3;Infected dialysis site;Type;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Infected dialysis site [ESRD];;;TRIAL;2.40;2.67 +71474-1;Date of infection hospitalization;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date of infection hospitalization [ESRD];;;TRIAL;2.40;2.67 +71475-8;New infection suspected;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;New infection suspected [ESRD];;;TRIAL;2.40;2.67 +71476-6;Clinical sepsis symptoms present;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Clinical sepsis symptoms present [ESRD];;;TRIAL;2.40;2.67 +71477-4;Did the infection require hospitalization;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Did the infection require hospitalization [ESRD];;;TRIAL;2.40;2.67 +71478-2;Signs of soft tissue infection present;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Signs of soft tissue infection present [ESRD];;;TRIAL;2.40;2.67 +71479-0;Date access infection confirmed;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date access infection confirmed [ESRD];;;TRIAL;2.40;2.67 +7148-0;Berry Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Berry IgE Ab [Units/volume] in Serum;Berry IgE Qn;;ACTIVE;1.0h(2);2.42 +71480-8;Location of death;Loc;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Location of death [ESRD];;;TRIAL;2.40;2.67 +71481-6;Did the death of this person involve injury of any kind;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Did the death of this person involve injury of any kind;;;ACTIVE;2.40;2.67 +71482-4;Risk assessment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Risk assessment Document;Risk assessment Doc;;ACTIVE;2.40;2.73 +71483-2;Total score;Score;Pt;^Patient;Qn;HKOI;SURVEY.AAOS;4;Total score [HKOI];;Copyright © American Academy of Orthopaedic Surgeons. Used with permission.;ACTIVE;2.40;2.67 +71484-0;Cup-disc ratio;LenRto;Pt;Optic nerve.left;Qn;Ophthalmoscopy;EYE.PX;2;Left optic nerve Cup-disc ratio by Ophthalmoscopy;L optic n Cup-disc ratio Ophthalmoscopy;;ACTIVE;2.40;2.73 +71485-7;Cup-disc ratio;LenRto;Pt;Optic nerve.right;Qn;Ophthalmoscopy;EYE.PX;2;Right optic nerve Cup-disc ratio by Ophthalmoscopy;R optic n Cup-disc ratio Ophthalmoscopy;;ACTIVE;2.40;2.73 +71486-5;Optic disc or retinal nerve fiber layer structural abnormalities;Find;Pt;Eye.left;Ord;Ophthalmoscopy;EYE.PX;2;Left eye Optic disc or retinal nerve fiber layer structural abnormalities by Ophthalmoscopy;Opt disc ret nerv abnor Eye-L Ophthal;;ACTIVE;2.40;2.68 +71487-3;Optic disc or retinal nerve fiber layer structural abnormalities;Find;Pt;Eye.right;Ord;Ophthalmoscopy;EYE.PX;2;Right eye Optic disc or retinal nerve fiber layer structural abnormalities by Ophthalmoscopy;Opt disc ret nerv abnor Eye-R Ophthal;;ACTIVE;2.40;2.68 +71488-1;Macular edema;Find;Pt;Eye.left;Ord;Ophthalmoscopy;EYE.PX;2;Left eye Macular edema by Ophthalmoscopy;L eye Macular edema Ophthalmoscopy;;ACTIVE;2.40;2.68 +71489-9;Macular edema;Find;Pt;Eye.right;Ord;Ophthalmoscopy;EYE.PX;2;Right eye Macular edema by Ophthalmoscopy;R eye Macular edema Ophthalmoscopy;;ACTIVE;2.40;2.68 +71490-7;Diabetic retinopathy severity level;Find;Pt;Eye.left;Ord;Ophthalmoscopy;EYE.PX;2;Left eye Diabetic retinopathy severity level by Ophthalmoscopy;L eye Diabet retinop sev Ophthalmoscopy;;ACTIVE;2.40;2.68 +71491-5;Diabetic retinopathy severity level;Find;Pt;Eye.right;Ord;Ophthalmoscopy;EYE.PX;2;Right eye Diabetic retinopathy severity level by Ophthalmoscopy;R eye Diabet retinop sev Ophthalmoscopy;;ACTIVE;2.40;2.68 +71492-3;Total score;Score;Pt;^Patient;Qn;SLUMS;SURVEY.MTLHLTH;4;Total score [SLUMS];;Copyright © Saint Louis University/Department of Veterans Affairs. Used with permission.;ACTIVE;2.40;2.67 +71493-1;Total score;Score;Pt;^Patient;Qn;IQCODE;SURVEY.MTLHLTH;4;Total score [IQCODE];;Copyright © Anthony Jorm. Used with permission.;ACTIVE;2.40;2.67 +71495-6;Network code;ID;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Network code Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71496-4;Corporate organization code;ID;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Corporate organization code Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71497-2;Dialysis organization affiliation;Type;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Dialysis organization affiliation Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +7149-8;Bipolanis curvularia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bipolanis curvularia IgE Ab [Units/volume] in Serum;B curvularia IgE Qn;;ACTIVE;1.0h(2);2.42 +71498-0;Manager;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Manager Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71499-8;Owner;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Owner Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71500-3;Program;Type;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Program Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71501-1;Open-closed Status;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Open-closed status Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71502-9;Profit status;Type;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Profit status Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71503-7;Date opened;Date;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Date opened Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71504-5;Date closed;Date;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Date closed Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71505-2;Date changed ownership;Date;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Date changed ownership Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +7150-6;Birch White Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Birch White Ab.IgE;Deprecated White Birch IgE Qn;;DEPRECATED;1.0h(2);2.69 +71506-0;Date initially certified by medicare;Date;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Date initially certified by medicare Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71507-8;Fax number;Tele;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Fax number Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71508-6;Website;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Website Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71509-4;Phone number extension;Tele;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Phone number extension Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71510-2;Medicaid certified stations;Num;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Medicaid certified stations Dialysis facility # [ESRD];;;TRIAL;2.40;2.67 +71511-0;Isolation stations;Num;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Isolation stations Dialysis facility # [ESRD];;;TRIAL;2.40;2.67 +71512-8;Medicare certified services offered;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Medicare certified services offered Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71513-6;Non-medicare certified services offered;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Non-medicare certified services offered Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +7151-4;Rubus fruticosus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blackberry IgE Ab [Units/volume] in Serum;Blackberry IgE Qn;;ACTIVE;1.0h(2);2.73 +71514-4;Opening time;TmStp;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Opening time Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71515-1;Closing time;TmStp;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Closing time Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71516-9;Personnel job code;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Personnel job code Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71518-5;Transplant referral;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Transplant referral [ESRD];;;TRIAL;2.40;2.67 +71519-3;On transplant waiting list;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;On transplant waiting list [ESRD];;;TRIAL;2.40;2.67 +71520-1;Hospitalized due to presumptive diagnosis;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Hospitalized due to presumptive diagnosis [ESRD];;;TRIAL;2.40;2.67 +71521-9;Location;Type;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Location Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +7152-2;Vaccinium myrtillus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blueberry IgE Ab [Units/volume] in Serum;Blueberry IgE Qn;;ACTIVE;1.0h(2);2.73 +71522-7;Certified program;Type;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Certified program Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71523-5;Date personnel record submitted;Date;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Date personnel record submitted Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71524-3;Partial owner organization;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Partial owner organization Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71525-0;Authorized batch submitting organization;Find;Pt;Agency;Nom;ESRD;SURVEY.ESRD;4;Authorized batch submitting organization Agency [ESRD];;;TRIAL;2.40;2.67 +71526-8;Personnel employment name;Find;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Personnel employment name Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71527-6;Record status;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Record status [ESRD];;;TRIAL;2.40;2.67 +71528-4;Personnel job description;Type;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Personnel job description Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71529-2;Back up NPI;ID;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Back up NPI Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +715-3;Normoblasts;NCnc;Pt;Bld;Qn;;HEM/BC;1;Normoblasts [#/volume] in Blood;Normoblasts # Bld;;ACTIVE;1.0;2.42 +7153-0;Vaccinium myrtillus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blueberry IgG Ab [Units/volume] in Serum;Blueberry IgG Qn;;ACTIVE;1.0h(2);2.73 +71530-0;Business name;ID;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Business name Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71531-8;Hospitalization panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;ESRD hospitalization panel;;;TRIAL;2.40;2.44 +71533-4;Dialysis shifts;Num;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Dialysis shifts Dialysis facility # [ESRD];;;TRIAL;2.40;2.67 +71534-2;Phone number;Tele;Pt;Dialysis facility;Nom;ESRD;SURVEY.ESRD;4;Phone number Dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71536-7;Information source;Find;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Source of information [ESRD];;;TRIAL;2.40;2.67 +71538-3;Sent to hospital directly from dialysis facility;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Sent to hospital directly from dialysis facility [ESRD];;;TRIAL;2.40;2.67 +71539-1;Record status;Type;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Record status ESRD type;;;TRIAL;2.40;2.67 +71540-9;Date personnel record submission;TmStp;Pt;Dialysis facility;Qn;ESRD;SURVEY.ESRD;4;Deprecated Date personnel record submission Dialysis facility ESRD;;;DEPRECATED;2.40;2.44 +71541-7;I feel sad, down in the dumps or unhappy in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel sad, down in the dumps or unhappy in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71542-5;Nothing seems to give me much pleasure in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;Nothing seems to give me much pleasure in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71543-3;I feel tired - have no energy in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel tired - have no energy in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71544-1;I have had thoughts of suicide in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have had thoughts of suicide in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71545-8;I have difficulty sleeping in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have difficulty sleeping in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71546-6;I have been sleeping too much in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have been sleeping too much in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71547-4;I have lost some appetite in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have lost some appetite in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +7154-8;Vaccinium myrtillus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Blueberry triggered histamine release [Units/volume] in Blood;Blueberry BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71548-2;I have been eating more in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have been eating more in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71549-0;I feel tense, anxious or can't sit still in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel tense, anxious or can't sit still in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71550-8;I feel worried or fearful in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel worried or fearful in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71551-6;I have attacks of anxiety or panic in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have attacks of anxiety or panic in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71552-4;I worry about dying or losing control in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I worry about dying or losing control in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71553-2;I am nervous or shaky in social situations in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I am nervous or shaky in social situations in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71554-0;I have nightmares or flashbacks in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have nightmares or flashbacks in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +7155-5;Acer negundo Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Boxelder IgE Ab [Units/volume] in Serum;Boxelder IgE Qn;;ACTIVE;1.0h(2);2.73 +71555-7;I am jumpy or feel startled easily in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I am jumpy or feel startled easily in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71556-5;I avoid places that strongly remind me of a bad experience in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I avoid places that strongly remind me of a bad experience in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71557-3;I feel dull, numb, or detached in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel dull, numb, or detached in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71558-1;I can't get certain things out of my mind in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I can't get certain things out of my mind in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71559-9;I feel I must repeat certain acts or rituals in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel I must repeat certain acts or rituals in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71560-7;I feel the need to check and recheck things in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel the need to check and recheck things in the last 2 weeks or more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71561-5;At any time in your life, have you had more energy than usual;Find;Lifetime;^Patient;Ord;M3;SURVEY.MTLHLTH;4;At any time in your life, have you had more energy than usual [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71562-3;At any time in your life, have you felt unusually irritable or angry;Find;Lifetime;^Patient;Ord;M3;SURVEY.MTLHLTH;4;At any time in your life, have you felt unusually irritable or angry [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +7156-3;Acer negundo Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Boxelder IgG Ab [Units/volume] in Serum;Boxelder IgG Qn;;ACTIVE;1.0h(2);2.73 +71563-1;At any time in your life have you felt unusually excited, revved up or high;Find;Lifetime;^Patient;Ord;M3;SURVEY.MTLHLTH;4;At any time in your life have you felt unusually excited, revved up or high [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71564-9;At any time in your life have you needed less sleep than usual;Find;Lifetime;^Patient;Ord;M3;SURVEY.MTLHLTH;4;At any time in your life have you needed less sleep than usual [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71565-6;These symptoms interfere with work or school;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;These symptoms interfere with work or school [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71566-4;These symptoms affect my relationships with friends or family;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;These symptoms affect my relationships with friends or family [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71567-2;These symptoms have led to my using alcohol to get by;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;These symptoms have led to my using alcohol to get by [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71568-0;These symptoms have led to my using drugs;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;These symptoms have led to my using drugs [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71569-8;M3 Checklist;-;Pt;^Patient;-;M3;PANEL.SURVEY.MTLHLTH;4;M3 Checklist [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.5 +71570-6;Changes in sleeping patterns;-;Pt;^Patient;-;M3;PANEL.SURVEY.MTLHLTH;4;Changes in sleeping patterns [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.5 +7157-1;Bertholletia excelsa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brazil Nut IgG Ab [Units/volume] in Serum;Brazil Nut IgG Qn;;ACTIVE;1.0h(2);2.73 +71571-4;Changes in appetite;-;Pt;^Patient;-;M3;PANEL.SURVEY.MTLHLTH;4;Changes in appetite [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.5 +71572-2;I can't concentrate or focus in the last 2W or more;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I can't concentrate or focus in the last 2 weeks more [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71573-0;Medication authorization;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Medication authorization NEMSIS;Medication authorization NEMSIS;;ACTIVE;2.40;2.67 +71574-8;Airway device confirmed for placement;Find;Pt;^Patient;Nom;;TRAUMA;2;Airway device confirmed for placement;Airway device being confirmed NEMSIS;;ACTIVE;2.40;2.7 +71575-5;ECG;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;ECG NEMSIS;ECG NEMSIS;;ACTIVE;2.40;2.73 +71576-3;Airway device placement confirmation method;Find;Pt;^Patient;Nom;;NEMSIS;2;Airway device placement confirmation method;Airway placement confirm method;;ACTIVE;2.40;2.72 +71577-1;ECG interpretation method;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;ECG interpretation method NEMSIS;ECG interpretation method NEMSIS;;ACTIVE;2.40;2.67 +71578-9;EMS transport destination;Type;Pt;^Facility;Nom;NEMSIS;NEMSIS;2;EMS transport destination NEMSIS;EMS destination NEMSIS;;ACTIVE;2.40;2.67 +71579-7;Unit transport and equipment capability;Find;Pt;EMS unit;Nom;;NEMSIS;2;Unit transport and equipment capability EMS unit;Trnsprt+Equip capability EMS unit;;ACTIVE;2.40;2.72 +71580-5;Certification;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Certification NEMSIS;Certification NEMSIS;;ACTIVE;2.40;2.67 +71581-3;Crew member response role;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Crew member response role NEMSIS;Crew member response role NEMSIS;;ACTIVE;2.40;2.67 +71582-1;Person performing procedure;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Person performing procedure NEMSIS;Person performing procedure NEMSIS;;ACTIVE;2.40;2.73 +71583-9;Service requested;Type;Pt;EMS unit;Nom;;TRAUMA;2;Service requested of EMS unit;Service requested of EMS;;ACTIVE;2.40;2.7 +71584-7;Exam finding location;Find;Pt;Abdomen;Nom;NEMSIS;NEMSIS;2;Exam finding location Abdomen NEMSIS;Exam finding location Abd NEMSIS;;ACTIVE;2.40;2.67 +71585-4;Exam finding location;Find;Pt;Extremity;Nom;NEMSIS;NEMSIS;2;Exam finding location Extremity NEMSIS;Exam finding location Extr NEMSIS;;ACTIVE;2.40;2.67 +71586-2;Exam finding location;Find;Pt;Eye;Nom;NEMSIS;NEMSIS;2;Exam finding location Eye NEMSIS;Exam finding location Eye NEMSIS;;ACTIVE;2.40;2.67 +71587-0;IV site;Loc;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;IV site NEMSIS;IV site NEMSIS;;ACTIVE;2.40;2.67 +71588-8;Chief complaint;Loc;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Chief complaint [Location] NEMSIS;Chief complaint NEMSIS;;ACTIVE;2.40;2.67 +7158-9;Bertholletia excelsa basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Brazil Nut triggered histamine release [Units/volume] in Blood;Brazil Nut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71589-6;Exam finding location;Find;Pt;Back+Spine;Nom;NEMSIS;NEMSIS;2;Exam finding location Back+Spine NEMSIS;Exam finding location Back+Spine NEMSIS;;ACTIVE;2.40;2.67 +71590-4;Hospitalized or emergency room;Find;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Hospitalized or emergency room [ESRD];;;TRIAL;2.40;2.67 +71591-2;Job title;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel Job title;Personnel Job title;;ACTIVE;2.40;2.67 +71592-0;Hemoglobinopathies conditions suspected;Prid;Pt;Bld.dot;Nom;;CHEM;1;Hemoglobinopathies conditions suspected [Identifier] in DBS;Hemoglobinopathies suspected DBS;;ACTIVE;2.40;2.61 +71593-8;Glucose-6-Phosphate dehydrogenase;CSub;Pt;RBC;Qn;;CHEM;1;Glucose-6-Phosphate dehydrogenase [Enzymatic activity/substance] in Red Blood Cells;G6PD cSub RBC;;ACTIVE;2.40;2.42 +71594-6;Macrophages/leukocytes;NFr.DF;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Macrophages/Leukocytes [Pure number fraction] in Bronchial specimen by Manual count;Macrophages NFr.DF Bronch Manual;;ACTIVE;2.42;2.42 +71595-3;Basophils/leukocytes;NFr.DF;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Bronchial specimen by Manual count;Basophils NFr.DF Bronch Manual;;ACTIVE;2.42;2.42 +71596-1;Eosinophils/leukocytes;NFr.DF;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Bronchial specimen by Manual count;Eosinophil NFr.DF Bronch Manual;;ACTIVE;2.42;2.42 +7159-7;Brassica oleracea var italica Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Broccoli IgG Ab [Units/volume] in Serum;Broccoli IgG Qn;;ACTIVE;1.0h(2);2.73 +71597-9;Lymphocytes/leukocytes;NFr.DF;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Bronchial specimen by Manual count;Lymphocytes NFr.DF Bronch Manual;;ACTIVE;2.42;2.42 +71598-7;Neutrophils/leukocytes;NFr.DF;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Bronchial specimen by Manual count;Neutrophils NFr.DF Bronch Manual;;ACTIVE;2.42;2.42 +71599-5;Mesothelial cells/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;Mesothl Cell NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +71600-1;Macrophages/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Macrophages/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;Macrophages NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +71601-9;Leukocytes other/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Leukocytes other/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;WBC Other NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +71602-7;Basophils/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;Basophils NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +71603-5;Eosinophils/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;Eosinophil NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +71604-3;Monocytes/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;Monocytes NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +7160-5;Brassica oleracea var gemmifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brussel Sprouts IgE Ab [Units/volume] in Serum;Brussel Sprouts IgE Qn;;ACTIVE;1.0h(2);2.73 +71605-0;Lymphocytes/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;Lymphocytes NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +71606-8;Neutrophils/leukocytes;NFr.DF;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Pericardial fluid by Manual count;Neutrophils NFr.DF Pcar Manual;;ACTIVE;2.42;2.42 +71607-6;Mesothelial cells/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Mesothl Cell NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +71608-4;Polymorphonuclear cells/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Polys NFr.DF Plr Manual;;ACTIVE;2.42;2.44 +71609-2;Macrophages/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Macrophages/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Macrophages NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +716-1;Heinz bodies;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Heinz bodies [Presence] in Blood by Light microscopy;Heinz Bod Bld Ql Smear;;ACTIVE;1.0;2.73 +71610-0;Mononuclear cells/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Mononuc Cells NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +71611-8;Leukocytes other/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Leukocytes other/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;WBC Other NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +71612-6;Basophils/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Basophils NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +7161-3;Brassica oleracea var gemmifera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brussel Sprouts IgG Ab [Units/volume] in Serum;Brussel Sprouts IgG Qn;;ACTIVE;1.0h(2);2.73 +71613-4;Eosinophils/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Eosinophil NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +71614-2;Monocytes/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Monocytes NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +71615-9;Lymphocytes/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Lymphocytes NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +71616-7;Neutrophils/leukocytes;NFr.DF;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Pleural fluid by Manual count;Neutrophils NFr.DF Plr Manual;;ACTIVE;2.42;2.42 +71617-5;Polymorphonuclear cells/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Polys NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71618-3;Macrophages/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Macrophages/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Macrophages NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71619-1;Mononuclear cells/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Mononuc Cells NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71620-9;Leukocytes other/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Leukocytes other/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;WBC Other NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +7162-1;Fagopyrum esculentum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Buckwheat IgG Ab [Units/volume] in Serum;Buckwheat IgG Qn;;ACTIVE;1.0h(2);2.73 +71621-7;Basophils/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Basophils NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71622-5;Eosinophils/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Eosinophil NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71623-3;Monocytes/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Monocytes NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71624-1;Lymphocytes/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Lymphocytes NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71625-8;Neutrophils/leukocytes;NFr.DF;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Synovial fluid by Manual count;Neutrophils NFr.DF Snv Manual;;ACTIVE;2.42;2.42 +71626-6;Mesothelial cells/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Mesothl Cell NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71627-4;Polymorphonuclear cells/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Polys NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71628-2;Macrophages/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Macrophages/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Macrophages NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71629-0;Mononuclear cells/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Mononuc Cells NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71630-8;Leukocytes other/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Leukocytes other/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;WBC Other NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71631-6;Basophils/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Basophils NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71632-4;Eosinophils/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Eosinophil NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71633-2;Monocytes/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Monocytes NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71634-0;Lymphocytes/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Lymphocytes NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71635-7;Neutrophils/leukocytes;NFr.DF;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Peritoneal fluid by Manual count;Neutrophils NFr.DF Prt Manual;;ACTIVE;2.42;2.42 +71636-5;Plasma cells/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Plasma cells/Leukocytes [Pure number fraction] in Body fluid by Manual count;Plasma Cells NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71637-3;Unspecified cells/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Unspecified cells/Leukocytes [Pure number fraction] in Body fluid by Manual count;Unspecified Cells NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71638-1;Unidentified cells/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Unidentified cells/Leukocytes [Pure number fraction] in Body fluid by Manual count;Unident Cells NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +7163-9;Kochia scoparia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Burning bush IgE Ab [Units/volume] in Serum;Deprecated Firebush IgE Qn;;DEPRECATED;1.0h(2);2.69 +71639-9;Monocytes+Macrophages/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/Leukocytes [Pure number fraction] in Body fluid by Manual count;Monos+Macros NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71640-7;Mesothelial cells/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Mesothelial cells/Leukocytes [Pure number fraction] in Body fluid by Manual count;Mesothl Cell NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71641-5;Macrophages/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Macrophages/Leukocytes [Pure number fraction] in Body fluid by Manual count;Macrophages NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71642-3;Promyelocytes/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Promyelocytes/Leukocytes [Pure number fraction] in Body fluid by Manual count;Promyelocytes NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71643-1;Metamyelocytes/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Metamyelocytes/Leukocytes [Pure number fraction] in Body fluid by Manual count;Metamyelocytes NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71644-9;Blasts/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Blasts/Leukocytes [Pure number fraction] in Body fluid by Manual count;Blasts NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71645-6;Neutrophils.band form/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Band form neutrophils/Leukocytes [Pure number fraction] in Body fluid by Manual count;Neuts Band NFr.DF Fld Manual;;ACTIVE;2.42;2.54 +71646-4;Eosinophils/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Body fluid by Manual count;Eosinophil NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +7164-7;Hymenoclea salsola Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Burrobrush IgE Ab [Units/volume] in Serum;Burrobrush IgE Qn;;ACTIVE;1.0h(2);2.73 +71647-2;Basophils/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Body fluid by Manual count;Basophils NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71648-0;Monocytes/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Body fluid by Manual count;Monocytes NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71649-8;Lymphocytes/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Body fluid by Manual count;Lymphocytes NFr.DF Fld Manual;;ACTIVE;2.42;2.42 +71650-6;Neutrophils.segmented/leukocytes;NFr.DF;Pt;Body fld;Qn;Manual count;HEM/BC;1;Segmented neutrophils/Leukocytes [Pure number fraction] in Body fluid by Manual count;Neuts Seg NFr.DF Fld Manual;;ACTIVE;2.42;2.54 +71651-4;Macrophages/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Macrophages/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Macrophages NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71652-2;Plasma cells/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Plasma cells/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Plasma Cells NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71653-0;Promyelocytes/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Promyelocytes/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Promyelocytes NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +7165-4;Hymenoclea salsola Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated White burrobrush IgE Ab [Units/volume] in Serum;Deprecated White burrobrush IgE Qn;;DEPRECATED;1.0h(2);2.69 +71654-8;Myelocytes/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Myelocytes/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Myelocytes NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71655-5;Metamyelocytes/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Metamyelocytes/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Metamyelocytes NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71656-3;Blasts/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Blasts/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Blasts NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71657-1;Neutrophils.band form/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Band form neutrophils/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Neuts Band NFr.DF CSF Manual;;ACTIVE;2.42;2.54 +71658-9;Neutrophils/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Neutrophils NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71659-7;Monocytes/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Monocytes NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71660-5;Lymphocytes/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Lymphocytes NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71661-3;Eosinophils/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Eosinophil NFr.DF CSF Manual;;ACTIVE;2.42;2.73 +7166-2;Burweed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Burweed IgE Ab [Units/volume] in Serum;Burweed IgE Qn;;ACTIVE;1.0h(2);2.61 +71662-1;Basophils/leukocytes;NFr.DF;Pt;CSF;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Cerebral spinal fluid by Manual count;Basophils NFr.DF CSF Manual;;ACTIVE;2.42;2.42 +71663-9;Plasma cells/leukocytes;NFr.DF;Pt;Bld;Qn;;HEM/BC;1;Plasma cells/Leukocytes [Pure number fraction] in Blood;Plasma Cells NFr.DF Bld;;ACTIVE;2.42;2.42 +71664-7;Smudge cells/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Smudge cells/Leukocytes [Pure number fraction] in Blood by Manual count;Smudge Cells NFr.DF Bld Manual;;ACTIVE;2.42;2.42 +71665-4;Lymphocytes.variant/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Variant lymphocytes/Leukocytes [Pure number fraction] in Blood by Manual count;Variant Lymphs NFr.DF Bld Manual;;ACTIVE;2.42;2.54 +71666-2;Promyelocytes/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Promyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count;Promyelocytes NFr.DF Bld Manual;;ACTIVE;2.42;2.42 +71667-0;Myelocytes/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Myelocytes/Leukocytes [Pure number fraction] in Blood by Manual count;Myelocytes NFr.DF Bld Manual;;ACTIVE;2.42;2.42 +71668-8;Metamyelocytes/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count;Metamyelocytes NFr.DF Bld Manual;;ACTIVE;2.42;2.42 +71669-6;Blasts/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Blasts/Leukocytes [Pure number fraction] in Blood by Manual count;Blasts NFr.DF Bld Manual;;ACTIVE;2.42;2.73 +7167-0;Butterfly Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Butterfly IgE Ab [Units/volume] in Serum;Butterfly IgE Qn;;ACTIVE;1.0h(2);2.42 +71670-4;Neutrophils.band form/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Band form neutrophils/Leukocytes [Pure number fraction] in Blood by Manual count;Neuts Band NFr.DF Bld Manual;;ACTIVE;2.42;2.54 +71671-2;Neutrophils/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Blood by Manual count;Neutrophils NFr.DF Bld Manual;;ACTIVE;2.42;2.42 +71672-0;Monocytes/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Blood by Manual count;Monocytes NFr.DF Bld Manual;;ACTIVE;2.42;2.42 +71673-8;Lymphocytes/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Blood by Manual count;Lymphocytes NFr.DF Bld Manual;;ACTIVE;2.42;2.73 +71674-6;Eosinophils/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Blood by Manual count;Eosinophil NFr.DF Bld Manual;;ACTIVE;2.42;2.73 +71675-3;Basophils/leukocytes;NFr.DF;Pt;Bld;Qn;Manual count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Blood by Manual count;Basophils NFr.DF Bld Manual;;ACTIVE;2.42;2.73 +71676-1;Neutrophils/leukocytes;NFr.DF;Pt;Bld;Qn;Automated count;HEM/BC;1;Neutrophils/Leukocytes [Pure number fraction] in Blood by Automated count;Neutrophils NFr.DF Bld Auto;;ACTIVE;2.42;2.73 +71677-9;Monocytes/leukocytes;NFr.DF;Pt;Bld;Qn;Automated count;HEM/BC;1;Monocytes/Leukocytes [Pure number fraction] in Blood by Automated count;Monocytes NFr.DF Bld Auto;;ACTIVE;2.42;2.73 +71678-7;Lymphocytes/leukocytes;NFr.DF;Pt;Bld;Qn;Automated count;HEM/BC;1;Lymphocytes/Leukocytes [Pure number fraction] in Blood by Automated count;Lymphocytes NFr.DF Bld Auto;;ACTIVE;2.42;2.73 +71679-5;Eosinophils/leukocytes;NFr.DF;Pt;Bld;Qn;Automated count;HEM/BC;1;Eosinophils/Leukocytes [Pure number fraction] in Blood by Automated count;Eosinophil NFr.DF Bld Auto;;ACTIVE;2.42;2.73 +71680-3;Basophils/leukocytes;NFr.DF;Pt;Bld;Qn;Automated count;HEM/BC;1;Basophils/Leukocytes [Pure number fraction] in Blood by Automated count;Basophils NFr.DF Bld Auto;;ACTIVE;2.42;2.73 +71681-1;PMI - Common side effects section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Common side effects section;FDA insert PMI-Common side effects;;ACTIVE;2.40;2.4 +71682-9;PMI - Get emergency medical help section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Get emergency medical help section;FDA insert PMI-Get emerg medical help;;ACTIVE;2.40;2.4 +71683-7;PMI - Stop taking and call your doctor section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Stop taking and call your doctor section;FDA insert PMI-Stop taking+call your doc;;ACTIVE;2.40;2.4 +71684-5;PMI - Directions for use section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Directions for use section;FDA insert PMI-Directions for use;;ACTIVE;2.40;2.4 +71685-2;PMI - Tell your doctor before taking section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Tell your doctor before taking section;FDA insert PMI-Tell doc before taking;;ACTIVE;2.40;2.4 +71686-0;PMI - Do not take section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Do not take section;FDA insert PMI-Do not take;;ACTIVE;2.40;2.4 +71687-8;PMI - Important information section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Important information section;FDA insert PMI-Important info;;ACTIVE;2.40;2.4 +7168-8;Buttermilk basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Buttermilk triggered histamine release [Units/volume] in Blood;Buttermilk BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71688-6;PMI - Uses section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert PMI - Uses section;FDA insert PMI - Uses section;;ACTIVE;2.40;2.4 +71689-4;Mononuclear cells;NCnc;Pt;Body fld;Qn;Automated count;HEM/BC;1;Mononuclear cells [#/volume] in Body fluid by Automated count;Mononuc Cells # Fld Auto;;ACTIVE;2.40;2.73 +71690-2;Nucleated cells;NCnc;Pt;Body fld;Qn;Automated count;HEM/BC;1;Nucleated cells [#/volume] in Body fluid by Automated count;Nuc cell # Fld Auto;;ACTIVE;2.40;2.73 +71691-0;Hematopoietic progenitor cells;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Hematopoietic progenitor cells [#/volume] in Blood by Automated count;HPC # Bld Auto;;ACTIVE;2.40;2.4 +71692-8;Platelets.reticulated;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Platelets reticulated [#/volume] in Blood by Automated count;Platelets.reticulated # Bld Auto;;ACTIVE;2.40;2.73 +71693-6;Platelets.reticulated/100 platelets;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Platelets reticulated/100 platelets in Blood by Automated count;Platelets.reticulated NFr Bld Auto;;ACTIVE;2.40;2.73 +71694-4;Hemoglobin;EntMass;Pt;Retic;Qn;Automated count;HEM/BC;1;Hemoglobin [Entitic mass] in Reticulocytes by Automated count;Hgb Retic Qn Auto;;ACTIVE;2.40;2.73 +71695-1;Granulocytes.immature/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Immature granulocytes/100 leukocytes in Blood by Automated count;Imm Granulocytes/leuk NFr Bld Auto;;ACTIVE;2.40;2.73 +7169-6;Brassica oleracea var capitata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cabbage IgE Ab [Units/volume] in Serum;Cabbage IgE Qn;;ACTIVE;1.0h(2);2.73 +71696-9;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Body fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Body fluid by Automated count;Polys/leuk NFr Fld Auto;;ACTIVE;2.40;2.5 +71697-7;Mononuclear cells/100 leukocytes;NFr;Pt;Body fld;Qn;Automated count;HEM/BC;1;Mononuclear cells/100 leukocytes in Body fluid by Automated count;Mononuc Cells/leuk NFr Fld Auto;;ACTIVE;2.40;2.5 +71698-5;Polymorphonuclear cells;NCnc;Pt;Body fld;Qn;Automated count;HEM/BC;1;Polymorphonuclear cells [#/volume] in Body fluid by Automated count;Polys # Fld Auto;;ACTIVE;2.40;2.73 +71699-3;Flavivirus Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Flavivirus Ag [Presence] in Specimen by Immune stain;Flavivirus Ag Spec Ql ImStn;;ACTIVE;2.40;2.69 +71700-9;Rotavirus RNA;Prid;Pt;Stool;Nom;Probe.amp.tar;MICRO;1;Rotavirus RNA [Identifier] in Stool by NAA with probe detection;RV RNA Stl NAA+probe;;ACTIVE;2.40;2.73 +71701-7;Rotavirus dsRNA;Prid;Pt;Stool;Nom;PAGE;MICRO;1;Rotavirus dsRNA [Identifier] in Stool by Polyacrylamide gel electrophoresis (PAGE);RV dsRNA Stl PAGE;;ACTIVE;2.40;2.42 +71702-5;Rotavirus dsRNA;Prid;Pt;Isolate;Nom;PAGE;MICRO;1;Rotavirus dsRNA [Identifier] in Isolate by Polyacrylamide gel electrophoresis (PAGE);RV dsRNA Islt PAGE;;ACTIVE;2.40;2.42 +71703-3;Rotavirus Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Rotavirus IgG Ab [Titer] in Serum by Immunoassay;RV IgG Titr Ser IA;;ACTIVE;2.40;2.56 +7170-4;Brassica oleracea var capitata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cabbage IgG Ab [Units/volume] in Serum;Cabbage IgG Qn;;ACTIVE;1.0h(2);2.73 +71704-1;Rotavirus Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rotavirus IgA Ab [Units/volume] in Serum by Immunoassay;RV IgA Ser IA-aCnc;;ACTIVE;2.40;2.56 +71705-8;Rotavirus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Rotavirus Ab [Units/volume] in Serum by Immunoassay;RV Ab Ser IA-aCnc;;ACTIVE;2.40;2.56 +71706-6;Marburg virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Marburg virus IgM Ab [Titer] in Serum by Immunoassay;MARV IgM Titr Ser IA;;ACTIVE;2.40;2.56 +71707-4;Marburg virus Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Marburg virus IgG Ab [Titer] in Serum by Immunoassay;MARV IgG Titr Ser IA;;ACTIVE;2.40;2.56 +71708-2;Marburg virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Marburg virus Ag [Presence] in Specimen by Immunoassay;MARV Ag Spec Ql IA;;ACTIVE;2.40;2.69 +71709-0;Lassa virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Lassa virus IgM Ab [Titer] in Serum by Immunoassay;LASV IgM Titr Ser IA;;ACTIVE;2.40;2.56 +71710-8;Lassa virus Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Lassa virus IgG Ab [Titer] in Serum by Immunoassay;LASV IgG Titr Ser IA;;ACTIVE;2.40;2.56 +71711-6;Ebola virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Ebola virus IgM Ab [Titer] in Serum by Immunoassay;EBOV IgM Titr Ser IA;;ACTIVE;2.40;2.56 +7171-2;Canary feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Canary feather IgE Ab [Units/volume] in Serum;Canary Feather IgE Qn;;ACTIVE;1.0h(2);2.73 +71712-4;Ebola virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ebola virus IgM Ab [Presence] in Serum by Immunoassay;EBOV IgM Ser Ql IA;;ACTIVE;2.40;2.56 +71713-2;Pyruvate kinase;CSub;Pt;RBC;Qn;;CHEM;1;Pyruvate kinase [Enzymatic activity/substance] in Red Blood Cells;PK cSub RBC;;ACTIVE;2.40;2.42 +71714-0;Brucella abortus Ab;PrThr;Pt;Milk;Ord;Aggl.ring test.heat inact;MICRO;1;Brucella abortus Ab [Presence] in Milk by Heat-inactivation ring test;B abortus Ab Mlk Ql HIRT;;ACTIVE;2.40;2.56 +71715-7;Brucella abortus Ab.IgG1+IgG2;PrThr;Pt;Ser;Ord;IA;MICRO;1;Brucella abortus IgG1 and IgG2 Ab [Presence] in Serum by Immunoassay;B abortus IgG1+IgG2 Ser Ql IA;;ACTIVE;2.40;2.56 +71716-5;Brucella suis Ab;Titr;Pt;Ser;Qn;Aggl.standard tube;MICRO;1;Brucella suis Ab [Titer] in Serum by Tube agglutination;B suis Ab Titr Ser Tube aggl;;ACTIVE;2.40;2.4 +71717-3;Brucella suis Ab;Titr;Pt;Ser;Qn;Aggl.plate;MICRO;1;Brucella suis Ab [Titer] in Serum by Plate agglutination;B suis Ab Titr Ser Plate aggl;;ACTIVE;2.40;2.4 +71718-1;Enterococcus sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterococcus sp DNA [Presence] in Specimen by NAA with probe detection;Enterococ DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +71719-9;Mycobacterium avium complex DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycobacterium avium complex DNA [Presence] in Specimen by NAA with probe detection;M avium Cmplx DNA Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +7172-0;Candida albicans Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Candida albicans IgG Ab [Units/volume] in Serum;C albicans IgG Qn;;ACTIVE;1.0h(2);2.73 +71720-7;Address;Addr;Pt;Personnel;Nom;;ADMIN;2;Personnel Address;Personnel Address;;ACTIVE;2.40;2.67 +71722-3;Total score;Score;Pt;^Patient;Qn;AD8;SURVEY.MTLHLTH;4;Total score [AD8];;"Copyright © 2005 The Eight-item Informant Interview to Differentiate Aging and Dementia is a copyrighted instrument of Washington University, St. Louis, Missouri. All Rights Reserved. Washington University grants permission to use and reproduce the Eight-item Informant Interview to Differentiate Aging and Dementia exactly as it appears in the PDF available here without modification or editing of any kind solely for end user use in investigating dementia in clinical care or research in clinical care or research (the ""Purpose""). For the avoidance of doubt, the Purpose does not include the (i) sale, distribution or transfer of the Eight-item Informant Interview to Differentiate Aging and Dementia or copies thereof for any consideration or commercial value; (ii) the creation of any derivative works, including translations; and/or (iii) use of the Eight-item Informant Interview to Differentiate Aging and Dementia as a marketing tool for the sale of any drug.";ACTIVE;2.40;2.67 +71723-1;Cell phone number;Tele;Pt;Personnel;Nom;;ADMIN;2;Personnel Cell phone number;Personnel Cell phone #;;ACTIVE;2.40;2.66 +71724-9;Home phone number;Tele;Pt;Personnel;Nom;;ADMIN;2;Personnel Home phone number;Personnel Home phone #;;ACTIVE;2.40;2.66 +71725-6;Business phone number extension;Tele;Pt;Personnel;Nom;;ADMIN;2;Personnel Business phone number extension;Personnel Business phone # ext;;ACTIVE;2.40;2.66 +71726-4;Business phone number;Tele;Pt;Personnel;Nom;;ADMIN;2;Personnel Business phone number;Personnel Business phone #;;ACTIVE;2.40;2.66 +71727-2;Fax number;Tele;Pt;Personnel;Nom;;ADMIN;2;Personnel Fax number;Personnel Fax #;;ACTIVE;2.40;2.66 +71728-0;Email address;EmailAddr;Pt;Personnel;Nom;;ADMIN;2;Personnel Email address;Personnel Email address;;ACTIVE;2.40;2.66 +71729-8;Nine-digit postal code;Loc;Pt;Personnel;Nom;;ADMIN;2;Personnel Nine-digit postal code;Personnel 9-digit postal code;;ACTIVE;2.40;2.67 +71730-6;Five-digit postal code;Loc;Pt;Personnel;Nom;;ADMIN;2;Personnel Five-digit postal code;Personnel 5-digit postal code;;ACTIVE;2.40;2.67 +71731-4;State;Addr;Pt;Personnel;Nom;;ADMIN;2;Personnel State;Personnel State;;ACTIVE;2.40;2.67 +71732-2;City;Addr;Pt;Personnel;Nom;;ADMIN;2;Personnel City;Personnel City;;ACTIVE;2.40;2.67 +71733-0;Address 2;Addr;Pt;Personnel;Nom;;ADMIN;2;Personnel Address 2;Personnel Address 2;;ACTIVE;2.40;2.67 +71734-8;Preferred mailing address;Addr;Pt;Personnel;Nom;;ADMIN;2;Personnel Preferred mailing address;Personnel Preferred mailing addr;;ACTIVE;2.40;2.67 +71735-5;Credentials;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel Credentials;Personnel Credentials;;ACTIVE;2.40;2.7 +71736-3;Name prefix;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel Name prefix;Personnel Name prefix;;ACTIVE;2.40;2.68 +71737-1;Name suffix;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel Name suffix;Personnel Name suffix;;ACTIVE;2.40;2.67 +7173-8;Candida albicans basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Candida albicans triggered histamine release [Units/volume] in Blood;C albicans BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71738-9;Middle initial;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel Middle initial;Personnel Middle initial;;ACTIVE;2.40;2.67 +71739-7;First name;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel First (Given) name;Personnel First name;;ACTIVE;2.40;2.7 +71740-5;Last name;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel Last (Family) name;Personnel Last name;;ACTIVE;2.40;2.7 +71742-1;Date most recent record submitted;Date;Pt;Facility;Qn;ESRD;SURVEY.ESRD;4;Date most recent record submitted Facility [ESRD];;;TRIAL;2.40;2.67 +71743-9;Generic drug facility identification submission;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Generic drug facility identification submission;FDA label Generic facility ID sub;;ACTIVE;2.40;2.67 +71744-7;Health care provider letter;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Health care provider letter;FDA insert Provider letter;;ACTIVE;2.40;2.4 +71745-4;Day closed;Type;Pt;Facility;Nom;;SURVEY.ESRD;4;Day closed Facility;;;ACTIVE;2.40;2.67 +7174-6;Candida sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Candida sp IgG Ab [Units/volume] in Serum;Candida IgG Qn;;ACTIVE;1.0h(2);2.73 +71746-2;Personnel contact information panel;-;Pt;Personnel;-;ESRD;PANEL.SURVEY.ESRD;4;Personnel contact information panel [ESRD] Personnel;;;TRIAL;2.40;2.66 +71747-0;Facility panel;-;Pt;Facility;-;ESRD;PANEL.SURVEY.ESRD;4;Facility panel [ESRD];;;TRIAL;2.40;2.44 +71748-8;Total dialysis stations;Num;Pt;Facility;Qn;ESRD;SURVEY.ESRD;4;Total dialysis stations Facility # [ESRD];;;TRIAL;2.40;2.67 +71749-6;Personnel unique identifier;ID;Pt;Personnel;Nom;;ADMIN.ID;2;Personnel unique identifier;Personnel unique ID;;TRIAL;2.40;2.67 +71750-4;Primary contact phone number extension;Tele;Pt;Facility;Nom;;SURVEY.ESRD;4;Primary contact phone number extension Facility;;;ACTIVE;2.40;2.67 +71751-2;Primary contact phone number;Tele;Pt;Facility;Nom;;SURVEY.ESRD;4;Primary contact phone number Facility;;;ACTIVE;2.40;2.67 +71752-0;Primary contact first name;Pn;Pt;Facility;Nom;;SURVEY.ESRD;4;Primary contact first name Facility;;;ACTIVE;2.40;2.67 +7175-3;Cucumis melo spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Melon IgE Ab [Units/volume] in Serum;Deprecated Melon IgE Qn;;DEPRECATED;1.0h(2);2.69 +71753-8;Primary contact last name;Pn;Pt;Facility;Nom;;SURVEY.ESRD;4;Primary contact last name Facility;;;ACTIVE;2.40;2.67 +71754-6;PTSD score;Score;Pt;^Patient;Qn;M3;SURVEY.MTLHLTH;4;PTSD score [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71755-3;Anxiety score;Score;Pt;^Patient;Qn;M3;SURVEY.MTLHLTH;4;Anxiety score [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71756-1;Score out of range;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;Score out of range [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71757-9;Depression score;Score;Pt;^Patient;Qn;M3;SURVEY.MTLHLTH;4;Depression score [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71758-7;Bipolar score;Score;Pt;^Patient;Qn;M3;SURVEY.MTLHLTH;4;Bipolar score [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71759-5;Rotavirus RNA;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Rotavirus RNA [Identifier] in Isolate by NAA with probe detection;RV RNA Islt NAA+probe;;ACTIVE;2.40;2.63 +71760-3;Rotavirus identified;Prid;Pt;Stool;Nom;Sequencing;MICRO;1;Rotavirus identified in Stool by Sequencing;RV Stl Seq;;ACTIVE;2.40;2.4 +7176-1;Cucumis melo spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Melon IgG Ab [Units/volume] in Serum;Deprecated Melon IgG Qn;;DEPRECATED;1.0h(2);2.69 +71761-1;Rotavirus identified;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus identified in Isolate by Sequencing;RV Islt Seq;;ACTIVE;2.40;2.4 +71762-9;Rotavirus Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rotavirus IgA Ab [Presence] in Serum by Immunoassay;RV IgA Ser Ql IA;;ACTIVE;2.40;2.56 +71763-7;Rotavirus Ab.IgA;Titr;Pt;Ser;Qn;IA;MICRO;1;Rotavirus IgA Ab [Titer] in Serum by Immunoassay;RV IgA Titr Ser IA;;ACTIVE;2.40;2.56 +71764-5;Rotavirus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Rotavirus Ab [Titer] in Serum by Immunoassay;RV Ab Titr Ser IA;;ACTIVE;2.40;2.56 +71765-2;Rotavirus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rotavirus Ab [Presence] in Serum by Immunoassay;RV Ab Ser Ql IA;;ACTIVE;2.40;2.56 +71766-0;Primary contact email;EmailAddr;Pt;Facility;Nom;;SURVEY.ESRD;4;Primary contact email Facility;;;ACTIVE;2.40;2.67 +71767-8;Ebola virus Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Ebola virus IgG Ab [Titer] in Serum by Immunoassay;EBOV IgG Titr Ser IA;;ACTIVE;2.40;2.56 +71768-6;Ebola virus Ag;PrThr;Pt;XXX;Ord;IA;MICRO;1;Ebola virus Ag [Presence] in Specimen by Immunoassay;EBOV Ag Spec Ql IA;;ACTIVE;2.40;2.69 +71769-4;Marburg virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Marburg virus IgG Ab [Presence] in Serum by Immunoassay;MARV IgG Ser Ql IA;;ACTIVE;2.40;2.56 +71770-2;Ebola virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ebola virus IgG Ab [Presence] in Serum by Immunoassay;EBOV IgG Ser Ql IA;;ACTIVE;2.40;2.56 +71771-0;Marburg virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Marburg virus IgM Ab [Presence] in Serum by Immunoassay;MARV IgM Ser Ql IA;;ACTIVE;2.40;2.56 +71772-8;Mitogen stimulated gamma interferon;ACnc;Pt;Bld;Qn;;MICRO;1;Mitogen stimulated gamma interferon [Units/volume] in Blood;Mitogen IGNF Bld-aCnc;;ACTIVE;2.40;2.73 +71773-6;Mycobacterium tuberculosis stimulated gamma interferon;Imp;Pt;Bld;Ord;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon [Interpretation] in Blood Qualitative;M TB IFN-g Bld-Imp;;ACTIVE;2.40;2.73 +71774-4;Mitogen stimulated gamma interferon^^corrected for background;ACnc;Pt;Bld;Qn;;MICRO;1;Mitogen stimulated gamma interferon [Units/volume] corrected for background in Blood;Mitogen IGNF bckgrd cor Bld-aCnc;;ACTIVE;2.40;2.73 +71775-1;Mycobacterium tuberculosis stimulated gamma interferon panel;-;Pt;Bld;-;;PANEL.MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon panel - Blood;M TB IFN-g Pnl Bld;;ACTIVE;2.40;2.73 +71776-9;Gamma interferon background;ACnc;Pt;Bld;Qn;IA;MICRO;1;Gamma interferon background [Units/volume] in Blood by Immunoassay;Gamma interferon background Bld IA-aCnc;;ACTIVE;2.40;2.73 +71777-7;Total score;Score;Pt;^Patient;Qn;M3;SURVEY.MTLHLTH;4;Total score [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71778-5;Rift valley fever virus Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rift valley fever virus Ag [Presence] in Serum by Immunoassay;RVFV Ag Ser Ql IA;;ACTIVE;2.40;2.56 +7177-9;Cucumis melo spp basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Deprecated Melon triggered histamine release [Units/volume] in Blood;Deprecated Melon BasoBnd Ab Qn;;DEPRECATED;1.0h(2);2.69 +71779-3;Rift valley fever virus Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Rift valley fever virus IgM Ab [Titer] in Serum by Immunoassay;RVFV IgM Titr Ser IA;;ACTIVE;2.40;2.56 +71780-1;Rift valley fever virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rift valley fever virus IgG Ab [Presence] in Serum by Immunoassay;RVFV IgG Ser Ql IA;;ACTIVE;2.40;2.56 +71781-9;Rift valley fever virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rift valley fever virus IgM Ab [Presence] in Serum by Immunoassay;RVFV IgM Ser Ql IA;;ACTIVE;2.40;2.56 +71782-7;Yellow fever virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Yellow fever virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;YFV IgM CSF Ql IA;;ACTIVE;2.40;2.56 +71783-5;Yellow fever virus Ab.Neut;Titr;Pt;CSF;Qn;Neut;MICRO;1;Yellow fever virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test;YFV NAb Titr CSF Nt;;ACTIVE;2.40;2.72 +71784-3;Rift valley fever virus Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Rift valley fever virus IgG Ab [Titer] in Serum by Immunoassay;RVFV IgG Titr Ser IA;;ACTIVE;2.40;2.56 +71785-0;Exam findings communicated to clinician managing diabetic care;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Exam findings communicated to clinician managing diabetic care;;;ACTIVE;2.40;2.67 +71786-8;Staphylococcus aureus exfoliative toxin A eta gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus exfoliative toxin A eta gene [Presence] in Specimen by NAA with probe detection;S aureus eta gene Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +7178-7;Carum carvi Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Caraway IgE Ab [Units/volume] in Serum;Caraway IgE Qn;;ACTIVE;1.0h(2);2.73 +71787-6;Staphylococcus aureus exfoliative toxin B etb gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus exfoliative toxin B etb gene [Presence] in Specimen by NAA with probe detection;S aureus etb gene Spec Ql NAA+probe;;ACTIVE;2.40;2.69 +71788-4;Neisseria meningitidis DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Identifier] in Specimen by NAA with probe detection;N men DNA Spec NAA+probe;;ACTIVE;2.40;2.69 +71789-2;Change in systolic blood pressure;PressDiff;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Change in systolic blood pressure;;;ACTIVE;2.40;2.67 +717-9;Hemoglobin;PrThr;Pt;Bld;Ord;;HEM/BC;1;Hemoglobin [Presence] in Blood;Hgb Bld Ql;;ACTIVE;1.0;2.73 +71790-0;Calcium;SCnc;XXX;Urine;Qn;;CHEM;1;Calcium [Moles/volume] in Urine collected for unspecified duration;Calcium ?Tm Ur-sCnc;;ACTIVE;2.40;2.73 +71791-8;Metanephrines;SCnc;24H;Urine;Qn;;CHEM;1;Metanephrines [Moles/volume] in 24 hour Urine;MetanephS 24h Ur-sCnc;;ACTIVE;2.40;2.73 +71792-6;Procollagen type III.N-terminal propeptide;MCnc;Pt;Ser;Qn;;CHEM;1;Procollagen type III.N-terminal propeptide [Mass/volume] in Serum;Procollagen III.N-term propep Ser-mCnc;;ACTIVE;2.40;2.52 +71793-4;Treponema pallidum Ab;Titr;Pt;Ser/Plas;Qn;Aggl;MICRO;1;Treponema pallidum Ab [Titer] in Serum or Plasma by Agglutination;T pallidum Ab Titr SerPl Aggl;;ACTIVE;2.40;2.4 +71794-2;Expiratory gas flow.max^pre therapy;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory gas flow Respiratory system airway --pre therapy;PEF pre therapy Airway;;ACTIVE;2.40;2.67 +7179-5;Ceratonia siliqua Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Carob IgE Ab [Units/volume] in Serum;Carob IgE Qn;;ACTIVE;1.0h(2);2.73 +71795-9;Expiratory gas flow.max^pre therapy;VRat;Pt;Respiratory system.airway;Qn;Peak flow meter;PULM;2;Maximum expiratory gas flow Respiratory system airway by Peak flow meter --pre therapy;PEF pre therapy Airway PFM;;ACTIVE;2.40;2.67 +71796-7;Promyelocytic leukemia protein distribution pattern;Imp;Pt;Bld/Tiss;Ord;IF;CHEM;1;Promyelocytic leukemia protein distribution pattern [Interpretation] in Blood or Tissue Qualitative by Immunofluorescence;PML protein pattern Bld/T IF-Imp;;ACTIVE;2.40;2.42 +71797-5;Protoporphyrin.zinc;SCnc;Pt;RBC;Qn;;CHEM;1;Protoporphyrin.zinc [Moles/volume] in Red Blood Cells;ZPP RBC-sCnc;;ACTIVE;2.40;2.73 +71798-3;Reason immunization not given;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Reason immunization not given;;;TRIAL;2.40;2.67 +71799-1;Adherence to prescribed medication instructions;Find;Pt;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Adherence to prescribed medication instructions [Reported];;;TRIAL;2.40;2.67 +71800-7;Reason medication not prescribed;Type;Pt;^Patient;Nom;Reported;SURVEY.GNHLTH;4;Reason medication not prescribed [Reported];;;TRIAL;2.40;2.67 +71801-5;Reason for intervention refusal;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Reason for intervention refusal;;;TRIAL;2.40;2.67 +71802-3;Housing status;Type;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Housing status;;;ACTIVE;2.40;2.72 +7180-3;Daucus carota Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Carrot IgG Ab [Units/volume] in Serum;Carrot IgG Qn;;ACTIVE;1.0h(2);2.73 +71803-1;Client status;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Client status;;;TRIAL;2.40;2.67 +71804-9;Serotonin;EntSub;Pt;Platelets;Qn;;CHEM;1;Serotonin [Entitic substance] in Platelets;Serotonin EntSub Plts;;ACTIVE;2.40;2.61 +71805-6;Cortisol.free/Cortisone.free;SRto;Pt;Urine;Qn;;CHEM;1;Cortisol Free/Cortisone free [Molar ratio] in Urine;Cortis F/Cortisone Free Ur-sRto;;ACTIVE;2.40;2.42 +71806-4;I feel sad, down in the dumps or unhappy since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel sad, down in the dumps or unhappy since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71807-2;Nothing seems to give me much pleasure since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;Nothing seems to give me much pleasure since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71808-0;I feel tired - have no energy since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel tired - have no energy since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71809-8;I have had thoughts of suicide since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have had thoughts of suicide since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71810-6;I have difficulty sleeping since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have difficulty sleeping since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +7181-1;Daucus carota basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Carrot triggered histamine release [Units/volume] in Blood;Carrot BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71811-4;I have been sleeping too much since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have been sleeping too much since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71812-2;I have lost some appetite since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have lost some appetite since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71813-0;I have been eating more since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have been eating more since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71814-8;I feel tense, anxious or can't sit still since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel tense, anxious or can't sit still since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71815-5;I feel worried or fearful since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel worried or fearful since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71816-3;I have attacks of anxiety or panic since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have attacks of anxiety or panic since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71817-1;I worry about dying or losing control since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I worry about dying or losing control since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71818-9;I am nervous or shaky in social situations since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I am nervous or shaky in social situations since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71819-7;I have nightmares or flashbacks since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I have nightmares or flashbacks since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71820-5;I am jumpy or feel startled easily since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I am jumpy or feel startled easily since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71821-3;I avoid places that strongly remind me of a bad experience since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I avoid places that strongly remind me of a bad experience since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71822-1;I feel dull, numb, or detached since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel dull, numb, or detached since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71823-9;I can't get certain things out of my mind since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I can't get certain things out of my mind since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71824-7;I feel I must repeat certain acts or rituals since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel I must repeat certain acts or rituals since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71825-4;I feel the need to check and recheck things since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I feel the need to check and recheck things since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71826-2;I can't concentrate or focus since I took my last screen;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;I can't concentrate or focus since I took my last screen [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71827-0;Score interpretation;Find;Pt;^Patient;Ord;M3;SURVEY.MTLHLTH;4;Score interpretation [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.67 +71828-8;Hematocrit;VFr.DF;Pt;Body fld;Qn;;HEM/BC;1;Hematocrit [Pure volume fraction] of Body fluid;Hct VFr.DF Fld;;ACTIVE;2.40;2.4 +7182-9;Casein Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Casein IgG Ab [Units/volume] in Serum;Casein IgG Qn;;ACTIVE;1.0h(2);2.73 +71829-6;Hematocrit;VFr.DF;Pt;BldV;Qn;;HEM/BC;1;Hematocrit [Pure volume fraction] of Venous blood;Hct VFr.DF BldV;;ACTIVE;2.40;2.73 +71830-4;Hematocrit;VFr.DF;Pt;BldMV;Qn;;HEM/BC;1;Hematocrit [Pure volume fraction] of Mixed venous blood;Hct VFr.DF BldMV;;ACTIVE;2.40;2.4 +71831-2;Hematocrit;VFr.DF;Pt;BldC;Qn;;HEM/BC;1;Hematocrit [Pure volume fraction] of Capillary blood;Hct VFr.DF BldC;;ACTIVE;2.40;2.4 +71832-0;Hematocrit;VFr.DF;Pt;BldA;Qn;;HEM/BC;1;Hematocrit [Pure volume fraction] of Arterial blood;Hct VFr.DF BldA;;ACTIVE;2.40;2.4 +71833-8;Hematocrit;VFr.DF;Pt;Bld;Qn;Automated count;HEM/BC;1;Hematocrit [Pure volume fraction] of Blood by Automated count;Hct VFr.DF Bld Auto;;ACTIVE;2.40;2.73 +71834-6;Cryoglobulin/Serum.total;VFr.DF;Pt;Ser;Qn;Spun Westergren tube;CHEM;1;Cryoglobulin/Serum.total [Pure volume fraction] in Serum by Spun Westergren;Cryoglob VFr.DF Ser Spun Westergren;;ACTIVE;2.40;2.4 +71835-3;Oxygen/Gas.total;VFr.DF;Pt;Inhl gas;Qn;;CLIN;2;Oxygen/Gas total [Pure volume fraction] Inhaled gas;FIO2;;ACTIVE;2.40;2.73 +71836-1;Oxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldV;Qn;;CHEM;1;Oxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Venous blood;OxyHgb MFr.DF BldV;;ACTIVE;2.40;2.73 +7183-7;Anacardium occidentale Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cashew nut IgG Ab [Units/volume] in Serum;Cashew nut IgG Qn;;ACTIVE;1.0h(2);2.73 +71837-9;Oxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldMV;Qn;;CHEM;1;Oxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Mixed venous blood;OxyHgb MFr.DF BldMV;;ACTIVE;2.40;2.4 +71838-7;Oxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldC;Qn;;CHEM;1;Oxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Capillary blood;OxyHgb MFr.DF BldC;;ACTIVE;2.40;2.4 +71839-5;Oxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldA;Qn;;CHEM;1;Oxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Arterial blood;OxyHgb MFr.DF BldA;;ACTIVE;2.40;2.73 +71840-3;Oxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;CHEM;1;Oxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Blood;OxyHgb MFr.DF Bld;;ACTIVE;2.40;2.73 +71841-1;Oxygen saturation;MFr.DF;Pt;BldV;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation [Pure mass fraction] Calculated from oxygen partial pressure in Venous blood;SaO2 DF BldV from pO2;;ACTIVE;2.40;2.69 +71842-9;Oxygen saturation;MFr.DF;Pt;BldC;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation [Pure mass fraction] Calculated from oxygen partial pressure in Capillary blood;SaO2 DF BldC from pO2;;ACTIVE;2.40;2.69 +71843-7;Oxygen saturation;MFr.DF;Pt;BldA;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation [Pure mass fraction] Calculated from oxygen partial pressure in Arterial blood;SaO2 DF BldA from pO2;;ACTIVE;2.40;2.69 +71844-5;Oxygen saturation;MFr.DF;Pt;Bld;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation [Pure mass fraction] Calculated from oxygen partial pressure in Blood;SaO2 DF Bld from pO2;;ACTIVE;2.40;2.69 +7184-5;Cat dander Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cat dander IgG Ab [Units/volume] in Serum;Cat Dander IgG Qn;;ACTIVE;1.0h(2);2.73 +71845-2;Oxygen saturation;MFr.DF;Pt;BldV;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Venous blood;SaO2 DF BldV;;ACTIVE;2.40;2.73 +71846-0;Oxygen saturation;MFr.DF;Pt;BldMV;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Mixed venous blood;SaO2 DF BldMV;;ACTIVE;2.40;2.73 +71847-8;Oxygen saturation;MFr.DF;Pt;BldCoV;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Venous cord blood;SaO2 DF BldCoV;;ACTIVE;2.40;2.69 +71848-6;Oxygen saturation;MFr.DF;Pt;BldCoA;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Arterial cord blood;SaO2 DF BldCoA;;ACTIVE;2.40;2.73 +71849-4;Oxygen saturation;MFr.DF;Pt;BldCo;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Cord blood;SaO2 DF BldCo;;ACTIVE;2.40;2.69 +71850-2;Oxygen saturation;MFr.DF;Pt;BldC;Qn;Oximetry;CHEM;1;Deprecated Oxygen saturation [Pure mass fraction] in Capillary blood by Oximetry;Deprecated SaO2 DF BldC Oximetry;;DEPRECATED;2.40;2.54 +71851-0;Oxygen saturation;MFr.DF;Pt;BldC;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Capillary blood;SaO2 DF BldC;;ACTIVE;2.40;2.69 +7185-2;Cat dander basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cat dander triggered histamine release [Units/volume] in Blood;Cat Dander BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71852-8;Oxygen saturation;MFr.DF;Pt;BldA;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Arterial blood;SaO2 DF BldA;;ACTIVE;2.40;2.69 +71853-6;Oxygen saturation;MFr.DF;Pt;Bld;Qn;;CHEM;1;Oxygen saturation [Pure mass fraction] in Blood;SaO2 DF Bld;;ACTIVE;2.40;2.69 +71854-4;Deoxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldA;Qn;;CHEM;1;Deoxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Arterial blood;DO-Hgb MFr.DF BldA;;ACTIVE;2.40;2.4 +71855-1;Hemoglobin.other/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin.other/Hemoglobin.total [Pure mass fraction] in Blood by Electrophoresis;Hgb Other MFr.DF Bld Elph;;ACTIVE;2.40;2.4 +71856-9;Hemoglobin.other/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin.other/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb Other MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +71857-7;Hemoglobin S/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin S/Hemoglobin.total [Pure mass fraction] in Blood;Hgb S MFr.DF Bld;;ACTIVE;2.40;2.4 +71858-5;Hemoglobin S/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin S/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb S MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +71859-3;Hemoglobin S/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin S/Hemoglobin.total [Pure mass fraction] in Blood by Electrophoresis;Hgb S MFr.DF Bld Elph;;ACTIVE;2.40;2.4 +7186-0;Cat hair Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cat hair IgE Ab [Units/volume] in Serum;Deprecated Cat Hair IgE Qn;;DEPRECATED;1.0h(2);2.69 +71860-1;Hemoglobin M/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin M/Hemoglobin.total [Pure mass fraction] in Blood;Hgb M MFr.DF Bld;;ACTIVE;2.40;2.4 +71861-9;Hemoglobin Lepore/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin Lepore/Hemoglobin.total [Pure mass fraction] in Blood;Hgb Lepore MFr.DF Bld;;ACTIVE;2.40;2.4 +71862-7;Hemoglobin H/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin H/Hemoglobin.total [Pure mass fraction] in Blood by Electrophoresis;Hgb H MFr.DF Bld Elph;;ACTIVE;2.40;2.4 +71863-5;Hemoglobin F/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;Kleihauer-Betke;HEM/BC;1;Hemoglobin F/Hemoglobin.total [Pure mass fraction] in Blood by Kleihauer-Betke method;Hgb F MFr.DF Bld Kleih Betke;;ACTIVE;2.40;2.4 +71864-3;Hemoglobin F/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin F/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb F MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +71865-0;Hemoglobin F/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin F/Hemoglobin.total [Pure mass fraction] in Blood by Electrophoresis;Hgb F MFr.DF Bld Elph;;ACTIVE;2.40;2.4 +71866-8;Hemoglobin E/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin E/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb E MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +71867-6;Hemoglobin D/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin D/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb D MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +71868-4;Hemoglobin D/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin D/Hemoglobin.total [Pure mass fraction] in Blood;Hgb D MFr.DF Bld;;ACTIVE;2.40;2.4 +71869-2;Hemoglobin C/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin C/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb C MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +718-7;Hemoglobin;MCnc;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Blood;Hgb Bld-mCnc;;ACTIVE;1.0;2.73 +71870-0;Hemoglobin C/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin C/Hemoglobin.total [Pure mass fraction] in Blood;Hgb C MFr.DF Bld;;ACTIVE;2.40;2.4 +71871-8;Hemoglobin Barts/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin Barts/Hemoglobin.total [Pure mass fraction] in Blood;Hgb Barts MFr.DF Bld;;ACTIVE;2.40;2.4 +71872-6;Hemoglobin A2/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A2/Hemoglobin.total [Pure mass fraction] in Blood;Hgb A2 MFr.DF Bld;;ACTIVE;2.40;2.4 +71873-4;Hemoglobin A2/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin A2/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb A2 MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +71874-2;Hemoglobin A2/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A2/Hemoglobin.total [Pure mass fraction] in Blood by Electrophoresis;Hgb A2 MFr.DF Bld Elph;;ACTIVE;2.40;2.4 +71875-9;Hemoglobin A1c/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;CHEM;1;Hemoglobin A1c/Hemoglobin.total [Pure mass fraction] in Blood;HbA1c MFr.DF Bld;;ACTIVE;2.40;2.73 +71876-7;Hemoglobin A/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin A/Hemoglobin.total [Pure mass fraction] in Blood;Hgb A MFr.DF Bld;;ACTIVE;2.40;2.4 +71877-5;Hemoglobin A/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;HPLC;HEM/BC;1;Hemoglobin A/Hemoglobin.total [Pure mass fraction] in Blood by HPLC;Hgb A MFr.DF Bld HPLC;;ACTIVE;2.40;2.4 +7187-8;Ictalurus punctatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Catfish IgE Ab [Units/volume] in Serum;Catfish IgE Qn;;ACTIVE;1.0h(2);2.73 +71878-3;Hemoglobin A/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin A/Hemoglobin.total [Pure mass fraction] in Blood by Electrophoresis;Hgb A MFr.DF Bld Elph;;ACTIVE;2.40;2.4 +71879-1;Methemoglobin/Hemoglobin.total;MFr.DF;Pt;BldV;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total [Pure mass fraction] in Venous blood;MetHgb MFr.DF BldV;;ACTIVE;2.40;2.69 +71880-9;Methemoglobin/Hemoglobin.total;MFr.DF;Pt;BldMV;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total [Pure mass fraction] in Mixed venous blood;MetHgb MFr.DF BldMV;;ACTIVE;2.40;2.69 +71881-7;Methemoglobin/Hemoglobin.total;MFr.DF;Pt;BldC;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total [Pure mass fraction] in Capillary blood;MetHgb MFr.DF BldC;;ACTIVE;2.40;2.69 +71882-5;Methemoglobin/Hemoglobin.total;MFr.DF;Pt;BldA;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total [Pure mass fraction] in Arterial blood;MetHgb MFr.DF BldA;;ACTIVE;2.40;2.69 +71883-3;Methemoglobin/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total [Pure mass fraction] in Blood;MetHgb MFr.DF Bld;;ACTIVE;2.40;2.69 +71884-1;Carboxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldV;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Venous blood;COHgb MFr.DF BldV;;ACTIVE;2.40;2.4 +71885-8;Carboxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldMV;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Mixed venous blood;COHgb MFr.DF BldMV;;ACTIVE;2.40;2.4 +7188-6;Ictalurus punctatus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Catfish triggered histamine release [Units/volume] in Blood;Catfish BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71886-6;Carboxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldCoV;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Venous cord blood;COHgb MFr.DF BldCoV;;ACTIVE;2.40;2.4 +71887-4;Carboxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldCoA;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Arterial cord blood;COHgb MFr.DF BldCoA;;ACTIVE;2.40;2.4 +71888-2;Carboxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldC;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Capillary blood;COHgb MFr.DF BldC;;ACTIVE;2.40;2.4 +71889-0;Carboxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;BldA;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Arterial blood;COHgb MFr.DF BldA;;ACTIVE;2.40;2.4 +71890-8;Carboxyhemoglobin/Hemoglobin.total;MFr.DF;Pt;Bld;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total [Pure mass fraction] in Blood;COHgb MFr.DF Bld;;ACTIVE;2.40;2.4 +71891-6;M3 Checklist - follow-up;-;Pt;^Patient;-;M3;PANEL.SURVEY.MTLHLTH;4;M3 Checklist - follow-up [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.40;2.5 +71892-4;Cortisone^AM peak specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisone [Moles/volume] in Saliva (oral fluid) --AM peak specimen;Cortisone AM peak Sal-sCnc;;ACTIVE;2.40;2.42 +71893-2;Cortisone^PM trough specimen;SCnc;Pt;Saliva;Qn;;CHAL;1;Cortisone [Moles/volume] in Saliva (oral fluid) --PM trough specimen;Cortisone PM Sal-sCnc;;ACTIVE;2.40;2.42 +7189-4;Typhaceae sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cattail IgE Ab [Units/volume] in Serum;Cattail IgE Qn;;ACTIVE;1.0h(2);2.42 +71894-0;Cortisone.free;SRat;24H;Urine;Qn;;CHEM;1;Cortisone free [Moles/time] in 24 hour Urine;Cortisone free 24h Ur-sRate;;ACTIVE;2.40;2.42 +71895-7;Pediatric blood pressure screening results;Imp;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Pediatric blood pressure screening results;;;ACTIVE;2.40;2.67 +71896-5;Pediatric blood pressure percentile;Prctl;Pt;^Patient;Qn;Per age, sex and height;SURVEY.GNHLTH;4;Pediatric blood pressure percentile [Per age, sex and height];;;ACTIVE;2.40;2.67 +71897-3;Compared to one Y ago, how would you rate your emotional problems, such as feeling anxious,depressed or irritable, now;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Compared to one year ago, how would you rate your emotional problems, such as feeling anxious,depressed or irritable, now [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71898-1;Compared to one Y ago, how would you rate your physical health in general now;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Compared to one year ago, how would you rate your physical health in general now [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71899-9;My health is excellent;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;My health is excellent [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71900-5;I expect my health to get worse;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;I expect my health to get worse [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71901-3;I am as healthy as anyone I know;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;I am as healthy as anyone I know [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7190-2;Brassica oleracea var botrytis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cauliflower IgG Ab [Units/volume] in Serum;Cauliflower IgG Qn;;ACTIVE;1.0h(2);2.73 +71902-1;I seem to get sick a lot easier than other people;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;I seem to get sick a lot easier than other people [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71903-9;During the past 4W, how much of the time has your physical health or emotional problems interfered with your social activities - like visiting with friends, relatives, etc.;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities - like visiting with friends, relatives, etc. [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71904-7;Did you feel tired during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Did you feel tired during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71905-4;Have you been a happy person during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Have you been a happy person during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71906-2;Did you feel worn out during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Did you feel worn out during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71907-0;Have you felt downhearted and blue during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Have you felt downhearted and blue during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71908-8;Did you have a lot of energy during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Did you have a lot of energy during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71909-6;Have you felt calm and peaceful during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Have you felt calm and peaceful during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7191-0;Brassica oleracea var botrytis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cauliflower triggered histamine release [Units/volume] in Blood;Cauliflower BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71910-4;Have you felt so down in the dumps that nothing could cheer you up during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Have you felt so down in the dumps that nothing could cheer you up during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71911-2;Have you been a very nervous person during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Have you been a very nervous person during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71912-0;Did you feel full of pep during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;Did you feel full of pep during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71913-8;During the past 4W, how much did pain interfere with your normal work - including both work outside the home and house work;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;During the past 4 weeks, much did pain interfere with your normal work - including both work outside the home and house work [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71914-6;How much bodily pain have you had during the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;How much bodily pain have you had during the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71915-3;During the past 4W, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors or groups;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors or groups [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71916-1;As a result of any emotional problems, you didn't do work or other activities as carefully as usual in the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;As a result of any emotional problems, you didn't do work or other activities as carefully as usual in the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71917-9;As a result of any emotional problems, have you accomplished less than you would like in the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;As a result of any emotional problems, have you accomplished less than you would like in the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71918-7;As a result of any emotional problems, have you cut down the amount of time you spent on work or other activities in the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;As a result of any emotional problems, have you cut down the amount of time you spent on work or other activities in the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71919-5;As a result of your physical health, have you had difficulty performing the work or other activities - for example, it took extra effort in the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;As a result of your physical health, have you had difficulty performing the work or other activities - for example, it took extra effort in the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71920-3;As a result of your physical health, were you limited in the kind of work in the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;As a result of your physical health, were you limited in the kind of work in the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71921-1;As a result of your physical health, have you accomplished less than you would like in the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;As a result of your physical health, have you accomplished less than you would like in the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71922-9;As a result of your physical health, have you cut down the amount of time you spent on work or other activities in the past 4W;Find;4W;^Patient;Ord;VR;SURVEY.GNHLTH;4;As a result of your physical health, have you cut down the amount of time you spent on work or other activities in the past 4 weeks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71923-7;Does your health now limit you in bathing or dressing yourself;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in bathing or dressing yourself [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71924-5;Does your health now limit you in walking one block;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in walking one block [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71925-2;Does your health now limit you in walking several blocks;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in walking several blocks [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71926-0;Does your health now limit you in walking more than a mile;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in walking more than a mile [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71927-8;Does your health now limit you in bending, kneeling, stooping;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in bending, kneeling, stooping [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7192-8;Cedar dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cedar dust IgE Ab [Units/volume] in Serum;Cedar Dust IgE Qn;;ACTIVE;1.0h(2);2.42 +71928-6;Does your health now limit you in climbing one flight of stairs;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in climbing one flight of stairs [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71929-4;Does your health now limit you in climbing several flights of stairs;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in climbing several flights of stairs [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71930-2;Does your health now limit you in lifting or carrying groceries;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in lifting or carrying groceries [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71931-0;Does your health now limit you in moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or playing golf;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or playing golf [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71932-8;Does your health now limit you in vigorous activities, such as running, lifting heavy objects, participating in strenuous sports;Find;Pt;^Patient;Ord;VR;SURVEY.GNHLTH;4;Does your health now limit you in vigorous activities, such as running, lifting heavy objects, participating in strenuous sports [Veterans RAND];;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71933-6;Veterans RAND health survey - 36 item;-;Pt;^Patient;-;VR;PANEL.SURVEY.GNHLTH;4;Veterans Rand health survey - 36 item (VR-36);;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.69 +71934-4;Veterans RAND health survey - 12 item;-;Pt;^Patient;-;VR;PANEL.SURVEY.GNHLTH;4;Veterans Rand health survey - 12 item (VR-12);;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.69 +71935-1;Parents' evaluation of developmental status - developmental milestones;-;Pt;^Patient;-;P.E.D.S.-DM;PANEL.SURVEY.GNHLTH;4;Parents' evaluation of developmental status - developmental milestones (PEDS_DM) [P.E.D.S.-DM];;Copyright © 2012 Frances Page Glascoe, PEDStest.com. Used with permission.;ACTIVE;2.40;2.5 +7193-6;Juniperus sabinoides Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mountain Juniper IgG Ab [Units/volume] in Serum;Mt Juniper IgG Qn;;ACTIVE;1.0h(2);2.73 +71936-9;Parents' evaluation of developmental status;-;Pt;^Patient;-;P.E.D.S.;PANEL.SURVEY.GNHLTH;4;Parents' Evaluation of Developmental Status (PEDS) [P.E.D.S.];;Copyright © 2012 Frances Page Glascoe, PEDStest.com. Used with permission.;ACTIVE;2.40;2.5 +71937-7;Tolerance, worried, eye- opener, amnesia, cutdown screening test;-;Pt;^Patient;-;TWEAK;PANEL.SURVEY.GNHLTH;4;Tolerance, worried, eye- opener, amnesia, cutdown screening test [TWEAK];;;TRIAL;2.40;2.44 +71938-5;Total score;Score;Pt;^Patient;Qn;MLHFQ;SURVEY.MLHFQ;4;Total score [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.40;2.61 +71939-3;Minnesota Living with Heart Failure Questionnaire;-;Pt;^Patient;-;MLHFQ;PANEL.SURVEY.MLHFQ;4;Minnesota Living with Heart Failure Questionnaire [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.40;2.61 +71940-1;Overall summary score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Overall summary score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.40;2.67 +71941-9;Kansas City cardiomyopathy questionnaire;-;Pt;^Patient;-;KCCQ;PANEL.SURVEY.GNHLTH;4;Kansas City Cardiomyopathy Questionnaire [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.40;2.5 +71942-7;Car, relax, alone, forget, friends, trouble screening test;-;Pt;^Patient;-;CRAFFT;PANEL.SURVEY.GNHLTH;4;Car, Relax, Alone, Forget, Friends, Trouble Screening Test [CRAFFT];;Copyright © 2009 Children's Hospital Boston. Used with permission.;ACTIVE;2.40;2.67 +71943-5;Michigan alcoholism screening test - geriatric version;-;Pt;^Patient;-;MAST-G;PANEL.SURVEY.GNHLTH;4;Michigan Alcoholism Screening Test - Geriatric Version [MAST-G];;Copyright © 1991 The Regents of the University of Michigan. Used with permission.;ACTIVE;2.40;2.5 +7194-4;Juniperus sabinoides basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Mountain Juniper triggered histamine release [Units/volume] in Blood;Mt Juniper BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71944-3;Michigan alcoholism screening test;-;Pt;^Patient;-;MAST;PANEL.SURVEY.GNHLTH;4;Michigan Alcoholism Screening Test [MAST];;;ACTIVE;2.40;2.46 +71945-0;Ascertain dementia 8;-;Pt;^Patient;-;AD8;PANEL.SURVEY.MTLHLTH;4;Ascertain Dementia 8 [AD8];;"Copyright © 2005 The Eight-item Informant Interview to Differentiate Aging and Dementia is a copyrighted instrument of Washington University, St. Louis, Missouri. All Rights Reserved. Washington University grants permission to use and reproduce the Eight-item Informant Interview to Differentiate Aging and Dementia exactly as it appears in the PDF available here without modification or editing of any kind solely for end user use in investigating dementia in clinical care or research in clinical care or research (the ""Purpose""). For the avoidance of doubt, the Purpose does not include the (i) sale, distribution or transfer of the Eight-item Informant Interview to Differentiate Aging and Dementia or copies thereof for any consideration or commercial value; (ii) the creation of any derivative works, including translations; and/or (iii) use of the Eight-item Informant Interview to Differentiate Aging and Dementia as a marketing tool for the sale of any drug.";ACTIVE;2.40;2.52 +71946-8;Short informant questionnaire on cognitive decline in the elderly;-;Pt;^Patient;-;IQCODE;PANEL.SURVEY.MTLHLTH;4;Short Informant Questionnaire on Cognitive Decline in the Elderly [IQCODE];;Copyright © Anthony Jorm. Used with permission.;ACTIVE;2.40;2.5 +71947-6;St. Louis University mental status examination;-;Pt;^Patient;-;SLUMS;PANEL.SURVEY.MTLHLTH;4;St. Louis University Mental Status (SLUMS) Examination [SLUMS];;Copyright © Saint Louis University/Department of Veterans Affairs. Used with permission.;ACTIVE;2.40;2.46 +71948-4;Hip and knee outcomes questionnaire;-;Pt;^Patient;-;HKOI;PANEL.SURVEY.GNHLTH;4;Hip and knee outcomes questionnaire [HKOI];;Copyright © American Academy of Orthopaedic Surgeons. Used with permission.;ACTIVE;2.40;2.52 +71949-2;Falls behavioral scale for older people;-;Pt;^Patient;-;FaB;PANEL.SURVEY.GNHLTH;4;Falls Behavioral Scale for Older People [FaB];;Copyright © 2003 Clemson, Cumming & Heard. Used with permission.;ACTIVE;2.40;2.5 +719-5;Hemoglobin;MCnc;Pt;CSF;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Cerebral spinal fluid;Hgb CSF-mCnc;;ACTIVE;1.0;2.34 +71950-0;Health assessment questionnaire;-;Pt;^Patient;-;HAQ;PANEL.SURVEY.HAQ;4;Health Assessment Questionnaire [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.40;2.65 +7195-1;Juniperus virginiana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Cedar IgE Ab [Units/volume] in Serum;Red Cedar IgE Qn;;ACTIVE;1.0h(2);2.73 +71951-8;Infant development inventory;-;Pt;^Patient;-;IDI;PANEL.SURVEY.GNHLTH;4;Infant Development Inventory [IDI];;Copyright © 1994 Harold R. Ireton. Used with permission.;ACTIVE;2.40;2.5 +71952-6;Child development inventory;-;Pt;^Patient;-;CDI;PANEL.SURVEY.GNHLTH;4;Child Development Inventory [CDI];;Copyright © 1992 Harold R. Ireton. Used with permission.;ACTIVE;2.40;2.46 +71953-4;Bayley infant neurodevelopmental screener;-;Pt;^Patient;-;BINS;PANEL.SURVEY.GNHLTH;4;Bayley Infant Neurodevelopmental Screener [BINS];;"Copyright © 1995 NCS Pearson, Inc. Reproduced with permission. All rights reserved. ""Bayley Infant Neurodevelopmental Screener"" and ""BINS"" are trademarks, in the US and/or other countries, of Pearson Education, Inc. or its affiliates(s).";ACTIVE;2.40;2.46 +71954-2;Ages and stages questionnaires;-;Pt;^Patient;-;ASQ;PANEL.SURVEY.GNHLTH;4;Ages and Stages Questionnaires [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.5 +71955-9;PROMIS-29 Sleep disturbance score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Sleep disturbance score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71956-7;PROMIS-29 Sleep disturbance score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Sleep disturbance score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71957-5;PROMIS-29 Satisfaction with participation in social roles score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Satisfaction with participation in social roles score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71958-3;PROMIS-29 Satisfaction with participation in social roles score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Satisfaction with participation in social roles score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71959-1;PROMIS-29 Physical function score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Physical function score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71960-9;PROMIS-29 Physical function score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Physical function score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71961-7;PROMIS-29 Pain interference score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Pain interference score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71962-5;PROMIS-29 Pain interference score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Pain interference score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71963-3;PROMIS-29 Fatigue score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Fatigue score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71964-1;PROMIS-29 Fatigue score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Fatigue score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71965-8;PROMIS-29 Depression score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Depression score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71966-6;PROMIS-29 Depression score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Depression score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71967-4;PROMIS-29 Anxiety score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Anxiety score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71968-2;PROMIS-29 Anxiety score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-29 Anxiety score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +7196-9;Tamarix spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saltcedar IgE Ab [Units/volume] in Serum;Saltcedar IgE Qn;;ACTIVE;1.0h(2);2.73 +71969-0;PROMIS-10 Global Mental Health score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-10 Global Mental Health (GMH) score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71970-8;PROMIS-10 Global Mental Health score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-10 Global Mental Health (GMH) score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71971-6;PROMIS-10 Global Physical Health score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-10 Global Physical Health (GPH) score T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71972-4;PROMIS-10 Global Physical Health score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.GNHLTH;4;PROMIS-10 Global Physical Health (GPH) score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.40;2.67 +71973-2;VR-36 Mental health score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Mental health (MH) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71974-0;VR-36 Role emotion score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role emotion (RE) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71975-7;VR-36 Social functioning score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Social functioning (SF) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71976-5;VR-36 Vitality score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Vitality (VT) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7197-7;Apium graveolens Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Celery IgG Ab [Units/volume] in Serum;Celery IgG Qn;;ACTIVE;1.0h(2);2.73 +71977-3;VR-36 General health score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 General health (GH) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71978-1;VR-36 Bodily pain score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Bodily pain (BP) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71979-9;VR-36 Role physical score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role physical (RP) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71980-7;VR-36 Physical functioning score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Physical functioning (PF) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71981-5;VR-36 Mental health score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Mental health (MH) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71982-3;VR-36 Role emotion score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role emotion (RE) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71983-1;VR-36 Social functioning score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Social functioning (SF) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71984-9;VR-36 Vitality score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Vitality (VT) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7198-5;Apium graveolens basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Celery triggered histamine release [Units/volume] in Blood;Celery BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +71985-6;VR-36 General health score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 General health (GH) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71986-4;VR-36 Bodily pain score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Bodily pain (BP) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71987-2;VR-36 Role physical score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role physical (RP) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71988-0;VR-36 Physical functioning score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Physical functioning (PF) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71989-8;VR-36 Physical component summary score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Physical component summary (PCS) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71990-6;VR-36 Mental component summary score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Mental component summary (MCS) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71991-4;VR-36 Mental health score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Mental health (MH) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71992-2;VR-36 Role emotion score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role emotion (RE) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7199-3;Cephalosporine mold Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cephalosporine mold IgE Ab [Units/volume] in Serum;Cephalospor Mold IgE Qn;;ACTIVE;1.0h(2);2.73 +71993-0;VR-36 Social functioning score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Social functioning (SF) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71994-8;VR-36 Vitality score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Vitality (VT) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71995-5;VR-36 General health score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 General health (GH) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71996-3;VR-36 Bodily pain score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Bodily pain (BP) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71997-1;VR-36 Role physical score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role physical (RP) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71998-9;VR-36 Physical functioning score - orthogonal method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Physical functioning (PF) score - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +71999-7;VR-36 Mental health score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Mental health (MH) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72000-3;VR-36 Role emotion score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role emotion (RE) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72001-1;VR-36 Social functioning score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Social functioning (SF) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72002-9;VR-36 Vitality score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Vitality (VT) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72003-7;VR-36 General health score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 General health (GH) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72004-5;VR-36 Bodily pain score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Bodily pain (BP) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72005-2;VR-36 Role physical score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Role physical (RP) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72006-0;VR-36 Physical functioning score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Physical functioning (PF) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72007-8;VR-36 Physical component summary score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Physical component summary (PCS) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72008-6;VR-36 Mental component summary score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-36 Mental component summary (MCS) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7200-9;Chaetomium globosum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chaetomium globosum IgE Ab [Units/volume] in Serum;C globosum IgE Qn;;ACTIVE;1.0h(2);2.73 +72009-4;VR-12 Mental health score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Mental health (MH) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72010-2;VR-12 Role emotion score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Role emotion (RE) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72011-0;VR-12 Social functioning score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Social functioning (SF) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72012-8;VR-12 Vitality score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Vitality (VT) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72013-6;VR-12 General health score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 General health (GH) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72014-4;VR-12 Bodily pain score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Bodily pain (BP) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72015-1;VR-12 Role physical score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Role physical (RP) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72016-9;VR-12 Physical functioning score - oblique method;Score;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Physical functioning (PF) score - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7201-7;Cheese American Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American Cheese IgE Ab [Units/volume] in Serum;American Cheese IgE Qn;;ACTIVE;1.0h(2);2.73 +72017-7;VR-12 Mental health score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Mental health (MH) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72018-5;VR-12 Role emotion score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Role emotion (RE) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72019-3;VR-12 Social functioning score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Social functioning (SF) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72020-1;VR-12 Vitality score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Vitality (VT) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72021-9;VR-12 General health score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 General health (GH) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72022-7;VR-12 Bodily pain score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Bodily pain (BP) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72023-5;VR-12 Role physical score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Role physical (RP) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72024-3;VR-12 Physical functioning score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Physical functioning (PF) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +7202-5;Cheese American Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;American Cheese IgG Ab [Units/volume] in Serum;American Cheese IgG Qn;;ACTIVE;1.0h(2);2.69 +72025-0;VR-12 Physical component summary score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Physical component summary (PCS) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72026-8;VR-12 Mental component summary score - oblique method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Mental component summary (MCS) score - oblique method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72027-6;VR-12 Physical component summary score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Physical component summary (PCS) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72028-4;VR-12 Mental component summary score - orthogonal method;Tscore;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Mental component summary (MCS) score - orthogonal method T-score;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.40;2.67 +72029-2;Vaccination exclusion - medical reason;Type;Pt;^Patient;Nom;;SURVEY.ESRD;4;Vaccination exclusion - medical reason;;;TRIAL;2.40;2.67 +720-3;Hemoglobin.free;PrThr;Pt;Plas;Ord;;HEM/BC;1;Free Hemoglobin [Presence] in Plasma;Hgb Free Plas Ql;;ACTIVE;1.0;2.73 +72030-0;Type oral vitamin D analog prescribed;Type;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Type oral vitamin D analog prescribed [ESRD];;;TRIAL;2.40;2.67 +72031-8;Oral vitamin D analog prescribed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Oral vitamin D analog prescribed [ESRD];;;TRIAL;2.40;2.67 +72032-6;Type non-oral vitamin D analog prescribed;Type;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Type non-oral vitamin D analog prescribed [ESRD];;;TRIAL;2.40;2.67 +7203-3;Cheese blue Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blue Cheese IgE Ab [Units/volume] in Serum;Blue Cheese IgE Qn;;ACTIVE;1.0h(2);2.73 +72033-4;Non-oral vitamin D analog prescribed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Non-oral vitamin D analog prescribed [ESRD];;;TRIAL;2.40;2.67 +72034-2;Vitamin D panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Vitamin D panel [ESRD];;;TRIAL;2.40;2.44 +72035-9;Arteriovenous graft assessed frequency;NRat;Pt;^Patient;Qn;;SURVEY.ESRD;4;Arteriovenous graft assessed frequency;;;TRIAL;2.40;2.67 +72036-7;Arteriovenous graft assessed using intra-access flow;Find;Pt;^Patient;Ord;;SURVEY.ESRD;4;Arteriovenous graft assessed using intra-access flow;;;TRIAL;2.40;2.67 +72037-5;Arteriovenous graft assessed frequency;NRat;Pt;^Patient;Qn;US.doppler;SURVEY.ESRD;4;Arteriovenous graft assessed frequency [US.doppler];;;TRIAL;2.40;2.67 +72038-3;Arteriovenous graft assessed using doppler;Find;Pt;^Patient;Ord;US.doppler;SURVEY.ESRD;4;Arteriovenous graft assessed using doppler [US.doppler];;;TRIAL;2.40;2.67 +72039-1;How often was static venous pressure measured;Find;Pt;^Patient;Ord;;SURVEY.ESRD;4;How often was static venous pressure measured;;;ACTIVE;2.40;2.67 +72040-9;Testing of arteriovenous graft performed using static venous pressure;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Testing of arteriovenous graft performed using static venous pressure [ESRD];;;TRIAL;2.40;2.67 +7204-1;Cheese cheddar type Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cheese cheddar type IgG Ab [Units/volume] in Serum;Cheddar IgG Qn;;ACTIVE;1.0h(2);2.73 +72041-7;Testing of arteriovenous graft for access dysfunction performed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Testing of arteriovenous graft for access dysfunction performed [ESRD];;;TRIAL;2.40;2.67 +72042-5;How often was arterial pre-pump pressure measured;NRat;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;How often was arterial pre-pump pressure measured [ESRD];;;TRIAL;2.40;2.67 +72043-3;Measurement of arterial pre-pump pressure performed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Measurement of arterial pre-pump pressure performed [ESRD];;;TRIAL;2.40;2.67 +72044-1;Dialysis access physical exam frequency;NRat;Pt;^Patient;Ord;;SURVEY.ESRD;4;Dialysis access physical exam frequency;;;TRIAL;2.40;2.67 +72045-8;Physical examination dialysis access performed prior, during and after cannulation;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Physical examination dialysis access performed prior, during and after cannulation [ESRD];;;TRIAL;2.40;2.67 +72046-6;Arteriovenous graft status;Find;Pt;^Patient;Nom;;SURVEY.ESRD;4;Arteriovenous graft status;;;TRIAL;2.40;2.67 +72047-4;Arteriovenous fistula status;Find;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Arteriovenous fistula status [ESRD];;;TRIAL;2.40;2.67 +72048-2;Date arteriovenous fistula usable;Date;Pt;^Patient;Qn;;SURVEY.ESRD;4;Date arteriovenous fistula usable;;;ACTIVE;2.40;2.67 +72049-0;Date dialysis session;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date dialysis session [ESRD];;;TRIAL;2.40;2.67 +72050-8;Dialysis access;Type;Pt;^Patient;Nom;;SURVEY.ESRD;4;Dialysis access;;;ACTIVE;2.40;2.72 +72051-6;Date catheter removal;Date;Pt;^Patient;Qn;;SURVEY.ESRD;4;Date catheter removal;;;ACTIVE;2.40;2.67 +72052-4;Date catheter placement;Date;Pt;^Patient;Qn;;SURVEY.ESRD;4;Date catheter placement;;;ACTIVE;2.40;2.67 +72053-2;Date arteriovenous fistula creation;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date arteriovenous fistula creation [ESRD];;;TRIAL;2.40;2.67 +72054-0;Date change of dialysis access type;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date change of dialysis access type [ESRD];;;TRIAL;2.40;2.67 +72055-7;Vascular access panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Vascular access panel [ESRD];;;TRIAL;2.40;2.48 +72056-5;Hepatitis B vaccination received;Find;Pt;^Patient;Ord;;SURVEY.ESRD;4;Hepatitis B vaccination received;;;TRIAL;2.40;2.67 +72057-3;Pneumococcal vaccination been received;Find;Pt;^Patient;Nom;;SURVEY.ESRD;4;Pneumococcal vaccination been received;;;ACTIVE;2.40;2.67 +7205-8;Cheese cheddar type basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cheese cheddar type triggered histamine release [Units/volume] in Blood;Cheddar BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72058-1;Influenza virus vaccination received;Find;Pt;^Patient;Ord;;SURVEY.ESRD;4;Influenza virus vaccination received;;;ACTIVE;2.40;2.67 +72059-9;Vaccination exclusion;Type;Pt;^Patient;Nom;;SURVEY.ESRD;4;Vaccination exclusion;;;TRIAL;2.40;2.67 +72060-7;Where was vaccine received;Loc;Pt;^Patient;Nom;;SURVEY.ESRD;4;Where was vaccine received;;;ACTIVE;2.40;2.67 +72061-5;Vaccination panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Vaccination panel [ESRD];;;TRIAL;2.40;2.44 +72062-3;Medication allergies panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Medication allergies panel [ESRD];;;TRIAL;2.40;2.44 +72063-1;Type oral iron prescribed;Type;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Type oral iron prescribed [ESRD];;;TRIAL;2.40;2.67 +72064-9;Oral iron prescribed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Oral iron prescribed [ESRD];;;TRIAL;2.40;2.67 +72065-6;Type intravenous iron prescribed;Type;Pt;^Patient;Nom;ESRD;SURVEY.ESRD;4;Type intravenous iron prescribed [ESRD];;;TRIAL;2.40;2.67 +7206-6;Cheese cottage Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cottage Cheese IgE Ab [Units/volume] in Serum;Cottage Cheese IgE Qn;;ACTIVE;1.0h(2);2.73 +72066-4;Intravenous iron prescribed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Intravenous iron prescribed [ESRD];;;TRIAL;2.40;2.67 +72067-2;Iron prescription current;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Iron prescription current [ESRD];;;TRIAL;2.40;2.67 +72068-0;Iron panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Iron panel [ESRD];;;TRIAL;2.40;2.44 +72069-8;Sodium profiling-modeling prescribed for any dialysis sessions in the reporting Mo;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Sodium profiling-modeling prescribed for any dialysis sessions in the reporting month [ESRD];;;TRIAL;2.40;2.67 +72070-6;Left ventricular hypertrophy;Find;Pt;^Patient;Ord;;SURVEY.ESRD;4;Left ventricular hypertrophy;;;TRIAL;2.40;2.67 +72071-4;Edema present;Find;Pt;^Patient;Ord;;SURVEY.ESRD;4;Edema present;;;TRIAL;2.40;2.67 +72072-2;Breath sounds;Imp;Pt;^Patient;Ord;;SURVEY.ESRD;4;Breath sounds;;;TRIAL;2.40;2.67 +72073-0;Post-dialysis target weight for session prescribed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Post-dialysis target weight for session prescribed [ESRD];;;TRIAL;2.40;2.67 +7207-4;Cheese cottage Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cottage Cheese IgG Ab [Units/volume] in Serum;Cottage Cheese IgG Qn;;ACTIVE;1.0h(2);2.69 +72074-8;Date last formal post dialysis weight;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date last formal post dialysis weight [ESRD];;;TRIAL;2.40;2.67 +72075-5;Did patient provide the home blood pressure values to the dialysis unit;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Did patient provide the home blood pressure values to the dialysis unit [ESRD];;;TRIAL;2.40;2.67 +72076-3;Blood pressure home reading;Imp;Pt;^Patient;Ord;;SURVEY.ESRD;4;Blood pressure home reading;;;TRIAL;2.40;2.67 +72077-1;Sodium restriction education received;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Sodium restriction education received [ESRD];;;TRIAL;2.40;2.67 +72078-9;Date of echocardiogram;Date;Pt;^Patient;Qn;;SURVEY.ESRD;4;Date of echocardiogram;;;TRIAL;2.40;2.67 +72079-7;Dry weight order present;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Dry weight order present [ESRD];;;TRIAL;2.40;2.67 +72080-5;Did prescribed dialysate sodium concentration exceed 138 mEq/L for any dialysis session during the Mo;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Did prescribed dialysate sodium concentration exceed 138 mEq/L for any dialysis session during the Mo [ESRD];;;TRIAL;2.40;2.67 +72081-3;Date of sodium education;Date;Pt;^Patient;Qn;ESRD;SURVEY.ESRD;4;Date of sodium education [ESRD];;;TRIAL;2.40;2.67 +7208-2;Cheese cream basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cream Cheese triggered histamine release [Units/volume] in Blood;Cream Cheese BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72082-1;Constant dialysate sodium prescribed;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Constant dialysate sodium prescribed [ESRD];;;TRIAL;2.40;2.67 +72083-9;Left ventricular hypertrophy change;Find;Pt;^Patient;Ord;ESRD;SURVEY.ESRD;4;Left ventricular hypertrophy change [ESRD];;;TRIAL;2.40;2.67 +72084-7;Fluid and weight panel;-;Pt;^Patient;-;ESRD;PANEL.SURVEY.ESRD;4;Fluid and weight panel [ESRD];;;TRIAL;2.40;2.44 +72085-4;Vaccination exclusion - patient reason;Type;Pt;^Patient;Nom;ESRD;SURVEY.GNHLTH;4;Vaccination exclusion - patient reason [ESRD];;;TRIAL;2.40;2.67 +72086-2;Brigance screens II;-;Pt;^Patient;-;BS II;PANEL.SURVEY.GNHLTH;4;Brigance Screens II [BS II];;Copyright © 2010, 2008 CURRICULUM ASSOCIATES®, LLC. Used with permission.;ACTIVE;2.40;2.5 +72087-0;Blessed orientation-memory-concentration test;-;Pt;^Patient;-;BOMC;PANEL.SURVEY.MTLHLTH;4;Blessed Orientation-Memory-Concentration Test [BOMC];;;ACTIVE;2.40;2.69 +72088-8;Clinical dementia rating scale;-;Pt;^Patient;-;CDR;PANEL.SURVEY.MTLHLTH;4;Clinical Dementia Rating scale [CDR];;Copyright © Washington University Charles F. and Joanne Knight Alzheimer's Disease Research Center (Knight ADRC). Used with permission.;ACTIVE;2.40;2.5 +72089-6;Total score;Score;Pt;^Patient;Qn;NIHSS;SURVEY.NEURO;4;Total score [NIH Stroke Scale];;;ACTIVE;2.40;2.67 +7209-0;Cheese mozzarella Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mozzarella Cheese IgE Ab [Units/volume] in Serum;Mozzarella IgE Qn;;ACTIVE;1.0h(2);2.73 +72090-4;Identification of CBER-regulated generic drug facility;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Identification of CBER-regulated generic drug facility;FDA label ID of CBER-reg GDF;;ACTIVE;2.40;2.4 +72091-2;Knee injury and osteoarthritis outcome score;-;Pt;^Patient;-;KOOS;PANEL.SURVEY.GNHLTH;4;Knee injury and Osteoarthritis Outcome Score [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.64 +72092-0;Hip dysfunction and osteoarthritis outcome score;-;Pt;^Patient;-;HOOS;PANEL.SURVEY.GNHLTH;4;Hip Dysfunction and Osteoarthritis Outcome Score [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.64 +72093-8;Quality of life score;Score;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Quality of life score [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72094-6;Sport-recreation score;Score;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Sport-recreation score [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72095-3;Activities of daily living score;Score;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Activities of daily living score [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72096-1;Symptoms score;Score;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Symptoms score [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72097-9;Pain score;Score;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Pain score [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72098-7;Quality of life score;Score;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Quality of life score [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72099-5;Sport-recreation score;Score;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Sport-recreation score [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72100-1;Activities of daily living score;Score;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Activities of daily living score [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72101-9;Symptoms score;Score;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Symptoms score [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72102-7;Pain score;Score;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Pain score [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.40;2.67 +72103-5;Acute & chronic leukemia fusion transcript panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;Acute and chronic leukemia fusion transcript panel - Blood or Tissue by Molecular genetics method;Acute+chron leuk Pnl Bld/T;;ACTIVE;2.40;2.44 +72104-3;Acute & chronic leukemia fusion transcript per control transcript panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;Acute and chronic leukemia fusion transcript per control transcript panel - Blood or Tissue by Molecular genetics method;Leuk FTperCT Pnl Bld/T;;ACTIVE;2.42;2.44 +72105-0;Vital signs & oximetry - admission, home health, interim, discharge;-;Pt;^Patient;-;CARE;PANEL.SURVEY.CARE;4;Vital signs and oximetry - admission, home health, interim, discharge [CARE];;;DISCOURAGED;2.40;2.64 +72106-8;Total score;Score;Pt;^Patient;Qn;MMSE;SURVEY.MTLHLTH;4;Total score [MMSE];;Copyright © Vicki King for Psychological Assessment Resources. Used with permission.;ACTIVE;2.40;2.73 +72107-6;Mini-mental state examination;-;Pt;^Patient;-;MMSE;PANEL.SURVEY.MTLHLTH;4;Mini-Mental State Examination [MMSE];;Copyright © Vicki King for Psychological Assessment Resources. Used with permission.;ACTIVE;2.40;2.5 +7210-8;Cheese mozzarella Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mozzarella Cheese IgG Ab [Units/volume] in Serum;Mozzarella IgG Qn;;ACTIVE;1.0h(2);2.69 +72109-2;Alcohol use disorder identification test-consumption;-;Pt;^Patient;-;AUDIT-C;PANEL.SURVEY.GNHLTH;4;Alcohol Use Disorder Identification Test - Consumption [AUDIT-C];;;ACTIVE;2.50;2.5 +721-1;Hemoglobin.free;MCnc;Pt;Plas;Qn;;HEM/BC;1;Free Hemoglobin [Mass/volume] in Plasma;Hgb Free Plas-mCnc;;ACTIVE;1.0;2.73 +72110-0;Alcohol use disorder identification test;-;Pt;^Patient;-;AUDIT;PANEL.SURVEY.GNHLTH;4;Alcohol Use Disorder Identification Test [AUDIT];;Copyright © 2001 World Health Organization. Used with permission.;ACTIVE;2.50;2.7 +72111-8;Sapovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Sapovirus RNA [Presence] in Specimen by NAA with probe detection;Sapovirus RNA Spec Ql NAA+probe;;ACTIVE;2.40;2.73 +72112-6;Reason procedure not performed;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Reason procedure not performed NEMSIS;Reason proced not performed NEMSIS;;ACTIVE;2.40;2.67 +72113-4;Reason medication not given;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Reason medication not given NEMSIS;Reason medication not Gvn NEMSIS;;ACTIVE;2.40;2.67 +72114-2;Complaint;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Complaint NEMSIS;Complaint NEMSIS;;ACTIVE;2.40;2.67 +72115-9;Resuscitation attempted;Type;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Resuscitation attempted NEMSIS;Resuscitation attempted NEMSIS;;ACTIVE;2.40;2.67 +7211-6;Cheese mozzarella basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Mozzarella Cheese triggered histamine release [Units/volume] in Blood;Mozzarella BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72116-7;Total score - Ages and stages questionnaires 36 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 36 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72117-5;Total score - Ages and stages questionnaires 33 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 33 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72118-3;Total score - Ages and stages questionnaires 30 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 30 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72119-1;Total score - Ages and stages questionnaires 27 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 27 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72120-9;Total score - Ages and stages questionnaires 24 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 24 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72121-7;Total score - Ages and stages questionnaires 22 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 22 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72122-5;Total score - Ages and stages questionnaires 20 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 20 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72123-3;Total score - Ages and stages questionnaires 18 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 18 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +7212-4;Cheese parmesan Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parmesan Cheese IgE Ab [Units/volume] in Serum;Parmesan IgE Qn;;ACTIVE;1.0h(2);2.73 +72124-1;Total score - Ages and stages questionnaires 16 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 16 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72125-8;Total score - Ages and stages questionnaires 14 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 14 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72126-6;Total score - Ages and stages questionnaires 12 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 12 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72127-4;Total score - Ages and stages questionnaires 10 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 10 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72128-2;Total score - Ages and stages questionnaires 9 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 9 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72129-0;Total score - Ages and stages questionnaires 8 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 8 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72130-8;Total score - Ages and stages questionnaires 6 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 6 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72131-6;Total score - Ages and stages questionnaires 4 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 4 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +7213-2;Cheese parmesan basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Parmesan Cheese triggered histamine release [Units/volume] in Blood;Parmesan BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72132-4;Total score - Ages and stages questionnaires 2 Mo;Score;Pt;^Patient;Qn;ASQ;SURVEY.GNHLTH;4;Total score - Ages and Stages Questionnaires 2 months [ASQ];;Copyright © 2009 Paul H. Brookes Publishing Co., Inc. Used with permission.;ACTIVE;2.40;2.67 +72133-2;Montreal cognitive assessment;-;Pt;^Patient;-;MoCA;PANEL.SURVEY.MTLHLTH;4;Montreal Cognitive Assessment [MoCA];;Copyright © Tina Brosseau for Center for Diagnosis & Research on Alzheimer's disease (CEDRA). Used with permission.;ACTIVE;2.42;2.5 +72134-0;Cancer event report;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Cancer event report;Cancer event report;;ACTIVE;2.42;2.61 +72135-7;Cancer diagnosis;Find;Pt;Cancer.XXX;Nar;;DOC.MISC;2;Cancer diagnosis Narrative;Cancer Dx;;ACTIVE;2.42;2.42 +72136-5;Risk for venous thromboembolism;Imp;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Risk for venous thromboembolism;;;ACTIVE;2.42;2.67 +72137-3;Multisection diagnostic;Find;Pt;Breast.right;Doc;MG.tomosynthesis;RAD;2;DBT Breast - right diagnostic;DBT Brst-R Dx;;ACTIVE;2.42;2.61 +72138-1;Multisection diagnostic;Find;Pt;Breast.left;Doc;MG.tomosynthesis;RAD;2;DBT Breast - left diagnostic;DBT Brst-L Dx;;ACTIVE;2.42;2.61 +72139-9;Multisection diagnostic;Find;Pt;Breast.bilateral;Doc;MG.tomosynthesis;RAD;2;DBT Breast - bilateral diagnostic;DBT Brst-Bl Dx;;ACTIVE;2.42;2.61 +7214-0;Cheese roquefort Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Roquefort Cheese IgE Ab [Units/volume] in Serum;Roquefort IgE Qn;;ACTIVE;1.0h(2);2.73 +72140-7;Multisection screening;Find;Pt;Breast.right;Doc;MG.tomosynthesis;RAD;2;DBT Breast - right screening;DBT Brst-R Screening;;ACTIVE;2.42;2.61 +72141-5;Multisection screening;Find;Pt;Breast.left;Doc;MG.tomosynthesis;RAD;2;DBT Breast - left screening;DBT Brst-L Screening;;ACTIVE;2.42;2.61 +72142-3;Multisection screening;Find;Pt;Breast.bilateral;Doc;MG.tomosynthesis;RAD;2;DBT Breast - bilateral screening;DBT Brst-Bl Screening;;ACTIVE;2.42;2.61 +72143-1;Sex;Type;Pt;^Patient;Nom;HL7.v3;SURVEY.GNHLTH;4;Sex [HL7.v3];;;ACTIVE;2.42;2.67 +72144-9;Post-natal maternal vital status;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Post-natal maternal vital status [RHEA];;;ACTIVE;2.42;2.67 +72145-6;Perineal tear classification;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Perineal tear classification [RHEA];;;ACTIVE;2.42;2.67 +72146-4;Neonatal vital status at delivery;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Neonatal vital status at delivery [RHEA];;;ACTIVE;2.42;2.67 +72147-2;Gestational age^at birth;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Gestational age--at birth [RHEA];;;ACTIVE;2.42;2.67 +72148-0;Person attending birth;Find;Pt;^Patient;Nom;RHEA;SURVEY.GNHLTH;4;Person attending birth [RHEA];;;ACTIVE;2.42;2.67 +72149-8;Delivery method;Find;Pt;^Patient;Nom;RHEA;SURVEY.GNHLTH;4;Delivery method [RHEA];;;ACTIVE;2.42;2.67 +72150-6;Delivery location;Type;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Delivery location;;;ACTIVE;2.42;2.67 +72151-4;Arrived at clinic with partner;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Arrived at clinic with partner [RHEA];;;ACTIVE;2.42;2.67 +72152-2;Tested for HIV;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Tested for HIV [RHEA];;;ACTIVE;2.42;2.67 +72153-0;Last born child vital status;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Last born child vital status [RHEA];;;ACTIVE;2.42;2.67 +72154-8;Pregnancy risk factors;Find;Pt;^Patient;Nom;RHEA;SURVEY.GNHLTH;4;Pregnancy risk factors [RHEA];;;ACTIVE;2.42;2.67 +72155-5;Position in womb;Find;Pt;^Fetus;Nom;RHEA;SURVEY.GNHLTH;4;Position in womb Fetus [RHEA];;;ACTIVE;2.42;2.67 +72156-3;Rwandan maternal screening panel;-;Pt;^Patient;-;RHEA;PANEL.SURVEY.GNHLTH;4;Rwandan maternal screening panel [RHEA];;;ACTIVE;2.42;2.5 +7215-7;Cheese swiss Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swiss Cheese IgE Ab [Units/volume] in Serum;Swiss Cheese IgE Qn;;ACTIVE;1.0h(2);2.73 +72157-1;Apo-transcobalamin II;SCnc;Pt;Ser;Qn;;CHEM;1;Apo-transcobalamin II [Moles/volume] in Serum;Apo-HC-II Ser-sCnc;;ACTIVE;2.42;2.42 +72158-9;Apo-transcobalamin I;SCnc;Pt;Ser;Qn;;CHEM;1;Apo-transcobalamin I [Moles/volume] in Serum;Apo-TC-1 Ser-sCnc;;ACTIVE;2.42;2.42 +72159-7;Inulin renal clearance/1.73 sq M;ArVRat;Stdy;Urine+Ser/Plas;Qn;;DRUG/TOX;1;Inulin renal clearance/1.73 sq M in Urine and Serum or Plasma;Inulin Cl/1.73 sq M Ur+SerPl-ArVRat;;ACTIVE;2.42;2.69 +72160-5;Holo-transcobalamin II;SCnc;Pt;Ser;Qn;;CHEM;1;Holo-transcobalamin II [Moles/volume] in Serum;Holo-TC-II Ser-sCnc;;ACTIVE;2.42;2.42 +72161-3;Epithelial cells;PrThr;Pt;XXX;Ord;Gram stain;HEM/BC;1;Epithelial cells [Presence] in Specimen by Gram stain;Epi Cells Spec Ql Gram Stn;;ACTIVE;2.42;2.73 +72162-1;Erythrocytes;PrThr;Pt;XXX;Ord;Gram stain;HEM/BC;1;Erythrocytes [Presence] in Specimen by Gram stain;RBC Spec Ql Gram Stn;;ACTIVE;2.42;2.69 +72163-9;Leukocytes;PrThr;Pt;XXX;Ord;Gram stain;HEM/BC;1;Leukocytes [Presence] in Specimen by Gram stain;WBC Spec Ql Gram Stn;;ACTIVE;2.42;2.69 +72164-7;Pediatric diastolic blood pressure percentile;Prctl;Pt;^Patient;Qn;Per age, sex and height;SURVEY.GNHLTH;4;Pediatric diastolic blood pressure percentile [Per age, sex and height];;;ACTIVE;2.42;2.67 +7216-5;Cheese swiss Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swiss Cheese IgG Ab [Units/volume] in Serum;Swiss Cheese IgG Qn;;ACTIVE;1.0h(2);2.69 +72165-4;Pediatric systolic blood pressure percentile;Prctl;Pt;^Patient;Qn;Per age, sex and height;SURVEY.GNHLTH;4;Pediatric systolic blood pressure percentile [Per age, sex and height];;;ACTIVE;2.42;2.67 +72166-2;Tobacco smoking status;Find;Pt;^Patient;Nom;;H&P.HX;2;Tobacco smoking status;Tobac smoke stat;;ACTIVE;2.42;2.73 +72167-0;Name of section completed;Find;Pt;Report;Nar;CARE;SURVEY.CARE;4;Deprecated Name of section completed;;;DEPRECATED;2.42;2.44 +72168-8;Ofloxacin 1.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Ofloxacin 1.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Ofloxacin 1.5 ug/mL Islt SlowMyco;;ACTIVE;2.42;2.42 +72169-6;Permission to release immunization data from school record;Find;Pt;^Patient;Ord;;DOC.MISC;2;Permission to release immunization data from school record;Permission to release immunization data;;ACTIVE;2.42;2.67 +72170-4;Photographic image;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Photographic image;Photo image;;ACTIVE;2.42;2.73 +72171-2;Glucose tolerance 2H panel;-;-;Ser/Plas;Qn;;PANEL.CHAL;1;Glucose tolerance 2 hours panel - Serum or Plasma;GTT 2h Pnl SerPl;;ACTIVE;2.42;2.73 +72172-0;Total score;Score;Pt;^Patient;Qn;MoCA;SURVEY.MTLHLTH;4;Total score [MoCA];;Copyright © Tina Brosseau for Center for Diagnosis & Research on Alzheimer's disease (CEDRA). Used with permission.;ACTIVE;2.42;2.67 +7217-3;Prunus avium Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cherry IgG Ab [Units/volume] in Serum;Cherry IgG Qn;;ACTIVE;1.0h(2);2.73 +72173-8;Total score;Score;Pt;^Patient;Qn;BOMC;SURVEY.MTLHLTH;4;Total score [BOMC];;;ACTIVE;2.42;2.7 +72174-6;Rotavirus Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Rotavirus Ag [Presence] in Stool by Rapid immunoassay;RV Ag Stl Ql IA.rapid;;ACTIVE;2.42;2.73 +72175-3;Physician assessment necessary;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Physician assessment necessary [RHEA];;;ACTIVE;2.42;2.67 +72176-1;Facility recommended for birth;Find;Pt;^Patient;Nom;RHEA;SURVEY.GNHLTH;4;Facility recommended for birth [RHEA];;;ACTIVE;2.42;2.67 +72177-9;Congenital anomalies noted;Find;Pt;^Patient;Nom;RHEA;SURVEY.GNHLTH;4;Congenital anomalies noted [RHEA];;;ACTIVE;2.42;2.67 +72178-7;Given a mosquito net;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Given a mosquito net [RHEA];;;ACTIVE;2.42;2.67 +72179-5;Given pyrimethamine sulfadoxine - starting at 4th Mo;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Given pyrimethamine sulfadoxine - starting at 4th month [RHEA];;;ACTIVE;2.42;2.67 +72180-3;Given iron and folic acid;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Given iron and folic acid [RHEA];;;ACTIVE;2.42;2.67 +7218-1;Prunus avium basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cherry triggered histamine release [Units/volume] in Blood;Cherry BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72181-1;HIV results shared with partner;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;HIV results shared with partner [RHEA];;;ACTIVE;2.42;2.67 +72182-9;Tested for HIV;Find;Pt;^Significant other;Ord;RHEA;SURVEY.GNHLTH;4;Tested for HIV Significant other [RHEA];;;ACTIVE;2.42;2.67 +72183-7;Treated for syphillis;Find;Pt;^Significant other;Ord;RHEA;SURVEY.GNHLTH;4;Treated for syphillis Significant other [RHEA];;;ACTIVE;2.42;2.67 +72184-5;Treated for syphillis;Find;Pt;^Patient;Ord;RHEA;SURVEY.GNHLTH;4;Treated for syphillis [RHEA];;;ACTIVE;2.42;2.67 +72185-2;Medical history;Find;Pt;^Patient;Nom;RHEA;SURVEY.GNHLTH;4;Medical history [RHEA];;;ACTIVE;2.42;2.67 +72186-0;Obstetrical risk;Find;Pt;^Patient;Nom;RHEA;SURVEY.GNHLTH;4;Obstetrical risk [RHEA];;;ACTIVE;2.42;2.67 +72187-8;Date tetanus vaccine given;Date;Pt;^Patient;Qn;RHEA;SURVEY.GNHLTH;4;Date tetanus vaccine given [RHEA];;;ACTIVE;2.42;2.67 +72188-6;Clinical summary score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Clinical summary score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72189-4;Quality of life score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Quality of life score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72190-2;Self-efficacy score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Self-efficacy score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72191-0;Total symptom score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Total symptom score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72192-8;Symptom burden score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Symptom burden score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72193-6;Symptom frequency score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Symptom frequency score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72194-4;Symptom stability score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Symptom stability score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72195-1;Physical limitation score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Physical limitation score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72196-9;Social limitation score;Score;Pt;^Patient;Qn;KCCQ;SURVEY.GNHLTH;4;Social limitation score [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.42;2.67 +72197-7;HEDIS 2013 Codes to identify group A Streptococcus tests (CWP-D);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2013 Codes to identify group A Streptococcus tests (CWP-D);HEDIS 2013 CWP-D;;DISCOURAGED;2.42;2.67 +72198-5;HEDIS 2013 Codes to identify sexually active women (CHL-B);-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2013 Codes to identify sexually active women (CHL-B);HEDIS 2013 CHL-B;;DISCOURAGED;2.42;2.67 +7219-9;Castanea sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Chestnut IgE Ab [Units/volume] in Serum;Deprecated Chestnut IgE Qn;;DEPRECATED;1.0h(2);2.69 +72199-3;HEDIS 2013 panel;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2013 panel;HEDIS 2013 panel;;DISCOURAGED;2.42;2.67 +72200-9;Influenza virus A neuraminidase segment sequence identifier;ID;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A neuraminidase segment sequence identifier;FLUAV NA seg sequence ID Islt Seq;;ACTIVE;2.42;2.44 +72201-7;Influenza virus A matrix protein segment sequence identifier;ID;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A matrix protein segment sequence identifier;FLUAV MP seg seqence ID Islt Seq;;ACTIVE;2.42;2.44 +72202-5;Discharge disposition - long term care hospital;Type;Pt;^Patient;Nom;CARE;SURVEY.CARE;4;Discharge disposition - long term care hospital [CARE];;;DISCOURAGED;2.42;2.66 +72203-3;Parathyrin.intact intraoperative panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Parathyrin.intact intraoperative panel - Serum or Plasma;PTH-Intact IO pnl SerPl;;ACTIVE;2.42;2.73 +72204-1;Changes in appetite - follow up;-;Pt;^Patient;-;M3;PANEL.SURVEY.MTLHLTH;4;Changes in appetite - follow up [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.42;2.5 +72205-8;Changes in sleeping patterns - follow up;-;Pt;^Patient;-;M3;PANEL.SURVEY.MTLHLTH;4;Changes in sleeping patterns - follow up [M3];;Copyright © 2002-2012 M3 Information. Used with permission.;ACTIVE;2.42;2.5 +72206-6;Epstein Barr virus nuclear 1 Ab.IgG & IgM;ColorRto;Pt;Ser/Plas;Nom;IA.rapid;MICRO;1;Epstein Barr virus nuclear 1 IgG and IgM [Color Ratio] in Serum or Plasma by Rapid immunoassay;EBV NA 1 IgG+IgM SerPl IA.rapid-ColRto;;ACTIVE;2.42;2.56 +7220-7;Aesculus hippocastanum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse Chestnut IgE Ab [Units/volume] in Serum;Horse Chestnut IgE Qn;;ACTIVE;1.0h(2);2.42 +72207-4;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(8;21)(RUNX1T1,RUNX1)/control Bld/T";;ACTIVE;2.42;2.73 +72208-2;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";"t(8;21)(RUNX1T1,RUNX1)/control Mar";;ACTIVE;2.42;2.42 +72209-0;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.INV;1;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";"inv(16)(p13;q22)/control Mar";;ACTIVE;2.42;2.73 +72210-8;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.INV;1;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"inv(16)(p13;q22)/control Bld/T";;ACTIVE;2.42;2.73 +72211-6;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr2 fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr2 fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";"t(15;17) BCR2/control Mar";;ACTIVE;2.42;2.42 +72212-4;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr1 fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr1 fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";"t(15;17) BCR1/control Mar";;ACTIVE;2.42;2.42 +72213-2;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr3 fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr3 fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";"t(15;17) BCR3/control Mar";;ACTIVE;2.42;2.42 +72214-0;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr3 fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr3 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(15;17) BCR3/control Bld/T";;ACTIVE;2.42;2.73 +7221-5;Chewing gum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chewing gum IgE Ab [Units/volume] in Serum;Chewing gum IgE Qn;;ACTIVE;1.0h(2);2.42 +72215-7;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr2 fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr2 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(15;17) BCR2/control Bld/T";;ACTIVE;2.42;2.73 +72216-5;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr1 fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) bcr1 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(15;17) BCR1/control Bld/T";;ACTIVE;2.42;2.73 +72217-3;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";"t(12;21)(ETV6,RUNX1)/control Mar";;ACTIVE;2.42;2.73 +72218-1;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(12;21)(ETV6,RUNX1)/control Bld/T";;ACTIVE;2.42;2.42 +72219-9;Lymphocytes;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;HEM/BC;1;Lymphocytes [#/area] in Urine sediment by Microscopy high power field;Lymphocytes #/area UrnS HPF;;ACTIVE;2.42;2.42 +72220-7;Macrophages;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;HEM/BC;1;Macrophages [#/area] in Urine sediment by Microscopy high power field;Macrophages #/area UrnS HPF;;ACTIVE;2.42;2.42 +72221-5;Study observation;Find;Pt;Yolk sac^Fetus;Nom;US;OB.US;2;Fetal Yolk sac Study observation US;US Yolk sac Fetus Study;;ACTIVE;2.42;2.42 +7222-3;Chicken Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicken IgG Ab [Units/volume] in Serum;Chicken IgG Qn;;ACTIVE;1.0h(2);2.73 +72223-1;Yeast;PrThr;Pt;Urine;Ord;Automated;UA;1;Yeast [Presence] in Urine by Automated;Yeast Ur Ql Auto;;ACTIVE;2.42;2.73 +72224-9;Pathologic casts;PrThr;Pt;Urine;Ord;Automated;UA;1;Pathologic casts [Presence] in Urine by Automated;Path casts Ur Ql Auto;;ACTIVE;2.42;2.73 +72225-6;Progress note - recommended C-CDA R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Progress note - recommended C-CDA R1.1 sections;Progress Nte C-CDA R1.1 Sections;;ACTIVE;2.42;2.56 +72227-2;Surgical operation note - recommended C-CDA R1.1 & R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Surgical operation note - recommended C-CDA R1.1 and R2.0 and R2.1 sections;Surg Op C-CDA R1.1+2.0+2.1 Sections;;ACTIVE;2.42;2.56 +72228-0;History and physical note - recommended C-CDA R1.1 & R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;History and physical note - recommended C-CDA R1.1 and R2.0 and R2.1 sections;H+P C-CDA R1.1+2.0+2.1 Sections;;ACTIVE;2.42;2.56 +72229-8;Discharge summary - recommended C-CDA R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Discharge summary - recommended C-CDA R1.1 sections;Discharge Sum C-CDA R1.1 Sections;;ACTIVE;2.42;2.56 +72230-6;Diagnostic imaging report - recommended C-CDA R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Diagnostic imaging report - recommended C-CDA R1.1 sections;DIR C-CDA R1.1 Sections;;ACTIVE;2.42;2.56 +7223-1;Chicken basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Chicken triggered histamine release [Units/volume] in Blood;Chicken BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72231-4;Consultation note - recommended C-CDA R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Consultation note - recommended C-CDA R1.1 sections;Consult note C-CDA R1.1 sections;;ACTIVE;2.42;2.56 +72232-2;Continuity of Care Document - recommended C-CDA R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Continuity of Care Document - recommended C-CDA R1.1 sections;CCD C-CDA R1.1 Sections;;ACTIVE;2.42;2.56 +72233-0;Total score;Score;Pt;^Patient;Qn;Mini-Cog;SURVEY.MTLHLTH;4;Total score [Mini-Cog];;Copyright © 2000 Soo Borson. Used with permission.;ACTIVE;2.42;2.67 +72234-8;Mini-Cog;-;Pt;^Patient;-;Mini-Cog;PANEL.SURVEY.MTLHLTH;4;Mini-Cog;;Copyright © 2000 Soo Borson. Used with permission.;ACTIVE;2.42;2.54 +72238-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Toes;Doc;MR;RAD;2;MR Toes - right WO and W contrast IV;MR Toes-R WO+W contr IV;;ACTIVE;2.42;2.61 +72239-7;Multisection^WO contrast;Find;Pt;Lower extremity.right>Toes;Doc;MR;RAD;2;MR Toes - right WO contrast;MR Toes-R WO contr;;ACTIVE;2.42;2.61 +72240-5;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Toes;Doc;MR;RAD;2;MR Toes - right W contrast IV;MR Toes-R W contr IV;;ACTIVE;2.42;2.61 +72241-3;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Toes;Doc;MR;RAD;2;MR Toes - left WO and W contrast IV;MR Toes-L WO+W contr IV;;ACTIVE;2.42;2.61 +72242-1;Multisection^WO contrast;Find;Pt;Lower extremity.left>Toes;Doc;MR;RAD;2;MR Toes - left WO contrast;MR Toes-L WO contr;;ACTIVE;2.42;2.61 +72243-9;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Toes;Doc;MR;RAD;2;MR Toes - left W contrast IV;MR Toes-L W contr IV;;ACTIVE;2.42;2.61 +72244-7;Multisection endorectal^WO & W contrast IV;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis Endorectal WO and W contrast IV;MR Pelvis Endorectal WO+W contr IV;;ACTIVE;2.42;2.61 +72245-4;Multisection^W contrast PR+at rest+maximal sphincter contraction+during straining+during defecation;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis Defecography W contrast PR;MR Pelvis Defe W cntr PR;;ACTIVE;2.42;2.64 +72246-2;Multisection^W contrast PO+WO & W contrast IV;Find;Pt;Abdomen+Pelvis;Doc;MR;RAD;2;MR Abdomen and Pelvis W contrast PO and WO and W contrast IV;MR Abd+Pelvis W contr PO+WO+W IV;;ACTIVE;2.42;2.61 +72247-0;Multisection^W contrast PO+WO contrast IV;Find;Pt;Abdomen+Pelvis;Doc;MR;RAD;2;MR Abdomen and Pelvis W contrast PO and WO contrast IV;MR Abd+Pelvis W contr PO+WO IV;;ACTIVE;2.42;2.61 +72248-8;Guidance for endoscopy^WO & W contrast IV;Find;Pt;Abdomen>Liver+Biliary ducts+Pancreas;Doc;MR;RAD;2;MRCP Abdomen WO and W contrast IV;MRCP Abd W+WO contr IV;;ACTIVE;2.42;2.61 +7224-9;Chicken feather Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicken feather IgG Ab [Units/volume] in Serum;Chicken Feather IgG Qn;;ACTIVE;1.0h(2);2.54 +72249-6;Multisection^WO contrast;Find;Pt;Head>Facial bones;Doc;CT;RAD;2;CT Facial bones WO contrast;CT Face WO contr;;ACTIVE;2.42;2.61 +72250-4;Multisection^W contrast PO+W contrast IV;Find;Pt;Abdomen>Small bowel;Doc;CT;RAD;2;CT Small bowel W contrast PO and W contrast IV;CT SB W contrast PO+IV;;ACTIVE;2.42;2.61 +72251-2;Multisection for pulmonary embolus;Find;Pt;Chest>Pulmonary arteries;Doc;CT;RAD;2;CT Pulmonary arteries for pulmonary embolus;CT PA for PE;;ACTIVE;2.42;2.73 +72252-0;Multisection^WO & W contrast IV;Find;Pt;Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Chest and Abdomen and Pelvis WO and W contrast IV;CT Chest+Abd+Pelvis WO+W contr IV;;ACTIVE;2.42;2.61 +72253-8;Multisection^WO contrast;Find;Pt;Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Chest and Abdomen and Pelvis WO contrast;CT Chest+Abd+Pelvis WO contr;;ACTIVE;2.42;2.61 +72254-6;Multisection^W contrast IV;Find;Pt;Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Chest and Abdomen and Pelvis W contrast IV;CT Chest+Abd+Pelvis W contr IV;;ACTIVE;2.42;2.61 +72255-3;Multisection^W contrast IV;Find;Pt;Aorta+Femoral artery.bilateral;Doc;CT.angio;RAD;2;Deprecated Aorta and Femoral artery - bilateral CT angiogram W contrast IV;Deprecated Aorta+Fem a-Bl CT.Angio W con;;DEPRECATED;2.42;2.58 +7225-6;Cichorium intybus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chicory IgE Ab [Units/volume] in Serum;Chicory IgE Qn;;ACTIVE;1.0h(2);2.73 +72256-1;Views for motility^W radioopaque markers;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen Views for motility W radioopaque markers;XR Abd Views for motility W ROMS;;ACTIVE;2.42;2.64 +72257-9;Platelet function.collagen+Adenosine diphosphate induced & EPINEPHrine induced panel;-;Pt;Bld;-;;PANEL.COAG;1;Platelet function.collagen + Adenosine diphosphate induced and EPINEPHrine induced panel - Blood;Close Tme Coll+ADP + Epinep pnl Bld;;ACTIVE;2.42;2.73 +72258-7;Malondialdehyde;EntSub;Pt;Platelets;Qn;;CHEM;1;Malondialdehyde [Entitic substance] in Platelets;Malondialdehyde EntSub Plts;;ACTIVE;2.42;2.61 +72259-5;Adefovir;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Adefovir [Mass/volume] in Serum or Plasma by LC/MS/MS;Adefovir SerPl LC/MS/MS-mCnc;;ACTIVE;2.42;2.42 +72260-3;Tau protein.phosphorylated 181;MCnc;Pt;CSF;Qn;IA;CHEM;1;Phosphorylated tau 181 [Mass/volume] in Cerebral spinal fluid by Immunoassay;p-tau181 CSF IA-mCnc;;ACTIVE;2.42;2.73 +72261-1;Bilirubin excess;SCnc;Pt;Ser+CSF;Qn;;CHEM;1;Bilirubin excess [Moles/volume] in Serum and CSF;Bilirubin excess Ser+CSF-sCnc;;ACTIVE;2.42;2.42 +72262-9;Methemoglobin;SCnc;Pt;CSF;Qn;;CHEM;1;Methemoglobin [Moles/volume] in Cerebral spinal fluid;MetHgb CSF-sCnc;;ACTIVE;2.42;2.42 +72263-7;Oxyhemoglobin;SCnc;Pt;CSF;Qn;;CHEM;1;Oxyhemoglobin [Moles/volume] in Cerebral spinal fluid;OxyHgb CSF-sCnc;;ACTIVE;2.42;2.42 +7226-4;Sapium sebiferum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chinese Tallow Tree IgE Ab [Units/volume] in Serum;Chinese Tallow Tree IgE Qn;;ACTIVE;1.0h(2);2.42 +72264-5;Bilirubin excess & oxyhemoglobin & methemoglobin & xanthochromia & albumin quotient panel;-;Pt;Ser+CSF;-;;PANEL.CHEM;1;Bilirubin excess and oxyhemoglobin and methemoglobin and xanthochromia and albumin quotient panel - Serum and CSF;Bld pigments Pnl Ser+CSF;;ACTIVE;2.42;2.42 +72265-2;Influenza virus B Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus B IgA Ab [Units/volume] in Serum by Immunoassay;FLUBV IgA Ser IA-aCnc;;ACTIVE;2.42;2.56 +72266-0;Influenza virus A Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A IgA Ab [Units/volume] in Serum by Immunoassay;FLUAV IgA Ser IA-aCnc;;ACTIVE;2.42;2.56 +72267-8;Evaluation of mental and physical incapacity certificate;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation of mental and physical incapacity certificate;Eval incapacity cert;;ACTIVE;2.42;2.54 +72268-6;Streptococcus pyogenes exotoxin B speB gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptococcus pyogenes exotoxin B speB gene [Presence] in Specimen by NAA with probe detection;S pyogenes speB Spec Ql NAA+probe;;ACTIVE;2.42;2.73 +72269-4;pH;LsCnc;Pt;Vag;Qn;Test strip;CHEM;1;pH of Vaginal fluid by Test strip;pH Vag Strip;;ACTIVE;2.42;2.73 +72270-2;Urea nitrogen^pre contrast;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Serum or Plasma --pre contrast;BUN pre contrast SerPl-mCnc;;ACTIVE;2.42;2.42 +72271-0;Creatinine^pre contrast;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Creatinine [Mass/volume] in Serum or Plasma --pre contrast;Creat pre contrast SerPl-mCnc;;ACTIVE;2.42;2.42 +7227-2;Chocolate basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Chocolate triggered histamine release [Units/volume] in Blood;Chocolate BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72272-8;Amylase & triacylglycerol lipase panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Amylase and triacylglycerol lipase panel - Serum or Plasma;Amylase+lipase Pnl SerPl;;ACTIVE;2.42;2.42 +72273-6;Blood product ordered;Vol;Pt;^BPU;Qn;;BLDBK;1;Blood product ordered [Volume] in Blood product unit;Blood prod order Vol BPU;;ACTIVE;2.42;2.42 +72274-4;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(15;17)(PML,RARA)/control Bld/T";;ACTIVE;2.42;2.42 +72275-1;Dedication to Excellence + Inspiration to All;Hx;Pt;^Patient;Nar;JP;H&P.HX;2;Dedication to Excellence and Inspiration to all;Dedication+Inspiration;;TRIAL;2.42;2.63 +72276-9;Mycobacterium tuberculosis gyrA gene fluoroquinolone resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis gyrA gene fluoroquinolone resistance mutation [Presence] by Molecular method;MTB gyrA fluoroquin res mut Islt/Spm Ql;;ACTIVE;2.42;2.65 +72277-7;Trichomonas vaginalis;PrThr;Pt;Prostatic fld;Ord;Microscopy.light;MICRO;1;Trichomonas vaginalis [Presence] in Prostatic fluid by Light microscopy;T vaginalis Prost fld Ql Micro;;ACTIVE;2.42;2.56 +72278-5;Specimen volume;Vol;Pt;Prostatic fld;Qn;;SPEC;1;Volume of Prostatic fluid;Specimen vol Prost fld;;ACTIVE;2.42;2.42 +72279-3;(Chicken feather+Duck feather+Goose feather+Turkey feather) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 71 (Chicken feather+Duck feather+Goose feather+Turkey feather) IgE Ab [Units/volume] in Serum by Multidisk;Epid Allerg Mix71 IgE Qn;;ACTIVE;2.42;2.73 +7228-0;Chymodiactin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Chymodiactin IgE Ab [Units/volume] in Serum;Deprecated Chymodiactin IgE Qn;;DEPRECATED;1.0h(2);2.69 +72280-1;Rh immune globulin expiration;TmStp;Pt;^BPU;Qn;;BLDBK;1;Rh immune globulin expiration [Date and time];Rh Ig expire BPU;;ACTIVE;2.42;2.42 +72281-9;Days in therapeutic INR range/Days INR result determined;Ratio;Pt;^Patient;Qn;;H&P.HX.LAB;1;Days in therapeutic INR range/Days INR result determined [Ratio];Ds INR range/Ds INR det Patient-Rto;;ACTIVE;2.42;2.73 +72282-7;Sagittal plane body position;Angle;Pt;^Patient;Ord;;CLIN;2;Sagittal plane body position;Sagittal plane body position;;ACTIVE;2.42;2.67 +72283-5;Nail assessment panel;-;Pt;Nail;-;;PANEL.H&P;2;Nail assessment panel;Nail assess pnl;;ACTIVE;2.42;2.42 +72284-3;Skin assessment panel;-;Pt;Skin;-;;PANEL.H&P;2;Skin assessment panel;Skin Assessment Pnl;;ACTIVE;2.42;2.42 +72285-0;Dressing purpose;Type;Pt;Wound;Nom;;H&P.PX;2;Dressing purpose for Wound;Dressing purpose Wnd;;ACTIVE;2.42;2.42 +72286-8;Wound dressing panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound dressing panel;Wnd dress pnl;;ACTIVE;2.42;2.42 +72287-6;Wound size panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound size panel;Wnd size pnl;;ACTIVE;2.42;2.73 +72288-4;Odor;Type;Pt;Wound.exudate;Nom;;H&P.PX;2;Odor of Exudate from wound;Odor Wnd.exdte;;ACTIVE;2.42;2.42 +72289-2;Color;Type;Pt;Wound.exudate;Nom;;H&P.PX;2;Color of Exudate from wound;Color Wnd.exdte;;ACTIVE;2.42;2.42 +722-9;Hemoglobin;MCnc;Pt;Plr fld;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Pleural fluid;Hgb Plr-mCnc;;ACTIVE;1.0;2.34 +72290-0;Appearance;Aper;Pt;Wound.exudate;Nom;;H&P.PX;2;Appearance of Exudate from wound;Appearance Wnd.exdte;;ACTIVE;2.42;2.42 +72291-8;Drainage amount from device;Vol;Pt;Wound.exudate;Qn;;H&P.PX;2;Drainage amount from device of Exudate from wound;Drain amt device Wnd.exdte;;ACTIVE;2.42;2.44 +72292-6;Wound exudate panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound exudate panel;Wnd Exudate pnl;;ACTIVE;2.42;2.42 +72293-4;Undermining;Len;Pt;Wound;Qn;;H&P.PX;2;Undermining [Length] of Wound;Undermining Wnd Len;;ACTIVE;2.42;2.42 +72294-2;Undermining clock position;Find;Pt;Wound;Nom;;H&P.PX;2;Undermining clock position of Wound;Undermining clck Wnd;;ACTIVE;2.42;2.42 +72295-9;Undermining;Find;Pt;Wound;Ord;;H&P.PX;2;Undermining of Wound;Undermining Wnd;;ACTIVE;2.42;2.42 +72296-7;Tunneling;Len;Pt;Wound;Qn;;H&P.PX;2;Tunneling [Length] of Wound;Tunneling Len Wnd;;ACTIVE;2.42;2.42 +72297-5;Tunneling clock position;Find;Pt;Wound;Nom;;H&P.PX;2;Tunneling clock position of Wound;Tunneling clck Wnd;;ACTIVE;2.42;2.42 +7229-8;Cinnamomum spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cinnamon IgG Ab [Units/volume] in Serum;Cinnamon IgG Qn;;ACTIVE;1.0h(2);2.73 +72298-3;Tunneling;Find;Pt;Wound;Ord;;H&P.PX;2;Tunneling of Wound;Tunneling Wnd;;ACTIVE;2.42;2.42 +72299-1;Wound tunneling & undermining panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound tunneling and undermining panel;Wnd Tunnel+Under pnl;;ACTIVE;2.42;2.42 +72300-7;Wound type;Type;Pt;Wound;Nom;;H&P.PX;2;Wound type;Wound type;;ACTIVE;2.42;2.64 +72301-5;Periwound description;Find;Pt;Periwound;Nom;;H&P.PX;2;Description of Periwound;Periwnd desc;;ACTIVE;2.42;2.54 +72302-3;Texture;Type;Pt;Nail;Nom;;H&P.PX;2;Texture of Nail;Texture Nail;;ACTIVE;2.42;2.42 +72303-1;Shape;Type;Pt;Nail;Nom;;H&P.PX;2;Shape of Nail;Shape Nail;;ACTIVE;2.42;2.42 +72304-9;Edge of wound description;Type;Pt;Wound.edge;Nom;;H&P.PX;2;Edge of wound description;Edge wnd descrp Wnd edge;;ACTIVE;2.42;2.42 +72305-6;Wound closure type;Type;Pt;Wound;Nom;;H&P.PX;2;Wound closure type;Wnd Close type;;ACTIVE;2.42;2.42 +7230-6;Cladosporium herbarum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium herbarum IgG Ab [Units/volume] in Serum;C herbarum IgG Qn;;ACTIVE;1.0h(2);2.73 +72306-4;Nicotinurate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nicotinurate [Mass/volume] in Serum or Plasma;Nicotinurate SerPl-mCnc;;ACTIVE;2.42;2.42 +72307-2;Brucella sp Ab.IgG^2nd specimen;Titr;Pt;Ser;Qn;;MICRO;1;Brucella sp IgG Ab [Titer] in Serum --2nd specimen;Brucella IgG sp2 Titr Ser;;ACTIVE;2.42;2.42 +72308-0;Brucella sp Ab.IgG^1st specimen;Titr;Pt;Ser;Qn;;MICRO;1;Brucella sp IgG Ab [Titer] in Serum --1st specimen;Brucella IgG sp1 Titr Ser;;ACTIVE;2.42;2.42 +72309-8;NPM1 gene.c.960insCCTG transcript/control transcript;NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;NPM1 gene c.960insCCTG transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method;NPM1 gene mut D/control Bld/T;;ACTIVE;2.42;2.5 +72310-6;NPM1 gene.c.960insCATG transcript/control transcript;NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;NPM1 gene c.960insCATG transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method;NPM1 gene mut B/control Bld/T;;ACTIVE;2.42;2.5 +72311-4;NPM1 gene.c.956dupTCTG transcript/control transcript;NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;NPM1 gene c.956dupTCTG transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method;NPM1 gene mut A/control Bld/T;;ACTIVE;2.42;2.73 +72312-2;"t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(1;19)(PBX1,TCF3)/control Bld/T";;ACTIVE;2.42;2.42 +72313-0;"t(4;11)(q21.3;q23)(AFF1,MLL) fusion transcript/control transcript";NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.TRNLOC;1;"t(4;11)(q21.3;q23)(AFF1,MLL) fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method";"t(4;11)(AFF1,MLL)/control Bld/T";;ACTIVE;2.42;2.42 +7231-4;Cladosporium herbarum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cladosporium herbarum triggered histamine release [Units/volume] in Blood;C herbarum BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72314-8;Th-To Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Th-To IgG Ab [Presence] in Serum or Plasma by Immunoassay;Th-To IgG SerPl Ql IA;;ACTIVE;2.42;2.56 +72315-5;Platelet-derived growth factor receptor Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Platelet-derived growth factor receptor IgG Ab [Presence] in Serum or Plasma by Immunoassay;PDGFR IgG SerPl Ql IA;;ACTIVE;2.42;2.56 +72316-3;RNA polymerase III RP155 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;RNA polymerase III RP155 IgG Ab [Presence] in Serum or Plasma by Immunoassay;RNAp III RP155 IgG SerPl Ql IA;;ACTIVE;2.42;2.56 +72317-1;RNA polymerase III RP11 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;RNA polymerase III RP11 IgG Ab [Presence] in Serum or Plasma by Immunoassay;RNAp III RP11 IgG SerPl Ql IA;;ACTIVE;2.42;2.56 +72318-9;Centromere protein A Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Centromere protein A IgG Ab [Presence] in Serum or Plasma by Immunoassay;CENP A IgG SerPl Ql IA;;ACTIVE;2.42;2.56 +72320-5;Mitochondria M2-3E Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Mitochondria M2-3E IgG Ab [Presence] in Serum by Immunoassay;M2-3E IgG Ser Ql IA;;ACTIVE;2.42;2.56 +72321-3;HLA-DP+DQ+DR Ab.IgG;PrThr;Pt;Ser;Ord;IA;HLA;1;HLA-DP+DQ+DR (class II) IgG Ab [Presence] in Serum by Immunoassay;HLA-DP+DQ+DR IgG Ser Ql IA;;ACTIVE;2.42;2.56 +7232-2;Ruditapes spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clam IgG Ab [Units/volume] in Serum;Clam IgG Qn;;ACTIVE;1.0h(2);2.73 +72322-1;HLA-A+B+C Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;HLA;1;HLA-A+B+C (class I) IgG Ab [Presence] in Serum or Plasma by Immunoassay;HLA-A+B+C IgG SerPl Ql IA;;ACTIVE;2.42;2.56 +72323-9;HLA-DP+DQ+DR Ab.IgG;PrThr;Pt;Ser;Ord;Flow cytometry;HLA;1;HLA-DP+DQ+DR (class II) IgG Ab [Presence] in Serum by Flow cytometry (FC);HLA-DP+DQ+DR IgG Ser Ql FC;;ACTIVE;2.42;2.56 +72324-7;Functional shunt volume^^adjusted to patient's actual temperature;VFr;Pt;BldA+BldMV;Qn;;HEMODYN.MOLEC;2;Arterial blood and Mixed venous blood Functional shunt volume adjusted to patient's actual temperature;BldA+BldMV Fshunt vol temp adj VFr;;ACTIVE;2.42;2.54 +72325-4;Functional shunt volume^^adjusted to patient's actual temperature;VFr;Pt;BldA;Qn;;HEMODYN.MOLEC;2;Arterial blood Functional shunt volume adjusted to patient's actual temperature;BldA Fshunt vol temp adj VFr;;ACTIVE;2.42;2.54 +72326-2;Functional shunt volume;VFr;Pt;BldA;Qn;;HEMODYN.MOLEC;2;Arterial blood Functional shunt volume;BldA Fshunt vol VFr;;ACTIVE;2.42;2.73 +72327-0;Amphiphysin Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Amphiphysin IgG Ab [Presence] in Serum by Immunoassay;Amphiphysin IgG Ser Ql IA;;ACTIVE;2.42;2.56 +72328-8;HLA-A+B+C Ab.IgG;PrThr;Pt;Ser;Ord;Flow cytometry;HLA;1;HLA-A+B+C (class I) IgG Ab [Presence] in Serum by Flow cytometry (FC);HLA-A+B+C IgG Ser Ql FC;;ACTIVE;2.42;2.56 +72329-6;Anucleated bodies/100 round cells;NFr;Pt;Semen;Qn;Manual count;FERT;1;Anucleated bodies/100 round cells in Semen by Manual count;Anuc bdy/100 rnd NFr Smn Manual;;ACTIVE;2.42;2.42 +7233-0;Ruditapes spp basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Clam triggered histamine release [Units/volume] in Blood;Clam BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72330-4;Nucleated cells/100 round cells;NFr;Pt;Semen;Qn;Manual count;HEM/BC;1;Nucleated cells/100 round cells in Semen by Manual count;Nuc cell/100 rnd NFr Smn Manual;;ACTIVE;2.42;2.42 +72331-2;Anucleated bodies/100 round cells;NFr;Pt;Prostatic fld;Qn;Manual count;FERT;1;Anucleated bodies/100 round cells in Prostatic fluid by Manual count;Anuc bdy/100 rnd NFr Prost fld Manual;;ACTIVE;2.42;2.42 +72332-0;Nucleated cells/100 round cells;NFr;Pt;Prostatic fld;Qn;Manual count;HEM/BC;1;Nucleated cells/100 round cells in Prostatic fluid by Manual count;Nuc cell/100 rnd NFr Prost fld Manual;;ACTIVE;2.42;2.42 +72333-8;JAK2 gene.p.Val617Phe;PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH.MUT;1;JAK2 gene p.Val617Phe [Presence] in Bone marrow by Molecular genetics method;JAK2 p.V617F Mar Ql;;ACTIVE;2.42;2.56 +72334-6;NPM1 gene.c.960insCATG transcript/control transcript;NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.MUT;1;NPM1 gene c.960insCATG transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method;NPM1 gene mut B/control Mar;;ACTIVE;2.42;2.5 +72335-3;NPM1 gene.c.956dupTCTG transcript/control transcript;NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.MUT;1;NPM1 gene c.956dupTCTG transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method;NPM1 gene mut A/control Mar;;ACTIVE;2.42;2.5 +72336-1;NPM1 gene.c.960insCCTG transcript/control transcript;NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.MUT;1;NPM1 gene c.960insCCTG transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method;NPM1 gene mut D/control Mar;;ACTIVE;2.42;2.5 +72337-9;Protein S Ag;ACnc;Pt;PPP;Qn;IA;COAG;1;Protein S Ag [Units/volume] in Platelet poor plasma by Immunoassay;Prot S Ag PPP IA-aCnc;;ACTIVE;2.42;2.73 +72338-7;Erythrocytes;PrThr;Pt;Prostatic fld;Ord;Microscopy.light;HEM/BC;1;Erythrocytes [Presence] in Prostatic fluid by Light microscopy;RBC Prost fld Ql Micro;;ACTIVE;2.42;2.56 +72339-5;Lecithin;PrThr;Pt;Prostatic fld;Ord;Microscopy.light;HEM/BC;1;Lecithin [Presence] in Prostatic fluid by Light microscopy;Lecithin Prost fld Ql Micro;;ACTIVE;2.42;2.56 +72340-3;Bacteria;PrThr;Pt;Prostatic fld;Ord;Microscopy.light;HEM/BC;1;Bacteria [Presence] in Prostatic fluid by Light microscopy;Bacteria Prost fld Ql Micro;;ACTIVE;2.42;2.56 +72341-1;Amyloid bodies;PrThr;Pt;Prostatic fld;Ord;Microscopy.light;FERT;1;Amyloid bodies [Presence] in Prostatic fluid by Light microscopy;Amyloid Prost fld Ql Micro;;ACTIVE;2.42;2.56 +72342-9;Neutrophils/100 round cells;NFr;Pt;Semen;Qn;Manual count;HEM/BC;1;Neutrophils/100 round cells in Semen by Manual count;Neutrophils/100 rnd NFr Smn Manual;;ACTIVE;2.42;2.42 +72343-7;Monocytes/100 round cells;NFr;Pt;Semen;Qn;Manual count;HEM/BC;1;Monocytes/100 round cells in Semen by Manual count;Monocytes/100 rnd NFr Smn Manual;;ACTIVE;2.42;2.42 +72344-5;Monocytes/100 round cells;NFr;Pt;Prostatic fld;Qn;Manual count;HEM/BC;1;Monocytes/100 round cells in Prostatic fluid by Manual count;Monocytes/100 rnd NFr Prost fld Manual;;ACTIVE;2.42;2.42 +72345-2;Neutrophils/100 round cells;NFr;Pt;Prostatic fld;Qn;Manual count;HEM/BC;1;Neutrophils/100 round cells in Prostatic fluid by Manual count;Neutrophils/100 rnd NFr Prost fld Manual;;ACTIVE;2.42;2.42 +72346-0;Round cells;NCnc;Pt;Prostatic fld;Qn;Manual count;HEM/BC;1;Round cells [#/volume] in Prostatic fluid by Manual count;Rnd Cells # Prost fld Manual;;ACTIVE;2.42;2.42 +72347-8;Neutrophils;NCnc;Pt;Prostatic fld;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Prostatic fluid by Manual count;Neutrophils # Prost fld Manual;;ACTIVE;2.42;2.42 +7234-8;Syzygium aromaticum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clove IgE Ab [Units/volume] in Serum;Clove IgE Qn;;ACTIVE;1.0h(2);2.73 +72348-6;Leukocytes;NCnc;Pt;Prostatic fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Prostatic fluid by Manual count;WBC # Prost fld Manual;;ACTIVE;2.42;2.42 +72349-4;Level of fatigue on average over the past Mo;Find;1Mo;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Level of fatigue on average over the past month [Reported];;;ACTIVE;2.42;2.67 +72350-2;Severity of pain on average over the past Mo;Find;1Mo;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Severity of pain on average over the past 1 month [Reported];;;ACTIVE;2.42;2.67 +72351-0;Social interaction with other people - family, friends, or others - over the past Mo;Find;1Mo;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Social interaction with other people - family, friends, or others - over the past month [Reported];;;ACTIVE;2.42;2.67 +72352-8;Overall emotional well being over the past 1Mo;Find;1Mo;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Overall emotional well being over the past month [Reported];;;ACTIVE;2.42;2.67 +72353-6;Overall physical well being over the past Mo;Find;1Mo;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Overall physical well being over the past month [Reported];;;ACTIVE;2.42;2.67 +72354-4;Overall quality of life over the past Mo;Find;1Mo;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Overall quality of life over the past month [Reported];;;ACTIVE;2.42;2.67 +7235-5;Syzygium aromaticum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clove IgG Ab [Units/volume] in Serum;Clove IgG Qn;;ACTIVE;1.0h(2);2.73 +72355-1;Patient reported outcome quality of life tool;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Patient Reported Outcome Quality of Life tool;;;ACTIVE;2.42;2.42 +72356-9;Influenza virus A & B Ag;Prid;Pt;XXX;Nom;IA.rapid;MICRO;1;Influenza virus A and B Ag [Identifier] in Specimen by Rapid immunoassay;FLUAV + FLUBV Ag Spec IA.rapid;;ACTIVE;2.42;2.73 +72357-7;Microscopic observation;PrThr;Pt;XXX;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Specimen by Acid fast stain;Acid fast Stn Spec Ql;;ACTIVE;2.42;2.73 +72360-1;Methemoglobin/Hemoglobin.total;MFr;Pt;BldCoV;Qn;;HEM/BC;1;Methemoglobin/Hemoglobin.total in Venous cord blood;MetHgb MFr BldCoV;;ACTIVE;2.42;2.73 +72361-9;Methemoglobin/Hemoglobin.total;MFr;Pt;BldCoA;Qn;;HEM/BC;1;Methemoglobin/Hemoglobin.total in Arterial cord blood;MetHgb MFr BldCoA;;ACTIVE;2.42;2.73 +72362-7;Starch granules;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Starch granules [#/area] in Urine sediment by Microscopy low power field;Starch Granules #/area UrnS LPF;;ACTIVE;2.42;2.42 +7236-3;Clover Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Clover IgE Ab [Units/volume] in Serum;Clover IgE Qn;;ACTIVE;1.0h(2);2.73 +72364-3;Lymphocytes/100 leukocytes;NFr;Pt;Vitr fld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Vitreous fluid by Manual count;Lymphocytes/leuk NFr Vitf Manual;;ACTIVE;2.42;2.5 +72365-0;Influenza virus A & B Ag;Prid;Pt;Nose;Nom;IF;MICRO;1;Influenza virus A and B Ag [Identifier] in Nose by Immunofluorescence;FLUAV + FLUBV Ag Nose IF;;ACTIVE;2.42;2.73 +72366-8;Influenza virus A & B Ag;Prid;Pt;Nose;Nom;IA.rapid;MICRO;1;Influenza virus A and B Ag [Identifier] in Nose by Rapid immunoassay;FLUAV + FLUBV Ag Nose IA.rapid;;ACTIVE;2.42;2.73 +72367-6;Influenza virus A+B Ag;PrThr;Pt;Nose;Ord;IA.rapid;MICRO;1;Influenza virus A+B Ag [Presence] in Nose by Rapid immunoassay;FLUAV+FLUBV Ag Nose Ql IA.rapid;;ACTIVE;2.42;2.73 +72368-4;"t(11;14)(q13;q32)(CCND1,IGH) fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH.TRNLOC;1;"t(11;14)(q13;q32)(CCND1,IGH) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"t(11;14)(CCND1,IGH) Mar Ql";;ACTIVE;2.42;2.56 +72369-2;Body site identification panel;-;Pt;^Patient;-;;PANEL.H&P;2;Body site identification panel;Body site Pnl;;ACTIVE;2.42;2.42 +723-7;Hemoglobin;MCnc;Pt;Periton fld;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Peritoneal fluid;Hgb Prt-mCnc;;ACTIVE;1.0;2.34 +72370-0;Area of identified wound bed appearance/Area of wound bed;ArArea;Pt;Wound.base;Qn;;H&P.PX;2;Area of identified wound bed appearance/Area of wound bed of Wound base;Wound bed appear % Area of Wnd base;;ACTIVE;2.42;2.64 +7237-1;Cockatoo Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cockatoo IgE Ab [Units/volume] in Serum;Cockatoo IgE Qn;;ACTIVE;1.0h(2);2.42 +72371-8;Appearance;Aper;Pt;Wound.base;Nom;;H&P.PX;2;Appearance of Wound base;Appearance Wnd base;;ACTIVE;2.42;2.42 +72372-6;Wound bed & edge panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound bed and edge panel;Wnd bed+edge pnl;;ACTIVE;2.42;2.42 +72373-4;Virus identified;Prid;Pt;Nph;Nom;Culture;MICRO;1;Virus identified in Nasopharynx by Culture;Virus Nph Cult;;ACTIVE;2.42;2.42 +72374-2;Virus identified;Prid;Pt;Lung tiss;Nom;Culture;MICRO;1;Virus identified in Lung tissue by Culture;Virus Lung tiss Cult;;ACTIVE;2.42;2.42 +72375-9;Microscopic method;Type;Pt;Urine;Nom;;UA;1;Microscopic method - Urine;Micro mthd Ur;;ACTIVE;2.42;2.44 +72376-7;Hepatitis C virus Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Hepatitis C virus Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HCV Ab SerPlBld Ql IA.rapid;;ACTIVE;2.42;2.73 +72377-5;Nordiazepam;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Saliva (oral fluid);Nordiazepam Sal-mCnc;;ACTIVE;2.42;2.73 +72378-3;Oxazepam;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Saliva (oral fluid);Oxazepam Sal-mCnc;;ACTIVE;2.42;2.73 +72379-1;Cannabinoids.synthetic;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Cannabinoids synthetic [Presence] in Specimen by Screen method;Cannabinoids synthetic Spec Ql Scn;;ACTIVE;2.42;2.73 +72380-9;LORazepam;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Saliva (oral fluid);LORazepam Sal-mCnc;;ACTIVE;2.42;2.73 +72381-7;ALPRAZolam;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Saliva (oral fluid);Alpraz Sal-mCnc;;ACTIVE;2.42;2.73 +72382-5;HER2;ACnc;Pt;Tiss;Qn;IA;PATH;1;HER2 [Units/volume] in Tissue by Immunoassay;Her2 Tiss IA-aCnc;;ACTIVE;2.42;2.73 +72383-3;HER2;PrThr;Pt;Tiss;Ord;IA;PATH;1;HER2 [Presence] in Tissue by Immunoassay;Her2 Tiss Ql IA;;ACTIVE;2.42;2.73 +72384-1;Meperidine+Normeperidine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Meperidine+Normeperidine [Presence] in Urine by Confirmatory method;Meperidine+Nor Ur Ql Cfm;;ACTIVE;2.42;2.73 +72385-8;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Mass/volume] in Saliva (oral fluid) by Confirmatory method;EDDP Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72386-6;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Saliva (oral fluid) by Confirmatory method;EDDP Sal Ql Cfm;;ACTIVE;2.42;2.73 +72387-4;Methadone;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Methadone [Presence] in Saliva (oral fluid) by Confirmatory method;Methadone Sal Ql Cfm;;ACTIVE;2.42;2.73 +72388-2;Methadone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methadone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Methadone Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +7238-9;Xanthium commune Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cocklebur IgG Ab [Units/volume] in Serum;Cocklebur IgG Qn;;ACTIVE;1.0h(2);2.73 +72389-0;Candida krusei DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida krusei DNA [Presence] in Vaginal fluid by NAA with probe detection;C krusei DNA Vag Ql NAA+probe;;ACTIVE;2.42;2.73 +72390-8;Candida lusitaniae DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida lusitaniae DNA [Presence] in Vaginal fluid by NAA with probe detection;C lusitaniae DNA Vag Ql NAA+probe;;ACTIVE;2.42;2.73 +72391-6;Candida tropicalis DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida tropicalis DNA [Presence] in Vaginal fluid by NAA with probe detection;C tropicls DNA Vag Ql NAA+probe;;ACTIVE;2.42;2.73 +72392-4;Cortisol/Cortisone;MRto;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cortisol/Cortisone [Mass Ratio] in Serum or Plasma;Cortis/Cortisone SerPl;;ACTIVE;2.42;2.73 +72393-2;Cell count & Differential panel;-;Pt;Vitr fld;-;Manual count;PANEL.HEM/BC;1;Cell count and Differential panel - Vitreous fluid by Manual count;Cell Cnt + Diff Pnl Vitf Manual;;ACTIVE;2.42;2.42 +72394-0;Cell count panel;-;Pt;Vitr fld;-;Manual count;PANEL.HEM/BC;1;Cell count panel - Vitreous fluid by Manual count;Cell Cnt Pnl Vitf Manual;;ACTIVE;2.42;2.42 +72395-7;Differential panel;-;Pt;Vitr fld;-;;PANEL.HEM/BC;1;Differential panel - Vitreous fluid;Diff Pnl Vitf;;ACTIVE;2.42;2.44 +72396-5;PHENobarbital;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;PHENobarbital [Mass/volume] in Blood by Confirmatory method;Phenobarb Bld Cfm-mCnc;;ACTIVE;2.42;2.73 +7239-7;Xanthium commune basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cocklebur triggered histamine release [Units/volume] in Blood;Cocklebur BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72397-3;Secobarbital;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Secobarbital [Mass/volume] in Blood by Confirmatory method;Secobarbital Bld Cfm-mCnc;;ACTIVE;2.42;2.73 +72398-1;Butalbital;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Butalbital [Mass/volume] in Blood by Confirmatory method;Butalbital Bld Cfm-mCnc;;ACTIVE;2.42;2.73 +72399-9;Amobarbital;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Amobarbital [Mass/volume] in Blood by Confirmatory method;Amobarbital Bld Cfm-mCnc;;ACTIVE;2.42;2.73 +72400-5;Methadone;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Methadone [Presence] in Blood by Screen method;Methadone Bld Ql Scn;;ACTIVE;2.42;2.73 +72401-3;Propoxyphene;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Propoxyphene [Presence] in Blood by Screen method;Propoxyph Bld Ql Scn;;ACTIVE;2.42;2.73 +72402-1;oxyCODONE;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;oxyCODONE [Presence] in Blood by Screen method;oxyCODONE Bld Ql Scn;;ACTIVE;2.42;2.73 +72403-9;3-epi-25-Hydroxyvitamin D3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-epi-25-Hydroxyvitamin D3 [Mass/volume] in Serum or Plasma;3-epi-25(OH)D3 SerPl-mCnc;;ACTIVE;2.42;2.73 +72404-7;3-epi-25-Hydroxyvitamin D2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-epi-25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma;3-epi-25(OH)D2 SerPl-mCnc;;ACTIVE;2.42;2.73 +7240-5;Cocos nucifera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coconut IgG Ab [Units/volume] in Serum;Coconut IgG Qn;;ACTIVE;1.0h(2);2.73 +72405-4;Cocaine;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Cocaine [Mass/volume] in Blood by Confirmatory method;Cocaine Bld Cfm-mCnc;;ACTIVE;2.42;2.73 +72406-2;Norchlordiazepoxide;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Norchlordiazepoxide [Mass/volume] in Blood by Confirmatory method;Norchlordiazep Bld Cfm-mCnc;;ACTIVE;2.42;2.73 +72407-0;Benzoylecgonine;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Benzoylecgonine [Presence] in Blood by Screen method;BZE Bld Ql Scn;;ACTIVE;2.42;2.73 +72408-8;Microscopic observation;Prid;Pt;Anal;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Anal by Gram stain;Gram Stn Anal;;ACTIVE;2.42;2.73 +72409-6;Testosterone^post dose HCG;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Moles/volume] in Serum or Plasma --post dose HCG;Testost p HCG SerPl-sCnc;;ACTIVE;2.42;2.42 +72410-4;Testosterone^pre dose HCG;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Testosterone [Moles/volume] in Serum or Plasma --pre dose HCG;Testost pre HCG SerPl-sCnc;;ACTIVE;2.42;2.42 +72411-2;Monocytes+Macrophages;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages [#] in Cerebral spinal fluid by Manual count;Monos+Macros CSF Manual;;ACTIVE;2.42;2.73 +72412-0;BK virus subtype;Type;Pt;Urine;Nom;Probe.amp.tar;MICRO;1;BK virus subtype in Urine by NAA with probe detection;BKV subtyp Ur NAA+probe;;ACTIVE;2.42;2.63 +7241-3;Cocos nucifera basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Coconut triggered histamine release [Units/volume] in Blood;Coconut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72413-8;BK virus subtype;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;BK virus subtype in Specimen by NAA with probe detection;BKV subtyp Spec NAA+probe;;ACTIVE;2.42;2.69 +72414-6;Acetoacetate^pre-meal;SCnc;Pt;Bld;Qn;;CHAL;1;Acetoacetate [Moles/volume] in Blood --pre-meal;Acetoacet pre-meal Bld-sCnc;;ACTIVE;2.42;2.42 +72415-3;Acetoacetate^post meal;SCnc;Pt;Bld;Qn;;CHAL;1;Acetoacetate [Moles/volume] in Blood --post meal;Acetoacet p meal Bld-sCnc;;ACTIVE;2.42;2.44 +72416-1;Beta hydroxybutyrate^post meal;SCnc;Pt;Bld;Qn;;CHAL;1;Beta hydroxybutyrate [Moles/volume] in Blood --post meal;B-OH-Butyr p meal Bld-sCnc;;ACTIVE;2.42;2.42 +72417-9;Beta hydroxybutyrate^pre-meal;SCnc;Pt;Bld;Qn;;CHAL;1;Beta hydroxybutyrate [Moles/volume] in Blood --pre-meal;B-OH-Butyr pre-meal Bld-sCnc;;ACTIVE;2.42;2.42 +72418-7;Beta hydroxybutyrate/Acetoacetate^pre-meal;SRto;Pt;Bld;Qn;;CHAL;1;Beta hydroxybutyrate/Acetoacetate [Molar ratio] in Blood --pre-meal;B-OH-Butyr/Acetoacet pre-meal Bld-sRto;;ACTIVE;2.42;2.44 +72419-5;Beta hydroxybutyrate/Acetoacetate^post meal;SRto;Pt;Bld;Qn;;CHAL;1;Beta hydroxybutyrate/Acetoacetate [Molar ratio] in Blood --post meal;B-OH-Butyr/Acetoacet p meal Bld-sRto;;ACTIVE;2.42;2.44 +72420-3;Gamma aminobutyrate.free;SCnc;Pt;CSF;Qn;;CHEM;1;Gamma aminobutyrate.free [Moles/volume] in Cerebral spinal fluid;GABA. free CSF-sCnc;;ACTIVE;2.42;2.44 +7242-1;Gadus morhua basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Codfish triggered histamine release [Units/volume] in Blood;Codfish BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72421-1;Bacterial vancomycin resistance vanB gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Vancomycin resistance vanB gene [Presence] by Molecular method;vanB Islt/Spm Ql;;ACTIVE;2.42;2.73 +72422-9;Gamma aminobutyrate;SCnc;Pt;Bld^Fetus;Qn;;CHEM;1;Gamma aminobutyrate [Moles/volume] in Blood from Fetus;GABA Bld Fetus-sCnc;;ACTIVE;2.42;2.44 +72423-7;3-Methylhistidine;SCnc;Pt;Bld^Fetus;Qn;;CHEM;1;3-Methylhistidine [Moles/volume] in Blood from Fetus;3Me-histidine Bld Fetus-sCnc;;ACTIVE;2.42;2.44 +72424-5;3-Methylhistidine/Amino acids.total;SFr;Pt;Ser/Plas;Qn;;CHEM;1;3-Methylhistidine/Amino acids.total in Serum or Plasma;3Me-histidine SFr SerPl;;ACTIVE;2.42;2.44 +72425-2;7-Hydroxyoctanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-Hydroxyoctanoate [Moles/volume] in Serum or Plasma;7OH-octanoate SerPl-sCnc;;ACTIVE;2.42;2.42 +72426-0;5-Hydroxyhexanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Hydroxyhexanoate [Moles/volume] in Serum or Plasma;5OH-Hexanoate SerPl-sCnc;;ACTIVE;2.42;2.42 +72427-8;4-Hydroxyphenylpyruvate;SCnc;Pt;CSF;Qn;;CHEM;1;4-Hydroxyphenylpyruvate [Moles/volume] in Cerebral spinal fluid;4OH-phenylpyruvate CSF-sCnc;;ACTIVE;2.42;2.42 +72428-6;4-Hydroxyphenylpyruvate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxyphenylpyruvate [Moles/volume] in Serum or Plasma;4OH-phenylpyruvate SerPl-sCnc;;ACTIVE;2.42;2.42 +72429-4;4-Hydroxyphenyllactate;SCnc;Pt;CSF;Qn;;CHEM;1;4-Hydroxyphenyllactate [Moles/volume] in Cerebral spinal fluid;4OH-phenyllactate CSF-sCnc;;ACTIVE;2.42;2.42 +72430-2;4-Hydroxyphenyllactate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxyphenyllactate [Moles/volume] in Serum or Plasma;4OH-phenyllactate SerPl-sCnc;;ACTIVE;2.42;2.42 +72431-0;4-Hydroxyphenylacetate;SCnc;Pt;CSF;Qn;;CHEM;1;4-Hydroxyphenylacetate [Moles/volume] in Cerebral spinal fluid;4OH-phenylacetate CSF-sCnc;;ACTIVE;2.42;2.42 +72432-8;4-Hydroxyphenylacetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxyphenylacetate [Moles/volume] in Serum or Plasma;4OH-phenylacetate SerPl-sCnc;;ACTIVE;2.42;2.42 +72433-6;Gamma hydroxybutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;Gamma hydroxybutyrate [Moles/volume] in Cerebral spinal fluid;G-OH-Butyr CSF-sCnc;;ACTIVE;2.42;2.42 +72434-4;4,5-Dihydroxyhexanolactone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4,5-Dihydroxyhexanolactone [Moles/volume] in Serum or Plasma;4,5-DiOH-hexanolactone SerPl-sCnc;;ACTIVE;2.42;2.44 +72435-1;4,5-Dihydroxyhexanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4,5-Dihydroxyhexanoate [Moles/volume] in Serum or Plasma;4,5-DiOH-hexanoate SerPl-sCnc;;ACTIVE;2.42;2.42 +72436-9;Phenylpyruvate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenylpyruvate [Moles/volume] in Serum or Plasma;Phenylpyruvate SerPl-sCnc;;ACTIVE;2.42;2.42 +72437-7;Phenyllactate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenyllactate [Moles/volume] in Serum or Plasma;Phenyllactate SerPl-sCnc;;ACTIVE;2.42;2.42 +72438-5;3-Methylglutarate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Methylglutarate [Moles/volume] in Cerebral spinal fluid;3Me-glutarate CSF-sCnc;;ACTIVE;2.42;2.42 +7243-9;Coffee bean Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coffee bean IgE Ab [Units/volume] in Serum;Coffee Bean IgE Qn;;ACTIVE;1.0h(2);2.73 +72439-3;3-Methylglutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methylglutarate [Moles/volume] in Serum or Plasma;3Me-glutarate SerPl-sCnc;;ACTIVE;2.42;2.42 +72440-1;3-Methylglutaconate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Methylglutaconate [Moles/volume] in Cerebral spinal fluid;3Me-glutaconate CSF-sCnc;;ACTIVE;2.42;2.42 +72441-9;3-Methylcrotonylglycine;SCnc;Pt;Amnio fld;Qn;;CHEM;1;3-Methylcrotonylglycine [Moles/volume] in Amniotic fluid;3Me-crotonylglycine Amn-sCnc;;ACTIVE;2.42;2.42 +72442-7;3-Methylcrotonylglycine;SCnc;Pt;CSF;Qn;;CHEM;1;3-Methylcrotonylglycine [Moles/volume] in Cerebral spinal fluid;3Me-crotonylglycine CSF-sCnc;;ACTIVE;2.42;2.42 +72443-5;3-Methyladipate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methyladipate [Moles/volume] in Serum or Plasma;3-Methyladipate SerPl-sCnc;;ACTIVE;2.42;2.42 +72444-3;3-Hydroxytetradecanedioate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxytetradecanedioate [Moles/volume] in Serum or Plasma;3OH-Tdecanedioate SerPl-sCnc;;ACTIVE;2.42;2.42 +72445-0;3-Hydroxysuberate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxysuberate [Moles/volume] in Cerebral spinal fluid;3OHsuberate CSF-sCnc;;ACTIVE;2.42;2.42 +72446-8;3-Hydroxysuberate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxysuberate [Moles/volume] in Serum or Plasma;3OHsuberate SerPl-sCnc;;ACTIVE;2.42;2.42 +7244-7;Cola Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cola IgE Ab [Units/volume] in Serum;Cola IgE Qn;;ACTIVE;1.0h(2);2.73 +72447-6;3-Hydroxysebacate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxysebacate ( 3-OH-C8) [Moles/volume] in Cerebral spinal fluid;3OHsebacate CSF-sCnc;;ACTIVE;2.42;2.42 +72448-4;3-Hydroxysebacate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxysebacate ( 3-OH-C8) [Moles/volume] in Serum or Plasma;3OHsebacate SerPl-sCnc;;ACTIVE;2.42;2.42 +72449-2;3-Hydroxyisovalerate;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxyisovalerate [Moles/volume] in Cerebral spinal fluid;3OH-Isovalerate CSF-sCnc;;ACTIVE;2.42;2.42 +724-5;Hemoglobin;MCnc;Pt;Synv fld;Qn;;HEM/BC;1;Hemoglobin [Mass/volume] in Synovial fluid;Hgb Snv-mCnc;;ACTIVE;1.0;2.34 +72450-0;3-Hydroxyisovalerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyisovalerate [Moles/volume] in Serum or Plasma;3OH-Isovalerate SerPl-sCnc;;ACTIVE;2.42;2.42 +72451-8;Barbiturates;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Barbiturates [Presence] in Saliva (oral fluid) by Confirmatory method;Barbiturates Sal Ql Cfm;;ACTIVE;2.42;2.73 +72452-6;Secobarbital;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Secobarbital [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Secobarbital Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72453-4;PHENobarbital;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;PHENobarbital [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Phenobarb Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +7245-4;Cola Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cola IgG Ab [Units/volume] in Serum;Cola IgG Qn;;ACTIVE;1.0h(2);2.69 +72454-2;Butalbital;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Butalbital [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Butalbital Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72455-9;Amobarbital;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Amobarbital [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Amobarbital Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72456-7;Benzodiazepines;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Benzodiazepines [Presence] in Saliva (oral fluid) by Confirmatory method;Benzodiaz Sal Ql Cfm;;ACTIVE;2.42;2.73 +72457-5;Desmin Ab;PrThr;Pt;Ser/Plas;Ord;IB;SERO;1;Desmin Ab [Presence] in Serum or Plasma by Immunoblot;Desmin Ab SerPl Ql IB;;ACTIVE;2.42;2.58 +72458-3;Myosin Ab;PrThr;Pt;Ser/Plas;Ord;IB;SERO;1;Myosin Ab [Presence] in Serum or Plasma by Immunoblot;Myosin Ab SerPl Ql IB;;ACTIVE;2.42;2.58 +72459-1;JWH-018 4+5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-018 4/5-hydroxypentyl (synthetic cannabinoid metabolites) [Presence] in Urine by Confirmatory method;JWH-018 4/5OH-pentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72460-9;JWH-073 3-hydroxybutyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-073 3-hydroxybutyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-073 3OH-butyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72461-7;JWH-018 pentanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-018 pentanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-018 pentanoate Ur Ql Cfm;;ACTIVE;2.42;2.73 +7246-2;Cola nut basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cola nut triggered histamine release [Units/volume] in Blood;Cola Nut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72462-5;JWH-200 4-Hydroxyindole;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-200 4-hydroxyindole (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-200 4OH-indole Ur Ql Cfm;;ACTIVE;2.42;2.73 +72463-3;AM-2201 4-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;AM-2201 4-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;AM-2201 4OH-pentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72464-1;JWH-073 4-hydroxybutyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-073 4-hydroxybutyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-073 4OH-butyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72465-8;JWH-073 butanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-073 butanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-073 butanoate Ur Ql Cfm;;ACTIVE;2.42;2.73 +72466-6;JWH-250 5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-250 5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-250 5OH-pentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72467-4;JWH-250 5-carboxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-250 5-carboxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-250 5-carboxypentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72468-2;RCS-4 5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;RCS-4 5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;RCS-4 5OH-pentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72469-0;RCS-4 5-carboxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;RCS-4 5-carboxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;RCS-4 5-carboxypentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +7247-0;Zea mays basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Corn triggered histamine release [Units/volume] in Blood;Corn BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72470-8;MAM-2201 pentanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;MAM-2201 pentanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;MAM-2201 pentanoate Ur Ql Cfm;;ACTIVE;2.42;2.73 +72471-6;UR-144 4+5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;UR-144 4/5-hydroxypentyl (synthetic cannabinoid metabolites) [Presence] in Urine by Confirmatory method;UR-144 4/5OH-pentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72472-4;UR-144 pentanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;UR-144 pentanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;UR-144 pentanoate Ur Ql Cfm;;ACTIVE;2.42;2.73 +72473-2;JWH-398 5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-398 5 hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-398 5OH-pentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72474-0;JWH-122 5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-122 5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-122 5OH-pentyl Ur Ql Cfm;;ACTIVE;2.42;2.73 +72475-7;Methadone+Metabolite;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Methadone+Metabolite [Presence] in Saliva (oral fluid) by Confirmatory method;Methadone+metab Sal Ql Cfm;;ACTIVE;2.42;2.73 +72476-5;Methadone panel;-;Pt;Saliva;-;Confirm;PANEL.DRUG/TOX;1;Methadone panel - Saliva (oral fluid) by Confirmatory method;Methadone pnl Sal Cfm;;ACTIVE;2.44;2.44 +72478-1;Synthetic cannabinoids panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;Synthetic cannabinoids panel - Urine by Confirmatory method;Synthetic cannabinoids pnl Ur Cfm;;ACTIVE;2.42;2.42 +72479-9;Drugs of abuse panel;-;Pt;Bld;-;Screen;PANEL.DRUG/TOX;1;Drugs of abuse panel - Blood by Screen method;Drugs of abuse Pnl Bld Scn;;ACTIVE;2.44;2.44 +72480-7;Barbiturates panel;-;Pt;Bld;-;Confirm;PANEL.DRUG/TOX;1;Barbiturates panel - Blood by Confirmatory method;Barbiturates Pnl Bld Cfm;;ACTIVE;2.44;2.44 +72481-5;Candida sp 6 panel;-;Pt;Vag;-;Probe.amp.tar;PANEL.MICRO;1;Candida sp 6 panel - Vaginal fluid by NAA with probe detection;Candida sp 6 pnl Vag NAA+probe;;ACTIVE;2.42;2.73 +72482-3;BK virus subtype;Type;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;BK virus subtype in Tissue by NAA with probe detection;BKV subtyp Tiss NAA+probe;;ACTIVE;2.42;2.63 +72483-1;BK virus subtype;Type;Pt;Ser/Plas;Nom;Probe.amp.tar;MICRO;1;BK virus subtype in Serum or Plasma by NAA with probe detection;BKV subtyp SerPl NAA+probe;;ACTIVE;2.42;2.63 +72484-9;BK virus subtype;Type;Pt;Bld;Nom;Probe.amp.tar;MICRO;1;BK virus subtype in Blood by NAA with probe detection;BKV subtyp Bld NAA+probe;;ACTIVE;2.42;2.63 +72485-6;Tapentadol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Tapentadol [Presence] in Urine by Screen method;Tapentadol Ur Ql Scn;;ACTIVE;2.42;2.73 +72486-4;Laboratory director name;Pn;Pt;Provider;Nom;;MISC;1;Laboratory director name in Provider;Lab director name Provider;;ACTIVE;2.42;2.73 +72487-2;TF gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;TF gene full mutation analysis in Blood or Tissue by Sequencing;TF gene Full Mut Anl Bld/T Seq;;ACTIVE;2.42;2.66 +7248-8;Zea mays pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Corn IgE Ab [Units/volume] in Serum;Cultivated Corn IgE Qn;;ACTIVE;1.0h(2);2.73 +72488-0;Beta 2 glycoprotein 1 Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.COAG;1;Beta 2 glycoprotein 1 IgG and IgM panel - Serum;B2 glycoprot 1 IgG+IgM pnl Ser;;ACTIVE;2.42;2.42 +72489-8;Androstenedione;SCnc;Pt;Saliva;Qn;;CHEM;1;Androstenedione [Moles/volume] in Saliva (oral fluid);Androst Sal-sCnc;;ACTIVE;2.42;2.42 +72490-6;17-Hydroxyprogesterone;SCnc;Pt;Saliva;Qn;;CHEM;1;17-Hydroxyprogesterone [Moles/volume] in Saliva (oral fluid);17OHP Sal-sCnc;;ACTIVE;2.42;2.42 +72491-4;Bile acid;SCnc;Pt;Stool;Qn;;CHEM;1;Bile acid [Moles/volume] in Stool;Bile Ac Stl-sCnc;;ACTIVE;2.42;2.73 +72492-2;Paraoxonase-arylesterase 1;CCnc;Pt;Ser;Qn;;CHEM;1;Paraoxonase-arylesterase 1 (PON1) [Enzymatic activity/volume] in Serum;PON1 Ser-cCnc;;ACTIVE;2.42;2.68 +72493-0;Cytomegalovirus DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;CMV DNA SerPl NAA+probe-aCnc;;ACTIVE;2.42;2.73 +72494-8;Cytomegalovirus DNA;LaCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [log units/volume] (viral load) in Serum or Plasma by NAA with probe detection;CMV DNA SerPl NAA+probe-Log IU;;ACTIVE;2.42;2.73 +72495-5;Candida parapsilosis DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida parapsilosis DNA [Presence] in Vaginal fluid by NAA with probe detection;C parap DNA Vag Ql NAA+probe;;ACTIVE;2.42;2.73 +7249-6;Cornish hen basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cornish hen triggered histamine release [Units/volume] in Blood;Cornish Hen BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72496-3;DNA double strand;MCnc;Pt;XXX;Qn;;MOLPATH;1;DNA double strand [Mass/volume] in Specimen;dsDNA Spec-mCnc;;ACTIVE;2.42;2.69 +72497-1;Dihydropteridine reductase;CCnt;Pt;Bld.dot;Qn;;CHEM;1;Dihydropteridine reductase [Enzymatic activity/mass] in DBS;DHP Reduct DBS-cCnt;;ACTIVE;2.42;2.61 +72498-9;Tripeptidyl peptidase I;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Tripeptidyl peptidase I [Enzymatic activity/volume] in DBS;Tripeptidyl peptidase I DBS-cCnc;;ACTIVE;2.42;2.61 +72499-7;Oval fat bodies (globules);Naric;Pt;Stool;Qn;Microscopy.light.LPF;CHEM;1;Oval fat bodies (globules) [#/area] in Stool by Microscopy low power field;Oval fat bodies #/area Stl LPF;;ACTIVE;2.42;2.42 +72500-2;Homocyst(e)ine^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Homocyst(e)ine [Moles/volume] in Serum or Plasma --fasting;Hcys p fast SerPl-sCnc;;ACTIVE;2.42;2.42 +72501-0;Homocyst(e)ine^6H post dose methionine;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Homocyst(e)ine [Moles/volume] in Serum or Plasma --6 hours post dose methionine;Hcys 6h p Met SerPl-sCnc;;ACTIVE;2.42;2.42 +72502-8;Homocyst(e)ine^6H post dose methionine - post CFst;SCncDiff;Pt;Ser/Plas;Qn;;CHAL;1;Homocyst(e)ine [Molar concentration difference] in Serum or Plasma --6 hours post dose methionine - post CFst;Hcys 6h p Met-CFst SerPl-SCDiff;;ACTIVE;2.42;2.5 +72503-6;WT1 gene exon 1+2 transcript/control transcript;NRto;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;WT1 gene exon 1+2 transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method;WT1 ex 1+2/control Bld/T;;ACTIVE;2.42;2.42 +7250-4;Cotton gin dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cotton gin dust IgE Ab [Units/volume] in Serum;Cotton Gin Dust IgE Qn;;ACTIVE;1.0h(2);2.42 +72504-4;CV2 Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;CV2 Ab [Presence] in Serum or Plasma by Immunofluorescence;CV2 Ab SerPl Ql IF;;ACTIVE;2.42;2.73 +72505-1;Exserohilum rostratum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Exserohilum rostratum DNA [Presence] in Specimen by NAA with probe detection;E rostratum DNA Spec Ql NAA+probe;;ACTIVE;2.42;2.69 +72506-9;ABCB1 gene.c.3435C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;ABCB1 gene c.3435C>T [Presence] in Blood or Tissue by Molecular genetics method;ABCB1 c.3435C>T Bld/T Ql;;ACTIVE;2.42;2.56 +72507-7;VKORC1 gene.c.1173C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;VKORC1 gene c.1173C>T [Presence] in Blood or Tissue by Molecular genetics method;VKORC1 c.1173C>T Bld/T Ql;;ACTIVE;2.42;2.67 +72508-5;UGT1A1 gene.c.A(TA)7TAA(*28);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;UGT1A1 gene c.A(TA)7TAA(*28) [Presence] in Blood or Tissue by Molecular genetics method;UGT1A1*28 Bld/T Ql;;ACTIVE;2.42;2.73 +72509-3;Reporting rate;NFr;RptPeriod;{Setting}^Population;Qn;Calculated;DOC.QUALITY;2;Reporting rate Reporting Period Population Calculated;Report rate RptPeriod NFr Pop Calc;;ACTIVE;2.42;2.52 +72510-1;Performance rate;NFr;RptPeriod;{Setting}^Population;Qn;Calculated;DOC.QUALITY;2;Performance rate Reporting Period Population Calculated;Perform rate RptPeriod NFr Pop Calc;;ACTIVE;2.42;2.52 +72511-9;CYP2B6 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;CYP2B6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP2B6 Mut Anl Bld/T;;ACTIVE;2.42;2.67 +7251-2;Cotton linters Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cotton linters IgE Ab [Units/volume] in Serum;Cotton Linters IgE Qn;;ACTIVE;1.0h(2);2.73 +72512-7;VKORC1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;VKORC1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;VKORC1 gene Mut Anl Bld/T;;ACTIVE;2.42;2.67 +72513-5;Vital signs with smoking status and pain scale;-;Pt;^Patient;-;VSP;PANEL.SURVEY.GNHLTH;4;Vital signs with smoking status and pain scale [VSP];;;ACTIVE;2.42;2.44 +72514-3;Pain severity - 0-10 verbal numeric rating;Score;Pt;^Patient;Qn;Reported;H&P.HX;2;Pain severity - 0-10 verbal numeric rating [Score] - Reported;Pain severity 0-10 Score Reported;;ACTIVE;2.42;2.73 +72515-0;Myeloperoxidase Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Myeloperoxidase IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;Myeloperoxidase IgG SerPl Ql IF;;ACTIVE;2.42;2.56 +72516-8;Glucose;SCnc;Pt;Bld;Qn;Test strip.automated;CHEM;1;Glucose [Moles/volume] in Blood by Automated test strip;Glucose Bld Strip.auto-sCnc;;ACTIVE;2.42;2.73 +72517-6;Spermatozoa^post ejaculate;Num;Pt;Semen;Qn;;FERT;1;Spermatozoa [#] in Semen --post ejaculate;Sperm post ejac Smn;;ACTIVE;2.42;2.73 +72518-4;CHEK2 gene.c.470C>T & 1100delC;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CHEK2 gene c.470C>T and 1100delC [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CHEK2 c.470C>T+1100delC Bld/T;;ACTIVE;2.42;2.61 +72519-2;Infections present &or treated during this pregnancy for live birth;Prid;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Infections present AndOr treated during this pregnancy for live birth [US Standard Certificate of Live Birth];;;ACTIVE;2.42;2.44 +725-2;Hemoglobin;PrThr;Pt;Urine;Ord;;HEM/BC;1;Hemoglobin [Presence] in Urine;Hgb Ur Ql;;ACTIVE;1.0;2.73 +7252-0;Cotton linters basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cotton linters triggered histamine release [Units/volume] in Blood;Cotton Linters BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72520-0;FLT3 gene.p.Asp835+Ile836 mutations;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;FLT3 gene.p.Asp835+Ile836 mutations [Presence] in Blood or Tissue by Molecular genetics method;FLT3 p.D835+I836 Bld/T Ql;;ACTIVE;2.42;2.73 +72521-8;p-ANCA formalin sensitive Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;p-ANCA formalin sensitive IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;p-ANCA frmln sens IgG SerPl Ql IF;;ACTIVE;2.42;2.56 +72522-6;p-ANCA formalin resistant Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;p-ANCA formalin resistant IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;p-ANCA frmln resist IgG SerPl Ql IF;;ACTIVE;2.42;2.56 +72523-4;Glutamate decarboxylase 65 Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Glutamate decarboxylase 65 Ab [Presence] in Serum or Plasma by Immunofluorescence;GAD65 Ab SerPl Ql IF;;ACTIVE;2.42;2.73 +72524-2;Myelin Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Myelin Ab [Presence] in Serum or Plasma by Immunofluorescence;Myelin Ab SerPl Ql IF;;ACTIVE;2.42;2.73 +72525-9;Raltegravir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Raltegravir [Susceptibility] by Genotype method;Raltegravir Islt Genotyp;;ACTIVE;2.42;2.73 +72526-7;Elvitegravir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Elvitegravir [Susceptibility] by Genotype method;Elvitegravir Islt Genotyp;;ACTIVE;2.42;2.73 +72527-5;Pressure ulcer stage;Find;Pt;^Patient;Nom;NPUAP;H&P.PX;2;Deprecated Pressure ulcer stage NPUAP;Deprecated Pressure ulcer stage NPUAP;Copyright © 2012 National Pressure Ulcer Advisory Panel (NPUAP). Used with permission.;DEPRECATED;2.42;2.73 +72528-3;Multisection;Find;Pt;Chest>Axilla.right;Doc;US;RAD;2;US Axilla - right;US Axilla-R;;ACTIVE;2.42;2.73 +72529-1;Multisection;Find;Pt;Chest>Axilla.left;Doc;US;RAD;2;US Axilla - left;US Axilla-L;;ACTIVE;2.42;2.61 +72530-9;Guidance for injection;Find;Pt;XXX>Joint;Doc;US;RAD;2;US Guidance for injection of Joint;US Guided Joint Inj;;ACTIVE;2.42;2.64 +72531-7;Multisection^W contrast IV+W air contrast PR;Find;Pt;Abdomen+Pelvis>Colon+Rectum;Doc;CT;RAD;2;CT Colon and Rectum W contrast IV and W air contrast PR;CT Colon+Rect W contr IV+Air contr PR;;ACTIVE;2.42;2.61 +72532-5;Guidance for ambulatory phlebectomy;Find;Pt;Extremity.right>Extremity vein;Doc;US;RAD;2;US Guidance for ambulatory phlebectomy of Extremity vein - right;US Guided Extr v-R Amb phleb;;ACTIVE;2.42;2.64 +72533-3;Guidance for ambulatory phlebectomy;Find;Pt;Extremity.left>Extremity vein;Doc;US;RAD;2;US Guidance for ambulatory phlebectomy of Extremity vein - left;US Guided Extr v-L Amb phleb;;ACTIVE;2.42;2.64 +72534-1;Guidance for laser ablation;Find;Pt;Extremity.right>Extremity vein;Doc;US;RAD;2;US Guidance for laser ablation of Extremity vein - right;US Guided Extr v-R Laser ablation;;ACTIVE;2.42;2.64 +72535-8;Guidance for laser ablation;Find;Pt;Extremity.left>Extremity vein;Doc;US;RAD;2;US Guidance for laser ablation of Extremity vein - left;US Guided Extr v-L Laser ablation;;ACTIVE;2.42;2.64 +72536-6;Guidance for vascular sclerotherapy;Find;Pt;Extremity.bilateral>Extremity veins;Doc;US;RAD;2;US Guidance for vascular sclerotherapy of Extremity veins - bilateral;US Guided Extr vv-Bl Vasc sclerotherapy;;ACTIVE;2.42;2.64 +72537-4;Guidance for vascular sclerotherapy;Find;Pt;Extremity.bilateral>Extremity vein;Doc;US;RAD;2;US Guidance for vascular sclerotherapy of Extremity vein - bilateral;US Guided Extr v-Bl Vasc sclerotherapy;;ACTIVE;2.42;2.64 +7253-8;Cottonseed Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cottonseed IgG Ab [Units/volume] in Serum;Cottonseed IgG Qn;;ACTIVE;1.0h(2);2.69 +72538-2;Guidance for removal of peripherally-inserted central venous catheter;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for removal of peripherally-inserted central venous catheter from Vein;RFA Guided Vein Periph CVC rem;;ACTIVE;2.42;2.67 +72539-0;Guidance for denervation;Find;Pt;XXX>Peripheral nerve;Doc;RF;RAD;2;RF Guidance for denervation of Peripheral nerve;RF Guided PN Denerv;;ACTIVE;2.42;2.64 +72540-8;Guidance for denervation;Find;Pt;XXX>Spine facet joint;Doc;RF;RAD;2;RF Guidance for denervation of Spine facet joint;RF Guided Spine FJ Denerv;;ACTIVE;2.42;2.65 +72541-6;Guidance for denervation;Find;Pt;Neck>Spine.cervical facet joint;Doc;RF;RAD;2;RF Guidance for denervation of Spine Cervical Facet Joint;RF Guided C-Spine facet joint Denerv;;ACTIVE;2.42;2.64 +72542-4;Guidance for denervation;Find;Pt;Abdomen>Spine.lumbar facet joint;Doc;RF;RAD;2;RF Guidance for denervation of Lumbar Spine Facet Joint;RF Guided L-spine facet joint Denerv;;ACTIVE;2.42;2.66 +72543-2;Guidance for denervation;Find;Pt;Chest>Spine.thoracic intercostal nerve;Doc;RF;RAD;2;RF Guidance for denervation of Thoracic spine intercostal nerve;RF Guided T-spine ICN Denerv;;ACTIVE;2.42;2.64 +72544-0;Guidance for percutaneous device removal of nephrostomy tube^W contrast;Find;Pt;Abdomen>Kidney.bilateral;Doc;RF;RAD;2;RF Guidance for percutaneous device removal of nephrostomy tube of Kidney - bilateral-- W contrast;RF Guided Kdny-Bl PNT removal--W contr;;ACTIVE;2.42;2.64 +72545-7;Guidance for percutaneous replacement of drainage catheter;Find;Pt;Abdomen>Biliary ducts+Gallbladder;Doc;RF;RAD;2;RF Guidance for percutaneous replacement of drainage catheter of Biliary ducts and Gallbladder;RF Guided BDs+GB PC drain cath replace;;ACTIVE;2.42;2.68 +7254-6;Populus nigra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Cottonwood IgE Ab [Units/volume] in Serum;Black Cottonwood IgE Qn;;ACTIVE;1.0h(2);2.73 +72546-5;Guidance for substance removal of central venous catheter lumen obstruction;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for removal of CV catheter lumen obstruction of Vein;RFA Guided Vein CVC lumen obs rem;;ACTIVE;2.42;2.64 +72547-3;Guidance for substance removal of central venous catheter pericatheter obstruction;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for removal of CV catheter pericatheter obstruction of Vein;RFA Guided Vein CVC pericath obs rem;;ACTIVE;2.42;2.64 +72548-1;Guidance for removal of central venous catheter^W contrast IV;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for removal of CV catheter from Vein-- W contrast IV;RFA Guided Vein CVC rem--W contr IV;;ACTIVE;2.42;2.67 +72549-9;Guidance for removal of tunneled central venous catheter;Find;Pt;XXX>Vein;Doc;RF;RAD;2;RF Guidance for removal of tunneled CV catheter;RF Guided Tunneled CVC rem;;ACTIVE;2.42;2.67 +72550-7;Guidance for repair of central venous catheter with port or pump;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for repair of CV catheter with port or pump of Vein;RFA Guided Vein CVC W pump repair;;ACTIVE;2.42;2.64 +72551-5;Guidance for repair of central venous catheter without port or pump;Find;Pt;XXX>Vein;Doc;RF.angio;RAD;2;RFA Guidance for repair of CV catheter without port or pump of Vein;RFA Guided Vein CVC WO pump repair;;ACTIVE;2.42;2.64 +72552-3;Guidance for kyphoplasty;Find;Pt;Abdomen>Spine.lumbar;Doc;RF;RAD;2;RF Guidance for kyphoplasty of Lumbar spine;RF Guided L-spine Kyphoplasty;;ACTIVE;2.42;2.64 +7255-3;Populus fremontii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Western Cottonwood IgE Ab [Units/volume] in Serum;West Cottonwood IgE Qn;;ACTIVE;1.0h(2);2.73 +72553-1;Guidance for kyphoplasty;Find;Pt;Chest>Spine.thoracic;Doc;RF;RAD;2;RF Guidance for kyphoplasty of Thoracic spine;RF Guided T-spine Kyphoplasty;;ACTIVE;2.42;2.64 +72554-9;Guidance for trigger point injection;Find;Pt;XXX>Muscle;Doc;RF;RAD;2;RF Guidance for trigger point injection of Muscle;RF Guided Muscle TPI;;ACTIVE;2.42;2.64 +72555-6;Consultation note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Consult note;IR Consult note;;ACTIVE;2.42;2.58 +72556-4;Progress note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Progress note;IR Prog note;;ACTIVE;2.42;2.73 +72557-2;Rilpivirine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Rilpivirine [Susceptibility] by Phenotype method;Rilpivirine Islt Phenotyp;;ACTIVE;2.42;2.73 +72558-0;Etravirine;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Etravirine [Susceptibility] by Phenotype method;Etravirine Islt Phenotyp;;ACTIVE;2.42;2.73 +72559-8;HIV integrase inhibitor susceptibility panel;-;Pt;Isolate;-;Phenotyping;PANEL.ABXBACT;1;HIV integrase inhibitor susceptibility panel by Phenotype method;HIV INI Susc Pnl Islt Phenotyp;;ACTIVE;2.42;2.63 +72560-6;HIV integrase inhibitor susceptibility panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;HIV integrase inhibitor susceptibility panel by Genotype method;HIV INI Susc Pnl Islt Genotyp;;ACTIVE;2.42;2.73 +7256-1;Populus fremontii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Western Cottonwood IgE Ab [Units/volume] in Serum;Deprecated West Cottonwood IgE Qn;;DEPRECATED;1.0h(2);2.69 +72561-4;Creatine kinase.aberrant band/Creatine kinase.total;CFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine Kinase aberrant band/Creatine kinase.total [Pure catalytic fraction] in Serum or Plasma by Electrophoresis;CK-AB CFr.DF SerPl Elph;;ACTIVE;2.42;2.5 +72562-2;Creatine kinase.MM/Creatine kinase.total;CFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.MM/Creatine kinase.total [Pure catalytic fraction] in Serum or Plasma by Electrophoresis;CK MM CFr.DF SerPl Elph;;ACTIVE;2.42;2.42 +72563-0;Creatine kinase.MB/Creatine kinase.total;CFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.MB/Creatine kinase.total [Pure catalytic fraction] in Serum or Plasma by Electrophoresis;CK MB CFr.DF SerPl Elph;;ACTIVE;2.42;2.42 +72564-8;Creatine kinase.MB/Creatine kinase.total;CFr.DF;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Creatine kinase.MB/Creatine kinase.total [Pure catalytic fraction] in Serum or Plasma by calculation;CK MB CFr.DF SerPl Calc;;ACTIVE;2.42;2.73 +72565-5;Creatine kinase.BB/Creatine kinase.total;CFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Creatine kinase.BB/Creatine kinase.total [Pure catalytic fraction] in Serum or Plasma by Electrophoresis;CK BB CFr.DF SerPl Elph;;ACTIVE;2.42;2.42 +72566-3;Cholinesterase.scoline inhibited/Cholinesterase;CFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.scoline inhibited/Cholinesterase [Pure catalytic fraction] in Serum or Plasma;Scoline Inhib/CHe CFr.DF SerPl;;ACTIVE;2.42;2.42 +72567-1;Cholinesterase.RO 020683 inhibited/Cholinesterase;CFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.RO 020683 inhibited/Cholinesterase [Pure catalytic fraction] in Serum or Plasma;RO 020683 Inhib/CHe CFr.DF SerPl;;ACTIVE;2.42;2.42 +72568-9;Cholinesterase.fluoride inhibited/Cholinesterase;CFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.fluoride inhibited/Cholinesterase [Pure catalytic fraction] in Serum or Plasma;Fluoride Inhib/CHe CFr.DF SerPl;;ACTIVE;2.42;2.42 +72569-7;Cholinesterase^dibucaine/Cholinesterase;CFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase [Pure catalytic fraction] in Serum or Plasma --dibucaine/Cholinesterase;CHe dibuc/CHe CFr.DF SerPl;;ACTIVE;2.42;2.52 +72570-5;Cholinesterase.chloride inhibited/Cholinesterase;CFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Cholinesterase.chloride inhibited/Cholinesterase [Pure catalytic fraction] in Serum or Plasma;Chloride Inhib/CHe CFr.DF SerPl;;ACTIVE;2.42;2.42 +72571-3;Amylase.pancreatic/Amylase.total;CFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.pancreatic/Amylase.total [Pure catalytic fraction] in Serum or Plasma;Amylase P CFr.DF SerPl;;ACTIVE;2.42;2.42 +72572-1;Amylase.salivary/Amylase.total;CFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Amylase.salivary/Amylase.total [Pure catalytic fraction] in Serum or Plasma;Amylase S CFr.DF SerPl;;ACTIVE;2.42;2.42 +72573-9;Uroporphyrin/Porphyrins.total;SFr.DF;24H;Urine;Qn;;CHEM;1;Uroporphyrin/Porphyrins.total [Pure substance fraction] in 24 hour Urine;Uropor 24h SFr.DF Ur;;ACTIVE;2.42;2.42 +72574-7;Coproporphyrin/Porphyrins.total;SFr.DF;24H;Urine;Qn;;CHEM;1;Coproporphyrin/Porphyrins.total [Pure substance fraction] in 24 hour Urine;Copro 24h SFr.DF Ur;;ACTIVE;2.42;2.42 +72575-4;Macroprolactin/Prolactin;MFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Macroprolactin/Prolactin [Pure mass fraction] in Serum or Plasma;Macroprolactin/Prolactin MFr.DF SerPl;;ACTIVE;2.42;2.42 +72576-2;Prostate specific Ag.free/Prostate specific Ag.total;MFr.DF;Pt;Ser/Plas;Qn;;CHEM;1;Prostate Specific Ag Free/Prostate specific Ag.total [Pure mass fraction] in Serum or Plasma;PSA Free MFr.DF SerPl;;ACTIVE;2.42;2.73 +72577-0;Protein.monoclonal/Protein.total;MFr.DF;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal/Protein.total [Pure mass fraction] in 24 hour Urine by Electrophoresis;M Protein 24h MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72578-8;Prealbumin/Protein.total;MFr.DF;Pt;Urine;Qn;Electrophoresis;CHEM;1;Prealbumin/Protein.total [Pure mass fraction] in Urine by Electrophoresis;Prealb MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +7257-9;Cow epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow epithelium IgE Ab [Units/volume] in Serum;Cow Epith IgE Qn;;ACTIVE;1.0h(2);2.73 +72579-6;Prealbumin/Protein.total;MFr.DF;Pt;CSF;Qn;Electrophoresis;CHEM;1;Prealbumin/Protein.total [Pure mass fraction] in Cerebral spinal fluid by Electrophoresis;Prealb MFr.DF CSF Elph;;ACTIVE;2.42;2.42 +72580-4;Gamma globulin/Protein.total;MFr.DF;24H;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total [Pure mass fraction] in 24 hour Urine by Electrophoresis;Gamma glob 24h MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72581-2;Gamma globulin/Protein.total;MFr.DF;Pt;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total [Pure mass fraction] in Urine by Electrophoresis;Gamma glob MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72582-0;Gamma globulin/Protein.total;MFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total [Pure mass fraction] in Serum or Plasma by Electrophoresis;Gamma glob MFr.DF SerPl Elph;;ACTIVE;2.42;2.73 +72583-8;Gamma globulin/Protein.total;MFr.DF;Pt;CSF;Qn;Electrophoresis;CHEM;1;Gamma globulin/Protein.total [Pure mass fraction] in Cerebral spinal fluid by Electrophoresis;Gamma glob MFr.DF CSF Elph;;ACTIVE;2.42;2.42 +72584-6;Beta globulin/Protein.total;MFr.DF;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total [Pure mass fraction] in 24 hour Urine by Electrophoresis;B-Globulin 24h MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72585-3;Beta globulin/Protein.total;MFr.DF;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total [Pure mass fraction] in Urine by Electrophoresis;B-Globulin MFr.DF Ur Elph;;ACTIVE;2.42;2.73 +72586-1;Beta globulin/Protein.total;MFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total [Pure mass fraction] in Serum or Plasma by Electrophoresis;B-Globulin MFr.DF SerPl Elph;;ACTIVE;2.42;2.73 +7258-7;Cow milk Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow milk IgE Ab [Units/volume] in Serum;Cow Milk IgE Qn;;ACTIVE;1.0h(2);2.73 +72587-9;Beta globulin/Protein.total;MFr.DF;Pt;CSF;Qn;Electrophoresis;CHEM;1;Beta globulin/Protein.total [Pure mass fraction] in Cerebral spinal fluid by Electrophoresis;B-Globulin MFr.DF CSF Elph;;ACTIVE;2.42;2.42 +72588-7;Alpha 2 globulin/Protein.total;MFr.DF;24H;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total [Pure mass fraction] in 24 hour Urine by Electrophoresis;Alpha2 Glob 24h MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72589-5;Alpha 2 globulin/Protein.total;MFr.DF;Pt;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total [Pure mass fraction] in Urine by Electrophoresis;Alpha2 Glob MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72590-3;Alpha 2 globulin/Protein.total;MFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total [Pure mass fraction] in Serum or Plasma by Electrophoresis;Alpha2 Glob MFr.DF SerPl Elph;;ACTIVE;2.42;2.73 +72591-1;Alpha 2 globulin/Protein.total;MFr.DF;Pt;CSF;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin/Protein.total [Pure mass fraction] in Cerebral spinal fluid by Electrophoresis;Alpha2 Glob MFr.DF CSF Elph;;ACTIVE;2.42;2.42 +72592-9;Alpha 1 globulin/Protein.total;MFr.DF;24H;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total [Pure mass fraction] in 24 hour Urine by Electrophoresis;Alpha1 Glob 24h MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72593-7;Alpha 1 globulin/Protein.total;MFr.DF;Pt;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total [Pure mass fraction] in Urine by Electrophoresis;Alpha1 Glob MFr.DF Ur Elph;;ACTIVE;2.42;2.73 +72594-5;Alpha 1 globulin/Protein.total;MFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total [Pure mass fraction] in Serum or Plasma by Electrophoresis;Alpha1 Glob MFr.DF SerPl Elph;;ACTIVE;2.42;2.73 +7259-5;Cow milk basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cow milk triggered histamine release [Units/volume] in Blood;Cow Milk BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72595-2;Alpha 1 globulin/Protein.total;MFr.DF;Pt;CSF;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin/Protein.total [Pure mass fraction] in Cerebral spinal fluid by Electrophoresis;Alpha1 Glob MFr.DF CSF Elph;;ACTIVE;2.42;2.42 +72596-0;Albumin/Protein.total;MFr.DF;24H;Urine;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total [Pure mass fraction] in 24 hour Urine by Electrophoresis;Albumin 24h MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72597-8;Albumin/Protein.total;MFr.DF;Pt;Urine;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total [Pure mass fraction] in Urine by Electrophoresis;Albumin MFr.DF Ur Elph;;ACTIVE;2.42;2.42 +72598-6;Albumin/Protein.total;MFr.DF;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total [Pure mass fraction] in Serum or Plasma by Electrophoresis;Albumin MFr.DF SerPl Elph;;ACTIVE;2.42;2.73 +72599-4;Albumin/Protein.total;MFr.DF;Pt;CSF;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total [Pure mass fraction] in Cerebral spinal fluid by Electrophoresis;Albumin MFr.DF CSF Elph;;ACTIVE;2.42;2.42 +726-0;Hemoglobin;MCnc;Pt;Urine;Qn;;UA;1;Hemoglobin [Mass/volume] in Urine;Hgb Ur-mCnc;;ACTIVE;1.0;2.73 +72600-0;Albumin/Protein.total;MFr.DF;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Albumin/Protein.total [Pure mass fraction] in Body fluid by Electrophoresis;Albumin MFr.DF Fld Elph;;ACTIVE;2.42;2.42 +72601-8;Beta hydroxybutyrate+Acetoacetate^pre-meal;SCnc;Pt;Bld;Qn;;CHAL;1;Beta hydroxybutyrate + Acetoacetate [Moles/volume] in Blood --pre-meal;B-OH-Butyr+Acetoacet pre-meal Bld-sCnc;;ACTIVE;2.42;2.42 +72602-6;Beta hydroxybutyrate+Acetoacetate^post meal;SCnc;Pt;Bld;Qn;;CHAL;1;Beta hydroxybutyrate + Acetoacetate [Moles/volume] in Blood --post meal;B-OH-Butyr+Acetoacet p meal Bld-sCnc;;ACTIVE;2.42;2.42 +7260-3;Cancer pagurus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Crab IgG Ab [Units/volume] in Serum;Crab IgG Qn;;ACTIVE;1.0h(2);2.73 +72603-4;Beta hydroxybutyrate+Acetoacetate;SCnc;Pt;Bld;Qn;;CHEM;1;Beta hydroxybutyrate + Acetoacetate [Moles/volume] in Blood;B-OH-Butyr+Acetoacet Bld-sCnc;;ACTIVE;2.42;2.73 +72604-2;Insulin^4.5H post 75 g glucose PO;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --4.5 hours post 75 g glucose PO;Insulin 4.5h p 75 g Glc PO SerPl-aCnc;;ACTIVE;2.42;2.42 +72605-9;Cytomegalovirus glycoprotein genotype;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Cytomegalovirus glycoprotein genotype in Specimen by NAA with probe detection;CMV gp Gentyp Spec NAA+probe;;ACTIVE;2.42;2.72 +72606-7;Hepatitis D virus genotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Hepatitis D virus genotype [Identifier] in Specimen by NAA with probe detection;HDV Gentyp Spec NAA+probe;;ACTIVE;2.42;2.72 +72607-5;Streptococcus agalactiae;PrThr;Pt;Vag+Rectum;Ord;Organism specific culture;MICRO;1;Streptococcus agalactiae [Presence] in Vag+Rectum by Organism specific culture;Gp B Strep Vag+Rectum Ql Cult;;ACTIVE;2.42;2.73 +72608-3;Apixaban;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Apixaban [Mass/volume] in Serum or Plasma;Apixaban SerPl-mCnc;;ACTIVE;2.42;2.73 +72609-1;Nonsteroidal antiinflammatory drugs;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Nonsteroidal antiinflammatory drugs [Presence] in Serum or Plasma by Screen method;NSAIDs SerPl Ql Scn;;ACTIVE;2.42;2.73 +72610-9;diazePAM;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;diazePAM [Mass/volume] in Saliva (oral fluid) by Confirmatory method;diazePAM Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +7261-1;Cancer pagurus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Crab triggered histamine release [Units/volume] in Blood;Crab BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72611-7;diazePAM;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;diazePAM [Presence] in Saliva (oral fluid);diazePAM Sal Ql;;ACTIVE;2.42;2.73 +72612-5;ALPRAZolam;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;ALPRAZolam [Presence] in Saliva (oral fluid);Alpraz Sal Ql;;ACTIVE;2.42;2.73 +72613-3;Oxazepam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Oxazepam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Oxazepam Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72614-1;Oxazepam;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Oxazepam [Presence] in Saliva (oral fluid);Oxazepam Sal Ql;;ACTIVE;2.42;2.73 +72615-8;Nordiazepam;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Nordiazepam [Presence] in Saliva (oral fluid);Nordiazepam Sal Ql;;ACTIVE;2.42;2.73 +72616-6;Benzodiazepines;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Benzodiazepines [Presence] in Saliva (oral fluid);Benzodiaz Sal Ql;;ACTIVE;2.42;2.56 +72617-4;Propoxyphene;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Propoxyphene [Presence] in Saliva (oral fluid) by Screen method;Propoxyph Sal Ql Scn;;ACTIVE;2.42;2.73 +72618-2;Propoxyphene+Norpropoxyphene;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Presence] in Saliva (oral fluid);Propoxyph+Nor Sal Ql;;ACTIVE;2.42;2.73 +72619-0;Norpropoxyphene;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Norpropoxyphene [Mass/volume] in Saliva (oral fluid);Norpropoxyph Sal-mCnc;;ACTIVE;2.42;2.73 +72620-8;Norpropoxyphene;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Norpropoxyphene [Presence] in Saliva (oral fluid);Norpropoxyph Sal Ql;;ACTIVE;2.42;2.73 +72621-6;Propoxyphene;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Propoxyphene [Mass/volume] in Saliva (oral fluid);Propoxyph Sal-mCnc;;ACTIVE;2.42;2.73 +72622-4;Propoxyphene;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Propoxyphene [Presence] in Saliva (oral fluid);Propoxyph Sal Ql;;ACTIVE;2.42;2.73 +72623-2;inFLIXimab Ab;MCnc;Pt;Ser/Plas;Qn;;SERO;1;inFLIXimab Ab [Mass/volume] in Serum or Plasma;inFLIXimab Ab SerPl-mCnc;;ACTIVE;2.42;2.73 +72624-0;Rivaroxaban;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Rivaroxaban [Mass/volume] in Serum or Plasma;Rivaroxaban SerPl-mCnc;;ACTIVE;2.42;2.73 +72625-7;Dabigatran;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dabigatran [Mass/volume] in Serum or Plasma;Dabigatran SerPl-mCnc;;ACTIVE;2.42;2.73 +72626-5;Methadone;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Methadone [Presence] in Saliva (oral fluid) by Screen method;Methadone Sal Ql Scn;;ACTIVE;2.42;2.73 +72627-3;Barbiturates;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Saliva (oral fluid) by Screen method;Barbiturates Sal Ql Scn;;ACTIVE;2.42;2.73 +72628-1;PHENobarbital;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;PHENobarbital [Presence] in Saliva (oral fluid) by Confirmatory method;Phenobarb Sal Ql Cfm;;ACTIVE;2.42;2.73 +7262-9;Vaccinium oxycoccos Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cranberry IgE Ab [Units/volume] in Serum;Cranberry IgE Qn;;ACTIVE;1.0h(2);2.73 +72629-9;Secobarbital;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Secobarbital [Presence] in Saliva (oral fluid) by Confirmatory method;Secobarbital Sal Ql Cfm;;ACTIVE;2.42;2.73 +72630-7;PENTobarbital;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;PENTobarbital [Presence] in Saliva (oral fluid) by Confirmatory method;Pentobarb Sal Ql Cfm;;ACTIVE;2.42;2.73 +72631-5;Amobarbital;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Amobarbital [Presence] in Saliva (oral fluid) by Confirmatory method;Amobarbital Sal Ql Cfm;;ACTIVE;2.42;2.73 +72632-3;Butalbital;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Butalbital [Presence] in Saliva (oral fluid) by Confirmatory method;Butalbital Sal Ql Cfm;;ACTIVE;2.42;2.73 +72633-1;Benzodiazepines;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Benzodiazepines [Presence] in Saliva (oral fluid) by Screen method;Benzodiaz Sal Ql Scn;;ACTIVE;2.42;2.73 +72634-9;Temazepam;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Temazepam [Presence] in Saliva (oral fluid);Temazepam Sal Ql;;ACTIVE;2.42;2.73 +72635-6;PENTobarbital;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;PENTobarbital [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Pentobarb Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72636-4;Total score;Score;Pt;^Patient;Qn;BSL-SUPP;SURVEY.MTLHLTH;4;Total score [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +7263-7;Vaccinium oxycoccos Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cranberry IgG Ab [Units/volume] in Serum;Cranberry IgG Qn;;ACTIVE;1.0h(2);2.69 +72637-2;I had uncontrollable sexual encounters of which I was later ashamed or which made me angry in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I had uncontrollable sexual encounters of which I was later ashamed or which made me angry in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72638-0;I had outbreaks of uncontrolled anger or physically attacked others in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I had outbreaks of uncontrolled anger or physically attacked others in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72639-8;I took medication that had not been prescribed or if had been prescribed, I took more than the prescribed dose in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I took medication that had not been prescribed or if had been prescribed, I took more than the prescribed dose in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72640-6;I took drugs in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I took drugs in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72641-4;I got drunk in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I got drunk in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72642-2;Guidance for vascular sclerotherapy;Find;Pt;Extremity.right>Extremity veins;Doc;US;RAD;2;US Guidance for vascular sclerotherapy of Extremity veins - right;US Guided Extr vv-R Vasc sclerotherapy;;ACTIVE;2.42;2.64 +72643-0;Guidance for vascular sclerotherapy;Find;Pt;Extremity.left>Extremity veins;Doc;US;RAD;2;US Guidance for vascular sclerotherapy of Extremity veins - left;US Guided Extr vv-L Vasc sclerotherapy;;ACTIVE;2.42;2.64 +72644-8;Guidance for vascular sclerotherapy;Find;Pt;Extremity.right>Extremity vein;Doc;US;RAD;2;US Guidance for vascular sclerotherapy of Extremity vein - right;US Guided Extr v-R Vasc sclerotherapy;;ACTIVE;2.42;2.64 +7264-5;Vaccinium oxycoccos basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cranberry triggered histamine release [Units/volume] in Blood;Cranberry BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72645-5;Guidance for vascular sclerotherapy;Find;Pt;Extremity.left>Extremity vein;Doc;US;RAD;2;US Guidance for vascular sclerotherapy of Extremity vein - left;US Guided Extr v-L Vasc sclerotherapy;;ACTIVE;2.42;2.64 +72646-3;Albumin.serum-albumin.pericard fld;MCncDiff;Pt;Pericard fld+Ser/Plas;Qn;;CHEM;1;Albumin in serum - albumin in pericardial fluid [Mass concentration difference];Albumin ser-peric fld-MCDiff;;ACTIVE;2.42;2.5 +72647-1;Albumin.serum-albumin.plr fld;MCncDiff;Pt;Ser/Plas+Plr fld;Qn;;CHEM;1;Albumin in serum - albumin in pleural fluid [Mass concentration difference];Albumin ser-plr fld-MCDiff;;ACTIVE;2.42;2.5 +72648-9;Glucose.serum-glucose.synv fld;SCncDiff;Pt;Ser/Plas+Synv fld;Qn;;CHEM;1;Glucose in serum - glucose in synovial fluid [Molar concentration difference];Glucose ser - synv fld-SCDiff;;ACTIVE;2.42;2.5 +72649-7;Glucose.serum-glucose.perition fld;SCncDiff;Pt;Periton fld+Ser/Plas;Qn;;CHEM;1;Glucose in serum - glucose in peritoneal fluid [Molar concentration difference];Glucose ser - prt fld-SCDiff;;ACTIVE;2.42;2.5 +72650-5;Glucose.serum-glucose.pericard fld;SCncDiff;Pt;Pericard fld+Ser/Plas;Qn;;CHEM;1;Glucose in serum - glucose in pericard fld [Molar concentration difference];Glucose ser - peric fld-SCDiff;;ACTIVE;2.42;2.5 +72651-3;Glucose.serum-glucose.plr fld;SCncDiff;Pt;Ser/Plas+Plr fld;Qn;;CHEM;1;Glucose in serum - glucose in pleural fluid [Molar concentration difference];Glucose ser - plr fld-SCDiff;;ACTIVE;2.42;2.5 +7265-2;Astacus astacus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Crawfish IgE Ab [Units/volume] in Serum;Crawfish IgE Qn;;ACTIVE;1.0h(2);2.73 +72652-1;Subtelomere analysis.long arm;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;Subtelomere analysis.long arm [Interpretation] in Blood or Tissue by FISH Narrative;Subtelomere.q arm Bld/T FISH-Imp;;ACTIVE;2.42;2.61 +72653-9;Subtelomere analysis.short arm;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;Subtelomere analysis.short arm [Interpretation] in Blood or Tissue by FISH Narrative;Subtelomere.p arm Bld/T FISH-Imp;;ACTIVE;2.42;2.61 +72654-7;SNRPN gene 15q11 deletion+duplication;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;SNRPN gene 15q11 deletion and duplication mutation analysis [Identifier] in Blood or Tissue by FISH Nominal;SNRPN 15q11 Del+Dup Bld/T FISH;;ACTIVE;2.42;2.61 +72655-4;Aldolase;CCnt;Pt;RBC;Qn;;CHEM;1;Aldolase [Enzymatic activity/mass] in Red Blood Cells;Aldolase RBC-cCnt;;ACTIVE;2.42;2.42 +72656-2;risperiDONE^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;risperiDONE [Mass/volume] in Serum or Plasma --trough;risperiDONE Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72657-0;Procainamide^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procainamide [Mass/volume] in Serum or Plasma --trough;Procainamide Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72658-8;PARoxetine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PARoxetine [Mass/volume] in Serum or Plasma --trough;PARoxetine Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72659-6;OXcarbazepine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OXcarbazepine [Mass/volume] in Serum or Plasma --trough;OXcarbazepine Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +7266-0;Cricket Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cricket IgE Ab [Units/volume] in Serum;Cricket IgE Qn;;ACTIVE;1.0h(2);2.42 +72660-4;Beta-trace protein;MCnc;Pt;Ear fluid;Qn;;CHEM;1;Beta-trace protein [Mass/volume] in Ear fluid;Beta-trace protein Ear fld-mCnc;;ACTIVE;2.42;2.42 +72661-2;Intrinsic coagulation factor activity 4 panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Intrinsic coagulation factor activity 4 panel - Platelet poor plasma by Coagulation assay;Intrnsc coag fctr act pnl PPP;;ACTIVE;2.42;2.42 +72662-0;Extrinsic coagulation factor activity 4 panel;-;Pt;PPP;-;;PANEL.COAG;1;Extrinsic coagulation factor activity 4 panel - Platelet poor plasma;Extrnsc coag fctr act pnl PPP;;ACTIVE;2.42;2.42 +72663-8;Bisphosphoglycerate mutase;CCnt;Pt;RBC;Qn;;CHEM;1;Bisphosphoglycerate mutase [Enzymatic activity/mass] in Red Blood Cells;BPGM RBC-cCnt;;ACTIVE;2.42;2.42 +72664-6;Phosphofructokinase;CCnt;Pt;RBC;Qn;;CHEM;1;Phosphofructokinase [Enzymatic activity/mass] in Red Blood Cells;PFK RBC-cCnt;;ACTIVE;2.42;2.42 +72665-3;Trans,trans-muconate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trans,trans-muconic acid [Mass/volume] in Urine;t,t-muconate Ur-mCnc;;ACTIVE;2.42;2.42 +72666-1;Nitrazepam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitrazepam [Mass/volume] in Serum or Plasma --trough;Nitrazepam Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72667-9;Mycophenolate^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mycophenolate [Mass/volume] in Serum or Plasma --trough;Mycophenolate Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72668-7;Mirtazapine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mirtazapine [Mass/volume] in Serum or Plasma --trough;Mirtazapine Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72669-5;Mianserin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mianserin [Mass/volume] in Serum or Plasma --trough;Mianserin Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72670-3;Metanephrine, Normetanephrine, 3-Methoxytyramine & Creatinine panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Metanephrine, Normetanephrine, 3-Methoxytyramine and Creatinine panel - Urine;Mtnphs+3MT+Creat pnl Ur;;ACTIVE;2.42;2.42 +72671-1;Everolimus^trough;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Everolimus [Mass/volume] in Plasma --trough;Everolimus Trough Plas-mCnc;;ACTIVE;2.42;2.42 +72672-9;traZODone^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;traZODone [Mass/volume] in Serum or Plasma --trough;traZODone Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72673-7;Theophylline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Serum or Plasma --trough;Theophylline Trough SerPl-mCnc;;ACTIVE;2.42;2.73 +72674-5;Sulfamethoxazole^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfamethoxazole [Mass/volume] in Serum or Plasma --trough;Sulfamethoxazole Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72675-2;Sotalol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sotalol [Mass/volume] in Serum or Plasma --trough;Sotalol Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +72676-0;Sirolimus^trough;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Sirolimus [Mass/volume] in Plasma --trough;Sirolimus Trough Plas-mCnc;;ACTIVE;2.42;2.42 +72677-8;Salicylates^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylates [Mass/volume] in Serum or Plasma --trough;Salicylates Trough SerPl-mCnc;;ACTIVE;2.42;2.42 +7267-8;Cryptococcus terreus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cryptococcus terreus IgE Ab [Units/volume] in Serum;C terreus IgE Qn;;ACTIVE;1.0h(2);2.42 +72678-6;Venlafaxine+O-desmethylvenlafaxine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Venlafaxine+O-desmethylvenlafaxine [Mass/volume] in Serum or Plasma --trough;Vnlfxn+ODV Trough SerPl-mCnc;;ACTIVE;2.42;2.69 +72679-4;Bile acid;SRat;24H;Stool;Qn;;CHEM;1;Bile acid [Moles/time] in 24 hour Stool;Bile Ac 24h Stl-sRate;;ACTIVE;2.42;2.44 +72680-2;Macroprolactin;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Macroprolactin [Presence] in Serum or Plasma;Macroprolactin SerPl Ql;;ACTIVE;2.42;2.56 +72681-0;I displayed high-risk behavior by knowingly driving too fast, running around on the roofs of high buildings, balancing on bridges, etc. in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I displayed high-risk behavior by knowingly driving too fast, running around on the roofs of high buildings, balancing on bridges, etc. in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72682-8;I induced vomiting in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I induced vomiting in lthe last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72683-6;I had episodes of binge eating in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I had episodes of binge eating in the last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72684-4;I tried to commit suicide in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I tried to commit suicide in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72685-1;I told other people that I was going to kill myself in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I told other people that I was going to kill myself in the last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +7268-6;Cucumis sativus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cucumber IgG Ab [Units/volume] in Serum;Cucumber IgG Qn;;ACTIVE;1.0h(2);2.73 +72686-9;I hurt myself by cutting, burning, strangling, headbanging etc. in last W;Find;1W;^Patient;Ord;BSL-SUPP;SURVEY.MTLHLTH;4;I hurt myself by cutting, burning, strangling, headbanging etc. in last week [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72687-7;Now we would like to know in addition the quality of your overall personal state in the course of the last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;Now we would like to know in addition the quality of your overall personal state in the course of the last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72688-5;Mean score;Score;Pt;^Patient;Qn;BSL-23;SURVEY.MTLHLTH;4;Mean score [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72689-3;Total score;Score;Pt;^Patient;Qn;BSL-23;SURVEY.MTLHLTH;4;Total score [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72690-1;I felt worthless in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I felt worthless in the last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72691-9;I felt as if I was far away from myself in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I felt as if I was far away from myself in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72692-7;I felt disgusted by myself in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I felt disgusted by myself in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72693-5;Insulin-like growth factor-II.high molecular weight;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor-II.high molecular weight [Mass/volume] in Serum or Plasma;Big IGF-II SerPl-mCnc;;ACTIVE;2.42;2.42 +7269-4;Cucumis sativus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cucumber triggered histamine release [Units/volume] in Blood;Cucumber BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72694-3;Cholinesterase activity panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Cholinesterase activity panel - Serum or Plasma;Cholinesterase actvty pnl SerPl;;ACTIVE;2.42;2.42 +72695-0;Erythrocyte enzyme panel;-;Pt;RBC;-;;PANEL.CHEM;1;Erythrocyte enzyme panel - Red Blood Cells;RBC enzy pnl RBC;;ACTIVE;2.42;2.73 +72696-8;SLC40A1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SLC40A1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SLC40A1 Mut Anl Bld/T;;ACTIVE;2.42;2.63 +72697-6;CYP3A5 gene.c.6986A>G(*3);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP3A5 gene c.6986A>G(*3) [Presence] in Blood or Tissue by Molecular genetics method;CYP3A5*3 Bld/T Ql;;ACTIVE;2.42;2.67 +72698-4;I was afraid of losing control in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I was afraid of losing control in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72699-2;Everything seemed senseless to me in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;Everything seemed senseless to me in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72700-8;The idea of death had a certain fascination for me in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;The idea of death had a certain fascination for me in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72701-6;I felt vulnerable in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I felt vulnerable in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +7270-2;Curry Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Curry IgE Ab [Units/volume] in Serum;Curry IgE Qn;;ACTIVE;1.0h(2);2.73 +72702-4;Criticism had a devastating effect on me in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;Criticism had a devastating effect on me in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72703-2;I suffered from voices and noises from inside or outside my head in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I suffered from voices and noises from inside or outside my head in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72704-0;My mood rapidly cycled in terms of anxiety, anger, and depression in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;My mood rapidly cycled in terms of anxiety, anger, and depression in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72705-7;I suffered from shame in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I suffered from shame in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72706-5;I wanted to punish myself in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I wanted to punish myself in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72707-3;I hated myself in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I hated myself in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72708-1;I had images that I was very much afraid of in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I had images that I was very much afraid of in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72709-9;I experienced stressful inner tension in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I experienced stressful inner tension in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +7271-0;Curvularia sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Curvularia sp IgE Ab [Units/volume] in Serum;Curvularia IgE Qn;;ACTIVE;1.0h(2);2.73 +72710-7;I was lonely in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I was lonely in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72711-5;I didn't believe in my right to live in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I didn't believe in my right to live in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72712-3;I didn't trust other people in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I didn't trust other people in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72713-1;I thought of hurting myself in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I thought of hurting myself in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72714-9;I felt disgust in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I felt disgust in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72715-6;I was absent-minded and unable to remember what I was actually doing in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I was absent-minded and unable to remember what I was actually doing in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72716-4;I felt helpless in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;I felt helpless in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72717-2;It was hard for me to concentrate in last W;Find;1W;^Patient;Ord;BSL-23;SURVEY.MTLHLTH;4;It was hard for me to concentrate in last week [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72718-0;Borderline symptom list - behavior supplement;-;Pt;^Patient;-;BSL-SUPP;PANEL.SURVEY.MTLHLTH;4;Borderline symptom list - behavior supplement [BSL-SUPP];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72719-8;Borderline symptom list - 23 item;-;Pt;^Patient;-;BSL-23;PANEL.SURVEY.MTLHLTH;4;Borderline symptom list - 23 item [BSL-23];;Copyright © Dr. Martin Bohus, PSM ZI Mannheim/Germany. Used with permission.;ACTIVE;2.42;2.68 +72720-6;Base excess.100% oxygenated^^standard;SCnc;Pt;BldC;Qn;Calculated;CHEM;1;Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation;Base ex.oxy std BldC Calc-sCnc;;ACTIVE;2.42;2.44 +72721-4;Base excess.100% oxygenated^^standard;SCnc;Pt;BldA;Qn;Calculated;CHEM;1;Base excess.100% oxygenated [Moles/volume] standard in Arterial blood by calculation;Base ex.oxy std BldA Calc-sCnc;;ACTIVE;2.42;2.44 +72722-2;Base excess.100% oxygenated^^standard;SCnc;Pt;BldMV;Qn;Calculated;CHEM;1;Base excess.100% oxygenated [Moles/volume] standard in Mixed venous blood by calculation;Base ex.oxy std BldMV Calc-sCnc;;ACTIVE;2.42;2.44 +72723-0;Base excess.100% oxygenated^^standard;SCnc;Pt;BldV;Qn;Calculated;CHEM;1;Base excess.100% oxygenated [Moles/volume] standard in Venous blood by calculation;Base ex.oxy std BldV Calc-sCnc;;ACTIVE;2.42;2.44 +72724-8;PM-SCL-75 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;PM-SCL-75 IgG Ab [Presence] in Serum or Plasma by Immunoassay;PM-SCL75 IgG SerPl Ql IA;;ACTIVE;2.42;2.56 +72725-5;"t(11;14)(q13.2;q32)(MYEOV,IGH) fusion transcript";Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.TRNLOC;1;"t(11;14)(q13.2;q32)(MYEOV,IGH) fusion transcript [Identifier] in Blood or Tissue by FISH Nominal";"t(11;14)(MYEOV,IGH) Bld/T FISH";;ACTIVE;2.42;2.61 +72726-3;"t(4;14)(p16;q32)(FGFR3,IGH) fusion transcript";Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.TRNLOC;1;"t(4;14)(p16;q32)(FGFR3,IGH) fusion transcript [Identifier] in Blood or Tissue by FISH Nominal";"t(4;14)(FGFR3,IGH) Bld/T FISH";;ACTIVE;2.42;2.73 +72727-1;Del(13)(q14) & del(17)(p13);-;Pt;Bld/Tiss;-;;PANEL.MOLPATH;1;Del(13)(q14) and del(17)(p13) in Blood or Tissue;Del(13)(q14)+del(17)(p13) Bld/T;;ACTIVE;2.42;2.42 +7272-8;Taxodium distichum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bald Cypress IgE Ab [Units/volume] in Serum;Bald Cypress IgE Qn;;ACTIVE;1.0h(2);2.73 +72728-9;Del(13)(q14);Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;Del(13)(q14) [Identifier] in Blood or Tissue by FISH Nominal;Del(13)(q14) Bld/T FISH;;ACTIVE;2.42;2.61 +72729-7;7-Hydroxymitragynine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;7-Hydroxymitragynine/Creatinine [Mass Ratio] in Urine;7-OH-mitragynine/Creat Ur;;ACTIVE;2.42;2.73 +72730-5;Mitragynine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Mitragynine/Creatinine [Mass Ratio] in Urine;Mitragynine/Creat Ur;;ACTIVE;2.42;2.73 +72731-3;7-Hydroxymitragynine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;7-Hydroxymitragynine [Mass/volume] in Urine by Confirmatory method;7-OH-mitragynine Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72732-1;Mitragynine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mitragynine [Mass/volume] in Urine by Confirmatory method;Mitragynine Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72733-9;HYDROmorphone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;HYDROmorphone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;HYDROmorphone Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72734-7;Methadone;MCnc;Pt;Saliva;Qn;Screen;DRUG/TOX;1;Methadone [Mass/volume] in Saliva (oral fluid) by Screen method;Methadone Sal Scn-mCnc;;ACTIVE;2.42;2.73 +72735-4;Methamphetamine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methamphetamine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Methamphet Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +7273-6;Dahlia sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dahlia IgE Ab [Units/volume] in Serum;Dahlia IgE Qn;;ACTIVE;1.0h(2);2.42 +72736-2;Methylenedioxyamphetamine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;MDA Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72737-0;Cocaine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Cocaine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Cocaine Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72738-8;Temazepam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Temazepam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Temazepam Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72739-6;Nordiazepam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Nordiazepam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Nordiazepam Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72740-4;traMADol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;traMADol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;traMADol Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72741-2;Nortramadol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Nortramadol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Nortramadol Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72742-0;Noroxycodone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Noroxycodone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Noroxycodone Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72743-8;Normeperidine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Normeperidine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Normeperidine Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +7274-4;Bellis perennis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Daisy IgE Ab [Units/volume] in Serum;Daisy IgE Qn;;ACTIVE;1.0h(2);2.42 +72744-6;Norhydrocodone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Norhydrocodone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Norhydrocodone Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72745-3;Norfentanyl;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Norfentanyl [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Norfentanyl Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72746-1;Norbuprenorphine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Norbuprenorphine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Norbuprenorphine Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72747-9;N-Nortramadol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;N-nortramadol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;N-nortramadol Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72748-7;Meprobamate;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Meprobamate [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Meprobamate Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72749-5;Meperidine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Meperidine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Meperidine Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72750-3;oxyCODONE;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;oxyCODONE [Mass/volume] in Saliva (oral fluid) by Confirmatory method;oxyCODONE Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +7275-1;Phoenix canariensis pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Date Palm Pollen IgE Ab [Units/volume] in Serum;Date Palm Poln IgE Qn;;ACTIVE;1.0h(2);2.73 +72751-1;oxyCODONE;MCnc;Pt;Saliva;Qn;Screen;DRUG/TOX;1;oxyCODONE [Mass/volume] in Saliva (oral fluid) by Screen method;oxyCODONE Sal Scn-mCnc;;ACTIVE;2.42;2.73 +72752-9;Morphine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Morphine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Morphine Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72753-7;HYDROcodone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;HYDROcodone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;HYDROcodone Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72754-5;LORazepam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;LORazepam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;LORazepam Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72755-2;clonazePAM;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;clonazePAM [Mass/volume] in Saliva (oral fluid) by Confirmatory method;clonazePAM Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72756-0;ALPRAZolam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Alpraz Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72757-8;Benzodiazepines;MCnc;Pt;Saliva;Qn;Screen;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Saliva (oral fluid) by Screen method;Benzodiaz Sal Scn-mCnc;;ACTIVE;2.42;2.73 +72758-6;Amphetamine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Amphetamine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Amphet Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72759-4;Codeine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Codeine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Codeine Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72760-2;fentaNYL;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;fentaNYL [Mass/volume] in Saliva (oral fluid) by Confirmatory method;fentaNYL Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72761-0;Carisoprodol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Carisoprodol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Carisoprodol Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72762-8;Buprenorphine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Buprenorphine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Buprenorphine Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72763-6;6-Monoacetylmorphine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Saliva (oral fluid) by Confirmatory method;6MAM Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72764-4;Carboxy tetrahydrocannabinol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;CarboxyTHC Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72765-1;Phencyclidine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Phencyclidine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;PCP Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72766-9;oxyMORphone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;oxyMORphone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;oxyMORphone Sal Cfm-mCnc;;ACTIVE;2.42;2.73 +72767-7;Influenza virus A hemagglutinin segment sequence identifier;ID;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A hemagglutinin segment sequence identifier;FLUAV HA seg sequence ID Islt Seq;;ACTIVE;2.42;2.44 +72768-5;Zolpidem phenyl-4-carboxylate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Zolpidem phenyl-4-carboxylate [Mass/volume] in Urine by Confirmatory method;Zolpidem phenyl-4-carb Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +7276-9;Dermatophagoides farinae Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite IgG Ab [Units/volume] in Serum;D farinae IgG Qn;;ACTIVE;1.0h(2);2.73 +72769-3;Zolpidem phenyl-4-carboxylate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Zolpidem phenyl-4-carboxylate/Creatinine [Mass Ratio] in Urine;Zolpidem phenyl-4-carb/Creat Ur;;ACTIVE;2.42;2.73 +72770-1;Zolpidem;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Zolpidem [Mass/volume] in Urine by Confirmatory method;Zolpidem Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72771-9;Zolpidem/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Zolpidem/Creatinine [Mass Ratio] in Urine;Zolpidem/Creat Ur;;ACTIVE;2.42;2.73 +72772-7;O-desmethylvenlafaxine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;O-desmethylvenlafaxine [Mass/volume] in Urine by Confirmatory method;ODV Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72773-5;O-desmethylvenlafaxine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;O-desmethylvenlafaxine/Creatinine [Mass Ratio] in Urine;ODV/Creat Ur;;ACTIVE;2.42;2.73 +72774-3;Venlafaxine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Venlafaxine [Mass/volume] in Urine by Confirmatory method;Venlafaxine Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72775-0;Venlafaxine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Venlafaxine/Creatinine [Mass Ratio] in Urine;Venlafaxine/Creat Ur;;ACTIVE;2.42;2.73 +72776-8;JWH-018 butanol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated JWH-018 butanol metabolite [Mass/volume] in Urine by Confirmatory method;Deprecated JWH-018 butanol Ur Cfm-mCnc;;DEPRECATED;2.42;2.44 +7277-7;Dermatophagoides farinae basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;American house dust mite triggered histamine release [Units/volume] in Blood;D farinae BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72777-6;JWH-018 butanol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated JWH-018 butanol metabolite/Creatinine [Mass Ratio] in Urine;Deprecated JWH-018 butanol/Creat Ur;;DEPRECATED;2.42;2.44 +72778-4;JWH-073 butanoate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-073 butanoate (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-073 butanoate Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72779-2;JWH-073 butanoate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-073 butanoate (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-073 butanoate/Creat Ur;;ACTIVE;2.42;2.44 +727-8;Hemoglobin distribution width;Len;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Hemoglobin distribution width [Length] in Blood by Automated count;Deprecated HDW Bld Auto;;DEPRECATED;1.0;2.44 +72780-0;JWH-018 pentanol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-018 pentanol (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-018 pentanol Ur Cfm-mCnc;;ACTIVE;2.42;2.44 +72781-8;JWH-018 pentanol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-018 pentanol (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-018 pentanol/Creat Ur;;ACTIVE;2.42;2.73 +72782-6;JWH-018 pentanoate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-018 pentanoate (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-018 pentanoate Ur Cfm-mCnc;;ACTIVE;2.42;2.44 +72783-4;JWH-018 pentanoate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-018 pentanoate (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-018 pentanoate/Creat Ur;;ACTIVE;2.42;2.73 +72784-2;PARoxetine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;PARoxetine [Mass/volume] in Urine by Confirmatory method;PARoxetine Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +7278-5;Dermatophagoides pteronyssinus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite IgG Ab [Units/volume] in Serum;D pteronyss IgG Qn;;ACTIVE;1.0h(2);2.73 +72785-9;PARoxetine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;PARoxetine/Creatinine [Mass Ratio] in Urine;PARoxetine/Creat Ur;;ACTIVE;2.42;2.73 +72786-7;Cotinine;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Cotinine [Mass/volume] in Urine by Screen method;Cotinine Ur Scn-mCnc;;ACTIVE;2.42;2.42 +72787-5;6-Beta naltrexone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deprecated 6-Beta naltrexone [Mass/volume] in Urine by Confirmatory method;Deprecated 6B-Naltrexone Ur Cfm-mCnc;;DEPRECATED;2.42;2.58 +72788-3;6-Beta naltrexone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated 6-Beta naltrexone/Creatinine [Mass Ratio] in Urine;Deprecated 6B-Naltrexone/Creat Ur;;DEPRECATED;2.42;2.58 +72789-1;Naltrexone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Naltrexone/Creatinine [Mass Ratio] in Urine;Naltrexone/Creat Ur;;ACTIVE;2.42;2.73 +72790-9;Alpha-Phenyl-2-Piperidine acetate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate [Mass/volume] in Urine by Confirmatory method;PPAA Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72791-7;Alpha-Phenyl-2-Piperidine acetate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate/Creatinine [Mass Ratio] in Urine;PPAA/Creat Ur;;ACTIVE;2.42;2.73 +72792-5;Methylphenidate/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methylphenidate/Creatinine [Mass Ratio] in Urine;Me-phenidate/Creat Ur;;ACTIVE;2.42;2.73 +7279-3;Dermatophagoides pteronyssinus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;European house dust mite triggered histamine release [Units/volume] in Blood;D pteronyss BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72793-3;Methylone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylone [Mass/volume] in Urine by Confirmatory method;Methylone Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72794-1;Methylone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methylone/Creatinine [Mass Ratio] in Urine;Methylone/Creat Ur;;ACTIVE;2.42;2.73 +72795-8;Mephedrone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mephedrone [Mass/volume] in Urine by Confirmatory method;Mephedrone Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72796-6;Mephedrone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Mephedrone/Creatinine [Mass Ratio] in Urine;Mephedrone/Creat Ur;;ACTIVE;2.42;2.73 +72797-4;Methylenedioxypyrovalerone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxypyrovalerone [Mass/volume] in Urine by Confirmatory method;MDPV Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72798-2;Methylenedioxypyrovalerone/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Methylenedioxypyrovalerone/Creatinine [Mass Ratio] in Urine;MDPV/Creat Ur;;ACTIVE;2.42;2.73 +72799-0;Norketamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norketamine [Mass/volume] in Urine by Confirmatory method;Norketamine Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72800-6;Norketamine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Norketamine/Creatinine [Mass Ratio] in Urine;Norketamine/Creat Ur;;ACTIVE;2.42;2.73 +7280-1;Anethum graveolens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dill IgE Ab [Units/volume] in Serum;Dill IgE Qn;;ACTIVE;1.0h(2);2.73 +72801-4;Ketamine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Ketamine/Creatinine [Mass Ratio] in Urine;Ketamine/Creat Ur;;ACTIVE;2.42;2.73 +72802-2;JWH-250 5-carboxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-250 5-carboxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-250 5-carboxypentyl Ur Cfm-mCnc;;ACTIVE;2.42;2.44 +72803-0;JWH-250 5-carboxypentyl/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-250 5-carboxypentyl (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-250 5-carboxypentyl/Creat Ur;;ACTIVE;2.42;2.44 +72804-8;JWH-210 5-carboxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-210 5-carboxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-210 carboxypentyl Ur Cfm-mCnc;;ACTIVE;2.42;2.44 +72805-5;JWH-210 5-carboxypentyl/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-210 5-carboxypentyl (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-210 carboxypentyl/Creat Ur;;ACTIVE;2.42;2.54 +72806-3;JWH-073 carboxylated;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-073 carboxylated (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-073 carboxylated Ur Cfm-mCnc;;ACTIVE;2.42;2.44 +72807-1;JWH-073 carboxylated/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-073 carboxylated (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-073 carboxylated/Creat Ur;;ACTIVE;2.42;2.44 +72808-9;JWH-018 carboxylated;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-018 carboxylated (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-018 carboxylated Ur Cfm-mCnc;;ACTIVE;2.42;2.44 +72809-7;JWH-018 carboxylated/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-018 carboxylated (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-018 carboxylated/Creat Ur;;ACTIVE;2.42;2.44 +72810-5;Gabapentin;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Gabapentin [Mass/volume] in Urine by Confirmatory method;Gabapentin Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72811-3;Gabapentin/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Gabapentin/Creatinine [Mass Ratio] in Urine;Gabapentin/Creat Ur;;ACTIVE;2.42;2.73 +72812-1;Norfluoxetine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Norfluoxetine/Creatinine [Mass Ratio] in Urine;Norfluoxetine/Creat Ur;;ACTIVE;2.42;2.73 +72813-9;FLUoxetine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;FLUoxetine/Creatinine [Mass Ratio] in Urine;FLUoxetine/Creat Ur;;ACTIVE;2.42;2.73 +72814-7;DULoxetine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;DULoxetine [Mass/volume] in Urine by Confirmatory method;DULoxetine Ur Cfm-mCnc;;ACTIVE;2.42;2.73 +72815-4;DULoxetine/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;DULoxetine/Creatinine [Mass Ratio] in Urine;DULoxetine/Creat Ur;;ACTIVE;2.42;2.73 +72816-2;DOPamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;DOPamine [Mass/volume] in Urine by Confirmatory method;DOPamine Ur Cfm-mCnc;;ACTIVE;2.42;2.42 +72817-0;AM-2201 4-hydroxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;AM-2201 4-hydroxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;AM-2201 4OH-pentyl Ur Cfm-mCnc;;ACTIVE;2.42;2.44 +72818-8;AM-2201 4-hydroxypentyl/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;AM-2201 4-hydroxypentyl (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;AM-2201 4OH-pentyl/Creat Ur;;ACTIVE;2.42;2.44 +7281-9;Anethum graveolens Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dill IgG Ab [Units/volume] in Serum;Dill IgG Qn;;ACTIVE;1.0h(2);2.73 +72819-6;Acetaminophen/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Acetaminophen/Creatinine [Mass Ratio] in Urine;APAP/Creat Ur;;ACTIVE;2.42;2.73 +72820-4;5-Hydroxyindoleacetate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;5-Hydroxyindoleacetate [Mass/volume] in Urine by Confirmatory method;5OH-indoleacetate Ur Cfm-mCnc;;ACTIVE;2.42;2.42 +72821-2;Creatinine;MRat;XXX;Urine;Qn;Calculated;CHEM;1;Creatinine [Mass/time] by Calculated in Urine collected for unspecified duration;Creat ?Tm Ur Calc-mRate;;ACTIVE;2.42;2.73 +72822-0;Staphylococcus aureus enterotoxin D sed gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus enterotoxin D sed gene [Presence] in Specimen by NAA with probe detection;S aureus Etx D gene Spec Ql NAA+probe;;ACTIVE;2.42;2.69 +72823-8;Staphylococcus aureus enterotoxin C sec gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus enterotoxin C sec gene [Presence] in Specimen by NAA with probe detection;S aureus Etx C gene Spec Ql NAA+probe;;ACTIVE;2.42;2.69 +72824-6;Del(17)(p13);Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;Del(17)(p13) [Identifier] in Blood or Tissue by FISH Nominal;Del(17)(p13) Bld/T FISH;;ACTIVE;2.42;2.73 +72825-3;Phencyclidine;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Phencyclidine [Mass/volume] in Urine by Screen method;PCP Ur Scn-mCnc;;ACTIVE;2.42;2.73 +72826-1;Race;Type;Pt;^Patient;Nom;OMB.1997;CLIN;2;Race OMB.1997;Race OMB.1997;;ACTIVE;2.42;2.44 +7282-7;Discase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Discase IgE Ab [Units/volume] in Serum;Discase IgE Qn;;ACTIVE;1.0h(2);2.42 +72827-9;"dic(9;20)(p11-13;q11)(wcp9+,wcp20+)";Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH;1;"dic(9;20)(p11-13;q11)(wcp9+,wcp20+) [Identifier] in Blood or Tissue by FISH Nominal";"dic(9;20)(wcp9+,wcp20+) Bld/T FISH";;ACTIVE;2.42;2.73 +72828-7;Chlamydia trachomatis & Neisseria gonorrhoeae DNA panel;-;Pt;XXX;-;;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae DNA panel - Specimen;CT+NG DNA Pnl Spec;;ACTIVE;2.42;2.69 +72829-5;Stalwart of Standardization + Vocabulary Curator Virtuoso;Hx;Pt;^Patient;Nar;KM;H&P.HX;2;Stalwart of Standardization and Vocabulary Curator Virtuoso;StalStn+VocCurVo;;ACTIVE;2.42;2.46 +72830-3;Multisection for physiologic artery study;Find;Pt;Extremity.bilateral>Extremity arteries;Doc;US.doppler;RAD;2;US.doppler Extremity arteries - bilateral for physiologic artery study;DOP Extr aa-Bl Phys stdy;;ACTIVE;2.44;2.61 +72831-1;Multisection limited for physiologic artery study;Find;Pt;Extremity.bilateral>Extremity arteries;Doc;US.doppler;RAD;2;US.doppler Extremity arteries - bilateral for physiologic artery study limited;DOP Extr aa-Bl Phys stdy Ltd;;ACTIVE;2.44;2.64 +72832-9;Multisection for physiologic artery study^at rest+W exercise;Find;Pt;Extremity.bilateral>Extremity arteries;Doc;US.doppler;RAD;2;US.doppler Extremity arteries - bilateral for physiologic artery study at rest and with exercise;DOP Extr aa-Bl Phys stdy Rest+excz;;ACTIVE;2.44;2.61 +72833-7;Cytomegalovirus UL97 gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;Cytomegalovirus UL97 gene mutations detected [Identifier];CMV UL97 gene Mut Det Islt;;ACTIVE;2.44;2.73 +72834-5;Foscarnet;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Foscarnet [Susceptibility] by Phenotype method;Foscarnet Islt Phenotyp;;ACTIVE;2.44;2.44 +7283-5;Rumex crispus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Yellow Dock triggered histamine release [Units/volume] in Blood;Yellow Dock BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72835-2;Raltegravir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Raltegravir [Mass/volume] in Serum or Plasma;Raltegravir SerPl-mCnc;;ACTIVE;2.44;2.44 +72836-0;Bacterial vancomycin resistance vanC2+vanC3 genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Vancomycin resistance vanC2+vanC3 genes [Presence] by Molecular method;vanC2+vanC3 Islt/Spm Ql;;ACTIVE;2.44;2.65 +72837-8;Bacterial vancomycin resistance vanC1 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Vancomycin resistance vanC1 gene [Presence] by Molecular method;vanC1 Islt/Spm Ql;;ACTIVE;2.44;2.65 +72838-6;Herpes simplex virus DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Identifier] in Specimen by NAA with probe detection;HSV DNA Spec NAA+probe;;ACTIVE;2.44;2.69 +72839-4;Famciclovir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Famciclovir [Susceptibility] by Genotype method;Famciclovir Islt Genotyp;;ACTIVE;2.44;2.66 +72840-2;Hepatitis B virus codon 250;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 250 [Identifier] by Genotype method;HBV 250 Islt Genotyp;;ACTIVE;2.44;2.44 +72841-0;Hepatitis B virus codon 237;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 237 [Identifier] by Genotype method;HBV 237 Islt Genotyp;;ACTIVE;2.44;2.44 +72842-8;Hepatitis B virus codon 233;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 233 [Identifier] by Genotype method;HBV 233 Islt Genotyp;;ACTIVE;2.44;2.44 +7284-3;Dog dander Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog dander IgG Ab [Units/volume] in Serum;Dog Dander IgG Qn;;ACTIVE;1.0h(2);2.73 +72843-6;Hepatitis B virus codon 215;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 215 [Identifier] by Genotype method;HBV 215 Islt Genotyp;;ACTIVE;2.44;2.44 +72844-4;Hepatitis B virus codon 214;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 214 [Identifier] by Genotype method;HBV 214 Islt Genotyp;;ACTIVE;2.44;2.44 +72845-1;Hepatitis B virus codon 202;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 202 [Identifier] by Genotype method;HBV 202 Islt Genotyp;;ACTIVE;2.44;2.44 +72846-9;Hepatitis B virus codon 194;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 194 [Identifier] by Genotype method;HBV 194 Islt Genotyp;;ACTIVE;2.44;2.44 +72847-7;Hepatitis B virus codon 191;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 191 [Identifier] by Genotype method;HBV 191 Islt Genotyp;;ACTIVE;2.44;2.44 +72848-5;Hepatitis B virus codon 184;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 184 [Identifier] by Genotype method;HBV 184 Islt Genotyp;;ACTIVE;2.44;2.44 +72849-3;Hepatitis B virus codon 169;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 169 [Identifier] by Genotype method;HBV 169 Islt Genotyp;;ACTIVE;2.44;2.44 +7285-0;Dog epithelium Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog epithelium IgG Ab [Units/volume] in Serum;Dog Epith IgG Qn;;ACTIVE;1.0h(2);2.73 +72850-1;Hepatitis B virus codon 85;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 85 [Identifier] by Genotype method;HBV 85 Islt Genotyp;;ACTIVE;2.44;2.44 +72851-9;Hepatitis B virus codon 84;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis B virus codon 84 [Identifier] by Genotype method;HBV 84 Islt Genotyp;;ACTIVE;2.44;2.44 +72852-7;Cytomegalovirus resistance panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;Cytomegalovirus resistance panel by Genotype method;CMV resis Pnl Islt Genotyp;;ACTIVE;2.44;2.5 +72853-5;Maribavir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Maribavir [Susceptibility] by Genotype method;Maribavir Islt Genotyp;;ACTIVE;2.44;2.66 +72854-3;Ganciclovir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Ganciclovir [Susceptibility] by Genotype method;Ganciclovir Islt Genotyp;;ACTIVE;2.44;2.73 +72855-0;Cidofovir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Cidofovir [Susceptibility] by Phenotype method;Cidofovir Islt Phenotyp;;ACTIVE;2.44;2.44 +72856-8;Cidofovir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Cidofovir [Susceptibility] by Genotype method;Cidofovir Islt Genotyp;;ACTIVE;2.44;2.73 +72857-6;Dolutegravir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Dolutegravir [Susceptibility] by Genotype method;Dolutegravir Islt Genotyp;;ACTIVE;2.44;2.73 +72858-4;Enfuvirtide;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Enfuvirtide [Susceptibility] by Genotype method;Enfuvirtide Islt Genotyp;;ACTIVE;2.44;2.66 +72859-2;Boceprevir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Boceprevir [Susceptibility] by Genotype method;Boceprevir Islt Genotyp;;ACTIVE;2.44;2.73 +728-6;Hypochromia;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Hypochromia [Presence] in Blood by Light microscopy;Hypochromia Bld Ql Smear;;ACTIVE;1.0;2.73 +72860-0;Telaprevir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Telaprevir [Susceptibility] by Genotype method;Telaprevir Islt Genotyp;;ACTIVE;2.44;2.73 +72861-8;Ganciclovir;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Ganciclovir [Susceptibility] by Phenotype method;Ganciclovir Islt Phenotyp;;ACTIVE;2.44;2.44 +72862-6;Hepatitis C virus resistance panel;-;Pt;Isolate;-;Genotyping;PANEL.ABXBACT;1;Hepatitis C virus resistance panel by Genotype method;HCV resis panell Islt Genotyp;;ACTIVE;2.44;2.73 +72863-4;Mycobacterium leprae gyrB gene fluoroquinolone resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium leprae gyrB gene fluoroquinolone resistance mutation [Presence] by Molecular method;M leprae gyrB FLQ res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +72864-2;Mycobacterium tuberculosis rpsL+rrs genes aminoglycoside resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis rpsL+rrs genes aminoglycoside resistance mutation [Presence] by Molecular method;MTB rpsL+rrs AMG res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +72865-9;Mycobacterium tuberculosis ethB gene ethionamide resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis ethB gene ethionamide resistance mutation [Presence] by Molecular method;MTB ethB ethion res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +72866-7;Mycobacterium tuberculosis ethA gene ethionamide resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis ethA gene ethionamide resistance mutation [Presence] by Molecular method;MTB ethA ethion res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +72867-5;Mycobacterium tuberculosis gyrB gene fluoroquinolone resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis gyrB gene fluoroquinolone resistance mutation [Presence] by Molecular method;MTB gyrB fluoroquin res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +7286-8;Dog epithelium basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Dog epithelium triggered histamine release [Units/volume] in Blood;Dog Epith BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72868-3;Mycobacterium leprae folP1 gene dapsone resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium leprae folP1 gene dapsone resistance mutation [Presence] by Molecular method;M leprae folP1 dap res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +72869-1;Mycobacterium leprae gyrA gene fluoroquinolone resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium leprae gyrA gene fluoroquinolone resistance mutation [Presence] by Molecular method;M leprae gyrA FLQ res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +72870-9;Mycobacterium leprae rpoB gene rifAMPin resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium leprae rpoB gene rifAMPin resistance mutation [Presence] by Molecular method;M leprae rpoB RIF res mut Islt/Spm Ql;;ACTIVE;2.44;2.65 +72871-7;NDC labeler code request.animal drug;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label NDC labeler code request - animal drug;FDA label NDC lbl rqst.anml drg;;ACTIVE;2.44;2.44 +72872-5;MCM6 gene.c.-13910C>T & -13915T>G;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MCM6 -13910C>T + -13915T>G Bld/T;;ACTIVE;2.44;2.44 +72873-3;Estradiol;SCnc;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;Estradiol (E2) [Moles/volume] in Serum or Plasma by High sensitivity method;Estradiol SerPl HS-sCnc;;ACTIVE;2.44;2.44 +72874-1;JWH-073 butanol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;JWH-073 butanol (synthetic cannabinoid metabolite)/Creatinine [Mass Ratio] in Urine;JWH-073 butanol/Creat Ur;;ACTIVE;2.44;2.44 +72875-8;JWH-073 butanol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-073 butanol (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-073 butanol Ur Cfm-mCnc;;ACTIVE;2.44;2.44 +7287-6;Anthemis cotula Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog Fennel IgE Ab [Units/volume] in Serum;Dog Fennel IgE Qn;;ACTIVE;1.0h(2);2.73 +72876-6;Views;Find;Pt;^Surgical specimen;Doc;XR;RAD;2;XR Surgical specimen Views;XR Surg Spec Views;;ACTIVE;2.44;2.64 +72877-4;CYP2B6 gene drug metabolism analysis overall interpretation;Imp;Pt;Bld/Tiss/Sal;Ord;Molgen;MOLPATH.MUT;1;Deprecated CYP2B6 gene drug metabolism analysis overall interpretation [Interpretation] in Blood, Tissue or Saliva Qualitative by Molecular genetics method;Deprecated CYP2B6 drg metab interp Bld/T/S-Imp;;DEPRECATED;2.44;2.67 +72878-2;UGT2B15 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;UGT2B15 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;UGT2B15 gene prod met act imp Bld/T-Imp;;ACTIVE;2.44;2.67 +72879-0;CYP2C19 gene drug metabolism analysis overall interpretation;Imp;Pt;Bld/Tiss/Sal;Ord;Molgen;MOLPATH.MUT;1;Deprecated CYP2C19 gene drug metabolism analysis overall interpretation [Interpretation] in Blood, Tissue or Saliva Qualitative by Molecular genetics method;Deprecated CYP2C19 drg metab interp Bld/T/S-Imp;;DEPRECATED;2.44;2.67 +72880-8;CYP2D6 gene drug metabolism analysis overall interpretation;Imp;Pt;Bld/Tiss/Sal;Ord;Molgen;MOLPATH.MUT;1;Deprecated CYP2D6 gene drug metabolism analysis overall interpretation [Interpretation] in Blood, Tissue or Saliva Qualitative by Molecular genetics method;Deprecated CYP2D6 drg metab interp Bld/T/S-Imp;;DEPRECATED;2.44;2.67 +72881-6;UGT2B15 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;UGT2B15 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;UGT2B15 Mut Anl Bld/T;;ACTIVE;2.44;2.67 +72882-4;CYP2B6 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2B6 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP2B6 allele Geno Bld/T;;ACTIVE;2.44;2.68 +72883-2;CYP2E1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CYP2E1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CYP2E1 Mut Anl Bld/T;;ACTIVE;2.44;2.63 +7288-4;Dogwood pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dogwood pollen IgE Ab [Units/volume] in Serum;Dogwood Poln IgE Qn;;ACTIVE;1.0h(2);2.42 +72884-0;CYP1A2 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP1A2 allele Geno Bld/T;;ACTIVE;2.44;2.68 +72885-7;Respiratory syncytial virus Ag;PrThr;Pt;Nph;Ord;IA.rapid;MICRO;1;Respiratory syncytial virus Ag [Presence] in Nasopharynx by Rapid immunoassay;RSV Ag Nph Ql IA.rapid;;ACTIVE;2.44;2.73 +72886-5;CYP2D6 gene & CYP2C19 gene targeted mutation analysis panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH.PHARMG;1;CYP2D6 gene and CYP2C19 gene targeted mutation analysis panel - Blood or Tissue by Molecular genetics method;CYP2D6+CYP2C19 pnl Bld/T;;ACTIVE;2.44;2.67 +72887-3;Staphylococcus aureus methicillin resistance SCCmec;PrThr;Pt;Nose;Ord;Probe.amp.tar;ABXBACT;1;Staphylococcus aureus methicillin resistance SCCmec [Presence] in Nose by NAA with probe detection;SCCmec Nose Ql NAA+probe;;ACTIVE;2.44;2.73 +72888-1;3-epi-25-Hydroxyvitamin D3/25-hydroxyvitamin D.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;3-epi-25-Hydroxyvitamin D3/25-hydroxyvitamin D.total in Serum or Plasma;3-epi-25(OH)D3/25-OH Vit D MFr SerPl;;ACTIVE;2.44;2.73 +72889-9;Progesterone.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Progesterone Free [Mass/volume] in Serum or Plasma;Progest Free SerPl-mCnc;;ACTIVE;2.44;2.73 +72890-7;Progesterone.free/Progesterone.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Progesterone Free/Progesterone.total in Serum or Plasma;Progest Free/Total MFr SerPl;;ACTIVE;2.44;2.73 +72891-5;Staphylococcus protein A spa gene;PrThr;Pt;Isolate/Specimen;Ord;Probe.amp.tar;ABXBACT;1;Staphylococcus protein A spa gene [Presence] in Isolate or Specimen by NAA with probe detection;Spa gene Islt/Spm Ql NAA+probe;;ACTIVE;2.44;2.73 +7289-2;Duck feather Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Duck feather IgG Ab [Units/volume] in Serum;Duck Feather IgG Qn;;ACTIVE;1.0h(2);2.69 +72892-3;Staphylococcus aureus methicillin resistance SCCmec & mecA genes panel;-;Pt;Nose;-;Probe.amp.tar;PANEL.ABXBACT;1;MRSA SCCmec and mecA genes panel - Nose by NAA with probe detection;SCCmec + mecA pnl Nose NAA+probe;;ACTIVE;2.44;2.73 +72893-1;Doripenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Doripenem [Susceptibility] by Disk diffusion (KB);Doripenem Islt KB;;ACTIVE;2.44;2.44 +72894-9;Telavancin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Telavancin [Susceptibility] by Minimum inhibitory concentration (MIC);Telavancin Islt MIC;;ACTIVE;2.44;2.73 +72895-6;Glucose^2.5H post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose lactose PO;Glucose 2.5h p Lac PO SerPl-sCnc;;ACTIVE;2.44;2.44 +72896-4;Glucose^15M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose lactose PO;Glucose 15M p Lac PO SerPl-sCnc;;ACTIVE;2.44;2.44 +72897-2;Xanthine;SCnc;Pt;Urine;Qn;;CHEM;1;Xanthine [Moles/volume] in Urine;Xanthine Ur-sCnc;;ACTIVE;2.44;2.44 +72898-0;Bilirubin;SCnc;Pt;Skin;Qn;Transcutaneous meter;CHEM;1;Bilirubin [Moles/volume] in Skin;Bilirub Skin-sCnc;;ACTIVE;2.44;2.44 +72899-8;Isoleucine+Leucine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isoleucine+Leucine [Moles/volume] in Serum or Plasma;Ile+Leu SerPl-sCnc;;ACTIVE;2.44;2.44 +72-9;Cefatrizine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefatrizine [Susceptibility] by Minimum inhibitory concentration (MIC);Cefatrizine Islt MIC;;ACTIVE;1.0;2.19 +7290-0;Egg white basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Egg white triggered histamine release [Units/volume] in Blood;Egg White BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72900-4;Insulin^3H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --3 hours post 75 g glucose PO;Insulin 3h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.44;2.44 +72901-2;Insulin^2H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --2 hours post 75 g glucose PO;Insulin 2h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.44;2.44 +72902-0;Insulin^1H post 75 g glucose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Moles/volume] in Serum or Plasma --1 hour post 75 g glucose PO;Insulin 1h p 75 g Glc PO SerPl-sCnc;;ACTIVE;2.44;2.44 +72903-8;Urea;SCnc;Pt;Bld;Qn;;CHEM;1;Urea [Moles/volume] in Blood;Urea Bld-sCnc;;ACTIVE;2.44;2.44 +72904-6;Formate;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Formate [Moles/volume] in Blood;Formate Bld-sCnc;;ACTIVE;2.44;2.44 +72905-3;Neutrophil Ab & HLA Ab screen panel;-;Pt;Ser/Plas;-;;PANEL.HNA;1;Neutrophil Ab and HLA Ab screen panel - Serum or Plasma;Neutrophil+HLA Ab screen pnl SerPl;;ACTIVE;2.44;2.44 +72906-1;HNA Ab panel;-;Pt;Ser/Plas;-;;PANEL.HNA;1;HNA Ab panel - Serum or Plasma;HNA Ab pnl SerPl;;ACTIVE;2.44;2.44 +72907-9;HNA genotype panel;-;Pt;Ser/Plas;-;;PANEL.HNA;1;HNA genotype panel - Serum or Plasma;HNA genotype pnl SerPl;;ACTIVE;2.44;2.44 +72908-7;Drug induced platelet Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Drug induced platelet Ab panel - Serum or Plasma;Drug induced platelet Ab pnl SerPl;;ACTIVE;2.44;2.44 +72909-5;Drug induced neutrophil Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Drug induced neutrophil Ab panel - Serum or Plasma;Drug induced neutrophil Ab pnl SerPl;;ACTIVE;2.44;2.44 +72910-3;HNA 4a-4b Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 4a/4b Ab [Presence] in Serum by Immunoassay;HNA 4a/4b Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72911-1;HNA 4b-4b Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 4b/4b Ab [Presence] in Serum by Immunoassay;HNA 4b/4b Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72912-9;HNA 4a-4a Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 4a/4a Ab [Presence] in Serum by Immunoassay;HNA 4a/4a Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72913-7;HNA 2 Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 2 Ab [Presence] in Serum by Immunoassay;HNA 2 Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72914-5;HNA 1c Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 1c Ab [Presence] in Serum by Immunoassay;HNA 1c Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72915-2;HNA 1a-1b Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 1a/1b Ab [Presence] in Serum by Immunoassay;HNA 1a/1b Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72916-0;HNA 1b-1b Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 1b/1b Ab [Presence] in Serum by Immunoassay;HNA 1b/1b Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72917-8;HNA 5 genotype;Type;Pt;Bld;Nom;;HNA;1;HNA 5 genotype in Blood;HNA 5 Gentyp Bld;;ACTIVE;2.44;2.72 +7291-8;Egg whole Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whole Egg IgE Ab [Units/volume] in Serum;Whole Egg IgE Qn;;ACTIVE;1.0h(2);2.73 +72918-6;HNA 4 genotype;Type;Pt;Bld;Nom;;HNA;1;HNA 4 genotype in Blood;HNA 4 Gentyp Bld;;ACTIVE;2.44;2.72 +72919-4;HNA 3 genotype;Type;Pt;Bld;Nom;;HNA;1;HNA 3 genotype in Blood;HNA 3 Gentyp Bld;;ACTIVE;2.44;2.72 +72920-2;HNA 1c genotype;PrThr;Pt;Bld;Ord;;HNA;1;HNA 1c genotype [Presence] in Blood;HNA 1c Gentyp Bld Ql;;ACTIVE;2.44;2.56 +72921-0;HNA 1 genotype;Type;Pt;Bld;Nom;;HNA;1;HNA 1 genotype in Blood;HNA 1 Gentyp Bld;;ACTIVE;2.44;2.72 +72922-8;HNA 1a-1a Ab;PrThr;Pt;Ser;Ord;IA;HNA;1;HNA 1a/1a Ab [Presence] in Serum by Immunoassay;HNA 1a-1a Ab Ser Ql IA;;ACTIVE;2.44;2.56 +72923-6;Specimen source;Prid;Pt;Synv fld;Nom;;SPEC;1;Specimen source [Identifier] of Synovial fluid;Specimen source Snv;;ACTIVE;2.44;2.73 +72924-4;Barium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Barium [Moles/volume] in Urine;Barium Ur-sCnc;;ACTIVE;2.44;2.44 +72925-1;Bilirubin;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Amniotic fluid;Bilirub Amn-sCnc;;ACTIVE;2.44;2.44 +7292-6;Egg whole Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whole Egg IgG Ab [Units/volume] in Serum;Whole Egg IgG Qn;;ACTIVE;1.0h(2);2.73 +72926-9;Urea;SCnc;Pt;BldV;Qn;;CHEM;1;Urea [Moles/volume] in Venous blood;Urea BldV-sCnc;;ACTIVE;2.44;2.44 +72927-7;Urea;SCnc;Pt;BldA;Qn;;CHEM;1;Urea [Moles/volume] in Arterial blood;Urea BldA-sCnc;;ACTIVE;2.44;2.44 +72928-5;Secobarbital;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Secobarbital [Moles/volume] in Urine;Secobarbital Ur-sCnc;;ACTIVE;2.44;2.44 +72929-3;Warfarin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Warfarin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Warfarin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72930-1;Warfarin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Warfarin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Warfarin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72931-9;Venlafaxine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Venlafaxine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Venlafaxine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72932-7;Venlafaxine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Venlafaxine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Venlafaxine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72933-5;Vancomycin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Vancomycin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Vancomycin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +7293-4;Egg whole basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Whole Egg triggered histamine release [Units/volume] in Blood;Whole Egg BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72934-3;Vancomycin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Vancomycin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Vancomycin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72935-0;Valproate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valproate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valproate (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72936-8;Valproate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valproate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valproate (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72937-6;Trimethoprim induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Trimethoprim induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Trimethoprim (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72938-4;Trimethoprim induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Trimethoprim induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Trimethoprim (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72939-2;Topiramate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Topiramate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Topiramate (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +729-4;Leukocytes other;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Leukocytes other [#/volume] in Blood by Manual count;WBC Other # Bld Manual;;ACTIVE;1.0;2.73 +72940-0;Topiramate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Topiramate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Topiramate (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72941-8;Terazosin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Terazosin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Terazosin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +7294-2;Egg yolk Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Egg yolk IgG Ab [Units/volume] in Serum;Egg Yolk IgG Qn;;ACTIVE;1.0h(2);2.73 +72942-6;Terazosin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Terazosin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Terazosin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72943-4;Tazobactam induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tazobactam induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tazobactam (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72944-2;Tazobactam induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tazobactam induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tazobactam (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72945-9;Tacrolimus induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tacrolimus induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tacrolimus (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72946-7;Tacrolimus induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tacrolimus induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tacrolimus (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72947-5;Sulfamethoxazole induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sulfamethoxazole induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulfamethoxazole (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72948-3;Sulfamethoxazole induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sulfamethoxazole induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulfamethoxazole (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72949-1;Spironolactone induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Spironolactone induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Spironolactone (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72950-9;Spironolactone induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Spironolactone induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Spironolactone (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72951-7;Simvastatin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Simvastatin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Simvastatin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72952-5;Simvastatin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Simvastatin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Simvastatin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72953-3;Sildenafil citrate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sildenafil citrate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sildenafil cit (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72954-1;Sildenafil citrate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sildenafil citrate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sildenafil cit (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72955-8;Sertraline induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sertraline induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sertraline (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72956-6;Sertraline induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sertraline induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sertraline (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72957-4;risperiDONE induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;risperiDONE induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);risperiDONE (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72958-2;risperiDONE induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;risperiDONE induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);risperiDONE (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7295-9;Egg yolk basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Egg yolk triggered histamine release [Units/volume] in Blood;Egg Yolk BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +72959-0;raNITIdine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;raNITIdine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);raNITIdine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72960-8;raNITIdine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;raNITIdine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);raNITIdine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72961-6;Ramipril induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ramipril induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ramipril (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72962-4;Ramipril induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ramipril induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ramipril (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72963-2;quiNINE induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNINE induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNINE (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72964-0;quiNINE induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNINE induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNINE (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72965-7;quiNIDine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNIDine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNIDine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72966-5;quiNIDine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNIDine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNIDine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7296-7;Solanum melongena Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Eggplant IgE Ab [Units/volume] in Serum;Eggplant IgE Qn;;ACTIVE;1.0h(2);2.73 +72967-3;QUEtiapine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;QUEtiapine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);QUEtiapine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72968-1;QUEtiapine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;QUEtiapine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);QUEtiapine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72969-9;Piperacillin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Piperacillin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Piperacillin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72970-7;Piperacillin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Piperacillin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Piperacillin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72971-5;Phenytoin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Phenytoin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenytoin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72972-3;Phenytoin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Phenytoin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenytoin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72973-1;PHENobarbital induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PHENobarbital induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenobarb (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72974-9;PHENobarbital induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PHENobarbital induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenobarb (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7297-5;Solanum melongena Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Eggplant IgG Ab [Units/volume] in Serum;Eggplant IgG Qn;;ACTIVE;1.0h(2);2.73 +72975-6;Penicillin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Penicillin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Penicillin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72976-4;Penicillin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Penicillin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Penicillin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72977-2;PARoxetine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PARoxetine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);PARoxetine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72978-0;PARoxetine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PARoxetine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);PARoxetine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72979-8;Pantoprazole induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pantoprazole induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pantoprazole (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72980-6;Pantoprazole induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pantoprazole induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pantoprazole (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72981-4;Omeprazole induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Omeprazole induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Omeprazole (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72982-2;Omeprazole induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Omeprazole induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Omeprazole (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7298-3;Sambucus nigra Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Elder IgG Ab [Units/volume] in Serum;Elder IgG Qn;;ACTIVE;1.0h(2);2.69 +72983-0;OLANZapine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;OLANZapine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);OLANZapine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72984-8;OLANZapine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;OLANZapine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);OLANZapine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72985-5;Mycophenolate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Mycophenolate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Mycophenolate (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72986-3;Mycophenolate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Mycophenolate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Mycophenolate (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72987-1;Montelukast induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Montelukast induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Montelukast (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72988-9;Montelukast induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Montelukast induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Montelukast (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72989-7;Metoprolol induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoprolol induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoprolol (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72990-5;Metoprolol induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoprolol induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoprolol (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7299-1;Sambucus nigra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Elderberry IgE Ab [Units/volume] in Serum;Deprecated Elderberry IgE Qn;;DEPRECATED;1.0h(2);2.69 +72991-3;Metoclopramide induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoclopramide induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoclopramide (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72992-1;Metoclopramide induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoclopramide induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoclopramide (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72993-9;Methylphenidate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methylphenidate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Me-phenidate (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72994-7;Methylphenidate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methylphenidate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Me-phenidate (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72995-4;metFORMIN induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;metFORMIN induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);metFORMIN (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72996-2;metFORMIN induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;metFORMIN induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);metFORMIN (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72997-0;Losartan induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Losartan induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Losartan (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +72998-8;Losartan induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Losartan induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Losartan (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +72999-6;Loratadine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Loratadine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Loratadine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73000-2;Loratadine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Loratadine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Loratadine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73001-0;Lisinopril induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lisinopril induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lisinopril (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73002-8;Lisinopril induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lisinopril induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lisinopril (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73003-6;levoFLOXacin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levoFLOXacin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levoFLOXacin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73004-4;levoFLOXacin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levoFLOXacin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levoFLOXacin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73005-1;levETIRAcetam induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levETIRAcetam induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levETIRAcetam (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73006-9;levETIRAcetam induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levETIRAcetam induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levETIRAcetam (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7300-7;Ulmus americana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated White Elm IgE Ab [Units/volume] in Serum;Deprecated White Elm IgE Qn;;DEPRECATED;1.0h(2);2.69 +73007-7;Lansoprazole induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lansoprazole induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lansoprazole (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73008-5;Lansoprazole induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lansoprazole induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lansoprazole (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73009-3;Ibuprofen induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ibuprofen induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ibuprofen (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73010-1;Ibuprofen induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ibuprofen induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ibuprofen (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73011-9;hydroCHLOROthiazide induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydroCHLOROthiazide induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HTCZ (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73012-7;hydroCHLOROthiazide induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydroCHLOROthiazide induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HTCZ (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73013-5;Gentamicin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gentamicin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gentamicin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73014-3;Gentamicin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gentamicin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gentamicin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7301-5;Ulmus americana basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;White Elm triggered histamine release [Units/volume] in Blood;White Elm BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73015-0;Gabapentin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gabapentin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gabapentin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73016-8;Gabapentin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gabapentin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gabapentin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73017-6;Furosemide induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Furosemide induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Furosemide (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73018-4;Furosemide induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Furosemide induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Furosemide (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73019-2;Fluconazole induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fluconazole induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fluconazole (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +730-2;Leukocytes other/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Leukocytes other/100 leukocytes in Blood by Manual count;WBC Other/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +73020-0;Fluconazole induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fluconazole induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fluconazole (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73021-8;Fexofenadine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fexofenadine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fexofenadine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73022-6;Fexofenadine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fexofenadine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fexofenadine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7302-3;Ulmus pumila Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chinese Elm IgE Ab [Units/volume] in Serum;Chinese Elm IgE Qn;;ACTIVE;1.0h(2);2.73 +73023-4;Fenofibrate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fenofibrate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fenofibrate (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73024-2;Fenofibrate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fenofibrate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fenofibrate (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73025-9;Escitalopram induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Escitalopram induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Escitalopram (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73026-7;Escitalopram induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Escitalopram induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Escitalopram (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73027-5;Enalapril induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Enalapril induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Enalapril (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73028-3;Enalapril induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Enalapril induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Enalapril (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73029-1;Clopidogrel induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clopidogrel induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clopidogrel (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73030-9;Clopidogrel induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clopidogrel induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clopidogrel (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7303-1;Ulmus pumila Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Chinese Elm IgE Ab [Units/volume] in Serum;Deprecated Chinese Elm IgE Qn;;DEPRECATED;1.0h(2);2.69 +73031-7;cloNIDine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cloNIDine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cloNIDine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73032-5;cloNIDine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cloNIDine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cloNIDine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73033-3;Clindamycin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clindamycin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clindamycin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73034-1;Clindamycin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clindamycin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clindamycin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73035-8;Citalopram induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Citalopram induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Citalopram (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73036-6;Citalopram induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Citalopram induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Citalopram (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73037-4;Ciprofloxacin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ciprofloxacin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ciprofloxacin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73038-2;Ciprofloxacin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ciprofloxacin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ciprofloxacin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73039-0;Celecoxib induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Celecoxib induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Celecoxib (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73040-8;Celecoxib induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Celecoxib induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Celecoxib (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73041-6;cefTRIAXone induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTRIAXone induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTRIAXone (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73042-4;cefTRIAXone induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTRIAXone induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTRIAXone (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73043-2;cefTAZidime induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTAZidime induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTAZidime (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73044-0;cefTAZidime induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTAZidime induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTAZidime (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73045-7;Cefepime induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefepime induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefepime (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73046-5;Cefepime induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefepime induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefepime (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73047-3;ceFAZolin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ceFAZolin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);ceFAZolin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73048-1;ceFAZolin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ceFAZolin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);ceFAZolin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +7304-9;Cichorium endivia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Endive IgE Ab [Units/volume] in Serum;Endive IgE Qn;;ACTIVE;1.0h(2);2.42 +73049-9;carBAMazepine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;carBAMazepine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);carBAMazepine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73050-7;carBAMazepine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;carBAMazepine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);carBAMazepine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73051-5;buPROPion induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;buPROPion induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);buPROPion (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73052-3;buPROPion induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;buPROPion induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);buPROPion (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73053-1;Atorvastatin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atorvastatin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atorvastatin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73054-9;Atorvastatin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atorvastatin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atorvastatin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73055-6;Atenolol induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atenolol induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atenolol (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +7305-6;Cichorium endivia Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Endive IgG Ab [Units/volume] in Serum;Endive IgG Qn;;ACTIVE;1.0h(2);2.69 +73056-4;Atenolol induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atenolol induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atenolol (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73057-2;Acetylsalicylate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetylsalicylate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acetylsalicylate (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73058-0;Acetylsalicylate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetylsalicylate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acetylsalicylate (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73059-8;Ampicillin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ampicillin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ampicillin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73060-6;Ampicillin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ampicillin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ampicillin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73061-4;Amoxicillin induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amoxicillin induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amoxicillin (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73062-2;Amoxicillin induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amoxicillin induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amoxicillin (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73063-0;amLODIPine induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;amLODIPine induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);amLODIPine (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +7306-4;Epicoccum purpurascens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Epicoccum purpurascens IgE Ab [Units/volume] in Serum;Deprecated E purpurascens IgE Qn;;DEPRECATED;1.0h(2);2.69 +73064-8;amLODIPine induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;amLODIPine induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);amLODIPine (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73065-5;Amitriptyline induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amitriptyline induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amitrip (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73066-3;Amitriptyline induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amitriptyline induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amitrip (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73067-1;Amiodarone induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amiodarone induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amiodarone (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73068-9;Amiodarone induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amiodarone induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amiodarone (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73069-7;Allopurinol induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Allopurinol induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Allopurinol (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73070-5;Allopurinol induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Allopurinol induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Allopurinol (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73071-3;Alendronate induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Alendronate induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Alendronate (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +7307-2;Epidermophyton floccosum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Epidermophyton floccosum IgE Ab [Units/volume] in Serum;E floccosum IgE Qn;;ACTIVE;1.0h(2);2.73 +73072-1;Alendronate induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Alendronate induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Alendronate (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73073-9;Acetaminophen induced neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetaminophen induced neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);APAP (neut) IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73074-7;Acetaminophen induced neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetaminophen induced neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);APAP (neut) IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73075-4;Drug induced neutrophil Ab;Imp;Pt;Ser/Plas;Nar;Flow cytometry;SERO;1;Drug induced neutrophil Ab [Interpretation] in Serum or Plasma by Flow cytometry (FC) Narrative;Drug (neut) Ab SerPl FC-Imp;;ACTIVE;2.44;2.44 +73076-2;Neutrophil Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Neutrophil IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Neutrophil IgM SerPl Ql FC;;ACTIVE;2.44;2.56 +73077-0;Neutrophil Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Neutrophil IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Neutrophil IgG SerPl Ql FC;;ACTIVE;2.44;2.56 +73078-8;Warfarin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Warfarin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Warfarin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73079-6;Warfarin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Warfarin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Warfarin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7308-0;Esterase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Esterase IgE Ab [Units/volume] in Serum;Est IgE Qn;;ACTIVE;1.0h(2);2.42 +73080-4;Voriconazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Voriconazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Voriconazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73081-2;Voriconazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Voriconazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Voriconazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73082-0;Verapamil induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Verapamil induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Verapamil ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73083-8;Verapamil induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Verapamil induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Verapamil ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73084-6;Venlafaxine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Venlafaxine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Venlafaxine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73085-3;Venlafaxine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Venlafaxine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Venlafaxine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73086-1;Vancomycin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Vancomycin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Vancomycin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73087-9;Vancomycin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Vancomycin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Vancomycin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73088-7;Valsartan induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valsartan induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valsartan ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73089-5;Valsartan induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valsartan induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valsartan ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73090-3;Valproate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valproate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valproate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73091-1;Valproate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valproate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valproate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73092-9;valGANciclovir induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;valGANciclovir induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);valGANciclovir ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73093-7;valGANciclovir induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;valGANciclovir induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);valGANciclovir ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73094-5;Valdecoxib induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valdecoxib induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valdecoxib ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73095-2;Valdecoxib induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Valdecoxib induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Valdecoxib ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73096-0;valACYclovir induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;valACYclovir induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);valACYclovir ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73097-8;valACYclovir induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;valACYclovir induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);valACYclovir ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7309-8;Ficus benjamina Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Weeping Fig IgE Ab [Units/volume] in Serum;Weeping Fig IgE Qn;;ACTIVE;1.0h(2);2.42 +73098-6;Ursodeoxycholate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ursodeoxycholate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ursodeoxycholate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73099-4;Ursodeoxycholate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ursodeoxycholate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ursodeoxycholate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +731-0;Lymphocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Lymphocytes [#/volume] in Blood by Automated count;Lymphocytes # Bld Auto;;ACTIVE;1.0;2.73 +73100-0;Trimethoprim induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Trimethoprim induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Trimethoprim ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73101-8;Trimethoprim induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Trimethoprim induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Trimethoprim ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73102-6;Triazolam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Triazolam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Triazolam ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73103-4;Triazolam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Triazolam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Triazolam ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73104-2;Triamterene induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Triamterene induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Triamterene ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73105-9;Triamterene induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Triamterene induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Triamterene ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7310-6;Pseudotsuga taxifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Douglas Fir IgE Ab [Units/volume] in Serum;Douglas Fir IgE Qn;;ACTIVE;1.0h(2);2.73 +73106-7;Triamcinolone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Triamcinolone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Triamcinolone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73107-5;Triamcinolone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Triamcinolone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Triamcinolone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73108-3;traMADol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;traMADol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);traMADol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73109-1;traMADol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;traMADol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);traMADol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73110-9;Topiramate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Topiramate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Topiramate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73111-7;Topiramate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Topiramate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Topiramate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73112-5;Tolterodine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tolterodine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tolterodine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73113-3;Tolterodine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tolterodine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tolterodine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7311-4;Fish Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fish IgE Ab [Units/volume] in Serum;Fish IgE Qn;;DISCOURAGED;1.0h(2);2.73 +73114-1;Tobramycin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tobramycin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tobramycin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73115-8;Tobramycin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tobramycin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tobramycin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73116-6;Tirofiban induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tirofiban induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tirofiban ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73117-4;Tirofiban induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tirofiban induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tirofiban ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73118-2;Timolol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Timolol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Timolol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73119-0;Timolol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Timolol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Timolol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73120-8;Tetracycline induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tetracycline induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tetracycline ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73121-6;Tetracycline induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tetracycline induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tetracycline ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7312-2;Linum usitatissimum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Flax IgE Ab [Units/volume] in Serum;Flax IgE Qn;;ACTIVE;1.0h(2);2.73 +73122-4;Terazosin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Terazosin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Terazosin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73123-2;Terazosin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Terazosin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Terazosin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73124-0;Telmisartan induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Telmisartan induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Telmisartan ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73125-7;Telmisartan induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Telmisartan induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Telmisartan ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73126-5;Tazobactam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tazobactam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tazobactam ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73127-3;Tazobactam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tazobactam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tazobactam ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73128-1;Tamsulosin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tamsulosin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tamsulosin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73129-9;Tamsulosin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tamsulosin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tamsulosin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7313-0;Ctenocephalides sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Flea IgE Ab [Units/volume] in Serum;Flea IgE Qn;;ACTIVE;1.0h(2);2.73 +73130-7;Tamoxifen induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tamoxifen induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tamoxifen ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73131-5;Tamoxifen induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tamoxifen induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tamoxifen ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73132-3;Tacrolimus induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tacrolimus induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tacrolimus ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73133-1;Tacrolimus induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Tacrolimus induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Tacrolimus ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73134-9;Sulindac induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sulindac induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulindac ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73135-6;Sulindac induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sulindac induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulindac ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73136-4;sulfiSOXAZOLE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;sulfiSOXAZOLE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulfisoxaz ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73137-2;sulfiSOXAZOLE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;sulfiSOXAZOLE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulfisoxaz ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73138-0;sulfaSALAzine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;sulfaSALAzine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);sulfaSALAzine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73139-8;sulfaSALAzine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;sulfaSALAzine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);sulfaSALAzine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73140-6;Sulfamethoxazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sulfamethoxazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulfamethoxazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73141-4;Sulfamethoxazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sulfamethoxazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sulfamethoxazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73142-2;Sucralfate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sucralfate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sucralfate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73143-0;Sucralfate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sucralfate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sucralfate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73144-8;Spironolactone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Spironolactone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Spironolactone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73145-5;Spironolactone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Spironolactone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Spironolactone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73146-3;Sotalol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sotalol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sotalol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73147-1;Sotalol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sotalol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sotalol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7314-8;Ctenocephalides sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Flea IgG Ab [Units/volume] in Serum;Flea IgG Qn;;ACTIVE;1.0h(2);2.69 +73148-9;Simvastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Simvastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Simvastatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73149-7;Simvastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Simvastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Simvastatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73150-5;Simethicone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Simethicone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Simethicone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73151-3;Simethicone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Simethicone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Simethicone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73152-1;Sildenafil citrate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sildenafil citrate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sildenafil cit ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73153-9;Sildenafil citrate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sildenafil citrate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sildenafil cit ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73154-7;Sertraline induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sertraline induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sertraline ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7315-5;Ctenocephalides sp basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Flea triggered histamine release [Units/volume] in Blood;Flea BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73155-4;Sertraline induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Sertraline induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Sertraline ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73156-2;Rosuvastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Rosuvastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Rosuvastatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73157-0;Rosuvastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Rosuvastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Rosuvastatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73158-8;Rosiglitazone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Rosiglitazone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Rosiglitazone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73159-6;Rosiglitazone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Rosiglitazone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Rosiglitazone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73160-4;Rofecoxib induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Rofecoxib induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Rofecoxib ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73161-2;Rofecoxib induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Rofecoxib induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Rofecoxib ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73162-0;risperiDONE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;risperiDONE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);risperiDONE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7316-3;Flounder Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Flounder IgE Ab [Units/volume] in Serum;Flounder IgE Qn;;ACTIVE;1.0h(2);2.73 +73163-8;risperiDONE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;risperiDONE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);risperiDONE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73164-6;Risedronate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Risedronate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Risedronate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73165-3;Risedronate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Risedronate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Risedronate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73166-1;rifAMPin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;rifAMPin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);rifAMPin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73167-9;rifAMPin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;rifAMPin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);rifAMPin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73168-7;raNITIdine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;raNITIdine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);raNITIdine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73169-5;raNITIdine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;raNITIdine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);raNITIdine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73170-3;Ramipril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ramipril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ramipril ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7317-1;Flounder Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Flounder IgG Ab [Units/volume] in Serum;Flounder IgG Qn;;ACTIVE;1.0h(2);2.73 +73171-1;Ramipril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ramipril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ramipril ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73172-9;Raloxifene induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Raloxifene induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Raloxifene ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73173-7;Raloxifene induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Raloxifene induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Raloxifene ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73174-5;RABEprazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;RABEprazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);RABEprazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73175-2;RABEprazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;RABEprazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);RABEprazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73176-0;quiNINE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNINE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNINE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73177-8;quiNINE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNINE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNINE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73178-6;quiNIDine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNIDine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNIDine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73179-4;quiNIDine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;quiNIDine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);quiNIDine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73180-2;Quinapril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Quinapril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Quinapril ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73181-0;Quinapril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Quinapril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Quinapril ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73182-8;QUEtiapine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;QUEtiapine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);QUEtiapine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73183-6;QUEtiapine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;QUEtiapine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);QUEtiapine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73184-4;Pseudoephedrine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pseudoephedrine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pseudoephedrine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73185-1;Pseudoephedrine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pseudoephedrine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pseudoephedrine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73186-9;Propranolol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Propranolol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Propranolol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73187-7;Propranolol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Propranolol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Propranolol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73188-5;Propoxyphene+Acetaminophen induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Propoxyphene+Acetaminophen induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Propoxyph+APAP ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7318-9;Flounder basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Flounder triggered histamine release [Units/volume] in Blood;Flounder BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73189-3;Propoxyphene+Acetaminophen induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Propoxyphene+Acetaminophen induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Propoxyph+APAP ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73190-1;Propoxyphene induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Propoxyphene induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Propoxyph ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73191-9;Propoxyphene induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Propoxyphene induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Propoxyph ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73192-7;Procainamide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Procainamide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Procainamide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73193-5;Procainamide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Procainamide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Procainamide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73194-3;Primidone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Primidone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Primidone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73195-0;Primidone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Primidone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Primidone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73196-8;predniSONE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;predniSONE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);predniSONE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7319-7;Chrysops flavidus (whole body) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deer Fly IgE Ab [Units/volume] in Serum;Deer Fly IgE Qn;;ACTIVE;1.0h(2);2.73 +73197-6;predniSONE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;predniSONE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);predniSONE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73198-4;Pravastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pravastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pravastatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73199-2;Pravastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pravastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pravastatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73200-8;Piperacillin+Tazobactam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Piperacillin+Tazobactam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pip+Tazo ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73201-6;Piperacillin+Tazobactam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Piperacillin+Tazobactam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pip+Tazo ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73202-4;Piperacillin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Piperacillin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Piperacillin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73203-2;Piperacillin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Piperacillin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Piperacillin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73204-0;Pioglitazone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pioglitazone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pioglitazone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7320-5;Tabanus spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse Fly IgG Ab [Units/volume] in Serum;Horse Fly IgG Qn;;ACTIVE;1.0h(2);2.69 +73205-7;Pioglitazone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pioglitazone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pioglitazone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73206-5;Phenytoin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Phenytoin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenytoin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73207-3;Phenytoin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Phenytoin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenytoin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73208-1;PHENobarbital induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PHENobarbital induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenobarb ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73209-9;PHENobarbital induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PHENobarbital induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Phenobarb ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73210-7;Perphenazine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Perphenazine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Perphenazine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73211-5;Perphenazine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Perphenazine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Perphenazine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73212-3;Penicillin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Penicillin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Penicillin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7321-3;Musca domestica basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Housefly triggered histamine release [Units/volume] in Blood;Housefly BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73213-1;Penicillin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Penicillin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Penicillin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73214-9;PARoxetine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PARoxetine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);PARoxetine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73215-6;PARoxetine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;PARoxetine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);PARoxetine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73216-4;Papaverine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Papaverine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Papaverine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73217-2;Papaverine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Papaverine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Papaverine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73218-0;Pantoprazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pantoprazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pantoprazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73219-8;Pantoprazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Pantoprazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Pantoprazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73220-6;oxyCODONE+Acetylsalicylate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;oxyCODONE+Acetylsalicylate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);oxyCODONE+ASA ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7322-1;Formaldehyde basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Formaldehyde triggered histamine release [Units/volume] in Blood;Formaldehyde BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73221-4;oxyCODONE+Acetylsalicylate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;oxyCODONE+Acetylsalicylate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);oxyCODONE+ASA ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73222-2;oxyCODONE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;oxyCODONE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);oxyCODONE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73223-0;oxyCODONE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;oxyCODONE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);oxyCODONE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73224-8;OXcarbazepine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;OXcarbazepine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);OXcarbazepine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73225-5;OXcarbazepine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;OXcarbazepine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);OXcarbazepine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73226-3;Oxaliplatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Oxaliplatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Oxaliplatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73227-1;Oxaliplatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Oxaliplatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Oxaliplatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73228-9;Oxacillin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Oxacillin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Oxacillin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73229-7;Oxacillin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Oxacillin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Oxacillin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73230-5;Ondansetron induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ondansetron induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ondansetron ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73231-3;Ondansetron induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ondansetron induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ondansetron ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73232-1;Omeprazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Omeprazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Omeprazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73233-9;Omeprazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Omeprazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Omeprazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73234-7;OLANZapine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;OLANZapine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);OLANZapine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73235-4;OLANZapine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;OLANZapine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);OLANZapine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73236-2;Nystatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nystatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nystatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73237-0;Nystatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nystatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nystatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73238-8;Nizatidine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nizatidine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nizatidine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7323-9;Fruit Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fruit IgE Ab [Units/volume] in Serum;Fruit IgE Qn;;ACTIVE;1.0h(2);2.73 +73239-6;Nizatidine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nizatidine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nizatidine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73240-4;Nitroglycerin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nitroglycerin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nitroglycerin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73241-2;Nitroglycerin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nitroglycerin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nitroglycerin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73242-0;Nitrofurantoin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nitrofurantoin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nitrofurantoin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73243-8;Nitrofurantoin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nitrofurantoin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nitrofurantoin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73244-6;NIFEdipine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;NIFEdipine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);NIFEdipine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73245-3;NIFEdipine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;NIFEdipine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);NIFEdipine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73246-1;Niacin+Lovastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Niacin+Lovastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Niacin+Lovastatin ind plt IgM SP Ql FC;;ACTIVE;2.44;2.66 +7324-7;Fusarium culmorum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium culmorum IgG Ab [Units/volume] in Serum;F culmorum IgG Qn;;ACTIVE;1.0h(2);2.69 +73247-9;Niacin+Lovastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Niacin+Lovastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Niacin+Lovastatin ind plt IgG SP Ql FC;;ACTIVE;2.44;2.66 +73248-7;Naproxen induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Naproxen induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Naproxen ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73249-5;Naproxen induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Naproxen induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Naproxen ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73250-3;Nafcillin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nafcillin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nafcillin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73251-1;Nafcillin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Nafcillin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Nafcillin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73252-9;Mycophenolate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Mycophenolate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Mycophenolate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73253-7;Mycophenolate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Mycophenolate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Mycophenolate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7325-4;Fusarium moniliforme Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium moniliforme IgG Ab [Units/volume] in Serum;F moniliforme IgG Qn;;ACTIVE;1.0h(2);2.73 +73254-5;Moxifloxacin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Moxifloxacin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Moxifloxacin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73255-2;Moxifloxacin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Moxifloxacin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Moxifloxacin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73256-0;Morphine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Morphine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Morphine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73257-8;Morphine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Morphine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Morphine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73258-6;Montelukast induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Montelukast induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Montelukast ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73259-4;Montelukast induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Montelukast induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Montelukast ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73260-2;Mirtazapine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Mirtazapine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Mirtazapine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73261-0;Mirtazapine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Mirtazapine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Mirtazapine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7326-2;Fusarium oxysporum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium oxysporum IgE Ab [Units/volume] in Serum;F oxysporum IgE Qn;;ACTIVE;1.0h(2);2.73 +73262-8;Minoxidil induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Minoxidil induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Minoxidil ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73263-6;Minoxidil induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Minoxidil induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Minoxidil ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73264-4;Minocycline induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Minocycline induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Minocycline ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73265-1;Minocycline induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Minocycline induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Minocycline ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73266-9;Milrinone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Milrinone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Milrinone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73267-7;Milrinone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Milrinone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Milrinone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73268-5;Midazolam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Midazolam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Midazolam ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73269-3;Midazolam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Midazolam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Midazolam ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7327-0;Fusarium solani Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium solani IgE Ab [Units/volume] in Serum;F solani IgE Qn;;ACTIVE;1.0h(2);2.73 +73270-1;metroNIDAZOLE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;metroNIDAZOLE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);metroNIDAZOLE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73271-9;metroNIDAZOLE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;metroNIDAZOLE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);metroNIDAZOLE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73272-7;Metoprolol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoprolol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoprolol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73273-5;Metoprolol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoprolol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoprolol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73274-3;Metoclopramide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoclopramide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoclopramide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73275-0;Metoclopramide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Metoclopramide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Metoclopramide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73276-8;Methylprednisolone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methylprednisolone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Me-prednisolone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73277-6;Methylprednisolone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methylprednisolone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Me-prednisolone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73278-4;Methylphenidate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methylphenidate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Me-phenidate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73279-2;Methylphenidate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methylphenidate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Me-phenidate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +732-8;Lymphocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes [#/volume] in Blood by Manual count;Lymphocytes # Bld Manual;;ACTIVE;1.0;2.73 +73280-0;Methyldopa induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methyldopa induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Methyldopa ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73281-8;Methyldopa induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methyldopa induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Methyldopa ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73282-6;Methotrexate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methotrexate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);MTX ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73283-4;Methotrexate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methotrexate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);MTX ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73284-2;Methocarbamol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methocarbamol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Methocarbamol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73285-9;Methocarbamol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Methocarbamol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Methocarbamol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73286-7;metFORMIN induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;metFORMIN induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);metFORMIN ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73287-5;metFORMIN induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;metFORMIN induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);metFORMIN ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7328-8;Fusarium solani Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fusarium solani IgG Ab [Units/volume] in Serum;F solani IgG Qn;;ACTIVE;1.0h(2);2.69 +73288-3;Meropenem induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Meropenem induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Meropenem ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73289-1;Meropenem induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Meropenem induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Meropenem ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73290-9;Lovastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lovastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lovastatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73291-7;Lovastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lovastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lovastatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73292-5;Losartan induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Losartan induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Losartan ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73293-3;Losartan induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Losartan induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Losartan ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73294-1;LORazepam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;LORazepam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);LORazepam ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73295-8;LORazepam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;LORazepam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);LORazepam ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7329-6;Fusarium oxysporum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Fusarium oxysporum IgE Ab [Units/volume] in Serum;Deprecated F oxysporum IgE Qn;;DEPRECATED;1.0h(2);2.69 +73296-6;Loratadine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Loratadine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Loratadine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73297-4;Loratadine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Loratadine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Loratadine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73298-2;Loperamide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Loperamide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Loperamide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73299-0;Loperamide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Loperamide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Loperamide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73300-6;Lisinopril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lisinopril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lisinopril ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73301-4;Lisinopril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lisinopril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lisinopril ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73302-2;Linezolid induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Linezolid induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Linezolid ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73303-0;Linezolid induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Linezolid induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Linezolid ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7330-4;Allium sativum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Garlic IgG Ab [Units/volume] in Serum;Garlic IgG Qn;;ACTIVE;1.0h(2);2.73 +73304-8;Lidocaine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lidocaine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lidocain ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73305-5;Lidocaine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lidocaine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lidocain ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73306-3;levoFLOXacin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levoFLOXacin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levoFLOXacin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73307-1;levoFLOXacin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levoFLOXacin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levoFLOXacin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73308-9;Levodopa induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Levodopa induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);L-Dopa ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73309-7;Levodopa induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Levodopa induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);L-Dopa ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73310-5;levETIRAcetam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levETIRAcetam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levETIRAcetam ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73311-3;levETIRAcetam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;levETIRAcetam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);levETIRAcetam ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7331-2;Allium sativum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Garlic triggered histamine release [Units/volume] in Blood;Garlic BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73312-1;Levalbuterol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Levalbuterol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Levalbuterol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73313-9;Levalbuterol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Levalbuterol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Levalbuterol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73314-7;Leuprolide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Leuprolide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Leuprolide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73315-4;Leuprolide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Leuprolide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Leuprolide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73316-2;Lepirudin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lepirudin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lepirudin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73317-0;Lepirudin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lepirudin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lepirudin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73318-8;Lansoprazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lansoprazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lansoprazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73319-6;Lansoprazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Lansoprazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Lansoprazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7332-0;Gelatin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gelatin IgE Ab [Units/volume] in Serum;Gelatin IgE Qn;;ACTIVE;1.0h(2);2.73 +73320-4;Ketorolac induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ketorolac induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ketorolac ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73321-2;Ketorolac induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ketorolac induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ketorolac ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73322-0;ISOtretinoin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ISOtretinoin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);ISOtretinoin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73323-8;ISOtretinoin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ISOtretinoin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);ISOtretinoin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73324-6;Isosorbide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Isosorbide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Isosorbide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73325-3;Isosorbide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Isosorbide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Isosorbide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73326-1;Irbesartan+hydroCHLOROthiazide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Irbesartan+hydroCHLOROthiazide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Irbesartan+HTCZ ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73327-9;Irbesartan+hydroCHLOROthiazide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Irbesartan+hydroCHLOROthiazide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Irbesartan+HTCZ ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73328-7;Irbesartan induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Irbesartan induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Irbesartan ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73329-5;Irbesartan induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Irbesartan induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Irbesartan ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73330-3;Ipratropium induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ipratropium induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ipratropium ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73331-1;Ipratropium induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ipratropium induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ipratropium ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73332-9;Imipenem+Cilastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Imipenem+Cilastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);IMP+CS ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73333-7;Imipenem+Cilastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Imipenem+Cilastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);IMP+CS ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73334-5;Imipenem induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Imipenem induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Imipenem ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73335-2;Imipenem induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Imipenem induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Imipenem ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73336-0;Ibuprofen induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ibuprofen induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ibuprofen ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73337-8;Ibuprofen induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ibuprofen induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ibuprofen ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7333-8;Geotrichum candidum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Geotrichum candidum IgE Ab [Units/volume] in Serum;G candidum IgE Qn;;ACTIVE;1.0h(2);2.73 +73338-6;hydrOXYzine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydrOXYzine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);hydrOXYzine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73339-4;hydrOXYzine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydrOXYzine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);hydrOXYzine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73340-2;HYDROmorphone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROmorphone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROmorphone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73341-0;HYDROmorphone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROmorphone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROmorphone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73342-8;Hydrocortisone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Hydrocortisone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Hydrocortisone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73343-6;Hydrocortisone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Hydrocortisone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Hydrocortisone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73344-4;HYDROcodone+Chlorpheniramine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROcodone+Chlorpheniramine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROcodone+CHL ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73345-1;HYDROcodone+Chlorpheniramine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROcodone+Chlorpheniramine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROcodone+CHL ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7334-6;Gerbil epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gerbil epithelium IgE Ab [Units/volume] in Serum;Gerbil Epith IgE Qn;;ACTIVE;1.0h(2);2.73 +73346-9;HYDROcodone+Acetaminophen induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROcodone+Acetaminophen induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROcodone+APAP ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73347-7;HYDROcodone+Acetaminophen induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROcodone+Acetaminophen induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROcodone+APAP ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73348-5;HYDROcodone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROcodone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROcodone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73349-3;HYDROcodone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;HYDROcodone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HYDROcodone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73350-1;hydroCHLOROthiazide+Losartan induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydroCHLOROthiazide+Losartan induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HTCZ+Losartan ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73351-9;hydroCHLOROthiazide+Losartan induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydroCHLOROthiazide+Losartan induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HTCZ+Losartan ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73352-7;hydroCHLOROthiazide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydroCHLOROthiazide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HTCZ ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7335-3;Zingiber officinale Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ginger IgE Ab [Units/volume] in Serum;Ginger IgE Qn;;ACTIVE;1.0h(2);2.73 +73353-5;hydroCHLOROthiazide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydroCHLOROthiazide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);HTCZ ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73354-3;hydrALAZINE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydrALAZINE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);hydrALAZINE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73355-0;hydrALAZINE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;hydrALAZINE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);hydrALAZINE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73356-8;Haloperidol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Haloperidol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Haloperidol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73357-6;Haloperidol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Haloperidol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Haloperidol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73358-4;glyBURIDE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;glyBURIDE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);glyBURIDE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73359-2;glyBURIDE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;glyBURIDE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);glyBURIDE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +733-6;Lymphocytes.variant;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Variant lymphocytes [Presence] in Blood by Light microscopy;Variant Lymphs Bld Ql Smear;;ACTIVE;1.0;2.73 +73360-0;glipiZIDE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;glipiZIDE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);glipiZIDE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7336-1;Zingiber officinale Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ginger IgG Ab [Units/volume] in Serum;Ginger IgG Qn;;ACTIVE;1.0h(2);2.73 +73361-8;glipiZIDE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;glipiZIDE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);glipiZIDE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73362-6;Glimepiride induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Glimepride induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Glimepiride ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73363-4;Glimepiride induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Glimepride induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Glimepiride ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73364-2;Gentamicin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gentamicin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gentamicin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73365-9;Gentamicin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gentamicin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gentamicin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73366-7;Gabapentin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gabapentin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gabapentin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73367-5;Gabapentin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Gabapentin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Gabapentin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73368-3;Furosemide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Furosemide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Furosemide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73369-1;Furosemide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Furosemide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Furosemide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73370-9;Fosinopril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fosinopril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fosinopril ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73371-7;Fosinopril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fosinopril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fosinopril ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73372-5;Fluvastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fluvastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fluvastatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73373-3;Fluvastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fluvastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fluvastatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73374-1;FLUoxetine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;FLUoxetine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);FLUoxetine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73375-8;FLUoxetine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;FLUoxetine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);FLUoxetine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73376-6;Fluconazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fluconazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fluconazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73377-4;Fluconazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fluconazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fluconazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73378-2;Finasteride induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Finasteride induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Finasteride ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7337-9;Gladiolus sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gladiolus IgE Ab [Units/volume] in Serum;Gladiolus IgE Qn;;ACTIVE;1.0h(2);2.42 +73379-0;Finasteride induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Finasteride induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Finasteride ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73380-8;Fexofenadine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fexofenadine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fexofenadine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73381-6;Fexofenadine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fexofenadine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fexofenadine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73382-4;fentaNYL induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;fentaNYL induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);fentaNYL ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73383-2;fentaNYL induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;fentaNYL induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);fentaNYL ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73384-0;Fenofibrate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fenofibrate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fenofibrate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73385-7;Fenofibrate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Fenofibrate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Fenofibrate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73386-5;Famotidine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Famotidine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Famotidine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7338-7;Gluten Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gluten IgG Ab [Units/volume] in Serum;Gluten IgG Qn;;ACTIVE;1.0h(2);2.73 +73387-3;Famotidine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Famotidine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Famotidine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73388-1;Ezetimibe induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ezetimibe induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ezetimibe ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73389-9;Ezetimibe induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ezetimibe induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ezetimibe ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73390-7;Esomeprazole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Esomeprazole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Esomeprazole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73391-5;Esomeprazole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Esomeprazole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Esomeprazole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73392-3;Escitalopram induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Escitalopram induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Escitalopram ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73393-1;Escitalopram induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Escitalopram induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Escitalopram ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73394-9;Erythromycin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Erythromycin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Erythromycin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7339-5;Gnat whole body Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gnat whole body IgE Ab [Units/volume] in Serum;Gnat WB IgE Qn;;ACTIVE;1.0h(2);2.42 +73395-6;Erythromycin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Erythromycin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Erythromycin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73396-4;Eptifibatide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Eptifibatide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Eptifibatide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73397-2;Eptifibatide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Eptifibatide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Eptifibatide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73398-0;Erythropoietin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Erythropoietin (EPO) induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);EPO ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73399-8;Erythropoietin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Erythropoietin (EPO) induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);EPO ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73400-4;Enalapril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Enalapril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Enalapril ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73401-2;Enalapril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Enalapril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Enalapril ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73402-0;Doxycycline induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Doxycycline induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Doxycycline ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7340-3;Goat milk Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goat milk IgE Ab [Units/volume] in Serum;Goat Milk IgE Qn;;ACTIVE;1.0h(2);2.73 +73403-8;Doxycycline induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Doxycycline induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Doxycycline ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73404-6;Doxazosin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Doxazosin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Doxazosin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73405-3;Doxazosin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Doxazosin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Doxazosin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73406-1;Donepezil induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Donepezil induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Donepezil ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73407-9;Donepezil induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Donepezil induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Donepezil ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73408-7;Docusate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Docusate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Docusate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73409-5;Docusate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Docusate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Docusate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73410-3;Dipyridamole induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Dipyridamole induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Dipyridamole ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7341-1;Goat milk Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goat milk IgG Ab [Units/volume] in Serum;Goat Milk IgG Qn;;ACTIVE;1.0h(2);2.69 +73411-1;Dipyridamole induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Dipyridamole induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Dipyridamole ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73412-9;Diphenoxylate+Atropine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Diphenoxylate and Atropine (Lomatil) induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Diphenox+Atropine ind plt IgM SP Ql FC;;ACTIVE;2.44;2.66 +73413-7;Diphenoxylate+Atropine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Diphenoxylate and Atropine (Lomatil) induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Diphenox+Atropine ind plt IgG SP Ql FC;;ACTIVE;2.44;2.66 +73414-5;diphenhydrAMINE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;diphenhydrAMINE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Diphenhy ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73415-2;diphenhydrAMINE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;diphenhydrAMINE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Diphenhy ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73416-0;dilTIAZem induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;dilTIAZem induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);dilTIAZem ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73417-8;dilTIAZem induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;dilTIAZem induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);dilTIAZem ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73418-6;Digoxin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Digoxin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Digoxin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73419-4;Digoxin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Digoxin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Digoxin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73420-2;Dicyclomine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Dicyclomine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Dicyclomine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73421-0;Dicyclomine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Dicyclomine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Dicyclomine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73422-8;diazePAM induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;diazePAM induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);diazePAM ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73423-6;diazePAM induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;diazePAM induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);diazePAM ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73424-4;Amphetamine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amphetamine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amphet ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73425-1;Amphetamine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amphetamine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amphet ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73426-9;cycloSPORINE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cycloSPORINE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cycloSPORINE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73427-7;cycloSPORINE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cycloSPORINE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cycloSPORINE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73428-5;Colchicine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Colchicine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Colchicine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7342-9;Solidago virgaurea Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goldenrod IgG Ab [Units/volume] in Serum;Goldenrod IgG Qn;;ACTIVE;1.0h(2);2.69 +73429-3;Colchicine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Colchicine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Colchicine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73430-1;Clopidogrel induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clopidogrel induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clopidogrel ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73431-9;Clopidogrel induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clopidogrel induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clopidogrel ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73432-7;cloNIDine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cloNIDine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cloNIDine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73433-5;cloNIDine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cloNIDine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cloNIDine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73434-3;clonazePAM induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;clonazePAM induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);clonazePAM ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73435-0;clonazePAM induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;clonazePAM induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);clonazePAM ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73436-8;Clindamycin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clindamycin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clindamycin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7343-7;Solidago virgaurea basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Goldenrod triggered histamine release [Units/volume] in Blood;Goldenrod BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73437-6;Clindamycin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clindamycin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clindamycin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73438-4;Clavulanate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clavulanate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clavulanate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73439-2;Clavulanate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clavulanate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clavulanate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +734-4;Lymphocytes.variant;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Variant lymphocytes [#/volume] in Blood by Manual count;Variant Lymphs # Bld Manual;;ACTIVE;1.0;2.73 +73440-0;Clarithromycin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clarithromycin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clarithro ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73441-8;Clarithromycin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Clarithromycin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Clarithro ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73442-6;Citalopram induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Citalopram induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Citalopram ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73443-4;Citalopram induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Citalopram induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Citalopram ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73444-2;Ciprofloxacin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ciprofloxacin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ciprofloxacin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7344-5;Goose feather Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goose feather IgG Ab [Units/volume] in Serum;Goose Feather IgG Qn;;ACTIVE;1.0h(2);2.69 +73445-9;Ciprofloxacin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ciprofloxacin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ciprofloxacin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73446-7;Cimetidine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cimetidine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cimetidine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73447-5;Cimetidine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cimetidine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cimetidine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73448-3;Cilastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cilastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cilastatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73449-1;Cilastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cilastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cilastatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73450-9;Chlorthalidone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Chlorthalidone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Chlorthalidone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73451-7;Chlorthalidone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Chlorthalidone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Chlorthalidone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7345-2;Grain Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grain IgE Ab [Units/volume] in Serum;Grain IgE Qn;;ACTIVE;1.0h(2);2.73 +73452-5;chlorproPAMIDE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;chlorproPAMIDE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);chlorproPAMIDE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73453-3;chlorproPAMIDE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;chlorproPAMIDE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);chlorproPAMIDE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73454-1;chlorproMAZINE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;chlorproMAZINE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);chlorproMAZINE ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73455-8;chlorproMAZINE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;chlorproMAZINE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);chlorproMAZINE ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73456-6;chlordiazePOXIDE induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;chlordiazePOXIDE induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Chlordiazep ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73457-4;chlordiazePOXIDE induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;chlordiazePOXIDE induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Chlordiazep ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73458-2;Cephalexin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cephalexin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cephalexin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73459-0;Cephalexin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cephalexin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cephalexin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7346-0;Grain dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grain dust IgE Ab [Units/volume] in Serum;Grain Dust IgE Qn;;ACTIVE;1.0h(2);2.42 +73460-8;Celecoxib induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Celecoxib induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Celecoxib ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73461-6;Celecoxib induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Celecoxib induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Celecoxib ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73462-4;Cefuroxime induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefuroxime induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefuroxime ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73463-2;Cefuroxime induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefuroxime induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefuroxime ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73464-0;cefTRIAXone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTRIAXone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTRIAXone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73465-7;cefTRIAXone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTRIAXone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTRIAXone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73466-5;Ceftizoxime induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ceftizoxime induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ceftizoxime ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73467-3;Ceftizoxime induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ceftizoxime induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ceftizoxime ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73468-1;cefTAZidime induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTAZidime induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTAZidime ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73469-9;cefTAZidime induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;cefTAZidime induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);cefTAZidime ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73470-7;Cefepime induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefepime induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefepime ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73471-5;Cefepime induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefepime induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefepime ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73472-3;ceFAZolin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ceFAZolin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);ceFAZolin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73473-1;ceFAZolin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ceFAZolin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);ceFAZolin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73474-9;Cefadroxil induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefadroxil induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefadroxil ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73475-6;Cefadroxil induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Cefadroxil induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Cefadroxil ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73476-4;Caspofungin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Caspofungin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Caspofungin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73477-2;Caspofungin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Caspofungin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Caspofungin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7347-8;Grain mill dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grain mill dust IgE Ab [Units/volume] in Serum;Grain Mill Dust IgE Qn;;ACTIVE;1.0h(2);2.73 +73478-0;Casanthranol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Casanthranol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Casanthranol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73479-8;Casanthranol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Casanthranol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Casanthranol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73480-6;Carvedilol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Carvedilol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Carvedilol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73481-4;Carvedilol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Carvedilol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Carvedilol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73482-2;Carisoprodol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Carisoprodol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Carisoprodol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73483-0;Carisoprodol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Carisoprodol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Carisoprodol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73484-8;Carbidopa induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Carbidopa induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Carbidopa ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73485-5;Carbidopa induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Carbidopa induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Carbidopa ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7348-6;Vitis vinifera Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grape IgG Ab [Units/volume] in Serum;Grape IgG Qn;;ACTIVE;1.0h(2);2.73 +73486-3;carBAMazepine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;carBAMazepine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);carBAMazepine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73487-1;carBAMazepine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;carBAMazepine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);carBAMazepine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73488-9;Captopril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Captopril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Captopril ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73489-7;Captopril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Captopril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Captopril ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73490-5;Candesartan induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Candesartan induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Candesartan ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73491-3;Candesartan induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Candesartan induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Candesartan ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73492-1;Butalbital+Acetylsalicylate+Caffeine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Butalbital+Acetylsalicylate+Caffeine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Butalb+ASA+Caff ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73493-9;Butalbital+Acetylsalicylate+Caffeine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Butalbital+Acetylsalicylate+Caffeine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Butalb+ASA+Caff ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7349-4;Grape raisin basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Grape raisin triggered histamine release [Units/volume] in Blood;Grape Raisin BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73494-7;busPIRone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;busPIRone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);busPIRone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73495-4;busPIRone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;busPIRone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);busPIRone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73496-2;buPROPion induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;buPROPion induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);buPROPion ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73497-0;buPROPion induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;buPROPion induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);buPROPion ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73498-8;Bumetanide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Bumetanide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Bumetanide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73499-6;Bumetanide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Bumetanide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Bumetanide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73500-1;Budesonide induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Budesonide induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Budesonide ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73501-9;Budesonide induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Budesonide induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Budesonide ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7350-2;Citrus paradisis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grapefruit IgG Ab [Units/volume] in Serum;Grapefruit IgG Qn;;ACTIVE;1.0h(2);2.73 +73502-7;Bivalirudin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Bivalirudin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Bivalirudin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73503-5;Bivalirudin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Bivalirudin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Bivalirudin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73504-3;Benztropine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Benztropine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Benztropine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73505-0;Benztropine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Benztropine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Benztropine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73506-8;Benazepril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Benazepril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Benazepril ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73507-6;Benazepril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Benazepril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Benazepril ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73508-4;Aztreonam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Aztreonam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Aztreonam ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73509-2;Aztreonam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Aztreonam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Aztreonam ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +735-1;Lymphocytes.variant/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Variant lymphocytes/100 leukocytes in Blood by Manual count;Variant Lymphs/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +7351-0;Citrus paradisis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Grapefruit triggered histamine release [Units/volume] in Blood;Grapefruit BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73510-0;Azithromycin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Azithromycin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Azithromycin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73511-8;Azithromycin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Azithromycin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Azithromycin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73512-6;Atorvastatin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atorvastatin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atorvastatin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73513-4;Atorvastatin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atorvastatin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atorvastatin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73514-2;Atomoxetine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atomoxetine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atomoxetine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73515-9;Atomoxetine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atomoxetine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atomoxetine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73516-7;Atenolol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atenolol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atenolol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73517-5;Atenolol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Atenolol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Atenolol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73518-3;Acetylsalicylate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetylsalicylate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acetylsalicylate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73519-1;Acetylsalicylate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetylsalicylate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acetylsalicylate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73520-9;Argatroban induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Argatroban induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Argatroban ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73521-7;Argatroban induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Argatroban induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Argatroban ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73522-5;Ampicillin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ampicillin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ampicillin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73523-3;Ampicillin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Ampicillin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Ampicillin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73524-1;Amoxicillin+Clavulanate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amoxicillin+Clavulanate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amoxicillin+Clav ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73525-8;Amoxicillin+Clavulanate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amoxicillin+Clavulanate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amoxicillin+Clav ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73526-6;Amoxicillin induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amoxicillin induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amoxicillin ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73527-4;Amoxicillin induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amoxicillin induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amoxicillin ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7352-8;Agrostis stolonifera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Red top grass IgE Ab [Units/volume] in Serum;Deprecated Red top grass IgE Qn;;DEPRECATED;1.0h(2);2.69 +73528-2;amLODIPine+Benazepril induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;amLODIPine+Benazepril induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);AM+BZ ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73529-0;amLODIPine+Benazepril induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;amLODIPine+Benazepril induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);AM+BZ ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73530-8;amLODIPine induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;amLODIPine induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);amLODIPine ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73531-6;amLODIPine induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;amLODIPine induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);amLODIPine ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73532-4;Amitriptyline induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amitriptyline induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amitrip ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73533-2;Amitriptyline induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amitriptyline induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amitrip ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73534-0;Amiodarone induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amiodarone induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amiodarone ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73535-7;Amiodarone induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Amiodarone induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Amiodarone ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7353-6;Cynodon dactylon Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass IgG Ab [Units/volume] in Serum;Bermuda grass IgG Qn;;ACTIVE;1.0h(2);2.73 +73536-5;ALPRAZolam induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ALPRAZolam induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Alpraz ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73537-3;ALPRAZolam induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;ALPRAZolam induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Alpraz ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73538-1;Allopurinol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Allopurinol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Allopurinol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73539-9;Allopurinol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Allopurinol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Allopurinol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73540-7;Alendronate induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Alendronate induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Alendronate ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73541-5;Alendronate induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Alendronate induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Alendronate ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73542-3;Albuterol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Albuterol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Albuterol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73543-1;Albuterol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Albuterol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Albuterol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +7354-4;Cynodon dactylon basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Bermuda grass triggered histamine release [Units/volume] in Blood;Bermuda grass BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73544-9;Acyclovir induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acyclovir induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acyclovir ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73545-6;Acyclovir induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acyclovir induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acyclovir ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73546-4;Acetaminophen induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetaminophen induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);APAP ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73547-2;Acetaminophen induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acetaminophen induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);APAP ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73548-0;Acebutolol induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acebutolol induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acebutolol ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73549-8;Acebutolol induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acebutolol induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acebutolol ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73550-6;Acarbose induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acarbose induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acarbose ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +7355-1;Poa annua Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Annual blue grass IgE Ab [Units/volume] in Serum;Annual blue grass IgE Qn;;ACTIVE;1.0h(2);2.73 +73551-4;Acarbose induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Acarbose induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Acarbose ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73552-2;Drug induced platelet Ab;Imp;Pt;Ser/Plas;Nar;;SERO;1;Drug induced platelet Ab [Interpretation] in Serum or Plasma Narrative;Drug ind plt Ab SerPl-Imp;;ACTIVE;2.44;2.66 +73553-0;Abciximab induced platelet Ab;Imp;Pt;Ser/Plas;Nom;;SERO;1;Abciximab induced platelet Ab [Interpretation] in Serum or Plasma;Abciximab ind plt Ab SerPl-Imp;;ACTIVE;2.44;2.66 +73554-8;Abciximab induced platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Abciximab induced platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Abciximab ind plt IgM SerPl Ql FC;;ACTIVE;2.44;2.66 +73555-5;Abciximab induced platelet Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Abciximab induced platelet IgG Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Abciximab ind plt IgG SerPl Ql FC;;ACTIVE;2.44;2.66 +73556-3;Platelet Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Platelet IgM Ab [Presence] in Serum or Plasma by Flow cytometry (FC);Platelet IgM SerPl Ql FC;;ACTIVE;2.44;2.73 +73557-1;Thyroxine.free;MCnc;Pt;BldCo;Qn;;CHEM;1;Thyroxine (T4) free [Mass/volume] in Cord blood;T4 Free BldCo-mCnc;;ACTIVE;2.44;2.44 +73558-9;Staphylococcus aureus & Staphylococcus sp.coagulase negative rRNA;Prid;Pt;Bld.pos growth;Nom;FISH;MICRO;1;Staphylococcus aureus and Staphylococcus sp.coagulase negative rRNA [Identifier] by FISH in Positive blood culture;S aureus+CoNS rRNA Bld Pos FISH;;ACTIVE;2.44;2.61 +73559-7;Herpes simplex virus 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Herpes simplex virus 1 IgG Ab [Titer] in Serum by Immunofluorescence;HSV1 IgG Titr Ser IF;;ACTIVE;2.44;2.73 +73560-5;Mumps virus Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Mumps virus IgG and IgM [Interpretation] in Serum;MuV IgG+IgM Ser-Imp;;ACTIVE;2.44;2.73 +73561-3;Insulin-like growth factor-I;Zscore;Pt;Ser/Plas;Qn;;CHEM;1;Insulin-like growth factor-I [Z-score] in Serum or Plasma;IGF-I Z-score SerPl;;ACTIVE;2.44;2.73 +73562-1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Mass/mass] in Meconium by Confirmatory method;EDDP Mec Cfm-mCnt;;ACTIVE;2.44;2.73 +73563-9;7-Aminoclonazepam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Mass/mass] in Meconium by Confirmatory method;7Aminoclonazepam Mec Cfm-mCnt;;ACTIVE;2.44;2.44 +73564-7;Alpha hydroxytriazolam;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Alpha hydroxytriazolam [Mass/mass] in Meconium by Confirmatory method;A-OH-triazolam Mec Cfm-mCnt;;ACTIVE;2.44;2.44 +73565-4;Trenbolone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Trenbolone [Presence] in Urine;Trenbolone Ur Ql;;ACTIVE;2.44;2.73 +73566-2;Dextrorphan;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dextrorphan [Mass/volume] in Urine;DXO Ur-mCnc;;ACTIVE;2.44;2.73 +73567-0;Propoxyphene;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Propoxyphene [Presence] in Meconium by Screen method;Propoxyph Mec Ql Scn;;ACTIVE;2.44;2.56 +73568-8;Communication of critical results;Desc;Pt;^Patient;Doc;;DOC.MISC;2;Communication of critical results [Description] Document;Comm critical results Doc;;ACTIVE;2.44;2.63 +7356-9;Poa compressa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Canadian blue grass IgE Ab [Units/volume] in Serum;Can blue grass IgE Qn;;ACTIVE;1.0h(2);2.42 +73569-6;Radiation exposure and protection information;Desc;Pt;^Patient;Doc;Diagnostic imaging;DOC.MISC;2;Radiation exposure and protection information [Description] Document Diagnostic imaging;Rad expo+protect info Doc Dx Imaging;;ACTIVE;2.44;2.63 +73570-4;Testosterone/Epitestosterone;Imp;Pt;Urine;Ord;;CHEM;1;Testosterone/Epitestosterone [Interpretation] in Urine Qualitative;Testost/Epitestost Ur-Imp;;ACTIVE;2.44;2.73 +73571-2;Osmol gap;Osmol;Pt;Stool;Qn;;CHEM;1;Osmol gap of Stool;Osmol gap Stl;;ACTIVE;2.44;2.73 +73572-0;Magnesium.ionized;SCnc;Pt;Bld;Qn;ISE;CHEM;1;Magnesium Ionized [Moles/volume] in Blood by Ion-selective membrane electrode (ISE);Mg Ionized Bld ISE-sCnc;;ACTIVE;2.44;2.73 +73573-8;Magnesium.ionized^^adjusted to pH 7.4;SCnc;Pt;Bld;Qn;ISE;CHEM;1;Magnesium Ionized [Moles/volume] adjusted to pH 7.4 in Blood by Ion-selective membrane electrode (ISE);Mg Ionized adj pH7.4 Bld ISE-sCnc;;ACTIVE;2.44;2.44 +73574-6;Acyclovir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Acyclovir [Susceptibility] by Genotype method;Acyclovir Islt Genotyp;;ACTIVE;2.44;2.66 +73575-3;Consultation note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Consult note;Radiology Consult note;;ACTIVE;2.44;2.58 +73576-1;Anion gap 4;SCnc;Pt;BldCoV;Qn;;CHEM;1;Anion gap 4 in Venous cord blood;Anion Gap4 BldCoV-sCnc;;ACTIVE;2.44;2.44 +7357-7;Poa pratensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Kentucky blue grass IgE Ab [Units/volume] in Serum;Deprecated Kent blue grass IgE Qn;;DEPRECATED;1.0h(2);2.69 +73577-9;Anion gap 4;SCnc;Pt;BldCoA;Qn;;CHEM;1;Anion gap 4 in Arterial cord blood;Anion Gap4 BldCoA-sCnc;;ACTIVE;2.44;2.44 +73578-7;Anion gap 4;SCnc;Pt;BldV;Qn;;CHEM;1;Anion gap 4 in Venous blood;Anion Gap4 BldV-sCnc;;ACTIVE;2.44;2.44 +73579-5;Anion gap 4;SCnc;Pt;BldMV;Qn;;CHEM;1;Anion gap 4 in Mixed venous blood;Anion Gap4 BldMV-sCnc;;ACTIVE;2.44;2.44 +73580-3;Anion gap 4;SCnc;Pt;BldC;Qn;;CHEM;1;Anion gap 4 in Capillary blood;Anion Gap4 BldC-sCnc;;ACTIVE;2.44;2.44 +73581-1;Anion gap 4;SCnc;Pt;BldA;Qn;;CHEM;1;Anion gap 4 in Arterial blood;Anion Gap4 BldA-sCnc;;ACTIVE;2.44;2.73 +73582-9;Anion gap 4;SCnc;Pt;Bld;Qn;;CHEM;1;Anion gap 4 in Blood;Anion Gap4 Bld-sCnc;;ACTIVE;2.44;2.73 +73583-7;Molybdenum/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Molybdenum/Creatinine [Mass Ratio] in Urine;Molybdenum/Creat Ur;;ACTIVE;2.44;2.73 +73584-5;Norcitalopram;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norcitalopram [Mass/volume] in Urine;Norcitalopram Ur-mCnc;;ACTIVE;2.44;2.73 +7358-5;Poa pratensis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Kentucky blue grass triggered histamine release [Units/volume] in Blood;Kent blue grass BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73585-2;Tizoxanide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tizoxanide [Susceptibility];Tizoxanide Susc Islt;;ACTIVE;2.44;2.44 +73586-0;Tedizolid;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tedizolid [Susceptibility];Tedizolid Susc Islt;;ACTIVE;2.44;2.44 +73587-8;Solithromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Solithromycin [Susceptibility];Solithromycin Susc Islt;;ACTIVE;2.44;2.44 +73588-6;Sarafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sarafloxacin [Susceptibility];Sarafloxacin Susc Islt;;ACTIVE;2.44;2.44 +73589-4;rifAXIMin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;rifAXIMin [Susceptibility];rifAXIMin Susc Islt;;ACTIVE;2.44;2.44 +73590-2;Razupenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Razupenem [Susceptibility];Razupenem Susc Islt;;ACTIVE;2.44;2.44 +73591-0;Premafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Premafloxacin [Susceptibility];Premafloxacin Susc Islt;;ACTIVE;2.44;2.44 +73592-8;Plazomicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Plazomicin [Susceptibility];Plazomicin Susc Islt;;ACTIVE;2.44;2.44 +7359-3;Festuca elatior basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Meadow Fescue triggered histamine release [Units/volume] in Blood;Meadow Fescue BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73593-6;Ormetroprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ormetroprim+Sulfamethoxazole [Susceptibility];Ormetroprim+Sulfamethoxazole Susc Islt;;ACTIVE;2.44;2.44 +73594-4;Omadacycline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Omadacycline [Susceptibility];Omadacycline Susc Islt;;ACTIVE;2.44;2.44 +73595-1;Nitazoxanide;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Nitazoxanide [Susceptibility];Nitazoxanide Susc Islt;;ACTIVE;2.44;2.44 +73596-9;Marbofloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Marbofloxacin [Susceptibility];Marbofloxacin Susc Islt;;ACTIVE;2.44;2.44 +73597-7;Iclaprim;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Iclaprim [Susceptibility];Iclaprim Susc Islt;;ACTIVE;2.44;2.44 +73598-5;Finafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Finafloxacin [Susceptibility];Finafloxacin Susc Islt;;ACTIVE;2.44;2.44 +73599-3;Fidaxomicin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Fidaxomicin [Susceptibility];Fidaxomicin Susc Islt;;ACTIVE;2.44;2.44 +73600-9;Faropenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Faropenem [Susceptibility];Faropenem Susc Islt;;ACTIVE;2.44;2.44 +7360-1;Bouteloua gracilis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gramma grass (Bouteloua gracilis) IgE Ab [Units/volume] in Serum;Gramma grass IgE Qn;;ACTIVE;1.0h(2);2.42 +73601-7;Danofloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Danofloxacin [Susceptibility];Danofloxacin Susc Islt;;ACTIVE;2.44;2.44 +73602-5;Ceftolozane+Tazobactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceftolozane+Tazobactam [Susceptibility];Ceftolozane+Tazobactam Susc Islt;;ACTIVE;2.44;2.73 +73603-3;cefTAZidime+Avibactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;cefTAZidime+Avibactam [Susceptibility];cefTAZidime+Avibactam Susc Islt;;ACTIVE;2.44;2.44 +73604-1;Ceftaroline+Avibactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceftaroline+Avibactam [Susceptibility];Ceftaroline+Avibactam Susc Islt;;ACTIVE;2.44;2.44 +73605-8;Ceftaroline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ceftaroline [Susceptibility];Ceftaroline Susc Islt;;ACTIVE;2.44;2.44 +73606-6;Besifloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Besifloxacin [Susceptibility];Besifloxacin Susc Islt;;ACTIVE;2.44;2.44 +73607-4;Tizoxanide;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tizoxanide [Susceptibility] by Minimum inhibitory concentration (MIC);Tizoxanide Islt MIC;;ACTIVE;2.44;2.44 +73608-2;Tedizolid;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tedizolid [Susceptibility] by Minimum inhibitory concentration (MIC);Tedizolid Islt MIC;;ACTIVE;2.44;2.44 +73609-0;Solithromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Solithromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Solithromycin Islt MIC;;ACTIVE;2.44;2.44 +73610-8;Sarafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sarafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Sarafloxacin Islt MIC;;ACTIVE;2.44;2.44 +73611-6;rifAXIMin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;rifAXIMin [Susceptibility] by Minimum inhibitory concentration (MIC);rifAXIMin Islt MIC;;ACTIVE;2.44;2.44 +73612-4;Razupenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Razupenem [Susceptibility] by Minimum inhibitory concentration (MIC);Razupenem Islt MIC;;ACTIVE;2.44;2.44 +73613-2;Premafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Premafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Premafloxacin Islt MIC;;ACTIVE;2.44;2.44 +73614-0;Plazomicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Plazomicin [Susceptibility] by Minimum inhibitory concentration (MIC);Plazomicin Islt MIC;;ACTIVE;2.44;2.44 +73615-7;Ormetroprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ormetroprim+Sulfamethoxazole [Susceptibility] by Minimum inhibitory concentration (MIC);Ormetroprim+Sulfamethoxazole Islt MIC;;ACTIVE;2.44;2.44 +73616-5;Omadacycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Omadacycline [Susceptibility] by Minimum inhibitory concentration (MIC);Omadacycline Islt MIC;;ACTIVE;2.44;2.44 +73617-3;Nitazoxanide;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Nitazoxanide [Susceptibility] by Minimum inhibitory concentration (MIC);Nitazoxanide Islt MIC;;ACTIVE;2.44;2.44 +73618-1;Marbofloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Marbofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Marbofloxacin Islt MIC;;ACTIVE;2.44;2.44 +7361-9;Sorghum halepense basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Johnson grass triggered histamine release [Units/volume] in Blood;Johnson grass BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73619-9;Iclaprim;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Iclaprim [Susceptibility] by Minimum inhibitory concentration (MIC);Iclaprim Islt MIC;;ACTIVE;2.44;2.44 +73620-7;Finafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Finafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Finafloxacin Islt MIC;;ACTIVE;2.44;2.44 +73621-5;Fidaxomicin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Fidaxomicin [Susceptibility] by Minimum inhibitory concentration (MIC);Fidaxomicin Islt MIC;;ACTIVE;2.44;2.44 +73622-3;Faropenem;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Faropenem [Susceptibility] by Minimum inhibitory concentration (MIC);Faropenem Islt MIC;;ACTIVE;2.44;2.44 +73623-1;Danofloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Danofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Danofloxacin Islt MIC;;ACTIVE;2.44;2.44 +73624-9;Ceftolozane+Tazobactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceftolozane+Tazobactam [Susceptibility] by Minimum inhibitory concentration (MIC);Ceftolozane+Tazobactam Islt MIC;;ACTIVE;2.44;2.73 +73625-6;cefTAZidime+Avibactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;cefTAZidime+Avibactam [Susceptibility] by Minimum inhibitory concentration (MIC);cefTAZidime+Avibactam Islt MIC;;ACTIVE;2.44;2.73 +73626-4;Ceftaroline+Avibactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceftaroline+Avibactam [Susceptibility] by Minimum inhibitory concentration (MIC);Ceftaroline+Avibactam Islt MIC;;ACTIVE;2.44;2.44 +7362-7;Grass koehlers Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Koehlers grass IgE Ab [Units/volume] in Serum;Koehlers grass IgE Qn;;ACTIVE;1.0h(2);2.42 +73627-2;Ceftaroline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ceftaroline [Susceptibility] by Minimum inhibitory concentration (MIC);Ceftaroline Islt MIC;;ACTIVE;2.44;2.73 +73628-0;Besifloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Besifloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Besifloxacin Islt MIC;;ACTIVE;2.44;2.44 +73629-8;Tizoxanide;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tizoxanide [Susceptibility] by Disk diffusion (KB);Tizoxanide Islt KB;;ACTIVE;2.44;2.44 +73630-6;Telavancin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Telavancin [Susceptibility] by Disk diffusion (KB);Telavancin Islt KB;;ACTIVE;2.44;2.44 +73631-4;Tedizolid;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tedizolid [Susceptibility] by Disk diffusion (KB);Tedizolid Islt KB;;ACTIVE;2.44;2.44 +73632-2;Solithromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Solithromycin [Susceptibility] by Disk diffusion (KB);Solithromycin Islt KB;;ACTIVE;2.44;2.44 +73633-0;Sarafloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Sarafloxacin [Susceptibility] by Disk diffusion (KB);Sarafloxacin Islt KB;;ACTIVE;2.44;2.44 +73634-8;rifAXIMin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;rifAXIMin [Susceptibility] by Disk diffusion (KB);rifAXIMin Islt KB;;ACTIVE;2.44;2.44 +7363-5;Festuca elatior Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Meadow Fescue IgE Ab [Units/volume] in Serum;Deprecated Meadow Fescue IgE Qn;;DEPRECATED;1.0h(2);2.69 +73635-5;Razupenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Razupenem [Susceptibility] by Disk diffusion (KB);Razupenem Islt KB;;ACTIVE;2.44;2.44 +73636-3;Premafloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Premafloxacin [Susceptibility] by Disk diffusion (KB);Premafloxacin Islt KB;;ACTIVE;2.44;2.44 +73637-1;Plazomicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Plazomicin [Susceptibility] by Disk diffusion (KB);Plazomicin Islt KB;;ACTIVE;2.44;2.44 +73638-9;Ormetroprim+Sulfamethoxazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ormetroprim+Sulfamethoxazole [Susceptibility] by Disk diffusion (KB);Ormetroprim+Sulfamethoxazole Islt KB;;ACTIVE;2.44;2.44 +73639-7;Omadacycline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Omadacycline [Susceptibility] by Disk diffusion (KB);Omadacycline Islt KB;;ACTIVE;2.44;2.44 +73640-5;Nitazoxanide;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Nitazoxanide [Susceptibility] by Disk diffusion (KB);Nitazoxanide Islt KB;;ACTIVE;2.44;2.44 +73641-3;Marbofloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Marbofloxacin [Susceptibility] by Disk diffusion (KB);Marbofloxacin Islt KB;;ACTIVE;2.44;2.44 +73642-1;Iclaprim;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Iclaprim [Susceptibility] by Disk diffusion (KB);Iclaprim Islt KB;;ACTIVE;2.44;2.44 +7364-3;Festuca elatior Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Meadow Fescue IgG Ab [Units/volume] in Serum;Meadow Fescue IgG Qn;;ACTIVE;1.0h(2);2.69 +73643-9;Finafloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Finafloxacin [Susceptibility] by Disk diffusion (KB);Finafloxacin Islt KB;;ACTIVE;2.44;2.44 +73644-7;Fidaxomicin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Fidaxomicin [Susceptibility] by Disk diffusion (KB);Fidaxomicin Islt KB;;ACTIVE;2.44;2.44 +73645-4;Faropenem;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Faropenem [Susceptibility] by Disk diffusion (KB);Faropenem Islt KB;;ACTIVE;2.44;2.44 +73646-2;Danofloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Danofloxacin [Susceptibility] by Disk diffusion (KB);Danofloxacin Islt KB;;ACTIVE;2.44;2.44 +73647-0;Ceftolozane+Tazobactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceftolozane+Tazobactam [Susceptibility] by Disk diffusion (KB);Ceftolozane+Tazobactam Islt KB;;ACTIVE;2.44;2.73 +73648-8;cefTAZidime+Avibactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;cefTAZidime+Avibactam [Susceptibility] by Disk diffusion (KB);cefTAZidime+Avibactam Islt KB;;ACTIVE;2.44;2.73 +73649-6;Ceftaroline+Avibactam;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceftaroline+Avibactam [Susceptibility] by Disk diffusion (KB);Ceftaroline+Avibactam Islt KB;;ACTIVE;2.44;2.44 +7365-0;Dactylis glomerata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cocksfoot IgG Ab [Units/volume] in Serum;Cocksfoot IgG Qn;;ACTIVE;1.0h(2);2.73 +73650-4;Ceftaroline;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Ceftaroline [Susceptibility] by Disk diffusion (KB);Ceftaroline Islt KB;;ACTIVE;2.44;2.44 +73651-2;Besifloxacin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Besifloxacin [Susceptibility] by Disk diffusion (KB);Besifloxacin Islt KB;;ACTIVE;2.44;2.44 +73652-0;Apramycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Apramycin [Susceptibility] by Minimum inhibitory concentration (MIC);Apramycin Islt MIC;;ACTIVE;2.44;2.44 +73653-8;Apramycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Apramycin [Susceptibility] by Disk diffusion (KB);Apramycin Islt KB;;ACTIVE;2.44;2.44 +73654-6;Hepatitis C virus NS3 gene mutations detected;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis C virus NS3 gene mutations detected [Identifier] by Genotype method;HCV NS3 Mut Det Islt Genotyp;;ACTIVE;2.44;2.73 +73655-3;Hepatitis C virus NS5 gene mutations detected;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis C virus NS5 gene mutations detected [Identifier] by Genotype method;HCV NS5 Mut Det Islt Genotyp;;ACTIVE;2.44;2.73 +73656-1;Varicella zoster virus ORF28 genotype;Prid;Pt;Isolate;Nom;;ABXBACT;1;Varicella zoster virus ORF28 genotype [Identifier];VZV ORF28 Gentyp Islt;;ACTIVE;2.44;2.72 +73657-9;Varicella zoster virus ORF36 genotype;Prid;Pt;Isolate;Nom;;ABXBACT;1;Varicella zoster virus ORF36 genotype [Identifier];VZV ORF36 Gentyp Islt;;ACTIVE;2.44;2.72 +73658-7;HIV 1 subtype;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;HIV 1 subtype in Specimen by NAA with probe detection;HIV 1 subtype Spec NAA+probe;;ACTIVE;2.44;2.73 +73659-5;HIV 2 subtype;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;HIV 2 subtype in Specimen by NAA with probe detection;HIV 2 subtype Spec NAA+probe;;ACTIVE;2.44;2.69 +73660-3;Propoxyphene panel;-;Pt;Saliva;-;;PANEL.DRUG/TOX;1;Propoxyphene panel - Saliva (oral fluid);Propoxyph pnl Sal;;ACTIVE;2.44;2.44 +73661-1;Methadone panel;-;Pt;Saliva;-;Screen;PANEL.DRUG/TOX;1;Methadone panel - Saliva (oral fluid) by Screen method;Methadone pnl Sal Scn;;ACTIVE;2.44;2.44 +73662-9;Benzodiazepines panel;-;Pt;Saliva;-;Screen;PANEL.DRUG/TOX;1;Benzodiazepines panel - Saliva (oral fluid) by Screen method;Benzodiazepines Pnl Sal Scn;;ACTIVE;2.44;2.44 +73663-7;Barbiturates panel;-;Pt;Saliva;-;Confirm;PANEL.DRUG/TOX;1;Barbiturates panel - Saliva (oral fluid) by Confirmatory method;Barbiturates Pnl Sal Cfm;;ACTIVE;2.44;2.44 +73664-5;Yersinia adhesion protein YadA;PrThr;Pt;Isolate;Ord;;MICRO;1;Yersinia adhesion protein YadA [Presence] in Isolate;Yersinia YadA Islt Ql;;ACTIVE;2.44;2.56 +73665-2;Optochin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Optochin [Susceptibility] by Disk diffusion (KB);Optochin Islt KB;;ACTIVE;2.44;2.44 +73666-0;Streptococcus.beta-hemolytic;Type;Pt;Isolate;Nom;LA;MICRO;1;Streptococcus.beta-hemolytic [Type] in Isolate by Latex agglutination;B-Hem Strep Islt LA;;ACTIVE;2.44;2.44 +73667-8;Bacteria producing hippuricase;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing hippuricase [Presence] in Isolate;Bacteria hippuricase Islt Ql;;ACTIVE;2.44;2.56 +7366-8;Dactylis glomerata basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cocksfoot triggered histamine release [Units/volume] in Blood;Cocksfoot BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73668-6;Bacteria soluble by bile;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria soluble by bile [Presence] in Isolate;Bacteria soluble bile Islt Ql;;ACTIVE;2.44;2.56 +73669-4;Bacteria producing DNAse;PrThr;Pt;Isolate;Ord;;MICRO;1;Bacteria producing DNAse [Presence] in Isolate;Bacteria DNAse Islt Ql;;ACTIVE;2.44;2.56 +73670-2;Bacteria producing coagulase+protein A;PrThr;Pt;Isolate;Ord;LA;MICRO;1;Bacteria producing coagulase and protein A [Presence] in Isolate by Latex agglutination;Bacteria coagulase+protein A Islt Ql LA;;ACTIVE;2.44;2.56 +73671-0;Legionella pneumophila serogroup;Type;Pt;Isolate;Nom;Aggl;MICRO;1;Legionella pneumophila serogroup [Type] in Isolate by Agglutination;L pneumophila group Islt Aggl;;ACTIVE;2.44;2.65 +73672-8;Salmonella sp phage type;Type;Pt;Isolate;Nom;;MICRO;1;Salmonella sp phage type in Isolate;Salmonella phage type Islt;;ACTIVE;2.44;2.44 +73673-6;Yersinia enterocolitica serotype;Type;Pt;Isolate;Nom;Aggl;MICRO;1;Yersinia enterocolitica serotype [Type] in Isolate by Agglutination;Y enterocol Sertyp Islt Aggl;;ACTIVE;2.44;2.44 +73674-4;Streptococcus pneumoniae serotype;Type;Pt;Isolate;Nom;Aggl;MICRO;1;Streptococcus pneumoniae serotype [Type] in Isolate by Agglutination;S pneum Sertyp Islt Aggl;;ACTIVE;2.44;2.44 +73675-1;Adenosine triphosphate/Adenosine diphosphate;EntSRto;Pt;Platelets;Qn;;CHEM;1;Adenosine triphosphate/Adenosine diphosphate [Entitic molar ratio] in Platelets;ATP/ADP Plts-EntSRto;;ACTIVE;2.44;2.61 +7367-6;Agropyron repens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Quack grass IgE Ab [Units/volume] in Serum;Quack grass IgE Qn;;ACTIVE;1.0h(2);2.73 +73676-9;Voriconazole^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Voriconazole [Mass/volume] in Serum or Plasma --trough;Voriconazole Trough SerPl-mCnc;;ACTIVE;2.44;2.44 +73677-7;Valproate^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Valproate [Mass/volume] in Serum or Plasma --peak;Valproate Peak SerPl-mCnc;;ACTIVE;2.44;2.44 +73678-5;Topotecan^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Topotecan [Mass/volume] in Serum or Plasma --trough;Topotecan Trough SerPl-mCnc;;ACTIVE;2.44;2.44 +73679-3;SORAfenib;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;SORAfenib [Mass/volume] in Serum or Plasma;SORAfenib SerPl-mCnc;;ACTIVE;2.44;2.44 +73680-1;Mycophenolate^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mycophenolate [Mass/volume] in Serum or Plasma --peak;Mycophenolate Peak SerPl-mCnc;;ACTIVE;2.44;2.44 +73681-9;CYP2D6 gene allele 2;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene allele 2 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CYP2D6 allele 2 Bld/T;;ACTIVE;2.44;2.73 +73682-7;CYP2D6 gene allele 1;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene allele 1 [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CYP2D6 allele 1 Bld/T;;ACTIVE;2.44;2.73 +73683-5;Busulfan^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Busulfan [Mass/volume] in Serum or Plasma --trough;Busulfan Trough SerPl-mCnc;;ACTIVE;2.44;2.44 +7368-4;Agrostis stolonifera basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Red top grass triggered histamine release [Units/volume] in Blood;Red top grass BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73684-3;Atovaquone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Atovaquone [Mass/volume] in Serum or Plasma;Atovaquone SerPl-mCnc;;ACTIVE;2.44;2.44 +73685-0;Streptococcus pneumoniae Ag;PrThr;Pt;Isolate;Ord;LA;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Isolate by Latex agglutination;S pneum Ag Islt Ql LA;;ACTIVE;2.44;2.56 +73686-8;Methylone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methylone [Presence] in Urine by Screen method;Methylone Ur Ql Scn;;ACTIVE;2.44;2.73 +73687-6;Methylenedioxypyrovalerone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methylenedioxypyrovalerone [Presence] in Urine by Screen method;MDPV Ur Ql Scn;;ACTIVE;2.44;2.73 +73688-4;Danazol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Danazol [Presence] in Urine by Screen method;Danazol Ur Ql Scn;;ACTIVE;2.44;2.73 +73689-2;Repaglinide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Repaglinide [Mass/volume] in Urine;Repaglinide Ur-mCnc;;ACTIVE;2.44;2.73 +736-9;Lymphocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Lymphocytes/100 leukocytes in Blood by Automated count;Lymphocytes/leuk NFr Bld Auto;;ACTIVE;1.0;2.73 +73690-0;Nateglinide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Nateglinide [Mass/volume] in Urine;Nateglinide Ur-mCnc;;ACTIVE;2.44;2.73 +73691-8;Glimepiride;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Glimepride [Mass/volume] in Urine;Glimepiride Ur-mCnc;;ACTIVE;2.44;2.73 +7369-2;Lolium perenne Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Perennial rye grass IgE Ab [Units/volume] in Serum;Per rye grass IgE Qn;;ACTIVE;1.0h(2);2.73 +73692-6;Escitalopram;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Escitalopram [Mass/volume] in Urine;Escitalopram Ur-mCnc;;ACTIVE;2.44;2.73 +73693-4;African swine fever virus DNA;ThreshNum;Pt;Tiss;Qn;Probe.amp.tar;MICRO;1;African swine fever virus DNA [Cycle Threshold #] in Tissue by NAA with probe detection;ASFV DNA Ct Tiss Qn NAA+probe;;ACTIVE;2.44;2.63 +73694-2;Microscopic observation;Prid;Pt;Bld;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Blood by KOH preparation;KOH Prep Bld;;ACTIVE;2.44;2.44 +73695-9;HIV reverse transcriptase+protease+integrase gene mutations detected;Prid;Pt;Isolate;Nom;;ABXBACT;1;Deprecated HIV reverse transcriptase+protease+integrase gene mutations detected [Identifier];Deprecated HIV RT+PR+IN Mut Det Islt;;DEPRECATED;2.44;2.56 +73696-7;Oxygen saturation.preductal-oxygen saturation.postductal;MFrDiff;Pt;Bld.preductal+Bld.postductal;Qn;;CARDIO-PULM;2;Oxygen saturation.preductal-oxygen saturation.postductal [Mass fraction difference] in Bld.preductal and Bld.postductal;SaO2%.pre-post MFrDiff Bld.pre+post;;ACTIVE;2.44;2.73 +73697-5;CCHD newborn screening protocol used;Type;Pt;^Patient;Nar;;H&P.HX.LAB;1;CCHD newborn screening protocol used [Type];CCHD NBS used Patient;;ACTIVE;2.44;2.73 +73698-3;Reason CCHD oxygen saturation screening not performed;Find;Pt;^Patient;Nom;;H&P.PX;2;Reason CCHD oxygen saturation screening not performed;CCHD SaO2 scrn not prfrmd;;ACTIVE;2.44;2.56 +73699-1;Number of prior CCHD screens;Num;Pt;^Patient;Ord;;H&P.HX.LAB;1;Number of prior CCHD screens [#] Qualitative;Num CCHD screen Patient Ql;;ACTIVE;2.44;2.52 +73-7;Cefatrizine;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefatrizine [Susceptibility] by Disk diffusion (KB);Cefatrizine Islt KB;;ACTIVE;1.0;2.19 +7370-0;Lolium perenne Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Perennial rye grass IgG Ab [Units/volume] in Serum;Per rye grass IgG Qn;;ACTIVE;1.0h(2);2.73 +73700-7;CCHD newborn screening interpretation;Imp;Pt;^Patient;Nom;;H&P.PX;2;CCHD newborn screening interpretation;CCHD NBS interp;;ACTIVE;2.44;2.73 +73701-5;Multiple carboxylase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Multiple carboxylase deficiency (MCD) newborn screen interpretation;MCD DBS-Imp;;ACTIVE;2.44;2.56 +73702-3;Neisseria meningitidis serosubtype;Type;Pt;Isolate;Nom;IA;MICRO;1;Neisseria meningitidis serosubtype [Type] in Isolate by Immunoassay;N men serosubtyp Islt IA;;ACTIVE;2.44;2.56 +73703-1;Path report.preliminary diagnosis;Imp;Pt;Specimen;Nom;;PATH;1;Pathology report preliminary diagnosis [Interpretation] in Specimen;Path report.Prelimin dx Spec-Imp;;ACTIVE;2.44;2.73 +73704-9;Fluid output.nasogastric tube;Vol;Pt;Upper GI tract;Qn;Measured;IO_OUT.MOLEC;2;Fluid output.nasogastric tube Measured;Fluid output NG-tube Measured;;ACTIVE;2.44;2.73 +73705-6;Intracellular fluid;Vol;Pt;^Patient;Qn;Estimated;H&P.PX;2;Intracellular fluid [Volume] Estimated;Intracell fld Vol Est;;ACTIVE;2.44;2.52 +73706-4;Extracellular fluid;Vol;Pt;^Patient;Qn;Measured;H&P.PX;2;Extracellular fluid [Volume] Measured;Extracell fld Vol Measured;;ACTIVE;2.44;2.52 +73707-2;Visceral fat;Area;Pt;^Patient;Qn;Measured;H&P.PX;2;Visceral fat [Area] Measured;Visceral fat Area Measured;;ACTIVE;2.44;2.52 +73708-0;Body fat mass;Mass;Pt;^Patient;Qn;Calculated;BDYWGT.ATOM;2;Body fat [Mass] Calculated;Body fat Calc;;ACTIVE;2.44;2.73 +73709-8;Prescription request;Find;Pt;Pharmacy;Doc;Pharmacist;DOC.ONTOLOGY;2;Prescription request Pharmacy Document from Pharmacist;PharmD Pharm Prescrip rqst;;ACTIVE;2.44;2.5 +73710-6;(Ambrosia elatior+Ambrosia psilostachya+Ambrosia trifida) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 209 (Common ragweed+Western ragweed+Giant ragweed) IgE Ab [Units/volume] in Serum by Multidisk;Weed Allerg Mix209 IgE Qn;;ACTIVE;2.44;2.66 +73711-4;(Arachis hypogaea+Glycine max+Pisum sativum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 18 (Peanut+Soybean+Peas) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix18 IgE Qn;;ACTIVE;2.44;2.66 +73712-2;(Artemisia dracunculus+Levisticum officinale+Origanum majorana+Thymus vulgaris) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 70 (Tarragon+Lovage+Marjoram+Thyme) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix70 IgE Qn;;ACTIVE;2.44;2.66 +73713-0;(Budgerigar feather+Canary feather+Finch feather+Parakeet feather+Parrot feather) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 72 (Budgerigar feather+Canary feather+Finch feather+Parakeet feather+Parrot feather) IgE Ab [Units/volume] in Serum by Multidisk;Epid Allerg Mix72 IgE Qn;;ACTIVE;2.44;2.66 +73714-8;(Carum carvi+Elettaria cardamomum+Mace+Syzygium aromaticum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 71 (Caraway+Cardamon+Mace+Clove) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix71 IgE Qn;;ACTIVE;2.44;2.66 +73715-5;(Chicken feather+Cow dander+Goose feather+Horse dander) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Occupational Allergen Mix 1 (Chicken feather+Cow dander+Goose feather+Horse dander) IgE Ab [Units/volume] in Serum by Multidisk;Occup Allerg Mix1 IgE Qn;;ACTIVE;2.44;2.66 +73716-3;(Chloramin T+Ethylene oxide+Formaldehyde+Phthalic anhydride) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Occupational Allergen Mix 6 (Chloramin T+Ethylene oxide+Formaldehyde+Phthalic anhydride) IgE Ab [Units/volume] in Serum by Multidisk;Occup Allerg Mix6 IgE Qn;;ACTIVE;2.44;2.66 +73717-1;(Cucumis sativus+Daucus carota+Solanum tuberosum+Spinacia oleracea) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 19 (Cucumber+Carrot+Potato+Spinach) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix19 IgE Qn;;ACTIVE;2.44;2.66 +7371-8;Lolium perenne Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Grass rye Italian IgE Ab [Units/volume] in Serum;Deprecated Per rye grass IgE Qn;;DEPRECATED;1.0h(2);2.69 +73718-9;(Hexamethylene diisocyanate (HDI)+Diphenylmethane diisocyanate (MDI)+Toluene diisocyanate (TDI)+Phthalic anhydride) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Occupational Allergen Mix 5 (Isocyanate HDI+MDI+TDI+Phthalic anhydride) IgE Ab [Units/volume] in Serum by Multidisk;Occup Allerg Mix5 IgE Qn;;ACTIVE;2.44;2.66 +73719-7;Glycine max native (nGly m) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Soybean native (nGly m) 5 IgE Ab [Units/volume] in Serum;Soybean (nGly m) 5 IgE Qn;;ACTIVE;2.44;2.66 +73720-5;Pholcodine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pholcodine IgE Ab [Units/volume] in Serum;Pholcodine IgE Qn;;ACTIVE;2.44;2.66 +73721-3;Rocuronium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rocuronium IgE Ab [Units/volume] in Serum;Rocuronium IgE Qn;;ACTIVE;2.44;2.66 +73722-1;Bile acid;SCnc;Pt;Urine;Qn;;CHEM;1;Bile acid [Moles/volume] in Urine;Bile Ac Ur-sCnc;;ACTIVE;2.44;2.44 +73723-9;Riboflavin;SCnc;Pt;Bld;Qn;;CHEM;1;Riboflavin [Moles/volume] in Blood;Vit B2 Bld-sCnc;;ACTIVE;2.44;2.54 +73724-7;Bile acid dihydroxy & trihydroxy panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Bile acid dihydroxy and trihydroxy panel - Serum or Plasma;Di+Tri-OH Bile ac pnl SerPl;;ACTIVE;2.44;2.44 +73725-4;Bile acid panel;-;24H;Stool;-;;PANEL.CHEM;1;Bile acid panel - 24 hour Stool;Bile acid pnl 24h Stl;;ACTIVE;2.44;2.44 +7372-6;Lolium perenne Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Grass Rye Perennial IgE Ab [Units/volume] in Serum;Deprecated Per rye grass IgE Qn;;DEPRECATED;1.0h(2);2.69 +73726-2;Lysergate diethylamide;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Lysergate diethylamide [Presence] in Hair;LSD Hair Ql;;ACTIVE;2.44;2.56 +73727-0;Methadone;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Methadone [Presence] in Hair;Methadone Hair Ql;;ACTIVE;2.44;2.56 +73728-8;Norcocaine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Norcocaine [Presence] in Meconium;Norcocaine Mec Ql;;ACTIVE;2.44;2.56 +73729-6;Meperidine;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Meperidine [Presence] in Hair;Meperidine Hair Ql;;ACTIVE;2.44;2.56 +73730-4;Lysergate diethylamide;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Lysergate diethylamide [Presence] in Meconium;LSD Mec Ql;;ACTIVE;2.44;2.56 +73731-2;Transaldolase;CCnt;Pt;Lymphoblasts;Qn;;CHEM;1;Transaldolase [Enzymatic activity/mass] in Lymphoblasts;Transaldolase Lymphblst-cCnt;;ACTIVE;2.44;2.44 +73732-0;Human papilloma virus 26+31+33+35+39+45+51+52+53+56+58+59+66+68+73+82 DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 26+31+33+35+39+45+51+52+53+56+58+59+66+68+73+82 DNA [Presence] in Genital specimen by NAA with probe detection;HPV H risk 16 DNA Genital Ql NAA+probe;;ACTIVE;2.44;2.63 +73733-8;Bacteria biotype;Type;Pt;Isolate;Nom;;MICRO;1;Bacteria biotype [Type] in Isolate;Bact biotype Islt;;ACTIVE;2.44;2.44 +7373-4;Lolium perenne Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Perennial rye grass IgG Ab [Units/volume] in Serum;Deprecated Per rye grass IgG Qn;;DEPRECATED;1.0h(2);2.69 +73735-3;ACADVL gene full mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.MUT;1;ACADVL gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;ACADVL Full Mut Anl Bld/T Seq;;ACTIVE;2.44;2.63 +73736-1;ACADVL gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACADVL gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ACADVL Fam Mut Anl Bld/T;;ACTIVE;2.44;2.66 +73737-9;Phospholipase A2 receptor Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Phospholipase A2 receptor IgG Ab [Units/volume] in Serum by Immunoassay;PLA2R IgG Ser IA-aCnc;;ACTIVE;2.44;2.73 +73738-7;Newborn screening test results panel;-;Pt;^Patient;-;;PANEL.H&P;2;Newborn screening test results panel - Point of Care;NBS test results pnl - POC;;ACTIVE;2.44;2.52 +73739-5;Newborn hearing screen reason not performed;Find;Pt;Ear.left;Nom;;H&P.PX;2;Newborn hearing screen reason not performed of Ear - left;NBS reason not prfmed Ear-L;;ACTIVE;2.44;2.56 +73740-3;Screening duration;Time;Pt;Ear.left;Qn;;H&P.PX;2;Screening duration of Ear - left;Screen dur Ear-L;;ACTIVE;2.44;2.52 +73741-1;Newborn hearing screen panel;-;Pt;Ear.left;-;;PANEL.H&P;2;Newborn hearing screen panel of Ear - left;NBS hear pnl Ear-L;;ACTIVE;2.44;2.52 +7374-2;Lolium perenne basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Perennial rye grass triggered histamine release [Units/volume] in Blood;Per rye grass BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73742-9;Newborn hearing screen reason not performed;Find;Pt;Ear.right;Nom;;H&P.PX;2;Newborn hearing screen reason not performed of Ear - right;NBS reason not prfmed Ear-R;;ACTIVE;2.44;2.52 +73743-7;Screening duration;Time;Pt;Ear.right;Qn;;H&P.PX;2;Screening duration of Ear - right;Screen dur Ear-R;;ACTIVE;2.44;2.52 +73744-5;Newborn hearing screen panel;-;Pt;Ear.right;-;;PANEL.H&P;2;Newborn hearing screen panel of Ear - right;NBS hear pnl Ear-R;;ACTIVE;2.44;2.52 +73745-2;Keyhole limpet hemocyanin Ab.IgA;MCnc;Pt;Ser;Qn;;SERO;1;Keyhole limpet hemocyanin IgA Ab [Mass/volume] in Serum;KLH IgA Ser-mCnc;;ACTIVE;2.44;2.44 +73746-0;Keyhole limpet hemocyanin Ab.IgG;MCnc;Pt;Ser;Qn;;SERO;1;Keyhole limpet hemocyanin IgG Ab [Mass/volume] in Serum;KLH IgG Ser-mCnc;;ACTIVE;2.44;2.44 +73747-8;Keyhole limpet hemocyanin Ab.IgM;MCnc;Pt;Ser;Qn;;SERO;1;Keyhole limpet hemocyanin IgM Ab [Mass/volume] in Serum;KLH IgM Ser-mCnc;;ACTIVE;2.44;2.44 +73748-6;APOB gene.p.Arg3500Gln & Arg3500Trp;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APOB gene p.Arg3500Gln and p.Arg3500Trp [Identifier] in Blood or Tissue by Molecular genetics method Nominal;APOB R3500Q+R3500W Bld/T;;ACTIVE;2.44;2.56 +73749-4;4p16.3 chromosome deletion;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;4p16.3 chromosome deletion [Identifier] in Blood or Tissue by FISH Nominal;4p16.3 Del Bld/T FISH;;ACTIVE;2.44;2.61 +73750-2;RAI1 gene 17p11.2 deletion+duplication;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;RAI1 gene 17p11.2 deletion and duplication mutation analysis [Identifier] in Blood or Tissue by FISH Nominal;RAI1 17p11.2 Del+Dup Bld/T FISH;;ACTIVE;2.44;2.61 +73751-0;5p15.2 chromosome deletion;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.DEL;1;5p15.2 (5p-) chromosome deletion [Identifier] in Blood or Tissue by FISH Nominal;5p15.2 Del Bld/T FISH;;ACTIVE;2.44;2.61 +73752-8;Reagin Ab & Treponema pallidum Ab.IgG & IgM;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Reagin and Treponema pallidum IgG and IgM [Interpretation] in Serum or Plasma;Reagin+T pallidum IgG+IgM SerPl-Imp;;ACTIVE;2.44;2.73 +73753-6;oxyCODONE;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;oxyCODONE [Presence] in Hair;oxyCODONE Hair Ql;;ACTIVE;2.44;2.56 +73754-4;Adenovirus C DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Adenovirus C DNA [Presence] in Nasopharynx by NAA with probe detection;AdV C DNA Nph Ql NAA+probe;;ACTIVE;2.44;2.73 +73755-1;Adenovirus B+E DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Adenovirus B+E DNA [Presence] in Nasopharynx by NAA with probe detection;AdV B+E DNA Nph Ql NAA+probe;;ACTIVE;2.44;2.63 +73756-9;Infant is being breastfed at discharge;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;Infant is being breastfed at discharge [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.44 +73757-7;Infant living at time of report;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;Infant living at time of report [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.44 +73758-5;Infant was transferred within 24H of delivery;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;Infant was transferred within 24 hours of delivery [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.61 +7375-9;Grass sorghum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sorghum grass IgE Ab [Units/volume] in Serum;Sorghum grass IgE Qn;;ACTIVE;1.0h(2);2.73 +73759-3;Hysterotomy or hysterectomy was performed at delivery;Find;Pt;^Patient;Ord;US standard report of fetal death;SURVEY.CDC;4;Hysterotomy or hysterectomy was performed at delivery [US Standard Report of Fetal Death];;;ACTIVE;2.44;2.44 +73760-1;If cesarean, a trial of labor was attempted;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;If cesarean, a trial of labor was attempted [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.44 +73761-9;Fetal presentation^at birth;Type;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Fetal presentation--at birth [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.61 +73762-7;Final route and method of delivery;Type;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Final route and method of delivery [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.44 +73763-5;Mother was transferred for maternal medical or fetal indications for delivery;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;Mother was transferred for maternal medical or fetal indications for delivery [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.44 +73764-3;Birth attendant title;Type;Pt;Provider;Nom;US standard certificate of live birth;SURVEY.CDC;4;Birth attendant title Provider [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.63 +73765-0;Planned to deliver at home;Find;Pt;^Mother;Ord;US standard certificate of live birth;SURVEY.CDC;4;Mother Planned to deliver at home [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.63 +73766-8;Place where birth occurred;Type;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Place where birth occurred [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.63 +7376-7;Sorghum sudanense Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sudan grass IgE Ab [Units/volume] in Serum;Sudan grass IgE Qn;;ACTIVE;1.0h(2);2.42 +73767-6;Histological placental examination was performed;Find;Pt;^Patient;Ord;US standard report of fetal death;SURVEY.CDC;4;Histological placental examination was performed [US Standard Report of Fetal Death];;;ACTIVE;2.44;2.44 +73768-4;Autopsy was performed;Find;Pt;^Patient;Ord;US standard report of fetal death;SURVEY.CDC;4;Autopsy was performed [US Standard Report of Fetal Death];;;ACTIVE;2.44;2.44 +73769-2;Infections present &or treated during this pregnancy for fetal death;Prid;Pt;^Patient;Nom;US standard report of fetal death;SURVEY.CDC;4;Infections present AndOr treated during this pregnancy for fetal death [US Standard Report of Fetal Death];;;ACTIVE;2.44;2.44 +737-7;Lymphocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Blood by Manual count;Lymphocytes/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +73770-0;Name of facility infant transferred to;ID;Pt;Facility;Nom;;SURVEY.CDC;4;Name of facility infant transferred to;;;ACTIVE;2.44;2.68 +73771-8;Birth order;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Birth order;;;ACTIVE;2.44;2.44 +73772-6;Number of fetal deaths delivered;Num;Pt;^Patient;Qn;;SURVEY.CDC;4;Number of fetal deaths delivered;;;ACTIVE;2.44;2.44 +73773-4;Number of infants in this delivery delivered alive;Num;Pt;^Patient;Qn;;SURVEY.CDC;4;Number of infants in this delivery delivered alive;;;ACTIVE;2.44;2.46 +73774-2;Onset of labor;Find;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Onset of labor [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.44 +7377-5;Anthoxanthum odoratum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Sweet Vernal grass triggered histamine release [Units/volume] in Blood;Sw Vernal grass BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73775-9;Risk factors in this pregnancy;Find;Pt;^Mother;Nom;US standard certificate of live birth;SURVEY.CDC;4;Mothers Risk factors in this pregnancy [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.66 +73776-7;No prenatal care;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;No prenatal care [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.44 +73777-5;Name of facility mother transferred from;ID;Pt;Facility;Nom;;SURVEY.CDC;4;Name of facility mother transferred from;;;ACTIVE;2.44;2.68 +73778-3;Suspected chromosomal disorder karyotype status;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;Suspected chromosomal disorder karyotype status [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.48 +73779-1;Down syndrome karyotype status;Find;Pt;^Patient;Ord;US standard certificate of live birth;SURVEY.CDC;4;Down syndrome karyotype status [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.48 +73780-9;Congenital anomalies of the newborn;Find;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Congenital anomalies of the newborn [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.48 +73781-7;Maternal morbidity;Find;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Maternal morbidity [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.48 +73782-5;Neonatal pressure injury risk evaluation;Imp;Pt;^Patient;Ord;NSRAS;SURVEY.NSRAS;4;Neonatal pressure ulcer risk evaluation [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.73 +7378-3;Grass tall oat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Tall oat grass IgE Ab [Units/volume] in Serum;Deprecated Tall oat grass IgE Qn;;DEPRECATED;1.0h(2);2.44 +73783-3;Neonatal pressure injury risk total score;Score;Pt;^Patient;Qn;NSRAS;SURVEY.NSRAS;4;Neonatal pressure injury risk total score [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.73 +73784-1;Moisture;Find;Pt;^Patient;Ord;NSRAS;SURVEY.NSRAS;4;Moisture [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.5 +73785-8;Nutrition;Find;Pt;^Patient;Ord;NSRAS;SURVEY.NSRAS;4;Nutrition [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.5 +73786-6;Activity;Find;Pt;^Patient;Ord;NSRAS;SURVEY.NSRAS;4;Activity [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.5 +73787-4;Mobility;Find;Pt;^Patient;Ord;NSRAS;SURVEY.NSRAS;4;Mobility [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.5 +73788-2;Mental status;Find;Pt;^Patient;Ord;NSRAS;SURVEY.NSRAS;4;Mental status [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.5 +73789-0;General physical condition;Find;Pt;^Patient;Ord;NSRAS;SURVEY.NSRAS;4;General physical condition [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.5 +73790-8;Neonatal skin risk assessment scale panel;-;Pt;^Patient;-;NSRAS;PANEL.SURVEY.NSRAS;4;Neonatal skin risk assessment scale panel [NSRAS];;Copyright © 1997 Barbara Huffines. Used with permission.;ACTIVE;2.44;2.5 +7379-1;Grass wheat Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat grass IgG Ab [Units/volume] in Serum;Wheat grass IgG Qn;;ACTIVE;1.0h(2);2.69 +73792-4;Infant activity during postductal oxygen saturation measurement;Find;Pt;^Patient;Nom;;H&P.HX.LAB;1;Infant activity during postductal oxygen saturation measurement;Infant active postductal Patient;;ACTIVE;2.44;2.52 +73793-2;Signal quality;Find;Pt;Bld.postductal;Ord;Pulse oximetry;CARDIO-PULM;2;Signal quality Blood Postductal Pulse oximetry;Signal quality Bld Postductal PulseOx;;ACTIVE;2.44;2.52 +73794-0;Perfusion index;Ratio;Pt;Bld.postductal;Qn;Pulse oximetry;CARDIO-PULM;2;Perfusion index Blood Postductal Pulse oximetry;Perfusion index Bld Postductal PulseOx;;ACTIVE;2.44;2.52 +73795-7;Heart rate;NRat;Pt;Bld.postductal;Qn;Pulse oximetry;CARDIO-PULM;2;Heart rate Blood Postductal Pulse oximetry;Heart rate Bld Postductal PulseOx;;ACTIVE;2.44;2.52 +73796-5;Infant activity during preductal oxygen saturation measurement;Find;Pt;^Patient;Nom;;H&P.HX.LAB;1;Infant activity during preductal oxygen saturation measurement;Infant active preductal Patient;;ACTIVE;2.44;2.52 +73797-3;Signal quality;Find;Pt;Bld.preductal;Ord;Pulse oximetry;CARDIO-PULM;2;Signal quality Blood Preductal Pulse oximetry;Signal quality Bld Preductal PulseOx;;ACTIVE;2.44;2.52 +73798-1;Perfusion index;Ratio;Pt;Bld.preductal;Qn;Pulse oximetry;CARDIO-PULM;2;Perfusion index Blood Preductal Pulse oximetry;Perfusion index Bld Preductal PulseOx;;ACTIVE;2.44;2.52 +73799-9;Heart rate;NRat;Pt;Bld.preductal;Qn;Pulse oximetry;CARDIO-PULM;2;Heart rate Blood Preductal Pulse oximetry;Heart rate Bld Preductal PulseOx;;ACTIVE;2.44;2.52 +73800-5;Oxygen saturation sensor wrap size;Type;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation sensor wrap size;SaO2% Device SaO2% sensor wrap size;;ACTIVE;2.44;2.52 +73801-3;Oxygen saturation sensor wrap type;Type;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation sensor wrap type;SaO2% Device SaO2% sensor wrp type;;ACTIVE;2.44;2.52 +73802-1;Oxygen saturation sensor wrap name;ID;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation sensor wrap name;SaO2% Device SaO2% sens wrap name;;ACTIVE;2.44;2.52 +73803-9;Oxygen saturation sensor type;Type;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation sensor type;SaO2% Device SaO2% sensor type;;ACTIVE;2.44;2.52 +73804-7;Oxygen saturation sensor name;ID;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation sensor name;SaO2% Device SaO2% sensor name;;ACTIVE;2.44;2.52 +73805-4;CCHD newborn screening panel;-;Pt;^Patient;-;;PANEL.H&P;2;CCHD newborn screening panel;CCHD NBS Pnl;;ACTIVE;2.44;2.52 +73806-2;Newborn age in hours;Time;Pt;^Patient;Qn;;H&P.PX;2;Newborn age in hours;Nwbrn age hours;;ACTIVE;2.44;2.52 +73807-0;B cell+T cell crossmatch.autologous;Imp;Pt;Ser+Bld;Ord;Complement dependent cytotoxicity;BLDBK;1;B cell+T cell crossmatch.autologous [Interpretation] Qualitative by Complement dependent cytotoxicity;B+T cell XM.auto Ser+Bld CDC-Imp;;ACTIVE;2.44;2.63 +73808-8;B cell+T cell crossmatch;Imp;Pt;Ser+Bld;Ord;Flow cytometry;BLDBK;1;B cell+T cell crossmatch [Interpretation] Qualitative by Flow cytometry (FC);B+T cell XM Ser+Bld FC-Imp;;ACTIVE;2.44;2.73 +7380-9;Grayfish Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Grayfish IgE Ab [Units/volume] in Serum;Grayfish IgE Qn;;ACTIVE;1.0h(2);2.42 +73809-6;B cell+T cell crossmatch;Imp;Pt;Ser+Bld;Ord;Complement dependent cytotoxicity;BLDBK;1;B cell+T cell crossmatch [Interpretation] Qualitative by Complement dependent cytotoxicity;B+T cell XM Ser+Bld CDC-Imp;;ACTIVE;2.44;2.56 +73810-4;Cells.CD3-CD16+CD56+HLA-DR+/100 cells.CD3-CD16+CD56+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD3-CD16+CD56+HLA-DR+ (activated Natural Killer) cells/100 cells.CD3-CD16+CD56+ (Natural killer) cells in Blood by Flow cytometry (FC);NK activated/100 NK NFr Bld FC;;ACTIVE;2.44;2.44 +73811-2;Estimated timing of fetal death;Find;Pt;^Patient;Nom;US standard report of fetal death;SURVEY.CDC;4;Estimated timing of fetal death [US Standard Report of Fetal Death];;;ACTIVE;2.44;2.48 +73812-0;Abnormal conditions of the newborn;Find;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Abnormal conditions of the newborn [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.48 +73813-8;Characteristics of labor and delivery;Find;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Characteristics of labor and delivery [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.48 +73814-6;Obstetric procedures performed;Find;Pt;^Patient;Nom;US standard certificate of live birth;SURVEY.CDC;4;Obstetric procedures performed [US Standard Certificate of Live Birth];;;ACTIVE;2.44;2.48 +73815-3;Indexing - product concept;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indexing - product concept;FDA insert Indexing - prod cncpt;;ACTIVE;2.44;2.46 +73816-1;Platelet factor 4 heparin complex induced Ab.IgG;Imp;Pt;Ser;Nar;;SERO;1;Heparin induced platelet IgG Ab [Interpretation] in Serum Narrative;PF4 heparin cmplx IgG Ser-Imp;;ACTIVE;2.44;2.73 +7381-7;Sarcobatus vermiculatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Greasewood IgE Ab [Units/volume] in Serum;Greasewood IgE Qn;;ACTIVE;1.0h(2);2.42 +73817-9;Percent heparin inhibition;Ratio;Pt;Ser;Qn;;SERO;1;Percent heparin inhibition [Ratio] in Serum;Prcnt hep inhibited Ser-Rto;;ACTIVE;2.44;2.44 +73818-7;Platelet factor 4 heparin complex induced Ab.IgG;OD;Pt;Ser/Plas;Qn;IA;SERO;1;Heparin induced platelet IgG Ab in Serum or Plasma by Immunoassay;PF4 heparin cmplx IgG SerPl IA;;ACTIVE;2.44;2.73 +73819-5;Platelet factor 4 heparin complex induced Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Heparin induced platelet IgG Ab [Presence] in Serum or Plasma by Immunoassay;PF4 heparin cmplx IgG SerPl Ql IA;;ACTIVE;2.44;2.73 +73820-3;External cephalic version outcome;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;External cephalic version outcome;;;ACTIVE;2.44;2.64 +73821-1;Fetal chromosome X & Y aneuploidy risk;Likelihood;Pt;Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Chromosome X and Y aneuploidy risk [Likelihood] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Chr X + Y aneup risk Plas.cfDNA Qn;;ACTIVE;2.44;2.73 +73822-9;Fetal chromosome X & Y aneuploidy;Find;Pt;Plas.cfDNA;Nom;Dosage of chromosome specific cf DNA;MOLPATH;1;Chromosome X and Y aneuploidy in Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Nominal;Chr X + Y aneup Plas.cfDNA;;ACTIVE;2.44;2.73 +73823-7;Cocaine+Benzoylecgonine;PrThr;Pt;Ser/Plas/Bld;Ord;Screen;DRUG/TOX;1;Cocaine+Benzoylecgonine [Presence] in Serum, Plasma or Blood by Screen method;Cocaine+BZE SerPlBld Ql Scn;;ACTIVE;2.44;2.73 +73824-5;Fetal trisomy 13 risk;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 13 risk [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ts 13 risk Plas.cfDNA Ql;;ACTIVE;2.44;2.73 +7382-5;Gum arabic Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gum arabic IgE Ab [Units/volume] in Serum;Gum Arabic IgE Qn;;ACTIVE;1.0h(2);2.73 +73825-2;Fetal trisomy 18 risk;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 18 risk [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ts 18 risk Plas.cfDNA Ql;;ACTIVE;2.44;2.73 +73826-0;Flurazepam+N-desalkylflurazepam;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Flurazepam+N-desalkylflurazepam [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Flurazepam+Desalkyl SerPlBld Cfm-mCnc;;ACTIVE;2.44;2.73 +73827-8;Gamma hydroxybutyrate;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Gamma hydroxybutyrate [Mass/volume] in Serum, Plasma or Blood;G-OH-Butyr SerPlBld-mCnc;;ACTIVE;2.44;2.73 +73828-6;Flunitrazepam;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Flunitrazepam [Mass/volume] in Serum, Plasma or Blood;Flunitrazepam SerPlBld-mCnc;;ACTIVE;2.44;2.73 +73829-4;7-Aminoflunitrazepam;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;7-Aminoflunitrazepam [Mass/volume] in Serum, Plasma or Blood;7Aminoflunitrazepam SerPlBld-mCnc;;ACTIVE;2.44;2.73 +73830-2;Fall risk assessment;Imp;Pt;^Patient;Ord;;H&P.HX;2;Fall risk assessment;Fall risk assessment;;ACTIVE;2.44;2.73 +73831-0;Adolescent depression screening assessment;Imp;Pt;^Patient;Ord;;H&P.HX;2;Adolescent depression screening assessment;Adlscnt depress scrn assess;;ACTIVE;2.44;2.73 +73832-8;Adult depression screening assessment;Imp;Pt;^Patient;Ord;;H&P.HX;2;Adult depression screening assessment;Adult depress scrn assess;;ACTIVE;2.44;2.73 +7383-3;Celtis occidentalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hackberry tree IgE Ab [Units/volume] in Serum;Hackberry tree IgE Qn;;ACTIVE;1.0h(2);2.73 +73833-6;Legionella sp Ab;PrThr;Pt;XXX;Ord;IF;MICRO;1;Legionella sp Ab [Presence] in Specimen by Immunofluorescence;Legionella Ab Spec Ql IF;;ACTIVE;2.44;2.73 +73834-4;Bacteria.carbapenem resistant identified;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Bacteria.carbapenem resistant identified in Anal by Organism specific culture;Bacteria.carbpm resist Anal Cult;;ACTIVE;2.44;2.73 +73835-1;Bacteria.extended spectrum beta lactamase resistance;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Bacteria.extended spectrum beta lactamase resistance [Identifier] in Anal by Organism specific culture;Bacteria.ESBL Anal Cult;;ACTIVE;2.44;2.73 +73836-9;Bacteria.fluoroquinolone resistant identified;Prid;Pt;Anal;Nom;Organism specific culture;MICRO;1;Bacteria.fluoroquinolone resistant identified in Anal by Organism specific culture;Bacteria.fluoroq resist Anal Cult;;ACTIVE;2.44;2.73 +73837-7;Galactose-alpha-1,3-galactose Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Galactose-alpha-1,3-galactose (Alpha-Gal) IgE Ab [Units/volume] in Serum;Alpha-Gal IgE Qn;;ACTIVE;2.44;2.73 +73838-5;11-Dehydrotetrahydrocorticosterone;SCnc;Pt;Urine;Qn;;CHEM;1;11-Dehydrotetrahydrocorticosterone [Moles/volume] in Urine;THA Ur-sCnc;;ACTIVE;2.44;2.44 +73839-3;11-Dehydrotetrahydrocorticosterone;SCnc;24H;Urine;Qn;;CHEM;1;11-Dehydrotetrahydrocorticosterone [Moles/volume] in 24 hour Urine;THA 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73840-1;11-Dehydrotetrahydrocorticosterone;SRat;24H;Urine;Qn;;CHEM;1;11-Dehydrotetrahydrocorticosterone [Moles/time] in 24 hour Urine;THA 24h Ur-sRate;;ACTIVE;2.44;2.46 +7384-1;Melanogrammus aeglefinus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Haddock IgE Ab [Units/volume] in Serum;Haddock IgE Qn;;ACTIVE;1.0h(2);2.73 +73841-9;Tetrahydrodeoxycortisol;SCnc;Pt;Urine;Qn;;CHEM;1;Tetrahydrodeoxycortisol [Moles/volume] in Urine;TH-DC Ur-sCnc;;ACTIVE;2.44;2.44 +73842-7;Tetrahydrodeoxycortisol;SCnc;24H;Urine;Qn;;CHEM;1;Tetrahydrodeoxycortisol [Moles/volume] in 24 hour Urine;TH-DC 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73843-5;Tetrahydrodeoxycortisol;SRat;24H;Urine;Qn;;CHEM;1;Tetrahydrodeoxycortisol [Moles/time] in 24 hour Urine;TH-DC 24h Ur-sRate;;ACTIVE;2.44;2.44 +73844-3;16-Alpha hydroxydehydroepiandrosterone;SCnc;Pt;Urine;Qn;;CHEM;1;16-Alpha hydroxydehydroepiandrosterone [Moles/volume] in Urine;16A OH-DHEA Ur-sCnc;;ACTIVE;2.44;2.44 +73845-0;16-Alpha hydroxydehydroepiandrosterone;SRat;24H;Urine;Qn;;CHEM;1;16-Alpha hydroxydehydroepiandrosterone [Moles/time] in 24 hour Urine;16A OH-DHEA 24h Ur-sRate;;ACTIVE;2.44;2.46 +73846-8;16-Alpha hydroxydehydroepiandrosterone;SCnc;24H;Urine;Qn;;CHEM;1;16-Alpha hydroxydehydroepiandrosterone [Moles/volume] in 24 hour Urine;16A OH-DHEA 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73847-6;16-Ketoandrostenediol;SCnc;24H;Urine;Qn;;CHEM;1;16-Ketoandrostenediol [Moles/volume] in 24 hour Urine;16-Ketoandrostenediol 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73848-4;16-Ketoandrostenediol;SRat;24H;Urine;Qn;;CHEM;1;16-Ketoandrostenediol [Moles/time] in 24 hour Urine;16-Ketoandrostenediol 24h Ur-sRate;;ACTIVE;2.44;2.46 +73849-2;16-Ketoandrostenediol;SCnc;Pt;Urine;Qn;;CHEM;1;16-Ketoandrostenediol [Moles/volume] in Urine;16-Ketoandrostenediol Ur-sCnc;;ACTIVE;2.44;2.44 +738-5;Macrocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Macrocytes [Presence] in Blood by Light microscopy;Macrocytes Bld Ql Smear;;ACTIVE;1.0;2.73 +73850-0;18-Beta glycyrrhetinate;MCnc;Pt;Urine;Qn;;CHEM;1;18-Beta glycyrrhetinate [Mass/volume] in Urine;GRA Ur-mCnc;;ACTIVE;2.44;2.44 +73851-8;18-Beta glycyrrhetinate;MCnc;24H;Urine;Qn;;CHEM;1;18-Beta glycyrrhetinate [Mass/volume] in 24 hour Urine;GRA 24h Ur-mCnc;;ACTIVE;2.44;2.44 +73852-6;7-Dehydrocholesterol & 8-Dehydrocholesterol panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;7-Dehydrocholesterol and 8-Dehydrocholesterol panel - Serum or Plasma;7-DHC+8-DHC Pnl SerPl;;ACTIVE;2.44;2.44 +73853-4;Aldosterone-18-glucuronide;SCnc;24H;Urine;Qn;;CHEM;1;Aldosterone-18-glucuronide [Moles/volume] in 24 hour Urine;Aldost-18 G 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73854-2;Aldosterone-18-glucuronide;SRat;24H;Urine;Qn;;CHEM;1;Aldosterone-18-glucuronide [Moles/time] in 24 hour Urine;Aldost-18 G 24h Ur-sRate;;ACTIVE;2.44;2.44 +73855-9;Aldosterone-18-glucuronide;SCnc;Pt;Urine;Qn;;CHEM;1;Aldosterone-18-glucuronide [Moles/volume] in Urine;Aldost-18 G Ur-sCnc;;ACTIVE;2.44;2.44 +73856-7;Allo-pregnanediol;SCnc;Pt;Urine;Qn;;CHEM;1;Allo-pregnanediol [Moles/volume] in Urine;Allo-pregnanediol Ur-sCnc;;ACTIVE;2.44;2.56 +73857-5;Allo-pregnanediol;SRat;24H;Urine;Qn;;CHEM;1;Allo-pregnanediol [Moles/time] in 24 hour Urine;Allo-pregnanediol 24h Ur-sRate;;ACTIVE;2.44;2.56 +7385-8;Melanogrammus aeglefinus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Haddock IgG Ab [Units/volume] in Serum;Haddock IgG Qn;;ACTIVE;1.0h(2);2.73 +73858-3;Allo-pregnanediol;SCnc;24H;Urine;Qn;;CHEM;1;Allo-pregnanediol [Moles/volume] in 24 hour Urine;Allo-pregnanediol 24h Ur-sCnc;;ACTIVE;2.44;2.56 +73859-1;Allo-tetrahydrocorticosterone;SCnc;Pt;Urine;Qn;;CHEM;1;Allo-tetrahydrocorticosterone [Moles/volume] in Urine;Allo-THB Ur-sCnc;;ACTIVE;2.44;2.44 +73860-9;Allo-tetrahydrocorticosterone;SCnc;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrocorticosterone [Moles/volume] in 24 hour Urine;Allo-THB 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73861-7;Allo-tetrahydrocorticosterone;SRat;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrocorticosterone [Moles/time] in 24 hour Urine;Allo-THB 24h Ur-sRate;;ACTIVE;2.44;2.44 +73862-5;Allo-tetrahydrocortisol;SRat;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrocortisol [Moles/time] in 24 hour Urine;Allo-THF 24h Ur-sRate;;ACTIVE;2.44;2.44 +73863-3;Allo-tetrahydrocortisol;SCnc;Pt;Urine;Qn;;CHEM;1;Allo-tetrahydrocortisol [Moles/volume] in Urine;Allo-THF Ur-sCnc;;ACTIVE;2.44;2.44 +73864-1;Allo-tetrahydrocortisol;SCnc;24H;Urine;Qn;;CHEM;1;Allo-tetrahydrocortisol [Moles/volume] in 24 hour Urine;Allo-THF 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73865-8;Catecholamines 3 panel;SCnc;Pt;Plas;-;;PANEL.CHEM;1;Catecholamines 3 panel [Moles/volume] - Plasma;Catecholamines 3 Pnl Plas-sCnc;;ACTIVE;2.44;2.44 +7386-6;Hippoglossus hippoglossus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Halibut IgG Ab [Units/volume] in Serum;Halibut IgG Qn;;ACTIVE;1.0h(2);2.73 +73866-6;Catecholamines 3 & creatinine panel;SRto;Pt;Urine;-;;PANEL.CHEM;1;Catecholamines 3 and creatinine panel [Molar ratio] - Urine;Catecholamines 3 + creat Pnl Ur-sRto;;ACTIVE;2.44;2.56 +73867-4;Alpha cortol;SRat;24H;Urine;Qn;;CHEM;1;Alpha cortol [Moles/time] in 24 hour Urine;A-Cortol 24h Ur-sRate;;ACTIVE;2.44;2.44 +73868-2;Alpha cortol;SCnc;Pt;Urine;Qn;;CHEM;1;Alpha cortol [Moles/volume] in Urine;A-Cortol Ur-sCnc;;ACTIVE;2.44;2.44 +73869-0;Alpha cortol;SCnc;24H;Urine;Qn;;CHEM;1;Alpha cortol [Moles/volume] in 24 hour Urine;A-Cortol 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73870-8;Alpha cortolone;SRat;24H;Urine;Qn;;CHEM;1;Alpha cortolone [Moles/time] in 24 hour Urine;A-cortolone 24h Ur-sRate;;ACTIVE;2.44;2.44 +73871-6;Alpha cortolone;SCnc;Pt;Urine;Qn;;CHEM;1;Alpha cortolone [Moles/volume] in Urine;A-cortolone Ur-sCnc;;ACTIVE;2.44;2.44 +73872-4;Alpha cortolone;SCnc;24H;Urine;Qn;;CHEM;1;Alpha cortolone [Moles/volume] in 24 hour Urine;A-cortolone 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73873-2;Androstenetriol;SCnc;24H;Urine;Qn;;CHEM;1;Androstenetriol [Moles/volume] in 24 hour Urine;AET 24h Ur-sCnc;;ACTIVE;2.44;2.44 +7387-4;Hippoglossus hippoglossus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Halibut triggered histamine release [Units/volume] in Blood;Halibut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73874-0;Androstenetriol;SRat;24H;Urine;Qn;;CHEM;1;Androstenetriol [Moles/time] in 24 hour Urine;AET 24h Ur-sRate;;ACTIVE;2.44;2.44 +73875-7;Androstenetriol;SCnc;Pt;Urine;Qn;;CHEM;1;Androstenetriol [Moles/volume] in Urine;AET Ur-sCnc;;ACTIVE;2.44;2.44 +73876-5;Beta cortolone;SCnc;Pt;Urine;Qn;;CHEM;1;Beta cortolone [Moles/volume] in Urine;B-cortolone Ur-sCnc;;ACTIVE;2.44;2.44 +73877-3;Beta cortolone;SRat;24H;Urine;Qn;;CHEM;1;Beta cortolone [Moles/time] in 24 hour Urine;B-cortolone 24h Ur-sRate;;ACTIVE;2.44;2.44 +73878-1;Beta cortolone;SCnc;24H;Urine;Qn;;CHEM;1;Beta cortolone [Moles/volume] in 24 hour Urine;B-cortolone 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73879-9;Catecholamine metabolites & creatinine panel;-;Pt;Urine;-;;PANEL.CHEM;1;Catecholamine metabolites and creatinine panel - Urine;Catecholamines creat Pnl Ur;;ACTIVE;2.44;2.68 +73880-7;Cortisone.free;SCnc;24H;Urine;Qn;;CHEM;1;Cortisone free [Moles/volume] in 24 hour Urine;Cortisone free 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73881-5;Cortisone.free;SCnc;Pt;Urine;Qn;;CHEM;1;Cortisone free [Moles/volume] in Urine;Cortisone free Ur-sCnc;;ACTIVE;2.44;2.44 +7388-2;Ham basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Ham triggered histamine release [Units/volume] in Blood;Ham BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73882-3;Glycolate;SCnc;24H;Urine;Qn;;CHEM;1;Glycolate [Moles/volume] in 24 hour Urine;Glycolate 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73883-1;Glycolate;SRat;24H;Urine;Qn;;CHEM;1;Glycolate [Moles/time] in 24 hour Urine;Glycolate 24h Ur-sRate;;ACTIVE;2.44;2.44 +73884-9;Steroid fractions interpretation;Imp;24H;Urine;Nar;;CHEM;1;Steroid fractions interpretation in 24 hour Urine Narrative;Steroid Fract 24h Ur-Imp;;ACTIVE;2.44;2.54 +73885-6;Steroid fractions panel;-;24H;Urine;-;;PANEL.CHEM;1;Steroid fractions panel - 24 hour Urine;Steroid Fract Pnl 24h Ur;;ACTIVE;2.44;2.63 +73886-4;Steroid fractions panel;-;Pt;Urine;-;;PANEL.CHEM;1;Steroid fractions panel - Urine;Steroid Fract Pnl Ur;;ACTIVE;2.44;2.48 +73887-2;Tetrahydrocorticosterone;SCnc;24H;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone [Moles/volume] in 24 hour Urine;THB 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73888-0;Tetrahydrocorticosterone;SRat;24H;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone [Moles/time] in 24 hour Urine;THB 24h Ur-sRate;;ACTIVE;2.44;2.44 +73889-8;Tetrahydrocorticosterone;SCnc;Pt;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone [Moles/volume] in Urine;THB Ur-sCnc;;ACTIVE;2.44;2.44 +7389-0;Hay Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hay IgE Ab [Units/volume] in Serum;Hay IgE Qn;;ACTIVE;1.0h(2);2.42 +73890-6;Tetrahydrocortisol;SCnc;Pt;Urine;Qn;;CHEM;1;Tetrahydrocortisol [Moles/volume] in Urine;THF Ur-sCnc;;ACTIVE;2.44;2.44 +73891-4;Tetrahydrocortisol;SCnc;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisol [Moles/volume] in 24 hour Urine;THF 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73892-2;Tetrahydrocortisol;SRat;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisol [Moles/time] in 24 hour Urine;THF 24h Ur-sRate;;ACTIVE;2.44;2.44 +73893-0;Tetrahydrocortisone;SCnc;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisone [Moles/volume] in 24 hour Urine;THcortisone 24h Ur-sCnc;;ACTIVE;2.44;2.44 +73894-8;Tetrahydrocortisone;SCnc;Pt;Urine;Qn;;CHEM;1;Tetrahydrocortisone [Moles/volume] in Urine;THcortisone Ur-sCnc;;ACTIVE;2.44;2.44 +73895-5;Hemoglobin;EntSub;Pt;Retic;Qn;Automated count;HEM/BC;1;Hemoglobin [Entitic substance] in Reticulocytes by Automated count;Hgb EntSub Retic Auto;;ACTIVE;2.44;2.44 +73897-1;Chronic lyme disease panel;-;Pt;Bld;-;Flow cytometry;PANEL.CELLMARK;1;Chronic lyme disease panel - Blood by Flow cytometry (FC);Chronic lyme dis Pnl Bld FC;;ACTIVE;2.44;2.44 +73898-9;Cells.CD8-CD57+/100 lymphocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD8-CD57+ cells/100 lymphocytes in Blood by Flow cytometry (FC);CD8-CD57+ Cells/lymph NFr Bld FC;;ACTIVE;2.44;2.73 +73899-7;Cells.CD3-CD8-CD57+;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD3- CD8- CD57+ Cells [#/volume] in Blood by Flow cytometry (FC);CD3-CD8-CD57+ # Bld FC;;ACTIVE;2.44;2.73 +73900-3;Cells.CD3-CD8-CD57+/100 leukocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD3- CD8- CD57+ Cells/100 leukocytes in Blood by Flow cytometry (FC);CD3-CD8-CD57+/leuk NFr Bld FC;;ACTIVE;2.44;2.73 +73901-1;Cells.CD3-CD8-CD57+/100 lymphocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD3- CD8- CD57+ Cells/100 lymphocytes in Blood by Flow cytometry (FC);CD3-CD8-CD57+/lymph NFr Bld FC;;ACTIVE;2.44;2.73 +73902-9;Cells.CD3-CD57+;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD3-CD57+ cells [#/volume] in Blood by Flow cytometry (FC);CD3-CD57+ Cells # Bld FC;;ACTIVE;2.44;2.73 +73903-7;Cells.CD3-CD57+/100 leukocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD3-CD57+ cells/100 leukocytes in Blood by Flow cytometry (FC);CD3-CD57+ Cells/leuk NFr Bld FC;;ACTIVE;2.44;2.73 +73904-5;Cells.CD3-CD57+/100 lymphocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD3-CD57+ cells/100 lymphocytes in Blood by Flow cytometry (FC);CD3-CD57+ Cells/lymph NFr Bld FC;;ACTIVE;2.44;2.73 +73905-2;HIV 1+2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA.rapid;MICRO;1;HIV 1+2 IgG Ab [Presence] in Serum or Plasma by Rapid immunoassay;HIV1+2 IgG SerPl Ql IA.rapid;;ACTIVE;2.44;2.73 +73906-0;HIV 1+2 Ab.IgG;PrThr;Pt;Bld;Ord;IA.rapid;MICRO;1;HIV 1+2 IgG Ab [Presence] in Blood by Rapid immunoassay;HIV1+2 IgG Bld Ql IA.rapid;;ACTIVE;2.44;2.56 +73907-8;Polio virus identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Polio virus identified in Specimen by Organism specific culture;PV Spec Cult;;ACTIVE;2.44;2.69 +7390-8;Corylus avellana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Hazelnut IgE Ab [Units/volume] in Serum;Deprecated Hazelnut IgE Qn;;DEPRECATED;1.0h(2);2.69 +73908-6;Alloisoleucine/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Alloisoleucine/Creatinine [Ratio] in Urine;Alloisoleucine/Creat Ur-Rto;;ACTIVE;2.44;2.73 +73909-4;D2-40 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;D2-40 Ag [Presence] in Tissue by Immune stain;D2-40 Ag Tiss Ql ImStn;;ACTIVE;2.44;2.56 +73910-2;PAX8 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PAX8 Ag [Presence] in Tissue by Immune stain;PAX8 Ag Tiss Ql ImStn;;ACTIVE;2.44;2.73 +73911-0;SOX10 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;SOX10 Ag [Presence] in Tissue by Immune stain;SOX10 Ag Tiss Ql ImStn;;ACTIVE;2.44;2.56 +73912-8;DOG1 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;DOG1 Ag [Presence] in Tissue by Immune stain;DOG1 Ag Tiss Ql ImStn;;ACTIVE;2.44;2.56 +73913-6;Glycine CSF/Glycine plas;RelSCnc;Pt;Plas+CSF;Qn;;CHEM;1;Glycine in CSF/Glycine in plasma;Glycine CSF/Glycine plas;;ACTIVE;2.44;2.73 +73914-4;JWH-018;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-018 (synthetic cannabinoid) [Presence] in Urine by Confirmatory method;JWH-018 Ur Ql Cfm;;ACTIVE;2.44;2.73 +73915-1;1,3-Dimethylamylamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;1,3-Dimethylamylamine [Presence] in Urine by Screen method;DMAA Ur Ql Scn;;ACTIVE;2.44;2.73 +7391-6;Corylus avellana Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut IgG Ab [Units/volume] in Serum;Hazelnut IgG Qn;;ACTIVE;1.0h(2);2.69 +73916-9;1,3-Dimethylamylamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;1,3-Dimethylamylamine [Mass/volume] in Urine by Confirmatory method;DMAA Ur Cfm-mCnc;;ACTIVE;2.44;2.44 +73917-7;JWH-250 4+5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-250 4/5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;JWH-250 4/5-OH-pentyl Ur Ql Cfm;;ACTIVE;2.44;2.73 +73918-5;JWH-073;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;JWH-073 (synthetic cannabinoid) [Presence] in Urine by Confirmatory method;JWH-073 Ur Ql Cfm;;ACTIVE;2.44;2.73 +73919-3;MAM-2201 pentanoate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;MAM-2201 pentanoate (synthetic cannabinoid metabolite) [Presence] in Blood;MAM-2201 pentanoate Bld Ql;;ACTIVE;2.44;2.73 +73920-1;JWH-018 4+5-hydroxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-018 4/5-hydroxypentyl (synthetic cannabinoid metabolites) [Presence] in Blood;JWH-018 4/5OH-pentyl Bld Ql;;ACTIVE;2.44;2.73 +73921-9;JWH-073 3-hydroxybutyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-073 3-hydroxybutyl (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-073 3OH-butyl Bld Ql;;ACTIVE;2.44;2.73 +73922-7;RCS-4 5-hydroxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;RCS-4 5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Blood;RCS-4 5OH-pentyl Bld Ql;;ACTIVE;2.44;2.73 +73923-5;JWH-018 pentanoate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-018 pentanoate (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-018 pentanoate Bld Ql;;ACTIVE;2.44;2.73 +7392-4;Corylus avellana basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Hazelnut triggered histamine release [Units/volume] in Blood;Hazelnut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +73924-3;JWH-200 4-Hydroxyindole;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-200 4-hydroxyindole (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-200 4OH-indole Bld Ql;;ACTIVE;2.44;2.73 +73925-0;AM-2201 4-hydroxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;AM-2201 4-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Blood;AM-2201 4OH-pentyl Bld Ql;;ACTIVE;2.44;2.73 +73926-8;JWH-073 4-hydroxybutyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-073 4-hydroxybutyl (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-073 4OH-butyl Bld Ql;;ACTIVE;2.44;2.73 +73927-6;JWH-073 butanoate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-073 butanoate (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-073 butanoate Bld Ql;;ACTIVE;2.44;2.73 +73928-4;JWH-250 5-hydroxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-250 5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-250 5OH-pentyl Bld Ql;;ACTIVE;2.44;2.73 +73929-2;JWH-250 5-carboxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-250 5-carboxypentyl (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-250 5-carboxypentyl Bld Ql;;ACTIVE;2.44;2.73 +739-3;Metamyelocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Metamyelocytes [#/volume] in Blood by Manual count;Metamyelocytes # Bld Manual;;ACTIVE;1.0;2.73 +73930-0;RCS-4 5-carboxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;RCS-4 5-carboxypentyl (synthetic cannabinoid metabolite) [Presence] in Blood;RCS-4 5-carboxypentyl Bld Ql;;ACTIVE;2.44;2.73 +73931-8;Propanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Propanol [Mass/volume] in Urine;Propanol Ur-mCnc;;ACTIVE;2.44;2.73 +7393-2;Helminthosporium interseminatum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Helminthosporium interseminatum IgE Ab [Units/volume] in Serum;H interseminatum IgE Qn;;ACTIVE;1.0h(2);2.73 +73932-6;traMADol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;traMADol [Mass/volume] in Blood;traMADol Bld-mCnc;;ACTIVE;2.44;2.73 +73933-4;Normeperidine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Normeperidine [Mass/volume] in Serum, Plasma or Blood;Normeperidine SerPlBld-mCnc;;ACTIVE;2.44;2.73 +73934-2;Meperidine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Meperidine [Mass/volume] in Serum, Plasma or Blood;Meperidine SerPlBld-mCnc;;ACTIVE;2.44;2.73 +73935-9;Tetrahydrocannabinol;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;THC SerPlBld Cfm-mCnc;;ACTIVE;2.44;2.73 +73936-7;fentaNYL;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;fentaNYL [Presence] in Blood by Screen method;fentaNYL Bld Ql Scn;;ACTIVE;2.44;2.73 +73937-5;Norfentanyl;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Norfentanyl [Mass/volume] in Blood by Confirmatory method;Norfentanyl Bld Cfm-mCnc;;ACTIVE;2.44;2.73 +73938-3;fentaNYL;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;fentaNYL [Mass/volume] in Blood by Confirmatory method;fentaNYL Bld Cfm-mCnc;;ACTIVE;2.44;2.73 +73939-1;HYDROcodone.free;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;HYDROcodone Free [Mass/volume] in Blood;HYDROcodone Free Bld-mCnc;;ACTIVE;2.44;2.73 +7394-0;Helminthosporium maydis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Helminthosporium maydis IgE Ab [Units/volume] in Serum;H maydis IgE Qn;;ACTIVE;1.0h(2);2.73 +73940-9;HYDROmorphone.free;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;HYDROmorphone Free [Mass/volume] in Blood;HYDROmorphone Free Bld-mCnc;;ACTIVE;2.44;2.73 +73941-7;6-Monoacetylmorphine.free;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;6-monoacetylmorphine free [Mass/volume] in Blood;6MAM Free Bld-mCnc;;ACTIVE;2.44;2.73 +73942-5;Buprenorphine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Buprenorphine [Presence] in Saliva (oral fluid) by Screen method;Buprenorphine Sal Ql Scn;;ACTIVE;2.44;2.73 +73943-3;Cannabinoids.synthetic;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Cannabinoids synthetic [Presence] in Blood;Cannabinoids synthetic Bld Ql;;ACTIVE;2.44;2.73 +73944-1;MAM-2201;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;MAM-2201 (synthetic cannabinoid) [Presence] in Blood;MAM-2201 Bld Ql;;ACTIVE;2.44;2.73 +73945-8;UR-144;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;UR-144 (synthetic cannabinoid) [Presence] in Blood;UR-144 Bld Ql;;ACTIVE;2.44;2.73 +73946-6;JWH-200;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-200 (synthetic cannabinoid) [Presence] in Blood;JWH-200 Bld Ql;;ACTIVE;2.44;2.73 +73947-4;JWH-398;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-398 (synthetic cannabinoid) [Presence] in Blood;JWH-398 Bld Ql;;ACTIVE;2.44;2.73 +73948-2;JWH-122;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-122 (synthetic cannabinoid) [Presence] in Blood;JWH-122 Bld Ql;;ACTIVE;2.44;2.73 +73949-0;JWH-018;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-018 (synthetic cannabinoid) [Presence] in Blood;JWH-018 Bld Ql;;ACTIVE;2.44;2.73 +73950-8;JWH-250;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-250 (synthetic cannabinoid) [Presence] in Blood;JWH-250 Bld Ql;;ACTIVE;2.44;2.73 +73951-6;RCS-4;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;RCS-4 (synthetic cannabinoid) [Presence] in Blood;RCS-4 Bld Ql;;ACTIVE;2.44;2.73 +73952-4;AM-2201;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;AM-2201 (synthetic cannabinoid) [Presence] in Blood;AM-2201 Bld Ql;;ACTIVE;2.44;2.73 +73953-2;JWH-073;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-073 (synthetic cannabinoid) [Presence] in Blood;JWH-073 Bld Ql;;ACTIVE;2.44;2.73 +73954-0;JWH-398 5-hydroxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-398 5 hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-398 5OH-pentyl Bld Ql;;ACTIVE;2.44;2.73 +73955-7;UR-144 4+5-hydroxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;UR-144 4/5-hydroxypentyl (synthetic cannabinoid metabolites) [Presence] in Blood;UR-144 4/5OH-pentyl Bld Ql;;ACTIVE;2.44;2.73 +73956-5;JWH-122 5-hydroxypentyl;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;JWH-122 5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Blood;JWH-122 5OH-pentyl Bld Ql;;ACTIVE;2.44;2.73 +7395-7;Helminthosporium sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Helminthosporium sp IgE Ab [Units/volume] in Serum;Helminthosporium IgE Qn;;ACTIVE;1.0h(2);2.73 +73957-3;UR-144 pentanoate;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;UR-144 pentanoate (synthetic cannabinoid metabolite) [Presence] in Blood;UR-144 pentanoate Bld Ql;;ACTIVE;2.44;2.73 +73958-1;Cholesterol esterase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Cholesterol esterase [Enzymatic activity/volume] in DBS;Cholest Est DBS-cCnc;;ACTIVE;2.44;2.73 +73959-9;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+66 DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+66 DNA [Presence] in Tissue by Probe;HPV H Risk 12 DNA Tiss Ql Probe;;ACTIVE;2.44;2.63 +73960-7;Bacteria identified;Prid;Pt;Mouth;Nom;Culture;MICRO;1;Bacteria identified in Mouth by Culture;Bacteria Mouth Cult;;ACTIVE;2.44;2.44 +73961-5;Escherichia coli & Klebsiella pneumoniae & Pseudomonas aeruginosa rRNA;Prid;Pt;Bld.pos growth;Nom;FISH;MICRO;1;Escherichia coli and Klebsiella pneumoniae and Pseudomonas aeruginosa rRNA [Identifier] by FISH in Positive blood culture;Ecoli+Kpneu+Paeru rRNA Bld Pos FISH;;ACTIVE;2.44;2.69 +73962-3;Candida sp rRNA;Prid;Pt;Bld.pos growth;Nom;FISH;MICRO;1;Candida sp rRNA [Identifier] by FISH in Positive blood culture;Candida rRNA Bld Pos FISH;;ACTIVE;2.44;2.61 +73963-1;Enterococcus faecalis & other enterococcus sp rRNA;Prid;Pt;Bld.pos growth;Nom;FISH;MICRO;1;Enterococcus faecalis and other enterococcus sp rRNA [Identifier] by FISH in Positive blood culture;E faecalis+othr E sp rRNA Bld Pos FISH;;ACTIVE;2.44;2.61 +73964-9;Body muscle mass;Mass;Pt;^Patient;Qn;Calculated;BDYWGT.MOLEC;2;Body muscle mass Calculated;Body muscle Calc;;ACTIVE;2.44;2.73 +7396-5;Helminthosporium sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Helminthosporium sp IgG Ab [Units/volume] in Serum;Helminthosporium IgG Qn;;ACTIVE;1.0h(2);2.73 +73965-6;Body muscle mass/body weight;MFr;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body muscle mass/Body weight Measured;Body muscle/BW MFr Measured;;ACTIVE;2.44;2.52 +73966-4;Fetal trisomy 21 risk;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 21 risk [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ts 21 risk Plas.cfDNA Ql;;ACTIVE;2.44;2.73 +73967-2;Noninvasive prenatal fetal aneuploidy panel;-;Pt;Plas.cfDNA;-;;PANEL.MOLPATH;1;Noninvasive prenatal fetal aneuploidy panel - Plasma cell-free DNA;NIP fet aneu Pnl Plas.cfDNA;;ACTIVE;2.44;2.73 +73968-0;Fetal trisomy 18 risk;Likelihood;Pt;Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 18 risk [Likelihood] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Ts 18 risk Plas.cfDNA Qn;;ACTIVE;2.44;2.73 +73969-8;Fetal trisomy 13 risk;Likelihood;Pt;Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 13 risk [Likelihood] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Ts 13 risk Plas.cfDNA Qn;;ACTIVE;2.44;2.73 +73970-6;Fetal trisomy 21 risk;Likelihood;Pt;Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 21 risk [Likelihood] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Ts 21 risk Plas.cfDNA Qn;;ACTIVE;2.44;2.73 +73971-4;Methylenedioxymethamphetamine+Methylenedioxyethylamphetamine+Methylenedioxyamphetamine;Imp;Pt;Urine;Ord;;DRUG/TOX;1;Methylenedioxymethamphetamine(MDMA)+Methylenedioxyethylamphetamine (MDEA)+Methylenedioxyamphetamine(MDA) [Interpretation] in Urine Qualitative;MDMA+MDEA+MDA Ur-Imp;;ACTIVE;2.44;2.73 +73972-2;Morphine.free;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Morphine Free [Mass/volume] in Blood;Morphine Free Bld-mCnc;;ACTIVE;2.44;2.73 +7397-3;Tsuga canadensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Eastern Hemlock IgE Ab [Units/volume] in Serum;East Hemlock IgE Qn;;ACTIVE;1.0h(2);2.73 +73973-0;O-nortramadol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;O-nortramadol [Mass/volume] in Blood;O-nortramadol Bld-mCnc;;ACTIVE;2.44;2.73 +73974-8;Cells.CD158e/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD158e cells/100 cells in Specimen;Cells.CD158e NFr Spec;;ACTIVE;2.44;2.73 +73975-5;Cells.CD158a/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD158a cells/100 cells in Specimen;CD158a cells NFr Spec;;ACTIVE;2.44;2.69 +73976-3;Cells.CD158b/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD158b cells/100 cells in Specimen;CD158b cells NFr Spec;;ACTIVE;2.44;2.73 +73977-1;Cancer related multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Cancer related multigene analysis in Blood or Tissue by Molecular genetics method;Cancer multigene analysis Bld/T;;ACTIVE;2.44;2.73 +73978-9;von Willebrand factor.activity;ACnc;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf).activity [Units/volume] in Platelet poor plasma by Immunoassay;vWf:Ac PPP IA-aCnc;;ACTIVE;2.44;2.73 +73979-7;Keyhole limpet hemocyanin Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Keyhole limpet hemocyanin Ab panel - Serum or Plasma;KLH Ab Pnl SerPl;;ACTIVE;2.44;2.46 +73980-5;Visit duration;Time;Pt;^Patient;Qn;;CLIN;2;Visit duration;Visit duration;;ACTIVE;2.46;2.48 +7398-1;Hemp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hemp IgE Ab [Units/volume] in Serum;Hemp IgE Qn;;ACTIVE;1.0h(2);2.42 +73981-3;Problem alleviating &or exacerbating factors;Find;Pt;^Patient;Nar;;H&P.HX;2;Problem alleviating AndOr exacerbating factors Narrative;Prob modifying factors;;ACTIVE;2.46;2.46 +73982-1;Bacterial carbapenem resistance blaNDM gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaNDM gene [Presence] by Molecular method;blaNDM Islt/Spm Ql;;ACTIVE;2.46;2.73 +73983-9;Report.section heading;-;Pt;XXX;Nom;;DOC.MISC;2;Report.section heading;Report section;;ACTIVE;2.46;2.69 +73984-7;Hemoglobin.other;Type;Pt;Bld;Nom;;HEM/BC;1;Hemoglobin.other [Type] in Blood;Hgb Other Bld;;ACTIVE;2.46;2.73 +73985-4;Exercise activity;Type;Pt;^Patient;Nom;;CLIN;2;Exercise activity;Exercise activity;;ACTIVE;2.46;2.46 +73986-2;Exercise aerobic category;Type;Pt;^Patient;Nom;;CLIN;2;Exercise aerobic category;Exercise category;;ACTIVE;2.46;2.46 +73987-0;2,2',3,4,4',5-Hexachlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,2',3,4,4',5-Hexachlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,2',3,4,4',5 PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.73 +73988-8;2,2',4,5,5'-Pentachlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,2',4,5,5'-Pentachlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,2',4,5,5'-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.73 +73989-6;2,3',4,4',5-Pentachlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,3',4,4',5-Pentachlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,3',4,4',5-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.73 +73990-4;2,3',4',5-Tetrachlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,3',4',5-Tetrachlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,3',4',5-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.46 +73991-2;2,2',5,5'-Tetrachlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,2',5,5'-Tetrachlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,2',5,5'-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.73 +73992-0;2,2',5-Trichlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,2',5-Trichlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,2',5-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.46 +73993-8;Polychlorinated biphenyl;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Presence] in Serum or Plasma by Confirmatory method;PCB SerPl Ql Cfm;;ACTIVE;2.46;2.56 +73994-6;Polychlorinated biphenyl;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Polychlorinated biphenyl (PCB) [Presence] in Serum or Plasma by Screen method;PCB SerPl Ql Scn;;ACTIVE;2.46;2.73 +73995-3;Mitragynine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Mitragynine [Presence] in Urine by Confirmatory method;Mitragynine Ur Ql Cfm;;ACTIVE;2.46;2.56 +73996-1;oxyCODONE;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;oxyCODONE [Presence] in Meconium by Screen method;oxyCODONE Mec Ql Scn;;ACTIVE;2.46;2.73 +73997-9;Ibuprofen;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ibuprofen [Mass/volume] in Urine;Ibuprofen Ur-mCnc;;ACTIVE;2.46;2.73 +73998-7;25H-NBOMe;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;25H-NBOMe [Presence] in Urine by Confirmatory method;25H-NBOMe Ur Ql Cfm;;ACTIVE;2.46;2.56 +7399-9;Hemp fiber Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hemp fiber IgE Ab [Units/volume] in Serum;Hemp Fiber IgE Qn;;ACTIVE;1.0h(2);2.42 +73999-5;2C-C-NBOMe;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;2C-C-NBOMe [Presence] in Urine by Confirmatory method;2C-C-NBOMe Ur Ql Cfm;;ACTIVE;2.46;2.56 +74000-1;25I-NBOMe;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;25I-NBOMe [Presence] in Urine by Confirmatory method;25I-NBOMe Ur Ql Cfm;;ACTIVE;2.46;2.56 +74001-9;NBOMe;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;NBOMe [Presence] in Urine by Screen method;NBOMe Ur Ql Scn;;ACTIVE;2.46;2.73 +74002-7;Tungsten/Creatinine;MRto;24H;Urine;Qn;;DRUG/TOX;1;Tungsten/Creatinine [Mass Ratio] in 24 hour Urine;Tungsten/Creat 24h Ur;;ACTIVE;2.46;2.46 +74003-5;CYP3A4 gene.c.-392A>G (*1B);PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP3A4 gene c.-392A>G (*1B) [Presence] in Blood or Tissue by Molecular genetics method;CYP3A4 c.-392A>G (*1B) Bld/T Ql;;ACTIVE;2.46;2.67 +74004-3;ABCB1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ABCB1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ABCB1 Mut Anl Bld/T;;ACTIVE;2.46;2.63 +7400-5;Amaranthus tuberculatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Water Hemp IgE Ab [Units/volume] in Serum;Water Hemp IgE Qn;;ACTIVE;1.0h(2);2.73 +74005-0;Serotonin release 0.5 IU/mL heparin.unfractionated;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 0.5 IU/mL heparin.unfractionated [Units/volume] in Serum;SRA 0.5 IU/mL UFH Ser-aCnc;;ACTIVE;2.46;2.73 +74006-8;Weight difference^pre dialysis-post dialysis;MDiff;Pt;^Patient;Qn;Calculated;BDYWGT.MOLEC;2;Weight difference [Mass difference] --pre dialysis - post dialysis;Weight diff pre-post dialysis MDiff Calc;;ACTIVE;2.46;2.48 +74007-6;CYP3A4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;CYP3A4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP3A4 Mut Anl Bld/T;;ACTIVE;2.46;2.73 +74008-4;Exercise intensity;Type;Pt;^Patient;Ord;;CLIN;2;Exercise intensity;Exercise intensity;;ACTIVE;2.46;2.46 +74009-2;Exercise duration/Exercise frequency;NRat;Pt;^Patient;Qn;;CLIN;2;Exercise duration/Exercise frequency;Exercise duration/freq;;ACTIVE;2.46;2.46 +740-1;Metamyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Metamyelocytes/100 leukocytes in Blood by Manual count;Metamyelocytes/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +74010-0;Date quit tobacco smoking;Date;Pt;^Patient;Qn;;H&P.HX;2;Date quit tobacco smoking;Date quit smoking;;ACTIVE;2.46;2.73 +74011-8;Lifetime tobacco use;NRat;Lifetime;^Patient;Qn;;H&P.HX;2;Lifetime tobacco use;Lifetime tobacco use nRate;;ACTIVE;2.46;2.66 +74012-6;Number of Y alcohol consumed;Time;Pt;^Patient;Qn;;H&P.HX;2;Number of years alcohol consumed [Time];Y alcohol consumed Time;;ACTIVE;2.46;2.5 +7401-3;Clupea harengus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Herring IgG Ab [Units/volume] in Serum;Herring IgG Qn;;ACTIVE;1.0h(2);2.69 +74013-4;Alcoholic drinks per D;NRat;Pt;^Patient;Qn;;H&P.HX;2;Alcoholic drinks per day;Alcohol drinks per D;;ACTIVE;2.46;2.73 +74014-2;Last drank alcohol;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Last drank alcohol [Date and time];Last drank alcohol;;ACTIVE;2.46;2.46 +74015-9;Date recorded;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Date recorded;Date recorded;;ACTIVE;2.46;2.73 +74017-5;Alert status;Find;Pt;^Patient;Nom;;H&P.HX;2;Alert status;Alert status;;ACTIVE;2.46;2.46 +74018-3;Alert;Type;Pt;^Patient;Nom;;H&P.HX;2;Alert;Alert;;ACTIVE;2.46;2.46 +74019-1;Probability of developing disease assessed;Likelihood;Pt;^Patient;Qn;;H&P.HX;2;Probability of developing disease assessed [Likelihood];Probability of disease;;ACTIVE;2.46;2.73 +74020-9;Genetic risk algorithm sensitivity;Ratio;Pt;^Patient;Qn;;H&P.HX;2;Genetic risk algorithm sensitivity [Ratio];Genetic algorithm sensitivity;;ACTIVE;2.46;2.73 +7402-1;Carya illinoinensis nut basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Pecan or Hickory Nut triggered histamine release [Units/volume] in Blood;Pecan/Hick Nut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74021-7;Genetic risk algorithm;Type;Pt;^Patient;Nom;;H&P.HX;2;Genetic risk algorithm;Genetic algorithm;;ACTIVE;2.46;2.46 +74022-5;Negative history for disease of interest;Find;Pt;^Family member;Ord;;H&P.HX;2;Negative history for disease of interest in family member;Neg hx for disease Fam Mem;;ACTIVE;2.46;2.46 +74023-3;Disease of interest;Find;Pt;^Family member;Nom;;H&P.HX;2;Disease of interest in family member;Disease of interest Fam Mem;;ACTIVE;2.46;2.46 +74024-1;Family member identifier;ID;Pt;^Family member;Nom;;ADMIN.ID;2;Family member identifier;Family member ID;;ACTIVE;2.46;2.66 +74025-8;Mother identifier;ID;Pt;^Mother;Nom;;ADMIN.ID;2;Mother identifier;Mother ID;;ACTIVE;2.46;2.66 +74026-6;Father identifier;ID;Pt;^Father;Nom;;ADMIN.ID;2;Father identifier;Father ID;;ACTIVE;2.46;2.66 +74027-4;Family pedigree identifier;ID;Pt;^Patient;Nom;;H&P.HX;2;Family pedigree identifier;Family pedigree ID;;ACTIVE;2.46;2.46 +74028-2;Virtual medical record for clinical decision support panel;-;Pt;^Patient;-;HL7.VMR-CDS;PANEL.CLIN;2;Virtual Medical Record for Clinical Decision Support panel HL7.VMR-CDS;VMR-CDS Pnl VMR-CDS;;ACTIVE;2.46;2.48 +74029-0;Periodontal attachment - recommended CDA set;-;Pt;{Setting};-;;PANEL.DOC;2;Periodontal attachment - recommended CDA set;Periodontal attachment set;;DISCOURAGED;2.46;2.61 +74030-8;Periodontal service attachment;Find;Pt;{Setting};Doc;{Role};DOC.ADMIN;2;Periodontal service attachment;Perio service attach;;ACTIVE;2.46;2.67 +74031-6;Arbovirus identified;Prid;Pt;Ser;Nom;IF;MICRO;1;Arbovirus identified in Serum by Immunofluorescence;Arbovirus Ser IF;;ACTIVE;2.46;2.46 +74032-4;Arbovirus Ab.IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Arbovirus IgM panel - Serum;Arbovirus IgM Pnl Ser;;ACTIVE;2.46;2.46 +74033-2;Arbovirus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Arbovirus IgM Ab [Presence] in Serum by Immunofluorescence;Arbovirus IgM Ser Ql IF;;ACTIVE;2.46;2.56 +74034-0;MAML2 11q21 gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH.REARRANGE;1;MAML2 11q21 gene rearrangements in Tissue by FISH;MAML2 11q21 Tiss FISH;;ACTIVE;2.46;2.66 +74035-7;Prion protein.abnormal;Prid;Pt;Tiss;Nom;Immune stain;MICRO;1;Abnormal Prion Protein [Identifier] in Tissue by Immune stain;Abn Prion Prot Tiss ImStn;;ACTIVE;2.46;2.46 +74036-5;Prion protein.abnormal;Prid;Pt;Tiss;Nom;IB;MICRO;1;Abnormal Prion Protein [Identifier] in Tissue by Immunoblot;Abn Prion Prot Tiss IB;;ACTIVE;2.46;2.58 +74037-3;Transmissible spongiform encephalopathy;Prid;Pt;Brain;Nom;Microscopy.light;MICRO;1;Transmissible spongiform encephalopathy [Identifier] in Brain by Light microscopy;TSE Brain Micro;;ACTIVE;2.46;2.46 +74038-1;Influenza virus A H1 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUAV H1 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.46;2.69 +7403-9;Hickory basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Deprecated Hickory basophil bound Ab;Deprecated Hickory BasoBnd Ab Qn;;DEPRECATED;1.0h(2);2.69 +74039-9;Influenza virus A H3 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUAV H3 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.46;2.69 +74040-7;Influenza virus A N2 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A N2 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUAV N2 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.46;2.69 +74041-5;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%^post treatment";PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;BCR-ABL1 p210 Major Molecular Response (MMR) [Presence] in Blood or Tissue by Molecular genetics method --post treatment;t(ABL1,BCR)p210/cntrl.0.1% p Tx Bld/T Ql;;ACTIVE;2.46;2.56 +74042-3;Genetic diseases history panel;-;Pt;^Family member;-;HL7.VMR-CDS;PANEL.CLIN;2;Genetic diseases history panel Family member HL7.VMR-CDS;Genetic diseases hx Pnl Fam Mem VMR-CDS;;ACTIVE;2.46;2.48 +74043-1;Alcohol use disorder;Find;Pt;^Patient;Ord;;H&P.HX;2;Alcohol use disorder;Alcohol use disorder;;ACTIVE;2.46;2.7 +74044-9;Disease of interest was cause of death;Find;Pt;^Family member;Ord;;H&P.HX;2;Disease of interest was cause of death in family member;Disease was COD Fam Mem;;ACTIVE;2.46;2.7 +74045-6;Measure description;Find;Pt;^Patient;Nar;;DOC.QUALITY;2;Measure description Narrative;Measure description;;ACTIVE;2.46;2.63 +74046-4;Supplemental information about periodontal condition;Find;Pt;Oral cavity;Doc;;DOC.ADMIN;2;Supplemental information about periodontal condition;Suppl info periodontal cond;;ACTIVE;2.46;2.67 +7404-7;Carya ovata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shagbark Hickory IgE Ab [Units/volume] in Serum;Shagbark Hickory IgE Qn;;ACTIVE;1.0h(2);2.73 +74047-2;Periodontal procedure is related to orthodontic treatment plan;Find;Pt;Oral cavity;Ord;HL7.Attach;ATTACH.PERIODONTAL;3;Periodontal procedure is related to orthodontic treatment plan;;;ACTIVE;2.46;2.46 +74048-0;Periodontal procedure is related to restorative treatment;Find;Pt;Oral cavity;Ord;HL7.Attach;ATTACH.PERIODONTAL;3;Periodontal procedure is related to restorative treatment;;;ACTIVE;2.46;2.46 +74049-8;Periodontal condition involves frenum;Find;Pt;Oral cavity;Ord;;DENTAL;2;Periodontal condition involves frenum;Involves frenum Oral cavity;;ACTIVE;2.46;2.61 +74050-6;Actual route of administration - attempted or completed;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Actual route of administration - attempted or completed [AHRQ];;;ACTIVE;2.46;2.48 +74051-4;Intended route of administration;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Intended route of administration [AHRQ];;;ACTIVE;2.46;2.48 +74052-2;Medication or substance was given;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Medication or substance was given [AHRQ];;;ACTIVE;2.46;2.48 +74053-0;Medication or substance was prescribed;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Medication or substance was prescribed [AHRQ];;;ACTIVE;2.46;2.48 +7405-4;Carya laciniosa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shellbark Hickory IgE Ab [Units/volume] in Serum;Shellbark Hickory IgE Qn;;ACTIVE;1.0h(2);2.42 +74054-8;Dose form - RxNorm RXCUI;ID;Pt;Medication;Nom;;MEDS;2;Dose form - RxNorm RXCUI of Medication;Dose form RxNorm RXCUI Medication;;ACTIVE;2.46;2.58 +74055-5;Dose form;Type;Pt;Medication;Nom;;MEDS;2;Dose form of Medication;Dose form Medication;;ACTIVE;2.46;2.58 +74056-3;Clinical drug component - RxNorm RXCUI;ID;Pt;Medication;Nom;;SURVEY.AHRQ;4;Clinical drug component - RxNorm RXCUI of Medication;;;ACTIVE;2.46;2.48 +74057-1;Medication strength;Dosage;Pt;Medication;Qn;;SURVEY.AHRQ;4;Medication strength;;;ACTIVE;2.46;2.58 +74058-9;Manufacturer name;ID;Pt;Medication;Nom;;SURVEY.AHRQ;4;Manufacturer name of Medication;;;ACTIVE;2.46;2.48 +74059-7;Brand name - RxNorm RXCUI;ID;Pt;Medication;Nom;;SURVEY.AHRQ;4;Brand name - RxNorm RXCUI of Medication;;;ACTIVE;2.46;2.48 +74060-5;Brand name;ID;Pt;Medication;Nom;;SURVEY.AHRQ;4;Brand name of Medication;;;ACTIVE;2.46;2.48 +74061-3;Ingredient - RxNorm RXCUI;ID;Pt;Medication;Nom;;SURVEY.AHRQ;4;Ingredient - RxNorm RXCUI of Medication;;;ACTIVE;2.46;2.48 +7406-2;Carya illinoinensis tree Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Pecan or Hickory Tree IgE Ab [Units/volume] in Serum;Deprecated Pecan/Hick Tree IgE Qn;;DEPRECATED;1.0h(2);2.69 +74062-1;Generic or investigational drug name;ID;Pt;Medication;Nom;;SURVEY.AHRQ;4;Generic or investigational drug name of Medication;;;ACTIVE;2.46;2.48 +74063-9;Stage in the process that the event originated, regardless of the stage at which it was discovered;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Stage in the process that the event originated, regardless of the stage at which it was discovered [AHRQ];;;ACTIVE;2.46;2.48 +74064-7;Medication or substance contraindication - potential or actual interaction;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Medication or substance contraindication - potential or actual interaction [AHRQ];;;ACTIVE;2.46;2.48 +74065-4;History of allergies or sensitivities to the medication or substance administered was documented;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;History of allergies or sensitivities to the medication or substance administered was documented [AHRQ];;;ACTIVE;2.46;2.48 +74066-2;Expiration date;Date;Pt;Medication;Qn;AHRQ;SURVEY.AHRQ;4;Expiration date of Medication [AHRQ];;;ACTIVE;2.46;2.5 +74067-0;Best description for incorrect strength or concentration;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Best description for incorrect strength or concentration [AHRQ];;;ACTIVE;2.46;2.48 +74068-8;Best description for the incorrect rate;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Best description for the incorrect rate [AHRQ];;;ACTIVE;2.46;2.48 +74069-6;Best description for the incorrect timing;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Best description for the incorrect timing [AHRQ];;;ACTIVE;2.46;2.48 +7407-0;Carya tomentosa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Hickory IgE Ab [Units/volume] in Serum;White Hickory IgE Qn;;ACTIVE;1.0h(2);2.73 +74070-4;Best description for the incorrect dose;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Best description for the incorrect dose [AHRQ];;;ACTIVE;2.46;2.48 +74071-2;Incorrect action;Type;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Incorrect action [AHRQ];;;ACTIVE;2.46;2.48 +74072-0;Best characterization of medication or other substance event;Find;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Best characterization of medication or other substance event [AHRQ];;;ACTIVE;2.46;2.48 +74073-8;Type of nutritional product;Type;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Type of nutritional product [AHRQ];;;ACTIVE;2.46;2.48 +74074-6;Biological product;Type;Pt;Medication;Nom;AHRQ;SURVEY.AHRQ;4;Biological product of Medication [AHRQ];;;ACTIVE;2.46;2.48 +74075-3;Medication;Type;Pt;Medication;Nom;AHRQ;SURVEY.AHRQ;4;Medication type [AHRQ];;;ACTIVE;2.46;2.48 +74076-1;Medication or substance involved;Type;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Medication or substance involved [AHRQ];;;ACTIVE;2.46;2.48 +74077-9;Ingredients for compounded preparations;Find;Pt;Medication;Nom;;SURVEY.AHRQ;4;Ingredients for compounded preparations Medication;;;ACTIVE;2.46;2.48 +74078-7;Medication or other substance details panel;-;Pt;Medication;-;AHRQ;PANEL.SURVEY.AHRQ;4;Medication or other substance details panel [AHRQ];;;ACTIVE;2.46;2.48 +74079-5;Event;Type;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Event [AHRQ];;;ACTIVE;2.46;2.48 +74080-3;Patient safety event report - hospital - medication or other substance - version 1.2;-;Pt;^Patient;-;AHRQ;PANEL.SURVEY.AHRQ;4;Patient safety event report - hospital - medication or other substance - version 1.2 [AHRQ];;;ACTIVE;2.46;2.54 +74081-1;Patient safety event;ID;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Patient safety event [AHRQ];;;ACTIVE;2.46;2.66 +74082-9;Urea;SRat;12H;Urine;Qn;;CHEM;1;Urea [Moles/time] in 12 hour Urine;Urea 12h Ur-sRate;;ACTIVE;2.46;2.46 +74083-7;Norolanzapine;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norolanzapine [Moles/volume] in Serum or Plasma;Norolanzapine SerPl-sCnc;;ACTIVE;2.46;2.46 +74084-5;Glucose^15M post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --15 minutes post 50 g lactose PO;Glucose 15M p 50 g Lac PO SerPl-sCnc;;ACTIVE;2.46;2.46 +74085-2;Isocoproporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Isocoproporphyrin [Moles/mass] in Stool;Isocopropor Stl-sCnt;;ACTIVE;2.46;2.46 +74086-0;Pentacarboxylporphyrin III;SCnt;Pt;Stool;Qn;;CHEM;1;Pentacarboxylporphyrin III [Moles/mass] in Stool;Penta-CP3 Stl-sCnt;;ACTIVE;2.46;2.46 +74087-8;Hexacarboxylporphyrin III;SCnt;Pt;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin III [Moles/mass] in Stool;Hexa-CPr3 Stl-sCnt;;ACTIVE;2.46;2.46 +7408-8;Histamine extract basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Histamine extract triggered histamine release [Units/volume] in Blood;Histamine Ext BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74088-6;Heptacarboxylporphyrin III;SCnt;Pt;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin III [Moles/mass] in Stool;Hepta-CP3 Stl-sCnt;;ACTIVE;2.46;2.46 +74089-4;Pentacarboxylporphyrin III/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pentacarboxylporphyrin III/Creatinine [Molar ratio] in Urine;Penta-CP3/Creat Ur-sRto;;ACTIVE;2.46;2.46 +74090-2;Hexacarboxylporphyrin III/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin III/Creatinine [Molar ratio] in Urine;Hexa-CPr3/Creat Ur-sRto;;ACTIVE;2.46;2.46 +74091-0;Heptacarboxylporphyrin III/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin III/Creatinine [Molar ratio] in Urine;Hepta-CP3/Creat Ur-sRto;;ACTIVE;2.46;2.46 +74092-8;Acidity.titratable;SCnc;Pt;Urine;Qn;;CHEM;1;Acidity.titratable [Moles/volume] in Urine;Titratable Acidity Ur-sCnc;;ACTIVE;2.46;2.46 +74093-6;Gliquidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gliquidone [Mass/volume] in Serum or Plasma;Gliquidone SerPl-mCnc;;ACTIVE;2.46;2.46 +74094-4;Gliclazide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gliclazide [Mass/volume] in Serum or Plasma;Gliclazide SerPl-mCnc;;ACTIVE;2.46;2.46 +74095-1;Didesmethylcitalopram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Didesmethylcitalopram [Mass/volume] in Serum or Plasma;Didesmet-citalopram SerPl-mCnc;;ACTIVE;2.46;2.46 +7409-6;Swine basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Swine triggered histamine release [Units/volume] in Blood;Swine BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74096-9;Tacrolimus;MCnc;Pt;Bld;Qn;IA;DRUG/TOX;1;Tacrolimus [Mass/volume] in Blood by Immunoassay;Tacrolimus Bld IA-mCnc;;ACTIVE;2.46;2.73 +74097-7;Tacrolimus;MCnc;Pt;Bld;Qn;LC/MS/MS;DRUG/TOX;1;Tacrolimus [Mass/volume] in Blood by LC/MS/MS;Tacrolimus Bld LC/MS/MS-mCnc;;ACTIVE;2.46;2.73 +74098-5;Endothelin;SCnc;Pt;Ser/Plas;Qn;;SERO;1;Endothelin [Moles/volume] in Serum or Plasma;Endothelin SerPl-sCnc;;ACTIVE;2.46;2.46 +74099-3;Neutrophil gelatinase-associated lipocalin;MCnc;Pt;Urine;Qn;IA.rapid;SERO;1;Neutrophil gelatinase-associated lipocalin [Mass/volume] in Urine by Rapid immunoassay;NGAL Ur IA.rapid-mCnc;;ACTIVE;2.46;2.73 +74100-9;Nitrate+Nitrite;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nitrate+Nitrite [Moles/volume] in Serum or Plasma;Nitrate+Nitrite SerPl-sCnc;;ACTIVE;2.46;2.46 +74101-7;Tissue inhibitor of metalloproteinases 1;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Tissue inhibitor of metalloproteinases 1 [Mass/volume] in Serum or Plasma by Immunoassay;TIMP-1 SerPl IA-mCnc;;ACTIVE;2.46;2.56 +74102-5;Matrix metallopeptidase 2;MCnc;Pt;Ser;Qn;;CHEM;1;Matrix metallopeptidase 2 [Mass/volume] in Serum;MMP2 Ser-mCnc;;ACTIVE;2.46;2.46 +74103-3;Neutrophil gelatinase-associated lipocalin;MCnc;Pt;Ser/Plas;Qn;IA.rapid;SERO;1;Neutrophil gelatinase-associated lipocalin [Mass/volume] in Serum or Plasma by Rapid immunoassay;NGAL SerPl IA.rapid-mCnc;;ACTIVE;2.46;2.56 +7410-4;Swine epithelium Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swine epithelium IgG Ab [Units/volume] in Serum;Swine Epith IgG Qn;;ACTIVE;1.0h(2);2.73 +74104-1;Alpha-amanitin+gamma-amanitin;MCnc;Pt;Urine;Qn;IA;DRUG/TOX;1;Alpha-Amanitin + gamma-Amanitin [Mass/volume] in Urine by Immunoassay;Alpha+gamma-amanitin Ur IA-mCnc;;ACTIVE;2.46;2.56 +74105-8;Oxygen saturation;MFr;Pt;BldMV;Qn;Calculated from oxygen partial pressure;CHEM;1;Oxygen saturation Calculated from oxygen partial pressure in Mixed venous blood;SaO2 % BldMV from pO2;;ACTIVE;2.46;2.46 +74106-6;Proteinase 3 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Proteinase 3 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Proteinase3 IgG SerPl IA-aCnc;;ACTIVE;2.46;2.73 +74107-4;Warfarin;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Warfarin [Presence] in Specimen by Screen method;Warfarin Spec Ql Scn;;ACTIVE;2.46;2.69 +74108-2;Meperidine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Meperidine [Presence] in Saliva (oral fluid) by Screen method;Meperidine Sal Ql Scn;;ACTIVE;2.46;2.73 +74109-0;4-hydroxycoumarins;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;4-hydroxycoumarins [Presence] in Specimen by Screen method;4OH-coumarins Spec Ql Scn;;ACTIVE;2.46;2.73 +74110-8;traMADol;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;traMADol [Presence] in Saliva (oral fluid) by Screen method;traMADol Sal Ql Scn;;ACTIVE;2.46;2.73 +74111-6;Brodifacoum;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Brodifacoum [Presence] in Specimen by Screen method;Brodifacoum Spec Ql Scn;;ACTIVE;2.46;2.69 +7411-2;Honey Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey IgG Ab [Units/volume] in Serum;Honey IgG Qn;;ACTIVE;1.0h(2);2.73 +74112-4;Bromadiolone;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Bromadiolone [Presence] in Specimen by Screen method;Bromadiolone Spec Ql Scn;;ACTIVE;2.46;2.69 +74113-2;Coumafuryl;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Coumafuryl [Presence] in Specimen by Screen method;Coumafuryl Spec Ql Scn;;ACTIVE;2.46;2.69 +74114-0;Coumatetralyl;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Coumatetralyl [Presence] in Specimen by Screen method;Coumatetralyl Spec Ql Scn;;ACTIVE;2.46;2.69 +74115-7;Difenacoum;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Difenacoum [Presence] in Specimen by Screen method;Difenacoum Spec Ql Scn;;ACTIVE;2.46;2.73 +74116-5;Adalimumab Ab;MCnc;Pt;Ser/Plas;Qn;;SERO;1;Adalimumab Ab [Mass/volume] in Serum or Plasma;Adalimumab Ab SerPl-mCnc;;ACTIVE;2.46;2.73 +74117-3;Adalimumab;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Adalimumab [Mass/volume] in Serum or Plasma;Adalimumab SerPl-mCnc;;ACTIVE;2.46;2.73 +74118-1;P27 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;P27 Ag [Presence] in Tissue by Immune stain;P27 Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74119-9;P504S Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;P504S Ag [Presence] in Tissue by Immune stain;P504S Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +7412-0;Honey Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey IgE Ab [Units/volume] in Serum;Honey IgE Qn;;ACTIVE;1.0h(2);2.73 +74120-7;PDGFR-alpha Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PDGFR-alpha Ag [Presence] in Tissue by Immune stain;PDGFR-alpha Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74121-5;Perforin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Perforin Ag [Presence] in Tissue by Immune stain;Perforin Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74122-3;Ubiquitin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Ubiquitin Ag [Presence] in Tissue by Immune stain;Ubiquitin Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74123-1;Phospho-S6 ribosomal protein Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Phospho-S6 ribosomal protein Ag [Presence] in Tissue by Immune stain;p-S6RP Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74124-9;Blood group 8 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Blood group 8 (BG8) Ag [Presence] in Tissue by Immune stain;BG8 Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74125-6;Mesothelin Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Mesothelin Ag [Presence] in Tissue by Immune stain;Mesothelin Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74126-4;Mucin-4 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Mucin-4 (MUC-4) Ag [Presence] in Tissue by Immune stain;MUC-4 Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74127-2;Akt1 phosphate Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Akt1 phosphate Ag [Presence] in Tissue by Immune stain;Akt1 phosphate Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74128-0;Neuroblastoma 84 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Neuroblastoma 84 Ag [Presence] in Tissue by Immune stain;NB 84 Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74129-8;Transforming growth factor alpha Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Transforming growth factor alpha Ag [Presence] in Tissue by Immune stain;TGF-alpha Ag Tiss Ql ImStn;;ACTIVE;2.46;2.56 +74130-6;6-Monoacetylmorphine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Serum, Plasma or Blood;6MAM SerPlBld-mCnc;;ACTIVE;2.46;2.73 +74131-4;Morphine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Morphine [Mass/volume] in Serum, Plasma or Blood;Morphine SerPlBld-mCnc;;ACTIVE;2.46;2.73 +74132-2;Aromatic solvents;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Aromatic solvents [Presence] in Blood;Arom Solvents Bld Ql;;ACTIVE;2.46;2.73 +74133-0;Volatiles;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Volatiles and gases [Presence] in Blood;Volatiles Bld Ql;;ACTIVE;2.46;2.73 +74134-8;Ezogabine;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Ezogabine [Mass/volume] in Plasma;Ezogabine Plas-mCnc;;ACTIVE;2.46;2.73 +74135-5;N-acetyl ezogabine;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;N-acetyl ezogabine [Mass/volume] in Plasma;N-acetyl ezogabine Plas-mCnc;;ACTIVE;2.46;2.73 +74136-3;fentaNYL;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;fentaNYL [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;fentaNYL SerPlBld Cfm-mCnc;;ACTIVE;2.46;2.73 +74137-1;Norfentanyl;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Norfentanyl [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Norfentanyl SerPlBld Cfm-mCnc;;ACTIVE;2.46;2.73 +7413-8;Honeysuckle Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honeysuckle IgE Ab [Units/volume] in Serum;Honeysuckle IgE Qn;;ACTIVE;1.0h(2);2.73 +74138-9;Monocytes.immature;PrThr;Pt;Bld;Ord;;HEM/BC;1;Immature monocytes [Presence] in Blood;Imm Moncytes Bld Ql;;ACTIVE;2.46;2.56 +74139-7;Mononuclear cells;NCnc;Pt;Dial fld prt;Qn;;HEM/BC;1;Mononuclear cells [#/volume] in Peritoneal dialysis fluid;Mononuc Cells # DiafP;;ACTIVE;2.46;2.46 +74140-5;Granulocytes;NCnc;Pt;Dial fld prt;Qn;;HEM/BC;1;Granulocytes [#/volume] in Peritoneal dialysis fluid;Granulocytes # DiafP;;ACTIVE;2.46;2.46 +74141-3;Granulocytes/100 leukocytes;NFr;Pt;Dial fld prt;Qn;;HEM/BC;1;Granulocytes/100 leukocytes in Peritoneal dialysis fluid;Granulocytes/leuk NFr DiafP;;ACTIVE;2.46;2.5 +74142-1;Granulocytes;NCnc;Pt;Body fld;Qn;;HEM/BC;1;Granulocytes [#/volume] in Body fluid;Granulocytes # Fld;;ACTIVE;2.46;2.46 +74143-9;Granulocytes/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Granulocytes/100 leukocytes in Body fluid;Granulocytes/leuk NFr Fld;;ACTIVE;2.46;2.5 +74144-7;Complex medical conditions action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Complex medical conditions action plan;Cmplx med cond action plan;;ACTIVE;2.46;2.54 +74145-4;Multiple sclerosis action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Multiple sclerosis action plan;MS action plan;;ACTIVE;2.46;2.54 +7414-6;Humulus lupus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hop IgG Ab [Units/volume] in Serum;Hop IgG Qn;;ACTIVE;1.0h(2);2.69 +74146-2;Heart disease action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Heart disease action plan;Heart disease action plan;;ACTIVE;2.46;2.54 +74147-0;Muscular dystrophy action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Muscular Dystrophy action plan;MD action plan;;ACTIVE;2.46;2.54 +74148-8;Cystic fibrosis action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Cystic fibrosis action plan;CF action plan;;ACTIVE;2.46;2.73 +74149-6;Inflammatory bowel disease action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Inflammatory bowel disease action plan;IBD action plan;;ACTIVE;2.46;2.73 +74150-4;Diabetes type I action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Diabetes Type I action plan;Diabetes type I action plan;;ACTIVE;2.46;2.54 +74151-2;Diabetes type II action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Diabetes Type II action plan;Diabetes type II action plan;;ACTIVE;2.46;2.54 +74152-0;Anaphylaxis action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Anaphylaxis action plan;Anaphylaxis action plan;;ACTIVE;2.46;2.54 +7415-3;Cladosporium sphaerospermum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cladosporium sphaerospermum IgE Ab [Units/volume] in Serum;C sphaerospermum IgE Qn;;ACTIVE;1.0h(2);2.73 +74153-8;Seizure disorder action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Seizure Disorder action plan;Seizure disorder action plan;;ACTIVE;2.46;2.54 +74154-6;Autism action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Autism action plan;Autism action plan;;ACTIVE;2.46;2.54 +74155-3;ADHD action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;ADHD action plan;ADHD action plan;;ACTIVE;2.46;2.73 +74156-1;Plan of care+summary note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Plan of care and summary note;Oncology Care plan+summary note;;ACTIVE;2.46;2.63 +74157-9;Cannabinoids;PrThr;Pt;Ser/Plas/Bld;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Serum, Plasma or Blood by Screen method;Cannabinoids SerPlBld Ql Scn;;ACTIVE;2.46;2.73 +74159-5;Work schedule;Find;Pt;^Patient;Nom;NIOSH;H&P.HX;2;Work schedule NIOSH;Work schedule NIOSH;;ACTIVE;2.46;2.46 +74160-3;Work Ds per W;NRat;Pt;^Patient;Qn;;H&P.HX;2;Work days per week;Work Ds per W nRate;;ACTIVE;2.46;2.48 +7416-1;Carpinus betulus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horn beam IgE Ab [Units/volume] in Serum;Horn beam IgE Qn;;ACTIVE;1.0h(2);2.73 +74161-1;Work Hs per W;NRat;Pt;^Patient;Qn;;H&P.HX;2;Work hours per week;Work Hs per W nRate;;ACTIVE;2.46;2.73 +74162-9;Usual industry duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Usual industry duration;Usual industry duration;;ACTIVE;2.46;2.46 +74163-7;Usual occupation duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Usual occupation duration;Occupation duration;;ACTIVE;2.46;2.46 +74164-5;Usual occupation and industry;Hx;Pt;^Patient;Nar;;H&P.HX;2;History of Usual occupation and industry Narrative;Hx of occupation+industry;;ACTIVE;2.46;2.56 +74165-2;History of employment status;Hx;Pt;^Patient;Nom;NIOSH;H&P.HX;2;History of employment status NIOSH;Hx employment status NIOSH;;ACTIVE;2.46;2.63 +74166-0;Occupational summary note;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Occupational summary note;Occupational summary note;;ACTIVE;2.46;2.54 +74167-8;Opiates;MCnc;Pt;Saliva;Qn;Screen;DRUG/TOX;1;Opiates [Mass/volume] in Saliva (oral fluid) by Screen method;Opiates Sal Scn-mCnc;;ACTIVE;2.46;2.46 +74168-6;Barbiturates;MCnc;Pt;Saliva;Qn;Screen;DRUG/TOX;1;Barbiturates [Mass/volume] in Saliva (oral fluid) by Screen method;Barbiturates Sal Scn-mCnc;;ACTIVE;2.46;2.46 +74169-4;Cocaine;MCnc;Pt;Saliva;Qn;Screen;DRUG/TOX;1;Cocaine [Mass/volume] in Saliva (oral fluid) by Screen method;Cocaine Sal Scn-mCnc;;ACTIVE;2.46;2.46 +74170-2;Ceftaroline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ceftaroline [Susceptibility] by Gradient strip;Ceftaroline Islt Grad strip;;ACTIVE;2.46;2.73 +74171-0;Total number of staff completing the job satisfaction survey;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Total number of staff completing the job satisfaction survey [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.52 +74172-8;Generally speaking, I am very satisfied with my own level of autonomy;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Generally speaking, I am very satisfied with my own level of autonomy [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74173-6;Generally speaking, I am very satisfied with interactions with non-physician health care team members;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Generally speaking, I am very satisfied with interactions with non-physician health care team members [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74174-4;Generally speaking, I am very satisfied with interactions with physicians;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Generally speaking, I am very satisfied with interactions with physicians [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74175-1;Generally speaking, I am very satisfied with nursing administration;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Generally speaking, I am very satisfied with nursing administration [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74176-9;Generally speaking, I am very satisfied with nursing management;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Generally speaking, I am very satisfied with nursing management [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74177-7;Nursing staff on this job rarely think of quitting;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Nursing staff on this job rarely think of quitting [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74178-5;Most nursing staff on this job are very satisfied with the job;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Most nursing staff on this job are very satisfied with the job [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +7417-9;Dolichovespula maculata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whitefaced Hornet IgG Ab [Units/volume] in Serum;Whitefaced Hornet IgG Qn;;ACTIVE;1.0h(2);2.73 +74179-3;I am generally satisfied with the kind of work I do in this job;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;I am generally satisfied with the kind of work I do in this job [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74180-1;I rarely think of quitting this job;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;I rarely think of quitting this job [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74181-9;Generally speaking, I am very satisfied with this job;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Generally speaking, I am very satisfied with this job [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74182-7;Job satisfaction panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Job satisfaction panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.52 +74183-5;Nursing job class;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Nursing job class [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.46;2.5 +74184-3;Lymphocytes.clefted;PrThr;Pt;Bld;Ord;;HEM/BC;1;Lymphocytes clefted [Presence] in Blood;Cleft Lymphs Bld Ql;;ACTIVE;2.46;2.73 +74185-0;Percent of U.S. federal poverty level;Find;Pt;^Patient;Ord;;H&P.HX;2;Percent of U.S. Federal Poverty Level;Prct U.S. Fed Pov Level;;ACTIVE;2.46;2.46 +74186-8;Health insurance funding was provided;Find;Pt;^Patient;Ord;;H&P.HX;2;Health insurance funding was provided;Heath insurance provided;;ACTIVE;2.46;2.46 +7418-7;Horse dander basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Horse dander triggered histamine release [Units/volume] in Blood;Horse Dander BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74187-6;interRAI emergency screener for psychiatry;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Emergency Screener for Psychiatry (ESP) Document;interRAI ESP Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74188-4;interRAI acute care;Find;Pt;Hospital;Doc;{Role};DOC.MISC;2;interRAI Acute Care (AC) Hospital Document;interRAI AC Hosp Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74189-2;interRAI palliative care;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Palliative Care (PC) Document;interRAI PC Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +741-9;Microcytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Microcytes [Presence] in Blood by Light microscopy;Microcytes Bld Ql Smear;;ACTIVE;1.0;2.73 +74190-0;interRAI community health assessment - deafblind supplement;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Community Health Assessment - Deafblind Supplement (CHA-Db) Document;interRAI CHA-Db Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74191-8;interRAI community health assessment - assisted living supplement;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Community Health Assessment - Assisted Living Supplement (CHA-AL) Document;interRAI CHA-AL Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74192-6;interRAI community health assessment - mental health supplement;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Community Health Assessment - Mental Health Supplement (CHA-MH) Document;interRAI CHA-MH Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74193-4;interRAI community health assessment - functional supplement;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Community Health Assessment - Functional Supplement (CHA-FS) Document;interRAI CHA-FS Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.73 +74194-2;interRAI community health assessment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Community Health Assessment (CHA) Document;interRAI CHA Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +7419-5;Horse epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horse epithelium IgE Ab [Units/volume] in Serum;Horse Epith IgE Qn;;ACTIVE;1.0h(2);2.73 +74195-9;interRAI long term care facility;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Long Term Care Facility (LTCF) Document;interRAI LTCF Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74196-7;interRAI home care;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Home Care (HC) Document;interRAI HC Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74197-5;interRAI contact assessment;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;interRAI Contact Assessment (CA) Document;interRAI CA Doc;Copyright © 2009 InterRAI. Used with permission.;ACTIVE;2.46;2.54 +74198-3;Summary registry report;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Summary registry report;Trauma Summary registry report;;ACTIVE;2.46;2.64 +74199-1;Transferred from another acute care facility;Find;Pt;^Patient;Ord;NTDS;TRAUMA;2;Transferred from another acute care facility [NTDS];Transfer acute care facility [NTDS];;ACTIVE;2.46;2.46 +74200-7;Ds in intensive care unit;Time;Pt;^Patient;Qn;;TRAUMA;2;Days in intensive care unit;Ds in ICU Time;;ACTIVE;2.46;2.46 +74201-5;Ds on ventilator;Time;Pt;^Patient;Qn;;PULM;2;Days on ventilator;Ds on ventilator Time;;ACTIVE;2.46;2.46 +74202-3;Payment source.primary;Type;Pt;^Patient;Nom;NTDS;TRAUMA;2;Primary payment source [NTDS];Pay source.primary [NTDS];;ACTIVE;2.46;2.67 +7420-3;Armoracia rusticana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Horseradish IgE Ab [Units/volume] in Serum;Horseradish IgE Qn;;ACTIVE;1.0h(2);2.73 +74203-1;Signs of life at arrival;Find;Pt;^Patient;Ord;NTDS;TRAUMA;2;Signs of life at arrival [NTDS];Signs of life at arrival [NTDS];;ACTIVE;2.46;2.46 +74204-9;Drug use;Find;Pt;^Patient;Nom;NTDS;TRAUMA;2;Drug use [NTDS];Drug use [NTDS];;ACTIVE;2.46;2.58 +74205-6;Alcohol use;Find;Pt;^Patient;Nom;NTDS;TRAUMA;2;Alcohol use [NTDS];Alcohol use [NTDS];;ACTIVE;2.46;2.46 +74206-4;Oxygen therapy was given;Find;Pt;^Patient;Ord;NTDS;TRAUMA;2;Oxygen therapy was given [NTDS];O2 therapy was Gvn [NTDS];;ACTIVE;2.46;2.5 +74207-2;Prehospital summary;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Prehospital summary Document;Prehosp summary Doc;;ACTIVE;2.46;2.54 +74208-0;Demographic information+history of occupation;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Demographic information + History of occupation Document;Demographic+occupation Doc;;ACTIVE;2.46;2.54 +74209-8;Injury event summary;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Injury event summary Document;Injury event summary Doc;;ACTIVE;2.46;2.54 +74210-6;Breath rate was assisted by respiratory device;Find;Pt;Respiratory system;Ord;NTDS;PULM;2;Breath rate was assisted by respiratory device by [NTDS];Breath rate assisted [NTDS];;ACTIVE;2.46;2.46 +7421-1;House dust AP Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust AP IgE Ab [Units/volume] in Serum;House Dust AP IgE Qn;;ACTIVE;1.0h(2);2.73 +74211-4;Summary of episode note;Find;Pt;Emergency department+Hospital;Doc;{Role};DOC.ONTOLOGY;2;Emergency department+Hospital Summary of episode note;ED+Hosp Summary of episode note;;ACTIVE;2.46;2.54 +74213-0;Discharge instructions;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Discharge instructions;Discharge instruct;;ACTIVE;2.46;2.73 +74214-8;Apixaban;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Apixaban [Mass/volume] in Platelet poor plasma by Chromogenic method;Apixaban PPP Chro-mCnc;;ACTIVE;2.46;2.73 +74215-5;Rivaroxaban;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Rivaroxaban [Mass/volume] in Serum or Plasma by LC/MS/MS;Rivaroxaban SerPl LC/MS/MS-mCnc;;ACTIVE;2.46;2.46 +74216-3;Fondaparinux;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Fondaparinux [Mass/volume] in Serum or Plasma by LC/MS/MS;Fondaparinux SerPl LC/MS/MS-mCnc;;ACTIVE;2.46;2.46 +74217-1;Fondaparinux;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Fondaparinux [Mass/volume] in Platelet poor plasma by Chromogenic method;Fondaparinux PPP Chro-mCnc;;ACTIVE;2.46;2.73 +74218-9;Apixaban;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Apixaban [Mass/volume] in Serum or Plasma by LC/MS/MS;Apixaban SerPl LC/MS/MS-mCnc;;ACTIVE;2.46;2.46 +74219-7;Weight difference pre dialysis & post dialysis panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Weight difference pre dialysis and post dialysis panel;Wght diff pre+post dialysis panel;;ACTIVE;2.46;2.46 +74220-5;Dabigatran;MCnc;Pt;PPP;Qn;Coag;COAG;1;Dabigatran [Mass/volume] in Platelet poor plasma by Coagulation assay;Dabigatran PPP-mCnc;;ACTIVE;2.46;2.73 +74221-3;Referring physician address;Addr;Pt;Provider;Nom;;ADMIN;2;Referring physician address;Refer physician addr;;ACTIVE;2.46;2.73 +74222-1;Reviewed material & summary of stains;Find;Pt;Bone mar;Nar;;HEM/BC;1;Reviewed material and summary of stains in Bone marrow Narrative;Revwd matrl+sum stains Mar;;ACTIVE;2.46;2.61 +74223-9;Immunohistochemical stains;Find;Pt;Bone mar;Nar;;HEM/BC;1;Immunohistochemical stains in Bone marrow Narrative;IHC stains Mar;;ACTIVE;2.46;2.46 +74224-7;Disease category;Imp;Pt;Bone mar;Nom;;HEM/BC;1;Disease category [Interpretation] in Bone marrow;Disease category Mar-Imp;;ACTIVE;2.46;2.73 +74225-4;Cytochemical stains;Find;Pt;Bone mar;Nar;;HEM/BC;1;Cytochemical stains in Bone marrow Narrative;Cyto stains Mar;;ACTIVE;2.46;2.46 +74226-2;Plasma cells assessment;Find;Pt;Bone mar;Nar;;HEM/BC;1;Plasma cells assessment in Bone marrow Narrative;Plasma cells assess Mar;;ACTIVE;2.46;2.73 +74227-0;Other observations;Find;Pt;Bone mar;Nar;;HEM/BC;1;Other observations in Bone marrow Narrative;Other obs Mar;;ACTIVE;2.46;2.46 +74228-8;Myelopoiesis assessment;Find;Pt;Bone mar;Nar;;HEM/BC;1;Myelopoiesis assessment in Bone marrow Narrative;Myelopoiesis Mar;;ACTIVE;2.46;2.46 +7422-9;House dust AP Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust AP IgG Ab [Units/volume] in Serum;House Dust AP IgG Qn;;ACTIVE;1.0h(2);2.73 +74229-6;Megakaryopoiesis assessment;Find;Pt;Bone mar;Nar;;HEM/BC;1;Megakaryopoiesis assessment in Bone marrow Narrative;Megakaryopoiesis Mar;;ACTIVE;2.46;2.46 +74230-4;Lymphocytes assessment;Find;Pt;Bone mar;Nar;;HEM/BC;1;Lymphocytes assessment in Bone marrow Narrative;Lymphs assessmnt Mar;;ACTIVE;2.46;2.73 +74231-2;Erythropoiesis assessment;Find;Pt;Bone mar;Nar;;HEM/BC;1;Erythropoiesis assessment in Bone marrow Narrative;Erythropoiesis Mar;;ACTIVE;2.46;2.46 +74232-0;Cellularity assessment;Find;Pt;Bone mar;Nar;;HEM/BC;1;Cellularity assessment in Bone marrow Narrative;Cellularity assessment Mar;;ACTIVE;2.46;2.46 +74233-8;Blasts assessment;Find;Pt;Bone mar;Nar;;HEM/BC;1;Blasts assessment in Bone marrow Narrative;Blasts assessmnt Mar;;ACTIVE;2.46;2.46 +74234-6;HEDIS 2014 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Sets;HEDIS 2014 Value Sets;;DISCOURAGED;2.46;2.67 +74235-3;HEDIS 2014-2019 Value Set - ABO;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2019 Value Set - ABO;HEDIS 2014-19 ABO;;DISCOURAGED;2.46;2.67 +74236-1;Unidentified cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Unidentified cells/100 leukocytes in Pericardial fluid by Manual count;Unident Cells/leuk NFr Pcar Manual;;ACTIVE;2.46;2.5 +7423-7;House dust basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;House dust triggered histamine release [Units/volume] in Blood;House Dust BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74237-9;HEDIS 2014, 2015 Value Set - ABO and Rh;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2015 Value Set - ABO and Rh;HEDIS 2014-15 ABORH;;DISCOURAGED;2.46;2.67 +74238-7;HEDIS 2014 Value Set - Blood Urea Nitrogen;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - Blood Urea Nitrogen;HEDIS 2014 BUN;;DISCOURAGED;2.46;2.67 +74239-5;HEDIS 2014 Value Set - carBAMazepine Level;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - carBAMazepine Level;HEDIS 2014 carBAMazepine;;DISCOURAGED;2.46;2.67 +74240-3;HEDIS 2014-2020 Value Set - Cervical Cytology;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2020 Value Set - Cervical Cytology;HEDIS 2014-20 Cerv Cyto;;DISCOURAGED;2.46;2.67 +74241-1;HEDIS 2014-2016 Value Set - Chlamydia Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2016 Value Set - Chlamydia Tests;HEDIS 2014-16 Chlamydia;;DISCOURAGED;2.46;2.67 +74242-9;HEDIS 2014-2016 Value Set - Cytomegalovirus Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2016 Value Set - Cytomegalovirus Antibody;HEDIS 2014-16 CMV Ab;;DISCOURAGED;2.46;2.67 +74243-7;HEDIS 2014-2016 Value Set - FOBT;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2016 Value Set - FOBT;HEDIS 2014-16 FOBT;;DISCOURAGED;2.46;2.67 +74244-5;HEDIS 2014 Value Set - Glucose Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - Glucose Tests;HEDIS 2014 GLUC;;DISCOURAGED;2.46;2.67 +7424-5;House dust Greer Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Greer IgG Ab [Units/volume] in Serum;House Dust Greer IgG Qn;;ACTIVE;1.0h(2);2.73 +74245-2;HEDIS 2014-2016 Value Set - Group A Strep Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2016 Value Set - Group A Strep Tests;HEDIS 2014-16 Grp A Strep;;DISCOURAGED;2.46;2.67 +74246-0;HEDIS 2014 Value Set - HbA1c Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - HbA1c Tests;HEDIS 2014 HbA1c;;DISCOURAGED;2.46;2.73 +74247-8;HEDIS 2014-2019 Value Set - Herpes Simplex Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2019 Value Set - Herpes Simplex Antibody;HEDIS 2014-19 HSV Ab;;DISCOURAGED;2.46;2.67 +74248-6;HEDIS 2014, 2015 Value Set - HPV Vaccine Administered;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014, 2015 Value Set - HPV Vaccine Administered;HEDIS 2014-15 HPV;;DISCOURAGED;2.46;2.67 +74249-4;HEDIS 2014 Value Set - LDL-C Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - LDL-C Tests;HEDIS 2014 LDL-C;;DISCOURAGED;2.46;2.67 +74250-2;HEDIS 2014, 2015 Value Set - Lead Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014, 2015 Value Set - Lead Tests;HEDIS 2014-15 Lead;;DISCOURAGED;2.46;2.67 +74251-0;HEDIS 2014, 2015 Value Set - Nephropathy Screening Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014, 2015 Value Set - Nephropathy Screening Tests;HEDIS 2014-15 Nephro Scrn;;DISCOURAGED;2.46;2.67 +7425-2;House dust Hollister Stier Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Hollister Stier IgE Ab [Units/volume] in Serum;House Dust HS IgE Qn;;ACTIVE;1.0h(2);2.73 +74252-8;HEDIS 2014 Value Set - PHENobarbital Level;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - PHENobarbital Level;HEDIS 2014 Phenobarb;;DISCOURAGED;2.46;2.67 +74253-6;HEDIS 2014 Value Set - Pregnancy Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - Pregnancy Tests;HEDIS 2014 Preg;;DISCOURAGED;2.46;2.67 +74254-4;HEDIS 2014-2018 Value Set - Rh;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2018 Value Set - Rh;HEDIS 2014-18 Rh;;DISCOURAGED;2.46;2.67 +74255-1;HEDIS 2014-2018 Value Set - Rubella Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2018 Value Set - Rubella Antibody;HEDIS 2014-18 Rubella Ab;;DISCOURAGED;2.46;2.67 +74256-9;HEDIS 2014-2019 Value Set - Serum Creatinine;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2019 Value Set - Serum Creatinine;HEDIS 2014-19 Ser Creat;;DISCOURAGED;2.46;2.67 +74257-7;HEDIS 2014-2016 Value Set - Serum Potassium;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2016 Value Set - Serum Potassium;HEDIS 2014-16 Ser K;;DISCOURAGED;2.46;2.67 +74258-5;HEDIS 2014 Value Set - Sexual Activity;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - Sexual Activity;HEDIS 2014 Sexual Actvty;;DISCOURAGED;2.46;2.67 +74259-3;HEDIS 2014, 2015 Value Set - Urine Macroalbumin Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014, 2015 Value Set - Urine Macroalbumin Tests;HEDIS 2014-15 Urin Macroalb;;DISCOURAGED;2.46;2.67 +7426-0;House dust Hollister Stier Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Hollister Stier IgG Ab [Units/volume] in Serum;House Dust HS IgG Qn;;ACTIVE;1.0h(2);2.73 +74260-1;HEDIS 2014 Value Set - Valproic Acid Level;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - Valproic Acid Level;HEDIS 2014 Valp Acid;;DISCOURAGED;2.46;2.67 +74261-9;HEDIS 2014 Value Set - Phenytoin Level;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014 Value Set - Phenytoin Level;HEDIS 2014 Phenytoin;;DISCOURAGED;2.46;2.67 +74262-7;HEDIS 2014-2018 Value Set - Toxoplasma Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2014-2018 Value Set - Toxoplasma Antibody;HEDIS 2014-18 Toxoplasma Ab;;DISCOURAGED;2.46;2.67 +74263-5;Dabigatran;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Dabigatran [Mass/volume] in Serum or Plasma by LC/MS/MS;Dabigatran SerPl LC/MS/MS-mCnc;;ACTIVE;2.46;2.46 +74264-3;Summary registry report;Find;Pt;{Setting};Doc;HIV;DOC.ONTOLOGY;2;HIV Summary registry report;HIV Summary registry report;;ACTIVE;2.46;2.5 +742-7;Monocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Monocytes [#/volume] in Blood by Automated count;Monocytes # Bld Auto;;ACTIVE;1.0;2.73 +74277-5;Mycobacterium tuberculosis stimulated gamma interferon.CFP10 Ag spot count;Num;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon CFP10 Ag spot count [#] in Blood;M TB IFN-g.CFP10 Ag Bld;;ACTIVE;2.46;2.64 +7427-8;Hymenopterase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Hymenopterase IgE Ab [Units/volume] in Serum;Deprecated Hymenopterase IgE Qn;;DEPRECATED;1.0h(2);2.65 +74278-3;Mycobacterium tuberculosis stimulated gamma interferon.ESAT-6 Ag spot count;Num;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon ESAT-6 Ag spot count [#] in Blood;M TB IFN-g.ESAT-6 Ag Bld;;ACTIVE;2.46;2.64 +74279-1;Gamma interferon.negative control spot count;Num;Pt;Bld;Qn;;MICRO;1;Gamma interferon negative control spot count [#] in Blood;IGNF neg cntrl Bld;;ACTIVE;2.46;2.46 +74280-9;Mitogen stimulated gamma interferon.positive control spot count;Num;Pt;Bld;Qn;;MICRO;1;Mitogen stimulated gamma interferon positive control spot count [#] in Blood;Mitogen IGNF.spot count Bld;;ACTIVE;2.46;2.73 +74281-7;Mycobacterium tuberculosis stimulated gamma interferon & spot count panel;-;Pt;Bld;-;;PANEL.MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon and spot count panel - Blood;M TB IFN-g+spot Pnl Bld;;ACTIVE;2.46;2.64 +74282-5;Individual counseling note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Individual counseling note;Indiv counsel note;;ACTIVE;2.46;2.54 +74283-3;Alternate residence status;Type;Pt;^Patient;Nom;NTDS;H&P.HX;2;Alternate residence status [NTDS];Alt residence status [NTDS];;ACTIVE;2.46;2.63 +74284-1;Type of complication;Type;Pt;^Patient;Nom;NTDS;TRAUMA;2;Type of complication [NTDS];Complication type [NTDS];;ACTIVE;2.46;2.46 +74285-8;ED discharge disposition;Type;Pt;^Patient;Nom;NTDS;TRAUMA;2;Deprecated ED discharge disposition [NTDS];Deprecated ED dc dispo [NTDS];;DEPRECATED;2.46;2.73 +7428-6;Allenrolfea occidentalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Iodinebush IgE Ab [Units/volume] in Serum;Iodinebush IgE Qn;;ACTIVE;1.0h(2);2.73 +74286-6;Transport mode to hospital;Type;Pt;^Patient;Nom;NTDS;TRAUMA;2;Transport mode to hospital [NTDS];Hospital transport [NTDS];;ACTIVE;2.46;2.46 +74287-4;Occupation;Type;Pt;^Patient;Nom;NTDS;ADMIN.PATIENT.DEMOG;2;Occupation [NTDS];Occupation [NTDS];;ACTIVE;2.46;2.66 +74288-2;Occupation industry;Type;Pt;^Patient;Nom;NTDS;ADMIN.PATIENT.DEMOG;2;Occupation industry [NTDS];Occupation industry [NTDS];;DISCOURAGED;2.46;2.66 +74289-0;Pre-hospital transport mode.other;Type;Pt;^Patient;Nom;NTDS;TRAUMA;2;Other pre-hospital transport mode [NTDS];Pre-hosp transportation [NTDS];;ACTIVE;2.46;2.46 +74290-8;Hospital discharge disposition;Type;Pt;^Patient;Nom;NTDS;TRAUMA;2;Hospital discharge disposition [NTDS];Hosp discharge dispo [NTDS];;ACTIVE;2.46;2.52 +74291-6;Comorbidities relevant to trauma care;Find;Pt;^Patient;Nom;NTDS;TRAUMA;2;Comorbidities relevant to trauma care [NTDS];Comorbidities trauma care [NTDS];;ACTIVE;2.46;2.67 +74292-4;Additional cause of injury;Find;Pt;^Patient;Nom;NTDS;TRAUMA;2;Additional cause of injury [NTDS];Addtnl cause of injury [NTDS];;ACTIVE;2.46;2.46 +74293-2;Oncology plan of care and summary - recommended CDA set;-;Pt;{Setting};-;;PANEL.DOC;2;Oncology plan of care and summary - recommended CDA set;Onc plan sum - recom CDA set;;ACTIVE;2.46;2.56 +7429-4;Hexamethylene diisocyanate (HDI) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate HDI IgE Ab [Units/volume] in Serum;Isocyanate HDI IgE Qn;;ACTIVE;1.0h(2);2.73 +74294-0;Isovaleric acidemia;Imp;Pt;Bld.dot;Nom;;CHEM;1;Isovaleric acidemia newborn screen interpretation;IVA DBS-Imp;;ACTIVE;2.46;2.46 +74295-7;Hydroxymethylglutaryl CoA lyase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Hydroxymethylglutaryl CoA lyase deficiency newborn screen interpretation;HMG-CoA Lyase deficiency DBS-Imp;;ACTIVE;2.46;2.46 +74296-5;3-Methylcrotonyl-CoA carboxylase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;3-Methylcrotonyl-CoA carboxylase deficiency newborn screen interpretation;3-MCC deficiency DBS-Imp;;ACTIVE;2.46;2.46 +74297-3;Isobutyryl-CoA dehydrogenase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Isobutyryl-CoA dehydrogenase deficiency newborn screen interpretation;IBG deficiency DBS-Imp;;ACTIVE;2.46;2.46 +74298-1;Short-chain acyl-CoA dehydrogenase deficiency;Imp;Pt;Bld.dot;Nom;;CHEM;1;Short-chain acyl-CoA dehydrogenase deficiency newborn screen interpretation;SCAD deficiency DBS-Imp;;ACTIVE;2.46;2.46 +74299-9;Tyrosine/Phenylalanine^post therapeutic diet;SRto;Pt;Bld.dot;Qn;;CHAL;1;Tyrosine/Phenylalanine [Molar ratio] in DBS --post therapeutic diet;Tyrosine/Phe p diet DBS-sRto;;ACTIVE;2.46;2.61 +74300-5;Phenylalanine/Tyrosine^post therapeutic diet;SRto;Pt;Bld.dot;Qn;;CHAL;1;Phenylalanine/Tyrosine [Molar ratio] in DBS --post therapeutic diet;Phe/Tyr p diet DBS-sRto;;ACTIVE;2.46;2.61 +74301-3;Succinylacetone^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Succinylacetone [Moles/volume] in DBS --post therapeutic diet;Succinylacetone p diet DBS-sCnc;;ACTIVE;2.46;2.61 +7430-2;Diphenylmethane diisocyanate (MDI) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate MDI IgE Ab [Units/volume] in Serum;Isocyanate MDI IgE Qn;;ACTIVE;1.0h(2);2.73 +74302-1;Tyrosine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Tyrosine [Moles/volume] in DBS --post therapeutic diet;Tyrosine p diet DBS-sCnc;;ACTIVE;2.46;2.61 +74303-9;Phenylalanine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Phenylalanine [Moles/volume] in DBS --post therapeutic diet;Phe p diet DBS-sCnc;;ACTIVE;2.46;2.61 +74304-7;Porcine reproductive and respiratory syndrome virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;PRRSV neutralizing antibody [Titer] in Serum by Neutralization test;PRRSV NAb Titr Ser Nt;;ACTIVE;2.46;2.64 +74305-4;Porcine reproductive and respiratory syndrome virus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;PRRSV Ag [Presence] in Specimen by Immunofluorescence;PRRSV Ag Spec Ql IF;;ACTIVE;2.46;2.69 +74306-2;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Fostera;NFr;Pt;Isolate;Qn;Sequencing;MICRO;1;PRRSV ORF5 gene sequence homology to Fostera in Isolate by Sequencing;PRRSV Fostera Hmlgy Islt Seq-NFr;;ACTIVE;2.46;2.64 +74307-0;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Lelystad;NFr;Pt;Isolate;Qn;Sequencing;MICRO;1;PRRSV ORF5 gene sequence homology to Lelystad in Isolate by Sequencing;PRRSV Lelystad Hmlgy Islt Seq-NFr;;ACTIVE;2.46;2.64 +74308-8;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Ingelvac ATP;NFr;Pt;Isolate;Qn;Sequencing;MICRO;1;PRRSV ORF5 gene sequence homology to Ingelvac ATP in Isolate by Sequencing;PRRSV IngATP Hmlgy Islt Seq-NFr;;ACTIVE;2.46;2.64 +74309-6;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Ingelvac MLV;NFr;Pt;Isolate;Qn;Sequencing;MICRO;1;PRRSV ORF5 gene sequence homology to Ingelvac MLV in Isolate by Sequencing;PRRSV IngMLV Hmlgy Islt Seq-NFr;;ACTIVE;2.46;2.64 +7431-0;Toluene diisocyanate (TDI) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Isocyanate TDI IgE Ab [Units/volume] in Serum;Isocyanate TDI IgE Qn;;ACTIVE;1.0h(2);2.73 +74310-4;Porcine reproductive and respiratory syndrome virus strain identified;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;PRRSV strain identified in Isolate by Sequencing;PRRSV strain Islt Seq;;ACTIVE;2.46;2.64 +74311-2;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;PRRSV ORF5 gene sequence [Nucleotide sequence] in Isolate by Sequencing;PRRSV ORF5 seq Islt-Seq;;ACTIVE;2.46;2.64 +74312-0;Porcine reproductive and respiratory syndrome virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;PRRSV [Presence] in Specimen by Organism specific culture;PRRSV Spec Ql Cult;;ACTIVE;2.46;2.69 +74313-8;Porcine reproductive and respiratory syndrome virus Ab/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;PRRSV Ab/Positive control in Specimen by Immunoassay;PRRSV Ab/Pos cntrl Spec IA;;ACTIVE;2.46;2.69 +74314-6;Porcine reproductive and respiratory syndrome virus ORF5 gene RNA pattern;ID;Pt;Isolate;Nom;RFLP;MICRO;1;PRRSV ORF5 gene RNA pattern [Identifier] in Isolate by RFLP;PRRSV ORF5 RNA pat Islt RFLP;;ACTIVE;2.46;2.64 +74315-3;Porcine reproductive and respiratory syndrome virus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PRRSV RNA [#/volume] (viral load) in Specimen by NAA with probe detection;PRRSV RNA # Spec NAA+probe;;ACTIVE;2.46;2.69 +74316-1;Porcine reproductive and respiratory syndrome virus ORF5 gene RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;PRRSV ORF5 gene RNA [Presence] in Specimen by NAA with probe detection;PRRSV ORF5 gene RNA Spec Ql NAA+probe;;ACTIVE;2.46;2.69 +74317-9;Porcine reproductive and respiratory syndrome virus European strain RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PRRSV European strain RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PRRSV European RNA Ct Spec Qn NAA+probe;;ACTIVE;2.46;2.69 +74318-7;Porcine reproductive and respiratory syndrome virus North American strain RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PRRSV North American strain RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PRRSV NA strain RNA Ct Spec Qn NAA+probe;;ACTIVE;2.46;2.69 +74319-5;MICA*051 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*051 IgG Ab [Presence] in Serum;MICA*051 IgG Ser Ql;;ACTIVE;2.46;2.58 +74320-3;MICA*050 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*050 IgG Ab [Presence] in Serum;MICA*050 IgG Ser Ql;;ACTIVE;2.46;2.58 +74321-1;MICA*046 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*046 IgG Ab [Presence] in Serum;MICA*046 IgG Ser Ql;;ACTIVE;2.46;2.58 +74322-9;MICA*043 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*043 IgG Ab [Presence] in Serum;MICA*043 IgG Ser Ql;;ACTIVE;2.46;2.58 +74323-7;MICA*042 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*042 IgG Ab [Presence] in Serum;MICA*042 IgG Ser Ql;;ACTIVE;2.46;2.58 +74324-5;MICA*041 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*041 IgG Ab [Presence] in Serum;MICA*041 IgG Ser Ql;;ACTIVE;2.46;2.58 +74325-2;MICA*037 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*037 IgG Ab [Presence] in Serum;MICA*037 IgG Ser Ql;;ACTIVE;2.46;2.58 +74326-0;MICA*036 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*036 IgG Ab [Presence] in Serum;MICA*036 IgG Ser Ql;;ACTIVE;2.46;2.58 +74327-8;MICA*033 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*033 IgG Ab [Presence] in Serum;MICA*033 IgG Ser Ql;;ACTIVE;2.46;2.58 +7432-8;Juniper Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Juniper IgE Ab [Units/volume] in Serum;Juniper IgE Qn;;ACTIVE;1.0h(2);2.42 +74328-6;MICA*030 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*030 IgG Ab [Presence] in Serum;MICA*030 IgG Ser Ql;;ACTIVE;2.46;2.58 +74329-4;MICA*029 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*029 IgG Ab [Presence] in Serum;MICA*029 IgG Ser Ql;;ACTIVE;2.46;2.58 +74330-2;MICA*028 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*028 IgG Ab [Presence] in Serum;MICA*028 IgG Ser Ql;;ACTIVE;2.46;2.58 +74331-0;MICA*024 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*024 IgG Ab [Presence] in Serum;MICA*024 IgG Ser Ql;;ACTIVE;2.46;2.58 +74332-8;MICA*019 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*019 IgG Ab [Presence] in Serum;MICA*019 IgG Ser Ql;;ACTIVE;2.46;2.58 +74333-6;MICA*018 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*018 IgG Ab [Presence] in Serum;MICA*018 IgG Ser Ql;;ACTIVE;2.46;2.58 +74334-4;MICA*017 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*017 IgG Ab [Presence] in Serum;MICA*017 IgG Ser Ql;;ACTIVE;2.46;2.58 +74335-1;MICA*016 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*016 IgG Ab [Presence] in Serum;MICA*016 IgG Ser Ql;;ACTIVE;2.46;2.58 +7433-6;Juniper basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Juniper triggered histamine release [Units/volume] in Blood;Juniper BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74336-9;MICA*015 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*015 IgG Ab [Presence] in Serum;MICA*015 IgG Ser Ql;;ACTIVE;2.46;2.58 +74337-7;MICA*012 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*012 IgG Ab [Presence] in Serum;MICA*012 IgG Ser Ql;;ACTIVE;2.46;2.58 +74338-5;MICA*011 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*011 IgG Ab [Presence] in Serum;MICA*011 IgG Ser Ql;;ACTIVE;2.46;2.58 +74339-3;MICA*009 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*009 IgG Ab [Presence] in Serum;MICA*009 IgG Ser Ql;;ACTIVE;2.46;2.58 +74340-1;MICA*008 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*008 IgG Ab [Presence] in Serum;MICA*008 IgG Ser Ql;;ACTIVE;2.46;2.58 +74341-9;MICA*007 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*007 IgG Ab [Presence] in Serum;MICA*007 IgG Ser Ql;;ACTIVE;2.46;2.58 +74342-7;MICA*006 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*006 IgG Ab [Presence] in Serum;MICA*006 IgG Ser Ql;;ACTIVE;2.46;2.58 +74343-5;MICA*005 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*005 IgG Ab [Presence] in Serum;MICA*005 IgG Ser Ql;;ACTIVE;2.46;2.58 +7434-4;Juniperus pinchotii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pinchot Juniper IgE Ab [Units/volume] in Serum;Pinchot Juniper IgE Qn;;ACTIVE;1.0h(2);2.42 +74344-3;MICA*004 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*004 IgG Ab [Presence] in Serum;MICA*004 IgG Ser Ql;;ACTIVE;2.46;2.58 +74345-0;MICA*002 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*002 IgG Ab [Presence] in Serum;MICA*002 IgG Ser Ql;;ACTIVE;2.46;2.58 +74346-8;MICA*001 Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;MICA*001 IgG Ab [Presence] in Serum;MICA*001 IgG Ser Ql;;ACTIVE;2.46;2.58 +74347-6;Leukocyte aggregates;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Leukocyte aggregates [Presence] in Blood by Light microscopy;Leukocyte aggregates Bld Ql Smear;;ACTIVE;2.46;2.56 +74348-4;Bacteria identified;Prid;Pt;Bone^Donor;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bone from Donor by Aerobe culture;Bacteria Bone Donr Aerobe Cult;;ACTIVE;2.46;2.46 +74349-2;Lactose^post CFst;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Moles/volume] in Serum or Plasma --fasting;Lactose p fast SerPl-sCnc;;ACTIVE;2.46;2.46 +743-5;Monocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Monocytes [#/volume] in Blood by Manual count;Monocytes # Bld Manual;;ACTIVE;1.0;2.73 +74350-0;17-Hydroxyprogesterone^20M post dose corticotropin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --20M post dose corticotropin;17OHP 20M p ATCH SerPl-sCnc;;ACTIVE;2.46;2.46 +7435-1;Juniperus occidentalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Western Juniper IgE Ab [Units/volume] in Serum;West Juniper IgE Qn;;ACTIVE;1.0h(2);2.73 +74351-8;Glucose;SCnc;XXX;Urine;Qn;;CHEM;1;Glucose [Moles/volume] in Urine collected for unspecified duration;Glucose ?Tm Ur-sCnc;;ACTIVE;2.46;2.52 +74352-6;Cryoglobulin & cryofibrinogen panel;-;Pt;Ser+Plas;-;;PANEL.CHEM;1;Cryoglobulin and cryofibrinogen panel - Serum and Plasma;Cryoglob+cryofib Pnl Ser+Pl;;ACTIVE;2.46;2.73 +74353-4;Sodium & Potassium panel;SCnc;Pt;Bld;Qn;;PANEL.CHEM;1;Sodium and Potassium panel [Moles/volume] - Blood;Sodium + Potassium Pnl Bld-sCnc;;ACTIVE;2.46;2.46 +74354-2;Epithelial cells/100 leukocytes;NFr;Pt;Sputum;Qn;;HEM/BC;1;Epithelial cells/100 leukocytes in Sputum;Epi Cells/leuk NFr Spt;;ACTIVE;2.46;2.5 +74355-9;Bacteria identified;Prid;Pt;Bartholin cyst;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bartholin cyst by Aerobe culture;Bacteria Barth cyst Aerobe Cult;;ACTIVE;2.46;2.46 +74356-7;Bacteria identified;Prid;Pt;VP shunt;Nom;Culture;MICRO;1;Bacteria identified in Ventriculoperitoneal (VP) shunt by Culture;Bacteria VP shunt Cult;;ACTIVE;2.46;2.73 +74357-5;Lymphocytes.immunoblastic;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Lymphocytes Immunoblastic [Presence] in Blood by Light microscopy;Ib Lymphs Bld Ql Smear;;ACTIVE;2.46;2.56 +74358-3;Adenine phosphoribosyltransferase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adenine phosphoribosyltransferase [Enzymatic activity/volume] in Serum or Plasma;APRT SerPl-cCnc;;ACTIVE;2.46;2.68 +74359-1;Cholesterol ester transfer protein actual/normal;RelACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol ester transfer protein actual/normal in Serum or Plasma;Cholest est trnsfr prot Act/Nor SerPl;;ACTIVE;2.46;2.46 +74360-9;Cortisone;SCnc;Pt;Saliva;Qn;;CHEM;1;Cortisone [Moles/volume] in Saliva (oral fluid);Cortisone Sal-sCnc;;ACTIVE;2.46;2.46 +74361-7;Dehydroepiandrosterone;SCnc;Pt;Saliva;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Moles/volume] in Saliva (oral fluid);DHEA Sal-sCnc;;ACTIVE;2.46;2.46 +74362-5;Lecithin cholesterol acyltransferase actual/normal;RelCCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lecithin cholesterol acyltransferase actual/normal in Serum or Plasma;LCAT Act/Nor SerPl;;ACTIVE;2.46;2.46 +74363-3;N,N-dimethylarginine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N,N-dimethylarginine [Moles/volume] in Serum or Plasma;N,N-dimethylarginine SerPl-sCnc;;ACTIVE;2.46;2.46 +74364-1;Oxytocin;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Oxytocin [Mass/volume] in Saliva (oral fluid);Oxytocin Sal-mCnc;;ACTIVE;2.46;2.46 +74365-8;Palmitoyl protein thioesterase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Palmitoyl protein thioesterase [Enzymatic activity/mass] in Fibroblast;PPT Fib-cCnt;;ACTIVE;2.46;2.46 +74366-6;Clorazepate^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clorazepate [Mass/volume] in Serum or Plasma --trough;Clorazepate Trough SerPl-mCnc;;ACTIVE;2.46;2.46 +74367-4;Norfluoxetine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Norfluoxetine [Mass/volume] in Serum or Plasma --trough;Deprecated Norfluoxetine Trough SerPl-mC;;DEPRECATED;2.46;2.54 +74368-2;Apelin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apelin [Mass/volume] in Serum or Plasma;APLN SerPl-mCnc;;ACTIVE;2.46;2.46 +7436-9;Chorchorus capsularis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Jute IgE Ab [Units/volume] in Serum;Jute IgE Qn;;ACTIVE;1.0h(2);2.42 +74369-0;Nitric oxide;SCnc;Pt;Exhl gas;Qn;;CHEM;1;Nitric oxide [Moles/volume] in Exhaled gas;NO ExG-sCnc;;ACTIVE;2.46;2.46 +74370-8;Cotinine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Cotinine [Presence] in Saliva (oral fluid) by Confirmatory method;Cotinine Sal Ql Cfm;;ACTIVE;2.46;2.56 +74371-6;Cotinine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Cotinine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Cotinine Sal Cfm-mCnc;;ACTIVE;2.46;2.73 +74372-4;Acetyl fentanyl;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acetyl fentanyl [Mass/volume] in Urine;Acetyl fentanyl Ur-mCnc;;ACTIVE;2.46;2.73 +74373-2;cloNIDine;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;cloNIDine [Mass/volume] in Unknown substance;cloNIDine Usub-mCnc;;ACTIVE;2.46;2.46 +74374-0;2,4,4'-Trichlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,4,4'-Trichlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,4,4'-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.73 +74375-7;2,2',3,5'-Tetrachlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,2',3,5'-Tetrachlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,2',3,5'-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.73 +74376-5;2,2',4,4',5,5'-Hexachlorobiphenyl;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;2,2',4,4',5,5'-Hexachlorobiphenyl (PCB) [Mass/volume] in Serum or Plasma by Confirmatory method;2,2',4,4',5,5'-PCB SerPl Cfm-mCnc;;ACTIVE;2.46;2.73 +7437-7;Kapok Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kapok IgE Ab [Units/volume] in Serum;Kapok IgE Qn;;ACTIVE;1.0h(2);2.73 +74377-3;Baclofen;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Baclofen [Mass/volume] in Unknown substance;Baclofen Usub-mCnc;;ACTIVE;2.46;2.46 +74378-1;Meperidine;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Meperidine [Mass/volume] in Unknown substance;Meperidine Usub-mCnc;;ACTIVE;2.46;2.46 +74379-9;Morphine;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Morphine [Mass/volume] in Unknown substance;Morphine Usub-mCnc;;ACTIVE;2.46;2.46 +74380-7;HYDROmorphone;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;HYDROmorphone [Mass/volume] in Unknown substance;HYDROmorphone Usub-mCnc;;ACTIVE;2.46;2.46 +74381-5;Midazolam;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Midazolam [Mass/volume] in Unknown substance;Midazolam Usub-mCnc;;ACTIVE;2.46;2.73 +74382-3;Bupivacaine;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Bupivacaine [Mass/volume] in Unknown substance;Bupivacaine Usub-mCnc;;ACTIVE;2.46;2.46 +74383-1;fentaNYL;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;fentaNYL [Mass/volume] in Unknown substance;fentaNYL Usub-mCnc;;ACTIVE;2.46;2.46 +74384-9;Specimen container;Type;Pt;Specimen;Nom;;SPEC;1;Specimen container [Type];Spec container Spec;;ACTIVE;2.46;2.73 +7438-5;Kapok basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Kapok triggered histamine release [Units/volume] in Blood;Kapok BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74385-6;Normirtazapine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Normirtazapine [Mass/mass] in Hair;Normirtazapine Hair-mCnt;;ACTIVE;2.46;2.46 +74386-4;Normirtazapine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Normirtazapine [Mass/mass] in Specimen;Normirtazapine Spec-mCnt;;ACTIVE;2.46;2.69 +74387-2;Normirtazapine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Normirtazapine [Mass/volume] in Urine;Normirtazapine Ur-mCnc;;ACTIVE;2.46;2.46 +74388-0;Normirtazapine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Normirtazapine [Mass/volume] in Body fluid;Normirtazapine Fld-mCnc;;ACTIVE;2.46;2.46 +74389-8;Normirtazapine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Normirtazapine [Mass/volume] in Blood;Normirtazapine Bld-mCnc;;ACTIVE;2.46;2.46 +74390-6;Baclofen;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Baclofen [Mass/mass] in Specimen;Baclofen Spec-mCnt;;ACTIVE;2.46;2.69 +74391-4;Baclofen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Baclofen [Mass/volume] in Blood;Baclofen Bld-mCnc;;ACTIVE;2.46;2.46 +74392-2;Zopiclone;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Zopiclone [Mass/mass] in Hair;Zopiclone Hair-mCnt;;ACTIVE;2.46;2.46 +7439-3;Karaya gum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Karaya gum IgE Ab [Units/volume] in Serum;Karaya Gum IgE Qn;;ACTIVE;1.0h(2);2.73 +74393-0;Reticulocytes.immature/100 erythrocytes;NFr;Pt;BldCo;Qn;Automated count;HEM/BC;1;Immature reticulocytes/100 erythrocytes in Cord blood by Automated count;Imm Retics/100 RBC NFr BldCo Auto;;ACTIVE;2.46;2.61 +74394-8;Normoblasts;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Normoblasts [#/volume] in Cord blood;Normoblasts # BldCo;;ACTIVE;2.46;2.46 +74395-5;Blasts;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Blasts [#/volume] in Cord blood;Blasts # BldCo;;ACTIVE;2.46;2.46 +74396-3;Large unstained cells/100 leukocytes;NFr;Pt;BldCo;Qn;Automated count;HEM/BC;1;Large unstained cells/100 leukocytes in Cord blood by Automated count;LUC/leuk NFr BldCo Auto;;ACTIVE;2.46;2.5 +74397-1;Reticulocytes/100 erythrocytes;NFr;Pt;BldCo;Qn;Automated count;HEM/BC;1;Reticulocytes/100 erythrocytes in Cord blood by Automated count;Retics/100 RBC NFr BldCo Auto;;ACTIVE;2.46;2.61 +74398-9;Neutrophils;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Neutrophils [#/volume] in Cord blood;Neutrophils # BldCo;;ACTIVE;2.46;2.46 +74399-7;Monocytes;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Monocytes [#/volume] in Cord blood;Monocytes # BldCo;;ACTIVE;2.46;2.46 +74400-3;Monocytes/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Monocytes/100 leukocytes in Cord blood;Monocytes/leuk NFr BldCo;;ACTIVE;2.46;2.5 +7440-1;Actinidia chinensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Kiwifruit IgG Ab [Units/volume] in Serum;Kiwifruit IgG Qn;;ACTIVE;1.0h(2);2.69 +74401-1;Lymphocytes;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Lymphocytes [#/volume] in Cord blood;Lymphocytes # BldCo;;ACTIVE;2.46;2.46 +74402-9;Lymphocytes/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Cord blood;Lymphocytes/leuk NFr BldCo;;ACTIVE;2.46;2.5 +74403-7;Normoblasts/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Normoblasts/100 leukocytes in Cord blood;Normoblasts/leuk NFr BldCo;;ACTIVE;2.46;2.5 +74404-5;Eosinophils;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Eosinophils [#/volume] in Cord blood;Eosinophil # BldCo;;ACTIVE;2.46;2.46 +74405-2;Eosinophils/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Eosinophils/100 leukocytes in Cord blood;Eosinophil/leuk NFr BldCo;;ACTIVE;2.46;2.5 +74406-0;Basophils;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Basophils [#/volume] in Cord blood;Basophils # BldCo;;ACTIVE;2.46;2.46 +74407-8;Basophils/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Basophils/100 leukocytes in Cord blood;Basophils/leuk NFr BldCo;;ACTIVE;2.46;2.5 +74408-6;Middle east respiratory syndrome coronavirus RNA panel;-;Pt;XXX;-;;PANEL.MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA panel - Specimen;MERS-CoV RNA Pnl Spec;;ACTIVE;2.46;2.69 +74409-4;MICA Ab.IgG panel;-;Pt;Ser;-;;PANEL.SERO;1;MICA IgG panel - Serum;MICA IgG Pnl Ser;;ACTIVE;2.46;2.46 +74410-2;Polychlorinated biphenyl panel;-;Pt;Ser/Plas;-;Confirm;PANEL.DRUG/TOX;1;Polychlorinated biphenyl (PCB) panel - Serum or Plasma by Confirmatory method;PCB panel SerPl Cfm;;ACTIVE;2.46;2.68 +74411-0;Consistency;Type;Pt;Lymph node;Nom;;HEM/BC;1;Consistency of Lymph node;Consistency LN;;ACTIVE;2.46;2.46 +74412-8;Complete blood count W Differential panel;-;Pt;BldCo;Qn;;PANEL.HEM/BC;1;CBC W Differential panel - Cord blood;CBC W Diff Pnl BldCo;;ACTIVE;2.46;2.68 +74413-6;Differential panel;-;Pt;BldCo;Qn;;PANEL.HEM/BC;1;Differential panel - Cord blood;Diff Pnl BldCo;;ACTIVE;2.46;2.46 +74414-4;Varicella zoster virus Ab.IgM;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Varicella zoster virus IgM Ab [Units/volume] in Body fluid by Immunoassay;VZV IgM Fld IA-aCnc;;ACTIVE;2.46;2.56 +74415-1;Rubella virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Rubella virus IgG Ab [Presence] in Body fluid by Immunoassay;RUBV IgG Fld Ql IA;;ACTIVE;2.46;2.56 +74416-9;Measles virus Ab.IgM;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Measles virus IgM Ab [Units/volume] in Body fluid by Immunoassay;MeV IgM Fld IA-aCnc;;ACTIVE;2.46;2.68 +74417-7;Measles virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Measles virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;MeV IgM CSF Ql IA;;ACTIVE;2.46;2.56 +74418-5;Measles virus Ab.IgG;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Measles virus IgG Ab [Units/volume] in Body fluid by Immunoassay;MeV IgG Fld IA-aCnc;;ACTIVE;2.46;2.73 +7441-9;Actinidia chinensis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Kiwifruit triggered histamine release [Units/volume] in Blood;Kiwifruit BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74419-3;Parvovirus B19 DNA;LaCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [log units/volume] (viral load) in Serum or Plasma by NAA with probe detection;B19V DNA SerPl NAA+probe-Log IU;;ACTIVE;2.46;2.73 +74420-1;Parvovirus B19 DNA;ACnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection;B19V DNA SerPl NAA+probe-aCnc;;ACTIVE;2.46;2.73 +74421-9;Mumps virus Ab.IgM;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Mumps virus IgM Ab [Units/volume] in Body fluid by Immunoassay;MuV IgM Fld IA-aCnc;;ACTIVE;2.46;2.68 +74422-7;Mumps virus Ab.IgG;PrThr;Pt;Body fld;Ord;IA;MICRO;1;Mumps virus IgG Ab [Presence] in Body fluid by Immunoassay;MuV IgG Fld Ql IA;;ACTIVE;2.46;2.56 +74423-5;Enterovirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Enterovirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;EV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.46;2.69 +74424-3;Enterovirus RNA;ThreshNum;Pt;Stool;Qn;Probe.amp.tar;MICRO;1;Enterovirus RNA [Cycle Threshold #] in Stool by NAA with probe detection;EV RNA Ct Stl Qn NAA+probe;;ACTIVE;2.46;2.63 +74425-0;Myelocytes.neutrophilic/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Myelocytes.neutrophilic/100 leukocytes in Blood by Manual count;Myelocytes.neut/leuk NFr Bld Manual;;ACTIVE;2.46;2.5 +74426-8;Myelocytes.neutrophilic/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Myelocytes.neutrophilic/100 cells in Bone marrow by Manual count;Myelocytes.neut NFr Mar Manual;;ACTIVE;2.46;2.46 +7442-7;Kochia scoparia Ab.IgA;ACnc;Pt;Ser;Qn;;ALLERGY;1;Firebush IgA Ab [Units/volume] in Serum;Firebush IgA Qn;;ACTIVE;1.0h(2);2.69 +74427-6;Myelocytes.eosinophilic/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Myelocytes.eosinophilic/100 leukocytes in Blood by Manual count;Myelocytes.eos/leuk NFr Bld Manual;;ACTIVE;2.46;2.5 +74428-4;Metamyelocytes.neutrophilic/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Metamyelocytes.neutrophilic/100 leukocytes in Blood by Manual count;Metamyelocytes.neut/leuk NFr Bld Manual;;ACTIVE;2.46;2.5 +74429-2;Metamyelocytes.eosinophilic/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Metamyelocytes.eosinophilic/100 cells in Bone marrow by Manual count;Metamyelocytes.eos NFr Mar Manual;;ACTIVE;2.46;2.46 +744-3;Monocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Blood by Manual count;Monocytes/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +74430-0;3-Hydroxykynurenin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxykynurenin [Moles/volume] in Serum or Plasma;3OH-kynurenin SerPl-sCnc;;ACTIVE;2.46;2.54 +74431-8;Acetoacetate;SCnc;Pt;Bld;Qn;;CHEM;1;Acetoacetate [Moles/volume] in Blood;Acetoacet Bld-sCnc;;ACTIVE;2.46;2.46 +74432-6;Cholestanol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholestanol [Moles/volume] in Serum or Plasma;Cholestanol SerPl-sCnc;;ACTIVE;2.46;2.46 +74433-4;Cholestanol/Cholesterol;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Cholestanol/Cholesterol in Serum or Plasma;Cholestanol/Cholest SFr SerPl;;ACTIVE;2.46;2.46 +74434-2;Bilirubin/Total;MFr;Pt;Calculus;Qn;Infrared spectroscopy;CHEM;1;Bilirubin.total/Total in Stone by Infrared spectroscopy;Bilirub MFr Stone IR;;ACTIVE;2.46;2.46 +7443-5;Kochia scoparia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Firebush IgE Ab [Units/volume] in Serum;Deprecated Firebush IgE Qn;;DEPRECATED;1.0h(2);2.69 +74435-9;Cholesterol.non-esterified/Cholesterol.total;SFr;Pt;Ser/Plas;Qn;GC;CHEM;1;Cholesterol.non-esterified/Cholesterol.total in Serum or Plasma by Gas chromatography;NE Cholest SFr SerPl GC;;ACTIVE;2.46;2.46 +74436-7;D-lactate;SCnt;Pt;Stool;Qn;;CHEM;1;D-Lactate [Moles/mass] in Stool;D-Lactate Stl-sCnt;;ACTIVE;2.46;2.46 +74437-5;Galactokinase;CCnt;Pt;WBC;Qn;;CHEM;1;Galactokinase [Enzymatic activity/mass] in Leukocytes;Galactokinase WBC-cCnt;;ACTIVE;2.46;2.46 +74438-3;Lactose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Lactose/Creatinine [Molar ratio] in Urine;Lactose/Creat Ur-sRto;;ACTIVE;2.46;2.46 +74439-1;Gamma aminobutyrate free and total panel;-;Pt;CSF;-;;PANEL.CHEM;1;GABA free and total panel - Cerebral spinal fluid;GABA free+total Pnl CSF;;ACTIVE;2.46;2.58 +74440-9;Pemptoporphyrin;SCnt;Pt;Stool;Qn;;CHEM;1;Pemptoporphyrin [Moles/mass] in Stool;Pemptoporphyrin Stl-sCnt;;ACTIVE;2.46;2.46 +74441-7;Porphobilinogen/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Porphobilinogen/Creatinine [Molar ratio] in 24 hour Urine;PBG/Creat 24h Ur-sRto;;ACTIVE;2.46;2.46 +74442-5;Pyridoxal phosphate;SCnc;Pt;Bld;Qn;;CHEM;1;Pyridoxal phosphate [Moles/volume] in Blood;Pyridoxal Phos Bld-sCnc;;ACTIVE;2.46;2.46 +7444-3;Lactalbumin Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin IgG Ab [Units/volume] in Serum;Lactalb IgG Qn;;ACTIVE;1.0h(2);2.73 +74443-3;Sucrose/Creatinine^post XXX g sugar solution PO;SRto;5H;Urine;Qn;;CHEM;1;Sucrose/Creatinine [Molar ratio] in 5 hour Urine --post XXX g sugar solution PO;Sucrose/Creat p sug sol 5h Ur-sRto;;ACTIVE;2.46;2.54 +74444-1;Thiamine pyrophosphate;SCnc;Pt;Bld;Qn;;CHEM;1;Thiamine pyrophosphate [Moles/volume] in Blood;Vit B1 Pyrophoshate Bld-sCnc;;ACTIVE;2.46;2.73 +74445-8;Porphyrin fractions panel;SCnt;Pt;Stool;-;;PANEL.CHEM;1;Porphyrin fractions panel [Moles/mass] - Stool;Porphyrin Fract Pnl Stl-sCnt;;ACTIVE;2.46;2.48 +74446-6;Calculus analysis panel;-;Pt;Calculus;-;;PANEL.CHEM;1;Stone analysis panel;Stone analysis Pnl;;ACTIVE;2.46;2.73 +74447-4;Sugars and polyols panel;SRto;Pt;Urine;-;;PANEL.CHEM;1;Sugars and polyols panel [Molar ratio] - Urine;Sugars+polyols Pnl Ur-sRto;;ACTIVE;2.46;2.69 +74448-2;Sugars and polyols pattern;Imp;Pt;Urine;Nom;;CHEM;1;Sugars and polyols pattern [Interpretation] in Urine;Sugars and polyols pattern Ur-Imp;;ACTIVE;2.46;2.46 +74449-0;Patient plan of care - recommended IHE set;-;Pt;{Setting};-;;PANEL.DOC;2;Patient plan of care - recommended IHE set;IHE PPOC set;;ACTIVE;2.46;2.66 +7445-0;Lactalbumin alpha Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactalbumin alpha IgE Ab [Units/volume] in Serum;A-Lactalb IgE Qn;;ACTIVE;1.0h(2);2.73 +74450-8;Other cells;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Other cells [#/volume] in Cord blood;Other cells # BldCo;;ACTIVE;2.46;2.46 +74451-6;Other cells/100 leukocytes;NFr;Pt;Bld^Fetus;Qn;;HEM/BC;1;Other cells/100 leukocytes in Blood from Fetus;Other cells/leuk NFr Bld Fetus;;ACTIVE;2.46;2.5 +74452-4;Platelet distribution width;EntVol;Pt;BldCo;Qn;Automated count;HEM/BC;1;Platelet distribution width [Entitic volume] in Cord blood by Automated count;PDW BldCo Auto;;ACTIVE;2.46;2.46 +74453-2;Histiocytes/100 cells;NFr;Pt;Bone mar;Qn;;HEM/BC;1;Histiocytes/100 cells in Bone marrow;Histiocytes NFr Mar;;ACTIVE;2.46;2.46 +74454-0;Normoblasts;NCnc;Pt;Bld^Fetus;Qn;;HEM/BC;1;Normoblasts [#/volume] in Blood from Fetus;Normoblasts # Bld Fetus;;ACTIVE;2.46;2.46 +74455-7;Blasts/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Blasts/100 leukocytes in Cord blood;Blasts/leuk NFr BldCo;;ACTIVE;2.46;2.5 +74456-5;Plasma cells/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Plasma cells/100 leukocytes in Cord blood;Plasma Cells/leuk NFr BldCo;;ACTIVE;2.46;2.5 +74457-3;Neutrophils/100 leukocytes;NFr;Pt;BldCo;Qn;;HEM/BC;1;Neutrophils/100 leukocytes in Cord blood;Neutrophils/leuk NFr BldCo;;ACTIVE;2.46;2.5 +74458-1;Large unstained cells/100 leukocytes;NFr;Pt;Bld^Fetus;Qn;Automated count;HEM/BC;1;Large unstained cells/100 leukocytes in Blood from Fetus by Automated count;LUC/leuk NFr Bld Fetus Auto;;ACTIVE;2.46;2.5 +74459-9;Granulocytes.immature/100 leukocytes;NFr;Pt;Bld^Fetus;Qn;;HEM/BC;1;Immature granulocytes/100 leukocytes in Blood from Fetus;Imm Granulocytes/leuk NFr Bld Fetus;;ACTIVE;2.46;2.5 +74460-7;Blasts/100 leukocytes;NFr;Pt;Bld^Fetus;Qn;;HEM/BC;1;Blasts/100 leukocytes in Blood from Fetus;Blasts/leuk NFr Bld Fetus;;ACTIVE;2.46;2.5 +74461-5;Lymphocytes/100 leukocytes;NFr;Pt;Bld^Fetus;Qn;;HEM/BC;1;Lymphocytes/100 leukocytes in Blood from Fetus;Lymphocytes/leuk NFr Bld Fetus;;ACTIVE;2.46;2.5 +74462-3;Basophils/100 leukocytes;NFr;Pt;Bld^Fetus;Qn;;HEM/BC;1;Basophils/100 leukocytes in Blood from Fetus;Basophils/leuk NFr Bld Fetus;;ACTIVE;2.46;2.5 +74463-1;Normoblasts/100 leukocytes;NFr;Pt;Bld^Fetus;Qn;;HEM/BC;1;Normoblasts/100 leukocytes in Blood from Fetus;Normoblasts/leuk NFr Bld Fetus;;ACTIVE;2.46;2.5 +74464-9;Platelets;NCnc;Pt;BldC;Qn;Manual count;HEM/BC;1;Platelets [#/volume] in Capillary blood by Manual count;Platelet # BldC Manual;;ACTIVE;2.46;2.46 +74465-6;Questionnaire response;Find;Pt;^Patient;Doc;;DOC.MISC;2;Questionnaire response Document;Quest resp Doc;;ACTIVE;2.46;2.63 +74466-4;Feedback to user^post question response;Find;Pt;Question;Nom;;SURVEY.MISC;4;Feedback to user--post question response;;;ACTIVE;2.46;2.61 +74467-2;Number of allowed answer responses interval;Num;Pt;Question;Qn;;SURVEY.MISC;4;Number of allowed answer responses interval Question;;;ACTIVE;2.46;2.5 +7446-8;Lactalbumin basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Lactalbumin triggered histamine release [Units/volume] in Blood;Lactalb BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74468-0;Questionnaire form definition;Find;Pt;Form;Doc;;DOC.MISC;2;Questionnaire form definition Document;Quest frm def Doc;;ACTIVE;2.46;2.63 +74469-8;Glucose-6-Phosphate dehydrogenase/Pyruvate kinase;Ratio;Pt;Bld;Qn;;CHEM;1;Glucose-6-Phosphate dehydrogenase/Pyruvate kinase [Ratio] in Blood;G6PD/PK Bld-Rto;;ACTIVE;2.46;2.48 +74470-6;Injury severity score body region;Type;Pt;^Patient;Nom;NTDS;TRAUMA;2;Injury severity score (ISS) body region [NTDS];ISS body region [NTDS];;ACTIVE;2.46;2.46 +74471-4;Injury severity score;Score;Pt;^Patient;Qn;Calculated;TRAUMA;2;Injury severity score Calculated;ISS Calc;;ACTIVE;2.46;2.63 +74472-2;Middle east respiratory syndrome coronavirus N3 gene RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) N3 gene RNA [Presence] in Specimen by NAA with probe detection;MERS-CoV N3 RNA Spec Ql NAA+probe;;ACTIVE;2.46;2.69 +74473-0;Middle east respiratory syndrome coronavirus N2 gene RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) N2 gene RNA [Presence] in Specimen by NAA with probe detection;MERS-CoV N2 RNA Spec Ql NAA+probe;;ACTIVE;2.46;2.69 +74474-8;Middle east respiratory syndrome coronavirus upE gene RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) upE gene RNA [Presence] in Specimen by NAA with probe detection;MERS-CoV upE RNA Spec Ql NAA+probe;;ACTIVE;2.46;2.69 +74475-5;Middle east respiratory syndrome coronavirus RNA;Imp;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Interpretation] in Specimen Qualitative by NAA with probe detection;MERS-CoV RNA Spec NAA+probe-Imp;;ACTIVE;2.46;2.69 +7447-6;Lactoglobulin Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lactoglobulin IgG Ab [Units/volume] in Serum;Lactoglob IgG Qn;;ACTIVE;1.0h(2);2.69 +74476-3;Setting;Find;Pt;Clinical document;Nom;LOINC Document Ontology;DOC.MISC;2;Clinical document Setting from LOINC Document Ontology;Clin Doc Setting LOINC DocOnt;;ACTIVE;2.46;2.46 +74477-1;Kind of document;Find;Pt;Clinical document;Nom;LOINC Document Ontology;DOC.MISC;2;Clinical document Kind of document from LOINC Document Ontology;Clin Doc KOD LOINC DocOnt;;ACTIVE;2.46;2.46 +74478-9;Type of service;Find;Pt;Clinical document;Nom;LOINC Document Ontology;DOC.MISC;2;Clinical document Type of service from LOINC Document Ontology;Clin Doc TOS LOINC DocOnt;;ACTIVE;2.46;2.46 +74479-7;Role;Find;Pt;Clinical document;Nom;LOINC Document Ontology;DOC.MISC;2;Clinical document Role from LOINC Document Ontology;Clin Doc Role LOINC DocOnt;;ACTIVE;2.46;2.46 +74480-5;Subject matter domain;Find;Pt;Clinical document;Nom;LOINC Document Ontology;DOC.MISC;2;Clinical document Subject matter domain from LOINC Document Ontology;Clin Doc SMD LOINC DocOnt;;ACTIVE;2.46;2.46 +74481-3;Tyrosine/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Tyrosine/Phenylalanine [Molar ratio] in DBS;Tyrosine/Phe DBS-sRto;;ACTIVE;2.46;2.61 +74482-1;Reason for unsatisfactory specimen not related to sample quality of dried blood spot;Type;Pt;Bld.dot;Nom;;SPEC;1;Reason for unsatisfactory specimen not related to sample quality of dried blood spot;Rsn unsat spec not quality DBS;;ACTIVE;2.46;2.73 +74483-9;Homocitrulline;SCnc;Pt;Urine;Qn;;CHEM;1;Homocitrulline [Moles/volume] in Urine;Homocitrulline Ur-sCnc;;ACTIVE;2.46;2.46 +7448-4;Lamb Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lamb IgG Ab [Units/volume] in Serum;Lamb IgG Qn;;ACTIVE;1.0h(2);2.73 +74484-7;Argininosuccinate;SCnc;Pt;Urine;Qn;;CHEM;1;Argininosuccinate [Moles/volume] in Urine;Argininosuccinate Ur-sCnc;;ACTIVE;2.46;2.46 +74485-4;CD3 & CD20 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;CD3 and CD20 Ag [Identifier] in Tissue by Immune stain;CD3+CD20 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74486-2;Cytokeratin 5 & p63 & Cytokeratin AE1 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;Cytokeratin 5 and p63 and Cytokeratin AE1 Ag [Identifier] in Tissue by Immune stain;CK5+p63+CK AE1 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74487-0;P504S & p63 & Cytokeratin 903 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;P504S and p63 and Cytokeratin 903 Ag [Identifier] in Tissue by Immune stain;P504S+p63+CK903 Ag Tiss ImStn;;ACTIVE;2.48;2.73 +74488-8;p63 & Smooth muscle myosin heavy chain & Cytokeratin 8 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;p63 and Smooth muscle myosin heavy chain and Cytokeratin 8 Ag [Identifier] in Tissue by Immune stain;p63 + SM-MHC + CK8 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74489-6;Melan-A & Ki67 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;Melan-A and Ki67 Ag [Identifier] in Tissue by Immune stain;Melan-A+Ki67 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74490-4;PAX5 & BCL2 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;PAX5 and BCL2 Ag [Identifier] in Tissue by Immune stain;PAX5+BCL2 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74491-2;Cytokeratin 7 & Thyroid transcription factor 1 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;Cytokeratin 7 and Thyroid transcription factor 1 Ag [Identifier] in Tissue by Immune stain;CK7+TTF-1 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +7449-2;Lamb basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Lamb triggered histamine release [Units/volume] in Blood;Lamb BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74492-0;PAX5 & CD43 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;PAX5 and CD43 Ag [Identifier] in Tissue by Immune stain;PAX5+CD43 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74493-8;PAX5 & CD5 Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;PAX5 and CD5 Ag [Identifier] in Tissue by Immune stain;PAX5+CD5 Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74494-6;CD34 & Coagulation factor XIII Ag;Prid;Pt;Tiss;Nom;Immune stain;PATH;1;CD34 and Coagulation factor XIII Ag [Identifier] in Tissue by Immune stain;CD34+Fac XIII Ag Tiss ImStn;;ACTIVE;2.48;2.48 +74495-3;Patient safety event report - hospital - healthcare event reporting form - version 1.2;-;Pt;^Patient;-;AHRQ;PANEL.SURVEY.AHRQ;4;Patient safety event report - hospital - healthcare event reporting form (HERF) - version 1.2 [AHRQ];;;ACTIVE;2.48;2.54 +74496-1;Injury location ICD code;Type;Pt;^Patient;Nom;;TRAUMA;2;Injury location ICD code;Injury Loc ICD;;ACTIVE;2.48;2.63 +74497-9;Medical examiner or coroner was contacted;Find;Pt;^Patient;Ord;US standard certificate of death;SURVEY.CDC;4;Medical examiner or coroner was contacted [US Standard Certificate of Death];;;ACTIVE;2.48;2.48 +74498-7;Autopsy or histological placental examination results were used;Find;Pt;^Patient;Ord;US standard report of fetal death;SURVEY.CDC;4;Autopsy or histological placental examination results were used [US Standard Report of Fetal Death];;;ACTIVE;2.48;2.48 +74499-5;Death pronouncer;Find;Pt;Provider;Doc;;SURVEY.CDC;4;Death pronouncer details;;;ACTIVE;2.48;2.63 +74-5;Cefatrizine;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefatrizine [Susceptibility] by Serum bactericidal titer;Cefatrizine Titr SBT;;ACTIVE;1.0;2.32 +745-0;Myeloblasts;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Myeloblasts [#/volume] in Blood by Automated count;Deprecated Myeloblasts # Bld Auto;;DEPRECATED;1.0;2.4 +7450-0;Chenopodium album basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Goosefoot triggered histamine release [Units/volume] in Blood;Goosefoot BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74500-0;Age at time of event;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Age at time of event [AHRQ];;;ACTIVE;2.48;2.48 +74501-8;Patient safety event report - hospital - summary of initial report - version 1.2;-;Pt;^Patient;-;AHRQ;PANEL.SURVEY.AHRQ;4;Patient safety event report - hospital - summary of initial report (SIR) - version 1.2 [AHRQ];;;ACTIVE;2.48;2.54 +74502-6;Patient safety event report - hospital - patient information form - version 1.2;-;Pt;^Patient;-;AHRQ;PANEL.SURVEY.AHRQ;4;Patient safety event report - hospital - patient information form (PIF) - version 1.2 [AHRQ];;;ACTIVE;2.48;2.54 +74503-4;16-Beta,18-dihydroxydehydroepiandrosterone;SCnc;Pt;Urine;Qn;;CHEM;1;16-Beta,18-dihydroxydehydroepiandrosterone [Moles/volume] in Urine;16B,18-diOH-DHEA Ur-sCnc;;ACTIVE;2.48;2.56 +74504-2;16-Beta,18-dihydroxydehydroepiandrosterone;SCnc;24H;Urine;Qn;;CHEM;1;16-Beta,18-dihydroxydehydroepiandrosterone [Moles/volume] in 24 hour Urine;16B,18-diOH-DHEA 24h Ur-sCnc;;ACTIVE;2.48;2.56 +74505-9;16-Beta,18-dihydroxydehydroepiandrosterone;SRat;24H;Urine;Qn;;CHEM;1;16-Beta,18-dihydroxydehydroepiandrosterone [Moles/time] in 24 hour Urine;16B,18-diOH-DHEA 24h Ur-sRate;;ACTIVE;2.48;2.56 +74506-7;16-Alpha hydroxypregnenolone;SRat;24H;Urine;Qn;;CHEM;1;16-Alpha hydroxypregnenolone [Moles/time] in 24 hour Urine;16A OH-Preg 24h Ur-sRate;;ACTIVE;2.48;2.48 +74507-5;16-Alpha hydroxypregnenolone;SCnc;Pt;Urine;Qn;;CHEM;1;16-Alpha hydroxypregnenolone [Moles/volume] in Urine;16A OH-Preg Ur-sCnc;;ACTIVE;2.48;2.48 +74508-3;16-Alpha hydroxypregnenolone;SCnc;24H;Urine;Qn;;CHEM;1;16-Alpha hydroxypregnenolone [Moles/volume] in 24 hour Urine;16A OH-Preg 24h Ur-sCnc;;ACTIVE;2.48;2.48 +74509-1;3-Hydroxydecanoylcarnitine (C10-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in Serum or Plasma;3-OH-decanoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74510-9;3-Hydroxyeicosanoylcarnitine (C20-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyeicosanoylcarnitine (C20-OH) [Moles/volume] in Serum or Plasma;3-OH-eicosanoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74511-7;COMT gene.c.1947G>A;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;COMT gene c.1947G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal;COMT c.1947G>A Geno Bld/T;;ACTIVE;2.48;2.68 +74512-5;Chemokine (C-C motif) ligand 18;MCnc;Pt;Ser;Qn;;CHEM;1;Chemokine (C-C motif) ligand 18 [Mass/volume] in Serum;CCL18 Ser-mCnc;;ACTIVE;2.48;2.48 +74513-3;Alpha tocopherol;EntSub;Pt;RBC;Qn;;CHEM;1;Alpha tocopherol [Entitic substance] in Red Blood Cells;A-Tocopherol Vit E EntSub RBC;;ACTIVE;2.48;2.48 +74514-1;Amino acids panel;SCnc;Pt;Urine;Qn;;PANEL.CHEM;1;Amino acids panel [Moles/volume] - Urine;Amino acids Pnl Ur-sCnc;;ACTIVE;2.48;2.48 +74515-8;Bile acid;SCnt;24H;Stool;Qn;;CHEM;1;Bile acid [Moles/mass] in 24 hour Stool;Bile Ac 24h Stl-sCnt;;ACTIVE;2.48;2.48 +74516-6;Calcium;SCnc;Pt;Saliva;Qn;;CHEM;1;Calcium [Moles/volume] in Saliva (oral fluid);Calcium Sal-sCnc;;ACTIVE;2.48;2.48 +74517-4;Cholesterol sulfate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol sulfate [Moles/volume] in Serum or Plasma;Cholest Sulf SerPl-sCnc;;ACTIVE;2.48;2.48 +7451-8;Latex ALK basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Latex ALK triggered histamine release [Units/volume] in Blood;Ltx ALK BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74518-2;Clara cell protein 16;MCnc;Pt;Ser;Qn;;CHEM;1;Clara cell protein 16 [Mass/volume] in Serum;CC16 Ser-mCnc;;ACTIVE;2.48;2.48 +74519-0;Complement activity panel;-;Pt;Ser;-;;PANEL.HEM/BC;1;Complement activity panel - Serum;Comp activity Pnl Ser;;ACTIVE;2.48;2.54 +74520-8;Complement alternate pathway AH50 actual/normal;RelACnc;Pt;Ser;Qn;IA;HEM/BC;1;Complement alternate pathway AH50 actual/normal in Serum by Immunoassay;AH50 Act/Nor Ser IA;;ACTIVE;2.48;2.73 +74521-6;Complement total hemolytic CH50 actual/normal;RelACnc;Pt;Ser;Qn;IA;HEM/BC;1;Complement total hemolytic CH50 actual/normal in Serum by Immunoassay;CH50 Act/Nor Ser IA;;ACTIVE;2.48;2.58 +74522-4;Complement lectin pathway actual/normal;RelACnc;Pt;Ser;Qn;IA;HEM/BC;1;Complement lectin pathway actual/normal in Serum by Immunoassay;Comp activity.lectin Act/Nor Ser IA;;ACTIVE;2.48;2.56 +74523-2;Nonanoylcarnitine (C9);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Nonanoylcarnitine (C9) [Moles/volume] in Serum or Plasma;Nonanoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74524-0;Decatrienoylcarnitine (C10:3);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decatrienoylcarnitine (C10:3) [Moles/volume] in Serum or Plasma;Decatrienoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74525-7;Dehydrosebacylcarnitine (C10:1-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dehydrosebacylcarnitine (C10:1-DC) [Moles/volume] in Serum or Plasma;Dehydrosebacylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +7452-6;Latex Bencard basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Latex Bencard triggered histamine release [Units/volume] in Blood;Ltx Bencard BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74526-5;Delta aminolevulinate, porphobilinogen and creatinine panel;-;24H;Urine;-;;PANEL.CHEM;1;Delta aminolevulinate, porphobilinogen and creatinine panel - 24 hour Urine;D-ALA+PBG+creat Pnl 24h Ur;;ACTIVE;2.48;2.63 +74527-3;Delta aminolevulinate, porphobilinogen and creatinine panel;-;Pt;Urine;-;;PANEL.CHEM;1;Delta aminolevulinate, porphobilinogen and creatinine panel - Urine;D-ALA+PBG+creat Pnl Ur;;ACTIVE;2.48;2.48 +74528-1;Dicarboxyeicosanoylcarnitine (C20-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxyeicosanoylcarnitine (C20-DC) [Moles/volume] in Serum or Plasma;Dicarboxyeicosanoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74529-9;Dicarboxyhexenoylcarnitine (C6:1-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxyhexenoylcarnitine (C6:1-DC) [Moles/volume] in Serum or Plasma;Dicarboxyhexenoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74530-7;Dicarboxypalmitoleylcarnitine (C16:1-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxypalmitoleylcarnitine (C16:1-DC) [Moles/volume] in Serum or Plasma;Dicarboxypalmitoleylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74531-5;Dicarboxytetradecanoylcarnitine (C14-DC);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dicarboxytetradecanoylcarnitine (C14-DC) [Moles/volume] in Serum or Plasma;Dicarboxytetradecanoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74532-3;Energy content;EngCnt;24H;Stool.wet;Qn;;SPEC;1;Energy content [Energy/mass] of 24 hour Stool.wet;Energy content 24h Stool.wet;;ACTIVE;2.48;2.48 +74533-1;Fatty acid oxidation panel;-;Pt;Fibroblasts;-;;PANEL.CHEM;1;Fatty acid oxidation panel - Fibroblast;Fatty acid oxidation Pnl Fib;;ACTIVE;2.54;2.54 +7453-4;Latex Greer basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Latex Greer triggered histamine release [Units/volume] in Blood;Ltx Greer BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74534-9;Neisseria meningitidis serogroup Y DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup Y DNA [Presence] in Specimen by NAA with probe detection;N men sg Y DNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74535-6;Neisseria meningitidis serogroup X DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup X DNA [Presence] in Specimen by NAA with probe detection;N men sg X DNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74536-4;Neisseria meningitidis serogroup w135 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup w135 DNA [Presence] in Specimen by NAA with probe detection;N men sg W135 DNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74537-2;Neisseria meningitidis serogroup C DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup C DNA [Presence] in Specimen by NAA with probe detection;N men sg C DNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74538-0;Neisseria meningitidis serogroup B DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup B DNA [Presence] in Specimen by NAA with probe detection;N men sg B DNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74539-8;Neisseria meningitidis serogroup A DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup A DNA [Presence] in Specimen by NAA with probe detection;N men sg A DNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74540-6;Hexenoylcarnitine (C6:1);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexenoylcarnitine (C6:1) [Moles/volume] in Serum or Plasma;Hexenoylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74541-4;Surfactant pulmonary-associated protein D;MCnc;Pt;Ser;Qn;;CHEM;1;Surfactant pulmonary-associated protein D [Mass/volume] in Serum;SFTPD Ser-mCnc;;ACTIVE;2.48;2.48 +7454-2;Latex Stallerg basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Latex Stallerg triggered histamine release [Units/volume] in Blood;Ltx Stallerg BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74542-2;Pyruvate kinase/Glucose-6-Phosphate dehydrogenase;CRto;Pt;RBC;Qn;;CHEM;1;Pyruvate kinase/Glucose-6-Phosphate dehydrogenase [Enzymatic activity ratio] in Red Blood Cells;PK/G6PD RBC-cRto;;ACTIVE;2.48;2.48 +74544-8;Tocopherols;EntSub;Pt;RBC;Qn;;CHEM;1;Tocopherols [Entitic substance] in Red Blood Cells;Tocopherols EntSub RBC;;ACTIVE;2.48;2.48 +74545-5;Tryptophan-related indole profiling panel;-;Pt;PRP;-;;PANEL.CHEM;1;Tryptophan-related indole profiling panel - Platelet rich plasma;Tryp-related indole profile pnl PRP;;ACTIVE;2.48;2.48 +74546-3;Reporter job or position;Type;Pt;^Event;Nom;;SURVEY.AHRQ;4;Reporter job or position;;;ACTIVE;2.48;2.48 +74547-1;Reporter email;EmailAddr;Pt;^Event;Nom;;SURVEY.AHRQ;4;Reporter email;;;ACTIVE;2.48;2.48 +74548-9;Reporter phone number;Tele;Pt;^Event;Nom;;SURVEY.AHRQ;4;Reporter phone number;;;ACTIVE;2.48;2.48 +74549-7;Reporter of adverse event or unsafe condition;Pn;Pt;^Event;Nom;;SURVEY.AHRQ;4;Reporter of adverse event or unsafe condition;;;ACTIVE;2.48;2.48 +74550-5;Anonymous reporter;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Anonymous reporter [AHRQ];;;ACTIVE;2.48;2.48 +74551-3;Perinatal incident that affected a neonate;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Perinatal incident that affected a neonate [AHRQ];;;ACTIVE;2.48;2.48 +74552-1;Categories associated with patient safety event or unsafe condition;Find;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Categories associated with patient safety event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.48 +74553-9;Location of patient safety event or unsafe condition;Find;Pt;^Event;Nar;AHRQ;SURVEY.AHRQ;4;Location of patient safety event or unsafe condition - Narrative [AHRQ];;;ACTIVE;2.48;2.48 +74554-7;Description of patient safety event or unsafe condition;Find;Pt;^Event;Nar;AHRQ;SURVEY.AHRQ;4;Description of patient safety event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.48 +74555-4;Event discovery date & time;TmStp;Pt;^Event;Qn;;SURVEY.AHRQ;4;Event discovery date and time;;;ACTIVE;2.48;2.48 +74556-2;Family or guardian was notified;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Family or guardian was notified [AHRQ];;;ACTIVE;2.48;2.48 +74557-0;Increased length of stay due to incident;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Increased length of stay due to incident [AHRQ];;;ACTIVE;2.48;2.48 +74558-8;Timing of harm assessment;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Timing of harm assessment [AHRQ];;;ACTIVE;2.48;2.48 +7455-9;Citrus limon Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lemon IgG Ab [Units/volume] in Serum;Lemon IgG Qn;;ACTIVE;1.0h(2);2.73 +74559-6;Anticipated duration of harm to the patient;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Anticipated duration of harm to the patient [AHRQ];;;ACTIVE;2.48;2.48 +74560-4;Extent of harm to the patient;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Extent of harm to the patient [AHRQ];;;ACTIVE;2.48;2.48 +74561-2;Documented rescue interventions;Type;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Documented rescue interventions [AHRQ];;;ACTIVE;2.48;2.48 +74562-0;Rescue intervention was attempted;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Rescue intervention was attempted [AHRQ];;;ACTIVE;2.48;2.48 +74563-8;Incident preventability;Find;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Incident preventability [AHRQ];;;ACTIVE;2.48;2.48 +74564-6;National Quality Forum (NQF) serious reportable event;Type;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;National Quality Forum (NQF) serious reportable event [AHRQ];;;ACTIVE;2.48;2.48 +74565-3;Event was a National Quality Forum (NQF) serious reportable event;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Event was a National Quality Forum (NQF) serious reportable event [AHRQ];;;ACTIVE;2.48;2.48 +74566-1;Contributing factors for event;Find;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Contributing factors for event [AHRQ];;;ACTIVE;2.48;2.48 +7456-7;Citrus limon basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Lemon triggered histamine release [Units/volume] in Blood;Lemon BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74567-9;Contributing factors for event were known;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Contributing factors for event were known [AHRQ];;;ACTIVE;2.48;2.52 +74568-7;Event was associated with a handover;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Event was associated with a handover [AHRQ];;;ACTIVE;2.48;2.48 +74569-5;Action that prevented the near miss incident from reaching the patient;Find;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Action that prevented the near miss incident from reaching the patient [AHRQ];;;ACTIVE;2.48;2.48 +74570-3;Additional details of event or unsafe condition;Find;Pt;^Event;Nar;AHRQ;SURVEY.AHRQ;4;Additional details of event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.48 +74571-1;Healthcare professional;Type;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Healthcare professional type [AHRQ];;;ACTIVE;2.48;2.48 +74572-9;Reporter of adverse event or unsafe condition;Type;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Reporter of adverse event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.48 +74573-7;Location of patient safety event or unsafe condition;Type;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Location of patient safety event or unsafe condition - Nominal [AHRQ];;;ACTIVE;2.48;2.48 +74574-5;Macroscopic observation;Imp;Pt;XXX;Nar;;MICRO;1;Macroscopic observation [Interpretation] in Specimen Narrative;Macroscopic obs Spec-Imp;;ACTIVE;2.48;2.69 +7457-5;Atriplex lentiformis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Lenscale IgE Ab [Units/volume] in Serum;Deprecated Lenscale IgE Qn;;DEPRECATED;1.0h(2);2.69 +74575-2;Pyruvate dehydrogenase E1;CCnt;Pt;Tiss;Qn;;CHEM;1;Pyruvate dehydrogenase E1 [Enzymatic activity/mass] in Tissue;PDH E1 Tiss-cCnt;;ACTIVE;2.48;2.48 +74576-0;Tripeptidyl peptidase I;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Tripeptidyl peptidase I [Enzymatic activity/mass] in Fibroblast;Tripeptidyl peptidase I Fib-cCnt;;ACTIVE;2.48;2.48 +74577-8;Pyruvate dehydrogenase complex;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Pyruvate dehydrogenase complex [Enzymatic activity/mass] in Fibroblast;PDC Fib-cCnt;;ACTIVE;2.48;2.48 +74578-6;Pyruvate dehydrogenase complex;CCnt;Pt;Tiss;Qn;;CHEM;1;Pyruvate dehydrogenase complex [Enzymatic activity/mass] in Tissue;PDC Tiss-cCnt;;ACTIVE;2.48;2.48 +74579-4;Pyruvate dehydrogenase E1;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Pyruvate dehydrogenase E1 [Enzymatic activity/mass] in Fibroblast;PDH E1 Fib-cCnt;;ACTIVE;2.48;2.48 +74580-2;Fumarase;CCnt;Pt;Tiss;Qn;;CHEM;1;Fumarase [Enzymatic activity/mass] in Tissue;Fumarase Tiss-cCnt;;ACTIVE;2.48;2.48 +74581-0;Fumarase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Fumarase [Enzymatic activity/mass] in Fibroblast;Fumarase Fib-cCnt;;ACTIVE;2.48;2.48 +74582-8;Fatty acids.very long chain.C26:0/C22:0;MRto;Pt;Fibroblasts;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate)/C22:0 (Docosanoate) [Mass Ratio] in Fibroblast;VLCFA C26:0/C22:0 Fib;;ACTIVE;2.48;2.48 +7458-3;Lens esculenta Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lentils IgE Ab [Units/volume] in Serum;Lentils IgE Qn;;ACTIVE;1.0h(2);2.73 +74583-6;Fatty acids.very long chain.C24:0/C22:0;MRto;Pt;Fibroblasts;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate)/C22:0 (Docosanoate) [Mass Ratio] in Fibroblast;VLCFA C24:0/C22:0 Fib;;ACTIVE;2.48;2.48 +74584-4;Cytochrome C oxidase/Citrate synthase;CRto;Pt;Tiss;Qn;;CHEM;1;Cytochrome C oxidase/Citrate synthase [Enzymatic activity ratio] in Tissue;CyC Oxidase/Cit Syn Tiss-cRto;;ACTIVE;2.48;2.48 +74585-1;Coenzyme Q cytochrome C reductase/Citrate synthase;CRto;Pt;Tiss;Qn;;CHEM;1;Coenzyme Q cytochrome C reductase (Complex III)/Citrate synthase [Enzymatic activity ratio] in Tissue;CoQ CyC Reduct/Cit Syn Tiss-cRto;;ACTIVE;2.48;2.48 +74586-9;Coenzyme Q cytochrome C reductase;CCnt;Pt;Tiss;Qn;;CHEM;1;Coenzyme Q cytochrome C reductase (Complex III) [Enzymatic activity/mass] in Tissue;CoQ CyC Reduct Tiss-cCnt;;ACTIVE;2.48;2.48 +74587-7;Succinate cytochrome C reductase/Citrate synthase;CRto;Pt;Tiss;Qn;;CHEM;1;Succinate cytochrome C reductase/Citrate synthase [Enzymatic activity ratio] in Tissue;Succinate CyC Reduct/Cit Syn Tiss-cRto;;ACTIVE;2.48;2.48 +74588-5;Succinate cytochrome C reductase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Succinate cytochrome C reductase [Enzymatic activity/mass] in Fibroblast;Succinate CyC Reduct Fib-cCnt;;ACTIVE;2.48;2.48 +74589-3;Succinate dehydrogenase/Citrate synthase;CRto;Pt;Tiss;Qn;;CHEM;1;Succinate dehydrogenase/Citrate synthase [Enzymatic activity ratio] in Tissue;Succinate Dehydrog/Cit Syn Tiss-cRto;;ACTIVE;2.48;2.48 +74590-1;NADH cytochrome C reductase/Citrate synthase;CRto;Pt;Tiss;Qn;;CHEM;1;NADH cytochrome C reductase/Citrate synthase [Enzymatic activity ratio] in Tissue;NADH CyC Reduct/Cit Syn Tiss-cRto;;ACTIVE;2.48;2.48 +7459-1;Lens esculenta Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lentils IgG Ab [Units/volume] in Serum;Lentils IgG Qn;;ACTIVE;1.0h(2);2.69 +74591-9;Suberylcarnitine (C8-DC);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Suberylcarnitine (C8-DC) [Enzymatic activity/mass] in Fibroblast;Suberylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74592-7;Octanoylcarnitine (C8);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Octanoylcarnitine (C8) [Enzymatic activity/mass] in Fibroblast;Octanoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74593-5;Adipoylcarnitine (C6-DC);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Adipoylcarnitine (C6-DC) [Enzymatic activity/mass] in Fibroblast;Adipoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74594-3;Hexanoylcarnitine (C6);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Hexanoylcarnitine (C6) [Enzymatic activity/mass] in Fibroblast;Hexanoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74595-0;3-Hydroxybutyrylcarnitine (C4-OH);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Hydroxybutyrylcarnitine (C4-OH) [Enzymatic activity/mass] in Fibroblast;3OH-Butyrcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74596-8;Butyrylcarnitine (C4);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Butyrylcarnitine (C4) [Enzymatic activity/mass] in Fibroblast;Butyrylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74597-6;3-Hydroxypalmitoylcarnitine (C16-OH);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Hydroxypalmitoylcarnitine (C16-OH) [Enzymatic activity/mass] in Fibroblast;3OH-Palmitoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74598-4;Dicarboxypalmitoylcarnitine (C16-DC);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Dicarboxypalmitoylcarnitine (C16-DC) [Enzymatic activity/mass] in Fibroblast;Dicarboxypalmitoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74599-2;3-Hydroxypalmitoleylcarnitine (C16:1-OH);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Enzymatic activity/mass] in Fibroblast;3OH-Palmitoleylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74600-8;Palmitoleylcarnitine (C16:1);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Palmitoleylcarnitine (C16:1) [Enzymatic activity/mass] in Fibroblast;Palmitoleylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74601-6;Palmitoylcarnitine (C16);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Palmitoylcarnitine (C16) [Enzymatic activity/mass] in Fibroblast;Palmitoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74602-4;3-Hydroxytetradecanoylcarnitine (C14-OH);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Hydroxytetradecanoylcarnitine (C14-OH) [Enzymatic activity/mass] in Fibroblast;3OH-Tdecanoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74603-2;Tetradecadienoylcarnitine (C14:2);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Tetradecadienoylcarnitine (C14:2) [Enzymatic activity/mass] in Fibroblast;Tdecadienoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74604-0;3-Hydroxymyristoleylcarnitine (C14:1-OH);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Hydroxymyristoleylcarnitine (C14:1-OH) [Enzymatic activity/mass] in Fibroblast;3OH-myristoleylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74605-7;Tetradecenoylcarnitine (C14:1);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1) [Enzymatic activity/mass] in Fibroblast;Tdecenoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74606-5;Tetradecanoylcarnitine (C14);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Tetradecanoylcarnitine (C14) [Enzymatic activity/mass] in Fibroblast;Tdecanoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74607-3;Dodecenoylcarnitine (C12:1);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Dodecenoylcarnitine (C12:1) [Enzymatic activity/mass] in Fibroblast;Dodecenoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74608-1;Dodecanoylcarnitine (C12);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Dodecanoylcarnitine (C12) [Enzymatic activity/mass] in Fibroblast;Dodecanoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +7460-9;Lactuca sativa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lettuce IgG Ab [Units/volume] in Serum;Lettuce IgG Qn;;ACTIVE;1.0h(2);2.73 +74609-9;Sebacylcarnitine (C10-DC);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Sebacylcarnitine (C10-DC) [Enzymatic activity/mass] in Fibroblast;Sebacylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74610-7;Decadienoylcarnitine (C10:2);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Decadienoylcarnitine (C10:2) [Enzymatic activity/mass] in Fibroblast;Decadienoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74611-5;Decenoylcarnitine (C10:1);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Decenoylcarnitine (C10:1) [Enzymatic activity/mass] in Fibroblast;Decenoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74612-3;Decanoylcarnitine (C10);CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Decanoylcarnitine (C10) [Enzymatic activity/mass] in Fibroblast;Decanoylcarn Fib-cCnt;;DISCOURAGED;2.48;2.5 +74613-1;Fatty acids.very long chain.C24:0;MCnt;Pt;Fibroblasts;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate) [Mass/mass] in Fibroblast;VLCFA C24:0 Fib-mCnt;;ACTIVE;2.48;2.48 +74614-9;Fatty acids.very long chain.C26:0;MCnt;Pt;Fibroblasts;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate) [Mass/mass] in Fibroblast;VLCFA C26:0 Fib-mCnt;;ACTIVE;2.48;2.48 +74615-6;Fatty acids.very long chain.C22:0;MCnt;Pt;Fibroblasts;Qn;;CHEM;1;Fatty acids.very long chain C22:0 (Docosanoate) [Mass/mass] in Fibroblast;VLCFA C22:0 Fib-mCnt;;ACTIVE;2.48;2.48 +74616-4;1,1-Dimethoxyoctadecane/octadecanoate;MRto;Pt;Fibroblasts;Qn;;CHEM;1;1,1-Dimethoxyoctadecane (DMA 18:0)/Octadecanoate (C18:0) [Mass Ratio] in Fibroblast;DMA 18:0/C18:0 Fib;;ACTIVE;2.48;2.48 +7461-7;Lactuca sativa basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Lettuce triggered histamine release [Units/volume] in Blood;Lettuce BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74617-2;1,1-Dimethoxyoctadecane/octadecanoate;SRto;Pt;RBC;Qn;;CHEM;1;1,1-Dimethoxyoctadecane (DMA 18:0)/Octadecanoate (C18:0) [Molar ratio] in Red Blood Cells;DMA 18:0/C18:0 RBC-sRto;;ACTIVE;2.48;2.48 +74618-0;1,1-Dimethoxyoctadecane;MCnt;Pt;Fibroblasts;Qn;;CHEM;1;1,1-Dimethoxyoctadecane (DMA 18:0) [Mass/mass] in Fibroblast;DMA 18:0 Fib-mCnt;;ACTIVE;2.48;2.48 +74619-8;1,1-Dimethoxyoctadecane;SCnt;Pt;RBC;Qn;;CHEM;1;1,1-Dimethoxyoctadecane (DMA 18:0) [Moles/mass] in Red Blood Cells;DMA 18:0 RBC-sCnt;;ACTIVE;2.48;2.66 +74620-6;1,1-Dimethoxy-(9Z)octadecene/oleate;MRto;Pt;Fibroblasts;Qn;;CHEM;1;1,1-Dimethoxy-(9Z)octadecene (DMA 18:1)/Oleate (C18:1w9) [Mass Ratio] in Fibroblast;DMA 18:1/Oleate Fib;;ACTIVE;2.48;2.48 +74621-4;1,1-Dimethoxy-(9Z)octadecene/oleate;SRto;Pt;RBC;Qn;;CHEM;1;1,1-Dimethoxy-(9Z)octadecene (DMA 18:1)/Oleate (C18:1w9) [Molar ratio] in Red Blood Cells;DMA 18:1/Oleate RBC-sRto;;ACTIVE;2.48;2.48 +74622-2;1,1-Dimethoxy-(9Z)octadecene;MCnt;Pt;Fibroblasts;Qn;;CHEM;1;1,1-Dimethoxy-(9Z)octadecene (DMA 18:1) [Mass/mass] in Fibroblast;DMA 18:1 Fib-mCnt;;ACTIVE;2.48;2.48 +74623-0;1,1-Dimethoxy-(9Z)octadecene;SCnt;Pt;RBC;Qn;;CHEM;1;1,1-Dimethoxy-(9Z)octadecene (DMA 18:1) [Moles/mass] in Red Blood Cells;DMA 18:1 RBC-sCnt;;ACTIVE;2.48;2.66 +74624-8;1,1-Dimethoxyhexadecane/palmitate;MRto;Pt;Fibroblasts;Qn;;CHEM;1;1,1-Dimethoxyhexadecane (DMA 16:0)/palmitate (C16:0) [Mass Ratio] in Fibroblast;DMA 16:0/C16:0 Fib;;ACTIVE;2.48;2.48 +7462-5;Glycyrrhiza lepidota Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Licorice IgE Ab [Units/volume] in Serum;Licorice IgE Qn;;ACTIVE;1.0h(2);2.73 +74625-5;1,1-Dimethoxyhexadecane/palmitate;SRto;Pt;RBC;Qn;;CHEM;1;1,1-Dimethoxyhexadecane (DMA 16:0)/palmitate (C16:0) [Molar ratio] in Red Blood Cells;DMA 16:0/C16:0 RBC-sRto;;ACTIVE;2.48;2.48 +74626-3;1,1-Dimethoxyhexadecane;MCnt;Pt;Fibroblasts;Qn;;CHEM;1;1,1-Dimethoxyhexadecane (DMA 16:0) [Mass/mass] in Fibroblast;DMA 16:0 Fib-mCnt;;ACTIVE;2.48;2.48 +74627-1;1,1-Dimethoxyhexadecane;SCnt;Pt;RBC;Qn;;CHEM;1;1,1-Dimethoxyhexadecane (DMA 16:0) [Moles/mass] in Red Blood Cells;DMA 16:0 RBC-sCnt;;ACTIVE;2.48;2.66 +74628-9;Adipoylcarnitine (C6-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Adipoylcarnitine (C6-DC) [Moles/volume] in DBS;Adipoylcarn DBS-sCnc;;ACTIVE;2.48;2.61 +74629-7;Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in Serum or Plasma;C4-DC+C5-OH SerPl-sCnc;;ACTIVE;2.48;2.48 +74630-5;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in Serum or Plasma;Malonyl+3OHbutyrylcarn SerPl-sCnc;;ACTIVE;2.48;2.48 +74631-3;Glycosaminoglycans/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Glycosaminoglycans/Creatinine [Ratio] in 24 hour Urine;GAG/Creat 24h Ur-Rto;;ACTIVE;2.48;2.48 +74632-1;Glycosaminoglycans;PrThr;24H;Urine;Ord;;CHEM;1;Glycosaminoglycans [Presence] in 24 hour Urine;GAG 24h Ur Ql;;ACTIVE;2.48;2.56 +7463-3;Lilium longiflorum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Easter lily IgE Ab [Units/volume] in Serum;Easter lily IgE Qn;;ACTIVE;1.0h(2);2.42 +74633-9;Dimethylacetal panel;-;Pt;Fibroblasts;-;;PANEL.CHEM;1;Dimethylacetal (DMA) panel - Fibroblast;DMA Pnl Fib;;ACTIVE;2.48;2.5 +74634-7;Dimethylacetal panel;-;Pt;RBC;-;;PANEL.CHEM;1;Dimethylacetal (DMA) panel - Red Blood Cells;DMA Pnl RBC;;ACTIVE;2.48;2.5 +74635-4;Bacterial vaginosis DNA panel;-;Pt;Vag;-;Probe.amp.tar;PANEL.MICRO;1;Bacterial vaginosis DNA panel - Vaginal fluid by NAA with probe detection;BV DNA Pnl Vag NAA+probe;;ACTIVE;2.48;2.73 +74636-2;Protein.monoclonal band 3;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 3 [Mass/time] in 24 hour Urine by Electrophoresis;M Protein 3 24h Ur Elph-mRate;;ACTIVE;2.48;2.73 +74637-0;Protein.monoclonal band 2;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 2 [Mass/time] in 24 hour Urine by Electrophoresis;M Protein 2 24h Ur Elph-mRate;;ACTIVE;2.48;2.73 +74638-8;Monoclonal band 3 observed;Prid;Pt;Urine;Nom;Immunofixation;CHEM;1;Monoclonal band 3 observed [Identifier] in Urine by Immunofixation;Monoclon Band 3 Obs Ur IFE;;ACTIVE;2.48;2.48 +74639-6;Monoclonal band 2 observed;Prid;Pt;Urine;Nom;Immunofixation;CHEM;1;Monoclonal band 2 observed [Identifier] in Urine by Immunofixation;Monoclon Band 2 Obs Ur IFE;;ACTIVE;2.48;2.48 +74640-4;Monoclonal band 3 observed;Prid;Pt;Ser/Plas;Nom;Immunofixation;CHEM;1;Monoclonal band 3 observed [Identifier] in Serum or Plasma by Immunofixation;Monoclon Band 3 Obs SerPl IFE;;ACTIVE;2.48;2.48 +7464-1;Citrus aurantifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lime IgE Ab [Units/volume] in Serum;Lime IgE Qn;;ACTIVE;1.0h(2);2.73 +74641-2;Monoclonal band 2 observed;Prid;Pt;Ser/Plas;Nom;Immunofixation;CHEM;1;Monoclonal band 2 observed [Identifier] in Serum or Plasma by Immunofixation;Monoclon Band 2 Obs SerPl IFE;;ACTIVE;2.48;2.48 +74642-0;1,3-Dichlorobenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1,3-Dichlorobenzene [Mass/volume] in Serum or Plasma;1,3DCB SerPl-mCnc;;ACTIVE;2.48;2.73 +74643-8;Aromatic solvents;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Aromatic solvents [Presence] in Urine;Arom Solvents Ur Ql;;ACTIVE;2.48;2.73 +74644-6;HYDROcodone;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;HYDROcodone [Presence] in Saliva (oral fluid) by Confirmatory method;HYDROcodone Sal Ql Cfm;;ACTIVE;2.48;2.73 +74645-3;HYDROmorphone;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;HYDROmorphone [Presence] in Saliva (oral fluid) by Confirmatory method;HYDROmorphone Sal Ql Cfm;;ACTIVE;2.48;2.73 +74646-1;Methamphetamine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Methamphetamine [Presence] in Saliva (oral fluid) by Confirmatory method;Methamphet Sal Ql Cfm;;ACTIVE;2.48;2.73 +74647-9;Methylenedioxyamphetamine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/volume] in Serum, Plasma or Blood;MDA SerPlBld-mCnc;;ACTIVE;2.48;2.73 +74648-7;Methylenedioxyamphetamine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Saliva (oral fluid) by Confirmatory method;MDA Sal Ql Cfm;;ACTIVE;2.48;2.73 +74649-5;Methylenedioxyethylamphetamine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;MDEA Sal Cfm-mCnc;;ACTIVE;2.48;2.73 +74650-3;Methylenedioxyethylamphetamine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Saliva (oral fluid) by Confirmatory method;MDEA Sal Ql Cfm;;ACTIVE;2.48;2.73 +74651-1;Methylenedioxymethamphetamine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;MDMA Sal Cfm-mCnc;;ACTIVE;2.48;2.73 +74652-9;Methylenedioxymethamphetamine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/volume] in Serum, Plasma or Blood;MDMA SerPlBld-mCnc;;ACTIVE;2.48;2.73 +74653-7;Methylenedioxymethamphetamine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Saliva (oral fluid) by Confirmatory method;MDMA Sal Ql Cfm;;ACTIVE;2.48;2.73 +74654-5;Morphine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Morphine [Presence] in Saliva (oral fluid) by Confirmatory method;Morphine Sal Ql Cfm;;ACTIVE;2.48;2.73 +74655-2;Norsertraline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norsertraline [Mass/volume] in Urine;Norsertraline Ur-mCnc;;ACTIVE;2.48;2.73 +74656-0;Opiates;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Opiates [Presence] in Saliva (oral fluid) by Confirmatory method;Opiates Sal Ql Cfm;;ACTIVE;2.48;2.73 +74657-8;oxyCODONE;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;oxyCODONE [Presence] in Saliva (oral fluid) by Confirmatory method;oxyCODONE Sal Ql Cfm;;ACTIVE;2.48;2.73 +7465-8;Citrus aurantifolia Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lime IgG Ab [Units/volume] in Serum;Lime IgG Qn;;ACTIVE;1.0h(2);2.73 +74658-6;oxyCODONE+Oxymorphone;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Saliva (oral fluid) by Confirmatory method;oxyCODONE+oxyMORphone Sal Ql Cfm;;ACTIVE;2.48;2.73 +74659-4;oxyMORphone;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;oxyMORphone [Presence] in Saliva (oral fluid) by Confirmatory method;oxyMORphone Sal Ql Cfm;;ACTIVE;2.48;2.73 +74660-2;Phencyclidine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Saliva (oral fluid) by Confirmatory method;PCP Sal Ql Cfm;;ACTIVE;2.48;2.73 +74661-0;Phosphatidylethanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Phosphatidylethanol [Mass/volume] in Blood;Peth Bld-mCnc;;ACTIVE;2.48;2.73 +74662-8;Sertraline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Sertraline [Mass/volume] in Urine;Sertraline Ur-mCnc;;ACTIVE;2.48;2.73 +74663-6;Zaleplon;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zaleplon [Mass/volume] in Urine;Zaleplon Ur-mCnc;;ACTIVE;2.48;2.73 +74664-4;Zolpidem;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Zolpidem [Mass/volume] in Blood;Zolpidem Bld-mCnc;;ACTIVE;2.48;2.73 +74665-1;Monoclonal band observed;Prid;Pt;Ser/Plas;Nom;Immunofixation;CHEM;1;Monoclonal band observed [Identifier] in Serum or Plasma by Immunofixation;Monoclon Band Obs SerPl IFE;;ACTIVE;2.48;2.48 +7466-6;Linen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Linen IgE Ab [Units/volume] in Serum;Linen IgE Qn;;ACTIVE;1.0h(2);2.42 +74666-9;Monoclonal band observed;Prid;Pt;Urine;Nom;Immunofixation;CHEM;1;Monoclonal band observed [Identifier] in Urine by Immunofixation;Monoclon Band Obs Ur IFE;;ACTIVE;2.48;2.73 +74667-7;Atopobium vaginae DNA;LnCnc;Pt;Vag;Qn;Probe.amp.tar;MICRO;1;Atopobium vaginae DNA [Log #/volume] in Vaginal fluid by NAA with probe detection;A vaginae DNA Vag NAA+probe-Log#;;ACTIVE;2.48;2.73 +74668-5;Gardnerella vaginalis DNA;LnCnc;Pt;Vag;Qn;Probe.amp.tar;MICRO;1;Gardnerella vaginalis DNA [Log #/volume] in Vaginal fluid by NAA with probe detection;G vaginalis DNA Vag NAA+probe-Log#;;ACTIVE;2.48;2.73 +74669-3;Lactobacillus sp DNA;LnCnc;Pt;Vag;Qn;Probe.amp.tar;MICRO;1;Lactobacillus sp DNA [Log #/volume] in Vaginal fluid by NAA with probe detection;Lactobacillus DNA Vag NAA+probe-Log#;;ACTIVE;2.48;2.73 +74670-1;Cocaine+Metabolites;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Cocaine+Metabolites [Presence] in Saliva (oral fluid) by Confirmatory method;Coc+Met Sal Ql Cfm;;ACTIVE;2.48;2.73 +74671-9;Cocaine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Saliva (oral fluid) by Confirmatory method;Cocaine Sal Ql Cfm;;ACTIVE;2.48;2.73 +74672-7;Carisoprodol+Meprobamate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Carisoprodol+Meprobamate [Mass/volume] in Urine;Carisoprodol+Meprob Ur-mCnc;;ACTIVE;2.48;2.73 +74673-5;Ethanol;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Ethanol [Presence] in Saliva (oral fluid) by Confirmatory method;Ethanol Sal Ql Cfm;;ACTIVE;2.48;2.73 +7467-4;Lipolase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lipolase IgE Ab [Units/volume] in Serum;Lipolase IgE Qn;;ACTIVE;1.0h(2);2.42 +74674-3;Chlorinated solvents;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chlorinated solvents [Presence] in Urine;Chlorinated solvents Ur Ql;;ACTIVE;2.48;2.73 +74675-0;Codeine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Codeine [Presence] in Saliva (oral fluid) by Confirmatory method;Codeine Sal Ql Cfm;;ACTIVE;2.48;2.73 +74676-8;Carbapenemase;Type;Pt;Isolate;Nom;Carbapenemase Nordmann-Poirel;MICRO;1;Carbapenemase [Type] in Isolate by Carba NP;Carbapenemase Islt;;ACTIVE;2.48;2.73 +74677-6;6-Monoacetylmorphine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Saliva (oral fluid) by Confirmatory method;6MAM Sal Ql Cfm;;ACTIVE;2.48;2.73 +74678-4;Carboxy tetrahydrocannabinol;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Saliva (oral fluid) by Confirmatory method;CarboxyTHC Sal Ql Cfm;;ACTIVE;2.48;2.73 +74679-2;Benzoylecgonine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Benzoylecgonine [Presence] in Saliva (oral fluid) by Confirmatory method;BZE Sal Ql Cfm;;ACTIVE;2.48;2.73 +746-8;Myeloblasts;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Myeloblasts [#/volume] in Blood by Manual count;Myeloblasts # Bld Manual;;ACTIVE;1.0;2.4 +74680-0;Amphetamine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Amphetamine [Presence] in Saliva (oral fluid) by Confirmatory method;Amphet Sal Ql Cfm;;ACTIVE;2.48;2.73 +74681-8;Amphetamines;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Amphetamines [Presence] in Saliva (oral fluid) by Confirmatory method;Amphetamines Sal Ql Cfm;;ACTIVE;2.48;2.73 +7468-2;Liver Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Liver IgE Ab [Units/volume] in Serum;Liver IgE Qn;;ACTIVE;1.0h(2);2.42 +74682-6;Trichloroethanol.free;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Trichloroethanol.free [Mass/volume] in Blood;TCOH.free Bld-mCnc;;ACTIVE;2.48;2.73 +74683-4;Ethyl sulfate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ethyl sulfate [Presence] in Urine by Confirmatory method;Ethyl sulfate Ur Ql Cfm;;ACTIVE;2.48;2.73 +74684-2;Carbon dioxide^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Serum or Plasma --post dialysis;CO2 p dialysis SerPl-sCnc;;ACTIVE;2.48;2.48 +74685-9;Sodium;SCnc;4H;Urine;Qn;;CHEM;1;Sodium [Moles/volume] in 4 hour Urine;Sodium 4h Ur-sCnc;;ACTIVE;2.48;2.48 +74686-7;Glucose;SRat;12H;Urine;Qn;;CHEM;1;Glucose [Moles/time] in 12 hour Urine;Glucose 12h Ur-sRate;;ACTIVE;2.48;2.48 +74687-5;Glucose;SCnc;12H;Urine;Qn;;CHEM;1;Glucose [Moles/volume] in 12 hour Urine;Glucose 12h Ur-sCnc;;ACTIVE;2.48;2.48 +74688-3;Sodium^post dialysis;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sodium [Moles/volume] in Serum or Plasma --post dialysis;Sodium p dialysis SerPl-sCnc;;ACTIVE;2.48;2.48 +74689-1;Nucleated cells;NCnc;Pt;Body fld;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Body fluid by Manual count;Nuc cell # Fld Manual;;ACTIVE;2.48;2.48 +7469-0;Liver calf Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Liver calf IgE Ab [Units/volume] in Serum;Liver Calf IgE Qn;;ACTIVE;1.0h(2);2.73 +74690-9;Weak D Ag;PrThr;Pt;RBCCo;Ord;;BLDBK;1;Weak D Ag [Presence] in Cord red blood cells;Weak D Ag RBCCo Ql;;ACTIVE;2.48;2.7 +74691-7;Round Cells;Naric;Pt;Semen;Qn;Microscopy.light.HPF;FERT;1;Round cells [#/area] in Semen by Microscopy high power field;Rnd Cells #/area Smn HPF;;ACTIVE;2.48;2.48 +74692-5;MT-ND6 gene.m.14459G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;MT-ND6 gene m.14459G>A [Presence] in Blood or Tissue by Molecular genetics method;MT-ND6 m.14459G>A Bld/T Ql;;ACTIVE;2.48;2.56 +74693-3;Race;Type;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Race [AHRQ];;;ACTIVE;2.48;2.48 +74694-1;Ethnicity;Type;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Ethnicity [AHRQ];;;ACTIVE;2.48;2.48 +74695-8;Nurse name;Pn;Pt;Provider;Nom;;CLIN;2;Nurse name;Nur Nm Provider;;ACTIVE;2.48;2.48 +74696-6;Magnesium;SCnc;12H;Urine;Qn;;CHEM;1;Magnesium [Moles/volume] in 12 hour Urine;Magnesium 12h Ur-sCnc;;ACTIVE;2.48;2.48 +74697-4;Acamprosate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acamprosate [Mass/volume] in Serum or Plasma;Acampro SerPl-mCnc;;ACTIVE;2.48;2.48 +74698-2;Sex;Type;Pt;^Patient;Nom;AHRQ;SURVEY.AHRQ;4;Sex [AHRQ];;;ACTIVE;2.48;2.56 +74699-0;Cefuroxime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefuroxime [Susceptibility] by Disk diffusion (KB);Cefuroxime Islt KB;;ACTIVE;2.48;2.48 +74700-6;Ergonomics or human &or device interface issue;Type;Pt;{Device};Nom;AHRQ;SURVEY.AHRQ;4;Ergonomics or human AndOr device interface issue [AHRQ];;;ACTIVE;2.48;2.66 +74701-4;Problem that resulted from the equipment or device function problem;Type;Pt;{Device};Nom;AHRQ;SURVEY.AHRQ;4;Problem that resulted from the equipment or device function problem [AHRQ];;;ACTIVE;2.48;2.66 +74702-2;Circumstances involving the health information technology device in the event or unsafe condition;Type;Pt;{Device};Nom;AHRQ;SURVEY.AHRQ;4;Circumstances involving the health information technology device in the event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.66 +74703-0;Electronic health record system component;Type;Pt;Electronic health record;Nom;AHRQ;SURVEY.AHRQ;4;Electronic health record system component [AHRQ];;;ACTIVE;2.48;2.66 +74704-8;Administrative or billing system component;Type;Pt;Administrative or billing system;Nom;AHRQ;SURVEY.AHRQ;4;Administrative or billing system component [AHRQ];;;ACTIVE;2.48;2.66 +74705-5;Best characterization of health information technology device;Find;Pt;{Device};Nom;AHRQ;SURVEY.AHRQ;4;Best characterization of health information technology (HIT) device [AHRQ];;;ACTIVE;2.48;2.66 +74706-3;Health information technology device was involved;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Health information technology (HIT) device was involved [AHRQ];;;ACTIVE;2.48;2.66 +74707-1;Medication or other substance was involved;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Medication or other substance was involved [AHRQ];;;ACTIVE;2.48;2.66 +7470-8;Llama fur Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Llama fur IgE Ab [Units/volume] in Serum;Llama Fur IgE Qn;;ACTIVE;1.0h(2);2.42 +74708-9;Device intended for single use was reused in the event or unsafe condition;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Device intended for single use was reused in the event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.66 +74709-7;Device intended for single use was involved in the event or unsafe condition;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Device intended for single use was involved in the event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.66 +74710-5;Asset tag number;ID;Pt;{Device};Nom;;DEVICES;2;Asset tag number;Asset tag number;;ACTIVE;2.48;2.66 +74711-3;Unique device identifier;ID;Pt;{Device};Nom;;DEVICES;2;Unique device identifier;UDI;;ACTIVE;2.48;2.66 +74712-1;Expiration date;Date;Pt;{Device};Qn;;DEVICES;2;Expiration date;Expiration date;;ACTIVE;2.48;2.66 +74713-9;Other unique product identifier;Type;Pt;{Device};Nom;;DEVICES;2;Other unique product identifier [Type];Other UDI [Type];;ACTIVE;2.48;2.66 +74714-7;Lot or batch number;ID;Pt;{Device};Nom;;DEVICES;2;Lot or batch number;Lot or batch no.;;ACTIVE;2.48;2.66 +74715-4;Vendor serial number;ID;Pt;{Device};Nom;;DEVICES;2;Vendor serial number;Serial #;;ACTIVE;2.48;2.66 +7471-6;Homarus gammarus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lobster IgG Ab [Units/volume] in Serum;Lobster IgG Qn;;ACTIVE;1.0h(2);2.73 +74716-2;Vendor firmware version;ID;Pt;{Device};Nom;;DEVICES;2;Vendor firmware version;Vendor firmware version;;ACTIVE;2.48;2.66 +74717-0;Vendor model number;ID;Pt;{Device};Nom;;DEVICES;2;Vendor model number;Model #;;ACTIVE;2.48;2.66 +74718-8;Device identifier;Type;Pt;{Device};Nom;;DEVICES;2;Type of device identifier [AHRQ];Device ID;;ACTIVE;2.48;2.66 +74719-6;Manufacturer name;ID;Pt;{Device};Nom;;DEVICES;2;Manufacturer name;Manufacturer name;;ACTIVE;2.48;2.66 +74720-4;Device name;ID;Pt;{Device};Nom;;DEVICES;2;Device name;Device name;;ACTIVE;2.48;2.73 +74721-2;Event resulted in the device being removed;Find;Pt;^Event;Ord;AHRQ;SURVEY.AHRQ;4;Event resulted in the device being removed [AHRQ];;;ACTIVE;2.48;2.66 +74722-0;At the time of the event, the device was placed within the patient's tissue;Find;Pt;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;At the time of the event, the device was placed within the patient's tissue [AHRQ];;;ACTIVE;2.48;2.66 +74723-8;Device involved in patient safety event or unsafe condition;Type;Pt;{Device};Nom;AHRQ;SURVEY.AHRQ;4;Device involved in patient safety event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.66 +7472-4;Locust tree Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Locust tree IgE Ab [Units/volume] in Serum;Locust Tree IgE Qn;;ACTIVE;1.0h(2);2.73 +74724-6;Best description of the event or unsafe condition;Find;Pt;^Event;Nom;AHRQ;SURVEY.AHRQ;4;Best description of the event or unsafe condition [AHRQ];;;ACTIVE;2.48;2.66 +74725-3;Patient safety event report - hospital - device or medical &or surgical supply, including health information technology - version 1.2;-;Pt;^Patient;-;AHRQ;PANEL.SURVEY.AHRQ;4;Patient safety event report - hospital - device or medical AndOr surgical supply, including health information technology (HIT) - version 1.2 [AHRQ];;;ACTIVE;2.48;2.54 +74726-1;Other unique product identifier;ID;Pt;{Device};Nom;;DEVICES;2;Other unique product identifier;Other UDI;;ACTIVE;2.48;2.66 +74727-9;Body condition score;Score;Pt;^Patient;Ord;Jefferies;H&P.PX;2;Body condition score Jefferies;Body Score;;ACTIVE;2.48;2.67 +74728-7;Vital signs, weight, height, head circumference, oximetry, BMI, & BSA panel;-;Pt;^Patient;-;HL7.CCDAr1.1;PANEL.VITALS;2;Vital signs, weight, height, head circumference, oximetry, BMI, and BSA panel - HL7.CCDAr1.1;Vitals+wt+ht+OFC+ox+BMI+BSA Pnl CCDAr1.1;;ACTIVE;2.48;2.58 +74729-5;Adrenoleukodystrophy protein;PrThr;Pt;Fibroblasts;Ord;Immune stain;PATH;1;Adrenoleukodystrophy protein (ALDP) [Presence] in Fibroblast by Immune stain;ALDP Fib Ql ImStn;;ACTIVE;2.48;2.56 +74730-3;Oligosaccharides pattern;Imp;24H;Urine;Nar;;CHEM;1;Oligosaccharides pattern [Interpretation] in 24 hour Urine Narrative;Oligosaccharide Pattern 24h Ur-Imp;;ACTIVE;2.48;2.48 +74731-1;Gram positive bacteria identified;Imp;Pt;Bld.pos growth;Nom;Probe.mag capture;MICRO;1;Deprecated Gram positive bacteria identified [Interpretation] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated GP bact Bld Pos Prb Mag-Imp;;DEPRECATED;2.48;2.63 +7473-2;Robinia pseudoacacia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Locust IgE Ab [Units/volume] in Serum;Black Locust IgE Qn;;ACTIVE;1.0h(2);2.73 +74732-9;Listeria sp (tuf) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Listeria sp (tuf) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Listeria sp tuf Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74733-7;Mycobacterium sp rRNA;Prid;Pt;Bld.pos growth;Nom;Probe.mag capture;MICRO;1;Deprecated Mycobacterium sp rRNA [Identifier] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Mycobacterium rRNA Bld Pos Prb Mag;;DEPRECATED;2.48;2.63 +74734-5;Death certifier details;Find;Pt;Provider;Doc;;SURVEY.CDC;4;Death certifier details;;;ACTIVE;2.48;2.63 +74735-2;Health data repository;ID;Pt;Repository;Nom;;MISC;1;Health data repository [Identifier];Health data repository ID;;ACTIVE;2.48;2.58 +74736-0;Streptococcus pyogenes hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Streptococcus pyogenes hsp60 gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated S pyogenes hsp60 Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74737-8;Streptococcus pneumoniae gryB gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Streptococcus pneumoniae gryB gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated S pneumoniae gryB Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74738-6;Streptococcus anginosus group gyrB gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Streptococcus anginosus group gyrB gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated S anginosus gryB Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74739-4;Streptococcus agalactiae hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Streptococcus agalactiae hsp60 gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated S agalactiae hsp60 Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +7474-0;Scomber scombrus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mackerel IgE Ab [Units/volume] in Serum;Mackerel IgE Qn;;ACTIVE;1.0h(2);2.73 +74740-2;Streptococcus sp tuf gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Streptococcus sp tuf gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Streptococcus sp tuf Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74741-0;Bacterial vancomycin resistance vanB gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Vancomycin resistance vanB gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated vanB Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.65 +74742-8;Bacterial vancomycin resistance vanA gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Vancomycin resistance vanA gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated vanA Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.65 +74743-6;Enterococcus faecalis hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Enterococcus faecalis hsp60 gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated E faecalis hsp60 Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74744-4;Staphylococcus lugdunensis sodA gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Staphylococcus lugdunensis sodA gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated S lugdunensis sodA Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74745-1;Bacterial methicillin resistance (mecA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Methicillin resistance (mecA) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated mecA Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.65 +74746-9;Staphylococcus epidermidis hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Staphylococcus epidermidis hsp60 gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated S epidermidis hsp60 Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74747-7;Staphylococcus aureus gyrB gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Staphylococcus aureus gyrB gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated S aureus gyrB Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74748-5;Staphylococcus sp tuf gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Staphylococcus sp tuf gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Staph sp tuf Bld Pos Ql Prb Mag;;DEPRECATED;2.48;2.63 +74749-3;Gram positive blood culture panel;-;Pt;Bld.pos growth;-;Probe.mag capture;PANEL.MICRO;1;Deprecated Gram positive blood culture panel by Nucleic acid capture and probe detection in Positive blood culture;Deprecated GP Bld Culture Pnl Bld Pos Prb Mag;;DEPRECATED;2.48;2.68 +74750-1;Lymphocytes.clefted;PrThr;Pt;Bld/Tiss;Ord;Microscopy.light;HEM/BC;1;Lymphocytes clefted [Presence] in Blood or Tissue by Light microscopy;Cleft Lymphs Bld/T Ql Micro;;ACTIVE;2.48;2.56 +74751-9;Collection time;TmStp;Pt;Urine;Qn;;SPEC;1;Collection time of Urine;Collect Tme Ur;;ACTIVE;2.48;2.73 +74752-7;Porcine epidemic diarrhea virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine epidemic diarrhea virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PEDv RNA Ct Spec Qn NAA+probe;;ACTIVE;2.48;2.69 +74753-5;Blood group antigens present;Prid;Pt;Bld;Nom;Indirect antiglobulin test;BLDBK;1;Blood group antigens present [Identifier] in Blood by IAT;Antigens Present Bld IAT;;ACTIVE;2.48;2.48 +74754-3;Blood group antigens present;Prid;Pt;Bld;Nom;Immediate spin;BLDBK;1;Blood group antigens present [Identifier] in Blood by Immediate spin;Antigens Present Bld Imm Spin;;ACTIVE;2.48;2.48 +74755-0;Placental growth factor;MCnc;Pt;Ser;Qn;;CHEM;1;Placental growth factor [Mass/volume] in Serum;PIGF Ser-mCnc;;ACTIVE;2.48;2.48 +74756-8;Soluble fms-like tyrosine kinase-1;MCnc;Pt;Ser;Qn;;CHEM;1;Soluble fms-like tyrosine kinase-1 [Mass/volume] in Serum;sFlt-1 Ser-mCnc;;ACTIVE;2.48;2.48 +7475-7;Scomber scombrus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Mackerel triggered histamine release [Units/volume] in Blood;Mackerel BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74757-6;Soluble fms-like tyrosine kinase-1/placental growth factor;Ratio;Pt;Ser;Qn;;CHEM;1;Soluble fms-like tyrosine kinase-1/placental growth factor [Ratio] in Serum;sFlt-1/PIGF d Ser-Rto;;ACTIVE;2.48;2.48 +74758-4;Ethyl sulfate+Ethyl glucuronide;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ethyl sulfate+Ethyl glucuronide [Presence] in Urine by Confirmatory method;ETG EtS Ur Ql Cfm;;ACTIVE;2.48;2.73 +74759-2;Yeast;PrThr;Pt;XXX;Ord;Gram stain;MICRO;1;Yeast [Presence] in Specimen by Gram stain;Yeast Spec Ql Gram Stn;;ACTIVE;2.48;2.73 +747-6;Myeloblasts/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Myeloblasts/100 leukocytes in Blood by Manual count;Myeloblasts/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +74760-0;HYDROcodone & metabolites panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;HYDROcodone and metabolites panel - Urine by Confirmatory method;HYDROcodone + metabs Pnl Ur Cfm;;ACTIVE;2.48;2.63 +74761-8;Microcytes/100 erythrocytes;NFr;Pt;Bld;Qn;;HEM/BC;1;Microcytes/100 erythrocytes in Blood;Microcytes/100 RBC NFr Bld;;ACTIVE;2.48;2.48 +74762-6;Megasphaera sp DNA;LnCnc;Pt;Vag;Qn;Probe.amp.tar;MICRO;1;Megasphaera sp DNA [Log #/volume] in Vaginal fluid by NAA with probe detection;Megasphaera sp DNA Vag NAA+probe-Log#;;ACTIVE;2.48;2.73 +74763-4;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 E6+E7 mRNA;PrThr;Pt;Anal;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus E6+E7 mRNA [Presence] in Anal by NAA with probe detection;HPV E6+E7 mRNA Anal Ql NAA+probe;;ACTIVE;2.48;2.73 +74764-2;Soluble fms-like tyrosine kinase-1 & placental growth factor panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Soluble fms-like tyrosine kinase-1 and placental growth factor panel - Serum or Plasma;sFlt1PIGF Pnl SerPl;;ACTIVE;2.48;2.48 +7476-5;Malt Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Malt IgG Ab [Units/volume] in Serum;Malt IgG Qn;;ACTIVE;1.0h(2);2.73 +74765-9;Bordetella pertussis.pertussis toxin Ab.IgA;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Bordetella pertussis.pertussis toxin IgA Ab [Presence] in Serum by Line blot;B pert.PT IgA Ser Ql Line blot;;ACTIVE;2.48;2.73 +74766-7;Bordetella pertussis.pertussis toxin 100 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Bordetella pertussis.pertussis toxin 100 IgG Ab [Presence] in Serum by Line blot;B pert.PT 100 IgG Ser Ql Line blot;;ACTIVE;2.48;2.73 +74767-5;Tryptophan;SCnc;Pt;PRP;Qn;;CHEM;1;Tryptophan [Moles/volume] in Platelet rich plasma;Tryptophan PRP-sCnc;;ACTIVE;2.48;2.48 +74768-3;5-hydroxytryptophan;SCnc;Pt;PRP;Qn;;CHEM;1;5-Hydroxytryptophan [Moles/volume] in Platelet rich plasma;5OH-Tryptophan PRP-sCnc;;ACTIVE;2.48;2.48 +74769-1;5-Hydroxyindoleacetate;SCnc;Pt;PRP;Qn;;CHEM;1;5-Hydroxyindoleacetate [Moles/volume] in Platelet rich plasma;5OH-indoleacetate PRP-sCnc;;ACTIVE;2.48;2.48 +74770-9;Reporter information;-;Pt;^Event;-;AHRQ;PANEL.SURVEY.AHRQ;4;Reporter Information [AHRQ];;;ACTIVE;2.48;2.48 +74771-7;Neonatal patient information;-;Pt;^Patient;-;AHRQ;PANEL.SURVEY.AHRQ;4;Neonatal Patient Information [AHRQ];;;ACTIVE;2.48;2.48 +74772-5;Patient information;-;Pt;^Patient;-;AHRQ;PANEL.SURVEY.AHRQ;4;Patient Information [AHRQ];;;ACTIVE;2.48;2.48 +7477-3;Mangifera indica pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mango Pollen IgE Ab [Units/volume] in Serum;Mango Poln IgE Qn;;ACTIVE;1.0h(2);2.73 +74773-3;Immunoglobulin light chains & heavy chains panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Immunoglobulin light chains and heavy chains panel - Serum or Plasma;Imm hevylite Pnl SerPl;;ACTIVE;2.48;2.48 +74774-1;Glucose;MCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Glucose [Mass/volume] in Serum, Plasma or Blood;Glucose SerPlBld-mCnc;;ACTIVE;2.48;2.73 +74775-8;Platelets;NCnc;Pt;PRP;Qn;Automated count;HEM/BC;1;Platelets [#/volume] in Platelet rich plasma by Automated count;Platelet # PRP Auto;;ACTIVE;2.48;2.48 +74776-6;Human papilloma virus 6 DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Human papilloma virus 6 DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HPV6 DNA Spec NAA+probe-Log#;;ACTIVE;2.48;2.69 +74777-4;Human papilloma virus 6 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Human papilloma virus 6 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HPV6 DNA # Spec NAA+probe;;ACTIVE;2.48;2.69 +74778-2;Human papilloma virus 11 DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Human papilloma virus 11 DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HPV11 DNA Spec NAA+probe-Log#;;ACTIVE;2.48;2.69 +74779-0;Human papilloma virus 11 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Human papilloma virus 11 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;HPV11 DNA # Spec NAA+probe;;ACTIVE;2.48;2.69 +74780-8;CPT1A gene.c.1436C>T;PrThr;Pt;Bld.dot;Ord;Molgen;MOLPATH.MUT;1;CPT1A gene c.1436C>T [Presence] in DBS by Molecular genetics method;CPT1A c.1436C>T DBS Ql;;ACTIVE;2.48;2.73 +7478-1;Acer macrophyllum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Coastal Maple IgE Ab [Units/volume] in Serum;Coastal Maple IgE Qn;;ACTIVE;1.0h(2);2.73 +74781-6;Vacuum dust collection contaminant panel;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Vacuum dust collection contaminant panel PhenX;Vac dust collection pnl PhenX;;ACTIVE;2.48;2.48 +74782-4;Arterial pulse intensity;Force;Pt;Dorsal pedal artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Dorsal pedal artery - right by palpation;Pulse intensity Dors pedal a-R Palpation;;ACTIVE;2.48;2.48 +74783-2;Malignant cells;PrThr;Pt;Body fld;Ord;Microscopy.light;HEM/BC;1;Malignant cells [Presence] in Body fluid by Light microscopy;Malignant cells Fld Ql Micro;;ACTIVE;2.48;2.56 +74784-0;Influenza virus B lineage RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Influenza virus B lineage RNA [Identifier] in Specimen by NAA with probe detection;FLUBV lineage RNA Spec NAA+probe;;ACTIVE;2.48;2.69 +74785-7;Influenza virus B Victoria lineage RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus B Victoria lineage RNA [Presence] in Specimen by NAA with probe detection;FLUBV Vic RNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74786-5;Influenza virus B Yamagata lineage RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus B Yamagata lineage RNA [Presence] in Specimen by NAA with probe detection;FLUBV Yam RNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74787-3;Influenza virus B Victoria & Yamagata lineage RNA panel;-;Pt;XXX;-;;PANEL.MICRO;1;Influenza virus B Victoria and Yamagata lineage RNA panel - Specimen;FLUBV Vic + Yam RNA Pnl Spec;;ACTIVE;2.48;2.69 +74788-1;Lactulose challenge panel;-;Pt;Exhl gas;Qn;;PANEL.CHAL;1;Lactulose challenge (hydrogen breath test) panel - Exhaled gas;Lactulose HBT Pnl ExG;;ACTIVE;2.48;2.48 +74789-9;Fructose challenge panel;-;Pt;Exhl gas;Qn;;PANEL.CHAL;1;Fructose challenge (hydrogen breath test) panel - Exhaled gas;Fructose HBT Pnl ExG;;ACTIVE;2.48;2.64 +74790-7;Glucose challenge panel;-;Pt;Exhl gas;Qn;;PANEL.CHAL;1;Glucose challenge (hydrogen breath test) panel - Exhaled gas;Glucose HBT Pnl ExG;;ACTIVE;2.48;2.48 +74791-5;Lactulose challenge;Imp;Pt;Exhl gas;Nom;;CHAL;1;Lactulose challenge (hydrogen breath test) [Interpretation] in Exhaled gas;Lactulose HBT ExG-Imp;;ACTIVE;2.48;2.54 +74792-3;Fructose.PO;Mass;Pt;Dose;Qn;;CHEM;1;Fructose.PO [Mass] in Dose;Fructose PO Dose Qn;;ACTIVE;2.48;2.48 +74793-1;Thyroid hormone uptake;NFr;Pt;Ser/Plas;Qn;;CHEM;1;Thyroid hormone uptake (T-uptake) in Serum or Plasma;T-uptake NFr SerPl;;ACTIVE;2.48;2.73 +74794-9;Thyroid hormone binding ratio;RelRto;Pt;Ser/Plas;Qn;;CHEM;1;Thyroid hormone binding ratio (THBR) in Serum or Plasma;THBR SerPl;;ACTIVE;2.48;2.48 +74795-6;Total thyroxine binding capacity;RelRto;Pt;Ser/Plas;Qn;;CHEM;1;Total thyroxine binding capacity in Serum or Plasma;Total TBC SerPl;;ACTIVE;2.48;2.73 +7479-9;Acer rubrum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Maple IgE Ab [Units/volume] in Serum;Red Maple IgE Qn;;ACTIVE;1.0h(2);2.73 +74802-0;Glucose challenge;Imp;Pt;Exhl gas;Nom;;CHAL;1;Glucose challenge (hydrogen breath test) [Interpretation] in Exhaled gas;Glucose HBT ExG-Imp;;ACTIVE;2.48;2.48 +74803-8;Lactose challenge;Imp;Pt;Exhl gas;Nom;;CHAL;1;Lactose challenge (hydrogen breath test) [Interpretation] in Exhaled gas;Lactose HBT ExG-Imp;;ACTIVE;2.48;2.48 +74804-6;Fructose challenge;Imp;Pt;Exhl gas;Nom;;CHAL;1;Fructose challenge (hydrogen breath test) [Interpretation] in Exhaled gas;Fructose HBT ExG-Imp;;ACTIVE;2.48;2.48 +74805-3;Penicillium sp Ab.IgG;MCnc;Pt;Ser/Plas;Qn;IA;ALLERGY;1;Penicillium sp IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay;Penicillium IgG IA-mCnc;;ACTIVE;2.48;2.56 +74806-1;Lithium^trough;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lithium [Moles/volume] in Serum or Plasma --trough;Lithium Trough SerPl-sCnc;;ACTIVE;2.48;2.73 +7480-7;Acer rubrum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Red Maple triggered histamine release [Units/volume] in Blood;Red Maple BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74807-9;Transferrin receptor.soluble/log Ferritin index;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin receptor.soluble/log Ferritin index [Mass Ratio] in Serum or Plasma;sTfR SerPl;;ACTIVE;2.48;2.48 +74808-7;von Willebrand factor.activity actual/Normal^immediately after 1:1 addition of normal plasma;RelRto;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay --immediately after 1:1 addition of normal plasma;vWf:Ac Act/Nor imm 1:1 NP PPP IA;;ACTIVE;2.48;2.73 +74809-5;von Willebrand factor.activity actual/Normal;RelRto;Pt;PPP^Control;Qn;IA;COAG;1;von Willebrand factor (vWf).activity actual/normal in Control Platelet poor plasma by Immunoassay;vWf:Ac Act/Nor PPP Cont IA;;ACTIVE;2.48;2.73 +74810-3;Acetyl fentanyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Acetyl fentanyl [Presence] in Urine by Confirmatory method;Acetyl fentanyl Ur Ql Cfm;;ACTIVE;2.48;2.73 +74811-1;Dihydrocodeine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Dihydrocodeine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;DHC Sal Cfm-mCnc;;ACTIVE;2.48;2.73 +74812-9;Mirtazapine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Mirtazapine [Presence] in Urine;Mirtazapine Ur Ql;;ACTIVE;2.48;2.73 +74813-7;Nucleated cells;NCnc;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Dialysis fluid by Manual count;Nuc cell # Dial fld Manual;;ACTIVE;2.48;2.48 +74814-5;Plasma cells.centroblasts/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Plasma cells.centroblasts/100 leukocytes in Blood by Manual count;Plms centblst/leuk NFr Bld Manual;;ACTIVE;2.48;2.73 +7481-5;Maple red+Silver Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red+Silver Maple IgE Ab [Units/volume] in Serum;Red+Silver Maple IgE Qn;;ACTIVE;1.0h(2);2.73 +74815-2;Ascaris sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Ascaris sp IgG Ab [Presence] in Serum by Immunoassay;Ascaris IgG Ser Ql IA;;ACTIVE;2.48;2.56 +74816-0;Bacteria identified;Prid;Pt;Eye;Nom;Anaerobic+Aerobic culture;MICRO;1;Bacteria identified in Eye by Anaerobe+Aerobe culture;Bacteria Eye Anaerobe+Aerobe Cult;;ACTIVE;2.48;2.48 +74817-8;Desomorphine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Desomorphine [Mass/volume] in Urine by Confirmatory method;Desom Ur Cfm-mCnc;;ACTIVE;2.48;2.48 +74818-6;Desomorphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Desomorphine [Presence] in Urine by Screen method;Desom Ur Ql Scn;;ACTIVE;2.48;2.73 +74819-4;Promazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Promazine [Presence] in Urine by Screen method;Promazine Ur Ql Scn;;ACTIVE;2.48;2.56 +74820-2;Plasma cells.centrocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Plasma cells.centrocytes/100 leukocytes in Blood by Manual count;Plms centcyts/leuk NFr Bld Manual;;ACTIVE;2.48;2.5 +74821-0;Chikungunya virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Chikungunya virus Ab [Presence] in Serum by Hemagglutination inhibition;CHIKV Ab Ser Ql HAI;;ACTIVE;2.48;2.56 +74822-8;Clostridioides difficile toxin B tcdB gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Clostridioides difficile toxin B tcdB gene [Presence] in Stool by NAA with probe detection;C diff Tox B tcdB Stl Ql NAA+probe;;ACTIVE;2.48;2.73 +7482-3;Maple sugar Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Maple sugar IgE Ab [Units/volume] in Serum;Maple sugar IgE Qn;;ACTIVE;1.0h(2);2.73 +74823-6;Jamestown canyon virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Jamestown canyon virus Ab [Presence] in Serum by Immunoassay;JCV Ab Ser Ql IA;;ACTIVE;2.48;2.56 +74824-4;Powassan virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Powassan virus Ab [Presence] in Serum by Hemagglutination inhibition;POWV Ab Ser Ql HAI;;ACTIVE;2.48;2.56 +74825-1;Saint Louis encephalitis virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Saint Louis encephalitis virus Ab [Presence] in Serum by Hemagglutination inhibition;SLEV Ab Ser Ql HAI;;ACTIVE;2.48;2.56 +74826-9;Semliki forest virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Semliki Forest virus Ab [Presence] in Serum by Hemagglutination inhibition;SFV Ab Ser Ql HAI;;ACTIVE;2.48;2.56 +74827-7;Snowshoe hare virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Snowshoe hare virus Ab [Presence] in Serum by Hemagglutination inhibition;SSHV Ab Ser Ql HAI;;ACTIVE;2.48;2.56 +74828-5;Snowshoe hare virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Snowshoe hare virus neutralizing antibody [Presence] in Serum by Neutralization test;SSHV NAb Ser Ql Nt;;ACTIVE;2.48;2.72 +74829-3;Snowshoe hare virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Snowshoe hare virus IgG Ab [Presence] in Serum by Immunofluorescence;SSHV IgG Ser Ql IF;;ACTIVE;2.48;2.56 +74830-1;Toxoplasma gondii Ab.IgA;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toxoplasma gondii IgA Ab [Presence] in Serum by Immunoassay;T gondii IgA Ser Ql IA;;ACTIVE;2.48;2.56 +7483-1;Maple syrup Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Maple syrup IgE Ab [Units/volume] in Serum;Maple Syrup IgE Qn;;ACTIVE;1.0h(2);2.73 +74831-9;Metanephrine & Normetanephrine panel;SCnc;Pt;Urine;-;;PANEL.CHEM;1;Deprecated Metanephrine and Normetanephrine panel [Moles/volume] - Urine;Deprecated Metaneph+Normetaneph Pnl Ur-sCnc;;DEPRECATED;2.48;2.63 +74832-7;OLANZapine;Mass;Pt;Dose;Qn;;DRUGDOSE;1;OLANZapine [Mass] of Dose;OLANZapine Dose;;ACTIVE;2.48;2.56 +74833-5;ACAT1 gene full mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.MUT;1;ACAT1 gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;ACAT1 Full Mut Anl Bld/T Seq;;ACTIVE;2.48;2.67 +74834-3;MARS2 gene full mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.MUT;1;MARS2 gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;MARS2 Full Mut Anl Bld/T Seq;;ACTIVE;2.48;2.67 +74835-0;Porphyrin fractions panel;SFr;Pt;Stool;-;;PANEL.CHEM;1;Porphyrin fractions panel - Stool;Porphyrin Fract Pnl SFr Stl;;ACTIVE;2.48;2.48 +74836-8;Transplant type;Anat;Pt;^Patient;Nom;;CLIN;2;Transplant type [Anatomy];Trns Typ;;ACTIVE;2.48;2.48 +74837-6;Cells.CD20;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD20 cells [#/volume] in Specimen;CD20 Cells # Spec;;ACTIVE;2.48;2.69 +74838-4;Cells.CD34;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD34 cells [#/volume] in Specimen;CD34 Cells # Spec;;ACTIVE;2.48;2.69 +74839-2;Cells.CD3-CD4+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD3-CD4+ cells/100 cells in Specimen;CD3-CD4+ NFr Spec;;ACTIVE;2.48;2.69 +748-4;Myelocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Myelocytes [#/volume] in Blood by Manual count;Myelocytes # Bld Manual;;ACTIVE;1.0;2.73 +74840-0;Cells.CD56;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD56 cells [#/volume] in Specimen;CD56 Cells # Spec;;ACTIVE;2.48;2.69 +74841-8;Cells.CD8+CD57+/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD8+CD57+ cells/100 cells in Specimen;CD8+CD57+ Cells NFr Spec;;ACTIVE;2.48;2.69 +74842-6;Cells.CD25;NCnc;Pt;XXX;Qn;;CELLMARK;1;CD25 cells [#/volume] in Specimen;CD25 Cells # Spec;;ACTIVE;2.48;2.69 +74843-4;Baylisascaris sp Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Baylisascaris sp IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;Baylis sp IgG CSF Ql IA;;ACTIVE;2.48;2.56 +74844-2;Baylisascaris sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Baylisascaris sp IgG Ab [Presence] in Serum by Immunoassay;Baylis sp IgG Ser Ql IA;;ACTIVE;2.48;2.56 +74845-9;Sindbis virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;Sindbis virus Ab [Presence] in Serum by Hemagglutination inhibition;SINV Ab Ser Ql HAI;;ACTIVE;2.48;2.56 +74846-7;Snowshoe hare virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Snowshoe hare virus IgM Ab [Presence] in Serum by Immunofluorescence;SSHV IgM Ser Ql IF;;ACTIVE;2.48;2.56 +74847-5;Toxoplasma gondii Ab.IgE;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toxoplasma gondii IgE Ab [Presence] in Serum by Immunoassay;T gondii IgE Ser Ql IA;;ACTIVE;2.48;2.56 +74848-3;Lymphocytes/100 cells;NFr;Pt;Lymph node;Qn;Manual count;HEM/BC;1;Lymphocytes/100 cells in Lymph node by Manual count;Lymphocytes NFr LN Manual;;ACTIVE;2.48;2.48 +7484-9;Iva xanthifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Burweed marshelder IgE Ab [Units/volume] in Serum;Burweed marshelder IgE Qn;;ACTIVE;1.0h(2);2.73 +74849-1;Plasma cells/100 cells;NFr;Pt;Lymph node;Qn;Manual count;HEM/BC;1;Plasma cells/100 cells in Lymph node by Manual count;Plasma Cells NFr LN Manual;;ACTIVE;2.48;2.48 +74850-9;Lymphoblasts/100 cells;NFr;Pt;Lymph node;Qn;Manual count;HEM/BC;1;Lymphoblasts/100 cells in Lymph node by Manual count;Lymphoblasts NFr LN Manual;;ACTIVE;2.48;2.48 +74851-7;Blasts/100 cells;NFr;Pt;Lymph node;Qn;Manual count;HEM/BC;1;Blasts/100 cells in Lymph node by Manual count;Blasts NFr LN Manual;;ACTIVE;2.48;2.48 +74852-5;Mesothelial cells/100 cells;NFr;Pt;Lymph node;Qn;Manual count;HEM/BC;1;Mesothelial cells/100 cells in Lymph node by Manual count;Mesothl Cell NFr LN Manual;;ACTIVE;2.48;2.48 +74853-3;HIV 1 proviral DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Presence] in Specimen by NAA with probe detection;HIV 1 pro DNA Spec Ql NAA+probe;;ACTIVE;2.48;2.69 +74854-1;HIV 1 proviral DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [#/volume] (viral load) in Blood by NAA with probe detection;HIV 1 pro DNA # Bld NAA+probe;;ACTIVE;2.48;2.63 +74855-8;HIV 1 proviral DNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;HIV 1 pro DNA Spec NAA+probe-Log#;;ACTIVE;2.48;2.69 +7485-6;Iva xanthifolia Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Burweed marshelder IgG Ab [Units/volume] in Serum;Burweed marshelder IgG Qn;;ACTIVE;1.0h(2);2.69 +74856-6;HIV 1 group O RNA+HIV 1 group M RNA+HIV 2 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA;PrThr;Pt;Ser/Plas^Donor;Ord;Probe.amp.tar;MICRO;1;HIV 1 group O RNA+HIV 1 group M RNA+HIV 2 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA [Presence] in Serum or Plasma from Donor by NAA with probe detection;HIV1+2+HCV+HBV DNA SerPl Donr Ql NAA+pr;;ACTIVE;2.48;2.63 +74857-4;West Nile Virus RNA;PrThr;Pt;Ser/Plas^Donor;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Serum or Plasma from Donor by NAA with probe detection;WNV RNA SerPl Donr Ql NAA+probe;;ACTIVE;2.48;2.63 +74858-2;Hepatitis E virus genotypes 1+2+3+4 RNA;PrThr;Pt;Ser/Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Hepatitis E virus genotypes 1+2+3+4 RNA [Presence] in Serum or Plasma from Donor by NAA with probe detection;HEV 1+2+3+4 RNA SerPl Donr Ql NAA+probe;;ACTIVE;2.48;2.63 +74859-0;Ethanol;MCnc;Pt;Bld;Qn;Estimated from serum or plasma level;DRUG/TOX;1;Ethanol [Mass/volume] in Blood Estimated from serum or plasma level;Bld Ethanol Est from SerPl-mCnc;;ACTIVE;2.48;2.73 +74860-8;ERBB2 gene copy number/nucleus;EntNum;Pt;Tiss;Qn;FISH;MOLPATH;1;ERBB2 gene copy number/nucleus in Tissue by FISH;ERBB2 copy num/nucleus EntNum Tiss FISH;;ACTIVE;2.48;2.73 +74861-6;Chromosome 17 copy number/nucleus;EntNum;Pt;Tiss;Qn;FISH;MOLPATH;1;Chromosome 17 copy number/nucleus in Tissue by FISH;Chr 17 copy num/nucleus EntNum Tiss FISH;;ACTIVE;2.48;2.73 +74862-4;IgG.kappa;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgG.kappa [Mass/volume] in Serum or Plasma;IgG Kappa SerPl-mCnc;;ACTIVE;2.48;2.73 +74863-2;IgG.lambda;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgG.lambda [Mass/volume] in Serum or Plasma;IgG lamba SerPl-mCnc;;ACTIVE;2.48;2.73 +7486-4;Mattress dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mattress dust IgE Ab [Units/volume] in Serum;Mattress Dust IgE Qn;;ACTIVE;1.0h(2);2.73 +74864-0;IgA.kappa;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgA.kappa [Mass/volume] in Serum or Plasma;IgA kappa SerPl-mCnc;;ACTIVE;2.48;2.73 +74865-7;IgA.lambda;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgA.lambda [Mass/volume] in Serum or Plasma;IgA lamba SerPl-mCnc;;ACTIVE;2.48;2.73 +74866-5;IgM.kappa;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgM.kappa [Mass/volume] in Serum or Plasma;IgM kappa SerPl-mCnc;;ACTIVE;2.48;2.73 +74867-3;IgM.lambda;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgM.lambda [Mass/volume] in Serum or Plasma;IgM lambda SerPl-mCnc;;ACTIVE;2.48;2.73 +74868-1;IgG.kappa/IgG.lambda;MRto;Pt;Ser/Plas;Qn;;CHEM;1;IgG.kappa/IgG.lambda [Mass Ratio] in Serum or Plasma;IgG Kappa/G lambda SerPl;;ACTIVE;2.48;2.73 +74869-9;IgA.kappa/IgA.lambda;MRto;Pt;Ser/Plas;Qn;;CHEM;1;IgA.kappa/IgA.lambda [Mass Ratio] in Serum or Plasma;IgA kappa/A lambda SerPl;;ACTIVE;2.48;2.73 +74870-7;IgM.kappa/IgM.lambda;MRto;Pt;Ser/Plas;Qn;;CHEM;1;IgM.kappa/IgM.lambda [Mass Ratio] in Serum or Plasma;IgM kappa/M lambda SerPl;;ACTIVE;2.48;2.73 +74871-5;Rivaroxaban;MCnc;Pt;PPP;Qn;Chromo;COAG;1;Rivaroxaban [Mass/volume] in Platelet poor plasma by Chromogenic method;Rivaroxaban PPP Chro-mCnc;;ACTIVE;2.48;2.73 +7487-2;Mayfly Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mayfly IgE Ab [Units/volume] in Serum;Mayfly IgE Qn;;ACTIVE;1.0h(2);2.42 +74872-3;21-Deoxycortisol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;21-Deoxycortisol [Mass/volume] in Serum or Plasma;21DC SerPl-mCnc;;ACTIVE;2.48;2.73 +74873-1;Metabolic disorder being monitored;Prid;Pt;Bld.dot;Nom;;CHEM;1;Metabolic disorder being monitored [Identifier] in DBS;Metabolic disorder monitored DBS;;ACTIVE;2.48;2.61 +74874-9;Metabolic disorder therapy monitoring panel;-;Pt;Bld.dot;-;;PANEL.CHAL;1;Metabolic disorder therapy monitoring panel - DBS;Metabolic disorder therapy Pnl DBS;;ACTIVE;2.48;2.61 +74875-6;Alloisoleucine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Alloisoleucine [Moles/volume] in DBS --post therapeutic diet;Alloisoleucine p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74876-4;Arginine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Arginine [Moles/volume] in DBS --post therapeutic diet;Arginine p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74877-2;Argininosuccinate^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Argininosuccinate [Moles/volume] in DBS --post therapeutic diet;Argininosuccinate p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74878-0;Carnitine.free (C0)^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Carnitine free (C0) [Moles/volume] in DBS --post therapeutic diet;Carnitine Free p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74879-8;Galactose 1 phosphate^post therapeutic diet;MCnc;Pt;Bld.dot;Qn;;CHAL;1;Galactose 1 phosphate [Mass/volume] in DBS --post therapeutic diet;Gal1PO4 p diet DBS-mCnc;;ACTIVE;2.48;2.61 +7488-0;Mayfly basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Mayfly triggered histamine release [Units/volume] in Blood;Mayfly BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74880-6;Hydroxyproline^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Hydroxyproline [Moles/volume] in DBS --post therapeutic diet;OH-Proline p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74881-4;Isoleucine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Isoleucine [Moles/volume] in DBS --post therapeutic diet;Isoleucine p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74882-2;Leucine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Leucine [Moles/volume] in DBS --post therapeutic diet;Leucine p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74883-0;Ornithine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Ornithine [Moles/volume] in DBS --post therapeutic diet;Ornithine p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74884-8;Valine^post therapeutic diet;SCnc;Pt;Bld.dot;Qn;;CHAL;1;Valine [Moles/volume] in DBS --post therapeutic diet;Valine p diet DBS-sCnc;;ACTIVE;2.48;2.61 +74885-5;ERBB2 gene duplication associated observations panel;-;Pt;Tiss;-;FISH;PANEL.MOLPATH;1;ERBB2 gene (HER2) duplication associated observations panel - Tissue by FISH;ERBB2 (HER2) Dup Pnl Tiss FISH;;ACTIVE;2.48;2.7 +74886-3;Stigmasterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Stigmasterol [Moles/volume] in Serum or Plasma;Stigmasterol SerPl-sCnc;;ACTIVE;2.48;2.48 +74887-1;Stigmastanol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Stigmastanol [Moles/volume] in Serum or Plasma;Stigmastanol SerPl-sCnc;;ACTIVE;2.48;2.48 +74888-9;Sterols panel;SCnc;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Sterols panel [Moles/volume] - Serum or Plasma;Sterols Pnl SerPl-sCnc;;ACTIVE;2.48;2.5 +74889-7;Phosphate;SCnc;Pt;Saliva;Qn;;CHEM;1;Phosphate [Moles/volume] in Saliva (oral fluid);Phosphate Sal-sCnc;;ACTIVE;2.48;2.48 +74890-5;Inositol.free/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Inositol Free/Creatinine [Molar ratio] in Urine;Inositol Free/Creat Ur-sRto;;ACTIVE;2.48;2.48 +74891-3;Medium-chain Acyl CoA dehydrogenase;CCnt;Pt;WBC;Qn;;CHEM;1;Medium-chain Acyl CoA dehydrogenase [Enzymatic activity/mass] in Leukocytes;MCAD WBC-cCnt;;ACTIVE;2.48;2.48 +74892-1;Medium-chain Acyl CoA dehydrogenase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Medium-chain Acyl CoA dehydrogenase [Enzymatic activity/mass] in Fibroblast;MCAD Fib-cCnt;;ACTIVE;2.48;2.48 +74893-9;Mannose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Mannose/Creatinine [Molar ratio] in Urine;Mannose/Creat Ur-sRto;;ACTIVE;2.48;2.48 +74894-7;Mannitol^post XXX g sugar solution PO;SRat;5H;Urine;Qn;;CHEM;1;Mannitol [Moles/time] in 5 hour Urine --post XXX g sugar solution PO;Mannitol p sug sol 5h Ur-sRate;;ACTIVE;2.48;2.54 +74895-4;Maltose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Maltose/Creatinine [Molar ratio] in Urine;Maltose/Creat Ur-sRto;;ACTIVE;2.48;2.48 +74896-2;Lactate;SCnt;Pt;Stool;Qn;;CHEM;1;Lactate [Moles/mass] in Stool;Lactate Stl-sCnt;;ACTIVE;2.48;2.48 +74897-0;Lithocholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lithocholate [Moles/volume] in Serum or Plasma;Lithocholate SerPl-sCnc;;ACTIVE;2.48;2.48 +7489-8;Melaleuca leucadendron basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cajeput tree triggered histamine release [Units/volume] in Blood;Cajeput tree BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74898-8;Lanosterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lanosterol [Moles/volume] in Serum or Plasma;Lanosterol SerPl-sCnc;;ACTIVE;2.48;2.48 +74899-6;Lactulose/mannitol^post XXX g sugar solution PO;SRto;5H;Urine;Qn;;CHEM;1;Lactulose/Mannitol [Molar ratio] in 5 hour Urine --post XXX g sugar solution PO;Lactulose/Mannitol p sug sol 5h Ur-sRto;;ACTIVE;2.48;2.54 +74900-2;Lactulose/Creatinine^post XXX g sugar solution PO;SRto;5H;Urine;Qn;;CHEM;1;Lactulose/Creatinine [Molar ratio] in 5 hour Urine --post XXX g sugar solution PO;Lactulose/Creat p sug sol 5h Ur-sRto;;ACTIVE;2.48;2.54 +74901-0;Gamma tocopherol;EntSub;Pt;RBC;Qn;;CHEM;1;Gamma tocopherol [Entitic substance] in Red Blood Cells;Gamma tocopherol EntSub RBC;;ACTIVE;2.48;2.48 +74902-8;Galactose 1 phosphate uridyl transferase;CCnt;Pt;WBC;Qn;;CHEM;1;Galactose 1 phosphate uridyl transferase [Enzymatic activity/mass] in Leukocytes;Gal1PUT WBC-cCnt;;ACTIVE;2.48;2.48 +74903-6;Fatty acids;MRat;24H;Stool;Qn;;CHEM;1;Fatty acids [Mass/time] in 24 hour Stool;FA 24h Stl-mRate;;ACTIVE;2.48;2.48 +74904-4;DOPamine;SCnc;Pt;CSF;Qn;;CHEM;1;DOPamine [Moles/volume] in Cerebral spinal fluid;DOPamine CSF-sCnc;;ACTIVE;2.48;2.48 +74905-1;Desmosterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Desmosterol [Moles/volume] in Serum or Plasma;Desmosterol SerPl-sCnc;;ACTIVE;2.48;2.48 +7490-6;Cucumis melo spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Melon IgG Ab [Units/volume] in Serum;Deprecated Melon IgG Qn;;DEPRECATED;1.0h(2);2.69 +74906-9;Bilirubin;SCnc;Pt;CSF;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Cerebral spinal fluid;Bilirub CSF-sCnc;;ACTIVE;2.48;2.48 +74907-7;Beta sitosterol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Beta sitosterol [Moles/volume] in Serum or Plasma;B-sitosterol SerPl-sCnc;;ACTIVE;2.48;2.48 +74908-5;3-ketoacyl-CoA thiolase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-ketoacyl-CoA thiolase [Enzymatic activity/mass] in Fibroblast;Thiolase I Fib-cCnt;;ACTIVE;2.48;2.48 +74909-3;Calcium oxalate dihydrate/Total;MFr;Pt;Calculus;Qn;;CHEM;1;Calcium oxalate dihydrate/Total in Stone;Calcium Oxalate Dihydrate MFr Stone;;ACTIVE;2.48;2.48 +74910-1;Porphyrin fractions & creatinine panel;SRto;24H;Urine;-;;PANEL.CHEM;1;Porphyrin fractions and creatinine panel [Molar ratio] - 24 hour Urine;Porph Fract+Creat Pnl 24h Ur-sRto;;ACTIVE;2.52;2.63 +74911-9;Sertraline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sertraline [Mass/volume] in Serum or Plasma --trough;Sertraline Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74912-7;Primidone^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Primidone [Mass/volume] in Serum or Plasma --trough;Primidone Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74913-5;Escitalopram^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Escitalopram [Mass/volume] in Serum or Plasma --trough;Deprecated Escitalopram Trough SerPl-mCn;;DEPRECATED;2.48;2.54 +7491-4;Firebush mexican Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mexican Firebush IgE Ab [Units/volume] in Serum;Mexican Firebush IgE Qn;;ACTIVE;1.0h(2);2.42 +74914-3;Acylglycines panel;SRto;Pt;Urine;-;;PANEL.CHEM;1;Acylglycines panel [Molar ratio] - Urine;Acylglycines Pnl Ur-sRto;;ACTIVE;2.48;2.48 +74915-0;Sulpiride^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulpiride [Mass/volume] in Serum or Plasma --trough;Sulpiride Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74916-8;Metoprolol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metoprolol [Mass/volume] in Serum or Plasma --trough;Metoprolol Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74917-6;CXCL13 Ag;MCnc;Pt;CSF;Qn;;CHEM;1;CXCL13 Ag [Mass/volume] in Cerebral spinal fluid;CXCL13 Ag CSF-mCnc;;ACTIVE;2.48;2.48 +74918-4;Fatty acids;MCnt;24H;Stool;Qn;;CHEM;1;Fatty acids [Mass/mass] in 24 hour Stool;FA 24h Stl-mCnt;;ACTIVE;2.48;2.48 +74919-2;Caffeine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Caffeine [Mass/volume] in Serum or Plasma --trough;Caffeine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +749-2;Myelocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Myelocytes/100 leukocytes in Blood by Manual count;Myelocytes/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +74920-0;Gamma hydroxybutyrate;SCnc;Pt;Bld;Qn;;CHEM;1;Gamma hydroxybutyrate [Moles/volume] in Blood;G-OH-Butyr Bld-sCnc;;ACTIVE;2.48;2.48 +74921-8;Norclobazam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Norclobazam [Mass/volume] in Serum or Plasma --trough;Deprecated Norclobazam Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +7492-2;Multiple inhalant allergen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Multiple inhalant allergen IgE Ab [Units/volume] in Serum;MIA IgE Qn;;ACTIVE;1.0h(2);2.73 +74922-6;N-acetyl-L-aspartate;SCnc;Pt;CSF;Qn;;CHEM;1;N-acetyl-L-aspartate [Moles/volume] in Cerebral spinal fluid;N-Ac-L-Asp CSF-sCnc;;ACTIVE;2.48;2.58 +74923-4;Temazepam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Temazepam [Mass/volume] in Serum or Plasma --trough;Deprecated Temazepam Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74924-2;Nortriptyline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nortriptyline [Mass/volume] in Serum or Plasma --trough;Nortrip Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74925-9;Flupenthixol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Flupenthixol [Mass/volume] in Serum or Plasma --trough;Deprecated Flupenthixol Trough SerPl-mCn;;DEPRECATED;2.48;2.54 +74926-7;PHENobarbital^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PHENobarbital [Mass/volume] in Serum or Plasma --trough;Phenobarb Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74927-5;Pipamperone^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Pipamperone [Mass/volume] in Serum or Plasma --trough;Deprecated Pipamperone Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74928-3;Allopurinol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Allopurinol [Mass/volume] in Serum or Plasma --trough;Allopurinol Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74929-1;Fluspirilene^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Fluspirilene [Mass/volume] in Serum or Plasma --trough;Deprecated Fluspirilene Trough SerPl-mCn;;DEPRECATED;2.48;2.54 +7493-0;Milk evaporated Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Milk evaporated IgE Ab [Units/volume] in Serum;Milk Evaporated IgE Qn;;ACTIVE;1.0h(2);2.42 +74930-9;3-Hydroxykynurenin;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxykynurenin [Moles/volume] in Cerebral spinal fluid;3OH-kynurenin CSF-sCnc;;ACTIVE;2.48;2.54 +74931-7;ARIPiprazole^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ARIPiprazole [Mass/volume] in Serum or Plasma --trough;ARIPiprazole Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74932-5;Citalopram^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Citalopram [Mass/volume] in Serum or Plasma --trough;Deprecated Citalopram Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74933-3;N-desalkylflurazepam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated N-desalkylflurazepam [Mass/volume] in Serum or Plasma --trough;Deprecated Desalkylfluraz Trough SerPl-m;;DEPRECATED;2.48;2.54 +74934-1;fluPHENAZine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;fluPHENAZine [Mass/volume] in Serum or Plasma --trough;fluPHENAZine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74935-8;Palmitoyl protein thioesterase;CCnt;Pt;WBC;Qn;;CHEM;1;Palmitoyl protein thioesterase [Enzymatic activity/mass] in Leukocytes;PPT WBC-cCnt;;ACTIVE;2.48;2.48 +74936-6;QUEtiapine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;QUEtiapine [Mass/volume] in Serum or Plasma --trough;QUEtiapine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74937-4;Chlorprothixene^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Chlorprothixene [Mass/volume] in Serum or Plasma --trough;Deprecated Chlorprothixene Trough SerPl-;;DEPRECATED;2.48;2.54 +74938-2;Lidocaine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Lidocaine [Mass/volume] in Serum or Plasma --trough;Deprecated Lidocain Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74939-0;Vigabatrin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vigabatrin [Mass/volume] in Serum or Plasma --trough;Vigabatrin Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74940-8;Moclobemide^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Moclobemide [Mass/volume] in Serum or Plasma --trough;Moclobemide Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74941-6;Moclobemide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Moclobemide [Mass/volume] in Serum or Plasma;Moclobemide SerPl-mCnc;;ACTIVE;2.48;2.48 +74942-4;Kynurenin;SCnc;Pt;CSF;Qn;;CHEM;1;Kynurenin [Moles/volume] in Cerebral spinal fluid;Kynurenin CSF-sCnc;;ACTIVE;2.48;2.48 +74943-2;busPIRone^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;busPIRone [Mass/volume] in Serum or Plasma --trough;busPIRone Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74944-0;lamoTRIgine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;lamoTRIgine [Mass/volume] in Serum or Plasma --trough;lamoTRIgine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74945-7;clomiPRAMINE+Norclomipramine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clomiPRAMINE+Norclomipramine [Mass/volume] in Serum or Plasma --trough;clomiPRAMINE+Nor Trough SerPl-mCnc;;ACTIVE;2.48;2.69 +74946-5;Normirtazapine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Normirtazapine [Mass/volume] in Serum or Plasma --trough;Deprecated Normirtazapine Trough SerPl-m;;DEPRECATED;2.48;2.54 +74947-3;Norclomipramine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Norclomipramine [Mass/volume] in Serum or Plasma --trough;Deprecated Norclomipramine Trough SerPl-;;DEPRECATED;2.48;2.54 +7494-8;Panicum milliaceum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common Millet IgG Ab [Units/volume] in Serum;Common Millet IgG Qn;;ACTIVE;1.0h(2);2.69 +74948-1;Fluoxetine+Norfluoxetine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;FLUoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma --trough;FLUoxetine+Nor Trough SerPl-mCnc;;ACTIVE;2.48;2.54 +74949-9;Perphenazine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Perphenazine [Mass/volume] in Serum or Plasma --trough;Perphenazine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74950-7;Galactocerebrosidase;CCnt;Pt;WBC;Qn;;CHEM;1;Deprecated Galactocerebrosidase [Enzymatic activity/mass] in Leukocytes;Deprecated Galactocerebrosidase WBC-cCnt;;DEPRECATED;2.48;2.52 +74951-5;E-10-Hydroxynortriptyline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated E-10-Hydroxynortriptyline [Mass/volume] in Serum or Plasma --trough;Deprecated E-10-OH-NT Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74952-3;Lymphocyte proliferation;Imp;Pt;Bld;Nar;;SERO;1;Lymphocyte proliferation [Interpretation] in Blood Narrative;Lymphocyte prolif Bld-Imp Nar;;ACTIVE;2.48;2.5 +74953-1;Macroprolactin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Macroprolactin [Units/volume] in Serum or Plasma;Macroprolactin SerPl-aCnc;;ACTIVE;2.48;2.73 +74954-9;Isomaltase;CCnt;Pt;Tsmi;Qn;;CHEM;1;Isomaltase [Enzymatic activity/mass] in Small intestine Tissue;Isomaltase TSMI-cCnt;;ACTIVE;2.48;2.48 +7495-5;Mite dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mite dust IgE Ab [Units/volume] in Serum;Mite Dust IgE Qn;;ACTIVE;1.0h(2);2.73 +74955-6;Cyproheptadine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Cyproheptadine [Mass/volume] in Serum or Plasma --trough;Deprecated Cyproheptadine Trough SerPl-m;;DEPRECATED;2.48;2.54 +74956-4;chlordiazePOXIDE^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated chlordiazePOXIDE [Mass/volume] in Serum or Plasma --trough;Deprecated Chlordiazep Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74957-2;Succinylacetone;SCnc;Pt;Plas;Qn;;CHEM;1;Succinylacetone [Moles/volume] in Plasma;Succinylacetone Plas-sCnc;;ACTIVE;2.48;2.48 +74958-0;clomiPRAMINE^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clomiPRAMINE [Mass/volume] in Serum or Plasma --trough;clomiPRAMINE Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74959-8;fluvoxaMINE^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated fluvoxaMINE [Mass/volume] in Serum or Plasma --trough;Deprecated fluvoxaMINE Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74960-6;valGANciclovir^trough;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;valGANciclovir [Mass/volume] in Plasma --trough;valGANciclovir Trough Plas-mCnc;;ACTIVE;2.48;2.48 +74961-4;10-Hydroxycarbazepine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated 10-Hydroxycarbazepine [Mass/volume] in Serum or Plasma --trough;Deprecated 10OH-Carbazepine Trough SerPl;;DEPRECATED;2.48;2.54 +74962-2;Maprotiline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Maprotiline [Mass/volume] in Serum or Plasma --trough;Maprotiline Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +7496-3;Cheese mold type Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cheese mold type IgG Ab [Units/volume] in Serum;Cheese Mold IgG Qn;;ACTIVE;1.0h(2);2.73 +74963-0;Promethazine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Promethazine [Mass/volume] in Serum or Plasma --trough;Deprecated Promethazine Trough SerPl-mCn;;DEPRECATED;2.48;2.54 +74964-8;Gabapentin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gabapentin [Mass/volume] in Serum or Plasma --trough;Gabapentin Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74965-5;Haloperidol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Haloperidol [Mass/volume] in Serum or Plasma --trough;Haloperidol Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74966-3;Acetaminophen^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Acetaminophen [Mass/volume] in Serum or Plasma --trough;Deprecated APAP Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74967-1;Adrenal cortex Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Adrenal cortex IgG Ab [Presence] in Serum by Immunofluorescence;Adrenal cortex IgG Ser Ql IF;;ACTIVE;2.48;2.56 +74968-9;Norsertraline^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Norsertraline [Mass/volume] in Serum or Plasma --trough;Deprecated Norsertraline Trough SerPl-mC;;DEPRECATED;2.48;2.54 +74969-7;Methotrimeprazine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Methotrimeprazine [Mass/volume] in Serum or Plasma --trough;Deprecated Methotrimeprazine Trough SerP;;DEPRECATED;2.48;2.54 +74970-5;Acetylsalicylate^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetylsalicylate [Mass/volume] in Serum or Plasma --trough;Acetylsalicylate Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +7497-1;Cheese mold type basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Cheese mold type triggered histamine release [Units/volume] in Blood;Cheese Mold BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +74971-3;Clopenthixol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Clopenthixol [Mass/volume] in Serum or Plasma --trough;Deprecated Clopenthixol Trough SerPl-mCn;;DEPRECATED;2.48;2.54 +74972-1;9-Hydroxyrisperidone^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated 9-Hydroxyrisperidone [Mass/volume] in Serum or Plasma --trough;Deprecated 9OH-risperiDONE Trough SerPl-;;DEPRECATED;2.48;2.54 +74973-9;carBAMazepine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine [Mass/volume] in Serum or Plasma --trough;carBAMazepine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74974-7;carBAMazepine.free^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine free [Mass/volume] in Serum or Plasma --trough;carBAMazepine free Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74975-4;Nordiazepam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Nordiazepam [Mass/volume] in Serum or Plasma --trough;Nordiazepam Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74976-2;Phenytoin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin [Mass/volume] in Serum or Plasma --trough;Phenytoin Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74977-0;Transferrin;MRat;24H;Urine;Qn;;CHEM;1;Transferrin [Mass/time] in 24 hour Urine;Transferrin 24h Ur-mRate;;ACTIVE;2.48;2.48 +74978-8;Cerebroside sulfatase & N-Acetylgalactosamine-4-Sulfatase panel;CCnt;Pt;WBC;-;;PANEL.CHEM;1;Cerebroside sulfatase and N-Acetylgalactosamine-4-Sulfatase panel [Enzymatic activity/mass] - Leukocytes;Arylsulfatase A+ B Pnl WBC-cCnt;;ACTIVE;2.48;2.48 +74979-6;Urate;SCnc;Pt;BAL;Qn;;CHEM;1;Urate [Moles/volume] in Bronchoalveolar lavage;Urate BAL-sCnc;;ACTIVE;2.48;2.48 +74980-4;LORazepam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;LORazepam [Mass/volume] in Serum or Plasma --trough;LORazepam Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74981-2;Pimozide^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pimozide [Mass/volume] in Serum or Plasma --trough;Pimozide Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74982-0;FLUoxetine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;FLUoxetine [Mass/volume] in Serum or Plasma --trough;FLUoxetine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74983-8;Phenytoin.free^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin Free [Mass/volume] in Serum or Plasma --trough;Phenytoin Free Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74984-6;5,10-Methylenetetrahydrofolate reductase;CCnt;Pt;Lymphoblasts;Qn;;CHEM;1;5,10-Methylenetetrahydrofolate reductase [Enzymatic activity/mass] in Lymphoblasts;MTHFR Lymphblst-cCnt;;ACTIVE;2.48;2.48 +74985-3;ALPRAZolam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ALPRAZolam [Mass/volume] in Serum or Plasma --trough;Alpraz Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74986-1;Hydroxychloroquine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxychloroquine [Mass/volume] in Serum or Plasma --trough;OH-Chloroquine Trough SerPl-mCnc;;ACTIVE;2.48;2.48 +74987-9;Pericyazine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Pericyazine [Mass/volume] in Serum or Plasma --trough;Deprecated Pericyazine Trough SerPl-mCnc;;DEPRECATED;2.48;2.54 +74988-7;Hexacarboxylporphyrin;SCnc;Pt;RBC;Qn;;CHEM;1;Hexacarboxylporphyrin [Moles/volume] in Red Blood Cells;Hexa-CP RBC-sCnc;;ACTIVE;2.48;2.48 +7498-9;Chrysonilia sitophila Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chrysonilia sitophila IgE Ab [Units/volume] in Serum;C sitophila IgE Qn;;ACTIVE;1.0h(2);2.73 +74989-5;Pentacarboxylporphyrins;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pentacarboxylporphyrins [Moles/volume] in Serum or Plasma;Penta-CP SerPl-sCnc;;ACTIVE;2.48;2.48 +74990-3;Alpha 1 antitrypsin;MRat;24H;Stool;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/time] in 24 hour Stool;A1AT 24h Stl-mRate;;ACTIVE;2.48;2.48 +74991-1;Amino acids panel;SRto;Pt;Urine;Qn;;PANEL.CHEM;1;Amino acids panel [Molar ratio] - Urine;Amino acids Pnl Ur-sRto;;ACTIVE;2.48;2.48 +74992-9;Amylase;CCnc;Pt;Saliva;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Saliva (oral fluid);Amylase Sal-cCnc;;ACTIVE;2.48;2.7 +74993-7;Chloride & sodium panel;SCnc;Pt;Sweat;Qn;;PANEL.CHEM;1;Chloride and sodium panel [Moles/volume] - Sweat;Chloride+sodium Pnl Sweat-sCnc;;ACTIVE;2.48;2.48 +74994-5;Collagen crosslinked C-telopeptide;Zscore;Pt;Ser/Plas;Qn;;CHEM;1;Collagen crosslinked C-telopeptide [Z-score] in Serum or Plasma;Collagen CTx Z-score SerPl;;ACTIVE;2.48;2.48 +74995-2;Osteocalcin;Zscore;Pt;Ser/Plas;Qn;;CHEM;1;Osteocalcin [Z-score] in Serum or Plasma;Osteocalcin Z-score SerPl;;ACTIVE;2.48;2.48 +74996-0;Alkaline phosphatase.bone;Zscore;Pt;Ser/Plas;Qn;;CHEM;1;Alkaline phosphatase.bone [Z-score] in Serum or Plasma;ALP Bone Z-score SerPl;;ACTIVE;2.48;2.48 +7499-7;Monkey epithelium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Monkey epithelium IgE Ab [Units/volume] in Serum;Monkey Epith IgE Qn;;ACTIVE;1.0h(2);2.42 +74997-8;Alpha 1 antitrypsin;MCnt;Pt;Stool.dried;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/mass] in Stool.dried;A1AT Stool.dried-mCnt;;ACTIVE;2.48;2.48 +74998-6;5,10-Methylenetetrahydrofolate reductase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;5,10-Methylenetetrahydrofolate reductase [Enzymatic activity/mass] in Fibroblast;MTHFR Fib-cCnt;;ACTIVE;2.48;2.48 +74999-4;5,10-Methylenetetrahydrofolate reductase;CCnt;Pt;WBC;Qn;;CHEM;1;5,10-Methylenetetrahydrofolate reductase [Enzymatic activity/mass] in Leukocytes;MTHFR WBC-cCnt;;ACTIVE;2.48;2.48 +7-5;Amdinocillin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Amdinocillin [Susceptibility] by Minimum lethal concentration (MLC);Amdinocillin Islt MLC;;ACTIVE;1.0;2.19 +750-0;Myelocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Myelocytes/100 leukocytes in Blood by Automated count;Deprecated Myelocytes Fr Bld Auto;;DEPRECATED;1.0;2.7 +75000-0;Coproporphyrin 3/Coproporphyrin.total;SFr;24H;Urine;Qn;;CHEM;1;Coproporphyrin 3/Coproporphyrin.total in 24 hour Urine;Copro3/Copro total 24h SFr Ur;;ACTIVE;2.48;2.48 +75001-8;Coproporphyrin 3/Coproporphyrin.total;SFr;Pt;Stool;Qn;;CHEM;1;Coproporphyrin 3/Coproporphyrin.total in Stool;Copro3/Copro total SFr Stl;;ACTIVE;2.48;2.48 +7500-2;Aedes communis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Aedes mosquito triggered histamine release [Units/volume] in Blood;Aedes mosquito BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75002-6;(Actinidia chinensis+Ananas comosus+Musa spp+Mangifera indica) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 50 (Kiwi+Pineapple+Banana+Mango) IgE Ab [Units/volume] in Serum by Multidisk;Food Allergen Mix50 IgE Qn;;ACTIVE;2.48;2.54 +75003-4;(Arachis hypogaea+Cow milk+Egg white+Glycine max+Triticum aestivum+Oryza sativa) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 7A (Peanut+Cow milk+Egg white+Soybean+Wheat+Rice) IgE Ab [Units/volume] in Serum by Multidisk;Food Allergen Mix7A IgE Qn;;ACTIVE;2.48;2.54 +75004-2;(Beef+Chicken+Pork+Lamb) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix fp73 (Beef+Chicken+Pork+Lamb) IgE Ab [Units/volume] in Serum by Multidisk;Food Allergen Mix fp73 IgE Qn;;ACTIVE;2.48;2.67 +75005-9;(Brassica oleracea var capitata+Capsicum annuum+Lycopersicon lycopersicum+Spinacia oleracea) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 14 (Cabbage+Paprika+Tomato+Spinach) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix14 IgE Qn;;ACTIVE;2.48;2.54 +75006-7;(Cancer pagurus+Fagopyrum esculentum+Pandalus borealis+Sesamum indicum+Zea mays) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix E (Crab+Buckwheat+Shrimp+Sesame seed+Corn) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix E IgE Qn;;ACTIVE;2.48;2.54 +75007-5;Aspergillus restrictus native (nAsp r) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus restrictus native (nAsp r) 1 IgE Ab [Units/volume] in Serum;Aspergillus restrictus (nAsp r) 1 IgE Qn;;ACTIVE;2.48;2.54 +75008-3;Canis familiaris native (nCan f) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog native (nCan f) 1 IgE Ab [Units/volume] in Serum;Dog native (nCan f) 1 IgE Qn;;ACTIVE;2.48;2.54 +75009-1;CEBPA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CEBPA gene full mutation analysis in Blood or Tissue by Sequencing;CEBPA gene Full Mut Anl Bld/T Seq;;ACTIVE;2.48;2.69 +7501-0;Tillandsia usneoides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spanish Moss IgE Ab [Units/volume] in Serum;Spanish Moss IgE Qn;;ACTIVE;1.0h(2);2.42 +75010-9;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH.INV;1;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"inv(16)(p13;q22) Mar Ql";;ACTIVE;2.48;2.56 +75011-7;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH;1;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"t(15;17)(PML,RARA) Mar Ql";;ACTIVE;2.48;2.56 +75012-5;"t(4;11)(q21.3;q23)(AFF1,MLL) fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH;1;"t(4;11)(q21.3;q23)(AFF1,MLL) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"t(4;11)(AFF1,MLL) Mar Ql";;ACTIVE;2.48;2.56 +75013-3;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH;1;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"t(8;21)(RUNX1T1,RUNX1) Mar Ql";;ACTIVE;2.48;2.56 +75014-1;"t(9;12)(q34.1;p13)(ABL1,ETV6) fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH;1;"t(9;12)(q34.1;p13)(ABL1,ETV6) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"t(9;12)(ABL1,ETV6) Mar Ql";;ACTIVE;2.48;2.56 +75015-8;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 fusion transcript";PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)b2a2 Bld/T Ql;;ACTIVE;2.48;2.56 +75016-6;"t(9;22)(q34.1;q11)(ABL1,BCR) b3a2 fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH;1;"t(9;22)(q34.1;q11)(ABL1,BCR) b3a2 fusion transcript [Presence] in Bone marrow by Molecular genetics method";t(ABL1,BCR)b3a2 Mar Ql;;ACTIVE;2.48;2.56 +75017-4;"t(9;22)(q34.1;q11)(ABL1,BCR) e19a2 fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH;1;"t(9;22)(q34.1;q11)(ABL1,BCR) e19a2 fusion transcript [Presence] in Bone marrow by Molecular genetics method";t(ABL1,BCR)e19a2 Mar Ql;;ACTIVE;2.48;2.56 +75018-2;"t(9;22)(q34.1;q11)(ABL1,BCR) e19a2 fusion transcript";PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;"t(9;22)(q34.1;q11)(ABL1,BCR) e19a2 fusion transcript [Presence] in Blood or Tissue by Molecular genetics method";t(ABL1,BCR)e19a2 Bld/T Ql;;ACTIVE;2.48;2.73 +75019-0;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH;1;"t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript [Presence] in Bone marrow by Molecular genetics method";t(ABL1,BCR)e1a2 Mar Ql;;ACTIVE;2.48;2.56 +75020-8;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript";Find;Pt;Bone mar;Doc;Molgen;MOLPATH;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript in Bone marrow by Molecular genetics method";"t(9;22)(ABL1,BCR) Mar";;ACTIVE;2.48;2.66 +75021-6;OLANZapine panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;OLANZapine panel - Serum or Plasma;OLANZapine Pnl SerPl;;ACTIVE;2.48;2.48 +75022-4;Fat.Microscopic Observation;PrThr;Pt;Urine sed;Ord;Oil red O stain;UA;1;Fat.microscopic observation [Presence] in Urine sediment by Oil red O stain;Fat UrnS Ql ORO Stn;;ACTIVE;2.48;2.56 +75023-2;Basophils.CD63/100 basophils;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD63 (Activated) Basophils/100 basophils in Blood by Flow cytometry (FC);CD63 Basophils NFr Bld FC;;ACTIVE;2.48;2.48 +75024-0;Coproporphyrin 1/Porphyrins.total;SFr;Pt;Stool;Qn;;CHEM;1;Coproporphyrin 1/Porphyrins.total in Stool;Copro1 SFr Stl;;ACTIVE;2.48;2.48 +75025-7;Coproporphyrin 3/Porphyrins.total;SFr;Pt;Stool;Qn;;CHEM;1;Coproporphyrin 3/Porphyrins.total in Stool;Copro3 SFr Stl;;ACTIVE;2.48;2.48 +75026-5;Deuteroporphyrin/Porphyrins.total;SFr;Pt;Stool;Qn;;CHEM;1;Deuteroporphyrin/Porphyrins.total in Stool;Deuteropor SFr Stl;;ACTIVE;2.48;2.48 +75027-3;Mesoporphyrin/Porphyrins.total;SFr;Pt;Stool;Qn;;CHEM;1;Mesoporphyrin/Porphyrins.total in Stool;Mesopor SFr Stl;;ACTIVE;2.48;2.48 +7502-8;Moth Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Moth IgE Ab [Units/volume] in Serum;Moth IgE Qn;;ACTIVE;1.0h(2);2.73 +75028-1;Protoporphyrin/Porphyrins.total;SFr;Pt;Stool;Qn;;CHEM;1;Protoporphyrin/Porphyrins.total in Stool;Protopor SFr Stl;;ACTIVE;2.48;2.48 +75029-9;Zanamivir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Zanamivir [Susceptibility] by Genotype method;Zanamivir Islt Genotyp;;ACTIVE;2.48;2.66 +75030-7;Wholesale drug distributors and third-party logistics facility registration;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Wholesale drug distributors and third-party logistics facility registration;FDA label Whlsale drg dist+3rd prty reg;;ACTIVE;2.48;2.48 +75031-5;Human compounded drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Human compounded drug label;FDA label Human comp drug label;;ACTIVE;2.48;2.63 +75032-3;CEBPA gene full mutation analysis;Find;Pt;Bone mar;Doc;Sequencing;MOLPATH.MUT;1;CEBPA gene full mutation analysis in Bone marrow by Sequencing;CEBPA gene Full Mut Anl Mar Seq;;ACTIVE;2.48;2.69 +75033-1;MPL gene mutations tested for;Prid;Pt;Bone mar;Nom;Molgen;MOLPATH.MUT;1;MPL gene mutations tested for in Bone marrow by Molecular genetics method Nominal;MPL gene Mut Tested Mar;;ACTIVE;2.48;2.48 +75034-9;NPM1 gene targeted mutation analysis;Prid;Pt;Bone mar;Nom;Molgen;MOLPATH.MUT;1;NPM1 gene mutations found [Identifier] in Bone marrow by Molecular genetics method Nominal;NPM1 gene Mut Anl Mar;;ACTIVE;2.48;2.63 +75035-6;Oxytocin;SCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Oxytocin [Moles/volume] in Saliva (oral fluid);Oxytocin Sal-sCnc;;ACTIVE;2.48;2.48 +7503-6;Moth basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Moth triggered histamine release [Units/volume] in Blood;Moth BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75036-4;2-Hydroxyglutarate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;2-Hydroxyglutarate [Moles/volume] in Amniotic fluid;2OH-gluterate Amn-sCnc;;ACTIVE;2.48;2.48 +75037-2;2-Hydroxyglutarate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;2-Hydroxyglutarate [Moles/volume] in DBS;2OH-gluterate DBS-sCnc;;ACTIVE;2.48;2.61 +75038-0;Bile acid pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Bile acid pattern [Interpretation] in Serum or Plasma Narrative;Bile Ac Pattern SerPl-Imp;;ACTIVE;2.48;2.48 +75039-8;Biopterin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Biopterin [Moles/volume] in Serum or Plasma;Biopterin SerPl-sCnc;;ACTIVE;2.48;2.48 +75040-6;D-lactate;SCnc;Pt;CSF;Qn;;CHEM;1;D-Lactate [Moles/volume] in Cerebral spinal fluid;D-Lactate CSF-sCnc;;ACTIVE;2.48;2.48 +75041-4;Pyridoxal;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pyridoxal [Moles/volume] in Serum or Plasma;Pyridoxal SerPl-sCnc;;ACTIVE;2.48;2.48 +75042-2;Pyridoxal;SCnc;Pt;CSF;Qn;;CHEM;1;Pyridoxal [Moles/volume] in Cerebral spinal fluid;Pyridoxal CSF-sCnc;;ACTIVE;2.48;2.48 +75043-0;Pyridoxine;SCnc;Pt;CSF;Qn;;CHEM;1;Pyridoxine [Moles/volume] in Cerebral spinal fluid;Vit B6 CSF-sCnc;;ACTIVE;2.48;2.48 +7504-4;Mouse hair Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse hair IgE Ab [Units/volume] in Serum;Mouse Hair IgE Qn;;ACTIVE;1.0h(2);2.42 +75044-8;Sepiapterin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sepiapterin/Creatinine [Molar ratio] in Urine;Sepiapterin/Creat Ur-sRto;;ACTIVE;2.48;2.54 +75045-5;Sialate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Sialate [Moles/volume] in Amniotic fluid;Sialate Amn-sCnc;;ACTIVE;2.48;2.48 +75046-3;Sialate;SCnc;Pt;CSF;Qn;;CHEM;1;Sialate [Moles/volume] in Cerebral spinal fluid;Sialate CSF-sCnc;;ACTIVE;2.48;2.48 +75047-1;Sialate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sialate [Moles/volume] in Serum or Plasma;Sialate SerPl-sCnc;;ACTIVE;2.48;2.48 +75048-9;Tetrahydrofolate;SCnc;Pt;CSF;Qn;;CHEM;1;Tetrahydrofolate [Moles/volume] in Cerebral spinal fluid;THfolate CSF-sCnc;;ACTIVE;2.48;2.48 +75049-7;Thiosulfate;SCnc;Pt;Urine;Qn;;CHEM;1;Thiosulfate [Moles/volume] in Urine;Thiosulfate Ur-sCnc;;ACTIVE;2.48;2.48 +75050-5;Ubiquinone 10;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Coenzyme Q10 [Moles/volume] in Serum or Plasma;Ubiquinone10 SerPl-sCnc;;ACTIVE;2.48;2.56 +7505-1;Mouse multi Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse multi IgE Ab [Units/volume] in Serum;Mouse Multi IgE Qn;;ACTIVE;1.0h(2);2.42 +75051-3;Xylose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Xylose/Creatinine [Molar ratio] in Urine;Xylose/Creat Ur-sRto;;ACTIVE;2.48;2.54 +75052-1;Adenosine deaminase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in DBS;Adenosine deaminase DBS-cCnc;;ACTIVE;2.48;2.61 +75053-9;Alpha-L-iduronidase;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-L-iduronidase [Enzymatic activity/volume] in Serum or Plasma;A-L-Iduronidase SerPl-cCnc;;ACTIVE;2.48;2.48 +75054-7;Glutaryl CoA dehydrogenase;CCnt;Pt;WBC;Qn;;CHEM;1;Glutaryl CoA dehydrogenase [Enzymatic activity/mass] in Leukocytes;GCDH WBC-cCnt;;ACTIVE;2.48;2.48 +75055-4;Glutaryl CoA dehydrogenase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Glutaryl CoA dehydrogenase [Enzymatic activity/mass] in Fibroblast;GCDH Fib-cCnt;;ACTIVE;2.48;2.48 +75056-2;Pyridoxal phosphate;SCnc;Pt;CSF;Qn;;CHEM;1;Pyridoxal phosphate [Moles/volume] in Cerebral spinal fluid;Pyridoxal Phos CSF-sCnc;;ACTIVE;2.48;2.48 +75057-0;Sialidase;CCnt;Pt;WBC;Qn;;CHEM;1;Sialidase [Enzymatic activity/mass] in Leukocytes;Sialidase WBC-cCnt;;ACTIVE;2.48;2.48 +75058-8;Thymidine phosphorylase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Thymidine phosphorylase [Enzymatic activity/volume] in DBS;ThdPase DBS-cCnc;;ACTIVE;2.48;2.61 +75059-6;Transaldolase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Transaldolase [Enzymatic activity/mass] in Fibroblast;Transaldolase Fib-cCnt;;ACTIVE;2.48;2.48 +75060-4;Pantothenate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pantothenate/Creatinine [Molar ratio] in Urine;Pantothenate/Creat Ur-sRto;;ACTIVE;2.48;2.54 +75061-2;Malonate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Malonate [Moles/volume] in Serum or Plasma;Malonate SerPl-sCnc;;ACTIVE;2.48;2.52 +75062-0;Phenylacetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenylacetate [Moles/volume] in Serum or Plasma;Phenylacetate SerPl-sCnc;;ACTIVE;2.48;2.52 +75063-8;Glycerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycerate [Moles/volume] in Serum or Plasma;Glycerate SerPl-sCnc;;ACTIVE;2.48;2.52 +75064-6;Vanillylmandelate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vanillylmandelate [Moles/volume] in Serum or Plasma;VMA SerPl-sCnc;;ACTIVE;2.48;2.52 +75065-3;Benzoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Benzoate [Moles/volume] in Serum or Plasma;Benzoate SerPl-sCnc;;ACTIVE;2.48;2.52 +75066-1;Pantothenate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pantothenate [Moles/volume] in Serum or Plasma;Pantothenate SerPl-sCnc;;ACTIVE;2.48;2.52 +75067-9;Indole-3-Acetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Indole-3-Acetate [Moles/volume] in Serum or Plasma;Indole-3-acetate SerPl-sCnc;;ACTIVE;2.48;2.52 +75068-7;Malate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Malate [Moles/volume] in Serum or Plasma;Malate SerPl-sCnc;;ACTIVE;2.48;2.52 +7506-9;Mucor plumbeus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mucor plumbeus IgE Ab [Units/volume] in Serum;M plumbeus IgE Qn;;ACTIVE;1.0h(2);2.73 +75069-5;Hippurate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hippurate [Moles/volume] in Serum or Plasma;Hippurate SerPl-sCnc;;ACTIVE;2.48;2.52 +75070-3;Catechol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Catechol [Moles/volume] in Serum or Plasma;Catechol SerPl-sCnc;;ACTIVE;2.48;2.52 +75071-1;Acetaminophen/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Acetaminophen/Creatinine [Molar ratio] in Urine;APAP/Creat Ur-sRto;;ACTIVE;2.48;2.54 +75072-9;Mandelate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Mandelate [Moles/volume] in Serum or Plasma;Mandelate SerPl-sCnc;;ACTIVE;2.48;2.52 +75073-7;Suberate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Suberate [Moles/volume] in Serum or Plasma;Suberate SerPl-sCnc;;ACTIVE;2.48;2.52 +75075-2;4-Hydroxybenzoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxybenzoate [Moles/volume] in Serum or Plasma;4OHBenzoate SerPl-sCnc;;ACTIVE;2.48;2.67 +75076-0;Vanillate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vanillate [Moles/volume] in Serum or Plasma;Vanillate SerPl-sCnc;;ACTIVE;2.48;2.67 +7507-7;Mucor racemosus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mucor racemosus IgG Ab [Units/volume] in Serum;M racemosus IgG Qn;;ACTIVE;1.0h(2);2.73 +75077-8;Quinolinate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Quinolinate [Moles/volume] in Serum or Plasma;Quinolinate SerPl-sCnc;;ACTIVE;2.48;2.67 +75078-6;3-Hydroxydodecanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydodecanoate (3-OH-C12:0)/Creatinine [Molar ratio] in Urine;3OH-dodecanoate/Creat Ur-sRto;;ACTIVE;2.48;2.67 +75079-4;Succinylacetone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Succinylacetone [Moles/volume] in Serum or Plasma;Succinylacetone SerPl-sCnc;;ACTIVE;2.48;2.67 +75080-2;N-acetyl-L-aspartate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N-acetyl-L-aspartate [Moles/volume] in Serum or Plasma;N-Ac-L-Asp SerPl-sCnc;;ACTIVE;2.48;2.67 +75081-0;Fumarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fumarate [Moles/volume] in Serum or Plasma;Fumarate SerPl-sCnc;;ACTIVE;2.48;2.67 +75083-6;Aconitate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aconitate [Moles/volume] in Serum or Plasma;Aconitate SerPl-sCnc;;ACTIVE;2.48;2.52 +75084-4;Sebacate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Sebacate (C8) [Moles/volume] in Serum or Plasma;Sebacate SerPl-sCnc;;ACTIVE;2.48;2.67 +7508-5;Mucor racemosus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Mucor racemosus triggered histamine release [Units/volume] in Blood;M racemosus BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75085-1;Homogentisate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Homogentisate/Creatinine [Molar ratio] in 24 hour Urine;Homogentisate/Creat 24h Ur-sRto;;ACTIVE;2.48;2.67 +75086-9;Catecholamine metabolites pattern;Imp;Pt;Urine;Nar;;CHEM;1;Catecholamine metabolites pattern [Interpretation] in Urine Narrative;Catecholamine pattern Ur-Imp;;ACTIVE;2.48;2.52 +75087-7;Adipate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adipate [Moles/volume] in Serum or Plasma;Adipate SerPl-sCnc;;ACTIVE;2.48;2.67 +75088-5;3-Indolelactate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Indolelactate [Moles/volume] in Serum or Plasma;3-Indolelactate SerPl-sCnc;;ACTIVE;2.48;2.67 +75089-3;5-Oxoproline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Oxoproline [Moles/volume] in Serum or Plasma;5Oxoproline SerPl-sCnc;;ACTIVE;2.48;2.67 +75090-1;Isocitrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isocitrate [Moles/volume] in Serum or Plasma;Isocitrate SerPl-sCnc;;ACTIVE;2.48;2.67 +75091-9;Catechol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Catechol/Creatinine [Molar ratio] in Urine;Catechol/Creat Ur-sRto;;ACTIVE;2.48;2.67 +75092-7;Birth date;Date;Pt;^Fetus;Qn;;PATH;1;Birth date of Fetus;Birth Date Act Fetus;;ACTIVE;2.48;2.48 +7509-3;Mucor sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mucor sp IgG Ab [Units/volume] in Serum;Mucor IgG Qn;;ACTIVE;1.0h(2);2.69 +75093-5;Galactose^post therapeutic diet;MCnc;Pt;Bld.dot;Qn;;CHAL;1;Galactose [Mass/volume] in DBS --post therapeutic diet;Galactose p diet DBS-mCnc;;ACTIVE;2.48;2.61 +75094-3;Galactose 1 phosphate uridyl transferase^post therapeutic diet;CCnc;Pt;Bld.dot;Qn;;CHAL;1;Galactose 1 phosphate uridyl transferase [Enzymatic activity/volume] in DBS --post therapeutic diet;Gal1PUT p diet DBS-cCnc;;ACTIVE;2.48;2.61 +75095-0;Docosahexaenoate;EntSub;Pt;RBC;Qn;;CHEM;1;Docosahexaenoate (C22:6w3) [Entitic substance] in Red Blood Cells;DHA EntSub RBC;;ACTIVE;2.48;2.64 +75096-8;Fatty acids.very long chain.C26:0;EntSub;Pt;RBC;Qn;;CHEM;1;Fatty acids.very long chain C26:0 (Hexacosanoate) [Entitic substance] in Red Blood Cells;VLCFA C26:0 EntSub RBC;;ACTIVE;2.48;2.52 +75097-6;Eicosapentaenoate;EntSub;Pt;RBC;Qn;;CHEM;1;Eicosapentaenoate (C20:5w3) [Entitic substance] in Red Blood Cells;EPA EntSub RBC;;ACTIVE;2.48;2.64 +75098-4;Nervonate;EntSub;Pt;RBC;Qn;;CHEM;1;Nervonate (C24:1) [Entitic substance] in Red Blood Cells;Nervonate EntSub RBC;;ACTIVE;2.48;2.52 +75099-2;Laurate;EntSub;Pt;RBC;Qn;;CHEM;1;Laurate (C12:0) [Entitic substance] in Red Blood Cells;Laurate EntSub RBC;;ACTIVE;2.48;2.52 +75100-8;Fatty acids;EntSub;Pt;RBC;Qn;;CHEM;1;Fatty acids [Entitic substance] in Red Blood Cells;FA EntSub RBC;;ACTIVE;2.48;2.52 +7510-1;Artemisia vulgaris basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Mugwort triggered histamine release [Units/volume] in Blood;Mugwort BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75101-6;Fatty acids.very long chain.C22:0;EntSub;Pt;RBC;Qn;;CHEM;1;Fatty acids.very long chain C22:0 (Docosanoate) [Entitic substance] in Red Blood Cells;VLCFA C22:0 EntSub RBC;;ACTIVE;2.48;2.52 +75102-4;Oleate;EntSub;Pt;RBC;Qn;;CHEM;1;Oleate (C18:1w9) [Entitic substance] in Red Blood Cells;Oleate EntSub RBC;;ACTIVE;2.48;2.52 +75103-2;Myristate;EntSub;Pt;RBC;Qn;;CHEM;1;Myristate (C14:0) [Entitic substance] in Red Blood Cells;Myristate EntSub RBC;;ACTIVE;2.48;2.52 +75104-0;Fatty acids.very long chain.C24:0;EntSub;Pt;RBC;Qn;;CHEM;1;Fatty acids.very long chain C24:0 (Tetracosanoate) [Entitic substance] in Red Blood Cells;VLCFA C24:0 EntSub RBC;;ACTIVE;2.48;2.52 +75105-7;Fatty acids.very long chain.C26:1;EntSub;Pt;RBC;Qn;;CHEM;1;Fatty acids.very long chain C26:1 (Hexacosenoate) [Entitic substance] in Red Blood Cells;VLCFA C26:1 EntSub RBC;;ACTIVE;2.48;2.52 +75106-5;Mead acid;EntSub;Pt;RBC;Qn;;CHEM;1;Mead acid (C20:3w9) [Entitic substance] in Red Blood Cells;Mead acid EntSub RBC;;ACTIVE;2.48;2.52 +75107-3;Pentadecanoate;EntSub;Pt;RBC;Qn;;CHEM;1;Pentadecanoate [Entitic substance] in Red Blood Cells;Pentadecanoate EntSub RBC;;ACTIVE;2.48;2.52 +75108-1;Arachidate;EntSub;Pt;RBC;Qn;;CHEM;1;Arachidate (C20:0) [Entitic substance] in Red Blood Cells;Arachidate EntSub RBC;;ACTIVE;2.48;2.52 +75109-9;Fatty acids.very long chain.C22:1n9;EntSub;Pt;RBC;Qn;;CHEM;1;Fatty acids.very long chain.C22:1n9 (Erucate) [Entitic substance] in Red Blood Cells;VLCFA.C22:1n9 EntSub RBC;;ACTIVE;2.48;2.52 +75110-7;Arachidonate;EntSub;Pt;RBC;Qn;;CHEM;1;Arachidonate (C20:4w6) [Entitic substance] in Red Blood Cells;AA EntSub RBC;;ACTIVE;2.48;2.64 +75111-5;Palmitoleate;EntSub;Pt;RBC;Qn;;CHEM;1;Palmitoleate (C16:1w7) [Entitic substance] in Red Blood Cells;Palmitoleate EntSub RBC;;ACTIVE;2.48;2.52 +75112-3;Docosatetraenoate;EntSub;Pt;RBC;Qn;;CHEM;1;Docosatetraenoate (C22:4w6) [Entitic substance] in Red Blood Cells;Docosatetraenoate EntSub RBC;;ACTIVE;2.48;2.52 +75113-1;Alpha linolenate;EntSub;Pt;RBC;Qn;;CHEM;1;Alpha linolenate (C18:3w3) [Entitic substance] in Red Blood Cells;A-Linolenate EntSub RBC;;ACTIVE;2.48;2.52 +75114-9;Fatty acids pattern;Imp;Pt;RBC;Nar;;CHEM;1;Fatty acids pattern [Interpretation] in Red Blood Cells Narrative;Fatty acids pattern RBC-Imp;;ACTIVE;2.48;2.52 +75115-6;Palmitate;EntSub;Pt;RBC;Qn;;CHEM;1;Palmitate (C16:0) [Entitic substance] in Red Blood Cells;Palmitate EntSub RBC;;ACTIVE;2.48;2.52 +75116-4;Decanoate;EntSub;Pt;RBC;Qn;;CHEM;1;Decanoate (C10:0) [Entitic substance] in Red Blood Cells;Decanoate EntSub RBC;;ACTIVE;2.48;2.52 +75117-2;Linoleate;EntSub;Pt;RBC;Qn;;CHEM;1;Linoleate (C18:2w6) [Entitic substance] in Red Blood Cells;Linoleate EntSub RBC;;ACTIVE;2.48;2.52 +75118-0;Octadecanoate;EntSub;Pt;RBC;Qn;;CHEM;1;Octadecanoate (C18:0) [Entitic substance] in Red Blood Cells;Octadecanoate EntSub RBC;;ACTIVE;2.48;2.52 +7511-9;Artemisia douglasiana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;California Mugwort IgE Ab [Units/volume] in Serum;Calif Mugwort IgE Qn;;ACTIVE;1.0h(2);2.42 +75119-8;Gamma linolenate;EntSub;Pt;RBC;Qn;;CHEM;1;Gamma Linolenate (C18:3w6) [Entitic substance] in Red Blood Cells;G-Linolenate EntSub RBC;;ACTIVE;2.48;2.52 +75120-6;Octanoate;EntSub;Pt;RBC;Qn;;CHEM;1;Octanoate (C8:0) [Entitic substance] in Red Blood Cells;Octanoate EntSub RBC;;ACTIVE;2.48;2.52 +75121-4;Thymine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thymine [Moles/volume] in Serum or Plasma;Thymine SerPl-sCnc;;ACTIVE;2.48;2.73 +75122-2;Deoxyadenosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deoxyadenosine [Moles/volume] in Serum or Plasma;Deoxyadenosine SerPl-sCnc;;ACTIVE;2.48;2.48 +75123-0;Hypoxanthine;SCnc;Pt;CSF;Qn;;CHEM;1;Hypoxanthine [Moles/volume] in Cerebral spinal fluid;Hypoxanthine CSF-sCnc;;ACTIVE;2.48;2.48 +75124-8;Deoxyadenosine;SCnc;Pt;CSF;Qn;;CHEM;1;Deoxyadenosine [Moles/volume] in Cerebral spinal fluid;Deoxyadenosine CSF-sCnc;;ACTIVE;2.48;2.48 +75125-5;Orotidine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Orotidine [Moles/volume] in Serum or Plasma;Orotidine SerPl-sCnc;;ACTIVE;2.48;2.48 +75126-3;Orotate;SCnc;Pt;CSF;Qn;;CHEM;1;Orotate [Moles/volume] in Cerebral spinal fluid;Orotate CSF-sCnc;;ACTIVE;2.48;2.48 +7512-7;Morus alba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated White mulberry IgE Ab [Units/volume] in Serum;Deprecated White mulberry IgE Qn;;DEPRECATED;1.0h(2);2.69 +75127-1;Deoxyinosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deoxyinosine [Moles/volume] in Serum or Plasma;Deoxyinosine SerPl-sCnc;;ACTIVE;2.48;2.73 +75128-9;Uracil;SCnc;Pt;CSF;Qn;;CHEM;1;Uracil [Moles/volume] in Cerebral spinal fluid;Uracil CSF-sCnc;;ACTIVE;2.48;2.48 +75129-7;Xanthine;SCnc;Pt;CSF;Qn;;CHEM;1;Xanthine [Moles/volume] in Cerebral spinal fluid;Xanthine CSF-sCnc;;ACTIVE;2.48;2.48 +75130-5;Uridine;SCnc;Pt;CSF;Qn;;CHEM;1;Uridine [Moles/volume] in Cerebral spinal fluid;Uridine CSF-sCnc;;ACTIVE;2.48;2.48 +75131-3;Adenine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adenine [Moles/volume] in Serum or Plasma;Adenine SerPl-sCnc;;ACTIVE;2.48;2.48 +75132-1;Oxipurinol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Oxipurinol/Creatinine [Molar ratio] in Urine;Oxipurinol/Creat Ur-sRto;;ACTIVE;2.48;2.54 +75133-9;Adenine;SCnc;Pt;CSF;Qn;;CHEM;1;Adenine [Moles/volume] in Cerebral spinal fluid;Adenine CSF-sCnc;;ACTIVE;2.48;2.48 +75134-7;Deoxyguanosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Deoxyguanosine [Moles/volume] in Serum or Plasma;Deoxyguanosine SerPl-sCnc;;ACTIVE;2.48;2.73 +7513-5;Morus alba Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White mulberry IgG Ab [Units/volume] in Serum;White mulberry IgG Qn;;ACTIVE;1.0h(2);2.73 +75135-4;Hypoxanthine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hypoxanthine [Moles/volume] in Serum or Plasma;Hypoxanthine SerPl-sCnc;;ACTIVE;2.48;2.73 +75136-2;Adenosine;SCnc;Pt;CSF;Qn;;CHEM;1;Adenosine [Moles/volume] in Cerebral spinal fluid;ADO CSF-sCnc;;ACTIVE;2.48;2.48 +75137-0;Acadesine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Acadesine [Moles/volume] in Serum or Plasma;Acadesine SerPl-sCnc;;ACTIVE;2.48;2.48 +75138-8;Succinylaminoimidazole carboxamide riboside/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Succinylaminoimidazole carboxamide riboside/Creatinine [Molar ratio] in Urine;SAICAR/Creat Ur-sRto;;ACTIVE;2.48;2.54 +75139-6;Urate;SCnc;Pt;CSF;Qn;;CHEM;1;Urate [Moles/volume] in Cerebral spinal fluid;Urate CSF-sCnc;;ACTIVE;2.48;2.48 +75140-4;Allantoine;SCnc;Pt;CSF;Qn;;CHEM;1;Allantoine [Moles/volume] in Cerebral spinal fluid;Allantoine CSF-sCnc;;ACTIVE;2.48;2.48 +75141-2;Acadesine;SCnc;Pt;CSF;Qn;;CHEM;1;Acadesine [Moles/volume] in Cerebral spinal fluid;Acadesine CSF-sCnc;;ACTIVE;2.48;2.48 +75142-0;Adenosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Adenosine [Moles/volume] in Serum or Plasma;ADO SerPl-sCnc;;ACTIVE;2.48;2.48 +7514-3;Morus rubra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red mulberry IgE Ab [Units/volume] in Serum;Red mulberry IgE Qn;;ACTIVE;1.0h(2);2.73 +75143-8;Deoxyuridine;SCnc;Pt;CSF;Qn;;CHEM;1;Deoxyuridine [Moles/volume] in Cerebral spinal fluid;Deoxyuridine CSF-sCnc;;ACTIVE;2.48;2.48 +75144-6;Xanthine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Xanthine [Moles/volume] in Serum or Plasma;Xanthine SerPl-sCnc;;ACTIVE;2.48;2.73 +75145-3;Succinyladenosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Succinyladenosine [Moles/volume] in Serum or Plasma;Succinyladenosine SerPl-sCnc;;ACTIVE;2.48;2.48 +75146-1;Succinylaminoimidazole carboxamide riboside;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Succinylaminoimidazole carboxamide riboside [Moles/volume] in Serum or Plasma;SAICAR SerPl-sCnc;;ACTIVE;2.48;2.48 +75147-9;Succinylaminoimidazole carboxamide riboside;SCnc;Pt;CSF;Qn;;CHEM;1;Succinylaminoimidazole carboxamide riboside [Moles/volume] in Cerebral spinal fluid;SAICAR CSF-sCnc;;ACTIVE;2.48;2.48 +75148-7;Orotidine;SCnc;Pt;CSF;Qn;;CHEM;1;Orotidine [Moles/volume] in Cerebral spinal fluid;Orotidine CSF-sCnc;;ACTIVE;2.48;2.48 +75149-5;Deoxyguanosine;SCnc;Pt;CSF;Qn;;CHEM;1;Deoxyguanosine [Moles/volume] in Cerebral spinal fluid;Deoxyguanosine CSF-sCnc;;ACTIVE;2.48;2.48 +7515-0;Agaricus hortensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mushroom IgG Ab [Units/volume] in Serum;Mushroom IgG Qn;;ACTIVE;1.0h(2);2.73 +75150-3;Inosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Inosine [Moles/volume] in Serum or Plasma;Inosine SerPl-sCnc;;ACTIVE;2.48;2.73 +75151-1;Acadesine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Acadesine/Creatinine [Molar ratio] in Urine;Acadesine/Creat Ur-sRto;;ACTIVE;2.48;2.73 +75152-9;Uracil;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Uracil [Moles/volume] in Serum or Plasma;Uracil SerPl-sCnc;;ACTIVE;2.48;2.73 +75153-7;Thymine;SCnc;Pt;CSF;Qn;;CHEM;1;Thymine [Moles/volume] in Cerebral spinal fluid;Thymine CSF-sCnc;;ACTIVE;2.48;2.48 +75154-5;Inosine;SCnc;Pt;CSF;Qn;;CHEM;1;Inosine [Moles/volume] in Cerebral spinal fluid;Inosine CSF-sCnc;;ACTIVE;2.48;2.48 +75155-2;Allantoine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Allantoine/Creatinine [Molar ratio] in Urine;Allantoine/Creat Ur-sRto;;ACTIVE;2.48;2.54 +75156-0;Thymidine;SCnc;Pt;CSF;Qn;;CHEM;1;Thymidine [Moles/volume] in Cerebral spinal fluid;Thymidine CSF-sCnc;;ACTIVE;2.48;2.48 +75157-8;Deoxyinosine;SCnc;Pt;CSF;Qn;;CHEM;1;Deoxyinosine [Moles/volume] in Cerebral spinal fluid;Deoxyinosine CSF-sCnc;;ACTIVE;2.48;2.48 +75158-6;Allantoine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Allantoine [Moles/volume] in Serum or Plasma;Allantoine SerPl-sCnc;;ACTIVE;2.48;2.48 +75159-4;Uridine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Uridine [Moles/volume] in Serum or Plasma;Uridine SerPl-sCnc;;ACTIVE;2.48;2.73 +75160-2;Adenosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adenosine/Creatinine [Molar ratio] in Urine;ADO/Creat Ur-sRto;;ACTIVE;2.48;2.73 +75161-0;BPAP activity;Find;Pt;Ventilator;Ord;;PULM;2;Bilevel positive airway pressure (BPAP) activity Ventilator;BPAP activity Vent;;ACTIVE;2.48;2.48 +75162-8;BIPAP activity;Find;Pt;Ventilator;Ord;;PULM;2;Biphasic positive airway pressure (BIPAP) activity Ventilator;BIPAP activity Vent;;ACTIVE;2.48;2.73 +75163-6;Trimester of first prenatal visit;Time;Pt;^Mother;Ord;CDC.CS;SURVEY.CDC;4;Mother's Trimester of first prenatal visit [CDC.CS];;;ACTIVE;2.48;2.48 +75164-4;Non-treponemal or treponemal test was performed at first prenatal visit;Find;Pt;^Mother;Ord;CDC.CS;SURVEY.CDC;4;Mother's Non-treponemal or treponemal test was performed at first prenatal visit [CDC.CS];;;ACTIVE;2.48;2.48 +75165-1;Non-treponemal or treponemal test was performed at 28-32 weeks gestation;Find;Pt;^Mother;Ord;CDC.CS;SURVEY.CDC;4;Mother's Non-treponemal or treponemal test was performed at 28-32 weeks gestation [CDC.CS];;;ACTIVE;2.48;2.48 +75166-9;Non-treponemal or treponemal test was performed at delivery;Find;Pt;^Mother;Ord;CDC.CS;SURVEY.CDC;4;Mother's Non-treponemal or treponemal test was performed at delivery [CDC.CS];;;ACTIVE;2.48;2.48 +75167-7;Date of most recent non-treponemal test;Date;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Date most recent non-treponemal test;;;ACTIVE;2.48;2.5 +7516-8;Agaricus hortensis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Mushroom triggered histamine release [Units/volume] in Blood;Mushroom BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75168-5;Most recent non-treponemal test result;Find;Pt;^Mother;Ord;CDC.CS;SURVEY.CDC;4;Mother's Most recent non-treponemal test result [CDC.CS];;;ACTIVE;2.48;2.48 +75169-3;Most recent non-treponemal test titer;Titr;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Most recent non-treponemal test titer;;;ACTIVE;2.48;2.48 +75170-1;Date first non-treponemal test;Date;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Date first non-treponemal test;;;ACTIVE;2.48;2.48 +75171-9;First non-treponemal test result;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's First non-treponemal test result [CDC.CS];;;ACTIVE;2.48;2.48 +75172-7;First non-treponemal test titer;Titr;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's First non-treponemal test titer;;;ACTIVE;2.48;2.48 +75173-5;Date of first treponemal test;Date;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Date of first treponemal test;;;ACTIVE;2.48;2.48 +75174-3;First treponemal test type;Type;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's First treponemal test type [CDC.CS];;;ACTIVE;2.48;2.48 +75175-0;First treponemal test result;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's First treponemal test result [CDC.CS];;;ACTIVE;2.48;2.48 +7517-6;Pleurotus ostreatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oyster Mushroom IgE Ab [Units/volume] in Serum;Oyster Mushroom IgE Qn;;ACTIVE;1.0h(2);2.73 +75176-8;Date of most recent treponemal test;Date;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Date of most recent treponemal test;;;ACTIVE;2.48;2.48 +75177-6;Most recent treponemal test type;Type;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's Most recent treponemal test type [CDC.CS];;;ACTIVE;2.48;2.48 +75178-4;Most recent treponemal result;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's Most recent treponemal result [CDC.CS];;;ACTIVE;2.48;2.48 +75179-2;HIV status during pregnancy;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's HIV status during pregnancy [CDC.CS];;;ACTIVE;2.48;2.48 +751-8;Neutrophils;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Neutrophils [#/volume] in Blood by Automated count;Neutrophils # Bld Auto;;ACTIVE;1.0;2.73 +75180-0;Clinical stage of syphilis during pregnancy;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's Clinical stage of syphilis during pregnancy [CDC.CS];;;ACTIVE;2.48;2.48 +75181-8;Surveillance stage of syphilis during pregnancy;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's Surveillance stage of syphilis during pregnancy [CDC.CS];;;ACTIVE;2.48;2.48 +75182-6;Date of first syphilis treatment during pregnancy;Date;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Date of first syphilis treatment during pregnancy;;;ACTIVE;2.48;2.48 +75183-4;When mother received first dose of benzathine penicillin;Find;Pt;^Mother;Ord;CDC.CS;SURVEY.CDC;4;When mother received first dose of benzathine penicillin [CDC.CS];;;ACTIVE;2.48;2.48 +7518-4;Cucumis melo spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Melon IgE Ab [Units/volume] in Serum;Deprecated Melon IgE Qn;;DEPRECATED;1.0h(2);2.69 +75184-2;Amount of benzathine penicillin treatment;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's Amount of benzathine penicillin treatment [CDC.CS];;;ACTIVE;2.48;2.48 +75185-9;Mother had appropriate serologic response following syphilis treatment;Find;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother had appropriate serologic response following syphilis treatment [CDC.CS];;;ACTIVE;2.48;2.48 +75186-7;Vital status;Find;Pt;^Patient;Nom;CDC.CS;SURVEY.CDC;4;Vital status [CDC.CS];;;ACTIVE;2.48;2.48 +75187-5;Non-treponemal test was reactive;Find;Pt;^Patient;Ord;CDC.CS;SURVEY.CDC;4;Non-treponemal test was reactive [CDC.CS];;;ACTIVE;2.48;2.48 +75188-3;Date of first reactive non-treponemal test;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Date of first reactive non-treponemal test;;;ACTIVE;2.48;2.48 +75189-1;First reactive non-treponemal test titer;Titr;Pt;^Patient;Qn;;SURVEY.CDC;4;First reactive non-treponemal test titer;;;ACTIVE;2.48;2.48 +75190-9;Treponemal test was reactive;Find;Pt;^Patient;Ord;CDC.CS;SURVEY.CDC;4;Treponemal test was reactive [CDC.CS];;;ACTIVE;2.48;2.48 +75191-7;Date of first reactive treponemal test;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Date of first reactive treponemal test;;;ACTIVE;2.48;2.48 +7519-2;Mytilus edulis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blue mussel IgG Ab [Units/volume] in Serum;Blue mussel IgG Qn;;ACTIVE;1.0h(2);2.73 +75192-5;Darkfield exam, DFA, or special stain was performed & test findings;Find;Pt;^Patient;Nom;CDC.CS;SURVEY.CDC;4;Darkfield exam, DFA, or special stain was performed and test findings [CDC.CS];;;ACTIVE;2.48;2.48 +75193-3;Clinical signs of congenital syphilis;Find;Pt;^Patient;Nom;CDC.CS;SURVEY.CDC;4;Clinical signs of congenital syphilis [CDC.CS];;;ACTIVE;2.48;2.48 +75194-1;Long bone x-rays were performed and consistent with congenital syphilis;Find;Pt;^Patient;Ord;CDC.CS;SURVEY.CDC;4;Long bone x-rays were performed and consistent with congenital syphilis [CDC.CS];;;ACTIVE;2.48;2.48 +75195-8;CSF Venereal Disease Research Laboratory test was performed & test findings;Find;Pt;^Patient;Nom;CDC.CS;SURVEY.CDC;4;CSF Venereal Disease Research Laboratory test was performed and test findings [CDC.CS];;;ACTIVE;2.48;2.48 +75196-6;Leukocyte count or protein test was performed on CSF & test findings;Find;Pt;^Patient;Nom;CDC.CS;SURVEY.CDC;4;Leukocyte count or protein test was performed on CSF and test findings [CDC.CS];;;ACTIVE;2.48;2.48 +75197-4;Syphilis treatment was given & treatment description;Find;Pt;^Patient;Nom;CDC.CS;SURVEY.CDC;4;Syphilis treatment was given and treatment description [CDC.CS];;;ACTIVE;2.48;2.48 +75198-2;Congenital syphilis case classification status;Find;Pt;^Patient;Nom;CDC.CS;SURVEY.CDC;4;Deprecated Congenital syphilis case classification status [CDC.CS];;;DEPRECATED;2.48;2.7 +75199-0;Congenital syphilis case investigation and report panel;-;Pt;^Patient;-;CDC.CS;PANEL.SURVEY.CDC;4;Congenital syphilis case investigation and report panel [CDC.CS];;;ACTIVE;2.48;2.48 +75-2;ceFAZolin;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;ceFAZolin [Susceptibility] by Minimum lethal concentration (MLC);ceFAZolin Islt MLC;;ACTIVE;1.0;2.19 +7520-0;Mytilus edulis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Blue mussel triggered histamine release [Units/volume] in Blood;Blue mussel BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75200-6;Date first prenatal visit;Date;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Date first prenatal visit;;;ACTIVE;2.48;2.5 +75201-4;Pregnancies;Num;Pt;^Mother;Qn;Reported;SURVEY.CDC;4;Mother's Pregnancies # [Reported];;;ACTIVE;2.48;2.48 +75202-2;Births.live;Num;Pt;^Mother;Qn;Reported;SURVEY.CDC;4;Mother's Births.live # [Reported];;;ACTIVE;2.48;2.48 +75203-0;Date last menstrual period^pre delivery;Date;Pt;^Mother;Qn;;SURVEY.CDC;4;Mother's Last menstrual period start date before delivery;;;ACTIVE;2.48;2.48 +75204-8;Prenatal care indicator;Arb;Pt;^Mother;Ord;CDC;SURVEY.CDC;4;Prenatal care indicator [CDC.CS];;;ACTIVE;2.48;2.61 +75205-5;Birth weight indicator;Arb;Pt;^Patient;Ord;CDC.CS;SURVEY.CDC;4;Deprecated Birth weight indicator [CDC.CS];;;DEPRECATED;2.48;2.7 +75206-3;Gestational age indicator;Arb;Pt;^Patient;Ord;CDC.CS;SURVEY.CDC;4;Deprecated Gestational age indicator [CDC.CS];;;DEPRECATED;2.48;2.7 +75207-1;Stillbirth indicator;Arb;Pt;^Patient;Ord;CDC.CS;SURVEY.CDC;4;Stillbirth indicator [CDC.CS];;;ACTIVE;2.48;2.48 +75208-9;Maternal information section;-;Pt;^Mother;-;CDC.CS;PANEL.SURVEY.CDC;4;Maternal information section [CDC.CS];;;ACTIVE;2.48;2.48 +75209-7;Infant or child information section;-;Pt;^Patient;-;CDC.CS;PANEL.SURVEY.CDC;4;Infant or child information section [CDC.CS];;;ACTIVE;2.48;2.48 +75210-5;Congenital syphilis case classification section;-;Pt;^Patient;-;CDC.CS;PANEL.SURVEY.CDC;4;Deprecated Congenital syphilis case classification section [CDC.CS];;;DEPRECATED;2.48;2.7 +75211-3;Propionylcarnitine (C3)+Palmitoylcarnitine (C16);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Propionylcarnitine (C3)+Palmitoylcarnitine (C16) [Moles/volume] in DBS;C3+C16 DBS-sCnc;;ACTIVE;2.48;2.73 +75212-1;Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10);SRto;Pt;Bld.dot;Qn;;CHEM;1;Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS;Malonylcarn/C10 DBS-sRto;;ACTIVE;2.48;2.73 +75213-9;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Decanoylcarnitine (C10);SRto;Pt;Bld.dot;Qn;;CHEM;1;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Decanoylcarnitine (C10) [Molar ratio] in DBS;Malonyl+3OHbutyrylcarn/C10 DBS-sRto;;ACTIVE;2.48;2.61 +75214-7;Arginine/Ornithine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Arginine/Ornithine [Molar ratio] in DBS;Arginine/Ornithine DBS-sRto;;ACTIVE;2.48;2.61 +75215-4;Ornithine/Citrulline;SRto;Pt;Bld.dot;Qn;;CHEM;1;Ornithine/Citrulline [Molar ratio] in DBS;Ornithine/Cit DBS-sRto;;ACTIVE;2.48;2.73 +75216-2;Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in DBS;Glutarylcarn/C3-DC DBS-sRto;;ACTIVE;2.48;2.61 +75217-0;Biotinidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Biotinidase [Enzymatic activity/volume] in DBS;Biotinidase DBS-cCnc;;ACTIVE;2.48;2.73 +7521-8;Mustard Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mustard IgG Ab [Units/volume] in Serum;Mustard IgG Qn;;ACTIVE;1.0h(2);2.73 +75218-8;Case report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Case report;Case rprt;;ACTIVE;2.48;2.73 +75219-6;Summary registry report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Summary registry report;Summary registry report;;ACTIVE;2.48;2.54 +75220-4;Progress note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Progress note;Urology Prog note;;ACTIVE;2.48;2.73 +75221-2;Progress note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Progress note;Neurology Prog note;;ACTIVE;2.48;2.73 +75222-0;Microscopic observation;Prid;Pt;Thrt;Nom;Alberts stain;MICRO;1;Microscopic observation [Identifier] in Throat by Alberts stain;Alberts Stn Throat;;ACTIVE;2.48;2.58 +75223-8;Dengue virus Ab.IgG & IgM;Prid;Pt;Ser/Plas/Bld;Nom;IA.rapid;MICRO;1;Dengue virus IgG and IgM [Identifier] in Serum, Plasma or Blood by Rapid immunoassay;DENV IgG+IgM SerPlBld IA.rapid;;ACTIVE;2.48;2.56 +75224-6;Chediak-Higashi cells;PrThr;Pt;Bld;Ord;;HEM/BC;1;Chediak-Higashi cells [Presence] in Blood;Ched-hig cells Bld Ql;;ACTIVE;2.48;2.56 +75225-3;Glutarylcarnitine (C5-DC)/Carnitine (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Carnitine (C0) [Molar ratio] in DBS;Glutarylcarn/C0 DBS-sRto;;ACTIVE;2.48;2.61 +7522-6;Mycogone sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mycogone sp IgE Ab [Units/volume] in Serum;Mycogone IgE Qn;;ACTIVE;1.0h(2);2.73 +75226-1;8-Hydroxyamoxapine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;8-Hydroxyamoxapine [Presence] in Urine;8OH-Amoxapine Ur Ql;;ACTIVE;2.48;2.73 +75227-9;Baclofen;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Baclofen [Mass/volume] in Urine;Baclofen Ur-mCnc;;ACTIVE;2.48;2.73 +75228-7;Carisoprodol+Meprobamate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Carisoprodol+Meprobamate [Mass/volume] in Urine by Confirmatory method;Carisoprodol+Meprob Ur Cfm-mCnc;;ACTIVE;2.48;2.48 +75229-5;DULoxetine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;DULoxetine [Presence] in Urine;DULoxetine Ur Ql;;ACTIVE;2.48;2.73 +75230-3;m-Chlorophenylpiperazine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;M-chlorophenylpiperazine [Presence] in Urine;m-CPP Ur Ql;;ACTIVE;2.48;2.73 +75231-1;Nefazodone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Nefazodone [Presence] in Urine;Nefazodone Ur Ql;;ACTIVE;2.48;2.73 +75232-9;Norcitalopram;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norcitalopram [Presence] in Urine;Norcitalopram Ur Ql;;ACTIVE;2.48;2.73 +75233-7;Norsertraline;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Norsertraline [Presence] in Urine;Norsertraline Ur Ql;;ACTIVE;2.48;2.73 +7523-4;Prunus persica var nucipersica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nectarine IgE Ab [Units/volume] in Serum;Nectarine IgE Qn;;ACTIVE;1.0h(2);2.73 +75234-5;O-desmethylvenlafaxine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;O-desmethylvenlafaxine [Presence] in Urine;ODV Ur Ql;;ACTIVE;2.48;2.73 +75235-2;Vilazodone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Vilazodone [Presence] in Urine;Vilaz Ur Ql;;ACTIVE;2.48;2.73 +75236-0;Crystals;Naric;Pt;Body fld;Qn;Microscopy.light;HEM/BC;1;Crystals [#/area] in Body fluid by Light microscopy;Crystals #/area Fld Micro;;ACTIVE;2.48;2.48 +75237-8;Erythrocytes;Naric;Pt;Synv fld;Qn;Microscopy.light.HPF;HEM/BC;1;Erythrocytes [#/area] in Synovial fluid by Microscopy high power field;RBC #/area Snv HPF;;ACTIVE;2.48;2.48 +75238-6;Procedure note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology procedure note;IR Procedure note;;ACTIVE;2.48;2.63 +75239-4;Albumin.ischemia modified;ACnc;Pt;Ser;Qn;;CHEM;1;Albumin.ischemia modified [Units/volume] in Serum;IMA Ser-aCnc;;ACTIVE;2.48;2.68 +75240-2;Meat fibers;Naric;Pt;Stool;Qn;Microscopy.light.LPF;CHEM;1;Meat fibers [#/area] in Stool by Microscopy low power field;Meat Fibers #/area Stl LPF;;ACTIVE;2.48;2.48 +75241-0;Procalcitonin;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Procalcitonin [Mass/volume] in Serum or Plasma by Immunoassay;Procalcitonin SerPl IA-mCnc;;ACTIVE;2.48;2.73 +7524-2;Prunus persica var nucipersica Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nectarine IgG Ab [Units/volume] in Serum;Nectarine IgG Qn;;ACTIVE;1.0h(2);2.69 +75242-8;Antipsychotics;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Antipsychotics [Presence] in Urine by Screen method;Antipsychotics Ur Ql Scn;;ACTIVE;2.48;2.56 +75243-6;Norton scale panel;-;Pt;^Patient;-;;PANEL.SURVEY.NORTON;4;Norton scale panel;;Copyright © 1962 Centre for Policy on Ageing (formerly NCCOP), London, UK. Reproduced with permission.;ACTIVE;2.48;2.5 +75244-4;Physical condition;Find;Pt;^Patient;Ord;Observed.Norton scale;SURVEY.NORTON;4;Physical condition [Norton scale];;Copyright © 1962 Centre for Policy on Ageing (formerly NCCOP), London, UK. Reproduced with permission.;ACTIVE;2.48;2.5 +75245-1;Mental condition;Find;Pt;^Patient;Ord;Observed.Norton scale;SURVEY.NORTON;4;Mental condition [Norton scale];;Copyright © 1962 Centre for Policy on Ageing (formerly NCCOP), London, UK. Reproduced with permission.;ACTIVE;2.48;2.5 +75246-9;Activity;Find;Pt;^Patient;Ord;Observed.Norton scale;SURVEY.NORTON;4;Activity [Norton scale];;Copyright © 1962 Centre for Policy on Ageing (formerly NCCOP), London, UK. Reproduced with permission.;ACTIVE;2.48;2.5 +75247-7;Mobility;Find;Pt;^Patient;Ord;Observed.Norton scale;SURVEY.NORTON;4;Mobility [Norton scale];;Copyright © 1962 Centre for Policy on Ageing (formerly NCCOP), London, UK. Reproduced with permission.;ACTIVE;2.48;2.5 +75248-5;Incontinence;Find;Pt;^Patient;Ord;Observed.Norton scale;SURVEY.NORTON;4;Incontinence [Norton scale];;Copyright © 1962 Centre for Policy on Ageing (formerly NCCOP), London, UK. Reproduced with permission.;ACTIVE;2.48;2.5 +75249-3;Norton scale score.total;Score;Pt;^Patient;Qn;Observed.Norton scale;SURVEY.NORTON;4;Norton scale total score;;Copyright © 1962 Centre for Policy on Ageing (formerly NCCOP), London, UK. Reproduced with permission.;ACTIVE;2.48;2.5 +75250-1;Are you deaf or do you have difficulty hearing;Find;Pt;^Patient;Ord;HHS.ACA Section 4302.ONC;SURVEY.HHS;4;Are you deaf or do you have difficulty hearing [HHS.ACA Section 4302.ONC];;;TRIAL;2.48;2.48 +75251-9;Are you blind or do you have difficulty seeing;Find;Pt;^Patient;Ord;HHS.ACA Section 4302.ONC;SURVEY.HHS;4;Are you blind or do you have difficulty seeing [HHS.ACA Section 4302.ONC];;;TRIAL;2.48;2.48 +75252-7;Do you have difficulty walking or climbing stairs;Find;Pt;^Patient;Ord;HHS.ACA Section 4302.ONC;SURVEY.HHS;4;Do you have difficulty walking or climbing stairs [HHS.ACA Section 4302.ONC];;;TRIAL;2.48;2.48 +75253-5;Because of a physical, mental, or emotional condition, do you have difficulty doing errands such as visiting a doctor's office or shopping;Find;Pt;^Patient;Ord;HHS.ACA Section 4302.ONC;SURVEY.HHS;4;Because of a physical, mental, or emotional condition, do you have difficulty doing errands such as visiting a doctor's office or shopping [HHS.ACA Section 4302.ONC];;;TRIAL;2.48;2.48 +75254-3;Do you have difficulty communicating, reading, or do you have limited proficiency in English;Find;Pt;^Patient;Ord;HHS.ACA Section 4302.ONC;SURVEY.HHS;4;Do you have difficulty communicating, reading, or do you have limited proficiency in English [HHS.ACA Section 4302.ONC];;;TRIAL;2.48;2.48 +75255-0;Assistance needed;Find;Pt;^Patient;Nom;HHS.ACA Section 4302.ONC;SURVEY.HHS;4;Assistance needed [HHS.ACA Section 4302.ONC];;;TRIAL;2.48;2.48 +75256-8;Disability information & assistance needed panel;-;Pt;^Patient;-;HHS.ACA Section 4302.ONC;PANEL.SURVEY.HHS;4;Disability information and assistance needed panel [HHS.ACA Section 4302.ONC];;;TRIAL;2.48;2.48 +75257-6;Marital status;Type;Pt;^Mother;Nom;CDC.CS;SURVEY.CDC;4;Mother's Marital status [CDC.CS];;;ACTIVE;2.48;2.48 +75258-4;PROMIS short form - sleep disturbance 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - sleep disturbance 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.48;2.52 +7525-9;Nigrospora oryzae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nigrospora oryzae IgE Ab [Units/volume] in Serum;N orzae IgE Qn;;ACTIVE;1.0h(2);2.73 +75259-2;PROMIS short form - pain intensity 3a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - pain intensity 3a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.48;2.52 +752-6;Neutrophils;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Neutrophils [#/volume] in Blood by Automated count;Deprecated Neutrophils # Bld Auto;;DEPRECATED;1.0;2.4 +75260-0;What is your level of pain right now;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;What is your level of pain right now [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.48;2.65 +75261-8;How intense was your average pain in the past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How intense was your average pain in the past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.48;2.65 +75262-6;How intense was your pain at its worse in the past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How intense was your pain at its worse in the past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.48;2.65 +75263-4;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;GEL;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by GEL;Bld gp Ab Scn SerPl Ql GEL;;ACTIVE;2.48;2.73 +75264-2;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;LISS;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by Low ionic strength saline (LISS);Bld gp Ab Scn SerPl Ql LISS;;ACTIVE;2.48;2.73 +75265-9;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;PEG;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by Polyethylene glycol (PEG) method;Bld gp Ab Scn SerPl Ql PEG;;ACTIVE;2.48;2.56 +75266-7;Glutarylcarnitine (C5-DC)/Octanoylcarnitine+Decanoylcarnitine (C8+C10);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Octanoylcarnitine+Decanoylcarnitine (C8+C10) [Molar ratio] in DBS;Glutarylcarn/C8+C10 DBS-sRto;;ACTIVE;2.48;2.61 +7526-7;Nigrospora sphaerica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nigrospora sphaerica IgE Ab [Units/volume] in Serum;N sphaerica IgE Qn;;ACTIVE;1.0h(2);2.73 +75267-5;Glutarylcarnitine (C5-DC)/Palmitoylcarnitine (C16);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Palmitoylcarnitine (C16) [Molar ratio] in DBS;Glutarylcarn/C16 DBS-sRto;;ACTIVE;2.48;2.61 +75268-3;Leucine/Phenylalanine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Leucine/Phenylalanine [Molar ratio] in DBS;Leucine/Phe DBS-sRto;;ACTIVE;2.48;2.61 +75269-1;Bacteria identified;Prid;Pt;Genital;Nom;Anaerobic+Aerobic culture;MICRO;1;Bacteria identified in Genital specimen by Anaerobe+Aerobe culture;Bacteria Genital Anaerobe+Aerobe Cult;;ACTIVE;2.48;2.73 +75270-9;Promethazine;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Promethazine [Presence] in Serum or Plasma or Urine by Screen method;Promethazine Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +75271-7;Other cells/100 cells;NFr;Pt;Lymph node;Qn;Manual count;HEM/BC;1;Other cells/100 cells in Lymph node by Manual count;Other cells NFr LN Manual;;ACTIVE;2.50;2.5 +75272-5;Age at event onset;Time;Pt;^Patient;Qn;;HL7.CCDA;2;Age at event onset;Age at onset;;ACTIVE;2.50;2.56 +75273-3;Age at event onset;Time;Pt;^Family member;Qn;;HL7.CCDA;2;Age at event onset Family member;Age at onset Fam Mem;;ACTIVE;2.50;2.56 +75274-1;Characteristics of residence;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Characteristics of residence;Charact of residence;;ACTIVE;2.50;2.56 +7527-5;Nutmeg Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nutmeg IgG Ab [Units/volume] in Serum;Nutmeg IgG Qn;;ACTIVE;1.0h(2);2.73 +75275-8;Cognitive function;Imp;Pt;^Patient;Nom;;HL7.CCDA;2;Cognitive function [Interpretation];Cogn func Imp;;ACTIVE;2.50;2.61 +75276-6;Functional status;Imp;Pt;^Patient;Nom;;HL7.CCDA;2;Functional status [Interpretation];Functional status Imp;;ACTIVE;2.50;2.56 +75277-4;Number of pressure injuries;Num;Pt;^Patient;Qn;;HL7.CCDA;2;Number of pressure injuries;Number of pressure injuries;;ACTIVE;2.50;2.64 +75278-2;Advance directive status;Type;Pt;^Patient;Nom;;HL7.CCDA;2;Deprecated Advance directive status;Deprecated Adv direct stat;;DEPRECATED;2.50;2.56 +75279-0;Provider responsible for medication monitoring;Pn;Pt;Provider;Nom;;HL7.CCDA;2;Provider responsible for medication monitoring;Prov resp med mon;;ACTIVE;2.50;2.5 +75280-8;Sequence number in substance administration series;Num;Pt;^Patient;Qn;;HL7.CCDA;2;Sequence number in substance administration series;Seq Num Subst Adm;;ACTIVE;2.50;2.5 +75281-6;Personal belief;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Personal belief;Personal belief;;ACTIVE;2.50;2.56 +75282-4;Nutrition assessment panel;-;Pt;^Patient;-;;PANEL.NUTRITION&DIET;2;Nutrition assessment panel;Nutr assess Pnl;;ACTIVE;2.50;2.5 +7528-3;Quercus velutina Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Oak IgE Ab [Units/volume] in Serum;Black Oak IgE Qn;;ACTIVE;1.0h(2);2.42 +75283-2;Food and nutrition history panel;-;Pt;^Patient;-;;PANEL.NUTRITION&DIET;2;Food and nutrition history panel;Food nutr history Pnl;;ACTIVE;2.50;2.5 +75284-0;Food and nutrient intake panel;-;Pt;^Patient;-;;PANEL.NUTRITION&DIET;2;Food and nutrient intake panel;Food and Nutr intake Pnl;;ACTIVE;2.50;2.56 +75285-7;Comparative nutrition assessment standards panel;-;Pt;^Patient;-;;PANEL.NUTRITION&DIET;2;Comparative nutrition assessment standards panel;Compare Nutrt Std Pnl;;ACTIVE;2.50;2.56 +75286-5;Nutrition related anthropometric measurements panel;-;Pt;^Patient;-;;PANEL.NUTRITION&DIET;2;Nutrition related anthropometric measurements panel;Nutrition Anthrop meas Pnl;;ACTIVE;2.50;2.56 +75287-3;Food and beverage intake panel;-;Pt;^Patient;-;;PANEL.NUTRITION&DIET;2;Food and beverage intake panel;Food and bev intake Pnl;;ACTIVE;2.50;2.56 +75288-1;Carbohydrate need;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Carbohydrate need [Mass/time] 24 hour Estimated;Carb need 24h mRate Est;;ACTIVE;2.50;2.56 +75289-9;Fat need;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Fat need [Mass/time] 24 hour Estimated;Fat need 24h mRate Est;;ACTIVE;2.50;2.5 +75290-7;Protein need;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Protein need [Mass/time] 24 hour Estimated;Protein need 24h mRate Est;;ACTIVE;2.50;2.5 +7529-1;Quercus kelloggii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;California Black Oak IgE Ab [Units/volume] in Serum;Calif Black Oak IgE Qn;;ACTIVE;1.0h(2);2.73 +75291-5;Fluid need;VRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Fluid need 24 hour Estimated;Fluid need 24h Est;;ACTIVE;2.50;2.5 +75292-3;Body weight^usual;Mass;Pt;^Patient;Qn;Reported;BDYWGT.MOLEC;2;Body weight - Reported --usual;Weight usual Reported;;ACTIVE;2.50;2.73 +75293-1;Physical findings.nutrition;Find;Pt;^Patient;Nom;;NUTRITION&DIETETICS;2;Physical findings of nutrition assessment;Phys fnd nutr;;ACTIVE;2.50;2.5 +75294-9;Adequacy of breastmilk &or formula;Find;Pt;^Patient;Ord;;NUTRITION&DIETETICS;2;Adequacy of breastmilk andor formula;Adeq brst milk;;ACTIVE;2.50;2.5 +75295-6;Fluid intake.oral;VRat;24H;^Patient;Qn;;IO_IN.TIMED.MOLEC;2;Deprecated Fluid intake oral 24 hour;Deprecated Fluid intake oral 24h;;DEPRECATED;2.50;2.5 +75296-4;Carbohydrate intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Carbohydrate intake 24 hour Estimated;Carbohydrate intake 24h Est;;ACTIVE;2.50;2.5 +75297-2;Fat intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Fat intake 24 hour Estimated;Fat intake 24h Est;;ACTIVE;2.50;2.5 +75298-0;Calorie intake;EngRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Calorie intake 24 hour Estimated;Calorie intake 24h Est;;ACTIVE;2.50;2.66 +75299-8;Protein intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Protein intake 24 hour Estimated;Protein intake 24h Est;;ACTIVE;2.50;2.5 +75300-4;Fluid intake;VRat;24H;^Patient;Qn;;IO_IN.TIMED.MOLEC;2;Deprecated Fluid intake 24 hour;Deprecated Fluid intake 24h;;DEPRECATED;2.50;2.5 +75301-2;Fluid intake;VRat;24H;^Patient;Qn;Estimated;IO_IN.TIMED.MOLEC;2;Fluid intake 24 hour Estimated;Fluid intake 24h Est;;ACTIVE;2.50;2.54 +75302-0;Calorie intake;EngRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calorie intake 24 hour;Calorie intake 24h;;ACTIVE;2.50;2.66 +75303-8;Nutrition assessment;Find;Pt;^Patient;Nar;;NUTRITION&DIETETICS;2;Nutrition assessment Narrative;Nutr assess;;ACTIVE;2.50;2.5 +75304-6;Nutrition status observation panel;-;Pt;^Patient;-;;PANEL.NUTRITION&DIET;2;Nutrition status observation panel;Nutr Dx Pnl;;ACTIVE;2.50;2.5 +75305-3;Nutrition status;Find;Pt;^Patient;Nom;;NUTRITION&DIETETICS;2;Nutrition status;Nutr Status;;ACTIVE;2.50;2.5 +75306-1;Nutrition status etiology;Find;Pt;^Patient;Nar;;NUTRITION&DIETETICS;2;Nutrition status etiology Narrative;Nutr dx etiology;;ACTIVE;2.50;2.5 +75307-9;Nutrition status signs and symptoms;Find;Pt;^Patient;Nar;;NUTRITION&DIETETICS;2;Nutrition status signs and symptoms Narrative;Nutr dx sign and sym;;ACTIVE;2.50;2.56 +75308-7;Fetal blood;Vol;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Fetal blood [Volume] in Blood by Flow cytometry (FC);Fetal blood Vol Bld FC;;ACTIVE;2.50;2.5 +7530-9;Quercus gambelii Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gamble Oak IgE Ab [Units/volume] in Serum;Gamble Oak IgE Qn;;ACTIVE;1.0h(2);2.73 +75309-5;Mental function;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Deprecated Mental function;Deprecated Mental function;;DEPRECATED;2.50;2.56 +75310-3;Health concerns;Find;Pt;^Patient;Doc;;HL7.CCDA;2;Health concerns Document;Health concern Doc;;ACTIVE;2.50;2.63 +75311-1;Discharge medications;Find;Pt;^Patient;Nar;;HL7.CCDA;2;Discharge medications Narrative;Discharge meds;;ACTIVE;2.50;2.5 +75312-9;Clinical finding;Find;Pt;^Family member;Nom;;HL7.CCDA;2;Clinical finding Family member;Clinical finding Fam Mem;;ACTIVE;2.50;2.5 +75313-7;Complaint;Find;Pt;^Family member;Nom;;HL7.CCDA;2;Complaint Family member;Complaint Fam Mem;;ACTIVE;2.50;2.5 +75314-5;Diagnosis;Imp;Pt;^Family member;Nom;;HL7.CCDA;2;Diagnosis Family member;Dx Fam Mem;;ACTIVE;2.50;2.5 +75315-2;Condition;Find;Pt;^Family member;Nom;;HL7.CCDA;2;Condition Family member;Condition Fam Mem;;ACTIVE;2.50;2.5 +75316-0;Functional performance;Find;Pt;^Family member;Nom;;HL7.CCDA;2;Functional performance Family member;Function performance Fam Mem;;ACTIVE;2.50;2.5 +7531-7;Chenopodium botrys Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Jerusalem oak IgE Ab [Units/volume] in Serum;Jerusalem oak IgE Qn;;ACTIVE;1.0h(2);2.42 +75317-8;Symptom;Find;Pt;^Family member;Nom;;HL7.CCDA;2;Symptom Family member;Symptom Fam Mem;;ACTIVE;2.50;2.5 +75318-6;Problem;Find;Pt;^Family member;Nom;;HL7.CCDA;2;Problem Family member;Problem Fam Mem;;ACTIVE;2.50;2.5 +75319-4;Mental function;Find;Pt;^Family member;Nom;;HL7.CCDA;2;Mental function Family member;Mental function Fam Mem;;ACTIVE;2.50;2.5 +75320-2;Advance directive;Type;Pt;^Patient;Nom;;HL7.CCDA;2;Advance directive;Advance directive;;ACTIVE;2.50;2.73 +75321-0;Clinical finding;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Clinical finding;Clinical finding;;ACTIVE;2.50;2.5 +75322-8;Complaint;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Complaint;Complaint;;ACTIVE;2.50;2.5 +75323-6;Condition;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Condition;Condition;;ACTIVE;2.50;2.73 +75324-4;Functional performance;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Deprecated Functional performance;Deprecated Function performance;;DEPRECATED;2.50;2.56 +7532-5;Quercus agrifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;California Live Oak IgE Ab [Units/volume] in Serum;Calif Live Oak IgE Qn;;ACTIVE;1.0h(2);2.73 +75325-1;Symptom;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Symptom;Symptom;;ACTIVE;2.50;2.73 +75326-9;Problem;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Problem;Problem;;ACTIVE;2.50;2.73 +75327-7;Life expectancy;Time;Pt;^Patient;Qn;Estimated;HL7.CCDA;2;Life expectancy [Time] Estimated;Life expect Time Est;;ACTIVE;2.50;2.5 +75328-5;Prognosis;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Prognosis;Prognosis;;ACTIVE;2.50;2.73 +75329-3;Date of intrauterine device insertion;Date;Pt;^Patient;Qn;;CLIN;2;Date of intrauterine device insertion;Date of IUD;;ACTIVE;2.50;2.5 +75330-1;Environmental condition panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Environmental condition panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.52 +75331-9;Total number of staff completing the environmental conditions survey;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Total number of staff completing the environmental conditions survey [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75332-7;To what extent do you agree or disagree with cultural factors contributing to the phenomenon of complexity;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;To what extent do you agree or disagree with cultural factors contributing to the phenomenon of complexity [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +7533-3;Quercus wislizeni Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Interior Live Oak IgE Ab [Units/volume] in Serum;Interior Live Oak IgE Qn;;ACTIVE;1.0h(2);2.42 +75333-5;Within the last Mo, how often have you experienced cultural factors;Find;1Mo;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Within the last month, how often have you experienced cultural factors [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.54 +75334-3;To what extent do you agree or disagree with psychosocial factors contributing to the phenomenon of complexity;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;To what extent do you agree or disagree with psychosocial factors contributing to the phenomenon of complexity [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75335-0;Within the last Mo, how often have you experienced psychosocial factors;Find;1Mo;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Within the last month, how often have you experienced psychosocial factors [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.54 +75336-8;To what extent do you agree or disagree with physical factors contributing to the phenomenon of complexity;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;To what extent do you agree or disagree with physical factors contributing to the phenomenon of complexity [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75337-6;Within the last Mo, how often have you experienced physical factors;Find;1Mo;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Within the last month, how often have you experienced physical factors [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.54 +75338-4;Cognitive judgment;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Cognitive judgment HL7.CCDAR2;Deprecated Cognitive judgment HL7CCDAR2;;DEPRECATED;2.50;2.56 +75339-2;Ability to comprehend;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Cognitive judgment HL7.CCDAR2;Deprecated Cognitive judgment HL7CCDAR2;;DEPRECATED;2.50;2.56 +753-4;Neutrophils;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Blood by Manual count;Neutrophils # Bld Manual;;ACTIVE;1.0;2.73 +75340-0;Ability to plan;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Ability to plan HL7.CCDAR2;Deprecated Ability to plan HL7CCDAR2;;DEPRECATED;2.50;2.56 +7534-1;Quercus rubra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Oak IgE Ab [Units/volume] in Serum;Red Oak IgE Qn;;ACTIVE;1.0h(2);2.73 +75341-8;Ability to process information;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Ability to process information HL7.CCDAR2;Deprecated Ability to process info HL7CC;;DEPRECATED;2.50;2.56 +75342-6;Ability to reason;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Ability to reason HL7.CCDAR2;Deprecated Ability to reason HL7CCDAR2;;DEPRECATED;2.50;2.56 +75343-4;Ability to think abstractly;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Ability to think abstractly HL7.CCDAR2;Deprecated Ability to think abstractly H;;DEPRECATED;2.50;2.56 +75344-2;Ability to verbalize understanding;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Ability to verbalize understanding HL7.CCDAR2;Deprecated Able to verbalize understand;;DEPRECATED;2.50;2.56 +75345-9;Ability to sequence logically;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Ability to sequence logically HL7.CCDAR2;Deprecated Ability to sequence logically;;DEPRECATED;2.50;2.56 +75346-7;Promethazine;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Promethazine [Mass/volume] in Blood by Confirmatory method;Promethazine Bld Cfm-mCnc;;ACTIVE;2.50;2.73 +75347-5;Tapentadol;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Tapentadol [Mass/volume] in Serum, Plasma or Blood;Tapentadol SerPlBld-mCnc;;ACTIVE;2.50;2.73 +75348-3;Cognitive function;Find;Pt;^Patient;Ord;HL7.CCDAR2;HL7.CCDA;2;Deprecated Cognitive function (Ordinal) HL7.CCDAR2;Deprecated Cogn func HL7CCDAR2;;DEPRECATED;2.50;2.56 +75349-1;Other cells;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Other cells [#/volume] in Peritoneal fluid by Manual count;Other cells # Prt Manual;;ACTIVE;2.50;2.5 +75350-9;Other cells/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Peritoneal fluid by Manual count;Other cells/leuk NFr Prt Manual;;ACTIVE;2.50;2.5 +75351-7;Other cells;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Other cells [#/volume] in Synovial fluid by Manual count;Other cells # Snv Manual;;ACTIVE;2.50;2.5 +75352-5;Other cells/100 leukocytes;NFr;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Pericardial fluid by Manual count;Other cells/leuk NFr Pcar Manual;;ACTIVE;2.50;2.5 +75353-3;Other cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Body fluid by Manual count;Other cells/leuk NFr Fld Manual;;ACTIVE;2.50;2.73 +75354-1;Other cells;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Other cells [#/volume] in Pleural fluid by Manual count;Other cells # Plr Manual;;ACTIVE;2.50;2.5 +75355-8;Other cells/100 leukocytes;NFr;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Synovial fluid by Manual count;Other cells/leuk NFr Snv Manual;;ACTIVE;2.50;2.5 +75356-6;Other cells/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Pleural fluid by Manual count;Other cells/leuk NFr Plr Manual;;ACTIVE;2.50;2.5 +75357-4;Bacteria identified;Prid;Pt;Abscess;Nom;Anaerobic+Aerobic culture;MICRO;1;Bacteria identified in Abscess by Anaerobe+Aerobe culture;Bacteria Absc Anaerobe+Aerobe Cult;;ACTIVE;2.50;2.73 +7535-8;Quercus lobata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Valley Oak IgE Ab [Units/volume] in Serum;Valley Oak IgE Qn;;ACTIVE;1.0h(2);2.42 +75358-2;Bacteria identified;Prid;Pt;Bone;Nom;Anaerobic+Aerobic culture;MICRO;1;Bacteria identified in Bone by Anaerobe+Aerobe culture;Bacteria Bone Anaerobe+Aerobe Cult;;ACTIVE;2.50;2.73 +75359-0;Bacteria identified;Prid;Pt;Bone mar;Nom;Anaerobic+Aerobic culture;MICRO;1;Bacteria identified in Bone marrow by Anaerobe+Aerobe culture;Bacteria Mar Anaerobe+Aerobe Cult;;ACTIVE;2.50;2.5 +75360-8;Date of supracervical hysterectomy;Date;Pt;^Patient;Qn;;CLIN;2;Date of supracervical hysterectomy;Date supracervical hyst;;ACTIVE;2.50;2.5 +75361-6;Date of total hysterectomy;Date;Pt;^Patient;Qn;;CLIN;2;Date of total hysterectomy;Date of t hyst;;ACTIVE;2.50;2.5 +75362-4;Tapentadol glucuronide;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Tapentadol glucuronide [Mass/volume] in Urine by Screen method;Tapen gluc Ur Scn-mCnc;;ACTIVE;2.50;2.5 +75363-2;Creatinine;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Vitreous fluid;Creat Vitf-sCnc;;ACTIVE;2.50;2.5 +75364-0;Urea;SCnc;Pt;Vitr fld;Qn;;CHEM;1;Urea [Moles/volume] in Vitreous fluid;Urea Vitf-sCnc;;ACTIVE;2.50;2.5 +75365-7;First & Second trimester integrated maternal screen;Imp;Pt;^Patient;Nar;;CHEM;1;First and Second trimester integrated maternal screen [Interpretation] Narrative;Integrated scn Patient-Imp Nar;;ACTIVE;2.50;2.5 +7536-6;Quercus alba Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Oak IgG Ab [Units/volume] in Serum;White Oak IgG Qn;;ACTIVE;1.0h(2);2.73 +75366-5;Lactate;SCnc;Pt;BldC^Fetus;Qn;Test strip;CHEM;1;Lactate [Moles/volume] in Capillary blood from Fetus by Test strip;Lactate BldC Fetus Strip-sCnc;;ACTIVE;2.50;2.5 +75367-3;Buprenorphine;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Buprenorphine [Mass/mass] in Meconium by Confirmatory method;Buprenorphine Mec Cfm-mCnt;;ACTIVE;2.50;2.5 +75368-1;Buprenorphine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Buprenorphine [Mass/volume] in Serum, Plasma or Blood;Buprenorphine SerPlBld-mCnc;;ACTIVE;2.50;2.73 +75369-9;Diuretics;Imp;Pt;Urine;Ord;Screen;DRUG/TOX;1;Diuretics [Interpretation] in Urine Qualitative by Screen method;Diuretics Ur Scn-Imp;;ACTIVE;2.50;2.73 +75370-7;Norbuprenorphine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Norbuprenorphine [Mass/volume] in Serum, Plasma or Blood;Norbuprenorphine SerPlBld-mCnc;;ACTIVE;2.50;2.73 +75371-5;Bartlett score;Score;Pt;Sputum;Ord;Microscopy.light;SPEC;1;Bartlett score of Sputum Qualitative by Light microscopy;Bartlett score Spt Ql Micro;;ACTIVE;2.50;2.5 +75372-3;Hexane;MCnc;Pt;Ser/Plas;Qn;Screen;DRUG/TOX;1;Hexane [Mass/volume] in Serum or Plasma by Screen method;Hexane SerPl Scn-mCnc;;ACTIVE;2.50;2.5 +75373-1;Erythrocytes.fetal/2000 erythrocytes;NFr;Pt;Bld;Qn;Kleihauer-Betke;HEM/BC;1;Erythrocytes.fetal/2000 erythrocytes in Blood by Kleihauer-Betke method;Fetal RBC/2000 RBC NFr Bld Kleih Betke;;ACTIVE;2.50;2.73 +7537-4;Quercus alba basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;White Oak triggered histamine release [Units/volume] in Blood;White Oak BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75374-9;Other cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Cerebral spinal fluid by Manual count;Other cells/leuk NFr CSF Manual;;ACTIVE;2.50;2.73 +75375-6;Other cells/100 leukocytes;NFr;Pt;Sputum;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Sputum by Manual count;Other cells/leuk NFr Spt Manual;;ACTIVE;2.50;2.5 +75376-4;Siderocytes.HPF;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Siderocytes per HPF [Presence] in Blood by Light microscopy;Siderocytes.HPF Bld Ql Smear;;ACTIVE;2.50;2.56 +75377-2;Dengue virus NS1 Ag;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Dengue virus NS1 Ag [Presence] in Serum, Plasma or Blood by Rapid immunoassay;DENV NS1 Ag SerPlBld Ql IA.rapid;;ACTIVE;2.50;2.73 +75378-0;Hepatitis B virus core Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Hepatitis B virus core Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HBV core Ab SerPlBld Ql IA.rapid;;ACTIVE;2.50;2.56 +75379-8;Norbuprenorphine;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Norbuprenorphine [Mass/mass] in Meconium by Confirmatory method;Norbuprenorphine Mec Cfm-mCnt;;ACTIVE;2.50;2.5 +75380-6;SERPING1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SERPING1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SERPING1 Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75381-4;TTR gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TTR gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;TTR gene Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +7538-2;Avena sativa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oat IgG Ab [Units/volume] in Serum;Oat IgG Qn;;ACTIVE;1.0h(2);2.73 +75382-2;ATP7B gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ATP7B gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ATP7B gene Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75383-0;DMD gene deletion+duplication;Find;Pt;Amnio fld/CVS;Doc;MLPA;MOLPATH.DEL;1;DMD gene deletion and duplication mutation analysis in Amniotic fluid or Chorionic villus sample by MLPA;DMD gene Del+Dup Amn/CVS MLPA;;ACTIVE;2.50;2.66 +75384-8;PMP22 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DEL;1;PMP22 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;PMP22 gene Del+Dup Bld/T MLPA;;ACTIVE;2.50;2.66 +75385-5;DMD gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DEL;1;DMD gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;DMD gene Del+Dup Bld/T MLPA;;ACTIVE;2.50;2.66 +75386-3;MEN1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MEN1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MEN1 gene Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75387-1;INS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;INS gene full mutation analysis in Blood or Tissue by Sequencing;INS Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +75388-9;CDKN1B gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CDKN1B gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;CDKN1B Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75389-7;CDKN1B gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CDKN1B gene full mutation analysis in Blood or Tissue by Sequencing;CDKN1B Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +7539-0;Avena sativa basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Oat triggered histamine release [Units/volume] in Blood;Oat BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75390-5;APP gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;APP gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;APP Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75391-3;FGFR3 gene targeted mutation analysis;Find;Pt;Amnio fld/CVS;Doc;Molgen;MOLPATH.MUT;1;FGFR3 gene targeted mutation analysis in Amniotic fluid or Chorionic villus sample by Molecular genetics method;FGFR3 gene Mut Anl Amn/CVS;;ACTIVE;2.50;2.66 +75392-1;FXN gene.GAA repeats;PrThr;Pt;Amnio fld/CVS;Ord;Molgen;MOLPATH.NUCREPEAT;1;FXN gene GAA repeats [Presence] in Amniotic fluid or Chorionic villus sample by Molecular genetics method;FXN gene GAA Rpt Amn/CVS Ql;;ACTIVE;2.50;2.64 +75393-9;HTT gene.CAG repeats;PrThr;Pt;Amnio fld/CVS;Ord;Molgen;MOLPATH.NUCREPEAT;1;HTT gene CAG repeats [Presence] in Amniotic fluid or Chorionic villus sample by Molecular genetics method;HTT gene CAG Rpt Amn/CVS Ql;;ACTIVE;2.50;2.64 +75394-7;Chromosome uniparental disomy;Prid;Pt;Amnio fld/CVS;Nar;Molgen;MOLPATH.TRISOMY;1;Chromosome uniparental disomy [Identifier] in Amniotic fluid or Chorionic villus sample by Molecular genetics method Narrative;Chr UpDi Amn/CVS;;ACTIVE;2.50;2.73 +75395-4;AIP gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;AIP gene full mutation analysis in Blood or Tissue by Sequencing;AIP Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +75396-2;AIP gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AIP gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;AIP Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75397-0;HNF1A gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HNF1A gene full mutation analysis in Blood or Tissue by Sequencing;HNF1A Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +75398-8;HNF1B gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HNF1B gene full mutation analysis in Blood or Tissue by Sequencing;HNF1B Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +75399-6;HNF4A gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HNF4A gene full mutation analysis in Blood or Tissue by Sequencing;HNF4A Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +75400-2;KCNJ11 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;KCNJ11 gene full mutation analysis in Blood or Tissue by Sequencing;KCNJ11 Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +75401-0;GCDH gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GCDH gene full mutation analysis in Blood or Tissue by Sequencing;GCDH Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.73 +75402-8;GCDH gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GCDH gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GCDH Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75403-6;PDHA1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;PDHA1 gene full mutation analysis in Blood or Tissue by Sequencing;PDHA1 Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +75404-4;West Nile virus Ab;PrThr;Pt;Ser;Ord;HAI;MICRO;1;West Nile virus Ab [Presence] in Serum by Hemagglutination inhibition;WNV Ab Ser Ql HAI;;ACTIVE;2.50;2.56 +75405-1;Glucose^1.5H post dose triple bolus;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose triple bolus;Glucose 1.5h p Triple Bolus SerPl-sCnc;;ACTIVE;2.50;2.5 +75406-9;Human papilloma virus 16 & 18+45 E6+E7 mRNA;PrThr;Pt;Cvx;Ord;Probe.amp;MICRO;1;Deprecated Human papilloma virus 16 and 18+45 E6+E7 mRNA [Presence] in Cervix by Probe with amplification;Deprecated HPV16+18+45 E6+E7mRNA Cervix;;DEPRECATED;2.50;2.58 +75407-7;Hepatitis B virus little e Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Hepatitis B virus e Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HBV e Ab SerPlBld Ql IA.rapid;;ACTIVE;2.50;2.56 +7540-8;Avena sativa cultivated Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Oat cultivated IgE Ab [Units/volume] in Serum;Deprecated Oat Poln IgE Qn;;DEPRECATED;1.0h(2);2.69 +75408-5;Hepatitis B virus little e Ag;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Hepatitis B virus e Ag [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HBV e Ag SerPlBld Ql IA.rapid;;ACTIVE;2.50;2.56 +75409-3;Hepatitis B virus surface Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Hepatitis B virus surface Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HBV surface Ab SerPlBld Ql IA.rapid;;ACTIVE;2.50;2.73 +75410-1;Hepatitis B virus surface Ag;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Hepatitis B virus surface Ag [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HBV surface Ag SerPlBld Ql IA.rapid;;ACTIVE;2.50;2.56 +75411-9;Ebola Zaire virus RNA;PrThr;Pt;Plas/Bld;Ord;Probe.amp.tar;MICRO;1;Ebola Zaire virus RNA [Presence] in Plasma or Blood by NAA with probe detection;EZ1 RNA PlasBld Ql NAA+probe;;ACTIVE;2.50;2.63 +75412-7;Rate all your health care in the last 12Mo;Score;12Mo;^Patient;Ord;AHRQ;SURVEY.AHRQ;4;Rate all your health care in the last 12 months [AHRQ];;;ACTIVE;2.50;2.61 +75413-5;I have a good life;Find;Pt;^Patient;Ord;NIH Toolbox;SURVEY.NIH_TOOLBOX;4;I have a good life [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.50;2.65 +75414-3;How often do your parents listen to your ideas;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How often do your parents listen to your ideas [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75415-0;How often do you have fun with friends;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How often do you have fun with friends [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +7541-6;Avena sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Oat IgE Ab [Units/volume] in Serum;Deprecated Oat IgE Qn;;DEPRECATED;1.0h(2);2.69 +75416-8;How often do you feel really sad;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How often do you feel really sad [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75417-6;I have trouble doing all of my regular leisure activities with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of my regular leisure activities with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75418-4;PCORI patient-reported outcomes common measures - core and recommended;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PCORI;4;PCORI patient-reported outcomes common measures - core and recommended [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.5 +75419-2;PCORI patient-reported outcomes recommended measures;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PCORI;4;PCORI patient-reported outcomes recommended measures [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.5 +754-2;Neutrophils;NCnc;Pt;CSF;Qn;Automated count;HEM/BC;1;Neutrophils [#/volume] in Cerebral spinal fluid by Automated count;Neutrophils # CSF Auto;;ACTIVE;1.0;2.73 +75420-0;PCORI patient-reported outcomes core pediatric measures;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PCORI;4;PCORI patient-reported outcomes core pediatric measures [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.5 +75421-8;PCORI patient-reported outcomes core adult measures;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PCORI;4;PCORI patient-reported outcomes core adult measures [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.5 +75422-6;Group counseling note;Find;Pt;{Setting};Doc;Addiction psychiatry;DOC.ONTOLOGY;2;Addiction psychiatry Group counseling note;Addiction psych Group counseling note;;ACTIVE;2.50;2.5 +75423-4;Note;Find;Pt;{Setting};Doc;Addiction psychiatry;DOC.ONTOLOGY;2;Addiction psychiatry Note;Addiction psych Note;;ACTIVE;2.50;2.5 +7542-4;Trisetum paniceum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wild Oats IgE Ab [Units/volume] in Serum;Wild Oats IgE Qn;;ACTIVE;1.0h(2);2.73 +75424-2;Consultation note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Consult note;Audiology Consult note;;ACTIVE;2.50;2.58 +75425-9;Diagnostic study note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Diagnostic study note;Cardiology Diag study note;;ACTIVE;2.50;2.5 +75426-7;Procedure note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology procedure note;Cardiology Procedure note;;ACTIVE;2.50;2.58 +75427-5;Note;Find;Pt;{Setting};Doc;Mental health.case manager;DOC.ONTOLOGY;2;Mental health Case manager Note;MH Case mgr Note;;ACTIVE;2.50;2.58 +75428-3;Note;Find;Pt;{Setting};Doc;Social work.case manager;DOC.ONTOLOGY;2;Deprecated Social work Case manager Note;Deprecated Social work Case mgr Note;;DEPRECATED;2.50;2.65 +75429-1;Note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Note;Cust care fac Note;;ACTIVE;2.50;2.54 +75430-9;Note;Find;Pt;{Setting};Doc;Obesity medicine;DOC.ONTOLOGY;2;Obesity medicine Note;Obesity med Note;;ACTIVE;2.50;2.73 +75431-7;Fall risk assessment note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Fall risk assessment note;Fall risk assess note;;ACTIVE;2.50;2.54 +7543-2;Oidiodendrum spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oidiodendrum spp IgE Ab [Units/volume] in Serum;Oidiodendrum IgE Qn;;ACTIVE;1.0h(2);2.42 +75432-5;Note;Find;Pt;Intensive care unit;Doc;{Role};DOC.ONTOLOGY;2;Intensive care unit Note;ICU Note;;ACTIVE;2.50;2.54 +75433-3;Education note;Find;Pt;{Setting};Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Education note;Interdiscip Educ note;;ACTIVE;2.50;2.58 +75434-1;Note;Find;Pt;Hospital;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Hospital Note;Internal Med Hosp Note;;ACTIVE;2.50;2.5 +75435-8;Note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Note;Internal Med Note;;ACTIVE;2.50;2.73 +75436-6;Note;Find;Pt;Outpatient;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Outpatient Note;Internal Med OP Note;;ACTIVE;2.50;2.5 +75437-4;Note;Find;Pt;{Setting};Doc;Licensed practical nurse;DOC.ONTOLOGY;2;Licensed practical nurse Note;LPN Note;;ACTIVE;2.50;2.5 +75438-2;Note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Note;LTC fac Note;;ACTIVE;2.50;2.58 +75439-0;Note;Find;Pt;{Setting};Doc;Medical student;DOC.ONTOLOGY;2;Medical student Note;MS Note;;ACTIVE;2.50;2.5 +7544-0;Abelmoschus esculentus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Okra IgE Ab [Units/volume] in Serum;Okra IgE Qn;;ACTIVE;1.0h(2);2.73 +75440-8;Administrative note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Administrative note;Mental health Administrative note;;ACTIVE;2.50;2.5 +75441-6;Diagnostic study note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Diagnostic study note;Mental health Diag study note;;ACTIVE;2.50;2.5 +75442-4;Medication management note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Medication management note;Mental health Med mgmt note;;ACTIVE;2.50;2.5 +75443-2;Note;Find;Pt;Outpatient;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Outpatient Note;Mental health OP Note;;ACTIVE;2.50;2.5 +75444-0;Note;Find;Pt;Telephone encounter;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Telephone encounter Note;Mental health Phone Note;;ACTIVE;2.50;2.58 +75445-7;Note;Find;Pt;Patient's home;Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Patient's home Note;Multi-spec prog Pt's home Note;;ACTIVE;2.50;2.58 +75446-5;Education note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Education note;Nurse Educ note;;ACTIVE;2.50;2.5 +75447-3;Fall risk assessment note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Fall risk assessment note;Nurse Fall risk assess note;;ACTIVE;2.50;2.5 +75448-1;Flowsheet;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Flowsheet;Nurse Flowsheet;;ACTIVE;2.50;2.5 +75449-9;Note;Find;Pt;Hospital;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Hospital Note;Nurse Hosp Note;;ACTIVE;2.50;2.5 +75450-7;Note;Find;Pt;Intensive care unit;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Intensive care unit Note;Nurse ICU Note;;ACTIVE;2.50;2.5 +75451-5;Note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Note;Nurse LTC fac Note;;ACTIVE;2.50;2.58 +75452-3;Medication management note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Medication management note;Nurse Med mgmt note;;ACTIVE;2.50;2.5 +75453-1;Note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Note;Nurse OP Note;;ACTIVE;2.50;2.5 +75454-9;Note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Note;Nurse pract Note;;ACTIVE;2.50;2.5 +75455-6;Procedure note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse procedure note;Nurse Procedure note;;ACTIVE;2.50;2.58 +75456-4;Risk assessment and screening note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Risk assessment and screening note;Nurse Risk assess+scrn note;;ACTIVE;2.50;2.58 +7545-7;Olive Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Olive IgE Ab [Units/volume] in Serum;Deprecated Olive IgE Qn;;DEPRECATED;1.0h(2);2.54 +75457-2;Triage note;Find;Pt;Telephone encounter;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Telephone encounter Triage note;Nurse Phone Triage note;;ACTIVE;2.50;2.58 +75458-0;Triage note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Triage note;Nurse Triage note;;ACTIVE;2.50;2.5 +75459-8;Note;Find;Pt;{Setting};Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Note;MH Nurse Note;;ACTIVE;2.50;2.58 +75460-6;Note;Find;Pt;{Setting};Doc;Preventive medicine.nurse;DOC.ONTOLOGY;2;Preventive medicine Nurse Note;Prevent med Nurse Note;;ACTIVE;2.50;2.58 +75461-4;Note;Find;Pt;{Setting};Doc;Primary care.nurse;DOC.ONTOLOGY;2;Primary care Nurse Note;Primary care Nurse Note;;ACTIVE;2.50;2.58 +75462-2;Note;Find;Pt;Outpatient;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Outpatient Note;Ophthalmol OP Note;;ACTIVE;2.50;2.5 +75463-0;Consultation note;Find;Pt;{Setting};Doc;Ophthalmology+Optometry;DOC.ONTOLOGY;2;Deprecated Ophthalmology+Optometry Consult note;Deprecated Ophthalmol+Optometry Consult;;DEPRECATED;2.50;2.68 +75464-8;Note;Find;Pt;{Setting};Doc;Ophthalmology+Optometry;DOC.ONTOLOGY;2;Deprecated Ophthalmology+Optometry Note;Deprecated Ophthalmol+Optometry Note;;DEPRECATED;2.50;2.56 +7546-5;Olea europaea Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Olive IgG Ab [Units/volume] in Serum;Olive IgG Qn;;ACTIVE;1.0h(2);2.73 +75465-5;Consultation note;Find;Pt;{Setting};Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Consult note;Orthotics prosthetics Consult note;;ACTIVE;2.50;2.58 +75466-3;Note;Find;Pt;{Setting};Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Note;Orthotics prosthetics Note;;ACTIVE;2.50;2.58 +75467-1;Evaluation and management of anticoagulation note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Evaluation and management of anticoagulation note;Pharmacology E/M coag note;;ACTIVE;2.50;2.56 +75468-9;Medication management note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Medication management note;Pharmacology Med mgmt note;;ACTIVE;2.50;2.56 +75469-7;Note;Find;Pt;Outpatient;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Outpatient Note;Pharmacology OP Note;;ACTIVE;2.50;2.56 +75470-5;Note;Find;Pt;Telephone encounter;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Telephone encounter Note;Pharmacology Phone Note;;ACTIVE;2.50;2.58 +75471-3;Note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending Note;Attend Note;;ACTIVE;2.50;2.65 +75472-1;Note;Find;Pt;{Setting};Doc;Internal medicine.attending;DOC.ONTOLOGY;2;Internal medicine Attending Note;Internal med Attend Note;;ACTIVE;2.50;2.65 +7547-3;Olive green Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Green Olive IgE Ab [Units/volume] in Serum;Deprecated Green Olive IgE Qn;;DEPRECATED;1.0h(2);2.54 +75473-9;Note;Find;Pt;{Setting};Doc;Primary care.attending;DOC.ONTOLOGY;2;Primary care Attending Note;Primary care Attend Note;;ACTIVE;2.50;2.65 +75474-7;Note;Find;Pt;{Setting};Doc;Psychiatry.attending;DOC.ONTOLOGY;2;Psychiatry Attending Note;Psychiatry Attend Note;;ACTIVE;2.50;2.65 +75475-4;Letter;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Letter;MD Letter;;ACTIVE;2.50;2.58 +75476-2;Note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Note;MD Note;;ACTIVE;2.50;2.58 +75477-0;Note;Find;Pt;{Setting};Doc;Resident;DOC.ONTOLOGY;2;Resident Note;Res Note;;ACTIVE;2.50;2.65 +75478-8;Note;Find;Pt;{Setting};Doc;Internal medicine.resident;DOC.ONTOLOGY;2;Internal medicine Resident Note;Internal med Res Note;;ACTIVE;2.50;2.65 +75479-6;Note;Find;Pt;{Setting};Doc;Primary care.physician;DOC.ONTOLOGY;2;Primary care Physician Note;Primary care MD Note;;ACTIVE;2.50;2.58 +75480-4;Note;Find;Pt;Outpatient;Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Outpatient Note;Podiatry OP Note;;ACTIVE;2.50;2.5 +7548-1;Allium cepa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Onion IgG Ab [Units/volume] in Serum;Onion IgG Qn;;ACTIVE;1.0h(2);2.73 +75481-2;Education note;Find;Pt;{Setting};Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Education note;Preventive med Educ note;;ACTIVE;2.50;2.5 +75482-0;Note;Find;Pt;{Setting};Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Note;Preventive med Note;;ACTIVE;2.50;2.5 +75483-8;Note;Find;Pt;Outpatient;Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Outpatient Note;Preventive med OP Note;;ACTIVE;2.50;2.5 +75484-6;Risk assessment and screening note;Find;Pt;{Setting};Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Risk assessment and screening note;Preventive med Risk assess+scrn note;;ACTIVE;2.50;2.58 +75485-3;Administrative note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Administrative note;Primary care Administrative note;;ACTIVE;2.50;2.5 +75486-1;Education note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Education note;Primary care Educ note;;ACTIVE;2.50;2.5 +75487-9;Letter;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Letter;Primary care Letter;;ACTIVE;2.50;2.5 +75488-7;Medication management note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Medication management note;Primary care Med mgmt note;;ACTIVE;2.50;2.5 +75489-5;Note;Find;Pt;Telephone encounter;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Telephone encounter Note;Primary care Phone Note;;ACTIVE;2.50;2.58 +75490-3;Note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Note;Radiology Note;;ACTIVE;2.50;2.73 +75491-1;Note;Find;Pt;{Setting};Doc;Registered nurse;DOC.ONTOLOGY;2;Registered nurse Note;RN Note;;ACTIVE;2.50;2.5 +75492-9;Risk assessment and screening note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Risk assessment and screening note;Risk assess+scrn note;;ACTIVE;2.50;2.58 +75493-7;Note;Find;Pt;Outpatient;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Outpatient Note;Surgery OP Note;;ACTIVE;2.50;2.5 +75494-5;Note;Find;Pt;{Setting};Doc;Team;DOC.ONTOLOGY;2;Team Note;Team Note;;ACTIVE;2.50;2.5 +75495-2;Note;Find;Pt;{Setting};Doc;Primary care.team;DOC.ONTOLOGY;2;Primary care Team Note;Primary care Team Note;;ACTIVE;2.50;2.58 +75496-0;Note;Find;Pt;Telehealth;Doc;{Role};DOC.ONTOLOGY;2;Telehealth Note;Telehealth Note;;ACTIVE;2.50;2.54 +75497-8;Progress note;Find;Pt;Telehealth;Doc;{Role};DOC.ONTOLOGY;2;Telehealth Progress note;Telehealth Prog note;;ACTIVE;2.50;2.73 +75498-6;Summary note;Find;Pt;Telehealth;Doc;{Role};DOC.ONTOLOGY;2;Telehealth Summary note;Telehealth Summary note;;ACTIVE;2.50;2.54 +7549-9;Allium cepa basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Onion triggered histamine release [Units/volume] in Blood;Onion BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75499-4;Triage note;Find;Pt;Telephone encounter;Doc;{Role};DOC.ONTOLOGY;2;Telephone encounter Triage note;Phone Triage note;;ACTIVE;2.50;2.58 +75500-9;Triage note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Triage note;Triage note;;ACTIVE;2.50;2.54 +75501-7;Note;Find;Pt;Outpatient;Doc;Urology;DOC.ONTOLOGY;2;Urology Outpatient Note;Urology OP Note;;ACTIVE;2.50;2.5 +75502-5;Note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Note;Vocational rehab Note;;ACTIVE;2.50;2.5 +75503-3;Note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Note;Pt's home Note;;ACTIVE;2.50;2.54 +75504-1;Note;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center Note;Urgent care Note;;ACTIVE;2.50;2.54 +75505-8;Diseases with serologic evidence of immunity;Find;Pt;^Patient;Nom;;VACCIN;2;Diseases with serologic evidence of immunity;Diseases w sero evidence of immunity;;ACTIVE;2.50;2.61 +75506-6;Coagulation surface induced.lupus sensitive.excess phospholipid;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive W excess phospholipid (LA confirm);Confirm aPTT;;ACTIVE;2.50;2.73 +7550-7;Citrus sinensis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Orange triggered histamine release [Units/volume] in Blood;Orange BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75507-4;Coagulation surface induced.lupus sensitive percent correction;PctDiff;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive W excess phospholipid percent correction;aPTT % correction;;ACTIVE;2.50;2.73 +75508-2;Coagulation surface induced.lupus sensitive.excess phospholipid actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive W excess phospholipid actual/Normal (normalized LA confirm);Confirm aPTT/normal;;ACTIVE;2.50;2.73 +75509-0;Coagulation surface induced.lupus sensitive with 1:1 Pooled Normal Plasma actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive with 1:1 PNP actual/Normal (normalized LA mix);Mixing aPTT/normal;;ACTIVE;2.50;2.73 +75510-8;Coagulation surface induced.lupus sensitive with 1:1 Pooled Normal Plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive with 1:1 PNP (LA mix);Mixing aPTT;;ACTIVE;2.50;2.73 +75511-6;DRVVT percent correction;PctDiff;Pt;PPP;Qn;Coag;COAG;1;dRVVT W excess phospholipid percent correction;dRVVT % correction;;ACTIVE;2.50;2.73 +75512-4;DRVVT with 1:1 Pooled Normal Plasma actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;dRVVT with 1:1 PNP actual/normal (normalized LA mix);Mixing dRVVT/normal;;ACTIVE;2.50;2.73 +75513-2;DRVVT with 1:1 Pooled Normal Plasma;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT with 1:1 PNP (LA mix);Mixing dRVVT;;ACTIVE;2.50;2.73 +75514-0;Lupus anticoagulant two screening tests W Reflex;Imp;Pt;PPP;Nom;Coag;COAG;1;Lupus anticoagulant two screening tests W Reflex [interpretation];LA 2 screen W Reflex-Imp;;ACTIVE;2.50;2.73 +7551-5;Citrus sinensis tree Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Orange Tree IgE Ab [Units/volume] in Serum;Orange Tree IgE Qn;;ACTIVE;1.0h(2);2.73 +75515-7;Lupus anticoagulant two screening tests W Reflex panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Lupus anticoagulant aPTT and dRVVT screening panel W Reflex;LA aPTT+dRVVT screen W reflex panel;;ACTIVE;2.50;2.67 +75516-5;Cortisol.free;SCnc;24H;Urine;Qn;;CHEM;1;Cortisol Free [Moles/volume] in 24 hour Urine;Cortis F 24h Ur-sCnc;;ACTIVE;2.50;2.5 +75517-3;Protein.monoclonal band 4;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 4 [Mass/time] in 24 hour Urine by Electrophoresis;M Protein 4 24h Ur Elph-mRate;;ACTIVE;2.50;2.63 +75518-1;Bacteria identified;Prid;Pt;CSF;Nom;LA;MICRO;1;Bacteria identified in Cerebral spinal fluid by Latex agglutination;Bacteria CSF LA;;ACTIVE;2.50;2.5 +75519-9;Encounter identifier;ID;Pt;^Patient;Nom;;SURVEY.PCORNET;4;Encounter identifier;;;ACTIVE;2.50;2.5 +75520-7;Biobank specimens are stored and available for research;PrThr;Pt;^Patient;Ord;;SURVEY.PCORNET;4;Biobank specimens are stored and available for research;;;ACTIVE;2.50;2.7 +75521-5;Information source for data;Type;Pt;^Patient;Nom;PCORnet;SURVEY.PCORNET;4;Information source for data [PCORnet];;;ACTIVE;2.50;2.7 +75522-3;Admission time;ClockTime;Pt;^Patient;Qn;;SURVEY.PCORNET;4;Admission time;;;ACTIVE;2.50;2.7 +7552-3;Origanum vulgare Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oregano IgE Ab [Units/volume] in Serum;Oregano IgE Qn;;ACTIVE;1.0h(2);2.73 +75523-1;Discharge time;ClockTime;Pt;^Patient;Qn;;SURVEY.PCORNET;4;Discharge time;;;ACTIVE;2.50;2.7 +75524-9;Facility identifier;ID;Pt;Facility;Nom;;SURVEY.PCORNET;4;Facility identifier;;;ACTIVE;2.50;2.5 +75525-6;Type of encounter;Type;Pt;^Patient;Nom;MSCDM;SURVEY.PCORNET;4;Type of encounter [MSCDM];;;ACTIVE;2.50;2.7 +75526-4;Internal identifier;ID;Pt;Provider;Nom;;SURVEY.PCORNET;4;Internal identifier for Provider;;;ACTIVE;2.50;2.7 +75527-2;Vital status^at discharge;Find;Pt;^Patient;Nom;;SURVEY.PCORNET;4;Vital status at discharge;;;ACTIVE;2.50;2.5 +75528-0;Discharge disposition;Type;Pt;^Patient;Nom;MSCDM;SURVEY.PCORNET;4;Deprecated Discharge disposition [MSCDM];;;DEPRECATED;2.50;2.73 +75529-8;Admitted from;Type;Pt;Facility;Nom;MSCDM;SURVEY.PCORNET;4;Admitted from Facility [MSCDM];;;ACTIVE;2.50;2.7 +75530-6;Able to request or review patient chart;Type;Pt;Abstractor;Ord;MSCDM;SURVEY.PCORNET;4;Able to request or review patient chart Abstractor [MSCDM];;;ACTIVE;2.50;2.7 +7553-1;Origanum vulgare Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oregano IgG Ab [Units/volume] in Serum;Oregano IgG Qn;;ACTIVE;1.0h(2);2.73 +75531-4;Enrollment basis;Type;Pt;^Patient;Nom;;SURVEY.PCORNET;4;Enrollment basis;;;ACTIVE;2.50;2.7 +75532-2;Applicable accrediting agency for unit;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Applicable accrediting agency for unit [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75533-0;Accreditation, certification, & licensure panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;NMMDS accreditation, certification, and licensure panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.52 +75534-8;Accreditation received;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Accreditation received [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75535-5;Certification received;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Certification received [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75536-3;Applicable certification agency for unit;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Applicable certification agency for unit [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75537-1;Applicable licensing agency for unit;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Applicable licensing agency for unit [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75538-9;Licensing received;Type;Pt;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Licensing received [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75539-7;Body temperature;Temp;Pt;Temporal artery;Qn;;BDYTMP.MOLEC;2;Body temperature - Temporal artery;Bdy temp Temporal a;;ACTIVE;2.50;2.73 +75540-5;Hepatitis A virus RNA+Parvovirus B19 DNA;Imp;Pt;Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Hepatitis A virus RNA+Parvovirus B19 DNA [Interpretation] in Plasma from Donor Qualitative by NAA with probe detection;HAV RNA+B19V DNA Plas Donr NAA+probe-Imp;;ACTIVE;2.50;2.63 +75541-3;Parvovirus B19 DNA;LaCnc;Pt;Plas^Donor;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [log units/volume] (viral load) in Plasma from Donor by NAA with probe detection;B19V DNA Plas Donr NAA+probe-Log IU;;ACTIVE;2.50;2.63 +75542-1;Hepatitis A virus RNA;Imp;Pt;Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Hepatitis A virus RNA [Interpretation] in Plasma from Donor Qualitative by NAA with probe detection;HAV RNA Plas Donr NAA+probe-Imp;;ACTIVE;2.50;2.63 +75543-9;Parvovirus B19 DNA;PrThr;Pt;Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Plasma from Donor by NAA with probe detection;B19V DNA Plas Donr Ql NAA+probe;;ACTIVE;2.50;2.63 +75544-7;Noninvasive prenatal testing overall interpretation;Imp;Pt;^Fetus;Ord;;MOLPATH;1;Noninvasive prenatal testing overall interpretation Qualitative;NIPT overall interpretation Ql;;ACTIVE;2.50;2.73 +75545-4;Noninvasive prenatal testing comment;Txt;Pt;^Fetus;Nar;;MOLPATH;1;Noninvasive prenatal testing comment [Text];NIPT comment;;ACTIVE;2.50;2.73 +75546-2;Trisomy 13 prior risk;Likelihood;Pt;^Fetus;Qn;Based on maternal age;MOLPATH.TRISOMY;1;Fetal Trisomy 13 prior risk [Likelihood] Based on maternal age;Fet Ts 13 prior risk from Mat age;;ACTIVE;2.50;2.73 +75547-0;Noninvasive prenatal fetal aneuploidy and microdeletion panel;-;Pt;WBC.DNA+Plas.cfDNA;-;Dosage of chromosome specific cf DNA;PANEL.MOLPATH;1;Noninvasive prenatal fetal aneuploidy and microdeletion panel based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific circulating cell free (ccf) DNA;NIP aneu microdel pnl WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75548-8;Fetal trisomy 13 risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 13 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet Ts 13 risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +7554-9;Origanum vulgare basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Oregano triggered histamine release [Units/volume] in Blood;Oregano BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75549-6;Performing laboratory phone number;Tele;Pt;Facility;Nom;;ADMIN.FACILITY;2;Performing laboratory phone number;Performing lab phone #;;ACTIVE;2.50;2.73 +75550-4;Trisomy 13 prior risk;Likelihood;Pt;^Fetus;Nar;Based on maternal age;MOLPATH.TRISOMY;1;Fetal Trisomy 13 prior risk [Likelihood] Based on maternal age Narrative;Fet Ts 13 prior risk from Mat age;;ACTIVE;2.50;2.73 +75551-2;Fetal trisomy 13 risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 13 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Ts 13 risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75552-0;Fetal trisomy 13 risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 13 risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ts 13 risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75553-8;Comment on fetal Trisomy 13 risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Comment on fetal Trisomy 13 risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Ts 13 risk comment;;ACTIVE;2.50;2.73 +75554-6;Trisomy 18 prior risk;Likelihood;Pt;^Fetus;Qn;Based on maternal age;MOLPATH.TRISOMY;1;Fetal Trisomy 18 prior risk [Likelihood] Based on maternal age;Fet Ts 18 prior risk from Mat age;;ACTIVE;2.50;2.73 +75555-3;Fetal trisomy 18 risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 18 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet Ts 18 risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +7555-6;Iris germanica var florentina Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Orris root IgE Ab [Units/volume] in Serum;Orris root IgE Qn;;ACTIVE;1.0h(2);2.73 +75556-1;Trisomy 18 prior risk;Likelihood;Pt;^Fetus;Nar;Based on maternal age;MOLPATH.TRISOMY;1;Fetal Trisomy 18 prior risk [Likelihood] Based on maternal age Narrative;Fet Ts 18 prior risk from Mat age;;ACTIVE;2.50;2.73 +75557-9;Fetal trisomy 18 risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 18 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Ts 18 risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75558-7;Fetal trisomy 18 risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 18 risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ts 18 risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75559-5;Comment on fetal Trisomy 18 risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Comment on fetal Trisomy 18 risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Ts 18 risk comment;;ACTIVE;2.50;2.73 +75560-3;Trisomy 21 prior risk;Likelihood;Pt;^Fetus;Qn;Based on maternal age;MOLPATH.TRISOMY;1;Fetal Trisomy 21 prior risk [Likelihood] Based on maternal age;Fet Ts 21 prior risk from Mat age;;ACTIVE;2.50;2.73 +75561-1;Fetal trisomy 21 risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 21 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet Ts 21 risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +75562-9;Trisomy 21 prior risk;Likelihood;Pt;^Fetus;Nar;Based on maternal age;MOLPATH.TRISOMY;1;Fetal Trisomy 21 prior risk [Likelihood] Based on maternal age Narrative;Fet Ts 21 prior risk from Mat age;;ACTIVE;2.50;2.73 +75563-7;Fetal trisomy 21 risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 21 risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Ts 21 risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +7556-4;Ovalbumin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ovalbumin IgE Ab [Units/volume] in Serum;Ovalb IgE Qn;;ACTIVE;1.0h(2);2.73 +75564-5;Fetal trisomy 21 risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Trisomy 21 risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ts 21 risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75565-2;Comment on fetal Trisomy 21 risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Comment on fetal Trisomy 21 risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Ts 21 risk comment;;ACTIVE;2.50;2.73 +75566-0;Monosomy X prior risk;Likelihood;Pt;^Fetus;Qn;Based on maternal age;MOLPATH;1;Fetal Monosomy X prior risk [Likelihood] Based on maternal age;Fet Ms X prior risk from Mat age;;ACTIVE;2.50;2.73 +75567-8;Fetal monosomy X risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Monosomy X risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet Ms X risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +75568-6;Monosomy X prior risk;Likelihood;Pt;^Fetus;Nar;Based on maternal age;MOLPATH;1;Fetal Monosomy X prior risk [Likelihood] Based on maternal age Narrative;Fet Ms X prior risk from Mat age;;ACTIVE;2.50;2.73 +75569-4;Fetal monosomy X risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Monosomy X risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Ms X risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75570-2;Fetal monosomy X risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Monosomy X risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ms X risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75571-0;Comment on fetal Monosomy X risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH;1;Comment on fetal Monosomy X risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Mon X 13 risk comment;;ACTIVE;2.50;2.73 +7557-2;Ovomucoid Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ovomucoid IgE Ab [Units/volume] in Serum;Ovomucoid IgE Qn;;ACTIVE;1.0h(2);2.73 +75572-8;Fetal triploidy risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Triploidy risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Trip risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75573-6;Comment on fetal Triploidy risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Comment on fetal Triploidy risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet Triploidy risk comment;;ACTIVE;2.50;2.73 +75574-4;22q11.2 deletion prior risk;Likelihood;Pt;^Fetus;Qn;Based on general population risk;MOLPATH.DEL;1;Fetal 22q11.2 deletion prior risk [Likelihood] based on general population risk;Fet 22q11.2 del prior risk from Pop risk;;ACTIVE;2.50;2.73 +75575-1;22q11.2 deletion prior risk;Likelihood;Pt;^Fetus;Nar;Based on general population risk;MOLPATH.DEL;1;Fetal 22q11.2 deletion prior risk [Likelihood] based on general population risk Narrative;Fet 22q11.2 del prior risk from Pop risk;;ACTIVE;2.50;2.73 +75576-9;Fetal 22q11.2 deletion risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 22q11.2 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet 22q11.2 del risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +75577-7;Fetal 22q11.2 deletion risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 22q11.2 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet 22q11.2 del risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75578-5;Fetal 22q11.2 deletion risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 22q11.2 deletion risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet 22q11.2 del risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75579-3;Comment on fetal 22q11.2 deletion risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Comment on fetal 22q11.2 deletion risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet 22q11.2 del risk comment;;ACTIVE;2.50;2.73 +7558-0;Ostrea edulis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oyster IgE Ab [Units/volume] in Serum;Oyster IgE Qn;;ACTIVE;1.0h(2);2.73 +75580-1;Prader-Willi syndrome prior risk;Likelihood;Pt;^Fetus;Qn;Based on general population risk;MOLPATH.DEL;1;Fetal Prader-Willi syndrome prior risk [Likelihood] based on general population risk;Fet PWS prior risk from Pop risk;;ACTIVE;2.50;2.73 +75581-9;Prader-Willi syndrome prior risk;Likelihood;Pt;^Fetus;Nar;Based on general population risk;MOLPATH.DEL;1;Fetal Prader-Willi syndrome prior risk [Likelihood] based on general population risk Narrative;Fet PWS prior risk from Pop risk;;ACTIVE;2.50;2.73 +75582-7;Fetal Prader-Willi syndrome risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal Prader-Willi syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet PWS risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +75583-5;Fetal Prader-Willi syndrome risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal Prader-Willi syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet PWS risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75584-3;Fetal Prader-Willi syndrome risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal Prader-Willi syndrome risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet PWS risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75585-0;Comment on fetal Prader-Willi syndrome risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Comment on fetal Prader-Willi syndrome risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet PWS risk comment;;ACTIVE;2.50;2.73 +75586-8;Angelman syndrome prior risk;Likelihood;Pt;^Fetus;Qn;Based on general population risk;MOLPATH;1;Fetal Angelman syndrome prior risk [Likelihood] based on general population risk;Fet AS prior risk from Pop risk;;ACTIVE;2.50;2.73 +75587-6;Angelman syndrome prior risk;Likelihood;Pt;^Fetus;Nar;Based on general population risk;MOLPATH;1;Fetal Angelman syndrome prior risk [Likelihood] based on general population risk Narrative;Fet AS prior risk from Pop risk;;ACTIVE;2.50;2.73 +75588-4;Fetal Angelman syndrome risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Angelman syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet AS risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +75589-2;Fetal Angelman syndrome risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Angelman syndrome risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet AS risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +755-9;Neutrophils;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Cerebral spinal fluid by Manual count;Neutrophils # CSF Manual;;ACTIVE;1.0;2.73 +75590-0;Fetal Angelman syndrome risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Angelman syndrome risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet AS risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75591-8;Comment on fetal Angelman syndrome risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH;1;Comment on fetal Angelman syndrome risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet AS risk comment;;ACTIVE;2.50;2.73 +75592-6;5p deletion prior risk;Likelihood;Pt;^Fetus;Qn;Based on general population risk;MOLPATH.DEL;1;Fetal 5p deletion prior risk [Likelihood] based on general population risk;Fet 5p del prior risk from Pop risk;;ACTIVE;2.50;2.73 +75593-4;5p deletion prior risk;Likelihood;Pt;^Fetus;Nar;Based on general population risk;MOLPATH.DEL;1;Fetal 5p deletion prior risk [Likelihood] based on general population risk Narrative;Fet 5p del prior risk from Pop risk;;ACTIVE;2.50;2.73 +75594-2;Fetal 5p deletion risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 5p deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet 5p del risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +75595-9;Fetal 5p deletion risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 5p deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet 5p del risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75596-7;Fetal 5p deletion risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 5p deletion risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet 5p del risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75597-5;Comment on fetal 5p deletion risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Comment on fetal 5p deletion risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet 5p del risk comment;;ACTIVE;2.50;2.73 +7559-8;Ostrea edulis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oyster IgG Ab [Units/volume] in Serum;Oyster IgG Qn;;ACTIVE;1.0h(2);2.73 +75598-3;1p36 deletion prior risk;Likelihood;Pt;^Fetus;Qn;Based on general population risk;MOLPATH.DEL;1;Fetal 1p36 deletion prior risk [Likelihood] based on general population risk;Fet 1p36 del prior risk from Pop risk;;ACTIVE;2.50;2.73 +75599-1;1p36 deletion prior risk;Likelihood;Pt;^Fetus;Nar;Based on general population risk;MOLPATH.DEL;1;Fetal 1p36 deletion prior risk [Likelihood] based on general population risk Narrative;Fet 1p36 del prior risk from Pop risk;;ACTIVE;2.50;2.73 +75600-7;Fetal 1p36 deletion risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 1p36 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;Fet 1p36 del risk WBC.DNA+cfDNA Qn;;ACTIVE;2.50;2.73 +75601-5;Fetal 1p36 deletion risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 1p36 deletion risk [Likelihood] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet 1p36 del risk WBC.DNA+cfDNA;;ACTIVE;2.50;2.73 +75602-3;Fetal 1p36 deletion risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Fetal 1p36 deletion risk [Interpretation] based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet 1p36 del risk WBC.DNA+cfDNA Ql;;ACTIVE;2.50;2.73 +75603-1;Comment on fetal 1p36 deletion risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH.DEL;1;Comment on fetal 1p36 deletion risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Fet 1p36 del risk comment;;ACTIVE;2.50;2.73 +75604-9;Fetal sex;Find;Pt;WBC.DNA+Plas.cfDNA;Nom;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal sex in Cell-free+Maternal WBC DNA by Dosage of chromosome specific circulating cell free (ccf) DNA;Fet sex cfDNA+DNA.Mat;;ACTIVE;2.50;2.73 +75605-6;Cell-free DNA.fetal/Cell-free DNA.total;SFr;Pt;Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH;1;Cell-free DNA.fetal/Cell-free DNA.total in Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;cfDNA.fet/cfDNA.total SFr Fetus;;ACTIVE;2.50;2.73 +7560-6;Ostrea edulis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Oyster triggered histamine release [Units/volume] in Blood;Oyster BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75606-4;Cell-free DNA.fetal/Cell-free DNA.total;Find;Pt;Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH;1;Cell-free DNA.fetal/Cell-free DNA.total in Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Narrative;cfDNA.fet/total Plas.cfDNA;;ACTIVE;2.50;2.73 +75607-2;Paternal sample received;Find;Pt;^Father;Ord;;MOLPATH;1;Paternal sample received Qualitative;Pat sample rec Father Ql;;ACTIVE;2.50;2.73 +75608-0;Citation;Bib;Pt;Referral lab test;Nar;;MISC;1;Citation [Bibliographic Citation] in Referral lab test Narrative;Citation Ref Lab Test;;ACTIVE;2.50;2.73 +75609-8;Registry report;Find;Pt;Outpatient;Doc;Birth defects;DOC.ONTOLOGY;2;Birth defects Outpatient Registry report;Birth defects OP Registry rpt;;ACTIVE;2.50;2.63 +75610-6;Oxygen therapy at arrival;Find;Pt;^Patient;Ord;;SURVEY.NHCS;4;Oxygen therapy at arrival;;;ACTIVE;2.50;2.52 +75611-4;Patient seen in this ED in last 72H and discharged;Find;Pt;^Patient;Ord;;SURVEY.NHCS;4;Patient seen in this ED in last 72 hours and discharged;;;ACTIVE;2.50;2.52 +75612-2;Number of visits to this healthcare entity in the last 12Mo;NRat;12Mo;^Patient;Qn;;SURVEY.NHCS;4;Number of visits to this healthcare entity in the last 12 months;;;ACTIVE;2.50;2.66 +75613-0;ED episode of care;Find;Pt;^Patient;Nom;;SURVEY.NHCS;4;ED episode of care;;;ACTIVE;2.50;2.52 +7561-4;Amaranthus palmeri Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Careless Weed IgE Ab [Units/volume] in Serum;Deprecated Careless Weed IgE Qn;;DEPRECATED;1.0h(2);2.69 +75614-8;Three level triage system;Find;Pt;^Patient;Ord;NAMCS;SURVEY.NHCS;4;Three level triage system [NAMCS];;;ACTIVE;2.50;2.52 +75615-5;Four level triage system;Find;Pt;^Patient;Ord;NAMCS;SURVEY.NHCS;4;Four level triage system [NAMCS];;;ACTIVE;2.50;2.52 +75616-3;Generic five level triage system;Find;Pt;^Patient;Ord;NAMCS;SURVEY.NHCS;4;Generic five level triage system [NAMCS];;;ACTIVE;2.50;2.52 +75617-1;Residence;Type;Pt;^Patient;Nom;NAMCS;SURVEY.NHCS;4;Residence [NAMCS];;;ACTIVE;2.50;2.73 +75618-9;Comorbid condition;Find;Pt;^Patient;Nom;;H&P.HX;2;Comorbid condition;Comorbid condition;;ACTIVE;2.50;2.7 +75619-7;National health care surveys report;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;National Health Care Surveys report;NHCS report;;ACTIVE;2.50;2.63 +75620-5;TNM clinical staging before treatment panel;-;Pt;Cancer.XXX;-;;PANEL.ONCO;2;TNM clinical staging before treatment panel Cancer;TNM clinical staging Pnl Cancer;;ACTIVE;2.50;2.5 +75621-3;TNM pathologic staging after surgery panel;-;Pt;Cancer.XXX;-;;PANEL.ONCO;2;TNM pathologic staging after surgery panel Cancer;TNM pathologic staging Pnl Cancer;;ACTIVE;2.50;2.5 +7562-2;Paper Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paper IgE Ab [Units/volume] in Serum;Paper IgE Qn;;ACTIVE;1.0h(2);2.42 +75622-1;HIV 1 & 2 tests - Meaningful Use set;-;Pt;^Patient;-;;PANEL.MICRO;1;HIV 1 and 2 tests - Meaningful Use set;HIV 1 and 2 - MU Set;;ACTIVE;2.50;2.5 +75624-7;Total score;Score;Pt;^Patient;Qn;AUDIT;SURVEY.GNHLTH;4;Total score [AUDIT];;Copyright © 2001 World Health Organization. Used with permission.;ACTIVE;2.50;2.73 +75626-2;Total score;Score;Pt;^Patient;Qn;AUDIT-C;SURVEY.GNHLTH;4;Total score [AUDIT-C];;;ACTIVE;2.50;2.58 +75627-0;Vascular adhesion protein 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vascular adhesion protein 1 [Mass/volume] in Serum or Plasma;VAP-1 SerPl-mCnc;;ACTIVE;2.50;2.73 +75628-8;Vascular endothelial growth factor A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vascular endothelial growth factor A [Mass/volume] in Serum or Plasma;VEGF-A SerPl-mCnc;;ACTIVE;2.50;2.5 +75629-6;Tumor necrosis factor receptor superfamily member 1A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tumor necrosis factor receptor superfamily member 1A [Mass/volume] in Serum or Plasma;TNFRSF1A SerPl-mCnc;;ACTIVE;2.50;2.5 +7563-0;Capsicum annuum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paprika IgE Ab [Units/volume] in Serum;Paprika IgE Qn;;ACTIVE;1.0h(2);2.73 +75630-4;Interstitial collagenase;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interstitial collagenase [Mass/volume] in Serum or Plasma;MMP-1 SerPl-mCnc;;ACTIVE;2.50;2.5 +75631-2;Stromelysin-1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Stromelysin-1 [Mass/volume] in Serum or Plasma;MMP-3 SerPl-mCnc;;ACTIVE;2.50;2.5 +75632-0;Resistin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Resistin [Mass/volume] in Serum or Plasma;Resistin SerPl-mCnc;;ACTIVE;2.50;2.5 +75633-8;Rheumatoid arthritis disease activity score;Score;Pt;Ser/Plas;Qn;Calculated.VectraDA;CHEM;1;Rheumatoid arthritis disease activity score Calculated by VectraDA;RA DAS Score Calc VectraDA;;ACTIVE;2.50;2.73 +75634-6;Rheumatoid arthritis disease activity score level;Imp;Pt;Ser/Plas;Ord;VectraDA;CHEM;1;Rheumatoid arthritis disease activity score level Qualitative by VectraDA;RA DAS level Ql VectraDA;;ACTIVE;2.50;2.52 +75635-3;Rheumatoid arthritis disease activity panel;-;Pt;Ser/Plas;-;VectraDA;PANEL.CHEM;1;Rheumatoid arthritis disease activity panel - Serum or Plasma by VectraDA;RA Disease Activity Pnl SerPl VectraDA;;ACTIVE;2.50;2.5 +75636-1;Emergency severity index;Find;Pt;^Patient;Ord;ESI;SURVEY.NHCS;4;Emergency severity index [ESI];;ESI Copyright © 2004, ESI Triage Research Team Used with permission.;ACTIVE;2.50;2.54 +75637-9;Glucose^45M post 50 g lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --45 minutes post 50 g lactose PO;Glucose 45M p 50 g Lac PO SerPl-sCnc;;ACTIVE;2.50;2.5 +75638-7;Homocarnosine;SCnc;Pt;CSF;Qn;;CHEM;1;Homocarnosine [Moles/volume] in Cerebral spinal fluid;Homocarnosine CSF-sCnc;;ACTIVE;2.50;2.5 +75639-5;Lactate dehydrogenase.body fld/Lactate dehydrogenase.serum;RelRto;Pt;Body fld+Ser/Plas;Qn;;CHEM;1;Lactate dehydrogenase in body fluid/Lactate dehydrogenase in serum;LDH.body fld/SerPl;;ACTIVE;2.50;2.5 +75640-3;Lysozyme;SCnc;24H;Urine;Qn;;CHEM;1;Lysozyme [Moles/volume] in 24 hour Urine;Lysozyme 24h Ur-sCnc;;ACTIVE;2.50;2.5 +75641-1;Electrolytes 3 panel;-;Pt;CSF;Qn;;PANEL.CHEM;1;Electrolytes 3 panel - Cerebral spinal fluid;Lytes 3 Pnl CSF;;ACTIVE;2.50;2.5 +75642-9;Urate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Urate/Creatinine [Molar ratio] in 24 hour Urine;Urate/Creat 24h Ur-sRto;;ACTIVE;2.50;2.54 +75643-7;7-Hydroxymitragynine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;7-Hydroxymitragynine [Presence] in Urine by Confirmatory method;7-OH-mitragynine Ur Ql Cfm;;ACTIVE;2.50;2.73 +75644-5;Amphetamine+Methamphetamine;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;Amphetamine+Methamphetamine [Presence] in Blood by Confirmatory method;Amphet+Methamphet Bld Ql Cfm;;ACTIVE;2.50;2.73 +75645-2;Butabarbital;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Butabarbital [Mass/volume] in Blood by Confirmatory method;Butabarbital Bld Cfm-mCnc;;ACTIVE;2.50;2.73 +75646-0;Ethylene glycol;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Ethylene glycol [Presence] in Gastric fluid;Ethylene Glycol Gast Ql;;ACTIVE;2.50;2.56 +75647-8;Meperidine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Meperidine [Presence] in Meconium;Meperidine Mec Ql;;ACTIVE;2.50;2.56 +7564-8;Parakeet droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parakeet droppings IgE Ab [Units/volume] in Serum;Parakeet Drop IgE Qn;;ACTIVE;1.0h(2);2.42 +75648-6;Methylenedioxymethamphetamine+Methylenedioxyamphetamine;PrThr;Pt;Bld;Ord;;DRUG/TOX;1;Methylenedioxymethamphetamine+Methylenedioxyamphetamine [Presence] in Blood;MDMA+MDA Bld Ql;;ACTIVE;2.50;2.73 +75649-4;Mitragynine+7-Hydroxymitragynine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Mitragynine+7-Hydroxymitragynine [Presence] in Urine by Confirmatory method;Mitragynine+7-OH Ur Ql Cfm;;ACTIVE;2.50;2.73 +75650-2;Sulfonamide;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfonamide [Moles/volume] in Serum or Plasma;Sulfonamide SerPl-sCnc;;ACTIVE;2.50;2.5 +75651-0;Tetrahydrocannabivarin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tetrahydrocannabivarin [Mass/volume] in Urine;CarboxyTHCV Ur-mCnc;;ACTIVE;2.50;2.73 +75652-8;Lymphocytes.immature;PrThr;Pt;Bld;Ord;;HEM/BC;1;Immature lymphocytes [Presence] in Blood;Imm Lymphs Bld Ql;;ACTIVE;2.50;2.56 +75653-6;Manual differential comment;Imp;Pt;Body fld;Nar;;HEM/BC;1;Manual differential comment [Interpretation] in Body fluid Narrative;Manual dif comment Fld-Imp;;ACTIVE;2.50;2.73 +75654-4;Manual differential comment;Imp;Pt;CSF;Nar;;HEM/BC;1;Manual differential comment [Interpretation] in Cerebral spinal fluid Narrative;Manual dif comment CSF-Imp;;ACTIVE;2.50;2.5 +7565-5;Parakeet feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parakeet feather IgE Ab [Units/volume] in Serum;Parakeet Feather IgE Qn;;ACTIVE;1.0h(2);2.73 +75655-1;Mononuclear cells;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Mononuclear cells [#] in Cerebral spinal fluid by Manual count;Mononuc Cells CSF Manual;;ACTIVE;2.50;2.5 +75656-9;Mononuclear cells;Num;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Mononuclear cells [#] in Pericardial fluid by Manual count;Mononuc Cells Pcar Manual;;ACTIVE;2.50;2.5 +75657-7;Mononuclear cells;Num;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Mononuclear cells [#] in Pleural fluid by Manual count;Mononuc Cells Plr Manual;;ACTIVE;2.50;2.5 +75658-5;Plasma cells/100 leukocytes;NFr;Pt;Bronchial;Qn;;HEM/BC;1;Plasma cells/100 leukocytes in Bronchial specimen;Plasma Cells/leuk NFr Bronch;;ACTIVE;2.50;2.5 +75659-3;Polymorphonuclear cells;Num;Pt;Pericard fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells [#] in Pericardial fluid by Manual count;Polys Pcar Manual;;ACTIVE;2.50;2.5 +75660-1;Polymorphonuclear cells;Num;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells [#] in Peritoneal fluid by Manual count;Polys Prt Manual;;ACTIVE;2.50;2.5 +75661-9;Polymorphonuclear cells;Num;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells [#] in Pleural fluid by Manual count;Polys Plr Manual;;ACTIVE;2.50;2.5 +75662-7;Polymorphonuclear cells;Num;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells [#] in Synovial fluid by Manual count;Polys Snv Manual;;ACTIVE;2.50;2.5 +7566-3;Parakeet serum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parakeet serum IgE Ab [Units/volume] in Serum;Parakeet Serum IgE Qn;;ACTIVE;1.0h(2);2.42 +75663-5;Prolymphocytes;PrThr;Pt;Bld;Ord;;HEM/BC;1;Prolymphocytes [Presence] in Blood;Prolymphocytes Bld Ql;;ACTIVE;2.50;2.56 +75664-3;Human papilloma virus 16 DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 16 DNA [Presence] in Anorectal specimen by Probe and signal amplification method;HPV16 DNA Anorectl Ql Probe+sig amp;;ACTIVE;2.50;2.73 +75665-0;Ova & parasites identified;Prid;Pt;Urine;Nom;Trichrome stain;MICRO;1;Ova and parasites identified in Urine by Trichrome stain;O+P Ur Tri Stn;;ACTIVE;2.50;2.73 +75666-8;HIV 1+2 Ab & HIV1 p24 Ag;Prid;Pt;Ser/Plas/Bld;Nom;IA.rapid;MICRO;1;HIV 1+2 Ab and HIV1 p24 Ag [Identifier] in Serum, Plasma or Blood by Rapid immunoassay;HIV 1+2 Ab+HIV1p24 Ag SerPlBld IA.rapid;;ACTIVE;2.50;2.73 +75667-6;Electrolytes 3 panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Electrolytes 3 panel - 24 hour Urine;Lytes 3 Pnl 24h Ur;;ACTIVE;2.50;2.63 +75668-4;Fetal sex;Likelihood;Pt;Plas.cfDNA;Qn;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal sex [Likelihood] in Plasma cell-free DNA by Dosage of chromosome specifi cell free (cf) DNA;Fet sex Likelihood Plas.cfDNA;;ACTIVE;2.50;2.73 +75669-2;Guidance for percutaneous biopsy;Find;Pt;XXX>Bone marrow;Doc;RF;RAD;2;RF Guidance for biopsy of Bone marrow;RF Guided Bone mar Bx;;ACTIVE;2.50;2.64 +756-7;Neutrophils;NCnc;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Neutrophils [#/volume] in Pleural fluid by Automated count;Neutrophils # Plr Auto;;ACTIVE;1.0;2.73 +75670-0;Views^W contrast EP;Find;Pt;Abdomen>Spine.lumbar epidural space;Doc;RF;RAD;2;RF Lumbar spine epidural space Views W contrast epidural;RF L-spine space Views W contr EP;;ACTIVE;2.50;2.66 +7567-1;Parrot serum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parrot serum IgE Ab [Units/volume] in Serum;Parrot Serum IgE Qn;;ACTIVE;1.0h(2);2.73 +75671-8;Multisection^WO & W contrast IV;Find;Pt;Head+Neck>Circle of Willis;Doc;CT.angio;RAD;2;CTA Circle of Willis WO and W contrast IV;CTA Circle of Willis WO+W contr IV;;ACTIVE;2.50;2.61 +75672-6;Guidance for placement of nephrostomy tube;Find;Pt;Abdomen>Kidney;Doc;US;RAD;2;US Guidance for placement of nephrostomy tube in Kidney;US Guided Kidney NT place;;ACTIVE;2.50;2.64 +75673-4;Gram negative blood culture panel;-;Pt;Bld.pos growth;-;Probe.mag capture;PANEL.MICRO;1;Deprecated Gram negative blood culture panel by Nucleic acid capture and probe detection in Positive blood culture;Deprecated GN Bld Culture Pnl Bld Pos Prb Mag;;DEPRECATED;2.50;2.68 +75674-2;Acinetobacter sp (rpsA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Acinetobacter sp (rpsA) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Acinetobacter sp rpsA Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75675-9;Citrobacter sp (ompA+mrkC) genes;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Citrobacter sp (ompA+mrkC) genes [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Citrobac sp ompA+mrkC Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75676-7;Enterobacter sp (gyrB+metB) genes;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Enterobacter sp (gyrB+metB) genes [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Enterobact gyrB+metB Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75677-5;Proteus sp (atpD) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Proteus sp (atpD) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated Proteus sp atpD Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75678-3;Escherichia coli (oppA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Escherichia coli (oppA) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated E coli oppA Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75679-1;Klebsiella pneumoniae yggE gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Klebsiella pneumoniae yggE gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated K pneumoniae yggE Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75680-9;Klebsiella oxytoca (ompA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Klebsiella oxytoca (ompA) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated K oxytoca ompA Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75681-7;Pseudomonas aeruginosa (sodA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Pseudomonas aeruginosa (sodA) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated P aeruginosa sodA Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75682-5;Bacterial cephalosporin resistance (bla(CTX-M)) gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Cephalosporin resistance (bla(CTX-M)) gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated bla(CTX-M) Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75683-3;Bacterial carbapenem resistance blaKPC gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Carbapenem resistance blaKPC gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated blaKPC Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.65 +75684-1;Bacterial carbapenem resistance blaNDM gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Carbapenem resistance blaNDM gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated blaNDM Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.65 +75685-8;Bacterial carbapenem resistance blaVIM gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Carbapenem resistance blaVIM gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated blaVIM Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.65 +75686-6;Bacterial carbapenem resistance blaIMP gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Carbapenem resistance blaIMP gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated blaIMP Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.65 +75687-4;Bacterial carbapenem resistance blaOXA gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;ABXBACT;1;Deprecated Carbapenem resistance blaOXA gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated blaOXA Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.65 +75688-2;Gram negative bacteria identified;Imp;Pt;Bld.pos growth;Nom;Probe.mag capture;MICRO;1;Deprecated Gram negative bacteria identified [Interpretation] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated GN bact Bld Pos Prb Mag-Imp;;DEPRECATED;2.50;2.63 +7568-9;Petroselinum crispum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parsley IgG Ab [Units/volume] in Serum;Parsley IgG Qn;;ACTIVE;1.0h(2);2.69 +75689-0;Iron panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Iron panel - Serum or Plasma;Iron Pnl SerPl;;ACTIVE;2.50;2.73 +75690-8;Enterococcus faecium hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe.mag capture;MICRO;1;Deprecated Enterococcus faecium hsp60 gene [Presence] by Nucleic acid capture and probe detection in Positive blood culture;Deprecated E faecium hsp60 Bld Pos Ql Prb Mag;;DEPRECATED;2.50;2.63 +75691-6;Peripheral sensory neuropathy grade;Imp;Pt;^Patient;Ord;NCICTC;ONCOLOGY;2;Peripheral sensory neuropathy grade NCICTC;Periph sens neuropathy grade NCI CTC;;ACTIVE;2.50;2.5 +75692-4;Cancer detection basis;Type;Pt;^Patient;Nom;;ONCOLOGY;2;Cancer detection basis;Cancer detection basis;;ACTIVE;2.50;2.5 +75693-2;Fetal sex;Find;Pt;Plas.cfDNA;Nom;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal sex in Plasma cell-free DNA by Dosage of chromosome specific cell free (cf) DNA;Fet sex Plas.cfDNA Dosage cfDNA;;ACTIVE;2.50;2.73 +75694-0;Human papilloma virus 18+45 E6+E7 mRNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 18+45 E6+E7 mRNA [Presence] in Cervix by NAA with probe detection;HPV18+45 E6+E7 mRNA Cvx Ql NAA+probe;;ACTIVE;2.50;2.73 +75695-7;Human papilloma virus 18 DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 18 DNA [Presence] in Anorectal specimen by Probe and signal amplification method;HPV18 DNA Anorectl Ql Probe+sig amp;;ACTIVE;2.50;2.73 +75696-5;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Anorectal specimen by Probe and signal amplification method;HPV HR 12 DNA Anorectl Ql Probe+sig amp;;ACTIVE;2.50;2.73 +7569-7;Pastinaca sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Parsnip IgE Ab [Units/volume] in Serum;Parsnip IgE Qn;;ACTIVE;1.0h(2);2.73 +75697-3;Bilirubin fractions panel;SCnc;-;Ser/Plas;-;;PANEL.CHEM;1;Bilirubin fractions panel [Moles/volume] - Serum or Plasma;Bilirubin fractions Pnl SerPl-sCnc;;ACTIVE;2.50;2.5 +75698-1;Total score;Score;Pt;^Patient;Qn;COOP.WONCA;SURVEY.COOP;4;Total score [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.58 +75699-9;During the past 2Ws, what was the hardest physical activity you could do for at least 2 minutes;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;During the past 2 weeks, what was the hardest physical activity you could do for at least 2 minutes [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75700-5;During the past 2Ws, how much have you been bothered by emotional problems such as feeling anxious, depressed, irritable or downhearted and blue;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;During the past 2 weeks, how much have you been bothered by emotional problems such as feeling anxious, depressed, irritable or downhearted and blue [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75701-3;During the past 2Ws, how much difficulty have you had doing your usual activities or tasks, both inside and outside the house because of your physical and emotional health;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;During the past 2 weeks, how much difficulty have you had doing your usual activities or tasks, both inside and outside the house because of your physical and emotional health [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75702-1;During the past 2Ws, has your physical and emotional health limited your social activities with family, friends, neighbors or groups;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;During the past 2 weeks, has your physical and emotional health limited your social activities with family, friends, neighbors or groups [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75703-9;During the past 2Ws, how much bodily pain have you generally had;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;During the past 2 weeks, how much bodily pain have you generally had [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75704-7;How would you rate your overall health now compared to 2Ws ago;Score;Pt;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;How would you rate your overall health now compared to 2 weeks ago [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +7570-5;Pisum sativum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pea IgG Ab [Units/volume] in Serum;Pea IgG Qn;;ACTIVE;1.0h(2);2.73 +75705-4;During the past 2Ws, how would you rate your health in general;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;During the past 2 weeks, how would you rate your health in general [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75706-2;During the past 2Ws, was someone available to help you if you needed and wanted help;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;During the past 2 weeks, was someone available to help you if you needed and wanted help [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75707-0;How have things been going for you during the past 2Ws;Score;2W;^Patient;Ord;COOP.WONCA;SURVEY.COOP;4;How have things been going for you during the past 2 weeks [COOP.WONCA];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75708-8;Bruton tyrosine kinase;Imp;Pt;B cells+monocytes;Nar;Flow cytometry;CELLMARK;1;Bruton tyrosine kinase [Interpretation] in B cells+monocytes by Flow cytometry (FC) Narrative;Btk B cells+mono FC-Imp;;ACTIVE;2.50;2.5 +75709-6;Calcitonin;MCnc;Pt;Lymph node.FNA;Qn;;CHEM;1;Calcitonin [Mass/volume] in Lymph node fine needle aspirate;Calcit LN FNA-mCnc;;ACTIVE;2.50;2.5 +75710-4;Coccidioides immitis+posadasii Ab.IgM;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Coccidioides immitis+posadasii IgM Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);C immitis+posadasii IgM CSF Ql ID;;ACTIVE;2.50;2.56 +75711-2;Date of autopsy;Date;Pt;^Patient;Qn;;MISC;1;Date of autopsy;Date of autopsy;;ACTIVE;2.50;2.5 +75712-0;Microscopic description;Desc;Pt;Endomyocardium;Nar;;PATH;1;Microscopic description [Description] in Endomyocardium Narrative;Microscopic desc Endomyocardium;;ACTIVE;2.50;2.5 +7571-3;Vigna sinensis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black-eye pea IgE Ab [Units/volume] in Serum;Black-eye Pea IgE Qn;;ACTIVE;1.0h(2);2.73 +75713-8;CYP1A2 gene.c.125C>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.125C>G [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.125C>G Bld/T Ql;;ACTIVE;2.50;2.67 +75714-6;CYP1A2 gene.c.-2467delT;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.-2467delT [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.-2467delT Bld/T Ql;;ACTIVE;2.50;2.67 +75715-3;CYP1A2 gene.c.2473G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.2473G>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.2473G>A Bld/T Ql;;ACTIVE;2.50;2.67 +75716-1;CYP1A2 gene.c.2499A>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.2499A>T [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.2499A>T Bld/T Ql;;ACTIVE;2.50;2.67 +75717-9;CYP1A2 gene.c.3497G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.3497G>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.3497G>A Bld/T Ql;;ACTIVE;2.50;2.67 +75718-7;CYP1A2 gene.c.3533G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.3533G>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.3533G>A Bld/T Ql;;ACTIVE;2.50;2.67 +75719-5;CYP1A2 gene.c.-3860G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.-3860G>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.-3860G>A Bld/T Ql;;ACTIVE;2.50;2.67 +75720-3;CYP1A2 gene.c.5090C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.5090C>T [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.5090C>T Bld/T Ql;;ACTIVE;2.50;2.67 +7572-1;Vigna sinensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black-eye pea IgG Ab [Units/volume] in Serum;Black-eye Pea IgG Qn;;ACTIVE;1.0h(2);2.69 +75721-1;CYP1A2 gene.c.5166G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.5166G>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.5166G>A Bld/T Ql;;ACTIVE;2.50;2.67 +75722-9;CYP1A2 gene.c.-163C>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.-163C>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.-163C>A Bld/T Ql;;ACTIVE;2.50;2.73 +75723-7;CYP1A2 gene.c.2385G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.2385G>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.2385G>A Bld/T Ql;;ACTIVE;2.50;2.67 +75724-5;CYP1A2 gene.c.558C>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.558C>A [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.558C>A Bld/T Ql;;ACTIVE;2.50;2.67 +75725-2;CYP1A2 gene.c.-729C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene c.-729C>T [Presence] in Blood or Tissue by Molecular genetics method;CYP1A2 c.-729C>T Bld/T Ql;;ACTIVE;2.50;2.67 +75726-0;HTR2A gene.c.-1438G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HTR2A gene c.-1438G>A [Presence] in Blood or Tissue by Molecular genetics method;HTR2A c.-1438G>A Bld/T Ql;;ACTIVE;2.50;2.56 +75727-8;HTR2A gene.c.IVS2+54538A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.INV;1;HTR2A gene c.IVS2+54538A>G [Presence] in Blood or Tissue by Molecular genetics method;HTR2A c.IVS2A>G Bld/T Ql;;ACTIVE;2.50;2.56 +75728-6;HTR2A gene.c.74C>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HTR2A gene c.74C>A [Presence] in Blood or Tissue by Molecular genetics method;HTR2A c.74C>A Bld/T Ql;;ACTIVE;2.50;2.56 +75729-4;HTR2A gene.c.1354C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HTR2A gene c.1354C>T [Presence] in Blood or Tissue by Molecular genetics method;HTR2A c.1354C>T Bld/T Ql;;ACTIVE;2.50;2.56 +75730-2;HTR2C gene.c.796G>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;HTR2C gene c.796G>C [Presence] in Blood or Tissue by Molecular genetics method;HTR2C c.796G>C Bld/T Ql;;ACTIVE;2.50;2.67 +75731-0;HTR2A gene.c.102T>C;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;HTR2A gene c.102T>C [Presence] in Blood or Tissue by Molecular genetics method;HTR2A c.102T>C Bld/T Ql;;ACTIVE;2.50;2.56 +75732-8;HTR2C gene.c.-759C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;HTR2C gene c.-759C>T [Presence] in Blood or Tissue by Molecular genetics method;HTR2C c.-759C>T Bld/T Ql;;ACTIVE;2.50;2.67 +75733-6;AXIN2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;AXIN2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;AXIN2 Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75734-4;AXIN2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;AXIN2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;AXIN2 Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75735-1;BMPR1A gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;BMPR1A gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;BMPR1A Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +75736-9;Lysophosphatidylcholine(16:0);SCnc;Pt;Plas;Qn;;CHEM;1;Lysophosphatidylcholine(16:0) [Moles/volume] in Plasma;LysoPC(16:0) Plas-sCnc;;ACTIVE;2.50;2.5 +75737-7;Lysophosphatidylcholine(18:0);SCnc;Pt;Plas;Qn;;CHEM;1;Lysophosphatidylcholine(18:0) [Moles/volume] in Plasma;LysoPC(18:0) Plas-sCnc;;ACTIVE;2.50;2.5 +75738-5;Campesterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Campesterol [Mass/volume] in Serum or Plasma;Campesterol SerPl-mCnc;;ACTIVE;2.50;2.73 +7573-9;Cicer arietinus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chick Pea IgE Ab [Units/volume] in Serum;Chick Pea IgE Qn;;ACTIVE;1.0h(2);2.73 +75739-3;Desmosterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Desmosterol [Mass/volume] in Serum or Plasma;Desmosterol SerPl-mCnc;;ACTIVE;2.50;2.73 +75740-1;Lathosterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lathosterol [Mass/volume] in Serum or Plasma;Lathosterol SerPl-mCnc;;ACTIVE;2.50;2.73 +75741-9;Beta sitosterol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta sitosterol [Mass/volume] in Serum or Plasma;B-sitosterol SerPl-mCnc;;ACTIVE;2.50;2.73 +75742-7;Dartmouth COOP Functional Assessment Charts - 2 weeks;-;Pt;^Patient;-;;PANEL.SURVEY.COOP;4;Dartmouth COOP Functional Assessment Charts - 2 weeks;;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75743-5;Dartmouth COOP Functional Assessment Charts - 4 weeks;-;Pt;^Patient;-;;PANEL.SURVEY.COOP;4;Dartmouth COOP Functional Assessment Charts - 4 weeks;;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75744-3;Electronic health record implementation stage panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Electronic Health Record (EHR) Implementation Stage panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.52 +75745-0;Electronic health record implementation stage;Find;Pt;{Nursing unit};Ord;NMMDS;SURVEY.NMMDS;4;Electronic Health Record (EHR) Implementation Stage [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.50;2.5 +75746-8;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space.bilateral;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of chest tube of Pleural space - bilateral;CT Guided Pl space-Bl Absc drn+CT place;;ACTIVE;2.50;2.66 +7574-7;Pisum sativum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Pea triggered histamine release [Units/volume] in Blood;Pea BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75747-6;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space.bilateral;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of chest tube of Pleural space - bilateral;RF Guided Pl space-Bl Absc drn+CT place;;ACTIVE;2.50;2.66 +75748-4;Guidance for percutaneous aspiration of fluid;Find;Pt;Neck>Spine.cervical intervertebral disc;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Cervical spine Intervertebral disc;CT Guided C-spine disc PC fluid asp;;ACTIVE;2.50;2.64 +75749-2;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Intervertebral disc;Doc;RF;RAD;2;RF Guidance for fluid aspiration of Intervertebral disc;RF Guided I-disc PC fluid asp;;ACTIVE;2.50;2.64 +757-5;Neutrophils;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Pleural fluid by Manual count;Neutrophils # Plr Manual;;ACTIVE;1.0;2.44 +75750-0;Guidance for percutaneous biopsy;Find;Pt;XXX>Intervertebral disc;Doc;RF;RAD;2;RF Guidance for biopsy of Intervertebral disc;RF Guided I-disc Bx;;ACTIVE;2.50;2.64 +75751-8;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space.left;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of chest tube of Pleural space - left;RF Guided Pl space-L Absc drn+CT place;;ACTIVE;2.50;2.66 +75752-6;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space.left;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of chest tube of Pleural space - left;CT Guided Pl space-L Absc drn+CT place;;ACTIVE;2.50;2.66 +75753-4;Bacterial vancomycin resistance vanD gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Vancomycin resistance vanD gene [Presence] by Molecular method;vanD Islt/Spm Ql;;ACTIVE;2.50;2.65 +7575-4;Prunus persica Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peach IgG Ab [Units/volume] in Serum;Peach IgG Qn;;ACTIVE;1.0h(2);2.73 +75754-2;Streptobacillus moniliformis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Streptobacillus moniliformis DNA [Presence] in Specimen by NAA with probe detection;S moniliformis DNA Spec Ql NAA+probe;;ACTIVE;2.50;2.69 +75755-9;Staphylococcus aureus.methicillin susceptible DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;ABXBACT;1;Methicillin susceptible Staphylococcus aureus DNA [Presence] in Specimen by NAA with probe detection;MSSA DNA Spec Ql NAA+probe;;ACTIVE;2.50;2.73 +75756-7;Bacteria identified;Prid;Pt;Isolate;Nom;MS.MALDI-TOF;MICRO;1;Bacteria identified in Isolate by MS.MALDI-TOF;Bacteria Islt MS.MALDI-TOF;;ACTIVE;2.50;2.73 +75757-5;Chlamydia sp Ab;PrThr;Pt;Ser;Ord;Comp fix;MICRO;1;Chlamydia sp Ab [Presence] in Serum by Complement fixation;Chlamydia Ab Ser Ql CF;;ACTIVE;2.50;2.56 +75758-3;Brompheniramine;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Brompheniramine [Presence] in Serum or Plasma or Urine by Screen method;Brompheniramine Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +75759-1;Chlorpheniramine;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Chlorpheniramine [Presence] in Serum or Plasma or Urine by Screen method;Chlorphenir Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +75760-9;Haloperidol;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Haloperidol [Presence] in Blood or Urine by Screen method;Haloperidol Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +75761-7;Doxylamine;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Doxylamine [Presence] in Serum or Plasma or Urine by Screen method;Doxylamine Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +7576-2;Prunus persica basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Peach triggered histamine release [Units/volume] in Blood;Peach BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75762-5;Methapyrilene;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Methapyrilene [Presence] in Serum or Plasma or Urine by Screen method;Methapyrilene Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +75763-3;Orphenadrine;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Orphenadrine [Presence] in Serum or Plasma or Urine by Screen method;Orphenadrine Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +75764-1;Tripelennamine;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Tripelennamine [Presence] in Serum or Plasma or Urine by Screen method;Tripelennamine Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +75765-8;Triprolidine;PrThr;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Triprolidine [Presence] in Serum or Plasma or Urine by Screen method;Triprolidine Ser/Plas/Urn Ql Scn;;ACTIVE;2.50;2.73 +75766-6;fluPHENAZine;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;fluPHENAZine [Presence] in Blood or Urine by Screen method;fluPHENAZine Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +75767-4;Mesoridazine;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Mesoridazine [Presence] in Blood or Urine by Screen method;Mesoridazine Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +75768-2;Prochlorperazine;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Prochlorperazine [Presence] in Blood or Urine by Screen method;Prochlorperazine Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +75769-0;Promazine;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Promazine [Presence] in Blood or Urine by Screen method;Promazine Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +7577-0;Arachis hypogaea basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Peanut triggered histamine release [Units/volume] in Blood;Peanut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75770-8;Thioridazine;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Thioridazine [Presence] in Blood or Urine by Screen method;Thioridazine Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +75771-6;Trifluoperazine;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Trifluoperazine [Presence] in Blood or Urine by Screen method;TriFperazine Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +75772-4;Advance directives panel;-;Pt;^Patient;-;ADVault;PANEL.SURVEY.ADVAULT;4;Advance directives panel [ADVault];;Copyright © 2014 ADVault, Inc. Used with permission.;ACTIVE;2.50;2.71 +75773-2;Goals, preferences, and priorities for medical treatment;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Goals, preferences, and priorities for medical treatment [Reported];;;ACTIVE;2.50;2.73 +75774-0;Allowance to change advance directive preferences in the future regardless of mental state;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Allowance to change advance directive preferences in the future regardless of mental state [Reported];;;ACTIVE;2.50;2.73 +75775-7;Decision to inform doctors and nurses about the role religion, faith, culture, or spirituality play in my life;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Decision to inform doctors and nurses about the role religion, faith, culture, or spirituality play in my life [Reported];;;ACTIVE;2.50;2.73 +75776-5;Preference on consulting a supportive and palliative care team to help treat physical, emotional, and spiritual discomfort and support family;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Preference on consulting a supportive and palliative care team to help treat physical, emotional, and spiritual discomfort and support family [Reported];;;ACTIVE;2.50;2.73 +75777-3;Information to tell doctors if my health deteriorates due to a terminal illness and I am unable to interact meaningfully with family, friends, or surroundings;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Information to tell doctors if my health deteriorates due to a terminal illness and I am unable to interact meaningfully with family, friends, or surroundings [Reported];;;ACTIVE;2.50;2.73 +75778-1;Information to tell doctors if I have a severe, irreversible brain injury or illness and can't dress, feed, or bathe myself, or communicate my medical wishes, but can be kept alive;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Information to tell doctors if I have a severe, irreversible brain injury or illness and can't dress, feed, or bathe myself, or communicate my medical wishes, but can be kept alive [Reported];;;ACTIVE;2.50;2.73 +75779-9;Thoughts on cardiopulmonary resuscitation;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on cardiopulmonary resuscitation (CPR) [Reported];;;ACTIVE;2.50;2.73 +75780-7;Preferred location to spend final days if possible to choose;Loc;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Preferred location to spend final days if possible to choose [Reported];;;ACTIVE;2.50;2.73 +75781-5;Thoughts on organ and tissue donations;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on organ and tissue donations [Reported];;;ACTIVE;2.50;2.73 +75782-3;Thoughts regarding autopsy;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts regarding autopsy [Reported];;;ACTIVE;2.50;2.73 +75783-1;Primary healthcare agent;Pn;Pt;^Patient;Nom;Reported;ADMIN;2;Primary healthcare agent [Reported];Primary HC agent;;ACTIVE;2.50;2.71 +75784-9;First alternate healthcare agent;Pn;Pt;^Patient;Nom;Reported;ADMIN;2;First alternate healthcare agent [Reported];First Alt HC agent;;ACTIVE;2.50;2.71 +75785-6;Second alternate healthcare agent;Pn;Pt;^Patient;Nom;Reported;ADMIN;2;Second alternate healthcare agent [Reported];Second Alt HC agent;;ACTIVE;2.50;2.71 +75786-4;Powers granted to healthcare agent;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Powers granted to healthcare agent [Reported];;;ACTIVE;2.50;2.73 +75787-2;Advance directive - request for intubation;Find;Pt;^Patient;Ord;;SURVEY.ADVAULT;4;Advance directive - request for intubation;;;ACTIVE;2.50;2.71 +7578-8;Pyrus communis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pear IgG Ab [Units/volume] in Serum;Pear IgG Qn;;ACTIVE;1.0h(2);2.73 +75788-0;Advance directive - request for tube feeding;Find;Pt;^Patient;Ord;;SURVEY.ADVAULT;4;Advance directive - request for tube feeding;;;ACTIVE;2.50;2.71 +75789-8;Advance directive - request for life support;Find;Pt;^Patient;Ord;;SURVEY.ADVAULT;4;Advance directive - request for life support;;;ACTIVE;2.50;2.71 +75790-6;Advance directive - request for IV fluid and support;Find;Pt;^Patient;Ord;;SURVEY.ADVAULT;4;Advance directive - request for IV fluid and support;;;ACTIVE;2.50;2.71 +75791-4;Advance directive - request for antibiotics;Find;Pt;^Patient;Ord;;SURVEY.ADVAULT;4;Advance directive - request for antibiotics;;;ACTIVE;2.50;2.71 +75792-2;Advance directive - request for resuscitation that differs from cardiopulmonary resuscitation;Find;Pt;^Patient;Ord;;SURVEY.ADVAULT;4;Advance directive - request for resuscitation that differs from cardiopulmonary resuscitation;;;ACTIVE;2.50;2.71 +75793-0;Other directives that have not otherwise been documented;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Other directives that have not otherwise been documented [Reported];;;ACTIVE;2.50;2.73 +75794-8;Assessment reference date;-;Pt;^Patient;Set;MDSv3;PANEL.SURVEY.MDS;4;Deprecated Assessment reference date Set [MDSv3];;;DEPRECATED;2.50;2.73 +75795-5;Special treatments &or programs - none of above;-;Pt;^Patient;Set;MDSv3;PANEL.SURVEY.MDS;4;Special treatments/programs - none of above Set [MDSv3];;;ACTIVE;2.50;2.54 +7579-6;Pyrus communis pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pear Pollen IgE Ab [Units/volume] in Serum;Pear Poln IgE Qn;;ACTIVE;1.0h(2);2.42 +75796-3;Physical well being - FACT-GP;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Physical well being - FACT-GP [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.50;2.5 +75797-1;Social - family well being - FACT-GP;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Social - family well being - FACT-GP [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.50;2.5 +75798-9;Emotional well being - FANLTC;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well being - FANLTC [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.50;2.5 +75799-7;Functional well being - FACT-GP;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Functional well being - FACT-GP [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.50;2.5 +75800-3;Emotional well being - FACT-GP;-;Pt;^Patient;-;FACIT;PANEL.SURVEY.GNHLTH;4;Emotional well being - FACT-GP [FACIT];;Copyright © 2010 FACIT.org. Used with permission. All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the intellectual property of, David Cella, Ph.D.;ACTIVE;2.50;2.5 +75801-1;How have things been going for you during the past 4Ws;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;How have things been going for you during the past 4 weeks [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75802-9;During the past 4Ws, was someone available to help you if you needed and wanted help;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;During the past 4 weeks, was someone available to help you if you needed and wanted help [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75803-7;During the past 4Ws, how would you rate your health in general;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;During the past 4 weeks, how would you rate your health in general [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.73 +7580-4;Carya illinoinensis nut Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pecan or Hickory Nut IgG Ab [Units/volume] in Serum;Pecan/Hick Nut IgG Qn;;ACTIVE;1.0h(2);2.73 +75804-5;How would you rate your overall health now compared to 4Ws ago;Score;Pt;^Patient;Ord;COOP;SURVEY.COOP;4;How would you rate your overall health now compared to 4 weeks ago [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75805-2;During the past 4Ws, how much bodily pain have you generally had;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;During the past 4 weeks, how much bodily pain have you generally had [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75806-0;During the past 4Ws, has your physical and emotional health limited your social activities with family, friends, neighbors or groups;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;During the past 4 weeks, has your physical and emotional health limited your social activities with family, friends, neighbors or groups [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75807-8;During the past 4Ws, how much difficulty have you had doing your usual activities or tasks, both inside and outside the house because of your physical and emotional health;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;During the past 4 weeks, how much difficulty have you had doing your usual activities or tasks, both inside and outside the house because of your physical and emotional health [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75808-6;During the past 4Ws, how much have you been bothered by emotional problems such as feeling anxious, depressed, irritable or downhearted and blue;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;During the past 4 weeks, how much have you been bothered by emotional problems such as feeling anxious, depressed, irritable or downhearted and blue [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75809-4;During the past 4Ws, what was the hardest physical activity you could do for at least 2 minutes;Score;4W;^Patient;Ord;COOP;SURVEY.COOP;4;During the past 4 weeks, what was the hardest physical activity you could do for at least 2 minutes [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.54 +75810-2;Total score;Score;Pt;^Patient;Qn;COOP;SURVEY.COOP;4;Total score [COOP];;Copyright © 2009 Trustees of Dartmouth College/COOP Project. Used with permission.;ACTIVE;2.50;2.58 +75811-0;Antipsychotics;Imp;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Antipsychotics [Interpretation] in Blood or Urine Qualitative by Screen method;Antipsychotics Bld/Urn Scn-Imp;;ACTIVE;2.50;2.73 +7581-2;Carya illinoinensis nut basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Deprecated Pecan or Hickory Nut triggered histamine release [Units/volume] in Blood;Deprecated Pecan/Hick Nut BasoBnd Ab Qn;;DEPRECATED;1.0h(2);2.69 +75812-8;Antihistamines;Imp;Pt;Ser/Plas/Urine;Ord;Screen;DRUG/TOX;1;Antihistamines [Interpretation] in Serum or Plasma or Urine Qualitative by Screen method;Antihistamines Ser/Plas/Urn Scn-Imp;;ACTIVE;2.50;2.73 +75813-6;Promethazine;PrThr;Pt;Bld/Urine;Ord;Screen;DRUG/TOX;1;Promethazine [Presence] in Blood or Urine by Screen method;Promethazine Bld/Urn Ql Scn;;ACTIVE;2.50;2.73 +75814-4;Antihistamines panel;-;Pt;Ser/Plas/Urine;-;Screen;PANEL.DRUG/TOX;1;Antihistamines panel - Serum or Plasma or Urine by Screen method;Antihistamines Pnl Ser/Plas/Urn Scn;;ACTIVE;2.50;2.5 +75815-1;Antipsychotics drug panel;-;Pt;Bld/Urine;-;Screen;PANEL.DRUG/TOX;1;Antipsychotics drug panel - Blood or Urine by Screen method;Antipsychotics Pnl Bld/Urn Scn;;ACTIVE;2.50;2.5 +75816-9;Views^W contrast EP;Find;Pt;Chest>Spine.thoracic epidural space;Doc;RF;RAD;2;RF Spine.thoracic epidural space Views W contrast epidural;RF T-spine space Views W contr EP;;ACTIVE;2.50;2.64 +75817-7;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space.right;Doc;RF;RAD;2;RF Guidance for drainage of abscess and placement of chest tube of Pleural space - right;RF Guided Pl space-R Absc drn+CT place;;ACTIVE;2.50;2.66 +75818-5;Guidance for drainage of abscess+placement of chest tube;Find;Pt;Chest>Pleural space.right;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of chest tube of Pleural space - right;CT Guided Pl space-R Absc drn+CT place;;ACTIVE;2.50;2.66 +75819-3;Erythrocyte chromasia;Prid;Pt;Bld;Nom;Microscopy.light;HEM/BC;1;Erythrocyte chromasia [Identifier] in Blood by Light microscopy;RBC Chrm Bld Smear;;ACTIVE;2.50;2.52 +7582-0;Carya illinoinensis nut Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Pecan or Hickory Nut IgE Ab [Units/volume] in Serum;Deprecated Pecan/Hick Nut IgE Qn;;DEPRECATED;1.0h(2);2.69 +75820-1;Over the past W, are you able to dress yourself, including shoelaces and buttons;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to dress yourself, including shoelaces and buttons [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75821-9;Over the past W, are you able to shampoo your hair;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to shampoo your hair [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75822-7;Over the past W, are you able to stand up from a straight chair;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to stand up from a straight chair [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75823-5;Over the past W, are you able to get in and out of bed;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to get in and out of bed [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75824-3;Over the past W, are you able to cut your meat;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to cut your meat [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75825-0;Over the past W, are you able to lift a full cup or glass to your mouth;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to lift a full cup or glass to your mouth [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75826-8;Over the past W, are you able to open a new milk carton;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to open a new milk carton [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75827-6;Over the past W, are you able to walk outdoors on flat ground;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to walk outdoors on flat ground [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75828-4;Over the past W, are you able to climb up five steps;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to climb up five steps [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75829-2;Over the past W, are you able to wash and dry your body;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to wash and dry your body [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +758-3;Neutrophils;NCnc;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Neutrophils [#/volume] in Peritoneal fluid by Automated count;Neutrophils # Prt Auto;;ACTIVE;1.0;2.73 +75830-0;Over the past W, are you able to take a tub bath;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to take a tub bath [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75831-8;Over the past W, are you able to get on and off the toilet;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to get on and off the toilet [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75832-6;Over the past W, are you able to reach and get down a 5 pound object (such as a bag of sugar) from just above your head;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to reach and get down a 5 pound object (such as a bag of sugar) from just above your head [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75833-4;Over the past W, are you able to bend down and pick up clothing from the floor;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to bend down and pick up clothing from the floor [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75834-2;Over the past W, are you able to open car doors;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to open car doors [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75835-9;Over the past W, are you able to open jars which have been previously opened;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to open jars which have been previously opened [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75836-7;Over the past W, are you able to turn faucets on and off;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to turn faucets on and off [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75837-5;Over the past W, are you able to run errands and shop;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to run errands and shop [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +7583-8;Penicillium sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium sp IgG Ab [Units/volume] in Serum;Penicillium IgG Qn;;ACTIVE;1.0h(2);2.69 +75838-3;Over the past W, are you able to get in and out of a car;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to get in and out of a car [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75839-1;Over the past W, are you able to do chores such as vacuuming or yard work;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to do chores such as vacuuming or yard work [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75840-9;Total score;Score;Pt;^Patient;Qn;PAS;SURVEY.PAS;4;Total score [PAS];;Copyright © 2005 The Journal of Rheumatology. Used with permission.;ACTIVE;2.50;2.58 +75841-7;Total score;Score;Pt;^Patient;Qn;PASII;SURVEY.PASII;4;Total score [PASII];;Copyright © 2005 The Journal of Rheumatology. Used with permission.;ACTIVE;2.50;2.58 +75842-5;Clinical disease activity index;-;Pt;^Patient;-;CDAI;PANEL.SURVEY.GNHLTH;4;Clinical disease activity index [CDAI];;;ACTIVE;2.50;2.64 +75843-3;Simplified disease activity index;-;Pt;^Patient;-;SDAI;PANEL.SURVEY.GNHLTH;4;Simplified disease activity index [SDAI];;;ACTIVE;2.50;2.71 +75844-1;Patient global assessment of disease activity - 0-10 numeric rating;Score;Pt;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Patient global assessment of disease activity - 0-10 numeric rating [Reported];;;ACTIVE;2.50;2.5 +75845-8;Total score;Score;Pt;^Patient;Qn;SDAI;SURVEY.GNHLTH;4;Total score [SDAI];;;ACTIVE;2.50;2.5 +7584-6;Penicillium notatum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium notatum IgG Ab [Units/volume] in Serum;P notatum IgG Qn;;ACTIVE;1.0h(2);2.73 +75846-6;Evaluator global assessment of disease activity - 0-10 (0.5 increments) numeric rating;Score;Pt;^Patient;Ord;Observed;SURVEY.GNHLTH;4;Evaluator global assessment of disease activity - 0-10 (0.5 increments) numeric rating [Observed];;;ACTIVE;2.50;2.64 +75847-4;Total score;Score;Pt;^Patient;Qn;CDAI;SURVEY.GNHLTH;4;Total score [CDAI];;;ACTIVE;2.50;2.5 +75848-2;Over the past W, are you able to do outside work (such as yard work);Find;1W;^Patient;Ord;HAQII;SURVEY.HAQ;4;Over the past week, are you able to do outside work (such as yard work) [HAQII];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75849-0;Over the past W, are you able to wait in line for 15 minutes;Find;1W;^Patient;Ord;HAQII;SURVEY.HAQ;4;Over the past week, are you able to wait in line for 15 minutes [HAQII];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +75850-8;Over the past W, are you able to lift heavy objects;Find;1W;^Patient;Ord;HAQII;SURVEY.HAQ;4;Over the past week, are you able to lift heavy objects [HAQII];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.69 +75851-6;Over the past W, are you able to move heavy objects;Find;1W;^Patient;Ord;HAQII;SURVEY.HAQ;4;Over the past week, are you able to move heavy objects [HAQII];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.69 +75852-4;Over the past W, are you able to go up two or more flights of stairs;Find;1W;^Patient;Ord;HAQII;SURVEY.HAQ;4;Over the past week, are you able to go up two or more flights of stairs [HAQII];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.54 +7585-3;Penicillium notatum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Penicillium notatum triggered histamine release [Units/volume] in Blood;P notatum BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75853-2;Views^W contrast VG;Find;Pt;Pelvis>Vagina;Doc;RF;RAD;2;RF Vagina Views W contrast VG;RF Vagina Views W contr VG;;ACTIVE;2.50;2.64 +75854-0;PCORnet common data model set - version 1.0;-;Pt;^Patient;-;PCORnet;PANEL.SURVEY.PCORNET;4;PCORnet common data model set - version 1.0 [PCORnet];;;ACTIVE;2.50;2.73 +75855-7;Do you sometimes drink alcoholic beverages;Find;Pt;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Do you sometimes drink alcoholic beverages [Reported];;;ACTIVE;2.50;2.5 +75856-5;Number of falls in the past 12Mo;NRat;12Mo;^Patient;Qn;Reported;SURVEY.GNHLTH;4;Number of falls in the past 12 months [Reported];;;ACTIVE;2.50;2.61 +75857-3;Access restriction by regulation;Type;Pt;^Patient;Nom;;CLIN;2;Access restriction by regulation;Access restrict by reg;;ACTIVE;2.50;2.5 +75858-1;Sterols panel;MCnc;Pt;Ser/Plas;-;;PANEL.CHEM;1;Sterols panel [Mass/volume] - Serum or Plasma;Sterols Pnl SerPl-mCnc;;ACTIVE;2.50;2.73 +75859-9;Modified rankin scale;Score;Pt;^Patient;Ord;;CLIN;2;Modified rankin scale;mRS;;ACTIVE;2.50;2.73 +75860-7;Hepatitis A virus RNA & Parvovirus B19 DNA panel;-;Pt;Plas^Donor;-;Probe.amp.tar;PANEL.MICRO;1;Hepatitis A virus RNA and Parvovirus B19 DNA panel - Plasma from Donor by NAA with probe detection;HAV RNA+B19 DNA Pnl Plas Donr NAA+probe;;ACTIVE;2.50;2.63 +7586-1;Pepper bell Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bell Pepper IgE Ab [Units/volume] in Serum;Bell Pepper IgE Qn;;ACTIVE;1.0h(2);2.73 +75861-5;HEDIS 2015-2020 Value Set - LDL-C Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015-2020 Value Set - LDL-C Tests;HEDIS 2015-20 LDL-C;;DISCOURAGED;2.50;2.69 +75862-3;HEDIS 2015-2020 Value Set - HbA1c Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015-2020 Value Set - HbA1C Tests;HEDIS 2015-20 HbA1C;;DISCOURAGED;2.50;2.69 +75863-1;HEDIS 2015-2018 Value Set - Digoxin Level;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015-2018 Value Set - Digoxin Level;HEDIS 2015-18 Digoxin Level;;DISCOURAGED;2.50;2.67 +75864-9;HEDIS 2015-2018 Value Set - Glucose Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015-2018 Value Set - Glucose Tests;HEDIS 2015-18 Glucose Tests;;DISCOURAGED;2.50;2.67 +75865-6;HEDIS 2015-2018 Value Set - PSA Test Exclusion;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015-2018 Value Set - PSA Test Exclusion;HEDIS 2015-18 PSA Test Excl;;DISCOURAGED;2.50;2.73 +75866-4;HEDIS 2015-2018 Value Set - PSA Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015-2018 Value Set - PSA Tests;HEDIS 2015-18 PSA Tests;;DISCOURAGED;2.50;2.67 +75867-2;HEDIS 2015-2018 Value Set - Cholesterol Tests Other Than LDL;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015-2018 Value Set - Cholesterol Tests Other Than LDL;HEDIS 2015-18 Chol Tests not LDL;;DISCOURAGED;2.50;2.67 +75868-0;HEDIS 2015 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015 Value Sets;HEDIS 2015 Value Sets;;DISCOURAGED;2.50;2.67 +75869-8;HEDIS 2015, 2016 Value Set - Pregnancy Test Exclusion;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2015, 2016 Value Set - Pregnancy Test Exclusion;HEDIS 2015-16 Preg Test Excl;;DISCOURAGED;2.50;2.67 +75870-6;PROMIS short form - pain interference 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - pain interference 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.67 +75871-4;PROMIS short form - pain interference 8a - version 1.0 raw score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;Deprecated PROMIS short form 8a - pain interference Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.50;2.7 +75872-2;Aids or devices usually used for dressing & grooming, arising, eating, &or walking;Type;Pt;^Patient;Nom;HAQ;SURVEY.HAQ;4;Aids or devices usually used for dressing and grooming, arising, eating, AndOr walking [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.61 +75873-0;Help from another person is usually needed for dressing & grooming, arising, eating, &or walking;Find;Pt;^Patient;Nom;HAQ;SURVEY.HAQ;4;Help from another person is usually needed for dressing and grooming, arising, eating, AndOr walking [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.5 +75874-8;Total score;Score;Pt;^Patient;Qn;HAQ-DI;SURVEY.HAQ;4;Total score [HAQ-DI];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.5 +75875-5;Total score;Score;Pt;^Patient;Qn;HAQII;SURVEY.HAQ;4;Total score [HAQII];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.5 +75876-3;Patient activity scale II;-;Pt;^Patient;-;PASII;PANEL.SURVEY.PASII;4;Patient activity scale II [PASII];;Copyright © 2005 The Journal of Rheumatology. Used with permission.;ACTIVE;2.50;2.67 +75877-1;Patient activity scale;-;Pt;^Patient;-;PAS;PANEL.SURVEY.PAS;4;Patient activity scale [PAS];;Copyright © 2005 The Journal of Rheumatology. Used with permission.;ACTIVE;2.50;2.67 +75878-9;Help from another person usually needed for hygiene, reach, gripping and opening things, &or errands and chores;Find;Pt;^Patient;Nom;HAQ;SURVEY.HAQ;4;Help from another person usually needed for hygiene, reach, gripping and opening things, AndOr errands and chores [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.5 +7587-9;Pepper bell Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bell Pepper IgG Ab [Units/volume] in Serum;Bell Pepper IgG Qn;;ACTIVE;1.0h(2);2.69 +75879-7;Aids or devices usually used for hygiene, reach, grip, &or activities;Type;Pt;^Patient;Nom;HAQ;SURVEY.HAQ;4;Aids or devices usually used for hygiene, reach, grip, AndOr activities [HAQ];;Copyright © Stanford University. Used with permission.;ACTIVE;2.50;2.5 +75880-5;14-3-3 eta Ag;MCnc;Pt;Ser;Qn;IA;SERO;1;14-3-3 eta Ag [Mass/volume] in Serum by Immunoassay;14-3-3 eta Ag Ser IA-mCnc;;ACTIVE;2.50;2.73 +75881-3;Lupus anticoagulant three screening tests W Reflex panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Lupus anticoagulant aPTT, dRVVT and PT screening panel W Reflex;LA aPTT+dRVVT+PT W Reflex PPP;;ACTIVE;2.50;2.67 +75882-1;Lupus anticoagulant three screening tests W Reflex;Imp;Pt;PPP;Nom;Coag;COAG;1;Lupus anticoagulant three screening tests W Reflex [interpretation];LA 3 screen W Reflex-Imp;;ACTIVE;2.50;2.73 +75883-9;dRVVT.hexagonal phase phospholipid;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT W excess hexagonal phospholipid (STA-StaClot confirm);Confirm dRVVT STA-StaClot;;ACTIVE;2.50;2.5 +75884-7;Coagulation surface induced.lupus sensitive/Coagulation surface induced.lupus sensitive.excess phospholipid;Ratio;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive/aPTT.lupus sensitive W excess phospholipid (screen to confirm ratio);aPTT screen to confirm ratio;;ACTIVE;2.50;2.73 +75885-4;IEEE Rosetta panel;-;-;^Patient;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta panel;IEEE Rosetta Pnl;;ACTIVE;2.54;2.63 +75886-2;HCV antibody screening tests - Meaningful Use set;-;Pt;^Patient;-;;PANEL.MICRO;1;HCV antibody screening - Meaningful Use set;HCV Ab MU Set Patient;;ACTIVE;2.50;2.58 +7588-7;Piper nigrum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Pepper IgG Ab [Units/volume] in Serum;Black Pepper IgG Qn;;ACTIVE;1.0h(2);2.73 +75887-0;HCV antibody RIBA tests - Meaningful Use set;-;Pt;^Patient;-;IB;PANEL.MICRO;1;HCV antibody RIBA tests - Meaningful Use set by Immunoblot;HCV Ab RIBA MU Set Patient IB;;ACTIVE;2.50;2.58 +75888-8;HCV RNA screening tests - Meaningful Use set;-;Pt;^Patient;-;;PANEL.MICRO;1;HCV RNA screening tests - Meaningful Use set;HCV RNA MU Set Patient;;ACTIVE;2.50;2.58 +75889-6;How often have you had four or more drinks in one D during the past Y;NRat;1Y;^Patient;Qn;Reported;SURVEY.GNHLTH;4;How often have you had four or more drinks in one day during the past year [Reported];;;ACTIVE;2.50;2.7 +75890-4;Abbreviated Injury Scale predot code;ID;Pt;^Patient;Nom;AAAM;TRAUMA;2;Abbreviated Injury Scale predot code AAAM;AIS PreDot code AAAM;Copyright © 2008 Association for the Advancement of Automotive Medicine (AAAM). Used with Permission. Use of the Abbreviated Injury Scale (AIS) requires a license. Both individual use and site licenses can be purchased from AAAM.;ACTIVE;2.50;2.58 +75891-2;Abbreviated Injury Scale severity score;Score;Pt;^Patient;Ord;AAAM;TRAUMA;2;Abbreviated Injury Scale severity score AAAM;AIS severity score AAAM;Copyright © 2008 Association for the Advancement of Automotive Medicine (AAAM). Used with Permission. Use of the Abbreviated Injury Scale (AIS) requires a license. Both individual use and site licenses can be purchased from AAAM.;ACTIVE;2.50;2.58 +75892-0;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript break points";Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript break points [Identifier] in Blood or Tissue by Molecular genetics method Nominal";"t(9;22)(ABL1,BCR) break pts Bld/T";;ACTIVE;2.50;2.5 +75893-8;Pain severity in the past W - 0-10 numeric rating;Score;1W;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Pain severity in the past week - 0-10 numeric rating [Reported];;;ACTIVE;2.50;2.65 +75894-6;Patient global assessment of disease activity - 0-10 (0.5 increments) numeric rating;Score;Pt;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Patient global assessment of disease activity - 0-10 (0.5 increments) numeric rating [Reported];;;ACTIVE;2.50;2.65 +7589-5;Piper nigrum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Black Pepper triggered histamine release [Units/volume] in Blood;Black Pepper BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75895-3;My child felt uneasy in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt uneasy in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75896-1;How often does your child feel that you listen to his or her ideas;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How often does your child feel that you listen to his or her ideas [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75897-9;How often does your child have fun with friends;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How often does your child have fun with friends [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75898-7;In general, would you say your child's health is;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;In general, would you say your child's health is [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75899-5;My child got tired easily in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child got tired easily in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75900-1;In general, how would you rate your child's mental health, including mood and ability to think;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;In general, how would you rate your child's mental health, including mood and ability to think [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75901-9;Rate all your child's health care in the last 12Mo;Score;12Mo;^Patient;Qn;AHRQ;SURVEY.AHRQ;4;Rate all your child's health care in the last 12 months [AHRQ];;;ACTIVE;2.50;2.61 +75902-7;How many D in the past W did your child miss taking one or more medications;Num;1W;^Patient;Qn;SAMHSA;SURVEY.SAMHSA;4;How many days in the past week did your child miss taking one or more medications # [SAMHSA];;;ACTIVE;2.50;2.54 +7590-3;Pepper cayenne Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cayenne IgG Ab [Units/volume] in Serum;Cayenne IgG Qn;;ACTIVE;1.0h(2);2.73 +75903-5;My child has a good life;Find;Pt;^Patient;Ord;NIH Toolbox;SURVEY.NIH_TOOLBOX;4;My child has a good life [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.50;2.58 +75904-3;How often does your child feel really sad;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How often does your child feel really sad [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75905-0;My child felt stressed in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt stressed in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75906-8;My child had trouble sleeping when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble sleeping when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75907-6;In general, would you say your child's quality of life is;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;In general, would you say your child's quality of life is [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75908-4;In general, how would you rate your child's physical health;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;In general, how would you rate your child's physical health [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +75909-2;Are you able to reach and get down an object (such as a can of soup) from above your head;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to reach and get down an object (such as a can of soup) from above your head [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.50;2.65 +759-1;Neutrophils;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Peritoneal fluid by Manual count;Neutrophils # Prt Manual;;ACTIVE;1.0;2.44 +75910-0;Canadian triage and acuity scale;Find;Pt;^Patient;Ord;CTAS;SURVEY.NHCS;4;Canadian triage and acuity scale [CTAS];;Copyright © Canadian Triage and Acuity Scale Used with permission;ACTIVE;2.50;2.52 +7591-1;Capsicum frutescens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chili Pepper IgE Ab [Units/volume] in Serum;Chili Pepper IgE Qn;;ACTIVE;1.0h(2);2.73 +75911-8;Advance directives panel;-;Pt;^Patient;-;;PANEL.HL7.CCDA;2;Advance directives panel;Advance Directives Pnl;;ACTIVE;2.50;2.63 +75912-6;Observation unit stay discharge;TmStp;Pt;^Patient;Qn;NAMCS;SURVEY.NHCS;4;Observation unit stay discharge [NAMCS];;;ACTIVE;2.50;2.52 +75913-4;dRVVT.hexagonal phase phospholipid actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;dRVVT W excess hexagonal phospholipid/Normal (StaClot LA confirm);Normalized confirm dRVVT StaClot;;ACTIVE;2.50;2.5 +75914-2;Coagulation surface induced.hexagonal phase phospholipid actual/Normal;RelTime;Pt;PPP;Qn;Coag;COAG;1;aPTT W hexagonal phospholipid/Normal (StaClot LA confirm);Normalized confirm aPTT StaClot;;ACTIVE;2.50;2.5 +75915-9;Air curtain status;Find;Pt;Infant microenvironment.incubator;Ord;;NEONAT;2;Air curtain status Infant microenvironment.incubator;Air curtain status Inf microenvt.incub;;ACTIVE;2.54;2.54 +75916-7;Bed type;Type;Pt;Infant microenvironment;Ord;;NEONAT;2;Bed type Infant microenvironment;Bed type Inf microenvt;;ACTIVE;2.58;2.58 +75917-5;Bed state;Type;Pt;Infant microenvironment.incubator;Ord;;NEONAT;2;Bed state Infant microenvironment.incubator;Bed state Inf microenvt.incub;;ACTIVE;2.58;2.58 +75918-3;Bispectral index;Score;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Bispectral index Cerebral cortex Electroencephalogram (EEG);Bispectral index Score Ctx EEG;;ACTIVE;2.54;2.69 +75919-1;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventricular Cardiac index;LV Cardiac index;;ACTIVE;2.54;2.73 +75920-9;Impedance;Resis;Pt;^Patient;Qn;Transthoracic;PULM;2;Transthoracic impedance;Transthor imped;;ACTIVE;2.54;2.69 +75921-7;Electrical potential;Elpot;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Electrical potential Cerebral cortex Electroencephalogram (EEG);Electrical potential Ctx EEG;;ACTIVE;2.54;2.69 +75922-5;Fan speed;Find;Pt;Infant microenvironment.incubator;Ord;;NEONAT;2;Fan speed Infant microenvironment.incubator;Fan speed Inf microenvt.incub;;ACTIVE;2.54;2.54 +75923-3;Fresh gas.air flow;VRat;Pt;Gas delivery system;Qn;;PULM;2;Fresh gas.air flow Gas delivery system;Fresh gas.air flow Gas DS;;ACTIVE;2.54;2.54 +75924-1;Fresh gas.nitrous oxide flow;VRat;Pt;Gas delivery system;Qn;;PULM;2;Fresh gas.nitrous oxide flow Gas delivery system;Fresh gas.N2O flow Gas DS;;ACTIVE;2.54;2.54 +75925-8;Fresh gas.oxygen flow;VRat;Pt;Gas delivery system;Qn;;PULM;2;Fresh gas.oxygen flow Gas delivery system;Fresh gas.O2 flow Gas DS;;ACTIVE;2.54;2.73 +75926-6;Heater type;Type;Pt;Infant microenvironment;Nom;;NEONAT;2;Heater type Infant microenvironment;Heater type Inf microenvt;;ACTIVE;2.54;2.54 +75927-4;Heater power;EngRatFr;Pt;Infant microenvironment;Qn;;NEONAT;2;Heater power Infant microenvironment;Heater power EngRatFr Inf microenvt;;ACTIVE;2.54;2.69 +75928-2;Hemoglobin;SCnc;Pt;BldA;Qn;;HEM/BC;1;Hemoglobin [Moles/volume] in Arterial blood;Hgb BldA-sCnc;;ACTIVE;2.54;2.54 +7592-9;Capsicum frutescens Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chili Pepper IgG Ab [Units/volume] in Serum;Chili Pepper IgG Qn;;ACTIVE;1.0h(2);2.73 +75929-0;Relative humidity;RelMCnc;Pt;Infant microenvironment.incubator;Qn;;NEONAT;2;Relative humidity Infant microenvironment.incubator;Relative humidity Inf microenvt.incub;;ACTIVE;2.54;2.54 +75930-8;Relative humidity setting;RelMCnc;Pt;Infant microenvironment.incubator;Qn;;NEONAT;2;Relative humidity setting Infant microenvironment.incubator;Rel humidity set Inf microenvt.incub;;ACTIVE;2.54;2.54 +75931-6;Inspiration/Expiration;TRto;Pt;Respiratory system;Qn;;PULM;2;Inspiration/Expiration time Ratio;Insp/Exp time Ratio;;ACTIVE;2.54;2.54 +75932-4;Inspiration/Inspiration+Expiration;TimeFr;Pt;Respiratory system;Qn;;PULM;2;Inspiratory time percent;Insp time percent;;ACTIVE;2.54;2.54 +75933-2;Intrachamber diastolic;Pres;Pt;Heart.atrium.left;Qn;;BP.CENT.MOLEC;2;Left atrial pressure Diastolic;LA pressure dias;;ACTIVE;2.54;2.54 +75934-0;Nitrogen dioxide;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen dioxide [VFr/PPres] Airway adaptor;NO2 VFr/PPres Away adap;;ACTIVE;2.56;2.56 +75935-7;Nitrogen dioxide^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen dioxide [VFr/PPres] Airway adaptor --during expiration;NO2 during expir VFr/PPres Away adap;;ACTIVE;2.56;2.56 +75936-5;Nitrogen dioxide^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen dioxide [VFr/PPres] Airway adaptor --during inspiration;NO2 during insp VFr/PPres Away adap;;ACTIVE;2.56;2.56 +7593-7;Capsicum frutescens basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Chili Pepper triggered histamine release [Units/volume] in Blood;Chili Pepper BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75937-3;Nitrogen dioxide^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitrogen dioxide [VFr/PPres] Airway adaptor --at end expiration;NO2 end exp VFr/PPres Away adap;;ACTIVE;2.56;2.56 +75938-1;Oxygen/Gas.total;VFr;Pt;Infant microenvironment.incubator;Qn;;NEONAT;2;Oxygen/Gas total Infant microenvironment.incubator;O2/Gas.total VFr Inf microenvt.incub;;ACTIVE;2.54;2.54 +75939-9;Oxygen/Gas.total setting;VFr;Pt;Infant microenvironment.incubator;Qn;;NEONAT;2;Oxygen/Total gas setting Infant microenvironment.incubator;O2 set VFr Inf microenvt.incub;;ACTIVE;2.54;2.69 +75940-7;Potassium;MCnc;Pt;Bld;Qn;;CHEM;1;Potassium [Mass/volume] in Blood;Potassium Bld-mCnc;;ACTIVE;2.54;2.73 +75941-5;Power spectrum.total;EngRat;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Total power of power spectrum on EEG;Total power EEG;;ACTIVE;2.54;2.69 +75942-3;Pressure^during inspiration;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure --during inspiration;Press during insp Airway;;ACTIVE;2.54;2.56 +75943-1;Pressure^during respiratory pause;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure --during respiratory pause;Press during resp pause Airway;;ACTIVE;2.54;2.56 +75944-9;Pupil reaction;Time;Pt;Eye.left;Qn;;EYE.PX;2;Left eye Pupil reaction [Time];L eye Pupil reaction [Time];;ACTIVE;2.54;2.68 +7594-5;Pepper green Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Green Pepper IgG Ab [Units/volume] in Serum;Green Pepper IgG Qn;;ACTIVE;1.0h(2);2.73 +75945-6;Pupil reaction;Time;Pt;Eye.right;Qn;;EYE.PX;2;Right eye Pupil reaction [Time];R eye Pupil reaction [Time];;ACTIVE;2.54;2.68 +75946-4;Resistance.airway;FldResist;Pt;Respiratory system.airway;Qn;;PULM;2;Airway resistance;Airway resist;;ACTIVE;2.54;2.56 +75947-2;Resistance.airway^during expiration;FldResist;Pt;Respiratory system.airway;Qn;;PULM;2;Airway resistance --during expiration;Airway resist during expir;;ACTIVE;2.54;2.56 +75948-0;Resistance.airway^during inspiration;FldResist;Pt;Respiratory system.airway;Qn;;PULM;2;Airway resistance --during inspiration;Airway resist during insp;;ACTIVE;2.54;2.56 +75949-8;Response entropy;Score;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Response entropy [Score] Cerebral cortex Electroencephalogram (EEG);Response entropy Score Ctx EEG;;ACTIVE;2.54;2.69 +75950-6;Signal quality index;Ratio;Pt;EEG device;Qn;Calculated;NEURO;2;Signal quality index EEG device Calculated;Signal quality index EEG device Calc;;ACTIVE;2.54;2.69 +75951-4;Skin temperature setting;Temp;Pt;Infant microenvironment;Qn;;NEONAT;2;Skin temperature setting Infant microenvironment;Skin temperature setting Inf microenvt;;ACTIVE;2.54;2.69 +7595-2;Pepper red basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Red Pepper triggered histamine release [Units/volume] in Blood;Red Pepper BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +75952-2;SNAP index;Score;Pt;Cerebral cortex;Qn;EEG;NEURO;2;SNAP index Cerebral cortex Electroencephalogram (EEG);SNAP index Score Ctx EEG;;ACTIVE;2.54;2.69 +75953-0;Spike count;NRat;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Spike count Cerebral cortex Electroencephalogram (EEG);Spike count nRate Ctx EEG;;ACTIVE;2.54;2.69 +75954-8;State entropy;Score;Pt;Cerebral cortex;Qn;EEG;NEURO;2;State entropy [Score] Cerebral cortex Electroencephalogram (EEG);State entropy Score Ctx EEG;;ACTIVE;2.54;2.69 +75955-5;Temperature;Temp;Pt;Infant microenvironment.incubator;Qn;;NEONAT;2;Temperature Infant microenvironment.incubator;Temp Inf microenvt.incub;;ACTIVE;2.54;2.69 +75956-3;Temperature sensor;Resis;Pt;Infant microenvironment;Qn;;NEONAT;2;Temperature sensor [Resistance] Infant microenvironment;Temperature sensor Inf microenvt;;ACTIVE;2.54;2.54 +75957-1;Temperature setting;Temp;Pt;Infant microenvironment.incubator;Qn;;NEONAT;2;Temperature setting Infant microenvironment.incubator;Temp setting Inf microenvt.incub;;ACTIVE;2.54;2.69 +75958-9;Tidal volume.expired;Vol;Pt;Respiratory system.airway;Qn;;PULM;2;Tidal volume expired Respiratory system airway;VT.expired Airway;;ACTIVE;2.54;2.56 +75959-7;Volume.expired per minute;VRat;1M;Respiratory system;Qn;;PULM;2;Volume expired per minute Respiratory system;Vol.exp/M Resp system;;ACTIVE;2.54;2.73 +7596-0;Pepper white Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Pepper IgE Ab [Units/volume] in Serum;White Pepper IgE Qn;;ACTIVE;1.0h(2);2.73 +75960-5;Volume.inspired per minute;VRat;1M;Respiratory system;Qn;;PULM;2;Inspired minute Volume;Vol.insp/M Resp system;;ACTIVE;2.54;2.54 +75961-3;Temperature control mode;Type;Pt;Infant microenvironment;Nom;;NEONAT;2;Temperature control mode Infant microenvironment;Temp control mode Inf microenvt;;ACTIVE;2.54;2.54 +75962-1;IEEE Rosetta cardiovascular panel;-;-;CVS;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta cardiovascular panel Chorionic villus sample;Rosetta CVS Pnl CVS;;ACTIVE;2.54;2.56 +75963-9;IEEE Rosetta gas monitoring panel;-;-;^Patient;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta gas monitoring panel;Rosetta GASMON Pnl;;ACTIVE;2.54;2.56 +75964-7;IEEE Rosetta gas delivery panel;-;Pt;Gas delivery system;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta gas delivery panel Gas delivery system;Rosetta GASDLV Pnl Gas DS;;ACTIVE;2.54;2.56 +75965-4;IEEE Rosetta temperature panel;-;Pt;^Patient;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta temperature panel;Rosetta TEMP panel;;ACTIVE;2.54;2.73 +75967-0;IEEE Rosetta laboratory panel;-;Pt;Bld;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta laboratory panel Blood;Rosetta lab Pnl Bld;;ACTIVE;2.54;2.56 +75968-8;IEEE Rosetta infusion panel;-;-;Infusion pump;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta infusion panel Infusion pump;Rosetta INFUS Pnl Inf pump;;ACTIVE;2.54;2.56 +75969-6;IEEE Rosetta respiratory panel;-;-;^Patient;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta respiratory panel;Rosetta RESP Pnl;;ACTIVE;2.54;2.56 +75970-4;IEEE Rosetta central nervous system panel;-;-;^Patient;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta central nervous system panel;Rosetta CNS Pnl;;ACTIVE;2.54;2.56 +75971-2;IEEE Rosetta skin transcutaneous panel;-;Pt;Transcutaneous monitor;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta skin transcutaneous panel Transcutaneous monitor;Rosetta SKIN_TCUT Pnl TC monitor;;ACTIVE;2.54;2.56 +75973-8;IEEE Rosetta infant microenvironment panel;-;Pt;Infant microenvironment;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta infant microenvironment panel Infant microenvironment;Rosetta INFANT Pnl Inf microenvt;;ACTIVE;2.54;2.56 +75974-6;KRAS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;KRAS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;KRAS gene Mut Anl Bld/T;;ACTIVE;2.50;2.73 +75975-3;Fetal chromosome 13+18+21 trisomy;PrThr;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 13+18+21 trisomy [Presence] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Chr 13+18+21 Ts Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +75976-1;Fetal chromosome 21 trisomy;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 21 trisomy [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Chr 21 Ts Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +75977-9;Fetal chromosome X & Y aneuploidy;PrThr;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.MISC;1;Fetal Chromosome X and Y aneuploidy [Presence] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Chr X + Y aneup Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +7597-8;Pepper white Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;White Pepper IgG Ab [Units/volume] in Serum;White Pepper IgG Qn;;ACTIVE;1.0h(2);2.69 +75978-7;Fetal chromosome 18 trisomy;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 18 trisomy [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Chr 18 Ts Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +75979-5;Fetal chromosome 13 trisomy;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 13 trisomy [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Chr 13 Ts Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +75980-3;Fetal chromosome 13+18+21+X+Y aneuploidy;PrThr;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 13+18+21+X+Y aneuploidy [Presence] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet 13+18+21+X+Y aneup Plas.cfDNA;;ACTIVE;2.50;2.73 +75981-1;Fetal chromosome 13 trisomy;PrThr;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 13 trisomy [Presence] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Chr 13 Ts Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +75982-9;Fetal chromosome 18 trisomy;PrThr;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 18 trisomy [Presence] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Chr 18 Ts Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +75983-7;Fetal chromosome 21 trisomy;PrThr;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal Chromosome 21 trisomy [Presence] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA;Fet Chr 21 Ts Plas.cfDNA Ql;;ACTIVE;2.50;2.73 +75984-5;Air delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Air delivered during case [Volume] from Gas delivery system;Air del dur case Vol Gas DS;;ACTIVE;2.54;2.54 +75985-2;Air delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Air delivered.total [Volume] in Reporting period from Gas delivery system;Air del.total RptPeriod Vol Gas DS;;ACTIVE;2.54;2.54 +7598-6;Perca spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Perch IgG Ab [Units/volume] in Serum;Perch IgG Qn;;ACTIVE;1.0h(2);2.69 +75986-0;Velocity index;Vel;Pt;Aorta;Qn;NI-ICG;CARDIO-PULM;2;Velocity index Aorta Non-invasive impedance cardiography (NI-ICG);Velocity index Aorta NI-ICG;;ACTIVE;2.54;2.54 +75987-8;Body temperature;Temp;Pt;BldV;Qn;;BDYTMP.MOLEC;2;Venous blood temperature;Venous blood temp;;ACTIVE;2.54;2.73 +75988-6;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;;CARDIO-PULM;2;Left ventricular End diastolic volume;LV ED Vol;;ACTIVE;2.54;2.73 +75989-4;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;;CARDIO-PULM;2;Left ventricular End systolic volume;LV ES Vol;;ACTIVE;2.54;2.73 +75990-2;Energy expended;EngRat;RptPeriod;^Patient;Qn;Indirect calorimetry;PULM;2;Energy expended Reporting Period by Indirect calorimetry;Energy expend RptPeriod Ind calorimetry;;ACTIVE;2.54;2.72 +75991-0;Oxygen extraction;VRto;RptPeriod;^Patient;Qn;;PULM;2;Oxygen extraction ratio;O2 extraction ratio;;ACTIVE;2.54;2.69 +75992-8;Heater power;EngRat;Pt;Transcutaneous monitor;Qn;;DEVICES;2;Transcutaneous monitor Heater power;TC monitor Heater power;;ACTIVE;2.54;2.69 +75993-6;Intravascular;Pres;Pt;Femoral artery;Qn;;BP.MOLEC;2;Femoral artery Blood pressure;Fem a BP;;ACTIVE;2.54;2.54 +7599-4;Phadiatop Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phadiatop IgE Ab [Units/volume] in Serum;Phadiotop IgE Qn;;ACTIVE;1.0h(2);2.73 +75994-4;Intravascular;Pres;Pt;Pulmonary artery.wedge;Qn;;BP.CENT.MOLEC;2;Pulmonary artery wedge pressure;PAW pressure;;ACTIVE;2.54;2.54 +75995-1;Intravascular diastolic;Pres;Pt;Arterial system;Qn;CNAP;BP.MOLEC;2;Diastolic blood pressure by Continuous non-invasive monitoring;BP dias by CNAP;;ACTIVE;2.54;2.54 +75996-9;Intravascular mean;Pres;Pt;Arterial system;Qn;CNAP;BP.MOLEC;2;Mean blood pressure by Continuous non-invasive monitoring;BP mean by CNAP;;ACTIVE;2.54;2.54 +75997-7;Intravascular systolic;Pres;Pt;Arterial system;Qn;CNAP;BP.MOLEC;2;Systolic blood pressure by Continuous non-invasive monitoring;BP sys by CNAP;;ACTIVE;2.54;2.54 +75998-5;Oxygen gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Oxygen gas delivered during case [Volume] from Gas delivery system;O2 gas del dur case Vol Gas DS;;ACTIVE;2.54;2.54 +75999-3;Oxygen gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Oxygen gas delivered.total [Volume] in Reporting period from Gas delivery system;O2 gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.54;2.54 +76-0;ceFAZolin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;ceFAZolin [Susceptibility] by Minimum inhibitory concentration (MIC);ceFAZolin Islt MIC;;ACTIVE;1.0;2.73 +7600-0;Phospholipase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phospholipase IgE Ab [Units/volume] in Serum;Phospholipase IgE Qn;;ACTIVE;1.0h(2);2.42 +76000-9;Beats.paced;NRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;Paced heart rate by EKG;Paced HR EKG;;ACTIVE;2.54;2.54 +76001-7;Physiological dead space;Vol;Pt;Respiratory system;Qn;;PULM;2;Physiological dead space [Volume] Respiratory system;Phys dead space Vol Respiratory;;ACTIVE;2.54;2.54 +76002-5;Physiological dead space/Tidal volume;VRto;Pt;Respiratory system;Qn;;PULM;2;Physiological dead space/Tidal volume Respiratory system;Phys dead space/TV Respiratory;;ACTIVE;2.54;2.54 +76003-3;Pressure^during inspiration on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure Respiratory system airway --during inspiration on ventilator;Press dur insp on vent Airway;;ACTIVE;2.54;2.56 +76004-1;Pressure.occlusion;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Airway occlusion pressure;Airway occlusion press;;ACTIVE;2.54;2.56 +76005-8;Temperature;Temp;Pt;Transcutaneous monitor sensor;Qn;;DEVICES;2;Transcutaneous monitor sensor temperature;TC monitor sensor temp;;ACTIVE;2.54;2.73 +76006-6;Temperature difference;TempDiff;Pt;^Patient;Qn;;BDYTMP.MOLEC;2;Temperature difference;Temp diff;;ACTIVE;2.54;2.54 +76007-4;Tidal volume.expired^on ventilator;Vol;Pt;Respiratory system.airway;Qn;;PULM;2;Tidal volume expired Respiratory system airway --on ventilator;VT.expired on vent Airway;;ACTIVE;2.54;2.56 +76008-2;Volume.expired per minute^on ventilator;VRat;1M;Respiratory system;Qn;;PULM;2;Expired minute Volume during Mechanical ventilation;Expired min Vol MV;;ACTIVE;2.58;2.58 +76009-0;Volume.inspired per minute^on ventilator;VRat;1M;Respiratory system;Qn;;PULM;2;Inspired minute Volume during Mechanical ventilation;Inspired min Vol MV;;ACTIVE;2.58;2.58 +76010-8;Body temperature;Temp;Pt;Nose;Qn;;BDYTMP.MOLEC;2;Nasal temperature;Nasal temp;;ACTIVE;2.54;2.54 +76011-6;Body temperature;Temp;Pt;Ear;Qn;;BDYTMP.MOLEC;2;Ear temperature;Ear temp;;ACTIVE;2.54;2.54 +76012-4;Desflurane liquid delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Desflurane liquid delivered during case [Volume] from Gas delivery system;Desfl liq del dur case Vol Gas DS;;ACTIVE;2.54;2.54 +76013-2;Desflurane liquid delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Desflurane liquid delivered.total [Volume] in Reporting period from Gas delivery system;Desfl liq del.tot RptPeriod Vol Gas DS;;ACTIVE;2.54;2.54 +76014-0;Enflurane liquid delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Enflurane liquid delivered during case [Volume] from Gas delivery system;Enfl liq del dur case Vol Gas DS;;ACTIVE;2.54;2.54 +76015-7;Enflurane liquid delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Enflurane liquid delivered.total [Volume] in Reporting period from Gas delivery system;Enfl liq del.total RptPeriod Vol Gas DS;;ACTIVE;2.54;2.54 +76016-5;Halothane liquid delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Halothane liquid delivered during case [Volume] from Gas delivery system;Halo liq del dur case Vol Gas DS;;ACTIVE;2.54;2.54 +76017-3;Halothane liquid delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Halothane liquid delivered.total [Volume] in Reporting period from Gas delivery system;Halo liq del.total RptPeriod Vol Gas DS;;ACTIVE;2.54;2.54 +7601-8;Phthalic anhydride Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phthalic anhydride IgE Ab [Units/volume] in Serum;PAN IgE Qn;;ACTIVE;1.0h(2);2.73 +76018-1;Sevoflurane liquid delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Sevoflurane liquid delivered during case [Volume] from Gas delivery system;Sevo liq del dur case Vol Gas DS;;ACTIVE;2.54;2.54 +76019-9;Sevoflurane liquid delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Sevoflurane liquid delivered.total [Volume] in Reporting period from Gas delivery system;Sevo liq del.total RptPeriod Vol Gas DS;;ACTIVE;2.54;2.54 +76020-7;Delta dRVVT;TimeDif;Pt;PPP;Qn;Coag;COAG;1;Delta dRVVT [Time] in Platelet poor plasma by Coagulation assay;Delta dRVVT PPP;;ACTIVE;2.50;2.5 +76021-5;Delta aPTT;TimeDif;Pt;PPP;Qn;Coag;COAG;1;Delta aPTT [Time] in Platelet poor plasma by Coagulation assay;Delta aPTT PPP;;ACTIVE;2.50;2.5 +76022-3;8(9)-Cholestenol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;8(9)-Cholestenol [Moles/volume] in Serum or Plasma;8(9)-Cholestenol SerPl-sCnc;;ACTIVE;2.50;2.5 +76023-1;N-acetyl-L-aspartate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N-acetyl-L-aspartate/Creatinine [Molar ratio] in Urine;N-Ac-L-Asp/Creat Ur-sRto;;ACTIVE;2.50;2.73 +76024-9;Sialate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sialate/Creatinine [Molar ratio] in Urine;Sialate/Creat Ur-sRto;;ACTIVE;2.50;2.5 +76025-6;Arylsulfatase C;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Arylsulfatase C [Enzymatic activity/mass] in Fibroblast;Arylsulfatase C Fib-cCnt;;ACTIVE;2.50;2.5 +7602-6;Salicornia spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pickleweed IgE Ab [Units/volume] in Serum;Pickleweed IgE Qn;;ACTIVE;1.0h(2);2.42 +76026-4;Phosphomannomutase 2;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Phosphomannomutase 2 [Enzymatic activity/mass] in Fibroblast;PMM2 Fib-cCnt;;ACTIVE;2.50;2.5 +76027-2;Mannose-6-phosphate isomerase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Mannose-6-phosphate isomerase [Enzymatic activity/mass] in Fibroblast;M6PI Fib-cCnt;;ACTIVE;2.50;2.54 +76028-0;IDUA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;IDUA gene full mutation analysis in Blood or Tissue by Sequencing;IDUA gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.73 +76029-8;HEXB gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HEXB gene full mutation analysis in Blood or Tissue by Sequencing;HEXB gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +76030-6;IDS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;IDS gene full mutation analysis in Blood or Tissue by Sequencing;IDS gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +76031-4;NPC1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;NPC1 gene full mutation analysis in Blood or Tissue by Sequencing;NPC1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.73 +76032-2;SGSH gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SGSH gene full mutation analysis in Blood or Tissue by Sequencing;SGSH gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +76033-0;HEXA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HEXA gene full mutation analysis in Blood or Tissue by Sequencing;HEXA gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.73 +7603-4;Pigeon droppings Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon droppings IgG Ab [Units/volume] in Serum;Pigeon Drop IgG Qn;;ACTIVE;1.0h(2);2.69 +76034-8;GAA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GAA gene full mutation analysis in Blood or Tissue by Sequencing;GAA Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +76035-5;ARSA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ARSA gene full mutation analysis in Blood or Tissue by Sequencing;ARSA gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +76036-3;GLA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GLA gene full mutation analysis in Blood or Tissue by Sequencing;GLA gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.66 +76037-1;GALT gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GALT gene full mutation analysis in Blood or Tissue by Sequencing;GALT gene Full Mut Anl Bld/T Seq;;ACTIVE;2.50;2.73 +76038-9;Tripeptidyl peptidase I;CCnt;Pt;WBC;Qn;;CHEM;1;Tripeptidyl peptidase I [Enzymatic activity/mass] in Leukocytes;Tripeptidyl peptidase I WBC-cCnt;;ACTIVE;2.50;2.5 +76039-7;Interleukin 2 receptor.soluble;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 Receptor Soluble [Mass/volume] in Serum or Plasma;Sol Il2 Recep SerPl-mCnc;;ACTIVE;2.50;2.73 +76040-5;levoFLOXacin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;levoFLOXacin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;levoFLOXacin 1 ug/mL Islt SlowMyco;;ACTIVE;2.50;2.5 +76041-3;levoFLOXacin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;levoFLOXacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;levoFLOXacin 2 ug/mL Islt SlowMyco;;ACTIVE;2.50;2.5 +7604-2;Pigweed common Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common Pigweed IgE Ab [Units/volume] in Serum;Common Pigweed IgE Qn;;ACTIVE;1.0h(2);2.73 +76042-1;levoFLOXacin 4.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;levoFLOXacin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;levoFLOXacin 4 ug/mL Islt SlowMyco;;ACTIVE;2.50;2.5 +76043-9;Moxifloxacin 0.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Moxifloxacin 0.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Moxifloxacin 0.5 ug/mL Islt SlowMyco;;ACTIVE;2.50;2.5 +76044-7;Moxifloxacin 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Moxifloxacin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Moxifloxacin 1 ug/mL Islt SlowMyco;;ACTIVE;2.50;2.5 +76045-4;Moxifloxacin 2.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Moxifloxacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Moxifloxacin 2 ug/mL Islt SlowMyco;;ACTIVE;2.50;2.5 +76046-2;IEEE Rosetta body measurement panel;-;Pt;^Patient;-;;PANEL.IEEE ROSETTA;2;IEEE 11073 Rosetta body measurement panel;Rosetta body meas Pnl;;ACTIVE;2.54;2.56 +76047-0;ST amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead V1;ST Amp L-V1;;ACTIVE;2.54;2.54 +76048-8;ST amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead V2;ST Amp L-V2;;ACTIVE;2.54;2.54 +76049-6;ST amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead V3;ST Amp L-V3;;ACTIVE;2.54;2.54 +76050-4;ST amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead V4;ST Amp L-V4;;ACTIVE;2.54;2.54 +76051-2;ST amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead V5;ST Amp L-V5;;ACTIVE;2.54;2.54 +76052-0;ST amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead V6;ST Amp L-V6;;ACTIVE;2.54;2.54 +76053-8;ST amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead I;ST Amp L-I;;ACTIVE;2.54;2.54 +76054-6;ST amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead II;ST Amp L-II;;ACTIVE;2.54;2.54 +76055-3;ST amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead III;ST Amp L-III;;ACTIVE;2.54;2.54 +76056-1;ST amplitude.lead aVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead aVF;ST Amp L-aVF;;ACTIVE;2.54;2.54 +76057-9;ST amplitude.lead aVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead aVL;ST Amp L-aVL;;ACTIVE;2.54;2.54 +76058-7;ST amplitude.lead aVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;ST amplitude.lead aVR;ST Amp L-aVR;;ACTIVE;2.54;2.54 +7605-9;Pigweed Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pigweed IgG Ab [Units/volume] in Serum;Pigweed IgG Qn;;ACTIVE;1.0h(2);2.69 +76059-5;Anesthetic agent.XXX;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Anesthetic agent.XXX Airway adaptor;Anesthetic Away adap;;ACTIVE;2.54;2.56 +76060-3;Initiating cause or condition of death;Find;Pt;^Fetus;Nom;US standard report of fetal death;SURVEY.CDC;4;Initiating cause or condition of fetal death [US Standard Report of Fetal Death];;;ACTIVE;2.50;2.66 +76061-1;Other significant causes or conditions of death;Find;Pt;^Fetus;Nom;US standard report of fetal death;SURVEY.CDC;4;Other significant causes or conditions of fetal death [US Standard Report of Fetal Death];;;ACTIVE;2.50;2.7 +76062-9;Schistocytes/100 cells;NFr;Pt;BldCo;Qn;Probe.amp.tar;HEM/BC;1;Deprecated Schistocytes/100 cells in Cord blood by Probe and target amplification method;Deprecated Schistocytes NFr BldCo PCR;;DEPRECATED;2.50;2.66 +76063-7;MSH2 gene+MLH1 gene+MSH6 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MSH2 gene+MLH1 gene+MSH6 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MSH2+MLH1+MSH6 gene Fam Mut Anl Bld/T;;ACTIVE;2.50;2.66 +76064-5;Rheumatoid arthritis disease activity score confidence interval;ScoreRange;Pt;Ser/Plas;Qn;VectraDA;CHEM;1;Rheumatoid arthritis disease activity score confidence interval by VectraDA;RA DAS CI VectraDA;;ACTIVE;2.50;2.73 +76065-2;6p25 & 6q23 & 11q & 8q24 & 9p21 chromosome partial aneuploidy;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.MUT;1;6p25 and 6q23 and 11q and 8q24 and 9p21 chromosome partial aneuploidy in Blood or Tissue by FISH;6p25+6q23+11q+8q24+9p21 aneup Bld/T FISH;;ACTIVE;2.50;2.66 +76066-0;Abbreviated Injury Scale version code;Type;Pt;^Patient;Nom;AAAM;TRAUMA;2;Abbreviated Injury Scale version code AAAM;AIS Version Code AAAM;Copyright © 2008 Association for the Advancement of Automotive Medicine (AAAM). Used with Permission. Use of the Abbreviated Injury Scale (AIS) requires a license. Both individual use and site licenses can be purchased from AAAM.;ACTIVE;2.50;2.5 +7606-7;Pigweed basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Pigweed triggered histamine release [Units/volume] in Blood;Pigweed BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.73 +76067-8;Abbreviated Injury Scale panel;-;Pt;^Patient;-;AAAM;PANEL.CLIN;2;Abbreviated Injury Scale panel AAAM;AIS panel AAAM;Copyright © 2008 Association for the Advancement of Automotive Medicine (AAAM). Used with Permission. Use of the Abbreviated Injury Scale (AIS) requires a license. Both individual use and site licenses can be purchased from AAAM.;ACTIVE;2.50;2.5 +76068-6;MBL2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MBL2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MBL2 Mut Anl Bld/T;;ACTIVE;2.50;2.66 +76069-4;Erythrocytes.hypochromic/100 erythrocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Erythrocytes.hypochromic/100 erythrocytes in Blood by Automated count;%HYPO/100 RBC NFr Bld Auto;;ACTIVE;2.50;2.66 +76070-2;Adenovirus DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Nasopharynx by NAA with probe detection;HAdV DNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +76071-0;Aspergillus sp DNA;PrThr;Pt;BAL;Ord;Probe.amp.tar;MICRO;1;Aspergillus sp DNA [Presence] in Bronchoalveolar lavage by NAA with probe detection;Aspergillus DNA BAL Ql NAA+probe;;ACTIVE;2.50;2.63 +76072-8;Enterovirus D68 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterovirus D68 RNA [Presence] in Specimen by NAA with probe detection;EV D68 RNA Spec Ql NAA+probe;;ACTIVE;2.50;2.69 +76073-6;Fungus identified;Prid;Pt;Nose;Nom;Culture;MICRO;1;Fungus identified in Nose by Culture;Fungus Nose Cult;;ACTIVE;2.50;2.5 +76074-4;Enterovirus RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Nasopharynx by NAA with probe detection;EV RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.63 +7607-5;Pinus strobus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Eastern White Pine IgE Ab [Units/volume] in Serum;Deprecated East White Pine IgE Qn;;DEPRECATED;1.0h(2);2.69 +76075-1;Galactomannan Ag;ACnc;Pt;BAL;Qn;;MICRO;1;Galactomannan Ag [Units/volume] in Bronchoalveolar lavage;Galactomannan Ag BAL-aCnc;;ACTIVE;2.50;2.69 +76076-9;Haemophilus ducreyi DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Haemophilus ducreyi DNA [Presence] in Genital specimen by NAA with probe detection;H ducreyi DNA Genital Ql NAA+probe;;ACTIVE;2.50;2.63 +76077-7;Influenza virus A RNA;PrThr;Pt;BAL;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Bronchoalveolar lavage by NAA with probe detection;FLUAV RNA BAL Ql NAA+probe;;ACTIVE;2.50;2.63 +76078-5;Influenza virus A RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Nasopharynx by NAA with probe detection;FLUAV RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +76079-3;Influenza virus B RNA;PrThr;Pt;BAL;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Bronchoalveolar lavage by NAA with probe detection;FLUBV RNA BAL Ql NAA+probe;;ACTIVE;2.50;2.63 +76080-1;Influenza virus B RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection;FLUBV RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +76081-9;Staphylococcus aureus.methicillin resistant isolate;PrThr;Pt;Pharynx;Ord;Organism specific culture;MICRO;1;Methicillin resistant Staphylococcus aureus [Presence] in Pharynx by Organism specific culture;MRSA Pharynx Ql Cult;;ACTIVE;2.50;2.56 +76082-7;Microscopic observation;Prid;Pt;BAL;Nom;Methenamine silver nitrate stain;MICRO;1;Microscopic observation [Identifier] in Bronchoalveolar lavage by Methenamine silver nitrate stain;MS Nitrate Stn BAL;;ACTIVE;2.50;2.5 +7608-3;Pinus taeda Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Loblolly Pine IgE Ab [Units/volume] in Serum;Loblolly Pine IgE Qn;;ACTIVE;1.0h(2);2.73 +76083-5;Microscopic observation;PrThr;Pt;BAL;Ord;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Presence] in Bronchoalveolar lavage by Acid fast stain.Ziehl-Neelsen;ZN Stn BAL Ql;;ACTIVE;2.50;2.56 +76084-3;Parainfluenza virus 1 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Nasopharynx by NAA with probe detection;HPIV1 RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +76085-0;Parainfluenza virus 2 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Nasopharynx by NAA with probe detection;HPIV2 RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +76086-8;Parainfluenza virus 3 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Nasopharynx by NAA with probe detection;HPIV3 RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +76087-6;Parainfluenza virus 4 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Nasopharynx by NAA with probe detection;HPIV4 RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +76088-4;Respiratory syncytial virus RNA;PrThr;Pt;BAL;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Bronchoalveolar lavage by NAA with probe detection;RSV RNA BAL Ql NAA+probe;;ACTIVE;2.50;2.63 +76089-2;Respiratory syncytial virus RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Nasopharynx by NAA with probe detection;RSV RNA Nph Ql NAA+probe;;ACTIVE;2.50;2.73 +760-9;Neutrophils;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Neutrophils [#/volume] in Synovial fluid by Manual count;Neutrophils # Snv Manual;;ACTIVE;1.0;2.44 +76090-0;Erythrocytes.hyperchromic/100 erythrocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Erythrocytes.hyperchromic/100 erythrocytes in Blood by Automated count;%HYPER/100 RBC NFr Bld Auto;;ACTIVE;2.50;2.5 +7609-1;Pinus radiata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pine IgE Ab [Units/volume] in Serum;Pine IgE Qn;;ACTIVE;1.0h(2);2.73 +76091-8;Respiratory pathogens DNA & RNA 4 panel;-;Pt;Nph;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA 4 panel - Nasopharynx by NAA with probe detection;Resp path 4 Pnl Nph NAA+probe;;ACTIVE;2.52;2.63 +76092-6;Gradient.systole.max;Pres;Pt;Aortic valve;Qn;;CARDIO-PULM;2;Maximum gradient during systole [Pressure] Aortic valve;Max grad sys AV;;ACTIVE;2.54;2.67 +76093-4;Nitric oxide;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitric oxide [VFr/PPres] Airway adaptor;NO VFr/PPres Away adap;;ACTIVE;2.56;2.56 +76094-2;Xenon;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Xenon [VFr/PPres] Airway adaptor;Xe VFr/PPres Away adap;;ACTIVE;2.56;2.56 +76095-9;Carbon dioxide^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Carbon dioxide [VFr/PPres] in Gas delivery system.expiratory limb --during expiration;CO2 during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76096-7;Carbon dioxide^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Carbon dioxide [VFr/PPres] in Gas delivery system.inspiratory limb --during inspiration;CO2 during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76097-5;Helium^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Helium [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Helium during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76098-3;Helium^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Helium [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Helium during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76099-1;Nitric oxide^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Nitric oxide [VFr/PPres] Gas delivery system.expiratory limb --during expiration;NO during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76100-7;Nitric oxide^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Nitric oxide [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;NO during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76101-5;Nitrogen dioxide^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Nitrogen dioxide [VFr/PPres] Gas delivery system.expiratory limb --during expiration;NO2 during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76102-3;Nitrogen dioxide^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Nitrogen dioxide [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;NO2 during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76103-1;Nitrogen^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Nitrogen [VFr/PPres] Gas delivery system.expiratory limb --during expiration;N2 during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76104-9;Nitrogen^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Nitrogen [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;N2 during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76105-6;Oxygen^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Oxygen [VFr/PPres] Gas delivery system.expiratory limb --during expiration;O2 during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76106-4;Oxygen^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Oxygen [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;O2 during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76107-2;Sevoflurane^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Sevoflurane [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Sevofl during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76108-0;Xenon^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Xenon [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Xe during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +7610-9;Pinus ponderosa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pondorosa Pine IgE Ab [Units/volume] in Serum;Pondorosa Pine IgE Qn;;ACTIVE;1.0h(2);2.73 +76109-8;Xenon^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Xenon [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Xe during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76110-6;Helium;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Helium [VFr/PPres] Gas delivery system;Helium VFr/PPres Gas DS;;ACTIVE;2.56;2.56 +76111-4;Nitric oxide;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Nitric oxide [VFr/PPres] Gas delivery system;NO VFr/PPres Gas DS;;ACTIVE;2.56;2.56 +76112-2;Nitrogen;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Nitrogen [VFr/PPres] Gas delivery system;N2 VFr/PPres Gas DS;;ACTIVE;2.56;2.56 +76113-0;Nitrogen dioxide;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Nitrogen dioxide [VFr/PPres] Gas delivery system;NO2 VFr/PPres Gas DS;;ACTIVE;2.56;2.56 +76114-8;Xenon;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Xenon [VFr/PPres] Gas delivery system;Xe VFr/PPres Gas DS;;ACTIVE;2.56;2.56 +76115-5;Nitric oxide^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitric oxide [VFr/PPres] Airway adaptor --at end expiration;NO end exp VFr/PPres Away adap;;ACTIVE;2.56;2.56 +76116-3;Xenon^at end expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Xenon [VFr/PPres] Airway adaptor --at end expiration;Xe end exp VFr/PPres Away adap;;ACTIVE;2.56;2.56 +7611-7;Pinus monticola Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Western White Pine IgE Ab [Units/volume] in Serum;West White Pine IgE Qn;;ACTIVE;1.0h(2);2.73 +76117-1;Nitric oxide^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitric oxide [VFr/PPres] Airway adaptor --during expiration;NO during expir VFr/PPres Away adap;;ACTIVE;2.56;2.56 +76118-9;Xenon^during expiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Xenon [VFr/PPres] Airway adaptor --during expiration;Xe during expir VFr/PPres Away adap;;ACTIVE;2.56;2.56 +76119-7;Helium gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Helium gas delivered during case [Volume] from Gas delivery system;He gas del dur case Vol Gas DS;;ACTIVE;2.56;2.56 +76120-5;Nitric oxide^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Nitric oxide [VFr/PPres] Airway adaptor --during inspiration;NO during insp VFr/PPres Away adap;;ACTIVE;2.56;2.56 +76121-3;Xenon^during inspiration;VFr/PPres;Pt;Airway adaptor;Qn;;PULM;2;Xenon [VFr/PPres] Airway adaptor --during inspiration;Xe during insp VFr/PPres Away adap;;ACTIVE;2.56;2.56 +76122-1;Helium gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Helium gas delivered.total [Volume] in Reporting period from Gas delivery system;He gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.56;2.56 +76123-9;Nitric oxide gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Nitric oxide gas delivered.total [Volume] in Reporting period from Gas delivery system;NO gas del.tot RptPeriod Vol Gas DS;;ACTIVE;2.56;2.56 +76124-7;Xenon gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Xenon gas delivered during case [Volume] from Gas delivery system;Xe gas del dur case Vol Gas DS;;ACTIVE;2.56;2.56 +7612-5;Ananas comosus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pineapple IgG Ab [Units/volume] in Serum;Pineapple IgG Qn;;ACTIVE;1.0h(2);2.73 +76125-4;Xenon gas delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Xenon gas delivered.total [Volume] in Reporting period from Gas delivery system;Xe gas del.total RptPeriod Vol Gas DS;;ACTIVE;2.56;2.56 +76126-2;Premature ventricular contractions;Num;Procedure dur;Heart;Qn;EKG;EKG.MEAS;2;Premature ventricular contractions [#];PVCs;;ACTIVE;2.54;2.73 +76127-0;Argon;VFr/PPres;Pt;Gas delivery system;Qn;;PULM;2;Argon [VFr/PPres] Gas delivery system;Argon VFr/PPres Gas DS;;ACTIVE;2.56;2.56 +76128-8;Argon^during inspiration;VFr/PPres;Pt;Gas delivery system.inspiratory limb;Qn;;PULM;2;Argon [VFr/PPres] Gas delivery system.inspiratory limb --during inspiration;Argon during insp VFr/PPres Gas DS.IL;;ACTIVE;2.56;2.56 +76129-6;Argon^during expiration;VFr/PPres;Pt;Gas delivery system.expiratory limb;Qn;;PULM;2;Argon [VFr/PPres] Gas delivery system.expiratory limb --during expiration;Argon during expir VFr/PPres Gas DS.EL;;ACTIVE;2.56;2.56 +76130-4;Isoflurane liquid delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Isoflurane liquid delivered during case [Volume] from Gas delivery system;Isofl liq del dur case Vol Gas DS;;ACTIVE;2.54;2.54 +76131-2;Isoflurane liquid delivered.total;Vol;RptPeriod;Gas delivery system;Qn;;PULM;2;Isoflurane liquid delivered.total [Volume] in Reporting period from Gas delivery system;Isofl liq del.tot RptPeriod Vol Gas DS;;ACTIVE;2.54;2.54 +76132-0;Sucrose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sucrose/Creatinine [Molar ratio] in Urine;Sucrose/Creat Ur-sRto;;ACTIVE;2.52;2.52 +7613-3;Pistacia vera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pistachio IgE Ab [Units/volume] in Serum;Pistachio IgE Qn;;ACTIVE;1.0h(2);2.73 +76133-8;Sugar absorption test panel;SRto;5H;Urine;-;;PANEL.CHEM;1;Sugar absorption test panel [Molar ratio] - 5 hour Urine;Sugar absorption test Pnl 5h Ur-sRto;;ACTIVE;2.54;2.58 +76134-6;Sucrose^post XXX g sugar solution PO;SRat;5H;Urine;Qn;;CHEM;1;Sucrose [Moles/time] in 5 hour Urine --post XXX g sugar solution PO;Sucrose p sug sol 5h Ur-sRate;;ACTIVE;2.54;2.54 +76135-3;Inositol.free/Creatinine^post XXX g sugar solution PO;SRto;5H;Urine;Qn;;CHEM;1;Inositol Free/Creatinine [Molar ratio] in 5 hour Urine --post XXX g sugar solution PO;Inositol Free/Creat p sug sol 5h Ur-sRto;;ACTIVE;2.54;2.54 +76136-1;Lactulose^post XXX g sugar solution PO;SRat;5H;Urine;Qn;;CHEM;1;Lactulose [Moles/time] in 5 hour Urine --post XXX g sugar solution PO;Lactulose p sug sol 5h Ur-sRate;;ACTIVE;2.54;2.54 +76137-9;Platelet component distribution width;MCnc;Pt;Bld;Qn;Calculated;HEM/BC;1;Platelet component distribution width [Mass/volume] in Blood by calculation;PCDW Bld Calc-mCnc;;ACTIVE;2.52;2.52 +76138-7;Reticulocyte distribution width;Ratio;Pt;Bld;Qn;Calculated;HEM/BC;1;Reticulocyte distribution width [Ratio] in Blood by calculation;RDWr Bld Calc-Rto;;ACTIVE;2.52;2.52 +76139-5;Reticulocyte hemoglobin distribution width;MCnc;Pt;Bld;Qn;Calculated;HEM/BC;1;Reticulocyte hemoglobin distribution width [Mass/volume] in Blood by calculation;HDWr Bld Calc-mCnc;;ACTIVE;2.52;2.52 +76140-3;Reticulocytes.hypochromic/100 erythrocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Reticulocytes.hypochromic/100 erythrocytes in Blood by Automated count;Retics.hypochromic/100 RBC NFr Auto;;ACTIVE;2.52;2.52 +7614-1;Pitosporium basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Pitosporium triggered histamine release [Units/volume] in Blood;Pitosporium BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76141-1;Reticulocyte corpuscular hemoglobin concentration mean;MCnc;Pt;Bld;Qn;;HEM/BC;1;Reticulocyte corpuscular hemoglobin concentration mean [Mass/volume] in Blood;CHCMr Bld-mCnc;;ACTIVE;2.52;2.52 +76142-9;Lymphocytes.immature;PrThr;Pt;Bld;Ord;Manual count;HEM/BC;1;Immature lymphocytes [Presence] in Blood by Manual count;Imm Lymphs Bld Ql Manual;;ACTIVE;2.52;2.56 +76143-7;Cefcapene;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefcapene [Susceptibility] by Minimum inhibitory concentration (MIC);Cefcapene Islt MIC;;ACTIVE;2.52;2.52 +76144-5;Cefteram;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefteram [Susceptibility] by Minimum inhibitory concentration (MIC);Cefteram Islt MIC;;ACTIVE;2.52;2.52 +76145-2;Prulifloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Prulifloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Prulifloxacin Islt MIC;;ACTIVE;2.52;2.52 +76146-0;Tosufloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tosufloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);Tosufloxacin Islt MIC;;ACTIVE;2.52;2.52 +76147-8;Cefovecin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefovecin [Susceptibility] by Minimum inhibitory concentration (MIC);Cefovecin Islt MIC;;ACTIVE;2.52;2.52 +76148-6;Pradofloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Pradofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);PRA Islt MIC;;ACTIVE;2.52;2.52 +76149-4;Tulathromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tulathromycin [Susceptibility] by Minimum inhibitory concentration (MIC);TUL Islt MIC;;ACTIVE;2.52;2.52 +76150-2;Cefquinome;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefquinome [Susceptibility] by Minimum inhibitory concentration (MIC);CEQ Islt MIC;;ACTIVE;2.52;2.52 +76151-0;Airway pressure backup setting;Pres;Pt;Ventilator;Qn;;PULM;2;Airway pressure backup setting Ventilator;Away press backup set Vent;;ACTIVE;2.58;2.58 +76152-8;Airway pressure delta setting;PressDiff;Pt;Ventilator;Qn;;PULM;2;Airway pressure delta setting Ventilator;Away press delta set PressDiff Vent;;ACTIVE;2.58;2.58 +76154-4;Airway pressure delta^on ventilator;PressDiff;Pt;Respiratory system.airway;Qn;;PULM;2;Airway pressure delta --on ventilator;Away press delta on vent PressDiff;;ACTIVE;2.58;2.69 +7615-8;Plantain Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Plantain Ab.IgE;Deprecated Plantain IgE Qn;;DEPRECATED;1.0h(2);2.69 +76164-3;Pressure^on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure Respiratory system airway --on ventilator;Press on vent Airway;;ACTIVE;2.58;2.69 +76165-0;Alveolar ventilation^on ventilator;Vol;Pt;Respiratory system;Qn;;PULM;2;Alveolar ventilation [Volume] Respiratory system --on ventilator;Alv vent on vent Vol Respiratory;;ACTIVE;2.54;2.56 +7616-6;Plantago lanceolata basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;English plantain triggered histamine release [Units/volume] in Blood;Engl plantain BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76166-8;Apnea duration setting;Time;Pt;Ventilator.alarm;Qn;;PULM;2;Apnea duration setting Ventilator alarm;Apnea dur set Vent alarm;;ACTIVE;2.63;2.63 +76168-4;Pressure.baseline setting;Pres;Pt;Ventilator;Qn;;PULM;2;Pressure.baseline setting Ventilator;Press.base set Vent;;ACTIVE;2.63;2.69 +76169-2;Pressure.baseline^on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure.baseline Respiratory system airway --on ventilator;Press.base on vent Airway;;ACTIVE;2.63;2.63 +761-7;Neutrophils;NCnc;Pt;Urine;Qn;Automated count;UA;1;Neutrophils [#/volume] in Urine by Automated count;Neutrophils # Ur Auto;;ACTIVE;1.0;2.42 +76170-0;Breaths;NRat;Pt;Respiratory system;Qn;Acoustic measurement;PULM;2;Respiratory rate by Acoustic measurement;Resp rate Acoustic meas;;ACTIVE;2.56;2.56 +76171-8;Breaths;NRat;Pt;Respiratory system;Qn;Airway flow measurement;PULM;2;Respiratory rate by Airway flow measurement;Resp rate Away flow meas;;ACTIVE;2.54;2.54 +76172-6;Breaths;NRat;Pt;Respiratory system;Qn;Carbon dioxide measurement;PULM;2;Respiratory rate by Carbon dioxide measurement;Resp rate CO2 meas;;ACTIVE;2.54;2.54 +76173-4;Breaths;NRat;Pt;Respiratory system;Qn;Non-airway pressure measurement;PULM;2;Respiratory rate by Non-airway pressure measurement;Resp rate Non-airway press meas;;ACTIVE;2.63;2.63 +7617-4;Prunus domestica Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Plum IgG Ab [Units/volume] in Serum;Plum IgG Qn;;ACTIVE;1.0h(2);2.73 +76174-2;Breaths;NRat;Pt;Respiratory system;Qn;Pulse oximetry.plethysmograph;PULM;2;Respiratory rate by Pulse oximetry.plethysmograph;Resp rate PulseOx.pleth;;ACTIVE;2.58;2.58 +7618-2;Prunus domestica pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Plum Pollen IgE Ab [Units/volume] in Serum;Plum Poln IgE Qn;;ACTIVE;1.0h(2);2.42 +76184-1;Carbon dioxide;PPres;Pt;Pulmonary artery;Qn;;PULM;2;Carbon dioxide [Partial pressure] in Pulmonary artery;pCO2 PA;;ACTIVE;2.54;2.73 +76185-8;Central apnea duration;Time;Pt;Respiratory system;Qn;;PULM;2;Central apnea duration Respiratory system;Cent apnea dur Respiratory;;ACTIVE;2.58;2.67 +76186-6;Expiratory hold time;Time;Pt;Ventilator;Qn;;PULM;2;Expiratory hold time Ventilator;Exp hold time Vent;;ACTIVE;2.58;2.69 +76187-4;Expiratory hold time setting;Time;Pt;Ventilator;Qn;;PULM;2;Expiratory hold time setting Ventilator;Exp hold time set Vent;;ACTIVE;2.58;2.69 +76188-2;Expiratory pause time;Time;Pt;Ventilator;Qn;;PULM;2;Expiratory pause time Ventilator;Exp pause time Vent;;ACTIVE;2.63;2.69 +7619-0;Poison ivy Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Poison ivy IgE Ab [Units/volume] in Serum;Poison Ivy IgE Qn;;ACTIVE;1.0h(2);2.42 +76190-8;High pressure hold time setting;Time;Pt;Ventilator;Qn;;PULM;2;High pressure hold time setting Ventilator;High press hold time set Vent;;ACTIVE;2.63;2.69 +76191-6;High pressure hold time;Time;Pt;Ventilator;Qn;;PULM;2;High pressure hold time Ventilator;High press hold time Vent;;ACTIVE;2.63;2.69 +76194-0;Inflation trigger flow;VRat;Pt;Ventilator;Qn;;PULM;2;Inflation trigger flow Ventilator;Infl trigger flow Vent;;ACTIVE;2.63;2.69 +76195-7;Gas flow;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Deprecated Gas flow Respiratory system airway;Deprecated Gas flow Airway;;DEPRECATED;2.54;2.56 +76196-5;Inflation trigger flow setting;VRat;Pt;Ventilator;Qn;;PULM;2;Inflation trigger flow setting Ventilator;Infl trigger flow set Vent;;ACTIVE;2.63;2.69 +76197-3;Breaths.multiple sigh delivered;NRat;1M;Ventilator;Qn;;PULM;2;Multiple sigh breaths delivered 1 minute Ventilator;Mult sigh breaths del 1M Vent;;ACTIVE;2.63;2.69 +76198-1;Breaths.sigh delivered;NRat;1M;Ventilator;Qn;;PULM;2;Breaths.sigh delivered 1 minute Ventilator;Breaths.sigh del 1M Vent;;ACTIVE;2.63;2.69 +76203-9;Pressure.occlusion^negative inspiratory force maneuver;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure.occlusion Respiratory system airway --negative inspiratory force maneuver;Pressure.occl NIF Airway;;ACTIVE;2.58;2.69 +76206-2;Pressure.min^on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure.min Respiratory system airway --on ventilator;Press.min on vent Airway;;ACTIVE;2.63;2.69 +7620-8;Populus nigra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Black Cottonwood IgE Ab [Units/volume] in Serum;Deprecated Black Cottonwood IgE Qn;;DEPRECATED;1.0h(2);2.69 +76210-4;Inspiratory hold time setting;Time;Pt;Ventilator;Qn;;PULM;2;Inspiratory hold time setting Ventilator;Insp hold time set Vent;;ACTIVE;2.58;2.69 +76211-2;Inspiratory hold time;Time;Pt;Ventilator;Qn;;PULM;2;Inspiratory hold time Ventilator;Insp hold time Vent;;ACTIVE;2.58;2.69 +76212-0;Intravascular;Pres;Pt;Arterial system;Qn;Invasive;BP.MOLEC;2;Invasive Blood pressure;Invasive BP;;ACTIVE;2.54;2.56 +76213-8;Intravascular diastolic;Pres;Pt;Arterial system;Qn;Invasive;BP.MOLEC;2;Invasive Diastolic blood pressure;Invasive dias BP;;ACTIVE;2.54;2.73 +76214-6;Intravascular mean;Pres;Pt;Arterial system;Qn;Invasive;BP.MOLEC;2;Invasive Mean blood pressure;Invasive mean BP;;ACTIVE;2.54;2.56 +76215-3;Intravascular systolic;Pres;Pt;Arterial system;Qn;Invasive;BP.MOLEC;2;Invasive Systolic blood pressure;Invasive sys BP;;ACTIVE;2.54;2.73 +7621-6;Poplar sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Poplar sp Ab.IgE;Deprecated Poplar IgE Qn;;DEPRECATED;1.0h(2);2.69 +76221-1;Tidal volume.inspired;Vol;Pt;Respiratory system;Qn;;PULM;2;Tidal volume.inspired;VT.inspired;;ACTIVE;2.63;2.69 +76222-9;Tidal volume^on ventilator;Vol;Pt;Ventilator;Qn;;PULM;2;Tidal volume Ventilator --on ventilator;Vt on vent Vent;;ACTIVE;2.54;2.56 +76223-7;Inflation trigger pressure;Pres;Pt;Ventilator;Qn;;PULM;2;Inflation trigger pressure Ventilator;Infl trig press Vent;;ACTIVE;2.63;2.69 +7622-4;Populus alba basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;White Poplar triggered histamine release [Units/volume] in Blood;White Poplar BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76224-5;Inflation trigger pressure setting;Pres;Pt;Ventilator;Qn;;PULM;2;Inflation trigger pressure setting Ventilator;Infl trig press set Vent;;ACTIVE;2.63;2.69 +76226-0;Inspiratory pause time setting;Time;Pt;Ventilator;Qn;;PULM;2;Inspiratory pause time setting Ventilator;Insp pause time set Vent;;ACTIVE;2.63;2.69 +76227-8;Inspiratory pause time;Time;Pt;Ventilator;Qn;;PULM;2;Inspiratory pause time Ventilator;Insp pause time Vent;;ACTIVE;2.63;2.69 +76228-6;Low pressure hold time;Time;Pt;Ventilator;Qn;;PULM;2;Low pressure hold time Ventilator;Low press hold time Vent;;ACTIVE;2.63;2.69 +76229-4;Low pressure hold time setting;Time;Pt;Ventilator;Qn;;PULM;2;Low pressure hold time setting Ventilator;Low press hold time set Vent;;ACTIVE;2.63;2.69 +7623-2;Papaver somniferum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Poppy Seed IgE Ab [Units/volume] in Serum;Poppy Seed IgE Qn;;ACTIVE;1.0h(2);2.73 +76239-3;Mixed apnea duration;Time;Pt;Respiratory system;Qn;;PULM;2;Mixed apnea duration Respiratory system;Mixed apnea dur Respiratory;;ACTIVE;2.58;2.67 +7624-0;Pork basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Pork triggered histamine release [Units/volume] in Blood;Pork BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76240-1;Pressure.occlusion;Pres;100ms;Respiratory system.airway;Qn;;PULM;2;Pressure.occlusion 100ms Respiratory system airway;Pressure.occl 100ms Airway;;ACTIVE;2.58;2.69 +76241-9;Nitric oxide gas delivered.case;Vol;Procedure dur;Gas delivery system;Qn;;PULM;2;Nitric oxide gas delivered.case [Volume] from Gas delivery system;NO gas del dur case Vol Gas DS;;ACTIVE;2.56;2.56 +76242-7;Obstructive apnea duration;Time;Pt;Respiratory system;Qn;;PULM;2;Obstructive apnea duration Respiratory system;Obstr apnea dur Respiratory;;ACTIVE;2.58;2.67 +76243-5;Oxygen.inspiratory-oxygen.expiratory;PressDiff;Pt;Airway adaptor;Qn;;PULM;2;Inspiratory oxygen - expiratory oxygen [Pressure Difference] Airway adaptor;PiO2-PeO2;;ACTIVE;2.56;2.69 +76244-3;Positive pressure phase duration;Time;Pt;Ventilator;Qn;;PULM;2;Positive pressure phase duration [Time] Ventilator;Pos press dur on vent in pos press mode;;ACTIVE;2.63;2.69 +76246-8;Pressure.positive end expiratory.intrinsic dynamic;Pres;Pt;Respiratory system;Qn;;PULM;2;Intrinsic dynamic PEEP Respiratory system;Intrinsic dyn PEEP Respiratory;;ACTIVE;2.58;2.69 +76247-6;Pressure.positive end expiratory.total;Pres;Pt;Respiratory system;Qn;;PULM;2;Total PEEP Respiratory system;Total PEEP Respiratory;;ACTIVE;2.58;2.69 +76248-4;Pressure.positive end expiratory^on ventilator;Pres;Pt;Respiratory system;Qn;;PULM;2;PEEP Respiratory system --on ventilator;PEEP on vent Respiratory;;ACTIVE;2.54;2.58 +76249-2;Expiratory pressure.max;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Maximum expiratory pressure Respiratory system airway;Max exp press Airway;;ACTIVE;2.63;2.69 +762-5;Neutrophils;NCnc;Pt;Urine;Qn;Manual count;UA;1;Neutrophils [#/volume] in Urine by Manual count;Neutrophils # Ur Manual;;ACTIVE;1.0;2.42 +76250-0;Expiratory pressure.min;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Minimum expiratory pressure Respiratory system airway;Min exp press Airway;;ACTIVE;2.63;2.69 +76251-8;Inspiratory pressure.min;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Minimum inspiratory pressure Respiratory system airway;Min insp press Airway;;ACTIVE;2.63;2.69 +76252-6;Pressure;Pres;Pt;Pleural space;Qn;;PULM;2;Pressure Pleural space;Press Pl space;;ACTIVE;2.58;2.69 +76253-4;Pressure;Pres;Pt;Cylinder.nitrous oxide;Qn;;DEVICES;2;Nitrous oxide cylinder Pressure;N2O cylinder Press;;ACTIVE;2.56;2.69 +76254-2;Pressure;Pres;Pt;Pipeline.nitrous oxide;Qn;;DEVICES;2;Nitrous oxide pipeline Pressure;N2O pipeline Press;;ACTIVE;2.56;2.69 +76255-9;Pressure;Pres;Pt;Cylinder.oxygen;Qn;;DEVICES;2;Oxygen cylinder Pressure;O2 cylinder Press;;ACTIVE;2.56;2.69 +76256-7;Pressure;Pres;Pt;Pipeline.oxygen;Qn;;DEVICES;2;Oxygen pipeline Pressure;O2 pipeline Press;;ACTIVE;2.56;2.69 +7625-7;Solanum tuberosum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Potato IgG Ab [Units/volume] in Serum;Potato IgG Qn;;ACTIVE;1.0h(2);2.73 +76257-5;Pressure;Pres;Pt;Cylinder.air;Qn;;DEVICES;2;Air cylinder Pressure;Air cylinder Press;;ACTIVE;2.56;2.69 +76258-3;Pressure;Pres;Pt;Pipeline.air;Qn;;DEVICES;2;Air pipeline Pressure;Air pipeline Press;;ACTIVE;2.56;2.69 +76259-1;Pressure.plateau^on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure.plateau Respiratory system airway --on ventilator;Press.plat on vent Airway;;ACTIVE;2.63;2.69 +76260-9;Expiratory pressure;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Expiratory pressure Respiratory system airway;Exp pressure Airway;;ACTIVE;2.63;2.69 +76263-3;Expiratory gas flow.max;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Deprecated Maximum expiratory gas flow Respiratory system airway;Deprecated PEF Airway;;DEPRECATED;2.54;2.56 +76264-1;Inspiratory gas flow;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Inspiratory gas flow Respiratory system airway;Insp gas flow Airway;;ACTIVE;2.63;2.69 +7626-5;Solanum tuberosum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Potato triggered histamine release [Units/volume] in Blood;Potato BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76265-8;Carbon dioxide production/Body surface area;VRat;Pt;Respiratory system;Qn;;PULM;2;Carbon dioxide production (VCO2)/Body surface area in Respiratory system;CO2 production/BSA Respiratory;;ACTIVE;2.56;2.56 +76266-6;Carbon dioxide production/Ideal body weight;VRat;Pt;Respiratory system;Qn;;PULM;2;Carbon dioxide production (VCO2)/Ideal body weight in Respiratory system;CO2 production/IBW Respiratory;;ACTIVE;2.56;2.58 +76267-4;Oxygen consumption/Ideal body weight;ArVRat;Pt;^Patient;Qn;;PULM;2;Oxygen consumption (VO2)/Ideal body weight [Volume Rate/Area];O2 consumption/IBW ArVRat;;ACTIVE;2.58;2.67 +76268-2;Pressure.ambient;Pres;Pt;Room;Qn;;PULM;2;Pressure.ambient Room;Press.ambient Room;;ACTIVE;2.54;2.56 +76269-0;Respiratory quotient;VRto;Pt;Respiratory system;Qn;;PULM;2;Respiratory quotient Respiratory system;Resp quot Respiratory;;ACTIVE;2.54;2.54 +76270-8;Breaths;NRat;Pt;Respiratory system;Qn;Impedance.transthoracic;PULM;2;Respiratory rate by Impedance.transthoracic;Resp rate Imped.transthoracic;;ACTIVE;2.54;2.56 +76271-6;Bias flow;VRat;Pt;Ventilator;Qn;;PULM;2;Bias flow Ventilator;Bias flow Vent;;ACTIVE;2.63;2.69 +76272-4;Bias flow setting;VRat;Pt;Ventilator;Qn;;PULM;2;Bias flow setting Ventilator;Bias flow set Vent;;ACTIVE;2.63;2.63 +7627-3;Ipomoea batatas Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sweet potato IgE Ab [Units/volume] in Serum;Sweet potato IgE Qn;;ACTIVE;1.0h(2);2.73 +76273-2;Continuous flow;VRat;Pt;Ventilator;Qn;;PULM;2;Continuous flow Ventilator;Cont flow Vent;;ACTIVE;2.63;2.69 +76274-0;Ventilation-perfusion index;VRto;Pt;Respiratory system;Qn;;PULM;2;Ventilation-perfusion index Respiratory system;VQI Respiratory;;ACTIVE;2.54;2.54 +76275-7;Inspiratory flow setting;VRat;Pt;Ventilator;Qn;;PULM;2;Inspiratory flow setting Ventilator;Insp flow set Vent;;ACTIVE;2.63;2.69 +76276-5;Continuous flow setting;VRat;Pt;Ventilator;Qn;;PULM;2;Continuous flow setting Ventilator;Cont flow set Vent;;ACTIVE;2.63;2.69 +76278-1;Body temperature;Temp;Pt;Urinary bladder;Qn;via Foley;BDYTMP.MOLEC;2;Bladder temperature via Foley;Bladder temp via Foley;;ACTIVE;2.54;2.73 +76280-7;Intramucosal pH;LsCnc;Pt;Stomach;Qn;;GI;2;Intramucosal gastric pH;Intramucosal pH Stom;;ACTIVE;2.58;2.58 +7628-1;Ipomoea batatas Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sweet potato IgG Ab [Units/volume] in Serum;Sweet potato IgG Qn;;ACTIVE;1.0h(2);2.73 +76281-5;Arrhythmia;Type;Pt;Heart;Nom;EKG;EKG.IMP;2;Type of arrhythmia on EKG;Arrhythmia type EKG;;ACTIVE;2.54;2.54 +76282-3;Heart rate.beat-to-beat;NRat;Pt;Heart;Qn;EKG;EKG.MEAS;2;Heart rate.beat-to-beat by EKG;Heart rate.btb by EKG;;ACTIVE;2.54;2.61 +76283-1;Blood flow rate;VRat;Pt;Pulmonary capillaries;Qn;;CARDIO-PULM;2;Blood flow rate Pulmonary capillaries;Bld flow rate Pulm cap;;ACTIVE;2.54;2.67 +76284-9;Intravascular;Pres;Pt;Pulmonary artery;Qn;;BP.CENT.MOLEC;2;Pulmonary artery Blood pressure;PA BP;;ACTIVE;2.54;2.54 +76285-6;Intravascular;Pres;Pt;Pulmonary capillaries;Qn;Estimated;BP.CENT.MOLEC;2;Pulmonary capillary Blood pressure;Pulm cap BP;;ACTIVE;2.54;2.54 +76286-4;Intravascular diastolic;Pres;Pt;Pulmonary capillaries;Qn;Estimated;BP.CENT.MOLEC;2;Pulmonary capillary Diastolic blood pressure;Pulm cap dias BP;;ACTIVE;2.54;2.54 +76287-2;Intravascular mean;Pres;Pt;Pulmonary capillaries;Qn;Estimated;BP.CENT.MOLEC;2;Pulmonary capillary Mean blood pressure;Pulm cap mean BP;;ACTIVE;2.54;2.54 +76288-0;Intravascular systolic;Pres;Pt;Pulmonary capillaries;Qn;Estimated;BP.CENT.MOLEC;2;Pulmonary capillary Systolic blood pressure;Pulm cap sys BP;;ACTIVE;2.54;2.54 +76295-5;Inflation phase duration;Time;Pt;Ventilator;Qn;;PULM;2;Inflation phase duration [Time] Ventilator;Infl phase dur vent timed infl;;ACTIVE;2.63;2.63 +76296-3;Leak;VRat;Pt;Ventilator airway circuit;Qn;;PULM;2;Ventilator airway circuit leakage volume;Vent away circuit leakage vol;;ACTIVE;2.54;2.54 +76297-1;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventricular Stroke volume index;LV SVI;;ACTIVE;2.54;2.54 +76298-9;Pressure;Pres;Pt;Stomach;Qn;;GI;2;Gastric pressure;Gastric press;;ACTIVE;2.54;2.54 +7629-9;Ipomoea batatas basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Sweet potato triggered histamine release [Units/volume] in Blood;Sweet potato BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76299-7;Time interval between start of doses;Time;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;Time interval between start of doses Infusion pump;Time int btwn dose start Inf pump;;ACTIVE;2.54;2.54 +76300-3;Doses.delivered;Num;RptPeriod;Infusion pump;Qn;;IO_IN.INFUS;2;Doses.delivered [#] in Reporting period Infusion pump;Doses.del RptPeriod Inf pump;;ACTIVE;2.54;2.56 +76301-1;Doses.requested;Num;RptPeriod;^Patient;Qn;;IO_IN.INFUS;2;Doses.requested [#] Reporting Period;Doses.req RptPeriod;;ACTIVE;2.54;2.56 +76302-9;Infused volume.segment;Vol;Procedure;^Patient;Qn;;IO_IN.INFUS;2;Infused volume.segment Procedure;Inf vol.seg;;ACTIVE;2.54;2.73 +76303-7;Infused volume.single container;Vol;Pt;^Patient;Qn;;IO_IN.INFUS;2;Infused volume.single container;Inf vol.single cont;;ACTIVE;2.54;2.56 +76304-5;Infused volume.total;Vol;RptPeriod;Infusion pump;Qn;;IO_IN.INFUS;2;Infused volume.total Reporting Period Infusion pump;Inf vol.tot RptPeriod Inf pump;;ACTIVE;2.54;2.56 +76305-2;Infusion dose.programmed;Mass;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;Infusion dose.programmed [Mass] Infusion pump;Inf dose.prog Inf pump;;ACTIVE;2.54;2.56 +76306-0;Infusion dose.remaining;Mass;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;Infusion dose.remaining [Mass] Infusion pump;Inf dose.remain Inf pump;;ACTIVE;2.54;2.56 +7630-7;Solanum tuberosum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Potato IgG Ab [Units/volume] in Serum;Deprecated Potato IgG Qn;;DEPRECATED;1.0h(2);2.69 +76307-8;Infusion time.programmed;Time;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;Infusion time.programmed Infusion pump;Inf time.prog Inf pump;;ACTIVE;2.54;2.56 +76308-6;Infusion time.remaining;Time;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;Infusion time.remaining Infusion pump;Inf time.remain Inf pump;;ACTIVE;2.54;2.56 +76309-4;Infusion time.remaining;Time;Pt;Infusion pump;Qn;Based on container volume;IO_IN.INFUS;2;Infusion time.remaining Infusion pump Based on container volume;Inf time.remain Based on container vol;;ACTIVE;2.54;2.56 +76310-2;Infusion volume.programmed;Vol;Procedure;Infusion pump;Qn;;IO_IN.INFUS;2;Infusion volume.programmed Procedure Infusion pump;Inf vol.prog Inf pump;;ACTIVE;2.54;2.56 +76311-0;Infusion volume.remaining;Vol;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;Infusion volume.remaining Infusion pump;Inf vol.remain Inf pump;;ACTIVE;2.54;2.56 +76312-8;PCA dose number.max;NRat;1H;Infusion pump;Qn;;IO_IN.INFUS;2;PCA dose number.max 1 hour Infusion pump;PCA dose num.max 1h nRate Inf pump;;ACTIVE;2.54;2.56 +76313-6;PCA dose volume.max;Vol;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;PCA dose volume.max Infusion pump;PCA dose vol.max Inf pump;;ACTIVE;2.54;2.56 +76314-4;PCA lockout time;Time;Pt;Infusion pump;Qn;;IO_IN.INFUS;2;PCA lockout time Infusion pump;PCA lockout time Inf pump;;ACTIVE;2.54;2.56 +7631-5;Iva axillaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Povertyweed IgE Ab [Units/volume] in Serum;Povertyweed IgE Qn;;ACTIVE;1.0h(2);2.73 +76315-1;Volume.actual;Vol;Pt;Syringe;Qn;;DEVICES;2;Syringe Volume.actual;Syringe Vol.act;;ACTIVE;2.54;2.56 +76316-9;Volume.remaining;Vol;Pt;Infusion pump;Qn;;DEVICES;2;Infusion pump Volume.remaining;Inf pump Vol.remain;;ACTIVE;2.54;2.56 +76317-7;Volume.start;Vol;Pt;Infusion pump;Qn;;DEVICES;2;Infusion pump Volume.start;Inf pump Vol.start;;ACTIVE;2.54;2.56 +76318-5;Manufacturer name;ID;Pt;Syringe;Nom;;DEVICES;2;Syringe Manufacturer name;Syringe Manufacturer name;;ACTIVE;2.54;2.56 +76319-3;Pump status;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Pump status;Inf pump Pump status;;ACTIVE;2.54;2.56 +76320-1;Expiratory gas flow;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Expiratory airway gas flow;Exp airway gas flow;;ACTIVE;2.54;2.56 +76322-7;Systolic time ratio;TRto;Pt;Heart;Qn;;CARDIO-PULM;2;Systolic time ratio;Sys time rto;;ACTIVE;2.54;2.54 +7632-3;Ligustrum vulgare Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Privet IgE Ab [Units/volume] in Serum;Privet IgE Qn;;ACTIVE;1.0h(2);2.73 +76323-5;Acceleration index;Accel;Pt;Aorta;Qn;;CARDIO-PULM;2;Aorta acceleration index;ACI;;ACTIVE;2.54;2.54 +76324-3;Alert type;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Alert type;Inf pump Alert type;;ACTIVE;2.54;2.54 +76325-0;Communication status;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Communication status;Inf pump Comm status;;ACTIVE;2.54;2.56 +76326-8;Alarm state;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Alarm state;Inf pump Alarm state;;ACTIVE;2.54;2.56 +76327-6;Alarm trigger;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Alarm trigger;Inf pump Alarm trigger;;ACTIVE;2.54;2.56 +76328-4;Alert priority;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Alert priority;Inf pump Alert priority;;ACTIVE;2.54;2.56 +76329-2;Pump mode;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Pump mode;Inf pump Pump mode;;ACTIVE;2.54;2.56 +763-3;Neutrophils.band form;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Band form neutrophils [#/volume] in Blood by Manual count;Neuts Band # Bld Manual;;ACTIVE;1.0;2.73 +76330-0;Pump mode.current;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Pump mode.current;Inf pump Pump mode.current;;ACTIVE;2.54;2.56 +7633-1;Ligustrum vulgare Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Privet IgG Ab [Units/volume] in Serum;Privet IgG Qn;;ACTIVE;1.0h(2);2.69 +76331-8;Pump mode.set;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Pump mode.set;Inf pump Pump mode.set;;ACTIVE;2.54;2.56 +76332-6;Reason pump stopped infusing;Type;Pt;Infusion pump;Nom;;DEVICES;2;Infusion pump Reason pump stopped infusing;Inf pump Reason pump stop infus;;ACTIVE;2.54;2.56 +76334-2;Inspiratory time setting;Time;Pt;Ventilator;Qn;;PULM;2;Inspiratory time setting Ventilator;Insp time set Vent;;ACTIVE;2.63;2.63 +76338-3;Porcine epidemic diarrhea virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine epidemic diarrhea virus RNA [Presence] in Specimen by NAA with probe detection;PEDv RNA Spec Ql NAA+probe;;ACTIVE;2.52;2.69 +76339-1;Porcine deltacoronavirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine deltacoronavirus RNA [Presence] in Specimen by NAA with probe detection;PDCoV RNA Spec Ql NAA+probe;;ACTIVE;2.52;2.69 +76340-9;Porcine deltacoronavirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine deltacoronavirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PDCoV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.52;2.69 +76341-7;Protoporphyrin;SCnc;Pt;Bld;Qn;;CHEM;1;Protoporphyrin [Moles/volume] in Blood;Protopor Bld-sCnc;;ACTIVE;2.52;2.52 +76342-5;PROMIS short form - fatigue 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - fatigue 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76343-3;PROMIS short form - emotional distress - depression 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional distress - depression 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +76344-1;PROMIS short form - emotional distress - anxiety 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional distress - anxiety 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +76345-8;I have trouble starting things because I am tired during the past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble starting things because I am tired during the past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76346-6;Microorganism identified;Prid;Pt;Isolate;Nom;MS.MALDI-TOF;MICRO;1;Microorganism identified in Isolate by MS.MALDI-TOF;Microorganism Islt MS.MALDI-TOF;;ACTIVE;2.52;2.73 +76347-4;Dehydroepiandrosterone sulfate/cortisol;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Dehydroepiandrosterone sulfate (DHEA-S)/Cortisol [Molar ratio] in Serum or Plasma;DHEA-S/Cortis SerPl-sRto;;ACTIVE;2.52;2.52 +76348-2;Pregnancy associated plasma protein A^^adjusted;MoM;Pt;Ser/Plas;Qn;;CHEM;1;Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma;PAPP-A adj MoM SerPl;;ACTIVE;2.52;2.73 +7634-9;Prune Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Prune IgE Ab [Units/volume] in Serum;Prune IgE Qn;;ACTIVE;1.0h(2);2.73 +76349-0;clonazePAM;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;clonazePAM [Mass/mass] in Meconium by Confirmatory method;clonazePAM Mec Cfm-mCnt;;ACTIVE;2.52;2.52 +76350-8;Other cells/100 leukocytes;NFr;Pt;Body fld;Qn;;HEM/BC;1;Other cells/100 leukocytes in Body fluid;Other cells/leuk NFr Fld;;ACTIVE;2.52;2.58 +76351-6;Methotrexate polyglutamates;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Methotrexate polyglutamates [Moles/volume] in Red Blood Cells;MTX-PGs RBC-sCnc;;ACTIVE;2.52;2.73 +76352-4;Testosterone/Cortisol;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Testosterone/Cortisol [Molar ratio] in Serum or Plasma;Testost/Cortis SerPl-sRto;;ACTIVE;2.52;2.52 +76353-2;Licensed nursing staff;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff # [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76354-0;Nurse demographics per unit or service panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nurse demographics per unit or service panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76355-7;Employment position panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Employment position panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7635-6;Psyllium seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Psyllium seed IgE Ab [Units/volume] in Serum;Psyllium seed IgE Qn;;ACTIVE;1.0h(2);2.42 +76356-5;Nurse employment position;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Nurse employment position Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76357-3;Licensed nursing staff.employment position;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by employment position [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76358-1;Licensed nursing staff.employment position/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff by employment position/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76359-9;Licensed nursing staff & sex panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Licensed nursing staff and sex panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76360-7;Licensed nursing staff.sex;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by sex [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76361-5;Licensed nursing staff.sex/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.sex/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76362-3;Race or ethnicity panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Race or ethnicity panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76363-1;Licensed nursing staff.race or ethnicity;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by race or ethnicity [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7636-4;Pullularia pullulans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Pullularia pullulans IgE Ab [Units/volume] in Serum;Deprecated P pullulans IgE Qn;;DEPRECATED;1.0h(2);2.69 +76364-9;Licensed nursing staff.race or ethnicity/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.race or ethnicity/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76365-6;Age category panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Age category panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76366-4;Nurse age range;Type;Pt;Provider;Ord;NMMDS;SURVEY.NMMDS;4;Nurse age range Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76367-2;Licensed nursing staff.age range;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by age range [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76368-0;Licensed nursing staff.age range/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.age range/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76369-8;Entry level nursing degree panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Entry level nursing degree panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76370-6;Entry level nursing degree;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Entry level nursing degree Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76371-4;Licensed nursing staff.entry level nursing degree;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by entry level nursing degree [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7637-2;Pullularia sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pullularia sp IgE Ab [Units/volume] in Serum;Pullaria IgE Qn;;ACTIVE;1.0h(2);2.73 +76372-2;Licensed nursing staff.entry level nursing degree/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.entry level nursing degree/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76373-0;Highest level of education in a nursing degree panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Highest level of education in a nursing degree panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76374-8;Highest level of education in a nursing degree;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Highest level of education in a nursing degree Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76375-5;Licensed nursing staff.highest level of education in a nursing degree;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by highest level of education in a nursing degree [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76376-3;Licensed nursing staff.highest level of education in a nursing degree/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.highest level of education in a nursing degree/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76377-1;Highest level of education in a non-nursing degree panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Highest level of education in non-nursing degree panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76378-9;Highest level of education in a non-nursing degree;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Highest level of education in a non-nursing degree Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76379-7;Licensed nursing staff.highest level of education in a non-nursing degree;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by highest level of education in a non-nursing degree [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7638-0;Pullularia sp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pullularia sp IgG Ab [Units/volume] in Serum;Pullaria IgG Qn;;ACTIVE;1.0h(2);2.73 +76380-5;Licensed nursing staff.highest level of education in a non-nursing degree/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.highest level of education in a non-nursing degree/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76381-3;Nursing license type panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing license type panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76382-1;Primary nursing license type;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Primary nursing license type Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76383-9;Licensed nursing staff.primary nursing license type;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by primary nursing license type [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76384-7;Licensed nursing staff.primary nursing license type/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.primary nursing license type/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76385-4;Nursing certification panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing certification panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.63 +76386-2;Nursing certification;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Nursing certification Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76387-0;Licensed nursing staff.nursing certification;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by nursing certification [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76388-8;Licensed nursing staff.nursing certification/Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff.nursing certification/Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76389-6;Employment specialty panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Employment specialty panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76390-4;Nurse employment specialty;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Nurse employment specialty Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76391-2;Licensed nursing staff.employment specialty;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing personnel [#] by employment specialty [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76392-0;Licensed nursing staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Licensed nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76393-8;National provider indentifier panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;National provider indentifier panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76394-6;Registered nurse staff;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Registered nurse staff # [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76395-3;Registered nurse staff with national provider ID;Num;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Registered nurse personnel [#] with a national provider ID [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76396-1;Registered nurse staff with national provider ID/Registered nurse staff;NFr;Pt;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Registered nurse staff with national provider ID/Registered nurse staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76397-9;Lymph node involvement;Find;Pt;Lymph node;Ord;;PATH;1;Lymph node involvement;LN involved LN Ql;;ACTIVE;2.52;2.73 +7639-8;Chrysanthemum cinerariifolium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pyrethrum IgE Ab [Units/volume] in Serum;Pyrethrum IgE Qn;;ACTIVE;1.0h(2);2.73 +76398-7;Provider has a national provider ID;Find;Pt;Provider;Ord;;SURVEY.NMMDS;4;Provider has a national provider ID;;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76399-5;Troponin I.cardiac;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;CHEM;1;Troponin I.cardiac [Presence] in Serum, Plasma or Blood by Rapid immunoassay;Troponin I SerPlBld Ql IA.rapid;;ACTIVE;2.52;2.56 +76400-1;Fetal delivery information;Find;Pt;^Patient;Doc;US standard report of fetal death;SURVEY.CDC;4;Fetal delivery information Document [US Standard Report of Fetal Death];;;ACTIVE;2.52;2.63 +76401-9;Albumin/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Albumin/Creatinine [Ratio] in 24 hour Urine;Albumin/Creat 24h Ur-Rto;;ACTIVE;2.52;2.52 +76402-7;Myelocytes;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Myelocytes [#] in Body fluid by Manual count;Myelocytes Fld Manual;;ACTIVE;2.52;2.52 +76403-5;Blasts;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Blasts [#] in Body fluid by Manual count;Blasts Fld Manual;;ACTIVE;2.52;2.52 +76404-3;Promyelocytes;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Promyelocytes [#] in Body fluid by Manual count;Promyelocytes Fld Manual;;ACTIVE;2.52;2.52 +76405-0;Metamyelocytes;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Metamyelocytes [#] in Body fluid by Manual count;Metamyelocytes Fld Manual;;ACTIVE;2.52;2.52 +7640-6;Chrysanthemum cinerariifolium basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Pyrethrum triggered histamine release [Units/volume] in Blood;Pyrethrum BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76406-8;Basophils;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Basophils [#] in Body fluid by Manual count;Basophils Fld Manual;;ACTIVE;2.52;2.73 +76407-6;Eosinophils;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Eosinophils [#] in Body fluid by Manual count;Eosinophil Fld Manual;;ACTIVE;2.52;2.73 +76408-4;Monocytes+Macrophages;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages [#] in Body fluid by Manual count;Monos+Macros Fld Manual;;ACTIVE;2.52;2.52 +76409-2;Lymphocytes;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Lymphocytes [#] in Body fluid by Manual count;Lymphocytes Fld Manual;;ACTIVE;2.52;2.52 +764-1;Neutrophils.band form/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Band form neutrophils/100 leukocytes in Blood by Manual count;Neuts Band/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +76410-0;Neutrophils.band form;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Band form neutrophils [#] in Body fluid by Manual count;Neuts Band Fld Manual;;ACTIVE;2.52;2.54 +76411-8;Neutrophils;Num;Pt;Body fld;Qn;Manual count;HEM/BC;1;Neutrophils [#] in Body fluid by Manual count;Neutrophils Fld Manual;;ACTIVE;2.52;2.52 +76412-6;Sheep prion protein codon 141;Type;Pt;Bld;Nom;Genotyping;MOLPATH;1;Sheep prion protein codon 141 [Type] in Blood by Genotype method;Sheep PrP codon 141 Bld Genotyp;;ACTIVE;2.52;2.52 +76413-4;Sheep prion protein codon 112;Type;Pt;Bld;Nom;Genotyping;MOLPATH;1;Sheep prion protein codon 112 [Type] in Blood by Genotype method;Sheep PrP codon 112 Bld Genotyp;;ACTIVE;2.52;2.52 +7641-4;Chrysothamnus nauseosus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit Bush IgE Ab [Units/volume] in Serum;Rabbit Bush IgE Qn;;ACTIVE;1.0h(2);2.73 +76414-2;Sheep prion protein codon 136;Type;Pt;Bld;Nom;Genotyping;MOLPATH;1;Sheep prion protein codon 136 [Type] in Blood by Genotype method;Sheep PrP codon 136 Bld Genotyp;;ACTIVE;2.52;2.52 +76415-9;Sheep prion protein codon 154;Type;Pt;Bld;Nom;Genotyping;MOLPATH;1;Sheep prion protein codon 154 [Type] in Blood by Genotype method;Sheep PrP codon 154 Bld Genotyp;;ACTIVE;2.52;2.52 +76416-7;Sheep prion protein codon 171;Type;Pt;Bld;Nom;Genotyping;MOLPATH;1;Sheep prion protein codon 171 [Type] in Blood by Genotype method;Sheep PrP codon 171 Bld Genotyp;;ACTIVE;2.52;2.52 +76417-5;First Name;Pn;Pt;Provider;Nom;;ADMIN;2;Provider First name;Provider First name;;ACTIVE;2.52;2.66 +76418-3;Middle Initial;Pn;Pt;Provider;Nom;;ADMIN;2;Provider Middle Initial;Provider MI;;ACTIVE;2.52;2.73 +76419-1;Last name;Pn;Pt;Provider;Nom;;ADMIN;2;Provider Last name;Provider Last name;;ACTIVE;2.52;2.66 +76420-9;Graduation year;Date;Pt;Provider;Qn;;ADMIN;2;Provider Graduation year;Provider Grad year;;ACTIVE;2.52;2.66 +76421-7;Physical therapy provider type;Type;Pt;Provider;Nom;APTA;APTA;2;Physical therapy provider type APTA;PT provider type APTA;;ACTIVE;2.52;2.54 +7642-2;Rabbit meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit meat IgE Ab [Units/volume] in Serum;Rabbit Meat IgE Qn;;ACTIVE;1.0h(2);2.73 +76422-5;Physical therapy provider specialty;Type;Pt;Provider;Nom;APTA;APTA;2;Physical therapy provider specialty APTA;PT provider specialty APTA;;ACTIVE;2.52;2.54 +76423-3;Date of first visit;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of first visit;Date of first visit;;ACTIVE;2.52;2.66 +76425-8;Date of onset;Date;Pt;^Patient;Qn;Reported;H&P.HX;2;Date of onset - Reported;Date of onset Reported;;ACTIVE;2.52;2.73 +76426-6;Start date for episode of care;Date;Pt;^Patient;Qn;;APTA;2;Start date for episode of care;Start date episode of care;;ACTIVE;2.52;2.56 +76427-4;Visit date;Date;Pt;^Patient;Qn;;H&P.HX;2;Visit date;Visit date;;ACTIVE;2.52;2.66 +76428-2;Visit charge;Num;Pt;^Patient;Qn;;ADMIN.PATIENT;2;Visit charge in dollars;Visit charge;;ACTIVE;2.52;2.66 +76429-0;Physical therapy discharge date;Date;Pt;^Patient;Qn;;H&P.HX;2;Physical therapy Discharge date;PT Discharge date;;ACTIVE;2.52;2.7 +7643-0;Raphanus sativus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Radish IgE Ab [Units/volume] in Serum;Radish IgE Qn;;ACTIVE;1.0h(2);2.73 +76430-8;CPT units;Num;Pt;^Patient;Qn;;ADMIN.PATIENT;2;CPT units [#];CPT units;;ACTIVE;2.52;2.66 +76431-6;Physical therapy location registry ID;ID;Pt;Facility;Nom;;APTA;2;Physical therapy location registry ID;PT loc registry ID;;ACTIVE;2.52;2.54 +76432-4;Episode of care unique identifier;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Episode of care unique identifier;Episode of care unique ID;;TRIAL;2.52;2.66 +76433-2;Physical therapy organization registry ID;ID;Pt;Organization;Nom;;APTA;2;Physical therapy organization registry ID;PT org registry ID;;ACTIVE;2.52;2.54 +76434-0;Physical therapist registry ID;ID;Pt;Provider;Nom;;APTA;2;Physical therapist registry ID;Phys therapist reg ID;;ACTIVE;2.52;2.54 +76435-7;Identifier;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Patient identifier;Pt ID;;ACTIVE;2.52;2.66 +76437-3;Primary insurance;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Primary insurance;Primary insurance;;ACTIVE;2.52;2.66 +76438-1;Secondary insurance;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Secondary insurance;Secondary insurance;;ACTIVE;2.52;2.66 +76439-9;Physical therapy referral source;Type;Pt;^Patient;Nom;APTA;APTA;2;Physical therapy referral source APTA;PT referral source APTA;;ACTIVE;2.52;2.54 +76440-7;Care transfer location;Type;Pt;^Patient;Nom;APTA;APTA;2;Care transfer location APTA;Care transfer loc APTA;;ACTIVE;2.52;2.54 +76441-5;Medical history relevant to physical therapy treatment;Type;Pt;^Patient;Nom;;APTA;2;Medical history relevant to physical therapy treatment;Med hx relevant to PT treatment;;ACTIVE;2.52;2.54 +76442-3;Primary health condition;Find;Pt;^Patient;Nom;;APTA;2;Primary health condition;Primary health cond;;ACTIVE;2.52;2.64 +76444-9;Body function ICF code;Find;Pt;^Patient;Nom;;APTA;2;Body function ICF code;Body function ICF code;;ACTIVE;2.52;2.61 +76445-6;Body structure ICF code;Find;Pt;^Patient;Nom;;APTA;2;Body structure ICF code;Body structure ICF code;;ACTIVE;2.52;2.61 +76446-4;Activities and participation ICF code;Find;Pt;^Patient;Nom;;APTA;2;Activities and participation ICF code;Activities and participation ICF code;;ACTIVE;2.52;2.61 +76447-2;General Health;Find;Pt;^Patient;Ord;;H&P.HX;2;General health;General health;;ACTIVE;2.52;2.73 +7644-8;Raphanus sativus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Radish IgG Ab [Units/volume] in Serum;Radish IgG Qn;;ACTIVE;1.0h(2);2.73 +76448-0;CPT billing code;Type;Pt;^Patient;Nom;;APTA;2;CPT billing code;CPT billing code;;ACTIVE;2.52;2.56 +76449-8;Primary functional limitation;Find;Pt;^Patient;Nom;;APTA;2;Primary functional limitation;Primary func limit;;ACTIVE;2.52;2.54 +76450-6;Current severity of limitation;Find;Pt;^Patient;Ord;;APTA;2;Current severity of limitation;Curr severity of limit;;ACTIVE;2.52;2.54 +76451-4;Projected goal of limitation;Find;Pt;^Patient;Ord;;APTA;2;Projected goal of limitation;Proj goal of limit;;ACTIVE;2.52;2.54 +76452-2;APTA Registry patient registration panel;-;-;^Patient;-;;PANEL.APTA;2;APTA Registry patient registration panel;APTA Reg pt reg pnl;;ACTIVE;2.52;2.56 +76453-0;Physical therapy initial visit panel;-;Pt;^Patient;-;;PANEL.APTA;2;Physical therapy initial visit panel;PT init visit Pnl;;ACTIVE;2.52;2.56 +76454-8;Physical therapy subsequent visit panel;-;Pt;^Patient;-;;PANEL.APTA;2;Physical therapy subsequent visit panel;PT sub visit Pnl;;ACTIVE;2.52;2.56 +7645-5;Ambrosia ambrosioides Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Canyon Ragweed IgE Ab [Units/volume] in Serum;Canyon Ragweed IgE Qn;;ACTIVE;1.0h(2);2.42 +76455-5;Physical therapy reexamination panel;-;Pt;^Patient;-;;PANEL.APTA;2;Physical therapy reexamination panel;PT reexam pnl;;ACTIVE;2.52;2.64 +76456-3;Physical therapy conclusion of care panel;-;Pt;^Patient;-;;PANEL.APTA;2;Physical therapy conclusion of care panel;PT concl of care Pnl;;ACTIVE;2.52;2.56 +76457-1;Physical therapy provider residency or fellowship;Type;Pt;Provider;Nom;APTA;APTA;2;Physical therapy provider residency or fellowship APTA;PT provider residency or fellowship APTA;;ACTIVE;2.52;2.54 +76458-9;Email address;EmailAddr;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient Email address;Patient Email address;;ACTIVE;2.52;2.66 +76459-7;Physical therapy billing diagnosis code;Type;Pt;^Patient;Nom;;APTA;2;Physical therapy billing diagnosis code;PT billing dx code;;ACTIVE;2.52;2.54 +76460-5;Physical Activity;Find;Pt;^Patient;Ord;APTA;APTA;2;Physical activity APTA;Physical Activity APTA;;ACTIVE;2.52;2.54 +76462-1;Reason for discharge;Find;Pt;^Patient;Nom;APTA;APTA;2;Reason for discharge APTA;Reason for discharge APTA;;ACTIVE;2.52;2.54 +7646-3;Ambrosia elatior Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common Ragweed IgG Ab [Units/volume] in Serum;Common Ragweed IgG Qn;;ACTIVE;1.0h(2);2.73 +76463-9;APTA Registry provider data panel;-;-;Provider;-;;PANEL.APTA;2;APTA Registry provider data panel;APTA Reg prov data panel;;ACTIVE;2.52;2.56 +76464-7;American Physical Therapy Association Registry panel;-;Pt;Organization;-;;PANEL.APTA;2;American Physical Therapy Association registry panel;APTA registry panel;;ACTIVE;2.52;2.66 +76465-4;Surgical history relevant to physical therapy ICD9 diagnosis code;Type;Pt;^Patient;Nom;;APTA;2;Deprecated Surgical history relevant to physical therapy ICD9 diagnosis code;Deprecated Surg hx relevant to PT ICD9 d;;DEPRECATED;2.52;2.54 +76466-2;Surgical history relevant to physical therapy ICD9 procedure code;Type;Pt;^Patient;Nom;;APTA;2;Deprecated Surgical history relevant to physical therapy ICD9 treatment code;Deprecated Surg hx relevant to PT ICD9 t;;DEPRECATED;2.52;2.54 +76467-0;Surgical history relevant to physical therapy treatment;Type;Pt;^Patient;Nom;;APTA;2;Surgical history relevant to physical therapy treatment;Surg hx relevant to PT tx;;ACTIVE;2.52;2.56 +76468-8;National provider ID;ID;Pt;Organization;Nom;;ADMIN.ID;2;Organization NPI;Organization NPI;;ACTIVE;2.54;2.66 +76469-6;Name;ID;Pt;Organization;Nom;;ADMIN;2;Organization name;Organization Name;;ACTIVE;2.54;2.66 +76470-4;Federal employer tax ID;ID;Pt;Organization;Nom;;ADMIN.ID;2;Organization federal tax ID;Federal employer tax ID Organization;;ACTIVE;2.54;2.69 +7647-1;Ambrosia dumosa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Desert Ragweed IgE Ab [Units/volume] in Serum;Desert Ragweed IgE Qn;;ACTIVE;1.0h(2);2.73 +76471-2;Organization episode of care unique identifier;ID;Pt;^Patient;Nom;;ADMIN.ID;2;Organization episode of care unique identifier;Organization EOC unique ID;;ACTIVE;2.52;2.66 +76472-0;Other health condition;Find;Pt;^Patient;Nom;;APTA;2;Other health condition;Other health condition;;ACTIVE;2.52;2.64 +76473-8;APTA Registry patient episode of care panel;-;-;^Patient;-;;PANEL.APTA;2;APTA Registry patient episode of care panel;APTA Reg pt EOC pnl;;ACTIVE;2.52;2.63 +76474-6;Ghrelin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ghrelin [Mass/volume] in Serum or Plasma;Ghrelin SerPl-mCnc;;ACTIVE;2.52;2.68 +76475-3;Cortisone.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisone free [Moles/volume] in Serum or Plasma;Cortisone free SerPl-sCnc;;ACTIVE;2.52;2.52 +76476-1;Heart rate;NRat;Pt;Heart;Qn;Impedance.transthoracic;HRTRATE.MOLEC;2;Heart rate by Transthoracic impedance;Heart rate by transth imped;;ACTIVE;2.58;2.58 +76477-9;Heart rate;NRat;Pt;XXX;Qn;Noninvasive;PULM;2;Heart rate by Noninvasive;Heart rate Noninvasive;;ACTIVE;2.54;2.54 +76478-7;Acetylcholinesterase panel;-;Pt;Amnio fld;-;;PANEL.CHEM;1;Acetylcholinesterase panel - Amniotic fluid;AChE Pnl Amn;;ACTIVE;2.52;2.52 +76479-5;Acetylcholinesterase;Imp;Pt;Amnio fld;Nar;;CHEM;1;Acetylcholinesterase [Interpretation] in Amniotic fluid Narrative;AChE Amn-Imp;;ACTIVE;2.52;2.73 +76480-3;Albumin;SCnc;Pt;CSF;Qn;;CHEM;1;Albumin [Moles/volume] in Cerebral spinal fluid;Albumin CSF-sCnc;;ACTIVE;2.52;2.52 +76481-1;Alpha 1 antitrypsin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha 1 antitrypsin [Moles/volume] in Serum or Plasma;A1AT SerPl-sCnc;;ACTIVE;2.52;2.52 +76482-9;Apolipoprotein B;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B [Moles/volume] in Serum or Plasma;Apo B SerPl-sCnc;;ACTIVE;2.52;2.52 +76483-7;Apolipoprotein A-I;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein A-I [Moles/volume] in Serum or Plasma;Apo A-I SerPl-sCnc;;ACTIVE;2.52;2.52 +76484-5;Beta-2-Microglobulin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-2-Microglobulin [Moles/volume] in Serum or Plasma;B2 Microglob SerPl-sCnc;;ACTIVE;2.52;2.52 +76485-2;C reactive protein;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;C reactive protein [Moles/volume] in Serum or Plasma;CRP SerPl-sCnc;;ACTIVE;2.52;2.68 +76486-0;C reactive protein;SCnc;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;C reactive protein [Moles/volume] in Serum or Plasma by High sensitivity method;CRP SerPl HS-sCnc;;ACTIVE;2.52;2.68 +76487-8;IgA;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgA [Moles/volume] in Serum or Plasma;IgA SerPl-sCnc;;ACTIVE;2.52;2.52 +76488-6;IgE;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;IgE [Mass/volume] in Serum or Plasma by Immunoassay;IgE SerPl IA-mCnc;;ACTIVE;2.52;2.56 +7648-9;Franseria acanthicarpa basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;False ragweed triggered histamine release [Units/volume] in Blood;False ragweed BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76489-4;IgG;SCnc;Pt;CSF;Qn;;CHEM;1;IgG [Moles/volume] in Cerebral spinal fluid;IgG CSF-sCnc;;ACTIVE;2.52;2.52 +76490-2;IgG;SCnc;Pt;Urine;Qn;;CHEM;1;IgG [Moles/volume] in Urine;IgG Ur-sCnc;;ACTIVE;2.52;2.52 +76491-0;IgM;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgM [Moles/volume] in Serum or Plasma;IgM SerPl-sCnc;;ACTIVE;2.52;2.52 +76492-8;Amphetamine+Methamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Amphetamine+Methamphetamine [Presence] in Urine by Screen method;Amphet+Methamphet Ur Ql Scn;;ACTIVE;2.52;2.56 +76493-6;Nitrazepam;SCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Nitrazepam [Moles/volume] in Gastric fluid;Nitrazepam Gast-sCnc;;ACTIVE;2.52;2.52 +76494-4;Tacrolimus;SCnc;Pt;Bld;Qn;IA;DRUG/TOX;1;Tacrolimus [Moles/volume] in Blood by Immunoassay;Tacrolimus Bld IA-sCnc;;ACTIVE;2.52;2.56 +76495-1;Titanium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Titanium [Moles/volume] in Blood;Titanium Bld-sCnc;;ACTIVE;2.52;2.58 +76496-9;Complement C4;SCnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4 [Moles/volume] in Serum or Plasma;C4 SerPl-sCnc;;ACTIVE;2.52;2.52 +7649-7;Ambrosia trifida basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Giant Ragweed triggered histamine release [Units/volume] in Blood;Giant Ragweed BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76497-7;Polymorphonuclear cells;Num;Pt;CSF;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells [#] in Cerebral spinal fluid by Manual count;Polys CSF Manual;;ACTIVE;2.52;2.52 +76498-5;Cervical cells.overexpressing HPV E6+E7 mRNA/cervical cells;NFr;Pt;Cvx;Qn;Flow cytometry;MICRO;1;Cervical cells.overexpressing HPV E6+E7 mRNA/cervical cells by Flow cytometry (FC);Cvx cel HPVE6+E7mRNA/Cvx cel FC-NFr;;ACTIVE;2.52;2.73 +76499-3;Humiliation, Afraid, Rape, and Kick questionnaire;-;Pt;^Patient;-;HARK;PANEL.SURVEY.HARK;4;Humiliation, Afraid, Rape, and Kick questionnaire [HARK];;;ACTIVE;2.52;2.52 +76500-8;Within the last Y, have you been humiliated or emotionally abused in other ways by your partner or ex-partner;Find;1Y;^Patient;Ord;;SURVEY.HARK;4;Within the last year, have you been humiliated or emotionally abused in other ways by your partner or ex-partner;;;ACTIVE;2.52;2.7 +76501-6;Within the last Y, have you been afraid of your partner or ex-partner;Find;1Y;^Patient;Ord;;SURVEY.HARK;4;Within the last year, have you been afraid of your partner or ex-partner;;;ACTIVE;2.52;2.7 +76502-4;Within the last Y, have you been raped or forced to have any kind of sexual activity by your partner or ex-partner;Find;1Y;^Patient;Ord;;SURVEY.HARK;4;Within the last year, have you been raped or forced to have any kind of sexual activity by your partner or ex-partner;;;ACTIVE;2.52;2.7 +76503-2;Within the last Y, have you been kicked, hit, slapped, or otherwise physically hurt by your partner or ex-partner;Find;1Y;^Patient;Ord;;SURVEY.HARK;4;Within the last year, have you been kicked, hit, slapped, or otherwise physically hurt by your partner or ex-partner;;;ACTIVE;2.52;2.7 +76504-0;Total score;Score;Pt;^Patient;Qn;HARK;SURVEY.HARK;4;Total score [HARK];;;ACTIVE;2.52;2.52 +7650-5;Ambrosia elatior Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Common Ragweed IgE Ab [Units/volume] in Serum;Deprecated Common Ragweed IgE Qn;;DEPRECATED;1.0h(2);2.69 +76505-7;Highest pressure injury stage;Find;Pt;^Patient;Nom;NPUAP;H&P.HX;2;Highest pressure ulcer stage NPUAP;Highest press ulcer stage NPUAP;;ACTIVE;2.52;2.73 +76506-5;Social connection and isolation panel;-;Pt;^Patient;-;;PANEL.SURVEY.NHANES;4;Social connection and isolation panel;;;ACTIVE;2.52;2.52 +76508-1;In a typical W, how many times do you talk on the telephone with family, friends, or neighbors;NRat;Pt;^Patient;Qn;NHANES III;SURVEY.NHANES;4;In a typical week, how many times do you talk on the telephone with family, friends, or neighbors [NHANES III];;;ACTIVE;2.52;2.52 +76509-9;How often do you get together with friends or relatives;NRat;Pt;^Patient;Qn;NHANES III;SURVEY.NHANES;4;How often do you get together with friends or relatives [NHANES III];;;ACTIVE;2.52;2.52 +76510-7;How often do you attend church or religious services;NRat;Pt;^Patient;Qn;NHANES;SURVEY.NHANES;4;How often do you attend church or religious services [NHANES];;;ACTIVE;2.52;2.52 +76511-5;Do you belong to any clubs or organizations such as church groups unions, fraternal or athletic groups, or school groups;Find;Pt;^Patient;Ord;NHANES III;SURVEY.NHANES;4;Do you belong to any clubs or organizations such as church groups unions, fraternal or athletic groups, or school groups [NHANES III];;;ACTIVE;2.52;2.52 +76512-3;Social isolation score;Score;Pt;^Patient;Qn;NHANES;SURVEY.NHANES;4;Social isolation score [NHANES];;;ACTIVE;2.52;2.58 +7651-3;Ambrosia elatior Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Common Ragweed IgG Ab [Units/volume] in Serum;Deprecated Common Ragweed IgG Qn;;DEPRECATED;1.0h(2);2.69 +76513-1;How hard is it for you to pay for the very basics like food, housing, medical care, and heating;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;How hard is it for you to pay for the very basics like food, housing, medical care, and heating;;;ACTIVE;2.52;2.7 +76514-9;Study observation.general;Find;Pt;^Fetus;Nar;Diagnostic imaging;OB.US;2;Fetal Narrative Study observation general Diagnostic imaging;Dx Imaging Fetus Study;;ACTIVE;2.52;2.63 +76515-6;Whether requested procedure is appropriate;Find;Pt;^Patient;Ord;;CLIN;2;Whether requested procedure is appropriate;Whether procedure is appropriate;;ACTIVE;2.52;2.68 +76516-4;Gestational age^at birth;Time;Pt;^Patient;Qn;;ADMIN.PATIENT.DEMOG;2;Gestational age--at birth;GA--@ birth;;ACTIVE;2.52;2.66 +76517-2;Premature infant;Find;Pt;^Patient;Ord;;H&P.HX;2;Premature infant;Prem infant;;ACTIVE;2.52;2.66 +76519-8;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;Continuous;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Continuous;LV Output Cont;;ACTIVE;2.54;2.54 +76520-6;Transmission.infrared;AFr;Pt;BldA;Qn;Pulse oximetry;CARDIO-PULM;2;Transmission.infrared Arterial blood Pulse oximetry;Transmission.infrared % BldA PulseOx;;ACTIVE;2.54;2.54 +7652-1;Ambrosia elatior basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Common Ragweed triggered histamine release [Units/volume] in Blood;Common Ragweed BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76521-4;Transmission.red;AFr;Pt;BldA;Qn;Pulse oximetry;CARDIO-PULM;2;Transmission.red Arterial blood Pulse oximetry;Transmission.red % BldA PulseOx;;ACTIVE;2.54;2.54 +76522-2;Transmission;AFr;Pt;BldA;Qn;Pulse oximetry;CARDIO-PULM;2;Transmission Arterial blood Pulse oximetry;Transmission % BldA PulseOx;;ACTIVE;2.54;2.54 +76523-0;Plethysmogram;AFr;Pt;BldA;Qn;Pulse oximetry;CARDIO-PULM;2;Plethysmogram Arterial blood Pulse oximetry;Pleth % BldA PulseOx;;ACTIVE;2.54;2.54 +76524-8;Acetone;SCnc;Pt;Bld;Qn;;CHEM;1;Acetone [Moles/volume] in Blood;Acetone Bld-sCnc;;ACTIVE;2.52;2.52 +76525-5;Thoracic fluid conductivity;FldConduct;Pt;Chest;Qn;;CARDIO-PULM;2;Thoracic fluid conductivity [Fluid Conductance] Chest;Thor fl conductivity Chest;;ACTIVE;2.54;2.54 +76526-3;Breaths^on ventilator;NRat;Pt;Respiratory system;Qn;Carbon dioxide measurement;PULM;2;Ventilation rate by Carbon dioxide measurement;Vent rate by CO2 meas;;ACTIVE;2.54;2.73 +76527-1;Work/Body surface area;ArEnrg;Pt;Heart.ventricle.left;Qn;NI-ICG;HEMODYN.MOLEC;2;Left ventricular Work/Body surface area [Energy/Area] by Non-invasive impedance cardiography (NI-ICG);LV Work/BSA NI-ICG;;ACTIVE;2.54;2.54 +76528-9;Breaths.spontaneous;NRat;Pt;Respiratory system;Qn;;PULM;2;Breath rate spontaneous;Breaths.spontaneous;;ACTIVE;2.65;2.65 +76529-7;Pressure;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure Respiratory system airway;Press Airway;;ACTIVE;2.54;2.56 +76530-5;Pressure.mean^on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Mean pressure Respiratory system airway --on ventilator;Mean Pres on vent Airway;;ACTIVE;2.63;2.63 +76531-3;Pressure.max^on ventilator;Pres;Pt;Respiratory system.airway;Qn;;PULM;2;Pressure.max Respiratory system airway --on ventilator;Press.max on vent Airway;;ACTIVE;2.63;2.63 +76532-1;Cuff pressure;Pres;Pt;Blood pressure device;Qn;;DEVICES;2;Blood pressure device Cuff pressure;BP device Cuff press;;ACTIVE;2.54;2.54 +76533-9;Intravascular;Pres;Pt;Arterial system;Qn;Noninvasive;BP.MOLEC;2;Blood pressure by Noninvasive;BP by Noninvasive;;ACTIVE;2.54;2.54 +76534-7;Intravascular systolic;Pres;Pt;Arterial system;Qn;Noninvasive;BP.MOLEC;2;Systolic blood pressure by Noninvasive;BP sys by Noninvasive;;ACTIVE;2.54;2.73 +76535-4;Intravascular diastolic;Pres;Pt;Arterial system;Qn;Noninvasive;BP.MOLEC;2;Diastolic blood pressure by Noninvasive;BP dias by Noninvasive;;ACTIVE;2.54;2.73 +76536-2;Intravascular mean;Pres;Pt;Arterial system;Qn;Noninvasive;BP.MOLEC;2;Mean blood pressure by Noninvasive;BP mean by Noninvasive;;ACTIVE;2.54;2.54 +76537-0;Cuff pressure.mean;Pres;Pt;Blood pressure device;Qn;;DEVICES;2;Blood pressure device Cuff pressure.mean;BP device Cuff press.mean;;ACTIVE;2.54;2.54 +76538-8;Cuff pressure.systolic;Pres;Pt;Blood pressure device;Qn;;DEVICES;2;Blood pressure device Cuff pressure.systolic;BP device Cuff press.sys;;ACTIVE;2.54;2.54 +7653-9;Ambrosia elatior+Ambrosia trifida Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Short+Giant Ragweed IgG Ab [Units/volume] in Serum;Short+Giant Ragweed IgG Qn;;ACTIVE;1.0h(2);2.69 +76539-6;Cuff pressure.diastolic;Pres;Pt;Blood pressure device;Qn;;DEVICES;2;Blood pressure device Cuff pressure.diastolic;BP device Cuff press.dias;;ACTIVE;2.54;2.54 +76540-4;Pathology diagnosis ICD code;Prid;Pt;^Patient;Nom;;PATH;1;Pathology dx ICD code [Identifier];Pathology ICD Patient;;ACTIVE;2.52;2.52 +76541-2;Indication ICD code;Prid;Pt;^Patient;Nom;;CLIN;2;Indication ICD code [Identifier];Indication ICD code;;ACTIVE;2.52;2.61 +76542-0;Do you feel stress - tense, restless, nervous, or anxious, or unable to sleep at night because your mind is troubled all the time - these days;Find;Pt;^Patient;Ord;OSQ;SURVEY.GNHLTH;4;Do you feel stress - tense, restless, nervous, or anxious, or unable to sleep at night because your mind is troubled all the time - these days [OSQ];;"Occupational stress questionnaire™ (OSQ™); Copyright by Finnish Institute of Occupational Health; Elo A-L, Leppänen A, Lindström K, Ropponen T (2012).www.ttl.fi Used with permission";ACTIVE;2.54;2.58 +76543-8;Weight management summary report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Weight management summary report;Weight management sum rpt;;ACTIVE;2.52;2.63 +76544-6;Breast cancer 10Y risk of distant recurrence score;Score;Pt;^Patient;Qn;Calculated.Prosigna;MOLPATH;1;Breast cancer 10-year risk of distant recurrence score Calculated by Prosigna;Brst ca 10Y dist recur score Prosigna;;ACTIVE;2.52;2.73 +76545-3;Breast cancer 10Y risk of distant recurrence classification;Imp;Pt;^Patient;Ord;Prosigna;MOLPATH;1;Breast cancer 10-year risk of distant recurrence classification [Interpretation] Qualitative by Prosigna;Brst ca 10Y dist recur class Prosigna;;ACTIVE;2.52;2.73 +76546-1;Breast cancer 10Y risk of distant recurrence panel;-;Pt;^Patient;-;Prosigna;PANEL.MOLPATH;1;Breast cancer 10-year risk of distant recurrence panel by Prosigna;Brst ca 10Y risk dist recur Pnl Prosigna;;ACTIVE;2.52;2.52 +7654-7;Ambrosia confertiflora Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Slender Ragweed IgE Ab [Units/volume] in Serum;Slender Ragweed IgE Qn;;ACTIVE;1.0h(2);2.73 +76547-9;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular End-diastolic volume by US.M-mode+Calculated by cube method;LV ED vol US.M-mode+cube;;ACTIVE;2.52;2.52 +76548-7;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by cube method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by cube method;LV ED vol US.2D+cube;;ACTIVE;2.52;2.52 +76549-5;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Teichholz method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by Teichholz method;LV ED vol 2D Teichholz;;ACTIVE;2.52;2.54 +76550-3;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Gibson method;CARD.US;2;Left ventricular End-diastolic volume by US.M-mode+Calculated by Gibson method;LV ED vol US.M-mode+Gibson;;ACTIVE;2.52;2.52 +76551-1;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Gibson method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by Gibson method;LV ED vol 2D Gibson;;ACTIVE;2.52;2.54 +76552-9;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular End-systolic volume by US.M-mode+Calculated by cube method;LV ES vol US.M-mode+cube;;ACTIVE;2.52;2.52 +76553-7;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by cube method;CARD.US;2;Left ventricular End-systolic volume by US.2D+Calculated by cube method;LV ES vol US.2D+cube;;ACTIVE;2.52;2.52 +7655-4;Ambrosia bidentata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Southern Ragweed IgE Ab [Units/volume] in Serum;Southern Ragweed IgE Qn;;ACTIVE;1.0h(2);2.73 +76554-5;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Teichholz method;CARD.US;2;Left ventricular End-systolic volume by US.2D+Calculated by Teichholz method;LV ES vol 2D Teichholz;;ACTIVE;2.52;2.54 +76555-2;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Gibson method;CARD.US;2;Left ventricular End-systolic volume by US.M-mode+Calculated by Gibson method;LV ES vol US.M-mode+Gibson;;ACTIVE;2.52;2.52 +76556-0;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Gibson method;CARD.US;2;Left ventricular End-systolic volume by US.2D+Calculated by Gibson method;LV ES vol 2D Gibson;;ACTIVE;2.52;2.54 +76557-8;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by modified Simpson method;CARD.US;2;Left ventricular End-systolic volume by US.2D+Calculated by modified Simpson method;LV ES vol US.2D+mod Simpson;;ACTIVE;2.52;2.52 +76558-6;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular Stroke volume by US.M-mode+Calculated by cube method;LV SV US.M-mode+cube;;ACTIVE;2.52;2.52 +76559-4;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by cube method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by cube method;LV SV US.2D+cube;;ACTIVE;2.52;2.52 +76560-2;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Teichholz method;CARD.US;2;Left ventricular Stroke volume by US.M-mode+Calculated by Teichholz method;LV SV US.M-mode+Teichholz;;ACTIVE;2.52;2.52 +76561-0;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Teichholz method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by Teichholz method;LV SV 2D Teichholz;;ACTIVE;2.52;2.54 +7656-2;Rubus idaeus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Raspberry IgE Ab [Units/volume] in Serum;Raspberry IgE Qn;;ACTIVE;1.0h(2);2.73 +76562-8;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Gibson method;CARD.US;2;Left ventricular Stroke volume by US.M-mode+Calculated by Gibson method;LV SV US.M-mode+Gibson;;ACTIVE;2.52;2.52 +76563-6;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Gibson method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by Gibson method;LV SV 2D Gibson;;ACTIVE;2.52;2.54 +76564-4;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated;CARD.US;2;Left ventricular Cardiac output by US.M-mode+Calculated;LV Output US.M-mode+Calc;;ACTIVE;2.52;2.52 +76565-1;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated;LV Output US.2D+Calc;;ACTIVE;2.52;2.52 +76566-9;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular Cardiac output by US.M-mode+Calculated by cube method;LV Output US.M-mode+cube;;ACTIVE;2.52;2.52 +76567-7;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by cube method;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated by cube method;LV Output US.2D+cube;;ACTIVE;2.52;2.52 +76568-5;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Teichholz method;CARD.US;2;Left ventricular Cardiac output by US.M-mode+Calculated by Teichholz method;LV Output US.M-mode+Teichholz;;ACTIVE;2.52;2.52 +76569-3;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Teichholz method;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated by Teichholz method;LV Output 2D Teichholz;;ACTIVE;2.52;2.54 +7657-0;Rubus idaeus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Raspberry IgG Ab [Units/volume] in Serum;Raspberry IgG Qn;;ACTIVE;1.0h(2);2.69 +76570-1;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by Gibson method;CARD.US;2;Left ventricular Cardiac output by US.M-mode+Calculated by Gibson method;LV Output US.M-mode+Gibson;;ACTIVE;2.52;2.52 +76571-9;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Gibson method;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated by Gibson method;LV Output 2D Gibson;;ACTIVE;2.52;2.54 +76572-7;Streptococcus pneumoniae nanA gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae nanA gene [Presence] in Swab specimen by NAA with probe detection;S pneum nanA Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76573-5;Moraxella catarrhalis g1b gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Moraxella catarrhalis g1b gene [Presence] in Swab specimen by NAA with probe detection;M catarr g1b Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76574-3;Haemophilus influenzae lex2 gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae lex2 gene [Presence] in Swab specimen by NAA with probe detection;H influenz lex2 Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76575-0;Bacterial 16S rRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bacterial 16S rRNA [Presence] in Specimen by NAA with probe detection;Bact 16S rRNA Spec Ql NAA+probe;;ACTIVE;2.52;2.69 +76576-8;Serratia marcescens gyrB gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Serratia marcescens gyrB gene [Presence] in Swab specimen by NAA with probe detection;S marcesc gyrB Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76577-6;Staphylococcus aureus sau3AI gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus sau3AI gene [Presence] in Swab specimen by NAA with probe detection;S aureus sau3AI Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76578-4;Pseudomonas aeruginosa regA gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Pseudomonas aeruginosa regA gene [Presence] in Swab specimen by NAA with probe detection;P aerug regA Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76579-2;Enterococcus faecium sodA gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecium sodA gene [Presence] in Swab specimen by NAA with probe detection;E faecium sodA Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +765-8;Neutrophils.hypersegmented;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Neutrophils.hypersegmented [Presence] in Blood by Light microscopy;Neuts Hyperseg Bld Ql Smear;;ACTIVE;1.0;2.73 +76580-0;Candida albicans its gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Candida albicans its gene [Presence] in Swab specimen by NAA with probe detection;C albicans its Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76581-8;Streptococcus pyogenes csrS gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Streptococcus pyogenes csrS gene [Presence] in Swab specimen by NAA with probe detection;S pyogenes csrS Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76582-6;Streptococcus agalactiae cfb gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae cfb gene [Presence] in Swab specimen by NAA with probe detection;S agalact cfb Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76583-4;Klebsiella pneumoniae phoE gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Klebsiella pneumoniae phoE gene [Presence] in Swab specimen by NAA with probe detection;Kl pneum phoE Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76584-2;Enterococcus faecalis cpn60 gene;PrThr;Pt;XXX.swab;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecalis cpn60 gene [Presence] in Swab specimen by NAA with probe detection;E faecal cpn60 Swab Ql NAA+probe;;ACTIVE;2.52;2.71 +76585-9;Wound microorganism gene identification panel;-;Pt;^Patient;-;Probe.amp.tar;PANEL.MICRO;1;Wound microorganism gene identification panel by NAA with probe detection;Wnd micro gene id pnl Patient NAA+probe;;ACTIVE;2.52;2.63 +76586-7;ENT microorganism gene identification panel;-;Pt;^Patient;-;Probe.amp.tar;PANEL.MICRO;1;ENT microorganism gene identification panel by NAA with probe detection;ENT micro gene id pnl Patient NAA+probe;;ACTIVE;2.52;2.63 +76587-5;Streptococcus pneumoniae nanA gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae nanA gene [#/mass] in XXX.tissue by NAA with probe detection;S pneum nanA XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +7658-8;Rubus idaeus basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Raspberry triggered histamine release [Units/volume] in Blood;Raspberry BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76588-3;Moraxella catarrhalis g1b gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Moraxella catarrhalis g1b gene [#/mass] in XXX.tissue by NAA with probe detection;M catarr g1b XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76589-1;Haemophilus influenzae lex2 gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae lex2 gene [#/mass] in XXX.tissue by NAA with probe detection;H influenz lex2 XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76590-9;Bacterial 16S rRNA;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Bacterial 16S rRNA [#/mass] in XXX.tissue by NAA with probe detection;Bact 16S rRNA XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76591-7;Serratia marcescens gyrB gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Serratia marcescens gyrB gene [#/mass] in XXX.tissue by NAA with probe detection;S marcesc gyrB XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76592-5;Staphylococcus aureus sau3AI gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Staphylococcus aureus sau3AI gene [#/mass] in XXX.tissue by NAA with probe detection;S aureus sau3AI XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76593-3;Pseudomonas aeruginosa regA gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Pseudomonas aeruginosa regA gene [#/mass] in XXX.tissue by NAA with probe detection;P aerug regA XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76594-1;Enterococcus faecium sodA gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Enterococcus faecium sodA gene [#/mass] in XXX.tissue by NAA with probe detection;E faecium sodA XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76595-8;Candida albicans its gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Candida albicans its gene [#/mass] in XXX.tissue by NAA with probe detection;C albicans its XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +7659-6;Rat hair Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rat hair IgE Ab [Units/volume] in Serum;Rat Hair IgE Qn;;ACTIVE;1.0h(2);2.42 +76596-6;Streptococcus pyogenes csrS gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Streptococcus pyogenes csrS gene [#/mass] in XXX.tissue by NAA with probe detection;S pyogenes csrS XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76597-4;Streptococcus agalactiae cfb gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Streptococcus agalactiae cfb gene [#/mass] in XXX.tissue by NAA with probe detection;S agalact cfb XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76598-2;Klebsiella pneumoniae phoE gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Klebsiella pneumoniae phoE gene [#/mass] in XXX.tissue by NAA with probe detection;Kl pneum phoE XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76599-0;Enterococcus faecalis cpn60 gene;NCnt;Pt;XXX.tissue;Qn;Probe.amp.tar;MICRO;1;Enterococcus faecalis cpn60 gene [#/mass] in XXX.tissue by NAA with probe detection;E faecal cpn60 XXX.tiss NAA+probe;;ACTIVE;2.52;2.63 +76600-6;Streptococcus pneumoniae nanA gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae nanA gene [#/volume] in XXX.body fluid by NAA with probe detection;S pneum nanA # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76601-4;Moraxella catarrhalis g1b gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Moraxella catarrhalis g1b gene [#/volume] in XXX.body fluid by NAA with probe detection;M catarr g1b # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76602-2;Haemophilus influenzae lex2 gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae lex2 gene [#/volume] in XXX.body fluid by NAA with probe detection;H influenz lex2 # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76603-0;Bacterial 16S rRNA;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Bacterial 16S rRNA [#/volume] in XXX.body fluid by NAA with probe detection;Bact 16S rRNA # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +7660-4;Rat muliialgro Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rat muliialgro IgE Ab [Units/volume] in Serum;Rat Muliialgro IgE Qn;;ACTIVE;1.0h(2);2.73 +76604-8;Serratia marcescens gyrB gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Serratia marcescens gyrB gene [#/volume] in XXX.body fluid by NAA with probe detection;S marcesc gyrB # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76605-5;Staphylococcus aureus sau3AI gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Staphylococcus aureus sau3AI gene [#/volume] in XXX.body fluid by NAA with probe detection;S aureus sau3AI # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76606-3;Pseudomonas aeruginosa regA gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Pseudomonas aeruginosa regA gene [#/volume] in XXX.body fluid by NAA with probe detection;P aerug regA # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76607-1;Enterococcus faecium sodA gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Enterococcus faecium sodA gene [#/volume] in XXX.body fluid by NAA with probe detection;E faecium sodA # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76608-9;Candida albicans its gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Candida albicans its gene [#/volume] in XXX.body fluid by NAA with probe detection;C albicans its # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76609-7;Streptococcus pyogenes csrS gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Streptococcus pyogenes csrS gene [#/volume] in XXX.body fluid by NAA with probe detection;S pyogenes csrS # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76610-5;Streptococcus agalactiae cfb gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Streptococcus agalactiae cfb gene [#/volume] in XXX.body fluid by NAA with probe detection;S agalact cfb # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76611-3;Klebsiella pneumoniae phoE gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Klebsiella pneumoniae phoE gene [#/volume] in XXX.body fluid by NAA with probe detection;Kl pneum phoE # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +7661-2;Snapper red Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Snapper IgE Ab [Units/volume] in Serum;Red Snapper IgE Qn;;ACTIVE;1.0h(2);2.73 +76612-1;Enterococcus faecalis cpn60 gene;NCnc;Pt;XXX.body fluid;Qn;Probe.amp.tar;MICRO;1;Enterococcus faecalis cpn60 gene [#/volume] in XXX.body fluid by NAA with probe detection;E faecal cpn60 # XXX.body fld NAA+probe;;ACTIVE;2.52;2.63 +76613-9;Transferrin.carbohydrate deficient.pentasialo+hexasialo/Transferrin.total;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.pentasialo+hexasialo/Transferrin.total in Serum or Plasma;CDT pentasialo+hexasialo/Tf MFr SerPl;;ACTIVE;2.52;2.54 +76614-7;Lysosomal acid lipase;CCnt;Pt;Fibroblasts;Qn;4-MU-oleate substrate;CHEM;1;Lysosomal acid lipase [Enzymatic activity/mass] in Fibroblast by 4-MU-oleate substrate;LAL Fib 4-MUO substrate-cCnt;;ACTIVE;2.52;2.52 +76615-4;Lysosomal acid lipase;CCnt;Pt;Fibroblasts;Qn;4-MU-palmitate substrate;CHEM;1;Lysosomal acid lipase [Enzymatic activity/mass] in Fibroblast by 4-MU-palmitate substrate;LAL Fib 4-MUP substrate-cCnt;;ACTIVE;2.52;2.73 +76616-2;Mitochondrial respiratory chain enzymes;CCnt;Pt;Fibroblasts;Qn;1-14C-pyruvate substrate;CHEM;1;Mitochondrial respiratory chain enzymes [Enzymatic activity/mass] in Fibroblast by 1-14C-pyruvate substrate;Mito enzy Fib 1-14C-pyr substr-cCnt;;ACTIVE;2.52;2.52 +76617-0;Mitochondrial respiratory chain enzymes;CCnt;Pt;Fibroblasts;Qn;2-14C-pyruvate substrate;CHEM;1;Mitochondrial respiratory chain enzymes [Enzymatic activity/mass] in Fibroblast by 2-14C-pyruvate substrate;Mito enzy Fib 2-14C-pyr substr-cCnt;;ACTIVE;2.52;2.52 +76618-8;Mitochondrial respiratory chain enzymes;CCnt;Pt;Fibroblasts;Qn;1-14C-glutamate substrate;CHEM;1;Mitochondrial respiratory chain enzymes [Enzymatic activity/mass] in Fibroblast by 1-14C-glutamate substrate;Mito enzy Fib 1-14C-glut substr-cCnt;;ACTIVE;2.52;2.52 +76619-6;Mitochondrial respiratory chain enzymes;CCnt;Pt;Fibroblasts;Qn;2,3-14C-succinate substrate;CHEM;1;Mitochondrial respiratory chain enzymes [Enzymatic activity/mass] in Fibroblast by 2,3-14C-succinate substrate;Mito enzy Fib 2,3-14C-succ substr-cCnt;;ACTIVE;2.52;2.52 +7662-0;Snapper red Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red Snapper IgG Ab [Units/volume] in Serum;Red Snapper IgG Qn;;ACTIVE;1.0h(2);2.73 +76620-4;Mitochondrial respiratory chain enzymes;CCnt;Pt;Fibroblasts;Qn;1-14C-leucine substrate;CHEM;1;Mitochondrial respiratory chain enzymes [Enzymatic activity/mass] in Fibroblast by 1-14C-leucine substrate;Mito enzy Fib 1-14C-leuc substr-cCnt;;ACTIVE;2.52;2.52 +76621-2;Lysosomal acid lipase panel;-;Pt;Fibroblasts;-;;PANEL.CHEM;1;Lysosomal acid lipase panel - Fibroblast;LAL panel Fib;;ACTIVE;2.52;2.73 +76622-0;Lysosomal acid lipase;Imp;Pt;Fibroblasts;Nar;;CHEM;1;Lysosomal acid lipase [Interpretation] in Fibroblast Narrative;LAL Fib-Imp;;ACTIVE;2.52;2.52 +76623-8;Mitochondrial respiratory chain enzyme analysis panel;-;Pt;Fibroblasts;-;;PANEL.CHEM;1;Mitochondrial respiratory chain enzyme analysis panel - Fibroblast;Mito resp chain enzyme anl pnl Fib;;ACTIVE;2.52;2.63 +76624-6;Mitochondrial respiratory chain enzyme analysis;Imp;Pt;Fibroblasts;Nar;;CHEM;1;Mitochondrial respiratory chain enzyme analysis [Interpretation] in Fibroblast Narrative;Mito resp chain enzyme anal Fib-Imp;;ACTIVE;2.52;2.52 +76625-3;Alanine aminotransferase;CCnc;Pt;Bld;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Blood;ALT Bld-cCnc;;ACTIVE;2.52;2.73 +76626-1;Measles virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Measles virus [Presence] in Specimen by Organism specific culture;MeV Spec Ql Cult;;ACTIVE;2.52;2.69 +76627-9;Rifapentine;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Rifapentine [Susceptibility] by Method for Slow-growing mycobacteria;Rifapentine Islt SlowMyco;;ACTIVE;2.52;2.52 +76628-7;Norovirus genogroup I & II RNA;Prid;Pt;Stool;Nom;Probe.amp.tar;MICRO;1;Norovirus genogroup I and II RNA [Identifier] in Stool by NAA with probe detection;Norovirus GI + GII RNA Stl NAA+probe;;ACTIVE;2.52;2.63 +76629-5;Glucose^post CFst;SCnc;Pt;Bld;Qn;;CHEM;1;Fasting glucose [Moles/volume] in Blood;Glucose p fast Bld-sCnc;;ACTIVE;2.52;2.73 +76630-3;Amylase;CCnc;Pt;Bld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Blood;Amylase Bld-cCnc;;ACTIVE;2.52;2.68 +76631-1;Albumin;MCnc;Pt;Bld;Qn;BCP;CHEM;1;Albumin [Mass/volume] in Blood by Bromocresol purple (BCP) dye binding method;Albumin Bld BCP-mCnc;;ACTIVE;2.52;2.52 +76632-9;Enterovirus sp;PrThr;Pt;Isolate;Ord;IF;MICRO;1;Enterovirus sp [Presence] in Isolate by Immunofluorescence;Entero sp Islt Ql IF;;ACTIVE;2.52;2.56 +76633-7;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Bld;Qn;Creatinine-based formula (MDRD);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted by Creatinine-based formula (MDRD) in Blood;GFR/BSA.pred Bld MDRD-ArVRat;;DISCOURAGED;2.52;2.73 +76634-5;QTc interval;Time;Pt;Heart;Qn;Fridericia formula;EKG.MEAS;2;Q-T interval corrected based on Fridericia formula;Q-T interval corrected Fridericia;;ACTIVE;2.52;2.52 +76635-2;QTc interval;Time;Pt;Heart;Qn;Bazett formula;EKG.MEAS;2;Q-T interval corrected based on Bazett formula;Q-T interval corrected Bazett;;ACTIVE;2.52;2.52 +76636-0;R wave amplitude.V5+S wave amplitude.V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude.V5+S wave amplitude.V1;R wave Amp L-V5+S wave Amp L-V1;;ACTIVE;2.52;2.52 +76637-8;Beats.total;Num;Stdy^total;Heart;Qn;EKG;EKG.MEAS;2;Total beats during EKG;Tot beats dur EKG;;ACTIVE;2.52;2.52 +7663-8;Sequoia spp dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Redwood Dust IgE Ab [Units/volume] in Serum;Redwood Dust IgE Qn;;ACTIVE;1.0h(2);2.42 +76638-6;RR interval;Time;Stdy^max;Heart;Qn;EKG;EKG.MEAS;2;R-R interval (Maximum value during study) by EKG;R-R interval Max EKG;;ACTIVE;2.52;2.54 +76639-4;RR interval;Time;Stdy^min;Heart;Qn;EKG;EKG.MEAS;2;R-R interval (Minimum value during study) by EKG;R-R interval Min EKG;;ACTIVE;2.52;2.54 +76640-2;Coronary artery catheterization study;Find;Pt;Coronary arteries;Doc;;CARD.PROC;2;Coronary artery catheterization study;Coronary aa cath study;;ACTIVE;2.52;2.72 +76641-0;Neurology study;Find;Pt;Neurologic system;Doc;Neurology;NEURO;2;Neurology study;Neurology study;;ACTIVE;2.52;2.72 +76642-8;Percutaneous coronary intervention study;Find;Pt;Heart;Doc;Cardiac catheterization;CARD.PROC;2;Percutaneous coronary intervention study;Perc coronary interv study;;ACTIVE;2.52;2.72 +76643-6;RR interval.standard deviation;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R-R interval.standard deviation (Heart rate variability) by EKG;RR.sd (HR var);;ACTIVE;2.52;2.54 +76644-4;RR interval.coefficient of variation;TRto;Procedure dur;Heart;Qn;EKG;EKG.MEAS;2;R-R interval.coefficient of variation by EKG;RR.coeff of var;;ACTIVE;2.52;2.54 +76645-1;Stress test type;Type;Pt;Cardiac stress study;Nom;EKG;CARD.RISK;2;Cardiac stress test EKG study Type;Cardiac stress test EKG study Type;;ACTIVE;2.52;2.52 +7664-6;Sequoia spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Redwood IgE Ab [Units/volume] in Serum;Redwood IgE Qn;;ACTIVE;1.0h(2);2.73 +76646-9;R wave amplitude.V6+S wave amplitude.V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude.V6+S wave amplitude.V1;R wave Amp L-V6+S wave Amp L-V1;;ACTIVE;2.52;2.52 +76647-7;Strontium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Strontium [Mass/mass] in Hair;Strontium Hair-mCnt;;ACTIVE;2.52;2.52 +76648-5;Palladium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Palladium [Mass/mass] in Hair;Palladium Hair-mCnt;;ACTIVE;2.52;2.52 +76649-3;Germanium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Germanium [Mass/mass] in Hair;Germanium Hair-mCnt;;ACTIVE;2.52;2.52 +76650-1;Gadolinium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Gadolinium [Mass/mass] in Hair;Gadolinium Hair-mCnt;;ACTIVE;2.52;2.52 +76651-9;Zinc transporter 8 Ab;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Zinc transporter 8 Ab [Units/volume] in Serum or Plasma by Immunoassay;ZnT8 Ab SerPl IA-aCnc;;ACTIVE;2.52;2.73 +76652-7;Thorium;MCnt;Pt;Hair;Qn;;CHEM;1;Thorium [Mass/mass] in Hair;Thorium Hair-mCnt;;ACTIVE;2.52;2.52 +7665-3;Rhodotorula spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rhodotorula spp IgE Ab [Units/volume] in Serum;Rhodatorula IgE Qn;;ACTIVE;1.0h(2);2.73 +76653-5;Barium;MCnt;Pt;Hair;Qn;;CHEM;1;Barium [Mass/mass] in Hair;Barium Hair-mCnt;;ACTIVE;2.52;2.52 +76654-3;Beryllium;MCnt;Pt;Hair;Qn;;CHEM;1;Beryllium [Mass/mass] in Hair;Beryllium Hair-mCnt;;ACTIVE;2.52;2.52 +76655-0;Tungsten;MCnt;Pt;Hair;Qn;;CHEM;1;Tungsten [Mass/mass] in Hair;Tungsten Hair-mCnt;;ACTIVE;2.52;2.52 +76656-8;Phosphate;MCnt;Pt;Hair;Qn;;CHEM;1;Phosphate [Mass/mass] in Hair;Phosphate Hair-mCnt;;ACTIVE;2.52;2.52 +76657-6;Iodine;MCnt;Pt;Hair;Qn;;CHEM;1;Iodine [Mass/mass] in Hair;Iodine Hair-mCnt;;ACTIVE;2.52;2.52 +76658-4;Zirconium;MCnt;Pt;Hair;Qn;;CHEM;1;Zirconium [Mass/mass] in Hair;Zirconium Hair-mCnt;;ACTIVE;2.52;2.52 +76659-2;Antipsychotics drug panel;-;Pt;Urine;-;Screen;PANEL.DRUG/TOX;1;Antipsychotics drug panel - Urine by Screen method;Antipsychotics Pnl Ur Scn;;ACTIVE;2.52;2.52 +766-6;Neutrophils.hypersegmented;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Neutrophils.hypersegmented [#/volume] in Blood by Manual count;Neuts Hyperseg # Bld Manual;;ACTIVE;1.0;2.73 +76660-0;Phosphatidylethanol;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Phosphatidylethanol [Presence] in Blood by Screen method;Peth Bld Ql Scn;;ACTIVE;2.52;2.7 +7666-1;Rhodotorula spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Rhodotorula spp IgE Ab [Units/volume] in Serum;Deprecated Rhodatorula IgE Qn;;DEPRECATED;1.0h(2);2.69 +76661-8;Sex;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Sex of Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76662-6;Instructions;Txt;Pt;Medication;Nar;;CLIN;2;Instructions [Text] Medication Narrative;Instructions Medication;;ACTIVE;2.52;2.52 +76663-4;Race or ethnicity;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Race or ethnicity of Provider [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +76664-2;Fetal chromosome X & Y aneuploidy;Imp;Pt;Plas.cfDNA;Nom;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Chromosome X and Y aneuploidy [interpretation] based on dosage of chromosome-specific cell-free DNA in Maternal plasma;Fet Chrom X + Y aneup cfDNA Imp;;ACTIVE;2.52;2.73 +76665-9;Protein^1st tube;MCnc;Pt;CSF;Qn;;CHEM;1;Protein [Mass/volume] in Cerebral spinal fluid --1st tube;Prot tube1 CSF-mCnc;;ACTIVE;2.52;2.52 +76666-7;Protein^2nd tube;MCnc;Pt;CSF;Qn;;CHEM;1;Protein [Mass/volume] in Cerebral spinal fluid --2nd tube;Prot tube2 CSF-mCnc;;ACTIVE;2.52;2.52 +76667-5;Protein^3rd tube;MCnc;Pt;CSF;Qn;;CHEM;1;Protein [Mass/volume] in Cerebral spinal fluid --3rd tube;Prot tube3 CSF-mCnc;;ACTIVE;2.52;2.52 +76668-3;Protein^4th tube;MCnc;Pt;CSF;Qn;;CHEM;1;Protein [Mass/volume] in Cerebral spinal fluid --4th tube;Prot tube4 CSF-mCnc;;ACTIVE;2.52;2.52 +76669-1;Glucose^1st tube;SCnc;Pt;CSF;Qn;;CHEM;1;Glucose [Moles/volume] in Cerebral spinal fluid --1st tube;Glucose tube1 CSF-sCnc;;ACTIVE;2.52;2.52 +76670-9;Glucose^2nd tube;SCnc;Pt;CSF;Qn;;CHEM;1;Glucose [Moles/volume] in Cerebral spinal fluid --2nd tube;Glucose tube2 CSF-sCnc;;ACTIVE;2.52;2.52 +76671-7;Glucose^3rd tube;SCnc;Pt;CSF;Qn;;CHEM;1;Glucose [Moles/volume] in Cerebral spinal fluid --3rd tube;Glucose tube3 CSF-sCnc;;ACTIVE;2.52;2.52 +76672-5;Glucose^4th tube;SCnc;Pt;CSF;Qn;;CHEM;1;Glucose [Moles/volume] in Cerebral spinal fluid --4th tube;Glucose tube4 CSF-sCnc;;ACTIVE;2.52;2.52 +76673-3;Erythrocytes^1st tube;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Cerebral spinal fluid by Manual count --1st tube;RBC tube1 # CSF Manual;;ACTIVE;2.52;2.52 +76674-1;Leukocytes^1st tube;NCnc;Pt;CSF;Qn;;HEM/BC;1;Leukocytes [#/volume] in Cerebral spinal fluid --1st tube;WBC tube1 # CSF;;ACTIVE;2.52;2.73 +76675-8;Appearance^1st tube;Aper;Pt;CSF;Nom;;SPEC;1;Appearance of Cerebral spinal fluid--1st tube;Appearance tube1 CSF;;ACTIVE;2.52;2.52 +76676-6;Appearance^2nd tube;Aper;Pt;CSF;Nom;;SPEC;1;Appearance of Cerebral spinal fluid--2nd tube;Appearance tube2 CSF;;ACTIVE;2.52;2.52 +76677-4;Appearance^3rd tube;Aper;Pt;CSF;Nom;;SPEC;1;Appearance of Cerebral spinal fluid--3rd tube;Appearance tube3 CSF;;ACTIVE;2.52;2.52 +76678-2;Appearance^4th tube;Aper;Pt;CSF;Nom;;SPEC;1;Appearance of Cerebral spinal fluid--4th tube;Appearance tube4 CSF;;ACTIVE;2.52;2.52 +7667-9;Rheum spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rhubarb IgE Ab [Units/volume] in Serum;Rhubarb IgE Qn;;ACTIVE;1.0h(2);2.73 +76679-0;Color^1st tube;Type;Pt;CSF;Nom;;SPEC;1;Color of Cerebral spinal fluid--1st tube;Color tube1 CSF;;ACTIVE;2.52;2.52 +76680-8;Color^2nd tube;Type;Pt;CSF;Nom;;SPEC;1;Color of Cerebral spinal fluid--2nd tube;Color tube2 CSF;;ACTIVE;2.52;2.52 +76681-6;Color^3rd tube;Type;Pt;CSF;Nom;;SPEC;1;Color of Cerebral spinal fluid--3rd tube;Color tube3 CSF;;ACTIVE;2.52;2.52 +76682-4;Color^4th tube;Type;Pt;CSF;Nom;;SPEC;1;Color of Cerebral spinal fluid--4th tube;Color tube4 CSF;;ACTIVE;2.52;2.52 +76683-2;Mean platelet component;MCnc;Pt;Bld;Qn;Calculated;HEM/BC;1;Mean platelet component [Mass/volume] in Blood by calculation;MPC Bld Calc-mCnc;;ACTIVE;2.52;2.52 +76684-0;Mean platelet dry mass;EntMass;Pt;Bld;Qn;Calculated;HEM/BC;1;Mean platelet dry mass [Entitic mass] in Blood by calculation;MPM Bld Qn Calc;;ACTIVE;2.52;2.52 +76685-7;Platelet dry mass distribution width;EntMass;Pt;Bld;Qn;Calculated;HEM/BC;1;Platelet dry mass distribution width [Entitic mass] in Blood by calculation;PMDW Bld Qn Calc;;ACTIVE;2.52;2.52 +76686-5;Reticulocyte cellular hemoglobin distribution width;EntMass;Pt;Bld;Qn;Calculated;HEM/BC;1;Reticulocyte cellular hemoglobin distribution width [Entitic mass] in Blood by calculation;CHDWr Bld Qn Calc;;ACTIVE;2.52;2.52 +7668-7;Oryza sativa Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rice IgG Ab [Units/volume] in Serum;Rice IgG Qn;;ACTIVE;1.0h(2);2.73 +76687-3;Mycobacterium sp identified;Prid;Pt;BAL;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Bronchoalveolar lavage by Organism specific culture;Mycobacterium BAL Cult;;ACTIVE;2.52;2.52 +76688-1;Alpha-1-acid glycoprotein/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Alpha-1-acid glycoprotein/Creatinine [Mass Ratio] in Urine;A1acid Glycoprotein/Creat Ur;;ACTIVE;2.52;2.52 +76689-9;Sex assigned^at birth;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Sex assigned at birth;Sex assigned at birth;;ACTIVE;2.52;2.71 +76690-7;Sexual orientation;Type;Pt;^Patient;Nom;Reported;CLIN;2;Sexual orientation;Sexual orientation;;ACTIVE;2.52;2.56 +76691-5;Gender identity;Type;Pt;^Patient;Nom;Reported;CLIN;2;Gender identity;Gender identity;;ACTIVE;2.52;2.73 +76692-3;Fungus identified;NCnc;Pt;Mouth;Qn;Culture;MICRO;1;Fungus identified [#/volume] in Mouth by Culture;Fungus # Mouth Cult;;ACTIVE;2.52;2.52 +76693-1;Bacteria identified;Prid;Pt;^BPU.autologous;Nom;Culture;MICRO;1;Bacteria identified in Blood product unit.autologous by Culture;Bacteria BPU.autologous Cult;;ACTIVE;2.52;2.52 +76694-9;APTA Registry organization data panel;-;Pt;Organization;-;APTA;PANEL.APTA;2;APTA Registry organization data panel;APTA Reg org data pnl;;ACTIVE;2.52;2.63 +7669-5;Oryza sativa basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Rice triggered histamine release [Units/volume] in Blood;Rice BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76695-6;Postal code;Loc;Pt;Organization;Nom;;ADMIN;2;Organization ZIP code;Organization ZIP code;;ACTIVE;2.52;2.66 +76696-4;Name;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Name [Identifier] Facility;Name Facility;;ACTIVE;2.52;2.66 +76697-2;APTA Registry identifiers panel;ID;Pt;Organization;Nom;APTA;PANEL.APTA;2;APTA Registry identifiers panel;APTA Reg ids pnl;;ACTIVE;2.52;2.56 +76698-0;Identifier assigning authority;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Patient identifier assigning authority;Pt ID assign auth;;ACTIVE;2.52;2.69 +76699-8;Filaria identified;Prid;Pt;Skin;Nom;Microscopy.light;MICRO;1;Filaria identified in Skin by Light microscopy;Filaria Skin Micro;;ACTIVE;2.52;2.52 +76700-4;PROMIS short form - physical function 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76701-2;PROMIS short form - satisfaction with participation in social roles 8a - version 1.0;-;1W;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in social roles 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76702-0;PROMIS short form - physical function 20a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function 20a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7670-3;Rubber tree brazilian Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Brazilian Rubber Tree IgE Ab [Units/volume] in Serum;Braz Rubber Tree IgE Qn;;ACTIVE;1.0h(2);2.73 +76703-8;PROMIS short form - sleep disturbance 6a - version 1.0;-;1W;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - sleep disturbance 6a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76704-6;PROMIS short form - satisfaction with participation in social roles 4a - version 1.0;-;1W;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in social roles 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76705-3;Trichomonas vaginalis;PrThr;Pt;XXX;Ord;Gram stain;MICRO;1;Trichomonas vaginalis [Presence] in Specimen by Gram stain;T vaginalis Spec Ql Gram Stn;;ACTIVE;2.52;2.69 +76706-1;I have to limit my regular family activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have to limit my regular family activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76707-9;I have to limit the things I do for fun with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have to limit the things I do for fun with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76708-7;I have trouble doing all of the family activities that I want to do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the family activities that I want to do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76709-5;I have trouble doing all of my usual work (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of my usual work (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76710-3;I have trouble doing all of the work that is really important to me (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the work that is really important to me (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7671-1;Salsola kali Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saltwort IgG Ab [Units/volume] in Serum;Saltwort IgG Qn;;ACTIVE;1.0h(2);2.73 +76711-1;I have to limit my regular activities with friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have to limit my regular activities with friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76712-9;I have trouble doing all of the activities with friends that I want to do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the activities with friends that I want to do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76713-7;Do you have someone with whom to have fun;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone with whom to have fun [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76714-5;Do you have someone with whom to relax;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone with whom to relax [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76715-2;Do you have someone with whom you can do something enjoyable;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone with whom you can do something enjoyable [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76716-0;Do you have someone to keep you company at home;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to keep you company at home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76717-8;Do you have someone to go with you to an event;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to go with you to an event [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76718-6;Can you find companionship when you want it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Can you find companionship when you want it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76719-4;I have someone who will listen to me when I need to talk;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone who will listen to me when I need to talk [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76720-2;I have someone to confide in or talk to about myself or my problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone to confide in or talk to about myself or my problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76721-0;I have someone with whom to share my most private worries and fears;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone with whom to share my most private worries and fears [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76722-8;I have someone who understands my problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone who understands my problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76723-6;I have someone who makes me feel appreciated;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone who makes me feel appreciated [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76724-4;I have someone I trust to talk with about my feelings;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone I trust to talk with about my feelings [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76725-1;I have someone to talk with when I have a bad day;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone to talk with when I have a bad day [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76726-9;I have someone I trust to talk with about my problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone I trust to talk with about my problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76727-7;I have someone to give me good advice about a crisis if I need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone to give me good advice about a crisis if I need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76728-5;I have someone to turn to for suggestions about how to deal with a problem;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone to turn to for suggestions about how to deal with a problem [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7672-9;Puccinia graminis triticu Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat Stem Rust IgE Ab [Units/volume] in Serum;Wheat Stem Rust IgE Qn;;ACTIVE;1.0h(2);2.42 +76729-3;I have someone to give me information if I need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone to give me information if I need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76730-1;I get useful advice about important things in life;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I get useful advice about important things in life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76731-9;PROMIS short form - ability to participate in social roles and activities 8a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - ability to participate in social roles and activities 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76732-7;PROMIS short form - companionship 4a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - companionship 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76733-5;PROMIS short form - companionship 6a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - companionship 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76734-3;PROMIS short form - emotional support 6a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional support 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76735-0;PROMIS short form - emotional support 4a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional support 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76736-8;PROMIS short form - emotional support 8a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional support 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7673-7;Secale cereale basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Rye triggered histamine release [Units/volume] in Blood;Rye BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76737-6;I am satisfied with my ability to do things for my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do things for my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76738-4;I am satisfied with my ability to do the work that is really important to me (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do the work that is really important to me (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76739-2;I am satisfied with my ability to do things for fun outside my home;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do things for fun outside my home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +767-4;Neutrophils.hypersegmented/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Neutrophils.hypersegmented/100 leukocytes in Blood by Manual count;Neuts Hyperseg/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +76740-0;I am satisfied with my ability to do things for fun with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do things for fun with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76741-8;I feel good about my ability to do things for my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel good about my ability to do things for my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76742-6;I am satisfied with my ability to meet the needs of my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to meet the needs of my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76743-4;I am satisfied with my ability to meet the needs of my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to meet the needs of my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76744-2;I am satisfied with my ability to perform my daily routines;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to perform my daily routines [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7674-5;Secale cereale Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rye IgE Ab [Units/volume] in Serum;Rye IgE Qn;;ACTIVE;1.0h(2);2.73 +76745-9;I can get helpful advice from others when dealing with a problem;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I can get helpful advice from others when dealing with a problem [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76746-7;I have people I can turn to for help with my problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have people I can turn to for help with my problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76747-5;Other people help me get information when I have a problem;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Other people help me get information when I have a problem [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76748-3;My friends have useful information to help me with my problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My friends have useful information to help me with my problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76749-1;Is someone available to help you if you need it;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Is someone available to help you if you need it;;;ACTIVE;2.52;2.72 +76750-9;Do you have someone to help you if you are confined to bed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to help you if you are confined to bed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76751-7;Do you have someone to take you to the doctor if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to take you to the doctor if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7675-2;Secale cereale Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rye IgG Ab [Units/volume] in Serum;Rye IgG Qn;;ACTIVE;1.0h(2);2.73 +76752-5;Do you have someone to prepare your meals if you are unable to do it yourself;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to prepare your meals if you are unable to do it yourself [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76753-3;Do you have someone to help with your daily chores if you are sick;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to help with your daily chores if you are sick [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76754-1;Do you have someone to help you clean up around the home if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to help you clean up around the home if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76755-8;Do you have someone to run errands if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to run errands if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76756-6;Do you have someone to take over all of your responsibilities at home if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to take over all of your responsibilities at home if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76757-4;I feel isolated even when I am not alone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel isolated even when I am not alone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76758-2;I feel that people avoid talking to me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel that people avoid talking to me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76759-0;I feel detached from other people;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel detached from other people [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7676-0;Carthamus tinctorius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Safflower IgE Ab [Units/volume] in Serum;Safflower IgE Qn;;ACTIVE;1.0h(2);2.73 +76760-8;I feel like a stranger to those around me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel like a stranger to those around me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76761-6;I feel left out;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel left out [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76762-4;I feel that people barely know me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel that people barely know me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76763-2;I feel isolated from others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel isolated from others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76764-0;I feel that people are around me but not with me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel that people are around me but not with me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76765-7;Phosphatidylcholine.saturated;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Phosphatidylcholine.saturated [Moles/volume] in Amniotic fluid;PC Satd Amn-sCnc;;ACTIVE;2.52;2.58 +76766-5;Treponema pallidum PolA gene;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Treponema pallidum polA gene [Presence] in Genital specimen by NAA with probe detection;T pallidum polA Genital Ql NAA+probe;;ACTIVE;2.52;2.73 +76767-3;Schistosoma sp identified;Prid;Pt;Semen;Nom;Microscopy.light;MICRO;1;Schistosoma sp identified in Semen by Light microscopy;Schistosoma Smn Micro;;ACTIVE;2.52;2.52 +76768-1;Hemoglobin;MCnc;Pt;BldMV;Qn;Oximetry;HEM/BC;1;Hemoglobin [Mass/volume] in Mixed venous blood by Oximetry;Hgb BldMV Oximetry-mCnc;;ACTIVE;2.52;2.73 +76769-9;Hemoglobin;MCnc;Pt;BldV;Qn;Oximetry;HEM/BC;1;Hemoglobin [Mass/volume] in Venous blood by Oximetry;Hgb BldV Oximetry-mCnc;;ACTIVE;2.52;2.73 +76770-7;Trace elements panel;-;Pt;Hair;-;;PANEL.DRUG/TOX;1;Trace elements panel - Hair;Trace Elements Pnl Hair;;ACTIVE;2.52;2.52 +76771-5;Respiratory pathogens RNA 8 panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens RNA 8 panel - Specimen by NAA with probe detection;Resp path RNA 8 panel Spec NAA+probe;;ACTIVE;2.52;2.69 +76772-3;Plasmodium falciparum Ag;PrThr;Pt;Bld;Ord;IA.rapid;MICRO;1;Plasmodium falciparum Ag [Presence] in Blood by Rapid immunoassay;P falciparum Ag Bld Ql IA.rapid;;ACTIVE;2.52;2.56 +76773-1;Heptacarboxylporphyrin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Heptacarboxylporphyrin [Moles/volume] in Serum or Plasma;Hepta-CP SerPl-sCnc;;ACTIVE;2.52;2.52 +76774-9;PROMIS item bank - satisfaction with social roles and activities - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - satisfaction with social roles and activities - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76775-6;I am satisfied with the extent of my social activities outside my home;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the extent of my social activities outside my home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76776-4;I am satisfied with my current level of family activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my current level of family activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76777-2;I am satisfied with my ability to maintain friendships;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to maintain friendships [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7677-8;Carthamus tinctorius Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Safflower IgG Ab [Units/volume] in Serum;Safflower IgG Qn;;ACTIVE;1.0h(2);2.69 +76778-0;I am satisfied with how often I go out for entertainment;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with how often I go out for entertainment [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76779-8;I am satisfied with my ability to socialize with friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to socialize with friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76780-6;I am satisfied with the amount of time I spend doing leisure activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the amount of time I spend doing leisure activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76781-4;I am satisfied with the amount of time I spend doing leisure activities with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the amount of time I spend doing leisure activities with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76782-2;I am satisfied with how much work I can do (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with how much work I can do (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76783-0;I feel good about my ability to do things for my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel good about my ability to do things for my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76784-8;I am satisfied with my current level of social activity;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my current level of social activity [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76785-5;I am satisfied with my ability to participate in family activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to participate in family activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7678-6;Salvia officinalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sage IgE Ab [Units/volume] in Serum;Sage IgE Qn;;ACTIVE;1.0h(2);2.73 +76786-3;I am satisfied with my ability to do all of the community activities that are really important to me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do all of the community activities that are really important to me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76787-1;PROMIS item bank - ability to participate in social roles and activities - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - ability to participate in social roles and activities - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76788-9;PROMIS item bank - companionship - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - companionship - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76789-7;PROMIS item bank - emotional support - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - emotional support - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76790-5;PROMIS item bank - informational support - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - informational support - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76791-3;PROMIS item bank - instrumental support - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - instrumental support - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76792-1;PROMIS short form - informational support 4a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - informational support 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76793-9;PROMIS short form - informational support 6a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - informational support 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7679-4;Salvia officinalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Sage IgE Ab [Units/volume] in Serum;Deprecated Sage IgE Qn;;DEPRECATED;1.0h(2);2.69 +76794-7;PROMIS short form - informational support 8a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - informational support 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76795-4;PROMIS short form - instrumental support 4a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - instrumental support 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76796-2;PROMIS short form - instrumental support 6a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - instrumental support 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76797-0;PROMIS short form - instrumental support 8a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - instrumental support 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76798-8;PROMIS short form - satisfaction with social roles and activities 4a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - satisfaction with social roles and activities 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76799-6;PROMIS short form - satisfaction with social roles and activities 6a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - satisfaction with social roles and activities 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76800-2;PROMIS short form - satisfaction with social roles and activities 8a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - satisfaction with social roles and activities 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76801-0;PROMIS short form - social isolation 4a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - social isolation 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7680-2;Salvia officinalis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sage IgG Ab [Units/volume] in Serum;Sage IgG Qn;;ACTIVE;1.0h(2);2.73 +76802-8;PROMIS short form - social isolation 6a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - social isolation 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76803-6;PROMIS short form - social isolation 8a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - social isolation 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76804-4;PROMIS short form - physical function 6b - version 1.2;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function 6b - version 1.2;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76805-1;PROMIS short form - physical function 8b - version 1.2;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function 8b - version 1.2;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +76806-9;PROMIS item bank - social isolation - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - social isolation - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76807-7;I am satisfied with my ability to do things for my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do things for my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76808-5;I am satisfied with the amount of time I spend doing work (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the amount of time I spend doing work (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76809-3;I am happy with how much I do for my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am happy with how much I do for my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7681-0;Artemisia tridentata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common Sagebrush IgE Ab [Units/volume] in Serum;Sagbrsh IgE Qn;;ACTIVE;1.0h(2);2.73 +76810-1;I am satisfied with my ability to do leisure activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do leisure activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76811-9;I am satisfied with my ability to do leisure activities with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do leisure activities with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76812-7;I am satisfied with my ability to work (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to work (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76813-5;I am satisfied with my current level of activities with my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my current level of activities with my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76814-3;I am satisfied with my ability to engage in activities with friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to engage in activities with friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76815-0;The quality of my work is as good as I want it to be (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;The quality of my work is as good as I want it to be (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76816-8;I am happy with how much I do for my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am happy with how much I do for my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76817-6;I am satisfied with the amount of time I spend visiting friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the amount of time I spend visiting friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76818-4;I am satisfied with the amount of time I spend performing my daily routines;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the amount of time I spend performing my daily routines [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76819-2;I am satisfied with the amount of time I spend doing things for my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the amount of time I spend doing things for my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +768-2;Neutrophils.segmented;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Segmented neutrophils [#/volume] in Blood by Manual count;Neuts Seg # Bld Manual;;ACTIVE;1.0;2.73 +76820-0;I am satisfied with my ability to do household chores and tasks;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do household chores and tasks [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76821-8;I am satisfied with the extent of my social activities with groups of people;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with the extent of my social activities with groups of people [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76822-6;I am satisfied with my ability to keep in touch with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to keep in touch with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76823-4;I am satisfied with my ability to do regular personal and household responsibilities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do regular personal and household responsibilities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76824-2;I am satisfied with my ability to do regular personal responsibilities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do regular personal responsibilities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76825-9;I am satisfied with my ability to do things for fun at home (like reading, listening to music, etc.);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do things for fun at home (like reading, listening to music, etc.) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76826-7;I am satisfied with my ability to meet the needs of those who depend on me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to meet the needs of those who depend on me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76827-5;I am satisfied with my ability to run errands;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to run errands [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7682-8;Artemisia tridentata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Common Sagebrush IgG Ab [Units/volume] in Serum;Sagbrsh IgG Qn;;ACTIVE;1.0h(2);2.73 +76828-3;I am satisfied with my ability to run errands for others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to run errands for others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76829-1;I am satisfied with my ability to do all of the leisure activities that are really important to me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do all of the leisure activities that are really important to me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76830-9;I am satisfied with my ability to do all of the group activities that are really important to me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am satisfied with my ability to do all of the group activities that are really important to me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76831-7;I have trouble doing my regular daily work around the house;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing my regular daily work around the house [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76832-5;I have trouble meeting the needs of my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble meeting the needs of my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76833-3;I have to limit social activities at home;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have to limit social activities at home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76834-1;I have trouble meeting the needs of my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble meeting the needs of my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76835-8;I am limited in doing my work (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am limited in doing my work (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7683-6;Artemisia californica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;California Sagebrush IgE Ab [Units/volume] in Serum;Calif Sagbrsh IgE Qn;;ACTIVE;1.0h(2);2.73 +76836-6;I have to limit social activities outside my home;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have to limit social activities outside my home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76837-4;I have trouble participating in recreational activities with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble participating in recreational activities with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76838-2;I have trouble doing everything for my family that I feel I should do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing everything for my family that I feel I should do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76839-0;I have trouble accomplishing my usual work (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble accomplishing my usual work (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76840-8;I have trouble doing all of the family activities that I feel I should do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the family activities that I feel I should do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76841-6;I have trouble doing all of the family activities that are really important to me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the family activities that are really important to me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76842-4;I have trouble doing everything for work that I want to do (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing everything for work that I want to do (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76843-2;I have to limit social activities with groups of people;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have to limit social activities with groups of people [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7684-4;Artemisia tridentata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Sagebrush IgE Ab [Units/volume] in Serum;Deprecated Sagbrsh IgE Qn;;DEPRECATED;1.0h(2);2.69 +76844-0;I have to do my work for shorter periods of time than usual (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have to do my work for shorter periods of time than usual (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76845-7;I feel limited in the amount of time I have for my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel limited in the amount of time I have for my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76846-5;I have trouble doing all of the activities with friends that are really important to me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the activities with friends that are really important to me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76847-3;I have trouble doing all the leisure activities with others that I want to do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all the leisure activities with others that I want to do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76848-1;I have trouble keeping up with my family responsibilities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble keeping up with my family responsibilities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76849-9;I have trouble taking care of my regular personal responsibilities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble taking care of my regular personal responsibilities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76850-7;I have trouble doing everything for my friends that I want to do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing everything for my friends that I want to do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7685-1;Salmo salar Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Salmon IgG Ab [Units/volume] in Serum;Salmon IgG Qn;;ACTIVE;1.0h(2);2.73 +76851-5;I have trouble doing all of the activities with friends that I feel I should do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the activities with friends that I feel I should do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76852-3;I have trouble doing all of the work that I feel I should do (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing all of the work that I feel I should do (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76853-1;I feel limited in my ability to visit friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel limited in my ability to visit friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76854-9;I have trouble keeping in touch with others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble keeping in touch with others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76855-6;I have trouble keeping up with my work responsibilities (include work at home);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble keeping up with my work responsibilities (include work at home) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76856-4;I have trouble doing everything for my friends that I feel I should do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have trouble doing everything for my friends that I feel I should do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76857-2;I feel limited in the amount of time I have to visit friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel limited in the amount of time I have to visit friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76858-0;Do you have someone to help you get your mind off things if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to help you get your mind off things if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76859-8;Do you have someone you can call when you want to chat;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone you can call when you want to chat [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76860-6;Do you have someone with whom you can celebrate holidays;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone with whom you can celebrate holidays [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76861-4;Do you have someone with whom you can celebrate special occasions;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone with whom you can celebrate special occasions [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76862-2;Do you have someone to call if you are bored;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to call if you are bored [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76863-0;Do you get invitations to go out and do things with other people;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you get invitations to go out and do things with other people [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76864-8;I have people who I can talk to about my health;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have people who I can talk to about my health [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76865-5;I feel close to my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel close to my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76866-3;I get emotional support from my family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I get emotional support from my family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76867-1;I have someone who makes me feel needed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone who makes me feel needed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76868-9;I have people who care about what happens to me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have people who care about what happens to me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7686-9;Saltbush Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Saltbush IgE Ab [Units/volume] in Serum;Saltbush IgE Qn;;ACTIVE;1.0h(2);2.73 +76869-7;I get love and affection;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I get love and affection [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76870-5;I feel there are people who really understand me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel there are people who really understand me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76871-3;There are people I can talk to;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;There are people I can talk to [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76872-1;I get support from my friends;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I get support from my friends [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76873-9;I feel close to my partner (or the person who is my main support);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel close to my partner (or the person who is my main support) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76874-7;My family has useful information to help me with my problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My family has useful information to help me with my problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76875-4;I have someone to talk with about money matters;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have someone to talk with about money matters [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76876-2;Do you have someone to bring you to an appointment if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to bring you to an appointment if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7687-7;Saltbush annual Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Annual Saltbush IgE Ab [Units/volume] in Serum;Annual Saltbush IgE Qn;;ACTIVE;1.0h(2);2.73 +76877-0;Could you get a friend or family member to help move furniture around your home if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Could you get a friend or family member to help move furniture around your home if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76878-8;Do you have someone to pick up a prescription if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Do you have someone to pick up a prescription if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76879-6;Could you get a friend or family member to help fix something at home if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Could you get a friend or family member to help fix something at home if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76880-4;Could you get a friend or family member to help you with your finances if you need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Could you get a friend or family member to help you with your finances if you need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76881-2;Could you get a friend or family member to help you if you have financial problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Could you get a friend or family member to help you if you have financial problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76882-0;I find that friends or relatives have difficulty talking with me about my health;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I find that friends or relatives have difficulty talking with me about my health [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76883-8;People get the wrong idea about my situation;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People get the wrong idea about my situation [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76884-6;I feel that some of my friends avoid me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel that some of my friends avoid me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7688-5;Sardine Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sardine IgG Ab [Units/volume] in Serum;Sardine IgG Qn;;ACTIVE;1.0h(2);2.69 +76885-3;I feel that some of my family members avoid me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel that some of my family members avoid me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76886-1;I feel that I am no longer close to anyone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel that I am no longer close to anyone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76887-9;I feel that I am alone in my interests and ideas;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel that I am alone in my interests and ideas [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76888-7;I like being alone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I like being alone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76889-5;PROMIS item bank - alcohol - positive expectancies - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - alcohol - positive expectancies - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76890-3;People are outgoing when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People are outgoing when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76891-1;People have more desire for sex when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People have more desire for sex when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76892-9;People sleep better when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People sleep better when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7689-3;Savinase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Savinase IgE Ab [Units/volume] in Serum;Savinase IgE Qn;;ACTIVE;1.0h(2);2.42 +76893-7;People have more fun at social occasions when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People have more fun at social occasions when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76894-5;Alcohol makes it easier to talk to people;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Alcohol makes it easier to talk to people [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76895-2;Drinking eases physical pain;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Drinking eases physical pain [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76896-0;People forget their problems when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People forget their problems when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76897-8;Drinking improves a person's mood;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Drinking improves a person's mood [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76898-6;People feel happy when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People feel happy when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76899-4;PROMIS item bank - alcohol - alcohol use - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - alcohol - alcohol use - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +769-0;Neutrophils.segmented/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Segmented neutrophils/100 leukocytes in Blood by Manual count;Neuts Seg/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +76900-0;Did you drink any type of alcoholic beverage in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Did you drink any type of alcoholic beverage in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7690-1;Atriplex polycarpa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Allscale IgE Ab [Units/volume] in Serum;Allscale IgE Qn;;ACTIVE;1.0h(2);2.42 +76901-8;I spent too much time drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I spent too much time drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76902-6;I finished several drinks fast to get a quick effect in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I finished several drinks fast to get a quick effect in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76903-4;I became drunk or intoxicated in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I became drunk or intoxicated in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76904-2;On a typical day when I drank alcohol, I had...;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;On a typical day when I drank alcohol, I had... [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76905-9;I spent a whole weekend drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I spent a whole weekend drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76906-7;I drank heavily at a single sitting in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank heavily at a single sitting in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76907-5;I drank too much in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank too much in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76908-3;I drank throughout the day in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank throughout the day in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76909-1;The largest number of drinks that I had in a single day in past 30D was...;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;The largest number of drinks that I had in a single day in past 30D was... [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76910-9;I used alcohol and other drugs together to get high in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I used alcohol and other drugs together to get high in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76911-7;In a typical week in past 30D, I drank...;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;In a typical week in past 30D, I drank... [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76912-5;I drank more than planned in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank more than planned in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76913-3;I had an urge to continue drinking once I started in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had an urge to continue drinking once I started in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76914-1;I felt that I should cut down on my drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt that I should cut down on my drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76915-8;I had trouble controlling my drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble controlling my drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76916-6;It was difficult for me to stop drinking after one or two drinks in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was difficult for me to stop drinking after one or two drinks in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76917-4;I had urges to drink in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had urges to drink in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76918-2;I had cravings for alcohol in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had cravings for alcohol in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7691-9;Pecten spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Scallop IgE Ab [Units/volume] in Serum;Scallop IgE Qn;;ACTIVE;1.0h(2);2.73 +76919-0;I felt I needed help for my drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt I needed help for my drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76920-8;I had trouble stopping drinking when I wanted to in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble stopping drinking when I wanted to in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76921-6;It was difficult to get the thought of drinking out of my mind in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was difficult to get the thought of drinking out of my mind in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76922-4;I drank when I was alone in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank when I was alone in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76923-2;I drank because I had nothing to do in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I had nothing to do in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76924-0;I drank when I arrived at home in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank when I arrived at home in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76925-7;I drank because I was angry with myself in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was angry with myself in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76926-5;I drank because someone made me angry in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because someone made me angry in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7692-7;Pecten spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Scallop IgG Ab [Units/volume] in Serum;Scallop IgG Qn;;ACTIVE;1.0h(2);2.73 +76927-3;I drank because I was irritable in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was irritable in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76928-1;I drank because I deserved it in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I deserved it in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76929-9;I drank because I was annoyed in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was annoyed in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76930-7;I drank because I felt tense in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I felt tense in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76931-5;I drank at the end of a busy day in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank at the end of a busy day in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76932-3;I drank because I was nervous in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was nervous in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76933-1;I drank because I was sad in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was sad in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76934-9;I drank because I was lonely in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was lonely in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7693-5;Schistosoma sp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Schistosoma sp IgE Ab [Units/volume] in Serum;Schistosoma IgE Qn;;ACTIVE;1.0h(2);2.73 +76935-6;I drank because I was depressed in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was depressed in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76936-4;I drank because I had physical pain in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I had physical pain in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76937-2;I drank because I was bored in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drank because I was bored in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76938-0;PROMIS item bank - alcohol - negative consequences - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - alcohol - negative consequences - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76939-8;PROMIS item bank - alcohol - positive outcomes - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - alcohol - positive outcomes - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76940-6;PROMIS item bank - alcohol - negative expectancies - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - alcohol - negative expectancies - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.56 +76941-4;People have trouble thinking when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People have trouble thinking when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76942-2;People feel sick the day after drinking;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People feel sick the day after drinking [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7694-3;Scorpion Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Scorpion IgE Ab [Units/volume] in Serum;Scorpion IgE Qn;;ACTIVE;1.0h(2);2.42 +76943-0;People do things they regret while drinking;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People do things they regret while drinking [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76944-8;People make bad decisions when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People make bad decisions when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76945-5;Drinking is harmful to mental health;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Drinking is harmful to mental health [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76946-3;People are careless when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People are careless when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76947-1;People are irresponsible when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People are irresponsible when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76948-9;People are pushy when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People are pushy when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76949-7;People are rude when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People are rude when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7695-0;Cytisus scoparius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Scotch broom IgE Ab [Units/volume] in Serum;Scotch broom IgE Qn;;ACTIVE;1.0h(2);2.73 +76950-5;Drinking can be harmful to physical health;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Drinking can be harmful to physical health [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76951-3;People are selfish when they drink;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People are selfish when they drink [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76952-1;I worried when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76953-9;I felt angry when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt angry when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76954-7;I felt nervous when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt nervous when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76955-4;My problems seemed worse when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My problems seemed worse when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76956-2;I had trouble keeping appointments after I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble keeping appointments after I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76957-0;I got confused when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I got confused when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76958-8;I took risks when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I took risks when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76959-6;I was critical of myself when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was critical of myself when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76960-4;I felt guilty when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt guilty when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76961-2;I had a headache after I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a headache after I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76962-0;I got sick when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I got sick when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76963-8;I felt anxious when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt anxious when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76964-6;I was clumsy when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was clumsy when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76965-3;I was unreliable after I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was unreliable after I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76966-1;Others complained about my drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Others complained about my drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76967-9;I was criticized about my drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was criticized about my drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7696-8;Sesamum indicum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sesame Seed IgG Ab [Units/volume] in Serum;Sesame Seed IgG Qn;;ACTIVE;1.0h(2);2.73 +76968-7;I got in an argument when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I got in an argument when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76969-5;I was loud when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was loud when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76970-3;I felt sad when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt sad when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76971-1;Drinking created problems between me and others in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Drinking created problems between me and others in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76972-9;I said or did embarrassing things when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I said or did embarrassing things when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76973-7;I lied about my drinking in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I lied about my drinking in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76974-5;I disappointed others when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I disappointed others when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76975-2;Others had trouble counting on me when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Others had trouble counting on me when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7697-6;Sesamum indicum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Sesame Seed triggered histamine release [Units/volume] in Blood;Sesame Seed BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76976-0;I looked sloppy when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I looked sloppy when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76977-8;I felt dizzy when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt dizzy when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76978-6;I had a hangover after I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had a hangover after I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76979-4;I used poor judgment when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I used poor judgment when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76980-2;I had trouble getting things done after I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble getting things done after I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76981-0;I was inconsiderate when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was inconsiderate when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76982-8;I had trouble trusting other people when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had trouble trusting other people when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76983-6;My future seemed better when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My future seemed better when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7698-4;Sheep epithelium basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Sheep epithelium triggered histamine release [Units/volume] in Blood;Sheep Epith BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76984-4;I was able to express myself better when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I was able to express myself better when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76985-1;I felt comfortable around others when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt comfortable around others when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76986-9;I felt relaxed when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt relaxed when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76987-7;I felt at ease when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt at ease when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76988-5;I felt good about myself when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt good about myself when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76989-3;I felt happy when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt happy when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76990-1;I felt a sense of control when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt a sense of control when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76991-9;I felt like I could do anything when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like I could do anything when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +7699-2;Rumex acetosella basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Sheep Sorrel triggered histamine release [Units/volume] in Blood;Sheep Sorrel BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +76992-7;I calmed down when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I calmed down when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76993-5;I felt creative when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt creative when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76994-3;I felt outgoing when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt outgoing when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76995-0;I enjoyed life when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I enjoyed life when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76996-8;I felt confident when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt confident when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76997-6;I slept better after I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I slept better after I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76998-4;I could relax when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I could relax when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +76999-2;I fit in better when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I fit in better when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +77000-8;I had more fun when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had more fun when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +77001-6;I had more desire for sex when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had more desire for sex when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +77002-4;It was easier to talk to people when I drank in past 30D;Find;30D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It was easier to talk to people when I drank in past 30D [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.65 +77003-2;PROMIS short form - alcohol - alcohol use 7a - version 1.0;-;30D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - alcohol - alcohol use 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77004-0;PROMIS short form - alcohol - negative consequences 7a - version 1.0;-;30D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - alcohol - negative consequences 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77005-7;PROMIS short form - alcohol - negative expectancies 7a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - alcohol - negative expectancies 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77006-5;PROMIS short form - alcohol - positive expectancies 7a - version 1.0;-;30D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - alcohol - positive expectancies 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77007-3;PROMIS short form - alcohol - positive consequences 7a - version 1.0;-;30D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - alcohol - positive consequences 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +7700-8;Pandalus borealis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Shrimp IgG Ab [Units/volume] in Serum;Shrimp IgG Qn;;ACTIVE;1.0h(2);2.73 +77008-1;Human coronavirus 229E+OC43 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E+OC43 RNA [Presence] in Nasopharynx by NAA with probe detection;HCoV 229E+OC43 RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.63 +77009-9;Porphyrin fractions panel;SCnc;Pt;Ser/Plas;-;;PANEL.CHEM;1;Porphyrin fractions panel [Moles/volume] - Serum or Plasma;Porphyrin Fract Pnl SerPl-sCnc;;ACTIVE;2.52;2.52 +77010-7;Urea^post dialysis/pre dialysis;SRto;Pt;Ser/Plas;Qn;;CHAL;1;Urea [Molar ratio] in Serum or Plasma --post dialysis/pre dialysis;Urea post/pre dialysis SerPl-sRto;;ACTIVE;2.52;2.52 +77011-5;Fetal chromosome 21 trisomy;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.TRISOMY;1;Fetal Chromosome 21 trisomy [Presence] based on Plasma cell-free DNA by Sequencing;Fet Chr 21 Ts Plas.cfDNA Ql;;ACTIVE;2.52;2.73 +77012-3;Fetal chromosome 18 trisomy;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.TRISOMY;1;Fetal Chromosome 18 trisomy [Presence] based on Plasma cell-free DNA by Sequencing;Fet Chr 18 Ts Plas.cfDNA Ql;;ACTIVE;2.52;2.73 +77013-1;Fetal chromosome 13 trisomy;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.TRISOMY;1;Fetal Chromosome 13 trisomy [Presence] based on Plasma cell-free DNA by Sequencing;Fet Chr 13 Ts Plas.cfDNA Ql;;ACTIVE;2.52;2.73 +77014-9;Fetal trisomy 21 risk;Imp;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.TRISOMY;1;Fetal Trisomy 21 risk [Interpretation] based on Plasma cell-free DNA by Sequencing Qualitative;Fet Ts 21 risk Plas.cfDNA Ql;;ACTIVE;2.52;2.73 +77015-6;Fetal trisomy 18 risk;Imp;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.TRISOMY;1;Fetal Trisomy 18 risk [Interpretation] based on Plasma cell-free DNA by Sequencing Qualitative;Fet Ts 18 risk Plas.cfDNA Ql;;ACTIVE;2.52;2.73 +7701-6;Pandalus borealis basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Shrimp triggered histamine release [Units/volume] in Blood;Shrimp BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77016-4;Fetal RhD antigen;Prid;Pt;Plas.cfDNA;Nom;MS.MALDI-TOF;MOLPATH;1;Fetal RhD antigen in Plasma cell-free DNA by MS.MALDI-TOF;Fet RhD Ag Type Plas.cfDNA MS.MALDI-TOF;;ACTIVE;2.52;2.68 +77017-2;CFTR gene targeted mutation analysis;Imp;Pt;Bld/Tiss;Ord;MS.MALDI-TOF;MOLPATH.MUT;1;CFTR gene mutation analysis [interpretation] in Blood or Tissue Qualitative by MS.MALDI;CFTR Mut Anl Bld/T MS.MALDI-Imp;;ACTIVE;2.52;2.63 +77018-0;Noninvasive prenatal fetal 13 & 18 & 21 aneuploidy panel;-;Pt;Plas.cfDNA;-;Sequencing;PANEL.MOLPATH;1;Noninvasive prenatal fetal 13 and 18 and 21 aneuploidy panel - Plasma cell-free DNA by Sequencing;Noninv fet 13+18+21 aneu pnl cfDNA seq;;ACTIVE;2.52;2.73 +77019-8;Noninvasive prenatal fetal 18 & 21 aneuploidy panel;-;Pt;Plas.cfDNA;-;Sequencing;PANEL.MOLPATH;1;Noninvasive prenatal fetal 18 and 21 aneuploidy panel - Plasma cell-free DNA by Sequencing;NIP fet 18+21 aneu pnl Plas.cfDNA Seq;;ACTIVE;2.52;2.73 +77020-6;Fetal Y chromosome;Imp;Pt;Plas.cfDNA;Nom;Sequencing;MOLPATH;1;Fetal Y chromosome [Interpretation] based on Plasma cell-free DNA by Sequencing;Fet Y Chrom Plas.cfDNA;;ACTIVE;2.52;2.73 +77021-4;Fetal Y chromosome;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH;1;Fetal Y chromosome [Presence] based on Plasma cell-free DNA by Sequencing;Fet Y Chrom Plas.cfDNA Ql;;ACTIVE;2.52;2.73 +77022-2;Respiratory syncytial virus A RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus A RNA [Presence] in Nasopharynx by NAA with probe detection;RSV A RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.73 +77023-0;Respiratory syncytial virus B RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus B RNA [Presence] in Nasopharynx by NAA with probe detection;RSV B RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.73 +7702-4;Smelt Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Smelt IgE Ab [Units/volume] in Serum;Smelt IgE Qn;;ACTIVE;1.0h(2);2.42 +77024-8;Human metapneumovirus RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Nasopharynx by NAA with probe detection;hMPV RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.73 +77025-5;Rhinovirus RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Rhinovirus RNA [Presence] in Nasopharynx by NAA with probe detection;Rhinovirus RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.73 +77026-3;Influenza virus A H1 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Presence] in Nasopharynx by NAA with probe detection;FLUAV H1 RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.73 +77027-1;Influenza virus A H3 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Nasopharynx by NAA with probe detection;FLUAV H3 RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.73 +77028-9;Influenza virus A H1 2009 pandemic RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic RNA [Presence] in Nasopharynx by NAA with probe detection;FLUAV H1 2009 pand RNA Nph Ql NAA+probe;;ACTIVE;2.52;2.73 +77029-7;Respiratory pathogens DNA & RNA 14 panel;-;Pt;Nph;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA 14 panel - Nasopharynx by NAA with probe detection;Resp path DNA+RNA 14 pnl Nph NAA+probe;;ACTIVE;2.52;2.63 +77030-5;"t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript in Blood or Tissue by FISH";"t(1;19)(PBX1,TCF3) Bld/T FISH";;ACTIVE;2.52;2.65 +77031-3;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript in Blood or Tissue by FISH";"t(15;17)(PML,RARA) Bld/T FISH";;ACTIVE;2.52;2.65 +7703-2;Ustilago maydis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Corn smut IgE Ab [Units/volume] in Serum;Corn smut IgE Qn;;ACTIVE;1.0h(2);2.73 +77032-1;"t(8;14)(q24;q32)(MYC,IGH) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(8;14)(q24;q32)(MYC,IGH) fusion transcript in Blood or Tissue by FISH";"t(8;14)(MYC,IGH) Bld/T FISH";;ACTIVE;2.52;2.65 +77033-9;"t(14;16)(q32;q23)(IGH,MAF) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(14;16)(q32;q23)(IGH,MAF) fusion transcript in Blood or Tissue by FISH";"t(14;16)(IGH,MAF) Bld/T FISH";;ACTIVE;2.52;2.65 +77034-7;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript in Blood or Tissue by FISH";"inv(16)(p13;q22) Bld/T FISH";;ACTIVE;2.52;2.65 +77035-4;"t(14;18)(q32;q21)(IGH,MALT1) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21)(IGH,MALT1) fusion transcript in Blood or Tissue by FISH";"t(14;18)(IGH,MALT1) Bld/T FISH";;ACTIVE;2.52;2.65 +77036-2;"t(11;18)(q21;q21)(BIRC3,MALT1) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(11;18)(q21;q21)(BIRC3,MALT1) fusion transcript in Blood or Tissue by FISH";"t(11;18)(BIRC3,MALT1) Bld/T FISH";;ACTIVE;2.52;2.65 +77037-0;"t(11;14)(q13;q32)(CCND1,IGH) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(11;14)(q13;q32)(CCND1,IGH) fusion transcript in Blood or Tissue by FISH";"t(11;14)(CCND1,IGH) Bld/T FISH";;ACTIVE;2.52;2.65 +77038-8;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript in Blood or Tissue by FISH";"t(14;18)(IGH,BCL2) Bld/T FISH";;ACTIVE;2.52;2.65 +77039-6;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript in Blood or Tissue by FISH";"t(12;21)(ETV6,RUNX1) Bld/T FISH";;ACTIVE;2.52;2.65 +7704-0;Ustilago cynodontis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bermuda grass smut IgE Ab [Units/volume] in Serum;Bermuda grass smut IgE Qn;;ACTIVE;1.0h(2);2.73 +77040-4;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript in Blood or Tissue by FISH";"t(8;21)(RUNX1T1,RUNX1) Bld/T FISH";;ACTIVE;2.52;2.65 +77041-2;"inv(3)(q21;q26.2)+t(3;3)(q21;q26.2)(PSMD2,MECOM) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"inv(3)(q21;q26.2)+t(3;3)(q21;q26.2)(PSMD2,MECOM) fusion transcript in Blood or Tissue by FISH";"inv(3)+t(3;3)(PSMD2,MECOM) Bld/T FISH";;ACTIVE;2.52;2.65 +77042-0;"t(6;9)(p22;q34)(DEK,NUP214) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(6;9)(p22;q34)(DEK,NUP214) fusion transcript in Blood or Tissue by FISH";"t(6;9)(DEK,NUP214) Bld/T FISH";;ACTIVE;2.52;2.65 +77043-8;ACAD8 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ACAD8 gene full mutation analysis in Blood or Tissue by Sequencing;ACAD8 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.63 +77044-6;ACAD8 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACAD8 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ACAD8 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77045-3;ACADSB gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ACADSB gene full mutation analysis in Blood or Tissue by Sequencing;ACADSB Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77046-1;ACADSB gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACADSB gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ACADSB Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77047-9;ACSF3 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ACSF3 gene full mutation analysis in Blood or Tissue by Sequencing;ACSF3 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77048-7;ACSF3 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ACSF3 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ACSF3 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77049-5;SUGCT gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SUGCT gene full mutation analysis in Blood or Tissue by Sequencing;SUGCT Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77050-3;SUGCT gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SUGCT gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;SUGCT Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77051-1;IFITM5 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;IFITM5 gene full mutation analysis in Blood or Tissue by Sequencing;IFITM5 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77052-9;IFITM5 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;IFITM5 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;IFITM5 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77053-7;MTR gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MTR gene full mutation analysis in Blood or Tissue by Sequencing;MTR Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77054-5;MTR gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MTR gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MTR Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77055-2;CYP11B1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CYP11B1 gene full mutation analysis in Blood or Tissue by Sequencing;CYP11B1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77056-0;CYP11B1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CYP11B1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;CYP11B1 gene Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +7705-7;Sphacelotheca cruenta Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Johnson grass smut IgE Ab [Units/volume] in Serum;Johnson grass smut IgE Qn;;ACTIVE;1.0h(2);2.73 +77057-8;CYP17A1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CYP17A1 gene full mutation analysis in Blood or Tissue by Sequencing;CYP17A1 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77058-6;CYP17A1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CYP17A1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;CYP17A1 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77059-4;GNMT gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GNMT gene full mutation analysis in Blood or Tissue by Sequencing;GNMT Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77060-2;GNMT gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GNMT gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;GNMT Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77061-0;HPD gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HPD gene full mutation analysis in Blood or Tissue by Sequencing;HPD Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77062-8;HPD gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HPD gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;HPD Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77063-6;TAT gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;TAT gene full mutation analysis in Blood or Tissue by Sequencing;TAT Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77064-4;TAT gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TAT gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;TAT Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +7706-5;Sphacelotheca cruenta Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Johnson grass smut IgG Ab [Units/volume] in Serum;Johnson grass smut IgG Qn;;ACTIVE;1.0h(2);2.69 +77065-1;AHCY gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;AHCY gene full mutation analysis in Blood or Tissue by Sequencing;AHCY Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77066-9;AHCY gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AHCY gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;AHCY Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77067-7;SEPT9 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SEPT9 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SEPT9 gene Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77068-5;AGA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;AGA gene full mutation analysis in Blood or Tissue by Sequencing;AGA Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.73 +77069-3;AGA gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AGA gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;AGA Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77070-1;PLOD2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;PLOD2 gene full mutation analysis in Blood or Tissue by Sequencing;PLOD2 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77071-9;PLOD2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PLOD2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;PLOD2 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77072-7;ATP5A1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ATP5A1 gene full mutation analysis in Blood or Tissue by Sequencing;ATP5A1 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +7707-3;Ustilago avenae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oat smut IgE Ab [Units/volume] in Serum;Oat smut IgE Qn;;ACTIVE;1.0h(2);2.73 +77073-5;ATP5A1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ATP5A1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ATP5A1 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77074-3;C12orf65 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;C12orf65 gene full mutation analysis in Blood or Tissue by Sequencing;C12orf65 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77075-0;C12orf65 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;C12orf65 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;C12orf65 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77076-8;MRPL40 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MRPL40 gene full mutation analysis in Blood or Tissue by Sequencing;MRPL40 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77077-6;MRPL40 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MRPL40 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MRPL40 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77078-4;MTFMT gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MTFMT gene full mutation analysis in Blood or Tissue by Sequencing;MTFMT Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77079-2;MTFMT gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MTFMT gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MTFMT Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +770-8;Neutrophils/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Neutrophils/100 leukocytes in Blood by Automated count;Neutrophils/leuk NFr Bld Auto;;ACTIVE;1.0;2.73 +77080-0;SERPINF1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SERPINF1 gene full mutation analysis in Blood or Tissue by Sequencing;SERPINF1 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +7708-1;Ustilago tritici Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat smut IgE Ab [Units/volume] in Serum;Wheat smut IgE Qn;;ACTIVE;1.0h(2);2.73 +77081-8;SERPINF1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SERPINF1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;SERPINF1 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77082-6;FARS2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;FARS2 gene full mutation analysis in Blood or Tissue by Sequencing;FARS2 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77083-4;FARS2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FARS2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;FARS2 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77084-2;ALPL gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ALPL gene full mutation analysis in Blood or Tissue by Sequencing;ALPL Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.73 +77085-9;ALPL gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ALPL gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;ALPL Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77086-7;TYROBP gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;TYROBP gene full mutation analysis in Blood or Tissue by Sequencing;TYROBP Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77087-5;TYROBP gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TYROBP gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;TYROBP Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77088-3;GFM1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GFM1 gene full mutation analysis in Blood or Tissue by Sequencing;GFM1 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77089-1;GFM1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GFM1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;GFM1 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77090-9;TFB1M gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;TFB1M gene full mutation analysis in Blood or Tissue by Sequencing;TFB1M Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77091-7;TFB1M gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TFB1M gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;TFB1M Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77092-5;MRRF gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MRRF gene full mutation analysis in Blood or Tissue by Sequencing;MRRF Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77093-3;MRRF gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MRRF gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MRRF Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77094-1;MRPS2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MRPS2 gene full mutation analysis in Blood or Tissue by Sequencing;MRPS2 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77095-8;MRPS2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MRPS2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MRPS2 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77096-6;MRPS22 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MRPS22 gene full mutation analysis in Blood or Tissue by Sequencing;MRPS22 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77097-4;MRPS22 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MRPS22 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MRPS22 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77098-2;MRPL44 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MRPL44 gene full mutation analysis in Blood or Tissue by Sequencing;MRPL44 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +7709-9;Solea solea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sole IgE Ab [Units/volume] in Serum;Sole IgE Qn;;ACTIVE;1.0h(2);2.73 +77099-0;MRPL44 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MRPL44 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MRPL44 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77100-6;MRPS18A gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MRPL18A gene full mutation analysis in Blood or Tissue by Sequencing;MRPL18A Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77101-4;MRPS18A gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MRPL18A gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MRPL18A Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77102-2;NARS2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;NARS2 gene full mutation analysis in Blood or Tissue by Sequencing;NARS2 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77103-0;NARS2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NARS2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;NARS2 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77104-8;HARS2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HARS2 gene full mutation analysis in Blood or Tissue by Sequencing;HARS2 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77105-5;HARS2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HARS2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;HARS2 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77106-3;SARS2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SARS2 gene full mutation analysis in Blood or Tissue by Sequencing;SARS2 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +7710-7;Solea solea Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sole IgG Ab [Units/volume] in Serum;Sole IgG Qn;;ACTIVE;1.0h(2);2.73 +77107-1;SARS2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SARS2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;SARS2 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77108-9;AARS2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;AARS2 gene full mutation analysis in Blood or Tissue by Sequencing;AARS2 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77109-7;AARS2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AARS2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;AARS2 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77110-5;KARS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;KARS gene full mutation analysis in Blood or Tissue by Sequencing;KARS Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77111-3;KARS gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;KARS gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;KARS Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77112-1;PLOD3 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;PLOD3 gene full mutation analysis in Blood or Tissue by Sequencing;PLOD3 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77113-9;PLOD3 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PLOD3 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;PLOD3 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77114-7;FBN1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;FBN1 gene full mutation analysis in Blood or Tissue by Sequencing;FBN1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.73 +7711-5;Spinacia oleracea Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spinach IgG Ab [Units/volume] in Serum;Spinach IgG Qn;;ACTIVE;1.0h(2);2.73 +77115-4;FKBP10 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;FKBP10 gene full mutation analysis in Blood or Tissue by Sequencing;FKBP10 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77116-2;FKBP10 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;FKBP10 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;FKBP10 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77117-0;RPGRIP1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;RPGRIP1 gene full mutation analysis in Blood or Tissue by Sequencing;RPGRIP1 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77118-8;RPGRIP1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RPGRIP1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;RPGRIP1 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77119-6;RPGR gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;RPGR gene full mutation analysis in Blood or Tissue by Sequencing;RPGR Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77120-4;RPGR gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RPGR gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;RPGR Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77121-2;DFNB31 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;DFNB31 gene full mutation analysis in Blood or Tissue by Sequencing;DFNB31 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77122-0;DFNB31 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;DFNB31 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;DFNB31 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +7712-3;Spondylocladium atrovirens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spondylocladium atrovirens IgE Ab [Units/volume] in Serum;S atrovirens IgE Qn;;ACTIVE;1.0h(2);2.73 +77123-8;GPR98 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GPR98 gene full mutation analysis in Blood or Tissue by Sequencing;GPR98 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77124-6;GPR98 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GPR98 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;GPR98 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77125-3;PCDH15 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;PCDH15 gene full mutation analysis in Blood or Tissue by Sequencing;PCDH15 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77126-1;PCDH15 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PCDH15 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;PCDH15 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.73 +77127-9;USH1C gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;USH1C gene full mutation analysis in Blood or Tissue by Sequencing;USH1C Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77128-7;USH1C gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;USH1C gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;USH1C Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77129-5;CERKL gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CERKL gene full mutation analysis in Blood or Tissue by Sequencing;CERKL Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77130-3;CERKL gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CERKL gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;CERKL Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +7713-1;Squash Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Squash IgE Ab [Units/volume] in Serum;Squash IgE Qn;;ACTIVE;1.0h(2);2.73 +77131-1;CDHR1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CDHR1 gene full mutation analysis in Blood or Tissue by Sequencing;CDHR1 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77132-9;CDHR1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CDHR1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;CDHR1 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77133-7;LCA5 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;LCA5 gene full mutation analysis in Blood or Tissue by Sequencing;LCA5 Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77134-5;LCA5 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LCA5 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;LCA5 Fam Mut Anl Bld/T;;ACTIVE;2.52;2.65 +77135-2;Glucose;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Glucose [Moles/volume] in Serum, Plasma or Blood;Glucose SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77136-0;Urea;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Urea [Moles/volume] in Serum, Plasma or Blood;Urea SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77137-8;Bilirubin;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Serum, Plasma or Blood;Bilirub SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77138-6;Chloride;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Chloride [Moles/volume] in Serum, Plasma or Blood;Chloride SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77139-4;Sodium;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Sodium [Moles/volume] in Serum, Plasma or Blood;Sodium SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77140-2;Creatinine;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Creatinine [Moles/volume] in Serum, Plasma or Blood;Creat SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77141-0;Alkaline phosphatase;CCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Alkaline phosphatase [Enzymatic activity/volume] in Serum, Plasma or Blood;ALP SerPlBld-cCnc;;ACTIVE;2.52;2.73 +77142-8;Potassium;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Potassium [Moles/volume] in Serum, Plasma or Blood;Potassium SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77143-6;Carbon dioxide;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Serum, Plasma or Blood;CO2 SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77144-4;Alanine aminotransferase;CCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in Serum, Plasma or Blood;ALT SerPlBld-cCnc;;ACTIVE;2.52;2.68 +77145-1;Glucose^post CFst;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Fasting glucose [Moles/volume] in Serum, Plasma or Blood;Glucose p fast SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77146-9;Amylase;CCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Amylase [Enzymatic activity/volume] in Serum, Plasma or Blood;Amylase SerPlBld-cCnc;;ACTIVE;2.52;2.73 +77147-7;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (MDRD);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD);GFR/BSA.pred SerPlBld MDRD-ArVRat;;ACTIVE;2.52;2.73 +77148-5;Albumin;MCnc;Pt;Ser/Plas/Bld;Qn;BCP;CHEM;1;Albumin [Mass/volume] in Serum, Plasma or Blood by Bromocresol purple (BCP) dye binding method;Albumin SerPlBld BCP-mCnc;;ACTIVE;2.52;2.68 +7714-9;Squash summer Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Summer Squash IgE Ab [Units/volume] in Serum;Summer Squash IgE Qn;;ACTIVE;1.0h(2);2.73 +77149-3;Specimen.dry weight/total;MFr;24H;Stool;Qn;;SPEC;1;Dry weight/Total of 24 hour Stool;Dry Spec Wt 24h MFr Stl;;ACTIVE;2.52;2.52 +77150-1;Energy content;EngCnt;24H;Stool.dried;Qn;;CHEM;1;Energy content [Energy/mass] in 24 hour Stool.dried;Energy content 24h Stool.dried;;ACTIVE;2.52;2.52 +77151-9;Energy content panel;-;24H;Stool;-;;PANEL.CHEM;1;Energy content panel - 24 hour Stool;Energy content Pnl 24h Stl;;ACTIVE;2.52;2.52 +77152-7;Cardiac arrest event outcome;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Cardiac arrest event outcome NEMSIS;Cardiac arrest event outcome NEMSIS;;ACTIVE;2.52;2.52 +77153-5;Transport mode descriptors;Type;Pt;EMS transport;Nom;NEMSIS;NEMSIS;2;EMS Transport mode descriptors NEMSIS;EMS Transport mode descriptors NEMSIS;;ACTIVE;2.52;2.52 +77154-3;Hospital inpatient destination;Type;Pt;^Patient;Nom;;NEMSIS;2;Hospital inpatient destination;Hospital inpatient destination;;ACTIVE;2.52;2.64 +77155-0;Hospital designation capability;Type;Pt;Facility;Nom;;TRAUMA;2;Hospital designation capability;Hospital designation capability;;ACTIVE;2.52;2.72 +7715-6;Squash summer Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Summer Squash IgG Ab [Units/volume] in Serum;Summer Squash IgG Qn;;ACTIVE;1.0h(2);2.73 +77156-8;EMS level of care capability;Type;Pt;EMS unit;Nom;;NEMSIS;2;EMS unit Level of care capability;EMS level of care;;ACTIVE;2.52;2.63 +77157-6;Response mode descriptors;Type;Pt;EMS response;Nom;NEMSIS;NEMSIS;2;EMS Response mode descriptors NEMSIS;EMS Response mode descriptors NEMSIS;;ACTIVE;2.52;2.52 +77158-4;Albumin;SCnc;Pt;Urine;Qn;Detection limit <= 3.0 mg/L;CHEM;1;Microalbumin [Moles/volume] in Urine by Detection limit <= 3.0 mg/L;Microalbumin Ur DL<=3.0 mg/L-sCnc;;ACTIVE;2.52;2.72 +77159-2;Erythrocytes.ghost cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Erythrocytes.ghost cells [Presence] in Blood by Light microscopy;RBCGhost Bld Ql Smear;;ACTIVE;2.52;2.56 +771-6;Erythrocytes.nucleated;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Blood by Automated count;nRBC # Bld Auto;;ACTIVE;1.0;2.73 +77160-0;Functional outcome score;Score;Pt;^Patient;Ord;GOSE;FUNCTION;2;Functional outcome score GOSE;Func Outcome Score GOSE;;ACTIVE;2.52;2.52 +77161-8;Prothrombin.activity^immediately after addition of factor II depleted plasma;ACnc;Pt;PPP;Qn;Coag;COAG;1;Prothrombin activity [Units/volume] in Platelet poor plasma by Coagulation assay --immediately after addition of factor II depleted plasma;Prothrom imm FII DP PPP-aCnc;;ACTIVE;2.52;2.52 +77162-6;Anidulafungin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Anidulafungin [Susceptibility] by Gradient strip;Anidulafungin Islt Grad strip;;ACTIVE;2.52;2.56 +77163-4;Alpha-1-Microglobulin;SCnc;Pt;Urine;Qn;;CHEM;1;Alpha-1-Microglobulin [Moles/volume] in Urine;A1 Microglob Ur-sCnc;;ACTIVE;2.52;2.52 +7716-4;Squash yellow Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Squash IgE Ab [Units/volume] in Serum;Yellow Squash IgE Qn;;ACTIVE;1.0h(2);2.73 +77164-2;Karyotype;Prid;Pt;POC;Nom;;MOLPATH;1;Karyotype [Identifier] in Products of Conception Nominal;Karyotyp POC;;ACTIVE;2.52;2.52 +77165-9;Anaplasma phagocytophilum & Ehrlichia chaffeensis IgG panel;Titr;Pt;Ser;-;;PANEL.MICRO;1;Anaplasma phagocytophilum and Ehrlichia chaffeensis IgG panel [Titer] - Serum;A phagocyt + E chaff Ab.IgG Pnl Titr Ser;;ACTIVE;2.52;2.58 +77166-7;Chlamydia sp Ab.IgG & IgM panel;Titr;Pt;Ser;Qn;IF;PANEL.MICRO;1;Chlamydia sp IgG and IgM panel [Titer] - Serum by Immunofluorescence;Chlamydia sp IgG+IgM Pnl Titr Ser IF;;ACTIVE;2.52;2.52 +77167-5;cycloSPORINE^3H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --3 hours post dose;cycloSPORINE 3h p Bld-mCnc;;ACTIVE;2.52;2.66 +77168-3;cycloSPORINE^4H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --4 hours post dose;cycloSPORINE 4h p Bld-mCnc;;ACTIVE;2.52;2.66 +77169-1;cycloSPORINE^1H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in Blood --1 hour post dose;cycloSPORINE 1h p Bld-mCnc;;ACTIVE;2.52;2.66 +77170-9;PDGFRA gene.p.Asp842Val;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PDGFRA gene p.Asp842Val [Presence] in Blood or Tissue by Molecular genetics method;PDGFRA p.D842V Bld/T Ql;;ACTIVE;2.52;2.56 +77171-7;KIT gene exon 11 targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;KIT gene exon 11 mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KIT Exon 11 Mut Anl Bld/T;;ACTIVE;2.52;2.63 +7717-2;Squash yellow Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Squash IgG Ab [Units/volume] in Serum;Yellow Squash IgG Qn;;ACTIVE;1.0h(2);2.73 +77172-5;KIT gene exon 9 targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;KIT gene exon 9 mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KIT Exon 9 Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77173-3;Hepatocyte growth factor receptor Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Hepatocyte growth factor receptor Ag [Presence] in Tissue by Immune stain;HGFR Ag Tiss Ql ImStn;;ACTIVE;2.52;2.73 +77174-1;CALR gene exon 9 targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;CALR gene exon 9 mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CALR Exon 9 Mut Anl Bld/T;;ACTIVE;2.52;2.73 +77175-8;Coxiella burnetii phase 1 & 2 Ab.IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Coxiella burnetii phase 1 and 2 IgG and IgM panel - Serum;C burnet Ph 1 + 2 IgG + IgM Pnl Ser;;ACTIVE;2.52;2.56 +77176-6;Hepatitis B virus little e Ag & Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis B virus little e Ag and Ab panel - Serum;HBV e Ag + Ab Pnl Ser;;ACTIVE;2.52;2.73 +77177-4;IgG;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;IgG [Moles/volume] in Serum or Plasma;IgG SerPl-sCnc;;ACTIVE;2.52;2.52 +77178-2;Boron;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Boron [Mass/mass] in Hair;Boron Hair-mCnt;;ACTIVE;2.52;2.7 +77179-0;Niobium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Niobium [Mass/mass] in Tissue;Nb Tiss-mCnt;;ACTIVE;2.52;2.52 +7718-0;Squash zucchini Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Zucchini IgE Ab [Units/volume] in Serum;Zucchini IgE Qn;;ACTIVE;1.0h(2);2.73 +77180-8;Niobium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Niobium [Mass/volume] in Urine;Nb Ur-mCnc;;ACTIVE;2.52;2.7 +77181-6;Niobium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Niobium [Moles/volume] in Blood;Nb Bld-sCnc;;ACTIVE;2.52;2.7 +77182-4;Niobium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Niobium [Mass/volume] in Blood;Nb Bld-mCnc;;ACTIVE;2.52;2.52 +77183-2;Niobium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Niobium [Moles/volume] in Urine;Nb Ur-sCnc;;ACTIVE;2.52;2.52 +77184-0;Niobium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Niobium/Creatinine [Molar ratio] in Urine;Nb/Creat Ur-sRto;;ACTIVE;2.52;2.52 +77185-7;Uranium;MCnt;Pt;Dentin;Qn;;DRUG/TOX;1;Uranium [Mass/mass] in Dentin;Uranium Dentin-mCnt;;ACTIVE;2.52;2.52 +77186-5;Uranium;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Uranium [Mass/mass] in Hair;Uranium Hair-mCnt;;ACTIVE;2.52;2.7 +77187-3;Zirconium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zirconium [Mass/volume] in Urine;Zirconium Ur-mCnc;;ACTIVE;2.52;2.52 +77188-1;Zirconium;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zirconium [Moles/volume] in Urine;Zirconium Ur-sCnc;;ACTIVE;2.52;2.52 +77189-9;Zirconium/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Zirconium/Creatinine [Molar ratio] in Urine;Zirconium/Creat Ur-sRto;;ACTIVE;2.52;2.52 +77190-7;Hepatitis B virus core & surface Ab & surface Ag panel;-;-;Ser;-;;PANEL.MICRO;1;Hepatitis B virus core and surface Ab and surface Ag panel - Serum;HBV core + surf Ab + surf Ag Pnl Ser;;ACTIVE;2.52;2.56 +77191-5;Human epididymis protein 4;SCnc;Pt;Ser/Plas;Qn;EIA;CHEM;1;Deprecated Human epididymis protein 4 [Moles/volume] in Serum or Plasma by Immunoassay;Deprecated HE4 SerPl EIA-sCnc;;DEPRECATED;2.54;2.54 +77192-3;Prealbumin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prealbumin [Moles/volume] in Serum or Plasma;Prealb SerPl-sCnc;;ACTIVE;2.52;2.52 +77193-1;Bacteria identified;Prid;Pt;Uterus;Nom;Culture;MICRO;1;Bacteria identified in Uterus by Culture;Bacteria Uterus Cult;;ACTIVE;2.52;2.52 +77194-9;Intravascular systolic.tibial artery/Brachial artery;PresRto;Pt;Arterial system;Qn;;BP.MOLEC;2;Ankle-brachial index;ABI;;ACTIVE;2.52;2.73 +77195-6;Cardio-ankle vascular index;Ratio;Pt;Arterial system;Qn;Calculated;CARD.RISK;2;Cardio-ankle vascular index Calculated;CAVI Calc;;ACTIVE;2.52;2.52 +77196-4;Pulse wave velocity;Vel;Pt;Arterial system;Qn;;CARD.RISK;2;Pulse wave velocity;PWV;;ACTIVE;2.52;2.52 +77197-2;Noninvasive arteriosclerosis studies panel;-;Pt;Arterial system;Qn;;PANEL.CARDIAC;2;Noninvasive arteriosclerosis studies panel;Noninv arteriosclerosis studies pnl;;ACTIVE;2.52;2.52 +7719-8;Staphylococcus aureus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Staphylococcus aureus IgE Ab [Units/volume] in Serum;S aureus IgE Qn;;ACTIVE;1.0h(2);2.73 +77198-0;Noninvasive arteriosclerosis study;Find;Pt;^Patient;Doc;;CLIN;2;Noninvasive arteriosclerosis study;Noninv arteriosclerosis study;;ACTIVE;2.52;2.72 +77199-8;Evoked potential study;Find;Pt;Neurologic system;Doc;Evoked potential;CLIN;2;Evoked potential study;Evoked pot study;;ACTIVE;2.52;2.72 +77200-4;SI gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;SI gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SI gene Mut Anl Bld/T;;ACTIVE;2.52;2.73 +77201-2;Buprenorphine+Norbuprenorphine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Buprenorphine+Norbuprenorphine [Presence] in Saliva (oral fluid) by Confirmatory method;Buprenorphine+Nor Sal Ql Cfm;;ACTIVE;2.52;2.73 +77202-0;Laboratory comment;Txt;Pt;Report;Nar;;MISC;1;Laboratory comment [Text] in Report Narrative;Laboratory comment Report;;ACTIVE;2.52;2.73 +77203-8;Ustilago nuda+Ustilago tritici+Ustilago maydis+Tilletia tritici Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Smut fungi (Ustilago nuda+Ustilago tritici+Ustilago maydis+Tilletia tritici) IgE Ab [Units/volume] in Serum;Smut fungi IgE Qn;;ACTIVE;2.52;2.73 +77204-6;Buprenorphine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Buprenorphine [Presence] in Saliva (oral fluid) by Confirmatory method;Buprenorphine Sal Ql Cfm;;ACTIVE;2.52;2.73 +77205-3;Buprenorphine;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Buprenorphine [Presence] in Meconium by Screen method;Buprenorphine Mec Ql Scn;;ACTIVE;2.52;2.73 +7720-6;Stemphylium solani Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Stemphylium solani IgE Ab [Units/volume] in Serum;S solani IgE Qn;;ACTIVE;1.0h(2);2.73 +77206-1;Norbuprenorphine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Norbuprenorphine [Presence] in Saliva (oral fluid) by Confirmatory method;Norbuprenorphine Sal Ql Cfm;;ACTIVE;2.52;2.73 +77207-9;Naloxone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naloxone [Mass/volume] in Urine by Confirmatory method;Naloxone Ur Cfm-mCnc;;ACTIVE;2.52;2.73 +77208-7;Salivary gland protein 1 Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Salivary gland protein 1 IgA Ab [Units/volume] in Serum by Immunoassay;SP-1 IgA Ser IA-aCnc;;ACTIVE;2.52;2.73 +77209-5;Salivary gland protein 1 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Salivary gland protein 1 IgM Ab [Units/volume] in Serum by Immunoassay;SP-1 IgM Ser IA-aCnc;;ACTIVE;2.52;2.73 +77210-3;Salivary gland protein 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Salivary gland protein 1 IgG Ab [Units/volume] in Serum by Immunoassay;SP-1 IgG Ser IA-aCnc;;ACTIVE;2.52;2.73 +77211-1;Carbonic anhydrase 6 Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Carbonic anhydrase 6 IgA Ab [Units/volume] in Serum by Immunoassay;CA6 IgA Ser IA-aCnc;;ACTIVE;2.52;2.73 +77212-9;Carbonic anhydrase 6 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Carbonic anhydrase 6 IgG Ab [Units/volume] in Serum by Immunoassay;CA6 IgG Ser IA-aCnc;;ACTIVE;2.52;2.73 +77213-7;Carbonic anhydrase 6 Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Carbonic anhydrase 6 IgM Ab [Units/volume] in Serum by Immunoassay;CA6 IgM Ser IA-aCnc;;ACTIVE;2.52;2.73 +7721-4;Fragaria vesca Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Strawberry IgG Ab [Units/volume] in Serum;Strawberry IgG Qn;;ACTIVE;1.0h(2);2.73 +77214-5;Parotid secretory protein Ab.IgA;ACnc;Pt;Ser;Qn;IA;SERO;1;Parotid secretory protein IgA Ab [Units/volume] in Serum by Immunoassay;PSP IgA Ser IA-aCnc;;ACTIVE;2.52;2.73 +77215-2;Parotid secretory protein Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Parotid secretory protein IgG Ab [Units/volume] in Serum by Immunoassay;PSP IgG Ser IA-aCnc;;ACTIVE;2.52;2.73 +77216-0;Parotid secretory protein Ab.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Parotid secretory protein IgM Ab [Units/volume] in Serum by Immunoassay;PSP IgM Ser IA-aCnc;;ACTIVE;2.52;2.73 +77217-8;Salivary gland protein 1 & Carbonic anhydrase 6 & Parotid secretory protein Ab.IgA & IgG & IgM panel;-;Pt;Ser;Qn;IA;PANEL.SERO;1;Salivary gland protein 1 and Carbonic anhydrase 6 and Parotid secretory protein IgA and IgG and IgM panel - Serum by Immunoassay;SP-1+CA6+PSP IgA+IgG+IgM Pnl Ser IA;;ACTIVE;2.52;2.58 +77218-6;Patient satisfaction with healthcare delivery;Find;Pt;^Patient;Nom;;H&P.HX;2;Patient satisfaction with healthcare delivery;Pt satisfaction w healthcare;;TRIAL;2.52;2.7 +77219-4;Provider satisfaction with healthcare delivery;Find;Pt;^Patient;Nom;;H&P.HX;2;Provider satisfaction with healthcare delivery;Provider satisfaction w healthcare;;TRIAL;2.52;2.52 +77220-2;Niobium;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Niobium [Moles/mass] in Tissue;Nb Tiss-sCnt;;ACTIVE;2.52;2.52 +77221-0;Clinical knowledge, decision making, & mental workload panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Clinical knowledge, decision making, and mental workload panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7722-2;Fragaria vesca basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Strawberry triggered histamine release [Units/volume] in Blood;Strawberry BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77222-8;Knowledge required level;Type;Pt;{Nursing unit}.{Job position};Ord;NMMDS;SURVEY.NMMDS;4;Knowledge required level [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77223-6;Nursing staff.knowledge required level/Nursing staff;NFr;Pt;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.knowledge required level/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77224-4;Decision making required level;Type;Pt;{Nursing unit}.{Job position};Ord;NMMDS;SURVEY.NMMDS;4;Decision making required level [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77225-1;Nursing staff.decision making required level/Nursing staff;NFr;Pt;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.decision making required level/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77226-9;Workload dimensions panel;-;Pt;{Nursing unit}.{Job position};-;NMMDS;PANEL.SURVEY.NMMDS;4;Workload dimensions panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.63 +77227-7;Time load level;Type;Pt;{Nursing unit}.{Job position};Ord;NMMDS;SURVEY.NMMDS;4;Time load level [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77228-5;Nursing staff.time load level/Nursing staff;NFr;Pt;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.time load level/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77229-3;Mental effort load level;Type;Pt;{Nursing unit}.{Job position};Ord;NMMDS;SURVEY.NMMDS;4;Mental effort load level [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7723-0;Saccharum officinarum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Cane IgE Ab [Units/volume] in Serum;Sugar Cane IgE Qn;;ACTIVE;1.0h(2);2.73 +77230-1;Nursing staff.mental effort load level/Nursing staff;NFr;Pt;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.mental effort load level/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77231-9;Psychological stress load level;Type;Pt;{Nursing unit}.{Job position};Ord;NMMDS;SURVEY.NMMDS;4;Psychological stress load level [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77232-7;Nursing staff.psychological stress load level/Nursing staff;NFr;Pt;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.psychological stress load level/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77233-5;Body fat percentage;MFr;Pt;^Patient;Qn;BIA;BDYWGT.ATOM;2;Percentage of body fat by Bioelectrical impedance analysis;Bdy fat % BIA;;ACTIVE;2.52;2.52 +77234-3;How often in the past 12Mo would you say the patient was worried or stressed about having enough money to buy nutritious meals;Find;12Mo;^Patient;Ord;BRFSS;SURVEY.HWS;4;How often in the past 12 months would you say the patient was worried or stressed about having enough money to buy nutritious meals [BRFSS];;;TRIAL;2.52;2.66 +77235-0;On a typical weekday in the past W, how much time did the patient spend watching TV &or DVDs;NRat;1W;^Patient;Qn;;SURVEY.HWS;4;On a typical weekday in the past week, how much time did the patient spend watching TV AndOr DVDs;;;TRIAL;2.52;2.52 +77236-8;On a typical weekend D in the past W, how much time did the patient spend watching TV &or DVDs;NRat;1W;^Patient;Qn;;SURVEY.HWS;4;On a typical weekend day in the past week, how much time did the patient spend watching TV AndOr DVDs;;;TRIAL;2.52;2.52 +77237-6;On a typical weekday in the past W, how much time did the patient spend playing video games and computer games;NRat;1W;^Patient;Qn;;SURVEY.HWS;4;On a typical weekday in the past week, how much time did the patient spend playing video games and computer games;;;TRIAL;2.52;2.52 +77238-4;On a typical weekend D in the past W, how much time did the patient spend playing video games and computer games;NRat;1W;^Patient;Qn;;SURVEY.HWS;4;On a typical weekend day in the past week, how much time did the patient spend playing video games and computer games;;;TRIAL;2.52;2.52 +77239-2;Is the patient fed something other than breast milk or formula;Find;Pt;^Patient;Ord;;SURVEY.HWS;4;Is the patient fed something other than breast milk or formula;;;TRIAL;2.52;2.52 +772-4;Erythrocytes.nucleated;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes [#/volume] in Blood by Manual count;nRBC # Bld Manual;;ACTIVE;1.0;2.73 +77240-0;How much formula does the patient drink per D;NRat;1D;^Patient;Qn;;SURVEY.HWS;4;How much formula does the patient drink per day;;;TRIAL;2.52;2.52 +77241-8;Is the patient having any problems breastfeeding;Find;Pt;^Patient;Ord;;SURVEY.HWS;4;Is the patient having any problems breastfeeding;;;TRIAL;2.52;2.52 +77242-6;Physical activity behavior;Find;Pt;^Patient;Nom;;SURVEY.HWS;4;Physical activity behavior;;;TRIAL;2.52;2.52 +77243-4;Dietary behavior;Find;Pt;^Patient;Nom;;SURVEY.HWS;4;Dietary behavior;;;TRIAL;2.52;2.52 +77244-2;Total combined household income range in last 12Mo;NRat;12Mo;^Patient;Ord;;SURVEY.HWS;4;Total combined household income range in last year;;;ACTIVE;2.52;2.72 +77245-9;Readiness for change for improved nutrition;Score;Pt;^Patient;Ord;Reported;SURVEY.HWS;4;Readiness for change for improved nutrition [Reported];;;TRIAL;2.52;2.52 +77246-7;Readiness for change for improved sleep patterns;Score;Pt;^Patient;Ord;Reported;SURVEY.HWS;4;Readiness for change for improved sleep patterns [Reported];;;TRIAL;2.52;2.52 +77247-5;Readiness for change for improved exercise;Score;Pt;^Patient;Ord;Reported;SURVEY.HWS;4;Readiness for change for improved exercise [Reported];;;TRIAL;2.52;2.73 +7724-8;Saccharum officinarum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Cane IgG Ab [Units/volume] in Serum;Sugar Cane IgG Qn;;ACTIVE;1.0h(2);2.73 +77248-3;Readiness for change for improved screen-time;Score;Pt;^Patient;Ord;Reported;SURVEY.HWS;4;Readiness for change for improved screen-time [Reported];;;TRIAL;2.52;2.52 +77249-1;Weight management summary - recommended IHE set;-;Pt;{Setting};-;;PANEL.DOC;2;Weight management summary - recommended IHE set;Weight Mngmt IHE Set;;TRIAL;2.52;2.56 +77250-9;Mumps virus IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Mumps virus IgG and IgM panel - Serum;MuV IgG+IgM Pnl Ser;;ACTIVE;2.52;2.58 +77251-7;Percent impairment - confidence;Prctl;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Percent impairment - confidence [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.52;2.67 +77252-5;Percent impairment - difficulty;Prctl;Pt;^Patient;Qn;OPTIMAL;SURVEY.OPTIMAL;4;Percent impairment - difficulty [OPTIMAL];;"Copyright © 2012, 2006, 2005 American Physical Therapy Association. All rights reserved. Used with permission per LOINC Terms of Use, and in addition: Any further distribution or reproduction must include the following copyright statement: ""Copyright ©2005 American Physical Therapy Association. All rights reserved."" Contact permissions@apta.org with questions or for further information.";ACTIVE;2.52;2.67 +77253-3;Albumin/Creatinine;Ratio;Pt;Urine;Qn;Detection limit <= 1.0 mg/L;CHEM;1;Microalbumin/Creatinine [Ratio] in Urine by Detection limit <= 1.0 mg/L;Microalbumin/Creat Ur DL<=1mg/L-Rto;;ACTIVE;2.52;2.54 +77254-1;Albumin/Creatinine;Ratio;24H;Urine;Qn;Detection limit <= 1.0 mg/L;CHEM;1;Microalbumin/Creatinine [Ratio] in 24 hour Urine by Detection limit <= 1.0 mg/L;Microalbumin/Creat 24h Ur DL<=1mg/L-Rto;;ACTIVE;2.52;2.54 +7725-5;Helianthus annuus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Sunflower Seed IgG Ab RAST class in Serum;Deprecated Sunflower IgG Qn;;DEPRECATED;1.0h(2);2.69 +77255-8;Nursing staff job positions, quantity, turnover, & retention panel;-;RptPeriod;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing staff job positions, quantity, turnover, and retention panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77256-6;Nursing staff quantity panel;-;RptPeriod;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing staff quantity panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77257-4;Actual nursing staff;Num;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of actual nursing staff by job position in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77258-2;Full time equivalent hours of actual nursing staff;Time;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Full time equivalent hours of actual nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77259-0;Budgeted nursing staff;Num;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of budgeted nursing staff by job position in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77260-8;Full time equivalent hours of budgeted nursing staff;Time;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Full time equivalent hours of budgeted nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77261-6;Nursing staff.voluntary turnover.transfer/nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.voluntary turnover.transfer/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77262-4;Nursing staff.voluntary turnover/nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.voluntary turnover/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7726-3;Helianthus annuus pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sunflower Pollen IgE Ab [Units/volume] in Serum;Sunflower Poln IgE Qn;;ACTIVE;1.0h(2);2.73 +77263-2;Productive staff;Num;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Number of productive staff in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77264-0;New nursing staff;Num;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of new nursing staff by job position in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77265-7;New nursing staff who remained;Num;RptPeriod^end;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of new nursing staff by job position who remained in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77266-5;New nursing staff who left;Num;RptPeriod^end;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of new nursing staff by job position who left in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77267-3;Nursing staff at beginning;Num;RptPeriod^start;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of nursing staff by job position at beginning of a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77268-1;Nursing staff at beginning who remained;Num;RptPeriod^end;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of nursing staff by job position at beginning of a reporting period who remained [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77269-9;Nursing staff at beginning who left;Num;RptPeriod^end;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of nursing staff by job position at beginning of a reporting period who left [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77270-7;Nursing staff who left;Num;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Number of nursing staff by job position who left in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7727-1;Helianthus annuus seed basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Sunflower Seed triggered histamine release [Units/volume] in Blood;Sunflower Seed BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77271-5;Mean number of nursing staff;Num;RptPeriod^mean;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Average number of nursing staff by job position in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77272-3;Unfilled nursing staff job positions;Num;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Number of unfilled nursing staff job positions in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77273-1;Nursing staff turnover panel;-;RptPeriod;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing staff turnover panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77274-9;Nursing staff.voluntary turnover.terminate/nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.voluntary turnover.terminate/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77275-6;Nursing staff.involuntary turnover/nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Nursing staff.involuntary turnover/Nursing staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77276-4;Nursing staff who left/Mean number of nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Turnover rate [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77277-2;Unfilled nursing staff job positions/Mean number of nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Vacancy rate [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77278-0;Budgeted nursing staff job positions filled;Num;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Number of budgeted nursing staff job positions filled in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77279-8;Nursing staff retention panel;-;RptPeriod;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing staff retention panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77280-6;New nursing staff/Mean number of nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Accession rate [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77281-4;Nursing staff at beginning who remained/Mean number of nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Stability rate [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77282-2;Nursing staff at beginning who left/Mean number of nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Instability rate [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77283-0;New nursing staff who remained/Mean number of nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Survival rate [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77284-8;Nursing staff job positions panel;-;RptPeriod;{Nursing unit}.{Job position};-;NMMDS;PANEL.SURVEY.NMMDS;4;Nursing staff job positions panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77285-5;New nursing staff who left/Mean number of nursing staff;NFr;RptPeriod;{Nursing unit}.{Job position};Qn;NMMDS;SURVEY.NMMDS;4;Wastage rate [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77286-3;Direct care staff;Type;RptPeriod;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Direct care staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77287-1;Management, administrative, &or support staff;Type;RptPeriod;{Nursing unit};Nom;NMMDS;SURVEY.NMMDS;4;Management, administrative, AndOr support staff [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77288-9;Indexing - warning letter alert;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indexing - warning letter alert;FDA insert Indexing - warn ltr alert;;ACTIVE;2.52;2.52 +7728-9;Xiphias gladius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swordfish IgE Ab [Units/volume] in Serum;Swordfish IgE Qn;;ACTIVE;1.0h(2);2.73 +77289-7;Identification of suspect product & notification;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Identification of suspect product and notification;FDA insert Id susp prod + notification;;ACTIVE;2.52;2.56 +77290-5;Lactation;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Lactation;FDA insert Lactation;;ACTIVE;2.52;2.52 +77291-3;Females & males of reproductive potential;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Females and males reproductive potential;FDA insert Female + male reprod potent;;ACTIVE;2.52;2.56 +77292-1;eFacility;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert eFacility;FDA insert eFacility;;ACTIVE;2.52;2.52 +77293-9;Ds per W of moderate to vigorous physical activity;NRat;Pt;^Patient;Qn;;SURVEY.HWS;4;Days per week of moderate to vigorous physical activity;;;TRIAL;2.52;2.52 +77294-7;Yesterday, how many times did the patient eat any vegetables;Num;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many times did the patient eat any vegetables #;;;TRIAL;2.52;2.52 +77295-4;Yesterday, how many times did the patient drink bottles or glasses of water;Num;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many times did the patient drink bottles or glasses of water #;;;TRIAL;2.52;2.52 +77296-2;Yesterday, how many times did the patient drink 100% fruit juice;Num;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many times did the patient drink 100% fruit juice #;;;TRIAL;2.52;2.52 +7729-7;Xiphias gladius Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Swordfish IgG Ab [Units/volume] in Serum;Swordfish IgG Qn;;ACTIVE;1.0h(2);2.69 +77297-0;Yesterday, how many times did the patient drink any punch, Kool-Aid, Tampico, other fruit-flavored drinks, or sports drinks;Num;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many times did the patient drink any punch, Kool-Aid, Tampico, other fruit-flavored drinks, or sports drinks #;;;TRIAL;2.52;2.52 +77298-8;Yesterday, how many times did the patient eat food from any type of restaurant;Num;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many times did the patient eat food from any type of restaurant? #;;;TRIAL;2.52;2.52 +77299-6;Yesterday, how many times the patient eat fruit;Num;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many times the patient eat fruit #;;;TRIAL;2.52;2.52 +77300-2;Yesterday, how many times did the patient drink any regular (not diet) sodas or soft drinks;Num;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many times did the patient drink any regular (not diet) sodas or soft drinks #;;;TRIAL;2.52;2.52 +77301-0;Reason care action performed or not;Find;Pt;^Patient;Nom;;H&P.HX;2;Reason care action performed or not;Rsn care action performed or not;;TRIAL;2.52;2.52 +77302-8;Patient preference for care action;Find;Pt;^Patient;Nom;;H&P.HX;2;Patient preference for care action;Patient pref for care action;;DISCOURAGED;2.52;2.69 +77303-6;Provider preference for care action;Find;Pt;^Patient;Nom;;H&P.HX;2;Provider preference for care action;Provider pref for care action;;DISCOURAGED;2.52;2.69 +77304-4;Radiation dose;EngCnt;Procedure dur;Dose;Qn;;H&P.HX;2;Radiation dose [Energy/mass];Radiation dose;;TRIAL;2.52;2.52 +7730-5;Platanus occidentalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated American Sycamore IgE Ab [Units/volume] in Serum;Deprecated Amer Sycamore IgE Qn;;DEPRECATED;1.0h(2);2.69 +77305-1;Transferred from;Type;Pt;Facility;Nom;;H&P.HX;2;Transferred from of Facility;Transferred from Facility;;TRIAL;2.52;2.52 +77306-9;Discharge disposition;Type;Pt;^Patient;Nom;;H&P.HX;2;Deprecated Discharge disposition;Deprecated Discharge disposition;;DEPRECATED;2.52;2.66 +77307-7;Lead;MCnc;Pt;BldV;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Venous blood;Lead BldV-mCnc;;ACTIVE;2.52;2.73 +77308-5;Yesterday, did the patient eat French fries or chips;Find;1D;^Patient;Nom;IHE.HW;SURVEY.HWS;4;Yesterday, did the patient eat French fries or chips [IHE.HW];;;TRIAL;2.52;2.52 +77309-3;Acylcarnitine pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Acylcarnitine pattern [Interpretation] in Serum or Plasma Narrative;Acylcarnitine pattern SerPl-Imp;;ACTIVE;2.52;2.52 +77310-1;Measles virus Ab.IgG associated observations panel;-;Pt;Ser;-;;PANEL.MICRO;1;Measles virus IgG associated observations panel - Serum;MeV Ab.IgG Assoc Obs Pnl Ser;;ACTIVE;2.52;2.58 +77311-9;Multisection for endograft;Find;Pt;Abdomen>Aorta.abdominal & Pelvis+Lower extremity.bilateral>Vessels;Doc;CT.angio;RAD;2;CTA Abdominal aorta and Bilateral vessels for endograft;CTA Abd Aorta+Ves-Bl for endograft;;ACTIVE;2.52;2.66 +77312-7;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis+Lower extremity.bilateral>Aorta.abdominal+Vessels.bilateral;Doc;CT.angio;RAD;2;Deprecated Abdomen+Pelvis+Lower extremity.bilateral>Aorta.abdominal+Vessels CT angiogram W contrast IV;Deprecated Ab+Pl+Lx.b>A.ab+V CT.Angio W;;DEPRECATED;2.52;2.58 +7731-3;Citrus reticulata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mandarin IgE Ab [Units/volume] in Serum;Mandarin IgE Qn;;ACTIVE;1.0h(2);2.73 +77313-5;DNA analysis discrete sequence variation basic associated observations panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;DNA analysis discrete sequence variation basic associated observations panel - Blood or Tissue by Molecular genetics method;DNA discrete seq var basic assoc obs Pnl;;TRIAL;2.52;2.63 +77314-3;Chromosome analysis basic associated observations panel;-;Pt;Bld/Tiss;-;Cytogenetics;PANEL.MOLPATH;1;Chromosome analysis basic associated observations panel - Blood or Tissue by Cytogenetics;Chromos cyto basic assoc obs Pnl Bld/T;;TRIAL;2.52;2.63 +77315-0;Yesterday, what percent of snacks were healthy;NFr;1D;^Patient;Qn;;SURVEY.HWS;4;Yesterday, what percent of snacks were healthy;;;TRIAL;2.52;2.52 +77316-8;How often have you added cereal to your baby's bottle of formula or pumped (or expressed) breast milk in the past 2W;Find;2W;^Patient;Ord;IFPS-II;SURVEY.HWS;4;How often have you added cereal to your baby's bottle of formula or pumped (or expressed) breast milk in the past 2 weeks [IFPS-II];;;TRIAL;2.52;2.58 +77317-6;In the past W, how many times were dinners prepared at home and eaten together;NRat;1W;^Patient;Qn;;SURVEY.HWS;4;In the past week, how many times were dinners prepared at home and eaten together;;;TRIAL;2.52;2.52 +77318-4;Is the patient breastfed;Find;Pt;^Patient;Ord;;SURVEY.HWS;4;Is the patient breastfed;;;TRIAL;2.52;2.52 +77319-2;Allergen.miscellaneous Ab.IgE.RAST class;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Miscellaneous allergen IgE Ab RAST class [Units/volume] in Serum;Deprecated Misc Allergen IgE RAST Qn;;DEPRECATED;2.52;2.54 +773-2;Erythrocytes.nucleated/100 erythrocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes/100 erythrocytes in Blood by Manual count;nRBC/100 RBC NFr Bld Manual;;DISCOURAGED;1.0;2.73 +77320-0;Benzoylecgonine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Benzoylecgonine [Moles/volume] in Specimen;BZE Spec-sCnc;;ACTIVE;2.52;2.69 +7732-1;Citrus reticulata Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mandarin IgG Ab [Units/volume] in Serum;Mandarin IgG Qn;;ACTIVE;1.0h(2);2.73 +77321-8;Cyanide;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cyanide [Moles/volume] in Specimen;Cyanide Spec-sCnc;;ACTIVE;2.52;2.69 +77322-6;Amitriptyline+Nortriptyline;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Amitriptyline+Nortriptyline [Moles/volume] in Specimen;Amitrip+Nor Spec-sCnc;;ACTIVE;2.52;2.69 +77323-4;diazePAM;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;diazePAM [Moles/volume] in Specimen;diazePAM Spec-sCnc;;ACTIVE;2.52;2.69 +77324-2;Flurazepam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Flurazepam [Moles/volume] in Specimen;Flurazepam Spec-sCnc;;ACTIVE;2.52;2.69 +77325-9;N-desalkylflurazepam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Moles/volume] in Specimen;Desalkylfluraz Spec-sCnc;;ACTIVE;2.52;2.69 +77326-7;LORazepam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;LORazepam [Moles/volume] in Specimen;LORazepam Spec-sCnc;;ACTIVE;2.52;2.69 +77327-5;Triazolam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Triazolam [Moles/volume] in Specimen;Triazolam Spec-sCnc;;ACTIVE;2.52;2.69 +77328-3;Methadone;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Methadone [Moles/volume] in Specimen;Methadone Spec-sCnc;;ACTIVE;2.52;2.69 +77329-1;Temazepam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Temazepam [Moles/volume] in Specimen;Temazepam Spec-sCnc;;ACTIVE;2.52;2.69 +77330-9;Protriptyline;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Protriptyline [Moles/volume] in Specimen;Protrip Spec-sCnc;;ACTIVE;2.52;2.69 +77331-7;Nortrimipramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nortrimipramine [Moles/volume] in Specimen;Nortrimipramine Spec-sCnc;;ACTIVE;2.52;2.69 +77332-5;Morphine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Morphine [Moles/volume] in Specimen;Morphine Spec-sCnc;;ACTIVE;2.52;2.69 +77333-3;Imipramine+Desipramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Imipramine+Desipramine [Moles/volume] in Specimen;Imipramine+Desipr Spec-sCnc;;ACTIVE;2.52;2.69 +77334-1;Norpropoxyphene;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Norpropoxyphene [Moles/volume] in Specimen;Norpropoxyph Spec-sCnc;;ACTIVE;2.52;2.69 +77335-8;Propoxyphene+Norpropoxyphene;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Moles/volume] in Specimen;Propoxyph+Nor Spec-sCnc;;ACTIVE;2.52;2.69 +77336-6;Oxazepam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Oxazepam [Moles/volume] in Specimen;Oxazepam Spec-sCnc;;ACTIVE;2.52;2.69 +77337-4;Trimipramine+Nortrimipramine;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Trimipramine+Nortrimipramine [Moles/volume] in Specimen;Trimipram+Nor Spec-sCnc;;ACTIVE;2.52;2.69 +77338-2;Indocyanine green^1M post dose indocyanine green;MCnc;Pt;Plas;Qn;;CHAL;1;Indocyanine green [Mass/volume] in Plasma --1 minute post dose indocyanine green;ICG 1M p dose ICG Plas-mCnc;;ACTIVE;2.52;2.52 +7733-9;Manihot esculenta crantz Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tapioca IgE Ab [Units/volume] in Serum;Tapioca IgE Qn;;ACTIVE;1.0h(2);2.73 +77339-0;Indocyanine green^15M post dose indocyanine green;MCnc;Pt;Plas;Qn;;CHAL;1;Indocyanine green [Mass/volume] in Plasma --15 minutes post dose indocyanine green;ICG 15M p dose ICG Plas-mCnc;;ACTIVE;2.52;2.52 +77340-8;Alpha 1 globulin;MCnc;XXX;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin [Mass/volume] by Electrophoresis in Urine collected for unspecified duration;Alpha1 Glob ?Tm Ur Elph-mCnc;;ACTIVE;2.52;2.73 +77341-6;Anion gap 4;SCnc;Pt;Ser/Plas/Bld;Qn;;CHEM;1;Anion gap 4 in Serum, Plasma or Blood;Anion Gap4 SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77342-4;Beta 1 globulin;MCnc;XXX;Urine;Qn;Electrophoresis;CHEM;1;Beta 1 globulin [Mass/volume] by Electrophoresis in Urine collected for unspecified duration;Beta1 Glob ?Tm Ur Elph-mCnc;;ACTIVE;2.52;2.52 +77343-2;Gamma globulin;MCnc;XXX;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin [Mass/volume] by Electrophoresis in Urine collected for unspecified duration;Gamma glob ?Tm Ur Elph-mCnc;;ACTIVE;2.52;2.73 +77344-0;Colony count;NCnc;Pt;Implanted device;Qn;Culture;MICRO;1;Colony count [#/volume] in Implanted device by Culture;CC # Implnt dev Cult;;ACTIVE;2.52;2.65 +77345-7;Enterobius vermicularis^2nd specimen;PrThr;Pt;Anal;Ord;Pinworm examination;MICRO;1;Enterobius vermicularis [Presence] in Anal by Pinworm exam --2nd specimen;E vermicularis sp2 Anal Ql Pinworm Exam;;ACTIVE;2.52;2.73 +77346-5;Enterobius vermicularis^3rd specimen;PrThr;Pt;Anal;Ord;Pinworm examination;MICRO;1;Enterobius vermicularis [Presence] in Anal by Pinworm exam --3rd specimen;E vermicularis sp3 Anal Ql Pinworm Exam;;ACTIVE;2.52;2.56 +7734-7;Manihot esculenta crantz Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tapioca IgG Ab [Units/volume] in Serum;Tapioca IgG Qn;;ACTIVE;1.0h(2);2.69 +77347-3;Beta-2 transferrin panel;-;Pt;Ser/Plas+CSF;-;;PANEL.CHEM;1;Beta-2 transferrin panel - Serum or Plasma and CSF;Beta-2 transferrin Pnl SerPl+CSF;;ACTIVE;2.52;2.52 +77348-1;Tacrolimus^trough;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Blood --trough;Tacrolimus Trough Bld-mCnc;;ACTIVE;2.52;2.73 +77349-9;Everolimus^trough;MCnc;Pt;Bld;Qn;LC/MS/MS;DRUG/TOX;1;Everolimus [Mass/volume] in Blood by LC/MS/MS --trough;Everolimus Trough Bld LC/MS/MS-mCnc;;ACTIVE;2.52;2.73 +77350-7;Erythropoietin Ab;PrThr;Pt;Ser;Ord;;CHEM;1;Erythropoietin (EPO) Ab [Presence] in Serum;EPO Ab Ser Ql;;ACTIVE;2.52;2.56 +77351-5;Probability of suspected pulmonary embolism prior to imaging;Likelihood;Pt;^Patient;Ord;;H&P.HX;2;Probability of suspected pulmonary embolism prior to imaging;Prob of PE prior to imaging;;ACTIVE;2.52;2.52 +77352-3;Thoughts on artificial nutrition and hydration;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on artificial nutrition and hydration [Reported];;;ACTIVE;2.52;2.73 +77353-1;Noninvasive colorectal cancer DNA+occult blood screening;Imp;Pt;Stool;Nar;;MOLPATH;1;Noninvasive colorectal cancer DNA and occult blood screening [Interpretation] in Stool Narrative;Noninv colon ca DNA+occ bld scrn Stl-Imp;;ACTIVE;2.52;2.73 +7735-4;Camellia sinensis Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tea IgG Ab [Units/volume] in Serum;Tea IgG Qn;;ACTIVE;1.0h(2);2.73 +77354-9;Noninvasive colorectal cancer DNA+occult blood screening;PrThr;Pt;Stool;Ord;;MOLPATH;1;Noninvasive colorectal cancer DNA and occult blood screening [Presence] in Stool;Noninv colon ca DNA+occ bld scrn Stl Ql;;ACTIVE;2.52;2.73 +77355-6;Non-hematopoietic stem cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Non-hematopoietic stem cells/100 leukocytes in Body fluid by Manual count;Nonhematop stem cell/leuk NFr Fld Manual;;ACTIVE;2.52;2.52 +77356-4;Non-hematopoietic stem cells/100 leukocytes;NFr;Pt;CSF;Qn;Manual count;HEM/BC;1;Non-hematopoietic stem cells/100 leukocytes in Cerebral spinal fluid by Manual count;Nonhematop stem cell/leuk NFr CSF Manual;;ACTIVE;2.52;2.52 +77357-2;Nitrogen;SCnt;24H;Stool;Qn;;CHEM;1;Nitrogen [Moles/mass] in 24 hour Stool;N2 24h Stl-sCnt;;ACTIVE;2.52;2.52 +77358-0;Nitrogen;MCnt;24H;Stool;Qn;;CHEM;1;Nitrogen [Mass/mass] in 24 hour Stool;N2 24h Stl-mCnt;;ACTIVE;2.52;2.52 +77359-8;Protein;MCnc;Pt;Saliva;Qn;;CHEM;1;Protein [Mass/volume] in Saliva (oral fluid);Prot Sal-mCnc;;ACTIVE;2.52;2.52 +77360-6;Triglyceride;MCnt;24H;Stool;Qn;;CHEM;1;Triglyceride [Mass/mass] in 24 hour Stool;Trigl 24h Stl-mCnt;;ACTIVE;2.52;2.52 +77361-4;Triglyceride;MRat;24H;Stool;Qn;;CHEM;1;Triglyceride [Mass/time] in 24 hour Stool;Trigl 24h Stl-mRate;;ACTIVE;2.52;2.56 +7736-2;Termamyl Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Termamyl IgE Ab [Units/volume] in Serum;Termamyl IgE Qn;;ACTIVE;1.0h(2);2.42 +77362-2;N-tau methylimidazoleacetate/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;N-tau methylimidazoleacetate/Creatinine [Molar ratio] in 24 hour Urine;N-tau MIAA/Creat 24h Ur-sRto;;ACTIVE;2.52;2.54 +77363-0;N-tau methylimidazoleacetate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N-tau methylimidazoleacetate/Creatinine [Molar ratio] in Urine;N-tau MIAA/Creat Ur-sRto;;ACTIVE;2.52;2.54 +77364-8;Tryptophan, kynurenin & 3-hydroxykynurenin panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Tryptophan, kynurenin and 3-hydroxykynurenin panel - Serum or Plasma;Tryptophan+metabolites Pnl SerPl;;ACTIVE;2.52;2.52 +77365-5;Nitrogen panel;-;24H;Stool;-;;PANEL.CHEM;1;Nitrogen panel - 24 hour Stool;Nitrogen Pnl 24h Stl;;ACTIVE;2.52;2.52 +77366-3;Metanephrine.free & Normetanephrine.free & 3-Methoxytyramine.free panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Metanephrine.free and Normetanephrine.free and 3-Methoxytyramine.free panel - Serum or Plasma;Free MN, NMN and 3-MT SerPl;;ACTIVE;2.52;2.63 +77367-1;Cholinesterase^dibucaine;CCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Cholinesterase [Enzymatic activity/volume] in Serum or Plasma by calculation --Dibucaine;Cholinesterase Dibucaine SerPl Calc-cCnc;;ACTIVE;2.52;2.58 +77368-9;HIV 1 proviral DNA;PrThr;Pt;Semen;Ord;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Presence] in Semen by NAA with probe detection;HIV 1 pro DNA Smn Ql NAA+probe;;ACTIVE;2.52;2.63 +77369-7;HIV 1 RNA;PrThr;Pt;Semen;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA [Presence] in Semen by NAA with probe detection;HIV1 RNA Smn Ql NAA+probe;;ACTIVE;2.52;2.63 +7737-0;Thymus vulgaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Thyme IgE Ab [Units/volume] in Serum;Thyme IgE Qn;;ACTIVE;1.0h(2);2.73 +77370-5;Procollagen type I.N-terminal propeptide;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Procollagen type I.N-terminal propeptide [Mass/volume] in Serum or Plasma by Immunoassay;PINP SerPl IA-mCnc;;ACTIVE;2.52;2.56 +77371-3;Brassicasterol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Brassicasterol [Moles/volume] in Serum or Plasma;Brassicasterol SerPl-sCnc;;ACTIVE;2.52;2.52 +77372-1;3-Methoxytyramine.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Methoxytyramine.free [Moles/volume] in Serum or Plasma;Free 3-MT SerPl-sCnc;;ACTIVE;2.52;2.52 +77373-9;Lathosterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lathosterol [Moles/volume] in Serum or Plasma;Lathosterol SerPl-sCnc;;ACTIVE;2.52;2.52 +77374-7;clomiPRAMINE trough & clomiPRAMINE+Norclomipramine trough & Norclomipramine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;clomiPRAMINE trough, clomiPRAMINE+Norclomipramine trough and Norclomipramine panel - Serum or Plasma;Clom, Clom+Nor Trgh + Nor Pnl SerPl;;ACTIVE;2.52;2.69 +77375-4;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Specimen by NAA with probe detection;HPV HR 12 DNA Spec Ql NAA+probe;;ACTIVE;2.52;2.69 +77376-2;Human papilloma virus 16 & 18 & 31+33+35+39+45+51+52+56+58+59+66+68 DNA panel;-;Pt;Anorectal;-;;PANEL.MICRO;1;Human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 DNA - Anorectal;HPV16+18+H Risk 12 DNA Pnl Anorectl;;ACTIVE;2.52;2.63 +77377-0;Human papilloma virus 16 & 18 & 31+33+35+39+45+51+52+56+58+59+66+68 DNA;Imp;Pt;XXX;Nom;;MICRO;1;Human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Interpretation] in Specimen;HPV16+18+H Risk 12 DNA Spec-Imp;;ACTIVE;2.52;2.73 +77378-8;Human papilloma virus 16 & 18 & 31+33+35+39+45+51+52+56+58+59+66+68 DNA panel;-;Pt;XXX;-;;PANEL.MICRO;1;Human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 DNA - Specimen;HPV16+18+H Risk 12 DNA Pnl Spec;;ACTIVE;2.52;2.69 +77379-6;Human papilloma virus 16 & 18 & 31+33+35+39+45+51+52+56+58+59+66+68 DNA;Imp;Pt;Cvx;Nom;;MICRO;1;Human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Interpretation] in Cervix;HPV16+18+H Risk 12 DNA Cvx-Imp;;ACTIVE;2.52;2.73 +77380-4;Human papilloma virus 16 & 18 & 31+33+35+39+45+51+52+56+58+59+66+68 DNA;Imp;Pt;Anorectal;Nom;;MICRO;1;Human papilloma virus 16 and 18 and 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Interpretation] in Anorectal;HPV16+18+H Risk 12 DNA Anorectl-Imp;;ACTIVE;2.52;2.63 +77381-2;Protein fractions panel;-;XXX;Urine;Qn;Electrophoresis;PANEL.CHEM;1;Protein electrophoresis panel in Urine collected for unspecified duration;Prot Elph Pnl Ur Elph;;ACTIVE;2.52;2.52 +77382-0;Adenovirus Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;HAdV Ag BAL Ql IF;;ACTIVE;2.52;2.56 +77383-8;Influenza virus A Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;FLUAV Ag BAL Ql IF;;ACTIVE;2.52;2.56 +77384-6;Influenza virus B Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;FLUBV Ag BAL Ql IF;;ACTIVE;2.52;2.56 +77385-3;Parainfluenza virus 1 Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;HPIV1 Ag BAL Ql IF;;ACTIVE;2.52;2.56 +77386-1;Parainfluenza virus 2 Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Parainfluenza virus 2 Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;HPIV2 Ag BAL Ql IF;;ACTIVE;2.52;2.56 +77387-9;Parainfluenza virus 3 Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Parainfluenza virus 3 Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;HPIV3 Ag BAL Ql IF;;ACTIVE;2.52;2.56 +7738-8;Phleum pratense basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Timothy triggered histamine release [Units/volume] in Blood;Timothy BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77388-7;Cytomegalovirus Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Cytomegalovirus Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;CMV Ag BAL Ql IF;;ACTIVE;2.52;2.56 +77389-5;Respiratory syncytial virus Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Respiratory syncytial virus Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;RSV Ag BAL Ql IF;;ACTIVE;2.52;2.56 +77390-3;Respiratory syncytial virus Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Respiratory syncytial virus Ag [Presence] in Nasopharynx by Immunofluorescence;RSV Ag Nph Ql IF;;ACTIVE;2.52;2.56 +77391-1;Parainfluenza virus 2 Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Parainfluenza virus 2 Ag [Presence] in Nasopharynx by Immunofluorescence;HPIV2 Ag Nph Ql IF;;ACTIVE;2.52;2.56 +77392-9;Parainfluenza virus 3 Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Parainfluenza virus 3 Ag [Presence] in Nasopharynx by Immunofluorescence;HPIV3 Ag Nph Ql IF;;ACTIVE;2.52;2.56 +77393-7;Yesterday, how many 8-ounce portions of milk did the patient drink;Num;Pt;^Patient;Qn;;SURVEY.HWS;4;Yesterday, how many 8-ounce portions of milk did the patient drink #;;;TRIAL;2.52;2.52 +77394-5;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Anorectal by NAA with probe detection;HPV HR 12 DNA Anorectl Ql NAA+probe;;ACTIVE;2.52;2.63 +77395-2;Human papilloma virus 18 DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 18 DNA [Presence] in Anorectal by NAA with probe detection;HPV18 DNA Anorectl Ql NAA+probe;;ACTIVE;2.52;2.63 +7739-6;Nicotiana tabacum Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tobacco IgG Ab [Units/volume] in Serum;Tobacco IgG Qn;;ACTIVE;1.0h(2);2.73 +77396-0;Human papilloma virus 16 DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16 DNA [Presence] in Anorectal by NAA with probe detection;HPV16 DNA Anorectl Ql NAA+probe;;ACTIVE;2.52;2.63 +77397-8;ABO & Rh group;Type;Pt;Bld;Nom;Confirm;BLDBK;1;ABO and Rh group [Type] in Blood by Confirmatory method;ABO + Rh Bld Cfm;;ACTIVE;2.52;2.73 +77398-6;Mumps virus IgG & IgM index associated observations panel;-;Pt;Ser;-;;PANEL.MICRO;1;Mumps virus IgG and IgM index panel - Serum;Mumps virus IgG.Ab index Pnl Ser;;ACTIVE;2.52;2.52 +77399-4;Human papilloma virus 16 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16 DNA [Presence] in Cervix by NAA with probe detection;HPV16 DNA Cvx Ql NAA+probe;;ACTIVE;2.52;2.73 +774-0;Ovalocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Ovalocytes [Presence] in Blood by Light microscopy;Ovalocytes Bld Ql Smear;;ACTIVE;1.0;2.73 +77400-0;Human papilloma virus 18 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 18 DNA [Presence] in Cervix by NAA with probe detection;HPV18 DNA Cvx Ql NAA+probe;;ACTIVE;2.52;2.73 +77401-8;Admission history and physical note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Admission history and physical note;Anesthesiology Admit H&P note;;ACTIVE;2.52;2.58 +77402-6;Evaluation note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Evaluation note;Anesthesiology Eval note;;ACTIVE;2.52;2.69 +77403-4;Consultation note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Consult note;Anesthesiology Consult note;;ACTIVE;2.52;2.58 +7740-4;Nicotiana tabacum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Tobacco triggered histamine release [Units/volume] in Blood;Tobacco BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77404-2;Education note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Education note;Anesthesiology Educ note;;ACTIVE;2.52;2.52 +77405-9;Referral note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Referral note;Anesthesiology Referral note;;ACTIVE;2.52;2.58 +77406-7;Transfer summary note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Transfer summary note;Anesthesiology Transfer sum note;;ACTIVE;2.52;2.58 +77407-5;Evaluation note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Evaluation note;Cardiology Eval note;;ACTIVE;2.52;2.69 +77408-3;Discharge instructions;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Discharge instructions;Cardiology Discharge instruct;;ACTIVE;2.52;2.54 +77409-1;Discharge summary note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Discharge summary;Cardiology D/C sum;;ACTIVE;2.52;2.73 +77410-9;Discharge teaching note;Find;Pt;Hospital;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Hospital Discharge teaching note;Cardiology Hosp Discharge teach note;;ACTIVE;2.52;2.52 +77411-7;Education note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Education note;Cardiology Educ note;;ACTIVE;2.52;2.52 +7741-2;Nicotiana tabacum cigarette Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Tobacco IgE Ab [Units/volume] in Serum;Deprecated Cigarette Tobacco IgE Qn;;DEPRECATED;1.0h(2);2.69 +77412-5;History and physical note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology History and physical note;Cardiology H&P note;;ACTIVE;2.52;2.58 +77413-3;Initial evaluation note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Initial evaluation note;Cardiology Initial eval note;;ACTIVE;2.52;2.52 +77414-1;Transfer summary note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Transfer summary note;Cardiology Transfer sum note;;ACTIVE;2.52;2.58 +77415-8;Admission history and physical note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Admission history and physical note;CCM Admit H&P note;;ACTIVE;2.52;2.58 +77416-6;Discharge instructions;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Discharge instructions;CCM Discharge instruct;;ACTIVE;2.52;2.54 +77417-4;Discharge summary note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Discharge summary;CCM D/C sum;;ACTIVE;2.52;2.73 +77418-2;Discharge teaching note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Discharge teaching note;CCM Discharge teach note;;ACTIVE;2.52;2.52 +77419-0;Education note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Education note;CCM Educ note;;ACTIVE;2.52;2.52 +7742-0;Lycopersicon lycopersicum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Tomato triggered histamine release [Units/volume] in Blood;Tomato BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77420-8;History and physical note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine History and physical note;CCM H&P note;;ACTIVE;2.52;2.58 +77421-6;Initial evaluation note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Initial evaluation note;CCM Initial eval note;;ACTIVE;2.52;2.52 +77422-4;Procedure note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine procedure note;CCM Procedure note;;ACTIVE;2.52;2.58 +77423-2;Education note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Education note;Audiology Educ note;;ACTIVE;2.52;2.52 +77424-0;Initial evaluation note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Initial evaluation note;Audiology Initial eval note;;ACTIVE;2.52;2.73 +77425-7;Procedure note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology procedure note;Audiology Procedure note;;ACTIVE;2.52;2.58 +77426-5;Progress note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Progress note;Audiology Prog note;;ACTIVE;2.52;2.73 +77427-3;Referral note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Referral note;Audiology Referral note;;ACTIVE;2.52;2.58 +77428-1;Treatment plan note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Deprecated Audiology Treatment plan note;Deprecated Audiology Tx plan note;;DEPRECATED;2.52;2.56 +77429-9;Consultation note;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Consult note;Allergy+Immunology Consult note;;ACTIVE;2.52;2.66 +77430-7;Education note;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Education note;Allergy+Immunology Educ note;;ACTIVE;2.52;2.66 +77431-5;Initial evaluation note;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Initial evaluation note;Allergy+Immunology Initial eval note;;ACTIVE;2.52;2.66 +77432-3;Referral note;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Referral note;Allergy+Immunology Referral note;;ACTIVE;2.52;2.66 +77433-1;Treatment plan note;Find;Pt;{Setting};Doc;Allergy and immunology;DOC.ONTOLOGY;2;Deprecated Allergy and immunology Treatment plan note;Deprecated Allergy+immunology Tx plan no;;DEPRECATED;2.52;2.56 +77434-9;Evaluation note;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Evaluation note;Allergy+Immunology Eval note;;ACTIVE;2.52;2.69 +77435-6;Evaluation note;Find;Pt;{Setting};Doc;Child and adolescent psychiatry;DOC.ONTOLOGY;2;Child and adolescent psychiatry Evaluation note;Child+teen psych Eval note;;ACTIVE;2.52;2.69 +77436-4;Summary note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Summary note;Anesthesiology Summary note;;ACTIVE;2.52;2.52 +77437-2;Flowsheet;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Flowsheet;Cardiology Flowsheet;;ACTIVE;2.52;2.52 +7743-8;Astragalus spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tragacanth IgE Ab [Units/volume] in Serum;Tragacanth IgE Qn;;ACTIVE;1.0h(2);2.73 +77438-0;Flowsheet;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Flowsheet;Allergy+Immunology Flowsheet;;ACTIVE;2.52;2.66 +77439-8;Flowsheet;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Flowsheet;Audiology Flowsheet;;ACTIVE;2.52;2.52 +77440-6;Flowsheet;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Flowsheet;CCM Flowsheet;;ACTIVE;2.52;2.52 +77441-4;Flowsheet;Find;Pt;{Setting};Doc;Child and adolescent psychiatry;DOC.ONTOLOGY;2;Child and adolescent psychiatry Flowsheet;Child+teen psych Flowsheet;;ACTIVE;2.52;2.52 +77442-2;Plan of care note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Plan of care note;Cardiology Plan of care note;;ACTIVE;2.52;2.58 +77443-0;Plan of care note;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Plan of care note;Allergy+Immunology Plan of care note;;ACTIVE;2.52;2.66 +77444-8;Plan of care note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Plan of care note;Audiology Plan of care note;;ACTIVE;2.52;2.58 +77445-5;Plan of care note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Plan of care note;CCM Plan of care note;;ACTIVE;2.52;2.58 +7744-6;Ailanthus altissima Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tree of Heaven IgE Ab [Units/volume] in Serum;Tree of Heaven IgE Qn;;ACTIVE;1.0h(2);2.73 +77446-3;Plan of care note;Find;Pt;{Setting};Doc;Child and adolescent psychiatry;DOC.ONTOLOGY;2;Child and adolescent psychiatry Plan of care note;Child+teen psych Plan of care note;;ACTIVE;2.52;2.58 +77447-1;Nordiazepam;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nordiazepam [Moles/volume] in Specimen;Nordiazepam Spec-sCnc;;ACTIVE;2.52;2.69 +77448-9;Multisection;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot and Midfoot;CT Hind+Mid ft;;ACTIVE;2.52;2.61 +77450-5;Multisection^W contrast IV;Find;Pt;Chest+Abdomen+Pelvis+Lower extremity.bilateral>Aorta.thoracic+Aorta.abdominal+Vessels.bilateral;Doc;CT.angio;RAD;2;Deprecated Chest+Abdomen+Pelvis+Lower extremity.bilateral>Aorta.thoracic+Aorta.abdominal+vessels CT angiogram W contrast IV;Deprecated C+A+P+LxB>A.th+A CT.Angio W c;;DEPRECATED;2.52;2.58 +77451-3;Multisection for endograft;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Pelvis+Lower extremity.bilateral>Vessels;Doc;CT.angio;RAD;2;CTA Thoracic and Abdominal Aorta and Bilateral Vessels for endograft;CTA T Ao+Abd Ao+Ves-Bl for endograf;;ACTIVE;2.52;2.61 +77452-1;Bilirubin;PrThr;Pt;Periton fld;Ord;;CHEM;1;Bilirubin [Presence] in Peritoneal fluid;Bilirub Prt Ql;;ACTIVE;2.52;2.56 +7745-3;Trichophyton Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trichophyton sp IgE Ab [Units/volume] in Serum;Trichophyton IgE Qn;;ACTIVE;1.0h(2);2.73 +77453-9;Bone density;MAric;Pt;Hindfoot+Midfoot;Qn;XR.DXA;RAD;2;Deprecated Hindfoot and Midfoot DXA Bone density;Deprecated Hind+Mid ft DXA BMD;;DEPRECATED;2.52;2.56 +77454-7;Bone density;Tscore;Pt;Hindfoot+Midfoot;Qn;XR.DXA;RAD;2;Deprecated Hindfoot and Midfoot DXA [T-score] Bone density;Deprecated Hind+Mid ft DXA T-score BMD;;DEPRECATED;2.52;2.58 +77455-4;Multisection;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR.tomography;RAD;2;Deprecated Hindfoot and Midfoot X-ray tomography;Deprecated Hind+Mid ft XR tomo;;DEPRECATED;2.52;2.58 +77456-2;Multisection^W contrast IV;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot and Midfoot W contrast IV;CT Hind+Mid ft W contr IV;;ACTIVE;2.52;2.61 +77457-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot and Midfoot WO and W contrast IV;CT Hind+Mid ft WO+W contr IV;;ACTIVE;2.52;2.61 +77458-8;Multisection^WO contrast;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot and Midfoot WO contrast;CT Hind+Mid ft WO contr;;ACTIVE;2.52;2.61 +77459-6;View 1;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot and Midfoot X-ray Single view;Deprecated Hind+Mid ft XR 1V;;DEPRECATED;2.52;2.58 +77460-4;Views;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot and Midfoot X-ray;Deprecated Hind+Mid ft XR;;DEPRECATED;2.52;2.58 +7746-1;Trimellitic anhydride Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trimellitic anhydride (TMA) IgE Ab [Units/volume] in Serum;TMA IgE Qn;;ACTIVE;1.0h(2);2.73 +77461-2;Views 2;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot and Midfoot X-ray 2 views;Deprecated Hind+Mid ft XR 2V;;DEPRECATED;2.52;2.58 +77462-0;Views AP+lateral+oblique;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot and Midfoot X-ray AP and lateral and oblique;Deprecated Hind+Mid ft XR AP+Lat+Obl;;DEPRECATED;2.52;2.58 +77463-8;Views Broden;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot and Midfoot X-ray Broden;Deprecated Hind+Mid ft XR Broden;;DEPRECATED;2.52;2.58 +77464-6;Views ski jump;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot and Midfoot X-ray ski jump;Deprecated Hind+Mid ft XR Ski Jump;;DEPRECATED;2.52;2.58 +77465-3;Views^standing;Find;Pt;Lower extremity>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot and Midfoot X-ray standing;Deprecated Hind+Mid ft XR stand;;DEPRECATED;2.52;2.58 +77466-1;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot - left and Midfoot - left W contrast IV;CT Hind+Mid ft-L W contr IV;;ACTIVE;2.52;2.61 +77467-9;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot - right and Midfoot - right W contrast IV;CT Hind+Mid ft-R W contr IV;;ACTIVE;2.52;2.61 +77468-7;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot - left and Midfoot - left WO and W contrast IV;CT Hind+Mid ft-L WO+W contr IV;;ACTIVE;2.52;2.61 +77469-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot - right and Midfoot - right WO and W contrast IV;CT Hind+Mid ft-R WO+W contr IV;;ACTIVE;2.52;2.61 +77470-3;Multisection^WO contrast;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot - left and Midfoot - left WO contrast;CT Hind+Mid ft-L WO contr;;ACTIVE;2.52;2.61 +77471-1;Multisection^WO contrast;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;CT;RAD;2;CT Hindfoot - right and Midfoot - right WO contrast;CT Hind+Mid ft-R WO contr;;ACTIVE;2.52;2.61 +77472-9;View 1;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray Single view;Deprecated Hind+Mid ft-L XR 1V;;DEPRECATED;2.52;2.58 +77473-7;View 1;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray Single view;Deprecated Hind+Mid ft-R XR 1V;;DEPRECATED;2.52;2.58 +77474-5;View Harris;Find;Pt;Lower extremity.bilateral>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - bilateral and Midfoot - bilateral X-ray Harris;Deprecated Hind+Mid ft-Bl XR Harris;;DEPRECATED;2.52;2.58 +77475-2;View Harris;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray Harris;Deprecated Hind+Mid ft-L XR Harris;;DEPRECATED;2.52;2.58 +77476-0;View Harris;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray Harris;Deprecated Hind+Mid ft-R XR Harris;;DEPRECATED;2.52;2.58 +77477-8;View^standing;Find;Pt;Lower extremity.bilateral>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - bilateral and Midfoot - bilateral X-ray standing;Deprecated Hind+Mid ft-Bl XR stand;;DEPRECATED;2.52;2.58 +77478-6;Views;Find;Pt;Lower extremity.bilateral>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - bilateral and Midfoot - bilateral X-ray;Deprecated Hind+Mid ft-Bl XR;;DEPRECATED;2.52;2.58 +7747-9;Oncorhynchus mykiss Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Trout IgG Ab [Units/volume] in Serum;Trout IgG Qn;;ACTIVE;1.0h(2);2.73 +77479-4;Views;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray;Deprecated Hind+Mid ft-L XR;;DEPRECATED;2.52;2.58 +77480-2;Views;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray;Deprecated Hind+Mid ft-R XR;;DEPRECATED;2.52;2.58 +77481-0;Views 2;Find;Pt;Lower extremity.bilateral>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - bilateral and Midfoot - bilateral X-ray 2 views;Deprecated Hind+Mid ft-Bl XR 2V;;DEPRECATED;2.52;2.58 +77482-8;Views 2;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray 2 views;Deprecated Hind+Mid ft-L XR 2V;;DEPRECATED;2.52;2.58 +77483-6;Views 2;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray 2 views;Deprecated Hind+Mid ft-R XR 2V;;DEPRECATED;2.52;2.58 +77484-4;Views AP+lateral;Find;Pt;Lower extremity.bilateral>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - bilateral and Midfoot - bilateral X-ray AP and lateral;Deprecated Hind+Mid ft-Bl XR AP+Lat;;DEPRECATED;2.52;2.58 +77485-1;Views AP+lateral;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray AP and lateral;Deprecated Hind+Mid ft-L XR AP+Lat;;DEPRECATED;2.52;2.58 +77486-9;Views AP+lateral;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray AP and lateral;Deprecated Hind+Mid ft-R XR AP+Lat;;DEPRECATED;2.52;2.58 +7748-7;Tryptase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tryptase IgE Ab [Units/volume] in Serum;Tryptase IgE Qn;;ACTIVE;1.0h(2);2.42 +77487-7;Views Broden;Find;Pt;Lower extremity.bilateral>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - bilateral and Midfoot - bilateral X-ray Broden;Deprecated Hind+Mid ft-Bl XR Broden;;DEPRECATED;2.52;2.58 +77488-5;Views Broden;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray Broden;Deprecated Hind+Mid ft-L XR Broden;;DEPRECATED;2.52;2.58 +77489-3;Views Broden;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray Broden;Deprecated Hind+Mid ft-R XR Broden;;DEPRECATED;2.52;2.58 +77490-1;Views ski jump;Find;Pt;Lower extremity.bilateral>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - bilateral and Midfoot - bilateral X-ray ski jump;Deprecated Hind+Mid ft-Bl XR Ski Jump;;DEPRECATED;2.52;2.58 +77491-9;Views ski jump;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray ski jump;Deprecated Hind+Mid ft-L XR Ski Jump;;DEPRECATED;2.52;2.58 +77492-7;Views ski jump;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray ski jump;Deprecated Hind+Mid ft-R XR Ski Jump;;DEPRECATED;2.52;2.58 +77493-5;Views^standing;Find;Pt;Lower extremity.left>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - left and Midfoot - left X-ray standing;Deprecated Hind+Mid ft-L XR stand;;DEPRECATED;2.52;2.58 +77494-3;Views^standing;Find;Pt;Lower extremity.right>Hindfoot+Midfoot;Doc;XR;RAD;2;Deprecated Hindfoot - right and Midfoot - right X-ray standing;Deprecated Hind+Mid ft-R XR stand;;DEPRECATED;2.52;2.58 +7749-5;Thunnus albacares Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tuna IgG Ab [Units/volume] in Serum;Tuna IgG Qn;;ACTIVE;1.0h(2);2.73 +77495-0;Bacillus cereus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bacillus cereus [Presence] in Specimen by Organism specific culture;B cereus Spec Ql Cult;;ACTIVE;2.52;2.69 +77496-8;Clostridium perfringens;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Clostridium perfringens [Presence] in Specimen by Organism specific culture;C perfringens Spec Ql Cult;;ACTIVE;2.52;2.69 +77497-6;Institution inventory number;ID;Pt;Specimen temperature device;Nom;;DEVICES;2;Specimen temperature device Institution inventory number;Spec temp device Inventory #;;ACTIVE;2.52;2.52 +77498-4;Can pronounce ache;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce ache [AmNART];;;ACTIVE;2.52;2.54 +77499-2;Can pronounce aisle;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce aisle [AmNART];;;ACTIVE;2.52;2.54 +77500-7;Can pronounce capon;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce capon [AmNART];;;ACTIVE;2.52;2.54 +77501-5;Can pronounce debt;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce debt [AmNART];;;ACTIVE;2.52;2.54 +77502-3;Can pronounce chord;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce chord [AmNART];;;ACTIVE;2.52;2.54 +7750-3;Thunnus albacares basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Tuna triggered histamine release [Units/volume] in Blood;Tuna BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77503-1;Can pronounce heir;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce heir [AmNART];;;ACTIVE;2.52;2.54 +77504-9;Can pronounce deny;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce deny [AmNART];;;ACTIVE;2.52;2.54 +77505-6;Can pronounce bouquet;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce bouquet [AmNART];;;ACTIVE;2.52;2.54 +77506-4;Can pronounce caprice;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce caprice [AmNART];;;ACTIVE;2.52;2.54 +77507-2;Can pronounce gauge;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce gauge [AmNART];;;ACTIVE;2.52;2.54 +77508-0;Can pronounce worsted;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce worsted [AmNART];;;ACTIVE;2.52;2.54 +77509-8;Can pronounce depot;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce depot [AmNART];;;ACTIVE;2.52;2.54 +77510-6;Can pronounce nausea;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce nausea [AmNART];;;ACTIVE;2.52;2.54 +7751-1;Turkey Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Turkey IgG Ab [Units/volume] in Serum;Turkey IgG Qn;;ACTIVE;1.0h(2);2.73 +77511-4;Can pronounce naive;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce naïve [AmNART];;;ACTIVE;2.52;2.54 +77512-2;Can pronounce subtle;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce subtle [AmNART];;;ACTIVE;2.52;2.54 +77513-0;Can pronounce pugilist;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce pugilist [AmNART];;;ACTIVE;2.52;2.54 +77514-8;Can pronounce fetal;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce fetal [AmNART];;;ACTIVE;2.52;2.54 +77515-5;Can pronounce blatant;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce blatant [AmNART];;;ACTIVE;2.52;2.54 +77516-3;Can pronounce placebo;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce placebo [AmNART];;;ACTIVE;2.52;2.54 +77517-1;Can pronounce hiatus;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce hiatus [AmNART];;;ACTIVE;2.52;2.54 +77518-9;Can pronounce smile;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce smile [AmNART];;;ACTIVE;2.52;2.54 +77519-7;Can pronounce meringue;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce meringue [AmNART];;;ACTIVE;2.52;2.54 +77520-5;Can pronounce sieve;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce sieve [AmNART];;;ACTIVE;2.52;2.54 +77521-3;Can pronounce chassis;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce chassis [AmNART];;;ACTIVE;2.52;2.54 +77522-1;Can pronounce cellist;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce cellist [AmNART];;;ACTIVE;2.52;2.54 +77523-9;Can pronounce algae;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce algae [AmNART];;;ACTIVE;2.52;2.54 +77524-7;Can pronounce superfluous;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce superfluous [AmNART];;;ACTIVE;2.52;2.54 +77525-4;Can pronounce chamois;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce chamois [AmNART];;;ACTIVE;2.52;2.54 +77526-2;Can pronounce thyme;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce thyme [AmNART];;;ACTIVE;2.52;2.54 +77527-0;Can pronounce apropos;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce apropos [AmNART];;;ACTIVE;2.52;2.54 +77528-8;Can pronounce virulent;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce virulent [AmNART];;;ACTIVE;2.52;2.54 +7752-9;Turkey basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Turkey triggered histamine release [Units/volume] in Blood;Turkey BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77529-6;Can pronounce zealot;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce zealot [AmNART];;;ACTIVE;2.52;2.54 +77530-4;Can pronounce facade;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce façade [AmNART];;;ACTIVE;2.52;2.54 +77531-2;Can pronounce cabal;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce cabal [AmNART];;;ACTIVE;2.52;2.54 +77532-0;Can pronounce abstemious;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce abstemious [AmNART];;;ACTIVE;2.52;2.54 +77533-8;Can pronounce detente;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce détente [AmNART];;;ACTIVE;2.52;2.54 +77534-6;Can pronounce scion;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce scion [AmNART];;;ACTIVE;2.52;2.54 +77535-3;Can pronounce papyrus;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce papyrus [AmNART];;;ACTIVE;2.52;2.54 +77536-1;Can pronounce quadruped;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce quadruped [AmNART];;;ACTIVE;2.52;2.54 +7753-7;Turkey feather Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Turkey feather IgE Ab [Units/volume] in Serum;Turkey Feather IgE Qn;;ACTIVE;1.0h(2);2.73 +77537-9;Can pronounce prelate;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce prelate [AmNART];;;ACTIVE;2.52;2.54 +77538-7;Can pronounce epitome;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce epitome [AmNART];;;ACTIVE;2.52;2.54 +77539-5;Can pronounce beautify;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce beautify [AmNART];;;ACTIVE;2.52;2.54 +77540-3;Can pronounce hyperbole;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce hyperbole [AmNART];;;ACTIVE;2.52;2.54 +77541-1;Can pronounce imbroglio;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce imbroglio [AmNART];;;ACTIVE;2.52;2.54 +77542-9;Can pronounce syncope;Find;Pt;^Patient;Ord;AmNART;SURVEY.AMNART;4;Can pronounce syncope [AmNART];;;ACTIVE;2.52;2.54 +77543-7;Correct responses count;Num;Pt;^Patient;Qn;AmNART;SURVEY.AMNART;4;Correct responses count # [AmNART];;;ACTIVE;2.52;2.54 +77544-5;Data collected;Date;Pt;^Patient;Qn;;SURVEY.MISC;4;Data collected;;;ACTIVE;2.52;2.52 +7754-5;Turnip Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Turnip IgE Ab [Units/volume] in Serum;Turnip IgE Qn;;ACTIVE;1.0h(2);2.73 +77545-2;Premorbid estimate;Num;Pt;^Patient;Qn;AmNART;SURVEY.AMNART;4;Premorbid estimate # [AmNART];;;ACTIVE;2.52;2.58 +77546-0;Incorrect responses count;Num;Pt;^Patient;Qn;AmNART;SURVEY.AMNART;4;Incorrect responses count # [AmNART];;;ACTIVE;2.52;2.54 +77547-8;American National Adult Reading Test panel;-;Pt;^Patient;-;;PANEL.SURVEY.AMNART;4;American National Adult Reading Test (AmNART) panel;;;ACTIVE;2.52;2.54 +77548-6;Client accessibility panel;-;Pt;{Nursing unit};-;NMMDS;PANEL.SURVEY.NMMDS;4;Client accessibility panel [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77549-4;Time to access a patient;Time;Pt;Provider;Qn;NMMDS;SURVEY.NMMDS;4;Time to access a patient [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77550-2;Time to access all patients;Time;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Time to access all patients in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77551-0;All patient encounters;Num;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Total number of patient encounters in a reporting period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7755-2;Upholstery dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Upholstery dust IgE Ab [Units/volume] in Serum;Upholstery Dust IgE Qn;;ACTIVE;1.0h(2);2.42 +77552-8;Mean time to access a patient;Time;RptPeriod^mean;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Average time to access a patient in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77553-6;Distance to access a patient;Len;Pt;Provider;Qn;NMMDS;SURVEY.NMMDS;4;Distance to access a patient [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77554-4;Distance to access all patients;Len;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Distance to access all patients in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77555-1;Mean distance to access a patient;Len;RptPeriod^mean;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Average distance to access a patient in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77556-9;Method used to connect with a patient;Type;Pt;Provider;Nom;NMMDS;SURVEY.NMMDS;4;Method used to connect with a patient [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77557-7;Time required to gather essential resources for a patient encounter;Time;Pt;Provider;Qn;NMMDS;SURVEY.NMMDS;4;Time required to gather essential resources for a patient encounter [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77558-5;Time required to gather essential resources for all patient encounters;Time;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Time required to gather essential resources for all patient encounters in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77559-3;Mean time required to gather essential resources for a patient encounter;Time;RptPeriod^mean;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Average time required to gather essential resources for a patient encounter in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +7756-0;Vanilla planifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Vanilla IgE Ab [Units/volume] in Serum;Vanilla IgE Qn;;ACTIVE;1.0h(2);2.73 +77560-1;Distance required to gather essential resources for a patient encounter;Len;Pt;Provider;Qn;NMMDS;SURVEY.NMMDS;4;Distance required to gather essential resources for a patient encounter [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77561-9;Distance required to gather essential resources for all patient encounters;Len;RptPeriod;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Distance required to gather essential resources for all patient encounters in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77562-7;Mean distance required to gather essential resources for a patient encounter;Len;RptPeriod^mean;{Nursing unit};Qn;NMMDS;SURVEY.NMMDS;4;Average distance required to gather essential resources for a patient encounter in a Report Period [NMMDS];;Copyright © 2006 Diane Huber and Connie Delaney. Used with permission.;ACTIVE;2.52;2.58 +77563-5;Leukocyte esterase;PrThr;Pt;Body fld;Ord;Test strip.automated;HEM/BC;1;Leukocyte esterase [Presence] in Body fluid by Automated test strip;Leukocyte esterase Fld Ql Strip.auto;;ACTIVE;2.52;2.56 +77564-3;Brief Pain Inventory short form - pain interference panel;-;24H;^Patient;-;;PANEL.SURVEY.BPI;4;Brief Pain Inventory Short Form - pain interference panel;;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77565-0;Pain interference score;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;Pain interference score [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77566-8;During the past 24H, how has pain interfered with your general activity;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;During the past 24 hours, how has pain interfered with your general activity [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77567-6;During the past 24H, how has pain interfered with your mood;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;During the past 24 hours, how has pain interfered with your mood [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77568-4;During the past 24H, how has pain interfered with your walking ability;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;During the past 24 hours, how has pain interfered with your walking ability [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77569-2;During the past 24H, how has pain interfered with your normal work;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;During the past 24 hours, how has pain interfered with your normal work [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +775-7;Platelet mean diameter;EntLen;Pt;Bld;Qn;Rees-Ecker;HEM/BC;1;Platelet mean diameter [Entitic length] in Blood by Rees-Ecker;PMD Bld Qn Rees-Ecker;;ACTIVE;1.0;2.42 +77570-0;During the past 24H, how has pain interfered with your relations with other people;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;During the past 24 hours, how has pain interfered with your relations with other people [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77571-8;During the past 24H, how has pain interfered with your sleep;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;During the past 24 hours, how has pain interfered with your sleep [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77572-6;During the past 24H, how has pain interfered with your enjoyment of life;Score;24H;^Patient;Ord;BPI.short;SURVEY.BPI;4;During the past 24 hours, how has pain interfered with your enjoyment of life [BPI Short Form];;Copyright © 1991 Dr. Charles S. Cleeland Used with permission.;ACTIVE;2.52;2.52 +77573-4;Withdrawal of wholesale drug distributors and third-party logistics facility report;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label Withdrawal of wholesale drug distributors and third-party logistics facility report;FDA label Wdraw wsale + 3rd prt fac rpt;;ACTIVE;2.52;2.56 +77574-2;Global measure of physical function panel;-;Pt;^Patient;-;APTA;PANEL.APTA;2;Global measure of physical function panel APTA;Glob meas of phys function Pnl APTA;;ACTIVE;2.52;2.56 +77575-9;Condition- or population-specific panel;-;Pt;^Patient;-;APTA;PANEL.APTA;2;Condition- or population-specific panel APTA;Condition-spec function Pnl APTA;;ACTIVE;2.52;2.56 +77576-7;Self-care and mobility panel;-;Pt;^Patient;-;APTA;PANEL.APTA;2;Self-care and mobility panel APTA;Self-care and mobility Pnl APTA;;ACTIVE;2.52;2.54 +77577-5;Chlamydia trachomatis & Neisseria gonorrhoeae DNA panel;-;Pt;Urethra;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae DNA panel - Urethra by NAA with probe detection;CT+NG DNA Pnl Urth NAA+probe;;ACTIVE;2.52;2.63 +7757-8;Veal Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Veal IgE Ab [Units/volume] in Serum;Veal IgE Qn;;ACTIVE;1.0h(2);2.73 +77578-3;PROMIS parent proxy mobility - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy mobility - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.68 +77579-1;PROMIS pediatric physical function - mobility - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric physical function: mobility - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77580-9;PROMIS physical function w mobility aids - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS physical function w mobility aids - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77581-7;Alpha 2 globulin;MCnc;XXX;Urine;Qn;Electrophoresis;CHEM;1;Alpha 2 globulin [Mass/volume] by Electrophoresis in Urine collected for unspecified duration;Alpha2 Glob ?Tm Ur Elph-mCnc;;ACTIVE;2.52;2.52 +77582-5;International Physical Activity Questionnaire self-administered short form;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;International Physical Activity Questionnaire Self-Administered Short Form [IPAQ];;;ACTIVE;2.61;2.61 +77583-3;During the last 7D, on how many D did you do vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.61;2.64 +77584-1;How much time did you usually spend doing vigorous physical activities on one of those D;NRat;1D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend doing vigorous physical activities on one of those days [IPAQ];;;ACTIVE;2.61;2.64 +77585-8;During the last 7D, on how many D did you do moderate physical activities like carrying light loads, bicycling at a regular pace, or doubles tennis for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do moderate physical activities like carrying light loads, bicycling at a regular pace, or doubles tennis for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.61;2.64 +7758-6;Veal basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Veal triggered histamine release [Units/volume] in Blood;Veal BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77586-6;How much time did you usually spend doing moderate physical activities on one of those D;NRat;1D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend doing moderate physical activities on one of those days [IPAQ];;;ACTIVE;2.61;2.64 +77587-4;During the last 7D, on how many D did you walk for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you walk for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.61;2.64 +77588-2;How much time did you usually spend walking on one of those D;NRat;1D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend walking on one of those days [IPAQ];;;ACTIVE;2.61;2.64 +77589-0;During the last 7D, how much time did you usually spend sitting on a weekday;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, how much time did you usually spend sitting on a weekday [IPAQ];;;ACTIVE;2.61;2.64 +77591-6;Walking physical activity;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Walking physical activity [IPAQ];;;ACTIVE;2.61;2.64 +77592-4;Moderate physical activity;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Moderate physical activity [IPAQ];;;ACTIVE;2.61;2.64 +77593-2;Vigorous physical activity;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Vigorous physical activity [IPAQ];;;ACTIVE;2.61;2.64 +7759-4;Venison Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Venison IgE Ab [Units/volume] in Serum;Venison IgE Qn;;ACTIVE;1.0h(2);2.73 +77594-0;Total physical activity;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Total physical activity [IPAQ];;;ACTIVE;2.61;2.64 +77595-7;Total physical activity score;Score;7D;^Patient;Ord;IPAQ;SURVEY.IPAQ;4;Total physical activity score [IPAQ];;;ACTIVE;2.61;2.61 +77596-5;Transportation summary;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Transportation summary Document;Transport summary Doc;;TRIAL;2.52;2.63 +77597-3;Orders placed;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Orders placed Document;Orders placed Doc;;TRIAL;2.52;2.63 +77598-1;Externally defined clinical data elements;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Externally defined clinical data elements Document;Externally defined CDEs Doc;;TRIAL;2.52;2.63 +77599-9;Additional documentation;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Additional documentation;Additional documentation;;TRIAL;2.52;2.63 +77600-5;Interval note;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Interval note;Interval note;;ACTIVE;2.52;2.63 +77601-3;Enhanced note;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Enhanced note;Enhanced note;;TRIAL;2.52;2.63 +7760-2;Wall pellitory Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wall pellitory IgE Ab [Units/volume] in Serum;Pellitory IgE Qn;;ACTIVE;1.0h(2);2.73 +77602-1;Research study consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Research study consent;Research study consent;;ACTIVE;2.52;2.67 +77603-9;Medication treatment plan.extended;Find;Pt;^Patient;Doc;;DOC.MISC;2;Medication treatment plan.extended Document;Med tx plan.extended Doc;;ACTIVE;2.52;2.52 +77604-7;Medication treatment plan.brief;Find;Pt;^Patient;Doc;;DOC.MISC;2;Medication treatment plan.brief Document;Med tx plan.brief Doc;;ACTIVE;2.52;2.52 +77605-4;Influenza virus A H5 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H5 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUAV H5 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.52;2.74 +77606-2;Weight-for-length;Prctl;Pt;^Patient;Qn;Per age and sex;BDYWGT.MOLEC;2;Weight-for-length Per age and sex;Wt-for-len Per age+sex;;ACTIVE;2.52;2.66 +77607-0;Cortisol^1M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --1 minute post XXX challenge;Cortis 1M p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77608-8;Androstenedione^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Androstenedione [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Androst 30M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77609-6;Aldosterone^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Aldosterone [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Aldost 4h p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +7761-0;Stizostedion vitreum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Walleye Pike IgE Ab [Units/volume] in Serum;Walleye Pike IgE Qn;;ACTIVE;1.0h(2);2.73 +77610-4;C peptide^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;C peptide 15M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77611-2;C peptide^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;C peptide 4h p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77612-0;C peptide^45M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge;C peptide 45M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77613-8;Calcitonin^1M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Moles/volume] in Serum or Plasma --1 minute post XXX challenge;Calcit 1M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77614-6;Calcitonin^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;Calcit 10M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77615-3;Liver stiffness;Pres;Pt;Abdomen>Liver;Qn;US.transient elastography;RAD;2;Liver stiffness by US.transient elastography;US.TE Liver stiffness;;ACTIVE;2.52;2.73 +77616-1;Liver fibrosis score;Score;Pt;Ser/Plas;Qn;Calculated.FibroMeter;PATH;1;Liver fibrosis score in Serum or Plasma Calculated by FibroMeter;Liver fibr score SerPl Calc.FibroMeter;;ACTIVE;2.52;2.73 +77617-9;Intravascular systolic.digital artery toe left/Brachial artery;PresRto;Pt;Peripheral vascular system;Qn;;BP.MOLEC;2;Toe brachial index - left;TBI left;;ACTIVE;2.52;2.52 +77618-7;Intravascular systolic.digital artery toe right/Brachial artery;PresRto;Pt;Peripheral vascular system;Qn;;BP.MOLEC;2;Toe brachial index - right;TBI right;;ACTIVE;2.52;2.52 +77619-5;Fetal chromosome 13+18+21+Y aneuploidy;PrThr;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.TRISOMY;1;Fetal chromosome 13+18+21+Y aneuploidy [Presence] based on dosage of chromosome-specific cell-free DNA from Maternal plasma;Fet chrom 13+18+21+Y aneup cfDNA Ql;;ACTIVE;2.52;2.66 +77620-3;Arginase-1;MCnc;Pt;Ser;Qn;IA;CHEM;1;Arginase-1 [Mass/volume] in Serum by Immunoassay;Arginase-1 Ser IA-mCnc;;ACTIVE;2.52;2.56 +77621-1;Natriuretic peptide.B prohormone N-Terminal;MCnc;Pt;Plr fld;Qn;IA;CHEM;1;Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Pleural fluid by Immunoassay;NT-proBNP Plr IA-mCnc;;ACTIVE;2.52;2.56 +77622-9;Natriuretic peptide.B prohormone N-Terminal;MCnc;Pt;Dial fld prt;Qn;IA;CHEM;1;Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Peritoneal dialysis fluid by Immunoassay;NT-proBNP DiafP IA-mCnc;;ACTIVE;2.52;2.56 +77623-7;Thyrotropin^2.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Thyrotropin [Units/volume] in Serum or Plasma --2.5 hours post XXX challenge;TSH 2.5h p chal SerPl-aCnc;;ACTIVE;2.52;2.52 +77624-5;SMAD4 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SMAD4 gene full mutation analysis in Blood or Tissue by Sequencing;SMAD4 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77625-2;ENG gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ENG gene full mutation analysis in Blood or Tissue by Sequencing;ENG Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.65 +77626-0;Pyruvate kinase;EntCat;Pt;RBC;Qn;;CHEM;1;Pyruvate kinase [Entitic Catalytic Activity] in Red Blood Cells;PK RBC Qn;;ACTIVE;2.52;2.52 +77627-8;HBB gene full mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.MUT;1;HBB gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;HBB gene Full Mut Anl Bld/T Seq;;ACTIVE;2.52;2.63 +7762-8;Juglans spp basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Walnut triggered histamine release [Units/volume] in Blood;Walnut BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77628-6;PSEN2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PSEN2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PSEN2 gene Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77629-4;PARK7 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PARK7 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PARK7 gene Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77630-2;ALS2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ALS2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ALS2 gene Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77631-0;VAPB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;VAPB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;VAPB gene Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77632-8;ANG gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ANG gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ANG gene Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77633-6;TARDBP gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TARDBP gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TARDBP gene Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77634-4;FUS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FUS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FUS gene Mut Anl Bld/T;;ACTIVE;2.52;2.63 +77635-1;C9orf72 gene.GGGGCC repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;C9orf72 gene GGGGCC repeats [Entitic number] in Blood or Tissue by Molecular genetics method;C9orf72 GGGGCC Rpt EntNum Bld/T;;ACTIVE;2.52;2.52 +7763-6;Juglans nigra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Walnut IgE Ab [Units/volume] in Serum;Black Walnut IgE Qn;;ACTIVE;1.0h(2);2.73 +77636-9;HLA-C;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-C [Type] by High resolution typing;HLA-C High Res;;ACTIVE;2.52;2.52 +77637-7;HLA-A & B & C (class I) Ab.IgG panel;Prid;Pt;Ser/Plas;-;IA;PANEL.HLA;1;HLA-A and B and C (class I) IgG panel [Identifier] - Serum or Plasma by Immunoassay;HLA class I IgG Pnl SerPl EIA;;ACTIVE;2.52;2.56 +77638-5;HLA-DP & DQ & DR (class II) Ab.IgG panel;Prid;Pt;Ser/Plas;-;IA;PANEL.HLA;1;HLA-DP and DQ and DR (class II) IgG panel [Identifier] - Serum or Plasma by Immunoassay;HLA class II IgG Pnl EIA;;ACTIVE;2.52;2.56 +77639-3;HLA class I & II Ab.IgG panel;-;Pt;Ser/Plas;-;IA;PANEL.HLA;1;HLA class I and II IgG panel - Serum or Plasma by Immunoassay;HLA class I + II IgG Pnl SerPl IA;;ACTIVE;2.52;2.56 +77640-1;HLA class I & II Ab.IgG;Imp;Pt;Ser/Plas;Nar;IA;HLA;1;HLA class I and II IgG Ab in Serum or Plasma by Immunoassay [interpretation] Narrative;HLA class I + II IgG SerPl IA-Imp;;ACTIVE;2.52;2.56 +77641-9;HLA-A Ab.IgG;Prid;Pt;Ser/Plas;Nom;IA;HLA;1;HLA-A IgG Ab [Identifier] in Serum or Plasma by Immunoassay;HLA-A IgG SerPl IA;;ACTIVE;2.52;2.56 +77642-7;HLA-B Ab.IgG;Prid;Pt;Ser/Plas;Nom;IA;HLA;1;HLA-B IgG Ab [Identifier] in Serum or Plasma by Immunoassay;HLA-B IgG SerPl IA;;ACTIVE;2.52;2.56 +77643-5;HLA-C Ab.IgG;Prid;Pt;Ser/Plas;Nom;IA;HLA;1;HLA-C IgG Ab [Identifier] in Serum or Plasma by Immunoassay;HLA-C IgG SerPl IA;;ACTIVE;2.52;2.56 +7764-4;Walnut black western Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black Western Walnut IgE Ab [Units/volume] in Serum;Black West Walnut IgE Qn;;ACTIVE;1.0h(2);2.42 +77644-3;HLA-DP Ab.IgG;Prid;Pt;Ser/Plas;Nom;IA;HLA;1;HLA-DP IgG Ab [Identifier] in Serum or Plasma by Immunoassay;HLA-DP IgG SerPl IA;;ACTIVE;2.52;2.56 +77645-0;HLA-DQ Ab.IgG;Prid;Pt;Ser/Plas;Nom;IA;HLA;1;HLA-DQ IgG Ab [Identifier] in Serum or Plasma by Immunoassay;HLA-DQ IgG SerPl IA;;ACTIVE;2.52;2.56 +77646-8;HLA-DR Ab.IgG;Prid;Pt;Ser/Plas;Nom;IA;HLA;1;HLA-DR IgG Ab [Identifier] in Serum or Plasma by Immunoassay;HLA-DR IgG SerPl IA;;ACTIVE;2.52;2.56 +77647-6;Animal compounded drug label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Animal compounded drug label;FDA label Animal compded drug label;;ACTIVE;2.52;2.52 +77648-4;Indexing - biologic or drug substance;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Indexing - biologic or drug substance;FDA label Index - biol or drug subst;;ACTIVE;2.52;2.52 +77649-2;17-Hydroxyprogesterone^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;17OHP 10M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +776-5;Platelet mean volume;EntVol;Pt;Bld;Qn;Rees-Ecker;HEM/BC;1;Platelet mean volume [Entitic volume] in Blood by Rees-Ecker;PMV Bld Rees-Ecker;;ACTIVE;1.0;2.73 +77650-0;17-Hydroxyprogesterone^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;17-Hydroxyprogesterone [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;17OHP 15M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +7765-1;Juglans regia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English Walnut IgE Ab [Units/volume] in Serum;English Walnut IgE Qn;;ACTIVE;1.0h(2);2.73 +77651-8;C peptide^75M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --75 minutes post XXX challenge;C peptide 75M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77652-6;C peptide^5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Moles/volume] in Serum or Plasma --5 hours post XXX challenge;C peptide 5h p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77653-4;Microscopic observation;Prid;Pt;Anorectal;Nom;Cyto stain.thin prep;CYTO;1;Microscopic observation [Identifier] in Anorectal Cyto stain.thin prep;Thin Prep Anorectl;;ACTIVE;2.52;2.52 +77654-2;Cells.diploid.G2 phase/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Diploid cells in G2 phase/100 cells in Cells.XXX by Flow cytometry (FC);Dipl cells in G2 NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77655-9;Cells.diploid/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Diploid cells/100 cells in Cells.XXX by Flow cytometry (FC);Dipl cells NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77656-7;Cells.diploid.S phase/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Diploid cells in S phase/100 cells in Cells.XXX by Flow cytometry (FC);Dipl cells in S NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77657-5;Cells.diploid.G1 phase/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Diploid cells in G1 phase/100 cells in Cells.XXX by Flow cytometry (FC);Dipl cells in G1 NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77658-3;Cells.aneuploid.G2 phase population/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Aneuploid cell population in G2 phase/100 cells in Cells.XXX by Flow cytometry (FC);Aneu cell pop in G2 NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77659-1;Cells.aneuploid.S phase population/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Aneuploid cell population in S phase/100 cells in Cells.XXX by Flow cytometry (FC);Aneu cell pop in S NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77660-9;Cells.aneuploid.G2 phase population 2/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Aneuploid cell population 2 in G2 phase/100 cells in Cells.XXX by Flow cytometry (FC);Aneu cell pop 2 in G2 NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77661-7;Cells.aneuploid.S phase population 2/100 cells;NFr;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Aneuploid cell population 2 in S phase/100 cells in Cells.XXX by Flow cytometry (FC);Aneu cells pop 2 in S NFr Cells.XXX FC;;ACTIVE;2.52;2.52 +77662-5;Diploid G1 phase cell population peak channel;Num;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Diploid G1 phase cell population peak channel [#] in Cells.XXX by Flow cytometry (FC);Diploid G1 peak chan Cells.XXX FC;;ACTIVE;2.52;2.52 +77663-3;Aneuploid G1 phase cell population peak channel;Num;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Aneuploid G1 phase cell population peak channel [#] in Cells.XXX by Flow cytometry (FC);Aneu G1 pop peak chan Cells.XXX FC;;ACTIVE;2.52;2.52 +77664-1;Aneuploid G1 phase cell population 2 peak channel;Num;Pt;Cells.XXX;Qn;Flow cytometry;MOLPATH;1;Aneuploid G1 phase cell population 2 peak channel [#] in Cells.XXX by Flow cytometry (FC);Aneu G1 pop 2 peak chan Cells.XXX FC;;ACTIVE;2.52;2.52 +77665-8;Dexamethasone;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Dexamethasone [Mass] of Dose;Dexamethasone Dose;;ACTIVE;2.52;2.73 +77666-6;Bacterial methicillin resistance mecA mRNA;PrThr;Pt;Bld.pos growth;Ord;FISH;ABXBACT;1;Methicillin resistance mecA mRNA [Presence] by FISH in Positive blood culture;mecA mRNA Bld Pos Ql FISH;;ACTIVE;2.52;2.65 +77667-4;Calcitonin^2M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Moles/volume] in Serum or Plasma --2 minutes post XXX challenge;Calcit 2M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77668-2;Calcitonin^5M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge;Calcit 5M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +7766-9;Juglans regia pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English Walnut Pollen IgE Ab [Units/volume] in Serum;Eng Walnut Poln IgE Qn;;ACTIVE;1.0h(2);2.42 +77669-0;Calcitonin^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Calcitonin [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Calcit 30M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77670-8;Gastrin^pre XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --pre XXX challenge;Gastrin pre chal SerPl-sCnc;;ACTIVE;2.54;2.54 +77671-6;Gastrin^1M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --1 minute post XXX challenge;Gastrin 1M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77672-4;Gastrin^3M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --3 minutes post XXX challenge;Gastrin 3M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77673-2;Gastrin^5M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge;Gastrin 5M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77674-0;Gastrin^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;Gastrin 10M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77675-7;Gastrin^15M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge;Gastrin 15M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77676-5;Gastrin^30M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Gastrin [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge;Gastrin 30M p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +7767-7;Juglans spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Walnut IgG Ab [Units/volume] in Serum;Walnut IgG Qn;;ACTIVE;1.0h(2);2.73 +77677-3;Glucose^2H post meal;SCnc;Pt;Ser/Plas/Bld;Qn;;CHAL;1;Glucose [Moles/volume] in Serum, Plasma or Blood --2 hours post meal;Glucose 2h p meal SerPlBld-sCnc;;ACTIVE;2.52;2.68 +77678-1;Insulin-like growth factor-I^2.5H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge;IGF-I 2.5h p chal SerPl-mCnc;;ACTIVE;2.52;2.52 +77679-9;Insulin-like growth factor-I^3H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --3 hours post XXX challenge;IGF-I 3h p chal SerPl-mCnc;;ACTIVE;2.52;2.52 +77680-7;Renin^4H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --4 hours post XXX challenge;Renin 4h p chal Plas-mCnc;;ACTIVE;2.52;2.52 +77681-5;Glucose^11H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Moles/volume] in Serum or Plasma --11 hour post XXX challenge;Glucose 11h p chal SerPl-sCnc;;ACTIVE;2.52;2.52 +77682-3;Staphylococcus aureus methicillin resistance SCCmec+orfX junction;PrThr;Pt;Nose;Ord;Probe.amp.tar;ABXBACT;1;Staphylococcus aureus methicillin resistance SCCmec+orfX junction [Presence] in Nose by NAA with probe detection;MRSA SCCmec+orfX Nose Ql NAA+probe;;ACTIVE;2.52;2.73 +77683-1;Thrombin activatable fibrinolysis inhibitor;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Thrombin activatable fibrinolysis inhibitor [Units/volume] in Platelet poor plasma by Chromogenic method;TAFI PPP Chro-aCnc;;ACTIVE;2.52;2.52 +77684-9;Legionella pneumophila 1 Ag;PrThr;Pt;Urine;Ord;IA.rapid;MICRO;1;Legionella pneumophila 1 Ag [Presence] in Urine by Rapid immunoassay;L pneumo1 Ag Ur Ql IA.rapid;;ACTIVE;2.52;2.73 +7768-5;Vespula spp Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yellow Jacket IgG Ab [Units/volume] in Serum;Yellow Jacket IgG Qn;;ACTIVE;1.0h(2);2.73 +77685-6;HIV 1 & 2 Ab.IgG;Prid;Pt;Ser/Plas;Nom;IB;MICRO;1;HIV 1 and 2 IgG Ab [Identifier] in Serum or Plasma by Immunoblot;HIV 1 & 2 IgG SerPl IB;;ACTIVE;2.52;2.58 +77686-4;Intellectual impairment scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Intellectual impairment scale [UPDRS];Intellectual impairment scale UPDRS;;ACTIVE;2.52;2.54 +77687-2;Thought disorder scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Thought disorder scale [UPDRS];Thought disorder scale UPDRS;;ACTIVE;2.52;2.54 +77688-0;Depression scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Depression scale [UPDRS];Depression scale UPDRS;;ACTIVE;2.52;2.54 +77689-8;Motivation or initiative scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Motivation or initiative scale [UPDRS];Motivation or initiative scale UPDRS;;ACTIVE;2.52;2.54 +77690-6;Speech scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Speech scale [UPDRS];Speech scale UPDRS;;ACTIVE;2.52;2.63 +77691-4;Salivation scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Salivation scale [UPDRS];Salivation scale UPDRS;;ACTIVE;2.52;2.54 +77692-2;Swallowing scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Swallowing scale [UPDRS];Swallowing scale UPDRS;;ACTIVE;2.52;2.54 +7769-3;Trapa natans Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Water Chestnut IgE Ab [Units/volume] in Serum;Water Chestnut IgE Qn;;ACTIVE;1.0h(2);2.42 +77693-0;Handwriting scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Handwriting scale [UPDRS];Handwriting scale UPDRS;;ACTIVE;2.52;2.54 +77694-8;Utensils scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Utensils scale [UPDRS];Utensils scale UPDRS;;ACTIVE;2.52;2.54 +77695-5;Dressing scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Dressing scale [UPDRS];Dressing scale UPDRS;;ACTIVE;2.52;2.54 +77696-3;Hygiene scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Hygiene scale [UPDRS];Hygiene scale UPDRS;;ACTIVE;2.52;2.54 +77697-1;Turning in bed and adjusting bed clothes scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Turning in bed and adjusting bed clothes scale [UPDRS];Turn in bed+adjust clothes UPDRS;;ACTIVE;2.52;2.54 +77698-9;Falling scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Fall scale [UPDRS];Fall scale UPDRS;;ACTIVE;2.52;2.63 +77699-7;Walking freeze scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Walking freeze scale [UPDRS];Walking freeze scale UPDRS;;ACTIVE;2.52;2.54 +77700-3;Walking scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Walking scale [UPDRS];Walking scale UPDRS;;ACTIVE;2.52;2.54 +7770-1;Citrullus lanatus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Watermelon IgE Ab [Units/volume] in Serum;Watermelon IgE Qn;;ACTIVE;1.0h(2);2.73 +77701-1;Tremor scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Tremor scale [UPDRS];Tremor scale UPDRS;;ACTIVE;2.52;2.54 +77702-9;Sensory complaints related to parkinsonism scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Sensory complaints related to parkinsonism scale [UPDRS];Sensory complaints scale UPDRS;;ACTIVE;2.52;2.54 +77703-7;Dyskinesia duration per D;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Dyskinesia duration per day in the past week [UPDRS];Dyskinesia dur per D 1W UPDRS;;ACTIVE;2.52;2.54 +77704-5;Dyskinesia disability;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Dyskinesia disability in the past week [UPDRS];Dyskinesia disability 1W UPDRS;;ACTIVE;2.52;2.54 +77705-2;Dyskinesia pain;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Dyskinesia pain in the past week [UPDRS];Dyskinesia pain 1W UPDRS;;ACTIVE;2.52;2.54 +77706-0;Early morning dystonia;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Early morning dystonia in the past week [UPDRS];Early morn dystonia 1W UPDRS;;ACTIVE;2.52;2.54 +77707-8;Predictable off period indicator;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Predictable off period indicator in the past week [UPDRS];Predictable off period 1W UPDRS;;ACTIVE;2.52;2.54 +77708-6;Unpredictable off period indicator;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Unpredictable off period indicator in the past week [UPDRS];Unpredictable off period 1W UPDRS;;ACTIVE;2.52;2.54 +77709-4;Sudden off period indicator;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Sudden off period indicator in the past week [UPDRS];Sudden off period 1W UPDRS;;ACTIVE;2.52;2.54 +77710-2;Average proportion of waking day the patient is off;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Average proportion of waking day the patient is off in the past week [UPDRS];Ave waking day off 1W UPDRS;;ACTIVE;2.52;2.54 +77711-0;Patient has anorexia, nausea or vomiting;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Patient has anorexia, nausea or vomiting in the past week [UPDRS];Anorexia, nausea or vomiting 1W UPDRS;;ACTIVE;2.52;2.54 +77712-8;Sleep disturbances indicator;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Sleep disturbances indicator in the past week [UPDRS];Sleep disturbances 1W UPDRS;;ACTIVE;2.52;2.54 +77713-6;Symptomatic orthostasis indicator;Find;1W;^Patient;Ord;UPDRS;UPDRS;2;Symptomatic orthostasis indicator in the past week [UPDRS];Symptomatic orthostasis 1W UPDRS;;ACTIVE;2.52;2.54 +77714-4;Modified Hoen and Yahr stage;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Modified Hoen and Yahr stage [UPDRS];Modified Hoen and Yahr UPDRS;;ACTIVE;2.52;2.54 +77715-1;Schwab England activities of daily living scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Schwab England activities of daily living scale [UPDRS];Schwab England ADL UPDRS;;ACTIVE;2.52;2.54 +77716-9;Schwab England activities of daily living with dyskinesia scale;Find;Pt;^Patient;Ord;UPDRS;UPDRS;2;Schwab England activities of daily living with dyskinesia scale [UPDRS];Schwab England ADL w dyskinesia UPDRS;;ACTIVE;2.52;2.54 +77717-7;Unified Parkinson's Disease Rating Scale panel;-;Pt;^Patient;-;;PANEL.UPDRS;2;Unified Parkinson's Disease Rating Scale (UPDRS) panel;UPDRS Panel;;ACTIVE;2.52;2.54 +77718-5;Mentation, behavior and mood panel;-;Pt;^Patient;-;UPDRS;PANEL.UPDRS;2;Mentation, behavior and mood panel [UPDRS];Mentation, behav, mood Pnl UPDRS;;ACTIVE;2.52;2.54 +7771-9;Citrullus lanatus Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Watermelon IgG Ab [Units/volume] in Serum;Watermelon IgG Qn;;ACTIVE;1.0h(2);2.73 +77719-3;Activities of daily living panel;-;Pt;^Patient;-;UPDRS;PANEL.UPDRS;2;Activities of daily living panel [UPDRS];ADL Pnl UPDRS;;ACTIVE;2.52;2.54 +77720-1;Motor examination panel;-;Pt;^Patient;-;UPDRS;PANEL.UPDRS;2;Motor examination panel [UPDRS];Motor examination Pnl UPDRS;;ACTIVE;2.52;2.54 +77721-9;Complications of therapy panel;-;1W;^Patient;-;UPDRS;PANEL.UPDRS;2;Complications of therapy panel in the past week [UPDRS];Complications therapy Pnl 1W UPDRS;;ACTIVE;2.52;2.54 +77722-7;Dyskinesias panel;-;Pt;^Patient;-;UPDRS;PANEL.UPDRS;2;Dyskinesias panel [UPDRS];Dyskinesias Pnl UPDRS;;ACTIVE;2.52;2.54 +77723-5;Clinical fluctuations panel;-;Pt;^Patient;-;UPDRS;PANEL.UPDRS;2;Clinical fluctuations panel [UPDRS];Clinical fluctuations Pnl UPDRS;;ACTIVE;2.52;2.54 +77724-3;Other complications panel;-;Pt;^Patient;-;UPDRS;PANEL.UPDRS;2;Other complications panel [UPDRS];Other complication Pnl UPDRS;;ACTIVE;2.52;2.54 +77725-0;Factor VIII+von Willebrand factor.ristocetin cofactor given;ACnc;Pt;Dose;Qn;vWF dosing;BLDBK;1;Factor VIII+von Willebrand factor (vWf) ristocetin cofactor given [Units/volume] by vWF dosing;FVIII+vWf:RCo Gvn Dose vWF dose-aCnc;;ACTIVE;2.52;2.68 +77726-8;Factor VIII+von Willebrand factor.ristocetin cofactor given;ACnc;Pt;Dose;Qn;FVIII dosing;BLDBK;1;Factor VIII+von Willebrand factor (vWf) ristocetin cofactor given [Units/volume] by FVIII dosing;FVIII+vWf:RCo Gvn Dose FVIII dose-aCnc;;ACTIVE;2.52;2.68 +7772-7;Triticum aestivum basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Wheat triggered histamine release [Units/volume] in Blood;Wheat BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77727-6;XXX allergen basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;XXX allergen triggered histamine release [Units/volume] in Blood;XXX allergen BasoBnd Ab Qn;;ACTIVE;2.52;2.52 +77728-4;Serotonin release 0.2 IU/mL heparin.unfractionated;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 0.2 IU/mL heparin.unfractionated [Units/volume] in Serum;SRA .2 IU/mL UFH Ser-aCnc;;ACTIVE;2.52;2.73 +77729-2;oxyMORphone;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;oxyMORphone [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;oxyMORphone SerPlBld Cfm-mCnc;;ACTIVE;2.52;2.73 +777-3;Platelets;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Platelets [#/volume] in Blood by Automated count;Platelet # Bld Auto;;ACTIVE;1.0;2.73 +77730-0;oxyCODONE;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;oxyCODONE [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;oxyCODONE SerPlBld Cfm-mCnc;;ACTIVE;2.52;2.73 +77731-8;oxyCODONE+oxymorphone;Imp;Pt;Ser/Plas/Bld;Ord;Confirm;DRUG/TOX;1;oxyCODONE+oxyMORphone [Interpretation] in Serum, Plasma or Blood Qualitative by Confirmatory method;oxyCODONE+oxyMORphone SerPlBld Cfm-Imp;;ACTIVE;2.52;2.73 +77732-6;oxyCODONE+oxymorphone;PrThr;Pt;Ser/Plas/Bld;Ord;Screen;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Serum, Plasma or Blood by Screen method;oxyCODONE+oxyMORphone SerPlBld Ql Scn;;ACTIVE;2.52;2.73 +77733-4;Gamma hydroxybutyrate;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Gamma hydroxybutyrate [Presence] in Specimen by Screen method;G-OH-Butyr Spec Ql Scn;;ACTIVE;2.52;2.73 +77734-2;Mycobacterium abscessus complex clarithromycin resistance erm(41) full length gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium abscessus complex clarithromycin resistance erm(41) full length gene [Presence] by Molecular method;M abscess erm(41) full Islt/Spm Ql;;ACTIVE;2.52;2.65 +7773-5;Triticum aestivum pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Cultivated Wheat IgE Ab [Units/volume] in Serum;Deprecated Cultivated Wheat IgE Qn;;DEPRECATED;1.0h(2);2.69 +77735-9;Mycobacterium abscessus complex clarithromycin resistance erm(41) truncated gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium abscessus complex clarithromycin resistance erm(41) truncated gene [Presence] by Molecular method;M absces erm(41) trunc Islt/Spm Ql;;ACTIVE;2.52;2.65 +77736-7;Mycobacterium abscessus complex clarithromycin resistance erm(41) gene;Imp;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Mycobacterium abscessus complex clarithromycin resistance erm(41) gene [Interpretation] by Molecular method;M abscessus erm(41) Islt/Spm-Imp;;ACTIVE;2.52;2.65 +77737-5;Mycobacterium abscessus complex clarithromycin resistance erm(41) gene panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Mycobacterium abscessus complex clarithromycin resistance erm(41) gene panel by Molecular genetics method;M abscessus erm(41) Pnl Islt/Spm;;ACTIVE;2.52;2.65 +77738-3;Flush;Type;Pt;Line;Nom;;CLIN;2;Line Flush [Type];Line Flush;;ACTIVE;2.52;2.52 +77739-1;Hepatitis B virus surface Ag;PrThr;Pt;^Mother;Ord;;MICRO;1;Mother's Hepatitis B virus surface Ag status;Mother's HBV surface Ag Ql;;ACTIVE;2.52;2.56 +77740-9;Norcotinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Norcotinine [Mass/volume] in Urine;Norcotinine Ur-mCnc;;ACTIVE;2.52;2.73 +77741-7;Streptavidin;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;Streptavidin [Presence] in Serum or Plasma by Immunoblot;Streptavidin SerPl Ql IB;;ACTIVE;2.52;2.73 +77742-5;HTLV I & II panel;-;Pt;Ser/Plas;-;IB;PANEL.MICRO;1;HTLV I and II panel - Serum or Plasma by Immunoblot;HTLV I+II Pnl SerPl IB;;ACTIVE;2.52;2.71 +7774-3;Cow whey Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cow whey IgE Ab [Units/volume] in Serum;Cow Whey IgE Qn;;ACTIVE;1.0h(2);2.73 +77743-3;Toxocara sp Ab;PrThr;Pt;Ocular fld;Ord;IA;MICRO;1;Toxocara sp Ab [Presence] in Ocular fluid by Immunoassay;Toxocara Ab Ocflu Ql IA;;ACTIVE;2.52;2.56 +77744-1;HTLV I & II Ab band pattern;Imp;Pt;Ser/Plas;Nom;;MICRO;1;HTLV I and II Ab band pattern [Interpretation] in Serum or Plasma;HTLV I+II Ab Patrn SerPl-Imp;;ACTIVE;2.52;2.73 +77745-8;HTLV I p19-I Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HTLV I p19-I Ab [Presence] in Serum or Plasma by Immunoblot;HTLV I p19-I Ab SerPl Ql IB;;ACTIVE;2.52;2.58 +77746-6;HTLV I gp46-I Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HTLV I gp46-I Ab [Presence] in Serum or Plasma by Immunoblot;HTLV I gp46-I Ab SerPl Ql IB;;ACTIVE;2.52;2.73 +77747-4;HTLV II gp46-II Ab;PrThr;Pt;Ser/Plas;Ord;IB;MICRO;1;HTLV II gp46-II Ab [Presence] in Serum or Plasma by Immunoblot;HTLV II gp46-II Ab SerPl Ql IB;;ACTIVE;2.52;2.73 +77748-2;PCDH15 gene.c.733C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PCDH15 gene c.733C>T [Presence] in Blood or Tissue by Molecular genetics method;PCDH15 c.733C>T Bld/T Ql;;ACTIVE;2.52;2.56 +77749-0;CLRN1 gene.c.144T>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CLRN1 gene c.144T>G [Presence] in Blood or Tissue by Molecular genetics method;CLRN1 c.144T>G Bld/T Ql;;ACTIVE;2.52;2.73 +7775-0;Whitefish Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whitefish IgE Ab [Units/volume] in Serum;Whitefish IgE Qn;;ACTIVE;1.0h(2);2.73 +77750-8;DLD gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;DLD gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;DLD gene Mut Anl Bld/T;;ACTIVE;2.52;2.73 +77751-6;TMEM216 gene.c.218G>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;TMEM216 gene c.218G>T [Presence] in Blood or Tissue by Molecular genetics method;TMEM216 c.218G>T Bld/T Ql;;ACTIVE;2.52;2.73 +77752-4;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) cutoff [Mass/volume] in Urine for Screen method;EDDP CtO Ur Scn-mCnc;;ACTIVE;2.52;2.73 +77753-2;Tumor morphology panel;-;Pt;Cancer.XXX;-;;PANEL.ONCO;2;Tumor morphology panel Cancer;Tumor morph Pnl Cancer;;ACTIVE;2.52;2.63 +77754-0;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) cutoff [Mass/volume] in Urine for Confirmatory method;EDDP CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77755-7;6-Monoacetylmorphine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;6MAM CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77756-5;7-Aminoclonazepam cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;7-Aminoclonazepam cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;7Aminoclonazepam CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77757-3;7-Hydroxyquetiapine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;7-Hydroxyquetiapine [Mass/volume] in Urine by Confirmatory method;7OH-quetiapine Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77758-1;7-Hydroxyquetiapine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;7-Hydroxyquetiapine cutoff [Mass/volume] in Urine for Confirmatory method;7OH-quetiapine CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77759-9;9-Hydroxyrisperidone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;9-Hydroxyrisperidone cutoff [Mass/volume] in Urine for Confirmatory method;9OH-risperidone CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77760-7;ARIPiprazole cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ARIPiprazole cutoff [Mass/volume] in Urine for Confirmatory method;ARIPiprazole CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77761-5;ARIPiprazole;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ARIPiprazole [Mass/volume] in Urine by Confirmatory method;ARIPiprazole Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77762-3;Alpha hydroxyalprazolam cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyalprazolam cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;A-OH Alpraz CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77763-1;ALPRAZolam cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;ALPRAZolam cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Alpraz CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77764-9;Buprenorphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Buprenorphine cutoff [Mass/volume] in Urine for Confirmatory method;Buprenorphine CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77765-6;Citalopram+Escitalopram;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Citalopram+Escitalopram [Mass/volume] in Urine by Confirmatory method;Citalopram+Escitalopram Ur Cfm-mCnc;;ACTIVE;2.52;2.73 +77766-4;clonazePAM cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;clonazePAM cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;clonazePAM CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77767-2;Codeine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Codeine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Codeine CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +7776-8;Whitefish Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Whitefish IgG Ab [Units/volume] in Serum;Whitefish IgG Qn;;ACTIVE;1.0h(2);2.73 +77768-0;Ethanol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethanol cutoff [Mass/volume] in Urine for Confirmatory method;Ethanol CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77769-8;Ethyl glucuronide cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethyl glucuronide cutoff [Mass/volume] in Urine for Confirmatory method;Ethyl glucuronide CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77770-6;HYDROmorphone cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;HYDROmorphone cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;HYDROmorphone CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77771-4;JWH-081 5-hydroxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-081 5-hydroxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-081 5OH-pentyl Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77772-2;Methylenedioxyethylamphetamine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine cutoff [Mass/volume] in Urine for Confirmatory method;MDEA CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77773-0;Morphine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Morphine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Morphine CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77774-8;Norbuprenorphine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norbuprenorphine cutoff [Mass/volume] in Urine for Confirmatory method;Norbuprenorphine CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77775-5;Norfentanyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norfentanyl cutoff [Mass/volume] in Urine for Confirmatory method;Norfentanyl CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +7777-6;Zizania spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wild Rice IgE Ab [Units/volume] in Serum;Wild Rice IgE Qn;;ACTIVE;1.0h(2);2.73 +77776-3;Norhydrocodone cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Norhydrocodone cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Norhydrocodone CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77777-1;Normeperidine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Normeperidine cutoff [Mass/volume] in Urine for Confirmatory method;Normeperidine CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77778-9;Noroxycodone cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Noroxycodone cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Noroxycodone CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77779-7;Noroxycodone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Noroxycodone cutoff [Mass/volume] in Urine for Confirmatory method;Noroxycodone CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77780-5;oxyMORphone cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;oxyMORphone cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;oxyMORphone CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77781-3;Pregabalin cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pregabalin cutoff [Mass/volume] in Urine for Confirmatory method;Pregabalin CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77782-1;PROMIS short form - alcohol - positive consequences 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - alcohol - positive consequences 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77783-9;PROMIS short form - alcohol - positive expectancies 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - alcohol - positive expectancies 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +7778-4;Salix discolor Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Pussy Willow IgE Ab [Units/volume] in Serum;Pussy Willow IgE Qn;;ACTIVE;1.0h(2);2.73 +77784-7;PROMIS alcohol - positive outcomes - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS alcohol - positive outcomes - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77785-4;PROMIS alcohol - negative consequences - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS alcohol - negative consequences - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77786-2;PROMIS alcohol - positive expectancies - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS alcohol - positive expectancies - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77787-0;Buprenorphine cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Buprenorphine cutoff [Mass/volume] in Urine for Screen method;Buprenorphine CtO Ur Scn-mCnc;;ACTIVE;2.52;2.73 +77788-8;cloZAPine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;cloZAPine cutoff [Mass/volume] in Urine for Confirmatory method;cloZAPine CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77789-6;PROMIS alcohol - negative expectancies - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS alcohol - negative expectancies - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77790-4;Cocaine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Cocaine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Cocaine CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77791-2;Benzoylecgonine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Benzoylecgonine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;BZE CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +7779-2;Atriplex canescens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wingscale IgE Ab [Units/volume] in Serum;Wingscale IgE Qn;;ACTIVE;1.0h(2);2.73 +77792-0;PROMIS short form - emotional support 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional support 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77793-8;PROMIS short form - alcohol - negative expectancies 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - alcohol - negative expectancies 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77794-6;PROMIS short form - alcohol - negative consequences 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - alcohol - negative consequences 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77795-3;PROMIS short form - alcohol - alcohol use 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - alcohol - alcohol use 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77796-1;PROMIS short form - physical function 8b - version 1.2 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function 8b - version 1.2 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77797-9;PROMIS short form - physical function 6b - version 1.2 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function 6b - version 1.2 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77798-7;PROMIS short form - social isolation 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - social isolation 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77799-5;PROMIS short form - social isolation 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - social isolation 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77-8;ceFAZolin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;ceFAZolin [Susceptibility] by Disk diffusion (KB);ceFAZolin Islt KB;;ACTIVE;1.0;2.73 +7780-0;Ceratoides arborescens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Winterfat IgE Ab [Units/volume] in Serum;Winterfat IgE Qn;;ACTIVE;1.0h(2);2.42 +77800-1;PROMIS short form - social isolation 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - social isolation 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77801-9;PROMIS short form - satisfaction with social roles and activities 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - satisfaction with social roles and activities 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77802-7;PROMIS short form - satisfaction with social roles and activities 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - satisfaction with social roles and activities 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77803-5;PROMIS short form - satisfaction with social roles and activities 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - satisfaction with social roles and activities 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77804-3;PROMIS short form - instrumental support 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - instrumental support 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77805-0;PROMIS short form - instrumental support 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - instrumental support 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77806-8;PROMIS short form - instrumental support 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - instrumental support 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77807-6;PROMIS short form - informational support 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - informational support 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77808-4;PROMIS short form - informational support 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - informational support 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77809-2;PROMIS short form - informational support 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - informational support 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +778-1;Platelets;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Platelets [#/volume] in Blood by Manual count;Platelet # Bld Manual;;ACTIVE;1.0;2.73 +77810-0;PROMIS short form - emotional support 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional support 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77811-8;PROMIS short form - emotional support 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional support 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77812-6;PROMIS short form - companionship 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - companionship 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77813-4;PROMIS short form - companionship 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - companionship 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77814-2;PROMIS short form - ability to participate in social roles and activities 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - ability to participate in social roles and activities 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77815-9;PROMIS short form - satisfaction with participation in social roles 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in social roles 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77816-7;PROMIS short form - sleep disturbance 6a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - sleep disturbance 6a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77817-5;PROMIS short form - physical function 20a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function 20a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7781-8;Artemisia absinthium Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wormwood IgG Ab [Units/volume] in Serum;Wormwood IgG Qn;;ACTIVE;1.0h(2);2.69 +77818-3;PROMIS short form - satisfaction with participation in social roles 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in social roles 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77819-1;PROMIS short form - physical function 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77820-9;PROMIS short form - emotional distress - anxiety 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional distress - anxiety 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77821-7;PROMIS short form - emotional distress - depression 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional distress - depression 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77822-5;PROMIS short form - fatigue 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - fatigue 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77824-1;PROMIS short form - pain interference 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - pain interference 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77825-8;PROMIS short form - pain intensity 3a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - pain intensity 3a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7782-6;Dioscorea batatas Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yam IgE Ab in Serum;Yam IgE Qn;;ACTIVE;1.0h(2);2.5 +77826-6;PROMIS short form - sleep disturbance 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - sleep disturbance 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77827-4;PROMIS short form - physical function 10a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function 10a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77828-2;PROMIS short form - sleep impairment 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - sleep impairment 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77829-0;PROMIS short form - sleep disturbance 8b - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - sleep disturbance 8b - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77830-8;PROMIS short form - satisfaction with participation in social roles 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in social roles 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77831-6;PROMIS short form - satisfaction with participation in DSA 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - satisfaction with participation in DSA 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77832-4;PROMIS short form - pain behavior 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - pain behavior 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77833-2;PROMIS short form - pain interference 6b - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - pain interference 6b - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7783-4;Yeast bakers Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Bakers Yeast IgE Ab [Units/volume] in Serum;Deprecated Bakers Yeast IgE Qn;;DEPRECATED;1.0h(2);2.54 +77834-0;PROMIS short form - fatigue 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - fatigue 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77835-7;PROMIS short form - emotional distress - depression 8b - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional distress - depression 8b - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77836-5;PROMIS short form - emotional distress - anxiety 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional distress - anxiety 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77837-3;PROMIS short form - emotional distress - anger 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional distress - anger 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77838-1;PROMIS short form - global - version 1.1 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - global - version 1.1 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77839-9;PROMIS pediatric short form - pain interference 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - pain interference 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77840-7;PROMIS pediatric short form - fatigue 10a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - fatigue 10a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77841-5;PROMIS pediatric short form - peer relationships 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - peer relationships 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7784-2;Saccharomyces cerevisiae basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Baker's yeast triggered histamine release [Units/volume] in Blood;Baker's yeast BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77842-3;PROMIS pediatric short form - asthma 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - asthma 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77843-1;PROMIS pediatric short form - physical function - upper extremity 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - physical function - upper extremity 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77844-9;PROMIS pediatric short form - physical function - mobility 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - physical function - mobility 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77845-6;PROMIS pediatric short form - emotional distress - anxiety 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - emotional distress - anxiety 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77846-4;PROMIS pediatric short form - emotional distress - anger - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - emotional distress - anger - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77847-2;PROMIS pediatric short form - depressive symptoms - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - depressive symptoms - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77848-0;PROMIS alcohol - alcohol use - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS alcohol - alcohol use - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77849-8;PROMIS social isolation - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS social isolation - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77850-6;PROMIS instrumental support - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS instrumental support - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77851-4;PROMIS informational support - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS informational support - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77852-2;PROMIS emotional support - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS emotional support - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77853-0;PROMIS companionship - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS companionship - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77854-8;PROMIS ability to participate in social roles and activities - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS ability to participate in social roles and activities - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77855-5;PROMIS satisfaction with social roles and activities - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS satisfaction with social roles and activities - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77856-3;PROMIS pain behavior - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS pain behavior - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77857-1;PROMIS satisfaction with participation in roles - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS satisfaction with participation in roles - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77858-9;PROMIS satisfaction with participation in DSA - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS satisfaction with participation in DSA - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7785-9;Yeast brewer's basophil bound Ab;ACnc;Pt;Bld;Qn;LHR;ALLERGY;1;Brewer's yeast triggered histamine release [Units/volume] in Blood;Brewer's yeast BasoBnd Ab Qn;;ACTIVE;1.0h(2);2.69 +77859-7;PROMIS sleep related impairment - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS sleep related impairment - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77860-5;PROMIS sleep disturbance - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS sleep disturbance - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77861-3;PROMIS emotional distress - depression - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS emotional distress - depression - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77862-1;PROMIS emotional distress - anxiety - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS emotional distress - anxiety - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77863-9;PROMIS emotional distress - anger - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS emotional distress - anger - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77864-7;PROMIS fatigue - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS fatigue - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77865-4;PROMIS pain interference - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS pain interference - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77866-2;PROMIS physical function - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS physical function - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7786-7;Taxus spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yew IgE Ab [Units/volume] in Serum;Yew IgE Qn;;ACTIVE;1.0h(2);2.42 +77867-0;PROMIS pediatric physical function - upper extremity - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric physical function - upper extremity - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77868-8;PROMIS pediatric peer relationships - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric peer relationships - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77869-6;PROMIS pediatric pain interference - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric pain interference - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77870-4;PROMIS pediatric physical function: mobility - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;Deprecated PROMIS pediatric physical function: mobility - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.52;2.7 +77871-2;PROMIS pediatric fatigue - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric fatigue - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77872-0;PROMIS pediatric asthma - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric asthma - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +77873-8;PROMIS pediatric emotional distress - anxiety - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric emotional distress - anxiety - version 1.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77874-6;PROMIS physical function - version 1.2 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS physical function - version 1.2 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.52 +7787-5;Yogurt Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yogurt IgE Ab [Units/volume] in Serum;Yogurt IgE Qn;;ACTIVE;1.0h(2);2.73 +77875-3;PROMIS pediatric short form - emotional distress - anxiety 8b - version 1.1;-;1W;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - emotional distress - anxiety 8b - version 1.1;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.52;2.54 +77876-1;Phencyclidine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Phencyclidine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;PCP CtO Sal Cfm-mCnc;;ACTIVE;2.52;2.52 +77877-9;Ziprasidone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ziprasidone [Mass/volume] in Urine by Confirmatory method;Ziprasidone Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77878-7;Ziprasidone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ziprasidone cutoff [Mass/volume] in Urine for Confirmatory method;Ziprasidone CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77879-5;Tapentadol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Tapentadol cutoff [Mass/volume] in Urine for Confirmatory method;Tapentadol CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77880-3;risperiDONE;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;risperiDONE [Mass/volume] in Urine by Confirmatory method;risperiDONE Ur Cfm-mCnc;;ACTIVE;2.52;2.73 +77881-1;risperiDONE cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;risperiDONE cutoff [Mass/volume] in Urine for Confirmatory method;risperiDONE CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77882-9;Dehydroaripiprazole cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dehydroaripiprazole cutoff [Mass/volume] in Urine for Confirmatory method;Dehydroaripiprazole CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +7788-3;Yogurt Ab.IgG;ACnc;Pt;Ser;Qn;;ALLERGY;1;Yogurt IgG Ab [Units/volume] in Serum;Yogurt IgG Qn;;ACTIVE;1.0h(2);2.69 +77883-7;QUEtiapine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;QUEtiapine cutoff [Mass/volume] in Urine for Confirmatory method;QUEtiapine CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77884-5;Dehydroaripiprazole;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dehydroaripiprazole [Mass/volume] in Urine by Confirmatory method;Dehydroaripiprazole Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77885-2;Ethyl sulfate cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethyl sulfate cutoff [Mass/volume] in Urine for Confirmatory method;Ethyl sulfate CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77886-0;Nortriptyline cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nortriptyline cutoff [Mass/volume] in Urine for Confirmatory method;Nortrip CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77887-8;OLANZapine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;OLANZapine cutoff [Mass/volume] in Urine for Confirmatory method;OLANZapine CtO Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77888-6;OLANZapine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;OLANZapine [Mass/volume] in Urine by Confirmatory method;OLANZapine Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77889-4;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular Ejection fraction by US.M-mode+Calculated by cube method;LV EF US.M-mode+cube;;ACTIVE;2.52;2.52 +77890-2;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by cube method;CARD.US;2;Left ventricular Ejection fraction by US.2D+Calculated by cube method;LV EF US.2D+cube;;ACTIVE;2.52;2.52 +7789-1;Acanthocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Acanthocytes [Presence] in Blood by Light microscopy;Acanthocytes Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77891-0;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Teichholz method;CARD.US;2;Left ventricular Ejection fraction by US.2D+Calculated by Teichholz method;LV EF 2D Teichholz;;ACTIVE;2.52;2.54 +77892-8;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by modified Simpson method;CARD.US;2;Left ventricular Ejection fraction by US.2D+Calculated by modified Simpson method;LV EF US.2D+mod Simpson;;ACTIVE;2.52;2.52 +77893-6;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular Myocardial mass by US.M-mode+Calculated by cube method;LV Myo mass US.M-mode+cube;;ACTIVE;2.52;2.54 +77894-4;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by truncated ellipsoid method;CARD.US;2;Left ventricular Myocardial mass by US.2D+Calculated by truncated ellipsoid method;LV Myo mass US.2D+trunc ellips;;ACTIVE;2.52;2.54 +77895-1;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Devereux method;CARD.US;2;Left ventricular Myocardial mass by US.2D+Calculated by Devereux method;LV Myo mass 2D Devereux;;ACTIVE;2.52;2.54 +77896-9;Myocardial mass;Mass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by area-length method;CARD.US;2;Left ventricular Myocardial mass by US.2D+Calculated by area-length method;LV Myo mass US.2D+A-L;;ACTIVE;2.52;2.54 +77897-7;Myocardial mass/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Myocardial mass/Body surface area [Mass/Area] by US 2D;LV Myo mass/BSA 2D US;;ACTIVE;2.52;2.54 +77898-5;Myocardial mass/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular Myocardial mass/Body surface area [Mass/Area] by US.M-mode+Calculated by cube method;LV Myo mass/BSA US.M-mode+cube;;ACTIVE;2.52;2.54 +77899-3;Myocardial mass/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by truncated ellipsoid method;CARD.US;2;Left ventricular Myocardial mass/Body surface area [Mass/Area] by US.2D+Calculated by truncated ellipsoid method;LV Myo mass/BSA US.2D+trunc ellips;;ACTIVE;2.52;2.54 +77900-9;Myocardial mass/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by area-length method;CARD.US;2;Left ventricular Myocardial mass/Body surface area [Mass/Area] by US.2D+Calculated by area-length method;LV Myo mass/BSA US.2D+A-L;;ACTIVE;2.52;2.54 +77901-7;Minor axis.end diastole.parasternal long axis;Len;Pt;Heart.ventricle.right;Qn;US.2D;CARD.US;2;Right ventricular Minor axis at end diastole.parasternal long axis [Length] by US 2D;RV ED minor axis PLAX 2D US;;ACTIVE;2.52;2.54 +77902-5;Minor axis.end diastole;Len;Pt;Heart.ventricle.right;Qn;US.2D.A4C;CARD.US;2;Right ventricular Minor axis at end diastole [Length] by US.2D.A4C;RV ED minor axis A4C;;ACTIVE;2.52;2.67 +77903-3;Excursion distance.systole;Len;Pt;Tricuspid valve.annulus;Qn;US.M-mode;CARD.US;2;Tricuspid valve annulus Excursion distance during systole by US.M-mode;TV ann Excursion dist sys M-mode;;ACTIVE;2.52;2.67 +77904-1;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by modified Simpson method;CARD.US;2;Left atrial End-systolic volume by US.2D+Calculated by modified Simpson method;LA ES vol US.2D+mod Simpson;;ACTIVE;2.52;2.52 +77905-8;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by area-length method;CARD.US;2;Left atrial End-systolic volume by US.2D+Calculated by area-length method;LA ES vol US.2D+A-L;;ACTIVE;2.52;2.52 +77906-6;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by modified Simpson method;CARD.US;2;Left atrial End-systolic volume/Body surface area [Volume/Area] by US.2D+Calculated by modified Simpson method;LA ES vol/BSA US.2D+mod Simpson;;ACTIVE;2.52;2.52 +77907-4;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by area-length method;CARD.US;2;Left atrial End-systolic volume/Body surface area [Volume/Area] by US.2D+Calculated by area-length method;LA ES vol/BSA US.2D+A-L;;ACTIVE;2.52;2.52 +77908-2;Vena contracta diameter;Len;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Vena contracta diameter by US.doppler;AV VC diam DOP;;ACTIVE;2.52;2.54 +7790-9;Burr cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Burr cells [Presence] in Blood by Light microscopy;Burr Cells Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77909-0;Effective regurgitant orifice area;Area;Pt;Aortic valve;Qn;US.doppler+Calculated by PISA method;CARD.US;2;Aortic valve Effective regurgitant orifice area by US.doppler+Calculated by PISA method;AV EROA PISA;;ACTIVE;2.52;2.56 +77910-8;Effective regurgitant orifice area;Area;Pt;Aortic valve;Qn;US.doppler+Calculated by volumetric method;CARD.US;2;Aortic valve Effective regurgitant orifice area by US.doppler+Calculated by volumetric method;AV EROA DOP+Calc by vol;;ACTIVE;2.52;2.56 +77911-6;Regurgitation degree;Find;Pt;Aortic valve.regurgitant jet;Ord;US;CARD.US;2;Deprecated Aortic valve regurgitant jet Regurgitation degree by US;Deprecated AV reg Reg deg US;;DEPRECATED;2.52;2.56 +77912-4;Stenosis degree;Find;Pt;Aortic valve;Ord;US;CARD.US;2;Aortic valve Stenosis degree by US;AV Sten deg US;;ACTIVE;2.52;2.52 +77913-2;Vena contracta diameter;Len;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Vena contracta diameter by US.doppler;MV VC diam DOP;;ACTIVE;2.52;2.54 +77914-0;Effective regurgitant orifice area;Area;Pt;Mitral valve;Qn;US.doppler+Calculated by volumetric method;CARD.US;2;Mitral valve Effective regurgitant orifice area by US.doppler+Calculated by volumetric method;MV EROA DOP+Calc by vol;;ACTIVE;2.52;2.56 +77915-7;Regurgitation degree;Find;Pt;Mitral valve.regurgitant jet;Ord;US;CARD.US;2;Deprecated Mitral valve regurgitant jet Regurgitation degree by US;Deprecated MV reg Reg deg US;;DEPRECATED;2.52;2.56 +77916-5;Stenosis degree;Find;Pt;Mitral valve;Ord;US;CARD.US;2;Mitral valve Stenosis degree by US;MV Sten deg US;;ACTIVE;2.52;2.52 +7791-7;Dacryocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Dacrocytes [Presence] in Blood by Light microscopy;Dacryocytes Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77917-3;Vena contracta diameter;Len;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Vena contracta diameter by US.doppler;TV VC diam DOP;;ACTIVE;2.52;2.54 +77918-1;Vena contracta diameter;Len;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Vena contracta diameter by US.doppler;PV VC diam DOP;;ACTIVE;2.52;2.67 +77919-9;Regurgitation degree;Find;Pt;Pulmonic valve.regurgitant jet;Ord;US;CARD.US;2;Deprecated Pulmonic valve regurgitant jet Regurgitation degree by US;Deprecated PV reg Reg deg US;;DEPRECATED;2.52;2.56 +77920-7;Myocardial mass/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Myocardial mass/Height exp 2.7 [Mass/Area] by US 2D;LV Myo mass/Ht exp 2.7 2D US;;ACTIVE;2.52;2.56 +77921-5;Myocardial mass/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by cube method;CARD.US;2;Left ventricular Myocardial mass/Height exp 2.7 [Mass/Area] by US.M-mode+Calculated by cube method;LV Myo/Ht exp 2.7 US.M-mode+cube;;ACTIVE;2.52;2.56 +77922-3;Myocardial mass/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by area-length method;CARD.US;2;Left ventricular Myocardial mass/Height exp 2.7 [Mass/Area] by US.2D+Calculated by area-length method;LV Myo mass/Ht exp 2.7 ArMass US.2D+A-L;;ACTIVE;2.52;2.56 +77923-1;Myocardial mass/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by truncated ellipsoid method;CARD.US;2;Left ventricular Myocardial mass/Height exp 2.7 [Mass/Area] by US.2D+Calculated by truncated ellipsoid method;LV Myo/Ht exp 2.7 US.2D+trunc ellips;;ACTIVE;2.52;2.56 +77924-9;Enterobacteriaceae.carbapenem resistant;PrThr;Pt;Anorectal/Stool;Ord;Organism specific culture;MICRO;1;Enterobacteriaceae.carbapenem resistant [Presence] in Anorectal or stool specimen by Organism specific culture;CRE Anorectl/Stl Ql Cult;;ACTIVE;2.52;2.73 +7792-5;Dohle body;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Dohle body [Presence] in Blood by Light microscopy;Dohle Bod Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77925-6;Cortisol^10M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge;Cortis 10M p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77926-4;Cortisol^3M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --3 minutes post XXX challenge;Cortis 3M p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77927-2;Cortisol^5M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge;Cortis 5M p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77928-0;Cortisol^75M post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --75 minutes post XXX challenge;Cortis 75M p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77929-8;Cortisol^3.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --3.5 hours post XXX challenge;Cortis 3.5h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77930-6;Cortisol^4H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --4 hours post XXX challenge;Cortis 4h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77931-4;Cortisol^6H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --6 hours post XXX challenge;Cortis 6h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77932-2;Cortisol^8H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --8 hours post XXX challenge;Cortis 8h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +7793-3;Howell-Jolly bodies;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Howell-Jolly bodies [Presence] in Blood by Light microscopy;Howell-Jolly Bod Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77933-0;Cortisol^9H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --9 hours post XXX challenge;Cortis 9h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77934-8;Cortisol^9.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --9.5 hours post XXX challenge;Cortis 9.5h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77935-5;Cortisol^10H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --10 hours post XXX challenge;Cortis 10h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77936-3;Cortisol^10.5H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --10.5 hours post XXX challenge;Cortis 10.5h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77937-1;Cortisol^12H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --12 hours post XXX challenge;Cortis 12h p chal SerPl-sCnc;;ACTIVE;2.52;2.58 +77938-9;Cortisol^124H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Deprecated Cortisol [Moles/volume] in Serum or Plasma --124 hours post XXX challenge;Deprecated Cortis 124H P XXX chal SerPl-;;DEPRECATED;2.52;2.58 +77939-7;Corticotropin^45M post XXX challenge;SCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Moles/volume] in Plasma --45 minutes post XXX challenge;ACTH 45M p chal Plas-sCnc;;ACTIVE;2.52;2.58 +77940-5;Albumin;MCnc;XXX;Urine;Qn;Electrophoresis;CHEM;1;Albumin [Mass/volume] by Electrophoresis in Urine collected for unspecified duration;Albumin ?Tm Ur Elph-mCnc;;ACTIVE;2.52;2.52 +7794-1;Normocytic/Normochromic polychromasia;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Normocytic/Normochromic polychromasia [Presence] in Blood by Light microscopy;Normocytic/NC Polychr Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77941-3;Final patient acuity;Find;Pt;^Patient;Nom;NEMSIS;NEMSIS;2;Final patient acuity NEMSIS;Final patient acuity NEMSIS;;ACTIVE;2.52;2.52 +77942-1;Cells.CD8+CD3-/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD8+CD3- cells/100 cells in Specimen;CD8+CD3- Cells NFr Spec;;ACTIVE;2.52;2.73 +77943-9;Schistosoma mansoni+haematobium+intercalatum;Titr;Pt;Ser;Qn;HA;MICRO;1;Schistosoma mansoni+haematobium+intercalatum [Titer] in Serum by Hemagglutination;S man+haem+interc Titr Ser HA;;ACTIVE;2.52;2.52 +77944-7;Cells.CD11a/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD11a cells/100 cells in Specimen;CD11a Cells NFr Spec;;ACTIVE;2.52;2.69 +77945-4;Cells.CD4+CD3-/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;Deprecated Cells.CD4+CD3-/100 cells in Unspecified specimen;Deprecated Cells.CD4+CD3- NFr XXX;;DEPRECATED;2.52;2.69 +77946-2;Cells.CD42b/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD42b cells/100 cells in Specimen;CD42b Cells NFr Spec;;ACTIVE;2.52;2.69 +77947-0;Cells.CD9/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;CD9 cells/100 cells in Specimen;CD9 Cells NFr Spec;;ACTIVE;2.52;2.69 +77948-8;Cells.FLAER/100 cells;NFr;Pt;XXX;Qn;;CELLMARK;1;FLAER cells/100 cells in Specimen;FLAER Cells NFr Spec;;ACTIVE;2.52;2.73 +77949-6;Streptococcus pneumoniae Ag;PrThr;Pt;Urine;Ord;IA.rapid;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Urine by Rapid immunoassay;S pneum Ag Ur Ql IA.rapid;;ACTIVE;2.52;2.73 +77950-4;Toscana virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toscana virus IgM Ab [Presence] in Serum by Immunoassay;TOSV IgM Ser Ql IA;;ACTIVE;2.52;2.56 +77951-2;Toscana virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toscana virus IgG Ab [Presence] in Serum by Immunoassay;TOSV IgG Ser Ql IA;;ACTIVE;2.52;2.56 +77952-0;Trypanosoma cruzi Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Trypanosoma cruzi Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;T cruzi Ab SerPlBld Ql IA.rapid;;ACTIVE;2.52;2.56 +77953-8;West Nile virus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;West Nile virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;WNV IgG CSF Ql IA;;ACTIVE;2.52;2.73 +77954-6;Yellow fever virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Yellow fever virus IgG Ab [Presence] in Serum by Immunofluorescence;YFV IgG Ser Ql IF;;ACTIVE;2.52;2.56 +77955-3;Yellow fever virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Yellow fever virus IgM Ab [Presence] in Serum by Immunofluorescence;YFV IgM Ser Ql IF;;ACTIVE;2.52;2.56 +77956-1;Yersinia enterocolitica O:3 Ab.IgG;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Yersinia enterocolitica O:3 IgG Ab [Presence] in Serum by Agglutination;Y entero O:3 IgG Ser Ql Aggl;;ACTIVE;2.52;2.61 +77957-9;Yersinia enterocolitica O:9 Ab.IgG;PrThr;Pt;Ser;Ord;Aggl;MICRO;1;Yersinia enterocolitica O:9 IgG Ab [Presence] in Serum by Agglutination;Y entero O:9 IgG Ser Ql Aggl;;ACTIVE;2.52;2.61 +7795-8;Pappenheimer bodies;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Pappenheimer bodies [Presence] in Blood by Light microscopy;Pappenheimer Bod Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77958-7;Dengue virus 1 & 2 & 3 & 4 RNA;Prid;Pt;CSF;Nom;Probe.amp.tar;MICRO;1;Dengue virus 1 and 2 and 3 and 4 RNA [Identifier] in Cerebral spinal fluid by NAA with probe detection;DENV 1+2+3+4 RNA CSF NAA+probe;;ACTIVE;2.52;2.63 +77959-5;Yellow fever virus ns5 gene;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Yellow fever virus ns5 gene [Presence] in Cerebral spinal fluid by NAA with non-probe detection;YFV ns5 gene CSF Ql NAA+non-probe;;ACTIVE;2.54;2.63 +77960-3;Penicillin.parenteral;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Penicillin Parenteral [Susceptibility] by Disk diffusion (KB);Penicillin Parenteral Islt KB;;ACTIVE;2.52;2.52 +77961-1;cloZAPine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;cloZAPine [Mass/volume] in Urine by Confirmatory method;cloZAPine Ur Cfm-mCnc;;ACTIVE;2.52;2.52 +77962-9;Summary note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Summary note;OBGYN Summary note;;DISCOURAGED;2.52;2.64 +77963-7;Birth defects diagnosis;Find;Pt;^Patient;Nar;;CLIN;2;Birth defects diagnosis Narrative;Birth defects;;ACTIVE;2.52;2.73 +77964-5;Cholesterol crystals;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Cholesterol crystals [#/area] in Urine sediment by Microscopy low power field;Cholest Cry #/area UrnS LPF;;ACTIVE;2.52;2.52 +77965-2;Immediate national notifiable condition;Find;Pt;^Event;Ord;;SURVEY.CDC;4;Immediate national notifiable condition;;;ACTIVE;2.52;2.52 +7796-6;Platelet clump;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Platelet clump [Presence] in Blood by Light microscopy;Platelet Clump Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77966-0;Reporting state;Loc;Pt;^Event;Nom;;SURVEY.CDC;4;Reporting state;;;ACTIVE;2.52;2.7 +77967-8;Reporting county;Loc;Pt;^Event;Nom;;SURVEY.CDC;4;Reporting county;;;ACTIVE;2.52;2.52 +77968-6;National reporting jurisdiction;Loc;Pt;^Event;Nom;;SURVEY.CDC;4;National reporting jurisdiction;;;ACTIVE;2.52;2.66 +77969-4;Jurisdiction code;ID;Pt;^Event;Nom;;SURVEY.CDC;4;Jurisdiction code;;;ACTIVE;2.52;2.52 +77970-2;Date of initial report;TmStp;Pt;^Event;Qn;;SURVEY.CDC;4;Date of initial report;;;ACTIVE;2.52;2.52 +77972-8;Earliest date reported to county;TmStp;Pt;^Event;Qn;;SURVEY.CDC;4;Earliest date reported to county;;;ACTIVE;2.52;2.52 +77973-6;Earliest date reported to state;TmStp;Pt;^Event;Qn;;SURVEY.CDC;4;Earliest date reported to state;;;ACTIVE;2.52;2.52 +7797-4;Rouleaux;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Rouleaux [Presence] in Blood by Light microscopy;Rouleaux Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77974-4;Hospitalized for condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether the patient was hospitalized for condition of interest;Hospitalized for condition;;ACTIVE;2.52;2.69 +77975-1;Earliest date of diagnosis;Date;Pt;^Patient;Qn;;H&P.HX;2;Earliest date of diagnosis;Earliest Date of Dx;;ACTIVE;2.52;2.52 +77976-9;Illness or injury end date;Date;Pt;^Patient;Qn;;H&P.HX;2;Illness or injury end date;Illness or injury end date;;ACTIVE;2.52;2.52 +77977-7;Illness duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Illness duration;Illness duration;;ACTIVE;2.52;2.52 +77978-5;Patient died from illness of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Patient died from illness of interest;Pt died from illness;;ACTIVE;2.52;2.54 +77979-3;Case investigation start date;Date;Pt;^Event;Qn;;SURVEY.CDC;4;Case investigation start date;;;ACTIVE;2.52;2.52 +77980-1;Case is associated with a known outbreak;Find;Pt;^Event;Ord;;SURVEY.CDC;4;Case is associated with a known outbreak;;;ACTIVE;2.52;2.52 +77981-9;Case outbreak name;ID;Pt;^Event;Nom;;SURVEY.CDC;4;Case outbreak name;;;ACTIVE;2.52;2.52 +7798-2;Smudge cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Smudge cells [Presence] in Blood by Light microscopy;Smudge Cells Bld Ql Smear;;ACTIVE;1.0h(2);2.73 +77982-7;Jurisdiction where disease acquired;Loc;Pt;^Patient;Nom;;SURVEY.CDC;4;Jurisdiction where disease acquired;;;ACTIVE;2.52;2.52 +77983-5;Country of usual residence;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Country of usual residence [Location];Country of usual residence;;ACTIVE;2.52;2.66 +77984-3;Country of exposure to illness;Loc;Pt;^Patient;Nom;;H&P.HX;2;Country of exposure to illness [Location];Country exp to illness;;ACTIVE;2.52;2.54 +77985-0;State or province of exposure to illness;Loc;Pt;^Patient;Nom;;H&P.HX;2;State or province of exposure to illness;St or Prov exposure to illness;;ACTIVE;2.52;2.52 +77986-8;City of exposure to illness;Loc;Pt;^Patient;Nom;;H&P.HX;2;City of exposure to illness;City of exposure to illness;;ACTIVE;2.52;2.52 +77987-6;County of exposure to illness;Loc;Pt;^Patient;Nom;;H&P.HX;2;County of exposure to illness [Location];Co. of exposure to illness;;ACTIVE;2.52;2.52 +77988-4;Binational reporting criteria;Type;Pt;^Event;Nom;CDC.PHIN;SURVEY.CDC;4;Binational reporting criteria [CDC.PHIN];;;ACTIVE;2.52;2.52 +77989-2;Disease transmission mode;Type;Pt;^Patient;Nom;;H&P.HX;2;Disease transmission mode;Disease transmission mode;;ACTIVE;2.52;2.52 +779-9;Poikilocytosis;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Poikilocytosis [Presence] in Blood by Light microscopy;Poikilocytosis Bld Ql Smear;;ACTIVE;1.0;2.73 +7799-0;Fibrin D-dimer;ACnc;Pt;PPP;Qn;;COAG;1;Deprecated Fibrin D-dimer [Units/volume] in Platelet poor plasma;Deprecated D Dimer PPP-aCnc;;DEPRECATED;1.0h(2);2.7 +77990-0;Case class status;Type;Pt;^Event;Nom;CDC.PHIN;SURVEY.CDC;4;Case class status [CDC.PHIN];;;ACTIVE;2.52;2.52 +77991-8;Week counted for Morbidity and Mortality Weekly Report;Num;Pt;^Event;Qn;CDC.PHIN;SURVEY.CDC;4;MMWR Week [CDC.PHIN];;;ACTIVE;2.52;2.52 +77992-6;Year included in Morbidity and Mortality Weekly Report;Date;Pt;^Event;Qn;CDC.PHIN;SURVEY.CDC;4;MMWR Year [CDC.PHIN];;;ACTIVE;2.52;2.52 +77993-4;State notifiable condition case identifier;ID;Pt;^Event;Nom;;SURVEY.CDC;4;State notifiable condition case identifier;;;ACTIVE;2.52;2.52 +77994-2;Date of first report to Centers for Disease Control and Prevention;TmStp;Pt;^Event;Qn;CDC.PHIN;SURVEY.CDC;4;Date of first report to Centers for Disease Control and Prevention [CDC.PHIN];;;ACTIVE;2.52;2.52 +77995-9;Date of first report to public health department;TmStp;Pt;^Event;Qn;;SURVEY.CDC;4;Date of first report to public health department;;;ACTIVE;2.52;2.52 +77996-7;Pregnancy status at time of illness or condition;Find;Pt;^Patient;Ord;;H&P.HX;2;Pregnancy status at time of illness or condition;Preg stat at illness cond;;ACTIVE;2.52;2.52 +77997-5;Legacy case identifier;ID;Pt;^Event;Nom;CDC.PHIN;SURVEY.CDC;4;Legacy case identifier [CDC.PHIN];;;ACTIVE;2.52;2.52 +77998-3;Age at time of case investigation;Time;Pt;^Patient;Qn;;SURVEY.CDC;4;Age at time of case investigation;;;ACTIVE;2.52;2.52 +77999-1;Case notification comment;Imp;Pt;^Event;Nom;;SURVEY.CDC;4;Case notification comment;;;ACTIVE;2.52;2.52 +78000-7;Case notification panel;-;Pt;^Patient;-;CDC.PHIN;PANEL.SURVEY.CDC;4;Case notification panel [CDC.PHIN];;;ACTIVE;2.52;2.61 +78001-5;Cytomegalovirus pp65 Ag/100000 PMN cells;NFr;Pt;Bld;Qn;IF;MICRO;1;Cytomegalovirus pp65 Ag/100000 PMN cells in Blood by Immunofluorescence;CMV pp65 Ag/100000 PMN Bld IF-NFr;;ACTIVE;2.52;2.52 +78002-3;CD34 dose in hematopoietic progenitor cell transfusion;NCnt;Pt;^Patient;Qn;;BLDBK;1;CD34 dose in hematopoietic progenitor cell transfusion [#/mass] per recipient body mass;CD34 dose in HPC per recipient body mass;;ACTIVE;2.52;2.52 +78003-1;Nucleated cell dose in hematopoietic progenitor cell transfusion;NCnt;Pt;^Patient;Qn;;BLDBK;1;Nucleated cell dose in hematopoietic progenitor cell transfusion [#/mass] per recipient body mass;Nuc cell dose HPC per recip body mass;;ACTIVE;2.52;2.52 +78004-9;Staphylococcus aureus.vancomycin resistance;Susc;Pt;Isolate;Ord;;ABXBACT;1;Staphylococcus aureus.vancomycin resistance [Susceptibility] Qualitative;VRSA Islt Ql;;ACTIVE;2.52;2.52 +78005-6;Summary registry report;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Summary registry report;PT Summary registry report;;ACTIVE;2.52;2.63 +7800-6;Phospholipid Ab;ACnc;Pt;Ser;Qn;;COAG;1;Phospholipid Ab [Units/volume] in Serum;Phospholipid Ab Ser-aCnc;;ACTIVE;1.0h(2);2.44 +78006-4;Glomerular filtration rate/1.73 sq M;ArVRat;Pt;Urine+Ser/Plas;Qn;Isotopic;CHEM;1;Isotopic Glomerular filtration rate/1.73 sq M [Volume Rate/Area] in Urine and Serum or Plasma;Isotopic GFR/1.73 sq M Ur+SerPl-ArVRat;;ACTIVE;2.52;2.72 +78007-2;HIV 1 proviral DNA;EntLogNum;Pt;Bld MC;Qn;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Logarithmic entitic number] (viral load) in Blood mononuclear cells by NAA with probe detection;HIV 1 pro DNA Bld MC NAA+probe-EntLogNum;;ACTIVE;2.52;2.66 +78008-0;HIV 1 proviral DNA;EntNum;Pt;XXX MC;Qn;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Entitic number] (viral load) in Mononuclear cells from unspecified specimen by NAA with probe detection;HIV 1 pro DNA XXX MC NAA+probe-EntNum;;ACTIVE;2.52;2.66 +78009-8;HIV 1 proviral DNA;EntNum;Pt;Bld MC;Qn;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Entitic number] (viral load) in Blood mononuclear cells by NAA with probe detection;HIV 1 pro DNA Bld MC NAA+probe-EntNum;;ACTIVE;2.52;2.66 +78010-6;HIV 1 proviral DNA;EntLogNum;Pt;XXX MC;Qn;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Logarithmic entitic number] (viral load) in Mononuclear cells from unspecified specimen by NAA with probe detection;HIV 1 pro DNA XXX MC NAA+probe-EntLogNum;;ACTIVE;2.52;2.66 +78011-4;Schistocytes/100 cells;NFr;Pt;BldCo;Qn;;HEM/BC;1;Schistocytes/100 cells in Cord blood;Schistocytes NFr BldCo;;ACTIVE;2.52;2.52 +78012-2;Streptococcus pyogenes Ag;PrThr;Pt;Thrt;Ord;IA.rapid;MICRO;1;Streptococcus pyogenes Ag [Presence] in Throat by Rapid immunoassay;S pyo Ag Throat Ql IA.rapid;;ACTIVE;2.54;2.73 +78013-0;HLA-A & B & DRB & DQB1 panel;Type;Pt;Bld/Tiss;-;Low resolution;PANEL.HLA;1;HLA-A and B and DRB and DQB1 panel [Type] - Blood or Tissue by Low resolution;HLA-A + B + DRB + DQB1 Pnl Bld/T Low res;;ACTIVE;2.52;2.56 +7801-4;Phospholipid Ab.IgG;ACnc;Pt;Ser;Qn;;COAG;1;Phospholipid IgG Ab [Units/volume] in Serum;Phospholipid IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78014-8;HLA-A;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-A [Type] by Low resolution;HLA-A Low res;;ACTIVE;2.52;2.52 +78015-5;HLA-B;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-B [Type] by Low resolution;HLA-B Low res;;ACTIVE;2.52;2.73 +78016-3;HLA-DRB;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DRB [Type] by Low resolution;HLA-DRB Low res;;ACTIVE;2.52;2.73 +78017-1;HLA-DQB1;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DQB1 [Type] by Low resolution;HLA-DQB1 Low res;;ACTIVE;2.52;2.52 +78018-9;Toscana virus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Toscana virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;TOSV IgG CSF Ql IA;;ACTIVE;2.52;2.56 +78019-7;Toscana virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Toscana virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;TOSV IgM CSF Ql IA;;ACTIVE;2.52;2.56 +78020-5;Admission priority;Type;Pt;^Patient;Ord;NHCS;SURVEY.NHCS;4;Admission priority [NHCS];;;ACTIVE;2.52;2.52 +78021-3;Specialty care unit;Type;Pt;Hospital;Nom;NHCS;SURVEY.NHCS;4;Specialty care unit Type [NHCS];;;ACTIVE;2.52;2.52 +7802-2;Phospholipid Ab.IgM;ACnc;Pt;Ser;Qn;;COAG;1;Phospholipid IgM Ab [Units/volume] in Serum;Phospholipid IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78022-1;Care setting;Type;Pt;Facility;Nom;NHCS;SURVEY.NHCS;4;Care setting Facility [NHCS];;;ACTIVE;2.52;2.52 +78023-9;Hospital discharge disposition;Type;Pt;^Patient;Nom;NHCS;SURVEY.NHCS;4;Deprecated Hospital discharge disposition [NHCS];;;DEPRECATED;2.52;2.73 +78024-7;ED discharge disposition;Type;Pt;^Patient;Nom;NHCS;SURVEY.NHCS;4;Deprecated ED discharge disposition [NHCS];;;DEPRECATED;2.52;2.73 +78025-4;Outpatient visit discharge disposition;Type;Pt;^Patient;Nom;NHCS;SURVEY.NHCS;4;Outpatient visit discharge disposition [NHCS];;;ACTIVE;2.52;2.52 +78026-2;Diagnosis present on admission;Find;Pt;^Patient;Ord;;SURVEY.NHCS;4;Diagnosis present on admission;;;ACTIVE;2.52;2.7 +78027-0;Follow-up attempt within 24H;Find;24H;^Patient;Ord;;SURVEY.NHCS;4;Follow-up attempt within 24 hours;;;ACTIVE;2.52;2.7 +78028-8;Follow-up attempt outcome;Type;Pt;^Patient;Nom;NHCS;SURVEY.NHCS;4;Follow-up attempt outcome [NHCS];;;ACTIVE;2.52;2.52 +78029-6;Arrived from;Type;Pt;^Patient;Nom;NHCS;SURVEY.NHCS;4;Patient Point of origin [NHCS];;;ACTIVE;2.52;2.52 +7803-0;Acanthamoeba sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Acanthamoeba sp Ab [Presence] in Serum;Acanthamoeba Ab Ser Ql;;ACTIVE;1.0h(2);2.56 +78030-4;Type of encounter;Type;Pt;^Patient;Nom;;SURVEY.NHCS;4;Episode of care Type;;;ACTIVE;2.52;2.7 +78031-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Aorta.abdominal & Pelvis+Lower extremity.bilateral>RO vessels;Doc;CT.angio;RAD;2;CTA Abdominal Aorta and Bilateral Runoff Vessels WO and W contrast IV;CTA Abd Aorta+ROves-Bl WO+WcontrIV;;ACTIVE;2.52;2.61 +78032-0;Multisection^WO & W contrast IV;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Pelvis+Lower extremity.bilateral>RO vessels;Doc;CT.angio;RAD;2;CTA Thoracic and Abdominal Aorta and Bilateral Runoff Vessels WO and W contrast IV;CTA T+A.Ao+RO v-Bl WO+W contr IV;;ACTIVE;2.52;2.61 +78033-8;Hospital stay duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Hospital stay duration;Hosp stay duration;;ACTIVE;2.52;2.52 +78034-6;Procedure that confirmed birth defect diagnosis;Type;Pt;^Patient;Nom;;CLIN;2;Procedure that confirmed birth defect diagnosis;Birth defect dx confirmed by;;TRIAL;2.52;2.52 +78035-3;Fibers;PrThr;Pt;Body fld;Ord;;CHEM;1;Fibers [Presence] in Body fluid;Fibers Fld Ql;;ACTIVE;2.52;2.56 +78036-1;Fibers;PrThr;Pt;Urine;Ord;;CHEM;1;Fibers [Presence] in Urine;Fibers Ur Ql;;ACTIVE;2.52;2.56 +78037-9;Multisection^W contrast IV;Find;Pt;Abdomen>Aorta.abdominal & Pelvis+Lower extremity.bilateral>RO vessels;Doc;CT.angio;RAD;2;CTA Abdominal Aorta and Bilateral Runoff Vessels W contrast IV;CTA Abd Aort+ROves-Bl W contr IV;;ACTIVE;2.52;2.61 +78038-7;Multisection^W contrast IV;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Pelvis+Lower extremity.bilateral>RO vessels;Doc;CT.angio;RAD;2;CTA Thoracic and Abdominal Aorta and Bilateral Runoff Vessels W contrast IV;CTA T+A.Ao+RO v-Bl W contr IV;;ACTIVE;2.52;2.61 +78039-5;Discharge teaching note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Discharge teaching note;Discharge teach note;;ACTIVE;2.52;2.54 +78040-3;FISH probe target gene;ID;Pt;Laboratory device;Nom;;MOLPATH;1;FISH probe target gene [Identifier] in Laboratory device;FISH probe target gene Lab Device;;TRIAL;2.54;2.67 +78041-1;FISH probe target locus;ID;Pt;Laboratory device;Nom;;MOLPATH;1;FISH probe target locus [Identifier] in Laboratory device;FISH probe target locus Lab Device;;TRIAL;2.54;2.67 +78042-9;Vendor FISH product name;ID;Pt;Bld/Tiss;Nom;;MOLPATH;1;Vendor FISH product name [Identifier] in Blood or Tissue;Vendor FISH prod name Bld/T;;TRIAL;2.54;2.54 +78043-7;Gene mutations tested for;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;Deprecated Gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal;Deprecated Gene Mut Tested Bld/T;;DEPRECATED;2.54;2.56 +78044-5;Disease assessed;ID;Pt;Bld/Tiss;Nom;;CLIN;2;Disease assessed [Identifier] Blood or Tissue;Disease assessed Bld/T;;TRIAL;2.54;2.54 +78045-2;Disease analysis overall interpretation;Imp;Pt;Bld/Tiss;Nar;;CLIN;2;Disease analysis overall interpretation Blood or Tissue Narrative;Disease anl overall imp Bld/T;;TRIAL;2.54;2.63 +78046-0;Pharmacogenomic analysis basic associated observations panel;-;Pt;Bld/Tiss;-;;PANEL.MOLPATH;1;Pharmacogenomic analysis basic associated observations panel - Blood or Tissue;Pharmacogen basic assoc obs Pnl Bld/T;;TRIAL;2.54;2.63 +78047-8;Cortisol^24H post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --24 hour post XXX challenge;Cortis 24H p XXX chal SerPl-sCnc;;ACTIVE;2.54;2.58 +7804-8;Actinomyces sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Actinomyces sp Ab [Units/volume] in Serum;Actinomyces Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78048-6;Are you able to dress yourself, including tying shoelaces and buttoning your clothes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dress yourself, including tying shoelaces and buttoning your clothes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78049-4;Are you able to run or jog for two miles (3 km);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run or jog for two miles (3 km) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78050-2;Are you able to get up from the floor from lying on your back without help;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get up from the floor from lying on your back without help [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78051-0;Are you able to run at a fast pace for two miles (3 km);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run at a fast pace for two miles (3 km) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78052-8;Does your health now limit you in hiking a couple of miles (3 km) on uneven surfaces, including hills;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in hiking a couple of miles (3 km) on uneven surfaces, including hills [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78053-6;Are you able to carry two bags filled with groceries 100 yards (100 m);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry two bags filled with groceries 100 yards (100 m) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78054-4;Are you able to lift 10 pounds (5 kg) above your shoulder;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift 10 pounds (5 kg) above your shoulder [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7805-5;Adenovirus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Adenovirus Ab [Units/volume] in Serum;HAdV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78055-1;Are you able to reach and get down a 5 pound (2 kg) object from above your head;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to reach and get down a 5 pound (2 kg) object from above your head [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78056-9;Are you able to lift one pound (0.5 kg) to shoulder level without bending your elbow;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift one pound (0.5 kg) to shoulder level without bending your elbow [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78057-7;Are you able to walk a block (about 100 m) on flat ground;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk a block (about 100 m) on flat ground [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78058-5;Are you able to run five miles (8 km);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run five miles (8 km) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78059-3;Does your health now limit you in climbing several flights of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Does your health now limit you in climbing several flights of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.54;2.7 +78060-1;Does your health now limit you in doing 2H of physical labor;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Does your health now limit you in doing two hours of physical labor [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.54;2.7 +78061-9;Are you able to run 100 yards (100 m);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run 100 yards (100 m) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78062-7;Are you able to run ten miles (16 km);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run ten miles (16 km) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7806-3;Ascaris lumbricoides Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Ascaris lumbricoides Ab [Units/volume] in Serum;A lumbric Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78063-5;Does your health now limit you in doing 8H of physical labor;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Does your health now limit you in doing eight hours of physical labor [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.54;2.7 +78064-3;Does your health now limit you in walking more than a mile (1.6 km);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in walking more than a mile (1.6 km) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78065-0;Does your health now limit you in climbing one flight of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Does your health now limit you in climbing one flight of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.54;2.7 +78066-8;Are you able to sit on and get up from the toilet;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to sit on and get up from the toilet [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78067-6;Does your health now limit you in getting in and out of the bathtub;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Does your health now limit you in getting in and out of the bathtub [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.54;2.7 +78068-4;Does your health now limit you in walking about the house;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Deprecated Does your health now limit you in walking about the house [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;DEPRECATED;2.54;2.7 +78069-2;I could pick up coins from a table in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could pick up coins from a table in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +780-7;Promyelocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Promyelocytes [#/volume] in Blood by Automated count;Deprecated Promyelocytes # Bld Auto;;DEPRECATED;1.0;2.4 +78070-0;I could wash my hair by myself in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could wash my hair by myself in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7807-1;Aspergillus sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus sp Ab [Units/volume] in Serum;Aspergillus Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78071-8;I could put beads on a string in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could put beads on a string in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78072-6;I could comb my hair by myself in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could comb my hair by myself in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78073-4;I could thread a needle in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could thread a needle in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78074-2;I could jump up and down in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could jump up and down in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78075-9;I needed to sleep during the day in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I needed to sleep during the day in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78076-7;I was too tired to eat in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was too tired to eat in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78077-5;Being tired made it hard for me to remember things in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Being tired made it hard for me to remember things in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78078-3;I felt tired even when I had not done anything in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt tired even when I had not done anything in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78079-1;I felt sad for no reason in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt sad for no reason in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78081-7;Are you able to carry a heavy object (over 10 pounds or 5 kg);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a heavy object (over 10 pounds or 5 kg) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78082-5;Are you able to pull heavy objects (10 pounds or 5 kg) towards yourself;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pull heavy objects (10 pounds or 5 kg) towards yourself [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78083-3;I felt really respected by my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt really respected by my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78084-1;I felt important in my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt important in my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78085-8;I felt my family believed in me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt my family believed in me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78086-6;My family was interested in what I was doing in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My family was interested in what I was doing in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78087-4;People in my family made me feel good about myself in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;People in my family made me feel good about myself in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78088-2;I felt totally accepted by my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt totally accepted by my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7808-9;Aspergillus sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus sp Ab [Presence] in Serum;Aspergillus Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +78089-0;I felt that my family understood me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt that my family understood me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78090-8;I could depend on my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could depend on my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78091-6;I got the support I needed from my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I got the support I needed from my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78092-4;I knew what I could expect from others in my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I knew what I could expect from others in my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78093-2;I got all the help I needed from my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I got all the help I needed from my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78094-0;I could talk to someone in my family if something was bothering me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could talk to someone in my family if something was bothering me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78095-7;I could talk to someone in my family about my problems in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could talk to someone in my family about my problems in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78096-5;I knew my family would help me if I needed it in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I knew my family would help me if I needed it in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7809-7;Astrovirus;PrThr;Pt;Stool;Ord;Microscopy.electron;MICRO;1;Astrovirus [Presence] in Stool by Electron microscopy;HAstV Stl Ql EM;;ACTIVE;1.0h(2);2.56 +78097-3;I felt that I could trust the people in my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt that I could trust the people in my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78098-1;I could trust others in my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could trust others in my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78099-9;My family treated me fairly in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My family treated me fairly in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78100-5;I knew that my family would be there if I needed them in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I knew that my family would be there if I needed them in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78101-3;I felt everyone in my family loved me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt everyone in my family loved me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78102-1;Everyone in my family loved each other in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Everyone in my family loved each other in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78103-9;I felt loved by my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt loved by my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78104-7;My family showed that they cared about me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My family showed that they cared about me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7810-5;Astrovirus Ag;PrThr;Pt;Stool;Ord;IA;MICRO;1;Astrovirus Ag [Presence] in Stool by Immunoassay;HAstV Ag Stl Ql IA;;ACTIVE;1.0h(2);2.73 +78105-4;I felt I really belonged in my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt I really belonged in my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78106-2;I felt I had a strong relationship with my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt I had a strong relationship with my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78107-0;I felt very close to my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt very close to my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78108-8;It was easy to be close to everyone in my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It was easy to be close to everyone in my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78109-6;I felt a sense of togetherness with my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt a sense of togetherness with my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78110-4;I believed in helping my family, no matter what in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I believed in helping my family, no matter what in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78111-2;I wanted to help my family however I could in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I wanted to help my family however I could in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78112-0;I felt that I had similar values and beliefs as others in my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt that I had similar values and beliefs as others in my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7811-3;Astrovirus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Astrovirus RNA [Presence] in Serum by NAA with probe detection;HAstV RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +78113-8;I could rely on my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could rely on my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78114-6;I felt really important to my family in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt really important to my family in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78115-3;People in my family helped each other in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;People in my family helped each other in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78116-1;I felt that my family really respected me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt that my family really respected me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78117-9;I could talk to someone in my family if I needed to in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could talk to someone in my family if I needed to in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78118-7;Everyone in my family could be completely trusted in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Everyone in my family could be completely trusted in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78119-5;Everyone in my family loved me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Everyone in my family loved me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78120-3;I felt that my family loved me in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt that my family loved me in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7812-1;Babesia microti Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Babesia microti Ab [Units/volume] in Serum;B microti Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78123-7;My child felt really respected by our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt really respected by our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78124-5;My child felt important in our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt important in our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78125-2;My child felt that our family believed in him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that our family believed in him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78126-0;My child knew our family was interested in what he or she was doing in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew our family was interested in what he or she was doing in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78127-8;People in our family made my child feel good about himself or herself in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;People in our family made my child feel good about himself or herself in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78128-6;My child felt totally accepted by our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt totally accepted by our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78129-4;My child felt that our family understood him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that our family understood him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78130-2;My child felt he or she could depend on our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she could depend on our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78131-0;My child felt he or she got the support he or she needed from our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she got the support he or she needed from our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78132-8;My child knew what he or she could expect from others in our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew what he or she could expect from others in our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78133-6;My child felt he or she got all the help he or she needed from our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she got all the help he or she needed from our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78134-4;My child felt he or she could talk to someone in our family if something was bothering him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she could talk to someone in our family if something was bothering him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78135-1;My child knew he or she could talk to someone in our family about his or her problems in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew he or she could talk to someone in our family about his or her problems in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78136-9;My child knew our family would help if he or she needed it in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew our family would help if he or she needed it in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78137-7;My child felt that he or she could trust the people in our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that he or she could trust the people in our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78138-5;My child knew he or she could trust others in our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew he or she could trust others in our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7813-9;Babesia sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Babesia sp Ab [Units/volume] in Serum;Babesia Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78139-3;My child felt our family treated him or her fairly in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt our family treated him or her fairly in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78140-1;My child knew that our family would be there if he or she needed them in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew that our family would be there if he or she needed them in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78141-9;My child felt everyone in our family loved him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt everyone in our family loved him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78142-7;My child felt everyone in our family loved each other in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt everyone in our family loved each other in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78143-5;My child felt loved by our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt loved by our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78144-3;My child felt that our family showed that they cared about him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that our family showed that they cared about him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78145-0;My child felt he or she really belonged in our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she really belonged in our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78146-8;My child felt he or she had a strong relationship with our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she had a strong relationship with our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7814-7;Bacillus anthracis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Bacillus anthracis Ab [Units/volume] in Serum;B anthracis Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78147-6;My child felt very close to our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt very close to our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78148-4;My child felt it was easy for him or her to be close to everyone in our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt it was easy for him or her to be close to everyone in our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78149-2;My child felt a sense of togetherness with our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt a sense of togetherness with our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +781-5;Promyelocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Promyelocytes [#/volume] in Blood by Manual count;Promyelocytes # Bld Manual;;ACTIVE;1.0;2.73 +78150-0;My child believed in helping our family, no matter what in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child believed in helping our family, no matter what in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78151-8;My child wanted to help our family however he or she could in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child wanted to help our family however he or she could in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78152-6;My child felt that he or she had similar values and beliefs as others in our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that he or she had similar values and beliefs as others in our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78153-4;My child knew he or she could rely on our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew he or she could rely on our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7815-4;Bartonella henselae Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bartonella henselae IgG Ab [Units/volume] in Serum by Immunoassay;B henselae IgG Ser IA-aCnc;;ACTIVE;1.0h(2);2.69 +78154-2;My child felt he or she was really important to our family in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she was really important to our family in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78155-9;My child felt that people in our family helped each other in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that people in our family helped each other in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78156-7;My child felt that our family really respected him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that our family really respected him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78157-5;My child knew he or she could talk to someone in our family if he or she needed to in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew he or she could talk to someone in our family if he or she needed to in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78158-3;My child knew that everyone in our family could be completely trusted in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew that everyone in our family could be completely trusted in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78159-1;My child knew everyone in our family loved him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child knew everyone in our family loved him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78160-9;My child felt that our family loved him or her in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that our family loved him or her in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78161-7;PROMIS pediatric item bank - physical function - upper extremity - version 2.0;-;1W;^Patient;Ord;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - physical function - upper extremity - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.56 +7816-2;Blastomyces dermatitidis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Blastomyces dermatitidis Ab [Presence] in Serum;B dermat Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +78162-5;It was hard for me to be away from home because I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It was hard for me to be away from home because I had pain in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78163-3;It was hard to have fun with friends because I was in pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It was hard to have fun with friends because I was in pain in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78164-1;I needed help walking when I was in pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I needed help walking when I was in pain in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78165-8;I walked carefully when I was in pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I walked carefully when I was in pain in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78166-6;My pain was so bad that I needed to take medicine to treat it in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My pain was so bad that I needed to take medicine to treat it in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78167-4;It was hard to do things with my family because I had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It was hard to do things with my family because I had pain in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78168-2;I felt too nervous to be with a group of kids my age in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt too nervous to be with a group of kids my age in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78169-0;I worried that something might happen to my parents or guardians in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I worried that something might happen to my parents or guardians in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7817-0;Borrelia burgdorferi Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi IgG Ab [Units/volume] in Serum;B burgdor IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78170-8;PROMIS pediatric short form - emotional distress - anxiety 8b - version 1.1 raw score;Score;1W;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - emotional distress - anxiety 8b - version 1.1 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.54 +78171-6;I was angry when things didn't go my way in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was angry when things didn't go my way in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78172-4;I wanted to be alone because I was so angry in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I wanted to be alone because I was so angry in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78173-2;I was so mad I did not want to talk to people in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was so mad I did not want to talk to people in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78174-0;I had a bad temper in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had a bad temper in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78175-7;Fractional area change;AreaRto;Pt;Heart.ventricle.right;Qn;US.2D;CARD.US;2;Right ventricular Fractional area change by US 2D;RV FAC 2D US;;ACTIVE;2.54;2.54 +78176-5;Diameter;Len;Pt;Aorta.root;Qn;US.2D;CARD.US;2;Aorta root Diameter by US 2D;AO root Diam 2D US;;ACTIVE;2.54;2.54 +78177-3;Regurgitant pressure gradient.diastole.mean;PressDiff;Pt;Aortic valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US;2;Aortic valve Mean regurgitant pressure gradient during diastole by US.doppler+Calculated by simplified Bernoulli;AV Mean reg press grad dias Simp Bern;;ACTIVE;2.54;2.67 +78178-1;Regurgitant pressure gradient.mean;PressDiff;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Mean regurgitant pressure gradient by US.doppler;MV Mean regurg press gradient DOP;;ACTIVE;2.54;2.67 +78179-9;Orifice area;Area;Pt;Mitral valve;Qn;US.2D+Measured by planimetry;CARD.US;2;Mitral valve Orifice area by US.2D+Measured by planimetry;MV Orifice area US.2D.PLN;;ACTIVE;2.54;2.67 +78180-7;Intrachamber.systole.max;Pres;Pt;Heart.ventricle.right;Qn;US.doppler;CARD.US;2;Right ventricular Intrachamber.systole.max by US.doppler;RV Intrachamber.sys.max DOP;;ACTIVE;2.54;2.54 +78181-5;Regurgitant velocity during diastolic rapid inflow;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Regurgitant velocity during diastolic rapid inflow by US.doppler;PV Regurg vel dias rapid inflow DOP;;ACTIVE;2.54;2.67 +78182-3;Regurgitant pressure gradient.diastole.max;PressDiff;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Maximum regurgitant pressure gradient during diastole by US.doppler;PV Max regurg press grad dia DOP;;ACTIVE;2.54;2.67 +78183-1;Stenosis degree;Find;Pt;Pulmonic valve;Ord;US;CARD.US;2;Pulmonic valve Stenosis degree by US;PV Sten deg US;;ACTIVE;2.54;2.54 +78184-9;A wave duration;Time;Pt;Pulmonary vein;Qn;US.doppler.PW;CARD.US;2;Pulmonary vein A-wave duration by Ultrasound.doppler.PW;Pulm vein A wave duration DOP.PW;;ACTIVE;2.54;2.54 +78185-6;Tissue velocity.E wave.max;Vel;Pt;Mitral valve.annulus.medial;Qn;US.tissue doppler;CARD.US;2;Mitral valve medial annulus Tissue velocity.E-wave.max by US.tissue doppler;MV med ann Peak e' wave US.TDI;;ACTIVE;2.54;2.54 +78186-4;Tissue velocity.E wave.max;Vel;Pt;Mitral valve.annulus.lateral;Qn;US.tissue doppler;CARD.US;2;Mitral valve lateral annulus Tissue velocity.E-wave.max by US.tissue doppler;MV lat ann e-prime Vmax TDI;;ACTIVE;2.54;2.54 +78187-2;Tissue velocity.S wave.max;Vel;Pt;Mitral valve.annulus.medial;Qn;US.tissue doppler;CARD.US;2;Mitral valve medial annulus Tissue velocity.S-wave.max by US.tissue doppler;MV med ann s-prime Vmax TDI;;ACTIVE;2.54;2.54 +7818-8;Borrelia burgdorferi Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Borrelia burgdorferi IgM Ab [Units/volume] in Serum;B burgdor IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78188-0;Tissue velocity.S wave.max;Vel;Pt;Mitral valve.annulus.lateral;Qn;US.tissue doppler;CARD.US;2;Mitral valve lateral annulus Tissue velocity.S-wave.max by US.tissue doppler;MV lat ann s-prime Vmax TDI;;ACTIVE;2.54;2.54 +78189-8;E wave/Tissue velocity.E wave.max;VelRto;Pt;Mitral valve.annulus.medial;Qn;US.doppler+tissue doppler;CARD.US;2;Mitral valve medial annulus E-wave/Tissue velocity.E-wave.max by US.doppler+tissue doppler;MV med ann E-wave/e-prime Vmax DOP+TDI;;ACTIVE;2.54;2.54 +78190-6;E wave/Tissue velocity.E wave.max;VelRto;Pt;Mitral valve.annulus.lateral;Qn;US.doppler+tissue doppler;CARD.US;2;Mitral valve lateral annulus E-wave/Tissue velocity.E-wave.max by US.doppler+tissue doppler;MV lat ann E-wave/e-prime Vmax DOP+TDI;;ACTIVE;2.54;2.54 +78191-4;Blood flow.deceleration time.E wave;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve E-wave deceleration time by US.doppler;MV E-wave deceleration time DOP;;ACTIVE;2.54;2.54 +78192-2;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal inferior septum;Ord;US;CARD.US;2;Heart ventricle Left basal inferior septum Segmental wall motion by US;LV.basal inf septum SWM US;;ACTIVE;2.54;2.54 +78193-0;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal inferior lateral;Ord;US;CARD.US;2;Heart ventricle Left basal inferior lateral Segmental wall motion by US;LV.basal inf lat SWM US;;ACTIVE;2.54;2.54 +78194-8;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal anterior lateral;Ord;US;CARD.US;2;Heart.ventricle.left.basal anterior lateral Segmental wall motion by US;LV.basal ant lat SWM US;;ACTIVE;2.54;2.54 +78195-5;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid inferior septum;Ord;US;CARD.US;2;Heart ventricle Left mid inferior septum Segmental wall motion by US;LV.mid inf septum SWM US;;ACTIVE;2.54;2.54 +7819-6;Brugia malayi Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Brugia malayi Ab [Presence] in Serum;B malayi Ab Ser Ql;;ACTIVE;1.0h(2);2.56 +78196-3;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid inferior lateral;Ord;US;CARD.US;2;Heart ventricle Left mid inferior lateral Segmental wall motion by US;LV.mid inf lat SWM US;;ACTIVE;2.54;2.54 +78197-1;Segmental wall motion;Find;Pt;Heart.ventricle.left.mid anterior lateral;Ord;US;CARD.US;2;Heart ventricle Left mid anterior lateral Segmental wall motion by US;LV.mid ant lat SWM US;;ACTIVE;2.54;2.54 +78198-9;Segmental wall motion;Find;Pt;Heart.ventricle.left.apex;Ord;US;CARD.US;2;Heart ventricle Left apex Segmental wall motion by US;LV apex SWM US;;ACTIVE;2.54;2.54 +78199-7;Study diagnosis;Imp;Pt;Cardiovascular system.central;Nar;US;CARD.US;2;Cardiovascular system.central US Study diagnosis;Cent CVS US Study dx;;ACTIVE;2.54;2.54 +78200-3;Resource identifier;URI;Pt;Study;Nom;;MISC;1;Resource identifier [URI] for Study;Resource ID URI Study;;TRIAL;2.54;2.54 +78201-1;4q12 chromosome region rearrangements;Prid;Pt;Bld/Tiss;Nom;FISH;MOLPATH.REARRANGE;1;4q12 chromosome region rearrangements [Identifier] in Blood or Tissue by FISH Nominal;4q12 rearrange Bld/T FISH;;ACTIVE;2.54;2.61 +78202-9;9q34 chromosome region deletion;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.DEL;1;9q34 chromosome region deletion [Presence] in Blood or Tissue by FISH;9q34 Del Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78203-7;BCL6 gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;BCL6 gene rearrangements [Presence] in Blood or Tissue by FISH;BCL6 gene Rear Bld/T Ql FISH;;ACTIVE;2.54;2.73 +7820-4;Candida albicans Ab;ACnc;Pt;Ser;OrdQn;;MICRO;1;Deprecated Candida albicans Ab;Deprecated C albicans Ab Ser;;DEPRECATED;1.0h(2);2.36 +78204-5;CCND1 gene duplication;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.DELDUP;1;CCND1 gene duplication [Presence] in Blood or Tissue by FISH;CCND1 gene Dp Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78205-2;ALK gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;ALK gene rearrangements [Presence] in Blood or Tissue by FISH;ALK rearrange Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78206-0;4q12 chromosome region rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;4q12 chromosome region rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;4q12 rearrange Bld/T FISH-Imp;;ACTIVE;2.54;2.73 +78207-8;9q34 chromosome region deletion;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.DEL;1;9q34 chromosome region deletion [Interpretation] in Blood or Tissue by FISH Narrative;9q34 Del Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78208-6;BCL6 gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;BCL6 gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;BCL6 gene Rear Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78209-4;CCND1 gene duplication;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.DELDUP;1;CCND1 gene duplication [Interpretation] in Blood or Tissue by FISH Narrative;CCND1 gene Dp Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78210-2;ALK gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;ALK gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;ALK rearrange Bld/T FISH-Imp;;ACTIVE;2.54;2.65 +78211-0;Cells.4q12 chromosome region rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.4q12 chromosome region rearrangements/Cells counted in Blood or Tissue by FISH;Cells.4q12 rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +7821-2;Chlamydophila pneumoniae rRNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae rRNA [Presence] in Serum by NAA with probe detection;C pneum rRNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +78212-8;Cells.9q34 chromosome region deletion/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.9q34 chromosome region deletion/Cells counted in Blood or Tissue by FISH;Cells.9q34 Del/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78213-6;Cells.BCL6 gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.BCL6 gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.BCL6 rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78214-4;Cells.CCND1 gene duplication/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.CCND1 gene duplication/Cells counted in Blood or Tissue by FISH;Cells.CCND1 Dup/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78215-1;MYC gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;MYC gene rearrangements [Presence] in Blood or Tissue by FISH;MYC gene Rear Bld/T Ql FISH;;ACTIVE;2.54;2.73 +78216-9;TRA+TRD gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;TRA+TRD gene rearrangements [Presence] in Blood or Tissue by FISH;TRA+TRD rearrange Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78217-7;RARA gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;RARA gene rearrangements [Presence] in Blood or Tissue by FISH;RARA rearrange Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78218-5;BCL2 gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;BCL2 gene rearrangements [Presence] in Blood or Tissue by FISH;BCL2 gene Rear Bld/T Ql FISH;;ACTIVE;2.54;2.73 +78219-3;MLL gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;MLL gene rearrangements [Presence] in Blood or Tissue by FISH;MLL gene Rear Bld/T Ql FISH;;ACTIVE;2.54;2.61 +7822-0;Chlamydophila psittaci Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydophila psittaci Ab [Units/volume] in Serum;C psittaci Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78220-1;PDGFRB gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;PDGFRB gene rearrangements [Presence] in Blood or Tissue by FISH;PDGFRB rearrange Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78221-9;IGH gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;IGH gene rearrangements [Presence] in Blood or Tissue by FISH;IGH gene rearrange Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78222-7;MYC gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;MYC gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;MYC gene Rear Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78223-5;TRA+TRD gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;TRA+TRD gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;TRA+TRD rearrange Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78224-3;RARA gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;RARA gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;RARA rearrange Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78225-0;BCL2 gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;BCL2 gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;BCL2 gene Rear Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78226-8;MLL gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;MLL gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;MLL gene Rear Bld/T FISH-Imp;;ACTIVE;2.54;2.73 +78227-6;PDGFRB gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;PDGFRB gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;PDGFRB rearrange Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78228-4;IGH gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;IGH gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;IGH gene rearrange Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78229-2;Cells.MYC gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.MYC gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.MYC rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +782-3;Promyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Deprecated Promyelocytes/100 leukocytes in Blood by Automated count;Deprecated Promyelocytes Fr Bld Auto;;DEPRECATED;1.0;2.7 +78230-0;Cells.RARA gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.RARA gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.RARA rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78231-8;Cells.TRA+TRD gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.TRA+TRD gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.TRA+TRD rear/Cells cnt NFr FISH;;ACTIVE;2.54;2.61 +78232-6;Cells.BCL2 gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.BCL2 gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.BCL2 rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78233-4;Cells.ALK gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.ALK gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.ALK rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78234-2;Cells.MLL gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.MLL gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.MLL rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78235-9;Cells.PDGFRB gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.PDGFRB gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.PDGFRB rear/Cells cnt Bld/T FISH;;ACTIVE;2.54;2.61 +78236-7;Cells.IGH gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.IGH gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.IGH rear/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78237-5;Chromosome 8 copy number/nucleus;EntNum;Pt;Bld/Tiss;Qn;FISH;MOLPATH.TRISOMY;1;Chromosome 8 copy number/nucleus in Blood or Tissue by FISH;Chr 8 copy num/nucleus EntNum Bld/T FISH;;ACTIVE;2.54;2.66 +7823-8;Chlamydia sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia sp Ab [Units/volume] in Serum;Chlamydia Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78238-3;Chromosome 3 copy number/nucleus;EntNum;Pt;Bld/Tiss;Qn;FISH;MOLPATH.TRISOMY;1;Chromosome 3 copy number/nucleus in Blood or Tissue by FISH;Chr 3 copy num/nucleus EntNum Bld/T FISH;;ACTIVE;2.54;2.66 +78239-1;Resource identifier;URI;Pt;Clinical document;Nom;;DOC.MISC;2;Resource identifier [URI] for Clinical document;Resource ID URI Clin Doc;;TRIAL;2.54;2.54 +78240-9;Surgical operation note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Surgical operation note;Trauma Operative note;;ACTIVE;2.54;2.73 +78241-7;Surgical operation note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Surgical operation note;Gastroenterology Operative note;;ACTIVE;2.54;2.58 +78242-5;Surgical operation note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Surgical operation note;HemOnc Operative note;;ACTIVE;2.54;2.58 +78243-3;Surgical operation note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Surgical operation note;Vascular surgery Operative note;;ACTIVE;2.54;2.58 +78244-1;Surgical operation note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Surgical operation note;Transpl surg Operative note;;ACTIVE;2.54;2.73 +78245-8;MYB gene deletion;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.DEL;1;MYB gene deletion [Presence] in Blood or Tissue by FISH;MYB Del Bld/T Ql FISH;;ACTIVE;2.54;2.61 +7824-6;Chlamydia trachomatis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Chlamydia trachomatis Ab [Units/volume] in Serum;C trach Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78246-6;Admission history and physical note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Admission history and physical note;Mental health Admit H&P note;;ACTIVE;2.54;2.58 +78247-4;Admission history and physical note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Admission history and physical note;Surgery Admit H&P note;;ACTIVE;2.54;2.58 +78248-2;Admission history and physical note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Admission history and physical note;Col+rec surg Admit H&P note;;ACTIVE;2.54;2.58 +78249-0;Admission history and physical note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Admission history and physical note;ED Admit H&P note;;ACTIVE;2.54;2.58 +78250-8;Consultation note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Consult note;Col+rec surg Consult note;;ACTIVE;2.54;2.58 +78251-6;Consultation note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Consult note;Hematology Consult note;;ACTIVE;2.54;2.58 +78252-4;Consultation note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Consult note;Multi-spec prog Consult note;;ACTIVE;2.54;2.58 +7825-3;Coccidioides immitis Ab;ACnc;Pt;Ser;OrdQn;;MICRO;1;Deprecated Coccidioides immitis Ab;Deprecated C immitis Ab Ser;;DEPRECATED;1.0h(2);2.36 +78253-2;Consultation note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Consult note;Fam Med Consult note;;ACTIVE;2.54;2.58 +78254-0;Consultation note;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Consult note;Clinical genetics Consult note;;ACTIVE;2.54;2.58 +78255-7;Diagnostic study note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Diagnostic study note;Fam Med Diag study note;;ACTIVE;2.54;2.54 +78256-5;Diagnostic study note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Diagnostic study note;Gastroenterology Diag study note;;ACTIVE;2.54;2.54 +78257-3;Diagnostic study note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Diagnostic study note;Endocrinology Diag study note;;ACTIVE;2.54;2.54 +78258-1;Diagnostic study note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Diagnostic study note;Infectious disease Diag study note;;ACTIVE;2.54;2.54 +78259-9;Diagnostic study note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Diagnostic study note;Dentistry Diag study note;;ACTIVE;2.54;2.54 +78260-7;Diagnostic study note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Diagnostic study note;Dermatology Diag study note;;ACTIVE;2.54;2.54 +7826-1;Coccidioides immitis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Coccidioides immitis IgG Ab [Units/volume] in Serum;C immitis IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78261-5;Discharge instructions;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Discharge instructions;Mental health Discharge instruct;;ACTIVE;2.54;2.54 +78262-3;Discharge instructions;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Discharge instructions;General medicine Discharge instruct;;ACTIVE;2.54;2.54 +78263-1;Discharge summary note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Discharge summary;Mental health D/C sum;;ACTIVE;2.54;2.73 +78264-9;Discharge summary note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Discharge summary;General medicine D/C sum;;ACTIVE;2.54;2.73 +78265-6;Discharge teaching note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Discharge teaching note;ED Discharge teach note;;ACTIVE;2.54;2.54 +78266-4;Discharge teaching note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Discharge teaching note;Mental health Discharge teach note;;ACTIVE;2.54;2.54 +78267-2;Discharge teaching note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Discharge teaching note;General medicine Discharge teach note;;ACTIVE;2.54;2.54 +78268-0;Education note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Education note;Multi-spec prog Educ note;;ACTIVE;2.54;2.58 +78269-8;Education note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Education note;Dermatology Educ note;;ACTIVE;2.54;2.54 +78270-6;Education note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Education note;Gastroenterology Educ note;;ACTIVE;2.54;2.54 +78271-4;Education note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Education note;Col+rec surg Educ note;;ACTIVE;2.54;2.54 +78272-2;Education note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Education note;General medicine Educ note;;ACTIVE;2.54;2.54 +78273-0;Education note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Education note;ED Educ note;;ACTIVE;2.54;2.54 +78274-8;Education note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Education note;Hematology Educ note;;ACTIVE;2.54;2.54 +78275-5;Education note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Education note;Dentistry Educ note;;ACTIVE;2.54;2.54 +78276-3;Education note;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Education note;Clinical genetics Educ note;;ACTIVE;2.54;2.54 +78277-1;Education note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Education note;Fam Med Educ note;;ACTIVE;2.54;2.54 +78278-9;Education note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Education note;Endocrinology Educ note;;ACTIVE;2.54;2.54 +7827-9;Coccidioides immitis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Coccidioides immitis IgM Ab [Units/volume] in Serum;C immitis IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78279-7;Education note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Education note;Mental health Educ note;;ACTIVE;2.54;2.54 +78280-5;Education note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Education note;Surgery Educ note;;ACTIVE;2.54;2.54 +78281-3;Education note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Education note;Infectious disease Educ note;;ACTIVE;2.54;2.54 +7828-7;Coxiella burnetii Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii Ab [Units/volume] in Serum;C burnet Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78290-4;Initial evaluation note;Find;Pt;Telephone encounter;Doc;{Role};DOC.ONTOLOGY;2;Telephone encounter Initial evaluation note;Phone Initial eval note;;ACTIVE;2.58;2.58 +78291-2;Flowsheet;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Flowsheet;Hematology Flowsheet;;ACTIVE;2.54;2.54 +78292-0;Flowsheet;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Flowsheet;Surgery Flowsheet;;ACTIVE;2.54;2.54 +78293-8;Flowsheet;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Flowsheet;Infectious disease Flowsheet;;ACTIVE;2.54;2.54 +78294-6;Flowsheet;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Flowsheet;Dermatology Flowsheet;;ACTIVE;2.54;2.54 +7829-5;Coxiella burnetii phase 1 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Units/volume] in Serum;C burnet Ph1 IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78295-3;Flowsheet;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Flowsheet;Endocrinology Flowsheet;;ACTIVE;2.54;2.54 +78296-1;Flowsheet;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Flowsheet;Mental health Flowsheet;;ACTIVE;2.54;2.54 +78297-9;Flowsheet;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Flowsheet;Gastroenterology Flowsheet;;ACTIVE;2.54;2.54 +78298-7;Flowsheet;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Flowsheet;General medicine Flowsheet;;ACTIVE;2.54;2.54 +78299-5;Flowsheet;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Flowsheet;Fam Med Flowsheet;;ACTIVE;2.54;2.54 +78300-1;Flowsheet;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Flowsheet;Col+rec surg Flowsheet;;ACTIVE;2.54;2.54 +78301-9;Flowsheet;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Flowsheet;Dentistry Flowsheet;;ACTIVE;2.54;2.54 +78302-7;Flowsheet;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Flowsheet;Emergency med ED Flowsheet;;ACTIVE;2.54;2.54 +7830-3;Coxiella burnetii phase 2 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Units/volume] in Serum;C burnet Ph2 IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78303-5;Flowsheet;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Flowsheet;ED Flowsheet;;ACTIVE;2.54;2.54 +78304-3;Flowsheet;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Flowsheet;Clinical genetics Flowsheet;;ACTIVE;2.54;2.54 +78305-0;Form;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Form;Mental health Form;;ACTIVE;2.54;2.54 +78306-8;History and physical note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health History and physical note;Mental health H&P note;;ACTIVE;2.54;2.58 +78307-6;History and physical note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department History and physical note;ED H&P note;;ACTIVE;2.54;2.58 +78308-4;History and physical note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine History and physical note;General medicine H&P note;;ACTIVE;2.54;2.58 +78309-2;Individual counseling note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Individual counseling note;Mental health Indiv counsel note;;ACTIVE;2.54;2.54 +783-1;Promyelocytes/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Promyelocytes/100 leukocytes in Blood by Manual count;Promyelocytes/leuk NFr Bld Manual;;ACTIVE;1.0;2.73 +78310-0;Initial evaluation note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Initial evaluation note;Hematology Initial eval note;;ACTIVE;2.54;2.54 +7831-1;Coxiella burnetii phase 1 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Units/volume] in Serum;C burnet Ph1 IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78311-8;Initial evaluation note;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Initial evaluation note;Clinical genetics Initial eval note;;ACTIVE;2.54;2.54 +78312-6;Initial evaluation note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Initial evaluation note;Endocrinology Initial eval note;;ACTIVE;2.54;2.54 +78313-4;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Preoperative evaluation and management note;Col+rec surg Pre-op note;;ACTIVE;2.54;2.54 +78314-2;Procedure note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology procedure note;Dermatology Procedure note;;ACTIVE;2.58;2.58 +78315-9;Procedure note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine procedure note;Fam Med Procedure note;;ACTIVE;2.58;2.58 +78316-7;Procedure note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department procedure note;ED Procedure note;;ACTIVE;2.58;2.58 +78317-5;Procedure note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology procedure note;Gastroenterology Procedure note;;ACTIVE;2.58;2.58 +78318-3;Procedure note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease procedure note;Infectious disease Procedure note;;ACTIVE;2.58;2.58 +78319-1;Procedure note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology procedure note;Hematology Procedure note;;ACTIVE;2.58;2.58 +78320-9;Procedure note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine procedure note;General medicine Procedure note;;ACTIVE;2.58;2.58 +78321-7;Procedure note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology procedure note;Endocrinology Procedure note;;ACTIVE;2.58;2.58 +78322-5;Procedure note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery procedure note;Surgery Procedure note;;ACTIVE;2.58;2.58 +78323-3;Progress note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Progress note;Gastroenterology Prog note;;ACTIVE;2.54;2.73 +78324-1;Progress note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Progress note;Fam Med Prog note;;ACTIVE;2.54;2.73 +78325-8;Progress note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Progress note;Infectious disease Prog note;;ACTIVE;2.54;2.73 +78326-6;Progress note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Progress note;Dermatology Prog note;;ACTIVE;2.54;2.73 +78327-4;Progress note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Progress note;Endocrinology Prog note;;ACTIVE;2.54;2.73 +78328-2;Progress note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Progress note;Hematology Prog note;;ACTIVE;2.54;2.73 +7832-9;Coxiella burnetii phase 2 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Units/volume] in Serum;C burnet Ph2 IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78329-0;Referral note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Referral note;Col+rec surg Referral note;;ACTIVE;2.54;2.58 +78330-8;Referral note;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Referral note;Clinical genetics Referral note;;ACTIVE;2.54;2.58 +78331-6;Referral note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Referral note;Multi-spec prog Referral note;;ACTIVE;2.54;2.58 +78332-4;Referral note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Referral note;Fam Med Referral note;;ACTIVE;2.54;2.58 +78333-2;Initial evaluation note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Initial evaluation note;Infectious disease Initial eval note;;ACTIVE;2.54;2.54 +78334-0;Initial evaluation note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Initial evaluation note;Dermatology Initial eval note;;ACTIVE;2.54;2.54 +78335-7;Initial evaluation note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Initial evaluation note;General medicine Initial eval note;;ACTIVE;2.54;2.54 +78336-5;Initial evaluation note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Initial evaluation note;Multi-spec prog Initial eval note;;ACTIVE;2.54;2.58 +7833-7;Coxsackievirus A16 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A16 Ab [Units/volume] in Serum;CV A16 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78337-3;Initial evaluation note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Initial evaluation note;ED Initial eval note;;ACTIVE;2.54;2.54 +78338-1;Initial evaluation note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Initial evaluation note;Fam Med Initial eval note;;ACTIVE;2.54;2.54 +78339-9;Initial evaluation note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Initial evaluation note;Gastroenterology Initial eval note;;ACTIVE;2.54;2.54 +78340-7;Transfer summary note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Transfer summary note;Col+rec surg Transfer sum note;;ACTIVE;2.54;2.58 +78341-5;Transfer summary note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Transfer summary note;ED Transfer sum note;;ACTIVE;2.54;2.58 +78342-3;MYB gene deletion;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.DEL;1;MYB gene deletion [Interpretation] in Blood or Tissue by FISH Narrative;MYB Del Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78343-1;Cells.MYB gene deletion/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DEL;1;Cells.MYB gene deletion/Cells counted in Blood or Tissue by FISH;Cells.MYB Del/Cells cnt NFr Bld/T FISH;;ACTIVE;2.54;2.61 +78344-9;Fatty acid panel.comprehensive C8-C26;-;Pt;RBC;Qn;;PANEL.CHEM;1;Fatty acid comprehensive (C8-C26) panel - Red Blood Cells;FA comp C8-C26 Pnl RBC;;ACTIVE;2.54;2.54 +7834-5;Coxsackievirus A7 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A7 Ab [Units/volume] in Serum;CV A7 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78345-6;Docosenoate;EntSub;Pt;RBC;Qn;;CHEM;1;Docosenoate (C22:1) [Entitic substance] in Red Blood Cells;Docosenoate EntSub RBC;;ACTIVE;2.54;2.54 +78346-4;Hexadecenoate;EntSub;Pt;RBC;Qn;;CHEM;1;Hexadecenoate (C16:1w9) [Entitic substance] in Red Blood Cells;Hexadecenoate EntSub RBC;;ACTIVE;2.54;2.54 +78347-2;Docosapentaenate w3;EntSub;Pt;RBC;Qn;;CHEM;1;Docosapentaenate (C22:5w3) [Entitic substance] in Red Blood Cells;DPA EntSub RBC;;ACTIVE;2.54;2.65 +78348-0;Docosapentaenate w6;EntSub;Pt;RBC;Qn;;CHEM;1;Docosapentaenate (C22:5w6) [Entitic substance] in Red Blood Cells;Docosapentaenate w6 EntSub RBC;;ACTIVE;2.54;2.54 +78349-8;Lauroleate;EntSub;Pt;RBC;Qn;;CHEM;1;Lauroleate (C12:1) [Entitic substance] in Red Blood Cells;Lauroleate EntSub RBC;;ACTIVE;2.54;2.54 +78350-6;Decenoate;EntSub;Pt;RBC;Qn;;CHEM;1;Decenoate (C10:1) [Entitic substance] in Red Blood Cells;Decenoate EntSub RBC;;ACTIVE;2.54;2.54 +78351-4;Tetradecadienoate;EntSub;Pt;RBC;Qn;;CHEM;1;Tetradecadienoate (C14:2) [Entitic substance] in Red Blood Cells;Tdecadienoate EntSub RBC;;ACTIVE;2.54;2.54 +7835-2;Coxsackievirus A9 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus A9 Ab [Units/volume] in Serum;CV A9 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78352-2;Vaccenate;EntSub;Pt;RBC;Qn;;CHEM;1;Vaccenate (C18:1w7) [Entitic substance] in Red Blood Cells;Vaccenate EntSub RBC;;ACTIVE;2.54;2.54 +78353-0;Hexadecadienoate;EntSub;Pt;RBC;Qn;;CHEM;1;Hexadecadienoate (C16:2) [Entitic substance] in Red Blood Cells;Hexadecadienoate EntSub RBC;;ACTIVE;2.54;2.54 +78354-8;Oxygen.arterial/Oxygen.alveolar;PPresRto;Pt;BldA+Resp.alv;Qn;Calculated;PULM;2;Arterial-alveolar oxygen Partial pressure ratio;a/A PO2 Rto;;ACTIVE;2.54;2.73 +78355-5;Lymphocytes.abnormal;PrThr;Pt;Bld;Ord;Manual count;HEM/BC;1;Abnormal lymphocytes [Presence] in Blood by Manual count;Lymph Abn Bld Ql Manual;;ACTIVE;2.54;2.56 +78356-3;Bacteria identified;Prid;Pt;Implanted device;Nom;Culture;MICRO;1;Bacteria identified in Implanted device by Culture;Bacteria Implnt dev Cult;;ACTIVE;2.54;2.65 +78357-1;Mycobacterium tuberculosis DNA;PrThr;Pt;BAL;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Bronchoalveolar lavage by NAA with probe detection;M tb DNA BAL Ql NAA+probe;;ACTIVE;2.54;2.67 +78358-9;Acyl CoA dehydrogenases;CCnt;Pt;Fibroblasts;Qn;[9,10-3H] palmitate substrate;CHEM;1;Acyl CoA dehydrogenases [Enzymatic activity/mass] in Fibroblast by [9,10-3H] palmitate substrate;ACADs Fib Palmitate-cCnt;;ACTIVE;2.54;2.54 +78359-7;Acyl CoA dehydrogenases.palmitate substrate/Acyl CoA dehydrogenases.myristate substrate;CRto;Pt;Fibroblasts;Qn;;CHEM;1;Acyl CoA dehydrogenases.palmitate substrate/Acyl CoA dehydrogenases.myristate substrate [Enzymatic activity ratio] in Fibroblast;ACADs.palmitate/ACADs.myristate Fib-cRto;;ACTIVE;2.54;2.54 +7836-0;Coxsackievirus B1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B1 Ab [Units/volume] in Serum;CV B1 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78360-5;Acyl CoA dehydrogenases;CCnt;Pt;Fibroblasts;Qn;[9,10-3H] myristate substrate;CHEM;1;Acyl CoA dehydrogenases [Enzymatic activity/mass] in Fibroblast by [9,10-3H] myristate substrate;ACADs Fib Myristate-cCnt;;ACTIVE;2.54;2.54 +78361-3;Fatty acid & triglyceride panel;-;24H;Stool;Qn;;PANEL.CHEM;1;Fatty acid and triglyceride panel - 24 hour Stool;Fatty acid + triglyceride Pnl 24h Stl;;ACTIVE;2.54;2.58 +78362-1;Imipramine+Desipramine^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imipramine+Desipramine [Mass/volume] in Serum or Plasma --trough;Imipramine+Desipr Trough SerPl-mCnc;;ACTIVE;2.54;2.54 +78363-9;Norhydrocodone;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Norhydrocodone [Presence] in Saliva (oral fluid) by Confirmatory method;Norhydrocodone Sal Ql Cfm;;ACTIVE;2.54;2.56 +78364-7;Amphetamine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Amphetamine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Amphet CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +78365-4;Imipramine trough & Imipramine+desimipramine trough & Desipramine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Imipramine trough, Imipramine+desimipramine trough and Desipramine panell - Serum or Plasma;Imiprn Trgh and Desiprn Pnl SerPl;;ACTIVE;2.54;2.54 +78366-2;Goose feather Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goose feather IgG Ab [Mass/volume] in Serum;Goose Feather IgG-mCnc;;ACTIVE;2.54;2.54 +78367-0;Pigeon serum proteins+feathers+droppings Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon serum proteins+feathers+droppings IgG Ab [Mass/volume] in Serum;Pigeon ser prot+feathers+dropp IgG-mCnc;;ACTIVE;2.54;2.54 +78368-8;Parrot serum proteins+feathers+droppings Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Parrot serum proteins+feathers+droppings IgG Ab [Mass/volume] in Serum;Parrot ser prot+feathers+dropp IgG-mCnc;;ACTIVE;2.54;2.54 +78369-6;ADHD hyperactive symptoms mean score difference;PctDiff;RptPeriod;^Patient;Qn;Calculated;SURVEY.ADHD;4;ADHD hyperactive symptoms mean score percent difference [Calculated];;Portions Copyright © 2002 American Academy of Pediatrics. Used with permission.;ACTIVE;2.54;2.7 +78370-4;ADHD diagnostic rating scale interpretation;Find;Pt;^Patient;Ord;Vanderbilt ADHD;SURVEY.ADHD;4;ADHD diagnostic rating scale interpretation [Vanderbilt ADHD];;Portions Copyright © 2002 American Academy of Pediatrics. Used with permission.;ACTIVE;2.54;2.54 +78371-2;ADHD inattentive symptoms mean score;Score;Pt;^Patient;Qn;Calculated;SURVEY.ADHD;4;ADHD inattentive symptoms mean score [Calculated];;Portions Copyright © 2002 American Academy of Pediatrics. Used with permission.;ACTIVE;2.54;2.7 +78372-0;ADHD hyperactive symptoms mean score;Score;Pt;^Patient;Qn;Calculated;SURVEY.ADHD;4;ADHD hyperactive symptoms mean score [Calculated];;Portions Copyright © 2002 American Academy of Pediatrics. Used with permission.;ACTIVE;2.54;2.7 +78373-8;ADHD inattentive symptoms mean score difference;PctDiff;RptPeriod;^Patient;Qn;Calculated;SURVEY.ADHD;4;ADHD inattentive symptoms mean score percent difference [Calculated];;Portions Copyright © 2002 American Academy of Pediatrics. Used with permission.;ACTIVE;2.54;2.7 +78374-6;Dermatophagoides farinae native (nDer f) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American house dust mite native (nDer f) 2 IgE Ab [Units/volume] in Serum;D farinae (nDer f) 2 IgE Qn;;ACTIVE;2.54;2.54 +78375-3;Discharge diagnosis;Imp;Pt;^Patient;Nar;;DOC.MISC;2;Discharge diagnosis Narrative;Discharge dx;;ACTIVE;2.54;2.63 +78376-1;Epipregnanolone;SRat;24H;Urine;Qn;;CHEM;1;Epipregnanolone [Moles/time] in 24 hour Urine;Epipregnanolone 24h Ur-sRate;;ACTIVE;2.54;2.54 +78377-9;Epipregnanolone;SCnc;24H;Urine;Qn;;CHEM;1;Epipregnanolone [Moles/volume] in 24 hour Urine;Epipregnanolone 24h Ur-sCnc;;ACTIVE;2.54;2.54 +7837-8;Coxsackievirus B2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B2 Ab [Units/volume] in Serum;CV B2 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78378-7;PON1 gene.c.575A>G;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;PON1 gene c.575A>G [Presence] in Blood or Tissue by Molecular genetics method;PON1 c.575A>G Bld/T Ql;;ACTIVE;2.54;2.56 +78379-5;Epipregnanolone;SCnc;Pt;Urine;Qn;;CHEM;1;Epipregnanolone [Moles/volume] in Urine;Epipregnanolone Ur-sCnc;;ACTIVE;2.54;2.54 +78380-3;Surgical operation note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Surgical operation note;CCM Operative note;;ACTIVE;2.54;2.58 +78381-1;Surgical operation note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Surgical operation note;Col+rec surg Operative note;;ACTIVE;2.54;2.58 +78382-9;CFTR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;MS.MALDI-TOF;MOLPATH.MUT;1;CFTR gene mutations found [Identifier] in Blood or Tissue by MS.MALDI-TOF Nominal;CFTR Mut Anl Bld/T MS.MALDI-TOF Nom;;ACTIVE;2.54;2.63 +78383-7;Discharge teaching note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Discharge teaching note;OT Discharge teach note;;ACTIVE;2.54;2.54 +78384-5;Cat dander native (nFel d) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cat dander native (nFel d) 1 IgE Ab [Units/volume] in Serum;Cat dander (nFel d) 1 IgE Qn;;ACTIVE;2.54;2.54 +78385-2;Budgerigar serum proteins+feathers+droppings Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Budgerigar serum proteins+feathers+droppings IgG Ab [Mass/volume] in Serum;Budgie ser prot+feathers+dropp IgG-mCnc;;ACTIVE;2.54;2.54 +7838-6;Coxsackievirus B3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B3 Ab [Units/volume] in Serum;CV B3 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78386-0;Admission history and physical note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Admission history and physical note;Neo peri med Admit H&P note;;ACTIVE;2.54;2.58 +78387-8;Admission history and physical note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Admission history and physical note;Nephrology Admit H&P note;;ACTIVE;2.54;2.58 +78388-6;Admission history and physical note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Admission history and physical note;Neuro surgery Admit H&P note;;ACTIVE;2.54;2.58 +78389-4;Admission history and physical note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Admission history and physical note;Neurology Admit H&P note;;ACTIVE;2.54;2.58 +78390-2;Admission history and physical note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Admission history and physical note;Nurse Admit H&P note;;ACTIVE;2.54;2.58 +78391-0;Admission history and physical note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Admission history and physical note;Nurse pract Admit H&P note;;ACTIVE;2.54;2.58 +78392-8;Admission history and physical note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Admission history and physical note;Oncology Admit H&P note;;ACTIVE;2.54;2.58 +7839-4;Coxsackievirus B4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B4 Ab [Units/volume] in Serum;CV B4 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +7840-2;Coxsackievirus B5 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B5 Ab [Units/volume] in Serum;CV B5 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78405-8;Consultation note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Consult note;Neo peri med Consult note;;ACTIVE;2.54;2.58 +78406-6;Consultation note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Consult note;Nurse pract Consult note;;ACTIVE;2.54;2.58 +78407-4;Counseling note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Counseling note;Nurse Counseling note;;ACTIVE;2.54;2.54 +78408-2;Counseling note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Counseling note;Nurse pract Counseling note;;ACTIVE;2.54;2.54 +78409-0;Daily or end of shift signout note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Daily or end of shift signout note;Nurse Daily/end shift signout note;;ACTIVE;2.54;2.54 +7841-0;Coxsackievirus B6 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Coxsackievirus B6 Ab [Units/volume] in Serum;CV B6 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78410-8;Discharge instructions;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Discharge instructions;Neo peri med Discharge instruct;;ACTIVE;2.54;2.54 +78411-6;Discharge instructions;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Discharge instructions;Nephrology Discharge instruct;;ACTIVE;2.54;2.54 +78412-4;Discharge instructions;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Discharge instructions;Neurology Discharge instruct;;ACTIVE;2.54;2.54 +78413-2;Discharge instructions;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Discharge instructions;Nurse Discharge instruct;;ACTIVE;2.54;2.54 +78414-0;Discharge instructions;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Discharge instructions;Nurse pract Discharge instruct;;ACTIVE;2.54;2.54 +78415-7;Discharge instructions;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Discharge instructions;Nutr+diet Discharge instruct;;ACTIVE;2.54;2.58 +78416-5;Discharge instructions;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Discharge instructions;OT Discharge instruct;;ACTIVE;2.54;2.54 +78417-3;Discharge instructions;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Discharge instructions;Oncology Discharge instruct;;ACTIVE;2.54;2.54 +78418-1;Discharge summary note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Discharge summary;Neo peri med D/C sum;;ACTIVE;2.54;2.73 +78419-9;Discharge summary note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Discharge summary;Nephrology D/C sum;;ACTIVE;2.54;2.73 +78420-7;Discharge summary note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Discharge summary;Neurology D/C sum;;ACTIVE;2.54;2.73 +78421-5;Discharge summary note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Discharge summary;Oncology D/C sum;;ACTIVE;2.54;2.73 +78422-3;Discharge teaching note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Discharge teaching note;Neo peri med Discharge teach note;;ACTIVE;2.54;2.54 +78423-1;Discharge teaching note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Discharge teaching note;Nephrology Discharge teach note;;ACTIVE;2.54;2.54 +78424-9;Discharge teaching note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Discharge teaching note;Neurology Discharge teach note;;ACTIVE;2.54;2.54 +78425-6;Discharge teaching note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Discharge teaching note;Nurse Discharge teach note;;ACTIVE;2.54;2.54 +78426-4;Discharge teaching note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Discharge teaching note;Nurse pract Discharge teach note;;ACTIVE;2.54;2.54 +78427-2;Discharge teaching note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Discharge teaching note;Nutr+diet Discharge teach note;;ACTIVE;2.54;2.58 +7842-8;Cryptococcus neoformans Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Cryptococcus neoformans Ab [Units/volume] in Serum;C neoform Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78428-0;Discharge teaching note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Discharge teaching note;Oncology Discharge teach note;;ACTIVE;2.54;2.54 +78429-8;Education note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Education note;Neo peri med Educ note;;ACTIVE;2.54;2.54 +78430-6;Education note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Education note;Nephrology Educ note;;ACTIVE;2.54;2.54 +78431-4;Education note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Education note;Neuro surgery Educ note;;ACTIVE;2.54;2.54 +78432-2;Education note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Education note;Neurology Educ note;;ACTIVE;2.54;2.54 +78433-0;Soluble liver Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Soluble liver IgG Ab [Presence] in Serum by Line blot;Soluble liver IgG Ser Ql Line blot;;ACTIVE;2.58;2.64 +78434-8;carBAMazepine free & total trough & 10,11-Epoxide panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;carBAMazepine free and total trough and 10,11-Epoxide panel - Serum or Plasma;Carbmzpn Trgh + Metab Pnl SerPl;;ACTIVE;2.54;2.54 +78435-5;Mirtazapine trough & Normirtazapine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Mirtazapine trough and Normirtazapine panel - Serum or Plasma;Mirtaz Trough + Normirtaz Pnl SerPl;;ACTIVE;2.54;2.54 +7843-6;Cryptococcus sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Cryptococcus sp Ab [Presence] in Serum;Cryptoc Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +78436-3;Primidone & PHENobarbital trough panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Primidone and PHENobarbital trough panel - Serum or Plasma;Primdne + PHENobar Trgh Pnl SerPl;;ACTIVE;2.54;2.54 +78437-1;Fluoxetine trough & Fluoxetine+norfluoxetine trough & Norfluoxetine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;FLUoxetine trough, FLUoxetine+norfluoxetine trough and Norfluoxetine panel - Serum or Plasma;Fluox, Floux+Nor Trgh + Nor Pnl SerPl;;ACTIVE;2.54;2.54 +78438-9;Sertraline trough & Norsertraline panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Sertraline trough and Norsertraline panel - Serum or Plasma;Sertraline Trough + Nor Pnl SerPl;;ACTIVE;2.54;2.54 +78439-7;Phenytoin free & total trough panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Phenytoin free and total trough panel - Serum or Plasma;Phyt Free + Total Trough Pnl SerPl;;ACTIVE;2.54;2.54 +78440-5;Risperidone trough & 9-Hydroxyrisperidone panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;risperiDONE trough and 9-Hydroxyrisperidone panel - Serum or Plasma;Risp Trgh + 9OH-Ris Pnl SerPl;;ACTIVE;2.54;2.54 +78441-3;Bilirubin.glucuronidated;SCnc;Pt;Periton fld;Qn;;CHEM;1;Bilirubin.conjugated [Moles/volume] in Peritoneal fluid;Bilirub Conj Prt-sCnc;;ACTIVE;2.54;2.54 +78442-1;Bilirubin.non-glucuronidated;SCnc;Pt;Periton fld;Qn;;CHEM;1;Bilirubin.indirect [Moles/volume] in Peritoneal fluid;Bilirub Indirect Prt-sCnc;;ACTIVE;2.54;2.54 +78443-9;Carbamazepine 10,11-Epoxide^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated carBAMazepine 10,11-Epoxide [Mass/volume] in Serum or Plasma --trough;Deprecated carBAMazepine EP Trough SerPl;;DEPRECATED;2.54;2.54 +7844-4;Taenia solium larva Ab.IgA;PrThr;Pt;CSF;Ord;;MICRO;1;Taenia solium larva IgA Ab [Presence] in Cerebral spinal fluid;T sol lar IgA CSF Ql;;ACTIVE;1.0h(2);2.56 +78444-7;Hepatitis A virus Ab.IgG+IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis A virus IgG+IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;HAV IgG+IgM SerPl IA-aCnc;;ACTIVE;2.54;2.56 +78445-4;Cytomegalovirus Ab.IgG avidity;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay;CMV IgG Avidity SerPl Ql IA;;ACTIVE;2.54;2.56 +78446-2;Flowsheet;Find;Pt;{Setting};Doc;Surgical critical care;DOC.ONTOLOGY;2;Surgical critical care Flowsheet;Surgical critical care Flowsheet;;ACTIVE;2.54;2.54 +78447-0;Checklist;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Checklist;ED Checklist;;ACTIVE;2.54;2.73 +78448-8;Checklist;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Checklist;Cardio+Pulm disease Checklist;;ACTIVE;2.54;2.54 +78449-6;Checklist;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Checklist;Neuro surgery Checklist;;ACTIVE;2.54;2.54 +78450-4;Education note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Education note;Nurse pract Educ note;;ACTIVE;2.54;2.54 +7845-1;Taenia solium larva Ab.IgA;PrThr;Pt;Ser;Ord;;MICRO;1;Taenia solium larva IgA Ab [Presence] in Serum;T sol lar IgA Ser Ql;;ACTIVE;1.0h(2);2.56 +78451-2;Education note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Education note;Nutr+diet Educ note;;ACTIVE;2.54;2.58 +78452-0;Education note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Education note;OT Educ note;;ACTIVE;2.54;2.54 +78453-8;Education note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Education note;Oncology Educ note;;ACTIVE;2.54;2.54 +78454-6;Flowsheet;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Flowsheet;Multi-spec prog Flowsheet;;ACTIVE;2.54;2.58 +78455-3;Flowsheet;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Flowsheet;Neo peri med Flowsheet;;ACTIVE;2.54;2.54 +78456-1;Flowsheet;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Flowsheet;Nephrology Flowsheet;;ACTIVE;2.54;2.54 +78457-9;Flowsheet;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Flowsheet;Neuro surgery Flowsheet;;ACTIVE;2.54;2.54 +78458-7;Flowsheet;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Flowsheet;Neurology Flowsheet;;ACTIVE;2.54;2.54 +78459-5;Flowsheet;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Flowsheet;Nurse pract Flowsheet;;ACTIVE;2.54;2.54 +78460-3;Flowsheet;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Flowsheet;Nutr+diet Flowsheet;;ACTIVE;2.54;2.58 +78461-1;Flowsheet;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Flowsheet;OT Flowsheet;;ACTIVE;2.54;2.54 +78462-9;Flowsheet;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Flowsheet;Oncology Flowsheet;;ACTIVE;2.54;2.54 +78463-7;History and physical note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology History and physical note;Nephrology H&P note;;ACTIVE;2.54;2.58 +78464-5;History and physical note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology History and physical note;Neurology H&P note;;ACTIVE;2.54;2.58 +78465-2;History and physical note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology History and physical note;Oncology H&P note;;ACTIVE;2.54;2.58 +78466-0;Initial evaluation note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Initial evaluation note;Mental health Initial eval note;;ACTIVE;2.54;2.54 +78467-8;Initial evaluation note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Initial evaluation note;Neo peri med Initial eval note;;ACTIVE;2.54;2.54 +78468-6;Initial evaluation note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Initial evaluation note;Nephrology Initial eval note;;ACTIVE;2.54;2.54 +7846-9;Taenia solium larva Ab.IgG;PrThr;Pt;CSF;Ord;;MICRO;1;Taenia solium larva IgG Ab [Presence] in Cerebral spinal fluid;T sol lar IgG CSF Ql;;ACTIVE;1.0h(2);2.56 +78469-4;Initial evaluation note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Initial evaluation note;Neurology Initial eval note;;ACTIVE;2.54;2.54 +78470-2;Initial evaluation note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Initial evaluation note;Nutr+diet Initial eval note;;ACTIVE;2.54;2.58 +78471-0;Initial evaluation note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Initial evaluation note;Oncology Initial eval note;;ACTIVE;2.54;2.54 +78472-8;Procedure note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health procedure note;Mental health Procedure note;;ACTIVE;2.58;2.58 +78473-6;Procedure note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine procedure note;Neo peri med Procedure note;;ACTIVE;2.58;2.58 +78474-4;Procedure note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology procedure note;Nephrology Procedure note;;ACTIVE;2.58;2.58 +78475-1;Procedure note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology procedure note;Neurology Procedure note;;ACTIVE;2.58;2.58 +78476-9;Procedure note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner procedure note;Nurse pract Procedure note;;ACTIVE;2.58;2.58 +7847-7;Taenia solium larva Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Taenia solium larva IgG Ab [Presence] in Serum;T sol lar IgG Ser Ql;;ACTIVE;1.0h(2);2.56 +78477-7;Procedure note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy procedure note;OT Procedure note;;ACTIVE;2.58;2.58 +78478-5;Procedure note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology procedure note;Oncology Procedure note;;ACTIVE;2.58;2.58 +78479-3;Progress note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Progress note;Neo peri med Prog note;;ACTIVE;2.54;2.73 +78480-1;Progress note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Progress note;Nephrology Prog note;;ACTIVE;2.54;2.73 +78481-9;Progress note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Progress note;Nutr+diet Prog note;;ACTIVE;2.54;2.73 +78482-7;Progress note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Progress note;Oncology Prog note;;ACTIVE;2.54;2.73 +78483-5;Referral note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Referral note;Neo peri med Referral note;;ACTIVE;2.54;2.58 +78484-3;Referral note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Referral note;Nurse pract Referral note;;ACTIVE;2.54;2.58 +7848-5;Taenia solium larva Ab.IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Taenia solium larva IgM Ab [Presence] in Cerebral spinal fluid;T sol lar IgM CSF Ql;;ACTIVE;1.0h(2);2.56 +78485-0;Restraint note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Restraint note;Mental health Restraint note;;ACTIVE;2.54;2.54 +78486-8;Risk assessment and screening note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Risk assessment and screening note;Mental health Risk assess+scrn note;;ACTIVE;2.54;2.58 +78487-6;Surgical operation note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Surgical operation note;Neuro surgery Operative note;;ACTIVE;2.54;2.58 +78488-4;Transfer summary note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Transfer summary note;Mental health Transfer sum note;;ACTIVE;2.54;2.58 +78489-2;Transfer summary note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Transfer summary note;Neo peri med Transfer sum note;;ACTIVE;2.54;2.58 +784-9;Erythrocyte mean corpuscular diameter;Len;Pt;RBC;Qn;Automated count;HEM/BC;1;Erythrocyte mean corpuscular diameter [Length] by Automated count;MCD RBC Auto;;ACTIVE;1.0;2.44 +78490-0;Transfer summary note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Transfer summary note;Nephrology Transfer sum note;;ACTIVE;2.54;2.58 +78491-8;Transfer summary note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Transfer summary note;Neurology Transfer sum note;;ACTIVE;2.54;2.58 +78492-6;Transfer summary note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Transfer summary note;Neuro surgery Transfer sum note;;ACTIVE;2.54;2.58 +7849-3;Taenia solium larva Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Taenia solium larva IgM Ab [Presence] in Serum;T sol lar IgM Ser Ql;;ACTIVE;1.0h(2);2.56 +78493-4;Transfer summary note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Transfer summary note;Oncology Transfer sum note;;ACTIVE;2.54;2.58 +78494-2;Procedure note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics procedure note;Nutr+diet Procedure note;;ACTIVE;2.58;2.58 +78495-9;Checklist;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Checklist;Anesthesiology Checklist;;ACTIVE;2.54;2.54 +78496-7;Consultation note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Consult note;CCM Consult note;;ACTIVE;2.54;2.58 +78497-5;Admission history and physical note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Admission history and physical note;Cardio+Pulm disease Admit H&P note;;ACTIVE;2.54;2.58 +78498-3;Consultation note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Consult note;Cardio+Pulm disease Consult note;;ACTIVE;2.54;2.58 +78499-1;Education note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Education note;Cardio+Pulm disease Educ note;;ACTIVE;2.54;2.54 +78500-6;Flowsheet;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Flowsheet;Cardio+Pulm disease Flowsheet;;ACTIVE;2.54;2.54 +7850-1;Taenia solium larva Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Taenia solium larva Ab [Units/volume] in Serum;T sol lar Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78501-4;Referral note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Referral note;Cardio+Pulm disease Referral note;;ACTIVE;2.54;2.58 +78502-2;Transfer summary note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Transfer summary note;Cardio+Pulm disease Transfer sum note;;ACTIVE;2.54;2.58 +78503-0;Checklist;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Checklist;Surgery Checklist;;ACTIVE;2.54;2.54 +78504-8;Checklist;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Checklist;Mental health Checklist;;ACTIVE;2.54;2.54 +78505-5;Checklist;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Checklist;Col+rec surg Checklist;;ACTIVE;2.54;2.54 +78506-3;Legal letter;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Legal letter;Legal letter;;ACTIVE;2.54;2.54 +78507-1;Admission history and physical note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Admission history and physical note;Peds Admit H&P note;;ACTIVE;2.54;2.58 +78508-9;Admission history and physical note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Admission history and physical note;Cardiothor surg Admit H&P note;;ACTIVE;2.54;2.58 +78509-7;Admission history and physical note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Admission history and physical note;Orthopaedic surgery Admit H&P note;;ACTIVE;2.54;2.58 +78510-5;Admission history and physical note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Admission history and physical note;Vascular surgery Admit H&P note;;ACTIVE;2.54;2.58 +78511-3;Admission history and physical note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Admission history and physical note;OMS Admit H&P note;;ACTIVE;2.54;2.58 +78512-1;Summary note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Summary note;Ophthalmol Summary note;;ACTIVE;2.54;2.63 +78513-9;Summary of encounters note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Summary of encounters note;Ophthalmol Summary encounters;;ACTIVE;2.54;2.63 +78514-7;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag;PrThr;Pt;XXX;Ord;LA;MICRO;1;Neisseria meningitidis serogroups A+B+C+w135+Y+Escherichia coli K1 Ag [Presence] in Specimen by Latex agglutination;N men sg A+B+C+W135+Y+EcK1 Ag Spec Ql LA;;ACTIVE;2.54;2.69 +78515-4;Lactose^15M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Moles/volume] in Serum or Plasma --15 minutes post dose lactose PO;Lactose 15M p Lac PO SerPl-sCnc;;ACTIVE;2.54;2.54 +78516-2;Lactose^45M post dose lactose PO;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Lactose [Moles/volume] in Serum or Plasma --45 minutes post dose lactose PO;Lactose 45M p Lac PO SerPl-sCnc;;ACTIVE;2.54;2.54 +78517-0;Renin^2H post XXX challenge;MCnc;Pt;Plas;Qn;;CHAL;1;Renin [Mass/volume] in Plasma --2 hours post XXX challenge;Renin 2h p chal Plas-mCnc;;ACTIVE;2.54;2.54 +78518-8;Cholesterol;SCnc;Pt;Pericard fld;Qn;;CHEM;1;Cholesterol [Moles/volume] in Pericardial fluid;Cholest Pcar-sCnc;;ACTIVE;2.54;2.54 +7851-9;Cytomegalovirus Ab;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus Ab [Units/volume] in Serum or Plasma;CMV Ab SerPl-aCnc;;ACTIVE;1.0h(2);2.69 +78519-6;Platelet aggregation.adenosine diphosphate induced^2 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --2 umol/L;PA ADP 2 umol/L PRP;;ACTIVE;2.54;2.54 +78520-4;Platelet aggregation.adenosine diphosphate induced^2.5 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --2.5 umol/L;PA ADP 2.5 umol/L PRP;;ACTIVE;2.54;2.54 +78521-2;Platelet aggregation.adenosine diphosphate induced^4 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --4 umol/L;PA ADP 4 umol/L PRP;;ACTIVE;2.54;2.54 +78522-0;Platelet aggregation.adenosine diphosphate induced^5 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --5 umol/L;PA ADP 5 umol/L PRP;;ACTIVE;2.54;2.73 +78523-8;Platelet aggregation.EPINEPHrine induced^100 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --100 umol/L;PA Epineph 100 umol/L PRP;;ACTIVE;2.54;2.54 +78524-6;Platelet aggregation.EPINEPHrine induced^6 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --6 umol/L;PA Epineph 6 umol/L PRP;;ACTIVE;2.54;2.54 +78525-3;Platelet aggregation.arachidonate induced^1.6 mmol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation arachidonate induced in Platelet rich plasma --1.6 mmol/L;PA AA 1.6 mmol/L PRP;;ACTIVE;2.54;2.54 +78526-1;Platelet aggregation.collagen induced^1.25 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation collagen induced in Platelet rich plasma --1.25 ug/ml;PA Coll 1.25 ug/ml PRP;;ACTIVE;2.54;2.54 +7852-7;Cytomegalovirus Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma;CMV IgG SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +78527-9;Platelet aggregation.collagen induced^5 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation collagen induced in Platelet rich plasma --5 ug/mL;PA Coll 5 ug/mL PRP;;ACTIVE;2.54;2.54 +78528-7;Platelet aggregation.ristocetin induced^1.25 mg/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --1.25 mg/ml;PA Rist 1.25 mg/ml PRP;;ACTIVE;2.54;2.54 +78529-5;Adenovirus Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Adenovirus Ag [Presence] in Stool by Rapid immunoassay;HAdV Ag Stl Ql IA.rapid;;ACTIVE;2.54;2.56 +78530-3;Vesicular stomatitis New Jersey virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Vesicular stomatitis New Jersey virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;VSNJV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.54;2.69 +78531-1;Vesicular stomatitis Indiana virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Vesicular stomatitis Indiana virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;VSIV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.54;2.69 +78532-9;Creatinine^2H dwell specimen;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Moles/volume] in Peritoneal dialysis fluid --2 hour dwell specimen;Creat 2H dwell spec DiafP-sCnc;;ACTIVE;2.54;2.54 +78533-7;Creatinine^4H dwell specimen;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Creatinine [Moles/volume] in Peritoneal dialysis fluid --4 hour dwell specimen;Creat 4H dwell spec DiafP-sCnc;;ACTIVE;2.54;2.54 +78534-5;Glucose^2H dwell specimen;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Moles/volume] in Peritoneal dialysis fluid --2 hour dwell specimen;Glucose 2H dwell spec DiafP-sCnc;;ACTIVE;2.54;2.54 +7853-5;Cytomegalovirus Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma;CMV IgM SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +78535-2;Glucose^4H dwell specimen;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Glucose [Moles/volume] in Peritoneal dialysis fluid --4 hour dwell specimen;Glucose 4H dwell spec DiafP-sCnc;;ACTIVE;2.54;2.54 +78536-0;Urea nitrogen^2H dwell specimen;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Moles/volume] in Peritoneal dialysis fluid --2 hour dwell specimen;Urea nit 2H dwell spec DiafP-sCnc;;ACTIVE;2.54;2.54 +78537-8;Urea nitrogen^4H dwell specimen;SCnc;Pt;Dial fld prt;Qn;;CHEM;1;Urea nitrogen [Moles/volume] in Peritoneal dialysis fluid --4 hour dwell specimen;Urea nit 4H dwell spec DiafP-sCnc;;ACTIVE;2.54;2.54 +78538-6;Admission history and physical note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Admission history and physical note;Palliative care Admit H&P note;;ACTIVE;2.54;2.58 +78539-4;Checklist;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Checklist;Transpl surg Checklist;;ACTIVE;2.54;2.73 +78540-2;Checklist;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Checklist;OMS Checklist;;ACTIVE;2.54;2.54 +78541-0;Checklist;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Checklist;Orthopaedic surgery Checklist;;ACTIVE;2.54;2.54 +78542-8;Checklist;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Checklist;Vascular surgery Checklist;;ACTIVE;2.54;2.54 +7854-3;Dengue virus 1 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Dengue virus 1 Ab [Presence] in Serum by Immunoassay;DENV1 Ab Ser Ql IA;;ACTIVE;1.0h(2);2.56 +78543-6;Checklist;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Checklist;Cardiothor surg Checklist;;ACTIVE;2.54;2.56 +78544-4;Checklist;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Checklist;Peds surgery Checklist;;ACTIVE;2.54;2.54 +78545-1;Checklist;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Checklist;Plastic surgery Checklist;;ACTIVE;2.54;2.54 +7855-0;Dengue virus 1+2+3+4 RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 RNA [Presence] in Serum by NAA with probe detection;DENV1+2+3+4 RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +785-6;Erythrocyte mean corpuscular hemoglobin;EntMass;Pt;RBC;Qn;Automated count;HEM/BC;1;MCH [Entitic mass] by Automated count;MCH RBC Qn Auto;;ACTIVE;1.0;2.73 +78567-5;Consultation note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Consult note;Pain medicine Consult note;;ACTIVE;2.54;2.58 +7856-8;Dengue virus 2 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Dengue virus 2 Ab [Presence] in Serum by Immunoassay;DENV2 Ab Ser Ql IA;;ACTIVE;1.0h(2);2.56 +78568-3;Consultation note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Consult note;Palliative care Consult note;;ACTIVE;2.54;2.58 +78569-1;Counseling note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Counseling note;Resp therapy Counseling note;;ACTIVE;2.54;2.54 +78570-9;Counseling note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Counseling note;Speech-lang path Counseling note;;ACTIVE;2.54;2.54 +78571-7;Diagnostic study note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Diagnostic study note;Rheumatology Diag study note;;ACTIVE;2.54;2.54 +78572-5;Diagnostic study note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Diagnostic study note;Radiation Onc Diag study note;;ACTIVE;2.54;2.58 +78573-3;Diagnostic study note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Diagnostic study note;Ophthalmol Diag study note;;ACTIVE;2.54;2.54 +78574-1;Diagnostic study note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Diagnostic study note;Optometry Diag study note;;ACTIVE;2.54;2.54 +78575-8;Diagnostic study note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Diagnostic study note;Otolaryngology Diag study note;;ACTIVE;2.54;2.54 +7857-6;Dengue virus 3 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Dengue virus 3 Ab [Presence] in Serum by Immunoassay;DENV3 Ab Ser Ql IA;;ACTIVE;1.0h(2);2.56 +78576-6;Diagnostic study note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Diagnostic study note;Urology Diag study note;;ACTIVE;2.54;2.54 +78577-4;Diagnostic study note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Diagnostic study note;Podiatry Diag study note;;ACTIVE;2.54;2.54 +78578-2;Discharge instructions;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Discharge instructions;Peds Discharge instruct;;ACTIVE;2.54;2.54 +78579-0;Discharge instructions;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Discharge instructions;Palliative care Discharge instruct;;ACTIVE;2.54;2.54 +78580-8;Discharge instructions;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Discharge instructions;Resp therapy Discharge instruct;;ACTIVE;2.54;2.54 +78581-6;Discharge instructions;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Discharge instructions;Rec therapy Discharge instruct;;ACTIVE;2.54;2.54 +78582-4;Discharge instructions;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Discharge instructions;PT Discharge instruct;;ACTIVE;2.54;2.54 +78583-2;Discharge instructions;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Discharge instructions;Pharmacology Discharge instruct;;ACTIVE;2.54;2.56 +7858-4;Dengue virus 4 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Dengue virus 4 Ab [Presence] in Serum by Immunoassay;DENV4 Ab Ser Ql IA;;ACTIVE;1.0h(2);2.56 +78584-0;Discharge instructions;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Discharge instructions;Speech-lang path Discharge instruct;;ACTIVE;2.54;2.54 +78585-7;Discharge summary note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Discharge summary;Palliative care D/C sum;;ACTIVE;2.54;2.73 +78586-5;Discharge teaching note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Discharge teaching note;Resp therapy Discharge teach note;;ACTIVE;2.54;2.54 +78587-3;Discharge teaching note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Discharge teaching note;Palliative care Discharge teach note;;ACTIVE;2.54;2.54 +78588-1;Discharge teaching note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Discharge teaching note;Rec therapy Discharge teach note;;ACTIVE;2.54;2.54 +78589-9;Discharge teaching note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Discharge teaching note;Pharmacology Discharge teach note;;ACTIVE;2.54;2.56 +78590-7;Discharge teaching note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Discharge teaching note;Peds Discharge teach note;;ACTIVE;2.54;2.54 +78591-5;Discharge teaching note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Discharge teaching note;PT Discharge teach note;;ACTIVE;2.54;2.54 +7859-2;Dengue virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Dengue virus Ab [Units/volume] in Serum;DENV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78592-3;Discharge teaching note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Discharge teaching note;Speech-lang path Discharge teach note;;ACTIVE;2.54;2.54 +78593-1;Education note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Education note;Orthopaedic surgery Educ note;;ACTIVE;2.54;2.54 +78594-9;Education note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Education note;OMS Educ note;;ACTIVE;2.54;2.54 +78595-6;Education note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Education note;Radiation Onc Educ note;;ACTIVE;2.54;2.58 +78596-4;Education note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Education note;Cardiothor surg Educ note;;ACTIVE;2.54;2.56 +78597-2;Education note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Education note;Vascular surgery Educ note;;ACTIVE;2.54;2.54 +78598-0;Education note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Education note;Transpl surg Educ note;;ACTIVE;2.54;2.73 +78599-8;Education note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Education note;Palliative care Educ note;;ACTIVE;2.54;2.54 +78-6;ceFAZolin;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;ceFAZolin [Susceptibility] by Serum bactericidal titer;ceFAZolin Titr SBT;;ACTIVE;1.0;2.32 +7860-0;Eastern equine encephalitis virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus IgG Ab [Units/volume] in Serum;EEEV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78600-4;Education note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Education note;Rheumatology Educ note;;ACTIVE;2.54;2.54 +78601-2;Education note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Education note;Pharmacology Educ note;;ACTIVE;2.54;2.56 +78602-0;Education note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Education note;Sports medicine Educ note;;ACTIVE;2.54;2.54 +78603-8;Education note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Education note;Urology Educ note;;ACTIVE;2.54;2.54 +78604-6;Education note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Education note;PT Educ note;;ACTIVE;2.54;2.54 +78605-3;Education note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Education note;Optometry Educ note;;ACTIVE;2.54;2.54 +78606-1;Education note;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Education note;Peds surgery Educ note;;ACTIVE;2.54;2.54 +78607-9;Education note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Education note;SW Educ note;;ACTIVE;2.54;2.65 +78608-7;Education note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Education note;Ophthalmol Educ note;;ACTIVE;2.54;2.54 +78609-5;Education note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Education note;Resp therapy Educ note;;ACTIVE;2.54;2.54 +78610-3;Education note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Education note;Pain medicine Educ note;;ACTIVE;2.54;2.54 +78611-1;Education note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Education note;Podiatry Educ note;;ACTIVE;2.54;2.54 +78612-9;Education note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Education note;Otolaryngology Educ note;;ACTIVE;2.54;2.54 +78613-7;Education note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Education note;Speech-lang path Educ note;;ACTIVE;2.54;2.54 +78614-5;Education note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Education note;Plastic surgery Educ note;;ACTIVE;2.54;2.54 +78615-2;Education note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Education note;Peds Educ note;;ACTIVE;2.54;2.54 +78616-0;Flowsheet;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Flowsheet;OMS Flowsheet;;ACTIVE;2.54;2.54 +78617-8;Flowsheet;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Flowsheet;Optometry Flowsheet;;ACTIVE;2.54;2.54 +7861-8;Eastern equine encephalitis virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Eastern equine encephalitis virus IgM Ab [Units/volume] in Serum;EEEV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78618-6;Flowsheet;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Flowsheet;Otolaryngology Flowsheet;;ACTIVE;2.54;2.54 +78619-4;Flowsheet;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Flowsheet;PM+R Flowsheet;;ACTIVE;2.54;2.58 +78620-2;Flowsheet;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Flowsheet;Vascular surgery Flowsheet;;ACTIVE;2.54;2.54 +78621-0;Flowsheet;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Flowsheet;Pain medicine Flowsheet;;ACTIVE;2.54;2.54 +78622-8;Flowsheet;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Flowsheet;Urology Flowsheet;;ACTIVE;2.54;2.54 +78623-6;Flowsheet;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Flowsheet;Sports medicine Flowsheet;;ACTIVE;2.54;2.54 +78624-4;Flowsheet;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Flowsheet;Primary care Flowsheet;;ACTIVE;2.54;2.54 +78625-1;Flowsheet;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Flowsheet;Psychiatric Flowsheet;;ACTIVE;2.54;2.54 +7862-6;Ebola virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Ebola virus Ab [Titer] in Serum by Immunofluorescence;EBOV Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +78626-9;Flowsheet;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Flowsheet;Cardiothor surg Flowsheet;;ACTIVE;2.54;2.56 +78627-7;Flowsheet;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Flowsheet;Peds surgery Flowsheet;;ACTIVE;2.54;2.54 +78628-5;Flowsheet;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Flowsheet;Radiation Onc Flowsheet;;ACTIVE;2.54;2.58 +78629-3;Flowsheet;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Flowsheet;Transpl surg Flowsheet;;ACTIVE;2.54;2.73 +78630-1;Flowsheet;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Flowsheet;Podiatry Flowsheet;;ACTIVE;2.54;2.54 +78631-9;Flowsheet;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Flowsheet;Orthopaedic surgery Flowsheet;;ACTIVE;2.54;2.54 +78632-7;Flowsheet;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Flowsheet;Speech-lang path Flowsheet;;ACTIVE;2.54;2.54 +78633-5;Flowsheet;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Flowsheet;Plastic surgery Flowsheet;;ACTIVE;2.54;2.54 +7863-4;Echinococcus sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echinococcus sp Ab [Units/volume] in Serum;Echinococcus Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78634-3;Flowsheet;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Flowsheet;Peds Flowsheet;;ACTIVE;2.54;2.54 +78635-0;Flowsheet;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Flowsheet;Rec therapy Flowsheet;;ACTIVE;2.54;2.54 +78636-8;Flowsheet;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Flowsheet;Palliative care Flowsheet;;ACTIVE;2.54;2.54 +78637-6;Flowsheet;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Flowsheet;PT Flowsheet;;ACTIVE;2.54;2.54 +78638-4;Flowsheet;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Flowsheet;Ophthalmol Flowsheet;;ACTIVE;2.54;2.54 +78639-2;Flowsheet;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Flowsheet;Rheumatology Flowsheet;;ACTIVE;2.54;2.54 +786-4;Erythrocyte mean corpuscular hemoglobin concentration;MCnc;Pt;RBC;Qn;Automated count;HEM/BC;1;MCHC [Mass/volume] by Automated count;MCHC RBC Auto-mCnc;;ACTIVE;1.0;2.73 +78640-0;Flowsheet;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Flowsheet;Resp therapy Flowsheet;;ACTIVE;2.54;2.54 +78641-8;Flowsheet;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Flowsheet;Psych Flowsheet;;ACTIVE;2.54;2.54 +7864-2;Echovirus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 1 Ab [Units/volume] in Serum;ECV1 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78642-6;Form;Find;Pt;{Setting};Doc;Public health;DOC.ONTOLOGY;2;Public health Form;Public health Form;;ACTIVE;2.54;2.54 +78643-4;History and physical note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care History and physical note;Palliative care H&P note;;ACTIVE;2.54;2.58 +78644-2;Initial evaluation note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Initial evaluation note;Peds Initial eval note;;ACTIVE;2.54;2.54 +78645-9;Initial evaluation note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Initial evaluation note;Urology Initial eval note;;ACTIVE;2.54;2.54 +78646-7;Initial evaluation note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Initial evaluation note;Rec therapy Initial eval note;;ACTIVE;2.54;2.54 +78647-5;Initial evaluation note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Initial evaluation note;Ophthalmol Initial eval note;;ACTIVE;2.54;2.54 +78648-3;Initial evaluation note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Initial evaluation note;Optometry Initial eval note;;ACTIVE;2.54;2.54 +78649-1;Initial evaluation note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Initial evaluation note;Otolaryngology Initial eval note;;ACTIVE;2.54;2.54 +78650-9;Initial evaluation note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Initial evaluation note;Palliative care Initial eval note;;ACTIVE;2.54;2.54 +78651-7;Initial evaluation note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Initial evaluation note;Pain medicine Initial eval note;;ACTIVE;2.54;2.54 +78652-5;Initial evaluation note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Initial evaluation note;Rheumatology Initial eval note;;ACTIVE;2.54;2.54 +78653-3;Initial evaluation note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Initial evaluation note;Radiation Onc Initial eval note;;ACTIVE;2.54;2.58 +78654-1;Procedure note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology procedure note;Speech-lang path Procedure note;;ACTIVE;2.58;2.58 +78655-8;Procedure note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology procedure note;Otolaryngology Procedure note;;ACTIVE;2.58;2.58 +78656-6;Procedure note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology procedure note;Radiation Onc Procedure note;;ACTIVE;2.58;2.58 +78657-4;Procedure note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology procedure note;Ophthalmol Procedure note;;ACTIVE;2.58;2.58 +78658-2;Procedure note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy procedure note;Resp therapy Procedure note;;ACTIVE;2.58;2.58 +7865-9;Echovirus 11 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 11 Ab [Units/volume] in Serum;ECV11 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78659-0;Procedure note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology procedure note;Urology Procedure note;;ACTIVE;2.58;2.58 +78660-8;Procedure note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology procedure note;Rheumatology Procedure note;;ACTIVE;2.58;2.58 +78661-6;Procedure note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry procedure note;Optometry Procedure note;;ACTIVE;2.58;2.58 +78662-4;Procedure note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy procedure note;PT Procedure note;;ACTIVE;2.58;2.58 +78663-2;Progress note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Progress note;Palliative care Prog note;;ACTIVE;2.54;2.73 +78664-0;Progress note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Progress note;Rec therapy Prog note;;ACTIVE;2.54;2.73 +78665-7;Progress note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Progress note;Radiation Onc Prog note;;ACTIVE;2.54;2.73 +78666-5;Progress note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Progress note;Rheumatology Prog note;;ACTIVE;2.54;2.73 +7866-7;Echovirus 19 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 19 Ab [Units/volume] in Serum;ECV19 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78667-3;Progress note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Progress note;Optometry Prog note;;ACTIVE;2.54;2.73 +78668-1;Progress note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Progress note;Pain medicine Prog note;;ACTIVE;2.54;2.73 +78669-9;Progress note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Progress note;Otolaryngology Prog note;;ACTIVE;2.54;2.73 +78670-7;Referral note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Referral note;Peds Referral note;;ACTIVE;2.54;2.58 +78671-5;Referral note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Referral note;Primary care Referral note;;ACTIVE;2.54;2.58 +78672-3;Referral note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Referral note;Pain medicine Referral note;;ACTIVE;2.54;2.58 +78673-1;Referral note;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Referral note;Peds surgery Referral note;;ACTIVE;2.54;2.58 +78674-9;Referral note;Find;Pt;{Setting};Doc;Public health;DOC.ONTOLOGY;2;Public health Referral note;Public health Referral note;;ACTIVE;2.54;2.58 +7867-5;Echovirus 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 3 Ab [Units/volume] in Serum;ECV3 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78675-6;Referral note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Referral note;Pastoral Care Referral note;;ACTIVE;2.54;2.58 +78676-4;Referral note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Referral note;Palliative care Referral note;;ACTIVE;2.54;2.58 +78677-2;Referral note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Referral note;Transpl surg Referral note;;ACTIVE;2.54;2.73 +78678-0;Surgical operation note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Surgical operation note;OMS Operative note;;ACTIVE;2.54;2.58 +78679-8;Surgical operation note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Surgical operation note;Cardiothor surg Operative note;;ACTIVE;2.54;2.58 +78680-6;Transfer summary note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Transfer summary note;Vascular surgery Transfer sum note;;ACTIVE;2.54;2.58 +78681-4;Transfer summary note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Transfer summary note;Cardiothor surg Transfer sum note;;ACTIVE;2.54;2.58 +78682-2;Transfer summary note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Transfer summary note;Palliative care Transfer sum note;;ACTIVE;2.54;2.58 +7868-3;Echovirus 30 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 30 Ab [Titer] in Serum;ECV30 Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +78683-0;Transfer summary note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Transfer summary note;Transpl surg Transfer sum note;;ACTIVE;2.54;2.73 +78684-8;Transfer summary note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Transfer summary note;OMS Transfer sum note;;ACTIVE;2.54;2.58 +78685-5;Platelet aggregation.collagen induced;ACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation collagen induced [Units/volume] in Blood;PA Coll Bld-aCnc;;ACTIVE;2.54;2.68 +78686-3;Platelet aggregation.ristocetin induced^high dose;ACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ristocetin induced [Units/volume] in Blood --High dose;PA Rist hi dose Bld-aCnc;;ACTIVE;2.54;2.68 +78687-1;Platelet aggregation.thrombin receptor activating peptide-6 induced;ACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation thrombin receptor activating peptide-6 induced [Units/volume] in Blood;PA TRAP-6 induced Bld-aCnc;;ACTIVE;2.54;2.68 +78688-9;Platelet aggregation.adenosine diphosphate+prostaglandin E1 induced;ACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation adenosine diphosphate+prostaglandin E1 induced [Units/volume] in Blood;PA ADP+PGE1 induced Bld-aCnc;;ACTIVE;2.54;2.68 +78689-7;Adenylosuccinate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adenylosuccinate/Creatinine [Molar ratio] in Urine;Adenylosuccinate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +78690-5;5-hydroxymethyluracil/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5-Hydroxymethyluracil/Creatinine [Molar ratio] in Urine;5OH-methyluracil/Creat Ur-sRto;;ACTIVE;2.54;2.54 +7869-1;Echovirus 4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 4 Ab [Units/volume] in Serum;ECV4 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78691-3;Guanosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Guanosine/Creatinine [Molar ratio] in Urine;Guanosine/Creat Ur-sRto;;ACTIVE;2.54;2.73 +78692-1;Pseudouridine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pseudouridine/Creatinine [Molar ratio] in Urine;Pseudouridine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +78693-9;Dihydrothymine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dihydrothymine/Creatinine [Molar ratio] in Urine;Dihydrothymine/Creat Ur-sRto;;ACTIVE;2.54;2.73 +78694-7;Dihydroorotate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dihydroorotate/Creatinine [Molar ratio] in Urine;Dihydroorotate/Creat Ur-sRto;;ACTIVE;2.54;2.73 +78695-4;Guanine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Guanine/Creatinine [Molar ratio] in Urine;Guanine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +78696-2;Selenium;SCnc;Pt;Bld;Qn;;CHEM;1;Selenium [Moles/volume] in Blood;Selenium Bld-sCnc;;ACTIVE;2.54;2.54 +78697-0;Olea europaea Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Olive IgG Ab [Mass/volume] in Serum;Olive IgG-mCnc;;ACTIVE;2.54;2.73 +78698-8;Liver fibrosis score panel;-;Pt;Ser/Plas;-;Calculated.HepaScore;PANEL.CHEM;1;Liver fibrosis score panel - Serum or Plasma Calculated by HepaScore;Liver fibr score Pnl SerPl HepaScore;;ACTIVE;2.54;2.54 +78699-6;Liver fibrosis score panel;-;Pt;Ser/Plas;-;Calculated.FibroMeter;PANEL.CHEM;1;Liver fibrosis score panel - Serum or Plasma Calculated by FibroMeter;Liver fibr score Pnl SerPl FibroMeter;;ACTIVE;2.54;2.54 +78700-2;Referral note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Referral note;Sports medicine Referral note;;ACTIVE;2.54;2.58 +78701-0;Ulmus crassifolia Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cedar elm IgE Ab [Units/volume] in Serum;Cedar elm IgE Qn;;ACTIVE;2.54;2.73 +78702-8;Multiple drug resistant gram negative organism;Prid;Pt;XXX;Nom;Culture;MICRO;1;Multiple drug resistant gram negative organism [Identifier] in Specimen by Culture;MDR gram neg org Spec Cult;;ACTIVE;2.54;2.69 +78703-6;Diagnostic study note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Diagnostic study note;Sports medicine Diag study note;;ACTIVE;2.54;2.54 +78704-4;Initial evaluation note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Initial evaluation note;Sports medicine Initial eval note;;ACTIVE;2.54;2.54 +78705-1;Progress note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Progress note;Sports medicine Prog note;;ACTIVE;2.54;2.73 +78706-9;Form;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Form;Oncology Form;;ACTIVE;2.54;2.54 +78707-7;Crisis intervention note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Crisis intervention note;Mental health Crisis intervention note;;ACTIVE;2.54;2.54 +78708-5;Daily or end of shift signout note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Daily or end of shift signout note;Daily/end shift signout note;;ACTIVE;2.54;2.54 +7870-9;Echovirus 40 Ab;Titr;Pt;Ser;Qn;;MICRO;1;Echovirus 40 Ab [Titer] in Serum;ECV40 Ab Titr Ser;;ACTIVE;1.0h(2);2.7 +78709-3;Crisis intervention note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Crisis intervention note;Crisis intervention note;;ACTIVE;2.54;2.54 +78710-1;Progress note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Progress note;Cardiology Prog note;;ACTIVE;2.54;2.73 +78711-9;Flowsheet;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Flowsheet;OBGYN Flowsheet;;DISCOURAGED;2.54;2.64 +78712-7;Checklist;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Checklist;Ophthalmol Checklist;;ACTIVE;2.54;2.54 +78713-5;Admission history and physical note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Admission history and physical note;Ophthalmol Admit H&P note;;ACTIVE;2.54;2.58 +78714-3;Surgical operation note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Surgical operation note;Ophthalmol Operative note;;ACTIVE;2.54;2.58 +78715-0;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Preoperative evaluation and management note;OMS Pre-op note;;ACTIVE;2.54;2.54 +78716-8;Counseling note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Counseling note;Nutr+diet Counseling note;;ACTIVE;2.54;2.58 +7871-7;Echovirus 6 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 6 Ab [Units/volume] in Serum;ECV6 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78717-6;Checklist;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Checklist;OBGYN Checklist;;DISCOURAGED;2.54;2.64 +78718-4;Admission history and physical note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Admission history and physical note;OBGYN Admit H&P note;;DISCOURAGED;2.54;2.64 +78719-2;Surgical operation note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Surgical operation note;OBGYN Operative note;;DISCOURAGED;2.54;2.64 +787-2;Erythrocyte mean corpuscular volume;EntVol;Pt;RBC;Qn;Automated count;HEM/BC;1;MCV [Entitic volume] by Automated count;MCV RBC Auto;;ACTIVE;1.0;2.73 +78720-0;Discharge instructions;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Discharge instructions;OBGYN Discharge instruct;;DISCOURAGED;2.54;2.64 +78721-8;Discharge teaching note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Discharge teaching note;OBGYN Discharge teach note;;DISCOURAGED;2.54;2.64 +78722-6;Education note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Education note;OBGYN Educ note;;DISCOURAGED;2.54;2.64 +78723-4;Initial evaluation note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Initial evaluation note;OBGYN Initial eval note;;DISCOURAGED;2.54;2.64 +78724-2;Admission history and physical note;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Admission history and physical note;Peds surgery Admit H&P note;;ACTIVE;2.54;2.58 +7872-5;Echovirus 9 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Echovirus 9 Ab [Units/volume] in Serum;ECV9 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78725-9;Surgical operation note;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Surgical operation note;Peds surgery Operative note;;ACTIVE;2.54;2.58 +78726-7;Consultation note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Consult note;Peds Consult note;;ACTIVE;2.54;2.58 +78727-5;Admission history and physical note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Admission history and physical note;Plastic surgery Admit H&P note;;ACTIVE;2.54;2.58 +78728-3;Initial evaluation note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Initial evaluation note;Resp therapy Initial eval note;;ACTIVE;2.54;2.54 +78729-1;Transfer summary note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Transfer summary note;Surgery Transfer sum note;;ACTIVE;2.54;2.58 +78730-9;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Preoperative evaluation and management note;Cardiothor surg Pre-op note;;ACTIVE;2.54;2.56 +78731-7;Admission history and physical note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Admission history and physical note;Transpl surg Admit H&P note;;ACTIVE;2.54;2.73 +78732-5;Consultation note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Consult note;Trauma Consult note;;ACTIVE;2.54;2.58 +7873-3;Echovirus NOS Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Echovirus NOS Ab [Units/volume] in Serum;Deprecated ECV NOS Ab Ser-aCnc;;DEPRECATED;1.0h(2);2.69 +78733-3;Admission history and physical note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Admission history and physical note;Urology Admit H&P note;;ACTIVE;2.54;2.58 +78734-1;Checklist;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Checklist;Urology Checklist;;ACTIVE;2.54;2.54 +78735-8;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Preoperative evaluation and management note;Urology Pre-op note;;ACTIVE;2.54;2.54 +78736-6;Transfer summary note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Transfer summary note;Urology Transfer sum note;;ACTIVE;2.54;2.58 +78737-4;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Preoperative evaluation and management note;Vascular surgery Pre-op note;;ACTIVE;2.54;2.54 +78738-2;Consultation note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Consult note;Sports medicine Consult note;;ACTIVE;2.54;2.58 +78739-0;Platelet aggregation.ristocetin induced^low dose;ACnc;Pt;Bld;Qn;;COAG;1;Platelet aggregation ristocetin induced [Units/volume] in Blood --Low dose;PA Rist lo dose Bld-aCnc;;ACTIVE;2.54;2.68 +78740-8;Pathologic casts;Naric;Pt;Urine;Qn;Automated count;UA;1;Pathologic casts [#/area] in Urine by Automated count;Path casts #/area Ur Auto;;ACTIVE;2.54;2.54 +7874-1;Ehrlichia canis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia canis Ab [Presence] in Serum;E canis Ab Ser Ql;;ACTIVE;1.0h(2);2.56 +78741-6;Pathologic casts;NCnc;Pt;Urine;Qn;Automated count;UA;1;Pathologic casts [#/volume] in Urine by Automated count;Path casts # Ur Auto;;ACTIVE;2.54;2.54 +78742-4;Yeast;Naric;Pt;Urine;Qn;Automated count;UA;1;Yeast [#/area] in Urine by Automated count;Yeast #/area Ur Auto;;ACTIVE;2.54;2.73 +78743-2;Steroid fractions interpretation;Imp;Pt;Urine;Nar;;CHEM;1;Steroid fractions interpretation in Urine Narrative;Steroid Fract Ur-Imp;;ACTIVE;2.54;2.54 +78744-0;Drug for further processing label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Drug for further processing label;FDA label Drug for further processing;;ACTIVE;2.54;2.54 +78745-7;Recombinant deoxyribonucleic acid construct label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Recombinant deoxyribonucleic acid construct label;FDA label rDNA construct;;ACTIVE;2.54;2.54 +78746-5;Country of birth;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Country of birth [Location];Country of birth;;ACTIVE;2.54;2.66 +78747-3;Peritoneal equilibration test panel;-;Pt;Dial fld prt;-;;PANEL.CHEM;1;Peritoneal equilibration test panel - Peritoneal dialysis fluid;PET Pnl DiafP;;ACTIVE;2.54;2.54 +78748-1;Hemoglobin pattern;Imp;Pt;Bld;Nom;Capillary electrophoresis;HEM/BC;1;Hemoglobin pattern [Interpretation] in Blood by Capillary electrophoresis (CE);Hgb Fract Bld CE-Imp;;ACTIVE;2.54;2.73 +78749-9;Glycolate;MCnc;Pt;Ser/Plas;Qn;GC;CHEM;1;Glycolate [Mass/volume] in Serum or Plasma by Gas chromatography;Glycolate SerPl GC-mCnc;;ACTIVE;2.54;2.54 +78750-7;Hepatitis E virus RNA;LaCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis E virus RNA [log units/volume] (viral load) in Serum or Plasma by NAA with probe detection;HEV RNA SerPl NAA+probe-Log IU;;ACTIVE;2.54;2.73 +78751-5;11-Hydroxy delta-9 tetrahydrocannabinol;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Mass/mass] in Hair;11OH-THC Hair-mCnt;;ACTIVE;2.54;2.54 +78752-3;11-Hydroxy delta-9 tetrahydrocannabinol;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Body fluid by Screen method;11OH-THC Fld Ql Scn;;ACTIVE;2.54;2.58 +78753-1;11-Hydroxy delta-9 tetrahydrocannabinol;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Serum or Plasma by Screen method;11OH-THC SerPl Ql Scn;;ACTIVE;2.54;2.56 +78754-9;11-Hydroxy delta-9 tetrahydrocannabinol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Urine by Screen method;11OH-THC Ur Ql Scn;;ACTIVE;2.54;2.56 +78755-6;1-Hydroxymidazolam;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1-Hydroxymidazolam [Mass/volume] in Blood;1OH-midazolam Bld-mCnc;;ACTIVE;2.54;2.54 +78756-4;2-Oxo-3-Hydroxy-Lysergate diethylamide;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;2-Oxo-3-Hydroxy-Lysergate diethylamide [Presence] in Blood by Screen method;2-oxo-3-OH-LDS Bld Ql Scn;;ACTIVE;2.54;2.56 +78757-2;2-Oxo-3-Hydroxy-Lysergate diethylamide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;2-Oxo-3-Hydroxy-Lysergate diethylamide [Presence] in Urine by Screen method;2-oxo-3-OH-LDS Ur Ql Scn;;ACTIVE;2.54;2.56 +7875-8;Ehrlichia chaffeensis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Ehrlichia chaffeensis IgG Ab [Units/volume] in Serum by Immunoassay;E chaffeensis IgG Ser IA-aCnc;;ACTIVE;1.0h(2);2.69 +78758-0;4-Hydroxymidazolam;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;4-Hydroxymidazolam [Mass/volume] in Urine;4OH-midazolam Ur-mCnc;;ACTIVE;2.54;2.54 +78759-8;6-Monoacetylmorphine;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Blood by Screen method;6MAM Bld Ql Scn;;ACTIVE;2.54;2.56 +78760-6;6-Monoacetylmorphine;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Body fluid by Screen method;6MAM Fld Ql Scn;;ACTIVE;2.54;2.58 +78761-4;7-Aminoclonazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;7-Aminoclonazepam [Mass/mass] in Hair;7Aminoclonazepam Hair-mCnt;;ACTIVE;2.54;2.54 +78762-2;7-Aminoflunitrazepam;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;7-Aminoflunitrazepam [Mass/mass] in Hair;7Aminoflunitrazepam Hair-mCnt;;ACTIVE;2.54;2.54 +78763-0;OPC3373^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;OPC3373 (Metabolite of Ariprazole) [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;OPC3373 adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.58 +78764-8;7-Hydroxyquetiapine^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;7-Hydroxyquetiapine [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;7OH-quetiapine adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.58 +78765-5;oxyMORphone^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;oxyMORphone [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;oxyMORphone adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.58 +7876-6;Ehrlichia chaffeensis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia chaffeensis IgM Ab [Presence] in Serum;E chaffeensis IgM Ser Ql;;ACTIVE;1.0h(2);2.73 +78766-3;fentaNYL^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;fentaNYL [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;fentaNYL adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.58 +78767-1;oxyCODONE^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;oxyCODONE [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;oxyCODONE adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.54 +78768-9;Morphine^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Morphine [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;Morphine adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.58 +78769-7;HYDROcodone^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;HYDROcodone [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;HYDROcodone adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.54 +78770-5;Methadone^^adjusted for lean body mass+urine creatinine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Urine -- adjusted for lean body mass+urine creatinine;Methadone adj bodymass+crea Ur-mCnc;;ACTIVE;2.54;2.58 +78771-3;9-Hydroxyrisperidone;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;9-Hydroxyrisperidone [Mass/mass] in Hair;9OH-risperidone Hair-mCnt;;ACTIVE;2.54;2.54 +78772-1;Abacavir;MCnc;Pt;Amnio fld;Qn;;DRUG/TOX;1;Abacavir [Mass/volume] in Amniotic fluid;Abacavir Amn-mCnc;;ACTIVE;2.54;2.54 +78773-9;Abacavir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Abacavir [Mass/volume] in Serum or Plasma;Abacavir SerPl-mCnc;;ACTIVE;2.54;2.54 +7877-4;Anaplasma phagocytophilum Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Anaplasma phagocytophilum Ab [Presence] in Serum;A phagocytoph Ab Ser Ql;;ACTIVE;1.0h(2);2.56 +78774-7;Acenocoumarol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acenocoumarol [Mass/volume] in Blood;Acenocoumarol Bld-mCnc;;ACTIVE;2.54;2.54 +78775-4;Acenocoumarol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Acenocoumarol [Mass/volume] in Urine;Acenocoumarol Ur-mCnc;;ACTIVE;2.54;2.54 +78776-2;Acepromazine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Acepromazine [Mass/mass] in Hair;Acepromazine Hair-mCnt;;ACTIVE;2.54;2.54 +78777-0;Alfentanil;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Alfentanil [Mass/mass] in Hair;Alfentanil Hair-mCnt;;ACTIVE;2.54;2.54 +78778-8;Alfentanil;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Alfentanil [Presence] in Blood by Screen method;Alfentanil Bld Ql Scn;;ACTIVE;2.54;2.56 +78779-6;Alizapride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Alizapride [Mass/volume] in Blood;Alizapride Bld-mCnc;;ACTIVE;2.54;2.54 +78780-4;Alminoprofen;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Alminoprofen [Mass/volume] in Blood;Alminoprofen Bld-mCnc;;ACTIVE;2.54;2.54 +78781-2;ALPRAZolam cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ALPRAZolam cutoff [Mass/volume] in Urine for Confirmatory method;Alpraz CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +7878-2;Anaplasma phagocytophilum Ab;ACnc;Pt;Ser;Ord;;MICRO;1;Deprecated Anaplasma phagocytophilum Ab [Presence] in Serum;Deprecated A phagocytoph Ab Ser Ql;;DEPRECATED;1.0h(2);2.36 +78782-0;Aluminum;SCnc;Pt;Water;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Water;Aluminum Wat-sCnc;;ACTIVE;2.54;2.54 +78783-8;AM-2201 4-hydroxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;AM-2201 4-hydroxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;AM-2201 4OH-pentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78784-6;Amiodarone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amiodarone [Mass/volume] in Urine;Amiodarone Ur-mCnc;;ACTIVE;2.54;2.54 +78785-3;Amitriptyline;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Amitriptyline [Mass/mass] in Hair;Amitrip Hair-mCnt;;ACTIVE;2.54;2.54 +78786-1;Amitriptyline;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Blood;Amitrip Bld-mCnc;;ACTIVE;2.54;2.54 +78787-9;amLODIPine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;amLODIPine [Mass/volume] in Blood;amLODIPine Bld-mCnc;;ACTIVE;2.54;2.54 +78788-7;amLODIPine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;amLODIPine [Mass/volume] in Urine;amLODIPine Ur-mCnc;;ACTIVE;2.54;2.54 +78789-5;Amoxapine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Amoxapine [Mass/mass] in Hair;Amoxapine Hair-mCnt;;ACTIVE;2.54;2.54 +7879-0;Ehrlichia sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Ehrlichia sp Ab [Presence] in Serum;Ehrlichia Ab Ser Ql;;ACTIVE;1.0h(2);2.56 +78790-3;Amphetamine;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Amphetamine [Presence] in Body fluid by Screen method;Amphet Fld Ql Scn;;ACTIVE;2.54;2.58 +78791-1;Amprenavir^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Amprenavir [Mass/volume] in Serum or Plasma --trough;Deprecated Amprenavir Trough SerPl-mCnc;;DEPRECATED;2.54;2.54 +78792-9;Anakinra;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Anakinra [Mass/volume] in Serum or Plasma;Anakinra SerPl-mCnc;;ACTIVE;2.54;2.54 +78793-7;ARIPiprazole;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;ARIPiprazole [Mass/mass] in Hair;ARIPiprazole Hair-mCnt;;ACTIVE;2.54;2.54 +78794-5;ARIPiprazole;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;ARIPiprazole [Mass/volume] in Blood;ARIPiprazole Bld-mCnc;;ACTIVE;2.54;2.54 +78795-2;Arsenic;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Arsenic [Moles/mass] in Tissue;Arsenic Tiss-sCnt;;ACTIVE;2.54;2.54 +78796-0;Atazanavir;MCnc;Pt;Amnio fld;Qn;;DRUG/TOX;1;Atazanavir [Mass/volume] in Amniotic fluid;Atazanavir Amn-mCnc;;ACTIVE;2.54;2.54 +78797-8;Atazanavir^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Atazanavir [Mass/volume] in Serum or Plasma --trough;Atazanavir Trough SerPl-mCnc;;ACTIVE;2.54;2.54 +78798-6;Atenolol;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Atenolol [Mass/mass] in Hair;Atenolol Hair-mCnt;;ACTIVE;2.54;2.54 +78799-4;Atenolol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Atenolol [Mass/volume] in Blood;Atenolol Bld-mCnc;;ACTIVE;2.54;2.54 +788-0;Erythrocyte distribution width;Ratio;Pt;RBC;Qn;Automated count;HEM/BC;1;Erythrocyte distribution width [Ratio] by Automated count;RDW RBC Auto-Rto;;ACTIVE;1.0;2.73 +78800-0;Atropine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Atropine [Mass/mass] in Hair;Atropine Hair-mCnt;;ACTIVE;2.54;2.58 +78801-8;Atropine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Atropine [Mass/volume] in Blood;Atropine Bld-mCnc;;ACTIVE;2.54;2.54 +78802-6;Baclofen;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Baclofen [Mass/mass] in Hair;Baclofen Hair-mCnt;;ACTIVE;2.54;2.54 +78803-4;Barbital;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Barbital [Mass/mass] in Hair;Barbital Hair-mCnt;;ACTIVE;2.54;2.54 +78804-2;Barbital;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Barbital [Mass/volume] in Blood;Barbital Bld-mCnc;;ACTIVE;2.54;2.54 +78805-9;Barium;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Barium [Moles/mass] in Tissue;Barium Tiss-sCnt;;ACTIVE;2.54;2.54 +78806-7;Alminoprofen;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Alminoprofen [Mass/volume] in Body fluid;Alminoprofen Fld-mCnc;;ACTIVE;2.54;2.58 +78807-5;Barium;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Barium [Moles/volume] in Serum or Plasma;Barium SerPl-sCnc;;ACTIVE;2.54;2.54 +7880-8;Entamoeba histolytica Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Entamoeba histolytica Ab [Units/volume] in Serum;E histolyt Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78808-3;Benzodiazepines;PrThr;Pt;Ser/Plas;Ord;Screen>200 ng/mL;DRUG/TOX;1;Benzodiazepines [Presence] in Serum or Plasma by Screen method >200 ng/mL;Benzodiaz SerPl Ql Scn>200 ng/mL;;ACTIVE;2.54;2.56 +78809-1;Benzylpiperazine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Benzylpiperazine [Mass/mass] in Hair;Benzylpiperazine Hair-mCnt;;ACTIVE;2.54;2.54 +78810-9;Beryllium;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Beryllium [Moles/mass] in Tissue;Beryllium Tiss-sCnt;;ACTIVE;2.54;2.54 +78811-7;Buprenorphine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Buprenorphine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Buprenorphine CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.56 +78812-5;buPROPion cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;buPROPion cutoff [Mass/volume] in Urine for Confirmatory method;buPROPion CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78813-3;Cannabicyclohexanol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cannabicyclohexanol [Mass/volume] in Urine by Confirmatory method;Cannabicyclohexanol Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78814-1;Cannabicyclohexanol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cannabicyclohexanol cutoff [Mass/volume] in Urine for Confirmatory method;Cannabicyclohexanol CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78815-8;Carisoprodol;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Carisoprodol [Mass/volume] in Blood by Confirmatory method;Carisoprodol Bld Cfm-mCnc;;ACTIVE;2.54;2.73 +7881-6;Enterovirus RNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Nose by NAA with probe detection;EV RNA Nose Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +78816-6;Carisoprodol+Meprobamate;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;Carisoprodol+Meprobamate [Presence] in Blood by Confirmatory method;Carisoprodol+Meprob Bld Ql Cfm;;ACTIVE;2.54;2.73 +78817-4;Cathinone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cathinone [Mass/volume] in Urine by Confirmatory method;Cathinone Ur Cfm-mCnc;;ACTIVE;2.54;2.73 +78818-2;Citalopram cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Citalopram cutoff [Mass/volume] in Urine for Confirmatory method;Citalopram CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78819-0;clomiPRAMINE cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;clomiPRAMINE cutoff [Mass/volume] in Urine for Confirmatory method;clomiPRAMINE CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78820-8;Cyclobenzaprine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cyclobenzaprine cutoff [Mass/volume] in Urine for Confirmatory method;Cyclobenzaprine CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78821-6;Desipramine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Desipramine cutoff [Mass/volume] in Urine for Confirmatory method;Desipramine CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78822-4;Doxepin cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Doxepin cutoff [Mass/volume] in Urine for Confirmatory method;Doxepin CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78823-2;DULoxetine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;DULoxetine [Presence] in Urine by Confirmatory method;DULoxetine Ur Ql Cfm;;ACTIVE;2.54;2.73 +7882-4;Epstein Barr virus early Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus early Ab [Presence] in Serum;EBV EA Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +78824-0;DULoxetine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;DULoxetine cutoff [Mass/volume] in Urine for Confirmatory method;DULoxetine CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78825-7;Ecgonine methyl ester;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Ecgonine methyl ester [Mass/mass] in Hair;EME Hair-mCnt;;ACTIVE;2.54;2.54 +78826-5;Ethyl acetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ethyl acetate [Mass/volume] in Urine;Ethyl Acetate Ur-mCnc;;ACTIVE;2.54;2.54 +78827-3;fentaNYL cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;fentaNYL cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;fentaNYL CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.56 +78828-1;fentaNYL;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;fentaNYL [Z-score] in Urine;fentaNYL Z-score Ur;;ACTIVE;2.54;2.58 +78829-9;Gamma hydroxybutyrate;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Gamma hydroxybutyrate [Mass/mass] in Hair;G-OH-Butyr Hair-mCnt;;ACTIVE;2.54;2.54 +78830-7;HYDROcodone;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;HYDROcodone [Z-score] in Urine;HYDROcodone Z-score Ur;;ACTIVE;2.54;2.58 +78831-5;Hydroxybupropion;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Hydroxybupropion [Presence] in Urine by Confirmatory method;OH-bupropion Ur Ql Cfm;;ACTIVE;2.54;2.56 +7883-2;Epstein Barr virus nuclear Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus nuclear IgG Ab [Presence] in Serum;EBV NA IgG Ser Ql;;ACTIVE;1.0h(2);2.73 +78832-3;Hydroxybupropion cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxybupropion cutoff [Mass/volume] in Urine for Confirmatory method;OH-bupropion CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78833-1;Hydroxylurasidone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxylurasidone [Mass/volume] in Urine by Confirmatory method;OH-Lurasidone Ur Cfm-mCnc;;ACTIVE;2.54;2.56 +78834-9;Hydroxylurasidone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxylurasidone cutoff [Mass/volume] in Urine for Confirmatory method;OH-Lurasidone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.56 +78835-6;Imipramine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Imipramine cutoff [Mass/volume] in Urine for Confirmatory method;Imipramine CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78836-4;JWH-018 5-hydroxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-018 5-hydroxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-018 5-hydroxypenty CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78837-2;JWH-018 pentanoate cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-018 pentanoate (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-018 pentanoate CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78838-0;JWH-073 4-hydroxybutyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-073 4-hydroxybutyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-073 4OH-butyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78839-8;JWH-073 butanoate cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-073 butanoate (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-073 butanoate CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +7884-0;Epstein Barr virus nuclear Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Epstein Barr virus nuclear IgM Ab [Presence] in Serum;EBV NA IgM Ser Ql;;ACTIVE;1.0h(2);2.73 +78840-6;JWH-081 5-hydroxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-081 5-hydroxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-081 5OH-pentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78841-4;JWH-122 5-hydroxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-122 5-hydroxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-122 5OH-pentyl Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78842-2;JWH-122 5-hydroxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-122 5-hydroxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-122 5OH-pentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78843-0;JWH-200 4-Hydroxyindole;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-200 4-hydroxyindole (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-200 4OH-indole Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78844-8;JWH-200 4-Hydroxyindole cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-200 4-hydroxyindole (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-200 4OH-indole CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78845-5;JWH-200 6-Hydroxyindole;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-200 6-Hydroxyindole (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-200 6-Hydroxyindole Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78846-3;JWH-200 6-Hydroxyindole cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-200 6-Hydroxyindole (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-200 6-Hydroxyindole CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78847-1;JWH-210 5-carboxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-210 5-carboxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-210 carboxypentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78848-9;JWH-210 5-Hydroxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-210 5-Hydroxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;JWH-210 5-Hydroxypentyl Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78849-7;JWH-210 5-hydroxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-210 5-Hydroxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-210 5-Hydroxypentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78850-5;JWH-250 5-hydroxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;JWH-250 5-hydroxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;JWH-250 5OH-pentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78851-3;M-chlorophenylpiperazine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;M-chlorophenylpiperazine [Mass/mass] in Hair;m-CPP Hair-mCnt;;ACTIVE;2.54;2.54 +78852-1;M-chlorophenylpiperazine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;M-chlorophenylpiperazine [Mass/volume] in Blood;m-CPP Bld-mCnc;;ACTIVE;2.54;2.54 +78853-9;M-chlorophenylpiperazine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;M-chlorophenylpiperazine [Mass/volume] in Body fluid;m-CPP Fld-mCnc;;ACTIVE;2.54;2.58 +78854-7;M-chlorophenylpiperazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;M-chlorophenylpiperazine [Mass/volume] in Serum or Plasma;m-CPP SerPl-mCnc;;ACTIVE;2.54;2.54 +78855-4;M-chlorophenylpiperazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;M-chlorophenylpiperazine [Mass/volume] in Urine;m-CPP Ur-mCnc;;ACTIVE;2.54;2.73 +78856-2;Meprobamate;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Meprobamate [Mass/volume] in Blood by Confirmatory method;Meprobamate Bld Cfm-mCnc;;ACTIVE;2.54;2.73 +7885-7;Epstein Barr virus capsid Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgG Ab [Units/volume] in Serum;EBV VCA IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78857-0;Methadone;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;Methadone [Z-score] in Urine;Methadone Z-score Ur;;ACTIVE;2.54;2.58 +78858-8;Methcathinone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methcathinone [Mass/volume] in Urine by Confirmatory method;Methcathinone Ur Cfm-mCnc;;ACTIVE;2.54;2.73 +78859-6;Mirtazapine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Mirtazapine [Presence] in Urine by Confirmatory method;Mirtazapine Ur Ql Cfm;;ACTIVE;2.54;2.73 +78860-4;Mirtazapine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mirtazapine cutoff [Mass/volume] in Urine for Confirmatory method;Mirtazapine CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78861-2;Morphine;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;Morphine [Z-score] in Urine;Morphine Z-score Ur;;ACTIVE;2.54;2.58 +78862-0;Naloxol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naloxol [Mass/volume] in Urine by Confirmatory method;Naloxol Ur Cfm-mCnc;;ACTIVE;2.54;2.73 +78863-8;Naloxol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naloxol cutoff [Mass/volume] in Urine for Confirmatory method;Naloxol CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78864-6;Naloxone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naloxone cutoff [Mass/volume] in Urine for Confirmatory method;Naloxone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +7886-5;Epstein Barr virus capsid Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Epstein Barr virus capsid IgM Ab [Units/volume] in Serum;EBV VCA IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78865-3;Naltrexol cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naltrexol cutoff [Mass/volume] in Urine for Confirmatory method;Naltrexol CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78866-1;Norbuprenorphine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Norbuprenorphine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Norbuprenorphine CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +78867-9;Norfentanyl cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Norfentanyl cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Norfentanyl CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +78868-7;Norhydrocodone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norhydrocodone cutoff [Mass/volume] in Urine for Confirmatory method;Norhydrocodone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78869-5;O-desmethylvenlafaxine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;O-desmethylvenlafaxine cutoff [Mass/volume] in Urine for Confirmatory method;ODV CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.69 +78870-3;OPC3373;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;OPC3373 (Metabolite of Ariprazole) [Mass/volume] in Urine by Confirmatory method;OPC3373 Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78871-1;OPC3373 cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;OPC3373 (Metabolite of Ariprazole) cutoff [Mass/volume] in Urine for Confirmatory method;OPC3373 CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78872-9;OPC3373;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;OPC3373 (Metabolite of Ariprazole) [Z-score] in Urine;OPC3373 Z-score Ur;;ACTIVE;2.54;2.58 +7887-3;Filaria Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Filaria Ab [Units/volume] in Serum;Filaria Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78873-7;oxyCODONE;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;oxyCODONE [Z-score] in Urine;oxyCODONE Z-score Ur;;ACTIVE;2.54;2.58 +78874-5;oxyMORphone;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;oxyMORphone [Z-score] in Urine;oxyMORphone Z-score Ur;;ACTIVE;2.54;2.58 +78875-2;PARoxetine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;PARoxetine cutoff [Mass/volume] in Urine for Confirmatory method;PARoxetine CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78876-0;Pheniramine;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Pheniramine [Presence] in Urine;Pheniramine Ur Ql;;ACTIVE;2.54;2.56 +78877-8;QUEtiapine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;QUEtiapine [Mass/volume] in Urine by Confirmatory method;QUEtiapine Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78878-6;RCS-4 5-carboxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;RCS-4 5-carboxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;RCS-4 5-carboxypentyl Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78879-4;RCS-4 5-carboxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;RCS-4 5-carboxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;RCS-4 5-carboxypentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78880-2;RCS-4 5-hydroxypentyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;RCS-4 5-hydroxypentyl (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;RCS-4 5OH-pentyl Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +7888-1;Francisella tularensis Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Francisella tularensis Ab [Presence] in Serum;F tular Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +78881-0;RCS-4 5-hydroxypentyl cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;RCS-4 5-hydroxypentyl (synthetic cannabinoid metabolite) cutoff [Mass/volume] in Urine for Confirmatory method;RCS-4 5OH-pentyl CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78882-8;Sertraline cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Sertraline cutoff [Mass/volume] in Urine for Confirmatory method;Sertraline CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78883-6;Triazolam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Triazolam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Triazolam Sal Cfm-mCnc;;ACTIVE;2.54;2.73 +78884-4;Lurasidone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Lurasidone [Mass/volume] in Urine by Confirmatory method;Lurasidone Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78885-1;traZODone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;traZODone cutoff [Mass/volume] in Urine for Confirmatory method;traZODone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78886-9;Venlafaxine cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Venlafaxine cutoff [Mass/volume] in Urine for Confirmatory method;Venlafaxine CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +78887-7;Trans-3-Hydroxycotinine;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Trans-3-Hydroxycotinine [Mass/volume] in Saliva (oral fluid);trans-3-OH-cotinine Sal-mCnc;;ACTIVE;2.54;2.54 +78888-5;Trimeprazine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trimeprazine [Mass/volume] in Urine;Trimeprazine Ur-mCnc;;ACTIVE;2.54;2.54 +78889-3;Tricyclic antidepressants;PrThr;Pt;Urine;Ord;Screen>300 ng/mL;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Urine by Screen method >300 ng/mL;Tricyclics Ur Ql Scn>300 ng/mL;;ACTIVE;2.54;2.56 +78890-1;Barium;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Barium [Moles/volume] in Blood;Barium Bld-sCnc;;ACTIVE;2.54;2.54 +78891-9;Tricyclic antidepressants;PrThr;Pt;Hair;Ord;;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Hair;Tricyclics Hair Ql;;ACTIVE;2.54;2.56 +78892-7;Silver;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Silver [Moles/mass] in Tissue;Silver Tiss-sCnt;;ACTIVE;2.54;2.54 +78893-5;Tricyclic antidepressants;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Gastric fluid;Tricyclics Gast Ql;;ACTIVE;2.54;2.56 +78894-3;Liver fibrosis score;Score;Pt;Ser/Plas;Qn;Calculated.HepaScore;CHEM;1;Liver fibrosis score in Serum or Plasma Calculated by HepaScore;Liver fibr score SerPl Calc HepaScore;;ACTIVE;2.54;2.54 +78895-0;Coronary segment stenosis panel;-;Pt;Coronary arteries;-;Angiogram;PANEL.CARDIAC;2;Coronary angiography panel;Coronary angiography panel;;ACTIVE;2.54;2.73 +78896-8;Number of diseased coronary segments;Find;Pt;Coronary arteries;Nom;Angiogram;CARD.PROC;2;Number of diseased coronary segments on Cardiac angiogram;Num dis coronary segments on Card Angio;;ACTIVE;2.54;2.54 +78897-6;Stenosis degree;LenFr;Pt;Proximal right coronary artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Proximal right coronary artery by Cardiac angiogram;Percent sten of pRCA by Angiogram;;ACTIVE;2.54;2.54 +78898-4;Stenosis degree;LenFr;Pt;Mid right coronary artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Mid right coronary artery by Cardiac angiogram;Percent sten of mRCA by Angiogram;;ACTIVE;2.54;2.54 +7889-9;Francisella tularensis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Francisella tularensis IgG Ab [Presence] in Serum;F tular IgG Ser Ql;;ACTIVE;1.0h(2);2.73 +78899-2;Stenosis degree;LenFr;Pt;Distal right coronary artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Distal right coronary artery by Cardiac angiogram;Percent sten of dRCA by Angiogram;;ACTIVE;2.54;2.54 +78900-8;Stenosis degree;LenFr;Pt;Atrioventricular nodal artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of AV nodal artery by Cardiac angiogram;Percent sten of AV nodal by Angiogram;;ACTIVE;2.54;2.54 +78901-6;Stenosis degree;LenFr;Pt;Posterior descending from right coronary artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Posterior descending branch from right coronary artery by Cardiac angiogram;Percent sten of R-PDA by Angiogram;;ACTIVE;2.54;2.54 +78902-4;Stenosis degree;LenFr;Pt;Left main coronary artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Left main coronary artery by Cardiac angiogram;Percent sten of LM by Angiogram;;ACTIVE;2.54;2.54 +78903-2;Stenosis degree;LenFr;Pt;Proximal left anterior descending artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Proximal left anterior descending artery by Cardiac angiogram;Percent sten of pLAD by Angiogram;;ACTIVE;2.54;2.54 +78904-0;Stenosis degree;LenFr;Pt;Mid left anterior descending artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Mid left anterior descending artery by Cardiac angiogram;Percent sten of mLAD by Angiogram;;ACTIVE;2.54;2.54 +78905-7;Stenosis degree;LenFr;Pt;Distal left anterior descending artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Distal left anterior descending artery by Cardiac angiogram;Percent sten of dLAD by Angiogram;;ACTIVE;2.54;2.54 +78906-5;Stenosis degree;LenFr;Pt;Diagonal artery 1;Qn;Angiogram;CARD.PROC;2;Percent stenosis of First diagonal artery by Cardiac angiogram;Percent sten of D1 by Angiogram;;ACTIVE;2.54;2.54 +7890-7;Francisella tularensis Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Francisella tularensis IgM Ab [Presence] in Serum;F tular IgM Ser Ql;;ACTIVE;1.0h(2);2.73 +78907-3;Stenosis degree;LenFr;Pt;Diagonal artery 2;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Second diagonal artery by Cardiac angiogram;Percent sten of D2 by Angiogram;;ACTIVE;2.54;2.54 +78908-1;Stenosis degree;LenFr;Pt;Proximal left circumflex artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Proximal left circumflex artery by Cardiac angiogram;Percent sten of pCx by Angiogram;;ACTIVE;2.54;2.54 +78909-9;Stenosis degree;LenFr;Pt;Obtuse marginal artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Obtuse marginal artery by Cardiac angiogram;Percent sten of OM by Angiogram;;ACTIVE;2.54;2.54 +78910-7;Stenosis degree;LenFr;Pt;Mid distal left circumflex artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Mid and distal left circumflex artery by Cardiac angiogram;Percent sten of LCx by Angiogram;;ACTIVE;2.54;2.54 +78911-5;Stenosis degree;LenFr;Pt;Posterolateral from left circumflex artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Posterolateral branch from left circumflex artery by Cardiac angiogram;Percent sten of L-PLB by Angiogram;;ACTIVE;2.54;2.54 +78912-3;Stenosis degree;LenFr;Pt;Posterior descending from left circumflex artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Posterior descending branch from left circumflex artery by Cardiac angiogram;Percent sten of L-PDA by Angiogram;;ACTIVE;2.54;2.54 +78913-1;Stenosis degree;LenFr;Pt;Ramus intermedius from left main coronary artery;Qn;Angiogram;CARD.PROC;2;Percent stenosis of Ramus intermedius branch from left main coronary artery by Cardiac angiogram;Percent sten of RI by Angiogram;;ACTIVE;2.54;2.64 +78914-9;Percutaneous coronary intervention panel;-;Pt;Heart;-;Cardiac catheterization;PANEL.CARDIAC;2;Percutaneous coronary intervention panel;PCI Pnl;;ACTIVE;2.54;2.54 +7891-5;Giardia lamblia Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Giardia lamblia IgG Ab [Units/volume] in Serum;G lamblia IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78915-6;FGFR1 gene rearrangements;PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.REARRANGE;1;FGFR1 gene rearrangements [Presence] in Blood or Tissue by FISH;FGFR1 gene rearr Bld/T Ql FISH;;ACTIVE;2.54;2.61 +78916-4;FGFR1 gene rearrangements;Imp;Pt;Bld/Tiss;Nar;FISH;MOLPATH.REARRANGE;1;FGFR1 gene rearrangements [Interpretation] in Blood or Tissue by FISH Narrative;FGFR1 gene rearr Bld/T FISH-Imp;;ACTIVE;2.54;2.61 +78917-2;Cells.FGFR1 gene rearrangements/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.REARRANGE;1;Cells.FGFR1 gene rearrangements/Cells counted in Blood or Tissue by FISH;Cells.FGFR1 rearr/Cells cnt Bld/T FISH;;ACTIVE;2.54;2.61 +78918-0;7-Hydroxyquetiapine;Zscore;Pt;Urine;Qn;;DRUG/TOX;1;7-Hydroxyquetiapine [Z-score] in Urine;7OH-quetiapine Z-score Ur;;ACTIVE;2.54;2.58 +78919-8;Sensory or speech status;Find;Pt;^Patient;Nom;;HL7.CCDA;2;Sensory or speech status;Sens or speech stat;;ACTIVE;2.54;2.56 +78920-6;cycloSPORINE;SCnc;Pt;Bld;Qn;IA;DRUG/TOX;1;cycloSPORINE [Moles/volume] in Blood by Immunoassay;cycloSPORINE Bld IA-sCnc;;ACTIVE;2.54;2.66 +78921-4;Bordetella pertussis & Bordetella parapertussis panel;-;Pt;Nph;-;;PANEL.MICRO;1;Bordetella pertussis and Bordetella parapertussis DNA and culture panel - Nasopharynx;B pert+parapert DNA+cult Pnl Nph;;ACTIVE;2.54;2.73 +78922-2;Respiratory pathogens DNA & RNA panel;-;Pt;Nph;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA panel - Nasopharynx by NAA with probe detection;Resp path DNA+RNA Pnl Nph NAA+probe;;ACTIVE;2.54;2.68 +7892-3;Giardia lamblia Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Giardia lamblia IgM Ab [Units/volume] in Serum;G lamblia IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78923-0;Comorbid condition panel;-;Pt;^Patient;-;;PANEL.H&P;2;Comorbid condition panel;Comorbid cond Pnl;;ACTIVE;2.54;2.54 +78924-8;Hyperuricemia;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Hyperuricemia;Hx of Hyperuricemia;;ACTIVE;2.54;2.56 +78925-5;Cerebrovascular accident;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of cerebrovascular accident;CVA hx;;ACTIVE;2.54;2.54 +78926-3;Myocardial infarction in past 24H;Find;1D;^Patient;Ord;;H&P.HX;2;Myocardial infarction in past 24 hours;MI in past 24H;;ACTIVE;2.54;2.54 +78927-1;Procedure urgency;Type;Pt;^Patient;Ord;;CLIN;2;Procedure urgency;Proc urgency;;ACTIVE;2.54;2.54 +78928-9;Teaching physician name;Pn;Pt;Provider;Nom;;CLIN;2;Teaching physician name;Teaching phys name;;ACTIVE;2.54;2.56 +78929-7;Peripheral vessels fluoroscopic angiogram performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Peripheral vessels fluoroscopic angiogram performed;Periph ves fluoro angio;;ACTIVE;2.54;2.54 +78930-5;Right heart catheterization performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Right heart catheterization performed;Right heart cath performed;;ACTIVE;2.54;2.54 +7893-1;Gliadin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Gliadin Ab [Units/volume] in Serum;Gliadin Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78931-3;Spasm load test performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Spasm load test performed;Spasm load test performed;;ACTIVE;2.54;2.54 +78932-1;Optical coherence tomography performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Optical coherence tomography performed;OCT performed;;ACTIVE;2.54;2.54 +78933-9;Assisted circulation procedures performed panel;Find;Pt;^Patient;-;;PANEL.CARDIAC;2;Assisted circulation procedures performed panel;Assist circ proc perf Pnl;;ACTIVE;2.54;2.54 +78934-7;Temporary pacing performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Temporary pacing performed;Temp pacing perf;;ACTIVE;2.54;2.54 +78935-4;Percutaneous cardiopulmonary support performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Percutaneous cardiopulmonary support performed;PCPS performed;;ACTIVE;2.54;2.56 +78936-2;Cardiac procedure complication;PrThr;Pt;^Patient;Ord;;CARD.PROC;2;Cardiac procedure complication [Presence];Cardiac proc comp;;ACTIVE;2.54;2.56 +78937-0;Cardiac procedure complication;Type;Pt;^Patient;Nom;;CARD.PROC;2;Cardiac procedure complication Type;Cardiac proc comp type;;ACTIVE;2.54;2.54 +78938-8;Cardiac procedure complication;Find;Pt;^Patient;Nar;;CARD.PROC;2;Cardiac procedure complication Narrative;Cardiac proc comp nar;;ACTIVE;2.54;2.56 +78939-6;Percutaneous coronary intervention device panel;-;Pt;^Patient;-;;PANEL.CARDIAC;2;Percutaneous coronary intervention device panel;PCI device Pnl;;ACTIVE;2.54;2.58 +78940-4;Coronary artery disease risk factor panel;-;Pt;^Patient;-;;PANEL.H&P;2;Coronary artery disease risk factor panel;CAD risk factor Pnl;;ACTIVE;2.54;2.63 +78941-2;Cardiovascular disease history panel;-;Pt;^Patient;-;;PANEL.H&P;2;Cardiovascular disease history panel;CVD hx Pnl;;ACTIVE;2.54;2.63 +78942-0;Catheterization & angiography device panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Catheterization and angiography device panel;Cath+angio device Pnl;;ACTIVE;2.54;2.58 +78943-8;Cardiac procedure complications panel;-;Pt;^Patient;-;;PANEL.CARDIAC;2;Cardiac procedure complications panel;Card proc complications Pnl;;ACTIVE;2.54;2.63 +78944-6;Procedure start time;TmStp;Pt;^Patient;Qn;;CARD.PROC;2;Procedure start time;Proc start time;;ACTIVE;2.54;2.73 +78945-3;Guiding catheter size;Circ;Pt;Catheterization device;Qn;;DEVICES;2;Catheterization device Guiding catheter size;Cath device Guid cath size;;ACTIVE;2.54;2.54 +78946-1;Coronary stent diameter;Len;Pt;Angioplasty device;Qn;;DEVICES;2;Coronary stent diameter;Cor stent diam;;ACTIVE;2.54;2.54 +78947-9;Coronary stent length;Len;Pt;Angioplasty device;Qn;;DEVICES;2;Coronary stent length;Cor stent len;;ACTIVE;2.54;2.54 +78948-7;Brinkman index;Score;Pt;^Patient;Qn;;CARDIO-PULM;2;Brinkman index;BI Score;;ACTIVE;2.54;2.54 +7894-9;Haemophilus influenzae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Haemophilus influenzae Ab [Units/volume] in Serum;Haem influ Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78949-5;Catheterization & angiography procedures performed panel;-;Pt;^Patient;-;;PANEL.CARDIAC;2;Catheterization and angiography procedures performed panel;Cath+angio proc perf Pnl;;ACTIVE;2.54;2.63 +78950-3;Segmental wall motion panel;-;Pt;Heart.ventricle.left;-;Angiogram;PANEL.CARDIAC;2;Left ventricle Segmental wall motion panel by Angiogram;LV SWM Pnl Angiogram;;ACTIVE;2.54;2.54 +78951-1;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal anterior;Ord;Angiogram;CARD.PROC;2;Left ventricular basal anterior Segmental wall motion by Cardiac angiogram;LV.basal ant SWM by Angiogram;;ACTIVE;2.54;2.54 +78952-9;Segmental wall motion;Find;Pt;Heart.ventricle.left.lateral anterior;Ord;Angiogram;CARD.PROC;2;Left ventricular lateral anterior Segmental wall motion by Cardiac angiogram;LV.lat ant SWM by Angiogram;;ACTIVE;2.54;2.54 +78953-7;Segmental wall motion;Find;Pt;Heart.ventricle.left.apex;Ord;Angiogram;CARD.PROC;2;Left ventricular apex Segmental wall motion by Cardiac angiogram;LV apex SWM by Angiogram;;ACTIVE;2.54;2.54 +78954-5;Segmental wall motion;Find;Pt;Heart.ventricle.left.inferior;Ord;Angiogram;CARD.PROC;2;Left ventricular inferior Segmental wall motion by Cardiac angiogram;LV inf SWM by Angiogram;;ACTIVE;2.54;2.54 +78955-2;Segmental wall motion;Find;Pt;Heart.ventricle.left.basal posterior;Ord;Angiogram;CARD.PROC;2;Left ventricular basal posterior Segmental wall motion by Cardiac angiogram;LV.basal post SWM by Angiogram;;ACTIVE;2.54;2.54 +7895-6;Hantavirus hantaan Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus hantaan IgG Ab [Units/volume] in Serum;HTNV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78956-0;Segmental wall motion;Find;Pt;Heart.ventricle.septum;Ord;Angiogram;CARD.PROC;2;Ventricular septal Segmental wall motion by Cardiac angiogram;VS SWM by Angiogram;;ACTIVE;2.54;2.54 +78957-8;Segmental wall motion;Find;Pt;Heart.ventricle.left.lateral posterior;Ord;Angiogram;CARD.PROC;2;Left ventricular lateral posterior Segmental wall motion by Cardiac angiogram;LV.lat post SWM by Angiogram;;ACTIVE;2.54;2.54 +78958-6;Cathepsin A;CCnt;Pt;WBC;Qn;;CHEM;1;Cathepsin A [Enzymatic activity/mass] in Leukocytes;Cathepsin A WBC-cCnt;;ACTIVE;2.54;2.54 +78959-4;Hyocholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hyocholate [Moles/volume] in Serum or Plasma;Hyocholate SerPl-sCnc;;ACTIVE;2.54;2.54 +78960-2;Aldosterone & renin concentration panel;-;Pt;Plas;Qn;;PANEL.CHEM;1;Aldosterone and renin concentration panel - Plasma;Aldosterone + ARC + ARR Pnl Plas;;ACTIVE;2.54;2.54 +78961-0;IgG clearance/Albumin clearance;Ratio;Pt;Urine+Ser/Plas;Qn;;CHEM;1;IgG clearance/Albumin clearance [Ratio] in Urine and Serum or Plasma;IgG/Alb clear Ur+SerPl-Rto;;ACTIVE;2.54;2.54 +78962-8;IgG clearance/Transferrin clearance;Ratio;Pt;Urine+Ser/Plas;Qn;;CHEM;1;IgG clearance/Transferrin clearance [Ratio] in Urine and Serum or Plasma;IgG/Transf clear Ur+SerPl-Rto;;ACTIVE;2.54;2.54 +78963-6;Mannose-6-phosphate isomerase;CCnt;Pt;WBC;Qn;;CHEM;1;Mannose-6-phosphate isomerase [Enzymatic activity/mass] in Leukocytes;M6PI WBC-cCnt;;ACTIVE;2.54;2.54 +7896-4;Hantavirus hantaan Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus hantaan IgM Ab [Units/volume] in Serum;HTNV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78964-4;N-acetylaspartylglutamate;SCnc;Pt;CSF;Qn;;CHEM;1;N-acetylaspartylglutamate [Moles/volume] in Cerebral spinal fluid;NAAG CSF-sCnc;;ACTIVE;2.54;2.54 +78965-1;Neurofilament medium chain Ab;MCnc;Pt;CSF;Qn;;CHEM;1;Neurofilament medium chain Ab [Mass/volume] in Cerebral spinal fluid;NfM Ab CSF-mCnc;;ACTIVE;2.54;2.54 +78966-9;S-adenosylmethionine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;S-adenosylmethionine [Moles/volume] in Serum or Plasma;SAMe SerPl-sCnc;;ACTIVE;2.54;2.54 +78967-7;Sedoheptulose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sedoheptulose/Creatinine [Molar ratio] in Urine;Sedoheptulose/Creat Ur-sRto;;ACTIVE;2.54;2.54 +78968-5;Benperidol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benperidol [Mass/volume] in Serum or Plasma;Benperidol SerPl-mCnc;;ACTIVE;2.54;2.54 +78969-3;Neurofilament heavy chain Ab;MCnc;Pt;CSF;Qn;;CHEM;1;Neurofilament heavy chain Ab [Mass/volume] in Cerebral spinal fluid;NfH Ab CSF-mCnc;;ACTIVE;2.54;2.54 +78970-1;Phosphomannomutase 1;CCnt;Pt;WBC;Qn;;CHEM;1;Phosphomannomutase 1 [Enzymatic activity/mass] in Leukocytes;PMM1 WBC-cCnt;;ACTIVE;2.54;2.54 +78971-9;Phosphomannomutase 1;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Phosphomannomutase 1 [Enzymatic activity/mass] in Fibroblast;PMM1 Fib-cCnt;;ACTIVE;2.54;2.54 +7897-2;Hantavirus puumala Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus puumala IgG Ab [Units/volume] in Serum;PUUV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +78972-7;CYP2C8 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP2C8 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP2C8 allele Geno Bld/T;;ACTIVE;2.54;2.73 +78973-5;Multisection for leg measurement^WO contrast;Find;Pt;Lower extremity.bilateral;Doc;CT.scanogram;RAD;2;CT scanogram Lower extremity - bilateral for leg measurement WO contrast;CT.scanogram LE-Bl leg meas WO contr;;ACTIVE;2.54;2.61 +78974-3;Intravenous contrast given;ID;Pt;^Patient;Nom;;CARD.PROC;2;IV contrast given [Identifier];IV contrast Gvn;;ACTIVE;2.54;2.54 +78975-0;Intravenous contrast given;Type;Pt;^Patient;Nom;;CARD.PROC;2;Type of Contrast given;Contrast given Type;;ACTIVE;2.54;2.54 +78976-8;Hospital admission ischemic heart disease dx;Imp;Pt;^Patient;Nom;;CARDIO-PULM;2;Hospital admission ischemic heart disease diagnosis;Hosp admit ischemic heart dis Dx;;ACTIVE;2.54;2.54 +78977-6;Cardiologist name;Pn;Pt;Provider;Nom;;CLIN;2;Cardiologist name Provider;Card name Provider;;ACTIVE;2.54;2.56 +78978-4;Guiding catheter product name;ID;Pt;Catheterization device;Nom;;DEVICES;2;Catheterization device Guiding catheter product name;Cath device Guid cath prod name;;ACTIVE;2.54;2.54 +78979-2;Guide wire product name;ID;Pt;Catheterization device;Nom;;DEVICES;2;Catheterization device Guide wire product name;Cath device Guide wire prod name;;ACTIVE;2.54;2.54 +789-8;Erythrocytes;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Blood by Automated count;RBC # Bld Auto;;ACTIVE;1.0;2.73 +7898-0;Hantavirus puumala Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hantavirus puumala IgM Ab [Units/volume] in Serum;PUUV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +78980-0;Angioplasty balloon product name;ID;Pt;Angioplasty device;Nom;;DEVICES;2;Angioplasty balloon product name;Angio balloon prod name;;ACTIVE;2.54;2.54 +78981-8;Coronary stent product name;ID;Pt;Angioplasty device;Nom;;DEVICES;2;Coronary stent product name;Cor stent prod name;;ACTIVE;2.54;2.54 +78982-6;D-3-phosphoglycerate dehydrogenase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;D-3-phosphoglycerate dehydrogenase [Enzymatic activity/mass] in Fibroblast;3-PGDH Fib-cCnt;;ACTIVE;2.54;2.54 +78983-4;4-Hydroxy-3-Methoxyphenyllactate;SCnc;Pt;CSF;Qn;;CHEM;1;4-Hydroxy-3-Methoxyphenyllactate [Moles/volume] in Cerebral spinal fluid;4OH3methoxyphenyllactate CSF-sCnc;;ACTIVE;2.54;2.54 +78984-2;Macroprolactin/Prolactin;AFr;Pt;Ser/Plas;Qn;;CHEM;1;Macroprolactin/Prolactin in Serum or Plasma;Macroprolactin/Prolactin % SerPl;;ACTIVE;2.54;2.54 +78985-9;Prolactin.dimeric;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin.dimeric [Units/volume] in Serum or Plasma;Prolactin.dim SerPl-aCnc;;ACTIVE;2.54;2.68 +78986-7;Prolactin.dimeric/Prolactin;AFr;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin.dimeric/Prolactin in Serum or Plasma;Prolactin.dim/Prolactin % SerPl;;ACTIVE;2.54;2.56 +78987-5;Provasopressin.C-terminal;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Provasopressin.C-terminal [Moles/volume] in Serum or Plasma by Immunoassay;CT-proAVP SerPl IA-sCnc;;ACTIVE;2.54;2.56 +78988-3;Cortisol;SCnt;Pt;Hair;Qn;;CHEM;1;Cortisol [Moles/mass] in Hair;Cortis Hair-sCnt;;ACTIVE;2.54;2.54 +78989-1;Cryoglobulin;MCnc;Pt;Ser;Qn;;SERO;1;Cryoglobulin [Mass/volume] in Serum;Cryoglob Ser-mCnc;;ACTIVE;2.54;2.73 +78990-9;Flavin adenine dinucleotide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Flavin adenine dinucleotide [Moles/volume] in Serum or Plasma;FAD SerPl-sCnc;;ACTIVE;2.54;2.54 +78991-7;Flavin adenine dinucleotide;SCnc;Pt;Bld;Qn;;CHEM;1;Flavin adenine dinucleotide [Moles/volume] in Blood;FAD Bld-sCnc;;ACTIVE;2.54;2.54 +78992-5;Melatonin;MCnc;Pt;Saliva;Qn;;CHEM;1;Melatonin [Mass/volume] in Saliva (oral fluid);Melatonin Sal-mCnc;;ACTIVE;2.54;2.54 +78993-3;Prolactin isoforms panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Prolactin isoforms panel - Serum or Plasma;Prolactin isoforms Pnl SerPl;;ACTIVE;2.54;2.54 +78994-1;Prolactin.monomeric;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin monomeric [Units/volume] in Serum or Plasma;Prolactin.monomeric SerPl-aCnc;;ACTIVE;2.54;2.73 +78995-8;Prolactin.monomeric/Prolactin;AFr;Pt;Ser/Plas;Qn;;CHEM;1;Prolactin monomeric/Prolactin in Serum or Plasma;Prolactin.monomeric/Prolactin % SerPl;;ACTIVE;2.54;2.56 +78997-4;Can you walk 25 feet on a level surface (with or without support);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Can you walk 25 feet on a level surface (with or without support) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7899-8;Hantavirus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Hantavirus RNA [Presence] in Serum by NAA with probe detection;Hantavirus RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +78998-2;Are you able to go OUTSIDE the home, for example to shop or visit a doctor's office;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to go OUTSIDE the home, for example to shop or visit a doctor's office [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +78999-0;Are you able to dial a number on a phone with large buttons;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dial a number on a phone with large buttons [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79000-6;Are you able to clean up after a meal;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to clean up after a meal [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79001-4;How much difficulty do you currently have opening previously opened jars;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have opening previously opened jars [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79002-2;Are you able to dial a number on the keypad of a cell phone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dial a number on the keypad of a cell phone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79003-0;Are you able to roll onto your stomach while lying in bed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to roll onto your stomach while lying in bed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7900-4;Helicobacter pylori Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Helicobacter pylori Ab [Units/volume] in Serum;H pylori Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79004-8;Are you able to pull up covers while lying in bed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pull up covers while lying in bed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79005-5;Are you able to hike a couple of miles on uneven surfaces, including hills;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to hike a couple of miles on uneven surfaces, including hills [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79006-3;Are you able to walk more than a mile;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk more than a mile [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79007-1;Are you able to open and squeeze a new tube of toothpaste;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to open and squeeze a new tube of toothpaste [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79008-9;How much difficulty do you currently have pulling up and fastening your pants after a bowel movement;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have pulling up and fastening your pants after a bowel movement [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79009-7;Are you able to fasten and unfasten a seatbelt;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to fasten and unfasten a seatbelt [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79010-5;Are you able to do chores such as vacuuming carpet or mopping floors;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do chores such as vacuuming carpet or mopping floors [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79011-3;Are you able to go up and down stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to go up and down stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7901-2;Helicobacter pylori Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Helicobacter pylori IgA Ab [Units/volume] in Serum;H pylori IgA Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79012-1;Are you able to lift small objects (such as a can of soup) above your shoulder;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift small objects (such as a can of soup) above your shoulder [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79013-9;Are you able to carry a bag of groceries for a short distance;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a bag of groceries for a short distance [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79014-7;Able to put on socks;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Able to put on socks [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.73 +79015-4;Are you able to pull a sweater or t-shirt over your head;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pull a sweater or t-shirt over your head [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79016-2;How much difficulty do you currently have cleaning yourself after a bowel movement;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have cleaning yourself after a bowel movement [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79017-0;Are you able to do an exercise of your choice for 20 minutes several times a week;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do an exercise of your choice for 20 minutes several times a week [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79018-8;Are you able to do strenuous tasks around the house like cleaning the bathroom or scrubbing floors;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do strenuous tasks around the house like cleaning the bathroom or scrubbing floors [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79019-6;Are you able to stand on a moving escalator;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand on a moving escalator [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7902-0;Helicobacter pylori Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Helicobacter pylori IgG Ab [Units/volume] in Serum;H pylori IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79020-4;Are you able to pour liquid from a container into a cup;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pour liquid from a container into a cup [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79021-2;Are you able to turn pages in a book;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to turn pages in a book [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79022-0;Are you able to prepare simple meals for yourself or for others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to prepare simple meals for yourself or for others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79023-8;Are you able to reach above your head;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to reach above your head [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79024-6;Are you able to do housework like vacuuming or sweeping floors;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do housework like vacuuming or sweeping floors [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79025-3;Are you able to do yard work like raking leaves or sweeping the driveway;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do yard work like raking leaves or sweeping the driveway [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79026-1;Are you able to take a letter out of an envelope;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to take a letter out of an envelope [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79027-9;Are you able to push the buttons on a television remote control;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to push the buttons on a television remote control [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79028-7;Are you able to get items in and out of a wallet;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get items in and out of a wallet [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79029-5;Are you able to turn a key to unlock a door;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to turn a key to unlock a door [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79030-3;Are you able to take a shower;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to take a shower [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79031-1;Are you able to turn sink faucets on and off;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to turn sink faucets on and off [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79032-9;Are you able to type a few sentences on a computer keyboard;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to type a few sentences on a computer keyboard [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79033-7;Are you able to move about the house;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to move about the house [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79034-5;Are you able to use a regular computer mouse;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to use a regular computer mouse [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79035-2;Are you able to move wet clothes from the washer to the dryer;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to move wet clothes from the washer to the dryer [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79036-0;Are you able to move around on a slippery surface outdoors;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to move around on a slippery surface outdoors [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79037-8;Are you able to move about in a dark room or hallway without falling;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to move about in a dark room or hallway without falling [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7903-8;Helicobacter pylori Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Helicobacter pylori IgM Ab [Units/volume] in Serum;H pylori IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79038-6;Are you able to do vigorous activities, such as playing sports;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do vigorous activities, such as playing sports [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79039-4;Are you able to carry a shopping bag;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a shopping bag [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79040-2;Are you able to dress yourself;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dress yourself [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79041-0;Are you able to wash and dry your feet;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to wash and dry your feet [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79042-8;Are you able to wash dishes and utensils by hand;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to wash dishes and utensils by hand [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79043-6;How much difficulty do you currently have sitting down on a low, soft couch;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have sitting down on a low, soft couch [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79044-4;How much difficulty do you currently have standing up from a low, soft couch;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have standing up from a low, soft couch [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79045-1;Are you able to stand upright briefly without support;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand upright briefly without support [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7904-6;Hepatitis A virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Hepatitis A virus RNA [Presence] in Serum by NAA with probe detection;HAV RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +79046-9;Are you able to transfer from a bed to a chair or a wheelchair;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to transfer from a bed to a chair or a wheelchair [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79047-7;If you need to, are you physically able to rush for a short distance, such as to cross a street;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;If you need to, are you physically able to rush for a short distance, such as to cross a street [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79048-5;Are you able to move from the street to the sidewalk without a curb cut;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to move from the street to the sidewalk without a curb cut [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79049-3;Are you able to use a moving escalator safely;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to use a moving escalator safely [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79050-1;Are you able to fasten buttons on a shirt or blouse;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to fasten buttons on a shirt or blouse [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79051-9;Are you able to hold a card or letter in order to read it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to hold a card or letter in order to read it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79052-7;Are you able to cut your toenails;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to cut your toenails [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7905-3;Hepatitis B virus surface Ag;PrThr;Pt;Ser/Plas;Ord;Neut;MICRO;1;Hepatitis B virus surface Ag [Presence] in Serum or Plasma by Neutralization test;HBV surface Ag SerPl Ql Nt;;ACTIVE;1.0h(2);2.73 +79053-5;Are you able to fold clean laundry;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to fold clean laundry [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79054-3;Are you able to get into a vehicle;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to get into a vehicle [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79055-0;How much difficulty do you currently have getting into and out of a truck, bus, shuttle van or sport utility vehicle;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have getting into and out of a truck, bus, shuttle van or sport utility vehicle [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79056-8;How much difficulty do you currently have applying spreads to breads using a knife;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have applying spreads to breads using a knife [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79057-6;How much difficulty do you currently have playing cards or Bingo or other light recreational activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have playing cards or Bingo or other light recreational activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79058-4;How much difficulty do you currently have removing wrappings from small objects;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much difficulty do you currently have removing wrappings from small objects [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79059-2;Are you able to exercise regularly;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to exercise regularly [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +790-6;Erythrocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Blood by Manual count;RBC # Bld Manual;;ACTIVE;1.0;2.42 +79060-0;Are you able to receive a call on a cell phone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to receive a call on a cell phone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +7906-1;Hepatitis D virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Hepatitis D virus RNA [Presence] in Serum by NAA with probe detection;HDV RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +79061-8;Are you able to open a tight or new jar;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to open a tight or new jar [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.65 +79062-6;PROMIS item bank - physical function w mobility aids - version 1.0;-;Pt;^Patient;Ord;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - physical function w mobility aids - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.54 +79063-4;PROMIS short form - physical function w mobility aids - version 1.0;-;Pt;^Patient;Ord;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function w mobility aids - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.54 +79064-2;PROMIS short form - physical function w mobility aids - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function w mobility aids - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.54;2.54 +79065-9;Multisection 3D post processing^WO contrast;Find;Pt;Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen and Pelvis 3D post processing WO contrast;CT Abd+Pelvis p 3D proc WO contr;;ACTIVE;2.54;2.61 +79066-7;Multisection 3D post processing^WO contrast;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen 3D post processing WO contrast;CT Abd p 3D proc WO contr;;ACTIVE;2.54;2.61 +79067-5;Multisection^WO contrast;Find;Pt;Chest>Airway;Doc;CT;RAD;2;CT Airway WO contrast;CT Airway WO contr;;ACTIVE;2.54;2.61 +79068-3;Multisection for screening^W contrast IV;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest for screening W contrast IV;CT Chest Screening W contr IV;;ACTIVE;2.54;2.61 +79069-1;Multisection for screening^WO contrast IV+W air contrast PR;Find;Pt;Abdomen+Pelvis>Colon+Rectum;Doc;CT;RAD;2;CT Colon and Rectum for screening WO contrast IV and W air contrast PR;CT Colon+Rec Screen WO contr IV+W air PR;;ACTIVE;2.54;2.61 +79070-9;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis>Colon+Rectum;Doc;CT;RAD;2;Deprecated Colon and Rectum CT W contrast IV;Deprecated;;DEPRECATED;2.54;2.58 +79071-7;Multisection^WO contrast IV+W air contrast PR;Find;Pt;Abdomen+Pelvis>Colon+Rectum;Doc;CT;RAD;2;CT Colon and Rectum WO contrast IV and W air contrast PR;CT Colon+Rect WO contr IV+W air contr PR;;ACTIVE;2.54;2.61 +79072-5;Guidance for radiation treatment;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for radiation treatment of Unspecified body region;CT Guided RT;;ACTIVE;2.54;2.66 +79073-3;Multisection^W contrast IV;Find;Pt;Chest>Heart+Coronary arteries;Doc;CT.angio;RAD;2;CTA Heart and Coronary arteries W contrast IV;CTA Hrt+CA W contr IV;;ACTIVE;2.54;2.61 +79074-1;Multisection 3D post processing^WO & W contrast IV;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;CT;RAD;2;CT Kidney and Ureter and Urinary bladder 3D post processing WO and W contrast IV;CT Kid+Uret+Blad p 3D proc WO+W contr IV;;ACTIVE;2.54;2.61 +79075-8;Multisection by reconstruction^W contrast IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis by reconstruction W contrast IV;CT Pelvis by reconstr W contr IV;;ACTIVE;2.54;2.61 +79076-6;Multisection by reconstruction^WO contrast;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis by reconstruction WO contrast;CT Pelvis by reconstr WO contr;;ACTIVE;2.54;2.61 +79077-4;Multisection for pulmonary embolus^W contrast IV;Find;Pt;Chest>Pulmonary arteries;Doc;CT.angio;RAD;2;CTA Pulmonary arteries for pulmonary embolus W contrast IV;CTA PA for PE W contr IV;;ACTIVE;2.54;2.61 +79078-2;Multisection by reconstruction^W contrast IV;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine by reconstruction W contrast IV;CT C-spine by reconstr W contr IV;;ACTIVE;2.54;2.61 +7907-9;Herpes simplex virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus Ab [Units/volume] in Serum;HSV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79079-0;Multisection by reconstruction^WO contrast;Find;Pt;Neck>Spine.cervical;Doc;CT;RAD;2;CT Cervical spine by reconstruction WO contrast;CT C-spine by reconstr WO contr;;ACTIVE;2.54;2.61 +79080-8;Multisection by reconstruction^W contrast IV;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine by reconstruction W contrast IV;CT L-spine by reconstr W contr IV;;ACTIVE;2.54;2.61 +79081-6;Multisection by reconstruction^WO contrast;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine by reconstruction WO contrast;CT L-spine by reconstr WO contr;;ACTIVE;2.54;2.61 +79082-4;Multisection by reconstruction^W contrast IV;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine by reconstruction W contrast IV;CT T-spine by reconstr W contr IV;;ACTIVE;2.54;2.61 +79083-2;Multisection by reconstruction^W contrast IV;Find;Pt;Head>Temporal bone;Doc;CT;RAD;2;CT Temporal bone by reconstruction W contrast IV;CT Temporal bone by reconstr W contr IV;;ACTIVE;2.54;2.61 +79084-0;Multisection by reconstruction^WO contrast;Find;Pt;Head>Temporal bone;Doc;CT;RAD;2;CT Temporal bone by reconstruction WO contrast;CT Temporal bone by reconstr WO contr;;ACTIVE;2.54;2.61 +79085-7;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Biliary ducts;Doc;CT;RAD;2;CT Biliary ducts WO and W contrast IV;CT BDs WO+W contr IV;;ACTIVE;2.54;2.61 +79086-5;Multisection for screening^WO contrast;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest for screening WO contrast;CT Chest Screening WO contr;;ACTIVE;2.54;2.61 +7908-7;Herpes simplex virus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 Ab [Units/volume] in Serum;HSV1 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79087-3;Multisection for calcium score^WO contrast;Find;Pt;Chest>Heart+Coronary arteries;Doc;CT;RAD;2;CT Heart and Coronary arteries for calcium scoring WO contrast;CT Hrt+CA for Calcium Score WO contr;;ACTIVE;2.54;2.61 +79088-1;Multisection for congenital disease^W contrast IV;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart for congenital disease W contrast IV;CT Hrt for congenital disease W contr IV;;ACTIVE;2.54;2.61 +79089-9;Multisection^W contrast IV;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart W contrast IV;CT Hrt W contr IV;;ACTIVE;2.54;2.61 +79090-7;Multisection^WO contrast;Find;Pt;Abdomen>Spine.lumbar;Doc;CT.densitometry;RAD;2;CT densitometry Lumbar spine WO contrast;CT.Dens L-spine WO contr;;ACTIVE;2.54;2.61 +79091-5;Multisection by reconstruction^WO contrast;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine by reconstruction WO contrast;CT T-spine by reconstr WO contr;;ACTIVE;2.54;2.61 +79092-3;Multisection^WO contrast;Find;Pt;Chest>Spine.thoracic;Doc;CT.densitometry;RAD;2;CT densitometry Thoracic spine WO contrast;CT.Dens T-spine WO contr;;ACTIVE;2.54;2.61 +79093-1;Multisection 3D post processing;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region 3D post processing;CT p 3D proc;;ACTIVE;2.54;2.64 +79094-9;Multisection^W contrast intra bladder;Find;Pt;Pelvis>Urinary bladder;Doc;CT;RAD;2;CT Urinary bladder W contrast intra bladder;CT Bladder W contr IUB;;ACTIVE;2.54;2.61 +7909-5;Herpes simplex virus 1 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 IgG Ab [Units/volume] in Serum;HSV1 IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79095-6;Multisection;Find;Pt;Head>Teeth;Doc;CT;RAD;2;CT Teeth;CT Teeth;;ACTIVE;2.54;2.61 +79096-4;Multisection 3D post processing^WO contrast;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest 3D post processing WO contrast;CT Chest p 3D proc WO contr;;ACTIVE;2.54;2.61 +79097-2;Multisection 3D post processing^WO contrast;Find;Pt;Chest+Abdomen;Doc;CT;RAD;2;CT Chest and Abdomen 3D post processing WO contrast;CT Chest+Abd p 3D proc WO contr;;ACTIVE;2.54;2.61 +79098-0;Multisection 3D post processing^WO contrast;Find;Pt;Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Chest and Abdomen and Pelvis 3D post processing WO contrast;CT Chest+Abd+Pelvis p 3D proc WO contr;;ACTIVE;2.54;2.61 +79099-8;Multisection 3D post processing^WO contrast;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis 3D post processing WO contrast;CT Pelvis p 3D proc WO contr;;ACTIVE;2.54;2.61 +79100-4;Multisection^WO contrast;Find;Pt;Spine;Doc;CT.densitometry;RAD;2;Deprecated Spine CT densitometry WO contrast;Deprecated Spine CT.Dens WO contr;;DEPRECATED;2.54;2.58 +79101-2;Multisection for screening^W air contrast PR;Find;Pt;Abdomen+Pelvis>Colon+Rectum;Doc;CT;RAD;2;CT Colon and Rectum for screening W air contrast PR;CT Colon+Rect Screening W Air contr PR;;ACTIVE;2.54;2.61 +79102-0;Heart transplant acute cellular rejection risk;Score;Pt;Bld MC;Qn;Calculated.AlloMap;MOLPATH;1;Heart transplant acute cellular rejection risk [Score] in Mononuclear cells Calculated by AlloMap;Heart tx acute reject Score MC AlloMap;;ACTIVE;2.54;2.73 +7910-3;Herpes simplex virus 1 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 1 IgM Ab [Units/volume] in Serum;HSV1 IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79103-8;Multisection^W contrast IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Abdomen W contrast IV;CT Abd W contr IV;;ACTIVE;2.54;2.73 +79104-6;Recall;-;Pt;^Patient;-;GPCOG;PANEL.SURVEY.GPCOG;4;Recall [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79105-3;Can provide correct date;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can provide correct date [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79106-1;Can correctly draw all the numbers to indicate the hours of a clock;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can correctly draw all the numbers to indicate the hours of a clock [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79107-9;Can correctly draw hands to show 10M past eleven o'clock;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can correctly draw hands to show 10M past eleven o'clock [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79108-7;Can report something that happened in the news recently;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can report something that happened in the news recently [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79109-5;Can recall John;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can recall John [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79110-3;Can recall Brown;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can recall Brown [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +7911-1;Herpes simplex virus 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 Ab [Units/volume] in Serum;HSV2 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79111-1;Can recall 42;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can recall 42 [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79112-9;Can recall West;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can recall West [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79113-7;Can recall Kensington;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Can recall Kensington [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79114-5;Total score - Patient examination;Score;Pt;^Patient;Qn;GPCOG;SURVEY.GPCOG;4;Total score - Patient examination [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79115-2;General Practitioner Assessment of Cognition;-;Pt;^Patient;-;GPCOG;PANEL.SURVEY.GPCOG;4;General Practitioner Assessment of Cognition [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79116-0;Informant interview panel;-;Pt;^Patient;-;GPCOG;PANEL.SURVEY.GPCOG;4;Informant interview panel [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.63 +79117-8;Patient examination panel;-;Pt;^Patient;-;GPCOG;PANEL.SURVEY.GPCOG;4;Patient examination panel [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.63 +79118-6;Compared to a few Y ago, does the patient have more trouble remembering things that have happened recently than she or he used to;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Compared to a few years ago, does the patient have more trouble remembering things that have happened recently than she or he used to [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.58 +79119-4;Compared to a few Y ago, does he or she have more trouble recalling conversations a few days later;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Compared to a few years ago, does he or she have more trouble recalling conversations a few days later [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.58 +79120-2;Compared to a few Y ago, when speaking, does the patient have more difficulty in finding the right word or tend to use the wrong words more often;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Compared to a few years ago, when speaking, does the patient have more difficulty in finding the right word or tend to use the wrong words more often [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.58 +79121-0;Compared to a few Y ago, is the patient less able to manage money and financial affairs (e.g. paying bills, budgeting);Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Compared to a few years ago, is the patient less able to manage money and financial affairs (e.g. paying bills, budgeting) [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.58 +79122-8;Compared to a few Y ago, is the patient less able to manage his or her medication independently;Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Compared to a few years ago, is the patient less able to manage his or her medication independently [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.58 +79123-6;Compared to a few Y ago, does the patient need more assistance with transport (either private or public);Find;Pt;^Patient;Ord;GPCOG;SURVEY.GPCOG;4;Compared to a few years ago, does the patient need more assistance with transport (either private or public) [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.58 +79124-4;Total score - Informant interview;Score;Pt;^Patient;Qn;GPCOG;SURVEY.GPCOG;4;Total score - Informant interview [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.58 +79125-1;Hawkinsin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hawkinsin [Moles/volume] in Serum or Plasma;Hawkinsin SerPl-sCnc;;ACTIVE;2.54;2.54 +79126-9;Uroporphyrin 1 isomer;MRat;24H;Urine;Qn;;CHEM;1;Uroporphyrin 1 isomer [Mass/time] in 24 hour Urine;Uropor1 24h Ur-mRate;;ACTIVE;2.54;2.73 +79127-7;Uroporphyrin 1 isomer/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Uroporphyrin 1 isomer/Creatinine [Mass Ratio] in Urine;Uropor1/Creat Ur;;ACTIVE;2.54;2.73 +79128-5;Uroporphyrin 3 isomer;MRat;24H;Urine;Qn;;CHEM;1;Uroporphyrin 3 isomer [Mass/time] in 24 hour Urine;Uropor3 24h Ur-mRate;;ACTIVE;2.54;2.73 +7912-9;Herpes simplex virus 2 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 IgG Ab [Units/volume] in Serum;HSV2 IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79129-3;Uroporphyrin 3 isomer/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Uroporphyrin 3 isomer/Creatinine [Mass Ratio] in Urine;Uropor3/Creat Ur;;ACTIVE;2.54;2.73 +79130-1;Platelet aggregation.ristocetin induced^500 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --500 ug/mL;PA Rist 500 ug/mL PRP;;ACTIVE;2.54;2.54 +79131-9;1-Hydroxymidazolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;1-Hydroxymidazolam [Mass/volume] in Body fluid;1OH-midazolam Fld-mCnc;;ACTIVE;2.54;2.58 +79132-7;4-Hydroxymidazolam;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;4-Hydroxymidazolam [Mass/volume] in Body fluid;4OH-midazolam Fld-mCnc;;ACTIVE;2.54;2.58 +79133-5;9-Hydroxyrisperidone;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;9-Hydroxyrisperidone [Mass/volume] in Body fluid;9OH-risperidone Fld-mCnc;;ACTIVE;2.54;2.58 +79134-3;Abacavir;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Abacavir [Mass/volume] in Cerebral spinal fluid;Abacavir CSF-mCnc;;ACTIVE;2.54;2.54 +79135-0;Acebutolol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acebutolol [Mass/volume] in Body fluid;Acebutolol Fld-mCnc;;ACTIVE;2.54;2.58 +79136-8;Acepromazine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acepromazine [Mass/volume] in Body fluid;Acepromazine Fld-mCnc;;ACTIVE;2.54;2.58 +7913-7;Herpes simplex virus 2 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus 2 IgM Ab [Units/volume] in Serum;HSV2 IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79137-6;Benzylpiperazine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Benzylpiperazine [Mass/volume] in Body fluid;Benzylpiperazine Fld-mCnc;;ACTIVE;2.54;2.58 +79138-4;Buprenorphine;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;Buprenorphine [Presence] in Blood by Confirmatory method;Buprenorphine Bld Ql Cfm;;ACTIVE;2.54;2.73 +79139-2;Buprenorphine;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Buprenorphine [Presence] in Blood by Screen method;Buprenorphine Bld Ql Scn;;ACTIVE;2.54;2.73 +791-4;Erythrocytes;NCnc;Pt;CSF;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Cerebral spinal fluid by Automated count;RBC # CSF Auto;;ACTIVE;1.0;2.73 +79140-0;Carisoprodol+Meprobamate;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Carisoprodol+Meprobamate [Presence] in Blood by Screen method;Carisoprodol+Meprob Bld Ql Scn;;ACTIVE;2.54;2.73 +79141-8;Cathinone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Cathinone [Presence] in Urine by Screen method;Cathinone Ur Ql Scn;;ACTIVE;2.54;2.73 +79142-6;Gamma hydroxybutyrate;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Gamma hydroxybutyrate [Mass/volume] in Body fluid;G-OH-Butyr Fld-mCnc;;ACTIVE;2.54;2.58 +79143-4;Mercury;SCnt;Pt;Nail;Qn;;DRUG/TOX;1;Mercury [Moles/mass] in Nail;Mercury Nail-sCnt;;ACTIVE;2.54;2.54 +79144-2;Methcathinone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methcathinone [Presence] in Urine by Screen method;Methcathinone Ur Ql Scn;;ACTIVE;2.54;2.73 +7914-5;Heterophile Ab after beef cell absorption;Titr;Pt;Ser;Qn;;MICRO;1;Heterophile Ab after beef cell absorption [Titer] in Serum;Heteroph Ab Beef Abs Titr Ser;;ACTIVE;1.0h(2);2.73 +79145-9;Tapentadol;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;Tapentadol [Presence] in Blood by Confirmatory method;Tapentadol Bld Ql Cfm;;ACTIVE;2.54;2.56 +79146-7;Tapentadol;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Tapentadol [Presence] in Blood by Screen method;Tapentadol Bld Ql Scn;;ACTIVE;2.54;2.56 +79147-5;traMADol;PrThr;Pt;Bld;Ord;Confirm;DRUG/TOX;1;traMADol [Presence] in Blood by Confirmatory method;traMADol Bld Ql Cfm;;ACTIVE;2.54;2.73 +79148-3;traMADol;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;traMADol [Presence] in Blood by Screen method;traMADol Bld Ql Scn;;ACTIVE;2.54;2.73 +79149-1;Trimeprazine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Trimeprazine [Mass/volume] in Body fluid;Trimeprazine Fld-mCnc;;ACTIVE;2.54;2.58 +79150-9;Clock drawing panel;-;Pt;^Patient;-;GPCOG;PANEL.SURVEY.GPCOG;4;Clock drawing panel [GPCOG];;Copyright © 2002 University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care Used with permission.;ACTIVE;2.54;2.54 +79151-7;Known allergies to food or environmental agents;Find;Pt;^Patient;Nom;;H&P.HX;2;Known allergies to food or environmental agents;Allergies to food environment;;ACTIVE;2.54;2.58 +7915-2;Heterophile Ab after guinea pig cell absorption;Titr;Pt;Ser;Qn;;MICRO;1;Heterophile Ab after guinea pig cell absorption [Titer] in Serum;Heteroph Ab GPK Abs Titr Ser;;ACTIVE;1.0h(2);2.73 +79152-5;Acenocoumarol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Acenocoumarol [Mass/volume] in Body fluid;Acenocoumarol Fld-mCnc;;ACTIVE;2.54;2.58 +79153-3;Alfentanil;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Alfentanil [Mass/volume] in Body fluid;Alfentanil Fld-mCnc;;ACTIVE;2.54;2.58 +79154-1;Alizapride;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Alizapride [Mass/volume] in Body fluid;Alizapride Fld-mCnc;;ACTIVE;2.54;2.58 +79155-8;HIV 1 tropism;Prid;Pt;Bld;Nom;;MICRO;1;Deprecated HIV 1 tropism [Identifier] in Blood;Deprecated HIV1 tropism Bld;;DEPRECATED;2.54;2.56 +79156-6;Cold agglutinin^1H post incubation;Titr;Pt;Ser;Qn;37 deg C incubation;SERO;1;Cold agglutinin [Titer] in Serum by 37 degree C incubation --1 hour post incubation;CA 1h p Inc Titr Ser Inc;;ACTIVE;2.54;2.73 +79157-4;Cold agglutinin^1H post incubation;Titr;Pt;Ser;Qn;22 deg C incubation;SERO;1;Cold agglutinin [Titer] in Serum by 22 degree C incubation --1 hour post incubation;CA 1h p Inc Titr Ser 22 deg C inc;;ACTIVE;2.54;2.54 +79158-2;Cold agglutinin^1H post incubation;Titr;Pt;Ser;Qn;4 deg C incubation;SERO;1;Cold agglutinin [Titer] in Serum by 4 deg C incubation --1 hour post incubation;CA 1h p Inc Titr Ser 4 deg C inc;;ACTIVE;2.54;2.73 +79159-0;Cold agglutinin^24H post incubation;Titr;Pt;Ser;Qn;4 deg C incubation;SERO;1;Cold agglutinin [Titer] in Serum by 4 deg C incubation --24 hour post incubation;CA 24H p inc Titr Ser 4 deg C inc;;ACTIVE;2.54;2.54 +7916-0;Histoplasma capsulatum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Histoplasma capsulatum Ab [Units/volume] in Serum;H capsul Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79160-8;Cold agglutinin panel;-;Pt;Ser;-;;PANEL.SERO;1;Cold agglutinin panel - Serum;Cold agg pnl Ser;;ACTIVE;2.54;2.54 +79161-6;Nortriptyline & E-10-hydroxynortriptyline & Z-10-hydroxynortriptyline panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Nortriptyline and E-10-hydroxynortriptyline and Z-10-hydroxynortriptyline panel - Serum or Plasma;Nortriptyline and metabs Pnl SerPl;;ACTIVE;2.54;2.54 +79162-4;Chlordiazepoxide & Norchlordiazepoxide panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;chlordiazePOXIDE and Norchlordiazepoxide panel - Serum or Plasma;chlordiazePOXIDE and Nor Pnl SerPl;;ACTIVE;2.54;2.54 +79163-2;Z-10-Hydroxynortriptyline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Z-10-Hydroxynortriptyline [Mass/volume] in Serum or Plasma;Z-10-OH-NT SerPl-mCnc;;ACTIVE;2.54;2.54 +79164-0;CES1 gene.c.428G>A;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;CES1 gene c.428G>A [Presence] in Blood or Tissue by Molecular genetics method;CES1 c.428G>A Bld/T Ql;;ACTIVE;2.54;2.61 +79165-7;OXcarbazepine trough & 10-hydroxycarbazepine panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;OXcarbazepine trough and 10-hydroxycarbazepine panel - Serum or Plasma;OXC Tgh + 10OH-Carbzp Pnl SerPl;;ACTIVE;2.54;2.54 +79166-5;Prunus persica native (nPru p) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peach natural (nPru p) 3 IgE Ab [Units/volume] in Serum;Peach (nPru p) 3 IgE Qn;;ACTIVE;2.54;2.68 +79167-3;Apis mellifera recombinant (rApi m) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee recombinant (rApi m) 2 IgE Ab [Units/volume] in Serum;Hyaluronidase (rApi m) 2 IgE Qn;;ACTIVE;2.54;2.68 +79168-1;Prunus avium recombinant (rPru av) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cherry recombinant (rPru av) 4 IgE Ab [Units/volume] in Serum;Cherry (rPru av) 4 IgE Qn;;ACTIVE;2.54;2.68 +79169-9;Prunus avium recombinant (rPru av) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cherry recombinant (rPru av) 3 IgE Ab [Units/volume] in Serum;Cherry (rPru av) 3 IgE Qn;;ACTIVE;2.54;2.68 +79170-7;Prunus avium recombinant (rPru av) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cherry recombinant (rPru av) 1 IgE Ab [Units/volume] in Serum;Cherry (rPru av) 1 IgE Qn;;ACTIVE;2.54;2.68 +79171-5;Malus domestica recombinant (rMal d) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apple recombinant (rMal d) 4 IgE Ab [Units/volume] in Serum;Apple (rMal d) 4 IgE Qn;;ACTIVE;2.54;2.68 +79172-3;Somatotropin^2.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post XXX challenge;GH 2.5h p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79173-1;Somatotropin^2H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --2 hours post XXX challenge;GH 2h p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79174-9;Somatotropin^1.5H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post XXX challenge;GH 1.5h p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79175-6;Somatotropin^1H post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --1 hour post XXX challenge;GH 1h p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79176-4;Somatotropin^30M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --30 minutes post XXX challenge;GH 30M p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79177-2;Clostridioides difficile glutamate dehydrogenase & toxins A+B;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Clostridioides difficile glutamate dehydrogenase and toxins A+B [Presence] in Stool by Rapid immunoassay;C diff GDH + toxins A+B Stl Ql IA.rapid;;ACTIVE;2.54;2.73 +7917-8;HIV 1 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 Ab [Presence] in Serum;HIV1 Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +79178-0;4-Hydroxycyclohexylacetate/creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxycyclohexylacetate/Creatinine [Molar ratio] in Urine;4OH-Cyclohexylacetate/Creat Ur-sRto;;ACTIVE;2.54;2.73 +79179-8;Somatotropin^75M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --75 minutes post XXX challenge;GH 75M p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79180-6;Somatotropin^45M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --45 minutes post XXX challenge;GH 45M p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79181-4;Somatotropin^15M post XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes post XXX challenge;GH 15M p chal SerPl-aCnc;;ACTIVE;2.54;2.54 +79182-2;RNA polymerase III Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;RNA polymerase III IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;RNAp III IgG SerPl IA-aCnc;;ACTIVE;2.54;2.73 +79183-0;First name;Pn;Pt;^Guardian or legally authorized representative;Nom;;MISC;1;First name of Guardian or legally authorized representative;First name Guardian;;ACTIVE;2.54;2.73 +79184-8;Last name;Pn;Pt;^Guardian or legally authorized representative;Nom;;MISC;1;Last name of Guardian or legally authorized representative;Last name Guardian;;ACTIVE;2.54;2.73 +7918-6;HIV 1+2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1+2 Ab [Presence] in Serum;HIV1+2 Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +79186-3;Cells.CD3+CD4+CD8+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cells.CD3+CD4+CD8+ (Double positive)/100 cells in Blood;CD3+CD4+CD8+ NFr Bld;;ACTIVE;2.54;2.73 +79187-1;Cells.CD3+CD4+CD8+;NCnc;Pt;Bld;Qn;;CELLMARK;1;Cells.CD3+CD4+CD8+ (Double positive) [#/volume] in Blood;CD3+CD4+CD8+ # Bld;;ACTIVE;2.54;2.73 +79188-9;Platelet aggregation.adenosine diphosphate induced^10 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --10 umol/L;PA ADP 10 umol/L PRP;;ACTIVE;2.54;2.54 +79189-7;Hepatitis C virus core Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis C virus core Ag [Presence] in Serum or Plasma by Immunoassay;HCV core Ag SerPl Ql IA;;ACTIVE;2.54;2.56 +79190-5;Zika virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Specimen by NAA with probe detection;ZIKV RNA Spec Ql NAA+probe;;ACTIVE;2.54;2.73 +79191-3;Patient demographics panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Patient demographics panel;Patient demographics Pnl;;ACTIVE;2.54;2.54 +79192-1;Pregnancy information;Find;Pt;^Mother;Nar;;H&P.HX;2;Maternal pregnancy information Narrative;Maternal pregnancy info;;ACTIVE;2.54;2.66 +79193-9;Glucose^15M post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 minutes post dose arginine+insulin;Glucose 15M p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +7919-4;HIV 2 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 2 Ab [Presence] in Serum;HIV 2 Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +79194-7;Glucose^30M post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose arginine+insulin;Glucose 30M p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79195-4;Glucose^45M post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose arginine+insulin;Glucose 45M p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79196-2;Glucose^1H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post dose arginine+insulin;Glucose 1h p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79197-0;Somatotropin^2H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose arginine+insulin;GH 2h p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79198-8;Somatotropin^2.25H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2.25 hours post dose arginine+insulin;GH 2.25h p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79199-6;Somatotropin^15M post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --15 minutes post dose arginine+insulin;GH 15M p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79200-2;Somatotropin^2.5H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --2.5 hours post dose arginine+insulin;GH 2.5h p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79201-0;Somatotropin^30M post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose arginine+insulin;GH 30M p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +7920-2;Influenza virus A Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Ab [Units/volume] in Serum;FLUAV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79202-8;Somatotropin^45M post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --45 minutes post dose arginine+insulin;GH 45M p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79203-6;Somatotropin^1H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose arginine+insulin;GH 1h p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79204-4;Somatotropin^1.25H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.25 hours post dose arginine+insulin;GH 1.25h p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79205-1;Somatotropin^1.5H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose arginine+insulin;GH 1.5h p Arg+Ins SerPl-mCnc;;ACTIVE;2.54;2.54 +79206-9;"inv(2)(p21;p23)(EML4,ALK) fusion transcript";PrThr;Pt;Bld/Tiss;Ord;FISH;MOLPATH.INV;1;"inv(2)(p21;p23)(EML4,ALK) fusion transcript [Presence] in Blood or Tissue by FISH";inv(2)(EML4,ALK) Bld/T Ql FISH;;ACTIVE;2.54;2.61 +79207-7;BRCA1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BRCA1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;BRCA1 gene Fam Mut Anl Bld/T;;ACTIVE;2.54;2.65 +79208-5;BRCA2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BRCA2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;BRCA2 gene Fam Mut Anl Bld/T;;ACTIVE;2.54;2.65 +79209-3;"t(2;3)(q13;p25)(PAX8,PPARG) fusion transcript";PrThr;Pt;Tiss;Ord;Molgen;MOLPATH.TRNLOC;1;"t(2;3)(q13;p25)(PAX8,PPARG) fusion transcript [Presence] in Tissue by Molecular genetics method";"t(2;3)(PAX8,PPARG) Tiss Ql";;ACTIVE;2.54;2.56 +7921-0;Influenza virus A Bangkok Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Bangkok Ab [Units/volume] in Serum;FLUAV Bang Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79210-1;FLT3 gene internal tandem duplication;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;FLT3 gene internal tandem duplication [Presence] in Blood or Tissue by Molecular genetics method;FLT3 ITD Dp Bld/T Ql;;ACTIVE;2.54;2.73 +79211-9;Fetal chromosome X & Y aneuploidy risk;Imp;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH;1;Fetal Chromosome X and Y aneuploidy risk [interpretation] in Plasma cell-free DNA Qualitative by Sequencing;Fet X + Y aneup risk Plas.cfDNA Seq-Imp;;ACTIVE;2.54;2.66 +79212-7;Fetal microdeletions risk;Imp;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH;1;Fetal Microdeletions risk [interpretation] in Plasma cell-free DNA Qualitative by Sequencing;Fet Microdel risk Plas.cfDNA Seq-Imp;;ACTIVE;2.54;2.66 +79213-5;Education program assigned to patient;Type;Pt;^Patient;Nom;;CLIN;2;Type of education program assigned to patient;Educ program assigned to Pt;;ACTIVE;2.54;2.54 +79214-3;Resource identifier;URI;Pt;Education program;Nom;;CLIN;2;Education program [URI];Education program URI;;ACTIVE;2.54;2.56 +79215-0;Education program online access code;ID;Pt;^Patient;Nom;;CLIN;2;Education program online access code;Educ prog online access code;;ACTIVE;2.54;2.54 +79216-8;Date education program assigned;Date;Pt;^Patient;Qn;;CLIN;2;Date education program assigned to Patient;Date educ prog assigned;;ACTIVE;2.54;2.54 +79217-6;Date education program started;Date;Pt;^Patient;Qn;;CLIN;2;Date education program started by Patient;Date educ prog started;;ACTIVE;2.54;2.54 +79218-4;Date education program completed;Date;Pt;^Patient;Qn;;CLIN;2;Date education program completed by Patient;Date ed prog completed;;ACTIVE;2.54;2.58 +79219-2;Date education program expires;Date;Pt;^Patient;Qn;;CLIN;2;Date education program expires for Patient;Date educ prog expires;;ACTIVE;2.54;2.54 +792-2;Erythrocytes;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Cerebral spinal fluid by Manual count;RBC # CSF Manual;;ACTIVE;1.0;2.73 +79220-0;Steroid fractions interpretation;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Steroid fractions interpretation in Serum or Plasma Narrative;Steroid Fract SerPl-Imp;;ACTIVE;2.54;2.54 +79221-8;Steroid fractions panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Steroid fractions panel - Serum or Plasma;Steroid Fract Pnl SerPl;;ACTIVE;2.54;2.7 +79222-6;Benzodiazepines;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Benzodiazepines [Presence] in Body fluid by Screen method;Benzodiaz Fld Ql Scn;;ACTIVE;2.54;2.56 +79223-4;Atenolol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Atenolol [Mass/volume] in Body fluid;Atenolol Fld-mCnc;;ACTIVE;2.54;2.54 +79224-2;Baclofen;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Baclofen [Mass/volume] in Body fluid;Baclofen Fld-mCnc;;ACTIVE;2.54;2.54 +79225-9;Barbital;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Barbital [Mass/volume] in Body fluid;Barbital Fld-mCnc;;ACTIVE;2.54;2.54 +79226-7;ARIPiprazole;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;ARIPiprazole [Mass/volume] in Body fluid;ARIPiprazole Fld-mCnc;;ACTIVE;2.54;2.54 +79227-5;Amobarbital;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Amobarbital [Mass/volume] in Body fluid;Amobarbital Fld-mCnc;;ACTIVE;2.54;2.54 +7922-8;Influenza virus A England Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A England Ab [Units/volume] in Serum;FLUAV Eng Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79228-3;amLODIPine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;amLODIPine [Mass/volume] in Body fluid;amLODIPine Fld-mCnc;;ACTIVE;2.54;2.54 +79229-1;Amitriptyline;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in Body fluid;Amitrip Fld-mCnc;;ACTIVE;2.54;2.54 +79230-9;Amiodarone;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Amiodarone [Mass/mass] in Hair;Amiodarone Hair-mCnt;;ACTIVE;2.54;2.54 +79231-7;Amoxapine;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Amoxapine [Mass/volume] in Body fluid;Amoxapine Fld-mCnc;;ACTIVE;2.54;2.54 +79232-5;Naphyrone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naphyrone [Mass/volume] in Urine by Confirmatory method;Naphyrone Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79233-3;Naphyrone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naphyrone cutoff [Mass/volume] in Urine for Confirmatory method;Naphyrone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79234-1;Butylone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butylone [Mass/volume] in Urine by Confirmatory method;bk-MBDB Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79235-8;Butylone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butylone cutoff [Mass/volume] in Urine for Confirmatory method;bk-MBDB CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +7923-6;Influenza virus A Hong Kong Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Hong Kong Ab [Units/volume] in Serum;FLUAV HK Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79236-6;Methcathinone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methcathinone cutoff [Mass/volume] in Urine for Confirmatory method;Methcathinone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79237-4;Mephedrone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Mephedrone cutoff [Mass/volume] in Urine for Confirmatory method;Mephedrone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79238-2;Methylenedioxypyrovalerone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylenedioxypyrovalerone cutoff [Mass/volume] in Urine for Confirmatory method;MDPV CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79239-0;Ethyl glucuronide cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Ethyl glucuronide cutoff [Mass/volume] in Urine for Screen method;Ethyl glucuronide CtO Ur Scn-mCnc;;ACTIVE;2.54;2.56 +79240-8;Tapentadol cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Tapentadol cutoff [Mass/volume] in Urine for Screen method;Tapentadol CtO Ur Scn-mCnc;;ACTIVE;2.54;2.54 +79241-6;Methedrone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methedrone cutoff [Mass/volume] in Urine for Confirmatory method;Methedrone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79242-4;Methylone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methylone cutoff [Mass/volume] in Urine for Confirmatory method;Methylone CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79243-2;Ethylone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethylone [Mass/volume] in Urine by Confirmatory method;bk-MDEA Ur Cfm-mCnc;;ACTIVE;2.54;2.73 +7924-4;Influenza virus A Leningrad Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Leningrad Ab [Units/volume] in Serum;FLUAV Lenin Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79244-0;Ethylone cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ethylone cutoff [Mass/volume] in Urine for Confirmatory method;bk-MDEA CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79245-7;Triazolam cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Triazolam cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Triazolam CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79246-5;Methedrone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methedrone [Mass/volume] in Urine by Confirmatory method;Methedrone Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79247-3;Methylenedioxymethamphetamine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;MDMA CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79248-1;Methylenedioxyethylamphetamine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;MDEA CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79249-9;Methadone cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methadone cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Methadone CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79250-7;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;EDDP CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +7925-1;Influenza virus A Mississippi Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Mississippi Ab [Units/volume] in Serum;FLUAV Miss Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79251-5;diazePAM cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;diazePAM cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;diazePAM CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79252-3;Nordiazepam cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Nordiazepam cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Nordiazepam CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79253-1;Oxazepam cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Oxazepam cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Oxazepam CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79254-9;LORazepam cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;LORazepam cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;LORazepam CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79255-6;oxyCODONE cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;oxyCODONE cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;oxyCODONE CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79256-4;Carisoprodol+Meprobamate cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Carisoprodol+Meprobamate cutoff [Mass/volume] in Urine for Screen method;Carisoprodol+Meprob CtO Ur Scn-mCnc;;ACTIVE;2.54;2.54 +79257-2;Methylenedioxyamphetamine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;MDA CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79258-0;Meprobamate cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Meprobamate cutoff [Mass/volume] in Urine for Confirmatory method;Meprobamate CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79259-8;fentaNYL cutoff;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;fentaNYL cutoff [Mass/volume] in Urine for Confirmatory method;fentaNYL CtO Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79260-6;fentaNYL cutoff;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;fentaNYL cutoff [Mass/volume] in Urine for Screen method;fentaNYL CtO Ur Scn-mCnc;;ACTIVE;2.54;2.54 +79261-4;HYDROcodone cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;HYDROcodone cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;HYDROcodone CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79262-2;Methamphetamine cutoff;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methamphetamine cutoff [Mass/volume] in Saliva (oral fluid) for Confirmatory method;Methamphet CtO Sal Cfm-mCnc;;ACTIVE;2.54;2.54 +79263-0;Creatinine^overnight dwell;SCnc;Pt;Dial fld prt;Qn;;CHAL;1;Creatinine [Moles/volume] in Peritoneal dialysis fluid --overnight dwell;Creat Ovrngt Dwell DiafP-sCnc;;ACTIVE;2.54;2.56 +79264-8;Glucose^overnight dwell;SCnc;Pt;Dial fld prt;Qn;;CHAL;1;Glucose [Moles/volume] in Peritoneal dialysis fluid --overnight dwell;Glucose Ovrngt Dwell DiafP-sCnc;;ACTIVE;2.54;2.56 +79265-5;Urea nitrogen^overnight dwell;SCnc;Pt;Dial fld prt;Qn;;CHAL;1;Urea nitrogen [Moles/volume] in Peritoneal dialysis fluid --overnight dwell;Urea nit Ovrngt Dwell DiafP-sCnc;;ACTIVE;2.54;2.56 +79266-3;Lead;MCnt;Pt;Dentin;Qn;;DRUG/TOX;1;Lead [Mass/mass] in Dentin;Lead Dentin-mCnt;;ACTIVE;2.54;2.54 +79267-1;Procedure note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine procedure note;Sports medicine Procedure note;;ACTIVE;2.58;2.58 +79268-9;3-Hydroxytrimethyl-L-lysine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine [Moles/volume] in Serum or Plasma;3OH-trimethyl-L-lysine SerPl-sCnc;;ACTIVE;2.54;2.54 +7926-9;Influenza virus A Phillipines Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Phillipines Ab [Units/volume] in Serum;FLUAV Phill Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79269-7;3-Hydroxytrimethyl-L-lysine;SCnc;Pt;CSF;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine [Moles/volume] in Cerebral spinal fluid;3OH-trimethyl-L-lysine CSF-sCnc;;ACTIVE;2.54;2.54 +79270-5;3-Hydroxytrimethyl-L-lysine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine [Moles/volume] in DBS;3OH-trimethyl-L-lysine DBS-sCnc;;ACTIVE;2.54;2.61 +79271-3;3-Hydroxytrimethyl-L-lysine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine/Creatinine [Molar ratio] in Urine;3OH-trimethyl-L-lysine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79272-1;3-Hydroxytrimethyl-L-lysine/Trimethyllysine;SRto;Pt;CSF;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine/Trimethyllysine [Molar ratio] in Cerebral spinal fluid;3OH-trimethyl-L-lysine/TML CSF-sRto;;ACTIVE;2.54;2.54 +79273-9;3-Hydroxytrimethyl-L-lysine/Trimethyllysine;SRto;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine/Trimethyllysine [Molar ratio] in DBS;3OH-trimethyl-L-lysine/TML DBS-sRto;;ACTIVE;2.54;2.61 +79274-7;3-Hydroxytrimethyl-L-lysine/Trimethyllysine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine/Trimethyllysine [Molar ratio] in Serum or Plasma;3OH-trimethyl-L-lysine/TML SerPl-sRto;;ACTIVE;2.54;2.54 +79275-4;3-Hydroxytrimethyl-L-lysine/Trimethyllysine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxytrimethyl-L-lysine/Trimethyllysine [Molar ratio] in Urine;3OH-trimethyl-L-lysine/TML Ur-sRto;;ACTIVE;2.54;2.54 +79276-2;7,8-Dihydrobiopterin;SCnc;Pt;CSF;Qn;;CHEM;1;7,8-Dihydrobiopterin [Moles/volume] in Cerebral spinal fluid;7,8-BH2 CSF-sCnc;;ACTIVE;2.54;2.54 +7927-7;Influenza virus A Port Chalmers Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Port Chalmers Ab [Units/volume] in Serum;FLUAV Pt Chal Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79277-0;7-lathosterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-lathosterol [Moles/volume] in Serum or Plasma;7-lathosterol SerPl-sCnc;;ACTIVE;2.54;2.54 +79278-8;8-lathosterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;8-lathosterol [Moles/volume] in Serum or Plasma;8-lathosterol SerPl-sCnc;;ACTIVE;2.54;2.54 +79279-6;Alpha-aminoadipic semialdehyde;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-aminoadipic semialdehyde [Moles/volume] in Serum or Plasma;Alpha-AASA SerPl-sCnc;;ACTIVE;2.54;2.54 +79280-4;Alpha-aminoadipic semialdehyde;SCnc;Pt;CSF;Qn;;CHEM;1;Alpha-aminoadipic semialdehyde [Moles/volume] in Cerebral spinal fluid;Alpha-AASA CSF-sCnc;;ACTIVE;2.54;2.54 +79281-2;Arabinose/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Arabinose/Creatinine [Molar ratio] in Urine;Arabinose/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79282-0;Biopterin/Biopterin+Neopterin;SRto;Pt;Urine;Qn;;CHEM;1;Biopterin/Biopterin+Neopterin [Molar ratio] in Urine;Biopterin/Biop+Neop Ur-sRto;;ACTIVE;2.54;2.54 +79283-8;C29 dicarboxylate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;C29 dicarboxylate [Moles/volume] in Serum or Plasma;C29 dicarboxylate SerPl-sCnc;;ACTIVE;2.54;2.54 +79284-6;Carnitine biosynthesis intermediates panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Carnitine biosynthesis intermediates panel - DBS;Carnitine biosynthesis Panel DBS;;ACTIVE;2.54;2.61 +7928-5;Influenza virus A Texas Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Texas Ab [Units/volume] in Serum;FLUAV Tex Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79285-3;Carnitine biosynthesis intermediates panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Carnitine biosynthesis intermediates panel - Serum or Plasma;Carnitine biosynthesis Panel SerPl;;ACTIVE;2.54;2.54 +79286-1;Carnitine biosynthesis intermediates panel;-;Pt;CSF;-;;PANEL.CHEM;1;Carnitine biosynthesis intermediates panel - Cerebral spinal fluid;Carnitine biosynthesis Panel CSF;;ACTIVE;2.54;2.54 +79287-9;Carnitine biosynthesis intermediates panel;-;Pt;Urine;-;;PANEL.CHEM;1;Carnitine biosynthesis intermediates panel - Urine;Carnitine biosynthesis Panel Ur;;ACTIVE;2.54;2.54 +79288-7;Creatine & guanidinoacetate panel;-;Pt;CSF;Qn;;PANEL.CHEM;1;Creatine and guanidinoacetate panel - Cerebral spinal fluid;Cr and GAA Pnl CSF;;ACTIVE;2.54;2.54 +79289-5;Creatine & guanidinoacetate panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Creatine and guanidinoacetate panel - Serum or Plasma;Cr and GAA Pnl SerPl;;ACTIVE;2.54;2.54 +79290-3;Creatine, guanidinoacetate & creatinine panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Creatine, guanidinoacetate and creatinine panel - Urine;Cr, GAA and Creat Pnl Ur;;ACTIVE;2.54;2.54 +79291-1;Creatine & guanidinoacetate pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Creatine and guanidinoacetate pattern [Interpretation] in Serum or Plasma Narrative;Cr and GAA pattern SerPl-Imp;;ACTIVE;2.54;2.54 +79292-9;Creatine, guanidinoacetate & creatinine pattern;Imp;Pt;Urine;Nar;;CHEM;1;Creatine, guanidinoacetate and creatinine pattern [Interpretation] in Urine Narrative;Cr, GAA and Creat pattern Ur-Imp;;ACTIVE;2.54;2.73 +7929-3;Influenza virus A Victoria Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A Victoria Ab [Units/volume] in Serum;FLUAV Vic Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79293-7;Creatine & guanidinoacetate pattern;Imp;Pt;CSF;Nar;;CHEM;1;Creatine and guanidinoacetate pattern [Interpretation] in Cerebral spinal fluid Narrative;Cr and GAA pattern CSF-Imp;;ACTIVE;2.54;2.54 +79294-5;D- & L-2-hydroxyglutarate panel;-;Pt;CSF;-;;PANEL.CHEM;1;D- and L-2-hydroxyglutarate panel - Cerebral spinal fluid;D2HG and L2HG Pnl CSF;;ACTIVE;2.54;2.54 +79295-2;D- & L-2-hydroxyglutarate panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;D- and L-2-hydroxyglutarate panel - Serum or Plasma;D2HG and L2HG Pnl SerPl;;ACTIVE;2.54;2.54 +79296-0;D- & L-2-hydroxyglutarate panel;-;Pt;Amnio fld;-;;PANEL.CHEM;1;D- and L-2-hydroxyglutarate panel - Amniotic fluid;D2HG and L2HG Pnl Amn;;ACTIVE;2.54;2.54 +79297-8;D- & L-2-hydroxyglutarate panel;-;Pt;Urine;-;;PANEL.CHEM;1;D- and L-2-hydroxyglutarate panel - Urine;D2HG and L2HG Pnl Ur;;ACTIVE;2.54;2.54 +79298-6;D- & L-2-hydroxyglutarate panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;D- and L-2-hydroxyglutarate panel - DBS;D2HG and L2HG Pnl DBS;;ACTIVE;2.54;2.61 +79299-4;D- & L-2-hydroxyglutarate pattern;Imp;Pt;CSF;Nar;;CHEM;1;D- and L-2-hydroxyglutarate pattern [Interpretation] in Cerebral spinal fluid Narrative;D2HG + L2HG pattern CSF-Imp;;ACTIVE;2.54;2.56 +793-0;Erythrocytes;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Pleural fluid by Manual count;RBC # Plr Manual;;ACTIVE;1.0;2.73 +79300-0;D- & L-2-hydroxyglutarate pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;D- and L-2-hydroxyglutarate pattern [Interpretation] in Serum or Plasma Narrative;D2HG + L2HG pattern SerPl-Imp;;ACTIVE;2.54;2.56 +7930-1;Influenza virus A+B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus A+B Ab [Units/volume] in Serum;FLUAV+FLUBV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79301-8;D- & L-2-hydroxyglutarate pattern;Imp;Pt;Bld.dot;Nar;;CHEM;1;D- and L-2-hydroxyglutarate pattern newborn screen interpretation;D2HG + L2HG pattern DBS-Imp;;ACTIVE;2.54;2.56 +79302-6;D- & L-2-hydroxyglutarate pattern;Imp;Pt;Amnio fld;Nar;;CHEM;1;D- and L-2-hydroxyglutarate pattern [Interpretation] in Amniotic fluid Narrative;D2HG + L2HG pattern Amn-Imp;;ACTIVE;2.54;2.56 +79303-4;D- & L-2-hydroxyglutarate pattern;Imp;Pt;Urine;Nar;;CHEM;1;D- and L-2-hydroxyglutarate pattern [Interpretation] in Urine Narrative;D2HG + L2HG pattern Ur-Imp;;ACTIVE;2.54;2.56 +79304-2;D-2-hydroxyglutarate;SCnc;Pt;CSF;Qn;;CHEM;1;D-2-hydroxyglutarate [Moles/volume] in Cerebral spinal fluid;D2HG CSF-sCnc;;ACTIVE;2.54;2.54 +79305-9;D-2-hydroxyglutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;D-2-hydroxyglutarate [Moles/volume] in Serum or Plasma;D2HG SerPl-sCnc;;ACTIVE;2.54;2.54 +79306-7;D-2-hydroxyglutarate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;D-2-hydroxyglutarate [Moles/volume] in DBS;D2HG DBS-sCnc;;ACTIVE;2.54;2.61 +79307-5;D-2-hydroxyglutarate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;D-2-hydroxyglutarate [Moles/volume] in Amniotic fluid;D2HG Amn-sCnc;;ACTIVE;2.54;2.54 +79308-3;Gamma butyrobetaine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gamma butyrobetaine [Moles/volume] in Serum or Plasma;G-butyrobetaine SerPl-sCnc;;ACTIVE;2.54;2.54 +79309-1;Gamma butyrobetaine;SCnc;Pt;CSF;Qn;;CHEM;1;Gamma butyrobetaine [Moles/volume] in Cerebral spinal fluid;G-butyrobetaine CSF-sCnc;;ACTIVE;2.54;2.54 +79310-9;Gamma butyrobetaine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Gamma butyrobetaine [Moles/volume] in DBS;G-butyrobetaine DBS-sCnc;;ACTIVE;2.54;2.61 +79311-7;Gamma butyrobetaine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Gamma butyrobetaine/Creatinine [Molar ratio] in Urine;G-butyrobetaine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79312-5;Gamma butyrobetaine/Trimethyllysine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Gamma butyrobetaine/Trimethyllysine [Molar ratio] in Serum or Plasma;G-butyrobetaine/TML SerPl-sRto;;ACTIVE;2.54;2.54 +79313-3;Gamma butyrobetaine/Trimethyllysine;SRto;Pt;Urine;Qn;;CHEM;1;Gamma butyrobetaine/Trimethyllysine [Molar ratio] in Urine;G-butyrobetaine/TML Ur-sRto;;ACTIVE;2.54;2.54 +79314-1;Gamma butyrobetaine/Trimethyllysine;SRto;Pt;Bld.dot;Qn;;CHEM;1;Gamma butyrobetaine/Trimethyllysine [Molar ratio] in DBS;G-butyrobetaine/TML DBS-sRto;;ACTIVE;2.54;2.61 +79315-8;Gamma butyrobetaine/Trimethyllysine;SRto;Pt;CSF;Qn;;CHEM;1;Gamma butyrobetaine/Trimethyllysine [Molar ratio] in Cerebral spinal fluid;G-butyrobetaine/TML CSF-sRto;;ACTIVE;2.54;2.54 +79316-6;Isoxanthopterin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isoxanthopterin [Moles/volume] in Serum or Plasma;Isoxanthopterin SerPl-sCnc;;ACTIVE;2.54;2.54 +79317-4;L-2-hydroxyglutarate;SCnc;Pt;CSF;Qn;;CHEM;1;L-2-hydroxyglutarate [Moles/volume] in Cerebral spinal fluid;L2HG CSF-sCnc;;ACTIVE;2.54;2.54 +79318-2;L-2-hydroxyglutarate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;L-2-hydroxyglutarate [Moles/volume] in Serum or Plasma;L2HG SerPl-sCnc;;ACTIVE;2.54;2.54 +7931-9;Influenza virus B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus B Ab [Units/volume] in Serum;FLUBV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79319-0;L-2-hydroxyglutarate;SCnc;Pt;Amnio fld;Qn;;CHEM;1;L-2-hydroxyglutarate [Moles/volume] in Amniotic fluid;L2HG Amn-sCnc;;ACTIVE;2.54;2.54 +79320-8;Lysophosphatidylcholine(26:0);SCnc;Pt;CSF;Qn;;CHEM;1;Lysophosphatidylcholine(26:0) [Moles/volume] in Cerebral spinal fluid;LysoPC(26:0) CSF-sCnc;;ACTIVE;2.54;2.54 +79321-6;Lysophosphatidylcholine(26:0);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Lysophosphatidylcholine(26:0) [Moles/volume] in DBS;LysoPC(26:0) DBS-sCnc;;ACTIVE;2.54;2.67 +79322-4;Lysophosphatidylcholine(26:0);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lysophosphatidylcholine(26:0) [Moles/volume] in Serum or Plasma;LysoPC(26:0) SerPl-sCnc;;ACTIVE;2.54;2.67 +79323-2;7-Isobiopterin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;7-Isobiopterin/Creatinine [Molar ratio] in Urine;7-Isobiopterin/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79324-0;Pyridoxal phosphate & pyridoxal & pyridoxine panel;-;Pt;CSF;-;;PANEL.CHEM;1;Pyridoxal phosphate and pyridoxal and pyridoxine panel - Cerebral spinal fluid;PLP + PL + Vit B6 Pnl CSF;;ACTIVE;2.54;2.63 +79325-7;Pyridoxal phosphate & pyridoxal & pyridoxine panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Pyridoxal phosphate and pyridoxal and pyridoxine panel - Serum or Plasma;PLP + PL + Vit B6 Pnl SerPl;;ACTIVE;2.54;2.63 +79326-5;Squalene;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Squalene [Moles/volume] in Serum or Plasma;Squalene SerPl-sCnc;;ACTIVE;2.54;2.54 +7932-7;Influenza virus C Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Influenza virus C Ab [Units/volume] in Serum;FLUCV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79327-3;Sterols pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Sterols pattern [Interpretation] in Serum or Plasma Narrative;Sterols pattern SerPl-Imp;;ACTIVE;2.54;2.54 +79328-1;Trimethyllysine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Trimethyllysine [Moles/volume] in Serum or Plasma;TML SerPl-sCnc;;ACTIVE;2.54;2.54 +79329-9;Trimethyllysine;SCnc;Pt;CSF;Qn;;CHEM;1;Trimethyllysine [Moles/volume] in Cerebral spinal fluid;TML CSF-sCnc;;ACTIVE;2.54;2.54 +79330-7;Trimethyllysine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Trimethyllysine [Moles/volume] in DBS;TML DBS-sCnc;;ACTIVE;2.54;2.61 +79331-5;Trimethyllysine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Trimethyllysine/Creatinine [Molar ratio] in Urine;TML/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79332-3;L-2-hydroxyglutarate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;L-2-hydroxyglutarate [Moles/volume] in DBS;L2HG DBS-sCnc;;ACTIVE;2.54;2.61 +79333-1;Viscosity;Visc;Pt;Cvm;Ord;;SPEC;1;Viscosity of Cervical mucus Qualitative;Visc Cerv mucus Ql;;ACTIVE;2.54;2.54 +79334-9;Hypoglycemics.oral;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Hypoglycemics.oral [Presence] in Hair by Screen method;Oral Hypogly Hair Ql Scn;;ACTIVE;2.54;2.56 +7933-5;Japanese encephalitis virus Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Japanese encephalitis virus Ab [Presence] in Cerebral spinal fluid by Immunoassay;JEV Ab CSF Ql IA;;ACTIVE;1.0h(2);2.56 +79335-6;Hypoglycemics.oral;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Hypoglycemics.oral [Presence] in Blood by Screen method;Oral Hypogly Bld Ql Scn;;ACTIVE;2.54;2.56 +79336-4;Hypoglycemics.oral;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Hypoglycemics.oral [Presence] in Serum or Plasma by Screen method;Oral Hypogly SerPl Ql Scn;;ACTIVE;2.54;2.56 +79337-2;Hypoglycemics.oral;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Hypoglycemics.oral [Presence] in Body fluid by Screen method;Oral Hypogly Fld Ql Scn;;ACTIVE;2.54;2.58 +79338-0;Hypoglycemics.oral;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hypoglycemics.oral [Presence] in Urine by Screen method;Oral Hypogly Ur Ql Scn;;ACTIVE;2.54;2.56 +79339-8;Carnitine biosynthesis intermediates pattern;Imp;Pt;Bld.dot;Nar;;CHEM;1;Carnitine biosynthesis intermediates pattern newborn screen interpretation;Carnitine biosynthesis pattern DBS-Imp;;ACTIVE;2.54;2.54 +79340-6;Carnitine biosynthesis intermediates pattern;Imp;Pt;CSF;Nar;;CHEM;1;Carnitine biosynthesis intermediates pattern [Interpretation] in Cerebral spinal fluid Narrative;Carnitine biosynthesis pattern CSF-Imp;;ACTIVE;2.54;2.54 +79341-4;Carnitine biosynthesis intermediates pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Carnitine biosynthesis intermediates pattern [Interpretation] in Serum or Plasma Narrative;Carnitine biosynthesis pattern SerPl-Imp;;ACTIVE;2.54;2.54 +79342-2;Carnitine biosynthesis intermediates pattern;Imp;Pt;Urine;Nar;;CHEM;1;Carnitine biosynthesis intermediates pattern [Interpretation] in Urine Narrative;Carnitine biosynthesis pattern Ur-Imp;;ACTIVE;2.54;2.54 +7934-3;Japanese encephalitis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Japanese encephalitis virus Ab [Presence] in Serum by Immunoassay;JEV Ab Ser Ql IA;;ACTIVE;1.0h(2);2.56 +79343-0;Dimethylacetals pattern;Imp;Pt;RBC;Nar;;CHEM;1;Dimethylacetals pattern [Interpretation] in Red Blood Cells Narrative;DMA pattern RBC-Imp;;ACTIVE;2.54;2.54 +79344-8;Pyridoxal phosphate & pyridoxal & pyridoxine pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Pyridoxal phosphate and pyridoxal and pyridoxine pattern [Interpretation] in Serum or Plasma Narrative;PLP + PL + Vit B6 pattern SerPl-Imp;;ACTIVE;2.54;2.54 +79345-5;Pyridoxal phosphate & pyridoxal & pyridoxine pattern;Imp;Pt;CSF;Nar;;CHEM;1;Pyridoxal phosphate and pyridoxal and pyridoxine pattern [Interpretation] in Cerebral spinal fluid Narrative;PLP + PL + Vit B6 pattern CSF-Imp;;ACTIVE;2.54;2.54 +79346-3;Alpha-aminoadipic semialdehyde/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha-aminoadipic semialdehyde/Creatinine [Molar ratio] in Urine;Alpha-AASA/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79347-1;Sulfate.total/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Sulfate.total/Creatinine [Molar ratio] in Urine;T sulfate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79348-9;Body weight^used for drug calculation;Mass;Pt;^Patient;Qn;;CLIN;2;Body weight --used for drug calculation;Weight used for drug calc;;ACTIVE;2.54;2.73 +79349-7;Views GE 6;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum GE 6 Views;XR L-spine+Sacrum GE 6V;;ACTIVE;2.54;2.61 +7935-0;Japanese encephalitis virus Ab;ACnc;Pt;Ser;Qn;HAI;MICRO;1;Japanese encephalitis virus Ab [Units/volume] in Serum by Hemagglutination inhibition;JEV Ab Ser HAI-aCnc;;ACTIVE;1.0h(2);2.69 +79350-5;Views GE 3;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen GE 3 Views;XR Abd GE 3V;;ACTIVE;2.54;2.61 +79351-3;Views GE 2;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine GE 2 Views;XR C-spine GE 2V;;ACTIVE;2.54;2.61 +79352-1;Views GE 6;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine GE 6 Views;XR C-spine GE 6V;;ACTIVE;2.54;2.61 +79353-9;Views GE 3;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow GE 3 Views;XR Elbow GE 3V;;ACTIVE;2.54;2.61 +79354-7;Views GE 2;Find;Pt;Upper extremity>Finger;Doc;XR;RAD;2;XR Finger GE 2 Views;XR Finger GE 2V;;ACTIVE;2.54;2.61 +79355-4;Views 3^W standing;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot 3 Views W standing;XR Foot 3V W Stand;;ACTIVE;2.54;2.61 +79356-2;Views 1 or 2;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand 1 or 2 Views;XR Hand 1V or 2V;;ACTIVE;2.54;2.61 +79357-0;Views GE 3;Find;Pt;Upper extremity>Hand;Doc;XR;RAD;2;XR Hand GE 3 Views;XR Hand GE 3V;;ACTIVE;2.54;2.61 +79358-8;Views GE 4;Find;Pt;Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Hip - bilateral GE 4 Views;XR Hip-Bl GE 4V;;ACTIVE;2.54;2.61 +79359-6;Views GE 2;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left GE 2 Views;XR Hip-L GE 2V;;ACTIVE;2.54;2.61 +79360-4;Views GE 2;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right GE 2 Views;XR Hip-R GE 2V;;ACTIVE;2.54;2.61 +79361-2;Views GE 2;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip GE 2 Views;XR Hip GE 2V;;ACTIVE;2.54;2.61 +79362-0;Views GE 2;Find;Pt;Upper extremity>Humerus;Doc;XR;RAD;2;XR Humerus GE 2 Views;XR Humerus GE 2V;;ACTIVE;2.54;2.61 +79363-8;(Views AP + lateral + Merchants) + (views^W standing);Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP and Lateral and Merchants and (Views W standing);XR Knee-Bl AP+Lat+Merch+views Stand;;ACTIVE;2.54;2.61 +79364-6;Views GE 4;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee GE 4 Views;XR Knee GE 4V;;ACTIVE;2.54;2.61 +79365-3;Views GE 3;Find;Pt;Chest>Ribs.bilateral;Doc;XR;RAD;2;XR Ribs - bilateral GE 3 Views;XR Ribs-Bl GE 3V;;ACTIVE;2.54;2.61 +79366-1;Views 2;Find;Pt;Chest>Ribs.unilateral & Chest;Doc;XR;RAD;2;XR Ribs - unilateral and Chest 2 Views;XR Ribs-Ul + Chest 2V;;ACTIVE;2.54;2.61 +79367-9;Views GE 2;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Sacrum and Coccyx GE 2 Views;XR Sacrum+Coccyx GE 2V;;ACTIVE;2.54;2.61 +7936-8;Japanese encephalitis virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Japanese encephalitis virus RNA [Presence] in Serum by NAA with probe detection;JEV RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +79368-7;Views GE 2;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left GE 2 Views;XR Should-L GE 2V;;ACTIVE;2.54;2.61 +79369-5;Views GE 2;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right GE 2 Views;XR Should-R GE 2V;;ACTIVE;2.54;2.61 +79370-3;Views GE 2;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder GE 2 Views;XR Should GE 2V;;ACTIVE;2.54;2.61 +79371-1;Views GE 2;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum GE 2 Views;XR L-spine+Sacrum GE 2V;;ACTIVE;2.54;2.61 +79372-9;Views GE 4;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum GE 4 Views;XR L-spine+Sacrum GE 4V;;ACTIVE;2.54;2.61 +79373-7;Views GE 2;Find;Pt;Lower extremity>Toe;Doc;XR;RAD;2;XR Toe GE 2 Views;XR Toe GE 2V;;ACTIVE;2.54;2.61 +79374-5;Multisection for screening;Find;Pt;Abdomen>Aorta.abdominal;Doc;US;RAD;2;US Abdominal Aorta for screening;US Abd Aorta Screening;;ACTIVE;2.54;2.61 +79375-2;Microscopic observation^2nd specimen;Prid;Pt;Sputum;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Sputum by Acid fast stain.Ziehl-Neelsen--2nd specimen;ZN Stn sp2 Spt;;ACTIVE;2.54;2.54 +7937-6;Junin virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Junin virus Ab [Presence] in Serum by Immunoassay;JUNV Ab Ser Ql IA;;ACTIVE;1.0h(2);2.56 +79376-0;Microscopic observation^3rd specimen;Prid;Pt;Sputum;Nom;Acid fast stain.Ziehl-Neelsen;MICRO;1;Microscopic observation [Identifier] in Sputum by Acid fast stain.Ziehl-Neelsen--3rd specimen;ZN Stn sp3 Spt;;ACTIVE;2.54;2.54 +79377-8;Naltrexol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naltrexol [Mass/volume] in Urine by Confirmatory method;Naltrexol Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +79378-6;Cause of death;Find;Pt;^Patient;Nom;;H&P.HX;2;Cause of death;Cause of death;;ACTIVE;2.54;2.54 +79379-4;HIV 1 RNA+proviral DNA;PrThr;Pt;Plas;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA+proviral DNA [Presence] in Plasma by NAA with probe detection;HIV 1 RNA+proviral DNA Plas Ql NAA+probe;;ACTIVE;2.54;2.73 +79380-2;HIV 1 RNA+proviral DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA+proviral DNA [Presence] in Blood by NAA with probe detection;HIV 1 RNA+proviral DNA Bld Ql NAA+probe;;ACTIVE;2.54;2.63 +79381-0;Gastrointestinal pathogens panel;-;Pt;Stool;-;Probe.amp.tar;PANEL.MICRO;1;Gastrointestinal pathogens panel - Stool by NAA with probe detection;GI pathogens Pnl Stl NAA+probe;;ACTIVE;2.54;2.73 +79382-8;Campylobacter coli+jejuni+lari fusA gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter coli+jejuni+lari fusA gene [Presence] in Stool by NAA with probe detection;C coli+jejuni+lari fusA Stl Ql NAA+probe;;ACTIVE;2.54;2.73 +79383-6;Salmonella sp rpoD gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Salmonella sp rpoD gene [Presence] in Stool by NAA with probe detection;Salmonella sp rpoD Stl Ql NAA+probe;;ACTIVE;2.54;2.73 +7938-4;La Crosse virus Ab;ACnc;Pt;Ser;OrdQn;EIA;MICRO;1;Deprecated La Crosse virus Ab by Immunoassay;Deprecated LACV Ab Ser EIA;;DEPRECATED;1.0h(2);2.4 +79384-4;Vibrio cholerae+parahaemolyticus rfbL+trkH+tnaA genes;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Vibrio cholerae+parahaemolyticus rfbL+trkH+tnaA genes [Presence] in Stool by NAA with probe detection;V chol+para rfbL+trkH+tnaA Stl Ql NAA+pr;;ACTIVE;2.54;2.73 +79385-1;Yersinia enterocolitica recN gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Yersinia enterocolitica recN gene [Presence] in Stool by NAA with probe detection;Y entero recN Stl Ql NAA+probe;;ACTIVE;2.54;2.73 +79386-9;Escherichia coli Stx1 toxin stx1 gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx1 toxin stx1 gene [Presence] in Stool by NAA with probe detection;EC stx1 gene Stl Ql NAA+probe;;ACTIVE;2.54;2.73 +79387-7;Escherichia coli Stx2 toxin stx2 gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx2 toxin stx2 gene [Presence] in Stool by NAA with probe detection;EC stx2 gene Stl Ql NAA+probe;;ACTIVE;2.54;2.73 +79388-5;Norovirus genogroup I+II orf1-orf2 junction region;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup I+II orf1-orf2 junction region [Presence] in Stool by NAA with probe detection;Norov GI+II orf1-orf2 jnc Stl Ql NAA+pr;;ACTIVE;2.54;2.73 +79389-3;Rotavirus A nsp5 gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Rotavirus A nsp5 gene [Presence] in Stool by NAA with probe detection;RVA nsp5 Stl Ql NAA+probe;;ACTIVE;2.54;2.73 +79390-1;Gastrointestinal pathogens identified;Prid;Pt;Stool;Nom;Probe.amp.tar;MICRO;1;Gastrointestinal pathogens identified in Stool by NAA with probe detection;GI pathogens Stl NAA+probe;;ACTIVE;2.54;2.64 +79391-9;Catecholamine metabolites panel;-;Pt;CSF;Qn;;PANEL.CHEM;1;Catecholamine metabolites panel - Cerebral spinal fluid;Catecholamine metab Pnl CSF;;ACTIVE;2.54;2.54 +7939-2;La Crosse virus Ab;ACnc;Pt;Ser;OrdQn;IF;MICRO;1;Deprecated La Crosse virus Ab by Immunofluorescence;Deprecated LACV Ab Ser IF;;DEPRECATED;1.0h(2);2.4 +79392-7;Catecholamine metabolites pattern;Imp;Pt;CSF;Nar;;CHEM;1;Catecholamine metabolites pattern [Interpretation] in Cerebral spinal fluid Narrative;Catecholamine pattern CSF-Imp;;ACTIVE;2.54;2.54 +79393-5;Flavin mononucleotide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Flavin mononucleotide [Moles/volume] in Serum or Plasma;Flavin mononucleotide SerPl-sCnc;;ACTIVE;2.54;2.54 +79394-3;Hepatocyte growth factor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hepatocyte growth factor [Mass/volume] in Serum or Plasma;HGF SerPl-mCnc;;ACTIVE;2.54;2.54 +79395-0;NADH:ubiquinone reductase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;NADH:ubiquinone reductase [Enzymatic activity/mass] in Fibroblast;NADH ubiq red Fib-cCnt;;ACTIVE;2.54;2.54 +79396-8;NADH:ubiquinone reductase;CCnt;Pt;Tiss;Qn;;CHEM;1;NADH:ubiquinone reductase [Enzymatic activity/mass] in Tissue;NADH ubiq red Tiss-cCnt;;ACTIVE;2.54;2.56 +79397-6;Pistacia lentiscus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mastic tree (Pistacia lentiscus) IgE Ab [Units/volume] in Serum;Mastic tree IgE Qn;;ACTIVE;2.54;2.68 +79398-4;Prolactin isoforms pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Prolactin isoforms pattern [Interpretation] in Serum or Plasma Narrative;Prolactin isoforms pattern SerPl-Imp;;ACTIVE;2.54;2.54 +79399-2;Synovial fluid analysis panel;-;Pt;Synv fld;-;;PANEL.CHEM;1;Synovial fluid analysis panel - Synovial fluid;Synovial fld analysis Pnl Snv;;ACTIVE;2.54;2.54 +79-4;Cefixime;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefixime [Susceptibility] by Minimum lethal concentration (MLC);Cefixime Islt MLC;;ACTIVE;1.0;2.19 +7940-0;La Crosse virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;La Crosse virus IgG Ab [Units/volume] in Serum;LACV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79400-8;Vanillylmandelate;SCnc;Pt;CSF;Qn;;CHEM;1;Vanillylmandelate [Moles/volume] in Cerebral spinal fluid;VMA CSF-sCnc;;ACTIVE;2.54;2.54 +79401-6;HBB gene full mutation analysis;Prid;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HBB gene full mutation analysis [Identifier] in Blood or Tissue by Sequencing;HBB gene Full Mut Anl Bld/T Seq;;ACTIVE;2.54;2.73 +79402-4;Niacin;SCnc;Pt;Bld;Qn;;CHEM;1;Niacin [Moles/volume] in Blood;Niacin Bld-sCnc;;ACTIVE;2.54;2.54 +79403-2;Nitrogen;SCnc;Pt;Urine;Qn;;CHEM;1;Nitrogen [Moles/volume] in Urine;N2 Ur-sCnc;;ACTIVE;2.54;2.54 +79404-0;Adenosine deaminase;CSub;Pt;RBC;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/substance] in Red Blood Cells;Adenosine deaminase cSub RBC;;ACTIVE;2.54;2.54 +79405-7;1,4-Alpha glucan branching enzyme;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;1,4-Alpha glucan branching enzyme [Enzymatic activity/mass] in Fibroblast;GLGB Fib-cCnt;;ACTIVE;2.54;2.54 +79406-5;IgM clearance/Albumin clearance;Ratio;Pt;Ser+CSF;Qn;;CHEM;1;IgM clearance/Albumin clearance [Ratio] in Serum and CSF;IgM/Alb clear Ser+CSF-Rto;;ACTIVE;2.54;2.54 +79407-3;Catecholamine metabolites pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Catecholamine metabolites pattern [Interpretation] in Serum or Plasma Narrative;Catecholamine pattern SerPl-Imp;;ACTIVE;2.54;2.54 +79408-1;Clobazam & norclobazam panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;cloBAZam and norclobazam panel - Serum or Plasma;cloBAZam + Nor Pnl SerPl;;ACTIVE;2.54;2.54 +79409-9;Dothiepin+nordothiepin trough & dothiepin sulfoxide panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Dothiepin+nordothiepin trough and dothiepin sulfoxide panel - Serum or Plasma;Dothiepin Trgh + metabs Pnl SerPl;;ACTIVE;2.54;2.54 +79410-7;Penfluridol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Penfluridol [Mass/volume] in Serum or Plasma --trough;Penfluridol Trough SerPl-mCnc;;ACTIVE;2.54;2.54 +79411-5;Creatine transport protein;CCnt;Pt;Fibroblasts;Qn;Creatine uptake;CHEM;1;Creatine transport protein [Enzymatic activity/mass] in Fibroblast by Creatine uptake assay;CrT protein Fib Creat uptake-cCnt;;ACTIVE;2.54;2.54 +79412-3;Mianserin trough & Normianserin panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Mianserin trough and Normianserin panel - Serum or Plasma;Mianserin Trgh + Nor Pnl SerPl;;ACTIVE;2.54;2.54 +79413-1;Dothiepin+Nordothiepin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dothiepin+Nordothiepin [Mass/volume] in Serum or Plasma --trough;Dothiepin+Nordothiepin Trough SerPl-mCnc;;ACTIVE;2.54;2.54 +79414-9;MSH6 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DELDUP;1;MSH6 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;MSH6 gene Del+Dup Bld/T MLPA;;ACTIVE;2.54;2.73 +79415-6;MSH2 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DELDUP;1;MSH2 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;MSH2 gene Del+Dup Bld/T MLPA;;ACTIVE;2.54;2.65 +79416-4;MLH1 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DELDUP;1;MLH1 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;MLH1 gene Del+Dup Bld/T MLPA;;ACTIVE;2.54;2.65 +79417-2;PMS2 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DELDUP;1;PMS2 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;PMS2 gene Del+Dup Bld/T MLPA;;ACTIVE;2.54;2.65 +7941-8;La Crosse virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;La Crosse virus IgM Ab [Units/volume] in Serum;LACV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79418-0;EPCAM gene exons 8 & 9 deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DELDUP;1;EPCAM gene exons 8 and 9 deletion and duplication mutation analysis in Blood or Tissue by MLPA;EPCAM Exons 8 + 9 Del+Dup Bld/T MLPA;;ACTIVE;2.54;2.73 +79419-8;PMS2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;PMS2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;PMS2 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.54;2.73 +79420-6;Allergen.miscellaneous Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Miscellaneous allergen IgE Ab [Units/volume] in Serum;Misc Allergen IgE Qn;;ACTIVE;2.54;2.73 +79421-4;Neuromuscular functional index;Score;Pt;^Patient;Qn;CareConnections;APTA;2;Neuromuscular functional index [CareConnections];NM func index Score CareConn;Portions Copyright © 2015 Therapeutic Associates, Inc. Used with permission.;ACTIVE;2.54;2.54 +79422-2;Orthopedic functional index;Score;Pt;^Patient;Qn;CareConnections;APTA;2;Orthopedic functional index [CareConnections];Ortho func index Score CareConn;Portions Copyright © 2015 Therapeutic Associates, Inc. Used with permission.;ACTIVE;2.54;2.54 +79423-0;Cardiovascular disease 10Y risk;Likelihood;Pt;^Patient;Qn;ACC-AHA Pooled Cohort.Goff 2013;CARD.RISK;2;Cardiovascular disease 10Y risk [Likelihood] ACC-AHA Pooled Cohort by Goff 2013;CVD 10Y risk ACC-AHA.Goff 2013;© 2013 American Heart Association Used with permission;ACTIVE;2.54;2.63 +79424-8;Serial smears for diagnosing pulmonary tuberculosis panel;-;Pt;Sputum;-;Acid fast stain;PANEL.MICRO;1;Serial sputum smears for diagnosing pulmonary tuberculosis panel - by Acid fast stain;Serial TB smears Pnl Spt Acid fast Stn;;ACTIVE;2.54;2.68 +79425-5;Bacteria identified;Prid;Pt;Respiratory.lower;Nom;Cystic fibrosis respiratory culture;MICRO;1;Bacteria identified in Lower respiratory specimen by Cystic fibrosis respiratory culture;Bacteria Lower resp CF Resp Cult;;ACTIVE;2.54;2.73 +7942-6;Lassa virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Lassa virus IgG Ab [Presence] in Serum by Immunoassay;LASV IgG Ser Ql IA;;ACTIVE;1.0h(2);2.56 +79426-3;Plasma cells/100 leukocytes;NFr;Pt;Bld;Qn;Manual count;HEM/BC;1;Plasma cells/100 leukocytes in Blood by Manual count;Plasma Cells/leuk NFr Bld Manual;;ACTIVE;2.54;2.73 +79427-1;Platelets;Naric;Pt;Bld;Qn;Microscopy.light.HPF;HEM/BC;1;Platelets [#/area] in Blood by Microscopy high power field;Platelet #/area Bld HPF;;ACTIVE;2.54;2.54 +79428-9;Consultation note;Find;Pt;{Setting};Doc;Rapid response team;DOC.ONTOLOGY;2;Rapid response team Consult note;Rapid response team Consult note;;ACTIVE;2.54;2.58 +79429-7;Admission notification note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Admission notification;Hosp Admission notification;;ACTIVE;2.54;2.71 +79430-5;Discharge notification note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Discharge notification;Hosp Discharge notification;;ACTIVE;2.54;2.71 +79431-3;Quality of life score change;ScoreDiff;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Quality of life score change [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79432-1;Sport-recreation score change;ScoreDiff;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Sport-recreation score change [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79433-9;Activities of daily living score change;ScoreDiff;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Activities of daily living score change [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +7943-4;Lassa virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Lassa virus IgG Ab [Titer] in Serum by Immunofluorescence;LASV IgG Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79434-7;Symptoms score change;ScoreDiff;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Symptoms score change [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79435-4;Pain score change;ScoreDiff;Pt;^Patient;Qn;HOOS;SURVEY.GNHLTH;4;Pain score change [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79436-2;Quality of life score change;ScoreDiff;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Quality of life score change [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79437-0;Sport-recreation score change;ScoreDiff;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Sport-recreation score change [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79438-8;Activities of daily living score change;ScoreDiff;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Activities of daily living score change [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79439-6;Symptoms score change;ScoreDiff;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Symptoms score change [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79440-4;Pain score change;ScoreDiff;Pt;^Patient;Qn;KOOS;SURVEY.GNHLTH;4;Pain score change [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.54;2.54 +79441-2;VR-12 Physical component summary score change - oblique method;TscoreDiff;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Physical component summary (PCS) score change - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.54;2.54 +7944-2;Lassa virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Lassa virus IgM Ab [Presence] in Serum by Immunoassay;LASV IgM Ser Ql IA;;ACTIVE;1.0h(2);2.56 +79442-0;VR-12 Physical component summary score change - orthogonal method;TscoreDiff;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Physical component summary (PCS) score change - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.54;2.54 +79443-8;VR-12 Mental component summary score change - oblique method;TscoreDiff;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Mental component summary (MCS) score change - oblique method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.54;2.54 +79444-6;VR-12 Mental component summary score change - orthogonal method;TscoreDiff;Pt;^Patient;Qn;VR;SURVEY.GNHLTH;4;VR-12 Mental component summary (MCS) score change - orthogonal method;;Copyright © 2004 RAND. Used with permission per LOINC Terms of Use. The Veterans RAND 12 Item Health Survey (VR-12) was developed from the Veterans RAND 36 Item Health Survey (VR-36) which was developed from the MOS RAND SF-36 Version 1.0. Details involving the VR-36 and VR-12 questionnaires, scoring algorithms for PCS and MCS summary measures, and imputation programs for missing values can be obtained on request by agreeing to the stipulations given by the RAND Corporation website (See http://www.rand.org/health/surveys_tools/mos/mos_core_36item_terms.html) in a letter to Dr. Lewis Kazis (lek@bu.edu) on institutional letter head. Users of the VR-12 or VR-36 in clinical research studies should also notify Dr. Kazis.;ACTIVE;2.54;2.54 +79445-3;Fluspirilene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Fluspirilene [Mass/volume] in Serum or Plasma;Fluspirilene SerPl-mCnc;;ACTIVE;2.54;2.54 +79446-1;Pericyazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pericyazine [Mass/volume] in Serum or Plasma;Pericyazine SerPl-mCnc;;ACTIVE;2.54;2.54 +79447-9;Staphylococcus aureus capsular polysaccharide enzyme (cpe) gene;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus capsular polysaccharide enzyme cpe gene [Presence] in Nose by NAA with probe detection;S aureus cpe Nose Ql NAA+probe;;ACTIVE;2.54;2.73 +79448-7;Staphylococcus aureus & Methicillin-resistant Staphylococcus aureus panel;-;Pt;Nose;-;Probe.amp.tar;PANEL.MICRO;1;Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus panel - Nose by NAA with probe detection;SA+MRSA Pnl Nose NAA+probe;;ACTIVE;2.54;2.73 +79449-5;Formate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Formate [Moles/volume] in Urine;Formate Ur-sCnc;;ACTIVE;2.54;2.54 +79450-3;Adenine phosphoribosyltransferase;CSub;Pt;RBC;Qn;;CHEM;1;Adenine phosphoribosyltransferase [Enzymatic activity/substance] in Red Blood Cells;APRT cSub RBC;;ACTIVE;2.54;2.54 +79451-1;Adenosine deaminase;CCnt;Pt;WBC;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/mass] in Leukocytes;Adenosine deaminase WBC-cCnt;;ACTIVE;2.54;2.54 +79452-9;Adenylosuccinate lyase;CSub;Pt;RBC;Qn;;CHEM;1;Adenylosuccinate lyase [Enzymatic activity/substance] in Red Blood Cells;ADSL cSub RBC;;ACTIVE;2.54;2.54 +79453-7;Alcohol dehydrogenase;CCnt;Pt;Liver;Qn;;CHEM;1;Alcohol dehydrogenase [Enzymatic activity/mass] in Liver;ADH Liver-cCnt;;ACTIVE;2.54;2.54 +79454-5;Alpha fucosidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Alpha fucosidase [Enzymatic activity/volume] in DBS;A-Fucosidase DBS-cCnc;;ACTIVE;2.54;2.61 +79455-2;Alpha-N-acetylgalactosaminidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Alpha-N-acetylgalactosaminidase [Enzymatic activity/volume] in DBS;A-NAGA DBS-cCnc;;ACTIVE;2.54;2.61 +79456-0;Arginase;CCnt;Pt;RBC;Qn;;CHEM;1;Arginase [Enzymatic activity/mass] in Red Blood Cells;Arginase RBC-cCnt;;ACTIVE;2.54;2.54 +79457-8;Beta glucuronidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Beta glucuronidase [Enzymatic activity/volume] in DBS;B-Glucuronidase DBS-cCnc;;ACTIVE;2.54;2.61 +79458-6;Beta-N-acetylhexosaminidase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Beta-N-acetylhexosaminidase [Enzymatic activity/volume] in DBS;B-NAH DBS-cCnc;;ACTIVE;2.54;2.61 +7945-9;Lassa virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Lassa virus IgM Ab [Titer] in Serum by Immunofluorescence;LASV IgM Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79459-4;Dihydropteridine reductase;CCnt;Pt;RBC;Qn;;CHEM;1;Dihydropteridine reductase [Enzymatic activity/mass] in Red Blood Cells;DHP Reduct RBC-cCnt;;ACTIVE;2.54;2.54 +79460-2;Galactose 1 phosphate uridyl transferase;CSub;Pt;RBC;Qn;;CHEM;1;Galactose 1 phosphate uridyl transferase [Enzymatic activity/substance] in Red Blood Cells;Gal1PUT cSub RBC;;ACTIVE;2.54;2.54 +79461-0;Hypoxanthine phosphoribosyltransferase;CSub;Pt;RBC;Qn;;CHEM;1;Hypoxanthine phosphoribosyltransferase [Enzymatic activity/substance] in Red Blood Cells;HPRT cSub RBC;;ACTIVE;2.54;2.54 +79462-8;Iduronate-2-Sulfatase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS;Iduronate2Sulfatas DBS-cCnc;;ACTIVE;2.54;2.61 +79463-6;N-Acetylgalactosamine-4-Sulfatase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase [Enzymatic activity/volume] in DBS;Arylsulfatase B DBS-cCnc;;ACTIVE;2.54;2.61 +79464-4;Phosphorylase;CCnt;Pt;RBC;Qn;;CHEM;1;Phosphorylase [Enzymatic activity/mass] in Red Blood Cells;Phosphorylase RBC-cCnt;;ACTIVE;2.54;2.54 +79465-1;Porphobilinogen synthase;CCnt;Pt;RBC;Qn;;CHEM;1;Porphobilinogen synthase [Enzymatic activity/mass] in Red Blood Cells;PBG Synthase RBC-cCnt;;ACTIVE;2.54;2.54 +79466-9;Purine nucleoside phosphorylase;CSub;Pt;RBC;Qn;;CHEM;1;Purine nucleoside phosphorylase [Enzymatic activity/substance] in Red Blood Cells;PNP cSub RBC;;ACTIVE;2.54;2.54 +7946-7;Lassa virus Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Lassa virus Ag [Presence] in Serum by Immunoassay;LASV Ag Ser Ql IA;;ACTIVE;1.0h(2);2.56 +79467-7;Purine nucleoside phosphorylase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Purine nucleoside phosphorylase [Enzymatic activity/volume] in DBS;PNP DBS-cCnc;;ACTIVE;2.54;2.61 +79468-5;Thiopurine methyltransferase;CSub;Pt;RBC;Qn;;CHEM;1;Thiopurine methyltransferase [Enzymatic activity/substance] in Red Blood Cells;TPMT cSub RBC;;ACTIVE;2.54;2.54 +79469-3;Uridine diphosphate glucose-4-Epimerase;CCnt;Pt;RBC;Qn;;CHEM;1;Uridine diphosphate glucose-4-Epimerase [Enzymatic activity/mass] in Red Blood Cells;UDPG4Epimerase RBC-cCnt;;ACTIVE;2.54;2.54 +79470-1;Uridine monophosphate synthetase;CCnt;Pt;RBC;Qn;;CHEM;1;Uridine monophosphate synthetase [Enzymatic activity/mass] in Red Blood Cells;UMP synthetase RBC-cCnt;;ACTIVE;2.54;2.54 +79471-9;1,4-Cyclohexanediol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;1,4-Cyclohexanediol/Creatinine [Molar ratio] in Urine;1,4-Cyclohexanediol/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79472-7;Phenylpropionylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenylpropionylglycine [Moles/volume] in Serum or Plasma;PPG SerPl-sCnc;;ACTIVE;2.54;2.54 +79473-5;Hexanoylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexanoylglycine [Moles/volume] in Serum or Plasma;Hexanoylgly SerPl-sCnc;;ACTIVE;2.54;2.54 +79474-3;3,4-Dihydroxybutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,4-Dihydroxybutyrate/Creatinine [Molar ratio] in Urine;3,4-Dihydroxybutyrate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +7947-5;Legionella pneumophila Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella pneumophila Ab [Presence] in Serum;L pneumo Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +79475-0;2,5-Furandicarboxylate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2,5-Furandicarboxylate [Moles/volume] in Serum or Plasma;2,5-Furandicarboxylate SerPl-sCnc;;ACTIVE;2.54;2.54 +79476-8;Ethylmalonate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Ethylmalonate [Moles/volume] in Serum or Plasma;Ethylmalonate SerPl-sCnc;;ACTIVE;2.54;2.73 +79477-6;5-Hydroxymethyl-2-Furoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5-Hydroxymethyl-2-Furoate/Creatinine [Molar ratio] in Urine;5OH-methyl-2-furoate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79478-4;Salicylurate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Salicylurate/Creatinine [Molar ratio] in Urine;Salicylurate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79479-2;3-Hydroxyadipate 3,6-lactone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyadipate 3,6-lactone [Moles/volume] in Serum or Plasma;3OH-adipate 3,6-lactone SerPl-sCnc;;ACTIVE;2.54;2.54 +794-8;Erythrocytes;NCnc;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Pleural fluid by Automated count;RBC # Plr Auto;;ACTIVE;1.0;2.44 +79480-0;3,4-Dihydroxyhydrocinnamate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3,4-Dihydroxyhydrocinnamate [Moles/volume] in Serum or Plasma;3,4-DHCA SerPl-sCnc;;ACTIVE;2.54;2.54 +79481-8;Hydantoin-5-propionate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hydantoin-5-propionate/Creatinine [Molar ratio] in Urine;Hydantoin-5-propionate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79482-6;3-(3-Hydroxyphenyl)propanoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-(3-Hydroxyphenyl)propanoate/Creatinine [Molar ratio] in Urine;hMPP/Creat Ur-sRto;;ACTIVE;2.54;2.54 +7948-3;Legionella pneumophila 1 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 1 Ab [Titer] in Serum by Immunofluorescence;L pneumo1 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.73 +79483-4;Vanilloylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Vanilloylglycine/Creatinine [Molar ratio] in Urine;Vanilloylglycine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79484-2;Levulinate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Levulinate [Moles/volume] in Serum or Plasma;Levulinate SerPl-sCnc;;ACTIVE;2.54;2.54 +79485-9;4-Hydroxyvalerate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxyvalerate/Creatinine [Molar ratio] in Urine;4OH-valerate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79486-7;3,5-Dihydroxybenzoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,5-Dihydroxybenzoate/Creatinine [Molar ratio] in Urine;3,5-Dihydroxybenzoate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79487-5;Lactyl lactate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Lactyl lactate/Creatinine [Molar ratio] in Urine;Lactyl lactate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79488-3;3,4-Dihydroxybutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3,4-Dihydroxybutyrate [Moles/volume] in Serum or Plasma;3,4-Dihydroxybutyrate SerPl-sCnc;;ACTIVE;2.54;2.54 +79489-1;Salicylurate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Salicylurate [Moles/volume] in Serum or Plasma;Salicylurate SerPl-sCnc;;ACTIVE;2.54;2.54 +79490-9;3,4-Dihydroxyhydrocinnamate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3,4-Dihydroxyhydrocinnamate/Creatinine [Molar ratio] in Urine;3,4-DHCA/Creat Ur-sRto;;ACTIVE;2.54;2.54 +7949-1;Legionella pneumophila 2 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 2 Ab [Titer] in Serum by Immunofluorescence;L pneumo2 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79491-7;3-Hydroxyphenylacetate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyphenylacetate [Moles/volume] in Serum or Plasma;3OH-phenylacetate SerPl-sCnc;;ACTIVE;2.54;2.54 +79492-5;Furoylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Furoylglycine [Moles/volume] in Serum or Plasma;Furoylglycine SerPl-sCnc;;ACTIVE;2.54;2.54 +79493-3;3-Hydroxysuberate.unsaturated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxysuberate.unsaturated [Moles/volume] in Serum or Plasma;3-OHsuberate.unsaturated SerPl-sCnc;;ACTIVE;2.54;2.54 +79494-1;Pimelate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pimelate/Creatinine [Molar ratio] in Urine;Pimelate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79495-8;Azelate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Azelate [Moles/volume] in Serum or Plasma;Azelate SerPl-sCnc;;ACTIVE;2.54;2.54 +79496-6;Hydantoin-5-propionate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hydantoin-5-propionate [Moles/volume] in Serum or Plasma;Hydantoin-5-propionate SerPl-sCnc;;ACTIVE;2.54;2.54 +79497-4;3-Hydroxybenzoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxybenzoate [Moles/volume] in Serum or Plasma;3OH-benzoate SerPl-sCnc;;ACTIVE;2.54;2.54 +79498-2;4-Hydroxyhippurate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Hydroxyhippurate/Creatinine [Molar ratio] in Urine;4OH-hippurate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79499-0;Catecholamine metabolites panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Catecholamine metabolites panel - Serum or Plasma;Catecholamine metab Pnl SerPl;;ACTIVE;2.54;2.58 +79500-5;Furoylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Furoylglycine/Creatinine [Molar ratio] in Urine;Furoylglycine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79501-3;3-Hydroxyhippurate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxyhippurate/Creatinine [Molar ratio] in Urine;3OH-hippurate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79502-1;4-Hydroxyvalerate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxyvalerate [Moles/volume] in Serum or Plasma;4OH-valerate SerPl-sCnc;;ACTIVE;2.54;2.54 +79503-9;4-Hydroxyhippurate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxyhippurate [Moles/volume] in Serum or Plasma;4OH-hippurate SerPl-sCnc;;ACTIVE;2.54;2.54 +79504-7;Levulinate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Levulinate/Creatinine [Molar ratio] in Urine;Levulinate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79505-4;4-Hydroxy-3-Methoxyphenyllactate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxy-3-Methoxyphenyllactate [Moles/volume] in Serum or Plasma;4OH3methoxyphenyllactate SerPl-sCnc;;ACTIVE;2.54;2.54 +79506-2;Desaminotyrosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Desaminotyrosine [Moles/volume] in Serum or Plasma;Desaminotyrosine SerPl-sCnc;;ACTIVE;2.54;2.54 +79507-0;P-cresol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;P-cresol/Creatinine [Molar ratio] in Urine;p-Cresol/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79508-8;4-Hydroxymandelate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Hydroxymandelate [Moles/volume] in Serum or Plasma;4OHMandelate SerPl-sCnc;;ACTIVE;2.54;2.54 +7950-9;Legionella pneumophila 3 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 3 Ab [Titer] in Serum by Immunofluorescence;L pneumo3 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79509-6;Decenedioate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Decenedioate [Moles/volume] in Serum or Plasma;Decenedioate SerPl-sCnc;;ACTIVE;2.54;2.54 +79510-4;3-Hydroxyhippurate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxyhippurate [Moles/volume] in Serum or Plasma;3OH-hippurate SerPl-sCnc;;ACTIVE;2.54;2.54 +79511-2;Suberylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Suberylglycine [Moles/volume] in Serum or Plasma;Suberylgly SerPl-sCnc;;ACTIVE;2.54;2.54 +79512-0;Vanilloylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vanilloylglycine [Moles/volume] in Serum or Plasma;Vanilloylglycine SerPl-sCnc;;ACTIVE;2.54;2.54 +79513-8;1,4-Cyclohexanediol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;1,4-Cyclohexanediol [Moles/volume] in Serum or Plasma;1,4-Cyclohexanediol SerPl-sCnc;;ACTIVE;2.54;2.54 +79514-6;N-acetyltyrosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N-acetyltyrosine [Moles/volume] in Serum or Plasma;NAT SerPl-sCnc;;ACTIVE;2.54;2.54 +79515-3;Gentisate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Gentisate [Moles/volume] in Serum or Plasma;Gentisate SerPl-sCnc;;ACTIVE;2.54;2.54 +79516-1;Octenedioate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octenedioate (C8:1) [Moles/volume] in Serum or Plasma;Octenedioate SerPl-sCnc;;ACTIVE;2.54;2.54 +7951-7;Legionella pneumophila 4 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 4 Ab [Titer] in Serum by Immunofluorescence;L pneumo4 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79517-9;Desaminotyrosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Desaminotyrosine/Creatinine [Molar ratio] in Urine;Desaminotyrosine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79518-7;3-Hydroxybenzoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxybenzoate/Creatinine [Molar ratio] in Urine;3OH-benzoate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79519-5;Pimelate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pimelate [Moles/volume] in Serum or Plasma;Pimelate SerPl-sCnc;;ACTIVE;2.54;2.54 +79520-3;4-Deoxythreonate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;4-Deoxythreonate [Moles/volume] in Serum or Plasma;4-Deoxythreonate SerPl-sCnc;;ACTIVE;2.54;2.54 +79521-1;Lactyl lactate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lactyl lactate [Moles/volume] in Serum or Plasma;Lactyl lactate SerPl-sCnc;;ACTIVE;2.54;2.54 +79522-9;2,5-Furandicarboxylate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2,5-Furandicarboxylate/Creatinine [Molar ratio] in Urine;2,5-Furandicarboxylate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79523-7;3-(3-Hydroxyphenyl)propanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-(3-Hydroxyphenyl)propanoate [Moles/volume] in Serum or Plasma;hMPP SerPl-sCnc;;ACTIVE;2.54;2.54 +79524-5;P-cresol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;P-cresol [Moles/volume] in Serum or Plasma;p-Cresol SerPl-sCnc;;ACTIVE;2.54;2.54 +7952-5;Legionella pneumophila 5 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 5 Ab [Titer] in Serum by Immunofluorescence;L pneumo5 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79525-2;3-Hydroxysebacate.unsaturated;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxysebacate (3-OH-C8) unsaturated [Moles/volume] in Serum or Plasma;3OHsebacate.unsaturated SerPl-sCnc;;ACTIVE;2.54;2.54 +79526-0;3,5-Dihydroxybenzoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3,5-Dihydroxybenzoate [Moles/volume] in Serum or Plasma;3,5-Dihydroxybenzoate SerPl-sCnc;;ACTIVE;2.54;2.54 +79527-8;4-Deoxythreonate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-Deoxythreonate/Creatinine [Molar ratio] in Urine;4-Deoxythreonate/Creat Ur-sRto;;ACTIVE;2.54;2.54 +79528-6;5-Hydroxymethyl-2-Furoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Hydroxymethyl-2-Furoate [Moles/volume] in Serum or Plasma;5OH-methyl-2-furoate SerPl-sCnc;;ACTIVE;2.54;2.54 +79529-4;Basic mobility score;Score;Pt;^Patient;Qn;AM-PAC;APTA;2;Basic mobility score [AM-PAC];Basic mobility score [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79530-2;Basic mobility score standard error;Score;Pt;^Patient;Qn;AM-PAC;APTA;2;Basic mobility score standard error [AM-PAC];Basic mobility score SE [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79531-0;Basic mobility items;Num;Pt;^Patient;Qn;AM-PAC;APTA;2;Basic mobility items number [Activity Measure for Post-Acute Care];Basic mobility items # [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79532-8;Daily activity score;Score;Pt;^Patient;Qn;AM-PAC;APTA;2;Daily activity score [AM-PAC];Daily activity score [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +7953-3;Legionella pneumophila 6 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 6 Ab [Titer] in Serum by Immunofluorescence;L pneumo6 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79533-6;Daily activity score standard error;Score;Pt;^Patient;Qn;AM-PAC;APTA;2;Daily activity score standard error [AM-PAC];Daily activity score SE [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79534-4;Daily activity items;Num;Pt;^Patient;Qn;AM-PAC;APTA;2;Daily activity items number [Activity Measure for Post-Acute Care];Daily activity items # [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79535-1;Applied cognitive score;Score;Pt;^Patient;Qn;AM-PAC;APTA;2;Applied cognitive score [AM-PAC];Applied cognitive score [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79536-9;Applied cognitive score standard error;Score;Pt;^Patient;Qn;AM-PAC;APTA;2;Applied cognitive score standard error [AM-PAC];Applied cognitive score SE [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79537-7;Applied cognitive items;Num;Pt;^Patient;Qn;AM-PAC;APTA;2;Applied cognitive items number [Activity Measure for Post-Acute Care];Applied cognitive items # [AM-PAC];Portions Copyright © 2013 CRE Care. Used with permission.;ACTIVE;2.54;2.58 +79538-5;Formate;SCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Formate [Moles/volume] in Serum or Plasma by Confirmatory method;Formate SerPl Cfm-sCnc;;ACTIVE;2.54;2.54 +79539-3;HEDIS 2016-2018 Value Set - Urine Protein Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2016-2018 Value Set - Urine Protein Tests;HEDIS 2016-18 Urine Prot Tests;;DISCOURAGED;2.54;2.67 +79540-1;HEDIS 2016-2018 Value Set - PHQ-9 Total Score;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2016-2018 Value Set - PHQ-9 Total Score;HEDIS 2016-18 PHQ-9 Total Score;;DISCOURAGED;2.54;2.73 +7954-1;Legionella pneumophila 7 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 7 Ab [Titer] in Serum by Immunofluorescence;L pneumo7 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79541-9;HEDIS 2016-2020 Value Set - Lead Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2016-2020 Value Set - Lead Tests;HEDIS 2016-20 Lead Tests;;DISCOURAGED;2.54;2.69 +79542-7;HEDIS 2016 Value Set - HPV Vaccine Administered;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2016 Value Set - HPV Vaccine Administered;HEDIS 2016 HPV Vacc Admin;;DISCOURAGED;2.54;2.67 +79543-5;HEDIS 2016-2019 Value Set - ABO and Rh;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2016-2019 Value Set - ABO and Rh;HEDIS 2016-19 ABO and Rh;;DISCOURAGED;2.54;2.67 +79544-3;HEDIS 2016 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2016 Value Sets;HEDIS 2016 Value Sets;;DISCOURAGED;2.54;2.67 +79545-0;Fluid intake.oral.medication;Vol;Pt;Upper GI tract;Qn;Measured;IO_IN.MOLEC;2;Oral medication fluid intake [Volume] Measured;Oral med fluid in Vol Meas;;ACTIVE;2.54;2.54 +79546-8;Fluid intake.enteral tube.nutritional formula;Vol;Pt;Upper GI tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake enteral tube nutritional formula [Volume] Measured;Fluid in enteral tube nutr form Vol Meas;;ACTIVE;2.54;2.54 +79547-6;Fluid intake.intravascular.lipids;Vol;Pt;Vascular system;Qn;Measured;IO_IN.MOLEC;2;Intravascular lipids fluid intake [Volume] Measured;Intravascular lipids fluid in Vol Meas;;ACTIVE;2.54;2.54 +79548-4;Fluid intake.total intraoperative;Vol;Procedure dur;^Patient;Qn;Measured;IO_IN.MOLEC;2;Fluid intake total intraoperative [Volume] Measured;Fluid intake total intraop Vol Meas;;ACTIVE;2.54;2.54 +79549-2;Fluid output.urine nephrostomy;Vol;Pt;Urinary tract;Qn;Measured;IO_OUT.MOLEC;2;Urine output measured by nephrostomy;Fluid output urine nephrostomy Measured;;ACTIVE;2.54;2.56 +795-5;Erythrocytes;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Peritoneal fluid by Manual count;RBC # Prt Manual;;ACTIVE;1.0;2.73 +79550-0;Voids;Num;Pt;Urinary tract;Qn;;IO_OUT.ATOM;2;Number of voids;Num voids;;ACTIVE;2.54;2.54 +79551-8;Stools;Num;Pt;Lower GI tract;Qn;;IO_OUT.ATOM;2;Number of stools;Num stools;;ACTIVE;2.54;2.54 +79552-6;Stools.incontinent;Num;Pt;Lower GI tract;Qn;;IO_OUT.ATOM;2;Number of incontinent stools;Num incont stools;;ACTIVE;2.54;2.54 +79553-4;Fluid output.emesis;Num;Pt;Upper GI tract;Qn;;IO_OUT.MOLEC;2;Fluid output emesis [#];Fluid output emesis;;ACTIVE;2.54;2.54 +79554-2;Sanitary pads;Num;Pt;Genitourinary system;Qn;;IO_OUT.MOLEC;2;Number of sanitary pads;Num sanitary pads;;ACTIVE;2.54;2.54 +79555-9;Fluid output.total intraoperative;Vol;Procedure dur;^Patient;Qn;Measured;IO_OUT.MOLEC;2;Fluid output total intraoperative [Volume] Measured;Fluid output total intraop Vol Meas;;ACTIVE;2.54;2.54 +79556-7;Fluid output.neurological drain;Vol;Pt;Neurologic system;Qn;Measured;IO_OUT.MOLEC;2;Fluid output neurological drain [Volume] Measured;Fluid output neuro drain Vol Meas;;ACTIVE;2.54;2.54 +79557-5;Fluid output.musculoskeletal drain;Vol;Pt;Musculoskeletal system;Qn;Measured;IO_OUT.MOLEC;2;Fluid output musculoskeletal drain [Volume] Measured;Fluid output musculoskel drain Vol Meas;;ACTIVE;2.54;2.54 +7955-8;Legionella pneumophila 8 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 8 Ab [Titer] in Serum by Immunofluorescence;L pneumo8 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79558-3;Fluid output.pressure injury;Vol;Pt;Skin;Qn;Measured;IO_OUT.MOLEC;2;Fluid output pressure injury [Volume] Measured;Fluid output pressure injury Vol Meas;;ACTIVE;2.54;2.64 +79559-1;Fluid output.gastrointestinal drain;Vol;Pt;Gastrointestinal system;Qn;Measured;IO_OUT.MOLEC;2;Fluid output gastrointestinal drain [Volume] Measured;Fluid output GI drain Vol Meas;;ACTIVE;2.54;2.54 +79560-9;Fluid output.gastrointestinal ostomy;Vol;Pt;Gastrointestinal system;Qn;Measured;IO_OUT.MOLEC;2;Fluid output gastrointestinal ostomy [Volume] Measured;Fluid output GI ostomy Vol Meas;;ACTIVE;2.54;2.54 +79561-7;Fluid output.enteral tube;Vol;Pt;Upper GI tract;Qn;Measured;IO_OUT.MOLEC;2;Fluid output enteral tube [Volume] Measured;Fluid output enteral tube Vol Meas;;ACTIVE;2.54;2.54 +79562-5;Endotracheal tube diameter;Len;Pt;Intubation tube;Qn;;PULM;2;Endotracheal tube Diameter;ETT Diam;;ACTIVE;2.54;2.54 +79563-3;Mucopolysaccharidosis type I newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Mucopolysaccharidosis type I newborn screening panel;MPS I NBS Pnl DBS;;ACTIVE;2.54;2.54 +79564-1;Mucopolysaccharidosis type I;Imp;Pt;Bld.dot;Nom;;CHEM;1;Mucopolysaccharidosis type I newborn screen interpretation;MPS I DBS-Imp;;ACTIVE;2.54;2.54 +79565-8;Mucopolysaccharidosis type I newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;Mucopolysaccharidosis type I newborn screening comment-discussion;MPS I NBS comment;;ACTIVE;2.54;2.54 +7956-6;Legionella pneumophila 9 Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 9 Ab [Titer] in Serum by Immunofluorescence;L pneumo9 Ab Titr Ser IF;;ACTIVE;1.0h(2);2.7 +79566-6;Collection method;Type;Pt;Bld.dot;Nom;;SPEC;1;Collection method - DBS;Collection method DBS;;ACTIVE;2.54;2.61 +79567-4;Lysophosphatidylcholine(26:0);SCnc;Pt;Bld.dot;Qn;LC/MS/MS;CHEM;1;Lysophosphatidylcholine(26:0) [Moles/volume] in DBS by LC/MS/MS;LysoPC(26:0) DBS LC/MS/MS-sCnc;;ACTIVE;2.54;2.61 +79568-2;ABCD1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;ABCD1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;ABCD1 gene Mut Anl Bld/T;;ACTIVE;2.54;2.63 +79569-0;Blood product given;Type;Pt;^Patient;Nom;;H&P.HX;2;Blood product given [Type];Blood product Gvn Type;;ACTIVE;2.54;2.54 +79570-8;MLH1+MSH2+MSH6+PMS2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;MLH1+MSH2+MSH6+PMS2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;MLH1+MSH2+MSH6+PMS2 gn Del+Dup+Ful M;;ACTIVE;2.54;2.73 +79571-6;BCHE gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;BCHE gene full mutation analysis in Blood or Tissue by Sequencing;BCHE gene Full Mut Anl Bld/T Seq;;ACTIVE;2.54;2.65 +79572-4;Folate & tryptophan & metabolites panel;-;Pt;CSF;-;;PANEL.CHEM;1;Folate and tryptophan and metabolites panel - Cerebral spinal fluid;Folate + Tryp + Metabs Pnl CSF;;ACTIVE;2.54;2.54 +79573-2;Riboflavin & flavin mononucleotide & flavin adenine dinucleotide panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Riboflavin and flavin mononucleotide and flavin adenine dinucleotide panel - Serum or Plasma;Flavins Pnl SerPl;;ACTIVE;2.54;2.54 +7957-4;Legionella sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Legionella sp Ab [Units/volume] in Serum;Legionella Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79574-0;Folate & tryptophan & metabolites pattern;Imp;Pt;CSF;Nar;;CHEM;1;Folate and tryptophan and metabolites pattern [Interpretation] in Cerebral spinal fluid Narrative;Folate + Tryp + Metabs Pattern CSF-Imp;;ACTIVE;2.54;2.54 +79575-7;Metanephrine, Normetanephrine, 3-methoxytyramine & Creatinine panel;-;24H;Urine;-;;PANEL.CHEM;1;Metanephrine, Normetanephrine, 3-Methoxytyramine and Creatinine panel - 24 hour Urine;Mtnphs+3MT+Creat pnl 24h Ur;;ACTIVE;2.54;2.63 +79576-5;Allocystathionine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Allocystathionine [Moles/volume] in Serum or Plasma;Allocystathionine SerPl-sCnc;;ACTIVE;2.54;2.56 +79577-3;Levodopa/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Levodopa/Creatinine [Molar ratio] in Urine;L-Dopa/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79578-1;N6-Acetyl-L-lysine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N6-Acetyl-L-lysine [Moles/volume] in Serum or Plasma;N6-Ac-L-lys SerPl-sCnc;;ACTIVE;2.54;2.56 +79579-9;Alanylproline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alanylproline/Creatinine [Molar ratio] in Urine;Alanylproline/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79580-7;R- & S-beta aminoisobutyrate & D- & L-serine pattern;Imp;Pt;Urine;Nar;;CHEM;1;R- and S-beta aminoisobutyrate and D- and L-serine pattern [Interpretation] in Urine Narrative;R- + S-BAIB + D- + L-ser patt Ur-Imp;;ACTIVE;2.54;2.56 +79581-5;Alanylproline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alanylproline [Moles/volume] in Serum or Plasma;Alanylproline SerPl-sCnc;;ACTIVE;2.54;2.56 +7958-2;Leishmania sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Leishmania sp Ab [Presence] in Serum;Leishmania Ab Ser Ql;;ACTIVE;1.0h(2);2.56 +79582-3;Beta-ureidoisobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-ureidoisobutyrate [Moles/volume] in Serum or Plasma;Beta-UIB SerPl-sCnc;;ACTIVE;2.54;2.73 +79583-1;R- & S-beta aminoisobutyrate & D- & L-serine panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;R- and S-beta aminoisobutyrate and D- and L-serine panel - Serum or Plasma;R- + S-BAIB + D- + L-serine panel SerPl;;ACTIVE;2.54;2.54 +79584-9;Beta alanine & Beta aminoisobutyrate & Gamma aminobutyrate panel;-;Pt;Urine;-;;PANEL.CHEM;1;Beta alanine and Beta aminoisobutyrate and Gamma aminobutyrate panel - Urine;B-Alanine + B-AIB + GABA Pnl Ur;;ACTIVE;2.54;2.54 +79585-6;Aspartylglycine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aspartylglycine [Moles/volume] in Serum or Plasma;Aspartylglycine SerPl-sCnc;;ACTIVE;2.54;2.56 +79586-4;R- & S-beta aminoisobutyrate & D- & L-serine panel;-;Pt;CSF;-;;PANEL.CHEM;1;R- and S-beta aminoisobutyrate and D- and L-serine panel - Cerebral spinal fluid;R- + S-BAIB + D- + L-serine panel CSF;;ACTIVE;2.54;2.54 +79587-2;L-homoarginine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;L-homoarginine/Creatinine [Molar ratio] in Urine;L-homoarginine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79588-0;Prolylhydroxyproline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Prolylhydroxyproline [Moles/volume] in Serum or Plasma;Prolyl-OH-proline SerPl-sCnc;;ACTIVE;2.54;2.56 +79589-8;Aspartylglycosamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aspartylglycosamine [Moles/volume] in Serum or Plasma;Aspartylglycosamine SerPl-sCnc;;ACTIVE;2.54;2.56 +7959-0;Leptospira sp Ab;Titr;Pt;Ser;Qn;;MICRO;1;Leptospira sp Ab [Titer] in Serum;Leptospira Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +79590-6;Alpha aminoisobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha aminoisobutyrate [Moles/volume] in Serum or Plasma;A-AIB SerPl-sCnc;;ACTIVE;2.54;2.56 +79591-4;N-alpha acetyllysine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N-alpha acetyllysine [Moles/volume] in Serum or Plasma;N-A-acetyllysine SerPl-sCnc;;ACTIVE;2.54;2.56 +79592-2;Homocitrulline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homocitrulline/Creatinine [Molar ratio] in Urine;Homocitrulline/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79593-0;Allocystathionine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Allocystathionine/Creatinine [Molar ratio] in Urine;Allocystathionine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79594-8;Glycylproline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glycylproline/Creatinine [Molar ratio] in Urine;Gly-pro/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79595-5;N,N'-dimethylarginine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N,N'-dimethylarginine [Moles/volume] in Serum or Plasma;N,N'-dimethylarginine SerPl-sCnc;;ACTIVE;2.54;2.56 +79596-3;D-serine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;D-serine/Creatinine [Molar ratio] in Urine;D-serine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79597-1;N-monomethylarginine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N-monomethylarginine/Creatinine [Molar ratio] in Urine;N-monomethylarginine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79598-9;Beta alanine & Beta aminoisobutyrate & Gamma aminobutyrate pattern;Imp;Pt;Urine;Nar;;CHEM;1;Beta alanine and Beta aminoisobutyrate and Gamma aminobutyrate pattern [Interpretation] in Urine Narrative;B-Alanine + B-AIB + GABA patt Ur-Imp;;ACTIVE;2.54;2.56 +79599-7;Cysteate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Cysteate/Creatinine [Molar ratio] in Urine;Cysteate/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79600-3;Glutathione.reduced;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutathione.reduced [Moles/volume] in Serum or Plasma;GSH SerPl-sCnc;;ACTIVE;2.54;2.56 +79601-1;L-serine;SCnc;Pt;CSF;Qn;;CHEM;1;L-serine [Moles/volume] in Cerebral spinal fluid;L-serine CSF-sCnc;;ACTIVE;2.54;2.56 +79602-9;Homocarnosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Homocarnosine [Moles/volume] in Serum or Plasma;Homocarnosine SerPl-sCnc;;ACTIVE;2.54;2.56 +79603-7;Beta alanine & Beta aminoisobutyrate & Gamma aminobutyrate panel;-;Pt;CSF;-;;PANEL.CHEM;1;Beta alanine and Beta aminoisobutyrate and Gamma aminobutyrate panel - Cerebral spinal fluid;B-Alanine + B-AIB + GABA Pnl CSF;;ACTIVE;2.54;2.56 +79604-5;S-beta aminoisobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;S-beta aminoisobutyrate [Moles/volume] in Serum or Plasma;S-B-AIB SerPl-sCnc;;ACTIVE;2.54;2.56 +79605-2;R- & S-beta aminoisobutyrate & D- & L-serine panel;-;Pt;Urine;-;;PANEL.CHEM;1;R- and S-beta aminoisobutyrate and D- and L-serine panel - Urine;R- + S-BAIB + D- + L-serine panel Ur;;ACTIVE;2.54;2.54 +79606-0;Cysteate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cysteate [Moles/volume] in Serum or Plasma;Cysteate SerPl-sCnc;;ACTIVE;2.54;2.56 +79607-8;Saccharopine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Saccharopine [Moles/volume] in Serum or Plasma;Saccharopine SerPl-sCnc;;ACTIVE;2.54;2.56 +7960-8;Leptospira interrogans Ab;ACnc;Pt;Ser;Qn;HA;MICRO;1;Leptospira interrogans Ab [Units/volume] in Serum by Hemagglutination;L inter Ab Ser HA-aCnc;;ACTIVE;1.0h(2);2.73 +79608-6;2-Methyltyrosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Methyltyrosine [Moles/volume] in Serum or Plasma;2Me-tyrosine SerPl-sCnc;;ACTIVE;2.54;2.56 +79609-4;Glutathione.oxidized;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutathione.oxidized [Moles/volume] in Serum or Plasma;GSS SerPl-sCnc;;ACTIVE;2.54;2.56 +79610-2;D-serine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;D-serine [Moles/volume] in Serum or Plasma;D-serine SerPl-sCnc;;ACTIVE;2.54;2.56 +79611-0;Prolylhydroxyproline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Prolylhydroxyproline/Creatinine [Molar ratio] in Urine;Prolyl-OH-proline/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79612-8;L-homoarginine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;L-homoarginine [Moles/volume] in Serum or Plasma;L-homoarginine SerPl-sCnc;;ACTIVE;2.54;2.56 +79613-6;R- & S-beta aminoisobutyrate & D- & L-serine pattern;Imp;Pt;CSF;Nar;;CHEM;1;R- and S-beta aminoisobutyrate and D- and L-serine pattern [Interpretation] in Cerebral spinal fluid Narrative;R- + S-BAIB + D- + L-ser patt CSF-Imp;;ACTIVE;2.54;2.56 +79614-4;N-monomethylarginine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N-monomethylarginine [Moles/volume] in Serum or Plasma;N-monomethylarginine SerPl-sCnc;;ACTIVE;2.54;2.56 +79615-1;R-beta aminoisobutyrate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;R-beta aminoisobutyrate [Moles/volume] in Serum or Plasma;R-B-AIB SerPl-sCnc;;ACTIVE;2.54;2.56 +7961-6;Measles virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus Ab [Units/volume] in Serum;MeV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79616-9;S-beta aminoisobutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;S-beta aminoisobutyrate [Moles/volume] in Cerebral spinal fluid;S-B-AIB CSF-sCnc;;ACTIVE;2.54;2.56 +79617-7;Glycylproline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycylproline [Moles/volume] in Serum or Plasma;Gly-pro SerPl-sCnc;;ACTIVE;2.54;2.56 +79618-5;L-serine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;L-serine [Moles/volume] in Serum or Plasma;L-serine SerPl-sCnc;;ACTIVE;2.54;2.56 +79619-3;S-beta aminoisobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;S-beta aminoisobutyrate/Creatinine [Molar ratio] in Urine;S-B-AIB/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79620-1;Formiminoglutamate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Formiminoglutamate/Creatinine [Molar ratio] in Urine;Formiminoglutamate/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79621-9;Phenylalanine & Tyrosine panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Phenylalanine and Tyrosine panel - DBS;Phe + Tyr Pnl DBS;;ACTIVE;2.54;2.61 +79622-7;R-beta aminoisobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;R-beta aminoisobutyrate/Creatinine [Molar ratio] in Urine;R-B-AIB/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79623-5;Alpha aminoisobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha aminoisobutyrate/Creatinine [Molar ratio] in Urine;A-AIB/Creat Ur-sRto;;ACTIVE;2.54;2.56 +7962-4;Measles virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus IgG Ab [Units/volume] in Serum;MeV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79624-3;5-S-cysteinyldopa;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-S-cysteinyldopa [Moles/volume] in Serum or Plasma;5-S-cysteinyldopa SerPl-sCnc;;ACTIVE;2.54;2.56 +79625-0;Aspartylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Aspartylglycine/Creatinine [Molar ratio] in Urine;Aspartylglycine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79626-8;L-leucyl-L-proline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;L-leucyl-L-proline/Creatinine [Molar ratio] in Urine;L-leu-L-pro/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79627-6;N-alpha acetyllysine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N-alpha acetyllysine/Creatinine [Molar ratio] in Urine;N-A-acetyllysine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79628-4;Formiminoglutamate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Formiminoglutamate [Moles/volume] in Serum or Plasma;Formiminoglutamate SerPl-sCnc;;ACTIVE;2.54;2.56 +79629-2;R-beta aminoisobutyrate;SCnc;Pt;CSF;Qn;;CHEM;1;R-beta aminoisobutyrate [Moles/volume] in Cerebral spinal fluid;R-B-AIB CSF-sCnc;;ACTIVE;2.54;2.56 +796-3;Erythrocytes;NCnc;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Synovial fluid by Automated count;RBC # Snv Auto;;ACTIVE;1.0;2.73 +79630-0;R- & S-beta aminoisobutyrate & D- & L-serine pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;R- and S-beta aminoisobutyrate and D- and L-serine pattern [Interpretation] in Serum or Plasma Narrative;R- + S-BAIB + D- + L-ser patt SerPl-Imp;;ACTIVE;2.54;2.56 +79631-8;L-homoserine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;L-homoserine [Moles/volume] in Serum or Plasma;L-homoserine SerPl-sCnc;;ACTIVE;2.54;2.56 +7963-2;Measles virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Measles virus IgM Ab [Units/volume] in Serum;MeV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79632-6;Homocarnosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homocarnosine/Creatinine [Molar ratio] in Urine;Homocarnosine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79633-4;L-leucyl-L-proline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;L-leucyl-L-proline [Moles/volume] in Serum or Plasma;L-leu-L-pro SerPl-sCnc;;ACTIVE;2.54;2.56 +79634-2;N6-Acetyl-L-lysine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N6-Acetyl-L-lysine/Creatinine [Molar ratio] in Urine;N6-Ac-L-lys/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79635-9;N,N-dimethylarginine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N,N-dimethylarginine/Creatinine [Molar ratio] in Urine;N,N-dimethylarginine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79636-7;Aspartylglycosamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Aspartylglycosamine/Creatinine [Molar ratio] in Urine;Aspartylglycosamine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79637-5;Glutathione.oxidized/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutathione.oxidized/Creatinine [Molar ratio] in Urine;GSS/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79638-3;Beta alanine & Beta aminoisobutyrate & Gamma aminobutyrate pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Beta alanine and Beta aminoisobutyrate and Gamma aminobutyrate pattern [Interpretation] in Serum or Plasma Narrative;B-Alanine + B-AIB + GABA patt SerPl-Imp;;ACTIVE;2.54;2.58 +79639-1;N,N'-dimethylarginine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;N,N'-dimethylarginine/Creatinine [Molar ratio] in Urine;N,N'-dimethylarginine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +7964-0;Measles virus RNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Measles virus RNA [Presence] in Nose by NAA with probe detection;MeV RNA Nose Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +79640-9;Saccharopine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Saccharopine/Creatinine [Molar ratio] in Urine;Saccharopine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79641-7;Glutathione.reduced/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutathione.reduced/Creatinine [Molar ratio] in Urine;GSH/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79642-5;Beta alanine & Beta aminoisobutyrate & Gamma aminobutyrate pattern;Imp;Pt;CSF;Nar;;CHEM;1;Beta alanine and Beta aminoisobutyrate and Gamma aminobutyrate pattern [Interpretation] in Cerebral spinal fluid Narrative;B-Alanine + B-AIB + GABA patt CSF-Imp;;ACTIVE;2.54;2.58 +79643-3;5-S-cysteinyldopa/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5-S-cysteinyldopa/Creatinine [Molar ratio] in Urine;5-S-cysteinyldopa/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79644-1;L-homoserine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;L-homoserine/Creatinine [Molar ratio] in Urine;L-homoserine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79645-8;L-serine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;L-serine/Creatinine [Molar ratio] in Urine;L-serine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79646-6;Delta aminolevulinate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Delta aminolevulinate [Moles/volume] in Serum or Plasma;D-ALA SerPl-sCnc;;ACTIVE;2.54;2.56 +79647-4;Beta-ureidoisobutyrate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Beta-ureidoisobutyrate/Creatinine [Molar ratio] in Urine;Beta-UIB/Creat Ur-sRto;;ACTIVE;2.54;2.73 +79648-2;D-serine;SCnc;Pt;CSF;Qn;;CHEM;1;D-serine [Moles/volume] in Cerebral spinal fluid;D-serine CSF-sCnc;;ACTIVE;2.54;2.56 +79649-0;Homocysteine cysteine disulfide/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Homocysteine cysteine disulfide/Creatinine [Molar ratio] in Urine;Hycs-Cys diS/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79650-8;Beta alanine & Beta aminoisobutyrate & Gamma aminobutyrate panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Beta alanine and Beta aminoisobutyrate and Gamma aminobutyrate panel - Serum or Plasma;B-Alanine + B-AIB + GABA Pnl SerPl;;ACTIVE;2.54;2.56 +79651-6;Dihydrothymine;SCnc;Pt;CSF;Qn;;CHEM;1;Dihydrothymine [Moles/volume] in Cerebral spinal fluid;Dihydrothymine CSF-sCnc;;ACTIVE;2.54;2.56 +79652-4;5-Aminoimidazole-4-carboxamide;SCnc;Pt;CSF;Qn;;CHEM;1;5-Aminoimidazole-4-carboxamide [Moles/volume] in Cerebral spinal fluid;5-Aminoimidazole-4-carboxamide CSF-sCnc;;ACTIVE;2.54;2.56 +79653-2;Dihydroorotate;SCnc;Pt;Urine;Qn;;CHEM;1;Dihydroorotate [Moles/volume] in Urine;Dihydroorotate Ur-sCnc;;ACTIVE;2.54;2.56 +79654-0;Dihydroorotate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dihydroorotate [Moles/volume] in Serum or Plasma;Dihydroorotate SerPl-sCnc;;ACTIVE;2.54;2.73 +79655-7;Cytosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cytosine [Moles/volume] in Serum or Plasma;Cytosine SerPl-sCnc;;ACTIVE;2.54;2.56 +79656-5;N-carbamoyl beta alanine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;N-carbamoyl beta alanine [Moles/volume] in Serum or Plasma;N-carbamoyl B-alanine SerPl-sCnc;;ACTIVE;2.54;2.73 +7965-7;Mumps virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus Ab [Units/volume] in Serum;MuV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79657-3;Pseudouridine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pseudouridine [Moles/volume] in Serum or Plasma;Pseudouridine SerPl-sCnc;;ACTIVE;2.54;2.56 +79658-1;Cytosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Cytosine/Creatinine [Molar ratio] in Urine;Cytosine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79659-9;Purine & Pyrimidine pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Purine and Pyrimidine pattern [Interpretation] in Serum or Plasma Narrative;Purine + Pyrimidine pattern SerPl-Imp;;ACTIVE;2.54;2.73 +79660-7;Guanosine;SCnc;Pt;CSF;Qn;;CHEM;1;Guanosine [Moles/volume] in Cerebral spinal fluid;Guanosine CSF-sCnc;;ACTIVE;2.54;2.56 +79661-5;Dihydroorotate;SCnc;Pt;CSF;Qn;;CHEM;1;Dihydroorotate [Moles/volume] in Cerebral spinal fluid;Dihydroorotate CSF-sCnc;;ACTIVE;2.54;2.56 +79662-3;Allopurinol;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Allopurinol [Moles/volume] in Serum or Plasma;Allopurinol SerPl-sCnc;;ACTIVE;2.54;2.54 +79663-1;Guanine;SCnc;Pt;CSF;Qn;;CHEM;1;Guanine [Moles/volume] in Cerebral spinal fluid;Guanine CSF-sCnc;;ACTIVE;2.54;2.56 +79664-9;N-carbamoyl beta alanine;SCnc;Pt;CSF;Qn;;CHEM;1;N-carbamoyl beta alanine [Moles/volume] in Cerebral spinal fluid;N-carbamoyl B-alanine CSF-sCnc;;ACTIVE;2.54;2.56 +7966-5;Mumps virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus IgG Ab [Units/volume] in Serum;MuV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79665-6;Purine & Pyrimidine panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Purine and Pyrimidine panel - Serum or Plasma;Purine + Pyrimidine Pnl SerPl;;ACTIVE;2.54;2.54 +79666-4;Purine & Pyrimidine pattern;Imp;Pt;CSF;Nar;;CHEM;1;Purine and Pyrimidine pattern [Interpretation] in Cerebral spinal fluid Narrative;Purine + Pyrimidine pattern CSF-Imp;;ACTIVE;2.54;2.56 +79667-2;5,6-Dihydrouridine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5,6-Dihydrouridine [Moles/volume] in Serum or Plasma;5,6-Dihydrouridine SerPl-sCnc;;ACTIVE;2.54;2.56 +79668-0;Purine & Pyrimidine panel;-;Pt;CSF;-;;PANEL.CHEM;1;Purine and Pyrimidine panel - Cerebral spinal fluid;Purine + Pyrimidine Pnl CSF;;ACTIVE;2.54;2.54 +79669-8;Dihydrothymine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Dihydrothymine [Moles/volume] in Serum or Plasma;Dihydrothymine SerPl-sCnc;;ACTIVE;2.54;2.73 +79670-6;Guanosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Guanosine [Moles/volume] in Serum or Plasma;Guanosine SerPl-sCnc;;ACTIVE;2.54;2.73 +79671-4;Cytidine;SCnc;Pt;CSF;Qn;;CHEM;1;Cytidine [Moles/volume] in Cerebral spinal fluid;Cytidine CSF-sCnc;;ACTIVE;2.54;2.56 +79672-2;5-Aminoimidazole-4-carboxamide/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5-Aminoimidazole-4-carboxamide/Creatinine [Molar ratio] in Urine;5-Aminoimidazole-4-carboxamide/Cr U-sCnc;;ACTIVE;2.54;2.68 +7967-3;Mumps virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Mumps virus IgM Ab [Units/volume] in Serum;MuV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79673-0;Purine & Pyrimidine panel;-;Pt;Urine;-;;PANEL.CHEM;1;Purine and Pyrimidine panel - Urine;Purine + Pyrimidine Pnl Ur;;ACTIVE;2.54;2.54 +79674-8;Pseudouridine;SCnc;Pt;CSF;Qn;;CHEM;1;Pseudouridine [Moles/volume] in Cerebral spinal fluid;Pseudouridine CSF-sCnc;;ACTIVE;2.54;2.56 +79675-5;Cytidine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cytidine [Moles/volume] in Serum or Plasma;Cytidine SerPl-sCnc;;ACTIVE;2.54;2.56 +79676-3;5,6-Dihydrouridine;SCnc;Pt;CSF;Qn;;CHEM;1;5,6-Dihydrouridine [Moles/volume] in Cerebral spinal fluid;5,6-Dihydrouridine CSF-sCnc;;ACTIVE;2.54;2.56 +79677-1;Purine & Pyrimidine pattern;Imp;Pt;Urine;Nar;;CHEM;1;Purine and Pyrimidine pattern [Interpretation] in Urine Narrative;Purine + Pyrimidine pattern Ur-Imp;;ACTIVE;2.54;2.73 +79678-9;5,6-Dihydrouridine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5,6-Dihydrouridine/Creatinine [Molar ratio] in Urine;5,6-Dihydrouridine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79679-7;5-Aminoimidazole-4-carboxamide;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Aminoimidazole-4-carboxamide [Moles/volume] in Serum or Plasma;5-Aminoimidazole-4-carboxamide SrPl-sCnc;;ACTIVE;2.54;2.56 +79680-5;2,8-Dihydroxyadenine;SCnc;Pt;CSF;Qn;;CHEM;1;2,8-dihydroxyadenine [Moles/volume] in Cerebral spinal fluid;2,8-dihydroxyadenine CSF-sCnc;;ACTIVE;2.54;2.56 +7968-1;Mumps virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Mumps virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;MuV RNA CSF Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +79681-3;Allopurinol/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Allopurinol/Creatinine [Molar ratio] in Urine;Allopurinol/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79682-1;5,6-Dihydrouracil;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5,6-Dihydrouracil [Moles/volume] in Serum or Plasma;5,6-Dihydrouracil SerPl-sCnc;;ACTIVE;2.54;2.73 +79683-9;Cytosine;SCnc;Pt;CSF;Qn;;CHEM;1;Cytosine [Moles/volume] in Cerebral spinal fluid;Cytosine CSF-sCnc;;ACTIVE;2.54;2.56 +79684-7;Cytidine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Cytidine/Creatinine [Molar ratio] in Urine;Cytidine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79685-4;5,6-Dihydrouracil/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;5,6-Dihydrouracil/Creatinine [Molar ratio] in Urine;5,6-Dihydrouracil/Creat Ur-sRto;;ACTIVE;2.54;2.73 +79686-2;5-hydroxymethyluracil;SCnc;Pt;CSF;Qn;;CHEM;1;5-Hydroxymethyluracil [Moles/volume] in Cerebral spinal fluid;5OH-methyluracil CSF-sCnc;;ACTIVE;2.54;2.56 +79687-0;2,8-Dihydroxyadenine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2,8-dihydroxyadenine/Creatinine [Molar ratio] in Urine;2,8-dihydroxyadenine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +79688-8;5-hydroxymethyluracil;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;5-Hydroxymethyluracil [Moles/volume] in Serum or Plasma;5OH-methyluracil SerPl-sCnc;;ACTIVE;2.54;2.56 +79689-6;Allopurinol;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Allopurinol [Moles/volume] in Cerebral spinal fluid;Allopurinol CSF-sCnc;;ACTIVE;2.54;2.54 +79690-4;Guanine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Guanine [Moles/volume] in Serum or Plasma;Guanine SerPl-sCnc;;ACTIVE;2.54;2.56 +79691-2;Oxipurinol;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Oxipurinol [Moles/volume] in Cerebral spinal fluid;Oxipurinol CSF-sCnc;;ACTIVE;2.54;2.54 +79692-0;2,8-Dihydroxyadenine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2,8-dihydroxyadenine [Moles/volume] in Serum or Plasma;2,8-dihydroxyadenine SerPl-sCnc;;ACTIVE;2.54;2.56 +79693-8;5,6-Dihydrouracil;SCnc;Pt;CSF;Qn;;CHEM;1;5,6-Dihydrouracil [Moles/volume] in Cerebral spinal fluid;5,6-Dihydrouracil CSF-sCnc;;ACTIVE;2.54;2.56 +79694-6;Eicosadienoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Eicosadienoate (C20:2w6) [Moles/volume] in Serum or Plasma;Eicosadienoate SerPl-sCnc;;ACTIVE;2.54;2.56 +79695-3;Octadecatetraenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Octadecatetraenoate (C18:4w3) [Moles/volume] in Serum or Plasma;Octadecatetraenoate SerPl-sCnc;;ACTIVE;2.54;2.56 +79696-1;cis-11-Eicosenoate;EntSub;Pt;RBC;Qn;;CHEM;1;cis-11-Eicosenoate (cis 11 C20:1w9) [Entitic substance] in Red Blood Cells;cis-11-Eicosenoate EntSub RBC;;ACTIVE;2.54;2.56 +79697-9;Docosadienoate;EntSub;Pt;RBC;Qn;;CHEM;1;Docosadienoate (C22:2w6) [Entitic substance] in Red Blood Cells;Docosadienoate EntSub RBC;;ACTIVE;2.54;2.56 +79698-7;Docosadienoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosadienoate (C22:2w6) [Moles/volume] in Serum or Plasma;Docosadienoate SerPl-sCnc;;ACTIVE;2.54;2.56 +7969-9;Mycoplasma pneumoniae Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae Ab [Units/volume] in Serum;M pneumo Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79699-5;cis-11-Eicosenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;cis-11-Eicosenoate (cis 11 C20:1w9) [Moles/volume] in Serum or Plasma;cis-11-Eicosenoate SerPl-sCnc;;ACTIVE;2.54;2.56 +79700-1;cis-11,14-Eicosadienoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;cis-11,14-Eicosadienoate (cis 11,14 C20:2w6) [Moles/volume] in Serum or Plasma;cis-11,14-Eicosadienoate SerPl-sCnc;;ACTIVE;2.54;2.56 +79701-9;Fatty acids.very long chain.C22:1n9;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain.C22:1n9 (Erucate) [Moles/volume] in Serum or Plasma;VLCFA.C22:1n9 SerPl-sCnc;;ACTIVE;2.54;2.56 +79702-7;cis-13-Eicosenoate;EntSub;Pt;RBC;Qn;;CHEM;1;cis-13-Eicosenoate (cis 13 C20:1w7) [Entitic substance] in Red Blood Cells;cis-13-Eicosenoate EntSub RBC;;ACTIVE;2.54;2.56 +79703-5;cis-13-Eicosenoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;cis-13-Eicosenoate (cis 13 C20:1w7) [Moles/volume] in Serum or Plasma;cis-13-Eicosenoate SerPl-sCnc;;ACTIVE;2.54;2.56 +79704-3;Homo-gamma linolenate;EntSub;Pt;RBC;Qn;;CHEM;1;Homo-gamma Linolenate (C20:3w6) [Entitic substance] in Red Blood Cells;Homo-G Linolenate EntSub RBC;;ACTIVE;2.54;2.56 +79705-0;Eicosadienoate;EntSub;Pt;RBC;Qn;;CHEM;1;Eicosadienoate (C20:2w6) [Entitic substance] in Red Blood Cells;Eicosadienoate EntSub RBC;;ACTIVE;2.54;2.56 +79706-8;Octadecatetraenoate;EntSub;Pt;RBC;Qn;;CHEM;1;Octadecatetraenoate (C18:4w3) [Entitic substance] in Red Blood Cells;Octadecatetraenoate EntSub RBC;;ACTIVE;2.54;2.56 +7970-7;Mycoplasma pneumoniae Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum;M pneumo IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79707-6;Fatty acids.very long chain.C26:1/C22:0;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Fatty acids.very long chain C26:1 (Hexacosenoate)/C22:0 (Docosanoate) [Molar ratio] in Serum or Plasma;VLCFA C26:1/C22:0 SerPl-sRto;;ACTIVE;2.54;2.56 +79708-4;Borrelia burgdorferi Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;B burgdor IgG SerPl Ql IF;;ACTIVE;2.54;2.56 +79709-2;Borrelia burgdorferi Ab.IgG;PrThr;Pt;CSF;Ord;IF;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;B burgdor IgG CSF Ql IF;;ACTIVE;2.54;2.56 +797-1;Erythrocytes;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Synovial fluid by Manual count;RBC # Snv Manual;;ACTIVE;1.0;2.73 +79710-0;Potassium;MCnt;Pt;Hair;Qn;;CHEM;1;Potassium [Mass/mass] in Hair;Potassium Hair-mCnt;;ACTIVE;2.54;2.54 +79711-8;HLA-B*58:01;PrThr;Pt;Bld/Tiss;Ord;;MOLPATH.PHARMG;1;HLA-B*58:01 [Presence] in Blood or Tissue;HLA-B*58:01 Bld/T Ql;;ACTIVE;2.54;2.73 +79712-6;HLA-A*31:01;PrThr;Pt;Bld/Tiss;Ord;;MOLPATH.PHARMG;1;HLA-A*31:01 [Presence] in Blood or Tissue;HLA-A*31:01 Bld/T Ql;;ACTIVE;2.54;2.56 +79713-4;TPMT gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;TPMT gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;TPMT gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.73 +79714-2;CYP2C19 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C19 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP2C19 gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.73 +7971-5;Naegleria fowleri Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Naegleria fowleri Ab [Presence] in Cerebral spinal fluid;N fowleri Ab CSF Ql;;ACTIVE;1.0h(2);2.56 +79715-9;CYP2D6 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2D6 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP2D6 gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.73 +79716-7;CYP2C9 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2C9 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP2C9 gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.73 +79717-5;CYP3A5 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP3A5 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP3A5 gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.73 +79718-3;UGT1A1 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;UGT1A1 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;UGT1A1 gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.67 +79719-1;DPYD gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;DPYD gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;DPYD gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.67 +79720-9;CYP2B6 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP2B6 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP2B6 gene prod met act imp Bld/T-Imp;;ACTIVE;2.54;2.67 +79721-7;CYP4F2 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP4F2 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP4F2 gene prod met activ imp Bld/T-Imp;;ACTIVE;2.54;2.67 +79722-5;SLCO1B1 gene product functional interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;SLCO1B1 gene product functional interpretation in Blood or Tissue Qualitative by Molecular genetics method;SLCO1B1 gene prod funct imp Bld/T;;ACTIVE;2.54;2.67 +7972-3;Neisseria meningitidis serogroup Y Ab;PrThr;Pt;XXX;Ord;;MICRO;1;Neisseria meningitidis serogroup Y Ab [Presence] in Specimen;N men sg Y Ab Spec Ql;;ACTIVE;1.0h(2);2.69 +79723-3;Age at 2nd eye involvement in a patient with initial unilateral retinoblastoma;Time;Pt;^Patient;Qn;;EYE.HX.NEI;2;Age at 2nd eye involvement in a patient with initial unilateral retinoblastoma;Age 2nd eye in initial unilat RB;;ACTIVE;2.54;2.54 +79724-1;Age at first awareness of night blindness;Time;Pt;^Patient;Qn;;EYE.HX.NEI;2;Age at first awareness of night blindness;Age at 1st night blindness aware;;ACTIVE;2.54;2.54 +79725-8;Amblyopia;Type;Pt;Eye;Nom;;EYE.PX.NEI;2;Amblyopia type;Amblyopia type;;ACTIVE;2.54;2.54 +79726-6;Can elevate above midline;Find;Pt;Eye.right;Ord;;EYE.PX.NEI;2;Eye.right Can elevate above midline;Eye-R Can elevate above midline;;ACTIVE;2.54;2.54 +79727-4;Can elevate above midline;Find;Pt;Eye.left;Ord;;EYE.PX.NEI;2;Eye.left Can elevate above midline;Eye-L Can elevate above midline;;ACTIVE;2.54;2.54 +79728-2;Coloboma location;Anat;Pt;Eye.right;Nom;;EYE.PX.NEI;2;Right eye Coloboma location [Anatomy];R eye Coloboma loc;;ACTIVE;2.54;2.68 +79729-0;Coloboma location;Anat;Pt;Eye.left;Nom;;EYE.PX.NEI;2;Left eye Coloboma location [Anatomy];L eye Coloboma loc;;ACTIVE;2.54;2.68 +79730-8;Color vision;Type;Pt;Eye.right;Nom;;EYE.PX.NEI;2;Right eye Color vision;R eye Color vision;;ACTIVE;2.54;2.68 +7973-1;Norovirus;PrThr;Pt;Stool;Ord;Microscopy.electron;MICRO;1;Norovirus [Presence] in Stool by Electron microscopy;Norovirus Stl Ql EM;;ACTIVE;1.0h(2);2.56 +79731-6;Color vision;Type;Pt;Eye.left;Nom;;EYE.PX.NEI;2;Left eye Color vision;L eye Color vision;;ACTIVE;2.54;2.68 +79732-4;Color vision exam method;Type;Pt;Eye;Nom;*;EYE.PX.NEI;2;Type of Color vision exam method;Color vision exam type;;ACTIVE;2.54;2.54 +79733-2;Visual convergence exam;Find;Pt;Eye;Nom;;EYE.PX.NEI;2;Eye Visual convergence exam;Eye Visual converg exam;;ACTIVE;2.54;2.68 +79734-0;Initial unilateral retinoblastoma that later developed into bilateral disease;Hx;Pt;^Patient;Ord;;EYE.HX.NEI;2;Initial unilateral retinoblastoma that later developed into bilateral disease;Initial unilat RB dev into bilat dis;;ACTIVE;2.54;2.54 +79735-7;Evidence supporting myopathy;Type;Pt;^Patient;Nom;;EYE.HX.NEI;2;Type of Evidence supporting myopathy;Type of Evid supp myopathy;;ACTIVE;2.54;2.54 +79736-5;Congenital cranial dysinnervation syndrome (CCDS) suspected;Type;Pt;^Patient;Nom;;EYE.HX.NEI;2;Type of Congenital cranial dysinnervation syndrome (CCDS) suspected;Type of CCDS susp;;ACTIVE;2.54;2.54 +79737-3;Gross defects;Find;Pt;Eye.right;Nom;;EYE.PX.NEI;2;Right eye Gross defects;R eye Gross defects;;ACTIVE;2.54;2.68 +79738-1;Gross defects;Find;Pt;Eye.left;Nom;;EYE.PX.NEI;2;Left eye Gross defects;L eye Gross defects;;ACTIVE;2.54;2.68 +79739-9;Horizontal diameter;Len;Pt;Cornea.left;Qn;;EYE.PX.NEI;2;Left cornea Horizontal diameter;L cornea Horiz diam;;ACTIVE;2.54;2.68 +79740-7;Horizontal diameter;Len;Pt;Cornea.right;Qn;;EYE.PX.NEI;2;Right cornea Horizontal diameter;R cornea Horiz diam;;ACTIVE;2.54;2.68 +79741-5;Eye-related brain MRI findings;Find;Pt;^Patient;Nom;;EYE.HX.NEI;2;Eye-related brain MRI findings;Eye-rel brain MRI find;;ACTIVE;2.54;2.54 +79742-3;Inheritance pattern based on family history;Hx;Pt;^Patient;Nom;;EYE.HX.NEI;2;Inheritance pattern based on family history;Inheritance pattern based on fam hx;;ACTIVE;2.54;2.54 +79743-1;Intraocular retinoblastoma classification^at initial diagnosis;Class;Pt;Eye.right;Ord;ICRB;EYE.HX.NEI;2;International classification of retinoblastoma Intraocular retinoblastoma classification at initial diagnosis Right eye;ICRB class at init diagnosis Eye-R;;ACTIVE;2.54;2.54 +79744-9;Intraocular retinoblastoma classification^at initial diagnosis;Class;Pt;Eye.left;Ord;ICRB;EYE.HX.NEI;2;International classification of retinoblastoma Intraocular retinoblastoma classification at initial diagnosis Left eye;ICRB class as init diagnosis Eye-L;;ACTIVE;2.54;2.54 +79745-6;Intraocular retinoblastoma classification^at final disease stage;Class;Pt;Eye.right;Ord;ICRB;EYE.HX.NEI;2;International classification of retinoblastoma Intraocular retinoblastoma classification at final disease stage Right eye;ICRB class final dis stage Eye-R;;ACTIVE;2.54;2.54 +79746-4;Intraocular retinoblastoma classification^at final disease stage;Class;Pt;Eye.left;Ord;ICRB;EYE.HX.NEI;2;International classification of retinoblastoma Intraocular retinoblastoma classification at final disease stage Left eye;ICRB class final dis stage Eye-L;;ACTIVE;2.54;2.54 +79747-2;Extraocular retinoblastoma classification^at final disease stage;Class;Pt;Eye.right;Ord;Reese-Ellsworth system;EYE.HX.NEI;2;Reese-Ellsworth Extraocular retinoblastoma classification at final disease stage Right eye;Reese-Ells class final dis stage Eye-R;;ACTIVE;2.54;2.54 +79748-0;Extraocular retinoblastoma classification^at final disease stage;Class;Pt;Eye.left;Ord;Reese-Ellsworth system;EYE.HX.NEI;2;Reese-Ellsworth Extraocular retinoblastoma classification at final disease stage Left eye;Reese-Ells class final dis stage Eye-L;;ACTIVE;2.54;2.54 +7974-9;Norovirus RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Norovirus RNA [Presence] in Stool by NAA with probe detection;Norovirus RNA Stl Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +79749-8;Jaw winking;Pr;Pt;Eye.right;Nom;;EYE.PX.NEI;2;Right eye Jaw winking [Presence];R eye Jaw winking;;ACTIVE;2.54;2.68 +79750-6;Jaw winking;Pr;Pt;Eye.left;Nom;;EYE.PX.NEI;2;Left eye Jaw winking [Presence];L eye Jaw winking;;ACTIVE;2.54;2.68 +79751-4;Eye problem;Hx;Pt;^Family member;Nar;;EYE.HX.NEI;2;Family history of Eye problems;Family hx Eye problems;;ACTIVE;2.54;2.54 +79752-2;Eye problem;Hx;Pt;Eye.right;Nom;;EYE.HX.NEI;2;History of Problem(s) affecting Right eye;Hx of Prob Eye-R;;ACTIVE;2.54;2.54 +79753-0;Eye problem;Hx;Pt;Eye.left;Nom;;EYE.HX.NEI;2;History of Problem(s) affecting Left eye;Hx of Prob Eye-L;;ACTIVE;2.54;2.54 +79754-8;Corneal dystrophy suspected;Type;Pt;Cornea;Nom;;EYE.HX.NEI;2;Type of Corneal dystrophy suspected;Type of Corneal dystrophy susp;;ACTIVE;2.54;2.68 +79755-5;Ophthalmologic treatment;Hx;Pt;Eye.right;Nom;;EYE.HX.NEI;2;Right eye Ophthalmologic treatment;R eye Ophthalmologic tx;;ACTIVE;2.54;2.68 +7975-6;Human papilloma virus Ab;PrThr;Pt;Genital;Ord;;MICRO;1;Human papilloma virus Ab [Presence] in Genital specimen;HPV Ab Genital Ql;;ACTIVE;1.0h(2);2.56 +79756-3;Ophthalmologic treatment;Hx;Pt;Eye.left;Nom;;EYE.HX.NEI;2;Left eye Ophthalmologic treatment;L eye Ophthalmologic tx;;ACTIVE;2.54;2.68 +79757-1;Prior molecular testing related to ophthalmological condition;Hx;Pt;^Patient;Nar;;EYE.HX.NEI;2;Prior molecular testing related to ophthalmological condition;Prior molec test related to ophth cond;;ACTIVE;2.54;2.68 +79758-9;Progression of problem since birth;Hx;Pt;^Patient;Nom;;EYE.HX.NEI;2;Progression of problem since birth;Progress of prob since birth;;ACTIVE;2.54;2.54 +79759-7;Strabismus;Type;Pt;Eye;Nom;;EYE.HX.NEI;2;Type of Strabismus;Type of Strabismus;;ACTIVE;2.54;2.54 +79760-5;Systemic findings and diseases associated with ophthalmological condition;Prid;Pt;^Patient;Nom;;EYE.HX.NEI;2;Systemic findings and diseases associated with ophthalmological condition;System find + dis assoc w ophth cond;;ACTIVE;2.54;2.54 +79761-3;Use of supplemental oxygen^at birth;Hx;Pt;^Patient;Ord;;EYE.HX.NEI;2;Use of supplemental oxygen--at birth;Use of suppl O2--@ birth;;ACTIVE;2.54;2.68 +79762-1;Vertical diameter;Len;Pt;Cornea.right;Qn;;EYE.PX.NEI;2;Right cornea Vertical diameter;R cornea Vert diam;;ACTIVE;2.54;2.68 +79763-9;Vertical diameter;Len;Pt;Cornea.left;Qn;;EYE.PX.NEI;2;Left cornea Vertical diameter;L cornea Vert diam;;ACTIVE;2.54;2.68 +7976-4;Paracoccidioides brasiliensis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Paracoccidioides brasiliensis Ab [Units/volume] in Serum;P brasilien Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79764-7;Tonometer;Type;Pt;Tonometry device;Nom;;EYE.TONOMETRY.NEI;2;Type of Tonometer;Type of Tonometer;;ACTIVE;2.54;2.54 +79765-4;Ocular alignment;Type;Pt;Eye;Nom;Cover test;EYE.PX.NEI;2;Type of Ocular alignment by Cover test;Type of Ocular align by Cover test;;ACTIVE;2.54;2.61 +79766-2;Head posture for nystagmus null-point;Find;Pt;Head;Nom;;EYE.PX.NEI;2;Head posture for nystagmus null-point;Head post nystag null-point;;ACTIVE;2.54;2.54 +79767-0;Nystagmus frequency;Find;Pt;Eye;Ord;;EYE.PX.NEI;2;Eye Nystagmus frequency;Eye Nystagmus freq;;ACTIVE;2.54;2.68 +79768-8;Platelet dense bodies;PrThr;Pt;Bld;Ord;Microscopy.electron;HEM/BC;1;Platelet dense bodies [Presence] in Blood by Electron microscopy;Plt dense bodies Bld Ql EM;;ACTIVE;2.54;2.73 +79769-6;Arden ratio;ElpotRto;Pt;Retina.right;Qn;Electrooculogram;EYE.EOG.NEI;2;Right retina Arden ratio by EOG;R ret Arden rto EOG;;ACTIVE;2.54;2.68 +79770-4;Arden ratio;ElpotRto;Pt;Retina.left;Qn;Electrooculogram;EYE.EOG.NEI;2;Left retina Arden ratio by EOG;L ret Arden rto EOG;;ACTIVE;2.54;2.68 +79771-2;Study observation.overall;Imp;Pt;Retina.right;Ord;Electrooculogram;EYE.EOG.NEI;2;Overall study interpretation Right retina by EOG;Overall study imp R ret EOG;;ACTIVE;2.54;2.68 +7977-2;Paragonimus sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Paragonimus sp Ab [Units/volume] in Serum;Paragonimus Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79772-0;Study observation.overall;Imp;Pt;Retina.left;Ord;Electrooculogram;EYE.EOG.NEI;2;Overall study interpretation Left retina by EOG;Overall study imp L ret EOG;;ACTIVE;2.54;2.68 +79773-8;a-wave amplitude^dark-adapted;Elpot;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave amplitude Right retina dark-adapted by ERG;a-wave amp R ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79774-6;a-wave amplitude^dark-adapted;Elpot;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave amplitude Left retina dark-adapted by ERG;a-wave amp L ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79775-3;a-wave amplitude^light-adapted;Elpot;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave amplitude Right retina light-adapted by ERG;a-wave amp R ret light-adapt ERG;;ACTIVE;2.54;2.68 +79776-1;a-wave amplitude^light-adapted;Elpot;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave amplitude Left retina light-adapted by ERG;a-wave amp L ret light-adapt ERG;;ACTIVE;2.54;2.68 +79777-9;a-wave implicit time^dark-adapted;Time;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave implicit time Right retina dark-adapted by ERG;a-wave impl time R ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79778-7;a-wave implicit time^dark-adapted;Time;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave implicit time Left retina dark-adapted by ERG;a-wave impl time L ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79779-5;a-wave implicit time^light-adapted;Time;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave implicit time Right retina light-adapted by ERG;a-wave impl time R ret light-adapt ERG;;ACTIVE;2.54;2.68 +7978-0;Parainfluenza virus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 1 Ab [Units/volume] in Serum;HPIV1 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79780-3;a-wave implicit time^light-adapted;Time;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;a-wave implicit time Left retina light-adapted by ERG;a-wave impl time L ret light-adapt ERG;;ACTIVE;2.54;2.68 +79781-1;b-wave amplitude^dark-adapted;Elpot;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave amplitude Right retina dark-adapted by ERG;b-wave amp R ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79782-9;b-wave amplitude^dark-adapted;Elpot;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave amplitude Left retina dark-adapted by ERG;b-wave amp L ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79783-7;b-wave amplitude^light-adapted;Elpot;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave amplitude Right retina light-adapted by ERG;b-wave amp R ret light-adapt ERG;;ACTIVE;2.54;2.68 +79784-5;b-wave amplitude^light-adapted;Elpot;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave amplitude Left retina light-adapted by ERG;b-wave amp L ret light-adapt ERG;;ACTIVE;2.54;2.68 +79785-2;b-wave implicit time^dark-adapted;Time;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave implicit time Left retina dark-adapted by ERG;b-wave impl time L ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79786-0;b-wave implicit time^dark-adapted;Time;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave implicit time Right retina dark-adapted by ERG;b-wave impl time R ret dark-adapt ERG;;ACTIVE;2.54;2.68 +79787-8;b-wave implicit time^light-adapted;Time;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave implicit time Right retina light-adapted by ERG;b-wave impl time R ret light-adapt ERG;;ACTIVE;2.54;2.68 +79788-6;b-wave implicit time^light-adapted;Time;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;b-wave implicit time Left retina light-adapted by ERG;b-wave impl time L ret light-adapt ERG;;ACTIVE;2.54;2.68 +79789-4;Oscillatory potentials;Find;Pt;Retina.right;Nom;Electroretinogram;EYE.ERG.NEI;2;Right retina Oscillatory potentials by ERG;R ret Oscillatory pot ERG;;ACTIVE;2.54;2.68 +79790-2;Oscillatory potentials;Find;Pt;Retina.left;Nom;Electroretinogram;EYE.ERG.NEI;2;Left retina Oscillatory potentials by ERG;L ret Oscillatory pot ERG;;ACTIVE;2.54;2.68 +79791-0;Reference electrode;Loc;Pt;Head;Nom;Electroretinogram;EYE.ERG.NEI;2;ERG Reference electrode [Location];ERG Ref electrode Loc;;ACTIVE;2.54;2.54 +79792-8;Study observation.overall;Imp;Pt;Retina.right;Nom;Electroretinogram;EYE.ERG.NEI;2;Overall study interpretation Right retina by ERG;Overall study imp R ret ERG;;ACTIVE;2.54;2.68 +79793-6;Study observation.overall;Imp;Pt;Retina.left;Nom;Electroretinogram;EYE.ERG.NEI;2;Overall study interpretation Left retina by ERG;Overall study imp L ret ERG;;ACTIVE;2.54;2.68 +79794-4;Electroretinogram procedure standard followed;Type;Pt;^Patient;Nom;Electroretinogram;EYE.ERG.NEI;2;ERG study standard procedure followed;ERG study standard proc used;;ACTIVE;2.54;2.54 +79795-1;Flicker response wave amplitude^light-adapted;Elpot;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;Flicker response wave amplitude Right retina light-adapted by ERG;Flicker resp amp R ret light-adapt ERG;;ACTIVE;2.54;2.68 +79796-9;Flicker response wave amplitude^light-adapted;Elpot;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;Flicker response wave amplitude Left retina light-adapted by ERG;Flicker resp amp L ret light-adapt ERG;;ACTIVE;2.54;2.68 +79797-7;Flicker response wave implicit time^light-adapted;Time;Pt;Retina.right;Qn;Electroretinogram;EYE.ERG.NEI;2;Flicker response wave implicit time Right retina light-adapted by ERG;Flick resp wave imp time Ret-R lt-ad ERG;;ACTIVE;2.54;2.54 +7979-8;Parainfluenza virus 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 2 Ab [Units/volume] in Serum;HPIV2 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79798-5;Flicker response wave implicit time^light-adapted;Time;Pt;Retina.left;Qn;Electroretinogram;EYE.ERG.NEI;2;Flicker response wave implicit time Left retina light-adapted by ERG;Flick resp wave imp time Ret-L lt-ad ERG;;ACTIVE;2.54;2.54 +79799-3;Vendor name;ID;Pt;ERG device;Nom;;EYE.ERG.NEI;2;Electroretinography device Vendor name [Identifier];ERG device Vendor name;;ACTIVE;2.54;2.68 +79800-9;ISCEV standard protocol used;Type;Pt;^Patient;Nom;Electroretinogram;EYE.ERG.NEI;2;ERG ISCEV standard protocol followed;ERG ISCEV standard protocol used;;ACTIVE;2.54;2.54 +79801-7;Recording electrode;Type;Pt;ERG device;Nom;;EYE.ERG.NEI;2;Type of ERG recording electrode;Type of ERG rec electrode;;ACTIVE;2.54;2.54 +79802-5;Reference electrode;Type;Pt;ERG device;Nom;;EYE.ERG.NEI;2;Type of ERG reference electrode;Type of ERG ref electrode;;ACTIVE;2.54;2.54 +79803-3;Ocular motility;Find;Pt;Eye;Nom;Finger following;EYE.PX.NEI;2;Ocular motility Eye by Finger following;Ocular motility Eye by Finger follow;;ACTIVE;2.54;2.54 +79804-1;Visual field defects;Find;Pt;Eye.right;Nom;;EYE.VISUAL_FIELD.NEI;2;Visual field defects Right eye;Visual field defects Eye-R;;ACTIVE;2.54;2.54 +79805-8;Visual field defects;Find;Pt;Eye.left;Nom;;EYE.VISUAL_FIELD.NEI;2;Visual field defects Left eye;Visual field defects Eye-L;;ACTIVE;2.54;2.54 +7980-6;Parainfluenza virus 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Parainfluenza virus 3 Ab [Units/volume] in Serum;HPIV3 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79806-6;Visual field exam method;Type;Pt;Eye.right;Nom;*;EYE.VISUAL_FIELD.NEI;2;Type of Visual field exam method;Type of Visual field exam method;;ACTIVE;2.54;2.54 +79807-4;Visual field defects;Find;Pt;Eye.right;Nom;Confrontation;EYE.VISUAL_FIELD.NEI;2;Right eye Visual field defects by Confrontation;R eye Visual field def Confrontation;;ACTIVE;2.54;2.68 +79808-2;Visual field defects;Find;Pt;Eye.left;Nom;Confrontation;EYE.VISUAL_FIELD.NEI;2;Left eye Visual field defects by Confrontation;L eye Visual field def Confrontation;;ACTIVE;2.54;2.68 +79809-0;Study observation^W fluorescein IV;Find;Pt;Ocular fundus.right;Nom;Angiography;EYE.ANGIO.NEI;2;Study observation Right ocular fundus Angiography W fluorescein IV;Study obs Ocular fund-R Angio W fluor IV;;ACTIVE;2.54;2.54 +79810-8;Study observation^W fluorescein IV;Find;Pt;Ocular fundus.left;Nom;Angiography;EYE.ANGIO.NEI;2;Study observation Left ocular fundus Angiography W fluorescein IV;Study obs Ocular fund-L Angio W fluor IV;;ACTIVE;2.54;2.54 +79811-6;Study observation^W indocyanine green IV;Find;Pt;Ocular fundus.right;Nom;Angiography;EYE.ANGIO.NEI;2;Study observation Right ocular fundus Angiography W indocyanine green IV;Study obs Ocul fund-R Angio W indocy gr;;ACTIVE;2.54;2.54 +79812-4;Study observation^W indocyanine green IV;Find;Pt;Ocular fundus.left;Nom;Angiography;EYE.ANGIO.NEI;2;Study observation Left ocular fundus Angiography W indocyanine green IV;Study obs Ocul fund-L Angio W indocy gr;;ACTIVE;2.54;2.54 +79813-2;Corneal curvature;InvLen;Pt;Cornea.right;Qn;Keratometry;EYE.PX.NEI;2;Right cornea Corneal curvature by Keratometry;R cornea Corneal curvature by KM;;ACTIVE;2.54;2.68 +7981-4;Parvovirus B19 Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Parvovirus B19 IgM Ab [Presence] in Serum;B19V IgM Ser Ql;;ACTIVE;1.0h(2);2.73 +79814-0;Corneal curvature;InvLen;Pt;Cornea.left;Qn;Keratometry;EYE.PX.NEI;2;Left cornea Corneal curvature by Keratometry;L cornea Corneal curvature by KM;;ACTIVE;2.54;2.68 +79815-7;Pupillary response;Find;Pt;Pupil.right;Nom;;EYE.PX.NEI;2;Right pupil Pupillary response;R pupil Pupillary resp;;ACTIVE;2.54;2.68 +79816-5;Foveal thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT.NEI;2;Right retina Foveal thickness by OCT;R ret Foveal thickness OCT;;ACTIVE;2.54;2.68 +79817-3;Foveal thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT.NEI;2;Left retina Foveal thickness by OCT;L ret Foveal thickness OCT;;ACTIVE;2.54;2.68 +79818-1;Study observation;Find;Pt;Retina.right;Nom;OCT;EYE.OCT.NEI;2;Study observation Right retina by OCT;Study obs R ret OCT;;ACTIVE;2.54;2.68 +79819-9;Study observation;Find;Pt;Retina.left;Nom;OCT;EYE.OCT.NEI;2;Study observation Left retina by OCT;Study obs L ret OCT;;ACTIVE;2.54;2.68 +79820-7;Physical findings;Find;Pt;Macula.right;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Right macula by Ophthalmoscopy;R macula Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +79821-5;Physical findings;Find;Pt;Macula.left;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Left macula by Ophthalmoscopy;L macula Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +7982-2;Parvovirus B19 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 Ab [Units/volume] in Serum;B19V Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79822-3;Fundus hypopigmentation;Find;Pt;Retinal pigment epithelium;Ord;Ophthalmoscopy;EYE.PX.NEI;2;Retinal pigment epithelium Fundus hypopigmentation by Ophthalmoscopy;RPE Fundus hypopig Ophthalmoscopy;;ACTIVE;2.54;2.68 +79823-1;Glaucoma;Type;Pt;Eye;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Type of Glaucoma by Ophthalmoscopy;Type of Glaucoma Ophthalmoscopy;;ACTIVE;2.54;2.54 +79824-9;Ophthalmoscopy method;Type;Pt;Eye;Nom;*;EYE.PX.NEI;2;Type of Ophthalmoscopy method;Type of Ophthalmoscopy method;;ACTIVE;2.54;2.54 +79825-6;Central corneal thickness;Len;Pt;Cornea.right;Qn;Pachymetry;EYE.PX.NEI;2;Right cornea Central corneal thickness Pachymetry;R cornea Cent corn thickness Pachymetry;;ACTIVE;2.54;2.68 +79826-4;Central corneal thickness;Len;Pt;Cornea.left;Qn;Pachymetry;EYE.PX.NEI;2;Left cornea Central corneal thickness Pachymetry;L cornea Cent corn thickness Pachymetry;;ACTIVE;2.54;2.68 +79827-2;Contrast sensitivity;LogInvPct;Pt;Eye.right;Qn;Pelli-Robson eye chart;EYE.PX.NEI;2;Contrast sensitivity [Log Inverse Percent] of Right eye by Pelli-Robson eye chart;R eye Contr sens Pelli-Robson;;ACTIVE;2.54;2.68 +79828-0;Contrast sensitivity;LogInvPct;Pt;Eye.left;Qn;Pelli-Robson eye chart;EYE.PX.NEI;2;Contrast sensitivity [Log Inverse Percent] of Left eye by Pelli-Robson eye chart;L eye Contr sens Pelli-Robson;;ACTIVE;2.54;2.68 +79829-8;Axis^W cycloplegia;Angle;Pt;Eye.right;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Right eye Axis--W cycloplegia by Objective refraction;R eye Axis--W cyclo Obj refraction;;ACTIVE;2.54;2.68 +7983-0;Parvovirus B19 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgG Ab [Units/volume] in Serum;B19V IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79830-6;Axis^W cycloplegia;Angle;Pt;Eye.left;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Left eye Axis--W cycloplegia by Objective refraction;L eye Axis--W cyclo Obj refraction;;ACTIVE;2.54;2.68 +79831-4;Axis^WO cycloplegia;Angle;Pt;Eye.right;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Right eye Axis--WO cycloplegia by Objective refraction;R eye Axis--WO cyclo Obj refraction;;ACTIVE;2.54;2.68 +79832-2;Axis^WO cycloplegia;Angle;Pt;Eye.left;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Left eye Axis--WO cycloplegia by Objective refraction;L eye Axis--WO cyclo Obj refraction;;ACTIVE;2.54;2.68 +79833-0;Cylinder^W cycloplegia;InvLen;Pt;Eye.right;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Right eye Cylinder--W cycloplegia by Objective refraction;R eye Cylinder--W cyclo Obj refraction;;ACTIVE;2.54;2.68 +79834-8;Cylinder^W cycloplegia;InvLen;Pt;Eye.left;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Left eye Cylinder--W cycloplegia by Objective refraction;L eye Cylinder--W cyclo Obj refraction;;ACTIVE;2.54;2.68 +79835-5;Cylinder^WO cycloplegia;InvLen;Pt;Eye.right;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Right eye Cylinder--WO cycloplegia by Objective refraction;R eye Cylinder--WO cyclo Obj refraction;;ACTIVE;2.54;2.68 +79836-3;Cylinder^WO cycloplegia;InvLen;Pt;Eye.left;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Left eye Cylinder--WO cycloplegia by Objective refraction;L eye Cylinder--WO cyclo Obj refraction;;ACTIVE;2.54;2.68 +79837-1;Sphere^W cycloplegia;InvLen;Pt;Eye.right;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Right eye Sphere--W cycloplegia by Objective refraction;R eye Sphere--W cyclo Obj refraction;;ACTIVE;2.54;2.68 +79838-9;Sphere^W cycloplegia;InvLen;Pt;Eye.left;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Left eye Sphere--W cycloplegia by Objective refraction;L eye Sphere--W cyclo Obj refraction;;ACTIVE;2.54;2.68 +79839-7;Sphere^WO cycloplegia;InvLen;Pt;Eye.right;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Right eye Sphere--WO cycloplegia by Objective refraction;R eye Sphere--WO cyclo Obj refraction;;ACTIVE;2.54;2.68 +79840-5;Sphere^WO cycloplegia;InvLen;Pt;Eye.left;Qn;Objective refraction;EYE.REFRACTION.NEI;2;Left eye Sphere--WO cycloplegia by Objective refraction;L eye Sphere--WO cyclo Obj refraction;;ACTIVE;2.54;2.68 +79841-3;Objective refraction method;Type;Pt;Eyes;Nom;;EYE.REFRACTION.NEI;2;Type of Objective refraction method;Type of Obj refract method;;ACTIVE;2.54;2.54 +79842-1;Axis^W cycloplegia;Angle;Pt;Eye.right;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Right eye Axis--W cycloplegia by Subjective refraction;R eye Axis--W cyclo Subj refraction;;ACTIVE;2.54;2.68 +79843-9;Axis^W cycloplegia;Angle;Pt;Eye.left;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Left eye Axis--W cycloplegia by Subjective refraction;L eye Axis--W cyclo Subj refraction;;ACTIVE;2.54;2.68 +79844-7;Axis^WO cycloplegia;Angle;Pt;Eye.right;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Right eye Axis--WO cycloplegia by Subjective refraction;R eye Axis--WO cyclo Subj refraction;;ACTIVE;2.54;2.68 +79845-4;Axis^WO cycloplegia;Angle;Pt;Eye.left;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Left eye Axis--WO cycloplegia by Subjective refraction;L eye Axis--WO cyclo Subj refraction;;ACTIVE;2.54;2.68 +79846-2;Cylinder^W cycloplegia;InvLen;Pt;Eye.right;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Right eye Cylinder--W cycloplegia by Subjective refraction;R eye Cylinder--W cyclo Subj refraction;;ACTIVE;2.54;2.68 +79847-0;Cylinder^W cycloplegia;InvLen;Pt;Eye.left;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Left eye Cylinder--W cycloplegia by Subjective refraction;L eye Cylinder--W cyclo Subj refraction;;ACTIVE;2.54;2.68 +7984-8;Parvovirus B19 Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Parvovirus B19 IgM Ab [Units/volume] in Serum;B19V IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79848-8;Cylinder^WO cycloplegia;InvLen;Pt;Eye.right;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Right eye Cylinder--WO cycloplegia by Subjective refraction;R eye Cylinder--WO cyclo Subj refraction;;ACTIVE;2.54;2.68 +79849-6;Cylinder^WO cycloplegia;InvLen;Pt;Eye.left;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Left eye Cylinder--WO cycloplegia by Subjective refraction;L eye Cylinder--WO cyclo Subj refraction;;ACTIVE;2.54;2.68 +79850-4;Sphere^W cycloplegia;InvLen;Pt;Eye.right;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Right eye Sphere--W cycloplegia by Subjective refraction;R eye Sphere--W cyclo Subj refraction;;ACTIVE;2.54;2.68 +79851-2;Sphere^W cycloplegia;InvLen;Pt;Eye.left;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Left eye Sphere--W cycloplegia by Subjective refraction;L eye Sphere--W cyclo Subj refraction;;ACTIVE;2.54;2.68 +79852-0;Sphere^WO cycloplegia;InvLen;Pt;Eye.right;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Right eye Sphere--WO cycloplegia by Subjective refraction;R eye Sphere--WO cyclo Subj refraction;;ACTIVE;2.54;2.68 +79853-8;Sphere^WO cycloplegia;InvLen;Pt;Eye.left;Qn;Subjective refraction;EYE.REFRACTION.NEI;2;Left eye Sphere--WO cycloplegia by Subjective refraction;L eye Sphere--WO cyclo Subj refraction;;ACTIVE;2.54;2.68 +79854-6;Subjective refraction method;Type;Pt;Eyes;Nom;;EYE.REFRACTION.NEI;2;Type of Subjective refraction method;Type of Subj refract method;;ACTIVE;2.54;2.54 +7985-5;Polio virus 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Polio virus 1 Ab [Units/volume] in Serum;PV1 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79855-3;Opening height;Len;Pt;Palpebral fissure.right;Qn;;EYE.PX.NEI;2;Right palpebral fissure Opening height;R palpebral fiss Opening ht;;ACTIVE;2.54;2.68 +79856-1;Opening height;Len;Pt;Palpebral fissure.left;Qn;;EYE.PX.NEI;2;Left palpebral fissure Opening height;L palpebral fiss Opening ht;;ACTIVE;2.54;2.68 +79857-9;Study observation;Find;Pt;Anterior chamber.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Right anterior chamber Slit lamp biomicroscopy;Study obs R ant chamber Slit lamp;;ACTIVE;2.54;2.68 +79858-7;Study observation;Find;Pt;Anterior chamber.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Left anterior chamber Slit lamp biomicroscopy;Study obs L Ant chamber Slit lamp;;ACTIVE;2.54;2.68 +79859-5;Study observation;Find;Pt;Conjunctiva+Sclera.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Right conjunctiva+sclera Slit lamp biomicroscopy;Study obs R conj+sclera Slit lamp;;ACTIVE;2.54;2.68 +79860-3;Study observation;Find;Pt;Conjunctiva+Sclera.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Left conjunctiva+sclera Slit lamp biomicroscopy;Study obs L conj+sclera Slit lamp;;ACTIVE;2.54;2.68 +79861-1;Study observation;Find;Pt;Cornea.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Right cornea Slit lamp biomicroscopy;Study obs R cornea Slit lamp;;ACTIVE;2.54;2.68 +79862-9;Study observation;Find;Pt;Cornea.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Left cornea Slit lamp biomicroscopy;Study obs L cornea Slit lamp;;ACTIVE;2.54;2.68 +7986-3;Polio virus 2 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Polio virus 2 Ab [Units/volume] in Serum;PV2 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79863-7;Study observation;Find;Pt;Iris.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Right iris Slit lamp biomicroscopy;Study obs R iris Slit lamp;;ACTIVE;2.54;2.68 +79864-5;Study observation;Find;Pt;Iris.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Left iris Slit lamp biomicroscopy;Study obs L iris Slit lamp;;ACTIVE;2.54;2.68 +79865-2;Study observation;Find;Pt;Optic lens.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Right optic lens Slit lamp biomicroscopy;Study obs R optic lens Slit lamp;;ACTIVE;2.54;2.68 +79866-0;Study observation;Find;Pt;Optic lens.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Left optic lens Slit lamp biomicroscopy;Study obs L optic lens Slit lamp;;ACTIVE;2.54;2.68 +79867-8;Opacity;Type;Pt;Optic lens.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Type of Opacity Right optic lens by Slit lamp biomicroscopy;Type of Opac Optic lens-R by Slit lamp;;ACTIVE;2.54;2.54 +79868-6;Opacity;Type;Pt;Optic lens.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Type of Opacity Left optic lens by Slit lamp biomicroscopy;Type of Opac Optic lens-L by Slit lamp;;ACTIVE;2.54;2.54 +79869-4;Study observation;Prid;Pt;Eyelid & Lashes & Adnexa;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Eyelid and Lashes and Adnexa Slit lamp biomicroscopy;Stu obs Lids & Lashes & Adnexa Slit lamp;;ACTIVE;2.54;2.54 +79870-2;Pupil shape;Shape;Pt;Pupil.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Pupil shape right eye by slit lamp biomicroscopy;Pupil shape eye-R Slit lamp;;ACTIVE;2.54;2.54 +7987-1;Polio virus 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Polio virus 3 Ab [Units/volume] in Serum;PV3 Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79871-0;Pupil shape;Shape;Pt;Pupil.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Pupil shape left eye by slit lamp biomicroscopy;Pupil shape eye-L Slit lamp;;ACTIVE;2.54;2.54 +79872-8;Study observation;Prid;Pt;Vitreous body.right;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Right vitreous body Slit lamp biomicroscopy;Study obs Vitreous body-R Slit lamp;;ACTIVE;2.54;2.54 +79873-6;Study observation;Prid;Pt;Vitreous body.left;Nom;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Study observation Left vitreous body Slit lamp biomicroscopy;Study obs Vitreous body-L Slit lamp;;ACTIVE;2.54;2.54 +79874-4;Transillumination;Find;Pt;Iris.right;Ord;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Right iris Transillumination Slit lamp biomicroscopy;R iris Transillumination Slit lamp;;ACTIVE;2.54;2.68 +79875-1;Transillumination;Find;Pt;Iris.left;Ord;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Left iris Transillumination Slit lamp biomicroscopy;L iris Transillumination Slit lamp;;ACTIVE;2.54;2.68 +79876-9;Visual acuity^best corrected;LogLenRto;Pt;Eye.right;Qn;ETDRS eye chart;EYE.REFRACTION.NEI;2;Visual acuity best corrected Right eye by ETDRS eye chart;R eye VA--corr ETDRS;;ACTIVE;2.54;2.72 +79877-7;Visual acuity^best corrected;LogLenRto;Pt;Eye.left;Qn;ETDRS eye chart;EYE.REFRACTION.NEI;2;Visual acuity best corrected Left eye by ETDRS eye chart;L eye VA--corr ETDRS;;ACTIVE;2.54;2.73 +79878-5;Visual acuity^uncorrected;LogLenRto;Pt;Eye.right;Qn;ETDRS eye chart;EYE.REFRACTION.NEI;2;Visual acuity uncorrected Right eye by ETDRS eye chart;R eye VA--uncorr ETDRS;;ACTIVE;2.54;2.72 +79879-3;Visual acuity^uncorrected;LogLenRto;Pt;Eye.left;Qn;ETDRS eye chart;EYE.REFRACTION.NEI;2;Visual acuity uncorrected Left eye by ETDRS eye chart;L eye VA--uncorr ETDRS;;ACTIVE;2.54;2.72 +79880-1;Visual acuity^best corrected;LenRto;Pt;Eye.right;Qn;Snellen eye chart;EYE.REFRACTION.NEI;2;Visual acuity best corrected Right eye by Snellen eye chart;R eye VA--corr Snellen;;ACTIVE;2.54;2.73 +79881-9;Visual acuity^best corrected;LenRto;Pt;Eye.left;Qn;Snellen eye chart;EYE.REFRACTION.NEI;2;Visual acuity best corrected Left eye by Snellen eye chart;L eye VA--corr Snellen;;ACTIVE;2.54;2.73 +79882-7;Visual acuity^uncorrected;LenRto;Pt;Eye.right;Qn;Snellen eye chart;EYE.REFRACTION.NEI;2;Visual acuity uncorrected Right eye by Snellen eye chart;R eye VA--uncorr Snellen;;ACTIVE;2.54;2.73 +79883-5;Visual acuity^uncorrected;LenRto;Pt;Eye.left;Qn;Snellen eye chart;EYE.REFRACTION.NEI;2;Visual acuity uncorrected Left eye by Snellen eye chart;L eye VA--uncorr Snellen;;ACTIVE;2.54;2.73 +79884-3;Study observation;Find;Pt;Visual pathway.right;Ord;VEP;EYE.PX.NEI;2;Study observation Right visual pathway VEP;Study obs Visual pathway-R VEP;;ACTIVE;2.54;2.54 +79885-0;Study observation;Find;Pt;Visual pathway.left;Ord;VEP;EYE.PX.NEI;2;Study observation Left visual pathway VEP;Study obs Visual pathway-L VEP;;ACTIVE;2.54;2.54 +79886-8;Cells;Num;Pt;Anterior chamber.right;Qn;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Right anterior chamber Cells Slit lamp biomicroscopy;R ant chamber Cells Slit lamp;;ACTIVE;2.54;2.68 +79887-6;Cells;Num;Pt;Anterior chamber.left;Qn;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Left anterior chamber Cells Slit lamp biomicroscopy;L Ant chamber Cells Slit lamp;;ACTIVE;2.54;2.68 +79888-4;Flare;Find;Pt;Anterior chamber.right;Ord;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Right anterior chamber Flare Slit lamp biomicroscopy;R ant chamber Flare Slit lamp;;ACTIVE;2.54;2.68 +7988-9;Burkholderia pseudomallei Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Burkholderia pseudomallei IgG Ab [Units/volume] in Serum;B pseudomal IgG Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79889-2;Flare;Find;Pt;Anterior chamber.left;Ord;Slit lamp biomicroscopy;EYE.SLITLAMP.NEI;2;Left anterior chamber Flare Slit lamp biomicroscopy;L Ant chamber Flare Slit lamp;;ACTIVE;2.54;2.68 +798-9;Erythrocytes;NCnc;Pt;Urine;Qn;Automated count;UA;1;Erythrocytes [#/volume] in Urine by Automated count;RBC # Ur Auto;;ACTIVE;1.0;2.73 +79890-0;Axial length;Len;Pt;Eye.right;Qn;;EYE.PX.NEI;2;Deprecated Axial length Right eye;Deprecated Axial length Eye-R;;DEPRECATED;2.54;2.63 +79891-8;Nystagmus;Type;Pt;Eye;Nom;;EYE.PX.NEI;2;Type of Nystagmus;Type of Nystagmus;;ACTIVE;2.54;2.54 +79892-6;Intraocular pressure;Pres;Pt;Eye.right;Qn;Tonometry;EYE.TONOMETRY.NEI;2;Right eye Intraocular pressure;R eye IOP Tono;;ACTIVE;2.54;2.73 +79893-4;Intraocular pressure;Pres;Pt;Eye.left;Qn;Tonometry;EYE.TONOMETRY.NEI;2;Left eye Intraocular pressure;L eye IOP Tono;;ACTIVE;2.54;2.73 +79894-2;Electroretinography panel;-;Pt;Eye;-;Electroretinogram;PANEL.EYE;2;Electroretinography (ERG) panel;ERG Pnl;;ACTIVE;2.54;2.72 +79895-9;Subjective refraction panel;-;Pt;Eye;-;Subjective refraction;PANEL.EYE;2;Subjective refraction panel;Subj refraction Pnl;;ACTIVE;2.54;2.72 +79896-7;Tonometry panel;-;Pt;Eye;-;Tonometry;PANEL.EYE;2;Tonometry panel;Tonometry Pnl;;ACTIVE;2.54;2.72 +7989-7;Burkholderia pseudomallei Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Burkholderia pseudomallei IgM Ab [Units/volume] in Serum;B pseudomal IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79897-5;Physical findings panel;-;Pt;Eye;-;;PANEL.EYE;2;Eye Physical findings panel;Eye Phys find Pnl;;ACTIVE;2.54;2.56 +79898-3;Objective refraction panel;-;Pt;Eye;-;;PANEL.EYE;2;Objective refraction panel;Obj refraction Pnl;;ACTIVE;2.54;2.72 +79899-1;Pupillary response;Find;Pt;Pupil.left;Nom;;EYE.PX.NEI;2;Left pupil Pupillary response;L pupil Pupillary resp;;ACTIVE;2.54;2.68 +79900-7;Nystagmus amplitude;Find;Pt;Eye;Ord;;EYE.PX.NEI;2;Eye Nystagmus amplitude;Eye Nystagmus amp;;ACTIVE;2.54;2.68 +79901-5;Nystagmus direction;Find;Pt;Eye;Nom;;EYE.PX.NEI;2;Eye Nystagmus direction;Eye Nystagmus dir;;ACTIVE;2.54;2.68 +79902-3;Physical findings;Find;Pt;Retinal vessels.left;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Left retinal vessels by Ophthalmoscopy;L retinal ves Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +79903-1;Physical findings;Find;Pt;Retinal vessels.right;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Right retinal vessels by Ophthalmoscopy;R retinal ves Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +79904-9;Pediatric visual acuity^uncorrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION.NEI;2;Pediatric visual acuity uncorrected Right eye;R eye Ped visual acuity--uncorr;;ACTIVE;2.54;2.68 +7990-5;Respiratory syncytial virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus Ab [Units/volume] in Serum;RSV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79905-6;Pediatric visual acuity^uncorrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION.NEI;2;Pediatric visual acuity uncorrected Left eye;L eye Ped visual acuity--uncorr;;ACTIVE;2.54;2.68 +79906-4;Pediatric visual acuity^best corrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION.NEI;2;Pediatric visual acuity best corrected Left eye;L eye Ped visual acuity--corr;;ACTIVE;2.54;2.68 +79907-2;Pediatric visual acuity^best corrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION.NEI;2;Pediatric visual acuity best corrected Right eye;R eye Ped visual acuity--corr;;ACTIVE;2.54;2.68 +79908-0;Visual acuity exam method;Type;Pt;Eye;Nom;;EYE.REFRACTION;2;Type of Visual acuity exam method;Type of Visual acuity exam method;;ACTIVE;2.54;2.72 +79909-8;Diameter.end systole;Len;Pt;Pulmonic valve.annulus;Qn;US.2D;CARD.US.DICOM;2;Pulmonic valve annulus Diameter at end systole by US 2D;PV ann ES diameter 2D US;;ACTIVE;2.54;2.54 +79910-6;Blood velocity-time integral.systole;Len;Pt;Pulmonic valve;Qn;US.doppler;CARD.US.DICOM;2;Pulmonic valve Velocity-time integral during systole by US.doppler;PV VTI sys;;ACTIVE;2.54;2.67 +79911-4;Tissue velocity.E wave.max;Vel;Pt;Mitral valve.annulus.medial;Qn;US.tissue doppler.A4C;CARD.US.DICOM;2;Mitral valve medial annulus Tissue velocity.E-wave.max by US.tissue doppler.A4C;MV med ann e-prime Vmax TDI.A4C;;ACTIVE;2.54;2.54 +79912-2;Pressure half time.diastole;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US.DICOM;2;Mitral valve Pressure half time during diastole by US.doppler;MV PHT dias;;ACTIVE;2.54;2.67 +7991-3;Respiratory syncytial virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus IgG Ab [Units/volume] in Serum;RSV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.44 +79913-0;Blood flow velocity.diastole.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US.DICOM;2;Mitral valve Maximum blood flow velocity during diastole by US.doppler;MV Vmax dias;;ACTIVE;2.54;2.67 +79914-8;Blood velocity-time integral.diastole;Len;Pt;Mitral valve;Qn;US.doppler;CARD.US.DICOM;2;Mitral valve Velocity-time integral during diastole by US.doppler;MV VTI dia;;ACTIVE;2.54;2.67 +79915-5;Blood flow velocity.A wave.max;Vel;Pt;Pulmonary vein;Qn;US.doppler.PW;CARD.US.DICOM;2;Pulmonary vein Maximum A-wave velocity by Ultrasound.doppler.PW;Pulm vein A wave Vmax;;ACTIVE;2.54;2.54 +79916-3;Blood flow velocity.D wave.max;Vel;Pt;Pulmonary vein;Qn;US.doppler.PW;CARD.US.DICOM;2;Pulmonary vein Maximum D-wave velocity by Ultrasound.doppler.PW;Pulm vein D wave Vmax;;ACTIVE;2.54;2.54 +79917-1;Blood flow velocity.S wave.max;Vel;Pt;Pulmonary vein;Qn;US.doppler.PW;CARD.US.DICOM;2;Pulmonary vein Maximum S-wave velocity by Ultrasound.doppler.PW;Pulm vein S wave Vmax;;ACTIVE;2.54;2.54 +79918-9;Regurgitant blood flow velocity.end diastole;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US.DICOM;2;Pulmonic valve Regurgitant blood flow velocity at end diastole by US.doppler;PV ED regurg velocity;;ACTIVE;2.54;2.54 +79919-7;Regurgitant blood flow velocity.E wave.max;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US.DICOM;2;Pulmonic valve Maximum regurgitant blood flow velocity.E wave by US.doppler;PV Max regurg blood flow vel.E wave;;ACTIVE;2.54;2.54 +79920-5;Blood flow velocity.systole.max;Vel;Pt;Pulmonic valve;Qn;US.doppler;CARD.US.DICOM;2;Deprecated Pulmonic valve Maximum blood flow velocity during systole by US.doppler;Deprecated PV Vmax sys;;DEPRECATED;2.54;2.68 +7992-1;Respiratory syncytial virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Respiratory syncytial virus IgM Ab [Units/volume] in Serum;RSV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.44 +79921-3;Regurgitant blood flow velocity.systole.max;Vel;Pt;Tricuspid valve;Qn;US.doppler.CW;CARD.US.DICOM;2;Tricuspid valve Maximum regurgitant blood flow velocity during systole by US.doppler continuous wave;TV Max regurg vel sys;;ACTIVE;2.54;2.67 +79922-1;Tissue velocity.A wave.max;Vel;Pt;Tricuspid valve.annulus;Qn;US.tissue doppler;CARD.US.DICOM;2;Tricuspid valve annulus Tissue velocity.A-wave.max by US.tissue doppler;TV ann a-prime Vmax TDI;;ACTIVE;2.54;2.54 +79923-9;Blood flow velocity.A wave.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US.DICOM;2;Tricuspid valve Maximum A-wave velocity by US.doppler;TV A-wave Vmax;;ACTIVE;2.54;2.54 +79924-7;Tissue velocity.E wave.max;Vel;Pt;Tricuspid valve.annulus;Qn;US.tissue doppler;CARD.US.DICOM;2;Tricuspid valve annulus Tissue velocity.E-wave.max by US.tissue doppler;TV ann e-prime Vmax TDI;;ACTIVE;2.54;2.54 +79925-4;Blood flow velocity.E wave.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US.DICOM;2;Tricuspid valve Maximum E-wave velocity by US.doppler;TV E-wave Vmax;;ACTIVE;2.54;2.54 +79926-2;Tissue velocity.S wave.max;Vel;Pt;Tricuspid valve.annulus;Qn;US.tissue doppler;CARD.US.DICOM;2;Tricuspid valve annulus Tissue velocity.S-wave.max by US.tissue doppler;TV ann s-prime Vmax TDI;;ACTIVE;2.54;2.54 +79927-0;Blood flow velocity.diastole.max;Vel;Pt;Tricuspid valve;Qn;US.doppler;CARD.US.DICOM;2;Tricuspid valve Maximum blood flow velocity during diastole by US.doppler;TV Vmax dias;;ACTIVE;2.54;2.67 +79928-8;Blood flow.acceleration time.systole;Time;Pt;Pulmonic valve;Qn;US.doppler;CARD.US.DICOM;2;Pulmonic valve Blood flow acceleration time during systole by US.doppler;PV Flow accel time sys;;ACTIVE;2.54;2.67 +79929-6;Ejection time;Time;Pt;Heart.ventricle.right;Qn;US.doppler;CARD.US.DICOM;2;Right ventricular Ejection time by US.doppler;RV Ejection time;;ACTIVE;2.54;2.54 +79930-4;Closure to opening;Time;Pt;Tricuspid valve;Qn;US.doppler;CARD.US.DICOM;2;Tricuspid valve Closure to opening [Time] by US.doppler;TV Closure to opening Time;;ACTIVE;2.54;2.54 +79931-2;Blood flow.deceleration time.diastole;Time;Pt;Tricuspid valve;Qn;US.doppler;CARD.US.DICOM;2;Tricuspid valve Blood flow deceleration time during diastole by US.doppler;TV Flow decel time dias;;ACTIVE;2.54;2.67 +79932-0;PISA radius.systole;Len;Pt;Tricuspid valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Tricuspid valve PISA radius during systole [Length] by US.2D+doppler;TV PISA radius sys US.2D+DOP;;ACTIVE;2.54;2.67 +79933-8;Vena contracta diameter.systole;Len;Pt;Tricuspid valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Tricuspid valve Vena contracta diameter during systole by US.2D+doppler;TV VC diameter sys US.2D+DOP;;ACTIVE;2.54;2.67 +79934-6;Pressure gradient.end diastole.max;PressDiff;Pt;Pulmonic valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Pulmonic valve Maximum pressure gradient at end diastole by US.doppler+Calculated by simplified Bernoulli;PV ED max press grad Simp Bern;;ACTIVE;2.54;2.54 +79935-3;Pressure gradient.systole.max;PressDiff;Pt;Pulmonic valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Pulmonic valve Maximum pressure gradient dur systole by US.doppler+Calculated by simplified Bernoulli;PV Max press grad sys Simp Bern;;ACTIVE;2.54;2.67 +79936-1;Fractional area change;AreaFr;Pt;Heart.ventricle.right;Qn;US.2D.A4C+Measured by planimetry;CARD.US.DICOM;2;Right ventricular Fractional area change by US.2D.A4C+Measured by planimetry;RV FAC A4C;;ACTIVE;2.54;2.54 +79937-9;Pressure gradient.systole.max;PressDiff;Pt;Tricuspid valve;Qn;US.doppler.CW+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Tricuspid valve Maximum pressure gradient dur systole by US.doppler.CW+Calculated by simplified Bernoulli;TV Max press grad sys Simp Bern;;ACTIVE;2.54;2.67 +79938-7;Pressure gradient.diastole.mean;PressDiff;Pt;Tricuspid valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Tricuspid valve Mean pressure gradient dur diastole by US.doppler+Calculated by simplified Bernoulli;TV Mean press grad dias Simp Bern;;ACTIVE;2.54;2.67 +7993-9;Rhinovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rhinovirus RNA [Presence] in Specimen by NAA with probe detection;Rhinovirus RNA Spec Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +79939-5;Pressure gradient.diastole.max;PressDiff;Pt;Tricuspid valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Tricuspid valve Maximum pressure gradient during diastole by US.doppler+Calculated by simplified Bernoulli;TV Max press grad dias Simp Bern;;ACTIVE;2.54;2.67 +79940-3;Diameter.end systole;Len;Pt;Aortic valve.annulus;Qn;US.2D;CARD.US.DICOM;2;Aortic valve annulus Diameter at end systole by US 2D;AV ann ES diameter 2D US;;ACTIVE;2.54;2.54 +79941-1;Regurgitant blood flow rate.diastole;VRat;Pt;Aortic valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Aortic valve Regurgitant blood flow rate during diastole by US.doppler+Calculated by PISA method;AV Regurg rate dias PISA;;ACTIVE;2.54;2.67 +79942-9;Regurgitant fraction;VFr;Pt;Aortic valve;Qn;US.doppler;CARD.US.DICOM;2;Aortic valve Regurgitant fraction by US.doppler;AV Regurg fraction;;ACTIVE;2.54;2.54 +79943-7;Regurgitant jet area/Left ventricular outflow tract area;AreaFr;Pt;Aortic valve;Qn;US.2D+Measured by planimetry;CARD.US.DICOM;2;Aortic valve Regurgitant jet area/Left ventricular outflow tract area by US.2D+Measured by planimetry;AV Regurg jet area/LVOT area US.2D.PLN;;ACTIVE;2.54;2.54 +79944-5;Regurgitant jet width/Left ventricular outflow tract width;LenFr;Pt;Aortic valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Aortic valve Regurgitant jet width/Left ventricular outflow tract width by US.2D+doppler;AV Regurg jet width/LVOT width US.2D+DOP;;ACTIVE;2.54;2.54 +79945-2;PISA radius.diastole;Len;Pt;Aortic valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Aortic valve PISA radius during diastole [Length] by US.2D+doppler;AV PISA radius dias US.2D+DOP;;ACTIVE;2.54;2.67 +79946-0;PISA velocity.diastole;Vel;Pt;Aortic valve;Qn;US.doppler;CARD.US.DICOM;2;Aortic valve PISA velocity during diastole by US.doppler;AV PISA velocity dias;;ACTIVE;2.54;2.67 +7994-7;Rickettsia sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia sp Ab [Units/volume] in Serum;Rickettsia Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79947-8;Pressure half time.diastole;Time;Pt;Aortic valve;Qn;US.doppler.CW;CARD.US.DICOM;2;Aortic valve Pressure half time during diastole by US.doppler continuous wave;AV PHT dias;;ACTIVE;2.54;2.67 +79948-6;Vena contracta diameter.diastole;Len;Pt;Aortic valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Aortic valve Vena contracta diameter during diastole by US.2D+doppler;AV VC diameter dias US.2D+DOP;;ACTIVE;2.54;2.67 +79949-4;Regurgitant blood flow velocity.diastole.max;Vel;Pt;Aortic valve;Qn;US.doppler.CW;CARD.US.DICOM;2;Aortic valve Maximum regurgitant blood flow velocity during diastole by US.doppler continuous wave;AV Max regurg vel dias;;ACTIVE;2.54;2.67 +79950-2;Regurgitant blood flow volume.diastole;Vol;Pt;Aortic valve;Qn;US.doppler+Calculated by continuity VTI;CARD.US.DICOM;2;Aortic valve Regurgitant blood flow volume during diastole by US.doppler+Calculated by continuity VTI;AV Regurg vol dias Continuity VTI;;ACTIVE;2.54;2.67 +79951-0;Regurgitant blood flow volume.diastole;Vol;Pt;Aortic valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Aortic valve Regurgitant blood flow volume during diastole by US.doppler+Calculated by PISA method;AV Regurg vol dias PISA;;ACTIVE;2.54;2.67 +79952-8;Blood velocity-time integral.diastole;Len;Pt;Aortic valve;Qn;US.doppler.CW;CARD.US.DICOM;2;Aortic valve Velocity-time integral during diastole by US.doppler continuous wave;AV VTI dia;;ACTIVE;2.54;2.67 +79953-6;Diameter.end systole;Len;Pt;Aorta.root;Qn;US.2D;CARD.US.DICOM;2;Aorta root Diameter at end systole by US 2D;AO root ES diameter 2D US;;ACTIVE;2.54;2.54 +7995-4;Rickettsia prowazekii Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia prowazekii Ab [Units/volume] in Serum;R prowazek Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79954-4;Diameter.end systole/Body surface area;ArLen;Pt;Aorta.root;Qn;US.2D;CARD.US.DICOM;2;Aorta root Diameter at end systole (by US 2D)/Body surface area;AO root ES diameter (2D US)/BSA;;ACTIVE;2.54;2.54 +79955-1;Diameter.end systole;Len;Pt;Aorta.sinotubular junction;Qn;US.2D;CARD.US.DICOM;2;Aorta.sinotubular junction Diameter at end systole by US 2D;AO.sinotub junc ES diameter 2D US;;ACTIVE;2.54;2.54 +79956-9;Effective orifice area.systole;Area;Pt;Aortic valve;Qn;US.doppler+Calculated by continuity Vmax;CARD.US.DICOM;2;Aortic valve Effective orifice area during systole by US.doppler+Calculated by continuity Vmax;AV EOA sys Continuity Vmax;;ACTIVE;2.54;2.67 +79957-7;Effective orifice area.systole/Body surface area;ArArea;Pt;Aortic valve;Qn;US.doppler+Calculated by continuity Vmax;CARD.US.DICOM;2;Aortic valve Effective orifice area during systole (by US.doppler+Calculated by continuity Vmax)/Body surface area;AV EOA sys (Continuity Vmax)/BSA;;ACTIVE;2.54;2.67 +79958-5;Effective orifice area.systole;Area;Pt;Aortic valve;Qn;US.doppler+Calculated by continuity VTI;CARD.US.DICOM;2;Aortic valve Effective orifice area during systole by US.doppler+Calculated by continuity VTI;AV EOA sys Continuity VTI;;ACTIVE;2.54;2.67 +79959-3;Effective orifice area.systole/Body surface area;ArArea;Pt;Aortic valve;Qn;US.doppler+Calculated by continuity VTI;CARD.US.DICOM;2;Aortic valve Effective orifice area during systole (by US.doppler+Calculated by continuity VTI)/Body surface area;AV EOA sys (Continuity VTI)/BSA;;ACTIVE;2.54;2.67 +79960-1;Effective regurgitant orifice area.diastole;Area;Pt;Aortic valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Aortic valve Effective regurgitant orifice area during diastole by US.doppler+Calculated by PISA method;AV EROA dias PISA;;ACTIVE;2.54;2.67 +79961-9;Blood flow velocity.systole.mean;Vel;Pt;Aortic valve;Qn;US.doppler;CARD.US.DICOM;2;Aortic valve Mean flow velocity during systole by US.doppler;AV Mean flow vel sys;;ACTIVE;2.54;2.67 +7996-2;Rickettsia prowazekii RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Rickettsia prowazekii RNA [Presence] in Serum by NAA with probe detection;R prowazek RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +79962-7;Pressure gradient.systole.mean;PressDiff;Pt;Aortic valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Aortic valve Mean systole pressure gradient by US.doppler+Calculated by simplified Bernoulli;AV Mean press grad sys Simp Bern;;ACTIVE;2.54;2.67 +79963-5;Gradient.systole.max;PressDiff;Pt;Aortic valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Aortic valve Maximum gradient during systole [Pressure Difference] by US.doppler+Calculated by simplified Bernoulli;AV Max grad sys Simp Bern;;ACTIVE;2.54;2.67 +79964-3;Blood flow velocity.systole.max;Vel;Pt;Aortic valve;Qn;US.doppler;CARD.US.DICOM;2;Aortic valve Maximum blood flow velocity during systole by US.doppler;AV Vmax sys;;ACTIVE;2.54;2.67 +79965-0;Blood velocity-time integral.systole;Len;Pt;Aortic valve;Qn;US.doppler;CARD.US.DICOM;2;Aortic valve Velocity-time integral during systole by US.doppler;AV VTI sys;;ACTIVE;2.54;2.67 +79966-8;Diameter.systole;Len;Pt;Aorta.thoracic.ascending;Qn;US.2D;CARD.US.DICOM;2;Ascending thoracic aorta Diameter during systole by US 2D;ATA Diam sys 2D US;;ACTIVE;2.54;2.67 +79967-6;Diameter.end expiration;Len;Pt;Vena cava.inferior;Qn;US.2D;CARD.US.DICOM;2;Inferior vena cava Diameter at end expiration by US 2D;IVC End exp diameter 2D US;;ACTIVE;2.54;2.54 +79968-4;Thickness.end diastole;Len;Pt;Heart.interventricular septum;Qn;US.M-mode;CARD.US.DICOM;2;Interventricular septum Thickness at end diastole by US.M-mode;IVS ED thickness M-mode;;ACTIVE;2.54;2.54 +79969-2;Thickness.end diastole;Len;Pt;Heart.interventricular septum;Qn;US.2D;CARD.US.DICOM;2;Interventricular septum Thickness at end diastole by US 2D;IVS ED thickness 2D US;;ACTIVE;2.54;2.54 +799-7;Erythrocytes;NCnc;Pt;Urine;Qn;Manual count;UA;1;Erythrocytes [#/volume] in Urine by Manual count;RBC # Ur Manual;;ACTIVE;1.0;2.73 +7997-0;Rickettsia spotted fever group Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group Ab [Units/volume] in Serum;Rick SF Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79970-0;Thickness.end systole;Len;Pt;Heart.interventricular septum;Qn;US.M-mode;CARD.US.DICOM;2;Interventricular septum Thickness at end systole by US.M-mode;IVS ES thickness M-mode;;ACTIVE;2.54;2.54 +79971-8;Thickness.end systole;Len;Pt;Heart.interventricular septum;Qn;US.2D;CARD.US.DICOM;2;Interventricular septum Thickness at end systole by US 2D;IVS ES thickness 2D US;;ACTIVE;2.54;2.54 +79972-6;Time to peak displacement.systole;Time;Pt;Heart.interventricular septum;Qn;US.M-mode+ECG;CARD.US.DICOM;2;Interventricular septum Time to peak displacement during systole by US.M-mode+ECG;IVS Time to peak displace US.M-mode+ECG;;ACTIVE;2.54;2.54 +79973-4;Area.end systole;Area;Pt;Heart.atrium.left;Qn;US.2D.A2C+Measured by planimetry;CARD.US.DICOM;2;Left atrial Area at end systole by US.2D.A2C+Measured by planimetry;LA ES area A2C;;ACTIVE;2.54;2.54 +79974-2;Area.end systole;Area;Pt;Heart.atrium.left;Qn;US.2D.A4C+Measured by planimetry;CARD.US.DICOM;2;Left atrial Area at end systole by US.2D.A4C+Measured by planimetry;LA ES area A4C;;ACTIVE;2.54;2.54 +79975-9;Minor axis.end systole;Len;Pt;Heart.atrium.left;Qn;US.2D;CARD.US.DICOM;2;Left atrial Minor axis at end systole [Length] by US 2D;LA ES minor axis 2D US;;ACTIVE;2.54;2.54 +79976-7;Minor axis.end systole/Body surface area;ArLen;Pt;Heart.atrium.left;Qn;US.2D;CARD.US.DICOM;2;Left atrial Minor axis at end systole (by US 2D)/Body surface area;LA ES minor axis (2D US)/BSA;;ACTIVE;2.54;2.54 +79977-5;Minor axis.end systole;Len;Pt;Heart.atrium.left;Qn;US.M-mode;CARD.US.DICOM;2;Left atrial Minor axis at end systole [Length] by US.M-mode;LA ES minor axis M-mode;;ACTIVE;2.54;2.54 +79978-3;Minor axis.end systole/Body surface area;ArLen;Pt;Heart.atrium.left;Qn;US.M-mode;CARD.US.DICOM;2;Left atrial Minor axis at end systole (by US.M-mode)/Body surface area;LA ES minor axis (M-mode)/BSA;;ACTIVE;2.54;2.54 +79979-1;Length.end systole;Len;Pt;Heart.atrium.left;Qn;US.2D.A2C;CARD.US.DICOM;2;Left atrial Length at end systole by US.2D.A2C;LA ES length A2C;;ACTIVE;2.54;2.54 +79980-9;Length.end systole;Len;Pt;Heart.atrium.left;Qn;US.2D.A4C;CARD.US.DICOM;2;Left atrial Length at end systole by US.2D.A4C;LA ES length A4C;;ACTIVE;2.54;2.54 +79981-7;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by biplane area-length method;CARD.US.DICOM;2;Left atrial End-systolic volume by US.2D+Calculated by biplane area-length method;LA ES vol Biplane area-length;;ACTIVE;2.54;2.54 +79982-5;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by biplane area-length method;CARD.US.DICOM;2;Left atrial End-systolic volume (by US.2D+Calculated by biplane area-length method)/Body surface area;LA ES vol (Biplane area-length)/BSA;;ACTIVE;2.54;2.54 +79983-3;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by biplane method of disks;CARD.US.DICOM;2;Left atrial End-systolic volume by US.2D+Calculated by biplane method of disks;LA ES vol biplane MOD;;ACTIVE;2.54;2.54 +79984-1;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D+Calculated by biplane method of disks;CARD.US.DICOM;2;Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area;LA ES vol (biplane MOD)/BSA;;ACTIVE;2.54;2.54 +79985-8;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D.A2C+Calc by single plane method of disks;CARD.US.DICOM;2;Left atrial End-systolic volume by US.2D.A2C+Calculated by single plane method of disks;LA ES vol A2C MOD;;ACTIVE;2.54;2.54 +79986-6;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D.A4C+Calc by single plane method of disks;CARD.US.DICOM;2;Left atrial End-systolic volume by US.2D.A4C+Calculated by single plane method of disks;LA ES vol A4C MOD;;ACTIVE;2.54;2.54 +79987-4;Diameter.end systole;Len;Pt;Pulmonary artery.left;Qn;US.2D;CARD.US.DICOM;2;Left pulmonary artery Diameter at end systole by US 2D;Left PA ES diameter 2D US;;ACTIVE;2.54;2.54 +7998-8;Rickettsia spotted fever group Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group IgG Ab [Units/volume] in Serum;Rick SF IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +79988-2;Time to peak displacement.systole;Time;Pt;Heart.ventricle.left.posterior wall;Qn;US.M-mode+ECG;CARD.US.DICOM;2;Left ventricular posterior wall Time to peak displacement during systole by US.M-mode+ECG;LVPW Time to peak displace US.M-mode+ECG;;ACTIVE;2.54;2.54 +79989-0;Pre ejection time;Time;Pt;Heart.ventricle.left;Qn;US.doppler;CARD.US.DICOM;2;Left ventricular Pre ejection time by US.doppler;LV Pre eject time;;ACTIVE;2.54;2.54 +79990-8;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.3D.segmentation;CARD.US.DICOM;2;Left ventricular Ejection fraction by US.3D.segmentation;LV EF 3D segmentation;;ACTIVE;2.54;2.54 +79991-6;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane method of disks;CARD.US.DICOM;2;Left ventricular Ejection fraction by US.2D+Calculated by biplane method of disks;LV EF biplane MOD;;ACTIVE;2.54;2.54 +79992-4;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane method of disks;CARD.US.DICOM;2;Left ventricular Ejection fraction by US.2D.A2C+Calculated by single plane method of disks;LV EF A2C MOD;;ACTIVE;2.54;2.54 +79993-2;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane method of disks;CARD.US.DICOM;2;Left ventricular Ejection fraction by US.2D.A4C+Calculated by single plane method of disks;LV EF A4C MOD;;ACTIVE;2.54;2.54 +79994-0;Length.end diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D.A4C;CARD.US.DICOM;2;Left ventricular Length at end diastole by US.2D.A4C;LV ED length A4C;;ACTIVE;2.54;2.54 +79995-7;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.3D.segmentation;CARD.US.DICOM;2;Left ventricular End-diastolic volume by US.3D.segmentation;LV ED vol 3D segmentation;;ACTIVE;2.54;2.54 +7999-6;Rickettsia spotted fever group Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia spotted fever group IgM Ab [Units/volume] in Serum;Rick SF IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +79996-5;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane method of disks;CARD.US.DICOM;2;Left ventricular End-diastolic volume by US.2D+Calculated by biplane method of disks;LV ED vol biplane MOD;;ACTIVE;2.54;2.54 +79997-3;End-diastolic volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane method of disks;CARD.US.DICOM;2;Left ventricular End-diastolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area;LV ED vol (biplane MOD)/BSA;;ACTIVE;2.54;2.54 +79998-1;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane method of disks;CARD.US.DICOM;2;Left ventricular End-diastolic volume by US.2D.A2C+Calculated by single plane method of disks;LV ED vol A2C MOD;;ACTIVE;2.54;2.54 +79999-9;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane method of disks;CARD.US.DICOM;2;Left ventricular End-diastolic volume by US.2D.A4C+Calculated by single plane method of disks;LV ED vol A4C MOD;;ACTIVE;2.54;2.54 +80000-3;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.3D.segmentation;CARD.US.DICOM;2;Left ventricular End-systolic volume by US.3D.segmentation;LV ES vol 3D segmentation;;ACTIVE;2.54;2.54 +80001-1;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane method of disks;CARD.US.DICOM;2;Left ventricular End-systolic volume by US.2D+Calculated by biplane method of disks;LV ES vol biplane MOD;;ACTIVE;2.54;2.54 +8000-2;Rickettsia typhus group Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia typhus group Ab [Units/volume] in Serum;Rick Typhus Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80002-9;End-systolic volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane method of disks;CARD.US.DICOM;2;Left ventricular End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area;LV ES vol (biplane MOD)/BSA;;ACTIVE;2.54;2.54 +80003-7;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane method of disks;CARD.US.DICOM;2;Left ventricular End-systolic volume by US.2D.A2C+Calculated by single plane method of disks;LV ES vol A2C MOD;;ACTIVE;2.54;2.54 +80004-5;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane method of disks;CARD.US.DICOM;2;Left ventricular End-systolic volume by US.2D.A4C+Calculated by single plane method of disks;LV ES vol A4C MOD;;ACTIVE;2.54;2.54 +80005-2;Area.end diastole;Area;Pt;Heart.ventricle.left;Qn;US.2D.SAX at PM+Measured by planimetry;CARD.US.DICOM;2;Left ventricular Area at end diastole by US.2D.SAX at PM+Measured by planimetry;LV ED area SAX at PM;;ACTIVE;2.54;2.54 +80006-0;Epicardial area.end diastole;Area;Pt;Heart.ventricle.left;Qn;US.2D.SAX at PM+Measured by planimetry;CARD.US.DICOM;2;Left ventricular Epicardial area at end diastole by US.2D.SAX at PM+Measured by planimetry;LV ED epicard area SAX at PM;;ACTIVE;2.54;2.54 +80007-8;Minor axis.end diastole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US.DICOM;2;Left ventricular Minor axis at end diastole [Length] by US 2D;LV ED minor axis 2D US;;ACTIVE;2.54;2.54 +80008-6;Minor axis.end diastole;Len;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US.DICOM;2;Left ventricular Minor axis at end diastole [Length] by US.M-mode;LV ED minor axis M-mode;;ACTIVE;2.54;2.54 +80009-4;Minor axis.end diastole/Body surface area;ArLen;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US.DICOM;2;Left ventricular Minor axis at end diastole (by US.M-mode)/Body surface area;LV ED minor axis (M-mode)/BSA;;ACTIVE;2.54;2.54 +8001-0;Rickettsia typhus group Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia typhus group IgG Ab [Units/volume] in Serum;Rick Typhus IgG Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80010-2;Minor axis.end diastole/Body surface area;ArLen;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US.DICOM;2;Left ventricular Minor axis at end diastole (by US 2D)/Body surface area;LV ED minor axis (2D US)/BSA;;ACTIVE;2.54;2.54 +80011-0;Minor axis.end systole;Len;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US.DICOM;2;Left ventricular Minor axis at end systole [Length] by US 2D;LV ES minor axis 2D US;;ACTIVE;2.54;2.54 +80012-8;Minor axis.end systole;Len;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US.DICOM;2;Left ventricular Minor axis at end systole [Length] by US.M-mode;LV ES minor axis M-mode;;ACTIVE;2.54;2.54 +80013-6;Minor axis.end systole/Body surface area;ArLen;Pt;Heart.ventricle.left;Qn;US.M-mode;CARD.US.DICOM;2;Left ventricular Minor axis at end systole (by US.M-mode)/Body surface area;LV ES minor axis (M-mode)/BSA;;ACTIVE;2.54;2.54 +80014-4;Minor axis.end systole/Body surface area;ArLen;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US.DICOM;2;Left ventricular Minor axis at end systole (by US 2D)/Body surface area;LV ES minor axis (2D US)/BSA;;ACTIVE;2.54;2.54 +80015-1;Isovolumic relaxation time;Time;Pt;Heart.ventricle.left;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular Isovolumic relaxation time by US.tissue doppler;LV Isovolumic relaxation time TDI;;ACTIVE;2.54;2.54 +80016-9;Myocardial mass.end diastole;Mass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by area-length method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole by US.2D+Calculated by area-length method;LV ED myo mass US.2D+A-L;;ACTIVE;2.54;2.54 +80017-7;Myocardial mass.end diastole/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by area-length method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.2D+Calculated by area-length method)/Body surface area;LV ED myo mass (US.2D+A-L)/BSA;;ACTIVE;2.54;2.54 +80018-5;Myocardial mass.end diastole/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by area-length method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.2D+Calculated by area-length method)/Height exp 2.7;LV ED myo mass (US.2D+A-L)/Ht exp 2.7;;ACTIVE;2.54;2.56 +80019-3;Myocardial mass.end diastole;Mass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by dimension method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole by US.2D+Calculated by dimension method;LV ED myo mass US.2D+dim;;ACTIVE;2.54;2.54 +80020-1;Myocardial mass.end diastole/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by dimension method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.2D+Calculated by dimension method)/Body surface area;LV ED myo mass (US.2D+dim)/BSA;;ACTIVE;2.54;2.54 +80021-9;Myocardial mass.end diastole/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by dimension method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.2D+Calculated by dimension method)/Height exp 2.7;LV ED myo mass (US.2D+dim)/Ht exp 2.7;;ACTIVE;2.54;2.56 +80022-7;Myocardial mass.end diastole;Mass;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by dimension method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole by US.M-mode+Calculated by dimension method;LV ED myo mass US.M-mode+dim;;ACTIVE;2.56;2.56 +80023-5;Myocardial mass.end diastole/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by dimension method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.M-mode+Calculated by dimension method)/Body surface area;LV ED myo mass (US.M-mode+dim)/BSA;;ACTIVE;2.54;2.54 +80024-3;Myocardial mass.end diastole/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.M-mode+Calculated by dimension method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.M-mode+Calculated by dimension method)/Height exp 2.7;LV ED myo mass (US.M-mode+dim)/Htexp2.7;;ACTIVE;2.54;2.56 +80025-0;Myocardial mass.end diastole;Mass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by truncated ellipsoid method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole by US.2D+Calculated by truncated ellipsoid method;LV ED myo mass US.2D+trunc ellips;;ACTIVE;2.54;2.54 +80026-8;Myocardial mass.end diastole/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by truncated ellipsoid method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.2D+Calculated by truncated ellipsoid method)/Body surface area;LV ED myo mass (US.2D+trunc ellips)/BSA;;ACTIVE;2.54;2.54 +80027-6;Myocardial mass.end diastole/Height exp 2.7;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by truncated ellipsoid method;CARD.US.DICOM;2;Left ventricular Myocardial mass at end diastole (by US.2D+Calculated by truncated ellipsoid method)/Height exp 2.7;LV ED myo mass (US.2D+tr ellip)/Htexp2.7;;ACTIVE;2.54;2.56 +8002-8;Rickettsia typhus group Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia typhus group IgM Ab [Units/volume] in Serum;Rick Typhus IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80028-4;Diameter.end diastole;Len;Pt;Heart.ventricle.left.outflow tract;Qn;US.2D;CARD.US.DICOM;2;Left ventricular outflow tract Diameter at end diastole by US 2D;LVOT ED diameter 2D US;;ACTIVE;2.54;2.54 +80029-2;Blood flow velocity.systole.max;Vel;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US.DICOM;2;Left ventricular outflow tract Maximum blood flow velocity during systole by US.doppler;LVOT Vmax sys;;ACTIVE;2.54;2.73 +800-3;Schistocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Schistocytes [Presence] in Blood by Light microscopy;Schistocytes Bld Ql Smear;;ACTIVE;1.0;2.73 +80030-0;Blood velocity-time integral.systole;Len;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US.DICOM;2;Left ventricular outflow tract Velocity-time integral during systole by US.doppler;LVOT VTI sys;;ACTIVE;2.54;2.67 +80031-8;Thickness.end diastole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.M-mode;CARD.US.DICOM;2;Left ventricular posterior wall Thickness at end diastole by US.M-mode;LVPW ED thickness M-mode;;ACTIVE;2.54;2.54 +80032-6;Thickness.end diastole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.2D;CARD.US.DICOM;2;Left ventricular posterior wall Thickness at end diastole by US 2D;LVPW ED thickness 2D US;;ACTIVE;2.54;2.54 +80033-4;Thickness.end systole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.M-mode;CARD.US.DICOM;2;Left ventricular posterior wall Thickness at end systole by US.M-mode;LVPW ES thickness M-mode;;ACTIVE;2.54;2.54 +80034-2;Thickness.end systole;Len;Pt;Heart.ventricle.left.posterior wall;Qn;US.2D;CARD.US.DICOM;2;Left ventricular posterior wall Thickness at end systole by US 2D;LVPW ES thickness 2D US;;ACTIVE;2.54;2.54 +80035-9;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.3D.segmentation;CARD.US.DICOM;2;Left ventricular Stroke volume by US.3D.segmentation;LV SV 3D segmentation;;ACTIVE;2.54;2.54 +8003-6;Rickettsia rickettsii Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia rickettsii IgG Ab [Units/volume] in Serum;R rickettsi IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80036-7;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.basal anterior;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular basal anterior Time to max tissue velocity during systole by US.tissue doppler;LV.basal ant Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80037-5;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.basal anterior septum;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular basal anterior septum Time to max tissue velocity during systole by US.tissue doppler;LV.basal ant septum Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80038-3;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.basal inferior;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular basal inferior Time to max tissue velocity during systole by US.tissue doppler;LV.basal inf Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80039-1;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.basal lateral;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular basal lateral Time to max tissue velocity during systole by US.tissue doppler;LV.basal lat Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80040-9;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.basal posterior;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular basal posterior Time to max tissue velocity during systole by US.tissue doppler;LV.basal post Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80041-7;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.basal septum;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular basal septum Time to max tissue velocity during systole by US.tissue doppler;LV.basal sept Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80042-5;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.mid anterior;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular mid anterior Time to max tissue velocity during systole by US.tissue doppler;LV.mid ant Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80043-3;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.mid anterior septum;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular mid anterior septum Time to max tissue velocity during systole by US.tissue doppler;LV.mid ant septum Time to S Vmax TDI;;ACTIVE;2.54;2.54 +8004-4;Rickettsia rickettsii Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia rickettsii IgM Ab [Units/volume] in Serum;R rickettsi IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80044-1;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.mid inferior;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular mid inferior Time to max tissue velocity during systole by US.tissue doppler;LV.mid inf Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80045-8;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.mid lateral;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular mid lateral Time to max tissue velocity during systole by US.tissue doppler;LV.mid lat Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80046-6;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.mid posterior;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular mid posterior Time to max tissue velocity during systole by US.tissue doppler;LV.mid post Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80047-4;Time to max tissue velocity.systole;Time;Pt;Heart.ventricle.left.mid septum;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular mid septum Time to max tissue velocity during systole by US.tissue doppler;LV.mid sept Time to S Vmax TDI;;ACTIVE;2.54;2.54 +80048-2;Dyssynchrony index.systole;Time;Pt;Heart.ventricle.left;Qn;US.tissue doppler;CARD.US.DICOM;2;Left ventricular Dyssynchrony index during systole by US.tissue doppler;LV Dyssynchrony index TDI;;ACTIVE;2.54;2.54 +80049-0;Diameter.end systole;Len;Pt;Pulmonary artery.main;Qn;US.2D;CARD.US.DICOM;2;Main pulmonary artery Diameter at end systole by US 2D;Main PA ES diameter 2D US;;ACTIVE;2.54;2.54 +80050-8;Diameter.end diastole;Len;Pt;Mitral valve.annulus;Qn;US.2D.A2C;CARD.US.DICOM;2;Mitral valve annulus Diameter at end diastole by US.2D.A2C;MV ann ED diameter A2C;;ACTIVE;2.54;2.54 +8005-1;Rickettsia rickettsii RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Rickettsia rickettsii RNA [Presence] in Serum by NAA with probe detection;R rickettsi RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +80051-6;Diameter.end diastole;Len;Pt;Mitral valve.annulus;Qn;US.2D.A4C;CARD.US.DICOM;2;Mitral valve annulus Diameter at end diastole by US.2D.A4C;MV ann ED diameter A4C;;ACTIVE;2.54;2.54 +80052-4;Diameter.end diastole;Len;Pt;Mitral valve.annulus;Qn;US.2D.PLAX;CARD.US.DICOM;2;Mitral valve annulus Diameter at end diastole by US.2D.PLAX;MV ann ED diameter PLAX;;ACTIVE;2.54;2.54 +80053-2;Blood velocity-time integral.diastole;Len;Pt;Mitral valve.annulus;Qn;US.doppler;CARD.US.DICOM;2;Mitral valve annulus Velocity-time integral during diastole by US.doppler;MV ann VTI dia;;ACTIVE;2.54;2.67 +80054-0;Tissue velocity.E wave.max;Vel;Pt;Mitral valve.annulus.lateral;Qn;US.tissue doppler.A4C;CARD.US.DICOM;2;Mitral valve lateral annulus Tissue velocity.E-wave.max by US.tissue doppler.A4C;MV lat ann e-prime Vmax TDI.A4C;;ACTIVE;2.54;2.54 +80055-7;Regurgitant fraction;VFr;Pt;Mitral valve;Qn;US.doppler+Calculated by continuity VTI;CARD.US.DICOM;2;Mitral valve Regurgitant fraction by US.doppler+Calculated by continuity VTI;MV Regurg fraction Continuity VTI;;ACTIVE;2.54;2.54 +80056-5;Regurgitant fraction;VFr;Pt;Mitral valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Mitral valve Regurgitant fraction by US.doppler+Calculated by PISA method;MV Regurg fraction PISA;;ACTIVE;2.54;2.54 +80057-3;Regurgitant blood flow rate.systole.max;VRat;Pt;Mitral valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Mitral valve Maximum regurgitant blood flow rate during systole by US.doppler+Calculated by PISA method;MV Max regurg rate sys PISA;;ACTIVE;2.54;2.67 +80058-1;Pressure gradient.systole.max;PressDiff;Pt;Mitral valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Mitral valve Maximum pressure gradient dur systole by US.doppler+Calculated by simplified Bernoulli;MV Max press grad sys Simp Bern;;ACTIVE;2.54;2.67 +80059-9;PISA radius.systole;Len;Pt;Mitral valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Mitral valve PISA radius during systole [Length] by US.2D+doppler;MV PISA radius sys US.2D+DOP;;ACTIVE;2.54;2.67 +80060-7;PISA velocity.systole;Vel;Pt;Mitral valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Mitral valve PISA velocity during systole by US.2D+doppler;MV PISA V sys US.2D+DOP;;ACTIVE;2.54;2.67 +80061-5;Vena contracta diameter.systole;Len;Pt;Mitral valve;Qn;US.2D+doppler;CARD.US.DICOM;2;Mitral valve Vena contracta diameter during systole by US.2D+doppler;MV VC diameter sys US.2D+DOP;;ACTIVE;2.54;2.67 +80062-3;Regurgitant blood flow velocity.systole.max;Vel;Pt;Mitral valve;Qn;US.doppler.CW;CARD.US.DICOM;2;Mitral valve Maximum regurgitant blood flow velocity during systole by US.doppler continuous wave;MV Max regurg vel sys;;ACTIVE;2.54;2.67 +80063-1;Regurgitant blood flow volume.systole;Vol;Pt;Mitral valve;Qn;US.doppler+Calculated by continuity VTI;CARD.US.DICOM;2;Mitral valve Regurgitant blood flow volume during systole by US.doppler+Calculated by continuity VTI;MV Regurg vol sys Continuity VTI;;ACTIVE;2.54;2.67 +80064-9;Regurgitant blood flow volume.systole;Vol;Pt;Mitral valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Mitral valve Regurgitant blood flow volume during systole by US.doppler+Calculated by PISA method;MV Regurg vol sys PISA;;ACTIVE;2.54;2.67 +80065-6;A wave duration;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US.DICOM;2;Mitral valve A-wave duration by US.doppler;MV A-wave duration;;ACTIVE;2.54;2.54 +80066-4;Blood flow velocity.A wave.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US.DICOM;2;Mitral valve Maximum A-wave velocity by US.doppler;MV A-wave Vmax;;ACTIVE;2.54;2.54 +80067-2;Effective orifice area.diastole;Area;Pt;Mitral valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Mitral valve Effective orifice area during diastole by US.doppler+Calculated by PISA method;MV EOA dias PISA;;ACTIVE;2.54;2.67 +80068-0;Orifice area.diastole.max;Area;Pt;Mitral valve;Qn;US.2D.PSAX+Measured by planimetry;CARD.US.DICOM;2;Mitral valve Maximum orifice area during diastole by US.2D.PSAX+Measured by planimetry;MV Max orifice area diastole Planimetry;;ACTIVE;2.54;2.54 +8006-9;Orientia tsutsugamushi Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Orientia tsutsugamushi Ab [Units/volume] in Serum;O tsut Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80069-8;Effective orifice area.diastole;Area;Pt;Mitral valve;Qn;US.doppler.pressure half time;CARD.US.DICOM;2;Mitral valve Effective orifice area during diastole by US.doppler pressure half time;MV EOA dias DOP PHT;;ACTIVE;2.54;2.67 +80070-6;Blood flow velocity.E wave.max;Vel;Pt;Mitral valve;Qn;US.doppler;CARD.US.DICOM;2;Mitral valve Maximum E-wave velocity by US.doppler;MV E-wave Vmax;;ACTIVE;2.54;2.54 +80071-4;Effective regurgitant orifice area.systole;Area;Pt;Mitral valve;Qn;US.doppler+Calculated by PISA method;CARD.US.DICOM;2;Mitral valve Effective regurgitant orifice area during systole by US.doppler+Calculated by PISA method;MV EROA sys PISA;;ACTIVE;2.54;2.67 +80072-2;Flow propagation velocity.E wave;Vel;Pt;Mitral valve;Qn;US.M-mode+doppler.A4C;CARD.US.DICOM;2;Mitral valve Flow propagation velocity.E-wave by US.M-mode+doppler.A4C;MV E-wave Vp US.M-mode+DOP.A4C;;ACTIVE;2.54;2.54 +80073-0;Pressure gradient.diastole.mean;PressDiff;Pt;Mitral valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Mitral valve Mean pressure gradient dur diastole by US.doppler+Calculated by simplified Bernoulli;MV Mean press grad dias Simp Bern;;ACTIVE;2.54;2.67 +80074-8;Pressure gradient.diastole.max;PressDiff;Pt;Mitral valve;Qn;US.doppler+Calculated by simplified Bernoulli;CARD.US.DICOM;2;Mitral valve Maximum pressure gradient during diastole by US.doppler+Calculated by simplified Bernoulli;MV Max press grad dias Simp Bern;;ACTIVE;2.54;2.67 +80075-5;Area.end systole;Area;Pt;Heart.atrium.right;Qn;US.2D.A4C+Measured by planimetry;CARD.US.DICOM;2;Right atrial Area at end systole by US.2D.A4C+Measured by planimetry;RA ES area A4C;;ACTIVE;2.54;2.54 +80076-3;Major axis.end systole;Len;Pt;Heart.atrium.right;Qn;US.2D.A4C;CARD.US.DICOM;2;Right atrial Major axis at end systole [Length] by US.2D.A4C;RA ES major axis A4C;;ACTIVE;2.54;2.54 +8007-7;Rickettsia typhi Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi IgG Ab [Units/volume] in Serum;R typhi IgG Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80077-1;Minor axis.end systole;Len;Pt;Heart.atrium.right;Qn;US.2D.A4C;CARD.US.DICOM;2;Right atrial Minor axis at end systole [Length] by US.2D.A4C;RA ES minor axis A4C;;ACTIVE;2.54;2.54 +80078-9;Minor axis.end systole/Body surface area;ArLen;Pt;Heart.atrium.right;Qn;US.2D.A4C;CARD.US.DICOM;2;Right atrial Minor axis at end systole (by US.2D.A4C)/Body surface area;RA ES minor axis (A4C)/BSA;;ACTIVE;2.54;2.54 +80079-7;Diameter.end systole;Len;Pt;Pulmonary artery.right;Qn;US.2D;CARD.US.DICOM;2;Right pulmonary artery Diameter at end systole by US 2D;Right PA ES diameter 2D US;;ACTIVE;2.54;2.54 +80080-5;Minor axis.end diastole;Len;Pt;Heart.ventricle.right.base;Qn;US.2D.A4C;CARD.US.DICOM;2;Right ventricular base Minor axis at end diastole [Length] by US.2D.A4C;RV basal ED minor axis A4C;;ACTIVE;2.54;2.54 +80081-3;Area.end diastole;Area;Pt;Heart.ventricle.right;Qn;US.2D.A4C+Measured by planimetry;CARD.US.DICOM;2;Right ventricular Area at end diastole by US.2D.A4C+Measured by planimetry;RV ED area A4C;;ACTIVE;2.54;2.54 +80082-1;Area.end systole;Area;Pt;Heart.ventricle.right;Qn;US.2D.A4C+Measured by planimetry;CARD.US.DICOM;2;Right ventricular Area at end systole by US.2D.A4C+Measured by planimetry;RV ES area A4C;;ACTIVE;2.54;2.54 +80083-9;Thickness.end diastole;Len;Pt;Heart.ventricle.right.anterior wall;Qn;US.2D;CARD.US.DICOM;2;Right ventricular anterior wall Thickness at end diastole by US 2D;RV.ant wall ED thickness 2D US;;ACTIVE;2.54;2.54 +80084-7;Thickness.end diastole;Len;Pt;Heart.ventricle.right.anterior wall;Qn;US.M-mode;CARD.US.DICOM;2;Right ventricular anterior wall Thickness at end diastole by US.M-mode;RV.ant wall ED thickness M-mode;;ACTIVE;2.54;2.54 +8008-5;Rickettsia typhi Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rickettsia typhi IgM Ab [Units/volume] in Serum;R typhi IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80085-4;Minor axis.end diastole;Len;Pt;Heart.ventricle.right.mid-cavity;Qn;US.2D.A4C;CARD.US.DICOM;2;Right ventricular mid-cavity Minor axis at end diastole [Length] by US.2D.A4C;RV mid-cavity ED minor axis A4C;;ACTIVE;2.54;2.54 +80086-2;Myocardial Performance Index;TRto;Pt;Heart.ventricle.right;Qn;US.doppler;CARD.US.DICOM;2;Right ventricular Myocardial performance index (Tei) by US.doppler;RV MPI;;ACTIVE;2.54;2.54 +80087-0;Diameter.end diastole;Len;Pt;Heart.ventricle.right.outflow tract.distal;Qn;US.2D.PSAX;CARD.US.DICOM;2;Right ventricular outflow tract distal Diameter at end diastole by US.2D.PSAX;Distal RVOT ED diameter PSAX;;ACTIVE;2.54;2.54 +80088-8;Diameter.end diastole;Len;Pt;Heart.ventricle.right.outflow tract.proximal;Qn;US.2D.parasternal;CARD.US.DICOM;2;Right ventricular outflow tract proximal Diameter at end diastole by US.2D.parasternal;Proximal RVOT ED diameter Parasternal;;ACTIVE;2.54;2.73 +80089-6;Blood velocity-time integral.systole;Len;Pt;Heart.ventricle.right.outflow tract;Qn;US.doppler;CARD.US.DICOM;2;Right ventricular outflow tract Velocity-time integral during systole by US.doppler;RVOT VTI sys;;ACTIVE;2.54;2.67 +80090-4;Pre ejection time;Time;Pt;Heart.ventricle.right;Qn;US.doppler+ECG;CARD.US.DICOM;2;Right ventricular Pre ejection time by US.doppler+ECG;RV Pre eject time DOP+ECG;;ACTIVE;2.54;2.54 +80091-2;Diameter.end diastole;Len;Pt;Tricuspid valve.annulus;Qn;US.2D.A4C;CARD.US.DICOM;2;Tricuspid valve annulus Diameter at end diastole by US.2D.A4C;TV ann ED diameter A4C;;ACTIVE;2.54;2.54 +80092-0;Glycyl-4-hydroxyproline/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glycyl-4-hydroxyproline/Creatinine [Molar ratio] in Urine;Glycyl-4-OH-proline/Creat Ur-sRto;;ACTIVE;2.54;2.56 +8009-3;Bartonella quintana Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Bartonella quintana IgG Ab [Units/volume] in Serum;B quintana IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80093-8;Glucosamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucosamine [Moles/volume] in Serum or Plasma;Glucosamine SerPl-sCnc;;ACTIVE;2.54;2.56 +80094-6;Glutamylphenylalanine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glutamylphenylalanine/Creatinine [Molar ratio] in Urine;Glutamyl-phe/Creat Ur-sRto;;ACTIVE;2.54;2.56 +80095-3;Galactosamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Galactosamine/Creatinine [Molar ratio] in Urine;Galactosamine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +80096-1;Glutamylphenylalanine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glutamylphenylalanine [Moles/volume] in Serum or Plasma;Glutamyl-phe SerPl-sCnc;;ACTIVE;2.54;2.56 +80097-9;Glycyl-4-hydroxyproline;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycyl-4-hydroxyproline [Moles/volume] in Serum or Plasma;Glycyl-4-OH-proline SerPl-sCnc;;ACTIVE;2.54;2.56 +80098-7;Glucosamine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Glucosamine/Creatinine [Molar ratio] in Urine;Glucosamine/Creat Ur-sRto;;ACTIVE;2.54;2.56 +80099-5;L-2-hydroxyglutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;L-2-hydroxyglutarate/Creatinine [Molar ratio] in Urine;L2HG/Creat Ur-sRto;;ACTIVE;2.54;2.54 +80100-1;D-2-hydroxyglutarate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;D-2-hydroxyglutarate/Creatinine [Molar ratio] in Urine;D2HG/Creat Ur-sRto;;ACTIVE;2.54;2.54 +8010-1;Bartonella quintana Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Bartonella quintana IgM Ab [Units/volume] in Serum;B quintana IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80101-9;Anterior chamber angle;Find;Pt;Eye.right;Nom;;EYE.PX.NEI;2;Right eye Anterior chamber angle;R eye Ant chamber angle;;ACTIVE;2.54;2.68 +80102-7;Anterior chamber angle;Find;Pt;Eye.left;Nom;;EYE.PX.NEI;2;Left eye Anterior chamber angle;L eye Ant chamber angle;;ACTIVE;2.54;2.68 +80103-5;Physical findings;Find;Pt;Chorioretina.right;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Right chorioretina by Ophthalmoscopy;R chorioretina Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +80104-3;Physical findings;Find;Pt;Chorioretina.left;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Left chorioretina by Ophthalmoscopy;L chorioretina Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +80105-0;Physical findings;Find;Pt;Optic nerve.left;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Left optic nerve by Ophthalmoscopy;L optic n Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +80106-8;Physical findings;Find;Pt;Optic nerve.right;Nom;Ophthalmoscopy;EYE.PX.NEI;2;Physical findings of Right optic nerve by Ophthalmoscopy;R optic n Phys find Ophthalmoscopy;;ACTIVE;2.54;2.68 +80107-6;Stereopsis;Angle;Pt;Eye;Ord;Randot;EYE.PX.NEI;2;Stereopsis by Randot;Stereopsis Randot;;ACTIVE;2.54;2.54 +80108-4;Stereopsis;Find;Pt;Eye;Nom;Titmus;EYE.PX.NEI;2;Stereopsis by Titmus;Stereopsis Titmus;;ACTIVE;2.54;2.54 +80109-2;Pregnancy risk factors for prenatal genetic testing;Find;Pt;^Fetus;Nom;;H&P.HX;2;Fetal Pregnancy risk factors for prenatal genetic testing;Fet Preg risk fact prenat genetic test;;ACTIVE;2.54;2.54 +801-1;Sickle cells;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Sickle cells [Presence] in Blood by Light microscopy;Sickle Cells Bld Ql Smear;;ACTIVE;1.0;2.73 +80110-0;Visit notification note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Visit notification;ED Visit notification;;ACTIVE;2.54;2.71 +80111-8;11-Hydroxy delta-9 tetrahydrocannabinol;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Mass/volume] in Blood by Confirmatory method;11OH-THC Bld Cfm-mCnc;;ACTIVE;2.54;2.54 +80112-6;11-Hydroxy delta-9 tetrahydrocannabinol;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Mass/volume] in Body fluid by Confirmatory method;11OH-THC Fld Cfm-mCnc;;ACTIVE;2.54;2.58 +80113-4;11-Hydroxy delta-9 tetrahydrocannabinol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;11-Hydroxy delta-9 tetrahydrocannabinol [Mass/volume] in Urine by Confirmatory method;11OH-THC Ur Cfm-mCnc;;ACTIVE;2.54;2.54 +80114-2;2-Oxo-3-Hydroxy-Lysergate diethylamide;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;2-Oxo-3-Hydroxy-Lysergate diethylamide [Mass/volume] in Blood by Confirmatory method;2-oxo-3-OH-LDS Bld Cfm-mCnc;;ACTIVE;2.54;2.54 +80115-9;6-Monoacetylmorphine;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Blood by Confirmatory method;6MAM Bld Cfm-mCnc;;ACTIVE;2.54;2.54 +80116-7;6-Monoacetylmorphine;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Mass/volume] in Body fluid by Confirmatory method;6MAM Fld Cfm-mCnc;;ACTIVE;2.54;2.58 +80117-5;7-Aminoflunitrazepam;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;7-Aminoflunitrazepam [Mass/volume] in Body fluid by Confirmatory method;7Aminoflunitrazepam Fld Cfm-mCnc;;ACTIVE;2.54;2.58 +80118-3;Abacavir;MCnc;Pt;BldCo;Qn;;DRUG/TOX;1;Abacavir [Mass/volume] in Cord blood;Abacavir BldCo-mCnc;;ACTIVE;2.54;2.54 +8011-9;Rotavirus;PrThr;Pt;Stool;Ord;Microscopy.electron;MICRO;1;Rotavirus [Presence] in Stool by Electron microscopy;RV Stl Ql EM;;ACTIVE;1.0h(2);2.73 +80119-1;Acebutolol;MCnt;Pt;Hair;Qn;Confirm;DRUG/TOX;1;Acebutolol [Mass/mass] in Hair by Confirmatory method;Acebutolol Hair Cfm-mCnt;;ACTIVE;2.54;2.54 +80120-9;Acenocoumarol;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Acenocoumarol [Mass/mass] in Hair;Acenocoumarol Hair-mCnt;;ACTIVE;2.54;2.54 +80121-7;Acyclovir;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Acyclovir [Mass/volume] in Cerebral spinal fluid;Acyclovir CSF-mCnc;;ACTIVE;2.54;2.54 +80122-5;Alfentanil;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Alfentanil [Mass/volume] in Blood by Confirmatory method;Alfentanil Bld Cfm-mCnc;;ACTIVE;2.54;2.54 +80123-3;Alizapride;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Alizapride [Mass/mass] in Hair;Alizapride Hair-mCnt;;ACTIVE;2.54;2.54 +80124-1;Alminoprofen;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Alminoprofen [Mass/mass] in Hair;Alminoprofen Hair-mCnt;;ACTIVE;2.54;2.54 +80125-8;Aluminum;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Aluminum [Mass/mass] in Tissue;Aluminum Tiss-mCnt;;ACTIVE;2.54;2.54 +80126-6;Aluminum;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Body fluid;Aluminum Fld-sCnc;;ACTIVE;2.54;2.54 +8012-7;Rotavirus dsRNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Rotavirus dsRNA [Presence] in Stool by NAA with probe detection;RV dsRNA Stl Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +80127-4;Aluminum;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Cerebral spinal fluid;Aluminum CSF-sCnc;;ACTIVE;2.54;2.54 +80128-2;Amisulpride;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Amisulpride [Mass/mass] in Hair;Amisulpride Hair-mCnt;;ACTIVE;2.54;2.54 +80129-0;Amisulpride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Amisulpride [Mass/volume] in Blood;Amisulpride Bld-mCnc;;ACTIVE;2.54;2.54 +80130-8;Amisulpride;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Amisulpride [Mass/volume] in Body fluid;Amisulpride Fld-mCnc;;ACTIVE;2.54;2.58 +80131-6;Amisulpride;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amisulpride [Mass/volume] in Urine;Amisulpride Ur-mCnc;;ACTIVE;2.54;2.54 +80132-4;amLODIPine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;amLODIPine [Mass/mass] in Hair;amLODIPine Hair-mCnt;;ACTIVE;2.54;2.54 +80133-2;Amoxicillin;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Amoxicillin [Mass/volume] in Cerebral spinal fluid;Amoxicillin CSF-mCnc;;ACTIVE;2.54;2.54 +80134-0;Amphetamine;MCnt;Pt;Hair;Qn;Confirm;DRUG/TOX;1;Amphetamine [Mass/mass] in Hair by Confirmatory method;Amphet Hair Cfm-mCnt;;ACTIVE;2.54;2.54 +8013-5;Rubella virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Rubella virus Ab [Units/volume] in Serum;RUBV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80135-7;Amphetamine;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Amphetamine [Mass/volume] in Body fluid by Confirmatory method;Amphet Fld Cfm-mCnc;;ACTIVE;2.54;2.58 +80136-5;Antihistamines;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Antihistamines [Presence] in Blood by Screen method;Antihistamines Bld Ql Scn;;ACTIVE;2.54;2.56 +80137-3;Antihistamines;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Antihistamines [Presence] in Body fluid by Screen method;Antihistamines Fld Ql Scn;;ACTIVE;2.54;2.58 +80138-1;Antimony;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Antimony [Mass/mass] in Tissue;Antimony Tiss-mCnt;;ACTIVE;2.54;2.54 +80139-9;Antimony;SCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Antimony [Moles/mass] in Tissue;Antimony Tiss-sCnt;;ACTIVE;2.54;2.54 +80140-7;Antimony;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Antimony [Moles/volume] in Body fluid;Antimony Fld-sCnc;;ACTIVE;2.54;2.54 +80141-5;Arsenic;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Arsenic [Moles/volume] in Body fluid;Arsenic Fld-sCnc;;ACTIVE;2.54;2.54 +80142-3;Atazanavir;MCnc;Pt;CSF;Qn;Confirm;DRUG/TOX;1;Atazanavir [Mass/volume] in Cerebral spinal fluid by Confirmatory method;Atazanavir CSF Cfm-mCnc;;ACTIVE;2.54;2.54 +8014-3;Rubella virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Rubella virus IgG Ab [Units/volume] in Serum;RUBV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80143-1;Atazanavir;MCnc;Pt;BldCo;Qn;;DRUG/TOX;1;Atazanavir [Mass/volume] in Cord blood;Atazanavir BldCo-mCnc;;ACTIVE;2.54;2.54 +80144-9;Ecgonine methyl ester;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Ecgonine methyl ester [Presence] in Urine by Screen method;EME Ur Ql Scn;;ACTIVE;2.54;2.56 +80145-6;Silver;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Silver [Moles/volume] in Body fluid;Silver Fld-sCnc;;ACTIVE;2.54;2.54 +80146-4;Tricyclic antidepressants;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Blood by Screen method;Tricyclics Bld Ql Scn;;ACTIVE;2.54;2.56 +80147-2;Tricyclic antidepressants;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Body fluid by Screen method;Tricyclics Fld Ql Scn;;ACTIVE;2.54;2.58 +80148-0;Tricyclic antidepressants;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Serum or Plasma by Screen method;Tricyclics SerPl Ql Scn;;ACTIVE;2.54;2.56 +80149-8;Tricyclic antidepressants;PrThr;Pt;Urine;Ord;Screen>1000 ng/mL;DRUG/TOX;1;Tricyclic antidepressants [Presence] in Urine by Screen method >1000 ng/mL;Tricyclics Ur Ql Scn>1000 ng/mL;;ACTIVE;2.54;2.56 +8015-0;Rubella virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Rubella virus IgM Ab [Units/volume] in Serum;RUBV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80150-6;Trimeprazine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Trimeprazine [Mass/mass] in Hair;Trimeprazine Hair-mCnt;;ACTIVE;2.54;2.54 +80151-4;Brucella abortus Ab.IgG;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Brucella abortus IgG Ab [Titer] in Serum by Agglutination;B abortus IgG Titr Ser Aggl;;ACTIVE;2.54;2.54 +80152-2;N-methylhistamine/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;N-methylhistamine/Creatinine [Molar ratio] in 24 hour Urine;Me-histamine/Creat 24h Ur-sRto;;ACTIVE;2.54;2.54 +80153-0;Soluble CD27;ACnc;Pt;CSF;Qn;;CHEM;1;Soluble CD27 [Units/volume] in Cerebral spinal fluid;sCD27 CSF-aCnc;;ACTIVE;2.54;2.68 +80154-8;Monolysocardiolipin/cardiolipin;SRto;Pt;Bld.dot;Qn;;CHEM;1;Monolysocardiolipin/Cardiolipin [Molar ratio] in DBS;MLCL/CL DBS-sRto;;ACTIVE;2.54;2.61 +80155-5;Soluble CD27;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Soluble CD27 [Units/volume] in Serum or Plasma;sCD27 SerPl-aCnc;;ACTIVE;2.54;2.68 +80156-3;3-Methoxytyramine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Methoxytyramine/Creatinine [Molar ratio] in Urine;3Me-tyramine/Creat Ur-sRto;;ACTIVE;2.54;2.54 +80157-1;Etiocholanolone;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Etiocholanolone [Moles/volume] in Serum or Plasma;Etiocholanolone SerPl-sCnc;;ACTIVE;2.54;2.54 +80158-9;Galactosylhydroxylysine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Galactosylhydroxylysine/Creatinine [Molar ratio] in Urine;Gal-Hyl/Creat Ur-sRto;;ACTIVE;2.54;2.54 +80159-7;27-Norcholestanehexol/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;27-Norcholestanehexol/Creatinine [Ratio] in Urine;27-Norcholestanehexol/Creat Ur-Rto;;ACTIVE;2.54;2.54 +80160-5;5-beta-cholestane-3-alpha,7-alpha,12-alpha,23-tetrol/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;5-beta-cholestane-3-alpha,7-alpha,12-alpha,23-tetrol/Creatinine [Ratio] in Urine;5b-cholest-3a,7a,12a,23-tetrol/Creat Ur;;ACTIVE;2.54;2.54 +80161-3;5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;5-beta-cholestane-3-alpha,7-alpha,12-alpha,24,25-pentol/Creatinine [Ratio] in Urine;5b-choles-3a,7a,12a,24,25-pent/Creat Ur;;ACTIVE;2.54;2.54 +80162-1;Bile alcohols;Imp;Pt;Urine;Ord;;CHEM;1;Bile alcohols [Interpretation] in Urine Qualitative;Bile alcohols Ur-Imp;;ACTIVE;2.54;2.54 +80163-9;Bile alcohols panel;-;Pt;Urine;-;;PANEL.CHEM;1;Bile alcohols panel - Urine;Bile alcohols Pnl Ur;;ACTIVE;2.54;2.54 +80164-7;Bile alcohols pattern;Imp;Pt;Urine;Nar;;CHEM;1;Bile alcohols pattern [Interpretation] in Urine Narrative;Bile alcohols pattern Ur-Imp;;ACTIVE;2.54;2.54 +80165-4;2-Amino-4-hydroxypteridine;SCnc;Pt;CSF;Qn;;CHEM;1;2-Amino-4-hydroxypteridine [Moles/volume] in Cerebral spinal fluid;2-Amino-4OH-pteridine CSF-sCnc;;ACTIVE;2.54;2.54 +80166-2;2-Amino-4-hydroxypteridine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;2-Amino-4-hydroxypteridine [Moles/volume] in Serum or Plasma;2-Amino-4OH-pteridine SerPl-sCnc;;ACTIVE;2.54;2.54 +80167-0;2-Amino-4-hydroxypteridine/Creatinine;SRto;Pt;Ser/Plas;Qn;;CHEM;1;2-Amino-4-hydroxypteridine/Creatinine [Molar ratio] in Serum or Plasma;2-Amino-4OH-pteridine/Creat SerPl-sRto;;ACTIVE;2.54;2.54 +8016-8;Saint Louis encephalitis virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus IgG Ab [Units/volume] in Serum;SLEV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80168-8;Pterins panel;-;Pt;CSF;-;;PANEL.CHEM;1;Pterins panel - Cerebral spinal fluid;Pterins Pnl CSF;;ACTIVE;2.54;2.54 +80169-6;Pterins panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Pterins panel - Serum or Plasma;Pterins Pnl SerPl;;ACTIVE;2.54;2.54 +80170-4;Pterins panel;-;Pt;Urine;-;;PANEL.CHEM;1;Pterins panel - Urine;Pterins Pnl Ur;;ACTIVE;2.54;2.54 +80171-2;Pterins pattern;Imp;Pt;Urine;Nar;;CHEM;1;Pterins pattern [Interpretation] in Urine Narrative;Pterins pattern Ur-Imp;;ACTIVE;2.54;2.54 +80172-0;Pterins pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;Pterins pattern [Interpretation] in Serum or Plasma Narrative;Pterins pattern SerPl-Imp;;ACTIVE;2.54;2.54 +80173-8;Pterins pattern;Imp;Pt;CSF;Nar;;CHEM;1;Pterins pattern [Interpretation] in Cerebral spinal fluid Narrative;Pterins pattern CSF-Imp;;ACTIVE;2.54;2.54 +80174-6;S-adenosylhomocysteine;SCnc;Pt;CSF;Qn;;CHEM;1;S-adenosylhomocysteine [Moles/volume] in Cerebral spinal fluid;SAH CSF-sCnc;;ACTIVE;2.54;2.54 +80175-3;S-adenosylhomocysteine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;S-adenosylhomocysteine [Moles/volume] in Serum or Plasma;SAH SerPl-sCnc;;ACTIVE;2.54;2.54 +8017-6;Saint Louis encephalitis virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Units/volume] in Serum;SLEV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80176-1;S-adenosylhomocysteine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;S-adenosylhomocysteine/Creatinine [Molar ratio] in Urine;SAH/Creat Ur-sRto;;ACTIVE;2.54;2.54 +80177-9;S-adenosylmethionine;SCnc;Pt;CSF;Qn;;CHEM;1;S-adenosylmethionine [Moles/volume] in Cerebral spinal fluid;SAMe CSF-sCnc;;ACTIVE;2.54;2.54 +80178-7;S-adenosylmethionine & S-adenosylhomocystine panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;S-adenosylmethionine and S-adenosylhomocystine panel - Serum or Plasma;SAMe and SAH Pnl SerPl;;ACTIVE;2.54;2.54 +80179-5;S-adenosylmethionine & S-adenosylhomocystine panel;-;Pt;CSF;-;;PANEL.CHEM;1;S-adenosylmethionine and S-adenosylhomocystine panel - Cerebral spinal fluid;SAMe and SAH Pnl CSF;;ACTIVE;2.54;2.54 +80180-3;S-adenosylmethionine & S-adenosylhomocystine pattern;Imp;Pt;CSF;Nar;;CHEM;1;S-adenosylmethionine and S-adenosylhomocystine pattern [Interpretation] in Cerebral spinal fluid Narrative;SAMe and SAH pattern CSF-Imp;;ACTIVE;2.54;2.54 +80181-1;S-adenosylmethionine & S-adenosylhomocystine pattern;Imp;Pt;Ser/Plas;Nar;;CHEM;1;S-adenosylmethionine and S-adenosylhomocystine pattern [Interpretation] in Serum or Plasma Narrative;SAMe and SAH pattern SerPl-Imp;;ACTIVE;2.54;2.54 +80182-9;S-adenosylmethionine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;S-adenosylmethionine/Creatinine [Molar ratio] in Urine;SAMe/Creat Ur-sRto;;ACTIVE;2.54;2.54 +80183-7;Xanthopterin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Xanthopterin [Moles/volume] in Serum or Plasma;Xanthopterin SerPl-sCnc;;ACTIVE;2.54;2.54 +8018-4;Schistosoma japonicum Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Schistosoma japonicum Ab [Units/volume] in Serum;S japonicum Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80184-5;Xanthopterin;SCnc;Pt;CSF;Qn;;CHEM;1;Xanthopterin [Moles/volume] in Cerebral spinal fluid;Xanthopterin CSF-sCnc;;ACTIVE;2.54;2.54 +80185-2;Xanthopterin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Xanthopterin/Creatinine [Molar ratio] in Urine;Xanthopterin/Creat Ur-sRto;;ACTIVE;2.54;2.54 +80186-0;JAK2 gene exon 12 targeted mutation analysis;Find;Pt;Bone mar;Doc;Molgen;MOLPATH.MUT;1;JAK2 gene exon 12 targeted mutation analysis in Bone marrow by Molecular genetics method;JAK2 exon 12 Mut Anl Mar;;ACTIVE;2.54;2.65 +80187-8;JAK2 gene exon 14 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method;JAK2 exon 14 Mut Anl Bld/T;;ACTIVE;2.54;2.63 +80188-6;JAK2 gene exon 14 targeted mutation analysis;Find;Pt;Bone mar;Doc;Molgen;MOLPATH.MUT;1;JAK2 gene exon 14 targeted mutation analysis in Bone marrow by Molecular genetics method;JAK2 exon 14 Mut Anl Mar;;ACTIVE;2.54;2.65 +80189-4;Galactosamine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Galactosamine [Moles/volume] in Serum or Plasma;Galactosamine SerPl-sCnc;;ACTIVE;2.54;2.54 +80190-2;Catheterization & angiography procedure details panel;-;Procedure;^Patient;-;;PANEL.CARDIAC;2;Catheterization and angiography procedure details panel;Cath+angio proc det Pnl;;ACTIVE;2.54;2.54 +80191-0;Spasm stress test panel;-;Pt;^Patient;-;;PANEL.CARDIAC;2;Spasm stress test panel;Spasm stress test Pnl;;ACTIVE;2.54;2.54 +8019-2;Schistosoma mansoni Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Schistosoma mansoni Ab [Units/volume] in Serum;S mansoni Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80192-8;Coronary segment additional details panel;-;Pt;Coronary arteries;-;Angiogram;PANEL.CARDIAC;2;Coronary segment additional details panel;Coronary segment addl details Pnl;;ACTIVE;2.54;2.63 +80193-6;Ecgonine methyl ester;MCnc;Pt;Bld;Qn;Confirm;DRUG/TOX;1;Ecgonine methyl ester [Mass/volume] in Blood by Confirmatory method;EME Bld Cfm-mCnc;;ACTIVE;2.54;2.54 +80194-4;Ecgonine methyl ester;MCnc;Pt;Body fld;Qn;Confirm;DRUG/TOX;1;Ecgonine methyl ester [Mass/volume] in Body fluid by Confirmatory method;EME Fld Cfm-mCnc;;ACTIVE;2.54;2.58 +80195-1;Ecgonine methyl ester;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Ecgonine methyl ester [Mass/volume] in Serum or Plasma by Confirmatory method;EME SerPl Cfm-mCnc;;ACTIVE;2.54;2.54 +80196-9;Ecgonine methyl ester;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Ecgonine methyl ester [Presence] in Blood by Screen method;EME Bld Ql Scn;;ACTIVE;2.54;2.56 +80197-7;Antihistamines;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Antihistamines [Presence] in Serum or Plasma by Screen method;Antihistamines SerPl Ql Scn;;ACTIVE;2.54;2.56 +80198-5;Nonsteroidal antiinflammatory drugs;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Nonsteroidal antiinflammatory drugs [Presence] in Blood by Screen method;NSAIDs Bld Ql Scn;;ACTIVE;2.54;2.56 +80199-3;Nonsteroidal antiinflammatory drugs;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Nonsteroidal antiinflammatory drugs [Presence] in Body fluid by Screen method;NSAIDs Fld Ql Scn;;ACTIVE;2.54;2.58 +80-2;Cefixime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefixime [Susceptibility] by Minimum inhibitory concentration (MIC);Cefixime Islt MIC;;ACTIVE;1.0;2.73 +8020-0;Schistosoma sp Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Schistosoma sp Ab [Presence] in Serum;Schistosoma Ab Ser Ql;;ACTIVE;1.0h(2);2.56 +80200-9;Nonsteroidal antiinflammatory drugs;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Nonsteroidal antiinflammatory drugs [Presence] in Urine by Screen method;NSAIDs Ur Ql Scn;;ACTIVE;2.54;2.56 +80201-7;Alizapride;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alizapride [Mass/volume] in Urine;Alizapride Ur-mCnc;;ACTIVE;2.54;2.54 +80202-5;Clotting time of depleted plasma with 1:1 phospholipid^after addition of factor X activated;Time;Pt;PPP;Qn;Coag;COAG;1;Clotting time of depleted plasma with 1:1 phospholipid by Coagulation assay --after addition of factor X activated;PPL p Fxa PPP;;ACTIVE;2.54;2.54 +80203-3;HIV 1 & 2 Ab;Prid;Pt;Ser/Plas/Bld;Nom;IA.rapid;MICRO;1;HIV 1 and 2 Ab [Identifier] in Serum, Plasma or Blood by Rapid immunoassay;HIV 1 & 2 Ab SerPlBld IA.rapid;;ACTIVE;2.54;2.73 +80204-1;Influenza virus A & B identified;Prid;Pt;Nph;Nom;Shell vial culture;MICRO;1;Influenza virus A and B identified in Nasopharynx by Shell vial culture;FLUAV + FLUBV Nph Shell Vial Cult;;ACTIVE;2.54;2.56 +80205-8;Japanese encephalitis+Tick-borne encephalitis+West Nile+Yellow fever virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Japanese encephalitis+Tick-borne encephalitis+West Nile+Yellow fever virus IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;JEV+TBEV+WNV+YFV IgG SerPl Ql IF;;ACTIVE;2.54;2.56 +80206-6;Japanese encephalitis+Tick-borne encephalitis+West Nile+Yellow fever virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Japanese encephalitis+Tick-borne encephalitis+West Nile+Yellow fever virus IgM Ab [Presence] in Serum by Immunofluorescence;JEV+TBEV+WNV+YFV IgM Ser Ql IF;;ACTIVE;2.54;2.56 +80207-4;Leishmania infantum+donovani Ab.IgM;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Leishmania infantum+donovani IgM Ab [Titer] in Serum or Plasma by Immunofluorescence;L infantum+donovani IgM Titr SerPl IF;;ACTIVE;2.54;2.54 +80208-2;Leishmania infantum+donovani Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;Leishmania infantum+donovani IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;L infantum+donovani IgG Titr SerPl IF;;ACTIVE;2.54;2.54 +80209-0;Barium;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Barium [Moles/volume] in Body fluid;Barium Fld-sCnc;;ACTIVE;2.54;2.54 +80210-8;Beryllium;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in Body fluid;Beryllium Fld-mCnc;;ACTIVE;2.54;2.54 +80211-6;Beryllium;SCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Beryllium [Moles/volume] in Body fluid;Beryllium Fld-sCnc;;ACTIVE;2.54;2.54 +80212-4;Beta blockers;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Beta blockers [Presence] in Hair by Screen method;Beta Blockers Hair Ql Scn;;ACTIVE;2.54;2.56 +80213-2;Beta blockers;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Beta blockers [Presence] in Blood by Screen method;Beta Blockers Bld Ql Scn;;ACTIVE;2.54;2.56 +80214-0;Beta blockers;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Beta blockers [Presence] in Serum or Plasma by Screen method;Beta Blockers SerPl Ql Scn;;ACTIVE;2.54;2.56 +80215-7;Beta blockers;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Beta blockers [Presence] in Body fluid by Screen method;Beta Blockers Fld Ql Scn;;ACTIVE;2.54;2.58 +80216-5;Social, psychological & behavioral observations - 2015 Edition Health IT Certification Criteria set;-;Pt;{Setting};-;;PANEL.CLIN;2;Social, psychological and behavioral observations - 2015 Edition Health IT Certification Criteria set;Soc Psych Behav 2015 set;;ACTIVE;2.54;2.54 +80217-3;Mycoplasma hyopneumoniae Ag;PrThr;Pt;Tiss fixed;Ord;Immune stain;MICRO;1;Mycoplasma hyopneumoniae Ag [Presence] in Fixed tissue by Immune stain;M hyopneumo Ag Ftis Ql ImStn;;ACTIVE;2.54;2.56 +8021-8;Saint Louis encephalitis virus Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Saint Louis encephalitis virus Ab [Presence] in Cerebral spinal fluid by Immunoassay;SLEV Ab CSF Ql IA;;ACTIVE;1.0h(2);2.56 +80218-1;Mycoplasma hyopneumoniae Ab sample/Buffer control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma hyopneumoniae Ab sample/Buffer control in Serum by Immunoassay;M hyop Ab sample/Bf contr Ser IA;;ACTIVE;2.54;2.56 +80219-9;Mycoplasma hyopneumoniae Ab sample/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma hyopneumoniae Ab sample/Positive control in Serum by Immunoassay;M hyop Ab sample/Pos cntrl Ser IA;;ACTIVE;2.54;2.56 +80220-7;N-methyl-D-aspartate receptor Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;NMDAR IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;NMDAR IgG Titr CSF IF;;ACTIVE;2.54;2.58 +80221-5;N-methyl-D-aspartate receptor Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;NMDAR IgG Ab [Titer] in Serum by Immunofluorescence;NMDAR IgG Titr Ser IF;;ACTIVE;2.54;2.73 +80222-3;Cells.CD8/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;CD8 cells/100 lymphocytes in Specimen;CD8 Cells/lymph NFr Spec;;ACTIVE;2.54;2.73 +80223-1;Cells.CD4/100 lymphocytes;NFr;Pt;XXX;Qn;;CELLMARK;1;CD4 cells/100 lymphocytes in Specimen;CD4 Cells/lymph NFr Spec;;ACTIVE;2.54;2.73 +80224-9;Right coronary artery catheter;Type;Pt;^Patient;Nom;;CARD.PROC;2;Type of Right coronary artery catheter;Type of RCA cath;;ACTIVE;2.54;2.54 +80225-6;Left coronary artery catheter;Type;Pt;^Patient;Nom;;CARD.PROC;2;Type of Left coronary artery catheter;Type of LCA cath;;ACTIVE;2.54;2.54 +8022-6;Saint Louis encephalitis virus Ab;ACnc;Pt;Ser;Qn;Comp fix;MICRO;1;Saint Louis encephalitis virus Ab [Units/volume] in Serum by Complement fixation;SLEV Ab Ser CF-aCnc;;ACTIVE;1.0h(2);2.69 +80226-4;Pigtail catheter;Type;Pt;^Patient;Nom;;CARD.PROC;2;Type of Pigtail catheter;Type of Pig cath;;ACTIVE;2.54;2.54 +80227-2;Stenosis degree;LenFr;Pt;Posterolateral from right coronary artery;Qn;;CARD.PROC;2;Percent stenosis of Posterolateral branch from right coronary artery;Percent sten of R-PLB;;ACTIVE;2.54;2.54 +80228-0;Stenosis degree;LenFr;Pt;Diagonal artery 1a;Qn;;CARD.PROC;2;Percent stenosis of Additional first diagonal artery;Percent sten of D1a;;ACTIVE;2.54;2.54 +80229-8;Stenosis degree;LenFr;Pt;Diagonal artery 2a;Qn;;CARD.PROC;2;Percent stenosis of Additional second diagonal artery;Percent sten of D2a;;ACTIVE;2.54;2.54 +80230-6;Orifice area;Area;Pt;Aortic valve;Qn;Cardiac catheterization;CARD.PROC;2;Orifice area Aortic valve Cardiac catheterization;Orifice area AV Cardiac Cath;;ACTIVE;2.54;2.67 +80231-4;Orifice area;Area;Pt;Mitral valve;Qn;Cardiac catheterization;CARD.PROC;2;Orifice area Mitral valve Cardiac catheterization;Orifice area MV Cardiac Cath;;ACTIVE;2.54;2.67 +80232-2;A wave amplitude;Pres;Pt;Pulmonary artery.wedge;Qn;Cardiac catheterization;CARD.PROC;2;A-wave amplitude [Pressure] Pulmonary artery wedge Cardiac catheterization;A-wave amp PAW Cardiac Cath;;ACTIVE;2.54;2.56 +80233-0;V wave amplitude;Pres;Pt;Pulmonary artery.wedge;Qn;Cardiac catheterization;CARD.PROC;2;V wave amplitude [Pressure] Pulmonary artery wedge Cardiac catheterization;V wave amp PAW Cardiac Cath;;ACTIVE;2.54;2.56 +8023-4;Saint Louis encephalitis virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Saint Louis encephalitis virus Ab [Presence] in Serum by Immunoassay;SLEV Ab Ser Ql IA;;ACTIVE;1.0h(2);2.56 +80234-8;A wave amplitude;Pres;Pt;Heart.atrium.right;Qn;Cardiac catheterization;CARD.PROC;2;A-wave amplitude [Pressure] Right atrium Cardiac catheterization;A-wave amp RA Cardiac Cath;;ACTIVE;2.54;2.56 +80235-5;V wave amplitude;Pres;Pt;Heart.atrium.right;Qn;Cardiac catheterization;CARD.PROC;2;V wave amplitude [Pressure] Right atrium Cardiac catheterization;V wave amp RA Cardiac Cath;;ACTIVE;2.54;2.56 +80236-3;A wave amplitude;Pres;Pt;Heart.atrium.left;Qn;Cardiac catheterization;CARD.PROC;2;A-wave amplitude [Pressure] Left atrium Cardiac catheterization;A-wave amp LA Cardiac Cath;;ACTIVE;2.54;2.56 +80237-1;V wave amplitude;Pres;Pt;Heart.atrium.left;Qn;Cardiac catheterization;CARD.PROC;2;V wave amplitude [Pressure] Left atrium Cardiac catheterization;V wave amp LA Cardiac Cath;;ACTIVE;2.54;2.56 +80238-9;Drug given for spasm stress test;ID;Pt;^Patient;Nom;;CARD.PROC;2;Drug given for spasm stress test [Identifier];Drug given for spasm stress test;;ACTIVE;2.54;2.54 +80239-7;Stenosis degree^post procedure;LenFr;Pt;Coronary arteries.segment;Qn;;CARD.PROC;2;Percent stenosis of Coronary artery segment --post procedure;Percent sten of Cor aa seg --p procedure;;ACTIVE;2.54;2.56 +80240-5;Coronary stent expansion pressure;Pres;Pt;Angioplasty device;Qn;;CARD.PROC;2;Coronary stent expansion pressure;Cor stent expan press;;ACTIVE;2.54;2.54 +80241-3;Coronary stent expansion time;Time;Pt;Angioplasty device;Qn;;CARD.PROC;2;Coronary stent expansion time;Cor stent expan time;;ACTIVE;2.54;2.54 +8024-2;Saint Louis encephalitis virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Saint Louis encephalitis virus Ab [Presence] in Serum by Immunofluorescence;SLEV Ab Ser Ql IF;;ACTIVE;1.0h(2);2.56 +80242-1;Intravenous contrast given;Vol;Pt;^Patient;Qn;;CARD.PROC;2;IV contrast given [Volume];IV contrast Gvn Vol;;ACTIVE;2.54;2.56 +80243-9;Cardiac catheterization access site;Anat;Pt;^Patient;Nom;;CARD.PROC;2;Cardiac catheterization access site;Cardiac cath access site;;ACTIVE;2.54;2.54 +80244-7;Mycoplasma hyopneumoniae DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma hyopneumoniae DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M hyopneumo DNA Ct Spec Qn NAA+probe;;ACTIVE;2.54;2.69 +80245-4;Procedure sequence;Type;Pt;^Patient;Nom;;CLIN;2;Procedure sequence;Proc seq;;ACTIVE;2.54;2.54 +80246-2;Atrioventricular nodal artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Atrioventricular nodal artery [Presence] on Angiogram;AV nodal Pr on Angio;;ACTIVE;2.54;2.66 +80247-0;Posterior descending from right coronary artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Posterior descending branch from right coronary artery [Presence] on Angiogram;R-PDA Pr on Angio;;ACTIVE;2.54;2.66 +80248-8;Posterolateral from right coronary artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Posterolateral branch from right coronary artery [Presence] on Angiogram;R-PLB Pr on Angio;;ACTIVE;2.54;2.66 +80249-6;Diagonal artery 1;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;First diagonal artery [Presence] on Angiogram;D1 Pr on Angio;;ACTIVE;2.54;2.66 +80250-4;Diagonal artery 1a;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Additional first diagonal artery [Presence] on Angiogram;D1a Pr on Angio;;ACTIVE;2.54;2.66 +80251-2;Diagonal artery 2;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Second diagonal artery [Presence] on Angiogram;D2 Pr on Angio;;ACTIVE;2.54;2.66 +80252-0;Diagonal artery 2a;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Additional second diagonal artery [Presence] on Angiogram;D2a Pr on Angio;;ACTIVE;2.54;2.66 +80253-8;Obtuse marginal artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Obtuse marginal artery [Presence] on Angiogram;OM Pr on Angio;;ACTIVE;2.54;2.66 +80254-6;Mid distal left circumflex artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Mid and distal left circumflex artery [Presence] on Angiogram;LCx Pr on Angio;;ACTIVE;2.54;2.66 +80255-3;Posterolateral from left circumflex artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Posterolateral from left circumflex artery [Presence] on Angiogram;L-PLB Pr on Angio;;ACTIVE;2.54;2.66 +80256-1;Posterior descending from left circumflex artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Posterior descending branch from left circumflex artery [Presence] on Angiogram;L-PDA Pr on Angio;;ACTIVE;2.54;2.66 +80257-9;Ramus intermedius from left main coronary artery;PrThr;Pt;Coronary arteries;Ord;Angiogram;CARD.PROC;2;Ramus intermedius branch from left main coronary artery [Presence] on Angiogram;RI Pr on Angio;;ACTIVE;2.54;2.66 +80258-7;Pre-cardiac catheterization diagnosis;Imp;Pt;^Patient;Nom;;CARDIO-PULM;2;Pre-cardiac catheterization diagnosis;Pre-cardiac cath dx;;ACTIVE;2.54;2.54 +8025-9;Saint Louis encephalitis virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Saint Louis encephalitis virus RNA [Presence] in Serum by NAA with probe detection;SLEV RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +80259-5;Gastrointestinal assessment panel;-;Pt;Gastrointestinal system;-;;PANEL.H&P;2;Gastrointestinal assessment panel;GI assessment Pnl;;ACTIVE;2.54;2.63 +80260-3;Bowel elimination pattern;Find;Pt;Gastrointestinal system;Nom;;H&P.PX;2;Bowel elimination pattern;Bowel elim pattern;;ACTIVE;2.54;2.73 +80261-1;Bowel movement frequency;Find;Pt;^Patient;Ord;;H&P.PX;2;Bowel movement frequency;BM freq;;ACTIVE;2.54;2.54 +80262-9;Bowel movement usual time of day;Find;Pt;^Patient;Nom;;H&P.PX;2;Bowel movement usual time of day;BM usual time of day;;ACTIVE;2.54;2.54 +80263-7;Bowel movement regularity;Find;Pt;^Patient;Ord;;H&P.PX;2;Bowel movement regularity;BM regularity;;ACTIVE;2.54;2.54 +80264-5;Usual consistency;Type;Pt;Stool;Nom;;H&P.PX;2;Usual consistency of Stool;Usual consistency Stl;;ACTIVE;2.54;2.54 +80265-2;Date of last bowel movement;Date;Pt;Gastrointestinal system;Qn;;H&P.PX;2;Date of last bowel movement;Date of last BM;;ACTIVE;2.54;2.54 +80266-0;Bowel sounds;Type;Pt;Gastrointestinal system;Nom;Auscultation;H&P.PX;2;Bowel sounds by Auscultation;Bowel sounds by Auscultation;;ACTIVE;2.54;2.54 +8026-7;Stain method;Type;Pt;XXX;Nom;*;MICRO;1;Stain method [Type] in Specimen;Stn Meth Spec;;ACTIVE;1.0h(2);2.73 +80267-8;Bowel sounds quality;Type;Pt;Gastrointestinal system;Nom;Auscultation;H&P.PX;2;Bowel sounds quality by Auscultation;Bowel sounds qual by Auscultation;;ACTIVE;2.54;2.54 +80268-6;Bowel sounds quadrant;Arb;Pt;Abdomen;Nom;;H&P.PX;2;Bowel sounds quadrant of Abdomen;BS quad Abd;;ACTIVE;2.54;2.54 +80269-4;Appearance;Aper;Pt;Abdomen;Nom;;H&P.PX;2;Appearance of Abdomen;Appearance Abd;;ACTIVE;2.54;2.54 +80270-2;Passing flatus;Find;Pt;Gastrointestinal system;Ord;;H&P.PX;2;Passing flatus;Passing flatus;;ACTIVE;2.54;2.54 +80271-0;Physical findings;Find;Pt;Abdomen;Nom;Palpation;H&P.PX;2;Physical findings of Abdomen by Palpation;Phys find Abd by Palpation;;ACTIVE;2.54;2.54 +80272-8;Amount;Find;Pt;Stool;Ord;;H&P.PX;2;Amount of Stool;Amount Stl;;ACTIVE;2.54;2.54 +80273-6;Gastrointestinal assessment;Imp;Pt;Gastrointestinal system;Nom;;H&P.PX;2;Gastrointestinal assessment [Interpretation];GI assess Imp;;ACTIVE;2.54;2.54 +80274-4;Surgical procedures of gastrointestinal system;Hx;Pt;^Patient;Nom;;H&P.PX;2;History of Surgical procedures of gastrointestinal system;Hx of Surg proc of GI system;;ACTIVE;2.54;2.56 +8027-5;Streptococcus pneumoniae 14 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 14 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum14 IgG Ser IA-aCnc;;DEPRECATED;1.0h(2);2.69 +80275-1;Cardiovascular assessment panel;-;Pt;Cardiovascular system;-;;PANEL.H&P;2;Cardiovascular physiologic assessment panel;CV Assessment Pnl;;ACTIVE;2.54;2.56 +80276-9;Heart sounds;Find;Pt;Heart;Nom;;H&P.PX;2;Heart sounds;Heart sounds;;ACTIVE;2.54;2.73 +80277-7;Heart murmur assessment panel;-;Pt;Cardiovascular system;-;;PANEL.H&P;2;Heart murmur assessment panel;Murmur assessment Pnl;;ACTIVE;2.54;2.56 +80278-5;Murmur grade;Find;Pt;Heart;Nom;Auscultation;H&P.PX;2;Heart Murmur grade;Hrt Murmur grade;;ACTIVE;2.54;2.54 +80279-3;Murmur quality;Type;Pt;Heart;Nom;Auscultation;H&P.PX;2;Heart Murmur quality;Hrt Murmur quality;;ACTIVE;2.54;2.54 +80280-1;Murmur pitch;Type;Pt;Heart;Nom;Auscultation;H&P.PX;2;Heart Murmur pitch;Hrt MUrmur pitch;;ACTIVE;2.54;2.54 +80281-9;Murmur timing;Find;Pt;Heart;Nom;Auscultation;H&P.PX;2;Heart Murmur timing;Hrt Murmur timing;;ACTIVE;2.54;2.54 +80282-7;Murmur location;Anat;Pt;^Patient;Nom;Auscultation;H&P.PX;2;Murmur location [Anatomy] by Auscultation;Murmur location Auscultation;;ACTIVE;2.54;2.54 +8028-3;Streptococcus pneumoniae Danish serotype 7F Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7F IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 7F IgG Ser IA-aCnc;;ACTIVE;1.0h(2);2.73 +80283-5;Murmur radiating to body location;Anat;Pt;^Patient;Nom;Auscultation;H&P.PX;2;Murmur radiating to body location [Anatomy] by Auscultation;Murmur radiating to bdy loc Auscultation;;ACTIVE;2.54;2.54 +80284-3;Pulse intensity assessment panel;-;Pt;Cardiovascular system;-;;PANEL.H&P;2;Pulse intensity assessment panel;Pulse intensity assessment Pnl;;ACTIVE;2.54;2.56 +80285-0;Cardiovascular assessment;Imp;Pt;^Patient;Nom;;H&P.PX;2;Cardiovascular physiologic assessment [Interpretation];CV assess Imp;;ACTIVE;2.54;2.54 +80286-8;Surgical procedures of cardiovascular system;Hx;Pt;^Patient;Nom;;H&P.PX;2;History of Surgical procedures of cardiovascular system;Hx of Surg proc of CV system;;ACTIVE;2.54;2.56 +80287-6;Neurological assessment panel;-;Pt;Neurologic system;-;;PANEL.H&P;2;Neurological assessment panel;Neurological assessment Pnl;;ACTIVE;2.54;2.56 +80288-4;Level of consciousness;Find;Pt;^Patient;Ord;;H&P.PX;2;Level of consciousness;Level of consciousness;;ACTIVE;2.54;2.73 +80289-2;Temporal orientation panel;-;Pt;Neurologic system;-;;PANEL.H&P;2;Temporal orientation panel;Temporal orientation Pnl;;ACTIVE;2.54;2.56 +802-9;Spherocytes;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Spherocytes [Presence] in Blood by Light microscopy;Spherocytes Bld Ql Smear;;ACTIVE;1.0;2.73 +80290-0;Temporal orientation - person;Find;Pt;^Patient;Ord;;H&P.PX;2;Temporal orientation - person;Temporal orientation - person;;ACTIVE;2.54;2.54 +8029-1;Streptococcus pneumoniae 9 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 9 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum9 IgG Ser IA-aCnc;;DEPRECATED;1.0h(2);2.69 +80291-8;Temporal orientation - place;Find;Pt;^Patient;Ord;;H&P.PX;2;Temporal orientation - place;Temporal orientation - place;;ACTIVE;2.54;2.54 +80292-6;Temporal orientation - time;Find;Pt;^Patient;Ord;;H&P.PX;2;Temporal orientation - time;Temporal orientation - time;;ACTIVE;2.54;2.54 +80293-4;Temporal orientation assessment;Imp;Pt;^Patient;Nom;;H&P.PX;2;Temporal orientation assessment [Interpretation];Temporal orientation assessessment Imp;;ACTIVE;2.54;2.54 +80294-2;Level of arousal;Find;Pt;^Patient;Nom;;H&P.PX;2;Level of arousal;Level of arousal;;ACTIVE;2.54;2.73 +80295-9;Speech clarity;Find;Pt;^Patient;Nom;;H&P.PX;2;Speech clarity;Speech clarity;;ACTIVE;2.54;2.54 +80296-7;Mood;Find;Pt;^Patient;Nom;;H&P.PX;2;Patient Mood;Pt Mood;;ACTIVE;2.54;2.54 +80297-5;Memory;Find;Pt;^Patient;Nom;;H&P.PX;2;Patient Memory;Pt Memory;;ACTIVE;2.54;2.73 +80298-3;Ability to concentrate;Find;Pt;^Patient;Ord;;H&P.PX;2;Ability to concentrate;Ability to concentrate;;ACTIVE;2.54;2.54 +80299-1;Ability to direct attention;Find;Pt;^Patient;Ord;;H&P.PX;2;Ability to direct attention;Ability to direct attention;;ACTIVE;2.54;2.54 +80300-7;Cranial nerve assessment panel;-;Pt;Nerves.cranial;-;;PANEL.H&P;2;Cranial nerve assessment panel;CN assessment Pnl;;ACTIVE;2.54;2.56 +80301-5;Olfactory nerve (CNI) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Olfactory nerve (CNI) exam;CN I exam;;ACTIVE;2.54;2.54 +80302-3;Oculomotor+trochlear+abducens nerves (CN III+IV+VI) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Oculomotor+trochlear+abducens nerves (CN III+IV+VI) exam;CN III+IV+VI exam;;ACTIVE;2.54;2.54 +80303-1;Trigeminal nerve (CN V) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Trigeminal nerve (CN V) exam;CN V exam;;ACTIVE;2.54;2.54 +80304-9;Facial nerve (CN VII) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Facial nerve (CN VII) exam;CN VII exam;;ACTIVE;2.54;2.54 +80305-6;Vestibulocochlear nerve (CN VIII) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Vestibulocochlear nerve (CN VIII) exam;CN VIII exam;;ACTIVE;2.54;2.54 +80306-4;Glossopharyngeal nerve (CN IX) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Glossopharyngeal nerve (CN IX) exam;CN IX exam;;ACTIVE;2.54;2.54 +80307-2;Vagus nerve (CN X) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Vagus nerve (CN X) exam;CN X exam;;ACTIVE;2.54;2.54 +80308-0;Accessory nerve (CN XI) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Accessory nerve (CN XI) exam;CN XI exam;;ACTIVE;2.54;2.54 +8030-9;Streptococcus pneumoniae Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcus pneumoniae Ab [Presence] in Serum;S pneum Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80309-8;Hypoglossal nerve (CN XII) exam;Find;Pt;Nerves.cranial;Ord;;H&P.PX;2;Hypoglossal nerve (CN XII) exam;CN XII exam;;ACTIVE;2.54;2.54 +80310-6;Pupil assessment panel;-;Pt;Pupil;-;;PANEL.H&P;2;Pupil assessment panel;Pupil assessment Pnl;;ACTIVE;2.54;2.56 +80311-4;Pupil shape;Shape;Pt;Pupil.left;Nom;;H&P.PX;2;Pupil shape [Shape] of Left pupil;Pupil shape Shape L pupil;;ACTIVE;2.54;2.68 +80312-2;Pupil shape;Shape;Pt;Pupil.right;Nom;;H&P.PX;2;Pupil shape [Shape] of Right pupil;Pupil shape Shape R pupil;;ACTIVE;2.54;2.68 +80313-0;Pupil assessment;Imp;Pt;Pupil;Ord;;H&P.PX;2;Pupil assessment [Interpretation];Pupil assessment Imp;;ACTIVE;2.54;2.54 +80314-8;Neurological assessment;Imp;Pt;Neurologic system;Nom;;H&P.PX;2;Neurological assessment [Interpretation];Neuro assessment Imp;;ACTIVE;2.54;2.54 +80315-5;Surgical procedures of neurological system;Hx;Pt;^Patient;Nom;;H&P.PX;2;History of Surgical procedures of neurological system;Hx of Surg proc of neuro system;;ACTIVE;2.54;2.56 +80316-3;Pain scale;Type;Pt;^Patient;Nom;;H&P.PX;2;Pain scale [Type];Pain scale type;;ACTIVE;2.54;2.73 +8031-7;Streptococcus pneumoniae Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae IgG Ab [Units/volume] in Serum;S pneum IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80317-1;Pain Assessment;Imp;Pt;^Patient;Ord;;H&P.PX;2;Pain assessment [Interpretation];Pain assessment Imp;;ACTIVE;2.54;2.73 +80318-9;Respiratory assessment panel;-;Pt;Respiratory system;-;;PANEL.H&P;2;Respiratory assessment panel;Resp assessment Pnl;;ACTIVE;2.54;2.73 +80319-7;Breath sounds;Find;Pt;Respiratory system;Nom;Auscultation;H&P.PX;2;Breath sounds by Auscultation;Breath sounds Auscultation;;ACTIVE;2.54;2.54 +80320-5;Respiratory assessment;Imp;Pt;Respiratory system;Nom;;H&P.PX;2;Respiratory assessment [Interpretation];Respiratory assessment Imp;;ACTIVE;2.54;2.54 +80321-3;Musculoskeletal assessment panel;-;Pt;Musculoskeletal system;-;;PANEL.H&P;2;Musculoskeletal assessment panel;Musculoskeletal assessment Pnl;;ACTIVE;2.54;2.56 +80322-1;Strength;Imp;Pt;Musculoskeletal system;Ord;;H&P.PX;2;Muscle strength;Muscle strength;;ACTIVE;2.54;2.54 +80323-9;Involuntary movements;Find;Pt;^Patient;Nom;;H&P.PX;2;Involuntary movements;Invol movements;;ACTIVE;2.54;2.54 +80324-7;Tendon reflex assessment panel;-;Pt;Neurologic deep tendon reflexes;-;;PANEL.H&P;2;Tendon reflex assessment panel;Tendon reflex assessment Pnl;;ACTIVE;2.54;2.56 +8032-5;Streptococcus pneumoniae Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae IgM Ab [Units/volume] in Serum;S pneum IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80325-4;Oculocephalic reflex;PrThr;Pt;Neurologic system;Ord;;H&P.PX;2;Oculocephalic reflex [Presence];Oculocephalic reflex Neurologic;;ACTIVE;2.54;2.56 +80326-2;Paralysis;Type;Pt;^Patient;Nom;;H&P.PX;2;Paralysis [Type];Paralysis type;;ACTIVE;2.54;2.54 +80327-0;Paresthesia;Type;Pt;^Patient;Nom;;H&P.PX;2;Paresthesia [Type];Paresthesia type;;ACTIVE;2.54;2.54 +80328-8;Musculoskeletal assessment;Imp;Pt;Musculoskeletal system;Nom;;H&P.PX;2;Musculoskeletal assessment [Interpretation];Musculoskeletal assessment Imp;;ACTIVE;2.54;2.54 +80329-6;Surgical procedures of musculoskeletal system;Hx;Pt;^Patient;Nom;;H&P.PX;2;History of Surgical procedures of musculoskeletal system;Hx of Surg proc of MS system;;ACTIVE;2.54;2.56 +80330-4;Genitourinary Assessment Panel;-;Pt;Genitourinary system;-;;PANEL.H&P;2;Genitourinary assessment panel;GU assessment Pnl;;ACTIVE;2.54;2.56 +80331-2;Date and time of last void;TmStp;Pt;Genitourinary system;Qn;;H&P.PX;2;Date and time of last void;Date+time last void GU;;ACTIVE;2.54;2.56 +80332-0;Voiding pattern;Find;Pt;Genitourinary system;Nom;;H&P.PX;2;Voiding pattern;Voiding pattern GU;;ACTIVE;2.54;2.54 +8033-3;Streptococcus pneumoniae 3 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 3 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum3 IgG Ser IA-aCnc;;DEPRECATED;1.0h(2);2.69 +80333-8;Other elements;Type;Pt;Urine;Nom;;H&P.PX;2;Other elements in Urine;Other elements Ur;;ACTIVE;2.54;2.54 +80334-6;Urine collection device;Type;Pt;Urine;Nom;;H&P.PX;2;Urine collection device;Urine collect device;;ACTIVE;2.54;2.54 +80335-3;Genitourinary assessment;Imp;Pt;Genitourinary system;Nom;;H&P.PX;2;Genitourinary assessment [Interpretation];Genitourinary assessment Imp;;ACTIVE;2.54;2.54 +80336-1;Surgical procedures of genitourinary system;Hx;Pt;^Patient;Nom;;H&P.PX;2;History of Surgical procedures of genitourinary system;Hx of Surg proc of GU system;;ACTIVE;2.54;2.56 +80337-9;Symptoms & diseases of genitourinary system;Hx;Pt;^Patient;Nom;Reported;H&P.PX;2;Deprecated History of genitourinary disorders - Reported;Deprecated Hx of GU disorders Reported;;DEPRECATED;2.54;2.56 +80338-7;Wound assessment;Imp;Pt;Wound;Nom;;H&P.PX;2;Wound assessment [Interpretation];Wound assessment Imp;;ACTIVE;2.54;2.54 +80339-5;Vital signs assessment;Imp;Pt;^Patient;Nom;;H&P.PX;2;Vital signs assessment [Interpretation];Vital signs assessment Imp;;ACTIVE;2.54;2.54 +80340-3;Nonpharmacologic intervention for pain;Type;Pt;^Patient;Nom;;CLIN;2;Nonpharmacologic intervention for pain;Nonpharm pain intervention;;ACTIVE;2.54;2.54 +8034-1;Strongyloides sp Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Strongyloides sp Ab [Units/volume] in Serum;Strongyloides Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80341-1;Respiratory effort;Type;Pt;^Patient;Nom;;H&P.PX;2;Respiratory effort;Resp effort;;ACTIVE;2.54;2.54 +80342-9;Breath sounds location;Anat;Pt;Lung;Nom;Auscultation;H&P.PX;2;Location of breath sounds by Auscultation;Loc breath sounds Ausc;;ACTIVE;2.54;2.54 +80343-7;Skin assessment;Imp;Pt;Skin;Nom;;H&P.PX;2;Skin assessment [Interpretation];Skin assessment Imp;;ACTIVE;2.54;2.54 +80344-5;Skin integrity;PrThr;Pt;Skin;Ord;;H&P.PX;2;Skin integrity;Skin integrity;;ACTIVE;2.54;2.56 +80345-2;Pressure points examined;Anat;Pt;Skin;Nom;;H&P.PX;2;Pressure points examined [Anatomy] of Skin;Pressure points examined Skin;;ACTIVE;2.54;2.54 +80346-0;Nursing physiologic assessment panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Nursing physiologic assessment panel;Nursing phys assessment Pnl;;ACTIVE;2.54;2.68 +80347-8;Mucous membrane integrity;PrThr;Pt;Mucous membrane;Ord;;H&P.PX;2;Mucous membrane integrity of Mucous membrane;Mucous membrane integrity;;ACTIVE;2.54;2.56 +80348-6;Escherichia coli enteropathogenic eae gene;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli enteropathogenic eae gene [Presence] in Stool by NAA with non-probe detection;EPEC eae gene Stl Ql NAA+non-probe;;ACTIVE;2.54;2.73 +80349-4;Escherichia coli enteroaggregative pAA plasmid aggR+aatA genes;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli enteroaggregative pAA plasmid aggR+aatA genes [Presence] in Stool by NAA with non-probe detection;EAEC pAA plas aggR+aatA St NAA+non-prb;;ACTIVE;2.54;2.73 +80350-2;Shigella species+EIEC invasion plasmid antigen H (ipaH) gene;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with non-probe detection;Shigella sp+EIEC ipaH St NAA+non-probe;;ACTIVE;2.54;2.73 +80351-0;Escherichia coli enterotoxigenic ltA+st1a+st1b genes;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli enterotoxigenic ltA+st1a+st1b genes [Presence] in Stool by NAA with non-probe detection;ETEC ltA+st1a+st1b tox St NAA+non-probe;;ACTIVE;2.54;2.73 +80352-8;Environment temperature during transport;Temp;Pt;Envir;Qn;;SPEC;1;Environment temperature during transport;Env temp transport;;ACTIVE;2.54;2.54 +80353-6;Herpes simplex virus 1 genome DNA polymerase region B+thymidine kinase region C;PrThr;Pt;Anogenital;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 genome DNA polymerase region B+thymidine kinase region C [Presence] in Anogenital specimen by NAA with probe detection;HSV 1 DNA pol regB+TK regC Anogn Ql NAA+pr;;ACTIVE;2.54;2.63 +80354-4;Herpes simplex virus 1 & 2 DNA panel;-;Pt;Anogenital;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Anogenital specimen by Probe and target amplification method;HSV 1+2 DNA Pnl Anogenital NAA+probe;;ACTIVE;2.54;2.73 +80355-1;Herpes simplex virus 2 genome glycoprotein B 3' end region+thymidine kinase region C;PrThr;Pt;Anogenital;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 genome glycoprotein B 3' end region+thymidine kinase region C [Presence] in Anogenital specimen by NAA with probe detection;HSV 2 glyco B 3'+TK regC Anogn Ql NAA+pr;;ACTIVE;2.54;2.63 +80356-9;Cause of death entity axis code;Find;Pt;^Patient;Nom;Automated;SURVEY.CDC;4;Cause of death entity axis code [Automated];;;ACTIVE;2.54;2.54 +80357-7;Cause of death record axis code;Find;Pt;^Patient;Nom;Automated;SURVEY.CDC;4;Cause of death record axis code [Automated];;;ACTIVE;2.54;2.54 +8035-8;Strongyloides stercoralis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Strongyloides stercoralis IgG Ab [Presence] in Serum;S stercoralis IgG Ser Ql;;ACTIVE;1.0h(2);2.73 +80358-5;Cause of death.underlying;Find;Pt;^Patient;Nom;Automated;SURVEY.CDC;4;Cause of death.underlying [Automated];;;ACTIVE;2.54;2.56 +80359-3;Cause of death.underlying;Find;Pt;^Patient;Nom;Manual;SURVEY.CDC;4;Cause of death.underlying [Manual];;;ACTIVE;2.54;2.56 +80360-1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Urine by NAA with probe detection;C trach+GC rRNA Ur Ql NAA+probe;;ACTIVE;2.54;2.73 +80361-9;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Cervix by NAA with probe detection;C trach+GC rRNA Cvx Ql NAA+probe;;ACTIVE;2.54;2.73 +80362-7;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by NAA with probe detection;C trach+GC rRNA Vag Ql NAA+probe;;ACTIVE;2.54;2.73 +80363-5;Chlamydia trachomatis DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Anorectal by NAA with probe detection;C trach DNA Anorectl Ql NAA+probe;;ACTIVE;2.54;2.73 +80364-3;Chlamydia trachomatis rRNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Anorectal by NAA with probe detection;C trach rRNA Anorectl Ql NAA+probe;;ACTIVE;2.54;2.73 +80365-0;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Anorectal by NAA with probe detection;C trach+GC rRNA Anorectl Ql NAA+probe;;ACTIVE;2.54;2.73 +8036-6;Taenia saginata Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Taenia saginata Ab [Units/volume] in Serum;T saginata Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80366-8;Neisseria gonorrhoeae rRNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Anorectal by NAA with probe detection;N gonorrhoea rRNA Anorectl Ql NAA+probe;;ACTIVE;2.54;2.73 +80367-6;Chlamydia trachomatis;PrThr;Pt;Anorectal;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Anorectal by Organism specific culture;C trach Anorectl Ql Cult;;ACTIVE;2.54;2.73 +80368-4;Neisseria gonorrhoeae;PrThr;Pt;Anorectal;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Anorectal by Organism specific culture;N gonorrhoea Anorectl Ql Cult;;ACTIVE;2.54;2.73 +80369-2;Neisseria sp identified;Prid;Pt;Anorectal;Nom;Organism specific culture;MICRO;1;Neisseria sp identified in Anorectal by Organism specific culture;Neisseria Anorectl Cult;;ACTIVE;2.54;2.73 +803-7;Toxic granules;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Toxic granules [Presence] in Blood by Light microscopy;Toxic Granules Bld Ql Smear;;ACTIVE;1.0;2.73 +80370-0;Biotinidase;CCnt;Pt;Ser/Plas;Qn;;CHEM;1;Biotinidase [Enzymatic activity/mass] in Serum or Plasma;Biotinidase SerPl-cCnt;;ACTIVE;2.54;2.54 +80371-8;Chitotriosidase;CCnt;Pt;Ser/Plas;Qn;;CHEM;1;Chitotriosidase [Enzymatic activity/mass] in Serum or Plasma;Chitotriosidase SerPl-cCnt;;ACTIVE;2.54;2.54 +80372-6;Hemoglobin.gastrointestinal;PrThr;Pt;Stool;Ord;IA.rapid;CHEM;1;Hemoglobin.gastrointestinal [Presence] in Stool by Rapid immunoassay;Hemoccult Stl Ql IA.rapid;;ACTIVE;2.54;2.73 +80373-4;Helicobacter pylori Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Helicobacter pylori Ag [Presence] in Stool by Rapid immunoassay;H pylori Ag Stl Ql IA.rapid;;ACTIVE;2.54;2.73 +8037-4;Taenia solium adult Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Taenia solium adult Ab [Units/volume] in Serum;T sol adult Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80374-2;Adenovirus & Norovirus & Rotavirus Ag panel;-;Pt;Stool;-;IA.rapid;PANEL.MICRO;1;Adenovirus and Norovirus and Rotavirus Ag panel - Stool by Rapid immunoassay;Adeno + Noro + Rota Ag Pnl Stl EIA.rap;;ACTIVE;2.58;2.58 +80375-9;Norovirus Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Norovirus Ag [Presence] in Stool by Rapid immunoassay;Norovirus Ag Stl Ql IA.rapid;;ACTIVE;2.58;2.58 +80376-7;Rotavirus & Adenovirus Ag panel;-;Pt;Stool;-;IA.rapid;PANEL.MICRO;1;Rotavirus and Adenovirus Ag panel - Stool by Rapid immunoassay;Rota + Adeno Ag Pnl Stl EIA.rapid;;ACTIVE;2.56;2.56 +80381-7;Influenza virus A & B Ag panel;-;Pt;Respiratory.upper;-;IA.rapid;PANEL.MICRO;1;Influenza virus A and B Ag panel - Upper respiratory specimen by Rapid immunoassay;FLUAV + FLUBV Ag Pnl Upper resp IA.rapid;;ACTIVE;2.54;2.7 +8038-2;Toxocara canis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Toxocara canis Ab [Units/volume] in Serum;T canis Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80382-5;Influenza virus A Ag;PrThr;Pt;Respiratory.upper;Ord;IA.rapid;MICRO;1;Influenza virus A Ag [Presence] in Upper respiratory specimen by Rapid immunoassay;FLUAV Ag Upper resp Ql IA.rapid;;ACTIVE;2.54;2.73 +80383-3;Influenza virus B Ag;PrThr;Pt;Respiratory.upper;Ord;IA.rapid;MICRO;1;Influenza virus B Ag [Presence] in Upper respiratory specimen by Rapid immunoassay;FLUBV Ag Upper resp Ql IA.rapid;;ACTIVE;2.54;2.73 +80384-1;Choriogonadotropin (pregnancy test);PrThr;Pt;Urine;Ord;IA.rapid;CHEM;1;Choriogonadotropin (pregnancy test) [Presence] in Urine by Rapid immunoassay;HCG Preg Ur Ql IA.rapid;;ACTIVE;2.54;2.56 +80385-8;Choriogonadotropin (pregnancy test);PrThr;Pt;Ser;Ord;IA.rapid;CHEM;1;Choriogonadotropin (pregnancy test) [Presence] in Serum by Rapid immunoassay;HCG Preg Ser Ql IA.rapid;;ACTIVE;2.54;2.73 +80386-6;Bladder tumor Ag;PrThr;Pt;Urine;Ord;IA.rapid;SERO;1;Bladder tumor Ag [Presence] in Urine by Rapid immunoassay;Bladder tumor Ag Ur Ql IA.rapid;;ACTIVE;2.54;2.56 +80387-4;HIV 1+2 Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;HIV 1+2 Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HIV1+2 Ab SerPlBld Ql IA.rapid;;ACTIVE;2.54;2.56 +80389-0;Special medical equipment &or resuscitation needs;Find;Pt;^Patient;Nom;;ED;2;Special medical equipment AndOr resuscitation needs;Medical/resuscitation needs;;TRIAL;2.54;2.54 +8039-0;Toxoplasma gondii Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Serum;T gondii IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80390-8;Family unification code;ID;Pt;^Patient;Nom;;H&P.HX;2;Family unification code;Family unification code;;TRIAL;2.54;2.54 +80391-6;Level of care;Type;Pt;^Patient;Nom;;ED;2;Level of care [Type];Level of care Type;;TRIAL;2.54;2.69 +80392-4;Special accommodation;Type;Pt;^Patient;Nom;;ED;2;Special accommodation [Type];Special accommodation Type;;TRIAL;2.54;2.54 +80393-2;Emergency management incident name;ID;Pt;^Event;Nom;;ED;2;Emergency management incident name;EM incident name;;TRIAL;2.54;2.66 +80394-0;Emergency management incident type;Type;Pt;^Event;Nom;;ED;2;Emergency management incident type;EM incident type;;TRIAL;2.54;2.66 +80395-7;Date of gestational age estimate;Date;Pt;^Patient;Qn;;CLIN;2;Date of gestational age estimate;Date of GA estimate;;TRIAL;2.54;2.54 +80396-5;Consultation note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Consult note;Gyn Onc Consult note;;ACTIVE;2.54;2.58 +80397-3;Number of W postpartum;Time;Pt;^Patient;Qn;;OBGYN;2;Number of weeks postpartum;Num of W postpartum;;TRIAL;2.54;2.54 +80398-1;Unique identifier;ID;Pt;Current sample;Nom;;SPEC;1;Unique identifier for Current sample;Unique ID Current sample;;ACTIVE;2.54;2.73 +80399-9;Occupational exposure information panel;-;Pt;^Patient;-;;PANEL.H&P;2;Occupational exposure information panel;Occup exp info Pnl;;TRIAL;2.54;2.54 +80400-5;Testing facility panel;-;Pt;Facility;-;;PANEL.CLIN;2;Testing facility panel;Testing facility Pnl;;TRIAL;2.54;2.66 +80401-3;Employment information panel;-;Pt;^Patient;-;;PANEL.H&P;2;Employment information panel;Employment info Pnl;;TRIAL;2.54;2.54 +80402-1;Egg source;Type;Pt;^Patient;Nom;;FERT;1;Egg source [Type];Egg source;;TRIAL;2.54;2.54 +80403-9;Respiratory wave amplitude;Elpot;Pt;Respiratory system;Qn;;CARDIO-PULM;2;Respiratory wave amplitude;Resp wave amp;;ACTIVE;2.54;2.54 +80404-7;RR interval.standard deviation;Time;Pt;Heart;Qn;;HRTRATE.ATOM;2;R-R interval.standard deviation (Heart rate variability);RR.sd (HR var);;ACTIVE;2.54;2.54 +80405-4;Certification;Type;Pt;Provider;Nom;;CLIN;2;Provider Certification [Type];Provider Certification [Type];;TRIAL;2.54;2.54 +80406-2;Date and time of initial encounter;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Date and time of initial encounter;TmStp initial encounter;;TRIAL;2.54;2.56 +80407-0;Contamination+radiation+contagion status;Find;Pt;^Patient;Ord;;ED;2;Contamination/radiation/contagion status;Contam+radiation+contagion status;;TRIAL;2.54;2.54 +8040-8;Toxoplasma gondii Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Toxoplasma gondii IgM Ab [Units/volume] in Serum;T gondii IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80408-8;Meets CDC field triage criteria;Find;Pt;^Patient;Ord;;ED;2;Meets CDC field triage criteria;Meets CDC field triage criteria;;TRIAL;2.54;2.54 +80409-6;Bed type;Type;Pt;^Patient;Nom;;CLIN;2;Bed type;Bed type;;TRIAL;2.54;2.54 +80410-4;Date and time of transfer departure;TmStp;Pt;^Patient;Qn;;ED;2;Date and time of transfer departure;Date+time trans departure;;TRIAL;2.54;2.56 +80411-2;Emergency management incident location;Loc;Pt;^Event;Nom;;ED;2;Emergency management incident location;EM incident location;;TRIAL;2.54;2.66 +80412-0;Encounter location;Loc;Pt;^Patient;Nom;;ED;2;Encounter location;Encounter location;;ACTIVE;2.54;2.7 +80413-8;Transferred to;Loc;Pt;^Patient;Nom;;H&P.HX;2;Transferred to [Location];Transferred to;;ACTIVE;2.54;2.54 +80414-6;Head circumference/Abdominal circumference;LenRto;Pt;^Fetus;Qn;US+Estimated from Campbell 1991;OB.US;2;Head circumference/Abdominal circumference US+Estimated from Campbell 1991;HC/AC from Campbell 1991;;ACTIVE;2.54;2.54 +80415-3;Body weight growth percentile;Prctl;Pt;^Fetus;Qn;US+Estimated from Hadlock 1991;OB.US;2;Fetal Body weight growth percentile US+Estimated from Hadlock 1991;FWP by Hadlock91;;ACTIVE;2.54;2.54 +8041-6;Treponema pallidum Ab;PrThr;Pt;Ser;Ord;HA;MICRO;1;Treponema pallidum Ab [Presence] in Serum by Hemagglutination;T pallidum Ab Ser Ql HA;;ACTIVE;1.0h(2);2.73 +80416-1;Head circumference/Abdominal circumference;LenRto;Pt;^Fetus;Qn;US+Estimated from Campbell 1977;OB.US;2;Head circumference/Abdominal circumference US+Estimated from Campbell 1977;HC/AC from Campbell 1977;;ACTIVE;2.54;2.54 +80417-9;Risk assessment and screening note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Risk assessment and screening note;Comm hlth care Risk assess+scrn note;;ACTIVE;2.54;2.58 +80418-7;Medical equipment or product list;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Medical equipment or product list;Comm hlth care Med equip or product list;;ACTIVE;2.54;2.54 +80419-5;Referral note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Referral note;Comm hlth care Referral note;;ACTIVE;2.54;2.58 +80420-3;Mandatory reporting form;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Mandatory reporting form;Mental health Mandatory reporting form;;ACTIVE;2.54;2.54 +80421-1;Mandatory reporting form;Find;Pt;{Setting};Doc;Public health;DOC.ONTOLOGY;2;Public health Mandatory reporting form;Public health Mandatory reporting form;;ACTIVE;2.54;2.54 +80422-9;Report;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Report;Comm hlth care Report;;ACTIVE;2.54;2.54 +80423-7;Safety issue assessment note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Safety issue assessment note;Comm hlth care Safety assessment note;;ACTIVE;2.54;2.54 +8042-4;Trichinella spiralis Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Trichinella spiralis Ab [Units/volume] in Serum;T spiralis Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80424-5;Inosine triphosphate pyrophosphatase;CSub;Pt;RBC;Qn;;CHEM;1;Inosine triphosphate pyrophosphatase [Enzymatic activity/substance] in Red Blood Cells;ITPase cSub RBC;;ACTIVE;2.54;2.54 +80425-2;Beta-N-acetylhexosaminidase.A;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Beta-N-acetylhexosaminidase.A [Enzymatic activity/volume] in DBS;Hexosaminidase A DBS-cCnc;;ACTIVE;2.54;2.61 +80426-0;Hepatitis D virus RNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Hepatitis D virus RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;HDV RNA # SerPl NAA+probe;;ACTIVE;2.54;2.73 +80427-8;Employer name;ID;Pt;^Patient;Nom;;H&P.HX;2;Employer name [Identifier];Employer name;;ACTIVE;2.54;2.73 +80428-6;Past employer name;ID;Pt;^Patient;Nom;;H&P.HX;2;Past employer name [Identifier];Past employer name;;ACTIVE;2.54;2.69 +80429-4;Employer address;Addr;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Employer address;Employer address;;ACTIVE;2.54;2.69 +80430-2;Past employer address;Addr;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Past employer address;Past employer addr;;ACTIVE;2.54;2.69 +80431-0;Employer city;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Employer city;Employer city;;ACTIVE;2.54;2.69 +8043-2;Trichinella spiralis Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Trichinella spiralis IgG Ab [Presence] in Serum;T spiralis IgG Ser Ql;;ACTIVE;1.0h(2);2.56 +80432-8;Past employer city;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Past employer city;Past employer city;;ACTIVE;2.54;2.69 +80433-6;Employer state;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Employer state;Employer state;;ACTIVE;2.54;2.69 +80434-4;Past employer state;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Past employer state;Past employer state;;ACTIVE;2.54;2.69 +80435-1;Employer postal code;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Employer postal code [Location];Employer postal code;;ACTIVE;2.54;2.66 +80436-9;Past employer postal code;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Past employer postal code [Location];Past employer postal code;;ACTIVE;2.54;2.66 +80437-7;Employer country;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Employer country [Location];Employer country;;ACTIVE;2.54;2.69 +80438-5;Past employer country;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Past employer country [Location];Past employer country;;ACTIVE;2.54;2.69 +80439-3;Alcohol intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Alcohol intake panel;Alcohol intake Pnl;;ACTIVE;2.54;2.54 +8044-0;Trypanosoma brucei Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Trypanosoma brucei Ab [Units/volume] in Serum;Deprecated T brucei Ab Ser-aCnc;;DEPRECATED;1.0h(2);2.69 +80440-1;Bioactive compound intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Bioactive compound intake panel;Bioactive compound intake Pnl;;ACTIVE;2.54;2.54 +80441-9;Breast milk &or formula intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Breast milk andor formula intake panel;Breast milk +or formula intake Pnl;;ACTIVE;2.54;2.56 +80442-7;Breast milk intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Breast milk intake panel;Breast milk intake Pnl;;ACTIVE;2.54;2.54 +80443-5;Calorie intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Calorie intake panel;Calorie in Pnl;;ACTIVE;2.54;2.54 +80444-3;Fluid intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Fluid intake panel;Fluid in Pnl;;ACTIVE;2.54;2.54 +80445-0;Food amounts panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Food amounts panel;Food amt Pnl;;ACTIVE;2.54;2.54 +80446-8;Infant formula intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Infant formula intake panel;Inf formula intake Pnl;;ACTIVE;2.54;2.54 +80447-6;Meal &or snack pattern panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Meal andor snack pattern panel;Meal +or snack pattern Pnl;;ACTIVE;2.54;2.56 +80448-4;Enteral tube flush volume;VRat;24H;^Patient;Qn;;CLIN;2;Enteral tube flush volume 24 hour;Enteral tube flush vol 24h;;ACTIVE;2.54;2.54 +80449-2;Adequacy of infant formula intake;Find;Pt;^Patient;Ord;;NUTRITION&DIETETICS;2;Adequacy of infant formula intake;Adeq infant formula intake;;ACTIVE;2.54;2.54 +804-5;Leukocytes;NCnc;Pt;Bld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Blood by Manual count;WBC # Bld Manual;;ACTIVE;1.0;2.73 +80450-0;Beer intake;VRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Beer intake 24 hour Measured;Beer intake 24h Measured;;ACTIVE;2.54;2.54 +80451-8;Beta glucan intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Beta glucan intake 24 hour Estimated;B glucan intake 24h Est;;ACTIVE;2.54;2.58 +80452-6;Beta glucan intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Beta glucan intake 24 hour Measured;B glucan intake 24h Measured;;ACTIVE;2.54;2.54 +80453-4;Food intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Food intake panel;Food in Pnl;;ACTIVE;2.54;2.54 +80454-2;Enteral tube.nutritional intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Enteral tube nutritional intake panel;Enteral tube.nutr int Pnl;;ACTIVE;2.54;2.54 +80455-9;Grain servings;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Grain servings 24 hour Estimated;Grain 24h nRate Est;;ACTIVE;2.54;2.58 +80456-7;Grain servings;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Grain servings 24 hour Measured;Grain 24h nRate Measured;;ACTIVE;2.54;2.54 +8045-7;Trypanosoma cruzi Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Trypanosoma cruzi Ab [Units/volume] in Serum;T cruzi Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80457-5;Fruit servings;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Fruit servings 24 hour Estimated;Fruit serving 24h nRate Est;;ACTIVE;2.54;2.58 +80458-3;Fruit servings;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Fruit servings 24 hour Measured;Fruit serving 24h nRate Measured;;ACTIVE;2.54;2.54 +80459-1;Vegetable servings;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vegetable servings 24 hour Estimated;Vegetable serv 24h nRate Est;;ACTIVE;2.54;2.58 +80460-9;Vegetable servings;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vegetable servings 24 hour Measured;Vegetable serv 24h nRate Measured;;ACTIVE;2.54;2.54 +80461-7;Dairy servings;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Dairy servings 24 hour Estimated;Dairy servings 24h nRate Est;;ACTIVE;2.54;2.58 +80462-5;Dairy servings;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Dairy servings 24 hour Measured;Dairy servings 24h nRate Measured;;ACTIVE;2.54;2.54 +80463-3;Protein servings;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Protein servings 24 hour Estimated;Protein servings 24h nRate Est;;ACTIVE;2.54;2.58 +80464-1;Protein servings;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Protein servings 24 hour Measured;Protein servings 24h nRate Measured;;ACTIVE;2.54;2.54 +8046-5;Varicella zoster virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus Ab [Units/volume] in Serum;VZV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80465-8;Oil servings;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Oil servings 24 hour Estimated;Oil serv 24h nRate Est;;ACTIVE;2.54;2.58 +80466-6;Oil servings;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Oil servings 24 hour Measured;Oil serv 24h nRate Measured;;ACTIVE;2.54;2.54 +80467-4;Empty calorie servings;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Empty calorie servings 24 hour Estimated;Empty calorie serv 24h nRate Est;;ACTIVE;2.54;2.58 +80468-2;Empty calorie servings;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Empty calorie servings 24 hour Measured;Empty calorie serv 24h nRate Measured;;ACTIVE;2.54;2.54 +80469-0;Infant formula intake;VRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Infant formula intake 24 hour Measured;Inf formula int 24h Measured;;ACTIVE;2.54;2.54 +80470-8;Plant stanol ester intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Plant stanol ester intake 24 hour Estimated;Plnt stanol ester int 24h Est;;ACTIVE;2.54;2.54 +80471-6;Plant stanol ester intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Plant stanol ester intake 24 hour Measured;Plnt stanol ester int 24h Measured;;ACTIVE;2.54;2.54 +80472-4;Psyllium intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Psyllium intake 24 hour Estimated;Psyllium intake 24h Est;;ACTIVE;2.54;2.54 +8047-3;Varicella zoster virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Serum;VZV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80473-2;Psyllium intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Psyllium intake 24 hour Measured;Psyllium intake 24h Measured;;ACTIVE;2.54;2.54 +80474-0;Infant formula intake;VRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Infant formula intake 24 hour Estimated;Inf formula int 24h Est;;ACTIVE;2.54;2.54 +80475-7;Fluid intake.enteral tube.nutritional formula composition;Find;Pt;^Patient;Nom;;NUTRITION&DIETETICS;2;Fluid intake enteral tube nutritional formula composition;Fluid intake ET nutr formula comp;;ACTIVE;2.54;2.54 +80476-5;Enteral tube.nutritional formula concentration;EngCnc;Pt;^Patient;Qn;;NUTRITION&DIETETICS;2;Enteral tube nutritional formula concentration [Energy/volume];Enteral tube.nutr formula conc EngCnc;;ACTIVE;2.54;2.54 +80477-3;Fluid intake.enteral tube.nutritional formula volume;VRat;24H;^Patient;Qn;;NUTRITION&DIETETICS;2;Fluid intake enteral tube nutritional formula volume 24 hour;Fluid intake ET nutr formula vol 24h;;ACTIVE;2.54;2.54 +80478-1;Distilled alcohol intake;VRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Distilled alcohol intake 24 hour Measured;Dist alcohol int 24h Measured;;ACTIVE;2.54;2.54 +80479-9;Wine intake;VRat;24H;^Patient;Qn;;NUTRITION&DIETETICS;2;Wine intake 24 hour;Wine intake 24h;;ACTIVE;2.54;2.54 +80480-7;Soy protein intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Soy protein intake 24 hour Estimated;Soy protein intake 24h Est;;ACTIVE;2.54;2.54 +8048-1;Varicella zoster virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Varicella zoster virus IgM Ab [Units/volume] in Serum;VZV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80481-5;Soy protein intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Soy protein intake 24 hour Measured;Soy protein intake 24h Measured;;ACTIVE;2.54;2.54 +80482-3;Breast milk feeding attempts;NRat;24H;^Patient;Qn;;NUTRITION&DIETETICS;2;Breast milk feeding attempts 24 hour;Breast milk feed attmpts 24h nRate;;ACTIVE;2.54;2.54 +80483-1;Breast milk intake volume;VRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Breast milk intake volume 24 hour Estimated;Breast milk intake vol 24h Est;;ACTIVE;2.54;2.54 +80484-9;Breast milk intake volume;VRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Breast milk intake volume 24 hour Measured;Breast milk intake vol 24h Measured;;ACTIVE;2.54;2.54 +80485-6;Breast milk intake adequacy;Find;Pt;^Patient;Ord;;NUTRITION&DIETETICS;2;Breast milk intake adequacy;Breast milk int adeq;;ACTIVE;2.54;2.54 +80486-4;Snacks;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Snacks 24 hour Estimated;Snacks 24h nRate Est;;ACTIVE;2.54;2.58 +80487-2;Snacks;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Snacks 24 hour Measured;Snacks 24h nRate Measured;;ACTIVE;2.54;2.54 +80488-0;Infant formula feedings;NRat;24H;^Patient;Qn;;NUTRITION&DIETETICS;2;Infant formula feedings 24 hour;Infant formula feed 24h nRate;;ACTIVE;2.54;2.54 +80489-8;Caffeine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Caffeine intake 24 hour Estimated;Caffeine intake 24h Est;;ACTIVE;2.54;2.54 +80490-6;Caffeine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Caffeine intake 24 hour Measured;Caffeine intake 24h Measured;;ACTIVE;2.54;2.54 +80491-4;Meals;NRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Meals 24 hour Estimated;Meals 24h nRate Est;;ACTIVE;2.54;2.58 +80492-2;Meals;NRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Meals 24 hour Measured;Meals 24h nRate Measured;;ACTIVE;2.54;2.54 +80493-0;Activity level;Accel;Pt;^Patient;Qn;;CLIN;2;Activity level [Acceleration];Activity level Accel;;ACTIVE;2.54;2.73 +80494-8;Calorie intake;EngRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Calorie intake 24 hour Measured;Calorie intake 24h Measured;;ACTIVE;2.54;2.66 +80495-5;Multisection^WO contrast;Find;Pt;Chest>Mediastinum;Doc;MR;RAD;2;MR Mediastinum WO contrast;MR Mediastinum WO contr;;ACTIVE;2.56;2.61 +80496-3;Multisection 3D post processing;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region 3D post processing;MR p 3D proc;;ACTIVE;2.56;2.64 +80497-1;Guidance for needle localization;Find;Pt;Breast.right;Doc;MR;RAD;2;MR Guidance for needle localization of Breast - right;MR Guided Brst-R Needle loc;;ACTIVE;2.56;2.64 +80498-9;Guidance for needle localization;Find;Pt;Breast.left;Doc;MR;RAD;2;MR Guidance for needle localization of Breast - left;MR Guided Brst-L Needle loc;;ACTIVE;2.56;2.64 +8049-9;Varicella zoster virus DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Serum by NAA with probe detection;VZV DNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.73 +80499-7;Multisection^WO & W Contrast IV;Find;Pt;Whole body;Doc;MR;RAD;2;MR Whole body WO and W contrast IV;MR Whole body WO+W contr IV;;ACTIVE;2.56;2.61 +80500-2;Multisection^W stress+WO contrast;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart W stress and WO contrast;MR Hrt W stress+WO contr;;ACTIVE;2.56;2.61 +80501-0;Multisection^W contrast PO+WO contrast IV;Find;Pt;Abdomen>Small bowel;Doc;MR;RAD;2;MR Small bowel W contrast PO and WO contrast IV;MR SB W contr PO+WO IV;;ACTIVE;2.56;2.61 +80502-8;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Aorta.abdominal & Pelvis+Lower extremity.bilateral>RO vessels;Doc;MR.angio;RAD;2;MRA Abdominal Aorta and Bilateral Runoff Vessels WO and W contrast IV;MRA Abd Aort+ROves-Bl WO+W contr IV;;ACTIVE;2.56;2.61 +80503-6;Multisection^W contrast PO+WO & W contrast IV;Find;Pt;Abdomen>Small bowel;Doc;MR;RAD;2;MR Small bowel W contrast PO and WO and W contrast IV;MR SB W contr PO+WO+W IV;;ACTIVE;2.56;2.61 +80504-4;Guidance for percutaneous biopsy;Find;Pt;XXX;Doc;MR;RAD;2;MR Guidance for biopsy of Unspecified body region;MR Guided Bx;;ACTIVE;2.56;2.64 +80505-1;Multisection for new diagnosis tumor^WO & W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain for new diagnosis tumor WO and W contrast IV;MR Brain for new dx tumor WO+W contr IV;;ACTIVE;2.56;2.61 +80506-9;Multisection for low grade tumor^WO & W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain for low grade tumor WO and W contrast IV;MR Brain for LG tumor WO+W contr IV;;ACTIVE;2.56;2.61 +8050-7;Venezuelan equine encephalitis virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Venezuelan equine encephalitis virus IgG Ab [Units/volume] in Serum;VEEV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80507-7;Multisection for high grade tumor^WO & W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain for high grade tumor WO and W contrast IV;MR Brain for HG tumor WO+W contr IV;;ACTIVE;2.56;2.61 +80508-5;Multisection^W contrast IS;Find;Pt;Upper extremity>Upper extremity joint;Doc;MR;RAD;2;MR Upper extremity.joint Arthrogram;MR UE joint W contr IS;;ACTIVE;2.56;2.61 +80509-3;Guidance for placement of clip;Find;Pt;XXX;Doc;MR;RAD;2;MR Guidance for placement of clip in Unspecified body region;MR Guided Clip place;;ACTIVE;2.56;2.64 +80510-1;Multisection for metastasis^WO & W contrast IV;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain for metastasis WO and W contrast IV;MR Brain for mets WO+W contr IV;;ACTIVE;2.56;2.61 +80511-9;Multisection for postoperative;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain for postoperative;MR Brain for postop;;ACTIVE;2.56;2.61 +80512-7;Multisection^WO contrast;Find;Pt;XXX>Bone marrow;Doc;MR;RAD;2;MR Bone marrow WO contrast;MR Bone mar WO contr;;ACTIVE;2.56;2.61 +80513-5;Multisection^W contrast IV;Find;Pt;XXX>Bone marrow;Doc;MR;RAD;2;MR Bone marrow W contrast IV;MR Bone mar W contr IV;;ACTIVE;2.56;2.61 +80514-3;Multisection^WO & W contrast IV;Find;Pt;XXX>Bone marrow;Doc;MR;RAD;2;MR Bone marrow WO and W contrast IV;MR Bone mar WO+W contr IV;;ACTIVE;2.56;2.61 +8051-5;Venezuelan equine encephalitis virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Venezuelan equine encephalitis virus IgM Ab [Units/volume] in Serum;VEEV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80515-0;Immunoglobulin light chains.kappa.free;MCnc;Pt;Ser;Qn;Nephelometry;CHEM;1;Kappa light chains.free [Mass/volume] in Serum by Nephelometry;Kappa LC Free Ser Neph-mCnc;;ACTIVE;2.56;2.73 +80516-8;Immunoglobulin light chains.lambda.free;MCnc;Pt;Ser;Qn;Nephelometry;CHEM;1;Lambda light chains.free [Mass/volume] in Serum by Nephelometry;Lambda LC Free Ser Neph-mCnc;;ACTIVE;2.56;2.73 +80517-6;Immunoglobulin light chains.kappa.free/Immunoglobulin light chains.lambda.free;MRto;Pt;Ser;Qn;Nephelometry;CHEM;1;Kappa light chains.free/Lambda light chains.free [Mass Ratio] in Serum by Nephelometry;Kappa LC Free/Lambda Free Ser Neph;;ACTIVE;2.56;2.73 +80518-4;Clostridium baratii toxin F bont gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium baratii toxin F bont gene [Presence] in Specimen by NAA with probe detection;C baratii F bont gene Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +80519-2;Urine flow.max;VRat;Pt;Genitourinary system;Qn;Uroflowmetry;IO_OUT.MOLEC;2;Maximum Urine flow by Uroflowmetry;Urine flow.max GU Uroflow;;ACTIVE;2.56;2.56 +805-2;Leukocytes;NCnc;Pt;CSF;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Cerebral spinal fluid by Automated count;WBC # CSF Auto;;ACTIVE;1.0;2.73 +80520-0;Flow time;Time;Pt;Urine;Qn;Uroflowmetry;IO_OUT.MOLEC;2;Flow time by Uroflowmetry;Flow time Ur Uroflow;;ACTIVE;2.56;2.56 +80521-8;Uroflowmetry study;Find;Pt;Genitourinary system;Doc;Uroflowmetry;CLIN;2;Uroflowmetry study;Uroflow study;;ACTIVE;2.56;2.72 +80522-6;Urine flow.mean;VRat;Pt;Genitourinary system;Qn;Uroflowmetry;IO_OUT.MOLEC;2;Mean urine flow by Uroflowmetry;Urineflow.mean GU Uroflow;;ACTIVE;2.56;2.56 +8052-3;Western equine encephalitis virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus IgG Ab [Units/volume] in Serum;WEEV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80523-4;Fluid output.urine;Vol;Pt;Genitourinary system;Qn;Uroflowmetry;IO_OUT.MOLEC;2;Urine output by Uroflowmetry;Fluid output urine Uroflow;;ACTIVE;2.56;2.56 +80524-2;Voiding time;Time;Pt;Urine;Qn;Uroflowmetry;IO_OUT.MOLEC;2;Voiding time by Uroflowmetry;Voiding time Ur Uroflow;;ACTIVE;2.56;2.58 +80525-9;Uroflowmetry panel;-;Pt;Genitourinary system;-;Uroflowmetry;PANEL.CLIN;2;Uroflowmetry panel;Uroflowmetry Pnl GU Uroflow;;ACTIVE;2.56;2.56 +80526-7;Time to max urine flow;Time;Pt;Genitourinary system;Qn;Uroflowmetry;IO_OUT.MOLEC;2;Time to max urine flow by Uroflowmetry;Time to max urine flow GU Uroflow;;ACTIVE;2.56;2.56 +80527-5;Percutaneous coronary intervention individual lesion procedure details panel;-;Pt;Heart;-;;PANEL.CARDIAC;2;Percutaneous coronary intervention individual lesion details panel;PCI indiv lesion details Pnl;;ACTIVE;2.56;2.56 +80528-3;Catheterization & angiography preoperative information panel;-;Pt;^Patient;-;;PANEL.CARDIAC;2;Catheterization and angiography preoperative information panel;Cath+angio preop Pnl;;ACTIVE;2.56;2.56 +80529-1;Everolimus;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Everolimus [Mass/volume] in DBS;Everolimus DBS-mCnc;;ACTIVE;2.56;2.61 +80530-9;Fluconazole;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Fluconazole [Mass/volume] in DBS;Fluconazole DBS-mCnc;;ACTIVE;2.56;2.61 +8053-1;Western equine encephalitis virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Western equine encephalitis virus IgM Ab [Units/volume] in Serum;WEEV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80531-7;Itraconazole;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Itraconazole [Mass/volume] in DBS;Itraconaz DBS-mCnc;;ACTIVE;2.56;2.61 +80532-5;Methadone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methadone [Mass/volume] in Blood;Methadone Bld-mCnc;;ACTIVE;2.56;2.56 +80533-3;Methamphetamine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Methamphetamine [Mass/mass] in Hair;Methamphet Hair-mCnt;;ACTIVE;2.56;2.56 +80534-1;Methylenedioxyamphetamine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Methylenedioxyamphetamine [Mass/mass] in Hair;MDA Hair-mCnt;;ACTIVE;2.56;2.56 +80535-8;Methylenedioxyethylamphetamine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/mass] in Hair;MDEA Hair-mCnt;;ACTIVE;2.56;2.56 +80536-6;Methylenedioxyethylamphetamine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Blood;MDEA Bld-mCnc;;ACTIVE;2.56;2.56 +80537-4;Methylenedioxymethamphetamine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Methylenedioxymethamphetamine [Mass/mass] in Hair;MDMA Hair-mCnt;;ACTIVE;2.56;2.56 +80538-2;Methylphenidate;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Methylphenidate [Mass/mass] in Hair;Me-phenidate Hair-mCnt;;ACTIVE;2.56;2.56 +80539-0;Morphine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Morphine [Mass/mass] in Hair;Morphine Hair-mCnt;;ACTIVE;2.56;2.56 +80540-8;Moxifloxacin;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Moxifloxacin [Mass/volume] in DBS;Moxifloxacin DBS-mCnc;;ACTIVE;2.56;2.61 +80541-6;Nicotine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Nicotine [Mass/mass] in Hair;Nicotine Hair-mCnt;;ACTIVE;2.56;2.56 +80542-4;Norcitalopram;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Norcitalopram [Mass/volume] in DBS;Norcitalopram DBS-mCnc;;ACTIVE;2.56;2.61 +80543-2;Norclozapine;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Norclozapine [Mass/volume] in DBS;Norclozapine DBS-mCnc;;ACTIVE;2.56;2.61 +80544-0;Nortriptyline;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Nortriptyline [Mass/volume] in DBS;Nortrip DBS-mCnc;;ACTIVE;2.56;2.61 +80545-7;Posaconazole;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Posaconazole [Mass/mass] in Hair;Posaconazole Hair-mCnt;;ACTIVE;2.56;2.56 +80546-5;rifAMPin;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;rifAMPin [Mass/volume] in DBS;rifAMPin DBS-mCnc;;ACTIVE;2.56;2.61 +80547-3;Rilpivirine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Rilpivirine [Mass/volume] in Serum or Plasma;Rilpivirine SerPl-mCnc;;ACTIVE;2.56;2.56 +80548-1;Sirolimus;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Sirolimus [Mass/volume] in DBS;Sirolimus DBS-mCnc;;ACTIVE;2.56;2.61 +8054-9;Yellow fever virus Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Yellow fever virus Ab [Units/volume] in Serum;YFV Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80549-9;Sulfamethoxazole;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Sulfamethoxazole [Mass/volume] in DBS;Sulfamethoxazole DBS-mCnc;;ACTIVE;2.56;2.61 +80550-7;Tacrolimus;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in DBS;Tacrolimus DBS-mCnc;;ACTIVE;2.56;2.61 +80551-5;Tetrahydrocannabinol;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/mass] in Hair;THC Hair-mCnt;;ACTIVE;2.56;2.56 +80552-3;Trimethoprim;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Trimethoprim [Mass/volume] in DBS;Trimethoprim DBS-mCnc;;ACTIVE;2.56;2.61 +80553-1;Voriconazole;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Voriconazole [Mass/volume] in DBS;Voriconazole DBS-mCnc;;ACTIVE;2.56;2.61 +80554-9;Zopiclone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zopiclone [Mass/volume] in Serum or Plasma;Zopiclone SerPl-mCnc;;ACTIVE;2.56;2.56 +80555-6;Diamorphine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Diamorphine [Mass/mass] in Hair;DAM Hair-mCnt;;ACTIVE;2.56;2.56 +8055-6;Yellow fever virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Yellow fever virus IgG Ab [Units/volume] in Serum;YFV IgG Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80556-4;cloZAPine;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;cloZAPine [Mass/volume] in DBS;cloZAPine DBS-mCnc;;ACTIVE;2.56;2.61 +80557-2;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Mass/mass] in Hair;EDDP Hair-mCnt;;ACTIVE;2.56;2.56 +80558-0;Amitriptyline;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Amitriptyline [Mass/volume] in DBS;Amitrip DBS-mCnc;;ACTIVE;2.56;2.61 +80559-8;Clarithromycin;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Clarithromycin [Mass/volume] in DBS;Clarithro DBS-mCnc;;ACTIVE;2.56;2.61 +80560-6;Citalopram;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Citalopram [Mass/volume] in DBS;Citalopram DBS-mCnc;;ACTIVE;2.56;2.61 +80561-4;cycloSPORINE;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;cycloSPORINE [Mass/volume] in DBS;cycloSPORINE DBS-mCnc;;ACTIVE;2.56;2.66 +80562-2;Diagram;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Diagram;Diagram;;DISCOURAGED;2.56;2.58 +80563-0;Report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Report;Report;;DISCOURAGED;2.56;2.73 +8056-4;Yellow fever virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Yellow fever virus IgM Ab [Units/volume] in Serum;YFV IgM Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80564-8;Mandatory reporting form;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Mandatory reporting form;Mandatory reporting form;;ACTIVE;2.56;2.56 +80565-5;Medication administration flowsheet;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Medication administration record;MAR;;ACTIVE;2.56;2.66 +80566-3;Checklist;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Checklist;Checklist;;DISCOURAGED;2.56;2.58 +80567-1;Flowsheet;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Flowsheet;Flowsheet;;DISCOURAGED;2.56;2.58 +80568-9;Form;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Form;Form;;DISCOURAGED;2.56;2.58 +80569-7;Progress note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Progress note;Pharmacology Prog note;;ACTIVE;2.56;2.73 +80570-5;Agreement;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Agreement;Agreement;;DISCOURAGED;2.56;2.58 +80571-3;Certificate;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Certificate;Certificate;;DISCOURAGED;2.56;2.58 +8057-2;Yellow fever virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Yellow fever virus RNA [Presence] in Serum by NAA with probe detection;YFV RNA Ser Ql NAA+probe;;ACTIVE;1.0h(2);2.63 +80572-1;Flowsheet;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Flowsheet;Cardiac surgery Flowsheet;;ACTIVE;2.56;2.56 +80573-9;Checklist;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Checklist;Cardiac surgery Checklist;;ACTIVE;2.56;2.56 +80574-7;Admission history and physical note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Admission history and physical note;Cardiac surgery Admit H&P note;;ACTIVE;2.56;2.58 +80575-4;Consultation note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Consult note;Cardiac surgery Consult note;;ACTIVE;2.56;2.58 +80576-2;Education note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Education note;Cardiac surgery Educ note;;ACTIVE;2.56;2.56 +80577-0;Referral note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Referral note;Cardiac surgery Referral note;;ACTIVE;2.56;2.58 +80578-8;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Preoperative evaluation and management note;Cardiac surgery Pre-op note;;ACTIVE;2.56;2.56 +80579-6;Surgical operation note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Surgical operation note;Cardiac surgery Operative note;;ACTIVE;2.56;2.58 +8058-0;Acetylcholine receptor Ab;ACnc;Pt;Ser;Qn;;SERO;1;Acetylcholine receptor Ab [Units/volume] in Serum;AChR Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80580-4;Transfer summary note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Transfer summary note;Cardiac surgery Transfer sum note;;ACTIVE;2.56;2.58 +80581-2;Incubation date & time range;TmStpRange;Pt;Specimen;Qn;;SPEC;1;Specimen incubation date and time range;Spec DtTmRng Inc;;ACTIVE;2.56;2.58 +80582-0;LOINC Document Ontology associated observations panel;-;Pt;Clinical document;-;;PANEL.DOC;2;LOINC Document Ontology associated observations panel;LOINC Doc Ont Assoc. Obs Pnl;;ACTIVE;2.56;2.56 +80583-8;Multisection for motor function;Find;Pt;Head>Brain;Doc;MR.functional;RAD;2;Functional MR Brain for motor function;fMR Brain for motor func;;ACTIVE;2.56;2.61 +80584-6;Multisection endovaginal^WO contrast;Find;Pt;Pelvis>Urethra;Doc;MR;RAD;2;MR Urethra Endovaginal WO contrast;MR Urethra Endovaginal WO contr;;ACTIVE;2.56;2.61 +80585-3;Multisection endorectal^W contrast IV;Find;Pt;Pelvis;Doc;MR;RAD;2;MR Pelvis Endorectal W contrast IV;MR Pelvis Endorectal W contr IV;;ACTIVE;2.56;2.61 +80586-1;Adenovirus hexon gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Adenovirus hexon gene [Presence] in Nasopharynx by NAA with probe detection;Adenovirus hexon gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80587-9;Human metapneumovirus A+B L+N genes;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus A+B L+N genes [Presence] in Nasopharynx by NAA with probe detection;hMPV A+B L+N genes Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80588-7;Influenza virus A M gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus A M gene [Presence] in Nasopharynx by NAA with probe detection;FLUAV M gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80589-5;Influenza virus A H1 HA gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 HA gene [Presence] in Nasopharynx by NAA with probe detection;FLUAV H1 HA gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80590-3;Influenza virus A H3 HA gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H3 HA gene [Presence] in Nasopharynx by NAA with probe detection;FLUAV H3 HA gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80591-1;Influenza virus B NS gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Influenza virus B NS gene [Presence] in Nasopharynx by NAA with probe detection;FLUBV NS gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80592-9;Parainfluenza virus 1 F gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 F gene [Presence] in Nasopharynx by NAA with probe detection;HPIV1 F gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80593-7;Parainfluenza virus 2 L gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 L gene [Presence] in Nasopharynx by NAA with probe detection;HPIV2 L gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80594-5;Parainfluenza virus 3 NP gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 NP gene [Presence] in Nasopharynx by NAA with probe detection;HPIV3 NP gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80595-2;Parainfluenza virus 4 P gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 P gene [Presence] in Nasopharynx by NAA with probe detection;HPIV4 P gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80596-0;Rhinovirus 5' UTR RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Rhinovirus 5' UTR RNA [Presence] in Nasopharynx by NAA with probe detection;Rhinovirus 5' UTR RNA Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80597-8;Respiratory syncytial virus A 5' UTR RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus A 5' UTR RNA [Presence] in Nasopharynx by NAA with probe detection;RSV A 5' UTR RNA Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +8059-8;Adrenal Ab;ACnc;Pt;Ser;Qn;;SERO;1;Adrenal Ab [Units/volume] in Serum;Adrenal Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80598-6;Respiratory syncytial virus B F gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus B F gene [Presence] in Nasopharynx by NAA with probe detection;RSV B F gene Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80599-4;Bordetella holmesii fumC gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Bordetella holmesii fumC gene [Presence] in Nasopharynx by NAA with probe detection;B holmesii fumC Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +806-0;Leukocytes;NCnc;Pt;CSF;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Cerebral spinal fluid by Manual count;WBC # CSF Manual;;ACTIVE;1.0;2.73 +80600-0;Bordetella pertussis.pertussis toxin promoter region;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis.pertussis toxin promoter region [Presence] in Nasopharynx by NAA with probe detection;B pert.PT Prmt Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80601-8;Bordetella pertussis+parapertussis+bronchiseptica gidA gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis+parapertussis+bronchiseptica gidA gene [Presence] in Nasopharynx by NAA with probe detection;B per+par+bron gidA Nph Ql NAA+probe;;ACTIVE;2.56;2.73 +80602-6;Respiratory pathogens identified;Type;Pt;Nph;Nom;Probe.amp.tar;MICRO;1;Respiratory pathogens identified [Type] in Nasopharynx by NAA with probe detection;Resp pathogens Nph NAA+probe;;ACTIVE;2.56;2.73 +80603-4;Coagulation factor XI inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor XI inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact XI Inhib PPP Ql;;ACTIVE;2.56;2.56 +80604-2;Desacetylrifampicin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Desacetylrifampicin [Mass/volume] in Serum or Plasma;Desacetylrifampicin SerPl-mCnc;;ACTIVE;2.56;2.56 +80605-9;Desacetylrifampicin;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Desacetylrifampicin [Mass/volume] in DBS;Desacetylrifampicin DBS-mCnc;;ACTIVE;2.56;2.61 +8060-6;Adrenal cortex Ab;ACnc;Pt;Ser;Qn;;SERO;1;Adrenal cortex Ab [Units/volume] in Serum;Adrenal cortex Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80606-7;14-Hydroxyclarithromycin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;14-Hydroxyclarithromycin [Mass/volume] in Serum or Plasma;14OH-clarithromycin SerPl-mCnc;;ACTIVE;2.56;2.56 +80607-5;14-Hydroxyclarithromycin;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;14-Hydroxyclarithromycin [Mass/volume] in DBS;14OH-clarithromycin DBS-mCnc;;ACTIVE;2.56;2.61 +80608-3;Cefuroxime;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefuroxime [Mass/volume] in Serum or Plasma;Cefuroxime SerPl-mCnc;;ACTIVE;2.56;2.56 +80609-1;Linezolid;MCnc;Pt;Bld.dot;Qn;;DRUG/TOX;1;Linezolid [Mass/volume] in DBS;Linezolid DBS-mCnc;;ACTIVE;2.56;2.61 +80610-9;A Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;A IgG Ab [Presence] in Serum or Plasma;A IgG SerPl Ql;;ACTIVE;2.56;2.56 +80611-7;Phosphate;SCnc;XXX;Urine;Qn;;CHEM;1;Phosphate [Moles/volume] in Urine collected for unspecified duration;Phosphate ?Tm Ur-sCnc;;ACTIVE;2.56;2.56 +80612-5;B Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;B IgG Ab [Presence] in Serum or Plasma;B IgG SerPl Ql;;ACTIVE;2.56;2.56 +80613-3;Bicarbonate;SCnc;XXX;Urine;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Urine collected for unspecified duration;HCO3 ?Tm Ur-sCnc;;ACTIVE;2.56;2.56 +8061-4;Nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Nuclear Ab [Presence] in Serum;ANA Ser Ql;;ACTIVE;1.0h(2);2.73 +80614-1;Baclofen;SCnc;Pt;XXX;Qn;;DRUG/TOX;1;Baclofen [Moles/volume] in Specimen;Baclofen Spec-sCnc;;ACTIVE;2.56;2.69 +80615-8;Recommended follow-up;Prid;Pt;^Patient;Nar;;CLIN;2;Recommended follow-up [Identifier] Narrative;Recom F/U;;ACTIVE;2.56;2.56 +80616-6;Date and time pronounced dead;TmStp;Pt;^Patient;Qn;US standard certificate of death;SURVEY.CDC;4;Date and time pronounced dead [US Standard Certificate of Death];;;ACTIVE;2.56;2.56 +80617-4;Cefuroxime.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefuroxime free [Mass/volume] in Serum or Plasma;Cefuroxime.free SerPl-mCnc;;ACTIVE;2.56;2.56 +80618-2;Zika virus Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Zika virus IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;ZIKV IgM CSF IA-aCnc;;ACTIVE;2.56;2.56 +80619-0;Zika virus Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Zika virus IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;ZIKV IgM SerPl IA-aCnc;;ACTIVE;2.56;2.73 +80620-8;Zika virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Zika virus neutralizing antibody [Titer] in Serum by Neutralization test;ZIKV NAb Titr Ser Nt;;ACTIVE;2.56;2.56 +80621-6;Zika virus Ab.Neut;Titr;Pt;CSF;Qn;Neut;MICRO;1;Zika virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test;ZIKV NAb Titr CSF Nt;;ACTIVE;2.56;2.56 +8062-2;Cardiolipin Ab;ACnc;Pt;Ser;Qn;;COAG;1;Cardiolipin Ab [Units/volume] in Serum;Cardiolipin Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80622-4;Zika virus Ab.Neut^1st specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Zika virus neutralizing antibody [Titer] in Serum by Neutralization test --1st specimen;ZIKV NAb sp1 Titr Ser Nt;;ACTIVE;2.56;2.56 +80623-2;Zika virus Ab.Neut^2nd specimen;Titr;Pt;Ser;Qn;Neut;MICRO;1;Zika virus neutralizing antibody [Titer] in Serum by Neutralization test --2nd specimen;ZIKV NAb sp2 Titr Ser Nt;;ACTIVE;2.56;2.56 +80624-0;Zika virus Ab.Neut^1st specimen;Titr;Pt;CSF;Qn;Neut;MICRO;1;Zika virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test --1st specimen;ZIKV NAb sp1 Titr CSF Nt;;ACTIVE;2.56;2.56 +80625-7;Zika virus Ab.Neut^2nd specimen;Titr;Pt;CSF;Qn;Neut;MICRO;1;Zika virus neutralizing antibody [Titer] in Cerebral spinal fluid by Neutralization test --2nd specimen;ZIKV NAb sp2 Titr CSF Nt;;ACTIVE;2.56;2.56 +80626-5;Activity at time of death;Type;Pt;^Patient;Nom;CDC;SURVEY.CDC;4;Activity at time of death [CDC];;;ACTIVE;2.56;2.56 +80627-3;Coagulation factor X activated inhibitor;MCnc;Pt;PPP;Qn;;COAG;1;Coagulation factor X activated inhibitor [Mass/volume] in Platelet poor plasma;Coag factor Xa inhib PPP-mCnc;;ACTIVE;2.56;2.73 +80628-1;1,1'-Sulfonylbis-2-Methylthioethane;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;1,1'-Sulfonylbis-2-Methylthioethane [Mass/volume] in Urine;SBMTE Ur-mCnc;;ACTIVE;2.56;2.56 +80629-9;1,2,2-Trimethylpropyl methylphosphonate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,2,2-Trimethylpropyl methylphosphonate [Mass/volume] in Blood;TMPA Bld-mCnc;;ACTIVE;2.56;2.56 +8063-0;Cardiolipin Ab.IgA;ACnc;Pt;Ser/Plas;Qn;;COAG;1;Cardiolipin IgA Ab [Units/volume] in Serum or Plasma;Cardiolipin IgA SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +80630-7;1,2-Dichloroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,2-Dichloroethane [Mass/volume] in Blood;1,2DCA Bld-mCnc;;ACTIVE;2.56;2.56 +80631-5;1,3-Dimethylbenzene+1,4-Dimethylbenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;1,3-Dimethylbenzene+1,4-Dimethylbenzene [Mass/volume] in Blood;1,3BDM+1,4BDM Bld-mCnc;;ACTIVE;2.56;2.56 +80632-3;2-Methylpropyl methylphosphonate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;2-Methylpropyl methylphosphonate [Mass/volume] in Blood;VX acid Bld-mCnc;;ACTIVE;2.56;2.56 +80633-1;Aldicarb;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aldicarb [Mass/volume] in Urine;Aldicarb Ur-mCnc;;ACTIVE;2.56;2.56 +80634-9;Aldicarb sulfone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aldicarb sulfone [Mass/volume] in Urine;Aldicarb sulfone Ur-mCnc;;ACTIVE;2.56;2.56 +80635-6;Aldicarb sulfoxide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Aldicarb sulfoxide [Mass/volume] in Urine;Aldicarb sulfoxide Ur-mCnc;;ACTIVE;2.56;2.56 +80636-4;Alpha-amanitin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Alpha-amanitin [Mass/volume] in Urine;Alpha-amanitin Ur-mCnc;;ACTIVE;2.56;2.56 +80637-2;Bedaquiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bedaquiline [Mass/volume] in Serum or Plasma;Bedaquiline SerPl-mCnc;;ACTIVE;2.56;2.56 +80638-0;Beta-amanitin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Beta-amanitin [Mass/volume] in Urine;Beta-amanitin Ur-mCnc;;ACTIVE;2.56;2.56 +80639-8;Gamma-amanitin;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Gamma-amanitin [Mass/volume] in Urine;Gamma-amanitin Ur-mCnc;;ACTIVE;2.56;2.56 +80640-6;Disopyramide+Nordisopyramide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Disopyramide+Nordisopyramide [Mass/volume] in Serum or Plasma;Disopyramide+Nordisopyramide SerPl-mCnc;;ACTIVE;2.56;2.56 +80641-4;Dothiepin+nordothiepin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dothiepin+Nordothiepin [Mass/volume] in Serum or Plasma;Dothiepin+Nordothiepin SerPl-mCnc;;ACTIVE;2.56;2.56 +80642-2;Floxacillin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Floxacillin Free [Mass/volume] in Serum or Plasma;Floxacillin free SerPl-mCnc;;ACTIVE;2.56;2.56 +80643-0;Gadolinium;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Gadolinium [Mass/mass] in Tissue;Gadolinium Tiss-mCnt;;ACTIVE;2.56;2.63 +80644-8;Isopropyl methylphosphonate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isopropyl methylphosphonate [Mass/volume] in Blood;IMPA Bld-mCnc;;ACTIVE;2.56;2.56 +80645-5;Maprotiline+Normaprotiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Maprotiline+normaprotiline [Mass/volume] in Serum or Plasma;Maprotiline+normaprotiline SerPl-mCnc;;ACTIVE;2.56;2.56 +80646-3;Monocyclohexyl methylphosphonate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Monocyclohexyl methylphosphonate [Mass/volume] in Blood;Monocyclohexyl Me-phosphonate Bld-mCnc;;ACTIVE;2.56;2.56 +80647-1;Monoethyl methylphosphonate;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Monoethyl methylphosphonate [Mass/volume] in Blood;Monoethyl Me-phosphonate Bld-mCnc;;ACTIVE;2.56;2.56 +8064-8;Cardiolipin Ab.IgG;ACnc;Pt;Ser;Qn;EIA;COAG;1;Deprecated Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated Cardiolipin IgG Ser EIA-aCnc;;DEPRECATED;1.0h(2);2.69 +80648-9;N-monodesmethyl bedaquiline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;N-monodesmethyl bedaquiline [Mass/volume] in Serum or Plasma;N-monodesmethyl bedaquiline SerPl-mCnc;;ACTIVE;2.56;2.56 +80649-7;Tetramethylenedisulfotetramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Tetramethylenedisulfotetramine [Mass/volume] in Urine;Tetramine Ur-mCnc;;ACTIVE;2.56;2.56 +80650-5;Tin;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tin [Moles/volume] in Blood;Tin Bld-sCnc;;ACTIVE;2.56;2.56 +80651-3;Voriconazole N-oxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Voriconazole N-oxide [Mass/volume] in Serum or Plasma;Voriconazole N-oxide SerPl-mCnc;;ACTIVE;2.56;2.56 +80652-1;Everolimus;Mass;Pt;Dose;Qn;;DRUGDOSE;1;Everolimus [Mass] of Dose;Everolimus Dose;;ACTIVE;2.56;2.56 +80653-9;Spermatozoa.normal chromatin/100 spermatozoa;NFr;Pt;Semen;Qn;Romanowsky stain;FERT;1;Spermatozoa Normal chromatin/100 spermatozoa in Semen by Romanowsky stain;Sperm norm chrom NFr Smn Romanowsky stn;;ACTIVE;2.56;2.56 +80654-7;Spermatozoa.progressive.grade 1+2/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa Progressive Grade 1+2/100 spermatozoa in Semen;Sperm prog 1+2 NFr Smn;;ACTIVE;2.56;2.73 +8065-5;Cardiolipin Ab.IgG;ACnc;Pt;Ser/Plas;Qn;;COAG;1;Cardiolipin IgG Ab [Units/volume] in Serum or Plasma;Cardiolipin IgG SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +80655-4;Hemoglobin G-Philadelphia/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin G - Philadelphia/Hemoglobin.total in Blood;Hgb G-Philad MFr Bld;;ACTIVE;2.56;2.56 +80656-2;Hemoglobin Hope/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin Hope/Hemoglobin.total in Blood;Hgb Hope MFr Bld;;ACTIVE;2.56;2.56 +80657-0;Hemoglobin Q/Hemoglobin.total;MFr;Pt;Bld;Qn;;HEM/BC;1;Hemoglobin Q/Hemoglobin.total in Blood;Hg Q MFr Bld;;ACTIVE;2.56;2.56 +80658-8;Activated clotting time.diatomaceous earth induced;Time;Pt;Bld;Qn;Coag;COAG;1;Activated clotting time (ACT) of Blood induced by Diatomaceous earth;ACT Diatom earth Ind Bld;;ACTIVE;2.56;2.69 +80659-6;Activated clotting time.kaolin induced;Time;Pt;Bld;Qn;Coag;COAG;1;Activated clotting time (ACT) of Blood induced by Kaolin;ACT Kaolin Ind Bld;;ACTIVE;2.56;2.73 +80660-4;Strongyloides sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Strongyloides sp IgG Ab [Presence] in Serum by Immunoassay;Strongyloides IgG Ser Ql IA;;ACTIVE;2.56;2.73 +80661-2;Color;Type;Pt;Dial fld prt;Nom;;SPEC;1;Color of Peritoneal dialysis fluid;Color DiafP;;ACTIVE;2.56;2.56 +80662-0;Specimen volume;Vol;Pt;Dial fld prt;Qn;;SPEC;1;Volume of Peritoneal dialysis fluid;Specimen vol DiafP;;ACTIVE;2.56;2.56 +8066-3;Cardiolipin Ab.IgM;ACnc;Pt;Ser;Qn;EIA;COAG;1;Deprecated Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay;Deprecated Cardiolipin IgM Ser EIA-aCnc;;DEPRECATED;1.0h(2);2.69 +80663-8;4-Hydroxy 3-Nitrophenylacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;4-Hydroxy 3-Nitrophenylacetate (HNPAA) [Mass/volume] in Urine;HNPAA Ur-mCnc;;ACTIVE;2.56;2.56 +80664-6;Consultation note;Find;Pt;{Setting};Doc;Clinical neurophysiology;DOC.ONTOLOGY;2;Clinical neurophysiology Consult note;Clinical Neurophys Consult note;;ACTIVE;2.56;2.58 +80665-3;Progress note;Find;Pt;{Setting};Doc;Clinical neurophysiology;DOC.ONTOLOGY;2;Clinical neurophysiology Progress note;Clinical Neurophys Prog note;;ACTIVE;2.56;2.73 +80666-1;Consultation note;Find;Pt;{Setting};Doc;Vascular neurology;DOC.ONTOLOGY;2;Vascular neurology Consult note;Vasc Neuro Consult note;;ACTIVE;2.56;2.58 +80667-9;Progress note;Find;Pt;{Setting};Doc;Vascular neurology;DOC.ONTOLOGY;2;Vascular neurology Progress note;Vasc Neuro Prog note;;ACTIVE;2.56;2.73 +80668-7;Surgical operation note;Find;Pt;{Setting};Doc;Vascular neurology;DOC.ONTOLOGY;2;Vascular neurology Surgical operation note;Vasc Neuro Operative note;;ACTIVE;2.56;2.58 +80669-5;Procedure note;Find;Pt;{Setting};Doc;Vascular neurology;DOC.ONTOLOGY;2;Vascular neurology procedure note;Vasc Neuro Procedure note;;ACTIVE;2.56;2.58 +80670-3;Procedure note;Find;Pt;{Setting};Doc;Clinical neurophysiology;DOC.ONTOLOGY;2;Clinical neurophysiology procedure note;Clinical Neurophys Procedure note;;ACTIVE;2.56;2.58 +8067-1;Cardiolipin Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;COAG;1;Cardiolipin IgM Ab [Units/volume] in Serum or Plasma;Cardiolipin IgM SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +80671-1;Progress note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Progress note;Pastoral Care Prog note;;ACTIVE;2.56;2.73 +80672-9;Conference note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Conference note;SW Conf eval note;;ACTIVE;2.56;2.65 +80673-7;Consultation note;Find;Pt;{Setting};Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Consult note;Mat fetal med Consult note;;ACTIVE;2.56;2.73 +80674-5;Adenovirus 40+41 fiber protein gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Adenovirus 40+41fiber protein gene [Presence] in Stool by NAA with probe detection;AdV 40+41 fib prot Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +80675-2;Rotavirus A VP6 gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Rotavirus A VP6 gene [Presence] in Stool by NAA with probe detection;RVA VP6 Stl Ql NAA+probe;;ACTIVE;2.56;2.64 +80676-0;Escherichia coli O157 rfbE gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli O157 rfbE gene [Presence] in Stool by NAA with probe detection;EC O157 rfbE gene Stl Ql NAA+probe;;ACTIVE;2.56;2.73 +80677-8;Escherichia coli enterotoxigenic eltA+estB genes;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enterotoxigenic eltA+estB genes [Presence] in Stool by NAA with probe detection;ETEC eltA+estB genes Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +80678-6;Salmonella sp invA+fliC genes;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Salmonella sp invA+fliC genes [Presence] in Stool by NAA with probe detection;Salmonella sp invA+fliC Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +80679-4;Escherichia coli Stx1+Stx2 toxin stx1+stx2 genes;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx1 and Stx2 toxin stx1+stx2 genes [Presence] in Stool by NAA with probe detection;EC stx1+stx2 genes Stl Ql NAA+probe;;ACTIVE;2.56;2.64 +80680-2;Vibrio cholerae toxin ctxA gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Vibrio cholerae toxin ctxA gene [Presence] in Stool by NAA with probe detection;Vibrio chol toxin ctxA Stl Ql NAA+probe;;ACTIVE;2.56;2.64 +80681-0;Cryptosporidium parvum+hominis oocyst wall protein (COWP) gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Cryptosporidium parvum+hominis oocyst wall protein COWP gene [Presence] in Stool by NAA with probe detection;C parvum+hominis COWP Stl Ql NAA+probe;;ACTIVE;2.56;2.65 +80682-8;Entamoeba histolytica 18S rRNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Entamoeba histolytica 18S rRNA [Presence] in Stool by NAA with probe detection;E histolytica 18S rRNA Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +80683-6;Giardia lamblia 18S rRNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Giardia lamblia 18S rRNA [Presence] in Stool by NAA with probe detection;G lamblia 18S rRNA Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +80684-4;Campylobacter coli+jejuni+lari 16S rRNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter coli+jejuni+lari 16S rRNA [Presence] in Stool by NAA with probe detection;C coli+jej+lar 16S rRNA Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +80685-1;Clostridioides difficile toxin A+B tcdA+tcdB genes;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Clostridioides difficile toxin A+B tcdA+tcdB genes [Presence] in Stool by NAA with probe detection;C dif tox tcdA+tcdB Stl Ql NAA+probe;;ACTIVE;2.56;2.73 +80686-9;CYP2C9 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;CYP2C9 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP2C9 gene Mut Anl Bld/T;;ACTIVE;2.56;2.67 +80687-7;CYP1A2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP1A2 Mut Anl Bld/T;;ACTIVE;2.56;2.67 +80688-5;HIV 1 RNA tropism;Prid;Pt;Plas;Nom;;ABXBACT;1;HIV 1 RNA tropism [Identifier] in Plasma;HIV1 RNA tropism Plas;;ACTIVE;2.56;2.56 +8068-9;Centromere Ab;ACnc;Pt;Ser;Qn;;SERO;1;Centromere Ab [Units/volume] in Serum;Centromere Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80689-3;HIV 1 RNA reverse transcriptase & protease & integrase gene mutations detected;Prid;Pt;Plas;Nom;Sequencing;ABXBACT;1;HIV 1 RNA reverse transcriptase and protease and integrase gene mutations detected [Identifier] in Plasma by Sequencing;HIV 1 RNA RT + PR + IN Mut Det Plas Seq;;ACTIVE;2.56;2.73 +80690-1;HIV 1 proviral DNA tropism;Prid;Pt;Bld MC;Nom;;ABXBACT;1;HIV 1 proviral DNA tropism [Identifier] in Blood mononuclear cells;HIV1 proviral DNA tropism Bld MC;;ACTIVE;2.56;2.73 +80691-9;HIV 1 proviral DNA integrase gene mutations detected;Prid;Pt;Bld MC;Nom;Sequencing;ABXBACT;1;HIV 1 proviral DNA integrase gene mutations detected [Identifier] in Blood mononuclear cells by Sequencing;HIV1 proviral DNA IN Mut Det Bld MC Seq;;ACTIVE;2.56;2.73 +80692-7;HIV 1 proviral DNA reverse transcriptase & protease gene mutations detected;Prid;Pt;Bld MC;Nom;Sequencing;ABXBACT;1;HIV 1 proviral DNA reverse transcriptase and protease gene mutations detected [Identifier] in Blood mononuclear cells by Sequencing;HIV1 proviral DNA RT + PR Mut Det Seq;;ACTIVE;2.56;2.73 +80693-5;HIV 1 proviral DNA reverse transcriptase & protease & integrase gene mutations detected;Prid;Pt;Bld MC;Nom;Sequencing;ABXBACT;1;HIV 1 proviral DNA reverse transcriptase and protease and integrase gene mutations detected [Identifier] in Blood mononuclear cells by Sequencing;HIV1 provir DNA RT + PR + IN Mut Det Seq;;ACTIVE;2.56;2.73 +80694-3;HIV 1 proviral DNA genotype;Imp;Pt;Bld MC;Nar;Genotyping;ABXBACT;1;HIV 1 proviral DNA genotype [Interpretation] in Mononuclear cells from whole blood Narrative;HIV1 proviral DNA Gentyp Bld MC Nar;;ACTIVE;2.56;2.73 +80695-0;HIV 1 proviral DNA genotype;Find;Pt;Bld MC;Doc;Genotyping;ABXBACT;1;HIV 1 proviral DNA genotype in Mononuclear cells from whole blood;HIV 1 proviral DNA Gentyp Bld MC Doc;;ACTIVE;2.56;2.73 +80696-8;2-Chlorovinyl arsonous acid;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2-Chlorovinyl arsonous acid [Mass/volume] in Urine;CVAA Ur-mCnc;;ACTIVE;2.56;2.56 +8069-7;Epidermis Ab;Titr;Pt;Ser;Qn;;SERO;1;Epidermis Ab [Titer] in Serum;Epidis Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +80697-6;Mycophenolate acyl-glucuronide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Mycophenolate acyl-glucuronide [Mass/volume] in Serum or Plasma;Mycophenolate acyl-G SerPl-mCnc;;ACTIVE;2.56;2.73 +80698-4;Viable CD34 cells/100 cells.CD34;NFr;Pt;Hematopoietic progenitor cells^BPU;Qn;;BLDBK;1;Viable CD34 cells/100 CD34 cells in Hematopoietic progenitor cells from Blood product unit;Viable CD34 cells/100 CD34 NFr HPC BPU;;ACTIVE;2.56;2.56 +80699-2;Cells.CD4-CD8-/100 Cells.CD3+TCR alpha beta+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD4-CD8-/100 CD3+TCR alpha beta+ cells in Blood;CD4-CD8-/100 CD3+TCR A-B+ NFr Bld;;ACTIVE;2.56;2.56 +80700-8;Cells.CD25+CD127-/100 cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25+CD127- (regulatory T) cells/100 CD3+CD4+ cells in Blood;CD25+CD127- cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.56;2.56 +80701-6;Cells.CD27-/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27- cells/100 CD3+CD8+ cells in Blood;CD27- cells/100 CD3+CD8+ NFr Bld;;ACTIVE;2.56;2.56 +80702-4;Cells.CD27+CD45RA-/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD45RA- cells/100 CD3+CD4+ cells in Blood;CD27+CD45RA- cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.56;2.56 +80703-2;Cells.CD27+CD45RA-/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD45RA- cells/100 CD3+CD8+ cells in Blood;CD27+CD45RA- cells/100 CD3+CD8+ NFr Bld;;ACTIVE;2.56;2.56 +80704-0;Cells.CD27+CD45RA+/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD45RA+ cells/100 CD3+CD4+ cells in Blood;CD27+CD45RA+ cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.56;2.56 +8070-5;Gliadin Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Gliadin IgM Ab [Units/volume] in Serum;Gliadin IgM Ser-aCnc;;ACTIVE;1.0h(2);2.68 +80705-7;Cells.CD27+CD45RA+/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD45RA+ cells/100 CD3+CD8+ cells in Blood;CD27+CD45RA+ cells/100 CD3+CD8+ NFr Bld;;ACTIVE;2.56;2.56 +80706-5;Cells.CD27+IgD-/100 Cells.CD19+CD20+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+IgD- cells/100 CD19+CD20+ cells in Blood;CD27+IgD- cells/100 CD19+CD20+ NFr Bld;;ACTIVE;2.56;2.56 +80707-3;Cells.CD27+IgD+/100 Cells.CD19+CD20+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+IgD+ cells/100 CD19+CD20+ cells in Blood;CD27+IgD+ cells/100 CD19+CD20+ NFr Bld;;ACTIVE;2.56;2.56 +80708-1;Cells.CD27-CD45RA-/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27-CD45RA- cells/100 CD3+CD4+ cells in Blood;CD27-CD45RA- cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.56;2.56 +80709-9;Cells.CD27-CD45RA+/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27-CD45RA+ cells/100 CD3+CD4+ cells in Blood;CD27-CD45RA+ cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.56;2.56 +80710-7;Cells.CD27-IgD+/100 Cells.CD19+CD20+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27-IgD+ cells/100 CD19+CD20+ cells in Blood;CD27-IgD+ cells/100 CD19+CD20+ NFr Bld;;ACTIVE;2.56;2.73 +80711-5;Cells.CD38+HLA-DR+/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38+HLA-DR+ cells/100 CD3+CD4+ cells in Blood;CD38+HLA-DR+ cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.56;2.56 +80712-3;Cells.CD38+HLA-DR+/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38+HLA-DR+ cells/100 CD3+CD8+ cells in Blood;CD38+HLA-DR+ cells/100 CD3+CD8+ NFr Bld;;ACTIVE;2.56;2.56 +8071-3;Histone Ab;PrThr;Pt;Ser;Ord;;SERO;1;Histone Ab [Presence] in Serum;Histone Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80713-1;Cells.TCR alpha beta/100 Cells.CD3;NFr;Pt;Bld;Qn;;CELLMARK;1;TCR alpha beta cells/100 CD3 cells in Blood;TCR A-B Cells/100 CD3 NFr Bld;;ACTIVE;2.56;2.56 +80714-9;Cells.TCR gamma delta/100 Cells.CD3;NFr;Pt;Bld;Qn;;CELLMARK;1;TCR gamma delta cells/100 CD3 cells in Blood;TCR G-D Cells/100 CD3 NFr Bld;;ACTIVE;2.56;2.56 +80715-6;FSHR gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;FSHR gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;FSHR gene Mut Anl Bld/T;;ACTIVE;2.56;2.63 +80716-4;T-cell activated (CD38+HLA-DR+) subsets panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;T-cell activated (CD38+HLA-DR+) subsets panel - Blood;T-cell activated subsets Pnl Bld;;ACTIVE;2.56;2.65 +80717-2;B-cell CD27 & IgD subsets panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;B-cell CD27 and IgD subsets panel - Blood;B-cell CD27 + IgD subsets Pnl Bld;;ACTIVE;2.56;2.56 +80718-0;Lymphocyte TCR gamma delta & alpha beta subsets panel;-;Pt;Bld;Qn;;PANEL.CELLMARK;1;Lymphocyte TCR gamma delta and alpha beta subsets panel - Blood;Lymph TCR gam delt + alpha beta sub Pnl;;ACTIVE;2.56;2.56 +80719-8;T-cell naive & memory & effector (CD27 and CD45RA) subsets;Imp;Pt;Bld;Nar;;CELLMARK;1;T-cell naive and memory and effector (CD27 and CD45RA) subsets [Interpretation] in Blood Narrative;T-cell naive + mem + eff subsets Imp;;ACTIVE;2.56;2.56 +80720-6;T-cell naive & memory & effector (CD27 and CD45RA) subsets panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;T-cell naive and memory and effector (CD27 and CD45RA) subsets panel - Blood;T-cell naive + mem + eff subsets Pnl;;ACTIVE;2.56;2.56 +8072-1;Insulin Ab;ACnc;Pt;Ser;Qn;;SERO;1;Insulin Ab [Units/volume] in Serum;Insulin Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80721-4;Lymphocyte T-cell & B-cell & Natural killer subsets panel;-;Pt;Bld;Qn;;PANEL.CELLMARK;1;Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood;Lymph T-cell + B-cell + NK subsets Pnl;;ACTIVE;2.56;2.63 +80722-2;Lymphocyte T-cell & B-cell & Natural killer subsets;Imp;Pt;Bld;Nar;;CELLMARK;1;Lymphocyte T-cell and B-cell and Natural killer subsets [Interpretation] in Blood Narrative;T-cell + B-cell + NK subsets Bld-Imp Nar;;ACTIVE;2.56;2.73 +80723-0;B-cell CD27 & IgD subsets;Imp;Pt;Bld;Nar;;CELLMARK;1;B-cell CD27 and IgD subsets [Interpretation] in Blood Narrative;B-cell CD27 + IgD subsets Bld-Imp Nar;;ACTIVE;2.56;2.56 +80724-8;Non-liquefied volume/Volume.total;VFr;Pt;Semen;Qn;Estimated;FERT;1;Estimated Non-liquefied volume [Volume Fraction] in Semen;Non-liquefact vol/Total vol VFr Smn Est;;ACTIVE;2.56;2.73 +80725-5;Trichomonas sp;PrThr;Pt;Semen;Ord;Microscopy.light;MICRO;1;Trichomonas sp [Presence] in Semen by Light microscopy;Trichomonas Smn Ql Micro;;ACTIVE;2.56;2.73 +80726-3;Blood sampling performed;Find;Pt;^Patient;Ord;Cardiac catheterization;CARD.PROC;2;Blood sampling performed Cardiac catheterization;Blood sampling perf Cardiac Cath;;ACTIVE;2.56;2.56 +80727-1;Percutaneous coronary intervention performed;Find;Pt;Heart;Ord;;H&P.HX;2;Percutaneous coronary intervention performed;PCI perf Hrt;;ACTIVE;2.56;2.58 +80728-9;Stenosis degree^pre procedure;LenFr;Pt;Coronary arteries.segment;Qn;;CARD.PROC;2;Percent stenosis of Coronary artery segment --pre procedure;Percent sten of Coron aa seg --pre proc;;ACTIVE;2.56;2.56 +80729-7;New or recurrent stenosis;Type;Pt;Coronary arteries.segment;Nom;;CARDIO-PULM;2;New or recurrent stenosis Coronary artery segment;New or recur sten Cor aa seg;;ACTIVE;2.56;2.56 +80730-5;Stenosis classification;Type;Pt;Coronary arteries.segment;Ord;ACC-AHA;CARD.PROC;2;Stenosis classification Coronary artery segment ACC-AHA;Stenosis class Cor aa seg ACC-AHA;;ACTIVE;2.56;2.56 +80731-3;Percutaneous coronary intervention individual lesion procedure results panel;-;Pt;Heart;-;;PANEL.CARDIAC;2;Percutaneous coronary intervention individual lesion procedure results panel Heart;PCI indiv lesion proc results Pnl Hrt;;ACTIVE;2.56;2.63 +80732-1;Checklist;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Checklist;Otolaryngology Checklist;;ACTIVE;2.56;2.56 +80733-9;Admission history and physical note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Admission history and physical note;Otolaryngology Admit H&P note;;ACTIVE;2.56;2.58 +80734-7;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Preoperative evaluation and management note;Otolaryngology Pre-op note;;ACTIVE;2.56;2.56 +80735-4;Transfer summary note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Transfer summary note;Otolaryngology Transfer sum note;;ACTIVE;2.56;2.58 +80736-2;Consultation note;Find;Pt;{Setting};Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Consult note;Bld Bnk+Trans Med Consult note;;ACTIVE;2.56;2.58 +80737-0;Calculated panel reactive antibody;RelRto;Pt;Ser;Qn;Calculated;HLA;1;Calculated panel reactive antibody - Serum;cPRA Ser Calc;;ACTIVE;2.56;2.65 +80738-8;TPMT gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.PHARMG;1;TPMT gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;TPMT gene Mut Anl Bld/T Seq;;ACTIVE;2.56;2.67 +8073-9;Insulin bovine Ab;ACnc;Pt;Ser;Qn;;SERO;1;Insulin bovine Ab [Units/volume] in Serum;Insulin Bovine Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80739-6;Plan of care note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Plan of care note;Infectious disease Plan of care note;;ACTIVE;2.56;2.58 +80740-4;Plan of care note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Plan of care note;Hematology Plan of care note;;ACTIVE;2.56;2.58 +80741-2;Plan of care note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Plan of care note;Emergency med ED Plan of care note;;ACTIVE;2.56;2.58 +80742-0;Plan of care note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Plan of care note;Mental health Plan of care note;;ACTIVE;2.56;2.58 +80743-8;Plan of care note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Plan of care note;Dentistry Plan of care note;;ACTIVE;2.56;2.58 +80744-6;Plan of care note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Plan of care note;Col+rec surg Plan of care note;;ACTIVE;2.56;2.58 +80745-3;Plan of care note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Plan of care note;General medicine Plan of care note;;ACTIVE;2.56;2.58 +80746-1;Plan of care note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Plan of care note;ED Plan of care note;;ACTIVE;2.56;2.58 +8074-7;Insulin human Ab;ACnc;Pt;Ser;Qn;;SERO;1;Insulin human Ab [Units/volume] in Serum;Insulin Human Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80747-9;Plan of care note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Plan of care note;Endocrinology Plan of care note;;ACTIVE;2.56;2.58 +80748-7;Plan of care note;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Plan of care note;Clinical genetics Plan of care note;;ACTIVE;2.56;2.58 +80749-5;Plan of care note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Plan of care note;Cardiothor surg Plan of care note;;ACTIVE;2.56;2.58 +80750-3;Plan of care note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Plan of care note;Gastroenterology Plan of care note;;ACTIVE;2.56;2.58 +80751-1;Plan of care note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Plan of care note;Dermatology Plan of care note;;ACTIVE;2.56;2.58 +80752-9;Plan of care note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Plan of care note;Fam Med Plan of care note;;ACTIVE;2.56;2.58 +80753-7;Plan of care note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Plan of care note;Surgery Plan of care note;;ACTIVE;2.56;2.58 +8075-4;Insulin porcine Ab;ACnc;Pt;Ser;Qn;;SERO;1;Insulin porcine Ab [Units/volume] in Serum;Insulin Porcine Ab Ser-aCnc;;ACTIVE;1.0h(2);2.69 +80754-5;Plan of care note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Plan of care note;Multi-spec prog Plan of care note;;ACTIVE;2.56;2.58 +80755-2;Plan of care note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Plan of care note;Nephrology Plan of care note;;ACTIVE;2.56;2.58 +80756-0;Plan of care note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Plan of care note;Neuro surgery Plan of care note;;ACTIVE;2.56;2.58 +80757-8;Plan of care note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Plan of care note;Nurse pract Plan of care note;;ACTIVE;2.56;2.58 +80758-6;Plan of care note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Plan of care note;OT Plan of care note;;ACTIVE;2.56;2.58 +80759-4;Plan of care note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Plan of care note;Oncology Plan of care note;;ACTIVE;2.56;2.58 +80760-2;Plan of care note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Plan of care note;Neo peri med Plan of care note;;ACTIVE;2.56;2.58 +80761-0;Plan of care note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Plan of care note;Neurology Plan of care note;;ACTIVE;2.56;2.58 +8076-2;Jo-1 extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Serum;ENA Jo1 Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80762-8;Plan of care note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Plan of care note;PT Plan of care note;;ACTIVE;2.56;2.58 +80763-6;Plan of care note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Plan of care note;Transpl surg Plan of care note;;ACTIVE;2.56;2.73 +80764-4;Plan of care note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Plan of care note;Pain medicine Plan of care note;;ACTIVE;2.56;2.58 +80765-1;Plan of care note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Plan of care note;Psychiatric Plan of care note;;ACTIVE;2.56;2.58 +80766-9;Plan of care note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Plan of care note;Orthopaedic surgery Plan of care note;;ACTIVE;2.56;2.58 +80767-7;Plan of care note;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Plan of care note;Peds surgery Plan of care note;;ACTIVE;2.56;2.58 +80768-5;Plan of care note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Plan of care note;Vascular surgery Plan of care note;;ACTIVE;2.56;2.58 +80769-3;Plan of care note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Plan of care note;OMS Plan of care note;;ACTIVE;2.56;2.58 +8077-0;Mitochondria Ab;ACnc;Pt;Ser;Qn;;SERO;1;Mitochondria Ab [Units/volume] in Serum;Mitochondria Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80770-1;Plan of care note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Plan of care note;Psych Plan of care note;;ACTIVE;2.56;2.58 +80771-9;Plan of care note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Plan of care note;Peds Plan of care note;;ACTIVE;2.56;2.58 +80772-7;Plan of care note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Plan of care note;Resp therapy Plan of care note;;ACTIVE;2.56;2.58 +80773-5;Plan of care note;Find;Pt;{Setting};Doc;Optometry;DOC.ONTOLOGY;2;Optometry Plan of care note;Optometry Plan of care note;;ACTIVE;2.56;2.58 +80774-3;Plan of care note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Plan of care note;Rheumatology Plan of care note;;ACTIVE;2.56;2.58 +80775-0;Plan of care note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Plan of care note;Podiatry Plan of care note;;ACTIVE;2.56;2.58 +80776-8;Plan of care note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Plan of care note;Plastic surgery Plan of care note;;ACTIVE;2.56;2.58 +80777-6;Plan of care note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Plan of care note;Primary care Plan of care note;;ACTIVE;2.56;2.58 +80778-4;Plan of care note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Plan of care note;Otolaryngology Plan of care note;;ACTIVE;2.56;2.58 +80779-2;Plan of care note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Plan of care note;Ophthalmol Plan of care note;;ACTIVE;2.56;2.58 +807-8;Leukocytes;NCnc;Pt;Plr fld;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Pleural fluid by Automated count;WBC # Plr Auto;;ACTIVE;1.0;2.73 +80780-0;Plan of care note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Plan of care note;Palliative care Plan of care note;;ACTIVE;2.56;2.58 +80781-8;Plan of care note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Plan of care note;Sports medicine Plan of care note;;ACTIVE;2.56;2.58 +80782-6;Plan of care note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Plan of care note;Speech-lang path Plan of care note;;ACTIVE;2.56;2.58 +80783-4;Plan of care note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Plan of care note;Urology Plan of care note;;ACTIVE;2.56;2.58 +80784-2;Plan of care note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Plan of care note;Rec therapy Plan of care note;;ACTIVE;2.56;2.58 +80785-9;Plan of care note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Plan of care note;Radiation Onc Plan of care note;;ACTIVE;2.56;2.66 +80786-7;Plan of care note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Plan of care note;PM+R Plan of care note;;ACTIVE;2.56;2.58 +80787-5;Plan of care note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Plan of care note;OBGYN Plan of care note;;DISCOURAGED;2.56;2.64 +8078-8;Mycoplasma pneumoniae Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Mycoplasma pneumoniae IgM Ab [Units/volume] in Serum;M pneumo IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80788-3;Plan of care note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Plan of care note;SW Plan of care note;;ACTIVE;2.56;2.65 +80789-1;Plan of care note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Plan of care note;Cardiac surgery Plan of care note;;ACTIVE;2.56;2.58 +80790-9;Plan of care note;Find;Pt;{Setting};Doc;Surgical critical care;DOC.ONTOLOGY;2;Surgical critical care Plan of care note;Surgical critical care Plan of care note;;ACTIVE;2.56;2.58 +80791-7;Plan of care note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Plan of care note;Nutr+diet Plan of care note;;ACTIVE;2.56;2.58 +80792-5;Diagnostic study note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Diagnostic study note;Pulmonary disease Diag study note;;ACTIVE;2.56;2.66 +80793-3;Education note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Education note;Pulmonary disease Educ note;;ACTIVE;2.56;2.56 +80794-1;Flowsheet;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Flowsheet;Pulmonary disease Flowsheet;;ACTIVE;2.56;2.56 +80795-8;Initial evaluation note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Initial evaluation note;Pulmonary disease Initial eval note;;ACTIVE;2.56;2.56 +8079-6;Myelin Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Myelin IgA Ab [Units/volume] in Serum;Myelin IgA Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80796-6;Plan of care note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Plan of care note;Pulmonary disease Plan of care note;;ACTIVE;2.56;2.58 +80797-4;Plan of care note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Plan of care note;Pharmacology Plan of care note;;ACTIVE;2.56;2.58 +80798-2;Procedure note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary procedure note;Pulmonary disease Procedure note;;ACTIVE;2.56;2.58 +80799-0;Admission history and physical note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Admission history and physical note;Surg Onc Admit H&P note;;ACTIVE;2.56;2.58 +80800-6;Checklist;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Checklist;Surg Onc Checklist;;ACTIVE;2.56;2.56 +80801-4;Consultation note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Consult note;Surg Onc Consult note;;ACTIVE;2.56;2.58 +80802-2;Education note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Education note;Surg Onc Educ note;;ACTIVE;2.56;2.56 +80803-0;Flowsheet;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Flowsheet;Surg Onc Flowsheet;;ACTIVE;2.56;2.56 +8080-4;Myelin Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Myelin IgG Ab [Units/volume] in Serum;Myelin IgG Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80804-8;Plan of care note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Plan of care note;Surg Onc Plan of care note;;ACTIVE;2.56;2.58 +80805-5;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Preoperative evaluation and management note;Surg Onc Pre-op note;;ACTIVE;2.56;2.56 +80806-3;Referral note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Referral note;Surg Onc Referral note;;ACTIVE;2.56;2.58 +80807-1;Surgical operation note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Surgical operation note;Surg Onc Operative note;;ACTIVE;2.56;2.58 +80808-9;Transfer summary note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Transfer summary note;Surg Onc Transfer sum note;;ACTIVE;2.56;2.58 +80809-7;Admission history and physical note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Admission history and physical note;Geri med Admit H&P note;;ACTIVE;2.56;2.58 +80810-5;Discharge instructions;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Discharge instructions;Geri med Discharge instruct;;ACTIVE;2.56;2.56 +80811-3;Discharge summary note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Discharge summary;Geri med D/C sum;;ACTIVE;2.56;2.73 +8081-2;Myelin Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Myelin IgM Ab [Units/volume] in Serum;Myelin IgM Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80812-1;Discharge teaching note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Discharge teaching note;Geri med Discharge teach note;;ACTIVE;2.56;2.56 +80813-9;History and physical note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine History and physical note;Geri med H&P note;;ACTIVE;2.56;2.58 +80814-7;Initial evaluation note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Initial evaluation note;Geri med Initial eval note;;ACTIVE;2.56;2.56 +80815-4;Progress note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Progress note;Geri med Prog note;;ACTIVE;2.56;2.73 +80816-2;Transfer summary note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Transfer summary note;Geri med Transfer sum note;;ACTIVE;2.56;2.58 +80817-0;Flowsheet;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Flowsheet;Geri med Flowsheet;;ACTIVE;2.56;2.56 +80818-8;Plan of care note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Plan of care note;Geri med Plan of care note;;ACTIVE;2.56;2.58 +80819-6;Progress note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Progress note;Pulmonary disease Prog note;;ACTIVE;2.56;2.73 +8082-0;Myelin basic protein Ab;Titr;Pt;Ser;Qn;;SERO;1;Myelin basic protein Ab [Titer] in Serum;MBP Ab Titr Ser;;ACTIVE;1.0h(2);2.7 +80820-4;Medication reconciliation form;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Medication reconciliation form;Med reconciliation form;;ACTIVE;2.56;2.56 +80821-2;Zika virus Ab.Neut;PrThr;Pt;CSF;Ord;Neut;MICRO;1;Zika virus neutralizing antibody [Presence] in Cerebral spinal fluid by Neutralization test;ZIKV NAb CSF Ql Nt;;ACTIVE;2.56;2.65 +80822-0;Zika virus Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;Zika virus neutralizing antibody [Presence] in Serum by Neutralization test;ZIKV NAb Ser Ql Nt;;ACTIVE;2.56;2.73 +80823-8;Zika virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Zika virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;ZIKV IgM CSF Ql IA;;ACTIVE;2.56;2.56 +80824-6;Zika virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Zika virus IgM Ab [Presence] in Serum or Plasma by Immunoassay;ZIKV IgM SerPl Ql IA;;ACTIVE;2.56;2.73 +80825-3;Zika virus envelope (E) gene;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Zika virus envelope E gene [Presence] in Serum by NAA with probe detection;Zika E gene Ser Ql NAA+probe;;ACTIVE;2.56;2.73 +80826-1;Zika virus envelope (E) gene;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Zika virus envelope E gene [Presence] in Cerebral spinal fluid by NAA with probe detection;Zika E gene CSF Ql NAA+probe;;ACTIVE;2.56;2.65 +80827-9;Clostridium botulinum & Clostridium baratii toxins gene panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Clostridium botulinum and Clostridium baratii toxins gene panel - Specimen by NAA with probe detection;C bot + C baratii toxn Pnl Spec NAA+prb;;ACTIVE;2.56;2.69 +80828-7;Pepsin A+Pepsinogen A;MCnc;Pt;Respiratory.lower;Qn;IA;CHEM;1;Pepsin A+Pepsinogen A [Mass/volume] in Lower respiratory specimen by Immunoassay;PepsinA+PepsinogenA Lower resp IA-mCnc;;ACTIVE;2.56;2.56 +80829-5;Pepsin A+Pepsinogen A;Imp;Pt;Respiratory.lower;Nar;;CHEM;1;Pepsin A+Pepsinogen A [Interpretation] in Lower respiratory specimen Narrative;PepsinA+PepsinogenA Lower resp-Imp;;ACTIVE;2.56;2.56 +80830-3;pH;LsCnc;Pt;Respiratory.lower;Qn;;CHEM;1;pH of Lower respiratory specimen;pH Lower resp;;ACTIVE;2.56;2.56 +80831-1;Pepsin A Panel;-;Pt;Respiratory.lower;-;;PANEL.CHEM;1;Pepsin A Panel - Lower respiratory specimen;Pepsin A Pnl Lower resp;;ACTIVE;2.56;2.56 +80832-9;Protein;MCnc;Pt;Respiratory.lower;Qn;;CHEM;1;Protein [Mass/volume] in Lower respiratory specimen;Prot Lower resp-mCnc;;ACTIVE;2.56;2.56 +80833-7;Multisection limited for multiple gestation pregnancy;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for multiple gestation pregnancy limited;US mult gest preg Ltd;;ACTIVE;2.56;2.64 +80834-5;Multisection for multiple gestation pregnancy+first trimester;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for multiple gestation pregnancy in first trimester;US mult gest 1st trim;;ACTIVE;2.56;2.58 +80835-2;Multisection transabdominal + transvaginal for multiple gestation pregnancy+first trimester;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US transabdominal and transvaginal for multiple gestation pregnancy in first trimester;US TA TV for mult gest preg 1st trim;;ACTIVE;2.56;2.58 +80836-0;Multisection for multiple gestation pregnancy+second or third trimester;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for multiple gestation pregnancy in second or third trimester;US mult gest 2nd or 3rd trim;;ACTIVE;2.56;2.58 +80837-8;Multisection for multiple gestation pregnancy+fetal abnormality;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for multiple gestation pregnancy with fetal abnormality;US mult gest w fet abnl;;ACTIVE;2.56;2.58 +8083-8;Myocardium Ab;ACnc;Pt;Ser;Qn;;SERO;1;Myocardium Ab [Units/volume] in Serum;Myocardium Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80838-6;Multisection limited;Find;Pt;Abdomen>Liver;Doc;US;RAD;2;US Liver limited;US Liver Ltd;;ACTIVE;2.56;2.73 +80839-4;Multisection limited;Find;Pt;Abdomen>Pancreas;Doc;US;RAD;2;US Pancreas limited;US Pancreas Ltd;;ACTIVE;2.56;2.61 +80840-2;Multisection limited;Find;Pt;Abdomen>Spleen;Doc;US;RAD;2;US Spleen limited;US Spleen Ltd;;ACTIVE;2.56;2.61 +80841-0;Guidance for placement of needle;Find;Pt;Breast;Doc;US;RAD;2;US Guidance for placement of needle in Breast;US Guided Brst Needle place;;ACTIVE;2.56;2.73 +80842-8;Guidance additional for aspiration of cyst;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for additional aspiration of cyst of Breast - left;US Guided Brst-L Cyst asp addl;;ACTIVE;2.56;2.64 +80843-6;Guidance for biopsy.vacuum;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for vacuum biopsy of Breast - left;US Guided Brst-L Vac Bx;;ACTIVE;2.56;2.64 +80844-4;Guidance for percutaneous biopsy.fine needle;Find;Pt;Breast.left;Doc;US;RAD;2;US Guidance for fine needle biopsy of Breast - left;US Guided Brst-L FN Bx;;ACTIVE;2.56;2.64 +80845-1;Guidance for biopsy.core needle;Find;Pt;Breast.left;Doc;US;RAD;2;Deprecated US Guidance for core needle biopsy of Breast - left;Deprecated US Brst-L CN Bx guide;;DEPRECATED;2.56;2.64 +8084-6;Neutrophil cytoplasmic Ab.classic;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic Ab.classic [Units/volume] in Serum;c-ANCA Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80846-9;Guidance additional for aspiration of cyst;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for additional aspiration of cyst of Breast - right;US Guided Brst-R Cyst asp addl;;ACTIVE;2.56;2.64 +80847-7;Guidance for biopsy.vacuum;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for vacuum biopsy of Breast - right;US Guided Brst-R Vac Bx;;ACTIVE;2.56;2.64 +80848-5;Guidance for percutaneous biopsy.fine needle;Find;Pt;Breast.right;Doc;US;RAD;2;US Guidance for fine needle biopsy of Breast - right;US Guided Brst-R FN Bx;;ACTIVE;2.56;2.64 +80849-3;Guidance for biopsy.core needle;Find;Pt;Breast.right;Doc;US;RAD;2;Deprecated US Guidance for core needle biopsy of Breast - right;Deprecated US Brst-R CN Bx guide;;DEPRECATED;2.56;2.64 +80850-1;Multisection limited;Find;Pt;Head+Neck>Carotid arteries;Doc;US.doppler;RAD;2;US.doppler Carotid arteries limited;DOP Carotid aa Ltd;;ACTIVE;2.56;2.61 +80851-9;Multisection for pregnancy;Find;Pt;Cerebral artery middle^Fetus;Doc;US.doppler;RAD;2;US.doppler Cerebral artery middle Fetal for pregnancy;DOP Cerebral a Middle Fet for pregnancy;;ACTIVE;2.56;2.61 +80852-7;Multisection;Find;Pt;Chest>Axilla;Doc;US;RAD;2;US Axilla;US Axilla;;ACTIVE;2.56;2.73 +8085-3;Neutrophil cytoplasmic Ab.perinuclear;ACnc;Pt;Ser;Qn;;SERO;1;Neutrophil cytoplasmic Ab.perinuclear [Units/volume] in Serum;p-ANCA Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80853-5;Guidance for injection;Find;Pt;Upper extremity>Elbow;Doc;US;RAD;2;US Guidance for injection of Elbow;US Guided Elbow Inj;;ACTIVE;2.56;2.64 +80854-3;Multisection limited;Find;Pt;Extremity>Musculoskeletal tissue;Doc;US;RAD;2;US Extremity musculoskeletal tissue limited;US Ext MSK tissue Ltd;;ACTIVE;2.56;2.61 +80855-0;Multisection;Find;Pt;Extremity>Musculoskeletal tissue;Doc;US;RAD;2;US Extremity musculoskeletal tissue;US Ext MSK tissue;;ACTIVE;2.56;2.61 +80856-8;Multisection limited;Find;Pt;Head;Doc;US.doppler;RAD;2;US.doppler Head limited;DOP Head Ltd;;ACTIVE;2.56;2.61 +80857-6;Multisection;Find;Pt;Head;Doc;US.doppler;RAD;2;US.doppler Head;DOP Head;;ACTIVE;2.56;2.61 +80858-4;Multisection;Find;Pt;Head+Neck>Soft tissue;Doc;US;RAD;2;US Head and neck soft tissue;US Head+neck soft tissue;;ACTIVE;2.56;2.61 +80859-2;Multisection;Find;Pt;Chest>Heart;Doc;US.doppler;RAD;2;US.doppler Heart;DOP Hrt;;ACTIVE;2.56;2.61 +808-6;Leukocytes;NCnc;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Pleural fluid by Manual count;WBC # Plr Manual;;ACTIVE;1.0;2.73 +80860-0;Multisection limited;Find;Pt;Lower extremity.unilateral>Lower extremity veins;Doc;US;RAD;2;US Lower extremity veins - unilateral limited;US LE vv-Ul Ltd;;ACTIVE;2.56;2.61 +8086-1;Pancreatic islet cell Ab;ACnc;Pt;Ser;Qn;;SERO;1;Pancreatic islet cell Ab [Units/volume] in Serum;Panc Islet Cell Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80861-8;Multisection;Find;Pt;Lower extremity>Soft tissue;Doc;US;RAD;2;US Lower extremity soft tissue;US LE soft tissue;;ACTIVE;2.56;2.61 +80862-6;Multisection for in vitro fertilization;Find;Pt;Pelvis;Doc;US;RAD;2;US Pelvis for in vitro fertilization;US Pelvis for IVF;;ACTIVE;2.56;2.61 +80863-4;Multisection for transplanted kidney;Find;Pt;Pelvis;Doc;US.doppler;RAD;2;US.doppler for transplanted kidney;DOP for transplanted kidney;;ACTIVE;2.56;2.58 +80864-2;Multisection for pregnancy;Find;Pt;Pelvis+^Fetus;Doc;US.doppler;RAD;2;US.doppler for pregnancy;DOP for pregnancy;;ACTIVE;2.56;2.58 +80865-9;Multisection transvaginal for pregnancy;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US transvaginal for pregnancy;US TV for preg;;ACTIVE;2.56;2.73 +80866-7;Multisection for pregnancy+second or third trimester;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for pregnancy in second or third trimester;US for preg 2nd or 3rd trim;;ACTIVE;2.56;2.58 +80867-5;Multisection transabdominal + transvaginal for pregnancy+first trimester;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US transabdominal and transvaginal for pregnancy in first trimester;US TA TV preg 1st trim;;ACTIVE;2.56;2.58 +80868-3;Multisection for pregnancy+fetal abnormality;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for pregnancy with fetal abnormality;US for preg w fetal abnl;;ACTIVE;2.56;2.58 +80869-1;Multisection for pregnancy+first trimester;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for pregnancy in first trimester;US for preg 1st trim;;ACTIVE;2.56;2.58 +80870-9;Multisection limited for pregnancy;Find;Pt;Pelvis+^Fetus;Doc;US;RAD;2;US for pregnancy limited;US Preg Ltd;;ACTIVE;2.56;2.64 +80871-7;Multisection for torsion;Find;Pt;Pelvis>Ovary;Doc;US;RAD;2;US Ovary for torsion;US Ovary for torsion;;ACTIVE;2.56;2.61 +80872-5;Multisection^W saline IU;Find;Pt;Pelvis>Uterus+Fallopian tubes;Doc;US.doppler;RAD;2;US.doppler Uterus and Fallopian tubes W saline IU;DOP Uterus+FT W saline IU;;ACTIVE;2.56;2.61 +80873-3;Multisection limited;Find;Pt;Pelvis>Penis;Doc;US.doppler;RAD;2;US.doppler Penis limited;DOP Penis Ltd;;ACTIVE;2.56;2.61 +80874-1;Multisection;Find;Pt;Pelvis>Penis vessels;Doc;US.doppler;RAD;2;US.doppler Penis vessels;DOP Penis ves;;ACTIVE;2.56;2.61 +80875-8;Multisection;Find;Pt;Pelvis>Penis.soft tissue;Doc;US;RAD;2;US Penis soft tissue;US Penis soft tissue;;ACTIVE;2.56;2.61 +80876-6;Multisection transrectal for volume measurement;Find;Pt;Pelvis>Prostate;Doc;US;RAD;2;US Prostate transrectal for volume measurement;US Prostate transrectal for vol meas;;ACTIVE;2.56;2.64 +80877-4;Multisection for torsion;Find;Pt;Pelvis>Scrotum+Testicle;Doc;US;RAD;2;US Scrotum and testicle for torsion;US Scrotum+Test for torsion;;ACTIVE;2.56;2.61 +80878-2;Multisection for pregnancy;Find;Pt;Umbilical artery^Fetus;Doc;US.doppler;RAD;2;US.doppler Umbilical artery Fetal for pregnancy;DOP Umb a Fet for pregnancy;;ACTIVE;2.56;2.61 +8087-9;Parietal cell Ab;ACnc;Pt;Ser;Qn;;SERO;1;Parietal cell Ab [Units/volume] in Serum;PCA Ab Ser-aCnc;;ACTIVE;1.0h(2);2.73 +80879-0;Multisection limited;Find;Pt;Upper extremity.unilateral>Upper extremity veins;Doc;US;RAD;2;US Upper extremity veins - unilateral limited;US UE vv-Ul Ltd;;ACTIVE;2.56;2.61 +80880-8;Guidance for injection;Find;Pt;Upper extremity>Carpal tunnel;Doc;US;RAD;2;US Guidance for injection of Carpal tunnel;US Guided Carpal tunnel Inj;;ACTIVE;2.56;2.64 +80881-6;Multisection;Find;Pt;Upper extremity>Soft tissue;Doc;US;RAD;2;US Upper extremity soft tissue;US UE soft tissue;;ACTIVE;2.56;2.61 +80882-4;Guidance^during surgery;Find;Pt;XXX;Doc;US;RAD;2;US Guidance of Unspecified body region-- during surgery;US Guided Guide--in Surg;;ACTIVE;2.56;2.64 +80883-2;American Urological Association Symptom Index;-;Pt;^Patient;-;AUASI;PANEL.SURVEY.GNHLTH;4;American Urological Association Symptom Index [AUASI];;;ACTIVE;2.56;2.56 +80884-0;How often have you had a sensation of not emptying your bladder completely after you finished urinating over the past Mo;Find;1Mo;^Patient;Ord;AUASI;SURVEY.GNHLTH;4;How often have you had a sensation of not emptying your bladder completely after you finished urinating over the past month [AUASI];;;ACTIVE;2.56;2.61 +80885-7;How often have you had to urinate again less than 2H after you finished urinating over the past Mo;Find;1Mo;^Patient;Ord;AUASI;SURVEY.GNHLTH;4;How often have you had to urinate again less than two hours after you finished urinating over the past month [AUASI];;;ACTIVE;2.56;2.61 +80886-5;How often have you found you stopped and started again several times when you urinated over the past Mo;Find;1Mo;^Patient;Ord;AUASI;SURVEY.GNHLTH;4;How often have you found you stopped and started again several times when you urinated over the past month [AUASI];;;ACTIVE;2.56;2.61 +8088-7;PCNA extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;PCNA extractable nuclear Ab [Presence] in Serum;ENA PCNA Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80887-3;How often have you found it difficult to postpone urination over the past Mo;Find;1Mo;^Patient;Ord;AUASI;SURVEY.GNHLTH;4;How often have you found it difficult to postpone urination over the past month [AUASI];;;ACTIVE;2.56;2.61 +80888-1;How often have you had a weak urinary stream over the past MO;Find;1Mo;^Patient;Ord;AUASI;SURVEY.GNHLTH;4;How often have you had a weak urinary stream in the last month [AUASI];;;ACTIVE;2.56;2.56 +80889-9;How often have you had to push or strain to begin urination over the past MO;Find;1Mo;^Patient;Ord;AUASI;SURVEY.GNHLTH;4;How often have you had to push or strain to begin urination over the past month [AUASI];;;ACTIVE;2.56;2.56 +80890-7;How many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning over the past Mo;Find;1Mo;^Patient;Ord;AUASI;SURVEY.GNHLTH;4;How many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning over the past month [AUASI];;;ACTIVE;2.56;2.61 +80891-5;Symptom score;Score;Pt;^Patient;Qn;AUASI;SURVEY.GNHLTH;4;Symptom score [AUASI];;;ACTIVE;2.56;2.56 +80892-3;Heparin.unfractionated;ACnc;Pt;Bld;Qn;Heparin protamine titration;COAG;1;Heparin unfractionated [Units/volume] in Blood by Heparin protamine titration;UFH Bld HPT-aCnc;;ACTIVE;2.56;2.68 +80893-1;Projected heparin concentration to reach target ACT;ACnc;Pt;Bld;Qn;Calculated;COAG;1;Projected heparin concentration to reach target ACT [Units/volume] in Blood by calculation;Proj heparin conc Bld Calc-aCnc;;ACTIVE;2.56;2.68 +80894-9;2-Methyltyrosine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Methyltyrosine/Creatinine [Molar ratio] in Urine;2Me-tyrosine/Creat Ur-sRto;;ACTIVE;2.56;2.56 +8089-5;Platelet associated Ab.IgG;ACnc;Pt;Bld;Qn;;SERO;1;Platelet associated IgG Ab [Units/volume] in Blood;PA IgG Bld-aCnc;;ACTIVE;1.0h(2);2.73 +80895-6;Multisection;Find;Pt;Upper extremity.bilateral>Upper extremity veins;Doc;US;RAD;2;US Upper extremity veins - bilateral;US UE vv-Bl;;ACTIVE;2.56;2.61 +80896-4;Multisection;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Abdomen+Pelvis>Iliac artery.bilateral;Doc;US.doppler;RAD;2;US.doppler Aorta and Iliac artery - bilateral;DOP Aorta+Iliac a-Bl;;ACTIVE;2.56;2.61 +80897-2;Multisection limited;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal & Abdomen+Pelvis>Iliac artery.bilateral;Doc;US.doppler;RAD;2;US.doppler Aorta and Iliac artery - bilateral limited;DOP Aorta+Iliac a-Bl Ltd;;ACTIVE;2.56;2.61 +80898-0;Multisection;Find;Pt;Pelvis>Groin+Pseudoaneurysm;Doc;US;RAD;2;US Groin and Pseudoaneurysm;US Groin+Pseudoaneurysm;;ACTIVE;2.56;2.61 +80899-8;Plant sterol ester intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Plant sterol ester intake 24 hour Estimated;Plnt sterol ester int 24h Est;;ACTIVE;2.56;2.56 +80900-4;Plant sterol ester intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Plant sterol ester intake 24 hour Measured;Plnt sterol ester int 24h Measured;;ACTIVE;2.56;2.56 +80901-2;Paternal information;Find;Pt;^Patient;Nar;;H&P.HX;2;Paternal information Narrative;Paternal info;;ACTIVE;2.56;2.66 +80902-0;Surfactant replacement given;Type;Pt;^Patient;Nom;;H&P.HX;2;Type of surfactant replacement given;Surfactant replace Gvn;;ACTIVE;2.56;2.56 +8090-3;Platelet associated Ab.IgM;ACnc;Pt;Bld;Qn;;SERO;1;Platelet associated IgM Ab [Units/volume] in Blood;PA IgM Bld-aCnc;;ACTIVE;1.0h(2);2.69 +80903-8;Birth certificate number;ID;Pt;^Patient;Nom;;SURVEY.CDC;4;Birth certificate ID;;;ACTIVE;2.56;2.56 +80904-6;Birth year;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Birth year;;;ACTIVE;2.56;2.56 +80905-3;Body disposition method;Type;Pt;^Patient;Nom;;SURVEY.CDC;4;Body disposition method;;;ACTIVE;2.56;2.63 +80906-1;Bridged race;Type;Pt;^Patient;Nom;CDC;SURVEY.CDC;4;Bridged race [CDC];;;ACTIVE;2.56;2.56 +80907-9;Death registration date;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Death registration date;;;ACTIVE;2.56;2.56 +80908-7;Ethnicity;Type;Pt;^Patient;Nom;CDC;SURVEY.CDC;4;Ethnicity [CDC];;;ACTIVE;2.56;2.61 +80909-5;Father's last name;Pn;Pt;^Father;Nom;;SURVEY.CDC;4;Father's last name;;;ACTIVE;2.56;2.56 +80910-3;State or province of birth;Loc;Pt;^Patient;Nom;;SURVEY.CDC;4;State or province of birth;;;ACTIVE;2.56;2.56 +8091-1;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Serum;ENA RNP Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80911-1;Death pronouncer;ExtendedID;Pt;Provider;Nom;;SURVEY.CDC;4;Death pronouncer Provider [Extended Identifier];;;ACTIVE;2.56;2.56 +80912-9;Gadolinium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gadolinium [Mass/volume] in Serum or Plasma;Gadolinium SerPl-mCnc;;ACTIVE;2.56;2.56 +80913-7;Highest level of education;Hx;Pt;^Patient;Ord;US standard certificate of death;SURVEY.CDC;4;Highest level of education [US Standard Certificate of Death];;;ACTIVE;2.56;2.56 +80914-5;Start coordinates;Type;Pt;Coronary arteries.segment;Nom;;CARD.PROC;2;Start coordinates Coronary artery segment;Start coord Cor aa seg;;ACTIVE;2.56;2.56 +80915-2;Stenosis degree;LenFr;Pt;Coronary arteries.segment;Qn;;CARD.PROC;2;Percent stenosis of Coronary artery segment;Percent sten of Cor aa seg;;ACTIVE;2.56;2.56 +80916-0;Lesion start segment;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Lesion start segment;Cor Lesion start segment;;ACTIVE;2.56;2.56 +80917-8;Lesion start coordinates;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Lesion start coordinates;Cor Lesion start coord;;ACTIVE;2.56;2.56 +80918-6;Lesion start segment position;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Lesion start segment position;Cor Lesion start seg position;;ACTIVE;2.56;2.56 +80919-4;Lesion end segment;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Lesion end segment;Cor Lesion end seg;;ACTIVE;2.56;2.56 +80920-2;Lesion end coordinates;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Lesion end coordinates;Cor Lesion end coord;;ACTIVE;2.56;2.56 +80921-0;Lesion end segment position;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Lesion end segment position;Cor Lesion end seg position;;ACTIVE;2.56;2.56 +80922-8;Lesion located at vessel bifurcation;PrThr;Pt;Coronary arteries;Ord;;CARD.PROC;2;Coronary Lesion located at vessel bifurcation;Cor Lesion loc at ves bifur;;ACTIVE;2.56;2.56 +80923-6;Bifurcated lesion end segment;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Bifurcated lesion end segment;Cor Bifur lesion end segment;;ACTIVE;2.56;2.56 +80924-4;Bifurcated lesion end coordinates;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Bifurcated lesion end coordinates;Cor Bifur lesion end coord;;ACTIVE;2.56;2.56 +80925-1;Bifurcated lesion end segment position;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary Bifurcated lesion end segment position;Cor Bifur lesion end segment pos;;ACTIVE;2.56;2.56 +80926-9;Coronary stent start segment;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary stent start segment;Cor stent start segment;;ACTIVE;2.56;2.56 +80927-7;Coronary stent end segment;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary stent end segment;Cor stent end segment;;ACTIVE;2.56;2.56 +80928-5;Coronary stent start segment position;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary stent start segment position;Cor stent start seg position;;ACTIVE;2.56;2.56 +8092-9;SCL-70 extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Serum;ENA Scl70 Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80929-3;Coronary stent start coordinates;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary stent start coordinates;Cor stent start coord;;ACTIVE;2.56;2.56 +80930-1;Coronary stent end coordinates;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary stent end coordinates;Cor stent end coord;;ACTIVE;2.56;2.56 +80931-9;Coronary stent end segment position;Type;Pt;Coronary arteries;Nom;;CARD.PROC;2;Coronary stent end segment position;Cor stent end seg position;;ACTIVE;2.56;2.56 +80932-7;Views for bone density;Zscore;Pt;Upper extremity>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna [Z-score] Bone density;DXA Radius+Ulna Z-score BMD;;ACTIVE;2.56;2.64 +80933-5;Views for bone density;Zscore;Pt;Lower extremity>Hip;Qn;DXA;RAD;2;DXA Hip [Z-score] Bone density;DXA Hip Z-score BMD;;ACTIVE;2.56;2.64 +80934-3;Views for bone density;Zscore;Pt;Lower extremity>Femur;Qn;DXA;RAD;2;DXA Femur [Z-score] Bone density;DXA Femur Z-score BMD;;ACTIVE;2.56;2.64 +80935-0;Views for bone density;Zscore;Pt;Upper extremity.right>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna - right [Z-score] Bone density;DXA Radius+Ulna-R Z-score BMD;;ACTIVE;2.56;2.64 +80936-8;Views for bone density;Zscore;Pt;Upper extremity.left>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna - left [Z-score] Bone density;DXA Radius+Ulna-L Z-score BMD;;ACTIVE;2.56;2.64 +8093-7;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum;ENA SS-A Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80937-6;Views for bone density;Zscore;Pt;Lower extremity.right>Hip;Qn;DXA;RAD;2;DXA Hip - right [Z-score] Bone density;DXA Hip-R Z-score BMD;;ACTIVE;2.56;2.64 +80938-4;Views for bone density;Zscore;Pt;Lower extremity.left>Hip;Qn;DXA;RAD;2;DXA Hip - left [Z-score] Bone density;DXA Hip-L Z-score BMD;;ACTIVE;2.56;2.64 +80939-2;Views for bone density;Zscore;Pt;Lower extremity.right>Femur;Qn;DXA;RAD;2;DXA Femur - right [Z-score] Bone density;DXA Femur-R Z-score BMD;;ACTIVE;2.56;2.64 +809-4;Leukocytes;NCnc;Pt;Periton fld;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Peritoneal fluid by Automated count;WBC # Prt Auto;;ACTIVE;1.0;2.44 +80940-0;Views for bone density;Zscore;Pt;Lower extremity.left>Femur;Qn;DXA;RAD;2;DXA Femur - left [Z-score] Bone density;DXA Femur-L Z-score BMD;;ACTIVE;2.56;2.64 +80941-8;Views for bone density;Zscore;Pt;Lower extremity.right>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus - right [Z-score] Bone density;DXA Heel-R Z-score BMD;;ACTIVE;2.56;2.64 +80942-6;Views for bone density;Zscore;Pt;Lower extremity.left>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus - left [Z-score] Bone density;DXA Heel-L Z-score BMD;;ACTIVE;2.56;2.64 +80943-4;Views for bone density;Tscore;Pt;Upper extremity.right>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna - right [T-score] Bone density;DXA Radius+Ulna-R T-score BMD;;ACTIVE;2.56;2.64 +80944-2;Views for bone density;Tscore;Pt;Upper extremity.left>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna - left [T-score] Bone density;DXA Radius+Ulna-L T-score BMD;;ACTIVE;2.56;2.64 +8094-5;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;Ser;Ord;;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum;ENA SS-B Ab Ser Ql;;ACTIVE;1.0h(2);2.73 +80945-9;Views for bone density;Tscore;Pt;Lower extremity.right>Hip;Qn;DXA;RAD;2;DXA Hip - right [T-score] Bone density;DXA Hip-R T-score BMD;;ACTIVE;2.56;2.64 +80946-7;Views for bone density;Tscore;Pt;Lower extremity.left>Hip;Qn;DXA;RAD;2;DXA Hip - left [T-score] Bone density;DXA Hip-L T-score BMD;;ACTIVE;2.56;2.64 +80947-5;Views for bone density;Tscore;Pt;Lower extremity.right>Femur;Qn;DXA;RAD;2;DXA Femur - right [T-score] Bone density;DXA Femur-R T-score BMD;;ACTIVE;2.56;2.64 +80948-3;Views for bone density;Tscore;Pt;Lower extremity.left>Femur;Qn;DXA;RAD;2;DXA Femur - left [T-score] Bone density;DXA Femur-L T-score BMD;;ACTIVE;2.56;2.64 +80949-1;Views for bone density;Tscore;Pt;Lower extremity.right>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus - right [T-score] Bone density;DXA Heel-R T-score BMD;;ACTIVE;2.56;2.64 +80950-9;Views for bone density;Tscore;Pt;Lower extremity.left>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus - left [T-score] Bone density;DXA Heel-L T-score BMD;;ACTIVE;2.56;2.64 +80951-7;Views for bone density;ArMass;Pt;Upper extremity.right>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna - right [Mass/Area] Bone density;DXA Radius+Ulna-R ArMass BMD;;ACTIVE;2.56;2.64 +8095-2;Smooth muscle Ab;Titr;Pt;Ser;Qn;;SERO;1;Smooth muscle Ab [Titer] in Serum;Smooth muscle Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +80952-5;Views for bone density;ArMass;Pt;Upper extremity.left>Radius+Ulna;Qn;DXA;RAD;2;DXA Radius and Ulna - left [Mass/Area] Bone density;DXA Radius+Ulna-L ArMass BMD;;ACTIVE;2.56;2.64 +80953-3;Views for bone density;ArMass;Pt;Lower extremity.right>Femur;Qn;DXA;RAD;2;DXA Femur - right [Mass/Area] Bone density;DXA Femur-R ArMass BMD;;ACTIVE;2.56;2.64 +80954-1;Views for bone density;ArMass;Pt;Lower extremity.left>Femur;Qn;DXA;RAD;2;DXA Femur - left [Mass/Area] Bone density;DXA Femur-L ArMass BMD;;ACTIVE;2.56;2.64 +80955-8;Views for bone density;ArMass;Pt;Lower extremity.right>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus - right [Mass/Area] Bone density;DXA Heel-R ArMass BMD;;ACTIVE;2.56;2.64 +80956-6;Views for bone density;ArMass;Pt;Lower extremity.left>Calcaneus;Qn;DXA;RAD;2;DXA Calcaneus - left [Mass/Area] Bone density;DXA Heel-L ArMass BMD;;ACTIVE;2.56;2.64 +80957-4;cefTRIAXone.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cefTRIAXone free [Mass/volume] in Serum or Plasma;cefTRIAXone free SerPl-mCnc;;ACTIVE;2.56;2.56 +80958-2;Fractional excretion of magnesium;Ratio;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Fractional excretion of magnesium [Ratio] in Urine and Serum or Plasma;Fracti excret of Mg Ur+SerPl-Rto;;ACTIVE;2.56;2.56 +80959-0;Glucose^1.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post meal;Glucose 1.5h p meal SerPl-mCnc;;ACTIVE;2.56;2.56 +8096-0;Somatotropin Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Somatotropin Ab [Units/volume] in Serum or Plasma;GH Ab SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +80960-8;cefTAZidime.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;cefTAZidime free [Mass/volume] in Serum or Plasma;cefTAZidime free SerPl-mCnc;;ACTIVE;2.56;2.56 +80961-6;Cefotaxime.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cefotaxime free [Mass/volume] in Serum or Plasma;Cefotaxime free SerPl-mCnc;;ACTIVE;2.56;2.56 +80962-4;ceFAZolin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;ceFAZolin free [Mass/volume] in Serum or Plasma;ceFAZolin free SerPl-mCnc;;ACTIVE;2.56;2.56 +80963-2;Salicylates.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Salicylates free [Mass/volume] in Serum or Plasma;Salicylates free SerPl-mCnc;;ACTIVE;2.56;2.56 +80964-0;Acetaminophen.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetaminophen free [Mass/volume] in Serum or Plasma;APAP free SerPl-mCnc;;ACTIVE;2.56;2.56 +80965-7;Topiramate.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Topiramate free [Mass/volume] in Serum or Plasma;Topiramate free SerPl-mCnc;;ACTIVE;2.56;2.56 +80966-5;Tobramycin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tobramycin free [Mass/volume] in Serum or Plasma;Tobramycin free SerPl-mCnc;;ACTIVE;2.56;2.56 +80967-3;Theophylline.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline free [Mass/volume] in Serum or Plasma;Theophylline free SerPl-mCnc;;ACTIVE;2.56;2.56 +80968-1;Teicoplanin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Teicoplanin free [Mass/volume] in Serum or Plasma;Teicoplanin free SerPl-mCnc;;ACTIVE;2.56;2.56 +80969-9;Methotrexate.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate free [Mass/volume] in Serum or Plasma;Methotrexate free SerPl-mCnc;;ACTIVE;2.56;2.56 +80970-7;Lithium.free;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lithium free [Moles/volume] in Serum or Plasma;Lithium free SerPl-sCnc;;ACTIVE;2.56;2.56 +80971-5;Gentamicin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin free [Mass/volume] in Serum or Plasma;Gentamicin free SerPl-mCnc;;ACTIVE;2.56;2.56 +80972-3;Amikacin.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amikacin free [Mass/volume] in Serum or Plasma;Amikacin free SerPl-mCnc;;ACTIVE;2.56;2.56 +80973-1;Trimethoprim.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trimethoprim free [Mass/volume] in Serum or Plasma;Trimethoprim free SerPl-mCnc;;ACTIVE;2.56;2.56 +80974-9;Sulfamethoxazole.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sulfamethoxazole free [Mass/volume] in Serum or Plasma;Sulfamethoxazole free SerPl-mCnc;;ACTIVE;2.56;2.56 +80975-6;Calcium intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Calcium intake 24 hour Measured;Calcium intake 24h Measured;;ACTIVE;2.56;2.56 +80976-4;International Prostate Symptom Score;-;Pt;^Patient;-;IPSS;PANEL.SURVEY.GNHLTH;4;International Prostate Symptom Score [IPSS];;;ACTIVE;2.56;2.56 +80977-2;Tabulated race;Type;Pt;^Patient;Nom;CDC;SURVEY.CDC;4;Tabulated race [CDC];;;ACTIVE;2.56;2.56 +8097-8;Striated muscle Ab;Titr;Pt;Ser;Qn;;SERO;1;Striated muscle Ab [Titer] in Serum;Stria Mus Ab Titr Ser;;ACTIVE;1.0h(2);2.73 +80978-0;Tabulated ethnicity;Type;Pt;^Patient;Nom;CDC;SURVEY.CDC;4;Tabulated ethnicity [CDC];;;ACTIVE;2.56;2.56 +80979-8;Frataxin;MCnc;Pt;Bld;Qn;;CHEM;1;Frataxin [Mass/volume] in Blood;Frataxin Bld-mCnc;;ACTIVE;2.56;2.56 +80980-6;Frataxin;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Frataxin [Mass/volume] in DBS;Frataxin DBS-mCnc;;ACTIVE;2.56;2.61 +80981-4;N,N-dimethylarginine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;N,N-dimethylarginine [Mass/volume] in Serum or Plasma;N,N-dimethylarginine SerPl-mCnc;;ACTIVE;2.56;2.73 +80982-2;Phytanoyl CoA hydroxlase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Phytanoyl CoA hydroxlase [Enzymatic activity/mass] in Fibroblast;PhyH Fib-cCnt;;ACTIVE;2.56;2.56 +80983-0;Chloride intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Chloride intake 24 hour Measured;Chloride intake 24h Measured;;ACTIVE;2.56;2.56 +80984-8;Fluoride intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Fluoride intake 24 hour Measured;Fluoride intake 24h Measured;;ACTIVE;2.56;2.56 +80985-5;Premature coronary artery disease;Hx;Pt;^Family member;Ord;;H&P.HX;2;Family history of Premature coronary artery disease;Family hx of Premature CAD;;ACTIVE;2.56;2.58 +8098-6;Thyroglobulin Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Thyroglobulin Ab [Units/volume] in Serum or Plasma;Thyroglob Ab SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +80986-3;Cardiac arrest within 24H prior to procedure;Hx;24H;^Patient;Ord;;H&P.HX;2;Cardiac arrest within 24 hours prior to procedure;Cardiac arrest 24 hours prior to proc;;ACTIVE;2.56;2.61 +80987-1;Cardiogenic shock within 24H prior to procedure;Hx;24H;^Patient;Ord;;H&P.HX;2;Cardiogenic shock within 24 hours prior to procedure;Cardiogenic shock 24 hours pre proc;;ACTIVE;2.56;2.61 +80988-9;Thrombus;PrThr;Pt;XXX stent;Ord;;CARD.PROC;2;Thrombus Stent;Thrombus Stent;;ACTIVE;2.56;2.56 +80989-7;Date of procedure;Date;Pt;^Patient;Qn;;CLIN;2;Date of procedure;Date of proc;;ACTIVE;2.56;2.73 +80990-5;Fluoroscopy duration;Time;Procedure dur;^Patient;Qn;RF;RAD;2;Fluoroscopy duration;Fluoro dur;;ACTIVE;2.56;2.73 +80991-3;Fluoroscopy dose;EngCnt;Procedure dur;^Patient;Qn;RF;RAD;2;Fluoroscopy [Energy/mass] dose;Fluoro dose;;ACTIVE;2.56;2.58 +80992-1;Date and time of surgery;TmStp;Pt;^Patient;Qn;;CLIN;2;Date and time of surgery;Date+time of surgery;;ACTIVE;2.56;2.56 +80993-9;Date and time of first balloon inflation;TmStp;Pt;Heart;Qn;Cardiac catheterization;CARD.PROC;2;Date and time of first balloon inflation Heart Cardiac catheterization;Dt+tm 1st balloon infl Hrt Cardiac Cath;;ACTIVE;2.56;2.56 +8099-4;Thyroperoxidase Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Thyroperoxidase Ab [Units/volume] in Serum or Plasma;Thyroperoxidase Ab SerPl-aCnc;;ACTIVE;1.0h(2);2.73 +80994-7;Coronary angiography performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Coronary angiography performed;CAG performed;;ACTIVE;2.56;2.56 +80995-4;Left ventriculography performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Left ventriculography performed;LVG performed;;ACTIVE;2.56;2.56 +80996-2;Intravascular ultrasound performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Intravascular ultrasound performed;IVUS performed;;ACTIVE;2.56;2.56 +80997-0;Fractional flow reserve performed;Find;Pt;^Patient;Ord;;CARD.PROC;2;Fractional flow reserve performed;FFR performed;;ACTIVE;2.56;2.56 +80998-8;Intra-aortic balloon pump used;Find;Pt;^Patient;Ord;;CARD.PROC;2;Intra-aortic balloon pump used;IABP used;;ACTIVE;2.56;2.56 +80999-6;Segment(s) affected by lesion;Find;Pt;Coronary arteries.segment;Nom;;CARD.PROC;2;Segment(s) affected by lesion Coronary artery segment;Segments affected Cor aa seg;;ACTIVE;2.56;2.56 +81-0;Cefixime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefixime [Susceptibility] by Disk diffusion (KB);Cefixime Islt KB;;ACTIVE;1.0;2.73 +8100-0;Specimen preparation;Type;Pt;XXX;Nom;*;SPEC;1;Specimen preparation [Type];Specimen preparation;;ACTIVE;1.0h(2);2.73 +81000-2;TIMI grade^pre procedure;Score;Pt;Coronary arteries.segment;Ord;Angiogram;CARD.PROC;2;TIMI grade Coronary artery segment --pre procedure;TIMI grade pre procedure;;ACTIVE;2.56;2.56 +81001-0;TIMI grade^post procedure;Score;Pt;Coronary arteries.segment;Ord;Angiogram;CARD.PROC;2;TIMI grade Coronary artery segment --post procedure;TIMI grade p procedure;;ACTIVE;2.56;2.56 +81002-8;Devices used;Type;Pt;Heart;Nom;Cardiac catheterization;CARD.PROC;2;Devices used during Cardiac catheterization;Devices used Cardiac Cath;;ACTIVE;2.56;2.56 +81003-6;Iodine intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Iodine intake 24 hour Estimated;Iodine intake 24h Est;;ACTIVE;2.56;2.56 +81004-4;Iodine intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Iodine intake 24 hour Measured;Iodine intake 24h Measured;;ACTIVE;2.56;2.56 +81005-1;Magnesium intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Magnesium intake 24 hour Estimated;Magnesium intake 24h Est;;ACTIVE;2.56;2.56 +81006-9;Magnesium intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Magnesium intake 24 hour Measured;Magnesium intake 24h Measured;;ACTIVE;2.56;2.56 +81007-7;Manganese intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Manganese intake 24 hour Estimated;Manganese intake 24h Est;;ACTIVE;2.56;2.56 +81008-5;Manganese intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Manganese intake 24 hour Measured;Manganese intake 24h Measured;;ACTIVE;2.56;2.56 +81009-3;Potassium intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Potassium intake 24 hour Measured;Potassium intake 24h Measured;;ACTIVE;2.56;2.56 +81010-1;Potassium intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Potassium intake 24 hour Estimated;Potassium intake 24h Est;;ACTIVE;2.56;2.56 +81011-9;Sodium intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Sodium intake 24 hour Estimated;Sodium intake 24h Est;;ACTIVE;2.56;2.56 +81012-7;Sodium intake;MRat;24H;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Sodium intake 24 hour Measured;Sodium intake 24h Measured;;ACTIVE;2.56;2.56 +81013-5;Alpha linolenate intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Alpha linolenate intake 24 hour Estimated;A-linolenate intake 24h Est;;ACTIVE;2.56;2.56 +81014-3;Alpha linolenate intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Alpha linolenate intake 24 hour Measured;A-linolenate intake 24h Measured;;ACTIVE;2.56;2.56 +81015-0;Arginine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Arginine intake 24 hour Estimated;Arginine intake 24h Est;;ACTIVE;2.56;2.56 +81016-8;Arginine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Arginine intake 24 hour Measured;Arginine intake 24h Measured;;ACTIVE;2.56;2.56 +81017-6;Vitamin B7 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B7 (Biotin) intake 24 hour Estimated;Vit B7 intake 24h Est;;ACTIVE;2.56;2.56 +8101-8;Cells.CD3+CD8+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells/100 cells in Blood;CD3+CD8+ Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81018-4;Vitamin B7 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B7 (Biotin) intake 24 hour Measured;Vit B7 intake 24h Measured;;ACTIVE;2.56;2.56 +81019-2;Casein intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Casein intake 24 hour Estimated;Casein intake 24h Est;;ACTIVE;2.56;2.56 +810-2;Leukocytes;NCnc;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Peritoneal fluid by Manual count;WBC # Prt Manual;;ACTIVE;1.0;2.73 +81020-0;Casein intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Casein intake 24 hour Measured;Casein intake 24h Measured;;ACTIVE;2.56;2.56 +81021-8;Cholesterol intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Cholesterol intake 24 hour Estimated;Cholesterol intake 24h Est;;ACTIVE;2.56;2.56 +81022-6;Cholesterol intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Cholesterol intake 24 hour Measured;Cholesterol intake 24h Measured;;ACTIVE;2.56;2.56 +81023-4;Chromium intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Chromium intake 24 hour Estimated;Chromium intake 24h Est;;ACTIVE;2.56;2.56 +81024-2;Chromium intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Chromium intake 24 hour Measured;Chromium intake 24h Measured;;ACTIVE;2.56;2.56 +81025-9;Complex carbohydrate intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Complex carbohydrate intake 24 hour Estimated;Complex carb intake 24h Est;;ACTIVE;2.56;2.56 +8102-6;Cells.CD33/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD33 cells/100 cells in Blood;CD33 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81026-7;Complex carbohydrate intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Complex carbohydrate intake 24 hour Measured;Complex carb intake 24h Measured;;ACTIVE;2.56;2.56 +81027-5;Copper intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Copper intake 24 hour Estimated;Copper intake 24h Est;;ACTIVE;2.56;2.56 +81028-3;Copper intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Copper intake 24 hour Measured;Copper intake 24h Measured;;ACTIVE;2.56;2.56 +81029-1;Eicosapentaenoate intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Eicosapentaenoate intake 24 hour Estimated;Eicosapentaenoate intake 24h Est;;ACTIVE;2.56;2.56 +81030-9;Eicosapentaenoate intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Eicosapentaenoate intake 24 hour Measured;Eicosapentaenoate intake 24h Measured;;ACTIVE;2.56;2.56 +81031-7;Alpha-linoate+Linoleate intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Alpha-linoate+Linoleate intake 24 hour Estimated;Alpha-linoate+Linoleate intake 24h Est;;ACTIVE;2.56;2.56 +81032-5;D per W alcoholic drinks consumed;NRat;Pt;^Patient;Qn;;NUTRITION&DIETETICS;2;Days per week alcoholic drinks consumed;Drinking days nRate;;ACTIVE;2.56;2.56 +81033-3;Fat.saturated intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Saturated fat intake 24 hour Estimated;Sat fat intake 24h Est;;ACTIVE;2.56;2.58 +8103-4;Cells.CD45+CD14+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45+CD14+ cells/100 cells in Blood;CD45+CD14+ Cells NFr Bld;;ACTIVE;1.0h(2);2.7 +81034-1;Trans fat intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Trans fat intake 24 hour Estimated;Trans fat intake 24h Est;;ACTIVE;2.56;2.56 +81035-8;Trans fat intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Trans fat intake 24 hour Measured;Trans fat intake 24h Measured;;ACTIVE;2.56;2.56 +81036-6;Polyunsaturated fat intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Polyunsaturated fat intake 24 hour Measured;Polyunsat fat intake 24h Measured;;ACTIVE;2.56;2.56 +81037-4;Docosahexaenoate intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Docosahexaenoate (DHA) intake 24 hour Estimated;DHA intake 24h Est;;ACTIVE;2.56;2.56 +81038-2;Docosahexaenoate intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Docosahexaenoate (DHA) intake 24 hour Measured;DHA intake 24h Measured;;ACTIVE;2.56;2.56 +81039-0;Gluten intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Gluten intake 24 hour Estimated;Gluten intake 24h Est;;ACTIVE;2.56;2.56 +81040-8;Gluten intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Gluten intake 24 hour Measured;Gluten intake 24h Measured;;ACTIVE;2.56;2.56 +81041-6;Isoleucine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Isoleucine intake 24 hour Estimated;Isoleucine intake 24h Est;;ACTIVE;2.56;2.56 +8104-2;Cells.CD5+CD20+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5+CD20+ cells/100 cells in Blood;CD5+CD20+ Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81042-4;Isoleucine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Isoleucine intake 24 hour Measured;Isoleucine intake 24h Measured;;ACTIVE;2.56;2.56 +81043-2;Leucine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Leucine intake 24 hour Estimated;Leucine intake 24h Est;;ACTIVE;2.56;2.56 +81044-0;Leucine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Leucine intake 24 hour Measured;Leucine intake 24h Measured;;ACTIVE;2.56;2.56 +81045-7;Threonine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Threonine intake 24 hour Estimated;Threonine intake 24h Est;;ACTIVE;2.56;2.56 +81046-5;Threonine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Threonine intake 24 hour Measured;Threonine intake 24h Measured;;ACTIVE;2.56;2.56 +81047-3;Valine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Valine intake 24 hour Estimated;Valine intake 24h Est;;ACTIVE;2.56;2.56 +81048-1;Valine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Valine intake 24 hour Measured;Valine intake 24h Measured;;ACTIVE;2.56;2.56 +81049-9;Sucrose intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Sucrose intake 24 hour Estimated;Sucrose intake 24h Est;;ACTIVE;2.56;2.56 +81050-7;Sucrose intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Sucrose intake 24 hour Measured;Sucrose intake 24h Measured;;ACTIVE;2.56;2.56 +81051-5;Lactose intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Lactose intake 24 hour Estimated;Lactose intake 24h Est;;ACTIVE;2.56;2.56 +81052-3;Lactose intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Lactose intake 24 hour Measured;Lactose intake 24h Measured;;ACTIVE;2.56;2.56 +81053-1;Galactose intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Galactose intake 24 hour Estimated;Galactose intake 24h Est;;ACTIVE;2.56;2.56 +81054-9;Galactose intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Galactose intake 24 hour Measured;Galactose intake 24h Measured;;ACTIVE;2.56;2.56 +81055-6;Fructose intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Fructose intake 24 hour Estimated;Fructose intake 24h Est;;ACTIVE;2.56;2.56 +81056-4;Fructose intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Fructose intake 24 hour Measured;Fructose intake 24h Measured;;ACTIVE;2.56;2.56 +81057-2;Fiber intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Fiber intake 24 hour Measured;Fiber intake 24h Measured;;ACTIVE;2.56;2.56 +81058-0;Fiber.soluble intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Soluble fiber intake 24 hour Estimated;Fiber sol intake 24h Est;;ACTIVE;2.56;2.56 +8105-9;Cells.CD5+CD8+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5+CD8+ cells/100 cells in Blood;CD5+CD8+ Cells NFr Bld;;ACTIVE;1.0h(2);2.7 +81059-8;Fiber.soluble intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Soluble fiber intake 24 hour Measured;Fiber sol intake 24h Measured;;ACTIVE;2.56;2.56 +81060-6;Fiber.insoluble intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Insoluble fiber intake 24 hour Estimated;Fiber insol intake 24h Est;;ACTIVE;2.56;2.56 +81061-4;Fiber.insoluble intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Insoluble fiber intake 24 hour Measured;Fiber insol intake 24h Measured;;ACTIVE;2.56;2.56 +81062-2;Vitamin B12 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B12 intake 24 hour Estimated;Vit B12 intake 24h Est;;ACTIVE;2.56;2.56 +81063-0;Vitamin B12 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B12 intake 24 hour Measured;Vit B12 intake 24h Measured;;ACTIVE;2.56;2.56 +81064-8;Vitamin B6 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B6 intake 24 hour Estimated;Vit B6 intake 24h Est;;ACTIVE;2.56;2.56 +81065-5;Vitamin B6 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B6 intake 24 hour Measured;Vit B6 intake 24h Measured;;ACTIVE;2.56;2.56 +81066-3;Vitamin B9 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B9 (Folate) intake 24 hour Estimated;Vit B9 intake 24h Est;;ACTIVE;2.56;2.56 +8106-7;Cells.CD1/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD1 cells/100 cells in Blood;CD1 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81067-1;Vitamin B3 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B3 (Niacin) intake 24 hour Measured;Vit B3 intake 24h Measured;;ACTIVE;2.56;2.56 +81068-9;Vitamin B5 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B5 (Pantothenate) intake 24 hour Estimated;Vit B5 24h Est;;ACTIVE;2.56;2.56 +81069-7;Vitamin B5 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B5 (Pantothenate) intake 24 hour Measured;Vit B5 24h Measured;;ACTIVE;2.56;2.56 +81070-5;Vitamin B2 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B2 (Riboflavin) intake 24 hour Estimated;Vit B2 intake 24h Est;;ACTIVE;2.56;2.56 +81071-3;Vitamin B2 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B2 (Riboflavin) intake 24 hour Measured;Vit B2 intake 24h Measured;;ACTIVE;2.56;2.56 +81072-1;Vitamin A intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin A intake 24 hour Estimated;Vit A intake 24h Est;;ACTIVE;2.56;2.56 +81073-9;Vitamin A intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin A intake 24 hour Measured;Vit A intake 24h Measured;;ACTIVE;2.56;2.56 +81074-7;Vitamin C intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin C intake 24 hour Estimated;Vit C intake 24h Est;;ACTIVE;2.56;2.56 +8107-5;Cells.CD10/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD10 cells/100 cells in Blood;CD10 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81075-4;Vitamin C intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin C intake 24 hour Measured;Vit C intake 24h Measured;;ACTIVE;2.56;2.56 +81076-2;Vitamin E intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin E intake 24 hour Estimated;Vit E intake 24h Est;;ACTIVE;2.56;2.56 +81077-0;Vitamin E intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin E intake 24 hour Measured;Vit E intake 24h Measured;;ACTIVE;2.56;2.56 +81078-8;Vitamin K intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin K intake 24 hour Estimated;Vit K intake 24h Est;;ACTIVE;2.56;2.56 +81079-6;Vitamin K intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin K intake 24 hour Measured;Vit K intake 24h Measured;;ACTIVE;2.56;2.56 +81080-4;Chloride intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Chloride intake 24 hour Estimated;Chloride intake 24h Est;;ACTIVE;2.56;2.56 +81081-2;Fluoride intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Fluoride intake 24 hour Estimated;Fluoride intake 24h Est;;ACTIVE;2.56;2.56 +81082-0;Iron intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Iron intake 24 hour Estimated;Iron intake 24h Est;;ACTIVE;2.56;2.56 +8108-3;Cells.CD11c+CD20+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11c+CD20+ cells/100 cells in Blood;CD11c+CD20+ Cells NFr Bld;;ACTIVE;1.0h(2);2.7 +81083-8;Iron intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Iron intake 24 hour Measured;Iron intake 24h Measured;;ACTIVE;2.56;2.56 +81084-6;Molybdenum intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Molybdenum intake 24 hour Estimated;Molybdenum intake 24h Est;;ACTIVE;2.56;2.56 +81085-3;Molybdenum intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Molybdenum intake 24 hour Measured;Molybdenum intake 24h Measured;;ACTIVE;2.56;2.56 +81086-1;Selenium intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Selenium intake 24 hour Measured;Selenium intake 24h Measured;;ACTIVE;2.56;2.56 +81087-9;Selenium intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Selenium intake 24 hour Estimated;Selenium intake 24h Est;;ACTIVE;2.56;2.56 +81088-7;Zinc intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Zinc intake 24 hour Measured;Zinc intake 24h Measured;;ACTIVE;2.56;2.56 +81089-5;Zinc intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Zinc intake 24 hour Estimated;Zinc intake 24h Est;;ACTIVE;2.56;2.56 +81090-3;If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that;Find;Pt;^Patient;Ord;IPSS;SURVEY.GNHLTH;4;If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS];;;ACTIVE;2.56;2.56 +8109-1;Cells.CD11c/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD11c cells/100 cells in Blood;CD11c Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81091-1;Orifice area;Area;Pt;Tricuspid valve;Qn;US.2D;CARD.US;2;Tricuspid valve Orifice area by US 2D;TV Orifice area 2D US;;ACTIVE;2.56;2.67 +81092-9;Orifice area;Area;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Orifice area by US.doppler;TV Orifice area DOP;;ACTIVE;2.56;2.67 +81093-7;Effective regurgitant orifice area;Area;Pt;Tricuspid valve;Qn;US.doppler+Calculated by PISA method;CARD.US;2;Tricuspid valve Effective regurgitant orifice area by US.doppler+Calculated by PISA method;TV EROA PISA;;ACTIVE;2.56;2.56 +81094-5;Effective regurgitant orifice area;Area;Pt;Tricuspid valve;Qn;US.doppler+Calculated by volumetric method;CARD.US;2;Tricuspid valve Effective regurgitant orifice area by US.doppler+Calculated by volumetric method;TV EROA DOP+Calc by vol;;ACTIVE;2.56;2.56 +81095-2;Myocardial mass/Body surface area;ArMass;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by Devereux method;CARD.US;2;Left ventricular Myocardial mass/Body surface area [Mass/Area] by US.2D+Calculated by Devereux method;LV Myo mass/BSA 2D Devereux;;ACTIVE;2.56;2.56 +81096-0;West Nile virus Kunjin strain Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;West Nile virus Kunjin strain IgM Ab [Presence] in Serum;WNV Kunjin IgM Ser Ql;;ACTIVE;2.56;2.56 +81097-8;West Nile virus Kunjin strain Ab;PrThr;Pt;Ser;Ord;;MICRO;1;West Nile virus Kunjin strain Ab [Presence] in Serum;WNV Kunjin Ab Ser Ql;;ACTIVE;2.56;2.56 +81098-6;Leptospira borgpetersenii serovar Arborea Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira borgpetersenii sv Arborea Ab [Titer] in Serum by Agglutination;L borg Arborea Ab Titr Ser Aggl;;ACTIVE;2.56;2.61 +81099-4;Leptospira interrogans serovar Bulgarica Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Bulgarica Ab [Titer] in Serum by Agglutination;L inter Bulgar Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +811-0;Leukocytes;NCnc;Pt;Semen;Qn;Automated count;FERT;1;Leukocytes [#/volume] in Semen by Automated count;WBC # Smn Auto;;ACTIVE;1.0;2.73 +81100-0;Leptospira interrogans serovar Celledoni Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Celledoni Ab [Titer] in Serum by Agglutination;L inter Celled Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81101-8;Leptospira interrogans serovar Copenhageni Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Copenhageni Ab [Titer] in Serum by Agglutination;L inter Copen Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81102-6;Leptospira interrogans serovar Cynopteri Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Cynopteri Ab [Titer] in Serum by Agglutination;L inter Cynop Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81103-4;Leptospira interrogans serovar Kremastos Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Kremastos Ab [Titer] in Serum by Agglutination;L inter Krema Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81104-2;Leptospira interrogans serovar Medanensis Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Medanensis Ab [Titer] in Serum by Agglutination;L inter Medane Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81105-9;Leptospira interrogans serovar Panama Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Panama Ab [Titer] in Serum by Agglutination;L inter Panam Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81106-7;Leptospira interrogans serovar Robinsoni Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Robinsoni Ab [Titer] in Serum by Agglutination;L inter Robins Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81107-5;Leptospira interrogans serovar Shermani Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Shermani Ab [Titer] in Serum by Agglutination;L inter Sherm Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81108-3;Leptospira interrogans serovar Szwajizak Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Szwajizak Ab [Titer] in Serum by Agglutination;L inter Szwaji Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +8110-9;Cells.CD13/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD13 cells/100 cells in Blood;CD13 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81109-1;Leptospira interrogans serovar Zanoni Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Zanoni Ab [Titer] in Serum by Agglutination;L inter Zanoni Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81110-9;Leptospira weilii serovar Topaz Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira weilii serovar Topaz Ab [Titer] in Serum by Agglutination;L weilii Topaz Ab Titr Ser Aggl;;ACTIVE;2.56;2.56 +81111-7;Murray Valley encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;;MICRO;1;Murray Valley encephalitis virus IgG Ab [Presence] in Serum;MVEV IgG Ser Ql;;ACTIVE;2.56;2.56 +81112-5;Murray Valley encephalitis virus Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Murray Valley encephalitis virus IgG Ab [Titer] in Serum;MVEV IgG Titr Ser;;ACTIVE;2.56;2.56 +81113-3;Murray Valley encephalitis virus Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Murray Valley encephalitis virus IgM Ab [Presence] in Serum;MVEV IgM Ser Ql;;ACTIVE;2.56;2.56 +81114-1;Murray Valley encephalitis virus Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Murray Valley encephalitis virus IgM Ab [Titer] in Serum;MVEV IgM Titr Ser;;ACTIVE;2.56;2.56 +81115-8;Murray Valley encephalitis virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Murray Valley encephalitis virus Ab [Titer] in Serum;MVEV Ab Titr Ser;;ACTIVE;2.56;2.56 +81116-6;Hepatitis C virus core Ab+Ag;PrThr;Pt;Ser;Ord;;MICRO;1;Hepatitis C virus core Ab+Ag [Presence] in Serum;HCV core Ab+Ag Ser Ql;;ACTIVE;2.56;2.56 +8111-7;Cells.CD14/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD14 cells/100 cells in Blood;CD14 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81117-4;Ross river virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Ross River virus RNA [Presence] in Serum by NAA with probe detection;RRV RNA Ser Ql NAA+probe;;ACTIVE;2.56;2.63 +81118-2;Legionella sp Ab.IgM;PrThr;Pt;Ser;Ord;;MICRO;1;Legionella sp IgM Ab [Presence] in Serum;Legionella IgM Ser Ql;;ACTIVE;2.56;2.56 +81119-0;Epstein Barr virus capsid Ab.IgG avidity;Ratio;Pt;Ser;Qn;IA;MICRO;1;Epstein Barr virus capsid IgG Ab avidity [Ratio] in Serum by Immunoassay;EBV VCA IgG Avidity Ser IA-Rto;;ACTIVE;2.56;2.56 +81120-8;Barmah forest virus Ab;Titr;Pt;Ser;Qn;;MICRO;1;Barmah forest virus Ab [Titer] in Serum;BFV Ab Titr Ser;;ACTIVE;2.56;2.56 +81121-6;Murray Valley encephalitis virus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Murray Valley encephalitis virus Ab [Presence] in Serum;MVEV Ab Ser Ql;;ACTIVE;2.56;2.56 +81122-4;HIV 1 RNA reverse transcriptase & protease gene;Seq;Pt;Ser/Plas/Bld;Nom;Sequencing;ABXBACT;1;HIV 1 RNA reverse transcriptase and protease gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing;HIV 1 RNA RT + PR Seq SerPlBld;;ACTIVE;2.56;2.65 +81123-2;Coagulation factor VII inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor VII inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact VII Inhib PPP Ql;;ACTIVE;2.56;2.56 +81124-0;Coagulation factor V inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor V inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact V Inhib PPP Ql;;ACTIVE;2.56;2.56 +8112-5;Cells.CD3-CD16+CD56+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells/100 cells in Blood;CD3-CD16+CD56+ Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81125-7;Platelet aggregation.ristocetin inhibitor;PrThr;Pt;PPP;Ord;;COAG;1;Platelet aggregation.ristocetin inhibitor [Presence] in Platelet poor plasma;PA rist inh PPP Ql;;ACTIVE;2.56;2.56 +81126-5;Cobalt intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Cobalt intake 24 hour Measured;Cobalt intake 24h Measured;;ACTIVE;2.56;2.56 +81127-3;Cobalt intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Cobalt intake 24 hour Estimated;Cobalt intake 24h Est;;ACTIVE;2.56;2.56 +81128-1;Alpha-linoate+Linoleate intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Alpha-linoate+Linoleate intake 24 hour Measured;Alpha-linoate+Linoleate intake 24h Meas;;ACTIVE;2.56;2.56 +81129-9;Glutamine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Glutamine intake 24 hour Estimated;Glutamine intake 24h Est;;ACTIVE;2.56;2.56 +81130-7;Glutamine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Glutamine intake 24 hour Measured;Glutamine intake 24h Measured;;ACTIVE;2.56;2.56 +81131-5;Polyunsaturated fat intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Polyunsaturated fat intake 24 hour Estimated;Polyunsat fat intake 24h Est;;ACTIVE;2.56;2.56 +81132-3;Phosphorus intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Phosphorus intake 24 hour Estimated;Phosphorus intake 24h Est;;ACTIVE;2.56;2.56 +8113-3;Cells.CD16+CD57-/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16+CD57- cells/100 cells in Blood;CD16+CD57- Cells NFr Bld;;ACTIVE;1.0h(2);2.7 +81133-1;Fiber intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Fiber intake 24 hour Estimated;Fiber intake 24h Est;;ACTIVE;2.56;2.56 +81134-9;Vitamin B9 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B9 (Folate) intake 24 hour Measured;Vit B9 intake 24h Measured;;ACTIVE;2.56;2.56 +81135-6;Vitamin B3 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B3 (Niacin) intake 24 hour Estimated;Vit B3 intake 24h Est;;ACTIVE;2.56;2.56 +81136-4;Fat.saturated intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Saturated fat intake 24 hour Measured;Sat fat intake 24h Measured;;ACTIVE;2.56;2.58 +81137-2;Calcium intake;MRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Calcium intake 24 hour Estimated;Calcium intake 24h Est;;ACTIVE;2.56;2.56 +81138-0;Spermatozoa.aggregated;PrThr;Pt;Semen;Ord;;FERT;1;Spermatozoa Aggregated [Presence] in Semen;Sperm.aggregated Smn Ql;;ACTIVE;2.56;2.73 +81139-8;CYP3A4 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP3A4 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP3A4 allele Geno Bld/T;;ACTIVE;2.56;2.73 +81140-6;CYP3A5 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP3A5 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP3A5 allele Geno Bld/T;;ACTIVE;2.56;2.73 +8114-1;Cells.CD16-CD57+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16-CD57+ cells/100 cells in Blood;CD16-CD57+ Cells NFr Bld;;ACTIVE;1.0h(2);2.7 +81141-4;Spermatozoa motility;Score;Pt;Semen;Qn;Automated;FERT;1;Spermatozoa motility [Score] in Semen by Automated;Sperm motility Score Smn Auto;;ACTIVE;2.56;2.56 +81142-2;PTPN22 gene.c.1858C>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH;1;PTPN22 gene.c.1858C>T [Presence] in Blood or Tissue by Molecular genetics method;PTPN22 c.1858C>T Bld/T Ql;;ACTIVE;2.56;2.56 +81143-0;Galactokinase;CCnt;Pt;RBC;Qn;;CHEM;1;Galactokinase [Enzymatic activity/mass] in Red Blood Cells;Galactokinase RBC-cCnt;;ACTIVE;2.56;2.56 +81144-8;Cerium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Cerium [Mass/volume] in Blood;Ce Bld-mCnc;;ACTIVE;2.56;2.56 +81145-5;CYP3A4 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP3A4 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP3A4 gene prod met act Bld/T-Imp;;ACTIVE;2.68;2.68 +81146-3;CYP3A4 & CYP3A5 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;CYP3A4 and CYP3A5 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP3A4 + CYP3A5 gene Mut Anl Bld/T;;ACTIVE;2.56;2.73 +81147-1;Specimen source identification;Imp;Pt;^Patient;Nar;;MOLPATH;1;Specimen source patient identification [Interpretation] Narrative;Spec source id Patient-Imp;;ACTIVE;2.56;2.56 +81148-9;Zika virus envelope (E) gene;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Zika virus envelope E gene [Presence] in Urine by NAA with probe detection;Zika E gene Ur Ql NAA+probe;;ACTIVE;2.56;2.65 +81149-7;Zika virus envelope (E) gene;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Zika virus envelope E gene [Presence] in Amniotic fluid by NAA with probe detection;Zika E gene Amn Ql NAA+probe;;ACTIVE;2.56;2.65 +81150-5;Dengue virus 1+2+3+4 5' UTR RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 5' UTR RNA [Presence] in Serum by NAA with probe detection;DENV 1+2+3+4 5' UTR RNA Ser Ql NAA+probe;;ACTIVE;2.56;2.63 +81151-3;Dengue virus 1+2+3+4 5' UTR RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 5' UTR RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;DENV 1+2+3+4 5' UTR RNA CSF Ql NAA+probe;;ACTIVE;2.56;2.63 +81152-1;Chikungunya virus non-structural protein 1 (nsP1) RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus non-structural protein 1 (nsP1) RNA [Presence] in Serum by NAA with probe detection;CHIKV nsP1 RNA Ser Ql NAA+probe;;ACTIVE;2.56;2.73 +81153-9;Chikungunya virus non-structural protein 1 (nsP1) RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus non-structural protein 1 (nsP1) RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;CHIKV nsP1 RNA CSF Ql NAA+probe;;ACTIVE;2.56;2.63 +81154-7;Dengue & Chikungunya & Zika virus panel;-;Pt;^Patient;-;Probe.amp.tar;PANEL.MICRO;1;Dengue and Chikungunya and Zika virus panel by NAA with probe detection;DENV + CHIKV + ZIKV Pnl NAA+pr;;ACTIVE;2.56;2.63 +81155-4;Islet cell 512 Ab;SCnc;Pt;Ser;Qn;;SERO;1;Islet cell 512 Ab [Moles/volume] in Serum;Islet Cell512 Ab Ser-sCnc;;ACTIVE;2.56;2.73 +81156-2;Ubiquinone 10.reduced/Ubiquinone 10;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Coenzyme Q10.reduced/Coenzyme Q10 in Serum or Plasma;Ubiquinone10.red/Ubiquinone10 MFr SerPl;;ACTIVE;2.56;2.73 +81157-0;Ubiquinone 10.reduced;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Coenzyme Q10.reduced [Mass/volume] in Serum or Plasma;Ubiquinone10.red SerPl-mCnc;;ACTIVE;2.56;2.73 +8115-8;Cells.CD16/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16 cells/100 cells in Blood;CD16 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81158-8;Multisection for pediatrics;Find;Pt;Head;Doc;US;RAD;2;US Pediatric Head;Ped Head US;;ACTIVE;2.56;2.61 +81159-6;Multisection for pediatrics;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;US;RAD;2;US Pediatric Cervical and thoracic and lumbar spine;Ped C+T+L-spine US;;ACTIVE;2.56;2.61 +81160-4;Multisection limited for pediatrics;Find;Pt;Head;Doc;US.doppler;RAD;2;US.doppler Pediatric limited Head;Ped Ltd Head DOP;;ACTIVE;2.56;2.61 +81161-2;Multisection for blood flow;Find;Pt;Chest>Heart;Doc;US.doppler;RAD;2;US.doppler Heart for blood flow;DOP Hrt bld flow;;ACTIVE;2.56;2.61 +81162-0;Guidance for needle localization && Views;Find;Pt;Breast.left && ^Breast specimen.left;Doc;US && MG;RAD;2;US Guidance for needle localization Breast - left and MG Views Breast specimen;US + Mam Ndle loc + View Br-L + Br spe;;ACTIVE;2.56;2.61 +81163-8;Guidance for needle localization && Views;Find;Pt;Breast.right && ^Breast specimen.right;Doc;US && MG;RAD;2;US Guidance for needle localization Breast - right and MG Views Breast specimen;US + Mam Ndle loc + View Br-R + Br spe;;ACTIVE;2.56;2.61 +81164-6;Multisection limited for pediatrics;Find;Pt;Lower extremity.bilateral>Hip;Doc;US;RAD;2;US Pediatric limited Hip - bilateral;Ped Ltd Hip-Bl US;;ACTIVE;2.56;2.61 +81165-3;Guidance for peripheral venous access;Find;Pt;XXX>Vein;Doc;US;RAD;2;US Guidance for peripheral venous access of Vein;US Guided Vein Periph ven access;;ACTIVE;2.56;2.64 +8116-6;Cells.CD19;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19 cells [#/volume] in Blood;CD19 Cells # Bld;;ACTIVE;1.0h(2);2.73 +81166-1;Surgical resection;Type;Pt;Stomach cancer;Nom;;SURG;2;Surgical resection Stomach cancer;Surgical resection Stomach cancer;;ACTIVE;2.56;2.56 +81167-9;Cancer treatment^preoperative;Type;Pt;^Patient;Nom;;H&P.HX;2;Cancer treatment --preoperative;Cancer treatment Preop;;ACTIVE;2.56;2.56 +81168-7;Site of adjacent organ or tissue involvement;Anat;Pt;Cancer specimen;Nom;;CLIN;2;Site of adjacent organ or tissue involvement Cancer specimen;Adj org or tiss involved Ca spec;;ACTIVE;2.56;2.61 +81169-5;Residual tumor^postoperative;Imp;Pt;Cancer.XXX;Nar;;SURG;2;Residual tumor [Interpretation] Cancer Narrative --postoperative;Residual tumor Postop Imp Cancer;;ACTIVE;2.56;2.58 +81170-3;Stomach.greater curvature;Len;Pt;Specimen;Qn;;PATH;1;Greater curvature of stomach [Length] in Specimen;Stom.greater curve Spec;;ACTIVE;2.56;2.56 +81171-1;Stomach.lesser curvature;Len;Pt;Specimen;Qn;;PATH;1;Lesser curvature of stomach [Length] in Specimen;Stom.lesser curve Spec;;ACTIVE;2.56;2.56 +81172-9;Esophagus length;Len;Pt;Specimen;Qn;;PATH;1;Esophagus [Length] in Specimen;Esophagus length Spec;;ACTIVE;2.56;2.56 +81173-7;Duodenum length;Len;Pt;Specimen;Qn;;PATH;1;Duodenum [Length] in Specimen;Duodenum length Spec;;ACTIVE;2.56;2.56 +8117-4;Cells.CD19/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD19 cells/100 cells in Blood;CD19 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81174-5;Tumor type;Type;Pt;Stomach cancer;Ord;Macroscopy;PATH;1;Tumor type in Stomach cancer by Macroscopy;Tumor Type Stomach cancer Ql Macro;;ACTIVE;2.56;2.56 +81175-2;Distance of tumor from closest margin;Len;Pt;Specimen;Qn;Macroscopy;PATH;1;Distance of tumor from closest margin [Length] in Specimen by Macroscopy;Tumor from Closest Margin Spec Macro;;ACTIVE;2.56;2.56 +81176-0;Distance of tumor from circumferential resection margin;Len;Pt;Specimen;Qn;Macroscopy;PATH;1;Distance of tumor from circumferential resection margin [Length] in Specimen by Macroscopy;Distance Tumor from CRM Spec Macro;;ACTIVE;2.56;2.56 +81177-8;Serosal classification;Aper;Pt;Stomach cancer;Nom;;PATH;1;Serosal classification [Appearance] in Stomach cancer;Serosal classification Stomach cancer;;ACTIVE;2.56;2.56 +81178-6;Tissue block description and site;Desc;Pt;Specimen;Nar;;PATH;1;Tissue block description and site Narrative;Block description and site Spec;;ACTIVE;2.56;2.73 +81179-4;Histologic type;Type;Pt;Stomach cancer;Nom;Lauren classification;PATH.HISTO;1;Histologic type of Stomach cancer by Lauren classification;Histo type Stomach cancer Lauren;;ACTIVE;2.56;2.61 +81180-2;Growth pattern;Type;Pt;Tumor;Nom;;PATH.HISTO;1;Growth pattern [Type] in Tumor;Growth pattern Tumor;;ACTIVE;2.56;2.61 +81181-0;Serosal surface involvement;PrThr;Pt;Tumor;Ord;Microscopy.light;PATH.HISTO;1;Serosal surface involvement [Presence] in Tumor by Light microscopy;Serosal surf involvmnt Tumor Ql Micro;;ACTIVE;2.56;2.61 +8118-2;Cells.CD2/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD2 cells/100 cells in Blood;CD2 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81182-8;Distance of tumor from closest proximal margin;Len;Pt;Specimen;Qn;Microscopy.light;PATH.HISTO;1;Distance of tumor from closest proximal margin [Length] in Specimen by Light microscopy;Tumor from proximal margin Spec Micro;;ACTIVE;2.56;2.61 +81183-6;Distance of tumor from closest distal margin;Len;Pt;Specimen;Qn;Microscopy.light;PATH.HISTO;1;Distance of tumor from closest distal margin [Length] in Specimen by Light microscopy;Tumor from Distal Margin Spec Micro;;ACTIVE;2.56;2.61 +81184-4;Distance of tumor from circumferential resection margin;Len;Pt;Specimen;Qn;Microscopy.light;PATH.HISTO;1;Distance of tumor from circumferential resection margin [Length] by Microscopy;Distance Tumor from CRM Micro;;ACTIVE;2.56;2.61 +81185-1;Non-regional lymph nodes positive;Num;Pt;Specimen;Qn;;PATH;1;Non-regional lymph nodes positive [#] in Specimen;Non-regional nodes pos Spec;;ACTIVE;2.56;2.56 +81186-9;Cancer pathology panel;-;Pt;Stomach cancer;-;;PANEL.PATH;1;Gastric cancer pathology panel;Gastric cancer Path Pnl;;ACTIVE;2.56;2.67 +81187-7;Non-regional lymph nodes examined;Num;Pt;Specimen;Qn;;PATH;1;Non-regional lymph nodes examined [#] in Specimen;Non-regional nodes examined Spec;;ACTIVE;2.56;2.56 +81188-5;Tumor site;Anat;Pt;Stomach cancer;Nom;;CLIN;2;Tumor site of Stomach cancer;Tumor site Stomach cancer;;ACTIVE;2.56;2.56 +81189-3;Tumor regression^post preoperative therapy;Type;Pt;Tumor;Ord;;PATH;1;Tumor regression [Type] in Tumor --post preoperative therapy;Tumor regression p preop therapy;;ACTIVE;2.56;2.56 +8119-0;Cells.CD20/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20 cells/100 cells in Blood;CD20 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81190-1;Histologic type;Type;Pt;Stomach cancer;Nom;WHO classification;PATH.HISTO;1;Histologic type of Stomach cancer by WHO Classification;Histo type Stomach cancer WHO;;ACTIVE;2.56;2.61 +81191-9;Consultation note;Find;Pt;{Setting};Doc;Chemical pathology;DOC.ONTOLOGY;2;Chemical pathology Consult note;Chem Path Consult note;;ACTIVE;2.56;2.58 +81192-7;Consultation note;Find;Pt;{Setting};Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Consult note;Clin Path Consult note;;ACTIVE;2.56;2.58 +81193-5;Consultation note;Find;Pt;{Setting};Doc;Medical microbiology - pathology;DOC.ONTOLOGY;2;Medical microbiology - pathology Consult note;Med Micro Path Consult note;;ACTIVE;2.56;2.58 +81194-3;Evaluation and management of workers compensation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation and management of workers compensation note;E+M Workers Comp;;ACTIVE;2.56;2.64 +81195-0;Evaluation and management of workers compensation form;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation and management of workers compensation form;E+M Workers Comp Form;;ACTIVE;2.56;2.56 +81196-8;Consultation note;Find;Pt;{Setting};Doc;Clinical pharmacology;DOC.ONTOLOGY;2;Clinical pharmacology Consult note;Clin Pharm Consult note;;ACTIVE;2.56;2.58 +81197-6;Amino acid intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Amino acid intake 24 hour Estimated;Amino acid intake 24h Est;;ACTIVE;2.56;2.56 +81198-4;Amino acid intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Amino acid intake 24 hour Measured;Amino acid intake 24h Measured;;ACTIVE;2.56;2.56 +81199-2;Beta-ureidopropionase;CCnt;Pt;Liver;Qn;;CHEM;1;Beta-ureidopropionase [Enzymatic activity/mass] in Liver;Beta-ureidopropionase Liver-cCnt;;ACTIVE;2.56;2.56 +81200-8;Plan of care note;Find;Pt;{Setting};Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Plan of care note;Interdiscip Plan of care note;;ACTIVE;2.56;2.58 +81201-6;Phospholipase A2 receptor Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Phospholipase A2 receptor IgG Ab [Titer] in Serum by Immunofluorescence;PLA2R IgG Titr Ser IF;;ACTIVE;2.56;2.73 +81202-4;Micronutrient form;Type;Pt;^Patient;Nar;;NUTRITION&DIETETICS;2;Micronutrient form Narrative;Micronutrient form;;ACTIVE;2.56;2.56 +81203-2;Bulk ingredient - animal drug;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Bulk ingredient - animal drug;FDA label Bulk ingredient - anml drg;;ACTIVE;2.56;2.56 +81204-0;NDC labeler code inactivation - animal drug;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label NDC labeler code inactivation - animal drug;FDA label NDC label code inact anml drg;;ACTIVE;2.56;2.56 +81205-7;Cryoglobulin IgA & IgG & IgM & C3 panel;-;Pt;Ser;-;;PANEL.CHEM;1;Cryoglobulin IgA and IgG and IgM and C3 panel - Serum;Cryo IgA + IgG + IgM + C3 Pnl Ser;;ACTIVE;2.56;2.56 +81206-5;Views^W Tc-99m SC IV;Find;Pt;Abdomen>Liver+Spleen;Doc;NM;RAD;2;NM Liver and Spleen Views W Tc-99m SC IV;NM Liver+Spleen Views W Tc99mSC IV;;ACTIVE;2.56;2.64 +81207-3;Amitriptyline & nortriptyline panel;-;Pt;Gast fld;-;;PANEL.DRUG/TOX;1;Amitriptyline and Nortriptyline panel - Gastric fluid;Amitrip+Nor Pnl Gast;;ACTIVE;2.56;2.56 +8120-8;Cells.CD21/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD21 cells/100 cells in Blood;CD21 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81208-1;Amitriptyline & nortriptyline panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Amitriptyline and Nortriptyline panel - Urine;Amitrip+Nor Pnl Ur;;ACTIVE;2.56;2.56 +81209-9;clomiPRAMINE & Norclomipramine panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;clomiPRAMINE and Norclomipramine panel - Urine;clomiPRAMINE+Nor Pnl Ur;;ACTIVE;2.56;2.69 +81210-7;clomiPRAMINE & Norclomipramine panel;-;Pt;Gast fld;-;;PANEL.DRUG/TOX;1;clomiPRAMINE and Norclomipramine panel - Gastric fluid;clomiPRAMINE+Nor Pnl Gast;;ACTIVE;2.56;2.69 +81211-5;Amitriptyline & nortriptyline panel;-;Pt;XXX;-;;PANEL.DRUG/TOX;1;Amitriptyline and Nortriptyline panel - Specimen;Amitrip+Nor Pnl Spec;;ACTIVE;2.56;2.69 +81212-3;clomiPRAMINE & Norclomipramine panel;-;Pt;XXX;-;;PANEL.DRUG/TOX;1;clomiPRAMINE and Norclomipramine panel - Specimen;clomiPRAMINE+Nor Pnl Spec;;ACTIVE;2.56;2.69 +81213-1;Laboratory communication about newborn screening;Find;Pt;^Patient;Nar;;CLIN;2;Laboratory communication about newborn screening Narrative;Lab Commun about NBS;;ACTIVE;2.56;2.56 +81214-9;Continuity of Care Document - recommended C-CDA R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Continuity of Care Document - recommended C-CDA R2.0 and R2.1 sections;CCD C-CDA R2.0+2.1 Sections;;ACTIVE;2.56;2.56 +81215-6;Care plan - recommended C-CDA R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Care plan - recommended C-CDA R2.0 and R2.1 sections;Care Plan C-CDA R2.0+2.1 Sections;;ACTIVE;2.56;2.56 +8121-6;Cells.CD25/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25 cells/100 cells in Blood;CD25 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81216-4;Progress note - recommended C-CDA R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Progress note - recommended C-CDA R2.0 and R2.1 sections;Prog note C-CDA R2.0+2.1 Sections;;ACTIVE;2.56;2.56 +81217-2;Procedure note - recommended C-CDA R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Procedure note - recommended C-CDA R2.0 and R2.1 sections;Proced Nte C-CDA R2.0+2.1 Sections;;ACTIVE;2.56;2.56 +81218-0;Discharge summary - recommended C-CDA R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Discharge summary - recommended C-CDA R2.1 sections;Discharge Sum C-CDA R2.1 Sections;;ACTIVE;2.56;2.56 +81219-8;Discharge summary - recommended C-CDA R2.0 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Discharge summary - recommended C-CDA R2.0 sections;Discharge Sum C-CDA R2.0 Sections;;ACTIVE;2.56;2.56 +81220-6;Diagnostic imaging report - recommended C-CDA R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Diagnostic imaging report - recommended C-CDA R2.0 and R2.1 sections;DIR C-CDA 2.0 + 2.1 Sections;;ACTIVE;2.56;2.56 +81221-4;Transfer summary note - recommended C-CDA R2.0 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Transfer summary note - recommended C-CDA R2.0 sections;Transfer Sum C-CDA R2.0 Sections;;ACTIVE;2.56;2.61 +81222-2;Consultation note - recommended C-CDA R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Consultation note - recommended C-CDA R2.0 and R2.1 sections;Consult note C-CDA R2.0+2.1 Sections;;ACTIVE;2.56;2.56 +81223-0;Referral note - recommended C-CDA R2.0 & R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Referral note - recommended C-CDA R2.0 and R2.1 sections;Referral Nte C-CDA R2.0+2.1 Sections;;ACTIVE;2.56;2.56 +8122-4;Cells.CD3;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3 cells [#/volume] in Blood;CD3 Cells # Bld;;ACTIVE;1.0h(2);2.73 +81224-8;Vomiting;Find;Pt;Gastrointestinal system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Vomiting [CCC];;;ACTIVE;2.56;2.56 +81225-5;Bleeding risk;Find;Pt;Cardiovascular system;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Bleeding risk [CCC];;;ACTIVE;2.56;2.56 +81226-3;Electrolyte imbalance;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Electrolyte imbalance [CCC];;;ACTIVE;2.56;2.56 +81227-1;Fall risk;Find;Pt;^Patient;Ord;Observed.CCC;SURVEY.NURSE.HHCC;4;Fall risk [CCC];;;ACTIVE;2.56;2.56 +81228-9;Tobacco product;Type;Pt;^Patient;Nom;;H&P.HX;2;Tobacco product;Tobacco prod;;ACTIVE;2.56;2.73 +81229-7;Tobacco smoking status.tobacco smoker;Find;Pt;^Patient;Ord;;H&P.HX;2;Tobacco smoking status for tobacco smoker;Tobacco smoke status.smoker;;ACTIVE;2.56;2.73 +81230-5;Referring physician phone number;Tele;Pt;Provider;Nom;;CLIN;2;Referring physician phone number;Referring MD Phone #;;ACTIVE;2.56;2.73 +81231-3;Protein fractions panel;-;24H;Urine;-;Electrophoresis;PANEL.CHEM;1;Protein electrophoresis panel - 24 hour Urine;Prot Elph Pnl 24h Ur Elph;;ACTIVE;2.56;2.74 +8123-2;Cells.CD3+CD4+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 cells in Blood;CD3+CD4+ Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81232-1;Supersaturation panel;-;24H;Urine;-;;PANEL.CHEM;1;Supersaturation panel - 24 hour Urine;Supersaturation Pnl 24h Ur;;ACTIVE;2.56;2.56 +81233-9;Influenza virus types A & B & subtypes RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus types A and B and subtypes RNA panel - Respiratory specimen by NAA with probe detection;FLUAV + FLUBV + subtypes Pnl Resp NAA+pr;;ACTIVE;2.56;2.7 +81234-7;Varicella zoster virus Ab.IgG & IgM panel;-;Pt;Ser/Plas;Ord;;PANEL.MICRO;1;Varicella zoster virus IgG and IgM panel - Serum or Plasma Qualitative;VZV IgG+IgM Pnl SerPl;;ACTIVE;2.56;2.56 +81235-4;Varicella zoster virus surveillance panel;-;Pt;^Patient;-;;PANEL.H&P;2;Varicella zoster virus surveillance panel;VZV surveillance Pnl;;ACTIVE;2.56;2.56 +81236-2;Send document that conforms to C-CDA R1.1 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to C-CDA R1.1 template;;;ACTIVE;2.56;2.56 +81237-0;Send document that conforms to C-CDA R2.1 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to C-CDA R2.1 template;;;ACTIVE;2.56;2.61 +81238-8;Send document that conforms to CDP Set 1 R1.0 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to CDP Set 1 R1.0 template;;;ACTIVE;2.56;2.61 +81239-6;Send document that conforms to CDP Set 1 R1.1 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to CDP Set 1 R1.1 template;;;ACTIVE;2.56;2.56 +8124-0;Cells.CD3/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3 cells/100 cells in Blood;CD3 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81240-4;Document template attachment request modifier codes;-;Pt;X12^277;-;;PANEL.ATTACH.MOD;3;Document template attachment request modifier codes;;;ACTIVE;2.56;2.56 +81241-2;Enhanced surgical operation note - recommended CDP Set 1 R1.0 & R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Enhanced surgical operation note - recommended CDP Set 1 R1.0 and R1.1sections;Encd Surg Op Nte CDP1 R1.0+R1.1;;ACTIVE;2.56;2.58 +81242-0;Enhanced discharge summary - recommended CDP Set 1 R1.0 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Enhanced discharge summary - recommended CDP Set 1 R1.0 sections;Encd Discharge Sum CDP1 R1.0;;ACTIVE;2.56;2.58 +81243-8;Enhanced encounter note - recommended CDP Set 1 R1.0 & R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Enhanced encounter note - recommended CDP Set 1 R1.0 and R1.1 sections;Encd Encounter Nte CDP1 R1.0+1.1;;ACTIVE;2.56;2.58 +81244-6;Enhanced procedure note - recommended CDP Set 1 R1.0 & R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Enhanced procedure note - recommended CDP Set 1 R1.0 and R1.1 sections;Encd Proced Nte CDP1 R1.0+R1.1;;ACTIVE;2.56;2.58 +81245-3;Interval document - recommended CDP Set 1 R1.0 & R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Interval document - recommended CDP Set 1 R1.0 and R1.1 sections;Interval Doc CDP1 R1.0+R1.1;;ACTIVE;2.56;2.58 +81246-1;HIV 2 RNA panel;-;Pt;Ser/Plas;-;Probe.amp.tar;PANEL.MICRO;1;HIV 2 RNA panel - Serum or Plasma by NAA with probe detection;HIV 2 RNA Pnl SerPl NAA+probe;;ACTIVE;2.56;2.63 +81247-9;Master HL7 genetic variant reporting panel;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Master HL7 genetic variant reporting panel;Master HL7 gen var Pnl;;TRIAL;2.56;2.56 +81248-7;Default transcript reference sequence coding system;Type;Pt;^Patient;Nom;;MOLPATH;1;Default transcript reference sequence coding system [Type];Default trans ref seq code system;;TRIAL;2.56;2.56 +81249-5;Default genomic reference sequence coding system;Type;Pt;^Patient;Nom;;MOLPATH;1;Default genomic reference sequence coding system [Type];Default gen ref seq code system;;TRIAL;2.56;2.56 +81250-3;Simple variant panel;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Discrete genetic variant panel;Simple var pnl;;TRIAL;2.56;2.58 +81251-1;Complex variant panel;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Complex genetic variant panel;Comp var pnl;;TRIAL;2.56;2.58 +81252-9;Simple variant;ID;Pt;^Patient;Nom;;MOLPATH;1;Discrete genetic variant;Simple var ID;;TRIAL;2.56;2.58 +81253-7;Simple variant name;Find;Pt;^Patient;Nom;;MOLPATH;1;Simple variant name Nominal;Simple var name;;TRIAL;2.56;2.56 +81254-5;Variant exact start-end;ID;Pt;^Patient;Nom;;MOLPATH;1;Genomic allele start-end;Gen allele loc ID;;TRIAL;2.56;2.68 +81255-2;dbSNP;ID;Pt;^Patient;Nom;;MOLPATH;1;dbSNP [ID];dbSNP ID;;TRIAL;2.56;2.58 +81256-0;COSMIC simple variant;ID;Pt;^Patient;Nom;;MOLPATH;1;COSMIC [ID];COSMIC simple var ID;;TRIAL;2.56;2.58 +8125-7;Cells.CD34/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD34 cells/100 cells in Blood;CD34 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81257-8;CIGAR;ID;Pt;^Patient;Nom;;MOLPATH;1;CIGAR [ID];CIGAR var ID;;TRIAL;2.56;2.58 +81258-6;Sample variant allelic frequency;NFr;Pt;^Patient;Qn;;MOLPATH;1;Sample variant allelic frequency [NFr];Sample VAF;;ACTIVE;2.56;2.73 +81259-4;Associated phenotype;Find;Pt;^Patient;Nom;;MOLPATH;1;Associated phenotype;Prob assoc phenotype;;TRIAL;2.56;2.71 +81260-2;Complex variant;ID;Pt;^Patient;Nom;;MOLPATH;1;Complex genetic variant [ID];Comp var ID;;TRIAL;2.56;2.58 +81261-0;Complex variant name;Find;Pt;^Patient;Nom;;MOLPATH;1;Complex variant name Nominal;Comp var name;;TRIAL;2.56;2.58 +81262-8;Complex variant HGVS name;Find;Pt;^Patient;Nom;;MOLPATH;1;Complex variant HGVS name;Comp var HGVS name;;TRIAL;2.56;2.56 +81263-6;Complex variant type;Type;Pt;^Patient;Nom;;MOLPATH;1;Complex variant type;Comp var type;;TRIAL;2.56;2.56 +81264-4;Fever duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Fever duration;Fever duration;;ACTIVE;2.56;2.56 +8126-5;Cells.CD38/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38 cells/100 cells in Blood;CD38 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81265-1;Body temperature.max;Temp;RptPeriod^max;^Patient;Qn;;H&P.HX;2;Maximum body temperature Reporting Period maximum;Body temp.max RptPeriod Max;;ACTIVE;2.56;2.69 +81266-9;Date of fever onset;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of fever onset;Date of fever onset;;ACTIVE;2.56;2.56 +81267-7;Setting of exposure to illness;Type;Pt;^Patient;Nom;;H&P.HX;2;Setting of exposure to illness;Setting of exposure to illness;;ACTIVE;2.56;2.56 +81268-5;Date of rash onset;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of rash onset;Date of rash onset;;ACTIVE;2.56;2.56 +81269-3;Rash duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Rash duration;Rash duration;;ACTIVE;2.56;2.56 +81270-1;Gestational age in W^at onset of illness;Time;Pt;^Patient;Qn;;H&P.HX;2;Gestational age in weeks--at onset of illness;GA (weeks)--at onset of illness;;ACTIVE;2.56;2.61 +81271-9;Trimester at onset of illness;Time;Pt;^Patient;Ord;;H&P.HX;2;Trimester at onset of illness;Trimester at onset of illness;;ACTIVE;2.56;2.56 +81272-7;Cell Count & Differential panel;-;Pt;Dial fld;-;;PANEL.HEM/BC;1;Cell count and Differential panel - Dialysis fluid;Cell Cnt + Diff Pnl Dial fld;;ACTIVE;2.56;2.56 +8127-3;Cells.CD4;NCnc;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD4 cells [#/volume] in Blood;Deprecated CD4 Cells # Bld;;DEPRECATED;1.0h(2);2.7 +81273-5;Fentanyl & Norfentanyl panel;-;Pt;XXX;-;;PANEL.DRUG/TOX;1;fentaNYL and Norfentanyl panel - Specimen;fentaNYL+Norfentanyl pnl Spec;;ACTIVE;2.56;2.69 +81274-3;Doxepin & Nordoxepin panel;-;Pt;Gast fld;-;;PANEL.DRUG/TOX;1;Doxepin and Nordoxepin panel - Gastric fluid;Doxepin+Nor Pnl Gast;;ACTIVE;2.56;2.56 +81275-0;Fentanyl & Norfentanyl panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;fentaNYL and Norfentanyl panel - Serum or Plasma;fentaNYL+Norfentanyl pnl SerPl;;ACTIVE;2.56;2.56 +81276-8;Doxepin & Nordoxepin panel;-;Pt;Urine;Qn;;PANEL.DRUG/TOX;1;Doxepin and Nordoxepin panel - Urine;Doxepin+Nor Pnl Ur;;ACTIVE;2.56;2.56 +81277-6;Fentanyl & Norfentanyl panel;-;Pt;Gast fld;-;;PANEL.DRUG/TOX;1;fentaNYL and Norfentanyl panel - Gastric fluid;fentaNYL+Norfentanyl pnl Gast;;ACTIVE;2.56;2.56 +81278-4;Meperidine & Normeperidine panel;-;Pt;Gast fld;-;;PANEL.DRUG/TOX;1;Meperidine and Normeperidine panel - Gastric fluid;Meperidine + Normeperidine Pnl Gast;;ACTIVE;2.56;2.56 +81279-2;Meperidine & Normeperidine panel;-;Pt;XXX;-;;PANEL.DRUG/TOX;1;Meperidine and Normeperidine panel - Specimen;Meperidine + Normeperidine Pnl Spec;;ACTIVE;2.56;2.69 +812-8;Leukocytes;NCnc;Pt;Semen;Qn;Manual count;FERT;1;Leukocytes [#/volume] in Semen by Manual count;WBC # Smn Manual;;ACTIVE;1.0;2.73 +81280-0;Differential panel;-;Pt;Dial fld;-;;PANEL.HEM/BC;1;Differential panel - Dialysis fluid;Diff Pnl Dial fld;;ACTIVE;2.56;2.56 +8128-1;Cells.CD4/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD4 cells/100 cells in Blood;Deprecated CD4 Cells NFr Bld;;DEPRECATED;1.0h(2);2.7 +81281-8;Heparin dose response panel;-;Pt;Bld;-;;PANEL.COAG;1;Heparin dose response panel - Blood;Hep dose resp Pnl Bld;;ACTIVE;2.56;2.58 +81282-6;Spermatozoa.motile;Num;Pt;Semen;Qn;Automated count;FERT;1;Spermatozoa Motile [#] in Semen by Automated count;Sperm Motile Smn Auto;;ACTIVE;2.56;2.71 +81283-4;Spermatozoa.nonprogressive;Num;Pt;Semen;Qn;Microscopy;FERT;1;Spermatozoa Nonprogressive [#] in Semen by Microscopy;Sperm Nonprog Smn Micro;;ACTIVE;2.56;2.73 +81284-2;Malignant cells/100 cells;NFr;Pt;BAL;Qn;Manual count;HEM/BC;1;Malignant cells/100 cells in Bronchoalveolar lavage by Manual count;Malignant cells NFr BAL Manual;;ACTIVE;2.56;2.56 +81285-9;Escherichia coli Stx1 & Stx2 toxin stx1 & stx2 genes;Prid;Pt;Stool;Nom;Probe.amp.tar;MICRO;1;Escherichia coli Stx1 and Stx2 toxin stx1 and stx2 genes [Identifier] in Stool by NAA with probe detection;EC stx1 + stx2 genes Stl NAA+probe;;ACTIVE;2.56;2.73 +81286-7;Structural variant;ID;Pt;^Patient;Nom;;MOLPATH;1;Structural variant [Identifier];Struct var ID;;TRIAL;2.56;2.56 +81287-5;Structural variant reported start-end;NumRange;Pt;^Patient;Qn;;MOLPATH;1;Structural variant reported start-end [NumRange];Struct var rep start-end NumRange;;TRIAL;2.56;2.56 +81288-3;Precision of boundaries;Find;Pt;^Patient;Nom;;MOLPATH;1;Precision of boundaries Nominal;Boundary precision;;TRIAL;2.56;2.56 +81289-1;Structural variant;Type;Pt;^Patient;Nom;;MOLPATH;1;Structural variant [Type];Struct var type;;TRIAL;2.56;2.56 +81290-9;Genomic DNA change;Find;Pt;^Patient;Nom;;MOLPATH;1;Genomic DNA change (gHGVS);Struct var HGVS name;;TRIAL;2.56;2.58 +81291-7;Structural variant ISCN name;Find;Pt;^Patient;Nom;;MOLPATH;1;Variant ISCN;Struct var ISCN name;;TRIAL;2.56;2.58 +81292-5;Simple variant;Type;Pt;^Patient;Nom;;MOLPATH;1;Simple variant [Type];Simple var type;;TRIAL;2.56;2.56 +81293-3;Range(s) of DNA sequences examined;Txt;Pt;^Patient;Nar;;MOLPATH;1;Description of ranges of DNA sequences examined;DNA range(s) examined Nar;;TRIAL;2.56;2.58 +81294-1;Genetic form configuration controls;Arb;Pt;^Patient;Nom;;MOLPATH;1;Genetic form configuration controls Nominal;Ref seq coding system pnl;;TRIAL;2.56;2.58 +81295-8;Other transcript reference sequence coding system OID;URI;Pt;^Patient;Nom;;MOLPATH;1;Other transcript reference sequence coding system OID;Oth trans ref seq code syst OID URI;;TRIAL;2.56;2.56 +81296-6;Other genomic reference sequence coding system OID;URI;Pt;^Patient;Nom;;MOLPATH;1;Other genomic reference sequence coding system OID;Oth genom ref seq code syst OID URI;;TRIAL;2.56;2.56 +81297-4;Structural variant panel;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Structural variant panel;Struct variant pnl;;TRIAL;2.56;2.56 +81298-2;Structural variant cytogenetic location;ID;Pt;^Patient;Nom;;MOLPATH;1;Structural variant cytogenetic location [Identifier];Struct var cyto loc ID;;TRIAL;2.56;2.56 +8129-9;Cells.CD4/Cells.CD8;NRto;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD4 cells/CD8 Cells [# Ratio] in Blood;Deprecated CD4 Cells/CD8 Cells Bld;;DEPRECATED;1.0h(2);2.7 +81299-0;Structural variant reported arrCGH;Ratio;Pt;^Patient;Qn;;MOLPATH;1;Structural variant reported arrCGH [Ratio];Struct var rep arrCGH Rto;;TRIAL;2.56;2.56 +81300-6;Structural variant;Len;Pt;^Patient;Qn;;MOLPATH;1;Structural variant [Length];Struct var len;;TRIAL;2.56;2.56 +81301-4;Variant outer start-end;NumRange;Pt;^Patient;Qn;;MOLPATH;1;Structural variant outer start and end;Struct var outer start-end NumRange;;TRIAL;2.56;2.68 +81302-2;Variant inner start-end;NumRange;Pt;^Patient;Qn;;MOLPATH;1;Structural variant inner start and end;Struct var inner start-end NumRange;;TRIAL;2.56;2.68 +81303-0;HGVS version;ID;Pt;^Patient;Nom;;MOLPATH;1;HGVS version [ID];HGVS version;;TRIAL;2.56;2.58 +81304-8;Structural variant analysis method;Type;Pt;^Patient;Nom;*;MOLPATH;1;Variant analysis method [Type];Struct var analysis method;;TRIAL;2.56;2.58 +81305-5;Influenza virus A H1 2009 pandemic RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;FLUAV H1 2009 pan RNA Ct Resp Qn NAA+pr;;ACTIVE;2.56;2.63 +81306-3;Variables that apply to the overall study;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Variables that apply to the overall study;Overall study variables type;;TRIAL;2.56;2.61 +8130-7;Cells.CD45/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45 (Lymphs) cells/100 cells in Blood;CD45 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81307-1;Influenza virus A H7 Eurasia RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H7 Eurasia RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;FLUAV H7 Euras RNA Ct Resp Qn NAA+probe;;ACTIVE;2.56;2.63 +81308-9;Influenza virus A RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;FLUAV RNA Ct Resp Qn NAA+probe;;ACTIVE;2.56;2.63 +81309-7;Influenza virus B RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;FLUBV RNA Ct Resp Qn NAA+probe;;ACTIVE;2.56;2.63 +81310-5;Carbonic anhydrase 2 Ab;PrThr;Pt;Ser;Ord;IA;SERO;1;Carbonic anhydrase 2 Ab [Presence] in Serum by Immunoassay;CA 2 Ab Ser Ql IA;;ACTIVE;2.56;2.56 +81311-3;Cryoglobulin.IgA;PrThr;Pt;Ser;Ord;;CHEM;1;Cryoglobulin.IgA [Presence] in Serum;Cryoglob IgA Ser Ql;;ACTIVE;2.56;2.56 +81312-1;Cryoglobulin.IgM;PrThr;Pt;Ser;Ord;;CHEM;1;Cryoglobulin.IgM [Presence] in Serum;Cryoglob IgM Ser Ql;;ACTIVE;2.56;2.56 +81313-9;Cryoglobulin.complement C3;PrThr;Pt;Ser;Ord;;CHEM;1;Cryoglobulin.complement C3 [Presence] in Serum;Cryoglobulin C3 Ser Ql;;ACTIVE;2.56;2.56 +81314-7;Palatinase;CCnt;Pt;Tsmi;Qn;;CHEM;1;Palatinase [Enzymatic activity/mass] in Small intestine Tissue;Palatinase TSMI-cCnt;;ACTIVE;2.56;2.56 +8131-5;Cells.CD5+CD19+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5+CD19+ cells/100 cells in Blood;CD5+CD19+ Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81315-4;Lactase;CCnt;Pt;Tsmi;Qn;;CHEM;1;Lactase [Enzymatic activity/mass] in Small intestine Tissue;Lactase TSMI-cCnt;;ACTIVE;2.56;2.56 +81316-2;Trichomonas vaginalis;PrThr;Pt;Urine sed;Ord;Organism specific culture;MICRO;1;Trichomonas vaginalis [Presence] in Urine sediment by Organism specific culture;T vaginalis UrnS Ql Cult;;ACTIVE;2.56;2.73 +81317-0;Additional pathological findings;Prid;Pt;Specimen;Nom;;PATH;1;Additional pathological findings [Identifier] in Specimen;Addl path findings Spec;;ACTIVE;2.56;2.63 +81318-8;Spermatozoa.normal morphology;Num;Pt;Semen;Qn;Automated count;FERT;1;Spermatozoa.normal morphology [#] in Semen by Automated count;Sperm.norm morph Smn Auto;;ACTIVE;2.56;2.56 +81319-6;Spermatozoa.progressive;Num;Pt;Semen;Qn;Automated count;FERT;1;Spermatozoa Progressive [#] in Semen by Automated count;Sperm Prog Smn Auto;;ACTIVE;2.56;2.73 +81320-4;Influenza virus A H5 Asian RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar.primer-probe set H5a;MICRO;1;Influenza virus A H5 Asian RNA [Cycle Threshold #] in Respiratory specimen by Nucleic acid amplification using primer-probe set H5a;FLUAV H5 Asian RNA Ct Resp Qn NAA H5a;;ACTIVE;2.56;2.63 +81321-2;Influenza virus A H5 Asian RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar.primer-probe set H5b;MICRO;1;Influenza virus A H5 Asian RNA [Cycle Threshold #] in Respiratory specimen by Nucleic acid amplification using primer-probe set H5b;FLUAV H5 Asian RNA Ct Resp Qn NAA H5b;;ACTIVE;2.56;2.63 +81322-0;Glucan 1,4 alpha glucosidase;CCnt;Pt;Tsmi;Qn;;CHEM;1;Glucan 1,4 alpha glucosidase [Enzymatic activity/mass] in Small intestine Tissue;Glucan 1,4-alpha-glucosidase TSMI-cCnt;;ACTIVE;2.56;2.56 +8132-3;Cells.CD5/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD5 cells/100 cells in Blood;CD5 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81323-8;Urine collection associated observations panel;-;24H;Urine;-;;PANEL.SPEC;1;Urine collection associated observations panel - 24 hour Urine;Urine collection assoc obs Pnl 24h Ur;;ACTIVE;2.56;2.63 +81324-6;Glucose tolerance 2H gestational panel;-;-;Ser/Plas;-;;PANEL.CHEM;1;Glucose tolerance 2 hours gestational panel - Serum or Plasma;GTT gest 2h Pnl SerPl;;ACTIVE;2.56;2.56 +81325-3;Influenza virus B Yamagata lineage RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Influenza virus B Yamagata lineage RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;FLUBV Yam RNA Ct Resp Qn NAA+probe;;ACTIVE;2.56;2.63 +81326-1;Human RNase P RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Human RNase P RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;Human RNase P RNA Ct Resp Qn NAA+probe;;ACTIVE;2.56;2.63 +81327-9;Influenza virus B Victoria lineage RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;Influenza virus B Victoria lineage RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;FLUBV Vic RNA Ct Resp Qn NAA+probe;;ACTIVE;2.56;2.63 +81328-7;Cytomegalovirus;PrThr;Pt;Respiratory.lower;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Lower respiratory specimen by Shell vial culture;CMV Lower resp Ql Shell Vial Cult;;ACTIVE;2.56;2.56 +81329-5;Thoughts on resuscitation;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on resuscitation [Reported];;;ACTIVE;2.56;2.73 +81330-3;Thoughts on intubation;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on intubation [Reported];;;ACTIVE;2.56;2.73 +8133-1;Cells.CD56/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD56 cells/100 cells in Blood;CD56 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81331-1;Thoughts on tube feeding;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on tube feeding [Reported];;;ACTIVE;2.56;2.73 +81332-9;Thoughts on IV fluid and support;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on IV fluid and support [Reported];;;ACTIVE;2.56;2.73 +81333-7;Thoughts on antibiotics;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on antibiotics [Reported];;;ACTIVE;2.56;2.73 +81334-5;Personal advance care plan;Find;Pt;{Setting};Doc;Patient;DOC.MISC;2;Patient Personal advance care plan;Personal adv care plan;;ACTIVE;2.56;2.63 +81335-2;Healthcare agent;Find;Pt;{Setting};Doc;Patient;DOC.MISC;2;Patient Healthcare agent;Healthcare agent;;ACTIVE;2.56;2.63 +81336-0;Goals, preferences, and priorities under certain health conditions;Find;Pt;{Setting};Doc;Patient;DOC.MISC;2;Patient Goals, preferences, and priorities under certain health conditions;GPP certain health cond;;ACTIVE;2.56;2.63 +81337-8;Goals, preferences, and priorities upon death;Find;Pt;{Setting};Doc;Patient;DOC.MISC;2;Patient Goals, preferences, and priorities upon death;GPP upon death;;ACTIVE;2.56;2.63 +81338-6;Goals, preferences, and priorities for care experience;Find;Pt;{Setting};Doc;Patient;DOC.MISC;2;Patient Goals, preferences, and priorities for care experience;GPP for care experience;;ACTIVE;2.56;2.63 +81339-4;Witness and notary;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Witness and notary Document;Witness and notary Doc;;ACTIVE;2.56;2.63 +81340-2;Goals &or preferences in order of priority;Find;Pt;^Patient;Nom;Reported;SURVEY.ADVAULT;4;Goals AndOr preferences in order of priority [Reported];;;ACTIVE;2.56;2.58 +81341-0;Circumstances that activate healthcare agent's powers;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Circumstances that activate healthcare agent's powers [Reported];;;ACTIVE;2.56;2.73 +81342-8;Healthcare agent appointment intended to be valid in any jurisdiction;Find;Pt;^Patient;Ord;Reported;SURVEY.ADVAULT;4;Healthcare agent appointment intended to be valid in any jurisdiction [Reported];;;ACTIVE;2.56;2.58 +81343-6;Healthcare agent advisor;Pn;Pt;^Patient;Nom;Reported;SURVEY.ADVAULT;4;Healthcare agent advisor [Reported];;;ACTIVE;2.56;2.58 +81344-4;Healthcare agent authority to inspect and disclose mental and physical health information;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Healthcare agent authority to inspect and disclose mental and physical health information [Reported];;;ACTIVE;2.56;2.73 +81345-1;Healthcare agent authority to inspect and disclose specially protected health information;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Healthcare agent authority to inspect and disclose specially protected health information [Reported];;;ACTIVE;2.56;2.73 +81346-9;Limitations placed on healthcare agent;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Limitations placed on healthcare agent [Reported];;;ACTIVE;2.56;2.73 +81347-7;Consent for healthcare agent to deviate from stated goals, preferences and priorities;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Consent for healthcare agent to deviate from stated goals, preferences and priorities [Reported];;;ACTIVE;2.56;2.73 +81348-5;Compensation for healthcare agent;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Compensation for healthcare agent [Reported];;;ACTIVE;2.56;2.73 +8134-9;Cells.CD57/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD57 cells/100 cells in Blood;CD57 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81349-3;Thoughts on life-sustaining procedures if pregnant;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on life-sustaining procedures if pregnant [Reported];;;ACTIVE;2.56;2.73 +81350-1;Thoughts on pain management;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on pain management [Reported];;;ACTIVE;2.56;2.73 +81351-9;Do Not Resuscitate, Do Not Attempt Resuscitation, or Allow Natural Death order is in place;Find;Pt;^Patient;Ord;Reported;SURVEY.ADVAULT;4;Do Not Resuscitate, Do Not Attempt Resuscitation, or Allow Natural Death order is in place [Reported];;;ACTIVE;2.56;2.58 +81352-7;Medical Order for Life-Sustaining Treatment, Physician Order for Life-Sustaining Treatment, or a similar medical order is in place;Find;Pt;^Patient;Ord;Reported;SURVEY.ADVAULT;4;Medical Order for Life-Sustaining Treatment, Physician Order for Life-Sustaining Treatment, or a similar medical order is in place [Reported];;;ACTIVE;2.56;2.58 +81353-5;Thoughts on hastening death;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Thoughts on hastening death [Reported];;;ACTIVE;2.56;2.73 +81354-3;Prescribed anticipatory medication;Find;Pt;^Patient;Nom;Reported;SURVEY.ADVAULT;4;Prescribed anticipatory medication [Reported];;;ACTIVE;2.56;2.73 +81355-0;Location of prescribed anticipatory medication;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Location of prescribed anticipatory medication [Reported];;;ACTIVE;2.56;2.73 +8135-6;Cells.CD7/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD7 cells/100 cells in Blood;CD7 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81356-8;Death arrangements;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Death arrangements [Reported];;;ACTIVE;2.56;2.58 +81357-6;Messages to be delivered after death;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Messages to be delivered after death [Reported];;;ACTIVE;2.56;2.73 +81358-4;Person(s) to notify upon death;Pn;Pt;^Patient;Nom;Reported;SURVEY.ADVAULT;4;Person(s) to notify upon death [Reported];;;ACTIVE;2.56;2.58 +81359-2;Near death thoughts and feelings to be shared;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Near death thoughts and feelings to be shared [Reported];;;ACTIVE;2.56;2.73 +813-6;Leukocytes;NCnc;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Synovial fluid by Automated count;WBC # Snv Auto;;ACTIVE;1.0;2.73 +81360-0;My likes and joys;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;My likes and joys [Reported];;;ACTIVE;2.56;2.73 +81361-8;Things that make me laugh;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Things that make me laugh [Reported];;;ACTIVE;2.56;2.73 +81362-6;My dislikes and fears;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;My dislikes and fears [Reported];;;ACTIVE;2.56;2.73 +81363-4;Things that matter to me;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Things that matter to me [Reported];;;ACTIVE;2.56;2.73 +8136-4;Cells.CD71/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD71 cells/100 cells in Blood;CD71 Cells NFr Bld;;ACTIVE;1.0h(2);2.73 +81364-2;Religious or cultural beliefs;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Religious or cultural beliefs [Reported];;;ACTIVE;2.56;2.73 +81365-9;Religious or cultural affiliation contact to notify;Pn;Pt;^Patient;Nom;Reported;SURVEY.ADVAULT;4;Religious or cultural affiliation contact to notify [Reported];;;ACTIVE;2.56;2.73 +81366-7;Unfinished business;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Unfinished business [Reported];;;ACTIVE;2.56;2.73 +81367-5;Personal advance care plan signer for declarant;Pn;Pt;^Guardian or legally authorized representative;Nom;Reported;SURVEY.ADVAULT;4;Personal advance care plan signer for declarant [Reported];;;ACTIVE;2.56;2.58 +81368-3;Statement of witness;Find;Pt;^Witness;Nar;Reported;SURVEY.ADVAULT;4;Statement of witness [Reported];;;ACTIVE;2.56;2.73 +81369-1;First witness;Pn;Pt;^Witness;Nom;;ADMIN;2;First witness;First witness;;ACTIVE;2.56;2.58 +81370-9;Second witness;Pn;Pt;^Witness;Nom;;ADMIN;2;Second witness;Second witness;;ACTIVE;2.56;2.58 +81371-7;Third witness;Pn;Pt;^Witness;Nom;;ADMIN;2;Third witness;Third witness;;ACTIVE;2.56;2.58 +8137-2;Cells.CD8;NCnc;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD8 cells [#/volume] in Blood;Deprecated CD8 Cells # Bld;;DEPRECATED;1.0h(2);2.7 +81372-5;Notary;Pn;Pt;^Witness;Nom;;ADMIN;2;Notary;Notary;;ACTIVE;2.56;2.58 +81373-3;Notary commission expiration date;Date;Pt;^Witness;Nom;;ADMIN;2;Notary commission expiration date;Notary commission expiration date;;ACTIVE;2.56;2.58 +81374-1;Notary seal ID;ID;Pt;^Witness;Nom;;ADMIN.ID;2;Notary seal ID;Notary seal ID;;ACTIVE;2.56;2.66 +81375-8;Self assessment of health status;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Self assessment of health status [Reported];;;ACTIVE;2.56;2.73 +81376-6;Mental health treatment preferences;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Mental health treatment preferences [Reported];;;ACTIVE;2.56;2.73 +81377-4;Goals, preferences, and priorities regarding the appointment of healthcare agents;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Goals, preferences, and priorities regarding the appointment of healthcare agents [Reported];;;ACTIVE;2.56;2.73 +81378-2;Goals, preferences, and priorities under certain health conditions;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Goals, preferences, and priorities under certain health conditions [Reported];;;ACTIVE;2.56;2.73 +81379-0;Goals, preferences, and priorities upon death;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Goals, preferences, and priorities upon death [Reported];;;ACTIVE;2.56;2.73 +8138-0;Cells.CD8/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD8 cells/100 cells in Blood;Deprecated CD8 Cells NFr Bld;;DEPRECATED;1.0h(2);2.7 +81380-8;Goals, preferences, and priorities for care experience;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Goals, preferences, and priorities for care experience [Reported];;;ACTIVE;2.56;2.73 +81381-6;Administrative information associated with this personal advance care plan;Find;Pt;^Patient;Nar;;SURVEY.ADVAULT;4;Administrative information associated with this personal advance care plan;;;ACTIVE;2.56;2.72 +81382-4;Statement of document creator;Find;Pt;^Patient;Nar;Reported;SURVEY.ADVAULT;4;Statement of document creator [Reported];;;ACTIVE;2.56;2.73 +81383-2;Tissue velocity.S wave.max;Vel;Pt;Mitral valve.annulus;Qn;US.tissue doppler;CARD.US;2;Mitral valve annulus Tissue velocity.S-wave.max by US.tissue doppler;MV ann s-prime Vmax TDI;;ACTIVE;2.56;2.71 +81384-0;Tissue velocity.E wave.max;Vel;Pt;Mitral valve.annulus;Qn;US.tissue doppler;CARD.US;2;Mitral valve annulus Tissue velocity.E-wave.max by US.tissue doppler;MV ann e-prime Vmax TDI;;ACTIVE;2.56;2.71 +81385-7;Tissue velocity.A wave.max;Vel;Pt;Mitral valve.annulus;Qn;US.tissue doppler;CARD.US;2;Mitral valve annulus Tissue velocity.A-wave.max by US.tissue doppler;MV ann a-prime Vmax TDI;;ACTIVE;2.56;2.71 +81386-5;Blood flow velocity.E wave.max/Tissue velocity.E wave.max;VelRto;Pt;Mitral valve;Qn;US.doppler+tissue doppler;CARD.US;2;Mitral valve Maximum E-wave velocity/Tissue velocity.E-wave.max by US.doppler+tissue doppler;MV E-wave Vmax/e-prime Vmax DOP+TDI;;ACTIVE;2.56;2.71 +81387-3;Regurgitant blood duration of 1 to 3 meters per second flow velocity;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Regurgitant blood duration of 1 to 3 meters per second flow velocity by US.doppler;MV Dur of 1-3 m/s regurg flow vel DOP;;ACTIVE;2.56;2.71 +81388-1;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;US.3D;CARD.US;2;Right ventricular Ejection fraction by US 3D;RV EF 3D US;;ACTIVE;2.56;2.71 +81389-9;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;US.continuity.VTI+Diameter;CARD.US;2;Right ventricular Stroke volume by US.continuity.VTI+Diameter;RV SV US.cont.VTI+diam;;ACTIVE;2.56;2.71 +81390-7;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Cardiac output by US 3D;LV Output 3D US;;ACTIVE;2.56;2.71 +81391-5;Ejection time;Time;Pt;Heart.ventricle.left.outflow tract;Qn;US.doppler;CARD.US;2;Left ventricular outflow tract Ejection time by US.doppler;LVOT Ejection time DOP;;ACTIVE;2.56;2.71 +81392-3;Orifice area/Body surface area;ArArea;Pt;Aortic valve;Qn;US.2D+Measured by planimetry;CARD.US;2;Aortic valve Orifice area/Body surface area [Area/Area] by US.2D+Measured by planimetry;AV Orifice area/BSA US.2D.PLN;;ACTIVE;2.56;2.71 +81393-1;Myocardial performance index;TRto;Pt;Heart.ventricle.left;Qn;US.doppler;CARD.US;2;Left ventricular Myocardial performance index (Tei) by US.doppler;LV MPI DOP;;ACTIVE;2.56;2.71 +81394-9;Regurgitant volume;Vol;Pt;Mitral valve;Qn;US.doppler+Calculated by volumetric method;CARD.US;2;Mitral valve Regurgitant volume by US.doppler+Calculated by volumetric method;MV Reg vol DOP+Calc by vol;;ACTIVE;2.56;2.71 +81395-6;Regurgitant fraction;VFr;Pt;Mitral valve;Qn;US.doppler+Calculated by volumetric method;CARD.US;2;Mitral valve Regurgitant fraction by US.doppler+Calculated by volumetric method;MV Regurg fraction DOP+Calc by vol;;ACTIVE;2.56;2.71 +81396-4;Tissue velocity.A wave.max;Vel;Pt;Mitral valve.annulus.medial;Qn;US.tissue doppler;CARD.US;2;Mitral valve medial annulus Tissue velocity.A-wave.max by US.tissue doppler;MV med ann a-prime Vmax TDI;;ACTIVE;2.56;2.71 +81397-2;Tissue velocity.A wave.max;Vel;Pt;Mitral valve.annulus.lateral;Qn;US.tissue doppler;CARD.US;2;Mitral valve lateral annulus Tissue velocity.A-wave.max by US.tissue doppler;MV lat ann a-prime Vmax TDI;;ACTIVE;2.56;2.71 +8139-8;Amphetamines;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Gastric fluid;Amphetamines Gast-mCnc;;ACTIVE;1.0h(2);2.34 +81398-0;Blood flow velocity.E wave.max/Flow propagation velocity.E wave;VelRto;Pt;Mitral valve;Qn;US.M-mode+doppler.A4C;CARD.US;2;Mitral valve Maximum E-wave velocity/Flow propagation velocity.E wave by US.M-mode+doppler.A4C;MV E-wave Vmax/Vp US.M-mode+DOP.A4C;;ACTIVE;2.56;2.71 +81399-8;Longitudinal strain.max;LenRto;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum longitudinal strain by US 2D;LV Max long strain 2D US;;ACTIVE;2.56;2.71 +81400-4;Radial strain.max;LenRto;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum radial strain by US 2D;LV Max radial strain 2D US;;ACTIVE;2.56;2.71 +81401-2;Circumferential strain.max;LenRto;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum circumferential strain by US 2D;LV Max circ strain 2D US;;ACTIVE;2.56;2.71 +81402-0;Strain.max;LenRto;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum strain by US 3D;LV Max strain 3D US;;ACTIVE;2.56;2.71 +81403-8;Longitudinal strain rate.systole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum longitudinal strain rate during systole by US 2D;LV Max long strain rate sys 2D US;;ACTIVE;2.56;2.71 +81404-6;Radial strain rate.systole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum radial strain rate during systole by US 2D;LV Max radial strain rate sys 2D US;;ACTIVE;2.56;2.71 +81405-3;Circumferential strain rate.systole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum circumferential strain rate during systole by US 2D;LV Max circ strain rate sys 2D US;;ACTIVE;2.56;2.71 +8140-6;Amphetamines;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Gastric fluid;Amphetamines Gast Ql;;ACTIVE;1.0h(2);2.56 +81406-1;Strain rate.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum strain rate by US 2D;LV Max strain rate 2D US;;ACTIVE;2.56;2.71 +81407-9;Longitudinal strain rate.early diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum longitudinal strain rate during early diastole by US 2D;LV Max long strain rate early dias 2D US;;ACTIVE;2.56;2.71 +81408-7;Radial strain rate.early diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum radial strain rate during early diastole by US 2D;LV Max rad strain rate early dias 2D US;;ACTIVE;2.56;2.71 +81409-5;Circumferential strain rate.early diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum circumferential strain rate during early diastole by US 2D;LV Max circ strain rate early dias 2D US;;ACTIVE;2.56;2.71 +81410-3;Strain rate.early diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum strain rate during early diastole by US 3D;LV Max strain rate early dias 3D US;;ACTIVE;2.56;2.71 +81411-1;Longitudinal strain rate.diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum longitudinal strain rate during diastole by US 2D;LV Max long strain rate dias 2D US;;ACTIVE;2.56;2.71 +81412-9;Radial strain rate.diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum radial strain rate during diastole by US 2D;LV Max radial strain rate dias 2D US;;ACTIVE;2.56;2.71 +81413-7;Circumferential strain rate.diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum circumferential strain rate during diastole by US 2D;LV Max circ strain rate dias 2D US;;ACTIVE;2.56;2.71 +8141-4;Amphetamines;PrThr;Pt;Gast fld;Ord;Confirm;DRUG/TOX;1;Amphetamines [Presence] in Gastric fluid by Confirmatory method;Amphetamines Gast Ql Cfm;;ACTIVE;1.0h(2);2.56 +81414-5;Strain rate.diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum strain rate during diastole by US 3D;LV Max strain rate dias 3D US;;ACTIVE;2.56;2.71 +81415-2;Apical rotation.max;Angle;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum apical rotation [Angle] by US 2D;LV Max apical rot Angle 2D US;;ACTIVE;2.56;2.71 +81416-0;Basal rotation.max;Angle;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum basal rotation [Angle] by US 2D;LV Max basal rot Angle 2D US;;ACTIVE;2.56;2.71 +81417-8;Torsion.max;Angle;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum torsion [Angle] by US 2D;LV Max torsion Angle 2D US;;ACTIVE;2.56;2.71 +81418-6;Twist rate.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum twist rate by US 2D;LV Max twist rate 2D US;;ACTIVE;2.56;2.71 +81419-4;Untwist rate.max;ARat;Pt;Heart.ventricle.left;Qn;US.2D;CARD.US;2;Left ventricular Maximum untwist rate by US 2D;LV Max untwist rate 2D US;;ACTIVE;2.56;2.71 +81420-2;KRAS & NRAS gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KRAS and NRAS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;KRAS + NRAS Mut Anl Bld/T;;ACTIVE;2.56;2.73 +81421-0;Saccharomyces cerevisiae Ab.IgG;PrThr;Pt;Ser;Ord;IA;ALLERGY;1;Baker's yeast IgG Ab [Presence] in Serum by Immunoassay;Baker's yeast IgG Ql IA;;ACTIVE;2.56;2.56 +8142-2;Amphetamines;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Gastric fluid by Screen method;Amphetamines Gast Ql Scn;;ACTIVE;1.0h(2);2.56 +81422-8;GATA1 gene exon 2 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GATA1 gene exon 2 targeted mutation analysis in Blood or Tissue by Sequencing;GATA1 exon 2 Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81423-6;Microscopic observation;Prid;Pt;Bone mar;Nom;Acetate esterase stain;PATH;1;Microscopic observation [Identifier] in Bone marrow by Acetate esterase stain;AE Stn Mar;;ACTIVE;2.56;2.56 +81424-4;Microscopic observation;Prid;Pt;Bone mar;Nom;Toluidine blue O stain;PATH;1;Microscopic observation [Identifier] in Bone marrow by Toluidine blue O stain;TBO Stn Mar;;ACTIVE;2.56;2.56 +81425-1;Microscopic observation;Prid;Pt;Bone mar;Nom;Oil red O stain;PATH;1;Microscopic observation [Identifier] in Bone marrow by Oil red O stain;ORO Stn Mar;;ACTIVE;2.56;2.56 +81426-9;Microscopic observation;Prid;Pt;BldV;Nom;Acetate esterase stain;PATH;1;Microscopic observation [Identifier] in Venous blood by Acetate esterase stain;AE Stn BldV;;ACTIVE;2.56;2.56 +81427-7;Microscopic observation;Prid;Pt;BldV;Nom;Oil red O stain;PATH;1;Microscopic observation [Identifier] in Venous blood by Oil red O stain;ORO Stn BldV;;ACTIVE;2.56;2.56 +81428-5;Influenza virus A H7 Eurasia RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H7 Eurasia RNA [Presence] in Respiratory specimen by NAA with probe detection;FLUAV H7 Euras RNA Resp Ql NAA+probe;;ACTIVE;2.56;2.63 +81429-3;Bismuth;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Bismuth [Moles/volume] in Blood;Bismuth Bld-sCnc;;ACTIVE;2.56;2.56 +8143-0;Amphetamines;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Meconium;Amphetamines Mec-mCnc;;DISCOURAGED;1.0h(2);2.73 +81430-1;Lactate dehydrogenase;CCnc;Pt;Dial fld prt;Qn;Reaction: lactate to pyruvate;CHEM;1;Lactate dehydrogenase [Enzymatic activity/volume] in Peritoneal dialysis fluid by Lactate to pyruvate reaction;LDH DiafP L to P-cCnc;;ACTIVE;2.56;2.68 +81431-9;Regurgitation degree;Find;Pt;Aortic valve;Ord;Angiography;CARD.PROC;2;Regurgitation degree Aortic valve Angiography;Reg deg AV Angio;;ACTIVE;2.56;2.56 +81432-7;Regurgitation degree;Find;Pt;Mitral valve;Ord;Angiography;CARD.PROC;2;Regurgitation degree Mitral valve Angiography;Reg deg MV Angio;;ACTIVE;2.56;2.56 +81433-5;Spasm induced;Find;Pt;Coronary arteries;Ord;;CARD.PROC;2;Spasm induced Coronary arteries;Spasm induced Coronary aa;;ACTIVE;2.56;2.56 +81434-3;Spasm symptom induced;Find;Pt;^Patient;Ord;;CARD.PROC;2;Spasm symptom induced;Spasm symp induced;;ACTIVE;2.56;2.56 +81435-0;Lesion treatment duration;Time;Pt;Coronary arteries;Qn;;CARD.PROC;2;Coronary Lesion treatment duration;Cor Lesion tx dur;;ACTIVE;2.56;2.56 +81436-8;Percutaneous coronary intervention site;Anat;Pt;*;Nom;;CARD.PROC;2;Percutaneous coronary intervention site;PCI site;;ACTIVE;2.56;2.56 +81437-6;Lesion treatment sequence;Num;Procedure dur;Coronary arteries;Qn;;CARD.PROC;2;Coronary Lesion treatment sequence;Cor Lesion tx seq;;ACTIVE;2.56;2.56 +81438-4;Coronary stent number;Num;Procedure dur;Heart;Qn;;CARD.PROC;2;Coronary stent number;Cor stent num;;ACTIVE;2.56;2.56 +81439-2;Human papilloma virus 31+33 DNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 31+33 DNA [Presence] in Tissue by Probe;HPV31+33 DNA Tiss Ql Probe;;ACTIVE;2.56;2.73 +814-4;Leukocytes;NCnc;Pt;Synv fld;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Synovial fluid by Manual count;WBC # Snv Manual;;ACTIVE;1.0;2.73 +81440-0;Vital capacity^pre bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Vital capacity [Volume] Respiratory system --pre bronchodilation;VC pre BD Vol Respiratory;;ACTIVE;2.56;2.56 +81441-8;Vital capacity^post bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Vital capacity [Volume] Respiratory system --post bronchodilation;VC p BD Vol Respiratory;;ACTIVE;2.56;2.56 +81442-6;Resistance.airway^post bronchodilation;FldResist;Pt;Respiratory system.airway;Qn;;PULM;2;Airway resistance --post bronchodilation;Airway resist p BD;;ACTIVE;2.56;2.56 +81443-4;Resistance.airway^pre bronchodilation;FldResist;Pt;Respiratory system.airway;Qn;;PULM;2;Airway resistance --pre bronchodilation;Airway resist pre BD;;ACTIVE;2.56;2.56 +81444-2;Inspiratory pressure.max^pre bronchodilation;Pres;Pt;Respiratory system;Qn;;PULM;2;Maximum inspiratory pressure Respiratory system --pre bronchodilation;Max insp press pre BD Respiratory;;ACTIVE;2.56;2.56 +81445-9;Inspiratory pressure.max^post bronchodilation;Pres;Pt;Respiratory system;Qn;;PULM;2;Maximum inspiratory pressure Respiratory system --post bronchodilation;Max insp press p BD Respiratory;;ACTIVE;2.56;2.56 +81446-7;Expiratory pressure.max^pre bronchodilation;Pres;Pt;Respiratory system;Qn;;PULM;2;Maximum expiratory pressure Respiratory system --pre bronchodilation;Max exp press pre BD Respiratory;;ACTIVE;2.56;2.56 +81447-5;Expiratory pressure.max^post bronchodilation;Pres;Pt;Respiratory system;Qn;;PULM;2;Maximum expiratory pressure Respiratory system --post bronchodilation;Max exp press p BD Respiratory;;ACTIVE;2.56;2.56 +8144-8;Amphetamines;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Meconium;Amphetamines Mec Ql;;ACTIVE;1.0h(2);2.73 +81448-3;Inspiratory gas flow.max^pre bronchodilation;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Inspiratory gas flow.max Respiratory system airway --pre bronchodilation;Insp gas flow.max pre BD Airway;;ACTIVE;2.56;2.56 +81449-1;Inspiratory gas flow.max^post bronchodilation;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Inspiratory gas flow.max Respiratory system airway --post bronchodilation;Insp gas flow.max p BD Airway;;ACTIVE;2.56;2.56 +81450-9;Capacity.total^pre bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Total lung capacity --pre bronchodilation;TLC pre BD;;ACTIVE;2.56;2.56 +81451-7;Capacity.total^post bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Total lung capacity --post bronchodilation;TLC p BD;;ACTIVE;2.56;2.56 +81452-5;Volume.residual^pre bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Residual volume --pre bronchodilation;Residual vol pre BD;;ACTIVE;2.56;2.56 +81453-3;Volume.residual^post bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Residual volume --post bronchodilation;Residual vol p BD;;ACTIVE;2.56;2.56 +81454-1;Volume.residual/Capacity.total^pre bronchodilation;VFr;Pt;Respiratory system;Qn;;PULM;2;Residual volume/Total capacity --pre bronchodilation;Residual vol/Total capacity pre BD;;ACTIVE;2.56;2.56 +8145-5;Amphetamines;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Amphetamines [Presence] in Meconium by Confirmatory method;Amphetamines Mec Ql Cfm;;ACTIVE;1.0h(2);2.56 +81455-8;Volume.residual/Capacity.total^post bronchodilation;VFr;Pt;Respiratory system;Qn;;PULM;2;Residual volume/Total capacity --post bronchodilation;Residual vol/Total capacity p BD;;ACTIVE;2.56;2.56 +81456-6;Capacity.functional residual^pre bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Functional residual capacity --pre bronchodilation;FRC pre BD;;ACTIVE;2.56;2.56 +81457-4;Capacity.functional residual^post bronchodilation;Vol;Pt;Respiratory system;Qn;;PULM;2;Functional residual capacity --post bronchodilation;FRC p BD;;ACTIVE;2.56;2.56 +81458-2;Pulmonary function test panel;-;Pt;Respiratory system;-;;PANEL.PULM;2;Pulmonary function test panel;PFT pnl;;ACTIVE;2.56;2.63 +81459-0;Spirometry panel;-;Pt;Respiratory system;-;Spirometry;PANEL.PULM;2;Spirometry panel;Spiro pnl;;ACTIVE;2.56;2.73 +81460-8;I have had trouble forming thoughts in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble forming thoughts in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81461-6;My thinking has been slow in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My thinking has been slow in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81462-4;My thinking has been foggy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My thinking has been foggy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +8146-3;Amphetamines;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Meconium by Screen method;Amphetamines Mec Ql Scn;;ACTIVE;1.0h(2);2.73 +81463-2;I have had trouble adding or subtracting numbers in my head in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble adding or subtracting numbers in my head in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81464-0;I have made mistakes when writing down phone numbers in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have made mistakes when writing down phone numbers in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81465-7;I have had trouble concentrating in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble concentrating in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81466-5;I have had trouble finding my way to a familiar place in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble finding my way to a familiar place in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81467-3;I have had trouble remembering where I put things, like my keys or my wallet in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble remembering where I put things, like my keys or my wallet in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81468-1;I have had trouble remembering whether I did things I was supposed to do, like taking a medicine or buying something I needed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble remembering whether I did things I was supposed to do, like taking a medicine or buying something I needed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81469-9;I have had trouble remembering new information, like phone numbers or simple instructions in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble remembering new information, like phone numbers or simple instructions in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81470-7;I have had trouble recalling the name of an object while talking to someone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble recalling the name of an object while talking to someone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +8147-1;Amphetamines;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Serum or Plasma;Amphetamines SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +81471-5;I have had trouble speaking fluently in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble speaking fluently in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81472-3;I have walked into a room and forgotten what I meant to get or do there in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have walked into a room and forgotten what I meant to get or do there in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81473-1;I have needed medical instructions repeated because I could not keep them straight in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have needed medical instructions repeated because I could not keep them straight in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81474-9;I have had to work really hard to pay attention or I would make a mistake in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had to work really hard to pay attention or I would make a mistake in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81475-6;I have forgotten names of people soon after being introduced in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have forgotten names of people soon after being introduced in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81476-4;My reactions in everyday situations have been slow in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My reactions in everyday situations have been slow in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81477-2;Other people have told me I seemed to have trouble remembering information in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Other people have told me I seemed to have trouble remembering information in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81478-0;It has seemed like my brain was not working as well as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It has seemed like my brain was not working as well as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81479-8;I have had to work harder than usual to keep track of what I was doing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had to work harder than usual to keep track of what I was doing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81480-6;My thinking has been slower than usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My thinking has been slower than usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81481-4;I have had to work harder than usual to express myself clearly in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had to work harder than usual to express myself clearly in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81482-2;I have had more problems conversing with others in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had more problems conversing with others in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81483-0;I have had to use written lists more often than usual so I would not forget things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had to use written lists more often than usual so I would not forget things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81484-8;I have had trouble keeping track of what I was doing when interrupted in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble keeping track of what I was doing when interrupted in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81485-5;I have had trouble shifting back and forth between different activities that require thinking in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble shifting back and forth between different activities that require thinking in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81486-3;I have hidden my problems with memory, concentration, or making mental mistakes so that others would not notice in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have hidden my problems with memory, concentration, or making mental mistakes so that others would not notice in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81487-1;I have been upset about my problems with memory, concentration, or making mental mistakes in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been upset about my problems with memory, concentration, or making mental mistakes in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81488-9;My problems with memory, concentration, or making mental mistakes have interfered with my ability to work in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My problems with memory, concentration, or making mental mistakes have interfered with my ability to work in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +8148-9;Amphetamines;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Amphetamines [Presence] in Serum or Plasma by Confirmatory method;Amphetamines SerPl Ql Cfm;;ACTIVE;1.0h(2);2.73 +81489-7;My problems with memory, concentration, or making mental mistakes have interfered with my ability to do things I enjoy in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My problems with memory, concentration, or making mental mistakes have interfered with my ability to do things I enjoy in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81490-5;My problems with memory, concentration, or making mental mistakes have interfered with the quality of my life in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My problems with memory, concentration, or making mental mistakes have interfered with the quality of my life in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81491-3;I have had difficulty multi-tasking in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had difficulty multi-tasking in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81492-1;PROMIS item bank - cognitive function - abilities subset - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - cognitive function - abilities subset - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81493-9;I have been able to bring to mind words that I wanted to use while talking to someone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to bring to mind words that I wanted to use while talking to someone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81494-7;I have been able to remember to do things, like take medicine or buy something I needed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to remember to do things, like take medicine or buy something I needed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81495-4;I have been able to pay attention and keep track of what I am doing without extra effort in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to pay attention and keep track of what I am doing without extra effort in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81496-2;I have been able to think clearly in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to think clearly in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +8149-7;Amphetamines;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Serum or Plasma by Screen method;Amphetamines SerPl Ql Scn;;ACTIVE;1.0h(2);2.73 +81497-0;My mind has been as sharp as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My mind has been as sharp as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81498-8;My memory has been as good as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My memory has been as good as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81499-6;My thinking has been as fast as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My thinking has been as fast as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81500-1;I have been able to shift back and forth between two activities that require thinking in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to shift back and forth between two activities that require thinking in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81501-9;I have been able to keep track of what I am doing, even if I am interrupted in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to keep track of what I am doing, even if I am interrupted in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81502-7;I have been able to concentrate in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to concentrate in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81503-5;I have been able to form thoughts clearly in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to form thoughts clearly in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81504-3;I have been able to remember telephone numbers in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to remember telephone numbers in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +8150-5;Amphetamines;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Urine;Amphetamines Ur-mCnc;;ACTIVE;1.0h(2);2.73 +81505-0;I have been able to get my point across when talking with someone in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to get my point across when talking with someone in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81506-8;I have been able to remember the name of a familiar object in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to remember the name of a familiar object in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81507-6;I have been able to think as clearly as usual without extra effort in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to think as clearly as usual without extra effort in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81508-4;I have been able to remember things as easily as usual without extra effort in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to remember things as easily as usual without extra effort in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81509-2;My ability to remember important dates has been as good as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My ability to remember important dates has been as good as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +815-1;A Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;A Ab [Presence] in Serum or Plasma from Blood product unit;A Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +81510-0;My ability to remember names has been as good as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My ability to remember names has been as good as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81511-8;My ability to keep track of lists has been as good as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My ability to keep track of lists has been as good as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81512-6;My thinking has been clear in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My thinking has been clear in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +8151-3;Amphetamines;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Amphetamines [Presence] in Urine by SAMHSA confirm method;Amphetamines Ur Ql SAMHSA Cfm;;ACTIVE;1.0h(2);2.73 +81513-4;My ability to count money has been as good as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My ability to count money has been as good as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81514-2;My ability to follow driving directions has been as good as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My ability to follow driving directions has been as good as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81515-9;I have been able to handle many tasks at once without losing track of what I was doing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to handle many tasks at once without losing track of what I was doing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81516-7;My ability to remember things that I need to do has been as good as usual in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My ability to remember things that I need to do has been as good as usual in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81517-5;I have been able to multi-task as easily as usual without extra effort in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to multi-task as easily as usual without extra effort in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81518-3;I have been able to think clearly without extra effort in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to think clearly without extra effort in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81519-1;My ability to concentrate has been good in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My ability to concentrate has been good in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81520-9;I have been able to focus my attention in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to focus my attention in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +8152-1;Amphetamines;PrThr;Pt;Urine;Ord;SAMHSA screen;DRUG/TOX;1;Amphetamines [Presence] in Urine by SAMHSA screen method;Amphetamines Ur Ql SAMHSA Scn;;ACTIVE;1.0h(2);2.56 +81521-7;I have been able to mentally focus in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to mentally focus in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81522-5;I have been able to remember the name of a familiar person in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to remember the name of a familiar person in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81523-3;I have been able to learn new things easily, like telephone numbers or instructions in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to learn new things easily, like telephone numbers or instructions in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.65 +81524-1;PROMIS item bank - cognitive function - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - cognitive function - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81525-8;PROMIS short form - cognitive function - abilities subset 4a - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - cognitive function - abilities subset 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81526-6;PROMIS short form - cognitive function - abilities subset 6a - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - cognitive function - abilities subset 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81527-4;PROMIS short form - cognitive function - abilities subset 8a - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - cognitive function - abilities subset 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81528-2;PROMIS short form - cognitive function 4a - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - cognitive function 4a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81529-0;PROMIS short form - cognitive function 6a - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - cognitive function 6a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81530-8;PROMIS short form - cognitive function 8a - version 2.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - cognitive function 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81531-6;PROMIS short form - cognitive function 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - cognitive function 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81532-4;PROMIS short form - cognitive function 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - cognitive function 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81533-2;PROMIS short form - cognitive function 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - cognitive function 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81534-0;PROMIS short form - cognitive function - abilities subset 4a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - cognitive function - abilities subset 4a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81535-7;PROMIS short form - cognitive function - abilities subset 6a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - cognitive function - abilities subset 6a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81536-5;PROMIS short form - cognitive function - abilities subset 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - cognitive function - abilities subset 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81537-3;PROMIS cognitive function - abilities subset - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cognitive function - abilities subset - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +81538-1;PROMIS cognitive function - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cognitive function - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.56;2.56 +8153-9;Amphetamines;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Amphetamines [Mass/volume] in Unknown substance;Amphetamines Usub-mCnc;;ACTIVE;1.0h(2);2.34 +81541-5;Resource identifier;URI;Pt;Patient education material;Nom;;CLIN;2;Resource identifier [URI] for Patient education material;Resource ID URI Pt Education;;ACTIVE;2.56;2.56 +81542-3;Views for CSF leak post lumbar puncture^W radionuclide IT;Find;Pt;Abdomen>Spine.lumbar;Doc;NM;RAD;2;NM Lumbar spine Views for CSF leak post lumbar puncture W radionuclide IT;NM L-spine Vs for CSF leak p LP W RNC IT;;ACTIVE;2.56;2.64 +81543-1;Views for CSF leak with rhinorrhea or otorrhea^W radionuclide IT;Find;Pt;Head;Doc;NM;RAD;2;NM Head Views for CSF leak with rhinorrhea or otorrhea W radionuclide IT;NM Head Vs CSF leak rhino+oto W RNC IT;;ACTIVE;2.56;2.64 +81544-9;Views for gastrointestinal bleeding^W radionuclide IV;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;NM;RAD;2;NM Gastrointestinal tract Views for gastrointestinal bleeding;NM GI tract Vs GI bleed W RNC IV;;ACTIVE;2.56;2.64 +81545-6;Views for shunt patency^W radionuclide IV;Find;Pt;Abdomen+Pelvis;Doc;NM;RAD;2;NM Abdomen and Pelvis Views for shunt patency;NM Abd+Pelvis Vs for shunt pat W RNC IV;;ACTIVE;2.56;2.64 +81546-4;Views for blood flow+kidney function^W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Views for blood flow and kidney function;NM Vs bld flow+kid fn W RNC IV;;ACTIVE;2.56;2.64 +8154-7;Amphetamines;PrThr;Pt;Unk sub;Ord;;DRUG/TOX;1;Amphetamines [Presence] in Unknown substance;Amphetamines Usub Ql;;ACTIVE;1.0h(2);2.56 +81547-2;Multisection^W In-111 pentetreotide IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body W In-111 pentetreotide IV;SPECT Whole body W In-111-P IV;;ACTIVE;2.56;2.61 +81548-0;Multisection^W tagged WBC IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Unspecified body region W tagged WBC IV;SPECT W tagged WBC IV;;ACTIVE;2.56;2.69 +81549-8;Multisection^W radionuclide IV;Find;Pt;XXX>Lymph node;Doc;NM.SPECT+CT;RAD;2;SPECT+CT Lymph node;SPECT+CT LN W RNC IV;;ACTIVE;2.56;2.61 +81550-6;Multisection^W radionuclide IV;Find;Pt;Neck>Parathyroid gland;Doc;NM.SPECT+CT;RAD;2;SPECT+CT Parathyroid gland;SPECT+CT Parathyroid gland W RNC IV;;ACTIVE;2.56;2.61 +81551-4;Multisection^W 18F-NaF IV;Find;Pt;Whole body>Skull base to mid-thigh.bone;Doc;PT+CT;RAD;2;PET+CT Bone from skull base to mid-thigh W 18F-NaF IV;PET+CT Bone skull to thigh W 18F-NaF IV;;ACTIVE;2.56;2.61 +81552-2;Multisection^W 18F-NaF IV;Find;Pt;Whole body>Bone;Doc;PT+CT;RAD;2;PET+CT Whole body Bone W 18F-NaF IV;PET+CT WB Bone W 18F-NaF IV;;ACTIVE;2.56;2.61 +81553-0;Guidance limited for localization of tumor^W 18F-FDG IV;Find;Pt;XXX;Doc;PT+CT;RAD;2;PET+CT Guidance limited for localization of tumor of Unspecified body region-- W 18F-FDG IV;PET+CT Guided Tum loc Ltd W 18F-FDG IV;;ACTIVE;2.56;2.64 +8155-4;Amphetamines;PrThr;Pt;Unk sub;Ord;Confirm;DRUG/TOX;1;Amphetamines [Presence] in Unknown substance by Confirmatory method;Amphetamines Usub Ql Cfm;;ACTIVE;1.0h(2);2.56 +81554-8;Guidance for localization of tumor^W 18F-FDG IV;Find;Pt;Whole body>Skull base to mid-thigh;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Skull base to mid-thigh-- W 18F-FDG IV;PET+CT Skull-thigh Tum loc 18F-FDG IV;;ACTIVE;2.56;2.64 +81555-5;Guidance for localization of tumor^W 18F-FDG IV;Find;Pt;Whole body;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Whole body-- W 18F-FDG IV;PT+CT Whole body Tum loc W 18F-FDG IV;;ACTIVE;2.56;2.61 +81556-3;Multisection for infection or inflammation^W radionuclide IV;Find;Pt;XXX;Doc;NM.SPECT;RAD;2;SPECT Unspecified body region for infection or inflammation;SPECT for infect+inflam W RNC IV;;ACTIVE;2.56;2.64 +81557-1;Multisection^W florbetapir IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W florbetapir IV;SPECT Brain W florbetapir IV;;ACTIVE;2.56;2.61 +81558-9;Multisection^W Tc-99m IV;Find;Pt;Head>Brain;Doc;NM.SPECT;RAD;2;SPECT Brain W Tc-99m IV;SPECT Brain W Tc99mIV;;ACTIVE;2.56;2.61 +81559-7;Multisection limited for simulation^W radionuclide IV;Find;Pt;XXX;Doc;PT+CT;RAD;2;PET+CT Unspecified body region for simulation limited;PET+CT for sim Ltd W RNC IV;;ACTIVE;2.56;2.64 +81560-5;Multisection^W In-111 capromab pendetide IV;Find;Pt;Whole body;Doc;NM.SPECT;RAD;2;SPECT Whole body W In-111 capromab pendetide IV;SPECT Whole body W In-111 Capr Pen IV;;ACTIVE;2.56;2.61 +81561-3;Multisection^W multiple states of exercise+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart W multiple states of exercise;SPECT Hrt W mult exer+W RNC IV;;ACTIVE;2.56;2.61 +8156-2;Amphetamines;PrThr;Pt;Unk sub;Ord;Screen;DRUG/TOX;1;Amphetamines [Presence] in Unknown substance by Screen method;Amphetamines Usub Ql Scn;;ACTIVE;1.0h(2);2.56 +81562-1;Multisection^W single state of exercise+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM.SPECT;RAD;2;SPECT Heart W single state of exercise;SPECT Hrt W sing exer+W RNC IV;;ACTIVE;2.56;2.61 +81563-9;Views first pass+blood pool^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart First pass and Blood pool;NM Hrt FP+BP W RNC IV;;ACTIVE;2.56;2.61 +81564-7;Multisection for sarcoidosis^W radionuclide IV;Find;Pt;Chest>Heart;Doc;PT;RAD;2;PT Heart for sarcoidosis;PT Hrt for sarcoidosis W RNC IV;;ACTIVE;2.56;2.61 +81565-4;Multisection for tissue viability^W radionuclide IV;Find;Pt;Chest>Heart;Doc;PT;RAD;2;PT Heart for tissue viability;PT Hrt for tiss viability W RNC IV;;ACTIVE;2.56;2.61 +81566-2;Views gated+blood pool+ejection fraction+wall motion^W multiple states of exercise+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Blood pool and Ejection fraction and Wall motion W multiple states of exercise;NM Hrt Gat+BP+EF+WM W mult exer+W RNC IV;;ACTIVE;2.56;2.61 +81567-0;Views gated+blood pool+ejection fraction+wall motion^W single state of exercise+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Gated and Blood pool and Ejection fraction and Wall motion W single state of exercise;NM Hrt Gat+BP+EF+WM W sing exer+W RNC IV;;ACTIVE;2.56;2.61 +81568-8;Multisection^W multiple states of exercise;Find;Pt;Chest>Heart;Doc;PT.perfusion;RAD;2;PT perfusion Heart W multiple states of exercise;PT.perfusion Hrt W mult exer;;ACTIVE;2.56;2.61 +81569-6;Multisection^W single state of exercise;Find;Pt;Chest>Heart;Doc;PT.perfusion;RAD;2;PT perfusion Heart W single state of exercise;PT.perfusion Hrt W sing exer;;ACTIVE;2.56;2.61 +8157-0;Arsenic;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Arsenic [Mass/mass] in Nail;Arsenic Nail-mCnt;;ACTIVE;1.0h(2);2.73 +81570-4;Views perfusion^W single state of exercise+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W single state of exercise;NM Hrt PF W sing exer+W RNC IV;;ACTIVE;2.56;2.61 +81571-2;Views perfusion^W multiple states of exercise+W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Perfusion W multiple states of exercise;NM Hrt PF W mult exer+W RNC IV;;ACTIVE;2.56;2.61 +81572-0;Views for function^W radionuclide IV;Find;Pt;Head>Salivary gland;Doc;NM;RAD;2;NM Salivary gland Views for function;NM Salivary gland Vs function W RNC IV;;ACTIVE;2.56;2.64 +81573-8;Views brain death protocol^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain Brain death protocol Views;NM Brain BD protocol W RNC IV;;ACTIVE;2.56;2.64 +81574-6;Views GE 4^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain GE 4 Views;NM Brain GE 4V W RNC IV;;ACTIVE;2.56;2.61 +81575-3;Views for blood flow GE 4^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain GE 4 Views for blood flow;NM Brain GE 4V for bld flow W RNC IV;;ACTIVE;2.56;2.64 +81576-1;Views for blood flow LT 4^W radionuclide IV;Find;Pt;Head>Brain;Doc;NM;RAD;2;NM Brain LT 4 Views for blood flow;NM Brain LT 4V for bld flow W RNC IV;;ACTIVE;2.56;2.64 +81577-9;Multisection for amyloidosis^W radionuclide IV;Find;Pt;Head>Brain;Doc;PT;RAD;2;PT Brain for amyloidosis;PT Brain for amyloidosis W RNC IV;;ACTIVE;2.56;2.61 +81578-7;Multisection metabolic^W radionuclide IV;Find;Pt;Head>Brain;Doc;PT;RAD;2;PT Brain metabolic;PT Brain metabolic W RNC IV;;ACTIVE;2.56;2.61 +81579-5;Multisection^W radionuclide IV;Find;Pt;Head>Brain;Doc;PT.perfusion;RAD;2;PT perfusion Brain;PT.perfusion Brain W RNC IV;;ACTIVE;2.56;2.61 +81580-3;Views for therapy^W I-131 PO;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views for therapy W I-131 PO;NM Thyroid Views for therapy W I-131 PO;;ACTIVE;2.56;2.64 +81581-1;Views for dosimetry^W radionuclide PO;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Views for dosimetry W radionuclide PO;NM Thyroid Views for dosimetry W RNC PO;;ACTIVE;2.56;2.64 +81582-9;Uptake^W radionuclide IV;Find;Pt;Neck>Thyroid gland;Doc;NM;RAD;2;NM Thyroid gland Uptake;NM Thyroid Uptake W RNC IV;;ACTIVE;2.56;2.61 +81583-7;Views^W Sm-153 IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W Sm-153 IV;NM Whole body Views W Sm-153 IV;;ACTIVE;2.56;2.64 +81584-5;Views^W tagged WBC IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W tagged WBC IV;NM Whole body Views W tagged WBC IV;;ACTIVE;2.56;2.64 +81585-2;Views^W tagged WBC IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Views W tagged WBC IV;NM Views W tagged WBC IV;;ACTIVE;2.56;2.64 +81586-0;Views^W Y-90 ibritumomab tiuxetan IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views W Y-90 ibritumomab tiuxetan IV;NM Whole body Views W Y-90 ibrit tiux IV;;ACTIVE;2.56;2.64 +81587-8;Views limited for infection or inflammation^W radionuclide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Limited Views for infection or inflammation;NM Vs infect+inflam Ltd W RNC IV;;ACTIVE;2.56;2.64 +8158-8;Arsenic;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Arsenic [Mass/mass] in Tissue;Arsenic Tiss-mCnt;;ACTIVE;1.0h(2);2.4 +81588-6;Views for thyroid tumor metastasis^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for thyroid tumor;NM Whole body Vs thyroid tumor W RNC IV;;ACTIVE;2.56;2.64 +81589-4;Views for infection or inflammation^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for infection or inflammation;NM Whole body Vs infect+inflam W RNC IV;;ACTIVE;2.56;2.64 +81590-2;Views for thrombosis^W radionuclide IV;Find;Pt;Extremity.bilateral>Extremity veins;Doc;NM;RAD;2;NM Extremity veins - bilateral Views for thrombosis;NM Extr vv-Bl Vs for thrombosis W RNC IV;;ACTIVE;2.56;2.64 +81591-0;Views for thrombosis^W radionuclide IV;Find;Pt;Extremity.unilateral>Extremity veins;Doc;NM;RAD;2;NM Extremity veins - unilateral Views for thrombosis;NM Extr vv-Ul Vs for thrombosis W RNC IV;;ACTIVE;2.56;2.64 +81592-8;Views for transplanted kidney^W radionuclide IV;Find;Pt;Pelvis;Doc;NM;RAD;2;NM Views for transplanted kidney;NM Views for trans kidney W RNC IV;;ACTIVE;2.56;2.64 +81593-6;Views^W radionuclide IV;Find;Pt;XXX>Lymph node;Doc;NM;RAD;2;NM Lymph node Views;NM LN Views W RNC IV;;ACTIVE;2.56;2.73 +81594-4;Views^W radionuclide IV;Find;Pt;XXX>Lymph node.bilateral;Doc;NM;RAD;2;NM Lymph node - bilateral Views;NM LN-Bl Views W RNC IV;;ACTIVE;2.56;2.64 +81595-1;Views for lymphedema^W radionuclide IV;Find;Pt;XXX>Lymph node;Doc;NM;RAD;2;NM Lymph node Views for lymphedema;NM LN Views for lymphedema W RNC IV;;ACTIVE;2.56;2.64 +8159-6;Beryllium;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in Blood;Beryllium Bld-mCnc;;ACTIVE;1.0h(2);2.73 +81596-9;Views ventilation+perfusion quantitative^W radionuclide IV;Find;Pt;Chest>Lung;Doc;NM;RAD;2;NM Lung Quantitative Views Ventilation and Perfusion;NM Lung VP Qn W RNC IV;;ACTIVE;2.56;2.64 +81597-7;Views for metastasis^W Ra-223 IV;Find;Pt;XXX>Bones;Doc;NM;RAD;2;NM Bones Views for metastasis W Ra-223 IV;NM Bones Views for mets W Ra-223 IV;;ACTIVE;2.56;2.65 +81598-5;Views for thyroid tumor metastasis post therapy^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for thyroid tumor metastasis post therapy;NM WB Vs for thyr mets p tx W RNC IV;;ACTIVE;2.56;2.64 +81599-3;Guidance multiple days for localization of tumor^W radionuclide IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Guidance for multiple days for localization of tumor of Whole body;NM Guided WB Ds tum loc--W RNC IV;;ACTIVE;2.56;2.64 +81600-9;Views limited for infection or inflammation^W Tc-99m tagged WBC IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Limited Views for infection or inflammation W Tc-99m tagged WBC IV;NM Vs Ltd infect+inflam W Tc99m WBC IV;;ACTIVE;2.56;2.64 +81601-7;Views limited for thyroid tumor metastasis^W radionuclide IV;Find;Pt;XXX;Doc;NM;RAD;2;NM Unspecified body region Limited Views for thyroid tumor metastasis;NM XXX Ltd thyroid tumor mets W RNC IV;;ACTIVE;2.56;2.64 +81602-5;Views for gastric emptying solid phase^W radionuclide PO;Find;Pt;Abdomen>Stomach;Doc;NM;RAD;2;NM Stomach Views for gastric emptying solid phase W radionuclide PO;NM Stom Views for SPGE W RNC PO;;ACTIVE;2.56;2.64 +81603-3;Views for blood flow+kidney function^W diuretic IV+W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Views for blood flow and kidney function W diuretic IV;NM Vs bld flow+kid fn W diur IV+RNC IV;;ACTIVE;2.56;2.64 +8160-4;Beryllium;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Beryllium [Mass/volume] in Saliva (oral fluid);Beryllium Sal-mCnc;;ACTIVE;1.0h(2);2.42 +81604-1;Views for glomerular filtration rate^W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Kidney Views for glomerular filtration rate;NM Kidney Views for GFR W RNC IV;;ACTIVE;2.56;2.64 +81605-8;Views^W radionuclide IV;Find;Pt;Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;NM;RAD;2;NM Ureter and Urinary bladder Views;NM Ureter+Blad Views W RNC IV;;ACTIVE;2.56;2.64 +81606-6;Views^W cholecystokinetic+W radionuclide IV;Find;Pt;Abdomen>Liver+Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Liver and Biliary ducts and Gallbladder Views W cholecystokinetic IV;NM Liver+BDs+GB Vs W cholecystokinet+RNC;;ACTIVE;2.56;2.64 +81607-4;Views^W radionuclide IV;Find;Pt;Abdomen>Kidney cortex;Doc;NM;RAD;2;NM Kidney cortex Views;NM Kidney cortex Views W RNC IV;;ACTIVE;2.56;2.64 +81608-2;Views for blood flow+kidney function^W ACE inhibitor PO+W radionuclide IV;Find;Pt;Abdomen>Kidney;Doc;NM;RAD;2;NM Views for blood flow and kidney function W ACE inhibitor PO;NM Vs bld flow+kid fn W ACE PO+RNC IV;;ACTIVE;2.56;2.64 +81609-0;Views^W SIR-spheres intraarterial hepatic injection;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views W SIR-spheres intraarterial hepatic injection;NM Liver Views W SIR-spheres;;ACTIVE;2.56;2.64 +81610-8;Views^W Theraspheres intraarterial hepatic injection;Find;Pt;Abdomen>Liver;Doc;NM;RAD;2;NM Liver Views W Theraspheres intraarterial hepatic injection;NM Liver Views W Theraspheres;;ACTIVE;2.56;2.64 +81611-6;Views for shunt patency^W radionuclide IV;Find;Pt;Head+Neck+Chest+Abdomen+Pelvis;Doc;NM;RAD;2;NM Head to Pelvis Views for shunt patency;NM Head to Pelvis Vs shunt pat W RNC IV;;ACTIVE;2.56;2.64 +8161-2;Bismuth;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Bismuth [Mass/volume] in Blood;Bismuth Bld-mCnc;;ACTIVE;1.0h(2);2.73 +81612-4;Views blood pool+ejection fraction+first pass^W radionuclide IV;Find;Pt;Chest>Heart;Doc;NM;RAD;2;NM Heart Blood pool and Ejection fraction and First pass;NM Hrt BP+EF+FP W RNC IV;;ACTIVE;2.56;2.61 +81613-2;Multisection for hemangioma^W radionuclide IV;Find;Pt;Abdomen>Liver;Doc;NM.SPECT;RAD;2;SPECT Liver for hemangioma;SPECT Liver for hemangioma W RNC IV;;ACTIVE;2.56;2.61 +81614-0;Transfer summary note - recommended C-CDA R2.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Transfer summary note - recommended C-CDA R2.1 sections;Transfer Sum C-CDA R2.1 Sections;;ACTIVE;2.56;2.61 +81615-7;Enhanced discharge summary - recommended CDP Set 1 R1.1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Enhanced discharge summary - recommended CDP Set 1 R1.1 sections;Encd Discharge Sum CDP1 R1.1;;ACTIVE;2.56;2.58 +8162-0;Tetrahydrocannabinol;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Gastric fluid;THC Gast-mCnc;;ACTIVE;1.0h(2);2.42 +81620-7;Differential panel;-;Pt;Bronchial;-;;PANEL.HEM/BC;1;Differential panel - Bronchial specimen;Diff Pnl Bronch;;ACTIVE;2.56;2.56 +81621-5;Herpes simplex virus 1 & 2 Ab.IgG panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Herpes simplex virus 1 and 2 IgG panel - Serum or Plasma;HSV 1 + 2 IgG Pnl SerPl;;ACTIVE;2.56;2.56 +81622-3;Hydroxyapatite;EngDiff;24H;Urine;Qn;;CHEM;1;Hydroxyapatite [Energy Difference] in 24 hour Urine;Hydroxyapatite 24h EngDiff Ur;;ACTIVE;2.56;2.56 +81623-1;Calcium oxalate;EngDiff;24H;Urine;Qn;;CHEM;1;Calcium oxalate [Energy Difference] in 24 hour Urine;CaOx 24h EngDiff Ur;;ACTIVE;2.56;2.56 +81624-9;Methotrexate pentaglutamate;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Methotrexate pentaglutamate [Moles/volume] in Red Blood Cells;MTX-PG5 RBC-sCnc;;ACTIVE;2.56;2.73 +81625-6;Methotrexate tetraglutamate;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Methotrexate tetraglutamate [Moles/volume] in Red Blood Cells;MTX-PG4 RBC-sCnc;;ACTIVE;2.56;2.73 +81626-4;Methotrexate triglutamate;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Methotrexate triglutamate [Moles/volume] in Red Blood Cells;MTX-PG3 RBC-sCnc;;ACTIVE;2.56;2.73 +81627-2;Methotrexate diglutamate;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Methotrexate diglutamate [Moles/volume] in Red Blood Cells;MTX-PG2 RBC-sCnc;;ACTIVE;2.56;2.73 +81628-0;Methotrexate monoglutamate;SCnc;Pt;RBC;Qn;;DRUG/TOX;1;Methotrexate monoglutamate [Moles/volume] in Red Blood Cells;MTX-PG1 RBC-sCnc;;ACTIVE;2.56;2.73 +81629-8;Gamma hydroxybutyrate;PrThr;Pt;XXX;Ord;Confirm;DRUG/TOX;1;Gamma hydroxybutyrate [Presence] in Specimen by Confirmatory method;G-OH-Butyr Spec Ql Cfm;;ACTIVE;2.56;2.69 +81630-6;Methotrexate polyglutamates 1-5 & total panel;-;Pt;RBC;-;;PANEL.DRUG/TOX;1;Methotrexate polyglutamates 1-5 and total panel - Red Blood Cells;MTX-PGs 1-5 + Total Pnl RBC;;ACTIVE;2.56;2.56 +81631-4;Methotrexate polyglutamates;Imp;Pt;RBC;Nar;;DRUG/TOX;1;Methotrexate polyglutamates [Interpretation] in Red Blood Cells Narrative;MTX-PGs RBC-Imp;;ACTIVE;2.56;2.56 +81632-2;Immunoglobulin light chains.free panel;-;Pt;Ser;-;Nephelometry;PANEL.CHEM;1;Immunoglobulin light chains.free panel - Serum by Nephelometry;Immunoglobulin LC free Pnl Ser Neph;;ACTIVE;2.56;2.69 +81633-0;Recommended follow-up tests or procedures;Find;Pt;{Setting};Doc;Oncology;DOC.MISC;2;Oncology Recommended follow-up tests or procedures;Oncology Rec f/u tests or procedures;;ACTIVE;2.56;2.63 +81634-8;Recommended cancer surveillance;Find;Pt;{Setting};Doc;Oncology;DOC.MISC;2;Oncology Recommended cancer surveillance;Oncology Cancer surveillance;;ACTIVE;2.56;2.63 +81635-5;Service &or equipment &or product note;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Service AndOr equipment AndOr product note;Service Equip Product Nte;;ACTIVE;2.56;2.63 +81636-3;Pressure injury risk level;Find;Pt;^Patient;Ord;Observed.Braden scale;H&P.HX;2;Pressure injury risk level Braden scale;Pressure ulcer risk Braden Scale;Copyright © 1988 Barbara Braden and Nancy Bergstrom. Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to Braden and Bergstrom remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.56;2.73 +81637-1;Glucose meter to reference method correlation;Ratio;Pt;Ser/Plas/Bld;Qn;Calculated;CHEM;1;Glucose meter to reference method correlation [Ratio] in Serum, Plasma or Blood by calculation;Glucose correlation SerPlBld Calc-Rto;;ACTIVE;2.56;2.56 +8163-8;Tetrahydrocannabinol;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Gastric fluid;THC Gast Ql;;ACTIVE;1.0h(2);2.56 +81638-9;Clotting time;Time;Pt;BldC;Qn;Sukharev;COAG;1;Clotting time of Capillary blood by Sukharev method;Clotting time BldC Sukharev;;ACTIVE;2.56;2.56 +81639-7;Heparin dose response slope;Arb;Pt;Bld;Qn;Coag;COAG;1;Heparin dose response slope in Blood by Coagulation assay;Hep dose resp slope Bld;;ACTIVE;2.56;2.56 +81640-5;Erythrocytes;NCnc;Pt;Dial fld prt;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Peritoneal dialysis fluid by Automated count;RBC # DiafP Auto;;ACTIVE;2.56;2.56 +81641-3;HIV 2 Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;HIV 2 Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HIV 2 Ab SerPlBld Ql IA.rapid;;ACTIVE;2.56;2.73 +81642-1;CYP3A4 & CYP3A5 gene targeted mutation analysis panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH.PHARMG;1;CYP3A4 and CYP3A5 gene targeted mutation analysis panel - Blood or Tissue by Molecular genetics method;CYP3A4 + CYP3A5 Pnl Bld/T;;ACTIVE;2.56;2.67 +81643-9;von Willebrand factor.ristocetin cofactor activity/von Willebrand factor Ag;Ratio;Pt;PPP;Qn;;COAG;1;von Willebrand factor (vWf) ristocetin cofactor/von Willebrand factor (vWf) Ag [Ratio] in Platelet poor plasma;vWf:RCo/vWF Ag PPP-Rto;;ACTIVE;2.56;2.73 +81644-7;Clostridium botulinum toxin C botC gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin C botC gene [Presence] in Specimen by NAA with probe detection;C botC gene Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +81645-4;Clostridium botulinum toxin D botD gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin D botD gene [Presence] in Specimen by NAA with probe detection;C botD gene Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +8164-6;Tetrahydrocannabinol;PrThr;Pt;Gast fld;Ord;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Gastric fluid by Confirmatory method;THC Gast Ql Cfm;;ACTIVE;1.0h(2);2.56 +81646-2;Clostridium botulinum toxin E botE gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin E botE gene [Presence] in Specimen by NAA with probe detection;C botE gene Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +81647-0;Clostridium botulinum toxin F botF gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin F botF gene [Presence] in Specimen by NAA with probe detection;C botF gene Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +81648-8;Clostridium botulinum toxin G botG gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Clostridium botulinum toxin G botG gene [Presence] in Specimen by NAA with probe detection;C botG gene Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +81649-6;Cryptococcus sp rRNA gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Cryptococcus sp rRNA gene [Presence] in Specimen by NAA with probe detection;Crypt sp rRNA gene Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +81650-4;West Nile virus Kunjin strain RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;West Nile virus Kunjin strain RNA [Presence] in Specimen by NAA with probe detection;WNV Kunjin RNA Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +81651-2;Murray Valley Encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Murray Valley encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;MVEV RNA Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +81652-0;HIV 2 RNA;LnCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;HIV 2 RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection;HIV 2 RNA SerPl NAA+probe-Log#;;ACTIVE;2.56;2.63 +8165-3;Tetrahydrocannabinol;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Gastric fluid by Screen method;THC Gast Ql Scn;;ACTIVE;1.0h(2);2.56 +81653-8;Blastomyces dermatitidis drk1 & Histoplasma capsulatum gapdh genes;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Blastomyces dermatitidis drk1 and Histoplasma capsulatum gapdh genes [Identifier] in Specimen by NAA with probe detection;B derm drk1 + H caps gapdh Spec NAA+pr;;ACTIVE;2.56;2.69 +81654-6;Repiratory pathogens DNA & RNA;Prid;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;Deprecated Respiratory bacteria and viruses DNA and RNA [Identifier] in Tissue by Probe and target amplification method;Deprecated Resp bac + virus DNA + RNA Ti;;DEPRECATED;2.56;2.58 +81655-3;Respiratory pathogens DNA & RNA identified;Prid;Pt;Respiratory;Nom;Probe.amp.tar;MICRO;1;Respiratory pathogens DNA and RNA identified in Respiratory specimen by NAA with probe detection;Resp bact + virus DNA + RNA Resp NAA+pr;;ACTIVE;2.56;2.63 +81656-1;Campylobacter coli+jejuni tuf gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter coli+jejuni tuf gene [Presence] in Stool by NAA with probe detection;C coli+jejuni tuf Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +81657-9;Salmonella sp spaO gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Salmonella sp spaO gene [Presence] in Stool by NAA with probe detection;Salmonella sp spaO Stl Ql NAA+probe;;ACTIVE;2.56;2.63 +81658-7;Suspected organism;Prid;Pt;XXX;Nom;;MICRO;1;Suspected organism [Identifier] in Specimen;Suspect org Spec;;ACTIVE;2.56;2.69 +81659-5;Escherichia coli Stx1 & Stx2 toxin stx1 & stx2 genes panel;-;Pt;Stool;-;Probe.amp.tar;PANEL.MICRO;1;Escherichia coli Stx1 and Stx2 toxin stx1 and stx2 genes panel - Stool by NAA with probe detection;EC stx1 + stx2 genes Pnl Stl NAA+probe;;ACTIVE;2.56;2.64 +81660-3;Nausea;PrThr;Pt;^Patient;Ord;;CLIN;2;Nausea [Presence];Nausea;;ACTIVE;2.56;2.56 +8166-1;Tetrahydrocannabinol;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Tetrahydrocannabinol [Mass/volume] in Meconium;THC Mec-mCnc;;DISCOURAGED;1.0h(2);2.73 +81661-1;Blood loss;Vol;Pt;^Patient;Qn;Measured;IO_OUT.MOLEC;2;Blood loss [Volume] Measured;Bld loss Vol Measured;;ACTIVE;2.56;2.7 +81662-9;Meal eaten;AFr;Pt;^Patient;Qn;;NUTRITION&DIETETICS;2;Percentage of meal eaten;Meal eaten %;;ACTIVE;2.56;2.56 +81663-7;Diet;Type;Pt;^Patient;Nom;;NUTRITION&DIETETICS;2;Diet [Type];Type of diet;;ACTIVE;2.56;2.56 +81664-5;Drain number;ID;Pt;^Patient;Nom;;IO.TUBE;2;Drain number [Identifier];Drain #;;ACTIVE;2.56;2.56 +81665-2;IV number;ID;Pt;^Patient;Nom;;IO.TUBE;2;IV number [Identifier];IV #;;ACTIVE;2.56;2.56 +81666-0;Wound number;ID;Pt;^Patient;Nom;;CLIN;2;Wound number [Identifier];Wound #;;ACTIVE;2.56;2.56 +81667-8;Output count panel;-;Pt;^Patient;-;;PANEL.H&P;2;Output count panel;Output count pnl;;ACTIVE;2.56;2.73 +81668-6;Voids.incontinent;Num;Pt;Urinary tract;Qn;;IO_OUT.MOLEC;2;Incontinent voids [#] Urinary tract;Incont voids Urinary;;ACTIVE;2.56;2.56 +81669-4;Diaper count;Num;Pt;^Patient;Qn;;IO_OUT.MOLEC;2;Diaper count;Diaper cnt;;ACTIVE;2.56;2.56 +81670-2;Perineal pad count;Num;Pt;^Patient;Qn;;IO_OUT.MOLEC;2;Perineal pad count;Perineal pad cnt;;ACTIVE;2.56;2.56 +81671-0;Tissue perfusion assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Tissue perfusion assessment panel;Tiss perf assess pnl;;ACTIVE;2.56;2.56 +81672-8;Tissue perfusion assessment;Imp;Pt;^Patient;Nom;;H&P.PX;2;Tissue perfusion assessment [Interpretation];Tiss perf assess Imp;;ACTIVE;2.56;2.56 +81673-6;Temperature;Find;Pt;Extremity;Ord;;H&P.PX;2;Temperature of Extremity;Temp Extr;;ACTIVE;2.56;2.56 +81674-4;Nutrition and fluid intake assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Nutrition and fluid intake assessment panel;Nutr+fluid intake assess pnl;;ACTIVE;2.56;2.56 +81675-1;Nutrition and fluid intake assessment;Imp;Pt;^Patient;Nom;;H&P.HX;2;Nutrition and fluid intake assessment [Interpretation];Nutr+fluid intake assess Imp;;ACTIVE;2.56;2.58 +81676-9;Hydration status;Find;Pt;^Patient;Nom;;IO_IN.SUMMARY;2;Hydration status;Hydr status;;ACTIVE;2.56;2.56 +81677-7;Output assessment panel;-;Pt;^Patient;-;;PANEL.H&P;2;Output assessment panel;Output assess pnl;;ACTIVE;2.56;2.56 +81678-5;Output assessment;Imp;Pt;^Patient;Nom;;H&P.HX;2;Output assessment [Interpretation];Output assess Imp;;ACTIVE;2.56;2.56 +8167-9;Tetrahydrocannabinol;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Meconium;THC Mec Ql;;ACTIVE;1.0h(2);2.73 +81679-3;Preoperative measures for patient safety panel;-;Pt;^Patient;-;;PANEL.SURG;2;Preoperative measures for patient safety panel;Preop measures for pt safety pnl;;ACTIVE;2.56;2.63 +81680-1;Preoperative verification process panel;-;Pt;^Patient;-;;PANEL.SURG;2;Preoperative verification process panel;Preop verif process pnl;;ACTIVE;2.56;2.63 +81681-9;Verified two types of patient identification;Find;Pt;^Patient;Ord;;SURG;2;Verified two types of patient identification;Verified 2 types pt ID;;ACTIVE;2.56;2.56 +81682-7;Verified side &or site of procedure;Find;Pt;^Patient;Ord;;SURG;2;Verified side andor site of procedure;Verified proc side +or site;;ACTIVE;2.56;2.56 +81683-5;Verified procedure;Find;Pt;^Patient;Ord;;SURG;2;Verified procedure;Verified proc;;ACTIVE;2.56;2.56 +81684-3;Verified patient position;Find;Pt;^Patient;Ord;;SURG;2;Verified patient position;Verified pt position;;ACTIVE;2.56;2.56 +81685-0;Verified availability of correct implants and any special equipment or requirements;Find;Pt;^Patient;Ord;;SURG;2;Verified availability of correct implants and any special equipment or requirements;Verified avail implants+special equip;;ACTIVE;2.56;2.56 +81686-8;Performed preoperative time-out assessment;Find;Pt;^Patient;Ord;;SURG;2;Performed preoperative time-out assessment;Perf preop time-out;;ACTIVE;2.56;2.56 +8168-7;Tetrahydrocannabinol;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Meconium by Confirmatory method;THC Mec Ql Cfm;;ACTIVE;1.0h(2);2.56 +81687-6;Marked operative site;Find;Pt;^Patient;Ord;;SURG;2;Marked operative site;Marked op site;;ACTIVE;2.56;2.56 +81688-4;Barmah forest virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Barmah forest virus RNA [Presence] in Blood by NAA with probe detection;BFV RNA Bld Ql NAA+probe;;ACTIVE;2.56;2.63 +81689-2;Hendra virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Hendra virus RNA [Presence] in Specimen by NAA with probe detection;HeV RNA Spec Ql NAA+probe;;ACTIVE;2.56;2.69 +816-9;A Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;A Ab [Presence] in Serum or Plasma from Donor;A Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +81690-0;Legionella longbeachae 1 & 2 DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Legionella longbeachae 1 and 2 DNA [Identifier] in Specimen by NAA with probe detection;L longbeachae 1 + 2 DNA Spec NAA+probe;;ACTIVE;2.56;2.69 +81691-8;DNA mismatch repair protein Mlh1;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;DNA mismatch repair protein Mlh1 [Presence] in Cancer specimen by Immune stain;MMR prot Mlh1 Ca spec Ql ImStn;;ACTIVE;2.56;2.61 +81692-6;DNA mismatch repair protein Msh2;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;DNA mismatch repair protein Msh2 [Presence] in Cancer specimen by Immune stain;MMR prot Msh2 Ca spec Ql ImStn;;ACTIVE;2.56;2.61 +81693-4;DNA mismatch repair protein Msh6;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;DNA mismatch repair protein Msh6 [Presence] in Cancer specimen by Immune stain;MMR prot Msh6 Ca spec Ql ImStn;;ACTIVE;2.56;2.61 +81694-2;Mismatch repair endonuclease PMS2;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;Mismatch repair endonuclease PMS2 [Presence] in Cancer specimen by Immune stain;MMR endo PMS2 Ca spec Ql ImStn;;ACTIVE;2.56;2.61 +8169-5;Tetrahydrocannabinol;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Meconium by Screen method;THC Mec Ql Scn;;ACTIVE;1.0h(2);2.73 +81695-9;Microsatellite instability;Imp;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability [Interpretation] in Cancer specimen Qualitative;MSI Ca spec-Imp;;ACTIVE;2.56;2.61 +81696-7;Microsatellite instability markers assessed;Num;Pt;Cancer specimen;Qn;;PATH;1;Microsatellite instability markers assessed [#] in Cancer specimen;MSI mark assess Ca spec;;ACTIVE;2.56;2.61 +81697-5;Microsatellite instability marker BAT25;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker BAT25 in Cancer specimen Qualitative;MSI mark BAT25 Ca spec Ql;;ACTIVE;2.56;2.61 +81698-3;Microsatellite instability marker BAT26;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker BAT26 in Cancer specimen Qualitative;MSI mark BAT26 Ca spec Ql;;ACTIVE;2.56;2.61 +81699-1;Microsatellite instability marker NR21;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker NR21 in Cancer specimen Qualitative;MSI mark NR21 Ca spec Ql;;ACTIVE;2.56;2.61 +81700-7;Microsatellite instability marker NR24;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker NR24 in Cancer specimen Qualitative;MSI mark NR24 Ca spec Ql;;ACTIVE;2.56;2.61 +81701-5;Microsatellite instability marker MONO27;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker MONO27 in Cancer specimen Qualitative;MSI mark MONO27 Ca spec Ql;;ACTIVE;2.56;2.61 +81702-3;Microsatellite instability marker D2S123;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker D2S123 in Cancer specimen Qualitative;MSI mark D2S123 Ca spec Ql;;ACTIVE;2.56;2.61 +8170-3;Cannabinoids;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Cannabinoids [Mass/volume] in Serum or Plasma;Cannabinoids SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +81703-1;Microsatellite instability marker D5S346;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker D5S346 in Cancer specimen Qualitative;MSI mark D5S346 Ca spec Ql;;ACTIVE;2.56;2.61 +81704-9;Microsatellite instability marker D17S250;Find;Pt;Cancer specimen;Ord;;PATH;1;Microsatellite instability marker D17S250 in Cancer specimen Qualitative;MSI mark D17S250 Ca spec Ql;;ACTIVE;2.56;2.61 +81705-6;Serine-threonine protein kinase B-raf;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;BRAF protein [Presence] in Cancer specimen by Immune stain;BRAF protein Ca spec Ql ImStn;;ACTIVE;2.56;2.61 +81706-4;Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;Phosphatase and tensin homolog (PTEN) protein [Presence] in Cancer specimen by Immune stain;PTEN protein Ca spec Ql ImStn;;ACTIVE;2.56;2.61 +81707-2;Dissection technique;Type;Pt;Tiss;Nom;*;PATH;1;Dissection technique [Type] in Tissue;Dissection tech Tiss;;ACTIVE;2.56;2.56 +81708-0;Microsatellite markers exhibiting instability/Microsatellite instability markers assessed;NFr;Pt;Cancer specimen;Qn;;PATH;1;Microsatellite markers exhibiting instability/Microsatellite instability markers assessed in Cancer specimen;MSI mark found/MSI mark stud NFr Ca spec;;ACTIVE;2.56;2.61 +81709-8;Microsatellite markers exhibiting instability;Num;Pt;Cancer specimen;Qn;;PATH;1;Microsatellite markers exhibiting instability [#] in Cancer specimen;MSI mark found Ca spec;;ACTIVE;2.56;2.61 +81710-6;PTEN gene;PrThr;Pt;Cancer specimen;Ord;FISH;MOLPATH.MISC;1;PTEN gene [Presence] in Cancer specimen by FISH;PTEN gene Ca spec Ql FISH;;ACTIVE;2.56;2.61 +8171-1;Cannabinoids;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Cannabinoids [Presence] in Serum or Plasma by Confirmatory method;Cannabinoids SerPl Ql Cfm;;ACTIVE;1.0h(2);2.73 +81711-4;Microsatellite instability marker panel;-;Pt;Cancer specimen;-;;PANEL.PATH;1;Microsatellite instability marker panel - Cancer specimen;MSI mark Pnl Ca spec;;ACTIVE;2.56;2.61 +81712-2;Actin.filamentous Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Actin.filamentous Ab [Presence] in Serum by Line blot;F-actin Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81713-0;Actin.smooth muscle Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Actin smooth muscle Ab [Presence] in Serum by Immunoblot;Deprecated SMA Ab Ser Ql IB;;DEPRECATED;2.56;2.58 +81714-8;Centromere protein A Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Centromere protein A Ab [Presence] in Serum by Line blot;CENP A Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81715-5;Centromere protein B Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Centromere protein B Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated Centromere B Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81716-3;DNA double strand Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;DNA double strand Ab [Presence] in Serum by Line blot;dsDNA Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81717-1;Ganglioside GM1 Ab.IgG;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Ganglioside GM1 IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated GM1 Gangl IgG CSF Ql IB;;DEPRECATED;2.56;2.58 +81718-9;Ganglioside GM1 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM1 IgG+IgM Ab [Presence] in Serum by Immunoblot;Deprecated GM1 Gangl IgG+IgM Ser Ql IB;;DEPRECATED;2.56;2.58 +81719-7;Ganglioside GM1 Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM1 IgM Ab [Presence] in Serum by Immunoblot;Deprecated GM1 Gangl IgM Ser Ql IB;;DEPRECATED;2.56;2.58 +81720-5;Ganglioside GM1 Ab.IgM;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Ganglioside GM1 IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated GM1 Gangl IgM CSF Ql IB;;DEPRECATED;2.56;2.58 +81721-3;Ganglioside GM2 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM2 IgG+IgM Ab [Presence] in Serum by Immunoblot;Deprecated GM2 Gangl IgG+IgM Ser Ql IB;;DEPRECATED;2.56;2.58 +81722-1;Ganglioside GT1b Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GT1b IgG+IgM Ab [Presence] in Serum by Immunoblot;Deprecated GT1b Ganlg IgG+IgM Ser Ql IB;;DEPRECATED;2.56;2.58 +81723-9;Ganglioside GT1b Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GT1b IgM Ab [Presence] in Serum by Immunoblot;Deprecated GT1b Ganlg IgM Ser Ql IB;;DEPRECATED;2.56;2.58 +81724-7;Glomerular basement membrane Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Glomerular basement membrane Ab [Presence] in Serum by Immunoblot;Deprecated GBM Ab Ser Ql IB;;DEPRECATED;2.56;2.58 +81725-4;Glutamate decarboxylase 65 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Glutamate decarboxylase 65 Ab [Presence] in Serum by Line blot;GAD65 Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81726-2;Mitochondria M2 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Mitochondria M2 Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated Mitochondria M2 Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81727-0;Mitochondria M2-3E Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Mitochondria M2-3E Ab [Presence] in Serum by Line blot;M2-3E Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81728-8;Neuronal nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Neuronal nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;Hu Ab CSF Ql Line blot;;ACTIVE;2.56;2.64 +8172-9;Cannabinoids;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Serum or Plasma by Screen method;Cannabinoids SerPl Ql Scn;;ACTIVE;1.0h(2);2.73 +81729-6;Neuronal nuclear type 2 Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot;Hu2 Ab CSF Ql IB;;ACTIVE;2.56;2.74 +81730-4;PCNA extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated PCNA extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA PCNA Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81731-2;PM-SCL extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated PM-SCL extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA PM/SCL Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81732-0;PM-SCL-100 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;PM-SCL-100 Ab [Presence] in Serum by Line blot;PM/SCL-100 Ab Ser Ql Line blot;;ACTIVE;2.56;2.73 +81733-8;PM-SCL-75 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;PM-SCL-75 Ab [Presence] in Serum by Line blot;PM-SCL75 Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81734-6;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Ribonucleoprotein extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA RNP Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81735-3;Ribosomal P Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Ribosomal P Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated Ribosomal P Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81736-1;RNA polymerase III Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated RNA polymerase III Ab [Presence] in Serum by Immunoblot;Deprecated RNAp III Ab Ser Ql IB;;DEPRECATED;2.56;2.58 +8173-7;Tetrahydrocannabinol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Deprecated Tetrahydrocannabinol [Mass/volume] in Urine;Deprecated THC Ur-mCnc;;DEPRECATED;1.0h(2);2.36 +81737-9;RNA polymerase III RP11 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;RNA polymerase III RP11 Ab [Presence] in Serum by Line blot;RNAp III RP11 Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81738-7;RNA polymerase III RP155 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;RNA polymerase III RP155 Ab [Presence] in Serum by Line blot;RNAp III RP155 Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81739-5;SCL-70 extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated SCL-70 extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA Scl70 Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81740-3;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA SS-A 52kD Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81741-1;Smith extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Smith extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA SM Ab CSF Ql IB;;DEPRECATED;2.56;2.58 +81742-9;Th-To Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Th-To Ab [Units/volume] in Serum by Line blot;Th-To Ab Ser Line blot-aCnc;;ACTIVE;2.56;2.73 +81743-7;Th-To Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Th-To Ab [Presence] in Serum by Line blot;Th-To Ab Ser Ql Line blot;;ACTIVE;2.56;2.64 +81744-5;Submitter's laboratory test method;Type;Pt;Specimen;Nom;*;MICRO;1;Submitter's laboratory test method [Type] in Specimen;Submitter's lab test method Spec;;ACTIVE;2.56;2.58 +8174-5;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by SAMHSA confirm method;THC Ur Ql SAMHSA Cfm;;ACTIVE;1.0h(2);2.73 +81745-2;Personal advance care plan R1.0 - recommended CDA sections;-;Pt;{Setting};-;;PANEL.DOC;2;Personal advance care plan R1.0 - recommended CDA sections;Pers adv care plan R1.0 - rec CDA sec;;ACTIVE;2.56;2.56 +81746-0;Chromosome region 17p13.1 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 17p13.1 deletion in Blood or Tissue by FISH;Chr 17p13.1 Del Bld/T FISH;;ACTIVE;2.56;2.66 +81747-8;Chromosome region 6q22 rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH.REARRANGE;1;Chromosome region 6q22 rearrangements in Tissue by FISH;Chr 6q22 region rearr Tiss FISH;;ACTIVE;2.56;2.65 +81748-6;Chromosome region Yp11.3 deletion &or rearrangement;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH;1;Chromosome region Yp11.3 deletion AndOr rearrangement in Blood or Tissue by FISH;Chr Yp11.3 Del +or Rearr Bld/T FISH;;ACTIVE;2.56;2.66 +81749-4;Chromosome region 13q14 deletion;Find;Pt;Bone mar;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 13q14 deletion in Bone marrow by FISH;Chr 13q14 Del Mar FISH;;ACTIVE;2.56;2.66 +81750-2;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript";Find;Pt;Bone mar;Doc;Molgen;MOLPATH.TRNLOC;1;"Deprecated t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript in Bone marrow by Molecular genetics method";"Deprecated t(9;22)(ABL1,BCR) Mar";;DEPRECATED;2.56;2.66 +81751-0;Chromosome region 17p13.1 deletion & chromosome region 14q32 rearrangements;Find;Pt;Bone mar;Doc;FISH;MOLPATH;1;Chromosome 17p13.1 deletion and 14q32 rearrangements in Bone marrow by FISH;Chr 17p13.1 Del + 14q32 Rearr Mar FISH;;ACTIVE;2.56;2.66 +8175-2;Tetrahydrocannabinol;PrThr;Pt;Urine;Ord;SAMHSA screen;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Urine by SAMHSA screen method;THC Ur Ql SAMHSA Scn;;ACTIVE;1.0h(2);2.7 +81752-8;Chromosome region 1q21 duplication;Find;Pt;Bone mar;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 1q21 duplication in Bone marrow by FISH;Chr 1q21 Dp Mar FISH;;ACTIVE;2.56;2.65 +81753-6;Somatotropin^1.75H post dose arginine+insulin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --1.75 hours post dose arginine+insulin;GH 1.75h p Arg+Ins SerPl-mCnc;;ACTIVE;2.56;2.56 +81754-4;Nortapentadol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nortapentadol [Mass/volume] in Urine by Confirmatory method;Nortapentadol Ur Cfm-mCnc;;ACTIVE;2.56;2.56 +81755-1;Lymphocyte proliferation.Interleukin 2.maximum/CD45;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Lymphocyte proliferation.Interleukin 2.maximum/CD45 in Blood by Flow cytometry (FC);LPT IL-2 max/CD45 NFr Bld FC;;ACTIVE;2.56;2.56 +81756-9;Lymphocyte proliferation.anti-CD3.maximum/CD3;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Lymphocyte proliferation.anti-CD3.maximum/CD3 in Blood by Flow cytometry (FC);LPT aCD3 max/CD3 NFr Bld FC;;ACTIVE;2.56;2.56 +81757-7;Lymphocyte proliferation.Interleukin 2.maximum/CD3;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Lymphocyte proliferation.Interleukin 2.maximum/CD3 in Blood by Flow cytometry (FC);LPT IL-2 max/CD3 NFr Bld FC;;ACTIVE;2.56;2.56 +81758-5;Lymphocyte proliferation.anti-CD28.maximum/CD3;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Lymphocyte proliferation.anti-CD28.maximum/CD3 in Blood by Flow cytometry (FC);LPT aCD28 max/CD3 NFr Bld FC;;ACTIVE;2.56;2.56 +81759-3;Lymphocyte proliferation.anti-CD28.maximum/CD45;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Lymphocyte proliferation.anti-CD28.maximum/CD45 in Blood by Flow cytometry (FC);LPT aCD28 max/CD45 NFr Bld FC;;ACTIVE;2.56;2.56 +8176-0;Cannabinoids;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Cannabinoids [Mass/volume] in Unknown substance;Cannabinoids Usub-mCnc;;ACTIVE;1.0h(2);2.34 +81760-1;Lymphocyte proliferation.anti-CD3.maximum/CD45;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Lymphocyte proliferation.anti-CD3.maximum/CD45 in Blood by Flow cytometry (FC);LPT aCD3 max/CD45 NFr Bld FC;;ACTIVE;2.56;2.56 +81761-9;F8 gene intron 1 & 22 inversion targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.INV;1;F8 gene intron 1 and 22 inversion targeted mutation analysis in Blood or Tissue by Molecular genetics method;F8 intron 1+22 Inv Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81762-7;F8 gene intron 1 inversion targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.INV;1;F8 gene intron 1 inversion targeted mutation analysis in Blood or Tissue by Molecular genetics method;F8 intron 1 Inv Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81763-5;Phytanate & pristanate panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Phytanate and pristanate panel - Serum or Plasma;Phytanate + pristanate Pnl SerPl;;ACTIVE;2.56;2.56 +81764-3;Docosatrienoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Docosatrienoate (C22:3w9) [Moles/volume] in Serum or Plasma;Docosatrienoate SerPl-sCnc;;ACTIVE;2.56;2.56 +81765-0;Docosatrienoate;EntSub;Pt;RBC;Qn;;CHEM;1;Docosatrienoate (C22:3w9) [Entitic substance] in Red Blood Cells;Docosatrienoate EntSub RBC;;ACTIVE;2.56;2.56 +81766-8;Eicosatrienoate;EntSub;Pt;Ser/Plas;Qn;;CHEM;1;Eicosatrienoate (C20:3w3) [Entitic substance] in Serum or Plasma;Eicosatrienoate EntSub SerPl;;ACTIVE;2.56;2.56 +81767-6;Eicosatrienoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Eicosatrienoate (C20:3w3) [Moles/volume] in Serum or Plasma;Eicosatrienoate SerPl-sCnc;;ACTIVE;2.56;2.56 +81768-4;U1 small nuclear ribonucleoprotein 70kD Ab.IgG;ACnc;Pt;Ser;Qn;IA;CHEM;1;U1 small nuclear ribonucleoprotein 70kD IgG Ab [Units/volume] in Serum by Immunoassay;U1 snRNP70 IgG Ser IA-aCnc;;ACTIVE;2.56;2.56 +81769-2;Adipoylcarnitine (C6-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Adipoylcarnitine (C6-DC)/Creatinine [Molar ratio] in Urine;Adipoylcarn/Creat Ur-sRto;;ACTIVE;2.56;2.56 +817-7;A Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;A Ab [Presence] in Serum or Plasma;A Ab SerPl Ql;;ACTIVE;1.0;2.73 +81770-0;Tiglylcarnitine (C5:1)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tiglylcarnitine (C5:1)/Creatinine [Molar ratio] in Urine;Tiglylcarn/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81771-8;Myeloperoxidase Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Myeloperoxidase IgG Ab [Presence] in Serum by Immunoblot;Myeloperoxidase IgG Ser Ql IB;;ACTIVE;2.56;2.58 +81772-6;Dermatophagoides pteronyssinus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite IgG Ab [Mass/volume] in Serum;D pteronyss IgG-mCnc;;ACTIVE;2.56;2.56 +81773-4;Amyloid A;MCnt;Pt;Tiss;Qn;;CHEM;1;Amyloid A [Mass/mass] in Tissue;Amyloid A Tiss-mCnt;;ACTIVE;2.56;2.56 +81774-2;Actin.smooth muscle Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Actin smooth muscle IgG Ab [Presence] in Serum;SMA IgG Ser Ql;;ACTIVE;2.56;2.56 +81775-9;Epipregnanolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Epipregnanolone/Creatinine [Molar ratio] in Urine;Epipregnanolone/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81776-7;Ureidopropionate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Ureidopropionate/Creatinine [Molar ratio] in Urine;Ureidopropionate/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81777-5;Nonanoylcarnitine (C9)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Nonanoylcarnitine (C9)/Creatinine [Molar ratio] in Urine;Nonanoylcarn/Creat Ur-sRto;;ACTIVE;2.56;2.56 +8177-8;Cannabinoids;PrThr;Pt;Unk sub;Ord;;DRUG/TOX;1;Cannabinoids [Presence] in Unknown substance;Cannabinoids Usub Ql;;ACTIVE;1.0h(2);2.56 +81778-3;Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH)/Creatinine [Molar ratio] in Urine;C4-DC+C5-OH/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81779-1;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Creatinine [Molar ratio] in Urine;Malonyl+3OHbutyrylcarn/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81780-9;Tetradecenoylcarnitine (C14:1)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Creatinine [Molar ratio] in Urine;Tdecenoylcarn/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81781-7;Saccharopine;SCnc;Pt;CSF;Qn;;CHEM;1;Saccharopine [Moles/volume] in Cerebral spinal fluid;Saccharopine CSF-sCnc;;ACTIVE;2.56;2.56 +81782-5;Phleum pratense Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Timothy IgG Ab [Mass/volume] in Serum;Timothy IgG-mCnc;;ACTIVE;2.56;2.56 +81783-3;Chicken feather Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken feather IgG Ab [Mass/volume] in Serum;Chicken Feather IgG-mCnc;;ACTIVE;2.56;2.56 +81784-1;Canary droppings Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Canary droppings IgG Ab [Mass/volume] in Serum;Canary Drop IgG-mCnc;;ACTIVE;2.56;2.56 +81785-8;Duck feather Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Duck feather IgG Ab [Mass/volume] in Serum;Duck Feather IgG-mCnc;;ACTIVE;2.56;2.56 +8178-6;Cannabinoids;PrThr;Pt;Unk sub;Ord;Confirm;DRUG/TOX;1;Cannabinoids [Presence] in Unknown substance by Confirmatory method;Cannabinoids Usub Ql Cfm;;ACTIVE;1.0h(2);2.73 +81786-6;Chemokine (C-C motif) ligand 17;MCnc;Pt;Ser;Qn;IA;CHEM;1;Chemokine (C-C motif) ligand 17 [Mass/volume] in Serum by Immunoassay;CCL17 Ser IA-mCnc;;ACTIVE;2.56;2.56 +81787-4;Myeloperoxidase Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;CHEM;1;Myeloperoxidase IgG Ab [Presence] in Serum or Plasma by Immunoassay;Myeloperoxidase IgG SerPl Ql IA;;ACTIVE;2.56;2.56 +81788-2;Corylus avellana recombinant (rCor a) 14 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut recombinant (rCor a) 14 IgE Ab [Units/volume] in Serum;Hazelnut (rCor a) 14 IgE Qn;;ACTIVE;2.56;2.73 +81789-0;Juglans regia recombinant (rJug r) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English walnut recombinant (rJug r) 3 IgE Ab [Units/volume] in Serum;English walnut (rJug r) 3 IgE Qn;;ACTIVE;2.56;2.73 +81790-8;Juglans regia recombinant (rJug r) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English walnut recombinant (rJug r) 1 IgE Ab [Units/volume] in Serum;English walnut (rJug r) 1 IgE Qn;;ACTIVE;2.56;2.73 +81791-6;Malus domestica recombinant (rMal d) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Apple recombinant (rMal d) 3 IgE Ab [Units/volume] in Serum;Apple (rMal d) 3 IgE Qn;;ACTIVE;2.56;2.56 +81792-4;Dermatophagoides pteronyssinus native (nDer p) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides pteronyssinus native (nDer p) 2 IgE Ab [Units/volume] in Serum;D pteronyss (nDer p) 2 IgE Qn;;ACTIVE;2.56;2.56 +81793-2;Tetrahydrodeoxycortisol/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Tetrahydrodeoxycortisol/Creatinine [Molar ratio] in 24 hour Urine;TH-DC/Creat 24h Ur-sRto;;ACTIVE;2.56;2.56 +8179-4;Cannabinoids;PrThr;Pt;Unk sub;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Unknown substance by Screen method;Cannabinoids Usub Ql Scn;;ACTIVE;1.0h(2);2.56 +81794-0;Tetrahydrocortisol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocortisol/Creatinine [Molar ratio] in Urine;THF/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81795-7;Tetrahydrocortisone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocortisone/Creatinine [Molar ratio] in Urine;THcortisone/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81796-5;Tetrahydrocorticosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone/Creatinine [Molar ratio] in Urine;THB/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81797-3;11-Dehydrotetrahydrocorticosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;11-Dehydrotetrahydrocorticosterone/Creatinine [Molar ratio] in Urine;THA/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81798-1;Pregnanediolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanediolone/Creatinine [Molar ratio] in Urine;PDL/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81799-9;16-Alpha hydroxypregnenolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;16-Alpha hydroxypregnenolone/Creatinine [Molar ratio] in Urine;16A OH-Preg/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81800-5;16-Ketoandrostenediol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;16-Ketoandrostenediol/Creatinine [Molar ratio] in Urine;16-Ketoandrostenediol/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81801-3;16-Alpha hydroxydehydroepiandrosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;16-Alpha hydroxydehydroepiandrosterone/Creatinine [Molar ratio] in Urine;16A OH-DHEA/Creat Ur-sRto;;ACTIVE;2.56;2.56 +8180-2;Chlorobenzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chlorobenzene [Mass/volume] in Blood;Chlorobenz Bld-mCnc;;ACTIVE;1.0h(2);2.42 +81802-1;16-Beta,18-dihydroxydehydroepiandrosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;16-Beta,18-dihydroxydehydroepiandrosterone/Creatinine [Molar ratio] in Urine;16B,18-diOH-DHEA/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81803-9;Beta cortolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Beta cortolone/Creatinine [Molar ratio] in Urine;B-cortolone/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81804-7;Allo-tetrahydrocortisol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Allo-tetrahydrocortisol/Creatinine [Molar ratio] in Urine;Allo-THF/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81805-4;Allo-tetrahydrocorticosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Allo-tetrahydrocorticosterone/Creatinine [Molar ratio] in Urine;Allo-THB/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81806-2;Alpha cortolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha cortolone/Creatinine [Molar ratio] in Urine;A-cortolone/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81807-0;Alpha cortol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Alpha cortol/Creatinine [Molar ratio] in Urine;A-Cortol/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81808-8;Androstenetriol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Androstenetriol/Creatinine [Molar ratio] in Urine;AET/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81809-6;3-Hydroxydodecanoylcarnitine (C12-OH)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydodecanoylcarnitine (C12-OH)/Creatinine [Molar ratio] in Urine;3OH-Dodecanoylcarn/Creat Ur-sRto;;ACTIVE;2.56;2.56 +8181-0;Chromium;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Saliva (oral fluid);Chromium Sal-mCnc;;ACTIVE;1.0h(2);2.42 +81810-4;3-Hydroxydecanoylcarnitine (C10-OH)/creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3-Hydroxydecanoylcarnitine (C10-OH)/Creatinine [Molar ratio] in Urine;3-OH-decanoylcarn/Creat Ur-sRto;;ACTIVE;2.56;2.56 +81811-2;3-Hydroxydecanoylcarnitine (C10-OH);SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in DBS;3-OH-decanoylcarn DBS-sCnc;;ACTIVE;2.56;2.61 +81812-0;TPP1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TPP1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TPP1 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81813-8;F11 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;F11 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;F11 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81814-6;HSD17B4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HSD17B4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HSD17B4 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81815-3;CTNS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CTNS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CTNS Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81816-1;OPA3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;OPA3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;OPA3 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81817-9;MPI gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MPI gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MPI Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81818-7;PMM2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PMM2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PMM2 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81819-5;CLN5 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CLN5 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CLN5 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81820-3;ASS1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ASS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ASS1 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81821-1;RMRP gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;RMRP gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;RMRP Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81822-9;BBS10 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BBS10 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BBS10 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81823-7;SACS gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SACS gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SACS Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81824-5;SLC12A6 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC12A6 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC12A6 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81825-2;MAN2B1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MAN2B1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MAN2B1 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81826-0;HGD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;HGD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;HGD Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81827-8;CNGB3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CNGB3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CNGB3 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +8182-8;Benzoylecgonine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Gastric fluid;BZE Gast-mCnc;;ACTIVE;1.0h(2);2.42 +81828-6;SLC37A4 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC37A4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC37A4 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81829-4;SDHA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SDHA gene full mutation analysis in Blood or Tissue by Sequencing;SDHA Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81830-2;AGL gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;AGL gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;AGL Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81831-0;LAMB3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LAMB3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LAMB3 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81832-8;SLC26A2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SLC26A2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLC26A2 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81833-6;ALDH3A2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;ALDH3A2 gene full mutation analysis in Blood or Tissue by Sequencing;ALDH3A2 Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81834-4;SLC17A5 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SLC17A5 gene full mutation analysis in Blood or Tissue by Sequencing;SLC17A5 Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81835-1;PEX7 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PEX7 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PEX7 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +8183-6;Benzoylecgonine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Benzoylecgonine [Presence] in Gastric fluid;BZE Gast Ql;;ACTIVE;1.0h(2);2.56 +81836-9;CTSK gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CTSK gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CTSK Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81837-7;GRHPR gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GRHPR gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GRHPR Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81838-5;PEX1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PEX1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PEX1 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81839-3;CLN8 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CLN8 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CLN8 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81840-1;POMGNT1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;POMGNT1 gene full mutation analysis in Blood or Tissue by Sequencing;POMGNT1 Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81841-9;MLC1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MLC1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;MLC1 Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81842-7;BCKDHB gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;BCKDHB gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;BCKDHB Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81843-5;GALC gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GALC gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GALC Mut Anl Bld/T;;ACTIVE;2.56;2.65 +8184-4;Benzoylecgonine;PrThr;Pt;Gast fld;Ord;Confirm;DRUG/TOX;1;Benzoylecgonine [Presence] in Gastric fluid by Confirmatory method;BZE Gast Ql Cfm;;ACTIVE;1.0h(2);2.56 +81844-3;IVD gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;IVD gene full mutation analysis in Blood or Tissue by Sequencing;IVD Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81845-0;PALB2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;PALB2 gene full mutation analysis in Blood or Tissue by Sequencing;PALB2 Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81846-8;C9orf72 gene GGGGCC repeat analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.NUCREPEAT;1;C9orf72 gene GGGGCC repeat analysis in Blood or Tissue by Molecular genetics method;C9orf72 GGGGCC repeat analysis Bld/T;;ACTIVE;2.56;2.65 +81847-6;C9orf72 gene GGGGCC repeat analysis;Find;Pt;Amnio fld;Doc;Molgen;MOLPATH.NUCREPEAT;1;C9orf72 gene GGGGCC repeat analysis in Amniotic fluid by Molecular genetics method;C9orf72 GGGGCC repeat analysis Amn;;ACTIVE;2.56;2.65 +81848-4;"t(1;13)(p36.13;q14.1)(PAX7,FOXO1) & t(2;13)(q36.1;q14.4)(PAX3,FOXO1) fusion transcript";Find;Pt;Bone mar;Doc;Molgen;MOLPATH.TRNLOC;1;"t(1;13)(p36.13;q14.1)(PAX7,FOXO1) and t(2;13)(q36.1;q14.4)(PAX3,FOXO1) fusion transcript in Bone marrow by Molecular genetics method";"t(1;13)(p36;q14)+t(2;13)(q36;q14) Mar";;ACTIVE;2.56;2.65 +81849-2;"t(1;13)(p36.13;q14.1)(PAX7,FOXO1) & t(2;13)(q36.1;q14.4)(PAX3,FOXO1) fusion transcript";Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.TRNLOC;1;"t(1;13)(p36.13;q14.1)(PAX7,FOXO1) and t(2;13)(q36.1;q14.4)(PAX3,FOXO1) fusion transcript in Blood or Tissue by Molecular genetics method";"t(1;13)(p36;q14)+t(2;13)(q36;q14) Bld/T";;ACTIVE;2.56;2.65 +818-5;A Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A Ag [Presence] on Red Blood Cells from Blood product unit;A Ag RBC BPU Ql;;ACTIVE;1.0;2.73 +81850-0;Chromosome region 11p15 methylation & deletion+duplication;Find;Pt;Amnio fld;Doc;Molgen;MOLPATH;1;Chromosome region 11p15 methylation and deletion+duplication in Amniotic fluid by Molecular genetics method;Chr 11p15 Methyl + Del+Dup Amn;;ACTIVE;2.56;2.65 +8185-1;Benzoylecgonine;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Benzoylecgonine [Presence] in Gastric fluid by Screen method;BZE Gast Ql Scn;;ACTIVE;1.0h(2);2.56 +81851-8;Chromosome region 11p15 methylation & deletion+duplication;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Chromosome region 11p15 methylation and deletion+duplication in Blood or Tissue by Molecular genetics method;Chr 11p15 Methyl + Del+Dup Bld/T;;ACTIVE;2.56;2.65 +81852-6;Chromosome region 7q11.23 deletion+duplication;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.DELDUP;1;Chromosome region 7q11.23 deletion and duplication mutation analysis in Blood or Tissue by Molecular genetics method;Chr 7q11.23 Del+Dup Bld/T;;ACTIVE;2.56;2.65 +81853-4;Chromosome 15 & 16 & 22 aneuploidy;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Chromosome 15 and 16 and 22 aneuploidy in Blood or Tissue by Molecular genetics method;Chr 15 + 16 + 22 aneu Bld/T;;ACTIVE;2.56;2.65 +81854-2;CYP21A2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CYP21A2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;CYP21A2 Fam Mut Anl Bld/T;;ACTIVE;2.56;2.68 +81855-9;DMPK gene CTG repeat analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.NUCREPEAT;1;DMPK gene CTG repeat analysis in Blood or Tissue by Molecular genetics method;DMPK gene CTG repeat analysis Bld/T;;ACTIVE;2.56;2.65 +81856-7;FMR1 gene CGG repeat analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.NUCREPEAT;1;FMR1 gene CGG repeat analysis in Blood or Tissue by Molecular genetics method;FMR1 CGG repeat analysis Bld/T;;ACTIVE;2.56;2.65 +81857-5;GDAP1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GDAP1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GDAP1 gene Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81858-3;GJB1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GJB1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;GJB1 gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81859-1;GRN gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GRN gene full mutation analysis in Blood or Tissue by Sequencing;GRN Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81860-9;Hypertrophic cardiomyopathy gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;Hypertrophic cardiomyopathy gene targeted mutation analysis in Blood or Tissue by Sequencing;HCM Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81861-7;Karyotype;Find;Pt;Bone mar;Doc;;MOLPATH.MUT;1;Karyotype in Bone marrow;Karyotyp Mar;;ACTIVE;2.56;2.73 +81862-5;Karyotype^post mitogen stimulation;Find;Pt;Bld/Tiss;Doc;;MOLPATH;1;Karyotype in Blood or Tissue --post mitogen stimulation;Karyotyp p mitogen stim Bld/T;;ACTIVE;2.56;2.65 +81863-3;KCNH2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;KCNH2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;KCNH2 Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81864-1;KCNQ1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;KCNQ1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;KCNQ1 gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81865-8;MYBPC3 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MYBPC3 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MYBPC3 Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81866-6;MYH7 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MYH7 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;MYH7 Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81867-4;NOTCH3 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NOTCH3 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;NOTCH3 gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81868-2;PRNP gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PRNP gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;PRNP gene Mut Anl Bld/T;;ACTIVE;2.56;2.65 +8186-9;Benzoylecgonine;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Meconium;BZE Mec-mCnc;;DISCOURAGED;1.0h(2);2.52 +81869-0;PRNP gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PRNP gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;PRNP gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81870-8;PSEN1 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PSEN1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;PSEN1 gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81871-6;PSEN2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;PSEN2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;PSEN2 gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81872-4;SCN5A gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SCN5A gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;SCN5A gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81873-2;Chromosome region Xp22.33 &or Yp11.32 deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.DELDUP;1;Chromosome region Xp22.33 AndOr Yp11.32 deletion and duplication mutation analysis in Blood or Tissue by MLPA;Xp22.33 +or Yp11.32 Del+Dup Bld/T MLPA;;ACTIVE;2.56;2.65 +81874-0;SLC12A3 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SLC12A3 gene full mutation analysis in Blood or Tissue by Sequencing;SLC12A3 Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +81875-7;SPAST gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SPAST gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;SPAST gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81876-5;SPG11 gene deletion+duplication & mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.DELDUP;1;SPG11 gene deletion+duplication and mutation analysis in Blood or Tissue by Molecular genetics method;SPG11 Del+Dup + Mut Anl Bld/T;;ACTIVE;2.56;2.65 +8187-7;Benzoylecgonine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Benzoylecgonine [Presence] in Meconium;BZE Mec Ql;;ACTIVE;1.0h(2);2.73 +81877-3;SPG3A gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SPG3A gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;SPG3A gene Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81878-1;Subtelomere analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;Subtelomere analysis in Blood or Tissue by Molecular genetics method;Subtelomere analysis Bld/T;;ACTIVE;2.56;2.65 +81879-9;"t(11;22)(q24;q12.2)(FLI1,EWSR1) & t(21;22)(q22.3;q12.2)(ERG,EWSR1) fusion transcript";Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.TRNLOC;1;"t(11;22)(q24;q12.2)(FLI1,EWSR1) and t(21;22)(q22.3;q12.2)(ERG,EWSR1) fusion transcript in Blood or Tissue by Molecular genetics method";EWSR1-FLI1 + EWSR1-ERG Bld/T;;ACTIVE;2.56;2.65 +81880-7;TNNT2 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TNNT2 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;TNNT2 Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81881-5;TNNT3 gene mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;TNNT3 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;TNNT3 Fam Mut Anl Bld/T;;ACTIVE;2.56;2.65 +81882-3;TSC2 gene & PKD1 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;MLPA;MOLPATH.MUT;1;TSC2 and PKD1 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA;TSC2+PKD1 Del+Dup Bld/T MLPA;;ACTIVE;2.56;2.65 +81883-1;CNBP gene CCTG repeat analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.NUCREPEAT;1;CNBP gene CCTG repeat analysis in Blood or Tissue by Molecular genetics method;CNBP CCTG repeat analysis Bld/T;;ACTIVE;2.56;2.65 +81884-9;NIPA1 gene & REEP1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;NIPA1 and REEP1 gene full mutation analysis in Blood or Tissue by Sequencing;NIPA1+REEP1 Full Mut Anl Bld/T Seq;;ACTIVE;2.56;2.65 +8188-5;Benzoylecgonine;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Benzoylecgonine [Presence] in Meconium by Confirmatory method;BZE Mec Ql Cfm;;ACTIVE;1.0h(2);2.73 +81885-6;Diagnosis.secondary;Imp;Pt;^Patient;Nom;;CLIN;2;Secondary diagnosis;Dx.secondary;;ACTIVE;2.56;2.73 +81886-4;Sex;Type;Pt;Provider;Nom;;ADMIN.DEMOG;2;Sex of Provider;Sex of Provider;;ACTIVE;2.56;2.56 +81887-2;Race;Type;Pt;Provider;Nom;OMB.1997;ADMIN.DEMOG;2;Provider race OMB.1997;Provider race OMB.1997;;ACTIVE;2.56;2.56 +81888-0;Ethnicity;Type;Pt;Provider;Nom;OMB.1997;ADMIN.DEMOG;2;Provider ethnicity OMB.1997;Provider ethnicity OMB.1997;;ACTIVE;2.56;2.56 +81889-8;Physical therapy entry-level degree;Type;Pt;Provider;Nom;;ADMIN.DEMOG;2;Physical therapy provider entry-level degree;PT Prov entry-level degree;;ACTIVE;2.56;2.66 +81890-6;Physical therapy highest level of education;Type;Pt;Provider;Nom;;ADMIN.DEMOG;2;Physical therapy provider post-professional degree;PT Prov highest educ;;ACTIVE;2.56;2.66 +81891-4;Episode of care diagnosis.secondary;Imp;Pt;^Patient;Nom;;CLIN;2;Episode of care secondary diagnosis;EOC dx.secondary;;ACTIVE;2.56;2.56 +81892-2;Episode of care diagnosis.primary;Imp;Pt;^Patient;Nom;;CLIN;2;Episode of care primary diagnosis;EOC dx.primary;;ACTIVE;2.56;2.56 +8189-3;Benzoylecgonine;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Benzoylecgonine [Presence] in Meconium by Screen method;BZE Mec Ql Scn;;ACTIVE;1.0h(2);2.73 +81893-0;Patient satisfaction with healthcare delivery;Score;Pt;^Patient;Qn;;MISC;1;Patient satisfaction with healthcare delivery [Score];Pt satisfaction w healthcare Score;;ACTIVE;2.56;2.56 +81894-8;Ultrasound attenuation;Pres;Pt;Liver;Qn;US.transient elastography;RAD;2;Liver ultrasound attenuation by transient elastography;US.TE Liver attenuation;;ACTIVE;2.56;2.66 +81895-5;Macronutrient intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Macronutrient intake panel;Macronutr intake Pnl;;ACTIVE;2.56;2.56 +81896-3;Fat intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Fat intake panel;Fat intake Pnl;;ACTIVE;2.56;2.56 +81897-1;Monounsaturated fat intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Monounsaturated fat intake 24 hour Estimated;MUFA intake 24h Est;;ACTIVE;2.56;2.56 +81898-9;Composite triage and nursing note - recommended IHE set;-;Pt;^Patient;-;;PANEL.DOC;2;Composite triage and nursing note - recommended IHE set;CTNN - recommended IHE set;;ACTIVE;2.56;2.56 +81899-7;Monounsaturated fat intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Monounsaturated fat intake 24 hour Measured;MUFA intake 24h Measured;;ACTIVE;2.56;2.56 +81900-3;Omega-3 fatty acid intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Omega-3 fatty acid intake 24 hour Estimated;Omega-3 fatty acid intake 24h Est;;ACTIVE;2.56;2.56 +8190-1;Cocaine;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Serum or Plasma by Confirmatory method;Cocaine SerPl Ql Cfm;;ACTIVE;1.0h(2);2.73 +81901-1;Omega-3 fatty acid intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Omega-3 fatty acid intake 24 hour Measured;Omega-3 fatty acid intake 24h Measured;;ACTIVE;2.56;2.56 +81902-9;Medium chain triglyceride intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Medium chain triglyceride intake 24 hour Estimated;MCT intake 24h Est;;ACTIVE;2.56;2.56 +81903-7;Medium chain triglyceride intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Medium chain triglyceride intake 24 hour Measured;MCT intake 24h Measured;;ACTIVE;2.56;2.56 +81904-5;Protein intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Protein intake panel;Protein intake Pnl;;ACTIVE;2.56;2.56 +81905-2;High biological value protein intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;High biological value protein intake 24 hour Estimated;High bio value protein intake 24h Est;;ACTIVE;2.56;2.58 +81906-0;High biological value protein intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;High biological value protein intake 24 hour Measured;High bio value protein intake 24h Meas;;ACTIVE;2.56;2.58 +81907-8;Send document that conforms to C-CDA R2.0 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to C-CDA R2.0 template;;;ACTIVE;2.56;2.56 +81908-6;Whey intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Whey intake 24 hour Estimated;Whey intake 24h Est;;ACTIVE;2.56;2.56 +81909-4;Whey intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Whey intake 24 hour Measured;Whey intake 24h Measured;;ACTIVE;2.56;2.56 +81910-2;Protein intake/body weight;RelMRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Protein intake/Body weight 24 hour Estimated;Protein intake/BW 24h Est;;ACTIVE;2.56;2.66 +81911-0;Protein intake/body weight;RelMRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Protein intake/Body weight 24 hour Measured;Protein intake/BW 24h Measured;;ACTIVE;2.56;2.66 +81912-8;Amino acid intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Amino acid intake panel;Amino acid intake Pnl;;ACTIVE;2.56;2.56 +81913-6;Amino acid.essential intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Essential amino acid intake panel;Amino acid essential intake Pnl;;ACTIVE;2.56;2.56 +81914-4;Amino acid.essential intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Essential amino acid intake 24 hour Estimated;Amino acid essential intake 24h Est;;ACTIVE;2.56;2.56 +81915-1;Amino acid.essential intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Essential amino acid intake 24 hour Measured;Amino acid essential intake 24h Measured;;ACTIVE;2.56;2.56 +81916-9;Histidine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Histidine intake 24 hour Estimated;Histidine intake 24h Est;;ACTIVE;2.56;2.56 +81917-7;Histidine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Histidine intake 24 hour Measured;Histidine intake 24h Measured;;ACTIVE;2.56;2.56 +81918-5;Methionine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Methionine intake 24 hour Estimated;Methionine intake 24h Est;;ACTIVE;2.56;2.56 +8191-9;Cocaine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Cocaine [Presence] in Serum or Plasma by Screen method;Cocaine SerPl Ql Scn;;ACTIVE;1.0h(2);2.73 +81919-3;Methionine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Methionine intake 24 hour Measured;Methionine intake 24h Measured;;ACTIVE;2.56;2.56 +81920-1;Lysine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Lysine intake 24 hour Estimated;Lysine intake 24h Est;;ACTIVE;2.56;2.56 +81921-9;Lysine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Lysine intake 24 hour Measured;Lysine intake 24h Measured;;ACTIVE;2.56;2.56 +81922-7;Tryptophan intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Tryptophan intake 24 hour Estimated;Tryptophan intake 24h Est;;ACTIVE;2.56;2.56 +81923-5;Tryptophan intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Tryptophan intake 24 hour Measured;Tryptophan intake 24h Measured;;ACTIVE;2.56;2.56 +81924-3;Phenylalanine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Phenylalanine intake 24 hour Estimated;Phe intake 24h Est;;ACTIVE;2.56;2.56 +81925-0;Phenylalanine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Phenylalanine intake 24 hour Measured;Phe intake 24h Measured;;ACTIVE;2.56;2.56 +81926-8;Fiber intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Fiber intake panel;Fiber intake Pnl;;ACTIVE;2.56;2.56 +8192-7;Benzoylecgonine;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Benzoylecgonine [Presence] in Urine by SAMHSA confirm method;BZE Ur Ql SAMHSA Cfm;;ACTIVE;1.0h(2);2.56 +81927-6;Vitamin B1 intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin B1 (Thiamine) intake 24 hour Estimated;Vit B1 intake 24h Est;;ACTIVE;2.56;2.56 +81928-4;Vitamin B1 intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin B1 (Thiamine) intake 24 hour Measured;Vit B1 intake 24h Measured;;ACTIVE;2.56;2.56 +81929-2;Vitamin D intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Vitamin D intake 24 hour Estimated;Vit D intake 24h Est;;ACTIVE;2.56;2.56 +819-3;A Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A Ag [Presence] on Red Blood Cells from Donor;A Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +81930-0;Vitamin D intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Vitamin D intake 24 hour Measured;Vit D intake 24h Measured;;ACTIVE;2.56;2.56 +81931-8;Amino acid.nonessential intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Nonessential amino acid intake panel;Amino acid nonessent intake Pnl;;ACTIVE;2.56;2.56 +81932-6;Amino acid.nonessential intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Nonessential amino acid intake 24 hour Estimated;Amino acid nonessent intake 24h Est;;ACTIVE;2.56;2.56 +81933-4;Amino acid.nonessential intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Nonessential amino acid intake 24 hour Measured;Amino acid nonessent intake 24h Measured;;ACTIVE;2.56;2.56 +81934-2;Homocysteine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Homocysteine intake 24 hour Estimated;Hcys intake 24h Est;;ACTIVE;2.56;2.56 +8193-5;Benzoylecgonine;PrThr;Pt;Urine;Ord;SAMHSA screen;DRUG/TOX;1;Benzoylecgonine [Presence] in Urine by SAMHSA screen method;BZE Ur Ql SAMHSA Scn;;ACTIVE;1.0h(2);2.56 +81935-9;Homocysteine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Homocysteine intake 24 hour Measured;Hcys intake 24h Measured;;ACTIVE;2.56;2.56 +81936-7;Tyramine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Tyramine intake 24 hour Estimated;Tyramine intake 24h Est;;ACTIVE;2.56;2.56 +81937-5;Tyramine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Tyramine intake 24 hour Measured;Tyramine intake 24h Measured;;ACTIVE;2.56;2.56 +81938-3;Tyrosine intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Tyrosine intake 24 hour Estimated;Tyrosine intake 24h Est;;ACTIVE;2.56;2.56 +81939-1;Tyrosine intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Tyrosine intake 24 hour Measured;Tyrosine intake 24h Measured;;ACTIVE;2.56;2.56 +81940-9;Carbohydrate intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Carbohydrate intake panel;Carb intake Pnl;;ACTIVE;2.56;2.56 +81941-7;Micronutrient intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Micronutrient intake panel;Micronutrient intake Pnl;;ACTIVE;2.56;2.56 +81942-5;Vitamin intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Vitamin intake panel;Vitamin intake Pnl;;ACTIVE;2.56;2.56 +8194-3;Cocaine;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Cocaine [Mass/volume] in Unknown substance;Cocaine Usub-mCnc;;ACTIVE;1.0h(2);2.34 +81943-3;Mineral &or trace element intake panel;-;-;^Patient;-;;PANEL.NUTRITION&DIET;2;Mineral AndOr trace element intake panel;Mineral +or trace element intake Pnl;;ACTIVE;2.56;2.56 +81944-1;Boron intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Boron intake 24 hour Estimated;Boron intake 24h Est;;ACTIVE;2.56;2.56 +81945-8;Boron intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Boron intake 24 hour Measured;Boron intake 24h Measured;;ACTIVE;2.56;2.56 +81946-6;Phosphorus intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Phosphorus intake 24 hour Measured;Phosphorus intake 24h Measured;;ACTIVE;2.56;2.56 +81947-4;Sulfate intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Sulfate intake 24 hour Measured;Sulfate intake 24h Measured;;ACTIVE;2.56;2.56 +81948-2;Sulfate intake;MRat;24H;^Patient;Qn;Estimated;NUTRITION&DIETETICS;2;Sulfate intake 24 hour Estimated;Sulfate intake 24h Est;;ACTIVE;2.56;2.56 +81949-0;Multi-trace element supplement intake;Find;24H;^Patient;Ord;;NUTRITION&DIETETICS;2;Multi-trace element supplement intake 24 hour;Multi-trace element intake 24h;;ACTIVE;2.56;2.56 +8195-0;Cocaine;PrThr;Pt;Unk sub;Ord;;DRUG/TOX;1;Cocaine [Presence] in Unknown substance;Cocaine Usub Ql;;ACTIVE;1.0h(2);2.56 +81950-8;Multivitamin &or mineral supplement intake;Find;24H;^Patient;Ord;;NUTRITION&DIETETICS;2;Multivitamin andor mineral supplement intake 24 hour;Multivit +or mineral intake 24h;;ACTIVE;2.56;2.56 +81951-6;Fluid intake;VRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Fluid intake 24 hour Measured;Fluid intake 24h Measured;;ACTIVE;2.56;2.56 +81952-4;Fat intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Fat intake 24 hour Measured;Fat intake 24h Measured;;ACTIVE;2.56;2.56 +81953-2;Carbohydrate intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Carbohydrate intake 24 hour Measured;Carbohydrate intake 24h Measured;;ACTIVE;2.56;2.56 +81954-0;Date of death;Date;Pt;^Patient;Qn;;ADMIN.PATIENT;2;Date of death [Date];Date of death;;ACTIVE;2.56;2.66 +81955-7;Time of death;ClockTime;Pt;^Patient;Qn;;H&P.HX;2;Time of death [ClockTime];Time of death Clock time;;ACTIVE;2.56;2.56 +81956-5;Date and time of death;TmStp;Pt;^Patient;Qn;;ADMIN.PATIENT;2;Date and time of death [TimeStamp];Date+time of death;;ACTIVE;2.56;2.66 +81957-3;Overall Plan of Care &or Advance Care Directives panel;-;Pt;^Patient;-;;PANEL.SURVEY.CARE;4;Overall Plan of Care/Advance Care Directives panel;;;DISCOURAGED;2.56;2.64 +81958-1;National health care surveys report R1 - recommended CDA set;-;Pt;^Patient;-;;PANEL.DOC;2;National Health Care Surveys report R1 - recommended CDA set;NHCS R1 - Rec CDA Set;;ACTIVE;2.56;2.73 +81959-9;Public health laboratory ask at order entry panel;-;-;^Patient;-;;PANEL.MISC;1;Public health laboratory ask at order entry panel;Pub health lab AOE pnl;;ACTIVE;2.56;2.69 +81960-7;Olea europaea native (nOle e) 7 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Olive pollen native (nOle e) 7 IgE Ab RAST class [Presence] in Serum;Olive (nOle e) 7 IgE RAST Ql;;ACTIVE;2.56;2.58 +81961-5;Chamaecyparis obtusa Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Japanese cypress IgE Ab RAST class [Presence] in Serum;Japanese cypress IgE RAST Ql;;ACTIVE;2.56;2.58 +81962-3;Olea europaea recombinant (rOle e) 9 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Olive pollen recombinant (rOle e) 9 IgE Ab RAST class [Presence] in Serum;Olive (rOle e) 9 IgE RAST Ql;;ACTIVE;2.56;2.58 +81963-1;Platanus acerifolia recombinant (rPla a) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;London Plane recombinant (rPla a) 1 IgE Ab RAST class [Presence] in Serum;London Plane (rPla a) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81964-9;Parietaria judaica recombinant (rPar j) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pellitory (Parietaria judaica) recombinant (rPar j) 2 IgE Ab RAST class [Presence] in Serum;Pellitory (rPar j) 2 IgE RAST Ql;;ACTIVE;2.56;2.58 +81965-6;Ambrosia artemisiifolia native (nAmb a) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Common ragweed native (nAmb a) 1 IgE Ab RAST class [Presence] in Serum;Common ragweed (nAmb a) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81966-4;Artemisia vulgaris native (nArt v) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mugwort native (nArt v) 1 IgE Ab RAST class [Presence] in Serum;Mugwort (nArt v) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81967-2;Salsola kali native (nSal k) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Saltwort native (nSal k) 1 IgE Ab RAST class [Presence] in Serum;Saltwort (nSal k) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +8196-8;Cocaine;PrThr;Pt;Unk sub;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Unknown substance by Confirmatory method;Cocaine Usub Ql Cfm;;ACTIVE;1.0h(2);2.73 +81968-0;Artemisia vulgaris native (nArt v) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mugwort native (nArt v) 3 IgE Ab RAST class [Presence] in Serum;Mugwort (nArt v) 3 IgE RAST Ql;;ACTIVE;2.56;2.58 +81969-8;Plantago lanceolata recombinant (rPla l) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;English plantain recombinant (rPla l) 1 IgE Ab RAST class [Presence] in Serum;English plantain (rPla l) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81970-6;Codeine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Codeine IgE Ab RAST class [Presence] in Serum;Codeine IgE RAST Ql;;ACTIVE;2.56;2.58 +81971-4;Pholcodine Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Pholcodine IgE Ab RAST class [Presence] in Serum;Pholcodine IgE RAST Ql;;ACTIVE;2.56;2.58 +81972-2;Dermatophagoides pteronyssinus native (nDer p) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European house dust mite native (nDer p) 1 IgE Ab RAST class [Presence] in Serum;D pteronyss (nDer p) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81973-0;Dermatophagoides pteronyssinus recombinant (rDer p) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European house dust mite recombinant (rDer p) 2 IgE Ab RAST class [Presence] in Serum;D pteronyss (rDer p) 2 IgE RAST Ql;;ACTIVE;2.56;2.58 +81974-8;Dermatophagoides pteronyssinus recombinant (rDer p) 10 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European house dust mite recombinant (rDer p) 10 IgE Ab RAST class [Presence] in Serum;D pteronyss (rDer p) 10 IgE RAST Ql;;ACTIVE;2.56;2.58 +81975-5;Dog recombinant (rCan f) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog recombinant (rCan f) 1 IgE Ab RAST class [Presence] in Serum;Dog (rCan f) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +8197-6;Cocaine;PrThr;Pt;Unk sub;Ord;Screen;DRUG/TOX;1;Cocaine [Presence] in Unknown substance by Screen method;Cocaine Usub Ql Scn;;ACTIVE;1.0h(2);2.73 +81976-3;Dog recombinant (rCan f) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog recombinant (rCan f) 2 IgE Ab RAST class [Presence] in Serum;Dog (rCan f) 2 IgE RAST Ql;;ACTIVE;2.56;2.58 +81977-1;Dog recombinant (rCan f) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog recombinant 5 IgE Ab RAST class [Presence] in Serum;Dog (rCan f) 5 IgE RAST Ql;;ACTIVE;2.56;2.58 +81978-9;Horse recombinant (rEqu c) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Horse recombinant (rEqu c) 1 IgE Ab RAST class [Presence] in Serum;Horse (rEqu c) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81979-7;Cat recombinant (rFel d) 4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cat recombinant (rFel d) 4 IgE Ab RAST class [Presence] in Serum;Cat (rFel d) 4 IgE RAST Ql;;ACTIVE;2.56;2.58 +81980-5;Cat recombinant (rFel d) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cat recombinant (rFel d) 1 IgE Ab RAST class [Presence] in Serum;Cat (rFel d) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81981-3;Conalbumin native (nGal d) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Conalbumin native (nGal d) 3 IgE Ab RAST class [Presence] in Serum;Conalb (nGal d) 3 IgE RAST Ql;;ACTIVE;2.56;2.58 +81982-1;Arachis hypogaea recombinant (rAra h) 8 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut recombinant (rAra h) 8 IgE Ab RAST class [Presence] in Serum;Peanut (rAra h) 8 IgE RAST Ql;;ACTIVE;2.56;2.58 +81983-9;Glycine max recombinant (rGly m) 4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Soybean recombinant (rGly m) 4 IgE Ab RAST class [Presence] in Serum;Soybean (rGly m) 4 IgE RAST Ql;;ACTIVE;2.56;2.58 +8198-4;Copper;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Copper [Mass/mass] in Tissue;Copper Tiss-mCnt;;ACTIVE;1.0h(2);2.73 +81984-7;Bertholletia excelsa recombinant (rBer e) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Brazil Nut recombinant (rBer e) 1 IgE Ab RAST class [Presence] in Serum;Brazil Nut (rBer e) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81985-4;Cyprinus carpio recombinant (rCyp c) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cyprinus carpio recombinant (rCyp c) 1 IgE Ab RAST class [Presence] in Serum;Carp (rCyp c) 1 IgE RAST Ql;;ACTIVE;2.56;2.72 +81986-2;Triticum aestivum recombinant (rTri a) 19 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat recombinant (rTri a) 19 IgE Ab RAST class [Presence] in Serum;Wheat (rTri a) 19 IgE RAST Ql;;ACTIVE;2.56;2.58 +81987-0;Prunus persica recombinant (rPru p) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peach recombinant (rPru p) 1 IgE Ab RAST class [Presence] in Serum;Peach (rPru p) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81988-8;Prunus persica recombinant (rPru p) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peach recombinant (rPru p) 3 IgE Ab RAST class [Presence] in Serum;Peach (rPru p) 3 IgE RAST Ql;;ACTIVE;2.56;2.58 +81989-6;Prunus persica recombinant (rPru p) 4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peach recombinant (rPru p) 4 IgE Ab RAST class [Presence] in Serum;Peach (rPru p) 4 IgE RAST Ql;;ACTIVE;2.56;2.58 +81990-4;Arachis hypogaea recombinant (rAra h) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut recombinant (rAra h) 1 IgE Ab RAST class [Presence] in Serum;Peanut (rAra h) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81991-2;Arachis hypogaea recombinant (rAra h) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut recombinant (rAra h) 2 IgE Ab RAST class [Presence] in Serum;Peanut (rAra h) 2 IgE RAST Ql;;ACTIVE;2.56;2.58 +8199-2;Ethyl benzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Ethyl benzene [Mass/volume] in Blood;Ethyl Benzene Bld-mCnc;;ACTIVE;1.0h(2);2.73 +81992-0;Arachis hypogaea recombinant (rAra h) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut recombinant (rAra h) 3 IgE Ab RAST class [Presence] in Serum;Peanut (rAra h) 3 IgE RAST Ql;;ACTIVE;2.56;2.58 +81993-8;Corylus avellana recombinant (rCor a) 8 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hazelnut recombinant (rCor a) 8 IgE Ab RAST class [Presence] in Serum;Hazelnut (rCor a) 8 IgE RAST Ql;;ACTIVE;2.56;2.58 +81994-6;Arachis hypogaea recombinant (rAra h) 9 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut recombinant (rAra h) 9 IgE Ab RAST class [Presence] in Serum;Peanut (rAra h) 9 IgE RAST Ql;;ACTIVE;2.56;2.58 +81995-3;Corylus avellana recombinant (rCor a) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hazelnut recombinant (rCor a) 1 IgE Ab RAST class [Presence] in Serum;Hazelnut (rCor a) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +81996-1;Actinidia deliciosa recombinant (rAct d) 8 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Kiwi recombinant (rAct d) 8 IgE Ab RAST class [Presence] in Serum;Kiwi (rAct d) 8 IgE RAST Ql;;ACTIVE;2.56;2.58 +81997-9;Glycine max native (nGly m) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Soybean native (nGly m) 5 IgE Ab RAST class [Presence] in Serum;Soybean (nGly m) 5 IgE RAST Ql;;ACTIVE;2.56;2.58 +81998-7;Glycine max native (nGly m) 6 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Soybean native (nGly m) 6 IgE Ab RAST class [Presence] in Serum;Soybean (nGly m) 6 IgE RAST Ql;;ACTIVE;2.56;2.58 +81999-5;Triticum aestivum recombinant (rTri a) 14 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat recombinant (rTri a) 14 IgE Ab RAST class [Presence] in Serum;Wheat (rTri a) 14 IgE RAST Ql;;ACTIVE;2.56;2.58 +82000-1;Malus domestica recombinant (rMal d) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Apple recombinant (rMal d) 1 IgE Ab RAST class [Presence] in Serum;Apple (rMal d) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82001-9;Actinidia deliciosa native (nAct d) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Kiwi native (nAct d) 1 IgE Ab RAST class [Presence] in Serum;Kiwi (nAct d) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82002-7;Corylus avellana native (nCor a) 9 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hazelnut native (nCor a) 9 IgE Ab RAST class [Presence] in Serum;Hazelnut (nCor a) 9 IgE RAST Ql;;ACTIVE;2.56;2.58 +82003-5;Dioscorea batatas Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Yam IgE Ab RAST class in Serum;Yam IgE RAST Ql;;ACTIVE;2.56;2.58 +82004-3;(Allium cepa+Allium sativum+Sesamum indicum+Yeast) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Food Allergen Mix 25A (Onion+Garlic+Sesame seed+Yeast) IgE Ab RAST class [Presence] in Serum;Food Allerg Mix25A IgE RAST Ql;;ACTIVE;2.56;2.58 +82005-0;Cynodon dactylon native (nCyn d) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bermuda grass native (nCyn d) 1 IgE Ab RAST class [Presence] in Serum;Bermuda grass (nCyn d) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82006-8;House dust Bencard Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;House dust Bencard IgE Ab RAST class [Presence] in Serum;House Dust Bencard IgE RAST Ql;;ACTIVE;2.56;2.58 +82007-6;Polistes spp recombinant (rPol d) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Paper wasp recombinant (rPol d) 5 IgE Ab RAST class [Presence] in Serum;Paper wasp (rPol d) 5 IgE RAST Ql;;ACTIVE;2.56;2.58 +8200-8;Gadolinium;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Gadolinium [Mass/volume] in Urine;Gadolinium Ur-mCnc;;ACTIVE;1.0h(2);2.42 +82008-4;Polistes dominulus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;European paper wasp IgE Ab RAST class [Presence] in Serum;European paper wasp IgE RAST Ql;;ACTIVE;2.56;2.58 +82009-2;Apis mellifera phospholipase A2 native (nApi m) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee phospholipase A2 native (nApi m) 1 IgE Ab RAST class [Presence] in Serum;PLA2 nApi m 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +820-1;A Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A Ag [Presence] on Red Blood Cells;A Ag RBC Ql;;ACTIVE;1.0;2.56 +82010-0;Latex recombinant (rHev b) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 1 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82011-8;Latex recombinant (rHev b) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 3 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 3 IgE RAST Ql;;ACTIVE;2.56;2.58 +82012-6;Latex recombinant (rHev b) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 5 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 5 IgE RAST Ql;;ACTIVE;2.56;2.58 +82013-4;Latex recombinant (rHev b) 6.01 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 6.01 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 6.01 IgE RAST Ql;;ACTIVE;2.56;2.58 +82014-2;Latex recombinant (rHev b) 6.02 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 6.02 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 6.02 IgE RAST Ql;;ACTIVE;2.56;2.58 +82015-9;Latex recombinant (rHev b) 8 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 8 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 8 IgE RAST Ql;;ACTIVE;2.56;2.58 +8201-6;Gadolinium;MRat;24H;Urine;Qn;;DRUG/TOX;1;Gadolinium [Mass/time] in 24 hour Urine;Gadolinium 24h Ur-mRate;;ACTIVE;1.0h(2);2.42 +82016-7;Latex recombinant (rHev b) 9 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 9 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 9 IgE RAST Ql;;ACTIVE;2.56;2.58 +82017-5;Latex recombinant (rHev b) 11 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 11 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 11 IgE RAST Ql;;ACTIVE;2.56;2.58 +82018-3;Lipolase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Lipolase IgE Ab RAST class [Presence] in Serum;Lipolase IgE RAST Ql;;ACTIVE;2.56;2.58 +82019-1;Termamyl Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Termamyl IgE Ab RAST class [Presence] in Serum;Termamyl IgE RAST Ql;;ACTIVE;2.56;2.58 +82020-9;Aspergillus flavus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus flavus IgE Ab RAST class [Presence] in Serum;A flavus IgE RAST Ql;;ACTIVE;2.56;2.58 +82021-7;Alternaria alternata recombinant (rAlt a) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alternaria alternata recombinant (rAlt a) 1 IgE Ab RAST class [Presence] in Serum;A alternata (rAlt a) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82022-5;Galactose-alpha-1,3-galactose Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Galactose-alpha-1,3-galactose (Alpha-Gal) IgE Ab RAST class [Presence] in Serum;Alpha-Gal IgE RAST Ql;;ACTIVE;2.56;2.58 +82023-3;Phadiatop Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Phadiatop IgE Ab RAST class [Presence] in Serum;Phadiotop IgE RAST Ql;;ACTIVE;2.56;2.58 +8202-4;Lead;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Lead [Mass/mass] in Nail;Lead Nail-mCnt;;ACTIVE;1.0h(2);2.73 +82024-1;Phadiatop Infant Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Phadiatop infant IgE Ab RAST class [Presence] in Serum;Phadiatop infant IgE RAST Ql;;ACTIVE;2.56;2.58 +82025-8;Epinephelus lanceolatus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Giant grouper IgE Ab RAST class [Presence] in Serum;Giant grouper IgE RAST Ql;;ACTIVE;2.56;2.58 +82026-6;Bromelin MUXF3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Bromelin MUXF3 IgE Ab RAST class [Presence] in Serum;Bromelin MUXF3 IgE RAST Ql;;ACTIVE;2.56;2.58 +82027-4;Ulmus crassifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cedar elm IgE Ab RAST class [Presence] in Serum;Cedar elm IgE RAST Ql;;ACTIVE;2.56;2.58 +82028-2;Elaeagnus angustifolia Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Russian olive IgE Ab RAST class [Presence] in Serum;Russian olive IgE RAST Ql;;ACTIVE;2.56;2.73 +82029-0;Olea europaea native (nOle e) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Olive pollen native (nOle e) 1 IgE Ab RAST class [Presence] in Serum;Olive (nOle e) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82030-8;Cupressus arizonica native (nCup a) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Arizona Cypress native (nCup a) 1 IgE Ab RAST class [Presence] in Serum;Arizona Cypress (nCup a) 1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82031-6;(Acer negundo+Quercus alba+Ulmus americana+Populus deltoides+Carya illinoinensis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 2 (Boxelder+White oak+White elm+Cottonwood+Pecan/Hickory) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix2 IgE Qn;;ACTIVE;2.56;2.73 +8203-2;Manganese;MRat;24H;Urine;Qn;;DRUG/TOX;1;Manganese [Mass/time] in 24 hour Urine;Manganese 24h Ur-mRate;;ACTIVE;1.0h(2);2.73 +82032-4;(Juniperus sabinoides+Quercus alba+Ulmus americana+Populus deltoides+Prosopis juliflora) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 3 (Mountain juniper+White oak+White elm+Cottonwood+Mesquite) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix3 IgE Qn;;ACTIVE;2.56;2.73 +82033-2;(Alnus incana+Corylus avellana+Ulmus americana+Salix caprea+Populus deltoides) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 5 (Grey alder+Hazelnut+White elm+Willow+Cottonwood) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix5 IgE RAST Ql;;ACTIVE;2.56;2.58 +82034-0;(Acer negundo+Betula verrucosa+Fagus grandifolia+Quercus alba+Juglans californica) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 6 (Boxelder+Silver birch+American beech+White oak+California walnut) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix6 IgE RAST Ql;;ACTIVE;2.56;2.58 +82035-7;(Acer negundo+Betula verrucosa+Fagus grandifolia+Quercus alba+Juglans californica) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 6 (Boxelder+Silver birch+American beech+White oak+California walnut) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix6 IgE Qn;;ACTIVE;2.56;2.56 +82036-5;(Olea europaea+Salix caprea+Pinus strobus+Eucalyptus spp+Acacia longifolia+Melaleuca leucadendron) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 7 (Olive+Willow+Eastern white pine+Eucalyptus spp+Wattle+Cajeput) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix7 IgE RAST Ql;;ACTIVE;2.56;2.58 +82037-3;(Acer negundo+Betula verrucosa+Corylus avellana+Quercus alba+Platanus acerifolia) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 8 (Boxelder+Silver birch+Hazelnut+White oak+London plane or Maple leaf sycamore) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix8 IgE RAST Ql;;ACTIVE;2.56;2.58 +82038-1;(Alnus incana+Betula verrucosa+Corylus avellana+Quercus alba+Salix caprea) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 9 (Grey alder+Silver birch+Hazelnut+White oak+Willow) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix 9 IgE RAST Ql;;ACTIVE;2.56;2.58 +82039-9;(Ambrosia elatior+Ambrosia psilostachya+Ambrosia trifida) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 209 (Common ragweed+Western ragweed+Giant ragweed) IgE Ab RAST class [Presence] in Serum by Multidisk;Weed Allerg Mix209 IgE RAST Ql;;ACTIVE;2.56;2.58 +8204-0;Mercury;MCnt;Pt;Nail;Qn;;DRUG/TOX;1;Mercury [Mass/mass] in Nail;Mercury Nail-mCnt;;ACTIVE;1.0h(2);2.73 +82040-7;(Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Solidago virgaurea+Urtica dioica) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 3 (Mugwort+Goosefoot or Lambs quarters+English plantain+Goldenrod+Nettle) IgE Ab RAST class [Presence] in Serum by Multidisk;Weed Allerg Mix3 IgE RAST Ql;;ACTIVE;2.56;2.58 +82041-5;(Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Solidago virgaurea+Urtica dioica) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 3 (Mugwort+Goosefoot or Lambs quarters+English plantain+Goldenrod+Nettle) IgE Ab [Units/volume] in Serum by Multidisk;Weed Allerg Mix3 IgE Qn;;ACTIVE;2.56;2.56 +82042-3;(Ambrosia elatior+Artemisia vulgaris+Chrysanthemum leucathemum+Taraxacum vulgare+Solidago virgaurea) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 5 (Common ragweed+Mugwort+Ox-eye daisy+Dandelion+Goldenrod) IgE Ab RAST class [Presence] in Serum by Multidisk;Weed Allerg Mix5 IgE RAST Ql;;ACTIVE;2.56;2.58 +82043-1;(Plantago lanceolata+Chenopodium album+Salsola kali+Rumex acetosella) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 6 (English plantain+Goosefoot or Lambs quarters+Saltwort+Sheep sorrel) IgE Ab RAST class [Presence] in Serum by Multidisk;Weed Allerg Mix6 IgE RAST Ql;;ACTIVE;2.56;2.58 +82044-9;(Chrysanthemum leucanthemum+Taraxacum vulgare+Plantago lanceolata+Chenopodium album+Solidago virgaurea) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Weed Allergen Mix 7 (Ox-eye daisy+Dandelion+English plantain+Goosefoot or Lambs quarters+Goldenrod) IgE Ab RAST class [Presence] in Serum by Multidisk;Weed Allerg Mix7 IgE RAST Ql;;ACTIVE;2.56;2.58 +82045-6;(Chrysanthemum leucanthemum+Taraxacum vulgare+Plantago lanceolata+Chenopodium album+Solidago virgaurea) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Weed Allergen Mix 7 (Ox-eye daisy+Dandelion+English plantain+Goosefoot or Lambs quarters+Goldenrod) IgE Ab [Units/volume] in Serum by Multidisk;Weed Allerg Mix7 IgE Qn;;ACTIVE;2.56;2.56 +82046-4;(Cat dander+Dog dander+Guinea pig epithelium+Mouse+Rat) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 2 (Cat dander+Dog dander+Guinea pig epithelium+Mouse+Rat) IgE Ab RAST class [Presence] in Serum by Multidisk;Epid Allerg Mix2 IgE RAST Ql;;ACTIVE;2.56;2.58 +82047-2;(Cat dander+Dog dander+Guinea pig epithelium+Mouse+Rat) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Epidermal Allergen Mix 2 (Cat dander+Dog dander+Guinea pig epithelium+Mouse+Rat) IgE Ab [Units/volume] in Serum by Multidisk;Epid Allerg Mix2 IgE Qn;;ACTIVE;2.56;2.56 +82048-0;(Guinea pig epithelium+Hamster epithelium+Mouse+Rabbit epithelium+Rat) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 70 (Guinea pig epithelium+Hamster epithelium+Mouse+Rabbit epithelium+Rat) IgE Ab RAST class [Presence] in Serum by Multidisk;Epidermal Mix 70 IgE RAST Ql;;ACTIVE;2.56;2.58 +82049-8;(Budgerigar feather+Canary feather+Finch feather+Parakeet feather+Parrot feather) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Epidermal Allergen Mix 72 (Budgerigar feather+Canary feather+Finch feather+Parakeet feather+Parrot feather) IgE Ab RAST class [Presence] in Serum by Multidisk;Epid Allerg Mix72 IgE RAST Ql;;ACTIVE;2.56;2.58 +82050-6;(Arachis hypogaea+Bertholletia excelsa+Cocos nucifera+Corylus avellana+Prunus dulcis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 1 (Peanut+Brazil nut+Coconut+Hazelnut+Almond) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82051-4;(Beef+Chicken meat+Egg yolk+Pork+Turkey meat) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 10 (Beef+Chicken meat+Egg yolk+Pork+Turkey meat) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix10 IgE RAST Ql;;ACTIVE;2.56;2.58 +82052-2;(Beef+Chicken meat+Egg yolk+Pork+Turkey meat) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 10 (Beef+Chicken meat+Egg yolk+Pork+Turkey meat) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix10 IgE Qn;;ACTIVE;2.56;2.56 +82053-0;(Agaricus hortensis+Cucurbita pepo+Oryza sativa+Secale cereale+Solanum tuberosum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 12 (Mushroom+Pumpkin+Rice+Rye+Potato) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix12 IgE RAST Ql;;ACTIVE;2.56;2.58 +82054-8;(Agaricus hortensis+Cucurbita pepo+Oryza sativa+Secale cereale+Solanum tuberosum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 12 (Mushroom+Pumpkin+Rice+Rye+Potato) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix12 IgE Qn;;ACTIVE;2.56;2.56 +82055-5;(Daucus carota+Phaseolus vulgaris+Pisum sativum+Solanum tuberosum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 13 (Carrot+White bean+Peas+Potato) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix13 IgE RAST Ql;;ACTIVE;2.56;2.58 +82056-3;(Brassica oleracea var capitata+Capsicum annuum+Lycopersicon lycopersicum+Spinacia oleracea) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 14 (Cabbage+Paprika+Tomato+Spinach) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix14 IgE RAST Ql;;ACTIVE;2.56;2.58 +8205-7;Mercury;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Mercury [Mass/mass] in Tissue;Mercury Tiss-mCnt;;ACTIVE;1.0h(2);2.4 +82057-1;(Citrus sinensis+Malus sylvestris+Musa spp+Prunus persica) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 15 (Orange+Apple+Banana+Peach) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix15 IgE RAST Ql;;ACTIVE;2.56;2.58 +82058-9;(Ananas comosus+ Citrus limon+ Fragaria vesca+ Pyrus communis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 16 (Pineapple+Lemon+Strawberry+Pear) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix16 IgE RAST Ql;;ACTIVE;2.56;2.58 +82059-7;(Ananas comosus+ Citrus limon+ Fragaria vesca+ Pyrus communis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 16 (Pineapple+Lemon+Strawberry+Pear) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix16 IgE Qn;;ACTIVE;2.56;2.56 +82060-5;(Arachis hypogaea+Glycine max+Pisum sativum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 18 (Peanut+Soybean+Peas) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix18 IgE RAST Ql;;ACTIVE;2.56;2.58 +82061-3;(Cucumis sativus+Daucus carota+Solanum tuberosum+Spinacia oleracea) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 19 (Cucumber+Carrot+Potato+Spinach) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix19 IgE RAST Ql;;ACTIVE;2.56;2.58 +82062-1;(Beef+Chicken meat+Pork+Turkey meat) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 23 (Beef+Chicken meat+Pork+Turkey meat) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix23 IgE RAST Ql;;ACTIVE;2.56;2.58 +82063-9;(Actinidia chinensis+Corylus avellana+Musa spp+Pandalus borealis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 24 (Kiwi+Hazelnut+Banana+Shrimp) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix24 IgE RAST Ql;;ACTIVE;2.56;2.58 +82064-7;(Arachis hypogaea+Cow milk+Egg white+Mustard) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 26 (Peanut+Cow milk+Egg white+Mustard) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix26 IgE RAST Ql;;ACTIVE;2.56;2.58 +8206-5;Molybdenum;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Molybdenum [Mass/volume] in Blood;Deprecated Molybdenum Bld-mCnc;;DEPRECATED;1.0h(2);2.36 +82065-4;(Corylus avellana+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 27 (Hazelnut+Codfish+Soybean+Wheat) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix27 IgE RAST Ql;;ACTIVE;2.56;2.58 +82066-2;(Actinidia chinensis+Beef+Pandalus borealis+Sesamum indicum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 28 (Kiwi+Beef+Shrimp+Sesame seed) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix28 IgE RAST Ql;;ACTIVE;2.56;2.58 +82067-0;(Citrus sinensis+Citrus limon+Citrus paradisi+Citrus reticulata) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Citrus Allergen Mix (Orange+Lemon+Grapefruit+Clementine) IgE Ab RAST class [Presence] in Serum by Multidisk;Citrus mix IgE RAST Ql;;ACTIVE;2.56;2.58 +82068-8;(Citrus sinensis+Citrus limon+Citrus paradisi+Citrus reticulata) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Citrus Allergen Mix (Orange+Lemon+Grapefruit+Clementine) IgE Ab [Units/volume] in Serum by Multidisk;Citrus mix IgE Qn;;ACTIVE;2.56;2.56 +82069-6;(Avena sativa+Fagopyrum esculentum+Sesamum indicum+Triticum aestivum+Zea mays) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 3 (Oat+Buckwheat+Sesame seed+Wheat+Corn) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix3 IgE RAST Ql;;ACTIVE;2.56;2.58 +82070-4;(Allium cepa+Allium sativum+Apium graveolens+Lycopersicon lycopersicum+Yeast) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 7 (Onion+Garlic+Celery+Tomato+Yeast) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix7 IgE RAST Ql;;ACTIVE;2.56;2.58 +82071-2;(Artemisia dracunculus+Levisticum officinale+Origanum majorana+Thymus vulgaris) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 70 (Tarragon+Lovage+Marjoram+Thyme) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix70 IgE RAST Ql;;ACTIVE;2.56;2.58 +82072-0;(Carum carvi+Elettaria cardamomum+Mace+Syzygium aromaticum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 71 (Caraway+Cardamon+Mace+Clove) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix71 IgE RAST Ql;;ACTIVE;2.56;2.58 +8207-3;Nickel;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Nickel [Mass/volume] in Saliva (oral fluid);Nickel Sal-mCnc;;ACTIVE;1.0h(2);2.42 +82073-8;(Foeniculum vulgare seed+Ocimum basilicum+Pimpinella anisum+Zingiber officinale) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 72 (Fennel seed+Basil+Anise+Ginger) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix72 IgE RAST Ql;;ACTIVE;2.56;2.58 +82074-6;(Foeniculum vulgare seed+Ocimum basilicum+Pimpinella anisum+Zingiber officinale) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 72 (Fennel seed+Basil+Anise+Ginger) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix72 IgE Qn;;ACTIVE;2.56;2.56 +82075-3;(Beef+Chicken+Pork) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix fx73 (Beef+Chicken+Pork) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allergen Mix fx73 IgE RAST Ql;;ACTIVE;2.56;2.66 +82076-1;(Clupea harengus+Gadus morhua+Pleuronectes platessa+Scomber scombrus) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 74 (Herring+Cod+Plaice+Mackerel) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix74 IgE RAST Ql;;ACTIVE;2.56;2.58 +82077-9;(Bertholletia excelsa+Citrus sinensis+Corylus avellana+Malus sylvestris+Theobroma cacao) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 8 (Brazil nut+Orange+Hazelnut+Apple+Cocoa) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix8 IgE RAST Ql;;ACTIVE;2.56;2.58 +82078-7;(Bertholletia excelsa+Citrus sinensis+Corylus avellana+Malus sylvestris+Theobroma cacao) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 8 (Brazil nut+Orange+Hazelnut+Apple+Cocoa) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix8 IgE Qn;;ACTIVE;2.56;2.56 +82079-5;(Actinidia chinensis+Cucumis melo+Musa spp+Prunus dulcis+Vitis vinifera) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 9 (Kiwi+Melon+Banana+Almond+Grape) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix9 IgE RAST Ql;;ACTIVE;2.56;2.58 +82080-3;(Actinidia chinensis+Cucumis melo+Musa spp+Prunus dulcis+Vitis vinifera) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 9 (Kiwi+Melon+Banana+Almond+Grape) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix9 IgE Qn;;ACTIVE;2.56;2.56 +8208-1;Nickel;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Nickel [Mass/volume] in Serum or Plasma;Deprecated Nickel Ser-mCnc;;DEPRECATED;1.0h(2);2.36 +82081-1;(Anthoxanthum odoratum+Lolium perenne+Phleum pratense+Secale cereale+Holcus lanatus) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 3 (Sweet vernal grass+Perennial rye grass+Timothy+Rye+Velvet grass) IgE Ab RAST class [Presence] in Serum by Multidisk;Grass Allerg Mix3 IgE RAST Ql;;ACTIVE;2.56;2.58 +82082-9;(Anthoxanthum odoratum+Holcus lanatus+Lolium perenne+Phragmites communis+Secale cereale) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 4 (Sweet vernal grass+Velvet grass+Perennial rye grass+Common reed+Rye) IgE Ab RAST class [Presence] in Serum by Multidisk;Grass Allerg Mix4 IgE RAST Ql;;ACTIVE;2.56;2.58 +82083-7;(Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Setomelanomma rostrata+Penicillium notatum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 2 (Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Setomelanomma rostrata+Penicillium notatum) IgE Ab RAST class [Presence] in Serum by Multidisk;Mold Allerg Mix2 IgE RAST Ql;;ACTIVE;2.56;2.58 +82084-5;(Aspergillus fumigatus+Aspergillus niger+Aspergillus terreus+Aspergillus flavus) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Mold Allergen Mix 4 (Aspergillus fumigatus+Aspergillus niger+Aspergillus terreus+Aspergillus flavus) IgE Ab RAST class [Presence] in Serum by Multidisk;Mold Allerg Mix4 IgE RAST Ql;;ACTIVE;2.56;2.58 +82085-2;(Aspergillus fumigatus+Aspergillus niger+Aspergillus terreus+Aspergillus flavus) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Mold Allergen Mix 4 (Aspergillus fumigatus+Aspergillus niger+Aspergillus terreus+Aspergillus flavus) IgE Ab [Units/volume] in Serum by Multidisk;Mold Allerg Mix4 IgE Qn;;ACTIVE;2.56;2.56 +82086-0;(Chicken feather+Cow dander+Goose feather+Horse dander) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 1 (Chicken feather+Cow dander+Goose feather+Horse dander) IgE Ab RAST class [Presence] in Serum by Multidisk;Occup Allerg Mix1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82087-8;(Acarus siro+Lepidoglyphus destructor+Gasterophilus intestinalis+Sitophilus granarius) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 2 (Acarus siro+Lepidoglyphus destructor+Horse bot fly+Grain weevel) IgE Ab RAST class [Presence] in Serum by Multidisk;Occup Allerg Mix2 IgE RAST Ql;;ACTIVE;2.56;2.58 +82088-6;(Acarus siro+Lepidoglyphus destructor+Gasterophilus intestinalis+Sitophilus granarius) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Occupational Allergen Mix 2 (Acarus siro+Lepidoglyphus destructor+Horse bot fly+Grain weevel) IgE Ab [Units/volume] in Serum by Multidisk;Occup Allerg Mix2 IgE Qn;;ACTIVE;2.56;2.56 +82089-4;(Alternaria alternata+Aspergillus fumigatus+Rye pollen+Wheat pollen) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 3 (Alternaria alternata+Aspergillus fumigatus+rye pollen+wheat pollen) IgE Ab RAST class [Presence] in Serum by Multidisk;Occup Allerg Mix3 IgE RAST Ql;;ACTIVE;2.56;2.58 +82090-2;(Alternaria alternata+Aspergillus fumigatus+Rye pollen+Wheat pollen) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Occupational Allergen Mix 3 (Alternaria alternata+Aspergillus fumigatus+rye pollen+wheat pollen) IgE Ab [Units/volume] in Serum by Multidisk;Occup Allerg Mix3 IgE Qn;;ACTIVE;2.56;2.56 +82091-0;(Amylase+Glycine max+Sitophilus granarius+Triticum sativum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 4 (Amylase+Soybean+Grain weevel+Wheat) IgE Ab RAST class [Presence] in Serum by Multidisk;Occup Allerg Mix4 IgE RAST Ql;;ACTIVE;2.56;2.58 +82092-8;(Amylase+Glycine max+Sitophilus granarius+Triticum sativum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Occupational Allergen Mix 4 (Amylase+Soybean+Grain weevel+Wheat) IgE Ab [Units/volume] in Serum by Multidisk;Occup Allerg Mix4 IgE Qn;;ACTIVE;2.56;2.56 +82093-6;(Hexamethylene diisocyanate (HDI)+Diphenylmethane diisocyanate (MDI)+Toluene diisocyanate (TDI)+Phthalic anhydride) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 5 (Isocyanate HDI+MDI+TDI+Phthalic anhydride) IgE Ab RAST class [Presence] in Serum by Multidisk;Occup Allerg Mix5 IgE RAST Ql;;ACTIVE;2.56;2.58 +82094-4;(Chloramin T+Ethylene oxide+Formaldehyde+Phthalic anhydride) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Occupational Allergen Mix 6 (Chloramin T+Ethylene oxide+Formaldehyde+Phthalic anhydride) IgE Ab RAST class [Presence] in Serum by Multidisk;Occup Allerg Mix6 IgE RAST Ql;;ACTIVE;2.56;2.58 +82095-1;(Brassica oleracea var italica+Daucus carota+Phaseolus vulgaris+Pisum sativum+Zea mays) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 11 (Broccoli+Carrot+White bean+Peas+Corn) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix11 IgE RAST Ql;;ACTIVE;2.56;2.58 +82096-9;(Malus sylvestris+Musa spp+Prunus persica+Pyrus communis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 17 (Apple+Banana+Pear+Peach) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix17 IgE RAST Ql;;ACTIVE;2.56;2.58 +82097-7;(Actinidia chinensis+Ananas comosus+Cucumis melo+Musa spp+Prunus persica) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 21 (Kiwi+Pineapple+Melon+Banana+Peach) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix21 IgE RAST Ql;;ACTIVE;2.56;2.58 +82098-5;(Actinidia chinensis+Ananas comosus+Cucumis melo+Musa spp+Prunus persica) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 21 (Kiwi+Pineapple+Melon+Banana+Peach) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix21 IgE Qn;;ACTIVE;2.56;2.56 +8209-9;Opiates;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Opiates [Mass/volume] in Gastric fluid;Opiates Gast-mCnc;;ACTIVE;1.0h(2);2.34 +82099-3;(Anacardium occidentale+Carya illinoinensis+Juglans spp+Pistacia vera) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 22 (Cashew+Pecan or Hickory nut+Walnut+Pistachio) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix22 IgE RAST Ql;;ACTIVE;2.56;2.58 +82100-9;(Bromus inermis+Cynodon dactylon+Holcus lanatus+Lolium perenne+Paspalum notatum+Sorghum halepense) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 6 (Brome+Bermuda grass+Velvet grass+Perennial rye grass+Bahia grass+Johnson grass) IgE Ab RAST class [Presence] in Serum by Multidisk;Grass Allerg Mix 6 IgE RAST Ql;;ACTIVE;2.56;2.58 +82101-7;(Bromus inermis+Cynodon dactylon+Holcus lanatus+Lolium perenne+Paspalum notatum+Sorghum halepense) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 6 (Brome+Bermuda grass+Velvet grass+Perennial rye grass+Bahia grass+Johnson grass) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allerg Mix 6 IgE Qn;;ACTIVE;2.56;2.56 +82102-5;(Artemisia vulgaris+Betula verrucosa+Parietaria judaica+phleum pratense+Plantago lanceolata) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 1 (Mugwort+Silver birch+Pellitory+Timothy+English plantain) IgE Ab RAST class [Presence] in Serum by Multidisk;Region Allerg Mix1 IgE RAST Ql;;ACTIVE;2.56;2.58 +82103-3;(Artemisia vulgaris+Betula verrucosa+Parietaria judaica+phleum pratense+Plantago lanceolata) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Regional Allergen Mix 1 (Mugwort+Silver birch+Pellitory+Timothy+English plantain) IgE Ab [Units/volume] in Serum by Multidisk;Region Allerg Mix1 IgE Qn;;ACTIVE;2.56;2.56 +82104-1;(Alternaria alternata+Cat dander+Dermatophagoides farinae+Dog dander+Horse dander) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 2 (Alternaria alternata+Cat dander+American house dust mite+Dog dander+Horse dander) IgE Ab RAST class [Presence] in Serum by Multidisk;Region Allerg Mix2 IgE RAST Ql;;ACTIVE;2.56;2.58 +82105-8;(Alternaria alternata+Cat dander+Dermatophagoides farinae+Dog dander+Horse dander) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Regional Allergen Mix 2 (Alternaria alternata+Cat dander+American house dust mite+Dog dander+Horse dander) IgE Ab [Units/volume] in Serum by Multidisk;Region Allerg Mix2 IgE Qn;;ACTIVE;2.56;2.56 +82106-6;(Ambrosia elatior+Chenopodium album+Cynodon dactylon+Lolium perenne+Plantago lanceolata+Paspalum notatum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 3 (Common Ragweed+Goosefoot+Bermuda grass+Perennial rye grass+English Plantain+Bahia grass) IgE Ab RAST class [Presence] in Serum by Multidisk;Region Allerg Mix3 IgE RAST Ql;;ACTIVE;2.56;2.58 +8210-7;Opiates;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Opiates [Presence] in Gastric fluid;Opiates Gast Ql;;ACTIVE;1.0h(2);2.56 +82107-4;(Ambrosia elatior+Chenopodium album+Cynodon dactylon+Lolium perenne+Plantago lanceolata+Paspalum notatum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Regional Allergen Mix 3 (Common Ragweed+Goosefoot+Bermuda grass+Perennial rye grass+English Plantain+Bahia grass) IgE Ab [Units/volume] in Serum by Multidisk;Region Allerg Mix3 IgE Qn;;ACTIVE;2.56;2.56 +82108-2;(Cynodon dactylon+Lolium perenne+Bromus inermis+Ambrosia elatior+Artemisia vulgaris+Plantago lanceolata) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergen Mix 4 (Bermuda grass+Perennial rye grass+Brome+Common ragweed+Mugwort+English plantain) IgE Ab RAST class [Presence] in Serum by Multidisk;Region Allerg Mix4 IgE RAST Ql;;ACTIVE;2.56;2.58 +82109-0;(Cynodon dactylon+Lolium perenne+Bromus inermis+Ambrosia elatior+Artemisia vulgaris+Plantago lanceolata) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Regional Allergen Mix 4 (Bermuda grass+Perennial rye grass+Brome+Common ragweed+Mugwort+English plantain) IgE Ab [Units/volume] in Serum by Multidisk;Region Allerg Mix4 IgE Qn;;ACTIVE;2.56;2.56 +82110-8;(Alnus incana+Betula verrucosa+Corylus avellana+Fraxinus americana) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Tree Allergen Mix 10 (Grey alder+Silver birch+Hazelnut+White ash) IgE Ab RAST class [Presence] in Serum by Multidisk;Tree Allerg Mix10 IgE RAST Ql;;ACTIVE;2.56;2.58 +82111-6;(Alnus incana+Betula verrucosa+Corylus avellana+Fraxinus americana) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Tree Allergen Mix 10 (Grey alder+Silver birch+Hazelnut+White ash) IgE Ab [Units/volume] in Serum by Multidisk;Tree Allerg Mix10 IgE Qn;;ACTIVE;2.56;2.56 +82112-4;(Aspergillus fumigatus+Blatella germanica+Cat dander+Dermatophagoides pteronyssinus) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Regional Allergy Mix 5 (Aspergillus fumigatus+Cockroach+Cat dander+European house dust mite) IgE Ab RAST class [Presence] in Serum by Multidisk;Region Allerg Mix5 IgE RAST Ql;;ACTIVE;2.56;2.58 +82113-2;(Dermatophagoides pteronyssinus+Cat dander+Cat epithelium+Horse dander+Dog dander+Rabbit epithelium) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Inhalant Allergen Mix 7 (Dermatophagoides pteronyssinus+Cat dander+Cat epithelium+Horse dander+Dog dander+Rabbit epithelium) IgE Ab RAST class [Presence] in Serum;Inhalant Allerg Mix 7 IgE RAST Ql;;ACTIVE;2.56;2.58 +82114-0;(Dermatophagoides pteronyssinus+Cat dander+Cat epithelium+Horse dander+Dog dander+Rabbit epithelium) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Inhalant Allergen Mix 7 (Dermatophagoides pteronyssinus+Cat dander+Cat epithelium+Horse dander+Dog dander+Rabbit epithelium) IgE Ab [Units/volume] in Serum;Inhalant Allerg Mix 7 IgE Qn;;ACTIVE;2.56;2.56 +8211-5;Opiates;PrThr;Pt;Gast fld;Ord;Confirm;DRUG/TOX;1;Opiates [Presence] in Gastric fluid by Confirmatory method;Opiates Gast Ql Cfm;;ACTIVE;1.0h(2);2.56 +82115-7;dbSNP version;ID;Pt;^Patient;Nom;;MOLPATH;1;dbSNP version [ID];dbSNP version;;TRIAL;2.56;2.58 +82116-5;Medication usage suggestion;Type;Pt;^Patient;Nom;;MOLPATH.PHARMG;1;Medication usage suggestion [Type];Med usage sugg;;TRIAL;2.56;2.56 +82117-3;Medication usage implications panel;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Medication usage implications panel;Med usage impl pnl;;TRIAL;2.56;2.63 +82118-1;Pharmacogenomics result panel;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Pharmacogenomics result panel;Pharmg result pnl;;TRIAL;2.56;2.73 +82119-9;COSMIC structural variant;ID;Pt;^Patient;Nom;;MOLPATH;1;COSMIC structural variant [Identifier];COSMIC struct var ID;;TRIAL;2.56;2.56 +82120-7;Allelic phase;Type;Pt;^Patient;Nom;;MOLPATH;1;Allelic phase;Allelic phase;;TRIAL;2.56;2.58 +82121-5;Allelic read depth;Num;Pt;^Patient;Qn;;MOLPATH;1;Allelic read depth;Allelic read depth;;TRIAL;2.56;2.58 +82122-3;Variant coding system;ID;Pt;^Patient;Nom;;MOLPATH;1;Variant coding system [Identifier];Variant coding sys ID;;TRIAL;2.56;2.56 +8212-3;Opiates;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Gastric fluid by Screen method;Opiates Gast Ql Scn;;ACTIVE;1.0h(2);2.56 +82123-1;Guidance for radiation treatment;Find;Pt;XXX;Doc;MR;RAD;2;MR Guidance for radiation treatment of Unspecified body region;MR Guided RT;;ACTIVE;2.56;2.64 +82124-9;Guidance for radiation treatment;Find;Pt;XXX;Doc;US;RAD;2;US Guidance for radiation treatment of Unspecified body region;US Guided RT;;ACTIVE;2.56;2.64 +82125-6;Respiratory pathogens DNA & RNA tested for;Prid;Pt;Plr fld;Nom;Probe.amp.tar;MICRO;1;Respiratory pathogens DNA and RNA tested for in Pleural fluid by NAA with probe detection;Resp path DNA+RNA Tested Plr NAA+probe;;ACTIVE;2.56;2.63 +82126-4;Guidance for radiation treatment;Find;Pt;XXX;Doc;PT;RAD;2;PT Guidance for radiation treatment of Unspecified body region;PT Guided RT;;ACTIVE;2.56;2.64 +82127-2;Respiratory pathogens DNA & RNA identified;Prid;Pt;Plr fld;Nom;Probe.amp.tar;MICRO;1;Respiratory pathogens DNA and RNA identified in Pleural fluid by NAA with probe detection;Resp path DNA+RNA Plr NAA+probe;;ACTIVE;2.56;2.63 +82128-0;Multisection^WO contrast;Find;Pt;Head>Brain+Face;Doc;MR;RAD;2;MR Brain and Face WO contrast;MR Brain+Face WO contr;;ACTIVE;2.56;2.61 +82129-8;Multisection^WO & W contrast IV;Find;Pt;Head>Brain+Face;Doc;MR;RAD;2;MR Brain and Face WO and W contrast IV;MR Brain+Face WO+W contr IV;;ACTIVE;2.56;2.61 +82130-6;Multisection^WO contrast;Find;Pt;Head>Face & Neck;Doc;MR;RAD;2;MR Face and Neck WO contrast;MR Face+Neck WO contr;;ACTIVE;2.56;2.61 +8213-1;Opiates;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Opiates [Mass/volume] in Meconium;Opiates Mec-mCnc;;DISCOURAGED;1.0h(2);2.73 +82131-4;Multisection^WO & W contrast IV;Find;Pt;Head>Face & Neck;Doc;MR;RAD;2;MR Face and Neck WO and W contrast IV;MR Face+Neck WO+W contr IV;;ACTIVE;2.56;2.61 +82132-2;Multisection^WO & W contrast IV;Find;Pt;Head>Face & Neck;Doc;CT;RAD;2;CT Face and Neck WO and W contrast IV;CT Face+Neck WO+W contr IV;;ACTIVE;2.56;2.61 +82133-0;Multisection^WO contrast;Find;Pt;Head>Face & Neck;Doc;CT;RAD;2;CT Face and Neck WO contrast;CT Face+Neck WO contr;;ACTIVE;2.56;2.61 +82134-8;Respiratory pathogens DNA & RNA tested for;Prid;Pt;Respiratory;Nom;Probe.amp.tar;MICRO;1;Respiratory pathogens DNA and RNA tested for in Respiratory specimen by NAA with probe detection;Resp path DNA+RNA Tested Resp NAA+probe;;ACTIVE;2.56;2.63 +82135-5;Respiratory pathogens DNA & RNA tested for;Prid;Pt;Tissue;Nom;Probe.amp.tar;MICRO;1;Deprecated Respiratory pathogens DNA and RNA tested for in Tissue by Probe and target amplification method;Deprecated Resp path DNA+RNA Tested tiss;;DEPRECATED;2.56;2.58 +82136-3;Views for tumor^W I-123 MIBG IV;Find;Pt;Whole body;Doc;NM;RAD;2;NM Whole body Views for tumor W I-123 MIBG IV;NM WB Vs tumor W I-123 MIBG IV;;ACTIVE;2.56;2.64 +82137-1;FGFR3 gene.p.Gly380Arg targeted mutation analysis;Find;Pt;Amnio fld/CVS;Doc;Molgen;MOLPATH.MUT;1;FGFR3 gene p.Gly380Arg targeted mutation analysis in Amniotic fluid or Chorionic villus sample by Molecular genetics method;FGFR3 p.G380R Mut Anl Amn/CVS;;ACTIVE;2.56;2.65 +82138-9;GJB2 gene.c.35delG targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GJB2 gene c.35delG targeted mutation analysis in Blood or Tissue by Molecular genetics method;GJB2 c.35delG Mut Anl Bld/T;;ACTIVE;2.56;2.65 +82139-7;LRRK2 gene.p.Arg1441Gly & p.Gly2019Ser targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LRRK2 gene Arg1441Gly and Gly2019Ser targeted mutation analysis in Blood or Tissue by Molecular genetics method;LRRK2 p.R1441G+p.G2019S Mut Anl Bld/T;;ACTIVE;2.56;2.65 +82140-5;MYD88 gene.p.Leu265Pro targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;MYD88 gene p.Leu265Pro targeted mutation analysis in Blood or Tissue by Molecular genetics method;MYD88 L265P Mut Anl Bld/T;;ACTIVE;2.56;2.73 +82141-3;Did you live with anyone who was depressed, mentally ill, or suicidal^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;Did you live with anyone who was depressed, mentally ill, or suicidal--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82142-1;Did you live with anyone who was a problem drinker or alcoholic^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;Did you live with anyone who was a problem drinker or alcoholic--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82143-9;Did you live with anyone who used illegal street drugs or who abused prescription medications^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;Did you live with anyone who used illegal street drugs or who abused prescription medications--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82144-7;Did you live with anyone who served time or was sentenced to serve time in a prison, jail, or other correctional facility^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;Did you live with anyone who served time or was sentenced to serve time in a prison, jail, or other correctional facility--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82145-4;Were your parents separated or divorced^pre 18Yo;Find;Pt;^Patient;Nom;ACE.BRFSS;SURVEY.MTLHLTH;4;Were your parents separated or divorced--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82146-2;How often did your parents or adults in your home ever slap, hit, kick, punch or beat each other up^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;How often did your parents or adults in your home ever slap, hit, kick, punch or beat each other up--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82147-0;How often did a parent or adult in your home ever hit, beat, kick, or physically hurt you in any way^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;Before age 18, how often did a parent or adult in your home ever hit, beat, kick, or physically hurt you in any way--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82148-8;How often did a parent or adult in your home ever swear at you, insult you, or put you down^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;How often did a parent or adult in your home ever swear at you, insult you, or put you down--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +8214-9;Opiates;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Opiates [Presence] in Meconium;Opiates Mec Ql;;ACTIVE;1.0h(2);2.73 +82149-6;How often did anyone at least 5Y older than you or an adult, ever touch you sexually^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;How often did anyone at least 5 years older than you or an adult, ever touch you sexually--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82150-4;How often did anyone at least 5Y older than you or an adult, try to make you touch sexually^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;How often did anyone at least 5 years older than you or an adult, try to make you touch sexually--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82151-2;How often did anyone at least 5Y older than you or an adult, force you to have sex^pre 18Yo;Find;Pt;^Patient;Ord;ACE.BRFSS;SURVEY.MTLHLTH;4;How often did anyone at least 5 years older than you or an adult, force you to have sex--before 18 years old [ACE.BRFSS];;;ACTIVE;2.56;2.61 +82152-0;BRFSS Adverse Childhood Experience Module;-;Pt;^Patient;-;ACE.BRFSS;PANEL.SURVEY.MTLHLTH;4;BRFSS ACE Module [ACE.BRFSS];;;ACTIVE;2.56;2.63 +82153-8;Total score;Score;Pt;^Patient;Qn;ACE.BRFSS;SURVEY.MTLHLTH;4;Total score [ACE.BRFSS];;;ACTIVE;2.56;2.58 +82154-6;Genomic structural variant name;Find;Pt;^Patient;Nom;;MOLPATH;1;Genomic structural variant name;Gen struct var name;;TRIAL;2.56;2.56 +82155-3;Genomic structural variant copy number;Num;Pt;^Patient;Qn;;MOLPATH;1;Genomic structural variant copy number;Gen struct var copy num;;TRIAL;2.56;2.73 +8215-6;Opiates;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Opiates [Presence] in Meconium by Confirmatory method;Opiates Mec Ql Cfm;;ACTIVE;1.0h(2);2.73 +82156-1;Protein intake;MRat;24H;^Patient;Qn;Measured;NUTRITION&DIETETICS;2;Protein intake 24 hour Measured;Protein intake 24h Measured;;ACTIVE;2.56;2.56 +82157-9;Birth date;Date;Pt;Provider;Qn;;ADMIN;2;Birth date Provider;Birth Date Provider;;ACTIVE;2.56;2.66 +82158-7;Graduation state;Loc;Pt;Provider;Nom;;ADMIN.DEMOG;2;Graduation state Provider;Grad state Provider;;ACTIVE;2.56;2.66 +82159-5;Respiratory pathogens DNA & RNA panel;-;Pt;Nph;-;Non-probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA panel - Nasopharynx by NAA with non-probe detection;Resp path DNA+RNA Pnl Nph NAA+non-probe;;ACTIVE;2.56;2.73 +82160-3;Adenovirus DNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Nasopharynx by NAA with non-probe detection;HAdV DNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82161-1;Human coronavirus HKU1 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HCoV HKU1 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82162-9;Human coronavirus NL63 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HCoV NL63 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82163-7;Human coronavirus 229E RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Nasopharynx by NAA with non-probe detection;HCoV 229E RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +8216-4;Opiates;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Meconium by Screen method;Opiates Mec Ql Scn;;ACTIVE;1.0h(2);2.73 +82164-5;Human coronavirus OC43 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HCoV OC43 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82165-2;Human metapneumovirus RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Nasopharynx by NAA with non-probe detection;hMPV RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82166-0;Influenza virus A RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Nasopharynx by NAA with non-probe detection;FLUAV RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82167-8;Influenza virus A H1 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Presence] in Nasopharynx by NAA with non-probe detection;FLUAV H1 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82168-6;Influenza virus A H1 2009 pandemic RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic RNA [Presence] in Nasopharynx by NAA with non-probe detection;FLUAV H1 2009 pan RNA Nph NAA+non-probe;;ACTIVE;2.56;2.73 +82169-4;Influenza virus A H3 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Nasopharynx by NAA with non-probe detection;FLUAV H3 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82170-2;Influenza virus B RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Nasopharynx by NAA with non-probe detection;FLUBV RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82171-0;Parainfluenza virus 1 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HPIV1 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +8217-2;Opiates;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Opiates [Mass/volume] in Serum or Plasma;Opiates SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +82172-8;Parainfluenza virus 2 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HPIV2 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82173-6;Parainfluenza virus 3 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HPIV3 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82174-4;Parainfluenza virus 4 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HPIV4 RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82175-1;Rhinovirus+Enterovirus RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus RNA [Presence] in Nasopharynx by NAA with non-probe detection;RV+EV RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82176-9;Respiratory syncytial virus RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Nasopharynx by NAA with non-probe detection;RSV RNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82177-7;Mycoplasma pneumoniae DNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Nasopharynx by NAA with non-probe detection;M pneumo DNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82178-5;Chlamydophila pneumoniae DNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Nasopharynx by NAA with non-probe detection;C pneum DNA Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82179-3;Bordetella pertussis.pertussis toxin promoter region;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Bordetella pertussis.pertussis toxin promoter region [Presence] in Nasopharynx by NAA with non-probe detection;B pert.PT Prmt Nph Ql NAA+non-probe;;ACTIVE;2.56;2.73 +8218-0;Opiates;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Opiates [Presence] in Serum or Plasma by Confirmatory method;Opiates SerPl Ql Cfm;;ACTIVE;1.0h(2);2.73 +82180-1;Meningitis+Encephalitis pathogens panel;-;Pt;CSF;-;Non-probe.amp.tar;PANEL.MICRO;1;Meningitis+Encephalitis pathogens panel - Cerebral spinal fluid by NAA with non-probe detection;Mening+Enc Pnl CSF NAA+non-probe;;ACTIVE;2.56;2.73 +82181-9;Cryptococcus gattii+neoformans DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Cryptococcus gattii+neoformans DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;C gattii+neofor DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82182-7;Escherichia coli K1 DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli K1 DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;E coli K1 DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82183-5;Haemophilus influenzae DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;Haem influ DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82184-3;Listeria monocytogenes DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Listeria monocytogenes DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;L monocytog DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82185-0;Neisseria meningitidis DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;N men DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82186-8;Streptococcus agalactiae DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;Gp B Strep DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82187-6;Streptococcus pneumoniae DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;S pneum DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82188-4;Varicella zoster virus DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;VZV DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82189-2;Cytomegalovirus DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;CMV DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +821-9;A little u super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Au sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Au sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +82190-0;Herpes simplex virus 1 DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;HSV1 DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82191-8;Herpes simplex virus 2 DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;HSV2 DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82192-6;Herpes virus 6 DNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;HHV6 DNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82193-4;Parechovirus A RNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Parechovirus A RNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;Parechovirus A RNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82194-2;Enterovirus RNA;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Cerebral spinal fluid by NAA with non-probe detection;EV RNA CSF Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82195-9;Gastrointestinal pathogens DNA & RNA panel;-;Pt;Stool;-;Non-probe.amp.tar;PANEL.MICRO;1;Gastrointestinal pathogens DNA and RNA panel - Stool by NAA with non-probe detection;GI path DNA+RNA Pnl Stl NAA+non-probe;;ACTIVE;2.56;2.73 +82196-7;Campylobacter coli+jejuni+upsaliensis DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Campylobacter coli+jejuni+upsaliensis DNA [Presence] in Stool by NAA with non-probe detection;C coli+jej+upsa DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82197-5;Clostridioides difficile toxin A+B tcdA+tcdB genes;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Clostridioides difficile toxin A+B tcdA+tcdB genes [Presence] in Stool by NAA with non-probe detection;C dif tox tcdA+tcdB Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +8219-8;Opiates;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Serum or Plasma by Screen method;Opiates SerPl Ql Scn;;ACTIVE;1.0h(2);2.73 +82198-3;Plesiomonas shigelloides DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection;P shigelloides DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82199-1;Salmonella enterica+bongori DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Salmonella enterica+bongori DNA [Presence] in Stool by NAA with non-probe detection;S ent+bong DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82200-7;Vibrio cholerae+parahaemolyticus+vulnificus DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Vibrio cholerae+parahaemolyticus+vulnificus DNA [Presence] in Stool by NAA with non-probe detection;V chol+para+vul DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82201-5;Vibrio cholerae DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Vibrio cholerae DNA [Presence] in Stool by NAA with non-probe detection;V cholerae DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82202-3;Yersinia enterocolitica DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Yersinia enterocolitica DNA [Presence] in Stool by NAA with non-probe detection;Y enterocol DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82203-1;Escherichia coli Stx1+Stx2 toxin stx1+stx2 genes;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli Stx1 and Stx2 toxin stx1+stx2 genes [Presence] in Stool by NAA with non-probe detection;EC stx1+stx2 genes Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82204-9;Escherichia coli O157 DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli O157 DNA [Presence] in Stool by NAA with non-probe detection;E coli O157 DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82205-6;Cryptosporidium sp DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Cryptosporidium sp DNA [Presence] in Stool by NAA with non-probe detection;Cryptosp DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +8220-6;Opiates;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Opiates [Mass/volume] in Urine;Opiates Ur-mCnc;;ACTIVE;1.0h(2);2.73 +82206-4;Cyclospora cayetanensis DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Cyclospora cayetanensis DNA [Presence] in Stool by NAA with non-probe detection;C cayetanensis DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82207-2;Entamoeba histolytica DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Entamoeba histolytica DNA [Presence] in Stool by NAA with non-probe detection;E histolyt DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82208-0;Giardia lamblia DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Giardia lamblia DNA [Presence] in Stool by NAA with non-probe detection;G lamblia DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82209-8;Adenovirus 40+41 DNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Adenovirus 40+41 DNA [Presence] in Stool by NAA with non-probe detection;AdV 40+41 DNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82210-6;Astrovirus subtypes 1-8 RNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Astrovirus subtypes 1-8 RNA [Presence] in Stool by NAA with non-probe detection;Astro typ 1-8 RNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82211-4;Norovirus genogroup I+II RNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Norovirus genogroup I+II RNA [Presence] in Stool by NAA with non-probe detection;Norovirus GI+II RNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82212-2;Rotavirus A RNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Rotavirus A RNA [Presence] in Stool by NAA with non-probe detection;RVA RNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +82213-0;Sapovirus genogroups I+II+IV+V RNA;PrThr;Pt;Stool;Ord;Non-probe.amp.tar;MICRO;1;Sapovirus genogroups I+II+IV+V RNA [Presence] in Stool by NAA with non-probe detection;Sapo I+II+IV+V RNA Stl Ql NAA+non-probe;;ACTIVE;2.56;2.73 +8221-4;Opiates;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Opiates [Presence] in Urine by SAMHSA confirm method;Opiates Ur Ql SAMHSA Cfm;;ACTIVE;1.0h(2);2.56 +82214-8;Safety issue assessment note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Safety issue assessment note;Safety assessment note;;ACTIVE;2.56;2.56 +82215-5;Medical equipment or product list;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Medical equipment or product list;Med equip or product list;;ACTIVE;2.56;2.56 +82216-3;3-Hydroxyisobutyrate dehydrogenase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Hydroxyisobutyrate dehydrogenase [Enzymatic activity/mass] in Fibroblast;HIBADH Fib-cCnt;;ACTIVE;2.58;2.58 +82217-1;3-Hydroxyisobutyryl-CoA hydrolase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Hydroxyisobutyryl-CoA hydrolase [Enzymatic activity/mass] in Fibroblast;HIBYL-CoA Fib-cCnt;;ACTIVE;2.58;2.58 +82218-9;3-Methylcrotonyl-CoA carboxylase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Methylcrotonyl-CoA carboxylase [Enzymatic activity/mass] in Fibroblast;3-MCC Fib-cCnt;;ACTIVE;2.58;2.58 +82219-7;3-Methylglutaconyl-CoA hydratase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;3-Methylglutaconyl-CoA hydratase [Enzymatic activity/mass] in Fibroblast;3-MGC-CoA Fib-cCnt;;ACTIVE;2.58;2.58 +82220-5;Alkyl-dihydroxyacetonephosphate synthase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alkyl-dihydroxyacetonephosphate synthase [Enzymatic activity/mass] in Fibroblast;Alkyl-DHAP synthase Fib-cCnt;;ACTIVE;2.58;2.58 +82221-3;Alpha-methylacyl CoA racemase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Alpha-methylacyl CoA racemase [Enzymatic activity/mass] in Fibroblast;AMACR Fib-cCnt;;ACTIVE;2.58;2.58 +8222-2;Opiates;PrThr;Pt;Urine;Ord;SAMHSA screen;DRUG/TOX;1;Opiates [Presence] in Urine by SAMHSA screen method;Opiates Ur Ql SAMHSA Scn;;ACTIVE;1.0h(2);2.56 +82222-1;Amylo-alpha-1,6-glucosidase;CCnt;Pt;WBC;Qn;;CHEM;1;Amylo-alpha-1,6-glucosidase [Enzymatic activity/mass] in Leukocytes;AGL WBC-cCnt;;ACTIVE;2.58;2.58 +82223-9;Cystathionine beta synthase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Cystathionine beta synthase [Enzymatic activity/mass] in Fibroblast;CBS Fib-cCnt;;ACTIVE;2.58;2.58 +82224-7;Ribose-5-phosphate isomerase;CCnt;Pt;Lymphoblasts;Qn;;CHEM;1;Ribose-5-phosphate isomerase [Enzymatic activity/mass] in Lymphoblasts;RPI Lymphblst-cCnt;;ACTIVE;2.58;2.58 +82225-4;Ribose-5-phosphate isomerase;CCnt;Pt;Fibroblasts;Qn;;CHEM;1;Ribose-5-phosphate isomerase [Enzymatic activity/mass] in Fibroblast;RPI Fib-cCnt;;ACTIVE;2.58;2.58 +82226-2;Neck Disability Index;-;Pt;^Patient;-;NDI;PANEL.SURVEY.GNHLTH;4;Neck Disability Index [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.58 +82227-0;Pain intensity;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Pain intensity [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82228-8;Personal care (washing, dressing, etc);Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Personal care (washing, dressing, etc) [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82229-6;Lifting;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Lifting [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +8223-0;Opiates;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Opiates [Mass/volume] in Unknown substance;Opiates Usub-mCnc;;ACTIVE;1.0h(2);2.34 +82230-4;Reading;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Reading [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82231-2;Headaches;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Headaches [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82232-0;Concentration;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Concentration [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82233-8;Work;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Work [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82234-6;Driving;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Driving [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82235-3;Sleeping;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Sleeping [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82236-1;Recreation;Find;Pt;^Patient;Ord;NDI;SURVEY.GNHLTH;4;Recreation [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82237-9;Total score;Score;Pt;^Patient;Qn;NDI;SURVEY.GNHLTH;4;Total score [NDI];;This article was published in the JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, vol14(7) Vernon, H. and Mior, S., The Neck Disability Index: a study of reliability and validity, pp.409 to 415, Copyright © Elsevier (1991) Used with permission;ACTIVE;2.56;2.56 +82238-7;Chromosome region 15q11-13 deletion+duplication;Find;Pt;Amnio fld/CVS;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 15q11-13 deletion and duplication mutation analysis in Amniotic fluid or Chorionic villus sample by FISH;Chr 15q11-13 Del+Dup Amn/CVS FISH;;ACTIVE;2.56;2.65 +82239-5;Chromosome region 16p13.3 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 16p13.3 deletion in Blood or Tissue by FISH;Chr 16p13.3 Del Bld/T FISH;;ACTIVE;2.56;2.65 +82240-3;Chromosome region 16p13.3 deletion;Find;Pt;Amnio fld/CVS;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 16p13.3 deletion in Amniotic fluid or Chorionic villus sample by FISH;Chr 16p13.3 Del Amn/CVS FISH;;ACTIVE;2.56;2.65 +82241-1;Chromosome region 17p11.2 deletion;Find;Pt;Amnio fld/CVS;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 17p11.2 deletion in Amniotic fluid or Chorionic villus sample by FISH;Chr 17p11.2 Del Amn/CVS FISH;;ACTIVE;2.56;2.65 +82242-9;Chromosome region 17p13.3 deletion;Find;Pt;Amnio fld/CVS;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 17p13.3 deletion in Amniotic fluid or Chorionic villus sample by FISH;Chr 17p13.3 Del Amn/CVS FISH;;ACTIVE;2.56;2.65 +82243-7;Chromosome region 17p13.3 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 17p13.3 deletion in Blood or Tissue by FISH;Chr 17p13.3 Del Bld/T FISH;;ACTIVE;2.56;2.65 +82244-5;Chromosome region 1p36 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 1p36 deletion in Blood or Tissue by FISH;Chr 1p36 Del Bld/T FISH;;ACTIVE;2.56;2.65 +82245-2;Chromosome region 22q11.2 deletion+duplication;Find;Pt;Amnio fld/CVS;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 22q11.2 deletion and duplication mutation analysis in Amniotic fluid or Chorionic villus sample by FISH;Chr 22q11.2 Del+Dup Amn/CVS FISH;;ACTIVE;2.56;2.67 +82246-0;Chromosome region 22q11.2 deletion+duplication;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 22q11.2 deletion and duplication mutation analysis in Blood or Tissue by FISH;Chr 22q11.2 Del+Dup Bld/T FISH;;ACTIVE;2.56;2.67 +82247-8;Chromosome region 7q11.23 deletion;Find;Pt;Amnio fld/CVS;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 7q11.23 deletion in Amniotic fluid or Chorionic villus sample by FISH;Chr 7q11.23 Del Amn/CVS FISH;;ACTIVE;2.56;2.65 +8224-8;Opiates;PrThr;Pt;Unk sub;Ord;;DRUG/TOX;1;Opiates [Presence] in Unknown substance;Opiates Usub Ql;;ACTIVE;1.0h(2);2.56 +82248-6;Chromosome region 7q11.23 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 7q11.23 deletion in Blood or Tissue by FISH;Chr 7q11.23 Del Bld/T FISH;;ACTIVE;2.56;2.65 +82249-4;Chromosome region 8q23.3-24.13 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 8q23.3-24.13 deletion in Blood or Tissue by FISH;Chr 8q23.3-24.13 Del Bld/T FISH;;ACTIVE;2.56;2.65 +82250-2;Chromosome region 1p subtelomere & 1p36 deletion & 1q25 rearrangement;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.MISC;1;Chromosome region 1p subtelomere and 1p36 deletion and 1q25 rearrangement in Blood or Tissue by FISH;1p tel+1p36 del + 1q25 rearr Bld/T FISH;;ACTIVE;2.56;2.65 +82251-0;Chromosome 3 & 7 & 17 aneuploidy & chromosome region 9p21 deletion;Find;Pt;Urine;Doc;FISH;MOLPATH.MISC;1;Chromosome 3 and 7 and 17 aneuploidy and chromosome region 9p21 deletion in Urine by FISH;Chr 3+7+17 aneu + 9p21 Del Ur FISH;;ACTIVE;2.56;2.73 +82252-8;Constitutive heterochromatin analysis;Find;Pt;Bld/Tiss;Doc;Banding;MOLPATH.MISC;1;Constitutive heterochromatin analysis in Blood or Tissue by Banding;Cons heterochrom analysis Bld/T Banding;;ACTIVE;2.56;2.65 +82253-6;JAG1 gene deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;JAG1 gene deletion in Blood or Tissue by FISH;JAG1 gene Del Bld/T FISH;;ACTIVE;2.56;2.65 +82254-4;Marker & derivative chromosome analysis;Find;Pt;Amnio fld/CVS;Doc;Cytogenetics;CYTO;1;Marker and derivative chromosome analysis in Amniotic fluid or Chorionic villus sample Document by Cytogenetics;Mar + der chrom analy Amn/CVS Doc;;ACTIVE;2.56;2.56 +8225-5;Opiates;PrThr;Pt;Unk sub;Ord;Confirm;DRUG/TOX;1;Opiates [Presence] in Unknown substance by Confirmatory method;Opiates Usub Ql Cfm;;ACTIVE;1.0h(2);2.56 +82255-1;Marker & derivative chromosome analysis;Find;Pt;Bld/Tiss;Doc;Cytogenetics;CYTO;1;Marker and derivative chromosome analysis in Blood or Tissue Document by Cytogenetics;Mar + der chrom analy Bld/T Doc;;ACTIVE;2.56;2.56 +82256-9;Chromosome 12 trisomy & chromosome region 11q22.3 & 13q14 & 17p13.1 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.MISC;1;Chromosome 12 trisomy and chromosome region 11q22.3 and 13q14 and 17p13.1 deletion in Blood or Tissue by FISH;12Ts+11p22.3+13q14+17p13.1 Del Bl/T FISH;;ACTIVE;2.56;2.65 +82257-7;SRY gene deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;SRY gene deletion in Blood or Tissue by FISH;SRY gene Del Bld/T FISH;;ACTIVE;2.56;2.65 +82258-5;Subtelomere analysis;Find;Pt;Bone mar;Doc;FISH;MOLPATH.MISC;1;Subtelomere analysis in Bone marrow by FISH;Subtelomere analysis Mar FISH;;ACTIVE;2.56;2.65 +82259-3;Metabolic equivalent of task & Resting metabolic rate panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Metabolic equivalent of task and Resting metabolic rate panel;MET + RMR Pnl;;ACTIVE;2.56;2.71 +82260-1;Metabolic equivalent of task by standard resting metabolic rate panel;-;1M^mean;^Patient;-;;PANEL.CLIN;2;MET by standard RMR panel;MET by stand RMR Pnl;;ACTIVE;2.56;2.71 +82261-9;Activity metabolic rate/Standard resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Measured;CLIN;2;Measured activity metabolic rate/Standard RMR [Relative energy/Time];Meas Act metab rate/Standard RMR;;ACTIVE;2.56;2.72 +82262-7;Activity metabolic rate/Standard resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Estimated;CLIN;2;Estimated activity metabolic rate/Standard RMR [Relative energy/Time];Est Act metab rate/Standard RMR;;ACTIVE;2.56;2.71 +8226-3;Opiates;PrThr;Pt;Unk sub;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Unknown substance by Screen method;Opiates Usub Ql Scn;;ACTIVE;1.0h(2);2.56 +82263-5;Activity metabolic rate/Standard resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Reported;CLIN;2;Reported activity metabolic rate/Standard RMR [Relative energy/Time];Reported Act metab rate/Standard RMR;;ACTIVE;2.56;2.72 +82264-3;Metabolic equivalent of task by measured resting metabolic rate panel;-;1M^mean;^Patient;-;;PANEL.CLIN;2;MET by measured RMR panel;MET by meas RMR Pnl;;ACTIVE;2.56;2.71 +82265-0;Activity metabolic rate/Measured resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Measured;CLIN;2;Measured Activity metabolic rate/Measured RMR [Relative energy/Time];Meas Act metab rate/Meas RMR;;ACTIVE;2.56;2.72 +82266-8;Activity metabolic rate/Measured resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Estimated;CLIN;2;Estimated Activity metabolic rate/Measured RMR [Relative energy/Time];Est Act metab rate/Meas RMR;;ACTIVE;2.56;2.72 +82267-6;Activity metabolic rate/Measured resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Reported;CLIN;2;Reported Activity metabolic rate/Measured RMR [Relative energy/Time];Reported Act metab rate/Meas RMR;;ACTIVE;2.56;2.72 +82268-4;Metabolic equivalent of task by population resting metabolic rate panel;-;1M^mean;^Patient;-;;PANEL.CLIN;2;MET by population RMR panel;MET by pop RMR Pnl;;ACTIVE;2.56;2.71 +82269-2;Activity metabolic rate/Population resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Estimated;CLIN;2;Estimated Activity metabolic rate/Population RMR [Relative energy/Time];Est Act metab rate/Pop RMR;;ACTIVE;2.56;2.72 +822-7;A little u super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Au sup(a) Ab [Presence] in Serum or Plasma from Donor;Au sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +82270-0;Activity metabolic rate/Population resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Measured;CLIN;2;Measured Activity metabolic rate/Population RMR [Relative energy/Time];Meas Act metab rate/Pop RMR;;ACTIVE;2.56;2.72 +8227-1;Phencyclidine;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Gastric fluid;PCP Gast-mCnc;;ACTIVE;1.0h(2);2.34 +82271-8;Activity metabolic rate/Standard resting metabolic rate^^adjusted for age+sex+race+BMI;RelEngRat;1M^mean;^Patient;Qn;Estimated;CLIN;2;Activity metabolic rate/Standard resting metabolic rate [Relative Energy/Time] adjusted for age+sex+race+BMI 1 minute mean Estimated;Act met rate/St RMR adj age+sex+race+BMI;;ACTIVE;2.56;2.72 +82272-6;Activity metabolic rate/Population resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Reported;CLIN;2;Reported Activity metabolic rate/Population RMR [Relative energy/Time];Reported Act metab rate/Pop RMR;;ACTIVE;2.56;2.72 +82273-4;Metabolic equivalent of task by predicted resting metabolic rate panel;-;1M^mean;^Patient;-;;PANEL.CLIN;2;MET by predicted RMR panel;MET by pred RMR Pnl;;ACTIVE;2.56;2.71 +82274-2;Activity metabolic rate/Predicted resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Estimated;CLIN;2;Estimated metabolic rate/Predicted RMR [Relative energy/Time];Est Act metab rate/Pred RMR;;ACTIVE;2.56;2.72 +82275-9;Activity metabolic rate/Predicted resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Reported;CLIN;2;Reported Activity metabolic rate/Predicted RMR [Relative energy/Time];Reported Act metab rate/Pred RMR;;ACTIVE;2.56;2.72 +82276-7;Activity metabolic rate/Predicted resting metabolic rate;RelEngRat;1M^mean;^Patient;Qn;Measured;CLIN;2;Measured Activity metabolic rate/Predicted RMR [Relative energy/Time];Meas Act metab rate/Pred RMR;;ACTIVE;2.56;2.72 +82277-5;Source used for predicted RMR;Type;Pt;Reference source;Nom;;CLIN;2;Source used for predicted RMR;Source for Predicted RMR;;ACTIVE;2.56;2.71 +82278-3;Metabolic rate^resting;EngRat;1M^mean;^Patient;Qn;Measured;CLIN;2;Measured RMR;Measured RMR;;ACTIVE;2.56;2.72 +82279-1;Resting metabolic rate panel;-;Pt;^Patient;Qn;;PANEL.CLIN;2;RMR panel;RMR Pnl;;ACTIVE;2.56;2.71 +82280-9;Source used to estimate activity metabolic rate;Type;Pt;Reference source;Nom;;CLIN;2;Source used to estimate activity metabolic rate;Source estim activ metab rate;;ACTIVE;2.56;2.71 +82281-7;Source used for reported activity metabolic rate;Type;Pt;Reference source;Nom;;CLIN;2;Source used for reported activity metabolic rate;Source reported activ metab rate;;ACTIVE;2.56;2.71 +82282-5;Source used for population RMR;Type;Pt;Reference source;Nom;;CLIN;2;Source used for population RMR;Source for pop RMR;;ACTIVE;2.56;2.71 +82283-3;Source used to adjust activity MET;Type;Pt;Reference source;Nom;;CLIN;2;Source used to adjust activity MET;Source to adj activity MET;;ACTIVE;2.56;2.71 +82284-1;Standard resting metabolic rate;EngRat;1M^mean;^Population;Qn;;CLIN;2;Standard RMR;Standard RMR;;ACTIVE;2.56;2.72 +82285-8;Population resting metabolic rate;EngRat;1M^mean;^Population;Qn;;CLIN;2;Population RMR;Population RMR;;ACTIVE;2.56;2.72 +82286-6;Predicted resting metabolic rate;EngRat;1M^mean;^Patient;Qn;;CLIN;2;Predicted RMR;Predicted RMR;;ACTIVE;2.56;2.72 +82287-4;Physical activity panel;-;RptPeriod;^Patient;-;;PANEL.CLIN;2;Physical activity panel;Physical activity Pnl;;ACTIVE;2.56;2.73 +82288-2;Absolute aerobic exercise intensity;Type;Pt;^Patient;Ord;;CLIN;2;Absolute aerobic exercise intensity;Absolute aerobic exer intensity;;ACTIVE;2.56;2.71 +8228-9;Phencyclidine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Gastric fluid;PCP Gast Ql;;ACTIVE;1.0h(2);2.56 +82289-0;Rating of perceived exertion;Score;Pt;^Patient;Ord;;CLIN;2;Rating of perceived exertion [Score];RPE Score;;ACTIVE;2.56;2.71 +82290-8;Frequency of moderate to vigorous aerobic physical activity;NRat;RptPeriod;^Patient;Qn;;CLIN;2;Frequency of moderate to vigorous aerobic physical activity;Freq aerobic physical activity;;ACTIVE;2.56;2.71 +82291-6;Frequency of muscle-strengthening physical activity;NRat;RptPeriod;^Patient;Qn;;CLIN;2;Frequency of muscle-strengthening physical activity;Freq muscle-strengthening;;ACTIVE;2.56;2.71 +82292-4;Meeting recommended guidelines for physical activity;Find;Pt;^Patient;Ord;;CLIN;2;Meeting recommended guidelines for physical activity;Meeting guidelines phys activity;;ACTIVE;2.56;2.71 +82293-2;Frequency of bone-strengthening physical activity;NRat;RptPeriod;^Patient;Qn;;CLIN;2;Frequency of bone-strengthening physical activity;Freq bone-strengthening;;ACTIVE;2.56;2.71 +82294-0;Physical activity guideline used;Type;Pt;Reference source;Nom;;CLIN;2;Physical activity guideline used;Phys Activity Guide used;;ACTIVE;2.56;2.71 +82295-7;Chromosome region Xp22.33 &or Yp11.32 deletion+duplication;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region Xp22.33 AndOr Yp11.32 deletion and duplication mutation analysis in Blood or Tissue by FISH;Xp22.33 +or Yp11.32 Del+Dup Bld/T FISH;;ACTIVE;2.56;2.65 +82296-5;Method used to measure RMR;Type;Pt;^Patient;Nom;;CLIN;2;Method used to measure RMR;Method used for RMR;;ACTIVE;2.56;2.71 +8229-7;Phencyclidine;PrThr;Pt;Gast fld;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Gastric fluid by Confirmatory method;PCP Gast Ql Cfm;;ACTIVE;1.0h(2);2.56 +82297-3;Chikungunya virus structural proteins (E1+E2) Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chikungunya virus structural proteins (E1+E2) IgG Ab [Presence] in Serum by Immunoassay;CHIKV E1+E2 IgG Ser Ql IA;;ACTIVE;2.56;2.73 +82298-1;Yersinia enterocolitica;PrThr;Pt;XXX;Ord;Culture;MICRO;1;Yersinia enterocolitica [Presence] in Specimen by Culture;Y enterocol Spec Ql Cult;;ACTIVE;2.58;2.69 +82299-9;Escherichia coli shiga-like toxin 1+2;PrThr;Pt;Stool;Ord;IA;MICRO;1;Escherichia coli shiga-like toxin 1+2 [Presence] in Stool by Immunoassay;E coli shiga-like toxin 1+2 Stl Ql IA;;ACTIVE;2.58;2.58 +82300-5;Shigella sp;PrThr;Pt;Stool;Ord;Culture;MICRO;1;Shigella sp [Presence] in Stool by Culture;Shigella Stl Ql Cult;;ACTIVE;2.58;2.58 +82301-3;Salmonella sp;PrThr;Pt;Stool;Ord;Culture;MICRO;1;Salmonella sp [Presence] in Stool by Culture;Salmonella Stl Ql Cult;;ACTIVE;2.58;2.58 +82302-1;Campylobacter sp;PrThr;Pt;Stool;Ord;Culture;MICRO;1;Campylobacter sp [Presence] in Stool by Culture;Campylobacter Stl Ql Cult;;ACTIVE;2.58;2.73 +82303-9;Escherichia coli O157;PrThr;Pt;Stool;Ord;Culture;MICRO;1;Escherichia coli O157 [Presence] in Stool by Culture;E coli O157 Stl Ql Cult;;ACTIVE;2.58;2.58 +82304-7;Plesiomonas shigelloides;PrThr;Pt;Stool;Ord;Culture;MICRO;1;Plesiomonas shigelloides [Presence] in Stool by Culture;P shigelloides Stl Ql Cult;;ACTIVE;2.58;2.73 +8230-5;Phencyclidine;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Gastric fluid by Screen method;PCP Gast Ql Scn;;ACTIVE;1.0h(2);2.56 +82305-4;Gastrointestinal pathogens panel;-;Pt;Stool;-;Culture;PANEL.MICRO;1;Gastrointestinal pathogens panel - Stool by Culture;GI pathogens Pnl Stl Cult;;ACTIVE;2.58;2.73 +82306-2;Chlamydia trachomatis rRNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Throat by NAA with probe detection;C trach rRNA Throat Ql NAA+probe;;ACTIVE;2.58;2.73 +82307-0;Vendor device information panel;-;Pt;{Device};-;;PANEL.DEVICES;2;Vendor device information panel;Vendor device info Pnl;;ACTIVE;2.58;2.68 +82308-8;Oncology plan of care and summary - recommended CDA R1.2 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Oncology plan of care and summary - recommended CDA R1.2 sections;Oncology plan CDA R1.2 Sections;;ACTIVE;2.58;2.58 +82309-6;Basis for allelic phase;Type;Pt;^Patient;Nom;*;MOLPATH;1;Basis for allelic phase [Type];Basis allelic phase;;ACTIVE;2.58;2.58 +82310-4;Duration of stay outside the U.S.;Time;Pt;^Patient;Qn;;H&P.HX;2;Duration of stay outside the U.S.;Duration of stay outside the U.S.;;ACTIVE;2.58;2.69 +82311-2;Time between start of treatment and onset of adverse event;Time;Pt;^Patient;Qn;;H&P.HX;2;Time between start of treatment and onset of adverse event;Time btw start treat onset adv evnt;;ACTIVE;2.58;2.69 +82312-0;Blood transfusion &or organ transplant;Hx;12Mo;^Patient;Ord;;H&P.HX;2;Blood transfusion andor organ transplant 12 months;Bld transf &or organ transp 12Mo;;ACTIVE;2.58;2.58 +8231-3;Phencyclidine;MCnc;Pt;Meconium;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Meconium;PCP Mec-mCnc;;DISCOURAGED;1.0h(2);2.73 +82314-6;Specimen sent to CDC;Find;Pt;Specimen;Ord;;SPEC;1;Specimen sent to CDC;Spec sent to CDC;;ACTIVE;2.58;2.58 +82315-3;Level 3 emergency medical services patient care report - recommended CDA R1 & R2 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Level 3 emergency medical services patient care report - recommended CDA R1 and R2 sections;L3 EMS Pt Care Rpt CDA R1+R2 Sec;;ACTIVE;2.58;2.58 +82316-1;Hip dysfunction and osteoarthritis outcome score for joint replacement;-;Pt;^Patient;-;HOOSJR;PANEL.SURVEY.GNHLTH;4;Hip dysfunction and osteoarthritis outcome score for joint replacement [HOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +82317-9;Amount of hip pain experienced while going up or down stairs in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while going up or down stairs in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.64 +82318-7;Amount of hip pain experienced while walking on an uneven surface in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while walking on an uneven surface in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82319-5;Degree of difficulty experienced due to your hip while rising from sitting in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while rising from sitting in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82320-3;Degree of difficulty experienced due to your hip while bending to floor &or pick up an object in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while bending to floor AndOr pick up an object in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +8232-1;Phencyclidine;PrThr;Pt;Meconium;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Meconium;PCP Mec Ql;;ACTIVE;1.0h(2);2.73 +82321-1;Degree of difficulty experienced due to your hip while lying in bed (turning over, maintaining hip position) in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while lying in bed (turning over, maintaining hip position) in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82322-9;Degree of difficulty experienced due to your hip while sitting in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while sitting in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82323-7;Total interval score;Score;Pt;^Patient;Qn;HOOSJR;SURVEY.GNHLTH;4;Total interval score [HOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +82324-5;Knee injury and osteoarthritis outcome score for joint replacement;-;Pt;^Patient;-;KOOSJR;PANEL.SURVEY.GNHLTH;4;Knee injury and osteoarthritis outcome score for joint replacement [KOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +82325-2;How severe is your knee stiffness after first wakening in the morning during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;How severe is your knee stiffness after first wakening in the morning during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.64 +82326-0;Amount of knee pain experienced while twisting &or pivoting on your knee in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while twisting AndOr pivoting on your knee in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82327-8;Amount of knee pain experienced while straightening knee fully in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while straightening knee fully in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82328-6;Amount of knee pain experienced while going up or down stairs in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while going up or down stairs in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82329-4;Amount of knee pain experienced while standing upright in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while standing upright in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.61 +82330-2;Degree of difficulty experienced due to your knee while rising from sitting in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while rising from sitting in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.64 +82331-0;Degree of difficulty experienced due to your knee while bending to floor &or pick up an object in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while bending to floor AndOr pick up an object in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.61;2.72 +82332-8;Total interval score;Score;Pt;^Patient;Qn;KOOSJR;SURVEY.GNHLTH;4;Total interval score [KOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +82334-4;Interleukin 17A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 17A [Mass/volume] in Serum or Plasma;Il17A SerPl-mCnc;;ACTIVE;2.58;2.73 +82335-1;Cytokines panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Cytokines panel - Serum or Plasma;Cytokines Pnl SerPl;;ACTIVE;2.58;2.7 +82336-9;REMS header;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS header;FDA insert REMS header;;ACTIVE;2.58;2.58 +82337-7;Intrachamber;Pres;Pt;Heart.atrium.right;Qn;US+Estimated;CARD.US;2;Right atrial Intrachamber pressure estimated by US;RA Intrachamber pres US+est;;ACTIVE;2.58;2.71 +82338-5;Diameter;Len;Pt;Aorta.sinotubular junction;Qn;US.M-mode;CARD.US;2;Aorta.sinotubular junction Diameter by US.M-mode;AO.sinotub junc Diam M-mode;;ACTIVE;2.58;2.58 +8233-9;Phencyclidine;PrThr;Pt;Meconium;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Meconium by Confirmatory method;PCP Mec Ql Cfm;;ACTIVE;1.0h(2);2.56 +82339-3;Diameter;Len;Pt;Aorta.sinotubular junction;Qn;US.2D;CARD.US;2;Aorta.sinotubular junction Diameter by US 2D;AO.sinotub junc Diam 2D US;;ACTIVE;2.58;2.58 +82340-1;Closure to opening;Time;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Closure to opening [Time] by US.doppler;MV Closure to opening Time DOP;;ACTIVE;2.58;2.71 +82341-9;Intrachamber systolic;Pres;Pt;Heart.ventricle.right;Qn;US+Estimated;CARD.US;2;Right ventricular Intrachamber systolic pressure estimated by US;RV Intrachamber sys pres US+est;;ACTIVE;2.58;2.71 +82342-7;F8 gene intron 1 inversion targeted mutation analysis;Find;Pt;Amnio fld/CVS;Doc;Molgen;MOLPATH.INV;1;F8 gene intron 1 inversion targeted mutation analysis in Amniotic fluid or Chorionic villus sample by Molecular genetics method;F8 intron 1 Inv Mut Anl Amn/CVS;;ACTIVE;2.58;2.65 +82343-5;F8 gene intron 1 & 22 inversion targeted mutation analysis;Find;Pt;Amnio fld/CVS;Doc;Molgen;MOLPATH.INV;1;F8 gene intron 1 and 22 inversion targeted mutation analysis in Amniotic fluid or Chorionic villus sample by Molecular genetics method;F8 intron 1+22 Inv Mut Anl Amn/CVS;;ACTIVE;2.58;2.65 +82344-3;REMS communication plan;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS communication plan;FDA insert REMS com plan;;ACTIVE;2.58;2.58 +82345-0;REMS elements to assure safe use;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS elements to assure safe use;FDA insert REMS elmnts assure safe use;;ACTIVE;2.58;2.58 +82346-8;REMS material;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS material;FDA insert REMS material;;ACTIVE;2.58;2.58 +8234-7;Phencyclidine;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Meconium by Screen method;PCP Mec Ql Scn;;ACTIVE;1.0h(2);2.73 +82347-6;REMS summary;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS summary;FDA insert REMS summary;;ACTIVE;2.58;2.58 +82348-4;REMS elements;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS elements;FDA insert REMS elements;;ACTIVE;2.58;2.58 +82349-2;REMS goals;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS goals;FDA insert REMS goals;;ACTIVE;2.58;2.58 +823-5;A little u super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Au sup(a) Ab [Presence] in Serum or Plasma;Au sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +82350-0;REMS implementation system;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS implementation system;FDA insert REMS implement syst;;ACTIVE;2.58;2.58 +82351-8;Risk evaluation & mitigation strategies;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Risk evaluation and mitigation strategies;FDA insert REMS;;ACTIVE;2.58;2.58 +82352-6;REMS timetable for submission assessments;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS timetable for submission assessments;FDA insert REMS timetab subm assess;;ACTIVE;2.58;2.58 +82353-4;Indexing - risk evaluation & mitigation strategies;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Indexing - risk evaluation and mitigation strategies;FDA insert Indexing - REMS;;ACTIVE;2.58;2.58 +8235-4;Phencyclidine;PrThr;Pt;Ser/Plas;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Serum or Plasma by Confirmatory method;PCP SerPl Ql Cfm;;ACTIVE;1.0h(2);2.73 +82354-2;Human papilloma virus 16 & 18+45 E6+E7 mRNA;Prid;Pt;Cvx;Nom;Probe.amp.tar;MICRO;1;Human papilloma virus 16 and 18+45 E6+E7 mRNA [Identifier] in Cervix by NAA with probe detection;HPV16+18+45 E6+E7mRNA Cvx NAA+probe;;ACTIVE;2.58;2.73 +82355-9;Procedure note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine procedure note;Geri med Procedure note;;ACTIVE;2.58;2.58 +82356-7;Consultation note;Find;Pt;{Setting};Doc;Obstetrics.midwife;DOC.ONTOLOGY;2;Obstetrics Midwife Consult note;OB Midwife Consult note;;ACTIVE;2.58;2.58 +82357-5;Procedure note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care procedure note;Palliative care Procedure note;;ACTIVE;2.58;2.58 +82358-3;Referral note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Referral note;REI Referral note;;ACTIVE;2.58;2.58 +82359-1;Consultation note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Consult note;REI Consult note;;ACTIVE;2.58;2.58 +82360-9;Diagnostic study note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Diagnostic study note;REI Diag study note;;ACTIVE;2.58;2.58 +82361-7;Education note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Education note;REI Educ note;;ACTIVE;2.58;2.58 +8236-2;Phencyclidine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Serum or Plasma by Screen method;PCP SerPl Ql Scn;;ACTIVE;1.0h(2);2.73 +82362-5;Flowsheet;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Flowsheet;REI Flowsheet;;ACTIVE;2.58;2.58 +82363-3;Initial evaluation note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Initial evaluation note;REI Initial eval note;;ACTIVE;2.58;2.58 +82364-1;Plan of care note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Plan of care note;REI Plan of care note;;ACTIVE;2.58;2.58 +82365-8;Progress note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility Progress note;REI Prog note;;ACTIVE;2.58;2.73 +82366-6;Procedure note;Find;Pt;{Setting};Doc;Reproductive endocrinology and infertility;DOC.ONTOLOGY;2;Reproductive endocrinology and infertility procedure note;REI Procedure note;;ACTIVE;2.58;2.58 +82367-4;Peripheral deiodinase activity;SRat;Pt;Ser/Plas;Qn;Calculated.SPINA;CHEM;1;Peripheral deiodinase activity [Moles/time] in Serum or Plasma by Calculated.SPINA;Per deiod act SerPl Calc SPINA-sRate;;ACTIVE;2.58;2.58 +82368-2;Thyroid secretory capacity;SRat;Pt;Ser/Plas;Qn;Calculated.SPINA;CHEM;1;Thyroid secretory capacity [Moles/time] in Serum or Plasma by Calculated.SPINA;Thyr secr cap SerPl Calc SPINA-sRate;;ACTIVE;2.58;2.58 +82369-0;Buprenorphine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Buprenorphine [Presence] in Serum or Plasma by Screen method;Buprenorphine SerPl Ql Scn;;ACTIVE;2.58;2.58 +8237-0;Phencyclidine;PrThr;Pt;Urine;Ord;SAMHSA confirm;DRUG/TOX;1;Phencyclidine [Presence] in Urine by SAMHSA confirm method;PCP Ur Ql SAMHSA Cfm;;ACTIVE;1.0h(2);2.56 +82370-8;Norbuprenorphine;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Norbuprenorphine [Presence] in Gastric fluid by Screen method;Norbuprenorphine Gast Ql Scn;;ACTIVE;2.58;2.58 +82371-6;Norbuprenorphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norbuprenorphine [Presence] in Urine by Screen method;Norbuprenorphine Ur Ql Scn;;ACTIVE;2.58;2.58 +82372-4;Buprenorphine;PrThr;Pt;Gast fld;Ord;Screen;DRUG/TOX;1;Buprenorphine [Presence] in Gastric fluid by Screen method;Buprenorphine Gast Ql Scn;;ACTIVE;2.58;2.58 +82373-2;Buprenorphine;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Buprenorphine [Presence] in Specimen by Screen method;Buprenorphine Spec Ql Scn;;ACTIVE;2.58;2.69 +82374-0;Norbuprenorphine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Norbuprenorphine [Presence] in Serum or Plasma by Screen method;Norbuprenorphine SerPl Ql Scn;;ACTIVE;2.58;2.58 +82375-7;Norbuprenorphine;PrThr;Pt;XXX;Ord;Screen;DRUG/TOX;1;Norbuprenorphine [Presence] in Specimen by Screen method;Norbuprenorphine Spec Ql Scn;;ACTIVE;2.58;2.69 +82376-5;Elbasvir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Elbasvir [Susceptibility] by Genotype method;Elbasvir Islt Genotyp;;ACTIVE;2.58;2.73 +82377-3;Ledipasvir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Ledipasvir [Susceptibility] by Genotype method;Ledipasvir Islt Genotyp;;ACTIVE;2.58;2.73 +82378-1;Ombitasvir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Ombitasvir [Susceptibility] by Genotype method;Ombitasvir Islt Genotyp;;ACTIVE;2.58;2.73 +82379-9;Daclatasvir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Daclatasvir [Susceptibility] by Genotype method;Daclatasvir Islt Genotyp;;ACTIVE;2.58;2.73 +82380-7;Hepatitis C virus genotype 1 NS5a gene mutations detected;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis C virus genotype 1 NS5a gene mutations detected [Identifier];HCV Gentyp 1 NS5a Mut Det Islt;;ACTIVE;2.58;2.73 +82381-5;Hepatitis C virus genotype 1 NS5b gene mutations detected;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis C virus genotype 1 NS5b gene mutations detected [Identifier];HCV Genotyp 1 NS5b Mut Det Islt;;ACTIVE;2.58;2.73 +82382-3;Sofosbuvir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Sofosbuvir [Susceptibility] by Genotype method;Sofosbuvir Islt Genotyp;;ACTIVE;2.58;2.73 +82383-1;Dengue virus 2+4 RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 2+4 RNA [Presence] in Serum by NAA with probe detection;DENV 2+4 RNA Ser Ql NAA+probe;;ACTIVE;2.58;2.73 +82384-9;Dengue virus 1+3 RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+3 RNA [Presence] in Serum by NAA with probe detection;DENV 1+3 RNA Ser Ql NAA+probe;;ACTIVE;2.58;2.73 +82385-6;Methylmalonate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Methylmalonate [Moles/volume] in DBS;Methylmalonate DBS-sCnc;;ACTIVE;2.58;2.61 +82386-4;2-Methylcitrate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;2-Methylcitrate [Moles/volume] in DBS;2Me-citrate DBS-sCnc;;ACTIVE;2.58;2.61 +82387-2;Mycobacterium avium tuberculin stimulated gamma interferon;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium avium tuberculin stimulated gamma interferon [Units/volume] in Blood;M avian tuberc IFN-g Bld-aCnc;;ACTIVE;2.58;2.64 +8238-8;Phencyclidine;PrThr;Pt;Urine;Ord;SAMHSA screen;DRUG/TOX;1;Phencyclidine [Presence] in Urine by SAMHSA screen method;PCP Ur Ql SAMHSA Scn;;ACTIVE;1.0h(2);2.56 +82388-0;3-Hydroxy-3-Methylglutaryl-coenzyme A reductase Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;3-Hydroxy-3-Methylglutaryl-coenzyme A reductase Ab [Units/volume] in Serum by Line blot;HMGCR Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82389-8;3-Hydroxy-3-methylglutaryl-coenzyme A reductase Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;3-Hydroxy-3-Methylglutaryl-coenzyme A reductase Ab [Presence] in Serum by Line blot;HMGCR Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82390-6;Centromere protein A Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Centromere protein A Ab [Units/volume] in Serum by Line blot;CENP A Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.73 +82391-4;Centromere protein B Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Centromere protein B Ab [Units/volume] in Serum by Line blot;Centromere B Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82392-2;Ej Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ej Ab [Presence] in Serum by Line blot;Ej Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82393-0;Fibrillarin Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Fibrillarin Ab [Units/volume] in Serum by Line blot;Fibrillarin Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.73 +82394-8;Fibrillarin Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Fibrillarin Ab [Presence] in Serum by Line blot;Fibrillarin Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82395-5;Ganglioside GD1a Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD1a IgG Ab [Presence] in Serum by Line blot;GD1a Gangl IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +8239-6;Phencyclidine;MCnc;Pt;Unk sub;Qn;;DRUG/TOX;1;Phencyclidine [Mass/volume] in Unknown substance;PCP Usub-mCnc;;ACTIVE;1.0h(2);2.34 +82396-3;Ganglioside GD1a Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD1a IgG+IgM Ab [Presence] in Serum by Line blot;GD1a Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82397-1;Ganglioside GD1a Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD1a IgM Ab [Presence] in Serum by Line blot;GD1a Gangl IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82398-9;Ganglioside GD1b Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD1b IgG+IgM Ab [Presence] in Serum by Line blot;GD1b Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82399-7;Ganglioside GD2 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD2 IgG Ab [Presence] in Serum by Line blot;GD2 Gangl IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82400-3;Ganglioside GD2 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD2 IgG+IgM Ab [Presence] in Serum by Line blot;GD2 Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82401-1;Ganglioside GD2 Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD2 IgM Ab [Presence] in Serum by Line blot;GD2 Gangl IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82402-9;Ganglioside GD3 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD3 IgG Ab [Presence] in Serum by Line blot;GD3 Gangl IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82403-7;Ganglioside GD3 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GD3 IgG+IgM Ab [Presence] in Serum by Immunoassay;Deprecated GD3 Gangl IgG+IgM Ser Ql IA;;DEPRECATED;2.58;2.58 +8240-4;Phencyclidine;PrThr;Pt;Unk sub;Ord;;DRUG/TOX;1;Phencyclidine [Presence] in Unknown substance;PCP Usub Ql;;ACTIVE;1.0h(2);2.56 +82404-5;Ganglioside GD3 Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD3 IgM Ab [Presence] in Serum by Line blot;GD3 Gangl IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82405-2;Ganglioside GM3 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM3 IgG+IgM Ab [Presence] in Serum by Immunoblot;Deprecated GM3 IgG+IgM Ser Ql IB;;DEPRECATED;2.58;2.58 +82406-0;Ganglioside GM3 Ab.IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GM3 IgM Ab [Presence] in Serum by Immunoblot;Deprecated GM3 IgM Ser Ql IB;;DEPRECATED;2.58;2.58 +82407-8;Ganglioside GM4 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM4 IgG Ab [Presence] in Serum by Line blot;GM4 IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82408-6;Ganglioside GM4 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM4 IgG+IgM Ab [Presence] in Serum by Line blot;GM4 IgG+IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82409-4;Ganglioside GM4 Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM4 IgM Ab [Presence] in Serum by Line blot;GM4 IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82410-2;Ganglioside GQ1b Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GQ1b IgG+IgM Ab [Presence] in Serum by Line blot;GQ1b Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82411-0;Ganglioside GT1a Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GT1a IgG Ab [Presence] in Serum by Line blot;GT1a Gangl IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +8241-2;Phencyclidine;PrThr;Pt;Unk sub;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Unknown substance by Confirmatory method;PCP Usub Ql Cfm;;ACTIVE;1.0h(2);2.56 +82412-8;Ganglioside GT1a Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ganglioside GT1a IgG+IgM Ab [Presence] in Serum by Immunoblot;Deprecated GT1a Gangl IgG+IgM Ser Ql IB;;DEPRECATED;2.58;2.58 +82413-6;Ganglioside GT1a Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GT1a IgM Ab [Presence] in Serum by Line blot;GT1a Gangl IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82414-4;Ha Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Ha Ab [Units/volume] in Serum by Line blot;Ha Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82415-1;Ha Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ha Ab [Presence] in Serum by Line blot;Ha Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82416-9;Histone Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Histone Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated Histone Ab CSF Ql IB;;DEPRECATED;2.58;2.58 +82417-7;Human upstream binding factor Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Human upstream binding factor Ab [Units/volume] in Serum by Line blot;hUBF Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82418-5;Human upstream binding factor Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Human upstream binding factor Ab [Presence] in Serum by Line blot;hUBF Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82419-3;Intrinsic factor Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Intrinsic factor Ab [Presence] in Serum by Immunoblot;Deprecated IF Ab Ser Ql IB;;DEPRECATED;2.58;2.58 +8242-0;Phencyclidine;PrThr;Pt;Unk sub;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Unknown substance by Screen method;PCP Usub Ql Scn;;ACTIVE;1.0h(2);2.56 +82420-1;Jo-1 extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Jo-1 extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA Jo1 Ab CSF Ql IB;;DEPRECATED;2.58;2.58 +82421-9;Ks Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Ks Ab [Units/volume] in Serum by Line blot;Ks Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82422-7;Ks Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ks Ab [Presence] in Serum by Line blot;Ks Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82423-5;Ma+Ta Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ma+Ta Ab [Presence] in Serum by Line blot;Ma+Ta Ab Ser Ql Line blot;;ACTIVE;2.58;2.64 +82424-3;MDA5 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;MDA5 Ab [Presence] in Serum by Line blot;MDA5 Ab Ser Ql Line blot;;ACTIVE;2.58;2.73 +82425-0;MJ Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Mj Ab [Units/volume] in Serum by Line blot;Mj Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82426-8;MJ Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Mj Ab [Presence] in Serum by Line blot;Mj Ab Ser Ql Line blot;;ACTIVE;2.58;2.73 +82427-6;Myeloperoxidase Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Myeloperoxidase Ab [Presence] in Serum by Immunoblot;Deprecated Myeloperoxidase Ab Ser Ql IB;;DEPRECATED;2.58;2.58 +82428-4;Nucleosome Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Nucleosome Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated Nucleosome Ab CSF Ql IB;;DEPRECATED;2.58;2.58 +82429-2;Nucleosome Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Nucleosome Ab [Presence] in Serum by Immunoblot;Deprecated Nucleosome Ab Ser Ql IB;;DEPRECATED;2.58;2.58 +824-3;A little u super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Au sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Au sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +82430-0;OJ Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;OJ Ab [Units/volume] in Serum by Line blot;OJ Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82431-8;Platelet-derived growth factor receptor Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Platelet-derived growth factor receptor Ab [Units/volume] in Serum by Line blot;PDGFR Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.66 +82432-6;Platelet-derived growth factor receptor Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Platelet-derived growth factor receptor Ab [Presence] in Serum by Line blot;PDGFR Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82433-4;Proteinase 3 Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Proteinase 3 Ab [Presence] in Serum by Immunoblot;Deprecated Proteinase3 Ab Ser Ql IB;;DEPRECATED;2.58;2.58 +82434-2;Ribosomal Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Ribosomal Ab [Presence] in Serum by Immunoblot;Deprecated Ribosomal Ab Ser Ql IB;;DEPRECATED;2.58;2.58 +82435-9;RNA polymerase III Ab;ACnc;Pt;Ser;Qn;IB;SERO;1;Deprecated RNA polymerase III Ab [Units/volume] in Serum by Immunoblot;Deprecated RNAp III Ab Ser IB-aCnc;;DEPRECATED;2.58;2.66 +82436-7;SCL-70 extractable nuclear Ab;ACnc;Pt;Ser;Qn;IB;SERO;1;Deprecated SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoblot;Deprecated ENA Scl70 Ab Ser IB-aCnc;;DEPRECATED;2.58;2.66 +82437-5;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Sjogrens syndrome-A extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA SS-A Ab CSF Ql IB;;DEPRECATED;2.58;2.58 +8243-8;Styrene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Styrene [Mass/volume] in Blood;Styrene Bld-mCnc;;ACTIVE;1.0h(2);2.73 +82438-3;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;CSF;Ord;IB;SERO;1;Deprecated Sjogrens syndrome-B extractable nuclear Ab [Presence] in Cerebral spinal fluid by Immunoblot;Deprecated ENA SS-B Ab CSF Ql IB;;DEPRECATED;2.58;2.58 +82439-1;SUMO-activating enzyme subunit 1 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;SUMO-activating enzyme subunit 1 Ab [Units/volume] in Serum by Line blot;SAE1 Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82440-9;SUMO-activating enzyme subunit 1 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;SUMO-activating enzyme subunit 1 Ab [Presence] in Serum by Line blot;SAE1 Ab Ser Ql Line blot;;ACTIVE;2.58;2.73 +82441-7;SUMO-activating enzyme subunit 2 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;SUMO-activating enzyme subunit 2 Ab [Units/volume] in Serum by Line blot;SAE2 Ab Ser Line blot-aCnc;;ACTIVE;2.58;2.68 +82442-5;SUMO-activating enzyme subunit 2 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;SUMO-activating enzyme subunit 2 Ab [Presence] in Serum by Line blot;SAE2 Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82443-3;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot;Deprecated ENA SM+RNP Ab Ser Ql IB;;DEPRECATED;2.58;2.58 +82444-1;Glial nuclear type 1 ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Glial nuclear type 1 Ab [Presence] in Serum by Line blot;Glial nuc type 1 Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82445-8;Sulfatide Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Sulfatide Ab [Presence] in Serum by Line blot;Sulfatide Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +8244-6;Titanium;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Titanium [Mass/volume] in Serum or Plasma;Titanium SerPl-mCnc;;ACTIVE;1.0h(2);2.73 +82446-6;Sulfatide Ab.IgG;PrThr;Pt;Ser;Ord;IB;SERO;1;Deprecated Sulfatide IgG Ab [Presence] in Serum by Immunoblot;Deprecated Sulfatide IgG Ser Ql IB;;DEPRECATED;2.58;2.58 +82447-4;Sulfatide Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Sulfatide IgM Ab [Presence] in Serum by Line blot;Sulfatide IgM Ser Ql Line blot;;ACTIVE;2.58;2.66 +82448-2;TIF1-gamma Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;TIF1-gamma Ab [Presence] in Serum by Line blot;TIF1-gamma Ab Ser Ql Line blot;;ACTIVE;2.58;2.73 +82449-0;Titin Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Titin Ab [Presence] in Serum by Line blot;Titin Ab Ser Ql Line blot;;ACTIVE;2.58;2.73 +82450-8;U1 small nuclear ribonucleoprotein 70kD Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;U1 small nuclear ribonucleoprotein 70kD Ab [Presence] in Serum by Line blot;U1 snRNP70 Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82451-6;U1 small nuclear ribonucleoprotein A Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;U1 small nuclear ribonucleoprotein A Ab [Presence] in Serum by Line blot;U1 snRNP-A Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82452-4;U1 small nuclear ribonucleoprotein C Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;U1 small nuclear ribonucleoprotein C Ab [Presence] in Serum by Line blot;U1 snRNP-C Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +8245-3;Zinc;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Blood;Zinc Bld-mCnc;;ACTIVE;1.0h(2);2.73 +82453-2;Zo ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Zo Ab [Presence] in Serum by Line blot;Zo Ab Ser Ql Line blot;;ACTIVE;2.58;2.66 +82454-0;Ganglioside Ab panel;-;Pt;Ser;-;IB;PANEL.SERO;1;Ganglioside Ab panel - Serum by Immunoblot;Gangl Ab Pnl Ser IB;;ACTIVE;2.58;2.58 +82455-7;Ganglioside Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Ganglioside Ab panel - Serum;Gangl Ab Pnl Ser;;ACTIVE;2.58;2.68 +82456-5;Human papilloma virus 16 E6+E7 mRNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16 E6+E7 mRNA [Presence] in Cervix by NAA with probe detection;HPV 16 E6+E7 mRNA Cvx Ql NAA+probe;;ACTIVE;2.58;2.73 +82457-3;Human papilloma virus 16 & 18+45 E6+E7 mRNA panel;-;Pt;Cvx;-;Probe.amp.tar;PANEL.MICRO;1;Human papilloma virus 16 and 18+45 E6+E7 mRNA panel - Cervix by NAA with probe detection;HPV16+18 + 45 E6+E7 mRNA Pnl Cvx NAA+pr;;ACTIVE;2.58;2.63 +82458-1;Gadus chalcogrammus roe Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alaska pollock roe IgE Ab [Units/volume] in Serum;Alaska pollock roe IgE Qn;;ACTIVE;2.58;2.58 +82459-9;Gadus chalcogrammus roe Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Alaska pollock roe IgE Ab RAST class [Presence] in Serum;Alaska pollock roe IgE RAST Ql;;ACTIVE;2.58;2.58 +82460-7;Malus domestica recombinant (rMal d) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Apple recombinant (rMal d) 3 IgE Ab RAST class [Presence] in Serum;Apple (rMal d) 3 IgE RAST Ql;;ACTIVE;2.58;2.58 +8246-1;Amorphous sediment;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Amorphous sediment [Presence] in Urine sediment by Light microscopy;Amorph Sed UrnS Ql Micro;;ACTIVE;1.0h(2);2.73 +82461-5;Influenza virus A & B & H1 2009 pandemic RNA;Prid;Pt;Respiratory.upper;Nom;Probe.amp.tar;MICRO;1;Influenza virus A and B and H1 2009 pandemic RNA [Identifier] in Upper respiratory specimen by NAA with probe detection;FLUAV+FLUBV+H1 09 pan RNA UpRes NAA+pr;;ACTIVE;2.58;2.63 +82462-3;Silver;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Silver [Moles/volume] in Blood;Silver Bld-sCnc;;ACTIVE;2.58;2.58 +82463-1;Aluminum;SCnc;Pt;Bld;Qn;;DRUG/TOX;1;Aluminum [Moles/volume] in Blood;Aluminum Bld-sCnc;;ACTIVE;2.58;2.58 +82464-9;Mosquitoes tested;Num;Pt;Environmental specimen;Qn;;MICRO;1;Mosquito count [#] in Environmental specimen;Mosquitoes tested Environ spec;;ACTIVE;2.58;2.58 +82465-6;Mosquito identified;Type;Pt;Environmental specimen;Nom;;MICRO;1;Mosquito identified [Type] in Environmental specimen;Mosquito Environ spec;;ACTIVE;2.58;2.58 +82466-4;riTUXimab Ab;MCnc;Pt;Ser/Plas;Qn;IA;SERO;1;riTUXimab Ab [Mass/volume] in Serum or Plasma by Immunoassay;riTUXimab Ab SerPl IA-mCnc;;ACTIVE;2.58;2.73 +82467-2;riTUXimab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;riTUXimab [Mass/volume] in Serum or Plasma by Immunoassay;riTUXimab SerPl IA-mCnc;;ACTIVE;2.58;2.73 +82468-0;Edoxaban;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Edoxaban [Mass/volume] in Serum or Plasma by LC/MS/MS;Edoxaban SerPl LC/MS/MS-mCnc;;ACTIVE;2.58;2.58 +82469-8;Etanercept Ab;MCnc;Pt;Ser/Plas;Qn;IA;SERO;1;Etanercept Ab [Mass/volume] in Serum or Plasma by Immunoassay;Etanercept Ab SerPl IA-mCnc;;ACTIVE;2.58;2.73 +82470-6;Etanercept;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Etanercept [Mass/volume] in Serum or Plasma by Immunoassay;Etanercept SerPl IA-mCnc;;ACTIVE;2.58;2.73 +82471-4;Borrelia garinii+afzelii oppA1 gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Borrelia garinii+afzelii oppA1 gene [Presence] in Blood by NAA with non-probe detection;B gar+afz oppA1 Bld Ql NAA+non-probe;;ACTIVE;2.58;2.68 +82472-2;Borrelia garinii+afzelii oppA1 gene;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Borrelia garinii+afzelii oppA1 gene [Presence] in Specimen by NAA with non-probe detection;B gar+afz oppA1 Spec Ql NAA+non-probe;;ACTIVE;2.58;2.69 +82473-0;Borrelia mayonii oppA1 gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Borrelia mayonii oppA1 gene [Presence] in Blood by NAA with non-probe detection;B mayonii oppA1 Bld Ql NAA+non-probe;;ACTIVE;2.58;2.68 +82474-8;Borrelia mayonii oppA1 gene;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Borrelia mayonii oppA1 gene [Presence] in Specimen by NAA with non-probe detection;B mayonii oppA1 Spec Ql NAA+non-probe;;ACTIVE;2.58;2.69 +82475-5;Borrelia miyamotoi glpQ gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Borrelia miyamotoi glpQ gene [Presence] in Blood by NAA with non-probe detection;B miyamotoi glpQ Bld Ql NAA+non-probe;;ACTIVE;2.58;2.73 +82476-3;Borrelia miyamotoi glpQ gene;PrThr;Pt;CSF;Ord;Non-probe.amp.tar;MICRO;1;Borrelia miyamotoi glpQ gene [Presence] in Cerebral spinal fluid by NAA with non-probe detection;B miyamotoi glpQ CSF Ql NAA+non-probe;;ACTIVE;2.58;2.68 +82477-1;Erythrocyte sedimentation rate;Vel;Pt;Bld;Qn;Photometric;HEM/BC;1;Erythrocyte sedimentation rate by Photometric method;ESR Bld Qn Photometric;;ACTIVE;2.58;2.58 +82478-9;3-Hydroxydecenoylcarnitine (C10:1-OH);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;3-Hydroxydecenoylcarnitine (C10:1-OH) [Moles/volume] in Serum or Plasma;3-OH-decenoylcarn SerPl-sCnc;;ACTIVE;2.58;2.58 +8247-9;Mucus;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Mucus [Presence] in Urine sediment by Light microscopy;Mucous Threads UrnS Ql Micro;;ACTIVE;1.0h(2);2.73 +82479-7;TRBV30 gene segment/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV30 gene segment/TRBV gene segments.total in Blood;TRBV30 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82480-5;TRBV29 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV29 gene segments/TRBV gene segments.total in Blood;TRBV29 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82481-3;TRBV28 gene segment/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV28 gene segment/TRBV gene segments.total in Blood;TRBV28 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82482-1;TRBV27 gene segment/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV27 gene segment/TRBV gene segments.total in Blood;TRBV27 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82483-9;TRBV25 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV25 gene segments/TRBV gene segments.total in Blood;TRBV25 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82484-7;TRBV24-1 gene segment/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV24-1 gene segment/TRBV gene segments.total in Blood;TRBV24-1 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82485-4;TRBV20-1 gene segment/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV20-1 gene segment/TRBV gene segments.total in Blood;TRBV20-1 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82486-2;TRBV19 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV19 gene segments/TRBV gene segments.total in Blood;TRBV19 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +8248-7;Spermatozoa;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Spermatozoa [Presence] in Urine sediment by Light microscopy;Sperm UrnS Ql Micro;;ACTIVE;1.0h(2);2.73 +82487-0;TRBV18 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV18 gene segments/TRBV gene segments.total in Blood;TRBV18 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82488-8;TRBV16 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV16 gene segments/TRBV gene segments.total in Blood;TRBV16 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82489-6;TRBV15 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV15 gene segments/TRBV gene segments.total in Blood;TRBV15 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82490-4;TRBV14 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV14 gene segments/TRBV gene segments.total in Blood;TRBV14 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82491-2;TRBV13 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV13 gene segments/TRBV gene segments.total in Blood;TRBV13 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82492-0;TRBV12 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV12 gene segments/TRBV gene segments.total in Blood;TRBV12 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82493-8;TRBV11 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV11 gene segments/TRBV gene segments.total in Blood;TRBV11 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82494-6;TRBV10 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV10 gene segments/TRBV gene segments.total in Blood;TRBV10 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +8249-5;Transitional cells;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Transitional cells [Presence] in Urine sediment by Light microscopy;Trans Cells UrnS Ql Micro;;ACTIVE;1.0h(2);2.73 +82495-3;TRBV9 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV9 gene segments/TRBV gene segments.total in Blood;TRBV9 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82496-1;TRBV7 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV7 gene segments/TRBV gene segments.total in Blood;TRBV7 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82497-9;TRBV6 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV6 gene segments/TRBV gene segments.total in Blood;TRBV6 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82498-7;TRBV5 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV5 gene segments/TRBV gene segments.total in Blood;TRBV5 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82499-5;TRBV4 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV4 gene segments/TRBV gene segments.total in Blood;TRBV4 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +825-0;A little u super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Au sup(a) Ag [Presence] on Red Blood Cells from Donor;Au sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +82500-0;TRBV3-1 gene segment/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV3-1 gene segment/TRBV gene segments.total in Blood;TRBV3-1 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82501-8;TRBV2 gene segments/TRBV gene segments.total;NFr;Pt;Bld;Qn;;MOLPATH;1;TRBV2 gene segments/TRBV gene segments.total in Blood;TRBV2 seg/TRBV seg total NFr Bld;;ACTIVE;2.58;2.58 +82502-6;Ethylmalonate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Ethylmalonate [Moles/volume] in DBS;Ethylmalonate DBS-sCnc;;ACTIVE;2.58;2.61 +8250-3;Microscopic observation;Prid;Pt;Stool;Nom;Microscopy.electron;MICRO;1;Microscopic observation [Identifier] in Stool by Electron microscopy;EM Stl;;ACTIVE;1.0h(2);2.73 +82503-4;Methylsuccinate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Methylsuccinate [Moles/volume] in DBS;Me-succinate DBS-sCnc;;ACTIVE;2.58;2.61 +82504-2;Glutarate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glutarate [Moles/volume] in DBS;Glutarate DBS-sCnc;;ACTIVE;2.58;2.61 +82505-9;3-Hydroxyglutarate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;3-Hydroxyglutarate [Moles/volume] in DBS;3OH-Glutarate DBS-sCnc;;ACTIVE;2.58;2.61 +82506-7;Oligosaccharides pattern;Imp;Pt;Fibroblasts;Nar;Screen;CHEM;1;Oligosaccharides pattern [Interpretation] in Fibroblast by Screen method Narrative;Oligosaccharide Pattern Fib Scn-Imp;;ACTIVE;2.58;2.58 +82507-5;Oligosaccharides pattern;Imp;Pt;WBC;Nar;Screen;CHEM;1;Oligosaccharides pattern [Interpretation] in Leukocytes by Screen method Narrative;Oligosaccharide Pattern WBC Scn-Imp;;ACTIVE;2.58;2.58 +82508-3;Ethyl sulfate;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Ethyl sulfate [Mass/volume] in Saliva (oral fluid);Ethyl sulfate Sal-mCnc;;ACTIVE;2.58;2.73 +82509-1;Gamma interferon.negative control;ACnc;Pt;Bld;Qn;;MICRO;1;Gamma interferon.negative control [Units/volume] in Blood;IGNF neg control Bld-aCnc;;ACTIVE;2.58;2.58 +82510-9;Mycobacterium bovis tuberculin stimulated gamma interferon;Imp;Pt;Bld;Ord;;MICRO;1;Mycobacterium bovis tuberculin stimulated gamma interferon [Interpretation] in Blood Qualitative;M bovis tuberc stim IFN-g Bld-Imp;;ACTIVE;2.58;2.64 +8251-1;Service comment;Imp;Pt;XXX;Nom;;MISC;1;Service comment;Service Cmnt-Imp;;ACTIVE;1.0h(2);2.73 +82511-7;Mycobacterium bovis tuberculin stimulated gamma interferon;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium bovis tuberculin stimulated gamma interferon [Units/volume] in Blood;M bovis tuberc stim IFN-g Bld-aCnc;;ACTIVE;2.58;2.64 +82512-5;Hepatitis C virus genotype 1;Type;Pt;Ser/Plas;Nom;Probe.amp.tar;ABXBACT;1;Hepatitis C virus genotype 1 [Type] in Serum or Plasma by NAA with probe detection;HCV Gentyp 1 SerPl NAA+probe;;ACTIVE;2.58;2.73 +82513-3;Hepatitis C virus genotype 3;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;ABXBACT;1;Hepatitis C virus genotype 3 [Presence] in Serum or Plasma by NAA with probe detection;HCV Gentyp 3 SerPl Ql NAA+probe;;ACTIVE;2.58;2.63 +82514-1;Hepatitis C virus genotype 3 NS5a gene mutations detected;Prid;Pt;Isolate;Nom;Genotyping;ABXBACT;1;Hepatitis C virus genotype 3 NS5a gene mutations detected [Identifier];HCV Gentyp 3 NS5a Mut Det Islt;;ACTIVE;2.58;2.73 +82515-8;NBN gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;NBN gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;NBN Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82516-6;LAMC2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LAMC2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LAMC2 Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82517-4;LAMA3 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;LAMA3 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;LAMA3 Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82518-2;IVD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;IVD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;IVD Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82519-0;Dengue virus 1+3 & 2+4 panel;-;Pt;Ser;-;Probe.amp.tar;PANEL.MICRO;1;Dengue virus 1+3 and 2+4 panel - Serum by NAA with probe detection;DENV 1+3 & 2+4 Pnl Ser NAA+probe;;ACTIVE;2.58;2.63 +82520-8;Velpatasvir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Velpatasvir [Susceptibility] by Genotype method;Velpatasvir Islt Genotyp;;ACTIVE;2.58;2.73 +82521-6;Paritaprevir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Paritaprevir [Susceptibility] by Genotype method;Paritaprevir Islt Genotyp;;ACTIVE;2.58;2.73 +82522-4;Simeprevir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Simeprevir [Susceptibility] by Genotype method;Simeprevir Islt Genotyp;;ACTIVE;2.58;2.73 +82523-2;Grazoprevir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Grazoprevir [Susceptibility] by Genotype method;Grazoprevir Islt Genotyp;;ACTIVE;2.58;2.73 +82524-0;6-Beta naltrexol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;6-Beta naltrexol [Mass/volume] in Urine by Confirmatory method;6-Beta naltrexol Ur Cfm-mCnc;;ACTIVE;2.58;2.73 +82525-7;Hepatitis C virus genotype & drug resistance panel;-;Pt;Isolate+Ser;-;;PANEL.ABXBACT;1;Hepatitis C virus genotype and drug resistance panel;HCV Gentype + Resist Pnl;;ACTIVE;2.58;2.66 +82526-5;6-Beta naltrexol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;6-Beta naltrexol [Mass/volume] in Serum or Plasma;6-Beta naltrexol SerPl-mCnc;;ACTIVE;2.58;2.58 +82527-3;6-Beta naltrexol/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;6-Beta naltrexol/Creatinine [Mass Ratio] in Urine;6-Beta naltrexol/Creat Ur;;ACTIVE;2.58;2.58 +82528-1;VHL gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;VHL gene full mutation analysis in Blood or Tissue by Sequencing;VHL gene Full Mut Anl Bld/T Seq;;ACTIVE;2.58;2.65 +8252-9;Service comment 10;Imp;Pt;XXX;Nom;;MISC;1;Service comment 10;Service Cmnt 10-Imp;;ACTIVE;1.0h(2);2.73 +82529-9;SDHD gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SDHD gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;SDHD gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82530-7;SDHB gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SDHB gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;SDHB gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82531-5;SDHC gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;SDHC gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;SDHC gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82532-3;SDHB & SDHC & SDHD gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;SDHB and SDHC and SDHD gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;SDHB+SDHC+SDHD Del+Dup + Full Mut Bld/T;;ACTIVE;2.58;2.65 +82533-1;VHL gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;VHL gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;VHL gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.58;2.65 +82534-9;CASR gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CASR gene full mutation analysis in Blood or Tissue by Sequencing;CASR gene Full Mut Anl Bld/T Seq;;ACTIVE;2.58;2.73 +82535-6;KRAS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;KRAS gene full mutation analysis in Blood or Tissue by Sequencing;KRAS gene Full Mut Anl Bld/T Seq;;ACTIVE;2.58;2.65 +82536-4;SOS1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SOS1 gene full mutation analysis in Blood or Tissue by Sequencing;SOS1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.58;2.65 +8253-7;Service comment 11;Imp;Pt;XXX;Nom;;MISC;1;Service comment 11;Service Cmnt 11-Imp;;ACTIVE;1.0h(2);2.73 +82537-2;RAF1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;RAF1 gene full mutation analysis in Blood or Tissue by Sequencing;RAF1 Full Mut Anl Bld/T Seq;;ACTIVE;2.58;2.65 +82538-0;CALR gene exon 9 full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CALR gene exon 9 full mutation analysis in Blood or Tissue by Molecular genetics method;CALR Exon 9 Full Mut Anl Bld/T;;ACTIVE;2.58;2.73 +82539-8;Anacardium occidentale recombinant (rAna o) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cashew nut recombinant (rAna o) 3 IgE Ab [Units/volume] in Serum;Cashew nut (rAna o) 3 IgE Qn;;ACTIVE;2.58;2.73 +82540-6;Anacardium occidentale recombinant (rAna o) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cashew nut recombinant (rAna o) 3 IgE Ab RAST class [Presence] in Serum;Cashew nut (rAna o) 3 IgE RAST Ql;;ACTIVE;2.58;2.58 +82541-4;Cetuximab Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cetuximab IgE Ab [Units/volume] in Serum;Cetuximab IgE Qn;;ACTIVE;2.58;2.58 +82542-2;Cetuximab Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cetuximab IgE Ab RAST class [Presence] in Serum;Cetuximab IgE RAST Ql;;ACTIVE;2.58;2.58 +82543-0;Dog recombinant (rCan f) 4 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog recombinant (rCan f) 4 IgE Ab [Units/volume] in Serum;Dog (rCan f) 4 IgE Qn;;ACTIVE;2.58;2.58 +82544-8;Dog recombinant (rCan f) 4 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog recombinant (rCan f) 4 IgE Ab RAST class [Presence] in Serum;Dog (rCan f) 4 IgE RAST Ql;;ACTIVE;2.58;2.58 +8254-5;Service comment 12;Imp;Pt;XXX;Nom;;MISC;1;Service comment 12;Service Cmnt 12-Imp;;ACTIVE;1.0h(2);2.73 +82545-5;Juglans regia recombinant (rJug r) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;English walnut recombinant (rJug r) 3 IgE Ab RAST class [Presence] in Serum;English walnut (rJug r) 3 IgE RAST Ql;;ACTIVE;2.58;2.58 +82546-3;Juglans regia recombinant (rJug r) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;English walnut recombinant (rJug r) 1 IgE Ab RAST class [Presence] in Serum;English walnut (rJug r) 1 IgE RAST Ql;;ACTIVE;2.58;2.58 +82547-1;(Actinidia deliciosa+Carica papaya+Mangifera indica+Musa spp+Persea americana) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 30A (Kiwi+Papaya+Mango+Banana+Avocado) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix 30A IgE Ql;;ACTIVE;2.58;2.66 +82548-9;(Actinidia deliciosa+Carica papaya+Mangifera indica+Musa spp+Persea americana) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 30A (Kiwi+Papaya+Mango+Banana+Avocado) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix 30A IgE RAST Ql;;ACTIVE;2.58;2.66 +82549-7;(Actinidia deliciosa+Carica papaya+Mangifera indica+Musa spp+Persea americana) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 30A (Kiwi+Papaya+Mango+Banana+Avocado) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix 30A IgE Qn;;ACTIVE;2.58;2.66 +82550-5;(Ceratonia siliqua+Lens esculenta+Phaseolus vulgaris+Pisum sativum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 32 (Carob+Lentil+White bean+Pea) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix32 IgE Ql;;ACTIVE;2.58;2.58 +82551-3;(Ceratonia siliqua+Lens esculenta+Phaseolus vulgaris+Pisum sativum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 32 (Carob+Lentil+White bean+Pea) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix32 IgE RAST Ql;;ACTIVE;2.58;2.58 +8255-2;Service comment 13;Imp;Pt;XXX;Nom;;MISC;1;Service comment 13;Service Cmnt 13-Imp;;ACTIVE;1.0h(2);2.73 +82552-1;(Ceratonia siliqua+Lens esculenta+Phaseolus vulgaris+Pisum sativum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 32 (Carob+Lentil+White bean+Pea) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix32 IgE Qn;;ACTIVE;2.58;2.58 +82553-9;(Fagopyrum esculentum+Oryza sativa+Sesamum indicum+Triticum aestivum+Zea mays) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 6 (Buckwheat+Rice+Sesame seed+Wheat+Corn) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix6 IgE Ql;;ACTIVE;2.58;2.58 +82554-7;(Fagopyrum esculentum+Oryza sativa+Sesamum indicum+Triticum aestivum+Zea mays) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 6 (Buckwheat+Rice+Sesame seed+Wheat+Corn) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix6 IgE RAST Ql;;ACTIVE;2.58;2.58 +82555-4;(Fagopyrum esculentum+Oryza sativa+Sesamum indicum+Triticum aestivum+Zea mays) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 6 (Buckwheat+Rice+Sesame seed+Wheat+Corn) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix6 IgE Qn;;ACTIVE;2.58;2.58 +82556-2;(Alternaria tenuis+Artemisia vulgaris+Betula verrucosa+Cladosporium herbarum+Phleum pratense) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Inhalant Allergen Mix 6 (Alternaria tenuis+Mugwort+Silver birch+Cladosporium herbarum+Timothy grass) IgE Ab RAST class [Presence] in Serum by Multidisk;Inhalant Allerg Mix 6 IgE RAST Ql;;ACTIVE;2.58;2.58 +82557-0;(Cow milk+Egg white+Gadus morhua+Triticum aestivum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 75 (Cow milk+Egg white+Cod+Wheat) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix75 IgE Ql;;ACTIVE;2.58;2.58 +82558-8;(Cow milk+Egg white+Gadus morhua+Triticum aestivum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 75 (Cow milk+Egg white+Cod+Wheat) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix75 IgE RAST Ql;;ACTIVE;2.58;2.58 +82559-6;(Cow milk+Egg white+Gadus morhua+Triticum aestivum) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Food Allergen Mix 75 (Cow milk+Egg white+Cod+Wheat) IgE Ab [Units/volume] in Serum;Food Allerg Mix75 IgE Qn;;ACTIVE;2.58;2.58 +8256-0;Service comment 14;Imp;Pt;XXX;Nom;;MISC;1;Service comment 14;Service Cmnt 14-Imp;;ACTIVE;1.0h(2);2.73 +82560-4;(Bertholletia excels+Cocos nucifera+Corylus avellana+Prunus dulcis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 76 (Brazil nut+Coconut+Hazelnut+Almond) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix76 IgE Ql;;ACTIVE;2.58;2.58 +82561-2;(Bertholletia excels+Cocos nucifera+Corylus avellana+Prunus dulcis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 76 (Brazil nut+Coconut+Hazelnut+Almond) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix76 IgE RAST Ql;;ACTIVE;2.58;2.58 +82562-0;(Bertholletia excels+Cocos nucifera+Corylus avellana+Prunus dulcis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 76 (Brazil nut+Coconut+Hazelnut+Almond) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix76 IgE Qn;;ACTIVE;2.58;2.58 +82563-8;(Actinidia chinensis+Anacardium occidentale+Corylus avellana+Lycopersicon lycopersicum+Sesamum indicum) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 77 (Kiwi+Cashew nut+Hazel nut+Tomato+Sesame seed) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix77 IgE Ql;;ACTIVE;2.58;2.58 +82564-6;(Actinidia chinensis+Anacardium occidentale+Corylus avellana+Lycopersicon lycopersicum+Sesamum indicum) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 77 (Kiwi+Cashew nut+Hazel nut+Tomato+Sesame seed) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix77 IgE RAST Ql;;ACTIVE;2.58;2.58 +82565-3;(Actinidia chinensis+Anacardium occidentale+Corylus avellana+Lycopersicon lycopersicum+Sesamum indicum) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 77 (Kiwi+Cashew nut+Hazel nut+Tomato+Sesame seed) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix77 IgE Qn;;ACTIVE;2.58;2.58 +82566-1;(Anthoxanthum odoratum+Cynodon dactylon+Dactylis glomerata+Phleum pratense+Phragmites communis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 5 (Sweet Vernal grass+Bermuda grass+Cocksfoot+Timothy+Common Reed) IgE Ab [Presence] in Serum by Multidisk;Grass Allerg Mix5 IgE Ql;;ACTIVE;2.58;2.58 +82567-9;(Anthoxanthum odoratum+Cynodon dactylon+Dactylis glomerata+Phleum pratense+Phragmites communis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Grass Allergen Mix 5 (Sweet Vernal grass+Bermuda grass+Cocksfoot+Timothy+Common Reed) IgE Ab RAST class [Presence] in Serum by Multidisk;Grass Allerg Mix5 IgE RAST Ql;;ACTIVE;2.58;2.58 +82568-7;(Anthoxanthum odoratum+Cynodon dactylon+Dactylis glomerata+Phleum pratense+Phragmites communis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 5 (Sweet Vernal grass+Bermuda grass+Cocksfoot+Timothy+Common Reed) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allerg Mix5 IgE Qn;;ACTIVE;2.58;2.58 +82569-5;Corylus avellana recombinant (rCor a) 14 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Hazelnut recombinant (rCor a) 14 IgE Ab RAST class [Presence] in Serum;Hazelnut (rCor a) 14 IgE RAST Ql;;ACTIVE;2.58;2.58 +82570-3;Coryphaena hippurus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mahi mahi IgE Ab [Units/volume] in Serum;Mahi mahi IgE Qn;;ACTIVE;2.58;2.58 +82571-1;Coryphaena hippurus Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Mahi mahi IgE Ab RAST class [Presence] in Serum;Mahi mahi IgE RAST Ql;;ACTIVE;2.58;2.58 +82572-9;Betula verrucosa recombinant (rBet v) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 6 IgE Ab [Units/volume] in Serum;Silver Birch (rBet v) 6 IgE Qn;;ACTIVE;2.58;2.58 +82573-7;Betula verrucosa recombinant (rBet v) 6 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Silver Birch recombinant (rBet v) 6 IgE Ab RAST class [Presence] in Serum;Silver Birch (rBet v) 6 IgE RAST Ql;;ACTIVE;2.58;2.58 +82574-5;Staphylococcus aureus enterotoxin E Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Staphylococcus aureus enterotoxin E IgE Ab [Units/volume] in Serum;S aureus Etx E IgE Qn;;ACTIVE;2.58;2.58 +82575-2;Urobilinogen;SCnt;Pt;Stool;Qn;;CHEM;1;Urobilinogen [Moles/mass] in Stool;Urobilinogen Stl-sCnt;;ACTIVE;2.58;2.58 +82576-0;Cyclic citrullinated peptide Ab.IgA;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Cyclic citrullinated peptide IgA Ab [Units/volume] in Serum or Plasma;cCP IgA SerPl-aCnc;;ACTIVE;2.58;2.58 +82577-8;(Malus domestica+Prunus avium+Prunus domestica+Prunus persica+Pyrus communis) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 31 (Apple+Cherry+Plum+Peach+Pear) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix31 IgE Ql;;ACTIVE;2.58;2.58 +8257-8;Service comment 15;Imp;Pt;XXX;Nom;;MISC;1;Service comment 15;Service Cmnt 15-Imp;;ACTIVE;1.0h(2);2.73 +82578-6;(Malus domestica+Prunus avium+Prunus domestica+Prunus persica+Pyrus communis) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 31 (Apple+Cherry+Plum+Peach+Pear) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix31 IgE RAST Ql;;ACTIVE;2.58;2.58 +82579-4;(Malus domestica+Prunus avium+Prunus domestica+Prunus persica+Pyrus communis) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 31 (Apple+Cherry+Plum+Peach+Pear) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix31 IgE Qn;;ACTIVE;2.58;2.58 +82580-2;(Allium sativum+Apium graveolens+Sesamum indicum+Yeast) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 25B (Garlic, Celery, Sesame seed, Yeast) IgE Ab [Presence] in Serum by Multidisk;Food Allerg Mix25B IgE Ql;;ACTIVE;2.58;2.58 +82581-0;(Allium sativum+Apium graveolens+Sesamum indicum+Yeast) Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Food Allergen Mix 25B (Garlic, Celery, Sesame seed, Yeast) IgE Ab RAST class [Presence] in Serum by Multidisk;Food Allerg Mix25B IgE RAST Ql;;ACTIVE;2.58;2.58 +82582-8;(Allium sativum+Apium graveolens+Sesamum indicum+Yeast) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Food Allergen Mix 25B (Garlic, Celery, Sesame seed, Yeast) IgE Ab [Units/volume] in Serum by Multidisk;Food Allerg Mix25B IgE Qn;;ACTIVE;2.58;2.58 +82583-6;Triticum aestivum native (nTri a) 19+20+21 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wheat native (nTri a) 19+20+21 IgE Ab [Units/volume] in Serum;Wheat (nTri a) 19+20+21 IgE Qn;;ACTIVE;2.58;2.58 +82584-4;Dicarboxyhexenoylcarnitine (C6:1-DC)/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Dicarboxyhexenoylcarnitine (C6:1-DC)/Creatinine [Molar ratio] in Urine;Dicarboxyhexenoylcarn/Creat Ur-sRto;;ACTIVE;2.58;2.58 +82585-1;Dicarboxyhexenoylcarnitine (C6:1-DC);SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dicarboxyhexenoylcarnitine (C6:1-DC) [Moles/volume] in DBS;Dicarboxyhexenoylcarn DBS-sCnc;;ACTIVE;2.58;2.61 +8258-6;Service comment 16;Imp;Pt;XXX;Nom;;MISC;1;Service comment 16;Service Cmnt 16-Imp;;ACTIVE;1.0h(2);2.73 +82586-9;Nucleated cells;Num;Pt;Bone mar;Qn;Automated count;HEM/BC;1;Nucleated cells [#] in Bone marrow by Automated count;Nuc cell Mar Auto;;ACTIVE;2.58;2.69 +82587-7;Leukocytes;NCnc;Pt;Bone mar;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Bone marrow by Automated count;WBC # Mar Auto;;ACTIVE;2.58;2.58 +82588-5;Erythrocytes;NCnc;Pt;Bone mar;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Bone marrow by Automated count;RBC # Mar Auto;;ACTIVE;2.58;2.58 +82589-3;Highest level of education;Hx;Pt;^Patient;Ord;;ADMIN.PATIENT.DEMOG;2;Highest level of education;Highest level of educ;;ACTIVE;2.58;2.73 +82590-1;Y of education;Num;Pt;^Patient;Qn;Reported;ADMIN.PATIENT.DEMOG;2;Years of education [#] - Reported;Y of education Reported;;ACTIVE;2.58;2.66 +82591-9;Reticulocytes.low light scatter/Reticulocytes.total;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Reticulocytes.low light scatter/Reticulocytes.total in Blood by Automated count;Retic.low scatter NFr Auto;;ACTIVE;2.58;2.58 +82592-7;Reticulocytes.mid light scatter/Reticulocytes.total;NFr;Pt;Bld;Qn;Automated count;HEM/BC;1;Reticulocytes.mid light scatter/Reticulocytes.total in Blood by Automated count;Mid Retics NFr Auto;;ACTIVE;2.58;2.58 +82593-5;Immunization summary report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Immunization summary report;Immunization summary Rpt;;ACTIVE;2.58;2.64 +8259-4;Service comment 17;Imp;Pt;XXX;Nom;;MISC;1;Service comment 17;Service Cmnt 17-Imp;;ACTIVE;1.0h(2);2.73 +82594-3;Blood velocity-time integral.E wave;Len;Pt;Mitral valve.leaflet.tip;Qn;US.doppler;CARD.US;2;Mitral valve leaflet tip Velocity-time integral (VTI) for the area under E wave by US.doppler;MV leaf tip VTI E-wave DOP;;ACTIVE;2.58;2.58 +82595-0;Blood velocity-time integral.A wave;Len;Pt;Mitral valve.leaflet.tip;Qn;US.doppler;CARD.US;2;Mitral valve leaflet tip Velocity-time integral (VTI) for the area under A wave by US.doppler;MV leaf tip VTI A-wave DOP;;ACTIVE;2.58;2.58 +82596-8;Strain rate.systole.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum strain rate during systole by US 3D;LV Max strain rate sys 3D US;;ACTIVE;2.58;2.67 +82597-6;Chromosome painting analysis;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH;1;Chromosome painting analysis in Blood or Tissue by FISH;Chr paint Bld/T FISH;;ACTIVE;2.58;2.65 +82598-4;REMS medication guide;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS medication guide;FDA insert REMS medication guide;;ACTIVE;2.58;2.58 +82599-2;Oncorhynchus keta roe Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chum salmon roe IgE Ab [Units/volume] in Serum;Chum salmon roe IgE Qn;;ACTIVE;2.58;2.58 +82600-8;Oncorhynchus keta roe Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Chum salmon roe IgE Ab RAST class [Presence] in Serum;Chum salmon roe IgE RAST Ql;;ACTIVE;2.58;2.58 +82601-6;Latex recombinant (rHev b) 10 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 10 IgE Ab [Units/volume] in Serum;Latex (rHev b) 10 IgE Qn;;ACTIVE;2.58;2.58 +8260-2;Service comment 18;Imp;Pt;XXX;Nom;;MISC;1;Service comment 18;Service Cmnt 18-Imp;;ACTIVE;1.0h(2);2.69 +82602-4;Latex recombinant (rHev b) 10 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 10 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 10 IgE RAST Ql;;ACTIVE;2.58;2.58 +82603-2;Latex recombinant (rHev b) 2 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Latex recombinant (rHev b) 2 IgE Ab [Units/volume] in Serum;Latex (rHev b) 2 IgE Qn;;ACTIVE;2.58;2.58 +82604-0;Latex recombinant (rHev b) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Latex recombinant (rHev b) 2 IgE Ab RAST class [Presence] in Serum;Latex (rHev b) 2 IgE RAST Ql;;ACTIVE;2.58;2.58 +82605-7;Triticum aestivum native (nTri a) 19+20+21 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Wheat native (nTri a) 19+20+21 IgE Ab RAST class [Presence] in Serum;Wheat (nTri a) 19+20+21 IgE RAST Ql;;ACTIVE;2.58;2.58 +82606-5;Allergy or intolerance criticality;Imp;Pt;^Patient;Ord;;VACCIN;2;Allergy or intolerance criticality;Allergy or intolerance criticality;;ACTIVE;2.58;2.58 +82607-3;Clinical data;TmStpRange;Pt;^Patient;Qn;;ADMIN;2;Clinical data [Date and Time Range];Clinical data TmStpRange;;ACTIVE;2.58;2.58 +82608-1;Advancing care information;Find;Pt;{Setting}^Population;Doc;;SURVEY.QRDA;4;Advancing care information for population;;;ACTIVE;2.58;2.63 +82609-9;Clinical practice improvement activity;Find;Pt;{Setting}^Population;Doc;;SURVEY.QRDA;4;Clinical practice improvement activity for population;;;ACTIVE;2.58;2.63 +8261-0;Service comment 19;Imp;Pt;XXX;Nom;;MISC;1;Service comment 19;Service Cmnt 19-Imp;;ACTIVE;1.0h(2);2.69 +82610-7;Note;Find;Pt;Observation unit;Doc;{Role};DOC.ONTOLOGY;2;Observation unit Note;Obs Unit Note;;ACTIVE;2.58;2.58 +82611-5;Wearable device external physiologic monitoring panel;-;RptPeriod;^Patient;-;;PANEL.H&P;2;Wearable device external physiologic monitoring panel;Wear device phys monitor Pnl;;ACTIVE;2.58;2.58 +82612-3;(Cynodon dactylon+Festuca elatior+Lolium perenne+Phleum pratense+Secale cereale pollen) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Grass Allergen Mix 7 (Bermuda grass+Meadow fescue+Rye grass+Timothy grass+Cultivated rye) IgE Ab [Units/volume] in Serum by Multidisk;Grass Allergen Mix 7 IgE Qn;;ACTIVE;2.58;2.58 +82613-1;Apis mellifera recombinant (rApi m) 10 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee recombinant (rApi m) 10 IgE Ab [Units/volume] in Serum;Honey bee (rApi m) 10 IgE Qn;;ACTIVE;2.58;2.58 +82614-9;Apis mellifera recombinant (rApi m) 10 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee recombinant (rApi m) 10 IgE Ab RAST class [Presence] in Serum;Honey bee (rApi m) 10 IgE RAST Ql;;ACTIVE;2.58;2.58 +82615-6;Vital capacity^pre bronchodilation;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation;VC pre BD Vol Respiratory Spirometry;;ACTIVE;2.58;2.58 +82616-4;Vital capacity^post bronchodilation;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Vital capacity [Volume] Respiratory system by Spirometry --post bronchodilation;VC p BD Vol Respiratory Spirometry;;ACTIVE;2.58;2.58 +82617-2;Capacity.total^pre bronchodilation;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Total lung capacity by Helium rebreathing --pre bronchodilation;TLC pre BD He Rebreath;;ACTIVE;2.58;2.58 +82618-0;Capacity.total^post bronchodilation;Vol;Pt;Respiratory system;Qn;Helium rebreathing;PULM;2;Total lung capacity by Helium rebreathing --post bronchodilation;TLC p BD He Rebreath;;ACTIVE;2.58;2.58 +82619-8;Diffusion capacity/Alveolar volume^pre bronchodilation;Inverse VI;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity/Alveolar volume --pre bronchodilation;Diff cap/Alv vol pre BD;;ACTIVE;2.58;2.58 +82620-6;Diffusion capacity/Alveolar volume^post bronchodilation;Inverse VI;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity/Alveolar volume --post bronchodilation;Diff cap/Alv vol p BD;;ACTIVE;2.58;2.58 +82621-4;Time to end-systole;Time;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Time to end-systole Left ventricle SPECT;TES LV SPECT;;ACTIVE;2.58;2.58 +82622-2;Filling rate.diastole.max^W stress;VRat;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Peak filling rate Left ventricle SPECT --W stress;PFR W Stress LV SPECT;;ACTIVE;2.58;2.58 +82623-0;Filling rate.diastole.max^resting;VRat;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Peak filling rate Left ventricle SPECT --resting;PFR Resting LV SPECT;;ACTIVE;2.58;2.58 +82624-8;Filling rate.first third of diastole.mean^resting;VRat;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;One-third mean filling rate Left ventricle SPECT --resting;1/3 MFR Resting LV SPECT;;ACTIVE;2.58;2.58 +82625-5;Time to peak filling rate^resting;Time;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Time to peak filling rate Left ventricle SPECT --resting;TPFR Resting LV SPECT;;ACTIVE;2.58;2.58 +82626-3;Phase.max^W stress;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Maximum phase [Angle] Left ventricle SPECT --W stress;Max phase W Stress Angle LV SPECT;;ACTIVE;2.58;2.58 +82627-1;Phase.mean^W stress;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Mean phase [Angle] Left ventricle SPECT --W stress;Mean phase W Stress Angle LV SPECT;;ACTIVE;2.58;2.58 +8262-8;Service comment 02;Imp;Pt;XXX;Nom;;MISC;1;Service comment 02;Service Cmnt 02-Imp;;ACTIVE;1.0h(2);2.73 +82628-9;Phase.standard deviation^W stress;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Phase.standard deviation [Angle] Left ventricle SPECT --W stress;Ph.sd W Stress Angle LV SPECT;;ACTIVE;2.58;2.58 +82629-7;Phase bandwidth^W stress;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Phase bandwidth Left ventricle SPECT --W stress;Phase bandwidth W Stress LV SPECT;;ACTIVE;2.58;2.58 +82630-5;Phase entropy^W stress;Score;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Phase entropy [Score] Left ventricle SPECT --W stress;Phase entropy W Stress Score LV SPECT;;ACTIVE;2.58;2.58 +82631-3;Time to end-systole.difference.max^W stress;TRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Maximum difference in time to end-systole Left ventricle SPECT --W stress;MDTES W Stress LV SPECT;;ACTIVE;2.58;2.58 +82632-1;Time to end-systole.difference.lateral and septal wall^W stress;TRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Difference in time to end-systole between lateral and septal wall Left ventricle SPECT --W stress;DTES-LS W Stress LV SPECT;;ACTIVE;2.58;2.58 +82633-9;Time to end-systole.standard deviation^W stress;TRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Standard deviation of time to end-systole Left ventricle SPECT --W stress;SDTES W Stress LV SPECT;;ACTIVE;2.58;2.58 +82634-7;Phase.max^resting;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Maximum phase [Angle] Left ventricle SPECT --resting;Max phase Resting Angle LV SPECT;;ACTIVE;2.58;2.58 +82635-4;Phase.mean^resting;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Mean phase [Angle] Left ventricle SPECT --resting;Mean phase Resting Angle LV SPECT;;ACTIVE;2.58;2.58 +8263-6;Service comment 20;Imp;Pt;XXX;Nom;;MISC;1;Service comment 20;Service Cmnt 20-Imp;;ACTIVE;1.0h(2);2.73 +82636-2;Phase.standard deviation^resting;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Phase.standard deviation [Angle] Left ventricle SPECT --resting;Ph.sd Resting Angle LV SPECT;;ACTIVE;2.58;2.58 +82637-0;Phase bandwidth^resting;Angle;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Phase bandwidth Left ventricle SPECT --resting;Phase bandwidth Resting LV SPECT;;ACTIVE;2.58;2.58 +82638-8;Phase entropy^resting;Score;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Phase entropy [Score] Left ventricle SPECT --resting;Phase entropy Resting Score LV SPECT;;ACTIVE;2.58;2.58 +82639-6;Time to end-systole.difference.max^resting;TRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Maximum difference in time to end-systole Left ventricle SPECT --resting;MDTES Resting LV SPECT;;ACTIVE;2.58;2.58 +82640-4;Time to end-systole.difference.lateral and septal wall^resting;TRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Difference in time to end-systole between lateral and septal wall Left ventricle SPECT --resting;DTES-LS Resting LV SPECT;;ACTIVE;2.58;2.58 +82641-2;Time to end-systole.standard deviation^resting;TRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Standard deviation of time to end-systole Left ventricle SPECT --resting;SDTES Resting LV SPECT;;ACTIVE;2.58;2.58 +82642-0;Summed stress score.17 segment model;Score;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed stress score for 17 segment model Myocardium SPECT;SSS.17 Myocardium SPECT;;ACTIVE;2.58;2.58 +82643-8;Summed rest score.17 segment model;Score;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed rest score for 17 segment model Myocardium SPECT;SRS.17 Myocardium SPECT;;ACTIVE;2.58;2.58 +8264-4;Service comment 03;Imp;Pt;XXX;Nom;;MISC;1;Service comment 03;Service Cmnt 03-Imp;;ACTIVE;1.0h(2);2.73 +82644-6;Summed difference score.17 segment model;Score;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed difference score for 17 segment model Myocardium SPECT;SDS.17 Myocardium SPECT;;ACTIVE;2.58;2.58 +82645-3;Summed stress score.20 segment model;Score;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed stress score for 20 segment model Myocardium SPECT;SSS.20 Myocardium SPECT;;ACTIVE;2.58;2.58 +82646-1;Summed rest score.20 segment model;Score;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed rest score for 20 segment model Myocardium SPECT;SRS.20 Myocardium SPECT;;ACTIVE;2.58;2.58 +82647-9;Summed difference score.20 segment model;Score;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed difference score for 20 segment model Myocardium SPECT;SDS.20 Myocardium SPECT;;ACTIVE;2.58;2.58 +82648-7;Summed stress score;Prctl;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed stress score Myocardium SPECT;SSS Myocardium SPECT;;ACTIVE;2.58;2.58 +82649-5;Summed rest score;Prctl;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed rest score Myocardium SPECT;SRS Myocardium SPECT;;ACTIVE;2.58;2.58 +82650-3;Summed difference score;Prctl;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Summed difference score Myocardium SPECT;SDS Myocardium SPECT;;ACTIVE;2.58;2.58 +8265-1;Service comment 04;Imp;Pt;XXX;Nom;;MISC;1;Service comment 04;Service Cmnt 04-Imp;;ACTIVE;1.0h(2);2.73 +82651-1;Washout rate;Ratio;Pt;Myocardium;Qn;NM.SPECT;CARD.PROC;2;Washout rate [Ratio] Myocardium SPECT;Washout Myocardium SPECT;;ACTIVE;2.58;2.58 +82652-9;Transient ischemic dilation;VRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Transient ischemic dilation Left ventricle SPECT;TID LV SPECT;;ACTIVE;2.58;2.58 +82653-7;Time to peak filling rate/RR interval^resting;TRto;Pt;Heart.ventricle.left;Qn;NM.SPECT;CARD.PROC;2;Time to peak filling rate/RR interval Left ventricle SPECT --resting;TPFR/RR Resting LV SPECT;;ACTIVE;2.58;2.58 +82654-5;Cardiac nuclear imaging panel;-;Pt;Heart;-;NM.SPECT;PANEL.CARDIAC;2;Cardiac nuclear imaging SPECT panel;Cardiac NM SPECT Pnl;;ACTIVE;2.58;2.73 +82655-2;Gated cardiac measurement panel;-;Pt;Heart.ventricle.left;-;NM.SPECT;PANEL.CARDIAC;2;Gated cardiac measurement panel Left ventricle SPECT;Gated NM Pnl LV SPECT;;ACTIVE;2.58;2.58 +82656-0;Cardiac summed score panel;-;Pt;Myocardium;-;NM.SPECT;PANEL.CARDIAC;2;Cardiac summed score panel Myocardium SPECT;Card summed score Pnl Myocardium SPECT;;ACTIVE;2.58;2.58 +82657-8;Cardiac phase measurement panel;-;Pt;Heart.ventricle.left;-;NM.SPECT;PANEL.CARDIAC;2;Cardiac phase measurement panel Left ventricle SPECT;Card phase meas Pnl LV SPECT;;ACTIVE;2.58;2.58 +82658-6;Glutamate decarboxylase Ab;PrThr;Pt;CSF;Ord;IF;CHEM;1;Glutamate decarboxylase Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;GAD Ab CSF Ql IF;;ACTIVE;2.58;2.58 +82659-4;Thyrotropin receptor Ab;PrThr;Pt;Ser;Ord;;CHEM;1;Thyrotropin receptor Ab [Presence] in Serum;TSH Recep Ab Ser Ql;;ACTIVE;2.58;2.73 +82660-2;Glutamate decarboxylase Ab;PrThr;Pt;Ser/Plas;Ord;IF;CHEM;1;Glutamate decarboxylase Ab [Presence] in Serum or Plasma by Immunofluorescence;GAD Ab SerPl Ql IF;;ACTIVE;2.58;2.58 +82661-0;Intrachamber systolic^post procedure;Pres;Pt;Heart.ventricle.left;Qn;;CARD.PROC;2;Intrachamber systolic pressure Left ventricle --post procedure;Intrachamber sys pres p procedure LV;;ACTIVE;2.58;2.58 +82662-8;Intrachamber diastolic^post procedure;Pres;Pt;Heart.ventricle.left;Qn;;CARD.PROC;2;Intrachamber diastolic pressure Left ventricle --post procedure;Intrachamber dias pres p procedure LV;;ACTIVE;2.58;2.58 +82663-6;Intravascular end diastolic^post procedure;Pres;Pt;Heart.ventricle.left;Qn;;CARD.PROC;2;End diastolic blood pressure Left ventricle --post procedure;BP end dias p procedure LV;;ACTIVE;2.58;2.58 +82664-4;Drug Abuse Screening Test;-;12Mo;^Patient;-;DAST;PANEL.SURVEY.DAST;4;Drug Abuse Screening Test [DAST];;Copyright © 1982 Center for Addiction and Mental Health. Used with permission.;ACTIVE;2.58;2.58 +82665-1;Total Score;Score;12Mo;^Patient;Qn;DAST;SURVEY.DAST;4;Total score [DAST];;Copyright © 1982 Center for Addiction and Mental Health. Used with permission.;ACTIVE;2.58;2.58 +82666-9;Drug Abuse Screening Test-10;-;12Mo;^Patient;-;DAST-10;PANEL.SURVEY.DAST;4;Drug Abuse Screening Test-10 [DAST-10];;Copyright © 1982 Center for Addiction and Mental Health. Used with permission.;ACTIVE;2.58;2.58 +82667-7;Total Score;Score;12Mo;^Patient;Qn;DAST-10;SURVEY.DAST;4;Total score [DAST-10];;Copyright © 1982 Center for Addiction and Mental Health. Used with permission.;ACTIVE;2.58;2.58 +82668-5;Total score;Score;4W;^Patient;Qn;ACT;SURVEY.ACT;4;Total score [ACT];;Portions © OPTUMInsight, Inc. Used with permission.;ACTIVE;2.58;2.66 +8266-9;Service comment 05;Imp;Pt;XXX;Nom;;MISC;1;Service comment 05;Service Cmnt 05-Imp;;ACTIVE;1.0h(2);2.73 +82669-3;How much of the time did your asthma keep you from getting as much done at work, school or at home in the past 4W;Find;4W;^Patient;Ord;ACT;SURVEY.ACT;4;How much of the time did your asthma keep you from getting as much done at work, school or at home in the past 4 weeks [ACT];;Portions © OPTUMInsight, Inc. Used with permission.;ACTIVE;2.58;2.66 +82670-1;How often have you had shortness of breath during the past 4W;Find;4W;^Patient;Ord;ACT;SURVEY.ACT;4;How often have you had shortness of breath during the past 4 weeks [ACT];;Portions © OPTUMInsight, Inc. Used with permission.;ACTIVE;2.58;2.66 +82671-9;How often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in the morning during the past 4W;Find;4W;^Patient;Ord;ACT;SURVEY.ACT;4;How often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in the morning during the past 4 weeks [ACT];;Portions © OPTUMInsight, Inc. Used with permission.;ACTIVE;2.58;2.66 +82672-7;How often have you used your rescue inhaler or nebulizer medication (such as albuterol) during the past 4W;Find;4W;^Patient;Ord;ACT;SURVEY.ACT;4;How often have you used your rescue inhaler or nebulizer medication (such as albuterol) during the past 4 weeks [ACT];;Portions © OPTUMInsight, Inc. Used with permission.;ACTIVE;2.58;2.66 +82673-5;How would you rate your asthma control during the past 4W;Find;4W;^Patient;Ord;ACT;SURVEY.ACT;4;How would you rate your asthma control during the past 4 weeks [ACT];;Portions © OPTUMInsight, Inc. Used with permission.;ACTIVE;2.58;2.66 +82674-3;Asthma Control Test;-;4W;^Patient;-;ACT;PANEL.SURVEY.ACT;4;Asthma Control Test [ACT];;Portions © OPTUMInsight, Inc. Used with permission.;ACTIVE;2.58;2.66 +82675-0;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Cervix by NAA with probe detection;HPV I/H Risk 4 DNA Cvx Ql NAA+probe;;ACTIVE;2.58;2.73 +82676-8;Guidance for percutaneous aspiration of fluid;Find;Pt;Lower extremity.left>Knee;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Knee - left;CT Guided Knee-L Arthrocentesis;;ACTIVE;2.58;2.66 +8267-7;Service comment 06;Imp;Pt;XXX;Nom;;MISC;1;Service comment 06;Service Cmnt 06-Imp;;ACTIVE;1.0h(2);2.73 +82677-6;Multisection^W contrast IV;Find;Pt;Abdomen>Aorta.abdominal;Doc;CT.angio;RAD;2;CTA Abdominal Aorta W contrast IV;CTA Abd Aorta W contr IV;;ACTIVE;2.58;2.61 +82678-4;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Aorta.abdominal;Doc;CT.angio;RAD;2;CTA Abdominal Aorta WO and W contrast IV;CTA Abd Aorta WO+W contr IV;;ACTIVE;2.58;2.61 +82679-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Abdominal vessels & Pelvis>Pelvis vessels;Doc;CT.angio;RAD;2;CTA Abdominal vessels and Pelvis vessels WO and W contrast IV;CTA Abd ves+Pelvis ves WO+W contr IV;;ACTIVE;2.58;2.61 +826-8;A little u super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Au sup(a) Ag [Presence] on Red Blood Cells;Au sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +82680-0;Multisection^WO & W contrast IV;Find;Pt;Head>Head vessels & Neck>Neck vessels;Doc;CT.angio;RAD;2;CTA Head vessels and Neck vessels WO and W contrast IV;CTA Head+Neck Ves WO+W contr IV;;ACTIVE;2.58;2.64 +82681-8;Guidance for percutaneous biopsy;Find;Pt;Head>Oral tissue;Doc;CT;RAD;2;CT Guidance for biopsy of Oral tissue;CT Guided Oral tiss Bx;;ACTIVE;2.58;2.64 +82682-6;Multisection^WO Contrast;Find;Pt;Chest>Clavicle.left;Doc;CT;RAD;2;CT Clavicle - left WO contrast;CT Clavicle-L WO contr;;ACTIVE;2.58;2.61 +82683-4;Multisection^WO Contrast;Find;Pt;Chest>Clavicle.right;Doc;CT;RAD;2;CT Clavicle - right WO contrast;CT Clavicle-R WO contr;;ACTIVE;2.58;2.61 +82684-2;Multisection^WO & W contrast IV;Find;Pt;Chest>Clavicle;Doc;CT;RAD;2;CT Clavicle WO and W contrast IV;CT Clavicle WO+W contr IV;;ACTIVE;2.58;2.61 +8268-5;Service comment 07;Imp;Pt;XXX;Nom;;MISC;1;Service comment 07;Service Cmnt 07-Imp;;ACTIVE;1.0h(2);2.73 +82685-9;Multisection^W Contrast IV;Find;Pt;Chest>Clavicle;Doc;CT;RAD;2;CT Clavicle W contrast IV;CT Clavicle W contr IV;;ACTIVE;2.58;2.61 +82686-7;Multisection^W Contrast IV;Find;Pt;Chest>Clavicle.right;Doc;CT;RAD;2;CT Clavicle - right W contrast IV;CT Clavicle-R W contr IV;;ACTIVE;2.58;2.61 +82687-5;Multisection^WO Contrast;Find;Pt;Chest>Clavicle;Doc;CT;RAD;2;CT Clavicle WO contrast;CT Clavicle WO contr;;ACTIVE;2.58;2.61 +82688-3;Multisection^WO & W contrast IV+W air contrast PR;Find;Pt;Abdomen+Pelvis>Colon+Rectum;Doc;CT;RAD;2;CT Colon and Rectum WO and W contrast IV and W air contrast PR;CT Colon+Rect WO+W contr IV+Air contr PR;;ACTIVE;2.58;2.61 +82689-1;Multisection^W contrast PO+WO & W contrast IV;Find;Pt;Abdomen>Small bowel;Doc;CT;RAD;2;CT Small bowel W contrast PO and WO and W contrast IV;CT SB W contr PO+WO+W IV;;ACTIVE;2.58;2.61 +82690-9;Multisection^WO contrast;Find;Pt;Head & Neck>Spine.cervical;Doc;CT;RAD;2;CT Head and Cervical spine WO contrast;CT Head+C-spine WO contr;;ACTIVE;2.58;2.61 +82691-7;Multisection^W contrast IV;Find;Pt;Head+Neck;Doc;CT;RAD;2;CT Head and Neck W contrast IV;CT Head+Neck W contr IV;;ACTIVE;2.58;2.61 +82692-5;Multisection^WO contrast;Find;Pt;Head+Neck;Doc;CT;RAD;2;CT Head and Neck WO contrast;CT Head+Neck WO contr;;ACTIVE;2.58;2.61 +8269-3;Service comment 08;Imp;Pt;XXX;Nom;;MISC;1;Service comment 08;Service Cmnt 08-Imp;;ACTIVE;1.0h(2);2.73 +82693-3;Multisection^W contrast IV;Find;Pt;Pelvis+Lower extremity;Doc;CT;RAD;2;CT Pelvis and Lower extremity W contrast IV;CT Pelvis+LE W contr IV;;ACTIVE;2.58;2.61 +82694-1;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral;Doc;CT;RAD;2;CT Lower extremity - bilateral WO and W contrast IV;CT LE-Bl WO+W contr IV;;ACTIVE;2.58;2.61 +82695-8;Multisection^W contrast IV;Find;Pt;Pelvis+Lower extremity.bilateral;Doc;CT;RAD;2;CT Pelvis and Lower extremity - bilateral W contrast IV;CT Pelvis+LE-Bl W contr IV;;ACTIVE;2.58;2.61 +82696-6;Multisection^W contrast IV;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;CT;RAD;2;CT Spine Lumbar and Sacrum W contrast IV;CT L-spine+Sacrum W contr IV;;ACTIVE;2.58;2.61 +82697-4;Multisection^WO contrast;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;CT;RAD;2;CT Spine Lumbar and Sacrum WO contrast;CT L-spine+Sacrum WO contr;;ACTIVE;2.58;2.61 +82698-2;Multisection^W contrast IV;Find;Pt;Chest>Ribs.left;Doc;CT;RAD;2;CT Ribs - left W contrast IV;CT Ribs-L W contr IV;;ACTIVE;2.58;2.61 +82699-0;Multisection^WO contrast;Find;Pt;Chest>Ribs.left;Doc;CT;RAD;2;CT Ribs - left WO contrast;CT Ribs-L WO contr;;ACTIVE;2.58;2.61 +82700-6;Multisection^W contrast IV;Find;Pt;Chest>Ribs.right;Doc;CT;RAD;2;CT Ribs - right W contrast IV;CT Ribs-R W contr IV;;ACTIVE;2.58;2.61 +8270-1;Service comment 09;Imp;Pt;XXX;Nom;;MISC;1;Service comment 09;Service Cmnt 09-Imp;;ACTIVE;1.0h(2);2.73 +82701-4;Multisection^WO contrast;Find;Pt;Chest>Ribs.right;Doc;CT;RAD;2;CT Ribs - right WO contrast;CT Ribs-R WO contr;;ACTIVE;2.58;2.61 +82702-2;Multisection^WO & W contrast IV;Find;Pt;Chest>Ribs.right;Doc;CT;RAD;2;CT Ribs - right WO and W contrast IV;CT Ribs-R WO+W contr IV;;ACTIVE;2.58;2.61 +82703-0;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;CT;RAD;2;CT Sacrum and Coccyx WO and W contrast IV;CT Sacrum+Coccyx WO+W contr IV;;ACTIVE;2.58;2.61 +82704-8;Multisection^W contrast IV;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;CT;RAD;2;CT Sacrum and Coccyx W contrast IV;CT Sacrum+Coccyx W contr IV;;ACTIVE;2.58;2.61 +82705-5;Multisection^WO contrast;Find;Pt;Chest>Scapula.left;Doc;CT;RAD;2;CT Scapula - left WO contrast;CT Scapula-L WO contr;;ACTIVE;2.58;2.61 +82706-3;Multisection^WO contrast;Find;Pt;Chest>Scapula.right;Doc;CT;RAD;2;CT Scapula - right WO contrast;CT Scapula-R WO contr;;ACTIVE;2.58;2.61 +82707-1;Multisection^WO & W contrast IV;Find;Pt;Chest>Scapula.left;Doc;CT;RAD;2;CT Scapula - left WO and W contrast IV;CT Scapula-L WO+W contr IV;;ACTIVE;2.58;2.61 +82708-9;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.bilateral>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - bilateral WO and W contrast IV;CTA LE ves-Bl WO+W contr IV;;ACTIVE;2.58;2.61 +82709-7;Multisection;Find;Pt;Chest>Aorta.thoracic;Doc;CT.angio;RAD;2;CTA Thoracic Aorta;CTA TA;;ACTIVE;2.58;2.61 +82710-5;Multisection;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - right;CTA LE ves-R;;ACTIVE;2.58;2.61 +82711-3;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - bilateral;CTA LE ves-Bl;;ACTIVE;2.58;2.61 +82712-1;Multisection;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - left;CTA LE ves-L;;ACTIVE;2.58;2.61 +82713-9;Multisection;Find;Pt;Upper extremity.left>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - left;CTA UE ves-L;;ACTIVE;2.58;2.61 +82714-7;Multisection;Find;Pt;Upper extremity.right>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - right;CTA UE ves-R;;ACTIVE;2.58;2.61 +82715-4;Guidance for percutaneous aspiration of fluid;Find;Pt;Lower extremity.right>Knee;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Knee - right;CT Guided Knee-R Arthrocentesis;;ACTIVE;2.58;2.66 +82716-2;Multisection^W contrast IV;Find;Pt;Chest>Clavicle.left;Doc;CT;RAD;2;CT Clavicle - left W contrast IV;CT Clavicle-L W contr IV;;ACTIVE;2.58;2.61 +82717-0;Multisection^WO & W contrast IV;Find;Pt;Chest>Ribs.left;Doc;CT;RAD;2;CT Ribs - left WO and W contrast IV;CT Ribs-L WO+W contr IV;;ACTIVE;2.58;2.61 +82718-8;Multisection^WO & W contrast IV;Find;Pt;Chest>Scapula.right;Doc;CT;RAD;2;CT Scapula - right WO and W contrast IV;CT Scapula-R WO+W contr IV;;ACTIVE;2.58;2.61 +8271-9;Haemophilus influenzae C Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Haemophilus influenzae C Ag [Presence] in Specimen by Immunofluorescence;Haem influ C Ag Spec Ql IF;;ACTIVE;1.0h(2);2.69 +82719-6;Enfuvirtide;Susc;Pt;Isolate;OrdQn;Phenotyping;ABXBACT;1;Enfuvirtide [Susceptibility] by Phenotype method;Enfuvirtide Islt Phenotyp;;ACTIVE;2.58;2.73 +82720-4;Natural killer cell cytotoxicity panel;-;Pt;Bld MC;-;;PANEL.HEM/BC;1;Natural killer cell cytotoxicity panel - Blood mononuclear cells;NK cytotox Pnl Bld MC;;ACTIVE;2.58;2.64 +82721-2;Intravenous lipid emulsion;MCnc;Pt;Ser;Qn;Nephelometry;CHEM;1;Intravenous lipid emulsion [Mass/volume] in Serum by Nephelometry;Intravenous lipid emulsion Ser Neph-mCnc;;ACTIVE;2.58;2.58 +82722-0;Potassium;MCnc;Pt;RBC;Qn;;CHEM;1;Potassium [Mass/volume] in Red Blood Cells;Potassium RBC-mCnc;;ACTIVE;2.58;2.58 +82723-8;Cocaine+Benzoylecgonine+Cocaethylene;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cocaine+Benzoylecgonine+Cocaethylene [Presence] in Urine by Confirmatory method;Coc+Benzoylecgon+Cocaethyl Ur Ql Cfm;;ACTIVE;2.58;2.58 +82724-6;Natural killer cell cytotoxicity.3.13:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.3.13:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.3.13:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.58;2.63 +82725-3;Natural killer cell cytotoxicity.6.25:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.6.25:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.6.25:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.58;2.63 +82726-1;Natural killer cell cytotoxicity.12.5:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.12.5:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.12.5:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.58;2.63 +8272-7;Cefepime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefepime [Susceptibility] by Disk diffusion (KB);Cefepime Islt KB;;ACTIVE;1.0h(2);2.73 +82727-9;Natural killer cell cytotoxicity.25:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.25:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.25:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.58;2.63 +82728-7;Natural killer cell cytotoxicity.50:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.50:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.50:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.58;2.63 +82729-5;Natural killer cell cytotoxicity.100:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.100:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.100:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.58;2.63 +82730-3;GlycA;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;GlycA [Moles/volume] in Serum or Plasma;GlycA SerPl-sCnc;;ACTIVE;2.58;2.73 +82731-1;Zika virus Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Zika virus IgM Ab [Presence] in Serum by Immunofluorescence;ZIKV IgM Ser Ql IF;;ACTIVE;2.58;2.58 +82732-9;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1+2 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;AMPAR1+AMPAR2 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;AMPAR 1+2 IgG CSF Ql IF;;ACTIVE;2.58;2.58 +82733-7;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1+2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;AMPAR1+AMPAR2 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;AMPAR 1+2 IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +82734-5;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;AMPAR1 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;AMPAR1 IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +8273-5;Cefepime;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefepime [Susceptibility] by Serum bactericidal titer;Cefepime Titr SBT;;ACTIVE;1.0h(2);2.32 +82735-2;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;AMPAR1 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;AMPAR1 IgG CSF Ql IF;;ACTIVE;2.58;2.58 +82736-0;Calcium-calmodulin-dependent protein kinase II activity actual/Normal;RelCCnc;Pt;Ser;Qn;;CHEM;1;Calcium-calmodulin-dependent protein kinase II activity actual/normal in Serum;CaM Kinase II activity Act/Nor Ser;;ACTIVE;2.58;2.58 +82737-8;Beta tubulin Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Beta tubulin IgG Ab [Titer] in Serum by Immunoassay;B-Tubulin IgG Titr Ser IA;;ACTIVE;2.58;2.58 +82738-6;Dopamine receptor D2 long Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Dopamine receptor D2 IgG Ab [Titer] in Serum by Immunoassay;DRD2L IgG Titr Ser IA;;ACTIVE;2.58;2.69 +82739-4;Dopamine receptor D1 Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Dopamine receptor D1 IgG Ab [Titer] in Serum by Immunoassay;DRD1 IgG Titr Ser IA;;ACTIVE;2.58;2.69 +82740-2;Lysoganglioside GM1 Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Lysoganglioside GM1 IgG Ab [Titer] in Serum by Immunoassay;Lyso-GM1 IgG Titr Ser IA;;ACTIVE;2.58;2.58 +82741-0;Pediatric autoimmune neuropsychiatric disorder associated with streptococcus diagnosis panel;-;Pt;Ser;-;;PANEL.SERO;1;Pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS) panel - Serum;PANDAS panel Ser;;ACTIVE;2.58;2.73 +82742-8;Multisection^WO & W contrast IV && Multisection^W contrast IV;Find;Pt;Head && Head>Orbit.bilateral;Doc;CT;RAD;2;CT Head WO and W contrast IV and CT Orbit - bilateral W contrast IV;CT Head WO+W and CT Orbit-Bl W contr IV;;ACTIVE;2.58;2.61 +8274-3;Cefpirome;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefpirome [Susceptibility] by Minimum lethal concentration (MLC);Cefpirome Islt MLC;;ACTIVE;1.0h(2);2.19 +82743-6;Cells.CD8+CD45RA+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD8+CD45RA+ cells [#/volume] in Blood;CD8+CD45RA+ Cells # Bld;;ACTIVE;2.61;2.73 +82744-4;Cells.CD8+CD45RA+/100 cells.CD8;NFr;Pt;Bld;Qn;;CELLMARK;1;CD8+CD45RA+ cells/100 CD8 cells in Blood;CD8+CD45RA+ Cells/100 CD8 NFr Bld;;ACTIVE;2.61;2.73 +82745-1;Doses of vaccine given^pre symptom onset;Num;Pt;^Patient;Qn;;VACCIN;2;Doses of vaccine given [#] --pre symptom onset;Vacc doses Gvn pre symp onset;;ACTIVE;2.58;2.66 +82746-9;Varicella zoster virus strain;Type;Pt;Isolate;Nom;;MICRO;1;Varicella zoster virus strain [Type] in Isolate;VZV strain Islt;;ACTIVE;2.58;2.58 +82747-7;Babesia microti Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Babesia microti IgG Ab [Presence] in Serum by Immunoblot;B microti IgG Ser Ql IB;;ACTIVE;2.58;2.64 +82748-5;Erythrocytes.Babesia sp infected/100 erythrocytes;NFr;Pt;Bld;Qn;;MICRO;1;Erythrocytes.Babesia sp infected/100 erythrocytes in Blood;Babesia infected RBC/100 RBC Bld-NFr;;ACTIVE;2.58;2.58 +82749-3;Date diagnosis confirmed;Date;Pt;^Mother;Qn;;H&P.HX;2;Date diagnosis confirmed from Mother;Mother's Dx confirm date;;ACTIVE;2.58;2.58 +8275-0;Cefpirome;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefpirome [Susceptibility] by Minimum inhibitory concentration (MIC);Cefpirome Islt MIC;;ACTIVE;1.0h(2);2.19 +82750-1;Diagnosis confirmed before or after delivery;Find;Pt;^Mother;Ord;;H&P.HX;2;Mother's Diagnosis confirmed before or after delivery;Mother's Dx pre- or post-delivery;;ACTIVE;2.58;2.58 +82751-9;Babesiosis during pregnancy;Find;Pt;^Mother;Ord;;H&P.HX;2;Maternal Babesiosis during pregnancy Qualitative;Mat Babesiosis dur preg Ql;;ACTIVE;2.58;2.58 +82752-7;Date travel started;Date;Pt;^Patient;Qn;;H&P.HX;2;Date travel started;Travel start date;;ACTIVE;2.58;2.58 +82753-5;County of travel;Loc;Pt;^Patient;Nom;;H&P.HX;2;County of travel [Location];Cnty of travel;;ACTIVE;2.58;2.58 +82754-3;State of travel;Loc;Pt;^Patient;Nom;;H&P.HX;2;State of travel;St of travel;;ACTIVE;2.58;2.58 +82755-0;Geographic location where tick bite occurred;Loc;Pt;^Patient;Nom;;H&P.HX;2;Geographic location where tick bite occurred;Tick bite geo loc;;ACTIVE;2.58;2.58 +82756-8;Date of blood donation;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of blood donation;Bld donation date;;ACTIVE;2.58;2.58 +82757-6;Immunodeficiency;Type;Pt;^Patient;Nom;;H&P.HX;2;Immunodeficiency;Immunodef;;ACTIVE;2.58;2.73 +82758-4;Date of previous diagnosis;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of previous diagnosis;Date prev dx;;ACTIVE;2.58;2.58 +82759-2;Reason for splenectomy;Find;Pt;^Patient;Nom;;H&P.HX;2;Reason for splenectomy;Splenectomy reason;;ACTIVE;2.58;2.58 +827-6;Am Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Am Ag [Presence] on Red Blood Cells from Blood product unit;Am Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +82760-0;Date of splenectomy;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of splenectomy;Splenectomy date;;ACTIVE;2.58;2.58 +82761-8;Identified based on transfusion investigation post blood product donation;Find;Pt;^Patient;Ord;;CLIN;2;Identified based on transfusion investigation post blood product donation;Ident based on transfusion invest;;ACTIVE;2.58;2.58 +82762-6;Outdoor activity^8 weeks pre symptom onset or diagnosis;PrThr;Pt;^Patient;Ord;;H&P.HX;2;Outdoor activity --8 weeks pre symptom onset or diagnosis;Outdoor act 8 wks pre symp;;ACTIVE;2.58;2.58 +82763-4;Outdoor activity;Type;Pt;^Patient;Nom;;H&P.HX;2;Outdoor activity;Outdoor act;;ACTIVE;2.58;2.58 +82764-2;Country of travel outside the U.S.;Loc;2Y;^Patient;Nom;;H&P.HX;2;Country of travel outside the U.S. [Location] 2 years;Trav country outside U.S. 2Y;;ACTIVE;2.58;2.58 +82765-9;Date prescription dispensed;Date;Pt;Medication;Qn;;MEDS;2;Date prescription dispensed Medication;Date rx disp Medication;;ACTIVE;2.58;2.58 +82766-7;Days' supply dispensed;Num;Pt;Medication;Qn;;MEDS;2;Days' supply dispensed [#] Medication;Days' supply disp Medication;;ACTIVE;2.58;2.58 +82767-5;Amount dispensed;Num;Pt;Medication;Qn;;MEDS;2;Amount dispensed [#] Medication;Amount disp Medication;;ACTIVE;2.58;2.58 +8276-8;Cefpirome;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefpirome [Susceptibility] by Disk diffusion (KB);Cefpirome Islt KB;;ACTIVE;1.0h(2);2.19 +82768-3;Lab order priority;Type;Pt;^Patient;Ord;;LABORDERS;1;Lab order priority [Type];Lab order priority Patient Ql;;ACTIVE;2.58;2.58 +82769-1;Smoked or non-smoked tobacco;Type;Pt;^Patient;Nom;;H&P.HX;2;Smoked or non-smoked tobacco;Smoked or non-smoked tob;;ACTIVE;2.58;2.58 +82770-9;Patient reported outcome Computer Adaptive Testing used;PrThr;Pt;^Patient;Ord;;CLINTRIAL;2;Patient reported outcome Computer Adaptive Testing used;PRO CAT used;;ACTIVE;2.58;2.58 +82771-7;Lab test location performed;Type;Pt;^Patient;Nom;;LABORDERS;1;Lab test location performed [Type];Lab test loc perf Patient;;ACTIVE;2.58;2.73 +82772-5;Lab result date reported;Date;Pt;^Patient;Qn;;LABORDERS;1;Lab result date reported;Lab result date rep;;ACTIVE;2.58;2.58 +82773-3;Lab result time reported;TmStp;Pt;^Patient;Qn;;LABORDERS;1;Lab result time reported;Lab result time rep Patient;;ACTIVE;2.58;2.58 +82774-1;Quantity prescribed;Num;Pt;Medication;Qn;;MEDS;2;Quantity prescribed [#] Medication;Quan prescribed Medication;;ACTIVE;2.58;2.58 +82775-8;Refills prescribed;Num;Pt;Medication;Qn;;MEDS;2;Refills prescribed [#] Medication;Refills presc Medication;;ACTIVE;2.58;2.58 +8277-6;Body surface;Area;Pt;^Patient;Qn;;BDYSURF.ATOM;2;Body surface area;BSA;;ACTIVE;1.0h(2);2.73 +82776-6;Days' supply prescribed;Num;Pt;Medication;Qn;;MEDS;2;Days' supply prescribed [#] Medication;Days' supply prescribed Medication;;ACTIVE;2.58;2.58 +82777-4;Frequency prescribed;NRat;Pt;Medication;Qn;;MEDS;2;Frequency prescribed Medication;Freq prescribed Medication;;ACTIVE;2.58;2.58 +82778-2;Trial enrollment date;Date;Pt;^Patient;Qn;;CLINTRIAL;2;Trial enrollment date;Trial enroll date;;ACTIVE;2.58;2.58 +82779-0;Trial participation end date;Date;Pt;^Patient;Qn;;CLINTRIAL;2;Trial participation end date;Trial partic end date;;ACTIVE;2.58;2.58 +82780-8;Borrelia miyamotoi flaB gene;PrThr;Pt;^Tick;Ord;Probe.amp.tar;MICRO;1;Borrelia miyamotoi flaB gene [Presence] in Tick by NAA with probe detection;B miyamotoi flaB Tick Ql NAA+probe;;ACTIVE;2.58;2.73 +82781-6;Borrelia miyamotoi flaB gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Borrelia miyamotoi flaB gene [Presence] in Specimen by NAA with probe detection;B miyamotoi flaB Spec Ql NAA+probe;;ACTIVE;2.58;2.73 +82782-4;Patient reported outcome item identifier;ID;Pt;^Patient;Nom;;CLINTRIAL;2;Patient reported outcome item identifier;PRO item id;;ACTIVE;2.58;2.58 +82783-2;Patient reported outcome response;Find;Pt;^Patient;Nom;;CLINTRIAL;2;Patient reported outcome response;PRO response;;ACTIVE;2.58;2.58 +8278-4;Formula used to compute body surface area;Type;Pt;Formula;Nom;*;BDYSURF.ATOM;2;Formula used to compute body surface area;BSA formula;;ACTIVE;1.0h(2);2.73 +82784-0;Patient reported outcome response method;Type;Pt;^Patient;Nom;;CLINTRIAL;2;Patient reported outcome response method;PRO response method;;ACTIVE;2.58;2.58 +82785-7;Lab order date;Date;Pt;^Patient;Qn;;LABORDERS;1;Lab order date;Lab order date;;ACTIVE;2.58;2.73 +82786-5;Identifier;Find;Pt;^Clinical trial protocol;Nom;;CLINTRIAL;2;Identifier Clinical trial protocol;ID CTP;;ACTIVE;2.58;2.73 +82787-3;Participant identifier;ID;Pt;^Patient;Nom;;CLINTRIAL;2;Participant identifier;Participant id;;ACTIVE;2.58;2.58 +82788-1;Study site identifier;ID;Pt;^Clinical trial protocol;Nom;;CLINTRIAL;2;Study site identifier Clinical trial protocol;Study site id CTP;;ACTIVE;2.58;2.58 +82789-9;Trial early withdrawal date;Date;Pt;^Patient;Qn;;CLINTRIAL;2;Trial early withdrawal date;Trial early withdrawal date;;ACTIVE;2.58;2.58 +82790-7;Trial invitation code;ID;Pt;^Patient;Nom;;CLINTRIAL;2;Trial invitation code;Trial invite code;;ACTIVE;2.58;2.58 +82791-5;Cause of death sequence;Type;Pt;^Patient;Ord;;CLIN;2;Cause of death sequence;Cause of death seq;;ACTIVE;2.58;2.58 +8279-2;Circumference.at nipple line;Len;Pt;Chest;Qn;;BDYCRC.MOLEC;2;Chest Circumference at nipple line;Chest Circumf.at nipple line;;ACTIVE;1.0h(2);2.48 +82792-3;Clot density;OD;Pt;PPP;Qn;Coag;COAG;1;Clot density in Platelet poor plasma;Clot D PPP;;ACTIVE;2.58;2.7 +82793-1;Clot size^30M post incubation;Len;Pt;PPP;Qn;Coag;COAG;1;Clot size [Length] in Platelet poor plasma --30 minutes post incubation;Clot size 30M p Inc PPP;;ACTIVE;2.58;2.7 +82794-9;Clot formation.spontaneous;Time;Pt;PPP;Qn;Coag;COAG;1;Spontaneous clot formation [Time] in Platelet poor plasma;CFT.spont PPP;;ACTIVE;2.58;2.7 +82795-6;Clot growth;Vel;Stdy^mean;PPP;Qn;Coag;COAG;1;Clot growth mean [Velocity] Platelet poor plasma;Clot growth Mean PPP Qn;;ACTIVE;2.58;2.7 +82796-4;Clot growth.stationary;Vel;Stdy^mean;PPP;Qn;Coag;COAG;1;Stationary clot growth mean [Velocity] Platelet poor plasma;Clot growth.stat Mean PPP Qn;;ACTIVE;2.58;2.7 +82797-2;Clot growth.initial;Vel;Pt;PPP;Qn;Coag;COAG;1;Initial clot growth [Velocity] in Platelet poor plasma;Clot growth.init PPP Qn;;ACTIVE;2.58;2.7 +82798-0;Clot formation lag time;Time;Pt;PPP;Qn;Coag;COAG;1;Clot formation lag time in Platelet poor plasma;Clot form lag PPP;;ACTIVE;2.58;2.7 +82799-8;Spatial clot growth analysis panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Spatial clot growth analysis panel - Platelet poor plasma;Spatial clot growth Pnl PPP;;ACTIVE;2.58;2.58 +82-8;Cefixime;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefixime [Susceptibility] by Serum bactericidal titer;Cefixime Titr SBT;;ACTIVE;1.0;2.32 +8280-0;Circumference.at umbilicus;Len;Pt;Abdomen.mid;Qn;Tape measure;BDYCRC.MOLEC;2;Waist Circumference at umbilicus by Tape measure;Circumf.at umbilicus by Tape measure;;ACTIVE;1.0h(2);2.73 +82800-4;Multisection^W radionuclide IV+W contrast IV;Find;Pt;Chest>Heart;Doc;PT+CT;RAD;2;PET+CT Heart W contrast IV;PET+CT Hrt W RNC IV+W contr IV;;ACTIVE;2.58;2.61 +82801-2;Multisection^W radionuclide IV+WO contrast;Find;Pt;Chest>Heart;Doc;PT+CT;RAD;2;PET+CT Heart WO contrast;PET+CT Hrt W RNC IV+WO contr;;ACTIVE;2.58;2.61 +82802-0;Multisection^WO & W contrast IV && Multisection^W contrast IV;Find;Pt;Head && Head>Sinuses;Doc;CT;RAD;2;CT Head WO and W contrast IV and CT Sinuses W contrast IV;CT Head WO+W and CT Sinuses W contr IV;;ACTIVE;2.58;2.61 +82803-8;Multisection^WO & W contrast IV && Multisection^W contrast IV;Find;Pt;Head && Head>Temporal bone;Doc;CT;RAD;2;CT Head WO and W contrast IV and CT Temporal bone W contrast IV;CT Head WO+W and CT Temp bone W contr IV;;ACTIVE;2.58;2.61 +82804-6;Multisection^WO & W contrast IV && Multisection^W contrast IV;Find;Pt;Head && Neck;Doc;CT;RAD;2;CT Head WO and W contrast IV and CT Neck W contrast IV;CT Head WO+W and CT Neck W contr IV;;ACTIVE;2.58;2.61 +82805-3;Guidance for localization of tumor^W 18F-FDG IV+WO Contrast;Find;Pt;Whole body;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Whole body-- W 18F-FDG IV and WO contrast;PT+CT Whole body Tum loc W FDG+WO contr;;ACTIVE;2.58;2.61 +82806-1;Guidance for localization of tumor^W 18F-FDG IV+W contrast IV;Find;Pt;Whole body;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Whole body-- W 18F-FDG IV and W contrast IV;PT+CT Whole body Tum loc W FDG+contr IV;;ACTIVE;2.58;2.61 +82807-9;Guidance for localization of tumor^W 18F-FDG IV+WO Contrast;Find;Pt;Whole body>Skull vertex to mid-thigh;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Skull vertex to mid-thigh-- W 18F-FDG IV and WO contrast;PT+CT Vert-thigh Tum loc W FDG+WO contr;;ACTIVE;2.58;2.61 +82808-7;Guidance for localization of tumor^W 18F-FDG IV+WO Contrast;Find;Pt;Whole body>Skull base to mid-thigh;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Skull base to mid-thigh-- W 18F-FDG IV and WO contrast;PT+CT Skull-thigh Tum loc W FDG+WO contr;;ACTIVE;2.58;2.61 +82809-5;Guidance for localization of tumor^W 18F-FDG IV+W contrast IV;Find;Pt;Whole body>Skull base to mid-thigh;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Skull base to mid-thigh-- W 18F-FDG IV and W contrast IV;PT+CT Skull-thigh Tum loc W FDG+contr;;ACTIVE;2.58;2.61 +82810-3;Pregnancy status;Find;Pt;^Patient;Nom;;H&P.HX;2;Pregnancy status;Pregnancy status;;ACTIVE;2.58;2.73 +82811-1;Nurse summary note - recommended sections;-;Pt;{Setting};-;;PANEL.DOC;2;Nurse summary note - recommended sections;Nurse summary note sections;;ACTIVE;2.58;2.58 +82812-9;Sodium;MCnc;Pt;RBC;Qn;;CHEM;1;Sodium [Mass/volume] in Red Blood Cells;Sodium RBC-mCnc;;ACTIVE;2.58;2.58 +82813-7;Adverse Childhood Experiences;-;Pt;^Patient;-;ACE;PANEL.SURVEY.MTLHLTH;4;Adverse Childhood Experiences [ACE];;;ACTIVE;2.58;2.58 +82814-5;Emotional abuse^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Emotional abuse--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82815-2;Physical abuse^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Physical abuse--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82816-0;Sexual abuse^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Sexual abuse--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82817-8;Emotional neglect^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Emotional neglect--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +8281-8;Circumference.at umbilicus;Len;Pt;Abdomen.mid;Qn;US;BDYCRC.MOLEC;2;Waist Circumference at umbilicus by US;Circumf.at umbilicus by US;;ACTIVE;1.0h(2);2.73 +82818-6;Physical neglect^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Physical neglect--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82819-4;Parental separation or divorce^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Parental separation or divorce--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82820-2;Domestic violence^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Domestic violence--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82821-0;Household substance abuse^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Household substance abuse--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82822-8;Mental illness in household^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Mental illness in household--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82823-6;Criminal household member^pre 18Yo;Find;Pt;^Patient;Ord;ACE;SURVEY.MTLHLTH;4;Criminal household member--before 18 years old [ACE];;;ACTIVE;2.58;2.63 +82824-4;Surgical operation note;Find;Pt;{Setting};Doc;Clinical neurophysiology;DOC.ONTOLOGY;2;Clinical neurophysiology Surgical operation note;Clinical Neurophys Operative note;;ACTIVE;2.58;2.58 +82825-1;Initial evaluation note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Initial evaluation note;Comm hlth care Initial eval note;;ACTIVE;2.58;2.58 +8282-6;Circumference.max;Len;Pt;Calf.left;Qn;;BDYCRC.MOLEC;2;Calf - left Maximum circumference;Calf-L Circumf.max;;ACTIVE;1.0h(2);2.48 +82826-9;Initial evaluation note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Initial evaluation note;Cardiac surgery Initial eval note;;ACTIVE;2.58;2.58 +82827-7;Initial evaluation note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Initial evaluation note;Col+rec surg Initial eval note;;ACTIVE;2.58;2.58 +82828-5;Initial evaluation note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Initial evaluation note;Cardio+Pulm disease Initial eval note;;ACTIVE;2.58;2.58 +82829-3;Initial evaluation note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Initial evaluation note;Cardiothor surg Initial eval note;;ACTIVE;2.58;2.58 +82830-1;Initial evaluation note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Initial evaluation note;Neuro surgery Initial eval note;;ACTIVE;2.58;2.58 +82832-7;Initial evaluation note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Initial evaluation note;Plastic surgery Initial eval note;;ACTIVE;2.58;2.58 +82833-5;Initial evaluation note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Initial evaluation note;Orthopaedic surgery Initial eval note;;ACTIVE;2.58;2.58 +8283-4;Circumference.max;Len;Pt;Calf.right;Qn;;BDYCRC.MOLEC;2;Calf - right Maximum circumference;Calf-R Circumf.max;;ACTIVE;1.0h(2);2.48 +82834-3;Initial evaluation note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Initial evaluation note;OMS Initial eval note;;ACTIVE;2.58;2.58 +82835-0;Initial evaluation note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Initial evaluation note;Transpl surg Initial eval note;;ACTIVE;2.58;2.73 +82836-8;Initial evaluation note;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Initial evaluation note;Peds surgery Initial eval note;;ACTIVE;2.58;2.58 +82837-6;Initial evaluation note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Initial evaluation note;Pharmacology Initial eval note;;ACTIVE;2.58;2.58 +82838-4;Initial evaluation note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Initial evaluation note;Vascular surgery Initial eval note;;ACTIVE;2.58;2.58 +82839-2;Initial evaluation note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Initial evaluation note;Surg Onc Initial eval note;;ACTIVE;2.58;2.58 +828-4;Am Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Am Ag [Presence] on Red Blood Cells from Donor;Am Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +82840-0;Mitochondria Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Mitochondria IgG Ab [Presence] in Serum by Immunofluorescence;Mitochondria IgG Ser Ql IF;;ACTIVE;2.58;2.58 +82841-8;PCNA extractable nuclear Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;PCNA extractable nuclear IgG Ab [Titer] in Serum by Immunofluorescence;ENA PCNA IgG Titr Ser IF;;ACTIVE;2.58;2.58 +8284-2;Circumference.max;Len;Pt;Whole body;Qn;;BDYCRC.MOLEC;2;Whole body Maximum circumference;Whole body Circumf.max;;ACTIVE;1.0h(2);2.48 +82842-6;Liver kidney microsomal Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Liver kidney microsomal IgG Ab [Presence] in Serum by Immunofluorescence;LKM IgG Ser Ql IF;;ACTIVE;2.58;2.58 +82843-4;Number dead from condition;Num;Pt;^Population;Qn;;CLIN;2;Number dead from condition Population;Num dead from condition Pop;;ACTIVE;2.58;2.58 +82844-2;Number affected by condition;Num;Pt;^Population;Qn;;CLIN;2;Number affected by condition Population;Num affected by condition Pop;;ACTIVE;2.58;2.58 +82845-9;Campylobacter jejuni Ab.IgA & IgG & IgM panel;-;Pt;Ser;Qn;;PANEL.MICRO;1;Campylobacter jejuni IgA and IgG and IgM panel - Serum;C jejuni IgA+IgG+IgM Pnl Ser;;ACTIVE;2.58;2.58 +82846-7;11-Dehydrocorticosterone+tetrahydrocorticosterone+Allo-tetrahydrocorticosterone/Androsterone+etiocholanolone;SRto;24H;Urine;Qn;;CHEM;1;11-Dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/Androsterone+etiocholanolone [Molar ratio] in 24 hour Urine;11-DHC+THB+5a-THB/An+Et 24h Ur-sRto;;ACTIVE;2.58;2.58 +82847-5;11-Dehydrocorticosterone+tetrahydrocorticosterone+Allo-tetrahydrocorticosterone/Androsterone+etiocholanolone;SRto;Pt;Urine;Qn;;CHEM;1;11-Dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/Androsterone+etiocholanolone [Molar ratio] in Urine;11-DHC+THB+5a-THB/An+Et Ur-sRto;;ACTIVE;2.58;2.58 +82848-3;11-Dehydrocorticosterone+tetrahydrocorticosterone+Allo-tetrahydrocorticosterone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;11-Dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;11-DHC+THB+5a-THB/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82849-1;11-Dehydrocorticosterone+tetrahydrocorticosterone+Allo-tetrahydrocorticosterone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;11-Dehydrocorticosterone+tetrahydrocorticosterone+allo-tetrahydrocorticosterone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;11-DHC+THB+5a-THB/THE+THF+5a-THF 24h Ur;;ACTIVE;2.58;2.58 +82850-9;Androsterone+etiocholanolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Androsterone+etiocholanolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;An+Et/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82851-7;Androsterone+etiocholanolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Androsterone+etiocholanolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;An+Et/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82852-5;Pregnanediolone+pregnanetriol/Androsterone+etiocholanolone;SRto;24H;Urine;Qn;;CHEM;1;Prenanediolone+pregnanetriol/Androsterone+etiocholanolone [Molar ratio] in 24 hour Urine;PDONE+PT/An+Et 24h Ur-sRto;;ACTIVE;2.58;2.58 +82853-3;Pregnanediolone+pregnanetriol/Androsterone+etiocholanolone;SRto;Pt;Urine;Qn;;CHEM;1;Prenanediolone+pregnanetriol/Androsterone+etiocholanolone [Molar ratio] in Urine;PDONE+PT/An+Et Ur-sRto;;ACTIVE;2.58;2.58 +82854-1;Pregnanediolone+pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Prenanediolone+pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;PDONE+PT/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82855-8;Pregnanediolone+pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Prenanediolone+pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;PDONE+PT/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82856-6;Tetrahydrocortisol+allo-tetrahydrocortisol/Tetrahydrocortisone;SRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocortisol+allo-tetrahydrocortisol/Tetrahydrocortisone [Molar ratio] in Urine;THF+Allo-THF/THE Ur-sRto;;ACTIVE;2.58;2.58 +82857-4;Tetrahydrocortisol+allo-tetrahydrocortisol/Tetrahydrocortisone;SRto;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisol+allo-tetrahydrocortisol/Tetrahydrocortisone [Molar ratio] in 24 hour Urine;THF+Allo-THF/THE 24h Ur-sRto;;ACTIVE;2.58;2.58 +82858-2;11-Deoxytetrahydrocorticosterone;SCnc;Pt;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocorticosterone [Moles/volume] in Urine;TH-DOC Ur-sCnc;;ACTIVE;2.58;2.58 +8285-9;Circumference.max;Len;Pt;Thigh.left;Qn;;BDYCRC.MOLEC;2;Thigh - left Maximum circumference;Thigh-L Circumf.max;;ACTIVE;1.0h(2);2.48 +82859-0;11-Deoxytetrahydrocorticosterone;SRat;24H;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocorticosterone [Moles/time] in 24 hour Urine;TH-DOC 24h Ur-sRate;;ACTIVE;2.58;2.58 +82860-8;11-Deoxytetrahydrocorticosterone;SCnc;24H;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocorticosterone [Moles/volume] in 24 hour Urine;TH-DOC 24h Ur-sCnc;;ACTIVE;2.58;2.58 +82861-6;11-Deoxytetrahydrocortisol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocortisol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;THS/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82862-4;11-Deoxytetrahydrocortisol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocortisol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;THS/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82863-2;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone;SCnc;Pt;Urine;Qn;;CHEM;1;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone [Moles/volume] in Urine;3a,15b,17a-TriOH-PDL Ur-sCnc;;ACTIVE;2.58;2.58 +82864-0;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone;SRat;24H;Urine;Qn;;CHEM;1;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone [Moles/time] in 24 hour Urine;3a,15b,17a-TriOH-PDL 24h Ur-sRate;;ACTIVE;2.58;2.58 +82865-7;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone;SCnc;24H;Urine;Qn;;CHEM;1;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone [Moles/volume] in 24 hour Urine;3a,15b,17a-TriOH-PDL 24h Ur-sCnc;;ACTIVE;2.58;2.58 +82866-5;Allo-pregnanediolone;SRat;24H;Urine;Qn;;CHEM;1;Allo-pregnanediolone [Moles/time] in 24 hour Urine;Allo-pregnanediolone 24h Ur-sRate;;ACTIVE;2.58;2.58 +8286-7;Circumference.max;Len;Pt;Thigh.right;Qn;;BDYCRC.MOLEC;2;Thigh - right Maximum circumference;Thigh-R Circumf.max;;ACTIVE;1.0h(2);2.48 +82867-3;Allo-pregnanediolone;SCnc;24H;Urine;Qn;;CHEM;1;Allo-pregnanediolone [Moles/volume] in 24 hour Urine;Allo-pregnanediolone 24h Ur-sCnc;;ACTIVE;2.58;2.58 +82868-1;Allo-pregnanediolone;SCnc;Pt;Urine;Qn;;CHEM;1;Allo-pregnanediolone [Moles/volume] in Urine;Allo-pregnanediolone Ur-sCnc;;ACTIVE;2.58;2.58 +82869-9;6-Thioguanine & 6-methylmercaptopurine panel;-;Pt;RBC;-;;PANEL.DRUG/TOX;1;6-Thioguanine and 6-methylmercaptopurine panel - Red Blood Cells;6-TG and 6-MMP Pnl RBC;;ACTIVE;2.58;2.58 +82870-7;A little u super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Au sup(b) Ab [Presence] in Serum or Plasma;Au sup(b) Ab SerPl Ql;;ACTIVE;2.58;2.67 +82871-5;Adenosine diphosphate;EntSub;Pt;Platelets;Qn;;CHEM;1;Adenosine diphosphate [Entitic substance] in Platelets;ADP EntSub Plts;;ACTIVE;2.58;2.61 +82872-3;A little n W little j Ab;PrThr;Pt;Ser/Plas;Ord;;SERO;1;AnWj Ab [Presence] in Serum or Plasma;AnWj Ab SerPl Ql;;ACTIVE;2.58;2.58 +82873-1;Brallobarbital;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Brallobarbital [Mass/volume] in Serum or Plasma;Brallobarbital SerPl-mCnc;;ACTIVE;2.58;2.58 +82874-9;Calprotectin;MCnc;Pt;Stool;Qn;;CHEM;1;Calprotectin [Mass/volume] in Stool;Calprotectin Stl-mCnc;;ACTIVE;2.58;2.73 +8287-5;Circumference.occipital-frontal;Len;Pt;Head;Qn;Tape measure;BDYCRC.MOLEC;2;Head Occipital-frontal circumference by Tape measure;Head Circumf OFC by Tape measure;;ACTIVE;1.0h(2);2.46 +82875-6;Campylobacter jejuni Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Campylobacter jejuni IgA Ab [Titer] in Serum;C jejuni IgA Titr Ser;;ACTIVE;2.58;2.58 +82876-4;Complement C1 esterase inhibitor;ACnc;Pt;Ser/Plas;Qn;Chromo;HEM/BC;1;Complement C1 esterase inhibitor [Units/volume] in Serum or Plasma by Chromogenic method;C1INH SerPl Chro-aCnc;;ACTIVE;2.58;2.66 +82877-2;Cytochrome C oxidase;CCnt;Pt;WBC;Qn;;CHEM;1;Cytochrome C oxidase [Enzymatic activity/mass] in Leukocytes;CyC Oxidase WBC-cCnt;;ACTIVE;2.58;2.58 +82878-0;Dehydroepiandrosterone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA)/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;DHEA/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82879-8;Dehydroepiandrosterone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA)/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;DHEA/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82880-6;Escitalopram+norescitalopram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Escitalopram+norescitalopram [Mass/volume] in Serum or Plasma;Escitalopram+norescitalopram SerPl-mCnc;;ACTIVE;2.58;2.58 +82881-4;Etiocholanolone/Androsterone;SRto;Pt;Urine;Qn;;CHEM;1;Etiocholanolone/Androsterone [Molar ratio] in Urine;Etiocholanolone/Androsterone Ur-sRto;;ACTIVE;2.58;2.58 +82882-2;Etiocholanolone/Androsterone;SRto;24H;Urine;Qn;;CHEM;1;Etiocholanolone/Androsterone [Molar ratio] in 24 hour Urine;Etiocholanolone/Androsterone 24h Ur-sRto;;ACTIVE;2.58;2.58 +8288-3;Circumference.occipital-frontal;Len;Pt;Head;Qn;US;BDYCRC.MOLEC;2;Head Occipital-frontal circumference by US;Head Circumf OFC by US;;ACTIVE;1.0h(2);2.48 +82883-0;Lysosomal acid lipase;CCnt;Pt;WBC;Qn;4-MU-palmitate substrate;CHEM;1;Lysosomal acid lipase [Enzymatic activity/mass] in Leukocytes by 4-MU-palmitate substrate;LAL WBC 4-MUP substrate-cCnt;;ACTIVE;2.58;2.58 +82884-8;MAOA gene.upstream VNTR repeats;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.NUCREPEAT;1;MAOA gene upstream VNTR repeats [Entitic number] in Blood or Tissue by Molecular genetics method;MAOA uVNTR EntNum Bld/T;;ACTIVE;2.58;2.58 +82885-5;Meta methylhippurate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Meta methylhippurate [Moles/volume] in Urine;m-Methylhippurate Ur-sCnc;;ACTIVE;2.58;2.58 +82886-3;Meta methylhippurate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Meta methylhippurate/Creatinine [Molar ratio] in Urine;m-Methylhippurate/Creat Ur-sRto;;ACTIVE;2.58;2.58 +82887-1;Ortho methylhippurate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Ortho methylhippurate [Moles/volume] in Urine;o-Methylhippurate Ur-sCnc;;ACTIVE;2.58;2.58 +82888-9;Ortho methylhippurate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Ortho methylhippurate/Creatinine [Molar ratio] in Urine;o-Methylhippurate/Creat Ur-sRto;;ACTIVE;2.58;2.58 +82889-7;Meta methylhippurate+ortho methylhippurate+para methylhippurate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Meta methylhippurate+Ortho methylhippurate+Para methylhippurate [Moles/volume] in Urine;m+o+p-Methylhippurate Ur-sCnc;;ACTIVE;2.58;2.58 +82890-5;Meta methylhippurate+ortho methylhippurate+para methylhippurate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Meta methylhippurate+Ortho methylhippurate+Para methylhippurate/Creatinine [Molar ratio] in Urine;m+o+p-Methylhippurate/Creat Ur-sRto;;ACTIVE;2.58;2.58 +8289-1;Circumference.occipital-frontal;Prctl;Pt;Head;Qn;;BDYCRC.MOLEC;2;Head Occipital-frontal circumference Percentile;Head Circumf OFC Prctl;;ACTIVE;1.0h(2);2.73 +82891-3;Para methylhippurate;SCnc;Pt;Urine;Qn;;DRUG/TOX;1;Para methylhippurate [Moles/volume] in Urine;p-Methylhippurate Ur-sCnc;;ACTIVE;2.58;2.58 +82892-1;Para methylhippurate/Creatinine;SRto;Pt;Urine;Qn;;DRUG/TOX;1;Para methylhippurate/Creatinine [Molar ratio] in Urine;p-Methylhippurate/Creat Ur-sRto;;ACTIVE;2.58;2.58 +82893-9;Penfluridol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Penfluridol [Mass/volume] in Serum or Plasma;Penfluridol SerPl-mCnc;;ACTIVE;2.58;2.58 +82894-7;Pregnanediol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanediol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;Pregnanediol/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82895-4;Pregnanediol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Pregnanediol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;Pregnanediol/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82896-2;Pregnanediolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanediolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;PDL/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82897-0;Pregnanediolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Pregnanediolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;PDL/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82898-8;Pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;Pregntrl/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82899-6;Pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-Alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanetriol/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;Pregntrl/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82900-2;Pregnanetriolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanetriolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in Urine;Pregntrlone/THE+THF+5a-THF Ur-sRto;;ACTIVE;2.58;2.58 +82901-0;Pregnanetriolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Pregnanetriolone/Tetrahydrocortisone+tetrahydrocortisol+5-alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;Pregntrlone/THE+THF+5a-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +82902-8;Somatotropin^15M pre XXX challenge;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Units/volume] in Serum or Plasma --15 minutes pre XXX challenge;GH 15M pre chal SerPl-aCnc;;ACTIVE;2.58;2.58 +82903-6;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript/control transcript";NRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript/control transcript [# Ratio] in Bone marrow by Molecular genetics method";"t(15;17)(PML,RARA)/control Mar";;ACTIVE;2.58;2.58 +82904-4;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript";PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript [Presence] in Bone marrow by Molecular genetics method";"t(9;22)(ABL1,BCR) Mar Ql";;ACTIVE;2.58;2.58 +82905-1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript";LnRto;Pt;Bone mar;Qn;Molgen;MOLPATH.TRNLOC;1;"t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript [Log Number Ratio] in Bone marrow by Molecular genetics method";"t(9;22)(ABL1,BCR)/control Mar-LnRto";;ACTIVE;2.58;2.58 +82906-9;Tetrahydrocorticosterone/Allo-tetrahydrocorticosterone;SRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone/Allo-tetrahydrocorticosterone [Molar ratio] in Urine;THB/Allo-THB Ur-sRto;;ACTIVE;2.58;2.58 +82907-7;Tetrahydrocorticosterone/Allo-tetrahydrocorticosterone;SRto;24H;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone/Allo-tetrahydrocorticosterone [Molar ratio] in 24 hour Urine;THB/Allo-THB 24h Ur-sRto;;ACTIVE;2.58;2.58 +82908-5;Tetrahydrocortisol/5-alpha tetrahydrocortisol;SRto;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisol/5-Alpha tetrahydrocortisol [Molar ratio] in 24 hour Urine;THF/5A-THF 24h Ur-sRto;;ACTIVE;2.58;2.58 +8290-9;Circumference.occipital-frontal^at birth;Len;Pt;Head;Qn;Tape measure;BDYCRC.MOLEC;2;Head Occipital-frontal circumference --at birth- by Tape measure;Head Circumf OFC @ birth by Tape measure;;ACTIVE;1.0h(2);2.48 +82909-3;Tetrahydrocortisol/5-alpha tetrahydrocortisol;SRto;Pt;Urine;Qn;;CHEM;1;Tetrahydrocortisol/5-Alpha tetrahydrocortisol [Molar ratio] in Urine;THF/5A-THF Ur-sRto;;ACTIVE;2.58;2.58 +82910-1;Thromboxane beta 2;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thromboxane beta 2 [Moles/volume] in Serum or Plasma;TXB2 SerPl-sCnc;;ACTIVE;2.58;2.58 +82911-9;Vascular endothelial growth factor D;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vascular endothelial growth factor D [Mass/volume] in Serum or Plasma;VEGF-D SerPl-mCnc;;ACTIVE;2.58;2.58 +82913-5;Centromere protein B Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Centromere protein B IgG Ab [Presence] in Serum by Line blot;Centromere B IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82914-3;Dothiepin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dothiepin [Mass/volume] in Serum or Plasma --trough;Dothiepin Trough SerPl-mCnc;;ACTIVE;2.58;2.58 +82915-0;Fibrillarin Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Fibrillarin IgG Ab [Presence] in Serum by Line blot;Fibrillarin IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82916-8;Flurazepam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Flurazepam [Mass/volume] in Serum or Plasma --trough;Flurazepam Trough SerPl-mCnc;;ACTIVE;2.58;2.58 +8291-7;Circumference.occipital-frontal^at birth;Len;Pt;Head;Qn;US;BDYCRC.MOLEC;2;Head Occipital-frontal circumference --at birth- by US;Head Circumf OFC @ birth by US;;ACTIVE;1.0h(2);2.48 +82917-6;Bromperidol^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bromperidol [Mass/volume] in Serum or Plasma --trough;Bromperidol Trough SerPl-mCnc;;ACTIVE;2.58;2.58 +82918-4;Jo-1 extractable nuclear Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Jo-1 extractable nuclear IgG Ab [Presence] in Serum by Line blot;ENA Jo1 IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82919-2;Ku Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ku IgG Ab [Presence] in Serum by Line blot;Ku IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +829-2;Am Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Am Ag [Presence] on Red Blood Cells;Am Ag RBC Ql;;ACTIVE;1.0;2.56 +82920-0;Legionella pneumophila Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Legionella pneumophila IgA Ab [Units/volume] in Serum by Immunoassay;L pneumo IgA Ser IA-aCnc;;ACTIVE;2.58;2.68 +82921-8;Liver cytosol Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Liver cytosol IgG Ab [Presence] in Serum by Line blot;Liver Cytosol IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82923-4;PML Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;PML IgG Ab [Presence] in Serum by Line blot;PML IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82924-2;Pl-7 Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;PL-7 IgG Ab [Presence] in Serum by Immunoassay;PL7 IgG Ser Ql IA;;ACTIVE;2.58;2.58 +8292-5;Circumference^expiration;Len;Pt;Chest;Qn;;BDYCRC.MOLEC;2;Chest Circumference --expiration;Chest Circumf exp;;ACTIVE;1.0h(2);2.48 +82925-9;PM-SCL-100 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;PM-SCL-100 IgG Ab [Presence] in Serum by Line blot;PM/SCL-100 IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82926-7;Phospholipase A2 receptor Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Phospholipase A2 receptor IgG Ab [Presence] in Serum by Line blot;PLA2R IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82928-3;Mitochondria M2 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Mitochondria M2 IgG Ab [Presence] in Serum by Line blot;Mitochondria M2 IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82931-7;Nuclear pore protein gp210 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Nuclear pore protein gp210 IgG Ab [Presence] in Serum by Line blot;Nucl pore prot gp210 IgG Ser Ql Ln blot;;ACTIVE;2.58;2.66 +82932-5;sp100 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;sp100 IgG Ab [Presence] in Serum by Line blot;sp100 IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +8293-3;Circumference^inspiration;Len;Pt;Chest;Qn;;BDYCRC.MOLEC;2;Chest Circumference --inspiration;Chest Circumf insp;;ACTIVE;1.0h(2);2.48 +82933-3;Sjogrens syndrome-A extractable nuclear 52kD Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD IgG Ab [Presence] in Serum by Line blot;ENA SS-A 52kD IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82934-1;clonazePAM^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clonazePAM [Mass/volume] in Serum or Plasma --trough;clonazePAM Trough SerPl-mCnc;;ACTIVE;2.58;2.58 +82935-8;Oxazepam^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Oxazepam [Mass/volume] in Serum or Plasma --trough;Oxazepam Trough SerPl-mCnc;;ACTIVE;2.58;2.58 +82936-6;Signal recognition particle Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Signal Recognition Particle (SRP) IgG Ab [Presence] in Serum by Line blot;SRP IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82937-4;Signaling lymphocytic activation molecule (SLAM)-associated & X-linked inhibitor of apoptosis protein;Imp;Pt;WBC;Nom;Flow cytometry;CHEM;1;SAP and XIAP [Interpretation] in Leukocytes by Flow cytometry (FC);SAP + XIAP WBC FC-Imp;;ACTIVE;2.58;2.58 +82938-2;Smith extractable nuclear D Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Smith extractable nuclear D IgG Ab [Units/volume] in Serum;ENA SM-D IgG Ser-aCnc;;ACTIVE;2.58;2.58 +82939-0;Genetic variant details;Find;Pt;Bld/Tiss;Nar;Molgen;MOLPATH;1;Genetic variant details in Blood or Tissue by Molecular genetics method Narrative;Genetic variant details Bld/T;;ACTIVE;2.58;2.73 +82940-8;Speech;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Speech [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +8294-1;Diameter.anterior-posterior;Len;Pt;Chest;Qn;XR;RAD;2;XR Chest Diameter.anterior-posterior;XR Chest Diam AP;;ACTIVE;1.0h(2);2.61 +82941-6;Salivation;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Salivation [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82942-4;Swallowing;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Swallowing [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82943-2;Handwriting;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Handwriting [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82944-0;Cutting food and handling utensils (patients without gastrostomy);Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Cutting food and handling utensils (patients without gastrostomy) [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82945-7;Cutting food and handling utensils (patients with gastrostomy);Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Cutting food and handling utensils (patients with gastrostomy) [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82946-5;Dressing and hygiene;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Dressing and hygiene [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82947-3;Turning in bed and adjusting bed clothes;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Turning in bed and adjusting bed clothes [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82948-1;Walking;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Walking [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82949-9;Climbing stairs;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Climbing stairs [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82950-7;Dyspnea;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Dyspnea [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82951-5;Orthopnea;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Orthopnea [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82952-3;Respiratory insufficiency;Find;Pt;^Patient;Ord;ALSFRS-R;SURVEY.ALSFRSR;4;Respiratory insufficiency [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82953-1;Total score;Score;Pt;^Patient;Qn;ALSFRS-R;SURVEY.ALSFRSR;4;Total score [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82954-9;Amyotrophic lateral sclerosis functional rating scale - revised (ALSFRS-R);-;Pt;^Patient;-;ALSFRS-R;PANEL.SURVEY.ALSFRSR;4;Amyotrophic lateral sclerosis functional rating scale - revised [ALSFRS-R];;Copyright © 1996 Regeneron Pharmaceuticals. Used with permission.;ACTIVE;2.58;2.58 +82955-6;HEDIS 2017 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017 Value Sets;HEDIS 2017 Value Sets;;DISCOURAGED;2.58;2.67 +82956-4;HEDIS 2017-2020 Value Set - FIT-DNA;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017-2020 Value Set - FIT-DNA;HEDIS 2017-20 FIT-DNA;;DISCOURAGED;2.58;2.69 +82957-2;HEDIS 2017, 2018 Value Set - Chlamydia Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017, 2018 Value Set - Chlamydia Tests;HEDIS 2017-18 Chlamydia;;DISCOURAGED;2.58;2.67 +8295-8;Diameter.anterior-posterior^W expiration;Len;Pt;Chest;Qn;XR;RAD;2;XR Chest Diameter.anterior-posterior W expiration;XR Chest Diam AP W Exp;;ACTIVE;1.0h(2);2.61 +82958-0;HEDIS 2017, 2018 Value Set - Cytomegalovirus Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017, 2018 Value Set - Cytomegalovirus Antibody;HEDIS 2017-18 CMV Ab;;DISCOURAGED;2.58;2.67 +82959-8;HEDIS 2017-2020 Value Set - FOBT;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017-2020 Value Set - FOBT;HEDIS 2017-20 FOBT;;DISCOURAGED;2.58;2.69 +82960-6;HEDIS 2017, 2018 Value Set - Group A Strep Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017, 2018 Value Set - Group A Strep Tests;HEDIS 2017-18 Grp A Strep;;DISCOURAGED;2.58;2.67 +82961-4;HEDIS 2017, 2018 Value Set - Pregnancy Test Exclusion;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017, 2018 Value Set - Pregnancy Test Exclusion;HEDIS 2017-18 Preg Test Excl;;DISCOURAGED;2.58;2.67 +82962-2;HEDIS 2017, 2018 Value Set - Serum Potassium;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017, 2018 Value Set - Serum Potassium;HEDIS 2017-18 Ser K;;DISCOURAGED;2.58;2.67 +82963-0;HEDIS 2017, 2018 Value Set - HPV Vaccine Administered;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2017, 2018 Value Set - HPV Vaccine Administered;HEDIS 2017-18 HPV Vaccn Adm;;DISCOURAGED;2.58;2.67 +82964-8;Cannabidiol;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Cannabidiol [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Cannabidiol SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82965-5;Methylenedioxyethylamphetamine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;MDEA SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +8296-6;Diameter.anterior-posterior^W inspiration;Len;Pt;Chest;Qn;XR;RAD;2;XR Chest Diameter.anterior-posterior W inspiration;XR Chest Diam AP W Insp;;ACTIVE;1.0h(2);2.61 +82966-3;Methamphetamine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Methamphetamine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Methamphet SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82967-1;Amphetamine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Amphetamine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Amphet SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82968-9;Secobarbital;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Secobarbital [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Secobarbital SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82969-7;PENTobarbital;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;PENTobarbital [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Pentobarb SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82970-5;PHENobarbital;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;PHENobarbital [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Phenobarb SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82971-3;Butalbital;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Butalbital [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Butalbital SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82972-1;Butabarbital;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Butabarbital [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Butabarbital SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82973-9;Amobarbital;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Amobarbital [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Amobarbital SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +8297-4;Volume;Vol;Pt;Foot.left;Qn;;VOLUME.MOLEC;2;Volume Foot - left;Volume Ft-L;;ACTIVE;1.0h(2);2.48 +82974-7;O-nortramadol;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;O-nortramadol [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;O-nortramadol SerPlBld Cfm-mCnc;;ACTIVE;2.58;2.73 +82975-4;Desmosome Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Desmosome IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;Desmosome IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +82976-2;Dipeptidyl aminopeptidase-like protein 6 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;DPPX IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +82977-0;Gamma aminobutyrate B receptor Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;GABABR IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;GABABR IgG SerPl Ql IF;;ACTIVE;2.58;2.65 +82978-8;Leucine-rich glioma-inactivated protein 1 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;LGI1 IgG SerPl Ql IF;;ACTIVE;2.58;2.73 +82979-6;Contactin-associated protein 2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Contactin-associated protein 2 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;CASPR2 IgG SerPl Ql IF;;ACTIVE;2.58;2.73 +82980-4;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;AMPAR2 IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;AMPAR2 IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +82981-2;N-methyl-D-aspartate receptor Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;NMDAR IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;NMDAR IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +8298-2;Volume;Vol;Pt;Foot.right;Qn;;VOLUME.MOLEC;2;Volume Foot - right;Volume Ft-R;;ACTIVE;1.0h(2);2.48 +82982-0;Exocrine pancreas Ab.IgA+IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Exocrine pancreas IgA+IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;Exocrine pancreas IgA+IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +82983-8;Ma+Ta Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Ma+Ta IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;Ma+Ta IgG SerPl Ql IF;;ACTIVE;2.58;2.58 +82984-6;Gamma aminobutyrate B receptor Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;GABABR IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;GABABR IgG CSF Ql IF;;ACTIVE;2.58;2.65 +82985-3;Leucine-rich glioma-inactivated protein 1 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;LGI1 IgG CSF Ql IF;;ACTIVE;2.58;2.58 +82986-1;Contactin-associated protein 2 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Contactin-associated protein 2 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;CASPR2 IgG CSF Ql IF;;ACTIVE;2.58;2.58 +82987-9;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;AMPAR2 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;AMPAR2 IgG CSF Ql IF;;ACTIVE;2.58;2.58 +82988-7;N-methyl-D-aspartate receptor Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;NMDAR IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;NMDAR IgG CSF Ql IF;;ACTIVE;2.58;2.58 +82989-5;Dipeptidyl aminopeptidase-like protein 6 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;DPPX IgG CSF Ql IF;;ACTIVE;2.58;2.58 +8299-0;Volume;Vol;Pt;^Patient;Qn;Estimated;VOLUME.MOLEC;2;Volume Estimated;Volume Est;;ACTIVE;1.0h(2);2.48 +82990-3;3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;3-Hydroxy-3-Methylglutaryl-coenzyme A reductase IgG Ab [Presence] in Serum or Plasma by Line blot;HMGCR IgG SerPl Ql Line blot;;ACTIVE;2.58;2.73 +82991-1;Phospholipase A2 receptor Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Phospholipase A2 receptor IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;PLA2R IgG SerPl Ql IF;;ACTIVE;2.58;2.73 +82992-9;SUMO-activating enzyme subunit 1 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;SUMO-activating enzyme subunit 1 IgG Ab [Presence] in Serum by Line blot;SAE1 IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82993-7;MJ Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Mj IgG Ab [Presence] in Serum by Line blot;Mj IgG Ser Ql Line blot;;ACTIVE;2.58;2.64 +82994-5;MDA5 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;MDA5 IgG Ab [Presence] in Serum by Line blot;MDA5 IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82995-2;TIF1-gamma Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;TIF1-gamma IgG Ab [Presence] in Serum by Line blot;TIF1-gamma IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82996-0;Mi-2 beta Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Mi-2 beta IgG Ab [Presence] in Serum by Line blot;Mi-2 beta IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82997-8;Mi-2 alpha Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Mi-2 alpha IgG Ab [Presence] in Serum by Line blot;Mi-2 alpha IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +82998-6;Dense fine speckled 70 protein Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;Dense fine speckled 70 protein IgG Ab [Presence] in Serum or Plasma by Line blot;DFS70 IgG SerPl Ql Line blot;;ACTIVE;2.58;2.66 +82999-4;Purkinje cell cytoplasmic type Tr Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;PCA-Tr IgG Ab [Presence] in Serum or Plasma by Line blot;PCA-Tr IgG SerPl Ql Line blot;;ACTIVE;2.58;2.66 +8-3;Amdinocillin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Amdinocillin [Susceptibility] by Minimum inhibitory concentration (MIC);Amdinocillin Islt MIC;;ACTIVE;1.0;2.19 +830-0;A variant subtype;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated A variant subtype Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated A Var Subtyp SerPl BPU Ql;;DEPRECATED;1.0;2.36 +83000-0;Titin Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;Titin IgG Ab [Presence] in Serum or Plasma by Line blot;Titin IgG SerPl Ql Line blot;;ACTIVE;2.58;2.66 +83001-8;Glial nuclear type 1 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;Glial nuclear type 1 IgG Ab [Presence] in Serum or Plasma by Line blot;Glial nuc type 1 IgG SerPl Ql Line blot;;ACTIVE;2.58;2.66 +83002-6;Zinc finger protein of the cerebellum 4 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;Zinc finger protein of the cerebellum 4 IgG Ab [Presence] in Serum or Plasma by Line blot;Zic4 IgG SerPl Ql Line blot;;ACTIVE;2.58;2.66 +83003-4;Recoverin Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;Recoverin IgG Ab [Presence] in Serum or Plasma by Line blot;Recoverin IgG SerPl Ql Line blot;;ACTIVE;2.58;2.66 +83004-2;Glutamate decarboxylase 65 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;SERO;1;Glutamate decarboxylase 65 IgG Ab [Presence] in Serum or Plasma by Line blot;GAD65 IgG SerPl Ql Line blot;;ACTIVE;2.58;2.66 +83005-9;Variant category;Type;Pt;^Patient;Nom;;MOLPATH;1;Variant category;Variant category;;TRIAL;2.58;2.58 +8300-6;Volume;Vol;Pt;^Patient;Qn;Immersion;VOLUME.MOLEC;2;Volume estimated by Immersion method;Volume Immersion;;ACTIVE;1.0h(2);2.48 +83006-7;Deletion-duplication overall interpretation;Imp;Pt;^Patient;Nom;;MOLPATH.DELDUP;1;Deletion-duplication overall interpretation;Del-dup interp Patient-Imp;;TRIAL;2.58;2.58 +83007-5;COSMIC version;ID;Pt;^Patient;Nom;;MOLPATH;1;COSMIC version [ID];COSMIC version;;TRIAL;2.58;2.58 +83008-3;ClinVar version;ID;Pt;^Patient;Nom;;MOLPATH;1;ClinVar version [ID];ClinVar version;;TRIAL;2.58;2.58 +83009-1;Genetic variation effect on high-risk allele;Imp;Pt;^Patient;Ord;;MOLPATH.PHARMG;1;Genetic variation's effect on high-risk allele;Genetic var eff high-risk allele;;TRIAL;2.58;2.73 +83010-9;Medication usage suggestion;Imp;Pt;^Patient;Nar;;MOLPATH.PHARMG;1;Medication usage suggestion [Narrative];Med usage sugg Patient-Imp;;TRIAL;2.58;2.71 +83011-7;Haplotype definition panel;-;Pt;^Patient;-;;PANEL.MOLPATH;1;Haplotype definition panel;Haplotype definition Pnl;;TRIAL;2.58;2.58 +83012-5;Views for bone density;Find;Pt;Whole body>Skeletal system.axial;Doc;DXA;RAD;2;DXA Skeletal system.axial Views for bone density;DXA Skeletal Sys Axial Views for BMD;;ACTIVE;2.58;2.64 +83013-3;Views for bone density;Find;Pt;Whole body>Skeletal system.peripheral;Doc;DXA;RAD;2;DXA Skeletal system.peripheral Views for bone density;DXA Skeletal Sys Periph Views for BMD;;ACTIVE;2.58;2.64 +8301-4;Body height;Len;Pt;^Patient;Qn;Estimated;BDYHGT.ATOM;2;Body height Estimated;Body height Est;;ACTIVE;1.0h(2);2.73 +83014-1;Views for bone density+vertebral fracture;Find;Pt;Whole body>Skeletal system.axial;Doc;DXA;RAD;2;DXA Skeletal system.axial Views for bone density and vertebral fracture;DXA Skeletal Sys Axial Vs BMD+Vert fx;;ACTIVE;2.58;2.64 +83015-8;Views 2 for renal calculus;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen 2 Views for renal calculus;XR Abd 2V for renal calc;;ACTIVE;2.58;2.61 +83016-6;Views GE 3 AP + oblique + cone;Find;Pt;Abdomen;Doc;XR;RAD;2;XR Abdomen GE 3 Views AP and Oblique and Cone;XR Abd GE 3V AP+oblique+cone;;ACTIVE;2.58;2.61 +83017-4;View && Views supine + upright;Find;Pt;Chest && Abdomen;Doc;XR;RAD;2;XR Chest View and Abdomen Supine and Upright;XR Chest View + Abd Sup+Up;;ACTIVE;2.58;2.64 +83018-2;Views 1 or 2;Find;Pt;Lower extremity>Ankle;Doc;XR;RAD;2;XR Ankle 1 or 2 Views;XR Ankle 1V or 2V;;ACTIVE;2.58;2.61 +83019-0;View babygram;Find;Pt;Chest+Abdomen+Pelvis;Doc;XR;RAD;2;XR Chest and Abdomen and Pelvis View babygram;XR Chest+Abd+Pelvis Babygram;;ACTIVE;2.58;2.61 +83020-8;Views survey complete;Find;Pt;XXX>Bones;Doc;XR;RAD;2;XR Bones Complete Survey Views;XR Bones Survey comp;;ACTIVE;2.58;2.64 +83021-6;(Views 2 or 3) + (Views^W flexion + W extension);Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 2 or 3 views and (Views W flexion and W extension);XR C-spine V2 or V3+views W FE;;ACTIVE;2.58;2.61 +8302-2;Body height;Len;Pt;^Patient;Qn;;BDYHGT.ATOM;2;Body height;Body height;;ACTIVE;1.0h(2);2.73 +83022-4;(Views 2 or 3) + (Views^W flexion + W extension) + (Views oblique);Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 2 or 3 views and (Views W flexion and W extension) and Views oblique;XR C-spn V2-3+views W FE+views obl;;ACTIVE;2.58;2.61 +83023-2;Views 4 or 5;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine 4 or 5 Views;XR C-spine 4V or 5V;;ACTIVE;2.58;2.64 +83024-0;Views 2 + Views lateral-decubitus;Find;Pt;Chest;Doc;XR;RAD;2;XR Chest 2 Views and Views Lateral-decubitus;XR Chest 2V+Views Lat-decub;;ACTIVE;2.58;2.64 +83025-7;Views GE 2;Find;Pt;Pelvis>Coccyx;Doc;XR;RAD;2;XR Coccyx GE 2 Views;XR Coccyx GE 2V;;ACTIVE;2.58;2.61 +83026-5;Views 1 or 2;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow 1 or 2 Views;XR Elbow 1V or 2V;;ACTIVE;2.58;2.61 +83027-3;Views GE 4;Find;Pt;Upper extremity>Elbow;Doc;XR;RAD;2;XR Elbow GE 4 Views;XR Elbow GE 4V;;ACTIVE;2.58;2.61 +83028-1;Views GE 2;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Cervical and thoracic and lumbar spine GE 2 Views;XR C+T+L-spine GE 2V;;ACTIVE;2.58;2.61 +83029-9;Views 1 or 2;Find;Pt;Head>Facial bones+Zygomatic arch;Doc;XR;RAD;2;XR Facial bones and Zygomatic arch 1 or 2 Views;XR Face+Zygomatic Arch 1V or 2V;;ACTIVE;2.58;2.61 +8303-0;Body height;Prctl;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Body height [Percentile];Body height Prctl;;ACTIVE;1.0h(2);2.73 +83030-7;Views 1 or 2;Find;Pt;Lower extremity>Foot;Doc;XR;RAD;2;XR Foot 1 or 2 Views;XR Foot 1V or 2V;;ACTIVE;2.58;2.61 +83031-5;View AP && Views GE 2;Find;Pt;Pelvis && Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Pelvis AP and Hip - bilateral GE 2 Views;XR Pelvis AP + Hip-Bl GE 2V;;ACTIVE;2.58;2.64 +83032-3;Views GE 2^preoperative;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip GE 2 Views preoperative;XR Hip GE 2V Preop;;ACTIVE;2.58;2.61 +83033-1;View^during surgery;Find;Pt;Lower extremity>Hip;Doc;XR;RAD;2;XR Hip single view during surgery;XR Hip 1 view in Surg;;ACTIVE;2.58;2.61 +83034-9;Views GE 2 for pediatrics;Find;Pt;Pelvis & Lower extremity.bilateral>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - bilateral GE 2 views for pediatrics;GE 2V for peds Pelvis and Hip-Bl XR;;ACTIVE;2.58;2.61 +83035-6;Views 1 or 2^during surgery;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee 1 or 2 Views during surgery;XR Knee 1V or 2V in Surg;;ACTIVE;2.58;2.61 +83036-4;Views GE 2;Find;Pt;Lower extremity;Doc;XR;RAD;2;XR Lower extremity GE 2 Views;XR LE GE 2V;;ACTIVE;2.58;2.61 +83037-2;View^during surgery;Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Single view during surgery;XR L-spine 1V in Surg;;ACTIVE;2.58;2.64 +83038-0;(Views GE 5) + (Views GE 1^W R-bending + W L-bending);Find;Pt;Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Lumbar spine Greater than 4 views and (Greater than 1 view W R-bending and W L-bending);XR L-spine GE 5V+GE 1V W R-bend+L-bend;;ACTIVE;2.58;2.61 +83039-8;Views GE 3;Find;Pt;Head>Mastoid.bilateral;Doc;XR;RAD;2;XR Mastoid - bilateral GE 3 Views;XR Mastoid-Bl GE 3V;;ACTIVE;2.58;2.61 +83040-6;Views 2;Find;Pt;Chest>Ribs.unilateral;Doc;XR;RAD;2;XR Ribs - unilateral 2 Views;XR Ribs-Ul 2V;;ACTIVE;2.58;2.61 +83041-4;Views 2 && View;Find;Pt;Chest>Ribs.unilateral && Chest;Doc;XR;RAD;2;XR Ribs - unilateral 2 Views and Chest Single view;XR Ribs-Ul 2V + Chest 1V;;ACTIVE;2.58;2.64 +83042-2;Views 2 && View AP;Find;Pt;Chest>Ribs.unilateral && Chest;Doc;XR;RAD;2;XR Ribs - unilateral 2 Views and Chest AP;XR Ribs-Ul 2V + Chest AP;;ACTIVE;2.58;2.64 +83043-0;Views 1 or 2;Find;Pt;Pelvis>Sacroiliac joint.bilateral;Doc;XR;RAD;2;XR Sacroiliac joint - bilateral 1 or 2 Views;XR SIJ-Bl 1V or 2V;;ACTIVE;2.58;2.61 +83044-8;Views GE 2;Find;Pt;Pelvis>Sacrum;Doc;XR;RAD;2;XR Sacrum GE 2 Views;XR Sacrum GE 2V;;ACTIVE;2.58;2.61 +83045-5;Views AP + lateral;Find;Pt;Chest>Scapula;Doc;XR;RAD;2;XR Scapula AP and Lateral;XR Scapula AP+Lat;;ACTIVE;2.58;2.61 +83046-3;Views LE 3 AP + lateral;Find;Pt;Head>Skull;Doc;XR;RAD;2;XR Skull LE 3 AP and Lateral Views;XR Skull LE 3V AP+Lat;;ACTIVE;2.58;2.64 +83047-1;Views GE 2;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum GE 2 Views;XR Sternum GE 2V;;ACTIVE;2.58;2.61 +8304-8;Body height special circumstances;Type;Pt;^Patient;Nom;;BDYHGT.ATOM;2;Body height special circumstances;Body height special circumstance;;ACTIVE;1.0h(2);2.64 +83048-9;Views GE 3;Find;Pt;Lower extremity>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula GE 3 Views;XR Tib+Fib GE 3V;;ACTIVE;2.58;2.61 +83049-7;Views GE 2;Find;Pt;Upper extremity;Doc;XR;RAD;2;XR Upper extremity GE 2 Views;XR UE GE 2V;;ACTIVE;2.58;2.61 +83050-5;Views 1 or 2;Find;Pt;Upper extremity>Wrist;Doc;XR;RAD;2;XR Wrist 1 or 2 Views;XR Wrist 1V or 2V;;ACTIVE;2.58;2.61 +83051-3;Views for vertebral fracture;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;DXA;RAD;2;DXA Cervical and thoracic and lumbar spine Views for vertebral fracture;DXA C+T+L-spine Views for vert fx;;ACTIVE;2.58;2.64 +83052-1;Programmed cell death ligand 1 by clone 22C3;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PD-L1 by clone 22C3 [Presence] in Tissue by Immune stain;PD-L1 by 22C3 Tiss Ql ImStn;;ACTIVE;2.58;2.73 +83053-9;Cells.programmed cell death ligand 1/100 viable tumor cells;NFr;Pt;Tiss;Qn;Immune stain;PATH;1;Cells.programmed cell death ligand 1/100 viable tumor cells in Tissue by Immune stain;Cells.PD-L1/100 viab tum NFr Tiss ImStn;;ACTIVE;2.58;2.73 +83054-7;Programmed cell death ligand 1 by clone 22C3;Imp;Pt;Tiss;Nar;Immune stain;PATH;1;PD-L1 by clone 22C3 [Interpretation] in Tissue by Immune stain Narrative;PD-L1 by 22C3 Tiss ImStn-Imp;;ACTIVE;2.58;2.73 +8305-5;Body height^post partum;Len;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Body height --post partum;Body height p partum;;ACTIVE;1.0h(2);2.69 +83055-4;Programmed cell death ligand 1 by clone 28-8;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PD-L1 by clone 28-8 [Presence] in Tissue by Immune stain;PD-L1 by 28-8 Tiss Ql ImStn;;ACTIVE;2.58;2.73 +83056-2;Programmed cell death ligand 1 by clone 28-8;Imp;Pt;Tiss;Nar;Immune stain;PATH;1;PD-L1 by clone 28-8 [Interpretation] in Tissue by Immune stain Narrative;PD-L1 by 28-8 Tiss ImStn-Imp;;ACTIVE;2.58;2.58 +83057-0;Programmed cell death ligand 1 by clone SP142;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;PD-L1 by clone SP142 [Presence] in Tissue by Immune stain;PD-L1 by SP142 Tiss Ql ImStn;;ACTIVE;2.58;2.73 +83058-8;Nucleoprotein expression;PrThr;Pt;Tiss^Control;Ord;Immune stain;PATH;1;Nucleoprotein expression [Presence] in Control Tissue by Immune stain;Nucleoprot express Tiss Cont Ql ImStn;;ACTIVE;2.58;2.58 +83059-6;KRAS gene;VCF;Pt;Cancer specimen;Doc;Sequencing;MOLPATH;1;KRAS gene [VCF] in Cancer specimen by Sequencing;KRAS gene VCF Ca spec Seq;;ACTIVE;2.58;2.65 +83060-4;NRAS gene;VCF;Pt;Cancer specimen;Doc;Sequencing;MOLPATH;1;NRAS gene [VCF] in Cancer specimen by Sequencing;NRAS gene VCF Ca spec Seq;;ACTIVE;2.58;2.65 +83061-2;BRAF gene;VCF;Pt;Cancer specimen;Doc;Sequencing;MOLPATH;1;BRAF gene [VCF] in Cancer specimen by Sequencing;BRAF gene VCF Ca spec Seq;;ACTIVE;2.58;2.65 +83062-0;PIK3CA gene;VCF;Pt;Cancer specimen;Doc;Sequencing;MOLPATH;1;PIK3CA gene [VCF] in Cancer specimen by Sequencing;PIK3CA gene VCF Ca spec Seq;;ACTIVE;2.58;2.65 +8306-3;Body height^lying;Len;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Body height --lying;Body height lying;;ACTIVE;1.0h(2);2.69 +83063-8;PTEN gene;VCF;Pt;Cancer specimen;Doc;Sequencing;MOLPATH;1;PTEN gene [VCF] in Cancer specimen by Sequencing;PTEN gene VCF Ca spec Seq;;ACTIVE;2.58;2.65 +83064-6;Calcium.ionized;SCnc;Pt;BldCRRT;Qn;;CHEM;1;Calcium.ionized [Moles/volume] in Blood drawn from CRRT circuit;Ca-I BldCRRT-sCnc;;ACTIVE;2.58;2.58 +83065-3;Cytomegalovirus DNA;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Saliva (oral fluid) by NAA with probe detection;CMV DNA Sal Ql NAA+probe;;ACTIVE;2.58;2.63 +83066-1;Mycobacterium tuberculosis complex immunogenic protein MPB64;PrThr;Pt;Isolate;Ord;IA;MICRO;1;Mycobacterium tuberculosis complex immunogenic protein MPB64 [Presence] in Isolate by Immunoassay;M TB cmplx MPB64 Islt Ql IA;;ACTIVE;2.58;2.58 +83067-9;Chikungunya virus structural proteins (E1+E2) Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Chikungunya virus structural proteins (E1+E2) IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;CHIKV E1+E2 IgM SerPl IA-aCnc;;ACTIVE;2.58;2.73 +83068-7;Chikungunya virus structural proteins (E1+E2) Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Chikungunya virus structural proteins (E1+E2) IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;CHIKV E1+E2 IgG SerPl IA-aCnc;;ACTIVE;2.58;2.73 +83069-5;Zika virus non-structural protein 1 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Zika virus non-structural protein 1 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;ZIKV NS1 IgG SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83070-3;Calcidiol+ercalcidiol;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma by Immunoassay;25(OH)D3+25(OH)D2 SerPl IA-mCnc;;ACTIVE;2.58;2.68 +8307-1;Body height^preoperative;Len;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Body height --preoperative;Body height Preop;;ACTIVE;1.0h(2);2.69 +83071-1;Calcidiol+ercalcidiol;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma by Immunoassay;25(OH)D3+25(OH)D2 SerPl IA-sCnc;;ACTIVE;2.58;2.68 +83072-9;Alpha-1-Fetoprotein;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma by Immunoassay;AFP SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83073-7;Alpha-1-Fetoprotein;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma by Immunoassay;AFP SerPl IA-mCnc;;ACTIVE;2.58;2.73 +83074-5;Alpha-1-Fetoprotein;ACnc;Pt;Amnio fld;Qn;IA;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Amniotic fluid by Immunoassay;AFP Amn IA-aCnc;;ACTIVE;2.58;2.58 +83075-2;Alpha-1-Fetoprotein;MCnc;Pt;Amnio fld;Qn;IA;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Amniotic fluid by Immunoassay;AFP Amn IA-mCnc;;ACTIVE;2.58;2.58 +83076-0;Beta-2-Microglobulin;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Beta-2-Microglobulin [Units/volume] in Serum or Plasma by Immunoassay;B2 Microglob SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83077-8;Beta-2-Microglobulin;MCnc;Pt;Urine;Qn;IA;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Urine by Immunoassay;B2 Microglob Ur IA-mCnc;;ACTIVE;2.58;2.58 +83078-6;Beta-2-Microglobulin;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Serum or Plasma by Immunoassay;B2 Microglob SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83079-4;Beta-2-Microglobulin;ACnc;Pt;Urine;Qn;IA;CHEM;1;Beta-2-Microglobulin [Units/volume] in Urine by Immunoassay;B2 Microglob Ur IA-aCnc;;ACTIVE;2.58;2.58 +83080-2;Borrelia burgdorferi Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Borrelia burgdorferi IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;B burgdor IgG CSF Ql IA;;ACTIVE;2.58;2.58 +83081-0;Borrelia burgdorferi Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia burgdorferi IgG+IgM Ab [Presence] in Serum by Immunoassay;B burgdor IgG+IgM Ser Ql IA;;ACTIVE;2.58;2.58 +83082-8;Cancer Ag 125;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Cancer Ag 125 [Units/volume] in Serum or Plasma by Immunoassay;Cancer Ag125 SerPl IA-aCnc;;ACTIVE;2.58;2.73 +83083-6;Cancer Ag 15-3;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay;Cancer Ag15-3 SerPl IA-aCnc;;ACTIVE;2.58;2.68 +83084-4;Cancer Ag 19-9;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay;Cancer Ag19-9 SerPl IA-aCnc;;ACTIVE;2.58;2.73 +83085-1;Carcinoembryonic Ag;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Serum or Plasma by Immunoassay;CEA SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83086-9;Choriogonadotropin;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Choriogonadotropin [Units/volume] in Serum or Plasma by Immunoassay;HCG SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83087-7;Clostridioides difficile glutamate dehydrogenase;PrThr;Pt;Stool;Ord;IA;MICRO;1;Clostridioides difficile glutamate dehydrogenase [Presence] in Stool by Immunoassay;C diff GDH Stl Ql IA;;ACTIVE;2.58;2.73 +83088-5;Cortisol;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma by Immunoassay;Cortis SerPl IA-mCnc;;ACTIVE;2.58;2.58 +8308-9;Body height^standing;Len;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Body height --standing;Body height stand;;ACTIVE;1.0h(2);2.73 +83089-3;Cortisol;MCnc;24H;Urine;Qn;IA;CHEM;1;Cortisol [Mass/volume] in 24 hour Urine by Immunoassay;Cortis 24h Ur IA-mCnc;;ACTIVE;2.58;2.58 +83090-1;Cortisol;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Cortisol [Moles/volume] in Serum or Plasma by Immunoassay;Cortis SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83091-9;Cortisol;SCnc;24H;Urine;Qn;IA;CHEM;1;Cortisol [Moles/volume] in 24 hour Urine by Immunoassay;Cortis 24h Ur IA-sCnc;;ACTIVE;2.58;2.58 +83092-7;Creatine kinase.MB;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Creatine kinase.MB [Mass/volume] in Serum or Plasma by Immunoassay;CK MB SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83093-5;Digoxin;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Digoxin [Mass/volume] in Serum or Plasma by Immunoassay;Digoxin SerPl IA-mCnc;;ACTIVE;2.58;2.73 +83094-3;Digoxin;SCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Digoxin [Moles/volume] in Serum or Plasma by Immunoassay;Digoxin SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83095-0;Epstein Barr virus capsid+early Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Epstein Barr virus capsid+early IgG Ab [Presence] in Serum by Immunoassay;EBV VCA+EA IgG Ser Ql IA;;ACTIVE;2.58;2.58 +83096-8;Estradiol;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Estradiol (E2) [Mass/volume] in Serum or Plasma by Immunoassay;Estradiol SerPl IA-mCnc;;ACTIVE;2.58;2.73 +8309-7;Body temperature;Temp;Pt;Incubator.pediatric;Qn;;BDYTMP.ATOM;2;Body temperature from Pediatric incubator;Bdy temp Incubator.pediatric;;ACTIVE;1.0h(2);2.69 +83097-6;Estradiol;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Estradiol (E2) [Moles/volume] in Serum or Plasma by Immunoassay;Estradiol SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83098-4;Follitropin;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Follitropin [Units/volume] in Serum or Plasma by Immunoassay;FSH SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83099-2;Galectin 3;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Galectin 3 [Mass/volume] in Serum or Plasma by Immunoassay;Galectin 3 SerPl IA-mCnc;;ACTIVE;2.58;2.73 +83100-8;Hepatitis B virus core Ab.IgG+IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis B virus core IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay;HBV core IgG+IgM SerPl Ql IA;;ACTIVE;2.58;2.73 +83101-6;HIV 1+2 Ab & HIV1 p24 Ag panel;-;Pt;Ser/Plas;-;IA;PANEL.MICRO;1;HIV 1+2 Ab and HIV1 p24 Ag panel - Serum or Plasma by Immunoassay;HIV 1+2 Ab + HIV 1 p24 Pnl SerPl IA;;ACTIVE;2.58;2.58 +83102-4;IgE;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;IgE [Units/volume] in Serum or Plasma by Immunoassay;IgE SerPl IA-aCnc;;ACTIVE;2.58;2.69 +83103-2;Lutropin;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Lutropin [Units/volume] in Serum or Plasma by Immunoassay;LH SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83104-0;Mullerian inhibiting substance;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Mullerian inhibiting substance [Mass/volume] in Serum or Plasma by Immunoassay;MIS SerPl IA-mCnc;;ACTIVE;2.58;2.73 +8310-5;Body temperature;Temp;Pt;^Patient;Qn;;BDYTMP.ATOM;2;Body temperature;Body temperature;;ACTIVE;1.0h(2);2.73 +83105-7;Mullerian inhibiting substance;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Mullerian inhibiting substance [Moles/volume] in Serum or Plasma by Immunoassay;MIS SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83106-5;Myoglobin;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Myoglobin [Mass/volume] in Serum or Plasma by Immunoassay;Myoglobin SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83107-3;Natriuretic peptide.B prohormone N-Terminal;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma by Immunoassay;NT-proBNP SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83108-1;Natriuretic peptide.B prohormone N-Terminal;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Natriuretic peptide.B prohormone N-Terminal [Moles/volume] in Serum or Plasma by Immunoassay;NT-proBNP SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83109-9;Progesterone;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Progesterone [Mass/volume] in Serum or Plasma by Immunoassay;Progest SerPl IA-mCnc;;ACTIVE;2.58;2.73 +83110-7;Progesterone;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Progesterone [Moles/volume] in Serum or Plasma by Immunoassay;Progest SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83111-5;Prolactin;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Prolactin [Units/volume] in Serum or Plasma by Immunoassay;Prolactin SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83112-3;Prostate specific Ag;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Prostate specific Ag [Mass/volume] in Serum or Plasma by Immunoassay;PSA SerPl IA-mCnc;;ACTIVE;2.58;2.73 +8311-3;Body temperature;Temp;1H^max;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 1 hour maximum;Bdy temp 1h Max;;ACTIVE;1.0h(2);2.69 +83113-1;Prostate specific Ag.free;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Prostate Specific Ag Free [Mass/volume] in Serum or Plasma by Immunoassay;PSA Free SerPl IA-mCnc;;ACTIVE;2.58;2.73 +83114-9;S100 calcium binding protein B;MCnc;Pt;Ser;Qn;IA;CHEM;1;S100 calcium binding protein B [Mass/volume] in Serum by Immunoassay;S100 Ca binding protein B Ser IA-mCnc;;ACTIVE;2.69;2.69 +83115-6;Testosterone;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Testosterone [Moles/volume] in Serum or Plasma by Immunoassay;Testost SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83116-4;Testosterone;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Testosterone [Mass/volume] in Serum or Plasma by Immunoassay;Testost SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83117-2;Thyroglobulin Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroglobulin IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Thyroglob IgG SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83118-0;Thyroperoxidase Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroperoxidase IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Thyroperoxidase IgG SerPl IA-aCnc;;ACTIVE;2.58;2.58 +83119-8;Thyroxine;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma by Immunoassay;T4 SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83120-6;Thyroxine;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroxine (T4) [Moles/volume] in Serum or Plasma by Immunoassay;T4 SerPl IA-sCnc;;ACTIVE;2.58;2.58 +8312-1;Body temperature;Temp;8H^max;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 8 hour maximum;Bdy temp 8h Max;;ACTIVE;1.0h(2);2.69 +83121-4;Thyroxine.free;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroxine (T4) free [Moles/volume] in Serum or Plasma by Immunoassay;T4 Free SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83122-2;Thyroxine.free;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroxine (T4) free [Mass/volume] in Serum or Plasma by Immunoassay;T4 Free SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83123-0;Toxoplasma gondii Ab.IgG+IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Toxoplasma gondii IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay;T gondii IgG+IgM SerPl Ql IA;;ACTIVE;2.58;2.58 +83124-8;Triiodothyronine;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Triiodothyronine (T3) [Mass/volume] in Serum or Plasma by Immunoassay;T3 SerPl IA-mCnc;;ACTIVE;2.58;2.58 +83125-5;Triiodothyronine;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma by Immunoassay;T3 SerPl IA-sCnc;;ACTIVE;2.58;2.73 +83126-3;Triiodothyronine.free;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma by Immunoassay;T3Free SerPl IA-sCnc;;ACTIVE;2.58;2.58 +83127-1;Triiodothyronine.free;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma by Immunoassay;T3Free SerPl IA-mCnc;;ACTIVE;2.58;2.73 +83128-9;Hepatitis E virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Hepatitis E virus IgM Ab [Presence] in Serum or Plasma by Immunoassay;HEV IgM SerPl Ql IA;;ACTIVE;2.64;2.64 +83129-7;Respondent type;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Respondent type;;;ACTIVE;2.58;2.58 +83130-5;11-Deoxytetrahydrocorticosterone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocorticosterone/Creatinine [Molar ratio] in Urine;TH-DOC/Creat Ur-sRto;;ACTIVE;2.58;2.58 +83131-3;Pregnanolone;SRat;24H;Urine;Qn;;CHEM;1;Pregnanolone [Moles/time] in 24 hour Urine;Pregnanolone 24h Ur-sRate;;ACTIVE;2.58;2.58 +83132-1;Pregnanolone;SCnc;Pt;Urine;Qn;;CHEM;1;Pregnanolone [Moles/volume] in Urine;Pregnanolone Ur-sCnc;;ACTIVE;2.58;2.58 +83133-9;Pregnanolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pregnanolone/Creatinine [Molar ratio] in Urine;Pregnanolone/Creat Ur-sRto;;ACTIVE;2.58;2.58 +83134-7;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;3 alpha, 15 beta, 17 alpha-Trihydroxypregnanediolone/Creatinine [Molar ratio] in Urine;3a,15b,17a-TriOH-PDL/Creat Ur-sRto;;ACTIVE;2.58;2.58 +83135-4;Allo-pregnanediolone/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Allo-pregnanediolone/Creatinine [Molar ratio] in Urine;Allo-pregnanediolone/Creat Ur-sRto;;ACTIVE;2.58;2.58 +83136-2;Allo-pregnanediol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Allo-pregnanediol/Creatinine [Molar ratio] in Urine;Allo-pregnanediol/Creat Ur-sRto;;ACTIVE;2.58;2.58 +83137-0;OJ Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;OJ IgG Ab [Presence] in Serum by Line blot;OJ IgG Ser Ql Line blot;;ACTIVE;2.58;2.66 +83138-8;17-Hydroxypregnenetriol;SRat;24H;Urine;Qn;;CHEM;1;17-Hydroxypregnenetriol [Moles/time] in 24 hour Urine;17-OH-PT 24h Ur-sRate;;ACTIVE;2.58;2.58 +8313-9;Body temperature;Temp;10H^max;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 10 hour maximum;Bdy temp 10h Max;;ACTIVE;1.0h(2);2.69 +83139-6;17-Hydroxypregnenetriol/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;17-Hydroxypregnenetriol/Creatinine [Molar ratio] in Urine;17-OH-PT/Creat Ur-sRto;;ACTIVE;2.58;2.58 +83140-4;17-Hydroxypregnenetriol;SCnc;Pt;Urine;Qn;;CHEM;1;17-Hydroxypregnenetriol [Moles/volume] in Urine;17-OH-PT Ur-sCnc;;ACTIVE;2.58;2.58 +83141-2;9-Hole Pegboard Dexterity Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.MOTOR;2;9-Hole Pegboard Dexterity Test [NIH Toolbox];Pegboard NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83142-0;Standing Balance Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.MOTOR;2;Standing Balance Test [NIH Toolbox];Standing balance test NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83143-8;2-Minute Walk Endurance Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.MOTOR;2;2-Minute Walk Endurance Test [NIH Toolbox];2-min walk test NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83144-6;4-Meter Walk Gait Speed Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.MOTOR;2;4-Meter Walk Gait Speed Test [NIH Toolbox];4 meter walk test NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83145-3;Grip Strength Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.MOTOR;2;Grip Strength Test [NIH Toolbox];Grip strength test NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83146-1;Able to hold position for 50S - trial 1^eyes open+on solid surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 1 [NIH Toolbox] --eyes open and on solid surface;Hold 50S trial 1 eyes open+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8314-7;Body temperature;Temp;12H^max;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 12 hour maximum;Bdy temp 12h Max;;ACTIVE;1.0h(2);2.69 +83147-9;Able to hold position for 50S - trial 2^eyes open+on solid surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 2 [NIH Toolbox] --eyes open and on solid surface;Hold 50S trial 2 eyes open+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83148-7;Able to hold position for 50S - trial 1^eyes closed+on solid surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 1 [NIH Toolbox] --eyes closed and on solid surface;Hold 50S trial 1 eyes closed+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83149-5;Able to hold position for 50S - trial 2^eyes closed+on solid surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 2 [NIH Toolbox] --eyes closed and on solid surface;Hold 50S trial 2 eyes closed+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83150-3;Able to hold position for 50S - trial 1^eyes open+on foam surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 1 [NIH Toolbox] --eyes open and on foam surface;Hold 50S trial 1 eyes open+foam NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83151-1;Able to hold position for 50S - trial 2^eyes open+on foam surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 2 [NIH Toolbox] --eyes open and on foam surface;Hold 50S trial 2 eyes open+foam NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83152-9;Able to hold position for 50S - trial 1^eyes closed+on foam surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 1 [NIH Toolbox] --eyes closed and on foam surface;Hold 50S trial 1 eyes closed+foam NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83153-7;Able to hold position for 50S - trial 2^eyes closed+on foam surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 2 [NIH Toolbox] --eyes closed and on foam surface;Hold 50S trial 2 eyes closed+foam NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8315-4;Body temperature;Temp;24H^max;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 24 hour maximum;Bdy temp 24h Max;;ACTIVE;1.0h(2);2.69 +83154-5;Able to hold position for 50S - trial 1^eyes open+tandem stance+on solid surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 1 [NIH Toolbox] --eyes open and in tandem stance and on solid surface;Hold 50S trial 1 eyes open+tnd+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83155-2;Able to hold position for 50S - trial 2^eyes open+tandem stance+on solid surface;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.MOTOR;2;Able to hold position for 50 seconds - trial 2 [NIH Toolbox] --eyes open and in tandem stance and on solid surface;Hold 50S trial 2 eyes open+tnd+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83156-0;9-Hole Pegboard Dexterity Test;Time;Pt;Hand.left;Qn;NIH Toolbox;NIH.MOTOR;2;9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox];Pegboard Time Hand-L NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83157-8;9-Hole Pegboard Dexterity Test;Time;Pt;Hand.right;Qn;NIH Toolbox;NIH.MOTOR;2;9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox];Pegboard Time Hand-R NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83158-6;9-Hole Pegboard Dexterity - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;Hand.dominant;Qn;NIH Toolbox;NIH.MOTOR;2;9-Hole Pegboard Dexterity - scale score fully adjusted Hand.dominant [NIH Toolbox];Pegboard full adj Hand.dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +83159-4;9-Hole Pegboard Dexterity - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;Hand.non-dominant;Qn;NIH Toolbox;NIH.MOTOR;2;9-Hole Pegboard Dexterity - scale score fully adjusted Hand.non-dominant [NIH Toolbox];Pegboard full adj Hand.non-dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +83160-2;AP postural sway score^eyes open+on solid surface;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;AP postural sway score [NIH Toolbox] --eyes open and on solid surface;AP sway score eyes open+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83161-0;AP postural sway score^eyes closed+on foam surface;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;AP postural sway score [NIH Toolbox] --eyes closed and on foam surface;AP sway score eyes closed+foam NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8316-2;Body temperature;Temp;1H^min;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 1 hour minimum;Bdy temp 1h Min;;ACTIVE;1.0h(2);2.69 +83162-8;Standing Balance Test computed score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Standing Balance Test computed score [NIH Toolbox];Standing balance test score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83163-6;Number of 10 [ft_i] marks^2M post trial start;Num;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Number of 10 foot marks [NIH Toolbox] --2M post trial start;10 ft marks past cone 2M post NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83164-4;Additional [ft_i] past last 10 [ft_i] mark^2M post trial start;Len;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Additional feet past last 10 foot mark [NIH Toolbox] --2M post trial start;Ft past last mark 2M post NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83165-1;Remainder [in_i] past last 10 [ft_i] mark^2M post trial start;Len;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Remainder of inches past last 10 foot mark [NIH Toolbox] --2M post trial start;Inches past last mark 2M post NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83166-9;Number of turns in 2M;NRat;2M;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Number of turns in 2 minutes [NIH Toolbox];Turns in 2M nRate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83167-7;Walk distance score;Len;2M;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Walk distance score 2 minutes [NIH Toolbox];Walk distance score 2M NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83168-5;2-minute Walk Endurance Test - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;2-minute Walk Endurance Test - unadjusted scale score [NIH Toolbox];2-min walk unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83169-3;Walk 4 meters at usual pace - trial 1;Time;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Walk 4 meters at usual pace - trial 1 [Time] [NIH Toolbox];4 meter time trial 1 Time NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8317-0;Body temperature;Temp;8H^min;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 8 hour minimum;Bdy temp 8h Min;;ACTIVE;1.0h(2);2.69 +83170-1;Walk 4 meters at usual pace - trial 2;Time;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Walk 4 meters at usual pace - trial 2 [Time] [NIH Toolbox];4 meter time trial 2 Time NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83171-9;2-minute Walk Endurance Test - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;2-minute Walk Endurance Test - scale score age adjusted [NIH Toolbox];2 min walk test score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83172-7;4-Meter Walk Gait Speed Test - computed score;Vel;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;4-Meter Walk Gait Speed Test - computed score [NIH Toolbox];4 meter walk computed score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83173-5;Grip strength;Force;Pt;Hand.left;Qn;Dynamometer;NIH.MOTOR;2;Grip strength Hand - left Dynamometer;Grip strength Hand-L Dynamometer;;ACTIVE;2.58;2.58 +83174-3;Grip strength;Force;Pt;Hand.right;Qn;Dynamometer;NIH.MOTOR;2;Grip strength Hand - right Dynamometer;Grip strength Hand-R Dynamometer;;ACTIVE;2.58;2.58 +83175-0;Grip Strength Test - scale score^^adjusted for age;Score;Pt;Hand.dominant;Qn;NIH Toolbox;NIH.MOTOR;2;Grip Strength Test - scale score age adjusted Hand.dominant [NIH Toolbox];Grip scale score age-adj Hand.dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83176-8;Grip Strength Test - scale score^^adjusted for age;Score;Pt;Hand.non-dominant;Qn;NIH Toolbox;NIH.MOTOR;2;Grip Strength Test - scale score age adjusted Hand.non-dominant [NIH Toolbox];Grip scale scr age-adj Hand.non-dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83177-6;AP postural sway score^eyes closed+on solid surface;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;AP postural sway score [NIH Toolbox] --eyes closed and on solid surface;AP sway score eyes closed+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83178-4;AP postural sway score^eyes open+on foam surface;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;AP postural sway score [NIH Toolbox] --eyes open and on foam surface;AP sway score eyes open+foam NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +83179-2;AP postural sway score^eyes open+tandem stance+on solid surface;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;AP postural sway score [NIH Toolbox] --eyes open and in tandem stance and on solid surface;AP sway score eyes open+tnd+solid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +831-8;A variant subtype;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated A variant subtype Ab [Presence] in Serum or Plasma from donor;Deprecated A Var Subtyp SerPl Donr Ql;;DEPRECATED;1.0;2.36 +83180-0;Self-care activities - functional ability panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Self-care activities - functional ability panel;Selfcare activities;;ACTIVE;2.58;2.7 +83181-8;Bathing - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Bathing - functional ability;Bathing ability;;ACTIVE;2.58;2.7 +83182-6;Dressing - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Dressing - functional ability;Dressing ability;;ACTIVE;2.58;2.73 +83183-4;Toileting - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Toileting - functional ability;Toileting ability;;ACTIVE;2.58;2.73 +83184-2;Feeding or eating - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Feeding or eating - functional ability;Feeding or eating ability;;ACTIVE;2.58;2.7 +83185-9;Transferring - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Transferring - functional ability;Transferring ability;;ACTIVE;2.58;2.73 +83186-7;Ambulation - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Ambulation - functional ability;Ambulation ability;;ACTIVE;2.58;2.73 +83187-5;Wheel 50 feet with two turns - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 50 feet with two turns - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +8318-8;Body temperature;Temp;10H^min;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 10 hour minimum;Bdy temp 10h Min;;ACTIVE;1.0h(2);2.69 +83188-3;Wheel 50 feet with two turns - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 50 feet with two turns - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.69 +83189-1;Picking up object - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Picking up object - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83190-9;Picking up object - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Picking up object - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83191-7;12 steps - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;12 steps - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83192-5;12 steps - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;12 steps - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83193-3;4 steps - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;4 steps - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83194-1;4 steps - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;4 steps - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83195-8;1 step (curb) - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;1 step (curb) - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +8319-6;Body temperature;Temp;12H^min;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 12 hour minimum;Bdy temp 12h Min;;ACTIVE;1.0h(2);2.69 +83196-6;1 step (curb) - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;1 step (curb) - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83197-4;Walking 10 feet on uneven surfaces - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walking 10 feet on uneven surfaces - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83198-2;Walking 10 feet on uneven surfaces - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walking 10 feet on uneven surfaces - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83199-0;Walk 150 feet - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 150 feet - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83200-6;Walk 150 feet - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 150 feet - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83201-4;Walk 50 feet with two turns - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 50 feet with two turns - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83202-2;Walk 50 feet with two turns - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 50 feet with two turns - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83203-0;Walk 10 feet - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 10 feet - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +8320-4;Body temperature;Temp;24H^min;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 24 hour minimum;Bdy temp 24h Min;;ACTIVE;1.0h(2);2.71 +83204-8;Walk 10 feet - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 10 feet - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83205-5;Car transfer - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Car transfer - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83206-3;Car transfer - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Car transfer - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83207-1;Toilet transfer - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet transfer - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83208-9;Toilet transfer - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet transfer - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83209-7;Bed-to-chair transfer - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bed-to-chair transfer - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83210-5;Bed-to-chair transfer - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bed-to-chair transfer - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83211-3;Sit to stand - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to stand - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +8321-2;Body temperature;Temp;1H;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 1 hour;Bdy temp 1h;;ACTIVE;1.0h(2);2.69 +83212-1;Sit to stand - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to stand - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83213-9;Lying to sitting on side of bed - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lying to sitting on side of bed - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83214-7;Lying to sitting on side of bed - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lying to sitting on side of bed - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.67 +83215-4;Sit to lying - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to lying - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83216-2;Sit to lying - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to lying - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83217-0;Roll left and right - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Roll left and right - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.64 +83218-8;Roll left and right - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Roll left and right - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.63 +83219-6;Putting on and taking off footwear - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Putting on/taking off footwear - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +8322-0;Body temperature;Temp;8H;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 8 hour;Bdy temp 8h;;ACTIVE;1.0h(2);2.69 +83220-4;Putting on and taking off footwear - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Putting on/taking off footwear - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83221-2;Lower body dressing - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lower body dressing - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83222-0;Lower body dressing - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lower body dressing - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83223-8;Upper body dressing - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Upper body dressing - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83224-6;Upper body dressing - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Upper body dressing - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83225-3;Shower &or bathe self - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Shower/bathe self - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83226-1;Shower &or bathe self - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Shower/bathe self - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83227-9;Toileting hygiene - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toileting hygiene - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83228-7;Toileting hygiene - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toileting hygiene - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83229-5;Oral hygiene - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Oral hygiene - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83230-3;Oral hygiene - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Oral hygiene - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83231-1;Eating - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83232-9;Eating - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.63 +83233-7;Self-care - admission performance;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Self-care - admission performance [CMS Assessment];;;ACTIVE;2.61;2.67 +83234-5;Prior device use;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Prior device use [CMS Assessment];;;ACTIVE;2.61;2.61 +83235-2;Wheel 150 feet - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 150 feet - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.69 +83236-0;Wheel 150 feet - functional goal recorded during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 150 feet - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83237-8;Bladder and bowel;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Bladder and bowel [CMS Assessment];;;ACTIVE;2.61;2.67 +8323-8;Body temperature;Temp;10H;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 10 hour;Bdy temp 10h;;ACTIVE;1.0h(2);2.69 +83238-6;Bladder continence during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bladder continence during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83239-4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2, OASIS E - Prior functioning: everyday activities;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2, OASIS E - Prior functioning: everyday activities [CMS Assessment];;;ACTIVE;2.61;2.72 +83240-2;Memory &or recall ability;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Memory/recall ability [CMS Assessment];;;ACTIVE;2.61;2.61 +83241-0;IRF-PAI - Staff assessment for mental status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Staff assessment for mental status [CMS Assessment];;;ACTIVE;2.61;2.61 +83242-8;Bowel continence during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bowel continence during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83243-6;Comorbidities and coexisting conditions;Find;Pt;^Patient;Nom;;SURVEY.CMS;4;Comorbidities and coexisting conditions;;;ACTIVE;2.61;2.72 +83244-4;IRF-PAI v2.0 - Swallowing &or nutritional status - admission;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0 - Swallowing/nutritional status - admission [CMS Assessment];;;ACTIVE;2.61;2.69 +83245-1;Usual ability to swallow during 3D assessment period;Find;3D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Usual ability to swallow during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +8324-6;Body temperature;Temp;12H;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 12 hour;Bdy temp 12h;;ACTIVE;1.0h(2);2.69 +83246-9;IRF-PAI v3.0, LCDS v4.00 - Current number of unhealed pressure injuries at each stage - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v4.00 - Current number of unhealed pressure injuries at each stage - admission [CMS Assessment];;;ACTIVE;2.61;2.69 +83247-7;IRF-PAI v2.0, LCDS v4.00 - Special treatments, procedures, and programs - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0, LCDS v4.00 - Special treatments, procedures, and programs - discharge [CMS Assessment];;;ACTIVE;2.61;2.69 +83248-5;Should brief interview for mental status be conducted during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Should brief interview for mental status be conducted during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.66 +83249-3;Understanding verbal content during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Understanding verbal content during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83250-1;Expression of ideas and wants during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Expression of ideas and wants during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83251-9;IRF-PAI - Hearing, speech, and vision - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Hearing, speech, and vision - admission [CMS Assessment];;;ACTIVE;2.61;2.61 +83252-7;Special treatments, procedures, and programs at admission;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Special treatments, procedures, and programs at admission [CMS Assessment];;;ACTIVE;2.61;2.69 +8325-3;Body temperature;Temp;24H;XXX;Qn;;BDYTMP.TIMED.MOLEC;2;Body temperature 24 hour;Bdy temp 24h;;ACTIVE;1.0h(2);2.69 +83254-3;Self-care - discharge performance;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Self-care - discharge performance [CMS Assessment];;;ACTIVE;2.61;2.67 +83256-8;IRF-PAI v3.0, LCDS v4.00 - Current number of unhealed pressure injuries at each stage - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v4.00 - Current number of unhealed pressure injuries at each stage - discharge [CMS Assessment];;;ACTIVE;2.61;2.69 +83258-4;IRF-PAI - Healed pressure injuries;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Healed pressure injuries [CMS Assessment];;;ACTIVE;2.61;2.63 +832-6;A variant subtype;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated A variant subtype Ab [Presence] in Serum or Plasma;Deprecated A Var Subtyp Ser Ql;;DEPRECATED;1.0;2.36 +83260-0;Number of pressure injuries noted on prior assessment that have completely closed - stage 1;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of pressure injuries noted on prior assessment that have completely closed - stage 1 [CMS Assessment];;;ACTIVE;2.61;2.63 +8326-1;Class;Type;Pt;Body temperature device;Nom;*;DEVICES;2;Type of Body temperature device;Bdy Temp Device Class;;ACTIVE;1.0h(2);2.29 +83261-8;IRF-PAI v3.0 - Special treatments, procedures, and programs - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Special treatments, procedures, and programs - admission [CMS Assessment];;;ACTIVE;2.61;2.69 +83264-2;IRF-PAI - Active diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Active diagnoses [CMS Assessment];;;ACTIVE;2.61;2.67 +83265-9;Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 1.4;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI) - version 1.4 [CMS Assessment];;;DEPRECATED;2.61;2.73 +83266-7;IRF-PAI - Quality indicators - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Quality indicators - admission [CMS Assessment];;;ACTIVE;2.61;2.61 +83267-5;IRF-PAI - Cognitive patterns - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Cognitive patterns - admission [CMS Assessment];;;ACTIVE;2.61;2.61 +83268-3;IRF-PAI - Functional abilities and goals - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Functional abilities and goals - admission [CMS Assessment];;;ACTIVE;2.61;2.61 +83269-1;IRF-PAI - Mobility - admission performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Mobility - admission performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.67 +83270-9;Does the patient walk - admission performance during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Does the patient walk - admission performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83271-7;Does the patient use a wheelchair or scooter during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Does the patient use a wheelchair or scooter during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83272-5;Indicate the type of wheelchair or scooter used during 3D assessment period;Type;3D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Indicate the type of wheelchair or scooter used during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +83273-3;IRF-PAI - Health conditions - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Health conditions - admission [CMS Assessment];;;ACTIVE;2.61;2.61 +83274-1;Did the patient have major surgery during the 100D prior to admission;Find;100D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Did the patient have major surgery during the 100 days prior to admission [CMS Assessment];;;ACTIVE;2.61;2.61 +83275-8;IRF-PAI - Quality indicators - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Quality indicators - discharge [CMS Assessment];;;ACTIVE;2.61;2.61 +83276-6;IRF-PAI - Functional abilities and goals - discharge;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Functional abilities and goals - discharge [CMS Assessment];;;ACTIVE;2.61;2.61 +83277-4;IRF-PAI - Mobility - discharge performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Mobility - discharge performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.67 +83278-2;Does the patient walk - discharge performance during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Does the patient walk - discharge performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +8327-9;Body temperature measurement site;Anat;Pt;*^Patient;Nom;;BDYTMP.ATOM;2;Body temperature measurement site;Bdy temp measurement site;;ACTIVE;1.0h(2);2.27 +83279-0;IRF-PAI v3.0, LCDS v4.00, OASIS E - Health conditions - discharge or expired or transfer;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v4.00, OASIS E - Health conditions - discharge or expired or transfer [CMS Assessment];;;ACTIVE;2.61;2.72 +83280-8;Has the patient had any falls since admission;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Has the patient had any falls since admission [CMS Assessment];;;ACTIVE;2.61;2.61 +83281-6;IRF-PAI - Skin conditions - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Skin conditions - discharge [CMS Assessment];;;ACTIVE;2.61;2.61 +83282-4;Worsening in pressure injury status since admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Worsening in pressure injury status since admission [CMS Assessment];;;ACTIVE;2.61;2.63 +83283-2;Stage 2 pressure injuries not present or at a lesser stage on admission &or reentry;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Stage 2 pressure injuries not present or at a lesser stage on admission/reentry # [CMS Assessment];;;ACTIVE;2.61;2.63 +83284-0;Stage 3 pressure injuries not present or at a lesser stage on admission &or reentry;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Stage 3 pressure injuries not present or at a lesser stage on admission/reentry # [CMS Assessment];;;ACTIVE;2.61;2.63 +83285-7;Stage 4 pressure injuries not present or at a lesser stage on admission &or reentry;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Stage 4 pressure injuries not present or at a lesser stage on admission/reentry # [CMS Assessment];;;ACTIVE;2.61;2.63 +83286-5;Unstageable pressure injuries due to non-removable dressing not present or at a lesser stage on admission &or reentry;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Unstageable pressure injuries due to non-removable dressing not present or at a lesser stage on admission/reentry # [CMS Assessment];;;ACTIVE;2.61;2.63 +8328-7;Body temperature;Temp;Pt;Axillary;Qn;;BDYTMP.MOLEC;2;Axillary temperature;Axil temp;;ACTIVE;1.0h(2);2.73 +83287-3;Unstageable pressure injury due to slough &or eschar not present or at a lesser stage on admission &or reenty;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Unstageable pressure injury due to slough/eschar not present or at a lesser stage on admission/reenty # [CMS Assessment];;;ACTIVE;2.61;2.63 +83288-1;Unstageable pressure injury due to deep tissue injury not present or at a lesser stage on admission &or reentry;Num;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Unstageable pressure injury due to deep tissue injury not present or at a lesser stage on admission/reentry # [CMS Assessment];;;ACTIVE;2.61;2.63 +83289-9;Multisection for calcium score^WO contrast && Multisection^W contrast IV;Find;Pt;Chest>Heart+Coronary arteries;Doc;CT && CT.angio;RAD;2;CT for calcium scoring WO contrast and CTA W contrast IV Heart and coronary arteries;CT Hrt+CA Ca score WO cont+CTA W cont IV;;ACTIVE;2.58;2.73 +83290-7;Multisection for pulmonary embolus+deep vein thrombosis^W contrast IV;Find;Pt;Chest>Pulmonary arteries.bilateral & Pelvis>Pelvis veins & Lower extremity.bilateral>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Pulmonary arteries - bilateral and Pelvis veins and Lower extremity veins - bilateral for pulmonary embolus and deep vein thrombosis W contrast IV;CTA PA-Bl+Pel+LE vv-Bl PE+DVT W contr IV;;ACTIVE;2.58;2.63 +83291-5;Multisection^ WO Contrast;Find;Pt;Upper extremity>Thumb;Doc;CT;RAD;2;CT Thumb WO contrast;CT Thumb WO contr;;ACTIVE;2.58;2.61 +83292-3;Multisection^W contrast;Find;Pt;Chest>Scapula;Doc;CT;RAD;2;CT Scapula W contrast;CT Scapula W contr;;ACTIVE;2.58;2.61 +83293-1;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Spine Cervical and Spine Lumbar W contrast IV;CT C-spine+L-spine W contr IV;;ACTIVE;2.58;2.61 +83294-9;Multisection^W contrast IV;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Thoracic and lumbar spine W contrast IV;CT T+L-Spine W contr IV;;ACTIVE;2.58;2.61 +8329-5;Body temperature;Temp;Pt;Core;Qn;;BDYTMP.MOLEC;2;Body temperature - Core;Bdy temp Core;;ACTIVE;1.0h(2);2.73 +83295-6;Multisection^W contrast IV;Find;Pt;Neck & Chest>Mediastinum.superior;Doc;CT;RAD;2;CT Neck and Superior mediastinum W contrast IV;CT Neck+Mediastinum.sup W contr IV;;ACTIVE;2.58;2.61 +83296-4;Multisection^W contrast IV && Multisection^WO & W contrast IV;Find;Pt;Head && Head>Orbit.bilateral;Doc;CT;RAD;2;CT Head W contrast IV and CT Orbit - bilateral WO and W contrast IV;CT Head W con IV + Orb-Bl WO+W contr IV;;ACTIVE;2.58;2.64 +83297-2;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Spine Cervical and Spine Lumbar WO and W contrast IV;CT C-spine+L-spine WO+W contr IV;;ACTIVE;2.58;2.61 +83298-0;Multisection^WO & W contrast IV;Find;Pt;Chest>Chest vessels & Abdomen>Abdominal vessels & Pelvis>Pelvis vessels;Doc;CT.angio;RAD;2;CTA Chest vessels and Abdominal vessels and Pelvis vessels WO and W contrast IV;CTA Chest+Abd+Pelv ves WO+W contr IV;;ACTIVE;2.58;2.61 +83299-8;Multisection^WO & W contrast IV;Find;Pt;Chest+Abdomen+Pelvis && Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;CT && CT.angio;RAD;2;CT Chest and Abdomen and Pelvis WO and W contrast IV and CTA Thoracic and abdominal aorta WO and W contrast IV;CTA Ch+Ab+Pel CT WO+W cont+Ao WO+W cont;;ACTIVE;2.58;2.61 +83300-4;Multisection^WO & W Contrast IV;Find;Pt;Chest>Scapula.bilateral;Doc;CT;RAD;2;CT Scapula - bilateral WO and W contrast IV;CT Scapula-Bl WO+W contr IV;;ACTIVE;2.58;2.61 +83301-2;Multisection^WO & W contrast IV;Find;Pt;Neck & Chest>Mediastinum.superior;Doc;CT;RAD;2;CT Neck and Superior mediastinum WO and W contrast IV;CT Neck+Mediastinum.sup WO+W contr IV;;ACTIVE;2.58;2.61 +83302-0;Multisection^WO contrast;Find;Pt;Head & Head>Temporal bone;Doc;CT;RAD;2;CT Head and Temporal bone WO contrast;CT Head+Temporal bone WO contr;;ACTIVE;2.58;2.61 +8330-3;Body temperature;Temp;Pt;Intravascular;Qn;;BDYTMP.MOLEC;2;Body temperature - Intravascular;Bdy temp IV;;ACTIVE;1.0h(2);2.73 +83303-8;Multisection^WO contrast;Find;Pt;Lower extremity>Toe;Doc;CT;RAD;2;CT Toe WO contrast;CT Toe WO contr;;ACTIVE;2.58;2.61 +83304-6;Multisection^WO contrast;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;CT;RAD;2;CT Cervical and thoracic spine WO contrast;CT C+T-spine WO contr;;ACTIVE;2.58;2.61 +83305-3;Multisection^WO contrast;Find;Pt;Neck>Spine.cervical & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Spine Cervical and Spine Lumbar WO contrast;CT C-spine+L-spine WO contr;;ACTIVE;2.58;2.61 +83306-1;Multisection^WO contrast;Find;Pt;Head & Head>Maxillofacial region;Doc;CT;RAD;2;CT Head and Maxillofacial region WO contrast;CT Head+Maxillofacial WO contr;;ACTIVE;2.58;2.61 +83307-9;Multisection^WO contrast;Find;Pt;Head & Head>Mandible;Doc;CT;RAD;2;CT Head and Mandible WO contrast;CT Head+Mandible WO contr;;ACTIVE;2.58;2.61 +83308-7;Multisection^WO contrast;Find;Pt;Neck & Chest>Mediastinum.superior;Doc;CT;RAD;2;CT Neck and Superior mediastinum WO contrast;CT Neck+Mediastinum.sup WO contr;;ACTIVE;2.58;2.61 +83309-5;Multisection^WO contrast;Find;Pt;Head>Sinuses+Mandible;Doc;CT;RAD;2;CT Sinuses and Mandible WO contrast;CT Sinuses+Mandible WO contr;;ACTIVE;2.58;2.61 +83310-3;Multisection^WO contrast;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Thoracic and lumbar spine WO contrast;CT T+L-Spine WO contr;;ACTIVE;2.58;2.61 +8331-1;Body temperature;Temp;Pt;Mouth;Qn;;BDYTMP.MOLEC;2;Oral temperature;Oral temp;;ACTIVE;1.0h(2);2.73 +83311-1;Bone density quantitative measurement panel;-;Pt;Whole body>Skeletal system;Qn;DXA;PANEL.RAD;2;Bone density quantitative measurement by DXA panel;BMD qn measurement Pnl;;ACTIVE;2.58;2.72 +83312-9;Exchanged drugs &or money for sex in the past Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Exchanged drugs AndOr money for sex in the past year;Exch drugs &or money for sex in past Y;;ACTIVE;2.58;2.58 +83313-7;Injection drug use in the past Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Injection drug use in the past year;Inj drug use in past Y;;ACTIVE;2.58;2.58 +83314-5;Sexual activity while intoxicated &or high on drugs in the past Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Sexual activity while intoxicated AndOr high on drugs in the past year;Sex while intox &or high in past Y;;ACTIVE;2.58;2.66 +83315-2;Sexual activity with a female in the past Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Sexual activity with a female in the past year;Sex w female in past Y;;ACTIVE;2.58;2.66 +83316-0;Sexual activity with a male in the past Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Sexual activity with a male in the past year;Sex w male in past Y;;ACTIVE;2.58;2.66 +83317-8;Sexual activity with anonymous partner in the past Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Sexual activity with anonymous partner in the past year;Sex w anonym partner in past Y;;ACTIVE;2.58;2.66 +83318-6;Sexual activity with known IV drug user in the past Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Sexual activity with known intravenous drug user in the past year;Sex w known IV drug user in past Y;;ACTIVE;2.58;2.66 +83319-4;Syphilis neurological involvement;Find;Pt;^Patient;Ord;;H&P.HX;2;Syphilis neurological involvement;Syph neuro involve;;ACTIVE;2.58;2.58 +83320-2;Adverse event note;Find;Pt;{Setting};Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Adverse event note;Allergy+Immunology Adverse event note;;ACTIVE;2.58;2.66 +83321-0;Pathology report.intraoperative observation;Find;Pt;Specimen;Doc;;PATH;1;Pathology report intraoperative observation in Specimen Document;Path report.intraop obs Spec Doc;;ACTIVE;2.58;2.63 +83322-8;Home environment safety and stability;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Home environment safety and stability [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.61 +83323-6;Daily activities impact on well-being;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Daily activities impact on well-being [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83324-4;Social network;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Social network [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83325-1;HIV 1 RNA genotype;Find;Pt;Isolate;Doc;Genotyping;ABXBACT;1;HIV 1 RNA genotype in Isolate;HIV 1 RNA genotype Islt;;ACTIVE;2.58;2.58 +83326-9;HIV 1 RNA genotype & phenotype;Find;Pt;Isolate;Doc;;ABXBACT;1;HIV 1 RNA genotype and phenotype in Isolate;HIV 1 RNA geno + pheno Islt;;ACTIVE;2.58;2.73 +83327-7;HIV 1 RNA phenotype;Find;Pt;Isolate;Doc;Phenotyping;ABXBACT;1;HIV 1 RNA phenotype in Isolate;HIV 1 RNA phenotype Islt;;ACTIVE;2.58;2.58 +83328-5;Physical health needs that require further investigation;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Physical health needs that require further investigation [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +8332-9;Body temperature;Temp;Pt;Rectum;Qn;;BDYTMP.MOLEC;2;Rectal temperature;Rectal temp;;ACTIVE;1.0h(2);2.73 +83329-3;Health and well-being panel;-;Pt;^Patient;-;PCAM;PANEL.SURVEY.GNHLTH;4;Health and well-being panel [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83330-1;Physical health impacting mental well-being;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Physical health impacting mental well-being [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83331-9;Patient Centered Assessment Method panel;-;Pt;^Patient;-;PCAM;PANEL.SURVEY.GNHLTH;4;Patient Centered Assessment Method panel [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.63 +83332-7;Lifestyle behaviors impacting physical or mental well-being;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Lifestyle behaviors impacting physical or mental well-being [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83333-5;Other mental well-being concerns;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Other mental well-being concerns [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83334-3;Social environmental panel;-;Pt;^Patient;-;PCAM;PANEL.SURVEY.GNHLTH;4;Social environmental panel [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.61 +83335-0;Financial resources;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Financial resources [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83336-8;Health literacy and communication panel;-;Pt;^Patient;-;PCAM;PANEL.SURVEY.GNHLTH;4;Health literacy and communication panel [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +8333-7;Body temperature;Temp;Pt;Tympanic membrane;Qn;;BDYTMP.MOLEC;2;Tympanic membrane temperature;Tymp memb temp;;ACTIVE;1.0h(2);2.73 +83337-6;Understand health and well-being and what they need to do to manage their health;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Understand health and well-being and what they need to do to manage their health [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83338-4;Can engage in healthcare discussions;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Can engage in healthcare discussions [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83339-2;Service coordination panel;-;Pt;^Patient;-;PCAM;PANEL.SURVEY.GNHLTH;4;Service coordination panel [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +833-4;A variant NOS Ag;ACnc;Pt;RBC^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated A variant subtype Ab [Presence] in RBC from Blood product unit;Deprecated A variant NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.4 +83340-0;Do other services need to be involved to help this client;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Do other services need to be involved to help this client [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83341-8;Are current services involved with this client well-coordinated;Find;Pt;^Patient;Ord;PCAM;SURVEY.GNHLTH;4;Are current services involved with this client well-coordinated [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83342-6;Barriers to action;Imp;Pt;^Patient;Nar;PCAM;SURVEY.GNHLTH;4;Barriers to action [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83343-4;Who needs to be involved;Imp;Pt;^Patient;Nar;PCAM;SURVEY.GNHLTH;4;Who needs to be involved [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +83344-2;What action is required;Imp;Pt;^Patient;Nar;PCAM;SURVEY.GNHLTH;4;What action is required [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +8334-5;Body temperature;Temp;Pt;Urinary bladder;Qn;;BDYTMP.MOLEC;2;Body temperature - Urinary bladder;Bdy temp Bladder;;ACTIVE;1.0h(2);2.73 +83345-9;What action will be taken;Imp;Pt;^Patient;Nar;PCAM;SURVEY.GNHLTH;4;What action will be taken [PCAM];;Copyright © Maxwell, Hibberd, Pratt, Peek and Baird 2013 Used with permission;ACTIVE;2.58;2.58 +8335-2;Body weight;Mass;Pt;^Patient;Qn;Estimated;BDYWGT.ATOM;2;Body weight Estimated;Weight Est;;ACTIVE;1.0h(2);2.73 +8336-0;Body weight;Prctl;Pt;^Patient;Qn;Per age;BDYWGT.MOLEC;2;Body weight [Percentile] Per age;Bdy weight Prctl Per Age;;ACTIVE;1.0h(2);2.73 +83366-5;Burst rate;NRat;Pt;Cerebral cortex;Qn;EEG;NEURO;2;Burst rate Cerebral cortex Electroencephalogram (EEG);Burst rate Ctx EEG;;ACTIVE;2.58;2.58 +83367-3;Fresh gas.air flow setting;VRat;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system Fresh gas.air flow setting [Flow];Fresh gas.air flow set Gas DS;;ACTIVE;2.58;2.58 +83368-1;Expiratory gas flow.max.personal best;VRat;Pt;Respiratory system.airway;Qn;;PULM;2;Personal best peak expiratory gas flow Respiratory system airway;PEF pers best Airway;;ACTIVE;2.58;2.58 +83369-9;Fresh gas.nitrous oxide flow setting;VRat;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system Fresh gas.nitrous oxide flow setting [Flow];Fresh gas.N2O flow set Gas DS;;ACTIVE;2.58;2.58 +83370-7;Fresh gas.oxygen flow setting;VRat;Pt;Gas delivery system;Qn;;PULM;2;Gas delivery system Fresh gas.oxygen flow setting [Flow];Fresh gas.O2 flow set Gas DS;;ACTIVE;2.58;2.58 +83371-5;Cycles.remaining;Num;Pt;Nebulizer;Qn;;PULM;2;Cycles.remaining [#] Nebulizer;Cycles.remain Neb;;ACTIVE;2.58;2.58 +83372-3;Cycles setting;Num;Pt;Nebulizer;Qn;;PULM;2;Cycles setting [#] Nebulizer;Cycles setting Neb;;ACTIVE;2.58;2.58 +83373-1;Mode setting;Type;Pt;Nebulizer;Nom;;PULM;2;Mode setting Nebulizer;Mode setting Neb;;ACTIVE;2.58;2.58 +83374-9;Class;Type;Pt;Nebulizer;Nom;;DEVICES;2;Type of Nebulizer;Neb Class;;ACTIVE;2.58;2.58 +83375-6;Current nebulization cycle time.elapsed;Time;Pt;Nebulizer;Qn;;PULM;2;Current nebulization cycle time.elapsed Nebulizer;Neb cycle time.elapsed Neb;;ACTIVE;2.58;2.61 +83376-4;Current set of nebulization cycles time.elapsed;Time;Pt;Nebulizer;Qn;;PULM;2;Current set of nebulization cycles time.elapsed Nebulizer;Set of neb cycles time.elaps Neb;;ACTIVE;2.58;2.61 +83377-2;Pause time setting;Time;Pt;Nebulizer;Qn;;PULM;2;Pause time setting Nebulizer;Pause time set Neb;;ACTIVE;2.58;2.58 +8337-8;Body weight special circumstances;Type;Pt;^Patient;Nom;;BDYWGT.ATOM;2;Body weight special circumstances;Bdy weight special circumstances;;ACTIVE;1.0h(2);2.64 +83378-0;Run time setting;Time;Pt;Nebulizer;Qn;;PULM;2;Run time setting Nebulizer;Run time set Neb;;ACTIVE;2.58;2.58 +83379-8;Current nebulization cycle time.remaining;Time;Pt;Nebulizer;Qn;;PULM;2;Current nebulization cycle time.remaining Nebulizer;Neb cycle time.remain Neb;;ACTIVE;2.58;2.61 +83380-6;Current set of nebulization cycles time.remaining;Time;Pt;Nebulizer;Qn;;PULM;2;Current set of nebulization cycles time.remaining Nebulizer;Set of neb cycles time.remain Neb;;ACTIVE;2.58;2.61 +83381-4;Current nebulization cycle volume.given;Vol;Pt;Nebulizer;Qn;;PULM;2;Current nebulization cycle volume.given Nebulizer;Neb cycle vol.given Neb;;ACTIVE;2.58;2.61 +83382-2;Current set of nebulization cycles volume.given;Vol;Pt;Nebulizer;Qn;;PULM;2;Current set of nebulization cycles volume.given Nebulizer;Set of neb cycles vol.given Neb;;ACTIVE;2.58;2.61 +83383-0;Cycle volume setting;Vol;Pt;Nebulizer;Qn;;PULM;2;Cycle volume setting Nebulizer;Cycle vol setting Neb;;ACTIVE;2.58;2.58 +83384-8;Current nebulization cycle volume.remaining;Vol;Pt;Nebulizer;Qn;;PULM;2;Current nebulization cycle volume.remaining Nebulizer;Neb cycle vol.remain Neb;;ACTIVE;2.58;2.61 +83385-5;Current set of nebulization cycles volume.remaining;Vol;Pt;Nebulizer;Qn;;PULM;2;Current set of nebulization cycles volume.remaining Nebulizer;Set of neb cycles vol.remain Neb;;ACTIVE;2.58;2.61 +8338-6;Body weight^ante partum;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --ante partum;Weight ante partum Measured;;ACTIVE;1.0h(2);2.73 +83386-3;Pressure.positive end expiratory.extrinsic;Pres;Pt;Respiratory system;Qn;;PULM;2;Extrinsic PEEP Respiratory system;Extrinsic PEEP Respiratory;;ACTIVE;2.58;2.58 +83387-1;Pressure.positive end expiratory.extrinsic dynamic;Pres;Pt;Respiratory system;Qn;;PULM;2;Extrinsic dynamic PEEP Respiratory system;Extrinsic dyn PEEP Respiratory;;ACTIVE;2.58;2.58 +83388-9;Pressure.positive end expiratory.total dynamic;Pres;Pt;Respiratory system;Qn;;PULM;2;Total dynamic PEEP Respiratory system;Total dynamic PEEP Respiratory;;ACTIVE;2.58;2.58 +83389-7;Intravascular;Pres;Pt;Brachial artery;Qn;;BP.MOLEC;2;Brachial artery Blood pressure;Brach a BP;;ACTIVE;2.58;2.58 +83390-5;Tube cuff pressure^at end expiration;Pres;Pt;Intubation tube;Qn;;PULM;2;Tube cuff pressure Intubation tube --at end expiration;Tube cuff pressure end exp Intub tube;;ACTIVE;2.58;2.58 +8339-4;Body weight^at birth;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Birth weight Measured;Birth weight Measured;;ACTIVE;1.0h(2);2.73 +8340-2;Dry body weight;Mass;Pt;^Patient;Qn;Estimated;BDYWGT.MOLEC;2;Dry body weight Estimated;Dry weight Est;;ACTIVE;1.0h(2);2.48 +8341-0;Dry body weight;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Dry body weight Measured;Dry weight Measured;;ACTIVE;1.0h(2);2.73 +834-2;A variant NOS Ag;ACnc;Pt;RBC^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated A variant subtype Ab [Presence] on Red Blood Cells from donor;Deprecated A variant NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.4 +8342-8;Lean body weight;Mass;Pt;^Patient;Qn;Immersion;BDYWGT.MOLEC;2;Lean body weight estimated by Immersion method;Lean body weight Immersion;;ACTIVE;1.0h(2);2.48 +8343-6;Lean body weight;Mass;Pt;^Patient;Qn;Skin fold;BDYWGT.MOLEC;2;Lean body weight estimated by Skin fold method;Lean body weight Skin Fold;;ACTIVE;1.0h(2);2.48 +8344-4;Body weight^post dialysis;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --post dialysis;Weight p dialysis Measured;;ACTIVE;1.0h(2);2.73 +83446-5;How difficult is it for you to read small print;Find;Pt;^Patient;Ord;;NIH.SENSORY;2;How difficult is it for you to read small print;Difficulty w small print;;ACTIVE;2.72;2.72 +8345-1;Body weight^post partum;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --post partum;Weight p partum Measured;;ACTIVE;1.0h(2);2.69 +8346-9;Body weight^postoperative;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --postoperative;Weight Postop Measured;;ACTIVE;1.0h(2);2.69 +8347-7;Body weight^pre dialysis;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --pre dialysis;Weight pre dial Measured;;ACTIVE;1.0h(2);2.73 +8348-5;Body weight^pre pregnancy;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --pre pregnancy;Weight pre pregnancy Measured;;ACTIVE;1.0h(2);2.73 +8349-3;Body weight^preoperative;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --preoperative;Weight Preop Measured;;ACTIVE;1.0h(2);2.69 +8350-1;Body weight^with clothes;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --with clothes;Weight W clothes Measured;;ACTIVE;1.0h(2);2.69 +83516-5;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease.attending;DOC.ONTOLOGY;2;Cardiology Attending Intensive care unit Admission evaluation note;Cardio Attend ICU Admit eval note;;ACTIVE;2.58;2.65 +83517-3;Note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease.attending;DOC.ONTOLOGY;2;Cardiology Attending Intensive care unit Note;Cardio Attend ICU Note;;ACTIVE;2.58;2.65 +83518-1;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.attending;DOC.ONTOLOGY;2;Cardiology Attending Note;Cardio Attend Note;;ACTIVE;2.58;2.65 +8351-9;Body weight^without clothes;Mass;Pt;^Patient;Qn;Measured;BDYWGT.MOLEC;2;Body weight Measured --without clothes;Weight WO clothes Measured;;ACTIVE;1.0h(2);2.69 +83519-9;Note;Find;Pt;Outpatient;Doc;Cardiovascular disease.attending;DOC.ONTOLOGY;2;Cardiology Attending Outpatient Note;Cardio Attend OP Note;;ACTIVE;2.58;2.65 +83520-7;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.case manager;DOC.ONTOLOGY;2;Cardiology Case manager Note;Cardio Case mgr Note;;ACTIVE;2.58;2.58 +83521-5;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.clinical nurse specialist;DOC.ONTOLOGY;2;Cardiology Clinical nurse specialist Note;Cardiology CNS Note;;ACTIVE;2.58;2.58 +83522-3;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Intensive care unit Admission evaluation note;Cardiology ICU Admit eval note;;ACTIVE;2.58;2.58 +83523-1;Discharge summary note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Intensive care unit Discharge summary;Cardiology ICU D/C sum;;ACTIVE;2.58;2.73 +83524-9;Note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Intensive care unit Note;Cardiology ICU Note;;ACTIVE;2.58;2.58 +83525-6;Procedure note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Intensive care unit procedure note;Cardiology ICU Procedure note;;ACTIVE;2.58;2.58 +83526-4;Transfer summary note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Intensive care unit Transfer summary note;Cardiology ICU Transfer sum note;;ACTIVE;2.58;2.58 +8352-7;Clothing worn during measure;Type;Pt;^Patient;Nom;;BDYWGT.ATOM;2;Clothing worn during measure;Clothing worn during measure;;ACTIVE;1.0h(2);2.66 +83527-2;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.fellow;DOC.ONTOLOGY;2;Cardiology Fellow Note;Cardio Fellow Note;;ACTIVE;2.58;2.65 +83528-0;Note;Find;Pt;Outpatient;Doc;Cardiovascular disease.fellow;DOC.ONTOLOGY;2;Cardiology Fellow Outpatient Note;Cardio Fellow OP Note;;ACTIVE;2.58;2.65 +83529-8;Note;Find;Pt;Patient's home;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Patient's home Note;Cardiology Pt's home Note;;ACTIVE;2.58;2.58 +83530-6;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.nurse practitioner;DOC.ONTOLOGY;2;Cardiology Nurse practitioner Note;Cardio NP Note;;ACTIVE;2.58;2.58 +83531-4;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.nurse;DOC.ONTOLOGY;2;Cardiology Nurse Note;Cardio Nurse Note;;ACTIVE;2.58;2.58 +83532-2;Note;Find;Pt;Outpatient;Doc;Cardiovascular disease.nurse;DOC.ONTOLOGY;2;Cardiology Nurse Outpatient Note;Cardio Nurse OP Note;;ACTIVE;2.58;2.58 +83533-0;Procedure note;Find;Pt;{Setting};Doc;Cardiovascular disease.nurse;DOC.ONTOLOGY;2;Cardiology Nurse procedure note;Cardio Nurse Procedure note;;ACTIVE;2.58;2.58 +83534-8;Note;Find;Pt;Observation unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Observation unit Note;Cardiology Obs Unit Note;;ACTIVE;2.58;2.58 +8353-5;Skin fold thickness;Len;Pt;Thigh;Qn;;SKNFLD.MOLEC;2;Skin fold thickness Thigh;Skin fold thickness Thigh;;ACTIVE;1.0h(2);2.48 +83535-5;Surgical operation note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Surgical operation note;Cardiology Operative note;;ACTIVE;2.58;2.58 +83536-3;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.physician assistant;DOC.ONTOLOGY;2;Cardiology Physician assistant Note;Cardiology PA Note;;ACTIVE;2.58;2.58 +83537-1;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Preoperative evaluation and management note;Cardiology Pre-op note;;ACTIVE;2.58;2.58 +83538-9;Note;Find;Pt;{Setting};Doc;Cardiovascular disease.resident;DOC.ONTOLOGY;2;Cardiology Resident Note;Cardio Res Note;;ACTIVE;2.58;2.65 +83539-7;Risk assessment and screening note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Risk assessment and screening note;Cardiology Risk assess+scrn note;;ACTIVE;2.58;2.58 +83540-5;Note;Find;Pt;Telephone encounter;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Telephone encounter Note;Cardiology Phone Note;;ACTIVE;2.58;2.58 +83541-3;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Transplant candidate evaluation note;Cardiology Trnsplt cand eval nte;;ACTIVE;2.58;2.58 +83542-1;Note;Find;Pt;{Setting};Doc;Colon and rectal surgery.nurse practitioner;DOC.ONTOLOGY;2;Colon and rectal surgery Nurse practitioner Note;Col+rec surg NP Note;;ACTIVE;2.58;2.58 +8354-3;Skin fold thickness;Len;Pt;Triceps;Qn;;SKNFLD.MOLEC;2;Skin fold thickness Triceps;Skin fold thickness Triceps;;ACTIVE;1.0h(2);2.48 +83543-9;Note;Find;Pt;{Setting};Doc;Dermatology.nurse practitioner;DOC.ONTOLOGY;2;Dermatology Nurse practitioner Note;Dermatology NP Note;;ACTIVE;2.58;2.58 +83544-7;Note;Find;Pt;{Setting};Doc;Endocrinology.nurse practitioner;DOC.ONTOLOGY;2;Endocrinology Nurse practitioner Note;Endocrin NP Note;;ACTIVE;2.58;2.58 +83545-4;Note;Find;Pt;{Setting};Doc;Geriatric medicine.nurse practitioner;DOC.ONTOLOGY;2;Geriatric medicine Nurse practitioner Note;Geri med NP Note;;ACTIVE;2.58;2.58 +83546-2;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.nurse practitioner;DOC.ONTOLOGY;2;Hematology+Medical oncology Nurse practitioner Note;HemOnc NP Note;;ACTIVE;2.58;2.58 +83547-0;Note;Find;Pt;{Setting};Doc;Mental health.nurse practitioner;DOC.ONTOLOGY;2;Mental health Nurse practitioner Note;MH NP Note;;ACTIVE;2.58;2.58 +83548-8;Note;Find;Pt;{Setting};Doc;Nephrology.nurse practitioner;DOC.ONTOLOGY;2;Nephrology Nurse practitioner Note;Nephrology NP Note;;ACTIVE;2.58;2.58 +83549-6;Note;Find;Pt;{Setting};Doc;Neurological surgery.nurse practitioner;DOC.ONTOLOGY;2;Neurological surgery Nurse practitioner Note;Neuro surg NP Note;;ACTIVE;2.58;2.58 +8355-0;Skin fold thickness;Len;Pt;Waist;Qn;;SKNFLD.MOLEC;2;Skin fold thickness Waist;Skin fold thickness Waist;;ACTIVE;1.0h(2);2.48 +83550-4;Admission evaluation note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Admission evaluation note;Nurse pract Admit eval note;;ACTIVE;2.58;2.58 +83551-2;Discharge summary note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Discharge summary;Nurse pract D/C sum;;ACTIVE;2.58;2.73 +83552-0;History and physical note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner History and physical note;Nurse pract H&P note;;ACTIVE;2.58;2.58 +83553-8;Note;Find;Pt;Patient's home;Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Patient's home Note;Nurse pract Pt's home Note;;ACTIVE;2.58;2.58 +83554-6;Note;Find;Pt;Hospital;Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Hospital Note;Nurse pract Hosp Note;;ACTIVE;2.58;2.58 +83555-3;Note;Find;Pt;Long term care facility;Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Long term care facility Note;Nurse pract LTC fac Note;;ACTIVE;2.58;2.58 +83556-1;Note;Find;Pt;Outpatient;Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Outpatient Note;Nurse pract OP Note;;ACTIVE;2.58;2.58 +83557-9;Note;Find;Pt;Telephone encounter;Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Telephone encounter Note;Nurse pract Phone Note;;ACTIVE;2.58;2.58 +83558-7;Note;Find;Pt;{Setting};Doc;Obstetrics and gynecology.nurse practitioner;DOC.ONTOLOGY;2;Obstetrics and gynecology Nurse practitioner Note;OBGYN NP Note;;DISCOURAGED;2.58;2.64 +83559-5;Note;Find;Pt;{Setting};Doc;Orthopaedic surgery.nurse practitioner;DOC.ONTOLOGY;2;Orthopaedic surgery Nurse practitioner Note;Ortho surg NP Note;;ACTIVE;2.58;2.58 +83560-3;Note;Find;Pt;{Setting};Doc;Primary care.nurse practitioner;DOC.ONTOLOGY;2;Primary care Nurse practitioner Note;Primary care NP Note;;ACTIVE;2.58;2.58 +83561-1;Note;Find;Pt;{Setting};Doc;Psychiatry.nurse practitioner;DOC.ONTOLOGY;2;Psychiatry Nurse practitioner Note;Psychiatry NP Note;;ACTIVE;2.58;2.58 +83562-9;Note;Find;Pt;{Setting};Doc;Surgery.nurse practitioner;DOC.ONTOLOGY;2;Surgery Nurse practitioner Note;Surg NP Note;;ACTIVE;2.58;2.58 +83563-7;Note;Find;Pt;{Setting};Doc;Urology.nurse practitioner;DOC.ONTOLOGY;2;Urology Nurse practitioner Note;Urology NP Note;;ACTIVE;2.58;2.58 +83564-5;Note;Find;Pt;{Setting};Doc;Vascular surgery.nurse practitioner;DOC.ONTOLOGY;2;Vascular surgery Nurse practitioner Note;Vascular surg NP Note;;ACTIVE;2.58;2.58 +83565-2;Note;Find;Pt;{Setting};Doc;Allergy+Immunology.nurse;DOC.ONTOLOGY;2;Allergy and Immunology Nurse Note;Allergy+Immunology Nurse Note;;ACTIVE;2.58;2.66 +83566-0;Note;Find;Pt;Outpatient;Doc;Allergy+Immunology.nurse;DOC.ONTOLOGY;2;Allergy and Immunology Nurse Outpatient Note;Allergy+Immunology Nurse OP Note;;ACTIVE;2.58;2.66 +83567-8;Note;Find;Pt;{Setting};Doc;Anesthesiology.nurse;DOC.ONTOLOGY;2;Anesthesiology Nurse Note;Anesthesiology Nurse Note;;ACTIVE;2.58;2.58 +8356-8;Class;Type;Pt;Weighing device;Nom;*;DEVICES;2;Type of Weighing device;Weighing Device Class;;ACTIVE;1.0h(2);2.29 +83568-6;Note;Find;Pt;{Setting};Doc;Dermatology.nurse;DOC.ONTOLOGY;2;Dermatology Nurse Note;Dermatology Nurse Note;;ACTIVE;2.58;2.58 +83569-4;Note;Find;Pt;Outpatient;Doc;Dermatology.nurse;DOC.ONTOLOGY;2;Dermatology Nurse Outpatient Note;Dermatology Nurse OP Note;;ACTIVE;2.58;2.58 +83570-2;Consultation note;Find;Pt;{Setting};Doc;Diabetology.nurse;DOC.ONTOLOGY;2;Diabetology Nurse Consult note;Diabetology Nurse Consult note;;ACTIVE;2.58;2.58 +83571-0;Note;Find;Pt;{Setting};Doc;Diabetology.nurse;DOC.ONTOLOGY;2;Diabetology Nurse Note;Diabetology Nurse Note;;ACTIVE;2.58;2.58 +83572-8;Note;Find;Pt;Outpatient;Doc;Diabetology.nurse;DOC.ONTOLOGY;2;Diabetology Nurse Outpatient Note;Diabetology Nurse OP Note;;ACTIVE;2.58;2.58 +83573-6;Note;Find;Pt;Outpatient;Doc;Endocrinology.nurse;DOC.ONTOLOGY;2;Endocrinology Nurse Outpatient Note;Endocrin Nurse OP Note;;ACTIVE;2.58;2.58 +83574-4;Note;Find;Pt;Outpatient;Doc;Ophthalmology.nurse;DOC.ONTOLOGY;2;Ophthalmology Nurse Outpatient Note;Ophthal Nurse OP Note;;ACTIVE;2.58;2.58 +83575-1;Note;Find;Pt;{Setting};Doc;Gastroenterology.nurse;DOC.ONTOLOGY;2;Gastroenterology Nurse Note;Gastroenterology Nurse Note;;ACTIVE;2.58;2.58 +8357-6;Blood pressure method;Type;Pt;^Patient;Nom;*;BP.ATOM;2;Blood pressure method;BP method;;ACTIVE;1.0h(2);2.73 +83576-9;Note;Find;Pt;Outpatient;Doc;Gastroenterology.nurse;DOC.ONTOLOGY;2;Gastroenterology Nurse Outpatient Note;Gastroenterology Nurse OP Note;;ACTIVE;2.58;2.58 +83577-7;Procedure note;Find;Pt;{Setting};Doc;Gastroenterology.nurse;DOC.ONTOLOGY;2;Gastroenterology Nurse procedure note;Gastroenterology Nurse Procedure note;;ACTIVE;2.58;2.58 +83578-5;Consultation note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.nurse;DOC.ONTOLOGY;2;Hematology+Medical oncology Nurse Consult note;HemOnc Nurse Consult note;;ACTIVE;2.58;2.63 +83579-3;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.nurse;DOC.ONTOLOGY;2;Hematology+Medical oncology Nurse Note;HemOnc Nurse Note;;ACTIVE;2.58;2.63 +83580-1;Note;Find;Pt;Outpatient;Doc;Hematology+Medical oncology.nurse;DOC.ONTOLOGY;2;Hematology+Medical oncology Nurse Outpatient Note;HemOnc Nurse OP Note;;ACTIVE;2.58;2.63 +83581-9;Note;Find;Pt;{Setting};Doc;Hepatology.nurse;DOC.ONTOLOGY;2;Hepatology Nurse Note;Hepato Nurse Note;;ACTIVE;2.58;2.58 +83582-7;Note;Find;Pt;{Setting};Doc;Interventional radiology.nurse;DOC.ONTOLOGY;2;Interventional radiology Nurse Note;IR Nurse Note;;ACTIVE;2.58;2.58 +83583-5;Note;Find;Pt;{Setting};Doc;Nephrology.nurse;DOC.ONTOLOGY;2;Nephrology Nurse Note;Nephrology Nurse Note;;ACTIVE;2.58;2.58 +8358-4;Cuff size;Len;Pt;Blood pressure device;OrdQn;;DEVICES;2;Blood pressure device Cuff size;BP device Cuff size;;ACTIVE;1.0h(2);2.73 +83584-3;Note;Find;Pt;Outpatient;Doc;Nephrology.nurse;DOC.ONTOLOGY;2;Nephrology Nurse Outpatient Note;Nephrology Nurse OP Note;;ACTIVE;2.58;2.58 +83585-0;Note;Find;Pt;{Setting};Doc;Neurology.nurse;DOC.ONTOLOGY;2;Neurology Nurse Note;Neuro Nurse Note;;ACTIVE;2.58;2.58 +83586-8;Note;Find;Pt;Outpatient;Doc;Neurology.nurse;DOC.ONTOLOGY;2;Neurology Nurse Outpatient Note;Neuro Nurse OP Note;;ACTIVE;2.58;2.58 +83587-6;Note;Find;Pt;{Setting};Doc;Obstetrics and gynecology.nurse;DOC.ONTOLOGY;2;Obstetrics and gynecology Nurse Note;OBGYN Nurse Note;;DISCOURAGED;2.58;2.64 +83588-4;Note;Find;Pt;Outpatient;Doc;Obstetrics and gynecology.nurse;DOC.ONTOLOGY;2;Obstetrics and gynecology Nurse Outpatient Note;OBGYN Nurse OP Note;;DISCOURAGED;2.58;2.64 +83589-2;Note;Find;Pt;{Setting};Doc;Ophthalmology.nurse;DOC.ONTOLOGY;2;Ophthalmology Nurse Note;Ophthal Nurse Note;;ACTIVE;2.58;2.58 +835-9;A variant subtype;ACnc;Pt;RBC^Patient;Ord;Aggl RBC;BLDBK;1;Deprecated A variant subtype Ab [Presence] in on Red Blood Cells;Deprecated A Var Subtyp RBC Patient Ql;;DEPRECATED;1.0;2.4 +83590-0;Note;Find;Pt;{Setting};Doc;Otolaryngology.nurse;DOC.ONTOLOGY;2;Otolaryngology Nurse Note;Otolaryngology Nurse Note;;ACTIVE;2.58;2.58 +83591-8;Note;Find;Pt;Outpatient;Doc;Otolaryngology.nurse;DOC.ONTOLOGY;2;Otolaryngology Nurse Outpatient Note;Otolaryngology Nurse OP Note;;ACTIVE;2.58;2.58 +8359-2;Measurement site;Anat;Pt;Peripheral artery;Nom;;BP.ATOM;2;Peripheral artery measurement site;Periph a measurement site;;ACTIVE;1.0h(2);2.27 +83592-6;Note;Find;Pt;{Setting};Doc;Pathology.nurse;DOC.ONTOLOGY;2;Pathology Nurse Note;Pathology Nurse Note;;ACTIVE;2.58;2.58 +83593-4;Education note;Find;Pt;{Setting};Doc;Radiation oncology.nurse;DOC.ONTOLOGY;2;Radiation oncology Nurse Education note;Radiation Nurse Educ note;;ACTIVE;2.58;2.58 +83594-2;Note;Find;Pt;{Setting};Doc;Radiation oncology.nurse;DOC.ONTOLOGY;2;Radiation oncology Nurse Note;Radiation Nurse Note;;ACTIVE;2.58;2.58 +83595-9;Note;Find;Pt;{Setting};Doc;Rheumatology.nurse;DOC.ONTOLOGY;2;Rheumatology Nurse Note;Rheumatology Nurse Note;;ACTIVE;2.58;2.58 +83596-7;Note;Find;Pt;Outpatient;Doc;Rheumatology.nurse;DOC.ONTOLOGY;2;Rheumatology Nurse Outpatient Note;Rheumatology Nurse OP Note;;ACTIVE;2.58;2.58 +83597-5;Note;Find;Pt;{Setting};Doc;Urology.nurse;DOC.ONTOLOGY;2;Urology Nurse Note;Urology Nurse Note;;ACTIVE;2.58;2.58 +83598-3;Note;Find;Pt;Outpatient;Doc;Urology.nurse;DOC.ONTOLOGY;2;Urology Nurse Outpatient Note;Urology Nurse OP Note;;ACTIVE;2.58;2.58 +83599-1;Procedure note;Find;Pt;{Setting};Doc;Urology.nurse;DOC.ONTOLOGY;2;Urology Nurse procedure note;Urology Nurse Procedure note;;ACTIVE;2.58;2.58 +83-6;Cefaclor;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefaclor [Susceptibility] by Minimum lethal concentration (MLC);Cefaclor Islt MLC;;ACTIVE;1.0;2.19 +8360-0;Body position head tilt;Angle;Pt;^Patient;Qn;*;BP.ATOM;2;Body position head tilt angle;Body position head tilt angle;;ACTIVE;1.0h(2);2.48 +83600-7;Note;Find;Pt;{Setting};Doc;Colon and rectal surgery.nurse;DOC.ONTOLOGY;2;Colon and rectal surgery Nurse Note;Col+rec surg Nurse Note;;ACTIVE;2.58;2.58 +83601-5;Note;Find;Pt;Long term care facility;Doc;Dentistry.nurse;DOC.ONTOLOGY;2;Dentistry Nurse Long term care facility Note;Dentistry Nurse LTC fac Note;;ACTIVE;2.58;2.58 +83602-3;Note;Find;Pt;{Setting};Doc;Neurological surgery.nurse;DOC.ONTOLOGY;2;Neurological surgery Nurse Note;Neuro surg Nurse Note;;ACTIVE;2.58;2.58 +83603-1;Note;Find;Pt;{Setting};Doc;Orthopaedic surgery.nurse;DOC.ONTOLOGY;2;Orthopaedic surgery Nurse Note;Ortho surg Nurse Note;;ACTIVE;2.58;2.65 +83604-9;Note;Find;Pt;Outpatient;Doc;Orthopaedic surgery.nurse;DOC.ONTOLOGY;2;Orthopaedic surgery Nurse Outpatient Note;Ortho surg Nurse OP Note;;ACTIVE;2.58;2.65 +83605-6;Note;Find;Pt;{Setting};Doc;Physical therapy.nurse;DOC.ONTOLOGY;2;Physical therapy Nurse Note;PT Nurse Note;;ACTIVE;2.58;2.58 +83606-4;Note;Find;Pt;Outpatient;Doc;Plastic surgery.nurse;DOC.ONTOLOGY;2;Plastic surgery Nurse Outpatient Note;Plastic surg Nurse OP Note;;ACTIVE;2.58;2.58 +83607-2;Note;Find;Pt;{Setting};Doc;Podiatry.nurse;DOC.ONTOLOGY;2;Podiatry Nurse Note;Podiatry Nurse Note;;ACTIVE;2.58;2.58 +83608-0;Note;Find;Pt;Outpatient;Doc;Podiatry.nurse;DOC.ONTOLOGY;2;Podiatry Nurse Outpatient Note;Podiatry Nurse OP Note;;ACTIVE;2.58;2.58 +83609-8;Consultation note;Find;Pt;{Setting};Doc;Psychiatry.nurse;DOC.ONTOLOGY;2;Psychiatry Nurse Consult note;Psychiatry Nurse Consult note;;ACTIVE;2.58;2.58 +83610-6;Note;Find;Pt;Hospital;Doc;Psychiatry.nurse;DOC.ONTOLOGY;2;Psychiatry Nurse Hospital Note;Psychiatry Nurse Hosp Note;;ACTIVE;2.58;2.58 +83611-4;Note;Find;Pt;{Setting};Doc;Psychiatry.nurse;DOC.ONTOLOGY;2;Psychiatry Nurse Note;Psychiatry Nurse Note;;ACTIVE;2.58;2.58 +83612-2;Note;Find;Pt;Hospital;Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Hospital Note;Surgery Nurse Hosp Note;;ACTIVE;2.58;2.58 +83613-0;Note;Find;Pt;{Setting};Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Note;Surgery Nurse Note;;ACTIVE;2.58;2.58 +83614-8;Surgical operation note;Find;Pt;{Setting};Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Surgical operation note;Surgery Nurse Operative note;;ACTIVE;2.58;2.58 +83615-5;Note;Find;Pt;Outpatient;Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Outpatient Note;Surgery Nurse OP Note;;ACTIVE;2.58;2.58 +83616-3;Procedure note;Find;Pt;Outpatient;Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Outpatient procedure note;Surgery Nurse OP Procedure note;;ACTIVE;2.58;2.58 +83617-1;Procedure note;Find;Pt;{Setting};Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse procedure note;Surgery Nurse Procedure note;;ACTIVE;2.58;2.58 +8361-8;Body position with respect to gravity;Type;Pt;^Patient;Nom;*;BP.ATOM;2;Body position with respect to gravity;Bdy position with respect to gravity;;ACTIVE;1.0h(2);2.73 +83618-9;Note;Find;Pt;{Setting};Doc;Vascular surgery.nurse;DOC.ONTOLOGY;2;Vascular surgery Nurse Note;Vascular surg Nurse Note;;ACTIVE;2.58;2.58 +83619-7;Note;Find;Pt;Outpatient;Doc;Vascular surgery.nurse;DOC.ONTOLOGY;2;Vascular surgery Nurse Outpatient Note;Vascular surg Nurse OP Note;;ACTIVE;2.58;2.58 +83620-5;Note;Find;Pt;{Setting};Doc;Blood banking and transfusion medicine.nurse;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Nurse Note;Bld Bnk+Trans Med Nurse Note;;ACTIVE;2.58;2.58 +83621-3;Consultation note;Find;Pt;{Setting};Doc;Geriatric medicine.nurse;DOC.ONTOLOGY;2;Geriatric medicine Nurse Consult note;Geri med Nurse Consult note;;ACTIVE;2.58;2.58 +83622-1;Note;Find;Pt;{Setting};Doc;Geriatric medicine.nurse;DOC.ONTOLOGY;2;Geriatric medicine Nurse Note;Geri med Nurse Note;;ACTIVE;2.58;2.58 +83623-9;Note;Find;Pt;Outpatient;Doc;Geriatric medicine.nurse;DOC.ONTOLOGY;2;Geriatric medicine Nurse Outpatient Note;Geri med Nurse OP Note;;ACTIVE;2.58;2.58 +83624-7;Risk assessment and screening note;Find;Pt;{Setting};Doc;Geriatric medicine.nurse;DOC.ONTOLOGY;2;Geriatric medicine Nurse Risk assessment and screening note;Geri med Nurse Risk assess+scrn note;;ACTIVE;2.58;2.58 +83625-4;Note;Find;Pt;Patient's home;Doc;Primary care.nurse;DOC.ONTOLOGY;2;Primary care Nurse Patient's home Note;Primary care Nurse Pt's home Note;;ACTIVE;2.58;2.58 +8362-6;Phase of heart cycle;Type;Pt;Heart;Nom;;BP.ATOM;2;Phase of heart cycle;Phase of heart cycle;;ACTIVE;1.0h(2);2.27 +83626-2;Note;Find;Pt;{Setting};Doc;Infectious disease.nurse;DOC.ONTOLOGY;2;Infectious disease Nurse Note;Infect disease Nurse Note;;ACTIVE;2.58;2.58 +83627-0;Note;Find;Pt;Outpatient;Doc;Infectious disease.nurse;DOC.ONTOLOGY;2;Infectious disease Nurse Outpatient Note;Infect disease Nurse OP Note;;ACTIVE;2.58;2.58 +83628-8;Admission evaluation note;Find;Pt;{Setting};Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Admission evaluation note;MH Nurse Admit eval note;;ACTIVE;2.58;2.58 +83629-6;Note;Find;Pt;Custodial care facility;Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Custodial care facility Note;MH Nurse Cust care fac Note;;ACTIVE;2.58;2.58 +83630-4;Group counseling note;Find;Pt;{Setting};Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Group counseling note;MH Nurse Group counseling note;;ACTIVE;2.58;2.58 +83631-2;Note;Find;Pt;Hospital;Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Hospital Note;MH Nurse Hosp Note;;ACTIVE;2.58;2.58 +83632-0;Note;Find;Pt;Long term care facility;Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Long term care facility Note;MH Nurse LTC fac Note;;ACTIVE;2.58;2.58 +83633-8;Medication management note;Find;Pt;{Setting};Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Medication management note;MH Nurse Med mgmt note;;ACTIVE;2.58;2.58 +8363-4;Respiratory phase;Type;Pt;Chest;Nom;;BP.ATOM;2;Respiratory phase;Resp phase;;ACTIVE;1.0h(2);2.27 +83634-6;Note;Find;Pt;Outpatient;Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Outpatient Note;MH Nurse OP Note;;ACTIVE;2.58;2.58 +83635-3;Plan of care note;Find;Pt;{Setting};Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Plan of care note;MH Nurse Plan of care note;;ACTIVE;2.58;2.58 +83636-1;Triage note;Find;Pt;{Setting};Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Triage note;MH Nurse Triage note;;ACTIVE;2.58;2.58 +83637-9;Note;Find;Pt;{Setting};Doc;Nutrition and dietetics.nurse;DOC.ONTOLOGY;2;Nutrition and dietetics Nurse Note;Nutr+diet Nurse Note;;ACTIVE;2.58;2.58 +83638-7;Note;Find;Pt;{Setting};Doc;Pulmonary disease.nurse;DOC.ONTOLOGY;2;Pulmonary Nurse Note;Pulmonary Nurse Note;;ACTIVE;2.58;2.58 +83639-5;Note;Find;Pt;Outpatient;Doc;Pulmonary disease.nurse;DOC.ONTOLOGY;2;Pulmonary Nurse Outpatient Note;Pulmonary Nurse OP Note;;ACTIVE;2.58;2.58 +83640-3;Procedure note;Find;Pt;{Setting};Doc;Pulmonary disease.nurse;DOC.ONTOLOGY;2;Pulmonary Nurse procedure note;Pulmonary Nurse Procedure note;;ACTIVE;2.58;2.58 +83641-1;Note;Find;Pt;{Setting};Doc;Palliative care.nurse;DOC.ONTOLOGY;2;Palliative care Nurse Note;Palltv care Nurse Note;;ACTIVE;2.58;2.58 +8364-2;Selection aggregation;Type;Pt;XXX;Nom;;BP.ATOM;2;Body region Selection aggregation;Body reg Selection aggr;;ACTIVE;1.0h(2);2.73 +83642-9;Triage note;Find;Pt;{Setting};Doc;Primary care.nurse;DOC.ONTOLOGY;2;Primary care Nurse Triage note;Primary care Nurse Triage note;;ACTIVE;2.58;2.58 +83643-7;Note;Find;Pt;Emergency department;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Emergency department Note;Pain medicine ED Note;;ACTIVE;2.58;2.58 +83644-5;Note;Find;Pt;Hospital;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Hospital Note;Pain medicine Hosp Note;;ACTIVE;2.58;2.58 +83645-2;Note;Find;Pt;Long term care facility;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Long term care facility Note;Pain medicine LTC fac Note;;ACTIVE;2.58;2.58 +83646-0;Medication management note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Medication management note;Pain medicine Med mgmt note;;ACTIVE;2.58;2.58 +83647-8;Note;Find;Pt;{Setting};Doc;Pain medicine.nurse;DOC.ONTOLOGY;2;Pain medicine Nurse Note;Pain med Nurse Note;;ACTIVE;2.58;2.58 +83648-6;Note;Find;Pt;Outpatient;Doc;Pain medicine.nurse;DOC.ONTOLOGY;2;Pain medicine Nurse Outpatient Note;Pain med Nurse OP Note;;ACTIVE;2.58;2.58 +83649-4;Initial evaluation note;Find;Pt;Outpatient;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Outpatient Initial evaluation note;Pain medicine OP Initial eval note;;ACTIVE;2.58;2.58 +83650-2;Note;Find;Pt;Outpatient;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Outpatient Note;Pain medicine OP Note;;ACTIVE;2.58;2.58 +83651-0;Procedure note;Find;Pt;Outpatient;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Outpatient procedure note;Pain medicine OP Procedure note;;ACTIVE;2.58;2.58 +83652-8;Risk assessment and screening note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Risk assessment and screening note;Pain medicine Risk assess+scrn note;;ACTIVE;2.58;2.58 +83653-6;Consultation note;Find;Pt;{Setting};Doc;Pain medicine.team;DOC.ONTOLOGY;2;Pain medicine Team Consult note;Pain med Team Consult note;;ACTIVE;2.58;2.58 +83654-4;Note;Find;Pt;{Setting};Doc;Pain medicine.team;DOC.ONTOLOGY;2;Pain medicine Team Note;Pain med Team Note;;ACTIVE;2.58;2.58 +83655-1;Note;Find;Pt;Telephone encounter;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Telephone encounter Note;Pain medicine Phone Note;;ACTIVE;2.58;2.58 +83656-9;Admission evaluation note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery.attending;DOC.ONTOLOGY;2;Cardiothoracic surgery Attending Admission evaluation note;Cardiothor surg Attend Admit eval note;;ACTIVE;2.58;2.65 +83657-7;Note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery.attending;DOC.ONTOLOGY;2;Cardiothoracic surgery Attending Note;Cardiothor surg Attend Note;;ACTIVE;2.58;2.65 +83658-5;Note;Find;Pt;{Setting};Doc;Colon and rectal surgery.attending;DOC.ONTOLOGY;2;Colon and rectal surgery Attending Note;Col+rec surg Attend Note;;ACTIVE;2.58;2.65 +8365-9;Intravascular diastolic;Pres;Pt;Aorta.abdominal.distal;Qn;;BP.CENT.MOLEC;2;Distal abdominal aorta Diastolic blood pressure;Distal Ab Ao BP dias;;ACTIVE;1.0h(2);2.54 +83659-3;Admission evaluation note;Find;Pt;{Setting};Doc;Neurological surgery.attending;DOC.ONTOLOGY;2;Neurological surgery Attending Admission evaluation note;Neuro surg Attend Admit eval note;;ACTIVE;2.58;2.65 +83660-1;Note;Find;Pt;{Setting};Doc;Neurological surgery.attending;DOC.ONTOLOGY;2;Neurological surgery Attending Note;Neuro surg Attend Note;;ACTIVE;2.58;2.65 +83661-9;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Neurological surgery.attending;DOC.ONTOLOGY;2;Neurological surgery Attending Preoperative evaluation and management note;Neuro surg Attend Pre-op note;;ACTIVE;2.58;2.65 +83662-7;Note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery.attending;DOC.ONTOLOGY;2;Oral and maxillofacial surgery Attending Note;OMS Attend Note;;ACTIVE;2.58;2.65 +83663-5;Note;Find;Pt;{Setting};Doc;Orthopaedic surgery.attending;DOC.ONTOLOGY;2;Orthopaedic surgery Attending Note;Ortho surg attend Note;;ACTIVE;2.58;2.65 +83664-3;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Orthopaedic surgery.attending;DOC.ONTOLOGY;2;Orthopaedic surgery Attending Preoperative evaluation and management note;Ortho surg attend Pre-op note;;ACTIVE;2.58;2.65 +83665-0;Admission evaluation note;Find;Pt;{Setting};Doc;Plastic surgery.attending;DOC.ONTOLOGY;2;Plastic surgery Attending Admission evaluation note;Plastic surg Attend Admit eval note;;ACTIVE;2.58;2.65 +83666-8;Note;Find;Pt;{Setting};Doc;Plastic surgery.attending;DOC.ONTOLOGY;2;Plastic surgery Attending Note;Plastic surg Attend Note;;ACTIVE;2.58;2.65 +8366-7;Intravascular diastolic;Pres;Pt;Aorta.abdominal.proximal;Qn;;BP.CENT.MOLEC;2;Proximal abdominal aorta Diastolic blood pressure;Prox Ab Ao BP dias;;ACTIVE;1.0h(2);2.54 +83667-6;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Plastic surgery.attending;DOC.ONTOLOGY;2;Plastic surgery Attending Preoperative evaluation and management note;Plastic surg Attend Pre-op note;;ACTIVE;2.58;2.65 +83668-4;Admission evaluation note;Find;Pt;{Setting};Doc;Psychiatry.attending;DOC.ONTOLOGY;2;Psychiatry Attending Admission evaluation note;Psychiatry Attend Admit eval note;;ACTIVE;2.58;2.65 +83669-2;Note;Find;Pt;Hospital;Doc;Psychiatry.attending;DOC.ONTOLOGY;2;Psychiatry Attending Hospital Note;Psychiatry Attend Hosp Note;;ACTIVE;2.58;2.65 +836-7;Ax Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Ax Ag [Presence] on Red Blood Cells from Blood product unit;Ax Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +83670-0;Admission evaluation note;Find;Pt;{Setting};Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Admission evaluation note;Surg attend Admit eval note;;ACTIVE;2.58;2.65 +83671-8;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Intensive care unit Admission evaluation note;Surg attend ICU Admit eval note;;ACTIVE;2.58;2.65 +83672-6;Note;Find;Pt;Intensive care unit;Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Intensive care unit Note;Surg attend ICU Note;;ACTIVE;2.58;2.65 +83673-4;Surgical operation note;Find;Pt;{Setting};Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Surgical operation note;Surg attend Operative note;;ACTIVE;2.58;2.65 +83674-2;Note;Find;Pt;Outpatient;Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Outpatient Note;Surg attend OP Note;;ACTIVE;2.58;2.65 +8367-5;Intravascular diastolic;Pres;Pt;Aorta.thoracic.proximal ascending;Qn;;BP.CENT.MOLEC;2;Proximal ascending thoracic aorta Diastolic blood pressure;Prox asc TA BP dias;;ACTIVE;1.0h(2);2.54 +83675-9;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Postoperative evaluation and management note;Surg attend Post-op E/M note;;ACTIVE;2.58;2.65 +83676-7;Note;Find;Pt;{Setting};Doc;Transplant surgery.attending;DOC.ONTOLOGY;2;Transplant surgery Attending Note;Transplant surg Attend Note;;ACTIVE;2.58;2.65 +83677-5;Admission evaluation note;Find;Pt;{Setting};Doc;Vascular surgery.attending;DOC.ONTOLOGY;2;Vascular surgery Attending Admission evaluation note;Vascular surg Attend Admit eval note;;ACTIVE;2.58;2.65 +83678-3;Note;Find;Pt;{Setting};Doc;Vascular surgery.attending;DOC.ONTOLOGY;2;Vascular surgery Attending Note;Vascular surg Attend Note;;ACTIVE;2.58;2.65 +83679-1;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Vascular surgery.attending;DOC.ONTOLOGY;2;Vascular surgery Attending Preoperative evaluation and management note;Vascular surg Attend Pre-op note;;ACTIVE;2.58;2.65 +83680-9;Note;Find;Pt;{Setting};Doc;Anesthesiology.attending;DOC.ONTOLOGY;2;Anesthesiology Attending Note;Anesthesiology Attend Note;;ACTIVE;2.58;2.65 +83681-7;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Anesthesiology.attending;DOC.ONTOLOGY;2;Anesthesiology Attending Preoperative evaluation and management note;Anesthesiology Attend Pre-op note;;ACTIVE;2.58;2.65 +83682-5;Note;Find;Pt;{Setting};Doc;Dermatology.attending;DOC.ONTOLOGY;2;Dermatology Attending Note;Dermatology Attend Note;;ACTIVE;2.58;2.65 +8368-3;Intravascular diastolic;Pres;Pt;Aorta.thoracic.ascending;Qn;;BP.CENT.MOLEC;2;Ascending thoracic aorta Diastolic blood pressure;ATA BP dias;;ACTIVE;1.0h(2);2.54 +83683-3;Note;Find;Pt;{Setting};Doc;Endocrinology.attending;DOC.ONTOLOGY;2;Endocrinology Attending Note;Endocrin Attend Note;;ACTIVE;2.58;2.65 +83684-1;Note;Find;Pt;{Setting};Doc;Gastroenterology.attending;DOC.ONTOLOGY;2;Gastroenterology Attending Note;Gastroenterology Attend Note;;ACTIVE;2.58;2.65 +83685-8;Consultation note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.attending;DOC.ONTOLOGY;2;Hematology+Medical oncology Attending Consult note;HemOnc Attend Consult note;;ACTIVE;2.58;2.65 +83686-6;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.attending;DOC.ONTOLOGY;2;Hematology+Medical oncology Attending Note;HemOnc Attend Note;;ACTIVE;2.58;2.65 +83687-4;Note;Find;Pt;{Setting};Doc;Nephrology.attending;DOC.ONTOLOGY;2;Nephrology Attending Note;Nephrology Attend Note;;ACTIVE;2.58;2.65 +83688-2;Admission evaluation note;Find;Pt;{Setting};Doc;Neurology.attending;DOC.ONTOLOGY;2;Neurology Attending Admission evaluation note;Neurology Attend Admit eval note;;ACTIVE;2.58;2.65 +83689-0;Note;Find;Pt;{Setting};Doc;Neurology.attending;DOC.ONTOLOGY;2;Neurology Attending Note;Neurology Attend Note;;ACTIVE;2.58;2.65 +83690-8;Note;Find;Pt;{Setting};Doc;Obstetrics and gynecology.attending;DOC.ONTOLOGY;2;Obstetrics and gynecology Attending Note;OBGYN Attend Note;;DISCOURAGED;2.58;2.65 +8369-1;Intravascular diastolic;Pres;Pt;Aorta.thoracic.descending;Qn;;BP.CENT.MOLEC;2;Descending thoracic aorta Diastolic blood pressure;DTA BP dias;;ACTIVE;1.0h(2);2.54 +83691-6;Note;Find;Pt;{Setting};Doc;Ophthalmology.attending;DOC.ONTOLOGY;2;Ophthalmology Attending Note;Ophthal Attend Note;;ACTIVE;2.58;2.65 +83692-4;Surgical operation note;Find;Pt;{Setting};Doc;Ophthalmology.attending;DOC.ONTOLOGY;2;Ophthalmology Attending Surgical operation note;Ophthal Attend Operative note;;ACTIVE;2.58;2.65 +83693-2;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Ophthalmology.attending;DOC.ONTOLOGY;2;Ophthalmology Attending Preoperative evaluation and management note;Ophthal Attend Pre-op note;;ACTIVE;2.58;2.65 +83694-0;Admission evaluation note;Find;Pt;{Setting};Doc;Otolaryngology.attending;DOC.ONTOLOGY;2;Otolaryngology Attending Admission evaluation note;Otolaryngology Attend Admit eval note;;ACTIVE;2.58;2.65 +83695-7;Note;Find;Pt;{Setting};Doc;Otolaryngology.attending;DOC.ONTOLOGY;2;Otolaryngology Attending Note;Otolaryngology Attend Note;;ACTIVE;2.58;2.65 +83696-5;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Otolaryngology.attending;DOC.ONTOLOGY;2;Otolaryngology Attending Preoperative evaluation and management note;Otolaryngology Attend Pre-op note;;ACTIVE;2.58;2.65 +83697-3;Note;Find;Pt;{Setting};Doc;Radiation oncology.attending;DOC.ONTOLOGY;2;Radiation oncology Attending Note;Radiation Attend Note;;ACTIVE;2.58;2.65 +83698-1;Note;Find;Pt;{Setting};Doc;Rheumatology.attending;DOC.ONTOLOGY;2;Rheumatology Attending Note;Rheumatology Attend Note;;ACTIVE;2.58;2.65 +83699-9;Admission evaluation note;Find;Pt;{Setting};Doc;Urology.attending;DOC.ONTOLOGY;2;Urology Attending Admission evaluation note;Urology Attend Admit eval note;;ACTIVE;2.58;2.65 +83700-5;Note;Find;Pt;{Setting};Doc;Urology.attending;DOC.ONTOLOGY;2;Urology Attending Note;Urology Attend Note;;ACTIVE;2.58;2.65 +83701-3;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Urology.attending;DOC.ONTOLOGY;2;Urology Attending Preoperative evaluation and management note;Urology Attend Pre-op note;;ACTIVE;2.58;2.65 +83702-1;Note;Find;Pt;{Setting};Doc;Geriatric medicine.attending;DOC.ONTOLOGY;2;Geriatric medicine Attending Note;Geri med Attend Note;;ACTIVE;2.58;2.65 +83703-9;Note;Find;Pt;Patient's home;Doc;Primary care.attending;DOC.ONTOLOGY;2;Primary care Attending Patient's home Note;Primary care Attend Pt's home Note;;ACTIVE;2.58;2.65 +83704-7;Note;Find;Pt;{Setting};Doc;Mental health.attending;DOC.ONTOLOGY;2;Mental health Attending Note;MH Attend Note;;ACTIVE;2.58;2.65 +83705-4;Note;Find;Pt;{Setting};Doc;Palliative care.attending;DOC.ONTOLOGY;2;Palliative care Attending Note;Palltv care Attend Note;;ACTIVE;2.58;2.65 +83706-2;Initial evaluation note;Find;Pt;{Setting};Doc;Primary care.attending;DOC.ONTOLOGY;2;Primary care Attending Initial evaluation note;Primary care Attend Initial eval note;;ACTIVE;2.58;2.65 +83707-0;Administrative note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Administrative note;PM+R Administrative note;;ACTIVE;2.58;2.58 +83708-8;Admission evaluation note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Admission evaluation note;PM+R Admit eval note;;ACTIVE;2.58;2.58 +83709-6;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab.attending;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Attending Note;PM+R Attend Note;;ACTIVE;2.58;2.65 +83710-4;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab.case manager;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Case manager Note;PM+R Case mgr Note;;ACTIVE;2.58;2.58 +83711-2;Conference note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Conference note;PM+R Conf eval note;;ACTIVE;2.58;2.58 +83712-0;Discharge summary note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Discharge summary;PM+R D/C sum;;ACTIVE;2.58;2.73 +83713-8;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab.interdisciplinary;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Interdisciplinary Note;PM+R Interdisciplinary Note;;ACTIVE;2.58;2.58 +83714-6;Education note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Education note;PM+R Educ note;;ACTIVE;2.58;2.58 +83715-3;History and physical note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab History and physical note;PM+R H&P note;;ACTIVE;2.58;2.58 +83716-1;Note;Find;Pt;Patient's home;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Patient's home Note;PM+R Pt's home Note;;ACTIVE;2.58;2.58 +83717-9;Initial evaluation note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Initial evaluation note;PM+R Initial eval note;;ACTIVE;2.58;2.58 +83718-7;Admission evaluation note;Find;Pt;Hospital;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Hospital Admission evaluation note;PM+R Hosp Admit eval note;;ACTIVE;2.58;2.58 +83719-5;Note;Find;Pt;Hospital;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Hospital Note;PM+R Hosp Note;;ACTIVE;2.58;2.58 +83720-3;Consultation note;Find;Pt;Long term care facility;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Long term care facility Consult note;PM+R LTC fac Consult note;;ACTIVE;2.58;2.58 +83721-1;Note;Find;Pt;Long term care facility;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Long term care facility Note;PM+R LTC fac Note;;ACTIVE;2.58;2.58 +83722-9;Consultation note;Find;Pt;{Setting};Doc;Physical medicine and rehab.nurse;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Nurse Consult note;PM+R Nurse Consult note;;ACTIVE;2.58;2.58 +83723-7;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab.nurse;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Nurse Note;PM+R Nurse Note;;ACTIVE;2.58;2.58 +83724-5;Initial evaluation note;Find;Pt;Outpatient;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Outpatient Initial evaluation note;PM+R OP Initial eval note;;ACTIVE;2.58;2.58 +83725-2;Note;Find;Pt;Outpatient;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Outpatient Note;PM+R OP Note;;ACTIVE;2.58;2.58 +83726-0;Initial evaluation note;Find;Pt;{Setting};Doc;Physical medicine and rehab.physician;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Physician Initial evaluation note;PM+R MD Initial eval note;;ACTIVE;2.58;2.58 +83727-8;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab.physician;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Physician Note;PM+R MD Note;;ACTIVE;2.58;2.58 +83728-6;Procedure note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab procedure note;PM+R Procedure note;;ACTIVE;2.58;2.58 +83729-4;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab.resident;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Resident Note;PM+R Res Note;;ACTIVE;2.58;2.65 +83730-2;Risk assessment and screening note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Risk assessment and screening note;PM+R Risk assess+scrn note;;ACTIVE;2.58;2.58 +83731-0;Conference note;Find;Pt;{Setting};Doc;Physical medicine and rehab.team;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Team Conference note;PM+R Team Conf eval note;;ACTIVE;2.58;2.58 +83732-8;Note;Find;Pt;{Setting};Doc;Physical medicine and rehab.team;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Team Note;PM+R Team Note;;ACTIVE;2.58;2.58 +83733-6;Note;Find;Pt;Telephone encounter;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Telephone encounter Note;PM+R Phone Note;;ACTIVE;2.58;2.58 +83734-4;Plan of care note;Find;Pt;{Setting};Doc;Physical medicine and rehab.interdisciplinary;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Interdisciplinary Plan of care note;PM+R Interdisciplinary Plan of care note;;ACTIVE;2.58;2.58 +83735-1;Note;Find;Pt;{Setting};Doc;Colon and rectal surgery.fellow;DOC.ONTOLOGY;2;Colon and rectal surgery Fellow Note;Col+rec surg Fellow Note;;ACTIVE;2.58;2.65 +83736-9;Note;Find;Pt;{Setting};Doc;Endocrinology.fellow;DOC.ONTOLOGY;2;Endocrinology Fellow Note;Endocrin Fellow Note;;ACTIVE;2.58;2.65 +83737-7;Note;Find;Pt;{Setting};Doc;Gastroenterology.fellow;DOC.ONTOLOGY;2;Gastroenterology Fellow Note;Gastroenterology Fellow Note;;ACTIVE;2.58;2.65 +83738-5;Note;Find;Pt;{Setting};Doc;Geriatric medicine.fellow;DOC.ONTOLOGY;2;Geriatric medicine Fellow Note;Geri med Fellow Note;;ACTIVE;2.58;2.65 +83739-3;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.fellow;DOC.ONTOLOGY;2;Hematology+Medical oncology Fellow Note;HemOnc Fellow Note;;ACTIVE;2.58;2.65 +83740-1;Note;Find;Pt;{Setting};Doc;Infectious disease.fellow;DOC.ONTOLOGY;2;Infectious disease Fellow Note;Infect disease Fellow Note;;ACTIVE;2.58;2.65 +83741-9;Note;Find;Pt;{Setting};Doc;Nephrology.fellow;DOC.ONTOLOGY;2;Nephrology Fellow Note;Nephrology Fellow Note;;ACTIVE;2.58;2.65 +83742-7;Note;Find;Pt;{Setting};Doc;Ophthalmology.fellow;DOC.ONTOLOGY;2;Ophthalmology Fellow Note;Ophthal Fellow Note;;ACTIVE;2.58;2.65 +83743-5;Note;Find;Pt;{Setting};Doc;Plastic surgery.fellow;DOC.ONTOLOGY;2;Plastic surgery Fellow Note;Plastic surg Fellow Note;;ACTIVE;2.58;2.65 +83744-3;Note;Find;Pt;{Setting};Doc;Pulmonary disease.fellow;DOC.ONTOLOGY;2;Pulmonary Fellow Note;Pulmonary Fellow Note;;ACTIVE;2.58;2.65 +83745-0;Note;Find;Pt;{Setting};Doc;Rheumatology.fellow;DOC.ONTOLOGY;2;Rheumatology Fellow Note;Rheumatology Fellow Note;;ACTIVE;2.58;2.65 +83746-8;Note;Find;Pt;Hospital;Doc;Spinal cord injury medicine.fellow;DOC.ONTOLOGY;2;Spinal cord injury medicine Fellow Hospital Note;SCIM Fellow Hosp Note;;ACTIVE;2.58;2.65 +83747-6;Note;Find;Pt;{Setting};Doc;Mental health.physician assistant;DOC.ONTOLOGY;2;Mental health Physician assistant Note;MH PA Note;;ACTIVE;2.58;2.58 +83748-4;Note;Find;Pt;{Setting};Doc;Orthopaedic surgery.physician assistant;DOC.ONTOLOGY;2;Orthopaedic surgery Physician assistant Note;Ortho surg PA Note;;ACTIVE;2.58;2.58 +83749-2;Note;Find;Pt;{Setting};Doc;Primary care.physician assistant;DOC.ONTOLOGY;2;Primary care Physician assistant Note;Primary care PA Note;;ACTIVE;2.58;2.58 +837-5;Ax Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Ax Ag [Presence] on Red Blood Cells from Donor;Ax Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +83750-0;Note;Find;Pt;{Setting};Doc;Spinal cord injury medicine.physician assistant;DOC.ONTOLOGY;2;Spinal cord injury medicine Physician assistant Note;SCIM PA Note;;ACTIVE;2.58;2.58 +83751-8;Note;Find;Pt;{Setting};Doc;Urology.physician assistant;DOC.ONTOLOGY;2;Urology Physician assistant Note;Urology PA Note;;ACTIVE;2.58;2.58 +83752-6;Note;Find;Pt;{Setting};Doc;Vascular surgery.physician assistant;DOC.ONTOLOGY;2;Vascular surgery Physician assistant Note;Vascular surg PA Note;;ACTIVE;2.58;2.58 +83753-4;Note;Find;Pt;{Setting};Doc;Colon and rectal surgery.resident;DOC.ONTOLOGY;2;Colon and rectal surgery Resident Note;Col+rec surg Res Note;;ACTIVE;2.58;2.65 +83754-2;Note;Find;Pt;{Setting};Doc;Dermatology.resident;DOC.ONTOLOGY;2;Dermatology Resident Note;Dermatology Res Note;;ACTIVE;2.58;2.65 +83755-9;Note;Find;Pt;{Setting};Doc;Endocrinology.resident;DOC.ONTOLOGY;2;Endocrinology Resident Note;Endocrin Res Note;;ACTIVE;2.58;2.65 +83756-7;Note;Find;Pt;{Setting};Doc;Gastroenterology.resident;DOC.ONTOLOGY;2;Gastroenterology Resident Note;Gastroenterology Res Note;;ACTIVE;2.58;2.65 +83757-5;Note;Find;Pt;{Setting};Doc;Geriatric medicine.resident;DOC.ONTOLOGY;2;Geriatric medicine Resident Note;Geri med Res Note;;ACTIVE;2.58;2.65 +8375-8;Intrachamber diastolic;Pres;Pt;Heart.ventricle.left;Qn;;BP.CENT.MOLEC;2;Left ventricular Intrachamber diastolic pressure;LV Intrachamber dias pres;;ACTIVE;1.0h(2);2.3 +83758-3;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.resident;DOC.ONTOLOGY;2;Hematology+Medical oncology Resident Note;HemOnc Res Note;;ACTIVE;2.58;2.65 +83759-1;Note;Find;Pt;{Setting};Doc;Infectious disease.resident;DOC.ONTOLOGY;2;Infectious disease Resident Note;Infect disease Res Note;;ACTIVE;2.58;2.65 +83760-9;Note;Find;Pt;{Setting};Doc;Interventional radiology.resident;DOC.ONTOLOGY;2;Interventional radiology Resident Note;IR Resident Note;;ACTIVE;2.58;2.65 +83761-7;Note;Find;Pt;{Setting};Doc;Mental health.resident;DOC.ONTOLOGY;2;Mental health Resident Note;MH Res Note;;ACTIVE;2.58;2.65 +83762-5;Note;Find;Pt;{Setting};Doc;Nephrology.resident;DOC.ONTOLOGY;2;Nephrology Resident Note;Nephrology Res Note;;ACTIVE;2.58;2.65 +83763-3;Note;Find;Pt;{Setting};Doc;Neurology.resident;DOC.ONTOLOGY;2;Neurology Resident Note;Neurology Res Note;;ACTIVE;2.58;2.65 +83764-1;Note;Find;Pt;{Setting};Doc;Neurological surgery.resident;DOC.ONTOLOGY;2;Neurological surgery Resident Note;Neuro surg Res Note;;ACTIVE;2.58;2.65 +83765-8;Note;Find;Pt;{Setting};Doc;Obstetrics and gynecology.resident;DOC.ONTOLOGY;2;Obstetrics and gynecology Resident Note;OBGYN Res Note;;DISCOURAGED;2.58;2.65 +8376-6;Intrachamber diastolic;Pres;Pt;Heart.ventricle.left.outflow tract;Qn;;BP.CENT.MOLEC;2;Left ventricular outflow tract Intrachamber diastolic pressure;LVOT Intrachamber dias pres;;ACTIVE;1.0h(2);2.4 +83766-6;Note;Find;Pt;{Setting};Doc;Ophthalmology.resident;DOC.ONTOLOGY;2;Ophthalmology Resident Note;Ophthal Res Note;;ACTIVE;2.58;2.65 +83767-4;Note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery.resident;DOC.ONTOLOGY;2;Oral and maxillofacial surgery Resident Note;OMS Res Note;;ACTIVE;2.58;2.65 +83768-2;Note;Find;Pt;{Setting};Doc;Orthopaedic surgery.resident;DOC.ONTOLOGY;2;Orthopaedic surgery Resident Note;Ortho surg Res Note;;ACTIVE;2.58;2.65 +83769-0;Note;Find;Pt;{Setting};Doc;Otolaryngology.resident;DOC.ONTOLOGY;2;Otolaryngology Resident Note;Otolaryngology Res Note;;ACTIVE;2.58;2.65 +83770-8;Note;Find;Pt;{Setting};Doc;Palliative care.resident;DOC.ONTOLOGY;2;Palliative care Resident Note;Palltv care Res Note;;ACTIVE;2.58;2.65 +83771-6;Note;Find;Pt;{Setting};Doc;Plastic surgery.resident;DOC.ONTOLOGY;2;Plastic surgery Resident Note;Plastic surg Res Note;;ACTIVE;2.58;2.65 +83772-4;Note;Find;Pt;{Setting};Doc;Primary care.resident;DOC.ONTOLOGY;2;Primary care Resident Note;Primary care Res Note;;ACTIVE;2.58;2.65 +83773-2;Note;Find;Pt;{Setting};Doc;Psychiatry.resident;DOC.ONTOLOGY;2;Psychiatry Resident Note;Psychiatry Res Note;;ACTIVE;2.58;2.65 +8377-4;Intrachamber diastolic;Pres;Pt;Heart.ventricle.right;Qn;;BP.CENT.MOLEC;2;Right ventricular Intrachamber diastolic pressure;RV Intrachamber dias pres;;ACTIVE;1.0h(2);2.3 +83774-0;Note;Find;Pt;{Setting};Doc;Pulmonary disease.resident;DOC.ONTOLOGY;2;Pulmonary Resident Note;Pulmonary Res Note;;ACTIVE;2.58;2.65 +83775-7;Note;Find;Pt;{Setting};Doc;Radiation oncology.resident;DOC.ONTOLOGY;2;Radiation oncology Resident Note;Radiation Res Note;;ACTIVE;2.58;2.65 +83776-5;Note;Find;Pt;{Setting};Doc;Rheumatology.resident;DOC.ONTOLOGY;2;Rheumatology Resident Note;Rheumatology Res Note;;ACTIVE;2.58;2.65 +83777-3;Note;Find;Pt;Hospital;Doc;Spinal cord injury medicine.resident;DOC.ONTOLOGY;2;Spinal cord injury medicine Resident Hospital Note;SCIM Resident Hosp Note;;ACTIVE;2.58;2.65 +83778-1;Admission evaluation note;Find;Pt;{Setting};Doc;Surgery.resident;DOC.ONTOLOGY;2;Surgery Resident Admission evaluation note;Surg Res Admit eval note;;ACTIVE;2.58;2.65 +83779-9;Note;Find;Pt;{Setting};Doc;Surgery.resident;DOC.ONTOLOGY;2;Surgery Resident Note;Surg Res Note;;ACTIVE;2.58;2.65 +83780-7;Note;Find;Pt;{Setting};Doc;Transplant surgery.resident;DOC.ONTOLOGY;2;Transplant surgery Resident Note;Transplant surg Res Note;;ACTIVE;2.58;2.65 +83781-5;Note;Find;Pt;{Setting};Doc;Urology.resident;DOC.ONTOLOGY;2;Urology Resident Note;Urology Res Note;;ACTIVE;2.58;2.65 +8378-2;Intravascular diastolic;Pres;Pt;Celiac trunk artery;Qn;;BP.CENT.MOLEC;2;Celiac trunk artery Diastolic blood pressure;Celiac trunk a BP dias;;ACTIVE;1.0h(2);2.4 +83782-3;Note;Find;Pt;{Setting};Doc;Vascular surgery.resident;DOC.ONTOLOGY;2;Vascular surgery Resident Note;Vascular surg Res Note;;ACTIVE;2.58;2.65 +83783-1;Note;Find;Pt;{Setting};Doc;Infectious disease.attending;DOC.ONTOLOGY;2;Infectious disease Attending Note;Infectious disease Attend Note;;ACTIVE;2.58;2.65 +83784-9;Note;Find;Pt;{Setting};Doc;Mental health.physician;DOC.ONTOLOGY;2;Mental health Physician Note;MH MD Note;;ACTIVE;2.58;2.58 +83785-6;Note;Find;Pt;{Setting};Doc;Palliative care.physician;DOC.ONTOLOGY;2;Palliative care Physician Note;Palltv care MD Note;;ACTIVE;2.58;2.58 +83786-4;History and physical note;Find;Pt;{Setting};Doc;Primary care.physician;DOC.ONTOLOGY;2;Primary care Physician History and physical note;Primary care MD H&P note;;ACTIVE;2.58;2.58 +83787-2;Note;Find;Pt;{Setting};Doc;Pulmonary disease.attending;DOC.ONTOLOGY;2;Pulmonary Attending Note;Pulmonary Attend Note;;ACTIVE;2.58;2.65 +83788-0;Note;Find;Pt;Outpatient;Doc;Pulmonary disease.attending;DOC.ONTOLOGY;2;Pulmonary Attending Outpatient Note;Pulmonary Attend OP Note;;ACTIVE;2.58;2.65 +83789-8;Procedure note;Find;Pt;{Setting};Doc;Pulmonary disease.attending;DOC.ONTOLOGY;2;Pulmonary Attending procedure note;Pulmonary Attend Procedure note;;ACTIVE;2.58;2.65 +8379-0;Intravascular diastolic;Pres;Pt;Coronary sinus;Qn;;BP.CENT.MOLEC;2;Coronary sinus Diastolic blood pressure;CS BP dias;;ACTIVE;1.0h(2);2.4 +83790-6;Note;Find;Pt;{Setting};Doc;Spinal cord injury medicine.attending;DOC.ONTOLOGY;2;Spinal cord injury medicine Attending Note;SCIM Attend Note;;ACTIVE;2.58;2.65 +83791-4;Note;Find;Pt;{Setting};Doc;Spinal cord injury medicine.physician;DOC.ONTOLOGY;2;Spinal cord injury medicine Physician Note;SCIM MD Note;;ACTIVE;2.58;2.58 +83792-2;Admission evaluation note;Find;Pt;{Setting};Doc;Surgery.intern;DOC.ONTOLOGY;2;Surgery Intern Admission evaluation note;Surg Intern Admit eval note;;ACTIVE;2.58;2.65 +83793-0;Note;Find;Pt;Long term care facility;Doc;Physician;DOC.ONTOLOGY;2;Physician Long term care facility Note;MD LTC fac Note;;ACTIVE;2.58;2.58 +83794-8;Note;Find;Pt;Urgent care center;Doc;Physician;DOC.ONTOLOGY;2;Physician Urgent care center Note;MD Urgent care Note;;ACTIVE;2.58;2.58 +83795-5;Note;Find;Pt;Telephone encounter;Doc;Physician;DOC.ONTOLOGY;2;Physician Telephone encounter Note;MD Phone Note;;ACTIVE;2.58;2.58 +83796-3;Summary of death note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Summary of death note;MD Summary of death;;ACTIVE;2.58;2.58 +83797-1;Referral note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Referral note;MD Referral note;;ACTIVE;2.58;2.58 +83798-9;Note;Find;Pt;Outpatient;Doc;Physician;DOC.ONTOLOGY;2;Physician Outpatient Note;MD OP Note;;ACTIVE;2.58;2.58 +83799-7;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Transplant candidate evaluation note;MD Trnsplt cand eval nte;;ACTIVE;2.58;2.58 +83800-3;Note;Find;Pt;Hospital;Doc;Physician;DOC.ONTOLOGY;2;Physician Hospital Note;MD Hosp Note;;ACTIVE;2.58;2.58 +83801-1;Note;Find;Pt;Patient's home;Doc;Physician;DOC.ONTOLOGY;2;Physician Patient's home Note;MD Pt's home Note;;ACTIVE;2.58;2.58 +83802-9;Discharge instructions;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Discharge instructions;MD Discharge instruct;;ACTIVE;2.58;2.73 +83803-7;Note;Find;Pt;Custodial care facility;Doc;Physician;DOC.ONTOLOGY;2;Physician Custodial care facility Note;MD Cust care fac Note;;ACTIVE;2.58;2.58 +83804-5;Administrative note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Administrative note;MD Administrative note;;ACTIVE;2.58;2.58 +83805-2;Admission evaluation note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Admission evaluation note;MD Admit eval note;;ACTIVE;2.58;2.58 +83806-0;Note;Find;Pt;{Setting};Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Note;PA Note;;ACTIVE;2.58;2.58 +83807-8;Note;Find;Pt;Custodial care facility;Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Custodial care facility Note;PA Cust care fac Note;;ACTIVE;2.58;2.58 +8380-8;Intravascular diastolic;Pres;Pt;Ductus arteriosus;Qn;;BP.CENT.MOLEC;2;Ductus arteriosus Diastolic blood pressure;DA BP dias;;ACTIVE;1.0h(2);2.4 +83808-6;Note;Find;Pt;Outpatient;Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Outpatient Note;PA OP Note;;ACTIVE;2.58;2.58 +83809-4;Admission evaluation note;Find;Pt;{Setting};Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Admission evaluation note;PA Admit eval note;;ACTIVE;2.58;2.58 +83810-2;Discharge summary note;Find;Pt;{Setting};Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Discharge summary;PA D/C sum;;ACTIVE;2.58;2.73 +83811-0;Note;Find;Pt;Long term care facility;Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Long term care facility Note;PA LTC fac Note;;ACTIVE;2.58;2.58 +83812-8;History and physical note;Find;Pt;{Setting};Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant History and physical note;PA H&P note;;ACTIVE;2.58;2.58 +83813-6;Note;Find;Pt;Patient's home;Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Patient's home Note;PA Pt's home Note;;ACTIVE;2.58;2.58 +83814-4;Note;Find;Pt;Hospital;Doc;Physician assistant;DOC.ONTOLOGY;2;Physician assistant Hospital Note;PA Hosp Note;;ACTIVE;2.58;2.58 +83815-1;Surgical operation note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending Surgical operation note;Attend Operative note;;ACTIVE;2.58;2.65 +8381-6;Intravascular diastolic;Pres;Pt;Hepatic artery;Qn;;BP.CENT.MOLEC;2;Hepatic artery Diastolic blood pressure;Hep a BP dias;;ACTIVE;1.0h(2);2.4 +83816-9;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Attending;DOC.ONTOLOGY;2;Attending Intensive care unit Admission evaluation note;Attend ICU Admit eval note;;ACTIVE;2.58;2.65 +83817-7;Note;Find;Pt;Intensive care unit;Doc;Attending;DOC.ONTOLOGY;2;Attending Intensive care unit Note;Attend ICU Note;;ACTIVE;2.58;2.65 +83818-5;Note;Find;Pt;Emergency department;Doc;Attending;DOC.ONTOLOGY;2;Attending Emergency department Note;Attend ED Note;;ACTIVE;2.58;2.65 +83819-3;History and physical note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending History and physical note;Attend H&P note;;ACTIVE;2.58;2.65 +83820-1;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending Preoperative evaluation and management note;Attend Pre-op note;;ACTIVE;2.58;2.65 +83821-9;Note;Find;Pt;Outpatient;Doc;Attending;DOC.ONTOLOGY;2;Attending Outpatient Note;Attend OP Note;;ACTIVE;2.58;2.65 +83822-7;Note;Find;Pt;Hospital;Doc;Attending;DOC.ONTOLOGY;2;Attending Hospital Note;Attend Hosp Note;;ACTIVE;2.58;2.65 +83823-5;Note;Find;Pt;Long term care facility;Doc;Attending;DOC.ONTOLOGY;2;Attending Long term care facility Note;Attend LTC fac Note;;ACTIVE;2.58;2.65 +8382-4;Intravascular diastolic;Pres;Pt;Mesenteric artery;Qn;;BP.CENT.MOLEC;2;Mesenteric artery Diastolic blood pressure;Mesenteric a BP dias;;ACTIVE;1.0h(2);2.4 +83824-3;Admission evaluation note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending Admission evaluation note;Attend Admit eval note;;ACTIVE;2.58;2.65 +83825-0;Note;Find;Pt;{Setting};Doc;Fellow;DOC.ONTOLOGY;2;Fellow Note;Fellow Note;;ACTIVE;2.58;2.65 +83826-8;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Fellow;DOC.ONTOLOGY;2;Fellow Intensive care unit Admission evaluation note;Fellow ICU Admit eval note;;ACTIVE;2.58;2.65 +83827-6;Note;Find;Pt;Intensive care unit;Doc;Fellow;DOC.ONTOLOGY;2;Fellow Intensive care unit Note;Fellow ICU Note;;ACTIVE;2.58;2.65 +83828-4;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Preoperative evaluation and management note;Dentistry Pre-op note;;ACTIVE;2.58;2.58 +83829-2;Administrative note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Administrative note;Dentistry Administrative note;;ACTIVE;2.58;2.58 +838-3;Ax Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Ax Ag [Presence] on Red Blood Cells;Ax Ag RBC Ql;;ACTIVE;1.0;2.56 +83830-0;History and physical note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry History and physical note;Dentistry H&P note;;ACTIVE;2.58;2.58 +83831-8;Note;Find;Pt;Hospital;Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Hospital Note;Dentistry Hosp Note;;ACTIVE;2.58;2.58 +8383-2;Intravascular diastolic;Pres;Pt;Inferior mesenteric artery;Qn;;BP.CENT.MOLEC;2;Inferior mesenteric artery Diastolic blood pressure;IM a BP dias;;ACTIVE;1.0h(2);2.4 +83832-6;Note;Find;Pt;Long term care facility;Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Long term care facility Note;Dentistry LTC fac Note;;ACTIVE;2.58;2.58 +83833-4;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Postoperative evaluation and management note;Dentistry Post-op E/M note;;ACTIVE;2.58;2.58 +83834-2;Note;Find;Pt;Emergency department;Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Emergency department Note;Dentistry ED Note;;ACTIVE;2.58;2.58 +83835-9;Risk assessment and screening note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Risk assessment and screening note;Dentistry Risk assess+scrn note;;ACTIVE;2.58;2.58 +83836-7;Summary note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Summary note;Dentistry Summary note;;ACTIVE;2.58;2.58 +83837-5;Note;Find;Pt;{Setting};Doc;Dentistry.technician;DOC.ONTOLOGY;2;Dentistry Technician Note;Dentistry Tech Note;;ACTIVE;2.58;2.58 +83838-3;Note;Find;Pt;Telephone encounter;Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Telephone encounter Note;Dentistry Phone Note;;ACTIVE;2.58;2.58 +83839-1;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Transplant candidate evaluation note;Dentistry Trnsplt cand eval nte;;ACTIVE;2.58;2.58 +8384-0;Intravascular diastolic;Pres;Pt;Superior mesenteric artery;Qn;;BP.CENT.MOLEC;2;Superior mesenteric artery Diastolic blood pressure;SM a BP dias;;ACTIVE;1.0h(2);2.4 +83840-9;Note;Find;Pt;{Setting};Doc;Vascular surgery.technician;DOC.ONTOLOGY;2;Vascular surgery Technician Note;Vascular surg Tech Note;;ACTIVE;2.58;2.58 +83841-7;Note;Find;Pt;{Setting};Doc;Transplant surgery.case manager;DOC.ONTOLOGY;2;Transplant surgery Case manager Note;Transplant surg Case mgr Note;;ACTIVE;2.58;2.65 +83842-5;Note;Find;Pt;{Setting};Doc;Surgery.interdisciplinary;DOC.ONTOLOGY;2;Surgery Interdisciplinary Note;Surg Interdiscip Note;;ACTIVE;2.58;2.58 +83843-3;Note;Find;Pt;{Setting};Doc;Surgery.case manager;DOC.ONTOLOGY;2;Surgery Case manager Note;Surg Case mgr Note;;ACTIVE;2.58;2.58 +83844-1;Body height method;Type;Pt;XXX;Nom;*;BDYHGT.ATOM;2;Body height method;Body hgt method;;ACTIVE;2.58;2.58 +83845-8;Body height;Len;Pt;^Father;Qn;;BDYHGT.ATOM;2;Body height Father;Body height Father;;ACTIVE;2.58;2.69 +83846-6;Body height;Len;Pt;^Mother;Qn;;BDYHGT.ATOM;2;Body height Mother;Body height Mother;;ACTIVE;2.58;2.69 +83847-4;Dose changed since previous visit;Find;Pt;^Patient;Ord;;MEDS;2;Dose changed since previous visit;Dose changed since prev visit;;ACTIVE;2.58;2.58 +83848-2;Provider stopped treatment;Find;Pt;^Patient;Ord;;MEDS;2;Provider stopped treatment;Provider stopped tx;;ACTIVE;2.58;2.58 +83849-0;Reason for dose change;Find;Pt;^Patient;Nom;;MEDS;2;Reason for dose change;Reason for dose change;;ACTIVE;2.58;2.58 +83850-8;Admission evaluation note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Admission evaluation note;Plastic surgery Admit eval note;;ACTIVE;2.58;2.58 +83851-6;Note;Find;Pt;Hospital;Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Hospital Note;Plastic surgery Hosp Note;;ACTIVE;2.58;2.58 +83852-4;Note;Find;Pt;Outpatient;Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Outpatient Note;Plastic surgery OP Note;;ACTIVE;2.58;2.58 +83853-2;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Postoperative evaluation and management note;Plastic surgery Post-op E/M note;;ACTIVE;2.58;2.58 +83854-0;Procedure note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery procedure note;Plastic surgery Procedure note;;ACTIVE;2.58;2.58 +83855-7;Note;Find;Pt;Telephone encounter;Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Telephone encounter Note;Plastic surgery Phone Note;;ACTIVE;2.58;2.58 +83856-5;Administrative note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Administrative note;Podiatry Administrative note;;ACTIVE;2.58;2.58 +8385-7;Intravascular diastolic;Pres;Pt;Pulmonary artery;Qn;;BP.CENT.MOLEC;2;Pulmonary artery Diastolic blood pressure;PA BP dias;;ACTIVE;1.0h(2);2.73 +83857-3;Admission evaluation note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Admission evaluation note;Podiatry Admit eval note;;ACTIVE;2.58;2.58 +83858-1;History and physical note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry History and physical note;Podiatry H&P note;;ACTIVE;2.58;2.58 +83859-9;Note;Find;Pt;Hospital;Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Hospital Note;Podiatry Hosp Note;;ACTIVE;2.58;2.58 +83860-7;Risk assessment and screening note;Find;Pt;Outpatient;Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Outpatient Risk assessment and screening note;Podiatry OP Risk assess+scrn note;;ACTIVE;2.58;2.58 +83861-5;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Postoperative evaluation and management note;Podiatry Post-op E/M note;;ACTIVE;2.58;2.58 +83862-3;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Preoperative evaluation and management note;Podiatry Pre-op note;;ACTIVE;2.58;2.58 +83863-1;Risk assessment and screening note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Risk assessment and screening note;Podiatry Risk assess+scrn note;;ACTIVE;2.58;2.58 +83864-9;Note;Find;Pt;Telephone encounter;Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Telephone encounter Note;Podiatry Phone Note;;ACTIVE;2.58;2.58 +8386-5;Intravascular diastolic;Pres;Pt;Pulmonary artery.left;Qn;;BP.CENT.MOLEC;2;Left pulmonary artery Diastolic blood pressure;PA-L BP dias;;ACTIVE;1.0h(2);2.54 +83865-6;Transfer summary note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Transfer summary note;Podiatry Transfer sum note;;ACTIVE;2.58;2.58 +83866-4;Group counseling note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Group counseling note;Multi-spec prog Group counseling note;;ACTIVE;2.58;2.58 +83867-2;Annual evaluation note;Find;Pt;{Setting};Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Annual evaluation note;Preventive med Annual eval note;;ACTIVE;2.58;2.58 +83868-0;Consultation note;Find;Pt;{Setting};Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Consult note;Preventive med Consult note;;ACTIVE;2.58;2.58 +83869-8;Counseling note;Find;Pt;{Setting};Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Counseling note;Preventive med Counseling note;;ACTIVE;2.58;2.58 +83870-6;Admission evaluation note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Admission evaluation note;Primary care Admit eval note;;ACTIVE;2.58;2.58 +83871-4;Annual evaluation note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Annual evaluation note;Primary care Annual eval note;;ACTIVE;2.58;2.58 +83872-2;Note;Find;Pt;{Setting};Doc;Primary care.case manager;DOC.ONTOLOGY;2;Primary care Case manager Note;Primary care Case mgr Note;;ACTIVE;2.58;2.58 +8387-3;Intravascular diastolic;Pres;Pt;Pulmonary artery.right;Qn;;BP.CENT.MOLEC;2;Right pulmonary artery Diastolic blood pressure;PA-R BP dias;;ACTIVE;1.0h(2);2.54 +83873-0;Consultation note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Consult note;Primary care Consult note;;ACTIVE;2.58;2.58 +83874-8;Note;Find;Pt;Custodial care facility;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Custodial care facility Note;Primary care Cust care fac Note;;ACTIVE;2.58;2.58 +83875-5;Initial evaluation note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Initial evaluation note;Primary care Initial eval note;;ACTIVE;2.58;2.58 +83876-3;Risk assessment and screening note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Risk assessment and screening note;Primary care Risk assess+scrn note;;ACTIVE;2.58;2.58 +83877-1;Triage note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Triage note;Primary care Triage note;;ACTIVE;2.58;2.58 +83878-9;Note;Find;Pt;Urgent care center;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Urgent care center Note;Primary care Urgent care Note;;ACTIVE;2.58;2.58 +83879-7;Administrative note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Administrative note;Psychiatric Administrative note;;ACTIVE;2.58;2.58 +83880-5;Admission evaluation note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Admission evaluation note;Psychiatric Admit eval note;;ACTIVE;2.58;2.58 +8388-1;Intravascular diastolic;Pres;Pt;Renal artery.left;Qn;;BP.CENT.MOLEC;2;Renal artery - left Diastolic blood pressure;Renal a-L BP dias;;ACTIVE;1.0h(2);2.4 +83881-3;Note;Find;Pt;{Setting};Doc;Psychiatry.case manager;DOC.ONTOLOGY;2;Psychiatry Case manager Note;Psychiatry Case mgr Note;;ACTIVE;2.58;2.58 +83882-1;Note;Find;Pt;{Setting};Doc;Psychiatry.interdisciplinary;DOC.ONTOLOGY;2;Psychiatry Interdisciplinary Note;Psychiatry Interdiscip Note;;ACTIVE;2.58;2.58 +83883-9;Education note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Education note;Psychiatric Educ note;;ACTIVE;2.58;2.58 +83884-7;Note;Find;Pt;Emergency department;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Emergency department Note;Psychiatric ED Note;;ACTIVE;2.58;2.58 +83885-4;Group counseling note;Find;Pt;Hospital;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Hospital Group counseling note;Psychiatric Hosp Group counseling note;;ACTIVE;2.58;2.58 +83886-2;History and physical note;Find;Pt;Hospital;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Hospital History and physical note;Psychiatric Hosp H&P note;;ACTIVE;2.58;2.58 +83887-0;Note;Find;Pt;Hospital;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Hospital Note;Psychiatric Hosp Note;;ACTIVE;2.58;2.58 +83888-8;Consultation note;Find;Pt;Long term care facility;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Long term care facility Consult note;Psychiatric LTC fac Consult note;;ACTIVE;2.58;2.58 +83889-6;Medication management note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Medication management note;Psychiatric Med mgmt note;;ACTIVE;2.58;2.58 +83890-4;Group counseling note;Find;Pt;Outpatient;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Outpatient Group counseling note;Psychiatric OP Group counseling note;;ACTIVE;2.58;2.58 +83891-2;Procedure note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry procedure note;Psychiatric Procedure note;;ACTIVE;2.58;2.58 +83892-0;Risk assessment and screening note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Risk assessment and screening note;Psychiatric Risk assess+scrn note;;ACTIVE;2.58;2.58 +83893-8;Note;Find;Pt;{Setting};Doc;Psychiatry.team;DOC.ONTOLOGY;2;Psychiatry Team Note;Psychiatry Team Note;;ACTIVE;2.58;2.58 +83894-6;Note;Find;Pt;Telephone encounter;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Telephone encounter Note;Psychiatric Phone Note;;ACTIVE;2.58;2.58 +83895-3;Plan of care note;Find;Pt;{Setting};Doc;Psychiatry.interdisciplinary;DOC.ONTOLOGY;2;Psychiatry Interdisciplinary Plan of care note;Psychiatry Interdiscip Plan of care note;;ACTIVE;2.58;2.58 +83896-1;Triage note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Triage note;Psychiatric Triage note;;ACTIVE;2.58;2.58 +83897-9;Administrative note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Administrative note;Psych Administrative note;;ACTIVE;2.58;2.58 +83898-7;Discharge summary note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Discharge summary;Psych D/C sum;;ACTIVE;2.58;2.73 +8389-9;Intravascular diastolic;Pres;Pt;Renal artery.right;Qn;;BP.CENT.MOLEC;2;Renal artery - right Diastolic blood pressure;Renal a-R BP dias;;ACTIVE;1.0h(2);2.4 +83899-5;Note;Find;Pt;Custodial care facility;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Custodial care facility Note;Psych Cust care fac Note;;ACTIVE;2.58;2.58 +83900-1;Education note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Education note;Psych Educ note;;ACTIVE;2.58;2.58 +83901-9;History and physical note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology History and physical note;Psych H&P note;;ACTIVE;2.58;2.58 +83902-7;Note;Find;Pt;Patient's home;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Patient's home Note;Psych Pt's home Note;;ACTIVE;2.58;2.58 +83903-5;Note;Find;Pt;Hospital;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Hospital Note;Psych Hosp Note;;ACTIVE;2.58;2.58 +83904-3;Note;Find;Pt;Long term care facility;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Long term care facility Note;Psych LTC fac Note;;ACTIVE;2.58;2.58 +83905-0;Note;Find;Pt;Outpatient;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Outpatient Note;Psych OP Note;;ACTIVE;2.58;2.58 +83906-8;Risk assessment and screening note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Risk assessment and screening note;Psych Risk assess+scrn note;;ACTIVE;2.58;2.58 +8390-7;Intravascular diastolic;Pres;Pt;Splenic artery;Qn;;BP.CENT.MOLEC;2;Splenic artery Diastolic blood pressure;Splenic a BP dias;;ACTIVE;1.0h(2);2.4 +83907-6;Note;Find;Pt;{Setting};Doc;Psychology.team;DOC.ONTOLOGY;2;Psychology Team Note;Psychology Team Note;;ACTIVE;2.58;2.58 +83908-4;Note;Find;Pt;Telephone encounter;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Telephone encounter Note;Psych Phone Note;;ACTIVE;2.58;2.58 +83909-2;Consultation note;Find;Pt;{Setting};Doc;Public health;DOC.ONTOLOGY;2;Public health Consult note;Public health Consult note;;ACTIVE;2.58;2.58 +839-1;A1 Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;A1 Ab [Presence] in Serum or Plasma from Blood product unit;A1 Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +83910-0;Note;Find;Pt;{Setting};Doc;Public health;DOC.ONTOLOGY;2;Public health Note;Public health Note;;ACTIVE;2.58;2.58 +83911-8;Admission evaluation note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Admission evaluation note;Pulmonary disease Admit eval note;;ACTIVE;2.58;2.58 +83912-6;Consultation note;Find;Pt;Patient's home;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Patient's home Consult note;Pulmonary disease Pt's home Consult note;;ACTIVE;2.58;2.58 +83913-4;Note;Find;Pt;Patient's home;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Patient's home Note;Pulmonary disease Pt's home Note;;ACTIVE;2.58;2.58 +83914-2;Transfer summary note;Find;Pt;Hospital;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Hospital Transfer summary note;Pulmonary disease Hosp Transfer sum note;;ACTIVE;2.58;2.58 +8391-5;Intravascular end diastolic;Pres;Pt;Heart.ventricle.left;Qn;;BP.CENT.MOLEC;2;Left ventricular End diastolic blood pressure;LV BP end dias;;ACTIVE;1.0h(2);2.4 +83915-9;Note;Find;Pt;Outpatient;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Outpatient Note;Pulmonary disease OP Note;;ACTIVE;2.58;2.58 +83916-7;Note;Find;Pt;Telephone encounter;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Telephone encounter Note;Pulmonary disease Phone Note;;ACTIVE;2.58;2.58 +83917-5;Note;Find;Pt;Hospital;Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Hospital Note;Radiation Onc Hosp Note;;ACTIVE;2.58;2.58 +83918-3;Note;Find;Pt;Outpatient;Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Outpatient Note;Radiation Onc OP Note;;ACTIVE;2.58;2.58 +83919-1;Note;Find;Pt;Telephone encounter;Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Telephone encounter Note;Radiation Onc Phone Note;;ACTIVE;2.58;2.58 +83920-9;Note;Find;Pt;{Setting};Doc;Radiation oncology.therapist;DOC.ONTOLOGY;2;Radiation oncology Therapist Note;Radiation Therapist Note;;ACTIVE;2.58;2.58 +83921-7;Discharge summary note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Discharge summary;Rec therapy D/C sum;;ACTIVE;2.58;2.73 +83922-5;Note;Find;Pt;Custodial care facility;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Custodial care facility Note;Rec therapy Cust care fac Note;;ACTIVE;2.58;2.58 +8392-3;Intravascular end diastolic;Pres;Pt;Heart.ventricle.right;Qn;;BP.CENT.MOLEC;2;Right ventricular End diastolic blood pressure;RV BP end dias;;ACTIVE;1.0h(2);2.4 +83923-3;Education note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Education note;Rec therapy Educ note;;ACTIVE;2.58;2.58 +83924-1;Note;Find;Pt;Hospital;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Hospital Note;Rec therapy Hosp Note;;ACTIVE;2.58;2.58 +83925-8;Note;Find;Pt;{Setting};Doc;Recreational therapy.interdisciplinary;DOC.ONTOLOGY;2;Recreational therapy Interdisciplinary Note;Rec therapy Interdiscip Note;;ACTIVE;2.58;2.65 +83926-6;Consultation note;Find;Pt;Long term care facility;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Long term care facility Consult note;Rec therapy LTC fac Consult note;;ACTIVE;2.58;2.58 +83927-4;Note;Find;Pt;Long term care facility;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Long term care facility Note;Rec therapy LTC fac Note;;ACTIVE;2.58;2.58 +83928-2;Note;Find;Pt;Outpatient;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Outpatient Note;Rec therapy OP Note;;ACTIVE;2.58;2.58 +83929-0;Risk assessment and screening note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Risk assessment and screening note;Rec therapy Risk assess+scrn note;;ACTIVE;2.58;2.58 +83930-8;Consent;Find;Pt;{Setting};Doc;Research;DOC.ONTOLOGY;2;Deprecated Research Consent Document;Deprecated Research Consent;;DEPRECATED;2.58;2.67 +8393-1;Intravascular end diastolic;Pres;Pt;Pulmonary artery;Qn;;BP.CENT.MOLEC;2;Pulmonary artery End diastolic blood pressure;dPAP;;ACTIVE;1.0h(2);2.67 +83931-6;Consultation note;Find;Pt;{Setting};Doc;Research;DOC.ONTOLOGY;2;Research Consult note;Research Consult note;;ACTIVE;2.58;2.58 +83932-4;Discharge summary note;Find;Pt;{Setting};Doc;Research;DOC.ONTOLOGY;2;Research Discharge summary;Research D/C sum;;ACTIVE;2.58;2.73 +83933-2;Evaluation and management of hypertension note;Find;Pt;{Setting};Doc;Research;DOC.ONTOLOGY;2;Research Evaluation and management of hypertension note;Research E/M hyperten note;;ACTIVE;2.58;2.58 +83934-0;Initial evaluation note;Find;Pt;{Setting};Doc;Research;DOC.ONTOLOGY;2;Research Initial evaluation note;Research Initial eval note;;ACTIVE;2.58;2.58 +83935-7;Medication management note;Find;Pt;{Setting};Doc;Research;DOC.ONTOLOGY;2;Research Medication management note;Research Med mgmt note;;ACTIVE;2.58;2.58 +83936-5;Note;Find;Pt;{Setting};Doc;Research.nurse;DOC.ONTOLOGY;2;Research Nurse Note;Research Nurse Note;;ACTIVE;2.58;2.58 +83937-3;Note;Find;Pt;Outpatient;Doc;Research;DOC.ONTOLOGY;2;Research Outpatient Note;Research OP Note;;ACTIVE;2.58;2.58 +83938-1;Procedure note;Find;Pt;{Setting};Doc;Research;DOC.ONTOLOGY;2;Research procedure note;Research Procedure note;;ACTIVE;2.58;2.58 +83939-9;Note;Find;Pt;Telephone encounter;Doc;Research;DOC.ONTOLOGY;2;Research Telephone encounter Note;Research Phone Note;;ACTIVE;2.58;2.58 +83940-7;Note;Find;Pt;Intensive care unit;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Intensive care unit Note;Resp therapy ICU Note;;ACTIVE;2.58;2.58 +83941-5;Consultation note;Find;Pt;Patient's home;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Patient's home Consult note;Resp therapy Pt's home Consult note;;ACTIVE;2.58;2.58 +83942-3;Note;Find;Pt;Patient's home;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Patient's home Note;Resp therapy Pt's home Note;;ACTIVE;2.58;2.58 +83943-1;Note;Find;Pt;Hospital;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Hospital Note;Resp therapy Hosp Note;;ACTIVE;2.58;2.58 +83944-9;Note;Find;Pt;Long term care facility;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Long term care facility Note;Resp therapy LTC fac Note;;ACTIVE;2.58;2.58 +83945-6;Note;Find;Pt;Outpatient;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Outpatient Note;Resp therapy OP Note;;ACTIVE;2.58;2.58 +83946-4;Note;Find;Pt;Telephone encounter;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Telephone encounter Note;Resp therapy Phone Note;;ACTIVE;2.58;2.58 +83947-2;Note;Find;Pt;Hospital;Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Hospital Note;Rheumatology Hosp Note;;ACTIVE;2.58;2.58 +83948-0;Note;Find;Pt;Outpatient;Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Outpatient Note;Rheumatology OP Note;;ACTIVE;2.58;2.58 +8394-9;Intravascular mean;Pres;Pt;Aorta.abdominal.distal;Qn;;BP.CENT.MOLEC;2;Distal abdominal aorta Mean blood pressure;Distal Ab Ao BP mean;;ACTIVE;1.0h(2);2.54 +83949-8;Note;Find;Pt;Telephone encounter;Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Telephone encounter Note;Rheumatology Phone Note;;ACTIVE;2.58;2.58 +83950-6;Transfer summary note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Transfer summary note;Rheumatology Transfer sum note;;ACTIVE;2.58;2.58 +83951-4;Risk assessment and screening note;Find;Pt;{Setting};Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Risk assessment and screening note;Interdiscip Risk assess+scrn note;;ACTIVE;2.58;2.58 +83952-2;Note;Find;Pt;Hospital;Doc;Registered nurse;DOC.ONTOLOGY;2;Registered nurse Hospital Note;RN Hosp Note;;ACTIVE;2.58;2.58 +83953-0;Evaluation and management of smoking cessation note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Evaluation and management of smoking cessation note;Nurse E/M smoke cess note;;ACTIVE;2.58;2.58 +83954-8;Admission evaluation note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Admission evaluation note;SW Admit eval note;;ACTIVE;2.58;2.65 +83955-5;Annual evaluation note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Annual evaluation note;SW Annual eval note;;ACTIVE;2.58;2.65 +8395-6;Intravascular mean;Pres;Pt;Aorta.abdominal.proximal;Qn;;BP.CENT.MOLEC;2;Proximal abdominal aorta Mean blood pressure;Prox Ab Ao BP mean;;ACTIVE;1.0h(2);2.54 +83956-3;Discharge summary note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Discharge summary;SW D/C sum;;ACTIVE;2.58;2.73 +83957-1;Note;Find;Pt;Custodial care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Custodial care facility Note;SW Cust care fac Note;;ACTIVE;2.58;2.65 +83958-9;Note;Find;Pt;Emergency department;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Emergency department Note;SW ED Note;;ACTIVE;2.58;2.65 +83959-7;History and physical note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker History and physical note;SW H&P note;;ACTIVE;2.58;2.65 +83960-5;Consultation note;Find;Pt;Patient's home;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Patient's home Consult note;SW Pt's home Consult note;;ACTIVE;2.58;2.65 +83961-3;Discharge summary note;Find;Pt;Patient's home;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Patient's home Discharge summary;SW Pt's home D/C sum;;ACTIVE;2.58;2.73 +83962-1;Initial evaluation note;Find;Pt;Patient's home;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Patient's home Initial evaluation note;SW Pt's home Initial eval note;;ACTIVE;2.58;2.65 +83963-9;Note;Find;Pt;Patient's home;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Patient's home Note;SW Pt's home Note;;ACTIVE;2.58;2.65 +8396-4;Intravascular mean;Pres;Pt;Aorta.thoracic.ascending;Qn;;BP.CENT.MOLEC;2;Ascending thoracic aorta Mean blood pressure;ATA BP mean;;ACTIVE;1.0h(2);2.54 +83964-7;Referral note;Find;Pt;Patient's home;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Patient's home Referral note;SW Pt's home Referral note;;ACTIVE;2.58;2.65 +83965-4;Note;Find;Pt;Hospital;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Hospital Note;SW Hosp Note;;ACTIVE;2.58;2.65 +83966-2;Note;Find;Pt;{Setting};Doc;Social work.interdisciplinary;DOC.ONTOLOGY;2;Deprecated Social work Interdisciplinary Note;Deprecated Social work Interdiscip Note;;DEPRECATED;2.58;2.65 +83967-0;Consultation note;Find;Pt;Long term care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Long term care facility Consult note;SW LTC fac Consult note;;ACTIVE;2.58;2.65 +83968-8;Discharge summary note;Find;Pt;Long term care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Long term care facility Discharge summary;SW LTC fac D/C sum;;ACTIVE;2.58;2.73 +83969-6;Initial evaluation note;Find;Pt;Long term care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Long term care facility Initial evaluation note;SW LTC fac Initial eval note;;ACTIVE;2.58;2.65 +83970-4;Note;Find;Pt;Long term care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Long term care facility Note;SW LTC fac Note;;ACTIVE;2.58;2.65 +83971-2;Referral note;Find;Pt;Long term care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Long term care facility Referral note;SW LTC fac Referral note;;ACTIVE;2.58;2.65 +8397-2;Intravascular mean;Pres;Pt;Aorta.thoracic.proximal ascending;Qn;;BP.CENT.MOLEC;2;Proximal ascending thoracic aorta Mean blood pressure;Prox asc TA BP mean;;ACTIVE;1.0h(2);2.54 +83972-0;Respite note;Find;Pt;Long term care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Long term care facility Respite note;SW LTC fac Respite note;;ACTIVE;2.58;2.65 +83973-8;Risk assessment and screening note;Find;Pt;Long term care facility;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Long term care facility Risk assessment and screening note;SW LTC fac Risk assess+scrn note;;ACTIVE;2.58;2.65 +83974-6;Note;Find;Pt;Long term care facility;Doc;Social work.nurse;DOC.ONTOLOGY;2;Deprecated Social work Nurse Long term care facility Note;Deprecated Social work Nurse LTC fac Note;;DEPRECATED;2.58;2.65 +83975-3;Group counseling note;Find;Pt;Outpatient;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Outpatient Group counseling note;SW OP Group counseling note;;ACTIVE;2.58;2.65 +83976-1;Note;Find;Pt;Outpatient;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Outpatient Note;SW OP Note;;ACTIVE;2.58;2.65 +83977-9;Outreach note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Outreach note;SW Outreach note;;ACTIVE;2.58;2.65 +83978-7;Respite note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Respite note;SW Respite note;;ACTIVE;2.58;2.65 +83979-5;Risk assessment and screening note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Risk assessment and screening note;SW Risk assess+scrn note;;ACTIVE;2.58;2.65 +8398-0;Intravascular mean;Pres;Pt;Aorta.thoracic.descending;Qn;;BP.CENT.MOLEC;2;Descending thoracic aorta Mean blood pressure;DTA BP mean;;ACTIVE;1.0h(2);2.54 +83980-3;Note;Find;Pt;{Setting};Doc;Social work.team;DOC.ONTOLOGY;2;Deprecated Social work Team Note;Deprecated Social work Team Note;;DEPRECATED;2.58;2.65 +83981-1;Transfer summary note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Transfer summary note;SW Transfer sum note;;ACTIVE;2.58;2.65 +83982-9;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;Social worker;DOC.ONTOLOGY;2;Social worker Transplant candidate evaluation note;SW Trnsplt cand eval nte;;ACTIVE;2.58;2.65 +83983-7;Plan of care note;Find;Pt;{Setting};Doc;Social work.interdisciplinary;DOC.ONTOLOGY;2;Deprecated Social work Interdisciplinary Plan of care note;Deprecated Social work Interdisc Plan of care note;;DEPRECATED;2.58;2.65 +83984-5;Consultation note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Consult note;Speech-lang path Consult note;;ACTIVE;2.58;2.58 +83985-2;Note;Find;Pt;Long term care facility;Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Long term care facility Note;Speech-lang path LTC fac Note;;ACTIVE;2.58;2.58 +83986-0;Risk assessment and screening note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Risk assessment and screening note;Speech-lang path Risk assess+scrn note;;ACTIVE;2.58;2.58 +83987-8;Note;Find;Pt;{Setting};Doc;Speech-language pathology.team;DOC.ONTOLOGY;2;Speech-language pathology Team Note;SLP Team Note;;ACTIVE;2.58;2.58 +83988-6;Note;Find;Pt;Telephone encounter;Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Telephone encounter Note;Speech-lang path Phone Note;;ACTIVE;2.58;2.58 +83989-4;Admission evaluation note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Admission evaluation note;SCIM Admit eval note;;ACTIVE;2.58;2.58 +83990-2;Annual evaluation note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Annual evaluation note;SCIM Annual eval note;;ACTIVE;2.58;2.58 +83991-0;Conference note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Conference note;SCIM Conf eval note;;ACTIVE;2.58;2.58 +83992-8;Consultation note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Consult note;SCIM Consult note;;ACTIVE;2.58;2.58 +83993-6;Discharge summary note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Discharge summary;SCIM D/C sum;;ACTIVE;2.58;2.73 +83994-4;Education note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Education note;SCIM Educ note;;ACTIVE;2.58;2.58 +83995-1;History and physical note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine History and physical note;SCIM H&P note;;ACTIVE;2.58;2.58 +83996-9;Consultation note;Find;Pt;Patient's home;Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Patient's home Consult note;SCIM Pt's home Consult note;;ACTIVE;2.58;2.58 +83997-7;Note;Find;Pt;Patient's home;Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Patient's home Note;SCIM Pt's home Note;;ACTIVE;2.58;2.58 +8399-8;Intrachamber mean;Pres;Pt;Heart.atrium.left;Qn;;BP.CENT.MOLEC;2;Left atrial Intrachamber mean pressure;LA Intrachamber mean pres;;ACTIVE;1.0h(2);2.4 +83998-5;Initial evaluation note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Initial evaluation note;SCIM Initial eval note;;ACTIVE;2.58;2.58 +83999-3;Note;Find;Pt;Hospital;Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Hospital Note;SCIM Hosp Note;;ACTIVE;2.58;2.58 +84000-9;Note;Find;Pt;{Setting};Doc;Spinal cord injury medicine.interdisciplinary;DOC.ONTOLOGY;2;Spinal cord injury medicine Interdisciplinary Note;SCIM Interdiscip Note;;ACTIVE;2.58;2.58 +84001-7;Note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Note;SCIM Note;;ACTIVE;2.58;2.58 +84002-5;Note;Find;Pt;{Setting};Doc;Spinal cord injury medicine.nurse;DOC.ONTOLOGY;2;Spinal cord injury medicine Nurse Note;SCIM Nurse Note;;ACTIVE;2.58;2.58 +84003-3;Note;Find;Pt;Outpatient;Doc;Spinal cord injury medicine.nurse;DOC.ONTOLOGY;2;Spinal cord injury medicine Nurse Outpatient Note;SCIM Nurse OP Note;;ACTIVE;2.58;2.58 +8400-4;Intrachamber mean;Pres;Pt;Heart.atrium.right;Qn;;BP.CENT.MOLEC;2;Right atrial Intrachamber mean pressure;RA Intrachamber mean pres;;ACTIVE;1.0h(2);2.3 +84004-1;Annual evaluation note;Find;Pt;Outpatient;Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Outpatient Annual evaluation note;SCIM OP Annual eval note;;ACTIVE;2.58;2.58 +84005-8;Note;Find;Pt;Outpatient;Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Outpatient Note;SCIM OP Note;;ACTIVE;2.58;2.58 +84006-6;Procedure note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine procedure note;SCIM Procedure note;;ACTIVE;2.58;2.58 +84007-4;Risk assessment and screening note;Find;Pt;{Setting};Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Risk assessment and screening note;SCIM Risk assess+scrn note;;ACTIVE;2.58;2.58 +84008-2;Note;Find;Pt;{Setting};Doc;Spinal cord injury medicine.team;DOC.ONTOLOGY;2;Spinal cord injury medicine Team Note;SCIM Team Note;;ACTIVE;2.58;2.58 +84009-0;Note;Find;Pt;Telehealth;Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Telehealth Note;SCIM Telehealth Note;;ACTIVE;2.58;2.58 +84010-8;Note;Find;Pt;Telephone encounter;Doc;Spinal cord injury medicine;DOC.ONTOLOGY;2;Spinal cord injury medicine Telephone encounter Note;SCIM Phone Note;;ACTIVE;2.58;2.58 +84011-6;Plan of care note;Find;Pt;{Setting};Doc;Spinal cord injury medicine.interdisciplinary;DOC.ONTOLOGY;2;Spinal cord injury medicine Interdisciplinary Plan of care note;SCIM Interdiscip Plan of care note;;ACTIVE;2.58;2.58 +84012-4;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Intensive care unit Admission evaluation note;Surgery ICU Admit eval note;;ACTIVE;2.58;2.58 +84013-2;Discharge summary note;Find;Pt;Intensive care unit;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Intensive care unit Discharge summary;Surgery ICU D/C sum;;ACTIVE;2.58;2.73 +84014-0;Note;Find;Pt;Intensive care unit;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Intensive care unit Note;Surgery ICU Note;;ACTIVE;2.58;2.58 +84015-7;Procedure note;Find;Pt;Intensive care unit;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Intensive care unit procedure note;Surgery ICU Procedure note;;ACTIVE;2.58;2.58 +84016-5;Transfer summary note;Find;Pt;Intensive care unit;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Intensive care unit Transfer summary note;Surgery ICU Transfer sum note;;ACTIVE;2.58;2.58 +84017-3;Discharge summary note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Discharge summary;Surgery D/C sum;;ACTIVE;2.58;2.73 +84018-1;Discharge summary note;Find;Pt;Outpatient;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Outpatient Discharge summary;Surgery OP D/C sum;;ACTIVE;2.58;2.73 +84019-9;History and physical note;Find;Pt;Outpatient;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Outpatient History and physical note;Surgery OP H&P note;;ACTIVE;2.58;2.58 +84020-7;Surgical operation note;Find;Pt;Outpatient;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Outpatient Surgical operation note;Surgery OP Operative note;;ACTIVE;2.58;2.58 +84021-5;Procedure note;Find;Pt;Outpatient;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Outpatient procedure note;Surgery OP Procedure note;;ACTIVE;2.58;2.58 +84022-3;Note;Find;Pt;Telephone encounter;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Telephone encounter Note;Surgery Phone Note;;ACTIVE;2.58;2.58 +84023-1;Conference note;Find;Pt;{Setting};Doc;Team;DOC.ONTOLOGY;2;Team Conference note;Team Conf eval note;;ACTIVE;2.58;2.58 +84024-9;Discharge summary note;Find;Pt;{Setting};Doc;Team;DOC.ONTOLOGY;2;Team Discharge summary;Team D/C sum;;ACTIVE;2.58;2.73 +84025-6;Note;Find;Pt;Custodial care facility;Doc;Team;DOC.ONTOLOGY;2;Team Custodial care facility Note;Team Cust care fac Note;;ACTIVE;2.58;2.58 +84026-4;Conference note;Find;Pt;Patient's home;Doc;Team;DOC.ONTOLOGY;2;Team Patient's home Conference note;Team Pt's home Conf eval note;;ACTIVE;2.58;2.58 +84027-2;Note;Find;Pt;Patient's home;Doc;Team;DOC.ONTOLOGY;2;Team Patient's home Note;Team Pt's home Note;;ACTIVE;2.58;2.58 +84028-0;Letter;Find;Pt;{Setting};Doc;Team;DOC.ONTOLOGY;2;Team Letter;Team Letter;;ACTIVE;2.58;2.58 +84029-8;Conference note;Find;Pt;Long term care facility;Doc;Team;DOC.ONTOLOGY;2;Team Long term care facility Conference note;Team LTC fac Conf eval note;;ACTIVE;2.58;2.58 +84030-6;Note;Find;Pt;Long term care facility;Doc;Team;DOC.ONTOLOGY;2;Team Long term care facility Note;Team LTC fac Note;;ACTIVE;2.58;2.58 +84031-4;Referral note;Find;Pt;Long term care facility;Doc;Team;DOC.ONTOLOGY;2;Team Long term care facility Referral note;Team LTC fac Referral note;;ACTIVE;2.58;2.58 +84032-2;Note;Find;Pt;Outpatient;Doc;Team;DOC.ONTOLOGY;2;Team Outpatient Note;Team OP Note;;ACTIVE;2.58;2.58 +84033-0;Note;Find;Pt;Telephone encounter;Doc;Team;DOC.ONTOLOGY;2;Team Telephone encounter Note;Team Phone Note;;ACTIVE;2.58;2.58 +84034-8;Plan of care note;Find;Pt;{Setting};Doc;Team;DOC.ONTOLOGY;2;Team Plan of care note;Team Plan of care note;;ACTIVE;2.58;2.58 +84035-5;Consultation note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Consult note;Transpl surg Consult note;;ACTIVE;2.58;2.73 +84036-3;Note;Find;Pt;Outpatient;Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Outpatient Note;Transpl surg OP Note;;ACTIVE;2.58;2.73 +84037-1;Note;Find;Pt;Telephone encounter;Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Telephone encounter Note;Transpl surg Phone Note;;ACTIVE;2.58;2.73 +84038-9;Administrative note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Administrative note;Urology Administrative note;;ACTIVE;2.58;2.58 +84039-7;Admission evaluation note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Admission evaluation note;Urology Admit eval note;;ACTIVE;2.58;2.58 +84040-5;Discharge summary note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Discharge summary;Urology D/C sum;;ACTIVE;2.58;2.73 +84041-3;History and physical note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology History and physical note;Urology H&P note;;ACTIVE;2.58;2.58 +84042-1;Note;Find;Pt;Hospital;Doc;Urology;DOC.ONTOLOGY;2;Urology Hospital Note;Urology Hosp Note;;ACTIVE;2.58;2.58 +84043-9;Note;Find;Pt;{Setting};Doc;Urology.interdisciplinary;DOC.ONTOLOGY;2;Urology Interdisciplinary Note;Urology Interdiscip Note;;ACTIVE;2.58;2.58 +84044-7;Procedure note;Find;Pt;Outpatient;Doc;Urology;DOC.ONTOLOGY;2;Urology Outpatient procedure note;Urology OP Procedure note;;ACTIVE;2.58;2.58 +84045-4;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Postoperative evaluation and management note;Urology Post-op E/M note;;ACTIVE;2.58;2.58 +8404-6;Intrachamber mean;Pres;Pt;Heart.ventricle.left;Qn;;BP.CENT.MOLEC;2;Left ventricular Intrachamber mean pressure;LV Intrachamber mean pres;;ACTIVE;1.0h(2);2.4 +84046-2;Note;Find;Pt;Telephone encounter;Doc;Urology;DOC.ONTOLOGY;2;Urology Telephone encounter Note;Urology Phone Note;;ACTIVE;2.58;2.58 +84047-0;Admission evaluation note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Admission evaluation note;Vascular surgery Admit eval note;;ACTIVE;2.58;2.58 +84048-8;History and physical note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery History and physical note;Vascular surgery H&P note;;ACTIVE;2.58;2.58 +84049-6;Note;Find;Pt;Hospital;Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Hospital Note;Vascular surgery Hosp Note;;ACTIVE;2.58;2.58 +84050-4;Note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Note;Vascular surgery Note;;ACTIVE;2.58;2.58 +84051-2;Postoperative evaluation and management note;Find;Pt;Outpatient;Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Outpatient Postoperative evaluation and management note;Vascular surgery OP Post-op E/M note;;ACTIVE;2.58;2.58 +84052-0;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Postoperative evaluation and management note;Vascular surgery Post-op E/M note;;ACTIVE;2.58;2.58 +8405-3;Intrachamber mean;Pres;Pt;Heart.ventricle.left.outflow tract;Qn;;BP.CENT.MOLEC;2;Left ventricular outflow tract Intrachamber mean pressure;LVOT Intrachamber mean pres;;ACTIVE;1.0h(2);2.4 +84053-8;Procedure note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery procedure note;Vascular surgery Procedure note;;ACTIVE;2.58;2.58 +84054-6;Note;Find;Pt;Telephone encounter;Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Telephone encounter Note;Vascular surgery Phone Note;;ACTIVE;2.58;2.58 +84055-3;Annual evaluation note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Annual evaluation note;Ophthalmol Annual eval note;;ACTIVE;2.58;2.58 +84056-1;Note;Find;Pt;Patient's home;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Patient's home Note;Ophthalmol Pt's home Note;;ACTIVE;2.58;2.58 +84057-9;Note;Find;Pt;Outpatient;Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Outpatient Note;Allergy+Immunology OP Note;;ACTIVE;2.58;2.66 +84058-7;Flowsheet;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Flowsheet;Anesthesiology Flowsheet;;ACTIVE;2.58;2.58 +84059-5;Note;Find;Pt;Hospital;Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Hospital Note;Anesthesiology Hosp Note;;ACTIVE;2.58;2.58 +84060-3;Note;Find;Pt;Outpatient;Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Outpatient Note;Anesthesiology OP Note;;ACTIVE;2.58;2.58 +8406-1;Intrachamber mean;Pres;Pt;Heart.ventricle.right;Qn;;BP.CENT.MOLEC;2;Right ventricular Intrachamber mean pressure;RV Intrachamber mean pres;;ACTIVE;1.0h(2);2.4 +84061-1;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Postoperative evaluation and management note;Anesthesiology Post-op E/M note;;ACTIVE;2.58;2.58 +84062-9;Procedure note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology procedure note;Anesthesiology Procedure note;;ACTIVE;2.58;2.58 +84063-7;Note;Find;Pt;Telephone encounter;Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Telephone encounter Note;Anesthesiology Phone Note;;ACTIVE;2.58;2.58 +84064-5;Annual evaluation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Annual evaluation note;Annual eval note;;ACTIVE;2.58;2.58 +84065-2;Administrative note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Administrative note;Audiology Administrative note;;ACTIVE;2.58;2.58 +84066-0;Note;Find;Pt;Telephone encounter;Doc;Audiology;DOC.ONTOLOGY;2;Audiology Telephone encounter Note;Audiology Phone Note;;ACTIVE;2.58;2.58 +84067-8;Note;Find;Pt;{Setting};Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Note;Bld Bnk+Trans Med Note;;ACTIVE;2.58;2.58 +84068-6;Admission evaluation note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Admission evaluation note;Cardiothor surg Admit eval note;;ACTIVE;2.58;2.58 +84069-4;Summary note;Find;Pt;Telehealth;Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Telehealth Summary note;Multi-spec prog Telehealth Summary note;;ACTIVE;2.58;2.58 +84070-2;Plan of care note;Find;Pt;Telehealth;Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Telehealth Plan of care note;Mult-spec prg Telehlth Plan of care note;;ACTIVE;2.58;2.58 +84071-0;Consultation note;Find;Pt;{Setting};Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine Consult note;Chiropractic med Consult note;;ACTIVE;2.58;2.58 +84072-8;Note;Find;Pt;Telephone encounter;Doc;Chiropractic medicine;DOC.ONTOLOGY;2;Chiropractic medicine Telephone encounter Note;Chiropractic med Phone Note;;ACTIVE;2.58;2.58 +84073-6;Note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Note;Col+rec surg Note;;ACTIVE;2.58;2.58 +84074-4;Procedure note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery procedure note;Col+rec surg Procedure note;;ACTIVE;2.58;2.58 +84075-1;Admission evaluation note;Find;Pt;Intensive care unit;Doc;{Role};DOC.ONTOLOGY;2;Intensive care unit Admission evaluation note;ICU Admit eval note;;ACTIVE;2.58;2.58 +84076-9;Administrative note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Administrative note;Dermatology Administrative note;;ACTIVE;2.58;2.58 +84077-7;History and physical note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology History and physical note;Dermatology H&P note;;ACTIVE;2.58;2.58 +84078-5;Note;Find;Pt;Hospital;Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Hospital Note;Dermatology Hosp Note;;ACTIVE;2.58;2.58 +8407-9;Intravascular mean;Pres;Pt;Celiac trunk artery;Qn;;BP.CENT.MOLEC;2;Celiac trunk artery Mean blood pressure;Celiac trunk a BP mean;;ACTIVE;1.0h(2);2.4 +84079-3;Surgical operation note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Surgical operation note;Dermatology Operative note;;ACTIVE;2.58;2.58 +84080-1;Note;Find;Pt;Outpatient;Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Outpatient Note;Dermatology OP Note;;ACTIVE;2.58;2.58 +84081-9;Procedure note;Find;Pt;Outpatient;Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Outpatient procedure note;Dermatology OP Procedure note;;ACTIVE;2.58;2.58 +84082-7;Note;Find;Pt;Telephone encounter;Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Telephone encounter Note;Dermatology Phone Note;;ACTIVE;2.58;2.58 +84083-5;Transfer summary note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Transfer summary note;Dermatology Transfer sum note;;ACTIVE;2.58;2.58 +84084-3;Note;Find;Pt;{Setting};Doc;Diabetology.case manager;DOC.ONTOLOGY;2;Diabetology Case manager Note;Diabetology Case mgr Note;;ACTIVE;2.58;2.58 +84085-0;Group counseling note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Group counseling note;Diabetology Group counseling note;;ACTIVE;2.58;2.58 +84086-8;Initial evaluation note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Initial evaluation note;Diabetology Initial eval note;;ACTIVE;2.58;2.58 +8408-7;Intravascular mean;Pres;Pt;Coronary sinus;Qn;;BP.CENT.MOLEC;2;Coronary sinus Mean blood pressure;CS BP mean;;ACTIVE;1.0h(2);2.4 +84087-6;Note;Find;Pt;Hospital;Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Hospital Note;Diabetology Hosp Note;;ACTIVE;2.58;2.58 +84088-4;Medication management note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Medication management note;Diabetology Med mgmt note;;ACTIVE;2.58;2.58 +84089-2;Group counseling note;Find;Pt;Outpatient;Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Outpatient Group counseling note;Diabetology OP Group counseling note;;ACTIVE;2.58;2.58 +840-9;A1 Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;A1 Ab [Presence] in Serum or Plasma from Donor;A1 Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +84090-0;Initial evaluation note;Find;Pt;Outpatient;Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Outpatient Initial evaluation note;Diabetology OP Initial eval note;;ACTIVE;2.58;2.58 +84091-8;Risk assessment and screening note;Find;Pt;Outpatient;Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Outpatient Risk assessment and screening note;Diabetology OP Risk assess+scrn note;;ACTIVE;2.58;2.58 +84092-6;Risk assessment and screening note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Risk assessment and screening note;Diabetology Risk assess+scrn note;;ACTIVE;2.58;2.58 +84093-4;Note;Find;Pt;Telephone encounter;Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Telephone encounter Note;Diabetology Phone Note;;ACTIVE;2.58;2.58 +84094-2;Plan of care note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Plan of care note;Diabetology Plan of care note;;ACTIVE;2.58;2.58 +8409-5;Intravascular mean;Pres;Pt;Ductus arteriosus;Qn;;BP.CENT.MOLEC;2;Ductus arteriosus Mean blood pressure;DA BP mean;;ACTIVE;1.0h(2);2.4 +84095-9;Do not resuscitate;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Do not resuscitate;DNR;;ACTIVE;2.58;2.58 +84096-7;Note;Find;Pt;Telephone encounter;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Telephone encounter Note;Emergency med Phone Note;;ACTIVE;2.58;2.58 +84097-5;History and physical note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology History and physical note;Endocrinology H&P note;;ACTIVE;2.58;2.58 +84098-3;Note;Find;Pt;Hospital;Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Hospital Note;Endocrinology Hosp Note;;ACTIVE;2.58;2.58 +84099-1;Note;Find;Pt;Outpatient;Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Outpatient Note;Endocrinology OP Note;;ACTIVE;2.58;2.58 +84100-7;Note;Find;Pt;Telephone encounter;Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Telephone encounter Note;Endocrinology Phone Note;;ACTIVE;2.58;2.58 +84101-5;Administrative note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Administrative note;Gastroenterology Administrative note;;ACTIVE;2.58;2.58 +84102-3;Admission evaluation note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Admission evaluation note;Gastroenterology Admit eval note;;ACTIVE;2.58;2.58 +8410-3;Intravascular mean;Pres;Pt;Hepatic artery;Qn;;BP.CENT.MOLEC;2;Hepatic artery Mean blood pressure;Hep a BP mean;;ACTIVE;1.0h(2);2.4 +84103-1;Note;Find;Pt;{Setting};Doc;Gastroenterology.clinical nurse specialist;DOC.ONTOLOGY;2;Gastroenterology Clinical nurse specialist Note;Gastroenterology CNS Note;;ACTIVE;2.58;2.58 +84104-9;History and physical note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology History and physical note;Gastroenterology H&P note;;ACTIVE;2.58;2.58 +84105-6;Note;Find;Pt;Hospital;Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Hospital Note;Gastroenterology Hosp Note;;ACTIVE;2.58;2.58 +84106-4;Letter;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Letter;Gastroenterology Letter;;ACTIVE;2.58;2.58 +84107-2;Note;Find;Pt;Outpatient;Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Outpatient Note;Gastroenterology OP Note;;ACTIVE;2.58;2.58 +84108-0;Note;Find;Pt;Telephone encounter;Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Telephone encounter Note;Gastroenterology Phone Note;;ACTIVE;2.58;2.58 +84109-8;Admission evaluation note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Admission evaluation note;Geri med Admit eval note;;ACTIVE;2.58;2.58 +84110-6;Annual evaluation note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Annual evaluation note;Geri med Annual eval note;;ACTIVE;2.58;2.58 +8411-1;Intravascular mean;Pres;Pt;Mesenteric artery;Qn;;BP.CENT.MOLEC;2;Mesenteric artery Mean blood pressure;Mesenteric a BP mean;;ACTIVE;1.0h(2);2.4 +84111-4;Note;Find;Pt;{Setting};Doc;Geriatric medicine.case manager;DOC.ONTOLOGY;2;Geriatric medicine Case manager Note;Geri med Case mgr Note;;ACTIVE;2.58;2.58 +84112-2;Group counseling note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Group counseling note;Geri med Group counseling note;;ACTIVE;2.58;2.58 +84113-0;Note;Find;Pt;Patient's home;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Patient's home Note;Geri med Pt's home Note;;ACTIVE;2.58;2.58 +84114-8;Note;Find;Pt;Hospital;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Hospital Note;Geri med Hosp Note;;ACTIVE;2.58;2.58 +84115-5;Consultation note;Find;Pt;Long term care facility;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Long term care facility Consult note;Geri med LTC fac Consult note;;ACTIVE;2.58;2.58 +84116-3;Note;Find;Pt;Long term care facility;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Long term care facility Note;Geri med LTC fac Note;;ACTIVE;2.58;2.58 +84117-1;Plan of care note;Find;Pt;Long term care facility;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Long term care facility Plan of care note;Geri med LTC fac Plan of care note;;ACTIVE;2.58;2.58 +84118-9;Initial evaluation note;Find;Pt;Outpatient;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Outpatient Initial evaluation note;Geri med OP Initial eval note;;ACTIVE;2.58;2.58 +84119-7;Note;Find;Pt;Outpatient;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Outpatient Note;Geri med OP Note;;ACTIVE;2.58;2.58 +84120-5;Note;Find;Pt;{Setting};Doc;Geriatric medicine.pharmacist;DOC.ONTOLOGY;2;Geriatric medicine Pharmacist Note;Geri med Pharmacist Note;;ACTIVE;2.58;2.58 +84121-3;Risk assessment and screening note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Risk assessment and screening note;Geri med Risk assess+scrn note;;ACTIVE;2.58;2.58 +84122-1;Note;Find;Pt;{Setting};Doc;Geriatric medicine.team;DOC.ONTOLOGY;2;Geriatric medicine Team Note;Geri med Team Note;;ACTIVE;2.58;2.58 +84123-9;Note;Find;Pt;Telephone encounter;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Telephone encounter Note;Geri med Phone Note;;ACTIVE;2.58;2.58 +84124-7;Plan of care note;Find;Pt;{Setting};Doc;Geriatric medicine.interdisciplinary;DOC.ONTOLOGY;2;Geriatric medicine Interdisciplinary Plan of care note;Geri med Interdispl Plan of care note;;ACTIVE;2.58;2.58 +84125-4;Admission evaluation note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Admission evaluation note;Hand Surgery Admit eval note;;ACTIVE;2.58;2.58 +84126-2;Consultation note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Consult note;Hand Surgery Consult note;;ACTIVE;2.58;2.58 +84127-0;Note;Find;Pt;Hospital;Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Hospital Note;Hand Surgery Hosp Note;;ACTIVE;2.58;2.58 +84128-8;Note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Note;Hand Surgery Note;;ACTIVE;2.58;2.58 +8412-9;Intravascular mean;Pres;Pt;Inferior mesenteric artery;Qn;;BP.CENT.MOLEC;2;Inferior mesenteric artery Mean blood pressure;IM a BP mean;;ACTIVE;1.0h(2);2.4 +84129-6;Note;Find;Pt;Outpatient;Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Outpatient Note;Hand Surgery OP Note;;ACTIVE;2.58;2.58 +84130-4;Annual evaluation note;Find;Pt;Patient's home;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Patient's home Annual evaluation note;Primary care Pt's home Annual eval note;;ACTIVE;2.58;2.58 +84131-2;Consultation note;Find;Pt;Patient's home;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Patient's home Consult note;Primary care Pt's home Consult note;;ACTIVE;2.58;2.58 +84132-0;Discharge summary note;Find;Pt;Patient's home;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Patient's home Discharge summary;Primary care Pt's home D/C sum;;ACTIVE;2.58;2.73 +84133-8;Medication management note;Find;Pt;Patient's home;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Patient's home Medication management note;Primary care Pt's home Med mgmt note;;ACTIVE;2.58;2.58 +84134-6;Note;Find;Pt;Patient's home;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Patient's home Note;Primary care Pt's home Note;;ACTIVE;2.58;2.58 +84135-3;Plan of care note;Find;Pt;Patient's home;Doc;Primary care.interdisciplinary;DOC.ONTOLOGY;2;Primary care Interdisciplinary Patient's home Plan of care note;PC Interdiscip Pt home Plan of care note;;ACTIVE;2.58;2.58 +84136-1;Plan of care note;Find;Pt;Patient's home;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Patient's home Plan of care note;Primary care Pt's home Plan of care note;;ACTIVE;2.58;2.58 +8413-7;Intravascular mean;Pres;Pt;Superior mesenteric artery;Qn;;BP.CENT.MOLEC;2;Superior mesenteric artery Mean blood pressure;SM a BP mean;;ACTIVE;1.0h(2);2.4 +84137-9;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.pharmacist;DOC.ONTOLOGY;2;Hematology+Medical oncology Pharmacist Note;HemOnc Pharmacist Note;;ACTIVE;2.58;2.58 +84138-7;Conference note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Conference note;HemOnc Conf eval note;;ACTIVE;2.58;2.58 +84139-5;Discharge summary note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Discharge summary;HemOnc D/C sum;;ACTIVE;2.58;2.73 +84140-3;Education note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Education note;HemOnc Educ note;;ACTIVE;2.58;2.58 +84141-1;Group counseling note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Group counseling note;HemOnc Group counseling note;;ACTIVE;2.58;2.58 +84142-9;Consultation note;Find;Pt;Hospital;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Hospital Consult note;HemOnc Hosp Consult note;;ACTIVE;2.58;2.58 +84143-7;Note;Find;Pt;Hospital;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Hospital Note;HemOnc Hosp Note;;ACTIVE;2.58;2.58 +84144-5;Medication management note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Medication management note;HemOnc Med mgmt note;;ACTIVE;2.58;2.58 +8414-5;Intravascular mean;Pres;Pt;Pulmonary artery;Qn;;BP.CENT.MOLEC;2;Pulmonary artery Mean blood pressure;PA BP mean;;ACTIVE;1.0h(2);2.3 +84145-2;Consultation note;Find;Pt;Outpatient;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Outpatient Consult note;HemOnc OP Consult note;;ACTIVE;2.58;2.58 +84146-0;Note;Find;Pt;Outpatient;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Outpatient Note;HemOnc OP Note;;ACTIVE;2.58;2.58 +84147-8;Procedure note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology procedure note;HemOnc Procedure note;;ACTIVE;2.58;2.58 +84148-6;Risk assessment and screening note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Risk assessment and screening note;HemOnc Risk assess+scrn note;;ACTIVE;2.58;2.58 +84149-4;Note;Find;Pt;{Setting};Doc;Hematology+Medical oncology.team;DOC.ONTOLOGY;2;Hematology+Medical oncology Team Note;HemOnc Team Note;;ACTIVE;2.58;2.58 +84150-2;Note;Find;Pt;Telephone encounter;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Telephone encounter Note;HemOnc Phone Note;;ACTIVE;2.58;2.58 +84151-0;Plan of care note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Plan of care note;HemOnc Plan of care note;;ACTIVE;2.58;2.58 +8415-2;Intravascular mean;Pres;Pt;Pulmonary artery.left;Qn;;BP.CENT.MOLEC;2;Left pulmonary artery Mean blood pressure;PA-L BP mean;;ACTIVE;1.0h(2);2.54 +84152-8;Consultation note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Consult note;Hepatology Consult note;;ACTIVE;2.58;2.58 +84153-6;Counseling note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Counseling note;Hepatology Counseling note;;ACTIVE;2.58;2.58 +84154-4;Education note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Education note;Hepatology Educ note;;ACTIVE;2.58;2.58 +84155-1;Initial evaluation note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Initial evaluation note;Hepatology Initial eval note;;ACTIVE;2.58;2.58 +84156-9;Note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Note;Hepatology Note;;ACTIVE;2.58;2.58 +84157-7;Note;Find;Pt;Outpatient;Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Outpatient Note;Hepatology OP Note;;ACTIVE;2.58;2.58 +84158-5;Procedure note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology procedure note;Hepatology Procedure note;;ACTIVE;2.58;2.58 +84159-3;Note;Find;Pt;Telephone encounter;Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Telephone encounter Note;Hepatology Phone Note;;ACTIVE;2.58;2.58 +8416-0;Intravascular mean;Pres;Pt;Pulmonary artery.right;Qn;;BP.CENT.MOLEC;2;Right pulmonary artery Mean blood pressure;PA-R BP mean;;ACTIVE;1.0h(2);2.54 +84160-1;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Transplant candidate evaluation note;Hepatology Trnsplt cand eval nte;;ACTIVE;2.58;2.58 +84161-9;Administrative note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Administrative note;Pt's home Administrative note;;ACTIVE;2.58;2.58 +84162-7;Admission evaluation note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Admission evaluation note;Pt's home Admit eval note;;ACTIVE;2.58;2.58 +84163-5;Note;Find;Pt;Patient's home;Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Patient's home Note;Interdiscip Pt's home Note;;ACTIVE;2.58;2.58 +84164-3;Plan of care note;Find;Pt;Patient's home;Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Patient's home Plan of care note;Interdiscip Pt's home Plan of care note;;ACTIVE;2.58;2.58 +84165-0;Plan of care note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Plan of care note;Pt's home Plan of care note;;ACTIVE;2.58;2.58 +84166-8;Counseling note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Counseling note;Infectious disease Counseling note;;ACTIVE;2.58;2.58 +84167-6;Group counseling note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Group counseling note;Infectious disease Group counseling note;;ACTIVE;2.58;2.58 +84168-4;Note;Find;Pt;Hospital;Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Hospital Note;Infectious disease Hosp Note;;ACTIVE;2.58;2.58 +84169-2;Note;Find;Pt;Outpatient;Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Outpatient Note;Infectious disease OP Note;;ACTIVE;2.58;2.58 +841-7;A1 Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;A1 Ab [Presence] in Serum or Plasma;A1 Ab SerPl Ql;;ACTIVE;1.0;2.56 +84170-0;Risk assessment and screening note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Risk assessment and screening note;Infectious disease Risk assess+scrn note;;ACTIVE;2.58;2.58 +84171-8;Note;Find;Pt;Telephone encounter;Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Telephone encounter Note;Infectious disease Phone Note;;ACTIVE;2.58;2.58 +84172-6;Plan of care note;Find;Pt;Hospital;Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Hospital Plan of care note;Interdiscip Hosp Plan of care note;;ACTIVE;2.58;2.58 +84173-4;Consultation note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Consult note;IC Consult note;;ACTIVE;2.58;2.58 +84174-2;Note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Note;IC Note;;ACTIVE;2.58;2.58 +84175-9;Surgical operation note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Surgical operation note;IC Operative note;;ACTIVE;2.58;2.58 +84176-7;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Postoperative evaluation and management note;IC Post-op E/M note;;ACTIVE;2.58;2.58 +84177-5;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Preoperative evaluation and management note;IC Pre-op note;;ACTIVE;2.58;2.58 +8417-8;Intravascular mean;Pres;Pt;Renal artery.left;Qn;;BP.CENT.MOLEC;2;Renal artery - left Mean blood pressure;Renal a-L BP mean;;ACTIVE;1.0h(2);2.4 +84178-3;Note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Note;IR Note;;ACTIVE;2.58;2.58 +84179-1;Discharge summary note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Discharge summary;Kinesiotherapy D/C sum;;ACTIVE;2.58;2.73 +84180-9;Education note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Education note;Kinesiotherapy Educ note;;ACTIVE;2.58;2.58 +84181-7;Note;Find;Pt;Patient's home;Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Patient's home Note;Kinesiotherapy Pt's home Note;;ACTIVE;2.58;2.58 +84182-5;Initial evaluation note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Initial evaluation note;Kinesiotherapy Initial eval note;;ACTIVE;2.58;2.58 +84183-3;Plan of care note;Find;Pt;Long term care facility;Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Long term care facility Plan of care note;Kinesiotherapy LTC fac Plan of care note;;ACTIVE;2.58;2.58 +84184-1;Note;Find;Pt;Outpatient;Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Outpatient Note;Kinesiotherapy OP Note;;ACTIVE;2.58;2.58 +84185-8;Plan of care note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Plan of care note;Kinesiotherapy Plan of care note;;ACTIVE;2.58;2.58 +8418-6;Intravascular mean;Pres;Pt;Renal artery.right;Qn;;BP.CENT.MOLEC;2;Renal artery - right Mean blood pressure;Renal a-R BP mean;;ACTIVE;1.0h(2);2.4 +84186-6;Note;Find;Pt;Long term care facility;Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Long term care facility Note;Interdiscip LTC fac Note;;ACTIVE;2.58;2.58 +84187-4;Plan of care note;Find;Pt;Long term care facility;Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Long term care facility Plan of care note;Interdiscip LTC fac Plan of care note;;ACTIVE;2.58;2.58 +84188-2;Note;Find;Pt;Long term care facility;Doc;Licensed practical nurse;DOC.ONTOLOGY;2;Licensed practical nurse Long term care facility Note;LPN LTC fac Note;;ACTIVE;2.58;2.58 +84189-0;Note;Find;Pt;Outpatient;Doc;Licensed practical nurse;DOC.ONTOLOGY;2;Licensed practical nurse Outpatient Note;LPN OP Note;;ACTIVE;2.58;2.58 +84190-8;Consultation note;Find;Pt;{Setting};Doc;Medical toxicology;DOC.ONTOLOGY;2;Medical toxicology Consult note;Med tox Consult note;;ACTIVE;2.58;2.58 +84191-6;Note;Find;Pt;{Setting};Doc;Medical toxicology;DOC.ONTOLOGY;2;Medical toxicology Note;Med tox Note;;ACTIVE;2.58;2.58 +84192-4;Admission evaluation note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Admission evaluation note;Mental health Admit eval note;;ACTIVE;2.58;2.58 +84193-2;Conference note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Conference note;Mental health Conf eval note;;ACTIVE;2.58;2.58 +8419-4;Intravascular mean;Pres;Pt;Splenic artery;Qn;;BP.CENT.MOLEC;2;Splenic artery Mean blood pressure;Splenic a BP mean;;ACTIVE;1.0h(2);2.4 +84194-0;Agreement;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Agreement;Mental health Agreement;;ACTIVE;2.58;2.64 +84195-7;Note;Find;Pt;Intensive care unit;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Intensive care unit Note;Mental health ICU Note;;ACTIVE;2.58;2.58 +84196-5;Note;Find;Pt;Custodial care facility;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Custodial care facility Note;Mental health Cust care fac Note;;ACTIVE;2.58;2.58 +84197-3;Plan of care note;Find;Pt;Custodial care facility;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Custodial care facility Plan of care note;MH Cust care fac Plan of care note;;ACTIVE;2.58;2.58 +84198-1;Note;Find;Pt;Emergency department;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Emergency department Note;Mental health ED Note;;ACTIVE;2.58;2.58 +84199-9;Note;Find;Pt;Patient's home;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Patient's home Note;Mental health Pt's home Note;;ACTIVE;2.58;2.58 +84200-5;Admission evaluation note;Find;Pt;Hospital;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Hospital Admission evaluation note;Mental health Hosp Admit eval note;;ACTIVE;2.58;2.58 +84201-3;Group counseling note;Find;Pt;Hospital;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Hospital Group counseling note;Mental health Hosp Group counseling note;;ACTIVE;2.58;2.58 +8420-2;Intravascular systolic;Pres;Pt;Aorta.abdominal.distal;Qn;;BP.CENT.MOLEC;2;Distal abdominal aorta Systolic blood pressure;Distal Ab Ao BP sys;;ACTIVE;1.0h(2);2.54 +84202-1;Note;Find;Pt;Hospital;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Hospital Note;Mental health Hosp Note;;ACTIVE;2.58;2.58 +84203-9;Plan of care note;Find;Pt;Hospital;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Hospital Plan of care note;Mental health Hosp Plan of care note;;ACTIVE;2.58;2.58 +84204-7;Note;Find;Pt;{Setting};Doc;Mental health.interdisciplinary;DOC.ONTOLOGY;2;Mental health Interdisciplinary Note;MH Interdisp Note;;ACTIVE;2.58;2.58 +84205-4;Note;Find;Pt;Long term care facility;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Long term care facility Note;Mental health LTC fac Note;;ACTIVE;2.58;2.58 +84206-2;Note;Find;Pt;Observation unit;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Observation unit Note;Mental health Obs Unit Note;;ACTIVE;2.58;2.58 +84207-0;Group counseling note;Find;Pt;Outpatient;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Outpatient Group counseling note;Mental health OP Group counseling note;;ACTIVE;2.58;2.58 +84208-8;Initial evaluation note;Find;Pt;Outpatient;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Outpatient Initial evaluation note;Mental health OP Initial eval note;;ACTIVE;2.58;2.58 +84209-6;Risk assessment and screening note;Find;Pt;Outpatient;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Outpatient Risk assessment and screening note;Mental health OP Risk assess+scrn note;;ACTIVE;2.58;2.58 +8421-0;Intravascular systolic;Pres;Pt;Aorta.abdominal.proximal;Qn;;BP.CENT.MOLEC;2;Proximal abdominal aorta Systolic blood pressure;Prox Ab Ao BP sys;;ACTIVE;1.0h(2);2.54 +84210-4;Plan of care note;Find;Pt;Outpatient;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Outpatient Plan of care note;Mental health OP Plan of care note;;ACTIVE;2.58;2.58 +84211-2;Outreach note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Outreach note;Mental health Outreach note;;ACTIVE;2.58;2.58 +84212-0;Conference note;Find;Pt;{Setting};Doc;Mental health.team;DOC.ONTOLOGY;2;Mental health Team Conference note;MH Team Conf eval note;;ACTIVE;2.58;2.58 +84213-8;Consultation note;Find;Pt;{Setting};Doc;Mental health.team;DOC.ONTOLOGY;2;Mental health Team Consult note;MH Team Consult note;;ACTIVE;2.58;2.58 +84214-6;Note;Find;Pt;{Setting};Doc;Mental health.team;DOC.ONTOLOGY;2;Mental health Team Note;MH Team Note;;ACTIVE;2.58;2.58 +84215-3;Note;Find;Pt;Telehealth;Doc;Mental health;DOC.ONTOLOGY;2;Mental health Telehealth Note;Mental health Telehealth Note;;ACTIVE;2.58;2.58 +84216-1;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Transplant candidate evaluation note;Mental health Trnsplt cand eval nte;;ACTIVE;2.58;2.58 +84217-9;Plan of care note;Find;Pt;{Setting};Doc;Mental health.interdisciplinary;DOC.ONTOLOGY;2;Mental health Interdisciplinary Plan of care note;MH Interdisp Plan of care note;;ACTIVE;2.58;2.58 +84218-7;Triage note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Triage note;Mental health Triage note;;ACTIVE;2.58;2.58 +84219-5;Note;Find;Pt;Patient's home;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Patient's home Note;Nephrology Pt's home Note;;ACTIVE;2.58;2.58 +84220-3;Note;Find;Pt;Hospital;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Hospital Note;Nephrology Hosp Note;;ACTIVE;2.58;2.58 +84221-1;Transfer summary note;Find;Pt;Hospital;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Hospital Transfer summary note;Nephrology Hosp Transfer sum note;;ACTIVE;2.58;2.58 +84222-9;Note;Find;Pt;Outpatient;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Outpatient Note;Nephrology OP Note;;ACTIVE;2.58;2.58 +84223-7;Note;Find;Pt;{Setting};Doc;Nephrology.team;DOC.ONTOLOGY;2;Nephrology Team Note;Nephrology Team Note;;ACTIVE;2.58;2.58 +84224-5;Note;Find;Pt;Telephone encounter;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Telephone encounter Note;Nephrology Phone Note;;ACTIVE;2.58;2.58 +84225-2;Administrative note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Administrative note;Neurology Administrative note;;ACTIVE;2.58;2.58 +84226-0;Admission evaluation note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Admission evaluation note;Neurology Admit eval note;;ACTIVE;2.58;2.58 +84227-8;Note;Find;Pt;Hospital;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Hospital Note;Neurology Hosp Note;;ACTIVE;2.58;2.58 +8422-8;Intravascular systolic;Pres;Pt;Aorta.thoracic.proximal ascending;Qn;;BP.CENT.MOLEC;2;Proximal ascending thoracic aorta Systolic blood pressure;Prox asc TA BP sys;;ACTIVE;1.0h(2);2.54 +84228-6;Transfer summary note;Find;Pt;Hospital;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Hospital Transfer summary note;Neurology Hosp Transfer sum note;;ACTIVE;2.58;2.58 +84229-4;Note;Find;Pt;Outpatient;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Outpatient Note;Neurology OP Note;;ACTIVE;2.58;2.58 +84230-2;Note;Find;Pt;{Setting};Doc;Neurology.team;DOC.ONTOLOGY;2;Neurology Team Note;Neurology Team Note;;ACTIVE;2.58;2.58 +84231-0;Consultation note;Find;Pt;Telehealth;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Telehealth Consult note;Neurology Telehealth Consult note;;ACTIVE;2.58;2.58 +84232-8;Note;Find;Pt;Telehealth;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Telehealth Note;Neurology Telehealth Note;;ACTIVE;2.58;2.58 +84233-6;Initial evaluation note;Find;Pt;Telehealth;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Telehealth Initial evaluation note;Neurology Telehealth Initial eval note;;ACTIVE;2.58;2.58 +84234-4;Note;Find;Pt;Telephone encounter;Doc;Neurology;DOC.ONTOLOGY;2;Neurology Telephone encounter Note;Neurology Phone Note;;ACTIVE;2.58;2.58 +84235-1;Admission evaluation note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Admission evaluation note;Neuro surgery Admit eval note;;ACTIVE;2.58;2.58 +8423-6;Intravascular systolic;Pres;Pt;Aorta.thoracic.ascending;Qn;;BP.CENT.MOLEC;2;Ascending thoracic aorta Systolic blood pressure;ATA BP sys;;ACTIVE;1.0h(2);2.54 +84236-9;Note;Find;Pt;Hospital;Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Hospital Note;Neuro surgery Hosp Note;;ACTIVE;2.58;2.58 +84237-7;Note;Find;Pt;Outpatient;Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Outpatient Note;Neuro surgery OP Note;;ACTIVE;2.58;2.58 +84238-5;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Postoperative evaluation and management note;Neuro surgery Post-op E/M note;;ACTIVE;2.58;2.58 +84239-3;Note;Find;Pt;Telephone encounter;Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Telephone encounter Note;Neuro surgery Phone Note;;ACTIVE;2.58;2.58 +84240-1;Administrative note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Administrative note;Nurse Administrative note;;ACTIVE;2.58;2.58 +84241-9;Consultation note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Consult note;Nurse Consult note;;ACTIVE;2.58;2.58 +84242-7;Crisis intervention note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Crisis intervention note;Nurse Crisis intervention note;;ACTIVE;2.58;2.58 +84243-5;Flowsheet;Find;Pt;Intensive care unit;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Intensive care unit Flowsheet;Nurse ICU Flowsheet;;ACTIVE;2.58;2.58 +8424-4;Intravascular systolic;Pres;Pt;Aorta.thoracic.descending;Qn;;BP.CENT.MOLEC;2;Descending thoracic aorta Systolic blood pressure;DTA BP sys;;ACTIVE;1.0h(2);2.54 +84244-3;Plan of care note;Find;Pt;Intensive care unit;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Intensive care unit Plan of care note;Nurse ICU Plan of care note;;ACTIVE;2.58;2.58 +84245-0;Diagram;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Diagram;Nurse Diagram;;ACTIVE;2.58;2.58 +84246-8;Note;Find;Pt;Custodial care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Custodial care facility Note;Nurse Cust care fac Note;;ACTIVE;2.58;2.58 +84247-6;Evaluation and management of anticoagulation note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Evaluation and management of anticoagulation note;Nurse E/M coag note;;ACTIVE;2.58;2.58 +84248-4;Discharge summary note;Find;Pt;Emergency department;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Emergency department Discharge summary;Nurse ED D/C sum;;ACTIVE;2.58;2.73 +84249-2;Triage note;Find;Pt;Emergency department;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Emergency department Triage note;Nurse ED Triage note;;ACTIVE;2.58;2.58 +842-5;A1 Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A1 Ag [Presence] on Red Blood Cells from Blood product unit;A1 Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +84250-0;Group counseling note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Group counseling note;Nurse Group counseling note;;ACTIVE;2.58;2.58 +84251-8;Note;Find;Pt;Patient's home;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Patient's home Note;Nurse Pt's home Note;;ACTIVE;2.58;2.58 +84252-6;Initial evaluation note;Find;Pt;Patient's home;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Patient's home Initial evaluation note;Nurse Pt's home Initial eval note;;ACTIVE;2.58;2.58 +84253-4;Admission evaluation note;Find;Pt;Hospital;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Hospital Admission evaluation note;Nurse Hosp Admit eval note;;ACTIVE;2.58;2.58 +84254-2;Discharge summary note;Find;Pt;Hospital;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Hospital Discharge summary;Nurse Hosp D/C sum;;ACTIVE;2.58;2.73 +84255-9;Admission evaluation note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Admission evaluation note;Nurse LTC fac Admit eval note;;ACTIVE;2.58;2.58 +84256-7;Annual evaluation note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Annual evaluation note;Nurse LTC fac Annual eval note;;ACTIVE;2.58;2.58 +84257-5;Discharge summary note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Discharge summary;Nurse LTC fac D/C sum;;ACTIVE;2.58;2.73 +84258-3;Initial evaluation note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Initial evaluation note;Nurse LTC fac Initial eval note;;ACTIVE;2.58;2.58 +84259-1;Referral note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Referral note;Nurse LTC fac Referral note;;ACTIVE;2.58;2.58 +84260-9;Risk assessment and screening note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Risk assessment and screening note;Nurse LTC fac Risk assess+scrn note;;ACTIVE;2.58;2.58 +84261-7;Admission evaluation note;Find;Pt;Observation unit;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Observation unit Admission evaluation note;Nurse Obs Unit Admit eval note;;ACTIVE;2.58;2.58 +84262-5;Discharge summary note;Find;Pt;Observation unit;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Observation unit Discharge summary;Nurse Obs Unit D/C sum;;ACTIVE;2.58;2.73 +84263-3;Note;Find;Pt;Observation unit;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Observation unit Note;Nurse Obs Unit Note;;ACTIVE;2.58;2.58 +84264-1;Surgical operation note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Surgical operation note;Nurse Operative note;;ACTIVE;2.58;2.58 +84265-8;Evaluation and management of anticoagulation note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Evaluation and management of anticoagulation note;Nurse OP E/M coag note;;ACTIVE;2.58;2.58 +84266-6;Initial evaluation note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Initial evaluation note;Nurse OP Initial eval note;;ACTIVE;2.58;2.58 +84267-4;Medication management note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Medication management note;Nurse OP Med mgmt note;;ACTIVE;2.58;2.58 +84268-2;Surgical operation note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Surgical operation note;Nurse OP Operative note;;ACTIVE;2.58;2.58 +84269-0;Triage note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Triage note;Nurse OP Triage note;;ACTIVE;2.58;2.58 +84270-8;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Postoperative evaluation and management note;Nurse Post-op E/M note;;ACTIVE;2.58;2.58 +84271-6;Referral note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Referral note;Nurse Referral note;;ACTIVE;2.58;2.58 +84272-4;Respite note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Respite note;Nurse Respite note;;ACTIVE;2.58;2.58 +84273-2;Summary of death note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Summary of death note;Nurse Summary of death;;ACTIVE;2.58;2.58 +84274-0;Note;Find;Pt;Telehealth;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Telehealth Note;Nurse Telehealth Note;;ACTIVE;2.58;2.58 +84275-7;Note;Find;Pt;Urgent care center;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Urgent care center Note;Nurse Urgent care Note;;ACTIVE;2.58;2.58 +84276-5;Triage note;Find;Pt;Urgent care center;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Urgent care center Triage note;Nurse Urgent care Triage note;;ACTIVE;2.58;2.58 +84277-3;Administrative note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Administrative note;Nutr+diet Administrative note;;ACTIVE;2.58;2.58 +84278-1;Discharge summary note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Discharge summary;Nutr+diet D/C sum;;ACTIVE;2.58;2.73 +84279-9;Group counseling note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Group counseling note;Nutr+diet Group counseling note;;ACTIVE;2.58;2.58 +84280-7;Consultation note;Find;Pt;Patient's home;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Patient's home Consult note;Nutr+diet Pt's home Consult note;;ACTIVE;2.58;2.58 +84281-5;Initial evaluation note;Find;Pt;Patient's home;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Patient's home Initial evaluation note;Nutr+diet Pt's home Initial eval note;;ACTIVE;2.58;2.58 +84282-3;Note;Find;Pt;Patient's home;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Patient's home Note;Nutr+diet Pt's home Note;;ACTIVE;2.58;2.58 +84283-1;Risk assessment and screening note;Find;Pt;Patient's home;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Patient's home Risk assessment and screening note;Nutr+diet Pt home Risk assess+scrn note;;ACTIVE;2.58;2.58 +84284-9;Note;Find;Pt;Hospital;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Hospital Note;Nutr+diet Hosp Note;;ACTIVE;2.58;2.58 +84285-6;Initial evaluation note;Find;Pt;Long term care facility;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Long term care facility Initial evaluation note;Nutr+diet LTC fac Initial eval note;;ACTIVE;2.58;2.58 +84286-4;Note;Find;Pt;Long term care facility;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Long term care facility Note;Nutr+diet LTC fac Note;;ACTIVE;2.58;2.58 +84287-2;Referral note;Find;Pt;Long term care facility;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Long term care facility Referral note;Nutr+diet LTC fac Referral note;;ACTIVE;2.58;2.58 +84288-0;Initial evaluation note;Find;Pt;Outpatient;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Outpatient Initial evaluation note;Nutr+diet OP Initial eval note;;ACTIVE;2.58;2.58 +84289-8;Note;Find;Pt;Outpatient;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Outpatient Note;Nutr+diet OP Note;;ACTIVE;2.58;2.58 +84290-6;Risk assessment and screening note;Find;Pt;Outpatient;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Outpatient Risk assessment and screening note;Nutr+diet OP Risk assess+scrn note;;ACTIVE;2.58;2.58 +84291-4;Risk assessment and screening note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Risk assessment and screening note;Nutr+diet Risk assess+scrn note;;ACTIVE;2.58;2.58 +84292-2;Consultation note;Find;Pt;{Setting};Doc;Nutrition and dietetics.team;DOC.ONTOLOGY;2;Nutrition and dietetics Team Consult note;Nutr+diet Team Consult note;;ACTIVE;2.58;2.58 +84293-0;Note;Find;Pt;{Setting};Doc;Nutrition and dietetics.team;DOC.ONTOLOGY;2;Nutrition and dietetics Team Note;Nutr+diet Team Note;;ACTIVE;2.58;2.58 +84294-8;Note;Find;Pt;Telephone encounter;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Telephone encounter Note;Nutr+diet Phone Note;;ACTIVE;2.58;2.58 +84295-5;Plan of care note;Find;Pt;{Setting};Doc;Nutrition and dietetics.interdisciplinary;DOC.ONTOLOGY;2;Nutrition and dietetics Interdisciplinary Plan of care note;Nutr+diet Interdiscip Plan of care note;;ACTIVE;2.58;2.58 +84296-3;Dose form changed since previous visit;Find;Pt;^Patient;Ord;;MEDS;2;Dose form changed since previous visit;Dose form chgd since prev visit;;ACTIVE;2.58;2.58 +84297-1;Dose(s) missed since previous visit;Find;Pt;^Patient;Ord;;MEDS;2;Dose(s) missed since previous visit;Dose(s) missed since prev visit;;ACTIVE;2.58;2.58 +84298-9;Treatment stopped for at least 1W;Find;Pt;^Patient;Ord;;MEDS;2;Treatment stopped for at least 1 week;Tx stopped for at least 1W;;ACTIVE;2.58;2.58 +84299-7;Reason for missed treatment;Find;Pt;^Patient;Nom;Reported;MEDS;2;Reason for missed treatement - Reported;Reason missed treatment Reported;;ACTIVE;2.58;2.58 +84300-3;Medication administered by;Find;Pt;^Patient;Nom;;MEDS;2;Medication administered by;Medication admin by;;ACTIVE;2.58;2.58 +8430-1;Intrachamber systolic;Pres;Pt;Heart.ventricle.left;Qn;;BP.CENT.MOLEC;2;Left ventricular Intrachamber systolic pressure;LV Intrachamber sys pres;;ACTIVE;1.0h(2);2.3 +84301-1;Dose adjusted after temporary treatment stop;Find;Pt;^Patient;Ord;;MEDS;2;Dose adjusted after temporary treatment stop;Dose adj after temp tx stop;;ACTIVE;2.58;2.58 +84302-9;Note;Find;Pt;{Setting};Doc;Wound care management.nurse;DOC.ONTOLOGY;2;Wound care management Nurse Note;Wound care Nurse Note;;ACTIVE;2.58;2.58 +84303-7;Consultation note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Consult note;Wound care management Consult note;;ACTIVE;2.58;2.58 +84304-5;Note;Find;Pt;Hospital;Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Hospital Note;OBGYN Hosp Note;;DISCOURAGED;2.58;2.64 +84305-2;Administrative note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Administrative note;OBGYN Administrative note;;DISCOURAGED;2.58;2.64 +84306-0;Plan of care note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Plan of care note;Vocational rehab Plan of care note;;ACTIVE;2.58;2.58 +84308-6;Initial evaluation note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Initial evaluation note;Vocational rehab Initial eval note;;ACTIVE;2.58;2.58 +84309-4;Note;Find;Pt;Custodial care facility;Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Custodial care facility Note;Vocational rehab Cust care fac Note;;ACTIVE;2.58;2.58 +84310-2;Discharge summary note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Discharge summary;Vocational rehab D/C sum;;ACTIVE;2.58;2.73 +84311-0;Counseling note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Counseling note;Vocational rehab Counseling note;;ACTIVE;2.58;2.58 +84312-8;Consultation note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Consult note;Vocational rehab Consult note;;ACTIVE;2.58;2.58 +84313-6;Admission evaluation note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Admission evaluation note;Vocational rehab Admit eval note;;ACTIVE;2.58;2.58 +84314-4;Plan of care note;Find;Pt;{Setting};Doc;Physical therapy.interdisciplinary;DOC.ONTOLOGY;2;Physical therapy Interdisciplinary Plan of care note;PT Interdiscip Plan of care note;;ACTIVE;2.58;2.58 +84315-1;Note;Find;Pt;Telephone encounter;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Telephone encounter Note;PT Phone Note;;ACTIVE;2.58;2.58 +84316-9;Note;Find;Pt;{Setting};Doc;Physical therapy.team;DOC.ONTOLOGY;2;Physical therapy Team Note;PT Team Note;;ACTIVE;2.58;2.58 +84317-7;Risk assessment and screening note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Risk assessment and screening note;PT Risk assess+scrn note;;ACTIVE;2.58;2.58 +84318-5;Note;Find;Pt;Outpatient;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Outpatient Note;PT OP Note;;ACTIVE;2.58;2.58 +8431-9;Intrachamber systolic;Pres;Pt;Heart.ventricle.left.outflow tract;Qn;;BP.CENT.MOLEC;2;Left ventricular outflow tract Intrachamber systolic pressure;LVOT Intrachamber sys pres;;ACTIVE;1.0h(2);2.4 +84319-3;Initial evaluation note;Find;Pt;Outpatient;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Outpatient Initial evaluation note;PT OP Initial eval note;;ACTIVE;2.58;2.58 +84320-1;Education note;Find;Pt;Outpatient;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Outpatient Education note;PT OP Educ note;;ACTIVE;2.58;2.58 +84321-9;Discharge summary note;Find;Pt;Outpatient;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Outpatient Discharge summary;PT OP D/C sum;;ACTIVE;2.58;2.73 +84322-7;Medication management note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Medication management note;PT Med mgmt note;;ACTIVE;2.58;2.58 +84323-5;Note;Find;Pt;Long term care facility;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Long term care facility Note;PT LTC fac Note;;ACTIVE;2.58;2.58 +84324-3;Consultation note;Find;Pt;Long term care facility;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Long term care facility Consult note;PT LTC fac Consult note;;ACTIVE;2.58;2.58 +84325-0;Note;Find;Pt;{Setting};Doc;Physical therapy.interdisciplinary;DOC.ONTOLOGY;2;Physical therapy Interdisciplinary Note;PT Interdiscip Note;;ACTIVE;2.58;2.58 +84326-8;Note;Find;Pt;Hospital;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Hospital Note;PT Hosp Note;;ACTIVE;2.58;2.58 +8432-7;Intrachamber systolic;Pres;Pt;Heart.ventricle.right;Qn;;BP.CENT.MOLEC;2;Right ventricular Intrachamber systolic pressure;RV Intrachamber sys pres;;ACTIVE;1.0h(2);2.3 +84327-6;Initial evaluation note;Find;Pt;Hospital;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Hospital Initial evaluation note;PT Hosp Initial eval note;;ACTIVE;2.58;2.58 +84328-4;Discharge summary note;Find;Pt;Hospital;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Hospital Discharge summary;PT Hosp D/C sum;;ACTIVE;2.58;2.73 +84329-2;Note;Find;Pt;Patient's home;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Patient's home Note;PT Pt's home Note;;ACTIVE;2.58;2.58 +843-3;A1 Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A1 Ag [Presence] on Red Blood Cells from Donor;A1 Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +84330-0;Initial evaluation note;Find;Pt;Patient's home;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Patient's home Initial evaluation note;PT Pt's home Initial eval note;;ACTIVE;2.58;2.58 +84331-8;Discharge summary note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Discharge summary;PT D/C sum;;ACTIVE;2.58;2.73 +84332-6;Administrative note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Administrative note;PT Administrative note;;ACTIVE;2.58;2.58 +84333-4;Note;Find;Pt;{Setting};Doc;Multi-specialty program.nurse;DOC.ONTOLOGY;2;Multi-specialty program Nurse Note;Multi-spec prog Nurse Note;;ACTIVE;2.58;2.65 +84334-2;Note;Find;Pt;Telephone encounter;Doc;Pathology;DOC.ONTOLOGY;2;Pathology Telephone encounter Note;Pathology Phone Note;;ACTIVE;2.58;2.58 +8433-5;Intravascular systolic;Pres;Pt;Celiac trunk artery;Qn;;BP.CENT.MOLEC;2;Celiac trunk artery Systolic blood pressure;Celiac trunk a BP sys;;ACTIVE;1.0h(2);2.4 +84335-9;Note;Find;Pt;Outpatient;Doc;Pathology;DOC.ONTOLOGY;2;Pathology Outpatient Note;Pathology OP Note;;ACTIVE;2.58;2.58 +84336-7;Letter;Find;Pt;{Setting};Doc;Pathology;DOC.ONTOLOGY;2;Pathology Letter;Pathology Letter;;ACTIVE;2.58;2.58 +84337-5;Plan of care note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Plan of care note;Pastoral Care Plan of care note;;ACTIVE;2.58;2.58 +84338-3;Note;Find;Pt;Telephone encounter;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Telephone encounter Note;Pastoral Care Phone Note;;ACTIVE;2.58;2.58 +84339-1;Note;Find;Pt;{Setting};Doc;Pastoral care.team;DOC.ONTOLOGY;2;Pastoral care Team Note;Pastor care Team Note;;ACTIVE;2.58;2.58 +84340-9;Risk assessment and screening note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Risk assessment and screening note;Pastoral Care Risk assess+scrn note;;ACTIVE;2.58;2.58 +84341-7;Note;Find;Pt;Outpatient;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Outpatient Note;Pastoral Care OP Note;;ACTIVE;2.58;2.58 +84342-5;Note;Find;Pt;Long term care facility;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Long term care facility Note;Pastoral Care LTC fac Note;;ACTIVE;2.58;2.58 +8434-3;Intravascular systolic;Pres;Pt;Coronary sinus;Qn;;BP.CENT.MOLEC;2;Coronary sinus Systolic blood pressure;CS BP sys;;ACTIVE;1.0h(2);2.4 +84343-3;Note;Find;Pt;Hospital;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Hospital Note;Pastoral Care Hosp Note;;ACTIVE;2.58;2.58 +84344-1;Initial evaluation note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Initial evaluation note;Pastoral Care Initial eval note;;ACTIVE;2.58;2.58 +84345-8;Note;Find;Pt;Patient's home;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Patient's home Note;Pastoral Care Pt's home Note;;ACTIVE;2.58;2.58 +84346-6;Group counseling note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Group counseling note;Pastoral Care Group counseling note;;ACTIVE;2.58;2.58 +84347-4;Education note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Education note;Pastoral Care Educ note;;ACTIVE;2.58;2.58 +84348-2;Counseling note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Counseling note;Pastoral Care Counseling note;;ACTIVE;2.58;2.58 +84349-0;Consultation note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Consult note;Pastoral Care Consult note;;ACTIVE;2.58;2.58 +8435-0;Intravascular systolic;Pres;Pt;Ductus arteriosus;Qn;;BP.CENT.MOLEC;2;Ductus arteriosus Systolic blood pressure;DA BP sys;;ACTIVE;1.0h(2);2.4 +84350-8;Note;Find;Pt;Telephone encounter;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Telephone encounter Note;Palliative care Phone Note;;ACTIVE;2.58;2.58 +84351-6;Note;Find;Pt;{Setting};Doc;Palliative care.team;DOC.ONTOLOGY;2;Palliative care Team Note;Palltv care Team Note;;ACTIVE;2.58;2.58 +84352-4;Consultation note;Find;Pt;{Setting};Doc;Palliative care.team;DOC.ONTOLOGY;2;Palliative care Team Consult note;Palltv care Team Consult note;;ACTIVE;2.58;2.58 +84353-2;Risk assessment and screening note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Risk assessment and screening note;Palliative care Risk assess+scrn note;;ACTIVE;2.58;2.58 +84354-0;Note;Find;Pt;{Setting};Doc;Palliative care.pharmacist;DOC.ONTOLOGY;2;Palliative care Pharmacist Note;Palltv care Pharmacist Note;;ACTIVE;2.58;2.58 +84355-7;Note;Find;Pt;Outpatient;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Outpatient Note;Palliative care OP Note;;ACTIVE;2.58;2.58 +84356-5;Note;Find;Pt;Long term care facility;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Long term care facility Note;Palliative care LTC fac Note;;ACTIVE;2.58;2.58 +84357-3;Note;Find;Pt;Patient's home;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Patient's home Note;Palliative care Pt's home Note;;ACTIVE;2.58;2.58 +84358-1;Consultation note;Find;Pt;Patient's home;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Patient's home Consult note;Palliative care Pt's home Consult note;;ACTIVE;2.58;2.58 +84359-9;Group counseling note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Group counseling note;Palliative care Group counseling note;;ACTIVE;2.58;2.58 +84360-7;Counseling note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Counseling note;Palliative care Counseling note;;ACTIVE;2.58;2.58 +84361-5;Note;Find;Pt;Outpatient;Doc;Interdisciplinary;DOC.ONTOLOGY;2;Interdisciplinary Outpatient Note;Interdiscip OP Note;;ACTIVE;2.58;2.58 +84362-3;Note;Find;Pt;Telephone encounter;Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Telephone encounter Note;Otolaryngology Phone Note;;ACTIVE;2.58;2.58 +84363-1;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Postoperative evaluation and management note;Otolaryngology Post-op E/M note;;ACTIVE;2.58;2.58 +84364-9;Note;Find;Pt;Outpatient;Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Outpatient Note;Otolaryngology OP Note;;ACTIVE;2.58;2.58 +84365-6;Note;Find;Pt;Hospital;Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Hospital Note;Otolaryngology Hosp Note;;ACTIVE;2.58;2.58 +84366-4;History and physical note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology History and physical note;Otolaryngology H&P note;;ACTIVE;2.58;2.58 +84367-2;Discharge summary note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Discharge summary;Otolaryngology D/C sum;;ACTIVE;2.58;2.73 +8436-8;Intravascular systolic;Pres;Pt;Hepatic artery;Qn;;BP.CENT.MOLEC;2;Hepatic artery Systolic blood pressure;Hep a BP sys;;ACTIVE;1.0h(2);2.4 +84368-0;Admission evaluation note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Admission evaluation note;Otolaryngology Admit eval note;;ACTIVE;2.58;2.58 +84369-8;Note;Find;Pt;Telephone encounter;Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Telephone encounter Note;Orthotics prosthetics Phone Note;;ACTIVE;2.58;2.58 +84370-6;Note;Find;Pt;Outpatient;Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Outpatient Note;Orthotics prosthetics OP Note;;ACTIVE;2.58;2.58 +84371-4;Note;Find;Pt;Patient's home;Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Patient's home Note;Orthotics prosthetics Pt's home Note;;ACTIVE;2.58;2.58 +84372-2;Education note;Find;Pt;{Setting};Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Education note;Orthotics prosthetics Educ note;;ACTIVE;2.58;2.58 +84373-0;Note;Find;Pt;Telephone encounter;Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Telephone encounter Note;Orthopaedic surgery Phone Note;;ACTIVE;2.58;2.58 +84374-8;Procedure note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery procedure note;Orthopaedic surgery Procedure note;;ACTIVE;2.58;2.58 +84375-5;Procedure note;Find;Pt;Outpatient;Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Outpatient procedure note;Orthopaedic surgery OP Procedure note;;ACTIVE;2.58;2.58 +8437-6;Intravascular systolic;Pres;Pt;Mesenteric artery;Qn;;BP.CENT.MOLEC;2;Mesenteric artery Systolic blood pressure;Mesenteric a BP sys;;ACTIVE;1.0h(2);2.4 +84376-3;Note;Find;Pt;Outpatient;Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Outpatient Note;Orthopaedic surgery OP Note;;ACTIVE;2.58;2.58 +84377-1;Note;Find;Pt;Hospital;Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Hospital Note;Orthopaedic surgery Hosp Note;;ACTIVE;2.58;2.58 +84378-9;Admission evaluation note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Admission evaluation note;Orthopaedic surgery Admit eval note;;ACTIVE;2.58;2.58 +84379-7;Procedure note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery procedure note;OMS Procedure note;;ACTIVE;2.58;2.58 +84380-5;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Postoperative evaluation and management note;OMS Post-op E/M note;;ACTIVE;2.58;2.58 +84381-3;Note;Find;Pt;Outpatient;Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Outpatient Note;OMS OP Note;;ACTIVE;2.58;2.58 +84382-1;Admission evaluation note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Admission evaluation note;OMS Admit eval note;;ACTIVE;2.58;2.58 +84383-9;Note;Find;Pt;Telephone encounter;Doc;Optometry;DOC.ONTOLOGY;2;Optometry Telephone encounter Note;Optometry Phone Note;;ACTIVE;2.58;2.58 +8438-4;Intravascular systolic;Pres;Pt;Inferior mesenteric artery;Qn;;BP.CENT.MOLEC;2;Inferior mesenteric artery Systolic blood pressure;IM a BP sys;;ACTIVE;1.0h(2);2.4 +84384-7;Note;Find;Pt;Outpatient;Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Outpatient Note;OBGYN OP Note;;DISCOURAGED;2.58;2.64 +84385-4;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Postoperative evaluation and management note;OBGYN Post-op E/M note;;DISCOURAGED;2.58;2.64 +84386-2;Note;Find;Pt;Telephone encounter;Doc;Obstetrics and Gynecology;DOC.ONTOLOGY;2;Obstetrics and Gynecology Telephone encounter Note;OBGYN Phone Note;;DISCOURAGED;2.58;2.64 +84387-0;Admission evaluation note;Find;Pt;Observation unit;Doc;{Role};DOC.ONTOLOGY;2;Observation unit Admission evaluation note;Obs Unit Admit eval note;;ACTIVE;2.58;2.58 +84388-8;Admission evaluation note;Find;Pt;{Setting};Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine Admission evaluation note;Occup med Admit eval note;;ACTIVE;2.58;2.58 +84389-6;Note;Find;Pt;{Setting};Doc;Occupational medicine.nurse;DOC.ONTOLOGY;2;Occupational medicine Nurse Note;Occup med Nurse Note;;ACTIVE;2.58;2.58 +84390-4;Note;Find;Pt;Outpatient;Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine Outpatient Note;Occup med OP Note;;ACTIVE;2.58;2.58 +84391-2;Procedure note;Find;Pt;{Setting};Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine procedure note;Occup med Procedure note;;ACTIVE;2.58;2.58 +8439-2;Intravascular systolic;Pres;Pt;Superior mesenteric artery;Qn;;BP.CENT.MOLEC;2;Superior mesenteric artery Systolic blood pressure;SM a BP sys;;ACTIVE;1.0h(2);2.4 +84392-0;Note;Find;Pt;Telephone encounter;Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine Telephone encounter Note;Occup med Phone Note;;ACTIVE;2.58;2.58 +84393-8;Discharge summary note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Discharge summary;OT D/C sum;;ACTIVE;2.58;2.73 +84394-6;Consultation note;Find;Pt;Patient's home;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Patient's home Consult note;OT Pt's home Consult note;;ACTIVE;2.58;2.58 +84395-3;Initial evaluation note;Find;Pt;Patient's home;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Patient's home Initial evaluation note;OT Pt's home Initial eval note;;ACTIVE;2.58;2.58 +84396-1;Note;Find;Pt;Patient's home;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Patient's home Note;OT Pt's home Note;;ACTIVE;2.58;2.58 +84397-9;Note;Find;Pt;Hospital;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Hospital Note;OT Hosp Note;;ACTIVE;2.58;2.58 +84398-7;Consultation note;Find;Pt;Long term care facility;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Long term care facility Consult note;OT LTC fac Consult note;;ACTIVE;2.58;2.58 +84399-5;Note;Find;Pt;Long term care facility;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Long term care facility Note;OT LTC fac Note;;ACTIVE;2.58;2.58 +84-4;Cefaclor;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefaclor [Susceptibility] by Minimum inhibitory concentration (MIC);Cefaclor Islt MIC;;ACTIVE;1.0;2.73 +8440-0;Intravascular systolic;Pres;Pt;Pulmonary artery;Qn;;BP.CENT.MOLEC;2;Pulmonary artery Systolic blood pressure;PA BP sys;;ACTIVE;1.0h(2);2.73 +84400-1;Note;Find;Pt;Outpatient;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Outpatient Note;OT OP Note;;ACTIVE;2.58;2.58 +84401-9;Risk assessment and screening note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Risk assessment and screening note;OT Risk assess+scrn note;;ACTIVE;2.58;2.58 +84402-7;Note;Find;Pt;Telephone encounter;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Telephone encounter Note;OT Phone Note;;ACTIVE;2.58;2.58 +84403-5;Note;Find;Pt;{Setting};Doc;Multi-specialty program.case manager;DOC.ONTOLOGY;2;Multi-specialty program Case manager Note;Multi-spec prog Case mgr Note;;ACTIVE;2.58;2.65 +84404-3;Note;Find;Pt;Telephone encounter;Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Telephone encounter Note;Multi-spec prog Phone Note;;ACTIVE;2.58;2.58 +84405-0;Admission evaluation note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Admission evaluation note;Ophthalmol Admit eval note;;ACTIVE;2.58;2.58 +84406-8;Diagram;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Diagram;Ophthalmol Diagram;;ACTIVE;2.58;2.58 +84407-6;Note;Find;Pt;Hospital;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Hospital Note;Ophthalmol Hosp Note;;ACTIVE;2.58;2.58 +84408-4;Procedure note;Find;Pt;Outpatient;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Outpatient procedure note;Ophthalmol OP Procedure note;;ACTIVE;2.58;2.58 +84409-2;Note;Find;Pt;{Setting};Doc;Ophthalmology.technician;DOC.ONTOLOGY;2;Ophthalmology Technician Note;Ophthal Tech Note;;ACTIVE;2.58;2.58 +844-1;A1 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A1 Ag [Presence] on Red Blood Cells;A1 Ag RBC Ql;;ACTIVE;1.0;2.73 +84410-0;Note;Find;Pt;Telephone encounter;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Telephone encounter Note;Ophthalmol Phone Note;;ACTIVE;2.58;2.58 +84411-8;Note;Find;Pt;Outpatient;Doc;Optometry;DOC.ONTOLOGY;2;Optometry Outpatient Note;Optometry OP Note;;ACTIVE;2.58;2.58 +84412-6;Risk assessment and screening note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Risk assessment and screening note;Ophthalmol Risk assess+scrn note;;ACTIVE;2.58;2.58 +84413-4;Genotype display name;Find;Pt;^Patient;Nom;;MOLPATH;1;Genotype display name;Genotype name Patient;;TRIAL;2.58;2.72 +84414-2;Haplotype name;ID;Pt;Bld/Tiss;Nom;;MOLPATH;1;Haplotype name;Haplotype name Bld/T;;TRIAL;2.58;2.58 +84415-9;2-minute Walk Endurance Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;2-minute Walk Endurance Test - scale score fully adjusted [NIH Toolbox];2 min walk test score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84416-7;Grip Strength Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;Hand.dominant;Qn;NIH Toolbox;NIH.MOTOR;2;Grip Strength Test - scale score fully adjusted Hand.dominant [NIH Toolbox];Grip scale score full adj Hand.dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84417-5;Grip Strength Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;Hand.non-dominant;Qn;NIH Toolbox;NIH.MOTOR;2;Grip Strength Test - scale score fully adjusted Hand.non-dominant [NIH Toolbox];Grip scale scr full adj Hand.non-dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +8441-8;Intravascular systolic;Pres;Pt;Pulmonary artery.left;Qn;;BP.CENT.MOLEC;2;Left pulmonary artery Systolic blood pressure;PA-L BP sys;;ACTIVE;1.0h(2);2.54 +84418-3;Grip Strength Test - unadjusted scale score;Score;Pt;Hand.dominant;Qn;NIH Toolbox;NIH.MOTOR;2;Grip Strength Test - unadjusted scale score Hand.dominant [NIH Toolbox];Grip unadj score Hand.dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84419-1;Grip Strength Test - national percentile;Prctl;Pt;Hand.dominant;Qn;NIH Toolbox;NIH.MOTOR;2;Grip Strength Test - national percentile Hand.dominant [NIH Toolbox];Grip national prctl Hand.dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84420-9;2-minute Walk Endurance Test - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;2-minute Walk Endurance Test - national percentile [NIH Toolbox];2 min walk national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84421-7;Standing Balance Test - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Standing Balance Test - unadjusted scale score [NIH Toolbox];Balance unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84422-5;Standing Balance Test - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Standing Balance Test - scale score age adjusted [NIH Toolbox];Balance score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84423-3;Standing Balance Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Standing Balance Test - scale score fully adjusted [NIH Toolbox];Balance score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84424-1;Standing Balance Test - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Standing Balance Test - national percentile [NIH Toolbox];Standing balance national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84425-8;9-Hole Pegboard Dexterity - scale score^^adjusted for age;Score;Pt;Hand.non-dominant;Qn;NIH Toolbox;NIH.MOTOR;2;9-Hole Pegboard Dexterity - scale score age adjusted Hand.non-dominant [NIH Toolbox];Pegboard age-adj Hand.non-dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8442-6;Intravascular systolic;Pres;Pt;Pulmonary artery.right;Qn;;BP.CENT.MOLEC;2;Right pulmonary artery Systolic blood pressure;PA-R BP sys;;ACTIVE;1.0h(2);2.54 +84426-6;9-Hole Pegboard Dexterity - scale score^^adjusted for age;Score;Pt;Hand.dominant;Qn;NIH Toolbox;NIH.MOTOR;2;9-Hole Pegboard Dexterity - scale score age adjusted Hand.dominant [NIH Toolbox];Pegboard age-adj Hand.dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84427-4;9-Hole Pegboard Dexterity - unadjusted scale score;Score;Pt;Hand.dominant;Qn;NIH Toolbox;NIH.MOTOR;2;9-Hole Pegboard Dexterity - unadjusted scale score Hand.dominant [NIH Toolbox];9 hold peg unadj score Hand.dom NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84428-2;National EMS Information System - version 3 set;-;Pt;{Setting};-;;PANEL.NEMSIS;2;National EMS Information System - version 3 set;NEMSIS v3 set;;ACTIVE;2.58;2.72 +84429-0;Level 3 emergency medical services patient care report - recommended CDA R1 & R2 set;-;Pt;{Setting};-;;PANEL.DOC;2;Level 3 emergency medical services patient care report - recommended CDA R1 and R2 set;L3 EMS Pt Care Rpt CDA R1+R2 set;;ACTIVE;2.58;2.72 +84430-8;Note;Find;Pt;{Setting};Doc;Occupational therapy.interdisciplinary;DOC.ONTOLOGY;2;Occupational therapy Interdisciplinary Note;OT Interdiscip Note;;ACTIVE;2.58;2.58 +84431-6;Note;Find;Pt;{Setting};Doc;Optometry.technician;DOC.ONTOLOGY;2;Optometry Technician Note;Optometry Tech Note;;ACTIVE;2.58;2.58 +84432-4;Dimensional Change Card Sort Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.COGNITIVE;2;Dimensional Change Card Sort Test [NIH Toolbox];DCCS NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84433-2;Flanker Inhibitory Control and Attention Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.COGNITIVE;2;Flanker Inhibitory Control and Attention Test [NIH Toolbox];Flanker Attention Test NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8443-4;Intravascular systolic;Pres;Pt;Renal artery.left;Qn;;BP.CENT.MOLEC;2;Renal artery - left Systolic blood pressure;Renal a-L BP sys;;ACTIVE;1.0h(2);2.4 +84434-0;List Sorting Working Memory Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.COGNITIVE;2;List Sorting Working Memory Test [NIH Toolbox];List Sorting Working Memory Test NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84435-7;Oral Reading Recognition Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.COGNITIVE;2;Oral Reading Recognition Test [NIH Toolbox];Oral reading NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.73 +84436-5;Pattern Comparison Processing Speed Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.COGNITIVE;2;Pattern Comparison Processing Speed Test [NIH Toolbox];Pattern comparison NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84437-3;Picture Sequence Memory Test;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.COGNITIVE;2;Picture Sequence Memory Test [NIH Toolbox];Picture Sequence Memory Test NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84438-1;Picture Vocabulary Test - English;-;Pt;^Patient;-;NIH Toolbox;PANEL.NIH.COGNITIVE;2;Picture Vocabulary Test - English [NIH Toolbox];PVT NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84439-9;Picture Sequence Memory Test - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Sequence Memory Test - national percentile [NIH Toolbox];Picture memory national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84440-7;Picture Sequence Memory Test - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Sequence Memory Test - scale score age adjusted [NIH Toolbox];Picture memory score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84441-5;Picture Sequence Memory Test - computed score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Sequence Memory Test - computed score [NIH Toolbox];Picture memory - computed score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8444-2;Intravascular systolic;Pres;Pt;Renal artery.right;Qn;;BP.CENT.MOLEC;2;Renal artery - right Systolic blood pressure;Renal a-R BP sys;;ACTIVE;1.0h(2);2.4 +84442-3;Picture Sequence Memory Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Sequence Memory Test - scale score fully adjusted [NIH Toolbox];Picture memory score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84443-1;Picture Sequence Memory Test - raw score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Sequence Memory Test - raw score [NIH Toolbox];Picture memory - raw score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84444-9;Picture Sequence Memory Test - theta score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Sequence Memory Test - theta score [NIH Toolbox];Picture memory - theta score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84445-6;Picture Sequence Memory Test - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Sequence Memory Test - unadjusted scale score [NIH Toolbox];Picture memory - unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84446-4;Picture Vocabulary Test - English - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Vocabulary Test - English - national percentile [NIH Toolbox];PVT national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84447-2;Picture Vocabulary Test - English - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Vocabulary Test - English - scale score age adjusted [NIH Toolbox];PVT score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84448-0;Picture Vocabulary Test - English - computed score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Vocabulary Test - English - computed score [NIH Toolbox];PVT - computed score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84449-8;Picture Vocabulary Test - English - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Vocabulary Test - English - scale score fully adjusted [NIH Toolbox];PVT score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84450-6;Picture Vocabulary Test - English - theta score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Vocabulary Test - English - theta score [NIH Toolbox];PVT - theta score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84451-4;Picture Vocabulary Test - English - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Picture Vocabulary Test - English - unadjusted scale score [NIH Toolbox];PVT - unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84452-2;Dimensional Change Card Sort Test - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Dimensional Change Card Sort Test - national percentile [NIH Toolbox];DCCS national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84453-0;Dimensional Change Card Sort Test - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Dimensional Change Card Sort Test - scale score age adjusted [NIH Toolbox];DCCS score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84454-8;Dimensional Change Card Sort Test - computed score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Dimensional Change Card Sort Test - computed score [NIH Toolbox];DCCS - computed score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84455-5;Dimensional Change Card Sort Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Dimensional Change Card Sort Test - scale score fully adjusted [NIH Toolbox];DCCS score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84456-3;Dimensional Change Card Sort Test - raw score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Dimensional Change Card Sort Test - raw score [NIH Toolbox];DCCS - raw score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84457-1;Dimensional Change Card Sort Test - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Dimensional Change Card Sort Test - unadjusted scale score [NIH Toolbox];DCCS - unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84458-9;Able to point to the letter b;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Able to point to the letter b [NIH Toolbox];Point to b NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8445-9;Intravascular systolic;Pres;Pt;Splenic artery;Qn;;BP.CENT.MOLEC;2;Splenic artery Systolic blood pressure;Splenic a BP sys;;ACTIVE;1.0h(2);2.4 +84459-7;Able to point to the letter e;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Able to point to the letter e [NIH Toolbox];Point to e NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84460-5;Able to point to the letter D;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Able to point to the letter D [NIH Toolbox];Point to D NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84461-3;Able to point to the letter S;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Able to point to the letter S [NIH Toolbox];Point to S NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84462-1;Can pronounce potable;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce potable [NIH Toolbox];Pronounce potable NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84463-9;Flanker Inhibitory Control and Attention Test - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Flanker Inhibitory Control and Attention Test - national percentile [NIH Toolbox];Flanker national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84464-7;Flanker Inhibitory Control and Attention Test - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Flanker Inhibitory Control and Attention Test - scale score age adjusted [NIH Toolbox];Flanker score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84465-4;Flanker Inhibitory Control and Attention Test - computed score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Flanker Inhibitory Control and Attention Test - computed score [NIH Toolbox];Flanker - computed score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84466-2;Flanker Inhibitory Control and Attention Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Flanker Inhibitory Control and Attention Test - scale score fully adjusted [NIH Toolbox];Flanker score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +8446-7;Intravascular diastolic^expiration;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure--expiration;BP dias--exp;;ACTIVE;1.0h(2);2.4 +84467-0;Flanker Inhibitory Control and Attention Test - raw score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Flanker Inhibitory Control and Attention Test - raw score [NIH Toolbox];Flanker - raw score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84468-8;Flanker Inhibitory Control and Attention Test - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Flanker Inhibitory Control and Attention Test - unadjusted scale score [NIH Toolbox];Flanker - unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84469-6;Can pronounce ballistics;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ballistics [NIH Toolbox];Pronounce ballistics NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84470-4;Can pronounce nihilism;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce nihilism [NIH Toolbox];Pronounce nihilism NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84471-2;List Sorting Working Memory Test - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;List Sorting Working Memory Test - national percentile [NIH Toolbox];List sorting national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84472-0;List Sorting Working Memory Test - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;List Sorting Working Memory Test - scale score age adjusted [NIH Toolbox];List sorting score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84473-8;List Sorting Working Memory Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;List Sorting Working Memory Test - scale score fully adjusted [NIH Toolbox];List sorting score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84474-6;List Sorting Working Memory Test - raw score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;List Sorting Working Memory Test - raw score [NIH Toolbox];List sorting - raw score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8447-5;Intravascular diastolic^inspiration;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure--inspiration;BP dias--insp;;ACTIVE;1.0h(2);2.4 +84475-3;List Sorting Working Memory Test - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;List Sorting Working Memory Test - unadjusted scale score [NIH Toolbox];List sorting - unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84476-1;Oral Reading Recognition Test - English - national percentile;Prctl;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Oral Reading Recognition Test - English - national percentile [NIH Toolbox];Oral reading national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84477-9;Oral Reading Recognition Test - English - computed score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Oral Reading Recognition Test - English - computed score [NIH Toolbox];Oral reading - computed score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84478-7;Oral Reading Recognition Test - English - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Oral Reading Recognition Test - English - scale score fully adjusted [NIH Toolbox];Oral reading score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84479-5;Oral Reading Recognition Test - English - theta score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Oral Reading Recognition Test - English - theta score [NIH Toolbox];Oral reading - theta score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84480-3;Oral Reading Recognition Test - English - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Oral Reading Recognition Test - English - scale score age adjusted [NIH Toolbox];Oral reading score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84481-1;Oral Reading Recognition Test - English - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Oral Reading Recognition Test - English - unadjusted scale score [NIH Toolbox];Oral reading - unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84482-9;Can pronounce pat;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pat [NIH Toolbox];Pronounce pat NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8448-3;Intravascular mean^expiration;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Mean blood pressure--expiration;BP mean--exp;;ACTIVE;1.0h(2);2.4 +84483-7;Pattern Comparison Processing Speed Test - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Pattern Comparison Processing Speed Test - national percentile [NIH Toolbox];Pattern comparison national prctl NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84484-5;Pattern Comparison Processing Speed Test - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Pattern Comparison Processing Speed Test - scale score age adjusted [NIH Toolbox];Pattern comparison score age-adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84485-2;Pattern Comparison Processing Speed Test - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Pattern Comparison Processing Speed Test - scale score fully adjusted [NIH Toolbox];Pattern comparison score full adj NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.66 +84486-0;Pattern Comparison Processing Speed Test - raw score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Pattern Comparison Processing Speed Test - raw score [NIH Toolbox];Pattern comparison - raw score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84487-8;Pattern Comparison Processing Speed Test - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;NIH.COGNITIVE;2;Pattern Comparison Processing Speed Test - unadjusted scale score [NIH Toolbox];Pattern comparison - unadj score NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84488-6;Can pronounce abate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce abate [NIH Toolbox];Pronounce abate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84489-4;Can pronounce ablation;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ablation [NIH Toolbox];Pronounce ablation NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84490-2;Can pronounce about;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce about [NIH Toolbox];Pronounce about NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8449-1;Intravascular mean^inspiration;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Mean blood pressure--inspiration;BP mean--insp;;ACTIVE;1.0h(2);2.4 +84491-0;Can pronounce abstemiously;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce abstemiously [NIH Toolbox];Pronounce abstemiously NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84492-8;Can pronounce abysm;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce abysm [NIH Toolbox];Pronounce abysm NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84493-6;Can pronounce amicability;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce amicability [NIH Toolbox];Pronounce amicability NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84494-4;Can pronounce bad;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce bad [NIH Toolbox];Pronounce bad NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84495-1;Can pronounce band;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce band [NIH Toolbox];Pronounce band NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84496-9;Can pronounce bank;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce bank [NIH Toolbox];Pronounce bank NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84497-7;Can pronounce be;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce be [NIH Toolbox];Pronounce be NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84498-5;Can pronounce beau;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce beau [NIH Toolbox];Pronounce beau NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84499-3;Can pronounce beguile;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce beguile [NIH Toolbox];Pronounce beguile NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84500-8;Can pronounce belie;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce belie [NIH Toolbox];Pronounce belie NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84501-6;Can pronounce belligerent;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce belligerent [NIH Toolbox];Pronounce belligerent NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84502-4;Can pronounce bet;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce bet [NIH Toolbox];Pronounce bet NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84503-2;Can pronounce biscuit;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce biscuit [NIH Toolbox];Pronounce biscuit NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84504-0;Can pronounce both;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce both [NIH Toolbox];Pronounce both NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84505-7;Can pronounce box;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce box [NIH Toolbox];Pronounce box NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84506-5;Can pronounce brobdingnagian;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce brobdingnagian [NIH Toolbox];Pronounce brobdingnagian NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84507-3;Can pronounce bucolic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce bucolic [NIH Toolbox];Pronounce bucolic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84508-1;Can pronounce bureau;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce bureau [NIH Toolbox];Pronounce bureau NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8450-9;Intravascular systolic^expiration;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure--expiration;BP sys--exp;;ACTIVE;1.0h(2);2.4 +84509-9;Can pronounce cucurbitaceous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce cucurbitaceous [NIH Toolbox];Pronounce cucurbitaceous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84510-7;Can pronounce debauchery;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce debauchery [NIH Toolbox];Pronounce debauchery NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84511-5;Can pronounce dissolubility;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce dissolubility [NIH Toolbox];Pronounce dissolubility NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84512-3;Can pronounce exacerbating;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce exacerbating [NIH Toolbox];Pronounce exacerbating NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84513-1;Can pronounce hyperbole;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce hyperbole [NIH Toolbox];Pronounce hyperbole NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84514-9;Can pronounce imbroglio;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce imbroglio [NIH Toolbox];Pronounce imbroglio NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84515-6;Can pronounce incorrigible;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce incorrigible [NIH Toolbox];Pronounce incorrigible NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84516-4;Can pronounce indebted;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce indebted [NIH Toolbox];Pronounce indebted NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8451-7;Intravascular systolic^inspiration;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure--inspiration;BP sys--insp;;ACTIVE;1.0h(2);2.4 +84517-2;Can pronounce irrevocability;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce irrevocability [NIH Toolbox];Pronounce irrevocability NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84518-0;Can pronounce libel;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce libel [NIH Toolbox];Pronounce libel NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84519-8;Can pronounce lugubriousness;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce lugubriousness [NIH Toolbox];Pronounce lugubriousness NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84520-6;Can pronounce obsequious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce obsequious [NIH Toolbox];Pronounce obsequious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84521-4;Can pronounce ostensibly;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ostensibly [NIH Toolbox];Pronounce ostensibly NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84522-2;Can pronounce subjugate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce subjugate [NIH Toolbox];Pronounce subjugate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84523-0;Can pronounce tenebrous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce tenebrous [NIH Toolbox];Pronounce tenebrous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84524-8;Can pronounce adjudicate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce adjudicate [NIH Toolbox];Pronounce adjudicate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8452-5;Intravascular systolic.inspiration - expiration;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure.inspiration - expiration;BP sys Insp-Exp;;ACTIVE;1.0h(2);2.4 +84525-5;Can pronounce androgynous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce androgynous [NIH Toolbox];Pronounce androgynous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84526-3;Can pronounce credulous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce credulous [NIH Toolbox];Pronounce credulous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84527-1;Can pronounce cylindrical;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce cylindrical [NIH Toolbox];Pronounce cylindrical NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84528-9;Can pronounce d;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce d [NIH Toolbox];Pronounce d NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84529-7;Can pronounce deferential;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce deferential [NIH Toolbox];Pronounce deferential NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84530-5;Can pronounce deliquescence;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce deliquescence [NIH Toolbox];Pronounce deliquescence NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84531-3;Can pronounce demur;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce demur [NIH Toolbox];Pronounce demur NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84532-1;Can pronounce deny;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce deny [NIH Toolbox];Pronounce deny NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8453-3;Intravascular diastolic^sitting;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Diastolic blood pressure--sitting;BP dias--sitting;;ACTIVE;1.0h(2);2.73 +84533-9;Can pronounce diamantiferous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce diamantiferous [NIH Toolbox];Pronounce diamantiferous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84534-7;Can pronounce did;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce did [NIH Toolbox];Pronounce did NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84535-4;Can pronounce dilemma;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce dilemma [NIH Toolbox];Pronounce dilemma NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84536-2;Can pronounce doctrine;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce doctrine [NIH Toolbox];Pronounce doctrine NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84537-0;Can pronounce dodecahedral;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce dodecahedral [NIH Toolbox];Pronounce dodecahedral NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84538-8;Can pronounce dolorific;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce dolorific [NIH Toolbox];Pronounce dolorific NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84539-6;Can pronounce doting;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce doting [NIH Toolbox];Pronounce doting NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84540-4;Can pronounce dowager;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce dowager [NIH Toolbox];Pronounce dowager NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8454-1;Intravascular diastolic^standing;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Diastolic blood pressure--standing;BP dias--stand;;ACTIVE;1.0h(2);2.73 +84541-2;Can pronounce during;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce during [NIH Toolbox];Pronounce during NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84542-0;Can pronounce edict;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce edict [NIH Toolbox];Pronounce edict NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84543-8;Can pronounce feed;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce feed [NIH Toolbox];Pronounce feed NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84544-6;Can pronounce gold;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce gold [NIH Toolbox];Pronounce gold NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84545-3;Can pronounce imparidigitate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce imparidigitate [NIH Toolbox];Pronounce imparidigitate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84546-1;Can pronounce innuendo;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce innuendo [NIH Toolbox];Pronounce innuendo NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84547-9;Can pronounce laid;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce laid [NIH Toolbox];Pronounce laid NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84548-7;Can pronounce pedagogue;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pedagogue [NIH Toolbox];Pronounce pedagogue NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84549-5;Can pronounce platitudinous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce platitudinous [NIH Toolbox];Pronounce platitudinous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84550-3;Can pronounce preponderance;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce preponderance [NIH Toolbox];Pronounce preponderance NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84551-1;Can pronounce pseudonym;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pseudonym [NIH Toolbox];Pronounce pseudonym NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84552-9;Can pronounce recrudescence;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce recrudescence [NIH Toolbox];Pronounce recrudescence NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84553-7;Can pronounce repudiate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce repudiate [NIH Toolbox];Pronounce repudiate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84554-5;Can pronounce sedate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce sedate [NIH Toolbox];Pronounce sedate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84555-2;Can pronounce sesquipedalian;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce sesquipedalian [NIH Toolbox];Pronounce sesquipedalian NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84556-0;Can pronounce side;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce side [NIH Toolbox];Pronounce side NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84557-8;Can pronounce stevedore;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce stevedore [NIH Toolbox];Pronounce stevedore NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8455-8;Intravascular diastolic^supine;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Diastolic blood pressure--supine;BP dias--sup;;ACTIVE;1.0h(2);2.73 +84558-6;Can pronounce synechdochism;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce synechdochism [NIH Toolbox];Pronounce synechdochism NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84559-4;Can pronounce valedictory;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce valedictory [NIH Toolbox];Pronounce valedictory NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84560-2;Can pronounce valetudinarian;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce valetudinarian [NIH Toolbox];Pronounce valetudinarian NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84561-0;Can pronounce verisimilitude;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce verisimilitude [NIH Toolbox];Pronounce verisimilitude NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84562-8;Can pronounce vicissitude;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce vicissitude [NIH Toolbox];Pronounce vicissitude NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84563-6;Can pronounce would;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce would [NIH Toolbox];Pronounce would NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84564-4;Can pronounce amplify;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce amplify [NIH Toolbox];Pronounce amplify NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84565-1;Can pronounce circumference;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce circumference [NIH Toolbox];Pronounce circumference NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8456-6;Intravascular mean^sitting;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Mean blood pressure--sitting;BP mean--sitting;;ACTIVE;1.0h(2);2.73 +84566-9;Can pronounce effete;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce effete [NIH Toolbox];Pronounce effete NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84567-7;Can pronounce effigial;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce effigial [NIH Toolbox];Pronounce effigial NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84568-5;Can pronounce facetious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce facetious [NIH Toolbox];Pronounce facetious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84569-3;Can pronounce fascist;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce fascist [NIH Toolbox];Pronounce fascist NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84570-1;Can pronounce fenestration;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce fenestration [NIH Toolbox];Pronounce fenestration NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84571-9;Can pronounce flux;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce flux [NIH Toolbox];Pronounce flux NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84572-7;Can pronounce fly;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce fly [NIH Toolbox];Pronounce fly NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84573-5;Can pronounce foment;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce foment [NIH Toolbox];Pronounce foment NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8457-4;Intravascular mean^standing;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Mean blood pressure--standing;BP mean--stand;;ACTIVE;1.0h(2);2.73 +84574-3;Can pronounce for;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce for [NIH Toolbox];Pronounce for NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84575-0;Can pronounce forisfamiliate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce forisfamiliate [NIH Toolbox];Pronounce forisfamiliate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84576-8;Can pronounce fringillaceous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce fringillaceous [NIH Toolbox];Pronounce fringillaceous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84577-6;Can pronounce fumigant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce fumigant [NIH Toolbox];Pronounce fumigant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84578-4;Can pronounce perfunctorily;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce perfunctorily [NIH Toolbox];Pronounce perfunctorily NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84579-2;Can pronounce safe;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce safe [NIH Toolbox];Pronounce safe NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +845-8;A1 B Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated A1 B Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated A1 B Ab SerPl BPU Ql;;DEPRECATED;1.0;2.4 +84580-0;Can pronounce saxifragaceous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce saxifragaceous [NIH Toolbox];Pronounce saxifragaceous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84581-8;Can pronounce stifle;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce stifle [NIH Toolbox];Pronounce stifle NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8458-2;Intravascular mean^supine;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Mean blood pressure--supine;BP mean--sup;;ACTIVE;1.0h(2);2.73 +84582-6;Can pronounce suffrutescent;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce suffrutescent [NIH Toolbox];Pronounce suffrutescent NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84583-4;Can pronounce of;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce of [NIH Toolbox];Pronounce of NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84584-2;Can pronounce achromatism;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce achromatism [NIH Toolbox];Pronounce achromatism NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84585-9;Can pronounce aesthetic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce aesthetic [NIH Toolbox];Pronounce aesthetic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84586-7;Can pronounce anachronistic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce anachronistic [NIH Toolbox];Pronounce anachronistic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84587-5;Can pronounce apocryphal;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce apocryphal [NIH Toolbox];Pronounce apocryphal NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84588-3;Can pronounce chassis;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce chassis [NIH Toolbox];Pronounce chassis NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84589-1;Can pronounce choreographer;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce choreographer [NIH Toolbox];Pronounce choreographer NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8459-0;Intravascular systolic^sitting;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Systolic blood pressure--sitting;BP sys--sitting;;ACTIVE;1.0h(2);2.73 +84590-9;Can pronounce chorus;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce chorus [NIH Toolbox];Pronounce chorus NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84591-7;Can pronounce echelon;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce echelon [NIH Toolbox];Pronounce echelon NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84592-5;Can pronounce gingham;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce gingham [NIH Toolbox];Pronounce gingham NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84593-3;Can pronounce have;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce have [NIH Toolbox];Pronounce have NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84594-1;Can pronounce he;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce he [NIH Toolbox];Pronounce he NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84595-8;Can pronounce heat;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce heat [NIH Toolbox];Pronounce heat NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84596-6;Can pronounce her;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce her [NIH Toolbox];Pronounce her NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84597-4;Can pronounce heretic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce heretic [NIH Toolbox];Pronounce heretic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84598-2;Can pronounce heuristic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce heuristic [NIH Toolbox];Pronounce heuristic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84599-0;Can pronounce hone;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce hone [NIH Toolbox];Pronounce hone NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84600-6;Can pronounce lymph;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce lymph [NIH Toolbox];Pronounce lymph NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84601-4;Can pronounce mischievous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce mischievous [NIH Toolbox];Pronounce mischievous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84602-2;Can pronounce much;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce much [NIH Toolbox];Pronounce much NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84603-0;Can pronounce myth;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce myth [NIH Toolbox];Pronounce myth NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84604-8;Can pronounce nonchalant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce nonchalant [NIH Toolbox];Pronounce nonchalant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84605-5;Can pronounce penchant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce penchant [NIH Toolbox];Pronounce penchant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84606-3;Can pronounce plethora;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce plethora [NIH Toolbox];Pronounce plethora NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84607-1;Can pronounce rhythm;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce rhythm [NIH Toolbox];Pronounce rhythm NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8460-8;Intravascular systolic^standing;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Systolic blood pressure--standing;BP sys--stand;;ACTIVE;1.0h(2);2.73 +84608-9;Can pronounce stochastic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce stochastic [NIH Toolbox];Pronounce stochastic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84609-7;Can pronounce synthesis;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce synthesis [NIH Toolbox];Pronounce synthesis NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84610-5;Can pronounce their;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce their [NIH Toolbox];Pronounce their NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84611-3;Can pronounce these;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce these [NIH Toolbox];Pronounce these NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84612-1;Can pronounce this;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce this [NIH Toolbox];Pronounce this NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84613-9;Can pronounce tough;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce tough [NIH Toolbox];Pronounce tough NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84614-7;Can pronounce vehement;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce vehement [NIH Toolbox];Pronounce vehement NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84615-4;Can pronounce vehicular;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce vehicular [NIH Toolbox];Pronounce vehicular NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8461-6;Intravascular systolic^supine;Pres;Pt;Arterial system;Qn;;BP.PSTN.MOLEC;2;Systolic blood pressure--supine;BP sys--sup;;ACTIVE;1.0h(2);2.73 +84616-2;Can pronounce whelp;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce whelp [NIH Toolbox];Pronounce whelp NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84617-0;Can pronounce writhe;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce writhe [NIH Toolbox];Pronounce writhe NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84618-8;Can pronounce accrementitial;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce accrementitial [NIH Toolbox];Pronounce accrementitial NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84619-6;Can pronounce acolyte;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce acolyte [NIH Toolbox];Pronounce acolyte NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84620-4;Can pronounce all;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce all [NIH Toolbox];Pronounce all NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84621-2;Can pronounce allotment;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce allotment [NIH Toolbox];Pronounce allotment NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84622-0;Can pronounce annul;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce annul [NIH Toolbox];Pronounce annul NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84623-8;Can pronounce anomalous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce anomalous [NIH Toolbox];Pronounce anomalous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8462-4;Intravascular diastolic;Pres;Pt;Arterial system;Qn;;BP.ATOM;2;Diastolic blood pressure;BP dias;;ACTIVE;1.0h(2);2.73 +84624-6;Can pronounce appellate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce appellate [NIH Toolbox];Pronounce appellate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84625-3;Can pronounce cello;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce cello [NIH Toolbox];Pronounce cello NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84626-1;Can pronounce clarity;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce clarity [NIH Toolbox];Pronounce clarity NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84627-9;Can pronounce conviviality;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce conviviality [NIH Toolbox];Pronounce conviviality NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84628-7;Can pronounce ecclesiastical;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ecclesiastical [NIH Toolbox];Pronounce ecclesiastical NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84629-5;Can pronounce eclecticism;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce eclecticism [NIH Toolbox];Pronounce eclecticism NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84630-3;Can pronounce ecstatically;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ecstatically [NIH Toolbox];Pronounce ecstatically NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84631-1;Can pronounce empirical;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce empirical [NIH Toolbox];Pronounce empirical NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8463-2;Intravascular diastolic;Pres;1H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 1 hour maximum;BP dias 1h Max;;ACTIVE;1.0h(2);2.4 +84632-9;Can pronounce epilogue;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce epilogue [NIH Toolbox];Pronounce epilogue NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84633-7;Can pronounce etymological;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce etymological [NIH Toolbox];Pronounce etymological NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84634-5;Can pronounce expostulate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce expostulate [NIH Toolbox];Pronounce expostulate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84635-2;Can pronounce gel;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce gel [NIH Toolbox];Pronounce gel NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84636-0;Can pronounce gelastic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce gelastic [NIH Toolbox];Pronounce gelastic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84637-8;Can pronounce interstitial;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce interstitial [NIH Toolbox];Pronounce interstitial NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84638-6;Can pronounce lieutenant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce lieutenant [NIH Toolbox];Pronounce lieutenant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84639-4;Can pronounce liver;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce liver [NIH Toolbox];Pronounce liver NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8464-0;Intravascular diastolic;Pres;8H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 8 hour maximum;BP dias 8h Max;;ACTIVE;1.0h(2);2.4 +84640-2;Can pronounce loquacious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce loquacious [NIH Toolbox];Pronounce loquacious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84641-0;Can pronounce lull;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce lull [NIH Toolbox];Pronounce lull NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84642-8;Can pronounce magniloquently;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce magniloquently [NIH Toolbox];Pronounce magniloquently NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84643-6;Can pronounce malapropism;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce malapropism [NIH Toolbox];Pronounce malapropism NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84644-4;Can pronounce malevolence;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce malevolence [NIH Toolbox];Pronounce malevolence NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84645-1;Can pronounce manila;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce manila [NIH Toolbox];Pronounce manila NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84646-9;Can pronounce oscillating;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce oscillating [NIH Toolbox];Pronounce oscillating NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84647-7;Can pronounce palate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce palate [NIH Toolbox];Pronounce palate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84648-5;Can pronounce pale;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pale [NIH Toolbox];Pronounce pale NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84649-3;Can pronounce penultimate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce penultimate [NIH Toolbox];Pronounce penultimate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84650-1;Can pronounce pool;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pool [NIH Toolbox];Pronounce pool NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84651-9;Can pronounce pupil;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pupil [NIH Toolbox];Pronounce pupil NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84652-7;Can pronounce ranunculaceous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ranunculaceous [NIH Toolbox];Pronounce ranunculaceous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84653-5;Can pronounce recalcitrant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce recalcitrant [NIH Toolbox];Pronounce recalcitrant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84654-3;Can pronounce recapitulatory;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce recapitulatory [NIH Toolbox];Pronounce recapitulatory NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84655-0;Can pronounce reliquary;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce reliquary [NIH Toolbox];Pronounce reliquary NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84656-8;Can pronounce scintillating;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce scintillating [NIH Toolbox];Pronounce scintillating NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8465-7;Intravascular diastolic;Pres;10H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 10 hour maximum;BP dias 10h Max;;ACTIVE;1.0h(2);2.4 +84657-6;Can pronounce supercilious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce supercilious [NIH Toolbox];Pronounce supercilious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84658-4;Can pronounce titular;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce titular [NIH Toolbox];Pronounce titular NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84659-2;Can pronounce trestle;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce trestle [NIH Toolbox];Pronounce trestle NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +846-6;A1 B Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated A1 B Ab [Presence] on Red Blood Cells from donor;Deprecated A1 B Ab SerPl Donr Ql;;DEPRECATED;1.0;2.4 +84660-0;Can pronounce vassal;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce vassal [NIH Toolbox];Pronounce vassal NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84661-8;Can pronounce annunciating;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce annunciating [NIH Toolbox];Pronounce annunciating NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84662-6;Can pronounce antagonizing;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce antagonizing [NIH Toolbox];Pronounce antagonizing NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84663-4;Can pronounce assuage;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce assuage [NIH Toolbox];Pronounce assuage NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84664-2;Can pronounce campaign;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce campaign [NIH Toolbox];Pronounce campaign NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8466-5;Intravascular diastolic;Pres;12H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 12 hour maximum;BP dias 12h Max;;ACTIVE;1.0h(2);2.4 +84665-9;Can pronounce exaggeration;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce exaggeration [NIH Toolbox];Pronounce exaggeration NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84666-7;Can pronounce excruciating;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce excruciating [NIH Toolbox];Pronounce excruciating NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84667-5;Can pronounce germane;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce germane [NIH Toolbox];Pronounce germane NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84668-3;Can pronounce regent;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce regent [NIH Toolbox];Pronounce regent NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84669-1;Can pronounce regime;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce regime [NIH Toolbox];Pronounce regime NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84670-9;Can pronounce sanguineous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce sanguineous [NIH Toolbox];Pronounce sanguineous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84671-7;Can pronounce sergeant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce sergeant [NIH Toolbox];Pronounce sergeant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84672-5;Can pronounce zeitgeist;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce zeitgeist [NIH Toolbox];Pronounce zeitgeist NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8467-3;Intravascular diastolic;Pres;24H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 24 hour maximum;BP dias 24h Max;;ACTIVE;1.0h(2);2.4 +84673-3;Can pronounce j;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce j [NIH Toolbox];Pronounce j NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84674-1;Can pronounce joist;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce joist [NIH Toolbox];Pronounce joist NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84675-8;Can pronounce juncous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce juncous [NIH Toolbox];Pronounce juncous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84676-6;Can pronounce kayak;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce kayak [NIH Toolbox];Pronounce kayak NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84677-4;Can pronounce poky;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce poky [NIH Toolbox];Pronounce poky NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84678-2;Can pronounce rock;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce rock [NIH Toolbox];Pronounce rock NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84679-0;Can pronounce seek;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce seek [NIH Toolbox];Pronounce seek NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84680-8;Can pronounce apopemptic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce apopemptic [NIH Toolbox];Pronounce apopemptic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8468-1;Intravascular diastolic;Pres;1H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 1 hour mean;BP dias 1h Mean;;ACTIVE;1.0h(2);2.4 +84681-6;Can pronounce automatism;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce automatism [NIH Toolbox];Pronounce automatism NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84682-4;Can pronounce camp;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce camp [NIH Toolbox];Pronounce camp NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84683-2;Can pronounce imperiousness;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce imperiousness [NIH Toolbox];Pronounce imperiousness NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84684-0;Can pronounce imperspicuity;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce imperspicuity [NIH Toolbox];Pronounce imperspicuity NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84685-7;Can pronounce imprimatur;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce imprimatur [NIH Toolbox];Pronounce imprimatur NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84686-5;Can pronounce m;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce m [NIH Toolbox];Pronounce m NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84687-3;Can pronounce may;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce may [NIH Toolbox];Pronounce may NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84688-1;Can pronounce meant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce meant [NIH Toolbox];Pronounce meant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84689-9;Can pronounce men;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce men [NIH Toolbox];Pronounce men NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84690-7;Can pronounce mere;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce mere [NIH Toolbox];Pronounce mere NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84691-5;Can pronounce minion;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce minion [NIH Toolbox];Pronounce minion NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84692-3;Can pronounce munity;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce munity [NIH Toolbox];Pronounce munity NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84693-1;Can pronounce mystique;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce mystique [NIH Toolbox];Pronounce mystique NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84694-9;Can pronounce parsimonious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce parsimonious [NIH Toolbox];Pronounce parsimonious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84695-6;Can pronounce some;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce some [NIH Toolbox];Pronounce some NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84696-4;Can pronounce temerity;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce temerity [NIH Toolbox];Pronounce temerity NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84697-2;Can pronounce acquiescence;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce acquiescence [NIH Toolbox];Pronounce acquiescence NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84698-0;Can pronounce as;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce as [NIH Toolbox];Pronounce as NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8469-9;Intravascular diastolic;Pres;8H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 8 hour mean;BP dias 8h Mean;;ACTIVE;1.0h(2);2.4 +84699-8;Can pronounce circuitous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce circuitous [NIH Toolbox];Pronounce circuitous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84700-4;Can pronounce conscious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce conscious [NIH Toolbox];Pronounce conscious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84701-2;Can pronounce eccentricities;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce eccentricities [NIH Toolbox];Pronounce eccentricities NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84702-0;Can pronounce ersatz;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ersatz [NIH Toolbox];Pronounce ersatz NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84703-8;Can pronounce inauspicious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce inauspicious [NIH Toolbox];Pronounce inauspicious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84704-6;Can pronounce insinuation;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce insinuation [NIH Toolbox];Pronounce insinuation NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84705-3;Can pronounce insouciant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce insouciant [NIH Toolbox];Pronounce insouciant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84706-1;Can pronounce is;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce is [NIH Toolbox];Pronounce is NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8470-7;Intravascular diastolic;Pres;10H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 10 hour mean;BP dias 10h Mean;;ACTIVE;1.0h(2);2.4 +84707-9;Can pronounce issuant;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce issuant [NIH Toolbox];Pronounce issuant NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84708-7;Can pronounce pernicious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pernicious [NIH Toolbox];Pronounce pernicious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84709-5;Can pronounce perspicuity;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce perspicuity [NIH Toolbox];Pronounce perspicuity NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84710-3;Can pronounce pious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce pious [NIH Toolbox];Pronounce pious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84711-1;Can pronounce poser;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce poser [NIH Toolbox];Pronounce poser NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84712-9;Can pronounce reconnaissance;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce reconnaissance [NIH Toolbox];Pronounce reconnaissance NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84713-7;Can pronounce resin;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce resin [NIH Toolbox];Pronounce resin NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84714-5;Can pronounce respite;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce respite [NIH Toolbox];Pronounce respite NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8471-5;Intravascular diastolic;Pres;12H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 12 hour mean;BP dias 12h Mean;;ACTIVE;1.0h(2);2.4 +84715-2;Can pronounce s;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce s [NIH Toolbox];Pronounce s NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84716-0;Can pronounce satiety;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce satiety [NIH Toolbox];Pronounce satiety NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84717-8;Can pronounce sinew;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce sinew [NIH Toolbox];Pronounce sinew NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84718-6;Can pronounce sir;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce sir [NIH Toolbox];Pronounce sir NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84719-4;Can pronounce spa;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce spa [NIH Toolbox];Pronounce spa NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84720-2;Can pronounce stay;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce stay [NIH Toolbox];Pronounce stay NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84721-0;Can pronounce succinct;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce succinct [NIH Toolbox];Pronounce succinct NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84722-8;Can pronounce suite;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce suite [NIH Toolbox];Pronounce suite NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8472-3;Intravascular diastolic;Pres;24H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 24 hour mean;BP dias 24h Mean;;ACTIVE;1.0h(2);2.4 +84723-6;Can pronounce surreptitious;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce surreptitious [NIH Toolbox];Pronounce surreptitious NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84724-4;Can pronounce transposition;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce transposition [NIH Toolbox];Pronounce transposition NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84725-1;Can pronounce usury;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce usury [NIH Toolbox];Pronounce usury NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84726-9;Can pronounce viscera;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce viscera [NIH Toolbox];Pronounce viscera NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84727-7;Can pronounce viscous;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce viscous [NIH Toolbox];Pronounce viscous NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84728-5;Can pronounce a;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce a [NIH Toolbox];Pronounce a NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84729-3;Can pronounce ancient;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce ancient [NIH Toolbox];Pronounce ancient NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84730-1;Can pronounce any;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce any [NIH Toolbox];Pronounce any NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8473-1;Intravascular diastolic;Pres;1H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 1 hour minimum;BP dias 1h Min;;ACTIVE;1.0h(3);2.4 +84731-9;Can pronounce art;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce art [NIH Toolbox];Pronounce art NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84732-7;Can pronounce at;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce at [NIH Toolbox];Pronounce at NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84733-5;Can pronounce c;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce c [NIH Toolbox];Pronounce c NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84734-3;Can pronounce coercive;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce coercive [NIH Toolbox];Pronounce coercive NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84735-0;Can pronounce crux;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce crux [NIH Toolbox];Pronounce crux NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84736-8;Can pronounce entrepreneur;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce entrepreneur [NIH Toolbox];Pronounce entrepreneur NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84737-6;Can pronounce enunciate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce enunciate [NIH Toolbox];Pronounce enunciate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84738-4;Can pronounce era;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce era [NIH Toolbox];Pronounce era NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84739-2;Can pronounce in;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce in [NIH Toolbox];Pronounce in NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +847-4;A1 B Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated A1 B Ab;Deprecated A1 B Ab Ser Ql;;DEPRECATED;1.0;2.36 +84740-0;Can pronounce it;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce it [NIH Toolbox];Pronounce it NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84741-8;Can pronounce n;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce n [NIH Toolbox];Pronounce n NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84742-6;Can pronounce nature;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce nature [NIH Toolbox];Pronounce nature NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84743-4;Can pronounce nutate;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce nutate [NIH Toolbox];Pronounce nutate NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84744-2;Can pronounce o;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce o [NIH Toolbox];Pronounce o NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84745-9;Can pronounce on;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce on [NIH Toolbox];Pronounce on NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84746-7;Can pronounce one;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce one [NIH Toolbox];Pronounce one NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84747-5;Can pronounce or;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce or [NIH Toolbox];Pronounce or NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84748-3;Can pronounce our;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce our [NIH Toolbox];Pronounce our NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8474-9;Intravascular diastolic;Pres;8H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 8 hour minimum;BP dias 8h Min;;ACTIVE;1.0h(3);2.4 +84749-1;Can pronounce p;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce p [NIH Toolbox];Pronounce p NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84750-9;Can pronounce picayune;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce picayune [NIH Toolbox];Pronounce picayune NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84751-7;Can pronounce poet;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce poet [NIH Toolbox];Pronounce poet NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84752-5;Can pronounce precipice;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce precipice [NIH Toolbox];Pronounce precipice NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84753-3;Can pronounce purport;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce purport [NIH Toolbox];Pronounce purport NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84754-1;Can pronounce quip;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce quip [NIH Toolbox];Pronounce quip NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84755-8;Can pronounce quixotic;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce quixotic [NIH Toolbox];Pronounce quixotic NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8475-6;Intravascular diastolic;Pres;10H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 10 hour minimum;BP dias 10h Min;;ACTIVE;1.0h(3);2.4 +84756-6;Can pronounce r;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce r [NIH Toolbox];Pronounce r NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84757-4;Can pronounce renown;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce renown [NIH Toolbox];Pronounce renown NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84758-2;Can pronounce tax;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce tax [NIH Toolbox];Pronounce tax NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84759-0;Can pronounce tea;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce tea [NIH Toolbox];Pronounce tea NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84760-8;Can pronounce to;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce to [NIH Toolbox];Pronounce to NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84761-6;Can pronounce town;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce town [NIH Toolbox];Pronounce town NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84762-4;Can pronounce try;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce try [NIH Toolbox];Pronounce try NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84763-2;Can pronounce type;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce type [NIH Toolbox];Pronounce type NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8476-4;Intravascular diastolic;Pres;12H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 12 hour minimum;BP dias 12h Min;;ACTIVE;1.0h(3);2.4 +84764-0;Can pronounce u;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce u [NIH Toolbox];Pronounce u NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84765-7;Can pronounce utopian;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce utopian [NIH Toolbox];Pronounce utopian NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84766-5;Can pronounce w;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce w [NIH Toolbox];Pronounce w NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84767-3;Can pronounce were;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce were [NIH Toolbox];Pronounce were NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84768-1;Can pronounce x;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce x [NIH Toolbox];Pronounce x NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84769-9;Can pronounce y;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce y [NIH Toolbox];Pronounce y NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84770-7;Can pronounce you;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce you [NIH Toolbox];Pronounce you NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +84771-5;Can pronounce z;Find;Pt;^Patient;Ord;NIH Toolbox;NIH.COGNITIVE;2;Can pronounce z [NIH Toolbox];Pronounce z NIH;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.58;2.59 +8477-2;Intravascular diastolic;Pres;24H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Diastolic blood pressure 24 hour minimum;BP dias 24h Min;;ACTIVE;1.0h(3);2.4 +84772-3;Total Score;Score;Pt;^Patient;Qn;BSDS;SURVEY.MTLHLTH;4;Total score [BSDS];;This article was published in Journal of Affective Disorders, Vol 84(2-3), Ghaemi et al, Sensitivity and specificity of a new bipolar spectrum diagnostic scale, Appendix A, Copyright © Elsevier 2005. Used with permission.;ACTIVE;2.58;2.58 +84773-1;Total Score;Score;Pt;^Patient;Qn;MDQ;SURVEY.MTLHLTH;4;Total score [MDQ];;Copyright 2002 © Dr. Robert Hirschfeld. Used with permission.;ACTIVE;2.58;2.58 +84775-6;Positive Affect Survey - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - self-report - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84777-2;Positive Affect Survey - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - self-report - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84779-8;Positive Affect Survey version 2.0 - ages 8-12 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey version 2.0 - ages 8-12 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8478-0;Intravascular mean;Pres;Pt;Arterial system;Qn;;BP.ATOM;2;Mean blood pressure;BP mean;;ACTIVE;1.0h(3);2.73 +84781-4;Positive Affect Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84782-2;Positive Affect Survey - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - self-report - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84787-1;Positive Affect Survey version 2.0 - ages 13-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey version 2.0 - ages 13-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84788-9;Positive Affect Survey - parent report - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - parent report - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84789-7;Positive Affect Survey - parent report - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - parent report - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84793-9;Positive Affect Survey version 2.0 - parent report - ages 3-7 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey version 2.0 - parent report - ages 3-7 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84794-7;Positive Affect Survey - parent report - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - parent report - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84795-4;Positive Affect Survey - parent report - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - parent report - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84796-2;Positive Affect Survey - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Affect Survey - self-report - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8479-8;Intravascular systolic;Pres;Pt;Arterial system;Qn;Palpation;BP.ATOM;2;Systolic blood pressure by palpation;BP sys by Palpation;;ACTIVE;1.0h(3);2.73 +84798-8;Perceived Stress Survey - parent report - fixed length form - ages 8-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Perceived Stress Survey - parent report - fixed length form - ages 8-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.69 +84799-6;Positive Affect Survey - CAT item bank - ages 18+;-;7D;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Affect Survey - self report - CAT item bank - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84800-2;Positive Affect Survey - fixed length form - ages 18+;-;7D;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Affect Survey - self report - fixed length form - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84801-0;Positive Affect Survey version 2.0 - CAT item bank - ages 13-17;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Affect Survey version 2.0 - self report - CAT item bank - ages 13-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84802-8;Positive Affect Survey version 2.0 - parent report - fixed length form - ages 3-7;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Affect Survey - parent report - fixed length form - ages 3-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8480-6;Intravascular systolic;Pres;Pt;Arterial system;Qn;;BP.ATOM;2;Systolic blood pressure;BP sys;;ACTIVE;1.0h(3);2.73 +8481-4;Intravascular systolic;Pres;1H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 1 hour maximum;BP sys 1h Max;;ACTIVE;1.0h(3);2.4 +848-2;A1 B Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A1 B Ag [Presence] on Red Blood Cells from Blood product unit;A1 B Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +8482-2;Intravascular systolic;Pres;8H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 8 hour maximum;BP sys 8h Max;;ACTIVE;1.0h(3);2.4 +8483-0;Intravascular systolic;Pres;10H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 10 hour maximum;BP sys 10h Max;;ACTIVE;1.0h(3);2.4 +8484-8;Intravascular systolic;Pres;12H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 12 hour maximum;BP sys 12h Max;;ACTIVE;1.0h(3);2.4 +8485-5;Intravascular systolic;Pres;24H^max;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 24 hour maximum;BP sys 24h Max;;ACTIVE;1.0h(3);2.4 +8486-3;Intravascular systolic;Pres;1H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 1 hour mean;BP sys 1h Mean;;ACTIVE;1.0h(3);2.4 +8487-1;Intravascular systolic;Pres;8H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 8 hour mean;BP sys 8h Mean;;ACTIVE;1.0h(3);2.4 +84871-3;Epstein Barr virus capsid p18 Ab.IgG;PrThr;Pt;Ser;Ord;IA.rapid;MICRO;1;Epstein Barr virus capsid p18 IgG Ab [Presence] in Serum by Rapid immunoassay;EBV capsid p18 IgG Ser Ql IA.rapid;;ACTIVE;2.58;2.65 +84872-1;Epstein Barr virus nuclear 1 Ab.IgG;PrThr;Pt;Ser;Ord;IA.rapid;MICRO;1;Epstein Barr virus nuclear 1 IgG Ab [Presence] in Serum by Rapid immunoassay;EBV NA 1 IgG Ser Ql IA.rapid;;ACTIVE;2.58;2.65 +84873-9;Myelin oligodendrocyte glycoprotein Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Myelin oligodendrocyte glycoprotein IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;MOG IgG Titr SerPl IF;;ACTIVE;2.58;2.73 +84874-7;Perforation into peritoneal cavity;Find;Pt;Tumor;Ord;;ONCOLOGY;2;Perforation into peritoneal cavity;Tumor perf into peritoneal cavity;;ACTIVE;2.58;2.71 +84875-4;Tumor perforation;Type;Pt;Tumor;Nom;;ONCOLOGY;2;Tumor perforation [Type];Tumor perforation Type;;ACTIVE;2.58;2.71 +84876-2;Obstruction;Find;Pt;Bowel;Ord;Observed;ONCOLOGY;2;Obstruction of Bowel [Presence];Obstruction of Bowel Ql;;ACTIVE;2.58;2.71 +84877-0;Synchronous tumor site;Anat;Pt;Cancer.XXX;Nom;;ONCOLOGY;2;Synchronous tumor site Cancer;Synchronous tumor site Cancer;;ACTIVE;2.58;2.71 +84878-8;Recurrence or distant metastases details;Find;Pt;Cancer;Nar;;ONCOLOGY;2;Recurrence or distant metastases details Cancer Narrative;Recur or distant metast details Cancer;;ACTIVE;2.58;2.71 +84879-6;Tumor perforation;PrThr;Pt;Tumor;Ord;Macroscopy;PATH;1;Tumor perforation [Presence] by Macroscopy;Tumor perforation Ql Macro;;ACTIVE;2.58;2.71 +84880-4;Position of rectal tumor in relation to anterior peritoneal reflection;Anat;Pt;Tumor;Nom;;PATH;1;Position of rectal tumor in relation to anterior peritoneal reflection [Anatomy] in Tumor;Pos rec tumor to ant peri relect Tumor;;ACTIVE;2.58;2.71 +84881-2;Polyps;PrThr;Pt;Specimen;Ord;;PATH;1;Polyps [Presence] in Specimen;Polyps Spec Ql;;ACTIVE;2.58;2.71 +84882-0;Histologic type;Type;Pt;Colorectal cancer specimen;Nom;WHO classification;PATH;1;Histologic type in Colorectal cancer specimen by WHO classification;Histo type CRC spec WHO;;ACTIVE;2.58;2.72 +84883-8;Deepest extent of tumor invasion;Type;Pt;Colorectal cancer specimen;Nom;;PATH;1;Deepest extent of tumor invasion [Type] in Colorectal cancer specimen;Deepest tumor invasion CRC spec;;ACTIVE;2.58;2.71 +84884-6;Distal &or proximal margin involvement;PrThr;Pt;Colorectal cancer specimen;Nom;;PATH;1;Distal AndOr proximal margin involvement [Presence] in Colorectal cancer specimen;Distal/proximal marg invlmnt CRC spec;;ACTIVE;2.58;2.71 +84885-3;Surgical margin tumor involvement.circumferential;PrThr;Pt;Colorectal cancer specimen;Ord;;PATH;1;Surgical margin tumor involvement.circumferential [Presence] in Colorectal cancer specimen;Marg tumor invol.circ CRC spec Ql;;ACTIVE;2.58;2.71 +84886-1;Satellite nodules;PrThr;Pt;Colorectal cancer specimen;Ord;;PATH;1;Satellite nodules [Presence] in Colorectal cancer specimen;Satellite nodules CRC spec Ql;;ACTIVE;2.58;2.69 +84887-9;Apical lymph node involvement;PrThr;Pt;Cancer specimen;Ord;;PATH;1;Apical lymph node involvement of Colorectal cancer;Apical LN involved Ca spec Ql;;ACTIVE;2.58;2.71 +84888-7;Intramural vein invasion;PrThr;Pt;Colorectal cancer specimen;Ord;Microscopy.light;PATH;1;Intramural vein invasion [Presence] in Colorectal cancer specimen by Light microscopy;Intramural vein invas CRC spec Ql Micro;;ACTIVE;2.58;2.71 +8488-9;Intravascular systolic;Pres;10H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 10 hour mean;BP sys 10h Mean;;ACTIVE;1.0h(3);2.4 +84889-5;Extramural vein invasion;PrThr;Pt;Colorectal cancer specimen;Ord;Microscopy.light;PATH;1;Extramural vein invasion [Presence] in Colorectal cancer specimen by Light microscopy;Extramural vein invas CRC spec Ql Micro;;ACTIVE;2.58;2.71 +84890-3;Distant metastases confirmed by histology;PrThr;Pt;Cancer specimen;Ord;;PATH;1;Distant metastases confirmed by histology [Presence] in Cancer specimen;Dist mets conf by histology Ca spec Ql;;ACTIVE;2.58;2.71 +84891-1;Response to neoadjuvant therapy;PrThr;Pt;Colorectal cancer specimen;Ord;;PATH;1;Tumor response to neoadjuvant therapy;Tumor resp to neoadjvt therapy;;ACTIVE;2.58;2.71 +84892-9;Residual tumor classification;Type;Pt;Cancer specimen;Ord;;PATH;1;Residual tumor classification [Type] in Cancer specimen;Residual tumor classification Ca spec Ql;;ACTIVE;2.58;2.71 +84893-7;Supporting information about local extention &or metastasis for staging;Find;Pt;Tumor;Nar;;ONCOLOGY;2;Supporting information about local extention AndOr metastasis for staging Tumor Narrative;Info local ext+meta for staging Tumor;;ACTIVE;2.58;2.71 +84894-5;Dimension;Len;Pt;Specimen;Qn;;PATH;1;Dimension [Length] of Specimen;Dimension Spec;;ACTIVE;2.58;2.68 +84895-2;Seminal vesicles;PrThr;Pt;Specimen;Ord;;PATH;1;Seminal vesicles [Presence] in Specimen;Seminal vesicles Spec Ql;;ACTIVE;2.58;2.71 +84896-0;Lymph node(s);PrThr;Pt;Specimen;Ord;;PATH;1;Lymph node(s) [Presence] in Specimen;Lymph node(s) Spec Ql;;ACTIVE;2.58;2.71 +8489-7;Intravascular systolic;Pres;12H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 12 hour mean;BP sys 12h Mean;;ACTIVE;1.0h(3);2.4 +84897-8;Dominant nodule quadrant;Anat;Pt;Prostate tumor;Nom;;PATH;1;Dominant nodule quadrant [Anatomy] in Prostate tumor;Dominant nodule quad PrT;;ACTIVE;2.58;2.71 +84898-6;Dominant nodule plane;Anat;Pt;Prostate tumor;Nom;;PATH;1;Dominant nodule plane [Anatomy] in Prostate tumor;Dominant nodule plane PrT;;ACTIVE;2.58;2.71 +84899-4;Other nodules greater than 10mm in diameter;PrThr;Pt;Prostate tumor;Ord;;PATH;1;Other nodules greater than 10mm in diameter [Presence] in Prostate tumor;Other nodules >10mm diameter PrT Ql;;ACTIVE;2.58;2.71 +849-0;A1 B Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A1 B Ag [Presence] on Red Blood Cells from Donor;A1 B Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +84900-0;Other nodule quadrant;Anat;Pt;Prostate tumor;Nom;;PATH;1;Other nodule quadrant [Anatomy] in Prostate tumor;Nodule quad PrT;;ACTIVE;2.58;2.71 +84901-8;Other nodule plane;Anat;Pt;Prostate tumor;Nom;;PATH;1;Other nodule plane [Anatomy] in Prostate tumor;Other nodule plane PrT;;ACTIVE;2.58;2.71 +84902-6;Extraprostatic extension site;Anat;Pt;Prostate tumor;Nom;;PATH;1;Extraprostatic extension site [Anatomy] of Prostate tumor;Extraprostatic ext site PrT;;ACTIVE;2.58;2.71 +84903-4;Extraprostatic extension extent;Type;Pt;Prostate tumor;Ord;;PATH;1;Extraprostatic extension extent [Type] of Prostate tumor;EPE extent PrT Ql;;ACTIVE;2.58;2.71 +84904-2;Gleason score at positive margin;Score;Pt;Prostate tumor;Ord;;PATH;1;Gleason score at positive margin in Prostate tumor Qualitative;Gleason score at pos margin PrT Ql;;ACTIVE;2.58;2.71 +8490-5;Intravascular systolic;Pres;24H^mean;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 24 hour mean;BP sys 24h Mean;;ACTIVE;1.0h(3);2.4 +84905-9;Margin involvement;Type;Pt;Prostate tumor;Nom;;PATH;1;Margin involvement [Type] in Prostate tumor;Margin involved PrT;;ACTIVE;2.58;2.71 +84906-7;Bladder neck involvement;PrThr;Pt;Prostate tumor;Ord;;PATH;1;Bladder neck involvement of Prostate tumor;Bladder neck involved PrT Ql;;ACTIVE;2.58;2.71 +84907-5;Cancer pathology panel;-;Pt;Colorectal cancer specimen;-;;PANEL.PATH;1;Cancer pathology panel - Colorectal cancer specimen;Cancer Path Pnl CRC spec;;ACTIVE;2.58;2.71 +84908-3;Cancer pathology panel;-;Pt;Prostate cancer.XXX;-;;PANEL.PATH;1;Cancer pathology panel - Prostate cancer;Cancer Path Pnl Prostate cancer;;ACTIVE;2.58;2.71 +84910-9;Positive Affect Survey version 2.0 - fixed length form - ages 13-17;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Affect Survey - fixed length form - ages 13-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84912-5;Cells.chromosome region 5q31 deletion/Cells counted;NFr;Pt;Bone mar;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome region 5q31 deletion/Cells counted in Bone marrow by FISH;Cells.5q31 Del/Cells NFr Mar FISH;;ACTIVE;2.58;2.63 +8491-3;Intravascular systolic;Pres;1H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 1 hour minimum;BP sys 1h Min;;ACTIVE;1.0h(3);2.4 +84913-3;Cells.chromosome 12 trisomy/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.TRISOMY;1;Cells.chromosome 12 trisomy/Cells counted in Blood or Tissue by FISH;Cells.Chr 12 Ts/Cells NFr Bld/T FISH;;ACTIVE;2.58;2.61 +84914-1;Cells.chromosome region 13q14 deletion/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome region 13q14 deletion/Cells counted in Blood or Tissue by FISH;Cells.13q14 Del/Cells NFr Bld/T FISH;;ACTIVE;2.58;2.61 +84915-8;Cells.chromosome region 11q22.3 deletion/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome region 11q22.3 deletion/Cells counted in Blood or Tissue by FISH;Cells.11q22.3 Del/Cells NFr Bld/T FISH;;ACTIVE;2.58;2.61 +84916-6;Cells.chromosome region 17p13.1 deletion/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome region 17p13.1 deletion/Cells counted in Blood or Tissue by FISH;Cells.17p13.1 Del/Cells NFr Bld/T FISH;;ACTIVE;2.58;2.61 +84917-4;Chromosome Y aneuploidy;PrThr;Pt;Amnio fld/CVS;Ord;FISH;MOLPATH;1;Chromosome Y aneuploidy [Presence] in Amniotic fluid or Chorionic villus sample by FISH;Chr Y aneup Amn/CVS Ql FISH;;ACTIVE;2.58;2.66 +84918-2;Chromosome X aneuploidy;PrThr;Pt;Amnio fld/CVS;Ord;FISH;MOLPATH;1;Chromosome X aneuploidy [Presence] in Amniotic fluid or Chorionic villus sample by FISH;Chr X aneup Amn/CVS Ql FISH;;ACTIVE;2.58;2.66 +84919-0;Chromosome 21 aneuploidy;PrThr;Pt;Amnio fld/CVS;Ord;FISH;MOLPATH;1;Chromosome 21 aneuploidy [Presence] in Amniotic fluid or Chorionic villus sample by FISH;Chr 21 aneup Amn/CVS Ql FISH;;ACTIVE;2.58;2.66 +84920-8;Cells.chromosome region 5q31 deletion/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome region 5q31 deletion/Cells counted in Blood or Tissue by FISH;Cells.5q31 Del/Cells NFr Bld/T FISH;;ACTIVE;2.58;2.61 +8492-1;Intravascular systolic;Pres;8H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 8 hour minimum;BP sys 8h Min;;ACTIVE;1.0h(3);2.4 +84921-6;Cells.chromosome region 7q31 deletion/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome region 7q31 deletion/Cells counted in Blood or Tissue by FISH;Cells.7q31 Del/Cells NFr Bld/T FISH;;ACTIVE;2.58;2.61 +84922-4;Cells.chromosome 7 monosomy/Cells counted;NFr;Pt;Bld/Tiss;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome 7 monosomy/Cells counted in Blood or Tissue by FISH;Cells.Chr Mono 7/Cells NFr Bld/T FISH;;ACTIVE;2.58;2.61 +84923-2;Purkinje cell cytoplasmic type 1 Ab;ACnc;Pt;Ser;Qn;IB;SERO;1;PCA-1 Ab [Units/volume] in Serum by Immunoblot;PCA-1 Ab Ser IB-aCnc;;ACTIVE;2.58;2.68 +84924-0;Purkinje cell cytoplasmic type 1 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;PCA-1 Ab [Presence] in Serum by Immunofluorescence;PCA-1 Ab Ser Ql IF;;ACTIVE;2.58;2.73 +84925-7;Purkinje cell cytoplasmic type 2 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;PCA-2 Ab [Presence] in Serum by Immunofluorescence;PCA-2 Ab Ser Ql IF;;ACTIVE;2.58;2.73 +84926-5;Purkinje cell cytoplasmic type Tr Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;PCA-Tr Ab [Presence] in Serum by Immunofluorescence;PCA-Tr Ab Ser Ql IF;;ACTIVE;2.58;2.73 +84927-3;Glial nuclear type 1 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Glial nuclear type 1 Ab [Presence] in Serum by Immunofluorescence;Glial nuc type 1 Ab Ser Ql IF;;ACTIVE;2.58;2.73 +84928-1;N-methyl-D-aspartate receptor subunit 1 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;NMDAR subunit 1 Ab [Presence] in Serum by Immunofluorescence;NMDAR1 Ab Ser Ql IF;;ACTIVE;2.58;2.73 +84929-9;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;AMPAR1 Ab [Presence] in Serum by Immunofluorescence;AMPAR1 Ab Ser Ql IF;;ACTIVE;2.58;2.73 +84930-7;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;AMPAR2 Ab [Presence] in Serum by Immunofluorescence;AMPAR2 Ab Ser Ql IF;;ACTIVE;2.58;2.58 +84931-5;Gamma aminobutyrate B receptor Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;GABABR Ab [Presence] in Serum by Immunofluorescence;GABABR Ab Ser Ql IF;;ACTIVE;2.58;2.65 +84932-3;Friendship Survey - fixed length form - ages 18+;-;1Mo;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Friendship Survey - fixed length form - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84933-1;Friendship Survey version 2.0 - fixed length form - ages 8-17;-;1Mo;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Friendship Survey - fixed length form - ages 8-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8493-9;Intravascular systolic;Pres;10H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 10 hour minimum;BP sys 10h Min;;ACTIVE;1.0h(3);2.4 +8494-7;Intravascular systolic;Pres;12H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 12 hour minimum;BP sys 12h Min;;ACTIVE;1.0h(3);2.4 +8495-4;Intravascular systolic;Pres;24H^min;Arterial system;Qn;;BP.TIMED.MOLEC;2;Systolic blood pressure 24 hour minimum;BP sys 24h Min;;ACTIVE;1.0h(3);2.4 +84956-2;Instrumental Support Survey - fixed length form - ages 18+;-;1Mo;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Instrumental Support Survey - fixed length form - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84957-0;Loneliness Survey - fixed length form - ages 18+;-;1Mo;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Loneliness Survey - fixed length form - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84958-8;Loneliness Survey version 2.0 - fixed length form - ages 8-17;-;1Mo;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Loneliness Survey - fixed length form - ages 8-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8496-2;Intravascular diastolic;Pres;Pt;Brachial artery;Qn;;BP.MOLEC;2;Brachial artery Diastolic blood pressure;Brach a BP dias;;ACTIVE;1.0h(3);2.4 +84962-0;Friendship Survey - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Friendship Survey - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84963-8;Friendship Survey - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Friendship Survey - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84964-6;Friendship Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Friendship Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84966-1;Friendship Survey version 2.0 - ages 8-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Friendship Survey version 2.0 - ages 8-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84968-7;Friendship Survey - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Friendship Survey - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84969-5;Friendship Survey - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Friendship Survey - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8497-0;Intravascular diastolic;Pres;Pt;Dorsal pedal artery;Qn;;BP.MOLEC;2;Dorsal pedal artery Diastolic blood pressure;Dors pedal a BP dias;;ACTIVE;1.0h(3);2.4 +84970-3;Instrumental Support Survey - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Instrumental Support Survey - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84971-1;Instrumental Support Survey - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Instrumental Support Survey - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84972-9;Instrumental Support Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Instrumental Support Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84974-5;Instrumental Support Survey - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Instrumental Support Survey - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84975-2;Instrumental Support Survey - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Instrumental Support Survey - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84976-0;Loneliness Survey - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Loneliness Survey - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84977-8;Loneliness Survey - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Loneliness Survey - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84978-6;Loneliness Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Loneliness Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84980-2;Loneliness Survey version 2.0 - ages 8-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Loneliness Survey version 2.0 - ages 8-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84982-8;Loneliness Survey - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Loneliness Survey - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +84983-6;Loneliness Survey - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Loneliness Survey - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8498-8;Intravascular diastolic;Pres;Pt;Femoral artery;Qn;;BP.MOLEC;2;Femoral artery Diastolic blood pressure;Fem a BP dias;;ACTIVE;1.0h(3);2.73 +8499-6;Intravascular diastolic;Pres;Pt;Posterior tibial artery;Qn;;BP.MOLEC;2;Posterior tibial artery Diastolic blood pressure;Post Tibl a BP dias;;ACTIVE;1.0h(3);2.4 +8500-1;Intravascular diastolic;Pres;Pt;Radial artery;Qn;;BP.MOLEC;2;Radial artery Diastolic blood pressure;Radial a BP dias;;ACTIVE;1.0h(3);2.4 +85008-1;General Life Satisfaction Survey - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85009-9;General Life Satisfaction Survey version 2.0 - parent report - fixed length form- ages 3-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;General Life Satisfaction Survey - parent report - fixed length form- ages 3-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85011-5;General Life Satisfaction Survey version 2.0 - parent report - ages 3-12 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey version 2.0 - parent report - ages 3-12 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85012-3;General Life Satisfaction Survey - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85013-1;General Life Satisfaction Survey - fixed length form B - ages 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;General Life Satisfaction Survey - fixed length form B - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85016-4;General Life Satisfaction Survey - fixed length form A - ages 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;General Life Satisfaction Survey - fixed length form A - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8501-9;Intravascular diastolic;Pres;Pt;Umbilical artery;Qn;;BP.MOLEC;2;Umbilical artery Diastolic blood pressure;Umb a BP dias;;ACTIVE;1.0h(3);2.4 +85019-8;General Life Satisfaction Survey version 2.0 - CAT item bank - ages 8-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;General Life Satisfaction Survey - CAT item bank - ages 8-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85021-4;General Life Satisfaction Survey version 2.0 - ages 8-12 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey version 2.0 - ages 8-12 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85022-2;General Life Satisfaction Survey - CAT item bank - ages 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;General Life Satisfaction Survey - CAT item bank - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85024-8;General Life Satisfaction Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85025-5;General Life Satisfaction Survey - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85026-3;General Life Satisfaction Survey - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8502-7;Intravascular mean;Pres;Pt;Brachial artery;Qn;;BP.MOLEC;2;Brachial artery Mean blood pressure;Brach a BP mean;;ACTIVE;1.0h(3);2.4 +85027-1;Emotional Support Survey - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Emotional Support Survey - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85028-9;Emotional Support Survey - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Emotional Support Survey - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85029-7;Emotional Support Survey version 2.0 - fixed length form - ages 8-17;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Emotional Support Survey - fixed length form - ages 8-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85031-3;Emotional Support Survey version 2.0 - ages 8-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Emotional Support Survey version 2.0 - ages 8-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85032-1;Emotional Support Survey - fixed length form - ages 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Emotional Support Survey - fixed length form - ages 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85034-7;Emotional Support Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Emotional Support Survey - fixed length form - ages 18+ - raw score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8503-5;Intravascular mean;Pres;Pt;Dorsal pedal artery;Qn;;BP.MOLEC;2;Dorsal pedal artery Mean blood pressure;Dors pedal a BP mean;;ACTIVE;1.0h(3);2.4 +85035-4;Emotional Support Survey - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Emotional Support Survey - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85036-2;Emotional Support Survey - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Emotional Support Survey - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85037-0;HIV 1 & 2 Ab & HIV 1 p24 Ag panel;-;Pt;Ser/Plas;-;IA;PANEL.MICRO;1;HIV 1 and 2 Ab and HIV 1 p24 Ag panel - Serum or Plasma by Immunoassay;HIV 1 + 2 Ab + HIV 1 p24 Ag Pnl SerPl IA;;ACTIVE;2.58;2.58 +85038-8;Somatotropin monitoring panel;-;Pt;^Patient;-;;PANEL.MEDS;2;Somatotropin monitoring panel;Somatotropin monitor Pnl;;TRIAL;2.58;2.58 +85039-6;JAK2 gene.p.Val617Phe mutant/normal;RelRto;Pt;Bone mar;Qn;Molgen;MOLPATH.MUT;1;JAK2 gene.p.Val617Phe mutant/Normal in Bone marrow by Molecular genetics method;JAK2 p.V617F mut/Nor Mar;;ACTIVE;2.63;2.63 +85040-4;3D printed model;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region 3D printed model;CT 3D model;;ACTIVE;2.58;2.64 +85041-2;3D printed model;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region 3D printed model;MR 3D model;;ACTIVE;2.58;2.64 +85042-0;Staphylococcus aureus.glycopeptide resistant identified;Type;Pt;Isolate;Nom;;MICRO;1;Staphylococcus aureus glycopeptide resistant identified [Type] in Isolate;SA glyco resist Islt;;ACTIVE;2.58;2.58 +8504-3;Intravascular mean;Pres;Pt;Femoral artery;Qn;;BP.MOLEC;2;Femoral artery Mean blood pressure;Fem a BP mean;;ACTIVE;1.0h(3);2.3 +85043-8;Extended-spectrum beta lactamase by cefepime to cefepime+clavulanate inhibitory concentration ratio;PrThr;Pt;Isolate;Ord;Gradient strip ARD;ABXBACT;1;ESBL by cefepime to cefepime-clavulanate IC ratio [Presence] by ARD gradient strip;ESBL cefep + cefep-clav IC Islt Ql Grad;;ACTIVE;2.58;2.58 +85044-6;Staphylococcus aureus glycopeptide resistance panel;-;Pt;Isolate;-;;PANEL.ABXBACT;1;Staphylococcus aureus glycopeptide resistance panel;SA glyco resist Pnl Islt;;ACTIVE;2.58;2.65 +85045-3;Staphylococcus aureus glycopeptide resistant based on vancomycin & teicoplanin inhibitory concentration;Prid;Pt;Isolate;Nom;Gradient strip ARD;ABXBACT;1;Staphylococcus aureus glycopeptide resistant based on vancomycin and teicoplanin IC [Identifier] by ARD gradient strip;SA glyc resist vanc + teic IC Islt Grad;;ACTIVE;2.58;2.58 +85046-1;AmpC beta-lactamase by cefoTEtan to cefoTEtan+cloxacillin inhibitory concentration ratio;PrThr;Pt;Isolate;Ord;Gradient strip ARD;ABXBACT;1;AmpC beta-lactamase by cefoTEtan to cefoTEtan+cloxacillin inhibitory concentration ratio [Presence] by ARD gradient strip;AmpC cefo + cefo-clox IC Islt Ql Grad;;ACTIVE;2.58;2.58 +85047-9;Metallo beta-lactamase by meropenem to meropenem+EDTA inhibitory concentration ratio;PrThr;Pt;Isolate;Ord;Gradient strip ARD;ABXBACT;1;MBL by meropenem to meropenem-EDTA IC ratio [Presence] by ARD gradient strip;MBL mero + mer-EDTA IC rto Islt Ql Grad;;ACTIVE;2.58;2.58 +85048-7;Micafungin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Micafungin [Susceptibility] by Gradient strip;Micafungin Islt Grad strip;;ACTIVE;2.58;2.58 +85049-5;Extended-spectrum beta lactamase by cefotaxime to cefotaxime+clavulanate inhibitory concentration ratio;PrThr;Pt;Isolate;Ord;Gradient strip ARD;ABXBACT;1;ESBL by cefotaxime to cefotaxime-clavulanate IC ratio [Presence] by ARD gradient strip;ESBL cefot + cefot-clav IC Islt Ql Grad;;ACTIVE;2.58;2.58 +8505-0;Intravascular mean;Pres;Pt;Posterior tibial artery;Qn;;BP.MOLEC;2;Posterior tibial artery Mean blood pressure;Post Tibl a BP mean;;ACTIVE;1.0h(3);2.4 +85050-3;Extended-spectrum beta lactamase by ceftazidime to ceftazidime+clavulanate inhibitory concentration ratio;PrThr;Pt;Isolate;Ord;Gradient strip ARD;ABXBACT;1;ESBL by ceftazidime to ceftazidime-clavulanate IC ratio [Presence] by ARD gradient strip;ESBL ceftaz + ceft-clav IC Islt Ql Grad;;ACTIVE;2.58;2.69 +85051-1;Telavancin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Telavancin [Susceptibility] by Gradient strip;Telavancin Islt Grad strip;;ACTIVE;2.58;2.58 +85052-9;Ceftobiprole;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ceftobiprole [Susceptibility] by Gradient strip;Ceftobiprole Islt Grad strip;;ACTIVE;2.58;2.58 +85053-7;Metallo beta-lactamase by imipenem to imipenem+EDTA inhibitory concentration ratio;PrThr;Pt;Isolate;Ord;Gradient strip ARD;ABXBACT;1;MBL by imipenem to imipenem-EDTA IC ratio [Presence] by ARD gradient strip;MBL imi + imi-EDTA IC rto Islt Ql Grad;;ACTIVE;2.58;2.58 +85054-5;Self-care - discharge goal;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Self-care - discharge goal [CMS Assessment];;;ACTIVE;2.61;2.67 +85055-2;IRF-PAI v3.0, LCDS v4.00 - Skin conditions - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v4.00 - Skin conditions - admission [CMS Assessment];;;ACTIVE;2.61;2.69 +85056-0;Mobility - discharge goal during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Mobility - discharge goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.67 +85057-8;PCORnet common data model set - version 3.0;-;Pt;^Patient;-;PCORnet;PANEL.SURVEY.PCORNET;4;PCORnet Common Data Model set - version 3.0 [PCORnet];;;ACTIVE;2.58;2.73 +85058-6;Imputed values for date of death;Prid;Pt;^Patient;Nom;;CLIN;2;Imputed values for date of death;Imputed values DOD;;ACTIVE;2.58;2.58 +85059-4;Confidence in date of death;Imp;Pt;^Patient;Ord;;CLIN;2;Confidence in date of death;Confidence in DOD;;ACTIVE;2.58;2.58 +85060-2;Confidence in cause of death;Imp;Pt;^Patient;Ord;;CLIN;2;Confidence in cause of death;Confidence in cause of death;;ACTIVE;2.58;2.58 +85061-0;Door-to-balloon time;Time;Pt;Heart;Qn;;CARD.PROC;2;Door-to-balloon time Heart;D2B time Hrt;;ACTIVE;2.58;2.58 +85062-8;Anticoagulant given^preoperative;Prid;Pt;^Patient;Nom;;MEDS;2;Anticoagulant given [Identifier] --preoperative;Anticoag Gvn Preop;;ACTIVE;2.58;2.58 +85063-6;Platelet aggregation inhibitor given^preoperative;Prid;Pt;^Patient;Nom;;MEDS;2;Platelet aggregation inhibitor given [Identifier] --preoperative;Plt aggreg inhib Gvn Preop;;ACTIVE;2.58;2.58 +85064-4;Procedure(s) performed^preoperative;Prid;Pt;^Patient;Nom;;H&P.HX;2;Procedure(s) performed --preoperative;Proc performed Preop;;ACTIVE;2.58;2.66 +85065-1;Estradiol^post dose follitropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --post dose follitropin;Estradiol p FSH SerPl-mCnc;;ACTIVE;2.58;2.58 +85066-9;Estradiol^post dose lutropin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --post dose lutropin;Estradiol p LH SerPl-mCnc;;ACTIVE;2.58;2.58 +85067-7;Estradiol^post dose gonadotropin releasing hormone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --post dose gonadotropin releasing hormone;Estradiol p GnRH SerPl-mCnc;;ACTIVE;2.58;2.58 +8506-8;Intravascular mean;Pres;Pt;Radial artery;Qn;;BP.MOLEC;2;Radial artery Mean blood pressure;Radial a BP mean;;ACTIVE;1.0h(3);2.4 +85068-5;Estradiol^post dose dexamethasone;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --post dose dexamethasone;Estradiol p Dex SerPl-mCnc;;ACTIVE;2.58;2.58 +85069-3;Lab test method;Type;Pt;Specimen;Nom;*;MISC;1;Lab test method [Type];Lab test method;;ACTIVE;2.58;2.58 +85070-1;Prior functioning.self care;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Prior functioning.self care [CMS Assessment];;;ACTIVE;2.61;2.72 +85071-9;Prior functioning.indoor mobility-ambulation;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Indoor mobility (Ambulation) [CMS Assessment];;;ACTIVE;2.61;2.61 +85072-7;Prior functioning.stairs;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Stairs [CMS Assessment];;;ACTIVE;2.61;2.61 +85073-5;Prior functioning.functional cognition;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Functional cognition [CMS Assessment];;;ACTIVE;2.61;2.61 +85074-3;General Life Satisfaction Survey - parent report - national percentile;Prctl;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - parent report - national percentile [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85075-0;General Life Satisfaction Survey - parent report - scale score^^adjusted for age;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - parent report - scale score age adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8507-6;Intravascular mean;Pres;Pt;Umbilical artery;Qn;;BP.MOLEC;2;Umbilical artery Mean blood pressure;Umb a BP mean;;ACTIVE;1.0h(3);2.4 +85076-8;General Life Satisfaction Survey - parent report - scale score^^adjusted for age+sex+race+ethnicity+educational attainment;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - parent report - scale score fully adjusted [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85077-6;General Life Satisfaction Survey - parent report - unadjusted scale score;Score;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey - parent report - unadjusted scale score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85078-4;Occupation industry;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Occupation industry [Type];Occupation industry Type;;ACTIVE;2.58;2.66 +85079-2;Nuclear Ab.IgG pattern.other;Titr;Pt;Ser;Qn;IF;SERO;1;Other nuclear IgG pattern [Titer] in Serum by Immunofluorescence;ANA IgG other Titr Ser IF;;ACTIVE;2.58;2.58 +850-8;A1 B Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A1 B Ag [Presence] on Red Blood Cells;A1 B Ag RBC Ql;;ACTIVE;1.0;2.56 +85080-0;Nuclear Ab.IgG pattern.nucleolar;Titr;Pt;Ser;Qn;IF;SERO;1;Nucleolar nuclear IgG pattern [Titer] in Serum by Immunofluorescence;ANA IgG nucleolar Titr Ser IF;;ACTIVE;2.58;2.58 +85081-8;Nuclear Ab.IgG pattern.multiple nuclear dots;Titr;Pt;Ser;Qn;IF;SERO;1;Multiple nuclear dots nuclear IgG pattern [Titer] in Serum by Immunofluorescence;ANA IgG multi nuclear dots Titr Ser IF;;ACTIVE;2.58;2.58 +85082-6;Nuclear Ab.IgG pattern.nuclear membrane pores;Titr;Pt;Ser;Qn;IF;SERO;1;Nuclear membrane pores nuclear IgG pattern [Titer] in Serum by Immunofluorescence;ANA IgG nuc mem pores Titr Ser IF;;ACTIVE;2.58;2.58 +85083-4;Nuclear Ab.IgG pattern.homogeneous;Titr;Pt;Ser;Qn;IF;SERO;1;Homogeneous nuclear IgG pattern [Titer] in Serum by Immunofluorescence;ANA IgG homogeneous Titr Ser IF;;ACTIVE;2.58;2.58 +8508-4;Intravascular systolic;Pres;Pt;Brachial artery;Qn;;BP.MOLEC;2;Brachial artery Systolic blood pressure;Brach a BP sys;;ACTIVE;1.0h(3);2.4 +85084-2;Nuclear Ab.IgG pattern.coarse speckled;Titr;Pt;Ser;Qn;IF;SERO;1;Coarse speckled nuclear IgG pattern [Titer] in Serum by Immunofluorescence;ANA IgG coarse speck Titr Ser IF;;ACTIVE;2.58;2.58 +85085-9;Nuclear Ab.IgG pattern.centrosomal;Titr;Pt;Ser;Qn;IF;SERO;1;Centrosomal nuclear IgG pattern [Titer] in Serum by Immunofluorescence;ANA IgG centrosomal Titr Ser IF;;ACTIVE;2.58;2.58 +85086-7;Elastase Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Elastase IgG Ab [Presence] in Serum by Immunoassay;Elastase IgG Ser Ql IA;;ACTIVE;2.58;2.63 +85087-5;Hexanoate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexanoate (C6:0) [Moles/volume] in Serum or Plasma;Hexanoate SerPl-sCnc;;ACTIVE;2.58;2.58 +85088-3;Maprotiline & normaprotiline panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Maprotiline and normaprotiline panel - Serum or Plasma;Maprotiline + Normap Pnl SerPl;;ACTIVE;2.58;2.58 +85089-1;Dothiepin & nordothiepin & dothiepin sulfoxide panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Dothiepin and nordothiepin and dothiepin sulfoxide panel - Serum or Plasma;Dothiepin+metabolites Pnl SerPl;;ACTIVE;2.58;2.58 +85090-9;Citalopram & norcitalopram & didesmethylcitalopram panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Citalopram and norcitalopram and didesmethylcitalopram panel - Serum or Plasma;Citalopram+metabolites Pnl SerPl;;ACTIVE;2.58;2.58 +85091-7;HBA2 gene alpha 3.7kb triplication;PrThr;Pt;Bld;Ord;Molgen;MOLPATH.MUT;1;HBA2 gene alpha 3.7kb triplication [Presence] in Blood by Molecular genetics method;HBA2 alpha 3.7kb triple Bld Ql;;ACTIVE;2.58;2.58 +8509-2;Intravascular systolic;Pres;Pt;Dorsal pedal artery;Qn;;BP.MOLEC;2;Dorsal pedal artery Systolic blood pressure;Dors pedal a BP sys;;ACTIVE;1.0h(3);2.4 +85092-5;Liver diseases autoimmune Ab.IgG panel;-;Pt;Ser/Plas;-;Line blot;PANEL.SERO;1;Liver diseases autoimmune IgG panel - Serum or Plasma by Line blot;Liver diseases IgG Pnl SerPl Line blot;;ACTIVE;2.58;2.68 +85093-3;Crystal casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Crystal casts [Presence] in Urine sediment by Light microscopy;Crystal casts UrnS Ql Micro;;ACTIVE;2.58;2.73 +85094-1;Escitalopram & norescitalopram panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Escitalopram and norescitalopram panel - Serum or Plasma;Escitalopram + norescitalo Pnl SerPl;;ACTIVE;2.58;2.58 +85095-8;D-3-phosphoglycerate dehydrogenase Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;D-3-phosphoglycerate dehydrogenase IgG Ab [Presence] in Serum by Line blot;3-PGDH IgG Ser Ql Line blot;;ACTIVE;2.58;2.67 +85096-6;Myoglobin casts;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Myoglobin casts [Presence] in Urine sediment by Light microscopy;Myoglobin casts UrnS Ql Micro;;ACTIVE;2.58;2.58 +85097-4;Meta methylhippurate & ortho methylhippurate & para methylhippurate & Creatinine panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Meta methylhippurate and ortho methylhippurate and para methylhippurate and creatinine panel - Urine;Methylhippurates + creat Pnl Ur;;ACTIVE;2.58;2.58 +85098-2;Nitisinone;SCnc;Pt;Bld.dot;Qn;LC/MS/MS;DRUG/TOX;1;Nitisinone [Moles/volume] in DBS by LC/MS/MS;NTBC DBS LC/MS/MS-sCnc;;ACTIVE;2.58;2.61 +85099-0;Norescitalopram;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norescitalopram [Mass/volume] in Serum or Plasma;Norescitalopram SerPl-mCnc;;ACTIVE;2.58;2.58 +85-1;Cefaclor;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefaclor [Susceptibility] by Disk diffusion (KB);Cefaclor Islt KB;;ACTIVE;1.0;2.73 +8510-0;Intravascular systolic;Pres;Pt;Femoral artery;Qn;;BP.MOLEC;2;Femoral artery Systolic blood pressure;Fem a BP sys;;ACTIVE;1.0h(3);2.3 +85100-6;FLT3 gene internal tandem duplication;PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH.MUT;1;FLT3 gene internal tandem duplication [Presence] in Bone marrow by Molecular genetics method;FLT3 ITD Dp Mar Ql;;ACTIVE;2.58;2.58 +85101-4;BRAF gene.p.Val600Glu;PrThr;Pt;Bone mar;Ord;Molgen;MOLPATH.MUT;1;BRAF gene p.Val600Glu [Presence] in Bone marrow by Molecular genetics method;BRAF p.V600E Mar Ql;;ACTIVE;2.58;2.61 +85102-2;Mood Disorder Questionnaire;-;Pt;^Patient;-;MDQ;PANEL.SURVEY.MTLHLTH;4;Mood Disorder Questionnaire [MDQ];;Copyright 2002 © Dr. Robert Hirschfeld. Used with permission.;ACTIVE;2.58;2.61 +85103-0;Bipolar Spectrum Diagnostic Scale;-;Pt;^Patient;-;BSDS;PANEL.SURVEY.MTLHLTH;4;Bipolar Spectrum Diagnostic Scale [BSDS];;This article was published in Journal of Affective Disorders, Vol 84(2-3), Ghaemi et al, Sensitivity and specificity of a new bipolar spectrum diagnostic scale, Appendix A, Copyright © Elsevier 2005. Used with permission.;ACTIVE;2.58;2.61 +85104-8;Employment type.compensation and sector;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Compensation and sector employment type;Employment type.comp+sector;;ACTIVE;2.58;2.66 +85105-5;Anger-Affect Survey - CAT item bank - age 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Anger-Affect Survey - CAT item bank - age 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85106-3;Peer Rejection Survey version 2.0 - parent report - fixed length form - ages 3-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Peer Rejection Survey version 2.0 - parent report - fixed length form - ages 3-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85108-9;Positive Peer Interaction Survey version 2.0 - parent report - ages 3-12 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Positive Peer Interaction Survey version 2.0 - parent report - ages 3-12 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85109-7;Positive Peer Interaction Survey version 2.0 - parent report - fixed length form - ages 3-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Peer Interaction Survey version 2.0 - parent report - fixed length form - ages 3-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85110-5;Peer Rejection Survey version 2.0 - parent report - ages 3-12 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Peer Rejection Survey version 2.0 - parent report - ages 3-12 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85111-3;Social Withdrawal Survey version 2.0 - parent report - ages 3-12 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Social Withdrawal Survey version 2.0 - parent report - ages 3-12 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85112-1;Social Withdrawal Survey version 2.0 - parent report - fixed length form - ages 3-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Social Withdrawal Survey version 2.0 - parent report - fixed length form - ages 3-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85115-4;Positive Affect Survey version 2.0 - parent report - CAT item bank - ages 3-7;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Affect Survey version 2.0 - parent report - CAT item bank - ages 3-7 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85117-0;Sadness Survey version 2.0 - parent report - ages 3-7 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Sadness Survey version 2.0 - parent report - ages 3-7 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8511-8;Intravascular systolic;Pres;Pt;Posterior tibial artery;Qn;;BP.MOLEC;2;Posterior tibial artery Systolic blood pressure;Post Tibl a BP sys;;ACTIVE;1.0h(3);2.4 +85118-8;Sadness Survey version 2.0 - parent report - fixed length form - ages 3-7;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Sadness Survey version 2.0 - parent report - fixed length form - ages 3-7 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85120-4;Fear-Separation Anxiety Survey version 2.0 - parent report - ages 3-7 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Fear-Separation Anxiety Survey version 2.0 - parent report - ages 3-7 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85121-2;Fear-Separation Anxiety Survey version 2.0 - parent report - fixed length form - ages 3-7;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Fear-Separation Anxiety Survey version 2.0 - parent report - fixed length form - ages 3-7 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85123-8;Fear-Over Anxious Survey version 2.0 - parent report - ages 3-7 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Fear-Over Anxious Survey version 2.0 - parent report - ages 3-7 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85124-6;Fear-Over Anxious Survey version 2.0 - parent report - fixed length form - ages 3-7;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Fear-Over Anxious Survey version 2.0 - parent report - fixed length form - ages 3-7 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +8512-6;Intravascular systolic;Pres;Pt;Radial artery;Qn;;BP.MOLEC;2;Radial artery Systolic blood pressure;Radial a BP sys;;ACTIVE;1.0h(3);2.4 +85126-1;Self-Efficacy Survey version 2.0 - ages 8-12 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Self-Efficacy Survey version 2.0 - ages 8-12 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85127-9;Self-Efficacy Survey version 2.0 - CAT item bank - ages 8-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Self-Efficacy Survey version 2.0 - CAT item bank - ages 8-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85129-5;Self-Efficacy Survey version 2.0 - ages 13-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Self-Efficacy Survey version 2.0 - ages 13-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85130-3;Anger-Affect Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Anger-Affect Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85132-9;General Life Satisfaction Survey version 2.0 - ages 13-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;General Life Satisfaction Survey version 2.0 - ages 13-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85133-7;General Life Satisfaction Survey version 2.0 - CAT item bank - ages 13-17;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;General Life Satisfaction Survey version 2.0 - CAT item bank - ages 13-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +8513-4;Intravascular systolic;Pres;Pt;Umbilical artery;Qn;;BP.MOLEC;2;Umbilical artery Systolic blood pressure;Umb a BP sys;;ACTIVE;1.0h(3);2.4 +85135-2;Positive Affect Survey version 2.0 - fixed length form - ages 8-12;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Positive Affect Survey version 2.0 - fixed length form - ages 8-12 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85136-0;Sadness Survey version 2.0 - fixed length form - ages 8-17;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Sadness Survey version 2.0 - fixed length form - ages 8-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85137-8;Sadness Survey version 2.0 - ages 8-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Sadness Survey version 2.0 - ages 8-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85139-4;Fear Survey version 2.0 - ages 8-17 - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Fear Survey version 2.0 - ages 8-17 - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85140-2;Sadness Survey - CAT item bank - age 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Sadness Survey - CAT item bank - age 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85141-0;Sadness Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Sadness Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +8514-2;Intravascular diastolic;Pres;Pt;Brachial artery.left;Qn;;BP.MOLEC;2;Brachial artery - left Diastolic blood pressure;Brach a-L BP dias;;ACTIVE;1.0h(3);2.4 +85143-6;Fear Survey version 2.0 - fixed length form - ages 8-17;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Fear Survey version 2.0 - fixed length form - ages 8-17 [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85145-1;Meaning and Purpose Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Meaning and Purpose Survey - age 18+ - T-score [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.66;2.66 +85146-9;Meaning and Purpose Survey - CAT item bank - age 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Meaning and Purpose Survey - CAT item bank - age 18+ [NIH Toolbox];;Copyright © 2006-2016 National Institutes of Health and Northwestern University. Used with permission.;ACTIVE;2.64;2.64 +85147-7;Programmed cell death ligand 1 by clone 22C3;Find;Pt;Tiss;Doc;Immune stain;PATH;1;PD-L1 by clone 22C3 in Tissue by Immune stain Report;PD-L1 by 22C3 Tiss ImStn Doc;;ACTIVE;2.58;2.66 +85148-5;Programmed cell death ligand 1 by clone 28-8;Find;Pt;Tiss;Doc;Immune stain;PATH;1;PD-L1 by clone 28-8 in Tissue by Immune stain Report;PD-L1 by 28-8 Tiss ImStn Doc;;ACTIVE;2.58;2.66 +85149-3;Programmed cell death ligand 1 by clone SP142;Find;Pt;Tiss;Doc;Immune stain;PATH;1;PD-L1 by clone SP142 in Tissue by Immune stain Report;PD-L1 by SP142 Tiss ImStn Doc;;ACTIVE;2.58;2.66 +85150-1;Bone age method;Type;Pt;XXX>Bones;Nom;*;H&P.HX;2;Bone age method;Bone age method;;ACTIVE;2.58;2.61 +85151-9;Bone age;Time;Pt;XXX>Bones;Qn;XR;RAD;2;XR Bone age;XR Bone age;;ACTIVE;2.58;2.61 +85152-7;Employment status;Type;Pt;^Family member;Nom;;H&P.HX;2;Employment status of family member;Employment status Fam Mem;;ACTIVE;2.58;2.58 +85153-5;Admission evaluation note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Admission evaluation note;Pharmacology Admit eval note;;ACTIVE;2.58;2.58 +85154-3;Discharge summary note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Discharge summary;Pharmacology D/C sum;;ACTIVE;2.58;2.73 +85155-0;Evaluation and management of hyperlipidemia note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Evaluation and management of hyperlipidemia note;Pharmacology E/M hyperlipidemia note;;ACTIVE;2.58;2.58 +85156-8;Evaluation and management of hypertension note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Evaluation and management of hypertension note;Pharmacology E/M hyperten note;;ACTIVE;2.58;2.58 +85157-6;Note;Find;Pt;Hospital;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Hospital Note;Pharmacology Hosp Note;;ACTIVE;2.58;2.58 +85158-4;Letter;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Letter;Pharmacology Letter;;ACTIVE;2.58;2.58 +8515-9;Intravascular diastolic;Pres;Pt;Brachial artery.right;Qn;;BP.MOLEC;2;Brachial artery - right Diastolic blood pressure;Brach a-R BP dias;;ACTIVE;1.0h(3);2.4 +85159-2;Admission evaluation note;Find;Pt;Long term care facility;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Long term care facility Admission evaluation note;Pharmacology LTC fac Admit eval note;;ACTIVE;2.58;2.58 +851-6;A2 Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated A2 Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated A2 Ab SerPl BPU Ql;;DEPRECATED;1.0;2.4 +85160-0;Medication management note;Find;Pt;Long term care facility;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Long term care facility Medication management note;Pharmacology LTC fac Med mgmt note;;ACTIVE;2.58;2.58 +85161-8;Note;Find;Pt;Long term care facility;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Long term care facility Note;Pharmacology LTC fac Note;;ACTIVE;2.58;2.58 +85162-6;Evaluation and management of anticoagulation note;Find;Pt;Outpatient;Doc;Pharmacology.nurse;DOC.ONTOLOGY;2;Pharmacology Nurse Outpatient Evaluation and management of anticoagulation note;Pharmacology Nurse OP E/M coag note;;ACTIVE;2.58;2.58 +85163-4;Counseling note;Find;Pt;Outpatient;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Outpatient Counseling note;Pharmacology OP Counseling note;;ACTIVE;2.58;2.58 +85164-2;Evaluation and management of anticoagulation note;Find;Pt;Outpatient;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Outpatient Evaluation and management of anticoagulation note;Pharmacology OP E/M coag note;;ACTIVE;2.58;2.58 +85165-9;Evaluation and management of hyperlipidemia note;Find;Pt;Outpatient;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Outpatient Evaluation and management of hyperlipidemia note;Pharmacology OP E/M hyperlipidemia note;;ACTIVE;2.58;2.58 +85166-7;Medication management note;Find;Pt;Outpatient;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Outpatient Medication management note;Pharmacology OP Med mgmt note;;ACTIVE;2.58;2.58 +8516-7;Intravascular diastolic;Pres;Pt;Dorsal pedal artery.right;Qn;;BP.MOLEC;2;Dorsal pedal artery - right Diastolic blood pressure;Dors pedal a-R BP dias;;ACTIVE;1.0h(3);2.4 +85167-5;Medication management note;Find;Pt;Patient's home;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Patient's home Medication management note;Pharmacology Pt's home Med mgmt note;;ACTIVE;2.58;2.58 +85168-3;Note;Find;Pt;Patient's home;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Patient's home Note;Pharmacology Pt's home Note;;ACTIVE;2.58;2.58 +85169-1;Note;Find;Pt;{Setting};Doc;Pharmacology.team;DOC.ONTOLOGY;2;Pharmacology Team Note;Pharmacology Team Note;;ACTIVE;2.58;2.58 +85170-9;Note;Find;Pt;{Setting};Doc;Pharmacology.technician;DOC.ONTOLOGY;2;Pharmacology Technician Note;Pharmacology Tech Note;;ACTIVE;2.58;2.58 +85171-7;Education note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Education note;Cust care fac Educ note;;ACTIVE;2.58;2.58 +85172-5;Note;Find;Pt;Custodial care facility;Doc;Case manager;DOC.ONTOLOGY;2;Case manager Custodial care facility Note;Case Manager Cust care fac Note;;ACTIVE;2.58;2.58 +85173-3;Admission evaluation note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Admission evaluation note;Cust care fac Admit eval note;;ACTIVE;2.58;2.58 +85174-1;Consultation note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Consult note;Cust care fac Consult note;;ACTIVE;2.58;2.58 +8517-5;Intravascular diastolic;Pres;Pt;Dorsal pedal artery.left;Qn;;BP.MOLEC;2;Dorsal pedal artery - left Diastolic blood pressure;Dors pedal a-L BP dias;;ACTIVE;1.0h(3);2.4 +85175-8;Counseling note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Counseling note;Cust care fac Counseling note;;ACTIVE;2.58;2.58 +85176-6;Discharge summary note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Discharge summary;Cust care fac D/C sum;;ACTIVE;2.58;2.73 +85177-4;Administrative note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Administrative note;Cust care fac Administrative note;;ACTIVE;2.58;2.58 +85178-2;Group counseling note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Group counseling note;Cust care fac Group counseling note;;ACTIVE;2.58;2.58 +85179-0;History and physical note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility History and physical note;Cust care fac H&P note;;ACTIVE;2.58;2.58 +85180-8;Risk assessment and screening note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Risk assessment and screening note;Cust care fac Risk assess+scrn note;;ACTIVE;2.58;2.58 +85181-6;Transfer summary note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Transfer summary note;Cust care fac Transfer sum note;;ACTIVE;2.58;2.58 +85182-4;Plan of care note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility Plan of care note;Cust care fac Plan of care note;;ACTIVE;2.58;2.63 +8518-3;Intravascular diastolic;Pres;Pt;Femoral artery.left;Qn;;BP.MOLEC;2;Femoral artery - left Diastolic blood pressure;Fem a-L BP dias;;ACTIVE;1.0h(3);2.4 +85183-2;Note;Find;Pt;Custodial care facility;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Custodial care facility Note;Internal Med Cust care fac Note;;ACTIVE;2.58;2.58 +85184-0;Transfer summary note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Transfer summary note;Hosp Transfer sum note;;ACTIVE;2.58;2.58 +85185-7;Initial evaluation note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Initial evaluation note;LTC fac Initial eval note;;ACTIVE;2.58;2.58 +85186-5;Plan of care note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Plan of care note;LTC fac Plan of care note;;ACTIVE;2.58;2.63 +85187-3;Transfer summary note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Transfer summary note;LTC fac Transfer sum note;;ACTIVE;2.58;2.58 +85188-1;Respite note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Respite note;LTC fac Respite note;;ACTIVE;2.58;2.58 +85189-9;Admission evaluation note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Admission evaluation note;LTC fac Admit eval note;;ACTIVE;2.58;2.58 +85190-7;Annual evaluation note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Annual evaluation note;LTC fac Annual eval note;;ACTIVE;2.58;2.58 +8519-1;Intravascular diastolic;Pres;Pt;Femoral artery.right;Qn;;BP.MOLEC;2;Femoral artery - right Diastolic blood pressure;Fem a-R BP dias;;ACTIVE;1.0h(3);2.4 +85191-5;Conference note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Conference note;LTC fac Conf eval note;;ACTIVE;2.58;2.58 +85192-3;Discharge summary note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Discharge summary;LTC fac D/C sum;;ACTIVE;2.58;2.73 +85193-1;Education note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Education note;LTC fac Educ note;;ACTIVE;2.58;2.58 +85194-9;Fall risk assessment note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Fall risk assessment note;LTC fac Fall risk assess note;;ACTIVE;2.58;2.58 +85195-6;Group counseling note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Group counseling note;LTC fac Group counseling note;;ACTIVE;2.58;2.58 +85196-4;History and physical note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility History and physical note;LTC fac H&P note;;ACTIVE;2.58;2.58 +85197-2;Risk assessment and screening note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Risk assessment and screening note;LTC fac Risk assess+scrn note;;ACTIVE;2.58;2.58 +85198-0;Living will;Find;Pt;Long term care facility;Doc;Patient;DOC.ONTOLOGY;2;Patient Long term care facility Living will;Patient LTC fac Living will;;ACTIVE;2.58;2.67 +85199-8;Referral note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Referral note;LTC fac Referral note;;ACTIVE;2.58;2.58 +85200-4;Discharge summary note;Find;Pt;Observation unit;Doc;{Role};DOC.ONTOLOGY;2;Observation unit Discharge summary;Obs Unit D/C sum;;ACTIVE;2.58;2.73 +85201-2;History and physical note;Find;Pt;Observation unit;Doc;{Role};DOC.ONTOLOGY;2;Observation unit History and physical note;Obs Unit H&P note;;ACTIVE;2.58;2.58 +85202-0;Evaluation and management of smoking cessation note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Evaluation and management of smoking cessation note;OP E/M smoke cess note;;ACTIVE;2.58;2.58 +85203-8;History and physical note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home History and physical note;Pt's home H&P note;;ACTIVE;2.58;2.58 +85204-6;Risk assessment and screening note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Risk assessment and screening note;Pt's home Risk assess+scrn note;;ACTIVE;2.58;2.58 +85205-3;Referral note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Referral note;Pt's home Referral note;;ACTIVE;2.58;2.58 +85206-1;Initial evaluation note;Find;Pt;Telehealth;Doc;{Role};DOC.ONTOLOGY;2;Telehealth Initial evaluation note;Telehealth Initial eval note;;ACTIVE;2.58;2.58 +85207-9;Education note;Find;Pt;Telehealth;Doc;{Role};DOC.ONTOLOGY;2;Telehealth Education note;Telehealth Educ note;;ACTIVE;2.58;2.58 +85208-7;Consultation note;Find;Pt;Telehealth;Doc;{Role};DOC.ONTOLOGY;2;Telehealth Consult note;Telehealth Consult note;;ACTIVE;2.58;2.58 +8520-9;Intravascular diastolic;Pres;Pt;Great toe arteries.left;Qn;;BP.MOLEC;2;Great toe arteries - left Diastolic blood pressure;Great toe aa-L BP dias;;ACTIVE;1.0h(3);2.4 +85209-5;Evaluation and management of smoking cessation note;Find;Pt;Telephone encounter;Doc;{Role};DOC.ONTOLOGY;2;Telephone encounter Evaluation and management of smoking cessation note;Phone E/M smoke cess note;;ACTIVE;2.58;2.58 +85210-3;Triage note;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center Triage note;Urgent care Triage note;;ACTIVE;2.58;2.58 +85211-1;Discharge instructions;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center Discharge instructions;Urgent care Discharge instruct;;ACTIVE;2.58;2.58 +85212-9;Respite note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Respite note;Respite note;;ACTIVE;2.58;2.58 +85213-7;Outreach note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Outreach note;Outreach note;;ACTIVE;2.58;2.58 +85214-5;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Transplant candidate evaluation note;Trnsplt cand eval nte;;ACTIVE;2.58;2.58 +85215-2;Transplant donor evaluation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Transplant donor evaluation note;Trsplnt donor eval note;;ACTIVE;2.58;2.58 +85216-0;Disability examination note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Disability examination note;Disability exam note;;ACTIVE;2.58;2.58 +8521-7;Intravascular diastolic;Pres;Pt;Great toe arteries.right;Qn;;BP.MOLEC;2;Great toe arteries - right Diastolic blood pressure;Great toe aa-R BP dias;;ACTIVE;1.0h(3);2.4 +85217-8;VA C&P exam.multiple exam note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;VA Compensation and Pension (C and P) multiple examination;VA C&P Multiple exam;;ACTIVE;2.58;2.58 +85218-6;Note;Find;Pt;Hospital;Doc;Internal medicine.attending;DOC.ONTOLOGY;2;Internal medicine Attending Hospital Note;Internal med Attend Hosp Note;;ACTIVE;2.58;2.65 +85219-4;Transfer summary note;Find;Pt;Intensive care unit;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Intensive care unit Transfer summary note;Internal Med ICU Transfer sum note;;ACTIVE;2.58;2.58 +85220-2;Note;Find;Pt;{Setting};Doc;Acupuncture;DOC.ONTOLOGY;2;Acupuncture Note;Acupuncture Note;;ACTIVE;2.58;2.58 +85221-0;Note;Find;Pt;{Setting};Doc;Acupuncture.nurse;DOC.ONTOLOGY;2;Acupuncture Nurse Note;Acupuncture Nurse Note;;ACTIVE;2.58;2.58 +85222-8;Consultation note;Find;Pt;{Setting};Doc;Case manager;DOC.ONTOLOGY;2;Case manager Consult note;Case Manager Consult note;;ACTIVE;2.58;2.58 +85223-6;Discharge summary note;Find;Pt;{Setting};Doc;Case manager;DOC.ONTOLOGY;2;Case manager Discharge summary;Case Manager D/C sum;;ACTIVE;2.58;2.73 +85224-4;Note;Find;Pt;Long term care facility;Doc;Case manager;DOC.ONTOLOGY;2;Case manager Long term care facility Note;Case Manager LTC fac Note;;ACTIVE;2.58;2.58 +8522-5;Intravascular diastolic;Pres;Pt;Iliac artery.left;Qn;;BP.MOLEC;2;Iliac artery - left Diastolic blood pressure;Iliac a-L BP dias;;ACTIVE;1.0h(3);2.4 +85225-1;Note;Find;Pt;Outpatient;Doc;Case manager;DOC.ONTOLOGY;2;Case manager Outpatient Note;Case Manager OP Note;;ACTIVE;2.58;2.58 +85226-9;Referral note;Find;Pt;{Setting};Doc;Case manager;DOC.ONTOLOGY;2;Case manager Referral note;Case Manager Referral note;;ACTIVE;2.58;2.58 +85227-7;Note;Find;Pt;Telephone encounter;Doc;Case manager;DOC.ONTOLOGY;2;Case manager Telephone encounter Note;Case Manager Phone Note;;ACTIVE;2.58;2.58 +85228-5;Plan of care note;Find;Pt;{Setting};Doc;Case manager;DOC.ONTOLOGY;2;Case manager Plan of care note;Case Manager Plan of care note;;ACTIVE;2.58;2.63 +85229-3;Note;Find;Pt;{Setting};Doc;Clinical nurse specialist;DOC.ONTOLOGY;2;Clinical nurse specialist Note;Clin nurse specialist Note;;ACTIVE;2.58;2.58 +85230-1;Procedure note;Find;Pt;{Setting};Doc;Medical genetics.nurse;DOC.ONTOLOGY;2;Medical genetics Nurse procedure note;Med Gen Nurse Procedure note;;ACTIVE;2.58;2.58 +85231-9;Note;Find;Pt;{Setting};Doc;Tumor board;DOC.ONTOLOGY;2;Tumor board Note;Tumor board Note;;ACTIVE;2.58;2.58 +85232-7;Consultation note;Find;Pt;{Setting};Doc;Tumor board;DOC.ONTOLOGY;2;Tumor board Consult note;Tumor board Consult note;;ACTIVE;2.58;2.58 +8523-3;Intravascular diastolic;Pres;Pt;Iliac artery.right;Qn;;BP.MOLEC;2;Iliac artery - right Diastolic blood pressure;Iliac a-R BP dias;;ACTIVE;1.0h(3);2.4 +85233-5;Admission evaluation note;Find;Pt;{Setting};Doc;Internal medicine.attending;DOC.ONTOLOGY;2;Internal medicine Attending Admission evaluation note;Internal med Attend Admit eval note;;ACTIVE;2.58;2.65 +85234-3;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Internal medicine.attending;DOC.ONTOLOGY;2;Internal medicine Attending Intensive care unit Admission evaluation note;Internal med MD Attend ICU Adm eval note;;ACTIVE;2.58;2.65 +85235-0;Note;Find;Pt;Intensive care unit;Doc;Internal medicine.attending;DOC.ONTOLOGY;2;Internal medicine Attending Intensive care unit Note;Internal med Attend ICU Note;;ACTIVE;2.58;2.65 +85236-8;Procedure note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine procedure note;Internal Med Procedure note;;ACTIVE;2.58;2.58 +85237-6;Consultation note;Find;Pt;{Setting};Doc;Acupuncture;DOC.ONTOLOGY;2;Acupuncture Consult note;Acupuncture Consult note;;ACTIVE;2.58;2.58 +85238-4;Consultation note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Consult note;Internal Med Consult note;;ACTIVE;2.58;2.58 +85239-2;Admission evaluation note;Find;Pt;Intensive care unit;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Intensive care unit Admission evaluation note;Internal Med ICU Admit eval note;;ACTIVE;2.58;2.58 +852-4;A2 Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated A2 Ab [Presence] on Red Blood Cells from donor;Deprecated A2 Ab SerPl Donr Ql;;DEPRECATED;1.0;2.4 +85240-0;Discharge summary note;Find;Pt;Intensive care unit;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Intensive care unit Discharge summary;Internal Med ICU D/C sum;;ACTIVE;2.58;2.73 +8524-1;Intravascular diastolic;Pres;Pt;Posterior tibial artery.left;Qn;;BP.MOLEC;2;Posterior tibial artery - left Diastolic blood pressure;Post Tibl a-L BP dias;;ACTIVE;1.0h(3);2.4 +85241-8;Note;Find;Pt;Intensive care unit;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Intensive care unit Note;Internal Med ICU Note;;ACTIVE;2.58;2.58 +85242-6;Procedure note;Find;Pt;Intensive care unit;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Intensive care unit procedure note;Internal Med ICU Procedure note;;ACTIVE;2.58;2.58 +85243-4;Discharge summary note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Discharge summary;Internal Med D/C sum;;ACTIVE;2.58;2.73 +85244-2;Education note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Education note;Internal Med Educ note;;ACTIVE;2.58;2.58 +85245-9;History and physical note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine History and physical note;Internal Med H&P note;;ACTIVE;2.58;2.58 +85246-7;Admission evaluation note;Find;Pt;{Setting};Doc;Internal medicine.intern;DOC.ONTOLOGY;2;Internal medicine Intern Admission evaluation note;Internal med intern Admit eval note;;ACTIVE;2.58;2.65 +85247-5;Note;Find;Pt;Long term care facility;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Long term care facility Note;Internal Med LTC fac Note;;ACTIVE;2.58;2.58 +85248-3;Note;Find;Pt;{Setting};Doc;Internal medicine.nurse practitioner;DOC.ONTOLOGY;2;Internal medicine Nurse practitioner Note;Internal med NP Note;;ACTIVE;2.58;2.58 +85249-1;Note;Find;Pt;{Setting};Doc;Internal medicine.nurse;DOC.ONTOLOGY;2;Internal medicine Nurse Note;Internal med Nurse Note;;ACTIVE;2.58;2.58 +85250-9;Admission evaluation note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Admission evaluation note;Internal Med Admit eval note;;ACTIVE;2.58;2.58 +85251-7;Admission evaluation note;Find;Pt;{Setting};Doc;Internal medicine.resident;DOC.ONTOLOGY;2;Internal medicine Resident Admission evaluation note;Internal med Res Admit eval note;;ACTIVE;2.58;2.65 +85252-5;Note;Find;Pt;Telephone encounter;Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Telephone encounter Note;Internal Med Phone Note;;ACTIVE;2.58;2.58 +85253-3;Transfer summary note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Transfer summary note;Internal Med Transfer sum note;;ACTIVE;2.58;2.58 +85254-1;Plan of care note;Find;Pt;{Setting};Doc;Internal medicine.interdisciplinary;DOC.ONTOLOGY;2;Internal medicine Interdisciplinary Plan of care note;Internal med Interdisc Plan of care note;;ACTIVE;2.58;2.63 +85255-8;Administrative note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Administrative note;Radiology Administrative note;;ACTIVE;2.58;2.58 +85256-6;Note;Find;Pt;{Setting};Doc;Radiology.attending;DOC.ONTOLOGY;2;Radiology Attending Note;Radiology Attend Note;;ACTIVE;2.58;2.65 +85257-4;Education note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Education note;Radiology Educ note;;ACTIVE;2.58;2.58 +8525-8;Intravascular diastolic;Pres;Pt;Posterior tibial artery.right;Qn;;BP.MOLEC;2;Posterior tibial artery - right Diastolic blood pressure;Post Tibl a-R BP dias;;ACTIVE;1.0h(3);2.4 +85258-2;Education note;Find;Pt;{Setting};Doc;Radiology.nurse;DOC.ONTOLOGY;2;Radiology Nurse Education note;Radiology Nurse Educ note;;ACTIVE;2.58;2.58 +85259-0;Note;Find;Pt;{Setting};Doc;Radiology.nurse;DOC.ONTOLOGY;2;Radiology Nurse Note;Radiology Nurse Note;;ACTIVE;2.58;2.58 +85260-8;Procedure note;Find;Pt;{Setting};Doc;Radiology.nurse;DOC.ONTOLOGY;2;Radiology Nurse procedure note;Radiology Nurse Procedure note;;ACTIVE;2.58;2.58 +85261-6;Procedure note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology procedure note;Radiology Procedure note;;ACTIVE;2.58;2.58 +85262-4;Note;Find;Pt;{Setting};Doc;Radiology.technician;DOC.ONTOLOGY;2;Radiology Technician Note;Radiology Tech Note;;ACTIVE;2.58;2.58 +85263-2;Note;Find;Pt;Telephone encounter;Doc;Radiology;DOC.ONTOLOGY;2;Radiology Telephone encounter Note;Radiology Phone Note;;ACTIVE;2.58;2.58 +85264-0;Transplant candidate evaluation note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Transplant candidate evaluation note;Infectious disease Trnsplt cand eval nte;;ACTIVE;2.58;2.58 +85265-7;Medication management note;Find;Pt;{Setting};Doc;Internal medicine.pharmacist;DOC.ONTOLOGY;2;Internal medicine Pharmacist Medication management note;Internal med Pharm Med mgmt note;;ACTIVE;2.58;2.58 +8526-6;Intravascular diastolic;Pres;Pt;Radial artery.left;Qn;;BP.MOLEC;2;Radial artery - left Diastolic blood pressure;Radial a-L BP dias;;ACTIVE;1.0h(3);2.4 +85266-5;Note;Find;Pt;{Setting};Doc;Internal medicine.interdisciplinary;DOC.ONTOLOGY;2;Internal medicine Interdisciplinary Note;Internal med Interdiscip Note;;ACTIVE;2.58;2.58 +85267-3;X-linked adrenoleukodystrophy (X-ALD) newborn screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;X-linked adrenoleukodystrophy (X-ALD) newborn screening panel;X-ALD NBS Pnl DBS;;ACTIVE;2.58;2.58 +85268-1;X-linked adrenoleukodystrophy newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;CHEM;1;X-linked adrenoleukodystrophy newborn screening comment-discussion;X-ALD NBS comment;;ACTIVE;2.58;2.58 +85269-9;X-linked adrenoleukodystrophy;Imp;Pt;Bld.dot;Nom;;CHEM;1;X-linked adrenoleukodystrophy newborn screen interpretation;X-ALD DBS-Imp;;ACTIVE;2.58;2.58 +85270-7;Furcation site;Anat;Pt;Tooth;Nom;;DENTAL;2;Furcation site Tooth;Furc site Tooth;;ACTIVE;2.58;2.58 +85271-5;Frenum involvement site;Anat;Pt;Oral cavity;Nom;;DENTAL;2;Frenum involvement site Oral cavity;Frenum involve site Oral cavity;;ACTIVE;2.58;2.58 +85272-3;Bleeding on probing;PrThr;Pt;Tooth;Ord;;DENTAL;2;Bleeding on probing Tooth;BOP Tooth;;ACTIVE;2.58;2.58 +85273-1;REMS Conversion to Shared System;-;-;^FDA package insert;-;;DOC.REF;2;FDA package insert REMS conversion to shared system;FDA insert REMS conversion to shared sys;;ACTIVE;2.61;2.61 +8527-4;Intravascular diastolic;Pres;Pt;Radial artery.right;Qn;;BP.MOLEC;2;Radial artery - right Diastolic blood pressure;Radial a-R BP dias;;ACTIVE;1.0h(3);2.4 +85274-9;REMS Release;-;-;^FDA package insert;-;;DOC.REF;2;FDA package insert REMS release;FDA insert REMS release;;ACTIVE;2.61;2.61 +85275-6;Adjacent structure invaded by tumor;Anat;Pt;Colorectal cancer specimen;Nom;Microscopy.light;PATH.HISTO;1;Adjacent structure invaded by tumor [Anatomy] in Colorectal cancer specimen by Light microscopy;Adj struct invaded CRC spec Micro;;ACTIVE;2.61;2.61 +85276-4;Closest surgical margin when all margins are uninvolved;Type;Pt;Colorectal cancer specimen;Nom;Microscopy.light;PATH;1;Closest surgical margin when all margins are uninvolved [Type] in Colorectal cancer specimen by Light microscopy;Clos uninvolv margin CRC spec Micro;;ACTIVE;2.61;2.61 +85277-2;Distance of carcinoma from closest mucosal margin when all mucosal margins are uninvolved;Len;Pt;Colorectal cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from closest mucosal margin when all mucosal margins are uninvolved [Length] in Colorectal cancer specimen by Light microscopy;Ca dist closest uninv muc marg CRC Micro;;ACTIVE;2.61;2.61 +85278-0;Distance of carcinoma from closest surgical margin when all margins are uninvolved;Len;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from closest surgical margin when all margins are uninvolved [Length] in Cancer specimen by Light microscopy;Ca dist closest uninv marg Ca spec Micro;;ACTIVE;2.61;2.61 +85279-8;Excised length;Len;Pt;Colon;Qn;Macroscopy;PATH;1;Excised length [Length] of Colon by Macroscopy;Excised len Colon Macro;;ACTIVE;2.61;2.61 +85281-4;Intratumoral lymphocytic response;Find;Pt;Cancer specimen;Ord;Microscopy.light;PATH;1;Intratumoral lymphocytic response in Cancer specimen Qualitative by Light microscopy;Intratum lymph resp Ca spec Ql Micro;;ACTIVE;2.61;2.61 +8528-2;Intravascular diastolic;Pres;Pt;Ulnar artery.left;Qn;;BP.MOLEC;2;Ulnar artery - left Diastolic blood pressure;Ulnar a-L BP dias;;ACTIVE;1.0h(3);2.4 +85282-2;Mucinous fraction;AreaFr;Pt;Colorectal cancer specimen;Qn;Microscopy.light;PATH;1;Mucinous fraction [Area Fraction] in Colorectal cancer specimen by Light microscopy;Mucinous fraction AreaFr CRC spec Micro;;ACTIVE;2.61;2.61 +85283-0;Organ tumor is adherent to;Anat;Pt;Colorectal cancer specimen;Nom;Microscopy.light;PATH;1;Organ tumor is adherent to [Anatomy] in Colorectal cancer specimen by Light microscopy;Organ tum adherent to CRC spec Micro;;ACTIVE;2.61;2.61 +85284-8;Peritumoral lymphocytic response;Find;Pt;Cancer specimen;Ord;Microscopy.light;PATH;1;Peritumoral lymphocytic response in Cancer specimen Qualitative by Light microscopy;Peritum lymph resp Ca spec Ql Micro;;ACTIVE;2.61;2.61 +85285-5;Polyp in which invasive carcinoma arose;Type;Pt;Colorectal cancer specimen;Nom;Microscopy.light;PATH;1;Polyp in which invasive carcinoma arose [Type] in Colorectal cancer specimen by Light microscopy;Polyp type in which inv carc arose Micro;;ACTIVE;2.61;2.61 +85286-3;Promoter methylation testing method;Type;Pt;Cancer specimen;Nom;*;PATH;1;Promoter methylation testing method [Type] in Cancer specimen;Prom methyl method Ca spec;;ACTIVE;2.61;2.61 +85287-1;Radial position of closest mucosal margin involved by invasive carcinoma;Angle;Pt;Colorectal cancer specimen;Qn;Microscopy.light;PATH.HISTO;1;Radial position of closest mucosal margin involved by invasive carcinoma [Angle] in Colorectal cancer specimen by Light microscopy;Radial pos inv muc margin CRC spec;;ACTIVE;2.61;2.61 +85288-9;Radial position of closest mucosal margin when mucosal margin uninvolved by invasive carcinoma;Angle;Pt;Colorectal cancer specimen;Qn;Microscopy.light;PATH.HISTO;1;Radial position of closest uninvolved mucosal margin [Angle] in Colorectal cancer specimen by Light microscopy;Radial pos uninv muc margin CRC spec;;ACTIVE;2.61;2.61 +85289-7;Signet ring cells/100 cells;NFr;Pt;Colorectal cancer specimen;Qn;Microscopy.light;PATH;1;Signet ring cells/100 cells in Colorectal cancer specimen by Light microscopy;Signet ring cells NFr CRC spec Micro;;ACTIVE;2.61;2.61 +8529-0;Intravascular diastolic;Pres;Pt;Ulnar artery.right;Qn;;BP.MOLEC;2;Ulnar artery - right Diastolic blood pressure;Ulnar a-R BP dias;;ACTIVE;1.0h(3);2.4 +85290-5;Surgical margin tumor involvement;PrThr;Pt;Colorectal cancer specimen;Ord;Microscopy.light;PATH;1;Surgical margin tumor involvement [Presence] in Colorectal cancer specimen by Light microscopy;Marg tumor involve CRC spec Ql Micro;;ACTIVE;2.61;2.61 +85291-3;Surgical margin tumor involvement.deep;PrThr;Pt;Colorectal cancer specimen;Ord;Microscopy.light;PATH;1;Surgical margin tumor involvement.deep [Presence] in Colorectal cancer specimen by Light microscopy;Marg tumor invol.deep CRC spec Ql Micro;;ACTIVE;2.61;2.61 +85292-1;Surgical margin tumor involvement.distant;PrThr;Pt;Colorectal cancer specimen;Ord;Microscopy.light;PATH;1;Surgical margin tumor involvement.distant [Presence] in Colorectal cancer specimen by Light microscopy;Marg tumor invol.dist CRC spec Ql Micro;;ACTIVE;2.61;2.61 +85293-9;Surgical margin tumor involvement.mesenteric;PrThr;Pt;Colorectal cancer specimen;Ord;Microscopy.light;PATH;1;Surgical margin tumor involvement.mesenteric [Presence] in Colorectal cancer specimen by Light microscopy;Marg tumor invol.mes CRC spec Ql Micro;;ACTIVE;2.61;2.61 +85294-7;Surgical margin tumor involvement.mucosal;Prid;Pt;Colorectal cancer specimen;Nom;Microscopy.light;PATH;1;Surgical margin tumor involvement.mucosal [Identifier] in Colorectal cancer specimen by Light microscopy;Marg tumor invol.muc CRC spec Micro;;ACTIVE;2.61;2.61 +85295-4;Surgical margin tumor involvement.proximal;PrThr;Pt;Colorectal cancer specimen;Ord;Microscopy.light;PATH;1;Surgical margin tumor involvement.proximal [Presence] in Colorectal cancer specimen by Light microscopy;Marg tumor invol.prox CRC spec Ql Micro;;ACTIVE;2.61;2.61 +85296-2;Tumor budding;PrThr;Pt;Cancer specimen;Ord;Microscopy.light;PATH;1;Tumor budding [Presence] in Cancer specimen by Light microscopy;Tumor budding Ca spec Ql Micro;;ACTIVE;2.61;2.61 +85297-0;Tumor buds;Naric;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Tumor buds [#/area] in Cancer specimen by Light microscopy;Tumor buds #/area Ca spec Micro;;ACTIVE;2.61;2.61 +85298-8;Body structure included in specimen;Anat;Pt;Specimen;Nom;;PATH;1;Body structure included in specimen [Anatomy] in Specimen;Struct incl in spec Spec;;ACTIVE;2.61;2.61 +85299-6;Serine-threonine protein kinase B-raf V600E;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;BRAF V600E mutant protein [Presence] in Cancer specimen by Immune stain;BRAF V600E Ca spec Ql ImStn;;ACTIVE;2.61;2.61 +85300-2;Mitotic rate;Score;Pt;Breast cancer specimen;Ord;Nottingham;PATH;1;Mitotic rate [Score] in Breast cancer specimen Qualitative by Nottingham;Mitotic rate Br ca spec Ql Nottingham;;ACTIVE;2.61;2.61 +85301-0;Adjacent structure invaded by tumor;Anat;Pt;Breast cancer specimen;Nom;Macroscopy;PATH.HISTO;1;Adjacent structure invaded by tumor [Anatomy] in Breast cancer specimen by Macroscopy;Adj struct invaded Br ca spec Macro;;ACTIVE;2.61;2.61 +85302-8;Growth pattern of DCIS;Type;Pt;Breast cancer specimen;Nom;Microscopy.light;PATH;1;Growth pattern of DCIS [Type] in Breast cancer specimen by Light microscopy;DCIS growth patt Br ca spec Micro;;ACTIVE;2.61;2.61 +85303-6;Body structure of origin;Anat;Pt;Breast cancer specimen;Nom;;PATH;1;Body structure of origin [Anatomy] in Breast cancer specimen;Struct of origin Br ca spec;;ACTIVE;2.61;2.61 +85304-4;Distance of carcinoma from uninvolved anterior margin;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from anterior margin [Length] in Breast cancer specimen by Light microscopy;Dist Ca ant marg Br ca spec Micro;;ACTIVE;2.61;2.61 +85305-1;Distance of carcinoma from uninvolved inferior margin;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from inferior margin [Length] in Breast cancer specimen by Light microscopy;Dist Ca infer marg Br ca spec Micro;;ACTIVE;2.61;2.61 +85306-9;Distance of carcinoma from uninvolved lateral margin;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from lateral margin [Length] in Breast cancer specimen by Light microscopy;Dist Ca lat marg Br ca spec Micro;;ACTIVE;2.61;2.61 +85307-7;Distance of carcinoma from uninvolved medial margin;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from medial margin [Length] in Breast cancer specimen by Light microscopy;Dist Ca med marg Br ca spec Micro;;ACTIVE;2.61;2.61 +8530-8;Intravascular mean;Pres;Pt;Brachial artery.left;Qn;;BP.MOLEC;2;Brachial artery - left Mean blood pressure;Brach a-L BP mean;;ACTIVE;1.0h(3);2.4 +85308-5;Distance of carcinoma from uninvolved posterior margin;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from posterior margin [Length] in Breast cancer specimen by Light microscopy;Dist Ca post marg Br ca spec Micro;;ACTIVE;2.61;2.61 +85309-3;Distance of carcinoma from uninvolved superior margin;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Distance of carcinoma from superior margin [Length] in Breast cancer specimen by Light microscopy;Dist Ca sup marg Br ca spec Micro;;ACTIVE;2.61;2.61 +85310-1;Estrogen receptor fluorescence intensity;Type;Pt;Breast cancer specimen;Ord;Immune stain;PATH;1;Estrogen receptor fluorescence intensity [Type] in Breast cancer specimen by Immune stain;ER fluor intensity Br ca spec Ql ImStn;;ACTIVE;2.61;2.61 +85311-9;Extent of anterior margin carcinoma involvement;Find;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Extent of anterior margin carcinoma involvement in Breast cancer specimen Qualitative by Light microscopy;Ant marg Ca extent Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85312-7;Extent of inferior margin carcinoma involvement;Find;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Extent of inferior margin carcinoma involvement in Breast cancer specimen Qualitative by Light microscopy;Inf marg Ca extent Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85313-5;Extent of lateral margin carcinoma involvement;Find;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Extent of lateral margin carcinoma involvement in Breast cancer specimen Qualitative by Light microscopy;Lat marg Ca extent Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85314-3;Extent of medial margin carcinoma involvement;Find;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Extent of medial margin carcinoma involvement in Breast cancer specimen Qualitative by Light microscopy;Med marg Ca extent Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85315-0;Extent of posterior margin carcinoma involvement;Find;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Extent of posterior margin carcinoma involvement in Breast cancer specimen Qualitative by Light microscopy;Post marg Ca extent Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +8531-6;Intravascular mean;Pres;Pt;Brachial artery.right;Qn;;BP.MOLEC;2;Brachial artery - right Mean blood pressure;Brach a-R BP mean;;ACTIVE;1.0h(3);2.4 +85316-8;Extent of superior margin carcinoma involvement;Find;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Extent of superior margin carcinoma involvement in Breast cancer specimen Qualitative by Light microscopy;Sup marg Ca extent Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85317-6;DCIS.max dimension;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;DCIS.max dimension [Length] in Breast cancer specimen by Light microscopy;DCIS.max dim Br ca spec Micro;;ACTIVE;2.61;2.61 +85318-4;ERBB2 gene duplication;PrThr;Pt;Breast cancer specimen;Ord;FISH;MOLPATH;1;ERBB2 gene duplication [Presence] in Breast cancer specimen by FISH;ERBB2 gene Dp Br ca spec Ql FISH;;ACTIVE;2.61;2.73 +85319-2;HER2;PrThr;Pt;Breast cancer specimen;Ord;Immune stain;PATH;1;HER2 [Presence] in Breast cancer specimen by Immune stain;Her2 Br ca spec Ql ImStn;;ACTIVE;2.61;2.65 +853-2;A2 Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated A2 Ab;Deprecated A2 Ab Ser Ql;;DEPRECATED;1.0;2.36 +85320-0;Foci;Type;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Foci [Type] in Breast cancer specimen by Light microscopy;Foci Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85321-8;Glandular differentiation;Score;Pt;Breast cancer specimen;Ord;Nottingham;PATH;1;Glandular differentiation [Score] in Breast cancer specimen Qualitative by Nottingham;Gland diff Br ca spec Ql Nottingham;;ACTIVE;2.61;2.61 +85322-6;Adjacent structure invaded by tumor;Anat;Pt;Breast cancer specimen;Nom;Microscopy.light;PATH.HISTO;1;Adjacent structure invaded by tumor [Anatomy] in Breast cancer specimen by Light microscopy;Adj struct invaded Br ca spec Micro;;ACTIVE;2.61;2.61 +85323-4;Response to neoadjuvant therapy;Find;Pt;Breast cancer specimen;Ord;;PATH;1;Response to neoadjuvant therapy in Breast cancer specimen Qualitative;Resp to neoadjvt therapy Br ca spec Ql;;ACTIVE;2.61;2.61 +8532-4;Intravascular mean;Pres;Pt;Dorsal pedal artery.left;Qn;;BP.MOLEC;2;Dorsal pedal artery - left Mean blood pressure;Dors pedal a-L BP mean;;ACTIVE;1.0h(3);2.4 +85325-9;Cells.progesterone receptor/100 cells;NFr;Pt;Breast cancer specimen;Qn;Immune stain;PATH;1;Cells.progesterone receptor/100 cells in Breast cancer specimen by Immune stain;PR+ cells NFr Br ca spec ImStn;;ACTIVE;2.61;2.61 +85326-7;Tissue blocks positive for DCIS;Num;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Tissue blocks positive for DCIS [#] in Breast cancer specimen by Light microscopy;Blocks pos for DCIS Br ca spec Micro;;ACTIVE;2.61;2.61 +85327-5;Foci;Num;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;Foci [#] in Breast cancer specimen by Light microscopy;Foci Br ca spec Micro;;ACTIVE;2.61;2.61 +85328-3;Cells.HER2 uniform intense membrane staining/100 cells;NFr;Pt;Breast cancer specimen;Qn;Immune stain;PATH;1;Cells.HER2 uniform intense membrane staining/100 cells in Breast cancer specimen by Immune stain;HER2 unif int NFr Br ca spec ImStn;;ACTIVE;2.61;2.61 +85329-1;Cells.estrogen receptor/100 cells;NFr;Pt;Breast cancer specimen;Qn;Immune stain;PATH;1;Cells.estrogen receptor/100 cells in Breast cancer specimen by Immune stain;ER+ cells NFr Br ca spec ImStn;;ACTIVE;2.61;2.61 +85330-9;Cells.Ki-67 nuclear Ag/100 cells;NFr;Pt;Breast cancer specimen;Qn;Immune stain;PATH;1;Cells.Ki-67 nuclear Ag/100 cells in Breast cancer specimen by Immune stain;Ki-67 nuclear Ag NFr Br ca spec ImStn;;ACTIVE;2.61;2.61 +85331-7;Progesterone receptor fluorescence intensity;Type;Pt;Breast cancer specimen;Ord;Immune stain;PATH;1;Progesterone receptor fluorescence intensity [Type] in Breast cancer specimen by Immune stain;PR fluor intensity Br ca spec Ql ImStn;;ACTIVE;2.61;2.61 +8533-2;Intravascular mean;Pres;Pt;Dorsal pedal artery.right;Qn;;BP.MOLEC;2;Dorsal pedal artery - right Mean blood pressure;Dors pedal a-R BP mean;;ACTIVE;1.0h(3);2.4 +85332-5;Radial position within breast;Angle;Pt;Breast cancer specimen;Qn;;PATH;1;Radial position in breast [Angle] in Breast cancer specimen;Radial pos in breast Angle Br ca spec;;ACTIVE;2.61;2.61 +85333-3;DCIS.additional dimension 1;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;DCIS.additional dimension 1 [Length] in Breast cancer specimen by Light microscopy;DCIS.addl dim 1 Br ca spec Micro;;ACTIVE;2.61;2.63 +85334-1;Surgical margin DCIS involvement;PrThr;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;Surgical margin DCIS involvement [Presence] in Breast cancer specimen by Light microscopy;Marg DCIS involve Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85335-8;DCIS.additional dimension 2;Len;Pt;Breast cancer specimen;Qn;Microscopy.light;PATH;1;DCIS.additional dimension 2 [Length] in Breast cancer specimen by Light microscopy;DCIS.addl dim 2 Br ca spec Micro;;ACTIVE;2.61;2.63 +85336-6;DCIS intraductal extension;Find;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;DCIS intraductal extension in Breast cancer specimen Qualitative by Light microscopy;DCIS intraduct ext Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85337-4;Estrogen receptor Ag;PrThr;Pt;Breast cancer specimen;Ord;Immune stain;PATH;1;Estrogen receptor Ag [Presence] in Breast cancer specimen by Immune stain;ER Ag Br ca spec Ql ImStn;;ACTIVE;2.61;2.61 +85338-2;Lobular carcinoma in situ;PrThr;Pt;Breast cancer specimen;Ord;Microscopy.light;PATH;1;LCIS [Presence] in Breast cancer specimen by Light microscopy;LCIS Br ca spec Ql Micro;;ACTIVE;2.61;2.61 +85339-0;Progesterone receptor Ag;PrThr;Pt;Breast cancer specimen;Ord;Immune stain;PATH;1;Progesterone receptor Ag [Presence] in Breast cancer specimen by Immune stain;PR Ag Br ca spec Ql ImStn;;ACTIVE;2.61;2.61 +8534-0;Intravascular mean;Pres;Pt;Femoral artery.left;Qn;;BP.MOLEC;2;Femoral artery - left Mean blood pressure;Fem a-L BP mean;;ACTIVE;1.0h(3);2.4 +85340-8;DCIS necrosis;Type;Pt;Breast cancer specimen;Nom;Microscopy.light;PATH;1;DCIS necrosis [Type] in Breast cancer specimen by Light microscopy;DCIS necrosis Br ca spec Micro;;ACTIVE;2.61;2.61 +85341-6;Pathology report reviewed;ID;Pt;Specimen;Nom;;PATH;1;Pathology report reviewed [Identifier] in Specimen;Path report reviewed Spec;;ACTIVE;2.61;2.61 +85342-4;Lymph node site of origin;Anat;Pt;Cancer specimen;Nom;;PATH;1;Lymph node site of origin [Anatomy] in Cancer specimen;LN origin Ca spec;;ACTIVE;2.61;2.61 +85343-2;Lymph nodes with macrometastases;Num;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Lymph nodes with macrometastases [#] in Cancer specimen by Light microscopy;LN macromets Ca spec Micro;;ACTIVE;2.61;2.61 +85344-0;Lymph nodes with micrometastases;Num;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Lymph nodes with micrometastases [#] in Cancer specimen by Light microscopy;LN micromets Ca spec Micro;;ACTIVE;2.61;2.61 +85345-7;Dermal lymph-vascular invasion;Find;Pt;Cancer specimen;Ord;Microscopy.light;PATH.HISTO;1;Dermal lymph-vascular invasion in Cancer specimen Qualitative by Light microscopy;Dermal LVI Ca spec Ql Micro;;ACTIVE;2.61;2.61 +85346-5;Tissue blocks examined;Num;Pt;Specimen;Qn;;PATH;1;Tissue blocks examined [#] in Specimen;Blocks examined Spec;;ACTIVE;2.61;2.61 +85347-3;Sentinel lymph nodes examined;Num;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Sentinel lymph nodes examined [#] in Cancer specimen by Light microscopy;Sent LN exam Ca spec Micro;;ACTIVE;2.61;2.61 +85348-1;Procedure used to obtain tumor specimen;Type;Pt;Specimen;Nom;;PATH;1;Procedure used to obtain tumor specimen [Type] in Specimen;Proc to obtain tumor spec Spec;;ACTIVE;2.61;2.61 +85349-9;Lymph node response to neoadjuvant therapy;Find;Pt;Cancer specimen;Nom;CAP cancer protocols;PATH;1;Lymph node response to neoadjuvant therapy in Cancer specimen by CAP cancer protocols;LN resp neoadj therapy Ca spec CAP prot;Copyright © 2017 College of American Pathologists Used with permission;ACTIVE;2.61;2.61 +85350-7;Extranodal extension of carcinoma;PrThr;Pt;Cancer specimen;Ord;Microscopy.light;PATH;1;Extranodal extension of carcinoma [Presence] in Cancer specimen by Light microscopy;Extranodal ext of ca Ca spec Ql Micro;;ACTIVE;2.61;2.61 +85351-5;Lymph node metastatic deposit.max dimension;Len;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Lymph node metastatic deposit.max dimension [Length] in Cancer specimen by Light microscopy;LN metastasis.max dim Ca spec Micro;;ACTIVE;2.61;2.61 +85352-3;Lymph nodes with isolated tumor cells;Num;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Lymph nodes with isolated tumor cells [#] in Cancer specimen by Light microscopy;LN with isol tum cells Ca spec Micro;;ACTIVE;2.61;2.61 +85353-1;Vital signs, weight, height, head circumference, oxygen saturation & BMI panel;-;Pt;^Patient;-;;PANEL.VITALS;2;Vital signs, weight, height, head circumference, oxygen saturation and BMI panel;Vitals+wt+ht+hc+SaO2+BMI Pnl;;ACTIVE;2.61;2.61 +85354-9;Blood pressure panel with all children optional;-;Pt;Arterial system;Qn;;PANEL.VITALS;2;Blood pressure panel with all children optional;BP pnl w all optional;;ACTIVE;2.61;2.61 +85355-6;Porcine epidemic diarrhea virus S INDEL strain S gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PEDV S INDEL strain S gene [Cycle Threshold #] in Specimen by NAA with probe detection;PEDV S INDEL S gene Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85356-4;Porcine epidemic diarrhea virus prototype strain S gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PEDV prototype strain S gene [Cycle Threshold #] in Specimen by NAA with probe detection;PEDV proto S Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +8535-7;Intravascular mean;Pres;Pt;Femoral artery.right;Qn;;BP.MOLEC;2;Femoral artery - right Mean blood pressure;Fem a-R BP mean;;ACTIVE;1.0h(3);2.4 +85357-2;Porcine epidemic diarrhea virus prototype & S INDEL strain S gene panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;PEDV prototype and S INDEL strain S gene panel - Specimen by NAA with probe detection;PEDV Pro+S INDEL S gene Pnl Spec NAA+pr;;ACTIVE;2.61;2.69 +85358-0;Phosphatidylserine-prothrombin complex Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;COAG;1;Phosphatidylserine-prothrombin complex IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;PS-prothrom cmplx IgM SerPl IA-aCnc;;ACTIVE;2.61;2.73 +85359-8;Phosphatidylserine-prothrombin complex Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;COAG;1;Phosphatidylserine-prothrombin complex IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;PS-prothrom cmplx IgG SerPl IA-aCnc;;ACTIVE;2.61;2.73 +85360-6;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA [Presence] in Nasopharynx by NAA with non-probe detection;B pert+bron+holm IS481 Nph NAA+non-Probe;;ACTIVE;2.61;2.63 +85361-4;HIV 1+2 RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HIV 1+2 RNA [Presence] in Blood by NAA with probe detection;HIV1+2 RNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +85362-2;Mycobacterium tuberculosis complex DNA;PrThr;Pt;Sputum/Bronchial;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis complex DNA [Presence] in Sputum or Bronchial by NAA with probe detection;M TB Cmplx DNA Spt/Bro Ql NAA+probe;;ACTIVE;2.61;2.63 +85363-0;21-Hydroxylase Ab;PrThr;Pt;Ser;Ord;;SERO;1;21-Hydroxylase Ab [Presence] in Serum;21Hydroxylase Ab Ser Ql;;ACTIVE;2.61;2.67 +85364-8;Muscarinic acetylcholine receptor M3 Ab;PrThr;Pt;Ser;Ord;;SERO;1;Muscarinic acetylcholine receptor M3 Ab [Presence] in Serum;Muscarinic AChR M3 Ab Ser Ql;;ACTIVE;2.61;2.67 +8536-5;Intravascular mean;Pres;Pt;Great toe arteries.left;Qn;;BP.MOLEC;2;Great toe arteries - left Mean blood pressure;Great toe aa-L BP mean;;ACTIVE;1.0h(3);2.4 +85365-5;Neutrophil membrane Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil membrane Ab [Presence] in Serum by Immunofluorescence;Neutrophil membrane Ab Ser Ql IF;;ACTIVE;2.61;2.61 +85366-3;Neutrophil membrane Ab.IgM;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil membrane IgM Ab [Presence] in Serum by Immunofluorescence;Neutrophil membrane IgM Ser Ql IF;;ACTIVE;2.61;2.61 +85367-1;Neutrophil membrane Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Neutrophil membrane IgG Ab [Presence] in Serum by Immunofluorescence;Neutrophil membrane IgG Ser Ql IF;;ACTIVE;2.61;2.61 +85368-9;HIV 1+2 RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;HIV 1+2 RNA [Presence] in Serum or Plasma by NAA with probe detection;HIV1+2 RNA SerPl Ql NAA+probe;;ACTIVE;2.61;2.63 +85369-7;Neutrophils;NCnc;Pt;Bld^Control;Qn;Flow cytometry;HEM/BC;1;Neutrophils [#/volume] in Control Blood by Flow cytometry (FC);Neutrophils # Cont Bld FC;;ACTIVE;2.61;2.73 +85370-5;Neutrophil.fMLP stimulated.DHR mean fluorescence intensity;Arb;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Neutrophil.fMLP stimulated.DHR mean fluorescence intensity in Blood by Flow cytometry (FC);Neut.fMLP stim.DHR MFI Bld FC;;ACTIVE;2.61;2.61 +85371-3;Neutrophil.fMLP stimulated.DHR mean fluorescence intensity;Arb;Pt;Bld^Control;Qn;Flow cytometry;HEM/BC;1;Neutrophil.fMLP stimulated.DHR mean fluorescence intensity in Control Blood by Flow cytometry (FC);Neut.fMLP stim.DHR MFI Cont Bld FC;;ACTIVE;2.61;2.61 +85372-1;Neutrophil.fMLP stimulated.DHR/Neutrophil.fMLP stimulated.total;NFr;Pt;Bld^Control;Qn;Flow cytometry;HEM/BC;1;Neutrophil.fMLP stimulated.DHR/Neutrophil.fMLP stimulated.total in Control Blood by Flow cytometry (FC);Neut.fMLP DHR/Neut fMLP NFr Cont Bld FC;;ACTIVE;2.61;2.61 +8537-3;Intravascular mean;Pres;Pt;Great toe arteries.right;Qn;;BP.MOLEC;2;Great toe arteries - right Mean blood pressure;Great toe aa-R BP mean;;ACTIVE;1.0h(3);2.4 +85373-9;Neutrophil.fMLP stimulated.DHR/Neutrophil.fMLP stimulated.total;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Neutrophil.fMLP stimulated.DHR/Neutrophil.fMLP stimulated.total in Blood by Flow cytometry (FC);Neut.fMLP DHR/Neut fMLP NFr Bld FC;;ACTIVE;2.61;2.61 +85374-7;Neutrophil.PMA stimulated.DHR mean fluorescence intensity;Arb;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Neutrophil.PMA stimulated.DHR mean fluorescence instensity in Blood by Flow cytometry (FC);Neut.PMA stim.DHR MFI Bld FC;;ACTIVE;2.61;2.73 +85375-4;Neutrophil.PMA stimulated.DHR mean fluorescence intensity;Arb;Pt;Bld^Control;Qn;Flow cytometry;HEM/BC;1;Neutrophil.PMA stimulated.DHR mean fluorescence instensity in Control Blood by Flow cytometry (FC);Neut.PMA stim.DHR MFI Cont Bld FC;;ACTIVE;2.61;2.73 +85376-2;Neutrophil.PMA stimulated.DHR/Neutrophil.PMA stimulated.total;NFr;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Neutrophil.PMA stimulated.DHR/Neutrophil.PMA stimulated.total in Blood by Flow cytometry (FC);Neut PMA DHR/Neut PMA NFr Bld FC;;ACTIVE;2.61;2.73 +85377-0;Neutrophil.PMA stimulated.DHR/Neutrophil.PMA stimulated.total;NFr;Pt;Bld^Control;Qn;Flow cytometry;HEM/BC;1;Neutrophil.PMA stimulated.DHR/Neutrophil.PMA stimulated.total in Control Blood by Flow cytometry (FC);Neut PMA DHR/Neut PMA NFr Cont Bld FC;;ACTIVE;2.61;2.73 +85378-8;Erythrocytes.EMA mean fluorescence intensity actual/normal;RelRto;Pt;Bld;Qn;Flow cytometry;HEM/BC;1;Erythrocytes.EMA mean fluorescence intensity actual/normal in Blood by Flow cytometry (FC);RBC.EMA MFI Act/Nor Bld FC;;ACTIVE;2.61;2.61 +85379-6;Purine/pyrimidine;Ratio;Pt;RBC;Qn;Spectrophotometry;CHEM;1;Purine/Pyrimidine [Ratio] in Red Blood Cells by Spectrophotometry;Purine/Pyrimidine RBC Spect-Rto;;ACTIVE;2.61;2.61 +85380-4;HIV immunoassay testing algorithm interpretation;Imp;Pt;Ser/Plas/Bld;Nom;;MICRO;1;HIV immunoassay testing algorithm interpretation in Serum, Plasma or Blood;HIV IA algorithm interp SerPlBld-Imp;;ACTIVE;2.61;2.61 +8538-1;Intravascular mean;Pres;Pt;Iliac artery.left;Qn;;BP.MOLEC;2;Iliac artery - left Mean blood pressure;Iliac a-L BP mean;;ACTIVE;1.0h(3);2.4 +85381-2;Isavuconazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Isavuconazole [Susceptibility] by Minimum inhibitory concentration (MIC);Isavuconazole Islt MIC;;ACTIVE;2.61;2.61 +85382-0;Osmolarity;Osmolarity;Pt;Tear;Qn;;CHEM;1;Osmolarity in Tear;Osmolarity Tear;;ACTIVE;2.61;2.61 +85383-8;EGFR gene.c.2369C>T actual/normal;RelRto;Pt;Plas.cfDNA;Qn;Molgen;MOLPATH.MUT;1;EGFR gene c.2369C>T actual/normal in Plasma cell-free DNA by Molecular genetics method;EGFR c.2369C>T Act/Nor Plas.cfDNA;;ACTIVE;2.61;2.61 +85384-6;Amisulpride;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amisulpride [Mass/volume] in Serum or Plasma;Amisulpride SerPl-mCnc;;ACTIVE;2.61;2.61 +85385-3;Views for bone density;ArMass;Pt;Upper extremity>Humerus;Qn;DXA;RAD;2;DXA Humerus [Mass/Area] Bone density;DXA Humerus ArMass BMD;;ACTIVE;2.61;2.64 +85386-1;Views for bone density;ArMass;Pt;Upper extremity.left>Humerus;Qn;DXA;RAD;2;DXA Humerus - left [Mass/Area] Bone density;DXA Humerus-L ArMass BMD;;ACTIVE;2.61;2.64 +85387-9;Views for bone density;ArMass;Pt;Upper extremity.right>Humerus;Qn;DXA;RAD;2;DXA Humerus - right [Mass/Area] Bone density;DXA Humerus-R ArMass BMD;;ACTIVE;2.61;2.64 +85388-7;Views for bone density;Tscore;Pt;Upper extremity.right>Humerus;Qn;DXA;RAD;2;DXA Humerus - right [T-score] Bone density;DXA Humerus-R T-score BMD;;ACTIVE;2.61;2.64 +85389-5;Views for bone density;Tscore;Pt;Upper extremity.left>Humerus;Qn;DXA;RAD;2;DXA Humerus - left [T-score] Bone density;DXA Humerus-L T-score BMD;;ACTIVE;2.61;2.64 +85390-3;Views for bone density;Tscore;Pt;Upper extremity>Humerus;Qn;DXA;RAD;2;DXA Humerus [T-score] Bone density;DXA Humerus T-score BMD;;ACTIVE;2.61;2.64 +85391-1;Views for bone density;Zscore;Pt;Upper extremity>Humerus;Qn;DXA;RAD;2;DXA Humerus [Z-score] Bone density;DXA Humerus Z-score BMD;;ACTIVE;2.61;2.64 +85392-9;Views for bone density;Zscore;Pt;Upper extremity.right>Humerus;Qn;DXA;RAD;2;DXA Humerus - right [Z-score] Bone density;DXA Humerus-R Z-score BMD;;ACTIVE;2.61;2.64 +85393-7;Views for bone density;Zscore;Pt;Upper extremity.left>Humerus;Qn;DXA;RAD;2;DXA Humerus - left [Z-score] Bone density;DXA Humerus-L Z-score BMD;;ACTIVE;2.61;2.64 +85394-5;Views for bone density;Zscore;Pt;Abdomen>Spine.lumbar;Qn;DXA;RAD;2;DXA Lumbar spine [Z-score] Bone density;DXA L-spine Z-score BMD;;ACTIVE;2.61;2.73 +85395-2;IRF-PAI v3.0 - Identification information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Identification information [CMS Assessment];;;ACTIVE;2.61;2.73 +85396-0;IRF-PAI - Facility information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Facility information [CMS Assessment];;;ACTIVE;2.61;2.67 +85397-8;Inpatient rehabilitation facility admission;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Inpatient rehabilitation facility admission [CMS Assessment];;;ACTIVE;2.61;2.61 +85398-6;Admitted from;Type;Pt;Facility;Nom;;SURVEY.CMS;4;Admitted from Facility;;;ACTIVE;2.61;2.64 +8539-9;Intravascular mean;Pres;Pt;Iliac artery.right;Qn;;BP.MOLEC;2;Iliac artery - right Mean blood pressure;Iliac a-R BP mean;;ACTIVE;1.0h(3);2.4 +85399-4;Prior residence;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Prior residence;;;ACTIVE;2.61;2.67 +854-0;A2 Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A2 Ag [Presence] on Red Blood Cells from Blood product unit;A2 Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +85400-0;Prior living arrangement;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Prior living arrangement [CMS Assessment];;;ACTIVE;2.61;2.61 +85401-8;IRF-PAI - Payer information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Payer information [CMS Assessment];;;ACTIVE;2.61;2.67 +85402-6;Payment source.primary;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Primary payment source [CMS Assessment];;;ACTIVE;2.61;2.61 +85403-4;Payment source.secondary;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Secondary payment source [CMS Assessment];;;ACTIVE;2.61;2.61 +85404-2;IRF-PAI - Medical information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Medical information [CMS Assessment];;;ACTIVE;2.61;2.61 +85405-9;IRF-PAI - Impairment group - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Impairment group - admission [CMS Assessment];;;ACTIVE;2.61;2.69 +85406-7;IRF-PAI - Impairment group - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Impairment group - discharge [CMS Assessment];;;ACTIVE;2.61;2.69 +8540-7;Intravascular mean;Pres;Pt;Posterior tibial artery.left;Qn;;BP.MOLEC;2;Posterior tibial artery - left Mean blood pressure;Post Tibl a-L BP mean;;ACTIVE;1.0h(3);2.4 +85407-5;Arthritis conditions recorded;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Arthritis conditions recorded [CMS Assessment];;;ACTIVE;2.61;2.61 +85408-3;Swallowing status - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Swallowing status - admission [CMS Assessment];;;ACTIVE;2.61;2.61 +85409-1;Swallowing status - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Swallowing status - discharge [CMS Assessment];;;ACTIVE;2.61;2.61 +85410-9;IRF-PAI - Discharge information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Discharge information [CMS Assessment];;;ACTIVE;2.61;2.67 +85411-7;Patient discharged against medical advice;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Patient discharged against medical advice [CMS Assessment];;;ACTIVE;2.61;2.61 +85412-5;Program interruption(s);PrThr;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Program interruption(s) [CMS Assessment];;;ACTIVE;2.61;2.61 +85413-3;Program interruption date;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Program interruption date [CMS Assessment];;;ACTIVE;2.61;2.61 +85414-1;Program return date;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Program return date [CMS Assessment];;;ACTIVE;2.61;2.61 +8541-5;Intravascular mean;Pres;Pt;Posterior tibial artery.right;Qn;;BP.MOLEC;2;Posterior tibial artery - right Mean blood pressure;Post Tibl a-R BP mean;;ACTIVE;1.0h(3);2.4 +85415-8;Patient discharged alive;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Patient discharged alive [CMS Assessment];;;ACTIVE;2.61;2.61 +85416-6;Discharge location;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Deprecated Discharge location;;;DEPRECATED;2.61;2.7 +85417-4;Discharge living arrangement;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Discharge living arrangement [CMS Assessment];;;ACTIVE;2.61;2.61 +85418-2;Diagnosis for interruption or death;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Diagnosis for interruption or death [CMS Assessment];;;ACTIVE;2.61;2.61 +85419-0;Complications during rehabilitation stay;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Complications during rehabilitation stay [CMS Assessment];;;ACTIVE;2.61;2.61 +85420-8;IRF-PAI - Therapy information;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Therapy information during assessment period [CMS Assessment];;;ACTIVE;2.61;2.69 +85421-6;Bacterial identification & susceptibility panel;-;Pt;Isolate;-;;PANEL.MICRO;1;Bacterial identification and susceptibility panel - Isolate;Bact ID + susc Pnl Islt;;ACTIVE;2.61;2.61 +85422-4;ceFAZolin;Susc;Pt;Isolate.UTI;OrdQn;MIC;ABXBACT;1;ceFAZolin [Susceptibility] for UTI by Minimum inhibitory concentration (MIC);ceFAZolin Islt.UTI MIC;;ACTIVE;2.61;2.61 +8542-3;Intravascular mean;Pres;Pt;Radial artery.left;Qn;;BP.MOLEC;2;Radial artery - left Mean blood pressure;Radial a-L BP mean;;ACTIVE;1.0h(3);2.4 +85423-2;Eravacycline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Eravacycline [Susceptibility] by Minimum inhibitory concentration (MIC);Eravacycline Islt MIC;;ACTIVE;2.61;2.61 +85424-0;Imipenem+Relebactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Imipenem+Relebactam [Susceptibility] by Minimum inhibitory concentration (MIC);Imi+Rel Islt MIC;;ACTIVE;2.61;2.61 +85425-7;Lefamulin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Lefamulin [Susceptibility] by Minimum inhibitory concentration (MIC);Lefamulin Islt MIC;;ACTIVE;2.61;2.61 +85426-5;Meropenem;Susc;Pt;Isolate.meningitis;OrdQn;MIC;ABXBACT;1;Meropenem [Susceptibility] for meningitis by Minimum inhibitory concentration (MIC);Meropenem Islt.mening MIC;;ACTIVE;2.61;2.61 +85427-3;Meropenem+Vaborbactam;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Meropenem+Vaborbactam [Susceptibility] by Minimum inhibitory concentration (MIC);Mero+Vab Islt MIC;;ACTIVE;2.61;2.61 +85428-1;Penicillin;Susc;Pt;Isolate.meningitis;OrdQn;MIC;ABXBACT;1;Penicillin [Susceptibility] for meningitis by Minimum inhibitory concentration (MIC);Penicillin Islt.mening MIC;;ACTIVE;2.61;2.61 +85429-9;Penicillin;Susc;Pt;Isolate.pneumonia;OrdQn;MIC;ABXBACT;1;Penicillin [Susceptibility] for pneumonia by Minimum inhibitory concentration (MIC);Penicillin Islt.pneum MIC;;ACTIVE;2.61;2.61 +85430-7;Diagnostic imaging report - example sections & entries;-;Pt;{Setting};-;;PANEL.DOC;2;Diagnostic imaging report - example sections and entries;DIR - example sections+entries;;ACTIVE;2.61;2.61 +8543-1;Intravascular mean;Pres;Pt;Radial artery.right;Qn;;BP.MOLEC;2;Radial artery - right Mean blood pressure;Radial a-R BP mean;;ACTIVE;1.0h(3);2.4 +85431-5;Marital status;Type;Pt;^Contact;Nom;;ADMIN;2;Marital status of Contact;Marital status Contact;;ACTIVE;2.61;2.66 +85432-3;Relationship to patient;Type;Pt;^Contact;Nom;;ADMIN;2;Contact Relationship to patient;Relationship to pt Contact;;ACTIVE;2.61;2.66 +85433-1;Discharge summary note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Discharge summary;Resp therapy D/C sum;;ACTIVE;2.61;2.73 +85434-9;Discharge summary note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Discharge summary;Rheumatology D/C sum;;ACTIVE;2.61;2.73 +85435-6;Note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Note;Palliative care Note;;ACTIVE;2.61;2.61 +85436-4;Note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Note;Cardiothor surg Note;;ACTIVE;2.61;2.61 +85437-2;Note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Note;Fam Med Note;;ACTIVE;2.61;2.61 +85438-0;Note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Note;Neo peri med Note;;ACTIVE;2.61;2.61 +85439-8;Note;Find;Pt;{Setting};Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Note;Mat fetal med Note;;ACTIVE;2.61;2.73 +85440-6;Discharge summary note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Discharge summary;Vascular surgery D/C sum;;ACTIVE;2.61;2.73 +85441-4;Progress note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Progress note;Vascular surgery Prog note;;ACTIVE;2.61;2.73 +85442-2;Discharge summary note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Discharge summary;Hematology D/C sum;;ACTIVE;2.61;2.73 +85443-0;Note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Note;Hematology Note;;ACTIVE;2.61;2.61 +85444-8;Note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Note;Gyn Onc Note;;ACTIVE;2.61;2.73 +85445-5;Note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Note;Geri med Note;;ACTIVE;2.61;2.61 +85446-3;Health and well-being total;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Health and well-being total [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85447-1;Health and well-being domain risk level;NFr;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Health and well-being domain risk level [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85448-9;Social enviromental total;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Social enviromental total [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +8544-9;Intravascular mean;Pres;Pt;Ulnar artery.left;Qn;;BP.MOLEC;2;Ulnar artery - left Mean blood pressure;Ulnar a-L BP mean;;ACTIVE;1.0h(3);2.4 +85449-7;Social enviromental domain risk level;NFr;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Social enviromental domain risk level [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85450-5;Health literacy and communication total;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Health literacy and communication total [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85451-3;Health literacy and communication domain risk level;NFr;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Health literacy and communication domain risk level [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85452-1;Service coordination total;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Service coordination total [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85453-9;Service coordination domain risk level;NFr;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Service coordination domain risk level [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85454-7;ePCAM Social Complexity;NFr;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;ePCAM Social Complexity [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85455-4;Health and well-being panel;-;Pt;^Patient;-;ePCAM;PANEL.SURVEY.GNHLTH;4;Health and well-being panel [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +8545-6;Intravascular mean;Pres;Pt;Ulnar artery.right;Qn;;BP.MOLEC;2;Ulnar artery - right Mean blood pressure;Ulnar a-R BP mean;;ACTIVE;1.0h(3);2.4 +85456-2;Physical health needs that require further investigation - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Physical health needs that require further investigation - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85457-0;Physical health impacting mental well-being - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Physical health impacting mental well-being - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85458-8;Lifestyle behaviors impacting physical or mental well-being - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Lifestyle behaviors impacting physical or mental well-being - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.67 +85459-6;Other mental well-being concerns - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Other mental well-being concerns - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.67 +85460-4;Social environmental panel;-;Pt;^Patient;-;ePCAM;PANEL.SURVEY.GNHLTH;4;Social environmental panel [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85461-2;Home environment safety and stability - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Home environment safety and stability - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85462-0;Daily activities impact on well-being - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Daily activities impact on well-being - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85463-8;Social network - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Social network - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +8546-4;Intravascular systolic;Pres;Pt;Brachial artery.left;Qn;;BP.MOLEC;2;Brachial artery - left Systolic blood pressure;Brach a-L BP sys;;ACTIVE;1.0h(3);2.73 +85464-6;Financial resources - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Financial resources - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85465-3;Health literacy and communication panel;-;Pt;^Patient;-;ePCAM;PANEL.SURVEY.GNHLTH;4;Health literacy and communication panel [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85466-1;Understand health and well-being and what they need to do to manage their health - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Understand health and well-being and what they need to do to manage their health - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85467-9;Can engage in healthcare discussions - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Can engage in healthcare discussions - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85468-7;Do other services need to be involved to help this client - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Do other services need to be involved to help this client - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85469-5;Are current services involved with this client well-coordinated - visual analog rating;Score;Pt;^Patient;Qn;ePCAM;SURVEY.GNHLTH;4;Are current services involved with this client well-coordinated - visual analog rating [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85470-3;Medication management note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Medication management note;Pt's home Med mgmt note;;ACTIVE;2.63;2.63 +85471-1;Medication management note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Medication management note;Hosp Med mgmt note;;ACTIVE;2.63;2.63 +8547-2;Intravascular systolic;Pres;Pt;Brachial artery.right;Qn;;BP.MOLEC;2;Brachial artery - right Systolic blood pressure;Brach a-R BP sys;;ACTIVE;1.0h(3);2.4 +85472-9;Note;Find;Pt;Telephone encounter;Doc;Obesity medicine;DOC.ONTOLOGY;2;Obesity medicine Telephone encounter Note;Obesity med Phone Note;;ACTIVE;2.63;2.65 +85473-7;Male sexual partner in last 12Mo;PrThr;Pt;^Patient;Ord;;DOC.PUBLICHEALTH;2;Male sexual partner in last 12 months;Male sexual partner in last 12Mo;;ACTIVE;2.61;2.66 +85474-5;Cardiac implantable loop monitor study;Find;Stdy;Heart;Doc;;CARD.PROC;2;Cardiac implantable loop monitor study;Card implant loop study;;ACTIVE;2.61;2.72 +85475-2;Multisection transesophageal;Find;Pt;Chest>Heart;Doc;US;CARD.US;2;US Heart Transesophageal;US Heart Transesophageal;;ACTIVE;2.61;2.64 +85476-0;Influenza virus A & B & Respiratory syncytial virus RNA panel;-;Pt;Respiratory.upper;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus A and B and Respiratory syncytial virus RNA panel - Upper respiratory specimen by NAA with probe detection;FLUAV+FLUBV+RSV RNA pnl Up resp NAA+pr;;ACTIVE;2.61;2.66 +85477-8;Influenza virus A RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Upper respiratory specimen by NAA with probe detection;FLUAV RNA Upper resp Ql NAA+probe;;ACTIVE;2.61;2.68 +85478-6;Influenza virus B RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Upper respiratory specimen by NAA with probe detection;FLUBV RNA Upper resp Ql NAA+probe;;ACTIVE;2.61;2.68 +85479-4;Respiratory syncytial virus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;RSV RNA Upper resp Ql NAA+probe;;ACTIVE;2.61;2.73 +8548-0;Intravascular systolic;Pres;Pt;Digital artery.left;Qn;;BP.MOLEC;2;Digital artery - left Systolic blood pressure;Digital a-L BP sys;;ACTIVE;1.0h(3);2.4 +85480-2;Establishment registration exempt notification;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Establishment registration exempt notification;FDA label Est exmpt notif;;ACTIVE;2.61;2.61 +85481-0;Blood establishment registration & product listing;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Blood establishment registration and product listing;FDA label Bld estabt reg + prod listing;;ACTIVE;2.61;2.61 +85482-8;Human cell and tissue establishment registration & product listing;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Human cell and tissue establishment registration and product listing;FDA label Cell Tiss Est Reg;;ACTIVE;2.61;2.61 +85483-6;IRF-PAI v3.0, LCDS v3.00 - Program interruption dates;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v3.00 - Program interruption dates [CMS Assessment];;;ACTIVE;2.61;2.69 +85484-4;Establishment temporary inactivation notification;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Establishment temporary inactivation notification;FDA label Est temp inact notif;;ACTIVE;2.61;2.61 +85485-1;B little g super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Bg sup(b) Ag [Presence] on Red Blood Cells;Bg sup(b) Ag RBC Ql;;ACTIVE;2.61;2.63 +85486-9;B little g super little c Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Bg sup(c) Ag [Presence] on Red Blood Cells;Bg sup(c) Ag RBC Ql;;ACTIVE;2.61;2.63 +85487-7;S little c 1 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Sc1 Ag [Presence] on Red Blood Cells;Sc1 Ag RBC Ql;;ACTIVE;2.61;2.69 +85488-5;S little c 2 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Sc2 Ag [Presence] on Red Blood Cells;Sc2 Ag RBC Ql;;ACTIVE;2.61;2.69 +85489-3;Speech-language pathology services - co-treatment minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - co-treatment minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85490-1;Speech-language pathology services - group minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - group minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85491-9;Speech-language pathology services - concurrent minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - concurrent minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85492-7;Speech-language pathology services - individual minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - individual minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85493-5;IRF-PAI - Speech-language pathology services - week 1;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Speech-language pathology services - week 1 [CMS Assessment];;;ACTIVE;2.61;2.67 +85494-3;IRF-PAI - Therapy provided - week 1;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Therapy provided - week 1 [CMS Assessment];;;ACTIVE;2.61;2.69 +85495-0;IRF-PAI - Therapy provided - week 2;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Therapy provided - week 2 [CMS Assessment];;;ACTIVE;2.61;2.69 +85496-8;Streptococcus pneumoniae serotype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae serotype [Identifier] in Specimen by NAA with probe detection;S pneum Sertyp Spec NAA+probe;;ACTIVE;2.61;2.69 +85497-6;cloZAPine N-oxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;clozapine N-oxide [Mass/volume] in Serum or Plasma;CNO SerPl-mCnc;;ACTIVE;2.61;2.73 +8549-8;Intravascular systolic;Pres;Pt;Digital artery.right;Qn;;BP.MOLEC;2;Digital artery - right Systolic blood pressure;Digital a-R BP sys;;ACTIVE;1.0h(3);2.4 +85498-4;Bacterial carbapenem resistance blaIMP gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaIMP gene [Presence] by Molecular method;blaIMP Islt/Spm Ql;;ACTIVE;2.61;2.73 +85499-2;Bacterial carbapenem resistance blaKPC gene;PrThr;Pt;Anorectal/isolate;Ord;Probe.amp.tar;ABXBACT;1;Carbapenem resistance blaKPC gene [Presence] by NAA with probe detection;blaKPC AnorectlIslt Ql NAA+probe;;DISCOURAGED;2.61;2.66 +85500-7;Bacterial carbapenem resistance blaNDM gene;PrThr;Pt;Anorectal/isolate;Ord;Probe.amp.tar;ABXBACT;1;Carbapenem resistance blaNDM gene [Presence] by NAA with probe detection;blaNDM AnorectlIslt Ql NAA+probe;;DISCOURAGED;2.61;2.66 +85501-5;Bacterial carbapenem resistance blaVIM gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaVIM gene [Presence] by Molecular method;blaVIM Islt/Spm Ql;;ACTIVE;2.61;2.73 +85502-3;Bacterial carbapenem resistance genes panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Carbapenemase resistance genes panel by Molecular genetics method;BCR gene pnl Islt/Spm;;ACTIVE;2.61;2.69 +85503-1;Bacterial carbapenem resistance blaOXA-48 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA-48 gene [Presence] by Molecular method;blaOXA-48 Islt/Spm Ql;;ACTIVE;2.61;2.69 +85504-9;ABO group.presumptive;Type;Pt;Saliva;Nom;Molgen;BLDBK;1;Presumptive ABO group [Type] in Saliva (oral fluid) by Molecular genetics method;ABO.presumptive Sal by Molgen;;ACTIVE;2.61;2.72 +85505-6;Rh.presumptive;Type;Pt;Saliva;Nom;Molgen;BLDBK;1;Presumptive Rh [Type] in Saliva (oral fluid) by Molecular genetics method;Rh.presumptive Sal by Molgen;;ACTIVE;2.61;2.61 +8550-6;Intravascular systolic;Pres;Pt;Dorsal pedal artery.left;Qn;;BP.MOLEC;2;Dorsal pedal artery - left Systolic blood pressure;Dors pedal a-L BP sys;;ACTIVE;1.0h(3);2.4 +85506-4;PTEN gene targeted mutation analysis;Prid;Pt;Colorectal cancer specimen;Nom;Molgen;MOLPATH.MUT;1;PTEN gene mutations found [Identifier] in Colorectal cancer specimen by Molecular genetics method Nominal;PTEN gene Mut Anl CRC spec;;ACTIVE;2.61;2.63 +85507-2;PIK3CA gene targeted mutation analysis;Prid;Pt;Colorectal cancer specimen;Nom;Molgen;MOLPATH.MUT;1;PIK3CA gene mutations found [Identifier] in Colorectal cancer specimen by Molecular genetics method Nominal;PIK3CA gene Mut Anl CRC spec;;ACTIVE;2.61;2.63 +85508-0;Satellite nodules;Num;Pt;Colorectal cancer specimen;Qn;Microscopy.light;PATH;1;Satellite nodules [#] in Colorectal cancer specimen by Light microscopy;Satellite nodules CRC spec Micro;;ACTIVE;2.61;2.61 +85509-8;KRAS gene targeted mutation analysis;Prid;Pt;Colorectal cancer specimen;Nom;Molgen;MOLPATH.MUT;1;KRAS gene mutations found [Identifier] in Colorectal cancer specimen by Molecular genetics method Nominal;KRAS gene Mut Anl CRC spec;;ACTIVE;2.61;2.63 +85510-6;NRAS gene targeted mutation analysis;Prid;Pt;Colorectal cancer specimen;Nom;Molgen;MOLPATH.MUT;1;NRAS gene mutations found [Identifier] in Colorectal cancer specimen by Molecular genetics method Nominal;NRAS gene Mut Anl CRC spec;;ACTIVE;2.61;2.63 +85511-4;BRAF gene targeted mutation analysis;Prid;Pt;Colorectal cancer specimen;Nom;Molgen;MOLPATH.MUT;1;BRAF gene mutations found [Identifier] in Colorectal cancer specimen by Molecular genetics method Nominal;BRAF gene Mut Anl CRC spec;;ACTIVE;2.61;2.63 +85512-2;Hepatitis D virus RNA;ACnc;Pt;Ser;Qn;Probe.amp.tar;MICRO;1;Hepatitis D virus RNA [Units/volume] (viral load) in Serum by NAA with probe detection;HDV RNA Ser NAA+probe-aCnc;;ACTIVE;2.61;2.63 +85513-0;Hepatitis D virus RNA;LaCnc;Pt;Ser;Qn;Probe.amp.tar;MICRO;1;Hepatitis D virus RNA [log units/volume] (viral load) in Serum by NAA with probe detection;HDV RNA Ser NAA+probe-Log IU;;ACTIVE;2.61;2.63 +8551-4;Intravascular systolic;Pres;Pt;Dorsal pedal artery.right;Qn;;BP.MOLEC;2;Dorsal pedal artery - right Systolic blood pressure;Dors pedal a-R BP sys;;ACTIVE;1.0h(3);2.4 +85514-8;Discharge summary note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Discharge summary;Bariatric surg D/C sum;;ACTIVE;2.61;2.73 +85515-5;Progress note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Progress note;Bariatric surg Prog note;;ACTIVE;2.61;2.73 +85516-3;Note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Note;Bariatric surg Note;;ACTIVE;2.61;2.61 +85517-1;Consultation note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Consult note;Bariatric surg Consult note;;ACTIVE;2.61;2.61 +85518-9;Initial evaluation note;Find;Pt;{Setting};Doc;Child and adolescent psychology;DOC.ONTOLOGY;2;Child and adolescent psychology Initial evaluation note;Child Adolsnt Psych Initial eval note;;ACTIVE;2.61;2.61 +85519-7;Consultation note;Find;Pt;{Setting};Doc;Child and adolescent psychology;DOC.ONTOLOGY;2;Child and adolescent psychology Consult note;Child Adolsnt Psych Consult note;;ACTIVE;2.61;2.61 +85520-5;Discharge summary note;Find;Pt;{Setting};Doc;Child and adolescent psychology;DOC.ONTOLOGY;2;Child and adolescent psychology Discharge summary;Child Adolsnt Psych D/C sum;;ACTIVE;2.61;2.73 +85521-3;Note;Find;Pt;{Setting};Doc;Undersea and hyperbaric medicine;DOC.ONTOLOGY;2;Undersea and hyperbaric medicine Note;Undersea+hyperbar Note;;ACTIVE;2.61;2.73 +8552-2;Intravascular systolic;Pres;Pt;Dorsal penile artery;Qn;;BP.MOLEC;2;Dorsal penile artery Systolic blood pressure;Dorsal penile a BP sys;;ACTIVE;1.0h(3);2.4 +85522-1;Initial evaluation note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Initial evaluation note;Bariatric surg Initial eval note;;ACTIVE;2.61;2.61 +85523-9;PROMIS short form - global - version 1.2 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - global - version 1.2 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.61;2.61 +85524-7;PROMIS short form - global - version 1.2;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - global - version 1.2;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.61;2.61 +85525-4;Porcine reproductive and respiratory syndrome virus North American strain Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;PRRSV North American strain IgG Ab [Titer] in Serum by Immunofluorescence;PRRSV NA strain IgG Titr Ser IF;;ACTIVE;2.61;2.64 +85526-2;Influenza virus D PB2 gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus D PB2 gene [Cycle Threshold #] in Specimen by NAA with probe detection;FLUDV PB2 gene Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85527-0;Mycoplasma hyopneumoniae P146 gene sequence & phylogenetic analysis;Find;Pt;XXX;Doc;;MICRO;1;Mycoplasma hyopneumoniae P146 gene sequence and phylogenetic analysis in Specimen Document;M hyopneumo seq + phylo Spec Doc;;ACTIVE;2.61;2.69 +85528-8;Porcine reproductive and respiratory syndrome virus European strain Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;PRRSV European strain IgG Ab [Titer] in Serum by Immunofluorescence;PRRSV European IgG Titr Ser IF;;ACTIVE;2.61;2.64 +85529-6;Porcine reproductive and respiratory syndrome virus North American strain Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;PRRSV North American strain IgG Ab [Presence] in Serum by Immunofluorescence;PRRSV NA strain IgG Ser Ql IF;;ACTIVE;2.61;2.64 +8553-0;Intravascular systolic;Pres;Pt;Femoral artery.left;Qn;;BP.MOLEC;2;Femoral artery - left Systolic blood pressure;Fem a-L BP sys;;ACTIVE;1.0h(3);2.4 +85530-4;Porcine reproductive and respiratory syndrome virus European strain Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;PRRSV European strain IgG Ab [Presence] in Serum by Immunofluorescence;PRRSV European IgG Ser Ql IF;;ACTIVE;2.61;2.64 +85531-2;Porcine reproductive and respiratory syndrome virus whole genome;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;PRRSV whole genome [Nucleotide sequence] in Isolate by Sequencing;PRRSV whole genome Islt-Seq;;ACTIVE;2.61;2.64 +85532-0;Influenza virus A whole genome;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A whole genome [Nucleotide sequence] in Isolate by Sequencing;FLUAV whole genome Islt-Seq;;ACTIVE;2.61;2.61 +85533-8;Influenza virus A porcine origin nucleoprotein Ab.IgG/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Influenza virus A porcine origin nucleoprotein IgG Ab/Positive control in Specimen by Immunoassay;FLUAV porcine NUC IgG/Pos cntrl Spec IA;;ACTIVE;2.61;2.69 +85534-6;Influenza virus A avian origin nucleoprotein Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A avian origin nucleoprotein Ab/Negative control in Serum by Immunoassay;FLUAV avian NUC Ab Ser IA;;ACTIVE;2.61;2.64 +85535-3;Influenza virus A RNA tissue culture infective dose 50;NCnc;Pt;XXX;Qn;;MICRO;1;Influenza virus A RNA TCID50 [#/volume] in Specimen;FLUAV RNA TCID50 # Spec;;ACTIVE;2.61;2.69 +85536-1;Mycoplasma hyopneumoniae DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma hyopneumoniae DNA [#/volume] in Specimen by NAA with probe detection;M hyopneumo DNA # Spec NAA+probe;;ACTIVE;2.61;2.69 +85537-9;Mycoplasma hyosynoviae 16S rRNA gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma hyosynoviae 16S rRNA gene [Cycle Threshold #] in Specimen by NAA with probe detection;M hyosyn 16S rRNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85538-7;Mycoplasma hyorhinis 16S rRNA gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma hyorhinis 16S rRNA gene [Cycle Threshold #] in Specimen by NAA with probe detection;M hyorhinis 16S rRNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +85539-5;Porcine reproductive and respiratory syndrome virus North American strain RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PRRSV North American strain RNA [#/volume] (viral load) in Specimen by NAA with probe detection;PRRSV NA strain RNA # Spec NAA+probe;;ACTIVE;2.61;2.69 +85540-3;Porcine reproductive and respiratory syndrome virus European strain RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PRRSV European strain RNA [#/volume] (viral load) in Specimen by NAA with probe detection;PRRSV European RNA # Spec NAA+probe;;ACTIVE;2.61;2.69 +85541-1;Porcine reproductive and respiratory syndrome virus Ingelvac MLV strain ORF5 gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PRRSV Ingelvac MLV strain ORF5 gene [Cycle Threshold #] in Specimen by NAA with probe detection;PRRSV Ingel MLV ORF5 Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +85542-9;Porcine reproductive and respiratory syndrome virus Ingelvac ATP strain ORF5 gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;PRRSV Ingelvac ATP strain ORF5 gene [Cycle Threshold #] in Specimen by NAA with probe detection;PRRSV Ingel ATP ORF5 Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +85543-7;Porcine reproductive and respiratory syndrome virus Ab.IgG/Positive control;RelRto;Pt;Saliva;Qn;IA;MICRO;1;PRRSV IgG Ab/Positive control in Saliva (oral fluid) by Immunoassay;PRRSV IgG/Pos cntrl Sal IA;;ACTIVE;2.61;2.64 +85544-5;Porcine reproductive and respiratory syndrome virus Ab/Positive control;RelRto;Pt;Ser/Plas;Qn;IA;MICRO;1;PRRSV Ab/Positive control in Serum or Plasma by Immunoassay;PRRSV Ab/Pos cntrl SerPl IA;;ACTIVE;2.61;2.64 +85545-2;Porcine reproductive and respiratory syndrome virus North American strain RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;PRRSV North American strain RNA [Presence] in Specimen by NAA with probe detection;PRRSV NA strain RNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +85546-0;Porcine reproductive and respiratory syndrome virus European strain RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;PRRSV European strain RNA [Presence] in Specimen by NAA with probe detection;PRRSV European RNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +85547-8;Porcine reproductive and respiratory syndrome virus North American strain Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;PRRSV North American strain neutralizing antibody [Titer] in Serum by Neutralization test;PRRSV NA strain NAb Titr Ser Nt;;ACTIVE;2.61;2.64 +8554-8;Intravascular systolic;Pres;Pt;Femoral artery.right;Qn;;BP.MOLEC;2;Femoral artery - right Systolic blood pressure;Fem a-R BP sys;;ACTIVE;1.0h(3);2.4 +85548-6;Porcine reproductive and respiratory syndrome virus European strain Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;PRRSV European strain neutralizing antibody [Titer] in Serum by Neutralization test;PRRSV European NAb Titr Ser Nt;;ACTIVE;2.61;2.64 +85549-4;Porcine reproductive and respiratory syndrome virus European strain Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;PRRSV European strain neutralizing antibody [Presence] in Serum by Neutralization test;PRRSV European NAb Ser Ql Nt;;ACTIVE;2.61;2.64 +85550-2;Porcine reproductive and respiratory syndrome virus North American strain Ab.Neut;PrThr;Pt;Ser;Ord;Neut;MICRO;1;PRRSV North American strain neutralizing antibody [Presence] in Serum by Neutralization test;PRRSV NA strain NAb Ser Ql Nt;;ACTIVE;2.61;2.64 +85551-0;Porcine reproductive and respiratory syndrome virus European & North American strains Ab.Neut panel;-;Pt;Ser;-;Neut;PANEL.MICRO;1;PRRSV European and North American strains neutralizing antibody panel - Serum by Neutralization test;PRRSV Euro + NA NAb Pnl Ser Nt;;ACTIVE;2.61;2.64 +85552-8;Influenza virus A porcine origin nucleoprotein Ab.IgA/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Influenza virus A porcine origin nucleoprotein IgA Ab/Positive control in Specimen by Immunoassay;FLUAV porcine NUC IgA/Pos cntrl Spec IA;;ACTIVE;2.61;2.69 +85553-6;Mycoplasma flocculare 16S rRNA gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma flocculare 16S rRNA gene [Presence] in Specimen by NAA with probe detection;M flocc 16S rRNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +85554-4;Electronic Patient Centered Assessment Method panel;-;Pt;^Patient;-;ePCAM;PANEL.SURVEY.GNHLTH;4;Electronic Patient Centered Assessment Method panel [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +8555-5;Intravascular systolic;Pres;Pt;Great toe arteries.left;Qn;;BP.MOLEC;2;Great toe arteries - left Systolic blood pressure;Great toe aa-L BP sys;;ACTIVE;1.0h(3);2.4 +85555-1;Service coordination panel;-;Pt;^Patient;-;ePCAM;PANEL.SURVEY.GNHLTH;4;Service coordination panel [ePCAM];;Copyright 2016 © Research Foundation for State University of New York Used with permission.;ACTIVE;2.61;2.66 +85556-9;Rothman Index;Score;Pt;^Patient;Qn;Calculated;CLIN;2;Rothman Index Calculated;RI Score Calc;Copyright © 2016 PeraHealth Used with permission;ACTIVE;2.61;2.61 +85557-7;Physical therapy - individual minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - individual minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85558-5;Physical therapy - concurrent minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - concurrent minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85559-3;Physical therapy - group minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - group minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85560-1;Physical therapy - co-treatment minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - co-treatment minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85561-9;IRF-PAI - Occupational therapy - week 1;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Occupational therapy - week 1 [CMS Assessment];;;ACTIVE;2.61;2.67 +85562-7;Occupational therapy - individual minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - individual minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +8556-3;Intravascular systolic;Pres;Pt;Great toe arteries.right;Qn;;BP.MOLEC;2;Great toe arteries - right Systolic blood pressure;Great toe aa-R BP sys;;ACTIVE;1.0h(3);2.4 +85563-5;Occupational therapy - concurrent minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - concurrent minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85564-3;Occupational therapy - group minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - group minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85565-0;Occupational therapy - co-treatment minutes^week 1;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - co-treatment minutes--week 1 [CMS Assessment];;;ACTIVE;2.61;2.61 +85566-8;IRF-PAI - Physical therapy - week 1;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Physical therapy - week 1 [CMS Assessment];;;ACTIVE;2.61;2.67 +85567-6;Physical therapy - individual minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - individual minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85568-4;Physical therapy - concurrent minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - concurrent minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85569-2;Physical therapy - group minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - group minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +855-7;A2 Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A2 Ag [Presence] on Red Blood Cells from Donor;A2 Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +85570-0;Physical therapy - co-treatment minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - co-treatment minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +8557-1;Intravascular systolic;Pres;Pt;Iliac artery.left;Qn;;BP.MOLEC;2;Iliac artery - left Systolic blood pressure;Iliac a-L BP sys;;ACTIVE;1.0h(3);2.4 +85571-8;Occupational therapy - individual minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - individual minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85572-6;Occupational therapy - concurrent minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - concurrent minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85573-4;Occupational therapy - group minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - group minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85574-2;Occupational Therapy - co-treatment minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - co-treatment minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85575-9;Speech-language pathology services - individual minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - individual minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85576-7;Speech-language pathology services - concurrent minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - concurrent minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85577-5;Speech-language pathology services - group minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - group minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85578-3;Speech-language pathology services - co-treatment minutes^week 2;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology services - co-treatment minutes--week 2 [CMS Assessment];;;ACTIVE;2.61;2.61 +85579-1;Porcine reproductive and respiratory syndrome virus European strain ORF5 gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;PRRSV European strain ORF5 gene [Presence] in Specimen by NAA with probe detection;PRRSV European ORF5 Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +85580-9;Registry report;Find;Pt;Hospital;Doc;Birth defects;DOC.ONTOLOGY;2;Birth defects Hospital Registry report;Birth defects Hosp Registry rpt;;ACTIVE;2.61;2.61 +85581-7;Mycobacterium avium & Mycobacterium intracellulare DNA;Prid;Pt;Sputum/Bronchial;Nom;Probe.amp.tar;MICRO;1;Mycobacterium avium and Mycobacterium intracellulare DNA [Identifier] in Sputum or Bronchial by NAA with probe detection;M avium+M intracel DNA Spt/Bro NAA+probe;;ACTIVE;2.61;2.63 +85582-5;Chikungunya virus RNA+Dengue virus RNA;PrThr;Pt;Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus RNA+Dengue virus RNA [Presence] in Plasma from Donor by NAA with probe detection;CHIKV RNA+DENV RNA Plas Donr Ql NAA+pr;;ACTIVE;2.61;2.63 +85583-3;Chikungunya virus RNA;PrThr;Pt;Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus RNA [Presence] in Plasma from Donor by NAA with probe detection;CHIKV RNA Plas Donr Ql NAA+probe;;ACTIVE;2.61;2.63 +85584-1;Dengue virus RNA;PrThr;Pt;Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Dengue virus RNA [Presence] in Plasma from Donor by NAA with probe detection;DENV RNA Plas Donr Ql NAA+probe;;ACTIVE;2.61;2.63 +85585-8;Date of condition onset;Date;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Date of condition onset;;;ACTIVE;2.61;2.61 +85586-6;Porcine reproductive and respiratory syndrome virus European & North American strains Ab.IgG panel;-;Pt;Ser;-;IF;PANEL.MICRO;1;PRRSV European and North American strains IgG panel - Serum by Immunofluorescence;PRRSV Euro + NA IgG Pnl Ser IF;;ACTIVE;2.61;2.65 +85587-4;Note;Find;Pt;{Setting};Doc;Aerospace medicine;DOC.ONTOLOGY;2;Aerospace medicine Note;Aerospace med Note;;ACTIVE;2.61;2.61 +85588-2;Diagnostic study note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Diagnostic study note;HemOnc Diag study note;;ACTIVE;2.61;2.61 +8558-9;Intravascular systolic;Pres;Pt;Iliac artery.right;Qn;;BP.MOLEC;2;Iliac artery - right Systolic blood pressure;Iliac a-R BP sys;;ACTIVE;1.0h(3);2.4 +85589-0;IRF-PAI - Physical therapy - week 2;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Physical therapy - week 2 [CMS Assessment];;;ACTIVE;2.61;2.67 +85590-8;IRF-PAI - Occupational therapy - week 2;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Occupational therapy - week 2 [CMS Assessment];;;ACTIVE;2.61;2.67 +85591-6;IRF-PAI - Speech-language pathology services - week 2;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Speech-language pathology services - week 2 [CMS Assessment];;;ACTIVE;2.61;2.67 +85592-4;Planned location for hemodialysis;Type;Pt;^Patient;Nom;;CLIN;2;Planned location for hemodialysis;Planned HD loc;;ACTIVE;2.61;2.63 +85593-2;Type of donor kidney;Type;Pt;^Patient;Nom;;CLIN;2;Type of donor kidney;Donor kidney type;;ACTIVE;2.61;2.63 +85594-0;Preferred type of dialysis if required before transplant;Type;Pt;^Patient;Nom;;CLIN;2;Preferred type of dialysis if required before transplant;Pref dial type if req before trans;;ACTIVE;2.61;2.63 +85595-7;Will hospice care be provided;Find;Pt;^Patient;Ord;;CLIN;2;Will hospice care be provided;Will hospice be provided;;ACTIVE;2.61;2.63 +85596-5;Preferred kidney failure treatment if kidney disease progresses to kidney failure;Type;Pt;^Patient;Nom;;CLIN;2;Preferred kidney failure treatment if kidney disease progresses to kidney failure;Pref kidney failure tx if needed;;ACTIVE;2.61;2.63 +8559-7;Intravascular systolic;Pres;Pt;Index finger arteries.left;Qn;;BP.MOLEC;2;Index finger arteries - left Systolic blood pressure;Index finger aa-L BP sys;;ACTIVE;1.0h(3);2.4 +85597-3;Renal replacement therapy goals panel;-;Pt;^Patient;-;NKDEP;PANEL.CLIN;2;Renal replacement therapy goals panel NKDEP;RRT goals Pnl NKDEP;;ACTIVE;2.61;2.61 +85598-1;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by causing swelling in your ankles or legs;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by causing swelling in your ankles or legs [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85599-9;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your walking about or climbing stairs difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your walking about or climbing stairs difficult [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85600-5;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your working around the house or yard difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your working around the house or yard difficult [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85601-3;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your going places away from home difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your going places away from home difficult? [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85602-1;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your sleeping well at night difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your sleeping well at night difficult [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85603-9;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your relating to or doing things with your friends or family difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your relating to or doing things with your friends or family difficult [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85604-7;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your working to earn a living difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your working to earn a living difficult [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +8560-5;Intravascular systolic;Pres;Pt;Index finger arteries.right;Qn;;BP.MOLEC;2;Index finger arteries - right Systolic blood pressure;Index finger aa-R BP sys;;ACTIVE;1.0h(3);2.4 +85605-4;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your recreational pastimes, sports or hobbies difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your recreational pastimes, sports or hobbies difficult [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85606-2;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making your sexual activities difficult;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making your sexual activities difficult [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85607-0;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you eat less of the foods you like;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4weeks) by making you eat less of the foods you like [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85608-8;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you short of breath;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you short of breath [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85609-6;Emotional score;Score;Pt;^Patient;Qn;MLHFQ;SURVEY.MLHFQ;4;Emotional score [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.61 +85610-4;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you stay in a hospital;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you stay in a hospital [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85611-2;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by costing you money for medical care;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by costing you money for medical care [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85612-0;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by giving you side effects from treatments;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by giving you side effects from treatments [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +8561-3;Intravascular systolic;Pres;Pt;Little finger arteries.left;Qn;;BP.MOLEC;2;Little finger arteries - left Systolic blood pressure;Little finger aa-L BP sys;;ACTIVE;1.0h(3);2.4 +85613-8;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you feel you are a burden to your family or friends;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you feel you are a burden to your family or friends [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85614-6;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you feel a loss of self-control in your life;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you feel a loss of self-control in your life [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85615-3;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you worry;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you worry [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85616-1;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making it difficult for you to concentrate or remember things;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making it difficult for you to concentrate or remember things [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85617-9;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you feel depressed;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you feel depressed [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85618-7;Physical score;Score;Pt;^Patient;Qn;MLHFQ;SURVEY.MLHFQ;4;Physical score [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.61 +85619-5;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you sit or lie down to rest during the day;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you sit or lie down to rest during the day [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +85620-3;Did your heart failure prevent you from living as you wanted during the past Mo (4W) by making you tired, fatigued or low on energy;Find;1Mo;^Patient;Ord;MLHFQ;SURVEY.MLHFQ;4;Did your heart failure prevent you from living as you wanted during the past month (4 weeks) by making you tired, fatigued or low on energy [MLHFQ];;Copyright ©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the University of Minnesota. Used with permission.;ACTIVE;2.61;2.63 +8562-1;Intravascular systolic;Pres;Pt;Little finger arteries.right;Qn;;BP.MOLEC;2;Little finger arteries - right Systolic blood pressure;Little finger aa-R BP sys;;ACTIVE;1.0h(3);2.4 +85621-1;Zika virus RNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Amniotic fluid by NAA with probe detection;ZIKV RNA Amn Ql NAA+probe;;ACTIVE;2.61;2.63 +85622-9;Zika virus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Serum or Plasma by NAA with probe detection;ZIKV RNA SerPl Ql NAA+probe;;ACTIVE;2.61;2.73 +85623-7;Zika virus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Urine by NAA with probe detection;ZIKV RNA Ur Ql NAA+probe;;ACTIVE;2.61;2.73 +85624-5;Kidney failure 2Y risk;Likelihood;Pt;^Patient;Qn;KFRE;CHEM;1;Kidney failure 2-year risk [Likelihood] by KFRE;Kidney fail 2Y risk KFRE.dynamic;Copyright © Dr. Navdeep Tangri Used with permission;ACTIVE;2.61;2.64 +85625-2;Kidney failure 5Y risk;Likelihood;Pt;^Patient;Qn;KFRE;CHEM;1;Kidney failure 5-year risk [Likelihood] by KFRE;Kidney fail 5Y risk KFRE.dynamic;Copyright © Dr. Navdeep Tangri Used with permission;ACTIVE;2.61;2.64 +85626-0;Kidney failure 2Y & 5Y risk panel;-;Pt;^Patient;Qn;KFRE;PANEL.CHEM;1;Kidney failure 2-year and 5-year risk panel by KFRE;Kidney fail 2Y + 5Y risk KFRE.dyn Pnl;Copyright © Dr. Navdeep Tangri Used with permission;ACTIVE;2.61;2.61 +85627-8;Haemophilus influenzae hpd gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae hpd gene [Cycle Threshold #] in Specimen by NAA with probe detection;H influenz hpd Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85628-6;Neisseria meningitidis sodC gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis sodC gene [Presence] in Specimen by NAA with probe detection;N mening sodC Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +85629-4;Comatose during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Comatose during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +85630-2;Did the (abnormal) behavior fluctuate during the day, that is, tend to come and go or increase and decrease in severity during 3D assessment period;Find;3D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Did the (abnormal) behavior fluctuate during the day, that is, tend to come and go or increase and decrease in severity during 3 day assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.67 +85631-0;Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said during 3D assessment period;Find;3D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said during 3 day assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.67 +85632-8;Facility type;Type;Pt;Facility;Nom;CMS Assessment;SURVEY.CMS;4;Facility type [CMS Assessment];;;ACTIVE;2.61;2.61 +85633-6;Indicate the patient's primary medical condition category during 3D assessment period;Find;3D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Indicate the patient's primary medical condition category during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +85634-4;Is there evidence of an acute change in mental status from the patient's baseline during 3D assessment period;Find;3D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Is there evidence of an acute change in mental status from the patient's baseline during 3 day assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.67 +85635-1;LCDS v3.00 - Active diagnoses;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Active diagnoses [CMS Assessment];;;ACTIVE;2.61;2.69 +85636-9;LCDS v4.00 - Administrative information - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Administrative information - admission [CMS Assessment];;;ACTIVE;2.61;2.69 +85637-7;LCDS v3.00 - Assessment administration;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Assessment administration [CMS Assessment];;;ACTIVE;2.61;2.67 +85638-5;LCDS v3.00 - Cognitive patterns;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Cognitive patterns [CMS Assessment];;;ACTIVE;2.61;2.69 +8563-9;Intravascular systolic;Pres;Pt;Middle finger arteries.left;Qn;;BP.MOLEC;2;Middle finger arteries - left Systolic blood pressure;Middle finger aa-L BP sys;;ACTIVE;1.0h(3);2.4 +85639-3;LCDS v3.00 - Functional abilities and goals;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Functional abilities and goals [CMS Assessment];;;ACTIVE;2.61;2.67 +85640-1;LCDS v3.00 - Hearing, speech, and vision;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Hearing, speech, and vision [CMS Assessment];;;ACTIVE;2.61;2.67 +85641-9;LCDS v3.00 - Mobility - admission performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Mobility - admission performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.68 +85642-7;LCDS - Prior functioning: everyday activities;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS - Prior functioning: everyday activities [CMS Assessment];;;ACTIVE;2.61;2.67 +85643-5;LCDS v3.00 - Special treatments, procedures, and programs - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Special treatments, procedures, and programs - admission [CMS Assessment];;;ACTIVE;2.61;2.67 +85644-3;LCDS v3.00 - Swallowing &or nutritional status;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Swallowing/nutritional status [CMS Assessment];;;ACTIVE;2.61;2.69 +85645-0;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Admission - version 3.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Admission - version 3.00 [CMS Assessment];;;DEPRECATED;2.61;2.73 +85646-8;Level of consciousness - Alert (normal) during 3D assessment;Find;3D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Level of consciousness - Alert (normal) during 3 day assessment [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.67 +8564-7;Intravascular systolic;Pres;Pt;Middle finger arteries.right;Qn;;BP.MOLEC;2;Middle finger arteries - right Systolic blood pressure;Middle finger aa-R BP sys;;ACTIVE;1.0h(3);2.4 +85647-6;Signature of person collecting or coordinating collection of assessment information;Pn;Pt;Provider;Nar;;SURVEY.CMS;4;Signature of person collecting or coordinating collection of assessment information Provider;;;ACTIVE;2.61;2.61 +85648-4;Signature of persons completing the assessment;-;Pt;Form;-;CMS Assessment;PANEL.SURVEY.CMS;4;Signature of persons completing the assessment [CMS Assessment];;;ACTIVE;2.61;2.61 +85649-2;LCDS v3.00 - Signs and Symptoms of Delirium (from CAM);-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Signs and Symptoms of Delirium (from CAM) [CMS Assessment];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.69 +856-5;A2 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A2 Ag [Presence] on Red Blood Cells;A2 Ag RBC Ql;;ACTIVE;1.0;2.56 +85650-0;Title of person collecting or coordinating collection of assessment information;Type;Pt;Provider;Nom;;SURVEY.CMS;4;Title of person collecting or coordinating collection of assessment information Provider;;;ACTIVE;2.61;2.61 +85651-8;Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject during 3D assessment period;Find;3D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject during 3 day assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.67 +85652-6;Wash upper body - functional ability during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wash upper body - functional ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.61 +85653-4;Wash upper body - functional goal during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wash upper body - functional goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.67 +8565-4;Intravascular systolic;Pres;Pt;Posterior tibial artery.left;Qn;;BP.MOLEC;2;Posterior tibial artery - left Systolic blood pressure;Post Tibl a-L BP sys;;ACTIVE;1.0h(3);2.73 +85654-2;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 3.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 3.00 [CMS Assessment];;;DEPRECATED;2.61;2.73 +85655-9;Level of consciousness - Vigilant or lethargic or stupor or coma during 3D assessment;Find;3D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Level of consciousness - Vigilant or lethargic or stupor or coma during 3 day assessment [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.67 +85656-7;Sexual activity with a new partner in past 60D;PrThr;Pt;^Patient;Ord;;H&P.HX;2;Sexual activity with a new partner in past 60D;Sex new partner past 60D;;ACTIVE;2.61;2.66 +85657-5;Occupation industry CDC Census code;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Occupation industry CDC Census code;Industry CDC Census code;;ACTIVE;2.61;2.66 +85658-3;Occupation;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Occupation [Type];Occupation Type;;ACTIVE;2.61;2.66 +85659-1;Occupation CDC Census code;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Occupation CDC Census code;Occup CDC Census code;;ACTIVE;2.61;2.66 +85660-9;LCDS v3.00 - Mobility - discharge goal during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Mobility - discharge goal during 3D assessment period [CMS Assessment];;;ACTIVE;2.61;2.69 +85661-7;LCDS v3.00 - Self-care - discharge goal;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Self-care - discharge goal [CMS Assessment];;;ACTIVE;2.61;2.69 +8566-2;Intravascular systolic;Pres;Pt;Posterior tibial artery.right;Qn;;BP.MOLEC;2;Posterior tibial artery - right Systolic blood pressure;Post Tibl a-R BP sys;;ACTIVE;1.0h(3);2.73 +85662-5;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Planned Discharge - version 3.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Planned Discharge - version 3.00 [CMS Assessment];;;DEPRECATED;2.61;2.73 +85663-3;LCDS v3.00 - Administrative information - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Administrative information - discharge [CMS Assessment];;;ACTIVE;2.61;2.67 +85664-1;LCDS v3.00 - Functional abilities and goals - planned discharge;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Functional abilities and goals - planned discharge [CMS Assessment];;;ACTIVE;2.61;2.67 +85665-8;LCDS v3.00 - Self-care - discharge performance;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Self-care - discharge performance [CMS Assessment];;;ACTIVE;2.61;2.69 +85666-6;LCDS v3.00 - Bladder and bowel - planned discharge;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Bladder and bowel - planned discharge [CMS Assessment];;;ACTIVE;2.61;2.69 +85667-4;LCDS v3.00 - Self-care - admission performance;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Self-care - admission performance [CMS Assessment];;;ACTIVE;2.61;2.69 +85668-2;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 3.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 3.00 [CMS Assessment];;;DEPRECATED;2.61;2.73 +85669-0;Number of program interruptions;Num;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of program interruptions during assessment period [CMS Assessment];;;ACTIVE;2.61;2.69 +8567-0;Intravascular systolic;Pres;Pt;Radial artery.left;Qn;;BP.MOLEC;2;Radial artery - left Systolic blood pressure;Radial a-L BP sys;;ACTIVE;1.0h(3);2.4 +85670-8;LCDS v3.00 - Skin conditions - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Skin conditions - discharge [CMS Assessment];;;ACTIVE;2.61;2.67 +85671-6;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Expired - version 3.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Expired - version 3.00 [CMS Assessment];;;DEPRECATED;2.61;2.73 +85672-4;LCDS v3.00 - Mobility - discharge performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Mobility - discharge performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.61;2.67 +85673-2;LCDS v4.00 - Administrative information - expired;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Administrative information - expired [CMS Assessment];;;ACTIVE;2.61;2.67 +85674-0;Date of serology test^pre pregnancy;Date;Pt;^Mother;Qn;;H&P.HX;2;Date of serology test in Mother --pre pregnancy;Date serology test pre pregnancy Mother;;ACTIVE;2.61;2.61 +85675-7;Serologic test result^pre pregnancy;Find;Pt;^Mother;Nom;;H&P.HX;2;Serologic test result for Mother --pre pregnancy;Serologic tx result pre pregnancy Mother;;ACTIVE;2.61;2.61 +85676-5;Previous illness diagnosed by;Find;Pt;^Mother;Nom;;H&P.HX;2;Mother's Previous illness diagnosed by;Moth Prev illness dx by;;ACTIVE;2.61;2.61 +85677-3;Congenital rubella syndrome case classification;Imp;Pt;^Patient;Nom;;SURVEY.CDC;4;Congenital rubella syndrome case classification;;;ACTIVE;2.61;2.61 +85678-1;Haemophilus influenzae acs gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae acs gene [Cycle Threshold #] in Specimen by NAA with probe detection;H influen acs Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85679-9;Haemophilus influenzae bex gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae bex gene [Cycle Threshold #] in Specimen by NAA with probe detection;H influen bex Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85680-7;Haemophilus influenzae ecs gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae ecs gene [Cycle Threshold #] in Specimen by NAA with probe detection;H influen ecs Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85681-5;Haemophilus influenzae dcs gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae dcs gene [Cycle Threshold #] in Specimen by NAA with probe detection;H influen dcs Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85682-3;Haemophilus influenzae ccs gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae ccs gene [Cycle Threshold #] in Specimen by NAA with probe detection;H influen ccs Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85683-1;Haemophilus influenzae bcs gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus influenzae bcs gene [Cycle Threshold #] in Specimen by NAA with probe detection;H influen bcs Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85684-9;Bordetella pertussis.pertussis toxin Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Bordetella pertussis.pertussis toxin IgG Ab [Presence] in Serum by Immunoassay;B pert.PT IgG Ser Ql IA;;ACTIVE;2.61;2.64 +85685-6;Mycoplasma hyopneumoniae P146 gene;Seq;Pt;XXX;Nom;Sequencing;MICRO;1;Mycoplasma hyopneumoniae P146 gene [Nucleotide sequence] in Specimen by Sequencing;M hyopneumo P146 Spec-Seq;;ACTIVE;2.61;2.69 +85686-4;HIV 1 Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IF;MICRO;1;HIV 1 Ab [Presence] in Serum, Plasma or Blood by Immunofluorescence;HIV1 Ab SerPlBld Ql IF;;ACTIVE;2.61;2.61 +85687-2;Treated for Chlamydia trachomatis or Neisseria gonorrhoeae in last 3 to 12Mo;PrThr;12Mo;^Patient;Ord;;H&P.HX;2;Treated for Chlamydia trachomatis or Neisseria gonorrhoeae in last 3 to 12 months;Tx for C trachomatis or N gonorrhoeae;;ACTIVE;2.64;2.66 +8568-8;Intravascular systolic;Pres;Pt;Radial artery.right;Qn;;BP.MOLEC;2;Radial artery - right Systolic blood pressure;Radial a-R BP sys;;ACTIVE;1.0h(3);2.4 +85688-0;Streptococcus pneumoniae lytA gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae lytA gene [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum lytA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85689-8;Sexual activity with known Chlamydia trachomatis &or Neisseria gonorhoeae case;PrThr;Pt;^Patient;Ord;;H&P.HX;2;Sexual activity with known Chlamydia trachomatis AndOr Neisseria gonorhoeae case;Sex cont w CT &or NG case;;ACTIVE;2.61;2.66 +85690-6;Rubella virus genotype;Type;Pt;XXX;Nom;;MICRO;1;Rubella virus genotype in Specimen;RUBV Gentyp Spec;;ACTIVE;2.61;2.72 +85691-4;Autopsy result;Find;Pt;^Patient;Nar;;H&P.HX;2;Autopsy result Narrative;Autopsy result;;ACTIVE;2.61;2.61 +85692-2;Year previously tested for rubella virus immunity;Date;Pt;^Patient;Qn;;VACCIN;2;Year previously tested for rubella virus immunity [Date];Y prev tested for rubella immun;;ACTIVE;2.61;2.61 +85693-0;Previous rubella virus test result;Find;Pt;^Patient;Nom;;VACCIN;2;Previous rubella virus test result;Prev rubella virus tx result;;ACTIVE;2.61;2.61 +85694-8;Documentation of previous rubella immunity testing;Find;Pt;^Patient;Ord;;H&P.HX;2;Documentation of previous rubella immunity testing;Documenation prev rubella tx;;ACTIVE;2.61;2.61 +85695-5;Prior condition onset year;Date;Pt;^Patient;Qn;;H&P.HX;2;Prior condition onset year [Date];Prior cond onset Y;;ACTIVE;2.61;2.66 +8569-6;Intravascular systolic;Pres;Pt;Retinal artery.left;Qn;;BP.MOLEC;2;Retinal artery - left Systolic blood pressure;Retinal a-L BP sys;;ACTIVE;1.0h(3);2.4 +85696-3;Previous rubella disease was serologically confirmed;Find;Pt;^Patient;Ord;;H&P.HX;2;Previous rubella disease was serologically confirmed;Prev rubella serologically confirm;;ACTIVE;2.61;2.61 +85697-1;Rubella diagnosis^pre pregnancy;Find;Pt;^Patient;Ord;;H&P.HX;2;Rubella diagnosis --pre pregnancy;Rubella dx pre pregnancy;;ACTIVE;2.61;2.61 +85698-9;Age at time of immunity testing;Time;Pt;^Patient;Qn;;H&P.HX;2;Age at time of immunity testing;Age at immunity testing;;ACTIVE;2.61;2.61 +85699-7;Autopsy was performed;Find;Pt;^Patient;Ord;;H&P.HX;2;Autopsy was performed;Autopsy performed;;ACTIVE;2.61;2.61 +85700-3;Age and setting of exposure to illness verified;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Age and setting of exposure to illness verified;;;ACTIVE;2.61;2.61 +85701-1;Rubella surveillance panel;-;Pt;^Patient;-;;PANEL.H&P;2;Rubella surveillance panel;Rubella surveillance Pnl;;ACTIVE;2.61;2.61 +85702-9;Received vaccination for illness of interest;Find;Pt;^Mother;Ord;;VACCIN;2;Mother Received vaccination for illness of interest;Mother Recvd vaccine for illness;;ACTIVE;2.61;2.66 +85703-7;Number of deliveries in the U.S.;Num;Pt;^Mother;Qn;;SURVEY.CDC;4;Mothers Number of deliveries in the U.S.;;;ACTIVE;2.61;2.61 +8570-4;Intravascular systolic;Pres;Pt;Retinal artery.right;Qn;;BP.MOLEC;2;Retinal artery - right Systolic blood pressure;Retinal a-R BP sys;;ACTIVE;1.0h(3);2.4 +85704-5;Year of previous delivery in the U.S.;Date;Pt;^Mother;Qn;;H&P.HX;2;Year of previous delivery in the U.S. [Date] from Mother;Year of prev delivery in U.S. Mother;;ACTIVE;2.61;2.61 +85705-2;Has had previous deliveries in the U.S.;Find;Pt;^Mother;Ord;;H&P.HX;2;Mother has had previous deliveries in U.S.;Prev deliveries in U.S. Mother;;ACTIVE;2.61;2.61 +85706-0;Date of exposure to individual with confirmed illness;Date;Pt;^Mother;Qn;;H&P.HX;2;Mother's date of exposure to individual with confirmed illness;Mother Date exposure to illness;;ACTIVE;2.61;2.61 +85707-8;Relationship to individual with confirmed illness;Type;Pt;^Mother;Nom;;H&P.HX;2;Mother's Relationship to individual with confirmed illness;Mother Rel to indiv w conf illness;;ACTIVE;2.61;2.61 +85708-6;Directly exposed to a confirmed case;Find;Pt;^Mother;Ord;;H&P.HX;2;Mother Directly exposed to a confirmed case;Exposed to confirmed case Mother;;ACTIVE;2.61;2.61 +85709-4;Traveled outside the U.S. during first trimester of pregnancy;Find;Pt;^Mother;Ord;;H&P.HX;2;Traveled outside the U.S. during first trimester of pregnancy of Mother;Travel outside US dur 1st tri Mother;;ACTIVE;2.61;2.61 +85710-2;Knows location of exposure to illness;Find;Pt;^Mother;Ord;;H&P.HX;2;Mother Knows location of exposure to illness;Mother Knows loc expose illness;;ACTIVE;2.61;2.61 +85711-0;Rubella was serologically confirmed at time of illness;Find;Pt;^Mother;Ord;;H&P.HX;2;Rubella was serologically confirmed at time of illness in Mother;Mother Rubella sero confirm dur illness;;ACTIVE;2.61;2.66 +8571-2;Intravascular systolic;Pres;Pt;Ring finger arteries.left;Qn;;BP.MOLEC;2;Ring finger arteries - left Systolic blood pressure;Ring finger aa-L BP sys;;ACTIVE;1.0h(3);2.4 +85712-8;Expected delivery location;Type;Pt;^Patient;Nom;;H&P.HX;2;Expected delivery location;Expected delivery loc;;ACTIVE;2.61;2.61 +85713-6;Vaccinated based on recommended guidelines;Find;Pt;^Patient;Ord;;VACCIN;2;Vaccinated based on recommended guidelines;Vaccinated based on guidelines;;ACTIVE;2.61;2.61 +85714-4;Reason vaccine not received;Find;Pt;^Patient;Nom;;VACCIN;2;Reason vaccine not received;Reason vacc not recvd;;ACTIVE;2.61;2.61 +85715-1;Mo of pregnancy when rubella-like symptoms appeared;Date;Pt;^Mother;Qn;;H&P.HX;2;Month of pregnancy when rubella-like symptoms appeared in Mother;Mo preg rubella symp Mother;;ACTIVE;2.61;2.61 +85716-9;Rubella-like illness during the pregnancy;Find;Pt;^Mother;Ord;;H&P.HX;2;Rubella-like illness during the pregnancy in Mother;Rubella-like illness dur preg Mother;;ACTIVE;2.61;2.61 +85717-7;Serologic testing was performed^pre pregnancy;Find;Pt;^Mother;Ord;;H&P.HX;2;Serologic testing was performed in Mother -- pre pregnancy;Serologic tx pre pregnancy Mother;;ACTIVE;2.61;2.61 +85718-5;Prenatal care location;Type;Pt;^Mother;Nom;;H&P.HX;2;Prenatal care location from Mother;Prenatal care location Mother;;ACTIVE;2.61;2.61 +85719-3;Gestational age in W^at cessation of pregnancy;Time;Pt;^Fetus;Qn;;H&P.HX;2;Gestational age in weeks--at cessation of pregnancy;GA (weeks)--at cess of preg;;ACTIVE;2.61;2.61 +8572-0;Intravascular systolic;Pres;Pt;Ring finger arteries.right;Qn;;BP.MOLEC;2;Ring finger arteries - right Systolic blood pressure;Ring finger aa-R BP sys;;ACTIVE;1.0h(3);2.4 +85720-1;Number of children under the age of 18 living in household during the pregnancy who received a rubella vaccine;Num;Pt;^Mother;Qn;;VACCIN;2;Number of children under the age of 18 living in mother's household during the pregnancy who received a rubella vaccine;Num in house under 18 rubella vac;;ACTIVE;2.61;2.61 +85721-9;Rubella vaccine was received by children under the age of 18 in the household during the pregnancy;Find;Pt;^Mother;Ord;;VACCIN;2;Rubella vaccine was received by children under the age of 18 in the mother's household during the pregnancy;Rubella vac rcvd by under 18;;ACTIVE;2.61;2.61 +85722-7;Number of children under the age of 18 living in household during the pregnancy;Num;Pt;^Mother;Qn;;H&P.HX;2;Number of children under the age of 18 living in mother's household during the pregnancy;Num in house under 18 dur preg;;ACTIVE;2.61;2.61 +85723-5;Attended a family planning clinic prior to conception;Find;Pt;^Mother;Ord;;H&P.HX;2;Mother attended a family planning clinic prior to conception;Attend fam plan prior conception Mother;;ACTIVE;2.61;2.61 +85724-3;Age^at delivery;Time;Pt;^Mother;Qn;;H&P.HX;2;Age of Mother --at delivery;Age at delivery Mother;;ACTIVE;2.61;2.73 +85725-0;Duration in the U.S.;Time;Pt;^Mother;Qn;;H&P.HX;2;Duration in the U.S. of Mother;Duration in the U.S. Mother;;ACTIVE;2.61;2.61 +85726-8;Other symptoms of illness;Find;Pt;^Mother;Nom;;H&P.HX;2;Other maternal symptoms of illness;Other maternal symp of illness;;ACTIVE;2.61;2.66 +85727-6;Lymphadenopathy;Find;Pt;^Mother;Ord;;H&P.HX;2;Lymphadenopathy in Mother;Lymphadenopathy Mother;;ACTIVE;2.61;2.61 +85728-4;Fever duration;Time;Pt;^Mother;Qn;;H&P.HX;2;Fever duration in Mother;Fever duration Mother;;ACTIVE;2.61;2.61 +85729-2;Date of fever onset;Date;Pt;^Mother;Qn;;H&P.HX;2;Date of fever onset in Mother;Date of fever onset Mother;;ACTIVE;2.61;2.61 +857-3;A2 B Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated A2 B Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated A2 B Ab SerPl BPU Ql;;DEPRECATED;1.0;2.4 +85730-0;Fever;Find;Pt;^Mother;Ord;;H&P.HX;2;Fever in Mother;Fever Mother;;ACTIVE;2.61;2.61 +85731-8;Rash duration;Time;Pt;^Mother;Qn;;H&P.HX;2;Rash duration in Mother;Rash duration Mother;;ACTIVE;2.61;2.61 +85732-6;Date of rash onset;Date;Pt;^Mother;Qn;;H&P.HX;2;Date of rash onset in Mother;Date of rash onset Mother;;ACTIVE;2.61;2.61 +85733-4;Maculopapular rash;Find;Pt;^Mother;Ord;;H&P.HX;2;Maculopapular rash in Mother;Maculopapular rash Mother;;ACTIVE;2.61;2.61 +85734-2;Date of last evaluation;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of last evaluation;Date of last eval;;ACTIVE;2.61;2.61 +85735-9;Congenital rubella case report panel;-;Pt;^Patient;-;;PANEL.H&P;2;Congenital rubella case report panel;Congenital rubella case report Pnl;;ACTIVE;2.61;2.61 +85736-7;Number of sexual partners in last 12Mo;NRat;12Mo;^Patient;Qn;;H&P.HX;2;Number of sexual partners in last 12 months;Num of sex partners nRate;;ACTIVE;2.61;2.66 +85737-5;Bombay phenotype;PrThr;Pt;RBC;Ord;;BLDBK;1;Bombay phenotype [Presence] on Red Blood Cells;Bombay phenotype RBC Ql;;ACTIVE;2.61;2.61 +8573-8;Intravascular systolic;Pres;Pt;Thumb arteries.left;Qn;;BP.MOLEC;2;Thumb arteries - left Systolic blood pressure;Thumb aa-L BP sys;;ACTIVE;1.0h(3);2.4 +85738-3;Bombay phenotype;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Bombay phenotype [Presence] on Red Blood Cells from Blood product unit;Bombay phenotype RBC BPU Ql;;ACTIVE;2.61;2.61 +85739-1;Bombay phenotype;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Bombay phenotype [Presence] on Red Blood Cells from Donor;Bombay phenotype RBC Donr Ql;;ACTIVE;2.61;2.61 +85740-9;Streptococcus pneumoniae Danish serotype 5 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 5 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 5 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85741-7;Streptococcus pneumoniae Danish serotype 4 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 4 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 4 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85742-5;Streptococcus pneumoniae Danish serotype 3 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 3 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 3 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85743-3;Streptococcus pneumoniae Danish serotype 23F DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 23F DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 23F DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85744-1;Streptococcus pneumoniae Danish serotype 2 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 2 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 2 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85745-8;Streptococcus pneumoniae Danish serotype 19F DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 19F DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pn Da sero 19F DNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +8574-6;Intravascular systolic;Pres;Pt;Thumb arteries.right;Qn;;BP.MOLEC;2;Thumb arteries - right Systolic blood pressure;Thumb aa-R BP sys;;ACTIVE;1.0h(3);2.4 +85746-6;Streptococcus pneumoniae Danish serotype 14 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 14 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 14 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85747-4;Streptococcus pneumoniae Danish serotype 1 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 1 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 1 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85748-2;Streptococcus pneumoniae Danish serotypes 7A+7F DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 7A+7F DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 7A+7F DNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +85749-0;Streptococcus pneumoniae Danish serotypes 22A+22F DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 22A+22F DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pn Da 22A+22F DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85750-8;Streptococcus pneumoniae Danish serotype 23A DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 23A DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 23A DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85751-6;Streptococcus pneumoniae Danish serotype 16F DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 16F DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 16F DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85752-4;Streptococcus pneumoniae Danish serotypes 9A+9V DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 9A+9V DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 9A+9V DNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +8575-3;Intravascular systolic;Pres;Pt;Ulnar artery.left;Qn;;BP.MOLEC;2;Ulnar artery - left Systolic blood pressure;Ulnar a-L BP sys;;ACTIVE;1.0h(3);2.4 +85753-2;Streptococcus pneumoniae Danish serotypes 6C+6D DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 6C+6D DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 6C+6D DNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +85754-0;Streptococcus pneumoniae Danish serotypes 6A+6B+6C+6D DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 6A+6B+6C+6D DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pn Da 6(A+B+C+D) DNA Ct Spec Qn NAA+pr;;ACTIVE;2.61;2.69 +85755-7;Streptococcus pneumoniae Danish serotypes 33A+33F+37 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 33A+33F+37 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pn Da 33A+33F+37 DNA Ct Spec Qn NAA+pr;;ACTIVE;2.61;2.69 +85756-5;Streptococcus pneumoniae Danish serotypes 18A+18B+18C+18F DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 18A+18B+18C+18F DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Spn Da 18A+B+C+F DNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +85757-3;Streptococcus pneumoniae Danish serotypes 15A+15F DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 15A+15F DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Spneu Da 15A+15F DNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +85758-1;Streptococcus pneumoniae Danish serotypes 12A+12F+44+46 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 12A+12F+44+46 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Spn Da 12A+12F+44+46 DNA Ct Spec NAA+pr;;ACTIVE;2.61;2.69 +85759-9;Streptococcus pneumoniae Danish serotypes 11A+11D DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotypes 11A+11D DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pn Da 11A+11D DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85760-7;Streptococcus pneumoniae Danish serotype 19A DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae Danish serotype 19A DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S pneum Da 19A DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +8576-1;Intravascular systolic;Pres;Pt;Ulnar artery.right;Qn;;BP.MOLEC;2;Ulnar artery - right Systolic blood pressure;Ulnar a-R BP sys;;ACTIVE;1.0h(3);2.4 +85761-5;Klebsiella pneumoniae DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella pneumoniae DNA [Presence] by NAA with non-probe detection in Positive blood culture;K pneumon DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85762-3;Blood pathogens panel;-;Pt;Bld.pos growth;-;Non-probe.amp.tar;PANEL.MICRO;1;Blood pathogens panel by NAA with non-probe detection in Positive blood culture;Blood path Pnl Bld Pos NAA+non-probe;;ACTIVE;2.61;2.73 +85763-1;Listeria monocytogenes DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Listeria monocytogenes DNA [Presence] by NAA with non-probe detection in Positive blood culture;L monocytog DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85764-9;Staphylococcus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus sp DNA [Presence] by NAA with non-probe detection in Positive blood culture;S aureus+CoNS DNA Bld Pos NAA+non-probe;;ACTIVE;2.61;2.73 +85765-6;Staphylococcus aureus DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [Presence] by NAA with non-probe detection in Positive blood culture;S aureus DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85766-4;Streptococcus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus sp DNA [Presence] by NAA with non-probe detection in Positive blood culture;Streptococcus DNA Bld Pos NAA+non-probe;;ACTIVE;2.61;2.73 +85767-2;Streptococcus agalactiae DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] by NAA with non-probe detection in Positive blood culture;Gp B Strep DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85768-0;Streptococcus pneumoniae DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] by NAA with non-probe detection in Positive blood culture;S pneum DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85769-8;Streptococcus pyogenes DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Presence] by NAA with non-probe detection in Positive blood culture;S pyo DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85770-6;Acinetobacter baumannii DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Acinetobacter baumannii DNA [Presence] by NAA with non-probe detection in Positive blood culture;A baumannii DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85771-4;Enterobacteriaceae DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Enterobacteriaceae DNA [Presence] by NAA with non-probe detection in Positive blood culture;Enterobact DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85772-2;Enterobacter cloacae complex DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [Presence] by NAA with non-probe detection in Positive blood culture;E cloac comp DNA Bld Pos NAA+non-probe;;ACTIVE;2.61;2.73 +85773-0;Escherichia coli DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli DNA [Presence] by NAA with non-probe detection in Positive blood culture;E coli DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85774-8;Klebsiella oxytoca DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [Presence] by NAA with non-probe detection in Positive blood culture;K oxytoca DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85775-5;Enterococcus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Enterococcus sp DNA [Presence] by NAA with non-probe detection in Positive blood culture;Enterococ DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85776-3;Proteus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Proteus sp DNA [Presence] by NAA with non-probe detection in Positive blood culture;Proteus sp DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85777-1;Serratia marcescens DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Serratia marcescens DNA [Presence] by NAA with non-probe detection in Positive blood culture;S marcescens DNA Bld Pos NAA+non-probe;;ACTIVE;2.61;2.73 +85778-9;Haemophilus influenzae DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] by NAA with non-probe detection in Positive blood culture;Haem influ DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +8577-9;Intravascular systolic.brachial artery right/Brachial artery;PresRto;Pt;Peripheral vascular system;Qn;;BP.MOLEC;2;Systolic blood pressure Brachial artery - right/Brachial artery;BP sys BA-r/Brach a;;ACTIVE;1.0h(3);2.48 +85779-7;Neisseria meningitidis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Presence] by NAA with non-probe detection in Positive blood culture;N men DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85780-5;Pseudomonas aeruginosa DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [Presence] by NAA with non-probe detection in Positive blood culture;P aeruginosa DNA Bld Pos NAA+non-probe;;ACTIVE;2.61;2.73 +85781-3;Candida albicans DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Candida albicans DNA [Presence] by NAA with non-probe detection in Positive blood culture;C albicans DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85782-1;Candida glabrata DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Candida glabrata DNA [Presence] by NAA with non-probe detection in Positive blood culture;C glabrata DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85783-9;Candida krusei DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Candida krusei DNA [Presence] by NAA with non-probe detection in Positive blood culture;C krusei DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85784-7;Candida parapsilosis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Candida parapsilosis DNA [Presence] by NAA with non-probe detection in Positive blood culture;C parap DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85785-4;Candida tropicalis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Candida tropicalis DNA [Presence] by NAA with non-probe detection in Positive blood culture;C tropicls DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.61;2.73 +85786-2;Bacterial methicillin resistance mecA gene;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;ABXBACT;1;Methicillin resistance mecA gene [Presence] by NAA with non-probe detection in Positive blood culture;mecA Bld Pos Ql NAA+non-probe;;DISCOURAGED;2.61;2.73 +8578-7;Intravascular systolic.penile artery/Brachial artery;PresRto;Pt;Peripheral vascular system;Qn;;BP.MOLEC;2;Systolic blood pressure Penile artery/Brachial artery;BP sys penile a/Brach a;;ACTIVE;1.0h(3);2.48 +85787-0;Bacterial vancomycin resistance vanA+vanB genes;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;ABXBACT;1;Vancomycin resistance vanA + vanB genes [Presence] by NAA with non-probe detection in Positive blood culture;vanA+vanB Bld Pos Ql NAA+non-probe;;DISCOURAGED;2.61;2.73 +85788-8;Bacterial carbapenem resistance blaKPC gene;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;ABXBACT;1;Carbapenem resistance blaKPC gene [Presence] by NAA with non-probe detection in Positive blood culture;blaKPC Bld Pos Ql NAA+non-probe;;DISCOURAGED;2.61;2.65 +85789-6;Cells.CD3+CD8+CD45RO+/100 cells.CD3;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD45RO+ cells/100 CD3 cells in Blood;CD3+CD8+CD45RO+/100 CD3 NFr Bld;;ACTIVE;2.61;2.73 +85790-4;Cells.CD3+CD8+CD45RO+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD45RO+ cells [#/volume] in Blood;CD3+CD8+CD45RO+ # Bld;;ACTIVE;2.61;2.73 +85791-2;Cells.CD3+CD4+CD45RO+/100 cells.CD3;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD45RO+ cells/100 CD3 cells in Blood;CD3+CD4+CD45RO+/100 CD3 NFr Bld;;ACTIVE;2.61;2.73 +85792-0;Cells.CD3+CD4+CD45RO+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD45RO+ cells [#/volume] in Blood;CD3+CD4+CD45RO+ # Bld;;ACTIVE;2.61;2.73 +85793-8;Specimen source subject;Type;Pt;*;Nom;;SPEC;1;Specimen source subject [Type];Spec source subj;;ACTIVE;2.61;2.61 +85794-6;Arthralgia &or arthritis;Find;Pt;^Mother;Ord;;H&P.HX;2;Arthralgia/arthritis [Presence] in Mother;Arthralgia AndOr arthritis Mother;;ACTIVE;2.61;2.61 +8579-5;Intravascular systolic.posterior tibial artery left/Brachial artery;PresRto;Pt;Peripheral vascular system;Qn;;BP.MOLEC;2;Systolic blood pressure Posterior tibial artery - left/Brachial artery;BP sys post TA-l/Brach a;;ACTIVE;1.0h(3);2.48 +85795-3;Rubella virus E1 gene & genotype panel;-;Pt;XXX;-;;PANEL.MICRO;1;Rubella virus E1 gene and genotype panel - Specimen;RUBV E1 + genotype Pnl Spec;;ACTIVE;2.61;2.69 +85796-1;Rubella virus E1 gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Rubella virus E1 gene [Cycle Threshold #] in Specimen by NAA with probe detection;RUBV E1 Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85797-9;Neisseria meningitidis serogroup DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Neisseria meningitidis serogroup DNA panel - Specimen by NAA with probe detection;N men sg DNA Pnl Spec NAA+probe;;ACTIVE;2.61;2.69 +85798-7;Measles virus N gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Measles virus N gene [Cycle Threshold #] in Specimen by NAA with probe detection;MeV N gene Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85799-5;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;B per+bron+holm IS481 DNA Ct Spec NAA+pr;;ACTIVE;2.61;2.69 +85800-1;Mumps virus SH gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mumps virus SH gene [Cycle Threshold #] in Specimen by NAA with probe detection;MuV SH gene Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +85801-9;Influenza virus B Yamagata lineage Ag;Titr;Pt;Isolate;Qn;HAI;MICRO;1;Influenza virus B Yamagata lineage Ag [Titer] in Isolate by Hemagglutination inhibition;FLUBV Yam Ag Titr Islt HAI;;ACTIVE;2.61;2.61 +85802-7;Influenza virus A H1 Ag;Titr;Pt;Isolate;Qn;HAI;MICRO;1;Influenza virus A H1 Ag [Titer] in Isolate by Hemagglutination inhibition;FLUAV H1 Ag Titr Islt HAI;;ACTIVE;2.61;2.61 +8580-3;Intravascular systolic.posterior tibial artery right/Brachial artery;PresRto;Pt;Peripheral vascular system;Qn;;BP.MOLEC;2;Systolic blood pressure Posterior tibial artery - right/Brachial artery;BP sys post TA-r/Brach a;;ACTIVE;1.0h(3);2.48 +85803-5;Influenza virus A H3 Ag;Titr;Pt;Isolate;Qn;HAI;MICRO;1;Influenza virus A H3 Ag [Titer] in Isolate by Hemagglutination inhibition;FLUAV H3 Ag Titr Islt HAI;;ACTIVE;2.61;2.61 +85804-3;Influenza virus A H5 Ag;Titr;Pt;Isolate;Qn;HAI;MICRO;1;Influenza virus A H5 Ag [Titer] in Isolate by Hemagglutination inhibition;FLUAV H5 Ag Titr Islt HAI;;ACTIVE;2.61;2.61 +85805-0;Influenza virus A H7 Ag;Titr;Pt;Isolate;Qn;HAI;MICRO;1;Influenza virus A H7 Ag [Titer] in Isolate by Hemagglutination inhibition;FLUAV H7 Ag Titr Islt HAI;;ACTIVE;2.61;2.61 +85806-8;Measles virus RNA & N gene panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Measles virus RNA and N gene panel - Specimen by NAA with probe detection;MeV RNA and N gene Pnl Spec NAA+probe;;ACTIVE;2.61;2.69 +85807-6;Mumps virus genotype;Type;Pt;XXX;Nom;;MICRO;1;Mumps virus genotype in Specimen;MuV Gentyp Spec;;ACTIVE;2.61;2.72 +85808-4;Mumps virus RNA & SH gene panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Mumps virus RNA and SH gene panel - Specimen by NAA with probe detection;MuV RNA and SH gene Pnl Spec NAA+probe;;ACTIVE;2.61;2.69 +85809-2;Bordetella pertussis & parapertussis & holmesii DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Bordetella pertussis and parapertussis and holmesii DNA panel - Specimen by NAA with probe detection;B per + parap + holm DNA Pnl Spec NAA+pr;;ACTIVE;2.61;2.69 +858-1;A2 B Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated A2 B Ab [Presence] on Red Blood Cells from donor;Deprecated A2 B Ab SerPl Donr Ql;;DEPRECATED;1.0;2.4 +85810-0;Adenovirus serotype DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Adenovirus serotype DNA panel - Specimen by NAA with probe detection;AdV serotype DNA Pnl Spec NAA+probe;;ACTIVE;2.61;2.69 +8581-1;Intravascular systolic.posterior tibial artery/Brachial artery;PresRto;Pt;Peripheral vascular system;Qn;;BP.MOLEC;2;Systolic blood pressure Posterior tibial artery/Brachial artery;BP sys post TA/Brach a;;ACTIVE;1.0h(3);2.73 +85811-8;LCDS v3.00 - Altered level of consciousness;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Altered level of consciousness [CMS Assessment];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.69 +85812-6;LCDS v3.00 - Acute onset and fluctuating course;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v3.00 - Acute onset and fluctuating course [CMS Assessment];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.61;2.69 +85813-4;IRF-PAI - Payment source;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Payment source [CMS Assessment];;;ACTIVE;2.61;2.69 +85814-2;IRF-PAI - Signature of persons completing the assessment;-;Pt;Form;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI - Signature of persons completing the assessment [CMS Assessment];;;ACTIVE;2.61;2.61 +85815-9;LCDS - Pre-admission service use;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS - Pre-admission Service Use [CMS Assessment];;;ACTIVE;2.61;2.69 +85816-7;LCDS v4.00 - Patient demographic information - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Patient demographic information - admission [CMS Assessment];;;ACTIVE;2.61;2.69 +85817-5;LCDS v4.00 - Patient demographic information - discharge and expired;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Patient demographic information - discharge and expired [CMS Assessment];;;ACTIVE;2.61;2.69 +85818-3;Clot formation+Clotting time;Time;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot formation+Clotting time of Blood by Thromboelastography;Clot form+Clot time Bld TEG;;ACTIVE;2.61;2.67 +85819-1;Clot firmness reduction^60M after maximum clot amplitude after addition of heparinase;LenFr;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot firmness reduction [Length fraction] in Blood by Thromboelastography --60 min p max clot amplitude + heparinase;CF reduc 60M p MA p hepase LenFr Bld TEG;;ACTIVE;2.61;2.61 +85820-9;Clot firmness reduction^30M after maximum clot amplitude after addition of heparinase;LenFr;Pt;Bld;Qn;Thromboelastography;COAG;1;Clot firmness reduction [Length fraction] in Blood by Thromboelastography --30 min p max clot amplitude + heparinase;CF reduc 30M p MA p hepase LenFr Bld TEG;;ACTIVE;2.61;2.61 +85821-7;Influenza Virus B Victoria lineage Ag;PrThr;Pt;Isolate;Ord;HAI;MICRO;1;Influenza virus B Victoria lineage Ag [Presence] in Isolate by Hemagglutination inhibition;FLUBV Vic Ag Islt Ql HAI;;ACTIVE;2.61;2.61 +85822-5;Bacterial beta-lactam resistance AmpC blaCMY+blaMOX genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance AmpC blaCMY+blaMOX genes [Presence] by Molecular method;AmpC blaCMY+blaMOX genes Islt/Spm Ql;;ACTIVE;2.61;2.67 +85823-3;Bacterial carbapenem resistance blaGES gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaGES gene [Presence] by Molecular method;blaGES Islt/Spm Ql;;ACTIVE;2.61;2.67 +85824-1;Bacterial carbapenem resistance blaIMP gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;ABXBACT;1;Carbapenem resistance blaIMP gene [Presence] by NAA with probe detection;blaIMP Islt Ql NAA+probe;;DISCOURAGED;2.61;2.67 +85825-8;Bacterial carbapenem resistance blaOXA-23-like gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA-23-like gene [Presence] by Molecular method;blaOXA-23-like Islt/Spm Ql;;ACTIVE;2.61;2.67 +85826-6;Bacterial carbapenem resistance blaOXA-24-like gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA-24-like gene [Presence] by Molecular method;blaOXA-24-like Islt/Spm Ql;;ACTIVE;2.61;2.67 +85827-4;Bacterial carbapenem resistance blaOXA-48-like gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance bla OXA-48-like gene [Presence] by Molecular method;blaOXA-48-like Islt/Spm Ql;;ACTIVE;2.61;2.67 +85828-2;Bacterial carbapenem resistance blaOXA-58-like gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA-58-like gene [Presence] by Molecular method;blaOXA-58-like Islt/Spm Ql;;ACTIVE;2.61;2.67 +8582-9;A wave amplitude;Pres;Pt;Heart.atrium.left;Qn;;BP.VENOUS.MOLEC;2;Left atrial A-wave amplitude;LA A-wave amp;;ACTIVE;1.0h(3);2.54 +85829-0;Bacterial carbapenem resistance blaSPM gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaSPM gene [Presence] by Molecular method;blaSPM Islt/Spm Ql;;ACTIVE;2.61;2.67 +85830-8;Bacterial carbapenem resistance blaVIM gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;ABXBACT;1;Carbapenem resistance blaVIM gene [Presence] by NAA with probe detection;blaVIM Islt Ql NAA+probe;;DISCOURAGED;2.61;2.66 +85831-6;Bacterial beta-lactam resistance ESBL blaBEL gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaBEL gene [Presence] by Molecular method;ESBL blaBEL gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85832-4;Bacterial beta-lactam resistance ESBL blaCTX-M-1 group gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaCTX-M-1 Group gene [Presence] by Molecular method;ESBL blaCTX-M-1 Grp gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85833-2;Bacterial carbapenem resistance blaGIM gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaGIM gene [Presence] by Molecular method;blaGIM Islt/Spm Ql;;ACTIVE;2.61;2.67 +85834-0;Bacterial beta-lactam resistance ESBL blaCTX-M-9 group gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaCTX-M-9 Group gene [Presence] by Molecular method;ESBL blaCTX-M9 Grp gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85835-7;Bacterial beta-lactam resistance ESBL blaCTX-M-8+blaCTX-M-25 group genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaCTX-M-8+blaCTX-M-25 Group genes [Presence] by Molecular method;blaCTX-M-8+blaCTX-M-25 Gr Islt/Spm Ql;;ACTIVE;2.61;2.67 +85836-5;Bacterial beta-lactam resistance ESBL blaGES gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaGES gene [Presence] by Molecular method;ESBL blaGES gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +8583-7;A wave amplitude;Pres;Pt;Heart.atrium.right;Qn;;BP.VENOUS.MOLEC;2;Right atrial A-wave amplitude;RA A-wave amp;;ACTIVE;1.0h(3);2.54 +85837-3;Bacterial beta-lactam resistance ESBL blaPER gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaPER gene [Presence] by Molecular method;ESBL blaPER gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85838-1;Bacterial beta-lactam resistance ESBL blaSHV gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaSHV gene [Presence] by Molecular method;ESBL blaSHV gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85839-9;Bacterial beta-lactam resistance ESBL blaTEM gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaTEM gene [Presence] by Molecular method;ESBL blaTEM gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85840-7;Bacterial beta-lactam resistance ESBL blaVEB gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaVEB gene [Presence] by Molecular method;ESBL blaVEB gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85841-5;Bacterial beta-lactam resistance AmpC blaACC gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance AmpC blaACC gene [Presence] by Molecular method;AmpC blaACC gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85842-3;Bacterial beta-lactam resistance AmpC blaACT+blaMIR genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance AmpC blaACT+blaMIR genes [Presence] by Molecular method;AmpC blaACT+blaMIR genes Islt/Spm Ql;;ACTIVE;2.61;2.67 +85843-1;Bacterial beta-lactam resistance AmpC blaFOX gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance AmpC blaFOX gene [Presence] by Molecular method;AmpC blaFOX gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +85844-9;Bacterial beta-lactam resistance ESBL blaCTX-M-2 group gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaCTX-M-2 Group gene [Presence] by Molecular method;ESBL blaCTX-M2 Grp gene Islt/Spm Ql;;ACTIVE;2.61;2.67 +8584-5;A wave amplitude;Pres;Pt;Pulmonary artery.wedge;Qn;;BP.VENOUS.MOLEC;2;Pulmonary artery wedge A-wave amplitude;PAW A-wave amp;;ACTIVE;1.0h(3);2.54 +85845-6;Impairment group;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Impairment group [CMS Assessment];;;ACTIVE;2.61;2.61 +85846-4;Swallowing status;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Swallowing status [CMS Assessment];;;ACTIVE;2.61;2.61 +85847-2;Care team information;Find;Pt;^Patient;Doc;;DOC.MISC;2;Patient Care team information;Pt Care team info;;ACTIVE;2.61;2.63 +85848-0;Restraint note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Restraint note;Nurse Restraint note;;ACTIVE;2.61;2.61 +85849-8;Discharge summary note;Find;Pt;Recovery room;Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Recovery room Discharge summary;Anesthesiology Recovery rm D/C sum;;ACTIVE;2.61;2.73 +85850-6;History and physical note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery History and physical note;Cardiothor surg H&P note;;ACTIVE;2.61;2.61 +85851-4;Note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery.interdisciplinary;DOC.ONTOLOGY;2;Cardiothoracic surgery Interdisciplinary Note;Cardiothorac surg Interdis Note;;ACTIVE;2.61;2.61 +8585-2;Intravascular mean;Pres;Pt;Hepatic artery.wedge;Qn;;BP.VENOUS.MOLEC;2;Hepatic artery wedge Mean blood pressure;Hep a.wedge BP mean;;ACTIVE;1.0h(3);2.4 +85852-2;Note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery.nurse;DOC.ONTOLOGY;2;Cardiothoracic surgery Nurse Note;Cardiothorac surg Nurse Note;;ACTIVE;2.61;2.61 +85853-0;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Postoperative evaluation and management note;Cardiothor surg Post-op E/M note;;ACTIVE;2.61;2.61 +85854-8;Procedure note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery procedure note;Cardiothor surg Procedure note;;ACTIVE;2.61;2.61 +85855-5;Note;Find;Pt;Telephone encounter;Doc;Womens health;DOC.ONTOLOGY;2;Womens health Telephone encounter Note;Wmns hlth Phone Note;;ACTIVE;2.61;2.61 +85856-3;Risk assessment and screening note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health Risk assessment and screening note;Wmns hlth Risk assess+scrn note;;ACTIVE;2.61;2.61 +85857-1;Procedure note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health procedure note;Wmns hlth Procedure note;;ACTIVE;2.61;2.61 +85858-9;Note;Find;Pt;Outpatient;Doc;Womens health;DOC.ONTOLOGY;2;Womens health Outpatient Note;Wmns hlth OP Note;;ACTIVE;2.61;2.61 +85859-7;Letter;Find;Pt;Outpatient;Doc;Womens health;DOC.ONTOLOGY;2;Womens health Outpatient Letter;Wmns hlth OP Letter;;ACTIVE;2.61;2.61 +8586-0;Intravascular mean;Pres;Pt;Vena cava.inferior;Qn;;BP.VENOUS.MOLEC;2;Inferior vena cava Mean blood pressure;IVC BP mean;;ACTIVE;1.0h(3);2.4 +85860-5;History and physical note;Find;Pt;Outpatient;Doc;Womens health;DOC.ONTOLOGY;2;Womens health Outpatient History and physical note;Wmns hlth OP H&P note;;ACTIVE;2.61;2.61 +85861-3;Note;Find;Pt;Outpatient;Doc;Womens health.nurse;DOC.ONTOLOGY;2;Womens health Nurse Outpatient Note;Wmns hlth Nurse OP Note;;ACTIVE;2.61;2.61 +85862-1;Note;Find;Pt;{Setting};Doc;Womens health.nurse;DOC.ONTOLOGY;2;Womens health Nurse Note;Wmns hlth Nurse Note;;ACTIVE;2.61;2.61 +85863-9;Note;Find;Pt;Teleimaging;Doc;{Role};DOC.ONTOLOGY;2;Teleimaging Note;Teleimaging Note;;ACTIVE;2.61;2.61 +85864-7;Note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Note;Sleep med Note;;ACTIVE;2.61;2.73 +85865-4;Diagnostic study note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Diagnostic study note;Sleep med Diag study note;;ACTIVE;2.61;2.61 +85866-2;Consultation note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Consult note;Sleep med Consult note;;ACTIVE;2.61;2.73 +85867-0;History and physical note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health History and physical note;Wmns hlth H&P note;;ACTIVE;2.61;2.61 +85868-8;Group counseling note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health Group counseling note;Wmns hlth Group counseling note;;ACTIVE;2.61;2.61 +85869-6;Education note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health Education note;Wmns hlth Educ note;;ACTIVE;2.61;2.61 +85870-4;Note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health Note;Wmns hlth Note;;ACTIVE;2.61;2.61 +85871-2;Consultation note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health Consult note;Wmns hlth Consult note;;ACTIVE;2.61;2.61 +85872-0;Restraint note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Restraint note;Psychiatric Restraint note;;ACTIVE;2.61;2.61 +85873-8;Restraint note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Restraint note;MD Restraint note;;ACTIVE;2.61;2.61 +85874-6;Note;Find;Pt;Recovery room;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Recovery room Note;Nurse Recovery rm Note;;ACTIVE;2.61;2.61 +85875-3;Discharge summary note;Find;Pt;Recovery room;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Recovery room Discharge summary;Nurse Recovery rm D/C sum;;ACTIVE;2.61;2.73 +85876-1;Note;Find;Pt;{Setting};Doc;Neuropsychology;DOC.ONTOLOGY;2;Neuropsychology Note;Neuropsych Note;;ACTIVE;2.61;2.73 +85877-9;Initial evaluation note;Find;Pt;{Setting};Doc;Neuropsychology;DOC.ONTOLOGY;2;Neuropsychology Initial evaluation note;Neuropsych Initial eval note;;ACTIVE;2.61;2.61 +8587-8;Intravascular mean;Pres;Pt;Pulmonary artery.wedge;Qn;;BP.VENOUS.MOLEC;2;Pulmonary artery wedge Mean blood pressure;PAW BP mean;;ACTIVE;1.0h(3);2.3 +85878-7;Discharge summary note;Find;Pt;{Setting};Doc;Neuropsychology;DOC.ONTOLOGY;2;Neuropsychology Discharge summary;Neuropsych D/C sum;;ACTIVE;2.61;2.73 +85879-5;Restraint note;Find;Pt;{Setting};Doc;Mental health.nurse;DOC.ONTOLOGY;2;Mental health Nurse Restraint note;MH Nurse Restraint note;;ACTIVE;2.61;2.61 +85880-3;Restraint note;Find;Pt;Long term care facility;Doc;{Role};DOC.ONTOLOGY;2;Long term care facility Restraint note;LTC fac Restraint note;;ACTIVE;2.61;2.61 +85881-1;Note;Find;Pt;Teleimaging;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Teleimaging Note;Ophthalmol Teleimaging Note;;ACTIVE;2.61;2.61 +85882-9;Consultation note;Find;Pt;Teleimaging;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Teleimaging Consult note;Ophthalmol Teleimaging Consult note;;ACTIVE;2.61;2.61 +85883-7;Note;Find;Pt;{Setting};Doc;Epilepsy;DOC.ONTOLOGY;2;Epilepsy Note;Epilepsy Note;;ACTIVE;2.61;2.61 +85884-5;Consultation note;Find;Pt;{Setting};Doc;Epilepsy;DOC.ONTOLOGY;2;Epilepsy Consult note;Epilepsy Consult note;;ACTIVE;2.61;2.61 +8588-6;Intravascular mean;Pres;Pt;Subclavian vein.left;Qn;;BP.VENOUS.MOLEC;2;Subclavian vein - left Mean blood pressure;Subclavian v-L BP mean;;ACTIVE;1.0h(3);2.4 +85886-0;Consultation note;Find;Pt;{Setting};Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology Consult note;Electrophysiology Consult note;;ACTIVE;2.63;2.63 +85887-8;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Postoperative evaluation and management note;Dermatology Post-op E/M note;;ACTIVE;2.61;2.61 +85888-6;Note;Find;Pt;Telehealth;Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Telehealth Note;Multi-spec prog Telehealth Note;;ACTIVE;2.61;2.61 +85889-4;Note;Find;Pt;Telephone encounter;Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Telephone encounter Note;Cardiothor surg Phone Note;;ACTIVE;2.61;2.61 +85890-2;Consultation note;Find;Pt;{Setting};Doc;Neuropsychology;DOC.ONTOLOGY;2;Neuropsychology Consult note;Neuropsych Consult note;;ACTIVE;2.61;2.61 +85891-0;Note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery.fellow;DOC.ONTOLOGY;2;Cardiothoracic surgery Fellow Note;Cardiothorac surg Fellow Note;;ACTIVE;2.61;2.65 +85892-8;Note;Find;Pt;{Setting};Doc;Womens health.nurse practitioner;DOC.ONTOLOGY;2;Womens health Nurse practitioner Note;Wmns hlth NP Note;;ACTIVE;2.61;2.61 +85893-6;Adverse event note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Adverse event note;Adverse event note;;ACTIVE;2.61;2.61 +8589-4;Intravascular mean;Pres;Pt;Subclavian vein.right;Qn;;BP.VENOUS.MOLEC;2;Subclavian vein - right Mean blood pressure;Subclavian v-R BP mean;;ACTIVE;1.0h(3);2.4 +85894-4;Counseling note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Counseling note;PM+R Counseling note;;ACTIVE;2.63;2.63 +85895-1;Diagnostic study note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine Diagnostic study note;Nuc Medicine Diag study note;;ACTIVE;2.65;2.65 +85896-9;Diagnostic study note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Diagnostic study note;Nurse Diag study note;;ACTIVE;2.61;2.61 +85898-5;Diagnostic study note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Diagnostic study note;Surgery Diag study note;;ACTIVE;2.65;2.65 +85899-3;Consultation note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Consult note;Comm hlth care Consult note;;ACTIVE;2.61;2.61 +85900-9;Note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery.resident;DOC.ONTOLOGY;2;Cardiothoracic surgery Resident Note;Cardiothorac surg Res Note;;ACTIVE;2.61;2.65 +85901-7;Note;Find;Pt;{Setting};Doc;Community health care;DOC.ONTOLOGY;2;Community health care Note;Comm hlth care Note;;ACTIVE;2.61;2.61 +8590-2;Intravascular mean;Pres;Pt;Vena cava.superior;Qn;;BP.VENOUS.MOLEC;2;Superior vena cava Mean blood pressure;SVC BP mean;;ACTIVE;1.0h(3);2.4 +85902-5;Note;Find;Pt;{Setting};Doc;Community health care.nurse;DOC.ONTOLOGY;2;Community health care Nurse Note;CHC Nurse Note;;ACTIVE;2.61;2.61 +85903-3;Note;Find;Pt;Telephone encounter;Doc;Community health care;DOC.ONTOLOGY;2;Community health care Telephone encounter Note;Comm hlth care Phone Note;;ACTIVE;2.61;2.61 +85904-1;Cancer pathology panel;-;Pt;Breast cancer specimen;-;CAP cancer protocols;PANEL.PATH;1;Cancer pathology panel - Breast cancer specimen by CAP cancer protocols;Cancer Path Pnl Br ca spec CAP prot;Copyright © 2017 College of American Pathologists Used with permission;ACTIVE;2.61;2.61 +85905-8;Cancer pathology panel;-;Pt;Colorectal cancer specimen;-;CAP cancer protocols;PANEL.PATH;1;Cancer pathology panel - Colorectal cancer specimen by CAP cancer protocols;Cancer Path Pnl CRC spec CAP prot;Copyright © 2017 College of American Pathologists Used with permission;ACTIVE;2.61;2.61 +85906-6;Home health patient tracking sheet - resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Home health patient tracking sheet - resumption of care [CMS Assessment];;;ACTIVE;2.63;2.67 +85907-4;Outcome and assessment information set (OASIS) form - version C2 - Start of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Outcome and assessment information set (OASIS) form - version C2 - Start of care [CMS Assessment];;;DEPRECATED;2.63;2.73 +85908-2;Home health patient tracking sheet - start of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Home health patient tracking sheet - start of care [CMS Assessment];;;ACTIVE;2.63;2.67 +85909-0;OASIS C2 - Patient history and diagnoses - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Patient history and diagnoses - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.63 +8591-0;Intravascular mean;Pres;Pt;BldCV;Qn;;BP.VENOUS.MOLEC;2;Central venous pressure (CVP) Mean;CVP mean;;ACTIVE;1.0h(3);2.7 +85910-8;Physical findings;Find;Pt;Teeth and gum;Nar;Observed;H&P.HX;2;Physical findings of Teeth and gum Narrative;Phys find Teeth+gum;;ACTIVE;2.61;2.61 +85911-6;Diagnoses, symptom control, and optional diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Diagnoses, symptom control, and optional diagnoses [CMS Assessment];;;ACTIVE;2.63;2.63 +85912-4;Primary diagnosis;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Primary diagnosis [CMS Assessment];;;ACTIVE;2.63;2.63 +85913-2;Other diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Other diagnoses [CMS Assessment];;;ACTIVE;2.63;2.63 +85914-0;Underlying resolved condition ICD code;Prid;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Underlying resolved condition ICD code [CMS Assessment];;;ACTIVE;2.63;2.63 +85915-7;Episode of care includes influenza vaccination season;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Episode of care includes influenza vaccination season [CMS Assessment];;;ACTIVE;2.63;2.63 +85916-5;Pneumococcal vaccination received;Find;Lifetime;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Deprecated Pneumococcal vaccination received [CMS Assessment];;;DEPRECATED;2.63;2.73 +85917-3;OASIS C2 - Integumentary status - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Integumentary status - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.63 +85918-1;Unhealed pressure injury at stage 2 or higher or designated as unstageable;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unhealed pressure injury at stage 2 or higher or designated as unstageable [CMS Assessment];;;ACTIVE;2.63;2.64 +85919-9;OASIS C2 - Current number of unhealed pressure injuries at each stage - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Current number of unhealed pressure injuries at each stage - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.64 +85920-7;Symptom control rating;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Symptom control rating [CMS Assessment];;;ACTIVE;2.63;2.63 +85921-5;OASIS C2 - Respiratory status - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Respiratory status - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.63 +85922-3;OASIS C2 - Elimination status - start of care or resumption of care;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Elimination status - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.63 +85923-1;OASIS C2 - ADL and IADLs - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - ADL and IADLs - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.63 +85924-9;OASIS C2 - Functional abilities and goals - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Functional abilities and goals - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.63 +85925-6;OASIS C2 - Mobility;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Mobility [CMS Assessment];;;ACTIVE;2.63;2.63 +85926-4;Lying to sitting on side of bed - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lying to sitting on side of bed - functional ability [CMS Assessment];;;ACTIVE;2.63;2.64 +85927-2;Lying to sitting on side of bed - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lying to sitting on side of bed - functional goal [CMS Assessment];;;ACTIVE;2.63;2.64 +8592-8;V wave amplitude;Pres;Pt;Heart.atrium.left;Qn;;BP.VENOUS.MOLEC;2;Left atrial V wave amplitude;LA V wave amp;;ACTIVE;1.0h(3);2.48 +85928-0;OASIS C2 - Medications - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Medications - SOC or ROC [CMS Assessment];;;ACTIVE;2.63;2.63 +85929-8;Salivary gland swelling duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Salivary gland swelling duration;Salivary gland swelling dur;;ACTIVE;2.61;2.66 +85930-6;Date specimen sent to CDC;Date;Pt;^Patient;Qn;;SPEC;1;Date specimen sent to CDC;Date specimen sent to CDC;;ACTIVE;2.61;2.61 +85931-4;Date of salivary gland swelling onset;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of salivary gland swelling onset;Date of salivary gland swelling onset;;ACTIVE;2.61;2.66 +85932-2;Date of cough onset;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of cough onset;Date of cough onset;;ACTIVE;2.61;2.66 +85933-0;Cough duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Cough duration;Cough duration;;ACTIVE;2.61;2.66 +85934-8;Age at cough onset;Time;Pt;^Patient;Qn;;H&P.HX;2;Age at cough onset;Age at cough onset;;ACTIVE;2.61;2.66 +85935-5;Education note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Education note;Vocational rehab Educ note;;ACTIVE;2.61;2.61 +8593-6;V wave amplitude;Pres;Pt;Heart.atrium.right;Qn;;BP.VENOUS.MOLEC;2;Right atrial V wave amplitude;RA V wave amp;;ACTIVE;1.0h(3);2.48 +85936-3;Risk assessment and screening note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Risk assessment and screening note;Vocational rehab Risk assess+scrn note;;ACTIVE;2.61;2.61 +85937-1;Note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Note;Gynecology Note;;ACTIVE;2.61;2.61 +85938-9;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Postoperative evaluation and management note;Cardiology Post-op E/M note;;ACTIVE;2.61;2.61 +85939-7;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology Preoperative evaluation and management note;Electrophysiology Pre-op note;;ACTIVE;2.61;2.61 +85940-5;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology Postoperative evaluation and management note;Electrophysiology Post-op E/M note;;ACTIVE;2.61;2.61 +85941-3;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Postoperative evaluation and management note;Gastroenterology Post-op E/M note;;ACTIVE;2.61;2.61 +85942-1;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Preoperative evaluation and management note;Gastroenterology Pre-op note;;ACTIVE;2.61;2.61 +85943-9;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Postoperative evaluation and management note;Orthopaedic surgery Post-op E/M note;;ACTIVE;2.61;2.61 +8594-4;V wave amplitude;Pres;Pt;Jugular vein;Ord;Visual;BP.VENOUS.MOLEC;2;Jugular vein V wave amplitude by Visual;Jugular v V wave amp by Visual;;ACTIVE;1.0h(3);2.27 +85944-7;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Preoperative evaluation and management note;Pulmonary disease Pre-op note;;ACTIVE;2.61;2.61 +85945-4;Postoperative evaluation and management note;Find;Pt;Outpatient;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Outpatient Postoperative evaluation and management note;Surgery OP Post-op E/M note;;ACTIVE;2.61;2.61 +85946-2;Preoperative evaluation and management note;Find;Pt;Outpatient;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Outpatient Preoperative evaluation and management note;Surgery OP Pre-op note;;ACTIVE;2.61;2.61 +85947-0;Preoperative evaluation and management note;Find;Pt;Outpatient;Doc;Surgery.nurse;DOC.ONTOLOGY;2;Surgery Nurse Outpatient Preoperative evaluation and management note;Surgery Nurse OP Pre-op note;;ACTIVE;2.61;2.61 +85948-8;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Surgery.attending;DOC.ONTOLOGY;2;Surgery Attending Preoperative evaluation and management note;Surg attend Pre-op note;;ACTIVE;2.61;2.65 +85949-6;Age at rash onset;Time;Pt;^Patient;Qn;;H&P.HX;2;Age at rash onset;Age at rash onset;;ACTIVE;2.61;2.66 +85950-4;Living situation and availability of assistance;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Living situation and availability of assistance [CMS Assessment];;;ACTIVE;2.63;2.63 +8595-1;V wave amplitude;Pres;Pt;Jugular vein;Qn;;BP.VENOUS.MOLEC;2;Jugular vein V wave amplitude;Jugular v V wave amp;;ACTIVE;1.0h(3);2.48 +85951-2;Living Arrangements;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Living arrangements [CMS Assessment];;;ACTIVE;2.63;2.67 +85952-0;Streptococcus pneumoniae Danish serotype 1 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Mass/volume] in Serum;S pneum Da 1 Ab Ser-mCnc;;ACTIVE;2.61;2.73 +85953-8;Streptococcus pneumoniae Danish serotype 1 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Units/volume] in Serum;S pneum Da 1 Ab Ser-aCnc;;ACTIVE;2.61;2.73 +85954-6;Streptococcus pneumoniae Danish serotype 1 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Mass/volume] in Serum;S pneum Da 1 IgG Ser-mCnc;;ACTIVE;2.61;2.73 +85955-3;Streptococcus pneumoniae Danish serotype 1 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 1 IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +85956-1;Streptococcus pneumoniae Danish serotype 1 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Units/volume] in Serum;S pneum Da 1 IgG Ser-aCnc;;ACTIVE;2.61;2.73 +85957-9;Streptococcus pneumoniae Danish serotype 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 1 IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +85958-7;Streptococcus pneumoniae Danish serotype 1 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 1 IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +85959-5;Streptococcus pneumoniae Danish serotype 1 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 1 IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +85960-3;Streptococcus pneumoniae Danish serotype 1 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 1 IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +85961-1;Streptococcus pneumoniae Danish serotype 1 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 1 IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +85962-9;Streptococcus pneumoniae Danish serotype 1 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 1 IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +85963-7;Streptococcus pneumoniae Danish serotype 1 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 1 IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +85964-5;Streptococcus pneumoniae Danish serotype 1 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 1 IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +85965-2;Streptococcus pneumoniae Danish serotype 1 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Mass/volume] in Serum --1st specimen;S pneum Da 1 Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +85966-0;Streptococcus pneumoniae Danish serotype 1 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pneum Da 1 Ab sp1 Ser IA-aCnc;;ACTIVE;2.61;2.61 +85967-8;Streptococcus pneumoniae Danish serotype 1 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Units/volume] in Serum --1st specimen;S pneum Da 1 Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +85968-6;Streptococcus pneumoniae Danish serotype 1 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 1 Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +8596-9;V wave amplitude;Pres;Pt;Pulmonary artery.wedge;Qn;;BP.VENOUS.MOLEC;2;Pulmonary artery wedge V wave amplitude;PAW V wave amp;;ACTIVE;1.0h(3);2.48 +85969-4;Streptococcus pneumoniae Danish serotype 1 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 1 Ab sp2 Ser IA-aCnc;;ACTIVE;2.61;2.61 +85970-2;Streptococcus pneumoniae Danish serotype 1 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 1 Ab [Units/volume] in Serum --2nd specimen;S pneum Da 1 Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +85971-0;Streptococcus pneumoniae Danish serotype 12F Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Mass/volume] in Serum;S pneum Da 12F Ab Ser-mCnc;;ACTIVE;2.61;2.73 +85972-8;Streptococcus pneumoniae Danish serotype 12F Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Units/volume] in Serum;S pneum Da 12F Ab Ser-aCnc;;ACTIVE;2.61;2.73 +85973-6;Streptococcus pneumoniae Danish serotype 12F Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Presence] in Serum;S pneum Da 12F Ab Ser Ql;;ACTIVE;2.61;2.61 +85974-4;Streptococcus pneumoniae Danish serotype 12F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 12F IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +85975-1;Streptococcus pneumoniae Danish serotype 12F Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Units/volume] in Serum;S pneum Da 12F IgG Ser-aCnc;;ACTIVE;2.61;2.73 +85976-9;Streptococcus pneumoniae Danish serotype 12F Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 12F IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +8597-7;V wave amplitude;Pres;Pt;Vena cava;Qn;;BP.VENOUS.MOLEC;2;Vena cava V wave amplitude;VC V wave amp;;ACTIVE;1.0h(3);2.48 +85977-7;Streptococcus pneumoniae Danish serotype 12F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Mass/volume] in Serum;S pneum Da 12F IgG Ser-mCnc;;ACTIVE;2.61;2.73 +85978-5;Streptococcus pneumoniae Danish serotype 12F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 12F IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +85979-3;Streptococcus pneumoniae Danish serotype 12F Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 12F IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +85980-1;Streptococcus pneumoniae Danish serotype 12F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 12F IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +85981-9;Streptococcus pneumoniae Danish serotype 12F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 12F IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +85982-7;Streptococcus pneumoniae Danish serotype 12F Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 12F IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +85983-5;Streptococcus pneumoniae Danish serotype 12F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 12F IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 12F IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +85984-3;Streptococcus pneumoniae Danish serotype 12F Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Units/volume] in Serum --1st specimen;S pneum Da 12F Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.73 +8598-5;Comparison.study;TmStp;Pt;Heart;Qn;EKG;EKG.ATOM;2;Comparison study [Date and time] by EKG;Comparison study EKG;;ACTIVE;1.0h(3);2.27 +85985-0;Streptococcus pneumoniae Danish serotype 12F Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Mass/volume] in Serum --1st specimen;S pneum Da 12F Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +85986-8;Streptococcus pneumoniae Danish serotype 12F Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Units/volume] in Serum --2nd specimen;S pneum Da 12F Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +85987-6;Streptococcus pneumoniae Danish serotype 12F Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 12F Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +85988-4;Streptococcus pneumoniae Danish serotype 12F Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 12F Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 12F Ab 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +85989-2;Streptococcus pneumoniae Danish serotype 14 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Mass/volume] in Serum;S pneum Da 14 Ab Ser-mCnc;;ACTIVE;2.61;2.73 +859-9;A2 B Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated A2 B Ab;Deprecated A2 B Ab Ser Ql;;DEPRECATED;1.0;2.36 +85990-0;Streptococcus pneumoniae Danish serotype 14 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Units/volume] in Serum;S pneum Da 14 Ab Ser-aCnc;;ACTIVE;2.61;2.61 +85991-8;Streptococcus pneumoniae Danish serotype 14 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Mass/volume] in Serum;S pneum Da 14 IgG Ser-mCnc;;ACTIVE;2.61;2.73 +85992-6;Streptococcus pneumoniae Danish serotype 14 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 14 IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +8599-3;Comparison.study;Imp;Pt;Heart;Nom;EKG;EKG.ATOM;2;Comparison study [Interpretation] by EKG;Comparison study Imp EKG;;ACTIVE;1.0h(3);2.5 +85993-4;Streptococcus pneumoniae Danish serotype 14 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Units/volume] in Serum;S pneum Da 14 IgG Ser-aCnc;;ACTIVE;2.61;2.73 +85994-2;Streptococcus pneumoniae Danish serotype 14 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 14 IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +85995-9;Streptococcus pneumoniae Danish serotype 14 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 14 IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +85996-7;Streptococcus pneumoniae Danish serotype 14 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 14 IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +85997-5;Streptococcus pneumoniae Danish serotype 14 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 14 IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +85998-3;Streptococcus pneumoniae Danish serotype 14 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 14 IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +85999-1;Streptococcus pneumoniae Danish serotype 14 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 14 IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86000-7;Streptococcus pneumoniae Danish serotype 14 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 14 IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +86001-5;Streptococcus pneumoniae Danish serotype 14 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Mass/volume] in Serum --1st specimen;S pneum Da 14 Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86002-3;Streptococcus pneumoniae Danish serotype 14 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pneum Da 14 Ab sp1 Ser IA-aCnc;;ACTIVE;2.61;2.73 +86003-1;Streptococcus pneumoniae Danish serotype 14 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Units/volume] in Serum --1st specimen;S pneum Da 14 Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.73 +86004-9;Streptococcus pneumoniae Danish serotype 14 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 14 Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86005-6;Streptococcus pneumoniae Danish serotype 14 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 14 Ab sp2 Ser IA-aCnc;;ACTIVE;2.61;2.73 +86006-4;Streptococcus pneumoniae Danish serotype 14 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Units/volume] in Serum --2nd specimen;S pneum Da 14 Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +86007-2;Streptococcus pneumoniae Danish serotype 14 Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Ratio] in Serum by Immunoassay --2nd specimen/1st specimen;S pneum Da 14 Ab 2:1 Ser IA-Rto;;ACTIVE;2.61;2.61 +86008-0;Streptococcus pneumoniae Danish serotype 14 Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 14 Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 14 Ab 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +8600-9;Class;Type;Pt;EKG device;Nom;;DEVICES;2;Type of EKG device;EKG Device Class;;ACTIVE;1.0h(3);2.27 +86009-8;Streptococcus pneumoniae Danish serotype 17F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 17F IgG Ab [Mass/volume] in Serum;S pneum Da 17F IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86010-6;Streptococcus pneumoniae Danish serotype 17F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 17F IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 17F IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86011-4;Streptococcus pneumoniae Danish serotype 17F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 17F IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 17F IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86012-2;Streptococcus pneumoniae Danish serotype 17F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 17F IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 17F IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86013-0;Streptococcus pneumoniae Danish serotype 17F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 17F IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 17F IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86014-8;Streptococcus pneumoniae Danish serotype 17F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 17F IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 17F IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86015-5;Streptococcus pneumoniae Danish serotype 17F Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 17F IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 17F IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.61 +86016-3;Streptococcus pneumoniae Danish serotype 18F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18F IgG Ab [Mass/volume] in Serum;S pneum Da 18F IgG Ser-mCnc;;ACTIVE;2.61;2.73 +8601-7;EKG impression;Imp;Pt;Heart;Nom;EKG;EKG.ATOM;2;EKG impression;EKG impression;;ACTIVE;1.0h(3);2.73 +86017-1;Streptococcus pneumoniae Danish serotype 18F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 18F IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 18F IgG Ser IA-mCnc;;ACTIVE;2.61;2.61 +86018-9;Streptococcus pneumoniae Danish serotype 18F Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 18F Ab [Units/volume] in Serum --1st specimen;S pneum Da 18F Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86019-7;Streptococcus pneumoniae Danish serotype 19F Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Units/volume] in Serum;S pn Da sero 19F Ab Ser-aCnc;;ACTIVE;2.61;2.73 +86020-5;Streptococcus pneumoniae Danish serotype 19F Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Mass/volume] in Serum;S pn Da sero 19F Ab Ser-mCnc;;ACTIVE;2.61;2.73 +86021-3;Streptococcus pneumoniae Danish serotype 19F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Mass/volume] in Serum by Immunoassay;S pn Da sero 19F IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86022-1;Streptococcus pneumoniae Danish serotype 19F Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Units/volume] in Serum;S pn Da sero 19F IgG Ser-aCnc;;ACTIVE;2.61;2.63 +86023-9;Streptococcus pneumoniae Danish serotype 19F Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Units/volume] in Serum by Immunoassay;S pn Da sero 19F IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +86024-7;Streptococcus pneumoniae Danish serotype 19F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Mass/volume] in Serum;S pn Da sero 19F IgG Ser-mCnc;;ACTIVE;2.61;2.73 +8602-5;Vendor model number;Prid;Pt;Pacemaker;Nom;EKG;DEVICES;2;Pacemaker Vendor model number by EKG;Pacemaker Model # EKG;;ACTIVE;1.0h(3);2.72 +86025-4;Streptococcus pneumoniae Danish serotype 19F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Mass/volume] in Serum --1st specimen;S pn Da sero 19F IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.63 +86026-2;Streptococcus pneumoniae Danish serotype 19F Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Units/volume] in Serum --1st specimen;S pn Da sero 19F IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.63 +86027-0;Streptococcus pneumoniae Danish serotype 19F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pn Da sero 19F IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86028-8;Streptococcus pneumoniae Danish serotype 19F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Mass/volume] in Serum --2nd specimen;S pn Da sero 19F IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.63 +86029-6;Streptococcus pneumoniae Danish serotype 19F Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Units/volume] in Serum --2nd specimen;S pn Da sero 19F IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.63 +86030-4;Streptococcus pneumoniae Danish serotype 19F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pn Da sero 19F IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86031-2;Streptococcus pneumoniae Danish serotype 19F Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pn Da sero 19F IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +86032-0;Streptococcus pneumoniae Danish serotype 19F Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pn Da sero 19F Ab sp1 Ser IA-aCnc;;ACTIVE;2.61;2.63 +8603-3;Vendor serial number;ID;Pt;Pacemaker;Nom;EKG;DEVICES;2;Pacemaker Vendor serial number by EKG;Pacemaker Serial # EKG;;ACTIVE;1.0h(3);2.72 +86033-8;Streptococcus pneumoniae Danish serotype 19F Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Units/volume] in Serum --1st specimen;S pn Da sero 19F Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.63 +86034-6;Streptococcus pneumoniae Danish serotype 19F Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Mass/volume] in Serum --1st specimen;S pn Da sero 19F Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86035-3;Streptococcus pneumoniae Danish serotype 19F Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pn Da sero 19F Ab sp2 Ser IA-aCnc;;ACTIVE;2.61;2.63 +86036-1;Streptococcus pneumoniae Danish serotype 19F Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Units/volume] in Serum --2nd specimen;S pn Da sero 19F Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.73 +86037-9;Streptococcus pneumoniae Danish serotype 19F Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 19F Ab [Mass/volume] in Serum --2nd specimen;S pn Da sero 19F Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.63 +86038-7;Streptococcus pneumoniae Danish serotype 2 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 2 IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 2 IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86039-5;Streptococcus pneumoniae Danish serotype 2 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 2 IgG Ab [Mass/volume] in Serum;S pneum Da 2 IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86040-3;Streptococcus pneumoniae Danish serotype 2 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 2 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 2 IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.61 +8604-1;Class;Type;Pt;Pacemaker;Nom;EKG;DEVICES;2;Type of Pacemaker by EKG;Pacemaker Class EKG;;ACTIVE;1.0h(3);2.72 +86041-1;Streptococcus pneumoniae Danish serotype 2 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 2 IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 2 IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86042-9;Streptococcus pneumoniae Danish serotype 2 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 2 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 2 IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86043-7;Streptococcus pneumoniae Danish serotype 2 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 2 IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 2 IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86044-5;Streptococcus pneumoniae Danish serotype 2 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 2 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 2 IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.61 +86045-2;Streptococcus pneumoniae Danish serotype 20A Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 20A IgG Ab [Mass/volume] in Serum;S pneum Da 20A IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86046-0;Streptococcus pneumoniae Danish serotype 20A Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 20A IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 20A IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86047-8;Streptococcus pneumoniae Danish serotype 20A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 20A IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 20A IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86048-6;Streptococcus pneumoniae Danish serotype 20A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 20A IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 20A IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86049-4;Streptococcus pneumoniae Danish serotype 20A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 20A IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 20A IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86050-2;Streptococcus pneumoniae Danish serotype 20A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 20A IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 20A IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86051-0;Streptococcus pneumoniae Danish serotype 20A Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 20A IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 20A IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.61 +86052-8;Streptococcus pneumoniae Danish serotype 22F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 22F IgG Ab [Mass/volume] in Serum;S pneum Da 22F IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86053-6;Streptococcus pneumoniae Danish serotype 22F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 22F IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 22F IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86054-4;Streptococcus pneumoniae Danish serotype 22F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 22F IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 22F IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86055-1;Streptococcus pneumoniae Danish serotype 22F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 22F IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 22F IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86056-9;Streptococcus pneumoniae Danish serotype 22F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 22F IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 22F IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86057-7;Streptococcus pneumoniae Danish serotype 22F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 22F IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 22F IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.61 +8605-8;Class;Type;Pt;EKG leads;Nom;EKG;EKG.ATOM;2;Type of EKG leads;EKG Leads Class;;ACTIVE;1.0h(3);2.29 +86058-5;Streptococcus pneumoniae Danish serotype 22F Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 22F IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 22F IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.61 +86059-3;Streptococcus pneumoniae Danish serotype 23F Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Units/volume] in Serum;S pneum Da 23F Ab Ser-aCnc;;ACTIVE;2.61;2.73 +86060-1;Streptococcus pneumoniae Danish serotype 23F Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Mass/volume] in Serum;S pneum Da 23F Ab Ser-mCnc;;ACTIVE;2.61;2.73 +86061-9;Streptococcus pneumoniae Danish serotype 23F Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 23F IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86062-7;Streptococcus pneumoniae Danish serotype 23F Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Units/volume] in Serum;S pneum Da 23F IgG Ser-aCnc;;ACTIVE;2.61;2.61 +86063-5;Streptococcus pneumoniae Danish serotype 23F Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 23F IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +86064-3;Streptococcus pneumoniae Danish serotype 23F Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Mass/volume] in Serum;S pneum Da 23F IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86065-0;Streptococcus pneumoniae Danish serotype 23F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 23F IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +8606-6;Study duration;Time;Stdy;Heart;Qn;EKG;EKG.ATOM;2;Study duration by EKG;Study duration EKG;;ACTIVE;1.0h(3);2.27 +86066-8;Streptococcus pneumoniae Danish serotype 23F Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 23F IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86067-6;Streptococcus pneumoniae Danish serotype 23F Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 23F IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86068-4;Streptococcus pneumoniae Danish serotype 23F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 23F IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86069-2;Streptococcus pneumoniae Danish serotype 23F Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 23F IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +860-7;A2 B Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A2 B Ag [Presence] on Red Blood Cells from Blood product unit;A2 B Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +86070-0;Streptococcus pneumoniae Danish serotype 23F Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 23F IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86071-8;Streptococcus pneumoniae Danish serotype 23F Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 23F IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +86072-6;Streptococcus pneumoniae Danish serotype 23F Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pneum Da 23F Ab sp1 Ser IA-aCnc;;ACTIVE;2.61;2.61 +86073-4;Streptococcus pneumoniae Danish serotype 23F Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Units/volume] in Serum --1st specimen;S pneum Da 23F Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.73 +8607-4;Axis;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Axis [Interpretation] by EKG;Axis Imp EKG;;ACTIVE;1.0h(3);2.5 +86074-2;Streptococcus pneumoniae Danish serotype 23F Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Mass/volume] in Serum --1st specimen;S pneum Da 23F Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86075-9;Streptococcus pneumoniae Danish serotype 23F Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 23F Ab sp2 Ser IA-aCnc;;ACTIVE;2.61;2.61 +86076-7;Streptococcus pneumoniae Danish serotype 23F Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Units/volume] in Serum --2nd specimen;S pneum Da 23F Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.73 +86077-5;Streptococcus pneumoniae Danish serotype 23F Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 23F Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 23F Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.73 +86078-3;Streptococcus pneumoniae Danish serotype 3 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Mass/volume] in Serum;S pneum Da 3 Ab Ser-mCnc;;ACTIVE;2.61;2.73 +86079-1;Streptococcus pneumoniae Danish serotype 3 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Units/volume] in Serum;S pneum Da 3 Ab Ser-aCnc;;ACTIVE;2.61;2.73 +86080-9;Streptococcus pneumoniae Danish serotype 3 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Mass/volume] in Serum;S pneum Da 3 IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86081-7;Streptococcus pneumoniae Danish serotype 3 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 3 IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +8608-2;Conduction;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Conduction [Interpretation] by EKG;Conduction Imp EKG;;ACTIVE;1.0h(3);2.5 +86082-5;Streptococcus pneumoniae Danish serotype 3 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Units/volume] in Serum;S pneum Da 3 IgG Ser-aCnc;;ACTIVE;2.61;2.61 +86083-3;Streptococcus pneumoniae Danish serotype 3 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 3 IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +86084-1;Streptococcus pneumoniae Danish serotype 3 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 3 IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86085-8;Streptococcus pneumoniae Danish serotype 3 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 3 IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86086-6;Streptococcus pneumoniae Danish serotype 3 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 3 IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86087-4;Streptococcus pneumoniae Danish serotype 3 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 3 IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86088-2;Streptococcus pneumoniae Danish serotype 3 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 3 IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86089-0;Streptococcus pneumoniae Danish serotype 3 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 3 IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +8609-0;Hypertrophy;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Hypertrophy [Interpretation] by EKG;Hypertrophy Imp EKG;;ACTIVE;1.0h(3);2.5 +86090-8;Streptococcus pneumoniae Danish serotype 3 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 3 IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +86091-6;Streptococcus pneumoniae Danish serotype 3 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Mass/volume] in Serum --1st specimen;S pneum Da 3 Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86092-4;Streptococcus pneumoniae Danish serotype 3 Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pneum Da 3 Ab sp1 Ser IA-aCnc;;ACTIVE;2.61;2.61 +86093-2;Streptococcus pneumoniae Danish serotype 3 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Units/volume] in Serum --1st specimen;S pneum Da 3 Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.73 +86094-0;Streptococcus pneumoniae Danish serotype 3 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 3 Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86095-7;Streptococcus pneumoniae Danish serotype 3 Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 3 Ab sp2 Ser IA-aCnc;;ACTIVE;2.61;2.61 +86096-5;Streptococcus pneumoniae Danish serotype 3 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Units/volume] in Serum --2nd specimen;S pneum Da 3 Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +86097-3;Streptococcus pneumoniae Danish serotype 3 Ab^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 3 Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 3 Ab 2:1 Ser-Rto;;ACTIVE;2.61;2.61 +86098-1;Streptococcus pneumoniae Danish serotype 10A Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 10A IgG Ab [Mass/volume] in Serum;S pneum Da 10A IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86099-9;Streptococcus pneumoniae Danish serotype 10A Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 10A IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 10A IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86100-5;Streptococcus pneumoniae Danish serotype 10A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 10A IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 10A IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86101-3;Streptococcus pneumoniae Danish serotype 10A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 10A IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 10A IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86102-1;Streptococcus pneumoniae Danish serotype 10A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 10A IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 10A IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86103-9;Streptococcus pneumoniae Danish serotype 10A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 10A IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 10A IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86104-7;Streptococcus pneumoniae Danish serotype 10A Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 10A IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 10A IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.61 +86105-4;Streptococcus pneumoniae Danish serotype 4 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 Ab [Mass/volume] in Serum;S pneum Da 4 Ab Ser-mCnc;;ACTIVE;2.61;2.73 +86106-2;Streptococcus pneumoniae Danish serotype 4 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 Ab [Units/volume] in Serum;S pneum Da 4 Ab Ser-aCnc;;ACTIVE;2.61;2.73 +86107-0;Streptococcus pneumoniae Danish serotype 4 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Mass/volume] in Serum;S pneum Da 4 IgG Ser-mCnc;;ACTIVE;2.61;2.73 +8610-8;Myocardial ischemia;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Myocardial ischemia [Interpretation] by EKG;Myocard Ischemia Imp EKG;;ACTIVE;1.0h(3);2.5 +86108-8;Streptococcus pneumoniae Danish serotype 4 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 4 IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86109-6;Streptococcus pneumoniae Danish serotype 4 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Units/volume] in Serum;S pneum Da 4 IgG Ser-aCnc;;ACTIVE;2.61;2.73 +86110-4;Streptococcus pneumoniae Danish serotype 4 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 4 IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +86111-2;Streptococcus pneumoniae Danish serotype 4 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 4 IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86112-0;Streptococcus pneumoniae Danish serotype 4 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 4 IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86113-8;Streptococcus pneumoniae Danish serotype 4 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 4 IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86114-6;Streptococcus pneumoniae Danish serotype 4 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 4 IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86115-3;Streptococcus pneumoniae Danish serotype 4 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 4 IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +8611-6;Myocardial infarction age;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Myocardial infarction age by EKG;MI age EKG;;ACTIVE;1.0h(3);2.27 +86116-1;Streptococcus pneumoniae Danish serotype 4 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 4 IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +86117-9;Streptococcus pneumoniae Danish serotype 4 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 4 IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +86118-7;Streptococcus pneumoniae Danish serotype 4 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 Ab [Mass/volume] in Serum --1st specimen;S pneum Da 4 Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86119-5;Streptococcus pneumoniae Danish serotype 4 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 Ab [Units/volume] in Serum --1st specimen;S pneum Da 4 Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.73 +86120-3;Streptococcus pneumoniae Danish serotype 4 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 4 Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86121-1;Streptococcus pneumoniae Danish serotype 4 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 4 Ab [Units/volume] in Serum --2nd specimen;S pneum Da 4 Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.73 +86122-9;Streptococcus pneumoniae Danish serotype 11A Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 11A IgG Ab [Mass/volume] in Serum;S pneum Da 11A IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86123-7;Streptococcus pneumoniae Danish serotype 11A Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 11A IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 11A IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +8612-4;Study observation.overall;Find;Pt;Heart;Nom;EKG;EKG.IMP;2;EKG Study overall;EKG Study;;ACTIVE;1.0h(3);2.29 +86124-5;Streptococcus pneumoniae Danish serotype 11A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 11A IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 11A IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86125-2;Streptococcus pneumoniae Danish serotype 11A Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 11A IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 11A IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86126-0;Streptococcus pneumoniae Danish serotype 11A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 11A IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 11A IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86127-8;Streptococcus pneumoniae Danish serotype 11A Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 11A IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 11A IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86128-6;Streptococcus pneumoniae Danish serotype 11A Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 11A IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 11A IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.61 +86129-4;Streptococcus pneumoniae Danish serotype 5 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 5 IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 5 IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86130-2;Streptococcus pneumoniae Danish serotype 5 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 5 IgG Ab [Mass/volume] in Serum;S pneum Da 5 IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86131-0;Streptococcus pneumoniae Danish serotype 5 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 5 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 5 IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.61 +8613-2;Cardiac pacemaker prosthetic;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Prosthetic cardiac pacemaker [Interpretation] by EKG;Pmkr Imp EKG;;ACTIVE;1.0h(3);2.5 +86132-8;Streptococcus pneumoniae Danish serotype 5 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 5 IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 5 IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86133-6;Streptococcus pneumoniae Danish serotype 5 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 5 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 5 IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.61 +86134-4;Streptococcus pneumoniae Danish serotype 5 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 5 IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 5 IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86135-1;Streptococcus pneumoniae Danish serotype 5 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 5 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 5 IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +86136-9;Streptococcus pneumoniae Danish serotype 6A Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A IgG Ab [Mass/volume] in Serum;S pneum Da 6A IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86137-7;Streptococcus pneumoniae Danish serotype 6A Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A IgG Ab [Units/volume] in Serum;S pneum Da 6A IgG Ser-aCnc;;ACTIVE;2.61;2.61 +86138-5;Streptococcus pneumoniae Danish serotype 6A Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 6A IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 6A IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86139-3;Streptococcus pneumoniae Danish serotype 6A Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A Ab [Units/volume] in Serum --2nd specimen;S pneum Da 6A Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +8614-0;Pauses;NRat;Stdy;Heart;Qn;EKG;EKG.MEAS;2;Pauses;Pauses nRate;;ACTIVE;1.0h(3);2.27 +86140-1;Streptococcus pneumoniae Danish serotype 6A Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 6A Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86141-9;Streptococcus pneumoniae Danish serotype 7A Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 7A IgG Ab [Units/volume] in Serum;S pneum Da 7A IgG Ser-aCnc;;ACTIVE;2.61;2.73 +86142-7;Streptococcus pneumoniae Danish serotype 7A Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 7A IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 7A IgG Ser IA-aCnc;;ACTIVE;2.61;2.64 +86143-5;Streptococcus pneumoniae Danish serotype 8 Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Presence] in Serum;S pneum Da 8 Ab Ser Ql;;ACTIVE;2.61;2.61 +86144-3;Streptococcus pneumoniae Danish serotype 8 Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Presence] in Serum by Immunoassay;S pneum Da 8 Ab Ser Ql IA;;ACTIVE;2.61;2.61 +86145-0;Streptococcus pneumoniae Danish serotype 8 Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Units/volume] in Serum;S pneum Da 8 Ab Ser-aCnc;;ACTIVE;2.61;2.73 +86146-8;Streptococcus pneumoniae Danish serotype 8 Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Mass/volume] in Serum;S pneum Da 8 Ab Ser-mCnc;;ACTIVE;2.61;2.73 +86147-6;Streptococcus pneumoniae Danish serotype 8 Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Mass/volume] in Serum;S pneum Da 8 IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86148-4;Streptococcus pneumoniae Danish serotype 8 Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 8 IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86149-2;Streptococcus pneumoniae Danish serotype 8 Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Units/volume] in Serum;S pneum Da 8 IgG Ser-aCnc;;ACTIVE;2.61;2.61 +861-5;A2 B Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A2 B Ag [Presence] on Red Blood Cells from Donor;A2 B Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +86150-0;Streptococcus pneumoniae Danish serotype 8 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 8 IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +86151-8;Streptococcus pneumoniae Danish serotype 8 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 8 IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86152-6;Streptococcus pneumoniae Danish serotype 8 Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 8 IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86153-4;Streptococcus pneumoniae Danish serotype 8 Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 8 IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86154-2;Streptococcus pneumoniae Danish serotype 8 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 8 IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86155-9;Streptococcus pneumoniae Danish serotype 8 Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 8 IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86156-7;Streptococcus pneumoniae Danish serotype 8 Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 8 IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +8615-7;Premature atrial contractions;NRat;Stdy;Heart;Qn;EKG;EKG.MEAS;2;Premature atrial contractions;PACs nRate;;ACTIVE;1.0h(3);2.73 +86157-5;Streptococcus pneumoniae Danish serotype 8 Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 8 IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +86158-3;Streptococcus pneumoniae Danish serotype 8 Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Mass/volume] in Serum --1st specimen;S pneum Da 8 Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86159-1;Streptococcus pneumoniae Danish serotype 8 Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Units/volume] in Serum --1st specimen;S pneum Da 8 Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86160-9;Streptococcus pneumoniae Danish serotype 8 Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 8 Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86161-7;Streptococcus pneumoniae Danish serotype 8 Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 8 Ab [Units/volume] in Serum --2nd specimen;S pneum Da 8 Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +86162-5;Streptococcus pneumoniae Danish serotype 9N Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Presence] in Serum by Immunoassay;S pneum Da 9N Ab Ser Ql IA;;ACTIVE;2.61;2.61 +86163-3;Streptococcus pneumoniae Danish serotype 9N Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Units/volume] in Serum;S pneum Da 9N Ab Ser-aCnc;;ACTIVE;2.61;2.73 +86164-1;Streptococcus pneumoniae Danish serotype 9N Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Mass/volume] in Serum;S pneum Da 9N Ab Ser-mCnc;;ACTIVE;2.61;2.73 +8616-5;Premature ventricular contractions;NRat;Stdy;Heart;Qn;EKG;EKG.MEAS;2;Premature ventricular contractions;PVCs nRate;;ACTIVE;1.0h(3);2.54 +86165-8;Streptococcus pneumoniae Danish serotype 9N Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Presence] in Serum;S pneum Da 9N Ab Ser Ql;;ACTIVE;2.61;2.61 +86166-6;Streptococcus pneumoniae Danish serotype 9N Ab.IgG;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Mass/volume] in Serum by Immunoassay;S pneum Da 9N IgG Ser IA-mCnc;;ACTIVE;2.61;2.73 +86167-4;Streptococcus pneumoniae Danish serotype 9N Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Units/volume] in Serum;S pneum Da 9N IgG Ser-aCnc;;ACTIVE;2.61;2.61 +86168-2;Streptococcus pneumoniae Danish serotype 9N Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 9N IgG Ser IA-aCnc;;ACTIVE;2.61;2.73 +86169-0;Streptococcus pneumoniae Danish serotype 9N Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Mass/volume] in Serum;S pneum Da 9N IgG Ser-mCnc;;ACTIVE;2.61;2.73 +86170-8;Streptococcus pneumoniae Danish serotype 9N Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Mass/volume] in Serum --1st specimen;S pneum Da 9N IgG sp1 Ser-mCnc;;ACTIVE;2.61;2.61 +86171-6;Streptococcus pneumoniae Danish serotype 9N Ab.IgG^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Units/volume] in Serum --1st specimen;S pneum Da 9N IgG sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86172-4;Streptococcus pneumoniae Danish serotype 9N Ab.IgG^1st specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Mass/volume] in Serum by Immunoassay --1st specimen;S pneum Da 9N IgG sp1 Ser IA-mCnc;;ACTIVE;2.61;2.73 +8617-3;QRS complex;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;QRS complex [Interpretation] by EKG;QRS Complex Imp EKG;;ACTIVE;1.0h(3);2.5 +86173-2;Streptococcus pneumoniae Danish serotype 9N Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 9N IgG sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86174-0;Streptococcus pneumoniae Danish serotype 9N Ab.IgG^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Units/volume] in Serum --2nd specimen;S pneum Da 9N IgG sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +86175-7;Streptococcus pneumoniae Danish serotype 9N Ab.IgG^2nd specimen;MCnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Mass/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 9N IgG sp2 Ser IA-mCnc;;ACTIVE;2.61;2.73 +86176-5;Streptococcus pneumoniae Danish serotype 9N Ab.IgG^2nd specimen/1st specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N IgG Ab [Ratio] in Serum --2nd specimen/1st specimen;S pneum Da 9N IgG 2:1 Ser-Rto;;ACTIVE;2.61;2.73 +86177-3;Streptococcus pneumoniae Danish serotype 9N Ab^1st specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Units/volume] in Serum by Immunoassay --1st specimen;S pneum Da 9N Ab sp1 Ser IA-aCnc;;ACTIVE;2.61;2.61 +86178-1;Streptococcus pneumoniae Danish serotype 9N Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Units/volume] in Serum --1st specimen;S pneum Da 9N Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86179-9;Streptococcus pneumoniae Danish serotype 9N Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Mass/volume] in Serum --1st specimen;S pneum Da 9N Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86180-7;Streptococcus pneumoniae Danish serotype 9N Ab^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Ratio] in Serum --1st specimen/2nd specimen;S pneum Da 9N Ab 1:2 Ser-Rto;;ACTIVE;2.61;2.61 +8618-1;Recording duration;Time;Stdy;Heart;Qn;EKG;EKG.IMP;2;Recording duration by EKG;Recording dur EKG;;ACTIVE;1.0h(3);2.27 +86181-5;Streptococcus pneumoniae Danish serotype 9N Ab^1st specimen/2nd specimen;Ratio;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Ratio] in Serum by Immunoassay --1st specimen/2nd specimen;S pneum Da 9N Ab 1:2 Ser IA-Rto;;ACTIVE;2.61;2.61 +86182-3;Streptococcus pneumoniae Danish serotype 9N Ab^2nd specimen;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Units/volume] in Serum by Immunoassay --2nd specimen;S pneum Da 9N Ab sp2 Ser IA-aCnc;;ACTIVE;2.61;2.61 +86183-1;Streptococcus pneumoniae Danish serotype 9N Ab^2nd specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Units/volume] in Serum --2nd specimen;S pneum Da 9N Ab sp2 Ser-aCnc;;ACTIVE;2.61;2.61 +86184-9;Streptococcus pneumoniae Danish serotype 9N Ab^2nd specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 9N Ab [Mass/volume] in Serum --2nd specimen;S pneum Da 9N Ab sp2 Ser-mCnc;;ACTIVE;2.61;2.61 +86185-6;Prior functioning.ambulation;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Prior functioning.ambulation [CMS Assessment];;;ACTIVE;2.63;2.63 +86186-4;Prior functioning.transfer;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Prior functioning.transfer [CMS Assessment];;;ACTIVE;2.63;2.67 +86187-2;Prior functioning.household tasks;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Prior functioning.household tasks [CMS Assessment];;;ACTIVE;2.63;2.67 +86188-0;Occupation industry;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Occupation industry;Hx of Occupation industry;;ACTIVE;2.61;2.61 +86189-8;Outcome and assessment information set (OASIS) form - version C2 - Resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Outcome and assessment information set (OASIS) form - version C2 - Resumption of care [CMS Assessment];;;DEPRECATED;2.63;2.73 +86190-6;Zika virus RNA;PrThr;Pt;Plas^Donor;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Plasma from Donor by NAA with probe detection;ZIKV RNA Plas Donr Ql NAA+probe;;ACTIVE;2.61;2.63 +86191-4;Eutylone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Eutylone [Mass/volume] in Urine by Confirmatory method;Eutylone Ur Cfm-mCnc;;ACTIVE;2.61;2.61 +86192-2;4-Methylethcathinone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;4-Methylethcathinone [Mass/volume] in Urine by Confirmatory method;4-MEC Ur Cfm-mCnc;;ACTIVE;2.61;2.61 +86193-0;Pentedrone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pentedrone [Mass/volume] in Urine by Confirmatory method;Pentedrone Ur Cfm-mCnc;;ACTIVE;2.61;2.73 +86194-8;3,4-Dimethylmethcathinone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;3,4-Dimethylmethcathinone [Mass/volume] in Urine by Confirmatory method;3,4-DMMC Ur Cfm-mCnc;;ACTIVE;2.61;2.61 +86195-5;4-Ethylmethcathinone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;4-Ethylmethcathinone [Mass/volume] in Urine by Confirmatory method;4-EMC Ur Cfm-mCnc;;ACTIVE;2.61;2.61 +86196-3;Alpha pyrrolidinovalerophenone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha pyrrolidinovalerophenone [Mass/volume] in Urine by Confirmatory method;a-PVP Ur Cfm-mCnc;;ACTIVE;2.61;2.61 +86197-1;Pentylone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pentylone [Mass/volume] in Urine by Confirmatory method;Pentylone Ur Cfm-mCnc;;ACTIVE;2.61;2.61 +86198-9;Neisseria meningitidis serogroup Y synF gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup Y synF gene [Cycle Threshold #] in Specimen by NAA with probe detection;N men sg Y synF Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +8619-9;Rhythm segment;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Rhythm segment [Interpretation] by EKG;Rhythm Seg Imp EKG;;ACTIVE;1.0h(3);2.5 +86199-7;Rotavirus A Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Rotavirus A Ag [Presence] in Tissue by Immune stain;RVA Ag Tiss Ql ImStn;;ACTIVE;2.61;2.64 +86200-3;Porcine epidemic diarrhea virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Porcine epidemic diarrhea virus [Presence] in Specimen by Organism specific culture;PEDv Spec Ql Cult;;ACTIVE;2.61;2.69 +86201-1;Porcine epidemic diarrhea virus gene sequence & phylogenetic analysis;Find;Pt;XXX;Doc;;MICRO;1;Porcine epidemic diarrhea virus gene sequence and phylogenetic analysis in Specimen Document;PEDV seq + phylo XXX Doc Spec Doc;;ACTIVE;2.61;2.69 +86202-9;Porcine epidemic diarrhea virus;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Porcine epidemic diarrhea virus [Presence] in Tissue by Immune stain;PEDv Tiss Ql ImStn;;ACTIVE;2.61;2.63 +86203-7;Lawsonia intracellularis Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Lawsonia intracellularis Ag [Presence] in Tissue by Immune stain;L intracell Ag Tiss Ql ImStn;;ACTIVE;2.61;2.63 +86204-5;Porcine deltacoronavirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Porcine deltacoronavirus [Presence] in Specimen by Organism specific culture;PDCoV Spec Ql Cult;;ACTIVE;2.61;2.69 +86205-2;Whole exome sequence analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Whole exome sequence analysis in Blood or Tissue by Molecular genetics method;Whole exome seq analysis Bld/T;;ACTIVE;2.61;2.73 +86206-0;Whole genome sequence analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Whole genome sequence analysis in Blood or Tissue by Molecular genetics method;Whole genome seq analysis Bld/T;;ACTIVE;2.61;2.73 +8620-7;ST-T segment;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;ST-T segment [Interpretation] by EKG;ST-T seg Imp EKG;;ACTIVE;1.0h(3);2.73 +86207-8;Porcine epidemic diarrhea virus Ab.IgG;PrThr;Pt;Ser;Ord;IF;MICRO;1;Porcine epidemic diarrhea virus IgG Ab [Presence] in Serum by Immunofluorescence;PEDv IgG Ser Ql IF;;ACTIVE;2.61;2.61 +86208-6;Note;Find;Pt;Telehealth;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Telehealth Note;Cardiology Telehealth Note;;ACTIVE;2.61;2.61 +86209-4;Note;Find;Pt;{Setting};Doc;Community health care.case manager;DOC.ONTOLOGY;2;Community health care Case manager Note;CHC Case mgr Note;;ACTIVE;2.61;2.61 +86210-2;Medical clearance note;Find;Pt;{Setting};Doc;Physician;DOC.ONTOLOGY;2;Physician Medical clearance note;MD Med clearance note;;ACTIVE;2.61;2.61 +86211-0;Note;Find;Pt;{Setting};Doc;Addiction medicine.physician;DOC.ONTOLOGY;2;Addiction medicine Physician Note;Addiction med MD Note;;ACTIVE;2.61;2.63 +86212-8;Note;Find;Pt;{Setting};Doc;Addiction medicine.attending;DOC.ONTOLOGY;2;Addiction medicine Attending Note;Addiction med Attend Note;;ACTIVE;2.61;2.65 +86213-6;Medical clearance note;Find;Pt;{Setting};Doc;Vocational rehabilitation;DOC.ONTOLOGY;2;Vocational rehabilitation Medical clearance note;Vocational rehab Med clearance note;;ACTIVE;2.61;2.61 +86214-4;Annual evaluation note;Find;Pt;{Setting};Doc;Womens health;DOC.ONTOLOGY;2;Womens health Annual evaluation note;Wmns hlth Annual eval note;;ACTIVE;2.61;2.73 +8621-5;Ventricular ectopics;NRat;Stdy;Heart;Qn;EKG;EKG.MEAS;2;Ventricular ectopics;VEs nRate;;ACTIVE;1.0h(3);2.27 +86215-1;Disease staging note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Disease staging note;HemOnc Disease staging;;ACTIVE;2.61;2.61 +86216-9;Porcine epidemic diarrhea virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Porcine epidemic diarrhea virus neutralizing antibody [Titer] in Serum by Neutralization test;PEDv NAb Titr Ser Nt;;ACTIVE;2.61;2.61 +86217-7;Rotavirus A VP6 capsid protein;PrThr;Pt;XXX;Ord;IA;MICRO;1;Rotavirus A VP6 capsid protein [Presence] in Specimen by Immunoassay;RVA VP6 capsid protein Spec Ql IA;;ACTIVE;2.61;2.69 +86218-5;Transmissible gastroenteritis virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Transmissible gastroenteritis virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;TGEV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86219-3;Porcine epidemic diarrhea virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Porcine epidemic diarrhea virus IgG Ab [Titer] in Serum by Immunofluorescence;PEDv IgG Titr Ser IF;;ACTIVE;2.61;2.61 +86220-1;Bacterial carbapenem resistance blaOXA-48 gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;ABXBACT;1;Carbapenem resistance blaOXA-48 gene [Presence] in Specimen by NAA with probe detection;blaOXA-48 Spec Ql NAA+probe;;DISCOURAGED;2.61;2.69 +86221-9;Bacterial colistin resistance mcr-1 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Colistin resistance mcr-1 gene [Presence] by Molecular method;Colistin res mcr-1 Islt/Spm Ql;;ACTIVE;2.61;2.65 +86222-7;Lipoprotein.alpha 3;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.alpha 3 [Moles/volume] in Serum;HDL alpha 3 Ser-sCnc;;ACTIVE;2.61;2.73 +8622-3;Ventricular morphology;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Ventricular morphology [Interpretation] by EKG;Ventricular morph Imp EKG;;ACTIVE;1.0h(3);2.5 +86223-5;Acetyl norfentanyl;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Acetyl norfentanyl [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Acetyl norfentanyl SerPlBld Cfm-mCnc;;ACTIVE;2.61;2.73 +86224-3;ALPRAZolam/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ALPRAZolam/Creatinine [Mass Ratio] in Urine by Confirmatory method;Alpraz/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86225-0;clonazePAM/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;clonazePAM/Creatinine [Mass Ratio] in Urine by Confirmatory method;clonazePAM/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86226-8;Codeine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Codeine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Codeine SerPlBld Cfm-mCnc;;ACTIVE;2.61;2.73 +86227-6;Dihydrocodeine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Dihydrocodeine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;DHC SerPlBld Cfm-mCnc;;ACTIVE;2.61;2.73 +86228-4;Ethyl sulfate;PrThr;Pt;Saliva;Ord;;DRUG/TOX;1;Ethyl sulfate [Presence] in Saliva (oral fluid);Ethyl sulfate Sal Ql;;ACTIVE;2.61;2.61 +86229-2;HYDROcodone;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;HYDROcodone [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;HYDROcodone SerPlBld Cfm-mCnc;;ACTIVE;2.61;2.73 +862-3;A2 B Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A2 B Ag [Presence] on Red Blood Cells;A2 B Ag RBC Ql;;ACTIVE;1.0;2.56 +86230-0;HYDROmorphone;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;HYDROmorphone [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;HYDROmorphone SerPlBld Cfm-mCnc;;ACTIVE;2.61;2.73 +86231-8;Midazolam/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Midazolam/Creatinine [Mass Ratio] in Urine by Confirmatory method;Midazolam/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86232-6;Norsufentanil;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Norsufentanil [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Norsufentanil SerPlBld Cfm-mCnc;;ACTIVE;2.61;2.73 +86233-4;HIV 1 Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IB;MICRO;1;HIV 1 Ab [Presence] in Serum, Plasma or Blood by Immunoblot;HIV1 Ab SerPlBld Ql IB;;ACTIVE;2.61;2.61 +86234-2;Neisseria meningitidis serogroup A sacB gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup A sacB gene [Cycle Threshold #] in Specimen by NAA with probe detection;N men sg A sacB Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86235-9;Neisseria meningitidis serogroup B synD gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup B synD gene [Cycle Threshold #] in Specimen by NAA with probe detection;N men sg B synD Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86236-7;Neisseria meningitidis serogroup C synE gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup C synE gene [Cycle Threshold #] in Specimen by NAA with probe detection;N men sg C synE Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86237-5;Neisseria meningitidis serogroup w135 synG gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup w135 synG gene [Cycle Threshold #] in Specimen by NAA with probe detection;N men sg w135 synG Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86238-3;Neisseria meningitidis serogroup X xcbB gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Neisseria meningitidis serogroup X xcbB gene [Cycle Threshold #] in Specimen by NAA with probe detection;N men sg X xcbB Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86239-1;Cells.chromosome 3 monosomy/cells counted;NFr;Pt;Cancer specimen;Qn;FISH;MOLPATH.DELDUP;1;Cells.chromosome 3 monosomy/Cells counted in Cancer specimen by FISH;Cells.chr 3 mono/Cells NFr Ca spec FISH;;ACTIVE;2.61;2.61 +86240-9;Aquaporin 4 water channel Ab.IgG;Titr;Pt;CSF;Qn;Flow cytometry;SERO;1;Aquaporin 4 water channel IgG Ab [Titer] in Cerebral spinal fluid by Flow cytometry (FC);AQP4 H2O channel IgG Titr CSF FC;;ACTIVE;2.61;2.67 +86241-7;Aquaporin 4 water channel Ab.IgG;Titr;Pt;Ser/Plas;Qn;Flow cytometry;SERO;1;Aquaporin 4 water channel IgG Ab [Titer] in Serum or Plasma by Flow cytometry (FC);AQP4 H2O channel IgG Titr SerPl FC;;ACTIVE;2.61;2.67 +86242-5;Color;Type;Pt;Nasal fluid;Nom;;SPEC;1;Color of Nasal fluid;Color Nasal fluid;;ACTIVE;2.61;2.61 +86243-3;Color;Type;Pt;Sputum;Nom;;SPEC;1;Color of Sputum;Color Spt;;ACTIVE;2.61;2.73 +86244-1;Outcome and assessment information set (OASIS) form - version C2 - Follow-up - recertification or other follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Outcome and assessment information set (OASIS) form - version C2 - Follow-up - recertification or other follow-up [CMS Assessment];;;DEPRECATED;2.63;2.73 +86245-8;OASIS E - Administrative Information - FU;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Administrative Information - FU [CMS Assessment];;;ACTIVE;2.63;2.72 +86246-6;OASIS C2 - Patient history and diagnoses - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Patient history and diagnoses - follow-up [CMS Assessment];;;ACTIVE;2.63;2.63 +86247-4;Sensory status - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Sensory status - follow-up [CMS Assessment];;;ACTIVE;2.63;2.63 +86248-2;OASIS C2 - Integumentary status - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Integumentary status - follow-up [CMS Assessment];;;ACTIVE;2.63;2.63 +8624-9;PP interval;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;PP interval;PP Interv;;ACTIVE;1.0h(3);2.48 +86249-0;OASIS C2, D - Respiratory status - follow-up or discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2, D - Respiratory status - follow-up or discharge [CMS Assessment];;;ACTIVE;2.63;2.67 +86250-8;OASIS C2, D - Elimination status - follow-up;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2, D - Elimination status - follow-up [CMS Assessment];;;ACTIVE;2.63;2.67 +86251-6;OASIS C2, D - ADL and IADLs - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2, D - ADL and IADLs - follow-up [CMS Assessment];;;ACTIVE;2.63;2.64 +86252-4;OASIS C2, D - Medications - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2, D - Medications - follow-up [CMS Assessment];;;ACTIVE;2.63;2.67 +86253-2;Therapy need and plan of care - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Therapy need and plan of care - follow-up [CMS Assessment];;;ACTIVE;2.63;2.63 +86254-0;Underlying resolved condition.multiple coding ICD code;Prid;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Underlying resolved condition.multiple coding ICD code [CMS Assessment];;;ACTIVE;2.63;2.63 +86255-7;Primary diagnosis ICD code;Type;Pt;^Patient;Nom;;CLIN;2;Primary diagnosis ICD code;Primary Dx ICD code;;ACTIVE;2.63;2.73 +8625-6;PR interval;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P-R Interval;P-R interval;;ACTIVE;1.0h(3);2.73 +86256-5;Patient history and diagnoses - transfer or discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Patient history and diagnoses - transfer or discharge from agency [CMS Assessment];;;ACTIVE;2.63;2.67 +86257-3;Clinical record items - transfer or discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Clinical Record Items - transfer or discharge [CMS Assessment];;;ACTIVE;2.63;2.67 +86258-1;OASIS C2, D - Medications - transfer to inpatient facility;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2, D - Medications - transfer to inpatient facility [CMS Assessment];;;ACTIVE;2.63;2.67 +86259-9;Outcome and assessment information set (OASIS) form - version C2 - Transfer to inpatient facility - patient discharged or not discharged;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Outcome and assessment information set (OASIS) form - version C2 - Transfer To inpatient facility - patient discharged or not discharged [CMS Assessment];;;DEPRECATED;2.63;2.73 +86260-7;Data items collected at inpatient facility admission or agency discharge only - transfer;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Data items collected at inpatient facility admission or agency discharge only - transfer [CMS Assessment];;;ACTIVE;2.63;2.63 +86261-5;Outcome and assessment information set (OASIS) form - version C2 - Discharged from agency - death at home;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Outcome and assessment information set (OASIS) form - version C2 - Discharged from agency - death at home [CMS Assessment];;;DEPRECATED;2.63;2.73 +86262-3;OASIS E - Medications - TRN;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Medications - TRN [CMS Assessment];;;ACTIVE;2.63;2.72 +86263-1;Data items collected at inpatient facility admission or agency discharge only - discharge from agency - death at home;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Data items collected at inpatient facility admission or agency discharge only - discharge from agency - death at home [CMS Assessment];;;ACTIVE;2.63;2.63 +8626-4;P wave axis;Angle;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave axis;P wave axis;;ACTIVE;1.0h(3);2.73 +86264-9;Outcome and assessment information set (OASIS) form - version C2 - Discharged from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Outcome and assessment information set (OASIS) form - version C2 - Discharged from agency [CMS Assessment];;;DEPRECATED;2.63;2.73 +86265-6;OASIS C2 - Medications - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Medications - discharge from agency [CMS Assessment];;;ACTIVE;2.63;2.63 +86266-4;Sensory status - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Sensory status - discharge from agency [CMS Assessment];;;ACTIVE;2.63;2.63 +86267-2;OASIS C2 - Integumentary status - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Integumentary status - discharge from agency [CMS Assessment];;;ACTIVE;2.63;2.63 +86268-0;Worsening in pressure injury status since start or resumption of home care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Worsening in pressure injury status since start or resumption of home care [CMS Assessment];;;ACTIVE;2.63;2.63 +86269-8;OASIS C2 - Elimination status - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS C2 - Elimination status - discharge from agency [CMS Assessment];;;ACTIVE;2.63;2.63 +86270-6;Current number of unhealed pressure injuries at each stage - follow-up or discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Current number of unhealed pressure injuries at each stage - follow-up or discharge [CMS Assessment];;;ACTIVE;2.63;2.64 +86271-4;Transferrin.gastrointestinal;MCnc;Pt;Stool;Qn;IA;CHEM;1;Transferrin.gastrointestinal [Mass/volume] in Stool by Immunoassay;Transferrin.gastrointestinal Stl IA-mCnc;;ACTIVE;2.61;2.61 +8627-2;P wave duration;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration;P wave dur;;ACTIVE;1.0h(3);2.73 +86272-2;Retinal nerve fiber layer.nasal inferior thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.nasal inferior thickness by OCT;L ret RNFL nasal inf thickness OCT;;ACTIVE;2.61;2.68 +86273-0;Retinal nerve fiber layer.temporal thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.temporal thickness by OCT;R ret RNFL temp thickness OCT;;ACTIVE;2.61;2.68 +86274-8;Retinal nerve fiber layer.temporal superior thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.temporal superior thickness by OCT;R ret RNFL temp sup thickness OCT;;ACTIVE;2.61;2.68 +86275-5;Retinal nerve fiber layer.temporal superior thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.temporal superior thickness by OCT;L ret RNFL temp sup thickness OCT;;ACTIVE;2.61;2.68 +86276-3;Retinal nerve fiber layer.superior thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.superior thickness by OCT;R ret RNFL sup thickness OCT;;ACTIVE;2.61;2.68 +86277-1;Retinal nerve fiber layer.superior thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.superior thickness by OCT;L ret RNFL sup thickness OCT;;ACTIVE;2.61;2.68 +86278-9;Retinal nerve fiber layer.temporal thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.temporal thickness by OCT;L ret RNFL temp thickness OCT;;ACTIVE;2.61;2.68 +86279-7;Retinal nerve fiber layer.nasal thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.nasal thickness by OCT;L ret RNFL nasal thickness OCT;;ACTIVE;2.61;2.68 +8628-0;Pacing interval;Time;Pt;Pacemaker;Qn;EKG;EKG.MEAS;2;Pacing interval Pacemaker;Pacing Interv Pacemaker;;ACTIVE;1.0h(3);2.72 +86280-5;Retinal nerve fiber layer.nasal superior thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.nasal superior thickness by OCT;R ret RNFL nasal sup thickness OCT;;ACTIVE;2.61;2.68 +86281-3;Retinal nerve fiber layer.nasal superior thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.nasal superior thickness by OCT;L ret RNFL nasal sup thickness OCT;;ACTIVE;2.61;2.68 +86282-1;Retinal nerve fiber layer.nasal inferior thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.nasal inferior thickness by OCT;R ret RNFL nasal inf thickness OCT;;ACTIVE;2.61;2.68 +86283-9;Retinal nerve fiber layer.inferior thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.inferior thickness by OCT;R ret RNFL inf thickness OCT;;ACTIVE;2.61;2.68 +86284-7;Retinal nerve fiber layer.nasal thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.nasal thickness by OCT;R ret RNFL nasal thickness OCT;;ACTIVE;2.61;2.68 +86285-4;Erythrocyte deformability;Imp;Pt;RBC;Nar;;HEM/BC;1;Erythrocyte deformability [Interpretation] in Red Blood Cells Narrative;Erythrocyte deformability RBC-Imp;;ACTIVE;2.61;2.61 +86286-2;Retinal nerve fiber layer.clock hour 9 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 9 thickness by OCT;L ret RNFL 9 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86287-0;Retinal nerve fiber layer.inferior temporal thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.inferior temporal thickness by OCT;R ret RNFL inf temp thickness OCT;;ACTIVE;2.61;2.68 +86288-8;Retinal nerve fiber layer.inferior thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.inferior thickness by OCT;L ret RNFL inf thickness OCT;;ACTIVE;2.61;2.68 +86289-6;Retinal nerve fiber layer.inferior temporal thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.inferior temporal thickness by OCT;L ret RNFL inf temp thickness OCT;;ACTIVE;2.61;2.68 +86290-4;Retinal nerve fiber layer.mean thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.mean thickness by OCT;L ret RNFL mean thickness OCT;;ACTIVE;2.61;2.68 +86291-2;Retinal nerve fiber layer panel;-;Pt;Retina;-;OCT;PANEL.EYE;2;Retina Retinal nerve fiber layer panel by OCT;Retina RNFL Pnl OCT;;ACTIVE;2.61;2.68 +86292-0;Retinal nerve fiber layer.clock hour 12 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 12 thickness by OCT;L ret RNFL 12 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86293-8;Retinal nerve fiber layer.clock hour 1 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 1 thickness by OCT;L ret RNFL 1 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86294-6;Retinal nerve fiber layer.clock hour 2 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 2 thickness by OCT;L ret RNFL 2 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86295-3;Retinal nerve fiber layer.clock hour 3 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 3 thickness by OCT;L ret RNFL 3 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86296-1;Retinal nerve fiber layer.clock hour 4 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 4 thickness by OCT;L ret RNFL 4 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86297-9;Retinal nerve fiber layer.clock hour 5 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 5 thickness by OCT;L ret RNFL 5 o'clock thickness OCT;;ACTIVE;2.61;2.68 +8629-8;Q wave depth;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth;Q wave Dpth;;ACTIVE;1.0h(3);2.48 +86298-7;Retinal nerve fiber layer.clock hour 6 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 6 thickness by OCT;L ret RNFL 6 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86299-5;Retinal nerve fiber layer.clock hour 7 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 7 thickness by OCT;L ret RNFL 7 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86300-1;Retinal nerve fiber layer.clock hour 8 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 8 thickness by OCT;L ret RNFL 8 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86301-9;Retinal nerve fiber layer.mean thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.mean thickness by OCT;R ret RNFL mean thickness OCT;;ACTIVE;2.61;2.68 +86302-7;Retinal nerve fiber layer.clock hour 10 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 10 thickness by OCT;L ret RNFL 10 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86303-5;Retinal nerve fiber layer.clock hour 11 thickness;Len;Pt;Retina.left;Qn;OCT;EYE.OCT;2;Left retina Retinal nerve fiber layer.clock hour 11 thickness by OCT;L ret RNFL 11 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86304-3;Retinal nerve fiber layer.clock hour 12 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 12 thickness by OCT;R ret RNFL 12 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86305-0;Retinal nerve fiber layer.clock hour 1 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 1 thickness by OCT;R ret RNFL 1 o'clock thickness OCT;;ACTIVE;2.61;2.68 +8630-6;Q wave depth.lead;Prid;Pt;Heart;Nom;EKG;EKG.MEAS;2;Q wave depth lead;Q wave Dpth Lead;;ACTIVE;1.0h(3);2.27 +86306-8;Retinal nerve fiber layer.clock hour 2 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 2 thickness by OCT;R ret RNFL 2 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86307-6;Retinal nerve fiber layer.clock hour 3 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 3 thickness by OCT;R ret RNFL 3 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86308-4;Retinal nerve fiber layer.clock hour 4 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 4 thickness by OCT;R ret RNFL 4 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86309-2;Retinal nerve fiber layer.clock hour 5 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 5 thickness by OCT;R ret RNFL 5 o'clock thickness OCT;;ACTIVE;2.61;2.68 +863-1;A3 Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated A3 Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated A3 Ab SerPl BPU Ql;;DEPRECATED;1.0;2.4 +86310-0;Retinal nerve fiber layer.clock hour 6 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 6 thickness by OCT;R ret RNFL 6 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86311-8;Retinal nerve fiber layer.clock hour 7 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 7 thickness by OCT;R ret RNFL 7 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86312-6;Retinal nerve fiber layer.clock hour 8 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 8 thickness by OCT;R ret RNFL 8 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86313-4;Retinal nerve fiber layer.clock hour 9 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 9 thickness by OCT;R ret RNFL 9 o'clock thickness OCT;;ACTIVE;2.61;2.68 +8631-4;Q wave duration;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration;Q wave dur;;ACTIVE;1.0h(3);2.48 +86314-2;Retinal nerve fiber layer.clock hour 10 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 10 thickness by OCT;R ret RNFL 10 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86315-9;Retinal nerve fiber layer.clock hour 11 thickness;Len;Pt;Retina.right;Qn;OCT;EYE.OCT;2;Right retina Retinal nerve fiber layer.clock hour 11 thickness by OCT;R ret RNFL 11 o'clock thickness OCT;;ACTIVE;2.61;2.68 +86316-7;Human RNase P RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Human RNase P RNA [Cycle Threshold #] in Specimen by NAA with probe detection;Human RNase P RNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86317-5;Influenza virus A H1 2009 pandemic RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUAV H1 2009 pand RNA Ct Spec Qn NAA+pr;;ACTIVE;2.61;2.69 +86318-3;Influenza Virus B Yamagata lineage Ag;PrThr;Pt;Isolate;Ord;HAI;MICRO;1;Influenza virus B Yamagata lineage Ag [Presence] in Isolate by Hemagglutination inhibition;FLUBV Yam Ag Islt Ql HAI;;ACTIVE;2.61;2.61 +86319-1;Staphylococcus aureus;PrThr;Pt;Food;Ord;Culture;MICRO;1;Staphylococcus aureus [Presence] in Food by Culture;S aureus Food Ql Cult;;ACTIVE;2.61;2.61 +86320-9;Zika virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Zika virus neutralizing antibody [Presence] in Specimen by Neutralization test;ZIKV NAb Spec Ql Nt;;ACTIVE;2.61;2.69 +86321-7;Zika virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Zika virus neutralizing antibody [Titer] in Specimen by Neutralization test;ZIKV NAb Titr Spec Nt;;ACTIVE;2.61;2.69 +8632-2;QRS axis;Angle;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS axis;QRS axis;;ACTIVE;1.0h(3);2.73 +86322-5;Enterovirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Enterovirus [Presence] in Specimen by Organism specific culture;EV Spec Ql Cult;;ACTIVE;2.61;2.69 +86323-3;Enterovirus Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Enterovirus Ag [Presence] in Specimen by Immunofluorescence;EV Ag Spec Ql IF;;ACTIVE;2.61;2.69 +86324-1;Coliform bacteria;NCnt;Pt;Food;Qn;Viability count;MICRO;1;Coliform bacteria [#/mass] in Food by Viability count;Coliform in Food Viab Cnt;;ACTIVE;2.61;2.66 +86325-8;Bordetella pertussis+parapertussis ptxS1 gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bordetella pertussis+parapertussis ptxS1 gene [Cycle Threshold #] in Specimen by NAA with probe detection;B pert+parap ptxS1 Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86326-6;Bordetella holmesii hIS1001 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bordetella holmesii hIS1001 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;B holm hIS1001 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86327-4;Bordetella parapertussis IS1001 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bordetella parapertussis IS1001 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;B parap IS1001 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86328-2;Adenovirus 21 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus B(21) DNA [Presence] in Specimen by NAA with probe detection;AdV B(21) DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86329-0;Adenovirus 16 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus B(16) DNA [Presence] in Specimen by NAA with probe detection;AdV B(16) DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +8633-0;QRS duration;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration;QRS dur;;ACTIVE;1.0h(3);2.73 +86330-8;Adenovirus 11 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus B(11) DNA [Presence] in Specimen by NAA with probe detection;AdV B(11) DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86331-6;Adenovirus 14 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus B(14) DNA [Presence] in Specimen by NAA with probe detection;AdV B(14) DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86332-4;Adenovirus 7 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus B(7) DNA [Presence] in Specimen by NAA with probe detection;AdV B(7) DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86333-2;Adenovirus 4 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus E(4) DNA [Presence] in Specimen by NAA with probe detection;AdV E(4) DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86334-0;Adenovirus 3 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus B(3) DNA [Presence] in Specimen by NAA with probe detection;AdV B(3) DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86335-7;Total interval score change;ScoreDiff;Pt;^Patient;Qn;HOOSJR;SURVEY.GNHLTH;4;Total interval score change [HOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +86336-5;Total interval score change;ScoreDiff;Pt;^Patient;Qn;KOOSJR;SURVEY.GNHLTH;4;Total interval score change [KOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +86337-3;Virus identified;Prid;Pt;Isolate;Nom;Shell vial culture;MICRO;1;Virus identified in Isolate by Shell vial culture;Virus Islt Shell Vial Cult;;ACTIVE;2.61;2.61 +86338-1;Streptococcus pneumoniae Danish serotype 6A+6B Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A+6B Ab [Units/volume] in Serum;S pneum Da 6A+6B Ab Ser-aCnc;;ACTIVE;2.61;2.61 +86339-9;Streptococcus pneumoniae Danish serotype 6A+6B IgG Ab;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A+6B IgG Ab [Units/volume] in Serum;S pneum Da 6A+6B IgG Ab Ser-aCnc;;ACTIVE;2.61;2.61 +86340-7;Streptococcus pneumoniae Danish serotype 6A+6B IgG Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 6A+6B IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 6A+6B IgG Ab Ser IA-aCnc;;ACTIVE;2.61;2.73 +86341-5;Streptococcus pneumoniae Danish serotype 6A+6B Ab^1st specimen;ACnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A+6B Ab [Units/volume] in Serum --1st specimen;S pneum Da 6A+6B Ab sp1 Ser-aCnc;;ACTIVE;2.61;2.61 +86342-3;Streptococcus pneumoniae Danish serotype 6A+6B Ab;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A+6B Ab [Mass/volume] in Serum;S pneum Da 6A+6B Ab Ser-mCnc;;ACTIVE;2.61;2.61 +86343-1;Streptococcus pneumoniae Danish serotype 6A+6B Ab^1st specimen;MCnc;Pt;Ser;Qn;;MICRO;1;Streptococcus pneumoniae Danish serotype 6A+6B Ab [Mass/volume] in Serum --1st specimen;S pneum Da 6A+6B Ab sp1 Ser-mCnc;;ACTIVE;2.61;2.73 +86345-6;U.S. standard certificate of death - recommended 2003 revision set;-;Pt;{Setting};-;;PANEL.DOC;2;U.S. standard certificate of death - recommended 2003 revision set;U.S. Death cert 2003 set;;ACTIVE;2.61;2.61 +86346-4;U.S. standard report of fetal death - recommended 2003 revision set;-;Pt;{Setting};-;;PANEL.DOC;2;U.S. standard report of fetal death - recommended 2003 revision set;U.S. FDR 2003 set;;ACTIVE;2.61;2.61 +86347-2;U.S. standard certificate of live birth - recommended 2003 revision set;-;Pt;{Setting};-;;PANEL.DOC;2;U.S. standard certificate of live birth - recommended 2003 revision set;U.S. Birth cert 2003 set;;ACTIVE;2.61;2.61 +8634-8;QT interval;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q-T interval;Q-T interval;;ACTIVE;1.0h(3);2.73 +86348-0;Guidance for needle localization && Views;Find;Pt;Breast.left && ^Breast specimen.left;Doc;MG;RAD;2;MG Breast - left Guidance for needle localization and Breast specimen Views;MG Brst-L Needle loc + Brst spec View;;ACTIVE;2.61;2.61 +86349-8;Diagnostic mammogram & ultrasound panel;Find;Pt;Breast.left;Doc;;PANEL.RAD;2;Diagnostic mammogram and ultrasound panel Breast - left Document;Diagnostic MG + US pnl Brst-L Doc;;ACTIVE;2.61;2.73 +86350-6;View for clip placement;Find;Pt;Breast.unilateral;Doc;MG;RAD;2;MG Breast - unilateral Single view for clip placement;MG Brst-Ul 1V for clip place;;ACTIVE;2.61;2.64 +86351-4;Guidance additional for aspiration of cyst;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for additional aspiration of cyst of Breast - left;MG Guided Brst-L Cyst asp addl;;ACTIVE;2.61;2.64 +86352-2;Guidance additional for aspiration of cyst;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for additional aspiration of cyst of Breast - right;MG Guided Brst-R Cyst asp addl;;ACTIVE;2.61;2.64 +86353-0;Guidance for placement of clip;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for placement of clip in Breast - left;MG Guided Brst-L Clip place;;ACTIVE;2.61;2.64 +86354-8;Guidance for placement of clip;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for placement of clip in Breast - right;MG Guided Brst-R Clip place;;ACTIVE;2.61;2.64 +86355-5;Guidance additional for needle localization;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for additional needle localization of Breast - left;MG Guided Brst-L Needle loc addl;;ACTIVE;2.61;2.64 +86356-3;Guidance additional for needle localization;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for additional needle localization of Breast - right;MG Guided Brst-R Needle loc addl;;ACTIVE;2.61;2.64 +86357-1;Guidance for needle localization;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for needle localization of Breast - left;MG Guided Brst-L Needle loc;;ACTIVE;2.61;2.64 +86358-9;Guidance for needle localization;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for needle localization of Breast - right;MG Guided Brst-R Needle loc;;ACTIVE;2.61;2.73 +86359-7;Diagnostic mammogram & ultrasound panel;Find;Pt;Breast.right;Doc;;PANEL.RAD;2;Diagnostic mammogram and ultrasound panel Breast - right Document;Diagnostic MG + US pnl Brst-R Doc;;ACTIVE;2.61;2.73 +86360-5;Guidance for needle localization && Views;Find;Pt;Breast.right && ^Breast specimen.right;Doc;MG;RAD;2;MG Breast - right Guidance for needle localization and Breast specimen Views;MG Brst-R Needle loc + Brst spec View;;ACTIVE;2.61;2.61 +86361-3;Guidance additional for biopsy;Find;Pt;Breast.left;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for additional biopsy of Breast - left;MG.stereo Guided Brst-L Bx addl;;ACTIVE;2.61;2.64 +86362-1;Guidance additional for biopsy;Find;Pt;Breast.right;Doc;MG.stereotactic;RAD;2;MG stereo Guidance for additional biopsy of Breast - right;MG.stereo Guided Brst-R Bx addl;;ACTIVE;2.61;2.64 +8636-3;QTC interval;Time;Pt;Heart;Qn;;EKG.MEAS;2;Q-T interval corrected;Q-T interval corrected;;ACTIVE;1.0h(3);2.73 +86363-9;Guidance additional for biopsy.vacuum;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for additional vacuum biopsy of Breast - left;MG Guided Brst-L Vac Bx addl;;ACTIVE;2.61;2.64 +86364-7;Guidance additional for biopsy.vacuum;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for additional vacuum biopsy of Breast - right;MG Guided Brst-R Vac Bx addl;;ACTIVE;2.61;2.64 +86365-4;Guidance for biopsy.vacuum;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Guidance for vacuum biopsy of Breast - left;MG Guided Brst-L Vac Bx;;ACTIVE;2.61;2.64 +86366-2;Guidance for biopsy.vacuum;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Guidance for vacuum biopsy of Breast - right;MG Guided Brst-R Vac Bx;;ACTIVE;2.61;2.64 +86367-0;Views diagnostic for clinical call back;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Diagnostic for clinical call back;MG Brst Dx for clin call back;;ACTIVE;2.61;2.61 +86368-8;Views diagnostic for clinical call back;Find;Pt;Breast.left;Doc;MG;RAD;2;MG Breast - left Diagnostic for clinical call back;MG Brst-L Dx for clin call back;;ACTIVE;2.61;2.61 +86369-6;Views diagnostic for clinical call back;Find;Pt;Breast.right;Doc;MG;RAD;2;MG Breast - right Diagnostic for clinical call back;MG Brst-R Dx for clin call back;;ACTIVE;2.61;2.61 +86370-4;Views diagnostic for technical call back;Find;Pt;Breast;Doc;MG;RAD;2;MG Breast Diagnostic for technical call back;MG Brst Dx for tech call back;;ACTIVE;2.61;2.61 +8637-1;RR interval;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R-R interval by EKG;R-R interval;;ACTIVE;1.0h(3);2.73 +86371-2;Interpretation of outside study;Find;Pt;Study;Ord;;RAD;2;Study Interpretation of outside study;Study Interp of outside study;;ACTIVE;2.61;2.61 +86372-0;Views^W contrast IV;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney and Ureter and Urinary bladder Views W contrast IV;RF Kid+Uret+Blad Views W contr IV;;ACTIVE;2.61;2.64 +86373-8;Views^W contrast via additional puncture;Find;Pt;XXX>AV fistula;Doc;RF;RAD;2;RF AV fistula Views W contrast via additional puncture;RF AVF Views W contr via addl punc;;ACTIVE;2.61;2.71 +86374-6;Views^W contrast intra lymphatic;Find;Pt;Lower extremity.bilateral>Pedal lymphatic vessels;Doc;RF.angio;RAD;2;RFA Pedal lymphatic vessels - bilateral Views W contrast intra lymphatic;RFA Ped lymph ves-Bl Views W contr IL;;ACTIVE;2.61;2.64 +86375-3;Views^W contrast intra lymphatic;Find;Pt;Lower extremity.unilateral>Pedal lymphatic vessels;Doc;RF.angio;RAD;2;RFA Pedal lymphatic vessels - unilateral Views W contrast intra lymphatic;RFA Ped lymph ves-Ul Views W contr IL;;ACTIVE;2.61;2.64 +86376-1;Views^W contrast via existing catheter;Find;Pt;Abdomen>Biliary ducts;Doc;RF;RAD;2;RF Biliary ducts Views W contrast via existing catheter;RF BDs Views W contr via exist cath;;ACTIVE;2.61;2.71 +86377-9;Guidance for advancement of feeding tube;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;RF;RAD;2;RF Guidance for advancement of feeding tube of Gastrointestinal tract;RF Guided GI tract Adv feed tube;;ACTIVE;2.61;2.64 +86378-7;Views for fistula;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;RF;RAD;2;RF Gastrointestinal tract Views for fistula;RF GI tract Views for fistula;;ACTIVE;2.61;2.64 +86379-5;Views for loop diversion;Find;Pt;Abdomen>Small bowel;Doc;RF;RAD;2;RF Small bowel Views for loop diversion;RF SB Views for loop diversion;;ACTIVE;2.61;2.71 +86380-3;Views for fistula;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney and Ureter and Urinary bladder Views for fistula;RF Kid+Uret+Blad Views for fistula;;ACTIVE;2.61;2.64 +86381-1;Views screening^W air contrast PR+W barium contrast PR;Find;Pt;Abdomen+Pelvis>Colon;Doc;RF;RAD;2;RF Colon Screening W air and barium contrast PR;RF Colon screening W Air+Ba PR;;ACTIVE;2.61;2.61 +86382-9;Views limited^during surgery;Find;Pt;Abdomen>Biliary ducts;Doc;RF;RAD;2;RF Biliary ducts Limited Views during surgery;RF BDs Views Ltd in Surg;;ACTIVE;2.61;2.64 +86383-7;Views^W contrast IV;Find;Pt;Abdomen>Biliary ducts;Doc;RF;RAD;2;RF Biliary ducts Views W contrast IV;RF BDs Views W contr IV;;ACTIVE;2.61;2.64 +86384-5;Views^post fatty meal+W contrast PO;Find;Pt;Abdomen>Gallbladder;Doc;RF;RAD;2;RF Gallbladder Views W contrast and fatty meal PO;RF GB Views W contr+Fatty Meal PO;;ACTIVE;2.61;2.64 +86385-2;Views^W contrast PO;Find;Pt;Abdomen>Gallbladder;Doc;RF;RAD;2;RF Gallbladder Views W contrast PO;RF GB Views W contr PO;;ACTIVE;2.61;2.64 +86386-0;Views^W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Gastrointestinal tract upper Views W barium contrast PO;RF UGI Views W Ba PO;;ACTIVE;2.61;2.64 +86387-8;Views^W contrast antegrade;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney and Ureter and Urinary bladder Views W contrast antegrade;RF Kid+Uret+Blad Views W contr Ante;;ACTIVE;2.61;2.71 +86388-6;Views^W contrast retrograde;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney and Ureter and Urinary bladder Views W contrast retrograde;RF Kid+Uret+Blad Views W contr Retro;;ACTIVE;2.61;2.71 +8638-9;T wave axis;Angle;Pt;Heart;Qn;EKG;EKG.MEAS;2;T wave axis;T wave axis;;ACTIVE;1.0h(3);2.73 +86389-4;Views^during surgery W contrast retrograde;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney and Ureter and Urinary bladder Views during surgery W contrast retrograde;RF Kid+Uret+Blad Vs in Surg W contr Retr;;ACTIVE;2.61;2.71 +86390-2;Views^W contrast via nephrostomy tube;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney and Ureter and Urinary bladder Views W contrast via nephrostomy tube;RF Kid+Uret+Blad Views W contr via NT;;ACTIVE;2.61;2.71 +86391-0;Views^W contrast via existing catheter;Find;Pt;XXX>AV fistula;Doc;RF;RAD;2;RF AV fistula Views W contrast via existing catheter;RF AVF Views W contr via exist cath;;ACTIVE;2.61;2.71 +86392-8;Views limited^W contrast IV;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney and Ureter and Urinary bladder Limited Views W contrast IV;RF Kid+Uret+Blad Views Ltd W contr IV;;ACTIVE;2.61;2.64 +86393-6;Views^W contrast retrograde;Find;Pt;Abdomen>Kidney.bilateral & Abdomen+Pelvis>Ureter.bilateral & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Kidney - bilateral and Ureter - bilateral and Urinary bladder Views W contrast retrograde;RF Kid-Bl+Uret-Bl+Blad Vs W contr Retr;;ACTIVE;2.61;2.71 +86394-4;Views^W contrast IA;Find;Pt;Chest>Aorta.thoracic;Doc;RF.angio;RAD;2;RFA Thoracic Aorta Views W contrast IA;RFA TA Views W contr IA;;ACTIVE;2.61;2.64 +86395-1;Views for swallowing function^W speech+W barium contrast PO;Find;Pt;Neck>Hypopharynx & Chest>Esophagus;Doc;RF.video;RAD;2;RF videography Hypopharynx and Esophagus Views for swallowing function W speech and W barium contrast PO;RF vid Hypoph+Eso swallow fn W Speech+Ba;;ACTIVE;2.61;2.71 +86396-9;Views^W contrast IV;Find;Pt;Extremity.unilateral>Extremity veins;Doc;RF.angio;RAD;2;RFA Extremity veins - unilateral Views W contrast IV;RFA Extr vv-Ul Views W contr IV;;ACTIVE;2.61;2.64 +8639-7;Pupillary distance.binocular;Len;Pt;Eye;Qn;;EYE;2;Eye Pupillary distance.binocular;Eye PD binoc;;ACTIVE;1.0h(3);2.68 +86397-7;Guidance for drainage+placement of suprapubic catheter;Find;Pt;Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Guidance for drainage and placement of suprapubic catheter of Urinary bladder;RF Guided Bladder Drain+SP cath place;;ACTIVE;2.61;2.67 +86398-5;Views^W contrast IT;Find;Pt;Head+Neck>Cerebral cisterns;Doc;RF;RAD;2;RF Cerebral cisterns Views W contrast IT;RF Cerebral cist Views W contr IT;;ACTIVE;2.61;2.64 +86399-3;Views & Guidance for injection of non-vascular shunt;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for Views and Guidance for injection of non-vascular shunt of Unspecified body region;RF Views+Guided Non-vasc shunt inject;;ACTIVE;2.61;2.71 +86400-9;Guidance for placement of needle;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for placement of needle in Unspecified body region;RF Guided Needle place;;ACTIVE;2.61;2.64 +86401-7;Views^W contrast intra bladder;Find;Pt;Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Urinary bladder Views W contrast intra bladder;RF Bladder Views W contr IUB;;ACTIVE;2.61;2.64 +86402-5;Views limited^W contrast IS;Find;Pt;Upper extremity>Shoulder;Doc;RF;RAD;2;RF Shoulder Arthrogram limited;RF Should Views Ltd W contr IS;;ACTIVE;2.61;2.65 +86403-3;Guidance for placement of catheter;Find;Pt;Pelvis>Fallopian tube;Doc;RF;RAD;2;RF Guidance for placement of catheter in Fallopian tube;RF Guided Fallopian tube Cath place;;ACTIVE;2.61;2.64 +86404-1;Guidance for percutaneous aspiration of fluid;Find;Pt;Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Guidance for fluid aspiration of Urinary bladder;RF Guided Bladder PC fluid asp;;ACTIVE;2.61;2.64 +8640-5;Diameter;Len;Pt;Pupil.left;Qn;Auto;EYE;2;Left pupil Diameter Auto;L pupil Diam Auto;;ACTIVE;1.0h(3);2.68 +86405-8;Guidance for exchange of tube;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance for exchange of tube of Unspecified body region;RF Guided Tube exch;;ACTIVE;2.61;2.64 +86406-6;Views^during surgery;Find;Lt 1H;XXX;Doc;RF;RAD;2;RF Unspecified body region Less than 1 hour Views during surgery;RF <1h Views in Surg;;ACTIVE;2.61;2.64 +86407-4;Guidance;Find;Pt;XXX;Doc;RF;RAD;2;RF Guidance of Unspecified body region;RF Guided Guide;;ACTIVE;2.61;2.71 +86408-2;Views for urinary pouch;Find;Pt;Pelvis;Doc;RF;RAD;2;RF Pelvis Views for urinary pouch;RF Pelvis Views for urinary pouch;;ACTIVE;2.61;2.71 +86409-0;Views for rectal dysfunction^W barium contrast PR;Find;Pt;Pelvis>Rectum;Doc;RF;RAD;2;RF Rectum Views for rectal dysfunction W barium contrast PR;RF Rectum Views for rect dysf W Ba PR;;ACTIVE;2.61;2.71 +86410-8;Views^W barium contrast PO;Find;Pt;Neck>Pharynx+Esophagus.cervical;Doc;RF;RAD;2;RF Pharynx and Cervical esophagus Views W barium contrast PO;RF Pharynx+Cerv esophagus Views W Ba PO;;ACTIVE;2.61;2.64 +86411-6;Views^W contrast IT;Find;Pt;Head>Posterior fossa.bilateral;Doc;RF;RAD;2;RF Posterior fossa - bilateral Views W contrast IT;RF Post fossa-Bl Views W contr IT;;ACTIVE;2.61;2.64 +86412-4;Views^W contrast intra lymphatic;Find;Pt;Lower extremity>Pedal lymphatic vessels;Doc;RF.angio;RAD;2;RFA Pedal lymphatic vessels Views W contrast intra lymphatic;RFA Ped lymph ves Views W contr IL;;ACTIVE;2.61;2.64 +8641-3;Pupil diameter;Len;Pt;Eye.left;Qn;Manual;EYE;2;Left eye Pupil diameter Manual;L eye Pupil diam Manual;;ACTIVE;1.0h(3);2.68 +86413-2;Guidance for placement of long feeding tube;Find;Pt;Abdomen+Pelvis>Gastrointestinal tract;Doc;RF;RAD;2;RF Guidance for placement of long feeding tube in Gastrointestinal tract;RF Guided GI tract Long feed tube place;;ACTIVE;2.61;2.64 +86414-0;Views^W contrast IA;Find;Pt;Abdomen>Renal arteries.unilateral;Doc;RF.angio;RAD;2;RFA Renal arteries - unilateral Views W contrast IA;RFA Renal aa-Ul Views W contr IA;;ACTIVE;2.61;2.64 +86415-7;Views^W contrast IV;Find;Pt;Abdomen>Renal vein.unilateral;Doc;RF.angio;RAD;2;RFA Renal vein - unilateral Views W contrast IV;RFA Renal v-Ul Views W contr IV;;ACTIVE;2.61;2.64 +86416-5;Guidance for needle localization && Views;Find;Pt;Breast.bilateral && ^Breast specimen.bilateral;Doc;MG;RAD;2;MG Breast - bilateral Guidance for needle localization and Breast specimen Views;MG Brst-Bl Needle loc + Brst spec View;;ACTIVE;2.61;2.61 +86417-3;Views^W contrast IA;Find;Pt;Head>Cerebral arteries.bilateral;Doc;RF.angio;RAD;2;RFA Cerebral arteries Bilateral Views W contrast IA;RFA Cerebral aa-Bl Views W contr IA;;ACTIVE;2.61;2.64 +86418-1;Views^W contrast IA;Find;Pt;Chest>Pulmonary arteries.unilateral;Doc;RF.angio;RAD;2;RFA Pulmonary arteries - unilateral Views W contrast IA;RFA Pulm aa-Ul Views W contr IA;;ACTIVE;2.61;2.64 +86419-9;Views^W contrast IA;Find;Pt;Abdomen>Visceral arteries;Doc;RF.angio;RAD;2;RFA Visceral arteries Views W contrast IA;RFA Visc aa Views W contr IA;;ACTIVE;2.61;2.64 +86420-7;Views^W air contrast PO+W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Gastrointestinal tract upper Views W air contrast PO and W barium contrast PO;RF UGI Views W air PO+W Ba PO;;ACTIVE;2.61;2.64 +8642-1;Diameter;Len;Pt;Pupil.right;Qn;Auto;EYE;2;Right pupil Diameter Auto;R pupil Diam Auto;;ACTIVE;1.0h(3);2.68 +86421-5;View && Views^W air contrast PO+W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;XR Abdomen and RF Gastrointestinal tract upper W air contrast PO and W barium contrast PO;AXR and Flr UGI W air PO+W Ba PO;;ACTIVE;2.61;2.61 +86422-3;View && Views^W water soluble contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;XR Abdomen and RF Gastrointestinal tract upper W water soluble contrast PO;AXR and Flr UGI W H2O soluble contr PO;;ACTIVE;2.61;2.61 +86423-1;View && Views^W contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;XR Abdomen and RF Gastrointestinal tract upper W contrast PO;AXR and Flr UGI W contr PO;;ACTIVE;2.61;2.61 +86424-9;View && Views^W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR && RF;RAD;2;XR Abdomen and RF Gastrointestinal tract upper W barium contrast PO;AXR and Flr UGI W Ba PO;;ACTIVE;2.61;2.61 +86425-6;Guidance for manometry;Find;Pt;Abdomen>Kidney;Doc;RF;RAD;2;RF Guidance for manometry of Kidney;RF Guided Kidney Manometry;;ACTIVE;2.61;2.71 +86426-4;Views^W contrast IV;Find;Pt;Head+Neck>Internal jugular vein.unilateral;Doc;RF.angio;RAD;2;RFA Jugular vein - unilateral Views W contrast IV;RFA Jugular v-Ul Views W contr IV;;ACTIVE;2.61;2.64 +86427-2;Views^W air contrast PO+W barium contrast PO;Find;Pt;Abdomen>Gastrointestinal tract.upper+Small bowel;Doc;RF;RAD;2;RF Upper gastrointestinal tract and Small bowel Views W air contrast PO and W barium contrast PO;RF UGI+SB Views W air PO+W Ba PO;;ACTIVE;2.61;2.64 +86428-0;Views^W contrast IA;Find;Pt;Extremity.unilateral>Extremity arteries;Doc;RF.angio;RAD;2;RFA Extremity arteries - unilateral Views W contrast IA;RFA Extr aa-Ul Views W contr IA;;ACTIVE;2.61;2.64 +86429-8;Views^W contrast IA;Find;Pt;Head>Cerebral arteries.unilateral;Doc;RF.angio;RAD;2;RFA Cerebral arteries - unilateral Views W contrast IA;RFA Cerebral aa-Ul Views W contr IA;;ACTIVE;2.61;2.64 +86430-6;Views^W contrast IT;Find;Pt;Head>Posterior fossa.unilateral;Doc;RF;RAD;2;RF Posterior fossa - unilateral Views W contrast IT;RF Post fossa-Ul Views W contr IT;;ACTIVE;2.61;2.64 +86431-4;Views^W contrast IA;Find;Pt;Head>Cerebral arteries.bilateral & Neck>Cervical arteries.bilateral;Doc;RF.angio;RAD;2;RFA Cerebral arteries - bilateral and Cervical arteries - bilateral Views W contrast IA;RFA Cereb aa-Bl+Cerv aa-Bl Vs W contr IA;;ACTIVE;2.61;2.64 +86432-2;Views^W contrast IA;Find;Pt;Head>Cerebral arteries.unilateral & Neck>Cervical arteries.unilateral;Doc;RF.angio;RAD;2;RFA Cerebral arteries - unilateral and Cervical arteries - unilateral Views W contrast IA;RFA Cereb aa-Ul+Cerv aa-Ul Vs W contr IA;;ACTIVE;2.61;2.64 +86433-0;Views^W contrast IA;Find;Pt;Abdomen>Spine.lumbar intercostal arteries;Doc;RF.angio;RAD;2;RFA Lumbar spine intercostal arteries Views W contrast IA;RFA L-spine intercost aa Vs W contr IA;;ACTIVE;2.61;2.64 +86434-8;Views^W contrast IA;Find;Pt;Head+Neck>Carotid arteries.unilateral;Doc;RF.angio;RAD;2;RFA Carotid arteries - unilateral Views W contrast IA;RFA Carotid aa-Ul Views W contr IA;;ACTIVE;2.61;2.64 +86435-5;Views^W contrast IV;Find;Pt;Head+Neck>Internal jugular vein.bilateral;Doc;RF.angio;RAD;2;RFA Jugular vein - bilateral Views W contrast IV;RFA Jugular v-Bl Views W contr IV;;ACTIVE;2.61;2.64 +86436-3;Guidance for treatment^W contrast intra fistula;Find;Pt;XXX>Fistula;Doc;RF;RAD;2;RF Guidance for treatment of Fistula-- W contrast intra fistula;RF Guided Fistula Tx W contr int fist;;ACTIVE;2.61;2.71 +86437-1;Views diagnostic^W contrast intra fistula;Find;Pt;XXX>Fistula;Doc;RF;RAD;2;RF Fistula Diagnostic W contrast intra fistula;RF Fistula Dx W contr intra fist;;ACTIVE;2.61;2.71 +86438-9;Guidance for check of feeding tube;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;RF;RAD;2;RF Guidance for check of feeding tube of Gastrointestinal tract upper;RF Guided UGI Feed tube check;;ACTIVE;2.61;2.71 +8643-9;Pupil diameter;Len;Pt;Eye.right;Qn;Manual;EYE;2;Right eye Pupil diameter Manual;R eye Pupil diam Manual;;ACTIVE;1.0h(3);2.68 +86439-7;Views^W contrast IV;Find;Pt;Head>Cerebral sinuses;Doc;RF;RAD;2;RF Cerebral sinuses Views W contrast IV;RF Cerebral sinuses Views W contr IV;;ACTIVE;2.61;2.64 +86440-5;Views^W contrast intra seminal vesicle;Find;Pt;Pelvis>Seminal vesicle;Doc;RF;RAD;2;RF Seminal vesicle Views W contrast intra seminal vesicle;RF Sem vesicle Vs W contr intra sem ves;;ACTIVE;2.61;2.71 +86441-3;Guidance for manometry;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;RF;RAD;2;RF Guidance for manometry of Kidney and Ureter and Urinary bladder;RF Guided Kid+Uret+Blad Manometry;;ACTIVE;2.61;2.71 +86442-1;Views^W contrast IA;Find;Pt;Head+Neck>Vertebral artery.unilateral;Doc;RF.angio;RAD;2;RFA Vertebral artery - unilateral Views W contrast IA;RFA Vertebral a-Ul Views W contr IA;;ACTIVE;2.61;2.64 +86443-9;Views^W contrast intra ureter;Find;Pt;Abdomen+Pelvis>Ureter;Doc;RF;RAD;2;RF Ureter Views W contrast intra ureter;RF Ureter Views W contr intra ureter;;ACTIVE;2.61;2.64 +86444-7;Manufacturing establishment information;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Manufacturing establishment information;FDA label Manufacturing estab infor;;ACTIVE;2.61;2.61 +86445-4;Blanket no changes certification of product listing;-;-;^FDA package insert;Nar;;DOCUMENT.REGULATORY;2;FDA package insert Blanket no changes certification of product listing;FDA insert Blnkt no chngs cert prod list;;ACTIVE;2.61;2.61 +86446-2;Blood establishment registration & product listing change in information;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Blood establishment registration and product listing change in information;FDA label Bld est reg + prd lst chg info;;ACTIVE;2.61;2.61 +8644-7;Visual acuity log mar;Cmplx;Pt;Eye.left;Qn;;EYE;2;Deprecated Visual acuity log MAR.right: Cmplx: Pt: Eye.left: Qn:;DeprecatedVisual acuity log mar;;DEPRECATED;1.0h(3);2.36 +86447-0;Human cell and tissue establishment registration & product listing change in information;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Human cell and tissue establishment registration and product listing change in information;FDA label Cell Tiss Est Reg info change;;ACTIVE;2.61;2.61 +86448-8;Human salvaged drug;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Human salvaged drug;FDA label Human salvaged drug;;ACTIVE;2.61;2.61 +86449-6;Against medical advice note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Against medical advice note;Against med advice note;;ACTIVE;2.61;2.61 +86450-4;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Preoperative evaluation and management note;Radiology Pre-op note;;ACTIVE;2.61;2.61 +86451-2;Consultation note;Find;Pt;{Setting};Doc;Ethics;DOC.ONTOLOGY;2;Ethics Consult note;Ethics Consult note;;ACTIVE;2.61;2.61 +86452-0;Note;Find;Pt;{Setting};Doc;Ethics;DOC.ONTOLOGY;2;Ethics Note;Ethics Note;;ACTIVE;2.61;2.61 +86453-8;O-nortramadol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;O-nortramadol [Presence] in Urine;O-nortramadol Ur Ql;;ACTIVE;2.61;2.73 +8645-4;Visual acuity log mar;Cmplx;Pt;Eye.right;Qn;;EYE;2;Deprecated Visual acuity log MAR.right: Cmplx: Pt: Eye.right: Qn:;DeprecatedVisual acuity log mar;;DEPRECATED;1.0h(3);2.36 +86454-6;N-nortramadol;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;N-nortramadol [Presence] in Urine;N-nortramadol Ur Ql;;ACTIVE;2.61;2.73 +86455-3;Brucella sp Ab;PrThr;Pt;Ser;Ord;Aggl.plate.buffered acidified;MICRO;1;Brucella sp Ab [Presence] in Serum by Acidified buffered plate agglutination;Brucella Ab Ser Ql Buff plate aggl;;ACTIVE;2.61;2.61 +86456-1;Brucella sp Ab;PrThr;Pt;Ser;Ord;Aggl.card;MICRO;1;Brucella sp Ab [Presence] in Serum by Card agglutination;Brucella Ab Ser Ql Card aggl;;ACTIVE;2.61;2.61 +86457-9;Brucella sp Ab;PrThr;Pt;Ser;Ord;Fluorescent polarization assay;MICRO;1;Brucella sp Ab [Presence] in Serum by Fluorescent polarization assay;Brucella Ab Ser Ql FPA;;ACTIVE;2.61;2.61 +86458-7;Brucella sp Ab;Titr;Pt;Ser;Qn;Aggl.rivanol;MICRO;1;Brucella sp Ab [Titer] in Serum by Rivanol agglutination;Brucella Ab Titr Ser Rivanol aggl;;ACTIVE;2.61;2.61 +86459-5;Brucella sp Ab;Titr;Pt;Ser;Qn;Aggl.plate;MICRO;1;Brucella sp Ab [Titer] in Serum by Plate agglutination;Brucella Ab Titr Ser Plate aggl;;ACTIVE;2.61;2.61 +86460-3;Views;Find;Pt;XXX>Spine vessel;Doc;RF.angio;RAD;2;RFA Spine vessel Views;RFA Spine ves Views;;ACTIVE;2.61;2.64 +86461-1;Views;Find;Pt;Abdomen>Adrenal vessel;Doc;RF.angio;RAD;2;RFA Adrenal vessel Views;RFA Adrenal ves Views;;ACTIVE;2.61;2.64 +8646-2;Hospital admission Dx;Imp;Pt;^Patient;Nom;;H&P.HX;2;Hospital admission diagnosis;Hospital admission Dx;;ACTIVE;1.0h(3);2.27 +86462-9;Multisection;Find;Pt;Breast.unilateral;Doc;MG.tomosynthesis;RAD;2;DBT Breast - unilateral;DBT Brst-Ul;;ACTIVE;2.61;2.61 +86463-7;Multisection;Find;Pt;Breast.bilateral;Doc;MG.tomosynthesis;RAD;2;DBT Breast - bilateral;DBT Brst-Bl;;ACTIVE;2.61;2.61 +86464-5;Guidance for repair of aneurysm or dissection;Find;Pt;Abdomen>Aorta.abdominal.infrarenal;Doc;RF.angio;RAD;2;RFA Guidance for repair of aneurysm or dissection of Infrarenal aorta;RFA Guided Infrarenal AA or dissect rep;;ACTIVE;2.61;2.64 +86465-2;AST to platelet ratio index;Ratio;Pt;Ser+Bld;Qn;Calculated;CHEM;1;AST to platelet ratio index in Serum and Blood by calculation;APRI Ser+Bld Calc-Rto;;ACTIVE;2.61;2.73 +86466-0;Maestro of scalable information infrastructure;Hx;Pt;^Patient;Nar;BH;H&P.HX;2;Maestro of scalable information infrastructure;Maestro scalable info infrastructure;;ACTIVE;2.61;2.66 +86467-8;Report comment;Find;Pt;^Patient;Nar;;CLIN;2;Report comment Narrative;Rpt comment;;ACTIVE;2.61;2.73 +86468-6;Report comment section;Find;Pt;^Patient;Doc;;CLIN;2;Report comment section;Rpt comment section;;ACTIVE;2.61;2.61 +86469-4;Conditions prior to medical or treatment regimen change or inpatient stay that took place within past 14D;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Conditions prior to medical or treatment regimen change or inpatient stay that took place within past 14 days [CMS Assessment];;;ACTIVE;2.63;2.63 +8647-0;Hospital consultations;Type;Pt;^Patient;Nom;;H&P.HX;2;Hospital consultations;Hospital consultations;;ACTIVE;1.0h(3);2.29 +86470-2;Most recent inpatient discharge date in the last 14D;Date;14D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Most recent inpatient discharge date in the last 14 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86471-0;Ostomy for bowel elimination in the last 14D;Find;14D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Ostomy for bowel elimination in the last 14 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86472-8;Shortness of breath limited your ability to do what you wanted over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Shortness of breath limited your ability to do what you wanted over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86473-6;Dressing yourself was limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Dressing yourself was limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86474-4;Walking 1 block on level ground was limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Walking 1 block on level ground was limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86475-1;Doing yardwork, housework or carrying groceries was limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Doing yardwork, housework or carrying groceries was limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86476-9;Climbing a flight of stairs without stopping was limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Climbing a flight of stairs without stopping was limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86477-7;Hurrying or jogging (as if to catch a bus) was limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Hurrying or jogging (as if to catch a bus) was limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86478-5;Change in symptoms of heart failure compared with 2W ago;Find;Pt;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Change in symptoms of heart failure compared with 2 weeks ago [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86479-3;Swelling in your feet, ankles or legs when you woke up over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Swelling in your feet, ankles or legs when you woke up over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86480-1;Bothered by swelling in your feet, ankles or legs over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Bothered by swelling in your feet, ankles or legs over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86481-9;Fatigue limited your ability to do what you wanted over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Fatigue limited your ability to do what you wanted over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86482-7;Bothered by fatigue over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Bothered by fatigue over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86483-5;Showering or bathing was limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Showering or bathing was limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86484-3;Bothered by shortness of breath over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Bothered by shortness of breath over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86485-0;Sleep sitting up in a chair or with at least 3 pillows to prop you up because of shortness of breath over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Sleep sitting up in a chair or with at least 3 pillows to prop you up because of shortness of breath over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86486-8;You know what to do, or whom to call, if your heart failure gets worse;Find;Pt;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;You know what to do, or whom to call, if your heart failure gets worse [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86487-6;Understand what things you are able to do to keep your heart failure symptoms from getting worse;Find;Pt;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Understand what things you are able to do to keep your heart failure symptoms from getting worse [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +8648-8;Hospital course;Find;Pt;^Patient;Nar;;H&P.HX;2;Hospital course Narrative;Hospital course;;ACTIVE;1.0h(3);2.63 +86488-4;Enjoyment of life limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Enjoyment of life limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86489-2;How would you feel if you had to spend the rest of your life with your heart failure the way it is right now;Find;Pt;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;How would you feel if you had to spend the rest of your life with your heart failure the way it is right now [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +864-9;A3 Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated A3 Ab [Presence] on Red Blood Cells from donor;Deprecated A3 Ab SerPl Donr Ql;;DEPRECATED;1.0;2.4 +86490-0;Felt discouraged or down in the dumps because of heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Felt discouraged or down in the dumps because of heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.61 +86491-8;Participation in hobbies, recreational activities limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Participation in hobbies, recreational activities limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86492-6;Participation in working or doing household chores limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Participation in working or doing household chores limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86493-4;Participation in visiting family or friends out of your home limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Participation in visiting family or friends out of your home limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86494-2;Participation in intimate relationships with loved ones limited by heart failure over the past 2W;Find;2W;^Patient;Ord;KCCQ;SURVEY.GNHLTH;4;Participation in intimate relationships with loved ones limited by heart failure over the past 2 weeks [KCCQ];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.61;2.63 +86495-9;When anxious within the last 14D;Find;14D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;When anxious within the last 14 days [CMS Assessment];;;ACTIVE;2.63;2.63 +8649-6;Hospital discharge date;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Hospital discharge date;Hospital discharge date;;ACTIVE;1.0h(3);2.27 +86502-2;Varicella zoster virus strain DNA;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Varicella zoster virus strain DNA [Type] in Specimen by NAA with probe detection;VZV strain DNA Spec NAA+probe;;ACTIVE;2.61;2.69 +86503-0;Streptococcus pneumoniae serotype DNA;ID;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Deprecated Streptococcus pneumoniae serotype DNA [Identifier] in Unspecified specimen by NAA with probe detection;Deprecated S pneum serotype DNA XXX NAA+probe;;DEPRECATED;2.61;2.72 +8650-4;Hospital discharge disposition;Type;Pt;^Patient;Nar;;H&P.HX;2;Hospital discharge disposition Narrative;Hosp discharge dispo;;ACTIVE;1.0h(3);2.52 +86504-8;These questions three panel;-;Pt;^Patient;-;;PANEL.MISC;1;These questions three panel;3 questions Pnl Patient;;ACTIVE;2.63;2.63 +86505-5;Quest;Find;Pt;^Patient;Nom;;SURVEY.MISC;4;Quest;;;ACTIVE;2.63;2.63 +86506-3;Color.favorite;Type;Pt;^Patient;Nom;;SURVEY.MISC;4;Favorite color;;;ACTIVE;2.63;2.63 +86507-1;Capital of Assyria;Loc;Pt;^Patient;Nom;;SURVEY.MISC;4;Capital of Assyria;;;ACTIVE;2.63;2.63 +86508-9;Airspeed^unladen;Vel;Pt;^Patient;Qn;;SURVEY.MISC;4;Airspeed--unladen;;;ACTIVE;2.63;2.63 +86509-7;Varicella zoster virus clade;Type;Pt;XXX;Nom;Molgen;MICRO;1;Varicella zoster virus clade [Type] in Specimen by Molecular genetics method;VZV clade Spec;;ACTIVE;2.61;2.69 +86510-5;Adenovirus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Tissue by NAA with probe detection;HAdV DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86511-3;Adenovirus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Blood by NAA with probe detection;HAdV DNA Bld Ql NAA+probe;;ACTIVE;2.61;2.73 +8651-2;Hospital discharge Dx;Imp;Pt;^Patient;Nom;;H&P.HX;2;Hospital discharge Dx;Hospital discharge Dx;;ACTIVE;1.0h(3);2.27 +86512-1;Adenovirus DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Urine by NAA with probe detection;HAdV DNA Ur Ql NAA+probe;;ACTIVE;2.61;2.63 +86513-9;Adenovirus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Adenovirus IgM Ab [Presence] in Serum by Immunoassay;HAdV IgM Ser Ql IA;;ACTIVE;2.61;2.61 +86514-7;Chikungunya virus RNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus RNA [Presence] in Amniotic fluid by NAA with probe detection;CHIKV RNA Amn Ql NAA+probe;;ACTIVE;2.61;2.63 +86515-4;Chikungunya virus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Chikungunya virus RNA [Presence] in Urine by NAA with probe detection;CHIKV RNA Ur Ql NAA+probe;;ACTIVE;2.61;2.63 +86516-2;Coxsackievirus A Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A Ab [Titer] in Serum by Complement fixation;CV A Ab Titr Ser CF;;ACTIVE;2.61;2.61 +86517-0;Cytomegalovirus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Cytomegalovirus Ag [Presence] in Tissue by Immunofluorescence;CMV Ag Tiss Ql IF;;ACTIVE;2.61;2.61 +86518-8;Ebola virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Ebola virus RNA [Presence] in Blood by NAA with probe detection;EBOV RNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +86519-6;European tick borne encephalitis virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;European tick borne encephalitis virus RNA [Presence] in Serum by NAA with probe detection;TBEV RNA Ser Ql NAA+probe;;ACTIVE;2.61;2.63 +8652-0;Hospital discharge history;Find;Pt;^Patient;Nom;;H&P.HX;2;Hospital discharge history;Hospital discharge Hx;;ACTIVE;1.0h(3);2.27 +86520-4;Hantavirus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Hantavirus RNA [Presence] in Blood by NAA with probe detection;Hantavirus RNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +86521-2;Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.14.1;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Minimum Data Set (MDS) - version 3.0 - Resident Assessment and Care Screening (RAI) version 1.14.1 [CMS Assessment];;;DEPRECATED;2.63;2.73 +86522-0;MDS v3.0 - RAI v1.14.1 - Nursing home comprehensive (NC) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home comprehensive (NC) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86523-8;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information [CMS Assessment];;;ACTIVE;2.63;2.64 +86524-6;Type of assessment;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Type of assessment [CMS Assessment];;;ACTIVE;2.63;2.63 +86525-3;SNF Part A PPS discharge assessment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;SNF Part A PPS discharge assessment [CMS Assessment];;;ACTIVE;2.63;2.63 +86526-1;Unit certification or licensure designation;Type;Pt;Facility;Nom;CMS Assessment;SURVEY.CMS;4;Unit certification or licensure designation Facility [CMS Assessment];;;ACTIVE;2.63;2.66 +86527-9;Conditions related to intellectual disability and developmental disability status;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Conditions related to intellectual disability and developmental disability status [CMS Assessment];;;ACTIVE;2.63;2.63 +86528-7;Most recent admission &or entry or reentry into this facility;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Most recent admission/entry or reentry into this facility [CMS Assessment];;;ACTIVE;2.63;2.74 +86529-5;MDS v3.0 - RAI v1.17.2 - Cognitive patterns;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Cognitive patterns [CMS Assessment];;;ACTIVE;2.63;2.68 +86530-3;Visit notification note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Visit notification;Visit notification;;ACTIVE;2.61;2.71 +86531-1;Discharge notification note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Discharge notification;Discharge notification;;ACTIVE;2.61;2.71 +86532-9;Admission notification note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Admission notification;Admission notification;;ACTIVE;2.61;2.71 +86533-7;Living will;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Patient Living will;Patient Living will;;ACTIVE;2.61;2.67 +86534-5;Disease staging note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Disease staging note;Disease staging;;ACTIVE;2.61;2.61 +86535-2;Healthcare associated infection report - recommended CDA R3 set;-;Pt;{Setting};-;;PANEL.DOC;2;Healthcare associated infection report - recommended CDA R3 set;HAI report CDA R3 set;;ACTIVE;2.61;2.68 +86536-0;Hantavirus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Hantavirus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Hantavirus RNA CSF Ql NAA+probe;;ACTIVE;2.61;2.63 +86537-8;Hantavirus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Hantavirus RNA [Presence] in Tissue by NAA with probe detection;Hantavirus RNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +8653-8;Discharge instructions;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Discharge instructions;Hosp Discharge instruct;;ACTIVE;1.0h(3);2.67 +86538-6;Hantavirus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Hantavirus RNA [Presence] in Urine by NAA with probe detection;Hantavirus RNA Ur Ql NAA+probe;;ACTIVE;2.61;2.63 +86539-4;Herpes simplex virus 1 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Tissue by NAA with probe detection;HSV1 DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.73 +86540-2;Herpes simplex virus 2 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Tissue by Immunofluorescence;HSV2 Ag Tiss Ql IF;;ACTIVE;2.61;2.61 +86541-0;Herpes simplex virus 2 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Tissue by NAA with probe detection;HSV2 DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.73 +86542-8;Herpes simplex virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Tissue by NAA with probe detection;HSV DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.73 +86543-6;Herpes virus 6 DNA;PrThr;Pt;Bone mar;Ord;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Presence] in Bone marrow by NAA with probe detection;HHV6 DNA Mar Ql NAA+probe;;ACTIVE;2.61;2.63 +86544-4;Herpes virus 7 DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Herpes virus 7 DNA [Presence] in Blood by NAA with probe detection;HHV7 DNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +86545-1;Herpes virus 8 DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [Presence] in Blood by NAA with probe detection;HHV8 DNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +8654-6;Hospital discharge medications;Find;Pt;^Patient;Nom;;H&P.HX;2;Hospital discharge medications;Hospital discharge medications;;ACTIVE;1.0h(3);2.27 +86546-9;Herpes virus 8 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Herpes virus 8 DNA [Presence] in Tissue by NAA with probe detection;HHV8 DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86547-7;HIV 2 RNA;NCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;HIV 2 RNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HIV 2 RNA # CSF NAA+probe;;ACTIVE;2.61;2.63 +86548-5;HIV 2 RNA;NCnc;Pt;Plas;Qn;Probe.amp.tar;MICRO;1;HIV 2 RNA [#/volume] (viral load) in Plasma by NAA with probe detection;HIV 2 RNA # Plas NAA+probe;;ACTIVE;2.61;2.63 +86549-3;HIV 2 RNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;HIV 2 RNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HIV 2 RNA CSF NAA+probe-Log#;;ACTIVE;2.61;2.63 +86550-1;HTLV I+II RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;HTLV I+II RNA [Presence] in Blood by NAA with probe detection;HTLV I+II RNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +86551-9;Influenza vaccine cycle;Type;Pt;Vaccine;Nom;;VACCIN;2;Influenza vaccine cycle;Influenza vaccine cycle;;ACTIVE;2.61;2.61 +86552-7;Staff who worked at facility at least one day from October 1 through March 31;Num;RptPeriod;{Setting}^Population;Qn;;SURVEY.CDC;4;Staff [#] who worked at facility at least one day from October 1 through March 31;;;ACTIVE;2.61;2.61 +8655-3;Hospital discharge procedures;Find;Pt;^Patient;Nom;;H&P.HX;2;Hospital discharge procedures;Hospital discharge procedures;;ACTIVE;1.0h(3);2.27 +86553-5;Staff who received influenza vaccination at the facility;Num;RptPeriod;{Setting}^Population;Qn;;SURVEY.CDC;4;Staff [#] who received influenza vaccination at the facility;;;ACTIVE;2.61;2.61 +86554-3;Staff who provided documentation of influenza vaccine receipt;Num;RptPeriod;{Setting}^Population;Qn;;SURVEY.CDC;4;Staff [#] who provided documentation of influenza vaccine receipt;;;ACTIVE;2.61;2.61 +86555-0;Staff who had a medical contraindication to the influenza vaccine;Num;RptPeriod;{Setting}^Population;Qn;;SURVEY.CDC;4;Staff [#] who had a medical contraindication to the influenza vaccine;;;ACTIVE;2.61;2.65 +86556-8;Staff who declined influenza vaccine;Num;RptPeriod;{Setting}^Population;Qn;;SURVEY.CDC;4;Staff [#] who declined influenza vaccine;;;ACTIVE;2.61;2.61 +86557-6;Staff with unknown influenza vaccination status;Num;RptPeriod;{Setting}^Population;Qn;;SURVEY.CDC;4;Staff [#] with unknown influenza vaccination status;;;ACTIVE;2.61;2.61 +86558-4;Healthcare personnel influenza vaccination summary report;Find;RptPeriod;{Setting}^Population;Doc;;DOC.MISC;2;Healthcare personnel influenza vaccination summary report Document;HCP flu vaccine report Doc;;ACTIVE;2.61;2.63 +86559-2;Human bocavirus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Human bocavirus DNA [Presence] in Tissue by NAA with probe detection;HBoV DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +865-6;A3 Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated A3 Ab;Deprecated A3 Ab Ser Ql;;DEPRECATED;1.0;2.36 +86560-0;Human papilloma virus 16 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16 DNA [Presence] in Tissue by NAA with probe detection;HPV16 DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +8656-1;Hospital admission date;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Hospital admission date;Hospital admission date;;ACTIVE;1.0h(3);2.27 +86561-8;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Tissue by NAA with probe detection;HPV I/H Risk 1 DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86562-6;Human papilloma virus 18 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 18 DNA [Presence] in Tissue by NAA with probe detection;HPV18 DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86563-4;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Tissue by NAA with probe detection;HPV HR 12 DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86564-2;Human papilloma virus DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus DNA [Presence] in Tissue by NAA with probe detection;HPV DNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86565-9;Influenza virus A Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Tissue by Immunofluorescence;FLUAV Ag Tiss Ql IF;;ACTIVE;2.61;2.61 +86566-7;Influenza virus A Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Influenza virus A IgG Ab [Presence] in Serum by Immunoassay;FLUAV IgG Ser Ql IA;;ACTIVE;2.61;2.61 +86567-5;Influenza virus A Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Influenza virus A IgM Ab [Presence] in Serum by Immunoassay;FLUAV IgM Ser Ql IA;;ACTIVE;2.61;2.61 +86568-3;Influenza virus A RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;FLUAV RNA CSF Ql NAA+probe;;ACTIVE;2.61;2.63 +86569-1;Influenza virus A RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Tissue by NAA with probe detection;FLUAV RNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86570-9;Influenza virus B Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Influenza virus B IgM Ab [Presence] in Serum by Immunoassay;FLUBV IgM Ser Ql IA;;ACTIVE;2.61;2.61 +86571-7;Influenza virus B RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;FLUBV RNA CSF Ql NAA+probe;;ACTIVE;2.61;2.63 +86572-5;Influenza virus B RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Tissue by NAA with probe detection;FLUBV RNA Tiss Ql NAA+probe;;ACTIVE;2.61;2.63 +86573-3;JC virus DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;JC virus DNA [Presence] in Blood by NAA with probe detection;JCPyV DNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +86574-1;Marburg virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Marburg virus RNA [Presence] in Blood by NAA with probe detection;MARV RNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +86575-8;Measles virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Measles virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;MeV RNA CSF Ql NAA+probe;;ACTIVE;2.61;2.63 +86576-6;Measles virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Measles virus RNA [Presence] in Serum by NAA with probe detection;MeV RNA Ser Ql NAA+probe;;ACTIVE;2.61;2.63 +86577-4;Measles virus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Measles virus RNA [Presence] in Urine by NAA with probe detection;MeV RNA Ur Ql NAA+probe;;ACTIVE;2.61;2.63 +86578-2;Middle East respiratory syndrome coronavirus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Blood by NAA with probe detection;MERS-CoV RNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +8657-9;Hospital discharge physical findings;Find;Pt;^Patient;Nom;;H&P.HX;2;Hospital discharge physical findings;Hospital discharge physical findings;;ACTIVE;1.0h(3);2.27 +86579-0;Middle East respiratory syndrome coronavirus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Urine by NAA with probe detection;MERS-CoV RNA Ur Ql NAA+probe;;ACTIVE;2.61;2.63 +86580-8;Mumps virus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Mumps virus RNA [Presence] in Urine by NAA with probe detection;MuV RNA Ur Ql NAA+probe;;ACTIVE;2.61;2.63 +86581-6;Neisseria meningitidis;PrThr;Pt;CSF;Ord;Organism specific culture;MICRO;1;Neisseria meningitidis [Presence] in Cerebral spinal fluid by Organism specific culture;N men CSF Ql Cult;;ACTIVE;2.61;2.61 +86582-4;Parechovirus A RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Parechovirus A RNA [Presence] in Blood by NAA with probe detection;Parechovirus A RNA Bld Ql NAA+probe;;ACTIVE;2.61;2.63 +86583-2;Memory &or recall ability in the last 7D;Find;7D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Memory/recall ability in the last 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86584-0;Delirium;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Delirium [CMS Assessment];;;ACTIVE;2.63;2.63 +86585-7;MDS v3.0 - RAI v1.17.2, OASIS E - Signs and symptoms of delirium (from CAM);-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2, OASIS E - Signs and symptoms of delirium (from CAM) [CMS Assessment];;;ACTIVE;2.63;2.72 +86586-5;Parechovirus A RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Parechovirus A RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Parechovirus A RNA CSF Ql NAA+probe;;ACTIVE;2.61;2.63 +8658-7;Allergies;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Allergies;Hx of Allergies;;ACTIVE;1.0h(3);2.63 +86587-3;Rabies virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rabies virus IgG Ab [Presence] in Serum by Immunoassay;RABV IgG Ser Ql IA;;ACTIVE;2.61;2.61 +86588-1;Rabies virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Rabies virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;RABV RNA CSF Ql NAA+probe;;ACTIVE;2.61;2.63 +86589-9;Rubella virus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Rubella virus RNA [Presence] in Urine by NAA with probe detection;RUBV RNA Ur Ql NAA+probe;;ACTIVE;2.61;2.63 +86590-7;Streptococcus pneumoniae Ag;PrThr;Pt;CSF;Ord;IA.rapid;MICRO;1;Streptococcus pneumoniae Ag [Presence] in Cerebral spinal fluid by Rapid immunoassay;S pneum Ag CSF Ql IA.rapid;;ACTIVE;2.61;2.61 +86591-5;Toscana virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Toscana virus RNA [Presence] in Serum by NAA with probe detection;TOSV RNA Ser Ql NAA+probe;;ACTIVE;2.61;2.63 +86592-3;Varicella zoster virus Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Varicella zoster virus Ag [Presence] in Tissue by Immunofluorescence;VZV Ag Tiss Ql IF;;ACTIVE;2.61;2.61 +86593-1;Varicella zoster virus DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Amniotic fluid by NAA with probe detection;VZV DNA Amn Ql NAA+probe;;ACTIVE;2.61;2.63 +86594-9;Zika virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;ZIKV RNA CSF Ql NAA+probe;;ACTIVE;2.61;2.63 +8659-5;Birth control method;Type;Pt;^Patient;Nom;Reported;H&P.HX;2;Birth control method - Reported;Birth control method Reported;;ACTIVE;1.0h(3);2.27 +86595-6;MDS v3.0 - RAI v1.16.1 - Staff assessment for mental status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Staff assessment for mental status [CMS Assessment];;;ACTIVE;2.63;2.7 +86596-4;Behavior;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Behavior [CMS Assessment];;;ACTIVE;2.63;2.63 +86597-2;Potential indicators of psychosis;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Potential indicators of psychosis during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86598-0;Influenza season;DateRange;RptPeriod;{Event};Qn;;VACCIN;2;Influenza season [DateRange];Influenza season DateRange;;ACTIVE;2.61;2.66 +86599-8;Staff assessment of daily and activity preferences;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Staff assessment of daily and activity preferences [CMS Assessment];;;ACTIVE;2.63;2.63 +86600-4;Preferences for customary routine and activities;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Preferences for customary routine and activities [CMS Assessment];;;ACTIVE;2.63;2.63 +86601-2;Functional status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional status [CMS Assessment];;;ACTIVE;2.63;2.63 +86602-0;Mobility devices normally used during assessment period;Type;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Mobility devices normally used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.74 +8660-3;Symptoms & diseases;Hx;Pt;Cardiovascular system;Nom;;H&P.HX;2;History of Cardiovascular system disorders;Hx of CVS disorders;;ACTIVE;1.0h(3);2.56 +86603-8;Periodontal attachment - recommended CDA R1 set;-;Pt;{Setting};-;;PANEL.DOC;2;Periodontal attachment - recommended CDA R1 set;Perio attach CDA R1 set;;ACTIVE;2.61;2.72 +86604-6;Alfentanil/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alfentanil/Creatinine [Mass Ratio] in Urine by Confirmatory method;Alfentanil/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86605-3;Alpha hydroxytriazolam/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha hydroxytriazolam/Creatinine [Mass Ratio] in Urine by Confirmatory method;A-OH-triazolam/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86606-1;Cocaethylene/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cocaethylene/Creatinine [Mass Ratio] in Urine by Confirmatory method;Cocaethylene/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86607-9;Cocaine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cocaine/Creatinine [Mass Ratio] in Urine by Confirmatory method;Cocaine/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86608-7;Norcodeine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norcodeine/Creatinine [Mass Ratio] in Urine by Confirmatory method;Norcodeine/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86609-5;Noroxymorphone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Noroxymorphone/Creatinine [Mass Ratio] in Urine by Confirmatory method;Noroxymorphone/Creat Ur Cfm;;ACTIVE;2.61;2.73 +86610-3;SUFentanil/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;SUFentanil/Creatinine [Mass Ratio] in Urine by Confirmatory method;SUFentanil/Creat Ur Cfm;;ACTIVE;2.61;2.73 +8661-1;Chief complaint;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Chief complaint - Reported;Chief complaint Reported;;ACTIVE;1.0h(3);2.73 +86611-1;Chromosome analysis;Find;Pt;Amnio fld/CVS;Doc;Microarray;MOLPATH;1;Chromosome analysis in Amniotic fluid or Chorionic villus sample by Microarray;Chrom analy Amn/CVS Microarray;;ACTIVE;2.61;2.65 +86612-9;MDS v3.0 - RAI v1.14.1, v1.15.1 - Functional abilities and goals - admission;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Functional abilities and goals - admission [CMS Assessment];;;ACTIVE;2.63;2.67 +86613-7;MDS v3.0 - RAI v1.14.1, v1.15.1 - Self-care - admission performance;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Self-care - admission performance [CMS Assessment];;;ACTIVE;2.63;2.67 +86614-5;MDS v3.0 - RAI v1.14.1, v1.15.1 - Mobility - admission performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Mobility - admission performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.63;2.67 +86615-2;MDS v3.0 - RAI v1.14.1, v1.15.1 - Functional abilities and goals - discharge;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Functional abilities and goals - discharge [CMS Assessment];;;ACTIVE;2.63;2.67 +86616-0;MDS v3.0 - RAI v1.14.1, v1.15.1 - Self-care - discharge performance;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Self-care - discharge performance [CMS Assessment];;;ACTIVE;2.63;2.67 +86617-8;MDS v3.0 - RAI v1.14.1, v1.15.1 - Mobility - discharge performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Mobility - discharge performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.63;2.67 +86618-6;MDS v3.0 - RAI v1.14.1, v1.15.1 - Self-care - discharge goal;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Self-care - discharge goal [CMS Assessment];;;ACTIVE;2.63;2.67 +86619-4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Mobility - discharge goal during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Mobility - discharge goal during 3 day assessment period [CMS Assessment];;;ACTIVE;2.63;2.67 +86620-2;Bacterial methicillin resistance mecA+mecC genes;PrThr;Pt;Nose;Ord;Probe.amp.tar;ABXBACT;1;Methicillin resistance mecA+mecC genes [Presence] in Nose by NAA with probe detection;mecA+mecC Nose Ql NAA+probe;;ACTIVE;2.61;2.64 +86621-0;Bacterial methicillin resistance mecC gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Methicillin resistance mecC gene [Presence] by Molecular method;MRB mecC Islt/Spm Ql;;ACTIVE;2.61;2.65 +86622-8;Staphylococcus aureus methicillin resistance SCCmec & mecA+mecC genes panel;-;Pt;Nose;-;;PANEL.ABXBACT;1;MRSA SCCmec and mecA+mecC genes panel - Nose;SCCmec + mecA+mecC pnl Nose;;ACTIVE;2.61;2.65 +86623-6;MDS v3.0 - RAI v1.14.1 - Bladder and bowel;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1 - Bladder and bowel [CMS Assessment];;;ACTIVE;2.63;2.63 +86624-4;Bladder and bowel appliances used;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Bladder and bowel appliances used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86625-1;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing &or nutritional status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing/nutritional status [CMS Assessment];;;ACTIVE;2.63;2.64 +86626-9;Send document that conforms to Level 3 EMS R2 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to Level 3 EMS R2 template;;;ACTIVE;2.61;2.61 +86627-7;Send document that conforms to Oncology Treatment Plan Summary R1.3 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to Oncology Treatment Plan Summary R1.3 template;;;ACTIVE;2.61;2.61 +86628-5;Send document that conforms to Oncology Treatment Plan Summary R1.2.1 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to Oncology Treatment Plan Summary R1.2.1 template;;;ACTIVE;2.61;2.61 +8662-9;Childhood diseases;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Childhood diseases;Hx of Childhood diseases;;ACTIVE;1.0h(3);2.56 +86629-3;Send document that conforms to Oncology Treatment Plan Summary R1.2 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to Oncology Treatment Plan Summary R1.2 template;;;ACTIVE;2.61;2.61 +86630-1;Send document that conforms to Level 3 EMS R1 template;Scope.modifier.doc template;Pt;X12^277;-;;ATTACH.MODIFIER;3;Send document that conforms to Level 3 EMS R1 template;;;ACTIVE;2.61;2.61 +86631-9;Pain panel;-;1W;^Patient;-;KOOSJR;PANEL.SURVEY.GNHLTH;4;Pain panel [KOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +86632-7;Function and daily living panel;-;1W;^Patient;-;KOOSJR;PANEL.SURVEY.GNHLTH;4;Function and daily living panel [KOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +86633-5;Pain panel;-;1W;^Patient;-;HOOSJR;PANEL.SURVEY.GNHLTH;4;Pain panel [HOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +86634-3;Function and daily living panel;-;1W;^Patient;-;HOOSJR;PANEL.SURVEY.GNHLTH;4;Function and daily living panel [HOOSJR];;Copyright © 2016 Hospital for Special Surgery. Used with permission;ACTIVE;2.61;2.61 +86635-0;Family planning report;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Family planning report Document;Family planning report Doc;;ACTIVE;2.61;2.61 +86636-8;Family planning report - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;Family planning report - FPAR 2.0 set;;;ACTIVE;2.61;2.7 +8663-7;Cigarettes smoked.current (pack per day);NRat;Pt;^Patient;Qn;Reported;H&P.HX;2;Cigarettes smoked current (pack per day) - Reported;Cigs smoked (pack/day) nRate Reported;;ACTIVE;1.0h(3);2.73 +86637-6;Provider role;Type;Pt;Provider;Nom;;ADMIN;2;Provider role;Provider role;;ACTIVE;2.61;2.66 +86638-4;Patient demographic & administrative information panel;-;Pt;^Patient;-;FPAR;PANEL.SURVEY.HHS;4;Patient demographic and administrative information panel [FPAR];;;ACTIVE;2.61;2.66 +86639-2;Household size;Num;Pt;^Patient;Qn;;ADMIN.PATIENT.DEMOG;2;Household size [#];Household size;;ACTIVE;2.61;2.66 +866-4;A3 Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A3 Ag [Presence] on Red Blood Cells from Blood product unit;A3 Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +86640-0;Limited English proficiency;Find;Pt;^Patient;Ord;;H&P.HX;2;Limited English proficiency;Ltd Eng prof;;ACTIVE;2.61;2.66 +86641-8;Height, weight & blood pressure panel;-;Pt;^Patient;-;FPAR;PANEL.SURVEY.HHS;4;Height, weight and blood pressure panel [FPAR];;;ACTIVE;2.61;2.66 +86642-6;Pregnancy and contraception panel;-;Pt;^Patient;-;FPAR;PANEL.SURVEY.HHS;4;Pregnancy and contraception panel [FPAR];;;ACTIVE;2.61;2.66 +86643-4;Information source for pregnancy status;Type;Pt;^Patient;Nom;;H&P.HX;2;Information source for pregnancy status;Source for pregnancy status;;ACTIVE;2.61;2.66 +86644-2;Pregnancy lab tests - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;Pregnancy lab tests - FPAR 2.0 set;;;ACTIVE;2.61;2.66 +8664-5;Cigarettes smoked.total (pack per year);NRat;Pt;^Patient;Qn;Reported;H&P.HX;2;Cigarettes smoked total (pack per year) - Reported;Cigs smoked (pack/year) nRate Reported;;ACTIVE;1.0h(3);2.48 +86645-9;Pregnancy intention in the next Y;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Pregnancy intention in the next year - Reported;Pregnancy intention next year Pt Rpted;;ACTIVE;2.61;2.66 +86646-7;Ever had sex;Find;Lifetime;^Patient;Ord;Reported;H&P.HX;2;Ever had sex - Reported;Ever had sex Lifetime Ql Reported;;ACTIVE;2.61;2.66 +86647-5;Sexual activity in the last 3Mo;Find;3Mo;^Patient;Ord;Reported;H&P.HX;2;Sexual activity in the last 3 months - Reported;Sex last 3Mo Ql Reported;;ACTIVE;2.61;2.66 +86648-3;Sexual activity in the last Y;Find;1Y;^Patient;Ord;Reported;H&P.HX;2;Sexual activity in the last year - Reported;Sex in last Y Ql Reported;;ACTIVE;2.61;2.66 +86649-1;Birth control method^at intake;Type;Pt;^Patient;Nom;Reported;H&P.HX;2;Birth control method at intake Reported;Birth control method at intake Reported;;ACTIVE;2.61;2.72 +86650-9;Reason for no birth control use^at intake;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Reason for no birth control use - Reported --at intake;Reason no birth control at intake;;ACTIVE;2.61;2.66 +86651-7;Birth control method^at exit;Type;Pt;^Patient;Nom;Reported;H&P.HX;2;Birth control method at exit Reported --at exit;Birth control method at exit Reported;;ACTIVE;2.61;2.66 +8665-2;Date last menstrual period;Date;Pt;^Patient;Qn;;H&P.HX;2;Last menstrual period start date;LMP Start date;;ACTIVE;1.0h(3);2.73 +86652-5;How birth control method was provided;Find;Pt;^Patient;Nom;;H&P.HX;2;How birth control method was provided;Birth control method provided;;ACTIVE;2.61;2.66 +86653-3;Reason for no birth control use^at exit;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Reason for no birth control use - Reported --at exit;Reason no birth control at exit Reported;;ACTIVE;2.61;2.66 +86654-1;Contraceptive counseling was provided;Find;Pt;^Patient;Ord;;H&P.HX;2;Contraceptive counseling was provided;Contraceptive counseling;;ACTIVE;2.61;2.66 +86655-8;Counseling to achieve pregnancy was provided;Find;Pt;^Patient;Ord;;H&P.HX;2;Counseling to achieve pregnancy was provided;Counseling achieve pregnancy;;ACTIVE;2.61;2.66 +86656-6;Lab tests - FPAR 2.0 sets;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;Lab tests - FPAR 2.0 sets;;;ACTIVE;2.61;2.66 +86657-4;HIV 1 & 2 tests - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;HIV 1 and 2 tests - FPAR 2.0 set;;;ACTIVE;2.61;2.66 +86658-2;HPV tests - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;HPV tests - FPAR 2.0 set;;;ACTIVE;2.61;2.66 +86659-0;Chlamydia sp tests - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;Chlamydia sp tests - FPAR 2.0 set;;;ACTIVE;2.61;2.66 +8666-0;Symptoms & diseases;Hx;Pt;Skin;Nom;;H&P.HX;2;History of Skin disorders;Hx of Skin disorders;;ACTIVE;1.0h(3);2.56 +86660-8;Neisseria gonorrhoeae tests - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;Neisseria gonorrhoeae tests - FPAR 2.0 set;;;ACTIVE;2.61;2.66 +86661-6;Chlamydia trachomatis+Neisseria gonorrhoeae tests - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;Chlamydia trachomatis+Neisseria gonorrhoeae tests - FPAR 2.0 set;;;ACTIVE;2.61;2.66 +86662-4;Pap smear tests - FPAR 2.0 set;-;Pt;^Patient;-;;PANEL.SURVEY.HHS;4;Pap smear tests - FPAR 2.0 set;;;ACTIVE;2.61;2.66 +86663-2;HIV referral information panel;-;Pt;^Patient;-;FPAR;PANEL.SURVEY.HHS;4;HIV referral information panel [FPAR];;;ACTIVE;2.61;2.66 +86664-0;Referral note;Find;Pt;{Setting};Doc;HIV;DOC.ONTOLOGY;2;HIV Referral note;HIV Referral note;;ACTIVE;2.61;2.61 +86666-5;Location within lymph node;Anat;Pt;Skin melanoma;Nom;Microscopy.light;PATH.HISTO;1;Location within lymph node [Anatomy] in Skin melanoma by Light microscopy;Loc within LN Mel Micro;;ACTIVE;2.61;2.61 +86667-3;Level of tumor invasion;Find;Pt;Skin melanoma;Ord;Clark;PATH.HISTO;1;Level of tumor invasion in Skin melanoma Qualitative by Clark;Tumor invasion level Mel Ql Clark;;ACTIVE;2.61;2.61 +86668-1;Depth of deep margin involved by invasive melanoma;Len;Pt;Skin melanoma;Qn;Microscopy.light;PATH.HISTO;1;Depth of deep margin involved by invasive melanoma [Length] in Skin melanoma by Light microscopy;Depth deep marg inv IM Mel Micro;;ACTIVE;2.61;2.61 +86669-9;Mitotic figures;Naric;Pt;Cancer specimen;Qn;Microscopy.light;PATH.HISTO;1;Mitotic figures [#/area] in Cancer specimen by Light microscopy;Mitotic figures #/area Ca spec Micro;;ACTIVE;2.61;2.61 +86670-7;MDS v3.0 - RAI v1.17.2 - Active diagnoses - ND;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Active diagnoses - ND [CMS Assessment];;;ACTIVE;2.63;2.68 +86671-5;Active diagnoses;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Active diagnoses during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86672-3;Staff assessment for pain;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Staff assessment for pain during assessment period [CMS Assessment];;;ACTIVE;2.63;2.74 +86673-1;Indicators of pain or possible pain;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Indicators of pain or possible pain during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86674-9;Other health conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Other health conditions [CMS Assessment];;;ACTIVE;2.63;2.74 +86675-6;Shortness of breath;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Shortness of breath during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86676-4;Problem conditions;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Problem conditions during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86677-2;Signs and symptoms of swallowing disorder;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Signs and symptoms of swallowing disorder during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +8667-8;Symptoms & diseases;Hx;Pt;Ear;Nom;;H&P.HX;2;History of Ear disorders;Hx of Ear disorders;;ACTIVE;1.0h(3);2.56 +86678-0;Weight gain of 5% or more in the last month or gain of 10% or more in last 6Mo;Find;6Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Weight gain of 5% or more in the last month or gain of 10% or more in last 6 months [CMS Assessment];;;ACTIVE;2.63;2.63 +86679-8;Percent intake by artificial route;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Percent intake by artificial route [CMS Assessment];;;ACTIVE;2.63;2.63 +86680-6;Proportion of total calories the resident received through parenteral or tube feeding in the 7D - while not a resident;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Proportion of total calories the resident received through parenteral or tube feeding in the 7 days - while not a resident [CMS Assessment];;;ACTIVE;2.63;2.63 +86681-4;Proportion of total calories the resident received through parenteral or tube feeding in last 7D - while a resident;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Proportion of total calories the resident received through parenteral or tube feeding in last 7 days - while a resident [CMS Assessment];;;ACTIVE;2.63;2.63 +86682-2;Mean fluid intake per day by IV or tube feeding in last 7D - while not a resident;VRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Mean fluid intake per day by IV or tube feeding in last 7 days - while not a resident [CMS Assessment];;;ACTIVE;2.63;2.69 +86683-0;Mean fluid intake per day by IV or tube feeding in last 7D - while a resident;VRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Mean fluid intake per day by IV or tube feeding in last 7 days - while a resident [CMS Assessment];;;ACTIVE;2.63;2.69 +86684-8;Mean fluid intake per day by IV or tube feeding during entire 7D;VRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Mean fluid intake per day by IV or tube feeding during entire 7 days [CMS Assessment];;;ACTIVE;2.63;2.69 +86685-5;Oral &or dental status;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Oral/dental status during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +8668-6;Symptoms & diseases;Hx;Pt;Endocrine system;Nom;;H&P.HX;2;History of Endocrine system disorders;Hx of Endocrine disorders;;ACTIVE;1.0h(3);2.56 +86686-3;MDS v3.0 - RAI v1.14.1, v1.15.1 - Health conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Health conditions [CMS Assessment];;;ACTIVE;2.63;2.64 +86687-1;Proportion of total calories the resident received through parenteral or tube feeding during entire 7D;Find;7D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Proportion of total calories the resident received through parenteral or tube feeding during entire 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86688-9;Rotavirus C;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Rotavirus C [Presence] in Specimen by Organism specific culture;RVC Spec Ql Cult;;ACTIVE;2.61;2.69 +86689-7;Rotavirus A;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Rotavirus A [Presence] in Specimen by Organism specific culture;RVA Spec Ql Cult;;ACTIVE;2.61;2.69 +86690-5;Rotavirus C RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rotavirus C RNA [Presence] in Specimen by NAA with probe detection;RVC RNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86691-3;Rotavirus B RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rotavirus B RNA [Presence] in Specimen by NAA with probe detection;RVB RNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86692-1;Rotavirus A RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rotavirus A RNA [Presence] in Specimen by NAA with probe detection;RVA RNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86693-9;Porcine epidemic diarrhea virus Ab.IgA/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Porcine epidemic diarrhea virus IgA Ab/Positive control in Specimen by Immunoassay;PEDv IgA/Pos cntrl Spec IA;;ACTIVE;2.61;2.69 +8669-4;Symptoms & diseases;Hx;Pt;Eyes;Nom;;H&P.HX;2;History of Eyes disorders;Hx of Eyes disorders;;ACTIVE;1.0h(3);2.56 +86694-7;Porcine epidemic diarrhea virus Ab.IgG/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Porcine epidemic diarrhea virus IgG Ab/Positive control in Specimen by Immunoassay;PEDv IgG/Pos cntrl Spec IA;;ACTIVE;2.61;2.69 +86695-4;Porcine epidemic diarrhea virus Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Porcine epidemic diarrhea virus Ab/Positive control in Serum by Immunoassay;PEDv Ab/Pos cntrl Ser IA;;ACTIVE;2.61;2.61 +86696-2;Rotavirus B RNA;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus B RNA [Nucleotide sequence] in Isolate by Sequencing;RVB RNA Islt-Seq;;ACTIVE;2.61;2.61 +86697-0;Rotavirus A RNA;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus A RNA [Nucleotide sequence] in Isolate by Sequencing;RVA RNA Islt-Seq;;ACTIVE;2.61;2.64 +86698-8;Porcine epidemic diarrhea virus RNA;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine epidemic diarrhea virus RNA [Nucleotide sequence] in Isolate by Sequencing;PEDv RNA Islt-Seq;;ACTIVE;2.61;2.61 +86699-6;Rotavirus C RNA;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus C RNA [Nucleotide sequence] in Isolate by Sequencing;RVC RNA Islt-Seq;;ACTIVE;2.61;2.61 +86700-2;Rotavirus C RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Rotavirus C RNA [Cycle Threshold #] in Specimen by NAA with probe detection;RVC RNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86701-0;Rotavirus A RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Rotavirus A RNA [Cycle Threshold #] in Specimen by NAA with probe detection;RVA RNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +8670-2;History of family member diseases;Hx;Pt;^Family member;Nom;;H&P.HX;2;History of family member diseases;Family member diseases Hx;;ACTIVE;1.0h(3);2.73 +86702-8;Rotavirus B RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Rotavirus B RNA [Cycle Threshold #] in Specimen by NAA with probe detection;RVB RNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86703-6;Porcine respiratory coronavirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine respiratory coronavirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PRCoV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86704-4;Lawsonia intracellularis RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Lawsonia intracellularis RNA [Cycle Threshold #] in Specimen by NAA with probe detection;L intracell RNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86705-1;Lawsonia intracellularis Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Lawsonia intracellularis Ab [Titer] in Serum by Immunoassay;L intracell Ab Titr Ser IA;;ACTIVE;2.61;2.63 +86706-9;Dental problems during assessment period;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Dental problems during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86707-7;MDS v3.00 - RAI v1.14.1 - Skin conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.00 - RAI v1.14.1 - Skin conditions [CMS Assessment];;;ACTIVE;2.63;2.63 +86708-5;Determination of pressure injury risk in last 7D;Find;7D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Determination of pressure injury risk in last 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86709-3;Lawsonia intracellularis RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Lawsonia intracellularis RNA [#/volume] in Specimen by NAA with probe detection;L intracell RNA # Spec NAA+probe;;ACTIVE;2.61;2.69 +8671-0;Functional status;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Functional status;Hx of Functional status;;ACTIVE;1.0h(3);2.56 +86710-1;Porcine epidemic diarrhea virus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine epidemic diarrhea virus RNA [#/volume] (viral load) in Specimen by NAA with probe detection;PEDv RNA # Spec NAA+probe;;ACTIVE;2.61;2.69 +86711-9;Porcine deltacoronavirus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Porcine deltacoronavirus Ag [Presence] in Tissue by Immune stain;PDCoV Ag Tiss Ql ImStn;;ACTIVE;2.61;2.63 +86712-7;Bacterial carbapenem resistance blaOXA gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA gene [Presence] by Molecular method;blaOXA Islt/Spm Ql;;ACTIVE;2.61;2.73 +86713-5;Bacterial carbapenem resistance blaOXA-134-like gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA-134-like gene [Presence] by Molecular method;blaOXA-134-like Islt/Spm Ql;;ACTIVE;2.61;2.66 +86714-3;Bacterial carbapenem resistance blaOXA-51-like gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA-51-like gene [Presence] by Molecular method;blaOXA-51-like Islt/Spm Ql;;ACTIVE;2.61;2.66 +86715-0;Actinobacillus pleuropneumoniae Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Actinobacillus pleuropneumoniae Ab [Titer] in Serum by Complement fixation;A pleuropn Ab Titr Ser CF;;ACTIVE;2.61;2.63 +86716-8;Actinobacillus pleuropneumoniae DNA;ThreshNum;Pt;Isolate;Qn;Probe.amp.tar;MICRO;1;Actinobacillus pleuropneumoniae DNA [Cycle Threshold #] in Isolate by NAA with probe detection;A pleuropn DNA Ct Islt Qn NAA+probe;;ACTIVE;2.61;2.63 +86717-6;Actinobacillus pleuropneumoniae serotype 1 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Actinobacillus pleuropneumoniae serotype 1 Ab [Titer] in Serum by Complement fixation;A pleuropn 1 Ab Titr Ser CF;;ACTIVE;2.61;2.63 +86718-4;Actinobacillus pleuropneumoniae serotype 3 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Actinobacillus pleuropneumoniae serotype 3 Ab [Titer] in Serum by Complement fixation;A pleuropn 3 Ab Titr Ser CF;;ACTIVE;2.61;2.63 +86719-2;Actinobacillus pleuropneumoniae serotype 5 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Actinobacillus pleuropneumoniae serotype 5 Ab [Titer] in Serum by Complement fixation;A pleuropn 5 Ab Titr Ser CF;;ACTIVE;2.61;2.63 +867-2;A3 Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A3 Ag [Presence] on Red Blood Cells from Donor;A3 Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +86720-0;Actinobacillus pleuropneumoniae serotype 7 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Actinobacillus pleuropneumoniae serotype 7 Ab [Titer] in Serum by Complement fixation;A pleuropn 7 Ab Titr Ser CF;;ACTIVE;2.61;2.63 +86721-8;Actinobacillus pleuropneumoniae serotype identified;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Actinobacillus pleuropneumoniae serotype identified in Isolate by NAA with probe detection;A pleuropn Sertyp Islt NAA+probe;;ACTIVE;2.61;2.72 +86722-6;Actinobacillus suis DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Actinobacillus suis DNA [Presence] in Specimen by NAA with probe detection;A suis DNA Spec Ql NAA+probe;;ACTIVE;2.61;2.69 +86723-4;Actinobacillus suis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Actinobacillus suis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;A suis DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86724-2;Erysipelothrix rhusiopathiae;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Erysipelothrix rhusiopathiae [Presence] in Specimen by Organism specific culture;E rhusiopathiae Spec Ql Cult;;ACTIVE;2.61;2.69 +86725-9;Erysipelothrix rhusiopathiae Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Erysipelothrix rhusiopathiae Ag [Presence] in Tissue by Immune stain;E rhusiopathiae Ag Tiss Ql ImStn;;ACTIVE;2.61;2.63 +86726-7;Erysipelothrix rhusiopathiae DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Erysipelothrix rhusiopathiae DNA [Cycle Threshold #] in Specimen by NAA with probe detection;E rhusiopathiae DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86727-5;Erysipelothrix sp strain 2 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Erysipelothrix sp strain 2 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Erysip sp str 2 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +8672-8;Symptoms & diseases;Hx;Pt;Neurologic system;Nar;;H&P.HX;2;History of Nervous system disorders Narrative;Hx of Neurologic disorders;;ACTIVE;1.0h(3);2.56 +86728-3;Erysipelothrix tonsillarum DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Erysipelothrix tonsillarum DNA [Cycle Threshold #] in Specimen by NAA with probe detection;E tonsillarum DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86729-1;Haemophilus parasuis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus parasuis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;H parasuis DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86730-9;Leptospira borgpetersenii serovar Hardjo-bovis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Leptospira borgpetersenii sv Hardjo-bovis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;L borg Har-bovis DNA Ct Spec Qn NAA+prb;;ACTIVE;2.61;2.69 +86731-7;Leptospira sp DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Leptospira sp DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Leptospira DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86732-5;Leptospira sp identified;Type;Pt;Isolate;Nom;Sequencing;MICRO;1;Leptospira sp identified [Type] in Isolate by Sequencing;Leptospira Islt Seq;;ACTIVE;2.61;2.63 +86733-3;Porcine parvovirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Porcine parvovirus [Presence] in Specimen by Organism specific culture;PPV Spec Ql Cult;;ACTIVE;2.61;2.69 +86734-1;Porcine parvovirus Ab;Titr;Pt;Ser;Qn;HAI;MICRO;1;Porcine parvovirus Ab [Titer] in Serum by Hemagglutination inhibition;PPV Ab Titr Ser HAI;;ACTIVE;2.61;2.61 +86735-8;Porcine parvovirus DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine parvovirus DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PPV DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +8673-6;Symptoms & diseases;Hx;Pt;Hematologic system;Nom;;H&P.HX;2;History of Hematologic system disorders;Hx of Hematologic disorders;;ACTIVE;1.0h(3);2.56 +86736-6;Porcine parvovirus type 1 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine parvovirus type 1 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PPV 1 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86737-4;Toxoplasma gondii Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Toxoplasma gondii Ag [Presence] in Tissue by Immune stain;T gondii Ag Tiss Ql ImStn;;ACTIVE;2.61;2.63 +86738-2;Toxoplasma gondii Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Specimen by Immunoassay;T gondii IgG Spec Ql IA;;ACTIVE;2.61;2.69 +86739-0;Streptococcus suis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Streptococcus suis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;S suis DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86740-8;Streptococcus suis Ag;PrThr;Pt;XXX;Ord;Immune stain;MICRO;1;Streptococcus suis Ag [Presence] in Specimen by Immune stain;S suis Ag Spec Ql ImStn;;ACTIVE;2.61;2.69 +86741-6;Porcine parvovirus type 2 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine parvovirus type 2 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PPV 2 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.61;2.69 +86742-4;Growth phase;Type;Pt;Skin melanoma;Nom;Microscopy.light;PATH.HISTO;1;Growth phase [Type] in Skin melanoma by Light microscopy;Growth phase Mel Micro;;ACTIVE;2.61;2.61 +86743-2;Surgical margin tumor involvement.deep;PrThr;Pt;Skin melanoma;Ord;Microscopy.light;PATH;1;Surgical margin tumor involvement.deep [Presence] in Skin melanoma by Light microscopy;Marg tumor invol.deep Mel Ql Micro;;ACTIVE;2.61;2.61 +8674-4;History source;Type;Pt;Interviewee;Nom;*;H&P.HX;2;History source;Hx source;;ACTIVE;1.0h(3);2.29 +86744-0;Care team;Type;Pt;^Patient;Nom;;CLIN;2;Care team;Care team;;ACTIVE;2.61;2.61 +86745-7;MDS v3.0 - RAI v1.14.1, v1.15.1 - Current number of unhealed pressure injuries at each stage;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Current number of unhealed pressure injuries at each stage [CMS Assessment];;;ACTIVE;2.63;2.64 +86746-5;Dimensions of unhealed stage 3 or 4 pressure injuries or eschar;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Dimensions of unhealed stage 3 or 4 pressure injuries or eschar [CMS Assessment];;;ACTIVE;2.63;2.63 +86747-3;Ulcers, wounds and skin problems;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Ulcers, wounds and skin problems [CMS Assessment];;;ACTIVE;2.63;2.63 +86748-1;Skin and pressure injury &or injury treatments during assessment period;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Skin and ulcer/injury treatments during assessment period [CMS Assessment];;;ACTIVE;2.63;2.73 +86749-9;Medications;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Medications [CMS Assessment];;;ACTIVE;2.63;2.63 +86750-7;Medications received;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Medications received [CMS Assessment];;;ACTIVE;2.63;2.63 +8675-1;History taker;Type;Pt;History taker;Nom;;H&P.HX;2;History taker;History taker;;ACTIVE;1.0h(3);2.29 +86751-5;Number of D antipsychotic received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days antipsychotic received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86752-3;Number of D antianxiety received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days antianxiety received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86753-1;Number of D antidepressant received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days antidepressant received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86754-9;Number of D hypnotic received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days hypnotic received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86755-6;Number of D anticoagulant received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days anticoagulant received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86756-4;Number of D antibiotic received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days antibiotic received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86757-2;Number of D diuretic received in last 7D or since admission &or reentry if less than 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days diuretic received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.63;2.63 +86758-0;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs [CMS Assessment];;;ACTIVE;2.63;2.64 +86759-8;MDS v3.0 - RAI v1.17.1, 1.17.2 - Special treatments, procedures, and programs;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Special treatments, procedures, and programs [CMS Assessment];;;ACTIVE;2.63;2.74 +86760-6;Procedures performed during last 14D - while not a resident;Find;14D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Procedures performed during last 14 days - while not a resident [CMS Assessment];;;ACTIVE;2.63;2.63 +86761-4;Procedures performed during last 14D - while a resident;Find;14D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Procedures performed during last 14 days - while a resident [CMS Assessment];;;ACTIVE;2.63;2.63 +86762-2;Therapies;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Therapies [CMS Assessment];;;ACTIVE;2.63;2.74 +86763-0;Speech-language pathology and audiology services;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Speech-language pathology and audiology services [CMS Assessment];;;ACTIVE;2.63;2.74 +86764-8;Occupational therapy - co-treatment minutes during 7D assessment period;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - co-treatment minutes during 7 day assessment period [CMS Assessment];;;ACTIVE;2.63;2.63 +86765-5;Speech-language pathology and audiology services - co-treatment minutes during 7D assessment period;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - co-treatment minutes during 7 day assessment period [CMS Assessment];;;ACTIVE;2.63;2.63 +86766-3;Physical therapy - co-treatment minutes during 7D assessment period;Time;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - co-treatment minutes during 7 day assessment period [CMS Assessment];;;ACTIVE;2.63;2.63 +86767-1;Occupational therapy;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Occupational therapy [CMS Assessment];;;ACTIVE;2.63;2.74 +86768-9;Physical therapy;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Physical therapy [CMS Assessment];;;ACTIVE;2.63;2.74 +8676-9;Industrial exposure;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Industrial exposure;Hx of Industrial exposure;;ACTIVE;1.0h(3);2.56 +86769-7;Distinct calendar days of therapy in last 7D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Distinct calendar days of therapy in last 7 days [CMS Assessment];;;ACTIVE;2.63;2.66 +86770-5;Resumption of therapy;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Resumption of therapy [CMS Assessment];;;ACTIVE;2.63;2.63 +86771-3;Date therapy regimen resumed;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Date therapy regimen resumed [CMS Assessment];;;ACTIVE;2.63;2.63 +86772-1;Previous rehabilitation therapy regimen (speech, occupational, &or physical therapy) ended, & regimen now resumed at exactly the same level for each discipline;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Previous rehabilitation therapy regimen (speech, occupational, and/or physical therapy) ended, and regimen now resumed at exactly the same level for each discipline [CMS Assessment];;;ACTIVE;2.63;2.63 +86773-9;Restorative nursing programs;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Restorative nursing programs [CMS Assessment];;;ACTIVE;2.63;2.74 +86774-7;Number of D of passive range of motion in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of passive range of motion in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86775-4;Number of D of active range of motion in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of active range of motion in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86776-2;Number of D of splint or brace assistance in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of splint or brace assistance in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +8677-7;Medication use;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Medication use;Hx of Medication use;;ACTIVE;1.0h(3);2.73 +86777-0;Number of D of training & skill practice in bed mobility in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of training and skill practice in bed mobility in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86778-8;Number of D of training & skill practice in transfer in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of training and skill practice in transfer in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86779-6;Number of D of training & skill practice in walking in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of training and skill practice in walking in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86780-4;Number of D of training & skill practice in dressing or grooming in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of training and skill practice in dressing or grooming in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86781-2;Number of D of training & skill practice in eating or swallowing in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of training and skill practice in eating or swallowing in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86782-0;Number of D of training & skill practice in amputation or prosthesis care in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of training and skill practice in amputation or prosthesis care in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86783-8;Number of D of training & skill practice in communication in last 7 calendar D;NRat;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days of training and skill practice in communication in last 7 calendar days [CMS Assessment];;;ACTIVE;2.63;2.63 +86784-6;Restraints;-;7D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Restraints [CMS Assessment];;;ACTIVE;2.63;2.63 +8678-5;Menstrual status;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Menstrual status - Reported;Menstrual status Reported;;ACTIVE;1.0h(3);2.27 +86785-3;Physical restraints;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Physical restraints during assessment period [CMS Assessment];;;ACTIVE;2.63;2.74 +86786-1;Physical restraints used in bed - bed rail used during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physical restraints used in bed - bed rail used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86787-9;Physical restraints used in bed - trunk restraint used during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physical restraints used in bed - trunk restraint used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86788-7;Physical restraints used in bed - limb restraint during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physical restraints used in bed - limb restraint during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86789-5;Other physical restraints used in bed during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Other physical restraints used in bed during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86790-3;Physical restraints used in chair or out of bed - trunk restraint used during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physical restraints used in chair or out of bed - trunk restraint used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86791-1;Physical restraints used in chair or out of bed - limb restraint used during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physical restraints used in chair or out of bed - limb restraint used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86792-9;Physical restraints used in chair or out of bed - chair prevents rising used during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physical restraints used in chair or out of bed - chair prevents rising used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +8679-3;Symptoms & diseases;Hx;Pt;Oral cavity;Nom;;H&P.HX;2;History of Oral cavity disorders;Hx of Oral cavity disorders;;ACTIVE;1.0h(3);2.56 +86793-7;Other physical restraints used in chair or out of bed used during assessment period;NRat;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Other physical restraints used in chair or out of bed used during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86794-5;MDS v3.0 - RAI v1.14.1 - Participation in assessment and goal setting;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1 - Participation in assessment and goal setting [CMS Assessment];;;ACTIVE;2.63;2.74 +86795-2;Clinical record documents a request that questions regarding possible return to the community be asked only on comprehensive assessments;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Clinical record documents a request that questions regarding possible return to the community be asked only on comprehensive assessments [CMS Assessment];;;ACTIVE;2.63;2.63 +86796-0;Resident's preference regarding being asked about returning to the community;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Resident's preference regarding being asked about returning to the community [CMS Assessment];;;ACTIVE;2.63;2.74 +86797-8;Resident (or legally authorized representative) wants to be asked about returning to the community on all assessments;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Resident (or legally authorized representative) wants to be asked about returning to the community on all assessments [CMS Assessment];;;ACTIVE;2.63;2.63 +86798-6;Information source for preference on return to community queries;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Information source for preference on return to community queries [CMS Assessment];;;ACTIVE;2.63;2.67 +86799-4;Coded cause of death - recommended CDA R1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Coded cause of death - recommended CDA R1 sections;Coded cause death CDA R1 Sec;;ACTIVE;2.61;2.68 +868-0;A3 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A3 Ag [Presence] on Red Blood Cells;A3 Ag RBC Ql;;ACTIVE;1.0;2.56 +86800-0;Coded race and ethnicity - recommended CDA R1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Coded race and ethnicity - recommended CDA R1 sections;Coded race+ethnicity CDA R2.1 Sec;;ACTIVE;2.61;2.68 +8680-1;Symptoms & diseases;Hx;Pt;Musculoskeletal system;Nom;;H&P.HX;2;History of Musculoskeletal system disorders;Hx of Musculoskeletal disorders;;ACTIVE;1.0h(3);2.56 +86801-8;Jurisdiction death information - recommended CDA R1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Jurisdiction death information - recommended CDA R1 sections;Jurisdiction death info CDA R2.1 Sec;;ACTIVE;2.61;2.68 +86802-6;Cause of death+related information;Find;Pt;^Patient;Doc;;DOC.MISC;2;Cause of death and related information Document;Cause of death+related info Doc;;ACTIVE;2.61;2.68 +86803-4;Provider death registration - recommended CDA R1 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Provider Death Registration - recommended CDA R1 sections;Provider death reg CDA R2.1 Sec;;ACTIVE;2.61;2.68 +86804-2;Cause of death classification+related information;Find;Pt;^Patient;Doc;;DOC.MISC;2;Cause of death classification and related information Document;Death classification+related info Doc;;ACTIVE;2.61;2.68 +86805-9;Race and ethnicity information;Find;Pt;^Patient;Doc;;DOC.MISC;2;Race and ethnicity information Document;Race and ethnicity info Doc;;ACTIVE;2.61;2.68 +86806-7;Jurisdiction death registration;Find;Pt;^Patient;Doc;;DOC.MISC;2;Jurisdiction death registration Document;Jurisdiction death reg Doc;;ACTIVE;2.61;2.68 +86807-5;Death administrative information;Find;Pt;^Patient;Doc;;DOC.MISC;2;Death administrative information Document;Death admin info Doc;;ACTIVE;2.61;2.68 +86808-3;Provider death registration;Find;Pt;^Patient;Doc;;DOC.MISC;2;Provider death registration Document;Provider death registration Doc;;ACTIVE;2.61;2.68 +86809-1;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NP, NQ;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NP, NQ [CMS Assessment];;;ACTIVE;2.63;2.64 +86810-9;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NS, SS;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NS, SS [CMS Assessment];;;ACTIVE;2.63;2.64 +86811-7;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NO, NSD, ND, NOD, SP, SO, SSD, SD, SOD, NPE;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NO, NSD, ND, NOD, SP, SO, SSD, SD, SOD, NPE [CMS Assessment];;;ACTIVE;2.63;2.64 +86812-5;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NT, ST;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Identification information - NT, ST [CMS Assessment];;;ACTIVE;2.63;2.64 +86813-3;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Hearing, speech, and vision - NO, NOD, SO, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Hearing, speech, and vision - NO, NOD, SO, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +86814-1;MDS v3.0 - RAI v1.17.2 - Staff assessment for mental status - ND, SD, IPA, OSA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Staff assessment for mental status - ND, SD, IPA, OSA during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86815-8;MDS v3.0 - RAI v1.17.2 - Behavior - NP, NQ, ND, SD, SP, IPA, OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Behavior - NP, NQ, ND, SD, SP, IPA, OSA [CMS Assessment];;;ACTIVE;2.63;2.68 +86816-6;MDS v3.0 - RAI v1.17.2 - Functional status - NP, NQ, SP;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Functional status - NP, NQ, SP during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86817-4;MDS v3.0 - RAI v1.17.2 - Functional status - OSA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Functional status - OSA during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86818-2;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Functional status - NSD, NOD, SSD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Functional status - NSD, NOD, SSD, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +8681-9;Symptoms & diseases;Hx;Pt;Neurologic system;Nom;;H&P.HX;2;History of Nervous system disorders;Hx of Neurologic disorders;;ACTIVE;1.0h(3);2.56 +86819-0;MDS v3.0 - RAI v1.17.2 - Functional status - ND, SD;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Functional status - ND, SD during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86820-8;MDS v3.0 - RAI v1.14.1 - Bladder and bowel - NP, NQ, NSD, NOD, SP, SSD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1 - Bladder and bowel - NP, NQ, NSD, NOD, SP, SSD, SOD [CMS Assessment];;;ACTIVE;2.63;2.63 +86821-6;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Active diagnoses - NO, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Active diagnoses - NO, SO [CMS Assessment];;;ACTIVE;2.63;2.64 +86822-4;MDS v3.0 - RAI v1.17.2 - Health conditions - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Health conditions - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.68 +86823-2;MDS v3.0 - RAI v1.17.2 - Health Conditions - NPE;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Health Conditions - NPE during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86824-0;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing &or nutritional status - NO, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing/nutritional status - NO, SO [CMS Assessment];;;ACTIVE;2.63;2.64 +86825-7;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing &or nutritional status - NSD, ND, SSD, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing/nutritional status - NSD, ND, SSD, SD [CMS Assessment];;;ACTIVE;2.63;2.64 +86826-5;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing &or nutritional status - NOD, SP, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Swallowing/nutritional status - NOD, SP, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +8682-7;Symptoms & diseases;Hx;Pt;Nose;Nom;;H&P.HX;2;History of Nose disorders;Hx of Nose disorders;;ACTIVE;1.0h(3);2.56 +86827-3;MDS v3.0 - RAI v1.14.1 - Skin conditions - NO, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1 - Skin conditions - NO, SO [CMS Assessment];;;ACTIVE;2.63;2.63 +86828-1;MDS v3.0 - RAI v1.14.1, v1.15.1 - Skin conditions - NSD, ND, SSD, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Skin conditions - NSD, ND, SSD, SD [CMS Assessment];;;ACTIVE;2.63;2.64 +86829-9;MDS v3.0 - RAI v1.14.1 - Skin conditions - NOD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1 - Skin conditions - NOD, SOD [CMS Assessment];;;ACTIVE;2.63;2.63 +86830-7;MDS v3.0 - RAI v1.17.2 - Skin conditions - NPE;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Skin conditions - NPE [CMS Assessment];;;ACTIVE;2.63;2.68 +86831-5;MDS v3.0 - RAI v1.17.2 - Medications - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medications - OSA [CMS Assessment];;;ACTIVE;2.63;2.68 +86832-3;MDS v3.0 - RAI v1.14.1 - Medications - NSD, ND, SSD, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1 - Medications - NSD, ND, SSD, SD [CMS Assessment];;;ACTIVE;2.63;2.63 +86833-1;Staff assessment of resident mood (PHQ-9-OV) - symptom presence in the last 2W;-;2W;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Staff assessment of resident mood (PHQ-9-OV) - symptom presence in the last 2 weeks [CMS Assessment];;;ACTIVE;2.63;2.74 +86834-9;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NP, NQ;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NP, NQ [CMS Assessment];;;ACTIVE;2.63;2.64 +8683-5;Occupational exposure;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Occupational exposure;Hx of Occupational exposure;;ACTIVE;1.0h(3);2.56 +86835-6;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NS, SS;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NS, SS [CMS Assessment];;;ACTIVE;2.63;2.64 +86836-4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NO, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NO, SO [CMS Assessment];;;ACTIVE;2.63;2.64 +86837-2;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NSD, SSD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NSD, SSD [CMS Assessment];;;ACTIVE;2.63;2.64 +86838-0;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.64 +86839-8;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NOD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - NOD, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +86840-6;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Special treatments, procedures, and programs - SP [CMS Assessment];;;ACTIVE;2.63;2.64 +86841-4;MDS v3.0 - RAI v1.17.2 - Therapies - NP, NQ;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Therapies - NP, NQ [CMS Assessment];;;ACTIVE;2.63;2.68 +86842-2;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Therapies - NS, NSD, SS, SSD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Therapies - NS, NSD, SS, SSD [CMS Assessment];;;ACTIVE;2.63;2.64 +8684-3;Present illness;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Present illness;Hx of Pres illness;;ACTIVE;1.0h(3);2.73 +86843-0;Resident mood interview (PHQ-9) - symptom presence in the last 2W;-;2W;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Resident mood interview (PHQ-9) - symptom presence in the last 2 weeks [CMS Assessment];;;ACTIVE;2.63;2.67 +86844-8;Resident mood interview (PHQ-9) - symptom frequency in the last 2W;-;2W;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Resident mood interview (PHQ-9) - symptom frequency in the last 2 weeks [CMS Assessment];;;ACTIVE;2.63;2.67 +86845-5;MDS v3.0 - RAI v1.17.2 - Therapies - ND;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Therapies - ND [CMS Assessment];;;ACTIVE;2.63;2.68 +86846-3;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Therapies - NOD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Therapies - NOD, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +86847-1;MDS v3.0 - RAI v1.17.2 - Therapies - SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Therapies - SP [CMS Assessment];;;ACTIVE;2.63;2.68 +86848-9;MDS v3.0 - RAI v1.17.2 - Occupational therapy - ND;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Occupational therapy - ND [CMS Assessment];;;ACTIVE;2.63;2.68 +86849-7;MDS v3.0 - RAI v1.17.2 - Respiratory therapy - NP, NQ, SP, IPA, OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Respiratory therapy - NP, NQ, SP, IPA, OSA [CMS Assessment];;;ACTIVE;2.63;2.68 +8685-0;History of psychiatric symptoms & diseases;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Deprecated History of psychiatric symptoms and diseases;Deprecated Psych symptoms & diseases Hx;;DEPRECATED;1.0h(3);2.38 +86850-5;MDS v3.0 - RAI v1.17.2 - Psychological therapy - NP, NQ;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Psychological therapy - NP, NQ [CMS Assessment];;;ACTIVE;2.63;2.68 +86851-3;Invasive mechanical ventilator liberation status at discharge;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Invasive mechanical ventilator liberation status at discharge [CMS Assessment];;;ACTIVE;2.63;2.67 +86852-1;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Participation in assessment and goal setting - NS, NO, SS, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Participation in assessment and goal setting - NS, NO, SS, SO [CMS Assessment];;;ACTIVE;2.63;2.64 +86853-9;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Participation in assessment and goal setting - NSD, NOD, SSD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Participation in assessment and goal setting - NSD, NOD, SSD, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +86854-7;MDS v3.0 - RAI v1.17.2 - Participation in assessment and goal setting - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Participation in assessment and goal setting - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.68 +86855-4;MDS v3.0 - RAI v1.17.2 - Speech-language pathology and audiology services - ND;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Speech-language pathology and audiology services - ND [CMS Assessment];;;ACTIVE;2.63;2.68 +86856-2;MDS v3.0 - RAI v1.14.1 - Nursing home PPS (NP) & Nursing home quarterly (NQ) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home PPS (NP) and Nursing home quarterly (NQ) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86857-0;Flavivirus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Flavivirus neutralizing antibody [Presence] in Specimen by Neutralization test;Flavivirus NAb Spec Ql Nt;;ACTIVE;2.61;2.69 +86858-8;Dengue virus 2 Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Dengue virus 2 neutralizing antibody [Titer] in Specimen by Neutralization test;DENV2 NAb Titr Spec Nt;;ACTIVE;2.61;2.69 +86859-6;Dengue virus 3 Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Dengue virus 3 neutralizing antibody [Titer] in Specimen by Neutralization test;DENV3 NAb Titr Spec Nt;;ACTIVE;2.61;2.69 +86860-4;Dengue virus 1 Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Dengue virus 1 neutralizing antibody [Titer] in Specimen by Neutralization test;DENV1 NAb Titr Spec Nt;;ACTIVE;2.61;2.69 +86861-2;Dengue virus 4 Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Dengue virus 4 neutralizing antibody [Titer] in Specimen by Neutralization test;DENV4 NAb Titr Spec Nt;;ACTIVE;2.61;2.69 +86862-0;Dengue virus 4 Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Dengue virus 4 neutralizing antibody [Presence] in Specimen by Neutralization test;DENV4 NAb Spec Ql Nt;;ACTIVE;2.61;2.69 +86863-8;Dengue virus 3 Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Dengue virus 3 neutralizing antibody [Presence] in Specimen by Neutralization test;DENV3 NAb Spec Ql Nt;;ACTIVE;2.61;2.69 +86864-6;Dengue virus 2 Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Dengue virus 2 neutralizing antibody [Presence] in Specimen by Neutralization test;DENV2 NAb Spec Ql Nt;;ACTIVE;2.61;2.69 +86865-3;Dengue virus 1 Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Dengue virus 1 neutralizing antibody [Presence] in Specimen by Neutralization test;DENV1 NAb Spec Ql Nt;;ACTIVE;2.61;2.69 +86866-1;MDS v3.0 - RAI v1.17.2 - Urinary toileting program - NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Urinary toileting program - NP, NQ, SP [CMS Assessment];;;ACTIVE;2.63;2.68 +86867-9;MDS v3.0 - RAI v1.14.1, v1.15.1 - Health conditions - NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Health conditions - NP, NQ, SP [CMS Assessment];;;ACTIVE;2.63;2.64 +8686-8;Symptoms & diseases;Hx;Pt;Respiratory system;Nom;;H&P.HX;2;History of Respiratory system disorders;Hx of Respiratory disorders;;ACTIVE;1.0h(3);2.56 +86868-7;MDS v3.0 - RAI v1.17.2 - Other health conditions - NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Other health conditions - NP, NQ, SP [CMS Assessment];;;ACTIVE;2.63;2.68 +86869-5;MDS v3.0 - RAI v1.17.2 - Hearing, speech, and vision - ND, SD;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Hearing, speech, and vision - ND, SD during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86870-3;MDS v3.0 - RAI v1.14.1 - Nursing home & Swing bed OMRA (NO & SO) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home and Swing bed OMRA (NO/SO) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86871-1;MDS v3.0 - RAI v1.14.1 - Nursing home OMRA start of therapy and discharge (NSD) & Swing bed OMRA start of therapy and discharge (SSD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home OMRA start of therapy and discharge (NSD) and Swing bed OMRA start of therapy and discharge (SSD) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86872-9;MDS v3.0 - RAI v1.14.1 - Nursing home discharge (ND) & Swing bed discharge (SD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home discharge (ND) and Swing bed discharge (SD) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86873-7;MDS v3.0 - RAI v1.14.1 - Nursing home OMRA-discharge (NOD) & Swing bed OMRA-discharge (SOD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home OMRA-discharge (NOD) and Swing bed OMRA-discharge (SOD) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86874-5;MDS v3.0 - RAI v1.14.1 - Nursing home & Swing bed OMRA start of therapy (NS & SS) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home and Swing bed OMRA start of therapy (NS/SS) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86875-2;MDS v3.0 - RAI v1.14.1 - Nursing home & Swing bed tracking (NT & ST) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home and Swing bed tracking (NT/ST) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +8687-6;Review of systems;Find;Pt;^Patient;Nom;Reported;H&P.HX;2;Review of systems - Reported;Review of systems;;ACTIVE;1.0h(3);2.73 +86876-0;MDS v3.0 - RAI v1.14.1 - Swing bed PPS (SP) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Swing bed PPS (SP) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86877-8;MDS v3.0 - RAI v1.14.1 - Nursing home part A PPS discharge (NPE) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.14.1 - Nursing home part A PPS discharge (NPE) item set [CMS Assessment];;;DEPRECATED;2.63;2.73 +86878-6;MDS v3.0 - RAI v1.14.1 - Bladder and bowel - NS, NO, SS, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1 - Bladder and bowel - NS, NO, SS, SO [CMS Assessment];;;ACTIVE;2.63;2.63 +86879-4;MDS v3.0 - RAI v1.16.1 - Bladder and bowel - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Bladder and bowel - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.7 +86880-2;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - self-performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - self-performance during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86881-0;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - support provided;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - support provided during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86882-8;MDS v3.0 - RAI v1.16.1 - Cognitive patterns - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Cognitive patterns - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.7 +86883-6;MDS v3.0 - RAI v1.14.1, v1.15.1 - Cognitive patterns - NO, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1 - Cognitive patterns - NO, SO [CMS Assessment];;;ACTIVE;2.63;2.64 +8688-4;Symptoms & diseases;Hx;Pt;Reproductive system;Nom;;H&P.HX;2;History of Reproductive system disorders;Hx of Reproductive disorders;;ACTIVE;1.0h(3);2.56 +86884-4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Activities of daily living (ADL) assistance - support provided - NSD, NOD, SSD, SOD;-;7D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Activities of daily living (ADL) assistance - support provided - NSD, NOD, SSD, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +86885-1;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - self-performance - OSA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - self-performance - OSA during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86886-9;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - support provided - OSA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Activities of daily living (ADL) assistance - support provided - OSA during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86887-7;MDS v3.0 - RAI v1.17.2 - Bathing - ND, SD;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Bathing - ND, SD during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86888-5;MDS v3.0 - RAI v1.17.2 - Health conditions - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Health conditions - OSA [CMS Assessment];;;ACTIVE;2.63;2.68 +86889-3;MDS v3.0 - RAI v1.17.2 - Other health conditions - IPA, OSA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Other health conditions - IPA, OSA during assessment period [CMS Assessment];;;ACTIVE;2.63;2.7 +86890-1;MDS v3.0 - RAI v1.17.2 - Other health conditions - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Other health conditions - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.68 +86891-9;Staff assessment of resident mood (PHQ-9-OV) - symptom frequency in the last 2W;-;2W;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Staff assessment of resident mood (PHQ-9-OV) - symptom frequency in the last 2 weeks [CMS Assessment];;;ACTIVE;2.63;2.74 +8689-2;Social function;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Social function;Hx of Social function;;ACTIVE;1.0h(3);2.56 +86892-7;MDS v3.0 - RAI v1.17.2 - Current number of unhealed pressure injuries at each stage - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Current number of unhealed pressure injuries at each stage - IPA [CMS Assessment];;;ACTIVE;2.63;2.68 +86893-5;MDS v3.0 - RAI v1.17.2 - Physical therapy - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Physical therapy - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.68 +86894-3;Adalimumab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Adalimumab [Mass/volume] in Serum or Plasma by Immunoassay;Adalimumab SerPl IA-mCnc;;ACTIVE;2.63;2.63 +86895-0;Adalimumab Ab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Adalimumab Ab [Mass/volume] in Serum or Plasma by Immunoassay;Adalimumab Ab SerPl IA-mCnc;;ACTIVE;2.63;2.63 +86896-8;inFLIXimab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;inFLIXimab [Mass/volume] in Serum or Plasma by Immunoassay;inFLIXimab SerPl IA-mCnc;;ACTIVE;2.63;2.63 +86897-6;inFLIXimab Ab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;inFLIXimab Ab [Mass/volume] in Serum or Plasma by Immunoassay;inFLIXimab Ab SerPl IA-mCnc;;ACTIVE;2.63;2.63 +86898-4;Vedolizumab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Vedolizumab [Mass/volume] in Serum or Plasma by Immunoassay;Vedolizumab SerPl IA-mCnc;;ACTIVE;2.63;2.73 +86899-2;Vedolizumab Ab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Vedolizumab Ab [Mass/volume] in Serum or Plasma by Immunoassay;Vedolizumab Ab SerPl IA-mCnc;;ACTIVE;2.63;2.73 +86-9;Cefaclor;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefaclor [Susceptibility] by Serum bactericidal titer;Cefaclor Titr SBT;;ACTIVE;1.0;2.32 +8690-0;Surgical procedures;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Surgical procedures;Hx of Surg proc;;ACTIVE;1.0h(3);2.73 +86900-8;Plasma cells.monotypic population;Prid;Pt;Bld;Nom;Flow cytometry;HEM/BC;1;Plasma cells monotypic population [Identifier] in Blood by Flow cytometry (FC);Monotypic plasma cells Bld FC;;ACTIVE;2.63;2.63 +86901-6;Length;Len;Pt;Pressure injury.largest stage 3 or 4;Qn;CMS Assessment;SURVEY.CMS;4;Length Pressure injury.largest stage 3 or 4 [CMS Assessment];;;ACTIVE;2.63;2.63 +86902-4;Width;Len;Pt;Pressure injury.largest stage 3 or 4;Qn;CMS Assessment;SURVEY.CMS;4;Width Pressure injury.largest stage 3 or 4 [CMS Assessment];;;ACTIVE;2.63;2.63 +86903-2;Tissue type;Type;Pt;Pressure injury.most advanced stage;Nom;CMS Assessment;SURVEY.CMS;4;Tissue type Pressure injury.most advanced stage [CMS Assessment];;;ACTIVE;2.63;2.63 +86904-0;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldA;Qn;Pulse oximetry;PULM;2;Carboxyhemoglobin/Hemoglobin.total in Arterial blood by Pulse oximetry;COHgb % BldA PulseOx;;ACTIVE;2.63;2.63 +86905-7;Outcome and assessment information set (OASIS) form - version C2;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Outcome and assessment information set (OASIS) form - version C2 [CMS Assessment];;;DEPRECATED;2.63;2.73 +86906-5;Chronic kidney disease education topic(s) discussed during this visit;Type;Pt;^Patient;Nom;;CLIN;2;Chronic kidney disease education topic(s) discussed during this visit;CKD educ topic(s) discussed;;ACTIVE;2.63;2.63 +86907-3;Provider's perception of patient comprehension of discussion;Find;Pt;^Patient;Nom;;CLIN;2;Provider's perception of patient comprehension of discussion;Prov percept pt comprehension;;ACTIVE;2.63;2.63 +86908-1;Intravascular systolic goal;Pres;Pt;Arterial system;Qn;;CLIN;2;Systolic blood pressure goal;BP sys goal;;ACTIVE;2.63;2.63 +86909-9;Intravascular diastolic goal;Pres;Pt;Arterial system;Qn;;CLIN;2;Diastolic blood pressure goal;BP dias goal;;ACTIVE;2.63;2.63 +86910-7;Hemoglobin A1c/Hemoglobin.total goal;MFr;Pt;Bld;Qn;;CLIN;2;Hemoglobin A1c/Hemoglobin.total goal Blood;Hgb A1c goal MFr Bld;;ACTIVE;2.63;2.63 +86911-5;Cholesterol.in LDL goal;MCnc;Pt;Ser/Plas;Qn;;CLIN;2;Cholesterol in LDL goal [Mass/volume] Serum or Plasma;LDLc goal mCnc SerPl;;ACTIVE;2.63;2.63 +86912-3;Hemoglobin goal;MCnc;Pt;Bld;Qn;;CLIN;2;Hemoglobin goal [Mass/volume] Blood;Hgb goal mCnc Bld;;ACTIVE;2.63;2.63 +86913-1;Iron saturation goal;MFr;Pt;Ser/Plas;Qn;;CLIN;2;Iron saturation goal Serum or Plasma;Iron Satn goal MFr SerPl;;ACTIVE;2.63;2.63 +86914-9;Ferritin goal;MCnc;Pt;Ser/Plas;Qn;;CLIN;2;Ferritin goal [Mass/volume] Serum or Plasma;Ferritin goal mCnc SerPl;;ACTIVE;2.63;2.63 +86915-6;Calcium goal;MCnc;Pt;Ser/Plas;Qn;;CLIN;2;Calcium goal [Mass/volume] Serum or Plasma;Calcium goal mCnc SerPl;;ACTIVE;2.63;2.63 +86916-4;Phosphate goal;MCnc;Pt;Ser/Plas;Qn;;CLIN;2;Phosphate goal [Mass/volume] Serum or Plasma;Phosphate goal mCnc SerPl;;ACTIVE;2.63;2.63 +86917-2;Parathyrin.intact goal;MCnc;Pt;Ser/Plas;Qn;;CLIN;2;Parathyrin.intact goal [Mass/volume] Serum or Plasma;PTH-Intact goal mCnc SerPl;;ACTIVE;2.63;2.63 +8691-8;Travel;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Travel;Hx of Travel;;ACTIVE;1.0h(3);2.73 +86918-0;Calcidiol+ercalcidiol goal;MCnc;Pt;Ser/Plas;Qn;;CLIN;2;25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 goal [Mass/volume] Serum or Plasma;25(OH)D3+25(OH)D2 goal mCnc SerPl;;ACTIVE;2.63;2.69 +86919-8;Potassium goal;SCnc;Pt;Ser/Plas;Qn;;CLIN;2;Potassium goal [Moles/volume] Serum or Plasma;Potassium goal sCnc SerPl;;ACTIVE;2.63;2.63 +86920-6;Bicarbonate goal;SCnc;Pt;Bld;Qn;;CLIN;2;Bicarbonate goal [Moles/volume] Blood;HCO3 goal sCnc Bld;;ACTIVE;2.63;2.63 +86921-4;Albumin goal;MCnc;Pt;Ser/Plas;Qn;;CLIN;2;Albumin goal [Mass/volume] Serum or Plasma;Albumin goal mCnc SerPl;;ACTIVE;2.63;2.63 +86922-2;Therapeutic goals panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Therapeutic goals panel;Therapeutic goals pnl;;ACTIVE;2.63;2.63 +86923-0;Kansas City Cardiomyopathy Questionnaire - 12 item;-;Pt;^Patient;-;KCCQ-12;PANEL.SURVEY.GNHLTH;4;Kansas City Cardiomyopathy Questionnaire - 12 item [KCCQ-12];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.63;2.72 +86924-8;Overall summary score;Score;Pt;^Patient;Qn;KCCQ-12;SURVEY.GNHLTH;4;Overall summary score [KCCQ-12];;Copyright © 1996-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.63;2.63 +86925-5;Lawsonia intracellularis Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Lawsonia intracellularis Ab [Presence] in Serum by Immunoassay;L intracell Ab Ser Ql IA;;ACTIVE;2.63;2.63 +8692-6;Symptoms & diseases;Hx;Pt;Urinary tract;Nom;;H&P.HX;2;History of Urinary tract disorders;Hx of Urinary disorders;;ACTIVE;1.0h(3);2.56 +86926-3;Transmissible gastroenteritis virus Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Transmissible gastroenteritis virus Ab/Negative control in Serum by Immunoassay;TGEV Ab Ser IA;;ACTIVE;2.63;2.63 +86927-1;Porcine respiratory coronavirus Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Porcine respiratory coronavirus Ab/Negative control in Serum by Immunoassay;PRCoV Ab Ser IA;;ACTIVE;2.63;2.63 +86928-9;Porcine epidemic diarrhea virus whole genome;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine epidemic diarrhea virus whole genome [Nucleotide sequence] in Isolate by Sequencing;PEDV whole genome Islt-Seq;;ACTIVE;2.63;2.63 +86929-7;Lawsonia intracellularis Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Lawsonia intracellularis Ab/Negative control in Serum by Immunoassay;L intracell Ab Ser IA;;ACTIVE;2.63;2.63 +86930-5;Carbapenemase;PrThr;Pt;Isolate;Ord;;MICRO;1;Carbapenemase [Presence] in Isolate;Carbapenemase Islt Ql;;ACTIVE;2.63;2.63 +86931-3;Metanephrine, Normetanephrine & Creatinine panel;-;24H;Urine;-;;PANEL.DRUG/TOX;1;Metanephrine, Normetanephrine and Creatinine panel - 24 hour Urine;Metanephs+Creat pnl 24h Ur;;ACTIVE;2.63;2.63 +86932-1;I am confident that I can follow through on medical treatments I may need to do at home;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can follow through on medical treatments I may need to do at home [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86933-9;Patient Activation Measure - 13;-;Pt;^Patient;-;PAM;PANEL.SURVEY.GNHLTH;4;Patient Activation Measure - 13 [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +8693-4;Mental status;Find;Pt;^Patient;Nom;Observed;H&P.PX;2;Mental status;Mental status;;ACTIVE;1.0h(3);2.73 +86934-7;I am confident I can figure out solutions when new problems arise with my health;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I am confident I can figure out solutions when new problems arise with my health [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86935-4;I know how to prevent problems with my health;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I know how to prevent problems with my health [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86936-2;I have been able to maintain (keep up with) lifestyle changes, like eating right or exercising;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I have been able to maintain (keep up with) lifestyle changes, like eating right or exercising [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86937-0;I know what treatments are available for my health problems;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I know what treatments are available for my health problems [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86938-8;Taking an active role in my own health care is the most important thing that affects my health;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;Taking an active role in my own health care is the most important thing that affects my health [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86939-6;I am confident that I can maintain lifestyle changes, like eating right and exercising, even during times of stress;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can maintain lifestyle changes, like eating right and exercising, even during times of stress [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86940-4;I am confident that I can tell a doctor concerns I have even when he or she does not ask;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can tell a doctor concerns I have even when he or she does not ask [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86941-2;I am confident that I can tell whether I need to go to the doctor or whether I can take care of a health problem myself;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can tell whether I need to go to the doctor or whether I can take care of a health problem myself [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +8694-2;Physical findings;Find;Pt;Abdomen;Nom;Observed;H&P.PX;2;Physical findings of Abdomen;Phys find Abd;;ACTIVE;1.0h(3);2.27 +86942-0;I know what each of my prescribed medications do;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I know what each of my prescribed medications do [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86943-8;I am confident I can help prevent or reduce problems associated with my health;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I am confident I can help prevent or reduce problems associated with my health [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86944-6;When all is said and done, I am the person who is responsible for taking care of my health;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;When all is said and done, I am the person who is responsible for taking care of my health [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86945-3;I understand my health problems and what causes them;Find;Pt;^Patient;Ord;PAM;SURVEY.GNHLTH;4;I understand my health problems and what causes them [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86946-1;Patient Activation Measure - 10;-;Pt;^Patient;-;PAM;PANEL.SURVEY.GNHLTH;4;Patient Activation Measure - 10 [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +86947-9;Reason for hospitalization;Type;Pt;^Patient;Nom;;H&P.HX;2;Reason for hospitalization;Reason for hospitalization;;ACTIVE;2.63;2.66 +86948-7;Date treatment or therapy started;Date;Pt;^Patient;Qn;;H&P.HX;2;Deprecated Date treatment or therapy started;Deprecated Date treatment or therapy started;;DEPRECATED;2.63;2.66 +86949-5;Trichomonas vaginalis & Mycoplasma genitalium DNA panel;-;Pt;XXX;-;;PANEL.MICRO;1;Trichomonas vaginalis and Mycoplasma genitalium DNA panel - Specimen;TV + MG DNA Pnl Spec;;ACTIVE;2.63;2.69 +86950-3;Thymus Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Thymus IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;Thymus IgG Titr SerPl IF;;ACTIVE;2.63;2.63 +86951-1;Lipoprotein associated phospholipase A2;CCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lipoprotein associated phospholipase A2 [Enzymatic activity/volume] in Serum or Plasma;Lp-PLA2 SerPl-cCnc;;ACTIVE;2.63;2.73 +86952-9;Preliminary testing done;PrThr;Pt;Specimen;Ord;;DOC.PUBLICHEALTH;2;Preliminary testing done Specimen;Preliminary testing done Spec;;ACTIVE;2.63;2.63 +86953-7;Preliminary testing result;Find;Pt;Specimen;Nom;;DOC.PUBLICHEALTH;2;Preliminary testing result Specimen;Preliminary testing result Spec;;ACTIVE;2.63;2.63 +86954-5;Foreign material;PrThr;Pt;Food;Ord;;MICRO;1;Foreign material [Presence] in Food;Foreign material Food Ql;;ACTIVE;2.63;2.63 +86955-2;Preliminary testing affected submission for further testing;PrThr;Pt;Specimen;Ord;;DOC.PUBLICHEALTH;2;Preliminary testing affected submission for further testing Specimen;Prelim test affect further test Spec;;ACTIVE;2.63;2.63 +86956-0;(Multisection^WO contrast) + (Multisection for left ventricular function^W contrast IV);Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart WO contrast IV and CT Heart for left ventricular function W contrast IV;CT Hrt;;ACTIVE;2.63;2.63 +86957-8;Multisection^WO & W contrast IV;Find;Pt;Head>Salivary gland;Doc;CT;RAD;2;CT Salivary gland WO and W contrast IV;CT Salivary gland WO+W contr IV;;ACTIVE;2.63;2.63 +86958-6;Multisection^WO & W contrast IV;Find;Pt;Neck+Chest;Doc;CT;RAD;2;CT Neck and Chest WO and W contrast IV;CT Neck+Chest WO+W contr IV;;ACTIVE;2.63;2.63 +8695-9;Physical findings;Find;Pt;Back;Nom;Observed;H&P.PX;2;Physical findings of Back;Phys find Back;;ACTIVE;1.0h(3);2.27 +86959-4;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;CT;RAD;2;CT Cervical and thoracic spine WO and W contrast IV;CT C+T-spine WO+W contr IV;;ACTIVE;2.63;2.63 +86960-2;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - right W contrast IV;CTA UE ves-R W contr IV;;ACTIVE;2.63;2.63 +86961-0;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - left W contrast IV;CTA UE ves-L W contr IV;;ACTIVE;2.63;2.63 +86962-8;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - bilateral W contrast IV;CTA UE ves-Bl W contr IV;;ACTIVE;2.63;2.63 +86963-6;Multisection^W contrast IV;Find;Pt;Lower extremity.right>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - right W contrast IV;CTA LE ves-R W contr IV;;ACTIVE;2.63;2.63 +86964-4;Multisection^W contrast IV;Find;Pt;Lower extremity.left>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - left W contrast IV;CTA LE ves-L W contr IV;;ACTIVE;2.63;2.63 +86965-1;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels - bilateral W contrast IV;CTA LE ves-Bl W contr IV;;ACTIVE;2.63;2.63 +86966-9;Multisection^WO contrast;Find;Pt;Head>Salivary gland;Doc;CT;RAD;2;CT Salivary gland WO contrast;CT Salivary gland WO contr;;ACTIVE;2.63;2.63 +8696-7;Physical findings;Find;Pt;Breasts;Nom;Observed;H&P.PX;2;Physical findings of Breasts;Phys find Brsts;;ACTIVE;1.0h(3);2.27 +86967-7;Multisection^WO Contrast;Find;Pt;Lower extremity.bilateral>Foot;Doc;CT;RAD;2;CT Foot - bilateral WO contrast;CT Foot-Bl WO contr;;ACTIVE;2.63;2.63 +86968-5;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Hand;Doc;CT;RAD;2;CT Hand - bilateral W contrast IV;CT Hand-Bl W contr IV;;ACTIVE;2.63;2.63 +86969-3;Multisection^W contrast IV;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;CT;RAD;2;CT Shoulder - bilateral W contrast IV;CT Shoulder-Bl W contr IV;;ACTIVE;2.63;2.63 +86970-1;Multisection^WO contrast;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;CT;RAD;2;CT Sacrum and Coccyx WO contrast;CT Sacrum+Coccyx WO contr;;ACTIVE;2.63;2.63 +86971-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Chest vessels & Abdomen>Abdominal vessels;Doc;CT.angio;RAD;2;CTA Chest and abdominal vessels WO and W contrast IV;CTA Chest+Abd ves WO+W contr IV;;ACTIVE;2.63;2.63 +86972-7;Multisection^WO & W contrast IV;Find;Pt;Head+Neck;Doc;CT;RAD;2;CT Head and Neck WO and W contrast IV;CT Head+Neck WO+W contr IV;;ACTIVE;2.63;2.63 +86973-5;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Foot;Doc;CT;RAD;2;CT Foot - bilateral W contrast IV;CT Foot-Bl W contr IV;;ACTIVE;2.63;2.63 +86974-3;Multisection^WO & W contrast IV;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Thoracic and lumbar spine WO and W contrast IV;CT T+L-Spine WO+W contr IV;;ACTIVE;2.63;2.63 +8697-5;Physical findings;Find;Pt;Neurologic deep tendon reflexes;Nom;Observed;H&P.PX;2;Physical findings of Neurologic deep tendon reflexes;Phys find Deep tendon reflexes;;ACTIVE;1.0h(3);2.27 +86975-0;Multisection for left ventricular function^W contrast IV;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart for left ventricular function W contrast IV;CT Hrt LV function W contr IV;;ACTIVE;2.63;2.63 +86976-8;Multisection metabolic^W radionuclide IV;Find;Pt;Head>Brain;Doc;PT+CT;RAD;2;PET+CT Brain metabolic;PET+CT Brain metabolic W RNC IV;;ACTIVE;2.63;2.63 +86977-6;Multisection^W contrast IV;Find;Pt;Head & Head>Temporal bone;Doc;CT;RAD;2;CT Head and Temporal bone W contrast IV;CT Head+Temporal bone W contr IV;;ACTIVE;2.63;2.63 +86978-4;Multisection^W contrast IV;Find;Pt;Head & Head>Sinuses;Doc;CT;RAD;2;CT Head and Sinuses W contrast IV;CT Head+Sinuses W contr IV;;ACTIVE;2.63;2.63 +86979-2;Multisection^WO contrast;Find;Pt;Pelvis & Lower extremity.bilateral>Hip;Doc;CT;RAD;2;CT Pelvis and Hip - bilateral WO contrast;CT Pelvis and Hip-Bl WO contr;;ACTIVE;2.63;2.63 +869-8;A3 B Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated A3 B Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated A3 B Ab SerPl BPU Ql;;DEPRECATED;1.0;2.4 +86980-0;Multisection^WO & W Contrast IV;Find;Pt;Chest>Heart+Coronary arteries;Doc;CT.angio;RAD;2;CTA Heart and Coronary arteries WO and W contrast IV;CTA Hrt+CA WO+W contr IV;;ACTIVE;2.63;2.63 +86981-8;Multisection;Find;Pt;Chest>Chest vessels;Doc;CT.angio;RAD;2;CTA Chest vessels;CTA Chest ves;;ACTIVE;2.63;2.63 +86982-6;Multisection^W contrast IV;Find;Pt;Chest>Chest vessels & Abdomen>Abdominal vessels;Doc;CT.angio;RAD;2;CTA Chest and abdominal vessels W contrast IV;CTA Chest+Abd ves W contr IV;;ACTIVE;2.63;2.63 +8698-3;Physical findings;Find;Pt;Ear;Nom;Observed;H&P.PX;2;Physical findings of Ear;Phys find Ear;;ACTIVE;1.0h(3);2.27 +86983-4;Multisection^W contrast IV;Find;Pt;Chest>Chest vessels & Abdomen>Abdominal vessels & Pelvis>Pelvis vessels;Doc;CT.angio;RAD;2;CTA Chest vessels and Abdominal vessels and Pelvis vessels W contrast IV;CTA Chest+Abd+Pelv ves W contr IV;;ACTIVE;2.63;2.63 +86984-2;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Cervical and thoracic and lumbar spine W contrast IV;CT C+T+L-spine W contr IV;;ACTIVE;2.63;2.63 +86985-9;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;CT;RAD;2;CT Cervical and thoracic spine W contrast IV;CT C+T-spine W contr IV;;ACTIVE;2.63;2.63 +86986-7;Multisection^W contrast IV;Find;Pt;Neck+Chest;Doc;CT;RAD;2;CT Neck and Chest W contrast IV;CT Neck+Chest W contr IV;;ACTIVE;2.63;2.63 +86987-5;Multisection^WO contrast;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Cervical and thoracic and lumbar spine WO contrast;CT C+T+L-spine WO contr;;ACTIVE;2.63;2.63 +86988-3;Multisection^WO contrast;Find;Pt;Head>Orbit+Face;Doc;CT;RAD;2;CT Orbit and Face WO contrast;CT Orbit+Face WO contr;;ACTIVE;2.63;2.63 +86989-1;Multisection^W contrast IV;Find;Pt;Head & Head>Orbit.bilateral;Doc;CT;RAD;2;CT Head and Orbit - bilateral W contrast IV;CT Head+Orbit-Bl W contr IV;;ACTIVE;2.63;2.63 +86990-9;Multisection^WO contrast;Find;Pt;Head & Head>Orbit.bilateral;Doc;CT;RAD;2;CT Head and Orbit - bilateral WO contrast;CT Head+Orbit-Bl WO contr;;ACTIVE;2.63;2.63 +8699-1;Physical findings;Find;Pt;Eye;Nom;Observed;H&P.PX;2;Physical findings of Eye;Phys find Eye;;ACTIVE;1.0h(3);2.27 +86991-7;Multisection^WO contrast;Find;Pt;Head & Head>Maxillofacial region & Neck>Spine.cervical;Doc;CT;RAD;2;CT Head and Maxillofacial region and Cervical spine WO contrast;CT Head+Maxillofacial+C-spine WO contr;;ACTIVE;2.63;2.63 +86992-5;Multisection^WO contrast;Find;Pt;Head & Head>Sinuses;Doc;CT;RAD;2;CT Head and Sinuses WO contrast;CT Head+Sinuses WO contr;;ACTIVE;2.63;2.63 +86993-3;Guidance 1 level for kyphoplasty;Find;Pt;XXX>Spine vertebra;Doc;{Imaging modality};RAD;2;Guidance for 1 level kyphoplasty of Spine vertebra;Guided Vertebra Kyphoplasty 1 level;;ACTIVE;2.63;2.64 +86994-1;Guidance 1 or 2 for injection of trigger point;Find;Pt;XXX>Muscle;Doc;{Imaging modality};RAD;2;Guidance for 1 or 2 injections of trigger point of Muscle;Guided Muscle Trigger pt inject 1-2;;ACTIVE;2.63;2.64 +86995-8;Guidance for abscess;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for abscess;Guided Unsp region Abscess;;ACTIVE;2.63;2.64 +86996-6;Guidance additional for augmentation;Find;Pt;XXX>Spine vertebra;Doc;{Imaging modality};RAD;2;Guidance for additional augmentation of Spine vertebra;Guided Vertebra Augmentation addl;;ACTIVE;2.63;2.64 +86997-4;Guidance additional day for infusion of thrombolytic^W thrombolytic via catheter;Find;Pt;XXX>Vessel;Doc;{Imaging modality};RAD;2;Guidance for additional day infusion of thrombolytic of Vessel-- W thrombolytic via catheter;Guided Throm inf add day W throm in cath;;ACTIVE;2.63;2.64 +86998-2;Guidance additional for percutaneous mechanical thrombectomy;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for additional percutaneous mechanical thrombectomy of Vein;Guided Vein Mech thromb addl;;ACTIVE;2.63;2.64 +86999-0;Guidance additional for percutaneous mechanical thrombectomy;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for additional percutaneous mechanical thrombectomy of Artery;Guided Artery Mech thromb addl;;ACTIVE;2.63;2.64 +87000-6;Guidance additional for placement of endovascular device;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for additional placement of endovascular device of Vein;Guided Vein Endovasc device place addl;;ACTIVE;2.63;2.64 +87001-4;Guidance additional for placement of stent;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for additional placement of stent of Artery;Guided Artery Stent place addl;;ACTIVE;2.63;2.64 +87002-2;Guidance additional for placement of wire;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for additional placement of wire;Guided Unsp region Wire place addl;;ACTIVE;2.63;2.64 +87003-0;Guidance additional for vertebroplasty;Find;Pt;XXX>Spine vertebra;Doc;{Imaging modality};RAD;2;Guidance for additional vertebroplasty of Spine vertebra;Guided Vertebra Vertebroplasty addl;;ACTIVE;2.63;2.64 +87004-8;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Joint.intermediate;Doc;{Imaging modality};RAD;2;Guidance for arthrocentesis of Intermediate joint;Guided Intermediate joint Arthrocentesis;;ACTIVE;2.63;2.66 +87005-5;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Joint.major;Doc;{Imaging modality};RAD;2;Guidance for arthrocentesis of Major joint;Guided Major joint Arthrocentesis;;ACTIVE;2.63;2.66 +87006-3;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Joint.small;Doc;{Imaging modality};RAD;2;Guidance for arthrocentesis of Small joint;Guided Small joint Arthrocentesis;;ACTIVE;2.63;2.66 +8700-7;Physical findings;Find;Pt;Genitourinary tract;Nom;Observed;H&P.PX;2;Physical findings of Genitourinary tract;Phys find GU Tract;;ACTIVE;1.0h(3);2.27 +87007-1;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Joint;Doc;{Imaging modality};RAD;2;Guidance for arthrocentesis of Joint;Guided Joint Arthrocentesis;;ACTIVE;2.63;2.66 +87008-9;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Bone marrow;Doc;{Imaging modality};RAD;2;Guidance for fluid aspiration of Bone marrow;Guided Bone mar PC fluid asp;;ACTIVE;2.63;2.64 +87009-7;Guidance for percutaneous aspiration of cyst;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for aspiration of cyst;Guided Unsp region Cyst asp;;ACTIVE;2.63;2.64 +87010-5;Guidance for percutaneous aspiration of cyst;Find;Pt;XXX>Bone;Doc;{Imaging modality};RAD;2;Guidance for aspiration of cyst of Bone;Guided Bone Cyst asp;;ACTIVE;2.63;2.64 +87011-3;Guidance for percutaneous aspiration of ganglion cyst;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for aspiration of ganglion cyst;Guided Unsp region Gang cyst asp;;ACTIVE;2.63;2.64 +87012-1;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Lymph node;Doc;{Imaging modality};RAD;2;Guidance for fluid aspiration of Lymph node;Guided LN PC fluid asp;;ACTIVE;2.63;2.64 +87013-9;Guidance for percutaneous biopsy;Find;Pt;XXX>Bone;Doc;{Imaging modality};RAD;2;Guidance for percutaneous biopsy of Bone;Guided Bone Bx;;ACTIVE;2.63;2.64 +87014-7;Guidance for percutaneous biopsy;Find;Pt;XXX>Bone marrow;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Bone marrow;Guided Bone mar Bx;;ACTIVE;2.63;2.64 +8701-5;Physical findings;Find;Pt;Head;Nom;Observed;H&P.PX;2;Physical findings of Head;Phys find Head;;ACTIVE;1.0h(3);2.27 +87015-4;Guidance for percutaneous biopsy;Find;Pt;XXX>Lymph node;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Lymph node;Guided LN Bx;;ACTIVE;2.63;2.64 +87016-2;Guidance for percutaneous biopsy;Find;Pt;XXX>Soft tissue;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Soft tissue;Guided Soft tiss Bx;;ACTIVE;2.63;2.64 +87017-0;Guidance for check of drainage catheter for abscess;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for check of drainage catheter for abscess;Guided Unsp region Absc drain cath check;;ACTIVE;2.63;2.64 +87018-8;Guidance for deep biopsy;Find;Pt;XXX>Bone;Doc;{Imaging modality};RAD;2;Guidance for deep biopsy of Bone;Guided Bone Deep Bx;;ACTIVE;2.63;2.64 +87019-6;Guidance for drainage+placement of drainage catheter;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for drainage and placement of drainage catheter;Guided Unsp region Drain+cath place;;ACTIVE;2.63;2.66 +87020-4;Guidance for embolization;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for embolization of Artery;Guided Artery Embol;;ACTIVE;2.63;2.64 +87021-2;Guidance for embolization;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for embolization of Vein;Guided Vein Embol;;ACTIVE;2.63;2.64 +87022-0;Guidance for embolization;Find;Pt;XXX>Vessels;Doc;{Imaging modality};RAD;2;Guidance for embolization of Vessels;Guided Vesl Embol;;ACTIVE;2.63;2.64 +8702-3;Physical findings;Find;Pt;Heart;Nom;Observed;H&P.PX;2;Physical findings of Heart;Phys find Hrt;;ACTIVE;1.0h(3);2.27 +87023-8;Guidance for exchange of drainage catheter for abscess;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for exchange of drainage catheter for abscess;Guided Unsp region Absc drain cath exch;;ACTIVE;2.63;2.64 +87024-6;Guidance additional day for infusion of thrombolytic^W thrombolytic via chest tube;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for additional day infusion of thrombolytic of Chest-- W thrombolytic via chest tube;Guided Thromb inf add day W throm via CT;;ACTIVE;2.63;2.64 +87025-3;Guidance additional level for kyphoplasty;Find;Pt;Chest>Spine.thoracic;Doc;{Imaging modality};RAD;2;Guidance for additional level kyphoplasty of Thoracic spine;Guided T-spine Kyphoplasty addl level;;ACTIVE;2.63;2.64 +87026-1;Guidance additional for vertebroplasty;Find;Pt;Chest>Spine.thoracic;Doc;{Imaging modality};RAD;2;Guidance for additional vertebroplasty of Thoracic spine;Guided T-spine Vertebroplasty addl;;ACTIVE;2.63;2.64 +87027-9;Guidance for percutaneous biopsy;Find;Pt;Chest>Pleura;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Chest Pleura;Guided Chest Pleura Bx;;ACTIVE;2.63;2.64 +87028-7;Guidance for percutaneous biopsy;Find;Pt;Chest>Lung;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Lung;Guided Lung Bx;;ACTIVE;2.63;2.64 +87029-5;Guidance for percutaneous biopsy;Find;Pt;Chest>Mediastinum;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Mediastinum;Guided Mediastinum Bx;;ACTIVE;2.63;2.64 +87030-3;Guidance for percutaneous biopsy;Find;Pt;Neck+Chest>Soft tissue;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Neck or Chest Soft tissue;Guided Neck or Chest Soft tissue Bx;;ACTIVE;2.63;2.64 +8703-1;Physical findings;Find;Pt;Extremities;Nom;Observed;H&P.PX;2;Physical findings of Extremities;Phys find Extremities;;ACTIVE;1.0h(3);2.27 +87031-1;Guidance for check of peritoneovenous shunt;Find;Pt;Chest+Abdomen;Doc;{Imaging modality};RAD;2;Guidance for check of peritoneovenous shunt of Chest and Abdomen;Guided Chest+Abd PV shunt check;;ACTIVE;2.63;2.64 +87032-9;Guidance for cryoablation;Find;Pt;Chest>Lung;Doc;{Imaging modality};RAD;2;Guidance for cryoablation of Lung;Guided Lung Cryoablation;;ACTIVE;2.63;2.64 +87033-7;Guidance for drainage+placement of chest tube;Find;Pt;Chest>Pleural space;Doc;{Imaging modality};RAD;2;Guidance for drainage and placement of chest tube of Pleural space;Guided Pl space Drain+CT place;;ACTIVE;2.63;2.66 +87034-5;Guidance for exchange of catheter portion only of central venous catheter with port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for exchange of catheter portion only of CV catheter with port of Chest;Guided Chest Cath part of CVC exch;;ACTIVE;2.63;2.64 +87035-2;Guidance for exchange of central venous catheter with port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for exchange of CV catheter with port of Chest;Guided Chest CVC w port exch;;ACTIVE;2.63;2.64 +87036-0;Guidance additional level for kyphoplasty;Find;Pt;Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for additional level kyphoplasty of Lumbar spine;Guided L-spine Kyphoplasty addl level;;ACTIVE;2.63;2.64 +87037-8;Guidance additional for placement of stent;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;{Imaging modality};RAD;2;Guidance for additional placement of stent of Iliac artery;Guided Iliac a Stent place addl;;ACTIVE;2.63;2.64 +87038-6;Guidance additional for percutaneous transluminal angioplasty;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;{Imaging modality};RAD;2;Guidance for additional transluminal angioplasty of Iliac artery;Guided Iliac a PTA addl;;ACTIVE;2.63;2.64 +87039-4;Guidance additional for vertebroplasty;Find;Pt;Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for additional vertebroplasty of Lumbar spine;Guided L-spine Vertebroplasty addl;;ACTIVE;2.63;2.64 +87040-2;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for aspiration of cyst of Kidney;Guided Kidney Cyst asp;;ACTIVE;2.63;2.64 +87041-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for percutaneous biopsy of Kidney;Guided Kidney Bx;;ACTIVE;2.63;2.64 +87042-8;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for percutaneous biopsy of Liver;Guided Liver Bx;;ACTIVE;2.63;2.64 +87043-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen+Pelvis>Ureter;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Ureter;Guided Ureter Bx;;ACTIVE;2.63;2.64 +87044-4;Guidance for check of tube;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for check of tube of Biliary ducts;Guided BDs Tube check;;ACTIVE;2.63;2.64 +87045-1;Guidance for cholangioscopy+removal of calculus;Find;Pt;Abdomen>Gallbladder;Doc;{Imaging modality};RAD;2;Guidance for cholangioscopy and removal of calculus of Gallbladder;Guided GB Cholangioscopy+calc removal;;ACTIVE;2.63;2.64 +87046-9;Guidance for cholangioscopy;Find;Pt;Abdomen>Gallbladder;Doc;{Imaging modality};RAD;2;Guidance for cholangioscopy of Gallbladder;Guided GB Cholangioscopy;;ACTIVE;2.63;2.64 +87047-7;Guidance for cholecystostomy;Find;Pt;Abdomen>Gallbladder;Doc;{Imaging modality};RAD;2;Guidance for cholecystostomy of Gallbladder;Guided GB Cholecystostomy;;ACTIVE;2.63;2.64 +87048-5;Guidance for conversion of gastrostomy tube to gastrojejunostomy tube;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;{Imaging modality};RAD;2;Guidance for conversion of G-tube to GJ-tube of Gastrointestinal tract upper;Guided UGI G- to GJ-tube conversion;;ACTIVE;2.63;2.64 +8704-9;Physical findings;Find;Pt;Mouth & Throat & Teeth;Nom;Observed;H&P.PX;2;Physical findings of Mouth and Throat and Teeth;Phys find Mouth+Throat+Teeth;;ACTIVE;1.0h(3);2.38 +87049-3;Guidance for cryoablation;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for cryoablation of Kidney;Guided Kidney Cryoablation;;ACTIVE;2.63;2.64 +87050-1;Guidance for cryoablation;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for cryoablation of Liver;Guided Liver Cryoablation;;ACTIVE;2.63;2.64 +87051-9;Guidance for dilation of stricture;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for dilation of stricture of Biliary ducts;Guided BDs Stricture dilation;;ACTIVE;2.63;2.64 +87052-7;Guidance for exchange of gastrostomy tube;Find;Pt;Abdomen>Stomach;Doc;{Imaging modality};RAD;2;Guidance for exchange of G-tube of Stomach;Guided Stom G-tube exch;;ACTIVE;2.63;2.64 +87053-5;Guidance for exchange of jejunostomy tube;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;{Imaging modality};RAD;2;Guidance for exchange of J-tube of Gastrointestinal tract upper;Guided UGI J-tube exch;;ACTIVE;2.63;2.64 +87054-3;Guidance for percutaneous exchange of nephrostomy tube;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for exchange of nephrostomy tube of Kidney;Guided Kidney Neph tube exchange;;ACTIVE;2.63;2.64 +87055-0;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Pancreas;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Pancreas;Guided Pancreas Bx;;ACTIVE;2.63;2.64 +8705-6;Physical findings;Find;Pt;Neurologic system;Nom;Observed;H&P.PX;2;Physical findings of Nervous system;Phys find Neurologic;;ACTIVE;1.0h(3);2.27 +87056-8;Guidance for percutaneous biopsy;Find;Pt;Abdomen;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Abdomen;Guided Abd Bx;;ACTIVE;2.63;2.64 +87057-6;Guidance for placement of fiducial marker;Find;Pt;Abdomen;Doc;{Imaging modality};RAD;2;Guidance for placement of fiducial marker in Abdomen;Guided Abd Fid marker place;;ACTIVE;2.63;2.64 +87058-4;Guidance for radiofrequency ablation;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for radiofrequency ablation of Kidney;Guided Kidney Radiofreq abl;;ACTIVE;2.63;2.64 +87059-2;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Biliary ducts;Guided BDs Bx;;ACTIVE;2.63;2.64 +870-6;A3 B Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated A3 B Ab [Presence] in Serum or Plasma from donor;Deprecated A3 B Ab SerPl Donr Ql;;DEPRECATED;1.0;2.4 +87060-0;Guidance for removal of calculus;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for removal of calculus from Biliary ducts;Guided BDs Calc removal;;ACTIVE;2.63;2.64 +87061-8;Guidance for injection of contrast;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for injection of contrast of Biliary ducts;Guided BDs Contrast inject;;ACTIVE;2.63;2.64 +87062-6;Guidance for nerve block;Find;Pt;Abdomen>Celiac plexus;Doc;{Imaging modality};RAD;2;Guidance for nerve block of Celiac plexus;Guided Celiac plexus Nerve block;;ACTIVE;2.63;2.64 +87063-4;Guidance for removal of gastrojejunostomy tube;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;{Imaging modality};RAD;2;Guidance for removal of GJ-tube from Gastrointestinal tract upper;Guided UGI GJ-tube removal;;ACTIVE;2.63;2.64 +8706-4;Physical findings;Find;Pt;Nose;Nom;Observed;H&P.PX;2;Physical findings of Nose;Phys find Nose;;ACTIVE;1.0h(3);2.27 +87064-2;Guidance for placement of gastrojejunostomy tube;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;{Imaging modality};RAD;2;Guidance for placement of GJ-tube in Gastrointestinal tract upper;Guided UGI GJ-tube place;;ACTIVE;2.63;2.64 +87065-9;Guidance for placement of gastrostomy tube;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;{Imaging modality};RAD;2;Guidance for placement of G-tube in Gastrointestinal tract upper;Guided UGI G-tube place;;ACTIVE;2.63;2.64 +87066-7;Guidance for percutaneous placement of nephrostomy tube;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for percutaneous placement of nephrostomy tube of Kidney;Guided Kidney NT perc place;;ACTIVE;2.63;2.64 +87067-5;Guidance for transjugular biopsy;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for transjugular biopsy of Kidney;Guided Kidney Transjugular Bx;;ACTIVE;2.63;2.64 +87068-3;Guidance for transjugular biopsy+venography;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for transjugular biopsy and venography of Kidney;Guided Kidney Transjugular Bx+venography;;ACTIVE;2.63;2.64 +87069-1;Guidance for hemodynamic evaluation;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for hemodynamic evaluation of Liver;Guided Liver Hemodynamic eval;;ACTIVE;2.63;2.64 +87070-9;Guidance for microwave ablation;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for microwave ablation of Liver;Guided Liver Microwave abl;;ACTIVE;2.63;2.64 +87071-7;Guidance for radiofrequency ablation;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for radiofrequency ablation of Liver;Guided Liver Radiofreq abl;;ACTIVE;2.63;2.64 +8707-2;Physical findings;Find;Pt;Pelvis;Nom;Observed;H&P.PX;2;Physical findings of Pelvis;Phys find Pelvis;;ACTIVE;1.0h(3);2.27 +87072-5;Guidance for transjugular placement of transjugular intrahepatic portosystemic shunt;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for placement of TIPS of Liver;Guided Liver TIPS place;;ACTIVE;2.63;2.64 +87073-3;Guidance for transjugular revision of transjugular intrahepatic portosystemic shunt;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for revision of TIPS of Liver;Guided Liver TIPS revision;;ACTIVE;2.63;2.64 +87074-1;Guidance for transhepatic revision of tube;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for transhepatic revision of tube of Liver;Guided Liver Transhepatic tube revision;;ACTIVE;2.63;2.64 +87075-8;Guidance for transjugular biopsy;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for transjugular biopsy of Liver;Guided Liver Transjugular Bx;;ACTIVE;2.63;2.64 +87076-6;Guidance for transjugular biopsy+hemodynamic evaluation;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for transjugular biopsy and hemodynamic evaluation of Liver;Guided Liver Transjugular Bx+hemo eval;;ACTIVE;2.63;2.64 +87077-4;Guidance for transjugular biopsy+venography;Find;Pt;Abdomen>Liver;Doc;{Imaging modality};RAD;2;Guidance for transjugular biopsy and venography of Liver;Guided Liver Transjugular Bx+venography;;ACTIVE;2.63;2.64 +87078-2;Guidance for percutaneous drainage+placement of drainage catheter;Find;Pt;Abdomen;Doc;{Imaging modality};RAD;2;Guidance for percutaneous drainage and placement of drainage catheter of Abdomen;Guided Abd PC drn+cath place;;ACTIVE;2.63;2.66 +87079-0;Guidance for paracentesis+insertion of tube;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for paracentesis and insertion of tube of Peritoneum;Guided Peritoneum Paracent+tube insert;;ACTIVE;2.63;2.64 +8708-0;Physical findings;Find;Pt;Rectum;Nom;Observed;H&P.PX;2;Physical findings of Rectum;Phys find Rectum;;ACTIVE;1.0h(3);2.27 +87080-8;Guidance for paracentesis;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for paracentesis of Peritoneum;Guided Peritoneum Paracentesis;;ACTIVE;2.63;2.64 +87081-6;Guidance for placement of catheter;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for placement of catheter in Peritoneum;Guided Peritoneum Cath place;;ACTIVE;2.63;2.64 +87082-4;Guidance for removal of catheter;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for removal of catheter from Peritoneum;Guided Peritoneum Cath rem;;ACTIVE;2.63;2.64 +87083-2;Guidance for reposition of catheter;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for reposition of catheter in Peritoneum;Guided Peritoneum Cath repos;;ACTIVE;2.63;2.64 +87084-0;Guidance for removal of foreign body;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for removal of foreign body from Peritoneum;Guided Peritoneum FB removal;;ACTIVE;2.63;2.64 +87085-7;Guidance for placement of port;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for placement of port in Peritoneum;Guided Peritoneum Port place;;ACTIVE;2.63;2.64 +87086-5;Guidance for removal of port;Find;Pt;Abdomen>Peritoneum;Doc;{Imaging modality};RAD;2;Guidance for removal of port from Peritoneum;Guided Peritoneum Port removal;;ACTIVE;2.63;2.64 +87087-3;Guidance for percutaneous transluminal angioplasty;Find;Pt;Abdomen>Renal artery;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Renal artery;Guided Renal a PTA;;ACTIVE;2.63;2.64 +87088-1;Guidance for puncture;Find;Pt;Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for puncture of Lumbar spine;Guided L-spine Puncture;;ACTIVE;2.63;2.64 +87089-9;Guidance for kyphoplasty;Find;Pt;Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for kyphoplasty of Lumbar spine;Guided L-spine Kyphoplasty;;ACTIVE;2.63;2.64 +87090-7;Guidance for myelography;Find;Pt;Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for myelography of Lumbar spine;Guided L-spine Myelography;;ACTIVE;2.63;2.64 +87091-5;Guidance for vertebroplasty;Find;Pt;Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for vertebroplasty of Lumbar spine;Guided L-spine Vertebroplasty;;ACTIVE;2.63;2.64 +87092-3;Guidance for placement of venous filter;Find;Pt;Abdomen>Vena cava.inferior;Doc;{Imaging modality};RAD;2;Guidance for placement of venous filter in Inferior vena cava;Guided IVC Filter place;;ACTIVE;2.63;2.64 +87093-1;Guidance for removal of venous filter;Find;Pt;Abdomen>Vena cava.inferior;Doc;{Imaging modality};RAD;2;Guidance for removal of venous filter from Inferior vena cava;Guided IVC Filter removal;;ACTIVE;2.63;2.64 +87094-9;Guidance for reposition of venous filter;Find;Pt;Abdomen>Vena cava.inferior;Doc;{Imaging modality};RAD;2;Guidance for reposition of venous filter in Inferior vena cava;Guided IVC Filter reposition;;ACTIVE;2.63;2.64 +87095-6;Guidance for percutaneous transluminal angioplasty;Find;Pt;Abdomen>Visceral artery;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Visceral artery;Guided Visceral a PTA;;ACTIVE;2.63;2.64 +87096-4;Guidance for placement of stent;Find;Pt;Abdomen>Visceral artery;Doc;{Imaging modality};RAD;2;Guidance for placement of stent in Visceral artery;Guided Visceral a Stent place;;ACTIVE;2.63;2.64 +87097-2;Guidance for placement of peritoneovenous shunt;Find;Pt;Chest+Abdomen;Doc;{Imaging modality};RAD;2;Guidance for placement of peritoneovenous shunt in Chest and Abdomen;Guided Chest+Abd PV shunt place;;ACTIVE;2.63;2.64 +8709-8;Physical findings;Find;Pt;Skin;Nom;Observed;H&P.PX;2;Physical findings of Skin;Phys find Skin;;ACTIVE;1.0h(3);2.27 +87098-0;Guidance for removal of peritoneovenous shunt;Find;Pt;Chest+Abdomen;Doc;{Imaging modality};RAD;2;Guidance for removal of peritoneovenous shunt from Chest and Abdomen;Guided Chest+Abd PV shunt removal;;ACTIVE;2.63;2.64 +87099-8;Guidance for revision of peritoneovenous shunt;Find;Pt;Chest+Abdomen;Doc;{Imaging modality};RAD;2;Guidance for revision of peritoneovenous shunt of Chest and Abdomen;Guided Chest+Abd PV shunt revision;;ACTIVE;2.63;2.64 +87100-4;Guidance for percutaneous transluminal angioplasty;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Thoracic and abdominal aorta;Guided TA + AA PTA;;ACTIVE;2.63;2.64 +87101-2;Guidance for percutaneous transluminal angioplasty;Find;Pt;Chest>Brachiocephalic artery;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Brachiocephalic artery;Guided BrachCeph a PTA;;ACTIVE;2.63;2.64 +87102-0;Guidance initial day for infusion of thrombolytic^W thrombolytic via chest tube;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for initial day infusion of thrombolytic of Chest-- W thrombolytic via chest tube;Guided Thromb inf D1 W thromb via CT;;ACTIVE;2.63;2.64 +87103-8;Guidance for infusion of thrombolytic^W thrombolytic via central venous catheter;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for infusion of thrombolytic of Chest-- W thrombolytic via CVC;Guided Thromb infus W thromb via CVC;;ACTIVE;2.63;2.64 +87104-6;Guidance for injection of central venous catheter;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for injection of CV catheter of Chest;Guided Chest CVC inject;;ACTIVE;2.63;2.64 +87105-3;Guidance for reposition of central venous catheter;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for reposition of CV catheter in Chest;Guided Chest CVC repos;;ACTIVE;2.63;2.64 +8710-6;Physical findings;Find;Pt;Thorax+Lungs;Nom;Observed;H&P.PX;2;Physical findings of Thorax and Lungs;Phys find Thorax+Lungs;;ACTIVE;1.0h(3);2.38 +87106-1;Guidance for placement of central venous catheter with port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for placement of CV catheter with port in Chest;Guided Chest CVC w port place;;ACTIVE;2.63;2.64 +87107-9;Guidance for removal of central venous catheter with port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for removal of CV catheter with port from Chest;Guided Chest CVC w port removal;;ACTIVE;2.63;2.64 +87108-7;Guidance for repair of central venous catheter with port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for repair of CV catheter with port of Chest;Guided Chest CVC w port repair;;ACTIVE;2.63;2.64 +87109-5;Guidance for placement of Swan-Ganz catheter;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for placement of Swan-Ganz catheter in Chest;Guided Chest Swan-Ganz cath place;;ACTIVE;2.63;2.64 +87110-3;Guidance for thoracentesis+insertion of tube;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for thoracentesis and insertion of tube of Chest;Guided Chest Thoracentesis+tube insert;;ACTIVE;2.63;2.64 +87111-1;Guidance for thoracentesis;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for thoracentesis of Chest;Guided Chest Thoracentesis;;ACTIVE;2.63;2.64 +87112-9;Guidance for exchange of tunneled central venous catheter without port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for exchange of tunneled CV catheter without port of Chest;Guided Chest Tun CVC wo port exch;;ACTIVE;2.63;2.64 +87113-7;Guidance for placement of tunneled central venous catheter without port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for placement of tunneled CV catheter without port in Chest;Guided Chest Tun CVC wo port place;;ACTIVE;2.63;2.64 +8711-4;Physical findings;Find;Pt;Vessels;Nom;Observed;H&P.PX;2;Physical findings of Vessels;Phys find Vesl;;ACTIVE;1.0h(3);2.34 +87114-5;Guidance for removal of tunneled central venous catheter without port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for removal of tunneled CV catheter without port from Chest;Guided Chest Tun CVC wo port removal;;ACTIVE;2.63;2.64 +87115-2;Guidance for repair of non-tunneled central venous catheter without port;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for repair of non-tunneled CV catheter without port of Chest;Guided Chest Non-tun CVC wo port repair;;ACTIVE;2.63;2.64 +87116-0;Guidance for placement of chest tube;Find;Pt;Chest>Pleural space;Doc;{Imaging modality};RAD;2;Guidance for placement of chest tube in Pleural space;Guided Pl space Chest tube place;;ACTIVE;2.63;2.66 +87117-8;Guidance for pericardiocentesis;Find;Pt;Chest>Heart;Doc;{Imaging modality};RAD;2;Guidance for pericardiocentesis of Heart;Guided Hrt Pericardiocentesis;;ACTIVE;2.63;2.64 +87118-6;Guidance for placement of fiducial marker;Find;Pt;Chest>Lung;Doc;{Imaging modality};RAD;2;Guidance for placement of fiducial marker in Lung;Guided Lung Fid marker place;;ACTIVE;2.63;2.64 +87119-4;Guidance for microwave ablation;Find;Pt;Chest>Lung;Doc;{Imaging modality};RAD;2;Guidance for microwave ablation of Lung;Guided Lung Microwave abl;;ACTIVE;2.63;2.64 +87120-2;Guidance for radiofrequency ablation;Find;Pt;Chest>Lung;Doc;{Imaging modality};RAD;2;Guidance for radiofrequency ablation of Lung;Guided Lung Radiofreq abl;;ACTIVE;2.63;2.64 +87121-0;Guidance for placement of tunneled catheter;Find;Pt;Chest>Pleura;Doc;{Imaging modality};RAD;2;Guidance for placement of tunneled catheter in Chest Pleura;Guided Chest Pleura Tun cath place;;ACTIVE;2.63;2.64 +8712-2;Physical findings;Find;Pt;Neurologic balance+Coordination;Nom;Observed;H&P.PX;2;Physical findings of Neurologic balance and Coordination;Phys find Balance+Coordination;;ACTIVE;1.0h(3);2.38 +87122-8;Guidance for kyphoplasty;Find;Pt;Chest>Spine.thoracic;Doc;{Imaging modality};RAD;2;Guidance for kyphoplasty of Thoracic spine;Guided T-spine Kyphoplasty;;ACTIVE;2.63;2.64 +87123-6;Guidance for myelography;Find;Pt;Chest>Spine.thoracic;Doc;{Imaging modality};RAD;2;Guidance for myelography of Thoracic spine;Guided T-spine Myelography;;ACTIVE;2.63;2.64 +87124-4;Guidance for vertebroplasty;Find;Pt;Chest>Spine.thoracic;Doc;{Imaging modality};RAD;2;Guidance for vertebroplasty of Thoracic spine;Guided T-spine Vertebroplasty;;ACTIVE;2.63;2.64 +87125-1;Guidance for nerve block;Find;Pt;Chest>Spine.thoracic intercostal nerve;Doc;{Imaging modality};RAD;2;Guidance for nerve block of Thoracic spine intercostal nerve;Guided T-spine ICN Nerve block;;ACTIVE;2.63;2.64 +87126-9;Guidance for removal of venous filter;Find;Pt;Chest>Vena cava.superior;Doc;{Imaging modality};RAD;2;Guidance for removal of venous filter from Superior vena cava;Guided SVC Filter removal;;ACTIVE;2.63;2.64 +87127-7;Guidance for reposition of venous filter;Find;Pt;Chest>Vena cava.superior;Doc;{Imaging modality};RAD;2;Guidance for reposition of venous filter in Superior vena cava;Guided SVC Filter reposition;;ACTIVE;2.63;2.64 +87128-5;Guidance for placement of venous filter;Find;Pt;Chest>Vena cava.superior;Doc;{Imaging modality};RAD;2;Guidance for placement of venous filter in Superior vena cava;Guided SVC Filter place;;ACTIVE;2.63;2.64 +87129-3;Guidance for percutaneous transluminal angioplasty;Find;Pt;Lower extremity>Lower leg;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Lower leg;Guided Lower leg PTA;;ACTIVE;2.63;2.64 +8713-0;Physical findings;Find;Pt;General status;Nom;Observed;H&P.PX;2;Physical findings of General status;Phys find General status;;ACTIVE;1.0h(3);2.27 +87130-1;Guidance for laser ablation;Find;Pt;Extremity>Extremity vein;Doc;{Imaging modality};RAD;2;Guidance for laser ablation of Extremity vein;Guided Extr v Laser ablation;;ACTIVE;2.63;2.64 +87131-9;Guidance GE 21 for stab phlebectomy;Find;Pt;Extremity>Extremity vein;Doc;{Imaging modality};RAD;2;Guidance for greater than 20 stab phlebectomy of Extremity vein;Guided Extr v Stab phlebectomy GE21;;ACTIVE;2.63;2.64 +87132-7;Guidance for injection;Find;Pt;Lower extremity>Ankle;Doc;{Imaging modality};RAD;2;Guidance for injection of Ankle;Guided Ankle Inj;;ACTIVE;2.63;2.64 +87133-5;Guidance for percutaneous transluminal angioplasty;Find;Pt;Lower extremity.unilateral>Femoral artery+Popliteal artery;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Femoral artery and Popliteal artery;Guided Fem a+Pop a PTA;;ACTIVE;2.63;2.64 +87134-3;Guidance for placement of stent;Find;Pt;Lower extremity.unilateral>Femoral artery+Popliteal artery;Doc;{Imaging modality};RAD;2;Guidance for placement of stent in Femoral artery and Popliteal artery;Guided Fem a+Pop a Stent place;;ACTIVE;2.63;2.64 +87135-0;Guidance for injection;Find;Pt;Lower extremity>Hip;Doc;{Imaging modality};RAD;2;Guidance for injection of Hip;Guided Hip Inj;;ACTIVE;2.63;2.64 +87136-8;Guidance for percutaneous aspiration of fluid;Find;Pt;Lower extremity>Knee;Doc;{Imaging modality};RAD;2;Guidance for arthrocentesis of Knee;Guided Knee Arthrocentesis;;ACTIVE;2.63;2.66 +87137-6;Guidance for injection;Find;Pt;Lower extremity>Knee;Doc;{Imaging modality};RAD;2;Guidance for injection of Knee;Guided Knee Inj;;ACTIVE;2.63;2.64 +87138-4;Guidance additional for laser ablation;Find;Pt;Extremity>Extremity vein;Doc;{Imaging modality};RAD;2;Guidance for additional laser ablation of Extremity vein;Guided Extr v Laser ablation addl;;ACTIVE;2.63;2.64 +87139-2;Guidance additional for percutaneous transluminal angioplasty;Find;Pt;Lower extremity>Lower leg;Doc;{Imaging modality};RAD;2;Guidance for additional transluminal angioplasty of Lower leg;Guided Lower leg PTA addl;;ACTIVE;2.63;2.64 +871-4;A3 B Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated A3 B Ab;Deprecated A3 B Ab Ser Ql;;DEPRECATED;1.0;2.36 +87140-0;Guidance additional for placement of stent;Find;Pt;Lower extremity>Lower leg vessel;Doc;{Imaging modality};RAD;2;Guidance for additional placement of stent of Lower leg vessel;Guided Lower leg ves Stent place addl;;ACTIVE;2.63;2.64 +87141-8;Guidance for placement of central venous catheter with port;Find;Pt;Upper extremity;Doc;{Imaging modality};RAD;2;Guidance for placement of CV catheter with port in Upper extremity;Guided UE CVC w port place;;ACTIVE;2.63;2.64 +87142-6;Guidance for exchange of central venous catheter with port;Find;Pt;Upper extremity;Doc;{Imaging modality};RAD;2;Guidance for exchange of CV catheter with port of Upper extremity;Guided UE CVC w port exch;;ACTIVE;2.63;2.64 +87143-4;Guidance for exchange of peripherally-inserted central venous catheter;Find;Pt;Upper extremity;Doc;{Imaging modality};RAD;2;Guidance for exchange of peripherally inserted central catheter of Upper extremity;Guided UE PICC exch;;ACTIVE;2.63;2.64 +87144-2;Guidance for placement of peripherally-inserted central venous catheter;Find;Pt;Upper extremity;Doc;{Imaging modality};RAD;2;Guidance for placement of peripherally-inserted central venous catheter in Upper extremity;Guided UE PICC place;;ACTIVE;2.63;2.64 +87145-9;Guidance for embolization;Find;Pt;Upper extremity>Brachial artery;Doc;{Imaging modality};RAD;2;Guidance for embolization of Brachial artery;Guided Brach a Embol;;ACTIVE;2.63;2.64 +87146-7;Guidance for injection;Find;Pt;Upper extremity>Shoulder;Doc;{Imaging modality};RAD;2;Guidance for injection of Shoulder;Guided Should Inj;;ACTIVE;2.63;2.64 +87147-5;Guidance for injection;Find;Pt;Upper extremity>Wrist;Doc;{Imaging modality};RAD;2;Guidance for injection of Wrist;Guided Wrist Inj;;ACTIVE;2.63;2.64 +8714-8;Physical findings;Find;Pt;Sense of touch;Nom;Observed;H&P.PX;2;Physical findings of Sense of touch;Phys find Sense of touch;;ACTIVE;1.0h(3);2.27 +87148-3;Guidance for injection of thrombin for pseudoaneurysm;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for injection of thrombin for pseudoaneurysm;Thromb inj for pseudoaneurysm;;ACTIVE;2.63;2.63 +87149-1;Guidance for exchange of chest tube;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for exchange of chest tube of Chest;Guided Chest Chest tube exch;;ACTIVE;2.63;2.64 +87150-9;Guidance for percutaneous transluminal angioplasty;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Iliac artery;Guided Iliac a PTA;;ACTIVE;2.63;2.64 +87151-7;Guidance for placement of stent;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;{Imaging modality};RAD;2;Guidance for placement of stent in Iliac artery;Guided Iliac a Stent place;;ACTIVE;2.63;2.64 +87152-5;Guidance for exchange of ureterostomy through ileal conduit;Find;Pt;Abdomen+Pelvis>Ureter;Doc;{Imaging modality};RAD;2;Guidance for exchange of ureterostomy through ileal conduit of Ureter;Guided Ureterostomy exch thr ileal cond;;ACTIVE;2.63;2.64 +87153-3;Guidance therapeutic for puncture+drainage;Find;Pt;Neck>Spine.cervical;Doc;{Imaging modality};RAD;2;Guidance for therapeutic puncture and drainage of Cervical spine;Guided C-spine Therapeutic punc+drainage;;ACTIVE;2.63;2.67 +87154-1;Guidance diagnostic for puncture;Find;Pt;Neck>Spine.cervical;Doc;{Imaging modality};RAD;2;Guidance for diagnostic puncture of Cervical spine;Guided C-spine Diag puncture;;ACTIVE;2.63;2.64 +8715-5;Physical findings;Find;Pt;Strength;Nom;Observed;H&P.PX;2;Physical findings of Strength;Phys find Strength;;ACTIVE;1.0h(3);2.27 +87155-8;Guidance for percutaneous aspiration.fine needle;Find;Pt;Neck>Thyroid gland;Doc;{Imaging modality};RAD;2;Guidance for fine needle aspiration of Thyroid gland;Guided Thyroid FNA;;ACTIVE;2.63;2.64 +87156-6;Guidance for percutaneous biopsy.core needle;Find;Pt;Neck>Thyroid gland;Doc;{Imaging modality};RAD;2;Guidance for percutaneous biopsy.core needle of Thyroid gland;Guided Thyroid PC Bx CN;;ACTIVE;2.63;2.64 +87157-4;Guidance for injection of platelet rich plasma;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for injection of platelet rich plasma;Guided Unsp region PRP inject;;ACTIVE;2.63;2.64 +87158-2;Guidance for injection;Find;Pt;XXX>Tendon;Doc;{Imaging modality};RAD;2;Guidance for injection of Tendon;Guided Tendon Inj;;ACTIVE;2.63;2.64 +87159-0;Guidance for injection;Find;Pt;Head>Temporomandibular joint;Doc;{Imaging modality};RAD;2;Guidance for injection of Temporomandibular joint;Guided TMJ Inj;;ACTIVE;2.63;2.64 +87160-8;Guidance for injection;Find;Pt;XXX>Spine facet joint;Doc;{Imaging modality};RAD;2;Guidance for injection of Spine facet joint;Guided Spine FJ Inj;;ACTIVE;2.63;2.65 +87161-6;Guidance for injection;Find;Pt;XXX>Spine epidural space;Doc;{Imaging modality};RAD;2;Guidance for injection of Spine epidural space;Guided Epidural space Inj;;ACTIVE;2.63;2.64 +87162-4;Guidance for placement of needle;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for placement of needle;Guided Unsp region Needle place;;ACTIVE;2.63;2.64 +8716-3;Vital signs;Find;Pt;^Patient;Nar;Observed;H&P.PX;2;Vital signs;Vital signs;;ACTIVE;1.0h(3);2.73 +87163-2;Guidance for placement of endovascular device;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for placement of endovascular device in Vein;Guided Vein Endovasc dev place;;ACTIVE;2.63;2.64 +87164-0;Guidance secondary for percutaneous mechanical thrombectomy;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for secondary mechanical thrombectomy of Artery;Guided Artery Secondary mech thromb;;ACTIVE;2.63;2.64 +87165-7;Guidance for placement of endograft;Find;Pt;Abdomen+Pelvis>Iliac artery;Doc;{Imaging modality};RAD;2;Guidance for placement of endograft in Iliac artery;Guided Iliac a Endograft place;;ACTIVE;2.63;2.64 +87166-5;Guidance for percutaneous transluminal angioplasty;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of Vein;Guided Vein PTA;;ACTIVE;2.63;2.64 +87167-3;Guidance for transcatheter biopsy;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for transcatheter biopsy;Guided Unsp region Transcath Bx;;ACTIVE;2.63;2.64 +87168-1;Guidance for transcatheter placement of stent;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for transcatheter placement of stent;Guided Unsp region Transcath stent place;;ACTIVE;2.63;2.64 +87169-9;Guidance initial for percutaneous mechanical thrombectomy;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for initial mechanical thrombectomy of Artery;Guided Artery Mech thromb initial;;ACTIVE;2.63;2.64 +87170-7;Guidance for ligation;Find;Pt;XXX>Lymphatic vessel;Doc;{Imaging modality};RAD;2;Guidance for ligation of Lymphatic vessel;Guided Lymph ves Ligation;;ACTIVE;2.63;2.64 +8717-1;Surgical operation note estimated blood loss;Vol;Procedure dur;^Patient;Qn;;H&P.SURG PROC;2;Surgical operation note estimated blood loss [Volume];Operative note estimated blood loss Vol;;ACTIVE;1.0h(3);2.27 +87171-5;Guidance for placement of clip;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for placement of clip;Guided Unsp region Clip place;;ACTIVE;2.63;2.64 +87172-3;Guidance for placement of clip^preoperative;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for placement of clip-- preoperative;Guided Unsp region Clip place--Preop;;ACTIVE;2.63;2.64 +87173-1;Guidance for biopsy;Find;Pt;Pelvis>Prostate;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Prostate;Guided Prostate Bx;;ACTIVE;2.63;2.64 +87174-9;Guidance for percutaneous biopsy;Find;Pt;XXX>Muscle;Doc;{Imaging modality};RAD;2;Guidance for biopsy of Muscle;Guided Muscle Bx;;ACTIVE;2.63;2.64 +87175-6;Guidance for deep drainage+placement of drainage catheter;Find;Pt;Pelvis;Doc;{Imaging modality};RAD;2;Guidance for deep drainage and placement of drainage catheter of Pelvis;Guided Pelvis Deep drain+cath place;;ACTIVE;2.63;2.66 +87176-4;Guidance for radiofrequency ablation;Find;Pt;XXX>Bone;Doc;{Imaging modality};RAD;2;Guidance for radiofrequency ablation of Bone;Guided Bone Radiofreq abl;;ACTIVE;2.63;2.64 +87177-2;Guidance for radiofrequency ablation;Find;Pt;Chest>Pleura;Doc;{Imaging modality};RAD;2;Guidance for radiofrequency ablation of Chest Pleura;Guided Chest Pleura Radiofreq abl;;ACTIVE;2.63;2.64 +87178-0;Guidance final day for infusion of thrombolytic^W thrombolytic via catheter;Find;Pt;XXX>Vessel;Doc;{Imaging modality};RAD;2;Guidance for final day of infusion of thrombolytic of Vessel-- W thrombolytic via catheter;Guided Ves Throm inf final W thr in cath;;ACTIVE;2.63;2.64 +87179-8;Guidance for percutaneous aspiration.fine needle;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for fine needle aspiration;Guided Unsp region FNA;;ACTIVE;2.63;2.64 +87180-6;Guidance for dilation;Find;Pt;Pelvis>Fallopian tube;Doc;{Imaging modality};RAD;2;Guidance for dilation of Fallopian tube;Guided Fallopian tube Dilation;;ACTIVE;2.63;2.64 +87181-4;Guidance for embolization;Find;Pt;Pelvis>Uterine artery;Doc;{Imaging modality};RAD;2;Guidance for embolization of Uterine artery;Guided Uterine a Embol;;ACTIVE;2.63;2.64 +87182-2;Guidance for placement of wire;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for placement of wire;Guided Unsp region Wire place;;ACTIVE;2.63;2.64 +87183-0;Guidance GE 3 for injection of trigger point;Find;Pt;XXX>Muscle;Doc;{Imaging modality};RAD;2;Guidance for greater than 2 injections of trigger point of Muscle;Guided Muscle Trigger point inject GE3;;ACTIVE;2.63;2.64 +87184-8;Guidance for percutaneous transluminal angioplasty of arterial anastomosis;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty of arterial anastomosis of Artery;Guided Artery PTA of art anast;;ACTIVE;2.63;2.64 +87185-5;Guidance for percutaneous sympathectomy;Find;Pt;XXX>Nerve;Doc;{Imaging modality};RAD;2;Guidance for sympathectomy of Nerve;Guided Nerve Sympathectomy;;ACTIVE;2.63;2.64 +87186-3;Guidance for mechanical thrombectomy of central venous catheter lumen obstruction;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for mechanical thrombectomy of central venous catheter lumen obstruction;Guided CVC lumen obstr mech thromb;;ACTIVE;2.63;2.64 +87187-1;Guidance for nerve block;Find;Pt;XXX>Nerve root;Doc;{Imaging modality};RAD;2;Guidance for nerve block of Nerve root;Guided Nerve root Nerve block;;ACTIVE;2.63;2.64 +87188-9;Guidance for percutaneous exchange of nephroureteral stent;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;{Imaging modality};RAD;2;Guidance for exchange of nephroureteral stent of Kidney and Ureter and Urinary bladder;Guided Kid+Uret+Blad Nephrour stent exch;;ACTIVE;2.63;2.64 +8718-9;Surgical operation note fluids;Type;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note fluids;Operative note fluids;;ACTIVE;1.0h(3);2.29 +87189-7;Guidance for transurethral removal of nephroureteral stent;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;{Imaging modality};RAD;2;Guidance for transurethral removal of nephroureteral stent of Kidney and Ureter and Urinary bladder;Guided Nephrouret stent rem via urethra;;ACTIVE;2.63;2.64 +87190-5;Guidance for percutaneous placement of nephroureteral stent;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;{Imaging modality};RAD;2;Guidance for percutaneous placement of nephroureteral stent of Kidney and Ureter and Urinary bladder;Guided PCNUS place;;ACTIVE;2.63;2.64 +87191-3;Guidance for percutaneous removal of nephroureteral stent;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;{Imaging modality};RAD;2;Guidance for removal of nephroureteral stent of Kidney and Ureter and Urinary bladder;Guided PCNUS removal;;ACTIVE;2.63;2.64 +87192-1;Guidance for thrombectomy;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for thrombectomy;Guided Unsp region Thrombect;;ACTIVE;2.63;2.64 +87193-9;Guidance initial day for infusion of thrombolytic^W thrombolytic via catheter;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for initial day infusion of thrombolytic of Artery-- W thrombolytic via catheter;Guided Art Throm inf D1 W throm in cath;;ACTIVE;2.63;2.64 +87194-7;Guidance initial for percutaneous mechanical thrombectomy;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for initial mechanical thrombectomy of Vein;Guided Vein Mech thromb initial;;ACTIVE;2.63;2.64 +87195-4;Guidance initial day for infusion of thrombolytic^W thrombolytic via catheter;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for initial day infusion of thrombolytic of Vein-- W thrombolytic via catheter;Guided Vein Throm inf D1 W throm in cath;;ACTIVE;2.63;2.64 +87196-2;Guidance for infusion of non-thrombolytic;Find;Pt;XXX>Vessel;Doc;{Imaging modality};RAD;2;Guidance for infusion of non-thrombolytic of Vessel;Guided Ves Non-thromb infus;;ACTIVE;2.63;2.64 +8719-7;Surgical operation note postoperative Dx;Imp;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note postoperative diagnosis;Operative note post-op Dx;;ACTIVE;1.0h(3);2.27 +87197-0;Guidance for retrieval of foreign body;Find;Pt;XXX>Vessel;Doc;{Imaging modality};RAD;2;Guidance for retrieval of foreign body of Vessel;Guided Ves FB retrieval;;ACTIVE;2.63;2.64 +87198-8;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for placement of drainage catheter for abscess;Guided Unsp region Absc drain+cath place;;ACTIVE;2.63;2.66 +87199-6;Guidance for substance removal of central venous catheter pericatheter obstruction;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance for substance removal of central venous catheter pericatheter obstruction;Guided Unsp region CVC pericath obs rem;;ACTIVE;2.63;2.64 +87200-2;Guidance for placement of stent;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for placement of stent in Artery;Guided Artery Stent place;;ACTIVE;2.63;2.64 +87201-0;Guidance for treatment;Find;Pt;XXX>AV fistula;Doc;{Imaging modality};RAD;2;Guidance for treatment of AV fistula;Guided AVF Treatment;;ACTIVE;2.63;2.64 +87202-8;Guidance for venous sampling;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for venous sampling of Vein;Guided Vein Venous sampling;;ACTIVE;2.63;2.64 +87203-6;Guidance for transurethral exchange of nephroureteral stent;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;{Imaging modality};RAD;2;Guidance for transurethral exchange of nephroureteral stent of Kidney and Ureter and Urinary bladder;Guided Nephrouret stent exch via urethra;;ACTIVE;2.63;2.64 +8720-5;Surgical operation note preoperative Dx;Imp;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note preoperative diagnosis;Operative note pre-op Dx;;ACTIVE;1.0h(3);2.27 +87205-1;Guidance for exchange of non-tunneled central venous catheter;Find;Pt;Chest;Doc;{Imaging modality};RAD;2;Guidance for exchange of non-tunneled CV catheter of Chest;Guided Chest Non-tun CVC exch;;ACTIVE;2.63;2.64 +87206-9;Guidance for nerve block;Find;Pt;XXX>Peripheral nerve;Doc;{Imaging modality};RAD;2;Guidance for nerve block of Peripheral nerve;Guided PN Nerve block;;ACTIVE;2.63;2.66 +87207-7;Care Area Assessment (CAA) Summary;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Care Area Assessment (CAA) Summary [CMS Assessment];;;ACTIVE;2.63;2.63 +87208-5;Items from the most recent prior OBRA or scheduled PPS Assessment;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Items from the most recent prior OBRA or scheduled PPS Assessment [CMS Assessment];;;ACTIVE;2.63;2.74 +87209-3;Correction attestation section;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Correction attestation section [CMS Assessment];;;ACTIVE;2.63;2.74 +87210-1;Care Area Assessment (CAA) and Care Planning;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Care Area Assessment (CAA) and care planning [CMS Assessment];;;ACTIVE;2.63;2.74 +87211-9;Care Area Assessment (CAA) results;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Care Area Assessment (CAA) results [CMS Assessment];;;ACTIVE;2.63;2.74 +87212-7;Care area triggered;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Care area triggered [CMS Assessment];;;ACTIVE;2.63;2.63 +8721-3;Surgical operation note specimens taken;Find;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note specimens taken;Operative note specimens taken;;ACTIVE;1.0h(3);2.27 +87213-5;Triggered care area included in care plan;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Triggered care area included in care plan [CMS Assessment];;;ACTIVE;2.63;2.63 +87214-3;LCDS v4.00 - Special treatments, procedures, and programs - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.0 - Special treatments, procedures, and programs - discharge [CMS Assessment];;;ACTIVE;2.63;2.69 +87215-0;LCDS v4.00 - Hearing, speech, and vision;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Hearing, speech, and vision [CMS Assessment];;;ACTIVE;2.63;2.69 +87216-8;Date on existing record to be modified or inactivated;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Date on existing record to be modified or inactivated [CMS Assessment];;;ACTIVE;2.63;2.74 +87217-6;Reasons for modification;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Reasons for modification [CMS Assessment];;;ACTIVE;2.63;2.63 +87218-4;RN asessment coordinator attestation of completion;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;RN asessment coordinator attestation of completion [CMS Assessment];;;ACTIVE;2.63;2.74 +87219-2;Attesting individual first name;Pn;Pt;Provider;Nom;CMS Assessment;SURVEY.CMS;4;Attesting individual first name Provider [CMS Assessment];;;ACTIVE;2.63;2.63 +872-2;A3 B Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A3 B Ag [Presence] on Red Blood Cells from Blood product unit;A3 B Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +87220-0;Attesting individual last name;Pn;Pt;Provider;Nom;CMS Assessment;SURVEY.CMS;4;Attesting individual last name Provider [CMS Assessment];;;ACTIVE;2.63;2.63 +8722-1;Surgical operation note anesthesia;Find;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note anesthesia;Operative note anesthesia;;ACTIVE;1.0h(3);2.27 +87221-8;Attesting individual title;Type;Pt;Provider;Nom;CMS Assessment;SURVEY.CMS;4;Attesting individual title Provider [CMS Assessment];;;ACTIVE;2.63;2.63 +87222-6;Attestation date;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Attestation date [CMS Assessment];;;ACTIVE;2.63;2.64 +87223-4;Assessment administration;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Assessment administration [CMS Assessment];;;ACTIVE;2.63;2.63 +87224-2;Correction Request;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Correction request [CMS Assessment];;;ACTIVE;2.63;2.63 +87225-9;Reasons for inactivation;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Reasons for inactivation [CMS Assessment];;;ACTIVE;2.63;2.64 +87226-7;Legal name of patient - first and last;-;Pt;^Patient;-;;PANEL.ADMIN;2;Legal name of patient - first and last;First and last name;;ACTIVE;2.63;2.74 +87227-5;Type of assessment on existing record to be modified or inactivated;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Type of assessment on existing record to be modified or inactivated [CMS Assessment];;;ACTIVE;2.63;2.63 +87228-3;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Assessment administration - NS, NO, NSD, NOD, SP, SS, SO, SSD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Assessment administration - NS, NO, NSD, NOD, SP, SS, SO, SSD, SOD [CMS Assessment];;;ACTIVE;2.63;2.64 +87229-1;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Assessment administration - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.14.1, v1.15.1, v1.16.1 - Assessment administration - ND, SD [CMS Assessment];;;ACTIVE;2.63;2.64 +87230-9;LCDS v4.00 - Special treatments, procedures, and programs - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Special treatments, procedures, and programs - admission [CMS Assessment];;;ACTIVE;2.63;2.69 +87231-7;Medication administration.extended;Find;Pt;^Patient;Doc;;DOC.MISC;2;Medication administration.extended Document;Med admin.extended Doc;;ACTIVE;2.63;2.72 +87232-5;Medication administration.brief;Find;Pt;^Patient;Doc;;DOC.MISC;2;Medication administration.brief;Med admin.brief;;ACTIVE;2.63;2.63 +87233-3;Consultation note;Find;Pt;{Setting};Doc;Dialysis;DOC.ONTOLOGY;2;Dialysis Consult note;Dialy Consult note;;ACTIVE;2.63;2.63 +87234-1;Education note;Find;Pt;{Setting};Doc;Dialysis;DOC.ONTOLOGY;2;Dialysis Education note;Dialy Educ note;;ACTIVE;2.63;2.63 +87235-8;Discharge summary note;Find;Pt;{Setting};Doc;Dialysis;DOC.ONTOLOGY;2;Dialysis Discharge summary;Dialy D/C sum;;ACTIVE;2.63;2.73 +87236-6;Summary note;Find;Pt;{Setting};Doc;Dialysis;DOC.ONTOLOGY;2;Dialysis Summary note;Dialy Summary note;;ACTIVE;2.63;2.63 +87237-4;Plan of care note;Find;Pt;{Setting};Doc;Dialysis;DOC.ONTOLOGY;2;Dialysis Plan of care note;Dialy Plan of care note;;ACTIVE;2.63;2.63 +87238-2;Note;Find;Pt;{Setting};Doc;Dialysis;DOC.ONTOLOGY;2;Dialysis Note;Dialy Note;;ACTIVE;2.63;2.63 +8723-9;Surgical operation note date;TmStp;Pt;^Patient;Qn;;H&P.SURG PROC;2;Surgical operation note date;Operative note date;;ACTIVE;1.0h(3);2.27 +87239-0;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Postoperative evaluation and management note;Mental health Post-op E/M note;;ACTIVE;2.63;2.63 +87240-8;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Preoperative evaluation and management note;Mental health Pre-op note;;ACTIVE;2.63;2.63 +87241-6;Bacillus atrophaeus;PrThr;Pt;Laboratory device;Ord;Culture;MICRO;1;Bacillus atrophaeus [Presence] in Laboratory device by Culture;B atrophaeus Lab Device Ql Cult;;ACTIVE;2.63;2.63 +87242-4;Geobacillus stearothermophilus;PrThr;Pt;Laboratory device;Ord;Culture;MICRO;1;Geobacillus stearothermophilus [Presence] in Laboratory device by Culture;G stearothermophilus Lab Device Ql Cult;;ACTIVE;2.63;2.63 +87243-2;Microscopic observation;PrThr;Pt;XXX;Ord;Auramine fluorochrome stain;MICRO;1;Microscopic observation [Presence] in Specimen by Auramine fluorochrome stain;Auramine stain Spec Ql;;ACTIVE;2.63;2.69 +87244-0;Note;Find;Pt;Telephone encounter;Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Telephone encounter Note;Addiction med Phone Note;;ACTIVE;2.63;2.63 +87245-7;Note;Find;Pt;Custodial care facility;Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Custodial care facility Note;Addiction med Cust care fac Note;;ACTIVE;2.63;2.63 +87246-5;Note;Find;Pt;Hospital;Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Hospital Note;Addiction med Hosp Note;;ACTIVE;2.63;2.63 +8724-7;Surgical operation note description;Find;Pt;^Patient;Nar;;H&P.SURG PROC;2;Surgical operation note description Narrative;Operative note description;;ACTIVE;1.0h(3);2.63 +87247-3;Medication management note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Medication management note;Addiction med Med mgmt note;;ACTIVE;2.63;2.63 +87248-1;Education note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Education note;Addiction med Educ note;;ACTIVE;2.63;2.63 +87249-9;Note;Find;Pt;Outpatient;Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Outpatient Note;Addiction med OP Note;;ACTIVE;2.63;2.63 +87250-7;Referral note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Referral note;Addiction med Referral note;;ACTIVE;2.63;2.63 +87251-5;Administrative note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Administrative note;Addiction med Administrative note;;ACTIVE;2.63;2.63 +87252-3;Admission evaluation note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Admission evaluation note;Addiction med Admit eval note;;ACTIVE;2.63;2.63 +87253-1;Plan of care note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Plan of care note;Addiction med Plan of care note;;ACTIVE;2.63;2.63 +8725-4;Surgical operation note open closing duration;Time;Procedure dur;Surgical procedure;Qn;;H&P.SURG PROC;2;Surgical operation note open closing duration;Operative note open closing duration;;ACTIVE;1.0h(3);2.27 +87254-9;Consultation note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Consult note;Addiction med Consult note;;ACTIVE;2.63;2.63 +87255-6;Counseling note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Counseling note;Addiction med Counseling note;;ACTIVE;2.63;2.63 +87256-4;Discharge summary note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Discharge summary;Addiction med D/C sum;;ACTIVE;2.63;2.73 +87257-2;Group counseling note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Group counseling note;Addiction med Group counseling note;;ACTIVE;2.63;2.63 +87258-0;Risk assessment and screening note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Risk assessment and screening note;Addiction med Risk assess+scrn note;;ACTIVE;2.63;2.63 +87259-8;History and physical note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine History and physical note;Addiction med H&P note;;ACTIVE;2.63;2.63 +87260-6;Initial evaluation note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Initial evaluation note;Addiction med Initial eval note;;ACTIVE;2.63;2.63 +87261-4;Note;Find;Pt;{Setting};Doc;Addiction medicine.case manager;DOC.ONTOLOGY;2;Addiction medicine Case manager Note;Addiction med Case mgr Note;;ACTIVE;2.63;2.63 +8726-2;Surgical operation note findings;Find;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note findings;Operative note findings;;ACTIVE;1.0h(3);2.27 +87262-2;Note;Find;Pt;{Setting};Doc;Addiction medicine.nurse;DOC.ONTOLOGY;2;Addiction medicine Nurse Note;Addiction med Nurse Note;;ACTIVE;2.63;2.63 +87263-0;Note;Find;Pt;{Setting};Doc;Addiction medicine.team;DOC.ONTOLOGY;2;Addiction medicine Team Note;Addiction med Team Note;;ACTIVE;2.63;2.63 +87264-8;Note;Find;Pt;{Setting};Doc;Addiction medicine.therapist;DOC.ONTOLOGY;2;Addiction medicine Therapist Note;Addiction med Therapist Note;;ACTIVE;2.63;2.63 +87265-5;Plan of care note;Find;Pt;{Setting};Doc;Dialysis.interdisciplinary;DOC.ONTOLOGY;2;Dialysis Interdisciplinary Plan of care note;Dialysis Interdisp Plan of care note;;ACTIVE;2.63;2.63 +87266-3;Note;Find;Pt;{Setting};Doc;Dialysis.nurse;DOC.ONTOLOGY;2;Dialysis Nurse Note;Dialysis Nurse Note;;ACTIVE;2.63;2.63 +87267-1;Note;Find;Pt;{Setting};Doc;Dialysis.physician;DOC.ONTOLOGY;2;Dialysis Physician Note;Dialysis MD Note;;ACTIVE;2.63;2.63 +87268-9;Immunization note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Immunization note;Hepatology Immunization note;;ACTIVE;2.63;2.63 +87269-7;Immunization note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Immunization note;Nurse Immunization note;;ACTIVE;2.63;2.63 +8727-0;Surgical operation note indications;Imp;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note indications [Interpretation];Operative note indications Imp;;ACTIVE;1.0h(3);2.5 +87270-5;Immunization note;Find;Pt;Outpatient;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Outpatient Immunization note;Nurse OP Immunization note;;ACTIVE;2.63;2.63 +87271-3;Immunization note;Find;Pt;{Setting};Doc;Occupational medicine;DOC.ONTOLOGY;2;Occupational medicine Immunization note;Occup med Immunization note;;ACTIVE;2.63;2.63 +87272-1;Immunization note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Immunization note;Primary care Immunization note;;ACTIVE;2.63;2.63 +87273-9;Immunization note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Immunization note;Immunization note;;ACTIVE;2.63;2.63 +87274-7;Borrelia afzelii+burgdorferi+garinii Ab.IgG & IgM panel;-;Pt;Ser;-;Line blot;PANEL.MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG and IgM panel - Serum by Line blot;B afz+burg+gari IgG+IgM Pnl Ser Ln blot;;ACTIVE;2.63;2.66 +87275-4;Borrelia afzelii+burgdorferi+garinii Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG Ab [Presence] in Serum by Line blot;B afz+burg+gari IgG Ser Ql Line blot;;ACTIVE;2.63;2.73 +87276-2;Borrelia afzelii+burgdorferi+garinii Ab.IgG band pattern;Imp;Pt;Ser;Nom;Line blot;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG band pattern [Interpretation] in Serum by Line blot;B afz+burg+gari IgG Ptrn Ser Ln blot;;ACTIVE;2.63;2.67 +87277-0;Borrelia afzelii+burgdorferi+garinii Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgM Ab [Presence] in Serum by Line blot;B afz+burg+gari IgM Ser Ql Line blot;;ACTIVE;2.63;2.66 +87278-8;Borrelia afzelii+burgdorferi+garinii Ab.IgM band pattern;Imp;Pt;Ser;Nom;Line blot;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgM band pattern [Interpretation] in Serum by Line blot;B afz+burg+gari IgM Ptrn Ser Line blot;;ACTIVE;2.63;2.67 +87279-6;Multisection for screening;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest for screening;CT Chest Screening;;ACTIVE;2.63;2.63 +87280-4;Multisection^W contrast IV;Find;Pt;Abdomen>Abdominal veins & Pelvis>Pelvis veins & Lower extremity.bilateral>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Abdominal veins and Pelvis veins and Lower extremity veins - bilateral W contrast IV;CTA Abd vv+Pelvis vv+LE vv-Bl W contr IV;;ACTIVE;2.63;2.63 +87281-2;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Lower extremity veins - bilateral W contrast IV;CTA LE vv-Bl W contr IV;;ACTIVE;2.63;2.63 +87282-0;Brachyspira hyodysenteriae DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Brachyspira hyodysenteriae DNA [Cycle Threshold #] in Specimen by NAA with probe detection;B hyody DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87283-8;Brachyspira hampsonii DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Brachyspira hampsonii DNA [Cycle Threshold #] in Specimen by NAA with probe detection;B hampsonii DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87284-6;Brachyspira hyodysenteriae DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Brachyspira hyodysenteriae DNA [Presence] in Isolate by NAA with probe detection;B hyody DNA Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87285-3;Brachyspira pilosicoli DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Brachyspira pilosicoli DNA [Presence] in Specimen by NAA with probe detection;B pilosicoli DNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87286-1;Birth attendant;ExtendedID;Pt;Provider;Nom;;ADMIN;2;Birth attendant [Extended Identifier];Birth attendant Ext ID Provider;;ACTIVE;2.63;2.63 +87287-9;Birth certifier;ExtendedID;Pt;Provider;Nom;;ADMIN;2;Birth certifier [Extended Identifier];Birth certifier Ext ID Provider;;ACTIVE;2.63;2.63 +8728-8;Operative note complications;Imp;Pt;^Patient;Nom;;H&P.SURG PROC;2;Deprecated Operative note complications;DeprecatedOperative note complications;;DEPRECATED;1.0h(3);2.36 +87288-7;Date of birth certification;Date;Pt;^Patient;Qn;;ADMIN.PATIENT;2;Date of birth certification;Date birth certified;;ACTIVE;2.63;2.66 +87289-5;Date of fetal death registration;Date;Pt;^Fetus;Qn;;ADMIN;2;Date of fetal death registration;Fetal death registration date;;ACTIVE;2.63;2.63 +87290-3;Date of Social Security Number request;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Date of Social Security Number request;;;ACTIVE;2.63;2.63 +87291-1;Information source;Pn;Pt;^Mother;Nom;;SURVEY.CDC;4;Mothers Source of information;;;ACTIVE;2.63;2.63 +87292-9;Name not yet chosen;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Name not yet chosen;;;ACTIVE;2.63;2.63 +87293-7;Relationship to patient's mother;Type;Pt;^Contact;Nom;;ADMIN;2;Relationship to patient's mother;Relation to patient's mother;;ACTIVE;2.63;2.67 +87294-5;Signature for Social Security Number request;Pn;Pt;^Guardian or legally authorized representative;Nom;;SURVEY.CDC;4;Guardian or legally authorized representative signature for Social Security Number request;;;ACTIVE;2.63;2.63 +87295-2;Social Security Number was requested;Find;Pt;^Patient;Ord;;SURVEY.CDC;4;Social Security Number was requested;;;ACTIVE;2.63;2.64 +8729-6;Surgical operation note procedure;Prid;Pt;^Patient;Nom;;H&P.SURG PROC;2;Surgical operation note procedure;Operative note procedure;;ACTIVE;1.0h(3);2.27 +87296-0;Age^at delivery;Time;Pt;^Father;Qn;;SURVEY.CDC;4;Age--at delivery Father;;;ACTIVE;2.63;2.63 +87297-8;Birth registration date;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Birth registration date;;;ACTIVE;2.63;2.63 +87298-6;Cigarettes smoked per D^1st trimester;NRat;Pt;^Mother;Qn;;SURVEY.CDC;4;Cigarettes smoked per day by Mother--1st trimester;;;ACTIVE;2.63;2.66 +87299-4;Cigarettes smoked per D^2nd trimester;NRat;Pt;^Mother;Qn;;SURVEY.CDC;4;Cigarettes smoked per day by Mother--2nd trimester;;;ACTIVE;2.63;2.66 +873-0;A3 B Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A3 B Ag [Presence] on Red Blood Cells from Donor;A3 B Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +87300-0;Highest level of education;Hx;Pt;^Father;Ord;;SURVEY.CDC;4;Highest level of education Father;;;ACTIVE;2.63;2.63 +87301-8;Married at any time during pregnancy;Find;Pt;^Mother;Ord;;SURVEY.CDC;4;Mother was married at any time during pregnancy;;;ACTIVE;2.63;2.64 +87302-6;Paternity acknowledgment form signed;Find;Pt;^Father;Ord;;SURVEY.CDC;4;Paternity acknowledgment form signed Father;;;ACTIVE;2.63;2.63 +87303-4;WIC services recipient;Find;Pt;^Mother;Ord;;SURVEY.CDC;4;Mother WIC food recipient;;;ACTIVE;2.63;2.63 +8730-4;Class;Type;Pt;Cardiac measurement device;Nom;*;DEVICES;2;Type of Cardiac measurement device;Cardiac Measurement Device Class;;ACTIVE;1.0h(3);2.29 +87304-2;Clostridium perfringens cpa gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Clostridium perfringens cpa gene [Presence] in Isolate by NAA with probe detection;C perfringens cpa Islt Ql NAA+probe;;ACTIVE;2.63;2.64 +87305-9;Clostridium perfringens cpb2 gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Clostridium perfringens cpb2 gene [Presence] in Isolate by NAA with probe detection;C perfringens cpb2 Islt Ql NAA+probe;;ACTIVE;2.63;2.64 +87306-7;Clostridium perfringens cpe gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Clostridium perfringens cpe gene [Presence] in Isolate by NAA with probe detection;C perfringens cpe Islt Ql NAA+probe;;ACTIVE;2.63;2.64 +87307-5;Clostridium perfringens etx gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Clostridium perfringens etx gene [Presence] in Isolate by NAA with probe detection;C perfringens etx gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87308-3;Guidance for transhepatic removal of catheter;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for transhepatic removal of catheter of Biliary ducts;Guided BDs Transhep cath remove;;ACTIVE;2.63;2.64 +87309-1;Guidance for transhepatic placement of catheter;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for transhepatic placement of catheter of Biliary ducts;Guided BDs Transhep cath place;;ACTIVE;2.63;2.64 +87310-9;Guidance for transhepatic exchange of catheter;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for transhepatic exchange of catheter of Biliary ducts;Guided BDs Transhep cath exchange;;ACTIVE;2.63;2.64 +87311-7;Guidance for embolization for tumor or ischemia or infarction;Find;Pt;XXX>Vessel;Doc;{Imaging modality};RAD;2;Guidance for embolization for tumor, ischemia or infarction of Vessel;Guided Ves Tum ischem or infarct embol;;ACTIVE;2.63;2.64 +8731-2;Cardiac output;VRat;Pt;Heart.ventricle;Qn;2D echo;HEMODYN.MOLEC;2;Ventricular Cardiac output by 2D echo;Hrt ventr Output 2D Echo;;ACTIVE;1.0h(3);2.48 +87312-5;Guidance for percutaneous transluminal angioplasty for dialysis;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for percutaneous transluminal angioplasty for dialysis of Vein;Guided Vein PTA for dial;;ACTIVE;2.63;2.64 +87313-3;Clostridium perfringens iota toxin DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Clostridium perfringens iota toxin DNA [Presence] in Isolate by NAA with probe detection;C perfrin iota tox DNA Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87314-1;Encephalomyocarditis virus;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Encephalomyocarditis virus [Presence] in Tissue by Organism specific culture;EMCV Tiss Ql Cult;;ACTIVE;2.63;2.63 +87315-8;Encephalomyocarditis virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Encephalomyocarditis virus RNA [Presence] in Tissue by NAA with probe detection;EMCV RNA Tiss Ql NAA+probe;;ACTIVE;2.63;2.63 +87316-6;Enterovirus G RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Enterovirus G RNA [Presence] in Specimen by NAA with probe detection;EV-G RNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87317-4;Escherichia coli;NCnc;Pt;Water;Qn;Viability count;MICRO;1;Escherichia coli [#/volume] in Water by Viability count;E coli # Wat Viab Cnt;;ACTIVE;2.63;2.66 +87318-2;Escherichia coli eaeA gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli eaeA gene [Presence] in Isolate by NAA with probe detection;EC eaeA gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87319-0;Escherichia coli enteroaggregative astA gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enteroaggregative astA gene [Presence] in Isolate by NAA with probe detection;EAEC astA gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +8732-0;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;Angiography.biplane;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Angiography biplane;LV Output Angio BP;;ACTIVE;1.0h(3);2.48 +87320-8;Escherichia coli enterotoxigenic heat-labile toxin DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enterotoxigenic heat-labile toxin DNA [Presence] in Isolate by NAA with probe detection;ETEC heat-lab tox DNA Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87321-6;Escherichia coli enterotoxigenic sta gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enterotoxigenic sta gene [Presence] in Isolate by NAA with probe detection;ETEC sta gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87322-4;Escherichia coli enterotoxigenic stb gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enterotoxigenic stb gene [Presence] in Isolate by NAA with probe detection;ETEC stb gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87323-2;Porcine circovirus type 1 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 1 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PCV1 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87324-0;Porcine circovirus type 2;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Porcine circovirus type 2 [Presence] in Specimen by Organism specific culture;PCV2 Spec Ql Cult;;ACTIVE;2.63;2.69 +87325-7;Porcine circovirus type 2 Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Porcine circovirus type 2 Ab [Titer] in Serum by Immunoassay;PCV2 Ab Titr Ser IA;;ACTIVE;2.63;2.63 +87326-5;Porcine circovirus type 2 Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Porcine circovirus type 2 IgG Ab [Titer] in Serum by Immunoassay;PCV2 IgG Titr Ser IA;;ACTIVE;2.63;2.63 +87327-3;Porcine circovirus type 2 Ab.IgG+IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Porcine circovirus type 2 IgG+IgM Ab [Titer] in Serum by Immunofluorescence;PCV2 IgG+IgM Titr Ser IF;;ACTIVE;2.63;2.63 +87328-1;Porcine circovirus type 2 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Porcine circovirus type 2 IgG+IgM Ab [Presence] in Serum by Immunofluorescence;PCV2 IgG+IgM Ser Ql IF;;ACTIVE;2.63;2.63 +87329-9;Porcine circovirus type 2 Ab.IgG/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Porcine circovirus type 2 IgG Ab/Positive control in Serum by Immunoassay;PCV2 IgG/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87330-7;Porcine Circovirus type 2 Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Porcine circovirus type 2 neutralizing antibody [Titer] in Serum by Neutralization test;PCV2 NAb Titr Ser Nt;;ACTIVE;2.63;2.63 +87331-5;Porcine circovirus type 2 Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Porcine circovirus type 2 Ab/Negative control in Serum by Immunoassay;PCV2 Ab Ser IA;;ACTIVE;2.63;2.63 +87332-3;Porcine circovirus type 2 Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Porcine circovirus type 2 Ag [Presence] in Tissue by Immune stain;PCV2 Ag Tiss Ql ImStn;;ACTIVE;2.63;2.63 +87333-1;Porcine circovirus type 2 ORF2 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine circovirus type 2 ORF2 gene [Nucleotide sequence] in Isolate by Sequencing;PCV 2 ORF2 gene Islt-Seq;;ACTIVE;2.64;2.64 +87334-9;Porcine circovirus type 2 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 2 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;PCV2 DNA # Spec NAA+probe;;ACTIVE;2.63;2.69 +87335-6;Porcine circovirus type 2 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 2 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PCV2 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87336-4;Porcine circovirus type 2 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine circovirus type 2 DNA [Presence] in Specimen by NAA with probe detection;PCV2 DNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87337-2;Porcine circovirus type 2 RFLP pattern;Type;Pt;Isolate;Nom;RFLP;MICRO;1;Porcine circovirus type 2 RFLP pattern [Type] in Isolate by RFLP;PCV2 RFLP patt Islt RFLP;;ACTIVE;2.63;2.63 +8733-8;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;Angiography.single plane;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Angiography single plane;LV Output Angio SP;;ACTIVE;1.0h(3);2.48 +87338-0;Porcine circovirus type 2 strain identified;Type;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine circovirus type 2 strain identified [Type] in Isolate by Sequencing;PCV2 Islt Seq;;ACTIVE;2.63;2.63 +87339-8;Porcine circovirus type 2a DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 2a DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PCV2a DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87340-6;Porcine circovirus type 2b DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 2b DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PCV2b DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87341-4;Pseudorabies virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Pseudorabies virus [Presence] in Specimen by Organism specific culture;PRV Spec Ql Cult;;ACTIVE;2.63;2.69 +87342-2;Pseudorabies virus DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Pseudorabies virus DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PRV DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87343-0;Pseudorabies virus glycoprotein 1 Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Pseudorabies virus glycoprotein 1 Ab/Negative control in Serum by Immunoassay;PRV glycoprot 1 Ab Ser IA;;ACTIVE;2.63;2.63 +87344-8;Pseudorabies virus glycoprotein B Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Pseudorabies virus glycoprotein B Ab/Negative control in Serum by Immunoassay;PRV glycoprot B Ab Ser IA;;ACTIVE;2.63;2.63 +87345-5;Senecavirus A;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Senecavirus A [Presence] in Specimen by Organism specific culture;SVA Spec Ql Cult;;ACTIVE;2.63;2.69 +8734-6;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;CT spiral;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Spiral CT;LV Output Spiral CT;;ACTIVE;1.0h(3);2.48 +87346-3;Senecavirus A Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Senecavirus A Ab [Titer] in Serum by Immunofluorescence;SVA Ab Titr Ser IF;;ACTIVE;2.63;2.63 +87347-1;Senecavirus A Ab.IgG/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Senecavirus A IgG Ab/Positive control in Serum by Immunoassay;SVA IgG/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87348-9;Senecavirus A RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Senecavirus A RNA [Presence] in Specimen by NAA with probe detection;SVA RNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87349-7;Senecavirus A VP1 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Senecavirus A VP1 gene [Nucleotide sequence] in Isolate by Sequencing;SVA VP1 gene Islt-Seq;;ACTIVE;2.64;2.64 +87350-5;Senecavirus A RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Senecavirus A RNA [Cycle Threshold #] in Specimen by NAA with probe detection;SVA RNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87351-3;Senecavirus A RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Senecavirus A RNA [#/volume] (viral load) in Specimen by NAA with probe detection;SVA RNA # Spec NAA+probe;;ACTIVE;2.63;2.69 +87352-1;Senecavirus A whole genome;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Senecavirus A whole genome [Nucleotide sequence] in Isolate by Sequencing;SVA whole genome Islt-Seq;;ACTIVE;2.63;2.63 +8735-3;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.doppler;HEMODYN.MOLEC;2;Left ventricular Cardiac output by US.doppler;LV Output DOP;;ACTIVE;1.0h(3);2.48 +87353-9;Actinobacillus pleuropneumoniae Ab.IgG/Positive control;RelRto;Pt;-;Qn;IA;MICRO;1;Deprecated Actinobacillus pleuropneumoniae IgG Ab/Positive control by Immunoassay;Deprecated A pleuropn IgG/Pos cntrl IA;;DEPRECATED;2.63;2.66 +87354-7;Actinobacillus pleuropneumoniae Ab/Positive control;RelRto;Pt;Ser/Plas;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae Ab/Positive control in Serum or Plasma by Immunoassay;A pleuropn Ab/Pos cntrl SerPl IA;;ACTIVE;2.63;2.63 +87355-4;Actinobacillus pleuropneumoniae serotype 10 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 10 Ab/Positive control in Serum by Immunoassay;A pleuropn 10 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87356-2;Actinobacillus pleuropneumoniae serotype 12 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 12 Ab/Positive control in Serum by Immunoassay;A pleuropn 12 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87357-0;Actinobacillus pleuropneumoniae serotype 2 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 2 Ab/Positive control in Serum by Immunoassay;A pleuropn 2 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87358-8;Actinobacillus pleuropneumoniae serotype 5 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotype 5 Ab/Positive control in Serum by Immunoassay;A pleuropn 5 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87359-6;Actinobacillus pleuropneumoniae serotypes 3+6+8 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotypes 3+6+8 Ab/Positive control in Serum by Immunoassay;A pleuropn 3+6+8 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87360-4;Actinobacillus pleuropneumoniae serotypes 4+5+7 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotypes 4+5+7 Ab/Positive control in Serum by Immunoassay;A pleuropn 4+5+7 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +8736-1;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;Fick;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Fick method;LV Output Fick;;ACTIVE;1.0h(3);2.48 +87361-2;Toxoplasma gondii Ab/Negative control;RelRto;Pt;Ser/Plas;Qn;IA;MICRO;1;Toxoplasma gondii Ab/Negative control in Serum or Plasma by Immunoassay;T gondii Ab SerPl IA;;ACTIVE;2.63;2.63 +87362-0;Actinobacillus pleuropneumoniae serotypes 1+2+9+11 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotypes 1+2+9+11 Ab/Positive control in Serum by Immunoassay;A pleuropn 1+2+9+11 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87363-8;Actinobacillus pleuropneumoniae serotypes 3+6+8+15 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotypes 3+6+8+15 Ab/Positive control in Serum by Immunoassay;A pleuropn 3+6+8+15 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87364-6;Haemophilus parasuis Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Haemophilus parasuis Ab/Positive control in Serum by Immunoassay;H parasuis Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87365-3;Actinobacillus pleuropneumoniae serotypes 4+7 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotypes 4+7 Ab/Positive control in Serum by Immunoassay;A pleuropn 4+7 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87366-1;Actinobacillus pleuropneumoniae serotypes 1+9+11 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotypes 1+9+11 Ab/Positive control in Serum by Immunoassay;A pleuropn 1+9+11 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87367-9;Erysipelothrix rhusiopathiae Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Erysipelothrix rhusiopathiae Ab/Positive control in Serum by Immunoassay;E rhusiopathiae Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87368-7;Actinobacillus pleuropneumoniae serotypes 10+12 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae serotypes 10+12 Ab/Positive control in Serum by Immunoassay;A pleuropn 10+12 Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87369-5;Lawsonia intracellularis VNTR pattern;Type;Pt;XXX;Nom;Molgen;MICRO;1;Lawsonia intracellularis VNTR pattern [Type] in Specimen by Molecular genetics method;L intracell VNTR patt Spec;;ACTIVE;2.63;2.69 +87370-3;Escherichia coli fasA gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli fasA gene [Presence] in Isolate by NAA with probe detection;EC fasA gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87371-1;Escherichia coli fedF gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli fedF gene [Presence] in Isolate by NAA with probe detection;EC fedF gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87372-9;Escherichia coli FimF41a gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli FimF41a gene [Presence] in Isolate by NAA with probe detection;EC FimF41a gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87373-7;Escherichia coli K88 DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli K88 DNA [Presence] in Isolate by NAA with probe detection;E coli K88 DNA Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87374-5;Escherichia coli K99 DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli K99 DNA [Presence] in Isolate by NAA with probe detection;E coli K99 DNA Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87375-2;Escherichia coli paa gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli paa gene [Presence] in Isolate by NAA with probe detection;EC paa gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87376-0;Escherichia coli Stx1 toxin stx1 gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx1 toxin stx1 gene [Presence] in Isolate by NAA with probe detection;EC stx1 gene Islt Ql NAA+probe;;ACTIVE;2.63;2.64 +87377-8;Escherichia coli Stx2 toxin stx2 gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx2 toxin stx2 gene [Presence] in Isolate by NAA with probe detection;EC stx2 gene Islt Ql NAA+probe;;ACTIVE;2.63;2.64 +87378-6;Tubular extraction rate/1.73 sq M;ArVRat;Pt;Ser/Bld;Qn;Isotopic;CHEM;1;Isotopic Tubular extraction rate/1.73 sq M [Volume Rate/Area] in Serum or Blood;Isotopic TER/1.73 sq M SerBld-ArVRat;;ACTIVE;2.63;2.63 +8737-9;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;Indicator dilution;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Indicator dilution;LV Output Indicator dilution;;ACTIVE;1.0h(3);2.48 +87379-4;Cannabinol;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Cannabinol [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Cannabinol SerPlBld Cfm-mCnc;;ACTIVE;2.63;2.73 +87380-2;Escherichia coli Stx2e toxin stx2e gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli Stx2e toxin stx2e gene [Presence] in Isolate by NAA with probe detection;EC stx2e gene Islt Ql NAA+probe;;ACTIVE;2.63;2.64 +87381-0;Porcine Adenovirus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Porcine adenovirus Ab [Titer] in Serum by Immunoassay;PAdV Ab Titr Ser IA;;ACTIVE;2.63;2.63 +87382-8;Porcine cytomegalovirus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine cytomegalovirus DNA [Presence] in Specimen by NAA with probe detection;PCMV DNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87383-6;Porcine hemagglutinating encephalomyelitis virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine hemagglutinating encephalomyelitis virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PHEV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87384-4;Porcine parainfluenza virus 1 HN gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine parainfluenza virus 1 HN gene [Nucleotide sequence] in Isolate by Sequencing;PPIV1 HN Islt-Seq;;ACTIVE;2.63;2.64 +87385-1;Porcine parainfluenza virus 1 F gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine parainfluenza virus 1 F gene [Nucleotide sequence] in Isolate by Sequencing;PPIV1 F Islt-Seq;;ACTIVE;2.63;2.64 +87386-9;Porcine parainfluenza virus 1 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine parainfluenza virus 1 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PPIV1 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +8738-7;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;MR;HEMODYN.MOLEC;2;Left ventricular Cardiac output by MR;LV Output MR;;ACTIVE;1.0h(3);2.56 +87387-7;Porcine parainfluenza virus 1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine parainfluenza virus 1 RNA [Presence] in Specimen by NAA with probe detection;PPIV1 RNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87388-5;Porcine sapelovirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Porcine sapelovirus [Presence] in Specimen by Organism specific culture;PSV Spec Ql Cult;;ACTIVE;2.63;2.69 +87389-3;Porcine sapelovirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine sapelovirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PSV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87390-1;Porcine sapelovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine sapelovirus RNA [Presence] in Specimen by NAA with probe detection;PSV RNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87391-9;Porcine teschovirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine teschovirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PTV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87392-7;Porcine teschovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine teschovirus RNA [Presence] in Specimen by NAA with probe detection;PTV RNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87393-5;Salmonella sp Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Salmonella sp Ab/Positive control in Serum by Immunoassay;Salmonella Ab/Pos cntrl Ser IA;;ACTIVE;2.63;2.63 +87394-3;Salmonella sp DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Salmonella sp DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Salmonella DNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +8739-5;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Left ventricular Cardiac output by Nuclear blood pool;LV Output Nuc BP;;ACTIVE;1.0h(3);2.48 +87395-0;West Nile virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;West Nile virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;WNV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.63;2.69 +87396-8;GenBank sequence accession number;ID;Pt;Isolate;Nom;;MOLPATH;1;GenBank accession number;GenBank accession ID Islt;;ACTIVE;2.63;2.7 +87397-6;Clostridium perfringens cpb gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Clostridium perfringens cpb gene [Presence] in Isolate by NAA with probe detection;C perfringens cpb Islt Ql NAA+probe;;ACTIVE;2.63;2.64 +87398-4;Brachyspira sp DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Brachyspira sp DNA [Presence] in Isolate by NAA with probe detection;Brachyspira DNA Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87399-2;Porcine teschovirus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Porcine teschovirus [Presence] in Specimen by Organism specific culture;PTV Spec Ql Cult;;ACTIVE;2.63;2.69 +87400-8;Brachyspira sp Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Brachyspira sp Ag [Presence] in Tissue by Immune stain;Brachyspira Ag Tiss Ql ImStn;;ACTIVE;2.63;2.63 +87401-6;Brachyspira pilosicoli DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Brachyspira pilosicoli DNA [Presence] in Isolate by NAA with probe detection;B pilosicoli DNA Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87402-4;Escherichia coli aidA-I gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Escherichia coli aidA-I gene [Presence] in Isolate by NAA with probe detection;EC aidA-I gene Islt Ql NAA+probe;;ACTIVE;2.63;2.63 +87403-2;Platelet aggregation.ristocetin induced^750 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --750 ug/mL;PA Rist 750 ug/mL PRP;;ACTIVE;2.63;2.63 +87404-0;Certolizumab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Certolizumab [Mass/volume] in Serum or Plasma by Immunoassay;Certolizumab SerPl IA-mCnc;;ACTIVE;2.63;2.63 +87405-7;Certolizumab Ab;ACnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Certolizumab Ab [Units/volume] in Serum or Plasma by Immunoassay;Certolizumab Ab SerPl IA-aCnc;;ACTIVE;2.63;2.68 +87406-5;Golimumab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Golimumab [Mass/volume] in Serum or Plasma by Immunoassay;Golimumab SerPl IA-mCnc;;ACTIVE;2.63;2.73 +87407-3;Golimumab Ab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Golimumab Ab [Mass/volume] in Serum or Plasma by Immunoassay;Golimumab Ab SerPl IA-mCnc;;ACTIVE;2.63;2.73 +87408-1;Ustekinumab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Ustekinumab [Mass/volume] in Serum or Plasma by Immunoassay;Ustekinumab SerPl IA-mCnc;;ACTIVE;2.63;2.73 +87409-9;Ustekinumab Ab;ACnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Ustekinumab Ab [Units/volume] in Serum or Plasma by Immunoassay;Ustekinumab Ab SerPl IA-aCnc;;ACTIVE;2.63;2.73 +87410-7;Thymidine synthase activity interpretation;Imp;Pt;Bld/Tiss;Ord;;MOLPATH.PHARMG;1;Thymidine synthase activity interpretation in Blood or Tissue Qualitative;TS act interp Bld/T-Imp;;ACTIVE;2.63;2.63 +8741-1;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;;HEMODYN.ATOM;2;Left ventricular Cardiac output;LV Output;;ACTIVE;1.0h(3);2.73 +87411-5;Brachyspira hyodysenteriae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Brachyspira hyodysenteriae DNA [Presence] in Specimen by NAA with probe detection;B hyody DNA Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87412-3;Brachyspira sp nox gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Brachyspira sp nox gene [Nucleotide sequence] in Isolate by Sequencing;Brachyspira sp nox gene Islt-Seq;;ACTIVE;2.63;2.63 +87413-1;Brachyspira sp;Type;Pt;Isolate;Nom;Sequencing;MICRO;1;Brachyspira sp [Type] in Isolate by Sequencing;Brachyspira Islt Seq;;ACTIVE;2.63;2.63 +87414-9;Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 1.5;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI) - version 1.5 [CMS Assessment];;;DEPRECATED;2.63;2.73 +87415-6;IRF-PAI v3.0 - Medical information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Medical Info [CMS Assessment];;;ACTIVE;2.63;2.69 +87416-4;Diagnostic imaging report - recommended DICOM PS3.20 sections;-;Pt;{Setting};-;;PANEL.DOC;2;Diagnostic imaging report - recommended DICOM PS3.20 sections;DIR DICOM PS3.20 Sections;;ACTIVE;2.63;2.63 +87417-2;Cytolethal distending toxin B & Vinculin Ab panel;-;Pt;Ser;-;IA;PANEL.MICRO;1;Cytolethal distending toxin B and Vinculin Ab panel - Serum by Immunoassay;CdtB + Vinculin Ab pnl Ser IA;;ACTIVE;2.63;2.63 +87418-0;Cytolethal distending toxin B Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Cytolethal distending toxin B Ab [Units/volume] in Serum by Immunoassay;CdtB Ab Ser IA-aCnc;;ACTIVE;2.63;2.73 +87419-8;Cytolethal distending toxin B+Vinculin Ab;Imp;Pt;Ser;Ord;IA;SERO;1;Cytolethal distending toxin B+Vinculin Ab [Interpretation] in Serum Qualitative by Immunoassay;CdtB+Vinculin Ab Ser IA-Imp;;ACTIVE;2.63;2.73 +87420-6;Vinculin Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Vinculin Ab [Units/volume] in Serum by Immunoassay;Vinculin Ab Ser IA-aCnc;;ACTIVE;2.63;2.73 +87421-4;Glucose^pre-meal;MCnc;-;Bld;Qn;;CHAL.ROUTINE;1;Deprecated Glucose [Mass/volume] in Blood --pre-meal;Deprecated Glucose pre-meal Bld-mCnc;;DEPRECATED;2.63;2.66 +87422-2;Glucose^post meal;MCnc;Pt;Bld;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Blood --post meal;Glucose p meal Bld-mCnc;;ACTIVE;2.63;2.63 +87423-0;Borrelia burgdorferi Ab.IgG & IgM panel;-;Pt;CSF;-;IB;PANEL.MICRO;1;Borrelia burgdorferi IgG and IgM panel - Cerebral spinal fluid by Immunoblot;B burgdor IgG+IgM Pnl CSF IB;;ACTIVE;2.63;2.74 +87424-8;Cytomegalovirus Ab.IgG & IgM Panel;-;Pt;Ser/Plas;Ord;;PANEL.MICRO;1;Cytomegalovirus IgG and IgM panel - Serum or Plasma Qualitative;CMV IgG+IgM Pnl SerPl;;ACTIVE;2.63;2.63 +87426-3;Inhibin A & B panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Inhibin A and B panel - Serum or Plasma;Inhibin A + B Pnl SerPl;;ACTIVE;2.63;2.63 +87427-1;Neutrophil cytoplasmic Ab panel;-;Pt;Ser;-;IF;PANEL.SERO;1;Neutrophil cytoplasmic Ab panel - Serum by Immunofluorescence;ANCA Pnl Ser IF;;ACTIVE;2.63;2.63 +87428-9;Drugs of abuse screen W Reflex confirm panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Drugs of abuse screen W Reflex confirm panel - Urine;Drugs of abuse W Reflex Pnl Ur;;ACTIVE;2.63;2.63 +8742-9;Cardiac output ventricle right/Ventricle left;VRto;Pt;Circulatory system;Qn;US.doppler;HEMODYN.MOLEC;2;Pulmonary blood flow/Systemic blood flow by US.doppler;Qp/Qs DOP;;ACTIVE;1.0h(3);2.48 +87429-7;Cortisol AM & PM panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Cortisol AM and PM panel - Serum or Plasma;Cortisol AM + PM Pnl SerPl;;ACTIVE;2.63;2.63 +87430-5;Cystatin C & Glomerular filtration rate by Cystatin C-based formula panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Cystatin C and Glomerular filtration rate by Cystatin C-based formula panel - Serum or Plasma;Cystatin C + GFR by Cystatin C Pnl SerPl;;ACTIVE;2.63;2.73 +87431-3;Herpes simplex virus 1 & 2 DNA panel;-;Pt;XXX;Ord;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Specimen Qualitative by NAA with probe detection;HSV 1+2 DNA Pnl Spec NAA+probe;;ACTIVE;2.63;2.73 +87432-1;Mycophenolate & mycophenolate glucuronide panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Mycophenolate and mycophenolate glucuronide panel - Serum or Plasma;Mycoph + Mycoph-G Pnl SerPl;;ACTIVE;2.63;2.63 +87433-9;Hemoglobin.free & oxyhemoglobin panel;-;Pt;Plas;Qn;;PANEL.HEM/BC;1;Free hemoglobin and oxyhemoglobin panel - Plasma;Hgb Free + OxyHgb Pnl Plas;;ACTIVE;2.63;2.63 +87434-7;Protein & creatinine panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Protein and creatinine panel - Urine;Protein + creat Pnl Ur;;ACTIVE;2.63;2.73 +87435-4;Coccidioides immitis Ab.IgG & IgM panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Coccidioides immitis IgG and IgM panel - Serum or Plasma;C immitis IgG + IgM Pnl SerPl;;ACTIVE;2.63;2.63 +87436-2;Chromosome X & Y aneuploidy;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH;1;Chromosome X and Y aneuploidy in Blood or Tissue by FISH;Chr X + Y aneup Bld/T FISH;;ACTIVE;2.63;2.66 +8743-7;Cardiac output ventricle right/Ventricle left;VRto;Pt;Circulatory system;Qn;Imaging;HEMODYN.MOLEC;2;Pulmonary blood flow/Systemic blood flow by Imaging;Qp/Qs Imaging;;ACTIVE;1.0h(3);2.48 +87437-0;Oxyhemoglobin;MCnc;Pt;Plas;Qn;;CHEM;1;Oxyhemoglobin [Mass/volume] in Plasma;OxyHgb Plas-mCnc;;ACTIVE;2.63;2.63 +87438-8;Dengue virus 1+2+3+4 & Zika virus Ab.IgA+IgG+IgM;Imp;Pt;XXX;Nom;IA;MICRO;1;Dengue virus 1+2+3+4 and Zika virus IgA+IgG+IgM Ab [Interpretation] in Specimen by Immunoassay;DENV1-4 + Zika IgA+IgG+IgM Spec IA-Imp;;ACTIVE;2.63;2.69 +87439-6;Zika virus Ab.IgA+IgG+IgM;Imp;Pt;XXX;Ord;IA;MICRO;1;Zika virus IgA+IgG+IgM Ab [Interpretation] in Specimen Qualitative by Immunoassay;ZIKV IgA+IgG+IgM Spec IA-Imp;;ACTIVE;2.63;2.69 +87440-4;Dengue virus 1+2+3+4 Ab.IgA+IgG+IgM;Imp;Pt;XXX;Ord;IA;MICRO;1;Dengue virus 1+2+3+4 IgA+IgG+IgM Ab [Interpretation] in Specimen Qualitative by Immunoassay;DENV1+2+3+4 IgA+IgG+IgM Spec IA-Imp;;ACTIVE;2.63;2.69 +87441-2;Dengue virus 1+2+3+4 & Zika virus Ab.IgA+IgG+IgM panel;-;Pt;XXX;-;IA;PANEL.MICRO;1;Dengue virus 1+2+3+4 and Zika virus IgA+IgG+IgM panel - Specimen by Immunoassay;DENV1-4 + Zika IgA+IgG+IgM Pnl Spec IA;;ACTIVE;2.63;2.69 +87442-0;Turbidity;Arb;Pt;Water;Qn;;SPEC;1;Turbidity of Water;Turbidity Wat;;ACTIVE;2.63;2.63 +87443-8;Hardness;MCnc;Pt;Water;Qn;Calculated;SPEC;1;Hardness [Mass/volume] of Water by Calculation;Hardness Wat Calc-mCnc;;ACTIVE;2.63;2.63 +87444-6;Electrical conductivity;FldConduct;Pt;Water;Qn;;SPEC;1;Electrical conductivity [Fluid Conductance] of Water;Elec conductivity Wat;;ACTIVE;2.63;2.63 +8744-5;Cardiac output ventricle right/Ventricle left;VRto;Pt;Circulatory system;Qn;Oximetry;HEMODYN.MOLEC;2;Pulmonary blood flow/Systemic blood flow by Oximetry;Qp/Qs Oximetry;;ACTIVE;1.0h(3);2.48 +87445-3;Fungus;PrThr;Pt;Food;Ord;Culture;MICRO;1;Fungus [Presence] in Food by Culture;Fungus Food Ql Cult;;ACTIVE;2.63;2.63 +87446-1;Zinc;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Zinc [Mass/mass] in Specimen;Zinc Spec-mCnt;;ACTIVE;2.63;2.69 +87447-9;Vanadium;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Vanadium [Mass/volume] in Specimen;Vanadium Spec-mCnc;;ACTIVE;2.63;2.69 +87448-7;Vanadium;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Vanadium [Mass/mass] in Specimen;Vanadium Spec-mCnt;;ACTIVE;2.63;2.69 +87449-5;Sulfur;MCnc;Pt;XXX;Qn;;CHEM;1;Sulfur [Mass/volume] in Specimen;Sulfur Spec-mCnc;;ACTIVE;2.63;2.69 +87450-3;Sulfur;MCnt;Pt;XXX;Qn;;CHEM;1;Sulfur [Mass/mass] in Specimen;Sulfur Spec-mCnt;;ACTIVE;2.63;2.69 +87451-1;Sodium;MCnc;Pt;XXX;Qn;;CHEM;1;Sodium [Mass/volume] in Specimen;Sodium Spec-mCnc;;ACTIVE;2.63;2.73 +8745-2;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.2D;HEMODYN.MOLEC;2;Left ventricular Cardiac index by US 2D;LV Cardiac index 2D US;;ACTIVE;1.0h(3);2.48 +87452-9;Sodium;MCnt;Pt;XXX;Qn;;CHEM;1;Sodium [Mass/mass] in Specimen;Sodium Spec-mCnt;;ACTIVE;2.63;2.69 +87453-7;Selenium;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Selenium [Mass/mass] in Specimen;Selenium Spec-mCnt;;ACTIVE;2.63;2.69 +87454-5;Potassium;MCnc;Pt;XXX;Qn;;CHEM;1;Potassium [Mass/volume] in Specimen;Potassium Spec-mCnc;;ACTIVE;2.63;2.69 +87455-2;Potassium;MCnt;Pt;XXX;Qn;;CHEM;1;Potassium [Mass/mass] in Specimen;Potassium Spec-mCnt;;ACTIVE;2.63;2.69 +87456-0;Phosphate;MCnc;Pt;XXX;Qn;;CHEM;1;Phosphate [Mass/volume] in Specimen;Phosphate Spec-mCnc;;ACTIVE;2.63;2.69 +87457-8;Phosphate;MCnt;Pt;XXX;Qn;;CHEM;1;Phosphate [Mass/mass] in Specimen;Phosphate Spec-mCnt;;ACTIVE;2.63;2.69 +87458-6;Particle diameter.mean;Len;Pt;Feed;Qn;;SPEC;1;Mean diameter [Length] of Feed particles;Mean diameter Feed particles;;ACTIVE;2.63;2.63 +87459-4;Nitrite;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nitrite [Mass/volume] in Specimen;Nitrite Spec-mCnc;;ACTIVE;2.63;2.69 +8746-0;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;Angiography.biplane;HEMODYN.MOLEC;2;Left ventricular Cardiac index by Angiography biplane;LV Cardiac index Angio BP;;ACTIVE;1.0h(3);2.48 +87460-2;Nitrite;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Nitrite [Mass/mass] in Specimen;Nitrite Spec-mCnt;;ACTIVE;2.63;2.69 +87461-0;Nitrate;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nitrate [Mass/volume] in Specimen;Nitrate Spec-mCnc;;ACTIVE;2.63;2.69 +87462-8;Nitrate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Nitrate [Mass/mass] in Specimen;Nitrate Spec-mCnt;;ACTIVE;2.63;2.69 +87463-6;Nickel;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Nickel [Mass/mass] in Specimen;Nickel Spec-mCnt;;ACTIVE;2.63;2.69 +87464-4;Monensin;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Monensin [Mass/volume] in Specimen;Monensin Spec-mCnc;;ACTIVE;2.63;2.69 +87465-1;Monensin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Monensin [Mass/mass] in Specimen;Monensin Spec-mCnt;;ACTIVE;2.63;2.69 +87466-9;Molybdenum;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Molybdenum [Mass/mass] in Specimen;Molybdenum Spec-mCnt;;ACTIVE;2.63;2.69 +87467-7;Manganese;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Manganese [Mass/volume] in Specimen;Manganese Spec-mCnc;;ACTIVE;2.63;2.69 +87468-5;Manganese;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Manganese [Mass/mass] in Specimen;Manganese Spec-mCnt;;ACTIVE;2.63;2.69 +87469-3;Magnesium;MCnc;Pt;XXX;Qn;;CHEM;1;Magnesium [Mass/volume] in Specimen;Magnesium Spec-mCnc;;ACTIVE;2.63;2.69 +87470-1;Magnesium;MCnt;Pt;XXX;Qn;;CHEM;1;Magnesium [Mass/mass] in Specimen;Magnesium Spec-mCnt;;ACTIVE;2.63;2.69 +87471-9;Iron;MCnc;Pt;XXX;Qn;;CHEM;1;Iron [Mass/volume] in Specimen;Iron Spec-mCnc;;ACTIVE;2.63;2.69 +87472-7;Copper;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Copper [Mass/mass] in Specimen;Copper Spec-mCnt;;ACTIVE;2.63;2.69 +87473-5;Cobalt;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Cobalt [Mass/mass] in Specimen;Cobalt Spec-mCnt;;ACTIVE;2.63;2.69 +87474-3;Chromium;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Chromium [Mass/mass] in Specimen;Chromium Spec-mCnt;;ACTIVE;2.63;2.69 +87475-0;Chloride;MCnc;Pt;XXX;Qn;;CHEM;1;Chloride [Mass/volume] in Specimen;Chloride Spec-mCnc;;ACTIVE;2.63;2.69 +87476-8;Chloride;MCnt;Pt;XXX;Qn;;CHEM;1;Chloride [Mass/mass] in Specimen;Chloride Spec-mCnt;;ACTIVE;2.63;2.69 +87477-6;Calcium;MFr;Pt;XXX;Qn;;CHEM;1;Calcium in Specimen;Calcium MFr Spec;;ACTIVE;2.63;2.69 +8747-8;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;Angiography.single plane;HEMODYN.MOLEC;2;Left ventricular Cardiac index by Angiography single plane;LV Cardiac index Angio SP;;ACTIVE;1.0h(3);2.48 +87478-4;Cadmium;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Cadmium [Mass/mass] in Specimen;Cadmium Spec-mCnt;;ACTIVE;2.63;2.69 +87479-2;Boron;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Boron [Mass/mass] in Specimen;Boron Spec-mCnt;;ACTIVE;2.63;2.69 +874-8;A3 B Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A3 B Ag [Presence] on Red Blood Cells;A3 B Ag RBC Ql;;ACTIVE;1.0;2.56 +87480-0;Bone ash/Bone.total;MFr;Pt;Bone;Qn;;CHEM;1;Bone ash/Bone.total in Bone;Bone ash MFr Bone;;ACTIVE;2.63;2.63 +87481-8;Arsenic;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Specimen;Arsenic Spec-mCnc;;ACTIVE;2.63;2.69 +87482-6;Aluminum;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Specimen;Aluminum Spec-mCnc;;ACTIVE;2.63;2.69 +87483-4;Aluminum;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aluminum [Mass/mass] in Specimen;Aluminum Spec-mCnt;;ACTIVE;2.63;2.69 +87484-2;BB-22 3-carboxyindole;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;BB-22 3-carboxyindole (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;BB-22 3-carboxyindole Ur Ql Cfm;;ACTIVE;2.63;2.73 +87485-9;ADBICA N-pentanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;ADBICA N-pentanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;ADBICA N-pentanoate Ur Ql Cfm;;ACTIVE;2.63;2.73 +8748-6;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;CT spiral;HEMODYN.MOLEC;2;Left ventricular Cardiac index by Spiral CT;LV Cardiac index Spiral CT;;ACTIVE;1.0h(3);2.48 +87486-7;PB-22 3-carboxyindole;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;PB-22 3-carboxyindole (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;PB-22 3-carboxyindole Ur Ql Cfm;;ACTIVE;2.63;2.73 +87487-5;MAB-CHMINACA butanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;MAB-CHMINACA butanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;MAB-CHMINACA butanoate Ur Ql Cfm;;ACTIVE;2.63;2.73 +87488-3;AM694 N-5-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;AM694 N-5-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;AM694 N-5OH-pentyl Ur Ql Cfm;;ACTIVE;2.63;2.73 +87489-1;AKB48 N-pentanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;AKB48 N-pentanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;AKB48 N-pentanoate Ur Ql Cfm;;ACTIVE;2.63;2.73 +87490-9;ADB-PINACA pentanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;ADB-PINACA pentanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;ADB-PINACA pentanoate Ur Ql Cfm;;ACTIVE;2.63;2.73 +87491-7;ADBICA N-4-hydroxypentyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;ADBICA N-4-hydroxypentyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;ADBICA N-4OH-pentyl Ur Ql Cfm;;ACTIVE;2.63;2.73 +87492-5;AB-PINACA pentanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;AB-PINACA pentanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;AB-PINACA pentanoate Ur Ql Cfm;;ACTIVE;2.63;2.73 +87493-3;AB-FUBINACA oxobutanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;AB-FUBINACA oxobutanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;AB-FUBINACA oxobutanoate Ur Ql Cfm;;ACTIVE;2.63;2.73 +8749-4;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;US.doppler;HEMODYN.MOLEC;2;Left ventricular Cardiac index by US.doppler;LV Cardiac index DOP;;ACTIVE;1.0h(3);2.48 +87494-1;AB-CHMINACA hydroxycyclohexyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;AB-CHMINACA hydroxycyclohexyl (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;AB-CHMINACA OH-cyclohexyl Ur Ql Cfm;;ACTIVE;2.63;2.73 +87495-8;AB-CHMINACA butanoate;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;AB-CHMINACA butanoate (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;AB-CHMINACA butanoate Ur Ql Cfm;;ACTIVE;2.63;2.73 +87496-6;Gabapentin;PrThr;Pt;Ser/Plas/Bld;Ord;Screen;DRUG/TOX;1;Gabapentin [Presence] in Serum, Plasma or Blood by Screen method;Gabapentin SerPlBld Ql Scn;;ACTIVE;2.63;2.73 +87497-4;Meperidine;PrThr;Pt;Ser/Plas/Bld;Ord;Screen;DRUG/TOX;1;Meperidine [Presence] in Serum, Plasma or Blood by Screen method;Meperidine SerPlBld Ql Scn;;ACTIVE;2.63;2.73 +87498-2;3-Methoxytyramine.free/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;3-Methoxytyramine.free/Creatinine [Molar ratio] in 24 hour Urine;Free 3-MT/Creat 24h Ur-sRto;;ACTIVE;2.63;2.63 +87499-0;3-Methoxytyramine.free;SRto;Pt;Urine;Qn;;CHEM;1;3-Methoxytyramine.free [Molar ratio] in Urine;Free 3-MT Ur-sRto;;ACTIVE;2.63;2.63 +87500-5;LCDS v4.00 - Skin conditions - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Skin conditions - discharge [CMS Assessment];;;ACTIVE;2.63;2.69 +87501-3;LCDS v4.00 - Mobility - discharge performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Mobility - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.63;2.69 +8750-2;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;Fick;HEMODYN.MOLEC;2;Left ventricular Cardiac index by Fick method;LV Cardiac index Fick;;ACTIVE;1.0h(3);2.48 +87502-1;LCDS v4.00 - Mobility - admission performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Mobility - admission performance during assessment period [CMS Assessment];;;ACTIVE;2.63;2.69 +87503-9;Understanding verbal and non-verbal content during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Understanding verbal and non-verbal content during 3 day assessment period [CMS Assessment];;;ACTIVE;2.63;2.63 +87504-7;LCDS v4.00 - Administrative information - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Administrative information - discharge [CMS Assessment];;;ACTIVE;2.63;2.63 +87505-4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 4.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 4.00 [CMS Assessment];;;ACTIVE;2.63;2.69 +87506-2;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Expired - version 4.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Expired - version 4.00 [CMS Assessment];;;ACTIVE;2.63;2.69 +87507-0;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Planned Discharge - version 4.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Planned Discharge - version 4.00 [CMS Assessment];;;ACTIVE;2.63;2.69 +87508-8;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 4.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 4.00 [CMS Assessment];;;ACTIVE;2.63;2.69 +87509-6;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Admission - version 4.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Admission - version 4.00 [CMS Assessment];;;ACTIVE;2.63;2.69 +8751-0;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;Indicator dilution;HEMODYN.MOLEC;2;Left ventricular Cardiac index by Indicator dilution;LV Cardiac index Indicator dilution;;ACTIVE;1.0h(3);2.48 +87510-4;Date of retirement;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of retirement;Date retired;;ACTIVE;2.63;2.63 +87511-2;Combat zone &or hazardous duty work dates;DateRange;Pt;^Patient;Qn;;H&P.HX;2;Combat zone AndOr hazardous duty work dates;Combat zone hazard duty work DateRange;;ACTIVE;2.63;2.66 +87512-0;Work Hs per D;NRat;Pt;^Patient;Qn;;H&P.HX;2;Work hours per day;Work Hs per D nRate;;ACTIVE;2.63;2.63 +87513-8;Process of care measures;Find;Pt;{Setting};Doc;Trauma;DOC.MISC;2;Trauma Process of care measures Document;Trauma Process of care meas Doc;;ACTIVE;2.63;2.63 +87514-6;Cerebral monitor;Type;Pt;^Patient;Nom;;NEURO;2;Cerebral monitor;Cerebral monitor;;ACTIVE;2.63;2.63 +87515-3;Pupillary response^at admission;Find;Pt;Pupil.bilateral;Nom;;EYE.PX;2;Pupil - bilateral Pupillary response--at admission;Bil pupil Pupillary resp;;ACTIVE;2.63;2.68 +87516-1;Life support was discontinued;Find;Pt;^Patient;Ord;;TRAUMA;2;Life support was discontinued;Life support discontinued;;ACTIVE;2.63;2.63 +87517-9;Physical abuse was reported;Find;Pt;^Patient;Ord;;TRAUMA;2;Physical abuse was reported;Physical abuse reported;;ACTIVE;2.63;2.63 +87518-7;Discharged to caregiver other than caregiver at admission due to suspected abuse;Find;Pt;^Patient;Ord;;TRAUMA;2;Discharged to caregiver other than caregiver at admission due to suspected abuse;Dischrgd to alt caregiver susp abuse;;ACTIVE;2.63;2.63 +87519-5;Physical abuse investigation was initiated;Find;Pt;^Patient;Ord;;TRAUMA;2;Physical abuse investigation was initiated;Phys abuse investigation initiated;;ACTIVE;2.63;2.63 +87520-3;Coverage type;Type;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Coverage type;Coverage type;;ACTIVE;2.63;2.66 +87521-1;IRF-PAI v3.0, LCDS v4.00 - Medications - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v4.00 - Medications - admission [CMS Assessment];;;ACTIVE;2.63;2.69 +87522-9;IRF-PAI v3.0, LCDS v4.00 - Medications - discharge and expired;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v4.00 - Medications - discharge and expired [CMS Assessment];;;ACTIVE;2.63;2.69 +87523-7;REMS Administrative Information;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS administrative information;FDA insert REMS admin inform;;ACTIVE;2.63;2.63 +87524-5;REMS requirements;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS requirements;FDA insert REMS requirements;;ACTIVE;2.63;2.63 +87525-2;REMS participant requirements;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS participant requirements;FDA insert REMS partic requirements;;ACTIVE;2.63;2.63 +87526-0;REMS applicant requirements;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert REMS applicant requirements;FDA insert REMS applic requirements;;ACTIVE;2.63;2.63 +87527-8;Fasting duration;Time;Pt;^Patient;Qn;;MISC;1;Fasting duration;Fasting duration Time Patient;;ACTIVE;2.63;2.63 +8752-8;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;MR;HEMODYN.MOLEC;2;Left ventricular Cardiac index by MR;LV Cardiac index MR;;ACTIVE;1.0h(3);2.56 +87528-6;Personal health goal;Find;Pt;^Patient;Nom;;CLIN;2;Personal health goal;Personal health goal;;ACTIVE;2.63;2.69 +87529-4;Most important functional area;Find;Pt;^Patient;Nom;;CLIN;2;Most important functional area;Important functional area;;ACTIVE;2.63;2.63 +87530-2;Most important health event to avoid;Find;Pt;^Patient;Nom;;CLIN;2;Most important health event to avoid;Important health event to avoid;;ACTIVE;2.63;2.63 +87531-0;Most important symptom to manage;Find;Pt;^Patient;Nom;;CLIN;2;Most important symptom to manage;Important symptom to manage;;ACTIVE;2.63;2.63 +87532-8;Most important mental health issue to address;Find;Pt;^Patient;Nom;;CLIN;2;Most important mental health issue to address;Important mental health issue to address;;ACTIVE;2.63;2.63 +87533-6;Chronic kidney disease management personal goals panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Chronic kidney disease management personal goals panel;CKD personal health goals pnl;;ACTIVE;2.63;2.63 +87534-4;Challenges for treatment plan maintenance panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Challenges for treatment plan maintenance panel;Treatment maint challenges pnl;;ACTIVE;2.63;2.63 +87535-1;Challenges to maintaining treatments or health behaviors;Find;Pt;^Patient;Nom;;CLIN;2;Challenges to maintaining treatments or health behaviors;Treatment maint challenges;;ACTIVE;2.63;2.63 +8753-6;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.left;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Left ventricular Cardiac index by Nuclear blood pool;LV Cardiac index Nuc BP;;ACTIVE;1.0h(3);2.48 +87536-9;Treatment or health behavior affected by challenges;Find;Pt;^Patient;Nom;;CLIN;2;Treatment or health behavior affected by challenges;Treatment or behavior affect by chal;;ACTIVE;2.63;2.63 +87537-7;LCDS v4.00 - Spontaneous breathing trial;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Spontaneous breathing trial [CMS Assessment];;;ACTIVE;2.63;2.67 +87538-5;Assessed for readiness for SBT by day 2 of stay;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Assessed for readiness for SBT by day 2 of stay [CMS Assessment];;;ACTIVE;2.63;2.63 +87539-3;Invasive mechanical ventilation support upon admission;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Invasive mechanical ventilation support upon admission [CMS Assessment];;;ACTIVE;2.63;2.67 +87540-1;Deemed medically ready for SBT by day 2 of stay;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Deemed medically ready for SBT by day 2 of stay [CMS Assessment];;;ACTIVE;2.63;2.63 +87541-9;Is there documentation of reason(s) in the patient's medical record that the patient was deemed medically unready for SBT by day 2 of stay;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Is there documentation of reason(s) in the patient's medical record that the patient was deemed medically unready for SBT by day 2 of stay? [CMS Assessment];;;ACTIVE;2.63;2.63 +87542-7;SBT performed by day 2 of stay;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;SBT performed by day 2 of stay [CMS Assessment];;;ACTIVE;2.63;2.63 +87543-5;Beta-N-acetylhexosaminidase.A & beta-N-acetylhexosaminidase with reflex to HEXA gene panel;CCnt;Pt;WBC;-;;PANEL.CHEM;1;Beta-N-acetylhexosaminidase.A and beta-N-acetylhexosaminidase with reflex to HEXA gene panel [Enzymatic activity/mass] - Leukocytes;Hex A & Total w Rflx HEXA Pnl WBC-cCnt;;ACTIVE;2.63;2.63 +87544-3;Beta-N-acetylhexosaminidase.A & beta-N-acetylhexosaminidase panel;CCnt;Pt;WBC;-;;PANEL.CHEM;1;Beta-N-acetylhexosaminidase.A and beta-N-acetylhexosaminidase panel [Enzymatic activity/mass] - Leukocytes;Hexosaminidase A & Total Pnl WBC-cCnt;;ACTIVE;2.63;2.63 +87545-0;Beta-N-acetylhexosaminidase.A & beta-N-acetylhexosaminidase panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Beta-N-acetylhexosaminidase.A and beta-N-acetylhexosaminidase panel - Serum or Plasma;Hexosaminidase A & Total Pnl SerPl;;ACTIVE;2.63;2.63 +87546-8;Dengue virus Ab.IgG & IgM panel;-;Pt;Ser;Ord;;PANEL.MICRO;1;Dengue virus IgG and IgM panel - Serum Qualitative;DENV IgG+IgM Pnl Ser;;ACTIVE;2.63;2.63 +87547-6;Borrelia burgdorferi Ab & Anaplasma phagocytophilum & Babesia microti & Ehrlichia chaffeensis Ab.IgG panel;-;Pt;Ser;-;;PANEL.MICRO;1;Borrelia burgdorferi Ab and Anaplasma phagocytophilum, Babesia microti and Ehrlichia chaffeensis IgG panel - Serum;Tick IgG + B burgdor Ab Pnl Ser;;ACTIVE;2.63;2.63 +87548-4;Anaplasma phagocytophilum & Ehrlichia sp groEL gene panel;-;Pt;Bld;Ord;Non-probe.amp.tar;PANEL.MICRO;1;Anaplasma phagocytophilum and Ehrlichia sp DNA panel - Blood Qualitative by NAA with non-probe detection;A phag+Ehrl sp DNA Pnl Bld NAA+non-probe;;ACTIVE;2.63;2.63 +87549-2;1,25-Dihydroxyvitamin D & 1,25-Dihydroxyvitamin D2 & 1,25-Dihydroxyvitamin D3 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;1,25-Dihydroxyvitamin D and 1,25-Dihydroxyvitamin D2 and 1,25-Dihydroxyvitamin D3 panel - Serum or Plasma;DHVD+DHVD2+DHVD3 Pnl SerPl;;ACTIVE;2.63;2.63 +875-5;A,B Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;A,B Ab [Presence] in Serum or Plasma from Blood product unit;A,B Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +87550-0;Haloperidol & haloperidol.reduced panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Haloperidol and reduced haloperidol panel - Serum or Plasma;Halo + Halo.reduced Pnl SerPl;;ACTIVE;2.63;2.63 +8755-1;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;2D echo;HEMODYN.MOLEC;2;Right ventricular Cardiac index by 2D echo;RV Cardiac index 2D Echo;;ACTIVE;1.0h(3);2.48 +87551-8;Neutrophil cytoplasmic Ab.IgG & Saccharomyces cerevisiae Ab.IgA & IgG;-;Pt;Ser;-;;PANEL.SERO;1;Neutrophil cytoplasmic Ab.IgG and Saccharomyces cerevisiae IgA and IgG in Serum;ANCA IgG + S cerev IgA + IgG Pnl Ser;;ACTIVE;2.63;2.63 +87552-6;IgA & IgA subclass 1 & IgA subclass 2 panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;IgA, IgA1 and IgA2 panel - Serum or Plasma;IgA + IgA1 + IgA2 Pnl SerPl;;ACTIVE;2.63;2.63 +87553-4;Aspergillus fumigatus & Saccharopolyspora rectivirgula & Thermoactinomyces vulgaris Ab.IgG panel;-;Pt;Ser;Qn;;PANEL.ALLERGY;1;Aspergillus fumigatus and Saccharopolyspora rectivirgula and Thermoactinomyces vulgaris IgG panel - Serum;A fumigts+S rectiv+Tvulgaris IgG Pnl Ser;;ACTIVE;2.63;2.63 +87554-2;Epstein Barr virus Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Epstein Barr virus Ab panel - Serum;EBV Ab Pnl Ser;;ACTIVE;2.63;2.7 +87555-9;Sjogrens syndrome-A & B extractable nuclear Ab.IgG panel;-;Pt;Ser;Qn;;PANEL.SERO;1;Sjogrens syndrome-A and B extractable nuclear IgG panel - Serum;ENA SS-A + SSB IgG Pnl Ser;;ACTIVE;2.63;2.63 +87556-7;Thyroglobulin & thyroperoxidase Ab panel;-;Pt;Ser/Plas;Qn;;PANEL.SERO;1;Thyroglobulin and thyroperoxidase Ab panel - Serum or Plasma;Thyroglob + thyroperox Ab Pnl SerPl;;ACTIVE;2.63;2.63 +87557-5;Protein S Ag & protein S Ag.free panel;RelMCnc;Pt;PPP;Qn;IA;PANEL.COAG;1;Protein S Ag and protein S Ag.free panel - Platelet poor plasma by Immunoassay;Prot S Ag + Prot S Ag.free Pnl PPP IA;;ACTIVE;2.63;2.63 +87558-3;Anaplasma phagocytophilum groEL gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Anaplasma phagocytophilum groEL gene [Presence] in Blood by NAA with non-probe detection;A phago groEL Bld Ql NAA+non-probe;;ACTIVE;2.63;2.73 +87559-1;Ehrlichia chaffeensis groEL gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Ehrlichia chaffeensis groEL gene [Presence] in Blood by NAA with non-probe detection;E chaff groEL Bld Ql NAA+non-probe;;ACTIVE;2.63;2.73 +87560-9;Ehrlichia canis+ewingii groEL gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Ehrlichia canis+ewingii groEL gene [Presence] in Blood by NAA with non-probe detection;E canis+ewin groEL Bld Ql NAA+non-probe;;ACTIVE;2.63;2.73 +87561-7;Ehrlichia muris eauclairensis groEL gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Ehrlichia muris eauclairensis groEL gene [Presence] in Blood by NAA with non-probe detection;E muris eaucl groEL Bld Ql NAA+non-prb;;ACTIVE;2.63;2.73 +87562-5;Ammonia nitrogen;MCnt;Pt;Feed;Qn;;DRUG/TOX;1;Ammonia nitrogen [Mass/mass] in Feed;Ammonia nitrogen Feed-mCnt;;ACTIVE;2.63;2.63 +87563-3;Antimony;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Antimony [Mass/mass] in Specimen;Antimony Spec-mCnt;;ACTIVE;2.63;2.69 +87564-1;Zearalenone;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Zearalenone [Mass/mass] in Specimen;ZEA Spec-mCnt;;ACTIVE;2.63;2.69 +87565-8;Zearalenol;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Zearalenol [Mass/mass] in Specimen;Zearalenol Spec-mCnt;;ACTIVE;2.63;2.69 +87566-6;Deoxynivalenol;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Deoxynivalenol [Mass/mass] in Specimen;DON Spec-mCnt;;ACTIVE;2.63;2.69 +87567-4;T-2 toxin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;T-2 toxin [Mass/mass] in Specimen;T-2 toxin Spec-mCnt;;ACTIVE;2.63;2.69 +87568-2;Ochratoxin A;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ochratoxin A [Mass/mass] in Specimen;OTA Spec-mCnt;;ACTIVE;2.63;2.69 +8756-9;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;Angiography.biplane;HEMODYN.MOLEC;2;Right ventricular Cardiac index by Angiography biplane;RV Cardiac index Angio BP;;ACTIVE;1.0h(3);2.48 +87569-0;Nivalenol;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Nivalenol [Mass/mass] in Specimen;NIV Spec-mCnt;;ACTIVE;2.63;2.69 +87570-8;Narasin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Narasin [Mass/mass] in Specimen;Narasin Spec-mCnt;;ACTIVE;2.63;2.69 +87571-6;Fumonisin B3;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Fumonisin B3 [Mass/mass] in Specimen;Fumonisin B3 Spec-mCnt;;ACTIVE;2.63;2.69 +87572-4;Fumonisin B2;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Fumonisin B2 [Mass/mass] in Specimen;Fumonisin B2 Spec-mCnt;;ACTIVE;2.63;2.69 +87573-2;Fumonisin B1;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Fumonisin B1 [Mass/mass] in Specimen;Fumonisin B1 Spec-mCnt;;ACTIVE;2.63;2.69 +87574-0;Ergovaline;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ergovaline [Mass/mass] in Specimen;Ergovaline Spec-mCnt;;ACTIVE;2.63;2.69 +87575-7;Ergotamine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ergotamine [Mass/mass] in Specimen;Ergotamine Spec-mCnt;;ACTIVE;2.63;2.69 +87576-5;Ergosine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ergosine [Mass/mass] in Specimen;Ergosine Spec-mCnt;;ACTIVE;2.63;2.69 +8757-7;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;Angiography.single plane;HEMODYN.MOLEC;2;Right ventricular Cardiac index by Angiography single plane;RV Cardiac index Angio SP;;ACTIVE;1.0h(3);2.48 +87577-3;Ergocryptine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ergocryptine [Mass/mass] in Specimen;Ergocryptine Spec-mCnt;;ACTIVE;2.63;2.69 +87578-1;Ergocristine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ergocristine [Mass/mass] in Specimen;Ergocristine Spec-mCnt;;ACTIVE;2.63;2.69 +87579-9;Ergocornine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ergocornine [Mass/mass] in Specimen;Ergocornine Spec-mCnt;;ACTIVE;2.63;2.69 +87580-7;Aflatoxin M1;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aflatoxin M1 [Mass/mass] in Specimen;Aflatoxin M1 Spec-mCnt;;ACTIVE;2.63;2.69 +87581-5;Aflatoxin G2;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aflatoxin G2 [Mass/mass] in Specimen;Aflatoxin G2 Spec-mCnt;;ACTIVE;2.63;2.69 +87582-3;Aflatoxin G1;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aflatoxin G1 [Mass/mass] in Specimen;Aflatoxin G1 Spec-mCnt;;ACTIVE;2.63;2.69 +87583-1;Aflatoxin B2;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aflatoxin B2 [Mass/mass] in Specimen;Aflatoxin B2 Spec-mCnt;;ACTIVE;2.63;2.69 +87584-9;Aflatoxin B1;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aflatoxin B1 [Mass/mass] in Specimen;Aflatoxin B1 Spec-mCnt;;ACTIVE;2.63;2.69 +8758-5;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;CT spiral;HEMODYN.MOLEC;2;Right ventricular Cardiac index by Spiral CT;RV Cardiac index Spiral CT;;ACTIVE;1.0h(3);2.48 +87585-6;Virginiamycin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Virginiamycin [Mass/mass] in Specimen;Virginiamycin Spec-mCnt;;ACTIVE;2.63;2.69 +87586-4;Tylvalosin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Tylvalosin [Mass/mass] in Specimen;Tylvalosin Spec-mCnt;;ACTIVE;2.63;2.69 +87587-2;Tylosin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Tylosin [Mass/mass] in Specimen;Tylosin Spec-mCnt;;ACTIVE;2.63;2.69 +87588-0;Tilmicosin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Tilmicosin [Mass/mass] in Specimen;Tilmicosin Spec-mCnt;;ACTIVE;2.63;2.69 +87589-8;Tiamulin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Tiamulin [Mass/mass] in Specimen;Tiamulin Spec-mCnt;;ACTIVE;2.63;2.69 +87590-6;Tetracycline;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Tetracycline [Mass/mass] in Specimen;Tetracycline Spec-mCnt;;ACTIVE;2.63;2.69 +87591-4;Sulfathiazole;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Sulfathiazole [Mass/mass] in Specimen;Sulfathiazole Spec-mCnt;;ACTIVE;2.63;2.69 +87592-2;Sulfamethazine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Sulfamethazine [Mass/mass] in Specimen;Sulfamethazine Spec-mCnt;;ACTIVE;2.63;2.69 +8759-3;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;US.doppler;HEMODYN.MOLEC;2;Right ventricular Cardiac index by US.doppler;RV Cardiac index DOP;;ACTIVE;1.0h(3);2.48 +87593-0;Salinomycin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Salinomycin [Mass/mass] in Specimen;Salinomycin Spec-mCnt;;ACTIVE;2.63;2.69 +87594-8;Penicillin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Penicillin [Mass/mass] in Specimen;Penicillin Spec-mCnt;;ACTIVE;2.63;2.69 +87595-5;Oxytetracycline;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Oxytetracycline [Mass/mass] in Specimen;Oxytetracycline Spec-mCnt;;ACTIVE;2.63;2.69 +87596-3;Nicotine;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Nicotine [Mass/mass] in Specimen;Nicotine Spec-mCnt;;ACTIVE;2.63;2.69 +87597-1;Lincomycin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Lincomycin [Mass/mass] in Specimen;Lincomycin Spec-mCnt;;ACTIVE;2.63;2.69 +87598-9;Lasalocid;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Lasalocid [Mass/mass] in Specimen;Lasalocid Spec-mCnt;;ACTIVE;2.63;2.69 +87599-7;Florfenicol;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Florfenicol [Mass/mass] in Specimen;Florfenicol Spec-mCnt;;ACTIVE;2.63;2.69 +87600-3;Chlortetracycline;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Chlortetracycline [Mass/mass] in Specimen;Chlortetracycline Spec-mCnt;;ACTIVE;2.63;2.69 +8760-1;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;Fick;HEMODYN.MOLEC;2;Right ventricular Cardiac index by Fick method;RV Cardiac index Fick;;ACTIVE;1.0h(3);2.48 +87601-1;Carbadox;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Carbadox [Mass/mass] in Specimen;Carbadox Spec-mCnt;;ACTIVE;2.63;2.69 +87602-9;Bambermycins;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Bambermycins [Mass/mass] in Specimen;Bambermycins Spec-mCnt;;ACTIVE;2.63;2.69 +87603-7;Bacitracin zinc;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Bacitracin zinc [Mass/mass] in Specimen;Bacitracin zinc Spec-mCnt;;ACTIVE;2.63;2.69 +87604-5;Ampicillin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ampicillin [Mass/mass] in Specimen;Ampicillin Spec-mCnt;;ACTIVE;2.63;2.69 +87605-2;Warfarin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Warfarin [Mass/mass] in Specimen;Warfarin Spec-mCnt;;ACTIVE;2.63;2.69 +87606-0;Diphacinone;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Diphacinone [Mass/mass] in Specimen;Diphacinone Spec-mCnt;;ACTIVE;2.63;2.69 +87607-8;Difethialone;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Difethialone [Mass/mass] in Specimen;Difethialone Spec-mCnt;;ACTIVE;2.63;2.69 +87608-6;Difenacoum;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Difenacoum [Mass/mass] in Specimen;Difenacoum Spec-mCnt;;ACTIVE;2.63;2.69 +87609-4;Dicoumarol;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Dicoumarol [Mass/mass] in Specimen;Dicoumarol Spec-mCnt;;ACTIVE;2.63;2.69 +87610-2;Chlorophacinone;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Chlorophacinone [Mass/mass] in Specimen;Chlorophacinone Spec-mCnt;;ACTIVE;2.63;2.69 +87611-0;Bromadiolone;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Bromadiolone [Mass/mass] in Specimen;Bromadiolone Spec-mCnt;;ACTIVE;2.63;2.69 +87612-8;Brodifacoum;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Brodifacoum [Mass/mass] in Specimen;Brodifacoum Spec-mCnt;;ACTIVE;2.63;2.69 +87613-6;Urea;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Urea [Mass/mass] in Specimen;Urea Spec-mCnt;;ACTIVE;2.63;2.69 +87614-4;Thallium;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Thallium [Mass/mass] in Specimen;Thallium Spec-mCnt;;ACTIVE;2.63;2.69 +87615-1;Sulfate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Sulfate [Mass/mass] in Specimen;Sulfate Spec-mCnt;;ACTIVE;2.63;2.69 +87616-9;Gossypol;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Gossypol [Mass/mass] in Specimen;Gossypol Spec-mCnt;;ACTIVE;2.63;2.69 +87617-7;Ethylene glycol;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ethylene glycol [Mass/mass] in Specimen;Ethylene Glycol Spec-mCnt;;ACTIVE;2.63;2.69 +87618-5;Cyanide;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Cyanide [Mass/mass] in Specimen;Cyanide Spec-mCnt;;ACTIVE;2.63;2.69 +8761-9;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;Indicator dilution;HEMODYN.MOLEC;2;Right ventricular Cardiac index by Indicator dilution;RV Cardiac index Indicator dilution;;ACTIVE;1.0h(3);2.48 +87619-3;Barium;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Barium [Mass/mass] in Specimen;Barium Spec-mCnt;;ACTIVE;2.63;2.69 +87620-1;Candida auris ITS2 gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Candida auris ITS2 gene [Presence] in Specimen by NAA with probe detection;C auris ITS2 Spec Ql NAA+probe;;ACTIVE;2.63;2.69 +87621-9;Bordetella parapertussis IS1001 DNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Bordetella parapertussis IS1001 DNA [Presence] in Nasopharynx by NAA with non-probe detection;B parap IS1001 DNA Nph Ql NAA+non-probe;;ACTIVE;2.63;2.73 +87622-7;Zika virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Zika virus IgM Ab [Presence] in Specimen by Immunoassay;ZIKV IgM Spec Ql IA;;ACTIVE;2.63;2.73 +87623-5;HEDIS 2018 Value Set - Depression Screen;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2018 Value Set - Depression Screen;HEDIS 2018 Depression Screen;;DISCOURAGED;2.63;2.67 +87624-3;HEDIS 2018 Value Set - Alcohol Screening;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2018 Alcohol Screening;HEDIS 2018 Alcohol Screen;;DISCOURAGED;2.63;2.7 +87625-0;HEDIS 2018 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2018 Value Sets;HEDIS 2018 Value Sets;;DISCOURAGED;2.63;2.7 +87626-8;Suicide prevention note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Suicide prevention note;Suicide prevention note;;ACTIVE;2.63;2.63 +8762-7;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;MR;HEMODYN.MOLEC;2;Right ventricular Cardiac index by MR;RV Cardiac index MR;;ACTIVE;1.0h(3);2.56 +87627-6;Consultation note;Find;Pt;{Setting};Doc;Brain injury;DOC.ONTOLOGY;2;Brain injury Consult note;Brain injury Consult note;;ACTIVE;2.63;2.63 +87628-4;Note;Find;Pt;{Setting};Doc;Brain injury;DOC.ONTOLOGY;2;Brain injury Note;Brain injury Note;;ACTIVE;2.63;2.63 +87629-2;Plan of care note;Find;Pt;{Setting};Doc;Brain injury;DOC.ONTOLOGY;2;Brain injury Plan of care note;Brain injury Plan of care note;;ACTIVE;2.63;2.63 +876-3;A,B Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;A,B Ab [Presence] in Serum or Plasma from Donor;A,B Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +87630-0;Mevinphos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Mevinphos [Mass/mass] in Specimen;Mevinphos Spec-mCnt;;ACTIVE;2.63;2.69 +87631-8;Mexacarbate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Mexacarbate [Mass/mass] in Specimen;Mexacarbate Spec-mCnt;;ACTIVE;2.63;2.69 +87632-6;Toxaphene;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Toxaphene [Mass/mass] in Specimen;Toxaphene Spec-mCnt;;ACTIVE;2.63;2.69 +87633-4;Phorate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Phorate [Mass/mass] in Specimen;Phorate Spec-mCnt;;ACTIVE;2.63;2.69 +87634-2;Aldicarb;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aldicarb [Mass/mass] in Specimen;Aldicarb Spec-mCnt;;ACTIVE;2.63;2.69 +8763-5;Cardiac output/Body surface area;ArVRat;Pt;Heart.ventricle.right;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Right ventricular Cardiac index by Nuclear blood pool;RV Cardiac index Nuc BP;;ACTIVE;1.0h(3);2.48 +87635-9;Aldicarb sulfone;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aldicarb sulfone [Mass/mass] in Specimen;Aldicarb sulfone Spec-mCnt;;ACTIVE;2.63;2.69 +87636-7;Crufomate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Crufomate [Mass/mass] in Specimen;Crufomate Spec-mCnt;;ACTIVE;2.63;2.69 +87637-5;Fenchlorphos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Fenchlorphos [Mass/mass] in Specimen;Fenchlorphos Spec-mCnt;;ACTIVE;2.63;2.69 +87638-3;p,p'- Dichlorodiphenyldichloroethane;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;p,p'- Dichlorodiphenyldichloroethane [Mass/mass] in Specimen;p,p'-DDD Spec-mCnt;;ACTIVE;2.64;2.69 +87639-1;Dichlorodiphenyltrichloroethane;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Dichlorodiphenyltrichloroethane [Mass/mass] in Specimen;DDT Spec-mCnt;;ACTIVE;2.64;2.69 +87640-9;Dichlorodiphenyldichloroethylene;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Dichlorodiphenyldichloroethylene [Mass/mass] in Specimen;DDE Spec-mCnt;;ACTIVE;2.64;2.69 +87641-7;o,p'- Dichlorodiphenyltrichloroethane;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;o,p'- Dichlorodiphenyltrichloroethane [Mass/mass] in Specimen;o,p' - DDT Spec-mCnt;;ACTIVE;2.64;2.69 +87642-5;o,p'- Dichlorodiphenyldichloroethylene;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;o,p'- DDE [Mass/mass] in Specimen;o,p'- DDE Spec-mCnt;;ACTIVE;2.64;2.69 +87643-3;o,p'- Dichlorodiphenyldichloroethane;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;o,p'- DDD [Mass/mass] in Specimen;o,p'- DDD Spec-mCnt;;ACTIVE;2.64;2.69 +87644-1;Ethoprop;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Ethoprop [Mass/mass] in Specimen;Ethoprop Spec-mCnt;;ACTIVE;2.63;2.69 +87645-8;Dechlorane;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Dechlorane [Mass/mass] in Specimen;Dechlorane Spec-mCnt;;ACTIVE;2.63;2.69 +87646-6;Methyl parathion;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Methyl parathion [Mass/mass] in Specimen;Methyl Parathion Spec-mCnt;;ACTIVE;2.63;2.69 +87647-4;Methoxychlor;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Methoxychlor [Mass/mass] in Specimen;Methoxychlor Spec-mCnt;;ACTIVE;2.63;2.69 +87648-2;Malathion;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Malathion [Mass/mass] in Specimen;Malathion Spec-mCnt;;ACTIVE;2.63;2.69 +87649-0;Lindane;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Lindane [Mass/mass] in Specimen;Lindane Spec-mCnt;;ACTIVE;2.63;2.69 +8765-0;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;2D echo;HEMODYN.MOLEC;2;Left ventricular Stroke volume by 2D echo;LV SV 2D Echo;;ACTIVE;1.0h(3);2.48 +87650-8;Methomyl;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Methomyl [Mass/mass] in Specimen;Methomyl Spec-mCnt;;ACTIVE;2.63;2.69 +87651-6;2,3,5-trimethylphenyl methylcarbamate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;2,3,5-trimethylphenyl methylcarbamate [Mass/mass] in Specimen;2,3,5-trimethacarb Spec-mCnt;;ACTIVE;2.63;2.69 +87652-4;Isofenphos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Isofenphos [Mass/mass] in Specimen;Isofenphos Spec-mCnt;;ACTIVE;2.63;2.69 +87653-2;Hexachlorobenzene;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Hexachlorobenzene [Mass/mass] in Specimen;HCB Spec-mCnt;;ACTIVE;2.63;2.69 +87654-0;Heptachlor;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Heptachlor [Mass/mass] in Specimen;Heptachlor Spec-mCnt;;ACTIVE;2.63;2.69 +87655-7;Heptachlor epoxide;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Heptachlor epoxide [Mass/mass] in Specimen;Heptachlor epoxide Spec-mCnt;;ACTIVE;2.63;2.69 +87656-5;Carbofuran;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Carbofuran [Mass/mass] in Specimen;Carbofuran Spec-mCnt;;ACTIVE;2.63;2.69 +87657-3;Fenthion;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Fenthion [Mass/mass] in Specimen;Fenthion Spec-mCnt;;ACTIVE;2.63;2.69 +87658-1;Famphur;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Famphur [Mass/mass] in Specimen;Famphur Spec-mCnt;;ACTIVE;2.63;2.69 +87659-9;Parathion;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Parathion [Mass/mass] in Specimen;Parathion Spec-mCnt;;ACTIVE;2.63;2.69 +87660-7;Endrin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Endrin [Mass/mass] in Specimen;Endrin Spec-mCnt;;ACTIVE;2.63;2.69 +87661-5;Endosulfan I;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Endosulfan I [Mass/mass] in Specimen;Endosulfan I Spec-mCnt;;ACTIVE;2.63;2.69 +87662-3;Fonofos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Fonofos [Mass/mass] in Specimen;Fonofos Spec-mCnt;;ACTIVE;2.63;2.69 +87663-1;Disulfoton;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Disulfoton [Mass/mass] in Specimen;Disulfoton Spec-mCnt;;ACTIVE;2.63;2.69 +87664-9;Dimethoate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Dimethoate [Mass/mass] in Specimen;Dimethoate Spec-mCnt;;ACTIVE;2.63;2.69 +87665-6;Dieldrin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Dieldrin [Mass/mass] in Specimen;Dieldrin Spec-mCnt;;ACTIVE;2.63;2.69 +87666-4;Diazinon;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Diazinon [Mass/mass] in Specimen;Diazinon Spec-mCnt;;ACTIVE;2.63;2.69 +87667-2;Alpha benzene hexachloride;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Alpha benzene hexachloride [Mass/mass] in Specimen;Alpha BHC Spec-mCnt;;ACTIVE;2.63;2.69 +8766-8;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;Angiography.biplane;HEMODYN.MOLEC;2;Left ventricular Stroke volume by Angiography biplane;LV SV Angio BP;;ACTIVE;1.0h(3);2.48 +87668-0;Aldrin;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Aldrin [Mass/mass] in Specimen;Aldrin Spec-mCnt;;ACTIVE;2.63;2.69 +87669-8;Chlorinated hydrocarbon panel;-;Pt;XXX;-;;PANEL.CHEM;1;Chlorinated hydrocarbon panel - Specimen;Chlorinated hydrocarb pnl Spec;;ACTIVE;2.63;2.69 +87670-6;Carbamate panel;-;Pt;XXX;-;;PANEL.CHEM;1;Carbamate panel - Specimen;Carbamate pnl Spec;;ACTIVE;2.63;2.69 +87671-4;Cholecalciferol;MCnt;Pt;XXX;Qn;;CHEM;1;Cholecalciferol (Vit D3) [Mass/mass] in Specimen;Vitamin D3 Spec-mCnt;;ACTIVE;2.63;2.69 +87672-2;Tocopherol+tocotrienol;MCnt;Pt;XXX;Qn;;CHEM;1;Tocopherol+tocotrienol [Mass/mass] in Specimen;Tocopherol+tocotrienol Spec-mCnt;;ACTIVE;2.63;2.69 +87673-0;Retinal+retinol+retinoic acid;MCnt;Pt;XXX;Qn;;CHEM;1;Retinal+retinol+retinoic acid [Mass/mass] in Specimen;Retinal+retinol+retinoic acid Spec-mCnt;;ACTIVE;2.63;2.69 +87674-8;Optical coherence tomography study;Find;Pt;Retina;Doc;;EYE.OCT;2;Optical coherence tomography study;OCT study;;ACTIVE;2.63;2.72 +87675-5;Parent Patient Activation Measure - 13;-;Pt;^Parent;-;PAM;PANEL.SURVEY.GNHLTH;4;Parent Patient Activation Measure - 13 [PAM] Parent;;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +8767-6;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;Angiography.single plane;HEMODYN.MOLEC;2;Left ventricular Stroke volume by Angiography single plane;LV SV Angio SP;;ACTIVE;1.0h(3);2.48 +87676-3;When all is said and done, I am the person who is responsible for taking care of my child's health;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;When all is said and done, I am the person who is responsible for taking care of my child's health Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87677-1;Taking an active role in my child's health care is the most important thing that affects his or her health;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;Taking an active role in my child's health care is the most important thing that affects his/her health Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87678-9;I am confident I can help prevent or reduce problems associated with my child's health;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I am confident I can help prevent or reduce problems associated with my child's health Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87679-7;I know what each of my child's prescribed medications do;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I know what each of my child's prescribed medications do Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87680-5;I am confident that I can tell whether I need to go to the doctor or whether I can take care of my child's health problem myself;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can tell whether I need to go to the doctor or whether I can take care of my child's health problem myself Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87681-3;I am confident that I can tell a doctor concerns I have abou my child's health even when he or she does not ask;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can tell a doctor concerns I have abou my child's health even when he or she does not ask Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87682-1;I am confident that I can follow through on medical treatments I need to do for my child at home;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can follow through on medical treatments I need to do for my child at home Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87683-9;I understand my child's health problems and what causes them;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I understand my child's health problems and what causes them Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +8768-4;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;CT spiral;HEMODYN.MOLEC;2;Left ventricular Stroke volume by Spiral CT;LV SV Spiral CT;;ACTIVE;1.0h(3);2.48 +87684-7;I know what treatments are available for my child's health problems;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I know what treatments are available for my child's health problems Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87685-4;I have been able to help my child maintain (keep up with) lifestyle changes, like eating right or exercising;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I have been able to help my child maintain (keep up with) lifestyle changes, like eating right or exercising Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87686-2;I know how to prevent problems with my child's health;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I know how to prevent problems with my child's health Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87687-0;I am confident I can figure out solutions when new problems arise with my child's health;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I am confident I can figure out solutions when new problems arise with my child's health Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87688-8;I am confident that I can help my child maintain lifestyle changes, like eating right and exercising, even during times of stress;Find;Pt;^Parent;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can help my child maintain lifestyle changes, like eating right and exercising, even during times of stress Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87689-6;Parent Patient Activation Measure - 10;-;Pt;^Parent;-;PAM;PANEL.SURVEY.GNHLTH;4;Parent Patient Activation Measure - 10 [PAM] Parent;;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87690-4;When all is said and done, I am responsible for seeing that this person's health is managed properly;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;When all is said and done, I am responsible for seeing that this person's health is managed properly Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87691-2;Taking an active role in this person's health care is one of the most important factors in determining her or his health and ability to function;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;Taking an active role in this person's health care is one of the most important factors in determining her/his health and ability to function Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +8769-2;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.doppler;HEMODYN.MOLEC;2;Left ventricular Stroke volume by US.doppler;LV SV DOP;;ACTIVE;1.0h(3);2.48 +87692-0;I am confident that I can take actions that will help prevent or minimize some symptoms or problems associated with this person's health;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can take actions that will help prevent or minimize some symptoms or problems associated with this person's health Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87693-8;I know what each of this person's prescribed medications do;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I know what each of this person's prescribed medications do Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87694-6;I am confident that I can tell when this person needs to get medical care and when I can handle the problem myself;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can tell when this person needs to get medical care and when I can handle the problem myself Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87695-3;I am confident I can tell a doctor the concerns that I have about this person's health even when he or she does not ask;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I am confident I can tell a doctor the concerns that I have about this person's health even when he or she does not ask Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87696-1;I am confident that I can follow through on medical treatments I need to do for this person at home;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I am confident that I can follow through on medical treatments I need to do for this person at home Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87697-9;I understand the nature and causes of this person's health;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I understand the nature and causes of this person's health Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87698-7;I know the different medical treatment options available for this person's health;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I know the different medical treatment options available for this person's health Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87699-5;I am able to help this person maintain lifestyle changes (like eating right or exercising) for her or his condition;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I am able to help this person maintain lifestyle changes (like eating right or exercising) for her/his condition Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87-7;Cefmetazole;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefmetazole [Susceptibility] by Minimum lethal concentration (MLC);Cefmetazole Islt MLC;;ACTIVE;1.0;2.19 +8770-0;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;Fick;HEMODYN.MOLEC;2;Left ventricular Stroke volume by Fick method;LV SV Fick;;ACTIVE;1.0h(3);2.48 +87700-1;I know how to prevent problems with this person's health;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I know how to prevent problems with this person's health Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87701-9;I am confident I can figure out solutions when new situations or problems arise with this person's health;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I am confident I can figure out solutions when new situations or problems arise with this person's health Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87702-7;I am confident I can help this person with lifestyle changes, like diet and exercise, even during times of stress;Find;Pt;^Caregiver;Ord;PAM;SURVEY.GNHLTH;4;I am confident I can help this person with lifestyle changes, like diet and exercise, even during times of stress Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87703-5;Caregiver Patient Activation Measure - 13;-;Pt;^Caregiver;-;PAM;PANEL.SURVEY.GNHLTH;4;Caregiver Patient Activation Measure - 13 [PAM] Caregiver;;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87704-3;Caregiver Patient Activation Measure - 10;-;Pt;^Caregiver;-;PAM;PANEL.SURVEY.GNHLTH;4;Caregiver Patient Activation Measure - 10 [PAM] Caregiver;;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +87705-0;Sedentary activity;NRat;24H;^Patient;Qn;;CLIN;2;Sedentary activity 24 hour;Sedentary activity 24h nRate;;TRIAL;2.63;2.63 +87706-8;Detection limit;Num;Pt;Laboratory device;Qn;;DEVICES;2;Laboratory device Detection limit;Lab device Detection limit;;ACTIVE;2.63;2.71 +87707-6;Job supervisory level or pay grade;Find;Pt;^Patient;Nom;;H&P.HX;2;Job supervisory level or pay grade;Supervisory level or pay grade;;ACTIVE;2.63;2.67 +87708-4;Beta-2-Microglobulin^post dialysis;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Serum or Plasma --post dialysis;B2 Microglob p dialysis SerPl-mCnc;;ACTIVE;2.63;2.63 +87709-2;Virus identified;Prid;Pt;Respiratory.lower;Nom;Culture;MICRO;1;Virus identified in Lower respiratory specimen by Culture;Virus Lower resp Cult;;ACTIVE;2.63;2.63 +877-1;A,B Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated A,B Ab;Deprecated A,B Ab Ser Ql;;DEPRECATED;1.0;2.36 +87710-0;Rotavirus C VP7 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus C VP7 gene [Nucleotide sequence] in Isolate by Sequencing;RVC VP7 Islt-Seq;;ACTIVE;2.63;2.64 +87711-8;Rotavirus B VP7 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus B VP7 gene [Nucleotide sequence] in Isolate by Sequencing;RVB VP7 Islt-Seq;;ACTIVE;2.63;2.64 +87712-6;Rotavirus A VP7 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus A VP7 gene [Nucleotide sequence] in Isolate by Sequencing;RVA VP7 Islt-Seq;;ACTIVE;2.63;2.64 +87713-4;Rotavirus A VP4 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Rotavirus A VP4 gene [Nucleotide sequence] in Isolate by Sequencing;RVA VP4 Islt-Seq;;ACTIVE;2.63;2.64 +87714-2;Influenza virus A M gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A M gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV M gene Islt-Seq;;ACTIVE;2.63;2.63 +87715-9;Influenza virus A HA gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A HA gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV HA gene Islt-Seq;;ACTIVE;2.63;2.64 +87716-7;Influenza virus A NA gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A NA gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV NA gene Islt-Seq;;ACTIVE;2.63;2.63 +87717-5;Apis mellifera recombinant (rApi m) 2 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee recombinant (rApi m) 2 IgE Ab RAST class [Presence] in Serum;Hyaluronidase (rApi m) 2 IgE RAST Ql;;ACTIVE;2.63;2.66 +8771-8;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;Indicator dilution;HEMODYN.MOLEC;2;Left ventricular Stroke volume by Indicator dilution;LV SV Indicator dilution;;ACTIVE;1.0h(3);2.48 +87718-3;Arachis hypogaea recombinant (rAra h) 6 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut recombinant (rAra h) 6 IgE Ab RAST class [Presence] in Serum;Peanut (rAra h) 6 IgE RAST Ql;;ACTIVE;2.63;2.63 +87719-1;Arachis hypogaea recombinant (rAra h) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Peanut recombinant (rAra h) 5 IgE Ab RAST class [Presence] in Serum;Peanut (rAra h) 5 IgE RAST Ql;;ACTIVE;2.63;2.63 +87720-9;Postal code;Loc;Pt;Provider;Nom;;ADMIN;2;Provider Postal code;Provider Postal code;;ACTIVE;2.63;2.73 +87721-7;County of residence;Loc;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;County of residence [Location];County of residence;;ACTIVE;2.63;2.73 +87722-5;Complement C1q.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C1q.functional [Units/volume] in Serum or Plasma;C1q.functional SerPl-aCnc;;ACTIVE;2.63;2.68 +87723-3;Complement C3.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C3.functional [Units/volume] in Serum or Plasma;C3.functional SerPl-aCnc;;ACTIVE;2.63;2.68 +87724-1;Complement C7.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C7.functional [Units/volume] in Serum or Plasma;C7.functional SerPl-aCnc;;ACTIVE;2.63;2.73 +87725-8;Cytomegalovirus Ab.IgM;PrThr;Pt;Ser/Plas^Donor;Ord;IA;MICRO;1;Cytomegalovirus IgM Ab [Presence] in Serum or Plasma from Donor by Immunoassay;CMV IgM SerPl Donr Ql IA;;ACTIVE;2.63;2.63 +8772-6;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;MR;HEMODYN.MOLEC;2;Left ventricular Stroke volume by MR;LV SV MR;;ACTIVE;1.0h(3);2.56 +87726-6;Cytomegalovirus Ab.IgG;PrThr;Pt;Ser/Plas^Donor;Ord;IA;MICRO;1;Cytomegalovirus IgG Ab [Presence] in Serum or Plasma from Donor by Immunoassay;CMV IgG SerPl Donr Ql IA;;ACTIVE;2.63;2.63 +87727-4;Complement C9.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C9.functional [Units/volume] in Serum or Plasma;C9.functional SerPl-aCnc;;ACTIVE;2.63;2.73 +87728-2;Appearance;Aper;Pt;XXX.swab;Nar;;SPEC;1;Description of swab specimen Narrative;Description of swab;;ACTIVE;2.63;2.71 +87729-0;Occupational hazard;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Occupational hazard;Hx of Occupational hazard;;ACTIVE;2.63;2.63 +87730-8;HBA1 & HBA2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;HBA1 and HBA2 gene full mutation analysis in Blood or Tissue by Sequencing;HBA1 + HBA2 Full Mut Anl Bld/T Seq;;ACTIVE;2.63;2.73 +87731-6;KIT gene exon 17 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;KIT gene exon 17 targeted mutation analysis in Blood or Tissue by Molecular genetics method;KIT Exon 17 Mut Anl Bld/T;;ACTIVE;2.63;2.65 +87732-4;KIT gene exon 13 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;KIT gene exon 13 targeted mutation analysis in Blood or Tissue by Molecular genetics method;KIT Exon 13 Mut Anl Bld/T;;ACTIVE;2.63;2.65 +87733-2;KIT gene exon 8 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;KIT gene exon 8 targeted mutation analysis in Blood or Tissue by Molecular genetics method;KIT Exon 8 Mut Anl Bld/T;;ACTIVE;2.63;2.65 +8773-4;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Left ventricular Stroke volume by Nuclear blood pool;LV SV Nuc BP;;ACTIVE;1.0h(3);2.48 +87734-0;cefTAZidime+Avibactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;cefTAZidime+Avibactam [Susceptibility] by Gradient strip;cefTAZidime+Avibactam Islt Grad strip;;ACTIVE;2.63;2.73 +87735-7;Ceftolozane+Tazobactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Ceftolozane+Tazobactam [Susceptibility] by Gradient strip;Ceftolozane+Tazobactam Islt Grad strip;;ACTIVE;2.63;2.63 +87736-5;Intravascular diastolic^post exercise;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure--post exercise;BP dias--p Exc;;ACTIVE;2.63;2.63 +87737-3;3,4,5-trimethylphenyl methylcarbamate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;3,4,5-trimethylphenyl methylcarbamate [Mass/mass] in Specimen;3,4,5-triMe-phenyl Me-carb Spec-mCnt;;ACTIVE;2.63;2.69 +87738-1;GALC gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;GALC gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;GALC Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.63;2.65 +87739-9;Intravascular systolic^W exercise;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure--W exercise;BP sys--W exercise;;ACTIVE;2.63;2.63 +87740-7;Intravascular diastolic^W exercise;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure--W exercise;BP dias--W exercise;;ACTIVE;2.63;2.63 +87741-5;Intravascular systolic^post exercise;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure--post exercise;BP sys--p Exc;;ACTIVE;2.63;2.63 +87742-3;Adalimumab Ab;ACnc;Pt;Ser/Plas;Qn;;SERO;1;Adalimumab Ab [Units/volume] in Serum or Plasma;Adalimumab Ab SerPl-aCnc;;ACTIVE;2.63;2.73 +87743-1;Bufencarb;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Bufencarb [Mass/mass] in Specimen;Bufencarb Spec-mCnt;;ACTIVE;2.63;2.69 +87744-9;Carbaryl;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Carbaryl [Mass/mass] in Specimen;Carbaryl Spec-mCnt;;ACTIVE;2.63;2.69 +87745-6;Carbophenothion;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Carbophenothion [Mass/mass] in Specimen;Carbophenothion Spec-mCnt;;ACTIVE;2.63;2.69 +87746-4;Chlordane;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Chlordane [Mass/mass] in Specimen;Chlordane Spec-mCnt;;ACTIVE;2.63;2.69 +87747-2;Chlorpyrifos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Chlorpyrifos [Mass/mass] in Specimen;Chlorpyrifos Spec-mCnt;;ACTIVE;2.63;2.69 +87748-0;Coumaphos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Coumaphos [Mass/mass] in Specimen;Coumaphos Spec-mCnt;;ACTIVE;2.63;2.69 +87749-8;Crotoxyphos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Crotoxyphos [Mass/mass] in Specimen;Crotoxyphos Spec-mCnt;;ACTIVE;2.63;2.69 +87750-6;Dichlorvos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Dichlorvos [Mass/mass] in Specimen;Dichlorvos Spec-mCnt;;ACTIVE;2.63;2.69 +87751-4;Endosulfan II;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Endosulfan II [Mass/mass] in Specimen;Endosulfan II Spec-mCnt;;ACTIVE;2.63;2.69 +87752-2;O-Ethyl O-(p-nitrophenyl) phenylphosphonothionate;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;O-Ethyl O-(p-nitrophenyl) phenylphosphonothionate [Mass/mass] in Specimen;EPN Spec-mCnt;;ACTIVE;2.63;2.69 +87753-0;Propoxur;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Propoxur [Mass/mass] in Specimen;Propoxur Spec-mCnt;;ACTIVE;2.63;2.69 +87754-8;Terbufos;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Terbufos [Mass/mass] in Specimen;Terbufos Spec-mCnt;;ACTIVE;2.63;2.69 +87755-5;Clostridioides difficile BI-NAP1-027 strain DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Clostridioides difficile BI-NAP1-027 strain DNA [Presence] in Stool by NAA with probe detection;C diff BI NAP1 027 DNA Stl Ql NAA+probe;;ACTIVE;2.63;2.73 +87756-3;BMPR1A & SMAD4 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;BMPR1A and SMAD4 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;BMPR1A+SMAD4 Del+Dup + Full Mut Bld/Tiss;;ACTIVE;2.63;2.65 +87757-1;Platelet glycoprotein IV Ab;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Platelet glycoprotein IV Ab [Presence] in Serum or Plasma by Immunoassay;Plat Gp IV Ab SerPl Ql IA;;ACTIVE;2.63;2.73 +87758-9;Naegleria fowleri DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Naegleria fowleri DNA [Presence] in Specimen by NAA with probe detection;N fowleri DNA Spec Ql NAA+probe;;ACTIVE;2.63;2.73 +8775-9;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;2D echo;HEMODYN.MOLEC;2;Right ventricular Stroke volume by 2D echo;RV SV 2D Echo;;ACTIVE;1.0h(3);2.48 +87759-7;Lifetime risk for developing genetic disease assessed;Likelihood;Lifetime;^Patient;Ord;;CLIN.RISK;2;Lifetime risk for developing genetic disease assessed Lifetime;Lifetime Risk for genetic disease;;ACTIVE;2.63;2.73 +87760-5;N-Nortramadol/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;N-nortramadol/Creatinine [Mass Ratio] in Urine by Confirmatory method;N-nortramadol/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87761-3;Atomoxetine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Atomoxetine/Creatinine [Mass Ratio] in Urine by Confirmatory method;Atomoxetine/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87762-1;Methcathinone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methcathinone/Creatinine [Mass Ratio] in Urine by Confirmatory method;Methcathinone/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87763-9;Ezogabine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ezogabine/Creatinine [Mass Ratio] in Urine by Confirmatory method;Ezogabine/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87764-7;Pregabalin/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pregabalin/Creatinine [Mass Ratio] in Urine by Confirmatory method;Pregabalin/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87765-4;levETIRAcetam/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;levETIRAcetam/Creatinine [Mass Ratio] in Urine by Confirmatory method;levETIRAcetam/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87766-2;10-Hydroxycarbazepine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;10-Hydroxycarbazepine/Creatinine [Mass Ratio] in Urine by Confirmatory method;10OH-Carbazepine/Creat Ur Cfm;;ACTIVE;2.63;2.73 +8776-7;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;Angiography.biplane;HEMODYN.MOLEC;2;Right ventricular Stroke volume by Angiography biplane;RV SV Angio BP;;ACTIVE;1.0h(3);2.48 +87767-0;Primidone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Primidone/Creatinine [Mass Ratio] in Urine by Confirmatory method;Primidone/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87768-8;Rufinamide/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Rufinamide/Creatinine [Mass Ratio] in Urine by Confirmatory method;Rufinamide/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87769-6;tiaGABine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;tiaGABine/Creatinine [Mass Ratio] in Urine by Confirmatory method;tiaGABine/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87770-4;Topiramate/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Topiramate/Creatinine [Mass Ratio] in Urine by Confirmatory method;Topiramate/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87771-2;Zonisamide/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Zonisamide/Creatinine [Mass Ratio] in Urine by Confirmatory method;Zonisamide/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87772-0;lamoTRIgine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;lamoTRIgine/Creatinine [Mass Ratio] in Urine by Confirmatory method;lamoTRIgine/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87773-8;Baclofen/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Baclofen/Creatinine [Mass Ratio] in Urine by Confirmatory method;Baclofen/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87774-6;tiZANidine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;tiZANidine/Creatinine [Mass Ratio] in Urine by Confirmatory method;tiZANidine/Creat Ur Cfm;;ACTIVE;2.63;2.73 +8777-5;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;Angiography.single plane;HEMODYN.MOLEC;2;Right ventricular Stroke volume by Angiography single plane;RV SV Angio SP;;ACTIVE;1.0h(3);2.48 +87775-3;Metaxalone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Metaxalone/Creatinine [Mass Ratio] in Urine by Confirmatory method;Metaxalone/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87776-1;Zaleplon/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Zaleplon/Creatinine [Mass Ratio] in Urine by Confirmatory method;Zaleplon/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87777-9;8-Hydroxyloxapine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;8-Hydroxyloxapine/Creatinine [Mass Ratio] in Urine by Confirmatory method;8OH-Loxapine/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87778-7;Molindone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Molindone/Creatinine [Mass Ratio] in Urine by Confirmatory method;Molindone/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87779-5;Pimozide/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pimozide/Creatinine [Mass Ratio] in Urine by Confirmatory method;Pimozide/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87780-3;Ziprasidone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ziprasidone/Creatinine [Mass Ratio] in Urine by Confirmatory method;Ziprasidone/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87781-1;ARIPiprazole/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;ARIPiprazole/Creatinine [Mass Ratio] in Urine by Confirmatory method;ARIPiprazole/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87782-9;Diclofenac/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Diclofenac/Creatinine [Mass Ratio] in Urine by Confirmatory method;Diclofenac/Creat Ur Cfm;;ACTIVE;2.63;2.63 +8778-3;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;CT spiral;HEMODYN.MOLEC;2;Right ventricular Stroke volume by Spiral CT;RV SV Spiral CT;;ACTIVE;1.0h(3);2.48 +87783-7;Ketoprofen/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ketoprofen/Creatinine [Mass Ratio] in Urine by Confirmatory method;Ketoprofen/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87784-5;Naproxen/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Naproxen/Creatinine [Mass Ratio] in Urine by Confirmatory method;Naproxen/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87785-2;Oxaprozin/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Oxaprozin/Creatinine [Mass Ratio] in Urine by Confirmatory method;Oxaprozin/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87786-0;Bupivacaine/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Bupivacaine/Creatinine [Mass Ratio] in Urine by Confirmatory method;Bupivacaine/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87787-8;guaiFENesin/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;guaiFENesin/Creatinine [Mass Ratio] in Urine by Confirmatory method;guaiFENesin/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87788-6;Milnacipran/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Milnacipran/Creatinine [Mass Ratio] in Urine by Confirmatory method;Milnacipran/Creat Ur Cfm;;ACTIVE;2.63;2.63 +87789-4;Theophylline/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Theophylline/Creatinine [Mass Ratio] in Urine by Confirmatory method;Theophylline/Creat Ur Cfm;;ACTIVE;2.63;2.73 +87790-2;Carbadox;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Carbadox [Susceptibility] by Minimum inhibitory concentration (MIC);Carbadox Islt MIC;;ACTIVE;2.63;2.63 +8779-1;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;US.doppler;HEMODYN.MOLEC;2;Right ventricular Stroke volume by US.doppler;RV SV DOP;;ACTIVE;1.0h(3);2.48 +87791-0;Carbadox;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Carbadox [Susceptibility];Carbadox Susc Islt;;ACTIVE;2.63;2.63 +87792-8;Cefovecin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefovecin [Susceptibility];Cefovecin Susc Islt;;ACTIVE;2.63;2.63 +87793-6;Nitrofurazone;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Nitrofurazone [Susceptibility] by Minimum inhibitory concentration (MIC);Nitrofurazone Islt MIC;;ACTIVE;2.63;2.63 +87794-4;Furazolidone;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Furazolidone [Susceptibility] by Minimum inhibitory concentration (MIC);Furazolidone Islt MIC;;ACTIVE;2.63;2.63 +87795-1;Ormetoprim+Sulfadimethoxine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Ormetoprim+Sulfadimethoxine [Susceptibility] by Minimum inhibitory concentration (MIC);Ormetoprim+Sulfadimethoxine Islt MIC;;ACTIVE;2.63;2.63 +87796-9;Sulfathiazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sulfathiazole [Susceptibility] by Minimum inhibitory concentration (MIC);Sulfathiazole Islt MIC;;ACTIVE;2.63;2.64 +87797-7;Sulfathiazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sulfathiazole [Susceptibility];Sulfathiazole Susc Islt;;ACTIVE;2.63;2.64 +87798-5;Tulathromycin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Tulathromycin [Susceptibility];TUL Susc Islt;;ACTIVE;2.63;2.63 +87799-3;Sulfadimethoxine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sulfadimethoxine [Susceptibility] by Minimum inhibitory concentration (MIC);Sulfadimethoxine Islt MIC;;ACTIVE;2.63;2.63 +87800-9;Pradofloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pradofloxacin [Susceptibility];PRA Susc Islt;;ACTIVE;2.63;2.63 +87801-7;Ormetoprim+Sulfadimethoxine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Ormetoprim+Sulfadimethoxine [Susceptibility];Ormetoprim+Sulfadimethoxine Susc Islt;;ACTIVE;2.63;2.63 +87802-5;Sulfachloropyridazine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sulfachloropyridazine [Susceptibility];Sulfachloropyridazine Susc Islt;;ACTIVE;2.63;2.63 +87803-3;Sulfadimethoxine;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Sulfadimethoxine [Susceptibility];Sulfadimethoxine Susc Islt;;ACTIVE;2.63;2.63 +87804-1;Sulfachloropyridazine;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Sulfachloropyridazine [Susceptibility] by Minimum inhibitory concentration (MIC);Sulfachloropyridazine Islt MIC;;ACTIVE;2.63;2.63 +87805-8;Methylphenidate;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Methylphenidate [Presence] in Saliva (oral fluid) by Screen method;Me-phenidate Sal Ql Scn;;ACTIVE;2.63;2.73 +87806-6;Methylphenidate;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Methylphenidate [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Me-phenidate Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87807-4;Naloxone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Naloxone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Naloxone Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87808-2;chlordiazePOXIDE;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Chlordiazep Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +8780-9;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;Fick;HEMODYN.MOLEC;2;Right ventricular Stroke volume by Fick method;RV SV Fick;;ACTIVE;1.0h(3);2.48 +87809-0;Benzoylecgonine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Benzoylecgonine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;BZE Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87810-8;Methylenedioxymethamphetamine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Saliva (oral fluid) by Screen method;MDMA Sal Ql Scn;;ACTIVE;2.63;2.73 +87811-6;Meprobamate;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Meprobamate [Presence] in Saliva (oral fluid) by Screen method;Meprobamate Sal Ql Scn;;ACTIVE;2.63;2.73 +87812-4;Flunitrazepam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Flunitrazepam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Flunitrazepam Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87813-2;Flurazepam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Flurazepam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Flurazepam Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87814-0;Midazolam;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Midazolam [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Midazolam Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87815-7;fentaNYL;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;fentaNYL [Presence] in Saliva (oral fluid) by Screen method;fentaNYL Sal Ql Scn;;ACTIVE;2.63;2.73 +87816-5;6-Monoacetylmorphine;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;6-Monoacetylmorphine (6-MAM) [Presence] in Saliva (oral fluid) by Screen method;6MAM Sal Ql Scn;;ACTIVE;2.63;2.73 +8781-7;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;Indicator dilution;HEMODYN.MOLEC;2;Right ventricular Stroke volume by Indicator dilution;RV SV Indicator dilution;;ACTIVE;1.0h(3);2.48 +87817-3;Propoxyphene;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Propoxyphene [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Propoxyph Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87818-1;Tapentadol;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Tapentadol [Presence] in Saliva (oral fluid) by Screen method;Tapentadol Sal Ql Scn;;ACTIVE;2.63;2.73 +87819-9;Tapentadol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Tapentadol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Tapentadol Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87820-7;Zolpidem;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Zolpidem [Presence] in Saliva (oral fluid) by Screen method;Zolpidem Sal Ql Scn;;ACTIVE;2.63;2.73 +87821-5;Zolpidem;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Zolpidem [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Zolpidem Sal Cfm-mCnc;;ACTIVE;2.63;2.73 +87822-3;Naltrexone;PrThr;Pt;Saliva;Ord;Screen;DRUG/TOX;1;Naltrexone [Presence] in Saliva (oral fluid) by Screen method;Naltrexone Sal Ql Scn;;ACTIVE;2.63;2.73 +87823-1;Naltrexone;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Naltrexone [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Naltrexone Sal Cfm-mCnc;;ACTIVE;2.63;2.63 +87824-9;6-Beta naltrexol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;6-Beta naltrexol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;6-Beta naltrexol Sal Cfm-mCnc;;ACTIVE;2.63;2.63 +8782-5;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;MR;HEMODYN.MOLEC;2;Right ventricular Stroke volume by MR;RV SV MR;;ACTIVE;1.0h(3);2.56 +87825-6;National Trauma Data Standard - version 2018 set;-;Pt;{Setting};-;;PANEL.TRAUMA;2;National Trauma Data Standard - version 2018 set;NTDS 2018 set;;ACTIVE;2.63;2.73 +87826-4;"t(11;18)(q21;q21)(BIRC3,MALT1) fusion transcript";Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.TRNLOC;1;"t(11;18)(q21;q21)(BIRC3,MALT1) fusion transcript in Blood or Tissue by Molecular genetics method";"t(11;18)(BIRC3,MALT1) Bld/T";;ACTIVE;2.63;2.65 +87827-2;Casts;PrThr;Pt;Urine;Ord;;UA;1;Casts [Presence] in Urine;Casts Ur Ql;;ACTIVE;2.63;2.63 +87828-0;Crystals;PrThr;Pt;Urine;Ord;;UA;1;Crystals [Presence] in Urine;Crystals Ur Ql;;ACTIVE;2.63;2.63 +87829-8;Bacteria;PrThr;Pt;Urine;Ord;;UA;1;Bacteria [Presence] in Urine;Bacteria Ur Ql;;ACTIVE;2.63;2.63 +87830-6;Epithelial cells;PrThr;Pt;Urine;Ord;;UA;1;Epithelial cells [Presence] in Urine;Epi Cells Ur Ql;;ACTIVE;2.63;2.63 +87831-4;Yeast;PrThr;Pt;Urine;Ord;;UA;1;Yeast [Presence] in Urine;Yeast Ur Ql;;ACTIVE;2.63;2.73 +87832-2;Fibroblast growth factor 21.intact;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fibroblast growth factor 21.intact [Mass/volume] in Serum or Plasma;FGF-21.intact SerPl-mCnc;;ACTIVE;2.63;2.63 +8783-3;Stroke volume;Vol;Pt;Heart.ventricle.right;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Right ventricular Stroke volume by Nuclear blood pool;RV SV Nuc BP;;ACTIVE;1.0h(3);2.48 +87833-0;Protein.monoclonal band 3;MCnc;Pt;Urine;Qn;Immunofixation;CHEM;1;Protein.monoclonal band 3 [Mass/volume] in Urine by Immunofixation;M Protein 3 Ur IFE-mCnc;;ACTIVE;2.63;2.63 +87834-8;Protein.monoclonal band 2;MCnc;Pt;Urine;Qn;Immunofixation;CHEM;1;Protein.monoclonal band 2 [Mass/volume] in Urine by Immunofixation;M Protein 2 Ur IFE-mCnc;;ACTIVE;2.63;2.63 +87835-5;Protein.monoclonal;MCnc;Pt;Urine;Qn;Immunofixation;CHEM;1;Protein.monoclonal [Mass/volume] in Urine by Immunofixation;M Protein Ur IFE-mCnc;;ACTIVE;2.63;2.63 +87836-3;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Hepatic vessels;Doc;CT.angio;RAD;2;CTA Hepatic vessels WO and W contrast IV;CTA Hep ves WO+W contr IV;;ACTIVE;2.63;2.63 +87837-1;Multisection^W contrast IV;Find;Pt;Chest>Aortic valve;Doc;CT.angio;RAD;2;CTA Aortic valve W contrast IV;CTA Aortic valve W contr IV;;ACTIVE;2.63;2.63 +87838-9;Multisection^W contrast IV;Find;Pt;Abdomen>Abdominal veins & Pelvis>Pelvis veins;Doc;CT.angio;RAD;2;CTA Abdominal veins and Pelvis veins W contrast IV;CTA Abd vv + Pelvis vv W contr IV;;ACTIVE;2.63;2.63 +87839-7;Multisection^W contrast IV;Find;Pt;Chest>Pulmonary veins;Doc;CT.angio;RAD;2;CTA Pulmonary veins W contrast IV;CTA Pulm vv W contr IV;;ACTIVE;2.63;2.63 +87840-5;Multisection^W contrast IV;Find;Pt;Chest>Coronary arteries+Pulmonary arteries;Doc;CT.angio;RAD;2;CTA Coronary arteries and Pulmonary arteries W contrast IV;CTA CA+PA W contr IV;;ACTIVE;2.63;2.63 +87841-3;Multisection^W contrast IV;Find;Pt;Chest>Coronary arteries+Aorta.thoracic;Doc;CT.angio;RAD;2;CTA Coronary arteries and Thoracic aorta W contrast IV;CTA CA+TA W contr IV;;ACTIVE;2.63;2.63 +87842-1;Multisection^W contrast IV;Find;Pt;Chest>Coronary arteries+Pulmonary arteries+Aorta.thoracic;Doc;CT.angio;RAD;2;CTA Coronary arteries and Pulmonary arteries and Thoracic aorta W contrast IV;CTA Coronary aa+PA+TA W contr IV;;ACTIVE;2.63;2.63 +87843-9;Multisection;Find;Pt;Pelvis>Pelvis veins & Lower extremity.bilateral>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Pelvis veins and Lower extremity veins - bilateral;CTA Pelvis vv + LE vv-Bl;;ACTIVE;2.63;2.63 +87844-7;Multisection;Find;Pt;Pelvis>Pelvis veins;Doc;CT.angio;RAD;2;CTA Pelvis veins;CTA Pelvis vv;;ACTIVE;2.63;2.63 +87845-4;Multisection;Find;Pt;Lower extremity>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Lower extremity vessels;CTA LE ves;;ACTIVE;2.63;2.63 +87846-2;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Renal vessels;Doc;CT.angio;RAD;2;CTA Renal vessels WO and W contrast IV;CTA Renal ves WO+W contr IV;;ACTIVE;2.63;2.63 +87847-0;Multisection^WO contrast && Multisection^W contrast IV;Find;Pt;Chest & Chest>Coronary arteries;Doc;CT && CT.angio;RAD;2;CT Chest WO and CT angiogram Coronary arteries W contrast IV;CT Chest WO + CTA Coronary aa W contr IV;;ACTIVE;2.63;2.63 +87848-8;Multisection for pulmonary embolus+deep vein thrombosis^W contrast IV;Find;Pt;Chest>Pulmonary arteries.bilateral & Lower extremity.bilateral>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Pulmonary arteries - bilateral and Lower extremity veins - bilateral for pulmonary embolus and deep vein thrombosis W contrast IV;CTA PA-Bl + LE vv-Bl for PE+DVT W cont IV;;ACTIVE;2.63;2.63 +87849-6;Multisection for pulmonary embolus+deep vein thrombosis;Find;Pt;Chest>Pulmonary arteries.bilateral & Lower extremity.bilateral>Lower extremity veins;Doc;CT.angio;RAD;2;CTA Pulmonary arteries - bilateral and Lower extremity veins - bilateral for pulmonary embolus and deep vein thrombosis;CTA PA-Bl + LE vv-Bl for PE+DVT;;ACTIVE;2.63;2.63 +87850-4;Multisection^WO & W contrast IV;Find;Pt;Abdomen+Pelvis>Deep inferior epigastric artery;Doc;CT.angio;RAD;2;CTA Deep inferior epigastric artery WO and W contrast IV;CTA Deep inf epigastric a WO+W contr IV;;ACTIVE;2.63;2.63 +87851-2;Multisection^W contrast IV;Find;Pt;Abdomen>Mesenteric vessels;Doc;CT.angio;RAD;2;CTA Mesenteric vessels W contrast IV;CTA Mesenteric ves W contr IV;;ACTIVE;2.63;2.63 +87852-0;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Mesenteric vessels;Doc;CT.angio;RAD;2;CTA Mesenteric vessels WO and W contrast IV;CTA Mesenteric ves WO+W contr IV;;ACTIVE;2.63;2.63 +87853-8;Multisection^WO & W contrast IV;Find;Pt;Abdomen+Pelvis && Abdomen>Aorta.abdominal;Doc;CT && CT.angio;RAD;2;CT Abdomen and Pelvis and CT angiogram Abdominal aorta WO and W contrast IV;CT Abd+Pel + CTA AA WO+W contr IV;;ACTIVE;2.63;2.63 +87854-6;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis && Abdomen>Aorta.abdominal;Doc;CT && CT.angio;RAD;2;CT Abdomen and Pelvis and CT angiogram Abdominal aorta W contrast IV;CT Abd+Pel + CTA AA W contr IV;;ACTIVE;2.63;2.63 +87855-3;Multisection^WO & W contrast IV;Find;Pt;Head+Neck>Circle of Willis+Carotid arteries;Doc;CT.angio;RAD;2;CTA Circle of Willis and Carotid arteries WO and W contrast IV;CTA Circ of Willis+Carot aa WO+W contr IV;;ACTIVE;2.63;2.63 +87856-1;Multisection^W contrast IV;Find;Pt;Head+Neck>Circle of Willis+Carotid arteries;Doc;CT.angio;RAD;2;CTA Circle of Willis and Carotid arteries W contrast IV;CTA Circ of Willis+Carot aa W contr IV;;ACTIVE;2.63;2.63 +87857-9;Multisection^WO & W contrast IV;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;CT.angio;RAD;2;CTA Thoracic and abdominal aorta WO and W contrast IV;CTA TA + AA WO+W contr IV;;ACTIVE;2.63;2.63 +8785-8;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;2D echo;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by 2D echo;LV SVI 2D Echo;;ACTIVE;1.0h(3);2.48 +87858-7;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis>Deep inferior epigastric artery;Doc;CT.angio;RAD;2;CTA Deep inferior epigastric artery W contrast IV;CTA Deep inf epigastric a W contr IV;;ACTIVE;2.63;2.63 +87859-5;Multisection^WO & W contrast IV;Find;Pt;Chest>Aorta.thoracic;Doc;CT;RAD;2;CT Thoracic Aorta WO and W contrast IV;CT TA WO+W contr IV;;ACTIVE;2.63;2.63 +87860-3;Multisection^WO contrast;Find;Pt;Chest>Aorta.thoracic;Doc;CT;RAD;2;CT Thoracic Aorta WO contrast;CT TA WO contr;;ACTIVE;2.63;2.63 +87861-1;Multisection^WO & W contrast IV;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal;Doc;CT;RAD;2;CT Thoracic and abdominal aorta WO and W contrast IV;CT TA + AA WO+W contr IV;;ACTIVE;2.63;2.63 +87862-9;Multisection^WO contrast && Multisection^W contrast IV;Find;Pt;Abdomen && Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen WO and CT Abdomen and Pelvis W contrast IV;CT Abd WO + CT Abd+Pel W contr IV;;ACTIVE;2.63;2.63 +87863-7;Multisection^WO contrast && Multisection^W contrast IV;Find;Pt;Abdomen && Chest+Abdomen;Doc;CT;RAD;2;CT Abdomen WO and CT Chest and Abdomen W contrast IV;CT Abd WO + CT Abd+Chest W contr IV;;ACTIVE;2.63;2.63 +87864-5;Multisection^WO contrast && Multisection^W contrast IV;Find;Pt;Abdomen && Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen WO and CT Chest and Abdomen and Pelvis W contrast IV;CT Abd WO + CT Chest+Abd+Pel W contr IV;;ACTIVE;2.63;2.63 +87865-2;Multisection^WO contrast && Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis && Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen and Pelvis WO and CT Chest and Abdomen and Pelvis W contrast IV;CT Abd+Pel WO + Chest+Abd+Pel W contr IV;;ACTIVE;2.63;2.63 +8786-6;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;Angiography.biplane;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by Angiography biplane;LV SVI Angio BP;;ACTIVE;1.0h(3);2.48 +87866-0;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urinary bladder;Doc;CT;RAD;2;CT Kidney and Ureter and Urinary bladder WO and W contrast IV;CT Kid+Uret+Blad WO+W contr IV;;ACTIVE;2.63;2.63 +87867-8;Multisection by reconstruction;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine by reconstruction;CT L-spine by reconstr;;ACTIVE;2.63;2.63 +87868-6;Multisection by reconstruction^WO & W contrast IV;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Lumbar spine by reconstruction WO and W contrast IV;CT L-spine by reconstr WO+W contr IV;;ACTIVE;2.63;2.63 +87869-4;Multisection;Find;Pt;Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Chest and Abdomen and Pelvis;CT Chest+Abd+Pelvis;;ACTIVE;2.63;2.63 +87870-2;Multisection^WO & W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx;Doc;CT;RAD;2;CT Cervical spine to Coccyx WO and W contrast IV;CT C+T+L-spine+Sacr+Coccyx WO+W contr IV;;ACTIVE;2.63;2.67 +87871-0;Multisection;Find;Pt;Chest>Clavicle.left;Doc;CT;RAD;2;CT Clavicle - left;CT Clavicle-L;;ACTIVE;2.63;2.63 +87872-8;Multisection;Find;Pt;Chest>Clavicle.right;Doc;CT;RAD;2;CT Clavicle - right;CT Clavicle-R;;ACTIVE;2.63;2.63 +87873-6;Multisection^WO & W contrast IV;Find;Pt;Chest>Lung parenchyma;Doc;CT;RAD;2;CT Lung parenchyma WO and W contrast IV;CT Lung parenchyma WO+W contr IV;;ACTIVE;2.63;2.63 +8787-4;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;Angiography.single plane;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by Angiography single plane;LV SVI Angio SP;;ACTIVE;1.0h(3);2.48 +87874-4;Multisection^W contrast IV;Find;Pt;Chest>Mediastinum;Doc;CT;RAD;2;CT Mediastinum W contrast IV;CT Mediastinum W contr IV;;ACTIVE;2.63;2.63 +87875-1;Multisection by reconstruction;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Thoracic spine by reconstruction;CT T-spine by reconstr;;ACTIVE;2.63;2.63 +87876-9;Multisection;Find;Pt;Chest>Thymus gland;Doc;CT;RAD;2;CT Thymus gland;CT Thymus gland;;ACTIVE;2.63;2.63 +87877-7;Multisection^WO contrast;Find;Pt;Neck+Chest;Doc;CT;RAD;2;CT Neck and Chest WO contrast;CT Neck+Chest WO contr;;ACTIVE;2.63;2.63 +87878-5;Multisection^W contrast IS;Find;Pt;Lower extremity.bilateral>Knee;Doc;CT;RAD;2;CT Knee - bilateral Arthrogram;CT Knee-Bl W contr IS;;ACTIVE;2.63;2.63 +87879-3;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Lower leg;Doc;CT;RAD;2;CT Lower leg - bilateral WO contrast;CT Lower leg-Bl WO contr;;ACTIVE;2.63;2.63 +87880-1;Multisection^W contrast IV;Find;Pt;Lower extremity.bilateral>Thigh;Doc;CT;RAD;2;CT Thigh - bilateral W contrast IV;CT Thigh-Bl W contr IV;;ACTIVE;2.63;2.63 +87881-9;Multisection^WO contrast;Find;Pt;Lower extremity.bilateral>Thigh;Doc;CT;RAD;2;CT Thigh - bilateral WO contrast;CT Thigh-Bl WO contr;;ACTIVE;2.63;2.63 +8788-2;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;CT spiral;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by Spiral CT;LV SVI Spiral CT;;ACTIVE;1.0h(3);2.48 +87882-7;Multisection;Find;Pt;Lower extremity.left>Lower leg;Doc;CT;RAD;2;CT Lower leg - left;CT Lower leg-L;;ACTIVE;2.63;2.63 +87883-5;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral;Doc;CT;RAD;2;CT Upper extremity - bilateral WO and W contrast IV;CT UE-Bl WO+W contr IV;;ACTIVE;2.63;2.63 +87884-3;Multisection^W contrast IS;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;CT;RAD;2;CT Shoulder - bilateral Arthrogram;CT Shoulder-Bl W contr IS;;ACTIVE;2.63;2.63 +87885-0;Multisection^WO contrast;Find;Pt;Upper extremity.bilateral>Upper arm;Doc;CT;RAD;2;CT Upper arm - bilateral WO contrast;CT Upper arm-Bl WO contr;;ACTIVE;2.63;2.63 +87886-8;Multisection^WO contrast;Find;Pt;Upper extremity.left>Finger.fifth;Doc;CT;RAD;2;CT Finger fifth - left WO contrast;CT Finger.5th-L WO contr;;ACTIVE;2.63;2.63 +87887-6;Multisection^W Contrast IV;Find;Pt;Upper extremity.left>Finger.fourth;Doc;CT;RAD;2;CT Finger fourth - left W contrast IV;CT Finger.4th-L W contr IV;;ACTIVE;2.63;2.63 +87888-4;Multisection^WO contrast;Find;Pt;Upper extremity.left>Finger.second;Doc;CT;RAD;2;CT Finger second - left WO contrast;CT Finger.2nd-L WO contr;;ACTIVE;2.63;2.63 +87889-2;Multisection^WO contrast;Find;Pt;Upper extremity.left>Thumb;Doc;CT;RAD;2;CT Thumb - left WO contrast;CT Thumb-L WO contr;;ACTIVE;2.63;2.63 +878-9;A,B Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;A,B Ag [Presence] on Red Blood Cells from Blood product unit;A,B Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +8789-0;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;US.doppler;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by US.doppler;LV SVI DOP;;ACTIVE;1.0h(3);2.48 +87890-0;Multisection^WO contrast;Find;Pt;Upper extremity.right>Finger.fifth;Doc;CT;RAD;2;CT Finger fifth - right WO contrast;CT Finger.5th-R WO contr;;ACTIVE;2.63;2.63 +87891-8;Multisection^WO contrast;Find;Pt;Upper extremity.right>Finger.fourth;Doc;CT;RAD;2;CT Finger fourth - right WO contrast;CT Finger.4th-R WO contr;;ACTIVE;2.63;2.63 +87892-6;Multisection^WO contrast;Find;Pt;Upper extremity.right>Finger.second;Doc;CT;RAD;2;CT Finger second - right WO contrast;CT Finger.2nd-R WO contr;;ACTIVE;2.63;2.63 +87893-4;Multisection^WO contrast;Find;Pt;Upper extremity.right>Finger.third;Doc;CT;RAD;2;CT Finger third - right WO contrast;CT Finger.3rd-R WO contr;;ACTIVE;2.63;2.63 +87894-2;Multisection^WO contrast;Find;Pt;Upper extremity.right>Thumb;Doc;CT;RAD;2;CT Thumb - right WO contrast;CT Thumb-R WO contr;;ACTIVE;2.63;2.63 +87895-9;Multisection^WO contrast;Find;Pt;Upper extremity>Finger;Doc;CT;RAD;2;CT Finger WO contrast;CT Finger WO contr;;ACTIVE;2.63;2.63 +87896-7;Multisection^W contrast IV;Find;Pt;Head>Teeth;Doc;CT;RAD;2;CT Teeth W contrast IV;CT Teeth W contr IV;;ACTIVE;2.63;2.63 +87897-5;Multisection^W contrast IV;Find;Pt;Head & Head>Pituitary+Sella turcica;Doc;CT;RAD;2;CT Head and Pituitary and Sella turcica W contrast IV;CT Head+Pit+Sella W contr IV;;ACTIVE;2.63;2.63 +87898-3;Multisection^WO contrast;Find;Pt;Head>Teeth.maxilla;Doc;CT;RAD;2;CT Teeth.maxilla WO contrast;CT Teeth.max WO contr;;ACTIVE;2.63;2.63 +87899-1;Multisection^WO contrast;Find;Pt;Head>Teeth.mandible;Doc;CT;RAD;2;CT Teeth.mandible WO contrast;CT Teeth.mand WO contr;;ACTIVE;2.63;2.63 +87900-7;Multisection^W contrast IV;Find;Pt;Head>Mastoid;Doc;CT;RAD;2;CT Mastoid W contrast IV;CT Mastoid W contr IV;;ACTIVE;2.63;2.63 +87901-5;Multisection^WO & W contrast IV;Find;Pt;Head>Temporal bone.bilateral;Doc;CT;RAD;2;CT Temporal bone - bilateral WO and W contrast IV;CT Temporal bone-Bl WO+W contr IV;;ACTIVE;2.63;2.63 +87902-3;Multisection^W contrast IV;Find;Pt;Head>Temporal bone.bilateral;Doc;CT;RAD;2;CT Temporal bone - bilateral W contrast IV;CT Temporal bone-Bl W contr IV;;ACTIVE;2.63;2.63 +87903-1;Multisection^WO contrast;Find;Pt;Head>Temporal bone.bilateral;Doc;CT;RAD;2;CT Temporal bone - bilateral WO contrast;CT Temporal bone-Bl WO contr;;ACTIVE;2.63;2.63 +87904-9;Multisection^WO contrast;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;CT;RAD;2;CT Temporomandibular joint - bilateral WO contrast;CT TMJ-Bl WO contr;;ACTIVE;2.63;2.63 +87905-6;Guidance for localization of tumor^W 18F-FDG IV;Find;Pt;Head+Neck;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Head and Neck-- W 18F-FDG IV;PET+CT Head+Neck Guid tum loc 18F-FDG IV;;ACTIVE;2.63;2.63 +87906-4;Multisection^W contrast IV;Find;Pt;Head>Maxillofacial region.right;Doc;CT;RAD;2;CT Maxillofacial region - right W contrast IV;CT Maxillofacial-R W contr IV;;DISCOURAGED;2.63;2.66 +87907-2;Multisection for amyloidosis^W radionuclide IV;Find;Pt;Head>Brain;Doc;PT+CT;RAD;2;PET+CT Brain for amyloidosis;PET+CT Brain for amyloidosis W RNC IV;;ACTIVE;2.63;2.63 +8790-8;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;Fick;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by Fick method;LV SVI Fick;;ACTIVE;1.0h(3);2.48 +87908-0;Multisection^W contrast IV;Find;Pt;Head & Head>Maxillofacial region;Doc;CT;RAD;2;CT Head and Maxillofacial region W contrast IV;CT Head+Maxillofacial W contr IV;;ACTIVE;2.63;2.63 +87909-8;Multisection^W contrast IS;Find;Pt;Head>Temporomandibular joint;Doc;CT;RAD;2;CT Temporomandibular joint Arthrogram;CT TMJ W contr IS;;ACTIVE;2.63;2.63 +87910-6;Multisection^WO & W contrast IV;Find;Pt;Head & Head>Sinuses;Doc;CT;RAD;2;CT Head and Sinuses WO and W contrast IV;CT Head+Sinuses WO+W contr IV;;ACTIVE;2.63;2.63 +87911-4;Multisection^WO & W contrast IV;Find;Pt;Head & Head>Maxillofacial region;Doc;CT;RAD;2;CT Head and Maxillofacial region WO and W contrast IV;CT Head+Maxillofacial WO+W contr IV;;ACTIVE;2.63;2.63 +87912-2;Multisection^WO contrast;Find;Pt;Head>Sinuses+Orbit;Doc;CT;RAD;2;CT Sinuses and Orbit WO contrast;CT Sinuses+Orbit WO contr;;ACTIVE;2.63;2.63 +87913-0;Multisection by reconstruction;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Pelvis by reconstruction;CT Pelvis by reconstr;;ACTIVE;2.63;2.63 +87914-8;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Pelvis bones;Doc;CT;RAD;2;CT Pelvis bones WO and W contrast IV;CT Pelvis bones WO+W contr IV;;ACTIVE;2.63;2.63 +87915-5;Guidance for localization of tumor^W 18F-FDG IV+W Contrast IV;Find;Pt;Whole body>Skull vertex to mid-thigh;Doc;PT+CT;RAD;2;PET+CT Guidance for localization of tumor of Skull vertex to mid-thigh-- W 18F-FDG IV and W contrast IV;PET+CT Vert-thgh Guid tum loc 18F-FDG IV;;ACTIVE;2.63;2.63 +8791-6;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;Indicator dilution;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by Indicator dilution;LV SVI Indicator dilution;;ACTIVE;1.0h(3);2.48 +87916-3;Guidance for injection of cyst;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for injection of cyst of Unspecified body region;CT Guided Cyst inject;;ACTIVE;2.63;2.64 +87917-1;Multisection^WO contrast;Find;Pt;Pelvis>Pelvis bones;Doc;CT;RAD;2;CT Pelvis bones WO contrast;CT Pelvis bones WO contr;;ACTIVE;2.63;2.63 +87918-9;Multisection^WO & W contrast IV;Find;Pt;Neck>Parathyroid gland;Doc;CT;RAD;2;CT Parathyroid gland WO and W contrast IV;CT Parathyroid gland WO+W contr IV;;ACTIVE;2.63;2.63 +87919-7;Multisection;Find;Pt;Pelvis>Pelvis bones;Doc;CT;RAD;2;CT Pelvis bones;CT Pelvis bones;;ACTIVE;2.63;2.63 +87920-5;Multisection^W contrast IV;Find;Pt;Pelvis>Pelvis bones;Doc;CT;RAD;2;CT Pelvis bones W contrast IV;CT Pelvis bones W contr IV;;ACTIVE;2.63;2.63 +87921-3;Multisection^WO contrast;Find;Pt;Neck+Chest>Trachea;Doc;CT;RAD;2;CT Trachea WO contrast;CT Trachea WO contr;;ACTIVE;2.63;2.63 +87922-1;Multisection^W contrast IT;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;CT;RAD;2;CT Cervical and thoracic spine W contrast IT;CT C+T-spine W contr IT;;ACTIVE;2.63;2.63 +87923-9;Rickettsia conorii Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rickettsia conorii IgM Ab [Presence] in Serum by Immunoassay;R conorii IgM Ser Ql IA;;ACTIVE;2.63;2.63 +8792-4;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;MR;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by MR;LV SVI MR;;ACTIVE;1.0h(3);2.56 +87924-7;Rickettsia conorii Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Rickettsia conorii IgG Ab [Presence] in Serum by Immunoassay;R conorii IgG Ser Ql IA;;ACTIVE;2.63;2.63 +87925-4;Reagin Ab;Titr;Pt;CSF;Qn;RPR;MICRO;1;Reagin Ab [Titer] in Cerebral spinal fluid by RPR;RPR CSF-Titr;;ACTIVE;2.66;2.66 +87926-2;Epithelial cells;NCnc;Pt;Urine;Qn;Automated;UA;1;Epithelial cells [#/volume] in Urine by Automated;Epi Cells # Ur Auto;;ACTIVE;2.63;2.68 +87927-0;Bacterial susceptibility panel;-;Pt;Isolate;-;MLC;PANEL.MICRO;1;Bacterial susceptibility panel - Isolate by Minimum lethal concentration (MLC);Bacterial Susc Pnl Islt MLC;;ACTIVE;2.63;2.63 +87928-8;Macroscopic observation;Imp;Pt;Stool;Nar;;MICRO;1;Macroscopic observation [Interpretation] in Stool Narrative;Macroscopic obs Stl-Imp;;ACTIVE;2.63;2.63 +87929-6;Bacteria identified;Prid;Pt;Amnio fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Amniotic fluid by Aerobe culture;Bacteria Amn Aerobe Cult;;ACTIVE;2.63;2.63 +87930-4;Bacteria identified;Prid;Pt;Burn;Nom;Aerobic culture;MICRO;1;Bacteria identified in Burn by Aerobe culture;Bacteria Burn Aerobe Cult;;ACTIVE;2.63;2.63 +87931-2;Bacteria identified;Prid;Pt;Implanted device;Nom;Aerobic culture;MICRO;1;Bacteria identified in Implanted device by Aerobe culture;Bacteria Implnt dev Aerobe Cult;;ACTIVE;2.63;2.65 +8793-2;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.left;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Left ventricular Stroke volume index by Nuclear blood pool;LV SVI Nuc BP;;ACTIVE;1.0h(3);2.48 +87932-0;Bacteria identified;Prid;Pt;Sinus;Nom;Aerobic culture;MICRO;1;Bacteria identified in Sinus by Aerobe culture;Bacteria Sinus Aerobe Cult;;ACTIVE;2.63;2.63 +87933-8;Bacteria identified;Prid;Pt;Amnio fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Amniotic fluid by Anaerobe culture;Bacteria Amn Anaerobe Cult;;ACTIVE;2.63;2.63 +87934-6;Bacteria identified;Prid;Pt;Bil fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Bile fluid by Anaerobe culture;Bacteria Bifl Anaerobe Cult;;ACTIVE;2.63;2.63 +87935-3;Bacteria identified;Prid;Pt;^BPU;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Blood product unit by Anaerobe culture;Bacteria BPU Anaerobe Cult;;ACTIVE;2.63;2.63 +87936-1;Bacteria identified;Prid;Pt;Burn;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Burn by Anaerobe culture;Bacteria Burn Anaerobe Cult;;ACTIVE;2.63;2.63 +87937-9;Bacteria identified;Prid;Pt;CSF;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Cerebral spinal fluid by Anaerobe culture;Bacteria CSF Anaerobe Cult;;ACTIVE;2.63;2.63 +87938-7;Bacteria identified;Prid;Pt;Implanted device;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Implanted device by Anaerobe culture;Bacteria Implnt dev Anaerobe Cult;;ACTIVE;2.63;2.65 +87939-5;Bacteria identified;Prid;Pt;Pericard fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Pericardial fluid by Anaerobe culture;Bacteria Pcar Anaerobe Cult;;ACTIVE;2.63;2.63 +87940-3;Bacteria identified;Prid;Pt;Periton fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Peritoneal fluid by Anaerobe culture;Bacteria Prt Anaerobe Cult;;ACTIVE;2.63;2.63 +87941-1;Bacteria identified;Prid;Pt;Placenta;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Placenta by Anaerobe culture;Bacteria Placenta Anaerobe Cult;;ACTIVE;2.63;2.63 +87942-9;Bacteria identified;Prid;Pt;Plr fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Pleural fluid by Anaerobe culture;Bacteria Plr Anaerobe Cult;;ACTIVE;2.63;2.63 +87943-7;Bacteria identified;Prid;Pt;Sinus;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Sinus by Anaerobe culture;Bacteria Sinus Anaerobe Cult;;ACTIVE;2.63;2.63 +87944-5;Bacteria identified;Prid;Pt;Synv fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Synovial fluid by Anaerobe culture;Bacteria Snv Anaerobe Cult;;ACTIVE;2.63;2.63 +87945-2;Borrelia sp identified;Prid;Pt;CSF;Nom;Organism specific culture;MICRO;1;Borrelia sp identified in Cerebral spinal fluid by Organism specific culture;Borrelia CSF Cult;;ACTIVE;2.63;2.63 +87946-0;Borrelia sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Borrelia sp identified in Tissue by Organism specific culture;Borrelia Tiss Cult;;ACTIVE;2.63;2.63 +87947-8;Borrelia sp DNA;Prid;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;Borrelia sp DNA identified in Tissue by NAA with probe detection;Borrelia DNA Tiss NAA+probe;;ACTIVE;2.63;2.63 +87948-6;Clostridium botulinum;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Clostridium botulinum [Presence] in Stool by Organism specific culture;C bot Stl Ql Cult;;ACTIVE;2.63;2.73 +87949-4;Chlamydia trachomatis DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Tissue by NAA with probe detection;C trach DNA Tiss Ql NAA+probe;;ACTIVE;2.63;2.63 +87950-2;Chlamydia trachomatis;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Tissue by Organism specific culture;C trach Tiss Ql Cult;;ACTIVE;2.63;2.63 +87951-0;Escherichia coli eaeA gene;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli eaeA gene [Presence] in Stool by NAA with probe detection;EC eaeA gene Stl Ql NAA+probe;;ACTIVE;2.63;2.63 +87952-8;Helicobacter pylori;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Helicobacter pylori [Presence] in Stool by Organism specific culture;H pylori Stl Ql Cult;;ACTIVE;2.63;2.63 +87953-6;Helicobacter pylori;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Helicobacter pylori [Presence] in Tissue by Organism specific culture;H pylori Tiss Ql Cult;;ACTIVE;2.63;2.63 +87954-4;Bacteria identified;Prid;Pt;BldCo;Nom;Aerobic culture;MICRO;1;Bacteria identified in Cord blood by Aerobe culture;Bacteria BldCo Aerobe Cult;;ACTIVE;2.63;2.63 +87955-1;Bacteria identified;Prid;Pt;BldCo;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Cord blood by Anaerobe culture;Bacteria BldCo Anaerobe Cult;;ACTIVE;2.63;2.63 +87956-9;Legionella sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Tissue by Organism specific culture;Legionella Tiss Cult;;ACTIVE;2.63;2.63 +8795-7;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;2D echo;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by 2D echo;RV SVI 2D Echo;;ACTIVE;1.0h(3);2.48 +87957-7;Legionella sp identified;Prid;Pt;Water;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Water by Organism specific culture;Legionella Wat Cult;;ACTIVE;2.63;2.63 +87958-5;Neisseria meningitidis;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Neisseria meningitidis [Presence] in Throat by Organism specific culture;N men Throat Ql Cult;;ACTIVE;2.63;2.63 +87959-3;Adenovirus Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Cerebral spinal fluid by Immunoassay;HAdV Ag CSF Ql IA;;ACTIVE;2.63;2.63 +87960-1;Enterovirus RNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Body fluid by NAA with probe detection;EV RNA Fld Ql NAA+probe;;ACTIVE;2.63;2.63 +87961-9;Varicella zoster virus DNA;PrThr;Pt;Body fld;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Body fluid by NAA with probe detection;VZV DNA Fld Ql NAA+probe;;ACTIVE;2.63;2.63 +87962-7;HIV 1 subtype;Type;Pt;CSF;Nom;Probe.amp.tar;MICRO;1;HIV 1 subtype identified in Cerebral spinal fluid by NAA with probe detection;HIV 1 subtype CSF NAA+probe;;ACTIVE;2.63;2.63 +87963-5;HIV 1 RNA tropism;Prid;Pt;CSF;Nom;;MICRO;1;HIV 1 RNA tropism [Identifier] in Cerebral spinal fluid;HIV1 RNA tropism CSF;;ACTIVE;2.63;2.63 +87964-3;Respiratory pathogens panel;-;Pt;BAL;-;IF;PANEL.MICRO;1;Respiratory pathogens panel - Bronchoalveolar lavage by Immunofluorescence;Respiratory path Pnl BAL IF;;ACTIVE;2.63;2.63 +8796-5;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;Angiography.biplane;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by Angiography biplane;RV SVI Angio BP;;ACTIVE;1.0h(3);2.48 +87965-0;Microscopic observation;Prid;Pt;CSF;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Cerebral spinal fluid by Giemsa stain;Gie Stn CSF;;ACTIVE;2.63;2.63 +87966-8;Microscopic observation;Prid;Pt;Bone mar;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Bone marrow by Giemsa stain;Gie Stn Mar;;ACTIVE;2.63;2.63 +87967-6;Microscopic observation;Prid;Pt;Bone mar;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Bone marrow by Gram stain;Gram Stn Mar;;ACTIVE;2.63;2.63 +87968-4;Microscopic observation;Prid;Pt;Body fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Body fluid by Giemsa stain;Gie Stn Fld;;ACTIVE;2.63;2.63 +87969-2;Microscopic observation;Prid;Pt;Bld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Blood by Gram stain;Gram Stn Bld;;ACTIVE;2.63;2.63 +879-7;A,B Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;A,B Ag [Presence] on Red Blood Cells from Donor;A,B Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +87970-0;Microscopic observation;Prid;Pt;Amnio fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Amniotic fluid by Giemsa stain;Gie Stn Amn;;ACTIVE;2.63;2.63 +87971-8;Microscopic observation;Prid;Pt;Amnio fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Amniotic fluid by Gram stain;Gram Stn Amn;;ACTIVE;2.63;2.63 +87972-6;Microscopic observation;Prid;Pt;Sinus;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Sinus by Gram stain;Gram Stn Sinus;;ACTIVE;2.63;2.63 +8797-3;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;Angiography.single plane;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by Angiography single plane;RV SVI Angio SP;;ACTIVE;1.0h(3);2.48 +87973-4;Microscopic observation;Prid;Pt;Semen;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Semen by Gram stain;Gram Stn Smn;;ACTIVE;2.63;2.63 +87974-2;Microscopic observation;Prid;Pt;Burn;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Burn by Gram stain;Gram Stn Burn;;ACTIVE;2.63;2.63 +87975-9;Microscopic observation;Prid;Pt;Isolate;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Isolate by Gram stain;Gram Stn Islt;;ACTIVE;2.63;2.63 +87976-7;Fungus identified;Prid;Pt;Implanted device;Nom;Culture;MICRO;1;Fungus identified in Implanted device by Culture;Fungus Implnt dev Cult;;ACTIVE;2.63;2.65 +87977-5;Fungus identified;Prid;Pt;Pericard fld;Nom;Culture;MICRO;1;Fungus identified in Pericardial fluid by Culture;Fungus Pcar Cult;;ACTIVE;2.63;2.63 +87978-3;Fungus identified;Prid;Pt;Dial fld prt;Nom;Culture;MICRO;1;Fungus identified in Peritoneal dialysis fluid by Culture;Fungus DiafP Cult;;ACTIVE;2.63;2.63 +87979-1;Fungus identified;Prid;Pt;Plr fld;Nom;Culture;MICRO;1;Fungus identified in Pleural fluid by Culture;Fungus Plr Cult;;ACTIVE;2.63;2.63 +87980-9;Fungus identified;Prid;Pt;Sinus;Nom;Culture;MICRO;1;Fungus identified in Sinus by Culture;Fungus Sinus Cult;;ACTIVE;2.63;2.63 +8798-1;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;CT spiral;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by Spiral CT;RV SVI Spiral CT;;ACTIVE;1.0h(3);2.29 +87981-7;Fungus identified;Prid;Pt;Burn;Nom;Culture;MICRO;1;Fungus identified in Burn by Culture;Fungus Burn Cult;;ACTIVE;2.63;2.63 +87982-5;Toxoplasma gondii;PrThr;Pt;Bone mar;Ord;Organism specific culture;MICRO;1;Toxoplasma gondii [Presence] in Bone marrow by Organism specific culture;T gondii Mar Ql Cult;;ACTIVE;2.63;2.63 +87983-3;Toxoplasma gondii DNA;PrThr;Pt;Placenta;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Placenta by NAA with probe detection;T gondii DNA Placenta Ql NAA+probe;;ACTIVE;2.63;2.63 +87984-1;Toxoplasma gondii DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Tissue by NAA with probe detection;T gondii DNA Tiss Ql NAA+probe;;ACTIVE;2.63;2.63 +87985-8;Trichinella spiralis DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Trichinella spiralis DNA [Presence] in Tissue by NAA with probe detection;T spiralis DNA Tiss Ql NAA+probe;;ACTIVE;2.63;2.63 +87986-6;Leishmania sp identified;Prid;Pt;Bone mar;Nom;Organism specific culture;MICRO;1;Leishmania sp identified in Bone marrow by Organism specific culture;Leishmania Mar Cult;;ACTIVE;2.63;2.63 +87987-4;Leishmania sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Leishmania sp identified in Blood by Organism specific culture;Leishmania Bld Cult;;ACTIVE;2.63;2.63 +87988-2;Acanthamoeba sp DNA;PrThr;Pt;Contact lens;Ord;Probe.amp.tar;MICRO;1;Acanthamoeba sp DNA [Presence] in Contact lens by NAA with probe detection;Acanthamoeba DNA Cont lens Ql NAA+probe;;ACTIVE;2.63;2.68 +87989-0;Toxoplasma gondii DNA;PrThr;Pt;Bone mar;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Bone marrow by NAA with probe detection;T gondii DNA Mar Ql NAA+probe;;ACTIVE;2.63;2.63 +87990-8;Acanthamoeba sp identified;Prid;Pt;CSF;Nom;Organism specific culture;MICRO;1;Acanthamoeba sp identified in Cerebral spinal fluid by Organism specific culture;Acanthamoeba CSF Cult;;ACTIVE;2.63;2.63 +87991-6;Acanthamoeba sp identified;Prid;Pt;Contact lens;Nom;Organism specific culture;MICRO;1;Acanthamoeba sp identified in Contact lens by Organism specific culture;Acanthamoeba Cont lens Cult;;ACTIVE;2.63;2.68 +87992-4;Onchocerca sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Onchocerca sp IgG Ab [Presence] in Serum by Immunoassay;Onchocerca IgG Ser Ql IA;;ACTIVE;2.63;2.63 +87993-2;Toxoplasma gondii DNA;PrThr;Pt;BldCo;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Cord blood by NAA with probe detection;T gondii DNA BldCo Ql NAA+probe;;ACTIVE;2.63;2.63 +87994-0;Trypanosoma cruzi Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trypanosoma cruzi IgG Ab [Presence] in Serum by Immunoassay;T cruzi IgG Ser Ql IA;;ACTIVE;2.63;2.63 +87995-7;Strongyloides sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Strongyloides sp identified in Stool by Organism specific culture;Strongyloides Stl Cult;;ACTIVE;2.63;2.63 +87996-5;Fasciola hepatica Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Fasciola hepatica Ab [Titer] in Serum by Complement fixation;F hepatica Ab Titr Ser CF;;ACTIVE;2.63;2.63 +87997-3;Trypanosoma cruzi Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Trypanosoma cruzi IgM Ab [Presence] in Serum by Immunoassay;T cruzi IgM Ser Ql IA;;ACTIVE;2.63;2.63 +87998-1;Amoeba identified;Prid;Pt;Stool;Nom;Wet preparation;MICRO;1;Amoeba identified in Stool by Wet preparation;Amoeba Stl Wet Prep;;ACTIVE;2.63;2.63 +8799-9;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;US.doppler;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by US.doppler;RV SVI DOP;;ACTIVE;1.0h(3);2.29 +87999-9;Microscopic observation;Prid;Pt;Contact lens;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Contact lens by Gram stain;Gram Stn Cont lens;;ACTIVE;2.63;2.68 +88000-5;Microscopic observation;Prid;Pt;Plr fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Pleural fluid by Giemsa stain;Gie Stn Plr;;ACTIVE;2.63;2.63 +88001-3;Microscopic observation;Prid;Pt;Dial fld prt;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Peritoneal dialysis fluid by Gram stain;Gram Stn DiafP;;ACTIVE;2.63;2.63 +88002-1;Kanamycin 2.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Kanamycin 2.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Kanamycin 2.5 ug/mL Islt SlowMyco;;ACTIVE;2.63;2.63 +88003-9;Acute ischemic stroke subtype;Class;Pt;^Patient;Nom;TOAST;CARD.PROC;2;TOAST Classification of subtypes of acute ischemic stroke;TOAST Classification;© 1992 American Heart Association Used with permission;ACTIVE;2.63;2.63 +88004-7;Trisomy 18 risk based on maternal age + Pregnancy associated plasma protein A + Choriogonadotropin + Nuchal translucency;Likelihood;Pt;^Fetus;Qn;;CHEM;1;Trisomy 18 risk based on maternal age + Pregnancy associated plasma protein A + Choriogonadotropin + Nuchal translucency [Likelihood] in Fetus;Ts 18 risk-age+PAPPA+HCG+NT Fetus;;ACTIVE;2.63;2.63 +8800-5;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;Fick;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by Fick method;RV SVI Fick;;ACTIVE;1.0h(3);2.29 +88005-4;Glutarylcarnitine (C5-DC)/Acetylcarnitine (C2);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Acetylcarnitine (C2) [Molar ratio] in Serum or Plasma;Glutarylcarn/C2 SerPl-sRto;;ACTIVE;2.63;2.63 +88006-2;Octanoylcarnitine (C8)/Carnitine.free (C0);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Octanoylcarnitine (C8)/Carnitine.free (C0) [Molar ratio] in Serum or Plasma;Octanoylcarn/C0 SerPl-sRto;;ACTIVE;2.63;2.63 +88007-0;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Carnitine.free (C0);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Carnitine.free (C0) [Molar ratio] in Serum or Plasma;Isovaleryl+MeButyrylcarn/C0 SerPl-sRto;;ACTIVE;2.63;2.63 +88008-8;Palmitoylcarnitine (C16)/Carnitine.free (C0);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoylcarnitine (C16)/Carnitine.free (C0) [Molar ratio] in Serum or Plasma;Palmitoylcarn/C0 SerPl-sRto;;ACTIVE;2.63;2.63 +88009-6;Palmitoylcarnitine (C16)/Acetylcarnitine (C2);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Palmitoylcarnitine (C16)/Acetylcarnitine (C2) [Molar ratio] in Serum or Plasma;Palmitoylcarn/C2 SerPl-sRto;;ACTIVE;2.63;2.63 +88010-4;Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2) [Molar ratio] in Serum or Plasma;Tdecenoylcarn/C2 SerPl-sRto;;ACTIVE;2.63;2.63 +88011-2;Tetradecenoylcarnitine (C14:1)/Carnitine.free (C0);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Carnitine.free (C0) [Molar ratio] in Serum or Plasma;Tdecenoylcarn/C0 SerPl-sRto;;ACTIVE;2.63;2.63 +88012-0;Sialate.lipid bound/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Sialate.lipid bound/Creatinine [Molar ratio] in Urine;LASA/Creat Ur-sRto;;ACTIVE;2.63;2.63 +8801-3;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;Indicator dilution;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by Indicator dilution;RV SVI Indicator dilution;;ACTIVE;1.0h(3);2.29 +88013-8;Glutarylcarnitine (C5-DC)/Palmitoylcarnitine (C16);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Palmitoylcarnitine (C16) [Molar ratio] in Serum or Plasma;Glutarylcarn/C16 SerPl-sRto;;ACTIVE;2.63;2.63 +88014-6;Octanoylcarnitine (C8)/Carnitine.free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Octanoylcarnitine (C8)/Carnitine.free (C0) [Molar ratio] in DBS;Octanoylcarn/C0 DBS-sRto;;ACTIVE;2.63;2.63 +88015-3;Palmitoylcarnitine (C16)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Palmitoylcarnitine (C16)/Acetylcarnitine (C2) [Molar ratio] in DBS;Palmitoylcarn/C2 DBS-sRto;;ACTIVE;2.63;2.63 +88016-1;Glutarylcarnitine (C5-DC)/Acetylcarnitine (C2);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Acetylcarnitine (C2) [Molar ratio] in DBS;Glutarylcarn/C2 DBS-sRto;;ACTIVE;2.63;2.63 +88017-9;Glutarylcarnitine (C5-DC)/Propionylcarnitine (C3);SRto;Pt;Bld.dot;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Propionylcarnitine (C3) [Molar ratio] in DBS;Glutarylcarn/C3 DBS-sRto;;ACTIVE;2.63;2.63 +88018-7;Alanine/Lysine;MRto;Pt;Bld.dot;Qn;;CHEM;1;Alanine/Lysine [Mass Ratio] in DBS;Alanine/Lysine DBS;;ACTIVE;2.63;2.63 +88019-5;N-acetylgalactosamine-6-sulfatase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;N-Acetylgalactosamine-6-Sulfatase [Enzymatic activity/volume] in DBS;GALNS DBS-cCnc;;ACTIVE;2.63;2.63 +88020-3;Functional capacity;Class;Pt;^Patient;Ord;NYHA;CARD.PROC;2;Functional capacity NYHA;Functional capacity NYHA;© 1994 American Heart Association Used with permission;ACTIVE;2.63;2.63 +8802-1;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;MR;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by MR;RV SVI MR;;ACTIVE;1.0h(3);2.56 +88021-1;Objective assessment of cardiovascular disease;Class;Pt;^Patient;Ord;NYHA;CARD.PROC;2;Objective assessment of cardiovascular disease NYHA;Objection Ax of CVD;© 1994 American Heart Association Used with permission;ACTIVE;2.63;2.63 +88022-9;5-fluoro PB-22 3-carboxyindole;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;5-F PB-22 3-carboxyindole (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;5-F PB-22 3-carboxyindole Ur Ql Cfm;;ACTIVE;2.63;2.73 +88023-7;XLR-11 N-(4-hydroxypentyl);PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;XLR-11 N-(4-hydroxypentyl) (synthetic cannabinoid metabolite) [Presence] in Urine by Confirmatory method;XLR-11 N-(4OH-pentyl) Ur Ql Cfm;;ACTIVE;2.63;2.73 +88024-5;Palmitoylcarnitine (C16)/Carnitine.free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Palmitoylcarnitine (C16)/Carnitine.free (C0) [Molar ratio] in DBS;Palmitoylcarn/C0 DBS-sRto;;ACTIVE;2.63;2.63 +88025-2;Tetradecenoylcarnitine (C14:1)/Carnitine.free (C0);SRto;Pt;Bld.dot;Qn;;CHEM;1;Tetradecenoylcarnitine (C14:1)/Carnitine.free (C0) [Molar ratio] in DBS;Tdecenoylcarn/C0 DBS-sRto;;ACTIVE;2.63;2.63 +88026-0;Glutarylcarnitine (C5-DC)/Propionylcarnitine (C3);SRto;Pt;Ser/Plas;Qn;;CHEM;1;Glutarylcarnitine (C5-DC)/Propionylcarnitine (C3) [Molar ratio] in Serum or Plasma;Glutarylcarn/C3 SerPl-sRto;;ACTIVE;2.63;2.63 +88027-8;Rh group Ag;Type;Pt;RBC;Nom;;BLDBK;1;Rh group Ag [Type] on Red Blood Cells;Rh Group Ag RBC;;ACTIVE;2.63;2.73 +88028-6;Tobacco use panel;-;Pt;^Patient;-;;PANEL.H&P;2;Tobacco use panel;Tobacco use pnl;;ACTIVE;2.63;2.63 +88029-4;Tobacco use duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Tobacco use duration;Tobacco use;;ACTIVE;2.63;2.66 +88030-2;Date quit smokeless tobacco;Date;Pt;^Patient;Qn;;H&P.HX;2;Date quit smokeless tobacco;Date quit smokeless tobacco;;ACTIVE;2.63;2.66 +88031-0;Smokeless tobacco status;Find;Pt;^Patient;Nom;;H&P.HX;2;Smokeless tobacco status;Smokeless tobacco status;;ACTIVE;2.63;2.66 +88032-8;Organophosphate panel;-;Pt;XXX;-;;PANEL.DRUG/TOX;1;Organophosphate panel - Specimen;Organophosphate pnl Spec;;ACTIVE;2.63;2.69 +88033-6;Safety checklist;Find;Pt;Ventilator;Doc;;DOC.MISC;2;Safety checklist Ventilator Document;Safety checklist Vent Doc;;ACTIVE;2.63;2.63 +88034-4;Settings;Find;Pt;Ventilator;Doc;;DOC.MISC;2;Ventilator settings Document;Vent settings Doc;;ACTIVE;2.63;2.73 +88035-1;Settings;Find;Pt;Ventilator.alarm;Doc;;DOC.MISC;2;Ventilator alarm settings Document;Vent alarm settings Doc;;ACTIVE;2.63;2.63 +88036-9;Ventilator alarm events;Find;Pt;^Patient;Doc;;DOC.MISC;2;Ventilator alarm events Document;Ventilator alarm events Doc;;ACTIVE;2.63;2.63 +88037-7;How often have you had five or more drinks in one D during the past Y;NRat;1Y;^Patient;Qn;Reported;SURVEY.GNHLTH;4;How often have you had five or more drinks in one day during the past year [Reported];;;ACTIVE;2.63;2.63 +88038-5;H little y Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Hy Ab [Presence] in Serum or Plasma;Hy Ab SerPl Ql;;ACTIVE;2.63;2.64 +8803-9;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by Nuclear blood pool;RV SVI Nuc BP;;ACTIVE;1.0h(3);2.29 +88039-3;little p phenotype;PrThr;Pt;RBC;Ord;;BLDBK;1;little p phenotype [Presence] on Red Blood Cells;little p phenotype RBC Ql;;ACTIVE;2.63;2.63 +88040-1;Response to cancer treatment;Find;Pt;^Patient;Nom;;ONCOLOGY;2;Response to cancer treatment;Response cancer treatment;;ACTIVE;2.63;2.63 +88041-9;little p phenotype;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;little p phenotype [Presence] on Red Blood Cells from Blood product unit;little p phenotype RBC BPU Ql;;ACTIVE;2.63;2.63 +88042-7;little p phenotype;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;little p phenotype [Presence] on Red Blood Cells from Donor;little p phenotype RBC Donr Ql;;ACTIVE;2.63;2.63 +88043-5;P super little k Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;P sup(k) Ab [Presence] in Serum or Plasma;P sup(k) Ab SerPl Ql;;ACTIVE;2.63;2.63 +88044-3;P super little k Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;P sup(k) Ab [Presence] in Serum or Plasma from Blood product unit;P sup(k) Ab SerPl BPU Ql;;ACTIVE;2.63;2.63 +88045-0;P super little k Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;P sup(k) Ab [Presence] in Serum or Plasma from Donor;P sup(k) Ab SerPl Donr Ql;;ACTIVE;2.63;2.63 +88046-8;P super little k Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;P sup(k) Ag [Presence] on Red Blood Cells;P sup(k) Ag RBC Ql;;ACTIVE;2.63;2.63 +8804-7;Stroke volume/Body surface area;ArVol;Pt;Heart.ventricle.right;Qn;Nuclear.myocardial;HEMODYN.MOLEC;2;Right ventricular Stroke volume index by Nuclear.myocardial;RV SVI Nuc.myocardial;;ACTIVE;1.0h(3);2.29 +88047-6;P super little k Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;P sup(k) Ag [Presence] on Red Blood Cells from Blood product unit;P sup(k) Ag RBC BPU Ql;;ACTIVE;2.63;2.63 +88048-4;P super little k Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;P sup(k) Ag [Presence] on Red Blood Cells from Donor;P sup(k) Ag RBC Donr Ql;;ACTIVE;2.63;2.63 +88049-2;P2 phenotype;PrThr;Pt;RBC;Ord;;BLDBK;1;P2 phenotype [Presence] on Red Blood Cells;P2 phenotype RBC Ql;;ACTIVE;2.63;2.63 +880-5;A,B Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;A,B Ag [Presence] on Red Blood Cells;A,B Ag RBC Ql;;ACTIVE;1.0;2.73 +88050-0;P2 phenotype;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;P2 phenotype [Presence] on Red Blood Cells from Blood product unit;P2 phenotype RBC BPU Ql;;ACTIVE;2.63;2.63 +88051-8;P2 phenotype;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;P2 phenotype [Presence] on Red Blood Cells from Donor;P2 phenotype RBC Donr Ql;;ACTIVE;2.63;2.63 +88052-6;Cells.CD4-CD8-CD45R+TCR alpha beta+/100 cells.CD3;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD4-CD8-CD45R+TCR alpha beta+/100 CD3 cells in Blood by Flow cytometry (FC);Cells.DNT-CD45R+TCR A-B+/100 CD3 Bld FC;;ACTIVE;2.63;2.63 +88053-4;Cells.CD4-CD8-CD45R+TCR alpha beta+;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD4-CD8-CD45R+TCR alpha beta+ [#/volume] in Blood by Flow cytometry (FC);Cell.DNT-CD45R+TCRa b # Bld FC;;ACTIVE;2.63;2.63 +88054-2;Lipopolysaccharide binding protein;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Lipopolysaccharide binding protein [Mass/volume] in Serum or Plasma by Immunoassay;LBP SerPl IA-mCnc;;ACTIVE;2.63;2.64 +88055-9;Liver fibrosis score;Score;Pt;Ser/Plas;Qn;Calculated.ELF;CHEM;1;Liver fibrosis score in Serum or Plasma by Calculated by ELF;Liver fibr score SerPl Calc.ELF;;ACTIVE;2.63;2.63 +88056-7;Aquaporin 4 water channel Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Aquaporin 4 water channel IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;AQP4 H2O channel IgG Titr CSF IF;;ACTIVE;2.63;2.67 +88057-5;Treatment for abnormal Pap test;Type;Pt;^Patient;Nom;;H&P.HX;2;Treatment for abnormal Pap test;Treatment abnl Pap test;;ACTIVE;2.63;2.63 +88058-3;Respiratory measurements;Find;Pt;^Patient;Doc;;DOC.MISC;2;Respiratory measurements Document;Respiratory measurements Doc;;ACTIVE;2.63;2.63 +88059-1;Acetaminophen;PrThr;Pt;Bld;Ord;Screen;DRUG/TOX;1;Acetaminophen [Presence] in Blood by Screen method;APAP Bld Ql Scn;;ACTIVE;2.63;2.63 +88060-9;Chemotherapy infusion start time;ClockTime;Pt;^Patient;Qn;;IO_IN.INFUS;2;Chemotherapy infusion start time;Chemo infusion start time Clock time;;ACTIVE;2.63;2.63 +88061-7;Chemotherapy infusion stop time;ClockTime;Pt;^Patient;Qn;;IO_IN.INFUS;2;Chemotherapy infusion stop time;Chemo infusion stop time Clock time;;ACTIVE;2.63;2.63 +8806-2;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;2D echo;HEMODYN.MOLEC;2;Left ventricular Ejection fraction by 2D echo;LV EF 2D Echo;;ACTIVE;1.0h(3);2.52 +88062-5;Chemotherapy infusion stop date;Date;Pt;^Patient;Qn;;IO_IN.INFUS;2;Chemotherapy infusion stop date;Chemotherapy infusion stop date;;ACTIVE;2.63;2.63 +88063-3;Chemotherapy infusion start date;Date;Pt;^Patient;Qn;;IO_IN.INFUS;2;Chemotherapy infusion start date;Chemotherapy infusion start date;;ACTIVE;2.63;2.63 +88064-1;Porcine epidemic diarrhea virus S1 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine epidemic diarrhea virus S1 gene [Nucleotide sequence] in Isolate by Sequencing;PEDV S1 gene Islt-Seq;;ACTIVE;2.63;2.63 +88065-8;Time of defibrillation;ClockTime;Pt;^Patient;Qn;;CARD.PROC;2;Time of defibrillation;Time of defibrillation;;ACTIVE;2.63;2.7 +88066-6;EMS physician qualification;Type;Pt;Provider;Nom;;TRAUMA;2;EMS physician qualification;EMS MD qualification;;ACTIVE;2.63;2.7 +88067-4;Unit on scene;Type;Pt;EMS system;Nom;;TRAUMA;2;EMS unit on scene;EMS unit on scene;;ACTIVE;2.63;2.7 +88068-2;Cause of intoxication;Find;Pt;^Patient;Nom;;H&P.HX;2;Cause of intoxication;Intoxication cause;;ACTIVE;2.63;2.7 +88069-0;Time of initial encounter;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Time of initial encounter;Time of initial encounter;;ACTIVE;2.63;2.7 +8807-0;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;2D echo.visual estimate;HEMODYN.MOLEC;2;Left ventricular Ejection fraction by 2D echo.visual estimate;LV EF 2D Echo est;;ACTIVE;1.0h(3);2.73 +88070-8;Time of extubation;TmStp;Pt;^Patient;Qn;;PULM;2;Time of extubation;Extubation time;;ACTIVE;2.63;2.7 +88071-6;Time of intubation;TmStp;Pt;^Patient;Qn;;PULM;2;Time of intubation;Intubation time;;ACTIVE;2.63;2.7 +88072-4;Dispatch center;ID;Pt;EMS system;Nom;;TRAUMA;2;Dispatch center [Identifier] EMS system;Dispatch center EMS Sys;;ACTIVE;2.63;2.7 +88073-2;EMS physician vehicle arrived before the paramedics;Find;Pt;^Patient;Ord;;TRAUMA;2;EMS physician vehicle arrived before the paramedics;EMS MD arrived before paramedics;;ACTIVE;2.63;2.7 +88074-0;Vehicle name;ID;Pt;EMS unit;Nom;;TRAUMA;2;Vehicle name [Identifier] EMS unit;Vehicle name EMS unit;;ACTIVE;2.63;2.7 +88075-7;EMS personnel drove themselves to scene;Find;Pt;Provider;Ord;;TRAUMA;2;EMS personnel drove themselves to scene;EMS personnel drove to scene;;ACTIVE;2.63;2.7 +88076-5;Injury severity score;Find;Pt;^Patient;Nom;NACA;TRAUMA;2;Injury severity score NACA;ISS NACA;;ACTIVE;2.63;2.7 +88077-3;Height range of fall;Find;Pt;^Patient;Ord;;TRAUMA;2;Height range of fall;Height range of fall;;ACTIVE;2.63;2.7 +88078-1;Provider assuming care for patient;Pn;Pt;Provider;Nom;;TRAUMA;2;Provider assuming care for patient;Provider assuming care;;ACTIVE;2.63;2.7 +88079-9;Transport start time;TmStp;Pt;^Patient;Qn;;TRAUMA;2;Transport start time;Transport start time;;ACTIVE;2.63;2.7 +88080-7;Multiple birth set identifier;ID;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Multiple birth set identifier;Multiple birth set ID;;ACTIVE;2.63;2.66 +88081-5;Person completing form title;Type;Pt;Provider;Nom;;ADMIN;2;Title of person completing the form Provider;Person completing form title Provider;;ACTIVE;2.63;2.63 +88082-3;Initial case report processing information;Find;Pt;Report;Doc;;DOC.MISC;2;Initial case report processing information Document;Initial case rprt processing info Doc;;TRIAL;2.63;2.63 +88083-1;Reportable condition response description.brief;Find;Pt;^Patient;Nar;;PUBLICHEALTH;2;Reportable condition response brief description Narrative;Reportable cond response desc.brief;;TRIAL;2.63;2.63 +88084-9;Reportable condition response information and summary;Find;Pt;^Patient;Doc;;DOC.MISC;2;Reportable condition response information and summary Document;Reportable cond response info+sum Doc;;TRIAL;2.63;2.63 +88085-6;Reportability response report;Find;Pt;{Setting};Doc;Public health;DOC.MISC;2;Reportability response report Document Public health;Reportability resp rprt Doc Public hlth;;TRIAL;2.63;2.63 +88086-4;Age range for infant less than 1Mo old;Find;Pt;^Patient;Nom;;H&P.HX;2;Age range for infant less than 1 month old;Age range < 1Mo old;;ACTIVE;2.63;2.7 +88087-2;Estimated body mass index greater than 40;Find;Pt;^Patient;Ord;;H&P.PX;2;Estimated BMI greater than 40;Estimated BMI >40;;ACTIVE;2.63;2.7 +8808-8;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;Angiogram;HEMODYN.MOLEC;2;Left ventricular Ejection fraction by Cardiac angiogram;LV EF Angiogram;;ACTIVE;1.0h(3);2.48 +88088-0;EMS transport destination name;ID;Pt;Facility;Nom;;H&P.HX;2;EMS transport destination name [Identifier] of Facility;EMS destination name Facility;;ACTIVE;2.63;2.7 +88089-8;Specialty services available;Type;Pt;Facility;Nom;;TRAUMA;2;Type of Specialty services available;Specialty services avail type;;ACTIVE;2.63;2.7 +88090-6;Physician specialty;Type;Pt;Provider;Nom;;ADMIN;2;Physician specialty;MD specialty;;ACTIVE;2.63;2.7 +88091-4;Bystander observed collapse;Find;Pt;^Patient;Ord;;TRAUMA;2;Bystander observed collapse;Bystander observed collapse;;ACTIVE;2.63;2.7 +88092-2;Rescue operation end;TmStp;Pt;^Patient;Qn;;TRAUMA;2;Rescue operation end [Date and time];Rescue operation end;;ACTIVE;2.63;2.7 +88093-0;Health status prior to emergency incident;Find;Pt;^Patient;Ord;;TRAUMA;2;Health status prior to emergency incident;Health stat prior emerg incident;;ACTIVE;2.63;2.7 +88094-8;Sufficiency of procedures performed by bystander;Find;Pt;^Patient;Ord;;TRAUMA;2;Sufficiency of procedures performed by bystander;Sufficiency proc perform bystander;;ACTIVE;2.63;2.7 +88095-5;Time of arrival of first responder;ClockTime;Pt;^Patient;Qn;;TRAUMA;2;Time of arrival of first responder;Arrival time first responder;;ACTIVE;2.63;2.7 +8809-6;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;Angiogram.visual estima;HEMODYN.MOLEC;2;Left ventricular Ejection fraction by Cardiac angiogram.visual estimate;LV EF Angiogram est;;ACTIVE;1.0h(3);2.48 +88096-3;Known bacterial drug resistant infection;Find;Pt;^Patient;Ord;;TRAUMA;2;Known bacterial drug resistant infection;Known bact drug resist infect;;ACTIVE;2.63;2.7 +88097-1;First degree burn area/Body surface area;ArArea;Pt;^Patient;Qn;Estimated;TRAUMA;2;First degree burn area/Body surface area [Area/Area] Estimated;1st deg burn area/BSA Est;;ACTIVE;2.63;2.7 +88098-9;Second degree burn area/Body surface area;ArArea;Pt;^Patient;Qn;Estimated;TRAUMA;2;Second degree burn area/Body surface area [Area/Area] Estimated;2nd deg burn area/BSA Est;;ACTIVE;2.63;2.7 +88099-7;Third degree burn area/Body surface area;ArArea;Pt;^Patient;Qn;Estimated;TRAUMA;2;Third degree burn area/Body surface area [Area/Area] Estimated;3rd deg burn area/BSA Est;;ACTIVE;2.63;2.7 +88100-3;Fourth degree burn area/Body surface area;ArArea;Pt;^Patient;Qn;Estimated;TRAUMA;2;Fourth degree burn area/Body surface area [Area/Area] Estimated;4th deg burn area/BSA Est;;ACTIVE;2.63;2.7 +88101-1;Cardiopulmonary resuscitation stop time;ClockTime;Pt;^Patient;Qn;;CARD.PROC;2;CPR stop time;CPR stop time;;ACTIVE;2.63;2.7 +88102-9;Provider who performed cardiopulmonary resuscitation;Type;Pt;^Patient;Nom;;CARD.PROC;2;Provider [Type] who performed CPR;Provider who performed CPR;;ACTIVE;2.64;2.7 +88103-7;Cardiopulmonary resuscitation was being given on arrival at destination;Find;Pt;^Patient;Ord;;CARD.PROC;2;CPR was being given on arrival at destination;CPR given on arrival at destination;;ACTIVE;2.63;2.7 +8810-4;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;CT spiral;HEMODYN.MOLEC;2;Left ventricular Ejection fraction by Spiral CT;LV EF Spiral CT;;ACTIVE;1.0h(3);2.48 +88104-5;Rhythmic or arrhythmic heart rate;Find;Pt;^Patient;Ord;;HRTRATE.ATOM;2;Rhythmic or arrhythmic heart rate;Rhyth or arrhyth heart rate;;ACTIVE;2.63;2.7 +88105-2;Injured body site;Anat;Pt;^Patient;Nom;;H&P.PX;2;Injured body site;Injured body site;;ACTIVE;2.63;2.7 +88106-0;Parathyrin.intact;MCnc;Pt;Tiss.FNA;Qn;;CHEM;1;Parathyrin.intact [Mass/volume] in Tissue fine needle aspirate;PTH-Intact Tiss FNA-mCnc;;ACTIVE;2.63;2.63 +88107-8;Suctioning frequency;NRat;Pt;^Patient;Qn;;PULM;2;Suctioning frequency;Suction freq;;ACTIVE;2.63;2.63 +88108-6;Symptoms present for at least 24H;Find;Pt;^Patient;Ord;Reported;H&P.HX;2;Symptoms present for at least 24 hours - Reported;Symptoms present 24H Reported;;ACTIVE;2.63;2.7 +88109-4;Role in accident;Type;Pt;^Patient;Nom;;TRAUMA;2;Role in accident;Role in accident;;ACTIVE;2.63;2.7 +88110-2;OXcarbazepine^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;OXcarbazepine [Moles/volume] in Serum or Plasma --trough;OXcarbazepine Trough SerPl-sCnc;;ACTIVE;2.63;2.63 +88111-0;Gentamicin^random post extended interval dosing;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Gentamicin [Moles/volume] in Serum or Plasma --random post extended interval dosing;Gentamicin Rand EID SerPl-sCnc;;ACTIVE;2.63;2.63 +8811-2;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;MR;HEMODYN.MOLEC;2;Left ventricular Ejection fraction by MR;LV EF MR;;ACTIVE;1.0h(3);2.56 +88112-8;Aspartate aminotransferase;CCnc;Pt;Ser/Plas;Qn;No addition of P-5'-P;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma by No addition of P-5'-P;AST SerPl w/o P-5'-P-cCnc;;ACTIVE;2.63;2.68 +88113-6;Erythrocytes;PrThr;Pt;CSF;Ord;Gram stain;HEM/BC;1;Erythrocytes [Presence] in Cerebral spinal fluid by Gram stain;RBC CSF Ql Gram Stn;;ACTIVE;2.63;2.63 +88114-4;Leukocytes;PrThr;Pt;CSF;Ord;Gram stain;HEM/BC;1;Leukocytes [Presence] in Cerebral spinal fluid by Gram stain;WBC CSF Ql Gram Stn;;ACTIVE;2.63;2.63 +88115-1;Round cells;PrThr;Pt;Semen;Ord;Microscopy.light;FERT;1;Round cells [Presence] in Semen by Light microscopy;Rnd Cells Smn Ql Micro;;ACTIVE;2.63;2.63 +88116-9;Escherichia coli gene panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Escherichia coli gene panel - Specimen by NAA with probe detection;EC gene pnl Spec NAA+probe;;ACTIVE;2.63;2.69 +88117-7;Tabulated ethnicity;Type;Pt;^Mother;Nom;CDC;SURVEY.CDC;4;Mother's Tabulated ethnicity [CDC];;;ACTIVE;2.63;2.63 +88118-5;Tabulated ethnicity;Type;Pt;^Father;Nom;CDC;SURVEY.CDC;4;Father's Tabulated ethnicity [CDC];;;ACTIVE;2.63;2.63 +88119-3;Bridged race;Type;Pt;^Mother;Nom;CDC;SURVEY.CDC;4;Mother's Bridged race [CDC];;;ACTIVE;2.63;2.63 +8812-0;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Left ventricular Ejection fraction by Nuclear blood pool;LV EF Nuc BP;;ACTIVE;1.0h(3);2.73 +88120-1;Bridged race;Type;Pt;^Father;Nom;CDC;SURVEY.CDC;4;Father's Bridged race [CDC];;;ACTIVE;2.63;2.63 +88121-9;Hunger Vital Sign;-;Pt;^Patient;-;HVS;PANEL.SURVEY.GNHLTH;4;Hunger Vital Sign [HVS];;© 2010 Dr. Erin Hager and Dr. Anna Quigg and the Children's HealthWatch research team Used with permission;ACTIVE;2.63;2.63 +88122-7;Within the past 12Mo we worried whether our food would run out before we got money to buy more;Find;Pt;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;Within the past 12 months we worried whether our food would run out before we got money to buy more [U.S. FSS];;;ACTIVE;2.63;2.7 +88123-5;Within the past 12Mo the food we bought just didn't last and we didn't have money to get more;Find;Pt;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;Within the past 12 months the food we bought just didn't last and we didn't have money to get more [U.S. FSS];;;ACTIVE;2.63;2.7 +88124-3;Food insecurity risk;Imp;Pt;^Patient;Ord;HVS;SURVEY.GNHLTH;4;Food insecurity risk [HVS];;© 2010 Dr. Erin Hager and Dr. Anna Quigg and the Children's HealthWatch research team Used with permission;ACTIVE;2.63;2.63 +88125-0;Escherichia coli enterotoxigenic gene panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Escherichia coli enterotoxigenic gene panel - Specimen by NAA with probe detection;ETEC gene pnl Spec NAA+probe;;ACTIVE;2.63;2.69 +88126-8;Injury severity;Find;Pt;^Patient;Ord;;H&P.PX;2;Injury severity;Injury severity;;ACTIVE;2.63;2.7 +88127-6;Herpes simplex virus identified;Prid;Pt;Cornea/Conjunctiva;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Cornea or Conjunctiva by Organism specific culture;HSV Corn/Cnjt Cult;;ACTIVE;2.63;2.63 +88128-4;Herpes simplex virus 1 DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HSV1 DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88129-2;Respiratory pathogens panel;-;Pt;Thrt;-;IF;PANEL.MICRO;1;Respiratory pathogens panel - Throat by Immunofluorescence;Respiratory path Pnl Throat IF;;ACTIVE;2.63;2.63 +881-3;ABO & Rh group;Type;Pt;Bld^BPU;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood from Blood product unit;ABO + Rh Bld BPU;;ACTIVE;1.0;2.73 +88130-0;Cytomegalovirus DNA;NCnc;Pt;Ocular fld;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Ocular fluid by NAA with probe detection;CMV DNA # Ocflu NAA+probe;;ACTIVE;2.63;2.63 +88131-8;Cytomegalovirus DNA;PrThr;Pt;Ocular fld;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Ocular fluid by NAA with probe detection;CMV DNA Ocflu Ql NAA+probe;;ACTIVE;2.63;2.63 +88132-6;Varicella zoster virus DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;VZV DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88133-4;Herpes simplex virus 2 DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HSV2 DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88134-2;Varicella zoster virus DNA;PrThr;Pt;Ocular fld;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Ocular fluid by NAA with probe detection;VZV DNA Ocflu Ql NAA+probe;;ACTIVE;2.63;2.63 +88135-9;Varicella zoster virus;PrThr;Pt;Cornea/Conjunctiva;Ord;Organism specific culture;MICRO;1;Varicella zoster virus [Presence] in Cornea or Conjunctiva by Organism specific culture;VZV Corn/Cnjt Ql Cult;;ACTIVE;2.63;2.63 +88136-7;Varicella zoster virus;PrThr;Pt;Ocular fld;Ord;Organism specific culture;MICRO;1;Varicella zoster virus [Presence] in Ocular fluid by Organism specific culture;VZV Ocflu Ql Cult;;ACTIVE;2.63;2.63 +88137-5;Respiratory pathogens panel;-;Pt;Nph;-;IF;PANEL.MICRO;1;Respiratory pathogens panel - Nasopharynx by Immunofluorescence;Respiratory path Pnl Nph IF;;ACTIVE;2.63;2.63 +8813-8;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;2D echo;HEMODYN.MOLEC;2;Right ventricular Ejection fraction by 2D echo;RV EF 2D Echo;;ACTIVE;1.0h(3);2.52 +88138-3;Herpes simplex virus DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HSV DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88139-1;Bacteria identified;Prid;Pt;Ocular fld;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Ocular fluid by Anaerobe culture;Bacteria Ocflu Anaerobe Cult;;ACTIVE;2.63;2.63 +88140-9;Tropheryma whipplei DNA;PrThr;Pt;Ocular fld;Ord;Probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Ocular fluid by NAA with probe detection;T whipplei DNA Ocflu Ql NAA+probe;;ACTIVE;2.63;2.7 +88141-7;Bacteria identified;Prid;Pt;Ocular fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Ocular fluid by Aerobe culture;Bacteria Ocflu Aerobe Cult;;ACTIVE;2.63;2.63 +88142-5;Bacteria identified;Prid;Pt;Cornea/Conjunctiva;Nom;Aerobic culture;MICRO;1;Bacteria identified in Cornea or Conjunctiva by Aerobe culture;Bacteria Corn/Cnjt Aerobe Cult;;ACTIVE;2.63;2.63 +88143-3;Fungus identified;Prid;Pt;Cornea/Conjunctiva;Nom;Culture;MICRO;1;Fungus identified in Cornea or Conjunctiva by Culture;Fungus Corn/Cnjt Cult;;ACTIVE;2.63;2.63 +88144-1;Microscopic observation;Prid;Pt;Periton fld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Peritoneal fluid by Acid fast stain;Acid fast Stn Prt;;ACTIVE;2.63;2.63 +88145-8;Microscopic observation;Prid;Pt;Pericard fld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Pericardial fluid by Acid fast stain;Acid fast Stn Pcar;;ACTIVE;2.63;2.63 +8814-6;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;2D echo.visual estimate;HEMODYN.MOLEC;2;Right ventricular Ejection fraction by 2D echo.visual estimate;RV EF 2D Echo est;;ACTIVE;1.0h(3);2.52 +88146-6;Microscopic observation;Prid;Pt;Placenta;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Placenta by Gram stain;Gram Stn Placenta;;ACTIVE;2.63;2.63 +88147-4;Microscopic observation;Prid;Pt;Pericard fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Pericardial fluid by Gram stain;Gram Stn Pcar;;ACTIVE;2.63;2.63 +88148-2;Microscopic observation;Prid;Pt;Genital;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Genital specimen by Acid fast stain;Acid fast Stn Genital;;ACTIVE;2.63;2.63 +88149-0;Microscopic observation;Prid;Pt;Nph;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Nasopharynx by Gram stain;Gram Stn Nph;;ACTIVE;2.63;2.63 +88150-8;Microscopic observation;Prid;Pt;Ocular fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Ocular fluid by Giemsa stain;Gie Stn Ocflu;;ACTIVE;2.63;2.63 +88151-6;Microscopic observation;Prid;Pt;Wound;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Wound by Acid fast stain;Acid fast Stn Wnd;;ACTIVE;2.63;2.63 +88152-4;Microscopic observation;Prid;Pt;Cvx;Nom;Acid fast stain.Kinyoun;MICRO;1;Microscopic observation [Identifier] in Cervix by Acid fast stain.Kinyoun;Acid fast Kiny Stn Cvx;;ACTIVE;2.63;2.63 +8815-3;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;Angiogram;HEMODYN.MOLEC;2;Right ventricular Ejection fraction by Cardiac angiogram;RV EF Angiogram;;ACTIVE;1.0h(3);2.48 +88153-2;Microscopic observation;Prid;Pt;Bone mar;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Bone marrow by Acid fast stain;Acid fast Stn Mar;;ACTIVE;2.63;2.63 +88154-0;Microscopic observation;Prid;Pt;Sinus;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Sinus by Acid fast stain;Acid fast Stn Sinus;;ACTIVE;2.63;2.63 +88155-7;Microscopic observation;Prid;Pt;Ocular fld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Ocular fluid by Acid fast stain;Acid fast Stn Ocflu;;ACTIVE;2.63;2.63 +88156-5;Microscopic observation;Prid;Pt;Amnio fld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Amniotic fluid by Acid fast stain;Acid fast Stn Amn;;ACTIVE;2.63;2.63 +88157-3;Microscopic observation;Prid;Pt;Semen;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Semen by Acid fast stain;Acid fast Stn Smn;;ACTIVE;2.63;2.63 +88158-1;Microscopic observation;Prid;Pt;Ocular fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Ocular fluid by Gram stain;Gram Stn Ocflu;;ACTIVE;2.63;2.63 +88159-9;Microscopic observation;Prid;Pt;Asp;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Aspirate by Acid fast stain;Acid fast Stn Aspirate;;ACTIVE;2.63;2.63 +88160-7;Microsporidia DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Microsporidia DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;Microsporid DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +8816-1;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;Angiogram.visual estima;HEMODYN.MOLEC;2;Right ventricular Ejection fraction by Cardiac angiogram.visual estimate;RV EF Angiogram est;;ACTIVE;1.0h(3);2.48 +88161-5;Toxoplasma gondii;PrThr;Pt;Ocular fld;Ord;Organism specific culture;MICRO;1;Toxoplasma gondii [Presence] in Ocular fluid by Organism specific culture;T gondii Ocflu Ql Cult;;ACTIVE;2.63;2.63 +88162-3;Acanthamoeba sp identified;Prid;Pt;Cornea/Conjunctiva;Nom;Organism specific culture;MICRO;1;Acanthamoeba sp identified in Cornea or Conjunctiva by Organism specific culture;Acanthamoeba Corn/Cnjt Cult;;ACTIVE;2.63;2.63 +88163-1;Acanthamoeba sp DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Acanthamoeba sp DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;Acanthamoeba DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88164-9;Toxoplasma gondii DNA;PrThr;Pt;Ocular fld;Ord;Probe.amp.tar;MICRO;1;Toxoplasma gondii DNA [Presence] in Ocular fluid by NAA with probe detection;T gondii DNA Ocflu Ql NAA+probe;;ACTIVE;2.63;2.73 +88165-6;Mycobacterium tuberculosis DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;M tb DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88166-4;Mycobacterium tuberculosis DNA;PrThr;Pt;Ocular fld;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Ocular fluid by NAA with probe detection;M tb DNA Ocflu Ql NAA+probe;;ACTIVE;2.63;2.63 +88167-2;Mycobacterium sp identified;Prid;Pt;Cornea/Conjunctiva;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Cornea or Conjunctiva by Organism specific culture;Mycobacterium Corn/Cnjt Cult;;ACTIVE;2.63;2.63 +88168-0;Mycobacterium sp identified;Prid;Pt;Ocular fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Ocular fluid by Organism specific culture;Mycobacterium Ocflu Cult;;ACTIVE;2.63;2.63 +88169-8;Microscopic observation;PrThr;-;Vomitus;Ord;Acid fast stain;MICRO;1;Deprecated Microscopic observation [Presence] in Vomitus by Acid fast stain;Deprecated Acid fast Stn Vom Ql;;DEPRECATED;2.63;2.66 +88170-6;Microscopic observation;Prid;Pt;Cornea/Conjunctiva;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Cornea or Conjunctiva by Gram stain;Gram Stn Corn/Cnjt;;ACTIVE;2.63;2.63 +88171-4;Microscopic observation;PrThr;Pt;Cornea/Conjunctiva;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Cornea or Conjunctiva by Acid fast stain;Acid fast Stn Corn/Cnjt Ql;;ACTIVE;2.63;2.63 +88172-2;Microscopic observation;PrThr;Pt;Isolate;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Isolate by Acid fast stain;Acid fast Stn Islt Ql;;ACTIVE;2.63;2.63 +88173-0;Microscopic observation;PrThr;Pt;Plr fld;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Pleural fluid by Acid fast stain;Acid fast Stn Plr Ql;;ACTIVE;2.63;2.63 +88174-8;Total score;Score;Pt;^Parent;Qn;PAM;SURVEY.GNHLTH;4;Total score Parent [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +88175-5;Total score;Score;Pt;^Patient;Qn;PAM;SURVEY.GNHLTH;4;Total score [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +88176-3;Total score;Score;Pt;^Caregiver;Qn;PAM;SURVEY.GNHLTH;4;Total score Caregiver [PAM];;"Insignia Health, LLC®. Patient Activation Measure®; Copyright 2003-2017, University of Oregon. Used with permission";ACTIVE;2.63;2.63 +88177-1;Coxiella burnetii DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Coxiella burnetii DNA [Presence] in Blood by NAA with probe detection;C burnet DNA Bld Ql NAA+probe;;ACTIVE;2.63;2.63 +88178-9;Coxiella burnetii DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Coxiella burnetii DNA [Presence] in Tissue by NAA with probe detection;C burnet DNA Tiss Ql NAA+probe;;ACTIVE;2.63;2.63 +8817-9;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;CT spiral;HEMODYN.MOLEC;2;Right ventricular Ejection fraction by Spiral CT;RV EF Spiral CT;;ACTIVE;1.0h(3);2.29 +88179-7;Wuchereria bancrofti+Brugia malayi Ab.IgG4;PrThr;Pt;Ser;Ord;IA;MICRO;1;Wuchereria bancrofti+Brugia malayi IgG4 Ab [Presence] in Serum by Immunoassay;W bancr+B malayi IgG4 Ser Ql IA;;ACTIVE;2.63;2.63 +88180-5;Wuchereria bancrofti+Brugia malayi Ab.IgG3;PrThr;Pt;Ser;Ord;IA;MICRO;1;Wuchereria bancrofti+Brugia malayi IgG3 Ab [Presence] in Serum by Immunoassay;W bancr+B malayi IgG3 Ser Ql IA;;ACTIVE;2.63;2.63 +88181-3;Wuchereria bancrofti+Brugia malayi Ab.IgG2;PrThr;Pt;Ser;Ord;IA;MICRO;1;Wuchereria bancrofti+Brugia malayi IgG2 Ab [Presence] in Serum by Immunoassay;W bancr+B malayi IgG2 Ser Ql IA;;ACTIVE;2.63;2.63 +88182-1;Wuchereria bancrofti+Brugia malayi Ab.IgG1;PrThr;Pt;Ser;Ord;IA;MICRO;1;Wuchereria bancrofti+Brugia malayi IgG1 Ab [Presence] in Serum by Immunoassay;W bancr+B malayi IgG1 Ser Ql IA;;ACTIVE;2.63;2.63 +88183-9;Mycobacterium sp identified;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Mycobacterium sp identified in Isolate by Sequencing;Mycobacterium Islt Seq;;ACTIVE;2.63;2.63 +88184-7;IgG+IgM.porcine;PrThr;Pt;Plr fld^Fetus;Ord;Immune diffusion;SERO;1;IgG+IgM.porcine [Presence] in Pleural fluid from Fetus by Immune diffusion (ID);IgG+IgM.porcine Plr Fetus Ql ID;;ACTIVE;2.63;2.63 +88185-4;IgG+IgM.porcine;PrThr;Pt;Ser^Fetus;Ord;Immune diffusion;SERO;1;IgG+IgM.porcine [Presence] in Serum from Fetus by Immune diffusion (ID);IgG+IgM.porcine Ser Fetus Ql ID;;ACTIVE;2.63;2.63 +88186-2;Ebola & Marburg virus RNA panel;-;Pt;Bld;-;Probe.amp.tar;PANEL.MICRO;1;Ebola and Marburg virus RNA Panel - Blood by NAA with probe detection;Ebola + Marburg RNA Pnl Bld NAA+probe;;ACTIVE;2.63;2.63 +8818-7;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;MR;HEMODYN.MOLEC;2;Right ventricular Ejection fraction by MR;RV EF MR;;ACTIVE;1.0h(3);2.56 +88187-0;Influenza virus A subtype;Prid;Pt;Cornea/Conjunctiva;Nom;Probe.amp.tar;MICRO;1;Influenza virus A subtype [Identifier] in Cornea or Conjunctiva by NAA with probe detection;FLUAV Subtyp Corn/Cnjt NAA+probe;;ACTIVE;2.63;2.63 +88188-8;Dengue virus 1+2+3+4 RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 RNA [Presence] in Urine by NAA with probe detection;DENV1+2+3+4 RNA Ur Ql NAA+probe;;ACTIVE;2.63;2.63 +88189-6;Dengue virus 1+2+3+4 RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 RNA [Presence] in Blood by NAA with probe detection;DENV1+2+3+4 RNA Bld Ql NAA+probe;;ACTIVE;2.63;2.63 +88190-4;Crimean-Congo hemorrhagic fever virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Crimean-Congo hemorrhagic fever virus IgM Ab [Presence] in Serum by Immunoassay;Crimean-Congo virus IgM Ser Ql IA;;ACTIVE;2.63;2.63 +88191-2;Crimean-Congo hemorrhagic fever virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Crimean-Congo hemorrhagic fever virus IgG Ab [Presence] in Serum by Immunoassay;Crimean-Congo virus IgG Ser Ql IA;;ACTIVE;2.63;2.63 +88192-0;Crimean-Congo hemorrhagic fever virus RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Crimean-Congo hemorrhagic fever virus RNA [Presence] in Serum by NAA with probe detection;Crimean-Congo virus RNA Ser Ql NAA+probe;;ACTIVE;2.63;2.63 +88193-8;Influenza virus A RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;FLUAV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88194-6;Influenza virus B Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Tissue by Immunofluorescence;FLUBV Ag Tiss Ql IF;;ACTIVE;2.63;2.63 +8819-5;Ejection fraction;VFr;Pt;Heart.ventricle.right;Qn;Nuclear.blood pool;HEMODYN.MOLEC;2;Right ventricular Ejection fraction by Nuclear blood pool;RV EF Nuc BP;;ACTIVE;1.0h(3);2.29 +88195-3;Influenza virus B RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;FLUBV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88196-1;Middle East respiratory syndrome coronavirus RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Stool by NAA with probe detection;MERS-CoV RNA Stl Ql NAA+probe;;ACTIVE;2.63;2.63 +88197-9;Middle East respiratory syndrome coronavirus RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Nasopharynx by NAA with probe detection;MERS-CoV RNA Nph Ql NAA+probe;;ACTIVE;2.63;2.63 +88198-7;Middle East respiratory syndrome coronavirus RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;MERS-CoV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88199-5;Middle East respiratory syndrome coronavirus RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Aspirate by NAA with probe detection;MERS-CoV RNA Aspirate Ql NAA+probe;;ACTIVE;2.63;2.63 +88200-1;Influenza virus identified;Prid;Pt;Cornea/Conjunctiva;Nom;Organism specific culture;MICRO;1;Influenza virus identified in Cornea or Conjunctiva by Organism specific culture;FLUV Corn/Cnjt Cult;;ACTIVE;2.63;2.63 +88201-9;Herpes simplex virus 1 Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Tissue by Immunofluorescence;HSV1 Ag Tiss Ql IF;;ACTIVE;2.63;2.63 +88202-7;Respiratory syncytial virus B RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus B RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;RSV B RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +8820-3;Ejection fraction geometry formula;Type;Pt;Heart.ventricle;Nom;*;HEMODYN.MOLEC;2;Ventricular Ejection fraction geometry formula;Hrt ventr EF geometry formula;;ACTIVE;1.0h(3);2.34 +88203-5;Dengue virus 1 & 2 & 3 & 4 RNA;Prid;Pt;Ser/Bld;Nom;Probe.amp.tar;MICRO;1;Dengue virus 1 and 2 and 3 and 4 RNA [Identifier] in Serum or Blood by NAA with probe detection;DENV 1+2+3+4 RNA SerBld NAA+probe;;ACTIVE;2.63;2.63 +88204-3;Respiratory syncytial virus A RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus A RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;RSV A RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88205-0;Lymphocytic choriomeningitis virus Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Presence] in Serum by Immunoassay;LCMV IgM Ser Ql IA;;ACTIVE;2.63;2.63 +88206-8;Lymphocytic choriomeningitis virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Presence] in Serum by Immunoassay;LCMV IgG Ser Ql IA;;ACTIVE;2.63;2.63 +88207-6;Lymphocytic choriomeningitis virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Lymphocytic choriomeningitis virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;LCMV RNA CSF Ql NAA+probe;;ACTIVE;2.63;2.63 +88208-4;Parainfluenza virus 1 RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HPIV1 RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88209-2;Parainfluenza virus 2 RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HPIV2 RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +882-1;ABO & Rh group;Type;Pt;Bld;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood;ABO + Rh Bld;;ACTIVE;1.0;2.73 +88210-0;Parainfluenza virus 3 RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HPIV3 RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +8821-1;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;Imaging;HEMODYN.MOLEC;2;Left ventricular End-diastolic volume by Imaging;LV ED vol Imaging;;ACTIVE;1.0h(3);2.52 +88211-8;Rabies virus Ag;PrThr;Pt;CSF;Ord;IA;MICRO;1;Rabies virus Ag [Presence] in Cerebral spinal fluid by Immunoassay;RABV Ag CSF Ql IA;;ACTIVE;2.63;2.63 +88212-6;HIV 1 proviral DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;HIV 1 proviral DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;HIV 1 pro DNA CSF Ql NAA+probe;;ACTIVE;2.63;2.63 +88213-4;Rhinovirus RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Rhinovirus RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;Rhinovirus RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.63;2.63 +88214-2;Rabies virus RNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Rabies virus RNA [Presence] in Tissue by NAA with probe detection;RABV RNA Tiss Ql NAA+probe;;ACTIVE;2.63;2.63 +88215-9;Rabies virus RNA;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;Rabies virus RNA [Presence] in Saliva (oral fluid) by NAA with probe detection;RABV RNA Sal Ql NAA+probe;;ACTIVE;2.63;2.63 +88216-7;Hantavirus puumala RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Hantavirus puumala RNA [Presence] in Urine by NAA with probe detection;PUUV RNA Ur Ql NAA+probe;;ACTIVE;2.63;2.63 +88217-5;Parechovirus RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Parechovirus RNA [Presence] in Aspirate by NAA with probe detection;PeV RNA Aspirate Ql NAA+probe;;ACTIVE;2.63;2.63 +88218-3;Parechovirus RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Parechovirus RNA [Presence] in Stool by NAA with probe detection;PeV RNA Stl Ql NAA+probe;;ACTIVE;2.63;2.63 +88219-1;Parechovirus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parechovirus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;PeV RNA Upper resp Ql NAA+probe;;ACTIVE;2.63;2.68 +88220-9;Hantavirus puumala RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Hantavirus puumala RNA [Presence] in Blood by NAA with probe detection;PUUV RNA Bld Ql NAA+probe;;ACTIVE;2.63;2.63 +88221-7;Chlamydia trachomatis DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis DNA [Presence] in Throat by NAA with probe detection;C trach DNA Throat Ql NAA+probe;;ACTIVE;2.63;2.63 +88222-5;Human metapneumovirus Ag;PrThr;Pt;Nph;Ord;IF;MICRO;1;Human metapneumovirus Ag [Presence] in Nasopharynx by Immunofluorescence;hMPV Ag Nph Ql IF;;ACTIVE;2.63;2.63 +88223-3;Francisella sp DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Francisella sp DNA [Presence] in Aspirate by NAA with probe detection;Francisella sp DNA Aspirate Ql NAA+probe;;ACTIVE;2.63;2.63 +88224-1;Neisseria gonorrhoeae DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Anorectal by NAA with probe detection;N gonorrhoea DNA Anorectl Ql NAA+probe;;ACTIVE;2.63;2.63 +88225-8;Neisseria gonorrhoeae DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Throat by NAA with probe detection;N gonorrhoea DNA Throat Ql NAA+probe;;ACTIVE;2.63;2.63 +88226-6;Mycoplasma genitalium DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Urine by NAA with probe detection;M genitalium DNA Ur Ql NAA+probe;;ACTIVE;2.63;2.73 +88227-4;Mycoplasma genitalium DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Cervix by NAA with probe detection;M genitalium DNA Cvx Ql NAA+probe;;ACTIVE;2.63;2.63 +88228-2;Mycoplasma genitalium DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Vaginal fluid by NAA with probe detection;M genitalium DNA Vag Ql NAA+probe;;ACTIVE;2.63;2.63 +8822-9;End-diastolic volume;Vol;Pt;Heart.ventricle.right;Qn;Imaging;HEMODYN.MOLEC;2;Right ventricular End-diastolic volume by Imaging;RV ED vol Imaging;;ACTIVE;1.0h(3);2.52 +88229-0;Mycoplasma genitalium DNA;PrThr;Pt;Anorectal;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Anorectal by NAA with probe detection;M genitalium DNA Anorectl Ql NAA+probe;;ACTIVE;2.63;2.63 +88230-8;Mycoplasma genitalium DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Throat by NAA with probe detection;M genitalium DNA Throat Ql NAA+probe;;ACTIVE;2.63;2.63 +88231-6;Microscopic observation;Prid;Pt;Bil fld;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Bile fluid by Acid fast stain;Acid fast Stn Bifl;;ACTIVE;2.63;2.63 +88232-4;Trypanosoma cruzi DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Trypanosoma cruzi DNA [Presence] in Tissue by NAA with probe detection;T cruzi DNA Tiss Ql NAA+probe;;ACTIVE;2.63;2.63 +88233-2;Babesia sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Babesia sp DNA [Presence] in Blood by NAA with probe detection;Babesia DNA Bld Ql NAA+probe;;ACTIVE;2.63;2.73 +88234-0;Microscopic observation;PrThr;Pt;Synv fld;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Synovial fluid by Acid fast stain;Acid fast Stn Snv Ql;;ACTIVE;2.63;2.63 +88235-7;Microscopic observation;Prid;Pt;Synv fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Synovial fluid by Giemsa stain;Gie Stn Snv;;ACTIVE;2.63;2.63 +88236-5;Bacteria identified;Prid;Pt;CSF;Nom;Aerobic culture;MICRO;1;Bacteria identified in Cerebral spinal fluid by Aerobe culture;Bacteria CSF Aerobe Cult;;ACTIVE;2.63;2.63 +8823-7;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;Imaging;HEMODYN.MOLEC;2;Left ventricular End-systolic volume by Imaging;LV ES vol Imaging;;ACTIVE;1.0h(3);2.52 +88237-3;LCDS v4.00 - Functional abilities and goals - planned discharge;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Functional abilities and goals - planned discharge [CMS Assessment];;;ACTIVE;2.63;2.69 +88238-1;LCDS v4.00 - Functional abilities and goals;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Functional abilities and goals [CMS Assessment];;;ACTIVE;2.63;2.63 +88239-9;Dialysis unit visit as part of chronic kidney disease education;Find;Pt;^Patient;Ord;;CLIN;2;Dialysis unit visit as part of chronic kidney disease education;Dial unit visit part of CKD educ;;ACTIVE;2.63;2.63 +88240-7;Chronic kidney disease education panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Chronic kidney disease education panel;CKD educ panel;;ACTIVE;2.63;2.63 +88241-5;Fetal remains disposition method;Type;Pt;^Patient;Nom;;SURVEY.CDC;4;Fetal remains disposition method;;;ACTIVE;2.63;2.64 +88242-3;Guidance for infusion of non-thrombolytic;Find;Pt;Head>Head arteries;Doc;{Imaging modality};RAD;2;Guidance for infusion of non-thrombolytic of Head Arteries;Guided Head Arteries Non-thromb infus;;ACTIVE;2.63;2.64 +88243-1;Guidance for removal of tunneled catheter;Find;Pt;Chest>Pleura;Doc;{Imaging modality};RAD;2;Guidance for removal of tunneled catheter from Chest Pleura;Guided Chest Pleura Tunneled Pl rem;;ACTIVE;2.63;2.64 +88244-9;Acinetobacter sp (rpsA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Acinetobacter sp rpsA gene [Presence] by Probe in Positive blood culture;Acinetobacter sp rpsA Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +8824-5;End-systolic volume;Vol;Pt;Heart.ventricle.right;Qn;Imaging;HEMODYN.MOLEC;2;Right ventricular End-systolic volume by Imaging;RV ES vol Imaging;;ACTIVE;1.0h(3);2.52 +88245-6;Bacterial carbapenem resistance blaIMP gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Carbapenem resistance blaIMP gene [Presence] by Probe in Positive blood culture;blaIMP Bld Pos Ql Probe;;DISCOURAGED;2.63;2.65 +88246-4;Bacterial carbapenem resistance blaKPC gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Carbapenem resistance blaKPC gene [Presence] by Probe in Positive blood culture;blaKPC Bld Pos Ql Probe;;DISCOURAGED;2.63;2.73 +88247-2;Bacterial carbapenem resistance blaNDM gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Carbapenem resistance blaNDM gene [Presence] by Probe in Positive blood culture;blaNDM Bld Pos Ql Probe;;DISCOURAGED;2.63;2.65 +88248-0;Bacterial carbapenem resistance blaOXA gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Carbapenem resistance blaOXA gene [Presence] by Probe in Positive blood culture;blaOXA Bld Pos Ql Probe;;DISCOURAGED;2.63;2.65 +88249-8;Bacterial carbapenem resistance blaVIM gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Carbapenem resistance blaVIM gene [Presence] by Probe in Positive blood culture;blaVIM Bld Pos Ql Probe;;DISCOURAGED;2.63;2.65 +88250-6;Bacterial cephalosporin resistance blaCTX-M gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Cephalosporin resistance blaCTX-M gene [Presence] by Molecular method;blaCTX-M Islt/Spm Ql;;ACTIVE;2.63;2.73 +88251-4;Bacterial methicillin resistance mecA gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Methicillin resistance mecA gene [Presence] by Probe in Positive blood culture;mecA Bld Pos Ql Probe;;DISCOURAGED;2.63;2.73 +8825-2;Hemodynamic measurement method;Type;Pt;Heart.ventricle.left;Nom;*;HEMODYN.ATOM;2;Hemodynamic measurement method;Hemodynamic measurement method;;ACTIVE;1.0h(3);2.42 +88252-2;Bacterial vancomycin resistance vanA gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Vancomycin resistance vanA gene [Presence] by Probe in Positive blood culture;vanA Bld Pos Ql Probe;;DISCOURAGED;2.63;2.65 +88253-0;Bacterial vancomycin resistance vanB gene;PrThr;Pt;Bld.pos growth;Ord;Probe;ABXBACT;1;Vancomycin resistance vanB gene [Presence] by Probe in Positive blood culture;vanB Bld Pos Ql Probe;;DISCOURAGED;2.63;2.65 +88254-8;Citrobacter sp (ompA+mrkC) genes;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Citrobacter sp ompA+mrkC genes [Presence] by Probe in Positive blood culture;Citrobac sp ompA+mrkC Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88255-5;Enterobacter sp (gyrB+metB) genes;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Enterobacter sp gyrB+metB genes [Presence] by Probe in Positive blood culture;Enterobact gyrB+metB Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88256-3;Enterococcus faecalis hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Enterococcus faecalis hsp60 gene [Presence] by Probe in Positive blood culture;E faecalis hsp60 Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88257-1;Enterococcus faecium hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Enterococcus faecium hsp60 gene [Presence] by Probe in Positive blood culture;E faecium hsp60 Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88258-9;Escherichia coli oppA gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Escherichia coli oppA gene [Presence] by Probe in Positive blood culture;EC oppA gene Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88259-7;Gram negative bacteria identified;Imp;Pt;Bld.pos growth;Nom;Probe;MICRO;1;Gram negative bacteria identified [Interpretation] by Probe in Positive blood culture;GN bact Bld Pos Probe-Imp;;ACTIVE;2.63;2.68 +8826-0;Hemodynamic resistance;Resis;Pt;Pulmonary vasculature;Qn;Fick;HEMODYN.MOLEC;2;Pulmonary vascular Resistance by Fick method;PV Res Fick;;ACTIVE;1.0h(3);2.29 +88260-5;Gram negative blood culture panel;-;Pt;Bld.pos growth;-;Probe;PANEL.MICRO;1;Gram negative blood culture panel by Probe in Positive blood culture;GN Bld Culture Pnl Bld Pos Probe;;ACTIVE;2.63;2.64 +88261-3;Gram positive bacteria identified;Imp;Pt;Bld.pos growth;Nom;Probe;MICRO;1;Gram positive bacteria identified [Interpretation] by Probe in Positive blood culture;GP bact Bld Pos Probe-Imp;;ACTIVE;2.63;2.64 +88262-1;Gram positive blood culture panel;-;Pt;Bld.pos growth;-;Probe;PANEL.MICRO;1;Gram positive blood culture panel by Probe in Positive blood culture;GP Bld Culture Pnl Bld Pos Probe;;ACTIVE;2.63;2.64 +88263-9;Klebsiella oxytoca (ompA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Klebsiella oxytoca ompA gene [Presence] by Probe in Positive blood culture;K oxytoca ompA Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88264-7;Klebsiella pneumoniae yggE gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Klebsiella pneumoniae yggE gene [Presence] by Probe in Positive blood culture;K pneumoniae yggE Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88265-4;Listeria sp (tuf) gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Listeria sp tuf gene [Presence] by Probe in Positive blood culture;Listeria sp tuf Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88266-2;Mycobacterium sp rRNA;Prid;Pt;Bld.pos growth;Nom;Probe;MICRO;1;Mycobacterium sp rRNA [Identifier] by Probe in Positive blood culture;Mycobacterium rRNA Bld Pos Probe;;ACTIVE;2.63;2.64 +88267-0;Proteus sp (atpD) gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Proteus sp atpD gene [Presence] by Probe in Positive blood culture;Proteus sp atpD Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88268-8;Pseudomonas aeruginosa (sodA) gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Pseudomonas aeruginosa sodA gene [Presence] by Probe in Positive blood culture;P aeruginosa sodA Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88269-6;Staphylococcus aureus gyrB gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Staphylococcus aureus gyrB gene [Presence] by Probe in Positive blood culture;S aureus gyrB Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88270-4;Staphylococcus epidermidis hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Staphylococcus epidermidis hsp60 gene [Presence] by Probe in Positive blood culture;S epidermidis hsp60 Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88271-2;Staphylococcus lugdunensis sodA gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Staphylococcus lugdunensis sodA gene [Presence] by Probe in Positive blood culture;S lugdunensis sodA Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88272-0;Staphylococcus sp tuf gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Staphylococcus sp tuf gene [Presence] by Probe in Positive blood culture;Staph sp tuf Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88273-8;Streptococcus agalactiae hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Streptococcus agalactiae hsp60 gene [Presence] by Probe in Positive blood culture;S agalactiae hsp60 Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88274-6;Streptococcus anginosus group gyrB gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Streptococcus anginosus group gyrB gene [Presence] by Probe in Positive blood culture;S anginosus gryB Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88275-3;Streptococcus pneumoniae gryB gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Streptococcus pneumoniae gryB gene [Presence] by Probe in Positive blood culture;S pneumoniae gryB Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88276-1;Streptococcus pyogenes hsp60 gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Streptococcus pyogenes hsp60 gene [Presence] by Probe in Positive blood culture;S pyogenes hsp60 Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +88277-9;Streptococcus sp tuf gene;PrThr;Pt;Bld.pos growth;Ord;Probe;MICRO;1;Streptococcus sp tuf gene [Presence] by Probe in Positive blood culture;Streptococcus sp tuf Bld Pos Ql Probe;;ACTIVE;2.63;2.73 +8827-8;Hemodynamic resistance;Resis;Pt;Pulmonary vasculature;Qn;Indicator dilution;HEMODYN.MOLEC;2;Pulmonary vascular Resistance by Indicator dilution;PV Res Indicator dilution;;ACTIVE;1.0h(3);2.29 +88278-7;Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.15.1;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.15.1 [CMS Assessment];;;DEPRECATED;2.64;2.73 +88279-5;MDS v3.0 - RAI v1.15.1 - Nursing home & Swing bed OMRA (NO & SO) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home and Swing bed OMRA (NO and SO) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88280-3;MDS v3.0 - RAI v1.15.1 - Nursing home & Swing bed OMRA start of therapy (NS & SS) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home and Swing bed OMRA start of therapy (NS and SS) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88281-1;MDS v3.0 - RAI v1.15.1 - Nursing home & Swing bed tracking (NT & ST) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home and Swing bed tracking (NT and ST) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88282-9;MDS v3.0 - RAI v1.15.1 - Nursing home comprehensive (NC) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home comprehensive (NC) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88283-7;MDS v3.0 - RAI v1.15.1 - Nursing home discharge (ND) & Swing bed discharge (SD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home discharge (ND) and Swing bed discharge (SD) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88284-5;MDS v3.0 - RAI v1.15.1 - Nursing home OMRA start of therapy and discharge (NSD) & Swing bed OMRA start of therapy and discharge (SSD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home OMRA start of therapy and discharge (NSD) and Swing bed OMRA start of therapy and discharge (SSD) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88285-2;MDS v3.0 - RAI v1.15.1 - Nursing home OMRA-discharge (NOD) & Swing bed OMRA-discharge (SOD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home OMRA-discharge (NOD) and Swing bed OMRA-discharge (SOD) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +8828-6;Hemodynamic resistance;Resis;Pt;Pulmonary vasculature;Qn;;HEMODYN.ATOM;2;Pulmonary vascular Resistance;PV Res;;ACTIVE;1.0h(3);2.44 +88286-0;MDS v3.0 - RAI v1.15.1 - Nursing home part A PPS discharge (NPE) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home part A PPS discharge (NPE) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88287-8;MDS v3.0 - RAI v1.15.1 - Nursing home PPS (NP) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home PPS (NP) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88288-6;MDS v3.0 - RAI v1.15.1 - Swing bed PPS (SP) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Swing bed PPS (SP) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88289-4;MDS v3.0 - RAI v1.15.1 - Medications;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.15.1 - Medications [CMS Assessment];;;ACTIVE;2.64;2.64 +88290-2;MDS v3.0 - RAI v1.17.2 - Medications received;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medications received [CMS Assessment];;;ACTIVE;2.64;2.68 +88291-0;Number of D opiod received in last 7D or since admission &or reentry if less than 7D;Num;7D;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days opiod received in last 7 days or since admission/reentry if less than 7 days [CMS Assessment];;;ACTIVE;2.64;2.64 +88292-8;MDS v3.0 - RAI v1.15.1 - Nursing home quarterly (NQ) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.15.1 - Nursing home quarterly (NQ) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88293-6;Glomerular filtration rate/1.73 sq M.predicted.black;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (CKD-EPI);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among blacks [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI);GFR/BSA pred.blk SerPlBld CKD-EPI-ArVRat;;ACTIVE;2.64;2.73 +8829-4;Hemodynamic resistance;Resis;Pt;Systemic vasculature;Qn;Fick;HEMODYN.MOLEC;2;Systemic vascular Resistance by Fick method;SV Res Fick;;ACTIVE;1.0h(3);2.29 +88294-4;Glomerular filtration rate/1.73 sq M.predicted.non black;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (CKD-EPI);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among non-blacks [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI);GFR/BSA pred.nonblk SerPl CKD-EPI-ArVRat;;ACTIVE;2.64;2.73 +88295-1;Antipsychotic medication review;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Antipsychotic medication review [CMS Assessment];;;ACTIVE;2.64;2.74 +88296-9;Antipsychotic medications since admission or entry or reentry or the prior OBRA assessment, whichever is more recent;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Antipsychotic medications since admission/entry or reentry or the prior OBRA assessment, whichever is more recent [CMS Assessment];;;ACTIVE;2.64;2.64 +88297-7;Gradual dose reduction (GDR) attempted;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Gradual dose reduction (GDR) attempted [CMS Assessment];;;ACTIVE;2.64;2.64 +88298-5;Date of last attempted gradual dose reduction;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Date of last attempted gradual dose reduction [CMS Assessment];;;ACTIVE;2.64;2.67 +88299-3;Physician documented GDR as clinically contraindicated;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Physician documented GDR as clinically contraindicated [CMS Assessment];;;ACTIVE;2.64;2.64 +88300-9;Date physician documented GDR as clinically contraindicated;Date;Pt;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Date physician documented GDR as clinically contraindicated [CMS Assessment];;;ACTIVE;2.64;2.64 +88301-7;Immunoglobulin light chains.kappa.free;PrThr;24H;Urine;Ord;Immunofixation;CHEM;1;Kappa light chains.free [Presence] in 24 hour Urine by Immunofixation;Kappa LC Free 24h Ur Ql IFE;;ACTIVE;2.64;2.64 +8830-2;Hemodynamic resistance;Resis;Pt;Systemic vasculature;Qn;Indicator dilution;HEMODYN.MOLEC;2;Systemic vascular Resistance by Indicator dilution;SV Res Indicator dilution;;ACTIVE;1.0h(3);2.29 +88302-5;Immunoglobulin light chains.lambda.free;PrThr;24H;Urine;Ord;Immunofixation;CHEM;1;Lambda light chains.free [Presence] in 24 hour Urine by Immunofixation;Lambda LC Free 24h Ur Ql IFE;;ACTIVE;2.64;2.64 +88303-3;Immunoglobulin light chains.lambda;PrThr;24H;Urine;Ord;Immunofixation;CHEM;1;Lambda light chains [Presence] in 24 hour Urine by Immunofixation;Lambda LC 24h Ur Ql IFE;;ACTIVE;2.64;2.64 +88304-1;Immunoglobulin light chains.kappa;PrThr;24H;Urine;Ord;Immunofixation;CHEM;1;Kappa light chains [Presence] in 24 hour Urine by Immunofixation;Kappa LC 24h Ur Ql IFE;;ACTIVE;2.64;2.64 +88305-8;MDS v3.0 - RAI v1.15.1 - Medications - NOD, NP, SOD, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.15.1 - Medications - NOD, NP, SOD, SP [CMS Assessment];;;ACTIVE;2.64;2.64 +88306-6;MDS v3.0 - RAI v1.15.1 - Medications - NSD, ND, SSD, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.15.1 - Medications - NSD, ND, SSD, SD [CMS Assessment];;;ACTIVE;2.64;2.64 +88307-4;Restraints and alarms;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Restraints and alarms during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88308-2;Other alarm used during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Other alarm used during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88309-0;Alarms;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Alarms during assessment period [CMS Assessment];;;ACTIVE;2.64;2.74 +8831-0;Hemodynamic resistance;Resis;Pt;Systemic vasculature;Qn;;HEMODYN.ATOM;2;Systemic vascular Resistance;SV Res;;ACTIVE;1.0h(3);2.73 +88310-8;Bed alarm used during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bed alarm used during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88311-6;Chair alarm used during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Chair alarm used during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88312-4;Floor mat alarm used during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Floor mat alarm used during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88313-2;Motion sensor alarm used during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Motion sensor alarm used during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88314-0;Wander or elopement alarm used during assessment period;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wander/elopement alarm used during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88315-7;Multisection for perfusion^WO & W contrast IV && Multisection^W contrast IV;Find;Pt;Head>Brain && Head>Head vessels & Neck>Neck vessels;Doc;CT.perfusion && CT.angio;RAD;2;CT Head WO contrast and CT Brain for perfusion W contrast IV and CT angiogram Head and neck vessels W contrast IV;CT WO+Brain perf+CTA Head+Nec ves W cont;;ACTIVE;2.64;2.66 +88316-5;Guidance for percutaneous biopsy;Find;Pt;XXX>Spinal cord;Doc;CT;RAD;2;CT Guidance for biopsy of Spinal cord;CT Guided Spinal cord Bx;;ACTIVE;2.64;2.64 +88317-3;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Chest;CT Guided Chest PC fluid asp;;ACTIVE;2.64;2.64 +88318-1;Multisection^W contrast IV;Find;Pt;Chest>Coronary arteries+Pulmonary veins;Doc;CT.angio;RAD;2;CTA Coronary arteries and Pulmonary veins W contrast IV;CTA CA+PV W contr IV;;ACTIVE;2.64;2.64 +88319-9;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis+Lower extremity.bilateral;Doc;CT;RAD;2;CT Abdomen and Pelvis and Lower extremity - bilateral W contrast IV;CT Abd+Pel+LE-Bl W contr IV;;ACTIVE;2.64;2.64 +88320-7;Multisection^W contrast IV;Find;Pt;Neck && Head>Head vessels & Neck>Neck vessels;Doc;CT && CT.angio;RAD;2;CT Neck W contrast IV and CT angiogram Head and neck vessels W contrast IV;CT Neck + CTA Head+Neck ves W cont IV;;ACTIVE;2.64;2.64 +88321-5;Guidance for stereotactic localization;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for stereotactic localization of Unspecified body region;CT Guided Str loc;;ACTIVE;2.64;2.64 +88322-3;Multisection^W contrast IV && Multisection for pulmonary embolus^W contrast IV;Find;Pt;Chest && Chest>Pulmonary arteries;Doc;CT && CT.angio;RAD;2;CT Chest W contrast IV and CT angiogram Pulmonary arteries for pulmonary embolus W contrast IV;CT Chest + CTA PA for PE W contr IV;;ACTIVE;2.64;2.64 +88323-1;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.right;Doc;CT;RAD;2;CT Guidance for biopsy of Kidney - right;CT Guided Kidney-R Bx;;ACTIVE;2.64;2.64 +88324-9;Guidance for percutaneous biopsy;Find;Pt;Chest>Lung.left;Doc;CT;RAD;2;CT Guidance for biopsy of Lung - left;CT Guided Lung-L Bx;;ACTIVE;2.64;2.64 +88325-6;Guidance for percutaneous biopsy;Find;Pt;Abdomen>Kidney.left;Doc;CT;RAD;2;CT Guidance for biopsy of Kidney - left;CT Guided Kidney-L Bx;;ACTIVE;2.64;2.64 +88326-4;Multisection^WO & W contrast IV;Find;Pt;Head>Brain && Head>Head vessels;Doc;CT.perfusion && CT.angio;RAD;2;CT Head WO contrast and CT Brain for perfusion W contrast IV and CT angiogram Head vessels W contrast IV;CT WO con+Brain perf+CTA Head ves W cont;;ACTIVE;2.64;2.64 +88327-2;Multisection^W contrast IV;Find;Pt;Head && Head>Head vessels & Neck>Neck vessels;Doc;CT && CT.angio;RAD;2;CT Head W contrast IV and CT angiogram Head and neck vessels W contrast IV;CT Head + CTA Head+Neck ves W cont IV;;ACTIVE;2.64;2.64 +8832-8;Hemodynamic resistance/Body surface area;ArResis;Pt;Pulmonary vasculature;Qn;Fick;HEMODYN.MOLEC;2;Pulmonary vascular Resistance index by Fick method;PV RI Fick;;ACTIVE;1.0h(3);2.48 +88328-0;MDS v3.0 - RAI v1.17.2 - Restraints and alarms - NP, ND, SP, SD;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Restraints and alarms - NP, ND, SP, SD during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88329-8;Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 2.0;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI) - version 2.0 [CMS Assessment];;;DEPRECATED;2.64;2.73 +88330-6;Mobility - admission performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Mobility - admission performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.64;2.67 +88331-4;Mobility - discharge performance during 3D assessment period;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Mobility - discharge performance during 3 day assessment period [CMS Assessment];;;ACTIVE;2.64;2.67 +88332-2;IRF-PAI v3.0 - Skin conditions - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Skin conditions - discharge [CMS Assessment];;;ACTIVE;2.64;2.69 +88333-0;Memory &or recall ability during 3D assessment period;Find;3D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Memory/recall ability during 3 day assessment period [CMS Assessment];;;ACTIVE;2.64;2.64 +88334-8;Lean body weight;Mass;Pt;^Patient;Qn;Calculated;BDYWGT.MOLEC;2;Lean body weight Calculated;Lean body weight Calc;;ACTIVE;2.64;2.64 +88335-5;Predominant leukocyte identified;Type;Pt;Ear;Nom;Microscopy.light;HEM/BC;1;Predominant leukocyte identified [Type] in Ear by Light microscopy;Predominant leukocyte Ear Micro;;ACTIVE;2.64;2.64 +8833-6;Hemodynamic resistance/Body surface area;ArResis;Pt;Pulmonary vasculature;Qn;Indicator dilution;HEMODYN.MOLEC;2;Pulmonary vascular Resistance index by Indicator dilution;PV RI Indicator dilution;;ACTIVE;1.0h(3);2.48 +88336-3;Microscopic observation;Imp;Pt;Ear;Nar;;MICRO;1;Microscopic observation [Interpretation] of Ear specimen Narrative;Ear-Imp;;ACTIVE;2.64;2.64 +88337-1;Mite identified;Prid;Pt;Ear;Nom;Microscopy.light;MICRO;1;Mite identified in Ear by Light microscopy;Mite Ear Micro;;ACTIVE;2.64;2.64 +88338-9;Coccal bacteria;PrThr;Pt;Ear;Ord;Microscopy.light;MICRO;1;Coccal bacteria [Presence] in Ear by Light microscopy;Coccal bact Ear Ql Micro;;ACTIVE;2.64;2.64 +88339-7;Bacilliform bacteria;PrThr;Pt;Ear;Ord;Microscopy.light;MICRO;1;Bacilliform bacteria [Presence] in Ear by Light microscopy;Bacilliform bact Ear Ql Micro;;ACTIVE;2.64;2.64 +88340-5;Mite;PrThr;Pt;Ear;Ord;Microscopy.light;MICRO;1;Mite [Presence] in Ear by Light microscopy;Mite Ear Ql Micro;;ACTIVE;2.64;2.64 +88341-3;Cerumen;PrThr;Pt;Ear;Ord;;PATH;1;Cerumen [Presence] in Ear;Cerumen Ear Ql;;ACTIVE;2.64;2.64 +88342-1;Malassezia sp;PrThr;Pt;Ear;Ord;Microscopy.light;MICRO;1;Malassezia sp [Presence] in Ear by Light microscopy;Malassezia sp Ear Ql Micro;;ACTIVE;2.64;2.64 +88343-9;Leukocytes;PrThr;Pt;Ear;Ord;Microscopy.light;HEM/BC;1;Leukocytes [Presence] in Ear by Light microscopy;WBC Ear Ql Micro;;ACTIVE;2.64;2.64 +8834-4;Hemodynamic resistance/Body surface area;ArResis;Pt;Pulmonary vasculature;Qn;;HEMODYN.MOLEC;2;Pulmonary vascular Resistance index;PV RI;;ACTIVE;1.0h(3);2.48 +88344-7;Intracellular bacteria;PrThr;Pt;Ear;Ord;Microscopy.light;MICRO;1;Intracellular bacteria [Presence] in Ear by Light microscopy;Intracellular bact Ear Ql Micro;;ACTIVE;2.64;2.64 +88345-4;Microscopic exam panel;-;Pt;Ear;-;Microscopy.light;PANEL.MICRO;1;Microscopic exam panel - Ear by Light microscopy;Microscopic exam pnl Ear Micro;;ACTIVE;2.64;2.64 +88346-2;Blood pressure with exercise & post exercise panel;-;Pt;Arterial system;Qn;;PANEL.BP;2;Blood pressure with exercise and post exercise panel;BP w and post exercise pnl;;ACTIVE;2.64;2.7 +88347-0;Procedure note;Find;Pt;{Setting};Doc;Psychiatry.nurse;DOC.ONTOLOGY;2;Psychiatry Nurse procedure note;Psychiatry Nurse Procedure note;;ACTIVE;2.64;2.64 +88348-8;Transfer summary note;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Transfer summary note;Nurse LTC fac Transfer sum note;;ACTIVE;2.64;2.64 +88349-6;Guidance^during surgery;Find;Pt;XXX;Doc;{Imaging modality};RAD;2;Guidance-- during surgery;Guided Unsp region Guide--in Surg;;ACTIVE;2.64;2.64 +88350-4;Note;Find;Pt;{Setting};Doc;Polytrauma.case manager;DOC.ONTOLOGY;2;Polytrauma Case manager Note;Polytrauma Case Mgr Note;;ACTIVE;2.64;2.64 +8835-1;Hemodynamic resistance/Body surface area;ArResis;Pt;Systemic vasculature;Qn;Fick;HEMODYN.MOLEC;2;Systemic vascular Resistance index by Fick method;SV RI Fick;;ACTIVE;1.0h(3);2.48 +88351-2;Consultation note;Find;Pt;{Setting};Doc;Polytrauma;DOC.ONTOLOGY;2;Polytrauma Consult note;Polytrauma Consult note;;ACTIVE;2.64;2.64 +88352-0;Education note;Find;Pt;{Setting};Doc;Polytrauma;DOC.ONTOLOGY;2;Polytrauma Education note;Polytrauma Educ note;;ACTIVE;2.64;2.64 +88353-8;History and physical note;Find;Pt;{Setting};Doc;Polytrauma;DOC.ONTOLOGY;2;Polytrauma History and physical note;Polytrauma H&P note;;ACTIVE;2.64;2.64 +88354-6;Note;Find;Pt;{Setting};Doc;Polytrauma;DOC.ONTOLOGY;2;Polytrauma Note;Polytrauma Note;;ACTIVE;2.64;2.64 +88355-3;Note;Find;Pt;{Setting};Doc;Polytrauma.nurse;DOC.ONTOLOGY;2;Polytrauma Nurse Note;Polytrauma nurse Note;;ACTIVE;2.64;2.64 +88356-1;Note;Find;Pt;Telephone encounter;Doc;Polytrauma;DOC.ONTOLOGY;2;Polytrauma Telephone encounter Note;Polytrauma Phone Note;;ACTIVE;2.64;2.64 +88357-9;Alert;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Alert;Infectious disease Alert;;TRIAL;2.64;2.64 +88358-7;Alert;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Alert;Mental health Alert;;TRIAL;2.64;2.64 +88359-5;Alert;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Alert;Nurse Alert;;TRIAL;2.64;2.64 +88360-3;Alert;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Alert;Pharmacology Alert;;TRIAL;2.64;2.64 +88361-1;Alert;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Alert;Addiction med Alert;;TRIAL;2.64;2.64 +88362-9;Medical equipment or product note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Medical equipment or product note;Audiology Med equip or prod note;;ACTIVE;2.64;2.64 +88363-7;Medical equipment or product note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Medical equipment or product note;Med equip or prod note;;ACTIVE;2.64;2.64 +88364-5;Actinobacillus pleuropneumoniae Ab.IgG/Positive control;RelRto;Pt;Saliva;Qn;IA;MICRO;1;Actinobacillus pleuropneumoniae IgG Ab/Positive control in Saliva (oral fluid) by Immunoassay;A pleuropn IgG/Pos cntrl Sal IA;;ACTIVE;2.64;2.64 +88365-2;Glucose^pre-meal;MCnc;Pt;Bld;Qn;;CHAL.ROUTINE;1;Glucose [Mass/volume] in Blood --pre-meal;Glucose pre-meal Bld-mCnc;;ACTIVE;2.64;2.64 +88366-0;Microscopic observation;PrThr;Pt;Vomitus;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Vomitus by Acid fast stain;Acid fast Stn Vom Ql;;ACTIVE;2.64;2.64 +88367-8;Outcome and assessment information set (OASIS) form - version D, D1 - Transfer to inpatient facility - patient discharged or not discharged;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D, D1 - Transfer to inpatient facility - patient discharged or not discharged [CMS Assessment];;;ACTIVE;2.64;2.73 +88368-6;Outcome and assessment information set (OASIS) form - version D, D1 - Resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D, D1 - Resumption of care [CMS Assessment];;;ACTIVE;2.64;2.68 +8836-9;Hemodynamic resistance/Body surface area;ArResis;Pt;Systemic vasculature;Qn;Indicator dilution;HEMODYN.MOLEC;2;Systemic vascular Resistance index by Indicator dilution;SV RI Indicator dilution;;ACTIVE;1.0h(3);2.48 +88369-4;Outcome and assessment information set (OASIS) form - version D - Follow-up - recertification or other follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D - Follow-up - recertification or other follow-up [CMS Assessment];;;ACTIVE;2.64;2.67 +88370-2;Outcome and assessment information set (OASIS) form - version D, D1 - Discharged from agency - death at home;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D, D1 - Discharged from agency - death at home [CMS Assessment];;;ACTIVE;2.64;2.68 +88371-0;Outcome and assessment information set (OASIS) form - version D, D1 - Discharged from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D, D1 - Discharged from agency [CMS Assessment];;;ACTIVE;2.64;2.73 +88372-8;Outcome and assessment information set (OASIS) form - version D;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D [CMS Assessment];;;ACTIVE;2.64;2.69 +88373-6;Outcome and assessment information set (OASIS) form - version D, D1 - Start of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D, D1 - Start of care [CMS Assessment];;;ACTIVE;2.64;2.69 +88374-4;Chemotherapy infusion start & stop date and time panel;-;Pt;^Patient;-;;PANEL.IO;2;Chemotherapy infusion start and stop date and time panel;Chemo infus date and time Pnl;;ACTIVE;2.64;2.64 +88375-1;Tildipirosin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Tildipirosin [Susceptibility] by Disk diffusion (KB);Tildipirosin Islt KB;;ACTIVE;2.64;2.64 +88376-9;Gamithromycin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Gamithromycin [Susceptibility] by Disk diffusion (KB);Gamithromycin Islt KB;;ACTIVE;2.64;2.64 +8837-7;Hemodynamic resistance/Body surface area;ArResis;Pt;Systemic vasculature;Qn;;HEMODYN.MOLEC;2;Systemic vascular Resistance index;SV RI;;ACTIVE;1.0h(3);2.73 +88377-7;Tildipirosin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Tildipirosin [Susceptibility] by Minimum inhibitory concentration (MIC);Tildipirosin Islt MIC;;ACTIVE;2.64;2.65 +88378-5;Gamithromycin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Gamithromycin [Susceptibility] by Minimum inhibitory concentration (MIC);Gamithromycin Islt MIC;;ACTIVE;2.64;2.64 +88379-3;International Physical Activity Questionnaire self-administered long form;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;International Physical Activity Questionnaire self-administered long form [IPAQ];;;ACTIVE;2.64;2.64 +88380-1;Job-related physical activity panel;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;Job-related physical activity panel [IPAQ];;;ACTIVE;2.64;2.64 +88381-9;Do you currently have a job or do any unpaid work outside your home;Find;Pt;^Patient;Ord;IPAQ;SURVEY.IPAQ;4;Do you currently have a job or do any unpaid work outside your home [IPAQ];;;ACTIVE;2.64;2.64 +88382-7;During the last 7D, on how many D did you do vigorous physical activities like heavy lifting, digging, heavy construction, or climbing up stairs as part of your work for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, heavy construction, or climbing up stairs as part of your work for at least 10M at a time [IPAQ];;;ACTIVE;2.64;2.64 +88383-5;How much time did you usually spend on one of those D doing vigorous physical activities as part of your work during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days doing vigorous physical activities as part of your work during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88384-3;During the last 7D, on how many D did you do moderate physical activities like carrying light loads as part of your work, not including walking, for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work, not including walking, greater than 10 minutes at a time [IPAQ];;;ACTIVE;2.64;2.64 +8838-5;Observation duration;Time;Stdy;XXX;Qn;;HEMODYN.ATOM;2;Observation duration;Observation duration;;ACTIVE;1.0h(3);2.73 +88385-0;How much time did you usually spend on one of those D doing moderate physical activities as part of your work during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days doing moderate physical activities as part of your work during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88386-8;During the last 7D, on how many D did you walk for at least 10M at a time as a part of your work, not counting any walking you did to travel to or from work;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you walk for at least 10 minutes at a time as a part of your work, not counting any walking you did to travel to or from work [IPAQ];;;ACTIVE;2.64;2.64 +88387-6;How much time did you usually spend on one of those D walking as part of your work during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days walking as part of your work during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88388-4;Transportation physical activity panel;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;Transportation physical activity panel [IPAQ];;;ACTIVE;2.64;2.64 +88389-2;During the last 7D, on how many D did you travel in a motor vehicle like a train, bus, car, or tram;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you travel in a motor vehicle like a train, bus, car, or tram [IPAQ];;;ACTIVE;2.64;2.64 +883-9;ABO group;Type;Pt;Bld;Nom;;BLDBK;1;ABO group [Type] in Blood;ABO Group Bld;;ACTIVE;1.0;2.73 +88390-0;How much time did you usually spend on one of those D traveling in a train, bus, car, tram, or other kind of motor vehicle during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days traveling in a train, bus, car, tram, or other kind of motor vehicle during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88391-8;During the last 7D, on how many D did you bicycle for at least 10M at a time to go from place to place;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you bicycle for at least 10 minutes at a time to go from place to place [IPAQ];;;ACTIVE;2.64;2.64 +88392-6;How much time did you usually spend on one of those D to bicycle from place to place during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days to bicycle from place to place during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +8839-3;Oxygen saturation;MFr;Pt;Aorta.root;Qn;;HEMODYN.MOLEC;2;Aorta root Oxygen saturation;SaO2 % AO root;;ACTIVE;1.0h(3);2.54 +88393-4;During the last 7D, on how many D did you walk for at least 10M at a time to go from place to place;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you walk for at least 10 minutes at a time to go from place to place [IPAQ];;;ACTIVE;2.64;2.64 +88394-2;How much time did you usually spend on one of those D walking from place to place during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days walking from place to place during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88395-9;Housework, house maintenance, and caring for family panel;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;Housework, house maintenance, and caring for family panel [IPAQ];;;ACTIVE;2.64;2.64 +88396-7;During the last 7D, on how many D did you do vigorous physical activities like heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.64;2.64 +88397-5;How much time did you usually spend on one of those D doing vigorous physical activities in the garden or yard during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88398-3;During the last 7D, on how many D did you do moderate activities like carrying light loads, sweeping, washing windows, and raking in the garden or yard for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do moderate activities like carrying light loads, sweeping, washing windows, and raking in the garden or yard for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.64;2.64 +88399-1;How much time did you usually spend on one of those D doing moderate physical activities in the garden or yard during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88400-7;During the last 7D, on how many D did you do moderate activities like carrying light loads, washing windows, scrubbing floors and sweeping inside your home for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do moderate activities like carrying light loads, washing windows, scrubbing floors and sweeping inside your home for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.64;2.64 +8840-1;Oxygen saturation;MFr;Pt;Heart.atrium.left;Qn;;HEMODYN.MOLEC;2;Left atrium Oxygen saturation;SaO2 % LA;;ACTIVE;1.0h(3);2.4 +88401-5;How much time did you usually spend on one of those D doing moderate physical activities inside your home during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days doing moderate physical activities inside your home during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88402-3;Recreation, sport, and leisure-time physical activity panel;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;Recreation, sport, and leisure-time physical activity panel [IPAQ];;;ACTIVE;2.64;2.64 +88403-1;Not counting any walking you have already mentioned, during the last 7D, on how many D did you walk for at least 10M at a time in your leisure time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Not counting any walking you have already mentioned, during the last 7 days, on how many days did you walk for at least 10 minutes at a time in your leisure time [IPAQ];;;ACTIVE;2.64;2.64 +88404-9;How much time did you usually spend on one of those D walking in your leisure time during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days walking in your leisure time during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88405-6;During the last 7D, on how many D did you do vigorous physical activities like aerobics, running, fast bicycling, or fast swimming in your leisure time for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do vigorous physical activities like aerobics, running, fast bicycling, or fast swimming in your leisure time for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.64;2.64 +88406-4;How much time did you usually spend on one of those D doing vigorous physical activities in your leisure time during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88407-2;During the last 7D, on how many D did you do moderate physical activities like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your leisure time for at least 10M at a time;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, on how many days did you do moderate physical activities like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your leisure time for at least 10 minutes at a time [IPAQ];;;ACTIVE;2.64;2.64 +88408-0;How much time did you usually spend on one of those D doing moderate physical activities in your leisure time during the last 7D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;How much time did you usually spend on one of those days doing moderate physical activities in your leisure time during the last 7 days [IPAQ];;;ACTIVE;2.64;2.64 +88409-8;Time spent sitting panel;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;Time spent sitting panel [IPAQ];;;ACTIVE;2.64;2.64 +88411-4;During the last 7D, how much time did you usually spend sitting on a weekend D;NRat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;During the last 7 days, how much time did you usually spend sitting on a weekend day [IPAQ];;;ACTIVE;2.64;2.64 +88412-2;International Physical Activity Questionnaire telephone short form;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;International Physical Activity Questionnaire telephone short form [IPAQ];;;ACTIVE;2.64;2.64 +8841-9;Oxygen saturation;MFr;Pt;Heart.atrium.right;Qn;;HEMODYN.MOLEC;2;Right atrium Oxygen saturation;SaO2 % RA;;ACTIVE;1.0h(3);2.4 +88419-7;Vigorous physical activity.work domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Vigorous physical activity.work domain [IPAQ];;;ACTIVE;2.64;2.64 +88420-5;Moderate physical activity.work domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Moderate physical activity.work domain [IPAQ];;;ACTIVE;2.64;2.64 +88421-3;Walking physical activity.work domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Walking physical activity.work domain [IPAQ];;;ACTIVE;2.64;2.64 +88422-1;Total physical activity.work domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Total physical activity.work domain [IPAQ];;;ACTIVE;2.64;2.64 +88423-9;Cycle physical activity.active transportation domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Cycle physical activity.active transportation domain [IPAQ];;;ACTIVE;2.64;2.64 +88424-7;Walking physical activity.active transportation domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Walking physical activity.active transportation domain [IPAQ];;;ACTIVE;2.64;2.64 +88425-4;Total physical activity.active transportation domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Total physical activity.active transportation domain [IPAQ];;;ACTIVE;2.64;2.64 +88426-2;Vigorous physical activity.yard work;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Vigorous physical activity.yard work [IPAQ];;;ACTIVE;2.64;2.64 +8842-7;Oxygen saturation;MFr;Pt;Heart.atrium.right.high;Qn;;HEMODYN.MOLEC;2;High right atrium Oxygen saturation;SaO2 % RA.high;;ACTIVE;1.0h(3);2.4 +88427-0;Moderate physical activity.yard work;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Moderate physical activity.yard work [IPAQ];;;ACTIVE;2.64;2.64 +88428-8;Moderate physical activity.inside chores;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Moderate physical activity.inside chores [IPAQ];;;ACTIVE;2.64;2.64 +88429-6;Total physical activity.domestic and garden domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Total physical activity.domestic and garden domain [IPAQ];;;ACTIVE;2.64;2.64 +88430-4;Walking physical activity.leisure-time domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Walking physical activity.leisure-time domain [IPAQ];;;ACTIVE;2.64;2.64 +88431-2;Vigorous physical activity.leisure-time domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Vigorous physical activity.leisure-time domain [IPAQ];;;ACTIVE;2.64;2.64 +88432-0;Moderate physical activity.leisure-time domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Moderate physical activity.leisure-time domain [IPAQ];;;ACTIVE;2.64;2.64 +88433-8;Total physical activity.leisure-time domain;ARat;7D;^Patient;Qn;IPAQ;SURVEY.IPAQ;4;Total physical activity.leisure-time domain [IPAQ];;;ACTIVE;2.64;2.64 +88434-6;International Physical Activity Questionnaire telephone long form;-;Pt;^Patient;-;IPAQ;PANEL.SURVEY.IPAQ;4;International Physical Activity Questionnaire telephone long form [IPAQ];;;ACTIVE;2.64;2.64 +8843-5;Oxygen saturation;MFr;Pt;Heart.atrium.right.low;Qn;;HEMODYN.MOLEC;2;Low right atrium Oxygen saturation;SaO2 % RA.low;;ACTIVE;1.0h(3);2.4 +88435-3;Cardiac compression start time;ClockTime;Pt;^Patient;Qn;;CARD.PROC;2;Cardiac compression start time;Cardiac comp start time Clock time;;ACTIVE;2.64;2.7 +88436-1;Patient counseling information;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Patient counseling information;FDA insert Patient counseling inform;;ACTIVE;2.64;2.64 +88437-9;How supplied & storage & handling section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert How supplied and storage and handling section;FDA insert how suppl + stor + hand sect;;ACTIVE;2.64;2.64 +88438-7;Cardiopulmonary resuscitation start time;ClockTime;Pt;^Patient;Qn;;CARD.PROC;2;CPR start time;CPR start time Clock time;;ACTIVE;2.64;2.7 +88439-5;Hydrogen/Expired gas^10M post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --10M post dose fructose PO;Breath H2 10M p fruct PO;;ACTIVE;2.64;2.64 +88440-3;Hydrogen/Expired gas^10M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --10M post dose lactose PO;Breath H2 10M p lact PO;;ACTIVE;2.64;2.64 +88441-1;Hydrogen/Expired gas^20M post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --20M post dose fructose PO;Breath H2 20M p fruct PO;;ACTIVE;2.64;2.64 +88442-9;Hydrogen/Expired gas^40M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --40 minutes post dose lactose PO;Breath H2 40M p Lac PO;;ACTIVE;2.64;2.64 +8844-3;Oxygen saturation;MFr;Pt;Heart.atrium.right.mid;Qn;;HEMODYN.MOLEC;2;Mid right atrium Oxygen saturation;SaO2 % RA.mid;;ACTIVE;1.0h(3);2.4 +88443-7;Hydrogen/Expired gas^40M post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --40M post dose fructose PO;Breath H2 40M p fruct PO;;ACTIVE;2.64;2.64 +88444-5;Hydrogen/Expired gas^50M post dose fructose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --50M post dose fructose PO;Breath H2 50M p fruct PO;;ACTIVE;2.64;2.64 +88445-2;Hydrogen/Expired gas^50M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --50M post dose lactose PO;Breath H2 50M p lact PO;;ACTIVE;2.64;2.64 +88446-0;Hydrogen/Expired gas^20M post dose lactose PO;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --20 minutes post dose lactose PO;Breath H2 20M p Lac PO;;ACTIVE;2.64;2.64 +88447-8;Liver fibrosis interpretation;Imp;Pt;Ser;Ord;;CHEM;1;Liver fibrosis interpretation in Serum Qualitative;Liver fibrosis interpretation Ser-Imp;;ACTIVE;2.64;2.64 +88448-6;Necroinflammatory activity interpretation;Imp;Pt;Ser;Ord;;CHEM;1;Necroinflammatory activity interpretation in Serum Qualitative;Necroinflammatory activ interp Ser-Imp;;ACTIVE;2.64;2.64 +88449-4;Coagulation factor IX activity actual/Normal;RelCCnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor IX activity actual/normal in Platelet poor plasma by Chromogenic method;Fact IX Act/Nor PPP Chro;;ACTIVE;2.64;2.73 +8845-0;Oxygen saturation;MFr;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventricular Oxygen saturation;SaO2 % LV;;ACTIVE;1.0h(3);2.73 +88450-2;Babesia divergens+MO-1 strain 18S rRNA gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Babesia divergens+MO-1 strain 18S rRNA gene [Presence] in Blood by NAA with non-probe detection;B div+MO-1 18S rRNA Bld Ql NAA+non-probe;;ACTIVE;2.64;2.64 +88451-0;Babesia duncani 18S rRNA gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Babesia duncani 18S rRNA gene [Presence] in Blood by NAA with non-probe detection;B duncani 18S rRNA Bld Ql NAA+non-probe;;ACTIVE;2.64;2.64 +88452-8;Babesia microti 18S rRNA gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Babesia microti 18S rRNA gene [Presence] in Blood by NAA with non-probe detection;B microti 18S rRNA Bld Ql NAA+non-probe;;ACTIVE;2.64;2.64 +88453-6;HIV 1 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA;PrThr;Pt;Ser/Plas/Bld^Donor;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA [Presence] in Serum, Plasma or Blood from Donor by NAA with probe detection;HIV1+HCV+HBV SerPlBld Donr NAA+prb;;ACTIVE;2.64;2.73 +88454-4;Mumps virus Ab.IgG+IgM;Imp;Pt;CSF;Ord;IF;MICRO;1;Mumps virus IgG+IgM Ab [Interpretation] in Cerebral spinal fluid Qualitative by Immunofluorescence;MuV IgG+IgM CSF IF-Imp;;ACTIVE;2.64;2.65 +88455-1;California encephalitis virus Ab.IgG & IgM panel;-;Pt;Ser;-;IF;PANEL.MICRO;1;California encephalitis virus Ab.IgG and IgM panel - Serum by Immunofluorescence;CEV Ab.IgG & IgM panel Ser IF;;ACTIVE;2.64;2.65 +88456-9;California encephalitis virus Ab.IgG+IgM;Imp;Pt;Ser;Ord;IF;MICRO;1;California encephalitis virus IgG+IgM Ab [Interpretation] in Serum Qualitative by Immunofluorescence;CEV IgG+IgM Ser IF-Imp;;ACTIVE;2.64;2.65 +88457-7;Herpes simplex virus 1 Ab.IgM;PrThr;Pt;CSF;Ord;IF;MICRO;1;Herpes simplex virus 1 IgM Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;HSV1 IgM CSF Ql IF;;ACTIVE;2.64;2.65 +88458-5;Mumps virus Ab.IgG & IgM panel;-;Pt;CSF;-;IF;PANEL.MICRO;1;Mumps virus Ab.IgG and IgM panel - Cerebral spinal fluid by Immunofluorescence;Mumps virus Ab.IgG & IgM panel CSF IF;;ACTIVE;2.64;2.65 +88459-3;Serotonin release 1.0 IU/mL heparin.low molecular weight;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 1.0 IU/mL heparin.low molecular weight [Units/volume] in Serum;SRA 1.0 IU/mL LMW heparin Ser-aCnc;;ACTIVE;2.64;2.64 +88460-1;Serotonin release 50 IU/mL heparin.low molecular weight;ACnc;Pt;Ser;Qn;;SERO;1;Serotonin release 50 IU/mL heparin.low molecular weight [Units/volume] in Serum;SRA 50 IU/mL LMW heparin Ser-aCnc;;ACTIVE;2.64;2.64 +88461-9;Babesia microti & divergens+MO-1 strain & duncani 18S rRNA gene panel;-;Pt;Bld;-;Non-probe.amp.tar;PANEL.MICRO;1;Babesia microti and B. divergens+MO-1 and B. duncani 18S rRNA gene panel - Blood by NAA with non-probe detection;Babesia sp 18S rRNA Pnl Bld NAA+non-pr;;ACTIVE;2.64;2.64 +88462-7;Carbapenem;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Carbapenem [Susceptibility];Carbapenem Susc Islt;;ACTIVE;2.64;2.66 +88463-5;OASIS E - Skin Conditions - SOC, ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Skin Conditions - SOC, ROC [CMS Assessment];;;ACTIVE;2.64;2.72 +88464-3;OASIS D - Integumentary status - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Integumentary status - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +88465-0;Types and sources of assistance - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Types and sources of assistance - start of care or resumption of care [CMS Assessment];;;ACTIVE;2.64;2.67 +88466-8;Care management - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Care management - start of care or resumption of care [CMS Assessment];;;DEPRECATED;2.64;2.7 +88467-6;Care management - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Care management - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +8846-8;Oxygen saturation;MFr;Pt;Heart.ventricle.right.outflow tract;Qn;;HEMODYN.MOLEC;2;Right ventricular outflow tract Oxygen saturation;SaO2 % RVOT;;ACTIVE;1.0h(3);2.4 +88468-4;Types and sources of assistance - discarge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Types and sources of assistance - discarge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +88469-2;How much has your chest pain, chest tightness or angina limited your enjoyment of life over the past 4W;Find;4W;^Patient;Ord;SAQ;SURVEY.GNHLTH;4;How much has your chest pain, chest tightness or angina limited your enjoyment of life over the past 4 weeks [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +884-7;ABO & Rh group;Type;Pt;BldC;Nom;;BLDBK;1;ABO and Rh group [Type] in Capillary blood;ABO + Rh BldC;;ACTIVE;1.0;2.72 +88470-0;Quality of life score;Score;Pt;^Patient;Qn;SAQ;SURVEY.GNHLTH;4;Quality of life score [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +88471-8;Symptom frequency score;Score;Pt;^Patient;Qn;SAQ;SURVEY.GNHLTH;4;Symptom frequency score [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +88472-6;Physical limitation score;Score;Pt;^Patient;Qn;SAQ;SURVEY.GNHLTH;4;Physical limitation score [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +88473-4;If you had to spend the rest of your life with your chest pain, chest tightness or angina the way it is right now, how would you feel about this;Find;Pt;^Patient;Ord;SAQ;SURVEY.GNHLTH;4;If you had to spend the rest of your life with your chest pain, chest tightness or angina the way it is right now, how would you feel about this [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +88474-2;Overall summary score;Score;Pt;^Patient;Qn;SAQ;SURVEY.GNHLTH;4;Overall summary score [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +88475-9;How many times have you had to take nitroglycerin (nitroglycerin tablets or spray) for your chest pain, chest tightness or angina on average over the past 4W;Find;4W;^Patient;Ord;SAQ;SURVEY.GNHLTH;4;How many times have you had to take nitroglycerin (nitroglycerin tablets or spray) for your chest pain, chest tightness or angina over the past 4 weeks [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.65 +8847-6;Oxygen saturation;MFr;Pt;Heart.ventricle.right;Qn;;HEMODYN.MOLEC;2;Right ventricular Oxygen saturation;SaO2 % RV;;ACTIVE;1.0h(3);2.4 +88476-7;How many times have you had chest pain, chest tightness or angina on average over the past 4W;Find;4W;^Patient;Ord;SAQ;SURVEY.GNHLTH;4;How many times have you had chest pain, chest tightness or angina over the past 4 weeks [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +88477-5;Lifting or moving heavy objects limited by chest pain, chest tightness or angina over the past 4W;Find;4W;^Patient;Ord;SAQ;SURVEY.GNHLTH;4;Lifting or moving heavy objects limited by chest pain, chest tightness or angina over the past 4 weeks [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.65 +88478-3;Gardening, vacuuming, or carrying groceries limited by chest pain, chest tightness or angina over the past 4W;Find;4W;^Patient;Ord;SAQ;SURVEY.GNHLTH;4;Gardening, vacuuming, or carrying groceries limited by chest pain, chest tightness or angina over the past 4 weeks [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.65 +88479-1;Seattle Angina Questionnaire - 7 items;-;Pt;^Patient;-;SAQ;PANEL.SURVEY.GNHLTH;4;Seattle Angina Questionnaire - 7 items [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.67 +88480-9;Walking indoors on level ground limited by chest pain, chest tightness or angina over the past 4W;Find;4W;^Patient;Ord;SAQ;SURVEY.GNHLTH;4;Walking indoors on level ground limited by chest pain, chest tightness or angina over the past 4 weeks [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.65 +88481-7;Activity limitations panel;-;-;^Patient;-;SAQ;PANEL.SURVEY.GNHLTH;4;Activity limitations panel [SAQ];;Copyright © 1995-2005 John Spertus, MD, MPH. Used with permission.;ACTIVE;2.64;2.64 +88482-5;Functional abilities and goals - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional abilities and goals - admission [CMS Assessment];;;ACTIVE;2.64;2.67 +88483-3;Functional abilities and goals - discharge;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional abilities and goals - discharge [CMS Assessment];;;ACTIVE;2.64;2.67 +8848-4;Oxygen saturation;MFr;Pt;Coronary sinus;Qn;;HEMODYN.MOLEC;2;Coronary sinus Oxygen saturation;SaO2 % CS;;ACTIVE;1.0h(3);2.4 +88484-1;OASIS D - Functional abilities and goals - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Functional abilities and goals - follow-up [CMS Assessment];;;ACTIVE;2.64;2.67 +88485-8;OASIS D - Self-care - follow-up performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Self-care - follow-up performance during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88486-6;OASIS D - Mobility - follow-up performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Mobility - follow-up performance during assessment period [CMS Assessment];;;ACTIVE;2.64;2.72 +88487-4;OASIS D - Patient history and diagnoses - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Patient history and diagnoses - SOC or ROC [CMS Assessment];;;ACTIVE;2.64;2.67 +88488-2;OASIS E - Diagnoses and symptom control;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Diagnoses and symptom control [CMS Assessment];;;ACTIVE;2.64;2.72 +88489-0;OASIS E - Primary diagnosis;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Primary diagnosis [CMS Assessment];;;ACTIVE;2.64;2.72 +88490-8;OASIS E - Other diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Other diagnoses [CMS Assessment];;;ACTIVE;2.64;2.72 +88491-6;OASIS D - Patient history and diagnoses - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Patient history and diagnoses - follow-up [CMS Assessment];;;ACTIVE;2.64;2.64 +8849-2;Oxygen saturation;MFr;Pt;Ductus arteriosus;Qn;;HEMODYN.MOLEC;2;Ductus arteriosus Oxygen saturation;SaO2 % DA;;ACTIVE;1.0h(3);2.4 +88492-4;OASIS D - Sensory status - start of care or resumption of care or follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Sensory status - SOC or ROC or follow-up [CMS Assessment];;;ACTIVE;2.64;2.67 +88493-2;OASIS D - Integumentary status - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated OASIS D - Integumentary status - SOC or ROC [CMS Assessment];;;DEPRECATED;2.64;2.72 +88494-0;OASIS E - Current number of unhealed pressure injuries at each stage - SOC, ROC, FU;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Current number of unhealed pressure injuries at each stage - SOC, ROC, FU [CMS Assessment];;;ACTIVE;2.64;2.72 +88495-7;OASIS D - Respiratory status - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Respiratory status - SOC or ROC [CMS Assessment];;;ACTIVE;2.64;2.67 +88496-5;OASIS E - Bladder and Bowel - SOC, ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Bladder and Bowel - SOC, ROC [CMS Assessment];;;ACTIVE;2.64;2.72 +88497-3;OASIS E - Bladder and Bowel - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Elimination status - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.72 +88498-1;OASIS D - Neuro & emotional & behavioral status - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Neuro and emotional and behavioral status - SOC or ROC [CMS Assessment];;;ACTIVE;2.64;2.67 +88499-9;OASIS D - ADL and IADLs - start of care or resumption of care;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - ADL and IADLs - SOC or ROC during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88-5;Cefmetazole;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefmetazole [Susceptibility] by Minimum inhibitory concentration (MIC);Cefmetazole Islt MIC;;ACTIVE;1.0;2.19 +8850-0;Oxygen saturation;MFr;Pt;Vena cava.inferior;Qn;;HEMODYN.MOLEC;2;Inferior vena cava Oxygen saturation;SaO2 % IVC;;ACTIVE;1.0h(3);2.4 +88500-4;OASIS D - ADL and IADLs - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - ADL and IADLs - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +88501-2;OASIS D - Medications - start of care or resumption of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Medications - start of care or resumption of care [CMS Assessment];;;ACTIVE;2.64;2.72 +88502-0;OASIS E - Preferences for Customary Routine Activities - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Preferences for Customary Routine Activities - DC [CMS Assessment];;;ACTIVE;2.64;2.72 +88503-8;OASIS D - Therapy need and plan of care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Therapy need and plan of care [CMS Assessment];;;ACTIVE;2.64;2.67 +88504-6;OASIS D - Data items collected at inpatient facility admission or agency discharge only - transfer;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Data items collected at inpatient facility admission or agency discharge only - transfer [CMS Assessment];;;ACTIVE;2.64;2.67 +88505-3;OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency - death at home;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency - death at home [CMS Assessment];;;ACTIVE;2.64;2.67 +88506-1;OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +88507-9;OASIS D - Sensory status - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Sensory status - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +88508-7;OASIS D - Current number of unhealed pressure injuries at each stage - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Current number of unhealed pressure injuries at each stage - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +88509-5;Helicobacter pylori 23S rRNA clarithromycin resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Helicobacter pylori 23S rRNA clarithromycin resistance mutation [Identifier] by Molecular method;H pylori 23S clarithro res mut Islt/Spm;;ACTIVE;2.64;2.65 +88510-3;Natural killer cell cytotoxicity.30:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.30:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.30:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.64;2.64 +88511-1;Natural killer cell cytotoxicity.0.9:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.0.9:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.0.9:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.64;2.64 +88512-9;Natural killer cell cytotoxicity.15:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.15:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.15:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.64;2.7 +88513-7;Natural killer cell cytotoxicity.7.5:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.7.5:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.7.5:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.64;2.7 +88514-5;Natural killer cell cytotoxicity.1.88:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.1.88:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.1.88:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.64;2.7 +88515-2;Natural killer cell cytotoxicity.3.75:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.3.75:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cytotox.3.75:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.64;2.7 +88516-0;Gastrointestinal pathogens identified;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Gastrointestinal pathogens identified in Specimen by NAA with probe detection;GI pathogens Spec NAA+probe;;ACTIVE;2.64;2.69 +88517-8;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells^^corrected for background;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] corrected for background in Blood;M TB IFN-g CD4+CD8+ bckgrnd cor Bld-aCnc;;ACTIVE;2.64;2.73 +8851-8;Oxygen saturation;MFr;Pt;Pulmonary artery.left;Qn;;HEMODYN.MOLEC;2;Left pulmonary artery Oxygen saturation;SaO2 % PA-L;;ACTIVE;1.0h(3);2.54 +88518-6;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood;M TBIFN-g CD4+ CD8+T-cells Bld-aCnc;;ACTIVE;2.64;2.64 +88519-4;KIT gene.c.2447A>T;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;KIT gene c.2447A>T [Presence] in Blood or Tissue by Molecular genetics method;KIT c.2447A>T Bld/T Ql;;ACTIVE;2.64;2.73 +88520-2;OASIS D - Medications - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D - Medications - discharge from agency [CMS Assessment];;;ACTIVE;2.64;2.67 +88521-0;IRF-PAI v2.0 - Staff assessment for mental status;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0 - Staff assessment for mental status [CMS Assessment];;;ACTIVE;2.64;2.69 +88522-8;IRF-PAI v2.0 - Hearing, speech, and vision - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0 - Hearing, speech, and vision - admission [CMS Assessment];;;ACTIVE;2.64;2.69 +88523-6;IRF-PAI v2.0 - Quality indicators - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0 - Quality indicators - admission [CMS Assessment];;;ACTIVE;2.64;2.69 +88524-4;IRF-PAI v2.0 - Cognitive patterns - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0 - Cognitive patterns - admission [CMS Assessment];;;ACTIVE;2.64;2.69 +88525-1;IRF-PAI v2.0 - Quality indicators - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0 - Quality indicators - discharge [CMS Assessment];;;ACTIVE;2.64;2.64 +8852-6;Oxygen saturation;MFr;Pt;Pulmonary artery.main;Qn;;HEMODYN.MOLEC;2;Main pulmonary artery Oxygen saturation;SaO2 % MPA;;ACTIVE;1.0h(3);2.4 +88526-9;Guidance for percutaneous biopsy;Find;Pt;Chest>Lung.right;Doc;CT;RAD;2;CT Guidance for biopsy of Lung - right;CT Guided Lung-R Bx;;ACTIVE;2.64;2.64 +88527-7;Respiratory syncytial virus;PrThr;Pt;Cornea/Conjunctiva;Ord;Organism specific culture;MICRO;1;Respiratory syncytial virus [Presence] in Cornea or Conjunctiva by Organism specific culture;RSV Corn/Cnjt Ql Cult;;ACTIVE;2.64;2.72 +88528-5;Respiratory syncytial virus RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;RSV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88529-3;Parainfluenza virus RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HPIV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88530-1;Parainfluenza virus 4 RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HPIV4 RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88531-9;Parainfluenza virus identified;Prid;Pt;Cornea/Conjunctiva;Nom;Organism specific culture;MICRO;1;Parainfluenza virus identified in Cornea or Conjunctiva by Organism specific culture;HPIV Corn/Cnjt Cult;;ACTIVE;2.64;2.64 +88532-7;Human metapneumovirus Identified;Prid;Pt;Cornea/Conjunctiva;Nom;Organism specific culture;MICRO;1;Human metapneumovirus identified in Cornea or Conjunctiva by Organism specific culture;hMPV Corn/Cnjt Cult;;ACTIVE;2.64;2.64 +88533-5;Adenovirus DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HAdV DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +8853-4;Oxygen saturation;MFr;Pt;Pulmonary artery.right;Qn;;HEMODYN.MOLEC;2;Right pulmonary artery Oxygen saturation;SaO2 % PA-R;;ACTIVE;1.0h(3);2.54 +88534-3;Human metapneumovirus RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;hMPV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88535-0;Cytomegalovirus DNA;PrThr;Pt;Bld.dot;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in DBS by NAA with probe detection;CMV DNA DBS Ql NAA+probe;;ACTIVE;2.64;2.64 +88536-8;Varicella zoster virus DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Aspirate by NAA with probe detection;VZV DNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88537-6;Enterovirus identified;Prid;Pt;Pericard fld;Nom;Organism specific culture;MICRO;1;Enterovirus identified in Pericardial fluid by Organism specific culture;EV Pcar Cult;;ACTIVE;2.64;2.64 +88538-4;Enterovirus RNA;PrThr;Pt;Pericard fld;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Pericardial fluid by NAA with probe detection;EV RNA Pcar Ql NAA+probe;;ACTIVE;2.64;2.64 +88539-2;Adenovirus DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Stool by NAA with probe detection;HAdV DNA Stl Ql NAA+probe;;ACTIVE;2.64;2.64 +885-4;Am Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Am Ab [Presence] in Serum or Plasma from Blood product unit;Am Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +88540-0;Enterovirus RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Aspirate by NAA with probe detection;EV RNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88541-8;Adenovirus DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Aspirate by NAA with probe detection;HAdV DNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +8854-2;Oxygen saturation;MFr;Pt;Pulmonary wedge;Qn;;HEMODYN.MOLEC;2;Pulmonary wedge Oxygen saturation;SaO2 % PW;;ACTIVE;1.0h(3);2.4 +88542-6;HIV 1 RNA integrase gene mutations detected;Prid;Pt;CSF;Nom;Sequencing;ABXBACT;1;HIV 1 RNA integrase gene mutations detected [Identifier] in Cerebral spinal fluid by Sequencing;HIV 1 RNA IN Mut Det CSF Seq;;ACTIVE;2.64;2.64 +88543-4;HIV 1 RNA protease gene mutations detected;Prid;Pt;CSF;Nom;Sequencing;ABXBACT;1;HIV 1 RNA protease gene mutations detected [Identifier] in Cerebral spinal fluid by Sequencing;HIV 1 RNA PR Mut Det CSF Seq;;ACTIVE;2.64;2.64 +88544-2;HIV 1 RNA reverse transcriptase gene mutations detected;Prid;Pt;CSF;Nom;Sequencing;ABXBACT;1;HIV 1 RNA reverse transcriptase gene mutations detected [Identifier] in Cerebral spinal fluid by Sequencing;HIV 1 RNA RT Mut Det CSF Seq;;ACTIVE;2.64;2.64 +88545-9;Cytomegalovirus DNA;NCnc;Pt;Bld.dot;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in DBS by NAA with probe detection;CMV DNA # DBS NAA+probe;;ACTIVE;2.64;2.64 +88546-7;Chlamydophila pneumoniae DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Aspirate by NAA with probe detection;C pneum DNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88547-5;Chlamydophila pneumoniae DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with probe detection;C pneum DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88548-3;Scedosporium apiospermum DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Scedosporium apiospermum DNA [Presence] in Tissue by NAA with probe detection;S apiospermum DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88549-1;Scedosporium apiospermum DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Scedosporium apiospermum DNA [Presence] in Isolate by NAA with probe detection;S apiospermum DNA Islt Ql NAA+probe;;ACTIVE;2.64;2.64 +88550-9;Scedosporium apiospermum DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Scedosporium apiospermum DNA [Presence] in Lower respiratory specimen by NAA with probe detection;S apiospermum DNA Low Resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88551-7;Scedosporium apiospermum DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Scedosporium apiospermum DNA [Presence] in Aspirate by NAA with probe detection;S apiospermum DNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88552-5;Scedosporium prolificans DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Scedosporium prolificans DNA [Presence] in Specimen by NAA with probe detection;S prolificans DNA Spec Ql NAA+probe;;ACTIVE;2.64;2.69 +88553-3;Scedosporium prolificans DNA;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Scedosporium prolificans DNA [Presence] in Isolate by NAA with probe detection;S prolificans DNA Islt Ql NAA+probe;;ACTIVE;2.64;2.64 +88554-1;Scedosporium prolificans DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Scedosporium prolificans DNA [Presence] in Tissue by NAA with probe detection;S prolificans DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88555-8;Galactomannan Ag;PrThr;Pt;BAL;Ord;;MICRO;1;Galactomannan Ag [Presence] in Bronchoalveolar lavage;Galactomannan Ag BAL Ql;;ACTIVE;2.64;2.73 +88556-6;Scedosporium prolificans DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Scedosporium prolificans DNA [Presence] in Lower respiratory specimen by NAA with probe detection;S prolificans DNA Low Resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88557-4;Scedosporium apiospermum DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Scedosporium apiospermum DNA [Presence] in Specimen by NAA with probe detection;S apiospermum DNA Spec Ql NAA+probe;;ACTIVE;2.64;2.69 +88558-2;Cytomegalovirus DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Lower respiratory specimen by NAA with probe detection;CMV DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +8855-9;Oxygen saturation;MFr;Pt;Vena cava.superior;Qn;;HEMODYN.MOLEC;2;Superior vena cava Oxygen saturation;SaO2 % SVC;;ACTIVE;1.0h(3);2.4 +88559-0;Parainfluenza virus 2 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HPIV2 RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88560-8;Parainfluenza virus 3 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HPIV3 RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88561-6;Parainfluenza virus 4 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HPIV4 RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88562-4;Parainfluenza virus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HPIV RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88563-2;Parainfluenza virus 1 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HPIV1 RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88564-0;Cytomegalovirus;PrThr;Pt;Bone mar;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Bone marrow by Organism specific culture;CMV Mar Ql Cult;;ACTIVE;2.64;2.65 +88565-7;Varicella zoster virus DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Lower respiratory specimen by NAA with probe detection;VZV DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88566-5;Cytomegalovirus Ag;PrThr;Pt;Bone mar;Ord;IF;MICRO;1;Cytomegalovirus Ag [Presence] in Bone marrow by Immunofluorescence;CMV Ag Mar Ql IF;;ACTIVE;2.64;2.65 +8856-7;Measurement site;Anat;Pt;Oxygen saturation device;Nom;;DEVICES;2;Oxygen saturation device measurement site;SaO2% Device measurement site;;ACTIVE;1.0h(3);2.32 +88567-3;Cytomegalovirus DNA;PrThr;Pt;Bone mar;Ord;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Presence] in Bone marrow by NAA with probe detection;CMV DNA Mar Ql NAA+probe;;ACTIVE;2.64;2.65 +88568-1;Influenza virus identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Influenza virus identified in Lower respiratory specimen by Organism specific culture;FLUV Lower resp Cult;;ACTIVE;2.64;2.64 +88569-9;Ocular pathogens panel;-;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;PANEL.MICRO;1;Ocular pathogens panel - Cornea or Conjunctiva Qualitative by NAA with probe detection;Ocular pathogens pnl Corn/Cnjt NAA+probe;;ACTIVE;2.64;2.64 +88570-7;Acanthamoeba sp DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Acanthamoeba sp DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Acanthamoeba DNA CSF Ql NAA+probe;;ACTIVE;2.64;2.64 +88571-5;Fetal monosomy X risk;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH;1;Fetal Monosomy X risk [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet Ms X risk Plas.cfDNA Ql;;ACTIVE;2.64;2.66 +88572-3;Fetal 22q11.2 deletion risk;Imp;Pt;Plas.cfDNA;Ord;Dosage of chromosome specific cf DNA;MOLPATH.DELDUP;1;Fetal 22q11.2 deletion risk [Interpretation] based on Plasma cell-free DNA by Dosage of chromosome-specific cfDNA Qualitative;Fet 22q11.2 del risk Plas.cfDNA Ql;;ACTIVE;2.64;2.66 +88573-1;Onchocerca sp Ab.IgG2;PrThr;Pt;Ser;Ord;IA;MICRO;1;Onchocerca sp IgG2 Ab [Presence] in Serum by Immunoassay;Onchocerca IgG2 Ser Ql IA;;ACTIVE;2.64;2.64 +88574-9;Onchocerca sp Ab.IgG3;PrThr;Pt;Ser;Ord;IA;MICRO;1;Onchocerca sp IgG3 Ab [Presence] in Serum by Immunoassay;Onchocerca IgG3 Ser Ql IA;;ACTIVE;2.64;2.64 +8857-5;Hemodynamic shunt method;Type;Pt;^Patient;Nom;*;HEMODYN.ATOM;2;Hemodynamic shunt method;Hemodynamic shunt method;;ACTIVE;1.0h(3);2.27 +88575-6;Onchocerca sp Ab.IgG4;PrThr;Pt;Ser;Ord;IA;MICRO;1;Onchocerca sp IgG4 Ab [Presence] in Serum by Immunoassay;Onchocerca IgG4 Ser Ql IA;;ACTIVE;2.64;2.64 +88576-4;Bordetella holmesii hIS1001 DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Bordetella holmesii hIS1001 DNA [Presence] in Nasopharynx by NAA with probe detection;B holm hIS1001 DNA Nph Ql NAA+probe;;ACTIVE;2.64;2.64 +88577-2;Legionella pneumophila DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Legionella pneumophila DNA [Presence] in Tissue by NAA with probe detection;L pneumo DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88578-0;Clostridium botulinum toxin;Prid;Pt;Stool;Nom;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin [Identifier] in Stool by Mouse bioassay neutralization;C bot Tox Stl MA Nt;;ACTIVE;2.64;2.64 +88579-8;Mycoplasma pneumoniae DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with probe detection;M pneumo DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88580-6;Burkholderia sp identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Burkholderia sp identified in Lower respiratory specimen by Organism specific culture;Burkholderia Lower resp Cult;;ACTIVE;2.64;2.64 +88581-4;Borrelia sp DNA;Prid;Pt;CSF;Nom;Probe.amp.tar;MICRO;1;Borrelia sp DNA [Identifier] in Cerebral spinal fluid by NAA with probe detection;Borrelia DNA CSF NAA+probe;;ACTIVE;2.64;2.64 +88582-2;Bordetella sp identified;Prid;Pt;Nph;Nom;Organism specific culture;MICRO;1;Bordetella sp identified in Nasopharynx by Organism specific culture;Bordetella Nph Cult;;ACTIVE;2.64;2.64 +8858-3;Shunt intrapulmonary;VRat;Pt;Pulmonary vasculature;Qn;;HEMODYN.MOLEC;2;Pulmonary vascular Intrapulmonary shunt;PV Intrapulmonary shunt;;ACTIVE;1.0h(3);2.48 +88583-0;Bordetella sp DNA;Prid;Pt;Nph;Nom;Probe.amp.tar;MICRO;1;Bordetella sp DNA [Identifier] in Nasopharynx by NAA with probe detection;Bordetella DNA Nph NAA+probe;;ACTIVE;2.64;2.64 +88584-8;Corynebacterium diphtheriae;PrThr;Pt;Respiratory.upper;Ord;Organism specific culture;MICRO;1;Corynebacterium diphtheriae [Presence] in Upper respiratory specimen by Organism specific culture;C diphtheriae Upper resp Ql Cult;;ACTIVE;2.64;2.68 +88585-5;Legionella sp identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Legionella sp identified in Lower respiratory specimen by Organism specific culture;Legionella Lower resp Cult;;ACTIVE;2.64;2.73 +88586-3;Shigella sp identified;Prid;Pt;Stool;Nom;Organism specific culture;MICRO;1;Shigella sp identified in Stool by Organism specific culture;Shigella Stl Cult;;ACTIVE;2.64;2.64 +88587-1;Legionella sp DNA;Prid;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;Legionella sp DNA [Identifier] in Tissue by NAA with probe detection;Legionella DNA Tiss NAA+probe;;ACTIVE;2.64;2.64 +88588-9;Legionella sp DNA;Prid;Pt;Respiratory.lower;Nom;Probe.amp.tar;MICRO;1;Legionella sp DNA [Identifier] in Lower respiratory specimen by NAA with probe detection;Legionella DNA Lower resp NAA+probe;;ACTIVE;2.64;2.64 +88589-7;Clostridium botulinum toxin;Prid;Pt;Ser;Nom;Mouse bioassay.neutralization;MICRO;1;Clostridium botulinum toxin [Identifier] in Serum by Mouse bioassay neutralization;C bot Tox Ser MA Nt;;ACTIVE;2.64;2.64 +88590-5;Legionella pneumophila DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Legionella pneumophila DNA [Presence] in Lower respiratory specimen by NAA with probe detection;L pneumo DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +8859-1;Shunt left-right intracardiac;VRat;Pt;Heart;Qn;;HEMODYN.MOLEC;2;Intracardiac shunt left-right;Intracardiac Shunt L-R;;ACTIVE;1.0h(3);2.48 +88591-3;Scedosporium prolificans DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Scedosporium prolificans DNA [Presence] in Aspirate by NAA with probe detection;S prolificans DNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88592-1;Influenza virus B RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Lower respiratory specimen by NAA with probe detection;FLUBV RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88593-9;Human bocavirus DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human bocavirus DNA [Presence] in Lower respiratory specimen by NAA with probe detection;HBoV DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88594-7;Human coronavirus HKU1 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HCoV HKU1 RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88595-4;Respiratory syncytial virus A RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus A RNA [Presence] in Lower respiratory specimen by NAA with probe detection;RSV A RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88596-2;Influenza virus B RNA;PrThr;Pt;Pericard fld;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Pericardial fluid by NAA with probe detection;FLUBV RNA Pcar Ql NAA+probe;;ACTIVE;2.64;2.64 +88597-0;Respiratory syncytial virus B RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus B RNA [Presence] in Lower respiratory specimen by NAA with probe detection;RSV B RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88598-8;Toscana virus RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Toscana virus RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;TOSV RNA CSF Ql NAA+probe;;ACTIVE;2.64;2.64 +88599-6;Influenza virus A RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Lower respiratory specimen by NAA with probe detection;FLUAV RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88600-2;Influenza virus A RNA;PrThr;Pt;Pericard fld;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Pericardial fluid by NAA with probe detection;FLUAV RNA Pcar Ql NAA+probe;;ACTIVE;2.64;2.64 +88601-0;Influenza virus A & B RNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus types A and B panel - Lower respiratory specimen by NAA with probe detection;FLUAV + FLUBV Pnl Lower resp NAA+probe;;ACTIVE;2.64;2.64 +88602-8;Adenovirus Ag;PrThr;Pt;Nph;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Nasopharynx by Immunoassay;HAdV Ag Nph Ql IA;;ACTIVE;2.64;2.64 +88603-6;Adenovirus Ag;PrThr;Pt;Respiratory.lower;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Lower respiratory specimen by Immunoassay;HAdV Ag Lower resp Ql IA;;ACTIVE;2.64;2.64 +88604-4;Human coronavirus HKU1 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HCoV HKU1 RNA Upper resp Ql NAA+probe;;ACTIVE;2.64;2.68 +88605-1;Human coronavirus OC43 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HCoV OC43 RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88606-9;Herpes simplex virus identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Lower respiratory specimen by Organism specific culture;HSV Lower resp Cult;;ACTIVE;2.64;2.64 +88607-7;Human coronavirus 229E RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Aspirate by NAA with probe detection;HCoV 229E RNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88608-5;Human coronavirus 229E RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HCoV 229E RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +8860-9;Shunt right-left intracardiac;VRat;Pt;Heart;Qn;;HEMODYN.MOLEC;2;Intracardiac shunt right-left;Intracardiac shunt R-L;;ACTIVE;1.0h(3);2.48 +88609-3;Human coronavirus 229E RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HCoV 229E RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88610-1;Human coronavirus 229E RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HCoV 229E RNA Upper resp Ql NAA+probe;;ACTIVE;2.64;2.68 +88611-9;Human coronavirus HKU1 RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Aspirate by NAA with probe detection;HCoV HKU1 RNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88612-7;Human coronavirus HKU1 RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HCoV HKU1 RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88613-5;Human bocavirus DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human bocavirus DNA [Presence] in Upper respiratory specimen by NAA with probe detection;HBoV DNA Upper resp Ql NAA+probe;;ACTIVE;2.64;2.68 +88614-3;Human coronavirus RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Human coronavirus RNA [Presence] in Aspirate by NAA with probe detection;HCoV RNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88615-0;Human coronavirus NL63 RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Aspirate by NAA with probe detection;HCoV NL63 RNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +88616-8;Human coronavirus NL63 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HCoV NL63 RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +8861-7;Work/Heart rate;Enrg;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventriclar Stroke work;LV Stroke work;;ACTIVE;1.0h(3);2.66 +88617-6;Human coronavirus NL63 RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HCoV NL63 RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88618-4;Human coronavirus NL63 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HCoV NL63 RNA Upper resp Ql NAA+probe;;ACTIVE;2.64;2.68 +88619-2;Human coronavirus OC43 RNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Aspirate by NAA with probe detection;HCoV OC43 RNA Aspirate Ql NAA+probe;;ACTIVE;2.64;2.64 +886-2;Am Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Am Ab [Presence] in Serum or Plasma from Donor;Am Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +88620-0;Human coronavirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human coronavirus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HCoV RNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88621-8;Human coronavirus OC43 RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HCoV OC43 RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88622-6;Cytomegalovirus;PrThr;Pt;Ocular fld;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Ocular fluid by Shell vial culture;CMV Ocflu Ql Shell Vial Cult;;ACTIVE;2.64;2.64 +88623-4;Cytomegalovirus;PrThr;Pt;CSF;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Cerebral spinal fluid by Organism specific culture;CMV CSF Ql Cult;;ACTIVE;2.64;2.64 +88624-2;Cytomegalovirus;PrThr;Pt;Amnio fld;Ord;Shell vial culture;MICRO;1;Cytomegalovirus [Presence] in Amniotic fluid by Shell vial culture;CMV Amn Ql Shell Vial Cult;;ACTIVE;2.64;2.64 +8862-5;Work/Heart rate;Enrg;Pt;Heart.ventricle.right;Qn;;HEMODYN.MOLEC;2;Right ventricular Stroke work;RV Stroke work;;ACTIVE;1.0h(3);2.29 +88625-9;Cytomegalovirus;PrThr;Pt;Ocular fld;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Ocular fluid by Organism specific culture;CMV Ocflu Ql Cult;;ACTIVE;2.64;2.64 +88626-7;Human coronavirus OC43 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HCoV OC43 RNA Upper resp Ql NAA+probe;;ACTIVE;2.64;2.68 +88627-5;Human coronavirus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human coronavirus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HCoV RNA Upper resp Ql NAA+probe;;ACTIVE;2.64;2.68 +88628-3;Human coronavirus RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Human coronavirus RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;HCoV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +88629-1;Chikungunya virus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Chikungunya virus IgM Ab [Presence] in Serum or Plasma by Immunoassay;CHIKV IgM SerPl Ql IA;;ACTIVE;2.64;2.72 +88630-9;Chikungunya virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Chikungunya virus IgG Ab [Presence] in Serum or Plasma by Immunoassay;CHIKV IgG SerPl Ql IA;;ACTIVE;2.64;2.72 +88631-7;Microscopic observation;PrThr;Pt;Respiratory.lower;Ord;Acid fast stain.Kinyoun;MICRO;1;Microscopic observation [Presence] in Lower respiratory specimen by Acid fast stain.Kinyoun;Acid fast Kiny Stn Lower resp Ql;;ACTIVE;2.64;2.64 +88632-5;Microscopic observation;Prid;Pt;Respiratory.lower;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Lower respiratory specimen by Gram stain;Gram Stn Lower resp;;ACTIVE;2.64;2.64 +8863-3;Work/Heart rate/Body surface area;ArEnrg;Pt;Heart.ventricle.left;Qn;;HEMODYN.MOLEC;2;Left ventricular stroke work index;LV Stroke work index;;ACTIVE;1.0h(3);2.66 +88633-3;Microscopic observation;Prid;Pt;Respiratory.lower;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Lower respiratory specimen by Giemsa stain;Gie Stn Lower resp;;ACTIVE;2.64;2.64 +88634-1;Microscopic observation;Prid;Pt;Saliva;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Saliva (oral fluid) by Gram stain;Gram Stn Sal;;ACTIVE;2.64;2.64 +88635-8;Microscopic observation;Prid;Pt;Vomitus;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Vomitus by Gram stain;Gram Stn Vom;;ACTIVE;2.64;2.64 +88636-6;Known exposure;Prid;Pt;^Patient;Nom;;H&P.HX;2;Known exposure [Identifier];Known exposure;;ACTIVE;2.64;2.73 +88637-4;Agreement;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Agreement;Nurse Agreement;;ACTIVE;2.64;2.64 +88638-2;Agreement;Find;Pt;Long term care facility;Doc;Nurse;DOC.ONTOLOGY;2;Nurse Long term care facility Agreement;Nurse LTC fac Agreement;;ACTIVE;2.64;2.64 +88639-0;Controlled substance agreement;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Controlled substance agreement;Pain medicine Cntrl Substance Agreement;;ACTIVE;2.64;2.67 +88640-8;Consultation note;Find;Pt;Adult day care center;Doc;Community health care;DOC.ONTOLOGY;2;Community health care Adult day care center Consult note;Comm hlth care ADCC Consult note;;ACTIVE;2.64;2.64 +8864-1;Work/Heart rate/Body surface area;ArEnrg;Pt;Heart.ventricle.right;Qn;;HEMODYN.MOLEC;2;Right ventricular Stroke work index;RV Stroke work index;;ACTIVE;1.0h(3);2.66 +88641-6;Discharge summary note;Find;Pt;Adult day care center;Doc;Community health care;DOC.ONTOLOGY;2;Community health care Adult day care center Discharge summary;Comm hlth care ADCC D/C sum;;ACTIVE;2.64;2.73 +88642-4;Note;Find;Pt;Adult day care center;Doc;Community health care;DOC.ONTOLOGY;2;Community health care Adult day care center Note;Comm hlth care ADCC Note;;ACTIVE;2.64;2.64 +88643-2;Note;Find;Pt;Adult day care center;Doc;Community health care.nurse;DOC.ONTOLOGY;2;Community health care Nurse Adult day care center Note;CHC Nurse ADCC Note;;ACTIVE;2.64;2.64 +88644-0;Consultation note;Find;Pt;Outpatient hospital;Doc;{Role};DOC.ONTOLOGY;2;Outpatient hospital Consult note;Outpt Hosp Consult note;;ACTIVE;2.64;2.64 +88645-7;Discharge summary note;Find;Pt;Outpatient hospital;Doc;{Role};DOC.ONTOLOGY;2;Outpatient hospital Discharge summary;Outpt Hosp D/C sum;;ACTIVE;2.64;2.73 +88646-5;Note;Find;Pt;Outpatient hospital;Doc;{Role};DOC.ONTOLOGY;2;Outpatient hospital Note;Outpt Hosp Note;;ACTIVE;2.64;2.64 +88647-3;Parenteral therapy note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Parenteral therapy note;ED Parentrl thrpy note;;ACTIVE;2.64;2.64 +88648-1;Parenteral therapy note;Find;Pt;{Setting};Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Parenteral therapy note;HemOnc Parentrl thrpy note;;ACTIVE;2.64;2.64 +88649-9;Parenteral therapy note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Parenteral therapy note;Internal Med Parentrl thrpy note;;ACTIVE;2.64;2.64 +88650-7;Parenteral therapy note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Parenteral therapy note;Nurse Parentrl thrpy note;;ACTIVE;2.64;2.64 +88651-5;Parenteral therapy note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Parenteral therapy note;Parentrl thrpy note;;ACTIVE;2.64;2.64 +88652-3;Parenteral therapy note;Find;Pt;{Setting};Doc;Surgery;DOC.ONTOLOGY;2;Surgery Parenteral therapy note;Surgery Parentrl thrpy note;;ACTIVE;2.64;2.64 +88653-1;Acute heart failure within 24H prior to procedure;Hx;24H;^Patient;Ord;;H&P.HX;2;Acute heart failure within 24 hours prior to procedure;AHF 24 hours prior to proc;;ACTIVE;2.64;2.64 +88654-9;Coronary artery bypass graft surgery;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Coronary artery bypass graft surgery;Hx of CABG;;ACTIVE;2.64;2.64 +88655-6;Hyperlipidemia;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Hyperlipidemia;Hx of Hyperlipidemia;;ACTIVE;2.64;2.64 +88656-4;Percutaneous coronary intervention;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Percutaneous coronary intervention;Hx of PCI;;ACTIVE;2.64;2.64 +88657-2;Time elapsed since stroke;Find;Pt;^Patient;Ord;;TRAUMA;2;Time elapsed since stroke;Time elapsed since stroke;;ACTIVE;2.64;2.7 +8865-8;Arterial pulse intensity;Type;Pt;XXX;Nom;Palpation;HRTRATE.ATOM;2;Pulse intensity by palpation;Pulse intensity Type Palpation;;ACTIVE;1.0h(3);2.38 +88658-0;Use of supplemental oxygen;Find;Pt;^Patient;Nom;;PULM;2;Use of supplemental oxygen;Use of suppl O2;;ACTIVE;2.64;2.7 +88659-8;Timing of thrombolytic administration in relation to cardiac arrest;Find;Pt;^Patient;Nom;;MEDS;2;Timing of thrombolytic administration in relation to cardiac arrest;Thrombolysis therapy timing;;ACTIVE;2.64;2.7 +88660-6;Needle gauge;Len;Pt;Intravascular tube;Qn;;IO.TUBE;2;Needle gauge [Length] Intravascular tube;Needle gauge IV tube;;ACTIVE;2.64;2.7 +88661-4;Number of unsuccessful attempts;Num;Pt;^Patient;Qn;;TRAUMA;2;Number of unsuccessful attempts;Unsuccessful attempts;;ACTIVE;2.64;2.7 +88662-2;Defibrillator type;Type;Pt;{Device};Nom;;DEVICES;2;Defibrillator type;Defibrillator type;;ACTIVE;2.64;2.7 +88663-0;Person who performed defibrillation;Type;Pt;^Patient;Nom;;CARD.PROC;2;Type of person who performed defibrillation;Type person perform defibrillation;;ACTIVE;2.64;2.72 +88664-8;Mode of defibrillation;Type;Pt;{Device};Nom;;DEVICES;2;Mode of defibrillation;Mode of defibrillation;;ACTIVE;2.64;2.7 +88665-5;Time of return of spontaneous circulation;ClockTime;Pt;^Patient;Qn;;CARD.PROC;2;Time of return of spontaneous circulation;Time of ROSC Clock time;;ACTIVE;2.64;2.7 +8866-6;Arterial pulse quality;Type;Pt;XXX;Nom;Palpation;HRTRATE.ATOM;2;Arterial pulse quality by palpation;Arterial pulse quality Type Palpation;;ACTIVE;1.0h(3);2.73 +88666-3;Number of defibrillation shocks given;Num;Pt;^Patient;Qn;;CARD.PROC;2;Number of defibrillation shocks given;Num defib shocks Gvn;;ACTIVE;2.64;2.7 +88667-1;Defibrillation dose.max;Enrg;Pt;Dose;Qn;;CARD.PROC;2;Maximum defibrillation dose [Energy];Max defibrillation dose;;ACTIVE;2.64;2.7 +88668-9;Prehospital therapeutic hypothermia method;Type;Pt;^Patient;Nom;*;TRAUMA;2;Prehospital therapeutic hypothermia method;Prehosp TH method;;ACTIVE;2.64;2.7 +88669-7;CPR guidance provided by dispatch prior to EMS arrival;PrThr;Pt;^Patient;Ord;;TRAUMA;2;CPR guidance provided by dispatch prior to EMS arrival;CPR guid prior EMS arrival;;ACTIVE;2.64;2.7 +88670-5;Return of spontaneous circulation;Find;Pt;^Patient;Nom;;CARD.PROC;2;Return of spontaneous circulation;Return of circulation;;ACTIVE;2.64;2.7 +88671-3;Position &or immobilizer used during EMS transport;Find;Pt;^Patient;Nom;;TRAUMA;2;Position AndOr immobilizer used during EMS transport;Position &or immobilizer used;;ACTIVE;2.64;2.7 +88672-1;Warming method;Type;Pt;^Patient;Nom;*;TRAUMA;2;Warming method;Warming method;;ACTIVE;2.64;2.7 +88673-9;Handover;Type;Pt;^Patient;Nom;;TRAUMA;2;Handover;Handover;;ACTIVE;2.64;2.7 +8867-4;Heart rate;NRat;Pt;XXX;Qn;;HRTRATE.ATOM;2;Heart rate;Heart rate;;ACTIVE;1.0h(3);2.73 +88674-7;Factors related to rescue;Find;Pt;^Patient;Nom;;TRAUMA;2;Factors related to rescue;Factors related to rescue;;ACTIVE;2.64;2.7 +88675-4;EMS physician responsible for management at scene;Pn;Pt;Provider;Nom;;TRAUMA;2;EMS physician responsible for management at scene;Lead EMS MD at scene;;ACTIVE;2.64;2.7 +88676-2;Wound coverage status;Find;Pt;^Patient;Nom;;TRAUMA;2;Wound coverage status;Wound coverage status;;ACTIVE;2.64;2.7 +88677-0;German Interdisciplinary Association of Intensive Care and Emergency Care Medicine - recommended MIND protocol set;-;Pt;{Setting};-;;PANEL.TRAUMA;2;German Interdisciplinary Association of Intensive Care and Emergency Care Medicine - recommended MIND protocol set;DIVI - recommended MIND set;;ACTIVE;2.64;2.7 +88678-8;Herpes simplex virus 1 Ag;PrThr;Pt;Cornea/Conjunctiva;Ord;IF;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Cornea or Conjunctiva by Immunofluorescence;HSV1 Ag Corn/Cnjt Ql IF;;ACTIVE;2.64;2.64 +88679-6;Herpes simplex virus 2 Ag;PrThr;Pt;Cornea/Conjunctiva;Ord;IF;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Cornea or Conjunctiva by Immunofluorescence;HSV2 Ag Corn/Cnjt Ql IF;;ACTIVE;2.64;2.64 +88680-4;Herpes simplex virus Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;HSV Ag CSF Ql IF;;ACTIVE;2.64;2.64 +88681-2;Herpes simplex virus Ag;PrThr;Pt;Cornea/Conjunctiva;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Cornea or Conjunctiva by Immunofluorescence;HSV Ag Corn/Cnjt Ql IF;;ACTIVE;2.64;2.64 +88682-0;Leishmania sp Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Leishmania sp IgM Ab [Titer] in Serum by Immunofluorescence;Leishmania IgM Titr Ser IF;;ACTIVE;2.64;2.64 +88683-8;Bacteria identified;Prid;Pt;BAL;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Bronchoalveolar lavage by Anaerobe culture;Bacteria BAL Anaerobe Cult;;ACTIVE;2.64;2.73 +88684-6;Microscopic observation;Prid;Pt;Asp;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Aspirate by Giemsa stain;Gie Stn Aspirate;;ACTIVE;2.64;2.64 +88685-3;Microscopic observation;Prid;Pt;Respiratory.lower;Nom;KOH preparation;MICRO;1;Microscopic observation [Identifier] in Lower respiratory specimen by KOH preparation;KOH Prep Lower resp;;ACTIVE;2.64;2.64 +88686-1;Fungus identified;Prid;Pt;BAL;Nom;Culture;MICRO;1;Fungus identified in Bronchoalveolar lavage by Culture;Fungus BAL Cult;;ACTIVE;2.64;2.64 +88687-9;Fungus identified;Prid;Pt;Mouth;Nom;Culture;MICRO;1;Fungus identified in Mouth by Culture;Fungus Mouth Cult;;ACTIVE;2.64;2.64 +88688-7;Pneumocystis jiroveci DNA;NCnc;Pt;Respiratory.lower;Qn;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [#/volume] in Lower respiratory specimen by NAA with probe detection;P jiroveci DNA # Lower resp NAA+probe;;ACTIVE;2.64;2.66 +88689-5;Pneumocystis jiroveci;PrThr;Pt;Respiratory.lower;Ord;Calcofluor white preparation;MICRO;1;Pneumocystis jiroveci [Presence] in Lower respiratory specimen by Calcofluor white;P jiroveci Lower Resp Ql Calco white;;ACTIVE;2.64;2.64 +8869-0;Heart rate;NRat;1H^max;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 1 hour maximum;Heart rate 1h Max;;ACTIVE;1.0h(3);2.42 +88690-3;Pneumocystis jiroveci DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [Presence] in Lower respiratory specimen by NAA with probe detection;P jiroveci DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +88691-1;Pneumocystis jiroveci Ag;PrThr;Pt;BAL;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Bronchoalveolar lavage by Immunofluorescence;P jiroveci Ag BAL Ql IF;;ACTIVE;2.64;2.64 +88692-9;Admission evaluation note;Find;Pt;Patient's home;Doc;Primary care;DOC.ONTOLOGY;2;Primary care Patient's home Admission evaluation note;Primary care Pt's home Admit eval note;;ACTIVE;2.64;2.64 +88693-7;Discharge summary note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Discharge summary;Pt's home D/C sum;;ACTIVE;2.64;2.73 +88694-5;Discharge teaching note;Find;Pt;Patient's home;Doc;{Role};DOC.ONTOLOGY;2;Patient's home Discharge teaching note;Pt's home Discharge teach note;;ACTIVE;2.64;2.64 +88695-2;Used bowel toileting program;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Used bowel toileting program during assessment period [CMS Assessment];;;ACTIVE;2.64;2.7 +88696-0;Ulcers, wounds and skin problems in the last 7D;Find;7D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Ulcers, wounds and skin problems in the last 7 days [CMS Assessment];;;ACTIVE;2.64;2.64 +88697-8;Electrolytes & Osmolality panel;-;Pt;Stool;Qn;;PANEL.CHEM;1;Electrolytes and Osmolality panel - Stool;Electrolytes & Osmolality panel Stl;;ACTIVE;2.64;2.64 +88698-6;Protein fractions panel;-;Pt;Body fld;-;Electrophoresis;PANEL.CHEM;1;Protein electrophoresis panel - Body fluid;Prot Elph Pnl Fld Elph;;ACTIVE;2.64;2.64 +88699-4;Procainamide & N-acetylprocainamide panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Procainamide and N-acetylprocainamide panel - Serum or Plasma;Procainamide & NAPA panel SerPl;;ACTIVE;2.64;2.64 +887-0;Am Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Am Ab [Presence] in Serum or Plasma;Am Ab SerPl Ql;;ACTIVE;1.0;2.56 +88700-0;Babesia microti Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Babesia microti IgG and IgM [Interpretation] in Serum;B microti IgG+IgM Ser-Imp;;ACTIVE;2.64;2.65 +88701-8;Norovirus genogroups I & II RNA panel;-;Pt;Stool;-;Probe.amp.tar;PANEL.MICRO;1;Norovirus genogroups I and II RNA panel - Stool by NAA with probe detection;NV G I & II RNA pnl Stl NAA+probe;;ACTIVE;2.64;2.65 +88702-6;Systemic sclerosis panel;-;Pt;Ser;-;IA;PANEL.SERO;1;Systemic sclerosis panel - Serum by Immunoassay;Systemic sclerosis panel Ser IA;;ACTIVE;2.64;2.65 +88703-4;Bedaquiline;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Bedaquiline [Susceptibility] by Minimum inhibitory concentration (MIC);Bedaquiline Islt MIC;;ACTIVE;2.64;2.64 +88704-2;Bedaquiline;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Bedaquiline [Susceptibility] by Method for Slow-growing mycobacteria;Bedaquiline Islt SlowMyco;;ACTIVE;2.64;2.64 +88705-9;Kanamycin 3.5 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Kanamycin 3.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Kanamycin 3.5 ug/mL Islt SlowMyco;;ACTIVE;2.64;2.64 +88706-7;Linezolid 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Linezolid 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Linezolid 1 ug/mL Islt SlowMyco;;ACTIVE;2.64;2.64 +88707-5;Moxifloxacin 0.25 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Moxifloxacin 0.25 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Moxifloxacin 0.25 ug/mL Islt SlowMyco;;ACTIVE;2.64;2.64 +8870-8;Heart rate;NRat;8H^max;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 8 hour maximum;Heart rate 8h Max;;ACTIVE;1.0h(3);2.42 +88708-3;Dermatophagoides pteronyssinus recombinant (rDer p) 1 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides pteronyssinus recombinant (rDer p) 1 IgE Ab [Units/volume] in Serum;D pteronyss (rDer p) 1 IgE Qn;;ACTIVE;2.64;2.7 +88709-1;Albumin/Globulin;MRto;Pt;Body fld;Qn;Electrophoresis;CHEM;1;Albumin/Globulin [Mass Ratio] in Body fluid by Electrophoresis;Albumin/Glob Fld Elph;;ACTIVE;2.64;2.65 +88710-9;Amylase.pancreatic;CCnc;Pt;Dial fld prt;Qn;;CHEM;1;Amylase.pancreatic [Enzymatic activity/volume] in Peritoneal dialysis fluid;Amylase P DiafP-cCnc;;ACTIVE;2.64;2.68 +88711-7;Beta-2-Microglobulin;MCnc;Pt;Dial fld prt;Qn;;CHEM;1;Beta-2-Microglobulin [Mass/volume] in Peritoneal dialysis fluid;B2 Microglob DiafP-mCnc;;ACTIVE;2.64;2.64 +88712-5;Triacylglycerol lipase;CCnc;Pt;Dial fld prt;Qn;;CHEM;1;Lipase [Enzymatic activity/volume] in Peritoneal dialysis fluid;Lipase DiafP-cCnc;;ACTIVE;2.64;2.68 +88713-3;Phosphate;MCnc;Pt;Stool;Qn;;CHEM;1;Phosphate [Mass/volume] in Stool;Phosphate Stl-mCnc;;ACTIVE;2.64;2.64 +88714-1;Dehydroaripiprazole;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Dehydroaripiprazole [Mass/volume] in Serum or Plasma by Confirmatory method;Dehydroaripiprazole SerPl Cfm-mCnc;;ACTIVE;2.64;2.64 +88715-8;Norquetiapine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Norquetiapine [Mass/volume] in Serum or Plasma by Confirmatory method;Norquetiapine SerPl Cfm-mCnc;;ACTIVE;2.64;2.64 +8871-6;Heart rate;NRat;10H^max;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 10 hour maximum;Heart rate 10h Max;;ACTIVE;1.0h(3);2.42 +88716-6;Adenovirus A+B+C+D+E+F DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Adenovirus A+B+C+D+E+F DNA [Presence] in Nasopharynx by NAA with probe detection;HAdV A+B+C+D+E+F DNA Nph Ql NAA+probe;;ACTIVE;2.64;2.64 +88717-4;Candida sp identified;Prid;Pt;Isolate;Nom;;MICRO;1;Candida sp identified in Isolate;Candida Islt;;ACTIVE;2.64;2.64 +88718-2;Chlamydophila pneumoniae DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Nasopharynx by NAA with probe detection;C pneum DNA Nph Ql NAA+probe;;ACTIVE;2.64;2.64 +88719-0;Human coronavirus 229E+HKU1+NL63+OC43 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E+HKU1+NL63+OC43 RNA [Presence] in Nasopharynx by NAA with probe detection;HCoV 229E+HKU1+NL63+OC43 Nph Ql NAA+Pr;;ACTIVE;2.64;2.64 +88720-8;Mycoplasma pneumoniae DNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Nasopharynx by NAA with probe detection;M pneumo DNA Nph Ql NAA+probe;;ACTIVE;2.64;2.64 +88721-6;Rhinovirus+enterovirus RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus RNA [Presence] in Nasopharynx by NAA with probe detection;RV+EV RNA Nph Ql NAA+probe;;ACTIVE;2.64;2.64 +88722-4;Streptococcus pneumoniae serotype;Type;Pt;Isolate;Nom;;MICRO;1;Streptococcus pneumoniae serotype [Type] in Isolate;S pneum Sertyp Islt;;ACTIVE;2.64;2.64 +88723-2;Asialoganglioside GM1 Ab.IgG+IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Asialoganglioside GM1 IgG+IgM Ab [Units/volume] in Serum by Immunoassay;GM1 Asialo IgG+IgM Ser IA-aCnc;;ACTIVE;2.64;2.73 +8872-4;Heart rate;NRat;12H^max;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 12 hour maximum;Heart rate 12h Max;;ACTIVE;1.0h(3);2.42 +88724-0;Ganglioside GD1a Ab.IgG+IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1a IgG+IgM Ab [Units/volume] in Serum by Immunoassay;GD1a Gangl IgG+IgM Ser IA-aCnc;;ACTIVE;2.64;2.73 +88725-7;MDA5 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;MDA5 Ab [Units/volume] in Serum by Line blot;MDA5 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88726-5;Glial nuclear type 1 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Glial nuclear type 1 Ab [Units/volume] in Serum by Line blot;Glial nuc type 1 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88727-3;Recoverin Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Recoverin Ab [Units/volume] in Serum by Line blot;Recoverin Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.73 +88728-1;Babesia microti Ab.IgG & IgM panel;-;-;Ser;-;IF;PANEL.MICRO;1;Babesia microti IgG and IgM panel - Serum by Immunofluorescence;B microti IgG+IgM Pnl Ser IF;;ACTIVE;2.64;2.64 +88729-9;Ganglioside GQ1b Ab.IgG+IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GQ1b IgG+IgM Ab [Units/volume] in Serum by Immunoassay;GQ1b Gangl IgG+IgM Ser IA-aCnc;;ACTIVE;2.64;2.73 +88730-7;Ganglioside GD1b Ab.IgG+IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1b IgG+IgM Ab [Units/volume] in Serum by Immunoassay;GD1b Gangl IgG+IgM Ser IA-aCnc;;ACTIVE;2.64;2.73 +88731-5;Ganglioside GM2 Ab.IgG+IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Ganglioside GM2 IgG+IgM Ab [Units/volume] in Serum by Immunoassay;GM2 Gangl IgG+IgM Ser IA-aCnc;;ACTIVE;2.64;2.73 +8873-2;Heart rate;NRat;24H^max;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 24 hour maximum;Heart rate 24h Max;;ACTIVE;1.0h(3);2.42 +88732-3;Mi-2 alpha Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Mi-2 alpha Ab [Units/volume] in Serum by Line blot;Mi-2 alpha Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88733-1;Mi-2 beta Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Mi-2 beta Ab [Units/volume] in Serum by Line blot;Mi-2 beta Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88734-9;Purkinje cell cytoplasmic type Tr Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;PCA-Tr Ab [Units/volume] in Serum by Line blot;PCA-Tr Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88735-6;PM-SCL-100 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;PM-SCL-100 Ab [Units/volume] in Serum by Line blot;PM/SCL-100 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88736-4;PM-SCL-75 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;PM-SCL-75 Ab [Units/volume] in Serum by Line blot;PM-SCL75 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88737-2;RNA polymerase III RP11 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;RNA polymerase III RP11 Ab [Units/volume] in Serum by Line blot;RNAp III RP11 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88738-0;RNA polymerase III RP155 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;RNA polymerase III RP155 Ab [Units/volume] in Serum by Line blot;RNAp III RP155 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88739-8;TIF1-gamma Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;TIF1-gamma Ab [Units/volume] in Serum by Line blot;TIF1-gamma Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +8874-0;Heart rate;NRat;1H;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 1 hour;Heart rate 1h;;ACTIVE;1.0h(3);2.42 +88740-6;Titin Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Titin Ab [Units/volume] in Serum by Line blot;Titin Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.73 +88741-4;U1 small nuclear ribonucleoprotein A Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;U1 small nuclear ribonucleoprotein A Ab [Units/volume] in Serum by Line blot;U1 snRNP-A Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88742-2;U1 small nuclear ribonucleoprotein C Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;U1 small nuclear ribonucleoprotein C Ab [Units/volume] in Serum by Line blot;U1 snRNP-C Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88743-0;Zinc finger protein of the cerebellum 4 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Zinc finger protein of the cerebellum 4 Ab [Units/volume] in Serum by Line blot;Zic4 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +88744-8;"inv(2)(p21;p23)(EML4,ALK) fusion transcript";PrThr;Pt;Tiss;Ord;Molgen;MOLPATH;1;"inv(2)(p21;p23)(EML4,ALK) fusion transcript [Presence] in Tissue by Molecular genetics method";inv(2)(EML4,ALK) Tiss Ql;;ACTIVE;2.64;2.72 +88745-5;Coccidioides immitis Ab.IgG & IgM panel;-;Pt;CSF;-;;PANEL.MICRO;1;Coccidioides immitis IgG and IgM panel - Cerebral spinal fluid;C immitis IgG + IgM Pnl CSF;;ACTIVE;2.64;2.68 +88746-3;Toxoplasma gondii Ab.IgG & IgM panel;-;Pt;Ser/Plas;-;IA;PANEL.MICRO;1;Toxoplasma gondii IgG and IgM panel - Serum or Plasma by Immunoassay;T gondii IgG+IgM pnl SerPl IA;;ACTIVE;2.64;2.65 +88747-1;Degree of difficulty experienced due to your hip while walking on uneven surface during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while walking on uneven surface during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88748-9;Degree of difficulty experienced due to your hip while twisting or pivoting on loaded leg during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while twisting or pivoting on loaded leg during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88749-7;Degree of difficulty experienced due to your hip while running during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while running during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88750-5;Degree of difficulty experienced due to your hip while squatting during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while squatting during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88751-3;How severe is your hip stiffness after sitting, lying or resting later in the day during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;How severe is your hip stiffness after sitting, lying or resting later in the day during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88752-1;How severe is your hip joint stiffness after first wakening in the morning during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;How severe is your hip joint stiffness after first wakening in the morning during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88753-9;Difficulties to stride out when walking during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Difficulties to stride out when walking during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88754-7;Difficulties spreading legs wide apart during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Difficulties spreading legs wide apart during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88755-4;Do you feel grinding, hear clicking or any other type of noise from your hip during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Do you feel grinding, hear clicking or any other type of noise from your hip during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88756-2;In general, how much difficulty do you have with your hip;Find;Pt;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;In general, how much difficulty do you have with your hip [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8875-7;Heart rate;NRat;8H;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 8 hour;Heart rate 8h;;ACTIVE;1.0h(3);2.42 +88757-0;How much are you troubled with lack of confidence in your hip;Find;Pt;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;How much are you troubled with lack of confidence in your hip [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88758-8;Have you modified your life style to avoid activities potentially damaging to your hip;Find;Pt;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Have you modified your life style to avoid activities potentially damaging to your hip [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88759-6;How often are you aware of your hip problem;Find;Pt;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;How often are you aware of your hip problem [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88760-4;Amount of hip pain experienced while walking of a hard surface (asphalt, concrete, etc.) in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while walking of a hard surface (asphalt, concrete, etc.) in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88761-2;Amount of hip pain experienced while standing upgright in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while standing upgright in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88762-0;Degree of difficulty experienced due to your hip while sitting or lying during the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while sitting or lying during the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.72 +88763-8;Amount of hip pain experienced at night while in bed in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while at night while in bed in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88764-6;Amount of hip pain experienced while walking on flat surface in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while walking on flat surface in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8876-5;Heart rate;NRat;10H;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 10 hour;Heart rate 10h;;ACTIVE;1.0h(3);2.42 +88765-3;Amount of hip pain experienced while bending your hip fully in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while bending your hip fully in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88766-1;Amount of hip pain experienced while straightening your hip fully in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Amount of hip pain experienced while straightening your hip fully in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88767-9;How often is your hip painful;Find;Pt;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;How often is your hip painful [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88768-7;Degree of difficulty experienced due to your hip while putting on socks or stockings in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while putting on socks or stockings in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88769-5;Degree of difficulty experienced due to your hip while going shopping in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while going shopping in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88770-3;Degree of difficulty experienced due to your hip while getting in or out of car in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while getting in or out of car in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88771-1;Degree of difficulty experienced due to your hip while walking on a flat surface in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while walking on a flat surface in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88772-9;Degree of difficulty experienced due to your hip while standing in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while standing in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8877-3;Heart rate;NRat;12H;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 12 hour;Heart rate 12h;;ACTIVE;1.0h(3);2.42 +88773-7;Degree of difficulty experienced due to your hip while ascending stairs in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while ascending stairs in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88774-5;Degree of difficulty experienced due to your hip while doing light domestic duties (cooking, dusting, etc) in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while doing light domestic duties (cooking, dusting, etc) in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88775-2;Degree of difficulty experienced due to your hip while doing heavy domestic duties (moving heavy boxes, scrubbing floors, etc) in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while doing heavy domestic duties (moving heavy boxes, scrubbing floors, etc) in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88776-0;Degree of difficulty experienced due to your hip while getting on or off toilet in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while getting on or off toilet in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88777-8;Degree of difficulty experienced due to your hip while getting in or out of bath in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while getting in or out of bath in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88778-6;Degree of difficulty experienced due to your hip while taking off socks or stockings in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while taking off socks or stockings in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88779-4;Degree of difficulty experienced due to your hip while rising from bed in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while rising from bed in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88780-2;Degree of difficulty experienced due to your hip while descending stairs in the last W;Find;1W;^Patient;Ord;HOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your hip while descending stairs in the last week [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8878-1;Heart rate;NRat;24H;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 24 hour;Heart rate 24h;;ACTIVE;1.0h(3);2.42 +88781-0;Quality of life panel;-;Pt;^Patient;-;HOOS;PANEL.SURVEY.GNHLTH;4;Quality of life panel [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88782-8;Function, sports and recreational activities panel;-;1W;^Patient;-;HOOS;PANEL.SURVEY.GNHLTH;4;Function, sports and recreational activities panel [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88783-6;Pain panel;-;Pt;^Patient;-;HOOS;PANEL.SURVEY.GNHLTH;4;Pain panel [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88784-4;Function and daily living panel;-;1W;^Patient;-;HOOS;PANEL.SURVEY.GNHLTH;4;Function and daily living panel [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88785-1;Stiffness panel;-;1W;^Patient;-;HOOS;PANEL.SURVEY.GNHLTH;4;Stiffness panel [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88786-9;Symptoms panel;-;1W;^Patient;-;HOOS;PANEL.SURVEY.GNHLTH;4;Symptoms panel [HOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88787-7;Degree of difficulty experienced due to your knee while kneeling during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while kneeling during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88788-5;Degree of difficulty experienced due to your knee while twisting or pivoting on your injured knee during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while twisting or pivoting on your injured knee during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88789-3;Degree of difficulty experienced due to your knee while jumping during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while jumping during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88790-1;Degree of difficulty experienced due to your knee while running during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while running during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88791-9;Degree of difficulty experienced due to your knee while squatting during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while squatting during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88792-7;How severe is your knee stiffness after sitting, lying or resting later in the day during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;How severe is your knee stiffness after sitting, lying or resting later in the day during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88793-5;Can you bend your knee fully during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Can you bend your knee fully during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88794-3;Can you straighten your knee fully during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Can you straighten your knee fully during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88795-0;Does your knee catch or hang up when moving during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Does your knee catch or hang up when moving during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88796-8;Do you feel grinding, hear clicking or any other type of noise when your knee moves during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Do you feel grinding, hear clicking or any other type of noise when your knee moves during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88797-6;Do you have swelling in your knee during the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Do you have swelling in your knee during the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88798-4;In general, how much difficulty do you have with your knee;Find;Pt;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;In general, how much difficulty do you have with your knee? [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8879-9;Heart rate;NRat;1H^min;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 1 hour minimum;Heart rate 1h Min;;ACTIVE;1.0h(3);2.42 +88799-2;How much are you troubled with lack of confidence in your knee;Find;Pt;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;How much are you troubled with lack of confidence in your knee? [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88800-8;Have you modified your life style to avoid activities potentially damaging to your knee;Find;Pt;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Have you modified your life style to avoid activities potentially damaging to your knee? [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88801-6;How often are you aware of your knee problem;Find;Pt;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;How often are you aware of your knee problem? [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88802-4;Amount of knee pain experienced while sitting or lying in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while sitting or lying in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88803-2;Amount of knee pain experienced at night while in bed in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while at night while in bed in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88804-0;Amount of knee pain experienced while walking on flat surface in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while walking on flat surface in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88805-7;Amount of knee pain experienced while bending knee fully in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Amount of knee pain experienced while bending the knee fully in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88806-5;How often do you experience knee pain;Find;Pt;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;How often do you experience knee pain [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8880-7;Heart rate;NRat;8H^min;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 8 hour minimum;Heart rate 8h Min;;ACTIVE;1.0h(3);2.42 +88807-3;Degree of difficulty experienced due to your knee while putting on socks or stockings in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while putting on socks or stockings in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88808-1;Degree of difficulty experienced due to your knee while going shopping in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while going shopping in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88809-9;Degree of difficulty experienced due to your knee while getting in or out of car in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while getting in or out of car in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88810-7;Degree of difficulty experienced due to your knee while walking on a flat surface in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while walking on a flat surface in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88811-5;Degree of difficulty experienced due to your knee while standing in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while standing in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88812-3;Degree of difficulty experienced due to your knee while ascending stairs in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while ascending stairs in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88813-1;Degree of difficulty experienced due to your knee while doing light domestic duties (cooking, dusting, etc) in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while doing light domestic duties (cooking, dusting, etc) in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88814-9;Degree of difficulty experienced due to your knee while doing heavy domestic duties (moving heavy boxes, scrubbing floors, etc) in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while doing heavy domestic duties (moving heavy boxes, scrubbing floors, etc) in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8881-5;Heart rate;NRat;10H^min;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 10 hour minimum;Heart rate 10h Min;;ACTIVE;1.0h(3);2.42 +88815-6;Degree of difficulty experienced due to your knee while getting on or off toilet in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while getting on or off toilet in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88816-4;Degree of difficulty experienced due to your knee while sitting in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while sitting in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88817-2;Degree of difficulty experienced due to your knee while getting in or out of bath in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while getting in or out of bath in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88818-0;Degree of difficulty experienced due to your knee while lying in bed (turning over, maintaining hip position) in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while lying in bed (turning over, maintaining hip position) in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88819-8;Degree of difficulty experienced due to your knee while taking off socks or stockings in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while taking off socks or stockings in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88820-6;Degree of difficulty experienced due to your knee while rising from bed in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while rising from bed in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88821-4;Degree of difficulty experienced due to your knee while descending stairs in the last W;Find;1W;^Patient;Ord;KOOS;SURVEY.GNHLTH;4;Degree of difficulty experienced due to your knee while descending stairs in the last week [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88822-2;Quality of life panel;-;Pt;^Patient;-;KOOS;PANEL.SURVEY.GNHLTH;4;Quality of life panel [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +8882-3;Heart rate;NRat;12H^min;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 12 hour minimum;Heart rate 12h Min;;ACTIVE;1.0h(3);2.42 +88823-0;Function, sports and recreational activities panel;-;1W;^Patient;-;KOOS;PANEL.SURVEY.GNHLTH;4;Function, sports and recreational activities panel [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88824-8;Pain panel;-;Pt;^Patient;-;KOOS;PANEL.SURVEY.GNHLTH;4;Pain panel [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88825-5;Function and daily living panel;-;1W;^Patient;-;KOOS;PANEL.SURVEY.GNHLTH;4;Function and daily living panel [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88826-3;Stiffness panel;-;1W;^Patient;-;KOOS;PANEL.SURVEY.GNHLTH;4;Stiffness panel [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88827-1;Symptoms panel;-;1W;^Patient;-;KOOS;PANEL.SURVEY.GNHLTH;4;Symptoms panel [KOOS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.64;2.64 +88828-9;Renal Impairment subsection;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Renal Impairment subsection;FDA insert Renal Impairment subsection;;ACTIVE;2.64;2.64 +88829-7;Hepatic Impairment subsection;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Hepatic Impairment subsection;FDA insert Hepatic Impairment subsection;;ACTIVE;2.64;2.64 +88830-5;Immunogenicity;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Immunogenicity;FDA insert Immunogenicity;;ACTIVE;2.64;2.64 +8883-1;Heart rate;NRat;24H^min;XXX;Qn;;HRTRATE.TIMED.MOL;2;Heart rate 24 hour minimum;Heart rate 24h Min;;ACTIVE;1.0h(3);2.42 +88831-3;Views^W contrast retrograde intra ureter;Find;Pt;Abdomen>Kidney.right & Abdomen+Pelvis>Ureter;Doc;RF;RAD;2;RF Kidney - right and Ureter Views W contrast retrograde intra ureter;RF Kid-R+Uret Views W contr retro IU;;ACTIVE;2.64;2.64 +88832-1;Views^W contrast retrograde intra ureter;Find;Pt;Abdomen>Kidney.left & Abdomen+Pelvis>Ureter;Doc;RF;RAD;2;RF Kidney - left and Ureter Views W contrast retrograde intra ureter;RF Kid-L+Uret Views W contr retro IU;;ACTIVE;2.64;2.64 +88833-9;Views^W contrast retrograde intra ureter;Find;Pt;Abdomen>Kidney.bilateral & Abdomen+Pelvis>Ureter;Doc;RF;RAD;2;RF Kidney - bilateral and Ureter Views W contrast retrograde intra ureter;RF Kid-Bl+Uret Views W contr retro IU;;ACTIVE;2.64;2.64 +88834-7;Guidance for dilation;Find;Pt;Abdomen>Kidney & Abdomen+Pelvis>Ureter & Pelvis>Urethra;Doc;RF;RAD;2;RF Guidance for dilation of nephrostomy tract, ureter, or urethra;RF Guided Kid+Uret+Urethra Dilation;;ACTIVE;2.64;2.64 +88835-4;Influenza virus A swine origin RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus A swine origin RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUAV swine RNA Ct Spec Qn NAA+probe;;ACTIVE;2.64;2.69 +88836-2;Microbiology CNAMTS panel;-;Pt;Thrt;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Throat;Micro CNAMTS panel Throat;;ACTIVE;2.64;2.64 +88837-0;Microbiology CNAMTS panel;-;Pt;Sputum;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Sputum;Micro CNAMTS panel Spt;;ACTIVE;2.64;2.64 +88838-8;Microbiology CNAMTS panel;-;Pt;Semen;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Semen;Micro CNAMTS panel Smn;;ACTIVE;2.64;2.64 +88839-6;Microbiology CNAMTS panel;-;Pt;Pus;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Pus;Micro CNAMTS panel Pus;;ACTIVE;2.64;2.64 +88840-4;Microbiology CNAMTS panel;-;Pt;Urethra;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Urethra;Micro CNAMTS panel Urth;;ACTIVE;2.64;2.64 +88841-2;Microbiology CNAMTS panel;-;Pt;Synv fld;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Synovial fluid;Micro CNAMTS panel Snv;;ACTIVE;2.64;2.64 +88842-0;Microbiology CNAMTS panel;-;Pt;CSF;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Cerebral spinal fluid;Micro CNAMTS panel CSF;;ACTIVE;2.64;2.64 +88843-8;Metabolic panel.dialysis patient;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Metabolic panel.dialysis patient - Serum or Plasma;Metabolic panel.dialysis patient SerPl;;ACTIVE;2.64;2.72 +88844-6;Microbiology CNAMTS panel;-;Pt;Bronchial;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Bronchial specimen;Micro CNAMTS panel Bronch;;ACTIVE;2.64;2.64 +88845-3;Microbiology CNAMTS panel;-;Pt;XXX;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Specimen;Micro CNAMTS panel Spec;;ACTIVE;2.64;2.69 +88846-1;Urinary cell count CNAMTS panel;-;3H;Urine;-;;PANEL.MICRO;1;Urinary cell count CNAMTS panel - 3 hour Urine;Ur cell cnt CNAMTS panel Ur;;ACTIVE;2.64;2.64 +88847-9;Microbiology CNAMTS panel;-;Pt;Stool;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Stool;Micro CNAMTS panel Stl;;ACTIVE;2.64;2.64 +88848-7;Microbiology CNAMTS panel;-;Pt;Urine;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Urine;Micro CNAMTS panel Ur;;ACTIVE;2.64;2.64 +8884-9;Heart rate rhythm;Type;Pt;XXX;Nom;;HRTRATE.ATOM;2;Heart rate rhythm;Heart rate rhythm;;ACTIVE;1.0h(3);2.73 +88849-5;Microbiology CNAMTS panel;-;Pt;Vag;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Vaginal fluid;Micro CNAMTS panel Vag;;ACTIVE;2.64;2.64 +88850-3;Microbiology CNAMTS panel;-;Pt;Bld;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Blood;Micro CNAMTS panel Bld;;ACTIVE;2.64;2.64 +88851-1;PROMIS cognitive function - abilities subset - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cognitive function - abilities subset - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.64;2.64 +88852-9;PROMIS item bank - applied cognition - abilities subset - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - applied cognition - abilities subset - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.64;2.66 +88853-7;I have been able to remember where I put things, like my keys or my wallet in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to remember where I put things, like my keys or my wallet in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.64;2.65 +88854-5;I have been able to add and subtract numbers in my head without difficulty in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have been able to add and subtract numbers in my head without difficulty in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.64;2.65 +88855-2;Diagnosis to transplant time duration score for risk calculation;Score;Pt;^Patient;Ord;;CLIN.RISK;2;Diagnosis to transplant time duration score for risk calculation;Risk time diag to transpl;;ACTIVE;2.64;2.7 +8885-6;Heart rate measurement site;Anat;Pt;^Patient;Nom;;HRTRATE.ATOM;2;Heart rate measurement site;Heart rate measurement site;;ACTIVE;1.0h(3);2.27 +88856-0;Hematopoietic stem cell transplantation risk score;Score;Pt;^Patient;Ord;EBMT;CLIN.RISK;2;Hematopoietic stem cell transplantation risk score EBMT;HSCT risk score EBMT;;ACTIVE;2.64;2.64 +88857-8;Donor-recipient gender combination score for risk calculation;Score;Pt;^Patient;Ord;;CLIN.RISK;2;Donor-recipient gender combination score for risk calculation;Don-rec gender comb score;;ACTIVE;2.64;2.7 +88858-6;Donor type score for risk calculation;Score;Pt;^Patient;Ord;;CLIN.RISK;2;Donor type score for risk calculation;Donor type risk score;;ACTIVE;2.64;2.7 +88859-4;Disease stage score for risk calculation;Score;Pt;^Patient;Ord;;CLIN.RISK;2;Disease stage score for risk calculation;Disease stage score for risk calculation;;ACTIVE;2.64;2.7 +88860-2;Age score for risk calculation;Score;Pt;^Patient;Ord;;CLIN.RISK;2;Age score for risk calculation;Age score for risk calculation;;ACTIVE;2.64;2.7 +88861-0;Hematopoietic stem cell transplantation risk panel;-;Pt;^Patient;-;EBMT;PANEL.CLIN.RISK;2;Hematopoietic stem cell transplantation risk panel EBMT;HSCT risk panel EBMT;;ACTIVE;2.64;2.64 +88862-8;Hematopoietic stem cell transplantation risk score interpretation;Imp;Pt;^Patient;Ord;EBMT;CLIN.RISK;2;Hematopoietic stem cell transplantation risk score interpretation EBMT;HSCT risk score interp EBMT;;ACTIVE;2.64;2.64 +88863-6;Lung cancer antibody panel;-;Pt;Ser/Plas;-;IA;PANEL.SERO;1;Lung cancer antibody panel - Serum or Plasma by Immunoassay;Lung cancer antibody panel SerPl IA;EarlyCDT® is a registered trademark of Oncimmune. Used with permission.;ACTIVE;2.64;2.64 +8886-4;Heart rate method;Type;Pt;Heart rate measure;Nom;*;HRTRATE.ATOM;2;Heart rate method;Heart rate method;;ACTIVE;1.0h(3);2.27 +88864-4;Microbiology CNAMTS panel;-;Pt;Cornea/Conjunctiva;-;;PANEL.MICRO;1;Microbiology CNAMTS panel - Cornea or Conjunctiva;Micro CNAMTS panel Corn/Cnjt;;ACTIVE;2.64;2.64 +88865-1;Chemical XXX;Prid;Pt;XXX;Nom;;DRUG/TOX;1;Other Chemical [Identifier] in Specimen;Other Chemical Spec;;ACTIVE;2.64;2.69 +88866-9;Chemical XXX;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Other Chemical [Mass/mass] in Specimen;Other Chemical Spec-mCnt;;ACTIVE;2.64;2.69 +88867-7;Chemical XXX;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Other Chemical [Mass/volume] in Specimen;Other Chemical Spec-mCnc;;ACTIVE;2.64;2.69 +88868-5;Veterinary toxicology panel;-;Pt;XXX;Qn;;PANEL.DRUG/TOX;1;Veterinary toxicology quantitative panel - Unspecified specimen;Vet toxic pnl XXX Qn;;ACTIVE;2.64;2.69 +88869-3;Veterinary toxicology panel;PrThr;Pt;XXX;Ord;;PANEL.DRUG/TOX;1;Veterinary toxicology panel [Presence] - Specimen;Vet toxic pnl Spec Ql;;ACTIVE;2.64;2.69 +88870-1;Drug regimen review identified potential medication issues in the last 3D;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Drug regimen review identified potential medication issues in the last 3 days [CMS Assessment];;;ACTIVE;2.64;2.67 +88871-9;Medication follow-up in the last 3D;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication follow-up in the last 3 days [CMS Assessment];;;ACTIVE;2.64;2.64 +8887-2;Class;Type;Pt;Heart rate device;Nom;;DEVICES;2;Type of Heart rate device;Hrt Rate Device Class;;ACTIVE;1.0h(3);2.27 +88872-7;IRF-PAI v2.0 - Medications - admission;-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v2.0 - Medications - admission [CMS Assessment];;;ACTIVE;2.64;2.69 +88873-5;Sympathomimetics;PrThr;Pt;Ser/Plas/Bld;Ord;Confirm;DRUG/TOX;1;Sympathomimetics [Presence] in Serum, Plasma or Blood by Confirmatory method;Sympathomimetics SerPlBld Ql Cfm;;ACTIVE;2.64;2.73 +88874-3;Mycobacterium tuberculosis complex DNA;PrThr;Pt;Isolate/Specimen;Ord;Molgen;MICRO;1;Mycobacterium tuberculosis complex DNA [Presence] in Isolate or Specimen by Molecular genetics method;M TB Cmplx DNA Islt/Spm Ql;;TRIAL;2.64;2.73 +88875-0;Measles virus genotype A vaccine strain N gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MOLPATH;1;Measles virus genotype A vaccine strain N gene [Presence] in Specimen by NAA with probe detection;MeVA vac str N gene Spec Ql NAA+probe;;ACTIVE;2.64;2.69 +88876-8;Measles virus genotype A vaccine strain N gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MOLPATH;1;Measles virus genotype A vaccine strain N gene [Cycle Threshold #] in Specimen by NAA with probe detection;MeVA vac str N gene Ct Spec Qn NAA+probe;;ACTIVE;2.64;2.69 +88877-6;Date vaccination indication effective;Date;Pt;^Patient;Qn;;VACCIN;2;Date vaccination indication effective;Date vaccine ind effective;;ACTIVE;2.64;2.64 +88878-4;Date of condition abatement;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of condition abatement;Date of condition abatement;;ACTIVE;2.64;2.64 +88879-2;Date vaccination indication expires;Date;Pt;^Patient;Qn;;VACCIN;2;Date vaccination indication expires;Date vaccination indication expires;;ACTIVE;2.64;2.64 +888-8;Blood group antibodies identified;Prid;Pt;Ser/Plas;Nom;;BLDBK;1;Blood group antibodies identified in Serum or Plasma;Blood group antibodies SerPl;;ACTIVE;1.0;2.73 +8888-0;Heart rate measure duration;Time;*;Heart study;Qn;;HRTRATE.ATOM;2;Heart rate measure duration;Heart rate measure duration;;ACTIVE;1.0h(3);2.48 +88880-0;Monocyte distribution width;EntVol;Pt;Bld;Qn;Automated;HEM/BC;1;Monocyte distribution width [Entitic volume] in Blood by Automated;MDW Bld Auto;;ACTIVE;2.64;2.64 +88881-8;Smith extractable nuclear D Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Smith extractable nuclear D Ab [Presence] in Serum by Line blot;ENA SM-D Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +88882-6;Smith extractable nuclear B Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Smith extractable nuclear B Ab [Presence] in Serum by Line blot;ENA SM-B Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +88883-4;Connective tissue autoimmune Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Connective tissue autoimmune Ab panel - Serum;Connective tiss Ab Pnl Ser;;ACTIVE;2.64;2.68 +88884-2;Fatty acid omega-3 & omega-6 panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Fatty acid omega-3 and omega-6 panel - Serum or Plasma;FA omega-3 + omega-6 panel SerPl;;ACTIVE;2.64;2.65 +88885-9;Delafloxacin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Delafloxacin [Susceptibility];DLX Susc Islt;;ACTIVE;2.64;2.64 +88886-7;Telavancin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Telavancin [Susceptibility];Telavancin Susc Islt;;ACTIVE;2.64;2.64 +88887-5;Isavuconazole;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Isavuconazole [Susceptibility];Isavuconazole Susc Islt;;ACTIVE;2.64;2.64 +88888-3;Pancreatic stone protein;MCnc;Pt;Ser/Plas/Bld;Qn;IA.rapid;CHEM;1;Pancreatic stone protein [Mass/volume] in Serum, Plasma or Blood by Rapid immunoassay;PSP SerPlBld IA.rapid-mCnc;;ACTIVE;2.64;2.64 +88889-1;Middle east respiratory syndrome coronavirus RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Nasopharynx by NAA with non-probe detection;MERS-CoV RNA Nph Ql NAA+non-probe;;ACTIVE;2.64;2.64 +88890-9;Parainfluenza virus 1+2+3+4 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 1+2+3+4 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HPIV 1+2+3+4 RNA Nph Ql NAA+non-probe;;ACTIVE;2.64;2.64 +88891-7;Human coronavirus 229E+HKU1+NL63+OC43 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus 229E+HKU1+NL63+OC43 RNA [Presence] in Nasopharynx by NAA with non-probe detection;HCoV 229E+HKU1+NL63+OC43 Np Ql NAA+nonpr;;ACTIVE;2.64;2.66 +88892-5;Meropenem+Vaborbactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Meropenem+Vaborbactam [Susceptibility];Mero+Vab Susc Islt;;ACTIVE;2.64;2.64 +88893-3;Coagulation tissue factor induced.PIVKA sensitive;Time;Pt;PPP;Qn;;COAG;1;Prothrombin time (PT) PIVKA sensitive in Platelet poor plasma;PT PIVKA sensitive PPP;;ACTIVE;2.64;2.64 +88894-1;Brivaracetam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Brivaracetam [Mass/volume] in Serum or Plasma;Brivaracetam SerPl-mCnc;;ACTIVE;2.64;2.65 +88895-8;Perampanel;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Perampanel [Mass/volume] - Serum or Plasma;Perampanel SerPl-mCnc;;ACTIVE;2.64;2.65 +88896-6;Reboxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Reboxetine [Mass/volume] in Serum or Plasma;Reboxetine SerPl-mCnc;;ACTIVE;2.64;2.64 +88897-4;Adenovirus Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Adenovirus Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HAdV Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +8889-8;Heart rate;NRat;Pt;Capillary bed;Qn;Pulse oximetry;HRTRATE.MOLEC;2;Heart rate by Pulse oximetry;Heart rate PulseOx;;ACTIVE;1.0h(3);2.7 +88898-2;Adenovirus;PrThr;Pt;Respiratory.lower;Ord;Organism specific culture;MICRO;1;Adenovirus [Presence] in Lower respiratory specimen by Organism specific culture;HAdV Lower resp Ql Cult;;ACTIVE;2.64;2.64 +88899-0;Adenovirus;PrThr;Pt;Cornea/Conjunctiva;Ord;Organism specific culture;MICRO;1;Adenovirus [Presence] in Cornea or Conjunctiva by Organism specific culture;HAdV Corn/Cnjt Ql Cult;;ACTIVE;2.64;2.64 +88900-6;Adenovirus;PrThr;Pt;Respiratory.upper;Ord;Organism specific culture;MICRO;1;Adenovirus [Presence] in Upper respiratory specimen by Organism specific culture;HAdV Upper resp Ql Cult;;ACTIVE;2.64;2.68 +88901-4;Adenovirus;PrThr;Pt;Stool;Ord;Organism specific culture;MICRO;1;Adenovirus [Presence] in Stool by Organism specific culture;HAdV Stl Ql Cult;;ACTIVE;2.64;2.64 +88902-2;Adenovirus;PrThr;Pt;Urine;Ord;Organism specific culture;MICRO;1;Adenovirus [Presence] in Urine by Organism specific culture;HAdV Ur Ql Cult;;ACTIVE;2.64;2.64 +88903-0;Influenza virus B Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Influenza virus B IgG Ab [Presence] in Serum by Immunoassay;FLUBV IgG Ser Ql IA;;ACTIVE;2.64;2.64 +88904-8;Influenza virus A Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Influenza virus A Ag [Presence] in Lower respiratory specimen by Immunofluorescence;FLUAV Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +88905-5;Influenza virus B Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Influenza virus B Ag [Presence] in Lower respiratory specimen by Immunofluorescence;FLUBV Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +8890-6;Heart rate;NRat;Pt;Cardiac apex;Qn;Auscultation;HRTRATE.MOLEC;2;Heart rate Cardiac apex by Auscultation;Heart rate Cardiac Apex Auscultation;;ACTIVE;1.0h(3);2.73 +88906-3;Parainfluenza virus 1 Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Parainfluenza virus 1 Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HPIV1 Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +88907-1;Parainfluenza virus 2 Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Parainfluenza virus 2 Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HPIV2 Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +88908-9;Parainfluenza virus 3 Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Parainfluenza virus 3 Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HPIV3 Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +88909-7;Respiratory syncytial virus Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Respiratory syncytial virus Ag [Presence] in Lower respiratory specimen by Immunofluorescence;RSV Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +88910-5;Taenia sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Taenia sp DNA [Presence] in Specimen by NAA with probe detection;Taenia DNA Spec Ql NAA+probe;;ACTIVE;2.64;2.69 +88911-3;Taenia solium larva DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Taenia solium larva DNA [Presence] in Tissue by NAA with probe detection;T sol lar DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88912-1;Taenia solium larva DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Taenia solium larva DNA [Presence] in Blood by NAA with probe detection;T sol lar DNA Bld Ql NAA+probe;;ACTIVE;2.64;2.64 +88913-9;Strongyloides stercoralis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Strongyloides stercoralis DNA [Presence] in Stool by NAA with probe detection;S stercoralis DNA Stl Ql NAA+probe;;ACTIVE;2.64;2.64 +8891-4;Heart rate;NRat;Pt;Cardiac apex;Qn;Palpation;HRTRATE.MOLEC;2;Heart rate Cardiac apex by palpation;Heart rate Cardiac Apex Palpation;;ACTIVE;1.0h(3);2.42 +88914-7;Acanthamoeba sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Acanthamoeba sp DNA [Presence] in Tissue by NAA with probe detection;Acanthamoeba DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88915-4;Filaria DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Filaria DNA [Presence] in Tissue by NAA with probe detection;Filaria DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88916-2;Leishmania sp DNA;Prid;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;Leishmania sp DNA [Identifier] in Tissue by NAA with probe detection;Leishmania DNA Tiss NAA+probe;;ACTIVE;2.64;2.64 +88917-0;Leishmania sp DNA;Prid;Pt;Bone mar;Nom;Probe.amp.tar;MICRO;1;Leishmania sp DNA [Identifier] in Bone marrow by NAA with probe detection;Leishmania DNA Mar NAA+probe;;ACTIVE;2.64;2.64 +88918-8;Filaria DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Filaria DNA [Presence] in Blood by NAA with probe detection;Filaria DNA Bld Ql NAA+probe;;ACTIVE;2.64;2.64 +88919-6;Taenia solium larva Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Taenia solium larva IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;T sol lar IgG CSF Ql IA;;ACTIVE;2.64;2.64 +88920-4;Taenia solium larva Ag;PrThr;Pt;Ser;Ord;IA;MICRO;1;Taenia solium larva Ag [Presence] in Serum by Immunoassay;T sol lar Ag Ser Ql IA;;ACTIVE;2.64;2.64 +88921-2;Echinococcus granulosus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echinococcus granulosus Ab [Titer] in Serum by Complement fixation;E granulosus Ab Titr Ser CF;;ACTIVE;2.64;2.64 +8892-2;Heart rate;NRat;Pt;Peripheral artery;Qn;US.doppler;HRTRATE.MOLEC;2;Heart rate Peripheral artery by US.doppler;Heart rate Periph a DOP;;ACTIVE;1.0h(3);2.42 +88922-0;Actinomyces sp identified;Prid;Pt;Tiss;Nom;Organism specific culture;MICRO;1;Actinomyces sp identified in Tissue by Organism specific culture;Actinomyces Tiss Cult;;ACTIVE;2.64;2.64 +88923-8;1,3 beta glucan;MCnc;Pt;Respiratory.lower;Qn;;MICRO;1;1,3 beta glucan [Mass/volume] in Lower respiratory specimen;1,3 beta glucan Lower resp-mCnc;;ACTIVE;2.64;2.64 +88924-6;Microsporidia DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Microsporidia DNA [Presence] in Tissue by NAA with probe detection;Microsporid DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88925-3;Microsporidia DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Microsporidia DNA [Presence] in Stool by NAA with probe detection;Microsporid DNA Stl Ql NAA+probe;;ACTIVE;2.64;2.64 +88926-1;Histoplasma capsulatum DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Histoplasma capsulatum DNA [Presence] in Tissue by NAA with probe detection;H capsul DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88927-9;Cryptosporidium sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Cryptosporidium sp DNA [Presence] in Tissue by NAA with probe detection;Cryptosp DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +88928-7;Cryptosporidium sp DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Cryptosporidium sp DNA [Presence] in Stool by NAA with probe detection;Cryptosp DNA Stl Ql NAA+probe;;ACTIVE;2.64;2.64 +88929-5;Guidance additional for percutaneous transluminal angioplasty;Find;Pt;XXX>Vein;Doc;{Imaging modality};RAD;2;Guidance for additional transluminal angioplasty of Vein;Guided Vein PTA addl;;ACTIVE;2.64;2.64 +8893-0;Heart rate;NRat;Pt;Peripheral artery;Qn;Palpation;HRTRATE.MOLEC;2;Heart rate Peripheral artery by palpation;Heart rate Periph a Palpation;;ACTIVE;1.0h(3);2.73 +88930-3;Guidance for dilation of stricture+placement of stent^W contrast IV;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for dilation of stricture and placement of stent of Biliary ducts-- W contrast IV;Guided BD Strict dil+stent plac W con IV;;ACTIVE;2.64;2.64 +88931-1;Guidance for embolization for tumor^W embolic agent IA;Find;Pt;Abdomen>Hepatic artery;Doc;{Imaging modality};RAD;2;Guidance for embolization for tumor of Hepatic artery-- W embolic agent IA;Guided Hep a Tum embol--W emb ag IA;;ACTIVE;2.64;2.64 +88932-9;Guidance for embolization for tumor^W embolic agent IA;Find;Pt;XXX>Spinal artery;Doc;{Imaging modality};RAD;2;Guidance for embolization for tumor of Spinal artery-- W embolic agent IA;Guided Spinal a Tum embol--W emb ag IA;;ACTIVE;2.64;2.64 +88933-7;Guidance for embolization^W embolic agent IV;Find;Pt;Abdomen>Portal vein;Doc;{Imaging modality};RAD;2;Guidance for embolization of Portal vein-- W embolic agent IV;Guided Portal v Embol--W emb ag IV;;ACTIVE;2.64;2.64 +88934-5;Guidance for embolization^W embolic agent IA;Find;Pt;Abdomen>Splenic artery;Doc;{Imaging modality};RAD;2;Guidance for embolization of Splenic artery-- W embolic agent IA;Guided Splenic a Embol--W emb ag IA;;ACTIVE;2.64;2.64 +88935-2;Guidance for chemoembolization for tumor^W chemotherapy IA+W embolic agent IA;Find;Pt;Abdomen>Hepatic artery;Doc;{Imaging modality};RAD;2;Guidance for chemoembolization of Hepatic artery-- W chemotherapy IA+W embolic agent IA;Guided HA Tum CE -w chem+emb ag IA;;ACTIVE;2.64;2.64 +88936-0;Guidance for injection^W Tc-99m MAA IA;Find;Pt;Abdomen>Hepatic artery;Doc;{Imaging modality};RAD;2;Guidance for injection of Hepatic artery-- W Tc-99m MAA IA;Guided Hep a Inj--W Tc-99m MAA IA;;ACTIVE;2.64;2.64 +88937-8;Guidance for placement of stent;Find;Pt;Abdomen>Biliary ducts;Doc;{Imaging modality};RAD;2;Guidance for placement of stent in Biliary ducts;Guided BDs Stent place;;ACTIVE;2.64;2.64 +88938-6;Guidance for placement of stent;Find;Pt;Abdomen+Pelvis>Ureter;Doc;{Imaging modality};RAD;2;Guidance for placement of stent in Ureter;Guided Ureter Stent place;;ACTIVE;2.64;2.64 +88939-4;Guidance for radioembolization for tumor^W Yttrium-90 IA;Find;Pt;Abdomen>Hepatic artery;Doc;{Imaging modality};RAD;2;Guidance for radioembolization for tumor of Hepatic artery-- W Yttrium-90 IA;Guided HA Tum radioemb -W Yttrium-90 IA;;ACTIVE;2.64;2.64 +88940-2;Guidance for repair of aneurysm;Find;Pt;Abdomen>Aorta.abdominal;Doc;{Imaging modality};RAD;2;Guidance for repair of aneurysm of Abdominal Aorta;Guided Abd Aorta Aneurysm repair;;ACTIVE;2.64;2.64 +88941-0;Guidance for repair of aneurysm;Find;Pt;Chest>Aorta.thoracic;Doc;{Imaging modality};RAD;2;Guidance for repair of aneurysm of Thoracic Aorta;Guided TA Aneurysm repair;;ACTIVE;2.64;2.64 +88942-8;Guidance for repair of endoleak;Find;Pt;XXX>Artery;Doc;{Imaging modality};RAD;2;Guidance for repair of endoleak of Artery;Guided Artery Endoleak repair;;ACTIVE;2.64;2.64 +88943-6;Guidance for venous sampling;Find;Pt;Abdomen>Adrenal vein;Doc;{Imaging modality};RAD;2;Guidance for venous sampling of Adrenal vein;Guided Adrenal v Venous sampling;;ACTIVE;2.64;2.64 +88944-4;Views for AV shunt^W Tc-99m MAA+W intraarterial hepatic injection;Find;Pt;Chest>Lung & Abdomen>Liver;Doc;NM;RAD;2;NM Lung and Liver Views for AV shunt W Tc-99m MAA+W intraarterial hepatic injection;NM Lung+Liver Views for AV shunt;;ACTIVE;2.64;2.64 +88945-1;MDS v3.0 - RAI v1.16.1 - Nursing home discharge (ND) & Swing bed discharge (SD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home discharge (ND) and Swing bed discharge (SD) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88946-9;MDS v3.0 - RAI v1.16.1 - Nursing home OMRA start of therapy and discharge (NSD) & Swing bed OMRA start of therapy and discharge (SSD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home OMRA start of therapy and discharge (NSD) and Swing bed OMRA start of therapy and discharge (SSD) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88947-7;MDS v3.0 - RAI v1.16.1 - Nursing home OMRA-discharge (NOD) & Swing bed OMRA-discharge (SOD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home OMRA-discharge (NOD) and Swing bed OMRA-discharge (SOD) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +8894-8;P wave;NRat;Pt;Heart.atria;Qn;EKG;HRTRATE.MOLEC;2;P wave Atrium by EKG;P wave Atrium by EKG;;ACTIVE;1.0h(3);2.73 +88948-5;MDS v3.0 - RAI v1.16.1 - Nursing home part A PPS discharge (NPE) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home part A PPS discharge (NPE) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88949-3;MDS v3.0 - RAI v1.16.1 - Nursing home PPS (NP) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home PPS (NP) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88950-1;MDS v3.0 - RAI v1.16.1 - Swing bed PPS (SP) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Swing bed PPS (SP) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88951-9;MDS v3.0 - RAI v1.16.1 - Nursing home & Swing bed OMRA (NO & SO) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home and Swing bed OMRA (NO and SO) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88952-7;MDS v3.0 - RAI v1.16.1 - Nursing home & Swing bed OMRA start of therapy (NS & SS) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home and Swing bed OMRA start of therapy (NS and SS) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88953-5;MDS v3.0 - RAI v1.16.1 - Nursing home & Swing bed tracking (NT & ST) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home and Swing bed tracking (NT and ST) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88954-3;MDS v3.0 - RAI v1.16.1 - Nursing home comprehensive (NC) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home comprehensive (NC) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +8895-5;P wave;NRat;Pt;Heart.atrium.left;Qn;EKG;HRTRATE.MOLEC;2;P wave Left atrium by EKG;P wave Left atrium by EKG;;ACTIVE;1.0h(3);2.64 +88955-0;MDS v3.0 - RAI v1.16.1 - Nursing home quarterly (NQ) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated MDS v3.0 - RAI v1.16.1 - Nursing home quarterly (NQ) item set [CMS Assessment];;;DEPRECATED;2.64;2.73 +88956-8;Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.16.1;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.16.1 [CMS Assessment];;;DEPRECATED;2.64;2.73 +88957-6;MDS v3.0 - RAI v1.16.1 - Active diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Active diagnoses [CMS Assessment];;;ACTIVE;2.64;2.65 +88958-4;MDS v3.0 - RAI v1.16.1 - Health conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Health conditions [CMS Assessment];;;ACTIVE;2.64;2.65 +88959-2;MDS v3.0 - RAI v1.16.1 - Health conditions - NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Health conditions - NP, NQ, SP [CMS Assessment];;;ACTIVE;2.64;2.65 +889-6;Blood group antibodies identified;Prid;Pt;^BPU;Nom;;BLDBK;1;Blood group antibodies identified in Blood product unit;Blood group antibodies BPU;;ACTIVE;1.0;2.52 +88960-0;MDS v3.0 - RAI v1.17.2 - Skin conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Skin conditions [CMS Assessment];;;ACTIVE;2.64;2.68 +88961-8;MDS v3.0 - RAI v1.17.2 - Current number of unhealed pressure injuries at each stage;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Current number of unhealed pressure injuries at each stage [CMS Assessment];;;ACTIVE;2.64;2.74 +88962-6;MDS v3.0 - RAI v1.17.2 - Medications;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medications [CMS Assessment];;;ACTIVE;2.64;2.68 +8896-3;P wave;NRat;Pt;Heart.atrium.right;Qn;EKG;HRTRATE.MOLEC;2;P wave Right atrium by EKG;P wave Right atrium by EKG;;ACTIVE;1.0h(3);2.64 +88963-4;MDS v3.0 - RAI v1.17.2 - Medications - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medications - ND, SD [CMS Assessment];;;ACTIVE;2.64;2.68 +88964-2;MDS v3.0 - RAI v1.16.1 - Medications - NOD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Medications - NOD, SOD [CMS Assessment];;;ACTIVE;2.64;2.65 +88965-9;MDS v3.0 - RAI v1.17.2 - Medications - NP, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medications - NP, SP [CMS Assessment];;;ACTIVE;2.64;2.68 +88966-7;Hyaline casts;Naric;Pt;Urine sed;Qn;;UA;1;Hyaline casts [#/area] in Urine sediment;Hyaline Casts #/area UrnS;;ACTIVE;2.64;2.64 +88967-5;Leucine crystals;Naric;Pt;Urine sed;Qn;;UA;1;Leucine crystals [#/area] in Urine sediment;Leucine Cry #/area UrnS;;ACTIVE;2.64;2.64 +88968-3;Waxy casts;Naric;Pt;Urine sed;Qn;;UA;1;Waxy casts [#/area] in Urine sediment;Waxy Casts #/area UrnS;;ACTIVE;2.64;2.64 +88969-1;Tyrosine crystals;Naric;Pt;Urine sed;Qn;;UA;1;Tyrosine crystals [#/area] in Urine sediment;Tyrosine Cry #/area UrnS;;ACTIVE;2.64;2.64 +88970-9;Erythrocyte casts;Naric;Pt;Urine sed;Qn;;UA;1;RBC casts [#/area] in Urine sediment;RBC Casts #/area UrnS;;ACTIVE;2.64;2.64 +8897-1;QRS complex;NRat;Pt;Heart.ventricles;Qn;EKG;HRTRATE.MOLEC;2;QRS complex Ventricles by EKG;QRS Complex nRate Hrt ventrs EKG;;ACTIVE;1.0h(3);2.73 +88971-7;Mixed cellular casts;Naric;Pt;Urine sed;Qn;;UA;1;Mixed cellular casts [#/area] in Urine sediment;Mixed Cell Casts #/area UrnS;;ACTIVE;2.64;2.64 +88972-5;Broad casts;Naric;Pt;Urine sed;Qn;;UA;1;Broad casts [#/area] in Urine sediment;Broad Casts #/area UrnS;;ACTIVE;2.64;2.64 +88973-3;Crystals.amorphous;Naric;Pt;Urine sed;Qn;;UA;1;Crystals.amorphous [#/area] in Urine sediment;Amorph Cry #/area UrnS;;ACTIVE;2.64;2.64 +88974-1;Granular casts;Naric;Pt;Urine sed;Qn;;UA;1;Granular casts [#/area] in Urine sediment;Gran Casts #/area UrnS;;ACTIVE;2.64;2.64 +88975-8;Fatty casts;Naric;Pt;Urine sed;Qn;;UA;1;Fatty casts [#/area] in Urine sediment;Fatty Casts #/area UrnS;;ACTIVE;2.64;2.64 +88976-6;Leukocyte casts;Naric;Pt;Urine sed;Qn;;UA;1;WBC casts [#/area] in Urine sediment;WBC Casts #/area UrnS;;ACTIVE;2.64;2.64 +88977-4;Epithelial casts;Naric;Pt;Urine sed;Qn;;UA;1;Epithelial casts [#/area] in Urine sediment;Epith Casts #/area UrnS;;ACTIVE;2.64;2.64 +88978-2;Fat;PrThr;Pt;Urine sed;Ord;;UA;1;Fat [Presence] in Urine sediment;Fat UrnS Ql;;ACTIVE;2.64;2.64 +88979-0;Mucus;PrThr;Pt;Urine sed;Ord;;UA;1;Mucus [Presence] in Urine sediment;Mucous Threads UrnS Ql;;ACTIVE;2.64;2.64 +88980-8;Swollen joint;Num;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Swollen joint #;;;ACTIVE;2.64;2.64 +88981-6;Tender joint;Num;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Tender joint #;;;ACTIVE;2.64;2.64 +88982-4;Rheumatoid arthritis disease activity level;Imp;Pt;^Patient;Ord;CDAI;SURVEY.GNHLTH;4;Rheumatoid arthritis disease activity level [CDAI];;;ACTIVE;2.64;2.65 +88983-2;Tender joint;Anat;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Tender joint;;;ACTIVE;2.64;2.64 +88984-0;Swollen joint;Anat;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Swollen joint;;;ACTIVE;2.64;2.64 +88985-7;Alpha-amanitin+gamma-amanitin;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Alpha-Amanitin + gamma-Amanitin [Mass/volume] in Serum or Plasma;Alpha+gamma-amanitin SerPl-mCnc;;ACTIVE;2.64;2.64 +88986-5;Elvitegravir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Elvitegravir [Mass/volume] in Serum or Plasma;Elvitegravir SerPl-mCnc;;ACTIVE;2.64;2.64 +88987-3;Maraviroc;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Maraviroc [Mass/volume] in Serum or Plasma;Maraviroc SerPl-mCnc;;ACTIVE;2.64;2.64 +88988-1;Melperone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Melperone [Mass/volume] in Serum or Plasma;Melperone SerPl-mCnc;;ACTIVE;2.64;2.65 +8898-9;Arterial pulse intensity;Force;Pt;Brachial artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Brachial artery - left by palpation;Pulse intensity Brach a-L Palpation;;ACTIVE;1.0h(3);2.38 +88989-9;Perazine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Perazine [Mass/volume] in Serum or Plasma;Perazine SerPl-mCnc;;ACTIVE;2.64;2.65 +88990-7;Sertindole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Sertindole [Mass/volume] in Serum or Plasma;Sertindole SerPl-mCnc;;ACTIVE;2.64;2.65 +88991-5;Zotepine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Zotepine [Mass/volume] in Serum or Plasma;Zotepine SerPl-mCnc;;ACTIVE;2.64;2.65 +88992-3;Ustekinumab Ab;MCnc;Pt;Ser/Plas;Qn;IA;DRUG/TOX;1;Ustekinumab Ab [Mass/volume] in Serum or Plasma by Immunoassay;Ustekinumab Ab SerPl IA-mCnc;;ACTIVE;2.64;2.73 +88993-1;Acute kidney injury risk;Likelihood;Pt;^Patient;Qn;Calculated.NephroCheck;CHEM;1;Acute kidney injury risk [Likelihood] by Calculated by NephroCheck;Acute kidney injury risk NephroCheck;;ACTIVE;2.64;2.69 +88994-9;Arachidonate/Fatty acids.C14-C24;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Arachidonate (C20:4w6)/Fatty acids.C14-C24 in Serum or Plasma;AA/Fatty acids.C14-C24 SFr SerPl;;ACTIVE;2.64;2.73 +88995-6;Docosahexaenoate/Fatty acids.C14-C24;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Docosahexaenoate (C22:6w3)/Fatty acids.C14-C24 in Serum or Plasma;DHA/Fatty acids.C14-C24 SFr SerPl;;ACTIVE;2.64;2.73 +88996-4;Eicosapentaenoate/Arachidonate;SRto;Pt;Ser/Plas;Qn;;CHEM;1;Eicosapentaenoate (C20:5w3)/Arachidonate (C20:4w6) [Molar ratio] in Serum or Plasma;EPA/AA SerPl-sRto;;ACTIVE;2.64;2.73 +8899-7;Arterial pulse intensity;Force;Pt;Brachial artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Brachial artery - right by palpation;Pulse intensity Brach a-R Palpation;;ACTIVE;1.0h(3);2.38 +88997-2;Eicosapentaenoate/Fatty acids.C14-C24;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Eicosapentaenoate (C20:5w3)/Fatty acids.C14-C24 in Serum or Plasma;EPA/Fatty acids.C14-C24 SFr SerPl;;ACTIVE;2.64;2.73 +88998-0;Eicosapentaenoate+Docosahexaenoate/Fatty acids.C14-C24;SFr;Pt;Ser/Plas;Qn;;CHEM;1;Omega-3 (EPA+DHA) index in Serum or Plasma;Omega-3 index SFr SerPl;;ACTIVE;2.64;2.73 +88999-8;Eicosapentaenoate+docosahexaenoate/Fatty acids.C14-C24 index risk;Imp;Pt;Ser/Plas;Ord;;CHEM;1;Omega-3 (EPA+DHA) index risk in Serum or Plasma;Omega-3 index risk SFr SerPl;;ACTIVE;2.64;2.73 +89000-4;Ethyl glucuronide;MCnt;Pt;Hair;Qn;Confirm;DRUG/TOX;1;Ethyl glucuronide [Mass/mass] in Hair by Confirmatory method;Ethyl glucuronide Hair Cfm-mCnt;;ACTIVE;2.64;2.65 +89001-2;Cancer-associated gene Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;CAGE Ab [Units/volume] in Serum or Plasma by Immunoassay;CAGE Ab SerPl IA-aCnc;;ACTIVE;2.64;2.73 +89002-0;GBU4-5 Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;GBU4-5 Ab [Units/volume] in Serum or Plasma by Immunoassay;GBU4-5 Ab SerPl IA-aCnc;;ACTIVE;2.64;2.73 +8900-3;Arterial pulse intensity;Force;Pt;Carotid artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Carotid artery - left by palpation;Pulse intensity Carot a-L Palpation;;ACTIVE;1.0h(3);2.38 +89003-8;HuD Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;HuD Ab [Units/volume] in Serum or Plasma by Immunoassay;HuD Ab SerPl IA-aCnc;;ACTIVE;2.64;2.73 +89004-6;Melanoma-associated antigen A4 Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;MAGE A4 Ab [Units/volume] in Serum or Plasma by Immunoassay;MAGE A4 Ab SerPl IA-aCnc;;ACTIVE;2.64;2.73 +89005-3;NY-ESO-1 Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;NY-ESO-1 Ab [Units/volume] in Serum or Plasma by Immunoassay;NY-ESO-1 Ab SerPl IA-aCnc;;ACTIVE;2.64;2.73 +89006-1;p53 Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;p53 Ab [Units/volume] in Serum or Plasma by Immunoassay;p53 Ab SerPl IA-aCnc;;ACTIVE;2.64;2.73 +89007-9;SOX-2 Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;SOX-2 Ab [Units/volume] in Serum or Plasma by Immunoassay;SOX-2 Ab SerPl IA-aCnc;;ACTIVE;2.64;2.73 +89008-7;Station name;ID;Pt;EMS system;Nom;;TRAUMA;2;Station name [Identifier] EMS system;Station name EMS Sys;;ACTIVE;2.64;2.7 +89009-5;Encounter location;Type;Pt;^Patient;Nom;;TRAUMA;2;Encounter location [Type];Encounter location Type;;ACTIVE;2.64;2.7 +89010-3;EMS physician name;Pn;Pt;Provider;Nom;;TRAUMA;2;EMS physician name;EMS MD name;;ACTIVE;2.64;2.7 +8901-1;Arterial pulse intensity;Force;Pt;Carotid artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Carotid artery - right by palpation;Pulse intensity Carot a-R Palpation;;ACTIVE;1.0h(3);2.38 +89011-1;EMS assistant name;Pn;Pt;Provider;Nom;;TRAUMA;2;EMS assistant name;EMS assistant name;;ACTIVE;2.64;2.7 +89012-9;EMS assistant qualification;Type;Pt;Provider;Nom;;TRAUMA;2;EMS assistant qualification;EMS assistant qual;;ACTIVE;2.64;2.7 +89013-7;Certified first responder was on site when EMS unit arrived;Find;Pt;^Patient;Ord;;TRAUMA;2;Certified first responder was on site when EMS unit arrived;Cert first responder on site pre EMS;;ACTIVE;2.64;2.7 +89014-5;Oxygen was used for preoxygenation;Find;Pt;^Patient;Nom;;PULM;2;Oxygen was used for preoxygenation;Oxygen for preoxygenation;;ACTIVE;2.64;2.7 +89015-2;Pure tone threshold audiometry panel;-;Pt;Ear;-;;PANEL.CLIN;2;Pure tone threshold audiometry panel;Pure tone thresh Pnl;;ACTIVE;2.64;2.72 +89016-0;Hearing threshold^1000 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --1000 Hz;Hearing threshold 1000 Hz Ear-L;;ACTIVE;2.64;2.64 +89017-8;Hearing threshold^1000 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --1000 Hz;Hearing threshold 1000 Hz Ear-R;;ACTIVE;2.64;2.64 +89018-6;Hearing threshold^2000 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --2000 Hz;Hearing threshold 2000 Hz Ear-L;;ACTIVE;2.64;2.64 +89019-4;Hearing threshold^2000 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --2000 Hz;Hearing threshold 2000 Hz Ear-R;;ACTIVE;2.64;2.64 +89020-2;Hearing threshold^3000 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --3000 Hz;Hearing threshold 3000 Hz Ear-L;;ACTIVE;2.64;2.64 +89021-0;Hearing threshold^3000 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --3000 Hz;Hearing threshold 3000 Hz Ear-R;;ACTIVE;2.64;2.64 +89022-8;Hearing threshold^4000 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --4000 Hz;Hearing threshold 4000 Hz Ear-L;;ACTIVE;2.64;2.64 +89023-6;Hearing threshold^4000 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --4000 Hz;Hearing threshold 4000 Hz Ear-R;;ACTIVE;2.64;2.64 +89024-4;Hearing threshold^500 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --500 Hz;Hearing threshold 500 Hz Ear-L;;ACTIVE;2.64;2.64 +89025-1;Hearing threshold^500 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --500 Hz;Hearing threshold 500 Hz Ear-R;;ACTIVE;2.64;2.64 +89026-9;Hearing threshold^6000 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --6000 Hz;Hearing threshold 6000 Hz Ear-L;;ACTIVE;2.64;2.64 +89027-7;Hearing threshold^6000 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --6000 Hz;Hearing threshold 6000 Hz Ear-R;;ACTIVE;2.64;2.64 +89028-5;Hearing threshold^8000 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --8000 Hz;Hearing threshold 8000 Hz Ear-L;;ACTIVE;2.64;2.64 +8902-9;Arterial pulse intensity;Force;Pt;Dorsal pedal artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Dorsal pedal artery - left by palpation;Pulse intensity Dors pedal a-L Palpation;;ACTIVE;1.0h(3);2.38 +89029-3;Hearing threshold^8000 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --8000 Hz;Hearing threshold 8000 Hz Ear-R;;ACTIVE;2.64;2.64 +89030-1;Progress note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Progress note;PM+R Prog note;;ACTIVE;2.64;2.73 +89031-9;Consultation note;Find;Pt;Telehealth;Doc;Hematology;DOC.ONTOLOGY;2;Hematology Telehealth Consult note;Hematology Telehealth Consult note;;ACTIVE;2.64;2.64 +89032-7;Consultation note;Find;Pt;Telehealth;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Telehealth Consult note;Nephrology Telehealth Consult note;;ACTIVE;2.64;2.64 +89033-5;Consultation note;Find;Pt;Telehealth;Doc;Urology;DOC.ONTOLOGY;2;Urology Telehealth Consult note;Urology Telehealth Consult note;;ACTIVE;2.64;2.64 +89034-3;Initial evaluation note;Find;Pt;{Setting};Doc;Vascular neurology;DOC.ONTOLOGY;2;Vascular neurology Initial evaluation note;Vasc Neuro Initial eval note;;ACTIVE;2.64;2.64 +89035-0;Note;Find;Pt;{Setting};Doc;Sleep medicine.physician;DOC.ONTOLOGY;2;Sleep medicine Physician Note;Sleep medicine MD Note;;ACTIVE;2.64;2.64 +89036-8;Note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Note;Trauma Note;;ACTIVE;2.64;2.64 +8903-7;Arterial pulse intensity;Force;Pt;Dorsal pedal artery;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Dorsal pedal artery by palpation;Pulse intensity Dors pedal a Palpation;;ACTIVE;1.0h(3);2.38 +89037-6;CDKN2A gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;CDKN2A gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;CDKN2A Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.64;2.65 +89038-4;CHEK2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;CHEK2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;CHEK2 Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.64;2.65 +89039-2;MSH2 gene deletion+duplication & full mutation analysis & EPCAM gene exons 8 & 9 deletion+duplication;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;MSH2 gene deletion+duplication and full mutation analysis and EPCAM gene exons 8 and 9 deletion and duplication mutation analysis in Blood or Tissue by Molecular genetics method;MSH2 DelDup+Full EPCAM 8+9 DelDup Bld/T;;ACTIVE;2.64;2.65 +890-4;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma;Bld gp Ab Scn SerPl Ql;;ACTIVE;1.0;2.73 +89040-0;Rubella virus Ab;PrThr;Pt;Ser;Ord;IF;MICRO;1;Rubella virus Ab [Presence] in Serum by Immunofluorescence;RUBV Ab Ser Ql IF;;ACTIVE;2.64;2.64 +89041-8;Lung cancer antibody;Imp;Pt;Ser/Plas;Nom;IA;SERO;1;Lung cancer antibody [Interpretation] in Serum or Plasma by Immunoassay;Lung cancer antibody SerPl IA-Imp;EarlyCDT® is a registered trademark of Oncimmune. Used with permission.;ACTIVE;2.64;2.73 +89042-6;Eszopiclone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Eszopiclone [Mass/volume] in Urine;Eszopiclone Ur-mCnc;;ACTIVE;2.64;2.73 +89043-4;Zopiclone-N-oxide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Zopiclone-N-oxide [Mass/volume] in Urine;Zopiclone-N-oxide Ur-mCnc;;ACTIVE;2.64;2.73 +89044-2;Basic metabolic & albumin panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Basic metabolic and albumin panel - Serum or Plasma;Basic metabolic & albumin panel SerPl;;ACTIVE;2.64;2.68 +8904-5;Arterial pulse intensity;Force;Pt;Femoral artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Femoral artery - left by palpation;Pulse intensity Fem a-L Palpation;;ACTIVE;1.0h(3);2.73 +89045-9;Indicate the patient's primary medical condition category;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Indicate the patient's primary medical condition category [CMS Assessment];;;ACTIVE;2.64;2.65 +89046-7;MDS v3.0 - RAI v1.17.2 - Skin conditions - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Skin conditions - ND, SD [CMS Assessment];;;ACTIVE;2.64;2.68 +89047-5;MDS v3.0 - RAI v1.16.1 - Skin conditions - NOD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Skin conditions - NOD, SOD [CMS Assessment];;;ACTIVE;2.64;2.65 +89048-3;MDS v3.0 - RAI v1.16.1 - Bladder and bowel - NC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Bladder and bowel - NC [CMS Assessment];;;ACTIVE;2.64;2.7 +89049-1;MDS v3.0 - RAI v1.16.1 - Bladder and bowel - NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Bladder and bowel - NP, NQ, SP [CMS Assessment];;;ACTIVE;2.64;2.7 +89050-9;MDS v3.0 - RAI v1.15.1, v1.16.1 - Bladder and bowel - NS, NO, SS, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.15.1, v1.16.1 - Bladder and bowel - NS, NO, SS, SO [CMS Assessment];;;ACTIVE;2.64;2.64 +89051-7;MDS v3.0 - RAI v1.17.2 - Skin conditions - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Skin conditions - IPA [CMS Assessment];;;ACTIVE;2.64;2.68 +8905-2;Arterial pulse intensity;Force;Pt;Femoral artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Femoral artery - right by palpation;Pulse intensity Fem a-R Palpation;;ACTIVE;1.0h(3);2.38 +89052-5;MDS v3.00 - RAI v1.15.1 - Skin conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.00 - RAI v1.15.1 - Skin conditions [CMS Assessment];;;ACTIVE;2.64;2.64 +89053-3;MDS v3.0 - RAI v1.15.1 - Skin conditions - NOD, SOD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.15.1 - Skin conditions - NOD, SOD [CMS Assessment];;;ACTIVE;2.64;2.64 +89054-1;Circulatory assistive device(s) used^preoperative;Prid;Pt;^Patient;Nom;;CARD.PROC;2;Circulatory assistive device(s) used [Identifier] --preoperative;Circ assist devices used Preop;;ACTIVE;2.64;2.64 +89055-8;Circulatory assistive device(s) used^postoperative;Prid;Pt;^Patient;Nom;;CARD.PROC;2;Circulatory assistive device(s) used [Identifier] --postoperative;Circ assist devices used Postop;;ACTIVE;2.64;2.64 +89056-6;Circulatory assistive device(s) used^during surgery;Prid;Pt;^Patient;Nom;;CARD.PROC;2;Circulatory assistive device(s) used [Identifier] --during surgery;Circ assist devices used in Surg;;ACTIVE;2.64;2.64 +89057-4;Permission to receive text messages;Find;Pt;^Patient;Ord;;ADMIN.PATIENT;2;Permission to receive text messages;Permission text messages;;ACTIVE;2.64;2.71 +89058-2;Email address;EmailAddr;Pt;^Contact;Nom;;ADMIN;2;Contact email address;Contact email address;;ACTIVE;2.64;2.71 +89059-0;Secondary contact name;Pn;Pt;^Contact;Nom;;ADMIN;2;Secondary contact name;Secondary contact name;;ACTIVE;2.64;2.71 +8906-0;Arterial pulse intensity;Force;Pt;Popliteal artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Popliteal artery - left by palpation;Pulse intensity Popliteal a-L Palpation;;ACTIVE;1.0h(3);2.38 +89060-8;Phone number;Tele;Pt;^Contact;Nom;;ADMIN;2;Contact Phone number;Contact Phone #;;ACTIVE;2.64;2.66 +89061-6;Insurance group number;ID;Pt;^Patient;Nom;;ADMIN.PATIENT.ID;2;Insurance group number [Identifier];Ins group num;;ACTIVE;2.64;2.71 +89062-4;Severe bleeding related to aspirin use;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Severe bleeding related to aspirin use;Hx of Severe bleeding due to aspirin use;;ACTIVE;2.64;2.71 +89063-2;Type of anticoagulant medication used;Type;Pt;^Patient;Nom;;H&P.HX;2;Type of anticoagulant medication used;Anticoagulant med used;;ACTIVE;2.64;2.71 +89064-0;Type of medication used for stomach upset;Type;Pt;^Patient;Nom;;H&P.HX;2;Type of medication used for stomach upset;Stomach upset meds;;ACTIVE;2.64;2.71 +89065-7;Type of nonsteroidal anti-inflammatory drugs (NSAIDs) used several times a week;Type;Pt;^Patient;Nom;;H&P.HX;2;Type of nonsteroidal anti-inflammatory drugs (NSAIDs) used several times a week;NSAID used several times a week;;ACTIVE;2.64;2.71 +89066-5;Year aspirin regimen began;Date;Pt;^Patient;Qn;;H&P.HX;2;Year aspirin regimen began [Date];Year aspirin regimen began;;ACTIVE;2.64;2.71 +89067-3;Type of blood thinning medication used;Type;Pt;^Patient;Nom;;H&P.HX;2;Type of blood thinning medication used;Blood thinning med used;;ACTIVE;2.64;2.71 +89068-1;Date aspirin discontinued;Date;Pt;^Patient;Qn;;H&P.HX;2;Date aspirin discontinued;Date aspirin discontinued;;ACTIVE;2.64;2.71 +89069-9;Enteric coated aspirin tablet;Find;Pt;^Patient;Ord;;H&P.HX;2;Enteric coated aspirin tablet;Enteric coated aspirin;;ACTIVE;2.64;2.71 +89070-7;ADAPTABLE patient reported item set;-;Pt;^Patient;-;ADAPTABLE;PANEL.SURVEY.GNHLTH;4;ADAPTABLE patient reported item set [ADAPTABLE];;;ACTIVE;2.64;2.71 +89071-5;Enrollment item set;-;Pt;^Patient;-;ADAPTABLE;PANEL.SURVEY.GNHLTH;4;Enrollment item set [ADAPTABLE];;;ACTIVE;2.64;2.71 +89072-3;Aspirin dose^post enrollment in ADAPTABLE study;Mass;Pt;^Patient;Qn;ADAPTABLE;SURVEY.GNHLTH;4;Aspirin dose--post enrollment in ADAPTABLE study [ADAPTABLE];;;ACTIVE;2.64;2.71 +89073-1;Reason for discontinuing aspirin use;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Reason for discontinuing aspirin use;;;ACTIVE;2.64;2.71 +89074-9;Aspirin usage^post enrollment in ADAPTABLE study;Find;Pt;^Patient;Ord;ADAPTABLE;SURVEY.GNHLTH;4;Aspirin usage--post enrollment in ADAPTABLE study [ADAPTABLE];;;ACTIVE;2.64;2.71 +89075-6;Willing to change aspirin dose;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Willing to change aspirin dose;;;ACTIVE;2.64;2.71 +89076-4;Aspirin usage^pre enrollment in ADAPTABLE study;Find;Pt;^Patient;Ord;ADAPTABLE;SURVEY.GNHLTH;4;Aspirin usage--pre enrollment in ADAPTABLE study [ADAPTABLE];;;ACTIVE;2.64;2.71 +89077-2;Adequacy of information on+time spent reading ADAPTABLE web site;Find;Pt;^Patient;Ord;ADAPTABLE;SURVEY.GNHLTH;4;Adequacy of information on+time spent reading ADAPTABLE web site [ADAPTABLE];;;ACTIVE;2.64;2.71 +8907-8;Arterial pulse intensity;Force;Pt;Popliteal artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Popliteal artery - right by palpation;Pulse intensity Popliteal a-R Palpation;;ACTIVE;1.0h(3);2.38 +89078-0;Hospitalization^post enrollment in ADAPTABLE study;Find;Pt;^Patient;Ord;ADAPTABLE;SURVEY.GNHLTH;4;History of hospitalization--post enrollment in ADAPTABLE study [ADAPTABLE];;;ACTIVE;2.64;2.71 +89079-8;Events^during hospitalization;Find;RptPeriod;^Patient;Nom;ADAPTABLE;SURVEY.GNHLTH;4;Events--during hospitalization [ADAPTABLE];;;ACTIVE;2.64;2.71 +89080-6;Satisfaction with using ADAPTABLE web site;Find;Pt;^Patient;Ord;ADAPTABLE;SURVEY.GNHLTH;4;Satisfaction with using ADAPTABLE web site [ADAPTABLE];;;ACTIVE;2.64;2.71 +89081-4;Aspirin dose^pre enrollment in ADAPTABLE study;Mass;Pt;Dose;Qn;ADAPTABLE;SURVEY.GNHLTH;4;Aspirin dose--pre enrollment in ADAPTABLE study Dose [ADAPTABLE];;;ACTIVE;2.64;2.71 +89082-2;Early visit item set;-;Pt;^Patient;-;ADAPTABLE;PANEL.SURVEY.GNHLTH;4;Early visit item set [ADAPTABLE];;;ACTIVE;2.64;2.71 +89083-0;Follow-up visit item set;-;Pt;^Patient;-;ADAPTABLE;PANEL.SURVEY.GNHLTH;4;Follow-up visit item set [ADAPTABLE];;;ACTIVE;2.64;2.71 +89084-8;I have trouble doing all of my regular leisure activities with others in the past 7D;Find;7D;^Patient;Ord;ADAPTABLE;SURVEY.GNHLTH;4;I have trouble doing all of my regular leisure activities with others in the past 7 days [ADAPTABLE];;;ACTIVE;2.64;2.71 +89085-5;Capacity.total/Capacity.predicted;RelVol;Pt;Respiratory system;Qn;Plethysmograph.body box;PULM;2;Total lung capacity measured/predicted by Plethysmograph body box;TLC meas/pred Plethysmograph;;ACTIVE;2.64;2.65 +8908-6;Arterial pulse intensity;Force;Pt;Posterior tibial artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Posterior tibial artery - right by palpation;Pulse intensity Post Tibl a-R Palpation;;ACTIVE;1.0h(3);2.38 +89086-3;Diameter;Len;Pt;Tracheostomy tube;Qn;;PULM;2;Tracheostomy tube diameter;Trach tube Diam;;ACTIVE;2.64;2.64 +89087-1;Body weight;Mass;Pt;^Fetus;Qn;Estimated;BDYWGT.ATOM;2;Fetal Body weight Estimated;Fet Weight Est;;DISCOURAGED;2.64;2.64 +89088-9;WIC services recipient;Find;Pt;^Patient;Ord;;ADMIN.PATIENT;2;WIC services recipient;WIC recipient;;ACTIVE;2.64;2.66 +89089-7;Immigration status;Find;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Immigration status;Immigration status;;ACTIVE;2.64;2.66 +89090-5;Everyday Cognition - Study Partner Report Form;-;Pt;^Patient;-;ECog.Partner;PANEL.SURVEY.GNHLTH;4;Everyday Cognition - Study Partner Report Form [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89092-1;Compared to 10Y ago, has there been any change in thinking things through before acting;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in thinking things through before acting [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89093-9;Compared to 10Y ago, has there been any change in cooking or working and talking at the same time;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in cooking or working and talking at the same time [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8909-4;Arterial pulse intensity;Force;Pt;Posterior tibial artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Posterior tibial artery - left by palpation;Pulse intensity Post Tibl a-L Palpation;;ACTIVE;1.0h(3);2.38 +89094-7;Compared to 10Y ago, has there been any change in the ability to concentrate on a task without being distracted by external things in the environment;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in the ability to concentrate on a task without being distracted by external things in the environment [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89095-4;Compared to 10Y ago, has there been any change in returning to a task after being interrupted;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in returning to a task after being interrupted [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89096-2;Compared to 10Y ago, has there been any change in the ability to do two things at once;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in the ability to do two things at once [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89097-0;Compared to 10Y ago, has there been any change in using an organized strategy to manage a medication schedule involving multiple medications;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in using an organized strategy to manage a medication schedule involving multiple medications [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89098-8;Compared to 10Y ago, has there been any change in keeping mail and papers organized;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in keeping mail and papers organized [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89099-6;Compared to 10Y ago, has there been any change in prioritizing tasks by importance;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in prioritizing tasks by importance [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89100-2;Compared to 10Y ago, has there been any change in keeping financial records organized;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in keeping financial records organized [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89101-0;Compared to 10Y ago, has there been any change in balancing the checkbook without error;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in balancing the checkbook without error [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8910-2;Arterial pulse intensity;Force;Pt;Radial artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Radial artery - left by palpation;Pulse intensity Radial a-L Palpation;;ACTIVE;1.0h(3);2.38 +89102-8;Compared to 10Y ago, has there been any change in keeping living and work space organized;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in keeping living and work space organized [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89103-6;Compared to 10Y ago, has there been any change in thinking ahead;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in thinking ahead [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89104-4;Compared to 10Y ago, has there been any change in developing a schedule in advance of anticipated events;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in developing a schedule in advance of anticipated events [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89105-1;Compared to 10Y ago, has there been any change in the ability to anticipate weather changes and plan accordingly (i.e., bring a coat or umbrella);Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in the ability to anticipate weather changes and plan accordingly (i.e.bring a coat or umbrella) [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89106-9;Compared to 10Y ago, has there been any change in planning the sequence of stops on a shopping trip;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in planning the sequence of stops on a shopping trip [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89107-7;Compared to 10Y ago, has there been any change in finding his or her way around a house visited many times;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding his or her way around a house visited many times [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89108-5;Compared to 10Y ago, has there been any change in finding his or her way around a familiar store;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding his or her way around a familiar store [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89109-3;Compared to 10Y ago, has there been any change in remembering things that happened recently (such as recent outings, events in the news);Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering things that happened recently (such as recent outings, events in the news) [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8911-0;Arterial pulse intensity;Force;Pt;Radial artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Radial artery - right by palpation;Pulse intensity Radial a-R Palpation;;ACTIVE;1.0h(3);2.38 +89110-1;Compared to 10Y ago, has there been any change in finding the way back to a meeting spot in the mall or other location;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding the way back to a meeting spot in the mall or other location [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89111-9;Compared to 10Y ago, has there been any change in finding one's car in a parking lot;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding one's car in a parking lot [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89112-7;Compared to 10Y ago, has there been any change in reading a map and helping with directions when someone else is driving;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in reading a map and helping with directions when someone else is driving [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89113-5;Compared to 10Y ago, has there been any change in following a map to find a new location;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in following a map to find a new location [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89114-3;Compared to 10Y ago, has there been any change in understanding spoken directions or instructions;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in understanding spoken directions or instructions [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89115-0;Compared to 10Y ago, has there been any change in describing a program he or she has watched on TV;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in describing a program he or she has watched on TV [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89116-8;Compared to 10Y ago, has there been any change in remembering the meaning of common words;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering the meaning of common words [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89117-6;Compared to 10Y ago, has there been any change in understanding the point of what other people are trying to say;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in understanding the point of what other people are trying to say [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89118-4;Compared to 10Y ago, has there been any change in following a story in a book or on TV;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in following a story in a book or on TV [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89119-2;Compared to 10Y ago, has there been any change in communicating thoughts in a conversation;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in communicating thoughts in a conversation [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +891-2;Blood group antibody screen.cell I;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Blood group antibody screen.cell I [Presence] in Serum or Plasma;Bld gp Ab Scn Cell I SerPl Ql;;ACTIVE;1.0;2.73 +89120-0;Compared to 10Y ago, has there been any change in finding the right words to use in a conversation;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding the right words to use in a conversation [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89121-8;Compared to 10Y ago, has there been any change in verbally giving instructions to others;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in verbally giving instructions to others [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89122-6;Compared to 10Y ago, has there been any change in forgetting the names of objects;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in forgetting the names of objects [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89123-4;Compared to 10Y ago, has there been any change in remembering appointments, meetings, or engagements;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering appointments, meetings, or engagements [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89124-2;Compared to 10Y ago, has there been any change in remembering he or she has already told someone something;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering he or she has already told someone something [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89125-9;Compared to 10Y ago, has there been any change in remembering the current date or day of the week;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering the current date or day of the week [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89126-7;Compared to 10Y ago, has there been any change in repeating stories &or questions;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in repeating stories AndOr questions [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89127-5;Compared to 10Y ago, has there been any change in remembering where he or she has placed objects;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering where he or she has placed objects [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8912-8;Arterial pulse intensity;Force;Pt;Ulnar artery.left;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Ulnar artery - left by palpation;Pulse intensity Ulnar a-L Palpation;;ACTIVE;1.0h(3);2.38 +89128-3;Compared to 10Y ago, has there been any change in recalling conversations a few days later;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in recalling conversations a few days later [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89129-1;Compared to 10Y ago, has there been any change in remembering a few shopping items without a list;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering a few shopping items without a list [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89130-9;Compared to 10Y ago, has there been any change in finding his or her way around a familiar neighborhood;Find;Pt;^Patient;Ord;ECog.Partner;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding his or her way around a familiar neighborhood [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89133-3;Everyday Cognition - Participant Self Report Form;-;Pt;^Patient;-;ECog;PANEL.SURVEY.GNHLTH;4;Everyday Cognition - Participant Self Report Form [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89135-8;Compared to 10Y ago, has there been any change in verbally giving instructions to others;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in verbally giving instructions to others [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8913-6;Arterial pulse intensity;Force;Pt;Ulnar artery.right;Ord;Palpation;HRTRATE.MOLEC;2;Pulse intensity Ulnar artery - right by palpation;Pulse intensity Ulnar a-R Palpation;;ACTIVE;1.0h(3);2.38 +89136-6;Compared to 10Y ago, has there been any change in using an organized strategy to manage a medication schedule involving multiple medications;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in using an organized strategy to manage a medication schedule involving multiple medications [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89137-4;Compared to 10Y ago, has there been any change in understanding the point of what other people are trying to say;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in understanding the point of what other people are trying to say [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89138-2;Compared to 10Y ago, has there been any change in understanding spoken directions or instructions;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in understanding spoken directions or instructions [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89139-0;Compared to 10Y ago, has there been any change in thinking things through before acting;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in thinking things through before acting [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89140-8;Compared to 10Y ago, has there been any change in thinking ahead;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in thinking ahead [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89141-6;Compared to 10Y ago, has there been any change in the ability to do two things at once;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in the ability to do two things at once [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89142-4;Compared to 10Y ago, has there been any change in the ability to concentrate on a task without being distracted by external things in the environment;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in the ability to concentrate on a task without being distracted by external things in the environment [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89143-2;Compared to 10Y ago, has there been any change in the ability to anticipate weather changes and plan accordingly (i.e. bring a coat or umbrella);Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in the ability to anticipate weather changes and plan accordingly (i.e. bring a coat or umbrella) [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8914-4;Pulse wave form;Imp;Pt;Brachial artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Brachial artery - left by US.doppler;Pulse wave form Brach a-L DOP;;ACTIVE;1.0h(3);2.29 +89144-0;Compared to 10Y ago, has there been any change in returning to a task after being interrupted;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in returning to a task after being interrupted [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89145-7;Compared to 10Y ago, has there been any change in repeating stories &or questions;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in repeating stories AndOr questions [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89146-5;Compared to 10Y ago, has there been any change in remembering where I have placed objects;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering where I have placed objects [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89147-3;Compared to 10Y ago, has there been any change in remembering things that happened recently (such as recent outings, events in the news);Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering things that happened recently (such as recent outings, events in the news) [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89148-1;Compared to 10Y ago, has there been any change in remembering the meaning of common words;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering the meaning of common words [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89149-9;Compared to 10Y ago, has there been any change in remembering the current date or day of the week;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering the current date or day of the week [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89150-7;Compared to 10Y ago, has there been any change in remembering I have already told someone something;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering I have already told someone something [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8915-1;Pulse wave form;Imp;Pt;Brachial artery.right;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Brachial artery - right by US.doppler;Pulse wave form Brach a-R DOP;;ACTIVE;1.0h(3);2.29 +89151-5;Compared to 10Y ago, has there been any change in remembering appointments, meetings, or engagements;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering appointments, meetings, or engagements [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89152-3;Compared to 10Y ago, has there been any change in remembering a few shopping items without a list;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in remembering a few shopping items without a list [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89153-1;Compared to 10Y ago, has there been any change in recalling conversations a few days later;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in recalling conversations a few days later [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89154-9;Compared to 10Y ago, has there been any change in reading a map and helping with directions when someone else is driving;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in reading a map and helping with directions when someone else is driving [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89155-6;Compared to 10Y ago, has there been any change in prioritizing tasks by importance;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in prioritizing tasks by importance [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89156-4;Compared to 10Y ago, has there been any change in planning a sequence of stops on a shopping trip;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in planning a sequence of stops on a shopping trip [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89157-2;Compared to 10Y ago, has there been any change in keeping mail and papers organized;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in keeping mail and papers organized [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89158-0;Compared to 10Y ago, has there been any change in keeping living and work space organized;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in keeping living and work space organized [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89159-8;Compared to 10Y ago, has there been any change in keeping financial records organized;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in keeping financial records organized [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89160-6;Compared to 10Y ago, has there been any change in forgetting the names of objects;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in forgetting the names of objects [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89161-4;Compared to 10Y ago, has there been any change in following a story in a book or on TV;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in following a story in a book or on TV [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89162-2;Compared to 10Y ago, has there been any change in following a map to find a new location;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in following a map to find a new location [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89163-0;Compared to 10Y ago, has there been any change in finding the right words to use in a conversation;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding the right words to use in a conversation [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89164-8;Compared to 10Y ago, has there been any change in finding my way back to a meeting spot in the mall or other location;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding my way back to a meeting spot in the mall or other location [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89165-5;Compared to 10Y ago, has there been any change in finding my way around a house visited many times;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding my way around a house visited many times [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89166-3;Compared to 10Y ago, has there been any change in finding my way around a familiar store;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding my way around a familiar store [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89167-1;Compared to 10Y ago, has there been any change in finding my way around a familiar neighborhood;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding my way around a familiar neighborhood [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89168-9;Compared to 10Y ago, has there been any change in finding my car in a parking lot;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in finding my car in a parking lot [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +8916-9;Pulse wave form;Imp;Pt;Carotid artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Carotid artery - left by US.doppler;Pulse wave form Carot a-L DOP;;ACTIVE;1.0h(3);2.29 +89169-7;Compared to 10Y ago, has there been any change in developing a schedule in advance of anticipated events;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in developing a schedule in advance of anticipated events [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89170-5;Compared to 10Y ago, has there been any change in describing a program I have watched on TV;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in describing a program I have watched on TV [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89171-3;Compared to 10Y ago, has there been any change in cooking or working and talking at the same time;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in cooking or working and talking at the same time [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89172-1;Compared to 10Y ago, has there been any change in communicating thoughts in a conversation;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in communicating thoughts in a conversation [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89173-9;Compared to 10Y ago, has there been any change in balancing the checkbook without error;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Compared to 10 years ago, has there been any change in balancing the checkbook without error [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89174-7;Are you concerned that you have a memory or other thinking problem;Find;Pt;^Patient;Ord;ECog;SURVEY.GNHLTH;4;Are you concerned that you have a memory or other thinking problem [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89175-4;Billing information panel;-;Pt;^Patient;-;;PANEL.ADMIN;2;Billing information panel;Billing info pnl;;ACTIVE;2.64;2.64 +89176-2;Intervention &or services provided panel;-;Pt;^Patient;-;;PANEL.APTA;2;Intervention AndOr services provided panel;Intervention or services provided pnl;;ACTIVE;2.64;2.66 +8917-7;Pulse wave form;Imp;Pt;Carotid artery.right;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Carotid artery - right by US.doppler;Pulse wave form Carot a-R DOP;;ACTIVE;1.0h(3);2.29 +89177-0;Movement system diagnosis;Find;Pt;^Patient;Nom;;APTA;2;Movement system diagnosis;Movement system dx;;ACTIVE;2.64;2.64 +89178-8;Financial responsibility amount;Num;Pt;^Patient;Qn;;ADMIN.PATIENT;2;Patient's Financial responsibility amount [#];Financial responsibility;;ACTIVE;2.64;2.66 +89179-6;Therapeutic exercise performed;Prid;Pt;^Patient;Nom;;APTA;2;Therapeutic exercise performed [Identifier];Ther exercise perf;;ACTIVE;2.64;2.64 +89180-4;Motor function training performed;Prid;Pt;^Patient;Nom;;APTA;2;Motor function training performed [Identifier];Motor function training perf;;ACTIVE;2.64;2.64 +89181-2;Manual therapy technique used;Prid;Pt;^Patient;Nom;;APTA;2;Manual therapy technique used [Identifier];Manual therapy technique used;;ACTIVE;2.64;2.64 +89182-0;Integumentary repair and protection technique used;Prid;Pt;^Patient;Nom;;APTA;2;Integumentary repair and protection technique used [Identifier];Integ repair protect technique;;ACTIVE;2.64;2.64 +89183-8;Functional training performed;Prid;Pt;^Patient;Nom;;APTA;2;Functional training performed [Identifier];Functional training perf;;ACTIVE;2.64;2.64 +89184-6;Biophysical agent used;Prid;Pt;^Patient;Nom;;APTA;2;Biophysical agent used;Biophysical agent used;;ACTIVE;2.64;2.64 +8918-5;Pulse wave form;Imp;Pt;Dorsal pedal artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Dorsal pedal artery - left by US.doppler;Pulse wave form Dors pedal a-L DOP;;ACTIVE;1.0h(3);2.32 +89185-3;Assistive technology provided;Prid;Pt;^Patient;Nom;;APTA;2;Assistive technology provided [Identifier];Assistive technology prov;;ACTIVE;2.64;2.64 +89186-1;Airway clearance technique performed;Prid;Pt;^Patient;Nom;;PULM;2;Airway clearance technique performed [Identifier];Airway clearance technique perf;;ACTIVE;2.64;2.64 +89187-9;Instructions provided;Prid;Pt;^Patient;Nom;;CLIN;2;Instructions provided [Identifier];Instructions provided;;ACTIVE;2.64;2.64 +89188-7;Medication documentation status;Type;Pt;^Patient;Nom;;CLIN;2;Medication documentation status;Medication documentation status;;ACTIVE;2.64;2.64 +89189-5;Clinical presentation status;Type;Pt;^Patient;Ord;;CLIN;2;Clinical presentation status;Clinical presentation status;;ACTIVE;2.64;2.64 +89190-3;Performance-based measure name;ID;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Performance-based measure name;;;ACTIVE;2.64;2.64 +89191-1;Performance-based measure score;Score;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Performance-based measure score;;;ACTIVE;2.64;2.64 +89192-9;Performance-based measure score interpretation;Imp;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Performance-based measure score interpretation;;;ACTIVE;2.64;2.64 +8919-3;Pulse wave form;Imp;Pt;Dorsal pedal artery;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Dorsal pedal artery by US.doppler;Pulse wave form Dors pedal a DOP;;ACTIVE;1.0h(3);2.73 +89193-7;Patient reported outcome measure score interpretation;Imp;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Patient reported outcome measure score interpretation;;;ACTIVE;2.64;2.64 +89194-5;Patient reported outcome measure score;Score;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Patient reported outcome measure score;;;ACTIVE;2.64;2.64 +89195-2;Patient reported outcome measure name;ID;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Patient reported outcome measure name;;;ACTIVE;2.64;2.64 +89196-0;Patient reported outcome measure panel;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Patient reported outcome measure panel;;;ACTIVE;2.64;2.64 +89197-8;Performance-based measure panel;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Performance-based measure panel;;;ACTIVE;2.64;2.64 +89198-6;Mean score;Score;Pt;^Patient;Qn;ECog;SURVEY.GNHLTH;4;Mean score [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89199-4;Mean score;Score;Pt;^Patient;Qn;ECog.Partner;SURVEY.GNHLTH;4;Mean score [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +892-0;Blood group antibody screen.cell III;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Blood group antibody screen.cell III [Presence] in Serum or Plasma;Bld gp Ab Scn Cell III SerPl Ql;;ACTIVE;1.0;2.56 +89200-0;Phenotypic lab test method used to determine resistance;Prid;Pt;Isolate;Nom;*;MISC;1;Phenotypic lab test method used to determine resistance [Identifier] in Isolate;Phenotypic resistance method Islt;;ACTIVE;2.64;2.64 +8920-1;Pulse wave form;Imp;Pt;Femoral artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Femoral artery - left by US.doppler;Pulse wave form Fem a-L DOP;;ACTIVE;1.0h(3);2.29 +89201-8;Molecular lab test method used to determine resistance;Prid;Pt;Isolate/Specimen;Nom;*;MISC;1;Molecular lab test method used to determine resistance [Identifier] in Isolate or Specimen;Molecular resistance method Islt/Spm;;ACTIVE;2.64;2.64 +89202-6;County;Loc;Pt;Facility;Nom;;ADMIN.FACILITY;2;County location of Facility;Facility county;;ACTIVE;2.64;2.64 +89203-4;Airway suction device;Type;Pt;{Device};Nom;;PULM;2;Airway suction device [Type];Airway suction device Type;;ACTIVE;2.64;2.7 +89204-2;Patient Health Questionnaire-9: Modified for Teens total score;Score;Pt;^Patient;Qn;Reported.PHQ.Teen;SURVEY.PHQ;4;Patient Health Questionnaire-9: Modified for Teens total score [Reported.PHQ.Teen];;© 2010 The Reach Institute. Used with permission. Permission granted from the GLAD-PC Steering Committee and the REACH Institute (www.TheReachInstitute.org);ACTIVE;2.64;2.64 +89205-9;Center for Epidemiologic Studies Depression Scale-Revised total score;Score;Pt;^Patient;Qn;Center for Epidemiologic Studies Depression Scale-Revised;SURVEY.CESD;4;Center for Epidemiologic Studies Depression Scale-Revised total score [CESD-R];;;ACTIVE;2.64;2.64 +89206-7;Patient Health Questionnaire-9: Modified for Teens;-;Pt;^Patient;-;Reported.PHQ.Teen;PANEL.SURVEY.PHQ;4;Patient Health Questionnaire-9: Modified for Teens [Reported.PHQ.Teen];;© 2010 The Reach Institute. Used with permission. Permission granted from the GLAD-PC Steering Committee and the REACH Institute (www.TheReachInstitute.org);ACTIVE;2.64;2.64 +89207-5;Center for Epidemiologic Studies Depression Scale-Revised;-;Pt;^Patient;-;Center for Epidemiologic Studies Depression Scale-Revised;PANEL.SURVEY.CESD;4;Center for Epidemiologic Studies Depression Scale-Revised [CESD-R];;;ACTIVE;2.64;2.64 +89208-3;Beck Depression Inventory Fast Screen total score;Score;Pt;^Patient;Qn;BDI;SURVEY.BDI;4;Beck Depression Inventory Fast Screen total score [BDI];;Copyright © 2017 NCS Pearson, Inc. Used with permission.;ACTIVE;2.64;2.64 +89209-1;Beck Depression Inventory II total score;Score;Pt;^Patient;Qn;BDI;SURVEY.BDI;4;Beck Depression Inventory II total score [BDI];;Copyright © 2017 NCS Pearson, Inc. Used with permission.;ACTIVE;2.64;2.64 +89210-9;Beck Depression Inventory II;-;Pt;^Patient;-;BDI;PANEL.SURVEY.BDI;4;Beck Depression Inventory II [BDI];;Copyright © 2017 NCS Pearson, Inc. Used with permission.;ACTIVE;2.64;2.64 +89211-7;Beck Depression Inventory Fast Screen;-;Pt;^Patient;-;BDI;PANEL.SURVEY.BDI;4;Beck Depression Inventory Fast Screen [BDI];;Copyright © 2017 NCS Pearson, Inc. Used with permission.;ACTIVE;2.64;2.64 +89212-5;Reason for difficult intubation;Find;Pt;^Patient;Nom;;PULM;2;Reason for difficult intubation;Difficult intubation reason;;ACTIVE;2.64;2.7 +89213-3;History and physical note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics History and physical note;OB H&P note;;ACTIVE;2.64;2.64 +89214-1;Discharge summary note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Discharge summary;OB D/C sum;;ACTIVE;2.64;2.73 +89215-8;Admission history and physical note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Admission history and physical note;Gynecology Admit H&P note;;ACTIVE;2.64;2.64 +89216-6;Consultation note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Consult note;Gynecology Consult note;;ACTIVE;2.64;2.64 +89217-4;Discharge instructions;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Discharge instructions;Gynecology Discharge instruct;;ACTIVE;2.64;2.64 +89218-2;Discharge summary note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Discharge summary;Gynecology D/C sum;;ACTIVE;2.64;2.73 +8921-9;Pulse wave form;Imp;Pt;Femoral artery.right;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Femoral artery - right by US.doppler;Pulse wave form Fem a-R DOP;;ACTIVE;1.0h(3);2.29 +89219-0;Discharge teaching note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Discharge teaching note;Gynecology Discharge teach note;;ACTIVE;2.64;2.64 +89220-8;Education note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Education note;Gynecology Educ note;;ACTIVE;2.64;2.64 +89221-6;History and physical note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology History and physical note;Gynecology H&P note;;ACTIVE;2.64;2.64 +89222-4;Initial evaluation note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Initial evaluation note;Gynecology Initial eval note;;ACTIVE;2.64;2.64 +89223-2;Procedure note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology procedure note;Gynecology Procedure note;;ACTIVE;2.64;2.64 +89224-0;Progress note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Progress note;Gynecology Prog note;;ACTIVE;2.64;2.73 +89225-7;Referral note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Referral note;Gynecology Referral note;;ACTIVE;2.64;2.64 +89226-5;Transfer summary note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Transfer summary note;Gynecology Transfer sum note;;ACTIVE;2.64;2.64 +8922-7;Pulse wave form;Imp;Pt;Popliteal artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Popliteal artery - left by US.doppler;Pulse wave form Popliteal a-L DOP;;ACTIVE;1.0h(3);2.29 +89227-3;Consultation note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Consult note;OB Consult note;;ACTIVE;2.64;2.64 +89228-1;Discharge instructions;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Discharge instructions;OB Discharge instruct;;ACTIVE;2.64;2.64 +89229-9;Discharge teaching note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Discharge teaching note;OB Discharge teach note;;ACTIVE;2.64;2.64 +89230-7;Education note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Education note;OB Educ note;;ACTIVE;2.64;2.64 +89231-5;Initial evaluation note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Initial evaluation note;OB Initial eval note;;ACTIVE;2.64;2.64 +89232-3;Procedure note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics procedure note;OB Procedure note;;ACTIVE;2.64;2.64 +89233-1;Progress note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Progress note;OB Prog note;;ACTIVE;2.64;2.73 +89234-9;Referral note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Referral note;OB Referral note;;ACTIVE;2.64;2.64 +8923-5;Pulse wave form;Imp;Pt;Popliteal artery.right;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Popliteal artery - right by US.doppler;Pulse wave form Popliteal a-R DOP;;ACTIVE;1.0h(3);2.29 +89235-6;Transfer summary note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Transfer summary note;OB Transfer sum note;;ACTIVE;2.64;2.64 +89236-4;Diagnostic study note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Diagnostic study note;OB Diag study note;;ACTIVE;2.64;2.64 +89237-2;Flowsheet;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Flowsheet;Gynecology Flowsheet;;ACTIVE;2.64;2.64 +89238-0;Flowsheet;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Flowsheet;OB Flowsheet;;ACTIVE;2.64;2.64 +89239-8;Plan of care note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Plan of care note;Gynecology Plan of care note;;ACTIVE;2.64;2.64 +89240-6;Plan of care note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Plan of care note;OB Plan of care note;;ACTIVE;2.64;2.64 +89241-4;Note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Note;OB Note;;ACTIVE;2.64;2.64 +89242-2;Discharge checklist;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Discharge checklist;Discharge checklist;;ACTIVE;2.64;2.64 +8924-3;Pulse wave form;Imp;Pt;Posterior tibial artery.right;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Posterior tibial artery - right by US.doppler;Pulse wave form Post Tibl a-R DOP;;ACTIVE;1.0h(3);2.29 +89243-0;Performance status;Score;Pt;^Patient;Qn;Karnofsky;CLIN;2;Karnofsky Performance Status score;KPS score;;ACTIVE;2.64;2.64 +89244-8;Performance status panel;-;Pt;^Patient;-;Karnofsky;PANEL.CLIN;2;Karnofsky Performance Status panel;KPS panel;;ACTIVE;2.64;2.64 +89245-5;Performance status;Imp;Pt;^Patient;Ord;Karnofsky;CLIN;2;Karnofsky Performance Status [Interpretation];KPS Imp;;ACTIVE;2.64;2.64 +89246-3;Performance status panel;-;Pt;^Patient;-;Eastern Cooperative Oncology Group;PANEL.CLIN;2;ECOG Performance Status panel;ECOG Perform Status Pnl;;ACTIVE;2.64;2.67 +89247-1;Performance status;Score;Pt;^Patient;Qn;Eastern Cooperative Oncology Group;CLIN;2;ECOG Performance Status score;ECOG Perform Status score;;ACTIVE;2.64;2.67 +89248-9;Microorganism identified;Prid;Pt;Index case^Event;Nom;;PUBLICHEALTH;2;Microorganism identified event index case;Microorganism index case;;ACTIVE;2.64;2.64 +89249-7;Carbapenem resistance gene identified;Prid;Pt;Index case^Event;Nom;;PUBLICHEALTH;2;Carbapenem resistance gene identified event index case;Carbapenem resistance gene index case;;ACTIVE;2.64;2.64 +8925-0;Pulse wave form;Imp;Pt;Posterior tibial artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Posterior tibial artery - left by US.doppler;Pulse wave form Post Tibl a-L DOP;;ACTIVE;1.0h(3);2.29 +89250-5;Device or anatomic structure visible in wound;Type;Pt;Wound;Nom;;H&P.PX;2;Device or anatomic structure visible in wound;Dev or anatom struc vis wnd;;ACTIVE;2.64;2.64 +89251-3;Condition present on admission;Find;Pt;^Patient;Ord;;H&P.PX;2;Condition present on admission;Condition present on admission;;ACTIVE;2.64;2.66 +89252-1;Episode;Type;Pt;Wound;Nom;;H&P.HX;2;Episode of Wound;Episode Wnd;;ACTIVE;2.64;2.64 +89253-9;Trend;Type;Pt;^Patient;Nom;;H&P.HX;2;Trend;Trend;;ACTIVE;2.64;2.64 +89254-7;Wound bed panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound bed panel;Wound bed panel;;ACTIVE;2.64;2.64 +89255-4;Area of identified wound bed color/Area of wound bed;ArArea;Pt;Wound.base;Qn;;H&P.HX;2;Wound bed area identified by color/Area of wound bed;Wound bed color % Area of Wnd base;;ACTIVE;2.64;2.65 +89256-2;Wound edge panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound edge panel;Wound edge panel;;ACTIVE;2.64;2.64 +89257-0;Wound tunneling panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound tunneling panel;Wound tunneling panel;;ACTIVE;2.64;2.64 +89258-8;Wound undermining panel;-;Pt;Wound;-;;PANEL.H&P;2;Wound undermining panel;Wound undermining panel;;ACTIVE;2.64;2.64 +89259-6;Exudate;PrThr;Pt;Wound;Ord;;H&P.HX;2;Presence of wound exudate;Exudate Wnd;;ACTIVE;2.64;2.64 +89260-4;Area of wound;Area;Pt;Wound;Qn;;H&P.HX;2;Area of wound;Area of wound;;ACTIVE;2.64;2.64 +89261-2;Clinical course;Find;Pt;^Patient;Nom;;H&P.HX;2;Clinical course;Clinical course;;ACTIVE;2.64;2.64 +89262-0;Performance status;Imp;Pt;^Patient;Ord;Eastern Cooperative Oncology Group;CLIN;2;ECOG Performance Status [Interpretation];ECOG Perform Status Imp;;ACTIVE;2.64;2.64 +89263-8;Special circumstances associated observations panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Special circumstances associated observations panel;Special circ assoc obs pnl;;ACTIVE;2.64;2.64 +89264-6;Date specimen sent to public health laboratory;Date;Pt;^Specimen;Qn;;PUBLICHEALTH;2;Date specimen was sent to public health laboratory;Date spec was sent to PH lab;;ACTIVE;2.64;2.65 +89265-3;Procedures, Services, or Supplies modifier;Type;Pt;^Patient;Nom;;ADMIN;2;Procedures, Services, or Supplies modifier;Proc+Serv+Supp mod;;ACTIVE;2.64;2.64 +89266-1;Procedures, Services, or Supplies code;Type;Pt;^Patient;Nom;;ADMIN;2;Procedures, Services, or Supplies code;Proc+Serv+Supp code;;ACTIVE;2.64;2.65 +89267-9;Intravascular diastolic^lying in L-lateral position;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure--lying in L-lateral position;BP dias--lying in L-lateral position;;ACTIVE;2.64;2.64 +8926-8;Pulse wave form;Imp;Pt;Radial artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Radial artery - left by US.doppler;Pulse wave form Radial a-L DOP;;ACTIVE;1.0h(3);2.29 +89268-7;Intravascular systolic^lying in L-lateral position;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure--lying in L-lateral position;BP sys--lying in L-lateral position;;ACTIVE;2.64;2.64 +89269-5;Body height^at birth;Len;Pt;^Patient;Qn;Measured;CLIN;2;Body height Measured --at birth;Body height @ birth Measured;;ACTIVE;2.64;2.69 +89270-3;Body mass index;Ratio;Pt;^Patient;Qn;Estimated;BDYWGT.ATOM;2;Body mass index (BMI) [Ratio] Estimated;BMI Est;;ACTIVE;2.64;2.73 +89271-1;Heart rate^during apnea;NRat;Pt;XXX;Qn;;HRTRATE.MOLEC;2;Heart rate --during apnea;Heart rate during apnea;;DISCOURAGED;2.64;2.64 +89272-9;Oxygen saturation^during apnea;MFr;Pt;BldA;Qn;Pulse oximetry;CHEM;1;Oxygen saturation in Arterial blood by Pulse oximetry --during apnea;SaO2 during apnea % BldA PulseOx;;DISCOURAGED;2.64;2.64 +89273-7;Heart rate^W exercise;NRat;Pt;XXX;Qn;;HRTRATE.PSTN.MOLEC;2;Heart rate --W exercise;Heart rate W exercise;;ACTIVE;2.64;2.64 +89274-5;Breaths^W exercise;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --W exercise;Resp rate W exercise;;ACTIVE;2.64;2.65 +89275-2;Reason rescue operation was canceled;Type;Pt;EMS unit;Nom;;TRAUMA;2;Reason rescue operation was canceled;Reason rescue canceled;;ACTIVE;2.64;2.7 +8927-6;Pulse wave form;Imp;Pt;Radial artery.right;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Radial artery - right by US.doppler;Pulse wave form Radial a-R DOP;;ACTIVE;1.0h(3);2.29 +89276-0;Oxygen saturation^W exercise;MFr;Pt;BldA;Qn;Pulse oximetry;CHEM;1;Oxygen saturation in Arterial blood by Pulse oximetry --W exercise;SaO2 W exercise % BldA PulseOx;;ACTIVE;2.64;2.64 +89277-8;Oxygen saturation^during anesthesia;MFr;Pt;BldA;Qn;Pulse oximetry;CHEM;1;Oxygen saturation in Arterial blood by Pulse oximetry --during anesthesia;SaO2 during anesthesia % BldA PulseOx;;ACTIVE;2.64;2.64 +89278-6;Heart rate^during anesthesia;NRat;Pt;XXX;Qn;;HRTRATE.MOLEC;2;Heart rate --during anesthesia;Heart rate during anesthesia;;ACTIVE;2.64;2.64 +89279-4;Breaths^during anesthesia;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --during anesthesia;Resp rate during anesthesia;;ACTIVE;2.64;2.64 +89280-2;Intravascular systolic^during anesthesia;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure--during anesthesia;BP sys--during anesthesia;;ACTIVE;2.64;2.64 +89281-0;Intravascular diastolic^during anesthesia;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure--during anesthesia;BP dias--during anesthesia;;ACTIVE;2.64;2.64 +89282-8;Heart rate^post bronchodilation;NRat;Pt;XXX;Qn;;HRTRATE.MOLEC;2;Heart rate --post bronchodilation;Heart rate p BD;;ACTIVE;2.64;2.64 +89283-6;Multisection^W contrast IV;Find;Pt;Neck+Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Neck+Chest+Abdomen+Pelvis W contrast IV;CT Neck to Pelvis W contr IV;;ACTIVE;2.64;2.72 +8928-4;Pulse wave form;Imp;Pt;Ulnar artery.left;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Ulnar artery - left by US.doppler;Pulse wave form Ulnar a-L DOP;;ACTIVE;1.0h(3);2.29 +89284-4;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;MR;RAD;2;MR Cervical and thoracic spine W contrast IV;MR C+T-spine W contr IV;;ACTIVE;2.64;2.64 +89285-1;Executive functioning: divided attention panel;-;Pt;^Patient;-;ECog;PANEL.SURVEY.GNHLTH;4;Executive functioning: divided attention panel [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89286-9;Memory panel;-;Pt;^Patient;-;ECog;PANEL.SURVEY.GNHLTH;4;Memory panel [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89287-7;Language panel;-;Pt;^Patient;-;ECog;PANEL.SURVEY.GNHLTH;4;Language panel [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89288-5;Visual-spatial and perceptual abilities panel;-;Pt;^Patient;-;ECog;PANEL.SURVEY.GNHLTH;4;Visual-spatial and perceptual abilities panel [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89289-3;Executive functioning: planning panel;-;Pt;^Patient;-;ECog;PANEL.SURVEY.GNHLTH;4;Executive functioning: planning panel [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89290-1;Executive functioning: organization panel;-;Pt;^Patient;-;ECog;PANEL.SURVEY.GNHLTH;4;Executive functioning: organization panel [ECog];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89291-9;Heart rate^W pain;NRat;Pt;XXX;Qn;;HRTRATE.PSTN.MOLEC;2;Heart rate --W pain;Heart rate W pain;;DISCOURAGED;2.64;2.64 +8929-2;Pulse wave form;Imp;Pt;Ulnar artery.right;Nom;US.doppler;HRTRATE.MOLEC;2;Pulse wave form Ulnar artery - right by US.doppler;Pulse wave form Ulnar a-R DOP;;ACTIVE;1.0h(3);2.29 +89292-7;Breaths^W pain;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --W pain;Resp rate W pain;;DISCOURAGED;2.64;2.64 +89293-5;Executive functioning: organization panel;-;Pt;^Patient;-;ECog.Partner;PANEL.SURVEY.GNHLTH;4;Executive functioning: organization panel [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89294-3;Executive functioning: planning panel;-;Pt;^Patient;-;ECog.Partner;PANEL.SURVEY.GNHLTH;4;Executive functioning: planning panel [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89295-0;Visual-spatial and perceptual abilities panel;-;Pt;^Patient;-;ECog.Partner;PANEL.SURVEY.GNHLTH;4;Visual-spatial and perceptual abilities panel [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89296-8;Language panel;-;Pt;^Patient;-;ECog.Partner;PANEL.SURVEY.GNHLTH;4;Language panel [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89297-6;Memory panel;-;Pt;^Patient;-;ECog.Partner;PANEL.SURVEY.GNHLTH;4;Memory panel [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.64 +89298-4;Executive functioning: divided attention panel;-;Pt;^Patient;-;ECog.Partner;PANEL.SURVEY.GNHLTH;4;Executive functioning: divided attention panel [ECog.Partner];;Copyright © 2008 Sarah Tomaszewski Farias Used with permission;ACTIVE;2.64;2.67 +89299-2;Heart rate special circumstances;Type;Pt;^Patient;Nom;;HRTRATE.ATOM;2;Heart rate special circumstances;Heart rate special circumstances;;ACTIVE;2.64;2.65 +89-3;Cefmetazole;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefmetazole [Susceptibility] by Disk diffusion (KB);Cefmetazole Islt KB;;ACTIVE;1.0;2.19 +8930-0;Class;Type;Pt;Chest tube;Nom;;IO.TUBE;2;Type of Chest tube;Chest tube Class;;ACTIVE;1.0h(3);2.27 +89300-8;Tapentadol glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Tapentadol glucuronide [Presence] in Urine by Screen method;Tapen gluc Ur Ql Scn;;ACTIVE;2.64;2.64 +89301-6;oxyMORphone-3-glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;oxymorphone-3-glucuronide [Presence] in Urine by Screen method;O3G Ur Ql Scn;;ACTIVE;2.64;2.64 +89302-4;Noroxymorphone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Noroxymorphone [Presence] in Urine by Screen method;Noroxymorphone Ur Ql Scn;;ACTIVE;2.64;2.73 +89303-2;Noroxycodone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Noroxycodone [Presence] in Urine by Screen method;Noroxycodone Ur Ql Scn;;ACTIVE;2.64;2.64 +89304-0;Norhydrocodone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norhydrocodone [Presence] in Urine by Screen method;Norhydrocodone Ur Ql Scn;;ACTIVE;2.64;2.64 +89305-7;Norbuprenorphine-3-glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norbuprenorphine-3-glucuronide [Presence] in Urine by Screen method;N3G Ur Ql Scn;;ACTIVE;2.64;2.64 +89306-5;Nortapentadol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Nortapentadol [Presence] in Urine by Screen method;Nortapentadol Ur Ql Scn;;ACTIVE;2.64;2.7 +89307-3;Naloxone-3-glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Naloxone-3-glucuronide [Presence] in Urine by Screen method;Naloxone-3G Ur Ql Scn;;ACTIVE;2.64;2.7 +89308-1;Morphine-6-glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Morphine-6-Glucuronide [Presence] in Urine by Screen method;Morphine-6-glucuronide Ur Ql Scn;;ACTIVE;2.64;2.7 +89309-9;HYDROmorphone-3-glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hydromorphone-3-glucuronide [Presence] in Urine by Screen method;H3G Ur Ql Scn;;ACTIVE;2.64;2.7 +89310-7;Codeine-6-glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Codeine-6-glucuronide [Presence] in Urine by Screen method;C6G Ur Ql Scn;;ACTIVE;2.64;2.64 +89311-5;Cells.CD3-CD45+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3-CD45+ cells/100 cells in Blood;CD3-CD45+ cells NFr Bld;;ACTIVE;2.64;2.64 +89312-3;Cells.CD3+CD45+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD45+ cells [#/volume] in Blood;CD3+CD45+ Cells # Bld;;ACTIVE;2.64;2.64 +89313-1;Cells.CD3-CD45+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3-CD45+ cells [#/volume] in Blood;CD3-CD45+ cells # Bld;;ACTIVE;2.64;2.64 +89314-9;Bacterial 23S rRNA gene azithromycin resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Bacterial 23S rRNA gene azithromycin resistance mutation [Presence] by Molecular method;Bact 23S rRNA azith res mut Islt/Spm Ql;;ACTIVE;2.64;2.65 +89315-6;Cells.CD4+CD25+CD45RA+CD127Low+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD25+CD45RA+CD127Low+ cells [#/volume] in Blood;CD4+CD25+CD45RA+CD127Low+ cells # Bld;;ACTIVE;2.64;2.64 +89316-4;Cells.CD4+CD25+CD45RO+CD127Low+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD25+CD45RO+CD127Low+ cells [#/volume] in Blood;CD4+CD25+CD45RO+CD127Low+ cells # Bld;;ACTIVE;2.64;2.64 +89317-2;Cells.CD4+CD25-CD127+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD4+CD25-CD127+ cells [#/volume] in Blood;CD4+CD25-CD127+ cells # Bld;;ACTIVE;2.64;2.64 +8931-8;Chest tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Chest tube site;Chest tube site;;ACTIVE;1.0h(3);2.27 +89318-0;Cells.CD25-CD127+/100 Cells.CD4;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25-CD127+ cells/100 CD4 cells in Blood;CD25-CD127+ cells/100 CD4 cells NFr Bld;;ACTIVE;2.64;2.64 +89319-8;Cells.CD25+CD45RA+CD127Low+/100 Cells.CD4;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25+CD45RA+CD127Low+ cells/100 CD4 cells in Blood;CD25+CD45RA+CD127L+/100 CD4 NFr Bld;;ACTIVE;2.64;2.64 +89320-6;Cells.CD25+CD45RO+CD127Low+/100 Cells.CD4;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25+CD45RO+CD127Low+ cells/100 CD4 cells in Blood;CD25+CD45RO+CD127L+/100 CD4 NFr Bld;;ACTIVE;2.64;2.64 +89321-4;Buprenorphine-3-glucuronide;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Buprenorphine-3-glucuronide [Mass/volume] in Serum or Plasma by Confirmatory method;B3G SerPl Cfm-mCnc;;ACTIVE;2.64;2.73 +89322-2;Norbuprenorphine-3-glucuronide;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Norbuprenorphine-3-glucuronide [Mass/volume] in Serum or Plasma by Confirmatory method;N3G SerPl Cfm-mCnc;;ACTIVE;2.64;2.73 +89323-0;APOB gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;APOB gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;APOB gene Mut Anl Bld/T;;ACTIVE;2.64;2.64 +89324-8;Insulin.intact;ACnc;Pt;Ser;Qn;LC/MS/MS;CHEM;1;Insulin intact [Units/volume] in Serum by LC/MS/MS;Insulin intact Ser LC/MS/MS-aCnc;;ACTIVE;2.64;2.73 +89325-5;Cells.CD3+CD8+CD28+HLA DR+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD28+HLA DR+ cells [#/volume] in Blood;CD3+CD8+CD28+HLA DR+ cellls # Bld;;ACTIVE;2.64;2.64 +8932-6;Class;Type;Pt;Enema device;Nom;;DEVICES;2;Type of Enema device;Enema Device Class;;ACTIVE;1.0h(3);2.27 +89326-3;Cells.CD3+CD4+CD28+HLA DR+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD28+HLA DR+ cells [#/volume] in Blood;CD3+CD4+CD28+HLA DR+ cells # Bld;;ACTIVE;2.64;2.64 +89327-1;Cells.CD3+CD8+CD27-CD45RO+CD62L-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD27-CD45RO+CD62L- cells [#/volume] in Blood;CD3+CD8+CD27-CD45RO+CD62L- cells # Bld;;ACTIVE;2.64;2.64 +89328-9;Cells.CD3+CD4+CD27-CD45RO+CD62L-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD27-CD45RO+CD62L- cells [#/volume] in Blood;CD3+CD4+CD27-CD45RO+CD62L- cells # Bld;;ACTIVE;2.64;2.64 +89329-7;Cells.CD3+CD4+CD27+CD45RO+CD62L+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD27+CD45RO+CD62L+ cells [#/volume] in Blood;CD3+CD4+CD27+CD45RO+CD62L+ cells # Bld;;ACTIVE;2.64;2.64 +89330-5;Cells.CD3+CD8+CD27+CD62L+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD27+CD62L+ cells [#/volume] in Blood;CD3+CD8+CD27+CD62L+ cells # Bld;;ACTIVE;2.64;2.64 +89331-3;Cells.CD3+CD4+CD27+CD62L+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD4+CD27+CD62L+ cells [#/volume] in Blood;CD3+CD4+CD27+CD62L+ cells # Bld;;ACTIVE;2.64;2.64 +89332-1;Cells.CD28+HLA DR+/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD28+HLA DR+ cells/100 CD3+CD8+ cells in Blood;CD28+HLA DR+ cells/100 CD3+CD8+ NFr Bld;;ACTIVE;2.64;2.64 +89333-9;Cells.CD28+HLA DR+/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD28+HLA DR+ cells/100 CD3+CD4+ cells in Blood;CD28+HLA DR+ cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.64;2.64 +8933-4;Class;Type;Pt;Enteral tube;Nom;;IO.TUBE;2;Type of Enteral tube;Enteral tube Class;;ACTIVE;1.0h(3);2.27 +89334-7;Cells.CD27-CD45RO+CD62L-CCR7-/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27-CD45RO+CD62L-CCR7- cells/100 CD3+CD8+ cells in Blood;CD27-CD45RO+CD62L-CCR7-/100 CD3+CD8+;;ACTIVE;2.64;2.64 +89335-4;Cells.CD27+CD45RO+CD62L+CCR7+/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD45RO+CD62L+CCR7+ cells/100 CD3+CD8+ cells in Blood;CD27+CD45RO+CD62L+CCR7+/100 CD3+CD8+;;ACTIVE;2.64;2.64 +89336-2;Cells.CD45RO/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45RO cells/100 CD3+CD8+ cells in Blood;CD45RO Cells/100 CD3+CD8+ NFr Bld;;ACTIVE;2.64;2.64 +89337-0;Cells.CD27-CD45RO+CD62L-CCR7-/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27-CD45RO+CD62L-CCR7- cells/100 CD3+CD4+ cells in Blood;CD27-CD45RO+CD62L-CCR7-/100 CD3+CD4+;;ACTIVE;2.64;2.64 +89338-8;Cells.CD27+CD45RO+CD62L+CCR7+/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD45RO+CD62L+CCR7+ cells/100 CD3+CD4+ cells in Blood;CD27+CD45RO+CD62L+CCR7+/100 CD3+CD4+;;ACTIVE;2.64;2.64 +89339-6;Cells.CD27+CD62L+/100 Cells.CD3+CD8+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD62L+ cells/100 CD3+CD8+ cells in Blood;CD27+CD62L+ cells/100 CD3+CD8+ NFr Bld;;ACTIVE;2.64;2.64 +89340-4;Cells.CD27+CD62L+/100 Cells.CD3+CD4+;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+CD62L+ cells/100 CD3+CD4+ cells in Blood;CD27+CD62L+ cells/100 CD3+CD4+ NFr Bld;;ACTIVE;2.64;2.64 +89341-2;Cells.CD38+IgM+/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38+IgM+ cells/100 CD19 cells in Blood;CD38+IgM+ cells/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.73 +8934-2;Enteral tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Enteral tube site;Enteral tube site;;ACTIVE;1.0h(3);2.27 +89342-0;Babesia sp 18S rRNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Babesia sp 18S rRNA [Presence] in Blood by NAA with probe detection;Babesia 18S rRNA Bld Ql NAA+probe;;ACTIVE;2.64;2.64 +89343-8;Cells.CD19+CD38+IgM-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD38+IgM- cells [#/volume] in Blood;CD19+CD38+IgM- cells # Bld;;ACTIVE;2.64;2.73 +89344-6;Cells.CD38+IgM-/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD38+IgM- cells/100 CD19 cells in Blood;CD38+IgM- cells/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.73 +89345-3;Cells.CD19+IgM+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+IgM+ cells [#/volume] in Blood;CD19+IgM+ cells # Bld;;ACTIVE;2.64;2.64 +89346-1;Cells.IgM/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;IgM cells/100 CD19 cells in Blood;IgM cells/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.64 +89347-9;Cells.CD19+CD27+IgD-IgM+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD27+IgD-IgM+ cells [#/volume] in Blood;CD19+CD27+IgD-IgM+ cells # Bld;;ACTIVE;2.64;2.64 +89348-7;Cells.CD27+IgD-IgM+/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+IgD-IgM+ cells/100 CD19 cells in Blood;CD27+IgD-IgM+/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.64 +89349-5;Cells.CD19+CD27+IgD-IgM-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD27+IgD-IgM- cells [#/volume] in Blood;CD19+CD27+IgD-IgM- cells # Bld;;ACTIVE;2.64;2.73 +89350-3;Cells.CD27+IgD-IgM-/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+IgD-IgM- cells/100 CD19 cells in Blood;CD27+IgD-IgM-/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.73 +89351-1;Cells.CD19+CD27+IgD+IgM+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD27+IgD+IgM+ cells [#/volume] in Blood;CD19+CD27+IgD+IgM+ cells # Bld;;ACTIVE;2.64;2.73 +89352-9;Cells.CD27+IgD+IgM+/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27+IgD+IgM+ cells/100 CD19 cells in Blood;CD27+IgD+IgM+/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.73 +89353-7;Cells.CD19+CD27+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD27+ cells [#/volume] in Blood;CD19+CD27+ cells # Bld;;ACTIVE;2.64;2.73 +89354-5;Cells.CD19+CD21-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+21- cells [#/volume] in Blood;CD19+21- cells # Bld;;ACTIVE;2.64;2.64 +89355-2;Cells.CD21-/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD21- cells/100 CD19 cells in Blood;CD21- cells/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.64 +89356-0;Cells.CD21/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD21 cells/100 CD19 cells in Blood;CD21 Cells/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.64 +89357-8;Cells.CD19+CD38+IgM+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD19+CD38+IgM+ cells [#/volume] in Blood;CD19+CD38+IgM+ cells # Bld;;ACTIVE;2.64;2.73 +89358-6;Cells.CD27/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD27 cells/100 CD19 cells in Blood;CD27 Cells/100 CD19 cells NFr Bld;;ACTIVE;2.64;2.73 +8935-9;IO tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;IO tube site;IO tube site;;ACTIVE;1.0h(3);2.27 +89359-4;Hepatitis C virus Ab.IgG;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Hepatitis C virus IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;HCV IgG SerPlBld Ql IA.rapid;;ACTIVE;2.64;2.64 +89360-2;Cells.CD45RA/100 Cells.CD4;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45RA cells/100 CD4 cells in Blood;CD45RA Cells/100 CD4 cells NFr Bld;;ACTIVE;2.64;2.64 +89362-8;Cells.CD45RO/100 Cells.CD4;NFr;Pt;Bld;Qn;;CELLMARK;1;CD45RO cells/100 CD4 cells in Blood;CD45RO Cells/100 CD4 cells NFr Bld;;ACTIVE;2.64;2.64 +89363-6;Cholinesterase;CCnc;Pt;Body fld;Qn;;CHEM;1;Cholinesterase [Enzymatic activity/volume] in Body fluid;Cholinesterase Fld-cCnc;;ACTIVE;2.64;2.64 +89364-4;Hemoglobin.free;MCnc;Pt;Body fld;Qn;;HEM/BC;1;Free Hemoglobin [Mass/volume] in Body fluid;Hgb Free Fld-mCnc;;ACTIVE;2.64;2.64 +89365-1;HIV 1 & 2 Ab panel;-;Pt;Ser/Plas/Bld;-;IA.rapid;PANEL.MICRO;1;HIV 1 and 2 Ab panel - Serum, Plasma or Blood by Rapid immunoassay;HIV 1 + 2 Ab Pnl SerPlBld IA.rapid;;ACTIVE;2.64;2.73 +89366-9;von Willebrand factor collagen binding adhesion inhibitor;ACnc;Pt;PPP;Qn;Chromo;COAG;1;von Willebrand factor collagen binding adhesion inhibitor [Units/volume] in Platelet poor plasma by Chromogenic method;vWF CBA inhibitor PPP Chro-aCnc;;ACTIVE;2.64;2.73 +8936-7;Fluid intake.chest tube;Vol;Pt;Pleural space;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake chest tube Estimated;Fluid intake chest tube Est;;ACTIVE;1.0h(3);2.48 +89367-7;von Willebrand factor.ristocetin cofactor inhibitor;ACnc;Pt;PPP;Qn;Coag;COAG;1;von Willebrand factor.ristocetin cofactor inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay;vWF.ristocetin cofactor inhibitor PPP;;ACTIVE;2.64;2.68 +89368-5;Zika virus non-structural protein 1 Ab.IgM panel;-;Pt;Ser/Plas;-;IA;PANEL.MICRO;1;Zika virus non-structural protein 1 IgM panel - Serum or Plasma by Immunoassay;ZIKV NS1 IgM Pnl SerPl IA;;ACTIVE;2.64;2.64 +89369-3;Zika virus non-structural protein 1 Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Zika virus non-structural protein 1 IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;ZIKV NS1 IgM SerPl IA-aCnc;;ACTIVE;2.64;2.65 +89370-1;Zika virus non-structural protein 1 Ab.IgM;Imp;Pt;Ser;Nom;IA;MICRO;1;Zika virus non-structural protein 1 IgM Ab [Interpretation] in Serum by Immunoassay;ZIKV NS1 IgM Ser IA-Imp;;ACTIVE;2.64;2.64 +89371-9;Mycobacterium tuberculosis complex DNA & rpoB gene rifAMPin resistance mutation panel;-;Pt;Isolate/Specimen;-;;PANEL.ABXBACT;1;MTB complex DNA and rpoB RIF resistance mutation panel [Presence];MTB and RIF resistance Pnl Islt/Spm;;ACTIVE;2.64;2.74 +89372-7;Mycobacterium tuberculosis complex rpoB gene rifAMPin resistance mutation;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Mycobacterium tuberculosis complex rpoB gene rifAMPin resistance mutation [Presence] by Molecular method;MTB rpoB RIF resist mut Islt/Spm Ql;;TRIAL;2.64;2.73 +89373-5;Hepatitis A virus genotype;Type;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Hepatitis A virus genotype in Specimen by NAA with probe detection;HAV Gentyp Spec NAA+probe;;ACTIVE;2.64;2.72 +89374-3;HIV 1 Ab;PrThr;Pt;XXX;Ord;IA;MICRO;1;HIV 1 Ab [Presence] in Specimen by Immunoassay;HIV1 Ab Spec Ql IA;;ACTIVE;2.64;2.73 +8937-5;Fluid intake.chest tube;Vol;Pt;Pleural space;Qn;Measured;IO_IN.MOLEC;2;Fluid intake chest tube Measured;Fluid intake chest tube Measured;;ACTIVE;1.0h(3);2.48 +89375-0;Wheel 50 feet with two turns - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 50 feet with two turns - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89376-8;Wheel 50 feet with two turns - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 50 feet with two turns - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89377-6;Wheel 150 feet - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 150 feet - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89378-4;Wheel 150 feet - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 150 feet - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89379-2;Walking 10 feet on uneven surfaces - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walking 10 feet on uneven surfaces - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +893-8;Blood group antibody screen.autologous;Imp;Pt;Ser/Plas;Nom;;BLDBK;1;Blood group antibody screen.autologous [Interpretation] in Serum or Plasma;Bld gp Ab Autol Scn SerPl-Imp;;ACTIVE;1.0;2.73 +89380-0;Walking 10 feet on uneven surfaces - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walking 10 feet on uneven surfaces - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89381-8;Walk 50 feet with two turns - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 50 feet with two turns - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89382-6;Walk 50 feet with two turns - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 50 feet with two turns - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +8938-3;Fluid intake.chest tube;VRat;1H;Pleural space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake chest tube 1 hour;Fluid intake chest tube 1h;;ACTIVE;1.0h(3);2.48 +89383-4;Walk 150 feet - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 150 feet - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89384-2;Walk 150 feet - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 150 feet - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89385-9;Walk 10 feet - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 10 feet - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89386-7;Walk 10 feet - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 10 feet - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89387-5;Upper body dressing - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Upper body dressing - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89388-3;Upper body dressing - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Upper body dressing - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89389-1;Toileting hygiene - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toileting hygiene - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89390-9;Toilet transfer - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet transfer - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +8939-1;Fluid intake.chest tube;VRat;8H;Pleural space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake chest tube 8 hour;Fluid intake chest tube 8h;;ACTIVE;1.0h(3);2.48 +89391-7;OASIS E - Functional abilities and goals - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Functional abilities and goals - DC [CMS Assessment];;;ACTIVE;2.64;2.72 +89392-5;Sit to stand - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to stand - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89393-3;Sit to stand - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to stand - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89394-1;Sit to lying - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to lying - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89395-8;Sit to lying - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to lying - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89396-6;Shower &or bathe self - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Shower/bathe self - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89397-4;Shower &or bathe self - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Shower/bathe self - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89398-2;Roll left and right - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Roll left and right - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89399-0;Roll left and right - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Roll left and right - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89400-6;Putting on and taking off footwear - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Putting on and taking off footwear - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89401-4;Putting on and taking off footwear - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Putting on and taking off footwear - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89402-2;Picking up object - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Picking up object - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89403-0;Picking up object - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Picking up object - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89404-8;Oral hygiene - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Oral hygiene - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89405-5;Oral hygiene - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Oral hygiene - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89406-3;Lower body dressing - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lower body dressing - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89407-1;Lower body dressing - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lower body dressing - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89408-9;Indicate the type of wheelchair or scooter used;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Indicate the type of wheelchair/scooter used [CMS Assessment];;;ACTIVE;2.64;2.68 +8940-9;Fluid intake.chest tube;VRat;10H;Pleural space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake chest tube 10 hour;Fluid intake chest tube 10h;;ACTIVE;1.0h(3);2.48 +89409-7;Eating - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89410-5;Eating - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89411-3;Does the patient use a wheelchair or scooter;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Does the patient use a wheelchair/scooter [CMS Assessment];;;ACTIVE;2.64;2.64 +89412-1;Car transfer - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Car transfer - functional goal [CMS Assessment];;;ACTIVE;2.64;2.64 +89413-9;Car transfer - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Car transfer - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89414-7;Chair &or bed-to-chair transfer - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Chair/bed-to-chair transfer - functional goal [CMS Assessment];;;ACTIVE;2.64;2.69 +89415-4;Bed-to-chair transfer - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bed-to-chair transfer - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89416-2;Go up and down 4 steps - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down 4 steps - functional goal [CMS Assessment];;;ACTIVE;2.64;2.69 +8941-7;Fluid intake.chest tube;VRat;12H;Pleural space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake chest tube 12 hour;Fluid intake chest tube 12h;;ACTIVE;1.0h(3);2.48 +89417-0;4 steps - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;4 steps - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89418-8;Go up and down 12 steps - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down 12 steps - functional goal [CMS Assessment];;;ACTIVE;2.64;2.69 +89419-6;12 steps - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;12 steps - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89420-4;Go up and down a curb &or step - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down a curb/step - functional goal [CMS Assessment];;;ACTIVE;2.64;2.7 +89421-2;1 step (curb) - functional ability;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;1 step (curb) - functional ability [CMS Assessment];;;ACTIVE;2.64;2.64 +89422-0;Timed Up and Go test & physical findings of gait panel;-;Pt;^Patient;-;CDC;PANEL.H&P;2;Timed Up and Go test and physical findings of gait panel CDC;TUG + Phys findings of gait Pnl CDC;;ACTIVE;2.64;2.64 +89423-8;Time to rise from chair, walk 10 feet and back, and return to sitting;Time;Pt;^Patient;Qn;TUG;H&P.PX;2;Time to rise from chair, walk 10 feet and back, and return to sitting [TUG];Time rise, walk 10ft, return sit [TUG];;ACTIVE;2.64;2.65 +89424-6;Long-term opioid therapy for pain consent;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Long-term opioid therapy for pain consent Document;Opioid therapy consent;;ACTIVE;2.64;2.65 +8942-5;Fluid intake.chest tube;VRat;24H;Pleural space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake chest tube 24 hour;Fluid intake chest tube 24h;;ACTIVE;1.0h(3);2.48 +89425-3;Cardiopulmonary resuscitation flowsheet;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;CPR flowsheet;CPR flowsheet;;ACTIVE;2.64;2.64 +89426-1;Cardiopulmonary resuscitation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;CPR note;CPR note;;ACTIVE;2.64;2.64 +89427-9;Evaluation and management consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Evaluation and management consent Document;E+M consent;;ACTIVE;2.64;2.65 +89428-7;Blood or blood product transfusion consent;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Blood or blood product transfusion consent Document;Transfusion consent;;ACTIVE;2.64;2.65 +89429-5;Surgical operation order;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Surgical operation order;Operative order;;ACTIVE;2.64;2.64 +89430-3;Medical history screening form;Find;Pt;Outpatient;Doc;Patient;DOC.ONTOLOGY;2;Outpatient Medical history screening form;OP Medical Hx screening form;;ACTIVE;2.64;2.67 +89431-1;Cells.CD25/100 Cells.CD4;NFr;Pt;Bld;Qn;;CELLMARK;1;CD25 cells/100 CD4 cells in Blood;CD25 Cells/100 CD4 cells NFr Bld;;ACTIVE;2.64;2.64 +89432-9;Group counseling note;Find;Pt;{Setting};Doc;Preventive medicine;DOC.ONTOLOGY;2;Preventive medicine Group counseling note;Preventive med Group counseling note;;ACTIVE;2.64;2.64 +8943-3;Fluid intake.enema;Vol;Pt;Lower GI tract;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake enema Estimated;Fluid intake enema Est;;ACTIVE;1.0h(3);2.48 +89433-7;Group counseling note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Group counseling note;Pain medicine Group counseling note;;ACTIVE;2.64;2.64 +89434-5;Group counseling note;Find;Pt;{Setting};Doc;Primary care;DOC.ONTOLOGY;2;Primary care Group counseling note;Primary care Group counseling note;;ACTIVE;2.64;2.64 +89435-2;Disabled from walking by any condition other than heart or lung disease;Find;Pt;^Patient;Ord;Rose Dyspnea Scale;SURVEY.GNHLTH;4;Disabled from walking by any condition other than heart or lung disease [Rose Dyspnea Scale];;Copyright © 2012 World Health Organization. Used with permission.;ACTIVE;2.64;2.64 +89436-0;Total score;Score;Pt;^Patient;Qn;Rose Dyspnea Scale;SURVEY.GNHLTH;4;Total score [Rose Dyspnea Scale];;Copyright © 2012 World Health Organization. Used with permission.;ACTIVE;2.64;2.64 +89437-8;Are you short of breath on washing or dressing;Find;Pt;^Patient;Ord;Rose Dyspnea Scale;SURVEY.GNHLTH;4;Are you short of breath on washing or dressing [Rose Dyspnea Scale];;Copyright © 2012 World Health Organization. Used with permission.;ACTIVE;2.64;2.64 +89438-6;Do you have to stop for breath when walking at your own pace on level ground;Find;Pt;^Patient;Ord;Rose Dyspnea Scale;SURVEY.GNHLTH;4;Do you have to stop for breath when walking at your own pace on level ground [Rose Dyspnea Scale];;Copyright © 2012 World Health Organization. Used with permission.;ACTIVE;2.64;2.64 +89439-4;Do you get short of breath walking with other people of your own age on level ground;Find;Pt;^Patient;Ord;Rose Dyspnea Scale;SURVEY.GNHLTH;4;Do you get short of breath walking with other people of your own age on level ground [Rose Dyspnea Scale];;Copyright © 2012 World Health Organization. Used with permission.;ACTIVE;2.64;2.64 +89440-2;Rose Dyspnea Scale panel;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Rose Dyspnea Scale;;Copyright © 2012 World Health Organization. Used with permission.;ACTIVE;2.64;2.64 +8944-1;Fluid intake.enema;Vol;Pt;Lower GI tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake enema Measured;Fluid intake enema Measured;;ACTIVE;1.0h(3);2.48 +89441-0;Note;Find;Pt;{Setting};Doc;Gynecology.resident;DOC.ONTOLOGY;2;Gynecology Resident Note;Gyn Res Note;;ACTIVE;2.64;2.65 +89442-8;Administrative note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Administrative note;OB Administrative note;;ACTIVE;2.64;2.65 +89443-6;Admission history and physical note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Admission history and physical note;OB Admit H&P note;;ACTIVE;2.64;2.65 +89444-4;Checklist;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Checklist;OB Checklist;;ACTIVE;2.64;2.65 +89445-1;Checklist;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Checklist;Gynecology Checklist;;ACTIVE;2.64;2.65 +89446-9;Consultation note;Find;Pt;Hospital;Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Hospital Consult note;OB Hosp Consult note;;ACTIVE;2.64;2.65 +89447-7;Consultation note;Find;Pt;Hospital;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Hospital Consult note;Gynecology Hosp Consult note;;ACTIVE;2.64;2.65 +89448-5;Letter;Find;Pt;Hospital;Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Hospital Letter;OB Hosp Letter;;ACTIVE;2.64;2.65 +89449-3;Letter;Find;Pt;Hospital;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Hospital Letter;Gynecology Hosp Letter;;ACTIVE;2.64;2.65 +89450-1;Note;Find;Pt;{Setting};Doc;Obstetrics.nurse;DOC.ONTOLOGY;2;Obstetrics Nurse Note;Ob Nurse Note;;ACTIVE;2.64;2.65 +89451-9;Note;Find;Pt;{Setting};Doc;Gynecology.nurse;DOC.ONTOLOGY;2;Gynecology Nurse Note;Gyn Nurse Note;;ACTIVE;2.64;2.65 +89452-7;Note;Find;Pt;{Setting};Doc;Obstetrics.nurse practitioner;DOC.ONTOLOGY;2;Obstetrics Nurse practitioner Note;Ob NP Note;;ACTIVE;2.64;2.65 +89453-5;Note;Find;Pt;{Setting};Doc;Gynecology.nurse practitioner;DOC.ONTOLOGY;2;Gynecology Nurse practitioner Note;Gyn NP Note;;ACTIVE;2.64;2.65 +89454-3;Note;Find;Pt;{Setting};Doc;Obstetrics.attending;DOC.ONTOLOGY;2;Obstetrics Attending Note;Ob Attend Note;;ACTIVE;2.64;2.65 +89455-0;Note;Find;Pt;{Setting};Doc;Gynecology.attending;DOC.ONTOLOGY;2;Gynecology Attending Note;Gyn Attend Note;;ACTIVE;2.64;2.65 +89456-8;Note;Find;Pt;{Setting};Doc;Obstetrics.resident;DOC.ONTOLOGY;2;Obstetrics Resident Note;Ob Res Note;;ACTIVE;2.64;2.65 +89457-6;Surgical operation note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Surgical operation note;OB Operative note;;ACTIVE;2.64;2.65 +8945-8;Fluid intake.enema;VRat;1H;Lower GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enema 1 hour;Fluid intake enema 1h;;ACTIVE;1.0h(3);2.48 +89458-4;Note;Find;Pt;Hospital;Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Hospital Note;OB Hosp Note;;ACTIVE;2.64;2.65 +89459-2;Note;Find;Pt;Hospital;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Hospital Note;Gynecology Hosp Note;;ACTIVE;2.64;2.65 +894-6;Blood group antibody screen.cell II;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Blood group antibody screen.cell II [Presence] in Serum or Plasma;Bld gp Ab Scn Cell II SerPl Ql;;ACTIVE;1.0;2.73 +89460-0;Note;Find;Pt;Outpatient;Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Outpatient Note;OB OP Note;;ACTIVE;2.64;2.65 +89461-8;Note;Find;Pt;Outpatient;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Outpatient Note;Gynecology OP Note;;ACTIVE;2.64;2.65 +89462-6;Note;Find;Pt;Outpatient;Doc;Obstetrics.nurse;DOC.ONTOLOGY;2;Obstetrics Nurse Outpatient Note;Ob Nurse OP Note;;ACTIVE;2.64;2.65 +89463-4;Note;Find;Pt;Outpatient;Doc;Gynecology.nurse;DOC.ONTOLOGY;2;Gynecology Nurse Outpatient Note;Gyn Nurse OP Note;;ACTIVE;2.64;2.65 +89464-2;Note;Find;Pt;Telephone encounter;Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Telephone encounter Note;OB Phone Note;;ACTIVE;2.64;2.65 +89465-9;Note;Find;Pt;Telephone encounter;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Telephone encounter Note;Gynecology Phone Note;;ACTIVE;2.64;2.65 +8946-6;Fluid intake.enema;VRat;8H;Lower GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enema 8 hour;Fluid intake enema 8h;;ACTIVE;1.0h(3);2.48 +89466-7;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Postoperative evaluation and management note;OB Post-op E/M note;;ACTIVE;2.64;2.65 +89467-5;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Postoperative evaluation and management note;Gynecology Post-op E/M note;;ACTIVE;2.64;2.65 +89468-3;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Preoperative evaluation and management note;OB Pre-op note;;ACTIVE;2.64;2.65 +89469-1;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Preoperative evaluation and management note;Gynecology Pre-op note;;ACTIVE;2.64;2.65 +89470-9;Summary note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Summary note;OB Summary note;;ACTIVE;2.64;2.65 +89471-7;Summary note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Summary note;Gynecology Summary note;;ACTIVE;2.64;2.65 +89472-5;Surgical operation note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Surgical operation note;Gynecology Operative note;;ACTIVE;2.64;2.65 +89473-3;Administrative note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Administrative note;Gynecology Administrative note;;ACTIVE;2.64;2.65 +8947-4;Fluid intake.enema;VRat;10H;Lower GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enema 10 hour;Fluid intake enema 10h;;ACTIVE;1.0h(3);2.48 +89474-1;OASIS E - Mobility - discharge performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Mobility - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.64;2.72 +89475-8;OASIS E - Self-care - discharge performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Self-care - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.64;2.72 +89476-6;Mobility - discharge goal;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Mobility - discharge goal [CMS Assessment];;;ACTIVE;2.64;2.72 +89477-4;OASIS E - Mobility - SOC and ROC performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Mobility - SOC and ROC performance during assessment period [CMS Assessment];;;ACTIVE;2.64;2.72 +89478-2;IRF-PAI v3.0, MDS v1.17.1, 1.17.2, OASIS E - Self-care - discharge goal;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2, OASIS E - Self-care - discharge goal [CMS Assessment];;;ACTIVE;2.64;2.72 +89479-0;OASIS E - Self-care - SOC and ROC performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Self-care - SOC and ROC performance during assessment period [CMS Assessment];;;ACTIVE;2.64;2.72 +89480-8;Azithromycin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Azithromycin [Susceptibility] by Genotype method;Azithromycin Islt Genotyp;;ACTIVE;2.64;2.69 +89481-6;Gentamicin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Gentamicin [Susceptibility] by Genotype method;Gentamicin Islt Genotyp;;ACTIVE;2.64;2.69 +8948-2;Fluid intake.enema;VRat;12H;Lower GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enema 12 hour;Fluid intake enema 12h;;ACTIVE;1.0h(3);2.48 +89482-4;Kanamycin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Kanamycin [Susceptibility] by Genotype method;Kanamycin Islt Genotyp;;ACTIVE;2.64;2.69 +89483-2;Capreomycin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Capreomycin [Susceptibility] by Genotype method;Capreomycin Islt Genotyp;;ACTIVE;2.64;2.69 +89484-0;Amikacin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Amikacin [Susceptibility] by Genotype method;Amikacin Islt Genotyp;;ACTIVE;2.64;2.69 +89485-7;Clarithromycin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Clarithromycin [Susceptibility] by Genotype method;Clarithro Islt Genotyp;;ACTIVE;2.64;2.69 +89486-5;Mycobacterial susceptibility panel;-;Pt;Isolate;Ord;Genotyping;PANEL.ABXBACT;1;Mycobacterial susceptibility panel Qualitative by Genotype method;Mycobacterial Susc Pnl Islt Genotyp;;ACTIVE;2.64;2.69 +89487-3;Fluoroquinolone;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Fluoroquinolone [Susceptibility] by Genotype method;FLQ Islt Genotyp;;ACTIVE;2.64;2.69 +89488-1;Isoniazid;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Isoniazid [Susceptibility] by Genotype method;Isoniazid Islt Genotyp;;ACTIVE;2.64;2.69 +89489-9;rifAMPin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;rifAMPin [Susceptibility] by Genotype method;rifAMPin Islt Genotyp;;ACTIVE;2.64;2.69 +8949-0;Fluid intake.enema;VRat;24H;Lower GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enema 24 hour;Fluid intake enema 24h;;ACTIVE;1.0h(3);2.48 +89490-7;Aminoglycoside;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Aminoglycoside [Susceptibility] by Genotype method;Aminoglycoside Islt Genotyp;;ACTIVE;2.64;2.69 +89491-5;Ethambutol;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Ethambutol [Susceptibility] by Genotype method;Ethambutol Islt Genotyp;;ACTIVE;2.64;2.69 +89492-3;Examination findings;Find;Pt;Umbilical cord;Doc;;DOC.MISC;2;Umbilical cord examination findings Document;Umbilical cord exam findings;;ACTIVE;2.64;2.64 +89493-1;Examination findings;Find;Pt;Placenta;Doc;;DOC.MISC;2;Placenta examination findings Document;Placenta exam findings;;ACTIVE;2.64;2.64 +89494-9;Diagnosis;Find;Pt;Placenta;Nom;;H&P.HX;2;Diagnosis of Placenta;Placental condition;;ACTIVE;2.64;2.64 +89495-6;Drug use^during pregnancy;Type;Pt;^Mother;Nom;;H&P.HX;2;Drug use by Mother --during pregnancy;Drug use preg Mother;;ACTIVE;2.64;2.66 +89496-4;Known exposure^during pregnancy;Type;Pt;^Mother;Nom;;H&P.HX;2;Maternal Known exposure --during pregnancy;Known exposure preg Mother;;ACTIVE;2.64;2.66 +89497-2;Prenatal tests;Type;Pt;^Mother;Nom;;H&P.HX;2;Mother's Prenatal tests;Prenatal tests Mother;;ACTIVE;2.64;2.66 +89498-0;Prenatal diagnosis;Find;Pt;^Patient;Nom;;H&P.HX;2;Prenatal diagnosis;Prenatal Dx;;ACTIVE;2.64;2.66 +89499-8;Diagnostic study note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Diagnostic study note;Gynecology Diag study note;;ACTIVE;2.64;2.64 +89500-3;Sulfatide Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Sulfatide IgG Ab [Presence] in Serum by Line blot;Sulfatide IgG Ser Ql Line blot;;ACTIVE;2.64;2.64 +89501-1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Smith extractable nuclear Ab+Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Line blot;ENA SM+RNP Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89502-9;SCL-70 extractable nuclear Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;SCL-70 extractable nuclear Ab [Units/volume] in Serum by Line blot;ENA Scl70 Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +89503-7;RNA polymerase III Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;RNA polymerase III Ab [Units/volume] in Serum by Line blot;RNAp III Ab Ser Line blot-aCnc;;ACTIVE;2.64;2.68 +89504-5;Ribosomal Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ribosomal Ab [Presence] in Serum by Line blot;Ribosomal Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89505-2;Proteinase 3 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Proteinase 3 Ab [Presence] in Serum by Line blot;Proteinase3 Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89506-0;Nucleosome Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Nucleosome Ab [Presence] in Serum by Line blot;Nucleosome Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89507-8;Myeloperoxidase Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Myeloperoxidase Ab [Presence] in Serum by Line blot;Myeloperoxidase Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +8950-8;Class;Type;Pt;Enema device;Nom;*;DEVICES;2;Type of Enema device*;Enema Device Class;;ACTIVE;1.0h(3);2.4 +89508-6;Intrinsic factor Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Intrinsic factor Ab [Presence] in Serum by Line blot;IF Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89509-4;Ganglioside GT1a Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GT1a IgG+IgM Ab [Presence] in Serum by Line blot;GT1a Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89510-2;Ganglioside GM3 Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM3 IgM Ab [Presence] in Serum by Line blot;GM3 IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89511-0;Ganglioside GM3 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM3 IgG+IgM Ab [Presence] in Serum by Line blot;GM3 IgG+IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89512-8;Ganglioside GD3 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GD3 IgG+IgM Ab [Presence] in Serum by Line blot;GD3 Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89513-6;RNA polymerase III Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;RNA polymerase III Ab [Presence] in Serum by Line blot;RNAp III Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89514-4;Glomerular basement membrane Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Glomerular basement membrane Ab [Presence] in Serum by Line blot;GBM Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89515-1;Ganglioside GT1b Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GT1b IgM Ab [Presence] in Serum by Line blot;GT1b Ganlg IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +8951-6;Enema device site;Anat;Pt;*^Patient;Nom;;DEVICES;2;Enema device site;Enema device site;;ACTIVE;1.0h(3);2.27 +89516-9;Ganglioside GT1b Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GT1b IgG+IgM Ab [Presence] in Serum by Line blot;GT1b Ganlg IgG+IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89517-7;Ganglioside GM2 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM2 IgG+IgM Ab [Presence] in Serum by Line blot;GM2 Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89518-5;Ganglioside GM1 Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM1 IgM Ab [Presence] in Serum by Line blot;GM1 Gangl IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89519-3;Ganglioside GM1 Ab.IgG+IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM1 IgG+IgM Ab [Presence] in Serum by Line blot;GM1 Gangl IgG+IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89520-1;Actin.smooth muscle Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Actin smooth muscle Ab [Presence] in Serum by Line blot;SMA Ab Ser Ql Line blot;;ACTIVE;2.64;2.64 +89521-9;Ganglioside GM1 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM1 IgG Ab [Presence] in Serum by Line blot;GM1 Gangl IgG Ser Ql Line blot;;ACTIVE;2.64;2.64 +89522-7;Ganglioside GM3 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM3 IgG Ab [Presence] in Serum by Line blot;GM3 IgG Ser Ql Line blot;;ACTIVE;2.64;2.64 +89523-5;Ganglioside GT1b Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GT1b IgG Ab [Presence] in Serum by Line blot;GT1b Ganlg IgG Ser Ql Line blot;;ACTIVE;2.64;2.64 +8952-4;Fluid intake.enteral tube;Vol;Pt;Upper GI tract;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake enteral tube Estimated;Fluid intake enteral tube Est;;ACTIVE;1.0h(3);2.48 +89524-3;Ganglioside GM2 Ab.IgM;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM2 IgM Ab [Presence] in Serum by Line blot;GM2 Gangl IgM Ser Ql Line blot;;ACTIVE;2.64;2.64 +89525-0;Ganglioside GM2 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Ganglioside GM2 IgG Ab [Presence] in Serum by Line blot;GM2 Gangl IgG Ser Ql Line blot;;ACTIVE;2.64;2.64 +89526-8;Sjogrens syndrome-B extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Sjogrens syndrome-B extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA SS-B Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89527-6;Sjogrens syndrome-A extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Sjogrens syndrome-A extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA SS-A Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89528-4;Nucleosome Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Nucleosome Ab [Presence] in Cerebral spinal fluid by Line blot;Nucleosome Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89529-2;Jo-1 extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Jo-1 extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA Jo1 Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +895-3;Blood group antibody screen.cells I+II+III;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Blood group antibody screen.cells I+II+III [Presence] in Serum or Plasma;Bld gp Ab Scn Cells x3 SerPl Ql;;ACTIVE;1.0;2.73 +89530-0;Histone Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Histone Ab [Presence] in Cerebral spinal fluid by Line blot;Histone Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89531-8;Smith extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Smith extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA SM Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +8953-2;Fluid intake.enteral tube;Vol;Pt;Upper GI tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake enteral tube Measured;Fluid intake enteral tube Measured;;ACTIVE;1.0h(3);2.48 +89532-6;Sjogrens syndrome-A extractable nuclear 52kD Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Presence] in Cerebral spinal fluid by Line blot;ENA SS-A 52kD Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89533-4;SCL-70 extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;SCL-70 extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA Scl70 Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89534-2;Ribosomal P Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Ribosomal P Ab [Presence] in Cerebral spinal fluid by Line blot;Ribosomal P Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89535-9;Ribonucleoprotein extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Ribonucleoprotein extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA RNP Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89536-7;PM-SCL extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;PM-SCL extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA PM/SCL Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89537-5;PCNA extractable nuclear Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;PCNA extractable nuclear Ab [Presence] in Cerebral spinal fluid by Line blot;ENA PCNA Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89538-3;Neuronal nuclear type 2 Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Neuronal nuclear type 2 Ab [Presence] in Cerebral spinal fluid by Line blot;Hu2 Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89539-1;Mitochondria M2 Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Mitochondria M2 Ab [Presence] in Cerebral spinal fluid by Line blot;Mitochondria M2 Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +8954-0;Fluid intake.enteral tube;VRat;1H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enteral tube 1 hour;Fluid intake enteral tube 1h;;ACTIVE;1.0h(3);2.48 +89540-9;Ganglioside GM1 Ab.IgM;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Ganglioside GM1 IgM Ab [Presence] in Cerebral spinal fluid by Line blot;GM1 Gangl IgM CSF Ql Line blot;;ACTIVE;2.64;2.64 +89541-7;Ganglioside GM1 Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Ganglioside GM1 IgG Ab [Presence] in Cerebral spinal fluid by Line blot;GM1 Gangl IgG CSF Ql Line blot;;ACTIVE;2.64;2.64 +89542-5;Centromere protein B Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Centromere protein B Ab [Presence] in Cerebral spinal fluid by Line blot;Centromere B Ab CSF Ql Line blot;;ACTIVE;2.64;2.64 +89543-3;Laboratory ask at order entry panel;-;Pt;^Patient;-;;PANEL.MISC;1;Laboratory ask at order entry panel;Lab AOE pnl Patient;;ACTIVE;2.64;2.64 +89544-1;Pulmonary Embolism Rule-out Criteria panel;-;Pt;^Patient;-;PERC;PANEL.CLIN.RISK;2;Pulmonary Embolism Rule-out Criteria panel PERC;PERC panel PERC;Copyright © 2004 Dr. Jeffery Kline Used with permission;ACTIVE;2.64;2.65 +89545-8;Total score;Score;Pt;^Patient;Qn;PERC;CLIN.RISK;2;PERC Total score;PERC Total score;Copyright © 2004 Dr. Jeffery Kline Used with permission;ACTIVE;2.64;2.65 +89546-6;Wells pulmonary embolism risk calculator panel;-;Pt;^Patient;-;Wells PE risk;PANEL.CLIN.RISK;2;Wells pulmonary embolism risk calculator panel;Wells PE risk pnl;© 2001 Dr. Phillip Wells. Used with permission.;ACTIVE;2.64;2.64 +89547-4;Total score;Score;Pt;^Patient;Qn;Wells PE risk;CLIN.RISK;2;Total score Wells pulmonary embolism risk calculator;Total score Wells PE risk;© 2001 Dr. Phillip Wells. Used with permission.;ACTIVE;2.64;2.64 +89548-2;Total score;Score;Pt;^Patient;Qn;Geneva.Revised;CLIN.RISK;2;Total score Revised Geneva Score;Total score Geneva.Revised;Copyright © 2006 American College of Physicians. Used with permission.;ACTIVE;2.64;2.65 +89549-0;Revised Geneva Score panel;-;Pt;^Patient;-;Geneva.Revised;PANEL.CLIN.RISK;2;Revised Geneva Score panel;Revised Geneva pnl;Copyright © 2006 American College of Physicians. Used with permission.;ACTIVE;2.64;2.65 +89550-8;Middle name;Pn;Pt;Provider;Nom;;ADMIN;2;Middle name Provider;Middle name Provider;;ACTIVE;2.64;2.66 +89551-6;Consultation note;Find;Pt;{Setting};Doc;Environmental health;DOC.ONTOLOGY;2;Environmental health Consult note;Envir Health Consult note;;ACTIVE;2.64;2.64 +89552-4;Note;Find;Pt;{Setting};Doc;Environmental health;DOC.ONTOLOGY;2;Environmental health Note;Envir Health Note;;ACTIVE;2.64;2.64 +89553-2;Evaluation and management of radiation exposure note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Evaluation and management of radiation exposure note;E+M Radiation exposure note;;ACTIVE;2.64;2.64 +89554-0;Evaluation and management of radiation exposure note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Evaluation and management of radiation exposure note;Nurse pract E+M Radiation exposure note;;ACTIVE;2.64;2.64 +89555-7;How many D per W did you engage in moderate to strenuous physical activity in the last 30D;NRat;30D;^Patient;Qn;;SURVEY.GNHLTH;4;How many days per week did you engage in moderate to strenuous physical activity in the last 30 days;;;ACTIVE;2.64;2.65 +89556-5;Comprehensive Universal Behavior Health Screen;-;Pt;^Patient;-;CUBS;PANEL.SURVEY.MTLHLTH;4;Comprehensive Universal Behavior Health Screen [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +8955-7;Fluid intake.enteral tube;VRat;8H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enteral tube 8 hour;Fluid intake enteral tube 8h;;ACTIVE;1.0h(3);2.48 +89557-3;Depression symptoms;Score;Pt;^Patient;Qn;CUBS;SURVEY.MTLHLTH;4;Depression symptoms score [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89558-1;Anxiety symptoms;Score;Pt;^Patient;Qn;CUBS;SURVEY.MTLHLTH;4;Anxiety symptoms score [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89559-9;Suicide risk;Score;Lifetime;^Patient;Qn;CUBS;SURVEY.MTLHLTH;4;Lifetime suicide risk score [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89560-7;Suicide risk;Score;Pt;^Patient;Qn;CUBS;SURVEY.MTLHLTH;4;Suicide risk score [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89561-5;Trauma symptoms;Score;Pt;^Patient;Qn;CUBS;SURVEY.MTLHLTH;4;Trauma symptoms score [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89562-3;Substance abuse symptoms;Score;Pt;^Patient;Qn;CUBS;SURVEY.MTLHLTH;4;Substance abuse symptoms score [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89563-1;Eating disorder symptoms;Score;Pt;^Patient;Qn;CUBS;SURVEY.MTLHLTH;4;Eating disorder symptoms score [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89564-9;Employment status;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Employment status [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +8956-5;Fluid intake.enteral tube;VRat;10H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enteral tube 10 hour;Fluid intake enteral tube 10h;;ACTIVE;1.0h(3);2.48 +89565-6;Housing status;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Housing status [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89566-4;Income status;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Income status [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89567-2;Food insecurity status;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Food insecurity status [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89568-0;Child care availability status;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Child care availability status [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89569-8;Access to transportation &or mobility status;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Access to transportation/mobility status [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89570-6;Involvement with criminal justice;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Involvement with criminal justice [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89571-4;Disability status;Find;Pt;^Patient;Ord;CUBS;SURVEY.MTLHLTH;4;Disability status [CUBS];;©2017 Medical Decision Logic Used with permission;ACTIVE;2.64;2.66 +89572-2;OASIS E - Functional abilities and goals - SOC, ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Functional abilities and goals - SOC, ROC [CMS Assessment];;;ACTIVE;2.64;2.72 +8957-3;Fluid intake.enteral tube;VRat;12H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enteral tube 12 hour;Fluid intake enteral tube 12h;;ACTIVE;1.0h(3);2.48 +89573-0;MDS v3.0 - RAI v1.16.1 - Cognitive patterns - NO, SO;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.16.1 - Cognitive patterns - NO, SO [CMS Assessment];;;ACTIVE;2.64;2.65 +89574-8;Exercise Vital Sign (EVS);-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Exercise Vital Sign (EVS);;;ACTIVE;2.64;2.65 +89575-5;Troponin T.cardiac;Imp;Pt;Ser/Plas;Ord;High sensitivity;CHEM;1;Troponin T.cardiac [Interpretation] in Serum or Plasma Qualitative by High sensitivity method;Troponin T SerPl HS-Imp;;ACTIVE;2.64;2.66 +89576-3;Troponin T.cardiac panel;-;Pt;Ser/Plas;-;High sensitivity;PANEL.CHEM;1;Troponin T.cardiac panel - Serum or Plasma by High sensitivity method;Cardiac troponin T pnl SerPl HS;;ACTIVE;2.64;2.68 +89577-1;Troponin I.cardiac panel;-;Pt;Ser/Plas;-;High sensitivity;PANEL.CHEM;1;Troponin I.cardiac panel - Serum or Plasma by High sensitivity method;Cardiac troponin I pnl SerPl HS;;ACTIVE;2.64;2.68 +89578-9;Troponin I.cardiac;Imp;Pt;Ser/Plas;Ord;High sensitivity;CHEM;1;Troponin I.cardiac [Interpretation] in Serum or Plasma Qualitative by High sensitivity method;Troponin I SerPl HS-Imp;;ACTIVE;2.64;2.66 +89579-7;Troponin I.cardiac;MCnc;Pt;Ser/Plas;Qn;High sensitivity;CHEM;1;Troponin I.cardiac [Mass/volume] in Serum or Plasma by High sensitivity method;Troponin I SerPl HS-mCnc;;ACTIVE;2.64;2.66 +89580-5;Coefficient of variation at 99th percentile URL;Ratio;Pt;Laboratory device;Qn;;DEVICES;2;Laboratory device Coefficient of variation at 99th percentile URL;Lab Device CV at 99% URL;;TRIAL;2.64;2.64 +8958-1;Fluid intake.enteral tube;VRat;24H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake enteral tube 24 hour;Fluid intake enteral tube 24h;;ACTIVE;1.0h(3);2.48 +89581-3;99th percentile upper reference limit;Arb;Pt;Laboratory device;Qn;;DEVICES;2;Laboratory device 99th percentile URL;Lab Device 99% URL;;TRIAL;2.64;2.65 +89582-1;Microscopic observation;Prid;Pt;Cvx;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Cervix by Acid fast stain;Acid fast Stn Cvx;;ACTIVE;2.64;2.64 +89583-9;Cytomegalovirus Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Cytomegalovirus Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;CMV Ag CSF Ql IF;;ACTIVE;2.64;2.64 +89584-7;Herpes simplex virus DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Lower respiratory specimen by NAA with probe detection;HSV DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +89585-4;Herpes simplex virus 1 DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Lower respiratory specimen by NAA with probe detection;HSV1 DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +89586-2;Herpes simplex virus 1 Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;HSV1 Ag CSF Ql IF;;ACTIVE;2.64;2.64 +89587-0;Herpes simplex virus 2 DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Lower respiratory specimen by NAA with probe detection;HSV2 DNA Lower resp Ql NAA+probe;;ACTIVE;2.64;2.64 +89588-8;Herpes simplex virus 2 Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;HSV2 Ag CSF Ql IF;;ACTIVE;2.64;2.64 +89589-6;Varicella zoster virus Ag;PrThr;Pt;CSF;Ord;IF;MICRO;1;Varicella zoster virus Ag [Presence] in Cerebral spinal fluid by Immunofluorescence;VZV Ag CSF Ql IF;;ACTIVE;2.64;2.64 +89590-4;Zika virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Zika virus IgG Ab [Titer] in Serum by Immunofluorescence;ZIKV IgG Titr Ser IF;;ACTIVE;2.64;2.64 +89591-2;Zika virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Zika virus IgM Ab [Titer] in Serum by Immunofluorescence;ZIKV IgM Titr Ser IF;;ACTIVE;2.64;2.64 +89592-0;Bartonella quintana DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Bartonella quintana DNA [Presence] in Tissue by NAA with probe detection;B quintana DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +89593-8;Bartonella sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Bartonella sp DNA [Presence] in Tissue by NAA with probe detection;Bartonella DNA Tiss Ql NAA+probe;;ACTIVE;2.64;2.64 +89594-6;Legionella pneumophila Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Legionella pneumophila Ag [Presence] in Lower respiratory specimen by Immunofluorescence;L pneumo Ag Lower resp Ql IF;;ACTIVE;2.64;2.64 +89595-3;Legionella pneumophila Ag;PrThr;Pt;Tiss;Ord;IF;MICRO;1;Legionella pneumophila Ag [Presence] in Tissue by Immunofluorescence;L pneumo Ag Tiss Ql IF;;ACTIVE;2.64;2.64 +89596-1;Listeria monocytogenes DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Listeria monocytogenes DNA [Presence] in Blood by NAA with probe detection;L monocytog DNA Bld Ql NAA+probe;;ACTIVE;2.64;2.64 +89597-9;Mycoplasma genitalium DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;M genitalium DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +89598-7;Mycoplasma hominis DNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Mycoplasma hominis DNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;M hominis DNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.64;2.64 +8959-9;Fluid intake.gastrostomy tube;Vol;Pt;Upper GI tract;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake gastrostomy tube Estimated;Fluid intake G-tube Est;;ACTIVE;1.0h(3);2.48 +89599-5;Toxoplasma gondii;PrThr;Pt;CSF;Ord;Organism specific culture;MICRO;1;Toxoplasma gondii [Presence] in Cerebral spinal fluid by Organism specific culture;T gondii CSF Ql Cult;;ACTIVE;2.64;2.64 +89600-1;FDA-initiated compliance action drug registration and listing inactivation;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label FDA-initiated compliance action drug registration and listing inactivation;FDA-init label compl act drug list inact;;ACTIVE;2.65;2.65 +89601-9;Proof of encounter certificate;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Proof of encounter certificate;Encounter certificate;;ACTIVE;2.65;2.65 +89602-7;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Kidney.left;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Kidney - left;CT Guided Kidney-L Cyst asp;;ACTIVE;2.65;2.65 +89603-5;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Kidney.right;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Kidney - right;CT Guided Kidney-R Cyst asp;;ACTIVE;2.65;2.65 +89604-3;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Kidney.bilateral;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Kidney - bilateral;CT Guided Kdny-Bl Cyst asp;;ACTIVE;2.65;2.65 +89605-0;Guidance for ablation of tissue;Find;Pt;Abdomen>Kidney.right;Doc;CT;RAD;2;CT Guidance for ablation of tissue of Kidney - right;CT Guided Kidney-R Ablation;;ACTIVE;2.65;2.65 +89606-8;Guidance for ablation of tissue;Find;Pt;Abdomen>Kidney.left;Doc;CT;RAD;2;CT Guidance for ablation of tissue of Kidney - left;CT Guided Kidney-L Ablation;;ACTIVE;2.65;2.65 +8960-7;Fluid intake.gastrostomy tube;Vol;Pt;Upper GI tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake gastrostomy tube Measured;Fluid intake G-tube Measured;;ACTIVE;1.0h(3);2.48 +89607-6;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Lung.right;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Lung - right;CT Guided Lung-R PC fluid asp;;ACTIVE;2.65;2.65 +89608-4;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Lung.left;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Lung - left;CT Guided Lung-L PC fluid asp;;ACTIVE;2.65;2.65 +89609-2;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Pericardial space;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Pericardial space;CT Guided Pericardial space PC fluid asp;;ACTIVE;2.65;2.65 +896-1;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;Cold absorption;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by Cold absorption;Bld gp Ab Scn SerPl Ql Cold Abs;;ACTIVE;1.0;2.73 +89610-0;Guidance for placement of catheter;Find;Pt;Abdomen>Peritoneal space;Doc;CT;RAD;2;CT Guidance for placement of catheter in Peritoneal space;CT Guided Peritoneal space Cath place;;ACTIVE;2.65;2.65 +89611-8;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Pleural space.right;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Pleural space - right;CT Guided Pl space-R PC fluid asp;;ACTIVE;2.65;2.65 +89612-6;Guidance for percutaneous aspiration of fluid;Find;Pt;Chest>Pleural space.left;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Pleural space - left;CT Guided Pl space-L PC fluid asp;;ACTIVE;2.65;2.65 +89613-4;Guidance for drainage+placement of drainage catheter^WO contrast;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Abdomen-- WO contrast;CT Guided Abd Drain+cath place--WO contr;;ACTIVE;2.65;2.66 +89614-2;Guidance for percutaneous biopsy^WO contrast;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for biopsy of Kidney-- WO contrast;CT Guided Kidney Bx--WO contr;;ACTIVE;2.65;2.65 +8961-5;Fluid intake.gastrostomy tube;VRat;1H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake gastrostomy tube 1 hour;Fluid intake G-tube 1h;;ACTIVE;1.0h(3);2.48 +89615-9;Guidance for drainage+placement of drainage catheter^W contrast IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Abdomen-- W contrast IV;CT Guided Abd Drain+cath plc--W contr IV;;ACTIVE;2.65;2.66 +89616-7;Guidance for percutaneous aspiration of cyst^WO contrast;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Pancreas-- WO contrast;CT Guided Pancreas Cyst asp--WO contr;;ACTIVE;2.65;2.65 +89617-5;Guidance for percutaneous aspiration of cyst^W contrast IV;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Kidney-- W contrast IV;CT Guided Kidney Cyst asp--W contr IV;;ACTIVE;2.65;2.65 +89618-3;Guidance for percutaneous aspiration of cyst^WO contrast;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Kidney-- WO contrast;CT Guided Kidney Cyst asp--WO contr;;ACTIVE;2.65;2.65 +89619-1;Guidance for percutaneous biopsy^W contrast IV;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Guidance for biopsy of Pancreas-- W contrast IV;CT Guided Pancreas Bx--W contr IV;;ACTIVE;2.65;2.65 +89620-9;Guidance for percutaneous biopsy^W contrast IV;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for biopsy of Abdomen-- W contrast IV;CT Guided Abd Bx--W contr IV;;ACTIVE;2.65;2.65 +89621-7;Guidance for percutaneous biopsy^W contrast IV;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for biopsy of Kidney-- W contrast IV;CT Guided Kidney Bx--W contr IV;;ACTIVE;2.65;2.65 +89622-5;Guidance for percutaneous aspiration of fluid;Find;Pt;Abdomen>Peritoneal space;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Peritoneal space;CT Guided Peritoneal space PC fluid asp;;ACTIVE;2.65;2.65 +8962-3;Fluid intake.gastrostomy tube;VRat;8H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake gastrostomy tube 8 hour;Fluid intake G-tube 8h;;ACTIVE;1.0h(3);2.48 +89623-3;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Peritoneal space;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Peritoneal space;CT Guided Peritoneal Drain+cath place;;ACTIVE;2.65;2.66 +89624-1;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Peritoneal space;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Peritoneal space;CT Guided Peritoneal Absc drain+cath plc;;ACTIVE;2.65;2.66 +89625-8;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Kidney;CT Guided Kidney Cyst asp;;ACTIVE;2.65;2.65 +89626-6;Multisection^W contrast IV;Find;Pt;Abdomen>Abdominal vessels & Pelvis>Pelvis vessels & Lower extremity.bilateral>Lower extremity vessels;Doc;CT.angio;RAD;2;CTA Abdominal, Pelvis and Lower extremity vessels W contrast IV;CTA Abd+Pelv+LE ves W contr IV;;ACTIVE;2.65;2.65 +89627-4;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Ileum.right;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Ileum - right;CT Guided Ileum-R Cyst asp;;ACTIVE;2.65;2.65 +89628-2;Guidance for percutaneous aspiration of cyst;Find;Pt;Abdomen>Ileum.left;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Ileum - left;CT Guided Ileum-L Cyst asp;;ACTIVE;2.65;2.65 +89629-0;Guidance for percutaneous aspiration of cyst;Find;Pt;Chest>Lung.left;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Lung - left;CT Guided Lung-L Cyst asp;;ACTIVE;2.65;2.65 +89630-8;Guidance for percutaneous aspiration of cyst;Find;Pt;Chest>Lung.right;Doc;CT;RAD;2;CT Guidance for aspiration of cyst of Lung - right;CT Guided Lung-R Cyst asp;;ACTIVE;2.65;2.65 +8963-1;Fluid intake.gastrostomy tube;VRat;10H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake gastrostomy tube 10 hour;Fluid intake G-tube 10h;;ACTIVE;1.0h(3);2.48 +89631-6;Guidance for localization of tumor^W Radionuclide IV;Find;Pt;Whole body;Doc;NM.SPECT+CT;RAD;2;SPECT+CT Guidance for localization of tumor of Whole body;SPECT+CT Guided WB Tum loc--W RNC IV;;ACTIVE;2.65;2.65 +89632-4;Toxoplasma gondii;PrThr;Pt;Placenta;Ord;Organism specific culture;MICRO;1;Toxoplasma gondii [Presence] in Placenta by Organism specific culture;T gondii Placenta Ql Cult;;ACTIVE;2.65;2.65 +89633-2;Actinomyces sp identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Actinomyces sp identified in Lower respiratory specimen by Organism specific culture;Actinomyces Lower resp Cult;;ACTIVE;2.65;2.65 +89634-0;Actinomyces sp identified;Prid;Pt;Implanted device;Nom;Organism specific culture;MICRO;1;Actinomyces sp identified in Implanted device by Organism specific culture;Actinomyces Implnt dev Cult;;ACTIVE;2.65;2.65 +89635-7;Mycobacterium tuberculosis DNA;PrThr;Pt;Implanted device;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Implanted device by NAA with probe detection;M tb DNA Implnt dev Ql NAA+probe;;ACTIVE;2.65;2.65 +89636-5;Mycobacterium sp identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Lower respiratory specimen by Organism specific culture;Mycobacterium Lower resp Cult;;ACTIVE;2.65;2.65 +89637-3;Mycobacterium sp identified;Prid;Pt;Implanted device;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Implanted device by Organism specific culture;Mycobacterium Implnt dev Cult;;ACTIVE;2.65;2.65 +89638-1;Nocardia sp identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Nocardia sp identified in Lower respiratory specimen by Organism specific culture;Nocardia Lower resp Cult;;ACTIVE;2.65;2.65 +89639-9;Nocardia sp identified;Prid;Pt;Implanted device;Nom;Organism specific culture;MICRO;1;Nocardia sp identified in Implanted device by Organism specific culture;Nocardia Implnt dev Cult;;ACTIVE;2.65;2.65 +89640-7;Chlamydophila pneumoniae Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay;C pneum IgM Ser Ql IA;;ACTIVE;2.65;2.65 +89641-5;Chlamydophila pneumoniae Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Chlamydophila pneumoniae IgG Ab [Presence] in Serum by Immunoassay;C pneum IgG Ser Ql IA;;ACTIVE;2.65;2.65 +89642-3;Corynebacterium diphtheriae toxin Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Corynebacterium diphtheriae toxin IgG Ab [Presence] in Serum by Immunoassay;C diphtheriae Tox IgG Ser Ql IA;;ACTIVE;2.65;2.65 +89643-1;Bacteria identified;Prid;Pt;Respiratory.lower;Nom;Aerobic culture;MICRO;1;Bacteria identified in Lower respiratory specimen by Aerobe culture;Bacteria Lower resp Aerobe Cult;;ACTIVE;2.65;2.65 +89644-9;Bacteria identified;Prid;Pt;Respiratory.lower;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Lower respiratory specimen by Anaerobe culture;Bacteria Lower resp Anaerobe Cult;;ACTIVE;2.65;2.65 +89645-6;Bartonella henselae DNA;PrThr;Pt;Implanted device;Ord;Probe.amp.tar;MICRO;1;Bartonella henselae DNA [Presence] in Implanted device by NAA with probe detection;B henselae DNA Implnt dev Ql NAA+probe;;ACTIVE;2.65;2.65 +89646-4;Bartonella quintana DNA;PrThr;Pt;Implanted device;Ord;Probe.amp.tar;MICRO;1;Bartonella quintana DNA [Presence] in Implanted device by NAA with probe detection;B quintana DNA Implnt dev Ql NAA+probe;;ACTIVE;2.65;2.65 +89647-2;Bartonella sp DNA;PrThr;Pt;Implanted device;Ord;Probe.amp.tar;MICRO;1;Bartonella sp DNA [Presence] in Implanted device by NAA with probe detection;Bartonella DNA Implnt dev Ql NAA+probe;;ACTIVE;2.65;2.65 +89648-0;Chlamydia trachomatis;PrThr;Pt;Thrt;Ord;Organism specific culture;MICRO;1;Chlamydia trachomatis [Presence] in Throat by Organism specific culture;C trach Throat Ql Cult;;ACTIVE;2.65;2.65 +8964-9;Fluid intake.gastrostomy tube;VRat;12H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake gastrostomy tube 12 hour;Fluid intake G-tube 12h;;ACTIVE;1.0h(3);2.48 +89649-8;Coxiella burnetii DNA;PrThr;Pt;Implanted device;Ord;Probe.amp.tar;MICRO;1;Coxiella burnetii DNA [Presence] in Implanted device by NAA with probe detection;C burnet DNA Implnt dev Ql NAA+probe;;ACTIVE;2.65;2.65 +89650-6;Tropheryma whipplei DNA;PrThr;Pt;Implanted device;Ord;Probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Implanted device by NAA with probe detection;T whipplei DNA Implnt dev Ql NAA+probe;;ACTIVE;2.65;2.7 +89651-4;Human metapneumovirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;hMPV RNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +89652-2;Human metapneumovirus Identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Human metapneumovirus identified in Lower respiratory specimen by Organism specific culture;hMPV Lower resp Cult;;ACTIVE;2.65;2.65 +89653-0;Parainfluenza virus identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Parainfluenza virus identified in Lower respiratory specimen by Organism specific culture;HPIV Lower resp Cult;;ACTIVE;2.65;2.65 +89654-8;Parainfluenza virus identified;Prid;Pt;Respiratory.upper;Nom;Organism specific culture;MICRO;1;Parainfluenza virus identified in Upper respiratory specimen by Organism specific culture;HPIV Upper resp Cult;;ACTIVE;2.65;2.68 +89655-5;Virus identified;Prid;Pt;Tiss;Nom;Shell vial culture;MICRO;1;Virus identified in Tissue by Shell vial culture;Virus Tiss Shell Vial Cult;;ACTIVE;2.65;2.65 +8965-6;Fluid intake.gastrostomy tube;VRat;24H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake gastrostomy tube 24 hour;Fluid intake G-tube 24h;;ACTIVE;1.0h(3);2.48 +89656-3;Fungus identified;Prid;Pt;Respiratory.lower;Nom;Culture;MICRO;1;Fungus identified in Lower respiratory specimen by Culture;Fungus Lower resp Cult;;ACTIVE;2.65;2.65 +89657-1;Microscopic observation;Prid;Pt;Respiratory.lower;Nom;Toluidine blue O stain;MICRO;1;Microscopic observation [Identifier] in Lower respiratory specimen by Toluidine blue O stain;TBO Stn Lower resp;;ACTIVE;2.65;2.65 +89658-9;Microscopic observation;Prid;Pt;Respiratory.lower;Nom;Methenamine silver nitrate stain;MICRO;1;Microscopic observation [Identifier] in Lower respiratory specimen by Methenamine silver nitrate stain;MS Nitrate Stn Lower resp;;ACTIVE;2.65;2.65 +89659-7;Microscopic observation;Prid;Pt;Implanted device;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Implanted device by Gram stain;Gram Stn Implnt dev;;ACTIVE;2.65;2.65 +89660-5;Microscopic observation;Prid;Pt;Implanted device;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Implanted device by Acid fast stain;Acid fast Stn Implnt dev;;ACTIVE;2.65;2.65 +89661-3;Microscopic observation;Prid;Pt;Respiratory.upper;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Upper respiratory specimen by Acid fast stain;Acid fast Stn Upper resp;;ACTIVE;2.65;2.68 +89662-1;Microscopic observation;Prid;Pt;Respiratory.lower;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Lower respiratory specimen by Acid fast stain;Acid fast Stn Lower resp;;ACTIVE;2.65;2.65 +89663-9;I felt irritable in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt irritable in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +8966-4;Class;Type;Pt;Gastrostomy tube;Nom;;IO.TUBE;2;Type of Gastrostomy tube;G-tube Class;;ACTIVE;1.0h(3);2.27 +89664-7;I felt lonely even when I was with other people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt lonely even when I was with other people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89665-4;I had mood swings in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had mood swings in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89666-2;I felt like crying in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like crying in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89667-0;I felt unloved in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt unloved in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89668-8;I felt like I needed help for my depression in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I felt like I needed help for my depression in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89669-6;PROMIS cancer emotional distress - depression - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cancer emotional distress - depression - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89670-4;PROMIS cancer item bank - emotional distress - depression - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS cancer item bank - emotional distress - depression - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89671-2;How much did pain interfere with your ability to pay attention in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did pain interfere with your ability to pay attention in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +8967-2;Fluid intake.upper GI tube;Vol;Pt;Upper GI tract;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake upper GI tube Estimated;Fluid intake UGI tube Est;;ACTIVE;1.0h(3);2.48 +89672-0;How often did pain make it hard for you to walk more than 5 minutes at a time in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How often did pain make it hard for you to walk more than 5 minutes at a time in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89673-8;How much did you worry about pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How much did you worry about pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89674-6;PROMIS cancer item bank - pain interference - version 1.1;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS cancer item bank - pain interference - version 1.1;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89675-3;PROMIS cancer pain interference - version 1.1 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cancer pain interference - version 1.1 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89676-1;PROMIS cancer fatigue - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cancer fatigue - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89677-9;PROMIS cancer item bank - fatigue - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS cancer item bank - fatigue - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89678-7;I had unpleasant thoughts that wouldn't leave my mind in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I had unpleasant thoughts that wouldn't leave my mind in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89679-5;PROMIS cancer item bank - emotional distress - anxiety - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS cancer item bank - emotional distress - anxiety - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +8968-0;Fluid intake.upper GI tube;Vol;Pt;Upper GI tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake upper GI tube Measured;Fluid intake UGI tube Measured;;ACTIVE;1.0h(3);2.48 +89680-3;PROMIS cancer emotional distress - anxiety - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cancer emotional distress - anxiety - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89681-1;Does your health now limit you in exercising regularly;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in exercising regularly [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89682-9;Are you able to climb several flights of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to climb several flights of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89683-7;Are you able to do 2H of physical labor;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do two hours of physical labor [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +89684-5;Are you able to run on uneven ground;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run on uneven ground [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89685-2;Does your health now limit you in doing housework or jobs around the house;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing housework or jobs around the house [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89686-0;Does your health now limit you in doing recreational activities which require little exertion (e.g., card playing, knitting, etc.);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing recreational activities which require little exertion (e.g., card playing, knitting, etc.) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89687-8;Does your health now limit you in pursuing your hobbies or other leisure activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in pursuing your hobbies or other leisure activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89688-6;Does your health now limit you in traveling out of town for an overnight stay;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in traveling out of town for an overnight stay [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89689-4;PROMIS cancer item bank - physical function - version 1.1;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS cancer item bank - physical function - version 1.1;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89690-2;PROMIS cancer physical function - version 1.1 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS cancer physical function - version 1.1 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89691-0;Pseudocasts;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Pseudocasts [#/area] in Urine by Computer assisted method;Pseudocasts #/area Ur Comp Assist;;ACTIVE;2.65;2.65 +89692-8;Heart rate;NRat;10M^mean;^Fetus;Qn;;HRTRATE.MOLEC;2;Heart rate 10 minutes mean Fetus;Fet 10M Mean Heart rate;;ACTIVE;2.65;2.65 +89693-6;Total score;Score;Pt;^Patient;Qn;PESI;CLIN.RISK;2;PESI Total score;PESI Total score;;ACTIVE;2.65;2.65 +89694-4;Pulmonary Embolism Severity Index panel;-;Pt;^Patient;-;PESI;PANEL.CLIN.RISK;2;Pulmonary Embolism Severity Index panel [PESI];PESI panel;;ACTIVE;2.65;2.65 +89695-1;Guidance for drainage+placement of drainage catheter^WO contrast;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Pelvis-- WO contrast;CT Guided Pelv Drain+cath place--WO cont;;ACTIVE;2.65;2.66 +89696-9;Guidance for drainage+placement of drainage catheter^W contrast IV;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Pelvis-- W contrast IV;CT Guided Pelv Drain+cath plc--W cont IV;;ACTIVE;2.65;2.66 +89697-7;Guidance for drainage of pseudocyst+placement of drainage catheter;Find;Pt;Abdomen>Pancreas;Doc;CT;RAD;2;CT Guidance for drainage of pseudocyst and placement of drainage catheter of Pancreas;CT Guided Pancreas Pcyst drain+cath plc;;ACTIVE;2.65;2.66 +8969-8;Fluid intake.upper GI tube;VRat;1H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake upper GI tube 1 hour;Fluid intake UGI tube 1h;;ACTIVE;1.0h(3);2.48 +89698-5;Guidance for injection;Find;Pt;Lower extremity.right>Ankle;Doc;CT;RAD;2;CT Guidance for injection of Ankle - right;CT Guided Ankle-R Inj;;ACTIVE;2.65;2.65 +89699-3;Guidance for injection;Find;Pt;Lower extremity.left>Ankle;Doc;CT;RAD;2;CT Guidance for injection of Ankle - left;CT Guided Ankle-L Inj;;ACTIVE;2.65;2.65 +89700-9;Guidance for injection;Find;Pt;Lower extremity.right>Hip;Doc;CT;RAD;2;CT Guidance for injection of Hip - right;CT Guided Hip-R Inj;;ACTIVE;2.65;2.65 +89701-7;Guidance for injection;Find;Pt;Lower extremity.left>Hip;Doc;CT;RAD;2;CT Guidance for injection of Hip - left;CT Guided Hip-L Inj;;ACTIVE;2.65;2.65 +89702-5;Guidance for injection;Find;Pt;Upper extremity.bilateral>Shoulder;Doc;CT;RAD;2;CT Guidance for injection of Shoulder - bilateral;CT Guided Shoulder-Bl Inj;;ACTIVE;2.65;2.65 +89703-3;Guidance for injection;Find;Pt;Upper extremity.left>Shoulder;Doc;CT;RAD;2;CT Guidance for injection of Shoulder - left;CT Guided Should-L Inj;;ACTIVE;2.65;2.65 +89704-1;Guidance for injection;Find;Pt;Upper extremity.right>Shoulder;Doc;CT;RAD;2;CT Guidance for injection of Shoulder - right;CT Guided Should-R Inj;;ACTIVE;2.65;2.65 +89705-8;Guidance for injection;Find;Pt;Upper extremity.left>Wrist;Doc;CT;RAD;2;CT Guidance for injection of Wrist - left;CT Guided Wrist-L Inj;;ACTIVE;2.65;2.65 +8970-6;Fluid intake.upper GI tube;VRat;8H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake upper GI tube 8 hour;Fluid intake UGI tube 8h;;ACTIVE;1.0h(3);2.48 +89706-6;Guidance for injection;Find;Pt;Lower extremity.bilateral>Knee;Doc;CT;RAD;2;CT Guidance for injection of Knee - bilateral;CT Guided Knee-Bl Inj;;ACTIVE;2.65;2.65 +89707-4;Guidance for injection;Find;Pt;Lower extremity.right>Knee;Doc;CT;RAD;2;CT Guidance for injection of Knee - right;CT Guided Knee-R Inj;;ACTIVE;2.65;2.65 +89708-2;Guidance for injection;Find;Pt;Lower extremity.left>Knee;Doc;CT;RAD;2;CT Guidance for injection of Knee - left;CT Guided Knee-L Inj;;ACTIVE;2.65;2.65 +89709-0;Guidance GE 3 levels for injection;Find;Pt;XXX>Spine facet joint;Doc;CT;RAD;2;CT Guidance for greater than 2 levels for injection of Spine facet joint;CT Guided Spine FJ Inj GE3 levels;;ACTIVE;2.65;2.65 +89710-8;Guidance 2 levels for injection;Find;Pt;XXX>Spine facet joint;Doc;CT;RAD;2;CT Guidance for 2 levels injection of Spine facet joint;CT Guided Spine FJ Inj 2 levels;;ACTIVE;2.65;2.65 +89711-6;Guidance 1 level for injection;Find;Pt;XXX>Spine facet joint;Doc;CT;RAD;2;CT Guidance for 1 level injection of Spine facet joint;CT Guided Spine FJ Inj 1 level;;ACTIVE;2.65;2.65 +89712-4;Guidance limited for localization of tumor^W 18F-FDG IV+W contrast IV;Find;Pt;XXX;Doc;PT+CT;RAD;2;PET+CT Guidance for limited for localization of tumor of Unspecified body region-- W 18F-FDG IV and W contrast IV;PET+CT Tum loc Ltd--W 18F-FDG+contr IV;;ACTIVE;2.65;2.65 +89713-2;Multisection^W contrast IS;Find;Pt;Upper extremity.right>Upper extremity joint;Doc;CT;RAD;2;CT Upper extremity joint - right Arthrogram;CT UE joint-R W contr IS;;ACTIVE;2.65;2.65 +8971-4;Fluid intake.upper GI tube;VRat;10H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake upper GI tube 10 hour;Fluid intake UGI tube 10h;;ACTIVE;1.0h(3);2.48 +89714-0;Multisection^W contrast IS;Find;Pt;Upper extremity.left>Upper extremity joint;Doc;CT;RAD;2;CT Upper extremity joint - left Arthrogram;CT UE joint-L W contr IS;;ACTIVE;2.65;2.65 +89715-7;Multisection^W contrast IS;Find;Pt;Lower extremity.right>Lower extremity joint;Doc;CT;RAD;2;CT Lower extremity joint - right Arthrogram;CT LE joint-R W contr IS;;ACTIVE;2.65;2.65 +89716-5;Multisection^W contrast IS;Find;Pt;Lower extremity.left>Lower extremity joint;Doc;CT;RAD;2;CT Lower extremity joint - left Arthrogram;CT LE joint-L W contr IS;;ACTIVE;2.65;2.65 +89717-3;Guidance for stereotactic localization^WO & W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for stereotactic localization of Unspecified body region-- WO and W contrast IV;CT Guided Str loc--WO+W contr IV;;ACTIVE;2.65;2.65 +89718-1;Guidance for stereotactic localization^W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for stereotactic localization of Unspecified body region-- W contrast IV;CT Guided Str loc--W contr IV;;ACTIVE;2.65;2.65 +89719-9;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Chest>Lung.right;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Lung - right;CT Guided Lung-R Absc drain+cath place;;ACTIVE;2.65;2.66 +89720-7;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Chest>Lung.left;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Lung - left;CT Guided Lung-L Absc drain+cath place;;ACTIVE;2.65;2.66 +89721-5;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Retroperitoneum;CT Guided Retroper Absc drain+cath plc;;ACTIVE;2.65;2.66 +8972-2;Fluid intake.upper GI tube;VRat;12H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake upper GI tube 12 hour;Fluid intake UGI tube 12h;;ACTIVE;1.0h(3);2.48 +89722-3;Multisection^W contrast IV;Find;Pt;Upper extremity.left>Upper extremity veins;Doc;CT.angio;RAD;2;CTA Upper extremity veins - left W contrast IV;CTA UE vv-L W contr IV;;ACTIVE;2.65;2.65 +89723-1;Multisection^W contrast IV;Find;Pt;Upper extremity.right>Upper extremity veins;Doc;CT.angio;RAD;2;CTA Upper extremity veins - right W contrast IV;CTA UE vv-R W contr IV;;ACTIVE;2.65;2.65 +89724-9;Minimum Data Set (MDS) for Public Health Emergency Operations Centers (EOC);-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Minimum Data Set (MDS) for Public Health Emergency Operations Centers (EOC) [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.69 +89725-6;Managing and commanding;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Managing and commanding [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89726-4;Operating;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Operating [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.69 +89727-2;Planning and intelligence;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Planning and intelligence [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.7 +89728-0;Logistics;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Logistics [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.69 +89729-8;Finance and administration;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Finance and administration [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +8973-0;Fluid intake.upper GI tube;VRat;24H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake upper GI tube 24 hour;Fluid intake UGI tube 24h;;ACTIVE;1.0h(3);2.48 +89730-6;Decisions and approvals;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Decisions and approvals [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89731-4;Coordination;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Coordination [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89732-2;Communication;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Communication [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89733-0;Leadership assigned;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Leadership assigned [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89734-8;Response status and response team;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Response status and response team [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89735-5;Activate and deactivate decision;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Activate and deactivate decision [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89736-3;Plan approval;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Plan approval [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89737-1;Partners list;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Partners list [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89738-9;Partner tasking;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Partner tasking [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89739-7;Public communication;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Public communication [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89740-5;Inter-agency communication;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Inter-agency communication [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89741-3;Intra-agency communication;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Intra-agency communication [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89742-1;Incident commander information;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Incident commander information [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89743-9;Response section information;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Response section information [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89744-7;Response plan;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Response plan [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89745-4;Daily schedule;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Daily schedule [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89746-2;Start and terminate response;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Start and terminate response [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89747-0;Response team;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Response team [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +8974-8;Fluid intake.intravascular;Vol;Pt;Vascular system;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake intravascular Estimated;Fluid intake IV Est;;ACTIVE;1.0h(3);2.48 +89748-8;Reporting to leadership;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Reporting to leadership [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89749-6;Standard operating procedures inventory;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Standard operating procedures inventory [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89750-4;Task tracing;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Task tracing [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89751-2;Event investigation;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Event investigation [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.69 +89752-0;Controlling;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Controlling [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89753-8;Task information;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Task information [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89754-6;Event status;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Event status [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.69 +8975-5;Fluid intake.intravascular;Vol;Pt;Vascular system;Qn;Measured;IO_IN.MOLEC;2;Fluid intake intravascular Measured;Fluid intake IV Measured;;ACTIVE;1.0h(3);2.63 +89755-3;Risk assessments;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Risk assessments [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89756-1;Laboratory operations report;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Laboratory operations report [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.69 +89757-9;Countermeasures operations;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Countermeasures operations [CDC Emergency Operations Centers];;;ACTIVE;2.65;2.68 +89758-7;Situation analysis;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Situation analysis [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.7 +89759-5;Planning;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Planning [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89760-3;After action review;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;After action review [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89761-1;Information management;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Information management [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89762-9;Infectious diseases reporting and surveillance;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Infectious diseases reporting and surveillance [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +8976-3;Fluid intake.intravascular;VRat;1H;Vascular system;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake intravascular 1 hour;Fluid intake IV 1h;;ACTIVE;1.0h(3);2.48 +89763-7;Laboratory reporting;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Laboratory reporting [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89764-5;Public health emergency event surveillance;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Public health emergency event surveillance [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89765-2;Rumors surveillance;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Rumors surveillance [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89766-0;Daily watch-keeping record;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Daily watch-keeping record [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89767-8;Risk assessment and consultation;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Risk assessment and consultation [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89768-6;Situational report;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Situational report [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89769-4;Plan development;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Plan development [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89770-2;Authority to plan;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Authority to plan [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +8977-1;Fluid intake.intravascular;VRat;8H;Vascular system;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake intravascular 8 hour;Fluid intake IV 8h;;ACTIVE;1.0h(3);2.48 +89771-0;Plan components;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Plan components [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89772-8;After action report;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;After action report [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89773-6;Improvement plan;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Improvement plan [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89774-4;Document management;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Document management [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89775-1;Resources management;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Resources management [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.69 +89776-9;Information and communications technology support;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Information and communications technology support [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89777-7;Health agencies;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Health agencies [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.69 +89778-5;Experts and staff;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Experts and staff [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89779-3;Rapid response team;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Rapid response team [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89780-1;Volunteers;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Volunteers [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89781-9;Reserves of emergency supplies;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Reserves of emergency supplies [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89782-7;Shelters;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Shelters [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89783-5;Technology assessment;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Technology assessment [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89784-3;Budget management;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Budget management [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89785-0;Purchase and dispatch;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Purchase and dispatch [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89786-8;Human resources management;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Human resources management [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89787-6;Budget;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Budget [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89788-4;Donor;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Donor [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +8978-9;Fluid intake.intravascular;VRat;10H;Vascular system;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake intravascular 10 hour;Fluid intake IV 10h;;ACTIVE;1.0h(3);2.48 +89789-2;Human resources;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Human resources [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +897-9;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;Elution;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by Elution;Bld gp Ab Scn SerPl Ql Elution;;ACTIVE;1.0;2.73 +89790-0;Purchase;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Purchase [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89791-8;Dispatch;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Dispatch [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +89792-6;Event activation or deactivation;Type;Pt;^Event;Ord;;SURVEY.CDC;4;Event activation or deactivation;;;ACTIVE;2.65;2.68 +89793-4;Event description;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Event description;;;ACTIVE;2.65;2.68 +89794-2;Conference note;Find;Pt;{Setting};Doc;Anesthesiology.team;DOC.ONTOLOGY;2;Anesthesiology Team Conference note;Anesthesiology Team Conf eval note;;ACTIVE;2.65;2.65 +89795-9;Progress note;Find;Pt;{Setting};Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Progress note;Bld Bnk+Trans Med Prog note;;ACTIVE;2.65;2.73 +89796-7;Procedure note;Find;Pt;{Setting};Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine procedure note;Bld Bnk+Trans Med Procedure note;;ACTIVE;2.65;2.65 +8979-7;Fluid intake.intravascular;VRat;12H;Vascular system;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake intravascular 12 hour;Fluid intake IV 12h;;ACTIVE;1.0h(3);2.48 +89797-5;Note;Find;Pt;Telephone encounter;Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Telephone encounter Note;Bld Bnk+Trans Med Phone Note;;ACTIVE;2.65;2.65 +89798-3;Conference note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Conference note;Cardiac surgery Conf eval note;;ACTIVE;2.65;2.65 +89799-1;Conference note;Find;Pt;{Setting};Doc;Endocrinology.team;DOC.ONTOLOGY;2;Endocrinology Team Conference note;Endocrin Team Conf eval note;;ACTIVE;2.65;2.65 +89800-7;Note;Find;Pt;Telephone encounter;Doc;Ethics;DOC.ONTOLOGY;2;Ethics Telephone encounter Note;Ethics Phone Note;;ACTIVE;2.65;2.65 +89801-5;Conference note;Find;Pt;{Setting};Doc;Ethics.team;DOC.ONTOLOGY;2;Ethics Team Conference note;Ethics Team Conf eval note;;ACTIVE;2.65;2.65 +89802-3;Progress note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Progress note;Gyn Onc Prog note;;ACTIVE;2.65;2.73 +89803-1;Procedure note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology procedure note;Gyn Onc Procedure note;;ACTIVE;2.65;2.65 +89804-9;Note;Find;Pt;Telephone encounter;Doc;Hematology;DOC.ONTOLOGY;2;Hematology Telephone encounter Note;Hematology Phone Note;;ACTIVE;2.65;2.65 +8980-5;Fluid intake.intravascular;VRat;24H;Vascular system;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake intravascular 24 hour;Fluid intake IV 24h;;ACTIVE;1.0h(3);2.48 +89805-6;Initial evaluation note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Initial evaluation note;IR Initial eval note;;ACTIVE;2.65;2.65 +89806-4;Note;Find;Pt;Telephone encounter;Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Telephone encounter Note;IR Phone Note;;ACTIVE;2.65;2.65 +89807-2;Progress note;Find;Pt;Telephone encounter;Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Telephone encounter Progress note;Mat fetal med Phone Prog note;;ACTIVE;2.65;2.73 +89808-0;Note;Find;Pt;Telephone encounter;Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Telephone encounter Note;Mat fetal med Phone Note;;ACTIVE;2.65;2.73 +89809-8;Note;Find;Pt;Telephone encounter;Doc;Clinical neurophysiology;DOC.ONTOLOGY;2;Clinical neurophysiology Telephone encounter Note;Clinical Neurophys Phone Note;;ACTIVE;2.65;2.65 +89810-6;Conference note;Find;Pt;{Setting};Doc;Neurological surgery.team;DOC.ONTOLOGY;2;Neurological surgery Team Conference note;Neuro surg Team Conf eval note;;ACTIVE;2.65;2.65 +89811-4;Progress note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Progress note;Anesthesiology Prog note;;ACTIVE;2.65;2.73 +89812-2;Procedure note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology procedure note;Psych Procedure note;;ACTIVE;2.65;2.65 +8981-3;Intravascular tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Intravascular tube site;Intravasc tube site;;ACTIVE;1.0h(3);2.27 +89813-0;Progress note;Find;Pt;{Setting};Doc;Rapid response team;DOC.ONTOLOGY;2;Rapid response team Progress note;Rapid response team Prog note;;ACTIVE;2.65;2.73 +89814-8;Procedure note;Find;Pt;{Setting};Doc;Rapid response team;DOC.ONTOLOGY;2;Rapid response team procedure note;Rapid response team Procedure note;;ACTIVE;2.65;2.65 +89815-5;Initial evaluation note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Initial evaluation note;Trauma Initial eval note;;ACTIVE;2.65;2.65 +89816-3;Progress note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Progress note;Trauma Prog note;;ACTIVE;2.65;2.73 +89817-1;Procedure note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma procedure note;Trauma Procedure note;;ACTIVE;2.65;2.65 +89818-9;Note;Find;Pt;Telephone encounter;Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Telephone encounter Note;Wound care management Phone Note;;ACTIVE;2.65;2.65 +89819-7;Conference note;Find;Pt;{Setting};Doc;Wound care management.team;DOC.ONTOLOGY;2;Wound care management Team Conference note;Wound care Team Conf eval note;;ACTIVE;2.65;2.65 +89820-5;Initial evaluation note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Initial evaluation note;Wound care management Initial eval note;;ACTIVE;2.65;2.65 +8982-1;Class;Type;Pt;Fluid intake intravascular substance;Nom;;IO_IN.MOLEC;2;Type of Fluid intake intravascular substance;Fluid Intake IV Subs Class;;ACTIVE;1.0h(3);2.27 +89821-3;Progress note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Progress note;Wound care management Prog note;;ACTIVE;2.65;2.73 +89822-1;Procedure note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery procedure note;Cardiac surgery Procedure note;;ACTIVE;2.65;2.65 +89823-9;Conference note;Find;Pt;{Setting};Doc;Cardiac surgery.team;DOC.ONTOLOGY;2;Cardiac surgery Team Conference note;Cardiac surg Team Conf eval note;;ACTIVE;2.65;2.65 +89824-7;Note;Find;Pt;Telephone encounter;Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Telephone encounter Note;Cardiac surgery Phone Note;;ACTIVE;2.65;2.65 +89825-4;Conference note;Find;Pt;{Setting};Doc;Vascular surgery.team;DOC.ONTOLOGY;2;Vascular surgery Team Conference note;Vascular surg Team Conf eval note;;ACTIVE;2.65;2.65 +89826-2;Procedure note;Find;Pt;{Setting};Doc;Clinical pharmacology;DOC.ONTOLOGY;2;Clinical pharmacology procedure note;Clin Pharm Procedure note;;ACTIVE;2.65;2.65 +89827-0;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;CT;RAD;2;CT Spine Lumbar and Sacrum WO and W contrast IV;CT L-spine+Sacrum WO+W contr IV;;ACTIVE;2.65;2.65 +89828-8;Guidance for superficial biopsy;Find;Pt;XXX>Muscle;Doc;CT;RAD;2;CT Guidance for superficial biopsy of Muscle;CT Guided Muscle Super Bx;;ACTIVE;2.65;2.65 +89829-6;Guidance for biopsy^WO contrast;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for biopsy of Retroperitoneum-- WO contrast;CT Guided Retroperitoneum Bx--WO contr;;ACTIVE;2.65;2.65 +89830-4;Guidance for biopsy^W contrast IV;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for biopsy of Retroperitoneum-- W contrast IV;CT Guided Retroperitoneum Bx--W contr IV;;ACTIVE;2.65;2.65 +89831-2;Guidance for drainage+placement of drainage catheter;Find;Pt;Abdomen>Subphrenic space;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Subphrenic space;CT Guided Subphrenic Drain+cath place;;ACTIVE;2.65;2.66 +89832-0;Guidance for deep biopsy;Find;Pt;XXX>Tissue;Doc;CT;RAD;2;CT Guidance for deep biopsy of Tissue;CT Guided Tiss Deep Bx;;ACTIVE;2.65;2.65 +89833-8;Multisection by reconstruction;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region by reconstruction;CT by reconstr;;ACTIVE;2.65;2.65 +89834-6;Multisection^WO Contrast;Find;Pt;Chest>Clavicle.bilateral;Doc;CT;RAD;2;CT Clavicle - bilateral WO contrast;CT Clavicle-Bl WO contr;;ACTIVE;2.65;2.65 +89835-3;Multisection^W contrast IV;Find;Pt;Chest>Brachial plexus;Doc;CT;RAD;2;CT Brachial plexus W contrast IV;CT Brachial plexus W contr IV;;ACTIVE;2.65;2.65 +89836-1;Multisection^WO contrast;Find;Pt;Chest>Brachial plexus;Doc;CT;RAD;2;CT Brachial plexus WO contrast;CT Brachial plexus WO contr;;ACTIVE;2.65;2.65 +89837-9;Multisection^WO & W contrast IV;Find;Pt;Head>Temporal bone.left;Doc;CT;RAD;2;CT Temporal bone - left WO and W contrast IV;CT Temporal bone-L WO+W contr IV;;ACTIVE;2.65;2.65 +89838-7;Multisection^WO & W contrast IV;Find;Pt;Head>Temporal bone.right;Doc;CT;RAD;2;CT Temporal bone - right WO and W contrast IV;CT Temporal bone-R WO+W contr IV;;ACTIVE;2.65;2.65 +8983-9;Class;Type;Pt;Intravascular tube;Nom;;IO.TUBE;2;Type of Intravascular tube;IV tube Class;;ACTIVE;1.0h(3);2.27 +89839-5;Guidance for biopsy;Find;Pt;Chest>Sternum;Doc;CT;RAD;2;CT Guidance for biopsy of Sternum;CT Guided Sternum Bx;;ACTIVE;2.65;2.65 +89840-3;Multisection^WO contrast;Find;Pt;Pelvis>Lumbosacral plexus;Doc;CT;RAD;2;CT Lumbosacral plexus WO contrast;CT Lumbosacral plexus WO contr;;ACTIVE;2.65;2.65 +89841-1;Multisection^WO & W contrast IV;Find;Pt;Upper extremity.bilateral>Upper extremity vessels;Doc;CT.angio;RAD;2;CTA Upper extremity vessels - bilateral WO and W contrast IV;CTA UE ves-Bl WO+W contr IV;;ACTIVE;2.65;2.65 +89842-9;Multisection^W radionuclide IV;Find;Pt;Whole body;Doc;NM.SPECT+CT;RAD;2;SPECT+CT Whole body;SPECT+CT Whole body W RNC IV;;ACTIVE;2.65;2.65 +89843-7;Emoji skin tone modifier;Type;Pt;^Patient;Nom;Unicode;H&P.PX;2;Unicode Emoji skin tone modifier;Emoji skin tone mod;;ACTIVE;2.65;2.65 +89844-5;Multisection^WO & W contrast IV;Find;Pt;Head & Head>Temporal bone;Doc;CT;RAD;2;CT Head and Temporal bone WO and W contrast IV;CT Head+Temporal bone WO+W contr IV;;ACTIVE;2.65;2.65 +89845-2;Multisection^WO & W contrast IV;Find;Pt;Head & Head>Orbit.bilateral;Doc;CT;RAD;2;CT Head and Orbit - bilateral WO and W contrast IV;CT Head+Orbit-Bl WO+W contr IV;;ACTIVE;2.65;2.65 +89846-0;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.left>Midfoot+Forefoot;Doc;CT;RAD;2;CT Midfoot - left and Forefoot - left WO and W contrast IV;CT Mid+Fore ft-L WO+W contr IV;;ACTIVE;2.65;2.65 +8984-7;Fluid intake;Vol;Pt;XXX;Qn;Estimated;IO_IN.ATOM;2;Fluid intake Estimated;Fluid intake Est;;ACTIVE;1.0h(3);2.48 +89847-8;Multisection;Find;Pt;Lower extremity.right>Midfoot+Forefoot;Doc;CT;RAD;2;CT Midfoot - right and Forefoot - right;CT Mid+Fore ft-R;;ACTIVE;2.65;2.65 +89848-6;Multisection^WO & W contrast IV;Find;Pt;Lower extremity.right>Midfoot;Doc;CT;RAD;2;CT Midfoot - right WO and W contrast IV;CT Mid ft-R WO+W contr IV;;ACTIVE;2.65;2.65 +89849-4;Multisection^WO Contrast;Find;Pt;Upper extremity.right>Finger;Doc;CT;RAD;2;CT Finger - right WO contrast;CT Finger-R WO contr;;ACTIVE;2.65;2.65 +89850-2;Multisection^WO Contrast;Find;Pt;Upper extremity.left>Finger;Doc;CT;RAD;2;CT Finger - left WO contrast;CT Finger-L WO contr;;ACTIVE;2.65;2.65 +89851-0;Multisection limited;Find;Pt;XXX;Doc;CT.angio;RAD;2;CTA Unspecified body region limited;CTA Ltd;;ACTIVE;2.65;2.69 +89852-8;Multisection limited^W Contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region limited W contrast IV;CT Ltd W contr IV;;ACTIVE;2.65;2.69 +89853-6;Multisection limited^WO Contrast;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region limited WO contrast;CT Ltd WO contr;;ACTIVE;2.65;2.69 +8985-4;Fluid intake;Vol;Pt;XXX;Qn;Measured;IO_IN.ATOM;2;Fluid intake Measured;Fluid intake Measured;;ACTIVE;1.0h(3);2.48 +89854-4;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Perirenal space.left;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Perirenal space - left;CT Guided Perirenal sp-L Absc drain+cath;;ACTIVE;2.65;2.67 +89855-1;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Perirenal space.right;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Perirenal space - right;CT Guided Perirenal sp-R Absc drain+cath;;ACTIVE;2.65;2.67 +89856-9;Guidance for stereotactic localization^WO contrast;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for stereotactic localization of Unspecified body region-- WO contrast;CT Guided Str loc--WO contr;;ACTIVE;2.65;2.65 +89857-7;Guidance for biopsy;Find;Pt;Chest>Pleura.right;Doc;CT;RAD;2;CT Guidance for biopsy of Pleura - right;CT Guided Pleura-R Bx;;ACTIVE;2.65;2.65 +89858-5;Guidance for biopsy;Find;Pt;Chest>Pleura.left;Doc;CT;RAD;2;CT Guidance for biopsy of Pleura - left;CT Guided Pleura-L Bx;;ACTIVE;2.65;2.65 +89859-3;Guidance for transrectal drainage of abscess;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for transrectal drainage of abscess of Pelvis;CT Guided Pelvis Transrect Absc drainage;;ACTIVE;2.65;2.65 +89860-1;Multisection^W inspiration + W expiration;Find;Pt;Chest;Doc;CT;RAD;2;CT Chest W inspiration and expiration;CT Chest W insp+exp;;ACTIVE;2.65;2.65 +89861-9;BRAF gene.p.Val600Lys;PrThr;Pt;Tiss;Ord;Molgen;MOLPATH.MUT;1;BRAF gene p.Val600Lys [Presence] in Tissue by Molecular genetics method;BRAF p.V600K Tiss Ql;;ACTIVE;2.65;2.65 +8986-2;Fluid intake;VRat;1H;XXX;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake 1 hour;Fluid intake 1h;;ACTIVE;1.0h(3);2.48 +89862-7;Patient-Oriented Eczema Measure;-;1W;^Patient;-;POEM;PANEL.SURVEY.GNHLTH;4;Patient-Oriented Eczema Measure [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89863-5;Over the last W, on how many D has your or your child's skin been itchy because of eczema;Find;1W;^Patient;Ord;POEM;SURVEY.GNHLTH;4;Over the last week, on how many days has your or your child's skin been itchy because of eczema [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89864-3;Over the last W, on how many nights has your or your child's sleep been disturbed because of the eczema;Find;1W;^Patient;Ord;POEM;SURVEY.GNHLTH;4;Over the last week, on how many nights has your or your child's sleep been disturbed because of the eczema [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89865-0;Over the last W, on how many D has your or your child's skin been bleeding because of the eczema;Find;1W;^Patient;Ord;POEM;SURVEY.GNHLTH;4;Over the last week, on how many days has your or your child's skin been bleeding because of the eczema [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89866-8;Over the last W, on how many D has your or your child's skin been weeping or oozing clear fluid because of the eczema;Find;1W;^Patient;Ord;POEM;SURVEY.GNHLTH;4;Over the last week, on how many days has your or your child's skin been weeping or oozing clear fluid because of the eczema [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89867-6;Over the last W, on how many D has your or your child's skin been cracked because of the eczema;Find;1W;^Patient;Ord;POEM;SURVEY.GNHLTH;4;Over the last week, on how many days has your or your child's skin been cracked because of the eczema [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89868-4;Over the last W, on how many D has your or your child's skin been flaking off because of the eczema;Find;1W;^Patient;Ord;POEM;SURVEY.GNHLTH;4;Over the last week, on how many days has your or your child's skin been flaking off because of the eczema [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89869-2;Over the last W, on how many D has your or your child's skin felt dry or rough because of the eczema;Find;1W;^Patient;Ord;POEM;SURVEY.GNHLTH;4;Over the last week, on how many days has your or your child's skin felt dry or rough because of the eczema [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +898-7;Blood group antibody screen.cell I;PrThr;Pt;Ser/Plas;Ord;Prewarmed;BLDBK;1;Blood group antibody screen.cell I [Presence] in Serum or Plasma by Prewarmed;Bld gp Ab Scn Cell I SerPl Ql Pwarm;;ACTIVE;1.0;2.56 +8987-0;Fluid intake;VRat;8H;XXX;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake 8 hour;Fluid intake 8h;;ACTIVE;1.0h(3);2.48 +89870-0;Total score;Score;1W;^Patient;Qn;POEM;SURVEY.GNHLTH;4;Total score [POEM];;Copyright © 2004 The University of Nottingham. Used with permission.;ACTIVE;2.65;2.65 +89871-8;Bilirubin;SCnc;Pt;BldV;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Venous blood;Bilirub BldV-sCnc;;ACTIVE;2.65;2.65 +89872-6;Bilirubin;SCnc;Pt;BldA;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Arterial blood;Bilirub BldA-sCnc;;ACTIVE;2.65;2.65 +89873-4;Unique identifier;ID;Pt;Initial sample;Nom;;SPEC;1;Unique identifier [Identifier] of Initial sample;Unique ID Initial sample;;ACTIVE;2.65;2.65 +89874-2;Anesthesia duration;Time;Procedure dur;^Patient;Qn;;SURG;2;Anesthesia duration;Anesth dur;;ACTIVE;2.65;2.65 +89875-9;Procedure duration;Time;Procedure dur;^Patient;Qn;;SURG;2;Procedure duration;Proc dur;;ACTIVE;2.65;2.65 +89876-7;Mycobacterium tuberculosis complex rifAMPin & isoniazid resistance panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;MTB complex rifAMPin and isoniazid resistance panel by Molecular genetics method;MTB RIF and INH resist Pnl Islt/Spm;;ACTIVE;2.65;2.74 +89877-5;Note;Find;Pt;Outpatient;Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Outpatient Note;Clinical genetics OP Note;;ACTIVE;2.65;2.65 +89878-3;Note;Find;Pt;Outpatient;Doc;Adolescent medicine;DOC.ONTOLOGY;2;Adolescent medicine Outpatient Note;Adolescent med OP Note;;ACTIVE;2.65;2.65 +89879-1;Note;Find;Pt;Outpatient;Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Outpatient Note;Peds OP Note;;ACTIVE;2.65;2.65 +89880-9;Note;Find;Pt;Outpatient;Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Outpatient Note;Neo peri med OP Note;;ACTIVE;2.65;2.65 +89881-7;Note;Find;Pt;Outpatient;Doc;Developmental-behavioral pediatrics;DOC.ONTOLOGY;2;Developmental-behavioral pediatrics Outpatient Note;Develop-behav peds OP Note;;ACTIVE;2.65;2.65 +89882-5;Note;Find;Pt;Outpatient;Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Outpatient Note;Sports medicine OP Note;;ACTIVE;2.65;2.65 +89883-3;Note;Find;Pt;Telehealth;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Telehealth Note;Emergency med Telehealth Note;;ACTIVE;2.65;2.65 +89884-1;Note;Find;Pt;Telehealth;Doc;Hematology+Medical oncology;DOC.ONTOLOGY;2;Hematology+Medical oncology Telehealth Note;HemOnc Telehealth Note;;ACTIVE;2.65;2.65 +89885-8;Note;Find;Pt;Telehealth;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Telehealth Note;Pain medicine Telehealth Note;;ACTIVE;2.65;2.65 +89886-6;Note;Find;Pt;Telehealth;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Telehealth Note;Palliative care Telehealth Note;;ACTIVE;2.65;2.65 +89887-4;Note;Find;Pt;Telehealth;Doc;Adolescent medicine;DOC.ONTOLOGY;2;Adolescent medicine Telehealth Note;Adolescent med Telehealth Note;;ACTIVE;2.65;2.65 +8988-8;Fluid intake;VRat;10H;XXX;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake 10 hour;Fluid intake 10h;;ACTIVE;1.0h(3);2.48 +89888-2;Note;Find;Pt;Telehealth;Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Telehealth Note;Peds Telehealth Note;;ACTIVE;2.65;2.65 +89889-0;Note;Find;Pt;Telehealth;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Telehealth Note;PM+R Telehealth Note;;ACTIVE;2.65;2.65 +89890-8;Note;Find;Pt;Telehealth;Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Telehealth Note;Diabetology Telehealth Note;;ACTIVE;2.65;2.65 +89891-6;Note;Find;Pt;Telehealth;Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Telehealth Note;Endocrinology Telehealth Note;;ACTIVE;2.65;2.65 +89892-4;Note;Find;Pt;Telehealth;Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Telehealth Note;Infectious disease Telehealth Note;;ACTIVE;2.65;2.65 +89893-2;Note;Find;Pt;Telehealth;Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Telehealth Note;Clinical genetics Telehealth Note;;ACTIVE;2.65;2.65 +89894-0;Note;Find;Pt;Telehealth;Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Telehealth Note;Neo peri med Telehealth Note;;ACTIVE;2.65;2.65 +89895-7;Note;Find;Pt;Telehealth;Doc;Allergy+Immunology;DOC.ONTOLOGY;2;Allergy and Immunology Telehealth Note;Allergy+Immunology Telehealth Note;;ACTIVE;2.65;2.66 +8989-6;Fluid intake;VRat;12H;XXX;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake 12 hour;Fluid intake 12h;;ACTIVE;1.0h(3);2.48 +89896-5;Note;Find;Pt;Telehealth;Doc;Developmental-behavioral pediatrics;DOC.ONTOLOGY;2;Developmental-behavioral pediatrics Telehealth Note;Develop-behav peds Telehealth Note;;ACTIVE;2.65;2.65 +89897-3;Note;Find;Pt;Telehealth;Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Telehealth Note;Gynecology Telehealth Note;;ACTIVE;2.65;2.65 +89898-1;Note;Find;Pt;Telehealth;Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Telehealth Note;Nephrology Telehealth Note;;ACTIVE;2.65;2.65 +89899-9;Note;Find;Pt;Telehealth;Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Telehealth Note;Orthopaedic surgery Telehealth Note;;ACTIVE;2.65;2.65 +89900-5;Note;Find;Pt;Telehealth;Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Telehealth Note;Rheumatology Telehealth Note;;ACTIVE;2.65;2.65 +89901-3;Note;Find;Pt;Telehealth;Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Telehealth Note;Sports medicine Telehealth Note;;ACTIVE;2.65;2.65 +89902-1;Note;Find;Pt;Telehealth;Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Telehealth Note;Otolaryngology Telehealth Note;;ACTIVE;2.65;2.65 +89903-9;Note;Find;Pt;Telehealth;Doc;Urology;DOC.ONTOLOGY;2;Urology Telehealth Note;Urology Telehealth Note;;ACTIVE;2.65;2.65 +8990-4;Fluid intake;VRat;24H;XXX;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake 24 hour;Fluid intake 24h;;ACTIVE;1.0h(3);2.48 +89904-7;Total score;Score;Pt;^Patient;Qn;CRQ-SAS;SURVEY.GNHLTH;4;Total score [CRQ-SAS];;Copyright © 2001 McMaster University, Hamilton, Ontario, Canada. The Chronic Respiratory Questionnaire Self-Administered, Standardized Format (CRQ-SAS), Principal authors Drs. G.H. Guyatt, and Dr. H.J. Schünemann, is the copyright of McMaster University (Copyright ©2001, McMaster University). Use of the CRQ-SAS name has been provided with permission from McMaster University. For use of the CRQ-SAS Questionnaire, please contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details.;ACTIVE;2.65;2.65 +89905-4;Chronic Respiratory Questionnaire Self-Administered Standardized Format;-;Pt;^Patient;-;CRQ-SAS;PANEL.SURVEY.GNHLTH;4;Chronic Respiratory Questionnaire Self-Administered Standardized Format [CRQ-SAS];;Copyright © 2001 McMaster University, Hamilton, Ontario, Canada. The Chronic Respiratory Questionnaire Self-Administered, Standardized Format (CRQ-SAS), Principal authors Drs. G.H. Guyatt, and Dr. H.J. Schünemann, is the copyright of McMaster University (Copyright ©2001, McMaster University). Use of the CRQ-SAS name has been provided with permission from McMaster University. For use of the CRQ-SAS Questionnaire, please contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details.;ACTIVE;2.65;2.65 +89906-2;Chronic Respiratory Questionnaire Self-Administered Individualized Format;-;Pt;^Patient;-;CRQ-SAI;PANEL.SURVEY.GNHLTH;4;Chronic Respiratory Questionnaire Self-Administered Individualized Format [CRQ-SAI];;Copyright © 2001 McMaster University, Hamilton, Ontario, Canada. The Chronic Respiratory Questionnaire Self-Administered, Individualized Format (CRQ-SAI), Principal authors Drs. G.H. Guyatt, and Dr. H.J. Schünemann, is the copyright of McMaster University (Copyright ©2001, McMaster University). Use of the CRQ-SAI name has been provided with permission from McMaster University. For use of the CRQ-SAI Questionnaire, please contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details.;ACTIVE;2.65;2.65 +89907-0;Total score;Score;Pt;^Patient;Qn;CRQ-SAI;SURVEY.GNHLTH;4;Total score [CRQ-SAI];;Copyright © 2001 McMaster University, Hamilton, Ontario, Canada. The Chronic Respiratory Questionnaire Self-Administered, Individualized Format (CRQ-SAI), Principal authors Drs. G.H. Guyatt, and Dr. H.J. Schünemann, is the copyright of McMaster University (Copyright ©2001, McMaster University). Use of the CRQ-SAI name has been provided with permission from McMaster University. For use of the CRQ-SAI Questionnaire, please contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details.;ACTIVE;2.65;2.65 +89908-8;Insulin was taken in last 8H;Find;8H;^Patient;Ord;;H&P.HX;2;Insulin was taken in last 8H 8 hour;Insulin taken in last 8H 8h;;ACTIVE;2.65;2.65 +89909-6;Takes creatine supplements;Find;Pt;^Patient;Ord;;NUTRITION&DIETETICS;2;Takes creatine supplements;Takes creatine supplements;;ACTIVE;2.65;2.65 +89910-4;Regular use of birth control when got pregnant;Find;Pt;^Patient;Ord;;H&P.HX;2;Regular use of birth control when got pregnant;Regular use of BC when got preg;;ACTIVE;2.65;2.65 +89911-2;Emergency management plan name;ID;Pt;^Event;Nom;;SURVEY.CDC;4;Emergency management plan name;;;ACTIVE;2.65;2.68 +8991-2;Fluid intake route;Type;Pt;XXX;Nom;;IO_IN.ATOM;2;Fluid intake route;Fluid intake route;;ACTIVE;1.0h(3);2.29 +89912-0;Emergency management plan purpose;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Emergency management plan purpose;;;ACTIVE;2.65;2.68 +89913-8;Event identifier;ID;Pt;^Event;Nom;;SURVEY.CDC;4;Event identifier;;;ACTIVE;2.65;2.68 +89914-6;Condition triggering emergency operation center response activation;Find;Pt;^Event;Nom;;SURVEY.CDC;4;Condition triggering EOC response activation;;;ACTIVE;2.65;2.68 +89915-3;Condition triggering emergency operation center response termination;Find;Pt;^Event;Nom;;SURVEY.CDC;4;Condition triggering EOC response termination;;;ACTIVE;2.65;2.68 +89916-1;Emergency management plan approved date;Date;Pt;^Event;Qn;;SURVEY.CDC;4;Emergency management plan approved date;;;ACTIVE;2.65;2.68 +89917-9;Emergency management plan estimated fulfillment date;Date;Pt;^Event;Qn;;SURVEY.CDC;4;Emergency management plan estimated fulfillment date;;;ACTIVE;2.65;2.68 +89918-7;Emergency management plan approver name;ID;Pt;^Event;Nom;;SURVEY.CDC;4;Emergency management plan approver name;;;ACTIVE;2.65;2.68 +89919-5;Emergency response capabilities;Find;Pt;Organization;Nar;;SURVEY.CDC;4;Organization Emergency response capabilities;;;ACTIVE;2.65;2.68 +8992-0;Fluid intake.nasogastric tube;Vol;Pt;Upper GI tract;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake nasogastric tube Estimated;Fluid intake NG-tube Est;;ACTIVE;1.0h(3);2.48 +89920-3;PROMIS item bank - anger - version 1.1;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - anger - version 1.1;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89921-1;PROMIS anger - version 1.1 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS anger - version 1.1 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89922-9;I worried about dying in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worried about dying in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89923-7;PROMIS item bank - pain interference - version 1.1;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - pain interference - version 1.1;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89924-5;PROMIS pain interference - version 1.1 T-score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS pain interference - version 1.1 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89925-2;Multisection^WO & W contrast IV;Find;Pt;Pelvis+Lower extremity.bilateral;Doc;CT;RAD;2;CT Pelvis and Lower extremity - bilateral WO and W contrast IV;CT Pelvis+LE-Bl WO+W contr IV;;ACTIVE;2.65;2.65 +89926-0;Note;Find;Pt;Adult day care center;Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Adult day care center Note;PM+R ADCC Note;;ACTIVE;2.65;2.65 +89927-8;Multisection for calcium score^WO contrast && Multisection^W contrast IV;Find;Pt;Chest>Heart+Aortic root;Doc;CT && CT.angio;RAD;2;CT Heart and aortic root WO contrast for calcium scoring + CTA W contrast IV;CT Hrt+AR WO Ca score + CTA W contr IV;;ACTIVE;2.65;2.65 +89928-6;Guidance for percutaneous aspiration of fluid;Find;Pt;Abdomen>Spine.lumbar intervertebral disc;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Lumbar spine Intervertebral disc;CT Guided L-spine disc PC fluid asp;;ACTIVE;2.65;2.65 +89929-4;Guidance for percutaneous aspiration of fluid;Find;Pt;XXX>Intervertebral disc;Doc;CT;RAD;2;CT Guidance for fluid aspiration of Intervertebral disc;CT Guided I-disc PC fluid asp;;ACTIVE;2.65;2.65 +89930-2;Guidance for radiofrequency ablation;Find;Pt;XXX>Bone;Doc;CT;RAD;2;CT Guidance for radiofrequency ablation of Bone;CT Guided Bone Radiofreq abl;;ACTIVE;2.65;2.65 +89931-0;Guidance for drainage+placement of drainage catheter;Find;Pt;Pelvis>Perirectal region;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Perirectal region;CT Guided Perirectal Drain+cath place;;ACTIVE;2.65;2.66 +89932-8;Guidance for deep placement of needle;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for deep placement of needle of Unspecified body region;CT Guided Deep placement of needle;;ACTIVE;2.65;2.65 +89933-6;Relative risk of developing disease assessed;RelRto;Pt;^Patient;Qn;;CLIN.RISK;2;Relative risk of developing disease assessed;Rel risk develop disease assessed;;ACTIVE;2.65;2.65 +89934-4;I had so much pain I had to stop what I was doing in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had so much pain I had to stop what I was doing in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89935-1;PROMIS pediatric item bank - pain interference - version 2.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - pain interference - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89936-9;PROMIS pediatric pain interference - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric pain interference - version 2.0 Tscore;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89937-7;It was hard for my child to walk one block when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to walk one block when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +8993-8;Fluid intake.nasogastric tube;Vol;Pt;Upper GI tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake nasogastric tube Measured;Fluid intake NG-tube Measured;;ACTIVE;1.0h(3);2.48 +89938-5;My child had trouble doing schoolwork when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble doing schoolwork when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89939-3;It was hard for my child to run when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to run when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89940-1;It was hard for my child to pay attention when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to pay attention when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89941-9;It was hard for my child to have fun when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to have fun when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89942-7;My child hurt all over his or her body in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child hurt all over his or her body in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89943-5;My child felt angry when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt angry when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89944-3;My child hurt a lot in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child hurt a lot in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89945-0;It was hard for my child to remember things when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to remember things when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +8994-6;Fluid intake.nasogastric tube;VRat;1H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake nasogastric tube 1 hour;Fluid intake NG-tube 1h;;ACTIVE;1.0h(3);2.48 +89946-8;It was hard for my child to get along with other people when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to get along with other people when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89947-6;My child missed school when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child missed school when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89948-4;It was hard for my child to stay standing when he or she had pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to stay standing when he or she had pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89949-2;PROMIS parent proxy item bank - pain interference - version 2.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - pain interference - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +899-5;Blood group antibody screen.cell II;PrThr;Pt;Ser/Plas;Ord;Prewarmed;BLDBK;1;Blood group antibody screen.cell II [Presence] in Serum or Plasma by Prewarmed;Bld gp Ab Scn Cell II SerPl Ql Pwarm;;ACTIVE;1.0;2.56 +89950-0;PROMIS parent proxy pain interference - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy pain interference - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +89951-8;Procedure note;Find;Pt;{Setting};Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine procedure note;Mat fetal med Procedure note;;ACTIVE;2.65;2.73 +89952-6;Guidance for percutaneous aspiration of fluid;Find;Pt;Pelvis>Sacroiliac joint.right;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Sacroiliac joint - right;CT Guided SIJ-R Arthrocentesis;;ACTIVE;2.65;2.66 +8995-3;Fluid intake.nasogastric tube;VRat;8H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake nasogastric tube 8 hour;Fluid intake NG-tube 8h;;ACTIVE;1.0h(3);2.48 +89953-4;Guidance for percutaneous aspiration of fluid;Find;Pt;Upper extremity.right>Shoulder;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Shoulder - right;CT Guided Should-R Arthrocentesis;;ACTIVE;2.65;2.66 +89954-2;Guidance for percutaneous aspiration of fluid;Find;Pt;Upper extremity.left>Shoulder;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Shoulder - left;CT Guided Should-L Arthrocentesis;;ACTIVE;2.65;2.66 +89955-9;Guidance for percutaneous aspiration of fluid;Find;Pt;Lower extremity.bilateral>Hip;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Hip - bilateral;CT Guided Hip-Bl Arthrocentesis;;ACTIVE;2.65;2.66 +89956-7;Guidance for percutaneous aspiration of fluid;Find;Pt;Lower extremity.left>Hip;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Hip - left;CT Guided Hip-L Arthrocentesis;;ACTIVE;2.65;2.66 +89957-5;Guidance for percutaneous aspiration of fluid;Find;Pt;Lower extremity.right>Hip;Doc;CT;RAD;2;CT Guidance for arthrocentesis of Hip - right;CT Guided Hip-R Arthrocentesis;;ACTIVE;2.65;2.66 +89958-3;Guidance for cryoablation;Find;Pt;Pelvis;Doc;CT;RAD;2;CT Guidance for cryoablation of Pelvis;CT Guided Pelvis Cryoablation;;ACTIVE;2.65;2.65 +89959-1;Guidance for percutaneous biopsy;Find;Pt;XXX>Soft tissue;Doc;CT;RAD;2;CT Guidance for biopsy of Soft tissue;CT Guided Soft tiss Bx;;ACTIVE;2.65;2.65 +89960-9;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Kidney.right;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Kidney - right;CT Guided Kidney-R Absc drain+cath place;;ACTIVE;2.65;2.66 +8996-1;Fluid intake.nasogastric tube;VRat;10H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake nasogastric tube 10 hour;Fluid intake NG-tube 10h;;ACTIVE;1.0h(3);2.48 +89961-7;Guidance for drainage of abscess+placement of drainage catheter;Find;Pt;Abdomen>Kidney.left;Doc;CT;RAD;2;CT Guidance for drainage of abscess and placement of drainage catheter of Kidney - left;CT Guided Kidney-L Absc drain+cath place;;ACTIVE;2.65;2.66 +89962-5;Guidance for radiofrequency ablation;Find;Pt;Chest>Lung;Doc;CT;RAD;2;CT Guidance for radiofrequency ablation of Lung;CT Guided Lung Radiofreq abl;;ACTIVE;2.65;2.65 +89963-3;Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 3.0;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI) - version 3.0 [CMS Assessment];;;ACTIVE;2.65;2.69 +89964-1;Ziprasidone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Ziprasidone [Presence] in Urine by Screen method;Ziprasidone Ur Ql Scn;;ACTIVE;2.65;2.65 +89965-8;Trifluoperazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Trifluoperazine [Presence] in Urine by Screen method;TriFperazine Ur Ql Scn;;ACTIVE;2.65;2.65 +89966-6;Norquetiapine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norquetiapine [Mass/volume] in Urine by Confirmatory method;Norquetiapine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89967-4;Norquetiapine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norquetiapine [Presence] in Urine by Screen method;Norquetiapine Ur Ql Scn;;ACTIVE;2.65;2.65 +89968-2;Norolanzapine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norolanzapine [Mass/volume] in Urine by Confirmatory method;Norolanzapine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89969-0;Norolanzapine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norolanzapine [Presence] in Urine by Screen method;Norolanzapine Ur Ql Scn;;ACTIVE;2.65;2.65 +89970-8;Molindone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Molindone [Presence] in Urine by Screen method;Molindone Ur Ql Scn;;ACTIVE;2.65;2.65 +89971-6;8-Hydroxyloxapine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;8-Hydroxyloxapine [Presence] in Urine by Screen method;8OH-Loxapine Ur Ql Scn;;ACTIVE;2.65;2.65 +89972-4;Loxapine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Loxapine [Mass/volume] in Urine by Confirmatory method;Loxapine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89973-2;7-Hydroxyfluphenazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;7-Hydroxyfluphenazine [Mass/volume] in Urine by Confirmatory method;7OH-fluphenazine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89974-0;7-Hydroxyfluphenazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;7-Hydroxyfluphenazine [Presence] in Urine by Screen method;7OH-fluphenazine Ur Ql Scn;;ACTIVE;2.65;2.65 +89975-7;Norclozapine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norclozapine [Mass/volume] in Urine by Confirmatory method;Norclozapine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89976-5;7-Hydroxychlorpromazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;7-Hydroxychlorpromazine [Mass/volume] in Urine by Confirmatory method;7OH-chlorpromazine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89977-3;7-Hydroxychlorpromazine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;7-Hydroxychlorpromazine [Presence] in Urine by Screen method;7OH-chlorpromazine Ur Ql Scn;;ACTIVE;2.65;2.65 +89978-1;ARIPiprazole;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;ARIPiprazole [Presence] in Urine by Screen method;ARIPiprazole Ur Ql Scn;;ACTIVE;2.65;2.65 +8997-9;Fluid intake.nasogastric tube;VRat;12H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake nasogastric tube 12 hour;Fluid intake NG-tube 12h;;ACTIVE;1.0h(3);2.48 +89979-9;Ziprasidone;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Ziprasidone [Presence] in Serum or Plasma by Screen method;Ziprasidone SerPl Ql Scn;;ACTIVE;2.65;2.65 +89980-7;Thiothixene;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Thiothixene [Presence] in Serum or Plasma by Screen method;Thiothixene SerPl Ql Scn;;ACTIVE;2.65;2.65 +89981-5;QUEtiapine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;QUEtiapine [Presence] in Serum or Plasma by Screen method;QUEtiapine SerPl Ql Scn;;ACTIVE;2.65;2.65 +89982-3;9-Hydroxyrisperidone;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;9-Hydroxyrisperidone [Presence] in Serum or Plasma by Screen method;9OH-risperidone SerPl Ql Scn;;ACTIVE;2.65;2.65 +89983-1;OLANZapine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;OLANZapine [Presence] in Serum or Plasma by Screen method;OLANZapine SerPl Ql Scn;;ACTIVE;2.65;2.65 +89984-9;Molindone;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Molindone [Presence] in Serum or Plasma by Screen method;Molindone SerPl Ql Scn;;ACTIVE;2.65;2.65 +89985-6;ARIPiprazole;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;ARIPiprazole [Presence] in Serum or Plasma by Screen method;ARIPiprazole SerPl Ql Scn;;ACTIVE;2.65;2.65 +89986-4;Vortioxetine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Vortioxetine [Mass/volume] in Urine by Confirmatory method;Vortioxetine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +8998-7;Fluid intake.nasogastric tube;VRat;24H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake nasogastric tube 24 hour;Fluid intake NG-tube 24h;;ACTIVE;1.0h(3);2.48 +89987-2;Vortioxetine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Vortioxetine [Presence] in Urine by Screen method;Vortioxetine Ur Ql Scn;;ACTIVE;2.65;2.65 +89988-0;Vilazodone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Vilazodone [Mass/volume] in Urine by Confirmatory method;Vilaz Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89989-8;Vilazodone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Vilazodone [Presence] in Urine by Screen method;Vilaz Ur Ql Scn;;ACTIVE;2.65;2.65 +89990-6;fluvoxaMINE;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;fluvoxaMINE [Mass/volume] in Urine by Confirmatory method;fluvoxaMINE Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +89991-4;Citalopram+Escitalopram;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Citalopram+Escitalopram [Presence] in Urine by Screen method;Citalopram+Escitalopram Ur Ql Scn;;ACTIVE;2.65;2.65 +89992-2;Hydroxybupropion;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hydroxybupropion [Presence] in Urine by Screen method;OH-bupropion Ur Ql Scn;;ACTIVE;2.65;2.65 +89993-0;Counseling note;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Counseling note;Clinical genetics Counseling note;;ACTIVE;2.65;2.65 +89994-8;Trypanosoma cruzi Ab.IgG;PrThr;Pt;Ser/Plas^Donor;Ord;IA.rapid;MICRO;1;Trypanosoma cruzi IgG Ab [Presence] in Serum or Plasma from Donor by Rapid immunoassay;T cruzi IgG SerPl Donr Ql IA.rapid;;ACTIVE;2.65;2.65 +8999-5;Fluid intake.oral;Vol;Pt;Upper GI tract;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake oral Estimated;Fluid intake oral Est;;ACTIVE;1.0h(3);2.48 +89995-5;Trypanosoma cruzi Ab.IgG;PrThr;Pt;Ser/Plas^Donor;Ord;IA;MICRO;1;Trypanosoma cruzi IgG Ab [Presence] in Serum or Plasma from Donor by Immunoassay;T cruzi IgG SerPl Donr Ql IA;;ACTIVE;2.65;2.65 +89996-3;Pneumocystis jiroveci DNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;P jiroveci DNA Low Resp Ql NAA+non-probe;;ACTIVE;2.65;2.65 +89997-1;SUMF1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SUMF1 gene full mutation analysis in Blood or Tissue by Sequencing;SUMF1 Full Mut Anl Bld/T Seq;;ACTIVE;2.65;2.65 +89998-9;Albumin/Creatinine;Ratio;Pt;Urine;Qn;Detection limit <= 3.0 mg/L;UA;1;Microalbumin/Creatinine [Ratio] in Urine by Detection limit <= 3.0 mg/L;Microalbumin/Creat Ur DL<=3.0 mg/L-Rto;;ACTIVE;2.65;2.72 +89999-7;Albumin;MCnc;Pt;Urine;Qn;Detection limit <= 3.0 mg/L;UA;1;Microalbumin [Mass/volume] in Urine by Detection limit <= 3.0 mg/L;Microalbumin Ur DL<=3.0 mg/L-mCnc;;ACTIVE;2.65;2.72 +90000-1;Albumin;MRat;24H;Urine;Qn;Detection limit <= 3.0 mg/L;UA;1;Microalbumin [Mass/time] in 24 hour Urine by Detection limit <= 3.0 mg/L;Microalbumin 24h Ur DL<=3.0 mg/L-mRate;;ACTIVE;2.65;2.72 +9000-1;Fluid intake.oral;Vol;Pt;Upper GI tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake oral Measured;Fluid intake oral Measured;;ACTIVE;1.0h(3);2.44 +90001-9;Staphylococcus aureus.methicillin resistant DNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Methicillin resistant Staphylococcus aureus (MRSA) DNA [Presence] in Nose by NAA with probe detection;MRSA DNA Nose Ql NAA+probe;;ACTIVE;2.65;2.73 +90002-7;Candida auris;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Candida auris [Presence] in Specimen by Organism specific culture;C auris Spec Ql Cult;;ACTIVE;2.65;2.69 +90003-5;Acinetobacter sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Acinetobacter sp identified in Specimen by Organism specific culture;Acinetobacter Spec Cult;;ACTIVE;2.65;2.69 +90004-3;Clinical significance of updated information;Find;Pt;^Patient;Ord;;CLIN;2;Clinical significance of updated information;Clinical sig updated info;;ACTIVE;2.65;2.65 +90005-0;Note;Find;Pt;Outpatient;Doc;Pharmacogenomics;DOC.ONTOLOGY;2;Pharmacogenomics Outpatient Note;Pharmacogenomics OP Note;;ACTIVE;2.65;2.65 +90006-8;Consultation note;Find;Pt;{Setting};Doc;Pharmacogenomics;DOC.ONTOLOGY;2;Pharmacogenomics Consult note;Pharmacogenomics Consult note;;ACTIVE;2.65;2.65 +90007-6;Progress note;Find;Pt;{Setting};Doc;Pharmacogenomics;DOC.ONTOLOGY;2;Pharmacogenomics Progress note;Pharmacogenomics Prog note;;ACTIVE;2.65;2.73 +90008-4;Note;Find;Pt;Telehealth;Doc;Pharmacogenomics;DOC.ONTOLOGY;2;Pharmacogenomics Telehealth Note;Pharmacogenomics Telehealth Note;;ACTIVE;2.65;2.65 +90009-2;Conference note;Find;Pt;{Setting};Doc;Clinical pathology.team;DOC.ONTOLOGY;2;Clinical pathology Team Conference note;Clinical path Team Conf eval note;;ACTIVE;2.65;2.65 +900-1;Blood group antibody screen.cell III;PrThr;Pt;Ser/Plas;Ord;Prewarmed;BLDBK;1;Blood group antibody screen.cell III [Presence] in Serum or Plasma by Prewarmed;Bld gp Ab Scn Cell III SerPl Ql Pwarm;;ACTIVE;1.0;2.56 +90010-0;Procedure note;Find;Pt;{Setting};Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology procedure note;Clin Path Procedure note;;ACTIVE;2.65;2.65 +90011-8;Progress note;Find;Pt;{Setting};Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Progress note;Clin Path Prog note;;ACTIVE;2.65;2.73 +90012-6;Consultation note;Find;Pt;{Setting};Doc;Burn management;DOC.ONTOLOGY;2;Burn management Consult note;Burn Consult note;;ACTIVE;2.65;2.65 +90013-4;Initial evaluation note;Find;Pt;{Setting};Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Initial evaluation note;Clin Path Initial eval note;;ACTIVE;2.65;2.65 +90014-2;Progress note;Find;Pt;{Setting};Doc;Burn management;DOC.ONTOLOGY;2;Burn management Progress note;Burn Prog note;;ACTIVE;2.65;2.73 +90015-9;Note;Find;Pt;Telephone encounter;Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Telephone encounter Note;Clin Path Phone Note;;ACTIVE;2.65;2.65 +90016-7;IRF-PAI v3.0 - Quality indicators - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Quality indicators - discharge [CMS Assessment];;;ACTIVE;2.65;2.69 +90017-5;Amount of beef, pork, tuna, or salmon eaten the last time you had anything to eat;Find;Pt;^Patient;Ord;;H&P.HX;2;Amount of beef, pork, tuna, or salmon eaten the last time you had anything to eat;Amount beef, pork, tuna, salmon eaten;;ACTIVE;2.65;2.68 +90018-3;Psoriasis care satisfaction questionnaire;-;Pt;^Patient;-;PsoSat;PANEL.SURVEY.GNHLTH;4;Psoriasis care satisfaction questionnaire [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +9001-9;Fluid intake.oral;VRat;1H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake oral 1 hour;Fluid intake oral 1h;;ACTIVE;1.0h(3);2.48 +90019-1;My current treatment meets my expectations;Find;Pt;^Patient;Ord;PsoSat;SURVEY.GNHLTH;4;My current treatment meets my expectations [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +90020-9;I am satisfied with the treatment;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;I am satisfied with the treatment;;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.72 +90021-7;I wish for a better treatment;Find;Pt;^Patient;Ord;PsoSat;SURVEY.GNHLTH;4;I wish for a better treatment [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +90022-5;There has been no progress in my treatment for quite some time;Find;Pt;^Patient;Ord;PsoSat;SURVEY.GNHLTH;4;There has been no progress in my treatment for quite some time [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +90023-3;The side effects are causing me discomfort;Find;Pt;^Patient;Ord;PsoSat;SURVEY.GNHLTH;4;The side effects are causing me discomfort [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +90024-1;The current treatment has been going on for too long without success;Find;Pt;^Patient;Ord;PsoSat;SURVEY.GNHLTH;4;The current treatment has been going on for too long without success [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +90025-8;The treatment itself is putting a great strain on me;Find;Pt;^Patient;Ord;PsoSat;SURVEY.GNHLTH;4;The treatment itself is putting a great strain on me [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.71 +90026-6;I am dependent on other people's assistance for my treatment;Find;Pt;^Patient;Ord;PsoSat;SURVEY.GNHLTH;4;I am dependent on other people's assistance for my treatment [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +9002-7;Fluid intake.oral;VRat;8H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake oral 8 hour;Fluid intake oral 8h;;ACTIVE;1.0h(3);2.48 +90027-4;Total score;Score;Pt;^Patient;Qn;PsoSat;SURVEY.GNHLTH;4;Total score [PsoSat];;Copyright © 2016 Matthias Augustin. Used with permission.;ACTIVE;2.65;2.65 +90028-2;Routine Assessment of Patient Index Data 3;-;Pt;^Patient;-;RAPID3;PANEL.SURVEY.GNHLTH;4;Routine Assessment of Patient Index Data 3 [RAPID3];;RAPID3 © 2008 - All rights reserved. Used with permission.;ACTIVE;2.65;2.65 +90030-8;Over the past W, are you able to get in and out of a car, bus, train, or airplane;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to get in and out of a car, bus, train, or airplane [HAQ];;;ACTIVE;2.65;2.65 +90031-6;Over the past W, are you able to walk two miles or three kilometers, if you wish;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to walk two miles or three kilometers, if you wish [HAQ];;;ACTIVE;2.65;2.65 +90032-4;Over the past W, are you able to participate in recreational activities and sports as you would like, if you wish;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to participate in recreational activities and sports as you would like, if you wish [HAQ];;;ACTIVE;2.65;2.65 +90033-2;Over the past W, are you able to get a good night's sleep;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to get a good night's sleep [HAQ];;;ACTIVE;2.65;2.65 +90034-0;Over the past W, are you able to deal with feelings of anxiety or being nervous;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to deal with feelings of anxiety or being nervous [HAQ];;;ACTIVE;2.65;2.65 +9003-5;Fluid intake.oral;VRat;10H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake oral 10 hour;Fluid intake oral 10h;;ACTIVE;1.0h(3);2.48 +90035-7;Over the past W, are you able to deal with feelings of depression or feeling blue;Find;1W;^Patient;Ord;HAQ;SURVEY.HAQ;4;Over the past week, are you able to deal with feelings of depression or feeling blue [HAQ];;;ACTIVE;2.65;2.65 +90036-5;Pain severity in the past W - 0-10 (0.5 increments) numeric rating;Score;1W;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Pain severity in the past week- 0-10 (0.5 increments) numeric rating [Reported];;;ACTIVE;2.65;2.65 +90037-3;Assessment of global health - 0-10 (0.5 increments) numeric rating;Score;Pt;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Assessment of global health - 0-10 (0.5 increments) numeric rating [Reported];;;ACTIVE;2.65;2.65 +90038-1;Weighted score;Score;Pt;^Patient;Qn;RAPID3;SURVEY.GNHLTH;4;Weighted score [RAPID3];;RAPID3 © 2008 - All rights reserved. Used with permission.;ACTIVE;2.65;2.65 +90039-9;ABO & Rh group^post transfusion reaction;Type;Pt;Bld;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood--after transfusion reaction;ABO + Rh p transf rx Bld;;ACTIVE;2.65;2.72 +90040-7;Alpha globin gene cluster & HS-40 region deletion+duplication;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.DELDUP;1;Alpha globin gene cluster and HS-40 region deletion and duplication mutation analysis in Blood or Tissue by Molecular genetics method;Alpha globin genes + HS-40 Del+Dup Bld/T;;ACTIVE;2.65;2.66 +90041-5;Collection setting;Type;Pt;Specimen;Nom;;SPEC;1;Specimen collection setting type;Spec collect setting type;;ACTIVE;2.65;2.65 +90042-3;Borrelia sp DNA;PrThr;Pt;^Tick;Ord;Probe.amp.tar;MICRO;1;Borrelia sp DNA [Presence] in Tick by NAA with probe detection;Borrelia DNA Tick Ql NAA+probe;;ACTIVE;2.65;2.65 +9004-3;Fluid intake.oral;VRat;12H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake oral 12 hour;Fluid intake oral 12h;;ACTIVE;1.0h(3);2.48 +90043-1;"t(14;20)(q32;q12)(IGH,MAFB) fusion transcript";Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.TRNLOC;1;"t(14;20)(q32;q12)(IGH,MAFB) fusion transcript in Blood or Tissue by FISH";"t(14;20)(IGH,MAFB) Bld/T FISH";;ACTIVE;2.65;2.65 +90044-9;Epithelial cells.renal;PrThr;Pt;Urine sed;Ord;;UA;1;Epithelial cells.renal [Presence] in Urine sediment;Renal Epi Cells UrnS Ql;;ACTIVE;2.65;2.65 +90045-6;Treatment history of specimen;Prid;Pt;Semen;Nom;;FERT;1;Treatment history of specimen [Identifier] in Semen;Treatment hx of specimen Smn;;ACTIVE;2.65;2.65 +90046-4;Spermatozoa.abnormal principal pieces/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa.abnormal principal pieces/100 spermatozoa in Semen;Abnormal principal pieces NFr Smn;;ACTIVE;2.65;2.65 +90047-2;Spermatozoa.excess residual cytoplasm/100 spermatozoa;NFr;Pt;Semen;Qn;;FERT;1;Spermatozoa.excess residual cytoplasm/100 spermatozoa in Semen;Excess residual cytoplasm NFr Smn;;ACTIVE;2.65;2.65 +90048-0;Somatotropin binding protein;MCnc;Pt;Ser/Plas;Qn;IA;SERO;1;Somatotropin binding protein [Mass/volume] in Serum or Plasma by Immunoassay;GHBP SerPl IA-mCnc;;ACTIVE;2.65;2.65 +90049-8;Guidance for placement of chest tube;Find;Pt;Chest>Pleural space.left;Doc;CT;RAD;2;CT Guidance for placement of chest tube in Pleural space - left;CT Guided Pl space-L Chest tube place;;ACTIVE;2.66;2.66 +90050-6;Guidance for placement of chest tube;Find;Pt;Chest>Pleural space.bilateral;Doc;CT;RAD;2;CT Guidance for placement of chest tube in Pleural space - bilateral;CT Guided Pl space-Bl Chest tube place;;ACTIVE;2.66;2.66 +90051-4;Guidance for placement of chest tube;Find;Pt;Chest>Pleural space.right;Doc;CT;RAD;2;CT Guidance for placement of chest tube in Pleural space - right;CT Guided Pl space-R Chest tube place;;ACTIVE;2.66;2.66 +90052-2;Address;Addr;Pt;Organization;Nom;;ADMIN;2;Organization Address;Organization Address;;ACTIVE;2.65;2.68 +90053-0;Phone number;Tele;Pt;Organization;Nom;;ADMIN;2;Organization Phone number;Organization Phone #;;ACTIVE;2.65;2.66 +90054-8;Email address;EmailAddr;Pt;Organization;Nom;;ADMIN;2;Organization Email address;Organization Email address;;ACTIVE;2.65;2.68 +90055-5;Organization contact information panel;-;Pt;Organization;-;;PANEL.ADMIN;2;Organization information panel;Organization info pnl;;ACTIVE;2.65;2.68 +90056-3;Date and time lab result reported;TmStp;Pt;^Patient;Qn;;LABORDERS;1;Date and time lab result reported;D/T lab result reported;;ACTIVE;2.65;2.68 +90057-1;Contact name;Pn;Pt;Organization;Nom;;ADMIN;2;Name of Contact at Organization;Organization Contact name;;ACTIVE;2.65;2.68 +90058-9;Person responsible for generating report;Pn;Pt;Personnel;Nom;;ADMIN;2;Person responsible for generating report;Personnel Person generating report;;ACTIVE;2.65;2.68 +90059-7;Task description;Find;Pt;^Event;Nar;;ADMIN;2;Task description Narrative;Task description;;ACTIVE;2.65;2.68 +90060-5;Date task due;Date;Pt;^Event;Qn;;ADMIN;2;Date task due;Date task due;;ACTIVE;2.65;2.68 +90061-3;Public communication document type;Type;Pt;Document;Nom;;DOC.PUBLICHEALTH;2;Public communication document type;Public commun doc type;;ACTIVE;2.65;2.68 +90062-1;Public communication document;Find;Pt;^Event;Doc;;DOC.PUBLICHEALTH;2;Public communication document;Public communication doc;;ACTIVE;2.65;2.68 +90063-9;Date and time task assigned;TmStp;Pt;^Event;Qn;;ADMIN;2;Date and time task assigned;D/T task assigned;;ACTIVE;2.65;2.68 +90064-7;Public health emergency event name;ID;Pt;^Event;Nom;;PUBLICHEALTH;2;Public health emergency event name;PH emerg event name;;ACTIVE;2.65;2.68 +90066-2;Corynebacterium sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Corynebacterium sp identified in Isolate by Organism specific culture;Corynebacterium Islt Cult;;ACTIVE;2.66;2.66 +90067-0;Enterobacteriaceae identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Enterobacteriaceae identified in Isolate by Organism specific culture;Enterobact Islt Cult;;ACTIVE;2.66;2.66 +90068-8;Gram negative bacilli identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Gram negative bacilli identified in Isolate by Organism specific culture;Gram neg bacilli Islt Cult;;ACTIVE;2.66;2.66 +90069-6;Gram positive bacilli identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Gram positive bacilli identified in Isolate by Organism specific culture;Gram pos bacilli Islt Cult;;ACTIVE;2.66;2.66 +90070-4;Gram positive catalase producing cocci identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Gram positive catalase producing cocci identified in Isolate by Organism specific culture;GP catalase producing cocci Islt Cult;;ACTIVE;2.66;2.66 +90071-2;Gram positive non-catalase producing cocci identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Gram positive non-catalase producing cocci identified in Isolate by Organism specific culture;GP non-catalase prod cocci Islt Cult;;ACTIVE;2.66;2.66 +90072-0;Haemophilus sp & Neisseria sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Haemophilus and Neisseria species identified in Isolate by Organism specific culture;Haem + Neiss Islt Cult;;ACTIVE;2.66;2.66 +90073-8;Lactobacillales identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Lactobacillales identified in Isolate by Organism specific culture;Lactobacillales Islt Cult;;ACTIVE;2.66;2.66 +90075-3;Non-Enterobacteriaceae identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Non-Enterobacteriaceae identified in Isolate by Organism specific culture;Non-enerobact Islt Cult;;ACTIVE;2.66;2.66 +9007-6;Fluid intake.oral;VRat;24H;Upper GI tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake oral 24 hour;Fluid intake oral 24h;;ACTIVE;1.0h(3);2.48 +90076-1;Staphylococcus sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Staphylococcus sp identified in Isolate by Organism specific culture;Staphylococcus Islt Cult;;ACTIVE;2.66;2.66 +90077-9;Urinary pathogens identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Urinary pathogens identified in Isolate by Organism specific culture;Urinary pathogens Islt Cult;;ACTIVE;2.66;2.66 +90078-7;Yeast identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Yeast identified in Isolate by Organism specific culture;Yeast Islt Cult;;ACTIVE;2.66;2.66 +90079-5;Were you trying to get pregnant;Find;Pt;^Patient;Ord;;H&P.HX;2;Were you trying to get pregnant;Trying to get pregnant;;ACTIVE;2.65;2.65 +90080-3;Bictegravir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Bictegravir [Susceptibility] by Genotype method;Bictegravir Islt Genotyp;;ACTIVE;2.65;2.69 +90081-1;Public communication document name;ID;Pt;Document;Nom;;DOC.PUBLICHEALTH;2;Public communication document name;Public communication doc name;;ACTIVE;2.65;2.68 +90082-9;Public communication template;Type;Pt;Document;Nom;;DOC.PUBLICHEALTH;2;Public communication template;Public communication template;;ACTIVE;2.65;2.68 +90083-7;Public communication target group;Type;Pt;^Event;Nom;;PUBLICHEALTH;2;Public communication target group;Public comm target group;;ACTIVE;2.65;2.68 +9008-4;Fluid intake.peritoneal;Vol;Pt;Peritoneal space;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake peritoneal Estimated;Fluid intake peritoneal Est;;ACTIVE;1.0h(3);2.48 +90084-5;Report identifier;ID;Pt;Report;Nom;;DOC.MISC;2;Report identifier;Report ID;;ACTIVE;2.65;2.68 +90085-2;Report name;ID;Pt;Report;Nom;;DOC.MISC;2;Report name;Report name;;ACTIVE;2.65;2.68 +90087-8;Date range of report;DateRange;Pt;Report;Qn;;DOC.MISC;2;Date range of report;Date range of report DateRange;;ACTIVE;2.65;2.68 +90088-6;Public communication target region;Loc;Pt;^Event;Nom;;PUBLICHEALTH;2;Public communication target region [Location];Public commun target region;;ACTIVE;2.65;2.68 +90089-4;Date and time report was released;TmStp;Pt;Report;Qn;;DOC.MISC;2;Date and time report was released;D/T report released;;ACTIVE;2.65;2.68 +90090-2;Inter-agency communication document type;Type;Pt;Document;Nom;;DOC.PUBLICHEALTH;2;Inter-agency communication document type;Inter-agency communication doc type;;ACTIVE;2.65;2.68 +90091-0;Date and time of incident management system activation;TmStp;Pt;^Event;Qn;;PUBLICHEALTH;2;Date and time of incident management system activation;D/T of IMS activation;;ACTIVE;2.65;2.68 +9009-2;Fluid intake.peritoneal;Vol;Pt;Peritoneal space;Qn;Measured;IO_IN.MOLEC;2;Fluid intake peritoneal Measured;Fluid intake peritoneal Measured;;ACTIVE;1.0h(3);2.48 +90093-6;Name;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel name;Personnel name;;ACTIVE;2.65;2.68 +90094-4;Rheumatoid arthritis disease severity level;Imp;Pt;^Patient;Ord;RAPID3;SURVEY.GNHLTH;4;Rheumatoid arthritis disease severity level [RAPID3];;RAPID3 © 2008 - All rights reserved. Used with permission.;ACTIVE;2.65;2.72 +90095-1;Event managing group at lead department or agency;ID;Pt;Organization;Nom;;SURVEY.CDC;4;Event managing group at lead department or agency Organization;;;ACTIVE;2.65;2.68 +90096-9;Event managing group at co-lead department or agency;ID;Pt;Organization;Nom;;SURVEY.CDC;4;Event managing group at co-lead department or agency Organization;;;ACTIVE;2.65;2.68 +90097-7;Person responsible for generating report;EmailAddr;Pt;Personnel;Nom;;ADMIN;2;Email address of person responsible for generating report;Email addr of person generating rprt;;ACTIVE;2.65;2.68 +90098-5;Report distribution frequency;NRat;Pt;Report;Ord;;DOC.MISC;2;Report distribution frequency;Report distribution freq;;ACTIVE;2.65;2.68 +90099-3;Emergency response report;Find;Pt;^Event;Doc;;DOC.MISC;2;Emergency response report Document;Emerg response report Doc;;ACTIVE;2.65;2.68 +90-1;Cefmetazole;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefmetazole [Susceptibility] by Serum bactericidal titer;Cefmetazole Titr SBT;;ACTIVE;1.0;2.32 +9010-0;Fluid intake.peritoneal;VRat;1H;Peritoneal space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake peritoneal 1 hour;Fluid intake peritoneal 1h;;ACTIVE;1.0h(3);2.48 +90100-9;Listeria sp identified;Prid;Pt;Isolate;Nom;Organism specific culture;MICRO;1;Listeria sp identified in Isolate by Organism specific culture;Listeria Islt Cult;;ACTIVE;2.66;2.66 +90101-7;Internal control result;PrThr;Pt;Specimen;Ord;;SPEC;1;Internal control result;Int control result;;ACTIVE;2.65;2.72 +90102-5;Date of emergency response plan release;Date;Pt;Document;Qn;;DOC.MISC;2;Date of emergency response plan release;Date emerg response plan release;;ACTIVE;2.65;2.68 +90103-3;Emergency response plan identifier;ID;Pt;Document;Nom;;DOC.MISC;2;Emergency response plan identifier;Emergency response plan ID;;ACTIVE;2.65;2.68 +90104-1;Emergency operations center standard operating procedure name;ID;Pt;Document;Nom;;DOC.MISC;2;Emergency operations center standard operating procedure name;EOC SOP name;;ACTIVE;2.65;2.68 +90105-8;Emergency operations center standard operating procedure identifier;ID;Pt;Document;Nom;;DOC.MISC;2;Emergency operations center standard operating procedure identifier;EOC SOP ID;;ACTIVE;2.65;2.68 +90106-6;Date emergency operations center standard operating procedure issued;Date;Pt;Document;Qn;;DOC.MISC;2;Date emergency operations center standard operating procedure issued;Date EOC SOP issued;;ACTIVE;2.65;2.68 +90107-4;Date emergency operations center standard operating procedure released;Date;Pt;Document;Qn;;DOC.MISC;2;Date emergency operations center standard operating procedure released;Date EOC SOP released;;ACTIVE;2.65;2.68 +90108-2;Incident commander name;Pn;Pt;Personnel;Nom;;ADMIN;2;Incident commander name;Incident commander name;;ACTIVE;2.65;2.68 +90109-0;Incident commander qualification;Type;Pt;Personnel;Nom;;ADMIN;2;Incident commander qualification;Incident commander qual;;ACTIVE;2.65;2.68 +90110-8;Incident commander phone number;Tele;Pt;Personnel;Nom;;ADMIN;2;Incident commander phone number;Incident commander phone #;;ACTIVE;2.65;2.68 +90111-6;Incident commander email address;EmailAddr;Pt;Personnel;Nom;;ADMIN;2;Incident commander email address;Incident commander email;;ACTIVE;2.65;2.68 +90112-4;Response section or team responsibility;Find;Pt;Organization;Nom;;SURVEY.CDC;4;Response section or team responsibility;;;ACTIVE;2.65;2.68 +90113-2;Chief of staff name;Pn;Pt;Personnel;Nom;;ADMIN;2;Chief of staff name;Chief of staff name;;ACTIVE;2.65;2.68 +90114-0;Chief of staff phone number;Tele;Pt;Personnel;Nom;;ADMIN;2;Chief of staff phone number;Chief of staff phone #;;ACTIVE;2.65;2.68 +90115-7;Chief of staff email address;EmailAddr;Pt;Personnel;Nom;;ADMIN;2;Chief of staff email address;Chief of staff email;;ACTIVE;2.65;2.68 +90116-5;Emergency response plan;Find;Pt;^Event;Doc;;DOC.MISC;2;Emergency response plan Document;Emergency response plan Doc;;ACTIVE;2.65;2.68 +90117-3;Estimated date of next emergency response plan release;Date;Pt;Document;Qn;;DOC.MISC;2;Estimated date of next emergency response plan release;Est date next emerg resp plan;;ACTIVE;2.65;2.68 +9011-8;Fluid intake.peritoneal;VRat;8H;Peritoneal space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake peritoneal 8 hour;Fluid intake peritoneal 8h;;ACTIVE;1.0h(3);2.48 +90118-1;Date and time of scheduled task;TmStp;Pt;^Event;Qn;;ADMIN;2;Date and time of scheduled task;Date and time of scheduled task;;ACTIVE;2.65;2.68 +90119-9;Location of task;Loc;Pt;^Event;Nom;;ADMIN;2;Location of task;Location of task;;ACTIVE;2.65;2.68 +90120-7;Date and time of event response status;TmStp;Pt;^Event;Qn;;SURVEY.CDC;4;Date and time of event response status;;;ACTIVE;2.65;2.68 +90121-5;Event response description;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Event response description;;;ACTIVE;2.65;2.68 +90122-3;Response team participation status;Type;Pt;^Event;Nom;;SURVEY.CDC;4;Response team participation status;;;ACTIVE;2.65;2.68 +90123-1;Response team leader name;Pn;Pt;Personnel;Nom;;ADMIN;2;Response team leader name;Response team leader name;;ACTIVE;2.65;2.68 +90124-9;Response team leader title;Type;Pt;Personnel;Nom;;ADMIN;2;Response team leader title;Response team leader title;;ACTIVE;2.65;2.68 +90125-6;Response team member name;Pn;Pt;Personnel;Nom;;ADMIN;2;Response team member name;Response team member name;;ACTIVE;2.65;2.68 +9012-6;Fluid intake.peritoneal;VRat;10H;Peritoneal space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake peritoneal 10 hour;Fluid intake peritoneal 10h;;ACTIVE;1.0h(3);2.48 +90126-4;Response team member title;Type;Pt;Personnel;Nom;;ADMIN;2;Response team member title;Response team member title;;ACTIVE;2.65;2.68 +90127-2;It is hard for your child to find his or her way to a place that he or she has visited several times before in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to find his or her way to a place that he or she has visited several times before in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90128-0;Your child has trouble remembering where he or she put things, like his or her watch or his or her homework in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble remembering where he or she put things, like his or her watch or his or her homework in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90130-6;It is hard for your child to take notes in class in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to take notes in class in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90131-4;It is hard for your child to learn new things in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to learn new things in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90132-2;It is hard for your child to understand pictures that show how to make something in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to understand pictures that show how to make something in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90133-0;It is hard for your child to pay attention to something boring he or she has to do in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to pay attention to something boring he or she has to do in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9013-4;Fluid intake.peritoneal;VRat;12H;Peritoneal space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake peritoneal 12 hour;Fluid intake peritoneal 12h;;ACTIVE;1.0h(3);2.48 +90134-8;It is hard for your child to pay attention to one thing for more than 5-10 minutes in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to pay attention to one thing for more than 5-10 minutes in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90135-5;Your child has trouble remembering the names of people he or she has just met in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble remembering the names of people he or she has just met in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90136-3;Your child has trouble keeping track of what he or she is doing if he or she gets interrupted in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble keeping track of what he or she is doing if he or she gets interrupted in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90137-1;It is hard for your child to do more than one thing at a time in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to do more than one thing at a time in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90138-9;Your child forgets what his or her parents or teachers ask him or her to do in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child forgets what his or her parents or teachers ask him or her to do in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90139-7;Your child walks into a room and forgets what he or she wanted to get or do in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child walks into a room and forgets what he or she wanted to get or do in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90140-5;Your child has trouble remembering the names of people he or she knows in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble remembering the names of people he or she knows in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90141-3;It is hard for your child to add or subtract numbers in his or her head in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to add or subtract numbers in his or her head in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9014-2;Fluid intake.peritoneal;VRat;24H;Peritoneal space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake peritoneal 24 hour;Fluid intake peritoneal 24h;;ACTIVE;1.0h(3);2.48 +90142-1;Your child has trouble remembering the date or day of the week in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble remembering the date or day of the week in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90143-9;When your child has a big project to do, he or she has trouble deciding where to start in past 4W;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When your child has a big project to do, he or she has trouble deciding where to start in past 4 weeks [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90144-7;Your child has to read things several times to understand them in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has to read things several times to understand them in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90145-4;Your child has to read things several times to understand them in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has to read things several times to understand them in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90146-2;Your child reacts slower than most people his or her age when he or she plays games in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child reacts slower than most people his or her age when he or she plays games in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90147-0;Your child reacts slower than most people his or her age when he or she plays games in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child reacts slower than most people his or her age when he or she plays games in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90148-8;It is hard for your child to find the right words to say what he or she means in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to find the right words to say what he or she means in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90149-6;It is hard for your child to find the right words to say what he or she means in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to find the right words to say what he or she means in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90150-4;Your child forgets things easily in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child forgets things easily in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90151-2;Your child forgets things easily in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child forgets things easily in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90152-0;It is hard for your child to concentrate in school in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to concentrate in school in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90153-8;It is hard for your child to concentrate in school in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It is hard for your child to concentrate in school in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90154-6;Your child has a hard time keeping track of his or her homework in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has a hard time keeping track of his or her homework in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90155-3;Your child has a hard time keeping track of his or her homework in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has a hard time keeping track of his or her homework in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90156-1;Your child forgets to bring things to and from school that he or she needs for homework in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child forgets to bring things to and from school that he or she needs for homework in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90157-9;Your child forgets to bring things to and from school that he or she needs for homework in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child forgets to bring things to and from school that he or she needs for homework in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90158-7;Your child forgets what he or she is going to say in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child forgets what he or she is going to say in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9015-9;Class;Type;Pt;Peritoneal tube;Nom;;IO.TUBE;2;Type of Peritoneal tube;Peritoneal tube Class;;ACTIVE;1.0h(3);2.27 +90159-5;Your child forgets what he or she is going to say in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child forgets what he or she is going to say in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90160-3;It takes your child longer than other people to get his or her school work done in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It takes your child longer than other people to get his or her school work done in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90161-1;It takes your child longer than other people to get his or her school work done in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It takes your child longer than other people to get his or her school work done in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90162-9;Your child has to use written lists more often than other people his or her age so he or she will not forget things in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has to use written lists more often than other people his or her age so he or she will not forget things in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90163-7;Your child has to use written lists more often than other people his or her age so he or she will not forget things in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has to use written lists more often than other people his or her age so he or she will not forget things in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90164-5;Your child has trouble remembering to do things like school projects or chores in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble remembering to do things like school projects or chores in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90165-2;Your child has trouble remembering to do things like school projects or chores in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble remembering to do things like school projects or chores in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90166-0;Your child has trouble paying attention to the teacher in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble paying attention to the teacher in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90167-8;Your child has trouble paying attention to the teacher in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has trouble paying attention to the teacher in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90168-6;Your child has to work really hard to pay attention or he or she makes mistakes in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has to work really hard to pay attention or he or she makes mistakes in past 4 weeks - frequency [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90169-4;Your child has to work really hard to pay attention or he or she makes mistakes in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Your child has to work really hard to pay attention or he or she makes mistakes in past 4 weeks - severity [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90170-2;PROMIS parent proxy item bank - cognitive function - version 1.0;-;4W;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - cognitive function - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90171-0;PROMIS parent proxy cognitive function - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy cognitive function - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90172-8;PROMIS parent proxy cognitive function - frequency - version 1.0;-;4W;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy cognitive function - frequency - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90173-6;PROMIS parent proxy cognitive function - severity - version 1.0;-;4W;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy cognitive function - severity - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90174-4;It is hard for me to find my way to a place that I have visited several times before in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to find my way to a place that I have visited several times before in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9017-5;Fluid intake.synovial;Vol;Pt;Synovial space;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake synovial Estimated;Fluid intake synovial Est;;ACTIVE;1.0h(3);2.48 +90175-1;I have trouble remembering where I put things, like my watch or my homework in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble remembering where I put things, like my watch or my homework in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90176-9;I have trouble remembering the names of people I have just met in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble remembering the names of people I have just met in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90177-7;It is hard for me to take notes in class in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to take notes in class in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90178-5;It is hard for me to learn new things in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to learn new things in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90179-3;It is hard for me to understand pictures that show how to make something in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to understand pictures that show how to make something in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90180-1;It is hard for me to pay attention to something boring I have to do in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to pay attention to something boring I have to do in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90181-9;It is hard for me to pay attention to one thing for more than 5-10 minutes in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to pay attention to one thing for more than 5-10 minutes in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90182-7;I have trouble recalling the names of things in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble recalling the names of things in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9018-3;Fluid intake.synovial;Vol;Pt;Synovial space;Qn;Measured;IO_IN.MOLEC;2;Fluid intake synovial Measured;Fluid intake synovial Measured;;ACTIVE;1.0h(3);2.48 +90183-5;I have trouble keeping track of what I am doing if I get interrupted in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble keeping track of what I am doing if I get interrupted in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90184-3;It is hard for me to do more than one thing at a time in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to do more than one thing at a time in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90185-0;I forget what my parents or teachers ask me to do in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forget what my parents or teachers ask me to do in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90186-8;I walk into a room and forget what I wanted to get or do in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I walk into a room and forget what I wanted to get or do in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90187-6;I have trouble remembering the names of people I know in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble remembering the names of people I know in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90188-4;It is hard for me to add or subtract numbers in my head in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to add or subtract numbers in my head in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90189-2;I have trouble remembering the date or day of the week in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble remembering the date or day of the week in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +901-9;Blood group antibody screen.cells I+II+III;PrThr;Pt;Ser/Plas;Ord;Prewarmed;BLDBK;1;Blood group antibody screen.cells I+II+III [Presence] in Serum or Plasma by Prewarmed;Bld gp Ab Scn Cells x3 SerPl Ql Pwarm;;ACTIVE;1.0;2.56 +90190-0;When I have a big project to do, I have trouble deciding where to start in past 4W;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;When I have a big project to do, I have trouble deciding where to start in past 4 weeks [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9019-1;Fluid intake.synovial;VRat;1H;Synovial space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake synovial 1 hour;Fluid intake synovial 1h;;ACTIVE;1.0h(3);2.48 +90191-8;I have to read things several times to understand them in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have to read things several times to understand them in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90192-6;I have to read things several times to understand them in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have to read things several times to understand them in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90193-4;I react slower than most people my age when I play games in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I react slower than most people my age when I play games in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90194-2;I react slower than most people my age when I play games in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I react slower than most people my age when I play games in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90195-9;It is hard for me to find the right words to say what I mean in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to find the right words to say what I mean in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90196-7;It is hard for me to find the right words to say what I mean in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to find the right words to say what I mean in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90197-5;I forget things easily in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forget things easily in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90198-3;I forget things easily in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forget things easily in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90199-1;It is hard for me to concentrate in school in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to concentrate in school in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90200-7;It is hard for me to concentrate in school in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It is hard for me to concentrate in school in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90201-5;I have a hard time keeping track of my homework in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have a hard time keeping track of my homework in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90202-3;I have a hard time keeping track of my homework in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have a hard time keeping track of my homework in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90203-1;I forget to bring things to and from school that I need for homework in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forget to bring things to and from school that I need for homework in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90204-9;I forget to bring things to and from school that I need for homework in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forget to bring things to and from school that I need for homework in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90205-6;I forget what I am going to say in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forget what I am going to say in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90206-4;I forget what I am going to say in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forget what I am going to say in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90207-2;It takes me longer than other people to get my school work done in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It takes me longer than other people to get my school work done in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90208-0;It takes me longer than other people to get my school work done in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;It takes me longer than other people to get my school work done in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9020-9;Fluid intake.synovial;VRat;8H;Synovial space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake synovial 8 hour;Fluid intake synovial 8h;;ACTIVE;1.0h(3);2.48 +90209-8;I have to use written lists more often than other people my age so I will not forget things in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have to use written lists more often than other people my age so I will not forget things in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90210-6;I have to use written lists more often than other people my age so I will not forget things in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have to use written lists more often than other people my age so I will not forget things in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90211-4;I have trouble remembering to do things like school projects or chores in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble remembering to do things like school projects or chores in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90212-2;I have trouble remembering to do things like school projects or chores in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble remembering to do things like school projects or chores in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90213-0;I have trouble paying attention to the teacher in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble paying attention to the teacher in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90214-8;I have trouble paying attention to the teacher in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have trouble paying attention to the teacher in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90215-5;I have to work really hard to pay attention or I make mistakes in past 4W - frequency;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have to work really hard to pay attention or I make mistakes in past 4 weeks - frequency [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90216-3;I have to work really hard to pay attention or I make mistakes in past 4W - severity;Find;4W;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I have to work really hard to pay attention or I make mistakes in past 4 weeks - severity [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9021-7;Fluid intake.synovial;VRat;10H;Synovial space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake synovial 10 hour;Fluid intake synovial 10h;;ACTIVE;1.0h(3);2.48 +90217-1;PROMIS pediatric item bank - cognitive function - version 1.0;-;4W;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - cognitive function - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90218-9;PROMIS pediatric cognitive function - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric cognitive function - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90219-7;PROMIS pediatric cognitive function - frequency - version 1.0;-;4W;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric cognitive function - frequency - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90220-5;PROMIS pediatric cognitive function - severity - version 1.0;-;4W;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric cognitive function - severity - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90221-3;Total score;Score;Pt;^Patient;Qn;CUDOS;SURVEY.MTLHLTH;4;Total score [CUDOS];;© 2008 Dr. Mark Zimmerman Used with permission;ACTIVE;2.65;2.65 +90222-1;Clinically Useful Depression Outcome Scale;-;Pt;^Patient;-;CUDOS;PANEL.SURVEY.MTLHLTH;4;Clinically Useful Depression Outcome Scale [CUDOS];;© 2008 Dr. Mark Zimmerman Used with permission;ACTIVE;2.65;2.68 +90223-9;Neutrophils.immature/Neutrophils.total;NFr.DF;Pt;Bld;Qn;;HEM/BC;1;Neutrophils.immature/Neutrophils.total [Pure number fraction] in Blood;Neut.immature/Neut.total NFr.DF Bld;;ACTIVE;2.65;2.65 +90224-7;Thyroxine & Thyroxine.free panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Thyroxine and Thyroxine.free panel - Serum or Plasma;Thyroxine & Thyroxine.free panel SerPl;;ACTIVE;2.65;2.73 +9022-5;Fluid intake.synovial;VRat;12H;Synovial space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake synovial 12 hour;Fluid intake synovial 12h;;ACTIVE;1.0h(3);2.48 +90225-4;Coagulation factor VII activity & inhibitor panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Coagulation factor VII activity and inhibitor panel - Platelet poor plasma by Coagulation assay;Fact VII Act + Inhib Pnl PPP;;ACTIVE;2.65;2.69 +90226-2;Nicotine & Cotinine panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Nicotine and Cotinine panel - Serum or Plasma;Nicotine & Cotinine panel SerPl;;ACTIVE;2.65;2.65 +90227-0;Histoplasma capsulatum H & M Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Histoplasma capsulatum H and M Ab panel - Serum;H capsulatum H+M Ab panel Ser;;ACTIVE;2.65;2.65 +90228-8;Extractable nuclear antigen Ab.IgG panel;-;Pt;Ser;-;;PANEL.SERO;1;Extractable nuclear antigen Ab.IgG panel - Serum;ENA Ab.IgG pnl Ser;;ACTIVE;2.65;2.65 +90229-6;Herpes simplex virus 1 & 2 Ab.IgG & IgM panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Herpes simplex virus 1 and 2 Ab.IgG and IgM panel - Serum or Plasma;HSV 1+2 Ab.IgG & IgM panel SerPl;;ACTIVE;2.65;2.73 +90230-4;Myeloperoxidase Ab.IgG & Proteinase 3 Ab.IgG Panel;-;Pt;Ser;-;;PANEL.SERO;1;Myeloperoxidase Ab.IgG and Proteinase 3 Ab.IgG Panel - Serum;MPO IgG & PR3 Ab.IgG Panel Ser;;ACTIVE;2.65;2.65 +90231-2;Thymoma & myasthenia gravis antibody panel;-;Pt;Ser;-;;PANEL.SERO;1;Thymoma and myasthenia gravis antibody panel - Serum;Thymoma + MS Ab panel Ser;;ACTIVE;2.65;2.65 +90232-0;Histoplasma capsulatum Ab;Prid;Pt;Ser/Plas;Nom;Immune diffusion;MICRO;1;Histoplasma capsulatum Ab [Identifier] in Serum or Plasma by Immune diffusion (ID);H capsul Ab SerPl ID;;ACTIVE;2.65;2.73 +9023-3;Fluid intake.synovial;VRat;24H;Synovial space;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake synovial 24 hour;Fluid intake synovial 24h;;ACTIVE;1.0h(3);2.48 +90233-8;Dermatan sulfate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Dermatan sulfate [Moles/volume] in DBS;Dermatan Sulfate DBS-sCnc;;ACTIVE;2.65;2.65 +90234-6;Globotriaosylsphingosine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Globotriaosylsphingosine [Mass/volume] in Serum or Plasma;Globotriaosylsphingosine SerPl-mCnc;;ACTIVE;2.65;2.68 +90235-3;Heparan sulfate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Heparan sulfate [Moles/volume] in DBS;Heparan sulfate DBS-sCnc;;ACTIVE;2.65;2.65 +90236-1;Keratan sulfate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Keratan sulfate [Moles/volume] in DBS;Keratan Sulfate DBS-sCnc;;ACTIVE;2.65;2.65 +90237-9;Phenylacetylcarnitine (PheC2);SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phenylacetylcarnitine (PheC2) [Moles/volume] in Serum or Plasma;Phenylacetylcarn SerPl-sCnc;;ACTIVE;2.65;2.65 +90238-7;Salicylcarnitine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Salicylcarnitine [Moles/volume] in Serum or Plasma;Salicylcarnitine SerPl-sCnc;;ACTIVE;2.65;2.65 +90239-5;Suppression of tumorigenicity 2.soluble;MCnc;Pt;Ser;Qn;IA;CHEM;1;ST2.soluble [Mass/volume] in Serum by Immunoassay;ST2.soluble Ser IA-mCnc;;ACTIVE;2.65;2.65 +90240-3;Eculizumab;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Eculizumab [Mass/volume] in Serum;Eculizumab Ser-mCnc;;ACTIVE;2.65;2.65 +9024-1;Class;Type;Pt;Upper GI tube;Nom;;IO.TUBE;2;Type of Upper GI tube;Upper GI tube Class;;ACTIVE;1.0h(3);2.27 +90241-1;Natural killer cell cytotoxicity.IL-2 stimulated 30:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.IL-2 stimulated 30:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cyto IL2 30:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.65;2.65 +90242-9;Natural killer cell cytotoxicity.IL-2 stimulated 0.9:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.IL-stimulated 0.9:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cyto IL2 0.9:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.65;2.65 +90243-7;Natural killer cell cytotoxicity.IL-2 stimulated 1.88:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.IL-stimulated 1.88:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cyto IL2 1.88:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.65;2.65 +90244-5;Natural killer cell cytotoxicity.IL-2 stimulated 15:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.IL-stimulated 15:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cyto IL2 15:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.65;2.65 +90245-2;Natural killer cell cytotoxicity.IL-2 stimulated 3.75:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.IL-stimulated 3.75:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cyto IL2 3.75:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.65;2.65 +90246-0;Bacterial whole genome;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Bacterial whole genome [Nucleotide sequence] in Isolate by Sequencing;Bacterial whole genome Islt-Seq;;ACTIVE;2.65;2.65 +90247-8;Trypanosoma cruzi Ab.IgG;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Trypanosoma cruzi IgG Ab [Presence] in Serum from Donor by Immunoassay;T cruzi IgG Ser Donr Ql IA;;ACTIVE;2.65;2.65 +90248-6;Myelin oligodendrocyte glycoprotein Ab.IgG1;PrThr;Pt;Ser/Plas;Ord;Flow cytometry;SERO;1;Myelin oligodendrocyte glycoprotein IgG1 Ab [Presence] in Serum or Plasma by Flow cytometry (FC);MOG IgG1 SerPl Ql FC;;ACTIVE;2.65;2.73 +90249-4;Natural killer cell cytotoxicity.IL-2 stimulated 7.5:1 effector to target cell ratio/Positive control;RelACnc;Pt;Bld MC;Qn;;HEM/BC;1;Natural killer cell cytotoxicity.IL-stimulated 7.5:1 effector to target cell ratio/Positive control in Blood mononuclear cells;NK cyto IL2 7.5:1 E:T/Pos cntrl Bld MC;;ACTIVE;2.65;2.65 +90250-2;Vanillylmandelate & Homovanillate panel;-;Pt;Urine;-;;PANEL.CHEM;1;Vanillylmandelate and Homovanillate panel - Urine;VMA + HMA panel Ur;;ACTIVE;2.65;2.65 +90251-0;Bartonella henselae & Bartonella quintana Ab.IgG & IgM panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Bartonella henselae and Bartonella quintana IgG and IgM panel [Titer] - Serum;B henselae+quintana IgG+IgM Pnl Titr Ser;;ACTIVE;2.65;2.65 +90252-8;Report no events;Find;Pt;^Patient;Doc;;DOC.PUBLICHEALTH;2;Report No Events section;Report no events;;ACTIVE;2.65;2.68 +90253-6;Measles virus Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Measles virus IgG and IgM Ql panel - Serum;MeV IgG+IgM Ql Pnl Ser;;ACTIVE;2.65;2.65 +90254-4;Measles virus Ab.IgG & IgM panel;Titr;Pt;CSF;Qn;;PANEL.MICRO;1;Measles virus IgG and IgM panel [Titer] - Cerebral spinal fluid;MeV IgG+IgM Pnl Titr CSF;;ACTIVE;2.65;2.65 +90255-1;Satisfaction with knee &or hip replacement result;Find;Pt;^Patient;Ord;;CLIN;2;Satisfaction with knee AndOr hip replacement result;Knee/hip replacement satisfaction;;ACTIVE;2.65;2.65 +90256-9;CFTR gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;CFTR gene full mutation analysis in Blood or Tissue by Sequencing;CFTR Full Mut Anl Bld/T Seq;;ACTIVE;2.65;2.66 +90257-7;GLA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;Deprecated GLA gene full mutation analysis in Blood or Tissue by Sequencing;Deprecated GLA gene Full Mut Anl Bld/T Seq;;DEPRECATED;2.65;2.66 +9025-8;Fluid intake.urinary bladder irrigation;Vol;Pt;Urinary tract;Qn;Estimated;IO_IN.MOLEC;2;Fluid intake urinary bladder irrigation Estimated;Fluid intake bladder irrigation Est;;ACTIVE;1.0h(3);2.48 +90258-5;LDLR gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;LDLR gene full mutation analysis in Blood or Tissue by Sequencing;LDLR gene Full Mut Anl Bld/T Seq;;ACTIVE;2.65;2.67 +90259-3;NAT2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;NAT2 gene full mutation analysis in Blood or Tissue by Sequencing;NAT2 Full Mut Anl Bld/T Seq;;ACTIVE;2.65;2.67 +90260-1;Rickettsia spotted fever group Ab.IgG & IgM panel;Titr;Pt;Ser;Qn;;PANEL.MICRO;1;Rickettsia spotted fever group Ab.IgG and IgM panel [Titer] - Serum;SF IgG+IgM Pnl Titr Ser;;ACTIVE;2.65;2.65 +90261-9;Microscopic observation;Prid;Pt;Bil fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Bile fluid by Giemsa stain;Gie Stn Bifl;;ACTIVE;2.65;2.65 +90262-7;Microscopic observation;Prid;Pt;Bil fld;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Bile fluid by Gram stain;Gram Stn Bifl;;ACTIVE;2.65;2.65 +90263-5;Microscopic observation;Prid;Pt;Milk;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Milk by Gram stain;Gram Stn Mlk;;ACTIVE;2.65;2.65 +90264-3;Fracture Risk Assessment;-;Pt;^Patient;-;FRAX;PANEL.CLIN.RISK;2;Fracture Risk Assessment [FRAX];Fracture Risk Assessment [FRAX];Copyright © 2008 Eugene McCloskey. Used with permission.;ACTIVE;2.65;2.67 +90265-0;Major osteoporotic fracture 10Y probability;Likelihood;Pt;^Patient;Qn;FRAX;CLIN.RISK;2;Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment;Osteoporotic fracture 10Y prob FRAX;Copyright © 2008 Eugene McCloskey. Used with permission.;ACTIVE;2.65;2.65 +9026-6;Fluid intake.urinary bladder irrigation;Vol;Pt;Urinary tract;Qn;Measured;IO_IN.MOLEC;2;Fluid intake urinary bladder irrigation Measured;Fluid intake bladder irrigation Measured;;ACTIVE;1.0h(3);2.48 +90266-8;Hip fracture 10Y probability;Likelihood;Pt;^Patient;Qn;FRAX;CLIN.RISK;2;Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment;Hip fracture 10Y prob FRAX;Copyright © 2008 Eugene McCloskey. Used with permission.;ACTIVE;2.65;2.65 +90267-6;Microscopic observation;Prid;Pt;Pericard fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Pericardial fluid by Giemsa stain;Gie Stn Pcar;;ACTIVE;2.65;2.65 +90268-4;Microscopic observation;Prid;Pt;Periton fld;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Peritoneal fluid by Giemsa stain;Gie Stn Prt;;ACTIVE;2.65;2.65 +90269-2;Microscopic observation;Prid;Pt;Milk;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Milk by Acid fast stain;Acid fast Stn Mlk;;ACTIVE;2.65;2.65 +902-7;Blood group antibody screen.autologous;PrThr;Pt;Ser/Plas;Ord;Prewarmed;BLDBK;1;Blood group antibody screen.autologous [Presence] in Serum or Plasma by Prewarmed;Bld gp Ab Autol Scn SerPl Ql Pwarm;;ACTIVE;1.0;2.56 +90270-0;Bacteria identified;Prid;Pt;Bil fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Bile fluid by Aerobe culture;Bacteria Bifl Aerobe Cult;;ACTIVE;2.65;2.65 +90271-8;Bacteria identified;Prid;Pt;Pericard fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Pericardial fluid by Aerobe culture;Bacteria Pcar Aerobe Cult;;ACTIVE;2.65;2.65 +90272-6;Streptococcus agalactiae DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Vaginal fluid by NAA with probe detection;Gp B Strep DNA Vag Ql NAA+probe;;ACTIVE;2.65;2.65 +90273-4;Bacteria identified;Prid;Pt;Ctp;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Catheter tip by Anaerobe culture;Bacteria Cath Tip Anaerobe Cult;;ACTIVE;2.65;2.65 +9027-4;Fluid intake.urinary bladder irrigation;VRat;1H;Urinary tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake urinary bladder irrigation 1 hour;Fluid intake bladder irrigation 1h;;ACTIVE;1.0h(3);2.48 +90274-2;Bacteria identified;Prid;Pt;Ctp;Nom;Aerobic culture;MICRO;1;Bacteria identified in Catheter tip by Aerobe culture;Bacteria Cath Tip Aerobe Cult;;ACTIVE;2.65;2.65 +90275-9;Gardnerella vaginalis;PrThr;Pt;Vag;Ord;Organism specific culture;MICRO;1;Gardnerella vaginalis [Presence] in Vaginal fluid by Organism specific culture;G vaginalis Vag Ql Cult;;ACTIVE;2.65;2.65 +90276-7;Bacteria identified;Prid;Pt;Semen;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Semen by Anaerobe culture;Bacteria Smn Anaerobe Cult;;ACTIVE;2.65;2.65 +90277-5;Bacteria identified;Prid;Pt;Dial fld prt;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Peritoneal dialysis fluid by Anaerobe culture;Bacteria DiafP Anaerobe Cult;;ACTIVE;2.65;2.65 +90278-3;Bacteria identified;Prid;Pt;Synv fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Synovial fluid by Aerobe culture;Bacteria Snv Aerobe Cult;;ACTIVE;2.65;2.65 +90279-1;Bacteria identified;Prid;Pt;Semen;Nom;Aerobic culture;MICRO;1;Bacteria identified in Semen by Aerobe culture;Bacteria Smn Aerobe Cult;;ACTIVE;2.65;2.65 +90280-9;Bacteria identified;Prid;Pt;Dial fld prt;Nom;Aerobic culture;MICRO;1;Bacteria identified in Peritoneal dialysis fluid by Aerobe culture;Bacteria DiafP Aerobe Cult;;ACTIVE;2.65;2.65 +90281-7;Bacteria identified;Prid;Pt;Periton fld;Nom;Aerobic culture;MICRO;1;Bacteria identified in Peritoneal fluid by Aerobe culture;Bacteria Prt Aerobe Cult;;ACTIVE;2.65;2.65 +9028-2;Fluid intake.urinary bladder irrigation;VRat;8H;Urinary tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake urinary bladder irrigation 8 hour;Fluid intake bladder irrigation 8h;;ACTIVE;1.0i;2.48 +90282-5;Microscopic observation;Prid;Pt;Ctp;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Catheter tip by Gram stain;Gram Stn Cath Tip;;ACTIVE;2.65;2.65 +90283-3;Mycobacterium tuberculosis DNA;PrThr;Pt;Bil fld;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Bile fluid by NAA with probe detection;M tb DNA Bifl Ql NAA+probe;;ACTIVE;2.65;2.65 +90284-1;Mycobacterium sp identified;Prid;Pt;Bil fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Bile fluid by Organism specific culture;Mycobacterium Bifl Cult;;ACTIVE;2.65;2.65 +90285-8;Trichomonas vaginalis;PrThr;Pt;Vag;Ord;Organism specific culture;MICRO;1;Trichomonas vaginalis [Presence] in Vaginal fluid by Organism specific culture;T vaginalis Vag Ql Cult;;ACTIVE;2.65;2.65 +90286-6;Trichomonas vaginalis;PrThr;Pt;Vag;Ord;Microscopy.light;MICRO;1;Trichomonas vaginalis [Presence] in Vaginal fluid by Light microscopy;T vaginalis Vag Ql Micro;;ACTIVE;2.65;2.65 +90287-4;Norovirus RNA;PrThr;Pt;Vomitus;Ord;Probe.amp.tar;MICRO;1;Norovirus RNA [Presence] in Vomitus by NAA with probe detection;Norovirus RNA Vom Ql NAA+probe;;ACTIVE;2.65;2.65 +90288-2;Norovirus genogroup I RNA;PrThr;Pt;Vomitus;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup I RNA [Presence] in Vomitus by NAA with probe detection;Norovirus GI RNA Vom Ql NAA+probe;;ACTIVE;2.65;2.65 +90289-0;Norovirus genogroup II RNA;PrThr;Pt;Vomitus;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup II RNA [Presence] in Vomitus by NAA with probe detection;Norovirus GII RNA Vom Ql NAA+probe;;ACTIVE;2.65;2.65 +9029-0;Fluid intake.urinary bladder irrigation;VRat;10H;Urinary tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake urinary bladder irrigation 10 hour;Fluid intake bladder irrigation 10h;;ACTIVE;1.0i;2.48 +90290-8;Alpha-1-Fetoprotein Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Alpha-1-Fetoprotein Ab [Units/volume] in Serum or Plasma by Immunoassay;AFP Ab SerPl IA-aCnc;;ACTIVE;2.65;2.68 +90291-6;Epithelial cell adhesion molecule Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;EpCAM Ab [Units/volume] in Serum or Plasma by Immunoassay;EpCAM Ab SerPl IA-aCnc;;ACTIVE;2.65;2.68 +90292-4;Liver cancer antibodies & Alpha-1-Fetoprotein;Imp;Pt;Ser/Plas;Ord;;SERO;1;Liver cancer antibodies and AFP [Interpretation] in Serum or Plasma Qualitative;Liver cancer Ab + AFP SerPl-Imp;;ACTIVE;2.65;2.65 +90293-2;Liver cancer antibodies & Alpha-1-Fetoprotein panel;-;Pt;Ser/Plas;-;IA;PANEL.SERO;1;Liver cancer antibodies and AFP panel - Serum or Plasma by Immunoassay;Liver cancer Ab + AFP pnl SerPl IA;;ACTIVE;2.65;2.65 +90294-0;Matrix metalloproteinases-9 Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;MMP-9 Ab [Units/volume] in Serum or Plasma by Immunoassay;MMP-9 Ab SerPl IA-aCnc;;ACTIVE;2.65;2.68 +90295-7;RalA Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;RalA Ab [Units/volume] in Serum or Plasma by Immunoassay;RalA Ab SerPl IA-aCnc;;ACTIVE;2.65;2.68 +90296-5;Microscopic observation;Prid;Pt;Skin;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Skin by Gram stain;Gram Stn Skin;;ACTIVE;2.65;2.65 +90297-3;Entamoeba histolytica Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Entamoeba histolytica Ab [Presence] in Serum by Immunoassay;E histolyt Ab Ser Ql IA;;ACTIVE;2.65;2.65 +90298-1;Entamoeba sp DNA;Prid;Pt;Stool;Nom;Sequencing;MICRO;1;Entamoeba sp DNA [Identifier] in Stool by Sequencing;Entamoeba DNA Stl Seq;;ACTIVE;2.65;2.65 +90299-9;Giardia sp DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Giardia sp DNA [Presence] in Stool by NAA with probe detection;Giardia DNA Stl Ql NAA+probe;;ACTIVE;2.65;2.65 +90300-5;Helminth identified;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Helminth identified in Specimen by NAA with probe detection;Worm Spec NAA+probe;;ACTIVE;2.65;2.69 +90301-3;Toxoplasma gondii;PrThr;Pt;Amnio fld;Ord;Organism specific culture;MICRO;1;Toxoplasma gondii [Presence] in Amniotic fluid by Organism specific culture;T gondii Amn Ql Cult;;ACTIVE;2.65;2.65 +90302-1;Trichomonas vaginalis DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis DNA [Presence] in Cervix by NAA with probe detection;T vaginalis DNA Cvx Ql NAA+probe;;ACTIVE;2.65;2.65 +90303-9;Trichomonas vaginalis;PrThr;Pt;Cvx;Ord;Microscopy.light;MICRO;1;Trichomonas vaginalis [Presence] in Cervix by Light microscopy;T vaginalis Cvx Ql Micro;;ACTIVE;2.65;2.65 +90304-7;Cells.CD3/100 lymphocytes;NFr;Pt;Bld;Qn;;CELLMARK;1;CD3 cells/100 lymphocytes in Blood;CD3 Cells/lymph NFr Bld;;ACTIVE;2.65;2.65 +90305-4;"t(2;5)(p23;q35.1)(ALK,NPM1) fusion transcript";Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.TRNLOC;1;"t(2;5)(p23;q35.1)(ALK,NPM1) fusion transcript in Blood or Tissue by Molecular genetics method";"t(2;5)(ALK,NPM1) Bld/T";;ACTIVE;2.65;2.66 +90306-2;Mycobacterium sp identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Mycobacterium sp identified in Specimen by Sequencing;Mycobacterium Spec Seq;;ACTIVE;2.65;2.69 +90307-0;Guidance for injection;Find;Pt;Lower extremity.right>Foot joint;Doc;CT;RAD;2;CT Guidance for injection of Foot joint - right;CT Guided Foot joint-R Inj;;ACTIVE;2.65;2.65 +9030-8;Fluid intake.urinary bladder irrigation;VRat;12H;Urinary tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake urinary bladder irrigation 12 hour;Fluid intake bladder irrigation 12h;;ACTIVE;1.0i;2.48 +90308-8;Guidance for needle localization;Find;Pt;Chest>Spine.thoracic;Doc;CT;RAD;2;CT Guidance for needle localization of Thoracic spine;CT Guided T-spine Needle loc;;ACTIVE;2.65;2.65 +90309-6;Guidance for drainage+placement of drainage catheter;Find;Pt;Chest>Lung.right;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Lung - right;CT Guided Lung-R Drain+cath place;;ACTIVE;2.65;2.66 +90310-4;Guidance for drainage+placement of drainage catheter^WO contrast;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Retroperitoneum-- WO contrast;CT Guided Retroper Drain+cath--WO cont;;ACTIVE;2.65;2.67 +90311-2;Guidance for percutaneous replacement of drainage catheter;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for percutaneous replacement of drainage catheter of Unspecified body region;CT Guided PC drain cath replace;;ACTIVE;2.65;2.68 +90312-0;Multisection^W radionuclide IV;Find;Pt;Whole body>Skeletal system;Doc;NM.SPECT+CT;RAD;2;SPECT+CT Skeletal system;SPECT+CT Skeletal W RNC IV;;ACTIVE;2.65;2.65 +90313-8;Guidance for drainage+placement of chest tube;Find;Pt;Chest>Pleural space.left;Doc;CT;RAD;2;CT Guidance for drainage and placement of chest tube of Pleural space - left;CT Guided Pl space-L Drain+CT place;;ACTIVE;2.65;2.66 +90314-6;Guidance for drainage+placement of drainage catheter^W contrast IV;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Retroperitoneum-- W contrast IV;CT Guided Retroper Drain+cath--W cont IV;;ACTIVE;2.65;2.67 +90315-3;Guidance for deep biopsy;Find;Pt;XXX>Soft tissue;Doc;CT;RAD;2;CT Guidance for deep biopsy of Soft tissue;CT Guided Soft tiss Deep Bx;;ACTIVE;2.65;2.65 +9031-6;Fluid intake.urinary bladder irrigation;VRat;24H;Urinary tract;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake urinary bladder irrigation 24 hour;Fluid intake bladder irrigation 24h;;ACTIVE;1.0i;2.48 +90316-1;Guidance for superficial biopsy;Find;Pt;XXX>Soft tissue;Doc;CT;RAD;2;CT Guidance for superficial biopsy of Soft tissue;CT Guided Soft tiss Super Bx;;ACTIVE;2.65;2.65 +90317-9;Guidance for drainage+placement of drainage catheter;Find;Pt;Lower extremity.left;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Lower extremity - left;CT Guided LE-L Drain+cath place;;ACTIVE;2.65;2.66 +90318-7;Guidance for drainage+placement of drainage catheter;Find;Pt;Lower extremity.right;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Lower extremity - right;CT Guided LE-R Drain+cath place;;ACTIVE;2.65;2.66 +90319-5;Guidance for drainage+placement of drainage catheter;Find;Pt;Chest>Lung.left;Doc;CT;RAD;2;CT Guidance for drainage and placement of drainage catheter of Lung - left;CT Guided Lung-L Drain+cath place;;ACTIVE;2.65;2.66 +90320-3;Aichivirus C RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Aichivirus C RNA [#/volume] (viral load) in Specimen by NAA with probe detection;Aichivirus C RNA # Spec NAA+probe;;ACTIVE;2.65;2.69 +90321-1;Aichivirus C RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Aichivirus C RNA [Cycle Threshold #] in Specimen by NAA with probe detection;Aichivirus C RNA Ct Spec Qn NAA+probe;;ACTIVE;2.65;2.69 +90322-9;Haemophilus parasuis serotype;ID;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Haemophilus parasuis serotype [Identifier] in Specimen by NAA with probe detection;H parasuis Sertyp Spec NAA+probe;;ACTIVE;2.65;2.69 +90323-7;Influenza virus A Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Influenza virus A Ab/Positive control in Serum by Immunoassay;FLUAV Ab/Pos cntrl Ser IA;;ACTIVE;2.65;2.65 +9032-4;Gastrostomy tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Gastrostomy tube site;G-tube site;;ACTIVE;1.0i;2.27 +90324-5;Mycoplasma hyopneumoniae DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mycoplasma hyopneumoniae DNA [Presence] in Specimen by NAA with probe detection;M hyopneumo DNA Spec Ql NAA+probe;;ACTIVE;2.65;2.69 +90325-2;Mycoplasma suis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma suis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Mycoplasma suis DNA Ct Spec Qn NAA+probe;;ACTIVE;2.65;2.69 +90326-0;Porcine circovirus type 2d DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 2d DNA [#/volume] (viral load) in Specimen by NAA with probe detection;PCV2d DNA # Spec NAA+probe;;ACTIVE;2.65;2.69 +90327-8;Porcine circovirus type 2d DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 2d DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PCV2d DNA Ct Spec Qn NAA+probe;;ACTIVE;2.65;2.69 +90328-6;Porcine circovirus type 3 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 3 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PCV3 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.65;2.69 +90329-4;Porcine deltacoronavirus Ab.IgG/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Porcine deltacoronavirus IgG Ab/Positive control in Specimen by Immunoassay;PDCoV IgG/Pos cntrl Spec IA;;ACTIVE;2.65;2.69 +90330-2;Porcine parainfluenza virus 1 RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine parainfluenza virus 1 RNA [#/volume] (viral load) in Specimen by NAA with probe detection;PPIV1 RNA # Spec NAA+probe;;ACTIVE;2.65;2.69 +90331-0;Porcine reproductive and respiratory syndrome virus Ab.IgA+IgM/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;PRRSV IgA+IgM/Positive control in Specimen by Immunoassay;PRRSV IgA+IgM/Pos cntrl Spec IA;;ACTIVE;2.65;2.69 +9033-2;Class;Type;Pt;GI tube;Nom;;IO.TUBE;2;Type of GI tube;GI tube Class;;ACTIVE;1.0i;2.27 +90332-8;Porcine reproductive and respiratory syndrome virus Ab.IgA/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;PRRSV IgA Ab/Positive control in Specimen by Immunoassay;PRRSV IgA/Pos cntrl Spec IA;;ACTIVE;2.65;2.69 +90333-6;Porcine reproductive and respiratory syndrome virus Ab.IgM/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;PRRSV IgM Ab/Positive control in Specimen by Immunoassay;PRRSV IgM/Pos cntrl Spec IA;;ACTIVE;2.65;2.69 +90334-4;Guidance for injection;Find;Pt;Chest>Spine.thoracic facet joint;Doc;CT;RAD;2;CT Guidance for injection of Spine Thoracic Facet Joint;CT Guided T-spine facet joint Inj;;ACTIVE;2.65;2.65 +90335-1;Guidance for injection;Find;Pt;Abdomen>Spine.lumbar facet joint;Doc;CT;RAD;2;CT Guidance for injection of Lumbar Spine Facet Joint;CT Guided L-spine facet joint Inj;;ACTIVE;2.65;2.66 +90336-9;Guidance for injection;Find;Pt;XXX>Muscle;Doc;CT;RAD;2;CT Guidance for injection of Muscle;CT Guided Muscle Inj;;ACTIVE;2.65;2.65 +90337-7;Cryptococcus sp rRNA gene;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Cryptococcus sp rRNA gene [Presence] in Cerebral spinal fluid by NAA with probe detection;Crypt sp rRNA gene CSF Ql NAA+probe;;ACTIVE;2.65;2.65 +90338-5;Cryptococcus sp rRNA gene;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Cryptococcus sp rRNA gene [Presence] in Blood by NAA with probe detection;Crypt sp rRNA gene Bld Ql NAA+probe;;ACTIVE;2.65;2.65 +90339-3;Aspergillus sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Aspergillus sp DNA [Presence] in Tissue by NAA with probe detection;Aspergillus DNA Tiss Ql NAA+probe;;ACTIVE;2.65;2.65 +90340-1;Aspergillus sp DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Aspergillus sp DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Aspergillus DNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +90341-9;Administrative note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine Administrative note;Nuc Medicine Administrative note;;ACTIVE;2.65;2.65 +90342-7;Note;Find;Pt;{Setting};Doc;Nuclear medicine.attending;DOC.ONTOLOGY;2;Nuclear medicine Attending Note;Nuc med Attend Note;;ACTIVE;2.65;2.65 +90343-5;Consultation note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine Consult note;Nuc Medicine Consult note;;ACTIVE;2.65;2.65 +90344-3;Note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine Note;Nuc Medicine Note;;ACTIVE;2.65;2.65 +90345-0;Note;Find;Pt;{Setting};Doc;Nuclear medicine.nurse;DOC.ONTOLOGY;2;Nuclear medicine Nurse Note;Nuc med Nurse Note;;ACTIVE;2.65;2.65 +90346-8;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine Postoperative evaluation and management note;Nuc Medicine Post-op E/M note;;ACTIVE;2.65;2.65 +90347-6;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine Preoperative evaluation and management note;Nuc Medicine Pre-op note;;ACTIVE;2.65;2.65 +90348-4;Note;Find;Pt;{Setting};Doc;Nuclear medicine.resident;DOC.ONTOLOGY;2;Nuclear medicine Resident Note;Nuc med Res Note;;ACTIVE;2.65;2.65 +90349-2;Note;Find;Pt;Telephone encounter;Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine Telephone encounter Note;Nuc Medicine Phone Note;;ACTIVE;2.65;2.65 +903-5;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;RESt absorption;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by RESt absorption;Bld gp Ab Scn SerPl Ql RESt Abs;;ACTIVE;1.0;2.56 +90350-0;Procedure note;Find;Pt;{Setting};Doc;Nuclear medicine;DOC.ONTOLOGY;2;Nuclear medicine procedure note;Nuc Medicine Procedure note;;ACTIVE;2.65;2.65 +90351-8;Postoperative evaluation and management note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Postoperative evaluation and management note;Radiology Post-op E/M note;;ACTIVE;2.65;2.65 +90352-6;Multisection^WO & W contrast IV;Find;Pt;Head && Head>Brain && Head>Head vessels;Doc;CT && CT.perfusion && CT.angio;RAD;2;CT Head and CT Brain for perfusion and CT angiogram Head vessels WO and W contrast IV;CT Head+Brain perf+CTA Head WO+W IV;;ACTIVE;2.65;2.65 +90353-4;Conscious sedation procedure note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Conscious sedation procedure note;Consc sedation proc note;;ACTIVE;2.65;2.65 +90354-2;Consultation note;Find;Pt;{Setting};Doc;Obesity medicine;DOC.ONTOLOGY;2;Obesity medicine Consult note;Obesity med Consult note;;ACTIVE;2.65;2.65 +90355-9;Group counseling note;Find;Pt;{Setting};Doc;Obesity medicine;DOC.ONTOLOGY;2;Obesity medicine Group counseling note;Obesity med Group counseling note;;ACTIVE;2.65;2.65 +90356-7;Initial evaluation note;Find;Pt;{Setting};Doc;Obesity medicine;DOC.ONTOLOGY;2;Obesity medicine Initial evaluation note;Obesity med Initial eval note;;ACTIVE;2.65;2.65 +90357-5;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;Nph;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Nasopharynx by NAA with probe detection;C trach+GC pnl Nph NAA+probe;;ACTIVE;2.65;2.73 +90358-3;Chlamydia trachomatis & Neisseria gonorrhoeae rRNA panel;-;Pt;Anorectal;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Anorectal by NAA with probe detection;C trach+GC pnl Anorectl NAA+probe;;ACTIVE;2.65;2.7 +90359-1;Fluid management note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Fluid management note;Nurse Fluid management note;;ACTIVE;2.65;2.65 +90360-9;Trimethylamine N-oxide;SCnc;Pt;Ser/Plas;Qn;LC/MS/MS;CHEM;1;Trimethylamine N-oxide [Moles/volume] in Serum or Plasma by LC/MS/MS;TMAO SerPl LC/MS/MS-sCnc;;ACTIVE;2.65;2.65 +90361-7;Chlamydia trachomatis L1 Ab.IgA;Titr;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis L1 IgA Ab [Titer] in Serum by Immunoassay;C trach L1 IgA Titr Ser IA;;ACTIVE;2.65;2.65 +90362-5;Chlamydia trachomatis L1 Ab.IgG;Titr;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis L1 IgG Ab [Titer] in Serum by Immunoassay;C trach L1 IgG Titr Ser IA;;ACTIVE;2.65;2.65 +90363-3;Chlamydia trachomatis L1 Ab.IgM;Titr;Pt;Ser;Qn;IA;MICRO;1;Chlamydia trachomatis L1 IgM Ab [Titer] in Serum by Immunoassay;C trach L1 IgM Titr Ser IA;;ACTIVE;2.65;2.65 +90364-1;Cholesterol.in LDL.small dense;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.in LDL.small dense [Mass/volume] in Serum or Plasma;Chol.in LDL.small dense SerPl-mCnc;;ACTIVE;2.65;2.73 +9036-5;Nasogastric tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Nasogastric tube site;NG- tube site;;ACTIVE;1.0i;2.27 +90365-8;Chlamydia trachomatis L1 Ab.IgG+IgA+IgM Interpretation;Imp;Pt;Ser;Nom;IA;MICRO;1;Chlamydia trachomatis L1 Ab.IgG+IgA+IgM Interpretation in Serum by Immunoassay;CT L1 Ab.IgG+IgA+IgM Intrp Ser IA-Imp;;ACTIVE;2.65;2.65 +90366-6;Received healthcare outside the U.S.;Find;Pt;^Patient;Ord;;H&P.HX;2;Received healthcare outside the U.S. in the past;Healthcare outside U.S. in past;;ACTIVE;2.65;2.68 +90367-4;Gestational age;Time;Pt;^Fetus;Qn;Estimated from physical examination;OB.US;2;Gestational age Estimated from physical exam;GA Est from PE;;ACTIVE;2.65;2.65 +90368-2;Delivery date;Date;Pt;^Patient;Qn;Estimated from physical examination;OB.US;2;Delivery date Estimated from physical exam;Deliv date Est from PE;;ACTIVE;2.65;2.65 +90369-0;Sample collection timing related to drug dose;Type;Pt;Specimen;Nom;;SPEC;1;Sample collection timing related to drug dose;Sample timing related to dose;;ACTIVE;2.65;2.65 +90370-8;Vendor test code to LOINC mapping data set;Find;Pt;{Device};Doc;;DOC.MISC;2;LIVD mapping data set;LIVD mapping data set;;TRIAL;2.65;2.65 +90371-6;Note;Find;Pt;{Setting};Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Note;Clin Path Note;;ACTIVE;2.65;2.65 +90372-4;Guidance for injection;Find;Pt;XXX>Tendon;Doc;CT;RAD;2;CT Guidance for injection of Tendon;CT Guided Tendon Inj;;ACTIVE;2.65;2.65 +9037-3;Class;Type;Pt;Nasogastric tube;Nom;;IO.TUBE;2;Type of Nasogastric tube;NG-tube Class;;ACTIVE;1.0i;2.27 +90373-2;Guidance for injection;Find;Pt;XXX>Tendon or ligament;Doc;CT;RAD;2;CT Guidance for injection of Tendon or ligament;CT Guided Tendon or ligament Inj;;ACTIVE;2.65;2.65 +90374-0;Clinical trials experience section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Clinical trials experience section;FDA insert Clinical trials exp section;;ACTIVE;2.65;2.65 +90375-7;Postmarketing experience section;-;-;^FDA package insert;Nar;;DOC.REF;2;FDA package insert Postmarketing experience section;FDA insert Postmarketing exp section;;ACTIVE;2.65;2.65 +90376-5;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when dressing yourself without help;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when dressing yourself without help [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90377-3;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking 50 steps or paces on flat ground at a normal speed without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking 50 steps/paces on flat ground at a normal speed without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90378-1;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking up 20 stairs (2 flights) without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking up 20 stairs (2 flights) without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90379-9;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when preparing meals;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when preparing meals [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90380-7;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when washing dishes;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when washing dishes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9038-1;Class;Type;Pt;Oral tube;Nom;;IO.TUBE;2;Type of Oral tube;Oral tube Class;;ACTIVE;1.0i;2.27 +90381-5;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when sweeping or mopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when sweeping or mopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90382-3;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when making a bed;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when making a bed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90383-1;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when lifting something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries);Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when lifting something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90384-9;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when carrying something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries) from one room to another;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when carrying something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries) from one room to another [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90385-6;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking (faster than your usual speed) for a half mile (almost 1 km) without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90386-4;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when taking a bath without help;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when taking a bath without help [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90387-2;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when taking a shower;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when taking a shower [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90388-0;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when putting on socks or stockings;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when putting on socks or stockings [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90389-8;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when standing for at least 5 minutes;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when standing for at least 5 minutes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90390-6;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking 10 steps or paces on flat ground at a normal speed without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking 10 steps/paces on flat ground at a normal speed without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90391-4;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking a half mile (almost 1 km) on flat ground at a normal speed without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking 1/2 mile (almost 1 km) on flat ground at a normal speed without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90392-2;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking up 5 stairs without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking up 5 stairs without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90393-0;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking up 10 stairs (1 flight) without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking up 10 stairs (1 flight) without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90394-8;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking up 30 stairs (3 flights) without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking up 30 stairs (3 flights) without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90395-5;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when scrubbing the floor or counter;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when scrubbing the floor or counter [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90396-3;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when lifting something weighing less than 5 lbs (about 2 kg, like a houseplant);Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when lifting something weighing less than 5 lbs (about 2 kg, like a houseplant) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90397-1;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes);Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90398-9;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase);Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9039-9;Oral tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Oral tube site;Oral tube site;;ACTIVE;1.0i;2.27 +90399-7;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90400-3;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90401-1;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when getting in or out of a car;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when getting in or out of a car [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90402-9;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when dining out;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when dining out [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90403-7;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when low-intensity leisure activity (gardening, etc.);Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when low-intensity leisure activity (gardening, etc.) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90404-5;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when moderate-intensity leisure activity (bicycling on level terrain, etc.);Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when moderate-intensity leisure activity (bicycling on level terrain, etc.) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90405-2;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking (faster than your usual speed) for 50 steps without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking (faster than your usual speed) for 50 steps without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90406-0;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when walking (faster than your usual speed) for at least 1 mile (a little more than 1.5 km) without stopping;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when walking (faster than your usual speed) for at least 1 mile (a little more than 1.5 km) without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9040-7;Peritoneal tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Peritoneal tube site;Peritoneal tube site;;ACTIVE;1.0i;2.27 +90407-8;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had singing or humming;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had singing or humming [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90408-6;Considering your shortness of breath over the past 7D, rate the amount of difficulty you had when talking while walking;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when talking while walking [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90409-4;PROMIS item bank - dyspnea functional limitations - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - dyspnea functional limitations - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90410-2;PROMIS dyspnea functional limitations - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS dyspnea functional limitations - version 1.0 T score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90411-0;Words I wanted to use have seemed to be on the tip of my tongue in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Words I wanted to use have seemed to be on the tip of my tongue in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90412-8;I have had trouble finding the right words to express myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I have had trouble finding the right words to express myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90413-6;T-cell regulatory subsets panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;T-cell regulatory (Treg) subsets panel - Blood;T-cell regulatory subsets Pnl Bld;;ACTIVE;2.65;2.65 +90414-4;B-cell phenotyping panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;B-cell phenotyping panel - Blood;B-cell phenotyping panel Bld;;ACTIVE;2.65;2.65 +9041-5;Class;Type;Pt;Synovial drain;Nom;;IO.TUBE;2;Type of Synovial drain;Synovial Drain Class;;ACTIVE;1.0i;2.27 +90415-1;B-cell TACI & BAFF-R subsets panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;B-cell TACI and BAFF-R subsets panel - Blood;B-cell TACI + BAFF-R subsets panel Bld;;ACTIVE;2.65;2.65 +90416-9;Lymphocyte subset & B-cell phenotyping panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;Lymphocyte subset and B-cell phenotyping panel - Blood;Lymph subset + B-cell phenotype Pnl Bld;;ACTIVE;2.65;2.65 +90417-7;Transferrin.carbohydrate deficient & Apolipoprotein CIII panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Transferrin.carbohydrate deficient and Apolipoprotein C-III panel - Serum or Plasma;CDT + Apo C-III Pnl SerPl;;ACTIVE;2.65;2.65 +90418-5;BAFF-R Cells/100 cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;BAFF-R cells/100 CD19 cells in Blood;BAFF-R cells/100 CD19 cells NFr Bld;;ACTIVE;2.65;2.65 +90419-3;Apolipoprotein CIII-0/Apolipoprotein CIII-2;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein CIII-0/Apolipoprotein CIII-2 [Mass Ratio] in Serum or Plasma;Apo CIII-0/Apo CIII-2 SerPl;;ACTIVE;2.65;2.65 +90420-1;Transferrin.carbohydrate deficient.trisialo/Transferrin.carbohydrate deficient.tetrasialo;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.trisialo/Transferrin.carbohydrate deficient.tetrasialo [Mass Ratio] in Serum or Plasma;CDT Trisialo/CDT Tetrasialo SerPl;;ACTIVE;2.65;2.65 +90421-9;Apolipoprotein CIII-1/Apolipoprotein CIII-2;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein CIII-1/Apolipoprotein CIII-2 [Mass Ratio] in Serum or Plasma;Apo CIII-1/Apo CIII-2 SerPl;;ACTIVE;2.65;2.65 +90422-7;Cells.TACI/100 cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;TACI cells/100 CD19 cells in Blood;TACI cells/100 CD19 cells NFr Bld;;ACTIVE;2.65;2.65 +9042-3;Synovial drain site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Synovial drain site;Synovial drain site;;ACTIVE;1.0i;2.73 +90423-5;Microorganism preliminary growth detection panel;-;Pt;Bld;-;Culture;PANEL.MICRO;1;Microorganism preliminary growth detection panel - Blood by Culture;Microorg prel grow det pnl Bld Cult;;ACTIVE;2.65;2.65 +90424-3;Microorganism preliminary growth detection panel;-;Pt;Body fld;-;Culture;PANEL.MICRO;1;Microorganism preliminary growth detection panel - Body fluid by Culture;Microorg prel grow det pnl Fld Cult;;ACTIVE;2.65;2.65 +90425-0;Microorganism preliminary growth detection panel;-;Pt;Platelets^BPU;-;Culture;PANEL.MICRO;1;Microorganism preliminary growth detection panel - Platelets from Blood product unit by Culture;Microorg prel grow det pnl Plts BPU Cult;;ACTIVE;2.65;2.65 +90426-8;Microorganism preliminary growth;PrThr;Pt;Bld;Ord;Aerobic culture+Antimicrobial neutralizer;MICRO;1;Microorganism preliminary growth [Presence] in Blood by Aerobic culture with antimicrobial neutralizer;Microorg prel Bld Ql Aer cult + neut;;ACTIVE;2.65;2.67 +90427-6;Microorganism preliminary growth;PrThr;Pt;Bld;Ord;Anaerobic culture+Antimicrobial neutralizer;MICRO;1;Microorganism preliminary growth [Presence] in Blood by Anaerobic culture with antimicrobial neutralizer;Microorg prel Bld Ql Anaer cult + neut;;ACTIVE;2.65;2.67 +90428-4;Microorganism preliminary growth;PrThr;Pt;Body fld;Ord;Aerobic culture+Antimicrobial neutralizer;MICRO;1;Microorganism preliminary growth [Presence] in Body fluid by Aerobic culture with antimicrobial neutralizer;Microorg prel Fld Ql Aer cult + neut;;ACTIVE;2.65;2.67 +90429-2;Microorganism preliminary growth;PrThr;Pt;Body fld;Ord;Aerobic culture;MICRO;1;Microorganism preliminary growth [Presence] in Body fluid by Aerobe culture;Microorg prel grow Fld Ql Aerobe Cult;;ACTIVE;2.65;2.67 +904-3;Blood group antibody screen;PrThr;Pt;Ser/Plas;Ord;Warm absorption;BLDBK;1;Blood group antibody screen [Presence] in Serum or Plasma by Warm absorption;Bld gp Ab Scn SerPl Ql Warm Abs;;ACTIVE;1.0;2.56 +90430-0;Microorganism preliminary growth;PrThr;Pt;Body fld;Ord;Anaerobic culture;MICRO;1;Microorganism preliminary growth [Presence] in Body fluid by Anaerobe culture;Microorg prel grow Fld Ql Anaerobe Cult;;ACTIVE;2.65;2.67 +9043-1;Class;Type;Pt;Urinary bladder irrigation tube;Nom;;IO.TUBE;2;Type of Bladder irrigation tube;Bladder irrigation tube Class;;ACTIVE;1.0i;2.27 +90431-8;Microorganism preliminary growth;PrThr;Pt;Body fld;Ord;Anaerobic culture+Antimicrobial neutralizer;MICRO;1;Microorganism preliminary growth [Presence] in Body fluid by Anaerobic culture with antimicrobial neutralizer;Microorg prel Fld Ql Anaer cult + neut;;ACTIVE;2.65;2.67 +90432-6;Microorganism preliminary growth;PrThr;Pt;Platelets^BPU;Ord;Anaerobic culture;MICRO;1;Microorganism preliminary growth [Presence] in Platelets from Blood product unit by Anaerobe culture;Microorg prel Plts BPU Ql Anaer Cult;;ACTIVE;2.65;2.67 +90433-4;Mycobacterium preliminary growth;PrThr;Pt;Sputum;Ord;Organism specific culture;MICRO;1;Mycobacterium preliminary growth [Presence] in Sputum by Organism specific culture;Mycobact prelim grow Spt Ql Cult;;ACTIVE;2.65;2.67 +90434-2;Microorganism preliminary growth;PrThr;Pt;Platelets^BPU;Ord;Aerobic culture;MICRO;1;Microorganism preliminary growth [Presence] in Platelets from Blood product unit by Aerobe culture;Microorg prel Plts BPU Ql Aerob Cult;;ACTIVE;2.65;2.67 +90435-9;Microorganism preliminary growth;PrThr;Pt;Bld;Ord;Aerobic culture;MICRO;1;Microorganism preliminary growth [Presence] in Blood by Aerobe culture;Microorg prel grow Bld Ql Aerobe Cult;;ACTIVE;2.65;2.67 +90436-7;Microorganism preliminary growth;PrThr;Pt;Body fld;Ord;Organism specific culture;MICRO;1;Microorganism preliminary growth [Presence] in Body fluid by Organism specific culture;Microorg prel grow Fld Ql Cult;;ACTIVE;2.65;2.67 +90437-5;Microorganism preliminary growth;PrThr;Pt;Bld;Ord;Anaerobic culture;MICRO;1;Microorganism preliminary growth [Presence] in Blood by Anaerobe culture;Microorg prel grow Bld Ql Anaerobe Cult;;ACTIVE;2.65;2.67 +90438-3;Mycobacterium preliminary growth;PrThr;Pt;Tiss;Ord;Organism specific culture;MICRO;1;Mycobacterium preliminary growth [Presence] in Tissue by Organism specific culture;Mycobact prelim grow Tiss Ql Cult;;ACTIVE;2.65;2.67 +90439-1;Atypical pneumonia pathogens panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;Atypical pneumonia pathogens panel - Respiratory specimen by NAA with probe detection;Atypical PNA path Pnl Resp NAA+probe;;ACTIVE;2.65;2.65 +90440-9;BK virus+JC Virus DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;BK virus + JC virus DNA [Presence] in Specimen by NAA with probe detection;BKV+JCPyV DNA Spec Ql NAA+probe;;ACTIVE;2.65;2.69 +90441-7;Bordetella pertussis & Bordetella parapertussis DNA panel;-;Pt;Nph;-;;PANEL.MICRO;1;Bordetella pertussis and Bordetella parapertussis DNA panel - Nasopharynx;B pert+parapert DNA Pnl Nph;;ACTIVE;2.65;2.65 +90442-5;Coxiella burnetii aroE gene;PrThr;Pt;Tiss;Ord;Non-probe.amp.tar;MICRO;1;Coxiella burnetii aroE gene [Presence] in Tissue by NAA with non-probe detection;C burnet aroE Tiss Ql NAA+non-probe;;ACTIVE;2.65;2.65 +90443-3;Coxiella burnetii aroE gene;PrThr;Pt;Ser/Plas/Bld;Ord;Non-probe.amp.tar;MICRO;1;Coxiella burnetii aroE gene [Presence] in Serum, Plasma or Blood by NAA with non-probe detection;C burnet aroE SerPlBld Ql NAA+non-probe;;ACTIVE;2.65;2.73 +90444-1;Diethylpropion;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Diethylpropion [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Diethylpropion SerPlBld Cfm-mCnc;;ACTIVE;2.65;2.65 +90445-8;ePHEDrine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;ePHEDrine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Ephedrin SerPlBld Cfm-mCnc;;ACTIVE;2.65;2.65 +90446-6;Pseudoephedrine;MCnc;Pt;Ser/Plas/Bld;Qn;Confirm;DRUG/TOX;1;Pseudoephedrine [Mass/volume] in Serum, Plasma or Blood by Confirmatory method;Pseudoephedrine SerPlBld Cfm-mCnc;;ACTIVE;2.65;2.65 +90447-4;Delafloxacin;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Delafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC);DLX Islt MIC;;ACTIVE;2.65;2.65 +90448-2;Coccidioides sp Ab.IgM;ACnc;Pt;Ser/Plas;Qn;;MICRO;1;Coccidioides sp IgM Ab [Units/volume] in Serum or Plasma;Coccidioides IgM SerPl-aCnc;;ACTIVE;2.65;2.73 +9044-9;Urinary bladder irrigation tube site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Urinary bladder irrigation tube site;Urinary bladder irrigation tube site;;ACTIVE;1.0i;2.27 +90449-0;Norovirus genogroup I & II RNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Norovirus genogroup I and II RNA [Identifier] in Specimen by NAA with probe detection;Norovirus GI + GII RNA Spec NAA+probe;;ACTIVE;2.65;2.69 +90450-8;Herpes simplex virus DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Aspirate by NAA with probe detection;HSV DNA Aspirate Ql NAA+probe;;ACTIVE;2.65;2.65 +90451-6;Herpes simplex virus 1 DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Aspirate by NAA with probe detection;HSV1 DNA Aspirate Ql NAA+probe;;ACTIVE;2.65;2.65 +90452-4;Herpes simplex virus 1 DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Upper respiratory specimen by NAA with probe detection;HSV1 DNA Upper resp Ql NAA+probe;;ACTIVE;2.65;2.68 +90453-2;Herpes simplex virus 2 DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Aspirate by NAA with probe detection;HSV2 DNA Aspirate Ql NAA+probe;;ACTIVE;2.65;2.65 +90454-0;Herpes simplex virus 2 DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Upper respiratory specimen by NAA with probe detection;HSV2 DNA Upper resp Ql NAA+probe;;ACTIVE;2.65;2.68 +90455-7;Influenza virus A & B RNA panel;-;Pt;Cornea/Conjunctiva;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus types A and B panel - Cornea or Conjunctiva by NAA with probe detection;FLUAV + FLUBV Pnl Corn/Cnjt NAA+probe;;ACTIVE;2.65;2.65 +9045-6;Calcium intake;Sub;Pt;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Calcium intake Estimated;Calcium intake Est;;ACTIVE;1.0i;2.48 +90456-5;Influenza virus A & B RNA panel;-;Pt;CSF;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus types A and B panel - Cerebral spinal fluid by NAA with probe detection;FLUAV + FLUBV Pnl CSF NAA+probe;;ACTIVE;2.65;2.65 +90457-3;Influenza virus A & B RNA panel;-;Pt;Tiss;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus types A and B panel - Tissue by NAA with probe detection;FLUAV + FLUBV Pnl Tiss NAA+probe;;ACTIVE;2.65;2.65 +90458-1;Actinomyces sp identified;Prid;Pt;Asp;Nom;Organism specific culture;MICRO;1;Actinomyces sp identified in Aspirate by Organism specific culture;Actinomyces Aspirate Cult;;ACTIVE;2.65;2.65 +90459-9;Yellow fever virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Yellow fever virus RNA [Presence] in Blood by NAA with probe detection;YFV RNA Bld Ql NAA+probe;;ACTIVE;2.65;2.65 +90460-7;Hepatitis E virus RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;Hepatitis E virus RNA [Presence] in Serum or Plasma by NAA with probe detection;HEV RNA SerPl Ql NAA+probe;;ACTIVE;2.65;2.65 +90461-5;Herpes simplex virus 1+2 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes simplex virus 1+2 IgG Ab [Presence] in Serum by Immunoassay;HSV1+2 IgG Ser Ql IA;;ACTIVE;2.65;2.65 +90462-3;Zika virus RNA;PrThr;Pt;BldCo;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Cord blood by NAA with probe detection;ZIKV RNA BldCo Ql NAA+probe;;ACTIVE;2.65;2.65 +90463-1;Adenovirus DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Lower respiratory specimen by NAA with probe detection;HAdV DNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +9046-4;Calcium intake;Sub;Pt;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Calcium intake Measured;Calcium intake Measured;;ACTIVE;1.0i;2.48 +90464-9;Herpes simplex virus 1+2 Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Herpes simplex virus 1+2 IgM Ab [Presence] in Serum by Immunoassay;HSV1+2 IgM Ser Ql IA;;ACTIVE;2.65;2.65 +90465-6;3-(4-fluorobenzoyl)propionate;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;3-(4-fluorobenzoyl)propionate [Mass/volume] in Urine by Confirmatory method;FBPA Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +90466-4;3-(4-fluorobenzoyl)propionate;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;3-(4-fluorobenzoyl)propionate [Presence] in Urine by Screen method;FBPA Ur Ql Scn;;ACTIVE;2.65;2.65 +90467-2;Hydroxyaripiprazole;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Hydroxyaripiprazole [Mass/volume] in Urine by Confirmatory method;OH-aripiprazole Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +90468-0;Hydroxyaripiprazole;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Hydroxyaripiprazole [Presence] in Urine by Screen method;OH-aripiprazole Ur Ql Scn;;ACTIVE;2.65;2.65 +90469-8;Norfluvoxamine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norfluvoxamine [Mass/volume] in Urine by Confirmatory method;Norfluvoxamine Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +90470-6;Norfluvoxamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norfluvoxamine [Presence] in Urine by Screen method;Norfluvoxamine Ur Ql Scn;;ACTIVE;2.65;2.65 +90471-4;9-Hydroxyrisperidone;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;9-Hydroxyrisperidone [Presence] in Urine by Screen method;9OH-risperidone Ur Ql Scn;;ACTIVE;2.65;2.65 +9047-2;Calcium intake;SRat;1H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calcium intake 1 hour;Calcium intake 1h;;ACTIVE;1.0i;2.48 +90472-2;Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.17.1, 1.17.2;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.17.1, 1.17.2 [CMS Assessment];;;ACTIVE;2.66;2.74 +90473-0;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home comprehensive (NC) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home comprehensive (NC) item set [CMS Assessment];;;ACTIVE;2.66;2.74 +90474-8;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home PPS (NP) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home PPS (NP) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +90475-5;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home quarterly (NQ) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home quarterly (NQ) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +90476-3;MDS v3.0 - RAI v1.17.1, 1.17.2 - Swing bed PPS (SP) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Swing bed PPS (SP) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +90477-1;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home discharge (ND) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home discharge (ND) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +90478-9;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home part A PPS discharge (NPE) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home part A PPS discharge (NPE) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +90479-7;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home & Swing bed tracking (NT & ST) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home and Swing bed tracking (NT and ST) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +9048-0;Calcium intake;SRat;8H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calcium intake 8 hour;Calcium intake 8h;;ACTIVE;1.0i;2.48 +90480-5;MDS v3.0 - RAI v1.17.1, 1.17.2 - Interim Payment Assessment (IPA) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Interim Payment Assessment (IPA) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +90481-3;MDS v3.0 - RAI v1.17.1, 1.17.2 - Optional State Assessment (OSA) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Optional State Assessment (OSA) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +90482-1;MDS v3.0 - RAI v1.17.1, 1.17.2 - Mood;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Mood [CMS Assessment];;;ACTIVE;2.66;2.7 +90483-9;MDS v3.0 - RAI v1.17.2 - Swallowing &or nutritional status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Swallowing/nutritional status [CMS Assessment];;;ACTIVE;2.66;2.68 +90484-7;MDS v3.0 - RAI v1.17.2 - Swallowing &or nutritional status - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Swallowing/nutritional status - ND, SD [CMS Assessment];;;ACTIVE;2.66;2.68 +90485-4;MDS v3.0 - RAI v1.17.2 - Active diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Active diagnoses [CMS Assessment];;;ACTIVE;2.66;2.68 +90486-2;MDS v3.0 - RAI v1.17.2 - Health conditions;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Health conditions [CMS Assessment];;;ACTIVE;2.66;2.68 +90487-0;MDS v3.0 - RAI v1.17.2 - Health conditions - NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Health conditions - NP, NQ, SP [CMS Assessment];;;ACTIVE;2.66;2.68 +90488-8;MDS v3.0 - RAI v1.17.2 - Health conditions - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Health conditions - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +90489-6;MDS v3.0 - RAI v1.17.2 - Type of assessment;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Type of assessment [CMS Assessment];;;ACTIVE;2.66;2.74 +90490-4;MDS v3.0 - RAI v1.17.2 - Correction request;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Correction request [CMS Assessment];;;ACTIVE;2.66;2.68 +90491-2;MDS v3.0 - RAI v1.17.2 - Correction request - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Correction request - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90492-0;MDS v3.0 - RAI v1.17.2 - Type of assessment on existing record to be modified or inactivated;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Type of assessment on existing record to be modified or inactivated [CMS Assessment];;;ACTIVE;2.66;2.74 +90493-8;MDS v3.0 - RAI v1.17.2 - Assessment administration - SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Assessment administration - SP [CMS Assessment];;;ACTIVE;2.66;2.68 +90494-6;MDS v3.0 - RAI v1.17.2 - Medicare stay - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medicare stay - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90495-3;MDS v3.0 - RAI v1.17.2 - Assessment administration - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Assessment administration - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +90496-1;MDS v3.0 - RAI v1.17.2 - Assessment administration - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Assessment administration - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90497-9;MDS v3.0 - RAI v1.17.2 - Assessment administration;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Assessment administration [CMS Assessment];;;ACTIVE;2.66;2.68 +9049-8;Calcium intake;SRat;10H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calcium intake 10 hour;Calcium intake 10h;;ACTIVE;1.0i;2.48 +90498-7;MDS v3.0 - RAI v1.17.2 - Medicare part A billing;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medicare part A billing [CMS Assessment];;;ACTIVE;2.66;2.74 +90499-5;MDS v3.0 - RAI v1.17.2 - Identification information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information [CMS Assessment];;;ACTIVE;2.66;2.68 +905-0;Blood group antigens absent;Prid;Pt;^BPU;Nom;;BLDBK;1;Blood group antigens absent [Identifier] in Blood product unit;Antigens Absent BPU;;ACTIVE;1.0;2.73 +90500-0;MDS v3.0 - RAI v1.17.2 - Identification information - NP, NQ;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information - NP, NQ [CMS Assessment];;;ACTIVE;2.66;2.68 +90501-8;MDS v3.0 - RAI v1.17.2 - Identification information - SD, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information - SD, SP [CMS Assessment];;;ACTIVE;2.66;2.68 +90502-6;MDS v3.0 - RAI v1.17.2 - Identification information - NT, ST;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information - NT, ST [CMS Assessment];;;ACTIVE;2.66;2.68 +90503-4;MDS v3.0 - RAI v1.17.2 - Identification information - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +90504-2;MDS v3.0 - RAI v1.17.2 - Identification information - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90505-9;MDS v3.0 - RAI v1.17.2 - Hearing, speech, and vision - IPA, OSA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Hearing, speech, and vision - IPA, OSA during assessment period [CMS Assessment];;;ACTIVE;2.66;2.7 +9050-6;Calcium intake;SRat;12H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calcium intake 12 hour;Calcium intake 12h;;ACTIVE;1.0i;2.48 +90506-7;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - OSA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - OSA during assessment period [CMS Assessment];;;ACTIVE;2.66;2.7 +90507-5;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - IPA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - IPA during assessment period [CMS Assessment];;;ACTIVE;2.66;2.7 +90508-3;MDS v3.0 - RAI v1.17.2 - Active diagnoses - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Active diagnoses - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90509-1;MDS v3.0 - RAI v1.17.2 - Swallowing &or nutritional status - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Swallowing/nutritional status - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +90510-9;MDS v3.0 - RAI v1.17.2 - Swallowing &or nutritional status - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Swallowing/nutritional status - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90511-7;MDS v3.0 - RAI v1.17.2 - Current number of unhealed pressure injuries at each stage - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Current number of unhealed pressure injuries at each stage - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90512-5;MDS v3.0 - RAI v1.17.2 - Skin conditions - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Skin conditions - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90513-3;MDS v3.0 - RAI v1.17.2 - Medications - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Medications - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +9051-4;Calcium intake;SRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calcium intake [moles/time] in 24 hour;Calcium intake 24H-sRate;;ACTIVE;1.0i;2.48 +90514-1;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs [CMS Assessment];;;ACTIVE;2.66;2.68 +90515-8;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - NP, NQ;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - NP, NQ [CMS Assessment];;;ACTIVE;2.66;2.68 +90516-6;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - ND;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - ND [CMS Assessment];;;ACTIVE;2.66;2.68 +90517-4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - NPE;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - NPE [CMS Assessment];;;ACTIVE;2.66;2.68 +90518-2;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +90519-0;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +90520-8;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - SP [CMS Assessment];;;ACTIVE;2.66;2.68 +90521-6;Optional state assessment;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Optional state assessment [CMS Assessment];;;ACTIVE;2.66;2.66 +9052-2;Calorie intake.total;EngRat;Pt;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calorie intake total;Calorie intake total;;ACTIVE;1.0i;2.61 +90522-4;Assessment for state payment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Assessment for state payment [CMS Assessment];;;ACTIVE;2.66;2.66 +90523-2;MDS v3.0 - RAI v1.17.2 - Optional state assessment;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Optional state assessment [CMS Assessment];;;ACTIVE;2.66;2.7 +90524-0;Type of assessment for state payment;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Type of assessment for state payment [CMS Assessment];;;ACTIVE;2.66;2.66 +90525-7;SNF Part A Interrupted Stay;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;SNF Part A Interrupted Stay [CMS Assessment];;;ACTIVE;2.66;2.66 +90526-5;Functional abilities and goals - IPA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional abilities and goals - IPA during assessment period [CMS Assessment];;;ACTIVE;2.66;2.7 +90527-3;Occupational therapy - concurrent minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - concurrent minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.66 +90528-1;Occupational therapy - co-treatment minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - co-treatment minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90529-9;Occupational therapy - group minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - group minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +9053-0;Calorie intake.total;EngRat;1H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calorie intake total 1 hour;Calorie intake total 1h;;ACTIVE;1.0i;2.61 +90530-7;Number of D with at least 15M of occupational therapy during assessment period;NRat;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of occupational therapy during assessment period [CMS Assessment];;;ACTIVE;2.66;2.66 +90531-5;Occupational therapy - individual minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Occupational therapy - individual minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90532-3;Physical therapy - concurrent minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - concurrent minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90533-1;Physical therapy - co-treatment minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - co-treatment minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90534-9;Physical therapy - group minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - group minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90535-6;Physical therapy - individual minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Physical therapy - individual minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90536-4;Speech-language pathology and audiology services - concurrent minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - concurrent minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90537-2;Speech-language pathology and audiology services - co-treatment minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - co-treatment minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90538-0;Speech-language pathology and audiology services - group minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - group minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90539-8;Speech-language pathology and audiology services - individual minutes during assessment period;Time;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Speech-language pathology and audiology services - individual minutes during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90540-6;MDS v1.17.1, 1.17.2 - Self-care - interim performance - IPA;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v1.17.1, 1.17.2 - Self-care - interim performance - IPA during assessment period [CMS Assessment];;;ACTIVE;2.66;2.7 +90541-4;Mobility - interim performance during assessment period;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Mobility - interim performance during assessment period [CMS Assessment];;;ACTIVE;2.66;2.7 +90542-2;Did the resident have a major surgical procedure during the prior inpatient hospital stay that requires active care during the SNF stay;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Did the resident have a major surgical procedure during the prior inpatient hospital stay that requires active care during the SNF stay [CMS Assessment];;;ACTIVE;2.66;2.7 +90543-0;Percent intake by artificial route while a resident and during the last 7D;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Percent intake by artificial route while a resident and during the last 7 days [CMS Assessment];;;ACTIVE;2.66;2.74 +90544-8;Therapies during Part A Medicare stay;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Therapies during Part A Medicare stay [CMS Assessment];;;ACTIVE;2.66;2.74 +90545-5;Speech-language pathology and audiology services since the start date of the residents most recent Medicare Part A stay;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Speech-language pathology and audiology services since the start date of the resident's most recent Medicare Part A stay [CMS Assessment];;;ACTIVE;2.66;2.74 +90546-3;Occupational therapy since the start date of the residents most recent Medicare Part A stay;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Occupational therapy since the start date of the resident's most recent Medicare Part A stay [CMS Assessment];;;ACTIVE;2.66;2.74 +90547-1;Physical therapy since the start date of the residents most recent Medicare Part A stay;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Physical therapy since the start date of the resident's most recent Medicare Part A stay [CMS Assessment];;;ACTIVE;2.66;2.74 +9054-8;Calorie intake.total;EngRat;8H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calorie intake total 8 hour;Calorie intake total 8h;;ACTIVE;1.0i;2.61 +90548-9;Distinct calendar days of therapy during assessment period;Num;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Distinct calendar days of therapy during assessment period [CMS Assessment];;;ACTIVE;2.66;2.69 +90549-7;Short stay assessment;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Short stay assessment [CMS Assessment];;;ACTIVE;2.66;2.66 +90550-5;Number of D with at least 15M of physical therapy during assessment period;NRat;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of physical therapy during assessment period [CMS Assessment];;;ACTIVE;2.66;2.66 +90551-3;Number of D with at least 15M of speech language pathology and audiology services during assessment period;NRat;RptPeriod;^Patient;Qn;CMS Assessment;SURVEY.CMS;4;Number of days with at least 15 minutes of speech language pathology and audiology services during assessment period [CMS Assessment];;;ACTIVE;2.66;2.66 +90552-1;Mixed apnea;Num;Stdy;^Patient;Qn;;PULM;2;Mixed apnea [#];Num mixed apnea;;ACTIVE;2.65;2.65 +90553-9;Central apnea;Num;Stdy;^Patient;Qn;;PULM;2;Central apnea [#];Num central apnea;;ACTIVE;2.65;2.65 +90554-7;Oxygen desaturation;Num;Stdy;^Patient;Qn;;PULM;2;Oxygen desaturation [#];Num O2 desaturation;;ACTIVE;2.65;2.65 +9055-5;Calorie intake.total;EngRat;10H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calorie intake total 10 hour;Calorie intake total 10h;;ACTIVE;1.0i;2.61 +90555-4;Hypopnea;Num;Stdy;^Patient;Qn;;PULM;2;Hypopnea [#];Num hypopnea;;ACTIVE;2.65;2.65 +90556-2;Obstructive hypopnea;Num;Stdy;^Patient;Qn;;PULM;2;Obstructive hypopnea [#];Num obstructive hypopnea;;ACTIVE;2.65;2.65 +90557-0;Respiratory effort-related arousal;Num;Stdy;^Patient;Qn;;PULM;2;Respiratory effort-related arousal [#];Num resp effort-related arousal;;ACTIVE;2.65;2.65 +90558-8;Central hypopnea;Num;Stdy;^Patient;Qn;;PULM;2;Central hypopnea [#];Num central hypopnea;;ACTIVE;2.65;2.65 +90559-6;Apnea+hypopnea;Num;Stdy;^Patient;Qn;;PULM;2;Apnea + hypopnea [#];Num apnea+hypopnea;;ACTIVE;2.65;2.65 +90560-4;Obstructive apnea;Num;Stdy;^Patient;Qn;;PULM;2;Obstructive apnea [#];Num obstructive apnea;;ACTIVE;2.65;2.65 +90561-2;Hypopnea index;NRat;Stdy;^Patient;Qn;;PULM;2;Hypopnea index;Hypopnea index nRate;;ACTIVE;2.65;2.65 +90562-0;Apnea index;NRat;Stdy;^Patient;Qn;;PULM;2;Apnea index;Apnea index nRate;;ACTIVE;2.65;2.65 +9056-3;Calorie intake.total;EngRat;12H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calorie intake total 12 hour;Calorie intake total 12h;;ACTIVE;1.0i;2.61 +90563-8;Obstructive apnea hypopnea index;NRat;Stdy;^Patient;Qn;;PULM;2;Obstructive apnea hypopnea index;Obstr apnea hypopnea index nRate;;ACTIVE;2.65;2.65 +90564-6;Central apnea hypopnea index;NRat;Stdy;^Patient;Qn;;PULM;2;Central apnea hypopnea index;Central apnea hypopnea index nRate;;ACTIVE;2.65;2.65 +90565-3;Respiratory effort-related arousal index;NRat;Stdy;^Patient;Qn;;PULM;2;Respiratory effort-related arousal index;Resp effort-related arousal index nRate;;ACTIVE;2.65;2.65 +90566-1;Respiratory disturbance index;NRat;Stdy;^Patient;Qn;;PULM;2;Respiratory disturbance index;Resp disturbance index nRate;;ACTIVE;2.65;2.65 +90567-9;Oxygen desaturation index;NRat;Stdy;^Patient;Qn;;PULM;2;Oxygen desaturation index;O2 desaturation index nRate;;ACTIVE;2.65;2.65 +90568-7;Polysomnography panel;-;Stdy;^Patient;-;;PANEL.PULM;2;Polysomnography panel;Polysomnography Pnl;©2019 American Academy of Sleep Medicine. Used with permission.;ACTIVE;2.67;2.67 +90569-5;MDS v3.0 - RAI v1.17.2 - Identification information - NPE;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information - NPE [CMS Assessment];;;ACTIVE;2.66;2.68 +90570-3;MDS v3.0 - RAI v1.17.2 - Type of assessment - NT, NPE, ST;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Type of assessment - NT, NPE, ST [CMS Assessment];;;ACTIVE;2.66;2.68 +9057-1;Calorie intake.total;EngRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Calorie intake total 24 hour;Calorie intake total 24h;;ACTIVE;1.0i;2.7 +90571-1;MDS v3.0 - RAI v1.17.2 - Type of assessment - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Type of assessment - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +90572-9;PROMIS parent proxy life satisfaction - version 1.0 T-Score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy life satisfaction - version 1.0 T-Score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90573-7;Thinking about the past 4W, my child's life was ideal;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was ideal [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90574-5;Thinking about the past 4W, my child was satisfied with his or her life in general;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was satisfied with his/her life in general [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90575-2;Thinking about the past 4W, my child felt he or she lived his or her life well;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child felt he/she lived his/her life well [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90576-0;Thinking about the past 4W, my child's life went well;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life went well [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90577-8;Thinking about the past 4W, my child's life was worthwhile;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was worthwhile [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90578-6;Thinking about the past 4W, my child liked the way he or she lived his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child liked the way he/she lived his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90579-4;Thinking about the past 4W, my child enjoyed his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child enjoyed his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90580-2;Thinking about the past 4W, my child had a lot of fun;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child had a lot of fun [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90581-0;Thinking about the past 4W, my child had fun;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child had fun [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90582-8;Thinking about the past 4W, my child felt positive about his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child felt positive about his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90583-6;Thinking about the past 4W, my child had a good life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child had a good life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90584-4;Thinking about the past 4W, my child felt good about his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child felt good about his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90585-1;Thinking about the past 4W, my child felt very good about his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child felt very good about his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90586-9;Thinking about the past 4W, my child was happy with his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90587-7;Thinking about the past 4W, my child felt extremely positive about his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child felt extremely positive about his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90588-5;Thinking about the past 4W, my child was satisfied with his or her life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was satisfied with his/her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9058-9;Calorie need;EngRat;24H;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Calorie need 24 hour Estimated;Calorie need 24h Est;;ACTIVE;1.0i;2.4 +90589-3;Thinking about the past 4W, my child was satisfied with his or her skills and talents;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was satisfied with his/her skills and talents [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90590-1;Thinking about the past 4W, my child was satisfied with his or her free time;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was satisfied with his/her free time [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90591-9;Thinking about the past 4W, my child was happy with life in his or her community;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with life in his/her community [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90592-7;Thinking about the past 4W, my child was happy with life in his or her neighborhood;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with life in his/her neighborhood [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90593-5;Thinking about the past 4W, my child was happy with his or her life at home;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with his/her life at home [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90594-3;Thinking about the past 4W, my child was happy with his or her life at school;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with his/her life at school [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90595-0;Thinking about the past 4W, my child was happy with his or her family life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with his/her family life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90596-8;Thinking about the past 4W, my child was happy with his or her social life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with his/her social life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9059-7;Carbohydrate intake;Mass;Pt;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Carbohydrate intake Estimated;Carbohydrate intake Est;;ACTIVE;1.0i;2.48 +90597-6;Thinking about the past 4W, my child was satisfied with the friends he or she has;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was satisfied with the friends he/she has [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90598-4;Thinking about the past 4W, my child's life was as good as most kids' lives;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was as good as most kids' lives [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90599-2;Thinking about the past 4W, my child felt he or she lived as well as other kids;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child felt he/she lived as well as other kids [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90600-8;Thinking about the past 4W, my child enjoyed his or her life more than most kids enjoyed their lives;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child enjoyed his/her life more than most kids enjoyed their lives [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90601-6;Thinking about the past 4W, my child felt that his or her life was better than most kids' lives;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child felt that his/her life was better than most kids' lives [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90602-4;Thinking about the past 4W, my child got the things he or she wanted in life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child got the things he/she wanted in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90603-2;Thinking about the past 4W, my child had what he or she needed in life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child had what he/she needed in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90604-0;Thinking about the past 4W, my child had what he or she wanted in life;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child had what he/she wanted in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9060-5;Carbohydrate intake;Mass;Pt;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Carbohydrate intake Measured;Carbohydrate intake Measured;;ACTIVE;1.0i;2.48 +90605-7;Thinking about the past 4W, my child was happy with the way things were;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child was happy with the way things were [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90606-5;Thinking about the past 4W, my child's life situation was excellent;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life situation was excellent [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90607-3;Thinking about the past 4W, the conditions of my child's life were excellent;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, the conditions of my child's life were excellent [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90608-1;Thinking about the past 4W, my child's life was just right;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was just right [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90609-9;Thinking about the past 4W, my child's life was going very well;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was going very well [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90610-7;Thinking about the past 4W, my child's life was good;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was good [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90611-5;Thinking about the past 4W, my child's life was great;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was great [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90612-3;Thinking about the past 4W, my child's life was excellent;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was excellent [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9061-3;Carbohydrate intake;MRat;1H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Carbohydrate intake 1 hour;Carbohydrate intake 1h;;ACTIVE;1.0i;2.48 +90613-1;Thinking about the past 4W, my child's life was outstanding;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was outstanding [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90614-9;Thinking about the past 4W, my child's life was the best;Find;4W;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my child's life was the best [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90615-6;PROMIS parent proxy item bank - life satisfaction - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - life satisfaction - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90616-4;PROMIS pediatric item bank - life satisfaction - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - life satisfaction - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90617-2;PROMIS pediatric life satisfaction - version 1.0 T-Score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric life satisfaction - version 1.0 T-Score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90618-0;Thinking about the past 4W, my life was ideal;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was ideal [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90619-8;Thinking about the past 4W, I was satisfied with my life in general;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was satisfied with my life in general [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90620-6;Thinking about the past 4W, I lived my life well;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I lived my life well [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9062-1;Carbohydrate intake;MRat;8H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Carbohydrate intake 8 hour;Carbohydrate intake 8h;;ACTIVE;1.0i;2.48 +90621-4;Thinking about the past 4W, my life went well;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life went well [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90622-2;Thinking about the past 4W, my life was worthwhile;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was worthwhile [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90623-0;Thinking about the past 4W, I liked the way I lived my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I liked the way I lived my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90624-8;Thinking about the past 4W, I enjoyed my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I enjoyed my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90625-5;Thinking about the past 4W, I had a lot of fun;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I had a lot of fun [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90626-3;Thinking about the past 4W, I had fun;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I had fun [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90627-1;Thinking about the past 4W, I felt positive about my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I felt positive about my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90628-9;Thinking about the past 4W, I had a good life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I had a good life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90629-7;Thinking about the past 4W, I felt good about my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I felt good about my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90630-5;Thinking about the past 4W, I felt very good about my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I felt very good about my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90631-3;Thinking about the past 4W, I was happy with my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90632-1;Thinking about the past 4W, I felt extremely positive about my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I felt extremely positive about my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90633-9;Thinking about the past 4W, I was satisfied with my life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was satisfied with my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90634-7;Thinking about the past 4W, I was satisfied with my skills and talents;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was satisfied with my skills and talents [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90635-4;Thinking about the past 4W, I was satified with my free time;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was satified with my free time [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90636-2;Thinking about the past 4W, I was happy with my life in my community;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with my life in my community [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90637-0;Thinking about the past 4W, I was happy with my life in my neighborhood;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with my life in my neighborhood [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90638-8;Thinking about the past 4W, I was happy with my life at home;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with my life at home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9063-9;Carbohydrate intake;MRat;10H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Carbohydrate intake 10 hour;Carbohydrate intake 10h;;ACTIVE;1.0i;2.48 +90639-6;Thinking about the past 4W, I was happy with my life at school;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with my life at school [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90640-4;Thinking about the past 4W, I was happy with my family life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with my family life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90641-2;Thinking about the past 4W, I was happy with my social life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with my social life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90642-0;Thinking about the past 4W, I was satisfied with the friends I have;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was satisfied with the friends I have [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90643-8;Thinking about the past 4W, my life was as good as most kids' lives;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was as good as most kids' lives [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90644-6;Thinking about the past 4W, I lived as well as other kids;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I lived as well as other kids [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90645-3;Thinking about the past 4W, I enjoyed my life more than most kids enjoyed their lives;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I enjoyed my life more than most kids enjoyed their lives [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90646-1;Thinking about the past 4W, my life was better than most kids' lives;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was better than most kids' lives [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9064-7;Carbohydrate intake;MRat;12H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Carbohydrate intake 12 hour;Carbohydrate intake 12h;;ACTIVE;1.0i;2.48 +90647-9;Thinking about the past 4W, I got the things I wanted in life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I got the things I wanted in life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90648-7;Thinking about the past 4W, I had what I needed in life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I had what I needed in life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90649-5;Thinking about the past 4W, I had what I wanted in life;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I had what I wanted in life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90650-3;Thinking about the past 4W, I was happy with the way things were;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, I was happy with the way things were [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90651-1;Thinking about the past 4W, my life situation was excellent;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life situation was excellent [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90652-9;Thinking about the past 4W, the conditions of my life were excellent;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, the conditions of my life were excellent [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90653-7;Thinking about the past 4W, my life was just right;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was just right [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9065-4;Carbohydrate intake;MRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Carbohydrate intake 24 hour;Carbohydrate intake 24h;;ACTIVE;1.0i;2.48 +90654-5;Thinking about the past 4W, my life was going very well;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was going very well [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90655-2;Thinking about the past 4W, my life was good;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was good [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90656-0;Thinking about the past 4W, my life was great;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was great [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90657-8;Thinking about the past 4W, my life was excellent;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was excellent [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90658-6;Thinking about the past 4W, my life was outstanding;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was outstanding [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90659-4;Thinking about the past 4W, my life was the best;Find;4W;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Thinking about the past 4 weeks, my life was the best [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90660-2;Pulmonary Embolism Severity Index score interpretation;Imp;Pt;^Patient;Ord;PESI;CLIN.RISK;2;Pulmonary Embolism Severity Index score interpretation PESI;PESI score interp PESI;;ACTIVE;2.65;2.65 +90661-0;Revised Geneva score interpretation;Find;Pt;^Patient;Ord;Geneva.Revised;CLIN.RISK;2;Revised Geneva score interpretation;Revised Geneva score interp;Copyright © 2006 American College of Physicians. Used with permission.;ACTIVE;2.65;2.65 +9066-2;Fat intake;Mass;Pt;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Fat intake Estimated;Fat intake Est;;ACTIVE;1.0i;2.48 +90662-8;Wells pulmonary embolism risk score interpretation;Imp;Pt;^Patient;Ord;Wells PE risk;CLIN.RISK;2;Wells pulmonary embolism risk score interpretation;Wells PE risk score interp;© 2001 Dr. Phillip Wells. Used with permission.;ACTIVE;2.65;2.65 +90663-6;Pulmonary Embolism Rule-out Criteria score interpretation;Imp;Pt;^Patient;Ord;PERC;CLIN.RISK;2;Pulmonary Embolism Rule-out Criteria score interpretation;PERC score interp;Copyright © 2004 Dr. Jeffery Kline Used with permission;ACTIVE;2.65;2.65 +90664-4;Other kids wanted to be my child's friend in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Other kids wanted to be my child's friend in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90665-1;My child felt good about his or her friendships in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt good about his/her friendships in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90666-9;My child was able to have fun with his or her friends in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was able to have fun with his/her friends in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90667-7;My child shared with other kids (food, games, pens, etc.) in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child shared with other kids (food, games, pens, etc.) in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90668-5;My child was a good friend in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was a good friend in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90669-3;Other kids wanted to talk to my child in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Other kids wanted to talk to my child in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9067-0;Fat intake;Mass;Pt;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Fat intake Measured;Fat intake Measured;;ACTIVE;1.0i;2.48 +90670-1;My child and his or her friends helped each other out in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child and his/her friends helped each other out in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90671-9;My child was good at making friends in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was good at making friends in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90672-7;My child felt accepted by other kids his or her age in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt accepted by other kids his/her age in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90673-5;Other kids wanted to be with my child in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Other kids wanted to be with my child in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90674-3;My child was able to talk about everything with his or her friends in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was able to talk about everything with his or her friends in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90675-0;My child was able to count on his or her friends in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was able to count on his/her friends in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90676-8;My child played alone and kept to himself or herself in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child played alone and kept to himself/herself in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90677-6;My child liked being around other kids his or her age in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child liked being around other kids his/her age in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90678-4;My child spent time with his or her friends in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child spent time with his/her friends in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90679-2;PROMIS parent proxy item bank - peer relationships - version 2.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - peer relationships - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +906-8;Blood group antigens present;Prid;Pt;Bld;Nom;;BLDBK;1;Blood group antigens present [Identifier] in Blood;Antigens Present Bld;;ACTIVE;1.0;2.73 +90680-0;PROMIS parent proxy peer relationships - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy peer relationships - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90681-8;My child has been physically able to do the activities he or she enjoys most in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child has been physically able to do the activities he/she enjoys most in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90682-6;My child could ride a bike in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could ride a bike in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90683-4;My child could do sports and exercise that other kids his or her age could do in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could do sports and exercise that other kids his/her age could do in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90684-2;My child could get down on his or her knees without holding on to something in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could get down on his/her knees without holding on to something in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90685-9;My child could go up one step in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could go up one step in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90686-7;My child could run a mile in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could run a mile in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90687-5;My child could walk up stairs without holding on to anything in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could walk up stairs without holding on to anything in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +9068-8;Fat intake;MRat;1H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Fat intake 1 hour;Fat intake 1h;;ACTIVE;1.0i;2.48 +90688-3;My child could get up from a regular toilet in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could get up from a regular toilet in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90689-1;My child could stand up on his or her tiptoes in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could stand up on his/her tiptoes in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90690-9;My child could turn his or her head all the way to the side in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could turn his/her head all the way to the side in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90691-7;My child could walk across the room in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could walk across the room in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90692-5;My child could get into bed by himself or herself in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could get into bed by himself/herself in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90693-3;My child could stand up without help in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could stand up without help in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90694-1;My child used a walker, cane or crutches to get around in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child used a walker, cane or crutches to get around in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90695-8;My child could move his or her legs in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could move his/her legs in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +9069-6;Fat intake;MRat;8H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Fat intake 8 hour;Fat intake 8h;;ACTIVE;1.0i;2.48 +90696-6;My child could get up from the floor in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could get up from the floor in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90697-4;My child could bend over to pick something up in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could bend over to pick something up in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90698-2;My child could get in and out of a car in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could get in and out of a car in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90699-0;My child could walk more than one block in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could walk more than one block in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90700-6;My child could keep up when he or she played with other kids in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could keep up when he/she played with other kids in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90701-4;My child could get out of bed by himself or herself in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could get out of bed by himself/herself in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90702-2;My child used a wheelchair to get around in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child used a wheelchair to get around in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90703-0;My child could carry his or her books in a backpack in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could carry his/her books in a backpack in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +9070-4;Fat intake;MRat;10H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Fat intake 10 hour;Fat intake 10h;;ACTIVE;1.0i;2.48 +90704-8;PROMIS parent proxy item bank - mobility - version 2.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - mobility - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90705-5;PROMIS parent proxy mobility - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy mobility - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90706-3;PROMIS pediatric item bank - peer relationships - version 2.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - peer relationships - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90707-1;PROMIS pediatric peer relationships - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric peer relationships - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90708-9;Note;Find;Pt;Outpatient;Doc;Trauma;DOC.ONTOLOGY;2;Trauma Outpatient Note;Trauma OP Note;;ACTIVE;2.65;2.65 +90709-7;Consultation note;Find;Pt;{Setting};Doc;Adolescent medicine;DOC.ONTOLOGY;2;Adolescent medicine Consult note;Adolescent med Consult note;;ACTIVE;2.65;2.65 +90710-5;Consultation note;Find;Pt;{Setting};Doc;Developmental-behavioral pediatrics;DOC.ONTOLOGY;2;Developmental-behavioral pediatrics Consult note;Develop-behav peds Consult note;;ACTIVE;2.65;2.65 +90711-3;Note;Find;Pt;Outpatient;Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Outpatient Note;Sleep med OP Note;;ACTIVE;2.65;2.65 +9071-2;Fat intake;MRat;12H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Fat intake 12 hour;Fat intake 12h;;ACTIVE;1.0i;2.48 +90712-1;Consultation note;Find;Pt;Telehealth;Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Telehealth Consult note;Sleep med Telehealth Consult note;;ACTIVE;2.65;2.65 +90713-9;Note;Find;Pt;Telehealth;Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Telehealth Note;Sleep med Telehealth Note;;ACTIVE;2.65;2.65 +90714-7;Consultation note;Find;Pt;Telehealth;Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Telehealth Consult note;Pain medicine Telehealth Consult note;;ACTIVE;2.65;2.65 +90715-4;Consultation note;Find;Pt;Telehealth;Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Telehealth Consult note;Palliative care Telehealth Consult note;;ACTIVE;2.65;2.65 +90716-2;Note;Find;Pt;Telehealth;Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Telehealth Note;Psychiatric Telehealth Note;;ACTIVE;2.65;2.65 +90717-0;Consultation note;Find;Pt;{Setting};Doc;Heart failure+Transplant cardiology;DOC.ONTOLOGY;2;Heart failure+Transplant cardiology Consult note;HF+TC Consult note;;ACTIVE;2.65;2.65 +90718-8;During the past Mo, how often did you eat hot or cold cereals;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat hot or cold cereals;;;ACTIVE;2.65;2.65 +90719-6;During the past Mo, how often did you drink regular soda or pop that contains sugar;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you drink regular soda or pop that contains sugar;;;ACTIVE;2.65;2.65 +9072-0;Fat intake;MRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Fat intake 24 hour;Fat intake 24h;;ACTIVE;1.0i;2.48 +90720-4;During the past Mo, how often did you drink coffee or tea that had sugar or honey added to it;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you drink coffee or tea that had sugar or honey added to it;;;ACTIVE;2.65;2.65 +90721-2;During the past Mo, how often did you eat a green leafy or lettuce salad, with or without other vegetables;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat a green leafy or lettuce salad, with or without other vegetables;;;ACTIVE;2.65;2.65 +90722-0;During the past Mo, how often did you eat any kind of fried potatoes, including french fries, home fries, or hash brown potatoes;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat any kind of fried potatoes, including french fries, home fries, or hash brown potatoes;;;ACTIVE;2.65;2.65 +90723-8;During the past Mo, how often did you eat any other kind of potatoes, such as baked, boiled, mashed potatoes, sweet potatoes, or potato salad;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat any other kind of potatoes, such as baked, boiled, mashed potatoes, sweet potatoes, or potato salad;;;ACTIVE;2.65;2.65 +90724-6;During the past Mo, how often did you eat refried beans, baked beans, beans in soup, pork and beans or any other type of cooked dried beans;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat refried beans, baked beans, beans in soup, pork and beans or any other type of cooked dried beans;;;ACTIVE;2.65;2.65 +90725-3;During the past Mo, how often did you eat brown rice or other cooked whole grains, such as bulgur, cracked wheat, or millet;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat brown rice or other cooked whole grains, such as bulgur, cracked wheat, or millet;;;ACTIVE;2.65;2.65 +90726-1;During the past Mo, how often did you eat pizza;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat pizza;;;ACTIVE;2.65;2.65 +90727-9;During the past Mo, how often did you eat any kind of cheese;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat any kind of cheese;;;ACTIVE;2.65;2.65 +90728-7;During the past Mo, how often did you eat red meat, such as beef, pork, ham, or sausage;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat red meat, such as beef, pork, ham, or sausage;;;ACTIVE;2.65;2.65 +90729-5;During the past Mo, how often did you eat ice cream or other frozen desserts;NRat;1Mo;^Patient;Qn;;SURVEY.NHANES;4;During the past month, how often did you eat ice cream or other frozen desserts;;;ACTIVE;2.65;2.65 +90730-3;Self-perception of body weight;Find;Pt;^Patient;Ord;;H&P.HX;2;Self-perception of body weight;Self-perception of body wgt;;ACTIVE;2.65;2.65 +90731-1;Frequency of creatine used to improve muscle mass or strength in past Y;NRat;1Y;^Patient;Ord;;H&P.HX;2;Frequency of creatine used to improve muscle mass or strength in past year;Freq creatine used in past Y;;ACTIVE;2.65;2.65 +90732-9;Frequency of DHEA, androstenedione, or human growth hormone used to improve muscle mass or strength in past Y;NRat;1Y;^Patient;Ord;;H&P.HX;2;Frequency of DHEA, androstenedione, or human growth hormone used to improve muscle mass or strength in past year;Freq DHEA, A4 or hGH in past Y;;ACTIVE;2.65;2.65 +90733-7;Frequency of anabolic steroids used to improve muscle mass or strength in past Y;NRat;1Y;^Patient;Ord;;H&P.HX;2;Frequency of anabolic steroids used to improve muscle mass or strength in past year;Freq anabolic steroids used in past Y;;ACTIVE;2.65;2.65 +90734-5;Body weight change goal;Find;Pt;^Patient;Nom;;H&P.HX;2;Body weight change goal;Body weight change goal;;ACTIVE;2.65;2.65 +90735-2;Paroxysmal nocturnal hemoglobinuria GPI-Linked WBC & RBC Ag Panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;PNH GPI-Linked WBC and RBC Ag Panel - Blood;PNH GPI-Lkd WBC + RBC Ag Pnl Bld;;ACTIVE;2.65;2.65 +90736-0;Cells.CD14-FLAER-/100 cells.CD33;NFr;Pt;Bld;Qn;;CELLMARK;1;CD14-FLAER- cells/100 cells.CD33 (Monocytes) in Blood;CD14-FLAER- cells/100 cells.CD33 NFr Bld;;ACTIVE;2.65;2.72 +90737-8;Cells.CD24-FLAER-/100 cells.CD15;NFr;Pt;Bld;Qn;;CELLMARK;1;CD24-FLAER- cells/100 cells.CD15 (Neutrophils) in Blood;CD24-FLAER- cells/100 CD15 cells NFr Bld;;ACTIVE;2.65;2.72 +9073-8;Potassium intake;Sub;Pt;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Potassium intake Estimated;Potassium intake Est;;ACTIVE;1.0i;2.48 +90738-6;Erythrocytes.CD59 complete loss/100 Cells.235a;NFr;Pt;Bld;Qn;;CELLMARK;1;Erythrocytes.CD59 complete loss/100 erythrocytes in Blood;RBC CD59 complete loss NFr;;ACTIVE;2.65;2.65 +90739-4;Paroxysmal nocturnal hemoglobinuria GPI-Linked WBC & RBC Ag;Imp;Pt;Bld;Nar;;CELLMARK;1;PHH GPI-Linked WBC and RBC Ag [Interpretation] in Blood Narrative;PNH GPI-Linked WBC + RBC Ag Bld-Imp;;ACTIVE;2.65;2.65 +90740-2;Aggressive prostate cancer risk;Likelihood;Pt;Ser/Plas;Qn;Calculated.4Kscore;CHEM;1;Aggressive prostate cancer risk [Likelihood] in Serum or Plasma by Calculated.4Kscore;Aggr PC risk SerPl Calculated.4Kscore;;ACTIVE;2.65;2.73 +90741-0;Parathyrin.1-84;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Parathyrin.1-84 [Mass/volume] in Serum or Plasma by Immunoassay;Parathyrin.1-84 SerPl IA-mCnc;;ACTIVE;2.65;2.65 +90742-8;Bovine Mullerian inhibiting substance;MCnc;Pt;Ser/Plas;Qn;IA;FERT;1;Bovine Mullerian inhibiting substance [Mass/volume] in Serum or Plasma by Immunoassay;Bovine MIS SerPl IA-mCnc;;ACTIVE;2.65;2.65 +90743-6;CYBB gene full & NCF1 gene c.75_76delGT analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CYBB gene full and NCF1 gene c.75_76delGT analysis in Blood or Tissue by Molecular genetics method;CYBB full + NCF1 c.75_76delGT Bld/T;;ACTIVE;2.65;2.65 +90744-4;Youth Risk Behavior Survey - body weight panel;-;Pt;^Patient;-;CDC;PANEL.SURVEY.CDC;4;Youth Risk Behavior Survey - body weight panel [CDC];;;ACTIVE;2.65;2.67 +90745-1;Surgical procedures requiring active SNF care;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Surgical procedures requiring active SNF care [CMS Assessment];;;ACTIVE;2.66;2.66 +9074-6;Potassium intake;Sub;Pt;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Potassium intake Measured;Potassium intake Measured;;ACTIVE;1.0i;2.48 +90746-9;5-fluoro ADB-M7;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;5F-ADB-M7 (synthetic cannabinoid metabolite) [Mass/volume] in Urine by Confirmatory method;5-F ADB-M7 Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +90747-7;MDMB-FUBINACA-M1;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;MDMB-FUBINACA-M1 [Mass/volume] in Urine by Confirmatory method;MDMB-FUBINACA-M1 Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +90748-5;Atomoxetine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Atomoxetine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Atomoxetine Sal Cfm-mCnc;;ACTIVE;2.65;2.65 +90749-3;4-Hydroxyatomoxetine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;4-Hydroxyatomoxetine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;4OH-atomoxetine Sal Cfm-mCnc;;ACTIVE;2.65;2.65 +90750-1;O-Nortramadol;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;O-nortramadol [Mass/volume] in Saliva (oral fluid) by Confirmatory method;O-nortramadol Sal Cfm-mCnc;;ACTIVE;2.65;2.65 +90751-9;Note;Find;Pt;Adult day care center;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Adult day care center Note;SW ADCC Note;;ACTIVE;2.65;2.65 +90752-7;Note;Find;Pt;{Setting};Doc;Community health care.social worker;DOC.ONTOLOGY;2;Community health care Social worker Note;CHC SW Note;;ACTIVE;2.65;2.65 +9075-3;Potassium intake;SRat;1H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Potassium intake 1 hour;Potassium intake 1h;;ACTIVE;1.0i;2.48 +90753-5;Note;Find;Pt;{Setting};Doc;Multi-specialty program.social worker;DOC.ONTOLOGY;2;Multi-specialty program Social worker Note;Multi-spec prog SW Note;;ACTIVE;2.65;2.65 +90754-3;Note;Find;Pt;{Setting};Doc;Mental health.social worker;DOC.ONTOLOGY;2;Mental health Social worker Note;MH SW Note;;ACTIVE;2.65;2.65 +90755-0;Note;Find;Pt;Long term care facility;Doc;Palliative care.social worker;DOC.ONTOLOGY;2;Palliative care Social worker Long term care facility Note;Palliative care SW LTC fac Note;;ACTIVE;2.65;2.65 +90756-8;Note;Find;Pt;{Setting};Doc;Palliative care.social worker;DOC.ONTOLOGY;2;Palliative care Social worker Note;Palliative care SW Note;;ACTIVE;2.65;2.65 +90757-6;Note;Find;Pt;Hospital;Doc;Physical medicine and rehab.social worker;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Social worker Hospital Note;PM+R SW Hosp Note;;ACTIVE;2.65;2.65 +90758-4;Note;Find;Pt;Outpatient hospital;Doc;Physical medicine and rehab.social worker;DOC.ONTOLOGY;2;Physical medicine and rehabilitation Social worker Outpatient hospital Note;PM+R SW Outpt Hosp Note;;ACTIVE;2.65;2.65 +90759-2;Note;Find;Pt;{Setting};Doc;Primary care.social worker;DOC.ONTOLOGY;2;Primary care Social worker Note;Primary care SW Note;;ACTIVE;2.65;2.65 +907-6;Blood group antigens present;Prid;Pt;^BPU;Nom;;BLDBK;1;Blood group antigens present [Identifier] in Blood product unit;Antigens Present BPU;;ACTIVE;1.0;2.26 +90760-0;Note;Find;Pt;{Setting};Doc;Addiction medicine.social worker;DOC.ONTOLOGY;2;Addiction medicine Social worker Note;Addiction med SW Note;;ACTIVE;2.65;2.65 +9076-1;Potassium intake;SRat;8H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Potassium intake 8 hour;Potassium intake 8h;;ACTIVE;1.0i;2.48 +90761-8;PROMIS item bank - applied cognitive - general concerns - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - applied cognitive - general concerns - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90762-6;PROMIS applied cognitive - general concerns - version 1.0 T-Score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS applied cognitive - general concerns - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90763-4;HEDIS 2019-2020 Value Set - Chlamydia Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - Chlamydia Tests;HEDIS 2019-20 Chlamydia;;DISCOURAGED;2.65;2.69 +90764-2;HEDIS 2019 Value Set - Toxoplasma Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019 Value Set - Toxoplasma Antibody;HEDIS 2019 Toxoplasma Ab;;DISCOURAGED;2.65;2.67 +90765-9;HEDIS 2019 Value Set - Rh;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019 Value Set - Rh;HEDIS 2019 Rh;;DISCOURAGED;2.65;2.67 +90766-7;HEDIS 2019 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019 Value Sets;HEDIS 2019 Value Sets;;DISCOURAGED;2.65;2.67 +90767-5;Pregnancy summary;Find;Pt;^Patient;Doc;;DOC.MISC;2;Pregnancy summary Document;Pregnancy summary Doc;;ACTIVE;2.65;2.65 +90768-3;Donor blood study;Find;Pt;Bld^Donor;Doc;;DOC.MISC;2;Donor blood study;Donor bld study;;ACTIVE;2.65;2.72 +90769-1;Plan of care note;Find;Pt;{Setting};Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Plan of care note;Heart failure Plan of care note;;ACTIVE;2.65;2.65 +90770-9;Initial evaluation note;Find;Pt;{Setting};Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Initial evaluation note;Heart failure Initial eval note;;ACTIVE;2.65;2.65 +90771-7;Consultation note;Find;Pt;{Setting};Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Consult note;Heart failure Consult note;;ACTIVE;2.65;2.65 +90772-5;Progress note;Find;Pt;{Setting};Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Progress note;Heart failure Prog note;;ACTIVE;2.65;2.73 +90773-3;Note;Find;Pt;Telephone encounter;Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Telephone encounter Note;Heart failure Phone Note;;ACTIVE;2.65;2.65 +90774-1;Conference note;Find;Pt;{Setting};Doc;Heart failure.team;DOC.ONTOLOGY;2;Heart failure Team Conference note;Heart failure Team Conf eval note;;ACTIVE;2.65;2.65 +90775-8;Disease severity level;Find;Pt;^Patient;Ord;Reported;SURVEY.GNHLTH;4;Disease severity level [Reported];;;ACTIVE;2.65;2.65 +90776-6;HEDIS 2019 Value Set - Rubella Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019 Value Set - Rubella Antibody;HEDIS 2019 Rubella Ab;;DISCOURAGED;2.65;2.67 +90777-4;HEDIS 2019 Value Set - Cytomegalovirus Antibody;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019 Value Set - Cytomegalovirus Antibody;HEDIS 2019 CMV Ab;;DISCOURAGED;2.65;2.67 +90778-2;Personal pronouns;Type;Pt;^Patient;Nom;Reported;CLIN;2;Personal pronouns - Reported;Personal pronoun Reported;;ACTIVE;2.65;2.66 +9077-9;Potassium intake;SRat;10H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Potassium intake 10 hour;Potassium intake 10h;;ACTIVE;1.0i;2.48 +90779-0;Adalimumab Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Adalimumab Ab [Units/volume] in Serum by Immunoassay;Adalimumab Ab Ser IA-aCnc;;ACTIVE;2.65;2.68 +90780-8;inFLIXimab Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;inFLIXimab Ab [Units/volume] in Serum by Immunoassay;inFLIXimab Ab Ser IA-aCnc;;ACTIVE;2.65;2.68 +90781-6;N,N'-Dimethylarginine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;N,N'-dimethylarginine [Mass/volume] in Serum or Plasma;N,N'-dimethylarginine SerPl-mCnc;;ACTIVE;2.65;2.65 +90782-4;F2-Isoprostanes;MCnc;Pt;Urine;Qn;;CHEM;1;F2-Isoprostanes [Mass/volume] in Urine;F2-IsoPs Ur-mCnc;;ACTIVE;2.65;2.65 +90783-2;F2-Isoprostanes/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;F2-Isoprostanes/Creatinine [Mass Ratio] in Urine;F2-IsoPs/Creat Ur;;ACTIVE;2.65;2.65 +90784-0;Cystinuria panel;-;Pt;Urine;-;;PANEL.CHEM;1;Cystinuria panel - Urine;Cystinuria Pnl Ur;;ACTIVE;2.65;2.65 +90785-7;Cystinuria panel;-;24H;Urine;-;;PANEL.CHEM;1;Cystinuria panel - 24 hour Urine;Cystinuria Pnl 24h Ur;;ACTIVE;2.65;2.65 +90786-5;Note;Find;Pt;{Setting};Doc;Dentistry.attending;DOC.ONTOLOGY;2;Dentistry Attending Note;Dentistry Attend Note;;ACTIVE;2.65;2.65 +9078-7;Potassium intake;SRat;12H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Potassium intake 12 hour;Potassium intake 12h;;ACTIVE;1.0i;2.48 +90787-3;Note;Find;Pt;{Setting};Doc;Dentistry.resident;DOC.ONTOLOGY;2;Dentistry Resident Note;Dentistry Res Note;;ACTIVE;2.65;2.65 +90788-1;Note;Find;Pt;{Setting};Doc;Optometry.resident;DOC.ONTOLOGY;2;Optometry Resident Note;Optometry Res Note;;ACTIVE;2.65;2.65 +90789-9;Note;Find;Pt;{Setting};Doc;Psychology.intern;DOC.ONTOLOGY;2;Psychology Intern Note;Psychology Intern Note;;ACTIVE;2.65;2.65 +90790-7;Note;Find;Pt;{Setting};Doc;Podiatry.resident;DOC.ONTOLOGY;2;Podiatry Resident Note;Podiatry Res Note;;ACTIVE;2.65;2.65 +90791-5;Note;Find;Pt;{Setting};Doc;Physical therapy.resident;DOC.ONTOLOGY;2;Physical therapy Resident Note;PT Res Note;;ACTIVE;2.65;2.65 +90792-3;Preoperative evaluation and management note;Find;Pt;{Setting};Doc;Podiatry.attending;DOC.ONTOLOGY;2;Podiatry Attending Preoperative evaluation and management note;Podiatry Attend Pre-op note;;ACTIVE;2.65;2.65 +90793-1;Note;Find;Pt;{Setting};Doc;Podiatry.attending;DOC.ONTOLOGY;2;Podiatry Attending Note;Podiatry Attend Note;;ACTIVE;2.65;2.65 +90794-9;Vedolizumab & Vedolizumab Ab Panel;MCnc;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Vedolizumab and Vedolizumab Ab panel [Mass/volume] - Serum or Plasma;Vedol + Vedol Ab Pnl SerPl-mCnc;;ACTIVE;2.65;2.65 +9079-5;Protein intake;Mass;Pt;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Protein intake Estimated;Protein intake Est;;ACTIVE;1.0i;2.48 +90795-6;Levothyroxine absorption panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Levothyroxine absorption panel - Serum or Plasma;Levothyroxine absorption pnl SerPl;;ACTIVE;2.65;2.65 +90796-4;Thyroxine^1H post dose levothyroxine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --1 hours post dose levothyroxine;T4 1h p levo SerPl-mCnc;;ACTIVE;2.65;2.65 +90797-2;Thyroxine^2H post dose levothyroxine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --2 hours post dose levothyroxine;T4 2h p levo SerPl-mCnc;;ACTIVE;2.65;2.65 +90798-0;Thyroxine^3H post dose levothyroxine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --3 hours post dose levothyroxine;T4 3h p levo SerPl-mCnc;;ACTIVE;2.65;2.65 +90799-8;Thyroxine^4H post dose levothyroxine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --4 hours post dose levothyroxine;T4 4h p levo SerPl-mCnc;;ACTIVE;2.65;2.65 +90800-4;Thyroxine^6H post dose levothyroxine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyroxine (T4) [Mass/volume] in Serum or Plasma --6 hours post dose levothyroxine;T4 6h p levo SerPl-mCnc;;ACTIVE;2.65;2.65 +90801-2;Thyrotropin^6H post dose levothyroxine;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Thyrotropin [Units/volume] in Serum or Plasma --6 hours post dose levothyroxine;TSH 6h p levo SerPl-aCnc;;ACTIVE;2.65;2.65 +90802-0;Medication volume of distribution;Vol;Pt;^Patient;Qn;Calculated;MEDS;2;Medication volume of distribution Calculated;Med Vd Calc;;ACTIVE;2.65;2.65 +9080-3;Protein intake;Mass;Pt;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Protein intake Measured;Protein intake Measured;;ACTIVE;1.0i;2.48 +90803-8;Peak concentration post XXX challenge - baseline concentration increment;MCncDiff;Pt;Ser/Plas;Qn;Calculated;DRUG/TOX;1;Post-challenge peak - baseline concentration increment [Mass concentration difference] in Serum or Plasma by calculation;Conc increment SerPl Calc-MCDiff;;ACTIVE;2.65;2.65 +90804-6;Levothyroxine absorption;MFr;Pt;Ser/Plas;Qn;Calculated;CHAL;1;Levothyroxine absorption in Serum or Plasma by calculation;Levothyroxine absorption MFr SerPl Calc;;ACTIVE;2.65;2.65 +90805-3;Vedolizumab^trough;MCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Vedolizumab [Mass/volume] in Serum or Plasma by LC/MS/MS --trough;Vedolizumab Trough SerPl LC/MS/MS-mCnc;;ACTIVE;2.65;2.65 +90806-1;Candida albicans DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Candida albicans DNA [Presence] in Serum by NAA with probe detection;C albicans DNA Ser Ql NAA+probe;;ACTIVE;2.65;2.65 +90807-9;Candida glabrata DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Candida glabrata DNA [Presence] in Serum by NAA with probe detection;C glabrata DNA Ser Ql NAA+probe;;ACTIVE;2.65;2.65 +90808-7;Candida krusei DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Candida krusei DNA [Presence] in Serum by NAA with probe detection;C krusei DNA Ser Ql NAA+probe;;ACTIVE;2.65;2.65 +90809-5;Candida parapsilosis DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Candida parapsilosis DNA [Presence] in Serum by NAA with probe detection;C parap DNA Ser Ql NAA+probe;;ACTIVE;2.65;2.65 +90810-3;Candida tropicalis DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Candida tropicalis DNA [Presence] in Serum by NAA with probe detection;C tropicls DNA Ser Ql NAA+probe;;ACTIVE;2.65;2.65 +9081-1;Protein intake;MRat;1H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Protein intake 1 hour;Protein intake 1h;;ACTIVE;1.0i;2.48 +90811-1;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;AMPAR1 Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;AMPAR1 Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +90812-9;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;AMPAR1 Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;AMPAR1 Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90813-7;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;AMPAR2 Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;AMPAR2 Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +90814-5;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;AMPAR2 Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;AMPAR2 Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90815-2;Amphiphysin Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Amphiphysin Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Amphiphysin Ab CSF Ql IF;;ACTIVE;2.65;2.65 +90816-0;Amphiphysin Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;Amphiphysin Ab [Units/volume] in Cerebral spinal fluid by Line blot;Amphiphysin Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +90817-8;Aquaporin 4 water channel Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Aquaporin 4 water channel Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;AQP4 H2O channel Ab CSF Ql IF;;ACTIVE;2.65;2.67 +90818-6;Aquaporin 4 water channel Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Aquaporin 4 water channel IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;AQP4 H2O channel IgG CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +90819-4;Aquaporin 4 water channel Ab.IgG;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;Aquaporin 4 water channel IgG Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;AQP4 H2O channel IgG Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90820-2;Contactin-associated protein 2 Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Contactin-associated protein 2 Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;CASPR2 Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +90821-0;Contactin-associated protein 2 Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;Contactin-associated protein 2 Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;CASPR2 Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90822-8;CV2 Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;CV2 Ab [Units/volume] in Cerebral spinal fluid by Line blot;CV2 Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +90823-6;Dipeptidyl aminopeptidase-like protein 6 Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Dipeptidyl aminopeptidase-like protein 6 Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;DPPX Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +90824-4;Dipeptidyl aminopeptidase-like protein 6 Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;Dipeptidyl aminopeptidase-like protein 6 Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;DPPX Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90825-1;Gamma aminobutyrate B receptor Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;GABABR Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;GABABR Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +90826-9;Gamma aminobutyrate B receptor Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;GABABR Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;GABABR Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90827-7;Glial nuclear type 1 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Glial nuclear type 1 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Glial nuc type 1 Ab CSF Ql IF;;ACTIVE;2.65;2.65 +90828-5;Glial nuclear type 1 Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;Glial nuclear type 1 Ab [Units/volume] in Cerebral spinal fluid by Line blot;Glial nuc type 1 Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +9082-9;Protein intake;MRat;8H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Protein intake 8 hour;Protein intake 8h;;ACTIVE;1.0i;2.48 +90829-3;Glutamate decarboxylase 65 Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;Glutamate decarboxylase 65 Ab [Units/volume] in Cerebral spinal fluid by Line blot;GAD65 Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +90830-1;Leucine-rich glioma-inactivated protein 1 Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Leucine-rich glioma-inactivated protein 1 Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;LGI1 Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +90831-9;Leucine-rich glioma-inactivated protein 1 Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;Leucine-rich glioma-inactivated protein 1 Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;LGI1 Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90832-7;Ma+Ta Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Ma+Ta Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Ma+Ta Ab CSF Ql IF;;ACTIVE;2.65;2.65 +90833-5;Ma+Ta Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;Ma+Ta Ab [Units/volume] in Cerebral spinal fluid by Line blot;Ma+Ta Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +90834-3;Myelin Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Myelin Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Myelin Ab Titr CSF IF;;ACTIVE;2.65;2.65 +90835-0;Myelin associated glycoprotein Ab.IgM;PrThr;Pt;CSF;Ord;IB;SERO;1;Myelin associated glycoprotein IgM Ab [Presence] in Cerebral spinal fluid by Immunoblot;MAG IgM CSF Ql IB;;ACTIVE;2.65;2.65 +90836-8;Neuronal nuclear type 3 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Neuronal nuclear type 3 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;Hu3 Ab CSF Ql IF;;ACTIVE;2.65;2.65 +9083-7;Protein intake;MRat;10H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Protein intake 10 hour;Protein intake 10h;;ACTIVE;1.0i;2.48 +90837-6;Neuronal nuclear type 3 Ab;Titr;Pt;CSF;Qn;IF;SERO;1;Neuronal nuclear type 3 Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Hu3 Ab Titr CSF IF;;ACTIVE;2.65;2.65 +90838-4;Neuronal nuclear type 3 Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;Neuronal nuclear type 3 Ab [Units/volume] in Cerebral spinal fluid by Line blot;Hu3 Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +90839-2;N-methyl-D-aspartate receptor subunit 1 Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;NMDAR subunit 1 Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;NMDAR1 Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +908-4;Ax Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Ax Ab [Presence] in Serum or Plasma from Blood product unit;Ax Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +90840-0;N-methyl-D-aspartate receptor subunit 1 Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;NMDAR subunit 1 Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;NMDAR1 Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90841-8;Purkinje cell cytoplasmic type 1 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;PCA-1 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;PCA-1 Ab CSF Ql IF;;ACTIVE;2.65;2.65 +90842-6;Purkinje cell cytoplasmic type 1 Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;PCA-1 Ab [Units/volume] in Cerebral spinal fluid by Line blot;PCA-1 Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +90843-4;Purkinje cell cytoplasmic type 2 Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;PCA-2 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;PCA-2 Ab CSF Ql IF;;ACTIVE;2.65;2.65 +90844-2;Purkinje cell cytoplasmic type Tr Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;PCA-Tr Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;PCA-Tr Ab CSF Ql CBA IFA;;ACTIVE;2.65;2.69 +9084-5;Protein intake;MRat;12H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Protein intake 12 hour;Protein intake 12h;;ACTIVE;1.0i;2.48 +90845-9;Purkinje cell cytoplasmic type Tr Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;PCA-Tr Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;PCA-Tr Ab CSF Ql IF;;ACTIVE;2.65;2.65 +90846-7;Purkinje cell cytoplasmic type Tr Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;PCA-Tr Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;PCA-Tr Ab Titr CSF CBA IFA;;ACTIVE;2.65;2.69 +90847-5;Zinc finger protein of the cerebellum 4 Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;Zinc finger protein of the cerebellum 4 Ab [Units/volume] in Cerebral spinal fluid by Line blot;Zic4 Ab CSF Line blot-aCnc;;ACTIVE;2.65;2.7 +90848-3;Myelin associated glycoprotein-sulfated glucuronic paragloboside Ab.IgM;Titr;Pt;CSF;Qn;IA;SERO;1;Myelin associated glycoprotein/Sulfated glucuronic paragloboside IgM Ab [Titer] in Cerebral spinal fluid by Immunoassay;MAG/SGPG IgM Titr CSF IA;;ACTIVE;2.65;2.65 +90849-1;Cefpodoxime 4.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Cefpodoxime 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Cefpodoxime 4 ug/mL Islt SlowMyco;;ACTIVE;2.65;2.65 +90850-9;cefTAZidime 1.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;cefTAZidime 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;cefTAZidime 1 ug/mL Islt SlowMyco;;ACTIVE;2.65;2.65 +90851-7;GJB2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GJB2 gene full mutation analysis in Blood or Tissue by Sequencing;GJB2 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.65;2.65 +9085-2;Protein intake;MRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Protein intake 24 hour;Protein intake 24h;;ACTIVE;1.0i;2.48 +90852-5;Fax number;Tele;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Patient Fax number;Patient Fax #;;ACTIVE;2.65;2.66 +90853-3;Final score;Score;Pt;^Patient;Qn;DUKE-AD;SURVEY.DUKE-AD;4;Final score [DUKE-AD];;Copyright © 1994 Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA. Used with permission.;ACTIVE;2.65;2.65 +90854-1;Duke Anxiety Depression Scale;-;Pt;^Patient;-;DUKE-AD;PANEL.SURVEY.DUKE-AD;4;Duke Anxiety Depression Scale [DUKE-AD];;Copyright © 1994 Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA. Used with permission.;ACTIVE;2.65;2.65 +90855-8;Posterior inter-arch deviation;Type;Pt;Teeth and gum;Nom;;DENTAL;2;Posterior inter-arch deviation Teeth and gum;Post inter-arch deviation Teeth+gum;;ACTIVE;2.65;2.65 +90856-6;Crossbite teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Crossbite teeth [#];Crossbite teeth;;ACTIVE;2.65;2.65 +90857-4;Closed-spaced teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Closed-spaced teeth [#];Closed-spaced teeth;;ACTIVE;2.65;2.65 +90858-2;Open-spaced teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Open-spaced teeth [#];Open-spaced teeth;;ACTIVE;2.65;2.65 +90859-0;Rotated teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Rotated teeth [#];Rotated teeth;;ACTIVE;2.65;2.65 +9086-0;Sodium intake;Sub;Pt;^Patient;Qn;Estimated;IO_IN_SALTS+CALS;2;Sodium intake Estimated;Sodium intake Est;;ACTIVE;1.0i;2.48 +90860-8;Crowded teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Crowded teeth [#];Crowded teeth;;ACTIVE;2.65;2.65 +90861-6;Missing teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Missing teeth [#];Missing teeth;;ACTIVE;2.65;2.65 +90862-4;Malocclusion index;Score;Pt;Teeth and gum;Qn;Calculated;DENTAL;2;Malocclusion index Teeth and gum Calculated;Malocclusion index Score Teeth+gum Calc;;ACTIVE;2.65;2.65 +90863-2;Labio-lingual spread;Len;Pt;Mouth;Qn;Measured;DENTAL;2;Labio-lingual spread [Length] Mouth Measured;Labio-lingual spread Mouth Measured;;ACTIVE;2.65;2.65 +90864-0;Dental abnormalities impacting orthodontic care;Find;Pt;Teeth and gum;Nom;;DENTAL;2;Dental abnormalities impacting orthodontic care;Dental abnormalities orthodontic care;;ACTIVE;2.65;2.65 +90865-7;Craniofacial anomalies impacting orthodontic care;Find;Pt;Head;Nom;;DENTAL;2;Craniofacial anomalies impacting orthodontic care;Craniofacial anomalies orthodontic care;;ACTIVE;2.65;2.65 +90866-5;Orthodontic preconditions;Find;Pt;^Patient;Nom;;DENTAL;2;Orthodontic preconditions;Orthodontic preconditions;;ACTIVE;2.65;2.65 +90867-3;Airway problem impacting orthodontic treatment;Type;Pt;^Patient;Nom;;DENTAL;2;Airway problem impacting orthodontic treatment;Airway prob impact orthodont trtmt;;ACTIVE;2.65;2.65 +90868-1;Orthognathic surgery consideration summary;Find;Pt;^Patient;Nar;;DENTAL;2;Orthognathic surgery consideration summary Narrative;Orthognathic surg consideration summary;;ACTIVE;2.65;2.65 +90869-9;Asymmetry of lower face;Find;Pt;Face;Nom;;DENTAL;2;Asymmetry of lower face;Asymmetry of lower face;;ACTIVE;2.65;2.65 +90870-7;Habits impacting orthodontic condition;Type;Pt;^Patient;Nom;;DENTAL;2;Habits impacting orthodontic condition;Habits impact orthodontic cond;;ACTIVE;2.65;2.65 +90871-5;Medical conditions impacting orthodontic condition;Hx;Pt;^Patient;Nom;;DENTAL;2;History of Medical conditions impacting orthodontic condition;Hx of Med cond impact orthodontic cond;;ACTIVE;2.65;2.65 +90872-3;Supplemental information about orthodontic condition;Find;Pt;Oral cavity;Doc;;DENTAL;2;Supplemental information about orthodontic condition Oral cavity Document;Info orthodontic cond Oral cavity Doc;;ACTIVE;2.65;2.65 +90873-1;Malocclusion severity assessment;Find;Pt;Teeth and gum;Doc;;DOC.MISC;2;Malocclusion severity assessment;Malocclusion severity assess Doc;;ACTIVE;2.65;2.65 +90874-9;Orthodontic evaluation summary;Find;Pt;^Patient;Doc;;DOC.MISC;2;Orthodontic evaluation summary Document;Orthodontic eval summary Doc;;ACTIVE;2.65;2.65 +90875-6;Orthodontic service attachment;Find;Pt;{Setting};Doc;{Role};DOC.ADMIN;2;Orthodontic service attachment;Orthodontic service attach;;ACTIVE;2.65;2.67 +90876-4;Progress note;Find;Pt;{Setting};Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism Progress note;Thromboemb Prog note;;ACTIVE;2.65;2.73 +90877-2;Procedure note;Find;Pt;{Setting};Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism procedure note;Thromboemb Procedure note;;ACTIVE;2.65;2.65 +9087-8;Sodium intake;Sub;Pt;^Patient;Qn;Measured;IO_IN_SALTS+CALS;2;Sodium intake Measured;Sodium intake Measured;;ACTIVE;1.0i;2.48 +90878-0;Note;Find;Pt;Telephone encounter;Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism Telephone encounter Note;Thromboemb Phone Note;;ACTIVE;2.65;2.65 +90879-8;Conference note;Find;Pt;{Setting};Doc;Thromboembolism.team;DOC.ONTOLOGY;2;Thromboembolism Team Conference note;Thromboemb Team Conf eval note;;ACTIVE;2.65;2.65 +90880-6;Arachis hypogaea recombinant (rAra h) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 6 IgE Ab [Units/volume] in Serum;Peanut (rAra h) 6 IgE Qn;;ACTIVE;2.65;2.73 +90881-4;(Alternaria tenuis+Artemisia vulgaris+Betula verrucosa+Cladosporium herbarum+Phleum pratense) Ab.IgE;PrThr;Pt;Ser;Ord;Multidisk;ALLERGY;1;Inhalant Allergen Mix 6 (Alternaria tenuis+Mugwort+Silver birch+Cladosporium herbarum+Timothy grass) IgE Ab [Presence] in Serum by Multidisk;Inhalant Allerg Mix 6 IgE Ql;;ACTIVE;2.65;2.65 +90882-2;Staphylococcus aureus enterotoxin E Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Staphylococcus aureus enterotoxin E IgE Ab RAST class [Presence] in Serum;S aureus Etx E IgE RAST Ql;;ACTIVE;2.65;2.65 +90883-0;PROMIS pediatric item bank - mobility - version 2.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - mobility - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90884-8;PROMIS pediatric mobility - version 2.0 T-Score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric mobility - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90885-5;Influenza virus D RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus D RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUDV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.65;2.69 +9088-6;Sodium intake;SRat;1H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Sodium intake 1 hour;Sodium intake 1h;;ACTIVE;1.0i;2.48 +90886-3;Influenza virus B RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Cycle Threshold #] in Specimen by NAA with probe detection;FLUBV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.65;2.69 +90887-1;Porcine circovirus type 3 ORF2 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Porcine circovirus type 3 ORF2 gene [Nucleotide sequence] in Isolate by Sequencing;PCV 3 ORF2 gene Islt-Seq;;ACTIVE;2.65;2.65 +90888-9;Porcine circovirus type 3 DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine circovirus type 3 DNA [#/volume] (viral load) in Specimen by NAA with probe detection;PCV3 DNA # Spec NAA+probe;;ACTIVE;2.65;2.69 +90889-7;Porcine circovirus type 2 Ab.IgG;Titr;Pt;XXX;Qn;IF;MICRO;1;Porcine circovirus type 2 IgG Ab [Titer] in Specimen by Immunofluorescence;PCV2 IgG Titr Spec IF;;ACTIVE;2.65;2.69 +90890-5;Benzodiazepines panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;Benzodiazepines panel - Urine by Confirmatory method;Benzodiazepines Pnl Ur Cfm;;ACTIVE;2.65;2.65 +90891-3;Estradiol^2H post XXX challenge;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Estradiol (E2) [Mass/volume] in Serum or Plasma --2 hours post XXX challenge;Estradiol 2h p chal SerPl-mCnc;;ACTIVE;2.65;2.65 +90892-1;Borrelia sp panel;-;Pt;Bld;-;Non-probe.amp.tar;PANEL.MICRO;1;Borrelia sp panel - Blood by NAA with non-probe detection;B sp panel Bld NAA+non-probe;;ACTIVE;2.65;2.68 +90893-9;Borrelia burgdorferi bba64 gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Borrelia burgdorferi bba64 gene [Presence] in Blood by NAA with non-probe detection;B burg bba64 gene Bld Ql NAA+non-probe;;ACTIVE;2.65;2.65 +9089-4;Sodium intake;SRat;8H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Sodium intake 8 hour;Sodium intake 8h;;ACTIVE;1.0i;2.48 +90894-7;Noroxymorphone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Noroxymorphone [Mass/volume] in Urine by Confirmatory method;Noroxymorphone Ur Cfm-mCnc;;ACTIVE;2.65;2.65 +90895-4;Task identifier;ID;Pt;^Event;Nom;;ADMIN.ID;2;Task identifier;Task ID;;ACTIVE;2.65;2.68 +90896-2;Person assigned to task;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel Person assigned to task;Personnel Person assigned to task;;ACTIVE;2.65;2.68 +90897-0;Percent of task completed;NFr;Pt;^Event;Qn;;ADMIN;2;Percent of task completed;Percent of task completed NFr;;ACTIVE;2.65;2.68 +90898-8;HIV 1 proviral DNA reverse transcriptase & protease & integrase gene;Seq;Pt;Bld MC;Nom;Sequencing;MICRO;1;HIV 1 proviral DNA reverse transcriptase and protease and integrase gene [Nucleotide sequence] in Blood mononuclear cells by Sequencing;HIV1 proviral DNA RT+PR+IN Bld MC-Seq;;ACTIVE;2.65;2.65 +90899-6;HIV 1 proviral DNA reverse transcriptase & protease gene;Seq;Pt;Bld MC;Nom;Sequencing;MICRO;1;HIV 1 proviral DNA reverse transcriptase and protease gene [Nucleotide sequence] in Blood mononuclear cells by Sequencing;HIV1 proviral DNA RT + PR Bld MC-Seq;;ACTIVE;2.65;2.65 +90900-2;HIV 1 proviral DNA integrase gene;Seq;Pt;Bld MC;Nom;Sequencing;MICRO;1;HIV 1 proviral DNA integrase gene [Nucleotide sequence] in Blood mononuclear cells by Sequencing;HIV1 proviral DNA IN Bld MC-Seq;;ACTIVE;2.65;2.65 +90901-0;HIV 1 RNA reverse transcriptase & protease & integrase gene;Seq;Pt;Ser/Plas/Bld;Nom;Sequencing;MICRO;1;HIV 1 RNA reverse transcriptase and protease and integrase gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing;HIV 1 RNA RT + PR + IN SerPlBld-Seq;;ACTIVE;2.65;2.65 +9090-2;Sodium intake;SRat;10H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Sodium intake 10 hour;Sodium intake 10h;;ACTIVE;1.0i;2.48 +90902-8;HIV 1 RNA reverse transcriptase gene;Seq;Pt;Ser/Plas/Bld;Nom;Sequencing;MICRO;1;HIV 1 RNA reverse transcriptase gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing;HIV 1 RNA RT SerPlBld-Seq;;ACTIVE;2.65;2.65 +90903-6;HIV 1 RNA integrase gene;Seq;Pt;Ser/Plas/Bld;Nom;Sequencing;MICRO;1;HIV 1 RNA integrase gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing;HIV 1 RNA IN SerPlBld-Seq;;ACTIVE;2.65;2.65 +90904-4;HIV 1 RNA protease gene;Seq;Pt;Ser/Plas/Bld;Nom;Sequencing;MICRO;1;HIV 1 RNA protease gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing;HIV 1 RNA PR SerPlBld-Seq;;ACTIVE;2.65;2.65 +90905-1;ABO & Rh group;Type;Pt;Bld^Mother;Nom;;BLDBK;1;Mother's ABO and Rh group Type;ABO + Rh Bld Mother;;ACTIVE;2.65;2.72 +90906-9;ABO & Rh group;Type;Pt;Bld^Father;Nom;;BLDBK;1;Father's ABO and Rh group Type;ABO + Rh Bld Father;;ACTIVE;2.65;2.72 +90907-7;Direct antiglobulin test.IgG specific reagent^post transfusion reaction;PrThr;Pt;RBC;Ord;;BLDBK;1;Direct antiglobulin test.IgG specific reagent [Presence] on Red Blood Cells --after transfusion reaction;DAT IgG-Sp Reag p transf rx RBC Ql;;ACTIVE;2.65;2.65 +90908-5;Eicosapentaenoate+Docosapentaenate w3+Docosahexaenoate/Fatty acids.C14-C22 risk;Imp;Pt;Bld;Ord;;CHEM;1;Eicosapentaenoate (C20:5w3)+Docosapentaenate (C22:5w3)+Docosahexaenoate (C22:6w3)/Fatty acids.C14-C22 risk [Interpretation] in Blood Qualitative;EPA+DPA+DHA/FA.C14-C22 risk Bld Imp;;ACTIVE;2.65;2.65 +90909-3;Arachidonate/Eicosapentaenoate;MRto;Pt;Bld;Qn;;CHEM;1;Arachidonate (C20:4w6)/Eicosapentaenoate (C20:5w3) [Mass Ratio] in Blood;AA/EPA Bld;;ACTIVE;2.65;2.65 +9091-0;Sodium intake;SRat;12H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Sodium intake 12 hour;Sodium intake 12h;;ACTIVE;1.0i;2.48 +90910-1;Fatty acids.omega 6/Fatty acids.omega 3;MRto;Pt;Bld;Qn;;CHEM;1;Omega 6 fatty acids (w6)/Omega 3 fatty acids (w3) [Mass Ratio] in Blood;w6 FA/w3 FA Bld;;ACTIVE;2.65;2.65 +90911-9;Eicosapentaenoate+Docosapentaenate w3+Docosahexaenoate/Fatty acids.C14-C22;MFr;Pt;Bld;Qn;;CHEM;1;Eicosapentaenoate (C20:5w3)+Docosapentaenate (C22:5w3)+Docosahexaenoate (C22:6w3)/Fatty acids.C14-C22 in Blood;EPA+DPA+DHA/Fatty acids.C14-C22 MFr Bld;;ACTIVE;2.65;2.65 +90912-7;Eicosapentaenoate/Fatty acids.C14-C22;MFr;Pt;Bld;Qn;;CHEM;1;Eicosapentaenoate (C20:5w3)/Fatty acids.C14-C22 in Blood;EPA/Fatty acids.C14-C22 MFr Bld;;ACTIVE;2.65;2.65 +90913-5;Docosapentaenate w3/Fatty acids.C14-C22;MFr;Pt;Bld;Qn;;CHEM;1;Docosapentaenate (C22:5w3)/Fatty acids.C14-C22 in Blood;DPA/Fatty acids.C14-C22 MFr Bld;;ACTIVE;2.65;2.65 +90914-3;Docosahexaenoate/Fatty acids.C14-C22;MFr;Pt;Bld;Qn;;CHEM;1;Docosahexaenoate (C22:6w3)/Fatty acids.C14-C22 in Blood;DHA/Fatty acids.C14-C22 MFr Bld;;ACTIVE;2.65;2.65 +90915-0;Arachidonate+Linoleate/Fatty acids.C14-C22;MFr;Pt;Bld;Qn;;CHEM;1;Arachidonate (C20:4w6)+Linoleate (C18:2w6)/Fatty acids.C14-C22 in Blood;AA+Linoleate/Fatty acids.C14-C22 MFr Bld;;ACTIVE;2.65;2.65 +90916-8;Arachidonate/Fatty acids.C14-C22;MFr;Pt;Bld;Qn;;CHEM;1;Arachidonate (C20:4w6)/Fatty acids.C14-C22 in Blood;AA/Fatty acids.C14-C22 MFr Bld;;ACTIVE;2.65;2.65 +90917-6;Linoleate/Fatty acids.C14-C22;MFr;Pt;Bld;Qn;;CHEM;1;Linoleate (C18:2w6)/Fatty acids.C14-C22 in Blood;Linoleate/Fatty acids.C14-C22 MFr Bld;;ACTIVE;2.65;2.65 +90918-4;Fatty acid omega-3 & omega-6 panel;-;Pt;Bld;-;;PANEL.CHEM;1;Fatty acid omega-3 and omega-6 panel - Blood;FA omega-3 + omega-6 panel Bld;;ACTIVE;2.65;2.65 +90919-2;Coagulation factor VIII.recombinant.bound/von Willebrand factor Ag;RelRto;Pt;Plas;Qn;IA;COAG;1;Coagulation factor VIII.recombinant.bound/von Willebrand factor (vWf) Ag in Plasma by Immunoassay;Fact VIII.recomb.bound/vWF Ag Plas IA;;ACTIVE;2.65;2.68 +909-2;Ax Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Ax Ab [Presence] in Serum or Plasma from Donor;Ax Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +90920-0;Lysophosphatidylcholine(20:0);MCnc;Pt;Bld.dot;Qn;;CHEM;1;Lysophosphatidylcholine(20:0) [Mass/volume] in DBS;LysoPC(20:0) DBS-mCnc;;ACTIVE;2.65;2.65 +90921-8;Lysophosphatidylcholine(22:0);MCnc;Pt;Bld.dot;Qn;;CHEM;1;Lysophosphatidylcholine(22:0) [Mass/volume] in DBS;LysoPC(22:0) DBS-mCnc;;ACTIVE;2.65;2.65 +90922-6;Lysophosphatidylcholine(24:0);MCnc;Pt;Bld.dot;Qn;;CHEM;1;Lysophosphatidylcholine(24:0) [Mass/volume] in DBS;LysoPC(24:0) DBS-mCnc;;ACTIVE;2.65;2.65 +90923-4;Lysophosphatidylcholine(26:0);MCnc;Pt;Bld.dot;Qn;;CHEM;1;Lysophosphatidylcholine(26:0) [Mass/volume] in DBS;LysoPC(26:0) DBS-mCnc;;ACTIVE;2.65;2.65 +90924-2;BK virus DNA;LnCnc;Pt;Urine;Qn;Probe.amp.tar;MICRO;1;BK virus DNA [Log #/volume] (viral load) in Urine by NAA with probe detection;BKV DNA Ur NAA+probe-Log#;;ACTIVE;2.65;2.65 +90925-9;HBB gene full mutation analysis;Find;Pt;Amnio fld/CVS;Doc;Sequencing;MOLPATH;1;HBB gene full mutation analysis in Amniotic fluid or Chorionic villus sample by Sequencing;HBB gene Full Mut Anl Amn/CVS Seq;;ACTIVE;2.65;2.65 +90926-7;MET gene amplification;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH;1;MET gene amplification in Blood or Tissue by FISH;MET amp Bld/T FISH;;ACTIVE;2.65;2.65 +90927-5;RET gene rearrangements;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.REARRANGE;1;RET gene rearrangements in Blood or Tissue by FISH;RET gene rearrange Bld/T FISH;;ACTIVE;2.65;2.65 +9092-8;Sodium intake;SRat;24H;^Patient;Qn;;IO_IN_SALTS+CALS;2;Sodium intake 24 hour;Sodium intake 24h;;ACTIVE;1.0i;2.48 +90928-3;Physical findings.mandibular condyle;Type;Pt;Mandible;Nom;;DENTAL;2;Physical findings of Mandible condyle;Physical findings of Mandible condyle;;ACTIVE;2.65;2.65 +90929-1;Overjet teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Overjet teeth [#];Overjet teeth;;ACTIVE;2.65;2.65 +90930-9;Overbite teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Overbite teeth [#];Overbite teeth;;ACTIVE;2.65;2.65 +90931-7;Openbite teeth;Num;Pt;Teeth and gum;Qn;;DENTAL;2;Openbite teeth [#];Openbite teeth;;ACTIVE;2.65;2.65 +90932-5;Severe traumatic deviations impacting orthodontic condition;Type;Pt;^Patient;Nom;;DENTAL;2;Severe traumatic deviations impacting orthodontic condition;Severe traumatic deviations;;ACTIVE;2.65;2.65 +90933-3;PROMIS pediatric short form - cognitive function 7a - version 1.0;-;4W;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - cognitive function 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90934-1;PROMIS parent proxy short form - cognitive function 7a - version 1.0;-;4W;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - cognitive function 7a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90935-8;PROMIS parent proxy short form - cognitive function 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - cognitive function 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9093-6;Fluid balance;VRat;1H;^Patient;Qn;;IO_IN.SUMMARY;2;Fluid balance 1 hour;Fluid balance 1h;;ACTIVE;1.0i;2.48 +90936-6;PROMIS parent proxy short form - life satisfaction 4a - version 1.0;-;4W;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - life satisfaction 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90937-4;PROMIS parent proxy short form - life satisfaction 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - life satisfaction 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.66 +90938-2;PROMIS parent proxy short form - life satisfaction 8a - version 1.0;-;4W;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - life satisfaction 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90939-0;PROMIS parent proxy short form - life satisfaction 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - life satisfaction 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90940-8;PROMIS parent proxy short form - mobility 8a - version 2.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - mobility 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90941-6;PROMIS parent proxy short form - mobility 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - mobility 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90942-4;PROMIS parent proxy short form - pain interference 8a - version 2.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - pain interference 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90943-2;PROMIS parent proxy short form - pain interference 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - pain interference 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9094-4;Fluid balance;VRat;8H;^Patient;Qn;;IO_IN.SUMMARY;2;Fluid balance 8 hour;Fluid balance 8h;;ACTIVE;1.0i;2.48 +90944-0;PROMIS parent proxy short form - peer relationship 7a - version 2.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - peer relationship 7a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90945-7;PROMIS parent proxy short form - peer relationship 7a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - peer relationship 7a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90946-5;Date of laboratory phone call to provider to communicate test result;Date;Pt;^Patient;Qn;;ADMIN.PATIENT;2;Date of laboratory phone call to provider to communicate test result;Lab to provid teleph call date;;ACTIVE;2.65;2.66 +90947-3;Pathology case identifier;ID;Pt;^Patient;Nom;;PATH;1;Pathology case identifier [Identifier];Pathology case identifier;;ACTIVE;2.65;2.65 +90948-1;PROMIS pediatric short form - cognitive function 7a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - cognitive function 7a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90949-9;PROMIS pediatric short form - depressive symptoms 8a - version 2.0;-;7D;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - depressive symptoms 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +90950-7;PROMIS pediatric short form - depressive symptoms 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - depressive symptoms 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9095-1;Fluid balance;VRat;10H;^Patient;Qn;;IO_IN.SUMMARY;2;Fluid balance 10 hour;Fluid balance 10h;;ACTIVE;1.0i;2.48 +90951-5;PROMIS pediatric short form - life satisfaction 4a - version 1.0;-;4W;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - life satisfaction 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90952-3;PROMIS pediatric short form - life satisfaction 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - life satisfaction 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90953-1;PROMIS pediatric short form - life satisfaction 8a - version 1.0;-;4W;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - life satisfaction 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90954-9;PROMIS pediatric short form - life satisfaction 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - life satisfaction 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90955-6;PROMIS pediatric short form - mobility 8a - version 2.0;-;7D;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - mobility 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90956-4;PROMIS pediatric short form - mobility 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - mobility 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90957-2;PROMIS pediatric short form - pain interference 8a - version 2.0;-;7D;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - pain interference 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90958-0;PROMIS pediatric short form - pain interference 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - pain interference 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90959-8;PROMIS pediatric short form - peer relationships 8a - version 2.0;-;7D;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - peer relationships 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90960-6;PROMIS pediatric short form - peer relationships 8a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - peer relationships 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90961-4;PROMIS short form - applied cognition - general concerns 4a - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - applied cognition - general concerns 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90962-2;PROMIS short form - applied cognition - general concerns 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - applied cognition - general concerns 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90963-0;PROMIS short form - applied cognition - general concerns 6a - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - applied cognition - general concerns 6a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90964-8;PROMIS short form - applied cognition - general concerns 6a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - applied cognition - general concerns 6a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90965-5;PROMIS short form - applied cognition - general concerns 8a - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - applied cognition - general concerns 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90966-3;PROMIS short form - applied cognition - general concerns 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - applied cognition - general concerns 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90967-1;PROMIS short form - dyspnea functional limitations 10a - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - dyspnea functional limitations 10a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90968-9;PROMIS short form - dyspnea functional limitations 10a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - dyspnea functional limitations 10a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +9096-9;Fluid balance;VRat;12H;^Patient;Qn;;IO_IN.SUMMARY;2;Fluid balance 12 hour;Fluid balance 12h;;ACTIVE;1.0i;2.48 +90969-7;PROMIS short form - emotional distress - anger 5a - version 1.1;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - emotional distress - anger 5a - version 1.1;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90970-5;PROMIS short form - emotional distress - anger 5a - version 1.1 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - emotional distress - anger 5a - version 1.1 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90971-3;PROMIS short form - pain interference 4a - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - pain interference 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90972-1;PROMIS short form - pain interference 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - pain interference 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90973-9;PROMIS short form - pain interference 6a - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - pain interference 6a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90974-7;PROMIS short form - pain interference 6a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - pain interference 6a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.65;2.65 +90975-4;Clomethiazole;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Clomethiazole [Mass/volume] in Serum or Plasma;Clomethiazole SerPl-mCnc;;ACTIVE;2.65;2.65 +90976-2;Opipramol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Opipramol [Mass/volume] in Serum or Plasma;Opipramol SerPl-mCnc;;ACTIVE;2.65;2.65 +9097-7;Fluid balance;VRat;24H;^Patient;Qn;;IO_IN.SUMMARY;2;Fluid balance 24 hour;Fluid balance 24h;;ACTIVE;1.0i;2.48 +90977-0;Tianeptine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tianeptine [Mass/volume] in Serum or Plasma;Tianeptine SerPl-mCnc;;ACTIVE;2.65;2.65 +90978-8;Vilazodone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vilazodone [Mass/volume] in Serum or Plasma;Vilaz SerPl-mCnc;;ACTIVE;2.65;2.65 +90979-6;Vortioxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vortioxetine [Mass/volume] in Serum or Plasma;Vortioxetine SerPl-mCnc;;ACTIVE;2.65;2.65 +90980-4;Meropenem+Vaborbactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Meropenem+Vaborbactam [Susceptibility] by Gradient strip;Mero+Vab Islt Grad strip;;ACTIVE;2.65;2.65 +90981-2;Pressure Injury Scale for Healing Tool 3.0 total score;Score;Pt;^Patient;Qn;PUSH;SURVEY.GNHLTH;4;Pressure Injury Scale for Healing Tool 3.0 total score [PUSH];;Copyright © 1998 National Pressure Ulcer Advisory Panel Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to the National Pressure Ulcer Advisory Panel remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.65;2.73 +90982-0;Pressure Injury Scale for Healing Tool 3.0;-;Pt;^Patient;-;PUSH;PANEL.SURVEY.GNHLTH;4;Pressure Injury Scale for Healing Tool 3.0 [PUSH];;Copyright © 1998 National Pressure Ulcer Advisory Panel Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to the National Pressure Ulcer Advisory Panel remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.65;2.73 +90983-8;HEDIS 2019-2020 Value Set - PSA Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - PSA Tests;HEDIS 2019-20 PSA Tests;;DISCOURAGED;2.65;2.69 +90984-6;HEDIS 2019-2020 Value Set - PSA Test Exclusion;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - PSA Test Exclusion;HEDIS 2019-20 PSA Test Excl;;DISCOURAGED;2.65;2.69 +9098-5;Class;Type;Pt;IO tube;Nom;*;IO.TUBE;2;Type of IO tube;IO tube Class;;ACTIVE;1.0i;2.29 +90985-3;HEDIS 2019-2020 Value Set - Pregnancy Test Exclusion;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - Pregnancy Test Exclusion;HEDIS 2019-20 Preg Test Excl;;DISCOURAGED;2.65;2.69 +90986-1;HEDIS 2019 Value Set - Serum Potassium;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019 Value Set - Serum Potassium;HEDIS 2019 Value Set - Ser K;;DISCOURAGED;2.65;2.67 +90987-9;HEDIS 2019-2020 Value Set - Cholesterol Tests Other Than LDL;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - Cholesterol Tests Other Than LDL;HEDIS 2019-20 Chol Tests not LDL;;DISCOURAGED;2.65;2.69 +90988-7;HEDIS 2019-2020 Value Set - HPV Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - HPV Tests;HEDIS 2019-20 HPV Tests;;DISCOURAGED;2.65;2.69 +90989-5;HEDIS 2019 Value Set - Urine Protein Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019 Value Set - Urine Protein Tests;HEDIS 2019 Urine Prot Tests;;DISCOURAGED;2.65;2.67 +90990-3;Protein.monoclonal isotype;Prid;Pt;Ser/Plas;Nom;MS.MALDI-TOF;CHEM;1;Protein.monoclonal isotype [Identifier] in Serum or Plasma by MS.MALDI-TOF;M Protein isotype SerPl MS.MALDI-TOF;;ACTIVE;2.65;2.65 +90991-1;Protein electrophoresis & monoclonal protein isotype panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Protein electrophoresis and M protein isotype panel - Serum or Plasma;Prot Elph + M isotype Pnl SerPl;;ACTIVE;2.65;2.73 +90992-9;Monoclonal gammopathy panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Monoclonal gammopathy panel - Serum or Plasma;Monoclonal gammopathy Pnl SerPl;;ACTIVE;2.65;2.65 +9099-3;Method;Type;Pt;Rate control;Nom;*;IO.TUBE;2;Rate control method;Rate control method;;ACTIVE;1.0i;2.29 +90993-7;Iothalamate clearance panel;-;Pt;Urine+Ser/Plas;-;;PANEL.CHEM;1;Iothalamate clearance panel - Urine and Serum or Plasma;Iothal clear Pnl Ur+SerPl;;ACTIVE;2.65;2.65 +90994-5;Iothalamate clearance;VRat;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Iothalamate renal clearance;Iothalamate renal clearance;;ACTIVE;2.65;2.65 +90995-2;Iothalamate clearance/Body surface area;ArVRat;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Iothalamate renal clearance/Body surface area;Iothalamate renal clearance/BSA;;ACTIVE;2.65;2.65 +90996-0;HEDIS 2019-2020 Value Set - Glucose Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - Glucose Tests;HEDIS 2019-20 Glucose Tests;;DISCOURAGED;2.65;2.69 +90997-8;HEDIS 2019-2020 Value Set - Group A Strep Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2019-2020 Value Set - Group A Strep Tests;HEDIS 2019-20 Grp A Strep;;DISCOURAGED;2.65;2.69 +90998-6;Analysis of information sources;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Analysis of information sources;;;ACTIVE;2.65;2.68 +90999-4;Analysis of emergency department visits;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Analysis of emergency department visits;;;ACTIVE;2.65;2.68 +9-1;Amdinocillin;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Amdinocillin [Susceptibility] by Disk diffusion (KB);Amdinocillin Islt KB;;ACTIVE;1.0;2.19 +910-0;Ax Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Ax Ab [Presence] in Serum or Plasma;Ax Ab SerPl Ql;;ACTIVE;1.0;2.56 +91000-0;Cases;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Event-associated cases [#] during reporting period;Event-associated cases # in RptPeriod;;ACTIVE;2.65;2.69 +91001-8;Myelin associated glycoprotein Ab.IgM;Titr;Pt;CSF;Qn;IA;SERO;1;Myelin associated glycoprotein IgM Ab [Titer] in Cerebral spinal fluid by Immunoassay;MAG IgM Titr CSF IA;;ACTIVE;2.65;2.65 +91002-6;Job position;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel Job position;Personnel Job position;;ACTIVE;2.65;2.68 +91003-4;Personnel contact information panel;-;Pt;Personnel;-;;PANEL.ADMIN;2;Personnel contact information panel;Personnel contact info Pnl;;ACTIVE;2.65;2.68 +91004-2;Email address;EmailAddr;Pt;Personnel;Nom;;ADMIN;2;Deprecated Email address Personnel;Deprecated Email address Personnel;;DEPRECATED;2.65;2.66 +91005-9;Organization assigned to task;ID;Pt;Organization;Nom;;ADMIN;2;Organization assigned to task;Org assigned to task;;ACTIVE;2.65;2.68 +91006-7;New cases per D;NRat;RptPeriod^mean;^Event;Qn;;PUBLICHEALTH;2;New cases per day Reporting Period mean;New cases per D RptPeriod Mean nRate;;ACTIVE;2.65;2.68 +91007-5;Total cases;Num;Pt;^Event;Qn;;PUBLICHEALTH;2;Total event-associated cases [#];Total event-associated cases #;;ACTIVE;2.65;2.69 +91008-3;Date and time of deaths assessment;TmStp;Pt;^Event;Qn;;PUBLICHEALTH;2;Date and time of deaths assessment;D/T of deaths assessment;;ACTIVE;2.65;2.69 +9100-9;Class;Type;Pt;Rate control device;Nom;;DEVICES;2;Type of Rate control device;Rate Control Device Class;;ACTIVE;1.0i;2.27 +91009-1;Deaths;Num;Pt;^Event;Qn;;PUBLICHEALTH;2;Total event-associated deaths [#];Total event-associated deaths #;;ACTIVE;2.65;2.69 +91010-9;Epidemiological investigation report;Find;Pt;^Event;Doc;;DOC.PUBLICHEALTH;2;Epidemiological investigation report Document;Epidemiological investigation report Doc;;ACTIVE;2.65;2.68 +91011-7;Etiology of a public health emergency;Type;Pt;^Event;Nom;;PUBLICHEALTH;2;Etiology of a public health emergency;Etiology of a PH emergency;;ACTIVE;2.65;2.68 +91012-5;Symptoms related to incident or outbreak;Find;Pt;^Population;Nom;;PUBLICHEALTH;2;Population Symptoms related to incident or outbreak;Symptoms incident or outbreak Pop;;ACTIVE;2.65;2.68 +91013-3;Impact level;Find;Pt;^Event;Ord;;PUBLICHEALTH;2;Event impact level;Event impact level;;ACTIVE;2.65;2.68 +91014-1;Status of water supply systems;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Status of water supply systems Narrative;Status of water supply systems;;ACTIVE;2.65;2.68 +91015-8;Status of waste water systems;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Status of waste water systems Narrative;Status of waste water systems;;ACTIVE;2.65;2.68 +91016-6;Regional hospitals closed due to event or incident;Num;Pt;^Event;Qn;;PUBLICHEALTH;2;Regional hospitals closed due to event or incident [#];Reg hosp closed;;ACTIVE;2.65;2.68 +9101-7;Class;Type;Pt;Fluid intake substance;Nom;;IO_IN.ATOM;2;Type of Fluid intake substance;Fluid intake substance Class;;ACTIVE;1.0i;2.27 +91017-4;Regional hospitals closed due to event or incident/Regional hospitals.total;NFr;Pt;^Event;Qn;;PUBLICHEALTH;2;Regional hospitals closed due to event or incident/Total regional hospitals;Reg hosp closed/Reg hosp.total NFr;;ACTIVE;2.65;2.68 +91018-2;Status of regional dialysis centers;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Status of regional dialysis centers;;;ACTIVE;2.65;2.68 +91019-0;Status of regional human shelters;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Status of regional human shelters;;;ACTIVE;2.65;2.68 +91020-8;Status of critical regional infrastructure;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Status of critical regional infrastructure;;;ACTIVE;2.65;2.68 +91021-6;Emergency department visits;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Emergency department visits [#] Reporting Period;ED visits RptPeriod;;ACTIVE;2.65;2.68 +91022-4;Date and time of risk assessment;TmStp;Pt;^Event;Qn;;PUBLICHEALTH;2;Date and time of risk assessment;D/T of risk assessment;;ACTIVE;2.65;2.68 +91023-2;Reason for risk assessment;Type;Pt;^Event;Nom;;PUBLICHEALTH;2;Reason for risk assessment;Reason for risk assessment;;ACTIVE;2.65;2.68 +91024-0;Risk assessment report;Find;Pt;^Event;Doc;Public health;DOC.PUBLICHEALTH;2;Risk assessment report Document Public health;Risk assessment rprt Doc Public health;;ACTIVE;2.65;2.68 +9102-5;Fluid intake.total;Vol;Pt;^Patient;Qn;Estimated;IO_IN.ATOM;2;Fluid intake total Estimated;Fluid intake total Est;;ACTIVE;1.0i;2.48 +91025-7;Lead department or agency name;ID;Pt;Organization;Nom;;SURVEY.CDC;4;Lead department or agency name Organization;;;ACTIVE;2.66;2.68 +91026-5;Inter-agency communication document;Find;Pt;^Event;Doc;;DOC.PUBLICHEALTH;2;Event Inter-agency communication documentation;Event Inter-agency communication doc;;ACTIVE;2.65;2.68 +91027-3;Buprenorphine-3-glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Buprenorphine-3-glucuronide [Presence] in Urine by Screen method;B3G Ur Ql Scn;;ACTIVE;2.65;2.65 +91028-1;Barbiturates;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Body fluid by Screen method;Barbiturates Fld Ql Scn;;ACTIVE;2.65;2.65 +91029-9;Cocaine+Benzoylecgonine;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Cocaine+Benzoylecgonine [Presence] in Meconium by Screen method;Cocaine+BZE Mec Ql Scn;;ACTIVE;2.65;2.67 +91030-7;Methadone+Metabolite;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Methadone+Metabolite [Presence] in Meconium by Screen method;Methadone+metab Mec Ql Scn;;ACTIVE;2.65;2.67 +91031-5;Methamphetamine+Methylenedioxymethamphetamine;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;Methamphetamine+Methylenedioxymethamphetamine [Presence] in Meconium by Screen method;Methamphet+MDMA Mec Ql Scn;;ACTIVE;2.65;2.67 +91032-3;oxyCODONE+Oxymorphone;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Meconium by Screen method;oxyCODONE+oxyMORphone Mec Ql Scn;;ACTIVE;2.65;2.67 +9103-3;Fluid intake.total;Vol;Pt;^Patient;Qn;Measured;IO_IN.ATOM;2;Fluid intake total Measured;Fluid intake total Measured;;ACTIVE;1.0i;2.48 +91033-1;Methadone+Metabolite;PrThr;Pt;Ser/Plas/Bld;Ord;Screen;DRUG/TOX;1;Methadone+Metabolite [Presence] in Serum, Plasma or Blood by Screen method;Methadone+metab SerPlBld Ql Scn;;ACTIVE;2.65;2.65 +91034-9;Methamphetamine+Methylenedioxymethamphetamine;PrThr;Pt;Ser/Plas/Bld;Ord;Screen;DRUG/TOX;1;Methamphetamine+Methylenedioxymethamphetamine [Presence] in Serum, Plasma or Blood by Screen method;Methamphet+MDMA SerPlBld Ql Scn;;ACTIVE;2.65;2.65 +91035-6;Phencyclidine;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Tissue by Screen method;PCP Tiss Ql Scn;;ACTIVE;2.65;2.65 +91036-4;Benzodiazepines;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Benzodiazepines [Presence] in Tissue by Screen method;Benzodiaz Tiss Ql Scn;;ACTIVE;2.65;2.65 +91037-2;Methamphetamine+Methylenedioxymethamphetamine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Methamphetamine+Methylenedioxymethamphetamine [Presence] in Urine by Screen method;Methamphet+MDMA Ur Ql Scn;;ACTIVE;2.65;2.65 +91038-0;Cocaine+Benzoylecgonine;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Cocaine+Benzoylecgonine [Presence] in Body fluid by Screen method;Cocaine+BZE Fld Ql Scn;;ACTIVE;2.65;2.67 +91039-8;Methadone+Metabolite;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Methadone+Metabolite [Presence] in Body fluid by Screen method;Methadone+metab Fld Ql Scn;;ACTIVE;2.65;2.67 +91040-6;Phencyclidine;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Body fluid by Screen method;PCP Fld Ql Scn;;ACTIVE;2.65;2.65 +9104-1;Fluid intake.total;VRat;1H;^Patient;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake total 1 hour;Fluid intake total 1h;;ACTIVE;1.0i;2.48 +91041-4;Cannabinoids;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Body fluid by Screen method;Cannabinoids Fld Ql Scn;;ACTIVE;2.65;2.67 +91042-2;Methamphetamine+Methylenedioxymethamphetamine;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Methamphetamine+Methylenedioxymethamphetamine [Presence] in Body fluid by Screen method;Methamphet+MDMA Fld Ql Scn;;ACTIVE;2.65;2.65 +91043-0;Opiates;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Body fluid by Screen method;Opiates Fld Ql Scn;;ACTIVE;2.65;2.65 +91044-8;oxyCODONE+Oxymorphone;PrThr;Pt;Body fld;Ord;Screen;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Body fluid by Screen method;oxyCODONE+oxyMORphone Fld Ql Scn;;ACTIVE;2.65;2.65 +91045-5;Methamphetamine+Methylenedioxymethamphetamine;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Methamphetamine+Methylenedioxymethamphetamine [Presence] in Hair by Screen method;Methamphet+MDMA Hair Ql Scn;;ACTIVE;2.65;2.65 +91046-3;Methadone+Metabolite;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Methadone+Metabolite [Presence] in Hair by Screen method;Methadone+metab Hair Ql Scn;;ACTIVE;2.65;2.65 +91047-1;Barbiturates;PrThr;Pt;Hair;Ord;Screen;DRUG/TOX;1;Barbiturates [Presence] in Hair by Screen method;Barbiturates Hair Ql Scn;;ACTIVE;2.65;2.65 +91048-9;Cannabinoids;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Cannabinoids [Presence] in Tissue by Screen method;Cannabinoids Tiss Ql Scn;;ACTIVE;2.65;2.65 +91049-7;Cocaine+Benzoylecgonine;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Cocaine+Benzoylecgonine [Presence] in Tissue by Screen method;Cocaine+BZE Tiss Ql Scn;;ACTIVE;2.65;2.65 +91050-5;Methadone+Metabolite;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Methadone+Metabolite [Presence] in Tissue by Screen method;Methadone+metab Tiss Ql Scn;;ACTIVE;2.65;2.65 +91051-3;Methamphetamine+Methylenedioxymethamphetamine;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Methamphetamine+Methylenedioxymethamphetamine [Presence] in Tissue by Screen method;Methamphet+MDMA Tiss Ql Scn;;ACTIVE;2.65;2.65 +91052-1;Opiates;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Opiates [Presence] in Tissue by Screen method;Opiates Tiss Ql Scn;;ACTIVE;2.65;2.65 +91053-9;oxyCODONE+Oxymorphone;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;oxyCODONE+oxyMORphone [Presence] in Tissue by Screen method;oxyCODONE+oxyMORphone Tiss Ql Scn;;ACTIVE;2.65;2.65 +91054-7;Drugs of abuse panel;-;Pt;Body fld;-;;PANEL.DRUG/TOX;1;Drugs of abuse panel - Body fluid;Drugs of abuse Pnl Fld;;ACTIVE;2.65;2.65 +91055-4;Drugs of abuse panel;-;Pt;Tiss;-;;PANEL.DRUG/TOX;1;Drugs of abuse panel - Tissue;Drugs of abuse Pnl Tiss;;ACTIVE;2.65;2.65 +91056-2;Drugs of abuse panel;-;Pt;Hair;-;;PANEL.DRUG/TOX;1;Drugs of abuse panel - Hair;Drugs of abuse Pnl Hair;;ACTIVE;2.65;2.65 +91057-0;Tropheryma whipplei DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Stool by NAA with probe detection;T whipplei DNA Stl Ql NAA+probe;;ACTIVE;2.65;2.7 +9105-8;Fluid intake.total;VRat;8H;^Patient;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake total 8 hour;Fluid intake total 8h;;ACTIVE;1.0i;2.48 +91058-8;Kingella kingae DNA;PrThr;Pt;Synv fld;Ord;Probe.amp.tar;MICRO;1;Kingella kingae DNA [Presence] in Synovial fluid by NAA with probe detection;K kingae DNA Snv Ql NAA+probe;;ACTIVE;2.65;2.65 +91059-6;Kingella kingae DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Kingella kingae DNA [Presence] in Blood by NAA with probe detection;K kingae DNA Bld Ql NAA+probe;;ACTIVE;2.65;2.65 +91060-4;Helicobacter pylori DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Helicobacter pylori DNA [Presence] in Tissue by NAA with probe detection;H pylori DNA Tiss Ql NAA+probe;;ACTIVE;2.65;2.65 +91061-2;Helicobacter pylori DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Helicobacter pylori DNA [Presence] in Stool by NAA with probe detection;H pylori DNA Stl Ql NAA+probe;;ACTIVE;2.65;2.65 +91062-0;Bacteria identified;Prid;Pt;Platelets^BPU;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Platelets from Blood product unit by Anaerobe culture;Bacteria Plts BPU Anaerobe Cult;;ACTIVE;2.65;2.65 +91063-8;Bacteria identified;Prid;Pt;Platelets^BPU;Nom;Aerobic culture;MICRO;1;Bacteria identified in Platelets from Blood product unit by Aerobe culture;Bacteria Plts BPU Aerobe Cult;;ACTIVE;2.65;2.65 +91064-6;Dengue virus NS1 Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Dengue virus NS1 Ag [Presence] in Serum or Plasma by Immunoassay;DENV NS1 Ag SerPl Ql IA;;ACTIVE;2.65;2.65 +91065-3;14-3-3 protein;PrThr;Pt;Tiss;Ord;Probe.amp.tar;SERO;1;14-3-3 protein [Presence] in Tissue by NAA with probe detection;14-3-3 protein Tiss Ql NAA+probe;;ACTIVE;2.65;2.65 +9106-6;Fluid intake.total;VRat;10H;^Patient;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake total 10 hour;Fluid intake total 10h;;ACTIVE;1.0i;2.48 +91066-1;Enterovirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;EV RNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +91067-9;Enterovirus RNA;PrThr;Pt;Cornea/Conjunctiva;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Cornea or Conjunctiva by NAA with probe detection;EV RNA Corn/Cnjt Ql NAA+probe;;ACTIVE;2.65;2.65 +91068-7;Enterovirus RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Stool by NAA with probe detection;EV RNA Stl Ql NAA+probe;;ACTIVE;2.65;2.65 +91069-5;Enterovirus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Urine by NAA with probe detection;EV RNA Ur Ql NAA+probe;;ACTIVE;2.65;2.65 +91070-3;Hepatitis A virus RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Hepatitis A virus RNA [Presence] in Stool by NAA with probe detection;HAV RNA Stl Ql NAA+probe;;ACTIVE;2.65;2.65 +91071-1;Hepatitis E virus RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Hepatitis E virus RNA [Presence] in Stool by NAA with probe detection;HEV RNA Stl Ql NAA+probe;;ACTIVE;2.65;2.72 +91072-9;Influenza virus A subtype;Prid;Pt;Respiratory.lower;Nom;Probe.amp.tar;MICRO;1;Influenza virus A subtype [Identifier] in Lower respiratory specimen by NAA with probe detection;FLUAV Subtyp Lower resp NAA+probe;;ACTIVE;2.65;2.65 +91073-7;Human papilloma virus genotype;Prid;Pt;Tiss;Nom;Probe.amp.tar;MICRO;1;Human papilloma virus genotype [Identifier] in Tissue by NAA with probe detection;HPV Gentyp Tiss NAA+probe;;ACTIVE;2.65;2.72 +9107-4;Fluid intake.total;VRat;12H;^Patient;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake total 12 hour;Fluid intake total 12h;;ACTIVE;1.0i;2.48 +91074-5;Phlebovirus sp RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Phlebovirus sp RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Phlebovirus sp RNA CSF Ql NAA+probe;;ACTIVE;2.65;2.65 +91075-2;Rabies virus Ag;PrThr;Pt;Saliva;Ord;IA;MICRO;1;Rabies virus Ag [Presence] in Saliva (oral fluid) by Immunoassay;RABV Ag Sal Ql IA;;ACTIVE;2.65;2.65 +91076-0;Rabies virus Ag;PrThr;Pt;Tiss;Ord;IA;MICRO;1;Rabies virus Ag [Presence] in Tissue by Immunoassay;RABV Ag Tiss Ql IA;;ACTIVE;2.65;2.65 +91077-8;Measles virus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Measles virus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;MeV RNA Upper resp Ql NAA+probe;;ACTIVE;2.65;2.68 +91078-6;Zika virus RNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Blood by NAA with probe detection;ZIKV RNA Bld Ql NAA+probe;;ACTIVE;2.65;2.65 +91079-4;Zika virus RNA;PrThr;Pt;Placenta;Ord;Probe.amp.tar;MICRO;1;Zika virus RNA [Presence] in Placenta by NAA with probe detection;ZIKV RNA Placenta Ql NAA+probe;;ACTIVE;2.65;2.65 +91080-2;Zika virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Zika virus IgG Ab [Presence] in Serum or Plasma by Immunoassay;ZIKV IgG SerPl Ql IA;;ACTIVE;2.65;2.65 +91081-0;Candida sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Candida sp DNA [Presence] in Specimen by NAA with probe detection;Candida DNA Spec Ql NAA+probe;;ACTIVE;2.65;2.69 +9108-2;Fluid intake.total;VRat;24H;^Patient;Qn;;IO_IN.TIMED.MOLEC;2;Fluid intake total 24 hour;Fluid intake total 24h;;ACTIVE;1.0i;2.48 +91082-8;Fungal 18S rRNA gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Fungal 18s rRNA gene [Presence] in Specimen by NAA with probe detection;Fungal 18s rRNA gene Spec Ql NAA+probe;;ACTIVE;2.65;2.69 +91083-6;Fungal 18S rRNA gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Fungal 18s rRNA gene [Presence] in Isolate by NAA with probe detection;Fungal 18s rRNA gene Islt Ql NAA+probe;;ACTIVE;2.65;2.65 +91084-4;Fungal 18S rRNA gene;PrThr;Pt;Hair/Nail/Skin;Ord;Probe.amp.tar;MICRO;1;Fungal 18s rRNA gene [Presence] in Dermatologic specimen by NAA with probe detection;Fungal 18s rRNA gene Derm Ql NAA+probe;;ACTIVE;2.65;2.65 +91085-1;Fungal 18S rRNA gene;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Fungal 18s rRNA gene [Presence] in Lower respiratory specimen by NAA with probe detection;Fungal 18s rRNA gene L. Resp Ql NAA+probe;;ACTIVE;2.65;2.65 +91086-9;Fungal BT2 gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Fungal BT2 gene [Presence] in Specimen by NAA with probe detection;Fungal BT2 gene Spec Ql NAA+probe;;ACTIVE;2.65;2.69 +91087-7;Fungal BT2 gene;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Fungal BT2 gene [Presence] in Isolate by NAA with probe detection;Fungal BT2 gene Islt Ql NAA+probe;;ACTIVE;2.65;2.65 +91088-5;Fungal BT2 gene;PrThr;Pt;Hair/Nail/Skin;Ord;Probe.amp.tar;MICRO;1;Fungal BT2 gene [Presence] in Dermatologic specimen by NAA with probe detection;Fungal BT2 gene Derm spec Ql NAA+probe;;ACTIVE;2.65;2.65 +91089-3;Fungal BT2 gene;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Fungal BT2 gene [Presence] in Lower respiratory specimen by NAA with probe detection;Fungal BT2 gene Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +9109-0;Blood loss.total intraoperative;Vol;Procedure dur;^Patient;Qn;Cell saver;IO_OUT.MOLEC;2;Blood loss.total intraoperative [Volume] Cell saver;Blood loss.total intraop Vol Cell Saver;;ACTIVE;1.0i;2.48 +91090-1;Fungal ITS region;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Fungal ITS region [Presence] in Specimen by NAA with probe detection;Fungal ITS region Spec Ql NAA+probe;;ACTIVE;2.65;2.69 +91091-9;Fungal ITS region;PrThr;Pt;Isolate;Ord;Probe.amp.tar;MICRO;1;Fungal ITS region [Presence] in Isolate by NAA with probe detection;Fungal ITS region Islt Ql NAA+probe;;ACTIVE;2.65;2.65 +91092-7;Fungal ITS region;PrThr;Pt;Hair/Nail/Skin;Ord;Probe.amp.tar;MICRO;1;Fungal ITS region [Presence] in Dermatologic specimen by NAA with probe detection;Fungal ITS region Derm spec Ql NAA+probe;;TRIAL;2.65;2.65 +91093-5;Fungal ITS region;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Fungal ITS region [Presence] in Lower respiratory specimen by NAA with probe detection;Fungal ITS region Low Resp Ql NAA+probe;;ACTIVE;2.65;2.65 +91094-3;Cause of deaths;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Cause of deaths Narrative;Cause of deaths;;ACTIVE;2.65;2.69 +91095-0;Analysis of pharmaceutical needs in a region;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Analysis of pharmaceutical needs in a region Narrative;Analysis pharmaceut needs region;;ACTIVE;2.65;2.68 +91096-8;Countermeasure description;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Countermeasure description Narrative;Countermeasure description;;ACTIVE;2.65;2.68 +91097-6;Countermeasure implementation progress;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Countermeasure implementation progress;Countermeasure implementation;;ACTIVE;2.65;2.66 +91098-4;Countermeasure name;ID;Pt;^Event;Nom;;PUBLICHEALTH;2;Countermeasure name;Countermeasure name;;ACTIVE;2.65;2.66 +91099-2;People tested;Num;Pt;^Population;Qn;;PUBLICHEALTH;2;People tested [#] Population;People tested Pop;;ACTIVE;2.65;2.68 +91100-8;People with confirmed positive lab results;Num;Pt;^Population;Qn;;PUBLICHEALTH;2;People with confirmed positive lab results [#] Population;Confirmed positive lab results Pop;;ACTIVE;2.65;2.68 +91101-6;People with preliminary positive lab results;Num;Pt;^Population;Qn;;PUBLICHEALTH;2;People with preliminary positive lab results [#] Population;Preliminary positive lab results Pop;;ACTIVE;2.65;2.68 +91102-4;People with confirmed negative lab results;Num;Pt;^Population;Qn;;PUBLICHEALTH;2;People with confirmed negative lab results [#] Population;Confirmed negative lab results Pop;;ACTIVE;2.65;2.68 +91103-2;Date next report due;TmStp;Pt;Report;Qn;;DOC.MISC;2;Date next report due;Date next report due;;ACTIVE;2.65;2.66 +91104-0;Coagulation surface induced.factor sensitive with 1:1 Pooled Normal Plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor sensitive with 1:1 Pooled Normal Plasma in Platelet poor plasma by Coagulation assay;Mixing aPTT PPP;;ACTIVE;2.65;2.65 +91105-7;Cholesterol.in LDL 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 1 [Mass/volume] in Serum or Plasma;LDL1c SerPl-mCnc;;ACTIVE;2.65;2.73 +91106-5;Cholesterol.in LDL 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 2 [Mass/volume] in Serum or Plasma;LDL2c SerPl-mCnc;;ACTIVE;2.65;2.73 +91107-3;Cholesterol.in LDL 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 3 [Mass/volume] in Serum or Plasma;LDL3c SerPl-mCnc;;ACTIVE;2.65;2.73 +9110-8;Blood loss.total intraoperative;Vol;Procedure dur;^Patient;Qn;Estimated;IO_OUT.MOLEC;2;Blood loss.total intraoperative [Volume] Estimated;Blood loss.total intraop Vol Est;;ACTIVE;1.0i;2.48 +91108-1;Cholesterol.in LDL 4;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 4 [Mass/volume] in Serum or Plasma;LDL4c SerPl-mCnc;;ACTIVE;2.65;2.73 +91109-9;Cholesterol.in LDL 5;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 5 [Mass/volume] in Serum or Plasma;LDL5c SerPl-mCnc;;ACTIVE;2.65;2.73 +91110-7;Cholesterol.in LDL 6;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 6 [Mass/volume] in Serum or Plasma;LDL6c SerPl-mCnc;;ACTIVE;2.65;2.73 +91111-5;Cholesterol.in LDL 7;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 7 [Mass/volume] in Serum or Plasma;LDL7c SerPl-mCnc;;ACTIVE;2.65;2.73 +91112-3;Cholesterol.in LDL 1;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 1 [Moles/volume] in Serum or Plasma;LDL1c SerPl-sCnc;;ACTIVE;2.65;2.73 +91113-1;Cholesterol.in LDL 2;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 2 [Moles/volume] in Serum or Plasma;LDL2c SerPl-sCnc;;ACTIVE;2.65;2.73 +91114-9;Cholesterol.in LDL 3;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 3 [Moles/volume] in Serum or Plasma;LDL3c SerPl-sCnc;;ACTIVE;2.65;2.65 +91115-6;Cholesterol.in LDL 4;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 4 [Moles/volume] in Serum or Plasma;LDL4c SerPl-sCnc;;ACTIVE;2.65;2.65 +9111-6;Cerebral ventricle drain site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Cerebral ventricle drain site;Cerebral ventricle drain site;;ACTIVE;1.0i;2.27 +91116-4;Cholesterol.in LDL 5;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 5 [Moles/volume] in Serum or Plasma;LDL5c SerPl-sCnc;;ACTIVE;2.65;2.65 +91117-2;Cholesterol.in LDL 6;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 6 [Moles/volume] in Serum or Plasma;LDL6c SerPl-sCnc;;ACTIVE;2.65;2.65 +91118-0;Cholesterol.in LDL 7;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in LDL 7 [Moles/volume] in Serum or Plasma;LDL7c SerPl-sCnc;;ACTIVE;2.65;2.65 +91119-8;Coagulation surface induced.factor substitution^immediately after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:1 addition of normal plasma;aPTT imm 1:1 NP PPP;;ACTIVE;2.65;2.65 +91120-6;Antithrombin;RelCCnc;Pt;PPP;Qn;Chromo.no addition of heparin;COAG;1;Antithrombin in Platelet poor plasma by Chromo.no addition of heparin;AT III PPP Chromo.no added heparin;;ACTIVE;2.65;2.65 +91121-4;Maltose binding protein Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Maltose binding protein IgE Ab RAST class [Presence] in Serum;Maltose BP IgE RAST Ql;;ACTIVE;2.65;2.65 +91122-2;Maltose binding protein Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Maltose binding protein IgE Ab [Units/volume] in Serum;Maltose BP IgE Qn;;ACTIVE;2.65;2.65 +91123-0;Apium graveolens recombinant (rApi g) 1 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Celery recombinant (rApi g) 1 IgE Ab RAST class [Presence] in Serum;Celery (rApi g) 1 IgE RAST Ql;;ACTIVE;2.65;2.65 +9112-4;Chest tube site;Type;Pt;*^Patient;Nom;;IO.TUBE;2;Chest tube site Type;Chest tube site type;;ACTIVE;1.0i;2.4 +91124-8;Platelet function with adenosine diphosphate induction panel;-;-;Bld;-;Thromboelastography.resonance;PANEL.COAG;1;Platelet function with adenosine diphosphate induction panel - Blood by Resonance TEG;Platelet func ADP-ind Pnl Bld Res TEG;;ACTIVE;2.65;2.65 +91125-5;Maximum clot strength amplitude.kaolin induced^after addition of heparinase;Len;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Maximum amplitude kaolin induced [Length] in Blood by Resonance TEG --after addition of heparinase;MA kaolin P Hpase Bld Res TEG;;ACTIVE;2.65;2.69 +91126-3;Maximum clot strength amplitude.activator F induced;Len;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Maximum amplitude activator F induced [Length] in Blood by Resonance TEG;MA ActF Bld Res TEG;;ACTIVE;2.65;2.65 +91127-1;Maximum clot strength amplitude.adenosine diphosphate induced;Len;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Maximum amplitude ADP induced [Length] in Blood by Resonance TEG;MA ADP Bld Res TEG;;ACTIVE;2.65;2.65 +91128-9;Clot strength.platelet adenosine diphosphate receptor inhibited;LenFr;Pt;Bld;Qn;Calculated;COAG;1;Clot strength ADP receptor inhibited [Length fraction] in Blood by calculation;Clot strength ADP-R inhib LenFr Bld Calc;;ACTIVE;2.65;2.7 +91129-7;Clot strength.adenosine diphosphate induced;LenFr;Pt;Bld;Qn;Calculated;COAG;1;Clot strength ADP induced [Length fraction] in Blood by calculation;Clot strength ADP-ind LenFr Bld Res TEG;;ACTIVE;2.65;2.7 +91130-5;Hantavirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Hantavirus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;Hantavirus RNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +91131-3;Rhinovirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Rhinovirus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;Rhinovirus RNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +9113-2;Fluid output.biliary drain;Vol;Pt;Biliary tract;Qn;;IO_OUT.MOLEC;2;Fluid output biliary drain;Fluid output bile drain;;ACTIVE;1.0i;2.54 +91132-1;Measles virus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Measles virus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;MeV RNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +91133-9;Respiratory syncytial virus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;RSV RNA Lower resp Ql NAA+probe;;ACTIVE;2.65;2.65 +91134-7;Sexually transmitted pathogens panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Sexually transmitted pathogens panel - Specimen by NAA with probe detection;STI Pnl Spec NAA+probe;;ACTIVE;2.65;2.73 +91135-4;Acanthocytes;PrThr;Pt;Urine sed;Ord;Microscopy.light;UA;1;Acanthocytes [Presence] in Urine sediment by Light microscopy;Acanthocytes UrnS Ql Micro;;ACTIVE;2.65;2.65 +91136-2;Lipoprotein metabolism panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Lipoprotein metabolism panel - Serum or Plasma;Lipoprotein metabolism Pnl SerPl;;ACTIVE;2.65;2.65 +91137-0;ITPA gene.g.9330C>A;Type;Pt;Ser/Plas;Nom;Molgen;MOLPATH.PHARMG;1;ITPA gene g.9330C>A [Type] in Serum or Plasma by Molecular genetics method;ITPA g.9330C>A SerPl;;ACTIVE;2.65;2.65 +91138-8;ITPA gene.g.9381A>C;Type;Pt;Ser/Plas;Nom;Molgen;MOLPATH.PHARMG;1;ITPA gene g.9381A>C [Type] in Serum or Plasma by Molecular genetics method;ITPA g.9381A>C SerPl;;ACTIVE;2.65;2.65 +91139-6;Thiopurine methyltransferase activity panel;-;Pt;RBC;-;;PANEL.CHEM;1;Thiopurine methyltransferase activity panel - Red Blood Cells;TPMT activity panel RBC;;ACTIVE;2.65;2.65 +9114-0;Fluid output.biliary drain;VRat;1H;Biliary tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output biliary drain 1 hour;Fluid output bile drain 1h;;ACTIVE;1.0i;2.48 +91140-4;Brucella sp Ab.IgG & IgM panel;-;Pt;Ser;Ord;;PANEL.MICRO;1;Brucella sp IgG and IgM panel - Serum Qualitative;Brucella sp IgG+IgM Ser Ql;;ACTIVE;2.65;2.65 +91141-2;Thiopurine methyltransferase;CCnc;Pt;RBC;Qn;Production of 6-Methylmercaptopurine;CHEM;1;TPMT activity in RBC by production of 6-MMP;TPMT RBC production of 6-MMP-cCnc;;ACTIVE;2.65;2.65 +91142-0;Thiopurine methyltransferase;CCnc;Pt;RBC;Qn;Production of 6-Methylmercaptopurine riboside;CHEM;1;TPMT activity in RBC by production of 6-MMP riboside;TPMT RBC production 6-MMP riboside-cCnc;;ACTIVE;2.65;2.65 +91143-8;Thiopurine methyltransferase;CCnc;Pt;RBC;Qn;Production of 6-Methylthioguanine riboside;CHEM;1;TPMT activity in RBC by production of 6-MTG riboside;TPMT RBC production 6-MTG riboside-cCnc;;ACTIVE;2.65;2.65 +91144-6;Pregnancy prevention intention;Find;Pt;^Patient;Ord;Reported;H&P.HX;2;Pregnancy prevention intention - Reported;Preg prevention intention Reported;;ACTIVE;2.65;2.66 +91145-3;What number best describes how pain has interfered with your enjoyment of life during the past W;Find;1W;^Patient;Ord;;SURVEY.PEG;4;What number best describes how pain has interfered with your enjoyment of life during the past week;;;ACTIVE;2.65;2.65 +91146-1;What number best describes how pain has interfered with your general activity during the past W;Find;1W;^Patient;Ord;;SURVEY.PEG;4;What number best describes how pain has interfered with your general activity during the past week;;;ACTIVE;2.65;2.65 +91147-9;Mean score;Score;Pt;^Patient;Qn;Pain intensity, Enjoyment of life, General activity (PEG);SURVEY.PEG;4;Mean score [PEG];;;ACTIVE;2.65;2.65 +91148-7;Pain intensity, Enjoyment of life, General activity scale;-;Pt;^Patient;-;Pain intensity, Enjoyment of life, General activity (PEG);PANEL.SURVEY.GNHLTH;4;Pain intensity, Enjoyment of life, General activity scale [PEG];;;ACTIVE;2.65;2.7 +91149-5;Reevaluation note;Find;Pt;{Setting};Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Reevaluation note;PT Reeval note;;ACTIVE;2.65;2.65 +91150-3;Pressure injury stage;Find;Pt;^Patient;Nom;NPUAP;H&P.PX;2;Pressure injury stage NPUAP;Pressure injury stage NPUAP;Copyright © 2016 National Pressure Ulcer Advisory Panel Used with permission. It is understood that the name of the instrument and the indication that the copyright belongs to the National Pressure Ulcer Advisory Panel remain on any copies and that you do not make any changes to the wording or scoring of this tool.;ACTIVE;2.65;2.65 +91151-1;Pregnancy complication;Find;Pt;^Family member;Nom;;H&P.HX;2;Pregnancy complication of Family member;Preg complication Fam Mem;;ACTIVE;2.66;2.66 +91152-9;When my child was in pain he or she tried not to move in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she tried not to move in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91153-7;When my child was in pain his or her face looked sad in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain his or her face looked sad in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91154-5;When my child was in pain he or she asked for help with doing things in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she asked for help with doing things in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91155-2;When my child was in pain he or she asked people to let him or her be by himself or herself in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she asked people to let him or her be by himself or herself in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91156-0;When my child was in pain he or she moved stiffly in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she moved stiffly in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9115-7;Fluid output.biliary drain;VRat;8H;Biliary tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output biliary drain 8 hour;Fluid output bile drain 8h;;ACTIVE;1.0i;2.48 +91157-8;When my child was in pain he or she yelled for someone to help him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she yelled for someone to help him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91158-6;When my child was in pain he or she cried in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she cried in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91159-4;When my child was in pain he or she used something for support (cane, crutches, wheelchair) to move from place to place in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she used something for support (cane, crutches, wheelchair) to move from place to place in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91160-2;When my child was in pain he or she limped in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she limped in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91161-0;When my child was in pain he or she became quiet in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she became quiet in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91162-8;When my child was in pain he or she asked for help getting around in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she asked for help getting around in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91163-6;When my child was in pain he or she groaned in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she groaned in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91164-4;When my child was in pain he or she stayed away from other people in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she stayed away from other people in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9116-5;Fluid output.biliary drain;VRat;10H;Biliary tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output biliary drain 10 hour;Fluid output bile drain 10h;;ACTIVE;1.0i;2.48 +91165-1;When my child was in pain he or she asked for medicine in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she asked for medicine in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91166-9;When my child was in pain he or she screamed in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she screamed in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91167-7;When my child was in pain he or she protected the part of his or her body that hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she protected the part of his or her body that hurt in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91168-5;When my child was in pain he or she tightened his or her jaw in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she tightened his or her jaw in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91169-3;When my child was in pain he or she talked about his or her pain in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she talked about his or her pain in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91170-1;When my child was in pain he or she didn't let anyone touch him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she didn't let anyone touch him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91171-9;When my child was in pain he or she rubbed his or her body where it hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she rubbed his or her body where it hurt in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91172-7;When my child was in pain he or she moved slower in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she moved slower in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9117-3;Fluid output.biliary drain;VRat;12H;Biliary tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output biliary drain 12 hour;Fluid output bile drain 12h;;ACTIVE;1.0i;2.48 +91173-5;When my child was in pain he or she got angry at people in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she got angry at people in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91174-3;When my child was in pain he or she didn't want anyone to touch him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she didn't want anyone to touch him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91175-0;When my child was in pain he or she avoided standing in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she avoided standing in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91176-8;When my child was in pain he or she asked people to bring him or her things (food, games) in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she asked people to bring him or her things (food, games) in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91177-6;When my child was in pain he or she couldn't stay still in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she couldn't stay still in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91178-4;When my child was in pain he or she was restless in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she was restless in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91179-2;When my child was in pain he or she tried to think of something nice or fun in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she tried to think of something nice or fun in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +911-8;B Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;B Ab [Presence] in Serum or Plasma from Blood product unit;B Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +91180-0;When my child was in pain he or she went to sleep in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she went to sleep in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9118-1;Fluid output.biliary drain;VRat;24H;Biliary tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output biliary drain 24 hour;Fluid output bile drain 24h;;ACTIVE;1.0i;2.48 +91181-8;When my child was in pain he or she had to stop what he or she was doing in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she had to stop what he or she was doing in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91182-6;When my child was in pain he or she avoided lifting or carrying heavy things in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she avoided lifting or carrying heavy things in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91183-4;When my child was in pain he or she stayed near to someone who cares about him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she stayed near to someone who cares about him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91184-2;When my child was in pain he or she tried to rest or relax in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she tried to rest or relax in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91185-9;When my child was in pain he or she complained in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she complained in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91186-7;When my child was in pain he or she asked to see a doctor in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she asked to see a doctor in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91187-5;When my child was in pain he or she pulled away if someone touched him or her where it hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she pulled away if someone touched him or her where it hurt in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91188-3;When my child was in pain he or she argued with people in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she argued with people in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91189-1;When my child was in pain he or she avoided using the part of his or her body that hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she avoided using the part of his or her body that hurt in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91190-9;When my child was in pain he or she said mean words to people in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she said mean words to people in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91191-7;When my child was in pain he or she got mad and threw or hit something in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she got mad and threw or hit something in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91192-5;When my child was in pain he or she had a fixed or dazed expression in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she had a fixed or dazed expression in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91193-3;When my child was in pain he or she had tears in his or her eyes in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she had tears in his or her eyes in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91194-1;When my child was in pain he or she had circles under his or her eyes in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she had circles under his or her eyes in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91195-8;When my child was in pain he or she sighed in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she sighed in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91196-6;When my child was in pain he or she took breaks from what he or she was doing in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she took breaks from what he or she was doing in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91197-4;When my child was in pain he or she told people he or she couldn't do his or her usual chores in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she told people he or she couldn't do his or her usual chores in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91198-2;When my child was in pain it showed on his or her face in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain it showed on his or her face in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9119-9;Fluid output.burn;VRat;8H;Skin;Qn;Estimated;IO_OUT.TIMED.MOLE;2;Fluid output burn 8 hour Estimated;Fluid output burn 8h Est;;ACTIVE;1.0i;2.48 +91199-0;When my child was in pain he or she told people he or she couldn't do things with them in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she told people he or she couldn't do things with them in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91200-6;When my child was in pain he or she asked for someone to help him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she asked for someone to help him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91201-4;When my child was in pain he or she lay down in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she lay down in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91202-2;When my child was in pain he or she felt his or her body get tense in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;When my child was in pain he or she felt his or her body get tense in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91203-0;PROMIS parent proxy pain behavior - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy pain behavior - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91204-8;PROMIS parent proxy item bank - pain behavior - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - pain behavior - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.68 +91205-5;How many D did your child run for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days did your child run for 10 minutes or more in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91206-3;How many D was your child physically active for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child physically active for 10 minutes or more in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9120-7;Fluid output.burn;VRat;12H;Skin;Qn;Estimated;IO_OUT.TIMED.MOLE;2;Fluid output burn 12 hour Estimated;Fluid output burn 12h Est;;ACTIVE;1.0i;2.48 +91207-1;How many D did your child exercise really hard for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days did your child exercise really hard for 10 minutes or more in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91208-9;On a usual day, how physically active was your child in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;On a usual day, how physically active was your child in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91209-7;How many D did your child exercise or play so hard that he or she felt tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days did your child exercise or play so hard that he or she felt tired in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91210-5;How many D did your child exercise or play so hard that his or her muscles burned in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days did your child exercise or play so hard that his or her muscles burned in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91211-3;How many D did your child exercise or play so hard that his or her body got tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days did your child exercise or play so hard that his or her body got tired in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91212-1;How many D was your child so physically active that he or she sweated in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child so physically active that he or she sweated in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91213-9;How many D did your child play sports for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days did your child play sports for 10 minutes or more in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91214-7;How many D did your child exercise so much that he or she breathed hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days did your child exercise so much that he or she breathed hard in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9121-5;Fluid output.burn;VRat;24H;Skin;Qn;Estimated;IO_OUT.TIMED.MOLE;2;Fluid output burn 24 hour Estimated;Fluid output burn 24h Est;;ACTIVE;1.0i;2.48 +91215-4;PROMIS parent proxy item bank - physical activity - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - physical activity - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91216-2;PROMIS parent proxy physical activity - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy physical activity - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91217-0;How many D did you run for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days did you run for 10 minutes or more in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91218-8;How many D were you physically active for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you physically active for 10 minutes or more in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91219-6;How many D did you exercise really hard for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days did you exercise really hard for 10 minutes or more in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91220-4;On a usual day, how physically active were you in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;On a usual day, how physically active were you in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91221-2;How many D did you exercise or play so hard that you felt tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days did you exercise or play so hard that you felt tired in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91222-0;How many D did you exercise or play so hard that your muscles burned in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days did you exercise or play so hard that your muscles burned in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9122-3;Fluid output.cerebral ventricle drain;Vol;Pt;Cerebral ventricles;Qn;;IO_OUT.MOLEC;2;Fluid output cerebral ventricle drain;Drain output Cerebral vents;;ACTIVE;1.0i;2.54 +91223-8;How many D did you exercise or play so hard that your body got tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days did you exercise or play so hard that your body got tired in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91224-6;How many D were you so physically active that you sweated in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you so physically active that you sweated in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91225-3;How many D did you play sports for 10M or more in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days did you play sports for 10 minutes or more in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91226-1;How many D did you exercise so much that you breathed hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days did you exercise so much that you breathed hard in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91227-9;PROMIS pediatric physical activity - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric physical activity - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91228-7;PROMIS pediatric item bank - physical activity - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - physical activity - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91229-5;I felt healthy in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt healthy in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91230-3;I felt strong in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt strong in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9123-1;Fluid output.cerebral ventricle drain;VRat;1H;Cerebral ventricles;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output cerebral ventricle drain 1 hour;Drain output 1h Cerebral vents;;ACTIVE;1.0i;2.48 +91231-1;I felt full of pep in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt full of pep in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91232-9;I felt active in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt active in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91233-7;I felt refreshed in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt refreshed in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91234-5;I felt wide awake in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt wide awake in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91235-2;I had a lot of energy in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had a lot of energy in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91236-0;I felt energetic in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt energetic in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91237-8;I felt enthusiastic in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt enthusiastic in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91238-6;I felt blissful in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt blissful in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91239-4;I felt good in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt good in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91240-2;I was in good spirits in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was in good spirits in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91241-0;I was in a good mood in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was in a good mood in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91242-8;I was merry in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was merry in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91243-6;I laughed a lot in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I laughed a lot in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91244-4;I smiled a lot in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I smiled a lot in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91245-1;My life was pleasurable in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My life was pleasurable in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91246-9;I felt delighted in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt delighted in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91247-7;I felt joyful in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt joyful in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91248-5;I had very strong happy feelings in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had very strong happy feelings in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9124-9;Fluid output.cerebral ventricle drain;VRat;8H;Cerebral ventricles;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output cerebral ventricle drain 8 hour;Drain output 8h Cerebral vents;;ACTIVE;1.0i;2.48 +91249-3;I felt happy in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt happy in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91250-1;I felt cheerful in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt cheerful in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91251-9;I felt great in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt great in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91252-7;I felt pleased in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt pleased in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91253-5;I had much to be proud about in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had much to be proud about in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91254-3;I felt proud in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt proud in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91255-0;I felt appreciated in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt appreciated in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9125-6;Fluid output.cerebral ventricle drain;VRat;10H;Cerebral ventricles;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output cerebral ventricle drain 10 hour;Drain output 10h Cerebral vents;;ACTIVE;1.0i;2.48 +91256-8;I felt respected in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt respected in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91257-6;I felt fulfilled in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt fulfilled in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91258-4;I felt comfortable in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt comfortable in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91259-2;I felt relaxed in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt relaxed in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +912-6;B Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;B Ab [Presence] in Serum or Plasma from Donor;B Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +91260-0;I felt carefree in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt carefree in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91261-8;I felt positive in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt positive in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91262-6;I felt thankful in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt thankful in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91263-4;I felt grateful in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt grateful in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9126-4;Fluid output.cerebral ventricle drain;VRat;12H;Cerebral ventricles;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output cerebral ventricle drain 12 hour;Drain output 12h Cerebral vents;;ACTIVE;1.0i;2.48 +91264-2;I felt content in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt content in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91265-9;I felt satisfied in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt satisfied in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91266-7;I felt peaceful in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt peaceful in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91267-5;My child felt healthy in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt healthy in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91268-3;My child felt strong in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt strong in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91269-1;My child felt full of pep in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt full of pep in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91270-9;My child felt active in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt active in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91271-7;My child felt refreshed in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt refreshed in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9127-2;Fluid output.cerebral ventricle drain;VRat;24H;Cerebral ventricles;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output cerebral ventricle drain 24 hour;Drain output 24h Cerebral vents;;ACTIVE;1.0i;2.48 +91272-5;My child felt wide awake in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt wide awake in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91273-3;My child had a lot of energy in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had a lot of energy in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91274-1;My child felt energetic in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt energetic in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91275-8;My child felt enthusiastic in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt enthusiastic in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91276-6;My child felt blissful in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt blissful in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91277-4;My child felt good in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt good in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91278-2;My child was in good spirits in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was in good spirits in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91279-0;My child was in a good mood in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was in a good mood in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9128-0;Fluid output.subarachnoid drain;Vol;Pt;Spinal subarachnoid space;Qn;;IO_OUT.MOLEC;2;Fluid output subarachnoid drain;Fluid output subarachnoid drain;;ACTIVE;1.0i;2.54 +91280-8;My child felt merry in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt merry in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91281-6;My child laughed a lot in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child laughed a lot in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91282-4;My child smiled a lot in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child smiled a lot in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91283-2;My child felt his or her life was pleasurable in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt his or her life was pleasurable in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91284-0;My child felt delighted in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt delighted in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91285-7;My child felt joyful in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt joyful in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91286-5;My child had very strong happy feelings in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had very strong happy feelings in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91287-3;My child felt happy in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt happy in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91288-1;My child felt cheerful in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt cheerful in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91289-9;My child felt great in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt great in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91290-7;My child felt pleased in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt pleased in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91291-5;My child felt he or she had much to be proud about in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she had much to be proud about in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91292-3;My child felt proud in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt proud in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91293-1;My child felt appreciated in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt appreciated in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91294-9;My child felt respected in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt respected in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91295-6;My child felt fulfilled in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt fulfilled in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91296-4;My child felt comfortable in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt comfortable in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91297-2;My child felt relaxed in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt relaxed in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9129-8;Fluid output.chest tube;Vol;Pt;Pleural space;Qn;;IO_OUT.MOLEC;2;Fluid output chest tube;Fluid output chest tube;;ACTIVE;1.0i;2.54 +91298-0;My child felt carefree in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt carefree in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91299-8;My child felt positive in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt positive in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91300-4;My child felt thankful in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt thankful in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91301-2;My child felt grateful in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt grateful in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91302-0;My child felt content in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt content in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91303-8;My child felt satisfied in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt satisfied in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91304-6;My child felt peaceful in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt peaceful in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91305-3;My child felt calm in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt calm in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9130-6;Fluid output.chest tube;VRat;1H;Pleural space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output chest tube 1 hour;Fluid output chest tube 1h;;ACTIVE;1.0i;2.48 +91306-1;PROMIS parent proxy positive affect - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy positive affect - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91307-9;PROMIS parent proxy item bank - positive affect - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - positive affect - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91308-7;I felt I had too much going on in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt I had too much going on in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91309-5;I felt unable to manage things in my life in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt unable to manage things in my life in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91310-3;I felt unable to react to something that bothered me in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt unable to react to something that bothered me in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91311-1;I was slow to react to things in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was slow to react to things in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91312-9;My thoughts went very fast in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My thoughts went very fast in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91313-7;I had trouble concentrating in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had trouble concentrating in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9131-4;Fluid output.chest tube;VRat;8H;Pleural space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output chest tube 8 hour;Fluid output chest tube 8h;;ACTIVE;1.0i;2.48 +91314-5;I felt so upset that I could not remember what happened or what I did in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt so upset that I could not remember what happened or what I did in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91315-2;I felt unable to remember answers, even for questions I knew the answer to in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt unable to remember answers, even for questions I knew the answer to in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91316-0;I felt like my thinking was slower than usual in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt like my thinking was slower than usual in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91317-8;I forgot things in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I forgot things in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91318-6;I felt overwhelmed in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt overwhelmed in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91319-4;I felt that my problems kept piling up in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt that my problems kept piling up in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91320-2;I felt under pressure in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt under pressure in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91321-0;Everything bothered me in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Everything bothered me in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9132-2;Fluid output.chest tube;VRat;10H;Pleural space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output chest tube 10 hour;Fluid output chest tube 10h;;ACTIVE;1.0i;2.48 +91322-8;Small things upset me in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Small things upset me in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91323-6;I felt concerned about what was going on in my life in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt concerned about what was going on in my life in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91324-4;PROMIS pediatric item bank - psychological stress experiences - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - psychological stress experiences - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91325-1;PROMIS pediatric psychological stress experiences - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric psychological stress experiences - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91326-9;How many D was your child strong enough to lift heavy things over his or her head in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to lift heavy things over his or her head in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91327-7;How many D was your child strong enough to get down on the floor in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to get down on the floor in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91328-5;How many D was your child strong enough to carry his or her school books in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to carry his or her school books in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91329-3;How many D was your child strong enough to open a jar by himself or herself in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to open a jar by himself or herself in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9133-0;Fluid output.chest tube;VRat;12H;Pleural space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output chest tube 12 hour;Fluid output chest tube 12h;;ACTIVE;1.0i;2.48 +91330-1;How many D was your child strong enough to pour a drink from a full pitcher or carton in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to pour a drink from a full pitcher or carton in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91331-9;How many D was your child strong enough to jump up and down in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to jump up and down in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91332-7;How many D was your child strong enough to get out of bed and stand without help in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to get out of bed and stand without help in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91333-5;How many D was your child strong enough to hold a full plate or tray of food in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to hold a full plate or tray of food in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91334-3;How many D was your child strong enough to open a heavy door in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to open a heavy door in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91335-0;How many D was your child strong enough to reach above his or her head to get heavy things in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to reach above his or her head to get heavy things in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91336-8;How many D was your child strong enough to go up and down stairs in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to go up and down stairs in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91337-6;How many D was your child strong enough to carry heavy things with his or her hands in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;How many days was your child strong enough to carry heavy things with his or her hands in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91338-4;PROMIS parent proxy item bank - strength impact - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - strength impact - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91339-2;PROMIS parent proxy strength impact - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy strength impact - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +913-4;B Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;B Ab [Presence] in Serum or Plasma;B Ab SerPl Ql;;ACTIVE;1.0;2.73 +91340-0;My back pain has spread down my leg(s) at some time in the last 2W;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;My back pain has spread down my leg(s) at some time in the last 2 weeks [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.66 +91341-8;I have had pain in the shoulder or neck at some time in the last 2W;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;I have had pain in the shoulder or neck at some time in the last 2 weeks [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.67 +91342-6;I have only walked short distances because of my back pain in the last 2W;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;I have only walked short distances because of my back pain in the last 2 weeks [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.67 +91343-4;I have dressed more slowly than usual because of back pain in the last 2W;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;I have dressed more slowly than usual because of back pain in the last 2 weeks [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.67 +91344-2;Thinking about the last 2W, it's not really safe for a person with a condition like mine to be physically active;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;Thinking about the last 2 weeks, it's not really safe for a person with a condition like mine to be physically active [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.67 +91345-9;Worrying thoughts have been going through my mind a lot of the time in the last 2W;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;Worrying thoughts have been going through my mind a lot of the time in the last 2 weeks [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.67 +91346-7;Thinking about the last 2W, I feel that my back pain is terrible and it's never going to get any better;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;Thinking about the last 2 weeks, I feel that my back pain is terrible and it's never going to get any better [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.67 +91347-5;Thinking about the last 2W, in general I have not enjoyed all the things I used to enjoy;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;Thinking about the last 2 weeks, in general I have not enjoyed all the things I used to enjoy [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.67 +9134-8;Fluid output.chest tube;VRat;24H;Pleural space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output chest tube 24 hour;Fluid output chest tube 24h;;ACTIVE;1.0i;2.48 +91348-3;Overall, how bothersome has your back pain been in the last 2W;Find;2W;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;Overall, how bothersome has your back pain been in the last 2 weeks [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.66 +91349-1;STarT Back Screening Tool panel;-;Pt;^Patient;-;STarT Back;PANEL.SURVEY.GNHLTH;4;STarT Back Screening Tool panel;;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.66 +91350-9;Distress subscore;Score;Pt;^Patient;Qn;STarT Back;SURVEY.GNHLTH;4;Distress subscore [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.66 +91351-7;Total score;Score;Pt;^Patient;Qn;STarT Back;SURVEY.GNHLTH;4;Total score [STarT Back];;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.66 +91352-5;STarT Back Screening risk level;Find;Pt;^Patient;Ord;STarT Back;SURVEY.GNHLTH;4;STarT Back Screening risk level;;Copyright © 2007 University of Keele. Used with permission.;ACTIVE;2.66;2.66 +91353-3;I felt calm in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt calm in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91354-1;PROMIS pediatric positive affect - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric positive affect - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9135-5;Fluid output.chest tube;Aper;Pt;Pleural space;Nom;;IO_OUT.MOLEC;2;Fluid output chest tube [Appearance];Fluid output chest tube;;ACTIVE;1.0i;2.27 +91355-8;PROMIS pediatric item bank - positive affect - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - positive affect - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91356-6;My child felt concerned about what was going on in his or her life in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt concerned about what was going on in his or her life in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91357-4;Small things upset my child in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Small things upset my child in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91358-2;Everything bothered my child in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Everything bothered my child in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91359-0;My child felt under pressure in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt under pressure in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91360-8;My child felt that his or her problems kept piling up in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt that his or her problems kept piling up in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91361-6;My child felt overwhelmed in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt overwhelmed in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91362-4;My child felt so upset that he or she could not remember what happened or what he or she did in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt so upset that he or she could not remember what happened or what he or she did in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91363-2;My child had trouble concentrating in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble concentrating in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91364-0;My child's thoughts went very fast in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's thoughts went very fast in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91365-7;My child felt unable to manage things in his or her life in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt unable to manage things in his or her life in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91366-5;My child felt he or she had too much going on in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt he or she had too much going on in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91367-3;PROMIS parent proxy item bank - psychological stress experiences - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - psychological stress experiences - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91368-1;PROMIS parent proxy psychological stress experiences - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy psychological stress experiences - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91369-9;I had trouble controlling my thoughts in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had trouble controlling my thoughts in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91370-7;Body height^used for drug calculation;Len;Pt;^Patient;Qn;;CLIN;2;Body height --used for drug calculation;Body height used for drug calc;;ACTIVE;2.66;2.69 +9137-1;Fluid output.emesis;Vol;Pt;Upper GI tract;Qn;;IO_OUT.MOLEC;2;Fluid output emesis;Fluid output emesis;;ACTIVE;1.0i;2.54 +91371-5;Body Temperature;Temp;Pt;Brain;Qn;;BDYTMP.MOLEC;2;Body temperature - Brain;Bdy temp Brain;;ACTIVE;2.66;2.69 +91372-3;Hearing threshold^1500 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --1500 Hz;Hearing threshold 1500 Hz Ear-R;;ACTIVE;2.66;2.66 +91373-1;Hearing threshold^1500 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --1500 Hz;Hearing threshold 1500 Hz Ear-L;;ACTIVE;2.66;2.66 +91374-9;Hearing threshold^250 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --250 Hz;Hearing threshold 250 Hz Ear-R;;ACTIVE;2.66;2.66 +91375-6;Hearing threshold^250 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --250 Hz;Hearing threshold 250 Hz Ear-L;;ACTIVE;2.66;2.66 +91376-4;Hearing threshold^5000 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --5000 Hz;Hearing threshold 5000 Hz Ear-R;;ACTIVE;2.66;2.66 +91377-2;Hearing threshold^5000 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --5000 Hz;Hearing threshold 5000 Hz Ear-L;;ACTIVE;2.66;2.66 +91378-0;Hearing threshold^750 Hz;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Hearing threshold Ear - right --750 Hz;Hearing threshold 750 Hz Ear-R;;ACTIVE;2.66;2.66 +91379-8;Hearing threshold^750 Hz;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Hearing threshold Ear - left --750 Hz;Hearing threshold 750 Hz Ear-L;;ACTIVE;2.66;2.66 +91380-6;Number of falls in the past 3Mo;NRat;3Mo;^Patient;Qn;Reported;H&P.HX;2;Number of falls in the past 3 months - Reported;Fall number past 3Mo nRate Reported;;ACTIVE;2.66;2.66 +91381-4;Date medication started;Date;Pt;^Patient;Qn;Reported;MEDS;2;Date medication started - Reported;Date med started Reported;;ACTIVE;2.66;2.66 +91382-2;Date medication stopped;Date;Pt;^Patient;Qn;Reported;MEDS;2;Date medication stopped - Reported;Date med stopped Reported;;ACTIVE;2.66;2.66 +91383-0;Medication duration;Time;Pt;^Patient;Qn;Reported;MEDS;2;Medication duration - Reported;Medication duration Reported;;ACTIVE;2.66;2.66 +91384-8;Age when first used marijuana;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first used marijuana;Age first used marijuana;;ACTIVE;2.66;2.66 +91385-5;Age when first used cocaine or crack;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first used cocaine or crack;Age first used cocaine or crack;;ACTIVE;2.66;2.66 +91386-3;Age when first used heroin;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first used heroin;Age first used heroin;;ACTIVE;2.66;2.66 +91387-1;Has valid driver license;Find;Pt;^Patient;Ord;;ADMIN.PATIENT;2;Has valid driver license;Has valid driver license;;ACTIVE;2.66;2.66 +91388-9;Has automobile available for use;Find;Pt;^Patient;Ord;;H&P.HX;2;Has automobile available for use;Has automobile available for use;;ACTIVE;2.66;2.66 +9138-9;Fluid output.emesis;VRat;1H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis 1 hour;Fluid output emesis 1h;;ACTIVE;1.0i;2.48 +91389-7;Substance abused;Type;Pt;^Family member;Nom;;H&P.HX;2;Type of substance abused by Family member;Type of substance abused by Fam Mem;© 2018 Dr. Lynn Webster. Used with permission.;ACTIVE;2.66;2.67 +91390-5;Preadolescent sexual abuse;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Preadolescent sexual abuse;Hx of Preadolescent sexual abuse;© 2018 Dr. Lynn Webster. Used with permission.;ACTIVE;2.66;2.67 +91391-3;Mental health diagnosis;Imp;Pt;^Patient;Nom;;H&P.HX;2;Mental health diagnosis;Mental health dx;© 2018 Dr. Lynn Webster. Used with permission.;ACTIVE;2.66;2.67 +91392-1;Total score;Score;Pt;^Patient;Qn;ORT;CLIN.RISK;2;Total score ORT;Total score ORT;© 2018 Dr. Lynn Webster. Used with permission.;ACTIVE;2.66;2.67 +91393-9;Opioid risk tool panel;-;Pt;^Patient;-;ORT;PANEL.CLIN.RISK;2;Opioid risk tool panel;ORT panel;© 2018 Dr. Lynn Webster. Used with permission.;ACTIVE;2.66;2.67 +91394-7;It was hard for my child to do school work because he or she felt sad in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to do school work because he or she felt sad in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91395-4;It was hard for my child to have fun in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to have fun in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91396-2;My child could not stop feeling sad in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could not stop feeling sad in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9139-7;Fluid output.emesis;VRat;8H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis 8 hour;Fluid output emesis 8h;;ACTIVE;1.0i;2.48 +91397-0;My child didn't care about anything in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child didn't care about anything in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91398-8;My child felt alone in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt alone in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91399-6;My child felt everything in his or her life went wrong in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt everything in his or her life went wrong in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91400-2;My child felt like he or she couldn't do anything right in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt like he or she couldn't do anything right in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91401-0;My child felt lonely in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt lonely in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91402-8;My child felt sad in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt sad in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91403-6;My child felt too sad to eat in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt too sad to eat in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91404-4;My child felt unhappy in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt unhappy in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9140-5;Fluid output.emesis;VRat;10H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis 10 hour;Fluid output emesis 10h;;ACTIVE;1.0i;2.48 +91405-1;My child wanted to be by himself or herself in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child wanted to be by himself or herself in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91406-9;PROMIS parent proxy depressive symptoms - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy depressive symptoms - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91407-7;PROMIS parent proxy item bank - depressive symptoms - version 2.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - depressive symptoms - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91408-5;It was hard for my child to play sports or exercise because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to play sports or exercise because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91409-3;It was hard for my child to play with pets because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to play with pets because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91410-1;It was hard for my child to take a deep breath because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to take a deep breath because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91411-9;My child coughed because of his or her asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child coughed because of his or her asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91412-7;My child felt scared that he or she might have trouble breathing because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt scared that he or she might have trouble breathing because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9141-3;Fluid output.emesis;VRat;12H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis 12 hour;Fluid output emesis 12h;;ACTIVE;1.0i;2.48 +91413-5;My child felt wheezy because of his or her asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt wheezy because of his or her asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91414-3;My child got tired easily because of his or her asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child got tired easily because of his or her asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91415-0;My child had asthma attacks in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had asthma attacks in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91416-8;My child had trouble breathing because of his or her asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble breathing because of his or her asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91417-6;My child had trouble sleeping at night because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble sleeping at night because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91418-4;My child had trouble walking because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble walking because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91419-2;My child missed school because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child missed school because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +914-2;B Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;B Ag [Presence] on Red Blood Cells from Blood product unit;B Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +91420-0;My child was bothered by asthma when he or she was with friends in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was bothered by asthma when he or she was with friends in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9142-1;Fluid output.emesis;VRat;24H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis 24 hour;Fluid output emesis 24h;;ACTIVE;1.0i;2.48 +91421-8;My child was bothered by the amount of time he or she spent wheezing in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was bothered by the amount of time he or she spent wheezing in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91422-6;My child's asthma bothered him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's asthma bothered him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91423-4;My child's body felt bad when he or she was out of breath in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's body felt bad when he or she was out of breath in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91424-2;My child's chest felt tight because of asthma in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's chest felt tight because of asthma in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91425-9;PROMIS parent proxy asthma impact - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy asthma impact - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91426-7;PROMIS parent proxy item bank - asthma impact - version 2.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - asthma impact - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91427-5;A sudden noise made me jump in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;A sudden noise made me jump in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91428-3;I could not stay still for long in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I could not stay still for long in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91429-1;I felt as if I needed to move my legs a lot in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt as if I needed to move my legs a lot in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91430-9;I felt dizzy in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt dizzy in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91431-7;I felt some food coming up into my throat in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I felt some food coming up into my throat in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91432-5;I had a bad stomach ache in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had a bad stomach ache in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91433-3;I had a headache in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had a headache in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91434-1;I had pain that really bothered me in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had pain that really bothered me in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91435-8;I had trouble breathing, even when I was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I had trouble breathing, even when I was not exercising or playing hard in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91436-6;I threw up in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I threw up in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91437-4;I was sweaty, even when I was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;I was sweaty, even when I was not exercising or playing hard in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91438-2;My appetite changed in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My appetite changed in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9143-9;Fluid output.emesis;Mass;Pt;Upper GI tract;Qn;;IO_OUT.MOLEC;2;Fluid output emesis [Mass];Fluid output emesis mass;;ACTIVE;1.0i;2.48 +91439-0;My back hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My back hurt in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91440-8;My body shook in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My body shook in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91441-6;My breathing was fast in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My breathing was fast in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91442-4;My breathing was fast, even when I was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My breathing was fast, even when I was not exercising or playing hard in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91443-2;My hands shook in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My hands shook in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91444-0;My heart beat faster than usual, even when I was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My heart beat faster than usual, even when I was not exercising or playing hard in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91445-7;My heart pounded, even when I was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My heart pounded, even when I was not exercising or playing hard in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91446-5;My legs shook in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My legs shook in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9144-7;Fluid output.emesis;MRat;1H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis [Mass/time] 1 hour;Fluid output emesis 1h mRate;;ACTIVE;1.0i;2.48 +91447-3;My mouth was dry in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My mouth was dry in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91448-1;My muscles felt tight in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My muscles felt tight in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91449-9;My neck felt tight in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My neck felt tight in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91450-7;My neck hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My neck hurt in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91451-5;My palms were sweaty in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;My palms were sweaty in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91452-3;PROMIS pediatric item bank - physical stress experiences - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - physical stress experiences - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91453-1;PROMIS pediatric physical stress experiences - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric physical stress experiences - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9145-4;Fluid output.emesis;MRat;8H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis [Mass/time] 8 hour;Fluid output emesis 8h mRate;;ACTIVE;1.0i;2.48 +91454-9;PROMIS pediatric item bank - meaning and purpose - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - meaning and purpose - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91455-6;PROMIS pediatric meaning and purpose - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric meaning and purpose - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91456-4;Thinking about my life, I always have hope;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I always have hope [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91457-2;Thinking about my life, I am full of hope;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I am full of hope [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91458-0;Thinking about my life, I am positive about my future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I am positive about my future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91459-8;Thinking about my life, I am satisfied with my purpose in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I am satisfied with my purpose in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91460-6;Thinking about my life, I can do almost anything if I have enough faith in myself;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I can do almost anything if I have enough faith in myself [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91461-4;Thinking about my life, I can reach my goals in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I can reach my goals in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9146-2;Fluid output.emesis;MRat;10H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis [Mass/time] 10 hour;Fluid output emesis 10h mRate;;ACTIVE;1.0i;2.48 +91462-2;Thinking about my life, I expect amazing things to happen to me;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect amazing things to happen to me [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91463-0;Thinking about my life, I expect things to work out for the best;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect things to work out for the best [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91464-8;Thinking about my life, I expect to achieve my goals;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to achieve my goals [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91465-5;Thinking about my life, I expect to achieve what I want in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to achieve what I want in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91466-3;Thinking about my life, I expect to be successful in the future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to be successful in the future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91467-1;Thinking about my life, I expect to enjoy my future life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to enjoy my future life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91468-9;Thinking about my life, I expect to have a family in the future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to have a family in the future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91469-7;Thinking about my life, I expect to have a job in the future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to have a job in the future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9147-0;Fluid output.emesis;MRat;12H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis [Mass/time] 12 hour;Fluid output emesis 12h mRate;;ACTIVE;1.0i;2.48 +91470-5;Thinking about my life, I expect to have a long life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to have a long life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91471-3;Thinking about my life, I expect to have success in the future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to have success in the future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91472-1;Thinking about my life, I expect to succeed at what I try to do;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I expect to succeed at what I try to do [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91473-9;Thinking about my life, I feel hopeful about my future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I feel hopeful about my future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91474-7;Thinking about my life, I feel hopeful about my plans for the future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I feel hopeful about my plans for the future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91475-4;Thinking about my life, I have a clear purpose in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I have a clear purpose in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91476-2;Thinking about my life, I have a reason for living;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I have a reason for living [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91477-0;Thinking about my life, I have goals for myself;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I have goals for myself [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91478-8;Thinking about my life, I have hope;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I have hope [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91479-6;Thinking about my life, I have things I need to do in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I have things I need to do in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91480-4;Thinking about my life, I have things I want to accomplish in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I have things I want to accomplish in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91481-2;Thinking about my life, I have things I want to do in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I have things I want to do in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91482-0;Thinking about my life, I know what makes my life meaningful;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I know what makes my life meaningful [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91483-8;Thinking about my life, I know where I am going in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I know where I am going in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91484-6;Thinking about my life, I look forward to what will happen in the future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I look forward to what will happen in the future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91485-3;Thinking about my life, I make plans for my future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I make plans for my future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91486-1;Thinking about my life, I try to find meaning in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I try to find meaning in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91487-9;Thinking about my life, I try to find purpose in life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I try to find purpose in life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9148-8;Fluid output.emesis;MRat;24H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output emesis [Mass/time] 24 hour;Fluid output emesis 24h mRate;;ACTIVE;1.0i;2.48 +91488-7;Thinking about my life, I want to do what is important;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I want to do what is important [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91489-5;Thinking about my life, I want to make the most out of my life;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, I want to make the most out of my life [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91490-3;Thinking about my life, my life has meaning;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, my life has meaning [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91491-1;Thinking about my life, my life has purpose;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, my life has purpose [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91492-9;Thinking about my life, my life is filled with important things;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, my life is filled with important things [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91493-7;Thinking about my life, my life is filled with meaning;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, my life is filled with meaning [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91494-5;Thinking about my life, my life is filled with purpose;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, my life is filled with purpose [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91495-2;Thinking about my life, my life is filled with things that interest me;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, my life is filled with things that interest me [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9149-6;Fluid output.gastric tube;Vol;Pt;Upper GI tract;Qn;;IO_OUT.MOLEC;2;Fluid output gastric tube;Fluid output G-tube;;ACTIVE;1.0i;2.54 +91496-0;Thinking about my life, my life is important;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, my life is important [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91497-8;Thinking about my life, people will remember me when I die;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, people will remember me when I die [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91498-6;Thinking about my life, the things I have done in the past will help me in the future;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, the things I have done in the past will help me in the future [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91499-4;Thinking about my life, when bad things happen, I expect them to get better;Find;Pt;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;Thinking about my life, when bad things happen, I expect them to get better [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91500-9;How many D were you strong enough to carry heavy things with your hands in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to carry heavy things with your hands in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91501-7;How many D were you strong enough to carry your school books in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to carry your school books in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91502-5;How many D were you strong enough to get down on the floor in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to get down on the floor in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91503-3;How many D were you strong enough to get out of bed and stand without help in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to get out of bed and stand without help in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9150-4;Fluid output.gastric tube;VRat;1H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output gastric tube 1 hour;Fluid output G-tube 1h;;ACTIVE;1.0i;2.48 +91504-1;How many D were you strong enough to go up and down stairs in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to go up and down stairs in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91505-8;How many D were you strong enough to hold a full plate or tray of food in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to hold a full plate or tray of food in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91506-6;How many D were you strong enough to jump up and down in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to jump up and down in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91507-4;How many D were you strong enough to lift heavy things over your head in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to lift heavy things over your head in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91508-2;How many D were you strong enough to open a heavy door in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to open a heavy door in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91509-0;How many D were you strong enough to open a jar by yourself in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to open a jar by yourself in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91510-8;How many D were you strong enough to pour a drink from a full pitcher or carton in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to pour a drink from a full pitcher or carton in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91511-6;How many D were you strong enough to reach above your head to get heavy things in past 7D;Find;7D;^Patient;Ord;PROMIS.PEDS;SURVEY.PROMIS;4;How many days were you strong enough to reach above your head to get heavy things in past 7 days [PROMIS.PEDS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9151-2;Fluid output.gastric tube;VRat;8H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output gastric tube 8 hour;Fluid output G-tube 8h;;ACTIVE;1.0i;2.48 +91512-4;PROMIS pediatric item bank - strength impact - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - strength impact - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91513-2;PROMIS pediatric strength impact - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric strength impact - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91514-0;Country where healthcare received outside U.S.;Loc;Pt;^Patient;Nom;;H&P.HX;2;Country where healthcare received outside U.S. [Location];Country HC received outside US;;ACTIVE;2.66;2.66 +91515-7;Received healthcare in U.S. but outside resident state;Loc;Pt;^Patient;Nom;;H&P.HX;2;Received healthcare in U.S. but outside resident state;Received HC in US outside resident state;;ACTIVE;2.66;2.66 +91516-5;State where healthcare received outside resident state;Loc;Pt;^Patient;Nom;;H&P.HX;2;State where healthcare received outside resident state;State HC received outside resident state;;ACTIVE;2.66;2.66 +91517-3;Multisection diagnostic for implant;Find;Pt;Breast.right;Doc;MG.tomosynthesis;RAD;2;DBT Breast - right diagnostic for implant;DBT Brst-R Dx for implant;;ACTIVE;2.66;2.67 +91518-1;Multisection diagnostic for implant;Find;Pt;Breast.left;Doc;MG.tomosynthesis;RAD;2;DBT Breast - left diagnostic for implant;DBT Brst-L Dx for implant;;ACTIVE;2.66;2.67 +91519-9;Multisection diagnostic for implant;Find;Pt;Breast.bilateral;Doc;MG.tomosynthesis;RAD;2;DBT Breast - bilateral diagnostic for implant;DBT Brst-Bl Dx for implant;;ACTIVE;2.66;2.67 +9152-0;Fluid output.gastric tube;VRat;10H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output gastric tube 10 hour;Fluid output G-tube 10h;;ACTIVE;1.0i;2.48 +91520-7;Multisection screening for implant;Find;Pt;Breast.right;Doc;MG.tomosynthesis;RAD;2;DBT Breast - right screen for implant;DBT Brst-R Screening for implant;;ACTIVE;2.66;2.67 +91521-5;Multisection screening for implant;Find;Pt;Breast.left;Doc;MG.tomosynthesis;RAD;2;DBT Breast - left screen for implant;DBT Brst-L Screening for implant;;ACTIVE;2.66;2.67 +91522-3;Multisection screening for implant;Find;Pt;Breast.bilateral;Doc;MG.tomosynthesis;RAD;2;DBT Breast - bilateral screen for implant;DBT Brst-Bl Screening for implant;;ACTIVE;2.66;2.67 +91523-1;Multisection^W contrast IV;Find;Pt;Chest+Abdomen+Pelvis;Doc;MR;RAD;2;MR Chest and Abdomen and Pelvis W contrast IV;MR Chest+Abd+Pelvis W contr IV;;ACTIVE;2.66;2.67 +91524-9;Multisection^WO & W contrast IV;Find;Pt;Chest+Abdomen+Pelvis;Doc;MR;RAD;2;MR Chest and Abdomen and Pelvis WO and W contrast IV;MR Chest+Abd+Pelvis WO+W contr IV;;ACTIVE;2.66;2.67 +91525-6;Multisection^WO contrast;Find;Pt;Chest+Abdomen+Pelvis;Doc;MR;RAD;2;MR Chest and Abdomen and Pelvis WO contrast;MR Chest+Abd+Pelvis WO contr;;ACTIVE;2.66;2.67 +91526-4;Fear-Affect Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Fear-Affect Survey - age 18+ - T-score [NIH Toolbox];;;ACTIVE;2.66;2.66 +91527-2;Perceived Stress Survey - age 18+ - T-score;Tscore;Pt;^Patient;Qn;NIH Toolbox;SURVEY.NIH.EMO;4;Perceived Stress Survey - age 18+ - T-score [NIH Toolbox];;;ACTIVE;2.66;2.66 +91528-0;Perceived Stress Survey - fixed length form - age 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Perceived Stress Survey - fixed length form - age 18+ [NIH Toolbox];;;ACTIVE;2.66;2.71 +91529-8;Fear-Affect Survey - CAT item bank - age 18+;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Fear-Affect Survey - CAT item bank - age 18+ [NIH Toolbox];;;ACTIVE;2.66;2.71 +91530-6;Self-Efficacy Survey version 2.0 - CAT item bank - ages 13-17;-;Pt;^Patient;-;NIH Toolbox;PANEL.SURVEY.NIH.EMO;4;Self-Efficacy Survey version 2.0 - CAT item bank - ages 13-17 [NIH Toolbox];;;ACTIVE;2.66;2.66 +91531-4;Note;Find;Pt;Telehealth;Doc;Social worker;DOC.ONTOLOGY;2;Social worker Telehealth Note;SW Telehealth Note;;ACTIVE;2.66;2.66 +91532-2;Age when first injected non-prescription drug;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first injected non-prescription drug;Age first non-prescrip drug injec;;ACTIVE;2.66;2.66 +91533-0;PROMIS pediatric fatigue - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric fatigue - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91534-8;PROMIS pediatric item bank - fatigue - version 2.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - fatigue - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91535-5;PROMIS pediatric depressive symptoms - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric depressive symptoms - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91536-3;PROMIS pediatric item bank - depressive symptoms - version 2.0;-;7D;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - depressive symptoms - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91537-1;PROMIS pediatric asthma impact - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric asthma impact - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9153-8;Fluid output.gastric tube;VRat;12H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output gastric tube 12 hour;Fluid output G-tube 12h;;ACTIVE;1.0i;2.48 +91538-9;PROMIS pediatric item bank - asthma impact - version 2.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - asthma impact - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91539-7;PROMIS pediatric anxiety - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric anxiety - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91540-5;PROMIS pediatric item bank - anxiety - version 2.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - anxiety - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91541-3;Disease outcome;Type;Pt;^Patient;Nom;;H&P.HX;2;Disease outcome [Type];Disease outcome Type;;ACTIVE;2.66;2.68 +91542-1;Myelin oligodendrocyte glycoprotein Ab;Titr;Pt;CSF;Qn;CBA IFA;SERO;1;Myelin oligodendrocyte glycoprotein Ab [Titer] in Cerebral spinal fluid by Cell binding immunofluorescent assay;MOG Ab Titr CSF CBA IFA;;ACTIVE;2.66;2.69 +91543-9;Myelin oligodendrocyte glycoprotein Ab;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Myelin oligodendrocyte glycoprotein Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;MOG Ab CSF Ql CBA IFA;;ACTIVE;2.66;2.69 +91544-7;Myelin oligodendrocyte glycoprotein Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;Myelin oligodendrocyte glycoprotein Ab [Titer] in Serum by Cell binding immunofluorescent assay;MOG Ab Titr Ser CBA IFA;;ACTIVE;2.66;2.69 +91545-4;Myelin oligodendrocyte glycoprotein Ab;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Myelin oligodendrocyte glycoprotein Ab [Presence] in Serum by Cell binding immunofluorescent assay;MOG Ab Ser Ql CBA IFA;;ACTIVE;2.66;2.69 +9154-6;Fluid output.gastric tube;VRat;24H;Upper GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output gastric tube 24 hour;Fluid output G-tube 24h;;ACTIVE;1.0i;2.48 +91546-2;ST deviation;Elpot;Stdy^max;Heart;Qn;EKG;EKG.MEAS;2;ST deviation (Maximum value during study) by EKG;ST Deviation Max EKG;;ACTIVE;2.66;2.66 +91547-0;Treadmill angina;Prid;Stdy;^Patient;Nom;;H&P.HX;2;Treadmill angina [Identifier];Treadmill angina;;ACTIVE;2.66;2.66 +91548-8;Duke Treadmill Score risk level;Imp;Pt;^Patient;Ord;DTS;CLIN.RISK;2;Duke Treadmill Score risk level;DTS risk level;;ACTIVE;2.66;2.66 +91549-6;Duke Treadmill Score;Score;Pt;^Patient;Qn;DTS;CLIN.RISK;2;Duke Treadmill Score;Duke treadmill score;;ACTIVE;2.66;2.66 +91550-4;Duke Treadmill Score panel;-;Pt;^Patient;-;DTS;PANEL.CLIN.RISK;2;Duke Treadmill Score panel;DTS panel;;ACTIVE;2.66;2.66 +91551-2;Other cells/100 leukocytes;NFr;Pt;Dial fld;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Dialysis fluid by Manual count;Other cells/leuk NFr Dial fld Manual;;ACTIVE;2.66;2.66 +91552-0;MDS v3.0 - RAI v1.17.1, 1.17.2 - Swing bed discharge (SD) item set;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.1, 1.17.2 - Swing bed discharge (SD) item set [CMS Assessment];;;ACTIVE;2.66;2.68 +9155-3;Fluid output.gastric tube;Aper;Pt;Upper GI tract;Nom;;IO_OUT.MOLEC;2;Fluid output gastric tube [Appearance];Fluid output G-tube;;ACTIVE;1.0i;2.27 +91553-8;Duration that patient was able to hold balance position;Time;Pt;^Patient;Qn;NIH Toolbox;NIH.MOTOR;2;Duration that patient was able to hold balance position [NIH Toolbox];Hold position duration NIH;;ACTIVE;2.66;2.66 +91554-6;MDS v3.0 - RAI v1.17.2 - Identification information - ND;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Identification information - ND [CMS Assessment];;;ACTIVE;2.66;2.68 +91555-3;Percent intake by artificial route during the last 7D;-;7D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Percent intake by artificial route during the last 7 days [CMS Assessment];;;ACTIVE;2.66;2.66 +91556-1;Fibrin D-dimer DDU;MCnc;Pt;Bld;Qn;IA;COAG;1;Fibrin D-dimer DDU [Mass/volume] in Blood by Immunoassay;D dimer DDU Bld IA-mCnc;;ACTIVE;2.66;2.66 +91557-9;Lean body weight;Mass;Pt;^Patient;Qn;;BDYWGT.ATOM;2;Lean body weight;Lean body weight;;ACTIVE;2.66;2.66 +91558-7;Coinfection;Find;Pt;^Patient;Nom;;H&P.HX;2;Coinfection type;Coinfection type;;ACTIVE;2.66;2.66 +91559-5;Date of arrival at travel destination;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of arrival at travel destination;Date arrived at destination;;ACTIVE;2.66;2.66 +91560-3;Date of departure from travel destination;Date;Pt;^Patient;Qn;;H&P.HX;2;Date of departure from travel destination;Date of departure from destination;;ACTIVE;2.66;2.66 +9156-1;Fluid output.insensible;VRat;8H;^Patient;Qn;Estimated;IO_OUT.TIMED.MOLE;2;Fluid output insensible 8 hour Estimated;Fluid output insensible 8h Est;;ACTIVE;1.0i;2.48 +91561-1;Multisection^W contrast IV;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Cervical and thoracic and lumbar spine W contrast IV;MR C+T+L-spine W contr IV;;ACTIVE;2.66;2.67 +91562-9;Performing laboratory identifier;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Performing laboratory identifier Facility;Performing laboratory ID Facility;;ACTIVE;2.66;2.68 +91563-7;Casualties;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Casualties [#] Reporting Period;Casualties RptPeriod;;ACTIVE;2.66;2.68 +91564-5;Information source for rumor related to public health emergency;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Information source for rumor related to public health emergency;Source for rumor PH emerg;;ACTIVE;2.66;2.68 +91565-2;Key words related to public health emergency;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Key words related to public health emergency;Key words for PH emerg;;ACTIVE;2.66;2.68 +91566-0;Rumor related to public health emergency;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Rumor related to public health emergency Narrative;Rumor related to PH emerg;;ACTIVE;2.66;2.68 +91567-8;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Special treatments, procedures, and programs - SD [CMS Assessment];;;ACTIVE;2.66;2.68 +91568-6;Shot up or injected any non-prescription drugs;Find;Lifetime;^Patient;Ord;;H&P.HX;2;Shot up or injected any non-prescription drugs Lifetime;Shot up injected non-rx drugs Lifetime;;ACTIVE;2.66;2.66 +91569-4;Frequency of medicine or drug injection with needle during time period with highest use;NRat;12Mo;^Patient;Ord;;H&P.HX;2;Frequency of medicine or drug injection with needle during time period with highest use 12 months;Freq drug inject needle highest use 12Mo;;ACTIVE;2.66;2.66 +91570-2;Employment net income;NRat;30D;^Patient;Qn;;ADMIN.PATIENT.DEMOG;2;Employment net income in past 30 days;Employment net income 30D nRate;;ACTIVE;2.66;2.66 +91571-0;Frequency of drug injection;NRat;12Mo;^Patient;Ord;;H&P.HX;2;Frequency of drug injection in past 12 months;Freq of drug injection 12Mo;;ACTIVE;2.66;2.66 +91572-8;Used erectile dysfunction drug;Find;12Mo;^Patient;Ord;;H&P.HX;2;Used erectile dysfunction drug in past 12 months;Used erectile dysfunction drug 12Mo;;ACTIVE;2.66;2.66 +91573-6;Twelve or more drinks in a D;NRat;12Mo;^Patient;Ord;;H&P.HX;2;Twelve or more drinks in a day in past 12 months;GE 12 drinks in a D 12Mo;;ACTIVE;2.66;2.66 +91574-4;Four or more drinks in 2H or less;Find;12Mo;^Patient;Ord;;H&P.HX;2;Four or more drinks in 2 hours or less in 12 months;GE 4 drinks in LE 2H 12Mo;;ACTIVE;2.66;2.66 +91575-1;Eight or more drinks in a D;NRat;12Mo;^Patient;Ord;;H&P.HX;2;Eight or more drinks in a day in past 12 months;GE 8 drinks in a D 12Mo;;ACTIVE;2.66;2.66 +91576-9;Five or more drinks in a period of 2H or less;NRat;12Mo;^Patient;Ord;;H&P.HX;2;Five or more drinks in a period of 2 hours or less in past 12 months;GE 5 drinks in LE 2H 12Mo;;ACTIVE;2.66;2.66 +91577-7;MDS v3.0 - RAI v1.17.2 - Therapies - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Therapies - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +91578-5;Probability of an event occurring;Likelihood;Pt;^Event;Ord;;SURVEY.CDC;4;Probability of an event occurring;;;ACTIVE;2.66;2.68 +9157-9;Fluid output.insensible;VRat;10H;^Patient;Qn;Estimated;IO_OUT.TIMED.MOLE;2;Fluid output insensible 10 hour Estimated;Fluid output insensible 10h Est;;ACTIVE;1.0i;2.48 +91579-3;MDS v3.0 - RAI v1.17.2 - Correction request - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Correction request - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +91580-1;MDS v3.0 - RAI v1.17.2 - Type of assessment on existing record to be modified or inactivated - IPA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Type of assessment on existing record to be modified or inactivated - IPA [CMS Assessment];;;ACTIVE;2.66;2.68 +91581-9;MDS v3.0 - RAI v1.17.2 - State Medicaid billing - OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - State Medicaid billing - OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +91582-7;Report status;Type;Pt;Report;Nom;;DOC.MISC;2;Report status;Report status;;ACTIVE;2.66;2.68 +91583-5;Date and time of public health emergency;TmStp;Pt;^Event;Qn;;ADMIN;2;Date and time of public health emergency;D/T public health emergency;;ACTIVE;2.66;2.68 +91584-3;Date and time rumor record was released;TmStp;Pt;^Event;Qn;;PUBLICHEALTH;2;Date and time rumor record was released;D/T rumor record released;;ACTIVE;2.66;2.68 +91585-0;Reliability of information source;Find;Pt;^Event;Ord;;ADMIN;2;Reliability of information source;Reliability of info source;;ACTIVE;2.66;2.68 +91586-8;Coding system;ID;Pt;Referral lab test;Nom;;MISC;1;Coding system [Identifier] in Referral lab test;Coding sys Ref Lab Test;;ACTIVE;2.66;2.7 +9158-7;Fluid output.insensible;VRat;12H;^Patient;Qn;Estimated;IO_OUT.TIMED.MOLE;2;Fluid output insensible 12 hour Estimated;Fluid output insensible 12h Est;;ACTIVE;1.0i;2.48 +91587-6;Accuracy of information from source;Find;Pt;^Event;Ord;;ADMIN;2;Accuracy of information from source;Accuracy of info from source;;ACTIVE;2.66;2.68 +91588-4;Latitude;Angle;Pt;^Event;Qn;;ADMIN;2;Latitude Event;Latitude Event;;ACTIVE;2.66;2.68 +91589-2;Longitude;Angle;Pt;^Event;Qn;;ADMIN;2;Longitude Event;Longitude Event;;ACTIVE;2.66;2.68 +915-9;B Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;B Ag [Presence] on Red Blood Cells from Donor;B Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +91590-0;Mycobacterium preliminary growth;PrThr;Pt;Body fld;Ord;Organism specific culture;MICRO;1;Mycobacterium preliminary growth [Presence] in Body fluid by Organism specific culture;Mycobact prelim grow Fld Ql Cult;;ACTIVE;2.66;2.67 +91591-8;Multisection^W contrast IV;Find;Pt;Head>Brain+orbit.bilateral;Doc;MR;RAD;2;MR Brain and Orbit - bilateral W contrast IV;MR Brain+Orbit-BI W contr IV;;ACTIVE;2.66;2.67 +91592-6;Multisection^WO & W contrast IV;Find;Pt;Head>Brain+orbit.bilateral;Doc;MR;RAD;2;MR Brain and Orbit - bilateral WO and W contrast IV;MR Brain+Orbit-BI WO+W contr IV;;ACTIVE;2.66;2.67 +91593-4;Multisection^WO contrast;Find;Pt;Head>Brain+orbit.bilateral;Doc;MR;RAD;2;MR Brain and Orbit - bilateral WO contrast;MR Brain+Orbit-BI WO contr;;ACTIVE;2.66;2.67 +91594-2;Multisection^W contrast IV;Find;Pt;Pelvis>Sacrum+Sacroiliac joint;Doc;MR;RAD;2;MR Sacrum and Sacroiliac joint W contrast IV;MR Sacrum and SIJ W contr IV;;ACTIVE;2.66;2.67 +9159-5;Fluid output.insensible;VRat;24H;^Patient;Qn;Estimated;IO_OUT.TIMED.MOLE;2;Fluid output insensible 24 hour Estimated;Fluid output insensible 24h Est;;ACTIVE;1.0i;2.48 +91595-9;Multisection^WO & W contrast IV;Find;Pt;Pelvis>Sacrum+Sacroiliac joint;Doc;MR;RAD;2;MR Sacrum and Sacroiliac joint WO and W contrast IV;MR Sacrum and SIJ WO+W contr IV;;ACTIVE;2.66;2.67 +91596-7;Multisection^WO contrast;Find;Pt;Pelvis>Sacrum+Sacroiliac joint;Doc;MR;RAD;2;MR Sacrum and Sacroiliac joint WO contrast;MR Sacrum and SIJ WO contr;;ACTIVE;2.66;2.67 +91597-5;Multisection^WO & W contrast IV;Find;Pt;Lower extremity>Toe;Doc;MR;RAD;2;MR Toe WO and W contrast IV;MR Toe WO+W contr IV;;ACTIVE;2.66;2.67 +91598-3;Views GE 2;Find;Pt;Lower extremity>Knee;Doc;XR;RAD;2;XR Knee GE 2 Views;XR Knee GE 2V;;ACTIVE;2.66;2.67 +91599-1;Emergency operations center activation level;Type;Pt;^Event;Ord;;PUBLICHEALTH;2;Emergency operations center activation level;EOC activation level;;ACTIVE;2.66;2.68 +91600-7;Operational objectives related to the emergency response activation;Find;RptPeriod;^Event;Nom;;PUBLICHEALTH;2;Operational objectives related to the emergency response activation Reporting Period;Operational objectives of emerg response;;ACTIVE;2.66;2.68 +91601-5;Priorities related to the emergency response activation;Find;RptPeriod;^Event;Nom;;PUBLICHEALTH;2;Priorities related to the emergency response activation Reporting Period;Priorities for emerg response activation;;ACTIVE;2.66;2.68 +91602-3;Critical information requirements related to the emergency response activation;Find;RptPeriod;^Event;Nom;;PUBLICHEALTH;2;Critical information requirements related to the emergency response activation Reporting Period;Critical info requirements for emerg resp;;ACTIVE;2.66;2.68 +9160-3;Fluid output.misc;Vol;Pt;XXX;Qn;Estimated;IO_OUT.MOLEC;2;Fluid output miscellaneous Estimated;Fluid output misc Est;;ACTIVE;1.0i;2.54 +91603-1;Summary of current situation related to public health emergency;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Summary of current situation related to public health emergency Narrative;Current situation summary for PH emerg;;ACTIVE;2.66;2.68 +91604-9;Device count;Num;Pt;{Device};Qn;;DEVICES;2;Device count;Device count;;ACTIVE;2.66;2.68 +91606-4;clomiPRAMINE+Norclomipramine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;clomiPRAMINE+Norclomipramine [Mass/volume] in Urine;clomiPRAMINE+Nor Ur-mCnc;;ACTIVE;2.66;2.69 +91607-2;Does your health now limit you in opening a previously opened jar;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in opening a previously opened jar [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91608-0;Are you able to pass a 20-pound (10 kg) turkey or ham to other people at the table;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pass a 20-pound (10 kg) turkey or ham to other people at the table [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91609-8;Are you able to continuously swing a baseball bat or tennis racket back and forth for 5M;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to continuously swing a baseball bat or tennis racket back and forth for 5 minutes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91610-6;Are you able to lift a heavy painting or picture to hang on your wall above eye-level;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift a heavy painting or picture to hang on your wall above eye-level [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9161-1;Fluid output.misc;Vol;Pt;XXX;Qn;Measured;IO_OUT.MOLEC;2;Fluid output miscellaneous Measured;Fluid output misc Measured;;ACTIVE;1.0i;2.54 +91611-4;PROMIS item bank - upper extremity - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - upper extremity - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91612-2;PROMIS upper extremity version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS upper extremity version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91613-0;PROMIS item bank - mobility - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - mobility - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91614-8;PROMIS mobility - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS mobility - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91615-5;How depressed or cheerful have you been during the past Mo;Score;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;How depressed or cheerful have you been during the past month [NHANES];;;ACTIVE;2.66;2.66 +91616-3;How much energy, pep, and vitality have you felt during the past Mo;Score;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;How much energy, pep, and vitality have you felt during the past month [NHANES];;;ACTIVE;2.66;2.66 +91617-1;How relaxed or tense have you been during the past Mo;Score;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;How relaxed or tense have you been during the past month [NHANES];;;ACTIVE;2.66;2.66 +91618-9;How concerned or worried about your health have you been during the past Mo;Score;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;How concerned or worried about your health have you been during the past month [NHANES];;;ACTIVE;2.66;2.66 +91619-7;Have you felt tired, worn out, used-up, or exhausted during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Have you felt tired, worn out, used-up, or exhausted during the past month [NHANES];;;ACTIVE;2.66;2.66 +91620-5;Have you been feeling emotionally stable and sure of yourself during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Have you been feeling emotionally stable and sure of yourself during the past month [NHANES];;;ACTIVE;2.66;2.66 +91621-3;Has your daily life been full of things that were interesting to you during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Has your daily life been full of things that were interesting to you during the past month [NHANES];;;ACTIVE;2.66;2.66 +91622-1;Have you been waking up fresh and rested during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Have you been waking up fresh and rested during the past month [NHANES];;;ACTIVE;2.66;2.66 +91623-9;Have you had any reason to wonder if you were losing your mind, or losing control over the way you act, talk, think, feel, or of your memory during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Have you had any reason to wonder if you were losing your mind, or losing control over the way you act, talk, think, feel, or of your memory during the past month [NHANES];;;ACTIVE;2.66;2.66 +91624-7;How happy, satisfied, or pleased have you been with your personal life during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;How happy, satisfied, or pleased have you been with your personal life during the past month [NHANES];;;ACTIVE;2.66;2.66 +91625-4;Have you felt so sad, discouraged, hopeless, or had so many problems that you wondered if anything was worthwhile during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Have you felt so sad, discouraged, hopeless, or had so many problems that you wondered if anything was worthwhile during the past month [NHANES];;;ACTIVE;2.66;2.66 +91626-2;Have you been in firm control of your behavior, thoughts, emotions, or feelings during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Have you been in firm control of your behavior, thoughts, emotions, or feelings during the past month [NHANES];;;ACTIVE;2.66;2.66 +91627-0;Have you been bothered by nervousness or your nerves during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;Have you been bothered by nervousness or your nerves during the past month [NHANES];;;ACTIVE;2.66;2.66 +91628-8;How have you been feeling in general during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.GNHLTH;4;How have you been feeling in general during the past month [NHANES];;;ACTIVE;2.66;2.66 +9162-9;Fluid output.misc;VRat;1H;XXX;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output miscellaneous 1 hour;Fluid output misc 1h;;ACTIVE;1.0i;2.48 +91629-6;General Well-Being Schedule - 18 item;-;Pt;^Patient;-;NHANES;PANEL.SURVEY.MTLHLTH;4;General Well-Being Schedule - 18 item [NHANES];;;ACTIVE;2.66;2.66 +91630-4;Have you felt down-hearted and blue during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.MTLHLTH;4;Have you felt down-hearted and blue during the past month [NHANES];;;ACTIVE;2.66;2.66 +91631-2;Have you been bothered by any illness, bodily disorder, pains, or fears about your health during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.MTLHLTH;4;Have you been bothered by any illness, bodily disorder, pains, or fears about your health during the past month [NHANES];;;ACTIVE;2.66;2.66 +91632-0;Have you been anxious, worried, or upset during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.MTLHLTH;4;Have you been anxious, worried, or upset during the past month [NHANES];;;ACTIVE;2.66;2.66 +91633-8;Have you been under or felt you were under any strain, stress, or pressure during the past Mo;Find;1Mo;^Patient;Ord;NHANES;SURVEY.MTLHLTH;4;Have you been under or felt you were under any strain, stress, or pressure during the past month [NHANES];;;ACTIVE;2.66;2.66 +91634-6;How often is the following kind of support available to you if you need it - someone you can count on to listen to you when you need to talk;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone you can count on to listen to you when you need to talk [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91635-3;How often is the following kind of support available to you if you need it - someone to give you good advice about a crisis;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to give you good advice about a crisis [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91636-1;How often is the following kind of support available to you if you need it - someone who shows you love and affection;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone who shows you love and affection [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +9163-7;Fluid output.misc;VRat;8H;XXX;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output miscellaneous 8 hour;Fluid output misc 8h;;ACTIVE;1.0i;2.48 +91637-9;How often is the following kind of support available to you if you need it - someone to confide in or talk to about yourself or your problems;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to confide in or talk to about yourself or your problems [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91638-7;How often is the following kind of support available to you if you need it - someone whose advice you really want;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone whose advice you really want [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91639-5;How often is the following kind of support available to you if you need it - someone to help with daily chores if you were sick;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to help with daily chores if you were sick [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91640-3;How often is the following kind of support available to you if you need it - someone to share your most private worries and fears with;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to share your most private worries and fears with [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91641-1;How often is the following kind of support available to you if you need it - someone to love and make you feel wanted;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to love and make you feel wanted [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91642-9;Medical Outcomes Study Social Support Survey panel;-;Pt;^Patient;-;MOS Social Support Survey;PANEL.SURVEY.MTLHLTH;4;Medical Outcomes Study Social Support Survey panel [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91643-7;Emotional+informational support;-;Pt;^Patient;-;MOS Social Support Survey;PANEL.SURVEY.MTLHLTH;4;Emotional/informational support [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91644-5;Tangible support;-;Pt;^Patient;-;MOS Social Support Survey;PANEL.SURVEY.MTLHLTH;4;Tangible support [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +9164-5;Fluid output.misc;VRat;10H;XXX;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output miscellaneous 10 hour;Fluid output misc 10h;;ACTIVE;1.0i;2.48 +91645-2;Affectionate support;-;Pt;^Patient;-;MOS Social Support Survey;PANEL.SURVEY.MTLHLTH;4;Affectionate support [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91646-0;Positive social interaction;-;Pt;^Patient;-;MOS Social Support Survey;PANEL.SURVEY.MTLHLTH;4;Positive social interaction [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91647-8;Emotional+informational support score;Score;Pt;^Patient;Qn;MOS Social Support Survey;SURVEY.MTLHLTH;4;Emotional/informational support score [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91648-6;Tangible support score;Score;Pt;^Patient;Qn;MOS Social Support Survey;SURVEY.MTLHLTH;4;Tangible support score [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91649-4;Affectionate support score;Score;Pt;^Patient;Qn;MOS Social Support Survey;SURVEY.MTLHLTH;4;Affectionate support score [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91650-2;Positive social interaction score;Score;Pt;^Patient;Qn;MOS Social Support Survey;SURVEY.MTLHLTH;4;Positive social interaction score [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91651-0;General Well-Being Schedule - 18 item - total score;Score;Pt;^Patient;Qn;NHANES;SURVEY.GNHLTH;4;General Well-Being Schedule - 18 item - total score [NHANES];;;ACTIVE;2.66;2.66 +9165-2;Fluid output.misc;VRat;12H;XXX;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output miscellaneous 12 hour;Fluid output misc 12h;;ACTIVE;1.0i;2.48 +91652-8;How often is the following kind of support available to you if you need it - someone to help you if you were confined to bed;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to help you if you were confined to bed [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91653-6;How often is the following kind of support available to you if you need it - someone to take you to the doctor if you needed it;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to take you to the doctor if you needed it [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91654-4;How often is the following kind of support available to you if you need it - someone to have a good time with;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to have a good time with [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91655-1;How often is the following kind of support available to you if you need it - someone to give you information to help you understand a situation;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to give you information to help you understand a situation [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91656-9;How often is the following kind of support available to you if you need it - someone who hugs you;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone who hugs you [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91657-7;How often is the following kind of support available to you if you need it - someone to get together with for relaxation;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to get together with for relaxation [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91658-5;How often is the following kind of support available to you if you need it - someone to prepare your meals if you were unable to do it yourself;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to prepare your meals if you were unable to do it yourself [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91659-3;How often is the following kind of support available to you if you need it - someone to do things with to help get your mind off things;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to do things with to help get your mind off things [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +9166-0;Fluid output.misc;VRat;24H;XXX;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output miscellaneous 24 hour;Fluid output misc 24h;;ACTIVE;1.0i;2.48 +91660-1;How often is the following kind of support available to you if you need it - someone to turn to for suggestions about how to deal with a personal problem;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to turn to for suggestions about how to deal with a personal problem [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91661-9;How often is the following kind of support available to you if you need it - someone to do something enjoyable with;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone to do something enjoyable with [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91662-7;How often is the following kind of support available to you if you need it - someone who understands your problems;Find;Pt;^Patient;Ord;MOS Social Support Survey;SURVEY.MTLHLTH;4;How often is the following kind of support available to you if you need it - someone who understands your problems [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91663-5;Social support index;Score;Pt;^Patient;Qn;MOS Social Support Survey;SURVEY.MTLHLTH;4;Social support index [MOS Social Support Survey];;Copyright © the RAND Corporation. RAND's permission to reproduce the survey is not an endorsement of the products, services, or other uses in which the survey appears or is applied.;ACTIVE;2.66;2.66 +91664-3;Ambrosia deltoidea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Triangle bur ragweed (Ambrosia deltoidea) IgE Ab [Units/volume] in Serum;Triangle bur ragweed IgE Qn;;ACTIVE;2.66;2.66 +91665-0;Ascorbate oxidase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ascorbate oxidase IgE Ab [Units/volume] in Serum;Ascorbate oxidase IgE Qn;;ACTIVE;2.66;2.66 +91666-8;Ascorbate oxidase Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Ascorbate oxidase IgE Ab RAST class [Presence] in Serum;Ascorbate oxidase IgE RAST Ql;;ACTIVE;2.66;2.66 +91667-6;Aspergillus clavatus Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus clavatus Ab [Units/volume] in Serum;A clavatus Ab Qn;;ACTIVE;2.66;2.66 +91668-4;Aspergillus oryzae Ab;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus oryzae Ab [Units/volume] in Serum;A. oryzae Ab Qn;;ACTIVE;2.66;2.67 +91669-2;CYP3A7 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;CYP3A7 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;CYP3A7 Mut Anl Bld/T;;ACTIVE;2.66;2.67 +916-7;B Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;B Ag [Presence] on Red Blood Cells;B Ag RBC Ql;;ACTIVE;1.0;2.56 +91670-0;Orexin-A;MCnc;Pt;CSF;Qn;;CHEM;1;Orexin-A [Mass/volume] in Cerebral spinal fluid;Orexin-A CSF-mCnc;;ACTIVE;2.66;2.66 +91671-8;Transferrin.carbohydrate deficient.disialo/Transferrin.total^^standardized per IFCC-RMP for CDT;MFr;Pt;Ser/Plas;Qn;;CHEM;1;Transferrin.carbohydrate deficient.disialo/Transferrin.total standardized per IFCC-RMP for CDT in Serum or Plasma;CDT Disialo/Tf per IFCC-RMP CDT MFr S/P;;ACTIVE;2.66;2.66 +91672-6;ABCB1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;ABCB1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ABCB1 Mut Anl Bld/T;;ACTIVE;2.66;2.66 +91673-4;Cells.CD3+CD16+CD56+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD16+CD56+ cells/100 cells in Bone marrow;CD3+CD16+CD56+ Cells NFr Mar;;ACTIVE;2.66;2.66 +91674-2;Cells.CD3+CD16+CD56+;NCnc;Pt;Bone mar;Qn;;CELLMARK;1;CD3+CD16+CD56+ cells [#/volume] in Bone marrow;CD3+CD16+CD56+ Cells # Mar;;ACTIVE;2.66;2.66 +91675-9;Giardia lamblia & Cryptosporidium parvum Ag panel;-;Pt;Stool;-;IA.rapid;PANEL.MICRO;1;Giardia lamblia and Cryptosporidium parvum Ag panel - Stool by Rapid immunoassay;G lamblia+C parvum Ag Pnl Stl IA.rapid;;ACTIVE;2.66;2.66 +91676-7;Giardia lamblia Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Giardia lamblia Ag [Presence] in Stool by Rapid immunoassay;G lamblia Ag Stl Ql IA.rapid;;ACTIVE;2.66;2.66 +91677-5;Cryptosporidium parvum Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Cryptosporidium parvum Ag [Presence] in Stool by Rapid immunoassay;C parvum Ag Stl Ql IA.rapid;;ACTIVE;2.66;2.66 +9167-8;Fluid output.misc.route;Type;Pt;XXX;Nom;;IO_OUT.MOLEC;2;Fluid output miscellaneous route;Fluid output misc.route;;ACTIVE;1.0i;2.73 +91678-3;Zika virus Ab.IgM;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Zika virus IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;ZIKV IgM SerPlBld Ql IA.rapid;;ACTIVE;2.66;2.66 +91679-1;F8 gene intron 22 inversion targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.INV;1;F8 gene intron 22 inversion targeted mutation analysis in Blood or Tissue by Molecular genetics method;F8 intron 22 Inv Mut Anl Bld/T;;ACTIVE;2.66;2.66 +91680-9;F8 gene intron 22 inversion targeted mutation analysis;Find;Pt;Amnio fld/CVS;Doc;Molgen;MOLPATH.INV;1;F8 gene intron 22 inversion targeted mutation analysis in Amniotic fluid or Chorionic villus sample by Molecular genetics method;F8 intron 22 Inv Mut Anl Amn/CVS;;ACTIVE;2.66;2.66 +91681-7;F9 gene mutation analysis limited to known familial mutations;Find;Pt;Amnio fld/CVS;Doc;Molgen;MOLPATH.MUT;1;F9 gene mutation analysis limited to known familial mutations in Amniotic fluid or Chorionic villus sample by Molecular genetics method;F9 gene Fam Mut Anl Amn/CVS;;ACTIVE;2.66;2.66 +91682-5;Histoplasma capsulatum Ab;Prid;Pt;CSF;Nom;Immune diffusion;MICRO;1;Histoplasma capsulatum Ab [Identifier] in Cerebral spinal fluid by Immune diffusion (ID);H capsul Ab CSF ID;;ACTIVE;2.66;2.73 +91683-3;Histoplasma capsulatum H & M Ab & Blastomyces dermatitidis Ab panel;-;Pt;CSF;-;;PANEL.MICRO;1;Histoplasma capsulatum H and M and Blastomyces dermatitidis Ab panel - Cerebral spinal fluid;H capsul H+M + B. derma Ab Pnl CSF;;ACTIVE;2.66;2.66 +91684-1;Histoplasma capsulatum H & M Ab panel;-;Pt;CSF;-;;PANEL.MICRO;1;Histoplasma capsulatum H and M Ab panel - Cerebral spinal fluid;H capsulatum H+M Ab panel CSF;;ACTIVE;2.66;2.66 +91685-8;Glutathione;MCnc;Pt;Bld;Qn;;CHEM;1;Glutathione [Mass/volume] in Blood;Glutathione Bld-mCnc;;ACTIVE;2.66;2.66 +9168-6;Fluid output.pericardial drain;Vol;Pt;Pericardial space;Qn;;IO_OUT.MOLEC;2;Fluid output pericardial drain;Fluid output pericardial drain;;ACTIVE;1.0i;2.54 +91686-6;Adult self-report short form total score;Score;Pt;^Patient;Qn;MFQ;SURVEY.MTLHLTH;4;Adult self-report long short form total score [MFQ];;"Copyright © Adrian Angold & Elizabeth J. Costello, 1987; Developmental Epidemiology Program; Duke University. Used with permission.";ACTIVE;2.66;2.66 +91687-4;Adult self-report long form total score;Score;Pt;^Patient;Qn;MFQ;SURVEY.MTLHLTH;4;Adult self-report long form total score [MFQ];;"Copyright © Adrian Angold & Elizabeth J. Costello, 1987; Developmental Epidemiology Program; Duke University. Used with permission.";ACTIVE;2.66;2.66 +91688-2;Mood and Feelings Questionnaire Adult self-report long form;-;Pt;^Patient;-;MFQ;PANEL.SURVEY.MTLHLTH;4;Mood and Feelings Questionnaire [MFQ] Adult self-report long form;;"Copyright © Adrian Angold & Elizabeth J. Costello, 1987; Developmental Epidemiology Program; Duke University. Used with permission.";ACTIVE;2.66;2.66 +91689-0;Mood and Feelings Questionnaire Adult self-report short form;-;Pt;^Patient;-;MFQ;PANEL.SURVEY.MTLHLTH;4;Mood and Feelings Questionnaire [MFQ] Adult self-report short form;;"Copyright © Adrian Angold & Elizabeth J. Costello, 1987; Developmental Epidemiology Program; Duke University. Used with permission.";ACTIVE;2.66;2.66 +91690-8;Testing services available;Type;Pt;Facility;Nom;;ADMIN.FACILITY;2;Testing services available at Facility;Test services available Facility;;ACTIVE;2.66;2.68 +91691-6;Age;Time;Pt;Personnel;Qn;;ADMIN.DEMOG;2;Personnel Age;Personnel Age;;ACTIVE;2.66;2.68 +91692-4;Sex;Type;Pt;Personnel;Nom;;ADMIN.DEMOG;2;Sex of Personnel;Sex of Personnel;;ACTIVE;2.66;2.68 +91693-2;Specialty;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel specialty;Personnel specialty;;ACTIVE;2.66;2.68 +9169-4;Fluid output.pericardial drain;VRat;1H;Pericardial space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output pericardial drain 1 hour;Fluid output pericardial drain 1h;;ACTIVE;1.0i;2.48 +91694-0;Highest level of education;Type;Pt;Personnel;Ord;;ADMIN;2;Highest level of education of Personnel;Personnel Highest level of educ;;ACTIVE;2.66;2.68 +91695-7;Qualification;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel Qualification;Personnel Qualification;;ACTIVE;2.66;2.68 +91696-5;Response team name;ID;Pt;EMS response;Nom;;ADMIN;2;Response team name;Response team name;;ACTIVE;2.66;2.68 +91697-3;Name;Pn;Pt;Volunteer;Nom;;ADMIN;2;Volunteer Name;Volunteer Name;;ACTIVE;2.66;2.68 +91698-1;Age;Time;Pt;Volunteer;Qn;;ADMIN.DEMOG;2;Volunteer age;Volunteer age;;ACTIVE;2.66;2.68 +91699-9;Sex;Type;Pt;Volunteer;Nom;;ADMIN.DEMOG;2;Sex of Volunteer;Sex of Volunteer;;ACTIVE;2.66;2.68 +91700-5;Specialty;Type;Pt;Volunteer;Nom;;ADMIN;2;Specialty Volunteer;Specialty Volunteer;;ACTIVE;2.66;2.68 +91701-3;Shelter category;Type;Pt;Facility;Nom;;PUBLICHEALTH;2;Shelter category Facility;Shelter category Facility;;ACTIVE;2.66;2.68 +9170-2;Fluid output.pericardial drain;VRat;8H;Pericardial space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output pericardial drain 8 hour;Fluid output pericardial drain 8h;;ACTIVE;1.0i;2.48 +91702-1;Shelter name;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Shelter name [Identifier] Facility;Shelter name Facility;;ACTIVE;2.66;2.68 +91703-9;Shelter address;Addr;Pt;Facility;Nom;;ADMIN.FACILITY;2;Shelter address Facility;Shelter address Facility;;ACTIVE;2.66;2.68 +91704-7;Primary contact information panel;-;Pt;Facility;-;;PANEL.ADMIN;2;Primary contact information panel Facility;Primary contact info pnl Facility;;ACTIVE;2.66;2.68 +91705-4;Corticotropin^5M pre 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --5 minutes pre 1 ug/kg CRH IV;ACTH 5M pre 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.66;2.66 +91706-2;Corticotropin^1M pre 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --1 minute pre 1 ug/kg CRH IV;ACTH 1M pre 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.66;2.66 +91707-0;Corticotropin post corticotropin releasing hormone stimulation panel;-;Pt;Plas;Qn;;PANEL.CHAL;1;Corticotropin post CRH stimulation panel - Plasma;ACTH p CRH stimulation Pnl Plas;;ACTIVE;2.66;2.66 +91708-8;Corticotropin^10M post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --10 minutes post 1 ug/kg CRH IV;ACTH 10M p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.66;2.66 +91709-6;Corticotropin^2M post 1 ug/kg CRH IV;MCnc;Pt;Plas;Qn;;CHAL;1;Corticotropin [Mass/volume] in Plasma --2 minutes post 1 ug/kg CRH IV;ACTH 2M p 1 ug/kg CRH IV Plas-mCnc;;ACTIVE;2.66;2.66 +9171-0;Fluid output.pericardial drain;VRat;10H;Pericardial space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output pericardial drain 10 hour;Fluid output pericardial drain 10h;;ACTIVE;1.0i;2.48 +91712-0;F5 gene.c.1691G>A;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F5 gene c.1691G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal;F5 c.1691G>A Geno Bld/T;;ACTIVE;2.66;2.68 +91714-6;Date of interview;Date;Pt;^Patient;Qn;;ADMIN;2;Date of interview;Interview date;;ACTIVE;2.66;2.66 +91715-3;Multisection^W contrast IV;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;MR;RAD;2;MR Spine Lumbar and Sacrum W contrast IV;MR L-spine+Sacrum W contr IV;;ACTIVE;2.66;2.67 +91716-1;Multisection^WO & W contrast IV;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;MR;RAD;2;MR Spine Lumbar and Sacrum WO and W contrast IV;MR L-spine+Sacrum WO+W contr IV;;ACTIVE;2.66;2.67 +91717-9;Multisection^WO contrast;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;MR;RAD;2;MR Spine Lumbar and Sacrum WO contrast;MR L-spine+Sacrum WO contr;;ACTIVE;2.66;2.67 +91718-7;Multisection post mortem;Find;Pt;XXX;Doc;MR;RAD;2;MR Unspecified body region Post mortem;MR PM;;ACTIVE;2.66;2.67 +91719-5;Multisection post mortem;Find;Pt;XXX;Doc;CT;RAD;2;CT Unspecified body region Post mortem;CT PM;;ACTIVE;2.66;2.67 +91720-3;Views for shunt patency;Find;Pt;Head+Neck+Chest+Abdomen;Doc;XR;RAD;2;XR Head to Abdomen Views for shunt patency;XR Head to Abdomen Vs for shunt pat;;ACTIVE;2.66;2.67 +91721-1;PROMIS physical function - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS physical function - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91722-9;PROMIS item bank - physical function - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - physical function - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91723-7;Are you able to rake leaves or sweep for 1H without stopping to rest;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to rake leaves or sweep for 1 hour without stopping to rest [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91724-5;Are you able to complete 5 push-ups without stopping;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to complete 5 push-ups without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91725-2;Are you able to hand wash and wax a car for 2H without stopping to rest;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to hand wash and wax a car for 2 hours without stopping to rest [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91726-0;Are you able to dance energetically for 1H;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dance energetically for 1 hour [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91727-8;Are you able to swim laps for 30M at a moderate pace;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to swim laps for 30 minutes at a moderate pace [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9172-8;Fluid output.pericardial drain;VRat;12H;Pericardial space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output pericardial drain 12 hour;Fluid output pericardial drain 12h;;ACTIVE;1.0i;2.48 +91728-6;Are you able to stand up from a push-up position five times quickly;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand up from a push-up position five times quickly [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91729-4;Are you able to pull a sled or a wagon with two children (total 100 lbs or 50 kg) for 100 yards (100 m);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to pull a sled or a wagon with two children (total 100 lbs or 50 kg) for 100 yards (100 m) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91730-2;Are you able to carry a 50 lb (25 kg) bag of sand 25 yards (25 m);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a 50 lb (25 kg) bag of sand 25 yards (25 m) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91731-0;Are you able to push an empty refrigerator forward 1 yard (1 m);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to push an empty refrigerator forward 1 yard (1 m) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91732-8;Are you able to climb a 6-foot (2 m) ladder;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to climb a 6-foot (2 m) ladder [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91733-6;Are you able to row a boat for 30M without stopping to rest;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to row a boat for 30 minutes without stopping to rest [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91734-4;Are you able to lift and load one 50-pound (25 kg) bag of sand into a car;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift and load one 50-pound (25 kg) bag of sand into a car [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91735-1;Are you able to carry a large baby (15 lbs or 7 kg) out of the house to a car or taxi;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a large baby (15 lbs or 7 kg) out of the house to a car or taxi [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9173-6;Fluid output.pericardial drain;VRat;24H;Pericardial space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output pericardial drain 24 hour;Fluid output pericardial drain 24h;;ACTIVE;1.0i;2.48 +91736-9;Are you able to put your hands flat on the floor with both feet flat on the ground;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to put your hands flat on the floor with both feet flat on the ground [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91737-7;Are you able to walk in a straight line putting one foot in front of the other (heel to toe) for 5 yards (5 m);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk in a straight line putting one foot in front of the other (heel to toe) for 5 yards (5 m) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91738-5;Are you able to stand on one foot with your eyes closed for 30S;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to stand on one foot with your eyes closed for 30 seconds [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91739-3;Are you able to walk across a balance beam;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk across a balance beam [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91740-1;Are you able to jump 2 feet (60 cm) high;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to jump 2 feet (60 cm) high [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91741-9;Are you able to paint the walls of a room with a brush or roller for 2H without stopping to rest;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to paint the walls of a room with a brush or roller for 2hours without stopping to rest [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91742-7;Are you able to jump over a puddle that is 3 feet (1 m) wide;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to jump over a puddle that is 3 feet (1 m) wide [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91743-5;Are you able to jump over an object that is 1 foot (30 cm) tall;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to jump over an object that is 1 foot (30 cm) tall [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9174-4;Fluid output.peritoneal drain;VRat;1H;Peritoneal space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output peritoneal drain 1 hour;Fluid output peritoneal drain 1h;;ACTIVE;1.0i;2.48 +91744-3;Are you able to jump rope for 10M without stopping;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to jump rope for 10M without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91745-0;Are you able to make sharp turns while running fast;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to make sharp turns while running fast [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91746-8;Are you able to come to a complete stop while running;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to come to a complete stop while running [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91747-6;Are you able to walk briskly for 20M without stopping to rest;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to walk briskly for 20 minutes without stopping to rest [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91748-4;Are you able to climb the stairs of a 10-story building without stopping;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to climb the stairs of a 10-story building without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91749-2;Are you able to complete 10 sit-ups without stopping;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to complete 10 sit-ups without stopping [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +917-5;B variant subtype Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;B variant subtype Ab [Presence] in Serum or Plasma from Blood product unit;B Var Subtyp Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +91750-0;Are you able to remove a heavy suitcase (50 lbs or 25 kg) from an overhead bin on an airplane or bus;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to remove a heavy suitcase (50 lbs or 25 kg) from an overhead bin on an airplane or bus [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9175-1;Fluid output.peritoneal drain;VRat;8H;Peritoneal space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output peritoneal drain 8 hour;Fluid output peritoneal drain 8h;;ACTIVE;1.0i;2.48 +91751-8;Are you able to hit the backboard with a basketball from the free-throw line (13 ft or 4 m);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to hit the backboard with a basketball from the free throw line 13 ft or 4 m [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91752-6;Are you able to lift a heavy object (20 lbs or 10 kg) above your head;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to lift a heavy object (20 lbs or 10 kg) above your head [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91753-4;Are you able to do a pull-up;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to do a pull-up [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91754-2;Are you able to dig a 2-foot (.5 m) deep hole in the dirt with a shovel;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to dig a 2-foot (1/2 m) deep hole in the dirt with a shovel [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91755-9;Are you able to carry household items, such as heavy boxes or furniture, up a flight of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry household items, such as heavy boxes or furniture, up a flight of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91756-7;Are you able to carry a suitcase up a flight of stairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to carry a suitcase up a flight of stairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91757-5;Are you able to run on even ground;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Are you able to run on even ground [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91758-3;Does your health now limit you in doing yard work like raking leaves, weeding, or pushing a lawn mower;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in doing yard work like raking leaves, weeding, or pushing a lawn mower [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91759-1;Does your health now limit you in taking part in any sports (swimming, bowling, and so forth);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in taking part in any sports (swimming, bowling, and so forth) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91760-9;Does your health now limit you in dancing for half an hour;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Does your health now limit you in dancing for half an hour [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91761-7;Giardia sp Ag;PrThr;Pt;Stool;Ord;IA.rapid;MICRO;1;Giardia sp Ag [Presence] in Stool by Rapid immunoassay;Giardia Ag Stl Ql IA.rapid;;ACTIVE;2.66;2.73 +91762-5;Watch record details;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Watch record details Narrative;Watch record details;;ACTIVE;2.66;2.68 +91763-3;Mycobacterium tuberculosis DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Aspirate by NAA with probe detection;M tb DNA Aspirate Ql NAA+probe;;ACTIVE;2.66;2.66 +91764-1;Nocardia sp identified;Prid;Pt;Asp;Nom;Organism specific culture;MICRO;1;Nocardia sp identified in Aspirate by Organism specific culture;Nocardia Aspirate Cult;;ACTIVE;2.66;2.66 +91765-8;Entamoeba sp DNA;Prid;Pt;Asp;Nom;Sequencing;MICRO;1;Entamoeba sp DNA [Identifier] in Aspirate by Sequencing;Entamoeba DNA Aspirate Seq;;ACTIVE;2.66;2.66 +91766-6;Entamoeba histolytica DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Entamoeba histolytica DNA [Presence] in Aspirate by NAA with probe detection;E histolyt DNA Aspirate Ql NAA+probe;;ACTIVE;2.66;2.66 +91767-4;Giardia sp DNA;PrThr;Pt;Duod fld;Ord;Probe.amp.tar;MICRO;1;Giardia sp DNA [Presence] in Duodenal fluid by NAA with probe detection;Giardia DNA Duod fl Ql NAA+probe;;ACTIVE;2.66;2.66 +91768-2;Ova & parasites identified;Prid;Pt;Sputum;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Sputum by Light microscopy;O+P Spt Micro;;ACTIVE;2.66;2.66 +9176-9;Fluid output.peritoneal drain;VRat;10H;Peritoneal space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output peritoneal drain 10 hour;Fluid output peritoneal drain 10h;;ACTIVE;1.0i;2.48 +91769-0;Enterovirus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;EV RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91770-8;Enterovirus identified;Prid;Pt;Respiratory.upper;Nom;Organism specific culture;MICRO;1;Enterovirus identified in Upper respiratory specimen by Organism specific culture;EV Upper resp Cult;;ACTIVE;2.66;2.68 +91771-6;Influenza virus A subtype;Prid;Pt;Respiratory.upper;Nom;Probe.amp.tar;MICRO;1;Influenza virus A subtype [Identifier] in Upper respiratory specimen by NAA with probe detection;FLUAV Subtyp Upper resp NAA+probe;;ACTIVE;2.66;2.68 +91772-4;Influenza virus identified;Prid;Pt;Respiratory.upper;Nom;Organism specific culture;MICRO;1;Influenza virus identified in Upper respiratory specimen by Organism specific culture;FLUV Upper resp Cult;;ACTIVE;2.66;2.68 +91773-2;Herpes simplex virus identified;Prid;Pt;Asp;Nom;Organism specific culture;MICRO;1;Herpes simplex virus identified in Aspirate by Organism specific culture;HSV Aspirate Cult;;ACTIVE;2.66;2.66 +91774-0;Varicella zoster virus Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Varicella zoster virus Ag [Presence] in Lower respiratory specimen by Immunofluorescence;VZV Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +91775-7;Bordetella sp identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Bordetella sp identified in Lower respiratory specimen by Organism specific culture;Bordetella Lower resp Cult;;ACTIVE;2.66;2.66 +91776-5;Mycoplasma sp.respiratory identified;Prid;Pt;Respiratory.lower;Nom;Organism specific culture;MICRO;1;Respiratory Mycoplasma identified in Lower respiratory specimen by Organism specific culture;Resp Mycoplasma Lower resp Cult;;ACTIVE;2.66;2.66 +9177-7;Fluid output.peritoneal drain;VRat;12H;Peritoneal space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output peritoneal drain 12 hour;Fluid output peritoneal drain 12h;;ACTIVE;1.0i;2.48 +91777-3;Bordetella sp identified;Prid;Pt;Respiratory.upper;Nom;Organism specific culture;MICRO;1;Bordetella sp identified in Upper respiratory specimen by Organism specific culture;Bordetella Upper resp Cult;;ACTIVE;2.66;2.68 +91778-1;Human metapneumovirus identified;Prid;Pt;Respiratory.upper;Nom;Organism specific culture;MICRO;1;Human metapneumovirus identified in Upper respiratory specimen by Organism specific culture;hMPV Upper resp Cult;;ACTIVE;2.66;2.68 +91779-9;Yeast identified;Prid;Pt;Respiratory.upper;Nom;Organism specific culture;MICRO;1;Yeast identified in Upper respiratory specimen by Organism specific culture;Yeast Upper resp Cult;;ACTIVE;2.66;2.68 +91780-7;Measles virus;PrThr;Pt;Respiratory.lower;Ord;Organism specific culture;MICRO;1;Measles virus [Presence] in Lower respiratory specimen by Organism specific culture;MeV Lower resp Ql Cult;;ACTIVE;2.66;2.66 +91781-5;Neisseria gonorrhoeae;PrThr;Pt;Asp;Ord;Organism specific culture;MICRO;1;Neisseria gonorrhoeae [Presence] in Aspirate by Organism specific culture;N gonorrhoea Aspirate Ql Cult;;ACTIVE;2.66;2.66 +91782-3;Respiratory syncytial virus;PrThr;Pt;Respiratory.lower;Ord;Organism specific culture;MICRO;1;Respiratory syncytial virus [Presence] in Lower respiratory specimen by Organism specific culture;RSV Lower resp Ql Cult;;ACTIVE;2.66;2.72 +91783-1;Cytomegalovirus;PrThr;Pt;Respiratory.lower;Ord;Organism specific culture;MICRO;1;Cytomegalovirus [Presence] in Lower respiratory specimen by Organism specific culture;CMV Lower resp Ql Cult;;ACTIVE;2.66;2.66 +91784-9;Varicella zoster virus;PrThr;Pt;Respiratory.lower;Ord;Organism specific culture;MICRO;1;Varicella zoster virus [Presence] in Lower respiratory specimen by Organism specific culture;VZV Lower resp Ql Cult;;ACTIVE;2.66;2.66 +9178-5;Fluid output.peritoneal drain;VRat;24H;Peritoneal space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output peritoneal drain 24 hour;Fluid output peritoneal drain 24h;;ACTIVE;1.0i;2.48 +91785-6;Respiratory syncytial virus;PrThr;Pt;Respiratory.upper;Ord;Organism specific culture;MICRO;1;Respiratory syncytial virus [Presence] in Upper respiratory specimen by Organism specific culture;RSV Upper resp Ql Cult;;ACTIVE;2.66;2.72 +91786-4;Measles virus;PrThr;Pt;Respiratory.upper;Ord;Organism specific culture;MICRO;1;Measles virus [Presence] in Upper respiratory specimen by Organism specific culture;MeV Upper resp Ql Cult;;ACTIVE;2.66;2.68 +91787-2;Mumps virus;PrThr;Pt;Respiratory.upper;Ord;Organism specific culture;MICRO;1;Mumps virus [Presence] in Upper respiratory specimen by Organism specific culture;MuV Upper resp Ql Cult;;ACTIVE;2.66;2.68 +91788-0;Neisseria meningitidis;PrThr;Pt;Respiratory.upper;Ord;Organism specific culture;MICRO;1;Neisseria meningitidis [Presence] in Upper respiratory specimen by Organism specific culture;N men Upper resp Ql Cult;;ACTIVE;2.66;2.68 +91789-8;Haemophilus ducreyi;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Haemophilus ducreyi [Presence] in Genital specimen by Organism specific culture;H ducreyi Genital Ql Cult;;ACTIVE;2.66;2.66 +91790-6;Trichomonas vaginalis;PrThr;Pt;Genital;Ord;Organism specific culture;MICRO;1;Trichomonas vaginalis [Presence] in Genital specimen by Organism specific culture;T vaginalis Genital Ql Cult;;ACTIVE;2.66;2.66 +91791-4;Varicella zoster virus DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Upper respiratory specimen by NAA with probe detection;VZV DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91792-2;Rubella virus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Rubella virus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;RUBV RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +9179-3;Fluid output.peritoneal drain;Vol;Pt;Peritoneal space;Qn;;IO_OUT.MOLEC;2;Fluid output peritoneal drain;Fluid output peritoneal drain;;ACTIVE;1.0i;2.54 +91793-0;Rhinovirus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Rhinovirus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;Rhinovirus RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91794-8;Respiratory syncytial virus B RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus B RNA [Presence] in Upper respiratory specimen by NAA with probe detection;RSV B RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91795-5;Respiratory syncytial virus A RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus A RNA [Presence] in Upper respiratory specimen by NAA with probe detection;RSV A RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91796-3;Parvovirus B19 DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Upper respiratory specimen by NAA with probe detection;B19V DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91797-1;Parvovirus B19 DNA;NCnc;Pt;Respiratory.upper;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [#/volume] (viral load) in Upper respiratory specimen by NAA with probe detection;B19V DNA # Upper resp NAA+probe;;ACTIVE;2.66;2.68 +91798-9;Parainfluenza virus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HPIV RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91799-7;Parainfluenza virus 4 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HPIV4 RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91800-3;Parainfluenza virus 3 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HPIV3 RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +9180-1;Fluid output.subarachnoid drain;VRat;1H;Spinal subarachnoid space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output subarachnoid drain 1 hour;Fluid output subarachnoid drain 1h;;ACTIVE;1.0i;2.48 +91801-1;Parainfluenza virus 2 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HPIV2 RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91802-9;Parainfluenza virus 1 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HPIV1 RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91803-7;Neisseria meningitidis DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Presence] in Upper respiratory specimen by NAA with probe detection;N men DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91804-5;Mycoplasma pneumoniae DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Upper respiratory specimen by NAA with probe detection;M pneumo DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91805-2;Mycobacterium leprae DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Mycobacterium leprae DNA [Presence] in Upper respiratory specimen by NAA with probe detection;M leprae DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91806-0;Mumps virus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Mumps virus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;MuV RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91807-8;Middle east respiratory syndrome coronavirus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Upper respiratory specimen by NAA with probe detection;MERS-CoV RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91808-6;Microscopic observation;Prid;Pt;Respiratory.upper;Nom;Gram stain;MICRO;1;Microscopic observation [Identifier] in Upper respiratory specimen by Gram stain;Gram Stn Upper resp;;ACTIVE;2.66;2.68 +91809-4;Human metapneumovirus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;hMPV RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91810-2;Human metapneumovirus Ag;PrThr;Pt;Respiratory.upper;Ord;IF;MICRO;1;Human metapneumovirus Ag [Presence] in Upper respiratory specimen by Immunofluorescence;hMPV Ag Upper resp Ql IF;;ACTIVE;2.66;2.68 +91811-0;Human bocavirus Ag;PrThr;Pt;Respiratory.upper;Ord;IF;MICRO;1;Human bocavirus Ag [Presence] in Upper respiratory specimen by Immunofluorescence;HBoV Ag Upper resp Ql IF;;ACTIVE;2.66;2.68 +91812-8;Fungus identified;Prid;Pt;Respiratory.upper;Nom;Culture;MICRO;1;Fungus identified in Upper respiratory specimen by Culture;Fungus Upper resp Cult;;ACTIVE;2.66;2.68 +91813-6;Bordetella sp DNA;Prid;Pt;Respiratory.upper;Nom;Probe.amp.tar;MICRO;1;Bordetella sp DNA [Identifier] in Upper respiratory specimen by NAA with probe detection;Bordetella DNA Upper resp NAA+probe;;ACTIVE;2.66;2.68 +91814-4;Bordetella sp Ag;PrThr;Pt;Respiratory.upper;Ord;IF;MICRO;1;Bordetella sp Ag [Presence] in Upper respiratory specimen by Immunofluorescence;Bordetella Ag Upper resp Ql IF;;ACTIVE;2.66;2.68 +91815-1;Bordetella pertussis DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis DNA [Presence] in Upper respiratory specimen by NAA with probe detection;B pert DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.73 +91816-9;Bordetella parapertussis DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Bordetella parapertussis DNA [Presence] in Upper respiratory specimen by NAA with probe detection;B parapert DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.73 +91817-7;Bordetella holmesii DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Bordetella holmesii DNA [Presence] in Upper respiratory specimen by NAA with probe detection;B holmseii DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91818-5;Bacteria identified;Prid;Pt;Respiratory.upper;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Upper respiratory specimen by Anaerobe culture;Bacteria Upper resp Anaerobe Cult;;ACTIVE;2.66;2.68 +9181-9;Fluid output.subarachnoid drain;VRat;8H;Spinal subarachnoid space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output subarachnoid drain 8 hour;Fluid output subarachnoid drain 8h;;ACTIVE;1.0i;2.48 +91819-3;Bacteria identified;Prid;Pt;Respiratory.upper;Nom;Aerobic culture;MICRO;1;Bacteria identified in Upper respiratory specimen by Aerobe culture;Bacteria Upper resp Aerobe Cult;;ACTIVE;2.66;2.68 +91820-1;Adenovirus DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Upper respiratory specimen by NAA with probe detection;HAdV DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +91821-9;Adenovirus Ag;PrThr;Pt;Respiratory.upper;Ord;IA.rapid;MICRO;1;Adenovirus Ag [Presence] in Upper respiratory specimen by Rapid immunoassay;HAdV Ag Upper resp Ql IA.rapid;;ACTIVE;2.66;2.68 +91822-7;Adenovirus Ag;PrThr;Pt;Respiratory.upper;Ord;IA;MICRO;1;Adenovirus Ag [Presence] in Upper respiratory specimen by Immunoassay;HAdV Ag Upper resp Ql IA;;ACTIVE;2.66;2.68 +91823-5;Rubella virus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Rubella virus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;RUBV RNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91824-3;Pneumocystis jiroveci Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Pneumocystis jiroveci Ag [Presence] in Lower respiratory specimen by Immunofluorescence;P jiroveci Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +91825-0;Parechovirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Parechovirus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;PeV RNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91826-8;Ova & parasites identified;Prid;Pt;Respiratory.lower;Nom;Microscopy.light;MICRO;1;Ova and parasites identified in Lower respiratory specimen by Light microscopy;O+P Lower resp Micro;;ACTIVE;2.66;2.66 +9182-7;Fluid output.subarachnoid drain;VRat;10H;Spinal subarachnoid space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output subarachnoid drain 10 hour;Fluid output subarachnoid drain 10h;;ACTIVE;1.0i;2.48 +91827-6;Mycoplasma hominis DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Mycoplasma hominis DNA [Presence] in Lower respiratory specimen by NAA with probe detection;M hominis DNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91828-4;Mycoplasma genitalium DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Lower respiratory specimen by NAA with probe detection;M genitalium DNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91829-2;Mycobacterium tuberculosis DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis DNA [Presence] in Lower respiratory specimen by NAA with probe detection;M tb DNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +918-3;B variant subtype Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;B variant subtype Ab [Presence] in Serum or Plasma from Donor;B Var Subtyp Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +91830-0;Middle east respiratory syndrome coronavirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Lower respiratory specimen by NAA with probe detection;MERS-CoV RNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91831-8;Human metapneumovirus Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Human metapneumovirus Ag [Presence] in Lower respiratory specimen by Immunofluorescence;hMPV Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +91832-6;Human bocavirus Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Human bocavirus Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HBoV Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +91833-4;Herpes simplex virus Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Herpes simplex virus Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HSV Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +91834-2;Herpes simplex virus 2 Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Herpes simplex virus 2 Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HSV2 Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +9183-5;Fluid output.subarachnoid drain;VRat;12H;Spinal subarachnoid space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output subarachnoid drain 12 hour;Fluid output subarachnoid drain 12h;;ACTIVE;1.0i;2.48 +91835-9;Herpes simplex virus 1 Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Herpes simplex virus 1 Ag [Presence] in Lower respiratory specimen by Immunofluorescence;HSV1 Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +91836-7;Giardia sp DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Giardia sp DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Giardia DNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91837-5;Francisella sp DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Francisella sp DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Francisella sp DNA Low Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91838-3;Bordetella sp DNA;Prid;Pt;Respiratory.lower;Nom;Probe.amp.tar;MICRO;1;Bordetella sp DNA [Identifier] in Lower respiratory specimen by NAA with probe detection;Bordetella DNA Lower resp NAA+probe;;ACTIVE;2.66;2.66 +91839-1;Bordetella sp Ag;PrThr;Pt;Respiratory.lower;Ord;IF;MICRO;1;Bordetella sp Ag [Presence] in Lower respiratory specimen by Immunofluorescence;Bordetella Ag Lower resp Ql IF;;ACTIVE;2.66;2.66 +91840-9;Bordetella holmesii DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Bordetella holmesii DNA [Presence] in Lower respiratory specimen by NAA with probe detection;B holmseii DNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +91841-7;Adenovirus Ag;PrThr;Pt;Respiratory.lower;Ord;IA.rapid;MICRO;1;Adenovirus Ag [Presence] in Lower respiratory specimen by Rapid immunoassay;HAdV Ag Lower resp Ql IA.rapid;;ACTIVE;2.66;2.66 +91842-5;Ureaplasma urealyticum DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Ureaplasma urealyticum DNA [Presence] in Genital specimen by NAA with probe detection;U urealyticum DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +9184-3;Fluid output.subarachnoid drain;VRat;24H;Spinal subarachnoid space;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output subarachnoid drain 24 hour;Fluid output subarachnoid drain 24h;;ACTIVE;1.0i;2.48 +91843-3;Ureaplasma parvum DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Ureaplasma parvum DNA [Presence] in Genital specimen by NAA with probe detection;U parvum DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91844-1;Trichomonas vaginalis DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis DNA [Presence] in Genital specimen by NAA with probe detection;T vaginalis DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.73 +91845-8;Trichomonas vaginalis;PrThr;Pt;Genital;Ord;Microscopy.light;MICRO;1;Trichomonas vaginalis [Presence] in Genital specimen by Light microscopy;T vaginalis Genital Ql Micro;;ACTIVE;2.66;2.66 +91846-6;Treponema pallidum DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Treponema pallidum DNA [Presence] in Genital specimen by NAA with probe detection;T pallidum DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91847-4;Streptococcus agalactiae DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Genital specimen by NAA with probe detection;Gp B Strep DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91848-2;Mycoplasma hominis DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Mycoplasma hominis DNA [Presence] in Genital specimen by NAA with probe detection;M hominis DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91849-0;Mycoplasma genitalium DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Genital specimen by NAA with probe detection;M genitalium DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.73 +9185-0;Fluid output.urinary incontinence;Vol;Pt;Urinary tract;Qn;Estimated;IO_OUT.MOLEC;2;Fluid output urinary incontinence Estimated;Fluid output UI Est;;ACTIVE;1.0i;2.54 +91850-8;Microscopic observation;Prid;Pt;Genital;Nom;Giemsa stain;MICRO;1;Microscopic observation [Identifier] in Genital specimen by Giemsa stain;Gie Stn Genital;;ACTIVE;2.66;2.66 +91851-6;Human papilloma virus genotype;Prid;Pt;Genital;Nom;Probe.amp.tar;MICRO;1;Human papilloma virus genotype [Identifier] in Genital specimen by NAA with probe detection;HPV Gentyp Genital NAA+probe;;ACTIVE;2.66;2.72 +91852-4;Human papilloma virus DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus DNA [Presence] in Genital specimen by NAA with probe detection;HPV DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91853-2;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Genital specimen by NAA with probe detection;HPV HR 12 DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91854-0;Human papilloma virus 18 DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 18 DNA [Presence] in Genital specimen by NAA with probe detection;HPV18 DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91855-7;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Genital specimen by NAA with probe detection;HPV I/H Risk 1 DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91856-5;Human papilloma virus 16 DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 16 DNA [Presence] in Genital specimen by NAA with probe detection;HPV16 DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91857-3;Herpes simplex virus DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus DNA [Presence] in Genital specimen by NAA with probe detection;HSV DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91858-1;Herpes simplex virus 2 DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Genital specimen by NAA with probe detection;HSV2 DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91859-9;Herpes simplex virus 1 DNA;PrThr;Pt;Genital;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Genital specimen by NAA with probe detection;HSV1 DNA Genital Ql NAA+probe;;ACTIVE;2.66;2.66 +91860-7;Chlamydia trachomatis Ag;PrThr;Pt;Genital;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Genital specimen by Immunofluorescence;C trach Ag Genital Ql IF;;ACTIVE;2.66;2.66 +91861-5;Chlamydia trachomatis Ag;PrThr;Pt;Asp;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Aspirate by Immunofluorescence;C trach Ag Aspirate Ql IF;;ACTIVE;2.66;2.66 +91862-3;Bartonella sp DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Bartonella sp DNA [Presence] in Aspirate by NAA with probe detection;Bartonella DNA Aspirate Ql NAA+probe;;ACTIVE;2.66;2.66 +91863-1;Bartonella quintana DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Bartonella quintana DNA [Presence] in Aspirate by NAA with probe detection;B quintana DNA Aspirate Ql NAA+probe;;ACTIVE;2.66;2.66 +91864-9;Bartonella henselae DNA;PrThr;Pt;Asp;Ord;Probe.amp.tar;MICRO;1;Bartonella henselae DNA [Presence] in Aspirate by NAA with probe detection;B henselae DNA Aspirate Ql NAA+probe;;ACTIVE;2.66;2.66 +91865-6;Bacteria identified;Prid;Pt;Genital;Nom;Anaerobic culture;MICRO;1;Bacteria identified in Genital specimen by Anaerobe culture;Bacteria Genital Anaerobe Cult;;ACTIVE;2.66;2.66 +91866-4;Bacteria identified;Prid;Pt;Mouth;Nom;Aerobic culture;MICRO;1;Bacteria identified in Mouth by Aerobe culture;Bacteria Mouth Aerobe Cult;;ACTIVE;2.66;2.66 +91867-2;Bordetella holmesii DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Bordetella holmesii DNA [Presence] in Throat by NAA with probe detection;B holmseii DNA Throat Ql NAA+probe;;ACTIVE;2.66;2.66 +9186-8;Fluid output.urinary incontinence;Vol;Pt;Urinary tract;Qn;Ring and weigh;IO_OUT.MOLEC;2;Fluid output urinary incontinence Ring + Weigh;Fluid output UI Ring+Weigh;;ACTIVE;1.0i;2.54 +91868-0;Bordetella parapertussis DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Bordetella parapertussis DNA [Presence] in Throat by NAA with probe detection;B parapert DNA Throat Ql NAA+probe;;ACTIVE;2.66;2.66 +91869-8;Bordetella pertussis DNA;PrThr;Pt;Thrt;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis DNA [Presence] in Throat by NAA with probe detection;B pert DNA Throat Ql NAA+probe;;ACTIVE;2.66;2.66 +91870-6;Bordetella sp Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Bordetella sp Ag [Presence] in Throat by Immunofluorescence;Bordetella Ag Throat Ql IF;;ACTIVE;2.66;2.66 +91871-4;Bordetella sp DNA;Prid;Pt;Thrt;Nom;Probe.amp.tar;MICRO;1;Bordetella sp DNA [Identifier] in Throat by NAA with probe detection;Bordetella DNA Throat NAA+probe;;ACTIVE;2.66;2.66 +91872-2;Bordetella sp identified;Prid;Pt;Thrt;Nom;Organism specific culture;MICRO;1;Bordetella sp identified in Throat by Organism specific culture;Bordetella Throat Cult;;ACTIVE;2.66;2.66 +91873-0;Chlamydia trachomatis Ag;PrThr;Pt;Thrt;Ord;IF;MICRO;1;Chlamydia trachomatis Ag [Presence] in Throat by Immunofluorescence;C trach Ag Throat Ql IF;;ACTIVE;2.66;2.66 +91874-8;Mycoplasma genitalium DNA;PrThr;Pt;Urethra;Ord;Probe.amp.tar;MICRO;1;Mycoplasma genitalium DNA [Presence] in Urethra by NAA with probe detection;M genitalium DNA Urth Ql NAA+probe;;ACTIVE;2.66;2.66 +91875-5;Streptococcus agalactiae DNA;PrThr;Pt;Vag+Rectum;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Vag+Rectum by NAA with probe detection;Gp B Strep DNA Vag+Rectum Ql NAA+probe;;ACTIVE;2.66;2.66 +9187-6;Fluid output.urine;Vol;Pt;Urinary tract;Qn;;IO_OUT.MOLEC;2;Urine output;Fluid output urine;;ACTIVE;1.0i;2.73 +91876-3;Brucella sp Ab;Titr;Pt;Ser;Qn;Aggl.capture;MICRO;1;Brucella sp Ab [Titer] in Serum by Immunocapture agglutination;Brucella Ab Titr Ser Capture aggl;;ACTIVE;2.66;2.66 +91877-1;Date and time report was received;TmStp;Pt;Report;Qn;;DOC.MISC;2;Date and time report was received;D/T report was received;;ACTIVE;2.66;2.68 +91878-9;Mode of communication;Type;Pt;^Event;Nom;;PUBLICHEALTH;2;Mode of communication;Communication mode;;ACTIVE;2.66;2.68 +91879-7;Reporter information;-;Pt;^Event;-;;PANEL.ADMIN;2;Reporter Information;Reporter info;;ACTIVE;2.66;2.68 +91880-5;Date and time of risk assessment meeting;TmStp;Pt;^Event;Qn;;ADMIN;2;Date and time of risk assessment meeting;D/T risk assessment meeting;;ACTIVE;2.66;2.68 +91881-3;Location of meeting;Loc;Pt;^Event;Nom;;ADMIN;2;Location of meeting;Meeting location;;ACTIVE;2.66;2.68 +91882-1;Emergency response plan objective;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Emergency response plan objective;Emerg response plan objective;;ACTIVE;2.66;2.68 +91883-9;Emergency response plan target outcome;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Emergency response plan target outcome;Emerg response target outcome;;ACTIVE;2.66;2.68 +9188-4;Fluid output.urine;VRat;1H;Urinary tract;Qn;;IO_OUT.TIMED.MOLE;2;Urine output 1 hour;Fluid output urine 1h;;ACTIVE;1.0i;2.56 +91884-7;Emergency response plan problem analysis;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Emergency response plan problem analysis Narrative;Emerg response plan prob analysis;;ACTIVE;2.66;2.68 +91885-4;Emergency response plan success analysis;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Emergency response plan success analysis;Emerg response plan success analysis;;ACTIVE;2.66;2.68 +91886-2;Document name;ID;Pt;Document;Nom;;DOC.ADMIN;2;Document name [Identifier];Document name;;ACTIVE;2.66;2.68 +91887-0;Agency type;Type;Pt;Agency;Nom;;ADMIN.FACILITY;2;Agency type;Agency type;;ACTIVE;2.66;2.68 +91888-8;Qualification;Type;Pt;Volunteer;Nom;;ADMIN;2;Qualification Volunteer;Qualification Volunteer;;ACTIVE;2.66;2.68 +91889-6;Volunteer contact information panel;-;Pt;Volunteer;-;;PANEL.ADMIN;2;Volunteer contact information panel;Volunteer contact info Pnl;;ACTIVE;2.66;2.68 +91890-4;Emergency supply category;Type;Pt;Supply;Nom;;PUBLICHEALTH;2;Emergency supply category;Emergency supply category;;ACTIVE;2.66;2.68 +91891-2;Bed type;Type;Pt;Facility;Nom;;ADMIN.FACILITY;2;Facility Bed type;Facility Bed type;;ACTIVE;2.66;2.68 +9189-2;Fluid output.urine;VRat;8H;Urinary tract;Qn;;IO_OUT.TIMED.MOLE;2;Urine output 8 hour;Fluid output urine 8h;;ACTIVE;1.0i;2.56 +91892-0;Address;Addr;Pt;Volunteer;Nom;;ADMIN;2;Address Volunteer;Address Volunteer;;ACTIVE;2.66;2.68 +91893-8;Email address;EmailAddr;Pt;Volunteer;Nom;;ADMIN;2;Email address Volunteer;Email address Volunteer;;ACTIVE;2.66;2.68 +91894-6;Phone number;Tele;Pt;Volunteer;Nom;;ADMIN;2;Volunteer Phone number;Volunteer Phone #;;ACTIVE;2.66;2.66 +91895-3;Bacterial strain;Type;Pt;Isolate;Nom;Sequencing;MICRO;1;Bacterial strain [Type] in Isolate by Sequencing;Bacterial strain Islt Seq;;ACTIVE;2.66;2.66 +91896-1;Mycoplasma pneumoniae Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Mycoplasma pneumoniae Ab [Titer] in Serum by Agglutination;M pneumo Ab Titr Ser Aggl;;ACTIVE;2.66;2.66 +91897-9;Doravirine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Doravirine [Susceptibility] by Genotype method;Doravirine Islt Genotyp;;ACTIVE;2.66;2.66 +91898-7;Epizootic hemorrhagic disease virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Epizootic hemorrhagic disease virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;EHDV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.66;2.69 +91899-5;Anaplasma phagocytophilum & Ehrlichia chaffeensis DNA panel;-;Pt;Bld;-;;PANEL.MICRO;1;Anaplasma phagocytophilum and Ehrlichia chaffeensis DNA panel - Blood;A phagocyt + E chaff DNA Pnl Bld;;ACTIVE;2.66;2.66 +91-9;Cefodizime;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefodizime [Susceptibility] by Minimum lethal concentration (MLC);Cefodizime Islt MLC;;ACTIVE;1.0;2.19 +9190-0;Fluid output.urine;VRat;10H;Urinary tract;Qn;;IO_OUT.TIMED.MOLE;2;Urine output 10 hour;Fluid output urine 10h;;ACTIVE;1.0i;2.56 +91900-1;Parasite;PrThr;Pt;Bld;Ord;Microscopy.light;MICRO;1;Parasite [Presence] in Blood by Light microscopy;Parasite Bld Ql Smear;;ACTIVE;2.66;2.66 +91901-9;Response team;Type;Pt;EMS response;Nom;;PUBLICHEALTH;2;Response team [Type];Response team Type;;ACTIVE;2.66;2.68 +91902-7;Supply item;Type;Pt;Supply;Nom;;PUBLICHEALTH;2;Supply item [Type];Supply item Type;;ACTIVE;2.66;2.68 +91903-5;Supply identifier;ID;Pt;Supply;Nom;;PUBLICHEALTH;2;Supply identifier;Supply ID;;ACTIVE;2.66;2.68 +91904-3;Response team member qualification;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel Response team member qualification;Personnel Response team member qual;;ACTIVE;2.66;2.68 +91905-0;Response team leader information panel;-;Pt;Personnel;-;;PANEL.ADMIN;2;Personnel Response team leader information panel;Personnel Response team leader info Pnl;;ACTIVE;2.66;2.68 +91906-8;Response team leader qualification;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel Response team leader qualification;Personnel Response team leader qual;;ACTIVE;2.66;2.68 +91907-6;Storage location;Loc;Pt;Supply;Nom;;PUBLICHEALTH;2;Storage location of Supply;Supply Storage location;;ACTIVE;2.66;2.68 +91908-4;Supply stockpile;Num;Pt;Supply;Qn;;PUBLICHEALTH;2;Supply stockpile [#] Supply;Supply stockpile Supply;;ACTIVE;2.66;2.68 +91909-2;Expiration date;Date;Pt;Supply;Qn;;PUBLICHEALTH;2;Expiration date of Supply;Supply Expiration date;;ACTIVE;2.66;2.68 +919-1;B variant subtype Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;B variant subtype Ab [Presence] in Serum or Plasma;B Var Subtyp Ab SerPl Ql;;ACTIVE;1.0;2.56 +91910-0;My child was too tired to read in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to read in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91911-8;My child was too tired to eat in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to eat in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91912-6;My child needed to sleep during the day in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child needed to sleep during the day in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91913-4;My child had trouble finishing things because he or she was too tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble finishing things because he/she was too tired in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91914-2;My child felt too tired to spend time with his or her friends in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt too tired to spend time with his/her friends in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91915-9;Being tired made it hard for my child to keep up with schoolwork in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Being tired made it hard for my child to keep up with schoolwork in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91916-7;My child was too tired to go out with his or her family in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to go out with his/her family in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91917-5;My child felt more tired than usual when he or she woke up in the morning in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt more tired than usual when he/she woke up in the morning in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9191-8;Fluid output.urine;VRat;12H;Urinary tract;Qn;;IO_OUT.TIMED.MOLE;2;Urine output 12 hour;Fluid output urine 12h;;ACTIVE;1.0i;2.56 +91918-3;My child was so tired it was hard for him or her to pay attention in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was so tired it was hard for him/her to pay attention in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91919-1;My child felt tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt tired in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91920-9;My child was too tired to do things outside in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to do things outside in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91921-7;Being tired kept my child from having fun in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Being tired kept my child from having fun in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91922-5;My child had trouble starting things because he or she was too tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble starting things because he/she was too tired in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91923-3;My child was too tired to do sports or exercise in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to do sports or exercise in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91924-1;My child was too tired to go up and down a lot of stairs in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to go up and down a lot of stairs in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91925-8;It was hard for my child to get out of bed in the morning because he or she was too tired in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to get out of bed in the morning because he/she was too tired in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9192-6;Fluid output.urine;VRat;24H;Urinary tract;Qn;;IO_OUT.TIMED.MOLE;2;Urine output 24 hour;Fluid output urine 24h;;ACTIVE;1.0i;2.73 +91926-6;Being tired made it hard for my child to play or go out with friends as much as he or she would like in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Being tired made it hard for my child to play or go out with friends as much as he/she would like in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91927-4;My child was too tired to focus on his or her work in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to focus on his/her work in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91929-0;My child was too tired to enjoy the things he or she likes to do in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to enjoy the things he/she likes to do in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91930-8;My child was too tired to watch television in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to watch television in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91931-6;My child was too tired to take a bath or shower in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was too tired to take a bath or shower in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91932-4;My child felt weak in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt weak in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91933-2;PROMIS parent proxy item bank - fatigue - version 2.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - fatigue version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9193-4;Fluid output.urine;Aper;Pt;Urinary tract;Nom;;IO_OUT.MOLEC;2;Urine output [Appearance];Fluid output urine;;ACTIVE;1.0i;2.56 +91934-0;PROMIS parent proxy fatigue - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy fatigue - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91935-7;PROMIS pediatric pain behavior - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric pain behavior - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91936-5;PROMIS pediatric item bank - pain behavior - version 1.0;-;7D;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric item bank - pain behavior - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91937-3;When I was in pain I felt my body get tense in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I felt my body get tense in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91938-1;When I was in pain I lay down in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I lay down in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91939-9;When I was in pain I asked for someone to help me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;WhenI was in pain I asked for someone to help me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91940-7;When I was in pain I told people I couldn't do things with them in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;WhenI was in pain I told people I couldn't do things with them in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91941-5;When I was in pain it showed on my face in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain it showed on my face in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9194-2;Class;Type;Pt;Urine collection method;Nom;*;IO_OUT.MOLEC;2;Type of Urine collection method;Urn Collect Method Class;;ACTIVE;1.0i;2.73 +91942-3;When I was in pain I told people I couldn't do my usual chores in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I told people I couldn't do my usual chores in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91943-1;When I was in pain I took breaks from what I was doing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I took breaks from what I was doing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91944-9;When I was in pain I sighed in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I sighed in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91945-6;When I was in pain I got mad and threw or hit something in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I got mad and threw or hit something in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91946-4;When I was in pain I said mean words to people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I said mean words to people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91947-2;When I was in pain I avoided using the part of my body that hurt in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I avoided using the part of my body that hurt in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91948-0;When I was in pain I argued with people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I argued with people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91949-8;When I was in pain I pulled away if someone touched me where it hurt in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I pulled away if someone touched me where it hurt in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91950-6;When I was in pain I asked to see a doctor in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked to see a doctor in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91951-4;When I was in pain I complained in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I complained in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91952-2;When I was in pain I tried to rest or relax in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I tried to rest or relax in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91953-0;When I was in pain I stayed near to someone who cares about me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I stayed near to someone who cares about me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91954-8;When I was in pain I avoided lifting or carrying heavy things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I avoided lifting or carrying heavy things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91955-5;When I was in pain I had to stop what I was doing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I had to stop what I was doing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91956-3;When I was in pain I went to sleep in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I went to sleep in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91957-1;When I was in pain I tried to think of something nice or fun in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I tried to think of something nice or fun in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91958-9;When I was in pain I was restless in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I was restless in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9195-9;Fluid output.urine in and out urethral catheter;Vol;Pt;Urinary tract;Qn;;IO_OUT.MOLEC;2;Urine output by in and out urethral catheter;Fluid output urine I/O cath;;ACTIVE;1.0i;2.56 +91959-7;When I was in pain I couldn't stay still in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I couldn't stay still in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91960-5;When I was in pain I asked people to bring me things (food, games) in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked people to bring me things (food, games) in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91961-3;When I was in pain I avoided standing in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I avoided standing in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91962-1;When I was in pain I didn't want anyone to touch me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I didn't want anyone to touch me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91963-9;When I was in pain I got angry at people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I got angry at people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91964-7;When I was in pain I moved slower in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I moved slower in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91965-4;When I was in pain I rubbed my body where it hurt in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I rubbed my body where it hurt in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91966-2;When I was in pain I didn't let anyone touch me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I didn't let anyone touch me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9196-7;Class;Type;Pt;Urine tube;Nom;;IO.TUBE;2;Type of Urine tube;Urine tube Class;;ACTIVE;1.0i;2.27 +91967-0;When I was in pain I talked about my pain in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I talked about my pain in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91968-8;When I was in pain I tightened my jaw in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I tightened my jaw in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91969-6;When I was in pain I asked for medicine in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked for medicine in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91970-4;When I was in pain I stayed away from other people in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I stayed away from other people in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91971-2;When I was in pain I asked for help getting around in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked for help getting around in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91972-0;When I was in pain I became quiet in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I became quiet in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91973-8;When I was in pain I limped in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I limped in the past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91974-6;When I was in pain I used something for support (cane, crutches, wheelchair) to move from place to place in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I used something for support (cane, crutches, wheelchair) to move from place to place in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9197-5;Fluid output.urine^post void;Vol;Pt;Urinary tract;Qn;;IO_OUT.MOLEC;2;Urine output --post void;Fluid output urine p vdg;;ACTIVE;1.0i;2.56 +91975-3;When I was in pain I criedin past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I cried in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91976-1;When I was in pain I yelled for someone to help me in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I yelled for someone to help me in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91977-9;When I was in pain I asked people to let me be by myself in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked people to let me be by myself in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91978-7;When I was in pain I asked for help with doing things in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I asked for help with doing things in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91979-5;When I was in pain I tried not to move in past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I was in pain I tried not to move in past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91980-3;Specific resistance.airway;FldResist;Stdy^mean;Respiratory system.airway;Qn;Plethysmograph.body box;PULM;2;Specific airway resistance by Plethysmograph body box;sRaw Plethysmography;;ACTIVE;2.66;2.67 +91981-1;Resistance.airway/predicted;RelFldResist;Stdy^mean;Respiratory system.airway;Qn;Plethysmograph.body box;PULM;2;Airway resistance measured/predicted by Plethysmograph body box;Airway resist meas/pred Plethysmography;;ACTIVE;2.66;2.66 +91982-9;Specific resistance.airway/predicted;RelFldResist;Stdy^mean;Respiratory system.airway;Qn;Plethysmograph.body box;PULM;2;Specific airway resistance measured/predicted by Plethysmograph body box;Specific airway resist meas/pred Pleth;;ACTIVE;2.66;2.66 +9198-3;Fluid output.wound drain;VRat;8H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output wound drain 8 hour;Fluid output wound drain 8h;;ACTIVE;1.0i;2.48 +91983-7;Care management note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Care management note;Care management note;;ACTIVE;2.66;2.66 +91984-5;Care management note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Care management note;OP Care management note;;ACTIVE;2.66;2.66 +91985-2;Note;Find;Pt;Outpatient;Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine Outpatient Note;Integrative medicine OP Note;;ACTIVE;2.66;2.66 +91986-0;Consultation note;Find;Pt;{Setting};Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine Consult note;Integrative medicine Consult note;;ACTIVE;2.66;2.66 +91987-8;PROMIS parent proxy anxiety - version 2.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy anxiety - version 2.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91988-6;PROMIS parent proxy item bank - anxiety - version 2.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - anxiety - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91989-4;My child felt worried in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt worried in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91990-2;My child was afraid of going to school in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was afraid of going to school in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9199-1;Fluid output.wound drain;VRat;10H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output wound drain 10 hour;Fluid output wound drain 10h;;ACTIVE;1.0i;2.48 +91991-0;My child worried when he or she was at home in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child worried when he or she was at home in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91992-8;My child worried when he or she went to bed at night in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child worried when he or she went to bed at night in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91993-6;My child was worried he or she might die in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was worried he or she might die in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91994-4;My child felt scared in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt scared in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91995-1;My child felt like something awful might happen in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt like something awful might happen in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91996-9;It was hard for my child to relax in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;It was hard for my child to relax in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91997-7;My child felt nervous in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt nervous in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91998-5;My child worried when he or she was away from home in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child worried when he or she was away from home in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +91999-3;My child woke up at night scared in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child woke up at night scared in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92000-9;My child worried about what could happen to him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child worried about what could happen to him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92001-7;My child got scared really easy in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child got scared really easy in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92002-5;SMN1 gene;ThreshNum;Pt;Bld.dot;Qn;Probe.amp.tar;MOLPATH;1;SMN1 gene [Cycle Threshold #] in DBS by NAA with probe detection;SMN1 gene Ct DBS Qn NAA+probe;;ACTIVE;2.66;2.66 +92003-3;Spinal muscular atrophy newborn screening comment-discussion;Txt;Pt;Bld.dot;Nar;;MOLPATH;1;Spinal muscular atrophy newborn screening comment-discussion;SMA NBS comment;;ACTIVE;2.66;2.66 +92004-1;Spinal muscular atrophy;Imp;Pt;Bld.dot;Nom;;MOLPATH;1;Spinal muscular atrophy newborn screen interpretation;SMA DBS-Imp;;ACTIVE;2.66;2.66 +92005-8;Spinal muscular atrophy newborn screening panel;-;Pt;Bld.dot;-;;PANEL.MOLPATH;1;Spinal muscular atrophy newborn screening panel;SMA NB scn pnl DBS;;ACTIVE;2.66;2.7 +92006-6;T-cell receptor excision circle;ThreshNum;Pt;Bld.dot;Qn;;CHEM;1;T-cell receptor excision circle [Cycle Threshold #] in DBS;TREC ThreshNum DBS Qn;;ACTIVE;2.66;2.66 +9200-7;Fluid output.wound drain;VRat;1H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output wound drain 1 hour;Fluid output wound drain 1h;;ACTIVE;1.0i;2.48 +92007-4;T-cell receptor excision circle;Zscore;Pt;Bld.dot;Qn;;CHEM;1;T-cell receptor excision circle [Z-score] in DBS;TREC Z-score DBS;;ACTIVE;2.66;2.66 +92008-2;T-cell receptor excision circle;MoM;Pt;Bld.dot;Qn;;CHEM;1;T-cell receptor excision circle [Multiple of the median] in DBS;TREC MoM DBS;;ACTIVE;2.66;2.66 +92009-0;Birth date;Date;Pt;Personnel;Qn;;ADMIN;2;Personnel Birth date;Personnel Birth Date;;ACTIVE;2.66;2.68 +92010-8;Jurisdiction fetal death report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Jurisdiction fetal death report Document;Jurisdiction fetal death rpt Doc;;ACTIVE;2.66;2.66 +92011-6;Jurisdiction live birth report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Jurisdiction live birth report Document;Jurisdiction live birth rpt Doc;;ACTIVE;2.66;2.66 +92012-4;Edit flags;Find;Pt;Document;Doc;;DOC.MISC;2;Edit flags section;Edit flags section;;ACTIVE;2.66;2.66 +92013-2;Administrative information;Find;Pt;^Father;Doc;;DOC.MISC;2;Father's administrative information;Father's admin info;;ACTIVE;2.66;2.66 +92014-0;Administrative information;Find;Pt;^Mother;Doc;;DOC.MISC;2;Mother's administrative information;Mother's admin info;;ACTIVE;2.66;2.66 +9201-5;Fluid output.wound drain;VRat;12H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output wound drain 12 hour;Fluid output wound drain 12h;;ACTIVE;1.0i;2.48 +92015-7;Newborn administrative information;Find;Pt;^Patient;Doc;;DOC.MISC;2;Newborn administrative information;Newborn admin info;;ACTIVE;2.66;2.66 +92016-5;Pregnancy risk factors;Find;Pt;^Mother;Doc;;DOC.MISC;2;Maternal pregnancy risk factors Document;Maternal preg risks Doc;;ACTIVE;2.66;2.66 +92017-3;Pregnancy summary;Find;Pt;^Mother;Doc;;DOC.MISC;2;Maternal pregnancy summary Document;Maternal pregnancy summary Doc;;ACTIVE;2.66;2.66 +92018-1;Provider supplied mother's live birth report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Provider supplied mother's live birth report Document;Provider supplied mother live birth rpt;;ACTIVE;2.66;2.66 +92019-9;Provider supplied mother's fetal death report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Provider supplied mother's fetal death report Document;Provider supplied mother fetal death rpt;;ACTIVE;2.66;2.66 +92020-7;Provider supplied facility live birth report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Provider supplied facility live birth report Document;Provider supplied fac live birth rpt;;ACTIVE;2.66;2.66 +92021-5;Provider supplied facility fetal death report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Provider supplied facility fetal death report Document;Provider supplied fac fetal death rpt;;ACTIVE;2.66;2.66 +92022-3;Coded initiating cause or condition of death;Find;Pt;^Fetus;Nom;;H&P.HX;2;Coded initiating cause or condition of fetal death;Coded fetal death cause;;ACTIVE;2.66;2.66 +9202-3;Fluid output.wound drain;VRat;24H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output wound drain 24 hour;Fluid output wound drain 24h;;ACTIVE;1.0i;2.48 +92023-1;Coded other significant causes or conditions of death;Find;Pt;^Fetus;Nom;;H&P.HX;2;Coded other significant causes or conditions of fetal death;Coded other fetal death cause;;ACTIVE;2.66;2.66 +92024-9;Plazomicin^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Plazomicin [Mass/volume] in Serum or Plasma --trough;Plazomicin Trough SerPl-mCnc;;ACTIVE;2.66;2.74 +92025-6;Multisection^W contrast IV;Find;Pt;Head & Neck>Spine.cervical;Doc;CT;RAD;2;CT Head and Cervical spine W contrast IV;CT Head+C-spine W contr IV;;ACTIVE;2.66;2.67 +92026-4;Supervisor contact information panel;-;Pt;Personnel;-;;PANEL.ADMIN;2;Personnel Supervisor contact information panel;Personnel Supervisor contact info Pnl;;ACTIVE;2.66;2.68 +92027-2;Report action level;Find;Pt;^Event;Ord;;PUBLICHEALTH;2;Report action level;Report action level;;ACTIVE;2.66;2.68 +92028-0;Supervisor name;Pn;Pt;Personnel;Nom;;ADMIN;2;Personnel Supervisor name;Personnel Supervisor name;;ACTIVE;2.66;2.68 +92029-8;Supervisor email address;EmailAddr;Pt;Personnel;Nom;;ADMIN;2;Personnel Supervisor email address;Personnel Supervisor Email;;ACTIVE;2.66;2.68 +92030-6;Supervisor address;Addr;Pt;Personnel;Nom;;ADMIN;2;Personnel Supervisor address;Personnel Supervisor address;;ACTIVE;2.66;2.68 +9203-1;Fluid output.wound drain;Vol;Pt;Surgical site;Qn;;IO_OUT.MOLEC;2;Fluid output wound drain;Fluid output wound drain;;ACTIVE;1.0i;2.54 +92031-4;Supervisor title;Type;Pt;Personnel;Nom;;ADMIN;2;Personnel Supervisor title;Personnel Supervisor title;;ACTIVE;2.66;2.68 +92032-2;Supervisor phone number;Tele;Pt;Personnel;Nom;;ADMIN;2;Supervisor phone number;Supervisor phone #;;ACTIVE;2.66;2.66 +92033-0;Purchase cost;Num;Pt;Supply;Qn;;ADMIN;2;Purchase cost [#] Supply;Purchase cost Supply;;ACTIVE;2.66;2.68 +92034-8;Quantity distributed;Num;Pt;Supply;Qn;;PUBLICHEALTH;2;Quantity distributed [#] Supply;Quantity distributed Supply;;ACTIVE;2.66;2.68 +92035-5;Job experience;Find;Pt;Personnel;Nom;;ADMIN;2;Personnel Job experience;Personnel Job experience;;ACTIVE;2.66;2.68 +92036-3;Action taken based on risk assessment meeting;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Action taken based on risk assessment meeting;Action taken per risk assessment mtg;;ACTIVE;2.66;2.68 +92037-1;Significant activities related to public health emergency event;Find;RptPeriod;^Event;Nom;;PUBLICHEALTH;2;Significant activities related to public health emergency event Reporting Period;Significant activities PH emerg RptPrd;;ACTIVE;2.66;2.68 +92038-9;Information communication technology type;Type;Pt;{Device};Nom;;DEVICES;2;Information communication technology type;ICT type;;ACTIVE;2.66;2.68 +92039-7;Information communication technology name;ID;Pt;{Device};Nom;;DEVICES;2;Information communication technology name;ICT name;;ACTIVE;2.66;2.68 +92040-5;Information communication technology description;Find;Pt;{Device};Nom;;DEVICES;2;Information communication technology description;ICT description;;ACTIVE;2.66;2.68 +92041-3;Physical security assessment system;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Physical security assessment system [CDC Emergency Operations Centers];;;ACTIVE;2.66;2.68 +92042-1;Physical security assessment system type;Type;Pt;^Event;Nom;;SURVEY.CDC;4;Physical security assessment system type;;;ACTIVE;2.66;2.68 +92043-9;Physical security assessment system name;Type;Pt;^Event;Nom;;SURVEY.CDC;4;Physical security assessment system name;;;ACTIVE;2.66;2.68 +92044-7;Physical security assessment system details;Find;Pt;^Event;Nar;;SURVEY.CDC;4;Physical security assessment system details;;;ACTIVE;2.66;2.68 +92045-4;Name;Pn;Pt;^Donor;Nom;;ADMIN;2;Name of Donor;Donor name;;ACTIVE;2.66;2.68 +92046-2;Donor contact information panel;-;Pt;^Donor;-;;PANEL.ADMIN;2;Donor contact information panel;Donor contact info Pnl;;ACTIVE;2.66;2.68 +92047-0;Donated item;Type;Pt;^Donor;Nom;;ADMIN;2;Donated item by Donor;Donated item;;ACTIVE;2.66;2.68 +92048-8;Donated item;Num;Pt;^Donor;Qn;;ADMIN;2;Donated item [#] Donor;# of donated item;;ACTIVE;2.66;2.68 +9204-9;Fluid output.wound drain identifier;Prid;Pt;Surgical site;Nom;;IO_OUT.MOLEC;2;Fluid output wound drain identifier [Identifier];Fluid output wound drain identifier;;ACTIVE;1.0i;2.27 +92049-6;Staphylococcus sp.methicillin resistant identified;Prid;Pt;Isolate/Specimen;Nom;Molgen;MICRO;1;Staphylococcus species methicillin resistant identified in Isolate or Specimen by Molecular genetics method;Staph methicillin resist Islt/Spm;;ACTIVE;2.66;2.66 +92050-4;Video electroencephalography study;Find;Pt;^Patient;Doc;{Role};NEURO;2;Video EEG study;Video EEG study;;ACTIVE;2.66;2.72 +92051-2;My child had trouble staying asleep in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble staying asleep in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92052-0;My child's neck felt tight in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's neck felt tight in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92053-8;My child felt as if he or she needed to move his or her legs a lot in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt as if he or she needed to move his or her legs a lot in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92054-6;A sudden noise made my child jump in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;A sudden noise made my child jump in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92055-3;My child's muscles felt tight in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's muscles felt tight in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9205-6;Wound drain site;Anat;Pt;*^Patient;Nom;;IO.TUBE;2;Wound drain site;Wound drain site;;ACTIVE;1.0i;2.27 +92056-1;My child could not stay still for long in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could not stay still for long in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92057-9;My child's mouth was dry in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's mouth was dry in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92058-7;My child's breathing was fast, even when he or she was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's breathing was fast, even when he or she was not exercising or playing hard in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92059-5;My child's palms were sweaty in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's palms were sweaty in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92060-3;My child was sweaty, even when he or she was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child was sweaty, even when he or she was not exercising or playing hard in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92061-1;My child's heart pounded, even when he or she was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's heart pounded, even when he or she was not exercising or playing hard in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92062-9;My child's heart beat faster than usual, even when he or she was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's heart beat faster than usual, even when he or she was not exercising or playing hard in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92063-7;My child had trouble breathing, even when he or she was not exercising or playing hard in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had trouble breathing, even when he or she was not exercising or playing hard in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9206-4;Fluid output.wound drain;VRat;1H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Deprecated Fluid output.wound drain: VRat: 1H: Surgical site: Qn:;DeprecatedFluid output.wound drain;;DEPRECATED;1.0i;2.36 +92064-5;My child felt dizzy in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt dizzy in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92065-2;My child's breathing was fast in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's breathing was fast in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92066-0;My child's hands shook in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's hands shook in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92067-8;My child's legs shook in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's legs shook in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92068-6;My child's body shook in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's body shook in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92069-4;My child had a headache in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had a headache in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92070-2;My child's neck hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's neck hurt in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92071-0;My child's back hurt in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's back hurt in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9207-2;Fluid output.wound drain;VRat;8H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Deprecated Fluid output.wound drain: VRat: 8H: Surgical site: Qn:;DeprecatedFluid output.wound drain;;DEPRECATED;1.0i;2.36 +92072-8;My child had a bad stomach ache in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had a bad stomach ache in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92073-6;My child had pain that really bothered him or her in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child had pain that really bothered him or her in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92074-4;My child's appetite changed in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child's appetite changed in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92075-1;My child felt some food coming up into his or her throat in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child felt some food coming up into his or her throat in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92076-9;My child threw up in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child threw up in past 7 days [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92077-7;PROMIS parent proxy item bank - physical stress experiences - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - physical stress experiences - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.68 +92078-5;PROMIS parent proxy physical stress experiences - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy physical stress experiences - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92079-3;PROMIS parent proxy meaning purpose - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy meaning purpose - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9208-0;Fluid output.wound drain;VRat;10H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Deprecated Fluid output.wound drain: VRat: 10H: Surgical site: Qn:;DeprecatedFluid output.wound drain;;DEPRECATED;1.0i;2.36 +92080-1;PROMIS parent proxy item bank - meaning purpose - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - meaning purpose - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92081-9;Thinking about your child's life, people will remember my child when he or she dies;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, people will remember my child when he or she dies [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92082-7;Thinking about your child's life, my child is satisfied with his or her purpose in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child is satisfied with his or her purpose in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92083-5;Thinking about your child's life, my child has a reason for living;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child has a reason for living [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92084-3;Thinking about your child's life, my child's life is filled with things that interest him or her;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child's life is filled with things that interest him or her [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92085-0;Thinking about your child's life, my child knows what makes his or her life meaningful;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child knows what makes his or her life meaningful [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92086-8;Thinking about your child's life, my child has a clear purpose in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child has a clear purpose in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92087-6;Thinking about your child's life, my child thinks his or her life is filled with purpose;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child thinks his or her life is filled with purpose [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92088-4;Thinking about your child's life, my child thinks his or her life has purpose;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child thinks his or her life has purpose [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92089-2;Thinking about your child's life, my child tries to find purpose in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child tries to find purpose in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +920-9;B variant NOS Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated B variant NOS Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated B Var NOS Ag RBC BPU Ql;;DEPRECATED;1.0;2.65 +92090-0;Thinking about your child's life, my child thinks his or her life is filled with meaning;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child thinks his or her life is filled with meaning [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92091-8;Thinking about your child's life, my child thinks his or her life has meaning;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child thinks his or her life has meaning [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92092-6;Thinking about your child's life, my child tries to find meaning in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child tries to find meaning in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92093-4;Thinking about your child's life, my child wants to do what is important;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child wants to do what is important [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92094-2;Thinking about your child's life, my child thinks his or her life is important;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child thinks his or her life is important [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92095-9;Thinking about your child's life, my child's life is filled with important things;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child's life is filled with important things [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92096-7;Thinking about your child's life, my child wants to make the most out of his or her life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child wants to make the most out of his or her life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92097-5;Thinking about your child's life, my child can reach his or her goals in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child can reach his or her goals in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9209-8;Fluid output.wound drain;VRat;12H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Deprecated Fluid output.wound drain: VRat: 12H: Surgical site: Qn:;DeprecatedFluid output.wound drain;;DEPRECATED;1.0i;2.36 +92098-3;Thinking about your child's life, my child knows where he or she is going in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child knows where he or she is going in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92099-1;Thinking about your child's life, my child expects to achieve his or her goals;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to achieve his or her goals [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92100-7;Thinking about your child's life, the things my child has done in the past will help him or her in the future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, the things my child has done in the past will help him or her in the future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92101-5;Thinking about your child's life, my child has things he or she wants to accomplish in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child has things he or she wants to accomplish in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92102-3;Thinking about your child's life, my child has things he or she needs to do in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child has things he or she needs to do in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92103-1;Thinking about your child's life, my child has things he or she wants to do in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child has things he or she wants to do in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92104-9;Thinking about your child's life, my child makes plans for his or her future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child makes plans for his or her future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92105-6;Thinking about your child's life, my child has goals for himself or herself;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child has goals for himself or herself [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9210-6;Fluid output.wound drain;VRat;24H;Surgical site;Qn;;IO_OUT.TIMED.MOLE;2;Deprecated Fluid output.wound drain: VRat: 24H: Surgical site: Qn:;DeprecatedFluid output.wound drain;;DEPRECATED;1.0i;2.36 +92106-4;Thinking about your child's life, my child can do almost anything if he or she has enough faith in himself or herself;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child can do almost anything if he or she has enough faith in himself or herself [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92107-2;Thinking about your child's life, my child is positive about his or her future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child is positive about his or her future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92108-0;Thinking about your child's life, my child is hopeful about his or her future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child is hopeful about his or her future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92109-8;Thinking about your child's life, my child is hopeful about his or her plans for the future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child is hopeful about his or her plans for the future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92110-6;Thinking about your child's life, my child always has hope;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child always has hope [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92111-4;Thinking about your child's life, my child is full of hope;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child is full of hope [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92112-2;Thinking about your child's life, my child has hope;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child has hope [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92113-0;Thinking about your child's life, when bad things happen, my child expects them to get better;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, when bad things happen, my child expects them to get better [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9211-4;Output.stool;Mass;Pt;Lower GI tract;Qn;;IO_OUT.MOLEC;2;Output.stool [Mass];Output.stool mass;;ACTIVE;1.0i;2.48 +92114-8;Thinking about your child's life, my child expects to succeed at what he or she tries to do;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to succeed at what he or she tries to do [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92115-5;Thinking about your child's life, my child looks forward to what will happen in the future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child looks forward to what will happen in the future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92116-3;Thinking about your child's life, my child expects to achieve what he or she wants in life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to achieve what he or she wants in life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92117-1;Thinking about your child's life, my child expects to have success in the future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to have success in the future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92118-9;Thinking about your child's life, my child expects to have a long life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to have a long life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92119-7;Thinking about your child's life, my child expects to enjoy his or her future life;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to enjoy his or her future life [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92120-5;Thinking about your child's life, my child expects to be successful in the future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to be successful in the future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92121-3;Thinking about your child's life, my child expects to have a family in the future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to have a family in the future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9212-2;Output.stool;MRat;1H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool [Mass/time] 1 hour;Output.stool 1h mRate;;ACTIVE;1.0i;2.48 +92122-1;Thinking about your child's life, my child expects to have a job in the future;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects to have a job in the future [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92123-9;Thinking about your child's life, my child expects things to work out for the best;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects things to work out for the best [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92124-7;Thinking about your child's life, my child expects amazing things to happen to him or her;Find;Pt;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;Thinking about your child's life, my child expects amazing things to happen to him or her [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92125-4;Streptococcus pneumoniae DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] in Respiratory specimen by NAA with probe detection;S pneum DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92126-2;Mycoplasma pneumoniae DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Respiratory specimen by NAA with probe detection;M pneumo DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92127-0;Haemophilus influenzae DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] in Respiratory specimen by NAA with probe detection;Haem influ DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92128-8;Bordetella pertussis DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis DNA [Presence] in Respiratory specimen by NAA with probe detection;B pert DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92129-6;Bordetella parapertussis DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Bordetella parapertussis DNA [Presence] in Respiratory specimen by NAA with probe detection;B parapert DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +9213-0;Output.stool;MRat;8H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool [Mass/time] 8 hour;Output.stool 8h mRate;;ACTIVE;1.0i;2.48 +92130-4;Rhinovirus RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Rhinovirus RNA [Presence] in Respiratory specimen by NAA with probe detection;Rhinovirus RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92131-2;Respiratory syncytial virus RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Respiratory specimen by NAA with probe detection;RSV RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92132-0;Enterovirus A+B+C RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Enterovirus A+B+C RNA [Presence] in Respiratory specimen by NAA with probe detection;EV-A+B+C RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92133-8;Chlamydophila pneumoniae DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Respiratory specimen by NAA with probe detection;C pneum DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92134-6;Human metapneumovirus RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Respiratory specimen by NAA with probe detection;hMPV RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92135-3;Human bocavirus 1+2+3 DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human bocavirus 1+2+3 DNA [Presence] in Respiratory specimen by NAA with probe detection;HBoV 1+2+3 DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92136-1;Adenovirus B+C+E DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Adenovirus B+C+E DNA [Presence] in Respiratory specimen by NAA with probe detection;AdV B+C+E DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92137-9;Parainfluenza virus 4 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Respiratory specimen by NAA with probe detection;HPIV4 RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92138-7;Parainfluenza virus 3 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Respiratory specimen by NAA with probe detection;HPIV3 RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92139-5;Parainfluenza virus 2 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Respiratory specimen by NAA with probe detection;HPIV2 RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92140-3;Parainfluenza virus 1 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Respiratory specimen by NAA with probe detection;HPIV1 RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92141-1;Influenza virus B RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Respiratory specimen by NAA with probe detection;FLUBV RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92142-9;Influenza virus A RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Respiratory specimen by NAA with probe detection;FLUAV RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92143-7;Respiratory pathogens DNA & RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA panel - Respiratory specimen by NAA with probe detection;Resp path DNA+RNA Pnl Resp NAA+probe;;ACTIVE;2.66;2.67 +92144-5;Moraxella catarrhalis DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Moraxella catarrhalis DNA [Presence] in Respiratory specimen by NAA with probe detection;M catarrhalis DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92145-2;Legionella pneumophila DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Legionella pneumophila DNA [Presence] in Respiratory specimen by NAA with probe detection;L pneumo DNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92146-0;Human coronavirus 229E+NL63 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E+NL63 RNA [Presence] in Respiratory specimen by NAA with probe detection;HCoV 229E+NL63 RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92147-8;Human coronavirus HKU1+OC43 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Human coronavirus HKU1+OC43 RNA [Presence] in Respiratory specimen by NAA with probe detection;HCoV HKU1+OC43 RNA Resp Ql NAA+probe;;ACTIVE;2.66;2.66 +9214-8;Output.stool;MRat;10H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool [Mass/time] 10 hour;Output.stool 10h mRate;;ACTIVE;1.0i;2.48 +92148-6;PROMIS item bank - dyspnea severity - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - dyspnea severity - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92149-4;PROMIS dyspnea severity - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS dyspnea severity - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92150-2;How short of breath did you get washing dishes over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get washing dishes over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92151-0;How short of breath did you get walking up 5 stairs without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking up 5 stairs without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92152-8;How short of breath did you get walking up 30 stairs (3 flights) without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking up 30 stairs (3 flights) without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92153-6;How short of breath did you get walking up 20 stairs (2 flights) without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking up 20 stairs (2 flights) without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92154-4;How short of breath did you get walking up 10 stairs (1 flight) without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking up 10 stairs (1 flight) without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9215-5;Output.stool;MRat;12H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool [Mass/time] 12 hour;Output.stool 12h mRate;;ACTIVE;1.0i;2.48 +92155-1;How short of breath did you get walking 50 steps or paces on flat ground at a normal speed without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking 50 steps or paces on flat ground at a normal speed without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92156-9;How short of breath did you get walking 10 steps or paces on flat ground at a normal speed without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking 10 steps or paces on flat ground at a normal speed without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92157-7;How short of breath did you get walking .5 mile (almost 1 km) on flat ground at a normal speed without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking .5 mile (almost 1 km) on flat ground at a normal speed without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92158-5;How short of breath did you get walking (faster than your usual speed) for at least 1 mile (a little more than 1.5 km) without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking (faster than your usual speed) for at least 1 mile (a little more than 1.5 km) without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92159-3;How short of breath did you get walking (faster than your usual speed) for 50 steps without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking (faster than your usual speed) for 50 steps without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92160-1;How short of breath did you get walking (faster than your usual speed) for .5 mile (almost 1 km) without stopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get walking (faster than your usual speed) for .5 mile (almost 1 km) without stopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92161-9;How short of breath did you get talking while walking over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get talking while walking over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92162-7;How short of breath did you get taking a shower over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get taking a shower over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9216-3;Output.stool;MRat;24H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool [Mass/time] 24 hour;Output.stool 24h mRate;;ACTIVE;1.0i;2.48 +92163-5;How short of breath did you get taking a bath without help over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get taking a bath without help over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92164-3;How short of breath did you get sweeping or mopping over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get sweeping or mopping over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92165-0;How short of breath did you get standing for at least 5M over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get standing for at least 5 minutes over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92166-8;How short of breath did you get singing or humming over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get singing or humming over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92167-6;How short of breath did you get scrubbing the floor or counter over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get scrubbing the floor or counter over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92168-4;How short of breath did you get putting on socks or stockings over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get putting on socks or stockings over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92169-2;How short of breath did you get preparing meals over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get preparing meals over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +921-7;B variant NOS Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated B variant NOS Ag [Presence] on Red Blood Cells from Donor;Deprecated B Var NOS Ag RBC Donr Ql;;DEPRECATED;1.0;2.65 +92170-0;How short of breath did you get moderate-intensity leisure activity (bicycling on level terrain, etc.) over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get moderate-intensity leisure activity (bicycling on level terrain, etc.) over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9217-1;Output.stool;Vol;Pt;Lower GI tract;Qn;;IO_OUT.MOLEC;2;Output.stool [Volume];Output.stool Vol;;ACTIVE;1.0i;2.48 +92171-8;How short of breath did you get making a bed over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get making a bed over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92172-6;How short of breath did you get low-intensity leisure activity (gardening, etc.) over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get low-intensity leisure activity (gardening, etc.) over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92173-4;How short of breath did you get lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase) over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase) over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92174-2;How short of breath did you get lifting something weighing less than 5 lbs (about 2 kg, like a houseplant) over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get lifting something weighing less than 5 lbs (about 2 kg, like a houseplant) over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92175-9;How short of breath did you get lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92176-7;How short of breath did you get lifting something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries) over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get lifting something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries) over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92177-5;How short of breath did you get getting in or out of a car over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get getting in or out of a car over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92178-3;How short of breath did you get dressing yourself without help over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get dressing yourself without help over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92179-1;How short of breath did you get dining out over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get dining out over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92180-9;How short of breath did you get carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92181-7;How short of breath did you get carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92182-5;How short of breath did you get carrying something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries) from one room to another over past 7D;Find;7D;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;How short of breath did you get carrying something weighing 10-20 lbs (about 4.5-9 kg, like a large bag of groceries) from one room to another over past 7 days [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92183-3;Document type;Type;Pt;Document;Nom;;DOC.ADMIN;2;Document type;Document type;;ACTIVE;2.66;2.68 +92184-1;Action taken based on watch record;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Action taken based on watch record;Action taken watch record;;ACTIVE;2.66;2.68 +92185-8;Report type;Type;Pt;Report;Nom;;DOC.MISC;2;Report type;Report type;;ACTIVE;2.66;2.68 +92186-6;Watch team report;Find;Pt;^Event;Doc;;PUBLICHEALTH;2;Watch team report Document;Watch team report Doc;;ACTIVE;2.66;2.68 +92187-4;Mission related to the emergency response activation;Find;Pt;^Event;Nar;;PUBLICHEALTH;2;Mission related to the emergency response activation Narrative;Mission emerg response activation;;ACTIVE;2.66;2.69 +92188-2;Emergency activation decision;Find;Pt;^Event;Nom;;PUBLICHEALTH;2;Emergency activation decision;Emerg activation decision;;ACTIVE;2.66;2.68 +9218-9;Output.stool;VRat;1H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool 1 hour;Output.stool 1h;;ACTIVE;1.0i;2.48 +92189-0;Date range for emergency response plan;DateRange;Pt;^Event;Qn;;PUBLICHEALTH;2;Date range for emergency response plan;Date range for emerg response plan;;ACTIVE;2.66;2.68 +92190-8;Emergency response improvement activity;Type;Pt;^Event;Nom;;PUBLICHEALTH;2;Emergency response improvement activity;Emerg response improvement activity;;ACTIVE;2.66;2.68 +92191-6;Staff;Num;Pt;Agency;Qn;;ADMIN.FACILITY;2;Staff [#] Agency;Staff # Agency;;ACTIVE;2.66;2.68 +92192-4;Equipment type available;Type;Pt;{Device};Nom;;DEVICES;2;Equipment type available;Equipment type available;;ACTIVE;2.66;2.68 +92193-2;Bed type;Num;Pt;Facility;Qn;;ADMIN.FACILITY;2;Bed type [#] Facility;Bed type # Facility;;ACTIVE;2.66;2.68 +92194-0;Bed category;Type;Pt;Facility;Nom;;ADMIN.FACILITY;2;Bed category Facility;Bed category Facility;;ACTIVE;2.66;2.68 +92195-7;Bed category;Num;Pt;Facility;Qn;;ADMIN.FACILITY;2;Bed category [#] Facility;Bed category # Facility;;ACTIVE;2.66;2.68 +92196-5;Supply owner;ID;Pt;Supply;Nom;;ADMIN;2;Supply owner [Identifier] Supply;Supply owner Supply;;ACTIVE;2.66;2.68 +9219-7;Output.stool;VRat;8H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool 8 hour;Output.stool 8h;;ACTIVE;1.0i;2.48 +92197-3;Public health emergency budget;Num;RptPeriod;^Event;Qn;;ADMIN;2;Public health emergency budget [#] Reporting Period;PH emergency budget RptPeriod;;ACTIVE;2.66;2.68 +92198-1;Public health emergency budget source;Type;Pt;^Event;Nom;;ADMIN;2;Public health emergency budget source;PH emerg budget source;;ACTIVE;2.66;2.68 +92199-9;Public health emergency budget breakdown details;Find;RptPeriod;^Event;Doc;;ADMIN;2;Public health emergency budget breakdown details Reporting Period Document;PH emerg budget breakdown details Doc;;ACTIVE;2.66;2.68 +92200-5;Public health emergency budget implementing unit name;ID;Pt;^Event;Nom;;ADMIN;2;Public health emergency budget implementing unit name [Identifier];PH emerg budget implement unit;;ACTIVE;2.66;2.68 +92201-3;Purchase activity;Type;Pt;Supply;Nom;;ADMIN;2;Purchase activity Supply;Purchase activity Supply;;ACTIVE;2.66;2.68 +92202-1;Recipient of supply;ID;Pt;Supply;Nom;;ADMIN;2;Recipient of supply [Identifier] Supply;Recipient of supply Supply;;ACTIVE;2.66;2.68 +92203-9;Bed category panel;-;Pt;Facility;-;;PANEL.ADMIN;2;Bed category panel Facility;Bed category Pnl Facility;;ACTIVE;2.66;2.69 +92204-7;Bed type panel;-;Pt;Facility;-;;PANEL.ADMIN;2;Bed type panel Facility;Bed type Pnl Facility;;ACTIVE;2.66;2.68 +9220-5;Output.stool;VRat;10H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool 10 hour;Output.stool 10h;;ACTIVE;1.0i;2.48 +92205-4;When I'm upset with someone, a cigarette helps me cope;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I'm upset with someone, a cigarette helps me cope [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92206-2;When I'm angry, a cigarette can calm me down;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I'm angry, a cigarette can calm me down [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92207-0;When I am worrying about something, a cigarette is helpful;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I am worrying about something, a cigarette is helpful [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92208-8;Smoking helps me when I'm upset about something;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking helps me when I'm upset about something [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92209-6;Smoking helps me reduce tension;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking helps me reduce tension [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92210-4;Smoking helps me deal with anxiety;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking helps me deal with anxiety [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92211-2;Smoking calms me down;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking calms me down [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92212-0;Smoking allows me to take a break from my problems for a few minutes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking allows me to take a break from my problems for a few minutes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9221-3;Output.stool;VRat;12H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool 12 hour;Output.stool 12h;;ACTIVE;1.0i;2.48 +92213-8;PROMIS smoking - coping expectancies for all smokers - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS smoking - coping expectancies for all smokers - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92214-6;PROMIS item bank - smoking - coping expectancies for all smokers - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - smoking - coping expectancies for all smokers - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.68 +92215-3;I rely on smoking to deal with stress;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I rely on smoking to deal with stress [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92216-1;I am tempted to smoke when I feel depressed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am tempted to smoke when I feel depressed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92217-9;I am tempted to smoke when I am anxious;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am tempted to smoke when I am anxious [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92218-7;When I stop what I'm doing to have a cigarette it feels like 'my time';Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I stop what I'm doing to have a cigarette it feels like 'my time' [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92219-5;Smoking stimulates me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking stimulates me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92220-3;Smoking makes me less depressed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking makes me less depressed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9222-1;Output.stool;VRat;24H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.stool 24 hour;Output.stool 24h;;ACTIVE;1.0i;2.48 +92221-1;Smoking makes me feel content;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking makes me feel content [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92222-9;Smoking is the fastest way to reward myself;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking is the fastest way to reward myself [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92223-7;Smoking is relaxing;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking is relaxing [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92224-5;Smoking helps me concentrate;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking helps me concentrate [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92225-2;PROMIS smoking - emotional and sensory expectancies for all smokers - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS smoking - emotional and sensory expectancies for all smokers - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92226-0;PROMIS item bank - smoking - emotional and sensory expectancies for all smokers - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - smoking - emotional and sensory expectancies for all smokers - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92227-8;I smoke to get a sense of pleasure;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I smoke to get a sense of pleasure [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92228-6;I smoke because smoking feels good;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I smoke because smoking feels good [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92229-4;I smoke because it is self-satisfying;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I smoke because it is self-satisfying [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92230-2;I love the feel of inhaling the smoke into my mouth;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I love the feel of inhaling the smoke into my mouth [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92231-0;I like the way a cigarette makes me feel physically;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I like the way a cigarette makes me feel physically [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92232-8;I feel better after smoking a cigarette;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel better after smoking a cigarette [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92233-6;I enjoy the sensations of a long, slow exhalation of smoke;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I enjoy the sensations of a long, slow exhalation of smoke [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92234-4;Even when I feel good, smoking helps me feel better;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Even when I feel good, smoking helps me feel better [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92235-1;Lab order result status;Type;Pt;^Patient;Nom;;LABORDERS;1;Lab order result status;Lab order result status;;ACTIVE;2.66;2.67 +92236-9;Lab observation result status;Type;Pt;^Patient;Nom;;LABORDERS;1;Lab observation result status;Lab obs result status;;ACTIVE;2.66;2.67 +92237-7;Lab observation sub-type;Type;Pt;^Patient;Nom;;LABORDERS;1;Lab observation sub-type;Lab obs sub-type;;ACTIVE;2.66;2.66 +92238-5;Differential diagnosis;Find;Pt;^Patient;Nom;;CLIN;2;Differential diagnosis;Differential dx;;ACTIVE;2.66;2.66 +9223-9;Output.colostomy;Mass;Pt;Lower GI tract;Qn;;IO_OUT.MOLEC;2;Output.colostomy [Mass];Output.colostomy mass;;ACTIVE;1.0i;2.48 +92239-3;Infectious pathogen carried;Prid;Pt;^Patient;Nom;;H&P.HX;2;Infectious pathogen carried [Identifier];Infectious pathogen carried;;ACTIVE;2.66;2.66 +92240-1;Healthcare-associated infection flag;Find;Pt;^Patient;Ord;;CLIN;2;Healthcare-associated infection flag;HAI flag;;ACTIVE;2.66;2.66 +92241-9;Vancomycin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Vancomycin [Susceptibility] by Genotype method;Vancomycin Islt Genotyp;;ACTIVE;2.66;2.69 +92242-7;Pyrazinamide;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Pyrazinamide [Susceptibility] by Genotype method;PZA Islt Genotyp;;ACTIVE;2.66;2.69 +92243-5;Microorganism resistance mutation tested for;Type;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Microorganism resistance mutation tested for by Molecular method;Microorganism resist mut Tested Islt/Spm;;ACTIVE;2.66;2.66 +92244-3;Microorganism resistance mutation nucleic acid change type;Type;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Microorganism resistance mutation nucleic acid change type by Molecular method;Micro resist mut NA change type Islt/Spm;;ACTIVE;2.66;2.66 +92245-0;Microorganism resistance mutation nucleic acid change;Type;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Microorganism resistance mutation nucleic acid change by Molecular method;Micro resist mut NA change Islt/Spm;;ACTIVE;2.66;2.66 +92246-8;Microorganism resistance mutation detected;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Microorganism resistance mutation detected [Presence] by Molecular method;Micro resist mut detected Islt/Spm Ql;;ACTIVE;2.66;2.66 +9224-7;Output.colostomy;MRat;1H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy [Mass/time] 1 hour;Output.colostomy 1h mRate;;ACTIVE;1.0i;2.48 +92247-6;Microorganism resistance mutation amino acid change type;Type;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Microorganism resistance mutation amino acid change type by Molecular method;Micro resist mut AA change type Islt/Spm;;ACTIVE;2.66;2.66 +92248-4;Microorganism resistance mutation amino acid change;Type;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Microorganism resistance mutation amino acid change by Molecular method;Micro resist mut AA change Islt/Spm;;ACTIVE;2.66;2.66 +92249-2;Microorganism gene tested for;ID;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Microorganism gene tested for [Identifier] by Molecular method;Microorganism gene Tested Islt/Spm;;ACTIVE;2.66;2.66 +922-5;B variant NOS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated B variant NOS Ag [Presence] on Red Blood Cells;Deprecated B Var NOS Ag RBC Ql;;DEPRECATED;1.0;2.65 +92250-0;Microorganism gene target region;Type;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Microorganism gene target region [Type] by Molecular method;Micro gene target region Islt/Spm;;ACTIVE;2.66;2.66 +92251-8;Microorganism gene detected;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Microorganism gene detected [Presence] by Molecular method;Micro gene detected Islt/Spm Ql;;ACTIVE;2.66;2.66 +92252-6;Microorganism molecular resistance panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Microorganism molecular resistance panel by Molecular genetics method;Micro molecular resistance Pnl Islt/Spm;;ACTIVE;2.66;2.7 +92253-4;Microorganism identified;Prid;Pt;Isolate/Specimen;Nom;Molgen;MICRO;1;Microorganism identified in Isolate or Specimen by Molecular genetics method;Microorganism Islt/Spm;;ACTIVE;2.66;2.66 +9225-4;Output.colostomy;MRat;8H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy [Mass/time] 8 hour;Output.colostomy 8h mRate;;ACTIVE;1.0i;2.48 +92254-2;Microorganism identification & resistance pattern determination panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Microorganism identification and resistance pattern determination panel by Molecular genetics method;Micro ID + resistance Pnl Islt/Spm;;ACTIVE;2.66;2.71 +92255-9;Methicillin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Methicillin [Susceptibility] by Genotype method;Methicillin Islt Genotyp;;ACTIVE;2.66;2.69 +92256-7;Has infectious disease or illness;Find;Pt;^Patient;Ord;;H&P.HX;2;Has infectious disease or illness;Has infectious disease or illness;;ACTIVE;2.66;2.66 +92257-5;Number of visits with usual provider;Num;12Mo;^Patient;Qn;;H&P.HX;2;Number of visits with usual provider 12 months;# visits usual provider 12Mo;;ACTIVE;2.66;2.66 +92258-3;Smoking makes my lungs hurt;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking makes my lungs hurt [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92259-1;Smoking makes me worry about getting heart troubles;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking makes me worry about getting heart troubles [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92260-9;Smoking makes me worry about getting emphysema;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking makes me worry about getting emphysema [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92261-7;Smoking makes me short of breath;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking makes me short of breath [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9226-2;Output.colostomy;MRat;10H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy [Mass/time] 10 hour;Output.colostomy 10h mRate;;ACTIVE;1.0i;2.48 +92262-5;Smoking is taking years off my life;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking is taking years off my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92263-3;Smoking irritates my mouth and throat;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking irritates my mouth and throat [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92264-1;Smoking causes me to get tired easily;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking causes me to get tired easily [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92265-8;Smoking causes damage to my gums and teeth;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking causes damage to my gums and teeth [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92266-6;PROMIS smoking - negative health expectancies for all smokers - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS smoking - negative health expectancies for all smokers - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92267-4;PROMIS item bank - smoking - negative health expectancies for all smokers - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - smoking - negative health expectancies for all smokers - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92268-2;It takes me longer to recover from a cold because I smoke;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It takes me longer to recover from a cold because I smoke [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92269-0;If I quit smoking I will feel more energetic;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;If I quit smoking I will feel more energetic [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9227-0;Output.colostomy;MRat;12H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy [Mass/time] 12 hour;Output.colostomy 12h mRate;;ACTIVE;1.0i;2.48 +92270-8;If I quit smoking I will breathe easier;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;If I quit smoking I will breathe easier [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92271-6;I worry that smoking will lower my quality of life;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I worry that smoking will lower my quality of life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92272-4;Stayed in intensive care unit;Find;Pt;^Newborn;Ord;;H&P.HX;2;Stayed in intensive care unit from Newborn;Stayed in ICU NB;;ACTIVE;2.66;2.66 +92273-2;Hospital stay duration;Find;Pt;^Newborn;Nom;;H&P.HX;2;Hospital stay duration for Newborn;Hosp stay duration NB;;ACTIVE;2.66;2.66 +92274-0;Rules for using smoked tobacco products inside home;Find;Pt;^Patient;Nom;;H&P.HX;2;Rules for using smoked tobacco products inside home;Rule smoked tobacco inside home;;ACTIVE;2.66;2.67 +92275-7;Cigarettes smoked per D^during pregnancy;NRat;Pt;^Patient;Ord;;H&P.HX;2;Cigarettes smoked per day --during pregnancy;Cigarettes smoked per D preg;;ACTIVE;2.66;2.66 +92276-5;Vital status;Find;Pt;^Newborn;Ord;;H&P.HX;2;Vital status from Newborn;Vital status NB;;ACTIVE;2.66;2.66 +92277-3;Is your baby living with you;Find;Pt;^Patient;Ord;;H&P.HX;2;Is your baby living with you;Is baby living with you;;ACTIVE;2.66;2.67 +92278-1;Lived with someone who smoked regularly inside the home during childhood;Find;Pt;^Patient;Ord;;H&P.HX;2;Lived with someone who smoked regularly inside the home during childhood;Lived w reg smoker inside home as child;;ACTIVE;2.66;2.66 +92279-9;Rules for using smokeless tobacco products inside home;Find;Pt;^Patient;Nom;;H&P.HX;2;Rules for using smokeless tobacco products inside home;Rule smokeless tobacco inside home;;ACTIVE;2.66;2.66 +92280-7;PhenX - house rules about tobacco use protocol 711101;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - house rules about tobacco use protocol 711101;House rules tobacco use proto;;ACTIVE;2.66;2.66 +92281-5;Brand name of cigarettes smoked most often;Type;30D;^Patient;Nom;;H&P.HX;2;Brand name of cigarettes smoked most often 30 days;Brand name cigs smoked often 30D;;ACTIVE;2.66;2.66 +92282-3;PROMIS smoking - negative psychosocial expectancies for all smokers - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS smoking - negative psychosocial expectancies for all smokers - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92283-1;People think less of me if they see me smoking;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People think less of me if they see me smoking [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92284-9;People think I'm foolish for ignoring the warnings about cigarette smoking;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People think I'm foolish for ignoring the warnings about cigarette smoking [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92285-6;People I care about respect me less because I smoke;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;People I care about respect me less because I smoke [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92286-4;My smoking makes me respect myself less;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My smoking makes me respect myself less [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92287-2;My smoking makes me less attractive to other people;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My smoking makes me less attractive to other people [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9228-8;Output.colostomy;MRat;24H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy [Mass/time] 24 hour;Output.colostomy 24h mRate;;ACTIVE;1.0i;2.48 +92288-0;My smoking makes me feel less attractive;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My smoking makes me feel less attractive [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92289-8;My need for cigarettes makes me feel disappointed in myself;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My need for cigarettes makes me feel disappointed in myself [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92290-6;My cigarette smoking bothers others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My cigarette smoking bothers others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92291-4;If I quit smoking my friends will respect me more;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;If I quit smoking my friends will respect me more [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92292-2;If I quit smoking I will be more in control of my life;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;If I quit smoking I will be more in control of my life [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92293-0;If I quit smoking I will be more attractive to others;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;If I quit smoking I will be more attractive to others [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92294-8;I look ridiculous while smoking;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I look ridiculous while smoking [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92295-5;I get upset when I think about my smoking;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I get upset when I think about my smoking [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9229-6;Output.colostomy;Vol;Pt;Lower GI tract;Qn;;IO_OUT.MOLEC;2;Output.colostomy [Volume];Output.colostomy Vol;;ACTIVE;1.0i;2.48 +92296-3;I feel embarrassed when I smoke;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel embarrassed when I smoke [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92297-1;PROMIS item bank - smoking - negative psychosocial expectancies for all smokers - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - smoking - negative psychosocial expectancies for all smokers - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92298-9;When I'm really craving a cigarette, it feels like I'm in the grip of some unknown force that I cannot control;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I'm really craving a cigarette, it feels like I'm in the grip of some unknown force that I cannot control [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92299-7;When I run out of cigarettes, I find it almost unbearable;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I run out of cigarettes, I find it almost unbearable [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92300-3;When I haven't been able to smoke for a few hours, the craving gets intolerable;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I haven't been able to smoke for a few hours, the craving gets intolerable [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92301-1;When I go without a cigarette for a few hours, I experience craving;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I go without a cigarette for a few hours, I experience craving [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92302-9;When I go too long without a cigarette I get strong urges that are hard to get rid of;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I go too long without a cigarette I get strong urges that are hard to get rid of [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92303-7;When I go too long without a cigarette I feel impatient;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;When I go too long without a cigarette I feel impatient [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9230-4;Output.colostomy;VRat;1H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy 1 hour;Output.colostomy 1h;;ACTIVE;1.0i;2.48 +92304-5;The idea of not having any cigarettes causes me stress;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;The idea of not having any cigarettes causes me stress [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92305-2;PROMIS smoking - nicotine dependence for all smokers - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS smoking - nicotine dependence for all smokers - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92306-0;PROMIS item bank - smoking - nicotine dependence for all smokers - version v1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - smoking - nicotine dependence for all smokers - version v1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92307-8;My urges to smoke keep getting stronger if I don't smoke;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My urges to smoke keep getting stronger if I don't smoke [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92308-6;My desire to smoke seems overpowering;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;My desire to smoke seems overpowering [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92309-4;It is hard to ignore urges to smoke;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;It is hard to ignore urges to smoke [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92310-2;I smoke more before going into a situation where smoking is not allowed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I smoke more before going into a situation where smoking is not allowed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92311-0;I smoke even when I am so ill that I am in bed most of the day;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I smoke even when I am so ill that I am in bed most of the day [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9231-2;Output.colostomy;VRat;8H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy 8 hour;Output.colostomy 8h;;ACTIVE;1.0i;2.48 +92312-8;I get a real gnawing hunger for a cigarette when l haven't smoked in a while;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I get a real gnawing hunger for a cigarette when l haven't smoked in a while [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92313-6;I frequently crave cigarettes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I frequently crave cigarettes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92314-4;I find myself reaching for cigarettes without thinking about it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I find myself reaching for cigarettes without thinking about it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92315-1;I drop everything to go out and buy cigarettes;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I drop everything to go out and buy cigarettes [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92316-9;I crave cigarettes at certain times of day;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I crave cigarettes at certain times of day [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92317-7;I am tempted to smoke when I realize I haven't smoked for a while;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I am tempted to smoke when I realize I haven't smoked for a while [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92318-5;Cravings for a cigarette make it difficult for me to quit;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Cravings for a cigarette make it difficult for me to quit [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92319-3;After not smoking for a while, I need to smoke in order to avoid feeling any discomfort;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;After not smoking for a while, I need to smoke in order to avoid feeling any discomfort [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9232-0;Output.colostomy;VRat;10H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy 10 hour;Output.colostomy 10h;;ACTIVE;1.0i;2.48 +92320-1;Smoking makes me feel better in social situations;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking makes me feel better in social situations [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92321-9;Smoking is a part of my self-image;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking is a part of my self-image [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92322-7;Smoking helps me feel more relaxed when I'm with other people;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Smoking helps me feel more relaxed when I'm with other people [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92323-5;PROMIS smoking - social motivations for all smokers - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS smoking - social motivations for all smokers - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92324-3;PROMIS item bank - smoking - social motivations for all smokers - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - smoking - social motivations for all smokers - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.68 +92325-0;If I quit smoking I will be less welcome around my friends who smoke;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;If I quit smoking I will be less welcome around my friends who smoke [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92326-8;I feel like part of a group when I'm around other smokers;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel like part of a group when I'm around other smokers [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92327-6;I feel a bond with other smokers;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I feel a bond with other smokers [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92328-4;I enjoy the social aspect of smoking with other smokers;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;I enjoy the social aspect of smoking with other smokers [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92329-2;PROMIS self-efficacy for managing emotions - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS self-efficacy for managing emotions - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +923-3;Blood collection bag lot identifier;ID;Pt;^BPU;Nom;;BLDBK;1;Blood collection bag lot [Identifier];Bld Coll Bag Lot Id BPU;;ACTIVE;1.0;2.32 +92330-0;PROMIS item bank - self-efficacy for managing emotions - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - self-efficacy for managing emotions - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92331-8;Current level of confidence when I'm feeling down, I can find ways to make myself feel better;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence when I'm feeling down, I can find ways to make myself feel better [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92332-6;Current level of confidence I can use relaxation to deal with worries;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can use relaxation to deal with worries [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92333-4;Current level of confidence I can use a strategy (for example: humor, leaving a situation) to keep from getting upset;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can use a strategy (for example: humor, leaving a situation) to keep from getting upset [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92334-2;Current level of confidence I can stay positive when I feel like I am the only one going through this;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can stay positive when I feel like I am the only one going through this [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92335-9;Current level of confidence I can relax my body to reduce my anxiety;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can relax my body to reduce my anxiety [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92336-7;Current level of confidence I can prevent my illness from making me feel discouraged;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can prevent my illness from making me feel discouraged [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92337-5;Current level of confidence I can manage the loss of my ability to do things that are important to me (for example: parenting, work, hobbies, attend school);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage the loss of my ability to do things that are important to me (for example: parenting, work, hobbies, attend school) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9233-8;Output.colostomy;VRat;12H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy 12 hour;Output.colostomy 12h;;ACTIVE;1.0i;2.48 +92338-3;Current level of confidence I can manage my frustration;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my frustration [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92339-1;Current level of confidence I can manage my anxiety about telling others I have health problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my anxiety about telling others I have health problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92340-9;Current level of confidence I can manage my anger when others make insensitive comments about my health problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my anger when others make insensitive comments about my health problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92341-7;Current level of confidence I can manage my anger when others don't understand what I am going through;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my anger when others don't understand what I am going through [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92342-5;Current level of confidence I can manage anxiety about injuring myself or others (for example: falling, dropping a child, a driving accident);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage anxiety about injuring myself or others (for example: falling, dropping a child, a driving accident) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92343-3;Current level of confidence I can keep emotional distress from interfering with things I want to do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep emotional distress from interfering with things I want to do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92344-1;Current level of confidence I can keep anxiety from becoming overwhelming;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep anxiety from becoming overwhelming [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92345-8;Current level of confidence I can hear about symptoms and side effects without getting discouraged;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can hear about symptoms and side effects without getting discouraged [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9234-6;Output.colostomy;VRat;24H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.colostomy 24 hour;Output.colostomy 24h;;ACTIVE;1.0i;2.48 +92346-6;Current level of confidence I can handle upsetting situations;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can handle upsetting situations [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92347-4;Current level of confidence I can handle the stress of going for treatment of my medical conditions;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can handle the stress of going for treatment of my medical conditions [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92348-2;Current level of confidence I can handle negative feelings;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can handle negative feelings [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92349-0;Current level of confidence I can focus on something else to decrease anxiety;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can focus on something else to decrease anxiety [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92350-8;Current level of confidence I can find ways to manage stress;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can find ways to manage stress [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92351-6;Current level of confidence I can bounce back from disappointment;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can bounce back from disappointment [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92352-4;Current level of confidence I can avoid upsetting thoughts;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can avoid upsetting thoughts [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9235-3;Output.ileostomy;Mass;Pt;Lower GI tract;Qn;;IO_OUT.MOLEC;2;Output.ileostomy [Mass];Output.ileostomy mass;;ACTIVE;1.0i;2.48 +92353-2;Current level of confidence I can avoid feeling helpless;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can avoid feeling helpless [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92354-0;Current level of confidence I can avoid feeling discouraged;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can avoid feeling discouraged [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92355-7;Current level of confidence I can avoid becoming angry;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can avoid becoming angry [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92356-5;Current level of confidence I can walk around inside my house;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can walk around inside my house [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92357-3;Current level of confidence I can walk a block (about 300 feet or 100 meters) on flat ground;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can walk a block (about 300 feet or 100 meters) on flat ground [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92358-1;Current level of confidence I can use public transportation;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can use public transportation [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92359-9;Current level of confidence I can use a telephone to schedule an appointment;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can use a telephone to schedule an appointment [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92360-7;Current level of confidence I can use a computer (for example: use keyboard, see screen, login);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can use a computer (for example: use keyboard, see screen, login) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9236-1;Output.ileostomy;MRat;1H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy [Mass/time] 1 hour;Output.ileostomy 1h mRate;;ACTIVE;1.0i;2.48 +92361-5;Current level of confidence I can travel to a new destination alone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can travel to a new destination alone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92362-3;Current level of confidence I can take my medications in the right doses and at the right times;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take my medications in the right doses and at the right times [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92363-1;Current level of confidence I can take care of others (for example: cook for others, help them dress, watch children);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take care of others (for example: cook for others, help them dress, watch children) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92364-9;Current level of confidence I can take care of my personal hygiene without help from anyone (for example: brush my teeth, comb my hair, shave, apply makeup);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take care of my personal hygiene without help from anyone (for example: brush my teeth, comb my hair, shave, apply makeup) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92365-6;Current level of confidence I can take a bath or shower;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take a bath or shower [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92366-4;Current level of confidence I can stand for 5 minutes (for example: waiting in a line, waiting for a bus);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can stand for 5 minutes (for example: waiting in a line, waiting for a bus) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92367-2;Current level of confidence I can recognize risks (for example: handling hot liquids, walking on uneven ground) and take steps to prevent accidents;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can recognize risks (for example: handling hot liquids, walking on uneven ground) and take steps to prevent accidents [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92368-0;Current level of confidence I can prepare my own meals (for example: plan and cook full meals by myself);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can prepare my own meals (for example: plan and cook full meals by myself) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92369-8;Current level of confidence I can perform my household chores;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can perform my household chores [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92370-6;Current level of confidence I can perform my daily activities even if someone is rushing me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can perform my daily activities even if someone is rushing me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92371-4;Current level of confidence I can manage my clothes when I need to use the toilet;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my clothes when I need to use the toilet [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92372-2;Current level of confidence I can maintain my finances (for example: write checks, pay bills);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can maintain my finances (for example: write checks, pay bills) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92373-0;Current level of confidence I can maintain a regular exercise program;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can maintain a regular exercise program [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92374-8;Current level of confidence I can lift and carry groceries;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can lift and carry groceries [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92375-5;Current level of confidence I can keep doing my usual activities at work;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep doing my usual activities at work [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92376-3;Current level of confidence I can go shopping and run errands;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can go shopping and run errands [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92377-1;Current level of confidence I can go outside in challenging weather for me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can go outside in challenging weather for me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92378-9;Current level of confidence I can get to the bathroom in time;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can get to the bathroom in time [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9237-9;Output.ileostomy;MRat;8H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy [Mass/time] 8 hour;Output.ileostomy 8h mRate;;ACTIVE;1.0i;2.48 +92379-7;Current level of confidence I can get in and out of bed without falling;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can get in and out of bed without falling [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92380-5;Current level of confidence I can get in and out of a chair;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can get in and out of a chair [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92381-3;Current level of confidence I can get around in an unfamiliar environment;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can get around in an unfamiliar environment [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92382-1;Current level of confidence I can find new ways to manage daily activities when the old way doesn't work;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can find new ways to manage daily activities when the old way doesn't work [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92383-9;Current level of confidence I can exercise at a vigorous level for 10 minutes (for example: running, jogging);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can exercise at a vigorous level for 10 minutes (for example: running, jogging) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92384-7;Current level of confidence I can exercise at a moderate level for 10 minutes (for example: walking briskly, biking, swimming, aerobics);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can exercise at a moderate level for 10 minutes (for example: walking briskly, biking, swimming, aerobics) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92385-4;Current level of confidence I can engage in hobbies or recreational activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can engage in hobbies or recreational activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92386-2;Current level of confidence I can eat without help from anyone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can eat without help from anyone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9238-7;Output.ileostomy;MRat;10H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy [Mass/time] 10 hour;Output.ileostomy 10h mRate;;ACTIVE;1.0i;2.48 +92387-0;Current level of confidence I can drive a car;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can drive a car [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92388-8;Current level of confidence I can dress myself in the way I want to be dressed (including buttoning clothes and putting on shoes);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can dress myself in the way I want to be dressed (including buttoning clothes and putting on shoes) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92389-6;Current level of confidence I can concentrate on something difficult;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can concentrate on something difficult [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92390-4;Current level of confidence I can climb one flight of stairs (with or without rails);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can climb one flight of stairs (with or without rails) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92391-2;PROMIS self-efficacy for managing daily activities - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS self-efficacy for managing daliy activities - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92392-0;PROMIS item bank - self-efficacy for managing daily activities - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - self-efficacy for managing daily activities - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92393-8;PROMIS self-efficacy for managing social interactions - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS self-efficacy for managing social interactions - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92394-6;PROMIS item bank - self-efficacy for managing social interactions - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - self-efficacy for managing social interactions - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.68 +9239-5;Output.ileostomy;MRat;12H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy [Mass/time] 12 hour;Output.ileostomy 12h mRate;;ACTIVE;1.0i;2.48 +92395-3;Current level of confidence people understand when I need help and when I don't need help;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence People understand when I need help and when I don't need help [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92396-1;Current level of confidence people are concerned about my health;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence People are concerned about my health [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92397-9;Current level of confidence people are accepting of my condition;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence People are accepting of my condition [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92398-7;Current level of confidence my doctors and nurses listen to my needs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence My doctors and nurses listen to my needs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92399-5;Current level of confidence if I need help, I have someone to help with my financial affairs;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence If I need help, I have someone to help with my financial affairs [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92400-1;Current level of confidence if I need help, I have someone to help me manage my daily activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence If I need help, I have someone to help me manage my daily activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92401-9;Current level of confidence if I need help, I can find someone to take me to the doctor's office;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence If I need help, I can find someone to take me to the doctor's office [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92402-7;Current level of confidence I know when to stop talking about my condition;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I know when to stop talking about my condition [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9240-3;Output.ileostomy;MRat;24H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy [Mass/time] 24 hour;Output.ileostomy 24h mRate;;ACTIVE;1.0i;2.48 +92403-5;Current level of confidence I have someone who will go out and do things with me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I have someone who will go out and do things with me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92404-3;Current level of confidence I have someone who helps me understand medical information;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I have someone who helps me understand medical information [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92405-0;Current level of confidence I have someone to help me plan and make decisions related to my illness;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I have someone to help me plan and make decisions related to my illness [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92406-8;Current level of confidence I can tell others about my health problems;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can tell others about my health problems [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92407-6;Current level of confidence I can talk to others about my condition without being embarrassed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can talk to others about my condition without being embarrassed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92408-4;Current level of confidence I can talk about my health problems with someone;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can talk about my health problems with someone [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92409-2;Current level of confidence I can stay involved in community or religious activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can stay involved in community or religious activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +924-1;Blood product dispensed;Vol;Pt;^BPU;Qn;;BLDBK;1;Blood product dispensed [Volume];Bld Prod Dispensed Vol BPU;;ACTIVE;1.0;2.42 +92410-0;Current level of confidence I can refuse help when I don't need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can refuse help when I don't need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9241-1;Output.ileostomy;Vol;Pt;Lower GI tract;Qn;;IO_OUT.MOLEC;2;Output.ileostomy [Volume];Output.ileostomy Vol;;ACTIVE;1.0i;2.48 +92411-8;Current level of confidence I can maintain my usual social activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can maintain my usual social activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92412-6;Current level of confidence I can keep in touch with friends and family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep in touch with friends and family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92413-4;Current level of confidence I can get emotional support when I need it;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can get emotional support when I need it [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92414-2;Current level of confidence I can communicate well with my doctors and nurses;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can communicate well with my doctors and nurses [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92415-9;Current level of confidence I can attend social events without being embarrassed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can attend social events without being embarrassed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92416-7;Current level of confidence I can ask for help when I don't understand something;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can ask for help when I don't understand something [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92417-5;Current level of confidence friends and family will come to see me when I am sick;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence Friends and family will come to see me when I am sick [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92418-3;PROMIS self-efficacy for managing medications and treatments - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS self-efficacy for managing medications and treatments - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92419-1;PROMIS item bank - self-efficacy for managing medications and treatments - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - self-efficacy for managing medications and treatments - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92420-9;Current level of confidence I understand the difference between my symptoms and medication side effects;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I understand the difference between my symptoms and medication side effects [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92421-7;Current level of confidence I know when and how to take my medications;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I know when and how to take my medications [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92422-5;Current level of confidence I know what to do when my medication refill looks different than usual;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I know what to do when my medication refill looks different than usual [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92423-3;Current level of confidence I know what to do if I forget to take my medication(s);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I know what to do if I forget to take my medication(s) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92424-1;Current level of confidence I can work with my doctor to choose the treatment that seems right for me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can work with my doctor to choose the treatment that seems right for me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92425-8;Current level of confidence I can use technology to help me manage my medication and treatments (for example: to get information, avoid side-effects, schedule reminders);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can use technology to help me manage my medication and treatments (for example: to get information, avoid side-effects, schedule reminders) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92426-6;Current level of confidence I can use my own judgment regarding treatment alternatives (including not having treatment);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can use my own judgment regarding treatment alternatives (including not having treatment) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92427-4;Current level of confidence I can travel to my local pharmacy to fill my prescriptions;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can travel to my local pharmacy to fill my prescriptions [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92428-2;Current level of confidence I can take several medications on different schedules;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take several medications on different schedules [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9242-9;Output.ileostomy;VRat;1H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy 1 hour;Output.ileostomy 1h;;ACTIVE;1.0i;2.48 +92429-0;Current level of confidence I can take my medicine even if it causes mild side effects;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take my medicine even if it causes mild side effects [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92430-8;Current level of confidence I can take my medication when there is a change in my usual day (unexpected things happen);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take my medication when there is a change in my usual day (unexpected things happen) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92431-6;Current level of confidence I can take my medication when I am working or away from home;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can take my medication when I am working or away from home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92432-4;Current level of confidence I can remember to take my medications when there is no one to remind me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can remember to take my medications when there is no one to remind me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92433-2;Current level of confidence I can remember to take my medication as prescribed;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can remember to take my medication as prescribed [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92434-0;Current level of confidence I can remember to refill my prescriptions before they run out;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can remember to refill my prescriptions before they run out [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92435-7;Current level of confidence I can manage my medication without help;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my medication without help [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92436-5;Current level of confidence I can list my medications, including the doses and schedule;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can list my medications, including the doses and schedule [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9243-7;Output.ileostomy;VRat;8H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy 8 hour;Output.ileostomy 8h;;ACTIVE;1.0i;2.48 +92437-3;Current level of confidence I can get help when I am not sure how to take my medicine;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can get help when I am not sure how to take my medicine [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92438-1;Current level of confidence I can follow directions when my doctor changes my medications;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can follow directions when my doctor changes my medications [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92439-9;Current level of confidence I can follow a full treatment plan (including medication, diet, physical activity);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can follow a full treatment plan (including medication, diet, physical activity) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92440-7;Current level of confidence I can fit my medication schedule into my daily routine;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can fit my medication schedule into my daily routine [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92441-5;Current level of confidence I can find information to learn more about my treatment;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can find information to learn more about my treatment [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92442-3;Current level of confidence I can figure out what treatment I need when my symptoms change;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can figure out what treatment I need when my symptoms change [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92443-1;Current level of confidence I can continue my treatment when traveling;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can continue my treatment when traveling [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92444-9;Current level of confidence I can continue my treatment when I am not feeling well;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can continue my treatment when I am not feeling well [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9244-5;Output.ileostomy;VRat;10H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy 10 hour;Output.ileostomy 10h;;ACTIVE;1.0i;2.48 +92445-6;Current level of confidence I can actively participate in decisions about my treatment;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can actively participate in decisions about my treatment [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92446-4;Document key words;Find;Pt;Document;Nom;;SURVEY.CDC;4;Document key words;;;ACTIVE;2.66;2.68 +92447-2;Document synopsis;Find;Pt;Document;Nar;;SURVEY.CDC;4;Document synopsis;;;ACTIVE;2.66;2.68 +92448-0;PROMIS self-efficacy for managing symptoms - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS self-efficacy for managing symptoms - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92449-8;PROMIS item bank - self-efficacy for managing symptoms - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - self-efficacy for managing symptoms - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92450-6;Current level of confidence I know what to do when my symptoms worsen;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I know what to do when my symptoms worsen [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92451-4;Current level of confidence I can work with my doctor to manage my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can work with my doctor to manage my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9245-2;Output.ileostomy;VRat;12H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy 12 hour;Output.ileostomy 12h;;ACTIVE;1.0i;2.48 +92452-2;Current level of confidence I can still accomplish most of my goals in life, despite my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can still accomplish most of my goals in life, despite my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92453-0;Current level of confidence I can rely on my judgment to manage my symptoms, even when others disagree with me;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can rely on my judgment to manage my symptoms, even when others disagree with me [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92454-8;Current level of confidence I can reduce my symptoms to my satisfaction;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can reduce my symptoms to my satisfaction [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92455-5;Current level of confidence I can recognize when my symptoms change;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can recognize when my symptoms change [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92456-3;Current level of confidence I can manage unexpected or new symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage unexpected or new symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92457-1;Current level of confidence I can manage my symptoms when I am tired;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my symptoms when I am tired [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92458-9;Current level of confidence I can manage my symptoms when I am in an unfamiliar place;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my symptoms when I am in an unfamiliar place [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92459-7;Current level of confidence I can manage my symptoms when I am at home;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my symptoms when I am at home [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9246-0;Output.ileostomy;VRat;24H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Output.ileostomy 24 hour;Output.ileostomy 24h;;ACTIVE;1.0i;2.48 +92460-5;Current level of confidence I can manage my symptoms in a public place;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my symptoms in a public place [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92461-3;Current level of confidence I can manage my symptoms during my daily activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my symptoms during my daily activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92462-1;Current level of confidence I can manage my symptoms as well as other people with symptoms like mine;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can manage my symptoms as well as other people with symptoms like mine [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92463-9;Current level of confidence I can make a moderate reduction in my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can make a moderate reduction in my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92464-7;Current level of confidence I can maintain my sense of humor, despite my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can maintain my sense of humor, despite my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92465-4;Current level of confidence I can live a normal life, despite my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can live a normal life, despite my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92466-2;Current level of confidence I can keep my symptoms from interfering with the work I need to do;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep my symptoms from interfering with the work I need to do [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92467-0;Current level of confidence I can keep my symptoms from interfering with relationships with friends and family;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep my symptoms from interfering with relationships with friends and family [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92468-8;Current level of confidence I can keep my symptoms from interfering with my sleep;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep my symptoms from interfering with my sleep [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92469-6;Current level of confidence I can keep my symptoms from interfering with my recreational activities;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep my symptoms from interfering with my recreational activities [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92470-4;Current level of confidence I can keep my symptoms from interfering with my personal care;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can keep my symptoms from interfering with my personal care [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92471-2;Current level of confidence I can find the information I need to manage my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can find the information I need to manage my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92472-0;Current level of confidence I can enjoy things, despite my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can enjoy things, despite my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92473-8;Current level of confidence I can do something to reduce my symptoms when they worsen;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can do something to reduce my symptoms when they worsen [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92474-6;Current level of confidence I can do something to prevent my symptoms from worsening;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can do something to prevent my symptoms from worsening [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92475-3;Current level of confidence I can control my symptoms by using methods other than taking medication (for example: relaxation exercises, distraction);Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can control my symptoms by using methods other than taking medication (for example: relaxation exercises, distraction) [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92476-1;Current level of confidence I can control my symptoms by taking my medications;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can control my symptoms by taking my medications [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92477-9;Current level of confidence I can be physically active, despite my symptoms;Find;Pt;^Patient;Ord;PROMIS;SURVEY.PROMIS;4;Current level of confidence I can be physically active, despite my symptoms [PROMIS];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9247-8;Output.ileostomy;Aper;Pt;Lower GI tract;Nom;;IO_OUT.MOLEC;2;Output.ileostomy [Appearance];Output.ileostomy;;ACTIVE;1.0i;2.27 +92478-7;VS Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;VS Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;VS Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92479-5;V Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;V Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;V Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92480-3;U Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;U Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;U Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92481-1;S little c 2 Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Sc2 Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Sc2 Ag inferred Bld/T Ql;;ACTIVE;2.66;2.69 +92482-9;S little c 1 Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Sc1 Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Sc1 Ag inferred Bld/T Ql;;ACTIVE;2.66;2.69 +92483-7;S Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;S Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;S Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92484-5;N Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;N Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;N Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92485-2;M Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;M Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;M Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +9248-6;Class;Type;Pt;Stool collection device;Nom;;DEVICES;2;Type of Stool collection device;Stl Collect Device Class;;ACTIVE;1.0i;2.27 +92486-0;LW super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;LW sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;LW sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92487-8;LW super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;LW sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;LW sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92488-6;little s Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;little s Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;little s Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92489-4;little k Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;little k Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;little k Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92490-2;little e Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;little e Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;little e Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92491-0;little c Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;little c Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;little c Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92492-8;L little u super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Lu sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Lu sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92493-6;L little u super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Lu sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Lu sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +9249-4;Stools;Aper;Pt;Lower GI tract;Nom;;IO_OUT.MOLEC;2;Stools [Appearance];Stools;;ACTIVE;1.0i;2.73 +92494-4;K little p super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Kp sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Kp sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92495-1;K little p super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Kp sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Kp sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92496-9;K Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;K Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;K Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92497-7;J little s super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Js sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Js sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92498-5;J little s super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Js sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Js sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92499-3;J little o super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Jo sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Jo sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92500-8;J little k super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Jk sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Jk sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92501-6;J little k super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Jk sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Jk sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +9250-2;Stools;NRat;8H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Stools 8 hour;Stools 8h nRate;;ACTIVE;1.0i;2.48 +92502-4;Hemoglobin S inferred;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Hemoglobin S inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Hemoglobin S inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92503-2;H little y Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Hy Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Hy Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92504-0;F little y super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Fy sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Fy sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92505-7;F little y super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Fy sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Fy sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92506-5;E Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;E Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;E Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92507-3;D little o super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Do sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Do sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92508-1;D little o super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Do sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Do sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92509-9;D little i super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Di sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Di sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +9251-0;Stools;NRat;10H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Stools 10 hour;Stools 10h nRate;;ACTIVE;1.0i;2.48 +92510-7;D little i super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Di sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Di sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92511-5;C little o super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Co sup(b) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Co sup(b) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92512-3;C little o super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;Co sup(a) Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;Co sup(a) Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92513-1;C Ag inferred phenotype;PrThr;Pt;Bld/Tiss;Ord;Molgen;BLDBK.GENOTYPING;1;C Ag inferred phenotype [Presence] in Blood or Tissue by Molecular genetics method;C Ag inferred Bld/T Ql;;ACTIVE;2.66;2.66 +92514-9;Blood group Ag & Hemoglobin S inferred phenotype panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.BLDBK.GENOTYPE;1;Blood group Ag and Hemoglobin S inferred panel - Blood or Tissue by Molecular genetics method;Blood group Ag + Hgb S inferred panel;;ACTIVE;2.66;2.66 +92515-6;Number of cigarettes smoked;Num;Lifetime;^Patient;Qn;;H&P.HX;2;Number of cigarettes smoked in Lifetime;# cigarettes smoked Lifetime;;ACTIVE;2.66;2.66 +92516-4;VS Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;VS Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;VS Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92517-2;V Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;V Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;V Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92518-0;U Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;U Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;U Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92519-8;S little c 2 Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Sc2 Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Sc2 Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.69 +92520-6;S little c 1 Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Sc1 Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Sc1 Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.69 +92521-4;S Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;S Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;S Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92522-2;N Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;N Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;N Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92523-0;M Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;M Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;M Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92524-8;LW super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;LW sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;LW sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92525-5;LW super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;LW sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;LW sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92526-3;little s Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;little s Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;little s Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92527-1;little k Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;little k Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;little k Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +9252-8;Stools;NRat;12H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Stools 12 hour;Stools 12h nRate;;ACTIVE;1.0i;2.48 +92528-9;little e Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;little e Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;little e Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92529-7;little c Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;little c Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;little c Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92530-5;L little u super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Lu sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Lu sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92531-3;L little u super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Lu sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Lu sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92532-1;K little p super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Kp sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Kp sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92533-9;K little p super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Kp sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Kp sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92534-7;K Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;K Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;K Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92535-4;J little s super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Js sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Js sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +9253-6;Stools;NRat;24H;Lower GI tract;Qn;;IO_OUT.TIMED.MOLE;2;Stools 24 hour;Stools 24h nRate;;ACTIVE;1.0i;2.48 +92536-2;J little s super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Js sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Js sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92537-0;J little o super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Jo sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Jo sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92538-8;J little k super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Jk sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Jk sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92539-6;J little k super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Jk sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Jk sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92540-4;Hemoglobin S inferred;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Hemoglobin S inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Hemoglobin S inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92541-2;H little y Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Hy Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Hy Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92542-0;F little y super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Fy sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Fy sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92543-8;F little y super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Fy sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Fy sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +9254-4;Class;Type;Pt;Wound drain device;Nom;;DEVICES;2;Type of Wound drain device;Wound drain device Class;;ACTIVE;1.0i;2.27 +92544-6;E Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;E Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;E Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92545-3;D little o super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Do sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Do sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92546-1;D little o super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Do sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Do sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92547-9;D little i super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Di sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Di sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92548-7;D little i super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Di sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Di sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92549-5;C little o super little b Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Co sup(b) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Co sup(b) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92550-3;C little o super little a Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;Co sup(a) Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;Co sup(a) Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +9255-1;Fluid output;Aper;Pt;XXX;Nom;;IO_OUT.ATOM;2;Fluid output [Appearance];Fluid output;;ACTIVE;1.0i;2.27 +92551-1;C Ag inferred phenotype;PrThr;Pt;Bld/Tiss^Donor;Ord;Molgen;BLDBK.GENOTYPING;1;C Ag inferred phenotype [Presence] in Blood or Tissue from Donor by Molecular genetics method;C Ag inferred Bld/T Donr Ql;;ACTIVE;2.66;2.66 +92552-9;Blood group Ag & Hemoglobin S inferred phenotype panel;-;Pt;Bld/Tiss^Donor;-;Molgen;PANEL.BLDBK.GENOTYPE;1;Blood group Ag and Hemoglobin S inferred panel - Blood or Tissue from Donor by Molecular genetics method;Blood group Ag + Hgb S inferred panel;;ACTIVE;2.66;2.66 +92553-7;Airway clearance technique plan to perform;Prid;Pt;^Patient;Nom;;PULM;2;Airway clearance technique plan to perform [Identifier];Airway clearance technique plan;;ACTIVE;2.66;2.66 +92554-5;Assistive technology plan to provide;Prid;Pt;^Patient;Nom;;APTA;2;Assistive technology plan to provide [Identifier];Assistive technology plan;;ACTIVE;2.66;2.66 +92555-2;Biophysical agent plan to use;Prid;Pt;^Patient;Nom;;APTA;2;Biophysical agent plan to use;Biophysical agent plan;;ACTIVE;2.66;2.66 +92556-0;Functional training plan to perform;Prid;Pt;^Patient;Nom;;APTA;2;Functional training plan to perform [Identifier];Functional training plan;;ACTIVE;2.66;2.66 +92557-8;Instructions plan to provide;Prid;Pt;^Patient;Nom;;CLIN;2;Instructions plan to provide [Identifier];Instructions plan;;ACTIVE;2.66;2.66 +92558-6;Integumentary repair and protection technique plan to use;Prid;Pt;^Patient;Nom;;APTA;2;Integumentary repair and protection technique plan to use [Identifier];Integ repair protect technique plan;;ACTIVE;2.66;2.66 +92559-4;Manual therapy technique plan to use;Prid;Pt;^Patient;Nom;;APTA;2;Manual therapy technique plan to use [Identifier];Manual therapy technique plan;;ACTIVE;2.66;2.66 +92560-2;Motor function training plan to perform;Prid;Pt;^Patient;Nom;;APTA;2;Motor function training plan to perform [Identifier];Motor function training plan;;ACTIVE;2.66;2.66 +92561-0;Other intervention &or service provided;Prid;Pt;^Patient;Nom;;APTA;2;Other intervention AndOr service provided [Identifier];Other intervention or service provided;;ACTIVE;2.66;2.66 +92562-8;Physical therapy goals panel;-;Pt;^Patient;-;;PANEL.APTA;2;Physical therapy goals panel;PT goals Pnl;;ACTIVE;2.66;2.66 +92563-6;Physical therapy health concerns panel;-;Pt;^Patient;-;;PANEL.APTA;2;Physical therapy health concerns panel;PT health concerns Pnl;;ACTIVE;2.66;2.66 +92564-4;Physical therapy plan of care panel;-;Pt;^Patient;-;;PANEL.APTA;2;Physical therapy plan of care panel;PT POC Pnl;;ACTIVE;2.66;2.66 +92565-1;Therapeutic exercise plan to perform;Prid;Pt;^Patient;Nom;;APTA;2;Therapeutic exercise plan to perform [Identifier];Ther exercise plan;;ACTIVE;2.66;2.66 +92566-9;Planned intervention &or services panel;-;Pt;^Patient;-;;PANEL.APTA;2;Planned intervention AndOr services panel;Planned intervention or services Pnl;;ACTIVE;2.66;2.66 +92567-7;Guidance for percutaneous drainage+placement of drainage catheter;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for percutaneous drainage and placement of drainage catheter of Unspecified body region;CT Guided PC drn+cath place;;ACTIVE;2.66;2.67 +92568-5;Chorion;Type;Pt;^Fetuses;Nom;;H&P.HX;2;Fetal Chorion [Type];Chorion type;;ACTIVE;2.66;2.66 +9256-9;Fluid output.total;Vol;Pt;^Patient;Qn;Estimated;IO_OUT.ATOM;2;Fluid output total Estimated;Fluid output total Est;;ACTIVE;1.0i;2.54 +92569-3;Guidance for drainage+placement of chest tube;Find;Pt;Chest>Pleural space.bilateral;Doc;CT;RAD;2;CT Guidance for drainage and placement of chest tube of Pleural space - bilateral;CT Guided Pl space-Bl Drain+CT place;;ACTIVE;2.66;2.67 +92571-9;Guidance for drainage+placement of chest tube;Find;Pt;Chest>Pleural space.right;Doc;CT;RAD;2;CT Guidance for drainage and placement of chest tube of Pleural space - right;CT Guided Pl space-R Drain+CT place;;ACTIVE;2.66;2.67 +92572-7;Sodium;Sub;24H;Dial fld;Qn;;CHEM;1;Sodium [Molar amount] in 24 hour Dialysis fluid;Sodium 24h sub Dial fld Qn;;ACTIVE;2.66;2.66 +92573-5;Resident of region that is endemic for the disease of interest;Find;Pt;^Patient;Ord;;ADMIN.PATIENT;2;Resident of region that is endemic for the disease of interest;Res of region with endemic disease;;ACTIVE;2.66;2.66 +92574-3;Labor and delivery summary - recommended IHE set;-;Pt;{Setting};-;;PANEL.DOC;2;Labor and delivery summary - recommended IHE set;LDS - recommended IHE set;;ACTIVE;2.66;2.66 +92575-0;Labor and delivery admission history and physical - recommended IHE set;-;Pt;{Setting};-;;PANEL.DOC;2;Labor and delivery admission history and physical - recommended IHE set;LDHP - recommended IHE set;;ACTIVE;2.66;2.66 +92576-8;Maternal discharge summary - recommended IHE set;-;Pt;{Setting};-;;PANEL.DOC;2;Maternal discharge summary - recommended IHE set;MDS - recommended IHE set;;ACTIVE;2.66;2.66 +9257-7;Fluid output.total;Vol;Pt;^Patient;Qn;Measured;IO_OUT.ATOM;2;Fluid output total Measured;Fluid output total Measured;;ACTIVE;1.0i;2.54 +92577-6;Chlamydophila pneumoniae DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Upper respiratory specimen by NAA with probe detection;C pneum DNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +92578-4;PROMIS short form - dyspnea severity 10a - version 1.0;-;7D;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - dyspnea severity 10a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92579-2;PROMIS short form - physical function 10b - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function 10b - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +925-8;Blood product disposition;Type;Pt;^BPU;Nom;;BLDBK;1;Blood product disposition [Type];Bld Prod Disposition BPU;;ACTIVE;1.0;2.73 +92580-0;PROMIS short form - physical function 10a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - physical function 10a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92581-8;PROMIS pediatric short form - pain behavior 8a - version 1.0;-;7D;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric short form - pain behavior 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92582-6;PROMIS parent proxy short form - meaning and purpose 8a - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - meaning and purpose 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92583-4;PROMIS parent proxy short form - meaning and purpose 4a - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - meaning and purpose 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92584-2;PROMIS parent proxy short form - physical stress experiences 8a - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - physical stress experiences 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9258-5;Fluid output.total;VRat;1H;^Patient;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output total 1 hour;Fluid output total 1h;;ACTIVE;1.0i;2.48 +92585-9;PROMIS parent proxy short form - physical stress experiences 4a - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - physical stress experiences 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92586-7;PROMIS parent proxy short form - anxiety 8a - version 2.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - anxiety 8a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92587-5;PROMIS parent proxy short form - fatigue 10a - version 2.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - fatigue 10a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92588-3;PROMIS short form - self-efficacy for managing symptoms 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing symptoms 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92589-1;PROMIS short form - self-efficacy for managing symptoms 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing symptoms 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92590-9;PROMIS short form - self-efficacy for managing social interactions 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing social interactions 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92591-7;PROMIS short form - self-efficacy for managing social interactions 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing social interactions 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92592-5;PROMIS short form - self-efficacy for managing medications and treatments 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing medications and treatments 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9259-3;Fluid output.total;VRat;8H;^Patient;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output total 8 hour;Fluid output total 8h;;ACTIVE;1.0i;2.48 +92593-3;PROMIS short form - self-efficacy for managing medications and treatments 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing medications and treatments 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92594-1;PROMIS short form - self-efficacy for managing emotions 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing emotions 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92595-8;PROMIS short form - self-efficacy for managing emotions 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing emotions 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92596-6;PROMIS short form - self-efficacy for managing daily activities 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing daily activities 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92597-4;PROMIS short form - self-efficacy for managing daily activities 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing daily activities 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92598-2;PROMIS short form - smoking - social motivations for all smokers 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - smoking - social motivations for all smokers 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92599-0;PROMIS short form - smoking - nicotine dependence for all smokers 8a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - smoking - nicotine dependence for all smokers 8a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92600-6;PROMIS short form - smoking - nicotine dependence for all smokers 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - smoking - nicotine dependence for all smokers 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9260-1;Fluid output.total;VRat;10H;^Patient;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output total 10 hour;Fluid output total 10h;;ACTIVE;1.0i;2.48 +92601-4;PROMIS short form - smoking - negative psychosocial expectancies for all smokers 6a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - smoking - negative psychosocial expectancies for all smokers 6a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92602-2;PROMIS short form - smoking - negative health expectancies for all smokers 6a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - smoking - negative health expectancies for all smokers 6a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92603-0;PROMIS short form - smoking - emotional and sensory expectancies for all smokers 6a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - smoking - emotional and sensory expectancies for all smokers 6a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92604-8;PROMIS short form - smoking - coping expectancies for all smokers 4a - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - smoking - coping expectancies for all smokers 4a - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92605-5;PROMIS short form - upper extremity 7a - version 2.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS short form - upper extremity 7a - version 2.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92606-3;PROMIS short form - dyspnea severity 10a - version 1.0 raw score;Score;7D;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - dyspnea severity 10a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92607-1;PROMIS short form - physical function 10b - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function 10b - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92608-9;PROMIS short form - physical function 10a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - physical function 10a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92609-7;PROMIS pediatric short form - pain behavior 8a - version 1.0 raw score;Score;7D;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric short form - pain behavior 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92610-5;PROMIS parent proxy short form - meaning and purpose 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - meaning and purpose 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92611-3;PROMIS parent proxy short form - meaning and purpose 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - meaning and purpose 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92612-1;PROMIS parent proxy short form - physical stress experiences 8a - version 1.0 raw score;Score;7D;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - physical stress experiences 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92613-9;PROMIS parent proxy short form - physical stress experiences 4a - version 1.0 raw score;Score;7D;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - physical stress experiences 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92614-7;PROMIS parent proxy short form - anxiety 8a - version 2.0 raw score;Score;7D;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - anxiety 8a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92615-4;PROMIS parent proxy short form - fatigue 10a - version 2.0 raw score;Score;7D;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - fatigue 10a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92616-2;PROMIS short form - self-efficacy for managing symptoms 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing symptoms 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92617-0;PROMIS short form - self-efficacy for managing symptoms 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing symptoms 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92618-8;PROMIS short form - self-efficacy for managing social interactions 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing social interactions 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9261-9;Fluid output.total;VRat;12H;^Patient;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output total 12 hour;Fluid output total 12h;;ACTIVE;1.0i;2.48 +92619-6;PROMIS short form - self-efficacy for managing social interactions 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing social interactions 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92620-4;PROMIS short form - self-efficacy for managing medications and treatments 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing medications and treatments 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92621-2;PROMIS short form - self-efficacy for managing medications and treatments 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing medications and treatments 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92622-0;PROMIS short form - self-efficacy for managing emotions 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing emotions 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92623-8;PROMIS short form - self-efficacy for managing emotions 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing emotions 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92624-6;PROMIS short form - self-efficacy for managing daily activities 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing daily activities 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92625-3;PROMIS short form - self-efficacy for managing daily activities 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - self-efficacy for managing daily activities 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92626-1;PROMIS short form - smoking - social motivations for all smokers 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - smoking - social motivations for all smokers 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +9262-7;Fluid output.total;VRat;24H;^Patient;Qn;;IO_OUT.TIMED.MOLE;2;Fluid output total 24 hour;Fluid output total 24h;;ACTIVE;1.0i;2.48 +92627-9;PROMIS short form - smoking - nicotine dependence for all smokers 8a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - smoking - nicotine dependence for all smokers 8a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92628-7;PROMIS short form - smoking - nicotine dependence for all smokers 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - smoking - nicotine dependence for all smokers 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92629-5;PROMIS short form - smoking - negative psychosocial expectancies for all smokers 6a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - smoking - negative psychosocial expectancies for all smokers 6a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92630-3;PROMIS short form - smoking - negative health expectancies for all smokers 6a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - smoking - negative health expectancies for all smokers 6a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92631-1;PROMIS short form - smoking - emotional and sensory expectancies for all smokers 6a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - smoking - emotional and sensory expectancies for all smokers 6a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92632-9;PROMIS short form - smoking - coping expectancies for all smokers 4a - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - smoking - coping expectancies for all smokers 4a - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92633-7;PROMIS short form - upper extremity 7a - version 2.0 raw score;Score;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS short form - upper extremity 7a - version 2.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.66;2.66 +92634-5;Address type;Type;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Address type;Addr type;;ACTIVE;2.66;2.66 +9263-5;Fluid output route;Type;Pt;*;Nom;;IO_OUT.ATOM;2;Fluid output route;Fluid output route;;ACTIVE;1.0i;2.29 +92635-2;Leukocytes;NCnc;Pt;Bld.buffy coat;Qn;;HEM/BC;1;Leukocytes [#/volume] in Buffy Coat;WBC # Buffy Coat;;ACTIVE;2.66;2.66 +92636-0;APOL1 inferred genotype;Prid;Pt;Plas^Donor;Nom;;MOLPATH;1;APOL1 inferred genotype [Identifier] in Plasma from Donor;APOL1 inferred Gentyp Plas Donr;;ACTIVE;2.66;2.72 +92637-8;traZODone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;traZODone [Mass/volume] in Urine by Confirmatory method;traZODone Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +92638-6;Sertraline;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Sertraline [Mass/volume] in Urine by Confirmatory method;Sertraline Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +92639-4;O-nortramadol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;O-nortramadol [Mass/volume] in Urine by Confirmatory method;O-nortramadol Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +92640-2;M-chlorophenylpiperazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;M-chlorophenylpiperazine [Mass/volume] in Urine by Confirmatory method;m-CPP Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +92641-0;diphenhydrAMINE;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;diphenhydrAMINE [Mass/volume] in Urine by Confirmatory method;Diphenhy Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +92642-8;Dextromethorphan;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Dextromethorphan [Mass/volume] in Urine by Confirmatory method;D-methorphan Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +9264-3;Apache II score;Score;Pt;^Patient;Ord;;FUNCTION;2;Apache II score;Apache II score;;ACTIVE;1.0i;2.5 +92643-6;Cotinine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cotinine [Mass/volume] in Urine by Confirmatory method;Cotinine Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +92644-4;Phentermine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Phentermine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Phentermine Sal Cfm-mCnc;;ACTIVE;2.66;2.66 +92645-1;Citalopram;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Citalopram [Presence] in Urine by Confirmatory method;Citalopram Ur Ql Cfm;;ACTIVE;2.66;2.67 +92646-9;Dextromethorphan;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Dextromethorphan [Presence] in Urine by Confirmatory method;D-methorphan Ur Ql Cfm;;ACTIVE;2.66;2.67 +92647-7;diphenhydrAMINE;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;diphenhydrAMINE [Presence] in Urine by Confirmatory method;Diphenhy Ur Ql Cfm;;ACTIVE;2.66;2.67 +92648-5;Gabapentin;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Gabapentin [Presence] in Urine by Confirmatory method;Gabapentin Ur Ql Cfm;;ACTIVE;2.66;2.73 +92649-3;Naloxone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Naloxone [Presence] in Urine by Confirmatory method;Naloxone Ur Ql Cfm;;ACTIVE;2.66;2.73 +9265-0;Apache III score;Score;Pt;^Patient;Ord;;FUNCTION;2;Apache III score;Apache III score;;ACTIVE;1.0i;2.5 +92650-1;PARoxetine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;PARoxetine [Presence] in Urine by Confirmatory method;PARoxetine Ur Ql Cfm;;ACTIVE;2.66;2.67 +92651-9;Pregabalin;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Pregabalin [Presence] in Urine by Confirmatory method;Pregabalin Ur Ql Cfm;;ACTIVE;2.66;2.73 +92652-7;Sertraline;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Sertraline [Presence] in Urine by Confirmatory method;Sertraline Ur Ql Cfm;;ACTIVE;2.66;2.67 +92653-5;traZODone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;traZODone [Presence] in Urine by Confirmatory method;traZODone Ur Ql Cfm;;ACTIVE;2.66;2.67 +92654-3;9-hydroxyrisperidone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;9-Hydroxyrisperidone [Mass/volume] in Urine by Confirmatory method;9OH-risperidone Ur Cfm-mCnc;;ACTIVE;2.66;2.66 +92655-0;Age diabetes-related problem occurred;Time;Pt;^Family member;Qn;;H&P.HX;2;Age diabetes-related problem occurred for Family member;Diabetes-related problem age Fam Mem;;ACTIVE;2.66;2.66 +92656-8;Number of menstrual periods per Y;NRat;Pt;^Patient;Qn;;H&P.HX;2;Number of menstrual periods per year;# menstrual periods per Y;;ACTIVE;2.66;2.66 +92657-6;Age when first fed formula;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first fed formula;Age first fed formula;;ACTIVE;2.66;2.66 +92658-4;Had both ovaries removed;Find;Pt;^Patient;Ord;;H&P.HX;2;Had both ovaries removed;Both ovaries removed;;ACTIVE;2.66;2.66 +92659-2;Age when stopped smoking cigarettes completely;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when stopped smoking cigarettes completely;Age stopped smoking cigarettes;;ACTIVE;2.66;2.66 +926-6;Blood product.other given;Vol;Pt;Dose;Qn;;BLDBK;1;Blood product.other given [Volume];Other Bld Prod Gvn Vol Dose;;ACTIVE;1.0;2.73 +92660-0;Time range until next menstrual period;Time;Pt;^Patient;Ord;;OBGYN;2;Time range until next menstrual period;Tme rnge til Nxt Menst;;ACTIVE;2.66;2.66 +92661-8;Age when first fed something other than breast milk or formula;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when first fed something other than breast milk or formula;Age 1st fed other than brst milk or form;;ACTIVE;2.66;2.66 +92662-6;Current age or age at death;Time;Pt;^Family member;Qn;;H&P.HX;2;Current age or age at death of Family member;Current age or death age Fam Mem;;ACTIVE;2.66;2.66 +92663-4;Problem related to diabetes;Find;Pt;^Family member;Ord;;H&P.HX;2;Problem related to diabetes Family member;Diabetes problem Fam Mem;;ACTIVE;2.66;2.66 +92664-2;Power of attorney+Living will;Find;Pt;{Setting};Doc;Patient;DOC.ONTOLOGY;2;Power of attorney and Living will;Patient POA+Living will;;ACTIVE;2.66;2.68 +92665-9;Growth and differentiation factor 15;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Growth and differentiation factor 15 [Mass/volume] in Serum or Plasma by Immunoassay;GDF-15 SerPl IA-mCnc;;ACTIVE;2.66;2.66 +92666-7;Growth hormone & glucose post cloNIDine stimulation panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Growth hormone and glucose post cloNIDine stimulation panel - Serum or Plasma;GH + glucose p cloNIDine stim pnl SerPl;;ACTIVE;2.66;2.66 +92667-5;Glucose^30M post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose cloNIDine;Glucose 30M p CLN SerPl-mCnc;;ACTIVE;2.66;2.66 +9266-8;Acute physiology score;Score;Pt;^Patient;Ord;;FUNCTION;2;Acute physiology score;APS score;;ACTIVE;1.0i;2.71 +92668-3;Glucose^1H post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post dose cloNIDine;Glucose 1h p CLN SerPl-mCnc;;ACTIVE;2.66;2.66 +92669-1;Glucose^1.5H post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose cloNIDine;Glucose 1.5h p CLN SerPl-mCnc;;ACTIVE;2.66;2.66 +92670-9;Glucose^2H post dose cloNIDine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2 hours post dose cloNIDine;Glucose 2h p CLN SerPl-mCnc;;ACTIVE;2.66;2.66 +92671-7;Basement membrane zone BP180 & BP230 Ab.IgG panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Basement membrane zone BP180 and BP230 IgG panel - Serum or Plasma;BMZ BP180 + BP230 IgG Pnl SerPl;;ACTIVE;2.66;2.66 +92672-5;Hydroxyglutarates & Glutarate & Ethylmalonate & Methylsuccinate panel;-;Pt;Bld.dot;Qn;;PANEL.CHEM;1;Hydroxyglutarates and glutarate and ethylmalonate and methylsuccinate panel - DBS;Gluts + Eth + Meth Pnl DBS;;ACTIVE;2.66;2.66 +92673-3;Hydroxyglutarates & Glutarate & Ethylmalonate & Methylsuccinate panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Hydroxyglutarates and glutarate and ethylmalonate and methylsuccinate panel - Serum or Plasma;Gluts + Eth + Meth Pnl SerPl;;ACTIVE;2.66;2.66 +92674-1;CSF3R gene exons 14 & 17 targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;CSF3R gene exons 14 and 17 targeted mutation analysis in Blood or Tissue by Molecular genetics method;CSF3R gene exon 14+17 Mut Anl Bld/T;;ACTIVE;2.66;2.66 +92675-8;MSH2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;MSH2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;MSH2 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.66;2.66 +9267-6;Glasgow coma score.eye opening;Fcn;Pt;^Patient;Ord;;FUNCTION;2;Glasgow coma score eye opening;GCS eye;;ACTIVE;1.0i;2.73 +92676-6;MLH1 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;MLH1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;MLH1 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.66;2.66 +92677-4;Views GE 4;Find;Pt;Pelvis & Lower extremity>Hip;Doc;XR;RAD;2;XR Pelvis and Hip GE 4 Views;XR Pelvis and Hip GE 4V;;ACTIVE;2.66;2.67 +92678-2;Multisection;Find;Pt;Chest>Lung;Doc;US.elastography;RAD;2;US.elastography Lung;USE Lung;;ACTIVE;2.66;2.72 +92679-0;Multisection for lesion;Find;Pt;Chest>Lung;Doc;US.elastography;RAD;2;US.elastography Lung for lesion;USE Lung for lesion;;ACTIVE;2.66;2.72 +92680-8;Multisection additional for lesion;Find;Pt;Chest>Lung;Doc;US.elastography;RAD;2;US.elastography Lung additional for lesion;USE Lung lesion addl;;ACTIVE;2.66;2.72 +92681-6;Guidance for dilation of existing nephrostomy tract;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for dilation of existing nephrostomy tract of Kidney;Guided Kidney Dilation exist nephr tract;;TRIAL;2.66;2.67 +92682-4;Guidance for dilation of existing nephrostomy tract+placement of nephrostomy tube at new site;Find;Pt;Abdomen>Kidney;Doc;{Imaging modality};RAD;2;Guidance for dilation of existing nephrostomy tract and placement of nephrostomy tube at new site of Kidney;Guided Dil exist nephr tr+tube new site;;TRIAL;2.66;2.67 +92683-2;Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis DNA panel;-;Pt;Genital;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA panel - Genital specimen by NAA with probe detection;CT + NG + TV DNA Pnl Genital NAA+probe;;ACTIVE;2.66;2.66 +9268-4;Glasgow coma score.motor;Fcn;Pt;^Patient;Ord;;FUNCTION;2;Glasgow coma score motor;GCS motor;;ACTIVE;1.0i;2.73 +92684-0;Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis DNA panel;-;Pt;Urine;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA panel - Urine by NAA with probe detection;CT + NG + TV DNA Pnl Ur NAA+probe;;ACTIVE;2.66;2.66 +92685-7;Trichomonas vaginalis DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Trichomonas vaginalis DNA [Presence] in Urine by NAA with probe detection;T vaginalis DNA Ur Ql NAA+probe;;ACTIVE;2.66;2.66 +92686-5;Vibrio cholerae+parahaemolyticus+vulnificus DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Vibrio cholerae+parahaemolyticus+vulnificus DNA [Presence] in Stool by NAA with probe detection;V chol+para+vul DNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92687-3;Giardia lamblia DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Giardia lamblia DNA [Presence] in Stool by NAA with probe detection;G lamblia DNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92688-1;Cryptosporidium parvum+hominis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Cryptosporidium parvum+hominis DNA [Presence] in Stool by NAA with probe detection;C parvum+hominis DNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92689-9;Entamoeba histolytica DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Entamoeba histolytica DNA [Presence] in Stool by NAA with probe detection;E histolyt DNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92690-7;Adenovirus 40+41 DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Adenovirus 40+41 DNA [Presence] in Stool by NAA with probe detection;AdV 40+41 DNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92691-5;Astrovirus RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Astrovirus RNA [Presence] in Stool by NAA with probe detection;HAstV RNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +9269-2;Glasgow coma score.total;Fcn;Pt;^Patient;Qn;;FUNCTION;2;Glasgow coma score total;GCS total;;ACTIVE;1.0i;2.73 +92692-3;Norovirus genogroup I+II RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup I+II RNA [Presence] in Stool by NAA with probe detection;Norovirus GI+II RNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92693-1;Rotavirus A RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Rotavirus A RNA [Presence] in Stool by NAA with probe detection;RVA RNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92694-9;Sapovirus genogroups I+II+IV+V RNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Sapovirus genogroups I+II+IV+V RNA [Presence] in Stool by NAA with probe detection;Sapo I+II+IV+V RNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92695-6;Gastrointestinal bacterial pathogens panel;-;Pt;Stool;-;Probe.amp.tar;PANEL.MICRO;1;Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection;GI bact pathogens Pnl Stl NAA+probe;;ACTIVE;2.66;2.7 +92696-4;Gastrointestinal viral pathogens panel;-;Pt;Stool;-;Probe.amp.tar;PANEL.MICRO;1;Gastrointestinal viral pathogens panel - Stool by NAA with probe detection;GI viral pathogens Pnl Stl NAA+probe;;ACTIVE;2.66;2.7 +92697-2;Gastrointestinal parasitic pathogens panel;-;Pt;Stool;-;Probe.amp.tar;PANEL.MICRO;1;Gastrointestinal parasitic pathogens panel - Stool by NAA with probe detection;GI parasitic pathogens Pnl Stl NAA+probe;;ACTIVE;2.66;2.7 +92698-0;Gardnerella vaginalis DNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Gardnerella vaginalis DNA [Presence] in Vaginal fluid by Probe;G vaginalis DNA Vag Ql Probe;;ACTIVE;2.66;2.66 +92699-8;Candida sp DNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Candida sp DNA [Presence] in Vaginal fluid by Probe;Candida DNA Vag Ql Probe;;ACTIVE;2.66;2.66 +92-7;Cefodizime;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefodizime [Susceptibility] by Minimum inhibitory concentration (MIC);Cefodizime Islt MIC;;ACTIVE;1.0;2.19 +9270-0;Glasgow coma score.verbal;Fcn;Pt;^Patient;Ord;;FUNCTION;2;Glasgow coma score verbal;GCS verbal;;ACTIVE;1.0i;2.27 +92700-4;Trichomonas vaginalis DNA;PrThr;Pt;Vag;Ord;Probe;MICRO;1;Trichomonas vaginalis DNA [Presence] in Vaginal fluid by Probe;T vaginalis DNA Vag Ql Probe;;ACTIVE;2.66;2.66 +92701-2;Staphylococcus aureus DNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [Presence] in Nose by NAA with probe detection;S aureus DNA Nose Ql NAA+probe;;ACTIVE;2.66;2.66 +92702-0;Lactobacillus crispatus+jensenii+Gardnerella vaginalis+Atopobium vaginae+Bacterial Vaginosis Associated Bacteria-2+Megasphaera sp type 1 DNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Lactobacillus crispatus+jensenii + Gardnerella vaginalis + Atopobium vaginae + Bacterial Vaginosis Associated Bacteria-2 + Megasphaera sp type 1 DNA [Presence] in Vaginal fluid by NAA with probe detection;BV bacteria DNA Vag Ql NAA+probe;;ACTIVE;2.66;2.66 +92703-8;Vaginal pathogens panel;-;Pt;Vag;-;Probe.amp.tar;PANEL.MICRO;1;Vaginal pathogens panel - Vaginal fluid by NAA with probe detection;Vag pathogens pnl Vag NAA+probe;;ACTIVE;2.66;2.74 +92704-6;Planned intervention &or services visit frequency;Find;Pt;^Patient;Nom;;APTA;2;Planned intervention AndOr services visit frequency;Planned interv +or serv visit freq;;ACTIVE;2.66;2.66 +92705-3;Planned intervention &or services duration - time frame;Time;Pt;^Patient;Qn;;APTA;2;Planned intervention AndOr services duration - time frame;Planned interv +or serv dur time frame;;ACTIVE;2.66;2.66 +92706-1;Other intervention &or service plan to provide;Prid;Pt;^Patient;Nom;;APTA;2;Other intervention AndOr service plan to provide [Identifier];Other intervention or service plan;;ACTIVE;2.66;2.66 +92707-9;Care team information panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Care team information panel;Care team info Pnl;;ACTIVE;2.66;2.66 +92708-7;Physical therapy goal attainment expected duration - visits;Num;Pt;^Patient;Qn;;APTA;2;Physical therapy goal attainment expected duration - visits;PT goal attain dur - visits;;ACTIVE;2.66;2.66 +92709-5;Physical therapy goal attainment expected duration - time frame;Time;Pt;^Patient;Qn;;APTA;2;Physical therapy goal attainment expected duration - time frame;PT goal attain dur - time frame;;ACTIVE;2.66;2.66 +92710-3;Physical therapy goal;Type;Pt;^Patient;Nom;;APTA;2;Physical therapy goal;PT goal;;ACTIVE;2.66;2.66 +92711-1;Lipoprotein.alpha.subparticle.small;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.alpha.subparticle.small [Moles/volume] in Serum;HDL small Ser-sCnc;;ACTIVE;2.66;2.66 +92712-9;Lipoprotein.beta.subparticle.very small-d;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.beta.subparticle.very small-d [Moles/volume] in Serum;LDL very small-d Ser-sCnc;;ACTIVE;2.66;2.66 +92713-7;Lipoprotein.beta.subparticle.very small-c;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.beta.subparticle.very small-c [Moles/volume] in Serum;LDL very small-c Ser-sCnc;;ACTIVE;2.66;2.66 +92714-5;Lipoprotein.beta.subparticle.very small-b;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.beta.subparticle.very small-b [Moles/volume] in Serum;LDL very small-b Ser-sCnc;;ACTIVE;2.66;2.66 +92715-2;Lipoprotein.beta.subparticle.very small-a;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.beta.subparticle.very small-a [Moles/volume] in Serum;LDL very small-a Ser-sCnc;;ACTIVE;2.66;2.66 +92716-0;Lipoprotein.beta.subparticle.large-b;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.beta.subparticle.large-b [Moles/volume] in Serum;LDL large-b Ser-sCnc;;ACTIVE;2.66;2.66 +92717-8;Lipoprotein.beta.subparticle.large-a;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.beta.subparticle.large-a [Moles/volume] in Serum;LDL large-a Ser-sCnc;;ACTIVE;2.66;2.66 +9271-8;Score^10M post birth;Fcn;Pt;^Patient;Qn;Apgar;NEONAT;2;10 minute Apgar Score;10M Apgar Score;;ACTIVE;1.0i;2.48 +92718-6;Lipoprotein.broad beta.subparticle.small;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.broad beta.subparticle.small [Moles/volume] in Serum;IDL small Ser-sCnc;;ACTIVE;2.66;2.66 +92719-4;Lipoprotein.broad beta.subparticle.large;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.broad beta.subparticle.large [Moles/volume] in Serum;IDL large Ser-sCnc;;ACTIVE;2.66;2.66 +92720-2;Lipoprotein.pre-beta.subparticle.small;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.pre-beta.subparticle.small [Moles/volume] in Serum;VLDL small Ser-sCnc;;ACTIVE;2.66;2.66 +92721-0;Lipoprotein.pre-beta.subparticle.medium;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.pre-beta.subparticle.medium [Moles/volume] in Serum;VLDL medium Ser-sCnc;;ACTIVE;2.66;2.66 +92722-8;Lipoprotein subparticle profile panel;-;Pt;Ser;-;;PANEL.CHEM;1;Lipoprotein subparticle profile panel - Serum;Lipoprotein subparticle profile Pnl Ser;;ACTIVE;2.66;2.66 +92723-6;Yersinia enterocolitica DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Yersinia enterocolitica DNA [Presence] in Stool by NAA with probe detection;Y enterocol DNA Stl Ql NAA+probe;;ACTIVE;2.66;2.66 +92724-4;Candida sp & Gardnerella vaginalis & Trichomonas vaginalis DNA panel;-;Pt;Vag;-;Probe;PANEL.MICRO;1;Candida sp and Gardnerella vaginalis and Trichomonas vaginalis DNA panel - Vaginal fluid by Probe;Candida sp + GV + TV DNA Pnl Vag Probe;;ACTIVE;2.66;2.66 +92725-1;Prognosis for rehabilitation;Find;Pt;^Patient;Ord;;CLIN;2;Prognosis for rehabilitation;Prognosis for rehabilitation;;ACTIVE;2.66;2.66 +9272-6;Score^1M post birth;Fcn;Pt;^Patient;Qn;Apgar;NEONAT;2;1 minute Apgar Score;1M Apgar Score;;ACTIVE;1.0i;2.73 +92726-9;17-Hydroxyprogesterone;MCnc;Pt;Bld.dot;Qn;LC/MS/MS;CHEM;1;17-Hydroxyprogesterone [Mass/volume] in DBS by LC/MS/MS;17OHP DBS LC/MS/MS-mCnc;;ACTIVE;2.66;2.66 +92727-7;Tacrolimus;TmMCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tacrolimus [AUC] in Blood;Tacrolimus Bld-AUC;;ACTIVE;2.66;2.66 +92728-5;Tacrolimus^4H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Blood --4 hours post dose;Tacrolimus 4h p Bld-mCnc;;ACTIVE;2.66;2.66 +92729-3;Tacrolimus^2H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Blood --2 hours post dose;Tacrolimus 2h p Bld-mCnc;;ACTIVE;2.66;2.66 +92730-1;Tacrolimus^1H post dose;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Tacrolimus [Mass/volume] in Blood --1 hour post dose;Tacrolimus 1h p Bld-mCnc;;ACTIVE;2.66;2.66 +92731-9;Hepatitis C virus genotype;Type;Pt;Ser/Plas;Nom;Sequencing;MICRO;1;Hepatitis C virus genotype in Serum or Plasma by Sequencing;HCV Gentyp SerPl Seq;;ACTIVE;2.66;2.72 +92732-7;Codon &or region with poor sequence quality;Prid;Pt;Isolate/Specimen;Nom;Sequencing;MOLPATH.MISC;1;Codon AndOr region with poor sequence quality [Identifier] in Isolate or Specimen by Sequencing Nominal;Codon or region w poor seq quality;;ACTIVE;2.66;2.66 +92733-5;Glecaprevir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Glecaprevir [Susceptibility] by Genotype method;Glecaprevir Islt Genotyp;;ACTIVE;2.66;2.66 +9273-4;Score^2M post birth;Fcn;Pt;^Patient;Qn;Apgar;NEONAT;2;2 minute Apgar Score;Apgar Score;;ACTIVE;1.0i;2.48 +92734-3;Voxilaprevir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Voxilaprevir [Susceptibility] by Genotype method;Voxilaprevir Islt Genotyp;;ACTIVE;2.66;2.66 +92735-0;Pibrentasvir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Pibrentasvir [Susceptibility] by Genotype method;Pibrentasvir Islt Genotyp;;ACTIVE;2.66;2.66 +92736-8;Cells.CD3+CD4+;NCnc;Pt;Bld;Qn;IA.rapid;CELLMARK;1;CD3+CD4+ (T4 helper) cells [#/volume] in Blood by Rapid immunoassay;CD3+CD4+ Cells # Bld IA.rapid;;ACTIVE;2.66;2.66 +92737-6;7-Alpha,12-alpha dihydroxycholest-4-en-3-one & 7-Alpha hydroxy-4-cholesten-3-one panel;-;Pt;Bld;-;;PANEL.CHEM;1;7-Alpha,12-alpha dihydroxycholest-4-en-3-one and 7-Alpha hydroxy-4-cholesten-3-one panel - Blood;CTX Pnl Bld;;ACTIVE;2.66;2.66 +92738-4;Cholestane-3-beta, 5-alpha, 6-beta triol & Lyso-sphingomyelin panel;-;Pt;Bld;-;;PANEL.CHEM;1;Cholestane-3-beta, 5-alpha, 6-beta triol and Lyso-sphingomyelin panel - Blood;Oxysterols Pnl Bld;;ACTIVE;2.66;2.66 +92739-2;7-Alpha,12-alpha dihydroxycholest-4-en-3-one & 7-Alpha hydroxy-4-cholesten-3-one panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;7-Alpha,12-alpha dihydroxycholest-4-en-3-one and 7-Alpha hydroxy-4-cholesten-3-one panel - DBS;CTX Pnl DBS;;ACTIVE;2.66;2.66 +927-4;Blood product identifier.pooled;ID;Pt;^BPU;Nom;;BLDBK;1;Blood product.pooled [Identifier];Pooled Bld Prod Id BPU;;ACTIVE;1.0;2.73 +92740-0;Oxysterols panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Oxysterols panel - Serum or Plasma;Oxysterols Pnl SerPl;;ACTIVE;2.66;2.66 +92741-8;Cholestane-3-beta, 5-alpha, 6-beta triol & Lyso-sphingomyelin panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Cholestane-3-beta, 5-alpha, 6-beta triol and Lyso-sphingomyelin panel - DBS;Oxysterols Pnl DBS;;ACTIVE;2.66;2.66 +9274-2;Score^5M post birth;Fcn;Pt;^Patient;Qn;Apgar;NEONAT;2;5 minute Apgar Score;5M Apgar Score;;ACTIVE;1.0i;2.73 +92742-6;Iron.microscopic observation;Prid;Pt;BAL;Nom;Potassium ferrocyanide stain;PATH;1;Iron.microscopic observation [Identifier] in Bronchoalveolar lavage by Potassium ferrocyanide stain;Iron BAL K Ferrocyanide Stn;;ACTIVE;2.66;2.66 +92743-4;Hepatosplenomegaly due to lysosomal storage disorders screening panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Hepatosplenomegaly due to lysosomal storage disorders screening panel - Serum or Plasma;HepSplenMeg Pnl SerPl;;ACTIVE;2.66;2.66 +92744-2;Hepatosplenomegaly due to lysosomal storage disorders screening panel;-;Pt;Bld;-;;PANEL.CHEM;1;Hepatosplenomegaly due to lysosomal storage disorders screening panel - Blood;HepSplenMeg Pnl Bld;;ACTIVE;2.66;2.66 +92745-9;Hepatosplenomegaly due to lysosomal storage disorders screening panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Hepatosplenomegaly due to lysosomal storage disorders screening panel - DBS;HepSplenMeg Pnl DBS;;ACTIVE;2.66;2.66 +92746-7;7-Alpha,12-alpha dihydroxycholest-4-en-3-one & 7-Alpha hydroxy-4-cholesten-3-one panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;7-Alpha,12-alpha dihydroxycholest-4-en-3-one and 7-Alpha hydroxy-4-cholesten-3-one panel - Serum or Plasma;CTX Pnl SerPl;;ACTIVE;2.66;2.66 +92747-5;Lyso-sphingomyelin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Lyso-sphingomyelin [Moles/volume] in Serum or Plasma;LSM SerPl-sCnc;;ACTIVE;2.66;2.66 +92748-3;Lyso-sphingomyelin;SCnc;Pt;Bld;Qn;;CHEM;1;Lyso-sphingomyelin [Moles/volume] in Blood;LSM Bld-sCnc;;ACTIVE;2.66;2.66 +92749-1;Lyso-sphingomyelin;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Lyso-sphingomyelin [Moles/volume] in DBS;LSM DBS-sCnc;;ACTIVE;2.66;2.66 +92750-9;Glucopsychosine;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glucopsychosine [Moles/volume] in Serum or Plasma;Glucopsychosine SerPl-sCnc;;ACTIVE;2.66;2.66 +92751-7;Glucopsychosine;SCnc;Pt;Bld;Qn;;CHEM;1;Glucopsychosine [Moles/volume] in Blood;Glucopsychosine Bld-sCnc;;ACTIVE;2.66;2.66 +92752-5;Glucopsychosine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Glucopsychosine [Moles/volume] in DBS;Glucopsychosine DBS-sCnc;;ACTIVE;2.66;2.66 +92753-3;Globotriaosylsphingosine;SCnc;Pt;Bld;Qn;;CHEM;1;Globotriaosylsphingosine [Moles/volume] in Blood;Globotriaosylsphingosine Bld-sCnc;;ACTIVE;2.66;2.66 +92754-1;Globotriaosylsphingosine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Globotriaosylsphingosine [Moles/volume] in DBS;Globotriaosylsphingosine DBS-sCnc;;ACTIVE;2.66;2.66 +92755-8;Cholestane-3-beta, 5-alpha, 6-beta triol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholestane-3-beta, 5-alpha, 6-beta triol [Moles/volume] in Serum or Plasma;Chol-3b,5a,6b-triol SerPl-sCnc;;ACTIVE;2.66;2.66 +92756-6;Cholestane-3-beta, 5-alpha, 6-beta triol;SCnc;Pt;Bld;Qn;;CHEM;1;Cholestane-3-beta, 5-alpha, 6-beta triol [Moles/volume] in Blood;Chol-3b,5a,6b-triol Bld-sCnc;;ACTIVE;2.66;2.66 +92757-4;Cholestane-3-beta, 5-alpha, 6-beta triol;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Cholestane-3-beta, 5-alpha, 6-beta triol [Moles/volume] in DBS;Chol-3b,5a,6b-triol DBS-sCnc;;ACTIVE;2.66;2.66 +92758-2;7-Alpha,12-alpha dihydroxycholest-4-en-3-one;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-Alpha,12-alpha dihydroxycholest-4-en-3-one [Moles/volume] in Serum or Plasma;7a12aDiOHchol4en3one SerPl-sCnc;;ACTIVE;2.66;2.66 +9275-9;Breath rate method;Type;Pt;Breath rate measurement;Nom;*;RESP.ATOM;2;Breath rate method;Breath rate method;;ACTIVE;1.0i;2.29 +92759-0;7-Alpha,12-alpha dihydroxycholest-4-en-3-one;SCnc;Pt;Bld;Qn;;CHEM;1;7-Alpha,12-alpha dihydroxycholest-4-en-3-one [Moles/volume] in Blood;7a12aDiOHchol4en3one Bld-sCnc;;ACTIVE;2.66;2.66 +92760-8;7-Alpha,12-alpha dihydroxycholest-4-en-3-one;SCnc;Pt;Bld.dot;Qn;;CHEM;1;7-Alpha,12-alpha dihydroxycholest-4-en-3-one [Moles/volume] in DBS;7a12aDiOHchol4en3one DBS-sCnc;;ACTIVE;2.66;2.66 +92761-6;7-Alpha hydroxy-4-cholesten-3-one;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-Alpha hydroxy-4-cholesten-3-one [Moles/volume] in Serum or Plasma;7a-OH-4-chol-3-one SerPl-sCnc;;ACTIVE;2.66;2.66 +92762-4;7-Alpha hydroxy-4-cholesten-3-one;SCnc;Pt;Bld;Qn;;CHEM;1;7-Alpha hydroxy-4-cholesten-3-one [Moles/volume] in Blood;7a-OH-4-chol-3-one Bld-sCnc;;ACTIVE;2.66;2.66 +92763-2;7-Alpha hydroxy-4-cholesten-3-one;SCnc;Pt;Bld.dot;Qn;;CHEM;1;7-Alpha hydroxy-4-cholesten-3-one [Moles/volume] in DBS;7a-OH-4-chol-3-one DBS-sCnc;;ACTIVE;2.66;2.66 +92764-0;7-Ketocholesterol;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-Ketocholesterol [Moles/volume] in Serum or Plasma;7-Ketochol SerPl-sCnc;;ACTIVE;2.66;2.66 +92765-7;Adalimumab Ab.Neut;Titr;Pt;Ser;Qn;Bioassay;SERO;1;Adalimumab neutralizing antibody [Titer] in Serum by Bioassay;Adalimumab NAb Titr Ser Bioassay;;ACTIVE;2.66;2.66 +92766-5;Alpha-aminoadipic semialdehyde+Delta-1-Piperideine-6-carboxylate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alpha-aminoadipic semialdehyde+Delta-1-piperideine-6-carboxylate [Moles/volume] in Serum or Plasma;AASA+P6C SerPl-sCnc;;ACTIVE;2.66;2.66 +92767-3;Listeria sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Listeria sp DNA [Presence] by NAA with probe detection in Positive blood culture;Listeria DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92768-1;Candida albicans+glabrata+krusei+parapsilosis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida albicans+glabrata+krusei+parapsilosis DNA [Presence] by NAA with probe detection in Positive blood culture;Pan Candida DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92769-9;Gram negative bacteria DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Gram negative bacteria DNA [Presence] by NAA with probe detection in Positive blood culture;GN bact DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92770-7;Streptococcus pyogenes DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Presence] by NAA with probe detection in Positive blood culture;S pyo DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92771-5;Streptococcus pneumoniae DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] by NAA with probe detection in Positive blood culture;S pneum DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92772-3;Streptococcus anginosus group DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Streptococcus anginosus group DNA [Presence] by NAA with probe detection in Positive blood culture;S anginosus grp DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92773-1;Streptococcus agalactiae DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] by NAA with probe detection in Positive blood culture;Gp B Strep DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92774-9;Streptococcus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Streptococcus sp DNA [Presence] by NAA with probe detection in Positive blood culture;Streptococcus DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +9277-5;Class;Type;Pt;Breath rate device;Nom;;DEVICES;2;Type of Breath rate device;Breath Rate Device Class;;ACTIVE;1.0i;2.73 +92775-6;Staphylococcus lugdunensis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Staphylococcus lugdunensis DNA [Presence] by NAA with probe detection in Positive blood culture;S lugdunensis DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92776-4;Staphylococcus epidermidis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Staphylococcus epidermidis DNA [Presence] by NAA with probe detection in Positive blood culture;S epidermidis DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92777-2;Staphylococcus aureus DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [Presence] by NAA with probe detection in Positive blood culture;S aureus DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92778-0;Staphylococcus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Staphylococcus sp DNA [Presence] by NAA with probe detection in Positive blood culture;Staphylococcus DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92779-8;Micrococcus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Micrococcus sp DNA [Presence] by NAA with probe detection in Positive blood culture;Microc sp DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92780-6;Listeria monocytogenes DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Listeria monocytogenes DNA [Presence] by NAA with probe detection in Positive blood culture;L monocytog DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92781-4;Lactobacillus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Lactobacillus sp DNA [Presence] by NAA with probe detection in Positive blood culture;Lactobacillus DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92782-2;Enterococcus faecium DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecium DNA [Presence] by NAA with probe detection in Positive blood culture;E faecium DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +9278-3;Breath rate special circumstances;Type;Pt;^Patient;Nom;;RESP.ATOM;2;Breath rate special circumstances;Breath rate special circumstances;;ACTIVE;1.0i;2.64 +92783-0;Enterococcus faecalis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecalis DNA [Presence] by NAA with probe detection in Positive blood culture;E faecalis DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92784-8;Enterococcus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Enterococcus sp DNA [Presence] by NAA with probe detection in Positive blood culture;Enterococ DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92785-5;Cutibacterium acnes DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Cutibacterium acnes DNA [Presence] by NAA with probe detection in Positive blood culture;C acnes DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92786-3;Corynebacterium sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Corynebacterium sp DNA [Presence] by NAA with probe detection in Positive blood culture;Corynebacterium DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92787-1;Bacillus subtilis group DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Bacillus subtilis group DNA [Presence] by NAA with probe detection in Positive blood culture;B subtilis grp DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92788-9;Bacillus cereus group DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Bacillus cereus group DNA [Presence] by NAA with probe detection in Positive blood culture;B cereus group DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92789-7;Gram positive blood culture panel;-;Pt;Bld.pos growth;-;Probe.amp.tar;PANEL.MICRO;1;Gram positive blood culture panel by NAA with probe detection in Positive blood culture;GP Bld Culture Pnl Bld Pos NAA+probe;;ACTIVE;2.66;2.67 +92790-5;Candida albicans DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida albicans DNA [Presence] by NAA with probe detection in Positive blood culture;C albicans DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +9279-1;Breaths;NRat;Pt;Respiratory system;Qn;;RESP.ATOM;2;Respiratory rate;Resp rate;;ACTIVE;1.0i;2.73 +92791-3;Candida auris DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida auris DNA [Presence] by NAA with probe detection in Positive blood culture;C auris DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92792-1;Candida dubliniensis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida dubliniensis DNA [Presence] by NAA with probe detection in Positive blood culture;C dubliniensis DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92793-9;Candida famata DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida famata DNA [Presence] by NAA with probe detection in Positive blood culture;C famata DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92794-7;Candida glabrata DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida glabrata DNA [Presence] by NAA with probe detection in Positive blood culture;C glabrata DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92795-4;Candida guilliermondii DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida guilliermondii DNA [Presence] by NAA with probe detection in Positive blood culture;C guilliermondii DNA Bld Pos Ql NAA+pr;;ACTIVE;2.66;2.66 +92796-2;Candida kefyr DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida kefyr DNA [Presence] by NAA with probe detection in Positive blood culture;C kefyr DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92797-0;Candida krusei DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida krusei DNA [Presence] by NAA with probe detection in Positive blood culture;C krusei DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92798-8;Candida lusitaniae DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida lusitaniae DNA [Presence] by NAA with probe detection in Positive blood culture;C lusitaniae DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92799-6;Candida parapsilosis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida parapsilosis DNA [Presence] by NAA with probe detection in Positive blood culture;C parap DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92800-2;Candida tropicalis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Candida tropicalis DNA [Presence] by NAA with probe detection in Positive blood culture;C tropicls DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92801-0;Cryptococcus gattii DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Cryptococcus gattii DNA [Presence] by NAA with probe detection in Positive blood culture;C. gattii DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92802-8;Cryptococcus neoformans DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Cryptococcus neoformans DNA [Presence] by NAA with probe detection in Positive blood culture;C neoform DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92803-6;Fusarium sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Fusarium sp DNA [Presence] by NAA with probe detection in Positive blood culture;Fusarium DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92804-4;Rhodotorula spp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Rhodotorula spp DNA [Presence] by NAA with probe detection in Positive blood culture;Rhodatorula DNA Bld Pos Ql NAA+probe;;ACTIVE;2.66;2.66 +92805-1;Blood fungal pathogens panel;-;Pt;Bld.pos growth;-;Probe.amp.tar;PANEL.MICRO;1;Blood Fungal Pathogens Panel by NAA with probe detection in Positive blood culture;Bld fungal path panel Bld Pos NAA+probe;;ACTIVE;2.66;2.66 +92806-9;Keratan sulfate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Keratan sulfate/Creatinine [Ratio] in Urine;Keratan Sulfate/Creat Ur-Rto;;ACTIVE;2.66;2.66 +92807-7;Rhinovirus+Enterovirus RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus RNA [Presence] in Upper respiratory specimen by NAA with probe detection;RV+EV RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +92808-5;Influenza virus A H3 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;FLUAV H3 RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +9280-9;Breaths;NRat;1H^max;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 1 hour maximum;Resp rate 1h Max;;ACTIVE;1.0i;2.42 +92809-3;Influenza virus A H1 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;FLUAV H1 RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +92810-1;Borrelia afzelii+burgdorferi+garinii Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG Ab [Units/volume] in Serum by Immunoassay;B afz+burg+gari IgG Ser IA-aCnc;;ACTIVE;2.66;2.66 +92811-9;Borrelia afzelii+burgdorferi+garinii Ab.IgG index;ACnc;Pt;Ser+CSF;Qn;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG Ab index [Units/volume] in Serum and CSF by Immunoassay;B afz+burg+gar IgG Index Ser+CSF IA-aCnc;;ACTIVE;2.66;2.66 +92812-7;Borrelia afzelii+burgdorferi+garinii Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B afz+burg+gari IgG CSF IA-aCnc;;ACTIVE;2.66;2.66 +92813-5;Borrelia afzelii+burgdorferi+garinii Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;B afz+burg+gari IgG CSF Ql IA;;ACTIVE;2.66;2.66 +92814-3;Borrelia afzelii+burgdorferi+garinii Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG Ab [Presence] in Serum by Immunoassay;B afz+burg+gari IgG Ser Ql IA;;ACTIVE;2.66;2.66 +92815-0;Borrelia afzelii+burgdorferi+garinii Ab.IgG panel;-;Pt;Ser+CSF;-;;PANEL.MICRO;1;Borrelia afzelii+burgdorferi+garinii IgG panel - Serum and CSF;Borrelia af+burg+gari IgG Pnl Ser+CSF;;ACTIVE;2.66;2.71 +92816-8;Phencyclidine;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Phencyclidine [Mass/mass] in Meconium by Confirmatory method;PCP Mec Cfm-mCnt;;ACTIVE;2.66;2.66 +9281-7;Breaths;NRat;8H^max;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 8 hour maximum;Resp rate 8h Max;;ACTIVE;1.0i;2.42 +92817-6;Glucose^30M post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose glucagon;Glucose 30M p Gc SerPl-mCnc;;ACTIVE;2.66;2.66 +92818-4;Glucose^20M post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --20 minutes post dose glucagon;Glucose 20M p Gc SerPl-mCnc;;ACTIVE;2.66;2.66 +92819-2;Glucose^10M post dose glucagon;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --10 minutes post dose glucagon;Glucose 10M p Gc SerPl-mCnc;;ACTIVE;2.66;2.66 +928-2;Blood product reaction;Type;Pt;^BPU;Nom;;BLDBK;1;Blood product reaction [Type];Bld Prod Reaction BPU;;ACTIVE;1.0;2.21 +92820-0;Glucose post glucagon stimulation panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Glucose post glucagon stimulation panel - Serum or Plasma;Glucose p glucagon stimulation Pnl SerPl;;ACTIVE;2.66;2.66 +92821-8;Allelic frequency;NFr;Pt;^Population;Qn;;MOLPATH;1;Allelic frequency in Population;Allelic freq NFr Pop;;ACTIVE;2.66;2.66 +92822-6;Genomic coordinate system;Type;Pt;XXX;Nom;Molgen;MOLPATH;1;Genomic coordinate system [Type];Genomic coord system;;ACTIVE;2.66;2.72 +92823-4;Planned intervention &or services duration - visits;Num;Pt;^Patient;Qn;;APTA;2;Planned intervention AndOr services duration - visits;Planned interv +or serv dur visits;;ACTIVE;2.66;2.66 +92824-2;Source of population allelic frequency data;Type;Pt;^Population;Nom;;MOLPATH;1;Source of population allelic frequency data;Pop allelic freq data source;;ACTIVE;2.66;2.66 +9282-5;Breaths;NRat;10H^max;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 10 hour maximum;Resp rate 10h Max;;ACTIVE;1.0i;2.42 +92825-9;Renin^upright;ACnc;Pt;Plas;Qn;;CHEM;1;Renin [Units/volume] in Plasma --upright;Renin upr Plas-aCnc;;ACTIVE;2.66;2.66 +92826-7;Renin^supine;ACnc;Pt;Plas;Qn;;CHAL;1;Renin [Units/volume] in Plasma --supine;Renin sup Plas-aCnc;;ACTIVE;2.66;2.68 +92827-5;Mycobacterium tuberculosis complex species identified;Prid;Pt;XXX;Nom;Sequencing;MICRO;1;Mycobacterium tuberculosis complex species identified in Specimen by Sequencing;MTB complex sp Spec Seq;;ACTIVE;2.66;2.69 +92828-3;Adenovirus B+E DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus B+E DNA [Presence] in Specimen by NAA with probe detection;AdV B+E DNA Spec Ql NAA+probe;;ACTIVE;2.66;2.69 +92829-1;Location of metastasis within sentinel lymph node;Anat;Pt;Cancer specimen;Nom;;PATH;1;Location of metastasis within sentinel lymph node [Anatomy] in Cancer specimen;Loc of met in sentinel LN Ca spec;;ACTIVE;2.66;2.66 +92830-9;Sentinel lymph node extranodal extension;PrThr;Pt;Cancer specimen;Ord;;PATH;1;Sentinel lymph node extranodal extension [Presence] in Cancer specimen;Sentinel LN extranodal ext Ca spec Ql;;ACTIVE;2.66;2.66 +92831-7;Lymph nodes with metastasis;Num;Pt;Cancer specimen;Qn;;PATH;1;Lymph nodes with metastasis [#] in Cancer specimen;LN met Ca spec;;ACTIVE;2.66;2.66 +92832-5;Sentinel lymph nodes with metastasis;Num;Pt;Cancer specimen;Qn;;PATH;1;Sentinel lymph nodes with metastasis [#] in Cancer specimen;Sentinel LN met Ca spec;;ACTIVE;2.66;2.66 +9283-3;Breaths;NRat;12H^max;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 12 hour maximum;Resp rate 12h Max;;ACTIVE;1.0i;2.42 +92833-3;Lymph nodes examined;Num;Pt;Cancer specimen;Qn;Microscopy.light;PATH;1;Lymph nodes examined [#] in Cancer specimen by Light microscopy;LN exam Ca spec Micro;;ACTIVE;2.66;2.66 +92834-1;Tumor regression at peripheral margin;PrThr;Pt;Skin melanoma;Ord;;PATH;1;Tumor regression at peripheral margin [Presence] in Skin melanoma;Tumor regression at margin Mel Ql;;ACTIVE;2.66;2.66 +92835-8;Associated nevus;PrThr;Pt;Skin melanoma;Ord;;PATH;1;Associated nevus [Presence] in Skin melanoma;Associated nevus Mel Ql;;ACTIVE;2.66;2.66 +92836-6;Desmoplastic melanoma;Prid;Pt;Skin melanoma;Nom;;PATH;1;Desmoplastic melanoma [Identifier] in Skin melanoma;Desmoplastic melanoma Mel;;ACTIVE;2.66;2.66 +92837-4;Perineural invasion;PrThr;Pt;Cancer specimen;Ord;;PATH;1;Perineural invasion [Presence] in Cancer specimen;Perineural invasion Ca spec Ql;;ACTIVE;2.66;2.66 +92838-2;Satellite nodules;PrThr;Pt;Skin melanoma;Ord;;PATH;1;Satellite nodules [Presence] in Skin melanoma;Satellite nodules Mel Ql;;ACTIVE;2.66;2.66 +92839-0;Breslow thickness;Len;Pt;Skin melanoma;Qn;;PATH;1;Breslow thickness [Length] of Skin melanoma;Breslow thickness Mel;;ACTIVE;2.66;2.72 +92840-8;Emergency operations standard operating procedure;Find;Pt;^Event;Doc;;DOC.MISC;2;Emergency operations standard operating procedure Document;Emergency operations SOP Doc;;ACTIVE;2.66;2.68 +9284-1;Breaths;NRat;24H^max;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 24 hour maximum;Resp rate 24h Max;;ACTIVE;1.0i;2.42 +92841-6;Countermeasure report;Find;Pt;^Event;Doc;;DOC.MISC;2;Countermeasure report;Countermeasure rpt;;ACTIVE;2.66;2.68 +92842-4;Situational report;Find;Pt;^Event;Doc;;DOC.MISC;2;Situational report;Situational report;;ACTIVE;2.66;2.68 +92843-2;FLT3 gene.p.Asp835 mutations;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.MUT;1;FLT3 gene p.Asp835 mutations [Presence] in Blood or Tissue by Molecular genetics method;FLT3 p.D835 mutations Bld/T Ql;;ACTIVE;2.66;2.66 +92844-0;FLT3 gene internal tandem duplication/normal;Ratio;Pt;Bld/Tiss;Qn;Molgen;MOLPATH.MUT;1;FLT3 gene internal tandem duplication/Normal [Ratio] in Blood or Tissue by Molecular genetics method;FLT3 ITD Dp/Nor Bld/T-Rto;;ACTIVE;2.66;2.71 +92845-7;Insulin resistance score;Score;Pt;Ser;Qn;Calculated.CardioIQ;CHEM;1;Insulin resistance score in Serum by Calculated.CardioIQ;Insulin resist score Ser Calc.CardioIQ;;ACTIVE;2.66;2.66 +92846-5;Ambulatory blood pressure monitor study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Ambulatory blood pressure monitor study;ABPM study;;ACTIVE;2.66;2.72 +92847-3;Herpes simplex virus 1 & 2 & Varicella zoster virus DNA panel;-;Pt;Bld;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 and Varicella zoster virus DNA panel - Blood by NAA with probe detection;HSV 1 + 2 + VZV DNA Pnl Bld NAA+probe;;ACTIVE;2.66;2.69 +92848-1;Varicella zoster virus DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [#/volume] (viral load) in Blood by NAA with probe detection;VZV DNA # Bld NAA+probe;;ACTIVE;2.66;2.66 +92849-9;Herpes simplex virus 1 & 2 & Varicella zoster virus DNA panel;-;Pt;CSF;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 and Varicella zoster virus DNA panel - Cerebral spinal fluid by NAA with probe detection;HSV 1 + 2 + VZV DNA Pnl CSF NAA+probe;;ACTIVE;2.66;2.69 +92850-7;Range of motion;Find;RptPeriod;Upper extremity;Ord;CMS Assessment;SURVEY.CMS;4;Range of motion during assessment period [CMS Assessment] Upper extremity;;;ACTIVE;2.66;2.7 +92851-5;Range of motion;Find;RptPeriod;Lower extremity;Ord;CMS Assessment;SURVEY.CMS;4;Range of motion during assessment period [CMS Assessment] Lower extremity;;;ACTIVE;2.66;2.7 +92852-3;Adenovirus & Bocavirus DNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Adenovirus and Bocavirus DNA panel - Lower respiratory specimen by NAA with probe detection;HAdV + HBoV DNA Pnl Lower resp NAA+probe;;ACTIVE;2.66;2.66 +92853-1;Adenovirus & Bocavirus DNA panel;-;Pt;Respiratory.upper;-;Probe.amp.tar;PANEL.MICRO;1;Adenovirus and Bocavirus DNA panel - Upper respiratory specimen by NAA with probe detection;HAdV + HBoV DNA Pnl Upper resp NAA+probe;;ACTIVE;2.66;2.68 +92854-9;Adenovirus DNA;NCnc;Pt;Cornea/Conjunctiva;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [#/volume] (viral load) in Cornea or Conjunctiva by NAA with probe detection;HAdV DNA # Corn/Cnjt NAA+probe;;ACTIVE;2.66;2.66 +92855-6;Bordetella parapertussis IS1001 DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Bordetella parapertussis IS1001 DNA [Presence] in Lower respiratory specimen by NAA with probe detection;B parap IS1001 DNA Lower Resp Ql NAA+pr;;ACTIVE;2.66;2.66 +92856-4;Bordetella parapertussis IS1001 DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Bordetella parapertussis IS1001 DNA [Presence] in Upper respiratory specimen by NAA with probe detection;B parap IS1001 DNA Upper resp Ql NAA+prb;;ACTIVE;2.66;2.68 +92857-2;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA [Presence] in Lower respiratory specimen by NAA with probe detection;B pert+bron+holm IS481 LowResp Ql NAA+pr;;ACTIVE;2.66;2.66 +9285-8;Breaths;NRat;1H;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 1 hour;Resp rate 1h;;ACTIVE;1.0i;2.42 +92858-0;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis+bronchiseptica+holmesii IS481 DNA [Presence] in Upper respiratory specimen by NAA with probe detection;B pert+bron+holm IS481 Up resp Ql NAA+pr;;ACTIVE;2.66;2.66 +92859-8;Chlamydophila pneumoniae & Mycoplasma pneumoniae DNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydophila pneumoniae and Mycoplasma pneumoniae DNA panel - Lower respiratory specimen by NAA with probe detection;C pn + M pn DNA Pnl Lower resp NAA+probe;;ACTIVE;2.66;2.66 +92860-6;Chlamydophila pneumoniae & Mycoplasma pneumoniae DNA panel;-;Pt;Respiratory.upper;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydophila pneumoniae and Mycoplasma pneumoniae DNA panel - Upper respiratory specimen by NAA with probe detection;C pn + M pn DNA Pnl Upper resp NAA+probe;;ACTIVE;2.66;2.68 +92861-4;Herpes simplex virus 1 & 2 & Varicella zoster virus DNA panel;-;Pt;Skin;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 and Varicella zoster virus DNA panel - Skin by NAA with probe detection;HSV 1 + 2 + VZV DNA Pnl Skin NAA+probe;;ACTIVE;2.66;2.69 +92862-2;Herpes simplex virus 1 & 2 & Varicella zoster virus DNA panel;-;Pt;Ser/Plas;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 and Varicella zoster virus DNA panel - Serum or Plasma by NAA with probe detection;HSV 1 + 2 + VZV DNA Pnl SerPl NAA+probe;;ACTIVE;2.66;2.69 +92863-0;Herpes simplex virus 1 & 2 DNA panel;-;Pt;Skin;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Skin by NAA with probe detection;HSV 1+2 DNA Pnl Skin NAA+probe;;ACTIVE;2.66;2.66 +92864-8;Herpes simplex virus 1 & 2 DNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Lower respiratory specimen by NAA with probe detection;HSV 1+2 DNA Pnl Lower resp NAA+probe;;ACTIVE;2.66;2.66 +92865-5;Herpes simplex virus 1 & 2 DNA panel;-;Pt;CSF;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Cerebral spinal fluid by NAA with probe detection;HSV 1+2 DNA Pnl CSF NAA+probe;;ACTIVE;2.66;2.66 +9286-6;Breaths;NRat;8H;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 8 hour;Resp rate 8h;;ACTIVE;1.0i;2.42 +92866-3;Herpes simplex virus 1 & 2 DNA panel;-;Pt;Ser/Plas;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Serum or Plasma by NAA with probe detection;HSV 1+2 DNA Pnl SerPl NAA+probe;;ACTIVE;2.66;2.66 +92867-1;Herpes simplex virus 1 & 2 DNA panel;-;Pt;Bld;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Blood by NAA with probe detection;HSV 1+2 DNA Pnl Bld NAA+probe;;ACTIVE;2.66;2.66 +92868-9;Herpes simplex virus 1 & 2 DNA panel;-;Pt;Respiratory.upper;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Upper respiratory specimen by NAA with probe detection;HSV 1+2 DNA Pnl Upper resp NAA+probe;;ACTIVE;2.66;2.68 +92869-7;Herpes simplex virus 1 & 2 DNA panel;-;Pt;BAL;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Bronchoalveolar lavage by NAA with probe detection;HSV 1+2 DNA Pnl BAL NAA+probe;;ACTIVE;2.66;2.66 +92870-5;Herpes simplex virus 1 DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Blood by NAA with probe detection;HSV1 DNA Bld Ql NAA+probe;;ACTIVE;2.66;2.66 +92871-3;Herpes simplex virus 1 DNA;PrThr;Pt;Skin;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Skin by NAA with probe detection;HSV1 DNA Skin Ql NAA+probe;;ACTIVE;2.66;2.66 +92872-1;Herpes simplex virus 1 DNA;PrThr;Pt;Anogenital;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Anogenital by NAA with probe detection;HSV1 DNA Anogenital Ql NAA+probe;;ACTIVE;2.66;2.66 +92873-9;Herpes simplex virus 2 DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Blood by NAA with probe detection;HSV2 DNA Bld Ql NAA+probe;;ACTIVE;2.66;2.66 +9287-4;Breaths;NRat;10H;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 10 hour;Resp rate 10h;;ACTIVE;1.0i;2.42 +92874-7;Herpes simplex virus 2 DNA;PrThr;Pt;Skin;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Skin by NAA with probe detection;HSV2 DNA Skin Ql NAA+probe;;ACTIVE;2.66;2.66 +92875-4;Herpes simplex virus 2 DNA;PrThr;Pt;Anogenital;Ord;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Anogenital by NAA with probe detection;HSV2 DNA Anogenital Ql NAA+probe;;ACTIVE;2.66;2.66 +92876-2;Human coronavirus 229E+HKU1+NL63+OC43 & Parainfluenza virus 1+2+3+4 RNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Human coronavirus 229E+HKU1+NL63+OC43 and Parainfluenza virus 1+2+3+4 RNA panel - Lower respiratory specimen by NAA with probe detection;4 HCoVs + HPIV1-4 RNA Pnl LowResp NAA+Pr;;ACTIVE;2.66;2.66 +92877-0;Human coronavirus 229E+HKU1+NL63+OC43 & Parainfluenza virus 1+2+3+4 RNA panel;-;Pt;Respiratory.upper;-;Probe.amp.tar;PANEL.MICRO;1;Human coronavirus 229E+HKU1+NL63+OC43 and Parainfluenza virus 1+2+3+4 RNA panel - Upper respiratory specimen by NAA with probe detection;4 HCoVs + HPIV1-4 RNA Pnl Up resp NAA+pr;;ACTIVE;2.66;2.66 +92878-8;Human coronavirus 229E+HKU1+NL63+OC43 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E+HKU1+NL63+OC43 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;4 HCoVs RNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92879-6;Human coronavirus 229E+HKU1+NL63+OC43 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Human coronavirus 229E+HKU1+NL63+OC43 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;4 HCoVs RNA Up resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92880-4;Human metapneumovirus & Respiratory syncytial virus RNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Human metapneumovirus and Respiratory syncytial virus RNA panel - Lower respiratory specimen by NAA with probe detection;hMPV + RSV RNA Pnl Lower resp NAA+probe;;ACTIVE;2.66;2.66 +92881-2;Human metapneumovirus & Respiratory syncytial virus RNA panel;-;Pt;Respiratory.upper;-;Probe.amp.tar;PANEL.MICRO;1;Human metapneumovirus and Respiratory syncytial virus RNA panel - Upper respiratory specimen by NAA with probe detection;hMPV + RSV RNA Pnl Upper resp NAA+probe;;ACTIVE;2.66;2.68 +9288-2;Breaths;NRat;12H;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 12 hour;Resp rate 12h;;ACTIVE;1.0i;2.42 +92882-0;Influenza virus A & B RNA panel;-;Pt;Respiratory.upper;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus types A and B panel - Upper respiratory specimen by NAA with probe detection;FLUAV + FLUBV Pnl Upper resp NAA+probe;;ACTIVE;2.66;2.68 +92883-8;Parainfluenza virus 1+2+3+4 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1+2+3+4 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;HPIV 1+2+3+4 RNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92884-6;Parainfluenza virus 1+2+3+4 RNA;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1+2+3+4 RNA [Presence] in Upper respiratory specimen by NAA with probe detection;HPIV 1+2+3+4 RNA Upper resp Ql NAA+probe;;ACTIVE;2.66;2.68 +92885-3;Rhinovirus+Enterovirus RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus RNA [Presence] in Lower respiratory specimen by NAA with probe detection;RV+EV RNA Lower resp Ql NAA+probe;;ACTIVE;2.66;2.66 +92886-1;Torque teno virus DNA;NCnc;Pt;Ser/Plas;Qn;Probe.amp.tar;MICRO;1;Torque teno virus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection;TTV DNA # SerPl NAA+probe;;ACTIVE;2.66;2.66 +92887-9;Torque teno virus DNA;NCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Torque teno virus DNA [#/volume] (viral load) in Blood by NAA with probe detection;TTV DNA # Bld NAA+probe;;ACTIVE;2.66;2.66 +92888-7;Varicella zoster virus DNA;PrThr;Pt;Skin;Ord;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Skin by NAA with probe detection;VZV DNA Skin Ql NAA+probe;;ACTIVE;2.66;2.66 +92889-5;Chronic hepatitis differentiation between B & C virus panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Chronic hepatitis differentiation between hepatitis B and C virus panel - Serum or Plasma;Chronic hepatitis diff Pnl SerPl;;ACTIVE;2.66;2.66 +9289-0;Breaths;NRat;24H;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 24 hour;Resp rate 24h;;ACTIVE;1.0i;2.42 +92890-3;Hepatitis A & B & C virus immunity &or previous exposure panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis A and B and C virus immunity AndOr previous exposure panel - Serum or Plasma;HAV+HBV+HCV immunity +or expos Pnl SerPl;;ACTIVE;2.66;2.66 +92891-1;Coagulation tissue factor induced.INR goal;RelTime;Pt;PPP;Qn;Coag;COAG;1;INR goal in Platelet poor plasma by Coagulation assay;INR goal PPP;;ACTIVE;2.66;2.66 +92892-9;Microbiology - parasitic studies;Find;Pt;^Patient;Doc;;DOC.MISC;2;Microbiology - parasitic studies;Parasite studies;;ACTIVE;2.66;2.66 +92893-7;Microbiology - viral studies;Find;Pt;^Patient;Doc;;DOC.MISC;2;Microbiology - viral studies;Viral studies;;ACTIVE;2.66;2.66 +92894-5;Microbiology - bacterial studies;Find;Pt;^Patient;Doc;;DOC.MISC;2;Microbiology - bacterial studies;Bacterial studies;;ACTIVE;2.66;2.66 +92895-2;Endocrinology studies;Find;Pt;^Patient;Doc;;DOC.MISC;2;Endocrinology studies;Endocrine studies;;ACTIVE;2.66;2.66 +92896-0;Aldosterone;MCnc;Pt;Ser/Plas;Qn;RIA;CHEM;1;Aldosterone [Mass/volume] in Serum or Plasma by Radioimmunoassay (RIA);Aldost SerPl RIA-mCnc;;ACTIVE;2.66;2.66 +92897-8;Aldosterone;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Aldosterone [Mass/volume] in Serum or Plasma by Immunoassay;Aldost SerPl IA-mCnc;;ACTIVE;2.66;2.66 +92898-6;Hepatitis B virus core Ab & surface and little e Ab & Ag panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis B virus core Ab and surface and little e Ab and Ag panel - Serum or Plasma;HBV core + surf + little e Pnl SerPl;;ACTIVE;2.66;2.66 +92899-4;Fetal chromosome region 11q23 deletion;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.DELDUP;1;Fetal Chromosome region 11q23 deletion [Presence] based on Plasma cell-free DNA by Sequencing;Fet Chr 11q23 Del Plas.cfDNA Ql;;ACTIVE;2.66;2.66 +929-0;Blood product release time;TmStp;Pt;^BPU;Qn;;BLDBK;1;Blood product release time;Bld Prod Release Tme BPU;;ACTIVE;1.0;2.73 +92900-0;Fetal chromosome region 4p16 deletion;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.DELDUP;1;Fetal Chromosome region 4p16 deletion [Presence] based on Plasma cell-free DNA by Sequencing;Fet Chr 4p16 Del Plas.cfDNA Ql;;ACTIVE;2.66;2.66 +92901-8;Noninvasive prenatal fetal aneuploidy and microdeletion panel;-;Pt;Plas.cfDNA;-;Sequencing;PANEL.MOLPATH;1;Noninvasive prenatal fetal aneuploidy and microdeletion panel - Plasma cell-free DNA by Sequencing;NIP fet aneu microdel pnl Plas.cfDNA Seq;;ACTIVE;2.66;2.7 +92902-6;Fetal chromosome region 8q24 deletion;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.DELDUP;1;Fetal Chromosome region 8q24 deletion [Presence] based on Plasma cell-free DNA by Sequencing;Fet Chr 8q24 Del Plas.cfDNA Ql;;ACTIVE;2.66;2.66 +92903-4;Fetal chromosome region 15q11 deletion;PrThr;Pt;Plas.cfDNA;Ord;Sequencing;MOLPATH.DELDUP;1;Fetal Chromosome region 15q11 deletion [Presence] based on Plasma cell-free DNA by Sequencing;Fet Chr 15q11 Del Plas.cfDNA Ql;;ACTIVE;2.66;2.66 +92904-2;N-nortramadol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;N-nortramadol [Mass/volume] in Urine by Confirmatory method;N-nortramadol Ur Cfm-mCnc;;ACTIVE;2.66;2.73 +92905-9;Chromosome 7 copy number/nucleus;EntNum;Pt;Bld/Tiss;Qn;FISH;MOLPATH;1;Chromosome 7 copy number/nucleus in Blood or Tissue by FISH;Chr 7 copy num/nucleus EntNum Bld/T FISH;;ACTIVE;2.66;2.66 +92906-7;MET gene copy number/nucleus;EntNum;Pt;Bld/Tiss;Qn;FISH;MOLPATH;1;MET gene copy number/nucleus in Blood or Tissue by FISH;MET copy num/nucleus EntNum Bld/T FISH;;ACTIVE;2.66;2.66 +92907-5;MET gene copy number/Chromosome 7 copy number;NRto;Pt;Bld/Tiss;Qn;FISH;MOLPATH;1;MET gene copy number/Chromosome 7 copy number in Blood or Tissue by FISH;MET copy num/Chr 7 copy num Bld/T FISH;;ACTIVE;2.66;2.66 +9290-8;Breaths;NRat;1H^min;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 1 hour minimum;Resp rate 1h Min;;ACTIVE;1.0i;2.42 +92908-3;Functional limitation in range of motion;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional limitation in range of motion during assessment period [CMS Assessment];;;ACTIVE;2.66;2.74 +92909-1;Note;Find;Pt;Outpatient;Doc;Aerodigestive medicine;DOC.ONTOLOGY;2;Aerodigestive medicine Outpatient Note;Aerodigestive med OP Note;;ACTIVE;2.66;2.66 +92910-9;Consultation note;Find;Pt;{Setting};Doc;Spinal surgery;DOC.ONTOLOGY;2;Spinal surgery Consult note;Spinal surgery Consult note;;ACTIVE;2.66;2.66 +92911-7;Note;Find;Pt;Outpatient;Doc;Eating disorders;DOC.ONTOLOGY;2;Eating disorders Outpatient Note;Eating disorders OP Note;;ACTIVE;2.66;2.66 +92912-5;Consultation note;Find;Pt;{Setting};Doc;Eating disorders;DOC.ONTOLOGY;2;Eating disorders Consult note;Eating disorders Consult note;;ACTIVE;2.66;2.66 +92913-3;Note;Find;Pt;Telehealth;Doc;Immunology;DOC.ONTOLOGY;2;Immunology Telehealth Note;Immunology Telehealth Note;;ACTIVE;2.66;2.66 +92914-1;Note;Find;Pt;Outpatient;Doc;Immunology;DOC.ONTOLOGY;2;Immunology Outpatient Note;Immunology OP Note;;ACTIVE;2.66;2.66 +92915-8;Consultation note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Consult note;Immunology Consult note;;ACTIVE;2.66;2.66 +9291-6;Breaths;NRat;8H^min;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 8 hour minimum;Resp rate 8h Min;;ACTIVE;1.0i;2.42 +92916-6;Guidance for aspiration;Find;Pt;Abdomen>Retroperitoneum;Doc;CT;RAD;2;CT Guidance for aspiration of Retroperitoneum;CT Guided Retroperitoneum Asp;;ACTIVE;2.66;2.67 +92917-4;Guidance for aspiration;Find;Pt;Abdomen>Kidney.right;Doc;CT;RAD;2;CT Guidance for aspiration of Kidney - right;CT Guided Kidney-R Asp;;ACTIVE;2.66;2.67 +92918-2;Guidance for aspiration;Find;Pt;Abdomen>Kidney.left;Doc;CT;RAD;2;CT Guidance for aspiration of Kidney - left;CT Guided Kidney-L Asp;;ACTIVE;2.66;2.67 +92919-0;Guidance 2 levels for injection;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;CT;RAD;2;CT Guidance for 2 levels injection of Spine Lumbar and Sacrum;CT Guided L-spine+Sacrum Inj 2 levels;;ACTIVE;2.66;2.67 +92920-8;Guidance 1 level for injection;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;CT;RAD;2;CT Guidance for 1 level injection of Spine Lumbar and Sacrum;CT Guided L-spine+Sacrum Inj 1 level;;ACTIVE;2.66;2.67 +92921-6;Guidance 1 level for injection;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic;Doc;CT;RAD;2;CT Guidance for 1 level injection of Cervical and thoracic spine;CT Guided C+T-spine Inj 1 level;;ACTIVE;2.66;2.67 +92922-4;Guidance for intrathecal injection;Find;Pt;Abdomen>Spine.lumbar;Doc;CT;RAD;2;CT Guidance for intrathecal injection of Lumbar spine;CT Guided L-spine IT Inj;;ACTIVE;2.66;2.67 +92923-2;Guidance for aspiration;Find;Pt;Abdomen>Kidney;Doc;CT;RAD;2;CT Guidance for aspiration of Kidney;CT Guided Kidney Asp;;ACTIVE;2.66;2.67 +9292-4;Breaths;NRat;10H^min;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 10 hour minimum;Resp rate 10h Min;;ACTIVE;1.0i;2.42 +92924-0;Guidance for aspiration;Find;Pt;Abdomen;Doc;CT;RAD;2;CT Guidance for aspiration of Abdomen;CT Guided Abd Asp;;ACTIVE;2.66;2.67 +92925-7;Guidance for injection;Find;Pt;Neck>Spine.cervical epidural space & Chest>Spine.thoracic epidural space;Doc;CT;RAD;2;CT Guidance for injection of Spine cervical and thoracic epidural space;CT Guided C-spine+T-spine epidural Inj;;ACTIVE;2.66;2.67 +92926-5;Guidance for radiation treatment^WO & W contrast IV;Find;Pt;XXX;Doc;CT;RAD;2;CT Guidance for radiation treatment of Unspecified body region-- WO and W contrast IV;CT Guided RT--WO+W contr IV;;ACTIVE;2.66;2.67 +92927-3;Multisection for tau protein^W radionuclide IV;Find;Pt;Head>Brain;Doc;PT+CT;RAD;2;PET+CT Brain for tau protein;PET+CT Brain for tau prot W RNC IV;;ACTIVE;2.66;2.67 +92928-1;Guidance for injection;Find;Pt;Abdomen>Spine.lumbar epidural space & Pelvis>Sacrum epidural space;Doc;CT;RAD;2;CT Guidance for injection of Spine lumbar and Sacrum epidural space;CT Guided L-spine+Sacrum epidural Inj;;ACTIVE;2.66;2.67 +92929-9;Measles & Mumps & Rubella virus Ab.IgG panel;ACnc;Pt;Ser/Plas;Qn;;PANEL.MICRO;1;Measles, Mumps and Rubella virus IgG panel [Units/volume] - Serum or Plasma;MeV + MuV + RUBV IgG Pnl SerPl-aCnc;;ACTIVE;2.66;2.73 +92930-7;LPA gene.c.3947+467T>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;LPA gene.c.3947+467T>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;LPA c.3947+467T>C Geno Bld/T;;ACTIVE;2.66;2.68 +92931-5;LPA gene.c.5673A>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;LPA gene.c.5673A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;LPA c.5673A>G Geno Bld/T;;ACTIVE;2.66;2.68 +9293-2;Breaths;NRat;12H^min;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 12 hour minimum;Resp rate 12h Min;;ACTIVE;1.0i;2.42 +92932-3;KIF6 gene.c.2155T>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;KIF6 gene.c.2155T>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;KIF6 c.2155T>C Geno Bld/T;;ACTIVE;2.66;2.68 +92933-1;9p21 g.22125503G>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;9p21 g.22125503G>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;9p21 g.22125503G>C Geno Bld/T;;ACTIVE;2.66;2.68 +92934-9;9p21 g.22124478A>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;9p21 g.22124478A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;9p21 g.22124478A>G Geno Bld/T;;ACTIVE;2.66;2.68 +92935-6;4q25 g.111720761T>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;4q25 g.111720761T>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;4q25 g.111720761T>G Geno Bld/T;;ACTIVE;2.66;2.68 +92936-4;4q25 g.111710169C>T;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;4q25 g.111710169C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal;4q25 g.111710169C>T Geno Bld/T;;ACTIVE;2.66;2.68 +92937-2;Eslicarbazepine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Eslicarbazepine [Mass/volume] in Serum or Plasma;Eslicarbazepine SerPl-mCnc;;ACTIVE;2.66;2.66 +92938-0;Catecholamines 3 panel;-;-;Urine;Qn;;PANEL.CHEM;1;Catecholamines 3 panel - Urine;Catecholamines 3 Pnl Ur;;ACTIVE;2.66;2.68 +92939-8;Number of residence renovations;Num;Pt;^Patient;Ord;;SURVEY.CDC;4;Number of residence renovations;;;ACTIVE;2.66;2.66 +9294-0;Breaths;NRat;24H^min;Respiratory system;Qn;;RESP.TIMED.MOLEC;2;Respiratory rate 24 hour minimum;Resp rate 24h Min;;ACTIVE;1.0i;2.42 +92940-6;Residence renovation completion date;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Residence renovation completion date;;;ACTIVE;2.66;2.66 +92941-4;Residence renovation start date;Date;Pt;^Patient;Qn;;SURVEY.CDC;4;Residence renovation start date;;;ACTIVE;2.66;2.66 +92942-2;Poison control record;Find;Pt;{Setting};Doc;{Role};DOC.MISC;2;Poison control record Document;Poison control record Doc;;ACTIVE;2.66;2.66 +92943-0;Severe weather event;Type;Pt;^Event;Nom;;PUBLICHEALTH;2;Severe weather event [Type];Weather event;;ACTIVE;2.66;2.66 +92944-8;Exposure source;Type;Pt;^Patient;Nom;;H&P.HX;2;Exposure source;Exposure source;;ACTIVE;2.66;2.66 +92945-5;Intent of carbon monoxide exposure;Find;Pt;^Patient;Nom;;SURVEY.CDC;4;Intent of carbon monoxide exposure;;;ACTIVE;2.66;2.66 +92946-3;Streptococcus pyogenes DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;S pyo DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92947-1;Streptococcus pyogenes DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;S pyo DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92948-9;Streptococcus pneumoniae DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;S pneum DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92949-7;Streptococcus pneumoniae DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;S pneum DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92950-5;Streptococcus agalactiae DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;Gp B Strep DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92951-3;Streptococcus agalactiae DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;Gp B Strep DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92952-1;Staphylococcus aureus DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;S aureus DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92953-9;Staphylococcus aureus DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;S aureus DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92954-7;Serratia marcescens DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Serratia marcescens DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;S marcescens DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92955-4;Serratia marcescens DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Serratia marcescens DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;S marcescens DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92956-2;Rhinovirus+Enterovirus RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;RV+EV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +9295-7;Breaths^post bronchoscopy;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --post bronchoscopy;Resp rate p bronchoscopy;;ACTIVE;1.0i;2.42 +92957-0;Respiratory syncytial virus RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Respiratory syncytial virus RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;RSV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92958-8;Respiratory pathogens DNA & RNA panel;-;Pt;Respiratory.lower;-;Non-probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA panel - Lower respiratory specimen by NAA with non-probe detection;Resp path DNA+RNA Pnl L Resp NAA+non-prb;;ACTIVE;2.66;2.69 +92959-6;Pseudomonas aeruginosa DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;P aeruginosa DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92960-4;Pseudomonas aeruginosa DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;P aeruginosa DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92961-2;Proteus sp DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Proteus sp DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;Proteus sp DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92962-0;Proteus sp DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Proteus sp DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;Proteus sp DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92963-8;Parainfluenza virus RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HPIV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92964-6;Mycoplasma pneumoniae DNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;M pneumo DNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +9296-5;Breaths^post cardioversion;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --post cardioversion;Resp rate p cardioversion;;ACTIVE;1.0i;2.42 +92965-3;Moraxella catarrhalis DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Moraxella catarrhalis DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;M catarrhalis DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92966-1;Moraxella catarrhalis DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Moraxella catarrhalis DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;M catarrhalis DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92967-9;Middle East respiratory syndrome coronavirus RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;MERS-CoV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92968-7;Bacterial methicillin resistance mecA+mecC genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;MICRO;1;Methicillin resistance mecA+mecC genes [Presence] in Isolate or Specimen by Molecular genetics method;mecA+mecC Islt/Spm Ql;;ACTIVE;2.66;2.66 +92969-5;Legionella pneumophila DNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Legionella pneumophila DNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;L pneumo DNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92970-3;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;K pneu grp DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92971-1;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;K pneu grp DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92972-9;Klebsiella oxytoca DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;K oxytoca DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +9297-3;Breaths^post conscious sedation;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --post conscious sedation;Resp rate p conscious sed;;ACTIVE;1.0i;2.42 +92973-7;Klebsiella oxytoca DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;K oxytoca DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92974-5;Klebsiella aerogenes DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;K aerogenes DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92975-2;Klebsiella aerogenes DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;K aerogenes DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92976-0;Influenza virus B RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus B RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;FLUBV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92977-8;Influenza virus A RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Influenza virus A RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;FLUAV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92978-6;Human Metapneumovirus RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Human metapneumovirus RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;hMPV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92979-4;Human Coronavirus RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HCoV RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92980-2;Haemophilus influenzae DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;Haem influ DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +9298-1;Breaths^post inhalation therapy;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --post inhalation therapy;Resp rate p inhalation therapy;;ACTIVE;1.0i;2.42 +92981-0;Haemophilus influenzae DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;Haem influ DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92982-8;Escherichia coli DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;E coli DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92983-6;Escherichia coli DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;E coli DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92984-4;Enterobacter cloacae complex DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;E cloac comp DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92985-1;Enterobacter cloacae complex DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;E cloac comp DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92986-9;Chlamydophila pneumoniae DNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Chlamydophila pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;C pneum DNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92987-7;Adenovirus DNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HAdV DNA Lower resp Ql NAA+non-probe;;ACTIVE;2.66;2.66 +92988-5;Acinetobacter calcoaceticus-baumannii complex DNA;NCncRange;Pt;Sputum;Ord;Non-probe.amp.tar;MICRO;1;Acinetobacter calcoaceticus-baumannii complex DNA [NCncRange] in Sputum Qualitative by NAA with non-probe detection;Acb cmplx DNA Spt NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92989-3;Acinetobacter calcoaceticus-baumannii complex DNA;NCncRange;Pt;BAL;Ord;Non-probe.amp.tar;MICRO;1;Acinetobacter calcoaceticus-baumannii complex DNA [NCncRange] in Bronchoalveolar lavage Qualitative by NAA with non-probe detection;Acb cmplx DNA BAL NAA+non-prb-NCncRng;;ACTIVE;2.66;2.69 +92990-1;F10 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F10 gene full mutation analysis in Blood or Tissue by Sequencing;F10 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.66;2.66 +92991-9;F13A1 gene & F13B gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F13A1 and F13B gene full mutation analysis in Blood or Tissue by Sequencing;F13A1 + F13B Full Mut Anl Bld/T Seq;;ACTIVE;2.66;2.66 +92992-7;FGA gene & FGB gene & FGG gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;FGA, FGB, and FGG gene full mutation analysis in Blood or Tissue by Sequencing;FGA + FGB + FGG Full Mut Anl Bld/T Seq;;ACTIVE;2.66;2.66 +92993-5;PROCR gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;PROCR gene full mutation analysis in Blood or Tissue by Sequencing;PROCR gene Full Mut Anl Bld/T Seq;;ACTIVE;2.66;2.66 +92994-3;PROS1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;PROS1 gene full mutation analysis in Blood or Tissue by Sequencing;PROS1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.66;2.66 +92995-0;THBD gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;THBD gene full mutation analysis in Blood or Tissue by Sequencing;THBD gene Full Mut Anl Bld/T Seq;;ACTIVE;2.66;2.66 +92996-8;Upper segment/Lower segment;LenRto;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Upper segment/Lower segment;Upper segment/Lower segment;;ACTIVE;2.66;2.66 +92997-6;Upper segment;Len;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Upper segment [Length];Upper segment;;ACTIVE;2.66;2.66 +92998-4;Lower segment;Len;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Lower segment [Length];Lower segment;;ACTIVE;2.66;2.66 +9299-9;Breaths^pre bronchoscopy;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --pre bronchoscopy;Resp rate pre bronchoscopy;;ACTIVE;1.0i;2.42 +92999-2;Body height^sitting;Len;Pt;^Patient;Qn;;BDYHGT.MOLEC;2;Body height --sitting;Body height sitting;;ACTIVE;2.66;2.69 +93000-8;PhenX - body proportions protocol 220201;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - body proportions protocol 220201;PhenX body proportions proto;;ACTIVE;2.66;2.67 +93001-6;Total ataxia score;Score;Pt;^Patient;Qn;SARA;NEURO;2;Total ataxia score SARA;Total ataxia score SARA;;ACTIVE;2.66;2.66 +93002-4;Heel-shin slide - left+right mean;Score;Pt;^Patient;Qn;;NEURO;2;Heel-shin slide - left+right mean [Score];Heel-shin - L+R mean Score;;ACTIVE;2.66;2.66 +93003-2;Heel-shin slide - left;Score;Pt;^Patient;Ord;;NEURO;2;Heel-shin slide - left;Heel-shin - L;;ACTIVE;2.66;2.66 +93004-0;Heel-shin slide - right;Score;Pt;^Patient;Ord;;NEURO;2;Heel-shin slide - right;Heel-shin - R;;ACTIVE;2.66;2.66 +9300-5;Breaths^pre cardioversion;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --pre cardioversion;Resp rate pre cardioversion;;ACTIVE;1.0i;2.42 +93005-7;Rapid alternating hand movements - left+right mean;Score;Pt;^Patient;Qn;;NEURO;2;Rapid alternating hand movements - left+right mean [Score];Rapid alt hand move - L+R mean Score;;ACTIVE;2.66;2.66 +93006-5;Finger-nose-finger - left+right mean;Score;Pt;^Patient;Qn;;NEURO;2;Finger-nose-finger - left+right mean [Score];Fngr-nose-fngr - L+R mean Score;;ACTIVE;2.66;2.66 +93007-3;Finger-nose-finger - left;Score;Pt;^Patient;Ord;;NEURO;2;Finger-nose-finger - left;Fngr-nose-fngr - L;;ACTIVE;2.66;2.66 +93008-1;Finger-nose-finger - right;Score;Pt;^Patient;Ord;;NEURO;2;Finger-nose-finger - right;Fngr-nose-fngr - R;;ACTIVE;2.66;2.66 +93009-9;Finger chase - left+right mean;Score;Pt;^Patient;Qn;;NEURO;2;Finger chase - left+right mean [Score];Finger chase - L+R mean Score;;ACTIVE;2.66;2.66 +93010-7;Finger chase - left;Score;Pt;^Patient;Ord;;NEURO;2;Finger chase - left;Finger chase - L;;ACTIVE;2.66;2.66 +93011-5;Finger chase - right;Score;Pt;^Patient;Ord;;NEURO;2;Finger chase - right;Finger chase - R;;ACTIVE;2.66;2.66 +93012-3;Speech disturbance;Score;Pt;^Patient;Ord;;NEURO;2;Speech disturbance;Speech disturbance;;ACTIVE;2.66;2.66 +9301-3;Breaths^pre conscious sedation;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --pre conscious sedation;Resp rate pre conscious sedation;;ACTIVE;1.0i;2.42 +93013-1;Sitting ability;Score;Pt;^Patient;Ord;;NEURO;2;Sitting ability;Sitting ability;;ACTIVE;2.66;2.66 +93014-9;Natural & feet together & tandem stance assessment;Score;Pt;^Patient;Ord;;NEURO;2;Natural and feet together and tandem stance assessment;Natrl+Feet tgthr+tandem;;ACTIVE;2.66;2.66 +93015-6;Gait & turn & tandem gait assessment;Score;Pt;^Patient;Ord;;NEURO;2;Gait and turn and tandem gait assessment;Gait+turn+tandem gait;;ACTIVE;2.66;2.66 +93016-4;Scale for the Assessment and Rating of Ataxia;-;Pt;^Patient;-;SARA;PANEL.H&P;2;Scale for the Assessment and Rating of Ataxia [SARA];SARA panel;;ACTIVE;2.66;2.66 +93017-2;Plasma cells.abnormal marker pattern;Num;Pt;Bone mar;Qn;Flow cytometry;HEM/BC;1;Plasma cells with abnormal marker pattern [#] in Bone marrow by Flow cytometry (FC);PC.abnormal Mar FC;;ACTIVE;2.66;2.69 +93018-0;Plasma cells.polyclonal;Num;Pt;Bone mar;Qn;Flow cytometry;HEM/BC;1;Polyclonal plasma cells [#] in Bone marrow by Flow cytometry (FC);Polyclonal PCs Mar FC;;ACTIVE;2.66;2.69 +93019-8;Plasma cells;Num;Pt;Bone mar;Qn;Flow cytometry;HEM/BC;1;Plasma cells [#] in Bone marrow by Flow cytometry (FC);Plasma Cells Mar FC;;ACTIVE;2.66;2.66 +93020-6;Plasma cells.polyclonal/Plasma cells.total;NFr;Pt;Bone mar;Qn;Flow cytometry;HEM/BC;1;Polyclonal plasma cells/Total plasma cells in Bone marrow by Flow cytometry (FC);Polyclonal PCs/Total PCs NFr Mar FC;;ACTIVE;2.66;2.66 +9302-1;Breaths^pre inhalation therapy;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --pre inhalation therapy;Resp rate pre inhalation therapy;;ACTIVE;1.0i;2.73 +93021-4;Plasma cells.abnormal marker pattern/Cells counted;NFr;Pt;Bone mar;Qn;Flow cytometry;HEM/BC;1;Plasma cells with abnormal marker pattern/Cells counted in Bone marrow by Flow cytometry (FC);PC.abnormal/Cells NFr Mar FC;;ACTIVE;2.66;2.66 +93022-2;Multiple myeloma minimal residual disease panel;-;Pt;Bone mar;-;Flow cytometry;PANEL.HEM/BC;1;Multiple myeloma minimal residual disease panel - Bone marrow by Flow cytometry (FC);Multiple myeloma MRD Pnl Mar FC;;ACTIVE;2.66;2.74 +93023-0;Plan of care note;Find;Pt;{Setting};Doc;Pharmacist;DOC.ONTOLOGY;2;Pharmacist Plan of care note;PharmD Plan of care note;;ACTIVE;2.66;2.66 +93024-8;Consultation note;Find;Pt;{Setting};Doc;Pharmacist;DOC.ONTOLOGY;2;Pharmacist Consult note;PharmD Consult note;;ACTIVE;2.66;2.66 +93025-5;Protocol for Responding to and Assessing Patients' Assets, Risks, and Experiences;-;Pt;^Patient;-;PRAPARE;PANEL.SURVEY.SDOH;4;Protocol for Responding to and Assessing Patients' Assets, Risks, and Experiences [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93026-3;Do you feel physically and emotionally safe where you currently live;Find;Pt;^Patient;Ord;PRAPARE;SURVEY.SDOH;4;Do you feel physically and emotionally safe where you currently live [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93027-1;Are you a refugee;Find;Pt;^Patient;Ord;;SURVEY.PRAPARE;4;Are you a refugee;;;ACTIVE;2.66;2.66 +93028-9;Have you spent more than 2 nights in a row in a jail, prison, detention center, or juvenile correctional facility in past 1Y;Find;1Y;^Patient;Ord;PRAPARE;SURVEY.SDOH;4;Have you spent more than 2 nights in a row in a jail, prison, detention center, or juvenile correctional facility in past 1 year [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93029-7;How often do you see or talk to people that you care about and feel close to;Find;Pt;^Patient;Ord;PRAPARE;SURVEY.SDOH;4;How often do you see or talk to people that you care about and feel close to [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93030-5;Has lack of transportation kept you from medical appointments, meetings, work, or from getting things needed for daily living;Find;Pt;^Patient;Nom;;SURVEY.SDOH;4;Has lack of transportation kept you from medical appointments, meetings, work, or from getting things needed for daily living;;;ACTIVE;2.66;2.7 +93031-3;Have you or any family members you live with been unable to get any of the following when it was really needed in past 1Y;Find;1Y;^Patient;Nom;PRAPARE;SURVEY.SDOH;4;Have you or any family members you live with been unable to get any of the following when it was really needed in past 1 year [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93033-9;Are you worried about losing your housing;Find;Pt;^Patient;Ord;PRAPARE;SURVEY.SDOH;4;Are you worried about losing your housing [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93034-7;Discharged from the U.S. Armed Forces;Find;Pt;^Patient;Ord;;SURVEY.PRAPARE;4;Discharged from the U.S. Armed Forces;;;ACTIVE;2.66;2.66 +93035-4;Has season or migrant farm work been your or your family's main source of income at any point in past 2Y;Find;2Y;^Patient;Ord;PRAPARE;SURVEY.SDOH;4;Has season or migrant farm work been your or your family's main source of income at any point in past 2 years [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93036-2;Note;Find;Pt;Outpatient;Doc;Cleft and Craniofacial;DOC.ONTOLOGY;2;Cleft and Craniofacial Outpatient Note;Cleft+Craniofacial OP Note;;ACTIVE;2.66;2.66 +93037-0;Portable medical order form;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Portable medical order form;Portable med order form;;ACTIVE;2.66;2.67 +93038-8;Stress level;Find;Pt;^Patient;Ord;;CLIN;2;Stress level;Stress level;;ACTIVE;2.66;2.7 +9303-9;Breaths^resting;NRat;Pt;Respiratory system;Qn;;RESP.MOLEC;2;Respiratory rate --resting;Resp rate Resting;;ACTIVE;1.0i;2.42 +93039-6;Optional additional questions;-;Pt;^Patient;-;PRAPARE;PANEL.SURVEY.SDOH;4;Optional additional questions [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93040-4;Social and emotional health;-;Pt;^Patient;-;PRAPARE;PANEL.SURVEY.SDOH;4;Social and emotional health [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93041-2;Money and resources;-;Pt;^Patient;-;PRAPARE;PANEL.SURVEY.SDOH;4;Money and resources [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93042-0;Family and home;-;Pt;^Patient;-;PRAPARE;PANEL.SURVEY.SDOH;4;Family and home [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93043-8;Personal characteristics;-;Pt;^Patient;-;PRAPARE;PANEL.SURVEY.SDOH;4;Personal characteristics [PRAPARE];;© 2019. This item comes from the national PRAPARE social determinants of health assessment protocol, developed and owned by the National Association of Community Health Centers (NACHC), in partnership with the Association of Asian Pacific Community Health Organization (AAPCHO), the Oregon Primary Care Association (OPCA), and the Institute for Alternative Futures (IAF). For more information, visit www.nachc.org/prapare Used with permission.;ACTIVE;2.66;2.69 +93044-6;Level of evidence;Find;Pt;Bld/Tiss;Nom;;MOLPATH;1;Level of evidence;Level of evidence;;ACTIVE;2.66;2.66 +93045-3;Carbon monoxide;MCnc;Pt;Air;Qn;;DRUG/TOX;1;Carbon monoxide [Mass/volume] in Air;CO Air-mCnc;;ACTIVE;2.66;2.66 +93046-1;Exposure treatment site;Type;Pt;^Patient;Nom;;CLIN;2;Exposure treatment site;Exposure tx site;;ACTIVE;2.66;2.66 +9304-7;Respiration rhythm;Fcn;Pt;Respiratory system;Nom;;RESP.ATOM;2;Respiration rhythm;Respiration rhythm;;ACTIVE;1.0i;2.73 +93047-9;Specimen condition;Type;Pt;Specimen;Nom;;SPEC;1;Specimen condition [Type];Specimen condition;;ACTIVE;2.66;2.73 +93048-7;Reason for specimen rejection;Type;Pt;Specimen;Nom;;SPEC;1;Reason for specimen rejection [Type];Reason spec reject;;ACTIVE;2.66;2.66 +93049-5;MDS v3.0 - RAI v1.17.2 - Correction request - SP, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Correction request - SP, SD [CMS Assessment];;;ACTIVE;2.66;2.68 +93050-3;MDS v3.0 - RAI v1.17.2 - Cognitive patterns - IPA, OSA;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Cognitive patterns - IPA, OSA [CMS Assessment];;;ACTIVE;2.66;2.68 +93051-1;MDS v3.0 - RAI v1.17.2 - Insurance billing;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Insurance billing [CMS Assessment];;;ACTIVE;2.66;2.74 +93052-9;MDS v3.0 - RAI v1.17.2 - Alternate state Medicaid billing;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Alternate state Medicaid billing [CMS Assessment];;;ACTIVE;2.66;2.74 +93053-7;MDS v3.0 - RAI v1.17.2 - State Medicaid billing;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - State Medicaid billing [CMS Assessment];;;ACTIVE;2.66;2.74 +9305-4;Mononuclear cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Body fluid by Manual count;Mononuc Cells/leuk NFr Fld Manual;;ACTIVE;1.0i;2.73 +93054-5;MDS v3.0 - RAI v1.17.2 - Assessment administration - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Assessment administration - ND, SD [CMS Assessment];;;ACTIVE;2.66;2.68 +93055-2;Outcome and assessment information set (OASIS) form - version D1;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D1 [CMS Assessment];;;ACTIVE;2.67;2.73 +93056-0;OASIS D1 - Patient history and diagnoses - follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D1 - Patient history and diagnoses - follow-up [CMS Assessment];;;ACTIVE;2.67;2.67 +93057-8;OASIS D1 - ADL and IADLs - follow-up;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS D1 - ADL and IADLs - follow-up during assessment period [CMS Assessment];;;ACTIVE;2.67;2.7 +93058-6;Outcome and assessment information set (OASIS) form - version D1 - Follow-up - recertification or other follow-up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version D1 - Follow-up - recertification or other follow-up [CMS Assessment];;;ACTIVE;2.67;2.68 +93059-4;Are you feeling bothered, upset, or worried at this point in your pregnancy about the effect of ongoing health problems such as high blood pressure or diabetes on your pregnancy;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about the effect of ongoing health problems such as high blood pressure or diabetes on your pregnancy [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93060-2;Are you feeling bothered, upset, or worried at this point in your pregnancy about feeling tired and having low energy during your pregnancy;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about feeling tired and having low energy during your pregnancy [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93061-0;Are you feeling bothered, upset, or worried at this point in your pregnancy about paying for your medical care during pregnancy;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about paying for your medical care during pregnancy [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +9306-2;Polymorphonuclear cells/100 leukocytes;NFr;Pt;Body fld;Qn;Manual count;HEM/BC;1;Polymorphonuclear cells/100 leukocytes in Body fluid by Manual count;Polys/leuk NFr Fld Manual;;ACTIVE;1.0i;2.73 +93062-8;Are you feeling bothered, upset, or worried at this point in your pregnancy about changes in your weight and body shape during pregnancy;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about changes in your weight and body shape during pregnancy [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93063-6;Are you feeling bothered, upset, or worried at this point in your pregnancy about whether you might have an unhealthy baby;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about whether you might have an unhealthy baby [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93064-4;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as vomiting;Find;Pt;^Patient;Ord;NuMoM2b;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as vomiting [NuMoM2b];;;ACTIVE;2.67;2.67 +93065-1;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as swollen feet;Find;Pt;^Patient;Ord;NuMoM2b;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as swollen feet [NuMoM2b];;;ACTIVE;2.67;2.67 +93066-9;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as backaches;Find;Pt;^Patient;Ord;NuMoM2b;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as backaches [NuMoM2b];;;ACTIVE;2.67;2.67 +93067-7;Are you feeling bothered, upset, or worried at this point in your pregnancy about the quality of your medical care during pregnancy;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about the quality of your medical care during pregnancy [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93068-5;Are you feeling bothered, upset, or worried at this point in your pregnancy about working or caring for your family during your pregnancy;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about working or caring for your family during your pregnancy [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93069-3;Are you feeling bothered, upset, or worried at this point in your pregnancy about whether the baby might be affected by alcohol, cigarettes, or drugs that you have taken;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about whether the baby might be affected by alcohol, cigarettes, or drugs that you have taken [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +9307-0;Insulin^30M post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --30 minutes post 75 g glucose PO;Insulin 30M p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0i;2.73 +93070-1;Are there other things that you are bothered, upset or worried about that have to do with your pregnancy, the birth, or the baby;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are there other things that you are bothered, upset or worried about that have to do with your pregnancy, the birth, or the baby [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93071-9;Other things you are feeling bothered, upset or worried about;Find;Pt;^Patient;Nom;NuPDQ;SURVEY.MTLHLTH;4;Other things you are feeling bothered, upset or worried about [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93072-7;Are you feeling bothered, upset, or worried at this point in your pregnancy about paying for the baby's clothes, food, or medical care;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about paying for the baby's clothes, food, or medical care [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93073-5;Are you feeling bothered, upset, or worried at this point in your pregnancy about taking care of a newborn baby;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about taking care of a newborn baby [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93074-3;Are you feeling bothered, upset, or worried at this point in your pregnancy about pain during labor and delivery;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about pain during labor and delivery [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93075-0;Are you feeling bothered, upset, or worried at this point in your pregnancy about whether the baby might come too early;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about whether the baby might come too early [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93076-8;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as vomiting, swollen feet, or backaches;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as vomiting, swollen feet, or backaches [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93077-6;Physical symptom of pregnancy that you are feeling bothered, upset or worried about;Find;Pt;^Patient;Nom;NuPDQ;SURVEY.MTLHLTH;4;Physical symptom of pregnancy that you are feeling bothered, upset or worried about [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93078-4;Are you feeling bothered, upset, or worried at this point in your pregnancy about changes in your relationships with other people due to having a baby;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about changes in your relationships with other people due to having a baby [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93079-2;Person who you are feeling bothered, upset or worried about having a relationship change with due to having a baby;Find;Pt;^Patient;Nom;NuPDQ;SURVEY.MTLHLTH;4;Person who you are feeling bothered, upset or worried about having a relationship change with due to having a baby [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +930-8;Blood product reservation;TmStp;Pt;^BPU;Qn;;BLDBK;1;Blood product reservation [Date and time];Bld Prod Reservation BPU;;ACTIVE;1.0;2.26 +93080-0;Are you feeling bothered, upset, or worried at this point in your pregnancy about what will happen during labor and delivery;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about what will happen during labor and delivery [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93081-8;Are you feeling bothered, upset, or worried at this point in your pregnancy about working at a job after the baby comes;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about working at a job after the baby comes [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93082-6;Are you feeling bothered, upset, or worried at this point in your pregnancy about getting day care, babysitters, or help to watch the baby after it comes;Find;Pt;^Patient;Ord;NuPDQ;SURVEY.MTLHLTH;4;Are you feeling bothered, upset, or worried at this point in your pregnancy about getting day care, babysitters, or help to watch the baby after it comes [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93083-4;Revised Prenatal Distress Questionnaire - Concurrent Self-Administered Version;-;Pt;^Patient;-;NuPDQ;PANEL.SURVEY.MTLHLTH;4;Revised Prenatal Distress Questionnaire (NuPDQ) - Concurrent Self-Administered Version;;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +93084-2;Nulliparous Pregnancy Outcomes Study Monitoring Mothers-to-Be Difficulties in Pregnancy form;-;Pt;^Patient;-;NuMoM2b;PANEL.SURVEY.MTLHLTH;4;NuMoM2b Difficulties in Pregnancy form [NuMoM2b];;;ACTIVE;2.67;2.67 +93085-9;Dirofilaria immitis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Dirofilaria immitis IgG Ab [Presence] in Serum by Immunoassay;D immitis IgG Ser Ql IA;;ACTIVE;2.67;2.67 +93086-7;Emergency procedure note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Emergency procedure note;OB Emerg procedure note;;TRIAL;2.67;2.67 +93087-5;Total score;Score;Pt;^Patient;Qn;NuPDQ;SURVEY.MTLHLTH;4;Total score [NuPDQ];;Copyright © 2008 Marci Lobel. Used with permission.;ACTIVE;2.67;2.67 +9308-8;2,4-Dinitrophenylhydrazine reacting substances;PrThr;Pt;Urine;Ord;;CHEM;1;2,4-Dinitrophenylhydrazine reacting substances [Presence] in Urine;DNPH Ur Ql;;ACTIVE;1.0i;2.56 +93088-3;Quality of Working Life Questionnaire for Cancer Survivors;-;4W;^Patient;-;QWLQ-CS;PANEL.SURVEY.GNHLTH;4;Quality of Working Life Questionnaire for Cancer Survivors [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93089-1;During the past 4W, working gives me structure in my life;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, working gives me structure in my life [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93090-9;During the past 4W, I think it is good to work;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I think it is good to work [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93091-7;During the past 4W, I consider that my work gives me a goal in life;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I consider that my work gives me a goal in life [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93092-5;During the past 4W, I consider my work important;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I consider my work important [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93093-3;During the past 4W, I do my work well;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I do my work well [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93094-1;During the past 4W, I am self-confident in my work;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I am self-confident in my work [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93095-8;During the past 4W, I am suited to my work;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I am suited to my work [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +9309-6;Ammonia;MRat;24H;Urine;Qn;;CHEM;1;Ammonia [Mass/time] in 24 hour Urine;Ammonia 24h Ur-mRate;;ACTIVE;1.0i;2.73 +93096-6;During the past 4W, I have control over the work I do;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I have control over the work I do [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93097-4;During the past 4W, I feel powerless in my work;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I feel powerless in my work [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93098-2;During the past 4W, I feel there is a positive atmosphere in my working environment;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I feel there is a positive atmosphere in my working environment [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93099-0;During the past 4W, I have the feeling I am taken seriously by people in my working environment;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I have the feeling I am taken seriously by people in my working environment [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93100-6;During the past 4W, I am content with my work;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I am content with my work [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93101-4;During the past 4W, I have good relations with my colleagues;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I have good relations with my colleagues [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93102-2;During the past 4W, I feel valuable to my colleagues;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I feel valuable to my colleagues [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93103-0;During the past 4W, my immediate superior understands my health situation and possible health problems;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, my immediate superior understands my health situation and possible health problems [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +9310-4;Androstenedione;MRat;24H;Urine;Qn;;CHEM;1;Androstenedione [Mass/time] in 24 hour Urine;Androst 24h Ur-mRate;;ACTIVE;1.0i;2.42 +93104-8;During the past 4W, I have good relations with my immediate superior;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I have good relations with my immediate superior [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93105-5;During the past 4W, I consider that employees with health problems are treated well in my organization;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I consider that employees with health problems are treated well in my organization [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93106-3;During the past 4W, I am content with the fringe benefits provided by my employer;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I am content with the fringe benefits provided by my employer [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93107-1;During the past 4W, I am content with my current income;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I am content with my current income [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93108-9;During the past 4W, because of my health situation I have problems in my work with fatigue AndOr lack of energy;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, because of my health situation I have problems in my work with fatigue/lack of energy [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93109-7;During the past 4W, I am limited in my work;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, I am limited in my work [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93110-5;During the past 4W, because of my health situation I have little trust in my own body;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, because of my health situation I have little trust in my own body [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93111-3;During the past 4W, because of my health situation I feel uncertain about the future;Find;4W;^Patient;Ord;QWLQ-CS;SURVEY.GNHLTH;4;During the past 4 weeks, because of my health situation I feel uncertain about the future [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +9311-2;Albuterol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Albuterol [Mass/volume] in Serum or Plasma;Albuterol SerPl-mCnc;;ACTIVE;1.0i;2.73 +93112-1;Total score;Score;Pt;^Patient;Qn;QWLQ-CS;SURVEY.GNHLTH;4;Total score [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93113-9;Meaning of work;-;4W;^Patient;-;QWLQ-CS;PANEL.SURVEY.GNHLTH;4;Meaning of work [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93114-7;Perception of your work situation;-;4W;^Patient;-;QWLQ-CS;PANEL.SURVEY.GNHLTH;4;Perception of your work situation [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93115-4;Atmosphere in your working environment;-;4W;^Patient;-;QWLQ-CS;PANEL.SURVEY.GNHLTH;4;Atmosphere in your working environment [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93116-2;Understanding and recognition in your organization;-;4W;^Patient;-;QWLQ-CS;PANEL.SURVEY.GNHLTH;4;Understanding and recognition in your organization [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93117-0;Problems due to your health situation;-;4W;^Patient;-;QWLQ-CS;PANEL.SURVEY.GNHLTH;4;Problems due to your health situation [Quality of Working Life Questionnaire for Cancer Survivors];;© 2016 Dr.Angela de Boer. Used with permission.;ACTIVE;2.67;2.67 +93118-8;Difficulties in Pregnancy total score;Score;Pt;^Patient;Qn;NuMoM2b;SURVEY.MTLHLTH;4;Difficulties in pregnancy total score [NuMoM2b];;;ACTIVE;2.67;2.67 +93119-6;Dark-mediated rod adaptation time;Time;Pt;Eye.right;Qn;;EYE.PX;2;Right eye Dark-mediated rod adaptation time;R eye Dark rod adaptation tm;;ACTIVE;2.67;2.68 +9312-0;Aminocaproate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Aminocaproate [Mass/volume] in Serum or Plasma;Amicaproate SerPl-mCnc;;ACTIVE;1.0i;2.4 +93120-4;Dark-mediated rod adaptation time;Time;Pt;Eye.left;Qn;;EYE.PX;2;Left eye Dark-mediated rod adaptation time;L eye Dark rod adaptation tm;;ACTIVE;2.67;2.68 +93121-2;Gabapentin;PrThr;Pt;Tiss;Ord;Screen;DRUG/TOX;1;Gabapentin [Presence] in Tissue by Screen method;Gabapentin Tiss Ql Scn;;ACTIVE;2.67;2.67 +93122-0;Contraindicated vaccine type;ID;Pt;^Patient;Nom;;VACCIN;2;Contraindicated vaccine type [Identifier];Contraindicated vaccine;;ACTIVE;2.67;2.67 +93123-8;Preferred vaccine type;ID;Pt;^Patient;Nom;;VACCIN;2;Preferred vaccine type [Identifier];Pref vaccine;;ACTIVE;2.67;2.67 +93124-6;New York Heart Association Functional Classification;-;Pt;^Patient;-;NYHA;PANEL.CARDIAC;2;New York Heart Association Functional Classification panel;NYHA Functional Class;© 1994 American Heart Association Used with permission;ACTIVE;2.67;2.68 +93125-3;Sit to stand^with use of upper extremities;NRat;30S;^Patient;Qn;;H&P.PX;2;Modified 30 seconds Sit to stand --with use of upper extremities;Modified 30s Sit to Stand w extremities;;ACTIVE;2.67;2.67 +93126-1;Comparison with previous results;Find;Pt;^Patient;Doc;;DOC.MISC;2;Comparison with previous results;Comparison with previous results;;ACTIVE;2.67;2.67 +93127-9;Risk adjustment factor;Score;Pt;^Patient;Qn;;CLIN.RISK;2;Risk adjustment factor [Score];RAF Score;;ACTIVE;2.67;2.67 +93128-7;Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 4.0;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Inpatient Rehabilitation Facility - Patient Assessment Instrument (IRF-PAI) - version 4.0 [CMS Assessment];;;ACTIVE;2.67;2.69 +93129-5;Bone development stage;Score;Pt;Upper extremity>Radius;Qn;XR;RAD;2;XR Radius Bone development stage;XR Radius Bone dev stage;;ACTIVE;2.67;2.67 +93130-3;Bone development stage;Score;Pt;Upper extremity>Wrist.trapezoid;Qn;XR;RAD;2;XR Trapezoid Bone development stage;XR Trapezoid Bone dev stage;;ACTIVE;2.67;2.67 +93131-1;Bone development stage;Score;Pt;Upper extremity>Wrist.trapezium;Qn;XR;RAD;2;XR Trapezium Bone development stage;XR Trapezium Bone dev stage;;ACTIVE;2.67;2.67 +93132-9;Bone development stage;Score;Pt;Upper extremity>Wrist.scaphoid;Qn;XR;RAD;2;XR Scaphoid Bone development stage;XR Scaphoid Bone dev stage;;ACTIVE;2.67;2.67 +93133-7;Bone development stage;Score;Pt;Upper extremity>Wrist.lunate;Qn;XR;RAD;2;XR Lunate Bone development stage;XR Lunate Bone dev stage;;ACTIVE;2.67;2.67 +93134-5;Bone development stage;Score;Pt;Upper extremity>Wrist.triquetrum;Qn;XR;RAD;2;XR Triquetrum Bone development stage;XR Triquetrum Bone dev stage;;ACTIVE;2.67;2.67 +93135-2;Bone development stage;Score;Pt;Upper extremity>Wrist.hamate;Qn;XR;RAD;2;XR Hamate Bone development stage;XR Hamate Bone dev stage;;ACTIVE;2.67;2.67 +93136-0;Bone development stage;Score;Pt;Upper extremity>Wrist.capitate;Qn;XR;RAD;2;XR Capitate Bone development stage;XR Capitate Bone dev stage;;ACTIVE;2.67;2.67 +93137-8;Bone development stage;Score;Pt;Upper extremity>Thumb.distal phalanx;Qn;XR;RAD;2;XR Distal phalanx of thumb Bone development stage;XR Thumb.distl phlnx Bone dev stage;;ACTIVE;2.67;2.67 +9313-8;Butorphanol;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Butorphanol [Mass/volume] in Body fluid;Butorphanol Fld-mCnc;;ACTIVE;1.0i;2.42 +93138-6;Bone development stage;Score;Pt;Upper extremity>Finger.fifth.distal phalanx;Qn;XR;RAD;2;XR Distal phalanx of fifth finger Bone development stage;XR Finger.5th.distl phlnx Bone dev stage;;ACTIVE;2.67;2.67 +93139-4;Bone development stage;Score;Pt;Upper extremity>Finger.third.distal phalanx;Qn;XR;RAD;2;XR Distal phalanx of third finger Bone development stage;XR Finger.3rd.distl phlnx Bone dev stage;;ACTIVE;2.67;2.67 +93140-2;Bone development stage;Score;Pt;Upper extremity>Finger.third.middle phalanx;Qn;XR;RAD;2;XR Middle phalanx of third finger Bone development stage;XR Finger.3rd.mid phlnx Bone dev stage;;ACTIVE;2.67;2.67 +93141-0;Bone development stage;Score;Pt;Upper extremity>Finger.fifth.middle phalanx;Qn;XR;RAD;2;XR Middle phalanx of fifth finger Bone development stage;XR Finger.5th.mid phlnx Bone dev stage;;ACTIVE;2.67;2.67 +93142-8;Bone development stage;Score;Pt;Upper extremity>Finger.fifth.proximal phalanx;Qn;XR;RAD;2;XR Proximal phalanx of fifth finger Bone development stage;XR Finger.5th.prox phlnx Bone dev stage;;ACTIVE;2.67;2.67 +93143-6;Bone development stage;Score;Pt;Upper extremity>Finger.third.proximal phalanx;Qn;XR;RAD;2;XR Proximal phalanx of third finger Bone development stage;XR Finger.3rd.prox phlnx Bone dev stage;;ACTIVE;2.67;2.67 +93144-4;Bone development stage;Score;Pt;Upper extremity>Thumb.proximal phalanx;Qn;XR;RAD;2;XR Proximal phalanx of thumb Bone development stage;XR Thumb.prox phlnx Bone dev stage;;ACTIVE;2.67;2.67 +93145-1;Bone development stage;Score;Pt;Upper extremity>Hand.metacarpal.fifth;Qn;XR;RAD;2;XR Fifth metacarpal Bone development stage;XR Metacarpal.5th Bone dev stage;;ACTIVE;2.67;2.67 +9314-6;Western equine encephalitis virus Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Western equine encephalitis virus Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;WEEV Ab Titr CSF IF;;ACTIVE;1.0i;2.7 +93146-9;Bone development stage;Score;Pt;Upper extremity>Hand.metacarpal.third;Qn;XR;RAD;2;XR Third metacarpal Bone development stage;XR Metacarpal.3rd Bone dev stage;;ACTIVE;2.67;2.67 +93147-7;Bone development stage;Score;Pt;Upper extremity>Hand.metacarpal.first;Qn;XR;RAD;2;XR First metacarpal Bone development stage;XR Metacarpal.1st Bone dev stage;;ACTIVE;2.67;2.67 +93148-5;Bone development stage;Score;Pt;Upper extremity>Ulna;Qn;XR;RAD;2;XR Ulna Bone development stage;XR Ulna Bone dev stage;;ACTIVE;2.67;2.67 +93149-3;PhenX - bone age protocol 220301;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - bone age protocol 220301;PhenX bone age protocol;;ACTIVE;2.67;2.68 +93150-1;Procedure note;Find;Pt;{Setting};Doc;Burn management;DOC.ONTOLOGY;2;Burn management procedure note;Burn Procedure note;;ACTIVE;2.67;2.67 +93151-9;Conference note;Find;Pt;{Setting};Doc;Radiology.team;DOC.ONTOLOGY;2;Radiology Team Conference note;Radiology Team Conf eval note;;ACTIVE;2.67;2.67 +93152-7;Initial evaluation note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Initial evaluation note;Radiology Initial eval note;;ACTIVE;2.67;2.67 +9315-3;Western equine encephalitis virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Western equine encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;WEEV IgG Titr CSF IF;;ACTIVE;1.0i;2.73 +93153-5;Drug classes of medications taken;Type;Pt;^Patient;Nom;;SURVEY.CMS;4;Drug classes of medications taken;;;ACTIVE;2.67;2.67 +93154-3;Drug classes that have an indication documented;Type;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Drug classes that have an indication documented [CMS Assessment];;;ACTIVE;2.67;2.67 +93155-0;IRF-PAI v4.0, LCDS v5.00, OASIS E - High risk drug classes - use and indication;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00, OASIS E - High risk drug classes - use and indication during assessment period [CMS Assessment];;;ACTIVE;2.67;2.74 +93156-8;How much of the time has pain made it hard for you to sleep at night;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How much of the time has pain made it hard for you to sleep at night during assessment period [CMS Assessment];;;ACTIVE;2.67;2.74 +93157-6;How often do you need to have someone help you when you read instructions, pamphlets, or other written material from your doctor or pharmacy;Find;Pt;^Patient;Ord;SILS;SURVEY.CMS;4;How often do you need to have someone help you when you read instructions, pamphlets, or other written material from your doctor or pharmacy [SILS];;© 2006 Morris et al. Used with permission;ACTIVE;2.67;2.67 +93158-4;How often have you limited your day-to-day activities because of pain;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How often have you limited your day-to-day activities because of pain during assessment period [CMS Assessment];;;ACTIVE;2.67;2.74 +93159-2;How often do you feel lonely or isolated from those around you;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How often do you feel lonely or isolated from those around you [CMS Assessment];;;ACTIVE;2.67;2.67 +931-6;Blood product source;Type;Pt;^BPU;Nom;;BLDBK;1;Blood product source [Type];Bld Prod Source BPU;;ACTIVE;1.0;2.73 +93160-0;How often have you limited your participation in rehabilitation therapy sessions due to pain over;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;How often have you limited your participation in rehabilitation therapy sessions due to pain over during assessment period [CMS Assessment];;;ACTIVE;2.67;2.74 +9316-1;Western equine encephalitis virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Western equine encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;WEEV IgM Titr CSF IF;;ACTIVE;1.0i;2.73 +93161-8;IRF-PAI v4.0 - Administrative information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Administrative information [CMS Assessment];;;ACTIVE;2.67;2.74 +93162-6;IRF-PAI v4.0 - Cognitive patterns - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Cognitive patterns - admission [CMS Assessment];;;ACTIVE;2.67;2.68 +93163-4;IRF-PAI v4.0 - Cognitive patterns - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Cognitive patterns - discharge [CMS Assessment];;;ACTIVE;2.67;2.68 +93164-2;IRF-PAI v4.0 - Health conditions - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Health conditions - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93165-9;IRF-PAI v4.0 - Hearing, speech, and vision - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Hearing, speech, and vision - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93166-7;IRF-PAI v4.0, OASIS E - Hearing, speech, and vision - ROC, DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, OASIS E - Hearing, speech, and vision - ROC, DC [CMS Assessment];;;ACTIVE;2.67;2.72 +93167-5;IRF-PAI v4.0 - Identification information;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Identification information [CMS Assessment];;;ACTIVE;2.67;2.73 +93168-3;IRF-PAI v4.0, LCDS v5.00 - Medications - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00 - Medications - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93169-1;IRF-PAI v4.0, LCDS v5.00 - Medications - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00 - Medications - discharge and expired [CMS Assessment];;;ACTIVE;2.67;2.67 +93170-9;IRF-PAI v4.0, LCDS v5.00, OASIS E - Mood;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00, OASIS E - Mood [CMS Assessment];;;ACTIVE;2.67;2.72 +93171-7;IRF-PAI v4.0 - Quality indicators - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Quality indicators - admission [CMS Assessment];;;ACTIVE;2.67;2.68 +93172-5;IRF-PAI v4.0 - Quality indicators - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Quality indicators - discharge [CMS Assessment];;;ACTIVE;2.67;2.68 +93173-3;IRF-PAI v4.0 - Special treatments, procedures, and programs - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Special treatments, procedures, and programs - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93174-1;IRF-PAI v4.0 - Special treatments, procedures, and programs - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Special treatments, procedures, and programs - discharge [CMS Assessment];;;ACTIVE;2.67;2.67 +93175-8;IRF-PAI v4.0 - Swallowing &or nutritional status - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Swallowing/nutritional status - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93176-6;IRF-PAI v4.0, LCDS v5.00 - Swallowing &or nutritional status - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00 - Swallowing/nutritional status - discharge [CMS Assessment];;;ACTIVE;2.67;2.68 +93177-4;IRF-PAI v4.0, LCDS v5.00 - Health conditions - discharge or expired;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00 - Health conditions - discharge or expired [CMS Assessment];;;ACTIVE;2.67;2.69 +93178-2;Nutritional approaches;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Nutritional approaches [CMS Assessment];;;ACTIVE;2.67;2.67 +9317-9;Platelets;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Platelet adequacy [Presence] in Blood by Light microscopy;Platelet Bld Ql Smear;;ACTIVE;1.0i;2.73 +93180-8;IRF-PAI v4.0, LCDS v5.00 - Nutritional approaches - last 7D and discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00 - Nutritional approaches - last 7D and discharge [CMS Assessment];;;ACTIVE;2.67;2.69 +93181-6;Provision of current reconciled medication list to patient at discharge;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Provision of current reconciled medication list to patient at discharge [CMS Assessment];;;ACTIVE;2.67;2.67 +93182-4;Provision of current reconciled medication list to subsequent provider at discharge;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Provision of current reconciled medication list to subsequent provider at discharge [CMS Assessment];;;ACTIVE;2.67;2.67 +93183-2;Route of current reconciled medication list transmission to patient;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Route of current reconciled medication list transmission to patient [CMS Assessment];;;ACTIVE;2.67;2.67 +93184-0;Route of current reconciled medication list transmission to subsequent provider;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Route of current reconciled medication list transmission to subsequent provider [CMS Assessment];;;ACTIVE;2.67;2.67 +93185-7;Special treatments, procedures, and programs at discharge;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Special treatments, procedures, and programs at discharge [CMS Assessment];;;ACTIVE;2.67;2.69 +93186-5;Preferred language & interpreter need;-;Pt;^Patient;-;;PANEL.ADMIN;2;Preferred language and interpreter need;Preferred lang + interp need;;ACTIVE;2.67;2.72 +9318-7;Albumin/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Albumin/Creatinine [Mass Ratio] in Urine;Albumin/Creat Ur;;ACTIVE;1.0i;2.73 +93187-3;Bone age assessment - Tanner-Whitehouse (TW2) associated observations panel;-;Pt;^Patient;-;;PANEL.RAD;2;Bone age assessment - Tanner-Whitehouse (TW2) associated observations panel;Bone age assess TW2 panel;;ACTIVE;2.67;2.67 +93188-1;IRF-PAI v4.0 - Administrative information - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0 - Administrative information - discharge [CMS Assessment];;;ACTIVE;2.67;2.74 +93189-9;Total skeletal maturity score;Score;Pt;Upper extremity>Wrist+Hand;Qn;XR;RAD;2;XR Wrist and Hand Total skeletal maturity score;XR Wrist+Hand Total maturity score;;ACTIVE;2.67;2.67 +93190-7;HTR2A gene.c.614-2211T>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;HTR2A gene c.614-2211T>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;HTR2A c.614-2211T>C Geno Bld/T;;ACTIVE;2.67;2.68 +93191-5;HTR2C gene.c.-759C>T;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;HTR2C gene c.-759C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal;HTR2C c.-759C>T Geno Bld/T;;ACTIVE;2.67;2.68 +93192-3;HTR2C gene.c.551-3008C>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;HTR2C gene c.551-3008C>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;HTR2C c.551-3008C>G Geno Bld/T;;ACTIVE;2.67;2.68 +93193-1;TPMT gene & NUDT15 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;TPMT gene and NUDT15 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;TPMT + NUDT15 Mut Anl Bld/T;;ACTIVE;2.67;2.67 +93194-9;NUDT15 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;NUDT15 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NUDT15 gene Mut Anl Bld/T;;ACTIVE;2.67;2.67 +9319-5;Androstenedione;MRat;24H;Urine;Qn;;CHEM;1;Deprecated Androstenedione [Mass/time] in 24 hour Urine;Deprecated Androst 24H Ur-mRate;;DEPRECATED;1.0i;2.36 +93195-6;NUDT15 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;NUDT15 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;NUDT15 gene prod met act imp Bld/T-Imp;;ACTIVE;2.67;2.68 +93196-4;Warfarin response genotype panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH.PHARMG;1;Warfarin response genotype panel - Blood or Tissue by Molecular genetics method;Warfarin genotype pnl Bld/T;;ACTIVE;2.67;2.67 +93197-2;CYP4F2 gene.c.1297G>A;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CYP4F2 gene c.1297G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CYP4F2 c.1297G>A Geno Bld/T;;ACTIVE;2.67;2.68 +93198-0;10q23 g.94645745G>A;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;10q23 g.94645745G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal;10q23 g.94645745G>A Geno Bld/T;;ACTIVE;2.67;2.68 +93199-8;DPYD gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;DPYD gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;DPYD gene Mut Anl Bld/T;;ACTIVE;2.67;2.67 +93200-4;Ehlers-Danlos syndrome multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Ehlers-Danlos syndrome multigene analysis in Blood or Tissue by Molecular genetics method;EDS Multigene Anl Bld/T;;ACTIVE;2.67;2.67 +93201-2;Coronary heart disease multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Coronary heart disease multigene analysis in Blood or Tissue by Molecular genetics method;CHD Multigene Anl Bld/T;;ACTIVE;2.67;2.67 +93202-0;Ventilator weaning status;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Ventilator weaning status [CMS Assessment];;;ACTIVE;2.67;2.67 +9320-3;Beta aminoisobutyrate;MRat;24H;Urine;Qn;;CHEM;1;Beta aminoisobutyrate [Mass/time] in 24 hour Urine;B-AIB 24h Ur-mRate;;DISCOURAGED;1.0i;2.44 +93203-8;LCDS v5.00 - Spontaneous breathing trial;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Spontaneous breathing trial [CMS Assessment];;;ACTIVE;2.67;2.67 +93204-6;LCDS v5.00 - Special treatments, procedures, and programs - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Special treatments, procedures, and programs - discharge [CMS Assessment];;;ACTIVE;2.67;2.67 +93205-3;LCDS v5.00 - Special treatments, procedures, and programs - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Special treatments, procedures, and programs - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93207-9;LCDS v5.00 - Swallowing &or nutritional status - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Swallowing/nutritional status - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93208-7;LCDS v5.00 - Health conditions - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Health conditions - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93209-5;LCDS v5.00 - Functional abilities and goals - planned discharge;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Functional abilities and goals - planned discharge [CMS Assessment];;;ACTIVE;2.67;2.69 +93210-3;LCDS v5.00 - Functional abilities and goals - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Functional abilities and goals - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +9321-1;Calcium/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Calcium/Creatinine [Mass Ratio] in Urine;Calcium/Creat Ur;;ACTIVE;1.0i;2.73 +93211-1;LCDS v5.00 - Cognitive patterns - unplanned discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Cognitive patterns - unplanned discharge [CMS Assessment];;;ACTIVE;2.67;2.68 +93212-9;LCDS v5.00 - Cognitive patterns - planned discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Deprecated LCDS v5.00 - Cognitive patterns - planned discharge [CMS Assessment];;;DEPRECATED;2.67;2.7 +93213-7;LCDS v5.00 - Cognitive patterns - admission and planned discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Cognitive patterns - admission and planned discharge [CMS Assessment];;;ACTIVE;2.67;2.69 +93214-5;LCDS v5.00 - Hearing, speech, and vision - discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Hearing, speech, and vision - discharge [CMS Assessment];;;ACTIVE;2.67;2.67 +93215-2;LCDS v5.00 - Hearing, speech, and vision - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Hearing, speech, and vision - admission [CMS Assessment];;;ACTIVE;2.67;2.67 +93216-0;LCDS v5.00 - Administrative information - expired;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Administrative information - expired [CMS Assessment];;;ACTIVE;2.67;2.67 +93217-8;LCDS v5.00 - Administrative information - planned discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Administrative information - planned discharge [CMS Assessment];;;ACTIVE;2.67;2.74 +93218-6;LCDS v5.00 - Administrative information - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Administrative information - admission [CMS Assessment];;;ACTIVE;2.67;2.74 +93219-4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Expired - version 5.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Expired - version 5.00 [CMS Assessment];;;ACTIVE;2.67;2.68 +93220-2;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 5.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 5.00 [CMS Assessment];;;ACTIVE;2.67;2.68 +93221-0;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Planned Discharge - version 5.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Planned Discharge - version 5.00 [CMS Assessment];;;ACTIVE;2.67;2.68 +93222-8;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Admission - version 5.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Admission - version 5.00 [CMS Assessment];;;ACTIVE;2.67;2.68 +93223-6;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 5.00;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - version 5.00 [CMS Assessment];;;ACTIVE;2.67;2.68 +93224-4;Coccidioides sp Ag;MCnc;Pt;BAL;Qn;IA;MICRO;1;Coccidioides sp Ag [Mass/volume] in Bronchoalveolar lavage by Immunoassay;Coccidioides Ag BAL IA-mCnc;;ACTIVE;2.67;2.67 +93225-1;Coccidioides sp Ag;MCnc;Pt;CSF;Qn;IA;MICRO;1;Coccidioides sp Ag [Mass/volume] in Cerebral spinal fluid by Immunoassay;Coccidioides Ag CSF IA-mCnc;;ACTIVE;2.67;2.67 +93226-9;Coccidioides sp Ag;MCnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Coccidioides sp Ag [Mass/volume] in Serum or Plasma by Immunoassay;Coccidioides Ag SerPl IA-mCnc;;ACTIVE;2.67;2.67 +93227-7;Coccidioides sp Ag;MCnc;Pt;Urine;Qn;IA;MICRO;1;Coccidioides sp Ag [Mass/volume] in Urine by Immunoassay;Coccidioides Ag Ur IA-mCnc;;ACTIVE;2.67;2.67 +93228-5;LCDS v5.00 - Patient demographic information - unplanned discharge and expired;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Patient demographic information - unplanned discharge and expired [CMS Assessment];;;ACTIVE;2.67;2.67 +9322-9;Cholesterol.total/Cholesterol.in HDL;Prctl;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.total/Cholesterol in HDL [Percentile];Cholest/HDLc Prctl SerPl;;ACTIVE;1.0i;2.73 +93229-3;LCDS v5.00 - Patient demographic information - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Patient demographic information - admission [CMS Assessment];;;ACTIVE;2.67;2.74 +93230-1;LCDS v5.00 - Patient demographic information - planned discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Patient demographic information - planned discharge [CMS Assessment];;;ACTIVE;2.67;2.74 +93231-9;LCDS v5.00 - Administrative information - unplanned discharge;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Administrative information - unplanned discharge [CMS Assessment];;;ACTIVE;2.67;2.67 +93232-7;Imipenem+Relebactam;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Imipenem+Relebactam [Susceptibility] by Gradient strip;Imi+Rel Islt Grad strip;;ACTIVE;2.67;2.67 +93233-5;Intercellular substance Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Intercellular substance IgG Ab [Presence] in Serum by Immunofluorescence;ICS IgG Ser Ql IF;;ACTIVE;2.67;2.67 +93234-3;Coagulation dilute Russell viper venom induced^post heparin neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT in Platelet poor plasma by Coagulation assay --post heparin neutralization;dRVVT p hep neut PPP;;ACTIVE;2.67;2.67 +93235-0;Coagulation surface induced.lupus sensitive^post heparin neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive in Platelet poor plasma by Coagulation assay --post heparin neutralization;aPTT-LA p hep neut PPP;;ACTIVE;2.67;2.67 +93236-8;Coagulation surface induced.lupus sensitive.excess phospholipid^post heparin neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.excess phospholipid in Platelet poor plasma by Coagulation assay --post heparin neutralization;aPTT-LA confirm p hep neut PPP;;ACTIVE;2.67;2.67 +9323-7;Sarcosine;SCnc;24H;Urine;Qn;;CHEM;1;Sarcosine [Moles/volume] in 24 hour Urine;Sarcosine 24h Ur-sCnc;;ACTIVE;1.0i;2.73 +93237-6;Coagulation surface induced.lupus sensitive.excess phospholipid actual/Normal^post heparin neutralization;RelTime;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.excess phospholipid actual/normal in Platelet poor plasma by Coagulation assay --post heparin neutralization;aPTT-LA confirm Act/Nor p hep neut PPP;;ACTIVE;2.67;2.67 +93238-4;Coagulation dilute Russell viper venom induced.excess phospholipid^post heparin neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT excess phospholipid in Platelet poor plasma by Coagulation assay --post heparin neutralization;dRVVT confirm p hep neut PPP;;ACTIVE;2.67;2.67 +93239-2;Coagulation dilute Russell viper venom induced.excess phospholipid actual/normal^post heparin neutralization;RelTime;Pt;PPP;Qn;Coag;COAG;1;dRVVT excess phospholipid actual/normal in Platelet poor plasma by Coagulation assay --post heparin neutralization;dRVVT confirm Act/Nor p hep neut PPP;;ACTIVE;2.67;2.67 +932-4;Blood product type;Type;Pt;BBL;Nom;;BLDBK;1;Deprecated Blood product type;Deprecated Bld Prod Typ BBL;;DEPRECATED;1.0;2.36 +93240-0;Coagulation dilute Russell viper venom induced.factor substitution^immediately after 1:1 addition of normal plasma+heparin neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:1 addition of normal plasma and heparin neutralization;dRVVT imm 1:1 NP+hep neut PPP;;ACTIVE;2.67;2.67 +93241-8;Multisection;Find;Pt;XXX;Doc;US.doppler;RAD;2;US.doppler Unspecified body region;DOP Unsp region;;ACTIVE;2.67;2.67 +93242-6;11-Ketotestosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Ketotestosterone [Mass/volume] in Serum or Plasma;11Ketotestost SerPl-mCnc;;ACTIVE;2.67;2.67 +93243-4;11-Hydroxytestosterone;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;11-Hydroxytestosterone [Mass/volume] in Serum or Plasma;11OH-Testost SerPl-mCnc;;ACTIVE;2.67;2.67 +93244-2;Complement Sc5b-9;MCnc;Pt;Ser/Plas;Qn;IA;SERO;1;Complement Sc5b-9 [Mass/volume] in Serum or Plasma by Immunoassay;SC5b9 SerPl IA-mCnc;;ACTIVE;2.67;2.67 +9324-5;Taurine;SCnc;24H;Urine;Qn;;CHEM;1;Taurine [Moles/volume] in 24 hour Urine;Taurine 24h Ur-sCnc;;ACTIVE;1.0i;2.73 +93245-9;Columbia - suicide severity rating scale - lifetime recent;-;Pt;^Patient;-;C-SSRS;PANEL.SURVEY.CSSRS;4;Columbia - suicide severity rating scale - lifetime recent [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.68 +93246-7;Wish to be dead;Find;1Mo;^Patient;Ord;;SURVEY.CSSRS;4;Wish to be dead 1 month;;;ACTIVE;2.67;2.67 +93247-5;Non-specific active suicidal thoughts;Find;1Mo;^Patient;Ord;;SURVEY.CSSRS;4;Non-specific active suicidal thoughts 1 month;;;ACTIVE;2.67;2.67 +93248-3;Active suicidal ideation with any methods (not plan) without intent to act;Find;1Mo;^Patient;Ord;;SURVEY.CSSRS;4;Active suicidal ideation with any methods (not plan) without intent to act 1 month;;;ACTIVE;2.67;2.67 +93249-1;Active suicidal ideation with some intent to act, without specific plan;Find;1Mo;^Patient;Ord;;SURVEY.CSSRS;4;Active suicidal ideation with some intent to act, without specific plan 1 month;;;ACTIVE;2.67;2.67 +93250-9;Active suicidal ideation with specific plan and intent;Find;1Mo;^Patient;Ord;;SURVEY.CSSRS;4;Active suicidal ideation with specific plan and intent 1 month;;;ACTIVE;2.67;2.67 +93251-7;Duration of most severe suicidal ideation;Find;Lifetime;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Duration of most severe suicidal ideation Lifetime [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +9325-2;Tryptophan;SCnc;24H;Urine;Qn;;CHEM;1;Tryptophan [Moles/volume] in 24 hour Urine;Tryptophan 24h Ur-sCnc;;ACTIVE;1.0i;2.7 +93252-5;Duration of most severe suicidal ideation;Find;1Mo;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Duration of most severe suicidal ideation 1 month [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93253-3;Actual suicide attempt;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Actual suicide attempt Lifetime;;;ACTIVE;2.67;2.67 +93254-1;Actual suicide attempts;Num;Lifetime;^Patient;Qn;;SURVEY.CSSRS;4;Actual suicide attempts # Lifetime;;;ACTIVE;2.67;2.67 +93255-8;Actual suicide attempt;Find;3Mo;^Patient;Ord;;SURVEY.CSSRS;4;Actual suicide attempt 3 months;;;ACTIVE;2.67;2.67 +93256-6;Actual suicide attempts;Num;3Mo;^Patient;Qn;;SURVEY.CSSRS;4;Actual suicide attempts # 3 months;;;ACTIVE;2.67;2.67 +93257-4;Has subject engaged in non-suicidal self-injurious behavior;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Has subject engaged in non-suicidal self-injurious behavior Lifetime;;;ACTIVE;2.67;2.67 +93258-2;Has subject engaged in non-suicidal self-injurious behavior;Find;3Mo;^Patient;Ord;;SURVEY.CSSRS;4;Has subject engaged in non-suicidal self-injurious behavior 3 months;;;ACTIVE;2.67;2.67 +93259-0;Interrupted suicide attempt;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Interrupted suicide attempt Lifetime;;;ACTIVE;2.67;2.67 +9326-0;Phosphatidylserine Ab.IgG;PrThr;Pt;Ser;Ord;IA;COAG;1;Phosphatidylserine IgG Ab [Presence] in Serum by Immunoassay;PS IgG Ser Ql IA;;ACTIVE;1.0i;2.73 +93260-8;Interrupted suicide attempts;Num;Lifetime;^Patient;Qn;;SURVEY.CSSRS;4;Interrupted suicide attempts # Lifetime;;;ACTIVE;2.67;2.67 +93261-6;Interrupted suicide attempt;Find;3Mo;^Patient;Ord;;SURVEY.CSSRS;4;Interrupted suicide attempt 3 months;;;ACTIVE;2.67;2.67 +93262-4;Interrupted suicide attempts;Num;3Mo;^Patient;Qn;;SURVEY.CSSRS;4;Interrupted suicide attempts # 3 months;;;ACTIVE;2.67;2.67 +93263-2;Aborted or self-interrupted suicide attempt;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Aborted or self-interrupted suicide attempt Lifetime;;;ACTIVE;2.67;2.67 +93264-0;Aborted or self-interrupted suicide attempts;Num;Lifetime;^Patient;Qn;;SURVEY.CSSRS;4;Aborted or self-interrupted suicide attempts # Lifetime;;;ACTIVE;2.67;2.67 +93265-7;Aborted or self-interrupted suicide attempt;Find;3Mo;^Patient;Ord;;SURVEY.CSSRS;4;Aborted or self-interrupted suicide attempt 3 months;;;ACTIVE;2.67;2.67 +93266-5;Aborted or self-interrupted suicide attempts;Num;3Mo;^Patient;Qn;;SURVEY.CSSRS;4;Aborted or self-interrupted suicide attempts # 3 months;;;ACTIVE;2.67;2.67 +93267-3;Preparatory acts or suicidal behavior;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Preparatory acts or suicidal behavior Lifetime;;;ACTIVE;2.67;2.67 +93268-1;Preparatory acts or suicidal behaviors;Num;Lifetime;^Patient;Qn;;SURVEY.CSSRS;4;Preparatory acts or suicidal behaviors # Lifetime;;;ACTIVE;2.67;2.67 +93269-9;Preparatory acts or suicidal behavior;Find;3Mo;^Patient;Ord;;SURVEY.CSSRS;4;Preparatory acts or suicidal behavior 3 months;;;ACTIVE;2.67;2.67 +93270-7;Preparatory acts or suicidal behaviors;Num;3Mo;^Patient;Ord;;SURVEY.CSSRS;4;Preparatory acts or suicidal behaviors # 3 months;;;ACTIVE;2.67;2.67 +93271-5;Actual lethality or medical damage most lethal suicide attempt;Find;Lifetime;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Actual lethality/medical damage most lethal suicide attempt Lifetime [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93272-3;Potential lethality most lethal suicide attempt;Find;Lifetime;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Potential lethality most lethal suicide attempt Lifetime [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93275-6;Date of most lethal suicide attempt;Date;Pt;^Patient;Qn;;SURVEY.CSSRS;4;Date of most lethal suicide attempt;;;ACTIVE;2.67;2.67 +9327-8;Phosphatidylserine Ab.IgM;PrThr;Pt;Ser;Ord;IA;COAG;1;Phosphatidylserine IgM Ab [Presence] in Serum by Immunoassay;PS IgM Ser Ql IA;;ACTIVE;1.0i;2.73 +93278-0;Suicidal ideation;-;Pt;^Patient;-;C-SSRS;PANEL.SURVEY.CSSRS;4;Suicidal ideation [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93279-8;Most severe suicidal ideation description;Find;1Mo;^Patient;Nom;;SURVEY.CSSRS;4;Most severe suicidal ideation description 1 month;;;ACTIVE;2.67;2.67 +93280-6;Most severe suicidal ideation description;Find;Lifetime;^Patient;Nom;;SURVEY.CSSRS;4;Most severe suicidal ideation description Lifetime;;;ACTIVE;2.67;2.67 +93281-4;Potential lethality initial or first suicide attempt;Find;Pt;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Potential lethality initial/first suicide attempt [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93282-2;Potential lethality most recent suicide attempt;Find;Pt;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Potential lethality most recent suicide attempt [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93283-0;Actual lethality or medical damage initial or first suicide attempt;Find;Pt;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Actual lethality/medical damage initial/first suicide attempt type [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93284-8;Actual lethality or medical damage most recent suicide attempt;Find;Pt;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Actual lethality/medical damage most recent suicide attempt [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93285-5;Reasons for most severe suicidal ideation;Find;1Mo;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Reasons for most severe suicidal ideation 1 month [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +9328-6;Carbidopa;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbidopa [Mass/volume] in Serum or Plasma;Carbidopa SerPl-mCnc;;ACTIVE;1.0i;2.73 +93286-3;Reasons for most severe suicidal ideation;Find;Lifetime;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Reasons for most severe suicidal ideation Lifetime [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93287-1;Deterrents of most severe suicidal ideation;Find;1Mo;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Deterrents of most severe suicidal ideation 1 month [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93288-9;Deterrents of most severe suicidal ideation;Find;Lifetime;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Deterrents of most severe suicidal ideation Lifetime [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93289-7;Controllability of most severe suicidal ideation;Find;1Mo;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Controllability of most severe suicidal ideation 1 month [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93290-5;Controllability of most severe suicidal ideation;Find;Lifetime;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Controllability of most severe suicidal ideation Lifetime [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93291-3;Frequency of most severe suicidal ideation;Find;1Mo;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Frequency of most severe suicidal ideation 1 month [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93292-1;Frequency of most severe suicidal ideation;Find;Lifetime;^Patient;Ord;C-SSRS;SURVEY.CSSRS;4;Frequency of most severe suicidal ideation Lifetime [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93293-9;Most severe suicidal ideation;Type;1Mo;^Patient;Ord;;SURVEY.CSSRS;4;Most severe suicidal ideation 1 month;;;ACTIVE;2.67;2.67 +9329-4;Basement membrane Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Basement membrane Ab [Units/volume] in Serum by Immunoassay;BM Ab Ser IA-aCnc;;ACTIVE;1.0i;2.73 +93294-7;Most severe suicidal ideation;Type;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Most severe suicidal ideation Lifetime;;;ACTIVE;2.67;2.67 +93295-4;Active suicidal ideation with specific plan and intent;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Active suicidal ideation with specific plan and intent Lifetime;;;ACTIVE;2.67;2.67 +93296-2;Active suicidal ideation with some intent to act, without specific plan;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Active suicidal ideation with some intent to act, without specific plan Lifetime;;;ACTIVE;2.67;2.67 +93297-0;Active suicidal ideation with any methods (not plan) without intent to act;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Active suicidal ideation with any methods (not plan) without intent to act Lifetime;;;ACTIVE;2.67;2.67 +93298-8;Non-specific active suicidal thoughts;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Non-specific active suicidal thoughts Lifetime;;;ACTIVE;2.67;2.7 +93299-6;Wish to be dead;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Wish to be dead Lifetime;;;ACTIVE;2.67;2.7 +93301-0;Date of initial or first suicide attempt;Date;Pt;^Patient;Qn;;SURVEY.CSSRS;4;Date of initial/first suicide attempt;;;ACTIVE;2.67;2.67 +9330-2;Benzene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Benzene [Mass/volume] in Blood;Benzene Bld-mCnc;;ACTIVE;1.0i;2.73 +93302-8;Date of most recent suicide attempt;Date;Pt;^Patient;Qn;;SURVEY.CSSRS;4;Date of most recent suicide attempt;;;ACTIVE;2.67;2.67 +93303-6;Intensity of ideation;-;Pt;^Patient;-;C-SSRS;PANEL.SURVEY.CSSRS;4;Intensity of ideation [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93304-4;Suicidal behavior;-;Pt;^Patient;-;C-SSRS;PANEL.SURVEY.CSSRS;4;Suicidal behavior [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.68 +93305-1;Lethality;-;Pt;^Patient;-;C-SSRS;PANEL.SURVEY.CSSRS;4;Lethality [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93306-9;Genetic risk score for coronary heart disease;Score;Lifetime;^Patient;Qn;;CLIN.RISK;2;Genetic risk score for coronary heart disease;GRS for CHD;;ACTIVE;2.67;2.67 +93307-7;Lifetime risk for developing coronary heart disease based on genetic risk score;Likelihood;Lifetime;^Patient;Ord;;CLIN.RISK;2;Lifetime risk for developing coronary heart disease based on genetic risk score;Lifetime Risk for CHD based on GRS;;ACTIVE;2.67;2.67 +93308-5;Risk of adverse drug reaction sequence variation interpretation;Imp;Pt;Bld/Tiss;Nar;;MOLPATH.PHARMG;1;Genetic variation's effect on risk of adverse drug reaction;Adverse drug seq var interp Bld/T-Imp;;TRIAL;2.67;2.67 +93309-3;Hearing.ability to hear during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Hearing.ability to hear during 3 day assessment period [CMS Assessment];;;ACTIVE;2.67;2.67 +9331-0;Boron;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Boron [Mass/volume] in Urine;Boron Ur-mCnc;;ACTIVE;1.0i;2.73 +93310-1;Vision.ability to see in adequate light during 3D assessment period;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Vision.ability to see in adequate light during 3 day assessment period [CMS Assessment];;;ACTIVE;2.67;2.67 +93313-5;Platelet glycoprotein disorder;Imp;Pt;Bld;Nar;Flow cytometry;CELLMARK;1;Platelet glycoprotein disorder [Interpretation] in Blood by Flow cytometry (FC) Narrative;Platelet GP disorder Bld FC-Imp;;ACTIVE;2.67;2.67 +93314-3;Platelet glycoprotein VI actual/normal;RelRto;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Platelet glycoprotein VI actual/normal in Blood by Flow cytometry (FC);Plt GPVI Act/Nor Bld FC;;ACTIVE;2.67;2.67 +93315-0;Platelet CD49b actual/normal;RelRto;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Platelet CD49b actual/normal in Blood by Flow cytometry (FC);Plt CD49b Act/Nor Bld FC;;ACTIVE;2.67;2.67 +93316-8;Platelet CD42b actual/normal;RelRto;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Platelet CD42b actual/normal in Blood by Flow cytometry (FC);Plt CD42b Act/Nor Bld FC;;ACTIVE;2.67;2.67 +93317-6;Platelet CD42a actual/normal;RelRto;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Platelet CD42a actual/normal in Blood by Flow cytometry (FC);Plt CD42a Act/Nor Bld FC;;ACTIVE;2.67;2.67 +93318-4;Platelet CD61 actual/normal;RelRto;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Platelet CD61 actual/normal in Blood by Flow cytometry (FC);Plt CD61 Act/Nor Bld FC;;ACTIVE;2.67;2.67 +93319-2;Platelet CD41 actual/normal;RelRto;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Platelet CD41 actual/normal in Blood by Flow cytometry (FC);Plt CD41 Act/Nor Bld FC;;ACTIVE;2.67;2.67 +933-2;Blood product type;Type;Pt;^BPU;Nom;;BLDBK;1;Blood product type;Bld Prod Typ BPU;;ACTIVE;1.0;2.73 +93320-0;Platelet glycoprotein disorder panel;-;Pt;Bld;Qn;Flow cytometry;PANEL.CELLMARK;1;Platelet surface glycoprotein disorders panel - Blood by Flow cytometry (FC);Platelet glycoprotein Pnl Bld FC;;ACTIVE;2.67;2.67 +93321-8;PT mixing study panel;-;Pt;PPP;Qn;Coag;PANEL.COAG;1;PT mixing study panel - Platelet poor plasma by Coagulation assay;PT mix Pnl PPP;;ACTIVE;2.67;2.67 +93323-4;Tauroursodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Tauroursodeoxycholate [Moles/volume] in Serum or Plasma;TUDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93324-2;Taurolithocholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurolithocholate [Moles/volume] in Serum or Plasma;TLCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93325-9;Taurohyodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurohyodeoxycholate [Moles/volume] in Serum or Plasma;THDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93326-7;Taurodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurodeoxycholate [Moles/volume] in Serum or Plasma;TDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93327-5;Taurocholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurocholate [Moles/volume] in Serum or Plasma;TCA SerPl-sCnc;;ACTIVE;2.67;2.67 +9332-8;Carbon tetrachloride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Carbon tetrachloride [Mass/volume] in Blood;Carbon Tet Bld-mCnc;;ACTIVE;1.0i;2.73 +93328-3;Taurochenodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Taurochenodeoxycholate [Moles/volume] in Serum or Plasma;TCDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93329-1;Hyodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hyodeoxycholate [Moles/volume] in Serum or Plasma;HDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93330-9;Glycoursodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycoursodeoxycholate [Moles/volume] in Serum or Plasma;GUDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93331-7;Glycolithocholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycolithocholate [Moles/volume] in Serum or Plasma;GLCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93332-5;Glycohyodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycohyodeoxycholate [Moles/volume] in Serum or Plasma;Glycohyodeoxycholate SerPl-sCnc;;ACTIVE;2.67;2.67 +93333-3;Glycodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycodeoxycholate [Moles/volume] in Serum or Plasma;GDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93334-1;Glycocholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycocholate [Moles/volume] in Serum or Plasma;GCA SerPl-sCnc;;ACTIVE;2.67;2.67 +93335-8;Glycochenodeoxycholate;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Glycochenodeoxycholate [Moles/volume] in Serum or Plasma;GCDCA SerPl-sCnc;;ACTIVE;2.67;2.67 +9333-6;Chloroform;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chloroform [Mass/volume] in Blood;Chloroform Bld-mCnc;;ACTIVE;1.0i;2.73 +93336-6;Bile acid;SRat;48H;Stool;Qn;;CHEM;1;Bile acid [Moles/time] in 48 hour Stool;Bile Ac 48h Stl-sRate;;ACTIVE;2.67;2.67 +93337-4;Chenodeoxycholate+Cholate/Bile acid.total;SFr;48H;Stool;Qn;;CHEM;1;Chenodeoxycholate+Cholate/Bile acid.total in 48 hour Stool;CDCA+CA 48h SFr Stl;;ACTIVE;2.67;2.67 +93338-2;Bile acid panel;-;48H;Stool;-;;PANEL.CHEM;1;Bile acid panel - 48 hour Stool;Bile acid pnl Stl;;ACTIVE;2.67;2.67 +93339-0;Thrombospondin type I domain-containing 7A Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;THSD7A IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;THSD7A IgG SerPl Ql IF;;ACTIVE;2.67;2.67 +93340-8;PhenX - complete blood count protocol 220501;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - complete blood count protocol 220501;PhenX - CBC protocol;;ACTIVE;2.67;2.67 +93341-6;Medication recommendation;Imp;Pt;^Patient;Nar;;MEDS;2;Medication recommendation;Medication recommendation;;ACTIVE;2.67;2.67 +93342-4;Power level^peak during exercise;EngRat;Pt;^Patient;Qn;;CLIN;2;Power level --peak during exercise;Power lev peak W exer;;ACTIVE;2.67;2.67 +93343-2;Treatment to which interaction between genetic variants confers synergy;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Treatment to which interaction between genetic variants confers synergy [Identifier] in Blood or Tissue Nominal;Variant interaction assoc therapy syner;;ACTIVE;2.67;2.67 +9334-4;Methanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Methanol [Mass/volume] in Blood;Methanol Bld-mCnc;;ACTIVE;1.0i;2.73 +93344-0;Treatment to which genetic variant confers resistance;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Treatment to which genetic variant confers resistance [Identifier] in Blood or Tissue Nominal;Variant assoc therapy resist;;ACTIVE;2.67;2.67 +93345-7;Genetic variant effect on drug resistance;Find;Pt;Bld/Tiss;Nar;;MOLPATH;1;Genetic variant effect on drug resistance in Blood or Tissue Narrative;Variant drug resist effect Nar;;ACTIVE;2.67;2.67 +93346-5;Genetic variant effect on drug sensitivity;Find;Pt;Bld/Tiss;Nar;;MOLPATH;1;Genetic variant effect on drug sensitivity in Blood or Tissue Narrative;Variant drug sens effect Nar;;ACTIVE;2.67;2.67 +93347-3;Available treatment related to genetic variant and not to patient diagnosis;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Available treatment related to genetic variant and not to patient diagnosis [Identifier] in Blood or Tissue Nominal;Avail tx for variant but not dx Bld/T;;ACTIVE;2.67;2.67 +93348-1;Available treatment related to genetic variant and to patient diagnosis;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Available treatment related to genetic variant and to patient diagnosis [Identifier] in Blood or Tissue Nominal;Avail tx for variant+dx Bld/T;;ACTIVE;2.67;2.67 +93349-9;Treatment to which interaction between genetic variants confers resistance;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Treatment to which interaction between genetic variants confers resistance [Identifier] in Blood or Tissue Nominal;Variant interaction assoc therapy resist;;ACTIVE;2.67;2.67 +93350-7;Monocytes.HLA-DR/100 Monocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Monocytes.HLA-DR/100 Monocytes in Blood by Flow cytometry (FC);Mono.HLA-DR/100 Mono NFr Bld FC;;ACTIVE;2.67;2.67 +9335-1;Appearance;Aper;Pt;Body fld;Nom;;SPEC;1;Appearance of Body fluid;Appearance Fld;;ACTIVE;1.0i;2.73 +93351-5;HLA-DR Ag;EntNum;Pt;Monocyte;Qn;Flow cytometry;CELLMARK;1;HLA-DR Ag [Entitic number] on Monocyte by Flow cytometry (FC);HLA-DR Ag EntNum Mono FC;;ACTIVE;2.67;2.67 +93352-3;Neutrophils.CD64/100 Neutrophils;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Neutrophils.CD64/100 Neutrophils in Blood by Flow cytometry (FC);Neut.CD64/100 Neut NFr Bld FC;;ACTIVE;2.67;2.67 +93353-1;CD64 Ag;EntNum;Pt;Neutrophil;Qn;Flow cytometry;CELLMARK;1;CD64 Ag [Entitic number] on Neutrophil by Flow cytometry (FC);CD64 Ag EntNum Neut FC;;ACTIVE;2.67;2.67 +93354-9;Neutrophil CD64 & Monocyte HLA DR panel;-;Pt;Bld;Qn;Flow cytometry;PANEL.CELLMARK;1;Neutrophil CD64 and Monocyte HLA DR panel - Blood by Flow cytometry (FC);Neut CD64 + Mono HLA DR Pnl Bld FC;;ACTIVE;2.67;2.67 +93356-4;Cells.cytogenetic abnormality;Num;Pt;Bld/Tiss;Qn;Molgen;MOLPATH;1;Cells with cytogenetic abnormality [#] in Blood or Tissue by Molecular genetics method;Cells w cytogenetic abnl Bld/T;;ACTIVE;2.67;2.67 +93357-2;Monotypic plasma cell identification & risk stratification panel;-;Pt;Bone mar;-;Molgen;PANEL.MOLPATH;1;Monotypic plasma cell identification and risk stratification panel - Bone marrow by Molecular genetics method;Mono PC ID + risk Pnl Mar;;ACTIVE;2.67;2.67 +93358-0;Plasma cells.polyclonal/Cells counted;NFr;Pt;Bone mar;Qn;Flow cytometry;HEM/BC;1;Polyclonal plasma cells/Cells counted in Bone marrow by Flow cytometry (FC);Polyclonal PCs/Cells NFr Mar FC;;ACTIVE;2.67;2.67 +93359-8;Monotypic plasma cell DNA ploidy;Type;Pt;Bone mar;Nom;Flow cytometry;MOLPATH;1;Monotypic plasma cell DNA ploidy [Type] in Bone marrow by Flow cytometry (FC);Monotypic PC DNA ploidy Mar FC;;ACTIVE;2.67;2.67 +93360-6;Monotypic plasma cell DNA index;Ratio;Pt;Bone mar;Qn;Flow cytometry;MOLPATH;1;Monotypic plasma cell DNA index in Bone marrow by Flow cytometry (FC);Monotypic PC DNA index Mar FC-Rto;;ACTIVE;2.67;2.67 +93361-4;Plasma cells.monotypic.S phase/100 cells;NFr;Pt;Bone mar;Qn;Flow cytometry;MOLPATH;1;Monotypic plasma cells in S phase/100 cells in Bone marrow by Flow cytometry (FC);Mono PC in S Phs NFr Mar FC;;ACTIVE;2.67;2.67 +93362-2;Plasma cells.monotypic population;Prid;Pt;Bone mar;Nom;Flow cytometry;HEM/BC;1;Plasma cells monotypic population [Identifier] in Bone marrow by Flow cytometry (FC);Monotypic plasma cells Mar FC;;ACTIVE;2.67;2.67 +93363-0;Plasma cell DNA content & proliferation panel;-;Pt;Bone mar;-;Flow cytometry;PANEL.HEM/BC;1;Plasma cell DNA content and proliferation panel - Bone marrow by Flow cytometry (FC);PC DNA content + prolif Pnl Mar FC;;ACTIVE;2.67;2.67 +93364-8;Genetic variant diagnostic significance;Imp;Pt;Bld/Tiss;Nar;;MOLPATH;1;Genetic variant diagnostic significance [Interpretation] in Blood or Tissue Narrative;Genetic variant diag sig Bld/T-Imp;;ACTIVE;2.67;2.67 +93365-5;Genetic variant prognostic significance;Imp;Pt;Bld/Tiss;Nar;;MOLPATH;1;Genetic variant prognostic significance [Interpretation] in Blood or Tissue Narrative;Genetic variant prog sig Bld/T-Imp;;ACTIVE;2.67;2.67 +93366-3;Gene studied with no variant found;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Gene studied with no variant found [Identifier] in Blood or Tissue Nominal;Gene studied w no variant found Bld/T;;ACTIVE;2.67;2.67 +93367-1;Variant of unknown significance;Prid;Pt;Bld/Tiss;Nom;;MOLPATH;1;Variant of unknown significance [Identifier] in Blood or Tissue Nominal;Variant unknown sig Bld/T;;ACTIVE;2.67;2.67 +93368-9;Summary of interaction between genetic variants;Imp;Pt;Bld/Tiss;Nar;;MOLPATH;1;Summary of interaction between genetic variants [Interpretation] in Blood or Tissue Narrative;Variant interaction summary Bld/T-Imp;;ACTIVE;2.67;2.67 +9336-9;IgA subclass 1/IgA.total;MFr;Pt;Ser;Qn;;CHEM;1;IgA subclass 1/IgA.total in Serum;IgA1 MFr Ser;;ACTIVE;1.0i;2.73 +93369-7;Krebs von den Lungen-6;ACnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Krebs von den Lungen-6 [Units/volume] in Serum or Plasma by Immunoassay;KL-6 SerPl IA-aCnc;;ACTIVE;2.67;2.67 +93370-5;Anaplasma phagocytophilum & Ehrlichia chaffeensis Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Anaplasma phagocytophilum and Ehrlichia chaffeensis IgG and IgM panel - Serum;A phagocyt + E chaff IgG + IgM Pnl Ser;;ACTIVE;2.67;2.67 +93371-3;von Willebrand factor cleaving protease activity;CCnc;Pt;PPP;Qn;Chromo;COAG;1;von Willebrand factor (vWf) cleaving protease activity [Enzymatic activity/volume] in Platelet poor plasma by Chromogenic method;vWF Cp Act PPP Chro-cCnc;;ACTIVE;2.67;2.68 +93372-1;Indexing - national clinical trial number;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Indexing - national clinical trial number;FDA label Indexing - NCT #;;ACTIVE;2.67;2.67 +93373-9;Columbia - suicide severity rating scale screener - recent;-;Pt;^Patient;-;C-SSRS;PANEL.SURVEY.CSSRS;4;Columbia - suicide severity rating scale screener - recent [C-SSRS];;© 2011 Dr. Kelly Posner, first author of the scale. Used with permission;ACTIVE;2.67;2.67 +93374-7;Suicide risk level;Find;Pt;^Patient;Ord;;SURVEY.CSSRS;4;Suicide risk level;;;ACTIVE;2.67;2.7 +9337-7;IgA subclass 1/IgA.total;MFr;Pt;Ser;Qn;;CHEM;1;Deprecated IgA subclass 1/IgA.total in Serum;Deprecated IgA1 Fr Ser;;DEPRECATED;1.0i;2.46 +93384-6;Serratia sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Serratia sp DNA [Presence] by NAA with probe detection in Positive blood culture;Serratia sp DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +9338-5;Rheumatoid factor.IgM;ACnc;Pt;Ser;Qn;IA;SERO;1;Rheumatoid factor IgM [Units/volume] in Serum by Immunoassay;RF IgM Ser IA-aCnc;;ACTIVE;1.0i;2.73 +93385-3;Salmonella sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Salmonella sp DNA [Presence] by NAA with probe detection in Positive blood culture;Salmonella DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93386-1;Pseudomonas aeruginosa DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [Presence] by NAA with probe detection in Positive blood culture;P aeruginosa DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93387-9;Proteus mirabilis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Proteus mirabilis DNA [Presence] by NAA with probe detection in Positive blood culture;P mirabilis DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93388-7;Neisseria meningitidis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Presence] by NAA with probe detection in Positive blood culture;N men DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93389-5;Gram positive bacteria DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Gram positive bacteria DNA [Presence] by NAA with probe detection in Positive blood culture;GP bact DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93390-3;Bacterial carbapenem resistance blaOXA-23-like+blaOXA-48-like genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;MICRO;1;Carbapenem resistance blaOXA-23-like+blaOXA-48-like genes [Presence] in Isolate or Specimen by Molecular method;blaOXA-23+48-like genes Islt/Spm Ql;;ACTIVE;2.67;2.7 +93391-1;Stenotrophomonas maltophilia DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Stenotrophomonas maltophilia DNA [Presence] by NAA with probe detection in Positive blood culture;S maltophilia DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93392-9;Serratia marcescens DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Serratia marcescens DNA [Presence] by NAA with probe detection in Positive blood culture;S marcescens DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +9339-3;Insulin^6H post 75 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Mass/volume] in Serum or Plasma --6 hours post 75 g glucose PO;Insulin 6h p 75 g Glc PO SerPl-mCnc;;ACTIVE;1.0i;2.73 +93393-7;Proteus sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Proteus sp DNA [Presence] by NAA with probe detection in Positive blood culture;Proteus sp DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93394-5;Morganella morganii DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Morganella morganii DNA [Presence] by NAA with probe detection in Positive blood culture;M. morganii DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93395-2;Klebsiella pneumoniae DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Klebsiella pneumoniae DNA [Presence] by NAA with probe detection in Positive blood culture;K pneumon DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93396-0;Fusobacterium nucleatum DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Fusobacterium nucleatum DNA [Presence] by NAA with probe detection in Positive blood culture;F. nucleatum DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93397-8;Haemophilus influenzae DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] by NAA with probe detection in Positive blood culture;Haem influ DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93398-6;Klebsiella oxytoca DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [Presence] by NAA with probe detection in Positive blood culture;K oxytoca DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93399-4;Fusobacterium necrophorum DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Fusobacterium necrophorum DNA [Presence] by NAA with probe detection in Positive blood culture;F. necrophorum DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +934-0;Blood product unit ID;Num;Pt;Dose;Qn;;BLDBK;1;Blood product unit ID [#];BPU ID;;ACTIVE;1.0;2.73 +93400-0;Enterobacter aerogenes+Enterobacter amnigenus+Enterobacter gergoviae DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Enterobacter aerogenes+Enterobacter amnigenus+Enterobacter gergoviae DNA [Presence] by NAA with probe detection in Positive blood culture;E. aerog+amn+gergo DNA Bld Pos Ql NAA+pr;;ACTIVE;2.67;2.67 +9340-1;Apolipoprotein B/Apolipoprotein A-I;Prctl;Pt;Ser/Plas;Qn;;CHEM;1;Apolipoprotein B/Apolipoprotein A-I [Percentile];Apo B/Apo A-I Prctl SerPl;;ACTIVE;1.0i;2.73 +93401-8;Escherichia coli DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Escherichia coli DNA [Presence] by NAA with probe detection in Positive blood culture;E coli DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93402-6;Cronobacter sakazakii DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Cronobacter sakazakii DNA [Presence] by NAA with probe detection in Positive blood culture;C sakazakii DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93403-4;Citrobacter sp DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Citrobacter sp DNA [Presence] by NAA with probe detection in Positive blood culture;Citrobac sp DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93404-2;Enterobacter cloacae complex DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [Presence] by NAA with probe detection in Positive blood culture;E cloac comp DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93405-9;Bacteroides fragilis DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Bacteroides fragilis DNA [Presence] by NAA with probe detection in Positive blood culture;B fragilis DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93406-7;Acinetobacter baumannii DNA;PrThr;Pt;Bld.pos growth;Ord;Probe.amp.tar;MICRO;1;Acinetobacter baumannii DNA [Presence] by NAA with probe detection in Positive blood culture;A baumannii DNA Bld Pos Ql NAA+probe;;ACTIVE;2.67;2.67 +93407-5;Gram negative blood culture panel;-;Pt;Bld.pos growth;-;Probe.amp.tar;PANEL.MICRO;1;Gram negative blood culture panel by NAA with probe detection in Positive blood culture;GN Bld Culture Pnl Bld Pos NAA+probe;;ACTIVE;2.67;2.67 +93408-3;Platelet aggregation.epinephrine induced^10 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --10 umol/L;PA Epineph 10 umol/L PRP;;ACTIVE;2.67;2.67 +93409-1;Platelet aggregation.epinephrine induced^5 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --5 umol/L;PA Epineph 5 umol/L PRP;;ACTIVE;2.67;2.67 +93410-9;Platelet aggregation.ristocetin induced^5 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --5 ug/mL;PA Rist 5 ug/mL PRP;;ACTIVE;2.67;2.67 +93411-7;COMT gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;COMT gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;COMT gene prod met activ Bld/T-Imp;;ACTIVE;2.67;2.68 +93412-5;SLCO1B1 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;SLCO1B1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;SLCO1B1 Mut Anl Bld/T;;ACTIVE;2.67;2.67 +93413-3;Mechanical circulatory support+consultation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Mechanical circulatory support Consultation note;MCS+consult note;;TRIAL;2.67;2.67 +93414-1;Altered level of consciousness in last 3D;Find;3D;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Altered level of consciousness in last 3 day [CAM.CMS];;;ACTIVE;2.68;2.68 +93415-8;Disorganized thinking in last 3D;Find;3D;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Deprecated Disorganized thinking in last 3 days [CMS Assessment];;;DEPRECATED;2.67;2.7 +93416-6;Inattention in last 3D;Find;3D;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Deprecated Inattention in last 3 days [CMS Assessment];;;DEPRECATED;2.67;2.7 +93417-4;IRF-PAI v4.0, LCDS v5.00 - Signs and Symptoms of Delirium (from CAM);-;3D;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v4.0, LCDS v5.00 - Signs and Symptoms of Delirium (from CAM) [CMS Assessment];;;DISCOURAGED;2.67;2.69 +93418-2;"(8;8)(q13;q21)(HEY1,NCOA2) fusion transcript";PrThr;Pt;Tiss;Ord;Molgen;MOLPATH;1;"(8;8)(q13;q21)(HEY1,NCOA2) fusion transcript [Presence] in Tissue by Molecular genetics method";"(8;8)(HEY1,NCOA2) Tiss Ql";;ACTIVE;2.67;2.67 +9341-9;Cerebroside sulfatase;MRat;24H;Urine;Qn;;CHEM;1;Cerebroside sulfatase [Mass/time] in 24 hour Urine;Arylsulfatase A 24h Ur-mRate;;ACTIVE;1.0i;2.7 +93419-0;Alpha 1 antitrypsin fecal clearance panel;-;Pt;Ser/Plas+Stool;Qn;;PANEL.CHEM;1;Alpha 1 antitrypsin fecal clearance panel - Serum or Plasma and Stool;A1AT Cl Pnl SerPl+Stl;;ACTIVE;2.67;2.67 +93420-8;APOA1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;APOA1 gene full mutation analysis in Blood or Tissue by Sequencing;APOA1 Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +93421-6;Glial fibrillary acidic protein.alpha subunit Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Glial fibrillary acidic protein alpha subunit IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;GFAP alpha IgG Titr CSF IF;;ACTIVE;2.67;2.68 +93422-4;Glial fibrillary acidic protein.alpha subunit Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Glial fibrillary acidic protein alpha subunit IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;GFAP alpha IgG CSF Ql CBA IFA;;ACTIVE;2.67;2.69 +93423-2;Glial fibrillary acidic protein.alpha subunit Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Glial fibrillary acidic protein alpha subunit IgG Ab [Titer] in Serum by Immunofluorescence;GFAP alpha IgG Titr Ser IF;;ACTIVE;2.67;2.68 +93424-0;Glial fibrillary acidic protein.alpha subunit Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Glial fibrillary acidic protein alpha subunit IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;GFAP alpha IgG Ser Ql CBA IFA;;ACTIVE;2.67;2.69 +93425-7;Gamma aminobutyrate B receptor Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;GABABR IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;GABABR IgG Titr CSF IF;;ACTIVE;2.67;2.67 +93426-5;Gamma aminobutyrate B receptor Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;GABABR IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;GABABR IgG CSF Ql CBA IFA;;ACTIVE;2.67;2.69 +9342-7;Cholesterol;Prctl;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol [Percentile];Cholest Prctl SerPl;;ACTIVE;1.0i;2.73 +93427-3;Gamma aminobutyrate B receptor Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;GABABR IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;GABABR IgG Titr SerPl IF;;ACTIVE;2.67;2.67 +93428-1;Gamma aminobutyrate B receptor Ab.IgG;PrThr;Pt;Ser/Plas;Ord;CBA IFA;SERO;1;GABABR IgG Ab [Presence] in Serum or Plasma by Cell binding immunofluorescent assay;GABABR IgG SerPl Ql CBA IFA;;ACTIVE;2.67;2.69 +93429-9;Blastomyces sp Ag;MCnc;Pt;Urine;Qn;IA;MICRO;1;Blastomyces sp Ag [Mass/volume] in Urine by Immunoassay;Blastomyces Ag Ur IA-mCnc;;ACTIVE;2.67;2.67 +93430-7;Blastomyces sp Ag;MCnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Blastomyces sp Ag [Mass/volume] in Serum or Plasma by Immunoassay;Blastomyces Ag SerPl IA-mCnc;;ACTIVE;2.67;2.67 +93431-5;Blastomyces sp Ag;MCnc;Pt;CSF;Qn;IA;MICRO;1;Blastomyces sp Ag [Mass/volume] in Cerebral spinal fluid by Immunoassay;Blastomyces Ag CSF IA-mCnc;;ACTIVE;2.67;2.67 +93432-3;Blastomyces sp Ag;MCnc;Pt;BAL;Qn;IA;MICRO;1;Blastomyces sp Ag [Mass/volume] in Bronchoalveolar lavage by Immunoassay;Blastomyces Ag BAL IA-mCnc;;ACTIVE;2.67;2.67 +93433-1;Busulfan^4H post busulfan infusion completion;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Busulfan [Mass/volume] in Plasma --4 hours post busulfan infusion completion;Busulfan 4h p busulfan Plas-mCnc;;ACTIVE;2.67;2.67 +93434-9;Busulfan^2H post busulfan infusion completion;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Busulfan [Mass/volume] in Plasma --2 hours post busulfan infusion completion;Busulfan 2h p busulfan Plas-mCnc;;ACTIVE;2.67;2.67 +9343-5;Coproporphyrin 1;MCnc;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 1 [Mass/volume] in Urine;Copro1 Ur-mCnc;;ACTIVE;1.0i;2.73 +93435-6;Busulfan^1H post busulfan infusion completion;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Busulfan [Mass/volume] in Plasma --1 hour post busulfan infusion completion;Busulfan 1h p busulfan Plas-mCnc;;ACTIVE;2.67;2.67 +93436-4;Busulfan^immediately post busulfan infusion completion;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Busulfan [Mass/volume] in Plasma --immediately post busulfan infusion completion;Busulfan immed p busulfan Plas-mCnc;;ACTIVE;2.67;2.67 +93437-2;Lurasidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Lurasidone [Mass/volume] in Serum or Plasma;Lurasidone SerPl-mCnc;;ACTIVE;2.67;2.67 +93438-0;Herpes Simplex Virus 2 DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Blood by NAA with non-probe detection;HSV2 DNA Bld Ql NAA+non-probe;;ACTIVE;2.67;2.67 +93439-8;Herpes Simplex Virus 1 DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Blood by NAA with non-probe detection;HSV1 DNA Bld Ql NAA+non-probe;;ACTIVE;2.67;2.67 +93440-6;Herpes Simplex Virus 1 & 2 DNA Panel;-;Pt;Bld;-;Non-probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Blood by NAA with non-probe detection;HSV 1+2 DNA Pnl Bld NAA+non-probe;;ACTIVE;2.67;2.67 +93441-4;Home accessibility modification date;Date;Pt;^Patient;Qn;;CLIN;2;Home accessibility modification date;Home access mod date;;ACTIVE;2.67;2.67 +93442-2;Advance directive document format;Find;Pt;^Patient;Nom;;CLIN;2;Advance directive document format;Advance directive document format;;ACTIVE;2.67;2.67 +9344-3;Coproporphyrin 1/Coproporphyrin.total;MRto;24H;Urine;Qn;;CHEM;1;Coproporphyrin 1/Coproporphyrin.total [Mass Ratio] in 24 hour Urine;Copro1/Copro total 24h Ur;;ACTIVE;1.0i;2.7 +93443-0;Self-care abilities;Find;Pt;^Patient;Nom;;CLIN;2;Self-care abilities;Self-care abilities;;ACTIVE;2.67;2.67 +93444-8;Accessibility of home entrance;Find;Pt;^Patient;Nom;;CLIN;2;Accessibility of home entrance;Access of home entrance;;ACTIVE;2.67;2.67 +93445-5;Accessibility note;Find;Pt;Patient's home;Doc;Nurse;DOC.MISC;2;Accessibility note Patient's home Nurse;Accessibility note Pt's home Nurse;;ACTIVE;2.67;2.67 +93446-3;Accessibility of home interior;Find;Pt;^Patient;Nom;;CLIN;2;Accessibility of home interior;Access home int;;ACTIVE;2.67;2.67 +93447-1;Home accessibility modification responsible party;Find;Pt;^Patient;Nom;;CLIN;2;Home accessibility modification responsible party;Home access mod responsible party;;ACTIVE;2.67;2.67 +93448-9;Home accessibility evaluation status;Find;Pt;^Patient;Nom;;DOC.MISC;2;Home accessibility evaluation status;Home access eval status;;ACTIVE;2.67;2.67 +93449-7;Appointment of legal guardian;Find;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Appointment of legal guardian;Appt legal guardian;;ACTIVE;2.67;2.67 +9345-0;Coproporphyrin 3;MCnc;Pt;Urine;Qn;;CHEM;1;Coproporphyrin 3 [Mass/volume] in Urine;Copro3 Ur-mCnc;;ACTIVE;1.0i;2.73 +93450-5;Coagulation factor VIII Inhibitor;ACnc;Pt;PPP;Qn;Chromo;COAG;1;Coagulation factor VIII inhibitor [Units/volume] in Platelet poor plasma by Chromogenic method;Fact VIII Inhib PPP Chro-aCnc;;ACTIVE;2.67;2.67 +93451-3;Nor-W-18+Nor-W-15;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nor-W-18+Nor-W-15 [Mass/volume] in Urine by Confirmatory method;Nor-W-18+Nor-W-15 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93452-1;W-19;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;W-19 [Mass/volume] in Urine by Confirmatory method;W-19 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93453-9;W-15;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;W-15 [Mass/volume] in Urine by Confirmatory method;W-15 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93454-7;W-18;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;W-18 [Mass/volume] in Urine by Confirmatory method;W-18 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93455-4;IC-26;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;IC-26 [Mass/volume] in Urine by Confirmatory method;IC-26 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93456-2;MT-45;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;MT-45 [Mass/volume] in Urine by Confirmatory method;MT-45 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93457-0;AH-8529;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;AH-8529 [Mass/volume] in Urine by Confirmatory method;AH-8529 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93458-8;AH-8533;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;AH-8533 [Mass/volume] in Urine by Confirmatory method;AH-8533 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93459-6;U-47700;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;U-47700 [Mass/volume] in Urine by Confirmatory method;U-47700 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93460-4;AH-7921;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;AH-7921 [Mass/volume] in Urine by Confirmatory method;AH-7921 Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93461-2;4-Methoxybutyrylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;4-Methoxybutyrylfentanyl [Mass/volume] in Urine by Confirmatory method;4-Methbutfentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93462-0;Norcarfentanil;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norcarfentanil [Mass/volume] in Urine by Confirmatory method;Norcarfentanil Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93463-8;Ocfentanil;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Ocfentanil [Mass/volume] in Urine by Confirmatory method;Ocfentanil Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93464-6;4-Fluorofentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;p-Fluorofentanyl [Mass/volume] in Urine by Confirmatory method;4-Fluorofentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93465-3;3-Methylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;3-Methylfentanyl [Mass/volume] in Urine by Confirmatory method;3-Me-fentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93466-1;Valerylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Valerylfentanyl [Mass/volume] in Urine by Confirmatory method;Valerylfentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93467-9;Butyrylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Butyrylfentanyl [Mass/volume] in Urine by Confirmatory method;Butyrylfentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +9346-8;Lipoprotein.beta;MCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Lipoprotein.beta [Mass/volume] in Serum or Plasma by calculation;LDL SerPl Calc-mCnc;;ACTIVE;1.0i;2.73 +93468-7;Acrylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Acrylfentanyl [Mass/volume] in Urine by Confirmatory method;Acrylfentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93469-5;4-Fluorobutyrylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;4-Fluorobutyrylfentanyl [Mass/volume] in Urine by Confirmatory method;4-Fluorobutyrylfentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93470-3;Furanylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Furanylfentanyl [Mass/volume] in Urine by Confirmatory method;Furanylfentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93471-1;Acetyl norfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Acetyl norfentanyl [Mass/volume] in Urine by Confirmatory method;Acetyl norfentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93472-9;4-Methylphenethylacetylfentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;4-Methylphenethylacetylfentanyl [Mass/volume] in Urine by Confirmatory method;4-MetPhenEthAcetFentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93473-7;Beta hydroxythiofentanyl;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Beta hydroxythiofentanyl [Mass/volume] in Urine by Confirmatory method;B-OH thiofentanyl Ur Cfm-mCnc;;ACTIVE;2.67;2.67 +93474-5;Synthetic opioids panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;Synthetic opioids panel - Urine by Confirmatory method;Synthetic opioids pnl Ur Cfm;;ACTIVE;2.67;2.67 +93475-2;Busulfan clearance;VRatCnt;Stdy;Plas;Qn;;DRUG/TOX;1;Busulfan clearance from plasma over study;Busulfan Cl from Plas;;ACTIVE;2.67;2.67 +9347-6;pH.combined acid;LsCnc;Pt;Gast fld;Qn;;CHEM;1;pH combined acid of Gastric fluid;pH Combined Ac Gast;;ACTIVE;1.0i;2.42 +93476-0;Busulfan;TmSCnc;Stdy;Plas;Qn;;DRUG/TOX;1;Busulfan [Area under the curve] in Plasma;Busulfan Plas-AUC;;ACTIVE;2.67;2.67 +93477-8;Busulfan given;Mass;XXX;Dose;Qn;;DRUGDOSE;1;Busulfan given [Mass] of Dose;Busulfan Gvn ?Tm Dose;;ACTIVE;2.67;2.68 +93478-6;Busulfan area under the curve panel;-;Stdy;Plas;Qn;;PANEL.DRUG/TOX;1;Busulfan area under the curve panel - Plasma;Busulfan AUC Pnl Plas;;ACTIVE;2.67;2.67 +93479-4;Observation interpretation;Imp;Pt;XXX;Nom;;MISC;1;Observation interpretation;Observation Imp;;ACTIVE;2.67;2.69 +93480-2;Cortisol post corticotropin releasing hormone stimulation panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Cortisol post CRH stimulation panel - Serum or Plasma;Cortisol p CRH stimulation Pnl SerPl;;ACTIVE;2.67;2.67 +93481-0;Cortisol^10M post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --10 minutes post 1 ug/kg CRH IV;Cortis 10M p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.67;2.67 +93482-8;Cortisol^1M pre 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 minute pre 1 ug/kg CRH IV;Cortis 1M pre 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.67;2.67 +93483-6;Cortisol^2M post 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2 minutes post 1 ug/kg CRH IV;Cortis 2M p 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.67;2.67 +9348-4;pH.free acid;LsCnc;Pt;Gast fld;Qn;;CHEM;1;pH free acid of Gastric fluid;pH Free Ac Gast;;ACTIVE;1.0i;2.73 +93484-4;Cortisol^5M pre 1 ug/kg CRH IV;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --5 minutes pre 1 ug/kg CRH IV;Cortis 5M pre 1 ug/kg CRH IV SerPl-mCnc;;ACTIVE;2.67;2.67 +93485-1;Columbia - suicide severity rating scale - very young child or cognitively impaired - lifetime recent;-;Pt;^Patient;-;C-SSRS;PANEL.SURVEY.CSSRS;4;Columbia - suicide severity rating scale - very young child or cognitively impaired - lifetime recent [C-SSRS];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.68 +93486-9;Has subject engaged in self-injurious behavior, intent unknown;Find;3Mo;^Patient;Ord;;SURVEY.CSSRS;4;Has subject engaged in self-injurious behavior, intent unknown 3 months;;;ACTIVE;2.67;2.67 +93487-7;Has subject engaged in self-injurious behavior, intent unknown;Find;Lifetime;^Patient;Ord;;SURVEY.CSSRS;4;Has subject engaged in self-injurious behavior, intent unknown Lifetime;;;ACTIVE;2.67;2.67 +93488-5;Guanidinoacetate;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Guanidinoacetate [Moles/volume] in DBS;Guanidinoacetate DBS-sCnc;;ACTIVE;2.67;2.67 +93489-3;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;CBA IFA;SERO;1;AMPAR2 IgG Ab [Presence] in Serum or Plasma by Cell binding immunofluorescent assay;AMPAR2 IgG SerPl Ql CBA IFA;;ACTIVE;2.67;2.69 +93490-1;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;AMPAR2 IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;AMPAR2 IgG Titr SerPl IF;;ACTIVE;2.67;2.67 +93491-9;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;AMPAR2 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;AMPAR2 IgG CSF Ql CBA IFA;;ACTIVE;2.67;2.69 +9349-2;pH.total acid;LsCnc;Pt;Gast fld;Qn;;CHEM;1;pH total acid of Gastric fluid;pH Total Ac Gast;;ACTIVE;1.0i;2.42 +93492-7;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;AMPAR2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;AMPAR2 IgG Titr CSF IF;;ACTIVE;2.67;2.67 +93493-5;3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Ab.IgG;ACnc;Pt;Ser;Qn;IA;CHEM;1;3-Hydroxy-3-Methylglutaryl-coenzyme A reductase IgG Ab [Units/volume] in Serum by Immunoassay;HMGCR IgG Ser IA-aCnc;;ACTIVE;2.67;2.67 +93494-3;Buprenorphine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Buprenorphine [Presence] in Urine by Screen method;Buprenorphine Ur Ql Scn;;ACTIVE;2.67;2.67 +93495-0;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Urine by Screen method;EDDP Ur Ql Scn;;ACTIVE;2.67;2.67 +93496-8;Nortriptyline;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Nortriptyline [Presence] in Urine by Screen method;Nortrip Ur Ql Scn;;ACTIVE;2.67;2.67 +93497-6;Moxifloxacin 3.0 ug/mL;Susc;Pt;Isolate;OrdQn;Method for Slow-growing mycobacteria;ABXBACT;1;Moxifloxacin 3 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria;Moxifloxacin 3 ug/mL Islt SlowMyco;;ACTIVE;2.67;2.67 +93498-4;Metabotropic glutamate receptor 1 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Metabotropic glutamate receptor 1 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;mGluR1 IgG Ser Ql CBA IFA;;ACTIVE;2.67;2.69 +93499-2;Metabotropic glutamate receptor 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Metabotropic glutamate receptor 1 IgG Ab [Titer] in Serum by Immunofluorescence;mGluR1 IgG Titr Ser IF;;ACTIVE;2.67;2.67 +93-5;Cefodizime;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefodizime [Susceptibility] by Disk diffusion (KB);Cefodizime Islt KB;;ACTIVE;1.0;2.19 +9350-0;Sulfhydryls;PrThr;Pt;Urine;Ord;;CHEM;1;Sulfhydryls [Presence] in Urine;Sulfhydryls Ur Ql;;ACTIVE;1.0i;2.56 +93500-7;Metabotropic glutamate receptor 1 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Metabotropic glutamate receptor 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;mGluR1 IgG CSF Ql CBA IFA;;ACTIVE;2.67;2.69 +93501-5;Metabotropic glutamate receptor 1 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Metabotropic glutamate receptor 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;mGluR1 IgG Titr CSF IF;;ACTIVE;2.67;2.67 +93502-3;N-methyl-D-aspartate receptor subunit 1 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;NMDAR subunit 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;NMDAR1 IgG CSF Ql CBA IFA;;ACTIVE;2.67;2.69 +93503-1;N-methyl-D-aspartate receptor subunit 1 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;NMDAR subunit 1 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;NMDAR1 IgG Ser Ql CBA IFA;;ACTIVE;2.67;2.69 +93504-9;Cholesterol crystals;PrThr;Pt;Calculus;Ord;XR diffraction;CHEM;1;Cholesterol crystals [Presence] in Stone by X-ray diffraction;Cholest Cry Stone Ql XR diff;;ACTIVE;2.67;2.67 +93505-6;Heptacarboxylporphyrin I;SRat;24H;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin I [Moles/time] in 24 hour Urine;Hepta-CP I 24h Ur-sRate;;ACTIVE;2.67;2.67 +93506-4;Heptacarboxylporphyrin III;SRat;24H;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin III [Moles/time] in 24 hour Urine;Hepta-CP3 24h Ur-sRate;;ACTIVE;2.67;2.67 +93507-2;Hexacarboxylporphyrin I;SRat;24H;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin I [Moles/time] in 24 hour Urine;Hexa-CP I 24h Ur-sRate;;ACTIVE;2.67;2.67 +93508-0;Hexacarboxylporphyrin III;SRat;24H;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin III [Moles/time] in 24 hour Urine;Hexa-CPr3 24h Ur-sRate;;ACTIVE;2.67;2.67 +93509-8;Pentacarboxylporphyrin I;SRat;24H;Urine;Qn;;CHEM;1;Pentacarboxylporphyrin I [Moles/time] in 24 hour Urine;Penta-CPI 24h Ur-sRate;;ACTIVE;2.67;2.67 +93510-6;Pentacarboxylporphyrin III;SRat;24H;Urine;Qn;;CHEM;1;Pentacarboxylporphyrin III [Moles/time] in 24 hour Urine;Penta-CP3 24h Ur-sRate;;ACTIVE;2.67;2.67 +93511-4;Rickettsia rickettsii & Coxiella burnetii phase 1 & Coxiella burnetii phase 2 Ab.IgG panel;-;Pt;Ser;-;;PANEL.MICRO;1;Rickettsia rickettsii and Coxiella burnetii phase 1 and Coxiella burnetii phase 2 IgG panel - Serum;R. rickettsii + C. burnetii 1 2 IgG Pnl;;ACTIVE;2.67;2.67 +9351-8;ALPRAZolam;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;ALPRAZolam [Presence] in Urine;Alpraz Ur Ql;;ACTIVE;1.0i;2.73 +9352-6;Amphetamines;MCnt;Pt;Hair;Qn;;DRUG/TOX;1;Amphetamines [Mass/mass] in Hair;Amphetamines Hair-mCnt;;ACTIVE;1.0i;2.73 +9353-4;Baclofen;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Baclofen [Mass/volume] in Serum or Plasma;Baclofen SerPl-mCnc;;ACTIVE;1.0i;2.73 +9354-2;Benztropine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benztropine [Mass/volume] in Urine;Benztropine Ur-mCnc;;ACTIVE;1.0i;2.7 +9355-9;Bumetanide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bumetanide [Mass/volume] in Serum or Plasma;Bumetanide SerPl-mCnc;;ACTIVE;1.0i;2.7 +9356-7;busPIRone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;busPIRone [Mass/volume] in Serum or Plasma;busPIRone SerPl-mCnc;;ACTIVE;1.0i;2.73 +935-7;Blood product unit expiration;TmStp;Pt;^BPU;Qn;;BLDBK;1;Blood product unit expiration [Date and time];BPU Expire Date BPU;;ACTIVE;1.0;2.73 +9357-5;Disulfiram;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Disulfiram [Mass/volume] in Urine;Disulfiram Ur-mCnc;;ACTIVE;1.0i;2.73 +9358-3;Lithium;MCnc;Pt;Saliva;Qn;;DRUG/TOX;1;Lithium [Mass/volume] in Saliva (oral fluid);Lithium Sal-mCnc;;ACTIVE;1.0i;2.73 +9359-1;Tacrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Tacrine [Mass/volume] in Serum or Plasma;Tacrine SerPl-mCnc;;ACTIVE;1.0i;2.73 +93598-1;Intensity of ideation;-;Pt;^Patient;-;C-SSRS.PCI;PANEL.SURVEY.CSSRS;4;Intensity of ideation [C-SSRS.PCI];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93599-9;Frequency of most severe suicidal ideation;Find;1Mo;^Patient;Ord;C-SSRS.PCI;SURVEY.CSSRS;4;Frequency of most severe suicidal ideation 1 month [C-SSRS.PCI];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93600-5;Frequency of most severe suicidal ideation;Find;Lifetime;^Patient;Ord;C-SSRS.PCI;SURVEY.CSSRS;4;Frequency of most severe suicidal ideation Lifetime [C-SSRS.PCI];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.67;2.67 +93603-9;Multisection^WO & W contrast IV;Find;Pt;Head & Neck>Spine.cervical;Doc;CT;RAD;2;CT Head and Cervical spine WO and W contrast IV;CT Head+C-spine WO+W contr IV;;ACTIVE;2.67;2.67 +93604-7;Multisection;Find;Pt;Lower extremity.bilateral>Lower extremity arteries+Lower extremity veins;Doc;US.doppler;RAD;2;US.doppler Lower extremity arteries+veins - bilateral;DOP LE aa+vv-Bl;;ACTIVE;2.67;2.67 +93605-4;Views 2 or 3;Find;Pt;Head>Skull & Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Skull to Coccyx 2 or 3 Views;XR Skull to Coccyx 2V or 3V;;ACTIVE;2.67;2.67 +93606-2;Views 4 or 5;Find;Pt;Head>Skull & Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Skull to Coccyx 4 or 5 Views;XR Skull to Coccyx 4V or 5V;;ACTIVE;2.67;2.67 +93607-0;Views GE 6;Find;Pt;Head>Skull & Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar & Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Skull to Coccyx GE 6 Views;XR Skull to Coccyx GE 6V;;ACTIVE;2.67;2.67 +93608-8;Atrial contraction strain rate.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum atrial contraction strain rate by US 3D;LV Max atrial contract strain rate 3D US;;ACTIVE;2.67;2.67 +9360-9;Bartonella quintana Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella quintana IgG Ab [Titer] in Serum;B quintana IgG Titr Ser;;ACTIVE;1.0i;2.73 +93609-6;Atrial contraction strain rate.circumferential.max;LenRto;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum circumferential atrial contraction strain rate by US 3D;LV Max circ atrial contract st rt 3D US;;ACTIVE;2.67;2.67 +93610-4;Atrial contraction strain rate.longitudinal.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum longitudinal atrial contraction strain rate by US 3D;LV Max long atrial contract str rt 3D US;;ACTIVE;2.67;2.67 +93611-2;Circumferential strain rate.early diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum circumferential strain rate during early diastole by US 3D;LV Max circ strain rate early dias 3D US;;ACTIVE;2.67;2.67 +93612-0;Longitudinal strain rate.early diastole.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum longitudinal strain rate during early diastole by US 3D;LV Max long strain rate early dias 3D US;;ACTIVE;2.67;2.67 +93613-8;Circumferential strain rate.systole.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum circumferential strain rate during systole by US 3D;LV Max circ strain rate sys 3D US;;ACTIVE;2.67;2.67 +93614-6;Longitudinal strain rate.systole.max;ARat;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum longitudinal strain rate during systole by US 3D;LV Max long strain rate sys 3D US;;ACTIVE;2.67;2.67 +93615-3;Area strain.max;LenRto;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum area strain by US 3D;LV Max area strain 3D US;;ACTIVE;2.67;2.67 +93616-1;Circumferential strain.max;LenRto;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum circumferential strain by US 3D;LV Max circ strain 3D US;;ACTIVE;2.67;2.67 +9361-7;Bartonella quintana Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Bartonella quintana IgM Ab [Titer] in Serum;B quintana IgM Titr Ser;;ACTIVE;1.0i;2.73 +93617-9;Longitudinal strain.max;LenRto;Pt;Heart.ventricle.left;Qn;US.3D;CARD.US;2;Left ventricular Maximum longitudinal strain by US 3D;LV Max long strain 3D US;;ACTIVE;2.67;2.67 +93618-7;Regurgitant volume;Vol;Pt;Tricuspid valve;Qn;US.doppler+Calculated by PISA method;CARD.US;2;Tricuspid valve Regurgitant volume by US.doppler+Calculated by PISA method;TV Reg vol PISA;;ACTIVE;2.67;2.67 +93619-5;Blood flow reversal.systolic;Find;Pt;Hepatic vein;Ord;US.doppler;CARD.US;2;Hepatic vein Systolic flow reversal by US.doppler;Hep v Sys flow reversal DOP;;ACTIVE;2.67;2.67 +93620-3;Regurgitant blood velocity-time integral;Len;Pt;Tricuspid valve;Qn;US.doppler;CARD.US;2;Tricuspid valve Regurgitant blood velocity-time integral by US.doppler;TV Regurg bld vel VTI DOP;;ACTIVE;2.67;2.67 +93621-1;Regurgitant orifice area;Area;Pt;Tricuspid valve;Qn;US.doppler.color;CARD.US;2;Tricuspid valve Regurgitant orifice area by US.doppler.color;TV ROA DOP.color;;ACTIVE;2.67;2.67 +93622-9;Systolic time;Time;Pt;Heart.ventricle.right;Qn;US.doppler;CARD.US;2;Right ventricular Systolic time by US.doppler;RV Sys time DOP;;ACTIVE;2.67;2.67 +93623-7;Blood flow reversal.diastolic;Find;Pt;Pulmonary artery.main;Ord;US.doppler;CARD.US;2;Main pulmonary artery Diastolic flow reversal by US.doppler;MPA Dia flow reversal DOP;;ACTIVE;2.67;2.67 +93624-5;Pressure gradient.early diastole.max;PressDiff;Pt;Pulmonic valve;Qn;US.doppler;CARD.US;2;Pulmonic valve Pressure gradient.early diastole.max by US.doppler;PV Pres grad.early dias.max DOP;;ACTIVE;2.67;2.67 +9362-5;Bordetella pertussis Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis IgA Ab [Units/volume] in Serum;B pert IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +93625-2;Regurgitant blood flow velocity.early diastole;Vel;Pt;Pulmonary valve;Qn;US.doppler.PW;CARD.US;2;Pulmonary valve Regurgitant blood flow velocity.early diastole by Ultrasound.doppler.PW;Pulm valve Regurg vel.early dia DOP.PW;;ACTIVE;2.67;2.67 +93626-0;Blood flow velocity.S2 wave;Vel;Pt;Pulmonary vein;Qn;US.doppler.PW;CARD.US;2;Pulmonary vein Blood flow velocity.S2 wave by Ultrasound.doppler.PW;Pulm v Bld vel.S2 wave DOP.PW;;ACTIVE;2.67;2.67 +93627-8;Blood flow velocity.S1 wave;Vel;Pt;Pulmonary vein;Qn;US.doppler.PW;CARD.US;2;Pulmonary vein Blood flow velocity.S1 wave by Ultrasound.doppler.PW;Pulm v Blood flow vel.S1 wave DOP.PW;;ACTIVE;2.67;2.67 +93628-6;Regurgitant blood velocity-time integral;Len;Pt;Mitral valve;Qn;US.doppler;CARD.US;2;Mitral valve Regurgitant blood velocity-time integral by US.doppler;MV Regurg bld vel VTI DOP;;ACTIVE;2.67;2.67 +93629-4;Blood flow reversal.holodiastolic;Find;Pt;Aorta.abdominal;Ord;US.doppler;CARD.US;2;Aorta abdominal Holodiastolic flow reversal by US.doppler;Ab Ao Holodias flow reversal DOP;;ACTIVE;2.67;2.67 +93630-2;Regurgitant fraction;VFr;Pt;Aortic valve;Qn;US.doppler+Calculated by PISA method;CARD.US;2;Aortic valve Regurgitant fraction by US.doppler+Calculated by PISA method;AV Regurg fraction PISA;;ACTIVE;2.67;2.67 +93631-0;Regurgitant blood velocity-time integral;Len;Pt;Aortic valve;Qn;US.doppler;CARD.US;2;Aortic valve Regurgitant blood velocity-time integral by US.doppler;AV Regurg bld vel VTI DOP;;ACTIVE;2.67;2.67 +93632-8;Velocity-time integral.left ventricular outflow tract/velocity-time integral.aortic valve;LenRto;Pt;Heart;Qn;US.doppler;CARD.US;2;Heart Left ventricular outflow tract/Aortic valve VTI by US.doppler;Hrt LVOT/AV VTI DOP;;ACTIVE;2.67;2.67 +9363-3;Bordetella pertussis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis IgG Ab [Units/volume] in Serum;B pert IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +93633-6;Blood flow velocity.max.left ventricular outflow tract/blood flow.max.aortic valve;VelRto;Pt;Heart;Qn;US.doppler;CARD.US;2;Heart Left ventricular outflow tract/Maximum blood flow aortic valve by US.doppler;Hrt LVOT/Aortic valve DOP;;ACTIVE;2.67;2.67 +93634-4;Collapse;Find;Pt;Vena cava.inferior;Ord;US;CARD.US;2;Inferior vena cava Collapse by US;IVC Collapse US;;ACTIVE;2.67;2.67 +93635-1;End-systolic volume;Vol;Pt;Heart.atrium.right;Qn;US.2D.A4C;CARD.US;2;Right atrial End-systolic volume by US.2D.A4C;RA ES vol A4C;;ACTIVE;2.67;2.67 +93636-9;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D.A2C+Calc by single plane area-length method;CARD.US;2;Left atrial End-systolic volume/Body surface area [Volume/Area] by US.2D.A2C+Calc by single plane area-length method;LA ES vol/BSA A2C SP A-L;;ACTIVE;2.67;2.67 +93637-7;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D.A4C+Calc by single plane area-length method;CARD.US;2;Left atrial End-systolic volume/Body surface area [Volume/Area] by US.2D.A4C+Calc by single plane area-length method;LA ES vol/BSA A4C SP A-L;;ACTIVE;2.67;2.67 +93638-5;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D.A2C+Calc by single plane method of disks;CARD.US;2;Left atrial End-systolic volume/Body surface area [Volume/Area] by US.2D.A2C+Calculated by single plane method of disks;LA ES vol/BSA A2C MOD;;ACTIVE;2.67;2.67 +93639-3;End-systolic volume/Body surface area;ArVol;Pt;Heart.atrium.left;Qn;US.2D.A4C+Calc by single plane method of disks;CARD.US;2;Left atrial End-systolic volume/Body surface area [Volume/Area] by US.2D.A4C+Calculated by single plane method of disks;LA ES vol/BSA A4C MOD;;ACTIVE;2.67;2.67 +93640-1;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D.A2C+Calc by single plane area-length method;CARD.US;2;Left atrial End-systolic volume by US.2D.A2C+Calc by single plane area-length method;LA ES vol A2C SP A-L;;ACTIVE;2.67;2.67 +9364-1;Bordetella pertussis Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Bordetella pertussis IgM Ab [Units/volume] in Serum;B pert IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +93641-9;End-systolic volume;Vol;Pt;Heart.atrium.left;Qn;US.2D.A4C+Calc by single plane area-length method;CARD.US;2;Left atrial End-systolic volume by US.2D.A4C+Calc by single plane area-length method;LA ES vol A4C SP A-L;;ACTIVE;2.67;2.67 +93642-7;Diameter;Len;Pt;Heart.ventricle.right.outflow tract.proximal;Qn;US.2D.PSAX;CARD.US;2;Right ventricular outflow tract proximal Diameter by US.2D.PSAX;Proximal RVOT Diam PSAX;;ACTIVE;2.67;2.67 +93643-5;Major axis.diastole;Len;Pt;Heart.ventricle.right;Qn;US.2D.A4C;CARD.US;2;Right ventricular Major axis diastole [Length] by US.2D.A4C;RV Major axis dias A4C;;ACTIVE;2.67;2.67 +93644-3;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane area-length method;CARD.US;2;Left ventricular Ejection fraction by US.2D.A2C+Calc by single plane area-length method;LV EF A2C SP A-L;;ACTIVE;2.67;2.67 +93645-0;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane area-length method;CARD.US;2;Left ventricular Ejection fraction by US.2D.A4C+Calc by single plane area-length method;LV EF A4C SP A-L;;ACTIVE;2.67;2.67 +93646-8;Ejection fraction;VFr;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane area-length method;CARD.US;2;Left ventricular Ejection fraction by US.2D+Calculated by biplane area-length method;LV EF Biplane area-length;;ACTIVE;2.67;2.67 +93647-6;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane area-length method;CARD.US;2;Left ventricular Cardiac output by US.2D.A2C+Calc by single plane area-length method;LV Output A2C SP A-L;;ACTIVE;2.67;2.67 +93648-4;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane area-length method;CARD.US;2;Left ventricular Cardiac output by US.2D.A4C+Calc by single plane area-length method;LV Output A4C SP A-L;;ACTIVE;2.67;2.67 +93649-2;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane area-length method;CARD.US;2;Left ventricular Cardiac output by US.2D+Calculated by biplane area-length method;LV Output Biplane area-length;;ACTIVE;2.67;2.67 +936-5;Blood product unit identifier;ID;Pt;^BPU;Nom;;BLDBK;1;Blood product unit [Identifier];Bld Unit Id BPU;;ACTIVE;1.0;2.73 +93650-0;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane method of disks;CARD.US;2;Left ventricular Cardiac output by US.2D.A2C+Calculated by single plane method of disks;LV Output A2C MOD;;ACTIVE;2.67;2.67 +93651-8;Cardiac output;VRat;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane method of disks;CARD.US;2;Left ventricular Cardiac output by US.2D.A4C+Calculated by single plane method of disks;LV Output A4C MOD;;ACTIVE;2.67;2.67 +93652-6;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane area-length method;CARD.US;2;Left ventricular Stroke volume by US.2D.A2C+Calc by single plane area-length method;LV SV A2C SP A-L;;ACTIVE;2.67;2.67 +93653-4;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane area-length method;CARD.US;2;Left ventricular Stroke volume by US.2D.A4C+Calc by single plane area-length method;LV SV A4C SP A-L;;ACTIVE;2.67;2.67 +93654-2;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane area-length method;CARD.US;2;Left ventricular Stroke volume by US.2D+Calculated by biplane area-length method;LV SV Biplane area-length;;ACTIVE;2.67;2.67 +93655-9;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane method of disks;CARD.US;2;Left ventricular Stroke volume by US.2D.A2C+Calculated by single plane method of disks;LV SV A2C MOD;;ACTIVE;2.67;2.67 +93656-7;Stroke volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane method of disks;CARD.US;2;Left ventricular Stroke volume by US.2D.A4C+Calculated by single plane method of disks;LV SV A4C MOD;;ACTIVE;2.67;2.67 +93657-5;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane area-length method;CARD.US;2;Left ventricular End-systolic volume by US.2D.A2C+Calc by single plane area-length method;LV ES vol A2C SP A-L;;ACTIVE;2.67;2.67 +9365-8;Clostridioides difficile Ab;Titr;Pt;Ser;Qn;;MICRO;1;Clostridioides difficile Ab [Titer] in Serum;C diff Ab Titr Ser;;ACTIVE;1.0i;2.73 +93658-3;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane area-length method;CARD.US;2;Left ventricular End-systolic volume by US.2D.A4C+Calc by single plane area-length method;LV ES vol A4C SP A-L;;ACTIVE;2.67;2.67 +93659-1;End-systolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane area-length method;CARD.US;2;Left ventricular End-systolic volume by US.2D+Calculated by biplane area-length method;LV ES vol Biplane area-length;;ACTIVE;2.67;2.67 +93660-9;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A2C+Calc by single plane area-length method;CARD.US;2;Left ventricular End-diastolic volume by US.2D.A2C+Calc by single plane area-length method;LV ED vol A2C SP A-L;;ACTIVE;2.67;2.67 +93661-7;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D.A4C+Calc by single plane area-length method;CARD.US;2;Left ventricular End-diastolic volume by US.2D.A4C+Calc by single plane area-length method;LV ED vol A4C SP A-L;;ACTIVE;2.67;2.67 +93662-5;End-diastolic volume;Vol;Pt;Heart.ventricle.left;Qn;US.2D+Calculated by biplane area-length method;CARD.US;2;Left ventricular End-diastolic volume by US.2D+Calculated by biplane area-length method;LV ED vol Biplane area-length;;ACTIVE;2.67;2.67 +93663-3;Sphericity index.end diastole;LenRto;Pt;Heart.ventricle.left;Qn;US;CARD.US;2;Left ventricular Sphericity index.end diastole by US;LV ED sphericity index US;;ACTIVE;2.67;2.67 +93664-1;Pericardial effusion;Find;Pt;Pericardial space;Ord;US;CARD.US;2;Pericardial effusion by US;Pericardial effusion US;;ACTIVE;2.67;2.67 +93665-8;Regurgitant blood flow pressure half-time;Time;Pt;Pulmonary valve;Qn;US.doppler;CARD.US;2;Pulmonary valve Regurgitant blood flow pressure half-time by US.doppler;Pulm valve Regurg PHT DOP;;ACTIVE;2.67;2.67 +9366-6;Arsenic;MCnt;Pt;XXX;Qn;;DRUG/TOX;1;Arsenic [Mass/mass] in Specimen;Arsenic Spec-mCnt;;ACTIVE;1.0i;2.73 +93666-6;Home accessibility modification panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Home accessibility modification panel;Home accessibility mod panel;;ACTIVE;2.67;2.67 +93667-4;WellRx Questionnaire - revised;-;Pt;^Patient;-;WellRx;PANEL.SURVEY.WELLRX;4;WellRx Questionnaire - revised;;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93668-2;Did you or others you live with eat smaller meals or skip meals because you didn't have money for food in the past 2M;Find;2M;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Did you or others you live with eat smaller meals or skip meals because you didn't have money for food in the past 2 months [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93669-0;Are you homeless or worried that you might be in the future;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Are you homeless or worried that you might be in the future [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93670-8;Do you have trouble paying for your gas or electricity bills;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Do you have trouble paying for your gas or electricity bills [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93671-6;Do you have trouble finding or paying for transportation;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Do you have trouble finding or paying for transportation [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93672-4;Do you need daycare, or better daycare, for your kids;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Do you need daycare, or better daycare, for your kids [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93673-2;Are you unemployed or without regular income;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Are you unemployed or without regular income [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +9367-4;Borate;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Borate [Mass/volume] in Specimen;Borate Spec-mCnc;;ACTIVE;1.0i;2.7 +93674-0;Do you need help finding a better job;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Do you need help finding a better job [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93675-7;Do you need help getting more education;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Do you need help getting more education [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93676-5;Are you concerned about someone in your home using drugs or alcohol;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Are you concerned about someone in your home using drugs or alcohol [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93677-3;Do you need help with legal issues;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Do you need help with legal issues [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93678-1;Have you been at the emergency department more than twice in the last 6Mo;Find;6Mo;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Have you been at the emergency department more than twice in the last 6 months [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93679-9;Emergency department visits in last 6Mo;Num;6Mo;^Patient;Qn;;H&P.HX;2;Number of visits to the emergency department in last 6 months;Visits to ED in last 6Mo;;ACTIVE;2.67;2.7 +93680-7;Hospitalized in the last 6Mo;Find;6Mo;^Patient;Ord;;SURVEY.WELLRX;4;Hospitalized in the last 6 months;;;ACTIVE;2.67;2.67 +93681-5;Number of times hospitalized in last 6Mo;Num;6Mo;^Patient;Qn;;SURVEY.WELLRX;4;Number of times hospitalized in last 6 months;;;ACTIVE;2.67;2.67 +9368-2;Boron;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Boron [Mass/volume] in Specimen;Boron Spec-mCnc;;ACTIVE;1.0i;2.7 +93682-3;Do you feel unsafe in your daily life;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Do you feel unsafe in your daily life [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93683-1;Is anyone in your home threatening or abusing you;Find;Pt;^Patient;Ord;WellRx;SURVEY.WELLRX;4;Is anyone in your home threatening or abusing you [WellRx];;©2016 Journal of the American Board of Family Medicine Used with permission;ACTIVE;2.67;2.67 +93684-9;Ammonia;SCnc;Pt;BldA;Qn;;CHEM;1;Ammonia [Moles/volume] in Arterial blood;Ammonia BldA-sCnc;;ACTIVE;2.67;2.67 +93685-6;Gas & CO & electrolytes panel;-;Pt;BldA;Qn;;PANEL.CHEM;1;Gas and Carbon monoxide and Electrolytes panel - Arterial blood;Gas + CO + Electrolytes Pnl BldA;;ACTIVE;2.67;2.67 +93686-4;Psychosine;SCnc;Pt;CSF;Qn;;CHEM;1;Psychosine [Moles/volume] in Cerebral spinal fluid;Psychosine CSF-sCnc;;ACTIVE;2.67;2.67 +93687-2;Psychosine;SCnt;Pt;RBC;Qn;;CHEM;1;Psychosine [Moles/mass] in Red Blood Cells;Psychosine RBC-sCnt;;ACTIVE;2.67;2.67 +93688-0;Psychosine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Psychosine [Moles/volume] in DBS;Psychosine DBS-sCnc;;ACTIVE;2.67;2.67 +93689-8;Thrombospondin type I domain-containing 7A Ab.IgG;Titr;Pt;Ser/Plas;Qn;CBA IFA;SERO;1;THSD7A IgG Ab [Titer] in Serum or Plasma by Cell binding immunofluorescent assay;THSD7A IgG Titr SerPl CBA IFA;;ACTIVE;2.67;2.69 +9369-0;Camphor;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Camphor [Mass/volume] in Blood;Camphor Bld-mCnc;;ACTIVE;1.0i;2.42 +93690-6;BRAF gene.p.Val600 mutations;Prid;Pt;Plas.cfDNA;Nom;Molgen;MOLPATH.MUT;1;BRAF gene V600 mutations [Identifier] in Plasma cell-free DNA by Molecular genetics method Nominal;BRAF p.V600 mutations Plas.cfDNA;;ACTIVE;2.67;2.67 +93691-4;Nonalcoholic steatohepatitis & fibrosis panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Nonalcoholic steatohepatitis and fibrosis panel - Serum or Plasma;NASH + fibrosis Pnl SerPl;;ACTIVE;2.67;2.67 +93692-2;Nonalcoholic steatohepatitis score;Score;Pt;Ser/Plas;Qn;;CHEM;1;Nonalcoholic steatohepatitis score in Serum or Plasma;NASH score SerPl;;ACTIVE;2.67;2.67 +93693-0;Nonalcoholic steatohepatitis grade;Find;Pt;Ser/Plas;Ord;;CHEM;1;Nonalcoholic steatohepatitis grade in Serum or Plasma Qualitative;NASH grade SerPl Ql;;ACTIVE;2.67;2.67 +93694-8;Nonalcoholic steatohepatitis interpretation;Imp;Pt;Ser/Plas;Ord;;CHEM;1;Nonalcoholic steatohepatitis interpretation in Serum or Plasma Qualitative;NASH interpretation SerPl-Imp;;ACTIVE;2.67;2.67 +93695-5;Liver steatosis score;Score;Pt;Ser/Plas;Qn;;CHEM;1;Liver steatosis score in Serum or Plasma;Liver steatosis score SerPl;;ACTIVE;2.67;2.67 +93696-3;Liver steatosis grade;Find;Pt;Ser/Plas;Ord;;CHEM;1;Liver steatosis grade in Serum or Plasma Qualitative;Liver steatosis grade SerPl Ql;;ACTIVE;2.67;2.67 +93697-1;Liver steatosis interpretation;Imp;Pt;Ser/Plas;Ord;;CHEM;1;Liver steatosis interpretation in Serum or Plasma Qualitative;Liver steatosis interp SerPl-Imp;;ACTIVE;2.67;2.67 +93698-9;Gram negative bacterial resistance panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Gram negative bacterial resistance panel by Molecular genetics method;GN resist Pnl Islt/Spm;;ACTIVE;2.67;2.67 +93699-7;Bacterial beta-lactam resistance AmpC blaCMY-2 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance AmpC blaCMY-2 gene [Presence] by Molecular method;AmpC blaCMY-2 gene Islt/Spm Ql;;ACTIVE;2.67;2.67 +93700-3;Bacterial beta-lactam resistance AmpC blaDHA gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance AmpC blaDHA gene [Presence] by Molecular method;AmpC blaDHA gene Islt/Spm Ql;;ACTIVE;2.67;2.67 +93701-1;Bacterial colistin resistance mcr-2 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Colistin resistance mcr-2 gene [Presence] by Molecular method;Colistin res mcr-2 Islt/Spm Ql;;ACTIVE;2.67;2.67 +93702-9;Platelet aggregation.ristocetin induced^15 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --15 ug/mL;PA Rist 15 ug/mL PRP;;ACTIVE;2.67;2.67 +93703-7;Palmitoyl protein thioesterase 1 & Tripeptidyl peptidase 1 panel;-;Pt;Fibroblasts;-;;PANEL.CHEM;1;Palmitoyl protein thioesterase 1 and Tripeptidyl peptidase 1 panel - Fibroblast;PPT1 + TPP1 Pnl Fib;;ACTIVE;2.67;2.67 +93704-5;Palmitoyl protein thioesterase 1 & Tripeptidyl peptidase 1 panel;-;Pt;WBC;-;;PANEL.CHEM;1;Palmitoyl protein thioesterase 1 and Tripeptidyl peptidase 1 panel - Leukocytes;PPT1 + TPP1 Pnl WBC;;ACTIVE;2.67;2.67 +93705-2;Ethyl sulfate & Ethyl glucuronide panel;-;Pt;Urine;-;;PANEL.DRUG/TOX;1;Ethyl sulfate and Ethyl glucuronide panel - Urine;ETG + EtS Pnl Ur;;ACTIVE;2.67;2.67 +93706-0;Ethyl sulfate+Ethyl glucuronide;MCnc;Pt;Urine;Qn;Screen;CHEM;1;Ethyl sulfate+Ethyl glucuronide [Mass/volume] in Urine by Screen method;ETG EtS Ur Scn-mCnc;;ACTIVE;2.67;2.67 +93707-8;Porphyrin fractions panel;-;Pt;Urine;-;;PANEL.CHEM;1;Porphyrin fractions panel - Urine;Porphyrin Fract Pnl Ur;;ACTIVE;2.67;2.7 +9370-8;Carbon tetrachloride;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Carbon tetrachloride [Mass/volume] in Blood;Deprecated Carbon Tet Bld-mCnc;;DEPRECATED;1.0i;2.7 +93708-6;Heptacarboxylporphyrin I/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Heptacarboxylporphyrin I/Creatinine [Molar ratio] in Urine;Hepta-CP I/Creat Ur-sRto;;ACTIVE;2.67;2.67 +93709-4;Hexacarboxylporphyrin I/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin I/Creatinine [Molar ratio] in Urine;Hexa-CP I/Creat Ur-sRto;;ACTIVE;2.67;2.67 +93710-2;Pentacarboxylporphyrin I/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Pentacarboxylporphyrin I/Creatinine [Molar ratio] in Urine;Penta-CPI/Creat Ur-sRto;;ACTIVE;2.67;2.67 +93711-0;Epstein Barr virus Ab panel;-;Pt;Ser^Donor;-;;PANEL.MICRO;1;Epstein Barr virus Ab panel - Serum from Donor;EBV Ab Pnl Ser Donr;;ACTIVE;2.67;2.67 +93712-8;Epstein Barr virus nuclear Ab;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Epstein Barr virus nuclear Ab [Presence] in Serum from Donor by Immunoassay;EBV NA Ab Ser Donr Ql IA;;ACTIVE;2.67;2.67 +93713-6;Epstein Barr virus capsid Ab.IgG;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Epstein Barr virus capsid IgG Ab [Presence] in Serum from Donor by Immunoassay;EBV VCA IgG Ser Donr Ql IA;;ACTIVE;2.67;2.67 +93714-4;Epstein Barr virus capsid Ab.IgM;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Epstein Barr virus capsid IgM Ab [Presence] in Serum from Donor by Immunoassay;EBV VCA IgM Ser Donr Ql IA;;ACTIVE;2.67;2.67 +93715-1;Francisella tularensis Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Francisella tularensis IgG and IgM panel - Serum;F. tularensis IgG+ IgM Pnl Ser;;ACTIVE;2.67;2.67 +9371-6;Chlorpyrifos;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chlorpyrifos [Mass/volume] in Blood;Chlorpyrifos Bld-mCnc;;ACTIVE;1.0i;2.73 +93716-9;Francisella tularensis Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Francisella tularensis IgM Ab [Presence] in Serum by Immunoassay;F tular IgM Ser Ql IA;;ACTIVE;2.67;2.67 +93717-7;Francisella tularensis Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Francisella tularensis IgG Ab [Presence] in Serum by Immunoassay;F tular IgG Ser Ql IA;;ACTIVE;2.67;2.67 +93718-5;Francisella tularensis Ab.IgG & IgM;Imp;Pt;Ser;Nom;;MICRO;1;Francisella tularensis IgG and IgM [Interpretation] in Serum;F tular IgG+IgM Ser-Imp;;ACTIVE;2.67;2.67 +93719-3;traMADol;PrThr;Pt;Meconium;Ord;Screen;DRUG/TOX;1;traMADol [Presence] in Meconium by Screen method;traMADol Mec Ql Scn;;ACTIVE;2.67;2.67 +93720-1;traMADol;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;traMADol [Mass/mass] in Meconium by Confirmatory method;traMADol Mec Cfm-mCnt;;ACTIVE;2.67;2.67 +93721-9;O-Nortramadol;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;O-nortramadol [Mass/mass] in Meconium by Confirmatory method;O-nortramadol Mec Cfm-mCnt;;ACTIVE;2.67;2.67 +93722-7;N-Nortramadol;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;N-nortramadol [Mass/mass] in Meconium by Confirmatory method;N-nortramadol Mec Cfm-mCnt;;ACTIVE;2.67;2.67 +93723-5;Indexing - drug interactions;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Indexing - drug interactions;FDA label Index - drug interactions;;ACTIVE;2.67;2.67 +9372-4;Cotinine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cotinine [Mass/volume] in Specimen;Cotinine Spec-mCnc;;ACTIVE;1.0i;2.73 +93724-3;Keratan sulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Keratan sulfate [Mass/volume] in Serum or Plasma;Keratan Sulfate SerPl-mCnc;;ACTIVE;2.67;2.67 +93725-0;Heparan sulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Heparan sulfate [Mass/volume] in Serum or Plasma;Heparan sulfate SerPl-mCnc;;ACTIVE;2.67;2.67 +93726-8;Dermatan sulfate & heparan sulfate & keratan sulfate panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Dermatan sulfate and heparan sulfate and keratan sulfate panel - Serum or Plasma;MPS panel SerPl;;ACTIVE;2.67;2.67 +93727-6;Insulin^post meal;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Insulin [Moles/volume] in Serum or Plasma --post meal;Insulin p meal SerPl-sCnc;;ACTIVE;2.67;2.67 +93728-4;Copper;SCnc;Pt;Dial fld;Qn;;CHEM;1;Copper [Moles/volume] in Dialysis fluid;Copper Dial fld-sCnc;;ACTIVE;2.67;2.67 +93729-2;Beta-2-Microglobulin/Creatinine;Ratio;24H;Urine;Qn;;CHEM;1;Beta-2-Microglobulin/Creatinine [Ratio] in 24 hour Urine;B2 Microglob/Creat 24h Ur-Rto;;ACTIVE;2.67;2.67 +937-3;Bombay Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated Bombay Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated Bombay Ab SerPl BPU Ql;;DEPRECATED;1.0;2.4 +93730-0;Testosterone;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Testosterone [Moles/volume] in Amniotic fluid;Testost Amn-sCnc;;ACTIVE;2.67;2.67 +93731-8;Androstenedione;SCnc;Pt;Amnio fld;Qn;;CHEM;1;Androstenedione [Moles/volume] in Amniotic fluid;Androst Amn-sCnc;;ACTIVE;2.67;2.67 +9373-2;Methanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Deprecated Methanol [Mass/volume] in Blood;Deprecated Methanol Bld-mCnc;;DEPRECATED;1.0i;2.7 +93732-6;IgE;ACnc;Pt;Tear;Qn;;CHEM;1;IgE [Units/volume] in Tear;IgE Tear-aCnc;;ACTIVE;2.67;2.68 +93733-4;Creatinine;MRat;5H;Urine;Qn;;CHEM;1;Creatinine [Mass/time] in 5 hour Urine;Creat 5h Ur-mRate;;ACTIVE;2.67;2.67 +93734-2;Creatinine;SRat;5H;Urine;Qn;;CHEM;1;Creatinine [Moles/time] in 5 hour Urine;Creat 5h Ur-sRate;;ACTIVE;2.67;2.67 +93735-9;Creatinine;SCnc;5H;Urine;Qn;;CHEM;1;Creatinine [Moles/volume] in 5 hour Urine;Creat 5h Ur-sCnc;;ACTIVE;2.67;2.67 +93736-7;Creatinine panel;-;5H;Urine;-;;PANEL.CHEM;1;Creatinine panel - 5 hour Urine;Creat Pnl Ur;;ACTIVE;2.67;2.67 +93737-5;Brassica oleracea var gongylodes Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;German turnip IgE Ab [Units/volume] in Serum;German turnip IgE Qn;;ACTIVE;2.67;2.67 +93738-3;Brassica oleracea var botrytis cooked Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cooked cauliflower IgE Ab [Units/volume] in Serum;Cooked cauliflower IgE Qn;;ACTIVE;2.67;2.67 +93739-1;Brassica oleracea var capitata f rubra Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Red cabbage IgE Ab [Units/volume] in Serum;Red cabbage IgE Qn;;ACTIVE;2.67;2.67 +9374-0;Character;Aper;Pt;CSF;Nom;;SPEC;1;Character of Cerebral spinal fluid;Character CSF;;ACTIVE;1.0i;2.73 +93740-9;Allium schoenoprasum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chives IgE Ab [Units/volume] in Serum;Chives IgE Qn;;ACTIVE;2.67;2.67 +93741-7;Melissa officinalis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Balm IgE Ab [Units/volume] in Serum;Balm IgE Qn;;ACTIVE;2.67;2.67 +93742-5;HTLV I & II Ab band pattern;Imp;Pt;CSF;Nom;Line blot;MICRO;1;HTLV I and II Ab band pattern [Interpretation] in Cerebral spinal fluid by Line blot;HTLV I+II Ab Patrn CSF Line blot-Imp;;ACTIVE;2.67;2.67 +93743-3;HTLV I & II Ab.IgG band;Type;Pt;CSF;Nom;Line blot;MICRO;1;HTLV I and II IgG band [Type] in Cerebral spinal fluid by Line blot;HTLV I + II ab band CSF Line blot;;ACTIVE;2.67;2.67 +93744-1;HTLV I & II Ab.IgG panel;-;Pt;CSF;-;;PANEL.MICRO;1;HTLV I and II IgG panel - Cerebral spinal fluid;HTLV I+II IgG Pnl CSF;;ACTIVE;2.67;2.67 +93745-8;HTLV I+II Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;MICRO;1;HTLV I+II IgG Ab [Presence] in Cerebral spinal fluid by Line blot;HTLV I+II IgG CSF Ql Line blot;;ACTIVE;2.67;2.67 +93746-6;Protein catabolic rate;MRat;24H;Urine;Qn;;CHEM;1;Protein catabolic rate based on 24 hour Urine [Calculated];Protein catabolic rate 24h Ur-mRate;;ACTIVE;2.67;2.67 +93747-4;Parainfluenza virus 1+2+3+4 Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Parainfluenza virus 1+2+3+4 IgG Ab [Presence] in Serum by Immunoassay;HPIV 1+2+3+4 IgG Ser Ql IA;;ACTIVE;2.67;2.67 +93748-2;Fibrin monomer;MCnc;Pt;PPP;Qn;IA;COAG;1;Fibrin monomer [Mass/volume] in Platelet poor plasma by Immunoassay;Fibrin Monomer PPP IA-mCnc;;ACTIVE;2.67;2.67 +93749-0;Mumps virus N gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mumps virus N gene [Cycle Threshold #] in Specimen by NAA with probe detection;MuV N gene Ct Spec Qn NAA+probe;;ACTIVE;2.67;2.69 +93750-8;Mumps virus RNA & N gene panel;-;Pt;XXX;-;;PANEL.MICRO;1;Mumps virus RNA and N gene panel - Specimen;MuV RNA and N gene Pnl Spec;;ACTIVE;2.67;2.69 +93751-6;Atypical porcine pestivirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Atypical porcine pestivirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;APPV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.67;2.69 +93752-4;Atypical porcine pestivirus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Atypical porcine pestivirus RNA [#/volume] (viral load) in Specimen by NAA with probe detection;APPV RNA # Spec NAA+probe;;ACTIVE;2.67;2.69 +93753-2;Porcine cytomegalovirus DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine cytomegalovirus DNA [Cycle Threshold #] in Specimen by NAA with probe detection;PCMV DNA Ct Spec Qn NAA+probe;;ACTIVE;2.67;2.69 +93754-0;Encephalomyocarditis virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Encephalomyocarditis virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;EMCV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.67;2.69 +93755-7;Porcine circovirus type 3 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Porcine circovirus type 3 DNA [Presence] in Specimen by NAA with probe detection;PCV3 DNA Spec Ql NAA+probe;;ACTIVE;2.67;2.69 +93756-5;Mycoplasma hyorhinis Ab.IgG/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma hyorhinis IgG Ab/Positive control in Serum by Immunoassay;M hyorhinis IgG/Pos cntrl Ser IA;;ACTIVE;2.67;2.67 +9375-7;Glucose^2.5H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.5 hours post 100 g glucose PO;Glucose 2.5h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0i;2.7 +93757-3;Salmonella choleraesuis+infantis+typhimurium Ab/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Salmonella choleraesuis+infantis+typhimurium Ab/Positive control in Specimen by Immunoassay;S chol+inf+typhimur Ab/Pos cntrl Spec IA;;ACTIVE;2.67;2.69 +93758-1;Erysipelothrix sp;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Erysipelothrix sp [Presence] in Tissue by Immune stain;Erysipelothrix sp Tiss Ql ImStn;;ACTIVE;2.67;2.67 +93759-9;Influenza virus A PB2 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A PB2 gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV PB2 gene Islt-Seq;;ACTIVE;2.67;2.67 +93760-7;Influenza virus A PB1 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A PB1 gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV PB1 gene Islt-Seq;;ACTIVE;2.67;2.67 +93761-5;Influenza virus A PA gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A PA gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV PA gene Islt-Seq;;ACTIVE;2.67;2.67 +93762-3;Influenza virus A NP gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A NP gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV NP gene Islt-Seq;;ACTIVE;2.67;2.67 +93763-1;Influenza virus A NS1 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Influenza virus A NS1 gene [Nucleotide sequence] in Isolate by Sequencing;FLUAV NS1 gene Islt-Seq;;ACTIVE;2.67;2.67 +93764-9;Porcine astrovirus type 3 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Porcine astrovirus type 3 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;PoAstV3 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.67;2.69 +9376-5;Glucose^3.5H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3.5 hours post 100 g glucose PO;Glucose 3.5h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0i;2.7 +93765-6;Trimethylamine N-oxide;Sub;Pt;Ser;Qn;;CHEM;1;Trimethylamine N-oxide [Molar amount] in Serum;TMAO sub Ser Qn;;ACTIVE;2.67;2.67 +93766-4;Cryptococcus sp Ag;Titr;Pt;Urine;Qn;IA.rapid;MICRO;1;Cryptococcus sp Ag [Titer] in Urine by Rapid immunoassay;Cryptoc Ag Titr Ur IA.rapid;;ACTIVE;2.67;2.67 +93767-2;Eravacycline;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Eravacycline [Susceptibility] by Gradient strip;Eravacycline Islt Grad strip;;ACTIVE;2.67;2.67 +93768-0;Acarboxyprothrombin;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Acarboxyprothrombin [Units/volume] in Serum or Plasma;Acarboxyprothrombin SerPl-aCnc;;ACTIVE;2.67;2.68 +93769-8;Choriogonadotropin.intact+Beta subunit;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma;HCG Intact+B SerPl-mCnc;;ACTIVE;2.67;2.7 +93770-6;Ceramide trihexoside;SRto;Pt;Urine;Qn;;CHEM;1;Ceramide trihexoside [Molar ratio] in Urine;Ceramide Trihexoside Ur-sRto;;ACTIVE;2.67;2.67 +93771-4;Calprotectin;MCnc;Pt;Synv fld;Qn;;CHEM;1;Calprotectin [Mass/volume] in Synovial fluid;Calprotectin Snv-mCnc;;ACTIVE;2.67;2.67 +93772-2;4-hydroxyglutamate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;4-hydroxyglutamate/Creatinine [Molar ratio] in Urine;4OHGlu/Creat Ur-sRto;;ACTIVE;2.67;2.67 +9377-3;Glucose^4.5H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4.5 hours post 100 g glucose PO;Glucose 4.5h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0i;2.7 +93773-0;11-Deoxycortisol;SCnc;Pt;Saliva;Qn;;CHEM;1;11-Deoxycortisol [Moles/volume] in Saliva (oral fluid);11DC Sal-sCnc;;ACTIVE;2.67;2.67 +93774-8;Trans-cinnamoylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Trans-cinnamoylglycine/Creatinine [Molar ratio] in Urine;tr-Cinnamoylgly/Creat Ur-sRto;;ACTIVE;2.67;2.67 +93775-5;2-Octenoate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Octenoate/Creatinine [Molar ratio] in Urine;2-Octenoate/Creat Ur-sRto;;ACTIVE;2.67;2.67 +93776-3;Babesia duncani Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia duncani IgG Ab [Titer] in Serum by Immunofluorescence;B duncani IgG Titr Ser IF;;ACTIVE;2.67;2.67 +93777-1;Human papilloma virus 16+18 E6+E7 mRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 16+18 E6+E7 mRNA [Presence] in Tissue by Probe;HPV16+18 E6+E7 mRNA Tiss Ql Probe;;ACTIVE;2.67;2.67 +93778-9;Human papilloma virus 6+11 E6+E7 mRNA;PrThr;Pt;Tiss;Ord;Probe;MICRO;1;Human papilloma virus 6+11 E6+E7 mRNA [Presence] in Tissue by Probe;HPV6+11 E6+E7 mRNA Tiss Ql Probe;;ACTIVE;2.67;2.67 +93779-7;Large B-cell lymphoma and cell of origin;Type;Pt;Tiss;Nom;;PATH;1;Large B-cell lymphoma and cell of origin [Type] in Tissue;Lg B-cell lymph+COO Tiss;;ACTIVE;2.67;2.67 +93780-5;Primary mediastinal large B-cell lymphoma;Likelihood;Pt;Tiss;Qn;;PATH;1;Primary mediastinal large B-cell lymphoma [Likelihood] in Tissue;Prim Med Lg B-cell lymph Tiss;;ACTIVE;2.67;2.67 +9378-1;Glucose^5.5H post 100 g glucose PO;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5.5 hours post 100 g glucose PO;Glucose 5.5h p 100 g Glc PO SerPl-mCnc;;ACTIVE;1.0i;2.7 +93781-3;Diffuse large B-cell lymphoma.activated B-cell subtype;Likelihood;Pt;Tiss;Qn;;PATH;1;Diffuse large B-cell lymphoma.activated B-cell subtype [Likelihood] in Tissue;Diff Lg B-cell Lymph.ABC Tiss;;ACTIVE;2.67;2.67 +93782-1;Large B-cell lymphoma;Type;Pt;Tiss;Nom;;PATH;1;Large B-cell lymphoma [Type] in Tissue;Lg B-cell lymph Tiss;;ACTIVE;2.67;2.67 +93783-9;Diffuse large B-cell lymphoma cell of origin;Type;Pt;Tiss;Nom;;PATH;1;Diffuse large B-cell lymphoma cell of origin [Type] in Tissue;Diff Lg B-cell lymph COO Tiss;;ACTIVE;2.67;2.67 +93784-7;Diffuse large B-Cell lymphoma cell of origin subclassification panel;-;Pt;Tiss;-;;PANEL.PATH;1;Diffuse large B-Cell lymphoma cell of origin subclassification panel - Tissue;Diff lg B-cell Lymph COO Pnl Tiss;;ACTIVE;2.67;2.67 +93785-4;Large B-cell lymphoma classification panel;-;Pt;Tiss;-;;PANEL.PATH;1;Large B-cell lymphoma classification panel - Tissue;Lg B-cell Lymph Pnl Tiss;;ACTIVE;2.67;2.67 +93786-2;Varicella zoster virus Ab.IgM+total;PrThr;Pt;CSF;Ord;;MICRO;1;Varicella zoster virus Ab.IgM+total [Presence] in Cerebral spinal fluid;VZV Ab.IgM+total CSF Ql;;ACTIVE;2.67;2.67 +93787-0;Lymphocytic choriomeningitis virus Ab.IgG+IgM;PrThr;Pt;CSF;Ord;;MICRO;1;Lymphocytic choriomeningitis virus IgG+IgM Ab [Presence] in Cerebral spinal fluid;LCMV IgG+IgM CSF Ql;;ACTIVE;2.67;2.67 +93788-8;F5 gene HR2 haplotype;Geno;Pt;Bld;Nom;Molgen;MOLPATH;1;F5 gene HR2 haplotype [Genotype] in Blood by Molecular genetics method Nominal;F5 HR2 Geno Bld;;ACTIVE;2.67;2.68 +93789-6;Time to microorganism growth detection;Time;*;Specimen;Qn;;MICRO;1;Time to microorganism growth detection in Specimen;Micro Detect Tm Spec;;ACTIVE;2.67;2.67 +93790-4;Delafloxacin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Delafloxacin [Susceptibility] by Gradient strip;DLX Islt Grad strip;;ACTIVE;2.67;2.67 +93791-2;Glucose;MCnc;Stdy^mean;Ser/Plas;Qn;;CHEM;1;Glucose [Mass/volume] mean in Serum or Plasma;Glucose Mean SerPl-mCnc;;ACTIVE;2.67;2.67 +93792-0;Insulin sensitivity index;Ratio;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Insulin sensitivity index in Serum or Plasma by calculation;Ins Sens Index SerPl Calc-Rto;;ACTIVE;2.67;2.67 +93793-8;Insulin;ACnc;Stdy^mean;Ser/Plas;Qn;;CHEM;1;Insulin [Units/volume] mean in Serum or Plasma;Insulin Mean SerPl-aCnc;;ACTIVE;2.67;2.67 +93794-6;Glucose tolerance & insulin sensitivity 2H panel;-;-;Ser/Plas;-;;PANEL.CHAL;1;Glucose tolerance and insulin sensitivity 2 hour panel - Serum or Plasma;GTT ISI 2h Pnl SerPl;;ACTIVE;2.67;2.67 +93795-3;NOP56 gene.GGCCTG repeats;PrThr;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.NUCREPEAT;1;NOP56 gene GGCCTG repeats [Presence] in Blood or Tissue by Molecular genetics method;NOP56 GGCCTG Rpt Bld/T Ql;;ACTIVE;2.67;2.67 +93796-1;MYCN gene amplification;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH;1;MYCN gene amplification in Blood or Tissue by FISH;MYCN amplification Bld/T FISH;;ACTIVE;2.67;2.68 +93797-9;MYCN gene copy number/Chromosome 2 copy number;NRto;Pt;Tiss;Qn;FISH;MOLPATH;1;MYCN gene copy number/Chromosome 2 copy number in Tissue by FISH;MYCN copy num/Chr 2 copy num Tiss FISH;;ACTIVE;2.67;2.67 +93798-7;MYCN gene copy number/nucleus;EntNum;Pt;Tiss;Qn;FISH;MOLPATH;1;MYCN gene copy number/nucleus in Tissue by FISH;MYCN copy num/nucleus EntNum Tiss FISH;;ACTIVE;2.67;2.67 +9379-9;Glutathione reductase;MCnc;Pt;RBC;Ord;;CHEM;1;Deprecated Glutathione reductase;Deprecated GR RBC Ql;;DEPRECATED;1.0i;2.36 +93799-5;Chromosome 2 copy number/nucleus;EntNum;Pt;Tiss;Qn;FISH;MOLPATH;1;Chromosome 2 copy number/nucleus in Tissue by FISH;Chr 2 copy num/nucleus EntNum Tiss FISH;;ACTIVE;2.67;2.67 +93800-1;1p chromosome deletion/1q chromosome deletion;NRto;Pt;Tiss;Qn;FISH;MOLPATH.DELDUP;1;1p/1q chromosome deletion [# Ratio] in Tissue by FISH;1p/1q Chrom Del Tiss FISH;;ACTIVE;2.67;2.67 +93801-9;Chromosome 1 polysomy;PrThr;Pt;Tiss;Ord;FISH;MOLPATH;1;Chromosome 1 polysomy [Presence] in Tissue by FISH;Chr 1 polysomy Tiss Ql FISH;;ACTIVE;2.67;2.67 +93802-7;19q chromosome deletion/19p chromosome deletion;NRto;Pt;Tiss;Qn;FISH;MOLPATH.DELDUP;1;19q/19p chromosome deletion [# Ratio] in Tissue by FISH;19q/19p Chrom Del Tiss FISH;;ACTIVE;2.67;2.67 +93803-5;Chromosome 19 polysomy;PrThr;Pt;Tiss;Ord;FISH;MOLPATH;1;Chromosome 19 polysomy [Presence] in Tissue by FISH;Chr 19 polysomy Tiss Ql FISH;;ACTIVE;2.67;2.67 +93804-3;Chromosome 12 copy number/nucleus;EntNum;Pt;Tiss;Qn;FISH;MOLPATH;1;Chromosome 12 copy number/nucleus in Tissue by FISH;Chr 12 copy num/nucleus EntNum Tiss FISH;;ACTIVE;2.67;2.67 +93805-0;MDM2 gene copy number/nucleus;EntNum;Pt;Tiss;Qn;FISH;MOLPATH;1;MDM2 gene copy number/nucleus in Tissue by FISH;MDM2 copy num/nucleus EntNum Tiss FISH;;ACTIVE;2.67;2.67 +93806-8;EWSR1 gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;EWSR1 gene rearrangements in Tissue by FISH;EWSR1 gene Rear Tiss FISH;;ACTIVE;2.67;2.67 +9380-7;Heptacarboxylporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/time] in unspecified time Stool;Hepta-CP ?Tm Stl-mRate;;ACTIVE;1.0i;2.73 +93807-6;FOXO1 gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;FOXO1 gene rearrangements in Tissue by FISH;FOXO1 gene Rear Tiss FISH;;ACTIVE;2.67;2.67 +93808-4;MDM2 gene amplification;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;MDM2 gene amplification in Tissue by FISH;MDM2 amplification Tiss FISH;;ACTIVE;2.67;2.67 +93809-2;MDM2 gene copy number/Chromosome 12 copy number;NRto;Pt;Tiss;Qn;FISH;MOLPATH;1;MDM2 gene copy number/Chromosome 12 copy number in Tissue by FISH;MDM2 copy num/Chr 12 copy num Tiss FISH;;ACTIVE;2.67;2.67 +938-1;Bombay Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated Bombay Ab [Presence] on Red Blood Cells from donor;Deprecated Bombay Ab SerPl Donr Ql;;DEPRECATED;1.0;2.4 +93810-0;SS18 gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;SS18 gene rearrangements in Tissue by FISH;SS18 gene Rear Tiss FISH;;ACTIVE;2.67;2.67 +93811-8;F9 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F9 gene full mutation analysis in Blood or Tissue by Sequencing;F9 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +93812-6;1,3 beta glucan;PrThr;Pt;Ser;Ord;;MICRO;1;1,3 beta glucan [Presence] in Serum;1,3 beta glucan Ser Ql;;ACTIVE;2.67;2.67 +93813-4;NTRK1 gene & NTRK2 gene & NTRK3 gene rearrangements;Find;Pt;Tiss;Doc;Molgen;MOLPATH.PHARMG;1;NTRK1, NTRK2 and NTRK3 gene rearrangements in Tissue by Molecular genetics method;NTRK1+NTRK2+NTRK3 rearr Tiss;;ACTIVE;2.67;2.67 +93814-2;SERPINC1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;SERPINC1 gene full mutation analysis in Blood or Tissue by Sequencing;SERPINC1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +9381-5;Pyridinoline;MRat;2H;Urine;Qn;;CHEM;1;Pyridinoline [Mass/time] in 2 hour Urine;PYD 2h Ur-mRate;;DISCOURAGED;1.0i;2.7 +93815-9;PROC gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;PROC gene full mutation analysis in Blood or Tissue by Sequencing;PROC Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +93816-7;Swimming distance;Len;XXX;^Patient;Qn;;CLIN;2;Swimming distance unspecified time;Swim distance ?Tm;;ACTIVE;2.67;2.67 +93817-5;Running distance;Len;XXX;^Patient;Qn;;CLIN;2;Running distance unspecified time;Run distance ?Tm;;ACTIVE;2.67;2.67 +93818-3;Cycling distance;Len;XXX;^Patient;Qn;;CLIN;2;Cycling distance unspecified time;Cycle distance ?Tm;;ACTIVE;2.67;2.67 +93819-1;Calories burned^during activity;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --during activity;Calories burned dur activity ?Tm;;ACTIVE;2.67;2.67 +93820-9;Calories burned^during weight training;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --during weight training;Calories burned dur wght training ?Tm;;ACTIVE;2.67;2.67 +93821-7;Calories burned^during aerobic activity;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --during aerobic activity;Calories burned dur aerobic activity ?Tm;;ACTIVE;2.67;2.67 +93822-5;Calories burned^while playing a sport;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --while playing a sport;Calories burned playing a sport ?Tm;;ACTIVE;2.67;2.67 +9382-3;Coproporphyrin;MRat;XXX;Stool;Qn;;CHEM;1;Coproporphyrin [Mass/time] in unspecified time Stool;Copro ?Tm Stl-mRate;;ACTIVE;1.0i;2.19 +93823-3;Calories burned^during swimming;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --during swimming;Calories burned dur swim ?Tm;;ACTIVE;2.67;2.67 +93824-1;Calories burned^during cycling;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --during cycling;Calories burned dur cycle ?Tm;;ACTIVE;2.67;2.67 +93825-8;Calories burned^during running;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --during running;Calories burned dur running ?Tm;;ACTIVE;2.67;2.67 +93826-6;Calories burned^during walking;EngRat;XXX;^Patient;Qn;;CLIN;2;Calories burned in unspecified time --during walking;Calories burned dur walking ?Tm;;ACTIVE;2.67;2.67 +93827-4;Nighttime awakening;Num;Pt;^Patient;Qn;;H&P.HX;2;Nighttime awakening;Nighttime awaken;;ACTIVE;2.67;2.67 +93828-2;Nighttime awakening duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Nighttime awakening duration;Nighttime awake duration;;ACTIVE;2.67;2.67 +93829-0;REM sleep duration;Time;Pt;^Patient;Qn;;H&P.HX;2;REM sleep duration;REM sleep duration;;ACTIVE;2.67;2.67 +93830-8;Light sleep duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Light sleep duration;Light sleep duration;;ACTIVE;2.67;2.67 +9383-1;9-Hydroxyrisperidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;9-Hydroxyrisperidone [Mass/volume] in Serum or Plasma;9OH-risperidone SerPl-mCnc;;ACTIVE;1.0i;2.73 +93831-6;Deep sleep duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Deep sleep duration;Deep sleep duration;;ACTIVE;2.67;2.67 +93832-4;Sleep duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Sleep duration;Sleep duration;;ACTIVE;2.67;2.67 +93833-2;Flights climbed;NRat;24H;^Patient;Qn;;H&P.HX;2;Flights climbed 24 hour;Flights climbed 24h nRate;;ACTIVE;2.67;2.67 +93834-0;Coccidioides sp Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Coccidioides sp IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Coccidioides IgM CSF IA-aCnc;;ACTIVE;2.67;2.67 +93835-7;Coccidioides sp Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Coccidioides sp IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;Coccidioides IgM SerPl IA-aCnc;;ACTIVE;2.67;2.67 +93836-5;Coccidioides sp Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Coccidioides sp IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Coccidioides IgG SerPl IA-aCnc;;ACTIVE;2.67;2.67 +93837-3;Coccidioides sp Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Coccidioides sp IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;Coccidioides IgG CSF IA-aCnc;;ACTIVE;2.67;2.67 +93838-1;Histoplasma capsulatum Ab.IgM;ACnc;Pt;CSF;Qn;IA;MICRO;1;Histoplasma capsulatum IgM Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;H capsul IgM CSF IA-aCnc;;ACTIVE;2.67;2.67 +93839-9;Histoplasma capsulatum Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Histoplasma capsulatum IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;H capsul IgG CSF IA-aCnc;;ACTIVE;2.67;2.67 +93840-7;Epstein Barr virus DNA;ACnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Units/volume] (viral load) in Blood by NAA with probe detection;EBV DNA Bld NAA+probe-aCnc;;ACTIVE;2.67;2.67 +93841-5;Epstein Barr virus DNA;LaCnc;Pt;Bld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [log units/volume] (viral load) in Blood by NAA with probe detection;EBV DNA Bld NAA+probe-Log IU;;ACTIVE;2.67;2.67 +93842-3;HOGA1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HOGA1 gene full mutation analysis in Blood or Tissue by Sequencing;HOGA1 Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +93843-1;Primary hyperoxaluria multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Primary hyperoxaluria multigene analysis in Blood or Tissue by Molecular genetics method;PH Multigene Anl Bld/T;;ACTIVE;2.67;2.67 +93844-9;UGT1A1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.PHARMG;1;UGT1A1 gene full mutation analysis in Blood or Tissue by Sequencing;UGT1A1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +93845-6;UGT1A1 gene allele;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;UGT1A1 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal;UGT1A1 allele Geno Bld/T;;ACTIVE;2.67;2.68 +93846-4;Hemoglobin;SCnc;Pt;BldV;Qn;;HEM/BC;1;Hemoglobin [Moles/volume] in Venous blood;Hgb BldV-sCnc;;ACTIVE;2.67;2.67 +93847-2;Aspergillus oryzae Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus oryzae IgE Ab [Units/volume] in Serum;A. oryzae IgE Qn;;ACTIVE;2.67;2.67 +93848-0;Setting of exposure to environmental or occupational hazard;Type;Pt;^Patient;Nom;;H&P.PX;2;Setting of exposure to environmental or occupational hazard;Set of hazard exposure;;ACTIVE;2.67;2.67 +9384-9;Benztropine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Benztropine [Mass/volume] in Serum or Plasma;Benztropine SerPl-mCnc;;ACTIVE;1.0i;2.73 +93849-8;Exercise distance;Len;24H;^Patient;Qn;;CLIN;2;Exercise distance in 24 hour;Exercise distance 24h;;ACTIVE;2.67;2.67 +93850-6;Pretomanid;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Pretomanid [Susceptibility];Pretomanid Susc Islt;;ACTIVE;2.67;2.67 +93851-4;Delamanid;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Delamanid [Susceptibility];Delamanid Susc Islt;;ACTIVE;2.67;2.67 +93852-2;N-acetylgalactosamine-4-sulfatase/N-acetylgalactosamine-6-sulfatase;CRto;Pt;Urine;Qn;;CHEM;1;N-Acetylgalactosamine-4-Sulfatase/N-Acetylgalactosamine-6-Sulfatase [Enzymatic activity ratio] in Urine;Arylsulfatase B/GALNS Ur-cRto;;ACTIVE;2.67;2.67 +93853-0;N-Acetylgalactosamine-6-Sulfatase;CCnc;Pt;Urine;Qn;;CHEM;1;N-Acetylgalactosamine-6-Sulfatase [Enzymatic activity/volume] in Urine;GALNS Ur-cCnc;;ACTIVE;2.67;2.68 +93854-8;Gadolinium/Creatinine;MRto;Pt;Urine;Qn;;DRUG/TOX;1;Gadolinium/Creatinine [Mass Ratio] in Urine;Gadolinium/Creat Ur;;ACTIVE;2.67;2.67 +93855-5;Iothalamate;MCnc;Pt;Urine;Qn;;CHEM;1;Iothalamate [Mass/volume] in Urine;Iothalamate Ur-mCnc;;ACTIVE;2.67;2.67 +9385-6;Levodopa;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Levodopa [Mass/volume] in Serum or Plasma;L-Dopa SerPl-mCnc;;ACTIVE;1.0i;2.73 +93856-3;Enterovirus RNA;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Specimen by NAA with non-probe detection;EV RNA Spec Ql NAA+non-probe;;ACTIVE;2.67;2.69 +93857-1;Date and time of obstetric delivery;TmStp;Pt;^Patient;Qn;;OBGYN;2;Date and time of obstetric delivery;Date+time OB delivery;;ACTIVE;2.67;2.67 +93858-9;Toxoplasma gondii Ab.IgG panel;-;Pt;Ser^Donor;-;;PANEL.MICRO;1;Toxoplasma gondii IgG panel - Serum from Donor;T gondii IgG pnl Ser Donr;;ACTIVE;2.67;2.67 +93859-7;Toxoplasma gondii Ab.IgG;PrThr;Pt;Ser^Donor;Ord;IA;MICRO;1;Toxoplasma gondii IgG Ab [Presence] in Serum from Donor by Immunoassay;T gondii IgG Ser Donr Ql IA;;ACTIVE;2.67;2.67 +93860-5;Toxoplasma gondii Ab.IgG;ACnc;Pt;Ser^Donor;Qn;IA;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Serum from Donor by Immunoassay;T gondii IgG Ser Donr IA-aCnc;;ACTIVE;2.67;2.67 +93861-3;Temperature;Temp;Pt;Veterinary cage;Qn;;CLIN.VET;2;Temperature Veterinary cage;Temp Vet cage;;ACTIVE;2.67;2.69 +93862-1;Temperature setting;Temp;Pt;Veterinary cage;Qn;;CLIN.VET;2;Temperature setting Veterinary cage;Temp setting Vet cage;;ACTIVE;2.67;2.69 +93863-9;Oxygen/Gas.total;VFr;Pt;Veterinary cage;Qn;;CLIN.VET;2;Oxygen/Gas total Veterinary cage;O2/Gas.total VFr Vet cage;;ACTIVE;2.67;2.67 +9386-4;NIFEdipine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;NIFEdipine [Mass/volume] in Serum or Plasma;NIFEdipine SerPl-mCnc;;ACTIVE;1.0i;2.73 +93864-7;Oxygen/Gas.total setting;VFr;Pt;Veterinary cage;Qn;;CLIN.VET;2;Oxygen/Total gas setting Veterinary cage;O2/Total gas setting VFr Vet cage;;ACTIVE;2.67;2.69 +93865-4;Conference note;Find;Pt;{Setting};Doc;General medicine.team;DOC.ONTOLOGY;2;General medicine Team Conference note;Gen med Team Conf eval note;;ACTIVE;2.67;2.67 +93866-2;C4 nephritic factor;PrThr;Pt;Ser/Plas;Ord;;HEM/BC;1;C4 nephritic factor [Presence] in Serum or Plasma;C4 NeF SerPl Ql;;ACTIVE;2.67;2.67 +93867-0;Gamma aminobutyrate B receptor Ab;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;GABABR Ab [Presence] in Serum by Cell binding immunofluorescent assay;GABABR Ab Ser Ql CBA IFA;;ACTIVE;2.67;2.69 +93868-8;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;AMPAR2 Ab [Presence] in Serum by Cell binding immunofluorescent assay;AMPAR2 Ab Ser Ql CBA IFA;;ACTIVE;2.67;2.69 +93869-6;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;AMPAR1 Ab [Presence] in Serum by Cell binding immunofluorescent assay;AMPAR1 Ab Ser Ql CBA IFA;;ACTIVE;2.67;2.69 +93870-4;N-methyl-D-aspartate receptor subunit 1 Ab;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;NMDAR subunit 1 Ab [Presence] in Serum by Cell binding immunofluorescent assay;NMDAR1 Ab Ser Ql CBA IFA;;ACTIVE;2.67;2.69 +93871-2;Borrelia miyamotoi Ab.IgG+IgM;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Borrelia miyamotoi IgG+IgM Ab [Interpretation] in Serum or Plasma;B miyamotoi IgG+IgM SerPl-Imp;;ACTIVE;2.67;2.71 +9387-2;Procyclidine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procyclidine [Mass/volume] in Serum or Plasma;Procyclidine SerPl-mCnc;;ACTIVE;1.0i;2.7 +93872-0;Tamoxifen metabolites pattern;Imp;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Tamoxifen metabolites pattern [Interpretation] in Serum or Plasma;Tamoxifen metab pattern SerPl-Imp;;ACTIVE;2.67;2.67 +93873-8;Borrelia miyamotoi Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Borrelia miyamotoi IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;B miyamotoi IgG SerPl IA-aCnc;;ACTIVE;2.67;2.71 +93874-6;Borrelia miyamotoi Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Borrelia miyamotoi IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;B miyamotoi IgM SerPl IA-aCnc;;ACTIVE;2.67;2.71 +93875-3;Phosphohistone H3;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Phosphohistone H3 [Presence] in Tissue by Immune stain;PHH3 Tiss Ql ImStn;;ACTIVE;2.67;2.67 +93876-1;Ceramide risk score;Score;Pt;Plas;Qn;Calculated;CHEM;1;Ceramide risk score in Plasma by calculation;Ceramide risk score Plas Calc;;ACTIVE;2.67;2.67 +93877-9;N-Nervonoylsphingosine/N-Lignoceroylsphingosine;SRto;Pt;Plas;Qn;;CHEM;1;N-Nervonoylsphingosine/N-Lignoceroylsphingosine [Molar ratio] in Plasma;C24:1 ceramide/C24 ceramide Plas-sRto;;ACTIVE;2.67;2.67 +93878-7;N-Stearoylsphingosine/N-Lignoceroylsphingosine;SRto;Pt;Plas;Qn;;CHEM;1;N-Stearoylsphingosine/N-Lignoceroylsphingosine [Molar ratio] in Plasma;C18 ceramide/C24 ceramide Plas-sRto;;ACTIVE;2.67;2.67 +93879-5;N-Palmitoylsphingosine/N-Lignoceroylsphingosine;SRto;Pt;Plas;Qn;;CHEM;1;N-Palmitoylsphingosine/N-Lignoceroylsphingosine [Molar ratio] in Plasma;C16 ceramide/C24 ceramide Plas-sRto;;ACTIVE;2.67;2.67 +9388-0;Propylthiouracil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propylthiouracil [Mass/volume] in Serum or Plasma;Propylthiouracil SerPl-mCnc;;ACTIVE;1.0i;2.7 +93880-3;N-Nervonoylsphingosine;SCnc;Pt;Plas;Qn;;CHEM;1;N-Nervonoylsphingosine [Moles/volume] in Plasma;C24:1 ceramide Plas-sCnc;;ACTIVE;2.67;2.67 +93881-1;N-Stearoylsphingosine;SCnc;Pt;Plas;Qn;;CHEM;1;N-Stearoylsphingosine [Moles/volume] in Plasma;C18 ceramide Plas-sCnc;;ACTIVE;2.67;2.67 +93882-9;N-Palmitoylsphingosine;SCnc;Pt;Plas;Qn;;CHEM;1;N-Palmitoylsphingosine [Moles/volume] in Plasma;C16 ceramide Plas-sCnc;;ACTIVE;2.67;2.67 +93883-7;Ceramide panel;-;Pt;Plas;Qn;;PANEL.CHEM;1;Ceramide panel - Plasma;Ceramide Pnl Plas;;ACTIVE;2.67;2.68 +93884-5;Methane/Expired gas^2H post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose carbohydrate;Breath methane 2h p carb;;ACTIVE;2.67;2.67 +93885-2;Methane/Expired gas^1.5H post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose carbohydrate;Breath methane 1.5h p carb;;ACTIVE;2.67;2.67 +93886-0;Methane/Expired gas^1H post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose carbohydrate;Breath methane 1h p carb;;ACTIVE;2.67;2.67 +93887-8;Methane/Expired gas^45M post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --45 minutes post dose carbohydrate;Breath methane 45M p carb;;ACTIVE;2.67;2.67 +93888-6;Methane/Expired gas^30M post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose carbohydrate;Breath methane 30M p carb;;ACTIVE;2.67;2.67 +93889-4;Methane/Expired gas^15M post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --15 minutes post dose carbohydrate;Breath methane 15M p carb;;ACTIVE;2.67;2.67 +93890-2;Methane/Expired gas^pre dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --pre dose carbohydrate;Breath methane pre carb;;ACTIVE;2.67;2.67 +93891-0;Methane/Expired gas^post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Methane/Expired gas [Volume Fraction] in Exhaled gas --post dose carbohydrate;Breath methane p carb;;ACTIVE;2.67;2.67 +93892-8;Progress note;Find;Pt;{Setting};Doc;Addiction medicine;DOC.ONTOLOGY;2;Addiction medicine Progress note;Addiction med Prog note;;ACTIVE;2.67;2.73 +93893-6;Conference note;Find;Pt;{Setting};Doc;Orthopaedic surgery.team;DOC.ONTOLOGY;2;Orthopaedic surgery Team Conference note;Ortho surg Team Conf eval note;;ACTIVE;2.67;2.67 +93894-4;Conference note;Find;Pt;{Setting};Doc;Hematology.team;DOC.ONTOLOGY;2;Hematology Team Conference note;Hematology Team Conf eval note;;ACTIVE;2.67;2.67 +93895-1;Conference note;Find;Pt;{Setting};Doc;Gynecologic oncology.team;DOC.ONTOLOGY;2;Gynecologic oncology Team Conference note;Gyn onc Team Conf eval note;;ACTIVE;2.67;2.67 +93896-9;Note;Find;Pt;Telephone encounter;Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Telephone encounter Note;Gyn Onc Phone Note;;ACTIVE;2.67;2.67 +93897-7;Progress note;Find;Pt;{Setting};Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Progress note;Mat fetal med Prog note;;ACTIVE;2.67;2.73 +9389-8;Pseudoephedrine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pseudoephedrine [Mass/volume] in Serum or Plasma;Pseudoephedrine SerPl-mCnc;;ACTIVE;1.0i;2.73 +93898-5;Note;Find;Pt;Telephone encounter;Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Telephone encounter Note;Fam Med Phone Note;;ACTIVE;2.67;2.67 +93899-3;Letter;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Letter;Psychiatric Letter;;ACTIVE;2.67;2.67 +93900-9;Progress note;Find;Pt;{Setting};Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Progress note;Navigator Prog note;;ACTIVE;2.67;2.73 +93901-7;Note;Find;Pt;Telephone encounter;Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Telephone encounter Note;Navigator Phone Note;;ACTIVE;2.67;2.67 +93902-5;Plan of care note;Find;Pt;{Setting};Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Plan of care note;Navigator Plan of care note;;ACTIVE;2.67;2.67 +93903-3;Discharge summary note;Find;Pt;{Setting};Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Discharge summary;Navigator D/C sum;;ACTIVE;2.67;2.73 +93904-1;Transfusion reaction panel;-;Pt;^Patient;-;;PANEL.BLDBK;1;Transfusion reaction panel;Transf React Pnl;;ACTIVE;2.67;2.67 +93905-8;ABO group^during infancy;Type;Pt;Bld;Nom;;BLDBK;1;ABO group [Type] in Blood--during infancy;ABO Group infant Bld;;ACTIVE;2.67;2.72 +9390-6;Pyridostigmine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Pyridostigmine [Mass/volume] in Serum or Plasma;Pyridostigmine SerPl-mCnc;;ACTIVE;1.0i;2.73 +93906-6;ABO & Rh group^during infancy;Type;Pt;Bld;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood--during infancy;ABO + Rh infant Bld;;ACTIVE;2.67;2.72 +93907-4;L little u 20 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Lu 20 Ag [Presence] on Red Blood Cells;Lu 20 Ag RBC Ql;;ACTIVE;2.67;2.67 +93908-2;A little u super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Au sup(b) Ag [Presence] on Red Blood Cells;Au sup(b) Ag RBC Ql;;ACTIVE;2.67;2.67 +93909-0;J little k3 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Jk3 Ag [Presence] on Red Blood Cells;Jk3 Ag RBC Ql;;ACTIVE;2.67;2.67 +93910-8;F little y3 Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Fy3 Ag [Presence] on Red Blood Cells;Fy3 Ag RBC Ql;;ACTIVE;2.67;2.67 +93911-6;little c E Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;little cE Ag [Presence] on Red Blood Cells;little cE Ag RBC Ql;;ACTIVE;2.67;2.67 +93912-4;CE Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;CE Ag [Presence] on Red Blood Cells;CE Ag RBC Ql;;ACTIVE;2.67;2.67 +93913-2;VS Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;VS Ag [Presence] on Red Blood Cells;VS Ag RBC Ql;;ACTIVE;2.67;2.67 +9391-4;Quazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Quazepam [Mass/volume] in Serum or Plasma;Quazepam SerPl-mCnc;;ACTIVE;1.0i;2.7 +93914-0;Blood group antigens panel;-;Pt;RBC;-;;PANEL.BLDBK;1;Blood group antigens panel - Red Blood Cells;Bld Grp Ag Pnl RBC;;ACTIVE;2.67;2.67 +93915-7;Rh antigens & K Ag panel;-;Pt;Bld^BPU;-;;PANEL.BLDBK;1;Rh antigens and K Ag panel - Blood from Blood product unit;Rh Ags+K Ag Pnl Bld BPU;;ACTIVE;2.67;2.67 +93916-5;ABO & Rh group panel;-;Pt;Bld^BPU;-;;PANEL.BLDBK;1;ABO and Rh group panel - Blood from Blood product unit;ABO + Rh Pnl Bld BPU;;ACTIVE;2.67;2.67 +93917-3;K Ag^post transfusion reaction;PrThr;Pt;RBC;Ord;;BLDBK;1;K Ag [Presence] on Red Blood Cells --after transfusion reaction;K Ag p transf rx RBC Ql;;ACTIVE;2.67;2.67 +93918-1;little e Ag^post transfusion reaction;PrThr;Pt;RBC;Ord;;BLDBK;1;little e Ag [Presence] on Red Blood Cells --after transfusion reaction;little e Ag p transf rx RBC Ql;;ACTIVE;2.67;2.67 +93919-9;little c Ag^post transfusion reaction;PrThr;Pt;RBC;Ord;;BLDBK;1;little c Ag [Presence] on Red Blood Cells --after transfusion reaction;little c Ag p transf rx RBC Ql;;ACTIVE;2.67;2.67 +93920-7;E Ag^post transfusion reaction;PrThr;Pt;RBC;Ord;;BLDBK;1;E Ag [Presence] on Red Blood Cells --after transfusion reaction;E Ag p transf rx RBC Ql;;ACTIVE;2.67;2.67 +93921-5;C Ag^post transfusion reaction;PrThr;Pt;RBC;Ord;;BLDBK;1;C Ag [Presence] on Red Blood Cells --after transfusion reaction;C Ag p transf rx RBC Ql;;ACTIVE;2.67;2.67 +9392-2;Quinethazone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Quinethazone [Mass/volume] in Urine;Quinethazone Ur-mCnc;;ACTIVE;1.0i;2.7 +93922-3;Rh antigens & K Ag post transfusion reaction panel;-;Pt;Bld;-;;PANEL.BLDBK;1;Rh antigens and K Ag post transfusion reaction panel - Blood;Rh Ags+K Ag Pnl p Transf Rx Bld;;ACTIVE;2.67;2.67 +93923-1;ABO & Rh group post transfusion reaction panel;-;Pt;Bld;-;;PANEL.BLDBK;1;ABO and Rh group post transfusion reaction panel - Blood;ABO + Rh Pnl p transf rx Bld;;ACTIVE;2.67;2.67 +93924-9;K Ag^post hematopoietic stem cell transplant;PrThr;Pt;RBC;Ord;;BLDBK;1;K Ag [Presence] on Red Blood Cells --post hematopoietic stem cell transplant;K Ag p HSCT RBC Ql;;ACTIVE;2.67;2.67 +93925-6;little e Ag^post hematopoietic stem cell transplant;PrThr;Pt;RBC;Ord;;BLDBK;1;little e Ag [Presence] on Red Blood Cells --post hematopoietic stem cell transplant;little e Ag p HSCT RBC Ql;;ACTIVE;2.67;2.67 +93926-4;little c Ag^post hematopoietic stem cell transplant;PrThr;Pt;RBC;Ord;;BLDBK;1;little c Ag [Presence] on Red Blood Cells --post hematopoietic stem cell transplant;little c Ag p HSCT RBC Ql;;ACTIVE;2.67;2.67 +93927-2;E Ag^post hematopoietic stem cell transplant;PrThr;Pt;RBC;Ord;;BLDBK;1;E Ag [Presence] on Red Blood Cells --post hematopoietic stem cell transplant;E Ag p HSCT RBC Ql;;ACTIVE;2.67;2.67 +93928-0;C Ag^post hematopoietic stem cell transplant;PrThr;Pt;RBC;Ord;;BLDBK;1;C Ag [Presence] on Red Blood Cells --post hematopoietic stem cell transplant;C Ag p HSCT RBC Ql;;ACTIVE;2.67;2.67 +93929-8;Rh antigens & K Ag post hematopoietic stem cell transplant panel;-;Pt;Bld;-;;PANEL.BLDBK;1;Rh antigens and K Ag post hematopoietic stem cell transplant panel - Blood;Rh Ags+K Ag Pnl p stem trnsplt Bld;;ACTIVE;2.67;2.67 +9393-0;risperiDONE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;risperiDONE [Mass/volume] in Serum or Plasma;risperiDONE SerPl-mCnc;;ACTIVE;1.0i;2.73 +93930-6;D Ag^post hematopoietic stem cell transplant;PrThr;Pt;RBC;Ord;;BLDBK;1;D Ag [Presence] on Red Blood Cells --post hematopoietic stem cell transplant;D Ag p HSCT RBC Ql;;ACTIVE;2.67;2.67 +93931-4;ABO group^post hematopoietic stem cell transplant;Type;Pt;Bld;Nom;;BLDBK;1;ABO group [Type] in Blood--post hematopoietic stem cell transplant;ABO Group p HSCT Bld;;ACTIVE;2.67;2.72 +93932-2;ABO & Rh group^post hematopoietic stem cell transplant;Type;Pt;Bld;Nom;;BLDBK;1;ABO and Rh group [Type] in Blood--post hematopoietic stem cell transplant;ABO + Rh p HSCT Bld;;ACTIVE;2.67;2.72 +93933-0;ABO & Rh group post hematopoietic stem cell transplant panel;-;Pt;Bld;-;;PANEL.BLDBK;1;ABO and Rh group post hematopoietic stem cell transplant panel - Blood;ABO+Rh Gp Pnl p stem trnsplt Bld;;ACTIVE;2.67;2.67 +93934-8;K Ag^during infancy;PrThr;Pt;RBC;Ord;;BLDBK;1;K Ag [Presence] on Red Blood Cells --during infancy;K Ag infant RBC Ql;;ACTIVE;2.67;2.67 +93935-5;little e Ag^during infancy;PrThr;Pt;RBC;Ord;;BLDBK;1;little e Ag [Presence] on Red Blood Cells --during infancy;little e Ag infant RBC Ql;;ACTIVE;2.67;2.67 +93936-3;little c Ag^during infancy;PrThr;Pt;RBC;Ord;;BLDBK;1;little c Ag [Presence] on Red Blood Cells --during infancy;little c Ag infant RBC Ql;;ACTIVE;2.67;2.67 +93937-1;E Ag^during infancy;PrThr;Pt;RBC;Ord;;BLDBK;1;E Ag [Presence] on Red Blood Cells --during infancy;E Ag infant RBC Ql;;ACTIVE;2.67;2.67 +93938-9;C Ag^during infancy;PrThr;Pt;RBC;Ord;;BLDBK;1;C Ag [Presence] on Red Blood Cells --during infancy;C Ag infant RBC Ql;;ACTIVE;2.67;2.67 +93939-7;Rh antigens & K Ag during infancy panel;-;Pt;Bld;-;;PANEL.BLDBK;1;Rh antigens and K Ag during infancy panel - Blood;Rh Ags+K Ag Pnl infant Bld;;ACTIVE;2.67;2.67 +93940-5;D Ag^during infancy;PrThr;Pt;RBC;Ord;;BLDBK;1;D Ag [Presence] on Red Blood Cells --during infancy;D Ag infant RBC Ql;;ACTIVE;2.67;2.67 +93941-3;ABO & Rh group during infancy panel;-;Pt;Bld;-;;PANEL.BLDBK;1;ABO and Rh group during infancy panel - Blood;ABO+Rh Gp Pnl infant Bld;;ACTIVE;2.67;2.67 +93942-1;K Ag;PrThr;Pt;RBCCo;Ord;;BLDBK;1;K Ag [Presence] in Cord red blood cells;K Ag RBCCo Ql;;ACTIVE;2.67;2.67 +93943-9;little e Ag;PrThr;Pt;RBCCo;Ord;;BLDBK;1;little e Ag [Presence] in Cord red blood cells;little e Ag RBCCo Ql;;ACTIVE;2.67;2.67 +93944-7;little c Ag;PrThr;Pt;RBCCo;Ord;;BLDBK;1;little c Ag [Presence] in Cord red blood cells;little c Ag RBCCo Ql;;ACTIVE;2.67;2.67 +93945-4;E Ag;PrThr;Pt;RBCCo;Ord;;BLDBK;1;E Ag [Presence] in Cord red blood cells;E Ag RBCCo Ql;;ACTIVE;2.67;2.67 +93946-2;C Ag;PrThr;Pt;RBCCo;Ord;;BLDBK;1;C Ag [Presence] in Cord red blood cells;C Ag RBCCo Ql;;ACTIVE;2.67;2.67 +93947-0;Rh antigens & K Ag panel;-;Pt;BldCo;-;;PANEL.BLDBK;1;Rh antigens and K Ag panel - Cord blood;Rh Ags+K Ag Pnl BldCo;;ACTIVE;2.67;2.67 +9394-8;Risperidone+9-Hydroxyrisperidone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;risperiDONE+9-Hydroxyrisperidone [Mass/volume] in Serum or Plasma;risperiDONE+9OH-Ris SerPl-mCnc;;ACTIVE;1.0i;2.73 +93948-8;D Ag;PrThr;Pt;RBCCo;Ord;;BLDBK;1;D Ag [Presence] in Cord red blood cells;D Ag RBCCo Ql;;ACTIVE;2.67;2.67 +93949-6;ABO & Rh group panel;-;Pt;BldCo;-;;PANEL.BLDBK;1;ABO and Rh group panel - Cord blood;ABO + Rh Pnl BldCo;;ACTIVE;2.67;2.67 +93950-4;D variant Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;D variant Ag [Presence] on Red Blood Cells;D Var Ag RBC Ql;;ACTIVE;2.67;2.67 +93951-2;Rh antigens & K Ag panel;-;Pt;Bld;-;;PANEL.BLDBK;1;Rh antigens and K Ag panel - Blood;Rh Ags+K Ag Pnl Bld;;ACTIVE;2.67;2.67 +93952-0;Metamyelocytes.neutrophilic/100 leukocytes;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Metamyelocytes.neutrophilic/100 leukocytes in Bone marrow by Manual count;Metamyelocytes.neut/leuk NFr Mar Manual;;ACTIVE;2.67;2.67 +93953-8;Lymphocytes.villous;PrThr;Pt;Bld;Ord;Microscopy.light;HEM/BC;1;Villous lymphocytes [Presence] in Blood by Light microscopy;Lymph Villous Bld Ql Smear;;ACTIVE;2.67;2.67 +93954-6;Note;Find;Pt;Outpatient;Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Outpatient Note;WOC OP Note;;ACTIVE;2.67;2.67 +9395-5;SUFentanil;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;SUFentanil [Mass/volume] in Serum or Plasma;SUFentanil SerPl-mCnc;;ACTIVE;1.0i;2.7 +93955-3;Consultation note;Find;Pt;{Setting};Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Consult note;WOC Consult note;;ACTIVE;2.67;2.67 +93956-1;Letter;Find;Pt;{Setting};Doc;Heart failure+Transplant cardiology;DOC.ONTOLOGY;2;Heart failure+Transplant cardiology Letter;HF+TC Letter;;ACTIVE;2.67;2.67 +93957-9;Diagnostic study note;Find;Pt;{Setting};Doc;Developmental-behavioral pediatrics;DOC.ONTOLOGY;2;Developmental-behavioral pediatrics Diagnostic study note;Develop-behav peds Diag study note;;ACTIVE;2.67;2.67 +93958-7;Diagnostic study note;Find;Pt;{Setting};Doc;Eating disorders;DOC.ONTOLOGY;2;Eating disorders Diagnostic study note;Eating disorders Diag study note;;ACTIVE;2.67;2.67 +93959-5;Diagnostic study note;Find;Pt;{Setting};Doc;Heart failure+Transplant cardiology;DOC.ONTOLOGY;2;Heart failure+Transplant cardiology Diagnostic study note;HF+TC Diag study note;;ACTIVE;2.67;2.67 +93960-3;Diagnostic study note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Diagnostic study note;Immunology Diag study note;;ACTIVE;2.67;2.67 +93961-1;Diagnostic study note;Find;Pt;{Setting};Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine Diagnostic study note;Integrative medicine Diag study note;;ACTIVE;2.67;2.67 +93962-9;Diagnostic study note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Diagnostic study note;Nephrology Diag study note;;ACTIVE;2.67;2.67 +9396-3;SUFentanil;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;SUFentanil [Mass/volume] in Urine;SUFentanil Ur-mCnc;;ACTIVE;1.0i;2.73 +93963-7;Diagnostic study note;Find;Pt;{Setting};Doc;Pediatrics;DOC.ONTOLOGY;2;Pediatrics Diagnostic study note;Peds Diag study note;;ACTIVE;2.67;2.67 +93964-5;Diagnostic study note;Find;Pt;{Setting};Doc;Pharmacogenomics;DOC.ONTOLOGY;2;Pharmacogenomics Diagnostic study note;Pharmacogenomics Diag study note;;ACTIVE;2.67;2.67 +93965-2;Diagnostic study note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Diagnostic study note;PM+R Diag study note;;ACTIVE;2.67;2.67 +93966-0;Diagnostic study note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Diagnostic study note;Plastic surgery Diag study note;;ACTIVE;2.67;2.67 +93967-8;Diagnostic study note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Diagnostic study note;Psychiatric Diag study note;;ACTIVE;2.67;2.67 +93968-6;Diagnostic study note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Diagnostic study note;Psych Diag study note;;ACTIVE;2.67;2.67 +93969-4;Diagnostic study note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Diagnostic study note;Trauma Diag study note;;ACTIVE;2.67;2.67 +93970-2;Diagnostic study note;Find;Pt;{Setting};Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Diagnostic study note;WOC Diag study note;;ACTIVE;2.67;2.67 +9397-1;Color;Type;Pt;Stool;Nom;;SPEC;1;Color of Stool;Color Stl;;ACTIVE;1.0i;2.73 +93971-0;Elevation climbed;LRat;24H;^Patient;Qn;;H&P.HX;2;Elevation climbed [Length/Time] 24 hour;Elevation climbed 24h lRate;;ACTIVE;2.67;2.67 +93972-8;Acetaminophen-cysteine adduct;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acetaminophen-cysteine adduct [Moles/volume] in Serum or Plasma;APAP-Cysteine SerPl-sCnc;;ACTIVE;2.67;2.72 +93973-6;Iohexol;MCnc;Pt;Urine;Qn;;CHEM;1;Iohexol [Mass/volume] in Urine;Iohexol Ur-mCnc;;ACTIVE;2.67;2.67 +93974-4;Iohexol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iohexol [Mass/volume] in Serum or Plasma;Iohexol SerPl-mCnc;;ACTIVE;2.67;2.67 +93975-1;Urea nitrogen^1H specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Urea nitrogen [Mass/volume] in Serum or Plasma --1 hour specimen;BUN 1h spec SerPl-mCnc;;ACTIVE;2.67;2.67 +93976-9;Chikungunya virus Ab.IgM & IgG panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Chikungunya virus Ab.IgM and IgG panel - Serum or Plasma;CHIKV IgG+IgM Pnl SerPl;;ACTIVE;2.67;2.72 +93977-7;Complement C2.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C2.functional [Units/volume] in Serum or Plasma;C2.functional SerPl-aCnc;;ACTIVE;2.67;2.68 +93978-5;Complement C4.functional;ACnc;Pt;Ser/Plas;Qn;;HEM/BC;1;Complement C4.functional [Units/volume] in Serum or Plasma;C4.functional SerPl-aCnc;;ACTIVE;2.67;2.68 +93979-3;Chikungunya virus Ab.IgG;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Chikungunya virus IgG Ab [Presence] in Serum or Plasma;CHIKV IgG SerPl Ql;;ACTIVE;2.67;2.72 +93980-1;Iothalamate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Iothalamate [Mass/volume] in Serum or Plasma;Iothalamate SerPl-mCnc;;ACTIVE;2.67;2.67 +93981-9;Hydrogen/Expired gas^2H post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose carbohydrate;Breath H2 2h p carb;;ACTIVE;2.67;2.67 +93982-7;Hydrogen/Expired gas^1.5H post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose carbohydrate;Breath H2 1.5h p carb;;ACTIVE;2.67;2.67 +93983-5;Hydrogen/Expired gas^1H post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose carbohydrate;Breath H2 1h p carb;;ACTIVE;2.67;2.67 +93984-3;Hydrogen/Expired gas^45M post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --45 minutes post dose carbohydrate;Breath H2 45M p carb;;ACTIVE;2.67;2.67 +93985-0;Hydrogen/Expired gas^30M post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose carbohydrate;Breath H2 30M p carb;;ACTIVE;2.67;2.67 +93986-8;Hydrogen/Expired gas^15M post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --15 minutes post dose carbohydrate;Breath H2 15M p carb;;ACTIVE;2.67;2.67 +93987-6;Hydrogen/Expired gas^pre dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --pre dose carbohydrate;Breath H2 pre carb;;ACTIVE;2.67;2.67 +93988-4;Hydrogen/Expired gas^post dose carbohydrate;VFr;Pt;Exhl gas;Qn;;CHAL;1;Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post dose carbohydrate;Breath H2 p carb;;ACTIVE;2.67;2.67 +9398-9;Reticulin Ab;Titr;Pt;Ser;Qn;;SERO;1;Reticulin Ab [Titer] in Serum;Reticulin Ab Titr Ser;;ACTIVE;1.0i;2.73 +93989-2;Carbohydrate challenge panel;-;Pt;Exhl gas;-;;PANEL.CHAL;1;Carbohydrate challenge panel - Exhaled gas;Carb chal Pnl ExG;;ACTIVE;2.67;2.67 +939-9;Bombay Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated Bombay Ab;Deprecated Bombay Ab Ser Ql;;DEPRECATED;1.0;2.36 +93990-0;Osmolality^post 1H FFst;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--1 hour post fluid fast;Osmolality p 1h FFST SerPl;;ACTIVE;2.67;2.67 +93991-8;Osmolality^post 2H FFst;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--2 hours post fluid fast;Osmolality p 2h FFST SerPl;;ACTIVE;2.67;2.67 +93992-6;Osmolality^post 3H FFst;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--3 hours post fluid fast;Osmolality p 3h FFST SerPl;;ACTIVE;2.67;2.67 +93993-4;Osmolality^post 4H FFst;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--4 hours post fluid fast;Osmolality p 4h FFST SerPl;;ACTIVE;2.67;2.67 +93994-2;Osmolality^post 5H FFst;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--5 hours post fluid fast;Osmolality p 5h FFST SerPl;;ACTIVE;2.67;2.67 +93995-9;Osmolality^post 6H FFst;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--6 hours post fluid fast;Osmolality p 6h FFST SerPl;;ACTIVE;2.67;2.67 +93996-7;Osmolality^post 7H FFst;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--7 hours post fluid fast;Osmolality p 7h FFST SerPl;;ACTIVE;2.67;2.67 +9399-7;Ribonucleoprotein extractable nuclear Ab;Titr;Pt;Ser;Qn;;SERO;1;Ribonucleoprotein extractable nuclear Ab [Titer] in Serum;ENA RNP Ab Titr Ser;;ACTIVE;1.0i;2.73 +93997-5;Sodium^1H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Sodium [Moles/volume] in Serum or Plasma --1 hour post dose vasopressin;Sodium 1h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +93998-3;Potassium^1H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Potassium [Moles/volume] in Serum or Plasma --1 hour post dose vasopressin;Potassium 1h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +93999-1;Creatinine^1H post dose vasopressin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --1 hour post dose vasopressin;Creat 1h p Vaso SerPl-mCnc;;ACTIVE;2.67;2.67 +94000-7;Chloride^1H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Chloride [Moles/volume] in Serum or Plasma --1 hour post dose vasopressin;Chloride 1h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +94001-5;Bicarbonate^1H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Bicarbonate [Moles/volume] in Serum or Plasma --1 hour post dose vasopressin;HCO3 1h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +94002-3;Anion Gap 3^1H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Anion gap 3 in Serum or Plasma --1 hour post dose vasopressin;Anion Gap3 1h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +9400-3;Platinum;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Platinum [Mass/volume] in Specimen;Platinum Spec-mCnc;;ACTIVE;1.0i;2.7 +94003-1;Urea nitrogen^1H post dose vasopressin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Urea nitrogen [Mass/volume] in Serum or Plasma --1 hour post dose vasopressin;BUN 1h p Vaso SerPl-mCnc;;ACTIVE;2.67;2.67 +94004-9;Osmolality^1H post dose vasopressin;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--1 hour post dose vasopressin;Osmolality 1h p Vaso SerPl;;ACTIVE;2.67;2.67 +94005-6;Osmolality^1H post dose vasopressin;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--1 hour post dose vasopressin;Osmolality 1h p Vaso Ur;;ACTIVE;2.67;2.67 +94006-4;Sodium^2H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Sodium [Moles/volume] in Serum or Plasma --2 hours post dose vasopressin;Sodium 2h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +94007-2;Potassium^2H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Potassium [Moles/volume] in Serum or Plasma --2 hours post dose vasopressin;Potassium 2h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +94008-0;Creatinine^2H post dose vasopressin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Creatinine [Mass/volume] in Serum or Plasma --2 hours post dose vasopressin;Creat 2h p Vaso SerPl-mCnc;;ACTIVE;2.67;2.67 +94009-8;Chloride^2H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Chloride [Moles/volume] in Serum or Plasma --2 hours post dose vasopressin;Chloride 2h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +94010-6;Bicarbonate^2H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Bicarbonate [Moles/volume] in Serum or Plasma --2 hours post dose vasopressin;HCO3 2h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +9401-1;Silicon;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Silicon [Mass/volume] in Specimen;Silicon Spec-mCnc;;ACTIVE;1.0i;2.7 +94011-4;Anion Gap 3^2H post dose vasopressin;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Anion gap 3 in Serum or Plasma --2 hours post dose vasopressin;Anion Gap3 2h p Vaso SerPl-sCnc;;ACTIVE;2.67;2.67 +94012-2;Urea nitrogen^2H post dose vasopressin;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Urea nitrogen [Mass/volume] in Serum or Plasma --2 hours post dose vasopressin;BUN 2h p Vaso SerPl-mCnc;;ACTIVE;2.67;2.67 +94013-0;Osmolality^2H post dose vasopressin;Osmol;Pt;Ser/Plas;Qn;;CHAL;1;Osmolality of Serum or Plasma--2 hours post dose vasopressin;Osmolality 2h p Vaso SerPl;;ACTIVE;2.67;2.67 +94014-8;Osmolality^2H post dose vasopressin;Osmol;Pt;Urine;Qn;;CHAL;1;Osmolality of Urine--2 hours post dose vasopressin;Osmolality 2h p Vaso Ur;;ACTIVE;2.67;2.67 +94015-5;Mental health screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Mental health screening report;MH screen report;;ACTIVE;2.67;2.67 +94016-3;Depression screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Depression screening report;Depression screen report;;ACTIVE;2.67;2.67 +94017-1;Anxiety screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Anxiety screening report;Anxiety screen report;;ACTIVE;2.67;2.67 +94018-9;ADHD screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;ADHD screening report;ADHD screen report;;ACTIVE;2.67;2.67 +94019-7;Bipolar screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Bipolar screening report;Bipolar screen report;;ACTIVE;2.67;2.67 +94020-5;Somatic symptom disorder screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Somatic symptom disorder screening report;SSD screen report;;ACTIVE;2.67;2.67 +94021-3;Substance use disorder screening report;Find;Pt;^Patient;Doc;;DOC.MISC;2;Substance use disorder screening report;SUD screen report;;ACTIVE;2.67;2.67 +94022-1;Depression score;Score;Pt;^Patient;Qn;;H&P.HX;2;Depression score;Depression score;;ACTIVE;2.67;2.67 +94023-9;Depression severity;Imp;Pt;^Patient;Ord;;H&P.HX;2;Depression severity;Depression severity;;ACTIVE;2.67;2.67 +94024-7;Anxiety score;Score;Pt;^Patient;Qn;;H&P.HX;2;Anxiety score;Anxiety score;;ACTIVE;2.67;2.67 +94025-4;Anxiety severity;Imp;Pt;^Patient;Ord;;H&P.HX;2;Anxiety severity;Anxiety severity;;ACTIVE;2.67;2.67 +94026-2;Bipolar disorder type;Type;Pt;^Patient;Nom;;H&P.HX;2;Bipolar disorder type;Bipolar type;;ACTIVE;2.67;2.67 +94027-0;Somatic symptom disorder score;Score;Pt;^Patient;Qn;;H&P.HX;2;Somatic symptom disorder score;SSD score;;ACTIVE;2.67;2.67 +94028-8;Somatic symptom disorder severity;Imp;Pt;^Patient;Ord;;H&P.HX;2;Somatic symptom disorder severity;SSD severity;;ACTIVE;2.67;2.67 +9402-9;Acyl carnitine;MCnc;Pt;Plas;Qn;;CHEM;1;Deprecated Acyl carnitine [Mass/volume] in Plasma;Deprecated Acyl carnitine Plas-mCnc;;DEPRECATED;1.0i;2.36 +94029-6;Substance use disorder score;Score;Pt;^Patient;Qn;;H&P.HX;2;Substance use disorder score;SUD score;;ACTIVE;2.67;2.67 +94030-4;Substance use disorder severity;Imp;Pt;^Patient;Ord;;H&P.HX;2;Substance use disorder severity;SUD severity;;ACTIVE;2.67;2.67 +94031-2;ADHD type;Type;Pt;^Patient;Nom;;H&P.HX;2;ADHD type;ADHD type;;ACTIVE;2.67;2.67 +94032-0;ADHD inattentive symptoms severity;Imp;Pt;^Patient;Ord;;H&P.HX;2;ADHD inattentive symptoms severity;ADHD inattentive severity;;ACTIVE;2.67;2.67 +94033-8;ADHD hyperactive symptoms severity;Imp;Pt;^Patient;Ord;;H&P.HX;2;ADHD hyperactive symptoms severity;ADHD hyperactive severity;;ACTIVE;2.67;2.67 +94034-6;Suicidal intent;Find;Pt;^Patient;Ord;;H&P.HX;2;Suicidal intent;Suicidal intent;;ACTIVE;2.67;2.67 +94035-3;Suicide plan;Find;Pt;^Patient;Ord;;H&P.HX;2;Suicide plan;Suicide plan;;ACTIVE;2.67;2.67 +94036-1;Suicide risk factor;Find;Pt;^Patient;Nom;;H&P.HX;2;Suicide risk factor;Suicide risk factor;;ACTIVE;2.67;2.67 +9403-7;Acylcarnitine;MCnc;Pt;Urine;Qn;;CHEM;1;Acylcarnitine [Mass/volume] in Urine;Acylcarnitine Ur-mCnc;;DISCOURAGED;1.0i;2.73 +94037-9;Suicidal ideation;Find;Pt;^Patient;Nom;;H&P.HX;2;Suicidal ideation;Suicidal ideation;;ACTIVE;2.67;2.67 +94038-7;Substance use disorder question consistency score;Score;Pt;^Patient;Qn;;H&P.HX;2;Substance use disorder question consistency score;SUD consistency score;;ACTIVE;2.67;2.67 +94039-5;ADHD question consistency score;Score;Pt;^Patient;Qn;;H&P.HX;2;ADHD question consistency score;ADHD consistency score;;ACTIVE;2.67;2.67 +94040-3;Adenovirus A+B+C+D+E DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Adenovirus A+B+C+D+E DNA [Presence] in Respiratory specimen by NAA with probe detection;HAdV A+B+C+D+E DNA Resp Ql NAA+probe;;ACTIVE;2.67;2.67 +94041-1;My practice makes it easy for me to get care;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;My practice makes it easy for me to get care [PCPCM];;;ACTIVE;2.67;2.67 +94042-9;My practice is able to provide most of my care;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;My practice is able to provide most of my care [PCPCM];;;ACTIVE;2.67;2.67 +94043-7;In caring for me, my doctor considers all the factors that affect my health;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;In caring for me, my doctor considers all the factors that affect my health [PCPCM];;;ACTIVE;2.67;2.67 +94044-5;My practice coordinates the care I get from multiple places;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;My practice coordinates the care I get from multiple places [PCPCM];;;ACTIVE;2.67;2.67 +9404-5;Adenosine deaminase;CCnc;Pt;Body fld;Qn;;CHEM;1;Adenosine deaminase [Enzymatic activity/volume] in Body fluid;Adenosine deaminase Fld-cCnc;;ACTIVE;1.0i;2.73 +94045-2;My doctor or practice knows me as a person;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;My doctor or practice knows me as a person [PCPCM];;;ACTIVE;2.67;2.67 +94046-0;My doctor and I have been through a lot together;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;My doctor and I have been through a lot together [PCPCM];;;ACTIVE;2.67;2.67 +94047-8;My doctor or practice stands up for me;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;My doctor or practice stands up for me [PCPCM];;;ACTIVE;2.67;2.67 +94048-6;The care I get takes into account knowledge of my family;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;The care I get takes into account knowledge of my family [PCPCM];;;ACTIVE;2.67;2.67 +94049-4;The care I get in this practice is informed by knowledge of my community;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;The care I get in this practice is informed by knowledge of my community [PCPCM];;;ACTIVE;2.67;2.67 +94050-2;Over time, my practice helps me to stay healthy;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;Over time, my practice helps me to stay healthy [PCPCM];;;ACTIVE;2.67;2.67 +94051-0;Over time, my practice helps me to meet my goals;Find;Pt;^Patient;Ord;PCPCM;SURVEY.GNHLTH;4;Over time, my practice helps me to meet my goals [PCPCM];;;ACTIVE;2.67;2.67 +9405-2;Albumin/Globulin;MRto;Pt;Urine;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in Urine;Albumin/Glob Ur;;ACTIVE;1.0i;2.73 +94052-8;Mean score;Score;Pt;^Patient;Qn;PCPCM;SURVEY.GNHLTH;4;Mean score [PCPCM];;;ACTIVE;2.67;2.67 +94053-6;Mycobacterium tuberculosis complex resistance panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Mycobacterium tuberculosis complex resistance panel by Molecular genetics method;MTB cmplx resist Pnl Islt/Spm;;ACTIVE;2.67;2.7 +94054-4;Bacterial katG gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial katG gene drug resistance mutation [Identifier] by Molecular method;Bacterial katG drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94055-1;Bacterial inhA gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial inhA gene drug resistance mutation [Identifier] by Molecular method;Bacterial inhA drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94056-9;Bacterial fabG1 gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial fabG1 gene drug resistance mutation [Identifier] by Molecular method;Bacterial fabG1 drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94057-7;Bacterial ahpC gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial ahpC gene drug resistance mutation [Identifier] by Molecular method;Bacterial ahpC drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94058-5;Bacterial embB gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial embB gene drug resistance mutation [Identifier] by Molecular method;Bacterial embB drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94059-3;Bacterial pncA gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial pncA gene drug resistance mutation [Identifier] by Molecular method;Bacterial pncA drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +9406-0;Albumin/Globulin;MRto;24H;Urine;Qn;;CHEM;1;Albumin/Globulin [Mass Ratio] in 24 hour Urine;Albumin/Glob 24h Ur;;ACTIVE;1.0i;2.73 +94060-1;Bacterial gyrA gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial gyrA gene drug resistance mutation [Identifier] by Molecular method;Bacterial gyrA drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94061-9;Bacterial gidB gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial gidB gene drug resistance mutation [Identifier] by Molecular method;Bacterial gidB drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94062-7;Bacterial rrs gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial rrs gene drug resistance mutation [Identifier] by Molecular method;Bacterial rrs drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94063-5;Bacterial rpsL gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial rpsL gene drug resistance mutation [Identifier] by Molecular method;Bacterial rpsL drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94064-3;Bacterial eis gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial eis gene drug resistance mutation [Identifier] by Molecular method;Bacterial eis drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94065-0;Bacterial rpoB gene drug resistance mutation;Prid;Pt;Isolate/Specimen;Nom;Molgen;ABXBACT;1;Bacterial rpoB gene drug resistance mutation [Identifier] by Molecular method;Bacterial rpoB drug res mut Islt/Spm;;ACTIVE;2.67;2.67 +94066-8;Person-Centered Primary Care Measure;-;Pt;^Patient;-;PCPCM;PANEL.SURVEY.GNHLTH;4;Person-Centered Primary Care Measure [PCPCM];;;ACTIVE;2.67;2.67 +94067-6;Color Me Healthy - children's symptom assessment app panel;-;Pt;^Patient;-;;PANEL.H&P;2;Color Me Healthy - children's symptom assessment app;Color Me Healthy panel;Copyright © 2019 Lauri Linder. Used with permission.;ACTIVE;2.67;2.71 +94068-4;Symptom distress level;Find;Pt;^Patient;Ord;;H&P.HX;2;Symptom distress level;Symptom distress level;;ACTIVE;2.67;2.71 +94069-2;Emesis occurred;Find;Pt;^Patient;Ord;;H&P.HX;2;Emesis occurred;Emesis occurred;;ACTIVE;2.67;2.71 +940-7;Bombay Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Deprecated Bombay Ag [Presence] on Red Blood Cells from Blood product unit;Deprecated Bombay Ag RBC BPU Ql;;DEPRECATED;1.0;2.61 +94070-0;Emesis count;NRat;24H;^Patient;Qn;;H&P.HX;2;Emesis count 24 hour;Emesis count 24h nRate;;ACTIVE;2.67;2.71 +94072-6;Attended school today;Find;Pt;^Patient;Ord;;H&P.HX;2;Attended school today;Attended school today;;ACTIVE;2.67;2.71 +94073-4;Best thing about your day;Find;Pt;^Patient;Nom;;H&P.HX;2;Best thing about your day;Best thing about your day;;ACTIVE;2.67;2.71 +94074-2;Most bothersome concern;Find;Pt;^Patient;Nom;;H&P.HX;2;Most bothersome concern;Most bothersome concern;;ACTIVE;2.67;2.71 +94075-9;Cause of sick feeling;Find;Pt;^Patient;Nom;;H&P.HX;2;Cause of sick feeling;Cause of sick feeling;;ACTIVE;2.67;2.71 +94076-7;Mutations/Megabase;NRto;Pt;Tumor;Qn;;MOLPATH.MUT;1;Mutations/Megabase [# Ratio] in Tumor;Muts/Mb Tumor;;ACTIVE;2.67;2.67 +94077-5;Tumor mutation burden;Imp;Pt;Tumor;Ord;;MOLPATH.MUT;1;Tumor mutation burden [Interpretation];TMB Tumor-Imp;;ACTIVE;2.67;2.67 +9407-8;Alpha 1 antitrypsin;MCnc;Pt;Stool;Qn;;CHEM;1;Alpha 1 antitrypsin [Mass/volume] in Stool;A1AT Stl-mCnc;;ACTIVE;1.0i;2.73 +94078-3;PDX1 gene full mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.MUT;1;PDX1 gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;PDX1 Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +94079-1;TYMP gene full mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.MUT;1;TYMP gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;TYMP Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +94080-9;RRM2B gene full mutation analysis;Prid;Pt;Bld/Tiss;Nom;Sequencing;MOLPATH.MUT;1;RRM2B gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal;RRM2B Full Mut Anl Bld/T Seq;;ACTIVE;2.67;2.67 +94081-7;Validation error details;Find;Pt;Document;Doc;;DOC.ADMIN;2;Validation error details Document;Validation error details Doc;;ACTIVE;2.67;2.67 +94082-5;Validation error summary;Find;Pt;Document;Doc;;DOC.ADMIN;2;Validation error summary Document;Validation error summary Doc;;ACTIVE;2.67;2.67 +94083-3;Wound volume;Vol;Pt;Wound;Qn;;H&P.HX;2;Wound volume;Wound vol;;ACTIVE;2.67;2.67 +94084-1;Nonverbal pain indicators;Find;Pt;^Patient;Nom;;H&P.HX;2;Nonverbal pain indicators;Nonverb pain ind;;ACTIVE;2.67;2.67 +94085-8;Pain category;Type;Pt;^Patient;Nom;;H&P.HX;2;Pain category;Pain cat;;ACTIVE;2.67;2.67 +9408-6;Aminobenzoate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Aminobenzoate [Mass/volume] in Serum or Plasma;Aminobenzoate SerPl-mCnc;;ACTIVE;1.0i;2.7 +94086-6;Wound shape;Shape;Pt;Wound;Nom;;H&P.PX;2;Wound shape;Wnd shape;;ACTIVE;2.67;2.67 +94087-4;Chromosome analysis;Find;Pt;Bld/Tiss;Doc;Microarray;MOLPATH;1;Chromosome analysis in Blood or Tissue by Microarray;Chrom analy Bld/T Microarray;;ACTIVE;2.67;2.67 +94088-2;Multisection^WO & W contrast;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;MR;RAD;2;MR Thoracic and lumbar spine WO and W contrast;MR T+L-Spine WO+W contr;;ACTIVE;2.67;2.67 +94089-0;Multisection^WO & W contrast IV && Multisection^W contrast IV;Find;Pt;Chest;Doc;MR && MR.angio;RAD;2;MR Chest WO and W contrast IV and MRA Chest W contrast IV;MR Chest WO+W contr IV+MRA W contr IV;;ACTIVE;2.67;2.67 +94090-8;Views for dialysis fistula^W contrast IA & Guidance for percutaneous transluminal angioplasty + transcatheter placement of stent;Find;Pt;XXX>Vessels;Doc;RF.angio;RAD;2;RFA Views for dialysis fistula W contrast IA and Guidance for percutaneous transluminal angioplasty transcatheter placement of stent;RFA dial fist W c IA + PTA + stent place;;ACTIVE;2.67;2.72 +94091-6;Views for dialysis fistula^W contrast IA & Guidance for percutaneous transluminal angioplasty;Find;Pt;XXX>Vessels;Doc;RF.angio;RAD;2;RFA Views for dialysis fistula W contrast IA and Guidance for percutaneous transluminal angioplasty;RFA dial fist W c IA + PTA;;ACTIVE;2.67;2.72 +94092-4;Views for dialysis fistula^W contrast IA;Find;Pt;XXX>Vessels;Doc;RF.angio;RAD;2;RFA Views for dialysis fistula W contrast IA;RFA Vs for dial fistula W contr IA;;ACTIVE;2.67;2.72 +94093-2;Itemized bill;Find;Pt;^Patient;Doc;;DOC.MISC;2;Itemized bill;Itemized bill;;ACTIVE;2.67;2.67 +9409-4;Anabolic steroids;Prid;Pt;Urine;Nom;;CHEM;1;Anabolic steroids [Identifier] in Urine;Anabolic Steroids Ur;;ACTIVE;1.0i;2.73 +94094-0;Views limited for therapy or embolization or infusion^W contrast via existing catheter;Find;Pt;XXX;Doc;RF.angio;RAD;2;RFA Unspecified body region Limited Views for therapy or embolization or infusion W contrast via existing catheter;RFA Vs Ltd W contr via exist cath;;ACTIVE;2.67;2.67 +94095-7;Views^W contrast IV;Find;Pt;Extremity.unilateral>Extremity vessels;Doc;RF.angio;RAD;2;RFA Extremity vessels Unilateral Views W contrast IV;RFA Ext ves-Ul Views W contr IV;;ACTIVE;2.67;2.67 +94096-5;Collagen type VII Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Collagen type VII IgG Ab [Presence] in Serum or Plasma by Immunoassay;CollagenVII IgG SerPl Ql IA;;ACTIVE;2.67;2.67 +94097-3;Cytosolic 5'-nucleotidase 1A Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Cytosolic 5'-nucleotidase 1A IgG Ab [Presence] in Serum or Plasma by Immunoassay;cN-1A IgG SerPl Ql IA;;ACTIVE;2.67;2.67 +94098-1;Dense fine speckled 70 protein Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Dense fine speckled 70 protein IgG Ab [Presence] in Serum or Plasma by Immunoassay;DFS70 IgG SerPl Ql IA;;ACTIVE;2.67;2.67 +94099-9;Hantavirus Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Hantavirus IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;Hantavirus IgM SerPl Ql IF;;ACTIVE;2.67;2.67 +94100-5;Hantavirus seoul Ab.IgM;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus seoul IgM Ab [Presence] in Serum or Plasma by Line blot;H seoul IgM SerPl Ql Line blot;;ACTIVE;2.67;2.67 +94101-3;Hantavirus seoul Ab.IgG;PrThr;Pt;Ser/Plas;Ord;Line blot;MICRO;1;Hantavirus seoul IgG Ab [Presence] in Serum or Plasma by Line blot;H seoul IgG SerPl Ql Line blot;;ACTIVE;2.67;2.67 +9410-2;Histamine;MRat;24H;Urine;Qn;;CHEM;1;Histamine [Mass/time] in 24 hour Urine;Histamine 24h Ur-mRate;;ACTIVE;1.0i;2.73 +94102-1;Epstein Barr virus early diffuse Ab.IgA;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Epstein Barr virus early diffuse IgA Ab [Units/volume] in Serum or Plasma by Immunoassay;EBV EA-D IgA SerPl IA-aCnc;;ACTIVE;2.67;2.67 +94103-9;Zolpidem phenyl-4-carboxylate;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Zolpidem phenyl-4-carboxylate [Presence] in Urine by Screen method;Zolpidem phenyl-4-carb Ur Ql Scn;;ACTIVE;2.67;2.73 +94104-7;Zolpidem;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Zolpidem [Presence] in Urine by Screen method;Zolpidem Ur Ql Scn;;ACTIVE;2.67;2.67 +94105-4;Alpha hydroxytriazolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Alpha hydroxytriazolam [Presence] in Urine by Screen method;A-OH-triazolam Ur Ql Scn;;ACTIVE;2.67;2.67 +94106-2;Temazepam glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Temazepam glucuronide [Presence] in Urine by Screen method;Temazepam glucuronide Ur Ql Scn;;ACTIVE;2.67;2.67 +94107-0;Oxazepam glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Oxazepam glucuronide [Presence] in Urine by Screen method;Oxazepam glucuronide Ur Ql Scn;;ACTIVE;2.67;2.67 +94108-8;1-Hydroxymidazolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;1-Hydroxymidazolam [Presence] in Urine by Screen method;1OH-midazolam Ur Ql Scn;;ACTIVE;2.67;2.73 +94109-6;LORazepam glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;LORazepam glucuronide [Presence] in Urine by Screen method;LORazepam glucuronide Ur Ql Scn;;ACTIVE;2.67;2.67 +9411-0;Hydrocorticosterone;MRat;24H;Urine;Qn;;CHEM;1;Hydrocorticosterone [Mass/time] in 24 hour Urine;Hydrocorticostern 24h Ur-mRate;;ACTIVE;1.0i;2.42 +94110-4;2-Hydroxyethylflurazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;2-Hydroxyethylflurazepam [Presence] in Urine by Screen method;2-OH-Ethylfluraz Ur Ql Scn;;ACTIVE;2.67;2.67 +94111-2;7-Aminoflunitrazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;7-Aminoflunitrazepam [Presence] in Urine by Screen method;7Aminoflunitrazepam Ur Ql Scn;;ACTIVE;2.67;2.67 +94112-0;7-Aminoclonazepam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Urine by Screen method;7Aminoclonazepam Ur Ql Scn;;ACTIVE;2.67;2.67 +94113-8;Norclobazam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norclobazam [Presence] in Urine by Screen method;Norclobazam Ur Ql Scn;;ACTIVE;2.67;2.67 +94114-6;cloBAZam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;cloBAZam [Presence] in Urine by Screen method;cloBAZam Ur Ql Scn;;ACTIVE;2.67;2.67 +94115-3;Alpha hydroxyalprazolam glucuronide;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Alpha hydroxyalprazolam glucuronide [Presence] in Urine by Screen method;A-OH Alpraz gluc Ur Ql Scn;;ACTIVE;2.67;2.67 +94116-1;ALPRAZolam;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;ALPRAZolam [Presence] in Urine by Screen method;Alpraz Ur Ql Scn;;ACTIVE;2.67;2.67 +94117-9;Benzodiazepines panel;PrThr;Pt;Urine;Ord;Screen;PANEL.DRUG/TOX;1;Benzodiazepines panel [Presence] - Urine by Screen method;Benzodiazepines Pnl Ur Scn;;ACTIVE;2.67;2.67 +94118-7;Medical records in response to authorization denial;Find;Pt;^Patient;Doc;;DOC.ADMIN;2;Medical records in response to authorization denial;Med records p auth denial;;ACTIVE;2.67;2.67 +94119-5;Volume.expired per minute/Carbon dioxide production^W exercise;VRto;Pt;^Patient;Qn;;CARDIO-PULM;2;Expired minute volume/Carbon dioxide production during exercise;VE/VCO2 slope dur exercise;;ACTIVE;2.67;2.67 +94120-3;Oxygen consumption/Heart rate^peak during exercise;VRat;Pt;^Patient;Qn;;CARDIO-PULM;2;Oxygen consumption (VO2)/Heart rate --peak during exercise;Peak oxygen pulse;;ACTIVE;2.67;2.67 +94121-1;Intravascular;Pres;Pt;Vena cava.inferior;Qn;US;BP.VENOUS.MOLEC;2;Inferior vena cava Blood pressure by US;IVC BP by US;;ACTIVE;2.67;2.67 +94122-9;Oxygen consumption/Body weight^peak during exercise;VRatCnt;Pt;^Patient;Qn;;PULM;2;Oxygen consumption (VO2)/Body weight [Volume Rate Content] --peak during exercise;VO2/BW max dur exercise;;ACTIVE;2.67;2.67 +94123-7;Intravascular end diastolic;Pres;Pt;Pulmonary artery;Qn;Cardiac catheterization;BP.CENT.MOLEC;2;Pulmonary artery End diastolic blood pressure by Cardiac catheterization;dPAP by Cardiac cath;;ACTIVE;2.67;2.67 +94124-5;Ventilatory threshold;VRatCnt;Pt;^Patient;Qn;;PULM;2;Ventilatory threshold [Volume Rate Content];Ventilatory threshold;;ACTIVE;2.67;2.67 +94125-2;Volume.residual/Predicted;VFr;Pt;Respiratory system;Qn;Plethysmograph.body box;PULM;2;Residual volume/Predicted by Plethysmograph body box;Residual vol/Predicted Plethysmograph;;ACTIVE;2.67;2.67 +94126-0;Ventilatory equivalent for carbon dioxide^W exercise;VRto;Pt;^Patient;Qn;;PULM;2;Ventilatory equivalent for carbon dioxide --W exercise;VEqCO2 W exercise;;ACTIVE;2.67;2.67 +94127-8;Clarity;Type;Pt;Body fld;Nom;;SPEC;1;Clarity of Body fluid;Clarity Fld;;ACTIVE;2.67;2.67 +9412-8;Leucine;SCnc;Pt;CSF;Qn;;CHEM;1;Leucine [Moles/volume] in Cerebral spinal fluid;Leucine CSF-sCnc;;ACTIVE;1.0i;2.73 +94128-6;Vasopressin challenge post water deprivation panel;-;Pt;Urine+Ser/Plas;-;;PANEL.CHAL;1;Vasopressin challenge post water deprivation panel - Urine and Serum or Plasma;Vasopressin chal p H2O depr Pnl U+SerPl;;ACTIVE;2.67;2.67 +94129-4;Water deprivation challenge panel;-;Pt;Urine+Ser/Plas;-;;PANEL.CHAL;1;Water deprivation challenge panel - Urine and Serum or Plasma;Water deprivation Pnl Ur+SerPl;;ACTIVE;2.67;2.67 +94130-2;Body disposition facility name;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Body disposition facility name [Identifier];Body disposition facility name;;ACTIVE;2.67;2.67 +94131-0;Body disposition facility address;Addr;Pt;Facility;Nom;;ADMIN.FACILITY;2;Body disposition facility address;Body disposition facility address;;ACTIVE;2.67;2.67 +94132-8;Funeral facility name;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Funeral facility name [Identifier];Funeral facility name;;ACTIVE;2.67;2.67 +94133-6;Funeral facility address;Addr;Pt;Facility;Nom;;ADMIN.FACILITY;2;Funeral facility address;Funeral facility address;;ACTIVE;2.67;2.67 +94134-4;Funeral service licensee or other agent assuming custody of the body of the deceased;Pn;Pt;Personnel;Nom;;ADMIN.FACILITY;2;Personnel Funeral service licensee or other agent assuming custody of the body of the deceased;Personnel Funeral service licensee;;ACTIVE;2.67;2.67 +94135-1;Funeral service licensee identifier;ID;Pt;Facility;Nom;;ADMIN.FACILITY;2;Funeral service licensee identifier Facility;Funeral service licensee ID Facility;;ACTIVE;2.67;2.67 +9413-6;Lipids;MRat;24H;Stool;Qn;;CHEM;1;Deprecated Lipids [Mass/time] in 24 hour Stool;Deprecated Lipids 24h Stl-mRate;;DEPRECATED;1.0i;2.7 +94136-9;Controlled substance agreement;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Controlled substance agreement;Cntrl Substance Agreement;;ACTIVE;2.67;2.67 +94137-7;HEDIS 2020 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Sets;HEDIS 2020 Value Sets;;DISCOURAGED;2.67;2.69 +94138-5;HEDIS 2020 Value Set - BMI;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Set - BMI;HEDIS 2020 BMI;;DISCOURAGED;2.67;2.69 +94139-3;HEDIS 2020 Value Set - BMI percentile;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Set - BMI percentile;HEDIS 2020 BMI prctl;;DISCOURAGED;2.67;2.69 +94140-1;HEDIS 2020 Value Set - CT Colonography;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Set - CT Colonography;HEDIS 2020 CT Colongrphy;;DISCOURAGED;2.67;2.69 +94141-9;HEDIS 2020 Value Set - Mammography;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Set - Mammography;HEDIS 2020 Mammography;;DISCOURAGED;2.67;2.69 +94142-7;HEDIS 2020 Value Set - Urine Protein Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Set - Urine Protein Tests;HEDIS 2020 Urine Prot Tests;;DISCOURAGED;2.67;2.69 +94143-5;HEDIS 2020 Value Set - Diastolic Blood Pressure;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Set - Diastolic Blood Pressure;HEDIS 2020 Diastolic BP;;DISCOURAGED;2.67;2.69 +9414-4;Phosphoserine;SCnc;24H;Urine;Qn;;CHEM;1;Phosphoserine [Moles/volume] in 24 hour Urine;Phosphoserine 24h Ur-sCnc;;ACTIVE;1.0i;2.73 +94144-3;HEDIS 2020 Value Set - Systolic Blood Pressure;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS 2020 Value Set - Systolic Blood Pressure;HEDIS 2020 Systolic BP;;DISCOURAGED;2.67;2.69 +94145-0;Crotonylglycine/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Crotonylglycine/Creatinine [Molar ratio] in Urine;Crotonylglycine/Creat Ur-sRto;;ACTIVE;2.68;2.68 +94146-8;2-Decenedioate/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;2-Decenedioate/Creatinine [Molar ratio] in Urine;2-Decenedioate/Creat Ur-sRto;;ACTIVE;2.68;2.68 +94147-6;B-bump;Find;Pt;Mitral valve;Ord;US.M-mode;CARD.US;2;Mitral valve B-bump by US.M-mode;MV B-bump M-mode;;ACTIVE;2.68;2.68 +94148-4;Blood flow reversal.holodiastolic;Find;Pt;Aorta.thoracic.descending;Ord;US.doppler;CARD.US;2;Descending thoracic aorta Holodiastolic flow reversal by US.doppler;DTA Holodias flow reversal DOP;;ACTIVE;2.68;2.68 +94149-2;Heterophile Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;Heterophile Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;Heteroph Ab SerPlBld Ql IA.rapid;;ACTIVE;2.68;2.68 +941-5;Bombay Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Deprecated Bombay Ag [Presence] on Red Blood Cells from donor;Deprecated Bombay Ag RBC Donr Ql;;DEPRECATED;1.0;2.61 +9415-1;carBAMazepine 10,11-Epoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbamazepine 10,11-Epoxide [Mass/volume] in Serum or Plasma;Carbamazepine EP SerPl-mCnc;;ACTIVE;1.0i;2.73 +94151-8;Bacteria.carbapenem resistant identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Bacteria.carbapenem resistant identified in Specimen by Organism specific culture;Bacteria.carbpm resist Spec Cult;;ACTIVE;2.68;2.69 +94157-5;PhenX - age of initiation of first cigarette use - adult protocol 030703;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - age of initiation of first cigarette use - adult protocol 030703;Age init cig use adult proto;;ACTIVE;2.68;2.68 +94158-3;PhenX - ethnicity protocol 010502;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - ethnicity protocol 010502;PhenX - ethnicity protocol;;ACTIVE;2.68;2.68 +94161-7;PROMIS parent proxy item bank - mobility - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - mobility - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94162-5;PROMIS parent proxy item bank - pain interference - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy item bank - pain interference - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94163-3;PROMIS parent proxy pain interference - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy pain interference - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94164-1;PROMIS parent proxy - global health 7 - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy - global health 7 - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94165-8;PROMIS parent proxy - global health 7 - version 1.0;-;Pt;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy - global health 7 - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94166-6;PROMIS parent proxy short form - mobility 8 - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - mobility 8 - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94167-4;PROMIS parent proxy short form mobility 8 - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form mobility 8 - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +9416-9;Acyclovir;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Acyclovir [Mass/volume] in Serum or Plasma;Acyclovir SerPl-mCnc;;ACTIVE;1.0i;2.73 +94169-0;PROMIS parent proxy short form - physical function - upper extremity 8 - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - physical function - upper extremity 8 - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94170-8;PROMIS parent proxy physical function - upper extremity - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy physical function - upper extremity - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94171-6;My child could pour a drink from a full pitcher in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could pour a drink from a full pitcher in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94172-4;My child could open a jar by himself or herself in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could open a jar by himself or herself in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94173-2;My child could pull open heavy doors in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could pull open heavy doors in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94174-0;My child could use a key to unlock a door in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could use a key to unlock a door in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94175-7;My child could pull a shirt on over his or her head without help in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could pull a shirt on over his or her head without help in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94176-5;My child could open the rings in school binders in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could open the rings in school binders in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +9417-7;Anthraquinone;MCnt;Pt;Stool;Qn;;DRUG/TOX;1;Anthraquinone [Mass/mass] in Stool;Anthraquinone Stl-mCnt;;ACTIVE;1.0i;2.73 +94177-3;My child could button his or her shirt or pants in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could button his or her shirt or pants in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94178-1;My child could put on his or her shoes without help in past 7D;Find;7D;^Patient;Ord;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;My child could put on his or her shoes without help in past 7D [PROMIS.PARENTPROXY];;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94179-9;PROMIS parent proxy short form - pain interference 8 - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy short form - pain interference 8 - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94180-7;PROMIS parent proxy short form - pain interference 8 - version 1.0;-;7D;^Patient;-;PROMIS.PARENTPROXY;PANEL.SURVEY.PROMIS;4;PROMIS parent proxy short form - pain interference 8 - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94181-5;PROMIS parent proxy global health - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy global health - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94182-3;PROMIS parent proxy physical function - upper extremity - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PARENTPROXY;SURVEY.PROMIS;4;PROMIS parent proxy physical function - upper extremity - version 1.0 T-score;;;ACTIVE;2.68;2.68 +94183-1;Heartland banyangvirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Heartland banyangvirus RNA [Presence] in Specimen by NAA with probe detection;HRTV RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94184-9;Yellow fever virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Yellow fever virus RNA [Presence] in Specimen by NAA with probe detection;YFV RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +9418-5;Hydroxybupropion;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hydroxybupropion [Mass/volume] in Serum or Plasma;OH-bupropion SerPl-mCnc;;ACTIVE;1.0i;2.73 +94185-6;Borrelia miyamotoi glpQ gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Borrelia miyamotoi glpQ gene [Presence] in Specimen by NAA with probe detection;B miyamotoi glpQ Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94186-4;Origin of germline genetic variant;Type;Pt;^Patient;Nom;;MOLPATH;1;Origin of germline genetic variant [Type];Origin germline gen var;;ACTIVE;2.68;2.68 +94187-2;Platelet aggregation;Imp;Pt;PRP;Nom;;COAG;1;Platelet aggregation [Interpretation] in Platelet rich plasma;PA PRP-Imp;;ACTIVE;2.68;2.68 +94188-0;APC gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;APC gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;APC gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94189-8;APOA2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;APOA2 gene full mutation analysis in Blood or Tissue by Sequencing;APOA2 Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.72 +94190-6;BPGM gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;BPGM gene full mutation analysis in Blood or Tissue by Sequencing;BPGM Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94191-4;BRCA1+BRCA2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;BRCA1+BRCA2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;BRCA1+BRCA2 Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94192-2;SLC25A20 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;SLC25A20 gene full mutation analysis in Blood or Tissue by Sequencing;SLC25A20 Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +9419-3;HLA-DQ6;PrThr;Pt;Bld/Tiss;Ord;;HLA;1;HLA-DQ6 [Presence];HLA-DQ6 Ql;;ACTIVE;1.0i;2.73 +94193-0;CDKN1C gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;CDKN1C gene full mutation analysis in Blood or Tissue by Sequencing;CDKN1C Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94194-8;CPOX gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;CPOX gene full mutation analysis in Blood or Tissue by Sequencing;CPOX Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94195-5;CPT2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;CPT2 gene full mutation analysis in Blood or Tissue by Sequencing;CPT2 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94196-3;CTRC gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;CTRC gene full mutation analysis in Blood or Tissue by Sequencing;CTRC Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94197-1;CYP21A2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;CYP21A2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;CYP21A2 Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94198-9;DPYD gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.PHARMG;1;DPYD gene full mutation analysis in Blood or Tissue by Sequencing;DPYD gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94199-7;FGA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;FGA gene full mutation analysis in Blood or Tissue by Sequencing;FGA Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94200-3;FTCD gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;FTCD gene full mutation analysis in Blood or Tissue by Sequencing;FTCD Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +9420-1;Entamoeba histolytica Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Entamoeba histolytica Ab [Titer] in Serum by Complement fixation;E histolyt Ab Titr Ser CF;;ACTIVE;1.0i;2.7 +94201-1;GNPTAB gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;GNPTAB gene full mutation analysis in Blood or Tissue by Sequencing;GNPTAB Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94202-9;GRHPR gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;GRHPR gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;GRHPR Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94203-7;GSN gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;GSN gene full mutation analysis in Blood or Tissue by Sequencing;GSN Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94204-5;HMBS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;HMBS gene full mutation analysis in Blood or Tissue by Sequencing;HMBS Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94205-2;LYZ gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;LYZ gene full mutation analysis in Blood or Tissue by Sequencing;LYZ Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94206-0;MMACHC gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;MMACHC gene full mutation analysis in Blood or Tissue by Sequencing;MMACHC Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94207-8;MMADHC gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;MMADHC gene full mutation analysis in Blood or Tissue by Sequencing;MMADHC Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94208-6;MLYCD gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;MLYCD gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;MLYCD Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94209-4;NAGLU gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;NAGLU gene full mutation analysis in Blood or Tissue by Sequencing;NAGLU Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94210-2;ARSB gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;ARSB gene full mutation analysis in Blood or Tissue by Sequencing;ARSB Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94211-0;NPC1 gene+NPC2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;NPC1 gene+NPC2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;NPC1+NPC2 Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94212-8;PKLR gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;PKLR gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;PKLR gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94213-6;PPOX gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;PPOX gene full mutation analysis in Blood or Tissue by Sequencing;PPOX Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94214-4;PRKAR1A gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;PRKAR1A gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;PRKAR1A Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94215-1;PRSS1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;PRSS1 gene full mutation analysis in Blood or Tissue by Sequencing;PRSS1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94216-9;STK11 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;STK11 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;STK11 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94217-7;TP53 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;TP53 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;TP53 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94218-5;UBE3A gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;UBE3A gene full mutation analysis in Blood or Tissue by Sequencing;UBE3A gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +9421-9;Entamoeba histolytica Ab;ACnc;Pt;Ser;Qn;Immune diffusion;MICRO;1;Entamoeba histolytica Ab [Units/volume] in Serum by Immune diffusion (ID);E histolyt Ab Ser ID-aCnc;;ACTIVE;1.0i;2.73 +94219-3;VWF gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;VWF gene full mutation analysis in Blood or Tissue by Sequencing;VWF gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94220-1;SPINK1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;SPINK1 gene full mutation analysis in Blood or Tissue by Sequencing;SPINK1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94221-9;SMN1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;SMN1 gene full mutation analysis in Blood or Tissue by Sequencing;SMN1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94222-7;SERPINA1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;SERPINA1 gene full mutation analysis in Blood or Tissue by Sequencing;SERPINA1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94223-5;PTEN gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;PTEN gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;PTEN gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94224-3;RET gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;RET gene full mutation analysis in Blood or Tissue by Sequencing;RET gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94225-0;TTR gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;TTR gene full mutation analysis in Blood or Tissue by Sequencing;TTR gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94226-8;PKHD1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;PKHD1 gene full mutation analysis in Blood or Tissue by Sequencing;PKHD1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +9422-7;Herpes simplex virus Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Herpes simplex virus IgG Ab [Units/volume] in Serum;HSV IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +94227-6;AGXT gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;AGXT gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;AGXT gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94228-4;MUTYH gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;MUTYH gene full mutation analysis in Blood or Tissue by Sequencing;MUTYH gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94229-2;MECP2 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;MECP2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;MECP2 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +942-3;Bombay Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Deprecated Bombay Ag [Presence] on Red Blood Cells;Deprecated Bombay Ag RBC Ql;;DEPRECATED;1.0;2.61 +94230-0;GBA gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;GBA gene full mutation analysis in Blood or Tissue by Sequencing;GBA gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94231-8;G6PD gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;G6PD gene full mutation analysis in Blood or Tissue by Sequencing;G6PD gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94232-6;FLCN gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;FLCN gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;FLCN gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94233-4;FECH gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;FECH gene full mutation analysis in Blood or Tissue by Sequencing;FECH gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94234-2;F8 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F8 gene full mutation analysis in Blood or Tissue by Sequencing;F8 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +9423-5;Nuclear Ab;ACnc;Pt;Ser;Qn;IF;SERO;1;Nuclear Ab [Units/volume] in Serum by Immunofluorescence;ANA Ser IF-aCnc;;ACTIVE;1.0i;2.73 +94235-9;F7 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F7 gene full mutation analysis in Blood or Tissue by Sequencing;F7 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94236-7;F5 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F5 gene full mutation analysis in Blood or Tissue by Sequencing;F5 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94237-5;F2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F2 gene full mutation analysis in Blood or Tissue by Sequencing;F2 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94238-3;F12 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F12 gene full mutation analysis in Blood or Tissue by Sequencing;F12 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94239-1;F11 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;F11 gene full mutation analysis in Blood or Tissue by Sequencing;F11 Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94240-9;CDH1 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;CDH1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;CDH1 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94241-7;BTK gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;BTK gene full mutation analysis in Blood or Tissue by Sequencing;BTK gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +94242-5;BTD gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;BTD gene full mutation analysis in Blood or Tissue by Sequencing;BTD gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +9424-3;Intercellular substance Ab;Titr;Pt;Ser;Qn;;SERO;1;Intercellular substance Ab [Titer] in Serum;ICS Ab Titr Ser;;ACTIVE;1.0i;2.73 +94243-3;Note;Find;Pt;{Setting};Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Note;Navigator Note;;ACTIVE;2.68;2.68 +94244-1;Plan of care note;Find;Pt;{Setting};Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Plan of care note;WOC Plan of care note;;ACTIVE;2.68;2.68 +94245-8;Progress note;Find;Pt;{Setting};Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Progress note;WOC Prog note;;ACTIVE;2.68;2.73 +94246-6;Note;Find;Pt;Telephone encounter;Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Telephone encounter Note;WOC Phone Note;;ACTIVE;2.68;2.68 +94247-4;Borrelia burgdorferi oppA2 gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Borrelia burgdorferi oppA2 gene [Presence] in Blood by NAA with non-probe detection;B burgdorferi oppA2 Bld Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94248-2;Borrelia mayonii oppA2 gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Borrelia mayonii oppA2 gene [Presence] in Blood by NAA with non-probe detection;B mayonii oppA2 Bld Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94249-0;Borrelia garinii+afzelii oppA2 gene;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Borrelia garinii+afzelii oppA2 gene [Presence] in Blood by NAA with non-probe detection;B gar+afz oppA2 Bld Ql NAA+non-probe;;ACTIVE;2.68;2.68 +9425-0;Acetone;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Acetone [Mass/volume] in Blood;Acetone Bld-mCnc;;ACTIVE;1.0i;2.73 +94250-8;Borrelia burgdorferi oppA2 gene;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Borrelia burgdorferi oppA2 gene [Presence] in Specimen by NAA with non-probe detection;B burgdorferi oppA2 Spec Ql NAA+non-prb;;ACTIVE;2.68;2.69 +94251-6;Borrelia mayonii oppA2 gene;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Borrelia mayonii oppA2 gene [Presence] in Specimen by NAA with non-probe detection;B mayonii oppA2 Spec Ql NAA+non-probe;;ACTIVE;2.68;2.69 +94252-4;Borrelia garinii+afzelii oppA2 gene;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Borrelia garinii+afzelii oppA2 gene [Presence] in Specimen by NAA with non-probe detection;B gar+afz oppA2 Spec Ql NAA+non-probe;;ACTIVE;2.68;2.69 +94253-2;Borrelia sp panel;-;Pt;XXX;-;Non-probe.amp.tar;PANEL.MICRO;1;Borrelia sp panel - Specimen by NAA with non-probe detection;B sp panel Spec NAA+non-probe;;ACTIVE;2.68;2.69 +94254-0;CYP1A2 gene product metabolic activity interpretation;Imp;Pt;Bld/Tiss;Ord;Molgen;MOLPATH.PHARMG;1;CYP1A2 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method;CYP1A2 gene prod met act Bld/T-Imp;;ACTIVE;2.68;2.68 +94255-7;Calcium;MCnc;Pt;Sweat;Qn;;CHEM;1;Calcium [Mass/volume] in Sweat;Calcium Sweat-mCnc;;ACTIVE;2.68;2.68 +94256-5;Magnesium;MCnc;Pt;Sweat;Qn;;CHEM;1;Magnesium [Mass/volume] in Sweat;Magnesium Sweat-mCnc;;ACTIVE;2.68;2.68 +94257-3;PROMIS pediatric - global health 7 - version 1.0;-;Pt;^Patient;-;PROMIS.PEDS;PANEL.SURVEY.PROMIS;4;PROMIS pediatric - global health 7 - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94258-1;PROMIS pediatric - global health 7 - version 1.0 raw score;Score;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric - global health 7 - version 1.0 raw score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.68;2.68 +94263-1;PROMIS pediatric - global health 7 - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS.PEDS;SURVEY.PROMIS;4;PROMIS pediatric - global health 7 - version 1.0 T-score;;;ACTIVE;2.68;2.68 +94264-9;Brucella sp Ab;Titr;Pt;CSF;Qn;Aggl.capture;MICRO;1;Brucella sp Ab [Titer] in Cerebral spinal fluid by Immunocapture agglutination;Brucella Ab Titr CSF Capture aggl;;ACTIVE;2.68;2.69 +94265-6;Cells.CD18;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD18 cells [Presence] in Blood;CD18 Cells Bld Ql;;ACTIVE;2.68;2.68 +94266-4;CD11a & CD11b & CD18 phenotyping panel;-;Pt;Bld;Ord;;PANEL.CELLMARK;1;CD11a, CD11b, and CD18 phenotyping panel - Blood Qualitative;CD11a + CD11b + CD18 Pnl Bld;;ACTIVE;2.68;2.68 +94267-2;Cells.CD11b;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD11b cells [Presence] in Blood;CD11b Cells Bld Ql;;ACTIVE;2.68;2.68 +9426-8;Barbiturates;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Barbiturates [Mass/volume] in Urine;Barbiturates Ur-mCnc;;ACTIVE;1.0i;2.73 +94268-0;Cells.CD11a;PrThr;Pt;Bld;Ord;;CELLMARK;1;CD11a cells [Presence] in Blood;CD11a Cells Bld Ql;;ACTIVE;2.68;2.68 +94269-8;Platelet aggregation.EPINEPHrine induced^50 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --50 umol/L;PA Epineph 50 umol/L PRP;;ACTIVE;2.68;2.68 +94270-6;Ubiquinone 10;SCnt;Pt;WBC;Qn;;CHEM;1;Coenzyme Q10 [Moles/mass] in Leukocytes;Ubiquinone10 WBC-sCnt;;ACTIVE;2.68;2.68 +94271-4;Purkinje cell cytoplasmic type 1 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;PCA-1 IgG Ab [Presence] in Serum by Line blot;PCA-1 IgG Ser Ql Line blot;;ACTIVE;2.68;2.68 +94272-2;Purkinje cell cytoplasmic type 1 Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;SERO;1;PCA-1 IgG Ab [Presence] in Cerebral spinal fluid by Line blot;PCA-1 IgG CSF Ql Line blot;;ACTIVE;2.68;2.68 +94273-0;Muscle specific receptor tyrosine kinase Ab.IgG;SCnc;Pt;Ser;Qn;IA;SERO;1;Muscle specific receptor tyrosine kinase IgG Ab [Moles/volume] in Serum by Immunoassay;MuSK IgG Ser IA-sCnc;;ACTIVE;2.68;2.68 +94274-8;Bedaquiline;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Bedaquiline [Susceptibility];Bedaquiline Susc Islt;;ACTIVE;2.68;2.68 +94275-5;Apis mellifera acid phosphatase recombinant (rApi m) 3 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee acid phosphatase recombinant (rApi m) 3 IgE Ab [Units/volume] in Serum;Honey bee (rApi m) 3 IgE Qn;;ACTIVE;2.68;2.68 +9427-6;Barbiturates;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Barbiturates [Mass/volume] in Gastric fluid;Barbiturates Gast-mCnc;;ACTIVE;1.0i;2.34 +94276-3;Apis mellifera dipeptidyl peptidase recombinant (rApi m) 5 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee dipeptidyl peptidase recombinant (rApi m) 5 IgE Ab [Units/volume] in Serum;Honey bee DPP (rApi m) 5 IgE Qn;;ACTIVE;2.68;2.68 +94277-1;Dog recombinant (rCan f) 6 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dog recombinant 6 IgE Ab [Units/volume] in Serum;Dog (rCan f) 6 IgE Qn;;ACTIVE;2.68;2.68 +94278-9;Cat recombinant (rFel d) 7 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cat recombinant (rFel d) 7 IgE Ab [Units/volume] in Serum;Cat (rFel d) 7 IgE Qn;;ACTIVE;2.68;2.68 +94279-7;Apis mellifera acid phosphatase recombinant (rApi m) 3 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee acid phosphatase recombinant (rApi m) 3 IgE Ab RAST class [Presence] in Serum;Honey bee (rApi m) 3 IgE RAST Ql;;ACTIVE;2.68;2.68 +94280-5;Apis mellifera dipeptidyl peptidase recombinant (rApi m) 5 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Honey bee dipeptidyl peptidase recombinant (rApi m) 5 IgE Ab RAST class [Presence] in Serum;Honey bee DPP (rApi m) 5 IgE RAST Ql;;ACTIVE;2.68;2.68 +94281-3;Dog recombinant (rCan f) 6 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Dog recombinant 6 IgE Ab RAST class [Presence] in Serum;Dog (rCan f) 6 IgE RAST Ql;;ACTIVE;2.68;2.68 +94282-1;Cat recombinant (rFel d) 7 Ab.IgE.RAST class;PrThr;Pt;Ser;Ord;;ALLERGY;1;Cat recombinant (rFel d) 7 IgE Ab RAST class [Presence] in Serum;Cat (rFel d) 7 IgE RAST Ql;;ACTIVE;2.68;2.68 +94283-9;Dipeptidyl aminopeptidase-like protein 6 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;DPPX IgG CSF Ql CBA IFA;;ACTIVE;2.68;2.69 +9428-4;Benzodiazepines;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzodiazepines [Mass/volume] in Urine;Benzodiaz Ur-mCnc;;ACTIVE;1.0i;2.73 +94284-7;Dipeptidyl aminopeptidase-like protein 6 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;DPPX IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94285-4;Contactin-associated protein 2 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Contactin-associated protein 2 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;CASPR2 IgG Ser Ql CBA IFA;;ACTIVE;2.68;2.69 +94286-2;Contactin-associated protein 2 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Contactin-associated protein 2 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;CASPR2 IgG CSF Ql CBA IFA;;ACTIVE;2.68;2.69 +94287-0;Leucine-rich glioma-inactivated protein 1 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;LGI1 IgG Ser Ql CBA IFA;;ACTIVE;2.68;2.69 +94288-8;Leucine-rich glioma-inactivated protein 1 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;LGI1 IgG CSF Ql CBA IFA;;ACTIVE;2.68;2.69 +94289-6;West Nile virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;West Nile virus neutralizing antibody [Presence] in Specimen by Neutralization test;WNV NAb Spec Ql Nt;;ACTIVE;2.68;2.72 +94290-4;Saint Louis encephalitis virus Ab.Neut;PrThr;Pt;XXX;Ord;Neut;MICRO;1;Saint Louis encephalitis virus neutralizing antibody [Presence] in Specimen by Neutralization test;SLEV NAb Spec Ql Nt;;ACTIVE;2.68;2.72 +94291-2;Hydroxybupropion;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Hydroxybupropion [Presence] in Serum or Plasma by Screen method;OH-bupropion SerPl Ql Scn;;ACTIVE;2.68;2.68 +9429-2;Indium;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Indium [Mass/volume] in Specimen;Indium Spec-mCnc;;ACTIVE;1.0i;2.7 +94292-0;Citalopram+Escitalopram;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Citalopram+Escitalopram [Presence] in Serum or Plasma by Screen method;Citalopram+Escitalopram SerPl Ql Scn;;ACTIVE;2.68;2.68 +94293-8;Citalopram+Escitalopram;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Citalopram+Escitalopram [Mass/volume] in Serum or Plasma by Confirmatory method;Citalopram+Escitalopram SerPl Cfm-mCnc;;ACTIVE;2.68;2.68 +94294-6;Norcitalopram;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Norcitalopram [Presence] in Serum or Plasma by Screen method;Norcitalopram SerPl Ql Scn;;ACTIVE;2.68;2.68 +94295-3;Duloxetine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;DULoxetine [Presence] in Serum or Plasma by Screen method;DULoxetine SerPl Ql Scn;;ACTIVE;2.68;2.68 +94296-1;Norfluvoxamine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Norfluvoxamine [Presence] in Serum or Plasma by Screen method;Norfluvoxamine SerPl Ql Scn;;ACTIVE;2.68;2.68 +94297-9;Norfluvoxamine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Norfluvoxamine [Mass/volume] in Serum or Plasma by Confirmatory method;Norfluvoxamine SerPl Cfm-mCnc;;ACTIVE;2.68;2.68 +94298-7;O-desmethylvenlafaxine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;O-desmethylvenlafaxine [Presence] in Serum or Plasma by Screen method;ODV SerPl Ql Scn;;ACTIVE;2.68;2.69 +94299-5;Vilazodone;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Vilazodone [Presence] in Serum or Plasma by Screen method;Vilaz SerPl Ql Scn;;ACTIVE;2.68;2.68 +94-3;Cefodizime;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefodizime [Susceptibility] by Serum bactericidal titer;Cefodizime Titr SBT;;ACTIVE;1.0;2.32 +9430-0;Isobutylcarbinol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isobutylcarbinol [Mass/volume] in Blood;Isobutylcarbinol Bld-mCnc;;ACTIVE;1.0i;2.73 +94300-1;Vilazodone;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Vilazodone [Mass/volume] in Serum or Plasma by Confirmatory method;Vilaz SerPl Cfm-mCnc;;ACTIVE;2.68;2.68 +94301-9;Vortioxetine;PrThr;Pt;Ser/Plas;Ord;Screen;DRUG/TOX;1;Vortioxetine [Presence] in Serum or Plasma by Screen method;Vortioxetine SerPl Ql Scn;;ACTIVE;2.68;2.68 +94302-7;Vortioxetine;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Vortioxetine [Mass/volume] in Serum or Plasma by Confirmatory method;Vortioxetine SerPl Cfm-mCnc;;ACTIVE;2.68;2.68 +94303-5;Pregnenolone & 17-Hydroxypregnenolone panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Pregnenolone and 17-Hydroxypregnenolone panel - Serum or Plasma;Preg + 17-OH Preg pnl SerPl;;ACTIVE;2.68;2.68 +94304-3;OxyCODONE & metabolites panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;OxyCODONE and metabolites panel - Urine by Confirmatory method;OxyCODONE+metabolites Pnl Ur Cfm;;ACTIVE;2.68;2.68 +94305-0;OxyMORphone & Noroxymorphone panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;OxyMORphone and Noroxymorphone panel - Urine by Confirmatory method;OxyMORphone+Noroxymorph Pnl Ur Cfm;;ACTIVE;2.68;2.68 +94306-8;SARS coronavirus 2 RNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection;SARS-CoV-2 RNA Pnl Spec NAA+probe;;ACTIVE;2.68;2.69 +94307-6;SARS coronavirus 2 N gene;PrThr;Pt;XXX;Ord;Probe.amp.tar.CDC primer-probe set N1;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N1;SARS-CoV-2 N gene Spec Ql NAA N1;;ACTIVE;2.68;2.69 +94308-4;SARS coronavirus 2 N gene;PrThr;Pt;XXX;Ord;Probe.amp.tar.CDC primer-probe set N2;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N2;SARS-CoV-2 N gene Spec Ql NAA N2;;ACTIVE;2.68;2.69 +94309-2;SARS coronavirus 2 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen by NAA with probe detection;SARS-CoV-2 RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.73 +943-1;C Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;C Ab [Presence] in Serum or Plasma from Blood product unit;C Ab SerPl BPU Ql;;ACTIVE;1.0;2.73 +94310-0;SARS-related coronavirus N gene;PrThr;Pt;XXX;Ord;Probe.amp.tar.CDC primer-probe set N3;MICRO;1;SARS-related coronavirus N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N3;SARS-related CoV N Spec Ql NAA N3;;ACTIVE;2.68;2.7 +94311-8;SARS coronavirus 2 N gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar.CDC primer-probe set N1;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N1;SARS-CoV-2 N gene Ct Spec Qn NAA N1;;ACTIVE;2.68;2.69 +94312-6;SARS coronavirus 2 N gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar.CDC primer-probe set N2;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N2;SARS-CoV-2 N gene Ct Spec Qn NAA N2;;ACTIVE;2.68;2.69 +94313-4;SARS-related coronavirus N gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar.CDC primer-probe set N3;MICRO;1;SARS-related coronavirus N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N3;SARS-related CoV N Ct Spec Qn NAA N3;;ACTIVE;2.68;2.7 +94314-2;SARS coronavirus 2 RdRp gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Specimen by NAA with probe detection;SARS-CoV-2 RdRp Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94315-9;SARS-related coronavirus E gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus E gene [Presence] in Specimen by NAA with probe detection;SARS-rel CoV E gene Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94316-7;SARS coronavirus 2 N gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by NAA with probe detection;SARS-CoV-2 N gene Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +9431-8;Isobutanol;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isobutanol [Mass/volume] in Blood;Isobutanol Bld-mCnc;;ACTIVE;1.0i;2.73 +94318-3;Plan of care note;Find;Pt;{Setting};Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying Plan of care note;MAiD Plan of care note;;ACTIVE;2.68;2.68 +94319-1;Consultation note;Find;Pt;{Setting};Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying Consult note;MAiD Consult note;;ACTIVE;2.68;2.68 +94320-9;Procedure note;Find;Pt;{Setting};Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying procedure note;MAiD Procedure note;;ACTIVE;2.68;2.68 +94321-7;Note;Find;Pt;{Setting};Doc;Medical aid in dying.team;DOC.ONTOLOGY;2;Medical Aid in Dying Team Note;MAiD Team Note;;ACTIVE;2.68;2.68 +94322-5;Note;Find;Pt;Telephone encounter;Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying Telephone encounter Note;MAiD Phone Note;;ACTIVE;2.68;2.68 +94323-3;Conference note;Find;Pt;{Setting};Doc;Wound, ostomy, and continence care.team;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Team Conference note;WOC Team Conf eval note;;ACTIVE;2.68;2.68 +94324-1;Care management note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Care management note;Orthopaedic surgery Care management note;;ACTIVE;2.68;2.68 +9432-6;Isobutyl acetate;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Isobutyl acetate [Mass/volume] in Specimen;Isobutyl Acetate Spec-mCnc;;ACTIVE;1.0i;2.7 +94327-4;PhenX - human papillomavirus vaccine use protocol 100802;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - human papillomavirus vaccine use protocol 100802;PhenX - HPV vaccine use protocol;;ACTIVE;2.68;2.68 +94328-2;Patient health questionnaire 8 item total score;Score;Pt;^Patient;Qn;Reported.PHQ;SURVEY.PHQ;4;Patient Health Questionnaire 8 item (PHQ-8) total score [Reported];;;ACTIVE;2.68;2.68 +94329-0;Patient Health Questionnaire 8 item;-;Pt;^Patient;-;Reported.PHQ;PANEL.SURVEY.PHQ;4;Patient Health Questionnaire 8 item (PHQ-8) [Reported];;;ACTIVE;2.68;2.68 +94330-8;Processing comment;Find;Pt;Specimen;Nom;;SPEC;1;Specimen Processing comment;Specimen Processing comment;;TRIAL;2.68;2.68 +94331-6;Collection procedure comment;Find;Pt;Specimen;Nom;;SPEC;1;Specimen Collection procedure comment;Spec Collect proc comment;;TRIAL;2.68;2.68 +94332-4;Microsporidia sp 18S rRNA gene panel;-;Pt;XXX;-;Non-probe.amp.tar;PANEL.MICRO;1;Microsporidia sp 18S rRNA gene panel - Specimen by NAA with non-probe detection;Microsporidia 18S rRNA Pnl NAA+non-prb;;ACTIVE;2.68;2.69 +94333-2;Encephalitozoon sp 18S rRNA gene;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Encephalitozoon sp 18S rRNA gene [Presence] in Specimen by NAA with non-probe detection;Encephalitozoon 18S rRNA Spec Ql NAA+prb;;ACTIVE;2.68;2.69 +9433-4;Isoflurane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Isoflurane [Mass/volume] in Blood;Isofl Bld-mCnc;;ACTIVE;1.0i;2.7 +94334-0;Enterocytozoon bieneusi 18S rRNA gene;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Enterocytozoon bieneusi 18S rRNA gene [Presence] in Specimen by NAA with non-probe detection;E bieneusi 18S rRNA Spec Ql NAA+non-prb;;ACTIVE;2.68;2.69 +94335-7;Desmoglein 1 & Desmoglein 3 Ab.IgG panel;-;Pt;Ser;Qn;IA;PANEL.SERO;1;Desmoglein 1 and Desmoglein 3 IgG panel - Serum by Immunoassay;Desmoglein 1+3 IgG Pnl Ser IA;;ACTIVE;2.68;2.68 +94336-5;Desmoglein 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Desmoglein 1 IgG Ab [Units/volume] in Serum by Immunoassay;Desmoglein 1 IgG Ser IA-aCnc;;ACTIVE;2.68;2.68 +94337-3;Desmoglein 3 Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Desmoglein 3 IgG Ab [Units/volume] in Serum by Immunoassay;Desmoglein 3 IgG Ser IA-aCnc;;ACTIVE;2.68;2.68 +94338-1;Chromosome 13+15+16+18+21+22+X+Y aneuploidy;Find;Pt;POC;Doc;FISH;MOLPATH;1;Chromosome 13+15+16+18+21+22+X+Y aneuploidy in Products of Conception by FISH;Chr 13+15+16+18+21+22+X+Y aneup POC FISH;;ACTIVE;2.68;2.68 +94339-9;Myelopathy autoimmune Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Myelopathy autoimmune Ab panel - Serum;Myelopathy Ab pnl Ser;;ACTIVE;2.68;2.68 +94340-7;Amphiphysin Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Amphiphysin IgG Ab [Titer] in Serum by Immunofluorescence;Amphiphysin IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94341-5;Glial nuclear type 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Glial nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence;Glial nuc type 1 IgG Titr Ser IF;;ACTIVE;2.68;2.68 +9434-2;Isopropanol;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Isopropanol [Mass/volume] in Urine;Isopropanol Ur-mCnc;;ACTIVE;1.0i;2.73 +94342-3;Neuronal nuclear type 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence;Hu1 IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94343-1;Neuronal nuclear type 2 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear type 2 IgG Ab [Titer] in Serum by Immunofluorescence;Hu2 IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94344-9;Neuronal nuclear type 3 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Neuronal nuclear type 3 IgG Ab [Titer] in Serum by Immunofluorescence;Hu3 IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94345-6;Glutamate decarboxylase 65 Ab.IgG+IgM;SCnc;Pt;Ser;Qn;IA;SERO;1;Glutamate decarboxylase 65 IgG+IgM Ab [Moles/volume] in Serum by Immunoassay;GAD65 IgG+IgM Ser IA-sCnc;;ACTIVE;2.68;2.68 +94346-4;Glial fibrillary acidic protein.alpha subunit Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Glial fibrillary acidic protein alpha subunit IgG Ab [Presence] in Serum by Immunofluorescence;GFAP alpha IgG Ser Ql IF;;ACTIVE;2.68;2.68 +94347-2;Metabotropic glutamate receptor 1 Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Metabotropic glutamate receptor 1 IgG Ab [Presence] in Serum by Immunofluorescence;mGluR1 IgG Ser Ql IF;;ACTIVE;2.68;2.68 +94348-0;Voltage-gated calcium channel N type binding Ab.IgG+IgM;SCnc;Pt;Ser;Qn;IA;SERO;1;Voltage-gated calcium channel N type binding IgG+IgM Ab [Moles/volume] in Serum by Immunoassay;VGCC-N Bind IgG+IgM Ser IA-sCnc;;ACTIVE;2.68;2.68 +94349-8;Voltage-gated calcium channel PQ type binding Ab.IgG+IgM;SCnc;Pt;Ser;Qn;IA;SERO;1;Voltage-gated calcium channel P/Q type binding IgG+IgM Ab [Moles/volume] in Serum by Immunoassay;VGCC-P/Q Bind IgG+IgM Ser IA-sCnc;;ACTIVE;2.68;2.68 +94350-6;Purkinje cell cytoplasmic type 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;PCA-1 IgG Ab [Titer] in Serum by Immunofluorescence;PCA-1 IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94351-4;Purkinje cell cytoplasmic type 2 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;PCA-2 IgG Ab [Titer] in Serum by Immunofluorescence;PCA-2 IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94352-2;Purkinje cell cytoplasmic type Tr Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;PCA-Tr IgG Ab [Titer] in Serum by Immunofluorescence;PCA-Tr IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94353-0;Myelopathy autoimmune Ab panel;-;Pt;CSF;-;;PANEL.SERO;1;Myelopathy autoimmune Ab panel - Cerebral spinal fluid;Myelopathy Ab pnl CSF;;ACTIVE;2.68;2.68 +94354-8;Amphiphysin Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Amphiphysin IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Amphiphysin IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94355-5;Glial nuclear type 1 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Glial nuclear type 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Glial nuc type 1 IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94356-3;Neuronal nuclear type 1 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Neuronal nuclear type 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Hu1 IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94357-1;Neuronal nuclear type 2 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Neuronal nuclear type 2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Hu2 IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94358-9;Neuronal nuclear type 3 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Neuronal nuclear type 3 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;Hu3 IgG Titr CSF IF;;ACTIVE;2.68;2.68 +9435-9;Isopropanol;MCnt;Pt;Tiss;Qn;;DRUG/TOX;1;Isopropanol [Mass/mass] in Tissue;Isopropanol Tiss-mCnt;;ACTIVE;1.0i;2.7 +94359-7;Glutamate decarboxylase 65 Ab.IgG+IgM;SCnc;Pt;CSF;Qn;IA;SERO;1;Glutamate decarboxylase 65 IgG+IgM Ab [Moles/volume] in Cerebral spinal fluid by Immunoassay;GAD65 IgG+IgM CSF IA-sCnc;;ACTIVE;2.68;2.68 +94360-5;Glial fibrillary acidic protein.alpha subunit Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Glial fibrillary acidic protein alpha subunit IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;GFAP alpha IgG CSF Ql IF;;ACTIVE;2.68;2.68 +94361-3;Metabotropic glutamate receptor 1 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Metabotropic glutamate receptor 1 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;mGluR1 IgG CSF Ql IF;;ACTIVE;2.68;2.68 +94362-1;Purkinje cell cytoplasmic type Tr Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;PCA-Tr IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;PCA-Tr IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94363-9;Purkinje cell cytoplasmic type 1 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;PCA-1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;PCA-1 IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94364-7;Purkinje cell cytoplasmic type 2 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;PCA-2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;PCA-2 IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94365-4;Bordetella pertussis DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis DNA [Presence] in Lower respiratory specimen by NAA with probe detection;B pert DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94366-2;Streptococcus pyogenes DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Presence] in Lower respiratory specimen by NAA with probe detection;S pyo DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +9436-7;Lead;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Body fluid;Lead Fld-mCnc;;ACTIVE;1.0i;2.7 +94367-0;Streptococcus pneumoniae DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with probe detection;S pneum DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94368-8;Streptococcus agalactiae DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Gp B Strep DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94369-6;Staphylococcus aureus DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [Presence] in Lower respiratory specimen by NAA with probe detection;S aureus DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94370-4;Serratia marcescens DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Serratia marcescens DNA [Presence] in Lower respiratory specimen by NAA with probe detection;S marcescens DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94371-2;Pseudomonas aeruginosa DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [Presence] in Lower respiratory specimen by NAA with probe detection;P aeruginosa DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94372-0;Proteus sp DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Proteus sp DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Proteus sp DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94373-8;Moraxella catarrhalis DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Moraxella catarrhalis DNA [Presence] in Lower respiratory specimen by NAA with probe detection;M catarrhalis DNA Lower Resp Ql NAA+prb;;ACTIVE;2.68;2.68 +94374-6;Klebsiella pneumoniae DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Klebsiella pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with probe detection;K pneumon DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +9437-5;Methylhippurate;MRat;Pt;Urine;Qn;;DRUG/TOX;1;Methylhippurate [Mass/time] in Urine;Methylhippurate Ur-mRate;;ACTIVE;1.0i;2.7 +94375-3;Klebsiella oxytoca DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [Presence] in Lower respiratory specimen by NAA with probe detection;K oxytoca DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94376-1;Klebsiella aerogenes DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [Presence] in Lower respiratory specimen by NAA with probe detection;K. aerogenes DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94377-9;Haemophilus influenzae DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Haem influ DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94378-7;Escherichia coli DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Escherichia coli DNA [Presence] in Lower respiratory specimen by NAA with probe detection;E coli DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94379-5;Enterobacter cloacae complex DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [Presence] in Lower respiratory specimen by NAA with probe detection;E cloac comp DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94380-3;Acinetobacter baumannii DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Acinetobacter baumannii DNA [Presence] in Lower respiratory specimen by NAA with probe detection;A baumannii DNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94381-1;2,3-dinor 11 beta-Prostaglandin F2 alpha/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;2,3-dinor 11 beta-Prostaglandin F2 alpha/Creatinine [Mass Ratio] in 24 hour Urine;2,3-dinor 11B-PG F2a/Creat 24h Ur;;ACTIVE;2.68;2.68 +94382-9;Glial nuclear type 1 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Deprecated Glial nuclear type 1 IgG Ab [Presence] in Serum by Line blot;Deprecated Glial nuc type 1 IgG Ser Ql Line blot;;DEPRECATED;2.68;2.69 +9438-3;Morphine;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Morphine [Presence] in Gastric fluid;Morphine Gast Ql;;ACTIVE;1.0i;2.56 +94383-7;Glial nuclear type 1 Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Glial nuclear type 1 IgG Ab [Presence] in Cerebral spinal fluid by Line blot;Glial nuc type 1 IgG CSF Ql Line blot;;ACTIVE;2.68;2.68 +94384-5;Amphiphysin Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Amphiphysin IgG Ab [Presence] in Cerebral spinal fluid by Line blot;Amphiphysin IgG CSF Ql Line blot;;ACTIVE;2.68;2.68 +94385-2;Amphiphysin Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Amphiphysin IgG Ab [Presence] in Serum by Line blot;Amphiphysin IgG Ser Ql Line blot;;ACTIVE;2.68;2.68 +94386-0;Purkinje cell cytoplasmic type Tr Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;SERO;1;PCA-Tr IgG Ab [Presence] in Cerebral spinal fluid by Line blot;PCA-Tr IgG CSF Ql Line blot;;ACTIVE;2.68;2.68 +94387-8;Neuronal nuclear type 2 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Neuronal nuclear type 2 IgG Ab [Presence] in Serum by Line blot;Hu2 IgG Ser Ql Line blot;;ACTIVE;2.68;2.68 +94388-6;Neuronal nuclear type 2 Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Neuronal nuclear type 2 IgG Ab [Presence] in Cerebral spinal fluid by Line blot;Hu2 IgG CSF Ql Line blot;;ACTIVE;2.68;2.68 +94389-4;Neuronal nuclear type 1 Ab.IgG;PrThr;Pt;Ser;Ord;Line blot;SERO;1;Neuronal nuclear type 1 IgG Ab [Presence] in Serum by Line blot;Hu1 IgG Ser Ql Line blot;;ACTIVE;2.68;2.68 +94390-2;Neuronal nuclear type 1 Ab.IgG;PrThr;Pt;CSF;Ord;Line blot;SERO;1;Neuronal nuclear type 1 IgG Ab [Presence] in Cerebral spinal fluid by Line blot;Hu1 IgG CSF Ql Line blot;;ACTIVE;2.68;2.68 +9439-1;Casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Casts [#/area] in Urine sediment by Microscopy high power field;Casts #/area UrnS HPF;;ACTIVE;1.0i;2.73 +94391-0;Respiratory viral pathogens DNA & RNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory viral pathogens DNA and RNA panel - Lower respiratory specimen by NAA with probe detection;Resp viral DNA+RNA Pnl Low Resp NAA+prb;;ACTIVE;2.68;2.69 +94392-8;Bordetella pertussis+parapertussis+bronchiseptica gidA gene;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis+parapertussis+bronchiseptica gidA gene [Presence] in Lower respiratory specimen by NAA with probe detection;B per+par+bron gidA Lo Resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94393-6;Respiratory pathogens DNA & RNA panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Respiratory pathogens DNA and RNA panel - Lower respiratory specimen by NAA with probe detection;Resp path DNA+RNA Pnl Lower Resp NAA+prb;;ACTIVE;2.68;2.69 +94394-4;Influenza virus A H3 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H3 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;FLUAV H3 RNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94395-1;Influenza virus A H1 2009 pandemic RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 2009 pandemic RNA [Presence] in Lower respiratory specimen by NAA with probe detection;FLUAV H1 09 pan RNA Lo Rsp Ql NAA+probe;;ACTIVE;2.68;2.68 +94396-9;Influenza virus A H1 RNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H1 RNA [Presence] in Lower respiratory specimen by NAA with probe detection;FLUAV H1 RNA Lower resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94397-7;Sulfocysteine, Hypoxanthine, Xanthine, Urate & Creatinine panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Sulfocysteine, Hypoxanthine, Xanthine, Urate and Creatinine panel - Urine;SSC HypoXan Xan Urate Pnl Ur;;ACTIVE;2.68;2.68 +94398-5;Ethyl sulfate;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Ethyl sulfate [Mass/mass] in Meconium by Confirmatory method;Ethyl sulfate Mec Cfm-mCnt;;ACTIVE;2.68;2.68 +94399-3;Ethyl glucuronide;MCnt;Pt;Meconium;Qn;Confirm;DRUG/TOX;1;Ethyl glucuronide [Mass/mass] in Meconium by Confirmatory method;Ethyl glucuronide Mec Cfm-mCnt;;ACTIVE;2.68;2.68 +94400-9;Protein.monoclonal;PrThr;Pt;Ser/Plas;Ord;;CHEM;1;Protein.monoclonal [Presence] in Serum or Plasma;M Protein SerPl Ql;;ACTIVE;2.68;2.68 +94401-7;ADRA2A gene.c.-1252G>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;ADRA2A gene c.-1252G>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;ADRA2A c.-1252G>C Geno Bld/T;;ACTIVE;2.68;2.68 +94402-5;ANKK1 gene.c.2137G>A;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;ANKK1 gene c.2137G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal;ANKK1 c.2137G>A Geno Bld/T;;ACTIVE;2.68;2.68 +94403-3;CHRNA3 gene.c.645C>T;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;CHRNA3 gene c.645C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal;CHRNA3 c.645C>T Geno Bld/T;;ACTIVE;2.68;2.68 +9440-9;Lymphocytes.IgA/100 lymphocytes;NFr;Pt;WBC;Qn;;CELLMARK;1;IgA lymphocytes/100 lymphocytes in Leukocytes;Lymphs IgA/lymph NFr WBC;;ACTIVE;1.0i;2.73 +94411-6;DRD2 gene.c.-585A>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;DRD2 gene c.-585A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;DRD2 c.-585A>G Geno Bld/T;;ACTIVE;2.68;2.68 +94412-4;EPHX1 gene.c.416A>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;EPHX1 gene.c.416A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;EPHX1 c.416A>G Geno Bld/T;;ACTIVE;2.68;2.68 +94413-2;GRIK4 gene.c.83-10039T>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;GRIK4 gene c.83-10039T>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;GRIK4 c.83-10039T>C Geno Bld/T;;ACTIVE;2.68;2.68 +94414-0;MTHFR gene.c.677C>T & c.1298A>C;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;MTHFR gene c.677C>T and c.1298A>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal;MTHFR c.677C>T + 1298A>C Geno Bld/T;;ACTIVE;2.68;2.68 +94415-7;OPRM1 gene.c.118A>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;OPRM1 gene c.118A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;OPRM1 c.118A>G Geno Bld/T;;ACTIVE;2.68;2.68 +94416-5;SCN1A gene.c.603-91G>A;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;SCN1A gene.c.603-91G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal;SCN1A c.603-91G>A Geno Bld/T;;ACTIVE;2.68;2.68 +9441-7;Lymphocytes.IgD/100 lymphocytes;NFr;Pt;WBC;Qn;;CELLMARK;1;IgD lymphocytes/100 lymphocytes in Leukocytes;Lymphs IgD/lymph NFr WBC;;ACTIVE;1.0i;2.73 +94417-3;SLC6A4 gene 5-HTTLPR variant;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;SLC6A4 gene 5-HTTLPR variant [Genotype] in Blood or Tissue by Molecular genetics method Nominal;SLC6A4 5-HTTLPR Geno Bld/T;;ACTIVE;2.68;2.68 +94418-1;UGT2B15 gene.c.253G>T;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;UGT2B15 gene c.253G>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal;UGT2B15 c.253G>T Geno Bld/T;;ACTIVE;2.68;2.68 +94419-9;Candida auris;PrThr;Pt;Isolate;Ord;MS.MALDI-TOF;MICRO;1;Candida auris [Presence] in Isolate by MS.MALDI-TOF;C auris Islt Ql MS.MALDI-TOF;;ACTIVE;2.68;2.68 +94420-7;Lactobacillus crispatus+gasseri+jensenii+Gardnerella vaginalis+Atopobium vaginae rRNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Lactobacillus crispatus+gasseri+jensenii + Gardnerella vaginalis + Atopobium vaginae rRNA [Presence] in Vaginal fluid by NAA with probe detection;BV bacteria rRNA Vag Ql NAA+probe;;ACTIVE;2.68;2.68 +94421-5;Candida glabrata RNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida glabrata RNA [Presence] in Vaginal fluid by NAA with probe detection;C glabrata RNA Vag Ql NAA+probe;;ACTIVE;2.68;2.68 +94422-3;Candida albicans+dubliniensis+parapsilosis+tropicalis RNA;PrThr;Pt;Vag;Ord;Probe.amp.tar;MICRO;1;Candida albicans, C. dubliniensis, C. parapsilosis, and C. tropicalis RNA [Presence] in Vaginal fluid by NAA with probe detection;Candida sp group RNA Vag Ql NAA+probe;;ACTIVE;2.68;2.68 +94423-1;Lysosomal enzymes screen;Imp;Pt;Urine;Nar;;CHEM;1;Lysosomal enzymes screen [Interpretation] in Urine Narrative;Lysosomal Enzymes Scn Ur-Imp;;ACTIVE;2.68;2.73 +94424-9;Staphylococcus aureus methicillin resistance SCCmec+orfX junction;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Staphylococcus aureus methicillin resistance SCCmec+orfX junction [Presence] by Molecular method;MRSA SCCmec+orfX Islt/Spm Ql;;ACTIVE;2.68;2.68 +9442-5;Lymphocytes.IgG/100 lymphocytes;NFr;Pt;WBC;Qn;;CELLMARK;1;IgG lymphocytes/100 lymphocytes in Leukocytes;Lymphs IgG/lymph NFr WBC;;ACTIVE;1.0i;2.73 +94425-6;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 E6+E7 mRNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus E6+E7 mRNA [Presence] in Specimen by NAA with probe detection;HPV E6+E7 mRNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94426-4;Dengue virus 1+2+3+4 3' UTR RNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 3' UTR RNA [Presence] in Cerebral spinal fluid by NAA with probe detection;DENV 1+2+3+4 3' UTR RNA CSF Ql NAA+probe;;ACTIVE;2.68;2.68 +94427-2;Dengue virus 1+2+3+4 3' UTR RNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 3' UTR RNA [Presence] in Serum by NAA with probe detection;DENV 1+2+3+4 3' UTR RNA Ser Ql NAA+probe;;ACTIVE;2.68;2.68 +94428-0;HLA class I & II Ab.IgG panel;-;Pt;Ser/Plas;-;Flow cytometry;PANEL.HLA;1;HLA class I and II IgG panel - Serum or Plasma by Flow cytometry (FC);HLA class I + II IgG Pnl SerPl FC;;ACTIVE;2.68;2.68 +94429-8;HLA-DP & DQ & DR (class II) Ab.IgG low risk;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DP and DQ and DR (class II) IgG low risk [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA class II Ab.IgG low risk SerPl FC;;ACTIVE;2.68;2.68 +94430-6;HLA-A & B & C (class I) Ab.IgG low risk;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-A and B and C (class I) IgG low risk [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA class I Ab.IgG low risk SerPl FC;;ACTIVE;2.68;2.68 +94431-4;Dilution factor;Titr;Pt;Ser/Plas;Qn;;MISC;1;Dilution factor [Titer] in Serum or Plasma;Dilution factor Titr SerPl;;ACTIVE;2.68;2.68 +94432-2;HLA-DP & DQ & DR (class II) Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DP and DQ and DR (class II) IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-DP+DQ+DR (class II) IgG SerPl FC;;ACTIVE;2.68;2.68 +9443-3;Lymphocytes.IgM/100 lymphocytes;NFr;Pt;WBC;Qn;;CELLMARK;1;IgM lymphocytes/100 lymphocytes in Leukocytes;Lymphs IgM/lymph NFr WBC;;ACTIVE;1.0i;2.73 +94433-0;HLA-DP & DQ & DR (class II) Ab.IgG with prozone effect;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DP and DQ and DR (class II) IgG with prozone effect [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA classII Ab.IgG prozone SerPl FC;;ACTIVE;2.68;2.68 +94434-8;HLA-DPB1 Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DPB1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-DPB1 IgG SerPl FC;;ACTIVE;2.68;2.68 +94435-5;HLA-DPA1 Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DPA1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-DPA1 IgG SerPl FC;;ACTIVE;2.68;2.68 +94436-3;HLA-DQB1 Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DQB1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-DQB1 IgG SerPl FC;;ACTIVE;2.68;2.68 +94437-1;HLA-DQA1 Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DQA1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-DQA1 IgG SerPl FC;;ACTIVE;2.68;2.68 +94438-9;HLA-DRB3 & HLA-DRB4 & HLA DRB5 Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-DRB3 + 4 + 5 IgG SerPl FC;;ACTIVE;2.68;2.68 +94439-7;HLA-DRB1 Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DRB1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-DRB1 IgG SerPl FC;;ACTIVE;2.68;2.68 +94440-5;HLA-DP & DQ & DR (class II) Ab.IgG panel;-;Pt;Ser/Plas;-;Flow cytometry;PANEL.HLA;1;HLA-DP and DQ and DR (class II) IgG panel - Serum or Plasma by Flow cytometry (FC);HLA class II Ab.IgG Pnl SerPl FC;;ACTIVE;2.68;2.68 +9444-1;House dust Hausstaub Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Hausstaub IgE Ab [Units/volume] in Serum;House Dust Hauss IgE Qn;;ACTIVE;1.0i;2.73 +94441-3;HLA-A & B & C (class I) Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-A and B and C (class I) IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-A+B+C (class I) IgG SerPl FC;;ACTIVE;2.68;2.68 +94442-1;HLA-A & B & C (class I) Ab.IgG with prozone effect;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-A and B and C (class I) IgG with prozone effect [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA class I Ab.IgG prozone SerPl FC;;ACTIVE;2.68;2.68 +94443-9;HLA-C Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-C IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-C IgG SerPl FC;;ACTIVE;2.68;2.68 +94444-7;HLA-B Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-B IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-B IgG SerPl FC;;ACTIVE;2.68;2.68 +94445-4;HLA-A Ab.IgG;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-A IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA-A IgG SerPl FC;;ACTIVE;2.68;2.68 +94446-2;HLA-A & B & C (class I) Ab.IgG panel;-;Pt;Ser/Plas;-;Flow cytometry;PANEL.HLA;1;HLA-A and B and C (class I) IgG panel - Serum or Plasma by Flow cytometry (FC);HLA-A + B + C (class I) IgG Pnl SerPl FC;;ACTIVE;2.68;2.68 +94447-0;HLA-DP & DQ & DR (class II) Ab.IgG high risk;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DP and DQ and DR (class II) IgG high risk [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA class II Ab.IgG high risk SerPl FC;;ACTIVE;2.68;2.68 +94448-8;HLA-DP & DQ & DR (class II) Ab.IgG intermediate risk;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-DP and DQ and DR (class II) IgG intermediate risk [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA class II Ab.IgG med risk SerPl FC;;ACTIVE;2.68;2.68 +94449-6;HLA-A & B & C (class I) Ab.IgG high risk;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-A and B and C (class I) IgG high risk [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA class I Ab.IgG high risk SerPl FC;;ACTIVE;2.68;2.68 +94450-4;HLA-A & B & C (class I) Ab.IgG intermediate risk;Prid;Pt;Ser/Plas;Nom;Flow cytometry;HLA;1;HLA-A and B and C (class I) IgG intermediate risk [Identifier] in Serum or Plasma by Flow cytometry (FC);HLA class I Ab.IgG med risk SerPl FC;;ACTIVE;2.68;2.68 +94451-2;PhenX - Use of creatine growth hormone and steroids protocol 230801;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;PhenX - Use of Creatine Growth Hormone and Steroids Protocol 230801;PhenX - Creatine GH+steroids use proto;;ACTIVE;2.68;2.68 +94454-6;Arsenite;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenite [Mass/volume] in Urine;Arsenite Ur-mCnc;;ACTIVE;2.68;2.68 +94455-3;Arsenobetaine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenobetaine [Mass/volume] in Urine;Arsenobetaine Ur-mCnc;;ACTIVE;2.68;2.68 +94456-1;Arsenocholine;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenocholine [Mass/volume] in Urine;Arsenocholine Ur-mCnc;;ACTIVE;2.68;2.68 +94457-9;Dimethylarsinate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Dimethylarsinate [Mass/volume] in Urine;Dimethylarsinate Ur-mCnc;;ACTIVE;2.68;2.68 +9445-8;11-Oxopregnanetriol;MRat;24H;Urine;Qn;;CHEM;1;11-Oxopregnanetriol [Mass/time] in 24 hour Urine;11oxoPregnanet 24h Ur-mRate;;ACTIVE;1.0i;2.7 +94458-7;Monomethylarsonate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Monomethylarsonate [Mass/volume] in Urine;MMA Ur-mCnc;;ACTIVE;2.68;2.68 +94459-5;Date treatment prescribed;Date;Pt;^Patient;Qn;;H&P.HX;2;Date treatment prescribed;Date treatment prescribed;;ACTIVE;2.68;2.68 +94460-3;Conference note;Find;Pt;{Setting};Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Conference note;Navigator Conf eval note;;ACTIVE;2.68;2.68 +94461-1;Consultation note;Find;Pt;{Setting};Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant Consult note;Solid Org Transplant Consult note;;ACTIVE;2.68;2.68 +94462-9;Consultation note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Intensive care unit Consult note;Cardiology ICU Consult note;;ACTIVE;2.68;2.68 +94463-7;Consultation note;Find;Pt;{Setting};Doc;Bone marrow transplant;DOC.ONTOLOGY;2;Bone Marrow Transplant Consult note;BM Transplant Consult note;;ACTIVE;2.68;2.68 +94464-5;Discharge summary note;Find;Pt;{Setting};Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant Discharge summary;Solid Org Transplant D/C sum;;ACTIVE;2.68;2.73 +94465-2;Discharge summary note;Find;Pt;{Setting};Doc;Bone marrow transplant;DOC.ONTOLOGY;2;Bone Marrow Transplant Discharge summary;BM Transplant D/C sum;;ACTIVE;2.68;2.73 +9446-6;Heptacarboxylporphyrin;MCnc;Pt;RBC;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/volume] in Red Blood Cells;Hepta-CP RBC-mCnc;;ACTIVE;1.0i;2.73 +94466-0;Progress note;Find;Pt;{Setting};Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant Progress note;Solid Org Transplant Prog note;;ACTIVE;2.68;2.73 +94467-8;Progress note;Find;Pt;Intensive care unit;Doc;Cardiovascular disease;DOC.ONTOLOGY;2;Cardiology Intensive care unit Progress note;Cardiology ICU Prog note;;ACTIVE;2.68;2.73 +94468-6;Progress note;Find;Pt;{Setting};Doc;Bone marrow transplant;DOC.ONTOLOGY;2;Bone Marrow Transplant Progress note;BM Transplant Prog note;;ACTIVE;2.68;2.73 +94469-4;F2 gene.c.20210G>A & F5 gene.c.1691G>A panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.MOLPATH;1;F2 gene.c.20210G>A and c.1691G>A panel - Blood or Tissue by Molecular genetics method;F2 20210G>A + F5 1691G>A Pnl Bld/T;;ACTIVE;2.68;2.68 +94470-2;VEGFA gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;VEGFA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;VEGFA Mut Anl Bld/T;;ACTIVE;2.68;2.68 +94471-0;VEGFA gene.c.-1154A>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;VEGFA gene c.-1154A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;VEGFA c.-1154A>G Geno Bld/T;;ACTIVE;2.68;2.68 +94472-8;VEGFA gene.c.-1498C>G & c.-1498C>T;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;VEGFA gene c.-1498C>G and c.-1498C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal;VEGFA c.-1498C>G + C>T Geno Bld/T;;ACTIVE;2.68;2.68 +94473-6;VEGFA gene.c.-2578A>C & c.-2578A>T;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;VEGFA gene c.-2578A>C and c.-2578A>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal;VEGFA c.-2578A>C + A>T Geno Bld/T;;ACTIVE;2.68;2.68 +9447-4;Heptacarboxylporphyrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Heptacarboxylporphyrin [Mass/volume] in Serum or Plasma;Hepta-CP SerPl-mCnc;;ACTIVE;1.0i;2.73 +94474-4;VEGFA gene.c.-634C>G;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;VEGFA gene c.-634C>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal;VEGFA c.-634C>G Geno Bld/T;;ACTIVE;2.68;2.68 +94475-1;Borrelia burgdorferi Ab.IgA & IgG & IgM;Imp;Pt;CSF;Nom;;MICRO;1;Borrelia burgdorferi IgA and IgG and IgM [Interpretation] in Cerebral spinal fluid;B burgdor IgA+IgG+IgM CSF-Imp;;ACTIVE;2.68;2.68 +94476-9;Borrelia burgdorferi G39_40 Ab.IgG bands;Num;Pt;Bld;Qn;IB;MICRO;1;Borrelia burgdorferi G39/40 IgG bands [#] in Blood by Immunoblot;B burgdor G39/40 IgG bands Bld IB;;ACTIVE;2.68;2.68 +94477-7;Borrelia burgdorferi 49736 Ab.IgG bands;Num;Pt;Bld;Qn;IB;MICRO;1;Borrelia burgdorferi 49736 IgG bands [#] in Blood by Immunoblot;B burgdor 49736 IgG bands Bld IB;;ACTIVE;2.68;2.68 +94478-5;Bordetella pertussis.pertussis toxin promoter region;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Bordetella pertussis.pertussis toxin promoter region [Presence] in Lower respiratory specimen by NAA with non-probe detection;B pert.PT Prmt Low resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94479-3;Human coronavirus 229E RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus 229E RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HCoV 229E RNA Low resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94480-1;Human coronavirus HKU1 RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus HKU1 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HCoV HKU1 RNA Low resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94481-9;Human coronavirus NL63 RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus NL63 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HCoV NL63 RNA Low resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +9448-2;Heptaporphyrin;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Heptaporphyrin [Mass/volume] in Urine;Deprecated Heptapor Ur-mCnc;;DEPRECATED;1.0i;2.7 +94482-7;Human coronavirus OC43 RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Human coronavirus OC43 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HCoV OC43 RNA Low resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94483-5;Parainfluenza virus 1 RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 1 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HPIV1 RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94484-3;Parainfluenza virus 2 RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 2 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HPIV2 RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94485-0;Parainfluenza virus 3 RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 3 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HPIV3 RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94486-8;Parainfluenza virus 4 RNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Parainfluenza virus 4 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;HPIV4 RNA Lower resp Ql NAA+non-probe;;ACTIVE;2.68;2.68 +94487-6;Galactosylceramidase;CCnt;Pt;WBC;Qn;Confirm;CHEM;1;Galactosylceramidase [Enzymatic activity/mass] in Leukocytes by Confirmatory method;GALC WBC Cfm-cCnt;;ACTIVE;2.68;2.68 +94488-4;Acid alpha glucosidase;CCnt;Pt;WBC;Qn;Confirm;CHEM;1;Acid alpha glucosidase [Enzymatic activity/mass] in Leukocytes by Confirmatory method;Acid A-Glucosidase WBC Cfm-cCnt;;ACTIVE;2.68;2.68 +94489-2;Lysosomal storage disorders panel;-;Pt;WBC;Qn;;PANEL.CHEM;1;Lysosomal storage disorders panel - Leukocytes;LSD pnl WBC;;ACTIVE;2.68;2.68 +944-9;C Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;C Ab [Presence] in Serum or Plasma from Donor;C Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +9449-0;Heptaporphyrin;MRat;24H;Urine;Qn;;CHEM;1;Deprecated Heptaporphyrin [Mass/time] in 24 hour Urine;Deprecated Heptapor 24h Ur-mRate;;DEPRECATED;1.0i;2.7 +94490-0;Protoporphyrin fractions panel;-;Pt;RBC;Qn;;PANEL.CHEM;1;Protoporphyrin fractions panel - Red Blood Cells;Protoporphyrin fract Pnl RBC;;ACTIVE;2.68;2.68 +94491-8;Protoporphyrin.free;MCnc;Pt;RBC;Qn;;CHEM;1;Protoporphyrin Free [Mass/volume] in Red Blood Cells;FEP RBC-mCnc;;ACTIVE;2.68;2.68 +94492-6;HLA-DQA1 & HLA-DQB1 typing panel;-;Pt;Bld/Tiss;-;Molgen;PANEL.HLA;1;HLA-DQA1 and HLA-DQB1 typing panel - Blood or Tissue by Molecular genetics method;HLA-DQA1 + HLA-DQB1 typing Pnl Bld/T;;ACTIVE;2.68;2.68 +94493-4;Celiac disease IgA & HLA typing & serology panel;-;Pt;Bld/Tiss;-;;PANEL.HLA;1;Celiac disease IgA and HLA typing and serology panel - Blood or Tissue;Celiac IgA + HLA + Sero Bld/T;;ACTIVE;2.68;2.68 +94494-2;Celiac disease serology panel;-;Pt;Ser;-;;PANEL.SERO;1;Celiac disease serology panel - Serum;Celiac disease serology panel Ser;;ACTIVE;2.68;2.68 +94495-9;HLA-DQA1;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DQA1 [Type];HLA-DQA1;;ACTIVE;2.68;2.68 +94496-7;Cell suspension;Vol;Pt;Specimen;Qn;;SPEC;1;Cell suspension [Volume] of Specimen;Cell susp Vol Spec;;ACTIVE;2.68;2.68 +94497-5;Packed erythrocytes;Vol;Pt;Specimen;Qn;;SPEC;1;Packed erythrocytes [Volume] of Specimen;Packed RBC Vol Spec;;ACTIVE;2.68;2.68 +94499-1;Respiratory viral pathogens DNA & RNA panel;-;Pt;Respiratory;Ord;Probe.amp.tar;PANEL.MICRO;1;Respiratory viral pathogens DNA and RNA panel - Respiratory specimen Qualitative by NAA with probe detection;Resp viral path DNA+RNA Pnl Resp NAA+prb;;ACTIVE;2.68;2.69 +94500-6;SARS coronavirus 2 RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 RNA Resp Ql NAA+probe;;ACTIVE;2.68;2.73 +94501-4;Middle east respiratory syndrome coronavirus RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Respiratory specimen by NAA with probe detection;MERS-CoV RNA Resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94502-2;SARS-related coronavirus RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection;SARS-rel CoV RNA Resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94503-0;SARS coronavirus 2 Ab panel;-;Pt;Ser/Plas/Bld;-;IA.rapid;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) Ab panel - Serum, Plasma or Blood by Rapid immunoassay;SARS-CoV-2 Ab Pnl SerPlBld IA.rapid;;ACTIVE;2.68;2.69 +94504-8;SARS coronavirus 2 Ab panel;-;Pt;Ser/Plas;-;IA;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) Ab panel - Serum or Plasma by Immunoassay;SARS-CoV-2 Ab Pnl SerPl IA;;ACTIVE;2.68;2.69 +94505-5;SARS coronavirus 2 Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgG SerPl IA-aCnc;;ACTIVE;2.68;2.73 +94506-3;SARS coronavirus 2 Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgM SerPl IA-aCnc;;ACTIVE;2.68;2.69 +94507-1;SARS coronavirus 2 Ab.IgG;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;SARS-CoV-2 IgG SerPlBld Ql IA.rapid;;ACTIVE;2.68;2.73 +9450-8;Hexacarboxylporphyrin;MCnc;Pt;RBC;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/volume] in Red Blood Cells;Hexa-CP RBC-mCnc;;ACTIVE;1.0i;2.73 +94508-9;SARS coronavirus 2 Ab.IgM;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;SARS-CoV-2 IgM SerPlBld Ql IA.rapid;;ACTIVE;2.68;2.69 +94509-7;SARS-related coronavirus E gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;SARS-related coronavirus E gene [Cycle Threshold #] in Specimen by NAA with probe detection;SARS-rel CoV E gene Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94510-5;SARS coronavirus 2 N gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by NAA with probe detection;SARS-CoV-2 N gene Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94511-3;SARS coronavirus 2 ORF1ab region;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Specimen by NAA with probe detection;SARS-CoV-2 ORF1ab Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94512-1;Staphylococcus aureus & Staphylococcus aureus.methicillin resistant identified;Prid;Pt;Isolate/Specimen;Nom;Molgen;MICRO;1;Staphylococcus aureus and Methicillin Resistant Staphylococcus aureus identified in Isolate or Specimen by Molecular genetics method;SA + MRSA Islt/Spm;;ACTIVE;2.68;2.7 +94515-4;Discharge summary note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Discharge summary;Anesthesiology D/C sum;;ACTIVE;2.68;2.73 +9451-6;Hexacarboxylporphyrin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/volume] in Serum or Plasma;Hexa-CP SerPl-mCnc;;ACTIVE;1.0i;2.73 +94516-2;Discharge summary note;Find;Pt;{Setting};Doc;Audiology;DOC.ONTOLOGY;2;Audiology Discharge summary;Audiology D/C sum;;ACTIVE;2.68;2.73 +94517-0;Discharge summary note;Find;Pt;{Setting};Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology Discharge summary;Electrophysiology D/C sum;;ACTIVE;2.68;2.73 +94518-8;Progress note;Find;Pt;{Setting};Doc;Clinical cardiac electrophysiology;DOC.ONTOLOGY;2;Clinical cardiac electrophysiology Progress note;Electrophysiology Prog note;;ACTIVE;2.68;2.73 +94519-6;Discharge summary note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Discharge summary;Dermatology D/C sum;;ACTIVE;2.68;2.73 +94520-4;Discharge summary note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Discharge summary;Gastroenterology D/C sum;;ACTIVE;2.68;2.73 +94521-2;Discharge summary note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Discharge summary;Endocrinology D/C sum;;ACTIVE;2.68;2.73 +94522-0;Discharge summary note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Discharge summary;Immunology D/C sum;;ACTIVE;2.68;2.73 +94523-8;Discharge summary note;Find;Pt;{Setting};Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Discharge summary;Orthotics prosthetics D/C sum;;ACTIVE;2.68;2.73 +9452-4;Hexaporphyrin;MCnc;Pt;Urine;Qn;;CHEM;1;Deprecated Hexaporphyrin [Mass/volume] in Urine;Deprecated Hexapor Ur-mCnc;;DEPRECATED;1.0i;2.7 +94524-6;Discharge summary note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Discharge summary;IR D/C sum;;ACTIVE;2.68;2.73 +94525-3;Discharge summary note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Discharge summary;Infectious disease D/C sum;;ACTIVE;2.68;2.73 +94526-1;Discharge summary note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Discharge summary;Pulmonary disease D/C sum;;ACTIVE;2.68;2.73 +94527-9;Discharge summary note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Discharge summary;Trauma D/C sum;;ACTIVE;2.68;2.73 +94528-7;Consultation note;Find;Pt;{Setting};Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism Consult note;Thromboemb Consult note;;ACTIVE;2.68;2.68 +94529-5;Discharge summary note;Find;Pt;{Setting};Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Discharge summary;WOC D/C sum;;ACTIVE;2.68;2.73 +94530-3;Discharge summary note;Find;Pt;{Setting};Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism Discharge summary;Thromboemb D/C sum;;ACTIVE;2.68;2.73 +94531-1;SARS coronavirus 2 RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) RNA panel - Respiratory specimen by NAA with probe detection;SARS-CoV-2 RNA Pnl Resp NAA+probe;;ACTIVE;2.68;2.69 +9453-2;Histidine;SCnc;Pt;CSF;Qn;;CHEM;1;Histidine [Moles/volume] in Cerebral spinal fluid;Histidine CSF-sCnc;;ACTIVE;1.0i;2.73 +94532-9;SARS-related coronavirus+MERS coronavirus RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus+MERS coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection;SARS-rel CoV+MERS RNA Resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94533-7;SARS coronavirus 2 N gene;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 N gene Resp Ql NAA+probe;;ACTIVE;2.68;2.69 +94534-5;SARS coronavirus 2 RdRp gene;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 RdRp Resp Ql NAA+probe;;ACTIVE;2.68;2.69 +94535-2;Skin tone;Type;Pt;Skin;Nom;;H&P.PX;2;Skin tone;Skin tone;;ACTIVE;2.68;2.68 +94536-0;Natural color;Type;Pt;Hair;Nom;;H&P.PX;2;Natural color of Hair;Hair Color;;ACTIVE;2.68;2.68 +94537-8;Hemoglobin panel;-;Pt;Bld;-;HPLC;PANEL.HEM/BC;1;Hemoglobin panel - Blood by HPLC;Hgb Pnl Bld HPLC;;ACTIVE;2.68;2.72 +94538-6;Hemoglobin HPLC & electrophoresis panel;-;Pt;Bld;-;;PANEL.HEM/BC;1;Hemoglobin HPLC and electrophoresis panel - Blood;Hgb HPLC + electrophoresis Pnl Bld;;ACTIVE;2.68;2.72 +94539-4;Hepatitis A virus Ab.IgM & total panel;-;Pt;Ser/Plas;Ord;;PANEL.MICRO;1;Hepatitis A virus IgM and total panel - Serum or Plasma Qualitative;HAV IgM + total Pnl SerPl;;ACTIVE;2.68;2.68 +9454-0;Herpes simplex virus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Herpes simplex virus Ab [Titer] in Cerebral spinal fluid by Complement fixation;HSV Ab Titr CSF CF;;ACTIVE;1.0i;2.7 +94540-2;Mycobacterial stain & culture panel;-;Pt;XXX;-;;PANEL.MICRO;1;Mycobacterial stain and culture panel - Specimen;Mycobacterial stain + cx Pnl Spec;;ACTIVE;2.68;2.69 +94541-0;Mycobacterial identification panel;-;Pt;XXX;-;Molgen;PANEL.MICRO;1;Mycobacterial identification panel - Specimen by Molecular genetics method;Mycobacterial ID Pnl Spec;;ACTIVE;2.68;2.69 +94542-8;Leprosy;Type;Pt;^Patient;Nom;;H&P.HX;2;Leprosy type;Leprosy type;;ACTIVE;2.68;2.68 +94543-6;Microscopic observation;Prid;Pt;Skin;Nom;Acid fast stain;MICRO;1;Microscopic observation [Identifier] in Skin by Acid fast stain;Acid fast Stn Skin;;ACTIVE;2.68;2.68 +94544-4;Exposure source in 30D prior to onset of illness;Type;Pt;^Patient;Nom;;H&P.HX;2;Exposure source in 30 days prior to onset of illness;Exp source 30D prior onset;;ACTIVE;2.68;2.68 +94545-1;Household contacts;Num;Pt;^Patient;Qn;;ADMIN;2;Household contacts [#];Household contacts;;ACTIVE;2.68;2.68 +94546-9;Relationship to individual with confirmed or suspected illness;Type;Pt;^Patient;Nom;;H&P.HX;2;Relationship to individual with confirmed or suspected illness;Rel to ind w conf/susp ill;;ACTIVE;2.68;2.68 +94547-7;SARS coronavirus 2 Ab.IgG+IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgG+IgM SerPl Ql IA;;ACTIVE;2.68;2.69 +94548-5;Porphyrin fractions panel;MRat;24H;Stool;Qn;;PANEL.CHEM;1;Porphyrin fractions panel [Mass/time] - 24 hour Stool;Porphyrin Fract Pnl 24h Stl-mRate;;ACTIVE;2.68;2.68 +94549-3;Isoheptacarboxylporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Isoheptacarboxylporphyrin [Mass/time] in 24 hour Stool;Isohepta-CP 24h Stl-mRate;;ACTIVE;2.68;2.68 +94550-1;Hexacarboxylporphyrin I;MRat;24H;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin I [Mass/time] in 24 hour Stool;Hexa-CP I 24h Stl-mRate;;ACTIVE;2.68;2.68 +94551-9;Hexacarboxylporphyrin III;MRat;24H;Stool;Qn;;CHEM;1;Hexacarboxylporphyrin III [Mass/time] in 24 hour Stool;Hexa-CPr3 24h Stl-mRate;;ACTIVE;2.68;2.68 +94552-7;Isohexacarboxylporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Isohexacarboxylporphyrin [Mass/time] in 24 hour Stool;Isohexa-CP 24h Stl-mRate;;ACTIVE;2.68;2.68 +94553-5;Isopentacarboxylporphyrin;MRat;24H;Stool;Qn;;CHEM;1;Isopentacarboxylporphyrin [Mass/time] in 24 hour Stool;Isopenta-CP 24h Stl-mRate;;ACTIVE;2.68;2.68 +94554-3;Soluble CD14 subtype;MCnc;Pt;Ser/Plas/Bld;Qn;IA;CHEM;1;Soluble CD14 subtype [Mass/volume] in Serum, Plasma or Blood by Immunoassay;sCD14-ST SerPlBld IA-mCnc;;ACTIVE;2.68;2.68 +94555-0;Coagulation dilute Russell viper venom induced/Coagulation dilute Russell viper venom induced.excess phospholipid^post DOAC neutralization;Ratio;Pt;PPP;Qn;Coag;COAG;1;dRVVT/dRVVT.excess phospholipid [Ratio] in Platelet poor plasma by Coagulation assay --post DOAC neutralization;dRVVT/dRVVT cfm p DOAC neut PPP-Rto;;ACTIVE;2.68;2.68 +94556-8;Coagulation dilute Russell viper venom induced.excess phospholipid^post DOAC neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT excess phospholipid in Platelet poor plasma by Coagulation assay --post DOAC neutralization;dRVVT confirm p DOAC neut PPP;;ACTIVE;2.68;2.68 +9455-7;Streptococcus pneumoniae 1 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 1 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum 1 IgG Ser IA-aCnc;;DEPRECATED;1.0i;2.69 +94557-6;Coagulation dilute Russell viper venom induced^post DOAC neutralization;Time;Pt;PPP;Qn;Coag;COAG;1;dRVVT in Platelet poor plasma by Coagulation assay --post DOAC neutralization;dRVVT p DOAC neut PPP;;ACTIVE;2.68;2.68 +94558-4;SARS coronavirus 2 Ag;PrThr;Pt;Respiratory;Ord;IA.rapid;MICRO;1;SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay;SARS-CoV-2 Ag Resp Ql IA.rapid;;ACTIVE;2.68;2.69 +94559-2;SARS coronavirus 2 ORF1ab region;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 ORF1ab Resp Ql NAA+probe;;ACTIVE;2.68;2.69 +945-6;C Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;C Ab [Presence] in Serum or Plasma;C Ab SerPl Ql;;ACTIVE;1.0;2.56 +94560-0;Diabetes risk;Score;Pt;^Patient;Qn;Calculated;CLIN.RISK;2;Diabetes risk [Score] Calculated;Diabetes risk Score Calc;;ACTIVE;2.68;2.68 +94561-8;Risk calculation method used;Type;Pt;^Patient;Nom;*;CLIN.RISK;2;Risk calculation method used;Risk calc method;;ACTIVE;2.68;2.68 +94562-6;SARS coronavirus 2 Ab.IgA;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgA SerPl Ql IA;;ACTIVE;2.68;2.69 +94563-4;SARS coronavirus 2 Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgG SerPl Ql IA;;ACTIVE;2.68;2.73 +94564-2;SARS coronavirus 2 Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgM SerPl Ql IA;;ACTIVE;2.68;2.69 +9456-5;Streptococcus pneumoniae 12 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 12 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum12 IgG Ser IA-aCnc;;DEPRECATED;1.0i;2.69 +94565-9;SARS coronavirus 2 RNA;PrThr;Pt;Nph;Ord;Non-probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection;SARS-CoV-2 RNA Nph Ql NAA+non-probe;;ACTIVE;2.68;2.73 +94566-7;Maple syrup urine disease therapy monitoring panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Maple syrup urine disease therapy monitoring panel - Serum or Plasma;MSUD therapy monitor Pnl SerPl;;ACTIVE;2.68;2.68 +94567-5;Valine^post therapeutic diet;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Valine [Moles/volume] in Serum or Plasma --post therapeutic diet;Valine p diet SerPl-sCnc;;ACTIVE;2.68;2.68 +94568-3;Isoleucine^post therapeutic diet;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Isoleucine [Moles/volume] in Serum or Plasma --post therapeutic diet;Isoleucine p diet SerPl-sCnc;;ACTIVE;2.68;2.68 +94569-1;Leucine^post therapeutic diet;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Leucine [Moles/volume] in Serum or Plasma --post therapeutic diet;Leucine p diet SerPl-sCnc;;ACTIVE;2.68;2.68 +94570-9;Alloisoleucine^post therapeutic diet;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in Serum or Plasma --post therapeutic diet;Alloisoleucine p diet SerPl-sCnc;;ACTIVE;2.68;2.68 +94571-7;Branched chain amino acid panel;-;Pt;Bld.dot;Qn;;PANEL.CHEM;1;Branched chain amino acid panel - DBS;Branched chain aa Pnl DBS;;ACTIVE;2.68;2.68 +94572-5;Alloisoleucine;SCnc;Pt;Bld.dot;Qn;;CHEM;1;Alloisoleucine [Moles/volume] in DBS;Alloisoleucine DBS-sCnc;;ACTIVE;2.68;2.68 +9457-3;Streptococcus pneumoniae 19 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 19 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum19 IgG Ser IA-aCnc;;DEPRECATED;1.0i;2.69 +94573-3;Tyrosinemia newborn screening follow-up & therapeutic monitoring panel;-;Pt;Bld.dot;Qn;;PANEL.CHEM;1;Tyrosinemia newborn screening follow-up and therapeutic monitoring panel - DBS;TYR NBS f/u + monitor Pnl DBS;;ACTIVE;2.68;2.68 +94574-1;Heavy metals panel;-;Pt;Nail;-;;PANEL.DRUG/TOX;1;Heavy metals panel - Nail;Heavy Met Pnl Nail;;ACTIVE;2.68;2.68 +94575-8;Heavy metals panel;-;24H;Urine;-;;PANEL.DRUG/TOX;1;Heavy metals panel - 24 hour Urine;Heavy Met Pnl 24h Ur;;ACTIVE;2.68;2.68 +94576-6;Mycobacterium tuberculosis complex species identified;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Mycobacterium tuberculosis complex species identified in Isolate by NAA with probe detection;MTB complex sp Islt NAA+probe;;ACTIVE;2.68;2.68 +94577-4;Maximum clot strength amplitude.arachidonate induced;Len;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Maximum amplitude arachidonate induced [Length] in Blood by Resonance TEG;MA AA Bld Res TEG;;ACTIVE;2.68;2.7 +94578-2;Clot strength.platelet thromboxane A2 receptor inhibited;LenFr;Pt;Bld;Qn;Calculated;COAG;1;Clot strength TXA2 receptor inhibited [Length fraction] in Blood by calculation;Clot strength TXA2-R inhib LenFr Bld;;ACTIVE;2.68;2.68 +94579-0;Clot strength.arachidonate induced;LenFr;Pt;Bld;Qn;Calculated;COAG;1;Clot strength arachidonate induced [Length fraction] in Blood by calculation;Clot strength AA induced LenFr Bld Calc;;ACTIVE;2.68;2.7 +94580-8;Herpes simplex virus 1 & 2 DNA panel;-;Pt;XXX;-;Non-probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Specimen by NAA with non-probe detection;HSV 1+2 DNA Pnl Spec NAA+non-probe;;ACTIVE;2.68;2.69 +9458-1;Streptococcus pneumoniae 23 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 23 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum23 IgG Ser IA-aCnc;;DEPRECATED;1.0i;2.69 +94581-6;Herpes simplex virus 1 DNA;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Presence] in Specimen by NAA with non-probe detection;HSV1 DNA Spec Ql NAA+non-probe;;ACTIVE;2.68;2.69 +94582-4;Herpes simplex virus 2 DNA;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Presence] in Specimen by NAA with non-probe detection;HSV2 DNA Spec Ql NAA+non-probe;;ACTIVE;2.68;2.69 +94583-2;Herpes simplex virus 1 & 2 DNA panel;-;Pt;CSF;-;Non-probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Cerebral spinal fluid by NAA with non-probe detection;HSV 1+2 DNA Pnl CSF NAA+non-probe;;ACTIVE;2.68;2.68 +94584-0;Varicella zoster virus DNA;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Presence] in Specimen by NAA with non-probe detection;VZV DNA Spec Ql NAA+non-probe;;ACTIVE;2.68;2.69 +94585-7;Herpes simplex virus 1 & 2 & Varicella zoster virus DNA panel;-;Pt;XXX;-;Non-probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 and Varicella zoster virus DNA panel - Specimen by NAA with non-probe detection;HSV 1 + 2 + VZV DNA Pnl Spec NAA+non-prb;;ACTIVE;2.68;2.69 +94586-5;Dermatan sulfate & heparan sulfate & keratan sulfate panel;-;Pt;Bld.dot;-;;PANEL.CHEM;1;Dermatan sulfate and heparan sulfate and keratan sulfate panel - DBS;MPS panel DBS;;ACTIVE;2.68;2.68 +94587-3;Germline disorder chromosome analysis;Find;Pt;Amnio fld/CVS;Doc;Mate pair sequencing;MOLPATH;1;Germline disorder chromosome analysis in Amniotic fluid or Chorionic villus sample by Mate pair sequencing;Germline chromo analy Amn/CVS MPSeq;;ACTIVE;2.68;2.68 +94588-1;Myeloid neoplasm chromosome analysis;Find;Pt;Bld/Bone mar;Doc;Mate pair sequencing;MOLPATH;1;Myeloid neoplasm chromosome analysis in Blood or Marrow by Mate pair sequencing;Myeloid neoplasm chr analy Bld/Mar MPSeq;;ACTIVE;2.68;2.68 +94589-9;Hematologic neoplasm chromosome analysis;Find;Pt;Bld/Bone mar;Doc;Mate pair sequencing;MOLPATH;1;Hematologic neoplasm chromosome analysis in Blood or Marrow by Mate pair sequencing;Hematologic chrom analy Bld/Mar MPSeq;;ACTIVE;2.68;2.68 +94590-7;Oncologic chromosome analysis;Find;Pt;Tiss;Doc;Mate pair sequencing;MOLPATH;1;Oncologic chromosome analysis in Tissue by Mate pair sequencing;Oncologic chrom analy Tiss MPSeq;;ACTIVE;2.68;2.68 +94591-5;Chromosome rearrangement;Prid;Pt;Bld/Tiss;Nar;Molgen;MOLPATH;1;Chromosome rearrangement [Identifier] in Blood or Tissue by Molecular genetics method Narrative;Chromosome rearrangement Bld/T;;ACTIVE;2.68;2.68 +94592-3;Chromosome rearrangement;Prid;Pt;Bld/Tiss;Nom;Mate pair sequencing;MOLPATH;1;Chromosome rearrangement [Identifier] in Blood or Tissue by Mate pair sequencing Nominal;AML chromo analys Bld/Mar MPSeq;;ACTIVE;2.68;2.68 +94593-1;Multiplex allergen panel;-;Pt;Ser/Plas;-;;PANEL.ALLERGY;1;Multiplex allergen panel - Serum or Plasma;Multiplex Allergy Pnl SerPl;;ACTIVE;2.68;2.68 +94594-9;Note;Find;Pt;Telehealth;Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Telehealth Note;Neuro surgery Telehealth Note;;ACTIVE;2.68;2.68 +94595-6;Medication management note;Find;Pt;Telehealth;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Telehealth Medication management note;Pharmacology Telehealth Med mgmt note;;ACTIVE;2.68;2.68 +94596-4;Equine infectious anemia virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Equine infectious anemia virus Ab [Units/volume] in Serum by Immunoassay;EIAV Ab Ser IA-aCnc;;ACTIVE;2.68;2.68 +94597-2;Equine adenovirus 1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Equine adenovirus 1 RNA [Presence] in Specimen by NAA with probe detection;EAdV1 RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94598-0;Equine herpesvirus 2 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 2 RNA [Presence] in Specimen by NAA with probe detection;EHV2 RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +9459-9;Streptococcus pneumoniae 4 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 4 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum4 IgG Ser IA-aCnc;;DEPRECATED;1.0i;2.69 +94599-8;Equine herpesvirus 3 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Equine herpesvirus 3 RNA [Presence] in Specimen by NAA with probe detection;EHV3 RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94600-4;Equine influenza virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Equine influenza virus [Presence] in Specimen by Organism specific culture;EIV Spec Ql Cult;;ACTIVE;2.68;2.69 +94601-2;Listeria monocytogenes Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Listeria monocytogenes Ag [Presence] in Tissue by Immune stain;L monocytog Ag Tiss Ql ImStn;;ACTIVE;2.68;2.68 +94602-0;West Nile virus Ab.IgM/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;West Nile virus IgM Ab/Positive control in Serum by Immunoassay;WNV IgM/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +94603-8;Bacterial 16S rRNA gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Bacterial 16S rRNA gene [Nucleotide sequence] in Isolate by Sequencing;Bact 16S rRNA gene Islt-Seq;;ACTIVE;2.68;2.68 +94604-6;Equine arteritis virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Equine arteritis virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;EAV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94605-3;Equine herpesvirus 1 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Equine herpesvirus 1 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;EHV1 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94606-1;Equine herpesvirus 4 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Equine herpesvirus 4 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;EHV4 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +9460-7;Streptococcus pneumoniae 6+26 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 6+26 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum6+26 IgG Ser IA-aCnc;;DEPRECATED;1.0i;2.69 +94607-9;Equine rhinitis A virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Equine rhinitis A virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;ERAV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94608-7;Erbovirus A RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Erbovirus A RNA [Cycle Threshold #] in Specimen by NAA with probe detection;Erbovirus A RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94609-5;Bovine leukemia virus Ab;ACnc;Pt;Ser;Qn;IA;MICRO;1;Bovine leukemia virus Ab [Units/volume] in Serum by Immunoassay;BLV Ab Ser IA-aCnc;;ACTIVE;2.68;2.68 +94610-3;Bovine diarrhea virus subtype;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Bovine diarrhea virus subtype [Identifier] in Specimen by NAA with probe detection;BVDV subtype Spec NAA+probe;;ACTIVE;2.68;2.69 +94611-1;Pasteurella multocida toxin toxA gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Pasteurella multocida toxin toxA gene [Presence] in Specimen by NAA with probe detection;P multoc Tox toxA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94612-9;Mycoplasma bovis Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Mycoplasma bovis Ag [Presence] in Tissue by Immune stain;Mp bovis Ag Tiss Ql ImStn;;ACTIVE;2.68;2.68 +94613-7;Bovine respiratory syncytial virus Ag;PrThr;Pt;Tiss;Ord;Immune stain;MICRO;1;Bovine respiratory syncytial virus Ag [Presence] in Tissue by Immune stain;BRSV Ag Tiss Ql ImStn;;ACTIVE;2.68;2.68 +94614-5;Bovine parainfluenza virus 3 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bovine parainfluenza virus 3 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;BPIV3 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +9461-5;Streptococcus pneumoniae 8 Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Deprecated Streptococcus pneumoniae 8 IgG Ab [Units/volume] in Serum by Immunoassay;Deprecated S pneum8 IgG Ser IA-aCnc;;DEPRECATED;1.0i;2.69 +94615-2;Bovine herpesvirus 1 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bovine herpesvirus 1 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;BoHV1 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94616-0;Bovine coronavirus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bovine coronavirus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;BCV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94617-8;Anaplasma marginale DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Anaplasma marginale DNA [Cycle Threshold #] in Specimen by NAA with probe detection;A marginale DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94618-6;Bovine respiratory syncytial virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bovine respiratory syncytial virus [Presence] in Specimen by Organism specific culture;BRSV Spec Ql Cult;;ACTIVE;2.68;2.69 +94619-4;Bovine herpesvirus 1;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bovine herpesvirus 1 [Presence] in Specimen by Organism specific culture;BoHV1 Spec Ql Cult;;ACTIVE;2.68;2.69 +94620-2;Bovine diarrhea virus;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bovine diarrhea virus [Presence] in Specimen by Organism specific culture;BVDV Spec Ql Cult;;ACTIVE;2.68;2.69 +94621-0;Mycobacterium avium subspecies paratuberculosis Ab/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Mycobacterium avium ss paratuberculosis Ab/Positive control in Specimen by Immunoassay;M avium paraTB Ab/Pos cntrl Spec IA;;ACTIVE;2.68;2.69 +94622-8;Bovine diarrhea virus Ag/Positive control;RelRto;Pt;XXX;Qn;IA;MICRO;1;Bovine diarrhea virus Ag/Positive control in Specimen by Immunoassay;BVDV Ag/Pos cntrl Spec IA;;ACTIVE;2.68;2.69 +9462-3;Aluminum;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Aluminum [Mass/volume] in Water;Aluminum Wat-mCnc;;ACTIVE;1.0i;2.7 +94623-6;Ureaplasma diversum DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Ureaplasma diversum DNA [Cycle Threshold #] in Specimen by NAA with probe detection;U diversum DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94624-4;Tritrichomonas foetus DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Tritrichomonas foetus DNA [Cycle Threshold #] in Specimen by NAA with probe detection;T foet DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94625-1;Pasteurella multocida DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Pasteurella multocida DNA [Cycle Threshold #] in Specimen by NAA with probe detection;P multoc DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94626-9;Ovine herpesvirus 2 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Ovine herpesvirus 2 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;OvHV2 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94627-7;Neospora caninum DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Neospora caninum DNA [Cycle Threshold #] in Specimen by NAA with probe detection;N caninum DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94628-5;Mycoplasma bovis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma bovis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;Mp bovis DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94629-3;Mycobacterium avium subspecies paratuberculosis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycobacterium avium ss paratuberculosis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M avium paraTB DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94630-1;Mannheimia haemolytica DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mannheimia haemolytica DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M haemolytica DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +9463-1;Arsenic;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Water;Arsenic Wat-mCnc;;ACTIVE;1.0i;2.7 +94631-9;Haemophilus somnus DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Haemophilus somnus DNA [Cycle Threshold #] in Specimen by NAA with probe detection;H somnus DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94632-7;Escherichia coli K99 DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Escherichia coli K99 DNA [Cycle Threshold #] in Specimen by NAA with probe detection;E coli K99 DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94633-5;Cryptosporidium parvum DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Cryptosporidium parvum DNA [Cycle Threshold #] in Specimen by NAA with probe detection;C parvum DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94634-3;Coxiella burnetii DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Coxiella burnetii DNA [Cycle Threshold #] in Specimen by NAA with probe detection;C burnet DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94635-0;Bovine diarrhea virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bovine diarrhea virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;BVDV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94636-8;Bovine respiratory syncytial virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Bovine respiratory syncytial virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;BRSV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94637-6;Mycobacterium avium subspecies paratuberculosis Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Mycobacterium avium ss paratuberculosis Ab [Titer] in Serum by Complement fixation;M avium paraTB Ab Titr Ser CF;;ACTIVE;2.68;2.68 +94638-4;Bovine respiratory syncytial virus Ab.Neut;Titr;Pt;Ser;Qn;Neut;MICRO;1;Bovine respiratory syncytial virus neutralizing antibody [Titer] in Serum by Neutralization test;BRSV NAb Titr Ser Nt;;ACTIVE;2.68;2.72 +94639-2;SARS coronavirus 2 ORF1ab region;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Specimen by NAA with probe detection;SARS-CoV-2 ORF1ab Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +946-4;C Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;C Ag [Presence] on Red Blood Cells from Blood product unit;C Ag RBC BPU Ql;;ACTIVE;1.0;2.73 +94640-0;SARS coronavirus 2 S gene;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 S gene Resp Ql NAA+probe;;ACTIVE;2.68;2.69 +94641-8;SARS coronavirus 2 S gene;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Presence] in Specimen by NAA with probe detection;SARS-CoV-2 S gene Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94642-6;SARS coronavirus 2 S gene;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 S gene Ct Resp Qn NAA+probe;;ACTIVE;2.68;2.69 +94643-4;SARS coronavirus 2 S gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Specimen by NAA with probe detection;SARS-CoV-2 S gene Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94644-2;SARS coronavirus 2 ORF1ab region;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 ORF1ab Ct Resp Qn NAA+probe;;ACTIVE;2.68;2.69 +94645-9;SARS coronavirus 2 RdRp gene;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Specimen by NAA with probe detection;SARS-CoV-2 RdRp Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94646-7;SARS coronavirus 2 RdRp gene;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 RdRp Ct Resp Qn NAA+probe;;ACTIVE;2.68;2.69 +94647-5;SARS-related coronavirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus RNA [Presence] in Specimen by NAA with probe detection;SARSr-CoV RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +94648-3;Date of case confirmation;Date;Pt;^Contact;Qn;;PUBLICHEALTH;2;Date contact confirmed as a case;Date contact confirmed as case;;ACTIVE;2.68;2.68 +9464-9;Barium;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Barium [Mass/volume] in Water;Barium Wat-mCnc;;ACTIVE;1.0i;2.7 +94649-1;Health department;ID;Pt;Organization;Nom;;ADMIN.FACILITY;2;Health department identifier;Health dept ID;;ACTIVE;2.68;2.68 +94650-9;Contact identifier;ID;Pt;^Contact;Nom;;ADMIN.ID;2;Contact identifier Contact;Contact ID Contact;;ACTIVE;2.68;2.68 +94651-7;Country of travel;Loc;Pt;^Patient;Nom;;H&P.HX;2;Country of travel [Location];Country of trav;;ACTIVE;2.68;2.68 +94652-5;Known exposure date;Date;Pt;^Patient;Qn;;H&P.HX;2;Known exposure date;Exposure date;;ACTIVE;2.68;2.68 +94653-3;City of travel;Loc;Pt;^Patient;Nom;;H&P.HX;2;City of travel [Location];City of trav;;ACTIVE;2.68;2.68 +94654-1;Known exposure panel;-;Pt;^Patient;-;;PANEL.H&P;2;Known exposure panel;Exposure pnl;;ACTIVE;2.68;2.68 +94655-8;Identifier & Assigning authority panel;-;Pt;^Patient;-;;PANEL.ADMIN;2;Identifier and Assigning authority panel;ID & Authority panel;;ACTIVE;2.68;2.68 +9465-6;Benzene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Benzene [Mass/volume] in Urine;Benzene Ur-mCnc;;ACTIVE;1.0i;2.73 +94656-6;State of known exposure;Loc;Pt;^Patient;Nom;;H&P.HX;2;State of known exposure;State of exposure;;ACTIVE;2.68;2.68 +94657-4;Case identifier;ID;Pt;^Contact;Nom;;ADMIN;2;Contact case identifier;Case ID Contact;;ACTIVE;2.68;2.68 +94658-2;City of known exposure;Loc;Pt;^Patient;Nom;;H&P.HX;2;City of known exposure;City of exposure;;ACTIVE;2.68;2.68 +94659-0;Case identifier;ID;Pt;^Patient;Nom;;ADMIN;2;Case identifier;Case ID;;ACTIVE;2.68;2.68 +94660-8;SARS coronavirus 2 RNA;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Serum or Plasma by NAA with probe detection;SARS-CoV-2 RNA SerPl Ql NAA+probe;;ACTIVE;2.68;2.69 +94661-6;SARS coronavirus 2 Ab;Imp;Pt;Ser/Plas;Nom;;MICRO;1;SARS-CoV-2 (COVID-19) Ab [Interpretation] in Serum or Plasma;SARS-CoV-2 Ab SerPl-Imp;;ACTIVE;2.68;2.69 +94662-4;Coccidioides immitis Ab.IgG;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Coccidioides immitis IgG Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);C immitis IgG CSF Ql ID;;ACTIVE;2.68;2.68 +94663-2;Coccidioides immitis Ab.IgM;PrThr;Pt;CSF;Ord;Immune diffusion;MICRO;1;Coccidioides immitis IgM Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID);C immitis IgM CSF Ql ID;;ACTIVE;2.68;2.68 +9466-4;Cadmium;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Water;Cadmium Wat-mCnc;;ACTIVE;1.0i;2.7 +94664-0;Anticipated discharge date;Date;Pt;^Patient;Qn;;H&P.HX;2;Anticipated discharge date;Anticipated discharge date;;ACTIVE;2.68;2.68 +94665-7;Granulomatous prostatitis;PrThr;Pt;Specimen;Ord;Microscopy;PATH;1;Granulomatous prostatitis [Presence] in Specimen by Microscopy;Granulomatous prostatitis Spec Ql Micro;;ACTIVE;2.68;2.68 +94666-5;High grade prostatic intraepithelial neoplasia;PrThr;Pt;Specimen;Ord;Microscopy;PATH;1;High grade prostatic intraepithelial neoplasia [Presence] in Specimen by Microscopy;HGPIN Spec Ql Micro;;ACTIVE;2.68;2.68 +94667-3;Delayed hypersensitivity anergy panel;-;Pt;Skin;-;;PANEL.CHAL;1;Delayed hypersensitivity anergy intradermal panel;DTH Anergy Pnl Skin;;ACTIVE;2.68;2.68 +94668-1;Reaction wheal^1D post control ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Reaction wheal [Diameter] --1 day post dose control intradermal;Rx wheal 1D p control ID Diam;;ACTIVE;2.68;2.68 +94669-9;Reaction wheal^2D post control ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Reaction wheal [Diameter] --2 day post dose control intradermal;Rx wheal 2D p control ID Diam;;ACTIVE;2.68;2.68 +94670-7;Tetanus reaction wheal^1D post tetanus toxoid ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tetanus reaction wheal [Diameter] --1 day post tetanus toxoid intradermal;Tetanus Rx 1D p tet tox ID Diam;;ACTIVE;2.68;2.68 +94671-5;Tetanus reaction wheal^2D post tetanus toxoid ID;Diam;Pt;Skin;Qn;;CHALSKIN;1;Tetanus reaction wheal [Diameter] --2 day post tetanus toxoid intradermal;Tetanus Rx 2D p tet tox ID Diam;;ACTIVE;2.68;2.68 +9467-2;Calcium;MCnc;Pt;Water;Qn;;CHEM;1;Calcium [Mass/volume] in Water;Calcium Wat-mCnc;;ACTIVE;1.0i;2.7 +94672-3;24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 [Mass/volume] in Serum or Plasma;24,25(OH)2 VitD SerPl-mCnc;;ACTIVE;2.68;2.68 +94673-1;Calcidiol+ercalcidiol/24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol;MRto;Pt;Ser/Plas;Qn;;CHEM;1;25-Hydroxyvitamin D3+25-Hydroxyvitamin D2/24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 [Mass Ratio] in Serum or Plasma;25(OH)D3+25(OH)D2/24,25(OH)2 VitD SerPl;;ACTIVE;2.68;2.68 +94674-9;Calcidiol+ercalcidiol/24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol ratio panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;25-Hydroxyvitamin D3+25-Hydroxyvitamin D2/24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 ratio panel in Serum or Plasma;25D3+25D2/24,25D3+24,25D2 Pnl SerPl;;ACTIVE;2.68;2.68 +94675-6;Dipeptidyl aminopeptidase-like protein 6 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Titer] in Serum by Immunofluorescence;DPPX IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94676-4;Dipeptidyl aminopeptidase-like protein 6 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;DPPX IgG Ser Ql CBA IFA;;ACTIVE;2.68;2.69 +94677-2;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine and Cystatin C-based formula (CKD-EPI);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI);GFR/BSA.pred SerPlBld Creat+Cyst CKD-EPI;;ACTIVE;2.68;2.72 +94678-0;Views for patency^W radionuclide IV;Find;Pt;Abdomen>Liver+Biliary ducts+Gallbladder;Doc;NM;RAD;2;NM Liver and Biliary ducts and Gallbladder Views for patency;NM Liver+BDs+GB Views for pat W RNC IV;;ACTIVE;2.68;2.69 +94679-8;View && Views supine + upright + lateral-decubitus;Find;Pt;Chest && Abdomen;Doc;XR;RAD;2;XR Chest Single View and Abdomen Supine and Upright and Lateral-decubitus;XR Chest 1V + Abd Sup+Upr+Lat-Decub;;ACTIVE;2.68;2.69 +9468-0;Chloramines;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Chloramines [Mass/volume] in Water;Chloramines Wat-mCnc;;ACTIVE;1.0i;2.7 +94680-6;Multisection limited;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal+Vena cava.inferior & Abdomen+Pelvis>Iliac vessels;Doc;US.doppler;RAD;2;US.doppler Thoracic and Abdominal Aorta and Inferior Vena Cava and Illiac vessels limited;DOP T Ao+Abd Ao+IVC+Ves-Il Ltd;;ACTIVE;2.68;2.69 +94681-4;Multisection;Find;Pt;Chest>Aorta.thoracic & Abdomen>Aorta.abdominal+Vena cava.inferior & Abdomen+Pelvis>Iliac vessels;Doc;US.doppler;RAD;2;US.doppler Thoracic and Abdominal Aorta and Inferior Vena Cava and Illiac vessels;DOP T Ao+Abd Ao+IVC+Ves-Il;;ACTIVE;2.68;2.69 +94682-2;Views GE 2;Find;Pt;Lower extremity>Calcaneus;Doc;XR;RAD;2;XR Calcaneus GE 2 Views;XR Heel GE 2V;;ACTIVE;2.68;2.69 +94683-0;Views GE 2;Find;Pt;Pelvis & Lower extremity.unilateral>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - unilateral GE 2 Views;XR Pelvis and Hip-Ul GE 2V;;ACTIVE;2.68;2.69 +94684-8;Views GE 6^W R-bending + W L-bending;Find;Pt;Abdomen>Spine.lumbar & Pelvis>Sacrum;Doc;XR;RAD;2;XR Spine Lumbar and Sacrum GE 6 Views W right bending and W left bending;XR L-spine+Sacrum GE 6V W R+L-bending;;ACTIVE;2.68;2.69 +94685-5;Views GE 3 && view PA;Find;Pt;Chest>Ribs.unilateral && Chest;Doc;XR;RAD;2;XR Ribs - unilateral GE 3 Views and Chest PA;XR Ribs-Ul GE 3V + Chest PA;;ACTIVE;2.68;2.69 +94686-3;Multisection^WO & W contrast IV && Multisection^WO contrast;Find;Pt;Head>Brain && Head>Head vessels;Doc;MR && MR.angio;RAD;2;MR Brain WO and W contrast IV and MRA Brain WO contrast;MR Brain WO+W contr IV+MRA WO contr;;ACTIVE;2.68;2.69 +94687-1;Multisection^WO contrast;Find;Pt;Abdomen>Abdominal vessels & Pelvis>Pelvis vessels;Doc;CT.angio;RAD;2;CTA Abdominal vessels and Pelvis vessels WO contrast;CTA Abd ves+Pelvis ves WO contr;;ACTIVE;2.68;2.69 +94688-9;Multisection^WO & W contrast IV;Find;Pt;Neck>Neck vessels & Chest>Chest vessels;Doc;CT.angio;RAD;2;CTA Neck vessels and Chest vessels WO and W contrast IV;CTA Neck+Chest Ves WO+W contr IV;;ACTIVE;2.68;2.69 +94689-7;Cells.CD20/100 cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD20 cells/100 CD19 cells in Blood;CD20 Cells/100 CD19 cells NFr Bld;;ACTIVE;2.68;2.73 +94690-5;Chondroitin-6-sulfate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Chondroitin-6-sulfate/Creatinine [Ratio] in Urine;C6S/Creat Ur-Rto;;ACTIVE;2.68;2.68 +94691-3;Dermatan sulfate & heparan sulfate & chondroitin-6-sulfate & keratan sulfate panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Dermatan sulfate, heparan sulfate, chondroitin-6-sulfate, keratan sulfate panel - Urine;MPS panel Ur;;ACTIVE;2.68;2.68 +94692-1;Dermatan sulfate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Dermatan sulfate/Creatinine [Ratio] in Urine;Dermatan Sulfate/Creat Ur-Rto;;ACTIVE;2.68;2.68 +94693-9;Heparan sulfate/Creatinine;Ratio;Pt;Urine;Qn;;CHEM;1;Heparan sulfate/Creatinine [Ratio] in Urine;Heparan sulfate/Creat Ur-Rto;;ACTIVE;2.68;2.73 +94694-7;Acetylcholine receptor ganglionic neuronal Ab;SCnc;Pt;Ser;Qn;IA;SERO;1;Acetylcholine receptor ganglionic neuronal Ab [Moles/volume] in Serum by Immunoassay;nAChR Ab Ser IA-sCnc;;ACTIVE;2.68;2.68 +94695-4;Axonal autoimmune Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Axonal autoimmune Ab panel - Serum or Plasma;Axonal autoimmune Ab pnl SerPl;;ACTIVE;2.68;2.68 +94696-2;Dementia autoimmune Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Dementia autoimmune Ab panel - Serum or Plasma;Dementia autoimmune Ab pnl SerPl;;ACTIVE;2.68;2.68 +94697-0;Encephalopathy autoimmune Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Encephalopathy autoimmune Ab panel - Serum or Plasma;Encephalopathy autoimmune Ab pnl SerPl;;ACTIVE;2.68;2.68 +9469-8;Chromium;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Water;Chromium Wat-mCnc;;ACTIVE;1.0i;2.7 +94698-8;Epilepsy autoimmune Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Epilepsy autoimmune Ab panel - Serum or Plasma;Epilepsy autoimmune Ab pnl SerPl;;ACTIVE;2.68;2.68 +94699-6;Glutamate decarboxylase 65 Ab;SCnc;Pt;Ser;Qn;IA;SERO;1;Glutamate decarboxylase 65 Ab [Moles/volume] in Serum by Immunoassay;GAD65 Ab Ser IA-sCnc;;ACTIVE;2.68;2.68 +94700-2;Liver diseases autoimmune Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Liver diseases autoimmune Ab panel - Serum or Plasma;Liver diseases autoimmune Ab pnl SerPl;;ACTIVE;2.68;2.68 +94701-0;Movement disorder autoimmune Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Movement disorder autoimmune Ab panel - Serum or Plasma;Movement autoimmune Ab pnl SerPl;;ACTIVE;2.68;2.68 +94702-8;Purkinje cell cytoplasmic type 1 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;PCA-1 Ab [Titer] in Serum by Immunofluorescence;PCA-1 Ab Titr Ser IF;;ACTIVE;2.68;2.68 +94703-6;Purkinje cell cytoplasmic type 2 Ab;Titr;Pt;Ser;Qn;IF;SERO;1;PCA-2 Ab [Titer] in Serum by Immunofluorescence;PCA-2 Ab Titr Ser IF;;ACTIVE;2.68;2.68 +94704-4;Voltage-gated calcium channel N type binding Ab;SCnc;Pt;Ser;Qn;IA;SERO;1;Voltage-gated calcium channel N type binding Ab [Moles/volume] in Serum by Immunoassay;VGCC-N Bind Ab Ser IA-sCnc;;ACTIVE;2.68;2.68 +94705-1;Voltage-gated calcium channel PQ type binding Ab;SCnc;Pt;Ser;Qn;IA;SERO;1;Voltage-gated calcium channel P/Q type binding Ab [Moles/volume] in Serum by Immunoassay;VGCC-P/Q Bind Ab Ser IA-sCnc;;ACTIVE;2.68;2.68 +9470-6;Copper;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Copper [Mass/volume] in Water;Copper Wat-mCnc;;ACTIVE;1.0i;2.7 +94706-9;CV2 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;CV2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;CV2 IgG Titr CSF IF;;ACTIVE;2.68;2.68 +94707-7;Dementia autoimmune Ab panel;-;Pt;CSF;-;;PANEL.SERO;1;Dementia autoimmune Ab panel - Cerebral spinal fluid;Dementia autoimmune Ab pnl CSF;;ACTIVE;2.68;2.68 +94708-5;Encephalopathy autoimmune Ab panel;-;Pt;CSF;-;;PANEL.SERO;1;Encephalopathy autoimmune Ab panel - Cerebral spinal fluid;Encephalopathy autoimmune Ab pnl CSF;;ACTIVE;2.68;2.68 +94709-3;Epilepsy autoimmune Ab panel;-;Pt;CSF;-;;PANEL.SERO;1;Epilepsy autoimmune Ab panel - Cerebral spinal fluid;Epilepsy autoimmune Ab pnl CSF;;ACTIVE;2.68;2.68 +94711-9;Glutamate decarboxylase 65 Ab;SCnc;Pt;CSF;Qn;IA;SERO;1;Glutamate decarboxylase 65 Ab [Moles/volume] in Cerebral spinal fluid by Immunoassay;GAD65 Ab CSF IA-sCnc;;ACTIVE;2.68;2.68 +94712-7;Movement disorder autoimmune Ab panel;-;Pt;CSF;-;;PANEL.SERO;1;Movement disorder autoimmune Ab panel - Cerebral spinal fluid;Movement autoimmune Ab pnl CSF;;ACTIVE;2.68;2.68 +94713-5;Aspartylglycosamine;SCnc;Pt;CSF;Qn;;CHEM;1;Aspartylglycosamine [Moles/volume] in Cerebral spinal fluid;Aspartylglycosamine CSF-sCnc;;ACTIVE;2.68;2.68 +9471-4;Fluoride;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Fluoride [Mass/volume] in Water;Fluoride Wat-mCnc;;ACTIVE;1.0i;2.7 +94714-3;Beta globulin;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin [Mass/time] in 24 hour Urine by Electrophoresis;B-Globulin 24h Ur Elph-mRate;;ACTIVE;2.68;2.68 +94715-0;Gamma globulin;MRat;24H;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin [Mass/time] in 24 hour Urine by Electrophoresis;Gamma glob 24h Ur Elph-mRate;;ACTIVE;2.68;2.68 +94716-8;AGTR1 gene.c.1166A>C;Geno;Pt;Bld;Nom;Molgen;MOLPATH.MUT;1;AGTR1 gene c.1166A>C [Genotype] in Blood by Molecular genetics method Nominal;AGTR1 c.1166A>C Geno Bld;;ACTIVE;2.68;2.68 +94717-6;SLC25A15 gene.c.562_564delTTC;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SLC25A15 gene c.562_564delTTC [Genotype] in Blood or Tissue by Molecular genetics method Nominal;SLC25A15 c.562_564delTTC Geno Bld/T;;ACTIVE;2.68;2.68 +94718-4;Alpha defensins 1+2+3;PrThr;Pt;Synv fld;Ord;IA;CHEM;1;Alpha defensins 1+2+3 [Presence] in Synovial fluid by Immunoassay;Alpha defensins 1+2+3 Snv Ql IA;;ACTIVE;2.68;2.72 +94719-2;Plazomicin;Susc;Pt;Isolate;OrdQn;Gradient strip;ABXBACT;1;Plazomicin [Susceptibility] by Gradient strip;Plazomicin Islt Grad strip;;ACTIVE;2.68;2.68 +947-2;C Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;C Ag [Presence] on Red Blood Cells from Donor;C Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +94720-0;SARS coronavirus 2 Ab.IgA;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgA Ab [Units/volume] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgA SerPl IA-aCnc;;ACTIVE;2.68;2.69 +94721-8;COVID-19+Evaluation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Evaluation note;COVID-19 Eval note;;ACTIVE;2.68;2.7 +9472-2;Heptachlor;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Heptachlor [Mass/volume] in Serum or Plasma;Heptachlor SerPl-mCnc;;ACTIVE;1.0i;2.73 +94722-6;COVID-19+Initial evaluation form;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Initial Evaluation form;COVID-19 Initial Eval form;;ACTIVE;2.68;2.7 +94723-4;COVID-19+Initial evaluation form;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department COVID-19 Initial Evaluation form;ED COVID-19 Initial Eval form;;ACTIVE;2.68;2.7 +94724-2;Note;Find;Pt;Telehealth;Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Telehealth Note;Pulmonary disease Telehealth Note;;ACTIVE;2.68;2.68 +94725-9;Note;Find;Pt;Telehealth;Doc;Aerodigestive medicine;DOC.ONTOLOGY;2;Aerodigestive medicine Telehealth Note;Aerodigestive med Telehealth Note;;ACTIVE;2.68;2.68 +94726-7;Note;Find;Pt;Telehealth;Doc;Cleft and Craniofacial;DOC.ONTOLOGY;2;Cleft and Craniofacial Telehealth Note;Cleft+Craniofacial Telehealth Note;;ACTIVE;2.68;2.68 +94727-5;Gabapentin;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Gabapentin [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Gabapentin Sal Cfm-mCnc;;ACTIVE;2.68;2.68 +94728-3;DULoxetine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;DULoxetine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;DULoxetine Sal Cfm-mCnc;;ACTIVE;2.68;2.68 +94729-1;Cyclobenzaprine;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Cyclobenzaprine [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Cyclobenzaprine Sal Cfm-mCnc;;ACTIVE;2.68;2.68 +9473-0;Heptachlorepoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Heptachlorepoxide [Mass/volume] in Serum or Plasma;Heptachlorepoxide SerPl-mCnc;;ACTIVE;1.0i;2.73 +94730-9;Hypnotics;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Hypnotics [Presence] in Saliva (oral fluid) by Confirmatory method;Hypnotics Sal Ql Cfm;;ACTIVE;2.68;2.68 +94731-7;Narcotics;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Narcotics and opioids [Presence] in Saliva (oral fluid) by Confirmatory method;Narcotics Sal Ql Cfm;;ACTIVE;2.68;2.68 +94732-5;DULoxetine;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;DULoxetine [Presence] in Saliva (oral fluid) by Confirmatory method;DULoxetine Sal Ql Cfm;;ACTIVE;2.68;2.68 +94733-3;Anticonvulsants;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Anticonvulsants [Presence] in Saliva (oral fluid) by Confirmatory method;Anticonvulsants Sal Ql Cfm;;ACTIVE;2.68;2.68 +94734-1;Prostate cancer grade group;Score;Pt;Prostate tumor;Ord;;PATH;1;Prostate cancer grade group [Score] in Prostate tumor Qualitative;Prostate CA grade grp PrT Ql;;ACTIVE;2.68;2.68 +94735-8;Prostate tumor area with Gleason pattern 4+5/Total tumor area;AreaFr;Pt;Prostate tumor;Qn;Microscopy;PATH;1;Prostate tumor area with Gleason pattern 4+5/Total tumor area [Area Fraction] in Prostate tumor by Microscopy;Gleason 4+5/Total AreaFr PrT Micro;;ACTIVE;2.68;2.68 +94736-6;Tissue block identifier;ID;Pt;Specimen;Nom;;PATH;1;Tissue block identifier [Identifier] in Specimen;Tissue block ID Spec;;ACTIVE;2.68;2.68 +94737-4;Intraductal carcinoma of prostate;PrThr;Pt;Specimen;Ord;Microscopy;PATH;1;Intraductal carcinoma of prostate [Presence] in Specimen by Microscopy;Intraductal CA Prostate Spec Ql Micro;;ACTIVE;2.68;2.68 +94738-2;Biopsy site;Anat;Pt;^Patient;Nom;;PATH;1;Biopsy site [Anatomy];Biopsy site Patient;;ACTIVE;2.68;2.68 +94739-0;Prostate cancer grade group basis;Type;Pt;Prostate tumor;Nom;;PATH;1;Prostate cancer grade group basis [Type] in Prostate tumor;Grade grp basis PrT;;ACTIVE;2.68;2.68 +94740-8;Gleason scoring basis;Type;Pt;Prostate tumor;Nom;;PATH;1;Gleason scoring basis [Type] in Prostate tumor;Gleason Basis PrT;;ACTIVE;2.68;2.68 +94741-6;Cancer chemotherapy received in the past 4W;Find;4W;^Patient;Ord;;ONCOLOGY;2;Cancer chemotherapy received in the past 4W;Chemotherapy rcvd past 4W;;ACTIVE;2.68;2.68 +94742-4;Disease stage classification method;Type;Pt;^Patient;Nom;*;CLIN;2;Disease stage classification method;Disease stg class method;;ACTIVE;2.68;2.68 +94743-2;Evaluation note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Evaluation note;Gyn Onc Eval note;;ACTIVE;2.68;2.68 +94744-0;Evaluation note;Find;Pt;{Setting};Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Evaluation note;Navigator Eval note;;ACTIVE;2.68;2.68 +94745-7;SARS coronavirus 2 RNA;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 RNA Ct Resp Qn NAA+probe;;ACTIVE;2.68;2.69 +94746-5;SARS coronavirus 2 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Specimen by NAA with probe detection;SARS-CoV-2 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +94747-3;Evaluation note;Find;Pt;{Setting};Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying Evaluation note;MAiD Eval note;;ACTIVE;2.68;2.68 +9474-8;Hexachlorobenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Hexachlorobenzene [Mass/volume] in Serum or Plasma;HCB SerPl-mCnc;;ACTIVE;1.0i;2.73 +94748-1;Consent;Find;Pt;{Setting};Doc;Medical aid in dying.patient;DOC.ONTOLOGY;2;Medical Aid in Dying Patient Consent Document;MAiD Patient Consent;;ACTIVE;2.68;2.68 +94749-9;Progress note;Find;Pt;{Setting};Doc;Medical aid in dying;DOC.ONTOLOGY;2;Medical Aid in Dying Progress note;MAiD Prog note;;ACTIVE;2.68;2.73 +94750-7;Evaluation note;Find;Pt;{Setting};Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Evaluation note;WOC Eval note;;ACTIVE;2.68;2.68 +94751-5;RHCE gene allele Ee;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;RHCE gene allele Ee [Genotype] in Blood or Tissue by Molecular genetics method Nominal;RHCE allele Ee Geno Bld/T;;ACTIVE;2.68;2.68 +94752-3;RHCE gene allele Cc;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH;1;RHCE gene allele Cc [Genotype] in Blood or Tissue by Molecular genetics method Nominal;RHCE allele Cc Geno Bld/T;;ACTIVE;2.68;2.68 +94753-1;Psychotropic medication pharmacogenomic analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;Psychotropic medication pharmacogenomic analysis in Blood or Tissue by Molecular genetics method;Psychotropic Pharmg Analy Bld/T;;ACTIVE;2.68;2.68 +94754-9;Cells.CD21lowCD38-/100 Cells.CD19;NFr;Pt;Bld;Qn;;CELLMARK;1;CD21lowCD38- cells/100 CD19 cells in Blood;CD21low38- Cells/100 CD19 cells NFr Bld;;ACTIVE;2.68;2.73 +9475-5;Hexane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hexane [Mass/volume] in Blood;Hexane Bld-mCnc;;ACTIVE;1.0i;2.73 +94755-6;Cells.CD21lowCD38-;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD21lowCD38- cells [#/volume] in Blood;CD21low38- Cells # Bld;;ACTIVE;2.68;2.73 +94756-4;SARS coronavirus 2 N gene;PrThr;Pt;Respiratory;Ord;Probe.amp.tar.CDC primer-probe set N1;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N1;SARS-CoV-2 N gene Resp Ql NAA N1;;ACTIVE;2.68;2.69 +94757-2;SARS coronavirus 2 N gene;PrThr;Pt;Respiratory;Ord;Probe.amp.tar.CDC primer-probe set N2;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N2;SARS-CoV-2 N gene Resp Ql NAA N2;;ACTIVE;2.68;2.69 +94758-0;SARS-related coronavirus E gene;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus E gene [Presence] in Respiratory specimen by NAA with probe detection;SARS-rel CoV E gene Resp Ql NAA+probe;;ACTIVE;2.68;2.68 +94759-8;SARS coronavirus 2 RNA;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection;SARS-CoV-2 RNA Nph Ql NAA+probe;;ACTIVE;2.68;2.69 +94760-6;SARS coronavirus 2 N gene;PrThr;Pt;Nph;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Nasopharynx by NAA with probe detection;SARS-CoV-2 N gene Nph Ql NAA+probe;;ACTIVE;2.68;2.69 +94761-4;SARS coronavirus 2 Ab.IgG;PrThr;Pt;Bld.dot;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgG Ab [Presence] in DBS by Immunoassay;SARS-CoV-2 IgG DBS Ql IA;;ACTIVE;2.68;2.69 +94762-2;SARS coronavirus 2 Ab;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) Ab [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 Ab SerPl Ql IA;;ACTIVE;2.68;2.69 +9476-3;Hexanoylglycine;SCnc;Pt;Urine;Qn;;CHEM;1;Hexanoylglycine [Moles/volume] in Urine;Hexanoylgly Ur-sCnc;;ACTIVE;1.0i;2.7 +94763-0;SARS coronavirus 2;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;SARS-CoV-2 (COVID-19) [Presence] in Specimen by Organism specific culture;SARS-CoV-2 Spec Ql Cult;;ACTIVE;2.68;2.69 +94764-8;SARS coronavirus 2 whole genome;Seq;Pt;Isolate/Specimen;Nom;Sequencing;MICRO;1;SARS-CoV-2 (COVID-19) whole genome [Nucleotide sequence] in Isolate or Specimen by Sequencing;SARS-CoV-2 genome Islt/Spm-Seq;;ACTIVE;2.68;2.69 +94765-5;SARS-related coronavirus E gene;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus E gene [Presence] in Serum or Plasma by NAA with probe detection;SARS-rel CoV E gene SerPl Ql NAA+probe;;ACTIVE;2.68;2.68 +94766-3;SARS coronavirus 2 N gene;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Serum or Plasma by NAA with probe detection;SARS-CoV-2 N gene SerPl Ql NAA+probe;;ACTIVE;2.68;2.69 +94767-1;SARS coronavirus 2 S gene;PrThr;Pt;Ser/Plas;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Presence] in Serum or Plasma by NAA with probe detection;SARS-CoV-2 S gene SerPl Ql NAA+probe;;ACTIVE;2.68;2.69 +94768-9;SARS coronavirus 2 Ab.IgA;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;SARS-CoV-2 IgA SerPlBld Ql IA.rapid;;ACTIVE;2.68;2.69 +94769-7;SARS coronavirus 2 Ab;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;SARS-CoV-2 (COVID-19) Ab [Units/volume] in Serum or Plasma by Immunoassay;SARS-CoV-2 Ab SerPl IA-aCnc;;ACTIVE;2.68;2.71 +94770-5;Note;Find;Pt;Telehealth;Doc;Wound, ostomy, and continence care;DOC.ONTOLOGY;2;Wound, Ostomy, and Continence Care Telehealth Note;WOC Telehealth Note;;ACTIVE;2.68;2.68 +9477-1;Lead;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Lead [Mass/volume] in Water;Lead Wat-mCnc;;ACTIVE;1.0i;2.7 +94771-3;Note;Find;Pt;Telehealth;Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology Telehealth Note;Anesthesiology Telehealth Note;;ACTIVE;2.68;2.68 +94772-1;Note;Find;Pt;Telehealth;Doc;Blood banking and transfusion medicine;DOC.ONTOLOGY;2;Blood banking and transfusion medicine Telehealth Note;Bld Bnk+Trans Med Telehealth Note;;ACTIVE;2.68;2.68 +94773-9;Note;Find;Pt;Telehealth;Doc;Burn management;DOC.ONTOLOGY;2;Burn management Telehealth Note;Burn Telehealth Note;;ACTIVE;2.68;2.68 +94774-7;Note;Find;Pt;Telehealth;Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Telehealth Note;Cardiac surgery Telehealth Note;;ACTIVE;2.68;2.68 +94775-4;Note;Find;Pt;Telehealth;Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Telehealth Note;CCM Telehealth Note;;ACTIVE;2.68;2.68 +94776-2;Note;Find;Pt;Telehealth;Doc;Dentistry;DOC.ONTOLOGY;2;Dentistry Telehealth Note;Dentistry Telehealth Note;;ACTIVE;2.68;2.68 +94777-0;Note;Find;Pt;Telehealth;Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Telehealth Note;Dermatology Telehealth Note;;ACTIVE;2.68;2.68 +94778-8;Note;Find;Pt;Telehealth;Doc;Ethics;DOC.ONTOLOGY;2;Ethics Telehealth Note;Ethics Telehealth Note;;ACTIVE;2.68;2.68 +94779-6;Note;Find;Pt;Telehealth;Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Telehealth Note;Fam Med Telehealth Note;;ACTIVE;2.68;2.68 +94780-4;Note;Find;Pt;Telehealth;Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Telehealth Note;Gastroenterology Telehealth Note;;ACTIVE;2.68;2.68 +94781-2;Note;Find;Pt;Telehealth;Doc;General medicine;DOC.ONTOLOGY;2;General medicine Telehealth Note;General medicine Telehealth Note;;ACTIVE;2.68;2.68 +94782-0;Note;Find;Pt;Telehealth;Doc;Surgery;DOC.ONTOLOGY;2;Surgery Telehealth Note;Surgery Telehealth Note;;ACTIVE;2.68;2.68 +94783-8;Note;Find;Pt;Telehealth;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Telehealth Note;Geri med Telehealth Note;;ACTIVE;2.68;2.68 +94784-6;Note;Find;Pt;Telehealth;Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Telehealth Note;Gyn Onc Telehealth Note;;ACTIVE;2.68;2.68 +94785-3;Note;Find;Pt;Telehealth;Doc;Healthcare navigator;DOC.ONTOLOGY;2;Healthcare navigator Telehealth Note;Navigator Telehealth Note;;ACTIVE;2.68;2.68 +94786-1;Note;Find;Pt;Telehealth;Doc;Hematology;DOC.ONTOLOGY;2;Hematology Telehealth Note;Hematology Telehealth Note;;ACTIVE;2.68;2.68 +94787-9;Note;Find;Pt;Telehealth;Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Telehealth Note;IR Telehealth Note;;ACTIVE;2.68;2.68 +94788-7;Note;Find;Pt;Telehealth;Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Telehealth Note;Clin Path Telehealth Note;;ACTIVE;2.68;2.68 +9478-9;Magnesium;MCnc;Pt;Water;Qn;;CHEM;1;Magnesium [Mass/volume] in Water;Magnesium Wat-mCnc;;ACTIVE;1.0i;2.7 +94789-5;Note;Find;Pt;Telehealth;Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Telehealth Note;Mat fetal med Telehealth Note;;ACTIVE;2.68;2.73 +94790-3;Note;Find;Pt;Telehealth;Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Telehealth Note;Nutr+diet Telehealth Note;;ACTIVE;2.68;2.68 +94791-1;Note;Find;Pt;Telehealth;Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Telehealth Note;OT Telehealth Note;;ACTIVE;2.68;2.68 +94792-9;Note;Find;Pt;Telehealth;Doc;Oncology;DOC.ONTOLOGY;2;Oncology Telehealth Note;Oncology Telehealth Note;;ACTIVE;2.68;2.68 +94793-7;Note;Find;Pt;Telehealth;Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Telehealth Note;Wound care management Telehealth Note;;ACTIVE;2.68;2.68 +94794-5;Note;Find;Pt;Telehealth;Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Telehealth Note;Ophthalmol Telehealth Note;;ACTIVE;2.68;2.68 +94795-2;Note;Find;Pt;Telehealth;Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Telehealth Note;Pastoral Care Telehealth Note;;ACTIVE;2.68;2.68 +94796-0;Note;Find;Pt;Telehealth;Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Telehealth Note;Pharmacology Telehealth Note;;ACTIVE;2.68;2.68 +9479-7;Mercury;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Water;Mercury Wat-mCnc;;ACTIVE;1.0i;2.7 +94797-8;Note;Find;Pt;Telehealth;Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Telehealth Note;Plastic surgery Telehealth Note;;ACTIVE;2.68;2.68 +94798-6;Note;Find;Pt;Telehealth;Doc;Psychology;DOC.ONTOLOGY;2;Psychology Telehealth Note;Psych Telehealth Note;;ACTIVE;2.68;2.68 +94799-4;Note;Find;Pt;Telehealth;Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Telehealth Note;Radiation Onc Telehealth Note;;ACTIVE;2.68;2.68 +948-0;C Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;C Ag [Presence] on Red Blood Cells;C Ag RBC Ql;;ACTIVE;1.0;2.73 +94800-0;Note;Find;Pt;Telehealth;Doc;Rapid response team;DOC.ONTOLOGY;2;Rapid response team Telehealth Note;Rapid response team Telehealth Note;;ACTIVE;2.68;2.68 +94801-8;Note;Find;Pt;Telehealth;Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Telehealth Note;Rec therapy Telehealth Note;;ACTIVE;2.68;2.68 +94802-6;Note;Find;Pt;Telehealth;Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Telehealth Note;Resp therapy Telehealth Note;;ACTIVE;2.68;2.68 +94803-4;Note;Find;Pt;Telehealth;Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Telehealth Note;Speech-lang path Telehealth Note;;ACTIVE;2.68;2.68 +94804-2;Note;Find;Pt;Telehealth;Doc;Trauma;DOC.ONTOLOGY;2;Trauma Telehealth Note;Trauma Telehealth Note;;ACTIVE;2.68;2.68 +9480-5;Nitrate;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Nitrate [Mass/volume] in Water;Nitrate Wat-mCnc;;ACTIVE;1.0i;2.7 +94805-9;Note;Find;Pt;Telehealth;Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Telehealth Note;Vascular surgery Telehealth Note;;ACTIVE;2.68;2.68 +94806-7;COVID-19+Intubation+Consultation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Intubation Consultation note;COVID-19 Intub+Consult;;ACTIVE;2.68;2.7 +94807-5;COVID-19+Intubation+Consultation note;Find;Pt;{Setting};Doc;Attending;DOC.ONTOLOGY;2;Attending COVID-19 Intubation Consultation note;Attend COVID-19 Intub+Consult;;ACTIVE;2.68;2.7 +94808-3;COVID-19+Intubation+Consultation note;Find;Pt;{Setting};Doc;Resident;DOC.ONTOLOGY;2;Resident COVID-19 Intubation Consultation note;Res COVID-19 Intub+Consult;;ACTIVE;2.68;2.7 +94809-1;COVID-19+Intubation+Progress note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Intubation Progress note;COVID-19 Intub+Progress;;ACTIVE;2.68;2.7 +94810-9;COVID-19+Intubation+Procedure note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Intubation Procedure note;COVID-19 Intub Proced;;ACTIVE;2.68;2.7 +94811-7;COVID-19+Intubation+Evaluation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Intubation Evaluation note;COVID-19 Intub Eval note;;ACTIVE;2.68;2.7 +94812-5;COVID-19+Intubation+Cardiopulmonary resuscitation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Intubation and Cardiopulmonary resuscitation note;COVID-19 Intub+CPR;;ACTIVE;2.68;2.7 +9481-3;pH;LsCnc;Pt;Water;Qn;;CHEM;1;pH of Water;pH Wat;;ACTIVE;1.0i;2.42 +94813-3;COVID-19+Intubation+Conference note;Find;Pt;{Setting};Doc;Team;DOC.ONTOLOGY;2;Team COVID-19 Intubation Conference note;Team COVID-19 Intub Conference;;ACTIVE;2.68;2.7 +94814-1;COVID-19+Consultation note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine COVID-19 Consultation note;CCM COVID-19 Consult note;;ACTIVE;2.68;2.7 +94815-8;CV2 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;CV2 IgG Ab [Titer] in Serum by Immunofluorescence;CV2 IgG Titr Ser IF;;ACTIVE;2.68;2.68 +94816-6;Voltage-gated potassium channel Ab;SCnc;Pt;Ser;Qn;IA;SERO;1;Voltage-gated potassium channel Ab [Moles/volume] in Serum by Immunoassay;VGKC Ab Ser IA-sCnc;;ACTIVE;2.68;2.68 +94817-4;Striated muscle Ab;Titr;Pt;Ser;Qn;IA;SERO;1;Striated muscle Ab [Titer] in Serum by Immunoassay;Stria Mus Ab Titr Ser IA;;ACTIVE;2.68;2.68 +94818-2;Paraneoplastic Ab panel;-;Pt;CSF;-;IF;PANEL.SERO;1;Paraneoplastic Ab panel - Cerebral spinal fluid by Immunofluorescence;Paraneoplastic Ab Pnl CSF IF;;ACTIVE;2.68;2.68 +94819-0;SARS coronavirus 2 RNA;LnCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection;SARS-CoV-2 RNA Spec NAA+probe-Log#;;ACTIVE;2.68;2.69 +94820-8;Whole mRNA transcriptome sequence analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;Whole mRNA transcriptome sequence analysis in Blood or Tissue by Sequencing;Whole mRNA Seq Analysis Bld/T Seq;;ACTIVE;2.68;2.68 +9482-1;Potassium;MCnc;Pt;Water;Qn;;CHEM;1;Potassium [Mass/volume] in Water;Potassium Wat-mCnc;;ACTIVE;1.0i;2.7 +94821-6;COVID-19+Intubation advance directives;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Intubation advance directives;COVID-19 Intubation Adv Dir;;ACTIVE;2.68;2.7 +94822-4;SARS coronavirus 2 RNA;PrThr;Pt;Saliva;Ord;Sequencing;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by Sequencing;SARS-CoV-2 RNA Sal Ql Seq;;ACTIVE;2.68;2.69 +94823-2;Cytomegalovirus DNA;LnCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection;CMV DNA Amn NAA+probe-Log#;;ACTIVE;2.68;2.68 +94824-0;Parvovirus B19 DNA;ACnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Units/volume] (viral load) in Amniotic fluid by NAA with probe detection;B19V DNA Amn NAA+probe-aCnc;;ACTIVE;2.68;2.68 +94825-7;Parvovirus B19 DNA;LaCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [log units/volume] (viral load) in Amniotic fluid by NAA with probe detection;B19V DNA Amn NAA+probe-Log IU;;ACTIVE;2.68;2.68 +94826-5;Parvovirus B19 DNA;LnCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection;B19V DNA Amn NAA+probe-Log#;;ACTIVE;2.68;2.68 +94827-3;Epstein Barr virus DNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Presence] in Amniotic fluid by NAA with probe detection;EBV DNA Amn Ql NAA+probe;;ACTIVE;2.68;2.68 +94828-1;Epstein Barr virus DNA;ACnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Units/volume] (viral load) in Amniotic fluid by NAA with probe detection;EBV DNA Amn NAA+probe-aCnc;;ACTIVE;2.68;2.68 +94829-9;Epstein Barr virus DNA;LaCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [log units/volume] (viral load) in Amniotic fluid by NAA with probe detection;EBV DNA Amn NAA+probe-Log IU;;ACTIVE;2.68;2.68 +94830-7;Epstein Barr virus DNA;LnCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Epstein Barr virus DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection;EBV DNA Amn NAA+probe-Log#;;ACTIVE;2.68;2.68 +94831-5;Varicella zoster virus DNA;ACnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Units/volume] (viral load) in Amniotic fluid by NAA with probe detection;VZV DNA Amn NAA+probe-aCnc;;ACTIVE;2.68;2.68 +94832-3;Varicella zoster virus DNA;LaCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [log units/volume] (viral load) in Amniotic fluid by NAA with probe detection;VZV DNA Amn NAA+probe-Log IU;;ACTIVE;2.68;2.68 +94833-1;Varicella zoster virus DNA;LnCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Varicella zoster virus DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection;VZV DNA Amn NAA+probe-Log#;;ACTIVE;2.68;2.68 +94834-9;Herpes simplex virus 1+2 DNA;LnCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1+2 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection;HSV1+2 DNA Amn NAA+probe-Log#;;ACTIVE;2.68;2.68 +94835-6;Herpes simplex virus 1 DNA;LnCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 1 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection;HSV1 DNA Amn NAA+probe-Log#;;ACTIVE;2.68;2.68 +94836-4;Herpes simplex virus 2 DNA;LnCnc;Pt;Amnio fld;Qn;Probe.amp.tar;MICRO;1;Herpes simplex virus 2 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection;HSV2 DNA Amn NAA+probe-Log#;;ACTIVE;2.68;2.68 +94837-2;Dengue virus 1+2+3+4 RNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Dengue virus 1+2+3+4 RNA [Presence] in Amniotic fluid by NAA with probe detection;DENV1+2+3+4 RNA Amn Ql NAA+probe;;ACTIVE;2.68;2.68 +94838-0;Enterovirus RNA;PrThr;Pt;Amnio fld;Ord;Probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Amniotic fluid by NAA with probe detection;EV RNA Amn Ql NAA+probe;;ACTIVE;2.68;2.68 +9483-9;Selenium;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Selenium [Mass/volume] in Water;Selenium Wat-mCnc;;ACTIVE;1.0i;2.7 +94839-8;Calcium;MCnc;Pt;Urine^Fetus;Qn;;CHEM;1;Calcium [Mass/volume] in Urine from Fetus;Calcium Ur Fetus-mCnc;;ACTIVE;2.68;2.68 +94840-6;Chloride;SCnc;Pt;Urine^Fetus;Qn;;CHEM;1;Chloride [Moles/volume] in Urine from Fetus;Chloride Ur Fetus-sCnc;;ACTIVE;2.68;2.68 +94841-4;Potassium;SCnc;Pt;Urine^Fetus;Qn;;CHEM;1;Potassium [Moles/volume] in Urine from Fetus;Potassium Ur Fetus-sCnc;;ACTIVE;2.68;2.68 +94842-2;Sodium;SCnc;Pt;Urine^Fetus;Qn;;CHEM;1;Sodium [Moles/volume] in Urine from Fetus;Sodium Ur Fetus-sCnc;;ACTIVE;2.68;2.68 +94843-0;Osmolality;Osmol;Pt;Urine^Fetus;Qn;;CHEM;1;Osmolality of Urine from Fetus;Osmolality Ur Fetus;;ACTIVE;2.68;2.68 +94844-8;Creatinine;MCnc;Pt;Urine^Fetus;Qn;;CHEM;1;Creatinine [Mass/volume] in Urine from Fetus;Creat Ur Fetus-mCnc;;ACTIVE;2.68;2.68 +94845-5;SARS coronavirus 2 RNA;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 RNA Sal Ql NAA+probe;;ACTIVE;2.68;2.69 +94846-3;Specimen collection problem;Hx;Pt;^Patient;Nom;;H&P.HX;2;History of Specimen collection problem;Hx of Spec collection problem;;ACTIVE;2.68;2.68 +9484-7;Silver;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Silver [Mass/volume] in Water;Silver Wat-mCnc;;ACTIVE;1.0i;2.7 +94847-1;Reason specimen not collected;Find;Pt;Specimen;Nom;;SPEC;1;Reason specimen not collected;Reason spec not collected;;ACTIVE;2.68;2.68 +94848-9;Functional assessment standardized items (FASI) - version 1.0;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Functional assessment standardized items (FASI) - version 1.0 [CMS Assessment];;;ACTIVE;2.68;2.68 +94849-7;FASI v1.0 - Self-care - usual performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Self-care - usual performance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94850-5;FASI v1.0 - Self-care - most dependent performance;-;1Mo;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Self-care - most dependent performance [CMS Assessment];;;ACTIVE;2.68;2.68 +94851-3;FASI v1.0 - Mobility - usual performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Mobility - usual performance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94852-1;FASI v1.0 - Mobility - most dependent performance;-;1Mo;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Mobility - most dependent performance [CMS Assessment];;;ACTIVE;2.68;2.68 +94853-9;West Nile virus Ab.IgG & IgM panel;-;Pt;CSF;Ord;;PANEL.MICRO;1;West Nile virus IgG and IgM panel - Cerebral spinal fluid Qualitative;WNV IgG+IgM Pnl CSF;;ACTIVE;2.68;2.68 +9485-4;Sodium;MCnc;Pt;Water;Qn;;CHEM;1;Sodium [Mass/volume] in Water;Sodium Wat-mCnc;;ACTIVE;1.0i;2.7 +94854-7;West Nile virus Ab.IgG & IgM panel;-;Pt;Ser;Ord;;PANEL.MICRO;1;West Nile virus IgG and IgM panel - Serum Qualitative;WNV IgG+IgM Pnl Ser;;ACTIVE;2.68;2.68 +94855-4;Carbamazepine hypersensitivity genotype panel;-;Pt;Bld/Tiss;-;;PANEL.MOLPATH.PHARMG;1;carBAMazepine hypersensitivity genotype panel - Blood or Tissue;carBAMazepine hypersens geno Pnl Bld/T;;ACTIVE;2.68;2.68 +94856-2;Microscopic observation^2nd specimen;PrThr;Pt;Sputum;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Sputum by Acid fast stain --2nd specimen;Acid fast Stn sp2 Spt Ql;;ACTIVE;2.68;2.68 +94857-0;Microscopic observation^3rd specimen;PrThr;Pt;Sputum;Ord;Acid fast stain;MICRO;1;Microscopic observation [Presence] in Sputum by Acid fast stain --3rd specimen;Acid fast Stn sp3 Spt Ql;;ACTIVE;2.68;2.68 +94858-8;Glycerol;SCnc;Pt;Ser;Qn;Calculated;CHEM;1;Glycerol [Moles/volume] in Serum by calculation;Glycerol Ser Calc-sCnc;;ACTIVE;2.68;2.68 +94859-6;Glycerol & Glycerol-corrected triglyceride panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Glycerol and glycerol-corrected triglyceride panel - Serum or Plasma;Glycerol + glycerol corr TG Pnl SerPl;;ACTIVE;2.68;2.68 +94860-4;Transthyretin;Mass;Pt;Bld;Qn;;CHEM;1;Transthyretin [Mass] in Blood;TTR Bld Qn;;ACTIVE;2.68;2.68 +94861-2;Transthyretin - transthyretin peak 2;MDiff;Pt;Bld;Qn;;CHEM;1;Transthyretin - transthyretin peak 2 [Mass difference] in Blood;TTR - TTR 2 MDiff Bld;;ACTIVE;2.68;2.68 +9486-2;Sulfate;MCnc;Pt;Water;Qn;;CHEM;1;Sulfate [Mass/volume] in Water;Sulfate Wat-mCnc;;ACTIVE;1.0i;2.7 +94862-0;Transthyretin peak 2;Mass;Pt;Bld;Qn;;CHEM;1;Transthyretin peak 2 [Mass] in Blood;TTR 2 Bld Qn;;ACTIVE;2.68;2.68 +94863-8;Transthyretin width at half peak height;Mass;Pt;Bld;Qn;;CHEM;1;Transthyretin width at half peak height [Mass] in Blood;TTR width at half height Bld Qn;;ACTIVE;2.68;2.68 +94864-6;Transthyretin-associated familial amyloidosis panel;-;Pt;Bld;-;;PANEL.CHEM;1;Transthyretin-associated familial amyloidosis panel - Blood;TTR-assoc familial amyloidosis Pnl Bld;;ACTIVE;2.68;2.68 +94865-3;Triglyceride^^corrected for glycerol;MCnc;Pt;Ser;Qn;;CHEM;1;Triglyceride [Mass/volume] corrected for glycerol in Serum;Trigl Glycer cor Ser-mCnc;;ACTIVE;2.68;2.68 +94866-1;7-Alpha hydroxy-4-cholesten-3-one;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;7-Alpha hydroxy-4-cholesten-3-one [Mass/volume] in Serum or Plasma;7a-OH-4-chol-3-one SerPl-mCnc;;ACTIVE;2.68;2.68 +94867-9;Ganglioside GD1b Ab.IgG;Titr;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1b IgG Ab [Titer] in Serum by Immunoassay;GD1b Gangl IgG Titr Ser IA;;ACTIVE;2.68;2.68 +94868-7;Ganglioside GD1b Ab.IgG;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GD1b IgG Ab [Presence] in Serum by Immunoassay;GD1b Gangl IgG Ser Ql IA;;ACTIVE;2.68;2.68 +94869-5;Ganglioside GD1b Ab.IgM;Titr;Pt;Ser;Qn;IA;SERO;1;Ganglioside GD1b IgM Ab [Titer] in Serum by Immunoassay;GD1b Gangl IgM Titr Ser IA;;ACTIVE;2.68;2.68 +9487-0;Zinc;MCnc;Pt;Water;Qn;;DRUG/TOX;1;Zinc [Mass/volume] in Water;Zinc Wat-mCnc;;ACTIVE;1.0i;2.7 +94870-3;Ganglioside GD1b Ab.IgM;PrThr;Pt;Ser;Ord;IA;SERO;1;Ganglioside GD1b IgM Ab [Presence] in Serum by Immunoassay;GD1b Gangl IgM Ser Ql IA;;ACTIVE;2.68;2.68 +94871-1;Aldosterone & sodium panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Aldosterone and sodium panel - 24 hour Urine;Aldosterone + Na Pnl 24h Ur;;ACTIVE;2.68;2.68 +94872-9;Cholesterol & triglyceride panel;-;Pt;Body fld;Qn;;PANEL.CHEM;1;Cholesterol and triglyceride panel - Body fluid;Chol + Trigl Pnl Fld;;ACTIVE;2.68;2.68 +94873-7;Cortisol.free post corticotropin stimulation panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Cortisol.free post corticotropin stimulation panel - Serum or Plasma;Cortis F p corticotropin stim Pnl SerPl;;ACTIVE;2.68;2.68 +94874-5;Cyclic citrullinated peptide Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Cyclic citrullinated peptide IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;cCP IgG SerPl IA-aCnc;;ACTIVE;2.68;2.68 +94875-2;Nuclear Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Nuclear IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Nuclear IgG SerPl IA-aCnc;;ACTIVE;2.68;2.68 +94876-0;Self-care priorities for the next 6Mo;Find;Pt;^Patient;Nar;CMS Assessment;SURVEY.CMS;4;Self-care priorities for the next 6 months [CMS Assessment];;;ACTIVE;2.68;2.68 +94877-8;Mobility priorities for the next 6Mo;Find;Pt;^Patient;Nar;CMS Assessment;SURVEY.CMS;4;Mobility priorities for the next 6 months [CMS Assessment];;;ACTIVE;2.68;2.68 +94878-6;Instrumental activities of daily living priorities for the next 6Mo;Find;Pt;^Patient;Nar;CMS Assessment;SURVEY.CMS;4;Instrumental activities of daily living priorities for the next 6 months [CMS Assessment];;;ACTIVE;2.68;2.68 +94879-4;Need for and availability of a cane &or crutch;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a cane/crutch [CMS Assessment];;;ACTIVE;2.68;2.68 +94880-2;Need for and availability of a walker;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a walker [CMS Assessment];;;ACTIVE;2.68;2.68 +94881-0;Need for and availability of a standard folding walker;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a standard folding walker [CMS Assessment];;;ACTIVE;2.68;2.68 +94882-8;Need for and availability of a walker with seat;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a walker with seat [CMS Assessment];;;ACTIVE;2.68;2.68 +94883-6;Need for and availability of a walker with wheels;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a walker with wheels [CMS Assessment];;;ACTIVE;2.68;2.68 +94884-4;Need for and availability of a wheelchair;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a wheelchair [CMS Assessment];;;ACTIVE;2.68;2.68 +94885-1;Need for and availability of a manual wheelchair;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a manual wheelchair [CMS Assessment];;;ACTIVE;2.68;2.68 +94886-9;Need for and availability of a motorized wheelchair &or scooter;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a motorized wheelchair/scooter [CMS Assessment];;;ACTIVE;2.68;2.68 +94887-7;Need for and availability of a limb prosthesis;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a limb prosthesis [CMS Assessment];;;ACTIVE;2.68;2.68 +94888-5;Need for and availability of a specialized seating pad;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a specialized seating pad [CMS Assessment];;;ACTIVE;2.68;2.68 +94889-3;Need for and availability of a mechanical lift;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a mechanical lift [CMS Assessment];;;ACTIVE;2.68;2.68 +94890-1;Need for and availability of a reacher &or grabber;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a reacher/grabber [CMS Assessment];;;ACTIVE;2.68;2.68 +94891-9;Need for and availability of a sock aid;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a sock aid [CMS Assessment];;;ACTIVE;2.68;2.68 +94892-7;Need for and availability of an orthotic &or brace;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of an orthotic/brace [CMS Assessment];;;ACTIVE;2.68;2.68 +94893-5;Need for and availability of a bed rail;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a bed rail [CMS Assessment];;;ACTIVE;2.68;2.68 +94894-3;Need for and availability of an electronic bed;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of an electronic bed [CMS Assessment];;;ACTIVE;2.68;2.68 +94895-0;Need for and availability of grab bars;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of grab bars [CMS Assessment];;;ACTIVE;2.68;2.68 +9489-6;Arsenic;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Arsenic [Mass/volume] in Body fluid;Arsenic Fld-mCnc;;ACTIVE;1.0i;2.34 +94896-8;Need for and availability of a transfer board;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a transfer board [CMS Assessment];;;ACTIVE;2.68;2.68 +94897-6;Need for and availability of a shower &or commode chair;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a shower/commode chair [CMS Assessment];;;ACTIVE;2.68;2.68 +94898-4;Need for and availability of a walk or wheel-in shower;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a walk/wheel-in shower [CMS Assessment];;;ACTIVE;2.68;2.68 +94899-2;Need for and availability of glasses or contact lenses;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of glasses or contact lenses [CMS Assessment];;;ACTIVE;2.68;2.68 +94900-8;Need for and availability of a hearing aid;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a hearing aid [CMS Assessment];;;ACTIVE;2.68;2.68 +94901-6;Need for and availability of a communication device;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a communication device [CMS Assessment];;;ACTIVE;2.68;2.68 +94902-4;Need for and availability of stair rails;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of stair rails [CMS Assessment];;;ACTIVE;2.68;2.68 +94903-2;Need for and availability of a lift chair;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a lift chair [CMS Assessment];;;ACTIVE;2.68;2.68 +9490-4;Aspergillus flavus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus flavus Ab [Presence] in Serum;A flavus Ab Ser Ql;;ACTIVE;1.0i;2.73 +94904-0;Need for and availability of ramps;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of ramps [CMS Assessment];;;ACTIVE;2.68;2.68 +94905-7;Need for and availability of a raised toilet seat;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a raised toilet seat [CMS Assessment];;;ACTIVE;2.68;2.68 +94906-5;Need for and availability of a glucometer;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of a glucometer [CMS Assessment];;;ACTIVE;2.68;2.68 +94907-3;Need for and availability of Continuous Positive Airway Pressure device;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of Continuous Positive Airway Pressure device [CMS Assessment];;;ACTIVE;2.68;2.68 +94908-1;Need for and availability of an oxygen concentrator;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of an oxygen concentrator [CMS Assessment];;;ACTIVE;2.68;2.68 +94909-9;Assistive devices needed;Find;Pt;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Assistive devices needed [CMS Assessment];;;ACTIVE;2.68;2.68 +94910-7;Need for and availability of other assistive devices;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Need for and availability of other assistive devices [CMS Assessment];;;ACTIVE;2.68;2.68 +94911-5;Living arrangement priorities for the next 6Mo;Find;Pt;^Patient;Nar;CMS Assessment;SURVEY.CMS;4;Living arrangement priorities for the next 6 months [CMS Assessment];;;ACTIVE;2.68;2.68 +9491-2;Aspergillus sp Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus sp IgA Ab [Units/volume] in Serum;Aspergillus IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +94912-3;Availability of caregiver assistance;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Availability of caregiver assistance [CMS Assessment];;;ACTIVE;2.68;2.68 +94913-1;Level of paid caregiver assistance in the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Level of paid caregiver assistance in the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94914-9;Level of unpaid caregiver assistance in the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Level of unpaid caregiver assistance in the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94915-6;Paid caregiver's ability and willingness to provide self-care assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide self-care assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94916-4;Unpaid caregiver's ability and willingness to provide self-care assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide self-care assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94917-2;Paid caregiver's ability and willingness to provide mobility assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide mobility assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94918-0;Unpaid caregiver's ability and willingness to provide mobility assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide mobility assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94919-8;Paid caregiver's ability and willingness to provide instrumental activities of daily living assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide instrumental activities of daily living assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +9492-0;Aspergillus sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Aspergillus sp IgM Ab [Units/volume] in Serum;Aspergillus IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +94920-6;Unpaid caregiver's ability and willingness to provide instrumental activities of daily living assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide instrumental activities of daily living assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94921-4;Paid caregiver's ability and willingness to provide medication administration assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide medication administration assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94922-2;Unpaid caregiver's ability and willingness to provide medication administration assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide medication administration assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94923-0;Paid caregiver's ability and willingness to provide medical procedure &or treatment assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide medical procedure/treatment assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94924-8;Unpaid caregiver's ability and willingness to provide medical procedure &or treatment assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide medical procedure/treatment assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94925-5;Paid caregiver's ability and willingness to provide management of equipment assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide management of equipment assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94926-3;Unpaid caregiver's ability and willingness to provide management of equipment assistance;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide management of equipment assistance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94927-1;Paid caregiver's ability and willingness to provide supervision;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide supervision during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94928-9;Unpaid caregiver's ability and willingness to provide supervision;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide supervision during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94929-7;Paid caregiver's ability and willingness to provide advocacy or facilitation of person's participation;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Paid caregiver's ability and willingness to provide advocacy or facilitation of person's participation during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94930-5;Unpaid caregiver's ability and willingness to provide advocacy or facilitation of person's participation;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Unpaid caregiver's ability and willingness to provide advocacy or facilitation of person's participation during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94931-3;Caregiving priorities for the next 6Mo;Find;Pt;^Patient;Nar;CMS Assessment;SURVEY.CMS;4;Caregiving priorities for the next 6 months [CMS Assessment];;;ACTIVE;2.68;2.68 +94932-1;Does the patient walk;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Does the patient walk [CMS Assessment];;;ACTIVE;2.68;2.68 +94933-9;Eating - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94934-7;Oral hygiene - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Oral hygiene - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94935-4;Wash upper body - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wash upper body - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94936-2;Shower &or bathe self - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Shower/bathe self - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94937-0;Upper body dressing - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Upper body dressing - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +9493-8;Bismuth;MCnc;Pt;Body fld;Qn;;DRUG/TOX;1;Bismuth [Mass/volume] in Body fluid;Bismuth Fld-mCnc;;ACTIVE;1.0i;2.34 +94938-8;Lower body dressing - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lower body dressing - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94939-6;Putting on and taking off footwear - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Putting on and taking off footwear - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94940-4;Roll left and right - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Roll left and right - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94941-2;Sit to lying - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to lying - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94942-0;Lying to sitting on side of bed - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lying to sitting on side of bed - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94943-8;Sit to stand - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to stand - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94944-6;Chair &or bed-to-chair transfer - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Chair/bed-to-chair transfer - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.69 +94945-3;Toilet transfer - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet transfer - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +9494-6;Blastomyces dermatitidis Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Blastomyces dermatitidis IgG Ab [Units/volume] in Serum;B dermat IgG Ser-aCnc;;ACTIVE;1.0i;2.69 +94946-1;Car transfer - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Car transfer - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94947-9;Walk 10 feet - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 10 feet - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.69 +94948-7;Walk 50 feet with two turns - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 50 feet with two turns - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.69 +94949-5;Walk 150 feet - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 150 feet - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.69 +94950-3;Walking 10 feet on uneven surfaces - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walking 10 feet on uneven surfaces - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.69 +94951-1;Go up and down a curb &or step - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down a curb/step - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94952-9;Go up and down 4 steps - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down 4 steps - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +9495-3;Brucella canis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella canis IgG Ab [Units/volume] in Serum by Immunoassay;B canis IgG Ser IA-aCnc;;ACTIVE;1.0i;2.69 +94953-7;Go up and down 12 steps - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down 12 steps - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94954-5;Picking up object - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Picking up object - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94955-2;Walks indoors - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walks indoors - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94956-0;Carries something in both hands - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Carries something in both hands - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94957-8;Walks for 15M - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walks for 15 minutes - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94958-6;Walks across a street - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walks across a street - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94959-4;Wheel 50 feet with two turns - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 50 feet with two turns - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94960-2;Wheel 150 feet - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 150 feet - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.69 +9496-1;Brucella canis Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Brucella canis IgM Ab [Units/volume] in Serum by Immunoassay;B canis IgM Ser IA-aCnc;;ACTIVE;1.0i;2.69 +94961-0;Wheels for 15M - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheels for 15 minutes - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94962-8;Wheels across a street - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheels across a street - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94963-6;Makes a light cold meal - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Makes a light cold meal - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94964-4;Makes a light hot meal - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Makes a light hot meal - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94965-1;Light daily housework - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Light daily housework - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94966-9;Heavier periodic housework - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Heavier periodic housework - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94967-7;Light shopping- most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Light shopping- most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94968-5;Answering telephone call - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Answering telephone call - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.69 +94969-3;Placing telephone call - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Placing telephone call - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94970-1;Medication management.oral medications - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication management.oral medications - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94971-9;Medication management.inhalant &or mist medications - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication management.inhalant/mist medications - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94972-7;Medication management.injectable medications - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication management.injectable medications - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94973-5;Simple financial management - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Simple financial management - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94974-3;Complex financial management - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Complex financial management - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94975-0;Living arrangement during the past 1Mo;Find;1Mo;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Living arrangement during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +94976-8;Makes a light cold meal - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Makes a light cold meal - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94977-6;Makes a light hot meal - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Makes a light hot meal - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94978-4;Light daily housework - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Light daily housework - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +9497-9;Butane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Butane [Mass/volume] in Blood;Butane Bld-mCnc;;ACTIVE;1.0i;2.42 +94979-2;Heavier periodic housework - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Heavier periodic housework - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +949-8;C little e Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;C little e Ab [Presence] in Serum or Plasma from Blood product unit;C little e Ab SerPl BPU Ql;;ACTIVE;1.0;2.67 +94980-0;Light shopping - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Light shopping - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94981-8;Answering telephone call - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Answering telephone call - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94982-6;Placing telephone call - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Placing telephone call - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94983-4;Medication management.oral medications - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication management.oral medications - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94984-2;Medication management.inhalant &or mist medications - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication management.inhalant/mist medications - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94985-9;Medication management.injectable medications - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Medication management.injectable medications - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94986-7;Simple financial management - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Simple financial management - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +9498-7;Candida sp Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Candida sp IgA Ab [Units/volume] in Serum;Candida IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +94987-5;Complex financial management - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Complex financial management - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94988-3;Living arrangement;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Living arrangement during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94989-1;Wheels across a street - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheels across a street - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94990-9;Wheels for 15 minutes - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheels for 15 minutes - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94991-7;Wheel 150 feet - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 150 feet - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94992-5;Wheel 50 feet with two turns - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wheel 50 feet with two turns - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94993-3;Walks across a street - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walks across a street - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94994-1;Walks for 15M - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walks for 15 minutes - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +9499-5;Candida sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Deprecated Candida sp IgG Ab [Units/volume] in Serum;Deprecated Candida IgG Ser-aCnc;;DEPRECATED;1.0i;2.69 +94995-8;Carries something in both hands - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Carries something in both hands - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94996-6;Walks indoors - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walks indoors - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94997-4;Picking up object - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Picking up object - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94998-2;Go up and down 12 steps - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down 12 steps - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +94999-0;Go up and down 4 steps - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down 4 steps - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95-0;Cefonicid;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefonicid [Susceptibility] by Minimum lethal concentration (MLC);Cefonocid Islt MLC;;ACTIVE;1.0;2.19 +9500-0;Candida sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Candida sp IgM Ab [Units/volume] in Serum;Candida IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +95000-6;Go up and down a curb &or step - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Go up and down a curb/step - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95001-4;Walking 10 feet on uneven surfaces - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walking 10 feet on uneven surfaces - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95002-2;Walk 150 feet - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 150 feet - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95003-0;Walk 50 feet with two turns - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 50 feet with two turns - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95004-8;Walk 10 feet - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Walk 10 feet - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95005-5;Car transfer - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Car transfer - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95006-3;Toilet transfer - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toilet transfer - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95007-1;Chair &or bed-to-chair transfer - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Chair/bed-to-chair transfer - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95008-9;Sit to stand - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to stand - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95009-7;Lying to sitting on side of bed - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lying to sitting on side of bed - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95010-5;Sit to lying - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Sit to lying - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95011-3;Roll left and right - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Roll left and right - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95012-1;Putting on &or taking off footwear - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Putting on/taking off footwear - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95013-9;Lower body dressing - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Lower body dressing - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95014-7;Upper body dressing - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Upper body dressing - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95015-4;Shower &or bathe self - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Shower/bathe self - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95016-2;Wash upper body - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wash upper body - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95017-0;Toileting hygiene - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toileting hygiene - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +9501-8;Candida sp Ag;Titr;Pt;Ser;Qn;;MICRO;1;Candida sp Ag [Titer] in Serum;Candida Ag Titr Ser;;ACTIVE;1.0i;2.73 +95018-8;Oral hygiene - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Oral hygiene - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95019-6;Eating - usual functional ability;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Eating - usual functional ability during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95020-4;FASI v1.0 - Self-care;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Self-care [CMS Assessment];;;ACTIVE;2.68;2.68 +95021-2;Manual wheelchair use;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Manual wheelchair use [CMS Assessment];;;ACTIVE;2.68;2.68 +95022-0;Motorized wheelchair &or scooter use;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Motorized wheelchair/scooter use [CMS Assessment];;;ACTIVE;2.68;2.68 +95023-8;FASI v1.0 - Mobility;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Mobility [CMS Assessment];;;ACTIVE;2.68;2.68 +95024-6;FASI v1.0 - Manual wheelchair - usual performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Manual wheelchair - usual performance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95025-3;FASI v1.0 - Manual wheelchair - most dependent performance;-;1Mo;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Manual wheelchair - most dependent performance [CMS Assessment];;;ACTIVE;2.68;2.68 +9502-6;Carbophenothion;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Carbophenothion [Mass/volume] in Specimen;Carbophenothion Spec-mCnc;;ACTIVE;1.0i;2.73 +95026-1;FASI v1.0 - Motorized wheelchair &or scooter - most dependent performance;-;1Mo;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Motorized wheelchair/scooter - most dependent performance [CMS Assessment];;;ACTIVE;2.68;2.68 +95027-9;FASI v1.0 - Motorized wheelchair &or scooter - usual performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Motorized wheelchair/scooter - usual performance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95028-7;FASI v1.0 - Instrumental Activities of Daily Living;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Instrumental Activities of Daily Living [CMS Assessment];;;ACTIVE;2.68;2.68 +95029-5;FASI v1.0 - Instrumental Activities of Daily Living - usual performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Instrumental Activities of Daily Living - usual performance during assessment period [CMS Assessment];;;ACTIVE;2.68;2.69 +95030-3;FASI v1.0 - Instrumental Activities of Daily Living - most dependent performance;-;1Mo;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Instrumental Activities of Daily Living - most dependent performance [CMS Assessment];;;ACTIVE;2.68;2.68 +95031-1;FASI v1.0 - Assistive Devices for Everyday Activities;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Assistive Devices for Everyday Activities [CMS Assessment];;;ACTIVE;2.68;2.68 +95032-9;FASI v1.0 - Functional Abilities and Goals;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Functional Abilities and Goals [CMS Assessment];;;ACTIVE;2.68;2.68 +95033-7;FASI v1.0 - Preferences for Customary Routine and Activities;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Preferences for Customary Routine and Activities [CMS Assessment];;;ACTIVE;2.68;2.68 +9503-4;Chloral hydrate;ACnc;Pt;Urine;Ord;;DRUG/TOX;1;Deprecated Chloral hydrate [Presence] in Urine;Deprecated Chloral Hydrate Ur Ql;;DEPRECATED;1.0i;2.36 +95034-5;FASI v1.0 - Availability of Assistance;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Availability of Assistance [CMS Assessment];;;ACTIVE;2.68;2.68 +95035-2;FASI v1.0 - Availability of Paid and Unpaid Assistance;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Availability of Paid and Unpaid Assistance [CMS Assessment];;;ACTIVE;2.68;2.68 +95036-0;FASI v1.0 - Availability of Paid Assistance;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Availability of Paid Assistance [CMS Assessment];;;ACTIVE;2.68;2.68 +95037-8;FASI v1.0 - Availability of Unpaid Assistance;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Availability of Unpaid Assistance [CMS Assessment];;;ACTIVE;2.68;2.68 +95038-6;Fracture reduction was performed;Find;Pt;^Patient;Ord;;TRAUMA;2;Fracture reduction was performed;Fracture reduction;;ACTIVE;2.68;2.68 +95039-4;Type of catheter placed during EMS transport;Type;Pt;^Patient;Nom;;TRAUMA;2;Type of catheter placed during EMS transport;Cath placed dur EMS trans;;ACTIVE;2.68;2.68 +95040-2;EMS crisis intervention;Find;Pt;^Witness;Ord;;TRAUMA;2;EMS crisis intervention Witness;EMS crisis intervention Witness;;ACTIVE;2.68;2.68 +95041-0;COVID-19+Progress note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Progress note;COVID-19 Progress note;;ACTIVE;2.68;2.7 +9504-2;Chloral hydrate;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated Chloral hydrate [Mass/volume] in Serum or Plasma;Deprecated Chloral Hydrate SerPl-mCnc;;DEPRECATED;1.0i;2.36 +95042-8;Used or needed assistive devices in the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Used or needed assistive devices in the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +95043-6;Toileting hygiene - most dependent performance during the past Mo;Find;1Mo;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Toileting hygiene - most dependent performance during the past month [CMS Assessment];;;ACTIVE;2.68;2.68 +95044-4;Refused specimen collection;Find;Pt;^Patient;Ord;;SPEC;1;Patient refused specimen collection;Patient refused spec collection;;ACTIVE;2.68;2.68 +95045-1;Entrapment;Find;Pt;^Patient;Nom;;TRAUMA;2;Entrapment;Entrapment;;ACTIVE;2.68;2.68 +95046-9;Peripheral venous access available;Find;Pt;^Patient;Ord;;H&P.PX;2;Peripheral venous access available;Perip ven access avail;;ACTIVE;2.68;2.68 +95047-7;Medication was administered transnasally;Find;Pt;^Patient;Ord;;H&P.PX;2;Medication was administered transnasally;Med admin transnasal;;ACTIVE;2.68;2.68 +95048-5;Airway was suctioned &or cleared;Find;Pt;^Patient;Ord;;H&P.PX;2;Airway was suctioned AndOr cleared;Airway suction &or cleared;;ACTIVE;2.68;2.68 +95049-3;Type of bag-mask ventilation used;Type;Pt;^Patient;Nom;;PULM;2;Type of bag-mask ventilation used;Bag-mask ventilation;;ACTIVE;2.68;2.68 +95050-1;Difficult intubation;Find;Pt;^Patient;Ord;;PULM;2;Difficult intubation;Difficult intubation;;ACTIVE;2.68;2.68 +95051-9;Intubation necessary;Type;Pt;^Patient;Nom;;PULM;2;Intubation necessary;Intubation necessary;;ACTIVE;2.68;2.68 +95052-7;Medical technology used during EMS transport;Type;Pt;^Patient;Nom;;TRAUMA;2;Medical technology used during EMS transport;Med tech EMS transp;;ACTIVE;2.68;2.68 +95053-5;DOPamine^supine;MCnc;Pt;Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Plasma --supine;DOPamine sup Plas-mCnc;;ACTIVE;2.68;2.68 +95054-3;EPINEPHrine^standing;MCnc;Pt;Plas;Qn;;CHAL;1;EPINEPHrine [Mass/volume] in Plasma --standing;Epineph stand Plas-mCnc;;ACTIVE;2.68;2.68 +95055-0;DOPamine^standing;MCnc;Pt;Plas;Qn;;CHAL;1;DOPamine [Mass/volume] in Plasma --standing;DOPamine stand Plas-mCnc;;ACTIVE;2.68;2.68 +95056-8;Catecholamines supine and standing panel;-;Pt;Plas;Qn;;PANEL.CHAL;1;Catecholamines supine and standing panel - Plasma;Catechols Sup Stand Pnl Plas;;ACTIVE;2.68;2.68 +9505-9;Chlorobenzene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlorobenzene [Mass/volume] in Serum or Plasma;Chlorobenz SerPl-mCnc;;ACTIVE;1.0i;2.42 +950-6;C little e Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;C little e Ab [Presence] in Serum or Plasma from Donor;C little e Ab SerPl Donr Ql;;ACTIVE;1.0;2.67 +9506-7;Chloroethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chloroethane [Mass/volume] in Blood;Chloroethane Bld-mCnc;;ACTIVE;1.0i;2.73 +95068-3;ADRB2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.PHARMG;1;ADRB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;ADRB2 Mut Anl Bld/T;;ACTIVE;2.68;2.68 +95069-1;Chromosome 1q & 9 & 11 & 15 aneuploidy & chromosome region 13q deletion;Find;Pt;Bone mar;Doc;FISH;MOLPATH.DELDUP;1;Chromosome 1q and 9 and 11 and 15 aneuploidy and 13q deletion in Bone marrow by FISH;Chr 1q+9+11+15 aneu 13q Del Mar FISH;;ACTIVE;2.68;2.68 +95070-9;Chromosome 9 & 11 & 15 aneuploidy;Find;Pt;Bone mar;Doc;FISH;MOLPATH;1;Chromosome 9 and 11 and 15 aneuploidy in Bone marrow by FISH;Chr 9+11+15 aneu Mar FISH;;ACTIVE;2.68;2.68 +95071-7;Chromosome region 14q32 rearrangements;Find;Pt;Bone mar;Doc;FISH;MOLPATH.REARRANGE;1;Chromosome region 14q32 rearrangements in Bone marrow by FISH;Chr 14q32 Rearr Mar FISH;;ACTIVE;2.68;2.68 +95072-5;1,3 beta glucan;MCnc;Pt;CSF;Qn;;MICRO;1;1,3 beta glucan [Mass/volume] in Cerebral spinal fluid;1,3 beta glucan CSF-mCnc;;ACTIVE;2.68;2.68 +95073-3;Histoplasma capsulatum Ag;MCnc;Pt;BAL;Qn;IA;MICRO;1;Histoplasma capsulatum Ag [Mass/volume] in Bronchoalveolar lavage by Immunoassay;H capsul Ag BAL IA-mCnc;;ACTIVE;2.68;2.68 +95074-1;Bacteria;PrThr;Pt;BAL;Ord;Microscopy.light;MICRO;1;Bacteria [Presence] in Bronchoalveolar lavage by Light microscopy;Bacteria BAL Ql Micro;;ACTIVE;2.68;2.68 +9507-5;Chloromethane;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Chloromethane [Mass/volume] in Blood;Chloromethane Bld-mCnc;;ACTIVE;1.0i;2.73 +95075-8;Cannabidiol/Tetrahydrocannabinol;Ratio;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cannabidiol/Tetrahydrocannabinol [Ratio] in Urine by Confirmatory method;Cannabidiol/THC Ur Cfm-Rto;;ACTIVE;2.68;2.68 +95076-6;C peptide^15M post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --15 min post meal;C peptide 15M p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95077-4;Glucagon^5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --5 hours post meal;Glucagon 5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95078-2;Glucose^15M post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --15 min post meal;Glucose 15M p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95079-0;Insulin^15M post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --15 min post meal;Insulin 15M p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95080-8;C peptide post fasting and meal stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;C peptide post fasting and meal stimulation panel - Serum or Plasma;C peptide p Cfst + meal Pnl SerPl;;ACTIVE;2.68;2.68 +95081-6;C peptide^1.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --1.5 hours post meal;C peptide 1.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95082-4;C peptide^1H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --1 hour post meal;C peptide 1h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +9508-3;Chlorothiazide;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Chlorothiazide [Presence] in Urine;Chlorothiazide Ur Ql;;ACTIVE;1.0i;2.73 +95083-2;C peptide^2.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2.5 hours post meal;C peptide 2.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95084-0;C peptide^2H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --2 hours post meal;C peptide 2h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95085-7;C peptide^3.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --3.5 hours post meal;C peptide 3.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95086-5;C peptide^30M post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --30 min post meal;C peptide 30M p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95087-3;C peptide^3H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --3 hours post meal;C peptide 3h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95088-1;C peptide^4.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --4.5 hours post meal;C peptide 4.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95089-9;C peptide^4H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --4 hours post meal;C peptide 4h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95090-7;C peptide^5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;C peptide [Mass/volume] in Serum or Plasma --5 hours post meal;C peptide 5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +9509-1;Cholinesterase;CCnc;Pt;Ser;Qn;;CHEM;1;Deprecated Cholinesterase [Enzymatic activity/volume] in Serum or Plasma;Deprecated Cholinesterase Ser-cCnc;;DEPRECATED;1.0i;2.36 +95091-5;Glucagon post fasting and meal stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Glucagon post fasting and meal stimulation panel - Serum or Plasma;Glucagon p Cfst + meal Pnl SerPl;;ACTIVE;2.68;2.68 +95092-3;Glucagon^1.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --1.5 hours post meal;Glucagon 1.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95093-1;Glucagon^1H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --1 hour post meal;Glucagon 1h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95094-9;Glucagon^2.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --2.5 hours post meal;Glucagon 2.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95095-6;Glucagon^2H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --2 hours post meal;Glucagon 2h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95096-4;Glucagon^3.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --3.5 hours post meal;Glucagon 3.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95097-2;Glucagon^30M post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --30 min post meal;Glucagon 30M p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95098-0;Glucagon^3H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --3 hours post meal;Glucagon 3h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95099-8;Glucagon^4.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --4.5 hours post meal;Glucagon 4.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95100-4;Glucagon^4H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --4 hours post meal;Glucagon 4h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95101-2;Glucagon^post Cfst;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucagon [Mass/volume] in Serum or Plasma --fasting;Glucagon p fast SerPl-mCnc;;ACTIVE;2.68;2.68 +95102-0;Glucose post fasting and meal stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Glucose post fasting and meal stimulation panel - Serum or Plasma;Glucose p Cfst + meal Pnl SerPl;;ACTIVE;2.68;2.68 +95103-8;Glucose^2.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --2.5 hours post meal;Glucose 2.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95104-6;Glucose^3.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3.5 hours post meal;Glucose 3.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95105-3;Glucose^30M post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 min post meal;Glucose 30M p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95106-1;Glucose^3H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --3 hours post meal;Glucose 3h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95107-9;Glucose^4.5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4.5 hours post meal;Glucose 4.5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95108-7;Glucose^4H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --4 hours post meal;Glucose 4h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +9510-9;Chromium;MCnc;Pt;Plas;Qn;;DRUG/TOX;1;Deprecated Chromium [Mass/volume] in Serum or Plasma;Deprecated Chromium Plas-mCnc;;DEPRECATED;1.0i;2.36 +95109-5;Glucose^5H post meal;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --5 hours post meal;Glucose 5h p meal SerPl-mCnc;;ACTIVE;2.68;2.68 +95110-3;Insulin post fasting and meal stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Insulin post fasting and meal stimulation panel - Serum or Plasma;Insulin p Cfst + meal Pnl SerPl;;ACTIVE;2.68;2.68 +95111-1;Insulin^1.5H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1.5 hours post meal;Insulin 1.5h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95112-9;Insulin^1H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --1 hour post meal;Insulin 1h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95113-7;Insulin^2.5H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2.5 hours post meal;Insulin 2.5h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95114-5;Insulin^2H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --2 hours post meal;Insulin 2h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95115-2;Insulin^3.5H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3.5 hours post meal;Insulin 3.5h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95116-0;Insulin^30M post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --30 min post meal;Insulin 30M p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +9511-7;Citrulline;MCnc;Pt;CSF;Qn;;CHEM;1;Citrulline [Mass/volume] in Cerebral spinal fluid;Citrulline CSF-mCnc;;DISCOURAGED;1.0i;2.44 +95117-8;Insulin^3H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --3 hours post meal;Insulin 3h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95118-6;Insulin^4.5H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --4.5 hours post meal;Insulin 4.5h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95119-4;Insulin^4H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --4 hours post meal;Insulin 4h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95120-2;Insulin^5H post meal;ACnc;Pt;Ser/Plas;Qn;;CHAL;1;Insulin [Units/volume] in Serum or Plasma --5 hours post meal;Insulin 5h p meal SerPl-aCnc;;ACTIVE;2.68;2.68 +95121-0;Coagulation factor VIII activity & inhibitor panel;-;Pt;PPP;-;Chromo;PANEL.COAG;1;Coagulation factor VIII activity and inhibitor panel - Platelet poor plasma by Chromogenic method;Fact VIII Act + Inhib Pnl PPP Chro;;ACTIVE;2.68;2.69 +95122-8;Coagulation factor VIII inhibitor;Imp;Pt;PPP;Nom;Chromo;COAG;1;Coagulation factor VIII inhibitor [Interpretation] in Platelet poor plasma by Chromogenic method;Fact VIII Inhib PPP Chro-Imp;;ACTIVE;2.68;2.68 +95123-6;Gene fusion transcript details;Find;Pt;Bld/Tiss;Nar;Molgen;MOLPATH;1;Gene fusion transcript details in Blood or Tissue by Molecular genetics method Narrative;Gene fusion details Bld/T;;ACTIVE;2.68;2.68 +95124-4;Sarcoma targeted gene fusion transcript analysis;Find;Pt;Tiss;Doc;Sequencing;MOLPATH;1;Sarcoma targeted gene fusion transcript analysis in Tissue by Sequencing;Sarcoma gene fusion analysis Tiss Seq;;ACTIVE;2.68;2.68 +9512-5;Creosol;PrThr;Pt;XXX;Ord;;DRUG/TOX;1;Creosol [Presence] in Specimen;Creosol Spec Ql;;ACTIVE;1.0i;2.69 +95125-1;SARS coronavirus 2 Ab.IgA+IgM;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgA+IgM [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgA+IgM SerPl Ql IA;;ACTIVE;2.68;2.69 +95126-9;Lipid & glucose panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Lipid and glucose panel - Serum or Plasma;Lipid & glucose Pnl SerPl;;ACTIVE;2.68;2.68 +95127-7;Mycobacterium tuberculosis lipoarabinomannan Ag;PrThr;Pt;Urine;Ord;IA.rapid;MICRO;1;Mycobacterium tuberculosis lipoarabinomannan Ag [Presence] in Urine by Rapid immunoassay;LAM Ag Ur Ql IA.rapid;;ACTIVE;2.68;2.69 +95128-5;Edoxaban;MCnc;Pt;PPP;Qn;Chromo;DRUG/TOX;1;Edoxaban [Mass/volume] in Platelet poor plasma by Chromogenic method;Edoxaban PPP Chro-mCnc;;ACTIVE;2.68;2.69 +95129-3;Dense fine speckled 70 protein Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Dense fine speckled 70 protein IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;DFS70 IgG SerPl IA-aCnc;;ACTIVE;2.68;2.68 +95130-1;Aggressive prostate cancer risk;Score;Pt;^Patient;Qn;Calculated.ExoDx;MOLPATH;1;Aggressive prostate cancer risk [Score] by Calculated by ExoDx;Aggr PC risk Score Patient Calc.ExoDx;;ACTIVE;2.68;2.69 +95131-9;FASI v1.0 - Mobility (Wheelchair);-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;FASI v1.0 - Mobility (Wheelchair) [CMS Assessment];;;ACTIVE;2.68;2.68 +95132-7;Consultation note;Find;Pt;{Setting};Doc;Dialysis+Therapeutic apheresis;DOC.ONTOLOGY;2;Dialysis and Therapeutic apheresis Consult note;Dialy+Ther Apher Consult note;;ACTIVE;2.68;2.68 +9513-3;Cytomegalovirus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Cytomegalovirus Ab [Titer] in Serum by Complement fixation;CMV Ab Titr Ser CF;;ACTIVE;1.0i;2.7 +95133-5;Discharge summary note;Find;Pt;{Setting};Doc;Dialysis+Therapeutic apheresis;DOC.ONTOLOGY;2;Dialysis and Therapeutic apheresis Discharge summary;Dialy+Ther Apher D/C sum;;ACTIVE;2.68;2.73 +95134-3;Progress note;Find;Pt;{Setting};Doc;Dialysis+Therapeutic apheresis;DOC.ONTOLOGY;2;Dialysis and Therapeutic apheresis Progress note;Dialy+Ther Apher Prog note;;ACTIVE;2.68;2.73 +95135-0;Noroxycodone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Noroxycodone [Mass/volume] in Urine;Noroxycodone Ur-mCnc;;ACTIVE;2.68;2.68 +95136-8;Cytomegalovirus DNA panel;-;Pt;Amnio fld;-;Probe.amp.tar;PANEL.MICRO;1;Cytomegalovirus DNA panel - Amniotic fluid by NAA with probe detection;CMV DNA Pnl Amn NAA+probe;;ACTIVE;2.68;2.68 +95137-6;Parvovirus B19 DNA panel;-;Pt;Amnio fld;-;Probe.amp.tar;PANEL.MICRO;1;Parvovirus B19 DNA panel - Amniotic fluid by NAA with probe detection;B19V DNA Pnl Amn NAA+probe;;ACTIVE;2.68;2.68 +95138-4;Epstein Barr virus DNA panel;-;Pt;Amnio fld;-;Probe.amp.tar;PANEL.MICRO;1;Epstein Barr virus DNA panel - Amniotic fluid by NAA with probe detection;EBV DNA Pnl Amn NAA+probe;;ACTIVE;2.68;2.68 +95139-2;Varicella zoster virus DNA panel;-;Pt;Amnio fld;-;Probe.amp.tar;PANEL.MICRO;1;Varicella zoster virus DNA panel - Amniotic fluid by NAA with probe detection;VZV DNA Pnl Amn NAA+probe;;ACTIVE;2.68;2.68 +951-4;C little e Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;C little e Ab [Presence] in Serum or Plasma;C little e Ab SerPl Ql;;ACTIVE;1.0;2.67 +95140-0;Herpes simplex virus 1 & 2 DNA panel;-;Pt;Amnio fld;-;Probe.amp.tar;PANEL.MICRO;1;Herpes simplex virus 1 and 2 DNA panel - Amniotic fluid by NAA with probe detection;HSV 1+2 DNA Pnl Amn NAA+probe;;ACTIVE;2.68;2.68 +9514-1;Cytomegalovirus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Cytomegalovirus Ab [Titer] in Cerebral spinal fluid by Complement fixation;CMV Ab Titr CSF CF;;ACTIVE;1.0i;2.7 +95141-8;Hepatitis D virus Ab panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis D virus Ab panel - Serum;HDV Ab Pnl Ser;;ACTIVE;2.68;2.68 +95142-6;Hepatitis A virus Ab.IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis A virus IgM panel - Serum;HAV IgM Pnl Ser;;ACTIVE;2.68;2.68 +95143-4;UGT1A1 gene.TA repeats;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.PHARMG;1;UGT1A1 gene TA repeats [Genotype] in Blood or Tissue by Molecular genetics method Nominal;UGT1A1 TA Geno Bld/T;;ACTIVE;2.68;2.68 +95144-2;Hepatitis D virus RNA panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis D virus RNA panel - Serum or Plasma;HDV RNA Pnl SerPl;;ACTIVE;2.68;2.68 +95145-9;Hepatitis B virus core Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis B virus core Ab panel - Serum or Plasma;HBV core Ab Pnl SerPl;;ACTIVE;2.68;2.68 +95146-7;Hepatitis B virus core Ab.IgM panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis B virus core IgM panel - Serum or Plasma;HBV core IgM Pnl SerPl;;ACTIVE;2.68;2.68 +95147-5;Hepatitis B virus DNA panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis B virus DNA panel - Serum or Plasma;HBV DNA Pnl SerPl;;ACTIVE;2.68;2.68 +95148-3;Hepatitis B virus surface Ag & little e Ab & Ag panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis B virus surface Ag and Hepatitis B virus e Ab and Ag panel - Serum or Plasma;HBV surf Ag + HBV e Ab + Ag Pnl SerPl;;ACTIVE;2.68;2.68 +95149-1;Hepatitis B virus surface Ag panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis B virus surface Ag panel - Serum or Plasma;HBV surface Ag Pnl SerPl;;ACTIVE;2.68;2.68 +95150-9;Avian infectious laryngotracheitis virus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Avian infectious laryngotracheitis virus RNA [#/volume] (viral load) in Specimen by NAA with probe detection;ILT RNA # Spec NAA+probe;;ACTIVE;2.68;2.69 +95151-7;Infectious bronchitis virus RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Infectious bronchitis virus RNA [#/volume] (viral load) in Specimen by NAA with probe detection;IBV RNA # Spec NAA+probe;;ACTIVE;2.68;2.69 +95152-5;Mycoplasma synoviae DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma synoviae DNA [#/volume] in Specimen by NAA with probe detection;M synoviae DNA # Spec NAA+probe;;ACTIVE;2.68;2.69 +95153-3;Ornithobacterium rhinotracheale RNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Ornithobacterium rhinotracheale RNA [#/volume] in Specimen by NAA with probe detection;ORT RNA # Spec NAA+probe;;ACTIVE;2.68;2.69 +95154-1;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Prime Pac;NFr;Pt;Isolate;Qn;Sequencing;MICRO;1;PRRSV ORF5 gene sequence homology to Prime Pac in Isolate by Sequencing;PRRSV Prime Pac Hmlgy Islt Seq-NFr;;ACTIVE;2.68;2.68 +95155-8;Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Prevacent;NFr;Pt;Isolate;Qn;Sequencing;MICRO;1;PRRSV ORF5 gene sequence homology to Prevacent in Isolate by Sequencing;PRRSV Prevacent Hmlgy Islt Seq-NFr;;ACTIVE;2.68;2.68 +95156-6;Hepatitis E virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Hepatitis E virus RNA [Presence] in Specimen by NAA with probe detection;HEV RNA Spec Ql NAA+probe;;ACTIVE;2.68;2.69 +95157-4;Salmonella gallinarum+Salmonella pullorum Ab;PrThr;Pt;Ser/Plas/Bld;Ord;Aggl;MICRO;1;Salmonella gallinarum+Salmonella pullorum Ab [Presence] in Serum, Plasma or Blood by Agglutination;S gallinarum+pullorum Ab SerPlBld Aggl;;ACTIVE;2.68;2.68 +9515-8;Diclofenac;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Diclofenac [Mass/volume] in Serum or Plasma;Diclofenac SerPl-mCnc;;ACTIVE;1.0i;2.4 +95158-2;Avian encephalomyelitis virus Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Avian encephalomyelitis virus Ab/Positive control in Serum by Immunoassay;AEV Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95159-0;Avian metapneumovirus Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Avian metapneumovirus Ab/Positive control in Serum by Immunoassay;aMPV Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95160-8;Avian paramyxovirus 1 Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Avian paramyxovirus 1 Ab/Positive control in Serum by Immunoassay;APMV1 Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95161-6;Avian reovirus Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Avian reovirus Ab/Positive control in Serum by Immunoassay;AVREOV Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95162-4;Bordetella avium Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Bordetella avium Ab/Positive control in Serum by Immunoassay;B avium Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95163-2;Infectious bronchitis virus Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Infectious bronchitis virus Ab/Positive control in Serum by Immunoassay;IBV Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95164-0;Infectious bursal disease virus Ab/positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Infectious bursal disease virus Ab/Positive control in Serum by Immunoassay;IBDV Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95165-7;Mycoplasma gallisepticum Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma gallisepticum Ab/Positive control in Serum by Immunoassay;M gallisep Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +9516-6;Echovirus 11 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Echovirus 11 Ab [Titer] in Cerebral spinal fluid by Complement fixation;ECV11 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +95166-5;Mycoplasma synoviae Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma synoviae Ab/Positive control in Serum by Immunoassay;M synoviae Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95167-3;Ornithobacterium rhinotracheale Ab/Positive control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Ornithobacterium rhinotracheale Ab/Positive control in Serum by Immunoassay;ORT Ab/Pos cntrl Ser IA;;ACTIVE;2.68;2.68 +95168-1;Avian infectious laryngotracheitis virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Avian infectious laryngotracheitis virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;ILT RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95169-9;Infectious bronchitis virus RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Infectious bronchitis virus RNA [Cycle Threshold #] in Specimen by NAA with probe detection;IBV RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95170-7;Mycoplasma gallisepticum DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma gallisepticum DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M gallisep DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95171-5;Mycoplasma synoviae DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma synoviae DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M synoviae DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95172-3;Mycoplasma iowae DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma iowae DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M iowae DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95173-1;Mycoplasma meleagridis DNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Mycoplasma meleagridis DNA [Cycle Threshold #] in Specimen by NAA with probe detection;M meleagridis DNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +9517-4;Echovirus 18 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Echovirus 18 Ab [Titer] in Serum by Complement fixation;ECV18 Ab Titr Ser CF;;ACTIVE;1.0i;2.7 +95174-9;Ornithobacterium rhinotracheale RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Ornithobacterium rhinotracheale RNA [Cycle Threshold #] in Specimen by NAA with probe detection;ORT RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95175-6;Avian encephalomyelitis virus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian encephalomyelitis virus Ab [Titer] in Serum by Immunoassay;AEV Ab Titr Ser IA;;ACTIVE;2.68;2.68 +95176-4;Avian metapneumovirus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian metapneumovirus Ab [Titer] in Serum by Immunoassay;aMPV Ab Titr Ser IA;;ACTIVE;2.68;2.68 +95177-2;Avian reovirus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Avian reovirus Ab [Titer] in Serum by Immunoassay;AVREOV Ab Titr Ser IA;;ACTIVE;2.68;2.68 +95178-0;Bordetella avium Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Bordetella avium Ab [Titer] in Serum by Immunoassay;B avium Ab Titr Ser IA;;ACTIVE;2.68;2.68 +95179-8;Infectious bursal disease virus Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Infectious bursal disease virus Ab [Titer] in Serum by Immunoassay;IBDV Ab Titr Ser IA;;ACTIVE;2.68;2.68 +95180-6;Mycoplasma gallisepticum Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma gallisepticum Ab [Titer] in Serum by Immunoassay;M gallisep Ab Titr Ser IA;;ACTIVE;2.68;2.68 +95181-4;Mycoplasma synoviae Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Mycoplasma synoviae Ab [Titer] in Serum by Immunoassay;M synoviae Ab Titr Ser IA;;ACTIVE;2.68;2.68 +9518-2;Echovirus 30 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Echovirus 30 Ab [Titer] in Cerebral spinal fluid by Complement fixation;ECV30 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +95182-2;Ornithobacterium rhinotracheale Ab;Titr;Pt;Ser;Qn;IA;MICRO;1;Ornithobacterium rhinotracheale Ab [Titer] in Serum by Immunoassay;ORT Ab Titr Ser IA;;ACTIVE;2.68;2.68 +95183-0;Clostridioides difficile toxin & BI-NAP1-027 strain DNA panel;-;Pt;Stool;-;Probe.amp.tar;PANEL.MICRO;1;Clostridioides difficile toxin and BI-NAP1-027 strain DNA panel - Stool by NAA with probe detection;C diff tox+BI-NAP1-027 Pnl Stl NAA+prb;;ACTIVE;2.68;2.68 +95184-8;Cytomegalovirus T-cell immunodeficiency panel;-;Pt;Bld;Qn;Flow cytometry;PANEL.CELLMARK;1;Cytomegalovirus T-cell immunodeficiency panel - Blood by Flow cytometry (FC);CMV T-cell panel Bld FC;;ACTIVE;2.68;2.68 +95185-5;Cells.CD8.HLA-A1 CMV specific;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;HLA-A1 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);HLA-A1 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.68 +95186-3;Cells.CD8.CMV specific.CMV antigen stimulated CD107a+b expressing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD107a+b expressing CMV-specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);CD107ab CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.68 +95187-1;Cells.CD8.HLA-B35 CMV specific.CMV antigen stimulated CD107a+b expressing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD107a+b expressing HLA-B35 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);CD107ab HLA-B35 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95188-9;Cells.CD8.HLA-B8 CMV specific.CMV antigen stimulated CD107a+b expressing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD107a+b expressing HLA-B8 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);CD107ab HLA-B8 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95189-7;Cells.CD8.HLA-B7 CMV specific.CMV antigen stimulated CD107a+b expressing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD107a+b expressing HLA-B7 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);CD107ab HLA-B7 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +9519-0;Echovirus 4 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Echovirus 4 Ab [Titer] in Cerebral spinal fluid by Complement fixation;ECV4 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +95190-5;Cells.CD8.HLA-A2 CMV specific.CMV antigen stimulated CD107a+b expressing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD107a+b expressing HLA-A2 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);CD107ab HLA-A2 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95191-3;Cells.CD8.HLA-A1 CMV specific.CMV antigen stimulated CD107a+b expressing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CD107a+b expressing HLA-A1 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);CD107ab HLA-A1 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95192-1;Cells.CD8.CMV specific.CMV antigen stimulated gamma interferon producing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Interferon-gamma producing CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);IFN-g CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.68 +95193-9;Cells.CD8.HLA-B35 CMV specific.CMV antigen stimulated gamma interferon producing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Interferon-gamma producing HLA-B35 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);IFN-g HLA-B35 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95194-7;Cells.CD8.HLA-B8 CMV specific.CMV antigen stimulated gamma interferon producing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Interferon-gamma producing HLA-B8 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);IFN-g HLA-B8 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95195-4;Cells.CD8.HLA-B7 CMV specific.CMV antigen stimulated gamma interferon producing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Interferon-gamma producing HLA-B7 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);IFN-g HLA-B7 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95196-2;Cells.CD8.HLA-A2 CMV specific.CMV antigen stimulated gamma interferon producing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Interferon-gamma producing HLA-A2 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);IFN-g HLA-A2 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95197-0;Cells.CD8.HLA-A1 CMV specific.CMV antigen stimulated gamma interferon producing;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Interferon-gamma producing HLA-A1 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);IFN-g HLA-A1 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95198-8;Cells.CD8.CMV specific;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;CMV-specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.68 +95199-6;Cells.CD8.HLA-B35 CMV specific;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;HLA-B35 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);HLA-B35 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95200-2;Cells.CD8.HLA-B8 CMV specific;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;HLA-B8 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);HLA-B8 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95201-0;Cells.CD8.HLA-B7 CMV specific;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;HLA-B7 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);HLA-B7 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95202-8;Cells.CD8.HLA-A2 CMV specific;NCnc;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;HLA-A2 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC);HLA-A2 CMV CD8 Cells # Bld FC;;ACTIVE;2.68;2.69 +95203-6;Cells.CD8.PMA+ionomycin stimulated CD107a+b expressing/100 cells.CD3+CD8+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;PMA+ionomycin stimulated CD107a+b expressing CD8 cells/100 CD3+CD8+ cells in Blood by Flow cytometry (FC);CD107ab CD8/100 CD3+CD8+ NFr Bld FC;;ACTIVE;2.68;2.68 +95204-4;Cells.CD8.PMA+ionomycin stimulated gamma interferon producing/100 cells.CD3+CD8+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;PMA+ionomycin stimulated gamma interferon producing CD8 Cells/100 CD3+CD8+ cells in Blood by Flow cytometry (FC);IFN-g CD8 Cells/100 CD3+CD8+ NFr Bld FC;;ACTIVE;2.68;2.68 +95205-1;Hepatitis B virus surface Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis B virus surface Ab panel - Serum or Plasma;HBV surface Ab Pnl SerPl;;ACTIVE;2.68;2.68 +95206-9;Hepatitis C virus Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis C virus Ab panel - Serum or Plasma;HCV Ab Pnl SerPl;;ACTIVE;2.68;2.68 +95207-7;Hepatitis E virus RNA panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hepatitis E virus RNA panel - Serum or Plasma;HEV RNA Pnl SerPl;;ACTIVE;2.68;2.68 +9520-8;Echovirus 9 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Echovirus 9 Ab [Titer] in Cerebral spinal fluid by Complement fixation;ECV9 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +95208-5;Bandage applied;Find;Pt;^Patient;Nom;;H&P.HX;2;Bandage applied;Bandage applied;;ACTIVE;2.68;2.68 +95209-3;SARS coronavirus+SARS coronavirus 2 Ag;PrThr;Pt;Respiratory;Ord;IA.rapid;MICRO;1;SARS-CoV+SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay;SARS-CoV+SARS-CoV-2 Ag Resp Ql IA.rapid;;ACTIVE;2.68;2.73 +95210-1;Anaplasma marginale Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Anaplasma marginale Ab/Negative control in Serum by Immunoassay;A marginale Ab Ser IA;;ACTIVE;2.68;2.68 +95211-9;Bluetongue virus Ag/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Bluetongue virus Ag/Negative control in Serum by Immunoassay;BTV Ag Ser IA;;ACTIVE;2.68;2.68 +95212-7;Neospora caninum Ab/Negative control;RelRto;Pt;Ser;Qn;IA;MICRO;1;Neospora caninum Ab/Negative control in Serum by Immunoassay;N caninum Ab Ser IA;;ACTIVE;2.68;2.68 +95213-5;Basophils/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Basophils/100 leukocytes in Stem cell product by Manual count;Basophils/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95214-3;Blasts/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Blasts/100 leukocytes in Stem cell product by Manual count;Blasts/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95215-0;Complete blood count W Differential panel;-;Pt;^Stem cell product;Qn;;PANEL.HEM/BC;1;CBC W Differential panel - Stem cell product;CBC W Diff Pnl Stem prod;;ACTIVE;2.68;2.68 +9521-6;Entamoeba histolytica Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Entamoeba histolytica IgA Ab [Units/volume] in Serum by Immunoassay;E histolyt IgA Ser IA-aCnc;;ACTIVE;1.0i;2.69 +95216-8;Eosinophils/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Stem cell product by Manual count;Eosinophil/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95217-6;Erythrocytes.nucleated/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Nucleated erythrocytes/100 leukocytes in Stem cell product by Manual count;nRBC/100 WBC NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95218-4;Leukocytes;NCnc;Pt;^Stem cell product;Qn;;HEM/BC;1;Leukocytes [#/volume] in Stem cell product;WBC # Stem prod;;ACTIVE;2.68;2.68 +95219-2;Lymphocytes.variant/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Variant lymphocytes/100 leukocytes in Stem cell product by Manual count;Variant Lymphs/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +952-2;C little e Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;C little e Ag [Presence] on Red Blood Cells from Blood product unit;C little e Ag RBC BPU Ql;;ACTIVE;1.0;2.67 +95220-0;Lymphocytes/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Stem cell product by Manual count;Lymphocytes/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95221-8;Metamyelocytes/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Metamyelocytes/100 leukocytes in Stem cell product by Manual count;Metamyelocytes/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95222-6;Monocytes/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Monocytes/100 leukocytes in Stem cell product by Manual count;Monocytes/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95223-4;Mononuclear cells/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Mononuclear cells/100 leukocytes in Stem cell product by Manual count;Mononuc Cells/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +9522-4;Entamoeba histolytica Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Entamoeba histolytica IgG Ab [Units/volume] in Serum by Immunoassay;E histolyt IgG Ser IA-aCnc;;ACTIVE;1.0i;2.73 +95224-2;Myelocytes/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Myelocytes/100 leukocytes in Stem cell product by Manual count;Myelocytes/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95225-9;Neutrophils.band form/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Band form neutrophils/100 leukocytes in Stem cell product by Manual count;Neuts Band/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95226-7;Neutrophils.segmented/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Segmented neutrophils/100 leukocytes in Stem cell product by Manual count;Neuts Seg/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95227-5;Other cells/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Other cells/100 leukocytes in Stem cell product by Manual count;Other cells/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95228-3;Promyelocytes/100 leukocytes;NFr;Pt;^Stem cell product;Qn;Manual count;HEM/BC;1;Promyelocytes/100 leukocytes in Stem cell product by Manual count;Promyelocytes/leuk NFr Stem prod Manual;;ACTIVE;2.68;2.68 +95229-1;Biliary tract neoplasm chromosome analysis;Find;Pt;Tiss;Doc;;MOLPATH;1;Biliary tract neoplasm chromosome analysis in Tissue;Biliary Neo Chrom Analysis Tiss;;ACTIVE;2.68;2.68 +95230-9;Biliary tract neoplasm chromosome aneuploidy & cytology analysis;Find;Pt;Tiss;Doc;;MOLPATH;1;Biliary tract neoplasm chromosome aneuploidy and cytology analysis in Tissue;Biliary Neo Chrom-Cyt Analysis Tiss;;ACTIVE;2.68;2.68 +95231-7;Chromosome aneuploidy details;Find;Pt;Bld/Tiss;Nar;Molgen;MOLPATH.MISC;1;Chromosome aneuploidy details in Blood or Tissue by Molecular genetics method Narrative;Chromosome aneup Bld/T;;ACTIVE;2.68;2.68 +9523-2;Entamoeba histolytica Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Entamoeba histolytica IgM Ab [Units/volume] in Serum by Immunoassay;E histolyt IgM Ser IA-aCnc;;ACTIVE;1.0i;2.69 +95232-5;Albumin;PrThr;Pt;Urine;Ord;Detection limit <= 20 mg/L test strip;CHEM;1;Microalbumin [Presence] in Urine by Test strip;Microalbumin Ur Ql Test Str;;ACTIVE;2.68;2.68 +95233-3;Albumin/Creatinine;PrThr;Pt;Urine;Ord;Detection limit <= 20 mg/L test strip;CHEM;1;Microalbumin/Creatinine Qualitative in Urine by Test strip;Microalbumin/Creat Ur Ql Test Str;;ACTIVE;2.68;2.71 +95234-1;Hepatitis B virus surface Ag;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Hepatitis B virus surface Ag [Interpretation] in Serum or Plasma;HBV surface Ag SerPl-Imp;;ACTIVE;2.68;2.68 +95235-8;Hepatitis B virus Ab;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Hepatitis B virus Ab [Interpretation] in Serum or Plasma;HBV Ab SerPl-Imp;;ACTIVE;2.68;2.68 +95236-6;Hepatitis B virus DNA;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Hepatitis B virus DNA [Interpretation] in Serum or Plasma;HBV DNA SerPl-Imp;;ACTIVE;2.68;2.68 +95237-4;Hepatitis C virus Ab;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Hepatitis C virus Ab [Interpretation] in Serum or Plasma;HCV Ab SerPl-Imp;;ACTIVE;2.68;2.68 +95238-2;Hepatitis D virus Ab;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Hepatitis D virus Ab [Interpretation] in Serum or Plasma;HDV Ab SerPl-Imp;;ACTIVE;2.68;2.68 +95239-0;Hepatitis D virus Ab.IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Hepatitis D virus IgM panel - Serum;HDV IgM Pnl Ser;;ACTIVE;2.68;2.68 +9524-0;Giardia lamblia Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Giardia lamblia Ab [Titer] in Serum by Immunofluorescence;G lamblia Ab Titr Ser IF;;ACTIVE;1.0i;2.73 +95240-8;Hepatitis E virus Ab;Imp;Pt;Ser/Plas;Nom;;MICRO;1;Hepatitis E virus Ab [Interpretation] in Serum or Plasma;HEV Ab SerPl-Imp;;ACTIVE;2.68;2.68 +95241-6;Platelet aggregation.adenosine diphosphate induced^0.6 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --0.6 umol/L;PA ADP 0.6 umol/L PRP;;ACTIVE;2.68;2.68 +95242-4;Platelet aggregation.adenosine diphosphate induced^1.2 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ADP induced in Platelet rich plasma --1.2 umol/L;PA ADP 1.2 umol/L PRP;;ACTIVE;2.68;2.68 +95243-2;Platelet aggregation.epinephrine induced^0.5 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --0.5 umol/L;PA Epineph 0.5 umol/L PRP;;ACTIVE;2.68;2.68 +95244-0;Platelet aggregation.EPINEPHrine induced^1 umol/L;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation EPINEPHrine induced in Platelet rich plasma --1 umol/L;PA Epineph 1 umol/L PRP;;ACTIVE;2.68;2.68 +95245-7;Platelet aggregation.ristocetin induced^375 ug/mL;RelACnc;Pt;PRP;Qn;;COAG;1;Platelet aggregation ristocetin induced in Platelet rich plasma --375 ug/mL;PA Rist 375 ug/mL PRP;;ACTIVE;2.68;2.68 +95246-5;U.S. Household Food Security Survey;-;12Mo;^Patient;-;U.S. Food Security Survey;PANEL.SURVEY.SDOH;4;U.S. Household Food Security Survey [U.S. FSS];;;ACTIVE;2.68;2.69 +95247-3;Which of these statements best describes the food eaten in your household in the last 12Mo;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;Which of these statements best describes the food eaten in your household in the last 12 months [U.S. FSS];;;ACTIVE;2.68;2.69 +95248-1;In the last 12Mo, we couldn't afford to eat balanced meals;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, we couldn't afford to eat balanced meals [U.S. FSS];;;ACTIVE;2.68;2.7 +95249-9;In the last 12Mo, did you ever cut the size of your meals or skip meals because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, did you ever cut the size of your meals or skip meals because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.69 +95250-7;In the last 12Mo, how often did you cut the size of your meals or skip meals because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, how often did you cut the size of your meals or skip meals because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.7 +95251-5;In the last 12Mo, did you ever eat less than you felt you should because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, did you ever eat less than you felt you should because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.69 +95252-3;In the last 12Mo, were you ever hungry but didn't eat because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, were you ever hungry but didn't eat because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.69 +95253-1;In the last 12Mo, did you lose weight because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, did you lose weight because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.69 +95254-9;In the last 12Mo, did you ever not eat for a whole day because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, did you ever not eat for a whole day because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.71 +95255-6;In the last 12Mo, how often did you not eat for a whole day because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, how often did you not eat for a whole day because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.71 +95256-4;In the last 12Mo, I relied on only a few kinds of low-cost food to feed my children because I was running out of money to buy food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, I relied on only a few kinds of low-cost food to feed my children because I was running out of money to buy food [U.S. FSS];;;ACTIVE;2.68;2.69 +9525-7;Hepatitis D virus Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Hepatitis D virus IgM Ab [Units/volume] in Serum;HDV IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +95257-2;In the last 12Mo, I couldn't feed my children a balanced meal, because I couldn't afford that;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, I couldn't feed my children a balanced meal, because I couldn't afford that [U.S. FSS];;;ACTIVE;2.68;2.7 +95258-0;In the last 12Mo, my children were not eating enough because I just couldn't afford enough food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, my children were not eating enough because I just couldn't afford enough food [U.S. FSS];;;ACTIVE;2.68;2.69 +95259-8;In the last 12Mo, did any of the children ever skip meals because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, did any of the children ever skip meals because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.69 +95260-6;In the last 12Mo, how often did any of the children skip meals because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, how often did any of the children skip meals because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.7 +95261-4;In the last 12Mo, were the children ever hungry but you just couldn't afford more food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, were the children ever hungry but you just couldn't afford more food [U.S. FSS];;;ACTIVE;2.68;2.69 +95262-2;In the last 12Mo, did any of the children ever not eat for a whole day because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, did any of the children ever not eat for a whole day because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.69 +95263-0;U.S. Household Food Security Survey Score;Score;12Mo;^Patient;Qn;U.S. Food Security Survey;SURVEY.SDOH;4;U.S. Household Food Security Survey Score [U.S. FSS];;;ACTIVE;2.68;2.69 +95264-8;Food security status;Imp;Pt;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;Food security status [U.S. FSS];;;ACTIVE;2.68;2.69 +9526-5;Hepatitis D virus Ag;ACnc;Pt;Ser;OrdQn;EIA;MICRO;1;Deprecated Hepatitis D virus Ag;Deprecated HDV Ag Ser EIA;;DEPRECATED;1.0i;2.36 +95265-5;In the last 12Mo, did you ever cut the size of any of the children's meals or skip meals because there wasn't enough money for food;Find;12Mo;^Patient;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;In the last 12 months, did you ever cut the size of any of the children's meals or skip meals because there wasn't enough money for food [U.S. FSS];;;ACTIVE;2.68;2.69 +95266-3;Vitamin B6 & metabolites panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Vitamin B6 and metabolites panel - Serum or Plasma;Vit B6 + metabolites Pnl SerPl;;ACTIVE;2.68;2.69 +95267-1;Connective tissue autoimmune Ab.IgG panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Connective tissue autoimmune IgG panel - Serum or Plasma;Connective Tiss IgG Pnl SerPl;;ACTIVE;2.68;2.68 +95268-9;Clinical factors affecting result interpretation;Prid;Pt;^Patient;Nom;;CLIN;2;Clinical factors affecting result interpretation [Identifier];Factors affect result imp;;ACTIVE;2.68;2.68 +95269-7;HLA-A+B+C Ab;PrThr;Pt;Ser/Plas;Ord;IA;HLA;1;HLA-A+B+C (class I) Ab [Presence] in Serum or Plasma by Immunoassay;HLA-A+B+C Ab SerPl Ql IA;;ACTIVE;2.68;2.68 +95270-5;Platelet & HLA glycoprotein antibody panel;-;Pt;Bld;-;;PANEL.SERO;1;Platelet and HLA glycoprotein antibody panel - Blood;Platelet + HLA glycoprotein Ab Pnl Bld;;ACTIVE;2.68;2.68 +95271-3;Bicarbonate^post secretin;SCnc;Pt;Body fld;Qn;;CHAL;1;Bicarbonate [Moles/volume] in Body fluid --post secretin;HCO3 p SCT Fld-sCnc;;ACTIVE;2.68;2.68 +95272-1;Aquaporin 4 water channel Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Aquaporin 4 water channel IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;AQP4 H2O channel IgG Ser Ql CBA IFA;;ACTIVE;2.68;2.69 +9527-3;Hexacarboxylporphyrin;MRat;24H;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin [Mass/time] in 24 hour Urine;Hexa-CP 24h Ur-mRate;;ACTIVE;1.0i;2.73 +95273-9;Aquaporin 4 water channel Ab.IgG;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;Aquaporin 4 water channel IgG Ab [Titer] in Serum by Cell binding immunofluorescent assay;AQP4 H2O channel IgG Titr Ser CBA IFA;;ACTIVE;2.68;2.69 +95274-7;DNM2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;DNM2 gene full mutation analysis in Blood or Tissue by Sequencing;DNM2 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95275-4;FGD4 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;FGD4 gene full mutation analysis in Blood or Tissue by Sequencing;FGD4 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95276-2;GARS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;GARS gene full mutation analysis in Blood or Tissue by Sequencing;GARS gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95277-0;GJB1 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.MUT;1;GJB1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;GJB1 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.68;2.68 +95278-8;HSPB1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HSPB1 gene full mutation analysis in Blood or Tissue by Sequencing;HSPB1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95279-6;HSPB8 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;HSPB8 gene full mutation analysis in Blood or Tissue by Sequencing;HSPB8 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95280-4;MTMR2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;MTMR2 gene full mutation analysis in Blood or Tissue by Sequencing;MTMR2 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +9528-1;Histoplasma capsulatum Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Histoplasma capsulatum IgA Ab [Units/volume] in Serum by Immunoassay;H capsul IgA Ser IA-aCnc;;ACTIVE;1.0i;2.73 +95281-2;NDRG1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;NDRG1 gene full mutation analysis in Blood or Tissue by Sequencing;NDRG1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95282-0;PARK2 gene deletion+duplication;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.DELDUP;1;PARK2 gene deletion and duplication mutation analysis in Blood or Tissue by Molecular genetics method;PARK2 gene Del+Dup Bld/T;;ACTIVE;2.68;2.68 +95283-8;PARK7 gene deletion;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.DELDUP;1;PARK7 gene deletion in Blood or Tissue by Molecular genetics method;PARK7 gene Del Bld/T;;ACTIVE;2.68;2.68 +95284-6;PINK1 gene deletion;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH.DELDUP;1;PINK1 gene deletion in Blood or Tissue by Molecular genetics method;PINK1 gene Del Bld/T;;ACTIVE;2.68;2.68 +95285-3;RAB7A gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;RAB7A gene full mutation analysis in Blood or Tissue by Sequencing;RAB7A gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95286-1;SBF2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;SBF2 gene full mutation analysis in Blood or Tissue by Sequencing;SBF2 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95287-9;TRPV4 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;TRPV4 gene full mutation analysis in Blood or Tissue by Sequencing;TRPV4 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95288-7;YARS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;YARS gene full mutation analysis in Blood or Tissue by Sequencing;YARS gene Full Mut Anl Bld/T Seq;;ACTIVE;2.68;2.68 +95289-5;Corneal vertex distance;Len;Pt;Eye;Qn;Autorefractor.auto;EYE.REFRACTION;2;Eye Corneal vertex distance Autorefractor.auto;Eye Corneal vertex AR.auto;;ACTIVE;2.68;2.68 +95290-3;Sphere measurement increment;Type;Pt;Refractometer;Nom;;EYE.REFRACTION;2;Sphere measurement increment Refractometer;Sph incr RM;;ACTIVE;2.68;2.68 +95291-1;Axis measurement increment;Type;Pt;Refractometer;Nom;;EYE.REFRACTION;2;Type of Axis measurement increment;Type of Axis step;;ACTIVE;2.68;2.68 +95292-9;Cylinder mode;Type;Pt;Refractometer;Ord;;EYE.REFRACTION;2;Cylinder mode Refractometer;Type of Cylinder mode;;ACTIVE;2.68;2.68 +95293-7;Device measurement mode;Type;Pt;{Device};Nom;;DEVICES;2;Device measurement mode;Device mode;;ACTIVE;2.68;2.68 +95294-5;Spherical equivalent;InvLen;Pt;Eye.right;Qn;Autorefractor.auto;EYE.REFRACTION;2;Right eye Spherical equivalent Autorefractor.auto;R eye Sph equiv AR.auto;;ACTIVE;2.68;2.68 +95295-2;Spherical equivalent;InvLen;Pt;Eye.left;Qn;Autorefractor.auto;EYE.REFRACTION;2;Left eye Spherical equivalent Autorefractor.auto;L eye Sph equiv AR.auto;;ACTIVE;2.68;2.68 +95296-0;Pupillary distance.binocular near;Len;Pt;Eye;Qn;Autorefractor.auto;EYE.REFRACTION;2;Eye Pupillary distance.binocular near Autorefractor.auto;Eye PD binoc near AR.auto;;ACTIVE;2.68;2.71 +95297-8;Pupillary distance.binocular far;Len;Pt;Eye;Qn;Autorefractor.auto;EYE.REFRACTION;2;Eye Pupillary distance.binocular far Autorefractor.auto;Eye PD binoc far AR.auto;;ACTIVE;2.68;2.71 +95298-6;Keratometry panel;-;Pt;Eye;-;Keratometry;PANEL.EYE;2;Keratometry panel;Keratometry pnl;;ACTIVE;2.68;2.72 +9529-9;Histoplasma capsulatum Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Histoplasma capsulatum IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;H capsul IgG SerPl IA-aCnc;;ACTIVE;1.0i;2.73 +95299-4;Refractive power measurement increment;Type;Pt;Keratometer;Nom;;EYE.REFRACTION;2;Type of Refractive power measurement increment;Type of Refract pwr step;;ACTIVE;2.68;2.68 +953-0;C little e Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;C little e Ag [Presence] on Red Blood Cells from Donor;C little e Ag RBC Donr Ql;;ACTIVE;1.0;2.67 +95300-0;Axis measurement increment;Type;Pt;Keratometer;Nom;;EYE.REFRACTION;2;Axis measurement increment Keratometer;Axis step KM;;ACTIVE;2.68;2.68 +95301-8;Cylinder mode;Type;Pt;Eye;Ord;Keratometry;EYE.REFRACTION;2;Cylinder mode by Keratometry;Type of Cylinder mode by by KM;;ACTIVE;2.68;2.68 +95302-6;Curvature radius.flat;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Flat curvature radius by Keratometry;R cornea Curvature radius.flat by KM;;ACTIVE;2.68;2.68 +95303-4;Curvature radius.steep;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Steep curvature radius by Keratometry;R cornea Curvature radius.steep by KM;;ACTIVE;2.68;2.68 +95304-2;Curvature radius.mean;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Mean curvature radius by Keratometry;R cornea Curvature radius.mean by KM;;ACTIVE;2.68;2.68 +95305-9;Curvature radius.flat;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Flat curvature radius by Keratometry;L cornea Curvature radius.flat by KM;;ACTIVE;2.68;2.68 +95306-7;Curvature radius.steep;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Steep curvature radius by Keratometry;L cornea Curvature radius.steep by KM;;ACTIVE;2.68;2.68 +9530-7;Histoplasma capsulatum Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Histoplasma capsulatum IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;H capsul IgM SerPl IA-aCnc;;ACTIVE;1.0i;2.73 +95307-5;Curvature radius.mean;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Mean curvature radius by Keratometry;L cornea Curvature radius.mean by KM;;ACTIVE;2.68;2.68 +95308-3;Refractive power.mean;InvLen;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Mean refractive power by Keratometry;R cornea Refractive power.mean by KM;;ACTIVE;2.68;2.68 +95309-1;Cylinder;InvLen;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Cylinder by Keratometry;R cornea Cylinder by KM;;ACTIVE;2.68;2.68 +95310-9;Refractive power.mean;InvLen;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Mean refractive power by Keratometry;L cornea Refractive power.mean by KM;;ACTIVE;2.68;2.68 +95311-7;Cylinder;InvLen;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Cylinder by Keratometry;L cornea Cylinder by KM;;ACTIVE;2.68;2.68 +95314-1;Diameter;Len;Pt;Pupil.right;Qn;Keratometry;EYE.REFRACTION;2;Right pupil Diameter by Keratometry;R pupil Diam by KM;;ACTIVE;2.68;2.68 +9531-5;Influenza virus A Ab;Titr;Pt;CSF;Qn;;MICRO;1;Influenza virus A Ab [Titer] in Cerebral spinal fluid;FLUAV Ab Titr CSF;;ACTIVE;1.0i;2.73 +95315-8;Diameter;Len;Pt;Pupil.left;Qn;Keratometry;EYE.REFRACTION;2;Left pupil Diameter by Keratometry;L pupil Diam by KM;;ACTIVE;2.68;2.68 +95316-6;Horizontal diameter;Len;Pt;Cornea.right;Qn;Keratometry;EYE.REFRACTION;2;Right cornea Horizontal diameter by Keratometry;R cornea Horiz diam by KM;;ACTIVE;2.68;2.68 +95317-4;Horizontal diameter;Len;Pt;Cornea.left;Qn;Keratometry;EYE.REFRACTION;2;Left cornea Horizontal diameter by Keratometry;L cornea Horiz diam by KM;;ACTIVE;2.68;2.68 +95318-2;Lensmeter panel;-;Pt;Corrective lens;-;Lensmeter;PANEL.EYE;2;Lensmeter panel;Lensmeter Pnl;;ACTIVE;2.68;2.72 +95319-0;Type of lens;Type;Pt;Corrective lens;Ord;;EYE;2;Corrective lens type;Corrective lens type;;ACTIVE;2.68;2.68 +95320-8;Sphere measurement increment;InvLen;Pt;Lensmeter;Nom;;EYE.LENSOMETRY;2;Lensmeter Sphere measurement increment;LM Sphere increment [InvLen];;ACTIVE;2.68;2.7 +95321-6;Axis measurement increment;Angle;Pt;Lensmeter;Nom;;EYE.LENSOMETRY;2;Lensmeter Axis measurement increment;LM Axis step;;ACTIVE;2.68;2.68 +95322-4;Cylinder mode;Type;Pt;Lensmeter;Ord;;EYE.LENSOMETRY;2;Cylinder mode;Cylinder mode;;ACTIVE;2.68;2.68 +9532-3;Influenza virus A Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A IgG Ab [Titer] in Serum;FLUAV IgG Titr Ser;;ACTIVE;1.0i;2.73 +95323-2;Prism measurement increment;InvLen;Pt;Lensmeter;Nom;;EYE.LENSOMETRY;2;Lensmeter Prism measurement increment [Inverse Length];LM Prism step InvLen;;ACTIVE;2.68;2.7 +95324-0;Prism mode;Type;Pt;Lensmeter;Ord;;EYE.LENSOMETRY;2;Prism mode;Prism mode;;ACTIVE;2.68;2.68 +95325-7;Axis;Angle;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Axis by Lensmeter;Corr lens Axis by LM;;ACTIVE;2.68;2.68 +95326-5;Spherical equivalent;InvLen;Pt;Corrective lens;Qn;Calculated;EYE.LENSOMETRY;2;Corrective lens Spherical equivalent Calculated;Corr lens Sph equiv Calc;;ACTIVE;2.68;2.68 +95327-3;Spherical equivalent;InvLen;Pt;Corrective lens.right;Qn;Calculated;EYE.LENSOMETRY;2;Right corrective lens Spherical equivalent Calculated;R corr lens Sph equiv Calc;;ACTIVE;2.68;2.68 +95328-1;Spherical equivalent;InvLen;Pt;Corrective lens.left;Qn;Calculated;EYE.LENSOMETRY;2;Left corrective lens Spherical equivalent Calculated;L corr lens Sph equiv Calc;;ACTIVE;2.68;2.68 +95329-9;Sphere near 1;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Sphere near 1 by Lensmeter;Corr lens Sphere N 1 by LM;;ACTIVE;2.68;2.68 +95330-7;Sphere near 2;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Sphere near 2 by Lensmeter;Corr lens Sphere N 2 by LM;;ACTIVE;2.68;2.68 +9533-1;Influenza virus A Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus A IgM Ab [Titer] in Serum;FLUAV IgM Titr Ser;;ACTIVE;1.0i;2.73 +95331-5;Prism;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Prism by Lensmeter;Corr lens Prism by LM;;ACTIVE;2.68;2.68 +95332-3;Prism;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.LENSOMETRY;2;Right corrective lens Prism by Lensmeter;R corr lens Prism by LM;;ACTIVE;2.68;2.68 +95333-1;Prism;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left corrective lens Prism by Lensmeter;L corr lens Prism by LM;;ACTIVE;2.68;2.68 +95334-9;Horizontal prism.in;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Horizontal prism - in by Lensmeter;Corr lens H prism-in by LM;;ACTIVE;2.68;2.68 +95335-6;Horizontal prism.out;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Horizontal prism - out by Lensmeter;Corr lens H prism-out by LM;;ACTIVE;2.68;2.68 +95336-4;Horizontal prism.in;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.LENSOMETRY;2;Right corrective lens Horizontal prism - in by Lensmeter;R corr lens H prism-in by LM;;ACTIVE;2.68;2.68 +95337-2;Horizontal prism.out;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.LENSOMETRY;2;Right corrective lens Horizontal prism - out by Lensmeter;R corr lens H prism-out by LM;;ACTIVE;2.68;2.68 +95338-0;Horizontal prism.in;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left corrective lens Horizontal prism - in by Lensmeter;L corr lens H prism-in by LM;;ACTIVE;2.68;2.68 +95339-8;Horizontal prism.out;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left corrective lens Horizontal prism - out by Lensmeter;L corr lens H prism-out by LM;;ACTIVE;2.68;2.68 +95340-6;Vertical prism.up;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Vertical prism - up by Lensmeter;Corr lens V prism-up by LM;;ACTIVE;2.68;2.68 +95341-4;Vertical prism.down;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Vertical prism - down by Lensmeter;Corr lens V prism-down by LM;;ACTIVE;2.68;2.68 +95342-2;Vertical prism.up;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.LENSOMETRY;2;Right corrective lens Vertical prism - up by Lensmeter;R corr lens V prism-up by LM;;ACTIVE;2.68;2.68 +95343-0;Vertical prism.down;InvLen;Pt;Corrective lens.right;Qn;Lensmeter;EYE.LENSOMETRY;2;Right corrective lens Vertical prism - down by Lensmeter;R corr lens V prism-down by LM;;ACTIVE;2.68;2.68 +95344-8;Vertical prism.up;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left corrective lens Vertical prism - up by Lensmeter;L corr lens V prism-up by LM;;ACTIVE;2.68;2.68 +95345-5;Vertical prism.down;InvLen;Pt;Corrective lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left corrective lens Vertical prism - down by Lensmeter;L corr lens V prism-down by LM;;ACTIVE;2.68;2.68 +95346-3;UV transmittance;NFr;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens UV transmittance by Lensmeter;Corr lens UVT by LM;;ACTIVE;2.68;2.68 +95347-1;UV transmittance;NFr;Pt;Corrective lens.right;Qn;Lensmeter;EYE.LENSOMETRY;2;Right corrective lens UV transmittance by Lensmeter;R corr lens UVT by LM;;ACTIVE;2.68;2.68 +95348-9;UV transmittance;NFr;Pt;Corrective lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left corrective lens UV transmittance by Lensmeter;L corr lens UVT by LM;;ACTIVE;2.68;2.68 +9534-9;Influenza virus B Ab;Titr;Pt;CSF;Qn;;MICRO;1;Influenza virus B Ab [Titer] in Cerebral spinal fluid;FLUBV Ab Titr CSF;;ACTIVE;1.0i;2.73 +95349-7;Pupillary distance.binocular near;Len;Pt;Glasses;Qn;Lensmeter;EYE.LENSOMETRY;2;Glasses Pupillary distance.binocular near by Lensmeter;Glasses PD binoc near by LM;;ACTIVE;2.68;2.71 +95350-5;Pupillary distance.monocular near;Len;Pt;Glasses.lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left glasses lens Pupillary distance.monocular near by Lensmeter;L glasses PD monoc near by LM;;ACTIVE;2.68;2.71 +95351-3;Axis;Angle;Pt;Corrective lens.left;Qn;Lensmeter;EYE.LENSOMETRY;2;Left corrective lens Axis by Lensmeter;L corr lens Axis by LM;;ACTIVE;2.68;2.68 +95352-1;Axis;Angle;Pt;Corrective lens.right;Qn;Lensmeter;EYE.LENSOMETRY;2;Right corrective lens Axis by Lensmeter;R corr lens Axis by LM;;ACTIVE;2.68;2.68 +95353-9;U.S. Adult Food Security Survey;-;12Mo;^Patient;-;U.S. Food Security Survey;PANEL.SURVEY.SDOH;4;U.S. Adult Food Security Survey [U.S. FSS];;;ACTIVE;2.68;2.69 +95354-7;Transfuse convalescent plasma;Vol;Pt;^Patient;Qn;;BLDBK;1;Transfuse convalescent plasma [Volume];Trans Convl Plasma Vol;;ACTIVE;2.68;2.68 +95355-4;Convalescent plasma given;Vol;Pt;^Patient;Qn;;BLDBK;1;Convalescent plasma given [Volume];Convl plasma Gvn Vol;;ACTIVE;2.68;2.68 +9535-6;Influenza virus B Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus B IgG Ab [Titer] in Serum;FLUBV IgG Titr Ser;;ACTIVE;1.0i;2.73 +95356-2;Pretransplant assessment of mortality score panel;-;Pt;^Patient;-;PAM.Revised;PANEL.CLIN.RISK;2;Revised Pretransplant Assessment of Mortality (PAM) Score panel;Revised PAM Score Pnl;©2015 Fred Hutchinson Cancer Research Center. Used with permission.;ACTIVE;2.68;2.69 +95357-0;Total score;Score;Pt;^Patient;Qn;PAM.Revised;CLIN.RISK;2;Revised Pretransplant Assessment of Mortality (PAM) Total score;Revised PAM Total score;©2015 Fred Hutchinson Cancer Research Center. Used with permission.;ACTIVE;2.68;2.69 +95358-8;Rabbit hemorrhagic disease virus RNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Rabbit hemorrhagic disease virus RNA panel - Specimen by NAA with probe detection;RHDV RNA Pnl Spec NAA+probe;;ACTIVE;2.68;2.69 +95359-6;Rabbit hemorrhagic disease virus type 1 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Rabbit hemorrhagic disease virus type 1 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;RHDV1 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95360-4;Rabbit hemorrhagic disease virus type 2 RNA;ThreshNum;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Rabbit hemorrhagic disease virus type 2 RNA [Cycle Threshold #] in Specimen by NAA with probe detection;RHDV2 RNA Ct Spec Qn NAA+probe;;ACTIVE;2.68;2.69 +95361-2;U.S. Household Food Security Survey - Six-Item Short Form;-;12Mo;^Patient;-;U.S. Food Security Survey;PANEL.SURVEY.SDOH;4;U.S. Household Food Security Survey - Six-Item Short Form [U.S. FSS];;;ACTIVE;2.68;2.69 +95362-0;Pancreatic exocrine function panel;-;Pt;Body fld;Qn;;PANEL.CHAL;1;Pancreatic exocrine function panel - Body fluid;Panc exo fnc Pnl Fld;;ACTIVE;2.68;2.68 +95363-8;Bicarbonate post secretin stimulation panel;-;Pt;Body fld;Qn;;PANEL.CHAL;1;Bicarbonate post secretin stimulation panel - Body fluid;HCO3 p secretin stim Pnl Fld;;ACTIVE;2.68;2.68 +9536-4;Influenza virus B Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Influenza virus B IgM Ab [Titer] in Serum;FLUBV IgM Titr Ser;;ACTIVE;1.0i;2.73 +95364-6;Organization;ID;Pt;Personnel;Nom;;ADMIN;2;Personnel Organization;Personnel;;ACTIVE;2.68;2.68 +95365-3;Criteria used for case classification;Find;Pt;^Patient;Nom;;PUBLICHEALTH;2;Criteria used for case classification;Criteria for case classification;;ACTIVE;2.68;2.68 +95366-1;Date of first positive specimen collection;Date;Pt;^Patient;Qn;;SPEC;1;Date of first positive specimen collection;Dt of 1st pos specimen collection;;ACTIVE;2.68;2.68 +95367-9;Intensive care unit admission date;Date;Pt;^Patient;Qn;;H&P.HX;2;Intensive care unit (ICU) admission date;ICU admission date;;ACTIVE;2.68;2.69 +95368-7;Intensive care unit discharge date;Date;Pt;^Patient;Qn;;H&P.HX;2;Intensive care unit (ICU) discharge date;ICU discharge date;;ACTIVE;2.68;2.69 +95369-5;Affiliated with a tribe;Find;Pt;^Patient;Ord;;ADMIN.DEMOG;2;Affiliated with a tribe;Affiliated with tribe;;ACTIVE;2.68;2.68 +95370-3;Tribal affiliation;Type;Pt;^Patient;Nom;;ADMIN.DEMOG;2;Tribal affiliation;Tribal affiliation;;ACTIVE;2.68;2.68 +95371-1;Enrolled in a tribe;Find;Pt;^Patient;Ord;;ADMIN.DEMOG;2;Enrolled in a tribe;Enrolled tribe;;ACTIVE;2.68;2.68 +9537-2;Intrinsic factor blocking Ab;PrThr;Pt;Ser;Ord;RIA;CHEM;1;Intrinsic factor blocking Ab [Presence] in Serum by Radioimmunoassay (RIA);IF Block Ab Ser Ql RIA;;ACTIVE;1.0i;2.73 +95372-9;Workplace setting;Type;Pt;^Patient;Nom;;ADMIN.DEMOG;2;Workplace setting;Workplace;;ACTIVE;2.68;2.68 +95373-7;Workplace is a part of critical infrastructure;Find;Pt;^Patient;Ord;;H&P.HX;2;Workplace is a part of critical infrastructure;Workplace part of crit infrastructure;;ACTIVE;2.68;2.68 +95374-5;Critical infrastructure workplace setting;Type;Pt;^Patient;Nom;;H&P.HX;2;Critical infrastructure workplace setting;Crit infrastructure workplace type;;ACTIVE;2.68;2.68 +95375-2;Contact was with U.S. or international case;Find;Pt;^Patient;Nom;;H&P.HX;2;Contact was with U.S. or international case;Contact w/U.S. case;;ACTIVE;2.68;2.68 +95376-0;Type of animal exposed to;Type;Pt;^Patient;Nom;;H&P.HX;2;Type of animal exposed to;Type of animal exposed to;;ACTIVE;2.68;2.68 +95377-8;Disability;Type;Pt;^Patient;Nom;;H&P.HX;2;Disability type;Disability;;ACTIVE;2.68;2.68 +95378-6;U.S. Adult Food Security Survey Score;Score;Pt;^Patient;Qn;U.S. Food Security Survey;SURVEY.SDOH;4;U.S. Adult Food Security Survey Score [U.S. FSS];;;ACTIVE;2.68;2.69 +95379-4;U.S. Household Food Security Survey - Six-Item Short Form Score;Score;Pt;^Patient;Qn;U.S. Food Security Survey;SURVEY.SDOH;4;U.S. Household Food Security Survey - Six-Item Short Form Score [U.S. FSS];;;ACTIVE;2.68;2.69 +9538-0;La Crosse virus Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;La Crosse virus Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;LACV Ab Titr CSF IF;;ACTIVE;1.0i;2.7 +95380-2;Influenza virus A & Influenza virus B & SARS coronavirus 2 & SARS-related coronavirus RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus A and B and SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory specimen by NAA with probe detection;FluAB+SARS-CoV-2+SARSr-CoV Resp NAA+prb;;ACTIVE;2.69;2.69 +95381-0;COVID-19 note;Find;Pt;Telephone encounter;Doc;{Role};DOC.ONTOLOGY;2;Telephone encounter COVID-19 note;Phone COVID-19 note;;ACTIVE;2.68;2.7 +95382-8;Date and time of symptom resolution;TmStp;Pt;^Patient;Qn;;CLIN;2;Date and time of symptom resolution;D/T symptom resolution;;ACTIVE;2.68;2.68 +95383-6;Symptom resolution status;Find;Pt;^Patient;Ord;;CLIN;2;Symptom resolution status;Symptom res status;;ACTIVE;2.68;2.68 +95384-4;Symptoms in the last 24H;Find;24H;^Patient;Nom;;H&P.PX;2;Symptoms in the last 24 hours;Symptoms 24H;;ACTIVE;2.68;2.68 +95385-1;Caregiver for person with age-related complaints, chronic diseases or frailty;Find;Pt;^Patient;Ord;;H&P.PX;2;Caregiver for person with age-related complaints, chronic diseases or frailty;Caregiver for person at-risk;;ACTIVE;2.68;2.68 +95386-9;Date and time of most recent contact with confirmed case;Date;Pt;^Patient;Qn;;H&P.PX;2;Date and time of most recent contact with confirmed case;D/T most recent contact w case;;ACTIVE;2.68;2.69 +95387-7;Safe Environment for Every Kid Impression;Imp;Pt;^Caregiver;Nom;SEEK;SURVEY.SEEK;4;Safe Environment for Every Kid Impression Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95388-5;Other things you'd like help with today;Find;Pt;^Caregiver;Nom;SEEK;SURVEY.SEEK;4;Other things you'd like help with today Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95389-3;Have you used an illegal drug or a prescription medication for nonmedical reasons in the past 3Mo;Find;3Mo;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Have you used an illegal drug or a prescription medication for nonmedical reasons in the past 3 months Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95390-1;Four or more drinks in 1D in the past 3Mo;Find;3Mo;^Caregiver;Ord;;SURVEY.SEEK;4;Four or more drinks in one day in the past 3 months Caregiver;;;ACTIVE;2.68;2.7 +95391-9;Has a partner threatened, shoved, hit or kicked you or hurt you physically in any way in the past 3Mo;Find;3Mo;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Has a partner threatened, shoved, hit or kicked you or hurt you physically in any way in the past 3 months Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95392-7;Have you and a partner fought a lot in the past 3Mo;Find;3Mo;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Have you and a partner fought a lot in the past 3 months Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95393-5;Little interest or pleasure in doing things in last 2W;Find;2W;^Caregiver;Ord;Reported.PHQ;SURVEY.PHQ;4;Little interest or pleasure in doing things in last 2 weeks Caregiver [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.68;2.68 +95394-3;Feeling down, depressed, or hopeless in last 2W;Find;2W;^Caregiver;Ord;Reported.PHQ;SURVEY.PHQ;4;Feeling down, depressed, or hopeless in last 2 weeks Caregiver [Reported.PHQ];;Copyright © Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.;ACTIVE;2.68;2.68 +95395-0;Do you often feel under extreme stress;Find;Pt;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Do you often feel under extreme stress Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95396-8;Do you wish you had more help with your child;Find;Pt;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Do you wish you had more help with your child Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95397-6;Do you sometimes find you need to slap or hit your child;Find;Pt;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Do you sometimes find you need to slap or hit your child Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +9539-8;La Crosse virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;La Crosse virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;LACV IgG Titr CSF IF;;ACTIVE;1.0i;2.73 +95398-4;Do you often feel your child is difficult to take care of;Find;Pt;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Do you often feel your child is difficult to take care of Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95399-2;Within the past 12Mo the food we bought just didn't last and we didn't have money to get more;Find;12Mo;^Caregiver;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;Within the past 12 months the food we bought just didn't last and we didn't have money to get more Caregiver [U.S. FSS];;;ACTIVE;2.68;2.69 +95400-8;Within the past 12Mo we worried whether our food would run out before we got money to buy more;Find;12Mo;^Caregiver;Ord;U.S. Food Security Survey;SURVEY.SDOH;4;Within the past 12 months we worried whether our food would run out before we got money to buy more Caregiver [U.S. FSS];;;ACTIVE;2.68;2.69 +95401-6;Needs smoke detector for home;Find;Pt;^Caregiver;Ord;;H&P.HX;2;Needs smoke detector for home from Caregiver;Needs smoke detector;;ACTIVE;2.68;2.68 +95402-4;Would you like us to give you the phone number for poison control;Find;Pt;^Caregiver;Ord;SEEK;SURVEY.SEEK;4;Would you like us to give you the phone number for poison control Caregiver [SEEK];;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95403-2;Safe Environment for Every Kid parent questionnaire - revised;-;Pt;^Caregiver;-;SEEK;PANEL.SURVEY.SEEK;4;Safe Environment for Every Kid parent questionnaire - revised [SEEK] Caregiver;;© 2019 SEEK Used with permission. Please visit www.SEEKwellbeing.org to access the SEEK model and training resources.;ACTIVE;2.68;2.68 +95404-0;Suicidal behavior;-;Pt;^Patient;-;C-SSRS.PCI;PANEL.SURVEY.CSSRS;4;Suicidal behavior [C-SSRS.PCI];;© 2008 Research Foundation of Mental Hygiene, Inc. Used with permission;ACTIVE;2.68;2.69 +95405-7;Assay related variables panel;-;Pt;^Patient;-;PhenX;PANEL.PHENX;2;Assay related variables panel [PhenX];Assay related variables pnl PhenX;;TRIAL;2.68;2.68 +9540-6;La Crosse virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;La Crosse virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;LACV IgM Titr CSF IF;;ACTIVE;1.0i;2.73 +95406-5;SARS coronavirus 2 RNA;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection;SARS-CoV-2 RNA Nose Ql NAA+probe;;ACTIVE;2.68;2.69 +95407-3;Note;Find;Pt;Telehealth;Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Telehealth Note;Cardio+Pulm disease Telehealth Note;;ACTIVE;2.68;2.68 +95408-1;Note;Find;Pt;Outpatient;Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Outpatient Note;Cardio+Pulm disease OP Note;;ACTIVE;2.68;2.68 +95409-9;SARS coronavirus 2 N gene;PrThr;Pt;Nose;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection;SARS-CoV-2 N gene Nose Ql NAA+probe;;ACTIVE;2.68;2.69 +95410-7;SARS coronavirus 2 Ab.neut;Titr;Pt;Ser;Qn;pVNT;MICRO;1;SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNT;SARS-CoV-2 NAb Titr Ser pVNT;;ACTIVE;2.68;2.69 +95411-5;SARS coronavirus 2 Ab.neut;PrThr;Pt;Ser;Ord;pVNT;MICRO;1;SARS-CoV-2 (COVID-19) neutralizing antibody [Presence] in Serum by pVNT;SARS-CoV-2 NAb Ser Ql pVNT;;ACTIVE;2.68;2.69 +95412-3;COVID-19 case report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 case report;COVID-19 Case rprt;;ACTIVE;2.68;2.7 +95413-1;Living arrangement panel;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Living arrangement panel [CMS Assessment];;;ACTIVE;2.68;2.68 +9541-4;Legionella pneumophila 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 1 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo1 IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95414-9;Level of paid and unpaid caregiver assistance;-;1Mo;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Level of paid and unpaid caregiver assistance [CMS Assessment];;;ACTIVE;2.68;2.68 +95415-6;Admitted as an inpatient;Find;Pt;^Patient;Ord;;H&P.HX;2;Admitted as an inpatient;Admitted as inpatient;;ACTIVE;2.68;2.68 +95416-4;SARS coronavirus 2 Ab.IgM;PrThr;Pt;Bld.dot;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgM Ab [Presence] in DBS by Immunoassay;SARS-CoV-2 IgM DBS Ql IA;;ACTIVE;2.68;2.69 +95417-2;First test for condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether this is the patient's first test for condition of interest;First test for condition of interest;;ACTIVE;2.69;2.71 +95418-0;Employed in a healthcare setting;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether patient is employed in a healthcare setting;Employed in healthcare setting;;ACTIVE;2.69;2.69 +95419-8;Has symptoms related to condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether the patient has symptoms related to condition of interest;Has symptoms for condition;;ACTIVE;2.69;2.69 +95420-6;Admitted to intensive care unit for condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether the patient was admitted to intensive care unit (ICU) for condition of interest;Admitted to ICU for condition;;ACTIVE;2.69;2.69 +95421-4;Resides in a congregate care setting;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether patient resides in a congregate care setting;Resides in a congregate care setting;;ACTIVE;2.69;2.69 +9542-2;Legionella pneumophila 1 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 1 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo1 IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95422-2;Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Respiratory specimen by NAA with probe detection;FLUABV + SARS-CoV-2 Pnl Resp NAA+prb;;ACTIVE;2.69;2.69 +95423-0;Influenza virus A & Influenza virus B & SARS coronavirus 2 identified;Prid;Pt;Respiratory;Nom;Probe.amp.tar;MICRO;1;Influenza virus A and B and SARS-CoV-2 (COVID-19) identified in Respiratory specimen by NAA with probe detection;FLUABV + SARS-CoV-2 Resp NAA+probe;;ACTIVE;2.69;2.69 +95424-8;SARS coronavirus 2 RNA;PrThr;Pt;Respiratory;Ord;Sequencing;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by Sequencing;SARS-CoV-2 RNA Resp Ql Seq;;ACTIVE;2.69;2.69 +95425-5;SARS coronavirus 2 N gene;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 N gene Sal Ql NAA+probe;;ACTIVE;2.69;2.69 +95426-3;Level of independence;Type;Pt;^Patient;Nom;;FUNCTION;2;Level of independence;Level of independence;;ACTIVE;2.69;2.69 +95427-1;SARS coronavirus 2 Ab.IgA;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;SARS-CoV-2 (COVID-19) IgA Ab [Titer] in Serum or Plasma by Immunofluorescence;SARS-CoV-2 IgA Titr SerPl IF;;ACTIVE;2.69;2.69 +95428-9;SARS coronavirus 2 Ab.IgM;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;SARS-CoV-2 (COVID-19) IgM Ab [Titer] in Serum or Plasma by Immunofluorescence;SARS-CoV-2 IgM Titr SerPl IF;;ACTIVE;2.69;2.69 +95429-7;SARS coronavirus 2 Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;MICRO;1;SARS-CoV-2 (COVID-19) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;SARS-CoV-2 IgG Titr SerPl IF;;ACTIVE;2.69;2.69 +9543-0;Legionella pneumophila 1 Ag;PrThr;Pt;Urine;Ord;RIA;MICRO;1;Legionella pneumophila 1 Ag [Presence] in Urine by Radioimmunoassay (RIA);L pneumo1 Ag Ur Ql RIA;;ACTIVE;1.0i;2.73 +95430-5;During the past 3Mo, how often have you used cannabis;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used cannabis;;;ACTIVE;2.69;2.69 +95431-3;During the past 3Mo, how often have you used cocaine;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used cocaine;;;ACTIVE;2.69;2.69 +95432-1;During the past 3Mo, how often have you used prescription stimulants;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used prescription stimulants;;;ACTIVE;2.69;2.69 +95433-9;During the past 3Mo, how often have you used methamphetamine;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used methamphetamine;;;ACTIVE;2.69;2.69 +95434-7;During the past 3Mo, how often have you used inhalants;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used inhalants;;;ACTIVE;2.69;2.69 +95435-4;During the past 3Mo, how often have you used sedatives or sleeping pills;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used sedatives or sleeping pills;;;ACTIVE;2.69;2.69 +95436-2;During the past 3Mo, how often have you used hallucinogens;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used hallucinogens;;;ACTIVE;2.69;2.69 +95437-0;During the past 3Mo, how often have you used street opioids;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used street opioids;;;ACTIVE;2.69;2.69 +95438-8;During the past 3Mo, how often have you used prescription opioids;Find;3Mo;^Patient;Ord;;SURVEY.NIDA;4;During the past 3 months, how often have you used prescription opioids;;;ACTIVE;2.69;2.69 +95439-6;During the past 3Mo, how often have you used other substances;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you used other substances [NIDA];;;ACTIVE;2.69;2.69 +95440-4;During the past 3Mo, how often have you had a strong desire or urge to use cannabis;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use cannabis [NIDA];;;ACTIVE;2.69;2.69 +95441-2;During the past 3Mo, how often have you had a strong desire or urge to use cocaine;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use cocaine [NIDA];;;ACTIVE;2.69;2.69 +95442-0;During the past 3Mo, how often have you had a strong desire or urge to use prescription stimulants;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use prescription stimulants [NIDA];;;ACTIVE;2.69;2.69 +95443-8;During the past 3Mo, how often have you had a strong desire or urge to use methamphetamine;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use methamphetamine [NIDA];;;ACTIVE;2.69;2.69 +95444-6;During the past 3Mo, how often have you had a strong desire or urge to use inhalants;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use inhalants [NIDA];;;ACTIVE;2.69;2.69 +95445-3;During the past 3Mo, how often have you had a strong desire or urge to use sedatives or sleeping pills;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use sedatives or sleeping pills [NIDA];;;ACTIVE;2.69;2.69 +95446-1;During the past 3Mo, how often have you had a strong desire or urge to use hallucinogens;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use hallucinogens [NIDA];;;ACTIVE;2.69;2.69 +95447-9;During the past 3Mo, how often have you had a strong desire or urge to use street opioids;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use street opioids [NIDA];;;ACTIVE;2.69;2.69 +9544-8;Legionella pneumophila 2 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 2 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo2 IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95448-7;During the past 3Mo, how often have you had a strong desire or urge to use prescription opioids;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use prescription opioids [NIDA];;;ACTIVE;2.69;2.69 +95449-5;During the past 3Mo, how often have you had a strong desire or urge to use other substances;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you had a strong desire or urge to use other substances [NIDA];;;ACTIVE;2.69;2.69 +95450-3;During the past 3Mo, how often has your use of cannabis led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of cannabis led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95451-1;During the past 3Mo, how often has your use of cocaine led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of cocaine led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95452-9;During the past 3Mo, how often has your use of prescription stimulants led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of prescription stimulants led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95453-7;During the past 3Mo, how often has your use of methamphetamine led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of methamphetamine led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95454-5;During the past 3Mo, how often has your use of inhalants led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of inhalants led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +9545-5;Legionella pneumophila 2 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 2 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo2 IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95455-2;During the past 3Mo, how often has your use of sedatives or sleeping pills led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of sedatives or sleeping pills led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95456-0;During the past 3Mo, how often has your use of hallucinogens led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of hallucinogens led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95457-8;During the past 3Mo, how often has your use of street opioids led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of street opioids led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95458-6;During the past 3Mo, how often has your use of prescription opioids led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of prescription opioids led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95459-4;During the past 3Mo, how often has your use of other substances led to health, social, legal or financial problems;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often has your use of other substances led to health, social, legal or financial problems [NIDA];;;ACTIVE;2.69;2.69 +95460-2;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of cannabis;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of cannabis [NIDA];;;ACTIVE;2.69;2.69 +95461-0;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of cocaine;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of cocaine [NIDA];;;ACTIVE;2.69;2.69 +95462-8;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of prescribed Amphetamine type stimulants;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of prescribed Amphetamine type stimulants [NIDA];;;ACTIVE;2.69;2.69 +9546-3;Legionella pneumophila 3 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 3 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo3 IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95463-6;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of methamphetamine;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of methamphetamine [NIDA];;;ACTIVE;2.69;2.69 +95464-4;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of inhalants;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of inhalants [NIDA];;;ACTIVE;2.69;2.69 +95465-1;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of sedatives or sleeping pills;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of sedatives or sleeping pills [NIDA];;;ACTIVE;2.69;2.69 +95466-9;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of hallucinogens;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of hallucinogens [NIDA];;;ACTIVE;2.69;2.69 +95467-7;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of street opioids;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of street opioids [NIDA];;;ACTIVE;2.69;2.69 +95468-5;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of prescription opioids;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of prescription opioids [NIDA];;;ACTIVE;2.69;2.69 +95469-3;During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of other substances;Find;3Mo;^Patient;Ord;NIDA;SURVEY.NIDA;4;During the past 3 months, how often have you failed to do what was normally expected of you because of your use of other substances [NIDA];;;ACTIVE;2.69;2.69 +95470-1;Has a friend or relative or anyone else ever expressed concern about your use of cannabis;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of cannabis [NIDA];;;ACTIVE;2.69;2.69 +9547-1;Legionella pneumophila 3 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 3 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo3 IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95471-9;Has a friend or relative or anyone else ever expressed concern about your use of cocaine;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of cocaine [NIDA];;;ACTIVE;2.69;2.69 +95472-7;Has a friend or relative or anyone else ever expressed concern about your use of prescribed Amphetamine type stimulants;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of prescribed Amphetamine type stimulants [NIDA];;;ACTIVE;2.69;2.69 +95473-5;Has a friend or relative or anyone else ever expressed concern about your use of methamphetamine;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of methamphetamine [NIDA];;;ACTIVE;2.69;2.69 +95474-3;Has a friend or relative or anyone else ever expressed concern about your use of inhalants;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of inhalants [NIDA];;;ACTIVE;2.69;2.69 +95475-0;Has a friend or relative or anyone else ever expressed concern about your use of sedatives or sleeping pills;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of sedatives or sleeping pills [NIDA];;;ACTIVE;2.69;2.69 +95476-8;Has a friend or relative or anyone else ever expressed concern about your use of hallucinogens;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of hallucinogens [NIDA];;;ACTIVE;2.69;2.69 +95477-6;Has a friend or relative or anyone else ever expressed concern about your use of street opioids;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of street opioids [NIDA];;;ACTIVE;2.69;2.69 +95478-4;Has a friend or relative or anyone else ever expressed concern about your use of prescription opioids;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of prescription opioids [NIDA];;;ACTIVE;2.69;2.69 +95479-2;Has a friend or relative or anyone else ever expressed concern about your use of other substances;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Has a friend or relative or anyone else ever expressed concern about your use of other substances [NIDA];;;ACTIVE;2.69;2.69 +954-8;C little e Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;C little e Ag [Presence] on Red Blood Cells;C little e Ag RBC Ql;;ACTIVE;1.0;2.67 +95480-0;Other substances that have caused a friend or relative or anyone else to ever express concern about your use of other substances;-;Pt;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;Other substances that have caused a friend or relative or anyone else to ever express concern about your use of other substances [NIDA];;;ACTIVE;2.69;2.69 +95481-8;Substances that have caused a friend or relative or anyone else to ever express concern about your use;Type;Pt;^Patient;Nom;NIDA;SURVEY.NIDA;4;Substances that have caused a friend or relative or anyone else to ever express concern about your use [NIDA];;;ACTIVE;2.69;2.69 +95482-6;Have you ever tried and failed to control, cut down or stop using cannabis;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using cannabis [NIDA];;;ACTIVE;2.69;2.69 +95483-4;Have you ever tried and failed to control, cut down or stop using cocaine;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using cocaine [NIDA];;;ACTIVE;2.69;2.69 +95484-2;Have you ever tried and failed to control, cut down or stop using prescribed Amphetamine type stimulants;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using prescribed Amphetamine type stimulants [NIDA];;;ACTIVE;2.69;2.69 +95485-9;Have you ever tried and failed to control, cut down or stop using methamphetamine;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using methamphetamine [NIDA];;;ACTIVE;2.69;2.69 +95486-7;Have you ever tried and failed to control, cut down or stop using inhalants;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using inhalants [NIDA];;;ACTIVE;2.69;2.69 +95487-5;Have you ever tried and failed to control, cut down or stop using sedatives or sleeping pills;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using sedatives or sleeping pills [NIDA];;;ACTIVE;2.69;2.69 +95488-3;Have you ever tried and failed to control, cut down or stop using hallucinogens;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using hallucinogens [NIDA];;;ACTIVE;2.69;2.69 +9548-9;Legionella pneumophila 4 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 4 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo4 IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95489-1;Have you ever tried and failed to control, cut down or stop using street opioids;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using street opioids [NIDA];;;ACTIVE;2.69;2.69 +95490-9;Have you ever tried and failed to control, cut down or stop using prescription opioids;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using prescription opioids [NIDA];;;ACTIVE;2.69;2.69 +95491-7;Have you ever tried and failed to control, cut down or stop using other substances;Find;Pt;^Patient;Ord;NIDA;SURVEY.NIDA;4;Have you ever tried and failed to control, cut down or stop using other substances [NIDA];;;ACTIVE;2.69;2.69 +95492-5;Injection drug use;Find;Lifetime;^Patient;Ord;;H&P.HX;2;Injection drug use Lifetime;Injection drug use Lifetime;;ACTIVE;2.69;2.69 +95493-3;Cannabis substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Cannabis substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95494-1;Substances used during the past 3Mo;Type;Pt;^Patient;Nom;;H&P.HX;2;Substances used during the past 3 months;Substances used past 3Mo;;ACTIVE;2.69;2.69 +95495-8;Other substances used during the past 3Mo;-;3Mo;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;Other substances used during the past 3 months [NIDA];;;ACTIVE;2.69;2.69 +95496-6;Other substances that you have had a strong desire or urge to use in the past 3Mo;-;3Mo;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;Other substances that you have had a strong desire or urge to use in the past 3 months [NIDA];;;ACTIVE;2.69;2.69 +9549-7;Legionella pneumophila 4 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 4 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo4 IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95497-4;Other substances that have led to health, social, legal or financial problems in the past 3Mo;-;3Mo;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;Other substances that have led to health, social, legal or financial problems in the past 3 months [NIDA];;;ACTIVE;2.69;2.69 +95498-2;Other substances that have caused you to fail to do what was normally expected of you in the past 3Mo;-;3Mo;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;Other substances that have caused you to fail to do what was normally expected of you in the past 3 months [NIDA];;;ACTIVE;2.69;2.69 +95499-0;Other substances that you have ever tried and failed to control, cut down or stop using;-;Pt;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;Other substances that you have ever tried and failed to control, cut down or stop using [NIDA];;;ACTIVE;2.69;2.69 +95500-5;Substances you have had a strong desire or urge to use during the past 3Mo;Type;3Mo;^Patient;Nom;NIDA;SURVEY.NIDA;4;Substances you have had a strong desire or urge to use during the past 3 months [NIDA];;;ACTIVE;2.69;2.69 +95501-3;Substances that have led to health, social, legal or financial problems during the past 3Mo;Type;3Mo;^Patient;Nom;NIDA;SURVEY.NIDA;4;Substances that have led to health, social, legal or financial problems during the past 3 months [NIDA];;;ACTIVE;2.69;2.69 +95502-1;Substances that have caused you to fail to do what was normally expected of you during the past 3Mo;Type;3Mo;^Patient;Nom;NIDA;SURVEY.NIDA;4;Substances that have caused you to fail to do what was normally expected of you during the past 3 months [NIDA];;;ACTIVE;2.69;2.69 +95503-9;Substances that you have ever tried and failed to control, cut down or stop using;Type;Pt;^Patient;Nom;NIDA;SURVEY.NIDA;4;Substances that you have ever tried and failed to control, cut down or stop using [NIDA];;;ACTIVE;2.69;2.69 +95504-7;Cocaine substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Cocaine substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +9550-5;Legionella pneumophila 5 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 5 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo5 IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95505-4;Prescription stimulants substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Prescription stimulants substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95506-2;Methamphetamine substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Methamphetamine substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95507-0;Inhalants substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Inhalants substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95508-8;Sedatives or sleeping pills substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Sedatives or sleeping pills substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95509-6;Hallucinogens substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Hallucinogens substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95510-4;Street opioids substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Street opioids substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95511-2;Prescription opioids substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Prescription opioids substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +95512-0;Other substance involvement score;Score;Pt;^Patient;Qn;NIDA;SURVEY.NIDA;4;Other substance involvement score [NIDA];;;ACTIVE;2.69;2.69 +9551-3;Legionella pneumophila 5 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 5 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo5 IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95513-8;NIDA-Modified ASSIST version 2.0;-;Pt;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;NIDA-Modified ASSIST version 2.0 [NIDA];;;ACTIVE;2.69;2.69 +95514-6;Refractive index;InvLen;Pt;Keratometer;Qn;;EYE.REFRACTION;2;Keratometer Refractive index;Keratometer Refract Indx;;TRIAL;2.69;2.69 +95515-3;Angiotensin II & angiotensin (1-7) panel;-;Pt;Plas;Qn;;PANEL.CHEM;1;Angiotensin II (1-8) and angiotensin (1-7) panel - Plasma;Ang II and Ang-(1-7) Pnl Plas;;ACTIVE;2.69;2.69 +95516-1;Angiotensin (1-7);MCnc;Pt;Plas;Qn;;CHEM;1;Angiotensin (1-7) [Mass/volume] in Plasma;Ang-(1-7) Plas-mCnc;;ACTIVE;2.69;2.69 +95520-3;Note;Find;Pt;Telehealth;Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine Telehealth Note;Integrative medicine Telehealth Note;;ACTIVE;2.69;2.69 +9552-1;Legionella pneumophila 6 Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 6 IgG Ab [Titer] in Serum by Immunofluorescence;L pneumo6 IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95521-1;SARS coronavirus 2 N gene;NCnc;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory specimen by NAA with probe detection;SARS-CoV-2 N gene # Resp NAA+probe;;ACTIVE;2.69;2.69 +95522-9;SARS coronavirus 2 N gene;LnCnc;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Log #/volume] (viral load) in Respiratory specimen by NAA with probe detection;SARS-CoV-2 N gene Resp NAA+probe-Log#;;ACTIVE;2.69;2.69 +95523-7;HIV 1 & 2 Ab panel;-;Pt;Ser/Plas;-;IA;PANEL.MICRO;1;HIV 1 and 2 Ab panel - Serum or Plasma by Immunoassay;HIV 1 + 2 Ab Pnl SerPl IA;;ACTIVE;2.69;2.69 +95524-5;HIV 1 & 2 Ab;Prid;Pt;Ser/Plas;Nom;IA;MICRO;1;HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Immunoassay;HIV 1 & 2 Ab SerPl IA;;ACTIVE;2.69;2.69 +95525-2;Chromium & cobalt panel;MCnc;Pt;Synv fld;Qn;;PANEL.DRUG/TOX;1;Chromium and cobalt panel [Mass/volume] - Synovial fluid;Chromium + cobalt pnl Snv-mCnc;;ACTIVE;2.69;2.69 +95526-0;Chromium;MCnc;Pt;Synv fld;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Synovial fluid;Chromium Snv-mCnc;;ACTIVE;2.69;2.69 +95527-8;Cytomegalovirus Ab.IgG;PrThr;Pt;Saliva;Ord;IA;MICRO;1;Cytomegalovirus IgG Ab [Presence] in Saliva (oral fluid) by Immunoassay;CMV IgG Sal Ql IA;;ACTIVE;2.69;2.69 +95528-6;NIDA Quick Screen;-;1Y;^Patient;-;NIDA;PANEL.SURVEY.NIDA;4;NIDA Quick Screen [NIDA];;;ACTIVE;2.69;2.7 +95529-4;Tobacco use in the past 1Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Tobacco use in the past year;Tobacco use 1Y;;ACTIVE;2.69;2.69 +95530-2;Prescription drug use for non-medical reasons in the past 1Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Prescription drug use for non-medical reasons in the past year;Prescription drug use 1Y;;ACTIVE;2.69;2.69 +95531-0;Illegal drug use in the past 1Y;Find;1Y;^Patient;Ord;;H&P.HX;2;Illegal drug use in the past year;Illegal drug use 1Y;;ACTIVE;2.69;2.69 +95532-8;Human papilloma virus high-risk genotypes panel;-;Pt;Cvx;-;Probe.amp.tar;PANEL.MICRO;1;Human papilloma virus high-risk genotypes panel - Cervix by NAA with probe detection;HPV HR genotypes Pnl Cvx NAA+probe;;ACTIVE;2.69;2.69 +95533-6;Human papilloma virus 56+59+66 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 56+59+66 DNA [Presence] in Cervix by NAA with probe detection;HPV56+59+66 DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +95534-4;Human papilloma virus 52 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 52 DNA [Presence] in Cervix by NAA with probe detection;HPV52 DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +95535-1;Human papilloma virus 51 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 51 DNA [Presence] in Cervix by NAA with probe detection;HPV51 DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +95536-9;Human papilloma virus 45 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 45 DNA [Presence] in Cervix by NAA with probe detection;HPV45 DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +95537-7;Human papilloma virus 35+39+68 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 35+39+68 DNA [Presence] in Cervix by NAA with probe detection;HPV35+39+68 DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +95538-5;Human papilloma virus 33+58 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 33+58 DNA [Presence] in Cervix by NAA with probe detection;HPV33+58 DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +9553-9;Legionella pneumophila 6 Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Legionella pneumophila 6 IgM Ab [Titer] in Serum by Immunofluorescence;L pneumo6 IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95539-3;Human papilloma virus 31 DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Human papilloma virus 31 DNA [Presence] in Cervix by NAA with probe detection;HPV31 DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +95540-1;Bacterial carbapenem resistance blaIMP+blaVIM genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaIMP+blaVIM genes [Presence] by Molecular method;blaIMP+blaVIM Islt/Spm Ql;;ACTIVE;2.69;2.69 +95541-9;Care experience preference;Find;Pt;^Patient;Nom;;H&P.HX;2;Care experience preference;Care experience preference;;ACTIVE;2.69;2.69 +95542-7;SARS coronavirus 2 Ab;PrThr;Pt;Ser/Plas/Bld;Ord;IA.rapid;MICRO;1;SARS-CoV-2 (COVID-19) Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay;SARS-CoV-2 Ab SerPlBld Ql IA.rapid;;ACTIVE;2.69;2.7 +95543-5;Aspergillus terreus Ab.IgG;PrThr;Pt;Ser;Ord;;ALLERGY;1;Aspergillus terreus IgG Ab [Presence] in Serum;A terreus IgG Ql;;ACTIVE;2.69;2.69 +95544-3;HTLV I DNA;NCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;HTLV I DNA [#/volume] in Specimen by NAA with probe detection;HTLV I DNA # Spec NAA+probe;;ACTIVE;2.69;2.69 +95545-0;Loprazolam;MCnc;Pt;Ser;Qn;Confirm;DRUG/TOX;1;Loprazolam [Mass/volume] in Serum by Confirmatory method;Loprazolam Ser Cfm-mCnc;;ACTIVE;2.69;2.69 +95546-8;Diabetes 8Y risk;Likelihood;Pt;^Patient;Qn;Calculation;CLIN.RISK;2;Diabetes 8Y risk [Likelihood] Calculation;Diabetes 8Y risk Calcn;;ACTIVE;2.69;2.69 +9554-7;Cells.CD10;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD10 cells [#/volume] in Blood;CD10 Cells # Bld;;ACTIVE;1.0i;2.73 +95547-6;Patient is being treated for high blood pressure;Find;Pt;^Patient;Ord;;H&P.HX;2;Patient is being treated for high blood pressure;Patient treated for high BP;;ACTIVE;2.69;2.69 +95548-4;Cardiovascular disease 10Y risk goal;Likelihood;Pt;^Patient;Qn;ACC-AHA Pooled Cohort.Goff 2013;CARD.RISK;2;Cardiovascular disease 10Y risk goal based on ACC-AHA Pooled Cohort by Goff 2013;CVD 10Y risk goal ACC-AHA.Goff 2013;;ACTIVE;2.69;2.69 +95549-2;Cardiovascular disease lifetime risk;Likelihood;Pt;^Patient;Qn;ACC-AHA Pooled Cohort.Goff 2013;CARD.RISK;2;Cardiovascular disease lifetime risk [Likelihood] ACC-AHA Pooled Cohort by Goff 2013;CVD Lifetime risk ACC-AHA.Goff 2013;;ACTIVE;2.69;2.69 +955-5;C super little w Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;C sup(w) Ab [Presence] in Serum or Plasma from Blood product unit;C sup(w) Ab SerPl BPU Ql;;ACTIVE;1.0;2.7 +95550-0;ABL1 gene.c.944C>T;PrThr;Pt;Bld/Bone mar;Ord;Molgen;MOLPATH.MUT;1;ABL1 gene c.944C>T [Presence] in Blood or Marrow by Molecular genetics method;ABL1 c.944C>T Bld/Mar Ql;;ACTIVE;2.69;2.69 +95551-8;Chromosome region 17p11.2 deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;Chromosome region 17p11.2 deletion in Blood or Tissue by FISH;Chr 17p11.2 Del Bld/T FISH;;ACTIVE;2.69;2.69 +95552-6;4p16.3 chromosome deletion;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;4p16.3 chromosome deletion in Blood or Tissue by FISH;4p16.3 Del Bld/T FISH;;ACTIVE;2.69;2.69 +95553-4;5p15.2 chromosome deletion;Prid;Pt;Bld/Tiss;Doc;FISH;MOLPATH.DELDUP;1;5p15.2 (5p-) chromosome deletion [Identifier] in Blood or Tissue by FISH;5p15.2 Del Bld/T FISH;;ACTIVE;2.69;2.69 +9555-4;Cells.CD11c;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD11c cells [#/volume] in Blood;CD11c Cells # Bld;;ACTIVE;1.0i;2.73 +95554-2;Pancreatic exocrine cell Ab;PrThr;Pt;Ser;Ord;IF;SERO;1;Pancreatic exocrine cell Ab [Presence] in Serum by Immunofluorescence;Pancreatic exocrine cell Ab Ser Ql IF;;ACTIVE;2.69;2.69 +95555-9;F7 gene.p.Arg353Gln;Geno;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;F7 gene p.Arg353Gln [Genotype] in Blood or Tissue by Molecular genetics method Nominal;F7 R353Q Geno Bld/T;;ACTIVE;2.69;2.69 +95556-7;Adrenal cancer risk assessment & urine steroid fractions panel;-;-;^Patient;-;;PANEL.CHEM;1;Adrenal cancer risk assessment and urine steroid fractions panel;Adrenal ca risk assess+ur steroid Pnl;;ACTIVE;2.69;2.69 +95557-5;Detection basis;Type;Pt;Tumor;Nom;;H&P.HX;2;Detection basis of Tumor;Detection basis Tumor;;ACTIVE;2.69;2.69 +95558-3;CT attenuation of mass;Rden;Pt;Abdomen>Adrenal gland;Qn;CT;RAD;2;CT attenuation of adrenal mass;CT attenuation of adrenal mass;;ACTIVE;2.69;2.69 +95559-1;Evidence of adrenal cortical hormone excess;PrThr;24H;Urine;Ord;;CHEM;1;Evidence of adrenal cortical hormone excess [Presence] in 24 hour Urine;Adrenal hormone excess 24h Ur Ql;;ACTIVE;2.69;2.69 +95560-9;Androsterone;Zscore;24H;Urine;Qn;;CHEM;1;Androsterone [Z-score] in 24 hour Urine;Androsterone 24h Z-score Ur;;ACTIVE;2.69;2.69 +95561-7;Etiocholanolone;Zscore;24H;Urine;Qn;;CHEM;1;Etiocholanolone [Z-score] in 24 hour Urine;Etiocholanolone 24h Z-score Ur;;ACTIVE;2.69;2.69 +9556-2;Cells.CD11c+20c+;NCnc;Pt;Bld;Qn;;CELLMARK;1;Deprecated Cells.CD11c+20c+;Deprecated Cells.CD11c+20c+ # Bld;;DEPRECATED;1.0i;2.4 +95562-5;Dehydroepiandrosterone;Zscore;24H;Urine;Qn;;CHEM;1;Dehydroepiandrosterone (DHEA) [Z-score] in 24 hour Urine;DHEA 24h Z-score Ur;;ACTIVE;2.69;2.69 +95563-3;16-Alpha hydroxydehydroepiandrosterone;MRat;24H;Urine;Qn;;CHEM;1;16-Alpha hydroxydehydroepiandrosterone [Mass/time] in 24 hour Urine;16A OH-DHEA 24h Ur-mRate;;ACTIVE;2.69;2.69 +95564-1;16-Alpha hydroxydehydroepiandrosterone;Zscore;24H;Urine;Qn;;CHEM;1;16-Alpha hydroxydehydroepiandrosterone [Z-score] in 24 hour Urine;16A OH-DHEA 24h Z-score Ur;;ACTIVE;2.69;2.69 +95565-8;5-Pregnenetriol;MRat;24H;Urine;Qn;;CHEM;1;5-Pregnenetriol [Mass/time] in 24 hour Urine;5-Pregnenetriol 24h Ur-mRate;;ACTIVE;2.69;2.69 +95566-6;5-Pregnenetriol;Zscore;24H;Urine;Qn;;CHEM;1;5-Pregnenetriol [Z-score] in 24 hour Urine;5-Pregnenetriol 24h Z-score Ur;;ACTIVE;2.69;2.69 +95567-4;5-Pregnenediol;MRat;24H;Urine;Qn;;CHEM;1;5-Pregnenediol [Mass/time] in 24 hour Urine;5-Pregnenediol 24h Ur-mRate;;ACTIVE;2.69;2.69 +95568-2;5-Pregnenediol;Zscore;24H;Urine;Qn;;CHEM;1;5-Pregnenediol [Z-score] in 24 hour Urine;5-Pregnenediol 24h Z-score Ur;;ACTIVE;2.69;2.69 +95569-0;Tetrahydro-11-corticosterone;MRat;24H;Urine;Qn;;CHEM;1;Tetrahydro-11-corticosterone [Mass/time] in 24 hour Urine;TH-11-corticosterone 24h Ur-mRate;;ACTIVE;2.69;2.69 +9557-0;Cells.CD2;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD2 cells [#/volume] in Blood;CD2 Cells # Bld;;ACTIVE;1.0i;2.73 +95570-8;Tetrahydro-11-corticosterone;Zscore;24H;Urine;Qn;;CHEM;1;Tetrahydro-11-corticosterone [Z-score] in 24 hour Urine;TH-11-corticosterone 24h Z-score Ur;;ACTIVE;2.69;2.69 +95571-6;11-Deoxytetrahydrocorticosterone;MRat;24H;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocorticosterone [Mass/time] in 24 hour Urine;TH-DOC 24h Ur-mRate;;ACTIVE;2.69;2.69 +95572-4;11-Deoxytetrahydrocorticosterone;Zscore;24H;Urine;Qn;;CHEM;1;11-Deoxytetrahydrocorticosterone [Z-score] in 24 hour Urine;TH-DOC 24h Z-score Ur;;ACTIVE;2.69;2.69 +95573-2;Pregnanediol;Zscore;24H;Urine;Qn;;CHEM;1;Pregnanediol [Z-score] in 24 hour Urine;Pregnanediol 24h Z-score Ur;;ACTIVE;2.69;2.69 +95574-0;17 alpha-Hydroxypregnanolone;MRat;24H;Urine;Qn;;CHEM;1;17 Alpha-hydroxypregnanolone [Mass/time] in 24 hour Urine;17A-OH-pregnanolone 24h Ur-mRate;;ACTIVE;2.69;2.69 +95575-7;17 alpha-Hydroxypregnanolone;Zscore;24H;Urine;Qn;;CHEM;1;17 Alpha-hydroxypregnanolone [Z-score] in 24 hour Urine;17A-OH-pregnanolone 24h Z-score Ur;;ACTIVE;2.69;2.69 +95576-5;Pregnanetriol;Zscore;24H;Urine;Qn;;CHEM;1;Pregnanetriol [Z-score] in 24 hour Urine;Pregntrl 24h Z-score Ur;;ACTIVE;2.69;2.69 +95577-3;Pregnanetriolone;Zscore;24H;Urine;Qn;;CHEM;1;Pregnanetriolone [Z-score] in 24 hour Urine;Pregntrlone 24h Z-score Ur;;ACTIVE;2.69;2.69 +95578-1;Tetrahydrodeoxycortisol;Zscore;24H;Urine;Qn;;CHEM;1;Tetrahydrodeoxycortisol [Z-score] in 24 hour Urine;TH-DC 24h Z-score Ur;;ACTIVE;2.69;2.69 +95579-9;Cortisol;Zscore;24H;Urine;Qn;;CHEM;1;Cortisol [Z-score] in 24 hour Urine;Cortis 24h Z-score Ur;;ACTIVE;2.69;2.69 +95580-7;6-Beta-Hydroxycortisol;Zscore;24H;Urine;Qn;;CHEM;1;6-Beta-Hydroxycortisol [Z-score] in 24 hour Urine;6B-OH-Cortisol 24h Z-score Ur;;ACTIVE;2.69;2.69 +95581-5;Tetrahydrocortisol;Zscore;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisol [Z-score] in 24 hour Urine;THF 24h Z-score Ur;;ACTIVE;2.69;2.69 +95582-3;5-Alpha tetrahydrocortisol;Zscore;24H;Urine;Qn;;CHEM;1;5-Alpha tetrahydrocortisol [Z-score] in 24 hour Urine;5-A THF 24h Z-score Ur;;ACTIVE;2.69;2.69 +95583-1;Beta cortol;Zscore;24H;Urine;Qn;;CHEM;1;Beta cortol [Z-score] in 24 hour Urine;Beta cortol 24h Z-score Ur;;ACTIVE;2.69;2.69 +95584-9;11-Hydroxyandrosterone;Zscore;24H;Urine;Qn;;CHEM;1;11-Hydroxyandrosterone [Z-score] in 24 hour Urine;11OH-Androst 24h Z-score Ur;;ACTIVE;2.69;2.69 +95585-6;11-Hydroxyetiocholanolone;Zscore;24H;Urine;Qn;;CHEM;1;11-Hydroxyetiocholanolone [Z-score] in 24 hour Urine;11OH-Etioch 24h Z-score Ur;;ACTIVE;2.69;2.69 +95586-4;Cortisone;Zscore;24H;Urine;Qn;;CHEM;1;Cortisone [Z-score] in 24 hour Urine;Cortisone 24h Z-score Ur;;ACTIVE;2.69;2.69 +95587-2;Tetrahydrocortisone;Zscore;24H;Urine;Qn;;CHEM;1;Tetrahydrocortisone [Z-score] in 24 hour Urine;THcortisone 24h Z-score Ur;;ACTIVE;2.69;2.69 +9558-8;Cells.CD20;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD20 cells [#/volume] in Blood;CD20 Cells # Bld;;ACTIVE;1.0i;2.73 +95588-0;Alpha cortolone;Zscore;24H;Urine;Qn;;CHEM;1;Alpha cortolone [Z-score] in 24 hour Urine;A-cortolone 24h Z-score Ur;;ACTIVE;2.69;2.69 +95589-8;Beta cortolone;MRat;24H;Urine;Qn;;CHEM;1;Beta cortolone [Mass/time] in 24 hour Urine;B-cortolone 24h Ur-mRate;;ACTIVE;2.69;2.69 +95590-6;Beta cortolone;Zscore;24H;Urine;Qn;;CHEM;1;Beta cortolone [Z-score] in 24 hour Urine;B-cortolone 24h Z-score Ur;;ACTIVE;2.69;2.69 +95591-4;11-Ketoetiocholanolone;Zscore;24H;Urine;Qn;;CHEM;1;11-Ketoetiocholanolone [Z-score] in 24 hour Urine;11Ketoetioch 24h Z-score Ur;;ACTIVE;2.69;2.69 +95592-2;Note;Find;Pt;Outpatient;Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Outpatient Note;Cardiac surgery OP Note;;ACTIVE;2.69;2.69 +95593-0;Ercalcidiol;MCnc;Pt;BldC;Qn;;CHEM;1;25-hydroxyvitamin D2 [Mass/volume] in Capillary blood;25(OH)D2 BldC-mCnc;;ACTIVE;2.69;2.69 +95594-8;Calcidiol;MCnc;Pt;BldC;Qn;;CHEM;1;25-hydroxyvitamin D3 [Mass/volume] in Capillary blood;25(OH)D3 BldC-mCnc;;ACTIVE;2.69;2.69 +95595-5;Calcidiol+ercalcidiol;MCnc;Pt;BldC;Qn;;CHEM;1;25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Capillary blood;25(OH)D3+25(OH)D2 BldC-mCnc;;ACTIVE;2.69;2.69 +9559-6;Cells.CD5;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD5 cells [#/volume] in Blood;CD5 Cells # Bld;;ACTIVE;1.0i;2.73 +95596-3;Purkinje cell cytoplasmic type Tr Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;PCA-Tr Ab [Units/volume] in Cerebral spinal fluid by Line blot;PCA-Tr Ab CSF Line blot-aCnc;;ACTIVE;2.69;2.69 +95597-1;Gelatinous bodies;PrThr;Pt;Semen;Ord;Microscopy;FERT;1;Gelatinous bodies [Presence] in Semen by Microscopy;Gel bodies Smn Ql Micro;;ACTIVE;2.69;2.69 +95598-9;Mucus strands;PrThr;Pt;Semen;Ord;Microscopy;FERT;1;Mucus strands [Presence] in Semen by Microscopy;Mucus strands Smn Ql Micro;;ACTIVE;2.69;2.69 +95599-7;Dipeptidyl aminopeptidase-like protein 6 Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;Dipeptidyl aminopeptidase-like protein 6 Ab [Titer] in Serum by Cell binding immunofluorescent assay;DPPX Ab Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +95600-3;Contactin-associated protein 2 Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;Contactin-associated protein 2 Ab [Titer] in Serum by Cell binding immunofluorescent assay;CASPR2 Ab Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +95601-1;Leucine-rich glioma-inactivated protein 1 Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;Leucine-rich glioma-inactivated protein 1 Ab [Titer] in Serum by Cell binding immunofluorescent assay;LGI1 Ab Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +95602-9;Gamma aminobutyrate B receptor Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;GABABR Ab [Titer] in Serum by Cell binding immunofluorescent assay;GABABR Ab Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +95603-7;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 2 Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;AMPAR2 Ab [Titer] in Serum by Cell binding immunofluorescent assay;AMPAR2 Ab Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +9560-4;Lymphocytes.CD5;NCnc;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD5 cells [#/volume] in Blood;Deprecated Lymphocytes.CD5 # Bld;;DEPRECATED;1.0i;2.4 +95604-5;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1 Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;AMPAR1 Ab [Titer] in Serum by Cell binding immunofluorescent assay;AMPAR1 Ab Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +95605-2;N-methyl-D-aspartate receptor subunit 1 Ab;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;NMDAR subunit 1 Ab [Titer] in Serum by Cell binding immunofluorescent assay;NMDAR1 Ab Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +95606-0;Stress level - 0-10 numeric rating;Score;24H^max;^Patient;Qn;;H&P.HX;2;Stress level - 0-10 numeric rating [Score] 24 hour maximum;Stress level 0-10 24h Max Score;;ACTIVE;2.69;2.69 +95607-8;Sleep quality - 1-5 numeric rating;Score;24H;^Patient;Qn;;H&P.HX;2;Sleep quality - 1-5 numeric rating [Score] 24 hour;Sleep quality 1-5 rating 24h;;ACTIVE;2.69;2.69 +95608-6;SARS coronavirus 2 RNA;PrThr;Pt;Respiratory;Ord;Non-probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with non-probe detection;SARS-CoV-2 RNA Resp Ql NAA+non-probe;;ACTIVE;2.69;2.69 +95609-4;SARS coronavirus 2 S gene;PrThr;Pt;Respiratory;Ord;Sequencing;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory specimen by Sequencing;SARS-CoV-2 S gene Resp Ql Seq;;ACTIVE;2.69;2.69 +95610-2;Views complete;Find;Pt;Head>Teeth;Doc;XR;RAD;2;XR Teeth Complete Views;XR Teeth Views complete;;ACTIVE;2.69;2.69 +95611-0;Views occlusal;Find;Pt;Head>Teeth;Doc;XR;RAD;2;XR Teeth Occlusal Views;XR Teeth Occlusal;;ACTIVE;2.69;2.69 +9561-2;Cells.CD5+CD19+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD5+CD19+ cells [#/volume] in Blood;CD5+CD19+ Cells # Bld;;ACTIVE;1.0i;2.73 +95612-8;Views;Find;Pt;XXX;Doc;XR.portable;RAD;2;Portable XR Unspecified body region Views;XR port Views;;ACTIVE;2.69;2.69 +95613-6;Unpaid caregiver relationship;Find;Pt;^Patient;Nom;;H&P.HX;2;Unpaid caregiver relationship;Unpaid care relation;;ACTIVE;2.69;2.69 +95614-4;Total score;Score;Pt;^Patient;Qn;HITS;SURVEY.HITS;4;Total score [HITS];;Copyright © 2005 Kevin Sherin, M.D. Used with permission;ACTIVE;2.69;2.69 +95615-1;Scream or curse at you;Find;12Mo;^Patient;Ord;HITS;SURVEY.HITS;4;Scream or curse at you [HITS];;Copyright © 2005 Kevin Sherin, M.D. Used with permission;ACTIVE;2.69;2.69 +95616-9;Threaten you with physical harm;Find;12Mo;^Patient;Ord;HITS;SURVEY.HITS;4;Threaten you with physical harm [HITS];;Copyright © 2005 Kevin Sherin, M.D. Used with permission;ACTIVE;2.69;2.69 +95617-7;Insult you or talk down to you;Find;12Mo;^Patient;Ord;HITS;SURVEY.HITS;4;Insult you or talk down to you [HITS];;Copyright © 2005 Kevin Sherin, M.D. Used with permission;ACTIVE;2.69;2.69 +95618-5;Physically hurt you;Find;12Mo;^Patient;Ord;HITS;SURVEY.HITS;4;Physically hurt you [HITS];;Copyright © 2005 Kevin Sherin, M.D. Used with permission;ACTIVE;2.69;2.69 +95619-3;Hurts, insults, threatens, and screams;-;12Mo;^Patient;-;HITS;PANEL.SURVEY.HITS;4;Hurts, insults, threatens, and screams [HITS];;Copyright © 2005 Kevin Sherin, M.D. Used with permission;ACTIVE;2.69;2.72 +9562-0;Lymphocytes.CD5+CD19+;NCnc;Pt;Bld;Qn;;CELLMARK;1;Deprecated CD5+CD19+ cells [#/volume] in Blood;Deprecated Lymphocytes.CD5+CD19+ # Bld;;DEPRECATED;1.0i;2.4 +95620-1;Neonatal pain, agitation, & sedation scale panel;-;Pt;^Patient;-;NPASS;PANEL.NEONAT;2;Neonatal pain, agitation, and sedation scale panel NPASS;NPASS pnl;© 2009 Pat Hummel Used with permission.;ACTIVE;2.69;2.69 +95621-9;Pain &or agitation panel;-;Pt;^Patient;-;NPASS;PANEL.NEONAT;2;Pain/agitation panel NPASS;Pain/agitat pnl NPASS;© 2009 Pat Hummel Used with permission.;ACTIVE;2.69;2.69 +95622-7;Pain &or agitation severity.crying or irritability;Find;Pt;^Patient;Ord;;NEONAT;2;Pain/agitation severity.crying or irritability;Pain/agit severity cry irritab;;ACTIVE;2.69;2.72 +95623-5;Pain &or agitation severity.behavior state;Find;Pt;^Patient;Ord;;NEONAT;2;Pain/agitation severity.behavior state;Pain/agit severity behav;;ACTIVE;2.69;2.72 +95624-3;Pain &or agitation severity.facial expression;Find;Pt;^Patient;Ord;;NEONAT;2;Pain/agitation severity.facial expression;Pain/agit severity face exp;;ACTIVE;2.69;2.72 +95625-0;Pain &or agitation severity.extremities tone;Find;Pt;^Patient;Ord;;NEONAT;2;Pain/agitation severity.extremities tone;Pain/agi severity extrem tone;;ACTIVE;2.69;2.72 +95626-8;Pain &or agitation severity.vital signs variability;Find;Pt;^Patient;Ord;;NEONAT;2;Pain/agitation severity.vital signs variability;Pain/agi severity vital sign var;;ACTIVE;2.69;2.72 +95627-6;Pain &or agitation total score;Score;Pt;^Patient;Qn;NPASS;NEONAT;2;Pain agitation total score NPASS;Pain agi tot score NPASS;© 2009 Pat Hummel Used with permission.;ACTIVE;2.69;2.69 +95628-4;Pain &or agitation severity level;Find;Pt;^Patient;Ord;;NEONAT;2;Pain/agitation severity level;Pain/agi sev level;;ACTIVE;2.69;2.72 +95629-2;Sedation panel;-;Pt;^Patient;-;NPASS;PANEL.NEONAT;2;Sedation panel NPASS;Sed pnl NPASS;© 2009 Pat Hummel Used with permission.;ACTIVE;2.69;2.69 +956-3;C super little w Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;C sup(w) Ab [Presence] in Serum or Plasma from Donor;C sup(w) Ab SerPl Donr Ql;;ACTIVE;1.0;2.7 +95630-0;Sedation level.crying or irritability;Find;Pt;^Patient;Ord;;NEONAT;2;Sedation level.crying or irritability;Sed level.cry irritab;;ACTIVE;2.69;2.72 +95631-8;Sedation level.behavior state;Find;Pt;^Patient;Ord;;NEONAT;2;Sedation level.behavior state;Sed level.behav state;;ACTIVE;2.69;2.72 +95632-6;Sedation level.facial expression;Find;Pt;^Patient;Ord;;NEONAT;2;Sedation level.facial expression;Sed level.facial exp;;ACTIVE;2.69;2.72 +95633-4;Sedation level.extremities tone;Find;Pt;^Patient;Ord;;NEONAT;2;Sedation level.extremities tone;Sed level.extrem tone;;ACTIVE;2.69;2.72 +95634-2;Sedation level.vital signs variability;Find;Pt;^Patient;Ord;;NEONAT;2;Sedation level.vital signs variability;Sed level.vital signs;;ACTIVE;2.69;2.72 +95635-9;Sedation total score;Score;Pt;^Patient;Qn;NPASS;NEONAT;2;Sedation total score NPASS;Sed total score NPASS;© 2009 Pat Hummel Used with permission.;ACTIVE;2.69;2.69 +95636-7;Sedation level;Find;Pt;^Patient;Ord;;NEONAT;2;Sedation level;Sed lvl;;ACTIVE;2.69;2.7 +95637-5;Jamestown Canyon virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Jamestown canyon virus neutralizing antibody [Titer] in Specimen by Neutralization test;JCV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +9563-8;Cells.CD7;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD7 cells [#/volume] in Blood;CD7 Cells # Bld;;ACTIVE;1.0i;2.73 +95638-3;California encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;California encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;CEV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95639-1;Cache Valley virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Cache valley virus neutralizing antibody [Titer] in Specimen by Neutralization test;CVV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95640-9;Colorado tick fever virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Colorado tick fever virus neutralizing antibody [Titer] in Specimen by Neutralization test;CTFV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95641-7;Barmah forest virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Barmah forest virus neutralizing antibody [Titer] in Specimen by Neutralization test;BFV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95642-5;Snowshoe hare virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Snowshoe hare virus neutralizing antibody [Titer] in Specimen by Neutralization test;SSHV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95643-3;Tahyna virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Tahyna virus neutralizing antibody [Titer] in Specimen by Neutralization test;TAHV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95644-1;Japanese encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Japanese encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;JEV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95645-8;Murray Valley encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Murray Valley encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;MVEV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +9564-6;Lymphocytic choriomeningitis virus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Lymphocytic choriomeningitis virus Ab [Titer] in Cerebral spinal fluid by Complement fixation;LCMV Ab Titr CSF CF;;ACTIVE;1.0i;2.7 +95646-6;Ross River virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Ross River virus neutralizing antibody [Titer] in Specimen by Neutralization test;RRV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95647-4;Powassan virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Powassan virus neutralizing antibody [Titer] in Specimen by Neutralization test;POWV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95648-2;Sindbis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Sindbis virus neutralizing antibody [Titer] in Specimen by Neutralization test;SINV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95649-0;Chikungunya virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Chikungunya virus neutralizing antibody [Titer] in Specimen by Neutralization test;CHIKV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95650-8;Mayaro virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Mayaro virus neutralizing antibody [Titer] in Specimen by Neutralization test;MAYV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95651-6;Yellow Fever virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Yellow fever virus neutralizing antibody [Titer] in Specimen by Neutralization test;YFV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95652-4;Venezuelan equine encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Venezuelan equine encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;VEEV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +9565-3;Measles virus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Measles virus Ab [Titer] in Cerebral spinal fluid by Complement fixation;MeV Ab Titr CSF CF;;ACTIVE;1.0i;2.7 +95653-2;La Crosse virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;La Crosse virus neutralizing antibody [Titer] in Specimen by Neutralization test;LACV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95654-0;Eastern equine encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Eastern equine encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;EEEV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95655-7;Western equine encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Western equine encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;WEEV NAb Titr Spec Nt;;ACTIVE;2.69;2.72 +95656-5;Gestational age <30 weeks;Find;Pt;^Patient;Ord;;NEONAT;2;Gestational age <30 weeks;GA<30w;;ACTIVE;2.69;2.7 +95657-3;Flavivirus identified;Prid;Pt;XXX;Nom;Neut;MICRO;1;Flavivirus identified in Specimen by Neutralization test;Flavivirus Spec Nt;;ACTIVE;2.69;2.69 +95658-1;Influenza virus A H7 Eurasia RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A H7 Eurasia RNA [Presence] in Specimen by NAA with probe detection;FLUAV H7 Euras RNA Spec Ql NAA+probe;;ACTIVE;2.69;2.69 +95659-9;Adenovirus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Adenovirus RNA [Presence] in Specimen by NAA with probe detection;HAdV RNA Spec Ql NAA+probe;;ACTIVE;2.69;2.69 +95660-7;Eastern equine encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Eastern equine encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;EEEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +9566-1;Measles virus Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Measles virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;MeV IgG CSF IA-aCnc;;ACTIVE;1.0i;2.73 +95661-5;Barmah forest virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Barmah forest virus IgG Ab [Presence] in Specimen by Immunoassay;BFV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95662-3;Japanese encephalitis virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Japanese encephalitis virus IgA Ab [Presence] in Specimen by Immunoassay;JEV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95663-1;Zika virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Zika virus IgG Ab [Presence] in Specimen by Immunoassay;ZIKV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95664-9;Jamestown Canyon virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Jamestown canyon virus IgG Ab [Presence] in Specimen by Immunoassay;JCV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95665-6;Snowshoe hare virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Snowshoe hare virus IgG Ab [Presence] in Specimen by Immunoassay;SSHV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95666-4;Tahyna virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Tahyna virus IgG Ab [Presence] in Specimen by Immunoassay;TAHV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95667-2;Japanese encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Japanese encephalitis virus IgG Ab [Presence] in Specimen by Immunoassay;JEV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95668-0;Highlands J virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Highlands J virus IgG Ab [Presence] in Specimen by Immunoassay;HJV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95669-8;Murray Valley encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Murray Valley encephalitis virus IgG Ab [Presence] in Specimen by Immunoassay;MVEV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95670-6;Ross River virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Ross River virus IgG Ab [Presence] in Specimen by Immunoassay;RRV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95671-4;Sindbis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Sindbis virus IgG Ab [Presence] in Specimen by Immunoassay;SINV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95672-2;Chikungunya virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Chikungunya virus IgG Ab [Presence] in Specimen by Immunoassay;CHIKV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95673-0;Dengue virus 1+2+3+4 Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Dengue virus 1+2+3+4 IgG Ab [Presence] in Specimen by Immunoassay;DENV1+2+3+4 IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95674-8;Mayaro virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Mayaro virus IgG Ab [Presence] in Specimen by Immunoassay;MAYV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95675-5;Yellow Fever virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Yellow fever virus IgG Ab [Presence] in Specimen by Immunoassay;YFV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95676-3;Venezuelan equine encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Venezuelan equine encephalitis virus IgG Ab [Presence] in Specimen by Immunoassay;VEEV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95677-1;Saint Louis encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgG Ab [Presence] in Specimen by Immunoassay;SLEV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +95678-9;Western equine encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Western equine encephalitis virus IgG Ab [Presence] in Specimen by Immunoassay;WEEV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +9567-9;Mumps virus Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Mumps virus Ab [Titer] in Cerebral spinal fluid by Complement fixation;MuV Ab Titr CSF CF;;ACTIVE;1.0i;2.7 +95679-7;Barmah forest virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Barmah forest virus IgM Ab [Presence] in Specimen by Immunoassay;BFV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95680-5;Snowshoe hare virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Snowshoe hare virus IgM Ab [Presence] in Specimen by Immunoassay;SSHV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95681-3;Tahyna virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Tahyna virus IgM Ab [Presence] in Specimen by Immunoassay;TAHV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95682-1;Japanese encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Japanese encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;JEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95683-9;Highlands J virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Highlands J virus IgM Ab [Presence] in Specimen by Immunoassay;HJV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95684-7;Murray Valley encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Murray Valley encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;MVEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95685-4;Ross River virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Ross River virus IgM Ab [Presence] in Specimen by Immunoassay;RRV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95686-2;Sindbis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Sindbis virus IgM Ab [Presence] in Specimen by Immunoassay;SINV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +9568-7;Neisseria gonorrhoeae Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Neisseria gonorrhoeae Ab [Titer] in Serum by Complement fixation;N gonorrhoea Ab Titr Ser CF;;DISCOURAGED;1.0i;2.73 +95687-0;Chikungunya virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Chikungunya virus IgM Ab [Presence] in Specimen by Immunoassay;CHIKV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95688-8;Dengue virus 1+2+3+4 Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Dengue virus 1+2+3+4 IgM Ab [Presence] in Specimen by Immunoassay;DENV1+2+3+4 IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95689-6;Mayaro virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Mayaro virus IgM Ab [Presence] in Specimen by Immunoassay;MAYV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95690-4;Yellow Fever virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Yellow fever virus IgM Ab [Presence] in Specimen by Immunoassay;YFV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95691-2;Venezuelan equine encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Venezuelan equine encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;VEEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95692-0;Saint Louis encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;SLEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95693-8;Western equine encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Western equine encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;WEEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +95694-6;Cache valley virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Cache valley virus IgA Ab [Presence] in Specimen by Immunoassay;CVV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +9569-5;Nocardia sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Nocardia sp IgG Ab [Units/volume] in Serum;Nocardia IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +95695-3;Colorado tick fever virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Colorado tick fever virus IgA Ab [Presence] in Specimen by Immunoassay;CTFV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95696-1;Barmah forest virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Barmah forest virus IgA Ab [Presence] in Specimen by Immunoassay;BFV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95697-9;Snowshoe hare virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Snowshoe hare virus IgA Ab [Presence] in Specimen by Immunoassay;SSHV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95698-7;Tahyna virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Tahyna virus IgA Ab [Presence] in Specimen by Immunoassay;TAHV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95699-5;Highlands J virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Highlands J virus IgA Ab [Presence] in Specimen by Immunoassay;HJV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95700-1;Murray Valley encephalitis virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Murray Valley encephalitis virus IgA Ab [Presence] in Specimen by Immunoassay;MVEV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95701-9;Ross River virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Ross River virus IgA Ab [Presence] in Specimen by Immunoassay;RRV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95702-7;Powassan virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Powassan virus IgA Ab [Presence] in Specimen by Immunoassay;POWV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +9570-3;Para aminobenzoate^6H post 500 mg bentiromide PO;MCnc;6H;Urine;Qn;;CHAL;1;Para aminobenzoate [Mass/volume] in 6 hour Urine --6 hours post 500 mg bentiromide PO;pABA 6h p 500 mg BT PO 6h Ur-mCnc;;ACTIVE;1.0i;2.42 +95703-5;West Nile virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;West Nile virus IgA Ab [Presence] in Specimen by Immunoassay;WNV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95704-3;Sindbis virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Sindbis virus IgA Ab [Presence] in Specimen by Immunoassay;SINV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95705-0;Chikungunya virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Chikungunya virus IgA Ab [Presence] in Specimen by Immunoassay;CHIKV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95706-8;Dengue virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Dengue virus IgA Ab [Presence] in Specimen by Immunoassay;DENV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95707-6;Mayaro virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Mayaro virus IgA Ab [Presence] in Specimen by Immunoassay;MAYV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95708-4;Yellow Fever virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Yellow fever virus IgA Ab [Presence] in Specimen by Immunoassay;YFV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95709-2;Venezuelan equine encephalitis virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Venezuelan equine encephalitis virus IgA Ab [Presence] in Specimen by Immunoassay;VEEV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +957-1;C super little w Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;C sup(w) Ab [Presence] in Serum or Plasma;C sup(w) Ab SerPl Ql;;ACTIVE;1.0;2.7 +95710-0;La Crosse virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;La Crosse virus IgA Ab [Presence] in Specimen by Immunoassay;LACV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +9571-1;Parvovirus B19 DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Specimen by NAA with probe detection;B19V DNA Spec Ql NAA+probe;;ACTIVE;1.0i;2.73 +95711-8;Saint Louis encephalitis virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Saint Louis encephalitis virus IgA Ab [Presence] in Specimen by Immunoassay;SLEV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95712-6;Eastern equine encephalitis virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Eastern equine encephalitis virus IgA Ab [Presence] in Specimen by Immunoassay;EEEV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95713-4;Western equine encephalitis virus Ab.IgA;PrThr;Pt;XXX;Ord;IA;MICRO;1;Western equine encephalitis virus IgA Ab [Presence] in Specimen by Immunoassay;WEEV IgA Spec Ql IA;;ACTIVE;2.69;2.69 +95714-2;Varicella zoster virus Ab.IgG;ACnc;Pt;XXX;Qn;IA;MICRO;1;Varicella zoster virus IgG Ab [Units/volume] in Specimen by Immunoassay;VZV IgG Spec IA-aCnc;;ACTIVE;2.69;2.69 +95715-9;Population group;Type;Pt;^Patient;Nom;;PUBLICHEALTH;2;Population group;Population group;;ACTIVE;2.69;2.69 +95716-7;17 alpha-Hydroxylase Ab;Titr;Pt;Ser;Qn;IF;SERO;1;17 alpha-Hydroxylase Ab [Titer] in Serum by Immunofluorescence;17A-Hydroxylase Ab Titr Ser IF;;ACTIVE;2.69;2.69 +95717-5;Barmah forest virus Ab;PrThr;Pt;Ser;Ord;IA;MICRO;1;Barmah forest virus Ab [Presence] in Serum by Immunoassay;BFV Ab Ser Ql IA;;ACTIVE;2.69;2.69 +95718-3;Anion gap 3;SCnc;Pt;Bld;Qn;;CHEM;1;Anion gap 3 in Blood;Anion Gap3 Bld-sCnc;;ACTIVE;2.69;2.69 +95719-1;Flavivirus Ab;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Flavivirus Ab [Presence] in Serum or Plasma;Flavivirus Ab SerPl Ql;;ACTIVE;2.69;2.69 +95720-9;Glycine receptor Ab;Titr;Pt;Ser/Plas;Qn;IA;SERO;1;Glycine receptor Ab [Titer] in Serum or Plasma by Immunoassay;GlyR Ab Titr SerPl IA;;ACTIVE;2.69;2.69 +95721-7;Glycine receptor Ab;Titr;Pt;CSF;Qn;IA;SERO;1;Glycine receptor Ab [Titer] in Cerebral spinal fluid by Immunoassay;GlyR Ab Titr CSF IA;;ACTIVE;2.69;2.69 +95722-5;Glycine receptor Ab;PrThr;Pt;Ser/Plas;Ord;IA;SERO;1;Glycine receptor Ab [Presence] in Serum or Plasma by Immunoassay;GlyR Ab SerPl Ql IA;;ACTIVE;2.69;2.69 +95723-3;Glycine receptor Ab;PrThr;Pt;CSF;Ord;IA;SERO;1;Glycine receptor Ab [Presence] in Cerebral spinal fluid by Immunoassay;GlyR Ab CSF Ql IA;;ACTIVE;2.69;2.69 +95724-1;Glycine receptor Ab;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Glycine receptor Ab [Presence] in Serum or Plasma by Immunofluorescence;GlyR Ab SerPl Ql IF;;ACTIVE;2.69;2.69 +95725-8;Glycine receptor Ab;PrThr;Pt;CSF;Ord;IF;SERO;1;Glycine receptor Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;GlyR Ab CSF Ql IF;;ACTIVE;2.69;2.69 +95726-6;3-Hydroxy-3-Methylglutaryl-Coenzyme A reductase Ab;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;3-Hydroxy-3-Methylglutaryl-coenzyme A reductase Ab [Units/volume] in Serum or Plasma by Immunoassay;HMGCR Ab SerPl IA-aCnc;;ACTIVE;2.69;2.69 +95727-4;Name;Pn;Pt;^Contact;Nom;;ADMIN;2;Contact Name;Contact Name;;ACTIVE;2.69;2.69 +95728-2;Address;Addr;Pt;^Contact;Nom;;ADMIN;2;Contact Address;Contact Address;;ACTIVE;2.69;2.69 +9572-9;Parvovirus B19 DNA;PrThr;Pt;Ser;Ord;Probe.amp.tar;MICRO;1;Parvovirus B19 DNA [Presence] in Serum by NAA with probe detection;B19V DNA Ser Ql NAA+probe;;ACTIVE;1.0i;2.73 +95729-0;Relationship to decedent;Type;Pt;^Contact;Nom;;ADMIN;2;Relationship to decedent Contact;Rel to decedent Contact;;ACTIVE;2.69;2.69 +95730-8;Surviving spouse name;Pn;Pt;^Patient;Nom;;ADMIN;2;Surviving spouse name;Surviving spouse name;;ACTIVE;2.69;2.69 +95731-6;Maiden name;Pn;Pt;^Mother;Nom;;ADMIN;2;Mother's Maiden name;Mother's Maiden name;;ACTIVE;2.69;2.69 +95732-4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Self-care - admission performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Self-care - admission performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.7 +95733-2;IRF-PAI v3.0, LCDS v4.00 - Bladder and bowel - admission;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, LCDS v4.00 - Bladder and bowel - admission during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95734-0;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Self-care - discharge performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAIv3.0, MDS v1.17.1, 1.17.2 - Self-care - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.7 +95735-7;Bladder continence;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bladder continence during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95736-5;Bowel continence;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Bowel continence during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +9573-7;Respiratory syncytial virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Respiratory syncytial virus IgG Ab [Titer] in Serum by Immunofluorescence;RSV IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95737-3;Expression of ideas and wants;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Expression of ideas and wants during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95738-1;Does the patient use a wheelchair or scooter;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Does the patient use a wheelchair/scooter during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95739-9;Indicate the type of wheelchair or scooter used;Type;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Indicate the type of wheelchair/scooter used during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95740-7;Understanding verbal and non-verbal content;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Understanding verbal and non-verbal content during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95741-5;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - admission performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - admission performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.7 +95742-3;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - discharge performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.7 +95743-1;Memory &or recall ability;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Memory/recall ability during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95744-9;Hearing.ability to hear;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Hearing.ability to hear during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +9574-5;Respiratory syncytial virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Respiratory syncytial virus IgM Ab [Titer] in Serum by Immunofluorescence;RSV IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95745-6;Vision.ability to see in adequate light;Find;RptPeriod;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Vision.ability to see in adequate light during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95746-4;Progress note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Progress note;Immunology Prog note;;ACTIVE;2.69;2.73 +95747-2;Referral note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Referral note;Immunology Referral note;;ACTIVE;2.69;2.69 +95748-0;Education note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Education note;Immunology Educ note;;ACTIVE;2.69;2.69 +95749-8;Initial evaluation note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Initial evaluation note;Immunology Initial eval note;;ACTIVE;2.69;2.69 +95750-6;Procedure note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology procedure note;Immunology Procedure note;;ACTIVE;2.69;2.69 +95751-4;Flowsheet;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Flowsheet;Immunology Flowsheet;;ACTIVE;2.69;2.69 +9575-2;Rotavirus Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Rotavirus Ab [Titer] in Serum by Complement fixation;RV Ab Titr Ser CF;;DISCOURAGED;1.0i;2.7 +95752-2;Plan of care note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Plan of care note;Immunology Plan of care note;;ACTIVE;2.69;2.69 +95753-0;Evaluation note;Find;Pt;{Setting};Doc;Immunology;DOC.ONTOLOGY;2;Immunology Evaluation note;Immunology Eval note;;ACTIVE;2.69;2.69 +95754-8;Referral note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Referral note;Allergy Referral note;;ACTIVE;2.69;2.69 +95755-5;Initial evaluation note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Initial evaluation note;Allergy Initial eval note;;ACTIVE;2.69;2.69 +95756-3;Procedure note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy procedure note;Allergy Procedure note;;ACTIVE;2.69;2.69 +95757-1;Progress note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Progress note;Allergy Prog note;;ACTIVE;2.69;2.73 +95758-9;Flowsheet;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Flowsheet;Allergy Flowsheet;;ACTIVE;2.69;2.69 +95759-7;Plan of care note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Plan of care note;Allergy Plan of care note;;ACTIVE;2.69;2.69 +9576-0;Rubella virus Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Rubella virus Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;RUBV Ab CSF IA-aCnc;;ACTIVE;1.0i;2.69 +95760-5;Education note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Education note;Allergy Educ note;;ACTIVE;2.69;2.69 +95761-3;Consultation note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Consult note;Allergy Consult note;;ACTIVE;2.69;2.69 +95762-1;Diagnostic study note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Diagnostic study note;Allergy Diag study note;;ACTIVE;2.69;2.69 +95763-9;Evaluation note;Find;Pt;{Setting};Doc;Allergy;DOC.ONTOLOGY;2;Allergy Evaluation note;Allergy Eval note;;ACTIVE;2.69;2.69 +95764-7;Candida auris DNA;PrThr;Pt;Urine;Ord;Non-probe.amp.tar;MICRO;1;Candida auris DNA [Presence] in Urine by NAA with non-probe detection;C auris DNA Ur Ql NAA+non-probe;;ACTIVE;2.69;2.69 +95765-4;Candida auris DNA;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Candida auris DNA [Presence] in Specimen by NAA with non-probe detection;C auris DNA Spec Ql NAA+non-probe;;ACTIVE;2.69;2.69 +95766-2;Candida auris DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Candida auris DNA [Presence] in Blood by NAA with non-probe detection;C auris DNA Bld Ql NAA+non-probe;;ACTIVE;2.69;2.69 +95767-0;Cefiderocol;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefiderocol [Susceptibility] by Disk diffusion (KB);Cefiderocol Islt KB;;ACTIVE;2.69;2.69 +95768-8;Parathyrin.1-84;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Parathyrin.1-84 [Moles/volume] in Serum or Plasma by Immunoassay;Parathyrin.1-84 SerPl IA-sCnc;;ACTIVE;2.69;2.71 +95769-6;BMPR1A gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;BMPR1A gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;BMPR1A Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.69;2.69 +95770-4;GALT gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;GALT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method;GALT gene Mut Anl Bld/T;;ACTIVE;2.69;2.69 +95771-2;GATA2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;GATA2 gene full mutation analysis in Blood or Tissue by Sequencing;GATA2 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.69 +95772-0;IDH1 gene & IDH2 gene targeted mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;IDH1 and IDH2 genes targeted mutation analysis in Blood or Tissue by Molecular genetics method;IDH1 + IDH2 Mut Anl Bld/T;;ACTIVE;2.69;2.69 +95773-8;ACADM gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;ACADM gene full mutation analysis in Blood or Tissue by Sequencing;ACADM gene Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.69 +95774-6;MSH6 gene deletion+duplication & full mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;MSH6 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method;MSH6 gene Del+Dup + Full Mut Anl Bld/T;;ACTIVE;2.69;2.69 +95775-3;HGSNAT gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;HGSNAT gene full mutation analysis in Blood or Tissue by Sequencing;HGSNAT Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.69 +95776-1;GNS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;GNS gene full mutation analysis in Blood or Tissue by Sequencing;GNS Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.69 +95777-9;ACADS gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;ACADS gene full mutation analysis in Blood or Tissue by Sequencing;ACADS gene Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.69 +9577-8;Saint Louis encephalitis virus Ab;Titr;Pt;CSF;Qn;IF;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;SLEV Ab Titr CSF IF;;ACTIVE;1.0i;2.7 +95778-7;TERT gene promotor region targeted mutation analysis;Find;Pt;Tiss;Doc;Molgen;MOLPATH;1;TERT gene promotor region targeted mutation analysis in Tissue by Molecular genetics method;TERT promotor region Mut Anl Tiss;;ACTIVE;2.69;2.69 +95779-5;TFE3 gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;TFE3 gene rearrangements in Tissue by FISH;TFE3 rearrange Tiss FISH;;ACTIVE;2.69;2.69 +95780-3;TFEB gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;TFEB gene rearrangements in Tissue by FISH;TFEB rearrange Tiss FISH;;ACTIVE;2.69;2.69 +95781-1;ATP7B gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;ATP7B gene full mutation analysis in Blood or Tissue by Sequencing;ATP7B gene Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.69 +95782-9;ABCD1 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;ABCD1 gene full mutation analysis in Blood or Tissue by Sequencing;ABCD1 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.69 +95783-7;ETV6 gene rearrangements;Find;Pt;Bld/Bone mar;Doc;FISH;MOLPATH;1;ETV6 gene rearrangements in Blood or Marrow by FISH;ETV6 rearrange Bld/Mar FISH;;ACTIVE;2.69;2.69 +95784-5;FGFR2 gene rearrangements;Find;Pt;Tiss;Doc;FISH;MOLPATH;1;FGFR2 gene rearrangements in Tissue by FISH;FGFR2 rearrange Tiss FISH;;ACTIVE;2.69;2.69 +95785-2;FOXL2 gene targeted mutation analysis;Find;Pt;Tiss;Doc;Molgen;MOLPATH;1;FOXL2 gene targeted mutation analysis in Tissue by Molecular genetics method;FOXL2 Mut Anl Tiss;;ACTIVE;2.69;2.69 +9578-6;Saint Louis encephalitis virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Saint Louis encephalitis virus Ab [Titer] in Serum by Immunofluorescence;SLEV Ab Titr Ser IF;;ACTIVE;1.0i;2.73 +95786-0;Gene XXX mutation analysis limited to known familial mutations;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Gene XXX mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method;Gene XXX Fam Mut Anl Bld/T;;ACTIVE;2.69;2.69 +95787-8;Adrenal cortical carcinoma probability;Likelihood;Pt;^Patient;Qn;Based on clinical data;CLIN.RISK;2;Adrenal cortical carcinoma probability [Likelihood] based on clinical data;ACC Prob from clin data;;ACTIVE;2.69;2.69 +95788-6;Adrenal malignancy other than adrenal cortical carcinoma probability;Likelihood;Pt;^Patient;Qn;Based on clinical data;CLIN.RISK;2;Adrenal malignancy other than ACC probability [Likelihood] based on clinical data;Other adrenal malig Prob from clin data;;ACTIVE;2.69;2.69 +95789-4;Benign mass probability;Likelihood;Pt;^Patient;Qn;Based on clinical data;CLIN.RISK;2;Benign mass probability [Likelihood] based on clinical data;Benign mass Prob from clin data;;ACTIVE;2.69;2.69 +95790-2;Adrenal cortical carcinoma probability;Likelihood;Pt;^Patient;Qn;Based on clinical+lab data;CLIN.RISK;2;Adrenal cortical carcinoma probability [Likelihood] based on clinical and lab data;ACC Prob from clin+lab data;;ACTIVE;2.69;2.69 +95791-0;Adrenal malignancy other than adrenal cortical carcinoma probability;Likelihood;Pt;^Patient;Qn;Based on clinical+lab data;CLIN.RISK;2;Adrenal malignancy other than ACC probability [Likelihood] based on clinical and lab data;Other adrenal malig Prob clin+lab data;;ACTIVE;2.69;2.69 +95792-8;Benign mass probability;Likelihood;Pt;^Patient;Qn;Based on clinical+lab data;CLIN.RISK;2;Benign mass probability [Likelihood] based on clinical and lab data;Benign mass Prob from clin+lab data;;ACTIVE;2.69;2.69 +95793-6;Immunization priority tier;Type;Pt;^Patient;Nom;;PUBLICHEALTH;2;Immunization priority tier;Immunization priority tier;;ACTIVE;2.69;2.69 +9579-4;Tetrahydrocorticosterone;MRat;24H;Urine;Qn;;CHEM;1;Tetrahydrocorticosterone [Mass/time] in 24 hour Urine;THB 24h Ur-mRate;;ACTIVE;1.0i;2.42 +95794-4;Adrenal insufficiency emergency action plan;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Adrenal insufficiency emergency action plan;Adrenal insufficiency action plan;;ACTIVE;2.69;2.69 +95795-1;HBG1 gene & HBG2 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;HBG1 and HBG2 genes full mutation analysis in Blood or Tissue by Sequencing;HBG1 + HBG2 Full Mut Anl Bld/T Seq;;ACTIVE;2.69;2.73 +95796-9;Opioids panel;-;Pt;Urine;-;Screen;PANEL.DRUG/TOX;1;Opioids panel - Urine by Screen method;Opioids Pnl Ur Scn;;ACTIVE;2.69;2.69 +95797-7;Norfentanyl;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Norfentanyl [Presence] in Urine by Screen method;Norfentanyl Ur Ql Scn;;ACTIVE;2.69;2.69 +95798-5;Normeperidine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Normeperidine [Presence] in Urine by Screen method;Normeperidine Ur Ql Scn;;ACTIVE;2.69;2.69 +95799-3;O-nortramadol;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;O-nortramadol [Presence] in Urine by Screen method;O-nortramadol Ur Ql Scn;;ACTIVE;2.69;2.69 +95800-9;Immunoglobulin light chains.free panel;-;-;Urine;-;;PANEL.CHEM;1;Immunoglobulin light chains.free panel - Urine;Immunoglobulin LC free Pnl Ur;;ACTIVE;2.69;2.69 +95801-7;Immunoglobulin light chains.free & immunofixation panel;-;-;Urine;-;;PANEL.CHEM;1;Immunoglobulin light chains.free and IFE panel - Urine;Immunoglobulin LC free + IFE Pnl Ur;;ACTIVE;2.69;2.74 +9580-2;Thyroxine Ab;ACnc;Pt;Ser;Qn;;SERO;1;Thyroxine (T4) Ab [Units/volume] in Serum;T4 Ab Ser-aCnc;;ACTIVE;1.0i;2.73 +95802-5;Progress note;Find;Pt;{Setting};Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Progress note;Breastfeeding Prog note;;ACTIVE;2.69;2.73 +95803-3;Note;Find;Pt;{Setting};Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Note;Breastfeeding Note;;ACTIVE;2.69;2.69 +95804-1;Note;Find;Pt;Telehealth;Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Telehealth Note;Breastfeeding Telehealth Note;;ACTIVE;2.69;2.69 +95805-8;Evaluation note;Find;Pt;{Setting};Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Evaluation note;Breastfeeding Eval note;;ACTIVE;2.69;2.69 +95806-6;Consultation note;Find;Pt;{Setting};Doc;Breastfeeding;DOC.ONTOLOGY;2;Breastfeeding Consult note;Breastfeeding Consult note;;ACTIVE;2.69;2.69 +95807-4;Chylomicrons;PrThr;Pt;Urine;Ord;;CHEM;1;Chylomicrons [Presence] in Urine;Chylo Ur Ql;;ACTIVE;2.69;2.69 +95808-2;Cholesterol & triglyceride & chylomicrons panel;-;Pt;Urine;-;;PANEL.CHEM;1;Cholesterol and triglyceride and chylomicrons panel - Urine;Cholest+triglyceride+chylomicrons Pnl Ur;;ACTIVE;2.69;2.69 +95809-0;Carbapenem resistance genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance genes [Presence] by Molecular method;CPR genes Islt/Spm Ql;;ACTIVE;2.69;2.69 +9581-0;Western equine encephalitis virus Ab;Titr;Pt;Ser;Qn;IF;MICRO;1;Western equine encephalitis virus Ab [Titer] in Serum by Immunofluorescence;WEEV Ab Titr Ser IF;;ACTIVE;1.0i;2.73 +95810-8;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - discharge;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - discharge [CMS Assessment];;;ACTIVE;2.69;2.7 +95811-6;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - admission;-;-;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - admission [CMS Assessment];;;ACTIVE;2.69;2.7 +95812-4;Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said;Find;RptPeriod;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said during assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.69;2.69 +95813-2;Is there evidence of an acute change in mental status from the patient's baseline;Find;RptPeriod;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Is there evidence of an acute change in mental status from the patient's baseline during assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.69;2.69 +95814-0;Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject;Find;RptPeriod;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject during assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.69;2.69 +95815-7;Altered level of consciousness;Find;RptPeriod;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Altered level of consciousness during assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.69;2.69 +95816-5;Signs and Symptoms of Delirium (from CAM);-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Signs and symptoms of delirium (from CAM) during assessment period [CMS Assessment];;;ACTIVE;2.69;2.72 +95817-3;Oxygen/Gas.total;VFr;24H^max;Inhl gas;Qn;;CLIN;2;Oxygen/Gas total 24 hour maximum Inhaled gas;FIO2 24h Max;;ACTIVE;2.69;2.69 +95818-1;Intravascular mean^during anesthesia;Pres;Pt;Pulmonary artery;Qn;;BP.MOLEC;2;Pulmonary artery Mean blood pressure--during anesthesia;PA BP mean--during anesthesia;;ACTIVE;2.69;2.69 +95819-9;Intravascular diastolic^during anesthesia;Pres;Pt;Pulmonary artery;Qn;;BP.MOLEC;2;Pulmonary artery Diastolic blood pressure--during anesthesia;PA BP dias--during anesthesia;;ACTIVE;2.69;2.69 +95820-7;Intravascular systolic^during anesthesia;Pres;Pt;Pulmonary artery;Qn;;BP.MOLEC;2;Pulmonary artery Systolic blood pressure--during anesthesia;PA BP sys--during anesthesia;;ACTIVE;2.69;2.69 +95821-5;Intravascular mean^during anesthesia;Pres;Pt;Arterial system;Qn;Noninvasive;BP.MOLEC;2;Mean blood pressure by Noninvasive--during anesthesia;BP mean by Noninv--during anesthesia;;ACTIVE;2.69;2.69 +95822-3;Intravascular mean^during anesthesia;Pres;Pt;Arterial system;Qn;;BP.MOLEC;2;Mean blood pressure--during anesthesia;BP mean--during anesthesia;;ACTIVE;2.69;2.69 +95823-1;SARS-related coronavirus E gene;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus E gene [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-rel CoV E gene Sal Ql NAA+probe;;ACTIVE;2.69;2.69 +95824-9;SARS coronavirus 2 ORF1ab region;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 ORF1ab Sal Ql NAA+probe;;ACTIVE;2.69;2.69 +95825-6;SARS coronavirus 2 Ab;PrThr;Pt;Bld.dot;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) Ab [Presence] in DBS by Immunoassay;SARS-CoV-2 Ab DBS Ql IA;;ACTIVE;2.69;2.69 +95826-4;SARS coronavirus 2 RNA panel;-;Pt;Saliva;-;Probe.amp.tar;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) RNA panel - Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 RNA Pnl Sal NAA+probe;;ACTIVE;2.69;2.7 +95827-2;Viable CD3 cells/100 cells.CD3;NFr;Pt;^BPU;Qn;;BLDBK;1;Viable CD3 cells/100 CD3 cells in Blood product unit;Viable CD3 cells/100 CD3 NFr BPU;;ACTIVE;2.69;2.69 +9582-8;Afipia felis Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Afipia felis IgG Ab [Titer] in Serum by Immunofluorescence;A felis IgG Titr Ser IF;;ACTIVE;1.0i;2.7 +95828-0;T cell product characterization panel;-;Pt;^BPU;-;Flow cytometry;PANEL.BLDBK;1;T cell product characterization panel - Blood product unit by Flow cytometry (FC);T cell product panel BPU FC;;ACTIVE;2.69;2.69 +95829-8;Viable CD45 cells/100 cells.CD45;NFr;Pt;^BPU;Qn;;BLDBK;1;Viable CD45 cells/100 CD45 cells in Blood product unit;Viable CD45 cells/100 CD45 NFr BPU;;ACTIVE;2.69;2.69 +95830-6;Hematopoietic progenitor cell product characterization panel;-;Pt;^BPU;-;Flow cytometry;PANEL.BLDBK;1;Hematopoietic progenitor cell product characterization panel - Blood product unit by Flow cytometry (FC);HPC product panel BPU FC;;ACTIVE;2.69;2.69 +95831-4;Lymphocyte dose in hematopoietic progenitor cell transfusion;NCnt;Pt;^Patient;Qn;;BLDBK;1;Lymphocyte dose in hematopoietic progenitor cell transfusion [#/mass];Lymphocyte dose in HPC trsplt Patient;;ACTIVE;2.69;2.69 +95832-2;CD3 dose in hematopoietic progenitor cell transfusion;NCnt;Pt;^Patient;Qn;;BLDBK;1;CD3 dose in hematopoietic progenitor cell transfusion [#/mass];CD3 dose in HPC transplant Patient;;ACTIVE;2.69;2.69 +95833-0;Nucleated cells;Num;Pt;^BPU;Qn;;BLDBK;1;Nucleated cells [#] in Blood product unit;Nuc cell BPU;;ACTIVE;2.69;2.69 +95834-8;Mononuclear cells;Num;Pt;^BPU;Qn;;BLDBK;1;Mononuclear cells [#] in Blood product unit;Mononuc Cells BPU;;ACTIVE;2.69;2.69 +95835-5;Cells.CD34;Num;Pt;^BPU;Qn;;BLDBK;1;CD34 cells [#] in Blood product unit;CD34 Cells BPU;;ACTIVE;2.69;2.69 +9583-6;Afipia felis Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Afipia felis IgM Ab [Titer] in Serum by Immunofluorescence;A felis IgM Titr Ser IF;;ACTIVE;1.0i;2.7 +95836-3;Cells.CD3;Num;Pt;^BPU;Qn;;BLDBK;1;CD3 cells [#] in Blood product unit;CD3 Cells BPU;;ACTIVE;2.69;2.69 +95837-1;Mononuclear cell dose in hematopoietic progenitor cell transfusion;NCnt;Pt;^Patient;Qn;;BLDBK;1;Mononuclear cell dose in hematopoietic progenitor cell transfusion [#/mass];Mono Cell dose in HPC transplant Patient;;ACTIVE;2.69;2.69 +95838-9;Nucleated cells.recovered/Nucleated cells.total;NFr;Pt;^Patient;Qn;;BLDBK;1;Nucleated cells.recovered/Nucleated cells.total;TNC Recovered/TNC NFr Patient;;ACTIVE;2.69;2.69 +95839-7;Mononuclear cells.recovered/Mononuclear cells.total;NFr;Pt;^Patient;Qn;;BLDBK;1;Mononuclear cells.recovered/Mononuclear cells.total;Monos Recovered/Monos Total NFr Patient;;ACTIVE;2.69;2.69 +95840-5;Microscopic exam;Imp;Pt;Sputum;Nar;Microscopy;HEM/BC;1;Microscopic exam [Interpretation] in Sputum by Microscopy Narrative;Microscopic Spt Micro-Imp;;ACTIVE;2.69;2.69 +95841-3;Monocytes+Macrophages/100 leukocytes;NFr;Pt;Sputum;Qn;Manual count;HEM/BC;1;Monocytes+Macrophages/100 leukocytes in Sputum by Manual count;Monos+Macros/leuk NFr Spt Manual;;ACTIVE;2.69;2.69 +95842-1;Lymphocytes/100 leukocytes;NFr;Pt;Sputum;Qn;Manual count;HEM/BC;1;Lymphocytes/100 leukocytes in Sputum by Manual count;Lymphocytes/leuk NFr Spt Manual;;ACTIVE;2.69;2.69 +95843-9;Neutrophils/100 leukocytes;NFr;Pt;Sputum;Qn;Manual count;HEM/BC;1;Neutrophils/100 leukocytes in Sputum by Manual count;Neutrophils/leuk NFr Spt Manual;;ACTIVE;2.69;2.69 +9584-4;Babesia sp Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia sp IgG Ab [Titer] in Serum by Immunofluorescence;Babesia IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +95844-7;Epithelial cells.squamous;NCnc;Pt;Sputum;Qn;Manual count;HEM/BC;1;Epithelial cells.squamous [#/volume] in Sputum by Manual count;Squamous # Spt Manual;;ACTIVE;2.69;2.69 +95845-4;Nucleated cells;NCnc;Pt;Sputum;Qn;Manual count;HEM/BC;1;Nucleated cells [#/volume] in Sputum by Manual count;Nuc cell # Spt Manual;;ACTIVE;2.69;2.69 +95846-2;Cell count & Differential panel;-;Pt;Sputum;Qn;Manual count;PANEL.HEM/BC;1;Cell count and Differential panel - Sputum by Manual count;Cell Cnt + Diff Pnl Spt Manual;;ACTIVE;2.69;2.69 +95847-0;Somatotropin^90M post dose macimorelin;MCnc;Pt;Ser;Qn;IA;CHEM;1;Somatotropin [Mass/volume] in Serum by Immunoassay --90 minutes post dose macimorelin;GH 90M p Macimorelin Ser IA-mCnc;;ACTIVE;2.69;2.69 +95848-8;Somatotropin^60M post dose macimorelin;MCnc;Pt;Ser;Qn;IA;CHEM;1;Somatotropin [Mass/volume] in Serum by Immunoassay --60 minutes post dose macimorelin;GH 60M p Macimorelin Ser IA-mCnc;;ACTIVE;2.69;2.69 +95849-6;Somatotropin^45M post dose macimorelin;MCnc;Pt;Ser;Qn;IA;CHEM;1;Somatotropin [Mass/volume] in Serum by Immunoassay --45 minutes post dose macimorelin;GH 45M p Macimorelin Ser IA-mCnc;;ACTIVE;2.69;2.69 +95850-4;Somatotropin^30M post dose macimorelin;MCnc;Pt;Ser;Qn;IA;CHEM;1;Somatotropin [Mass/volume] in Serum by Immunoassay --30 minutes post dose macimorelin;GH 30M p Macimorelin Ser IA-mCnc;;ACTIVE;2.69;2.69 +9585-1;Babesia sp Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Babesia sp IgM Ab [Titer] in Serum by Immunofluorescence;Babesia IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +95851-2;Somatotropin post macimorelin stimulation panel;-;Pt;Ser;-;IA;PANEL.CHEM;1;Somatotropin post macimorelin stimulation panel - Serum by Immunoassay;GH p Macimorelin Stil Pnl Ser IA;;ACTIVE;2.69;2.69 +95852-0;LCDS v4.00 - Signs and Symptoms of Delirium (from CAM);-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Signs and Symptoms of Delirium (from CAM) during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95853-8;LCDS v4.00 - Acute onset and fluctuating course;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Acute onset and fluctuating course during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95854-6;LCDS v4.00 - Cognitive patterns;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Cognitive patterns during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95855-3;Did the (abnormal) behavior fluctuate during the day, that is, tend to come and go or increase and decrease in severity;Find;RptPeriod;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Did the (abnormal) behavior fluctuate during the day, that is, tend to come and go or increase and decrease in severity during assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.69;2.69 +95856-1;LCDS v4.00 - Altered level of consciousness;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Altered level of consciousness during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95857-9;Level of consciousness - Alert (normal);Find;RptPeriod;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Level of consciousness - Alert (normal) during assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.69;2.69 +95858-7;Level of consciousness - Vigilant or lethargic or stupor or coma;Find;RptPeriod;^Patient;Ord;CAM.CMS;SURVEY.CMS;4;Level of consciousness - Vigilant or lethargic or stupor or coma during assessment period [CAM.CMS];;"Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.";ACTIVE;2.69;2.69 +95859-5;LCDS v4.00 - Self-care - admission performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Self-care - admission performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95860-3;LCDS v4.00 - Self-care - discharge goal;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Self-care - discharge goal [CMS Assessment];;;ACTIVE;2.69;2.69 +95861-1;LCDS v4.00 - Self-care - discharge performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Self-care - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95862-9;LCDS v4.00 - Mobility - discharge goal;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Mobility - discharge goal [CMS Assessment];;;ACTIVE;2.69;2.69 +95863-7;LCDS v4.00 - Bladder and bowel - planned discharge;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Bladder and bowel - planned discharge during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95864-5;LCDS v4.00 - Active diagnoses;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Active diagnoses [CMS Assessment];;;ACTIVE;2.69;2.69 +95865-2;LCDS v4.00 - Swallowing &or nutritional status;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v4.00 - Swallowing/nutritional status [CMS Assessment];;;ACTIVE;2.69;2.69 +95866-0;BRIEF health literacy screening tool;-;Pt;^Patient;-;BRIEF;PANEL.SURVEY.BRIEF;4;BRIEF health literacy screening tool [BRIEF];;;ACTIVE;2.69;2.69 +95867-8;Help reading hospital materials;Find;Pt;^Patient;Ord;;CLIN;2;Help reading hospital materials;Help read hosp materials;;ACTIVE;2.69;2.69 +95868-6;Difficulty understanding written information about medical condition;Find;Pt;^Patient;Ord;;CLIN;2;Difficulty understanding written information about medical condition;Diff understand med cond;;ACTIVE;2.69;2.69 +9586-9;Borrelia burgdorferi Ab;Imp;Pt;Ser;Nom;;MICRO;1;Borrelia burgdorferi Ab [Interpretation] in Serum;B burgdor Ab Ser-Imp;;ACTIVE;1.0i;2.74 +95869-4;Problem understanding medical condition;Find;Pt;^Patient;Ord;;CLIN;2;Problem understanding medical condition;Prob understand med cond;;ACTIVE;2.69;2.69 +95870-2;Confidence filling out medical forms;Find;Pt;^Patient;Ord;;CLIN;2;Confidence filling out medical forms;Conf fill med form;;ACTIVE;2.69;2.69 +95871-0;Total score;Score;Pt;^Patient;Qn;BRIEF;SURVEY.BRIEF;4;Total score [BRIEF];;;ACTIVE;2.69;2.72 +95872-8;Brief cognitive assessment tool short form;-;Pt;^Patient;-;BCAT;PANEL.SURVEY.GNHLTH;4;Brief cognitive assessment tool short form [BCAT];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +95873-6;BCAT short form total score;Score;Pt;^Patient;Qn;BCAT;SURVEY.GNHLTH;4;BCAT short form total score [BCAT];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +95874-4;BCAT short form memory score;Score;Pt;^Patient;Qn;BCAT;SURVEY.GNHLTH;4;BCAT short form memory score [BCAT];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +95875-1;Brief anxiety and depression scale;-;Pt;^Patient;-;BADS;PANEL.SURVEY.MTLHLTH;4;Brief anxiety and depression scale [BADS];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +95876-9;Total score;Score;Pt;^Patient;Qn;BADS;SURVEY.MTLHLTH;4;Total score [BADS];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +9587-7;Borrelia burgdorferi 41kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor41kD IgM Ser Ql IB;;ACTIVE;1.0i;2.73 +95877-7;Depression score;Score;Pt;^Patient;Qn;BADS;SURVEY.MTLHLTH;4;Depression score [BADS];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +95878-5;Anxiety score;Score;Pt;^Patient;Qn;BADS;SURVEY.MTLHLTH;4;Anxiety score [BADS];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +95879-3;Healthcare personnel with known health status;Num;Pt;^Event;Qn;;PUBLICHEALTH;2;Healthcare personnel with known health status [#];HCP with known health status;;ACTIVE;2.69;2.69 +95880-1;Hospitalizations/100,000 population;NFr;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Event-associated hospitalization rate per 100,000 population in a reporting period;Hospitalization rate per 100,000 RptPeriod;;ACTIVE;2.69;2.69 +95881-9;Laboratory test results reported;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Event-associated test results reported [#] during reporting period;Lab test results reported in RptPeriod;;ACTIVE;2.69;2.69 +95882-7;Positive laboratory test results reported;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Positive event-associated test results reported [#] during reporting period;Pos lab test results in RptPeriod;;ACTIVE;2.69;2.69 +95883-5;Positive laboratory test results reported/Laboratory test results reported;NFr;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Percent positive event-associated test results reported [#] during reporting period;% pos lab test results in RptPeriod;;ACTIVE;2.69;2.69 +95884-3;Data collected;Date;Pt;Report;Qn;;PUBLICHEALTH;2;Date data collected for Report;Date data collected for Report;;ACTIVE;2.69;2.69 +9588-5;Borrelia burgdorferi 18kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 18kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor18kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95885-0;Inpatient beds;Num;Pt;{Setting};Qn;;PUBLICHEALTH;2;Inpatient beds [#];Inpt beds;;ACTIVE;2.69;2.69 +95886-8;Inpatient beds occupied;Num;Pt;{Setting};Qn;;PUBLICHEALTH;2;Inpatient beds occupied [#];Inpt beds occup;;ACTIVE;2.69;2.69 +95887-6;Inpatient beds occupied/Inpatient beds;NFr;Pt;{Setting};Qn;;PUBLICHEALTH;2;Inpatient beds occupied/Inpatient beds;Inpt beds occup/Inpt beds NFr;;ACTIVE;2.69;2.69 +95888-4;Inpatient beds occupied by patients with disease of interest;Num;Pt;{Setting};Qn;;PUBLICHEALTH;2;Inpatient beds occupied by patients with disease of interest [#];Beds occup w illness;;ACTIVE;2.69;2.69 +95889-2;Inpatient beds occupied by patients with disease of interest/Inpatient beds occupied;NFr;Pt;{Setting};Qn;;PUBLICHEALTH;2;Inpatient beds occupied by patients with disease of interest/Inpatient beds occupied;Beds occup w illness/Inpt beds occup NFr;;ACTIVE;2.69;2.69 +958-9;C super little w Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;C sup(w) Ag [Presence] on Red Blood Cells from Blood product unit;C sup(w) Ag RBC BPU Ql;;ACTIVE;1.0;2.7 +95890-0;Intensive care unit beds occupied;Num;Pt;{Setting};Qn;;PUBLICHEALTH;2;Intensive care unit beds occupied [#];ICU beds occupied;;ACTIVE;2.69;2.69 +95891-8;Intensive care unit beds occupied/Intensive care unit beds;NFr;Pt;{Setting};Qn;;PUBLICHEALTH;2;Intensive care unit beds occupied/ICU beds;ICU beds occupied/ICU beds NFr;;ACTIVE;2.69;2.69 +95892-6;Healthcare personnel status;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Healthcare personnel status [CDC Emergency Operations Centers];;;ACTIVE;2.69;2.69 +9589-3;Borrelia burgdorferi 23kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor23kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95893-4;Hospital or facility beds utilization panel;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Hospital or facility beds utilization panel [CDC Emergency Operations Centers];;;ACTIVE;2.69;2.69 +95894-2;Deaths/100,000 population;NFr;Pt;^Event;Qn;;PUBLICHEALTH;2;Total event-associated death rate per 100,000 population;Death rate per 100,000 pop;;ACTIVE;2.69;2.69 +95895-9;Start date;Date;Pt;^Event;Qn;;PUBLICHEALTH;2;Event start date;Event start date;;ACTIVE;2.69;2.69 +95896-7;Increase or decrease in cases compared to previous reporting period;NumDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Increase or decrease in event-associated cases compared to previous reporting period [#];Event cases # since prev RptPeriod;;ACTIVE;2.69;2.69 +95897-5;Percent increase or decrease in cases compared to previous reporting period;PctDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Percent increase or decrease in event-associated cases compared to previous reporting period;% diff in cases since prev RptPeriod;;ACTIVE;2.69;2.69 +95898-3;All-cause deaths since start of event;Num;Pt;^Population;Qn;;PUBLICHEALTH;2;All-cause deaths since start of event;All-cause deaths since start of event;;ACTIVE;2.69;2.69 +95899-1;Deaths;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Event-associated deaths [#] during reporting period;Event deaths # in RptPeriod;;ACTIVE;2.69;2.69 +95900-7;Percent increase or decrease in deaths compared to previous reporting period;PctDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Percent increase or decrease in event-associated deaths compared to previous reporting period;% diff in deaths since prev RptPeriod;;ACTIVE;2.69;2.69 +9590-1;Borrelia burgdorferi 28kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 28kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor28kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95901-5;Hospitalizations;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Event-associated hospitalizations [#] during reporting period;Hospitalizations # in RptPeriod;;ACTIVE;2.69;2.69 +95902-3;Hospitalizations;Num;Pt;^Event;Qn;;PUBLICHEALTH;2;Total event-associated hospitalizations [#];Total Event hospitalizations;;ACTIVE;2.69;2.69 +95903-1;Cases among healthcare personnel;Num;Pt;^Event;Qn;;PUBLICHEALTH;2;Total event-associated cases among healthcare personnel [#];Total Event cases among HCP;;ACTIVE;2.69;2.69 +95904-9;Cases among healthcare personnel;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Event-associated cases among healthcare personnel [#] during reporting period;Event HCP cases dur RptPeriod;;ACTIVE;2.69;2.69 +95905-6;Increase or decrease in cases among healthcare personnel compared to previous reporting period;NumDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Increase or decrease in event-associated cases among healthcare personnel compared to previous reporting period [#];Event HCP cases # since prev RptPeriod;;ACTIVE;2.69;2.69 +95906-4;Percent increase or decrease in cases among healthcare personnel compared to previous reporting period;PctDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Percent increase or decrease in event-associated cases among healthcare personnel compared to previous reporting period;% diff in HCP cases since prev RptPeriod;;ACTIVE;2.69;2.69 +95907-2;Deaths among healthcare personnel;Num;Pt;^Event;Qn;;PUBLICHEALTH;2;Total event-associated deaths among healthcare personnel [#];Total Event HCP deaths #;;ACTIVE;2.69;2.69 +95908-0;Deaths among healthcare personnel;Num;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Event-associated deaths among healthcare personnel [#] during reporting period;Event HCP deaths # in RptPeriod;;ACTIVE;2.69;2.69 +95909-8;Increase or decrease in deaths among healthcare personnel compared to previous reporting period;NumDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Increase or decrease in event-associated deaths among healthcare personnel compared to previous reporting period [#];Event HCP deaths # since prev RptPeriod;;ACTIVE;2.69;2.69 +95910-6;Percent increase or decrease in deaths among healthcare personnel compared to previous reporting period;PctDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Percent increase or decrease in event-associated deaths among healthcare personnel compared to previous reporting period [#];% diff in HCP deaths since prev RptPeriod;;ACTIVE;2.69;2.69 +95911-4;Increase or decrease in deaths compared to previous reporting period;NumDiff;RptPeriod;^Event;Qn;;PUBLICHEALTH;2;Increase or decrease in event-associated deaths compared to previous reporting period [#];Event deaths # since prev RptPeriod;;ACTIVE;2.69;2.69 +95912-2;Pneumocystis jiroveci DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Pneumocystis jiroveci DNA [Presence] in Tissue by NAA with probe detection;P jiroveci DNA Tiss Ql NAA+probe;;ACTIVE;2.69;2.69 +95913-0;Coccidioides sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Coccidioides sp DNA [Presence] in Tissue by NAA with probe detection;Coccidioides DNA Tiss Ql NAA+probe;;ACTIVE;2.69;2.69 +95914-8;Blastomyces sp DNA;PrThr;Pt;Tiss;Ord;Probe.amp.tar;MICRO;1;Blastomyces sp DNA [Presence] in Tissue by NAA with probe detection;Blastomyces DNA Tiss Ql NAA+probe;;ACTIVE;2.69;2.69 +95915-5;Coccidioides sp DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Coccidioides sp DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Coccidioides DNA Lower resp Ql NAA+probe;;ACTIVE;2.69;2.69 +95916-3;Blastomyces sp DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Blastomyces sp DNA [Presence] in Lower respiratory specimen by NAA with probe detection;Blastomyces DNA Lower resp Ql NAA+probe;;ACTIVE;2.69;2.69 +95917-1;Histoplasma capsulatum DNA;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Histoplasma capsulatum DNA [Presence] in Lower respiratory specimen by NAA with probe detection;H capsul DNA Lower resp Ql NAA+probe;;ACTIVE;2.69;2.69 +95918-9;Fungal pathogens panel;-;Pt;Tiss;-;Probe.amp.tar;PANEL.MICRO;1;Fungal pathogens panel - Tissue by NAA with probe detection;Fungal path panel Tiss NAA+probe;;ACTIVE;2.69;2.69 +9591-9;Borrelia burgdorferi 30kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 30kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor30kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95919-7;Fungal pathogens panel;-;Pt;Respiratory.lower;-;Probe.amp.tar;PANEL.MICRO;1;Fungal pathogens panel - Lower respiratory specimen by NAA with probe detection;Fungal path panel Lower resp NAA+probe;;ACTIVE;2.69;2.69 +95920-5;Galantamine;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Galantamine [Mass/volume] in Serum, Plasma or Blood;Galantamine SerPlBld-mCnc;;ACTIVE;2.69;2.69 +95921-3;Hydroxychloroquine;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Hydroxychloroquine [Mass/volume] in Blood;OH-Chloroquine Bld-mCnc;;ACTIVE;2.69;2.69 +95922-1;Tocilizumab;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Tocilizumab [Mass/volume] in Serum;Tocilizumab Ser-mCnc;;ACTIVE;2.69;2.69 +95923-9;Multisection^W stress+W contrast IV;Find;Pt;Chest>Heart;Doc;MR;RAD;2;MR Heart W stress and W contrast IV;MR Hrt W stress+W contr IV;;ACTIVE;2.69;2.69 +95924-7;Multisection for bone density;Find;Pt;Whole body>Skeletal system;Doc;CT;RAD;2;CT Skeletal system Multisection for bone density;CT Skeletal for BMD;;ACTIVE;2.69;2.69 +95925-4;Multisection for bone density;Find;Pt;Whole body>Skeletal system.axial;Doc;CT;RAD;2;CT Skeletal system.axial Multisection for bone density;CT Skeletal Sys Axial for BMD;;ACTIVE;2.69;2.69 +95926-2;Multisection for bone density;Find;Pt;Whole body>Skeletal system.peripheral;Doc;CT;RAD;2;CT Skeletal system.peripheral Multisection for bone density;CT Skeletal Sys Periph for BMD;;ACTIVE;2.69;2.69 +9592-7;Borrelia burgdorferi 39kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor39kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95927-0;Multisection for bone density;Find;Pt;Upper extremity>Radius;Doc;CT;RAD;2;CT Radius Multisection for bone density;CT Radius for BMD;;ACTIVE;2.69;2.69 +95928-8;Multisection for bone density;Find;Pt;Upper extremity>Wrist;Doc;CT;RAD;2;CT Wrist Multisection for bone density;CT Wrist for BMD;;ACTIVE;2.69;2.69 +95929-6;Multisection for bone density;Find;Pt;Lower extremity>Calcaneus;Doc;CT;RAD;2;CT Calcaneus Multisection for bone density;CT Heel for BMD;;ACTIVE;2.69;2.69 +95930-4;Pulmonary vasodilator test panel;-;Pt;^Patient;-;;PANEL.PULM;2;Pulmonary vasodilator test panel;Pulm vasodil pnl;;ACTIVE;2.69;2.69 +95931-2;Drug given for pulmonary vasodilator test;ID;Pt;^Patient;Nom;;PULM;2;Drug given for pulmonary vasodilator test [Identifier];Drug given for pulm vaso test;;ACTIVE;2.69;2.69 +95932-0;Pulmonary hypertension;Class;Pt;^Patient;Nom;;PULM;2;Pulmonary hypertension [Class];Pulmonary hypertension class;;ACTIVE;2.69;2.69 +95933-8;Transpulmonary pressure gradient;PressDiff;Pt;Pulmonary artery;Qn;Calculated;PULM;2;Transpulmonary pressure gradient;Transpulm press grad;;ACTIVE;2.69;2.69 +95934-6;Volume;Find;Pt;Heart.ventricle.left;Ord;US+Estimated;CARD.US;2;Left ventricular Volume by estimated by US;LV Volume US+est;;ACTIVE;2.69;2.69 +9593-5;Borrelia burgdorferi 41kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 41kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor41kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95935-3;Volume;Find;Pt;Heart.ventricle.right;Ord;US+Estimated;CARD.US;2;Right ventricular Volume by estimated by US;RV Volume US+est;;ACTIVE;2.69;2.69 +95936-1;Contractility;Find;Pt;Heart.ventricle.right;Ord;US+Estimated;CARD.US;2;Right ventricular Contractility by estimated by US;RV Contractility US+est;;ACTIVE;2.69;2.69 +95937-9;Pulmonary vasodilation induced;Find;Pt;Pulmonary vasculature;Ord;;PULM;2;Pulmonary vasodilation induced;Pulm vasodilation induced;;ACTIVE;2.69;2.69 +95938-7;Diameter.transverse;Prctl;Pt;Cerebellum^Fetus;Qn;Per estimated gestational age;OB.US;2;Fetal Cerebellum Diameter transverse percentile per estimated gestational age;Fetal TCD US Prctl per est GA;;ACTIVE;2.69;2.69 +95939-5;Length.crown rump;Prctl;Pt;^Fetus;Qn;Per estimated gestational age;OB.US;2;Fetal Crown Rump length percentile per estimated gestational age;Fet CRL US Prctl per est GA;;ACTIVE;2.69;2.72 +95940-3;Diameter.biparietal;Prctl;Pt;Head^Fetus;Qn;Per estimated gestational age;OB.US;2;Fetal Head Diameter.biparietal percentile per estimated gestational age;Fet BPD US Prctl per est GA;;ACTIVE;2.69;2.69 +95941-1;Influenza virus A & Influenza virus B & SARS coronavirus 2 & Respiratory syncytial virus RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory specimen by NAA with probe detection;FLUABV+SARS-CoV-2+RSV Pnl Resp NAA+probe;;ACTIVE;2.69;2.73 +95942-9;Influenza virus A & Influenza virus B & SARS coronavirus+SARS coronavirus 2 Ag panel;-;Pt;Respiratory.upper;-;IA.rapid;PANEL.MICRO;1;Influenza virus A and B and SARS-CoV+SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay;FLUABV+SARS-CoV Ag Pnl Up resp IA.rapid;;ACTIVE;2.69;2.69 +9594-3;Borrelia burgdorferi 45kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 45kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor45kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95943-7;IRF-PAI v3.0 - Hearing, speech, and vision - admission;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Hearing, speech, and vision - admission during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95944-5;IRF-PAI v3.0 - Staff assessment for mental status;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Staff assessment for mental status during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95945-2;IRF-PAI v3.0 - Swallowing &or nutritional status - admission;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Swallowing/nutritional status - admission during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95946-0;Usual ability to swallow;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Usual ability to swallow during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +95947-8;Alcuronium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Alcuronium IgE Ab [Units/volume] in Serum;Alcuronium IgE Qn;;ACTIVE;2.69;2.69 +95948-6;Aloe vera Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aloe vera IgE Ab [Units/volume] in Serum;Aloe vera IgE Qn;;ACTIVE;2.69;2.69 +95949-4;Glucan 1,4 alpha glucosidase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Glucan 1,4 alpha glucosidase IgE Ab [Units/volume] in Serum;Glucan 1,4-A glucosidase IgE Qn;;ACTIVE;2.69;2.69 +9595-0;Borrelia burgdorferi 58kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 58kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor58kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95950-2;Arnica montana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Arnica montana IgE Ab [Units/volume] in Serum;A montana IgE Qn;;ACTIVE;2.69;2.69 +95951-0;Azalea spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Azalea spp IgE Ab [Units/volume] in Serum;Azalea spp IgE Qn;;ACTIVE;2.69;2.69 +95952-8;Azorubine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Azorubine IgE Ab [Units/volume] in Serum;Azorubine IgE Qn;;ACTIVE;2.69;2.69 +95953-6;(Gentamycin+Lincomycin+Neomycin+Streptomycin+Tobramycin) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aminoglycoside Mix (Gentamycin+Lincomycin+Neomycin+Streptomycin+Tobramycin) IgE Ab [Units/volume] in Serum;Aminoglycoside Mix IgE Qn;;ACTIVE;2.69;2.72 +95954-4;Pinus pinea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Stone pine IgE Ab [Units/volume] in Serum;Stone pine IgE Qn;;ACTIVE;2.69;2.69 +95955-1;Butylparaben Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Butylparaben IgE Ab [Units/volume] in Serum;Butylparaben IgE Qn;;ACTIVE;2.69;2.69 +95956-9;Cymbopogon citratus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lemon grass IgE Ab [Units/volume] in Serum;Lemon grass IgE Qn;;ACTIVE;2.69;2.69 +95957-7;Aspalathus linearis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Rooibos IgE Ab [Units/volume] in Serum;Rooibos IgE Qn;;ACTIVE;2.69;2.69 +95958-5;Cichorium intybus var foliosum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Italian chicory Radicchio IgE Ab [Units/volume] in Serum;Italian chicory Rad IgE Qn;;ACTIVE;2.69;2.69 +95959-3;Scorzonera hispanica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Black salsify IgE Ab [Units/volume] in Serum;Black salsify IgE Qn;;ACTIVE;2.69;2.69 +95960-1;Tetrachlorophthalic anhydride Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tetrachlorophthalic anhydride IgE Ab [Units/volume] in Serum;TCPA IgE Qn;;ACTIVE;2.69;2.69 +95961-9;House dust Japan Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Japan IgE Ab [Units/volume] in Serum;House dust Japan IgE Qn;;ACTIVE;2.69;2.69 +95962-7;(Quercus alba+Quercus rubra+Quercus velutina) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tree Allergen Oak Mix (White oak+Red oak+Black Oak) IgE Ab [Units/volume] in Serum;Tree Allerg Oak Mix IgE Qn;;ACTIVE;2.69;2.72 +95963-5;Cydonia oblonga Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Quince IgE Ab [Units/volume] in Serum;Quince IgE Qn;;ACTIVE;2.69;2.69 +95964-3;Ribes uva-crispa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European gooseberry IgE Ab [Units/volume] in Serum;Euro gooseberry IgE Qn;;ACTIVE;2.69;2.69 +95965-0;Ethylparaben Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ethylparaben IgE Ab [Units/volume] in Serum;Ethylparaben IgE Qn;;ACTIVE;2.69;2.69 +95966-8;Aspergillus glaucus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus glaucus IgE Ab [Units/volume] in Serum;A glaucus IgE Qn;;ACTIVE;2.69;2.69 +95967-6;Freesia spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Freesia spp IgE Ab [Units/volume] in Serum;Freesia spp IgE Qn;;ACTIVE;2.69;2.69 +9596-8;Borrelia burgdorferi 66kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 66kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor66kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95968-4;Gerbera spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gerbera spp IgE Ab [Units/volume] in Serum;Gerbera spp IgE Qn;;ACTIVE;2.69;2.69 +95969-2;Intensive care unit beds;Num;Pt;{Setting};Qn;;PUBLICHEALTH;2;ICU beds [#];ICU beds;;ACTIVE;2.69;2.69 +959-7;C super little w Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;C sup(w) Ag [Presence] on Red Blood Cells from Donor;C sup(w) Ag RBC Donr Ql;;ACTIVE;1.0;2.7 +95970-0;SARS coronavirus 2 specific TCRB gene rearrangements;PrThr;Pt;Bld;Ord;Sequencing;MICRO;1;SARS-CoV-2 (COVID-19) specific TCRB gene rearrangements [Presence] in Blood by Sequencing;SARS-CoV-2 TCRB Bld Ql Seq;;ACTIVE;2.69;2.69 +95971-8;SARS coronavirus 2 stimulated gamma interferon;PrThr;Pt;Bld;Ord;;MICRO;1;SARS-CoV-2 stimulated gamma interferon [Presence] in Blood;SARS-CoV-2 IFN-g Bld Ql;;ACTIVE;2.69;2.7 +95972-6;SARS coronavirus 2 stimulated gamma interferon release by T-cells^^corrected for background;ACnc;Pt;Bld;Qn;;MICRO;1;SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] corrected for background in Blood;SARS CoV-2 IFN-g Tcel bkgrd cor Bld-aCnc;;ACTIVE;2.69;2.72 +95973-4;SARS coronavirus 2 stimulated gamma interferon release by T-cells;ACnc;Pt;Bld;Qn;;MICRO;1;SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] in Blood;SARS-CoV-2 IFN-g T cells Bld-aCnc;;ACTIVE;2.69;2.7 +95974-2;SARS coronavirus 2 stimulated gamma interferon panel;-;Pt;Bld;-;;PANEL.MICRO;1;SARS-CoV-2 stimulated gamma interferon panel - Blood;SARS-CoV-2 IFN-g Pnl Bld;;ACTIVE;2.69;2.7 +95975-9;Skindex-16;-;1W;^Patient;-;Skindex-16;PANEL.SURVEY.GNHLTH;4;Skindex-16 [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +9597-6;Borrelia burgdorferi 93kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 93kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor93kD IgG Ser Ql IB;;ACTIVE;1.0i;2.73 +95976-7;Symptom score;Score;1W;^Patient;Qn;Skindex-16;SURVEY.GNHLTH;4;Symptom score [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95977-5;Emotion score;Score;1W;^Patient;Qn;Skindex-16;SURVEY.GNHLTH;4;Emotion score [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95978-3;Function score;Score;1W;^Patient;Qn;Skindex-16;SURVEY.GNHLTH;4;Function score [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95979-1;Total score;Score;1W;^Patient;Qn;Skindex-16;SURVEY.GNHLTH;4;Total score [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95980-9;During the past 1W, how often have you been bothered by your skin condition itching;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by your skin condition itching [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95981-7;During the past 1W, how often have you been bothered by your skin condition burning or stinging;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by your skin condition burning or stinging [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95982-5;During the past 1W, how often have you been bothered by your skin condition being irritated;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by your skin condition being irritated [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95983-3;During the past 1W, how often have you been bothered by the persistence or reoccurrence of your skin condition;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by the persistence or reoccurrence of your skin condition [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +9598-4;Borrelia burgdorferi 23kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 23kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor23kD IgM Ser Ql IB;;ACTIVE;1.0i;2.73 +95984-1;During the past 1W, how often have you been bothered by worry about your skin condition;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by worry about your skin condition [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95985-8;During the past 1W, how often have you been bothered by the appearance of your skin condition;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by the appearance of your skin condition [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95986-6;During the past 1W, how often have you been bothered by frustration about your skin condition;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by frustration about your skin condition [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95987-4;During the past 1W, how often have you been bothered by embarrassment about your skin condition;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by embarrassment about your skin condition [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95988-2;During the past 1W, how often have you been bothered by being annoyed about your skin condition;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by being annoyed about your skin condition [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95989-0;During the past 1W, how often have you been bothered by feeling depressed about your skin condition;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by feeling depressed about your skin condition [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95990-8;During the past 1W, how often have you been bothered by the effects of your skin condition on your interactions with others;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by the effects of your skin condition on your interactions with others [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95991-6;During the past 1W, how often have you been bothered by the effects of your skin condition on your desire to be with people;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by the effects of your skin condition on your desire to be with people [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +9599-2;Borrelia burgdorferi 39kD Ab.IgM;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 39kD IgM Ab [Presence] in Serum by Immunoblot;B burgdor39kD IgM Ser Ql IB;;ACTIVE;1.0i;2.73 +95992-4;During the past 1W, how often have you been bothered by your skin condition making it hard to show affection;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by your skin condition making it hard to show affection [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95993-2;During the past 1W, how often have you been bothered by the effects of your skin condition on your daily activities;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by the effects of your skin condition on your daily activities [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95994-0;During the past 1W, how often have you been bothered by your skin condition making it hard to work or do what you enjoy;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by your skin condition making it hard to work or do what you enjoy [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95995-7;During the past 1W, how often have you been bothered by your skin condition hurting;Find;1W;^Patient;Ord;Skindex-16;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by your skin condition hurting [Skindex-16];;Copyright © 2001 The Regents of the University of California. Used with permission.;ACTIVE;2.69;2.69 +95996-5;Skindex-29;-;4W;^Patient;-;Skindex-29;PANEL.SURVEY.GNHLTH;4;Skindex-29 [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +95997-3;Symptom score;Score;4W;^Event;Qn;Skindex-29;SURVEY.GNHLTH;4;Symptom score [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +95998-1;Emotion score;Score;4W;^Event;Qn;Skindex-29;SURVEY.GNHLTH;4;Emotion score [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +95999-9;Function score;Score;4W;^Event;Qn;Skindex-29;SURVEY.GNHLTH;4;Function score [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96000-5;Total score;Score;4W;^Event;Qn;Skindex-29;SURVEY.GNHLTH;4;Total score [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96001-3;During the past 4W, my skin hurts;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin hurts [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96002-1;During the past 4W, my skin condition affects how well I sleep;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition affects how well I sleep [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96003-9;During the past 4W, I worry that my skin condition may be serious;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I worry that my skin condition may be serious [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96004-7;During the past 4W, my skin condition makes it hard to work or do hobbies;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition makes it hard to work or do hobbies [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96005-4;During the past 4W, my skin condition affects my social life;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition affects my social life [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96006-2;During the past 4W, my skin condition makes me feel depressed;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition makes me feel depressed [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96007-0;During the past 4W, my skin condition burns or stings;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition burns or stings [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +9600-8;Taenia solium larva Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva Ab [Presence] in Serum by Immunoblot;T sol lar Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96008-8;During the past 4W, I tend to stay at home because of my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I tend to stay at home because of my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96009-6;During the past 4W, I worry about getting scars from my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I worry about getting scars from my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96010-4;During the past 4W, my skin itches;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin itches [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96011-2;During the past 4W, my skin condition affects how close I can be with those I love;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition affects how close I can be with those I love [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96012-0;During the past 4W, I am ashamed of my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I am ashamed of my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96013-8;During the past 4W, I worry that my skin condition may get worse;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I worry that my skin condition may get worse [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96014-6;During the past 4W, I tend to do things by myself because of my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I tend to do things by myself because of my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96015-3;During the past 4W, my skin condition makes me tired;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition makes me tired [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +9601-6;Taenia solium larva 13kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 13kD Ab [Presence] in Serum by Immunoblot;T sol lar13kD Ab Ser Ql IB;;ACTIVE;1.0i;2.58 +96016-1;During the past 4W, my skin condition interferes with my sex life;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition interferes with my sex life [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96017-9;During the past 4W, I am annoyed by my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I am annoyed by my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96018-7;During the past 4W, my skin condition bleeds;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks,, my skin condition bleeds [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96019-5;During the past 4W, I am humiliated by my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I am humiliated by my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96020-3;During the past 4W, my skin condition affects my desire to be with people;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition affects my desire to be with people [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96021-1;During the past 4W, my skin is sensitive;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin is sensitive [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96022-9;During the past 4W, I am frustrated by my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I am frustrated by my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96023-7;During the past 4W, my skin condition is a problem for the people I love;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition is a problem for the people I love [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +9602-4;Taenia solium larva 14kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 14kD Ab [Presence] in Serum by Immunoblot;T sol lar 14kD Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96024-5;During the past 4W, I am embarrassed by my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I am embarrassed by my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96025-2;During the past 4W, my skin condition affects my interactions with others;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition affects my interactions with others [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96026-0;During the past 4W, my skin is irritated;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin is irritated [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96027-8;During the past 4W, I worry about side-effects from skin medications or treatments;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I worry about side-effects from skin medications or treatments [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96028-6;During the past 4W, my skin condition makes showing affection difficult;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, my skin condition makes showing affection difficult [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96029-4;During the past 4W, water bothers my skin condition (bathing, washing hands);Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, water bothers my skin condition (bathing, washing hands) [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96030-2;During the past 4W, I am angry about my skin condition;Find;4W;^Patient;Ord;Skindex-29;SURVEY.GNHLTH;4;During the past 4 weeks, I am angry about my skin condition [Skindex-29];;© 1997 Dr. Mary-Margaret Chren. Used with permission.;ACTIVE;2.69;2.69 +96031-0;During the past 1W, how often have you been bothered by symptoms of your skin problem;Find;1W;^Patient;Ord;Skindex mini;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by symptoms of your skin problem [Skindex Mini];;Copyright © 2016 The Regents of the University of California and Emory University. Used with permission.;ACTIVE;2.69;2.69 +9603-2;Taenia solium larva 18kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 18kD Ab [Presence] in Serum by Immunoblot;T sol lar 18kD Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96032-8;During the past 1W, how often have you been emotionally bothered by your skin problem;Find;1W;^Patient;Ord;Skindex mini;SURVEY.GNHLTH;4;During the past 1 week, how often have you been emotionally bothered by your skin problem [Skindex Mini];;Copyright © 2016 The Regents of the University of California and Emory University. Used with permission.;ACTIVE;2.69;2.7 +96033-6;During the past 1W, how often have you been bothered by effects of your skin problem on your activities;Find;1W;^Patient;Ord;Skindex mini;SURVEY.GNHLTH;4;During the past 1 week, how often have you been bothered by effects of your skin problem on your activities [Skindex Mini];;Copyright © 2016 The Regents of the University of California and Emory University. Used with permission.;ACTIVE;2.69;2.69 +96034-4;Skindex mini;-;1W;^Patient;-;Skindex mini;PANEL.SURVEY.GNHLTH;4;Skindex mini [Skindex Mini];;Copyright © 2016 The Regents of the University of California and Emory University. Used with permission.;ACTIVE;2.69;2.69 +96035-1;Microscopic observation;Prid;Pt;Tiss;Nom;Alcian blue stain.with hyaluronidase;PATH;1;Microscopic observation [Identifier] in Tissue by Alcian blue stain.with hyaluronidase;AB-Hyalur Stn Tiss;;ACTIVE;2.69;2.69 +96036-9;Wound, ischemia, and foot infection classification system panel;-;Pt;Lower extremity;-;WIfI;PANEL.CLIN.RISK;2;Wound, ischemia, and foot infection classification system panel Lower extremity WIfI;WIfI pnl LE WIfI;;ACTIVE;2.69;2.69 +96037-7;Wound grade;Find;Pt;Lower extremity;Ord;WIfI;CLIN;2;Wound grade Lower extremity WIfI;Wound grade LE WIfI;;ACTIVE;2.69;2.69 +96038-5;Ischemia grade;Find;Pt;Lower extremity;Ord;WIfI;CLIN;2;Ischemia grade Lower extremity WIfI;Ischemia grade LE WIfI;;ACTIVE;2.69;2.69 +96039-3;Infection grade;Find;Pt;Lower extremity;Ord;WIfI;CLIN;2;Infection grade Lower extremity WIfI;Infection grade LE WIfI;;ACTIVE;2.69;2.69 +9604-0;Taenia solium larva 21kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 21kD Ab [Presence] in Serum by Immunoblot;T sol lar 21kD Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96040-1;WIfI classification;Find;Pt;Lower extremity;Ord;WIfI;CLIN.RISK;2;WIfI classification Lower extremity WIfI;WIfI class LE WIfI;;ACTIVE;2.69;2.69 +96041-9;Amputation risk;Find;Pt;Lower extremity;Ord;WIfI;CLIN.RISK;2;Amputation risk Lower extremity WIfI;Amputation risk LE WIfI;;ACTIVE;2.69;2.69 +96042-7;Focus distance during near pupillary distance measurement;Len;Pt;Eye;Qn;;EYE.REFRACTION;2;Eye Focus distance during near pupillary distance measurement;Eye Focus dist n PD;;TRIAL;2.69;2.69 +96043-5;Uracil;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Uracil [Mass/volume] in Serum or Plasma;Uracil SerPl-mCnc;;ACTIVE;2.69;2.69 +96044-3;Human epididymis protein 4;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Human epididymis protein 4 [Mass/volume] in Serum or Plasma;HE4 SerPl-mCnc;;ACTIVE;2.69;2.69 +96045-0;Osmotic fragility^10% glucose 48H 37 deg C incubation;NFr;Pt;RBC;Qn;;HEM/BC;1;Osmotic fragility of Red Blood Cells--10% glucose 48 hour 37 degree C incubation;OF 10% Glu 48h Inc NFr RBC;;ACTIVE;2.69;2.69 +96046-8;B & T cell crossmatch panel;-;Pt;Ser^Patient+Bld^Donor;-;Flow cytometry;PANEL.BLDBK;1;B and T cell crossmatch panel - Patient serum and Donor blood by Flow cytometry (FC);B + T crossmatch Pnl Pt ser+Don bld FC;;ACTIVE;2.69;2.69 +96047-6;T cell crossmatch;PrThr;Pt;Ser^Patient+Bld^Donor;Ord;Flow cytometry;BLDBK;1;T cell crossmatch [Presence] in Patient serum and Donor blood by Flow cytometry (FC);T Cell XM Pt ser+Don bld Ql FC;;ACTIVE;2.69;2.69 +96048-4;T cell median channel shift;Arb;Pt;Ser^Patient+Bld^Donor;Qn;Flow cytometry;BLDBK;1;T cell median channel shift in Patient serum and Donor blood by Flow cytometry (FC);T cell MCS Pt ser+Don bld FC;;ACTIVE;2.69;2.69 +96049-2;B cell crossmatch;PrThr;Pt;Ser^Patient+Bld^Donor;Ord;Flow cytometry;BLDBK;1;B cell crossmatch [Presence] in Patient serum and Donor blood by Flow cytometry (FC);B Cell XM Pt ser+Don bld Ql FC;;ACTIVE;2.69;2.69 +960-5;C super little w Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;C sup(w) Ag [Presence] on Red Blood Cells;C sup(w) Ag RBC Ql;;ACTIVE;1.0;2.7 +96050-0;B cell median channel shift;Arb;Pt;Ser^Patient+Bld^Donor;Qn;Flow cytometry;BLDBK;1;B cell median channel shift in Patient serum and Donor blood by Flow cytometry (FC);B cell MCS Pt ser+Don bld FC;;ACTIVE;2.69;2.69 +96051-8;Prism base direction measurement increment;Angle;Pt;Lensmeter;Qn;;EYE.LENSOMETRY;2;Lensmeter Prism base direction measurement increment;LM Prism step;;TRIAL;2.69;2.69 +96052-6;Additional power mode;Type;Pt;Lensmeter;Ord;;EYE.LENSOMETRY;2;Additional power mode;Add mode;;TRIAL;2.69;2.69 +96053-4;Sphere far;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Sphere far by Lensmeter;Corr lens Sphere far by LM;;ACTIVE;2.69;2.71 +96054-2;Cylinder far;InvLen;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Cylinder far by Lensmeter;Corr lens Cylinder far by LM;;ACTIVE;2.69;2.71 +96055-9;Prism base direction;Angle;Pt;Corrective lens;Qn;Lensmeter;EYE.LENSOMETRY;2;Corrective lens Prism base direction by Lensmeter;Corr lens Prism base dir by LM;;TRIAL;2.69;2.69 +96056-7;Borrelia sp DNA;PrThr;Pt;Bld;Ord;Probe.amp.tar;MICRO;1;Borrelia sp DNA [Presence] in Blood by NAA with probe detection;Borrelia DNA Bld Ql NAA+probe;;ACTIVE;2.69;2.69 +9605-7;Taenia solium larva 24kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 24kD Ab [Presence] in Serum by Immunoblot;T sol lar 24kD Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96057-5;Interferon.beta Ab.IgG;PrThr;Pt;Ser;Ord;;SERO;1;Interferon beta IgG Ab [Presence] in Serum;IFN-B IgG Ser Ql;;ACTIVE;2.69;2.69 +96058-3;Mitragynine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Mitragynine [Presence] in Urine by Screen method;Mitragynine Ur Ql Scn;;ACTIVE;2.69;2.69 +96059-1;Mitragynine;MCnc;Pt;Urine;Qn;Screen;DRUG/TOX;1;Mitragynine [Mass/volume] in Urine by Screen method;Mitragynine Ur Scn-mCnc;;ACTIVE;2.69;2.69 +96060-9;Hematologic cancer;Type;Pt;^Patient;Nom;;H&P.HX;2;Hematologic cancer;Hematologic cancer;;ACTIVE;2.69;2.69 +96061-7;HLA donor match status;Type;Pt;^Patient;Nom;;HLA;1;HLA donor match status [Type];HLA donor match status Patient;;ACTIVE;2.69;2.69 +96062-5;HEDIS Measurement Year 2020 Value Set - BMI percentile;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - BMI percentile;HEDIS MY 2020 BMI prctl;;DISCOURAGED;2.69;2.72 +96063-3;HEDIS Measurement Year 2020 Value Set - CT Colonography;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - CT Colonography;HEDIS MY 2020 CT Colongrphy;;DISCOURAGED;2.69;2.72 +96064-1;HEDIS Measurement Year 2020 Value Set - Diastolic Blood Pressure;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Diastolic Blood Pressure;HEDIS MY 2020 Diastolic BP;;DISCOURAGED;2.69;2.72 +9606-5;Taenia solium larva 39-42kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 39-42kD Ab [Presence] in Serum by Immunoblot;T sol lar 39-42kD Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96065-8;HEDIS Measurement Year 2020 Value Set - Mammography;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Mammography;HEDIS MY 2020 Mammography;;DISCOURAGED;2.69;2.72 +96066-6;HEDIS Measurement Year 2020 Value Set - Systolic Blood Pressure;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Systolic Blood Pressure;HEDIS MY 2020 Systolic BP;;DISCOURAGED;2.69;2.72 +96067-4;HEDIS Measurement Year 2020 Value Set - Urine Protein Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Urine Protein Tests;HEDIS MY 2020 Urine Prot Tests;;DISCOURAGED;2.69;2.72 +96068-2;HEDIS Measurement Year 2020 Value Sets;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Sets;HEDIS MY 2020 Value Sets;;DISCOURAGED;2.69;2.72 +96069-0;HEDIS Measurement Year 2020 Value Set - Cervical Cytology;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Cervical Cytology;HEDIS MY 2020 Cerv Cyto;;DISCOURAGED;2.69;2.72 +96070-8;HEDIS Measurement Year 2020 Value Set - HbA1c Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - HbA1C Tests;HEDIS MY 2020 HbA1C Tests;;DISCOURAGED;2.69;2.72 +96071-6;HEDIS Measurement Year 2020 Value Set - LDL-C Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - LDL-C Tests;HEDIS MY 2020 LDL-C Tests;;DISCOURAGED;2.69;2.72 +96072-4;HEDIS Measurement Year 2020 Value Set - Lead Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Lead Tests;HEDIS MY 2020 Lead Tests;;DISCOURAGED;2.69;2.72 +9607-3;Taenia solium larva 50kD Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Taenia solium larva 50kD Ab [Presence] in Serum by Immunoblot;T sol lar 50kD Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96073-2;HEDIS Measurement Year 2020 Value Set - FIT-DNA;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - FIT-DNA;HEDIS MY 2020 FIT-DNA;;DISCOURAGED;2.69;2.72 +96074-0;HEDIS Measurement Year 2020 Value Set - FOBT;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - FOBT;HEDIS MY 2020 FOBT;;DISCOURAGED;2.69;2.72 +96075-7;HEDIS Measurement Year 2020 Value Set - Chlamydia Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Chlamydia Tests;HEDIS MY 2020 Chlamydia Tests;;DISCOURAGED;2.69;2.72 +96076-5;HEDIS Measurement Year 2020 Value Set - Cholesterol Tests Other Than LDL;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Cholesterol Tests Other Than LDL;HEDIS MY 2020 Chol Tests not LDL;;DISCOURAGED;2.69;2.72 +96077-3;HEDIS Measurement Year 2020 Value Set - Glucose Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Glucose Tests;HEDIS MY 2020 Glucose Tests;;DISCOURAGED;2.69;2.72 +96078-1;HEDIS Measurement Year 2020 Value Set - Group A Strep Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Group A Strep Tests;HEDIS MY 2020 Grp A Strep;;DISCOURAGED;2.69;2.72 +96079-9;HEDIS Measurement Year 2020 Value Set - HPV Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - HPV Tests;HEDIS MY 2020 HPV Tests;;DISCOURAGED;2.69;2.72 +96080-7;HEDIS Measurement Year 2020 Value Set - Pregnancy Test Exclusion;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Pregnancy Test Exclusion;HEDIS MY 2020 Preg Test Excl;;DISCOURAGED;2.69;2.72 +9608-1;Hepatitis C virus 100-3 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus 100-3 Ab [Presence] in Serum by Immunoblot;HCV100-3 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96081-5;HEDIS Measurement Year 2020 Value Set - PSA Test Exclusion;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - PSA Test Exclusion;HEDIS MY 2020 PSA Test Excl;;DISCOURAGED;2.69;2.72 +96082-3;HEDIS Measurement Year 2020 Value Set - PSA Tests;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - PSA Tests;HEDIS MY 2020 PSA Tests;;DISCOURAGED;2.69;2.72 +96083-1;HEDIS Measurement Year 2020 Value Set - Estimated Glomerular Filtration Rate Lab Test;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Estimated Glomerular Filtration Rate Lab Test;HEDIS MY 2020 eGFR Lab Test;;DISCOURAGED;2.69;2.72 +96084-9;HEDIS Measurement Year 2020 Value Set - Quantitative Urine Albumin Lab Test;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Quantitative Urine Albumin Lab Test;HEDIS MY 2020 Qn Ur Alb Lab Test;;DISCOURAGED;2.69;2.72 +96085-6;HEDIS Measurement Year 2020 Value Set - Urine Albumin Creatinine Ratio Lab Test;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Urine Albumin Creatinine Ratio Lab Test;HEDIS MY 2020 Ur Alb Creat Rto Lab Test;;DISCOURAGED;2.69;2.72 +96086-4;HEDIS Measurement Year 2020 Value Set - Urine Creatinine Lab Test;-;Pt;^Patient;-;;PANEL.HEDIS;1;HEDIS MY 2020 Value Set - Urine Creatinine Lab Test;HEDIS MY 2020 Ur Creat Lab Test;;DISCOURAGED;2.69;2.72 +96087-2;Standard thickness parameter;Len;Pt;Cornea.right;Qn;Tonometry;EYE.TONOMETRY;2;Right cornea Standard thickness parameter;R cornea Standard thickness Tono;;TRIAL;2.69;2.69 +96088-0;Standard thickness parameter;Len;Pt;Cornea.left;Qn;Tonometry;EYE.TONOMETRY;2;Left cornea Standard thickness parameter;L cornea Standard thickness Tono;;TRIAL;2.69;2.69 +96089-8;Volume adjustment parameter;InvLen;Pt;Cornea.right;Qn;Tonometry;EYE.TONOMETRY;2;Right cornea Volume adjustment parameter;R cornea Vol Adj Tono;;TRIAL;2.69;2.69 +96090-6;Volume adjustment parameter;InvLen;Pt;Cornea.left;Qn;Tonometry;EYE.TONOMETRY;2;Left cornea Volume adjustment parameter;L cornea Vol Adj Tono;;TRIAL;2.69;2.69 +96091-4;SARS coronavirus 2 RdRp gene;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 RdRp Sal Ql NAA+probe;;ACTIVE;2.69;2.69 +96092-2;Intraocular pressure^compensated;Pres;Pt;Eye.left;Qn;Calculated;EYE.TONOMETRY;2;Left eye Intraocular pressure--compensated Calculated;L eye IOP--comp Calc;;TRIAL;2.69;2.69 +96093-0;Intraocular pressure^compensated;Pres;Pt;Eye.right;Qn;Calculated;EYE.TONOMETRY;2;Right eye Intraocular pressure--compensated Calculated;R eye IOP--comp Calc;;TRIAL;2.69;2.69 +96094-8;SARS coronavirus 2 & SARS-related coronavirus RNA panel;-;Pt;Respiratory;-;Probe.amp.tar;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory specimen by NAA with probe detection;SARS-CoV-2+SARSr-CoV pnl Resp NAA+probe;;ACTIVE;2.69;2.7 +96095-5;Indicate the patient's primary medical condition category;Find;RptPeriod;^Patient;Nom;CMS Assessment;SURVEY.CMS;4;Indicate the patient's primary medical condition category during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +96098-9;Wash upper body - functional goal;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Wash upper body - functional goal [CMS Assessment];;;ACTIVE;2.69;2.69 +9609-9;Hepatitis C virus 22-3 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus 22-3 Ab [Presence] in Serum by Immunoblot;HCV22-3 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96099-7;LCDS v5.00 - Mobility - admission performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Mobility - admission performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +96100-3;LCDS v5.00 - Mobility - discharge performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;LCDS v5.00 - Mobility - discharge performance during assessment period [CMS Assessment];;;ACTIVE;2.69;2.69 +96101-1;Tobacco use frequency;NRat;Pt;^Patient;Ord;;H&P.HX;2;Tobacco use frequency;Tobacco use freq;;ACTIVE;2.69;2.69 +96102-9;Age when stopped substance abuse;Time;Pt;^Patient;Qn;;H&P.HX;2;Age when stopped substance abuse;Age when stopped substance abuse;;ACTIVE;2.69;2.69 +96103-7;Tobacco amount per D;NRat;Pt;^Patient;Qn;;H&P.HX;2;Tobacco amount per day;Tobacco amount per D nRate;;ACTIVE;2.69;2.69 +96104-5;Wound stage;Find;Pt;Foot;Ord;UT-DWCS;CLIN;2;Wound stage Foot University of Texas diabetic wound classification system;Wound stage Ft UT-DWCS;;ACTIVE;2.69;2.69 +96105-2;Wound grade;Find;Pt;Foot;Ord;UT-DWCS;CLIN;2;Wound grade Foot University of Texas diabetic wound classification system;Wound grade Ft UT-DWCS;;ACTIVE;2.69;2.69 +96106-0;University of Texas diabetic wound classification system panel;-;Pt;Foot;-;UT-DWCS;PANEL.CLIN;2;University of Texas diabetic wound classification system panel Foot University of Texas diabetic wound classification system;UT-DWCS pnl Ft UT-DWCS;;ACTIVE;2.69;2.69 +9610-7;Hepatitis C virus c33c Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;Hepatitis C virus c33c Ab [Presence] in Serum by Immunoblot;HCV C33c Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96107-8;Bedaquiline;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Bedaquiline [Susceptibility] by Genotype method;Bedaquiline Islt Genotyp;;ACTIVE;2.69;2.69 +96108-6;Clofazimine;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Clofazimine [Susceptibility] by Genotype method;Clofazamine Islt Genotyp;;ACTIVE;2.69;2.69 +96109-4;Delamanid;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Delamanid [Susceptibility] by Genotype method;Delamanid Islt Genotyp;;ACTIVE;2.69;2.69 +96110-2;Ethionamide;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Ethionamide [Susceptibility] by Genotype method;Ethionamide Islt Genotyp;;ACTIVE;2.69;2.69 +96111-0;Linezolid;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Linezolid [Susceptibility] by Genotype method;Linezolid Islt Genotyp;;ACTIVE;2.69;2.69 +96112-8;Moxifloxacin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Moxifloxacin [Susceptibility] by Genotype method;Moxifloxacin Islt Genotyp;;ACTIVE;2.69;2.69 +96113-6;Rifabutin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Rifabutin [Susceptibility] by Genotype method;Rifabutin Islt Genotyp;;ACTIVE;2.69;2.69 +96114-4;Streptomycin;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Streptomycin [Susceptibility] by Genotype method;Streptomycin Islt Genotyp;;ACTIVE;2.69;2.69 +9611-5;Streptococcus pneumoniae Danish serotype 18C Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Streptococcus pneumoniae Danish serotype 18C IgG Ab [Units/volume] in Serum by Immunoassay;S pneum Da 18C IgG Ser IA-aCnc;;ACTIVE;1.0i;2.73 +96115-1;Level of tumor invasion;Type;Pt;Colorectal cancer specimen;Nom;Haggitt;PATH.HISTO;1;Level of tumor invasion [Type] in Colorectal cancer specimen by Haggitt;Tumor invasion level CRC spec Haggitt;;ACTIVE;2.69;2.69 +96116-9;Anterior surgical resection;Type;Pt;Lower GI tract;Nom;;PATH;1;Anterior surgical resection [Type] in Lower GI tract;Anterior surg resection Lower GI tract;;ACTIVE;2.69;2.7 +96117-7;Resection adequacy of non-malignant polyp;Find;Pt;Specimen;Ord;;PATH;1;Resection adequacy of non-malignant polyp in Specimen Qualitative;Resection adeq non-malig polyp Spec Ql;;ACTIVE;2.69;2.69 +96118-5;SARS coronavirus 2 Ab panel;-;Pt;Bld.dot;-;IA;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) Ab panel - DBS by Immunoassay;SARS-CoV-2 Ab Pnl DBS IA;;ACTIVE;2.69;2.69 +96119-3;SARS coronavirus 2 Ag;PrThr;Pt;Respiratory.upper;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay;SARS-CoV-2 Ag Upper resp Ql IA;;ACTIVE;2.69;2.69 +96120-1;SARS coronavirus 2 RdRp gene;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Lower respiratory specimen by NAA with probe detection;SARS-CoV-2 RdRp Lower resp Ql NAA+probe;;ACTIVE;2.69;2.69 +96121-9;SARS-related coronavirus E gene;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus E gene [Presence] in Lower respiratory specimen by NAA with probe detection;SARS-rel CoV E gene Low resp Ql NAA+prb;;ACTIVE;2.69;2.69 +96122-7;SARS-related coronavirus E gene;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;SARS-related coronavirus E gene [Presence] in Upper respiratory specimen by NAA with probe detection;SARS-rel CoV E gene Upper resp Ql NAA+prb;;ACTIVE;2.69;2.69 +9612-3;Cortisol^15M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --15 minutes post 250 ug corticotropin IM;Cortis 15M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0i;2.73 +96123-5;SARS coronavirus 2 RdRp gene;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Upper respiratory specimen by NAA with probe detection;SARS-CoV-2 RdRp Upper resp Ql NAA+probe;;ACTIVE;2.69;2.69 +96124-3;Long axis;Prctl;Pt;Femur.diaphysis^Fetus;Qn;Per estimated gestational age;OB.US;2;Fetal femur diaphysis length percentile per estimated gestational age;Fet FDL Prctl per est GA;;ACTIVE;2.69;2.69 +96125-0;Perimeter;Prctl;Pt;Abdomen^Fetus;Qn;Per estimated gestational age;OB.US;2;Fetal Abdomen Circumference Per estimated gestational age;Fet Abd Prctl Circum Per est GA;;ACTIVE;2.69;2.69 +96126-8;Evaluation note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy Evaluation note;Rec therapy Eval note;;ACTIVE;2.69;2.69 +96127-6;Evaluation note;Find;Pt;{Setting};Doc;General medicine;DOC.ONTOLOGY;2;General medicine Evaluation note;General medicine Eval note;;ACTIVE;2.69;2.69 +96128-4;Evaluation note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Evaluation note;Col+rec surg Eval note;;ACTIVE;2.69;2.69 +96129-2;Evaluation note;Find;Pt;{Setting};Doc;Neurological surgery;DOC.ONTOLOGY;2;Neurological surgery Evaluation note;Neuro surgery Eval note;;ACTIVE;2.69;2.69 +961-3;C super little x Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;C sup(x) Ab [Presence] in Serum or Plasma from Blood product unit;C sup(x) Ab SerPl BPU Ql;;ACTIVE;1.0;2.7 +96130-0;Evaluation note;Find;Pt;{Setting};Doc;Surgical oncology;DOC.ONTOLOGY;2;Surgical oncology Evaluation note;Surg Onc Eval note;;ACTIVE;2.69;2.69 +9613-1;Cortisol^2H post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --2 hours post 250 ug corticotropin IM;Cortis 2h p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0i;2.7 +96131-8;Evaluation note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Evaluation note;OMS Eval note;;ACTIVE;2.69;2.69 +96132-6;Evaluation note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Evaluation note;Cardiac surgery Eval note;;ACTIVE;2.69;2.69 +96133-4;Evaluation note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology Evaluation note;Pharmacology Eval note;;ACTIVE;2.69;2.69 +96134-2;Evaluation note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy Evaluation note;OT Eval note;;ACTIVE;2.69;2.69 +96135-9;Evaluation note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics Evaluation note;Nutr+diet Eval note;;ACTIVE;2.69;2.69 +96136-7;Evaluation note;Find;Pt;{Setting};Doc;Palliative care;DOC.ONTOLOGY;2;Palliative care Evaluation note;Palliative care Eval note;;ACTIVE;2.69;2.69 +96137-5;Evaluation note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Evaluation note;Oncology Eval note;;ACTIVE;2.69;2.69 +96138-3;Evaluation note;Find;Pt;{Setting};Doc;Obstetrics;DOC.ONTOLOGY;2;Obstetrics Evaluation note;OB Eval note;;ACTIVE;2.69;2.69 +96139-1;Evaluation note;Find;Pt;{Setting};Doc;Neurology;DOC.ONTOLOGY;2;Neurology Evaluation note;Neurology Eval note;;ACTIVE;2.69;2.69 +96140-9;Evaluation note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Evaluation note;Nephrology Eval note;;ACTIVE;2.69;2.69 +96141-7;Evaluation note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Evaluation note;Neo peri med Eval note;;ACTIVE;2.69;2.69 +96142-5;Evaluation note;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Evaluation note;Mental health Eval note;;ACTIVE;2.69;2.69 +96143-3;Evaluation note;Find;Pt;{Setting};Doc;Gynecology;DOC.ONTOLOGY;2;Gynecology Evaluation note;Gynecology Eval note;;ACTIVE;2.69;2.69 +96144-1;Evaluation note;Find;Pt;{Setting};Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Evaluation note;Geri med Eval note;;ACTIVE;2.69;2.69 +96145-8;Evaluation note;Find;Pt;{Setting};Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Evaluation note;Emergency med Eval note;;ACTIVE;2.69;2.69 +96146-6;Evaluation note;Find;Pt;{Setting};Doc;Critical Care Medicine;DOC.ONTOLOGY;2;Critical care medicine Evaluation note;CCM Eval note;;ACTIVE;2.69;2.69 +96147-4;Evaluation note;Find;Pt;{Setting};Doc;Vascular surgery;DOC.ONTOLOGY;2;Vascular surgery Evaluation note;Vascular surgery Eval note;;ACTIVE;2.69;2.69 +96148-2;Evaluation note;Find;Pt;{Setting};Doc;Transplant surgery;DOC.ONTOLOGY;2;Transplant surgery Evaluation note;Transpl surg Eval note;;ACTIVE;2.69;2.73 +9614-9;Cortisol^45M post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --45 minutes post 250 ug corticotropin IM;Cortis 45M p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0i;2.7 +96149-0;Evaluation note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Evaluation note;Cardiothor surg Eval note;;ACTIVE;2.69;2.69 +96150-8;Evaluation note;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Evaluation note;Plastic surgery Eval note;;ACTIVE;2.69;2.69 +96151-6;Evaluation note;Find;Pt;{Setting};Doc;Pediatric surgery;DOC.ONTOLOGY;2;Pediatric surgery Evaluation note;Peds surgery Eval note;;ACTIVE;2.69;2.69 +96152-4;Evaluation note;Find;Pt;{Setting};Doc;Orthopaedic surgery;DOC.ONTOLOGY;2;Orthopaedic surgery Evaluation note;Orthopaedic surgery Eval note;;ACTIVE;2.69;2.69 +96153-2;Evaluation note;Find;Pt;{Setting};Doc;Gastroenterology;DOC.ONTOLOGY;2;Gastroenterology Evaluation note;Gastroenterology Eval note;;ACTIVE;2.69;2.69 +96154-0;Evaluation note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary Evaluation note;Pulmonary disease Eval note;;ACTIVE;2.69;2.69 +96155-7;Evaluation note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Evaluation note;Wound care management Eval note;;ACTIVE;2.69;2.69 +9615-6;Cortisol^1.5H post 250 ug corticotropin IM;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1.5 hours post 250 ug corticotropin IM;Cortis 1.5h p 250 ug ACTH IM SerPl-mCnc;;ACTIVE;1.0i;2.73 +96156-5;Evaluation note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma Evaluation note;Trauma Eval note;;ACTIVE;2.69;2.69 +96157-3;Evaluation note;Find;Pt;{Setting};Doc;Sports medicine;DOC.ONTOLOGY;2;Sports medicine Evaluation note;Sports medicine Eval note;;ACTIVE;2.69;2.69 +96158-1;Evaluation note;Find;Pt;{Setting};Doc;Urology;DOC.ONTOLOGY;2;Urology Evaluation note;Urology Eval note;;ACTIVE;2.69;2.69 +96159-9;Evaluation note;Find;Pt;{Setting};Doc;Otolaryngology;DOC.ONTOLOGY;2;Otolaryngology Evaluation note;Otolaryngology Eval note;;ACTIVE;2.69;2.69 +96160-7;Evaluation note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Evaluation note;Endocrinology Eval note;;ACTIVE;2.69;2.69 +96161-5;Evaluation note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease Evaluation note;Infectious disease Eval note;;ACTIVE;2.69;2.69 +96162-3;Evaluation note;Find;Pt;{Setting};Doc;Nurse practitioner;DOC.ONTOLOGY;2;Nurse practitioner Evaluation note;Nurse pract Eval note;;ACTIVE;2.69;2.69 +96163-1;Evaluation note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse Evaluation note;Nurse Eval note;;ACTIVE;2.69;2.69 +9616-4;17-Hydroxyprogesterone;MRat;24H;Urine;Qn;;CHEM;1;17-Hydroxyprogesterone [Mass/time] in 24 hour Urine;17OHP 24h Ur-mRate;;ACTIVE;1.0i;2.73 +96164-9;Evaluation note;Find;Pt;{Setting};Doc;Speech-language pathology;DOC.ONTOLOGY;2;Speech-language pathology Evaluation note;Speech-lang path Eval note;;ACTIVE;2.69;2.69 +96165-6;Evaluation note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy Evaluation note;Resp therapy Eval note;;ACTIVE;2.69;2.69 +96166-4;Evaluation note;Find;Pt;{Setting};Doc;Bariatric surgery;DOC.ONTOLOGY;2;Bariatric surgery Evaluation note;Bariatric surg Eval note;;ACTIVE;2.69;2.69 +96167-2;Evaluation note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Evaluation note;Cardio+Pulm disease Eval note;;ACTIVE;2.69;2.69 +96168-0;Evaluation note;Find;Pt;{Setting};Doc;Child and adolescent psychology;DOC.ONTOLOGY;2;Child and adolescent psychology Evaluation note;Child Adolsnt Psych Eval note;;ACTIVE;2.69;2.69 +96169-8;Evaluation note;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Evaluation note;Dermatology Eval note;;ACTIVE;2.69;2.69 +96170-6;Evaluation note;Find;Pt;Telephone encounter;Doc;{Role};DOC.ONTOLOGY;2;Telephone encounter Evaluation note;Phone Eval note;;ACTIVE;2.69;2.69 +96171-4;Evaluation note;Find;Pt;{Setting};Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Evaluation note;Heart failure Eval note;;ACTIVE;2.69;2.69 +9617-2;Chylomicrons;MCnc;Pt;Plr fld;Qn;;CHEM;1;Chylomicrons [Mass/volume] in Pleural fluid;Chylo Plr-mCnc;;ACTIVE;1.0i;2.42 +96172-2;Evaluation note;Find;Pt;{Setting};Doc;Clinical genetics;DOC.ONTOLOGY;2;Clinical genetics Evaluation note;Clinical genetics Eval note;;ACTIVE;2.69;2.69 +96173-0;Evaluation note;Find;Pt;{Setting};Doc;Clinical pathology;DOC.ONTOLOGY;2;Clinical pathology Evaluation note;Clin Path Eval note;;ACTIVE;2.69;2.69 +96174-8;Evaluation note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Evaluation note;IR Eval note;;ACTIVE;2.69;2.69 +96175-5;Evaluation note;Find;Pt;{Setting};Doc;Kinesiotherapy;DOC.ONTOLOGY;2;Kinesiotherapy Evaluation note;Kinesiotherapy Eval note;;ACTIVE;2.69;2.69 +96176-3;Evaluation note;Find;Pt;{Setting};Doc;Ophthalmology;DOC.ONTOLOGY;2;Ophthalmology Evaluation note;Ophthalmol Eval note;;ACTIVE;2.69;2.69 +96177-1;Evaluation note;Find;Pt;{Setting};Doc;Pain medicine;DOC.ONTOLOGY;2;Pain medicine Evaluation note;Pain medicine Eval note;;ACTIVE;2.69;2.69 +96178-9;Evaluation note;Find;Pt;{Setting};Doc;Physical medicine and rehab;DOC.ONTOLOGY;2;Physical medicine and rehab Evaluation note;PM+R Eval note;;ACTIVE;2.69;2.69 +96179-7;Evaluation note;Find;Pt;{Setting};Doc;Podiatry;DOC.ONTOLOGY;2;Podiatry Evaluation note;Podiatry Eval note;;ACTIVE;2.69;2.69 +9618-0;Cholesterol;MCnc;Pt;Plr fld;Qn;;CHEM;1;Cholesterol [Mass/volume] in Pleural fluid;Cholest Plr-mCnc;;ACTIVE;1.0i;2.73 +96180-5;Evaluation note;Find;Pt;{Setting};Doc;Psychology;DOC.ONTOLOGY;2;Psychology Evaluation note;Psych Eval note;;ACTIVE;2.69;2.69 +96181-3;Evaluation note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology Evaluation note;Rheumatology Eval note;;ACTIVE;2.69;2.69 +96182-1;Photographic image;Find;Pt;{Setting};Doc;Plastic surgery;DOC.ONTOLOGY;2;Plastic surgery Photographic image;Plastic surgery Photo image;;ACTIVE;2.69;2.69 +96183-9;Photographic image;Find;Pt;{Setting};Doc;Dermatology;DOC.ONTOLOGY;2;Dermatology Photographic image;Dermatology Photo image;;ACTIVE;2.69;2.69 +96184-7;Photographic image;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Photographic image;Wound care management Photo image;;ACTIVE;2.69;2.69 +96185-4;Indoor respiratory allergen Ab.IgE panel;-;Pt;Ser;-;;PANEL.ALLERGY;1;Indoor respiratory allergen IgE panel - Serum;Indoor resp allergen IgE Pnl Ser;;ACTIVE;2.69;2.69 +96186-2;Dermatology autoimmune Ab panel;-;Pt;Ser/Plas;-;;PANEL.SERO;1;Dermatology autoimmune Ab panel - Serum or Plasma;Derm autoimmune Ab pnl SerPl;;ACTIVE;2.69;2.69 +96187-0;Function;Find;Pt;Optic nerve.right;Ord;VEP;EYE.PX;2;Right optic nerve Function VEP;R optic n Function VEP;;ACTIVE;2.69;2.69 +96188-8;Function;Find;Pt;Optic nerve.left;Ord;VEP;EYE.PX;2;Left optic nerve Function VEP;L optic n Function VEP;;ACTIVE;2.69;2.69 +96189-6;Function;Find;Pt;Macula.right;Ord;Electroretinogram;EYE.ERG;2;Right macula Function by ERG;R macula Function ERG;;ACTIVE;2.69;2.69 +96190-4;Function;Find;Pt;Macula.left;Ord;Electroretinogram;EYE.ERG;2;Left macula Function by ERG;L macula Function ERG;;ACTIVE;2.69;2.69 +96191-2;Function;Find;Pt;Optic nerve.right;Ord;Electroretinogram;EYE.ERG;2;Right optic nerve Function by ERG;R optic n Function ERG;;ACTIVE;2.69;2.69 +96192-0;Function;Find;Pt;Optic nerve.left;Ord;Electroretinogram;EYE.ERG;2;Left optic nerve Function by ERG;L optic n Function ERG;;ACTIVE;2.69;2.69 +96193-8;Function;Find;Pt;Cones.right;Ord;Electroretinogram;EYE.ERG;2;Right cones Function by ERG;R cones Function ERG;;ACTIVE;2.69;2.69 +96194-6;Function;Find;Pt;Cones.left;Ord;Electroretinogram;EYE.ERG;2;Left cones Function by ERG;L cones Function ERG;;ACTIVE;2.69;2.69 +96195-3;Function;Find;Pt;Rods.right;Ord;Electroretinogram;EYE.ERG;2;Right rods Function by ERG;R rods Function ERG;;ACTIVE;2.69;2.69 +96196-1;Function;Find;Pt;Rods.left;Ord;Electroretinogram;EYE.ERG;2;Left rods Function by ERG;L rods Function ERG;;ACTIVE;2.69;2.69 +96197-9;Function;Find;Pt;Cones+rods.right;Ord;Electroretinogram;EYE.ERG;2;Right cones and rods Function by ERG;R cones+rods Function ERG;;ACTIVE;2.69;2.69 +9619-8;Triglyceride;MCnc;Pt;Plr fld;Qn;;CHEM;1;Triglyceride [Mass/volume] in Pleural fluid;Trigl Plr-mCnc;;ACTIVE;1.0i;2.73 +96198-7;Function;Find;Pt;Cones+rods.left;Ord;Electroretinogram;EYE.ERG;2;Left cones and rods Function by ERG;L cones+rods Function ERG;;ACTIVE;2.69;2.69 +96199-5;Function;Find;Pt;Ganglion cells.right;Ord;Electroretinogram;EYE.ERG;2;Right ganglion cells Function by ERG;R ganglion cells Function ERG;;ACTIVE;2.69;2.69 +96200-1;Function;Find;Pt;Ganglion cells.left;Ord;Electroretinogram;EYE.ERG;2;Left ganglion cells Function by ERG;L ganglion cells Function ERG;;ACTIVE;2.69;2.69 +96201-9;Function;Find;Pt;Optic disc+retinal nerve fiber layer.right;Ord;Electroretinogram;EYE.ERG;2;Right optic disc and retinal nerve fiber layer Function by ERG;R optic disc+RNFL Function ERG;;ACTIVE;2.69;2.69 +96202-7;Function;Find;Pt;Optic disc+retinal nerve fiber layer.left;Ord;Electroretinogram;EYE.ERG;2;Left optic disc and retinal nerve fiber layer Function by ERG;L optic disc+RNFL Function ERG;;ACTIVE;2.69;2.69 +96203-5;Function compared to previous assessment;Find;Pt;Optic nerve.right;Ord;VEP;EYE.ERG;2;Right optic nerve Function compared to previous assessment VEP;R optic n Comp func VEP;;ACTIVE;2.69;2.69 +96204-3;Function compared to previous assessment;Find;Pt;Optic nerve.left;Ord;VEP;EYE.ERG;2;Left optic nerve Function compared to previous assessment VEP;L optic n Comp func VEP;;ACTIVE;2.69;2.69 +96205-0;Function compared to previous assessment;Find;Pt;Optic nerve.right;Ord;Electroretinogram;EYE.ERG;2;Right optic nerve Function compared to previous assessment by ERG;R optic n Comp func ERG;;ACTIVE;2.69;2.69 +9620-6;Lipoprotein.beta;MCnc;Pt;Plr fld;Qn;;CHEM;1;Lipoprotein.beta [Mass/volume] in Pleural fluid;LDL Plr-mCnc;;ACTIVE;1.0i;2.42 +96206-8;Function compared to previous assessment;Find;Pt;Optic nerve.left;Ord;Electroretinogram;EYE.ERG;2;Left optic nerve Function compared to previous assessment by ERG;L optic n Comp func ERG;;ACTIVE;2.69;2.69 +96207-6;Function compared to previous assessment;Find;Pt;Macula.right;Ord;Electroretinogram;EYE.ERG;2;Right macula Function compared to previous assessment by ERG;R macula Comp func ERG;;ACTIVE;2.69;2.69 +96208-4;Function compared to previous assessment;Find;Pt;Macula.left;Ord;Electroretinogram;EYE.ERG;2;Left macula Function compared to previous assessment by ERG;L macula Comp func ERG;;ACTIVE;2.69;2.69 +96209-2;Function compared to previous assessment;Find;Pt;Rods.left;Ord;Electroretinogram;EYE.ERG;2;Left rods Function compared to previous assessment by ERG;L rods Comp func ERG;;ACTIVE;2.69;2.69 +962-1;C super little x Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;C sup(x) Ab [Presence] in Serum or Plasma from Donor;C sup(x) Ab SerPl Donr Ql;;ACTIVE;1.0;2.7 +96210-0;Function compared to previous assessment;Find;Pt;Rods.right;Ord;Electroretinogram;EYE.ERG;2;Right rods Function compared to previous assessment by ERG;R rods Comp func ERG;;ACTIVE;2.69;2.69 +96211-8;Function compared to previous assessment;Find;Pt;Cones.left;Ord;Electroretinogram;EYE.ERG;2;Left cones Function compared to previous assessment by ERG;L cones Comp func ERG;;ACTIVE;2.69;2.69 +96212-6;Function compared to previous assessment;Find;Pt;Cones.right;Ord;Electroretinogram;EYE.ERG;2;Right cones Function compared to previous assessment by ERG;R cones Comp func ERG;;ACTIVE;2.69;2.69 +96213-4;Function compared to previous assessment;Find;Pt;Cones+rods.left;Ord;Electroretinogram;EYE.ERG;2;Left cones and rods Function compared to previous assessment by ERG;L cones+rods Comp func ERG;;ACTIVE;2.69;2.69 +9621-4;Lipoprotein.pre-beta;MCnc;Pt;Plr fld;Qn;;CHEM;1;Lipoprotein.pre-beta [Mass/volume] in Pleural fluid;VLDL Plr-mCnc;;ACTIVE;1.0i;2.42 +96214-2;Function compared to previous assessment;Find;Pt;Cones+rods.right;Ord;Electroretinogram;EYE.ERG;2;Right cones and rods Function compared to previous assessment by ERG;R cones+rods Comp func ERG;;ACTIVE;2.69;2.69 +96215-9;Function compared to previous assessment;Find;Pt;Ganglion cells.left;Ord;Electroretinogram;EYE.ERG;2;Left ganglion cells Function compared to previous assessment by ERG;L ganglion cells Comp func ERG;;ACTIVE;2.69;2.69 +96216-7;Function compared to previous assessment;Find;Pt;Ganglion cells.right;Ord;Electroretinogram;EYE.ERG;2;Right ganglion cells Function compared to previous assessment by ERG;R ganglion cells Comp func ERG;;ACTIVE;2.69;2.69 +96217-5;Function compared to previous assessment;Find;Pt;Optic disc+retinal nerve fiber layer.left;Ord;Electroretinogram;EYE.ERG;2;Left optic disc and retinal nerve fiber layer Function compared to previous assessment by ERG;L optic disc+RNFL Comp func ERG;;ACTIVE;2.69;2.69 +96218-3;Function compared to previous assessment;Find;Pt;Optic disc+retinal nerve fiber layer.right;Ord;Electroretinogram;EYE.ERG;2;Right optic disc and retinal nerve fiber layer Function compared to previous assessment by ERG;R optic disc+RNFL Comp func ERG;;ACTIVE;2.69;2.69 +96219-1;Functional findings;Imp;Pt;Retina.right;Nar;Electroretinogram;EYE.ERG;2;Right retina Functional findings [Interpretation] by ERG;R ret Func find [Imp] ERG;;ACTIVE;2.69;2.69 +96220-9;Functional findings;Imp;Pt;Retina.left;Nar;Electroretinogram;EYE.ERG;2;Left retina Functional findings [Interpretation] by ERG;L ret Func find [Imp] ERG;;ACTIVE;2.69;2.69 +96221-7;Functional findings;Imp;Pt;Visual pathway.right;Nar;VEP;EYE.PX;2;Right visual pathway Functional findings [Interpretation] VEP;Visual pathway-R Func find [Imp] VEP;;ACTIVE;2.69;2.69 +9622-2;Phytonadione;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Phytonadione [Mass/volume] in Serum or Plasma;Phytonadione SerPl-mCnc;;ACTIVE;1.0i;2.73 +96222-5;Functional findings;Imp;Pt;Visual pathway.left;Nar;VEP;EYE.PX;2;Left visual pathway Functional findings [Interpretation] VEP;Visual pathway-L Func find [Imp] VEP;;ACTIVE;2.69;2.69 +96223-3;Functional findings;Imp;Pt;Retina.right;Nar;;EYE.PX;2;Right retina Functional findings [Interpretation];R ret Func find [Imp];;ACTIVE;2.69;2.69 +96224-1;Functional findings;Imp;Pt;Retina.left;Nar;;EYE.PX;2;Left retina Functional findings [Interpretation];L ret Func find [Imp];;ACTIVE;2.69;2.69 +96225-8;Functional findings;Imp;Pt;Visual pathway.right;Nar;;EYE.PX;2;Right visual pathway Functional findings [Interpretation];Visual pathway-R Func find [Imp];;ACTIVE;2.69;2.69 +96226-6;Functional findings;Imp;Pt;Visual pathway.left;Nar;;EYE.PX;2;Left visual pathway Functional findings [Interpretation];Visual pathway-L Func find [Imp];;ACTIVE;2.69;2.69 +96227-4;Multifocal electroretinography panel;-;Pt;Macula;-;Electroretinogram.multifocal;PANEL.EYE;2;Multifocal electroretinography (mfERG) panel;mfERG Pnl;;ACTIVE;2.69;2.72 +96228-2;N1 amplitude ^light-adapted;Elpot;Pt;Macula.left;Qn;Electroretinogram.multifocal;EYE.ERG;2;Left macula N1 amplitude--light-adapted by mfERG;L macula N1 amp--light-adapt mfERG;;ACTIVE;2.69;2.69 +96229-0;N1 amplitude^light-adapted;Elpot;Pt;Macula.right;Qn;Electroretinogram.multifocal;EYE.ERG;2;Right macula N1 amplitude--light-adapted by mfERG;R macula N1 amp--light-adapt mfERG;;ACTIVE;2.69;2.69 +9623-0;Valine;PrThr;Pt;Urine;Ord;;CHEM;1;Valine [Presence] in Urine;Valine Ur Ql;;ACTIVE;1.0i;2.73 +96230-8;N1 implicit time^light-adapted;Time;Pt;Macula.right;Qn;Electroretinogram.multifocal;EYE.ERG;2;Right macula N1 implicit time--light-adapted by mfERG;R macula N1 impl time--light-adapt mfERG;;ACTIVE;2.69;2.69 +96231-6;N1 implicit time^light-adapted;Time;Pt;Macula.left;Qn;Electroretinogram.multifocal;EYE.ERG;2;Left macula N1 implicit time--light-adapted by mfERG;L macula N1 impl time--light-adapt mfERG;;ACTIVE;2.69;2.69 +96232-4;N2 amplitude^light-adapted;Elpot;Pt;Macula.right;Qn;Electroretinogram.multifocal;EYE.ERG;2;Right macula N2 amplitude--light-adapted by mfERG;R macula N2 amp--light-adapt mfERG;;ACTIVE;2.69;2.69 +96233-2;N2 amplitude^light-adapted;Elpot;Pt;Macula.left;Qn;Electroretinogram.multifocal;EYE.ERG;2;Left macula N2 amplitude--light-adapted by mfERG;L macula N2 amp--light-adapt mfERG;;ACTIVE;2.69;2.69 +96234-0;N2 implicit time^light-adapted;Time;Pt;Macula.right;Qn;Electroretinogram.multifocal;EYE.ERG;2;Right macula N2 implicit time--light-adapted by mfERG;R macula N2 impl time--light-adapt mfERG;;ACTIVE;2.69;2.69 +96235-7;N2 implicit time^light-adapted;Time;Pt;Macula.left;Qn;Electroretinogram.multifocal;EYE.ERG;2;Left macula N2 implicit time--light-adapted by mfERG;L macula N2 impl time--light-adapt mfERG;;ACTIVE;2.69;2.69 +96236-5;N95 amplitude^light-adapted;Elpot;Pt;Retina.right;Qn;Electroretinogram.pattern;EYE.ERG;2;Right retina N95 amplitude--light-adapted by PERG;R ret N95 amp--light-adapt PERG;;ACTIVE;2.69;2.69 +96237-3;N95 amplitude^light-adapted;Elpot;Pt;Retina.left;Qn;Electroretinogram.pattern;EYE.ERG;2;Left retina N95 amplitude--light-adapted by PERG;L ret N95 amp--light-adapt PERG;;ACTIVE;2.69;2.69 +96238-1;P1 amplitude^light-adapted;Elpot;Pt;Macula.right;Qn;Electroretinogram.multifocal;EYE.ERG;2;Right macula P1 amplitude--light-adapted by mfERG;R macula P1 amp--light-adapt mfERG;;ACTIVE;2.69;2.69 +96239-9;P1 amplitude^light-adapted;Elpot;Pt;Macula.left;Qn;Electroretinogram.multifocal;EYE.ERG;2;Left macula P1 amplitude--light-adapted by mfERG;L macula P1 amp--light-adapt mfERG;;ACTIVE;2.69;2.69 +96240-7;P1 implicit time^light-adapted;Time;Pt;Macula.right;Qn;Electroretinogram.multifocal;EYE.ERG;2;Right macula P1 implicit time--light-adapted by mfERG;R macula P1 impl time--light-adapt mfERG;;ACTIVE;2.69;2.69 +96241-5;P1 implicit time^light-adapted;Time;Pt;Macula.left;Qn;Electroretinogram.multifocal;EYE.ERG;2;Left macula P1 implicit time--light-adapted by mfERG;L macula P1 impl time--light-adapt mfERG;;ACTIVE;2.69;2.69 +96242-3;P50 amplitude^light-adapted;Elpot;Pt;Retina.right;Qn;Electroretinogram.pattern;EYE.ERG;2;Right retina P50 amplitude--light-adapted by PERG;R ret P50 amp--light-adapt PERG;;ACTIVE;2.69;2.69 +96243-1;P50 amplitude^light-adapted;Elpot;Pt;Retina.left;Qn;Electroretinogram.pattern;EYE.ERG;2;Left retina P50 amplitude--light-adapted by PERG;L ret P50 amp--light-adapt PERG;;ACTIVE;2.69;2.69 +96244-9;P50 peak time^light-adapted;Time;Pt;Retina.right;Qn;Electroretinogram.pattern;EYE.ERG;2;Right retina--light-adapted by PERG;R ret--light-adapt PERG;;ACTIVE;2.69;2.69 +96245-6;P50 peak time^light-adapted;Time;Pt;Retina.left;Qn;Electroretinogram.pattern;EYE.ERG;2;Left retina--light-adapted by PERG;L ret--light-adapt PERG;;ACTIVE;2.69;2.69 +96246-4;Pattern electroretinography panel;-;Pt;Retina;-;Electroretinogram.pattern;PANEL.EYE;2;Pattern electroretinography (PERG) panel;PERG Pnl;;ACTIVE;2.69;2.72 +96247-2;Phase shift^light-adapted;Time;Pt;Retina.right;Qn;Electroretinogram.pattern;EYE.ERG;2;Right retina Phase shift--light-adapted [Time] by PERG;R ret Ph shift--light-adapt [Time] PERG;;ACTIVE;2.69;2.69 +9624-8;Vanillylmandelate;MCnc;Pt;Urine;Qn;;CHEM;1;Vanillylmandelate [Mass/volume] in Urine;VMA Ur-mCnc;;ACTIVE;1.0i;2.73 +96248-0;Phase shift^light-adapted;Time;Pt;Retina.left;Qn;Electroretinogram.pattern;EYE.ERG;2;Left retina Phase shift--light-adapted [Time] by PERG;L ret Ph shift--light-adapt [Time] PERG;;ACTIVE;2.69;2.69 +96249-8;Artifact;Naric;Pt;Urine;Qn;Computer assisted;UA;1;Artifact [#/area] in Urine by Computer assisted method;Artifact #/area Ur Comp Assist;;ACTIVE;2.69;2.69 +96250-6;Arsenic.inorganic+methylated;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic+methylated [Mass/volume] in Urine;Arsenic.inorganic+methylated Ur-mCnc;;ACTIVE;2.69;2.69 +96251-4;Arsenic.inorganic+methylated;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Arsenic.inorganic+methylated [Mass/volume] in 24 hour Urine;Arsenic.inorganic+methylated 24h Ur-mCnc;;ACTIVE;2.69;2.69 +96252-2;Arsenic.methylated;MCnc;24H;Urine;Qn;;DRUG/TOX;1;Arsenic.methylated [Mass/volume] in 24 hour Urine;Arsenic.methylated 24h Ur-mCnc;;ACTIVE;2.69;2.69 +96253-0;Arsenic fractions panel;-;24H;Urine;Qn;;PANEL.DRUG/TOX;1;Arsenic fractions panel - 24 hour Urine;Arsenic fractions Pnl 24h Ur;;ACTIVE;2.69;2.69 +96254-8;Saint Louis encephalitis virus Ab.IgG & IgM panel;-;Pt;CSF;-;;PANEL.MICRO;1;Saint Louis encephalitis virus IgG and IgM panel - Cerebral spinal fluid;SLEV IgG+IgM Pnl CSF;;ACTIVE;2.69;2.69 +9625-5;Amoxapine+8-Hydroxyamoxapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amoxapine+8-Hydroxyamoxapine [Mass/volume] in Serum or Plasma;Amoxapine+8OH-Amox SerPl-mCnc;;ACTIVE;1.0i;2.73 +96255-5;Saint Louis encephalitis virus Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Saint Louis encephalitis virus IgG and IgM panel - Serum;SLEV IgG+IgM Pnl Ser;;ACTIVE;2.69;2.69 +96256-3;Copper.free;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Copper free [Moles/volume] in Serum or Plasma;Copper free SerPl-sCnc;;ACTIVE;2.69;2.69 +96257-1;Copper.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Copper free [Mass/volume] in Serum or Plasma;Copper free SerPl-mCnc;;ACTIVE;2.69;2.69 +96258-9;Cholesterol.in LDL;SCnc;Pt;Ser/Plas;Qn;Calculated.Martin-Hopkins;CHEM;1;Cholesterol in LDL [Moles/volume] in Serum or Plasma by Calculated by Martin-Hopkins;LDLc SerPl Mart-Hopk-sCnc;;ACTIVE;2.69;2.69 +96259-7;Cholesterol.in LDL;MCnc;Pt;Ser/Plas;Qn;Calculated.Martin-Hopkins;CHEM;1;Cholesterol in LDL [Mass/volume] in Serum or Plasma by Calculated by Martin-Hopkins;LDLc SerPl Mart-Hopk-mCnc;;ACTIVE;2.69;2.69 +96260-5;Coagulation tissue factor induced.factor substitution^2H post incubation after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with 1:1 normal plasma;PT 2h p 1:1 NP PPP;;ACTIVE;2.69;2.69 +96261-3;Coagulation tissue factor induced.factor substitution^1H post incubation after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with 1:1 normal plasma;PT 1h p 1:1 NP PPP;;ACTIVE;2.69;2.69 +96262-1;Coagulation tissue factor induced.factor substitution^immediately after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:1 addition of normal plasma;PT imm 1:1 NP PPP;;ACTIVE;2.69;2.69 +9626-3;Propoxyphene+Norpropoxyphene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propoxyphene + Norpropoxyphene [Mass/volume] in Serum or Plasma;Propoxyph+Nor SerPl-mCnc;;ACTIVE;1.0i;2.73 +96263-9;Coagulation surface induced.lupus sensitive.factor substitution^2H post incubation after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with 1:1 normal plasma;aPTT-LA 2h p 1:1 NP PPP;;ACTIVE;2.69;2.69 +96264-7;Coagulation surface induced.lupus sensitive.factor substitution^1H post incubation after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.lupus sensitive.factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with 1:1 normal plasma;aPTT-LA 1h p 1:1 NP PPP;;ACTIVE;2.69;2.69 +96265-4;Coagulation surface induced.factor substitution^2H post incubation after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --2H post incubation with 1:1 normal plasma;aPTT 2h p 1:1 NP PPP;;ACTIVE;2.69;2.69 +96266-2;Coagulation surface induced.factor substitution^1H post incubation after 1:1 addition of normal plasma;Time;Pt;PPP;Qn;Coag;COAG;1;aPTT.factor substitution in Platelet poor plasma by Coagulation assay --1H post incubation with 1:1 normal plasma;aPTT 1h p 1:1 NP PPP;;ACTIVE;2.69;2.69 +96267-0;Delta coagulation surface induced.hexagonal phase phospholipid;TimeDif;Pt;PPP;Qn;Coag;COAG;1;Delta aPTT W excess hexagonal phospholipid [Time] in Platelet poor plasma by Coagulation assay;Delta aPTT Hex PPP;;ACTIVE;2.69;2.69 +96268-8;Monocytes.programmed cell death ligand 1/100 monocytes;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Monocytes.PD-L1/100 Monocytes in Blood by Flow cytometry (FC);Mono.PD-L1/100 Mono NFr Bld FC;;ACTIVE;2.69;2.69 +96269-6;Nitric oxide/Expired gas;VFr;Pt;Exhl gas;Qn;;PULM;2;Fractional concentration of exhaled nitric oxide;FeNO VFr;;ACTIVE;2.69;2.69 +96270-4;Cyclin-dependent kinase 4;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;Cyclin-dependent kinase 4 [Presence] in Cancer specimen by Immune stain;CDK4 Ca spec Ql ImStn;;ACTIVE;2.69;2.69 +9627-1;Imipramine+Desipramine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Imipramine+Desipramine [Mass/volume] in Serum or Plasma;Imipramine+Desipr SerPl-mCnc;;ACTIVE;1.0i;2.73 +96271-2;DNA mismatch repair protein Msh3;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;DNA mismatch repair protein Msh3 [Presence] in Cancer specimen by Immune stain;hMSH3 Ca spec Ql ImStn;;ACTIVE;2.69;2.69 +96272-0;DNA mismatch repair protein Mlh3;PrThr;Pt;Cancer specimen;Ord;Immune stain;PATH;1;DNA mismatch repair protein Mlh3 [Presence] in Cancer specimen by Immune stain;MLH3 Ca spec Ql ImStn;;ACTIVE;2.69;2.69 +96273-8;HIV 1 RNA+HIV 2 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA;PrThr;Pt;Ser/Plas/Bld^Donor;Ord;Probe.amp.tar;MICRO;1;HIV 1 RNA+HIV 2 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA [Presence] in Serum, Plasma or Blood from Donor by NAA with probe detection;HIV1+2+HCV+HBV SerPlBld Donr Ql NAA+prb;;ACTIVE;2.69;2.69 +96274-6;Fagus grandifolia wood dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;American Beech wood dust IgE Ab [Units/volume] in Serum;Amer Beech wood dust IgE Qn;;ACTIVE;2.69;2.69 +96275-3;Ammonium persulfate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ammonium persulfate IgE Ab [Units/volume] in Serum;Ammonium persulfate IgE Qn;;ACTIVE;2.69;2.69 +96276-1;Ribes nigrum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Blackcurrant IgE Ab [Units/volume] in Serum;Blackcurrant IgE Qn;;ACTIVE;2.69;2.69 +96277-9;carBAMazepine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;carBAMazepine IgE Ab [Units/volume] in Serum;carBAMazepine IgE Qn;;ACTIVE;2.69;2.69 +96278-7;Dermatophagoides pteronyssinus recombinant (rDer p) 23 Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides pteronyssinus recombinant (rDer p) 23 IgE Ab [Units/volume] in Serum;D pteronyss (rDer p) 23 IgE Qn;;ACTIVE;2.69;2.69 +96279-5;Abies alba wood dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European silver fir wood dust IgE Ab [Units/volume] in Serum;Euro silver fir wood dust IgE Qn;;ACTIVE;2.69;2.69 +96280-3;Fraxinus excelsior wood dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European Ash wood dust IgE Ab [Units/volume] in Serum;European Ash wood dust IgE Qn;;ACTIVE;2.69;2.69 +96281-1;Argas reflexus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European pigeon tick IgE Ab [Units/volume] in Serum;European pigeon tick IgE Qn;;ACTIVE;2.69;2.69 +96282-9;Coagulation factor XII inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor XII inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact XII Inhib PPP Ql;;ACTIVE;2.69;2.69 +96283-7;Gliadin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gliadin IgE Ab [Units/volume] in Serum;Gliadin IgE Qn;;ACTIVE;2.69;2.69 +96284-5;Hay dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hay dust IgE Ab [Units/volume] in Serum;Hay dust IgE Qn;;ACTIVE;2.69;2.69 +96285-2;Indomethacin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Indomethacin IgE Ab [Units/volume] in Serum;Indomethacin IgE Qn;;ACTIVE;2.69;2.69 +96286-0;Ketoprofen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ketoprofen IgE Ab [Units/volume] in Serum;Ketoprofen IgE Qn;;ACTIVE;2.69;2.69 +96287-8;(Amphotericin B+Erythromycin+Nystatin+Spiramycin) Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Macrolide Mix (Amphotericin B+Erythromycin+Nystatin+Spiramycin) IgE Ab [Units/volume] in Serum;Macrolide Mix IgE Qn;;ACTIVE;2.69;2.72 +96288-6;Methylene blue Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Methylene blue IgE Ab [Units/volume] in Serum;Methylene blue IgE Qn;;ACTIVE;2.69;2.69 +9628-9;O-desmethylvenlafaxine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;O-desmethylvenlafaxine [Mass/volume] in Serum or Plasma;ODV SerPl-mCnc;;ACTIVE;1.0i;2.73 +96289-4;Morphine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Morphine IgE Ab [Units/volume] in Serum;Morphine IgE Qn;;ACTIVE;2.69;2.69 +96290-2;predniSONE Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;predniSONE IgE Ab [Units/volume] in Serum;predniSONE IgE Qn;;ACTIVE;2.69;2.69 +96291-0;Pregnenolone sulfate;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pregnenolone sulfate [Mass/volume] in Serum or Plasma;Pregnenolone sulfate SerPl-mCnc;;ACTIVE;2.69;2.69 +96292-8;Quinoline Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Quinoline IgE Ab [Units/volume] in Serum;Quinoline IgE Qn;;ACTIVE;2.69;2.69 +96293-6;Sodium nitrite Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sodium nitrite IgE Ab [Units/volume] in Serum;Sodium nitrite IgE Qn;;ACTIVE;2.69;2.69 +96294-4;Straw dust Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Straw dust IgE Ab [Units/volume] in Serum;Straw dust IgE Qn;;ACTIVE;2.69;2.69 +96295-1;Streptomycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Streptomycin IgE Ab [Units/volume] in Serum;Streptomycin IgE Qn;;ACTIVE;2.69;2.69 +96296-9;Thuja spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Thuja spp IgE Ab [Units/volume] in Serum;Thuja spp IgE Qn;;ACTIVE;2.69;2.7 +9629-7;TOLAZamide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;TOLAZamide [Mass/volume] in Serum or Plasma;TOLAZamide SerPl-mCnc;;ACTIVE;1.0i;2.73 +96297-7;Cobalamins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cobalamin (Vitamin B12) IgE Ab [Units/volume] in Serum;Vit B12 IgE Qn;;ACTIVE;2.69;2.69 +96298-5;IRF-PAI v3.0 - Quality indicators - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Quality indicators - admission [CMS Assessment];;;ACTIVE;2.69;2.69 +96299-3;IRF-PAI v3.0 - Cognitive patterns - admission;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;IRF-PAI v3.0 - Cognitive patterns - admission [CMS Assessment];;;ACTIVE;2.69;2.69 +96300-9;Cell growth;PrThr;Pt;Fibroblasts;Ord;Tissue culture;SPEC;1;Cell growth [Presence] of Fibroblast in Tissue culture;Cell growth Fib Ql Tiss culture;;ACTIVE;2.69;2.69 +96301-7;Bacteroides fragilis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Bacteroides fragilis DNA [Presence] by NAA with non-probe detection in Positive blood culture;B fragilis DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.69;2.69 +96302-5;Candida auris DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Candida auris DNA [Presence] by NAA with non-probe detection in Positive blood culture;C auris DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.69;2.69 +96303-3;Cryptococcus gattii+neoformans DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Cryptococcus gattii+neoformans DNA [Presence] by NAA with non-probe detection in Positive blood culture;C gattii+neofor DNA Bld Pos Ql NAA+n-prb;;ACTIVE;2.69;2.69 +96304-1;Enterococcus faecalis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Enterococcus faecalis DNA [Presence] by NAA with non-probe detection in Positive blood culture;E faecalis DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.69;2.69 +9630-5;Venlafaxine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Venlafaxine [Mass/volume] in Serum or Plasma;Venlafaxine SerPl-mCnc;;ACTIVE;1.0i;2.73 +96305-8;Enterococcus faecium DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Enterococcus faecium DNA [Presence] by NAA with non-probe detection in Positive blood culture;E faecium DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.69;2.69 +96306-6;Enterobacterales DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Enterobacterales DNA [Presence] by NAA with non-probe detection in Positive blood culture;Enterobacterales DNA Bld Pos NAA+n-prb;;ACTIVE;2.69;2.69 +96307-4;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA [Presence] by NAA with non-probe detection in Positive blood culture;Klebsiella sp DNA Bld Pos Ql NAA+non-prb;;ACTIVE;2.69;2.69 +96308-2;Klebsiella aerogenes DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [Presence] by NAA with non-probe detection in Positive blood culture;Klebsiella sp DNA Bld Pos Ql NAA+non-prb;;ACTIVE;2.69;2.69 +96309-0;Bacterial methicillin resistance mecA+mecC genes+SCCmec+OrfX junction;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Methicillin resistance mecA+mecC genes+SCCmec+OrfX junction [Presence] by Molecular method;mecA+mecC+MREJ Islt/Spm Ql;;ACTIVE;2.69;2.69 +96310-8;Staphylococcus epidermidis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus epidermidis DNA [Presence] by NAA with non-probe detection in Positive blood culture;S epidermidis DNA Bld Pos Ql NAA+non-prb;;ACTIVE;2.69;2.69 +96311-6;Staphylococcus lugdunensis DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus lugdunensis DNA [Presence] by NAA with non-probe detection in Positive blood culture;S lugdunensis DNA Bld Pos Ql NAA+non-prb;;ACTIVE;2.69;2.69 +96312-4;Stenotrophomonas maltophilia DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Stenotrophomonas maltophilia DNA [Presence] by NAA with non-probe detection in Positive blood culture;S maltophilia DNA Bld Pos Ql NAA+non-prb;;ACTIVE;2.69;2.69 +9631-3;Viscosity;Visc;Pt;Semen;Qn;;SPEC;1;Viscosity of Semen;Visc Smn;;ACTIVE;1.0i;2.73 +96313-2;Salmonella sp DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Salmonella sp DNA [Presence] by NAA with non-probe detection in Positive blood culture;Salmonella DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.69;2.69 +96314-0;Work or school D missed due to illness;Num;Pt;^Patient;Qn;;H&P.HX;2;Work or school days missed due to illness [#];Work/school D missed due to illness;;ACTIVE;2.69;2.69 +96315-7;Gaps in care report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Gaps in care report;Gaps in care report;;ACTIVE;2.69;2.69 +96316-5;Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor 1+2 Ab.IgG;Titr;Pt;Ser;Qn;CBA IFA;SERO;1;AMPAR1+AMPAR2 IgG Ab [Titer] in Serum by Cell binding immunofluorescent assay;AMPAR 1+2 IgG Titr Ser CBA IFA;;ACTIVE;2.69;2.69 +96317-3;Acinetobacter calcoaceticus-baumannii complex DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Acinetobacter calcoaceticus-baumannii complex DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;ACB cmplx DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96318-1;Enterobacter cloacae complex DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;E cloac com DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96319-9;Escherichia coli DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;E coli DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96320-7;Streptococcus agalactiae DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;Gp B Strep DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +9632-1;Aspergillus fumigatus Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Aspergillus fumigatus Ab [Presence] in Serum;A fumigatus Ab Ser Ql;;ACTIVE;1.0i;2.73 +96321-5;Haemophilus influenzae DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;Haem influ DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96322-3;Klebsiella oxytoca DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;K oxytoca DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96323-1;Klebsiella aerogenes DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;K aerog DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96324-9;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;K pneumo grp L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96325-6;Moraxella catarrhalis DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Moraxella catarrhalis DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;M catarrhls DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96326-4;Pseudomonas aeruginosa DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;P aerug DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96327-2;Proteus sp DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Proteus sp DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;Proteus DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96328-0;Staphylococcus aureus DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;S aureus DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96329-8;Serratia marcescens DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Serratia marcescens DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;S marc DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96330-6;Streptococcus pneumoniae DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;S pneum DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96331-4;Streptococcus pyogenes DNA;NCncRange;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [NCncRange] in Lower respiratory specimen Qualitative by NAA with non-probe detection;S pyo DNA L resp NAA+non-prb-NCncRng;;ACTIVE;2.69;2.69 +96332-2;Note;Find;Pt;Telehealth;Doc;Case manager;DOC.ONTOLOGY;2;Case manager Telehealth Note;Case Manager Telehealth Note;;ACTIVE;2.69;2.69 +96333-0;Procedure note;Find;Pt;Custodial care facility;Doc;{Role};DOC.ONTOLOGY;2;Custodial care facility procedure note;Cust care fac Procedure note;;ACTIVE;2.69;2.69 +96334-8;Diagnostic study note;Find;Pt;{Setting};Doc;Diabetology;DOC.ONTOLOGY;2;Diabetology Diagnostic study note;Diabetology Diag study note;;ACTIVE;2.69;2.69 +96335-5;Summary note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Summary note;ED Summary note;;ACTIVE;2.69;2.69 +96336-3;Note;Find;Pt;Outpatient;Doc;Environmental health;DOC.ONTOLOGY;2;Environmental health Outpatient Note;Envir Health OP Note;;ACTIVE;2.69;2.69 +96337-1;Note;Find;Pt;Outpatient;Doc;Hematology;DOC.ONTOLOGY;2;Hematology Outpatient Note;Hematology OP Note;;ACTIVE;2.69;2.69 +96338-9;Progress note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Progress note;Hepatology Prog note;;ACTIVE;2.69;2.73 +9633-9;Epstein Barr virus capsid Ab.IgA;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus capsid IgA Ab [Titer] in Serum by Immunofluorescence;EBV VCA IgA Titr Ser IF;;ACTIVE;1.0i;2.73 +96339-7;Summary note;Find;Pt;Hospital;Doc;{Role};DOC.ONTOLOGY;2;Hospital Summary note;Hosp Summary note;;ACTIVE;2.69;2.69 +96340-5;Note;Find;Pt;{Setting};Doc;Integrative medicine;DOC.ONTOLOGY;2;Integrative medicine Note;Integrative medicine Note;;ACTIVE;2.69;2.69 +96341-3;Note;Find;Pt;Outpatient;Doc;Obesity medicine;DOC.ONTOLOGY;2;Obesity medicine Outpatient Note;Obesity med OP Note;;ACTIVE;2.69;2.69 +96342-1;Progress note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Progress note;OMS Prog note;;ACTIVE;2.69;2.73 +96343-9;Note;Find;Pt;Outpatient;Doc;Oncology;DOC.ONTOLOGY;2;Oncology Outpatient Note;Oncology OP Note;;ACTIVE;2.69;2.69 +96344-7;Summary note;Find;Pt;{Setting};Doc;Oncology;DOC.ONTOLOGY;2;Oncology Summary note;Oncology Summary note;;ACTIVE;2.69;2.69 +96345-4;Summary note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Summary note;OP Summary note;;ACTIVE;2.69;2.69 +96346-2;Administrative note;Find;Pt;{Setting};Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Administrative note;Orthotics prosthetics Admin note;;ACTIVE;2.69;2.69 +9634-7;Saint Louis encephalitis virus Ab.IgG;Titr;Pt;XXX;Qn;;MICRO;1;Saint Louis encephalitis virus IgG Ab [Titer] in Specimen;SLEV IgG Titr Spec;;ACTIVE;1.0i;2.7 +96347-0;Consent;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Consent Document;Radiology Consent;;ACTIVE;2.69;2.69 +96348-8;Note;Find;Pt;Outpatient;Doc;Radiology;DOC.ONTOLOGY;2;Radiology Outpatient Note;Radiology OP Note;;ACTIVE;2.69;2.69 +96349-6;Referral letter;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Referral letter;Referral letter;;ACTIVE;2.69;2.69 +96350-4;Progress note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Progress note;Sleep med Prog note;;ACTIVE;2.69;2.73 +96351-2;Procedure note;Find;Pt;Urgent care center;Doc;{Role};DOC.ONTOLOGY;2;Urgent care center procedure note;Urgent care Procedure note;;ACTIVE;2.69;2.69 +96352-0;Note;Find;Pt;Outpatient;Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Outpatient Note;Wound care management OP Note;;ACTIVE;2.69;2.69 +96353-8;Procedure note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management procedure note;Wound care management Procedure note;;ACTIVE;2.69;2.69 +9635-4;Saint Louis encephalitis virus Ab.IgM;Titr;Pt;XXX;Qn;;MICRO;1;Saint Louis encephalitis virus IgM Ab [Titer] in Specimen;SLEV IgM Titr Spec;;ACTIVE;1.0i;2.7 +96354-6;Platelets.large;NCnc;Pt;Bld;Qn;Automated count;HEM/BC;1;Platelets Large [#/volume] in Blood by Automated count;Lg Platelets # Bld Auto;;ACTIVE;2.69;2.69 +96355-3;Equine herpesvirus 1;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Equine herpesvirus 1 [Presence] in Specimen by Organism specific culture;EHV1 Spec Ql Cult;;ACTIVE;2.69;2.69 +96356-1;Equine herpesvirus 3;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Equine herpesvirus 3 [Presence] in Specimen by Organism specific culture;EHV3 Spec Ql Cult;;ACTIVE;2.69;2.69 +96357-9;Equine herpesvirus 4;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Equine herpesvirus 4 [Presence] in Specimen by Organism specific culture;EHV4 Spec Ql Cult;;ACTIVE;2.69;2.69 +96358-7;Bovine parainfluenza virus 3;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Bovine parainfluenza virus 3 [Presence] in Specimen by Organism specific culture;BPIV3 Spec Ql Cult;;ACTIVE;2.69;2.69 +96359-5;7-Aminoclonazepam;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Saliva (oral fluid) by Confirmatory method;7Aminoclonazepam Sal Ql Cfm;;ACTIVE;2.69;2.69 +96360-3;Dextromethorphan;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Dextromethorphan [Mass/volume] in Saliva (oral fluid) by Confirmatory method;D-methorphan Sal Cfm-mCnc;;ACTIVE;2.69;2.69 +96361-1;Dextromethorphan;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Dextromethorphan [Presence] in Saliva (oral fluid) by Confirmatory method;D-methorphan Sal Ql Cfm;;ACTIVE;2.69;2.69 +9636-2;Varicella zoster virus Ab;PrThr;Pt;CSF;Ord;;MICRO;1;Varicella zoster virus Ab [Presence] in Cerebral spinal fluid;VZV Ab CSF Ql;;ACTIVE;1.0i;2.56 +96362-9;Dextrorphan;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Dextrorphan [Mass/volume] in Saliva (oral fluid) by Confirmatory method;DXO Sal Cfm-mCnc;;ACTIVE;2.69;2.69 +96363-7;Dextrorphan+Levorphanol;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Dextrorphan+Levorphanol [Presence] in Saliva (oral fluid) by Confirmatory method;DXO+Levorphanol Sal Ql Cfm;;ACTIVE;2.69;2.69 +96364-5;Gabapentin;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Gabapentin [Presence] in Saliva (oral fluid) by Confirmatory method;Gabapentin Sal Ql Cfm;;ACTIVE;2.69;2.69 +96365-2;Naltrexol;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Naltrexol [Presence] in Saliva (oral fluid) by Confirmatory method;Naltrexol Sal Ql Cfm;;ACTIVE;2.69;2.69 +96366-0;Naltrexone;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Naltrexone [Presence] in Saliva (oral fluid) by Confirmatory method;Naltrexone Sal Ql Cfm;;ACTIVE;2.69;2.69 +96367-8;Pregabalin;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Pregabalin [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Pregabalin Sal Cfm-mCnc;;ACTIVE;2.69;2.69 +96368-6;Pregabalin;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Pregabalin [Presence] in Saliva (oral fluid) by Confirmatory method;Pregabalin Sal Ql Cfm;;ACTIVE;2.69;2.69 +96369-4;Sertraline;MCnc;Pt;Saliva;Qn;Confirm;DRUG/TOX;1;Sertraline [Mass/volume] in Saliva (oral fluid) by Confirmatory method;Sertraline Sal Cfm-mCnc;;ACTIVE;2.69;2.69 +9637-0;Toluene;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Toluene [Mass/volume] in Blood;Toluene Bld-mCnc;;ACTIVE;1.0i;2.73 +96370-2;Sertraline;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Sertraline [Presence] in Saliva (oral fluid) by Confirmatory method;Sertraline Sal Ql Cfm;;ACTIVE;2.69;2.69 +96371-0;Tapentadol;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Tapentadol [Presence] in Saliva (oral fluid) by Confirmatory method;Tapentadol Sal Ql Cfm;;ACTIVE;2.69;2.69 +96372-8;Imipenem+Relebactam;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Imipenem+Relebactam [Susceptibility];Imi+Rel Susc Islt;;ACTIVE;2.69;2.69 +96373-6;Admission evaluation note;Find;Pt;{Setting};Doc;Bone marrow transplant;DOC.ONTOLOGY;2;Bone Marrow Transplant Admission evaluation note;BM Transplant Admit eval note;;ACTIVE;2.69;2.69 +96374-4;Admission evaluation note;Find;Pt;{Setting};Doc;Dialysis+Therapeutic apheresis;DOC.ONTOLOGY;2;Dialysis and Therapeutic apheresis Admission evaluation note;Dialy+Ther Apher Admit eval note;;ACTIVE;2.69;2.69 +96375-1;Surgical operation note;Find;Pt;{Setting};Doc;Endocrinology;DOC.ONTOLOGY;2;Endocrinology Surgical operation note;Endocrinology Operative note;;ACTIVE;2.69;2.69 +96376-9;Surgical operation note;Find;Pt;{Setting};Doc;Neonatal perinatal medicine;DOC.ONTOLOGY;2;Neonatal perinatal medicine Surgical operation note;Neo peri med Operative note;;ACTIVE;2.69;2.69 +96377-7;Surgical operation note;Find;Pt;{Setting};Doc;Nephrology;DOC.ONTOLOGY;2;Nephrology Surgical operation note;Nephrology Operative note;;ACTIVE;2.69;2.69 +96378-5;Discharge summary note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management Discharge summary;Wound care management D/C sum;;ACTIVE;2.69;2.73 +96379-3;History and physical note;Find;Pt;{Setting};Doc;Wound care management;DOC.ONTOLOGY;2;Wound care management History and physical note;Wound care management H&P note;;ACTIVE;2.69;2.69 +96380-1;Wound duration;Time;Pt;^Patient;Qn;;H&P.HX;2;Wound duration;Wound duration;;ACTIVE;2.69;2.69 +96381-9;Immune status;Find;Pt;^Patient;Ord;;H&P.HX;2;Immune status;Immune status;;ACTIVE;2.69;2.69 +96382-7;Healed wound information;Find;Pt;^Patient;Doc;;H&P.HX;2;Healed wound information Document;Healed wnd info Doc;;ACTIVE;2.69;2.69 +96383-5;Health-related behaviors and treatment compliance;Find;Pt;^Patient;Doc;;CLIN;2;Health-related behaviors and treatment compliance Document;Health behav + tx compliance Doc;;ACTIVE;2.69;2.69 +96384-3;Health-related behaviors;Find;Pt;^Patient;Nom;;CLIN;2;Health-related behaviors;Health behav;;ACTIVE;2.69;2.69 +96385-0;Adherence to treatment;Find;Pt;^Patient;Ord;;CLIN;2;Adherence to treatment;Adher to treatment;;ACTIVE;2.69;2.69 +96386-8;Physical impairment information;Find;Pt;^Patient;Doc;;CLIN;2;Physical impairment information Document;Phys impair info Doc;;ACTIVE;2.69;2.69 +96387-6;Sensory symptoms;Find;Pt;^Patient;Nom;;H&P.HX;2;Sensory symptoms;Sensory symptoms;;ACTIVE;2.69;2.69 +9638-8;Toluene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Toluene [Mass/volume] in Urine;Toluene Ur-mCnc;;ACTIVE;1.0i;2.73 +96388-4;Psychosocial effect of wound odor;Find;Pt;^Patient;Nom;;CLIN;2;Psychosocial effect of wound odor;Effect of wound odor;;ACTIVE;2.69;2.69 +96389-2;Wound impact on quality of life;Find;Pt;^Patient;Nom;;H&P.HX;2;Wound impact on quality of life;Wound impact on QOL;;ACTIVE;2.69;2.69 +963-9;C super little x Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;C sup(x) Ab [Presence] in Serum or Plasma;C sup(x) Ab SerPl Ql;;ACTIVE;1.0;2.7 +96390-0;Wound impact on emotional health;Find;Pt;^Patient;Nom;;H&P.HX;2;Wound impact on emotional health;Wound impact on emot health;;ACTIVE;2.69;2.69 +96391-8;Wound classification and diagnoses;Find;Pt;^Patient;Doc;;H&P.PX;2;Wound classification and diagnoses;Wound class + dx;;ACTIVE;2.69;2.69 +96392-6;Debridement method;Type;Pt;Wound;Nom;;CLIN;2;Debridement method Wound;Debride method Wnd;;ACTIVE;2.69;2.69 +96393-4;Wound care instructions;Find;Pt;^Patient;Nom;;CLIN;2;Wound care instructions;Wound care instruct;;ACTIVE;2.69;2.69 +96394-2;Education completion status;Find;Pt;^Patient;Nom;;H&P.HX;2;Education completion status;Educ completion status;;ACTIVE;2.69;2.69 +96395-9;Acceptance of treatment;Find;Pt;^Patient;Ord;;CLIN;2;Acceptance of treatment;Treatment accept;;ACTIVE;2.69;2.69 +9639-6;18-Hydroxycorticosterone;MRat;24H;Urine;Qn;;CHEM;1;18-Hydroxycorticosterone [Mass/time] in 24 hour Urine;18OHB 24h Ur-mRate;;ACTIVE;1.0i;2.73 +96396-7;Cytomegalovirus DNA;LaCnc;Pt;XXX;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [log units/volume] (viral load) in Specimen by NAA with probe detection;CMV DNA Spec NAA+probe-Log IU;;ACTIVE;2.69;2.69 +96397-5;Microbiology - mycobacteriology studies;Find;Pt;^Patient;Doc;;DOC.MISC;2;Microbiology - mycobacteriology studies Document;Mycobacteriology studies Doc;;ACTIVE;2.69;2.69 +96398-3;Microbiology - mycology studies;Find;Pt;^Patient;Doc;;DOC.MISC;2;Microbiology - mycology studies Document;Mycology studies Doc;;ACTIVE;2.69;2.69 +96399-1;Retinol binding protein panel;-;24H;Urine;Qn;;PANEL.CHEM;1;Retinol binding protein panel - 24 hour Urine;RBP panel 24h Ur;;ACTIVE;2.69;2.69 +96400-7;Retinol binding protein/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Retinol binding protein/Creatinine [Mass Ratio] in 24 hour Urine;Retinol Bind Prot/Creat 24h Ur;;ACTIVE;2.69;2.69 +96401-5;Retinol binding protein panel;-;Pt;Urine;Qn;;PANEL.CHEM;1;Retinol binding protein panel - Urine;RBP panel Ur;;ACTIVE;2.69;2.69 +96402-3;Retinol binding protein/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Retinol binding protein/Creatinine [Mass Ratio] in Urine;Retinol Bind Prot/Creat Ur;;ACTIVE;2.69;2.69 +96403-1;Renal clearance & Renal plasma flow panel;-;Stdy;Urine+Ser/Plas;Qn;;PANEL.CHEM;1;Renal clearance and Renal plasma flow panel - Urine and Serum or Plasma;Renal Cl + RPF panel Ur+SerPl;;ACTIVE;2.69;2.69 +9640-4;Androstanediol;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Androstanediol [Mass/volume] in Serum or Plasma;Androstanediol SerPl-mCnc;;ACTIVE;1.0i;2.7 +96404-9;Para aminohippurate renal clearance/1.73 sq M;ArVRat;Stdy;Urine+Ser/Plas;Qn;;CHEM;1;Para aminohippurate renal clearance/1.73 sq M in Urine and Serum or Plasma;PAH Cl/1.73 sq M Ur+SerPl-ArVRat;;ACTIVE;2.69;2.69 +96405-6;Filtration Fraction;AFr;Stdy;Urine+Ser/Plas;Qn;;CHEM;1;Filtration Fraction in Urine and Serum or Plasma;Filtration Fr % Ur+SerPl;;ACTIVE;2.69;2.69 +96406-4;Retinol binding protein;MCnc;24H;Urine;Qn;;CHEM;1;Retinol binding protein [Mass/volume] in 24 hour Urine;Retinol Bind Prot 24h Ur-mCnc;;ACTIVE;2.69;2.69 +96407-2;Pancreatic polypeptide^30M post sham feeding;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma --30M post sham feeding;Panc Polypept 30M p Sham Feed SerPl-mCnc;;ACTIVE;2.69;2.69 +96408-0;Pancreatic polypeptide^25M post sham feeding;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma --25M post sham feeding;Panc Polypept 25M p Sham Feed SerPl-mCnc;;ACTIVE;2.69;2.69 +96409-8;Pancreatic polypeptide^20M post sham feeding;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma --20M post sham feeding;Panc Polypept 20M p Sham Feed SerPl-mCnc;;ACTIVE;2.69;2.69 +96410-6;Pancreatic polypeptide^15M post sham feeding;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma --15M post sham feeding;Panc Polypept 15M p Sham Feed SerPl-mCnc;;ACTIVE;2.69;2.69 +96411-4;Pancreatic polypeptide^10M post sham feeding;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma --10M post sham feeding;Panc Polypept 10M p Sham Feed SerPl-mCnc;;ACTIVE;2.69;2.69 +9641-2;Catecholamines/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Catecholamines/Creatinine [Mass Ratio] in Urine;Catechols/Creat Ur;;ACTIVE;1.0i;2.73 +96412-2;Pancreatic polypeptide^5M post sham feeding;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma --5M post sham feeding;Panc Polypept 5M p Sham Feed SerPl-mCnc;;ACTIVE;2.69;2.69 +96413-0;Pancreatic polypeptide^post CFst;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Pancreatic polypeptide [Mass/volume] in Serum or Plasma --fasting;Panc Polypept p fast SerPl-mCnc;;ACTIVE;2.69;2.69 +96414-8;Pancreatic polypeptide sham feeding panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Pancreatic polypeptide sham feeding panel - Serum or Plasma;PP Sham Feed Pnl SerPl;;ACTIVE;2.69;2.69 +96415-5;DOCK8 expression panel;-;Pt;Bld;-;Flow cytometry;PANEL.CELLMARK;1;DOCK8 expression panel - Blood by Flow cytometry (FC);DOCK8 Expr Pnl Bld FC;;ACTIVE;2.69;2.69 +96416-3;Cells.CD3+CD14-CD45+DOCK8+/100 Cells.CD3+CD14-CD45+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD3+CD14-CD45+DOCK8+/100 Cells.CD3+CD14-CD45+ in Blood by Flow cytometry (FC);T Cells DOCK8+/T Cells NFr Bld FC;;ACTIVE;2.69;2.69 +96417-1;Cells.CD3-CD14-CD19+CD45+DOCK8+/100 Cells.CD3-CD14-CD19+CD45+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD3-CD14-CD19+CD45+DOCK8+/100 Cells.CD3-CD14-CD19+CD45+ in Blood by Flow cytometry (FC);B Cells DOCK8+/B Cells NFr Bld FC;;ACTIVE;2.69;2.69 +96418-9;Cells.CD3-CD14-CD45+CD56+DOCK8+/100 Cells.CD3-CD14-CD45+CD56+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD3-CD14-CD45+CD56+DOCK8+/100 Cells.CD3-CD14-CD45+CD56+ in Blood by Flow cytometry (FC);NK Cells DOCK8+/NK Cells NFr Bld FC;;ACTIVE;2.69;2.69 +96419-7;Cells.CD3-CD14+CD45+DOCK8+/100 Cells.CD3-CD14+CD45+;NFr;Pt;Bld;Qn;Flow cytometry;CELLMARK;1;Cells.CD3-CD14+CD45+DOCK8+/100 Cells.CD3-CD14+CD45+ in Blood by Flow cytometry (FC);Monocytes DOCK8+/Monocytes NFr Bld FC;;ACTIVE;2.69;2.69 +9642-0;Creatine kinase.BB/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.BB/Creatine kinase.total in Serum or Plasma;CK BB CFr SerPl;;ACTIVE;1.0i;2.73 +96420-5;Daratumumab;PrThr;Pt;Ser;Ord;Immunofixation;CHEM;1;Daratumumab [Presence] in Serum by Immunofixation;Daratumumab Ser Ql IFE;;ACTIVE;2.69;2.69 +96421-3;Testosterone;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Testosterone [Mass/volume] in DBS;Testost DBS-mCnc;;ACTIVE;2.69;2.69 +96422-1;Cortisone;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Cortisone [Mass/volume] in DBS;Cortisone DBS-mCnc;;ACTIVE;2.69;2.69 +96423-9;Progesterone;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Progesterone [Mass/volume] in DBS;Progest DBS-mCnc;;ACTIVE;2.69;2.69 +96424-7;Testosterone/Cortisol;MRto;Pt;Bld.dot;Qn;;CHEM;1;Testosterone/Cortisol [Mass Ratio] in DBS;Testost/Cortis DBS;;ACTIVE;2.69;2.69 +96425-4;Cortisol/Cortisone;MRto;Pt;Bld.dot;Qn;;CHEM;1;Cortisol/Cortisone [Mass Ratio] in DBS;Cortis/Cortisone DBS;;ACTIVE;2.69;2.69 +96426-2;Nasal bone;PrThr;Pt;^Fetus;Ord;;OB.US;2;Fetal Nasal bone;Fet Nasal bn;;ACTIVE;2.69;2.69 +96427-0;Borrelia burgdorferi Ab.IgM;PrThr;Pt;XXX;Ord;;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Specimen;B burgdor IgM Spec Ql;;ACTIVE;2.69;2.69 +96428-8;Borrelia burgdorferi Ab.IgA;PrThr;Pt;XXX;Ord;;MICRO;1;Borrelia burgdorferi IgA Ab [Presence] in Specimen;B burgdor IgA Spec Ql;;ACTIVE;2.69;2.69 +96429-6;Borrelia burgdorferi G39_40 Ab.IgG bands;Prid;Pt;XXX;Nom;IB;MICRO;1;Borrelia burgdorferi G39/40 IgG bands [Identifier] in Specimen by Immunoblot;B burgdor G39/40 IgG bands Spec IB;;ACTIVE;2.69;2.69 +96430-4;Borrelia burgdorferi G39_40 Ab.IgG bands;Num;Pt;XXX;Qn;IB;MICRO;1;Borrelia burgdorferi G39/40 IgG bands [#] in Specimen by Immunoblot;B burgdor G39/40 IgG bands Spec IB;;ACTIVE;2.69;2.69 +96431-2;Borrelia burgdorferi 49736 Ab.IgG bands;Prid;Pt;XXX;Nom;IB;MICRO;1;Borrelia burgdorferi 49736 IgG bands [Identifier] in Specimen by Immunoblot;B burgdor 49736 IgG bands Spec IB;;ACTIVE;2.69;2.69 +96432-0;Borrelia burgdorferi 49736 Ab.IgG bands;Num;Pt;XXX;Qn;IB;MICRO;1;Borrelia burgdorferi 49736 IgG bands [#] in Specimen by Immunoblot;B burgdor 49736 IgG bands Spec IB;;ACTIVE;2.69;2.69 +96433-8;Would like help finding daycare for child;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Would like help finding daycare for child Caregiver;;;ACTIVE;2.70;2.7 +96434-6;Always has enough food for family;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Always has enough food for family Caregiver;;;ACTIVE;2.70;2.7 +96435-3;At risk of having utilities shut off in the next week;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;At risk of having utilities shut off in the next week Caregiver;;;ACTIVE;2.70;2.7 +96436-1;Trouble paying heating bill &or electricity bill;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Trouble paying heating bill AndOr electricity bill Caregiver;;;ACTIVE;2.70;2.7 +96437-9;Needs help getting food for family for tonight;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Needs help getting food for family for tonight Caregiver;;;ACTIVE;2.70;2.7 +9643-8;Creatine kinase.MM/Creatine kinase.total;CFr;Pt;Ser/Plas;Qn;;CHEM;1;Creatine kinase.MM/Creatine kinase.total in Serum or Plasma;CK MM CFr SerPl;;ACTIVE;1.0i;2.73 +96438-7;Would like help getting food for family;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Would like help getting food for family Caregiver;;;ACTIVE;2.70;2.7 +96439-5;Emergent risk of becoming homeless;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Emergent risk of becoming homeless Caregiver;;;ACTIVE;2.70;2.7 +96440-3;Would like help for being at risk of becoming homeless;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Would like help for being at risk of becoming homeless Caregiver;;;ACTIVE;2.70;2.7 +96441-1;At risk of becoming homeless;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;At risk of becoming homeless Caregiver;;;ACTIVE;2.70;2.7 +96442-9;Needs daycare for child;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Needs daycare for child Caregiver;;;ACTIVE;2.70;2.7 +96443-7;Would like help finding employment &or job training;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Would like help finding employment AndOr job training Caregiver;;;ACTIVE;2.70;2.7 +96444-5;Has a job;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Has a job Caregiver;;;ACTIVE;2.70;2.7 +96445-2;Would like help to get a GED;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Would like help to get a GED Caregiver;;;ACTIVE;2.70;2.7 +9644-6;Cystine;PrThr;Pt;Urine;Ord;;CHEM;1;Cystine [Presence] in Urine;Cystine Ur Ql;;ACTIVE;1.0i;2.73 +96446-0;High school degree;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;High school degree Caregiver;;;ACTIVE;2.70;2.7 +96447-8;WE CARE Survey;-;Pt;^Caregiver;-;WE CARE;PANEL.SURVEY.GNHLTH;4;WE CARE Survey [WE CARE] Caregiver;;;ACTIVE;2.70;2.7 +96448-6;SARS coronavirus 2 N gene;PrThr;Pt;Saliva;Ord;Probe.amp.tar.CDC primer-probe set N1;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N1;SARS-CoV-2 N gene Sal Ql NAA N1;;ACTIVE;2.69;2.69 +96449-4;Cell growth;PrThr;Pt;Tumor;Ord;Tissue culture;SPEC;1;Cell growth [Presence] of Tumor in Tissue culture;Cell growth Tumor Ql Tiss culture;;ACTIVE;2.69;2.69 +96450-2;Hepatocellular carcinoma risk;Score;Pt;^Patient;Qn;GALAD;CHEM;1;Hepatotocellular carcinoma risk [Score] GALAD;GALAD Score;;ACTIVE;2.69;2.7 +96451-0;Alpha-1-Fetoprotein & Alpha-1-Fetoprotein.L3 panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Alpha-1-Fetoprotein and Alpha-1-Fetoprotein.L3 panel - Serum or Plasma;AFP+AFP.L3 Pnl SerPl;;ACTIVE;2.69;2.69 +96452-8;Hepatocellular carcinoma risk panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Hepatocellular carcinoma risk panel - Serum or Plasma;Hep Ca Risk Pnl SerPl;;ACTIVE;2.69;2.69 +9645-3;Metanephrine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Metanephrine/Creatinine [Mass Ratio] in Urine;Metaneph/Creat Ur;;ACTIVE;1.0i;2.73 +96453-6;Coagulation factor XI activity & inhibitor panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Coagulation factor XI activity and inhibitor panel - Platelet poor plasma by Coagulation assay;Fact XI Act + Inhib Pnl PPP;;ACTIVE;2.69;2.69 +96454-4;Coagulation factor II inhibitor;PrThr;Pt;PPP;Ord;Coag;COAG;1;Coagulation factor II inhibitor [Presence] in Platelet poor plasma by Coagulation assay;Fact II Inhib PPP Ql;;ACTIVE;2.69;2.69 +96455-1;Coagulation factor II activity & inhibitor panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Coagulation factor II activity and inhibitor panel - Platelet poor plasma by Coagulation assay;Fact II Act + Inhib Pnl PPP;;ACTIVE;2.69;2.69 +96456-9;Coagulation factor VIII activity & inhibitor panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Coagulation factor VIII activity and inhibitor panel - Platelet poor plasma by Coagulation assay;Fact VIII Act + Inhib Pnl PPP;;ACTIVE;2.69;2.69 +96457-7;Coagulation factor X activity & inhibitor panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Coagulation factor X activity and inhibitor panel - Platelet poor plasma by Coagulation assay;Fact X Act + Inhib Pnl PPP;;ACTIVE;2.69;2.69 +96458-5;Coagulation factor V activity & inhibitor panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Coagulation factor V activity and inhibitor panel - Platelet poor plasma by Coagulation assay;Fact V Act + Inhib Pnl PPP;;ACTIVE;2.69;2.69 +96459-3;Coagulation factor IX activity & inhibitor panel;-;Pt;PPP;-;Coag;PANEL.COAG;1;Coagulation factor IX activity and inhibitor panel - Platelet poor plasma by Coagulation assay;Fact IX Act + Inhib Pnl PPP;;ACTIVE;2.69;2.69 +96460-1;Thyroglobulin^post thyroglobulin antibody neutralization;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Thyroglobulin [Mass/volume] in Serum or Plasma by Immunoassay --post thyroglobulin antibody neutralization;Thyrogl p thyrogl Ab neut SerPl IA-mCnc;;ACTIVE;2.69;2.69 +9646-1;Sulfide;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;Sulfide [Mass/volume] in Blood;Sulfide Bld-mCnc;;ACTIVE;1.0i;2.7 +96461-9;Gastrin releasing polypeptide prohormone;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Gastrin releasing polypeptide prohormone [Mass/volume] in Serum or Plasma by Immunoassay;ProGRP SerPl IA-mCnc;;ACTIVE;2.69;2.69 +96462-7;Sirolimus;SCnc;Pt;Bld;Qn;IA;DRUG/TOX;1;Sirolimus [Moles/volume] in Blood by Immunoassay;Sirolimus Bld IA-sCnc;;ACTIVE;2.69;2.69 +96463-5;Copper.free/Copper.total;MFr;Pt;Ser/Plas;Qn;Calculated;DRUG/TOX;1;Copper free/Total copper in Serum or Plasma by calculation;Copper free/Total copper MFr SerPl Calc;;ACTIVE;2.69;2.69 +96464-3;Inositol 1,4,5-trisphosphate receptor type 1 Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Inositol 1,4,5-trisphosphate receptor type 1 IgG Ab [Presence] in Serum by Immunofluorescence;IP3R 1 IgG Ser Ql IF;;ACTIVE;2.69;2.69 +96465-0;Inositol 1,4,5-trisphosphate receptor type 1 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Inositol 1,4,5-trisphosphate receptor type 1 IgG Ab [Titer] in Serum by Immunofluorescence;IP3R 1 IgG Titr Ser IF;;ACTIVE;2.69;2.69 +96466-8;Inositol 1,4,5-trisphosphate receptor type 1 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Inositol 1,4,5-trisphosphate receptor type 1 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;IP3R 1 IgG Ser Ql CBA IFA;;ACTIVE;2.69;2.69 +96467-6;Inositol 1,4,5-trisphosphate receptor type 1 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Inositol 1,4,5-trisphosphate receptor type 1 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;IP3R 1 IgG CSF Ql IF;;ACTIVE;2.69;2.69 +96468-4;Inositol 1,4,5-trisphosphate receptor type 1 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Inositol 1,4,5-trisphosphate receptor type 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;IP3R 1 IgG CSF Ql CBA IFA;;ACTIVE;2.69;2.69 +96469-2;Inositol 1,4,5-trisphosphate receptor type 1 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Inositol 1,4,5-trisphosphate receptor type 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;IP3R 1 IgG Titr CSF IF;;ACTIVE;2.69;2.69 +964-7;C super little x Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;C sup(x) Ag [Presence] on Red Blood Cells from Blood product unit;C sup(x) Ag RBC BPU Ql;;ACTIVE;1.0;2.73 +96470-0;Rho GTPase-activating protein 26 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Rho GTPase-activating protein 26 IgG Ab [Titer] in Serum by Immunofluorescence;GRAF IgG Titr Ser IF;;ACTIVE;2.69;2.69 +96471-8;Rho GTPase-activating protein 26 Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Rho GTPase-activating protein 26 IgG Ab [Presence] in Serum by Immunofluorescence;GRAF IgG Ser Ql IF;;ACTIVE;2.69;2.69 +96472-6;Rho GTPase-activating protein 26 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Rho GTPase-activating protein 26 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;GRAF IgG Ser Ql CBA IFA;;ACTIVE;2.69;2.69 +96473-4;Rho GTPase-activating protein 26 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Rho GTPase-activating protein 26 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;GRAF IgG CSF Ql IF;;ACTIVE;2.69;2.69 +96474-2;Rho GTPase-activating protein 26 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Rho GTPase-activating protein 26 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;GRAF IgG Titr CSF IF;;ACTIVE;2.69;2.69 +96475-9;Rho GTPase-activating protein 26 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Rho GTPase-activating protein 26 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;GRAF IgG CSF Ql CBA IFA;;ACTIVE;2.69;2.69 +96476-7;IgLON family member 5 Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;IgLON5 IgG Ab [Presence] in Serum by Immunofluorescence;IgLON5 IgG Ser Ql IF;;ACTIVE;2.69;2.69 +96477-5;IgLON family member 5 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;IgLON5 IgG Ab [Titer] in Serum by Immunofluorescence;IgLON5 IgG Titr Ser IF;;ACTIVE;2.69;2.69 +96478-3;IgLON family member 5 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;IgLON5 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;IgLON5 IgG Ser Ql CBA IFA;;ACTIVE;2.69;2.69 +9647-9;Thiosulfate;MCnc;Pt;Bld;Qn;;CHEM;1;Thiosulfate [Mass/volume] in Blood;Thiosulfate Bld-mCnc;;ACTIVE;1.0i;2.73 +96479-1;IgLON family member 5 Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;IgLON5 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;IgLON5 IgG CSF Ql IF;;ACTIVE;2.69;2.69 +96480-9;IgLON family member 5 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;IgLON5 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;IgLON5 IgG Titr CSF IF;;ACTIVE;2.69;2.69 +96481-7;IgLON family member 5 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;IgLON5 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;IgLON5 IgG CSF Ql CBA IFA;;ACTIVE;2.69;2.69 +96482-5;Alpha-internexin Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Alpha-internexin IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;Alpha-internexin IgG CSF Ql CBA IFA;;ACTIVE;2.69;2.69 +96483-3;Alpha-internexin Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Alpha-internexin IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;Alpha-internexin IgG Ser Ql CBA IFA;;ACTIVE;2.69;2.69 +96484-1;Neuronal intermediate filament heavy chain Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Neuronal intermediate filament heavy chain IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;NIF-H IgG Ser Ql CBA IFA;;ACTIVE;2.69;2.69 +96485-8;Neuronal intermediate filament light chain Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Neuronal intermediate filament light chain IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;NIF-L IgG Ser Ql CBA IFA;;ACTIVE;2.69;2.69 +96486-6;Neuronal intermediate filament Ab.IgG;PrThr;Pt;Ser;Ord;IF;SERO;1;Neuronal intermediate filament IgG Ab [Presence] in Serum by Immunofluorescence;NIF IgG Ser Ql IF;;ACTIVE;2.69;2.69 +9648-7;Chlorothiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Chlorothiazide [Mass/volume] in Urine;Chlorothiazide Ur-mCnc;;ACTIVE;1.0i;2.73 +96487-4;Neuronal intermediate filament Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Neuronal intermediate filament IgG Ab [Titer] in Serum by Immunofluorescence;NIF IgG Titr Ser IF;;ACTIVE;2.69;2.69 +96488-2;Neuronal intermediate filament heavy chain Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Neuronal intermediate filament heavy chain IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;NIF-H IgG CSF Ql CBA IFA;;ACTIVE;2.69;2.69 +96489-0;Neuronal intermediate filament light chain Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Neuronal intermediate filament light chain IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;NIF-L IgG CSF Ql CBA IFA;;ACTIVE;2.69;2.69 +96490-8;Neuronal intermediate filament Ab.IgG;PrThr;Pt;CSF;Ord;IF;SERO;1;Neuronal intermediate filament IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;NIF IgG CSF Ql IF;;ACTIVE;2.69;2.69 +96491-6;Neuronal intermediate filament Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Neuronal intermediate filament IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;NIF IgG Titr CSF IF;;ACTIVE;2.69;2.69 +96492-4;Cells.CD3+CD8+CD27+CD45RO+CD62L+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3+CD8+CD27+CD45RO+CD62L+ cells [#/volume] in Blood;CD3+CD8+CD27+CD45RO+CD62L+ cells # Bld;;ACTIVE;2.69;2.69 +96493-2;T-cell naive & memory & activated subsets panel;-;Pt;Bld;Qn;;PANEL.CELLMARK;1;T-cell naive and memory and activated subsets panel - Blood;T-cell naive + mem + act subsets Pnl Bld;;ACTIVE;2.69;2.69 +96494-0;ABL1 & ABL2 & PDGFRB gene rearrangements;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.REARRANGE;1;ABL1 and ABL2 and PDGFRB gene rearrangements in Blood or Tissue by FISH;ABL1 + ABL2 + PDGFRB rearr Bld/T FISH;;ACTIVE;2.69;2.69 +9649-5;Hydroflumethiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Hydroflumethiazide [Mass/volume] in Urine;Hydroflumethiazide Ur-mCnc;;ACTIVE;1.0i;2.73 +96495-7;ABL2 gene rearrangements;Find;Pt;Bld/Tiss;Doc;FISH;MOLPATH.REARRANGE;1;ABL2 gene rearrangements in Blood or Tissue by FISH;ABL2 rearrange Bld/T FISH;;ACTIVE;2.69;2.69 +96496-5;Glycine receptor alpha-1 subunit Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Glycine receptor alpha-1 subunit IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;GlyRa-1 IgG Ser Ql CBA IFA;;ACTIVE;2.69;2.69 +96497-3;Glycine receptor alpha-1 subunit Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Glycine receptor alpha-1 subunit IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;GlyRa-1 IgG CSF Ql CBA IFA;;ACTIVE;2.69;2.69 +96498-1;La Crosse virus Ab.IgG & IgM panel;-;Pt;CSF;-;;PANEL.MICRO;1;La Crosse virus Ab.IgG and IgM panel - Cerebral spinal fluid;LACV Ab.IgG & IgM panel CSF;;ACTIVE;2.69;2.69 +96499-9;La Crosse virus Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;La Crosse virus Ab.IgG and IgM panel - Serum;LACV Ab.IgG & IgM panel Ser;;ACTIVE;2.69;2.69 +96500-4;Hyperoxaluria panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Hyperoxaluria panel - Serum or Plasma;Hyperoxaluria Pnl SerPl;;ACTIVE;2.69;2.69 +96501-2;TIF1-gamma Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;TIF1-gamma Ab [Units/volume] in Serum by Immunoassay;TIF1-gamma Ab Ser IA-aCnc;;ACTIVE;2.69;2.69 +96502-0;Number of wheelchair pushes;NRat;XXX;^Patient;Qn;;H&P.HX;2;Number of wheelchair pushes per time period;# wheelchair push nRate;;ACTIVE;2.69;2.69 +9650-3;Methyclothiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Methyclothiazide [Mass/volume] in Urine;Methyclothiazide Ur-mCnc;;ACTIVE;1.0i;2.73 +96503-8;Adenovirus DNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Adenovirus DNA [Presence] in Respiratory specimen by NAA with probe detection;HAdV DNA Resp Ql NAA+probe;;ACTIVE;2.69;2.69 +96504-6;Protein/Osmolality;Ratio;Pt;Urine;Qn;;CHEM;1;Protein/Osmolality [Ratio] in Urine;Prot/Osmolality Ur-Rto;;ACTIVE;2.69;2.69 +96505-3;Colorado tick fever virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Colorado tick fever virus IgM Ab [Presence] in Specimen by Immunoassay;CTFV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96506-1;Oropouche virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Oropouche virus IgG Ab [Presence] in Specimen by Immunoassay;Oropouche virus IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96507-9;California encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;California encephalitis virus IgG Ab [Presence] in Specimen by Immunoassay;CEV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96508-7;Bunyamwera virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bunyamwera virus IgG Ab [Presence] in Specimen by Immunoassay;Bunyamwera virus IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96509-5;Tick-borne encephalitis virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Tick-borne encephalitis virus IgG Ab [Presence] in Specimen by Immunoassay;TBEV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96510-3;Heartland banyangvirus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Heartland banyangvirus IgG Ab [Presence] in Specimen by Immunoassay;HRTV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +9651-1;metOLazone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;metOLazone [Mass/volume] in Urine;metOLazone Ur-mCnc;;ACTIVE;1.0i;2.73 +96511-1;Bwamba virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bwamba virus IgG Ab [Presence] in Specimen by Immunoassay;Bwamba virus IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96512-9;Rift Valley fever virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Rift valley fever virus IgG Ab [Presence] in Specimen by Immunoassay;RVFV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96513-7;Sandfly fever Naples virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Sandfly fever Naples virus IgG Ab [Presence] in Specimen by Immunoassay;SFNV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96514-5;Cache Valley virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Cache valley virus IgM Ab [Presence] in Specimen by Immunoassay;CVV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96515-2;Sandfly fever Sicilian virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Sandfly fever Sicilian virus IgG Ab [Presence] in Specimen by Immunoassay;SFSV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96516-0;Toscana virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Toscana virus IgG Ab [Presence] in Specimen by Immunoassay;TOSV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96517-8;Bourbon virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bourbon virus IgG Ab [Presence] in Specimen by Immunoassay;Bourbon virus IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96518-6;Onyong-nyong virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Onyong-nyong virus IgG Ab [Presence] in Specimen by Immunoassay;ONN virus IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96519-4;Semliki forest virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Semliki Forest virus IgG Ab [Presence] in Specimen by Immunoassay;SFV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96520-2;Ilheus virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Ilheus virus IgG Ab [Presence] in Specimen by Immunoassay;ILHV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96521-0;Cache Valley virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Cache valley virus IgG Ab [Presence] in Specimen by Immunoassay;CVV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96522-8;Colorado tick fever virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Colorado tick fever virus IgG Ab [Presence] in Specimen by Immunoassay;CTFV IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96523-6;Ilheus virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Ilheus virus IgM Ab [Presence] in Specimen by Immunoassay;ILHV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96524-4;Rocio virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Rocio virus IgM Ab [Presence] in Specimen by Immunoassay;Rocio virus IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96525-1;Semliki forest virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Semliki Forest virus IgM Ab [Presence] in Specimen by Immunoassay;SFV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96526-9;Onyong-nyong virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Onyong-nyong virus IgM Ab [Presence] in Specimen by Immunoassay;ONN virus IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96527-7;Bourbon virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bourbon virus IgM Ab [Presence] in Specimen by Immunoassay;Bourbon virus IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96528-5;Toscana virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Toscana virus IgM Ab [Presence] in Specimen by Immunoassay;TOSV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +9652-9;N-desalkylflurazepam;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;N-desalkylflurazepam [Mass/volume] in Serum or Plasma;Desalkylfluraz SerPl-mCnc;;ACTIVE;1.0i;2.73 +96529-3;Sandfly fever Sicilian virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Sandfly fever Sicilian virus IgM Ab [Presence] in Specimen by Immunoassay;SFSV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96530-1;Sandfly fever Naples virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Sandfly fever Naples virus IgM Ab [Presence] in Specimen by Immunoassay;SFNV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96531-9;Oropouche virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Oropouche virus IgM Ab [Presence] in Specimen by Immunoassay;Oropouche virus IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96532-7;Rift Valley fever virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Rift valley fever virus IgM Ab [Presence] in Specimen by Immunoassay;RVFV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96533-5;Bwamba virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bwamba virus IgM Ab [Presence] in Specimen by Immunoassay;Bwamba virus IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96534-3;Heartland banyangvirus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Heartland banyangvirus IgM Ab [Presence] in Specimen by Immunoassay;HRTV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96535-0;Tick-borne encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Tick-borne encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;TBEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96536-8;Bunyamwera virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;Bunyamwera virus IgM Ab [Presence] in Specimen by Immunoassay;Bunyamwera virus IgM Spec Ql IA;;ACTIVE;2.69;2.69 +9653-7;Trichlormethiazide;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trichlormethiazide [Mass/volume] in Urine;TCM Ur-mCnc;;ACTIVE;1.0i;2.73 +96537-6;California encephalitis virus Ab.IgM;PrThr;Pt;XXX;Ord;IA;MICRO;1;California encephalitis virus IgM Ab [Presence] in Specimen by Immunoassay;CEV IgM Spec Ql IA;;ACTIVE;2.69;2.69 +96538-4;Rocio virus Ab.IgG;PrThr;Pt;XXX;Ord;IA;MICRO;1;Rocio virus IgG Ab [Presence] in Specimen by Immunoassay;Rocio virus IgG Spec Ql IA;;ACTIVE;2.69;2.69 +96539-2;Mechanical ventilation for condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether the patient received mechanical ventilation for condition of interest;Mech vent for condition;;ACTIVE;2.69;2.69 +965-4;C super little x Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;C sup(x) Ag [Presence] on Red Blood Cells from Donor;C sup(x) Ag RBC Donr Ql;;ACTIVE;1.0;2.7 +96540-0;Extracorporeal membrane oxygenation for condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether the patient received ECMO for condition of interest;ECMO for condition;;ACTIVE;2.69;2.69 +96541-8;Patient is within 6 weeks postpartum;Find;Pt;^Patient;Ord;;H&P.HX;2;Patient is within 6 weeks postpartum;Within 6 wks postpartum;;ACTIVE;2.69;2.69 +96542-6;Travel in 14 days prior to symptom onset;Find;Pt;^Patient;Ord;;H&P.HX;2;Travel in 14 days prior to symptom onset;Travel 14D prior to symp;;ACTIVE;2.69;2.69 +96543-4;Visited healthcare facility in 14 days prior to symptom onset;Find;Pt;^Patient;Ord;;H&P.HX;2;Visited healthcare facility in 14 days prior to symptom onset;Visit healthcare fac 14D prior to symp;;ACTIVE;2.69;2.69 +96544-2;Contact with confirmed case in 14 days prior to symptom onset;Find;Pt;^Patient;Ord;;H&P.HX;2;Contact with confirmed case in 14 days prior to symptom onset;Cont w conf case 14D prior to symp;;ACTIVE;2.69;2.69 +9654-5;Interleukin 2 receptor.soluble;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 2 Receptor Soluble [Units/volume] in Serum or Plasma;Sol Il2 Recep SerPl-aCnc;;ACTIVE;1.0i;2.73 +96545-9;Date and time of first contact with confirmed case;TmStp;Pt;^Patient;Qn;;H&P.HX;2;Date and time of first contact with confirmed case;D/T first contact w case;;ACTIVE;2.69;2.69 +96546-7;Country where diagnosed;Loc;Pt;^Patient;Nom;;PUBLICHEALTH;2;Country where diagnosed;Country where dx;;ACTIVE;2.69;2.69 +96547-5;Province, state, or region where diagnosed;Loc;Pt;^Patient;Nom;;PUBLICHEALTH;2;Province, state, or region where diagnosed;Province, state or region where dx;;ACTIVE;2.69;2.69 +96548-3;Isolated per Infection Prevention and Control guidelines;Find;Pt;^Patient;Ord;;PUBLICHEALTH;2;Whether the patient was isolated per Infection Prevention and Control guidelines;Isolated per IPC guidelines;;ACTIVE;2.69;2.69 +96549-1;Date and time of infection control isolation;TmStp;Pt;^Patient;Qn;;PUBLICHEALTH;2;Date and time of infection control isolation;D/T infection cont isolation;;ACTIVE;2.69;2.69 +96550-9;Date of most recent lab test for condition of interest;Date;Pt;^Patient;Qn;;PUBLICHEALTH;2;Date of most recent lab test for condition of interest;Date latest lab test for cond of int;;ACTIVE;2.69;2.69 +96551-7;Number of contacts followed for contact tracing;Num;Pt;^Patient;Qn;;PUBLICHEALTH;2;Number of contacts followed for contact tracing;# contacts for contact tracing;;ACTIVE;2.69;2.69 +9655-2;Campylobacter jejuni Ab;Titr;Pt;Ser;Qn;;MICRO;1;Campylobacter jejuni Ab [Titer] in Serum;C jejuni Ab Titr Ser;;ACTIVE;1.0i;2.73 +96552-5;Result of most recent lab test for condition of interest;Find;Pt;^Patient;Nom;;PUBLICHEALTH;2;Result of most recent lab test for condition of interest;Result latest lab test for cond of int;;ACTIVE;2.69;2.69 +96553-3;Date of subsequent report to public health department;Date;Pt;^Patient;Qn;;PUBLICHEALTH;2;Date of subsequent report to public health department;Subseq rpt date to PHD;;ACTIVE;2.69;2.69 +96554-1;Eutylone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Eutylone [Mass/volume] in Serum or Plasma;Eutylone SerPl-mCnc;;ACTIVE;2.69;2.69 +96555-8;Eutylone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;Eutylone [Presence] in Urine;Eutylone Ur Ql;;ACTIVE;2.69;2.69 +96556-6;HIV 1 & 2 RNA;Prid;Pt;Ser/Plas;Nom;Probe.amp.tar;MICRO;1;HIV 1 and 2 RNA [Identifier] in Serum or Plasma by NAA with probe detection;HIV 1 & 2 RNA SerPl NAA+probe;;ACTIVE;2.69;2.69 +96557-4;HIV 1 & 2 RNA panel;-;Pt;Ser/Plas;-;Probe.amp.tar;PANEL.MICRO;1;HIV 1 and 2 RNA panel - Serum or Plasma by NAA with probe detection;HIV 1 + 2 RNA Pnl SerPl NAA+probe;;ACTIVE;2.69;2.69 +96558-2;Wound healing stage;Find;Pt;Wound;Nom;;H&P.PX;2;Wound healing stage;Wound heal stage;;ACTIVE;2.69;2.69 +96559-0;Testosterone.free;SCnc;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Testosterone Free [Moles/volume] in Serum or Plasma by calculation;Testost Free SerPl Calc-sCnc;;ACTIVE;2.69;2.69 +9656-0;Echinococcus sp Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echinococcus sp IgG Ab [Units/volume] in Serum by Immunoassay;Echinococcus IgG Ser IA-aCnc;;ACTIVE;1.0i;2.73 +96560-8;Nuclear pore protein gp210 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Nuclear pore protein gp210 Ab [Units/volume] in Serum by Immunoassay;Nuclear pore prot gp210 Ab Ser IA-aCnc;;ACTIVE;2.69;2.69 +96561-6;Citrullinated alpha enolase peptide 1 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Citrullinated alpha enolase peptide 1 Ab [Units/volume] in Serum by Immunoassay;CEP-1 Ab Ser IA-aCnc;;ACTIVE;2.69;2.69 +96562-4;Cytosolic 5'-nucleotidase 1A Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Cytosolic 5'-nucleotidase 1A Ab [Units/volume] in Serum by Immunoassay;cN-1A Ab Ser IA-aCnc;;ACTIVE;2.69;2.69 +96563-2;Inner ear 68kD Ab.IgG;ACnc;Pt;Ser;Qn;IA;SERO;1;Inner ear 68kD IgG Ab [Units/volume] in Serum by Immunoassay;Inner ear 68kD IgG Ser IA-aCnc;;ACTIVE;2.69;2.69 +96564-0;Inner ear Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;Inner ear Ab [Units/volume] in Serum by Immunoassay;Inner ear Ab Ser IA-aCnc;;ACTIVE;2.69;2.69 +96565-7;sp100 Ab;ACnc;Pt;Ser;Qn;IA;SERO;1;sp100 Ab [Units/volume] in Serum by Immunoassay;sp100 Ab Ser IA-aCnc;;ACTIVE;2.69;2.69 +96566-5;Cabotegravir;Susc;Pt;Isolate;Ord;Genotyping;ABXBACT;1;Cabotegravir [Susceptibility] by Genotype method;Cabotegravir Islt Genotyp;;ACTIVE;2.69;2.69 +96567-3;Toxocara sp Ab.IgG;PrThr;Pt;Ocular fld;Ord;IA;MICRO;1;Toxocara sp IgG Ab [Presence] in Ocular fluid by Immunoassay;Toxocara IgG Ocflu Ql IA;;ACTIVE;2.69;2.69 +96568-1;Toxocara sp Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Toxocara sp IgG Ab [Presence] in Serum by Immunoassay;Toxocara IgG Ser Ql IA;;ACTIVE;2.69;2.69 +96569-9;LACE index panel;-;Pt;^Patient;-;LACE index;PANEL.CLIN.RISK;2;LACE index panel;LACE index panel;;ACTIVE;2.70;2.7 +96571-5;Admitted via emergency department;Find;Pt;^Patient;Ord;;CLIN;2;Admitted via emergency department;ED Admit;;ACTIVE;2.70;2.7 +96574-9;LACE index score;Score;Pt;^Patient;Qn;LACE index;CLIN.RISK;2;LACE index score LACE index;LACE score LACE;;ACTIVE;2.70;2.7 +96575-6;During the last Mo did you not eat for a whole day because your family didn't have enough money for food;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month did you not eat for a whole day because your family didn't have enough money for food [U.S. FSS - Child];;;ACTIVE;2.69;2.7 +96576-4;U.S. Child Food Security Survey;-;1Mo;^Patient;-;U.S. Food Security Survey.Child;PANEL.SURVEY.SDOH;4;U.S. Child Food Security Survey [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96577-2;During the last Mo were you hungry but didn't eat because your family didn't have enough food;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month were you hungry but didn't eat because your family didn't have enough food [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +9657-8;Echinococcus sp Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Echinococcus sp IgM Ab [Units/volume] in Serum by Immunoassay;Echinococcus IgM Ser IA-aCnc;;ACTIVE;1.0i;2.69 +96578-0;U.S. Child Food Security Survey Score;Score;Pt;^Patient;Qn;U.S. Food Security Survey.Child;SURVEY.SDOH;4;U.S. Child Food Security Survey Score [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96579-8;During the last Mo did you have to skip a meal because your family didn't have enough money for food;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month did you have to skip a meal because your family didn't have enough money for food [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96580-6;During the last Mo has the size of your meals been cut because your family didn't have enough money for food;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month has the size of your meals been cut because your family didn't have enough money for food [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96581-4;During the last Mo did you have to eat less because your family didn't have enough money to buy food;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month did you have to eat less because your family didn't have enough money to buy food [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96582-2;During the last Mo how often were you not able to eat a balanced meal because your family didn't have enough money;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month how often were you not able to eat a balanced meal because your family didn't have enough money [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96583-0;During the last Mo did your meals only include a few kinds of cheap foods because your family was running out of money to buy food;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month did your meals only include a few kinds of cheap foods because your family was running out of money to buy food [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96584-8;During the last Mo did the food that your family bought run out, and you didn't have money to get more;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month did the food that your family bought run out, and you didn't have money to get more [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +96585-5;During the last Mo did you worry that food at home would run out before your family got money to buy more;Find;1Mo;^Patient;Ord;U.S. Food Security Survey.Child;SURVEY.SDOH;4;During the last month did you worry that food at home would run out before your family got money to buy more [U.S. FSS - Child];;;ACTIVE;2.69;2.69 +9658-6;Giardia lamblia Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Giardia lamblia IgA Ab [Units/volume] in Serum;G lamblia IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +96586-3;Alanine aminotransferase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Alanine aminotransferase [Enzymatic activity/volume] in DBS;ALT DBS-cCnc;;ACTIVE;2.69;2.69 +96587-1;Aspartate aminotransferase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Aspartate aminotransferase [Enzymatic activity/volume] in DBS;AST DBS-cCnc;;ACTIVE;2.69;2.69 +96588-9;Cholesterol;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Cholesterol [Mass/volume] in DBS;Cholest DBS-mCnc;;ACTIVE;2.69;2.69 +96589-7;Cholesterol.total/Cholesterol.in HDL;MRto;Pt;Bld.dot;Qn;;CHEM;1;Cholesterol.total/Cholesterol in HDL [Mass Ratio] in DBS;Cholest/HDLc DBS;;ACTIVE;2.69;2.69 +96590-5;Creatinine;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Creatinine [Mass/volume] in DBS;Creat DBS-mCnc;;ACTIVE;2.69;2.69 +96591-3;Glomerular filtration rate/1.73 sq M.predicted.black;ArVRat;Pt;Bld.dot;Qn;;CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among blacks [Volume Rate/Area] in DBS;GFR/BSA pred.black DBS-ArVRat;;ACTIVE;2.69;2.69 +96592-1;Glomerular filtration rate/1.73 sq M.predicted.non black;ArVRat;Pt;Bld.dot;Qn;;CHEM;1;Glomerular filtration rate/1.73 sq M.predicted among non-blacks [Volume Rate/Area] in DBS;GFR/BSA pred.non black DBS-ArVRat;;ACTIVE;2.69;2.69 +96593-9;Gamma glutamyl transferase;CCnc;Pt;Bld.dot;Qn;;CHEM;1;Gamma glutamyl transferase [Enzymatic activity/volume] in DBS;GGT DBS-cCnc;;ACTIVE;2.69;2.69 +9659-4;Herpes simplex virus Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Herpes simplex virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;HSV IgG CSF IA-aCnc;;ACTIVE;1.0i;2.73 +96594-7;Glucose;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Glucose [Mass/volume] in DBS;Glucose DBS-mCnc;;ACTIVE;2.69;2.69 +96595-4;Hemoglobin A1c/Hemoglobin.total;MFr;Pt;Bld.dot;Qn;;CHEM;1;Hemoglobin A1c/Hemoglobin.total in DBS;HbA1c MFr DBS;;ACTIVE;2.69;2.7 +96596-2;Cholesterol.in HDL;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Cholesterol in HDL [Mass/volume] in DBS;HDLc DBS-mCnc;;ACTIVE;2.69;2.69 +96597-0;Cholesterol.in LDL;MCnc;Pt;Bld.dot;Qn;Direct assay;CHEM;1;Cholesterol in LDL [Mass/volume] in DBS by Direct assay;LDLc DBS Direct Assay-mCnc;;ACTIVE;2.69;2.69 +96598-8;Triglyceride;MCnc;Pt;Bld.dot;Qn;;CHEM;1;Triglyceride [Mass/volume] in DBS;Trigl DBS-mCnc;;ACTIVE;2.69;2.69 +96599-6;Neisseria gonorrhoeae DNA;PrThr;Pt;Cvx;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Cervix by NAA with probe detection;N gonorrhoea DNA Cvx Ql NAA+probe;;ACTIVE;2.69;2.69 +96600-2;Retinol & Alpha tocopherol panel;-;Pt;Ser/Plas;Qn;;PANEL.CHEM;1;Retinol and Alpha tocopherol panel - Serum or Plasma;Retinol + A-Tocopherol Pnl SerPl;;ACTIVE;2.69;2.69 +96601-0;Bacilliform bacteria;PrThr;Pt;Skin;Ord;Microscopy.light;MICRO;1;Bacilliform bacteria [Presence] in Skin by Light microscopy;Bacilliform bact Skin Ql Micro;;ACTIVE;2.69;2.69 +9660-2;HIV 1 gp160 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp160 Ab [Presence] in Serum by Immunoblot;HIV1 gp160 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96602-8;Methadone & 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine panel;-;Pt;Ser/Plas;-;;PANEL.DRUG/TOX;1;Methadone and EDDP panel - Serum or Plasma;Methadone + EDDP Pnl SerPl;;ACTIVE;2.69;2.69 +96603-6;SARS coronavirus 2 spike protein RBD Ab.neut;PrThr;Pt;Ser/Plas;Ord;sVNT;MICRO;1;SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by sVNT;SARS-CoV-2 S RBD NAb SerPl Ql sVNT;;ACTIVE;2.69;2.72 +96604-4;Acrylic fiber Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Acrylic fiber IgE Ab [Units/volume] in Serum;Acrylic fiber IgE Qn;;ACTIVE;2.69;2.69 +96605-1;Saccharum officinarum pollen Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sugar cane pollen IgE Ab [Units/volume] in Serum;Sugar cane pollen IgE Qn;;ACTIVE;2.69;2.69 +96606-9;Treated sheep wool Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Treated sheep wool IgE Ab [Units/volume] in Serum;Treated sheep wool IgE Qn;;ACTIVE;2.69;2.69 +96607-7;Blood pressure panel;-;XXX^mean;Arterial system;-;;PANEL.BP;2;Blood pressure panel mean systolic and mean diastolic;BP Pnl Avg Sys+Avg Dias;;ACTIVE;2.69;2.73 +96608-5;Intravascular systolic;Pres;XXX^mean;Arterial system;Qn;;BP.MOLEC;2;Systolic blood pressure mean;BP Sys Avg;;ACTIVE;2.69;2.73 +96609-3;Intravascular diastolic;Pres;XXX^mean;Arterial system;Qn;;BP.MOLEC;2;Diastolic blood pressure mean;BP Dias Avg;;ACTIVE;2.69;2.73 +9661-0;HIV 1 gp120 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp120 Ab [Presence] in Serum by Immunoblot;HIV1 gp120 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96610-1;Observation setting;Type;Pt;^Patient;Nom;;H&P.HX;2;Observation setting;Obs set;;ACTIVE;2.69;2.69 +96611-9;Treponema pallidum & Haemophilus ducreyi & Herpes simplex virus DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Treponema pallidum and Haemophilus ducreyi and Herpes simplex virus DNA panel - Specimen by NAA with probe detection;T pall+H ducr+HSV DNA Pnl Spec NAA+probe;;ACTIVE;2.69;2.71 +96612-7;Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis DNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA panel - Specimen by NAA with probe detection;CT + NG + TV DNA Pnl Spec NAA+probe;;ACTIVE;2.69;2.69 +96613-5;HLA-A;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-A [Type] in Donor by High resolution;HLA-A Donr High Res;;ACTIVE;2.69;2.69 +96614-3;HLA-A & B & C (class I) typing panel;-;Pt;Bld/Tiss^Donor;-;High resolution;PANEL.HLA;1;HLA-A and B and C (class I) typing panel - Blood or Tissue from Donor by High resolution;HLA Cls I Typ Pnl Bld/T Donr High Res;;ACTIVE;2.69;2.69 +96615-0;HLA-A & B & C (class I) typing panel;-;Pt;Bld/Tiss;-;High resolution;PANEL.HLA;1;HLA-A and B and C (class I) typing panel - Blood or Tissue by High resolution;HLA Cls I Typ Pnl Bld/T High Res;;ACTIVE;2.69;2.69 +96616-8;HLA-A unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-A unresolved alleles [Type] in Donor by High resolution;HLA-A Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +96617-6;HLA-A unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-A unresolved alleles [Type] by High resolution;HLA-A Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96618-4;HLA-B;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-B [Type] in Donor by High resolution;HLA-B Donr High Res;;ACTIVE;2.69;2.69 +96619-2;HLA-B unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-B unresolved alleles [Type] in Donor by High resolution;HLA-B Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +966-2;C super little x Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;C sup(x) Ag [Presence] on Red Blood Cells;C sup(x) Ag RBC Ql;;ACTIVE;1.0;2.7 +96620-0;HLA-B unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-B unresolved alleles [Type] by High resolution;HLA-B Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96621-8;HLA-C;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-C [Type] in Donor by High resolution;HLA-C Donr High Res;;ACTIVE;2.69;2.69 +96622-6;HLA-C unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-C unresolved alleles [Type] in Donor by High resolution;HLA-C Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +96623-4;HLA-C unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-C unresolved alleles [Type] by High resolution;HLA-C Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96624-2;HLA typing comment;Imp;Pt;Bld/Tiss^Donor;Nar;;HLA;1;Donor HLA typing comment [Interpretation] Narrative;HLA typ comm Donr-Imp;;ACTIVE;2.69;2.69 +96625-9;HLA typing comment;Imp;Pt;Bld/Tiss;Nar;;HLA;1;HLA typing comment [Interpretation] Narrative;HLA typ comm-Imp;;ACTIVE;2.69;2.69 +96626-7;HLA-A;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-A [Type] in Donor by Low resolution;HLA-A Donr Low res;;ACTIVE;2.69;2.69 +96627-5;HLA-A;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-A [Type] in Donor;HLA-A Donr;;ACTIVE;2.69;2.69 +9662-8;HIV 1 gp41 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 gp41 Ab [Presence] in Serum by Immunoblot;HIV1 gp41 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96628-3;HLA-A & B & C (class I) typing panel;-;Pt;Bld/Tiss^Donor;-;Low resolution;PANEL.HLA;1;HLA-A and B and C (class I) typing panel - Blood or Tissue from Donor by Low resolution;HLA Cls I Typ Pnl Bld/T Donr Low res;;ACTIVE;2.69;2.69 +96629-1;HLA-A & B & C (class I) typing panel;-;Pt;Bld/Tiss;-;Low resolution;PANEL.HLA;1;HLA-A and B and C (class I) typing panel - Blood or Tissue by Low resolution;HLA Cls I Typ Pnl Bld/T Low res;;ACTIVE;2.69;2.69 +96630-9;HLA-B;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-B [Type] in Donor by Low resolution;HLA-B Donr Low res;;ACTIVE;2.69;2.69 +96631-7;HLA-B;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-B [Type] in Donor;HLA-B Donr;;ACTIVE;2.69;2.69 +96632-5;HLA-Bw;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-Bw [Type] in Donor;HLA-Bw Donr;;ACTIVE;2.69;2.69 +96633-3;HLA-Bw;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-Bw [Type];HLA-Bw;;ACTIVE;2.69;2.73 +96634-1;HLA-C;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-C [Type] in Donor by Low resolution;HLA-C Donr Low res;;ACTIVE;2.69;2.69 +96635-8;HLA-C;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-C [Type] in Donor;HLA-C Donr;;ACTIVE;2.69;2.69 +9663-6;HIV 1 p17 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p17 Ab [Presence] in Serum by Immunoblot;HIV1 p17 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96636-6;HLA-C;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-C [Type] by Low resolution;HLA-C Low res;;ACTIVE;2.69;2.69 +96637-4;HLA-DP & DQ & DR (class II) typing panel;-;Pt;Bld/Tiss;-;High resolution;PANEL.HLA;1;HLA-DP and DQ and DR (class II) typing panel - Blood or Tissue by High resolution;HLA Cls II Typ Pnl Bld/T High Res;;ACTIVE;2.69;2.69 +96638-2;HLA-DP & DQ & DR (class II) typing panel;-;Pt;Bld/Tiss^Donor;-;Low resolution;PANEL.HLA;1;HLA-DP and DQ and DR (class II) typing panel - Blood or Tissue from Donor by Low resolution;HLA Cls II Typ Pnl Bld/T Donr Low res;;ACTIVE;2.69;2.69 +96639-0;HLA-DP & DQ & DR (class II) typing panel;-;Pt;Bld/Tiss^Donor;-;High resolution;PANEL.HLA;1;HLA-DP and DQ and DR (class II) typing panel - Blood or Tissue from Donor by High resolution;HLA Cls II Typ Pnl Bld/T Donr High Res;;ACTIVE;2.69;2.69 +96640-8;HLA-DP & DQ & DR (class II) typing panel;-;Pt;Bld/Tiss;-;Low resolution;PANEL.HLA;1;HLA-DP and DQ and DR (class II) typing panel - Blood or Tissue by Low resolution;HLA Cls II Typ Pnl Bld/T Low res;;ACTIVE;2.69;2.69 +96641-6;HLA-DPA1;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DPA1 [Type] in Donor by High resolution;HLA-DPA1 Donr High Res;;ACTIVE;2.69;2.69 +96642-4;HLA-DPA1;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-DPA1 [Type] in Donor by Low resolution;HLA-DPA1 Donr Low res;;ACTIVE;2.69;2.69 +96643-2;HLA-DPA1;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DPA1 [Type] by Low resolution;HLA-DPA1 Low res;;ACTIVE;2.69;2.69 +9664-4;HIV 1 p24 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p24 Ab [Presence] in Serum by Immunoblot;HIV1 p24 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96644-0;HLA-DPA1 unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DPA1 unresolved alleles [Type] in Donor by High resolution;HLA-DPA1 Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +96645-7;HLA-DPA1 unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DPA1 unresolved alleles [Type] by High resolution;HLA-DPA1 Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96646-5;HLA-DPB1;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DPB1 [Type] in Donor by High resolution;HLA-DPB1 Donr High Res;;ACTIVE;2.69;2.69 +96647-3;HLA-DPB1;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-DPB1 [Type] in Donor by Low resolution;HLA-DPB1 Donr Low res;;ACTIVE;2.69;2.69 +96648-1;HLA-DPB1;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DPB1 [Type] by Low resolution;HLA-DPB1 Low res;;ACTIVE;2.69;2.69 +96649-9;HLA-DPB1 T-cell epitope match;Type;Pt;Bld/Tiss^Donor+Patient;Nom;High resolution;HLA;1;HLA-DPB1 T-cell epitope match [Type] in Donor+Patient by High resolution;HLA-DPB1 Ept Match Don+Pt High Res;;ACTIVE;2.69;2.69 +96650-7;HLA-DPB1 unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DPB1 unresolved alleles [Type] in Donor by High resolution;HLA-DPB1 Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +9665-1;HIV 1 p24 Ag;ACnc;Pt;Ser;Qn;;MICRO;1;HIV 1 p24 Ag [Units/volume] in Serum;HIV1 p24 Ag Ser-aCnc;;ACTIVE;1.0i;2.73 +96651-5;HLA-DPB1 unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DPB1 unresolved alleles [Type] by High resolution;HLA-DPB1 Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96652-3;HLA-DQA1;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DQA1 [Type] in Donor by High resolution;HLA-DQA1 Donr High Res;;ACTIVE;2.69;2.69 +96653-1;HLA-DQA1;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-DQA1 [Type] in Donor by Low resolution;HLA-DQA1 Donr Low res;;ACTIVE;2.69;2.69 +96654-9;HLA-DQA1;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DQA1 [Type] by Low resolution;HLA-DQA1 Low res;;ACTIVE;2.69;2.69 +96655-6;HLA-DQA1 unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DQA1 unresolved alleles [Type] in Donor by High resolution;HLA-DQA1 Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +96656-4;HLA-DQA1 unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DQA1 unresolved alleles [Type] by High resolution;HLA-DQA1 Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96657-2;HLA-DQB1;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DQB1 [Type] in Donor by High resolution;HLA-DQB1 Donr High Res;;ACTIVE;2.69;2.69 +96658-0;HLA-DQB1;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-DQB1 [Type] in Donor by Low resolution;HLA-DQB1 Donr Low res;;ACTIVE;2.69;2.69 +96659-8;HLA-DQB1;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-DQB1 [Type] in Donor;HLA-DQB1 Donr;;ACTIVE;2.69;2.69 +96660-6;HLA-DQB1 unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DQB1 unresolved alleles [Type] in Donor by High resolution;HLA-DQB1 Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +96661-4;HLA-DQB1 unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DQB1 unresolved alleles [Type] by High resolution;HLA-DQB1 Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96662-2;HLA-DRB1;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DRB1 [Type] in Donor by High resolution;HLA-DRB1 Donr High Res;;ACTIVE;2.69;2.69 +96663-0;HLA-DRB1;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-DRB1 [Type] in Donor by Low resolution;HLA-DRB1 Donr Low res;;ACTIVE;2.69;2.69 +96664-8;HLA-DRB1;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DRB1 [Type] by Low resolution;HLA-DRB1 Low res;;ACTIVE;2.69;2.69 +96665-5;HLA-DRB1;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-DRB1 [Type] in Donor;HLA-DRB1 Donr;;ACTIVE;2.69;2.69 +96666-3;HLA-DRB1 unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DRB1 unresolved alleles [Type] in Donor by High resolution;HLA-DRB1 Unreslvd Alleles Donr High Res;;ACTIVE;2.69;2.69 +96667-1;HLA-DRB1 unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB1 unresolved alleles [Type] by High resolution;HLA-DRB1 Unreslvd Alleles High Res;;ACTIVE;2.69;2.69 +96668-9;HLA-DRB3 & HLA-DRB4 & HLA DRB5;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 [Type] in Donor by High resolution;HLA-DRB3 + 4 + 5 Donr High Res;;ACTIVE;2.69;2.69 +9666-9;HIV 1 p31 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p31 Ab [Presence] in Serum by Immunoblot;HIV1 p31 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96669-7;HLA-DRB3 & HLA-DRB4 & HLA DRB5;Type;Pt;Bld/Tiss^Donor;Nom;Low resolution;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 [Type] in Donor by Low resolution;HLA-DRB3 + 4 + 5 Donr Low res;;ACTIVE;2.69;2.69 +96670-5;HLA-DRB3 & HLA-DRB4 & HLA DRB5;Type;Pt;Bld/Tiss^Donor;Nom;;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 [Type] in Donor;HLA-DRB3 + 4 + 5 Donr;;ACTIVE;2.69;2.69 +96671-3;HLA-DRB3 & HLA-DRB4 & HLA DRB5;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 [Type] by High resolution;HLA-DRB3 + 4 + 5 High Res;;ACTIVE;2.69;2.69 +96672-1;HLA-DRB3 & HLA-DRB4 & HLA DRB5;Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 [Type] by Low resolution;HLA-DRB3 + 4 + 5 Low res;;ACTIVE;2.69;2.69 +96673-9;HLA-DRB3 & HLA-DRB4 & HLA DRB5;Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 [Type];HLA-DRB3 + 4 + 5;;ACTIVE;2.69;2.69 +96674-7;HLA-DRB3 & HLA-DRB4 & HLA DRB5 unresolved alleles;Type;Pt;Bld/Tiss^Donor;Nom;High resolution;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 unresolved alleles [Type] in Donor by High resolution;HLA-DRB345 Unreslvd Donr High Res;;ACTIVE;2.69;2.69 +96675-4;HLA-DRB3 & HLA-DRB4 & HLA DRB5 unresolved alleles;Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-DRB3 and HLA-DRB4 and HLA DRB5 unresolved alleles [Type] by High resolution;HLA-DRB345 Unreslvd High Res;;ACTIVE;2.69;2.69 +96676-2;Employer phone number;Tele;Pt;^Patient;Nom;;ADMIN.PATIENT;2;Employer phone number;Employer phone #;;ACTIVE;2.69;2.69 +9667-7;HIV 1 p51 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p51 Ab [Presence] in Serum by Immunoblot;HIV1 p51 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96677-0;Address;Addr;Pt;School;Nom;;ADMIN;2;School Address;School Address;;ACTIVE;2.69;2.69 +96678-8;School code;ID;Pt;School;Nom;;ADMIN.ID;2;School code [ID];School code ID;;ACTIVE;2.69;2.69 +96679-6;Identifier assigning authority;ID;Pt;School;Nom;;ADMIN.ID;2;School Identifier assigning authority;School ID assign auth;;ACTIVE;2.69;2.69 +96680-4;Activated clotting time.diatomaceous earth induced;Time;Pt;Bld;Qn;Microviscometry;COAG;1;Activated clotting time.diatomaceous earth induced of Blood by Microviscometry;ACT Diatom earth Ind Bld MicrVisc;;ACTIVE;2.69;2.69 +96681-2;Activated clotting time.diatomaceous earth+clay induced;Time;Pt;Bld;Qn;Microviscometry;COAG;1;Activated clotting time.diatomaceous earth+clay induced of Blood by Microviscometry;ACT Diatom Earth+Clay Ind Bld MicrVisc;;ACTIVE;2.69;2.69 +96682-0;Activated clotting time.glass bead induced;Time;Pt;Bld;Qn;Microviscometry;COAG;1;Activated clotting time.glass bead induced of Blood by Microviscometry;ACT Glass Bead Ind Bld MicrVisc;;ACTIVE;2.69;2.69 +96683-8;Activated clotting time.glass bead induced^post heparin neutralization;Time;Pt;Bld;Qn;Microviscometry;COAG;1;Activated clotting time.glass bead induced of Blood by Microviscometry --post heparin neutralization;ACT Glass Bead Ind HepNtr Bld MicrVisc;;ACTIVE;2.69;2.69 +96684-6;Activated clotting time.kaolin induced;Time;Pt;Bld;Qn;Microviscometry;COAG;1;Activated clotting time.kaolin induced of Blood by Microviscometry;ACT Kaolin Ind Bld MicrVisc;;ACTIVE;2.69;2.69 +9668-5;HIV 1 p55 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p55 Ab [Presence] in Serum by Immunoblot;HIV1 p55 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96685-3;Clot formation & Platelet function.glass bead induced post heparin neutralization panel;-;Pt;Bld;-;Microviscometry;PANEL.COAG;1;Clot formation and Platelet function.glass bead induced post heparin neutralization panel - Blood by Microviscometry;Clt Frm+PltFn Gls -Hep Pnl Bld MicrVisc;;ACTIVE;2.69;2.69 +96686-1;Clot formation & Platelet function.glass bead induced panel;-;Pt;Bld;-;Microviscometry;PANEL.COAG;1;Clot formation and Platelet function.glass bead induced panel - Blood by Microviscometry;Clt Frm+Plt Fnc Gls Ind Pnl Bld MicrVisc;;ACTIVE;2.69;2.69 +96687-9;Clot formation.diatomaceous earth induced panel;-;Pt;Bld;-;Microviscometry;PANEL.COAG;1;Clot formation.diatomaceous earth induced panel - Blood by Microviscometry;Clt Frm Diat Erth Ind Pnl Bld MicrVisc;;ACTIVE;2.69;2.69 +96688-7;Clot formation.diatomaceous earth+clay induced panel;-;Pt;Bld;-;Microviscometry;PANEL.COAG;1;Clot formation.diatomaceous earth+clay induced panel - Blood by Microviscometry;Clt Frm Diat Erth+Cly Pnl Bld MicrVisc;;ACTIVE;2.69;2.69 +96689-5;Clot formation.glass bead induced panel;-;Pt;Bld;-;Microviscometry;PANEL.COAG;1;Clot formation.glass bead induced panel - Blood by Microviscometry;Clt Frm Glss Bd Ind Pnl Bld MicrVisc;;ACTIVE;2.69;2.69 +96690-3;Clot formation.kaolin induced panel;-;Pt;Bld;-;Microviscometry;PANEL.COAG;1;Clot formation.kaolin induced panel - Blood by Microviscometry;Clot Form Kaolin Ind Pnl Bld MicrVisc;;ACTIVE;2.69;2.69 +96691-1;Coagulation viscoelastic tracing;Find;Stdy;Bld;Doc;;COAG;1;Coagulation viscoelastic tracing in Blood Document;Coag Viscoelast Tracing Bld Doc;;ACTIVE;2.69;2.69 +96692-9;Platelet-induced clot retraction.glass bead induced;Arb;Pt;Bld;Qn;Microviscometry;COAG;1;Platelet-induced clot retraction.glass bead induced in Blood by Microviscometry;Plt Ind Clt Retr Gls Bld MicrVisc;;ACTIVE;2.69;2.69 +9669-3;HIV 1 p66 Ab;PrThr;Pt;Ser;Ord;IB;MICRO;1;HIV 1 p66 Ab [Presence] in Serum by Immunoblot;HIV1 p66 Ab Ser Ql IB;;ACTIVE;1.0i;2.73 +96693-7;Platelet-induced clot retraction.glass bead induced^post heparin neutralization;Arb;Pt;Bld;Qn;Microviscometry;COAG;1;Platelet-induced clot retraction.glass bead induced in Blood by Microviscometry --post heparin neutralization;Plt-Ind CltRetr Gls HepNtr Bld MicrVisc;;ACTIVE;2.69;2.69 +96694-5;Rate of fibrin formation.diatomaceous earth induced;ARat;Pt;Bld;Qn;Microviscometry;COAG;1;Rate of fibrin formation.diatomaceous earth induced [Units] in Blood by Microviscometry;Clot Rate Diatom Earth Ind Bld MicrVisc;;ACTIVE;2.69;2.69 +96695-2;Rate of fibrin formation.diatomaceous earth+clay induced;ARat;Pt;Bld;Qn;Microviscometry;COAG;1;Rate of fibrin formation.diatomaceous earth+clay induced [Units] in Blood by Microviscometry;Clot Rt Diat Erth+Kaoln Bld MicrVisc;;ACTIVE;2.69;2.69 +96696-0;Rate of fibrin formation.glass bead induced;ARat;Pt;Bld;Qn;Microviscometry;COAG;1;Rate of fibrin formation.glass bead induced [Units] in Blood by Microviscometry;Clot Rate Glass Bead Ind Bld MicrVisc;;ACTIVE;2.69;2.69 +96697-8;Rate of fibrin formation.glass bead induced^post heparin neutralization;ARat;Pt;Bld;Qn;Microviscometry;COAG;1;Rate of fibrin formation.glass bead induced [Units] in Blood by Microviscometry --post heparin neutralization;Clot Rate GlsBead HepNtr Bld MicrVisc;;ACTIVE;2.69;2.69 +96698-6;Rate of fibrin formation.kaolin induced;ARat;Pt;Bld;Qn;Microviscometry;COAG;1;Rate of fibrin formation.kaolin induced [Units] in Blood by Microviscometry;Clot Rate Kaolin Ind Bld MicrVisc;;ACTIVE;2.69;2.69 +96699-4;Total score;Score;Pt;^Patient;Qn;MyMemCheck;SURVEY.GNHLTH;4;Total score [MyMemCheck];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +967-0;D little u Ab;ACnc;Pt;Ser/Plas^BPU;Ord;Aggl RBC;BLDBK;1;Deprecated D little u Ab [Presence] in Serum or Plasma from Blood product unit;Deprecated Du Ab SerPl BPU Ql;;DEPRECATED;1.0;2.4 +96700-0;MyMemCheck assessment panel;-;Pt;^Patient;-;MyMemCheck;PANEL.SURVEY.GNHLTH;4;MyMemCheck assessment panel [MyMemCheck];;© 2012 Dr. William Mansbach. Used with permission.;ACTIVE;2.69;2.69 +9670-1;Plasmodium malariae Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Plasmodium malariae IgG Ab [Units/volume] in Serum;P malariae IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +96701-8;Carbon monoxide/gas.total^at end expiration^corrected for ambient CO;VFr;Pt;Exhl gas;Qn;;PULM;2;Carbon monoxide/Gas total corrected for ambient CO Exhaled gas --at end expiration;ETCOc;;ACTIVE;2.69;2.69 +96702-6;Clot initiation.kaolin induced;Time;Pt;Bld;Qn;US;COAG;1;Clot initiation.kaolin induced [Time] in Blood by US;Clot init kaolin ind Bld US;;ACTIVE;2.69;2.7 +96703-4;Clot initiation.kaolin induced/Clot initiation.kaolin induced^post heparin neutralization;TRto;Pt;Bld;Qn;Calculated;COAG;1;Clot initiation.kaolin induced/Clot initiation.kaolin induced post heparin neutralization [Time Ratio] in Blood by calculation;Clot init kaol ind to post hep neut TRto;;ACTIVE;2.69;2.7 +96704-2;Clot initiation.kaolin induced^post heparin neutralization;Time;Pt;Bld;Qn;US;COAG;1;Clot initiation.kaolin induced [Time] in Blood by US --post heparin neutralization;Clot init kaolin ind p hep neut Bld US;;ACTIVE;2.69;2.7 +96705-9;Clot stiffness reduction due to fibrinolysis;PresRto;Pt;Bld;Qn;Calculated;COAG;1;Clot stiffness reduction percent due to fibrinolysis in Blood by calculation;Clot stiff red % due to fibrinolysis;;ACTIVE;2.69;2.7 +96706-7;Clot stiffness.platelet contribution;Pres;Pt;Bld;Qn;Calculated;COAG;1;Clot stiffness.platelet contribution (elasticity) in Blood by calculation;Clot stiff plt cont Bld Calc;;ACTIVE;2.69;2.7 +96707-5;Clot stiffness.fibrinogen contribution.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited^post heparin neutralization;Pres;Pt;Bld;Qn;US;COAG;1;Clot stiffness.fibrinogen contribution.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited (elasticity) in Blood by US --post heparin neutralization;Clot stiff TF ind+IIb-IIIa inh p hep neu;;ACTIVE;2.69;2.7 +96708-3;Clot stiffness.tissue factor induced^post heparin neutralization;Pres;Pt;Bld;Qn;US;COAG;1;Clot stiffness.tissue factor induced (elasticity) in Blood by US --post heparin neutralization;Clot stiff TF ind p hep neut Bld US;;ACTIVE;2.69;2.7 +96709-1;Probability of developing hepatocellular carcinoma;Likelihood;Pt;^Patient;Qn;;CLIN.RISK;2;Probability of developing hepatocellular carcinoma [Likelihood];Probability HCC;;ACTIVE;2.69;2.69 +96710-9;Clot;PrThr;Pt;Body fld;Ord;;SPEC;1;Clot [Presence] of Body fluid Qualitative;Clot Fld Ql;;ACTIVE;2.69;2.69 +96711-7;Erythrocytes;Naric;Pt;Body fld;Qn;Microscopy.light;HEM/BC;1;Erythrocytes [#/area] in Body fluid by Light microscopy;RBC #/area Fld Micro;;ACTIVE;2.69;2.69 +96712-5;Leukocytes;Naric;Pt;Body fld;Qn;Microscopy.light;HEM/BC;1;Leukocytes [#/area] in Body fluid by Light microscopy;WBC #/area Fld Micro;;ACTIVE;2.69;2.69 +96713-3;Microscopic observation;Prid;Pt;Body fld;Nom;Microscopy.light;PATH;1;Microscopic observation [Identifier] in Body fluid by Light microscopy;Fld Micro;;ACTIVE;2.69;2.69 +96714-1;Epithelial cells.squamous;NCnc;Pt;Bronchial;Qn;Manual count;HEM/BC;1;Epithelial cells.squamous [#/volume] in Bronchial specimen by Manual count;Squamous # Bronch Manual;;ACTIVE;2.69;2.69 +96715-8;Color;Type;Pt;Prostatic fld;Nom;;SPEC;1;Color of Prostatic fluid;Color Prost fld;;ACTIVE;2.69;2.69 +96716-6;Odor;Type;Pt;Prostatic fld;Nom;;SPEC;1;Odor of Prostatic fluid;Odor Prost fld;;ACTIVE;2.69;2.69 +96717-4;pH;LsCnc;Pt;Prostatic fld;Qn;;CHEM;1;pH of Prostatic fluid;pH Prost fld;;ACTIVE;2.69;2.69 +96718-2;Leukocytes;Naric;Pt;Prostatic fld;Qn;Microscopy.light;HEM/BC;1;Leukocytes [#/area] in Prostatic fluid by Light microscopy;WBC #/area Prost fld Micro;;ACTIVE;2.69;2.69 +9671-9;Plasmodium malariae Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Plasmodium malariae IgM Ab [Units/volume] in Serum;P malariae IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +96719-0;Erythrocytes;Naric;Pt;Prostatic fld;Qn;Microscopy.light;HEM/BC;1;Erythrocytes [#/area] in Prostatic fluid by Light microscopy;RBC #/area Prost fld Micro;;ACTIVE;2.69;2.69 +96720-8;Epithelial cells;Naric;Pt;Prostatic fld;Qn;Microscopy.light;HEM/BC;1;Epithelial cells [#/area] in Prostatic fluid by Light microscopy;Epi Cells #/area Prost fld Micro;;ACTIVE;2.69;2.69 +96721-6;Macrophages;Naric;Pt;Prostatic fld;Qn;Microscopy.light;HEM/BC;1;Macrophages [#/area] in Prostatic fluid by Light microscopy;Macrophages #/area Prost fld Micro;;ACTIVE;2.69;2.69 +96722-4;Amyloid bodies;Naric;Pt;Prostatic fld;Qn;Microscopy.light;PATH;1;Amyloid bodies [#/area] in Prostatic fluid by Light microscopy;Amyloid #/area Prost fld Micro;;ACTIVE;2.69;2.69 +96723-2;Odor;Type;Pt;Respiratory.lower;Nom;;SPEC;1;Odor of Lower respiratory specimen;Odor Lower resp;;ACTIVE;2.69;2.69 +96724-0;Macrophages.alveolar;NCnc;Pt;Respiratory.lower;Qn;Manual count;HEM/BC;1;Alveolar macrophages [#/volume] in Lower respiratory specimen by Manual count;Alv macro # Lower resp Manual;;ACTIVE;2.69;2.69 +96725-7;Xanthoma cells;NCnc;Pt;Respiratory.lower;Qn;Manual count;HEM/BC;1;Xanthoma cells [#/volume] in Lower respiratory specimen by Manual count;Xanthoma cells # Lower resp Manual;;ACTIVE;2.69;2.69 +96726-5;Epithelial cells.ciliated;NCnc;Pt;Respiratory.lower;Qn;Manual count;HEM/BC;1;Epithelial cells.ciliated [#/volume] in Lower respiratory specimen by Manual count;Ciliated # Lower resp Manual;;ACTIVE;2.69;2.69 +9672-7;Salmonella sp Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella sp IgA Ab [Units/volume] in Serum;Salmonella IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +96727-3;Erythrocytes;NCnc;Pt;Respiratory.lower;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Lower respiratory specimen by Manual count;RBC # Lower resp Manual;;ACTIVE;2.69;2.69 +96728-1;Elastic fibers;NCnc;Pt;Respiratory.lower;Qn;Manual count;PATH;1;Elastic fibers [#/volume] in Lower respiratory specimen by Manual count;Elastic fibers # Lower resp Manual;;ACTIVE;2.69;2.69 +96729-9;Coral fibers;NCnc;Pt;Respiratory.lower;Qn;Manual count;PATH;1;Coral fibers [#/volume] in Lower respiratory specimen by Manual count;Coral fibers # Lower resp Manual;;ACTIVE;2.69;2.69 +96730-7;Elastic fibers.calcified;NCnc;Pt;Respiratory.lower;Qn;Manual count;PATH;1;Calcified elastic fibers [#/volume] in Lower respiratory specimen by Manual count;Elastic fibers.calc # Lower resp Manual;;ACTIVE;2.69;2.69 +96731-5;Curschmann's spirals & crystals;Prid;Pt;Respiratory.lower;Nom;Microscopy.light;HEM/BC;1;Curschmann's spirals and crystals [type] in Lower respiratory specimen by Light microscopy;Cursch spir + crys Lower resp Micro;;ACTIVE;2.69;2.69 +96732-3;Spermine;PrThr;Pt;Semen;Nom;Microscopy.light;FERT;1;Spermine [Presence] in Semen by Light microscopy;Spermine Smn Micro;;ACTIVE;2.69;2.69 +96733-1;Connective tissue;PrThr;Pt;Stool;Ord;Microscopy.light;CHEM;1;Connective tissue [Presence] in Stool by Light microscopy;Conn tiss Stl Ql Micro;;ACTIVE;2.69;2.69 +96734-9;Fatty acid salts;PrThr;Pt;Stool;Ord;Microscopy.light;CHEM;1;Fatty acid salts [Presence] in Stool by Light microscopy;FA salts Stl Ql Micro;;ACTIVE;2.69;2.69 +9673-5;Salmonella sp Ab.IgG;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella sp IgG Ab [Units/volume] in Serum;Salmonella IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +96735-6;Lipoprotein.beta.subparticle.medium;SCnc;Pt;Ser;Qn;;CHEM;1;Lipoprotein.beta.subparticle.medium [Moles/volume] in Serum;LDL med Ser-sCnc;;ACTIVE;2.69;2.69 +96736-4;COVID-19+Procedure note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Procedure note;COVID-19 Proced note;;ACTIVE;2.70;2.7 +96737-2;COVID-19+Consultation note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Consultation note;COVID-19 Consult note;;ACTIVE;2.70;2.7 +96738-0;COVID-19 letter;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 letter;COVID-19 letter;;ACTIVE;2.70;2.7 +96739-8;COVID-19 note;Find;Pt;Telehealth;Doc;{Role};DOC.ONTOLOGY;2;Telehealth COVID-19 note;Telehealth COVID-19 note;;ACTIVE;2.70;2.7 +96740-6;COVID-19 note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 note;COVID-19 note;;ACTIVE;2.70;2.7 +96741-4;SARS coronavirus 2 variant;Type;Pt;XXX;Nom;Sequencing;MICRO;1;SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing;SARS-CoV-2 variant Spec Seq;;ACTIVE;2.70;2.72 +96742-2;SARS coronavirus 2 Ab.IgG;MCnc;Pt;Ser/Plas;Qn;IA;MICRO;1;SARS-CoV-2 (COVID-19) IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay;SARS-CoV-2 IgG SerPl IA-mCnc;;ACTIVE;2.70;2.7 +9674-3;Salmonella sp Ab.IgM;ACnc;Pt;Ser;Qn;;MICRO;1;Salmonella sp IgM Ab [Units/volume] in Serum;Salmonella IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +96743-0;Cannot read or write in primary language;Find;Pt;^Patient;Ord;;CLIN;2;Cannot read or write in primary language;Cannot read/write prim lang;;ACTIVE;2.70;2.7 +96744-8;Intervention or enabling service minutes;Num;Pt;^Patient;Qn;;CLIN;2;Intervention or enabling service minutes [#];Interv/enab serv min;;ACTIVE;2.70;2.7 +96745-5;Intervention or enabling service group size;Type;Pt;^Patient;Nom;;CLIN;2;Intervention or enabling service group size;I/E service grp size;;ACTIVE;2.70;2.7 +96746-3;Appointment type;Type;Pt;^Patient;Nom;;ADMIN;2;Appointment type;Appt type;;ACTIVE;2.70;2.7 +96747-1;Service provided in a language other than English;Find;Pt;^Patient;Ord;;CLIN;2;Service provided in a language other than English;Serv prov not in Eng;;ACTIVE;2.70;2.7 +96748-9;Interventions or enabling services provided;Type;Pt;^Patient;Nom;;CLIN;2;Interventions or enabling services provided;I/E services provided;;ACTIVE;2.70;2.7 +96749-7;Association of Asian Pacific Community Health Organizations enabling services and social intervention panel;-;Pt;^Patient;-;AAPCHO;PANEL.CLIN;2;Association of Asian Pacific Community Health Organizations enabling services and social intervention panel AAPCHO;AAPCHO I/E Pnl;;ACTIVE;2.70;2.7 +9675-0;Silicone Ab.IgA;ACnc;Pt;Ser;Qn;;SERO;1;Silicone IgA Ab [Units/volume] in Serum;Silicone IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +96750-5;Comorbidity score;Score;Pt;^Patient;Ord;;CLIN.RISK;2;Comorbidity score;Comorbidity score;;ACTIVE;2.70;2.7 +96751-3;SARS coronavirus 2 S gene mutation detected;Prid;Pt;XXX;Nom;Molgen;MICRO;1;SARS-CoV-2 (COVID-19) S gene mutation detected [Identifier] in Specimen by Molecular genetics method;SARS-CoV-2 S gene mut Spec;;ACTIVE;2.70;2.74 +96752-1;SARS coronavirus 2 S gene mutation;PrThr;Pt;XXX;Ord;Molgen;MICRO;1;SARS-CoV-2 (COVID-19) S gene mutation [Presence] in Specimen by Molecular genetics method;SARS-CoV-2 S gene mut Spec Ql;;ACTIVE;2.70;2.7 +96753-9;Would like help with paying heating &or electricity bill;Find;Pt;^Caregiver;Ord;;SURVEY.GNHLTH;4;Would like help with paying heating AndOr electricity bill Caregiver;;;ACTIVE;2.70;2.7 +96754-7;Mycobacterium tuberculosis stimulated gamma interferon release by T-cells^^corrected for background;ACnc;Pt;Bld;Qn;;MICRO;1;Mycobacterium tuberculosis stimulated gamma interferon release by T-cells [Units/volume] corrected for background in Blood;M TB IFN-g T-cells bckgrd cor Bld-aCnc;;ACTIVE;2.70;2.7 +96755-4;SARS coronavirus 2 variant interpretation;Imp;Pt;XXX;Nar;;MICRO;1;SARS-CoV-2 (COVID-19) variant interpretation in Specimen Narrative;SARS-CoV-2 variant Imp Spec;;ACTIVE;2.70;2.7 +96756-2;SARS coronavirus 2 S gene codon N501=;PrThr;Pt;XXX;Ord;Molgen;MICRO;1;SARS-CoV-2 (COVID-19) S gene codon N501= [Presence] in Specimen by Molecular genetics method;SARS-CoV-2 S gene N501= Spec Ql;;ACTIVE;2.70;2.7 +96757-0;SARS coronavirus 2 S gene codon N501Y;PrThr;Pt;XXX;Ord;Molgen;MICRO;1;SARS-CoV-2 (COVID-19) S gene codon N501Y [Presence] in Specimen by Molecular genetics method;SARS-CoV-2 S gene N501Y Spec Ql;;ACTIVE;2.70;2.7 +96758-8;Stairs - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Stairs - functional ability;Stairs ability;;ACTIVE;2.70;2.7 +96759-6;Bowel control - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Bowel control - functional ability;Bowel control ability;;ACTIVE;2.70;2.7 +96760-4;Bladder control - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Bladder control - functional ability;Bladder control ability;;ACTIVE;2.70;2.7 +96761-2;Total score;Score;Pt;^Patient;Qn;Barthel Index;CLIN;2;Total score Barthel Index;Total score Barthel Index;"Barthel Index© MedChi, 1965. All Rights Reserved. The Maryland State Medical Society holds the copyright for the Barthel Index. Mahoney FI, Barthel D. ""Functional evaluation: the Barthel Index."" Maryland State Med Journal 1965;14:56-61. Used with permission. Permission is required to modify the Barthel Index or to use it for commercial purposes.";ACTIVE;2.70;2.7 +96762-0;Barthel index panel;-;Pt;^Patient;-;Barthel Index;PANEL.CLIN;2;Barthel index panel;Barthel index;"Barthel Index© MedChi, 1965. All Rights Reserved. The Maryland State Medical Society holds the copyright for the Barthel Index. Mahoney FI, Barthel D. ""Functional evaluation: the Barthel Index."" Maryland State Med Journal 1965;14:56-61. Used with permission. Permission is required to modify the Barthel Index or to use it for commercial purposes.";ACTIVE;2.70;2.7 +96763-8;SARS coronavirus 2 E gene;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) E gene [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 E gene Resp Ql NAA+probe;;ACTIVE;2.70;2.7 +96764-6;SARS coronavirus 2 E gene;ThreshNum;Pt;Respiratory;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) E gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 E gene Ct Resp Qn NAA+probe;;ACTIVE;2.70;2.7 +96765-3;SARS coronavirus 2 S gene;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 S gene Sal Ql NAA+probe;;ACTIVE;2.70;2.7 +96766-1;GISAID sequence accession number;ID;Pt;Isolate;Nom;;MICRO;1;GISAID sequence accession number;GISAID seq accession ID;;ACTIVE;2.70;2.7 +96767-9;Grooming - functional ability;Find;Pt;^Patient;Ord;;CLIN;2;Grooming - functional ability;Grooming ability;;ACTIVE;2.70;2.7 +9676-8;Silicone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Silicone IgE Ab [Units/volume] in Serum;Silicone IgE Qn;;ACTIVE;1.0i;2.73 +96768-7;Pregnancy outcome related to illness or condition;Find;Pt;^Patient;Nom;;H&P.HX;2;Pregnancy outcome related to illness or condition;Pregnancy outcome;;ACTIVE;2.70;2.7 +96769-5;Type of immunosuppressive medication used;Type;Pt;^Patient;Nom;;MEDS;2;Type of immunosuppressive medication used;Immunosuppressive medication;;ACTIVE;2.70;2.7 +96770-3;Fresh water supply was treated prior to use;Find;Pt;^Patient;Ord;;PUBLICHEALTH;2;Fresh water supply was treated prior to use;Fresh water supply was treated;;ACTIVE;2.70;2.7 +96771-1;Service integration panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Service integration panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.72 +96772-9;Service integration total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Service integration total score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +96773-7;How well do services work together: services talk to each other;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How well do services work together: services talk to each other;;;ACTIVE;2.70;2.7 +96774-5;How well do services work together: staff know what other services do;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How well do services work together: staff know what other services do;;;ACTIVE;2.70;2.7 +96775-2;How well do services work together: I don't have to repeat my story;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How well do services work together: I don't have to repeat my story;;;ACTIVE;2.70;2.7 +9677-6;Silicone Ab.IgG;ACnc;Pt;Ser;Qn;;SERO;1;Silicone IgG Ab [Units/volume] in Serum;Silicone IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +96776-0;How well do services work together: different services work well together;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How well do services work together: different services work well together;;;ACTIVE;2.70;2.7 +96777-8;Accountable health communities health-related social needs screening tool;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Accountable health communities (AHC) health-related social needs screening (HRSN) tool;;;ACTIVE;2.70;2.7 +96778-6;Problems with place where you live;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Problems with place where you live;;;ACTIVE;2.70;2.7 +96779-4;Has the electric, gas, oil, or water company threatened to shut off services in your home in past 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.GNHLTH;4;Has the electric, gas, oil, or water company threatened to shut off services in your home in past 12 months;;;ACTIVE;2.70;2.7 +96780-2;Wants help finding or keeping work or a job;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Wants help finding or keeping work or a job;;;ACTIVE;2.70;2.7 +96781-0;Able to get help with daily activities when needed;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Able to get help with daily activities when needed;;;ACTIVE;2.70;2.7 +96782-8;Wants help with school or training;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Wants help with school or training;;;ACTIVE;2.70;2.7 +96783-6;howRwe panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;howRwe panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.72 +9678-4;Silicone Ab.IgM;ACnc;Pt;Ser;Qn;;SERO;1;Silicone IgM Ab [Units/volume] in Serum;Silicone IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +96784-4;howRwe score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;howRwe score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +96785-1;How are we doing: treat you kindly;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are we doing: treat you kindly;;;ACTIVE;2.70;2.7 +96786-9;How are we doing: listen and explain;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are we doing: listen and explain;;;ACTIVE;2.70;2.7 +96787-7;How are we doing: see you promptly;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are we doing: see you promptly;;;ACTIVE;2.70;2.7 +96788-5;How are we doing: well organized;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are we doing: well organized;;;ACTIVE;2.70;2.7 +96789-3;Sequential Organ Failure Assessment;-;Pt;^Patient;-;SOFA;PANEL.CLIN.RISK;2;Sequential Organ Failure Assessment SOFA;SOFA;;ACTIVE;2.70;2.7 +96790-1;SOFA total score;Score;Pt;^Patient;Qn;SOFA;CLIN.RISK;2;SOFA Total Score;SOFA total score SOFA;;ACTIVE;2.70;2.7 +96791-9;Quick SOFA score;Score;Pt;^Patient;Qn;SOFA.quick;CLIN.RISK;2;Quick SOFA score SOFA.quick;QSOFA QSOFA;;ACTIVE;2.70;2.7 +9679-2;Squamous cell carcinoma Ag;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Squamous cell carcinoma Ag [Mass/volume] in Serum or Plasma;SCC Ag SerPl-mCnc;;ACTIVE;1.0i;2.7 +96792-7;Modified SOFA score;Score;Pt;^Patient;Qn;SOFA.modified;CLIN.RISK;2;Modified SOFA score;MSOFA;;ACTIVE;2.70;2.7 +96793-5;(Fagus grandifolia+Pinus strobus+Thuja plicata+Abies alba) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Softwood Mix (Beech+Pine+Red cedar+Silver fir) IgE Ab [Units/volume] in Serum by Multidisk;Softwood Mix IgE Qn;;ACTIVE;2.70;2.72 +96794-3;(Quercus alba+Swietenia+Thuja plicata+Triplochiton scleroxylon) Ab.IgE;ACnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Hardwood Mix (Oak+Mahogany+West Red Cedar+Abachi) IgE Ab [Units/volume] in Serum by Multidisk;Hardwood Mix IgE Qn;;ACTIVE;2.70;2.72 +96795-0;Hexacarboxylporphyrins;SCnc;Pt;Urine;Qn;;CHEM;1;Hexacarboxylporphyrins [Moles/volume] in Urine;Hexa-CPs Ur-sCnc;;ACTIVE;2.70;2.7 +96797-6;SARS coronavirus 2 RNA;PrThr;Pt;Oropharyngeal wash;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Oropharyngeal wash by NAA with probe detection;SARS-CoV-2 RNA OPA wash Ql NAA+probe;;ACTIVE;2.70;2.7 +96798-4;Cortisol & glucose & somatotropin post arginine stimulation panel;-;Pt;Ser/Plas;Qn;;PANEL.CHAL;1;Cortisol, glucose, and somatotropin post arginine stimulation panel - Serum or Plasma;Cortisol+glucose+GH p arginine Pnl SerPl;;ACTIVE;2.70;2.7 +96799-2;Glucose^30M post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose arginine;Glucose 30M p Arg SerPl-mCnc;;ACTIVE;2.70;2.7 +96-8;Cefonicid;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefonicid [Susceptibility] by Minimum inhibitory concentration (MIC);Cefonocid Islt MIC;;ACTIVE;1.0;2.19 +9680-0;Cells.CD16+CD57+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;CD16+CD57+ cells/100 cells in Blood;CD16+CD57+ Cells NFr Bld;;ACTIVE;1.0i;2.7 +96800-8;Glucose^1H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1 hour post dose arginine;Glucose 1h p Arg SerPl-mCnc;;ACTIVE;2.70;2.7 +96801-6;Cortisol^1H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Mass/volume] in Serum or Plasma --1 hour post dose arginine;Cortis 1h p Arg SerPl-mCnc;;ACTIVE;2.70;2.7 +96802-4;Glucose^1.5H post dose arginine;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose arginine;Glucose 1.5h p Arg SerPl-mCnc;;ACTIVE;2.70;2.7 +96803-2;24H predicted protein;MRat;Pt;Urine;Qn;Calculated;CHEM;1;24 hour predicted protein [Mass/time] based on random Urine by calculation;24H predicted prot Ur Calc-mRate;;ACTIVE;2.70;2.7 +96804-0;24H predicted protein;MRatRange;Pt;Urine;Qn;Calculated;CHEM;1;24 hour predicted protein [Mass/time range] based on random Urine by calculation;24H predicted prot mRatRange Ur Calc;;ACTIVE;2.70;2.7 +96805-7;Cobalamins & folate panel;-;Pt;Ser;Qn;;PANEL.CHEM;1;Cobalamin (Vitamin B12) and folate panel - Serum;Vit B12 + folate Pnl Ser;;ACTIVE;2.70;2.7 +96806-5;Panax ginseng Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ginseng IgE Ab [Units/volume] in Serum;Ginseng IgE Qn;;ACTIVE;2.70;2.7 +96807-3;Vancomycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Vancomycin IgE Ab [Units/volume] in Serum;Vancomycin IgE Qn;;ACTIVE;2.70;2.7 +96808-1;Thiamine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Thiamine IgE Ab [Units/volume] in Serum;Vit B1 IgE Qn;;ACTIVE;2.70;2.7 +96809-9;Cyanocobalamin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cyanocobalamin IgE Ab [Units/volume] in Serum;Cyanocobalamin IgE Qn;;ACTIVE;2.70;2.7 +96810-7;Salix alba Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;White willow IgE Ab [Units/volume] in Serum;White willow IgE Qn;;ACTIVE;2.70;2.7 +96811-5;Calluna vulgaris Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Heather IgE Ab [Units/volume] in Serum;Heather IgE Qn;;ACTIVE;2.70;2.7 +96812-3;Anthriscus cerefolium Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chervil IgE Ab [Units/volume] in Serum;Chervil IgE Qn;;ACTIVE;2.70;2.7 +96813-1;Goat milk cheese Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Goat milk cheese IgE Ab [Units/volume] in Serum;Goat milk cheese IgE Qn;;ACTIVE;2.70;2.7 +96814-9;Sheep milk cheese Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sheep milk cheese IgE Ab [Units/volume] in Serum;Sheep milk cheese IgE Qn;;ACTIVE;2.70;2.7 +96815-6;Trigla spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Piper gurnard IgE Ab [Units/volume] in Serum;Piper gurnard IgE Qn;;ACTIVE;2.70;2.7 +96816-4;Tetracaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Tetracaine IgE Ab [Units/volume] in Serum;Tetracaine IgE Qn;;ACTIVE;2.70;2.7 +96817-2;Thermoactinomyces candidus Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Thermoactinomyces candidus IgE Ab [Units/volume] in Serum;T candidus IgE Qn;;ACTIVE;2.70;2.7 +9681-8;1-Naphthol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;1-Naphthol [Mass/volume] in Serum or Plasma;1Naphthol SerPl-mCnc;;ACTIVE;1.0i;2.73 +96818-0;Taxus baccata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;English yew IgE Ab [Units/volume] in Serum;English yew IgE Qn;;ACTIVE;2.70;2.7 +96819-8;Roxithromycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Roxithromycin IgE Ab [Units/volume] in Serum;Roxithromycin IgE Qn;;ACTIVE;2.70;2.7 +96820-6;Eruca vesicaria subspecies sativa Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Arugula IgE Ab [Units/volume] in Serum;Arugula IgE Qn;;ACTIVE;2.70;2.7 +96821-4;Propylparaben Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Propylparaben IgE Ab [Units/volume] in Serum;Propylparaben IgE Qn;;ACTIVE;2.70;2.7 +96822-2;Euphorbia spp. Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Spurge IgE Ab [Units/volume] in Serum;Spurge IgE Qn;;ACTIVE;2.70;2.7 +96823-0;Respiration;Score;Pt;^Patient;Qn;SOFA;CLIN.RISK;2;Respiration [Score] SOFA;Respiration Score SOFA;;ACTIVE;2.70;2.7 +96824-8;Coagulation;Score;Pt;^Patient;Qn;SOFA;CLIN.RISK;2;Coagulation [Score] SOFA;Coag Score SOFA;;ACTIVE;2.70;2.7 +96825-5;Liver;Score;Pt;^Patient;Qn;SOFA;CLIN.RISK;2;Liver [Score] SOFA;Liver Score SOFA;;ACTIVE;2.70;2.7 +9682-6;2-Butanol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;2-Butanol [Mass/volume] in Specimen;2Butanol Spec-mCnc;;ACTIVE;1.0i;2.7 +96826-3;Cardiovascular;Score;Pt;^Patient;Qn;SOFA;CLIN.RISK;2;Cardiovascular [Score] SOFA;Cardio Score SOFA;;ACTIVE;2.70;2.7 +96827-1;Central nervous system;Score;Pt;^Patient;Qn;SOFA;CLIN.RISK;2;Central nervous system [Score] SOFA;CNS Score SOFA;;ACTIVE;2.70;2.7 +96828-9;Renal;Score;Pt;^Patient;Qn;SOFA;CLIN;2;Renal [Score] SOFA;Renal Score SOFA;;ACTIVE;2.70;2.7 +96829-7;SARS coronavirus 2 RNA;PrThr;Pt;XXX^Donor;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen from Donor by NAA with probe detection;SARS-CoV-2 RNA Spec Donr Ql NAA+probe;;ACTIVE;2.70;2.7 +96830-5;Specimen source;Prid;Pt;XXX^Donor;Nom;;SPEC;1;Specimen source [Identifier] from Donor;Specimen source from Donor;;ACTIVE;2.70;2.7 +96831-3;Coronavirus racial bias scale;-;Pt;^Patient;-;CRBS;PANEL.SURVEY.COVID;4;Coronavirus racial bias scale [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96832-1;Due to the coronavirus I have been cyberbullied because of my race or ethnicity;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;Due to the coronavirus I have been cyberbullied because of my race/ethnicity [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96833-9;Since the coronavirus I have seen a lot more cyberbullying of people of my race or ethnicity;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;Since the coronavirus I have seen a lot more cyberbullying of people of my race/ethnicity [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +9683-4;2-Methyl-2-Propanol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;2-Methyl-2-Propanol [Mass/volume] in Specimen;2Me2Propanol Spec-mCnc;;ACTIVE;1.0i;2.7 +96834-7;Coronavirus anxiety scale;-;2W;^Patient;-;CAS;PANEL.SURVEY.COVID;4;Coronavirus anxiety scale;;;ACTIVE;2.70;2.71 +96835-4;Dizzy, lightheaded, or faint, when exposed to news about the coronavirus in past 2W;Find;2W;^Patient;Ord;;SURVEY.COVID;4;Dizzy, lightheaded, or faint, when exposed to news about the coronavirus in past 2 weeks;;;ACTIVE;2.70;2.71 +96836-2;Trouble falling or staying asleep due to thinking about the coronavirus in past 2W;Find;2W;^Patient;Ord;;SURVEY.COVID;4;Trouble falling or staying asleep due to thinking about the coronavirus in past 2 weeks;;;ACTIVE;2.70;2.71 +96837-0;Paralyzed or frozen when I thought about or was exposed to information about the coronavirus in past 2W;Find;2W;^Patient;Ord;;SURVEY.COVID;4;Paralyzed or frozen when I thought about or was exposed to information about the coronavirus in past 2 weeks;;;ACTIVE;2.70;2.71 +96838-8;Lost interest in eating when I thought about or was exposed to information about the coronavirus in past 2W;Find;2W;^Patient;Ord;;SURVEY.COVID;4;Lost interest in eating when I thought about or was exposed to information about the coronavirus in past 2 weeks;;;ACTIVE;2.70;2.71 +96839-6;Nauseous or had stomach problems when I thought about or was exposed to information about the coronavirus in past 2W;Find;2W;^Patient;Ord;;SURVEY.COVID;4;Nauseous or had stomach problems when I thought about or was exposed to information about the coronavirus in past 2 weeks;;;ACTIVE;2.70;2.71 +96841-2;Tobacco, Alcohol, Prescription medications, and other Substance use screen;-;12Mo;^Patient;-;TAPS;PANEL.SURVEY.MTLHLTH;4;Tobacco, Alcohol, Prescription medications, and other Substance use screen [TAPS];;;ACTIVE;2.70;2.7 +9684-2;Bendiocarb;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Bendiocarb [Mass/volume] in Serum or Plasma;Bendiocarb SerPl-mCnc;;ACTIVE;1.0i;2.73 +96842-0;How often have you used any tobacco product in past 12Mo;NRat;12Mo;^Patient;Ord;;H&P.HX;2;How often have you used any tobacco product in past 12 months;Tobacco freq 12Mo;;ACTIVE;2.70;2.7 +96843-8;How often have you used illegal or recreational drugs in past 12Mo;NRat;12Mo;^Patient;Ord;;H&P.HX;2;How often have you used illegal or recreational drugs in past 12 months;Drug use freq 12Mo;;ACTIVE;2.70;2.7 +96844-6;How often have you used any prescription medications just for the feeling, more than prescribed or that were not prescribed for you in past 12Mo;NRat;12Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;How often have you used any prescription medications just for the feeling, more than prescribed or that were not prescribed for you in past 12 months [TAPS];;;ACTIVE;2.70;2.7 +96845-3;Tobacco, Alcohol, Prescription medications, and other Substance use assessment;-;3Mo;^Patient;-;TAPS;PANEL.SURVEY.MTLHLTH;4;Tobacco, Alcohol, Prescription medications, and other Substance use assessment [TAPS];;;ACTIVE;2.70;2.7 +96846-1;Smoked at least one cigarette containing tobacco in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Smoked at least one cigarette containing tobacco in past 3 months;Smkd 1+ cigarette past 3Mo;;ACTIVE;2.70;2.7 +96847-9;Smoked more than 10 cigarettes per D in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Smoked more than 10 cigarettes per day in past 3 months;Smkd >10 cig D past 3Mo;;ACTIVE;2.70;2.7 +96848-7;Smoked cigarette within 30M after waking in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Smoked cigarette within 30M after waking in past 3 months;Smk cig w/in 30M wake past 3Mo;;ACTIVE;2.70;2.7 +96849-5;At least one drink in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;At least one drink in past 3 months;1+ drink past 3Mo;;ACTIVE;2.70;2.7 +96850-3;Four or more drinks in 1D in the past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Four or more drinks in one day in the past 3 months;4+ drinks 1D past 3Mo;;ACTIVE;2.70;2.7 +96851-1;Five or more drinks in 1D in the past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Five or more drinks in one day in the past 3 months;5+ drinks 1D past 3Mo;;ACTIVE;2.70;2.7 +96852-9;Have you tried and failed to control, cut down or stop drinking in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Have you tried and failed to control, cut down or stop drinking in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96853-7;Has anyone expressed concern about your drinking in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Has anyone expressed concern about your drinking in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96854-5;Used marijuana in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used marijuana in past 3 months;Used marijuana past 3Mo;;ACTIVE;2.70;2.7 +96855-2;Have you had a strong desire or urge to use marijuana at least once a week or more often in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Have you had a strong desire or urge to use marijuana at least once a week or more often in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96856-0;Has anyone expressed concern about your use of marijuana in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Has anyone expressed concern about your use of marijuana in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96857-8;Used cocaine, crack, or methamphetamine in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used cocaine, crack, or methamphetamine in past 3 months;Used cocaine/crack/meth past 3Mo;;ACTIVE;2.70;2.7 +96858-6;Used cocaine, crack, or methamphetamine at least once a week in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used cocaine, crack, or methamphetamine at least once a week in past 3 months;Used cocaine/crack/meth once W past 3Mo;;ACTIVE;2.70;2.7 +9685-9;Butanol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Butanol [Mass/volume] in Specimen;Butanol Spec-mCnc;;ACTIVE;1.0i;2.73 +96859-4;Has anyone expressed concern about your use of cocaine, crack, or methamphetamine in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Has anyone expressed concern about your use of cocaine, crack, or methamphetamine (crystal meth) in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96860-2;Used heroin in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used heroin in past 3 months;Used heroin past 3Mo;;ACTIVE;2.70;2.7 +96861-0;Have you tried and failed to control, cut down or stop using heroin in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Have you tried and failed to control, cut down or stop using heroin in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96862-8;Has anyone expressed concern about your use of heroin in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Has anyone expressed concern about your use of heroin in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96863-6;Used prescription opiate pain reliever not as prescribed or not prescribed for you in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used prescription opiate pain reliever not as prescribed or not prescribed for you in past 3 months;Misused opiates past 3Mo;;ACTIVE;2.70;2.7 +96864-4;Have you tried and failed to control, cut down or stop using an opiate pain reliever in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Have you tried and failed to control, cut down or stop using an opiate pain reliever in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96865-1;Has anyone expressed concern about your use of an opiate pain reliever in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Has anyone expressed concern about your use of an opiate pain reliever in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96866-9;Used medication for anxiety or sleep not as prescribed or not prescribed for you in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used medication for anxiety or sleep not as prescribed or not prescribed for you in past 3 months;Misused anxiety/sleep meds past 3Mo;;ACTIVE;2.70;2.7 +9686-7;Cadmium;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Cerebral spinal fluid;Cadmium CSF-mCnc;;ACTIVE;1.0i;2.7 +96867-7;Have you had a strong desire or urge to use medications for anxiety or sleep at least once a week or more often in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Have you had a strong desire or urge to use medications for anxiety or sleep at least once a week or more often in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96868-5;Has anyone expressed concern about your use of medication for anxiety or sleep in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Has anyone expressed concern about your use of medication for anxiety or sleep in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96869-3;Used medication for ADHD not as prescribed or not prescribed for you in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used medication for ADHD not as prescribed or not prescribed for you in past 3 months;Misused ADHD meds past 3Mo;;ACTIVE;2.70;2.7 +96870-1;Used medication for ADHD not as prescribed or not prescribed for you at least once a week in past 3Mo;Find;3Mo;^Patient;Ord;;H&P.HX;2;Used medication for ADHD not as prescribed or not prescribed for you at least once a week in past 3 months;Misused ADHD meds once W past 3Mo;;ACTIVE;2.70;2.7 +96871-9;Has anyone expressed concern about your use of a medication for ADHD in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;SURVEY.MTLHLTH;4;Has anyone expressed concern about your use of a medication for ADHD (for example, Adderall or Ritalin) in past 3 months [TAPS];;;ACTIVE;2.70;2.7 +96872-7;Used other illegal or recreational drug in past 3Mo;Find;3Mo;^Patient;Ord;TAPS;H&P.HX;2;Used other illegal or recreational drug in past 3 months TAPS;Other illegal/recreation drug past 3Mo;;ACTIVE;2.70;2.7 +96873-5;Illegal or recreational drug(s) used in past 3Mo;Find;3Mo;^Patient;Nom;;SURVEY.MTLHLTH;4;Illegal or recreational drug(s) used in past 3 months;;;ACTIVE;2.70;2.7 +96874-3;COVID-19+Immunization note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;COVID-19 Immunization note;COVID-19 Immunization note;;ACTIVE;2.70;2.7 +9687-5;Cadmium;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cadmium [Mass/volume] in Specimen;Cadmium Spec-mCnc;;ACTIVE;1.0i;2.7 +96875-0;I believe the country has become more dangerous for people in my racial or ethnic group because of fear of the coronavirus;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;I believe the country has become more dangerous for people in my racial/ethnic group because of fear of the coronavirus [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96876-8;People of my race or ethnicity are more likely to lose their job because of the coronavirus;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;People of my race/ethnicity are more likely to lose their job because of the coronavirus [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96877-6;I worry about people thinking I have the coronavirus simply because of my race or ethnicity;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;I worry about people thinking I have the coronavirus simply because of my race/ethnicity [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96878-4;Most social and mass media reports about the coronavirus create bias against people of my racial or ethnic group;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;Most social and mass media reports about the coronavirus create bias against people of my racial/ethnic group [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96879-2;People of my race or ethnicity are more likely to get the coronavirus;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;People of my race/ethnicity are more likely to get the coronavirus [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +968-8;D little u Ab;ACnc;Pt;Ser/Plas^Donor;Ord;Aggl RBC;BLDBK;1;Deprecated D little u Ab [Presence] n Serum or Plasma from donor;Deprecated Du Ab SerPl Donr Ql;;DEPRECATED;1.0;2.4 +96880-0;People of my race or ethnicity will not receive coronavirus healthcare as good as the care received by other groups;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;People of my race/ethnicity will not receive coronavirus healthcare as good as the care received by other groups [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96881-8;Negative social media posts against people of my race or ethnicity have increased because of the coronavirus;Find;Pt;^Patient;Ord;CRBS;SURVEY.COVID;4;Negative social media posts against people of my race/ethnicity have increased because of the coronavirus [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +96882-6;In the past Mo, have recommendations for socially distancing caused stress for you;Find;1Mo;^Patient;Ord;;SURVEY.COVID;4;In the past month, have recommendations for socially distancing caused stress for you?;;;ACTIVE;2.70;2.71 +9688-3;Carbaryl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbaryl [Mass/volume] in Serum or Plasma;Carbaryl SerPl-mCnc;;ACTIVE;1.0i;2.73 +96883-4;Stayed home all day;Find;5D;^Patient;Ord;;SURVEY.COVID;4;Stayed home all day;;;ACTIVE;2.70;2.71 +96884-2;Went to workplace or volunteer site outside home;Find;5D;^Patient;Ord;;SURVEY.COVID;4;Went to workplace or volunteer site outside home;;;ACTIVE;2.70;2.71 +96885-9;Attended social gatherings outside my home of more than 10 people;Find;5D;^Patient;Ord;;SURVEY.COVID;4;Thinking about your current social habits, in the last 5 days: I have attended social gatherings outside my home of more than 10 people;;;ACTIVE;2.70;2.71 +96886-7;Attended social gatherings outside my home of less than 10 people;Find;5D;^Patient;Ord;;SURVEY.COVID;4;Thinking about your current social habits, in the last 5 days: I have attended social gatherings outside my home of less than 10 people;;;ACTIVE;2.70;2.71 +96887-5;Gone on shopping trips or outings that were just for fun;Find;5D;^Patient;Ord;;SURVEY.COVID;4;Thinking about your current social habits, in the last 5 days: I have gone on shopping trips or outings that were just for fun;;;ACTIVE;2.70;2.71 +96888-3;Visited nursing homes or long-term care facilities (outside of work duties);Find;5D;^Patient;Ord;;SURVEY.COVID;4;Thinking about your current social habits, in the last 5 days: I have visited nursing homes or long-term care facilities (outside of work duties);;;ACTIVE;2.70;2.71 +96889-1;Close contact with someone who is in a risk group for COVID-19;Find;5D;^Patient;Ord;;SURVEY.COVID;4;Close contact with someone who is in a risk group for COVID-19;;;ACTIVE;2.70;2.71 +96890-9;Frequency of social interaction with people outside my home;Find;5D;^Patient;Ord;;SURVEY.COVID;4;Frequency of social interaction with people outside my home;;;ACTIVE;2.70;2.71 +9689-1;Carbofuran;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Carbofuran [Mass/volume] in Serum or Plasma;Carbofuran SerPl-mCnc;;ACTIVE;1.0i;2.73 +96891-7;How often in the past Mo are you doing the recommended pandemic hygiene;Find;1Mo;^Patient;Ord;;SURVEY.COVID;4;How often in the past month are you doing the recommended pandemic hygiene;;;ACTIVE;2.70;2.71 +96892-5;COVID-19 participant experience survey;-;Pt;^Patient;-;COPE;PANEL.SURVEY.COVID;4;COVID-19 participant experience survey;;;ACTIVE;2.70;2.71 +96893-3;ERBB2 gene duplication;Find;Pt;Tumor;Doc;FISH;MOLPATH;1;ERBB2 gene duplication in Tumor by FISH;ERBB2 gene Dp Tumor FISH;;ACTIVE;2.70;2.7 +96894-1;SARS coronavirus 2 sequencing & identification panel;-;Pt;XXX;-;Molgen;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) sequencing and identification panel - Specimen by Molecular genetics method;SARS-CoV-2 Seq and ID Pnl Spec;;ACTIVE;2.70;2.7 +96895-8;SARS coronavirus 2 lineage;Prid;Pt;XXX;Nom;Molgen;MICRO;1;SARS-CoV-2 (COVID-19) lineage [Identifier] in Specimen by Molecular genetics method;SARS-CoV-2 lineage Spec;;ACTIVE;2.70;2.72 +96896-6;SARS coronavirus 2 clade;Type;Pt;XXX;Nom;Molgen;MICRO;1;SARS-CoV-2 (COVID-19) clade [Type] in Specimen by Molecular genetics method;SARS-CoV-2 clade Spec;;ACTIVE;2.70;2.72 +96897-4;SARS coronavirus 2 RNA panel;-;Pt;Oropharyngeal wash;-;Probe.amp.tar;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) RNA panel - Oropharyngeal wash by NAA with probe detection;SARS-CoV-2 RNA Pnl OPA wash NAA+probe;;ACTIVE;2.70;2.7 +96898-2;SARS coronavirus 2 N gene;ThreshNum;Pt;Oropharyngeal wash;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection;SARS-CoV-2 N gene Ct OPA wash Qn NAA+prb;;ACTIVE;2.70;2.7 +96899-0;SARS coronavirus 2 ORF1ab region;ThreshNum;Pt;Oropharyngeal wash;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection;SARS-CoV-2 ORF1ab Ct OPA wash Qn NAA+prb;;ACTIVE;2.70;2.7 +96900-6;SARS coronavirus 2 S gene;ThreshNum;Pt;Oropharyngeal wash;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection;SARS-CoV-2 S gene Ct OPA wash Qn NAA+prb;;ACTIVE;2.70;2.7 +96901-4;MDS v3.0 - RAI v1.17.2 - Delirium;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Delirium during assessment period [CMS Assessment];;;ACTIVE;2.70;2.74 +96902-2;MDS v3.0 - RAI v1.17.2 - Hearing, speech, and vision - NC, NP, NQ, SP;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Hearing, speech, and vision - NC, NP, NQ, SP during assessment period [CMS Assessment];;;ACTIVE;2.70;2.7 +96903-0;MDS v3.0 - RAI v1.17.2 - Cognitive patterns - NC, NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Cognitive patterns - NC, NP, NQ, SP [CMS Assessment];;;ACTIVE;2.70;2.74 +96904-8;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - NC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - NC [CMS Assessment];;;ACTIVE;2.70;2.7 +96905-5;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - ND, SD;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - ND, SD during assessment period [CMS Assessment];;;ACTIVE;2.70;2.7 +96906-3;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - NP, NQ, SP;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Bladder and bowel - NP, NQ, SP [CMS Assessment];;;ACTIVE;2.70;2.7 +96907-1;MDS v3.0 - RAI v1.17.2 - Cognitive patterns - ND, SD;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Cognitive patterns - ND, SD [CMS Assessment];;;ACTIVE;2.70;2.7 +96908-9;MDS v3.0 - RAI v1.17.2 - Staff assessment for mental status;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;MDS v3.0 - RAI v1.17.2 - Staff assessment for mental status during assessment period [CMS Assessment];;;ACTIVE;2.70;2.74 +9690-9;Chromium;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Chromium [Mass/volume] in Specimen;Chromium Spec-mCnc;;ACTIVE;1.0i;2.73 +96909-7;Cenobamate;MCnc;Pt;Ser/Plas;Qn;Confirm;DRUG/TOX;1;Cenobamate [Mass/volume] in Serum or Plasma by Confirmatory method;Cenobamate SerPl Cfm-mCnc;;ACTIVE;2.70;2.7 +96910-5;Acanthamoeba sp & Naegleria fowleri & Balamuthia mandrillaris DNA panel;-;Pt;XXX;-;;PANEL.MICRO;1;Acanthamoeba sp and Naegleria fowleri and Balamuthia mandrillaris DNA panel - Specimen;Free-living amoeba Pnl Spec;;ACTIVE;2.70;2.7 +96911-3;Delta aminolevulinate & porphobilinogen panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Delta aminolevulinate and porphobilinogen panel - Serum or Plasma;D-ALA + PBG Pnl SerPl;;ACTIVE;2.70;2.7 +96912-1;CT global noise;Rden;Pt;Study;Qn;Calculated;RAD;2;Calculated CT global noise;Calc CT global noise;;ACTIVE;2.70;2.7 +96913-9;CT size-adjusted dose;EngCnt;Pt;Study;Qn;Calculated;RAD;2;Calculated CT size-adjusted dose;Calc CT size-adj dose;;ACTIVE;2.70;2.7 +96914-7;CT dose & image quality category;Type;Pt;Study;Nom;;RAD;2;CT dose and image quality category;CT dose + image qual;;ACTIVE;2.70;2.7 +96915-4;CT quality measure out of range;Find;Pt;Study;Ord;;RAD;2;CT quality measure out of range;CT qual meas out of range;;ACTIVE;2.70;2.7 +96916-2;Average diameter on axial mid-scan image;Len;Pt;^Patient;Qn;CT;RAD;2;CT Average diameter on axial mid-scan image;CT Avg diam axial mid-scan;;ACTIVE;2.70;2.7 +9691-7;Cobalt;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Cobalt [Mass/volume] in Specimen;Cobalt Spec-mCnc;;ACTIVE;1.0i;2.7 +96917-0;Average diameter on frontal scout image;Len;Pt;^Patient;Qn;CT;RAD;2;CT Average diameter on frontal scout image;CT Avg diam frontal scout;;ACTIVE;2.70;2.7 +96918-8;Fodrin.alpha subunit Ab.IgA;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Fodrin alpha subunit IgA Ab [Units/volume] in Serum or Plasma by Immunoassay;Fodrin alpha IgA SerPl IA-aCnc;;ACTIVE;2.70;2.7 +96919-6;Nuclear Ab pattern.homogeneous;Titr;Pt;CSF;Qn;IF;SERO;1;Homogenous nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA Homogen Titr CSF IF;;ACTIVE;2.70;2.7 +96920-4;Nuclear Ab pattern.nucleolar;Titr;Pt;CSF;Qn;IF;SERO;1;Nucleolar nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA nucleolar Titr CSF IF;;ACTIVE;2.70;2.7 +96921-2;Nuclear Ab pattern.speckled;Titr;Pt;CSF;Qn;IF;SERO;1;Speckled nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA Speckled Titr CSF IF;;ACTIVE;2.70;2.7 +96922-0;Nuclear Ab pattern.spindle fibers;Titr;Pt;CSF;Qn;IF;SERO;1;Spindle fibers nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA spindle fibers Titr CSF IF;;ACTIVE;2.70;2.7 +96923-8;Nuclear Ab pattern.smooth nuclear envelope;Titr;Pt;CSF;Qn;IF;SERO;1;Smooth nuclear envelope nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA smooth nucl env Titr CSF IF;;ACTIVE;2.70;2.7 +96924-6;Nuclear Ab pattern.intercellular bridge;Titr;Pt;CSF;Qn;IF;SERO;1;Intercellular bridge nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA intercell bridge Titr CSF IF;;ACTIVE;2.70;2.7 +9692-5;Isobutanol;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Isobutanol [Mass/volume] in Specimen;Isobutanol Spec-mCnc;;ACTIVE;1.0i;2.7 +96925-3;Nuclear Ab pattern.nuclear dots;Titr;Pt;CSF;Qn;IF;SERO;1;Nuclear dots nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA nuclear dots Titr CSF IF;;ACTIVE;2.70;2.7 +96926-1;PCNA extractable nuclear Ab;Titr;Pt;CSF;Qn;IF;SERO;1;PCNA extractable nuclear Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;ENA PCNA Ab Titr CSF IF;;ACTIVE;2.70;2.7 +96927-9;Nuclear Ab pattern.centrosomal;Titr;Pt;CSF;Qn;IF;SERO;1;Centrosomal nuclear Ab pattern [Titer] in Cerebral spinal fluid by Immunofluorescence;ANA centrosomal Titr CSF IF;;ACTIVE;2.70;2.7 +96928-7;Fodrin.alpha subunit Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Fodrin alpha subunit IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Fodrin alpha IgG SerPl IA-aCnc;;ACTIVE;2.70;2.7 +96929-5;Personal well-being panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Personal well-being panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.72 +96930-3;Personal well-being score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Personal well-being score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +96931-1;How are you feeling in general: I am satisfied with my life;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are you feeling in general: I am satisfied with my life;;;ACTIVE;2.70;2.7 +96932-9;How are you feeling in general: what I do in my life is worthwhile;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are you feeling in general: What I do in my life is worthwhile;;;ACTIVE;2.70;2.7 +9693-3;Mercury;MCnc;Pt;CSF;Qn;;DRUG/TOX;1;Mercury [Mass/volume] in Cerebral spinal fluid;Mercury CSF-mCnc;;ACTIVE;1.0i;2.7 +96933-7;How are you feeling in general: I was happy yesterday;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are you feeling in general: I was happy yesterday;;;ACTIVE;2.70;2.7 +96934-5;How are you feeling in general: I was not anxious yesterday;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How are you feeling in general: I was not anxious yesterday;;;ACTIVE;2.70;2.7 +96935-2;Heart rate;NRat;XXX^min;Arterial system;Qn;Pedometer;HRTRATE.MOLEC;2;Heart rate unspecified time minimum by Pedometer;Heart rate ?Tm Min Pedometer;;ACTIVE;2.70;2.7 +96936-0;Person-specific outcome panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Person-specific outcome panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +96937-8;Issue you would like help with;Find;Pt;^Patient;Nom;;SURVEY.R-OUTCOMES;4;Issue you would like help with;;;ACTIVE;2.70;2.7 +96938-6;How much concern does the issue you would like help with cause;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How much concern does the issue you would like help with cause;;;ACTIVE;2.70;2.7 +96939-4;Social contact panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Social contact panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.73 +96940-2;Social contact score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Social contact score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.73 +9694-1;Propoxur;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Propoxur [Mass/volume] in Serum or Plasma;Propoxur SerPl-mCnc;;ACTIVE;1.0i;2.73 +96941-0;Thinking about your friends and family: I have people to talk to;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about your friends and family: I have people to talk to;;;ACTIVE;2.70;2.7 +96942-8;Thinking about your friends and family: I have someone I can confide in;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about your friends and family: I have someone I can confide in;;;ACTIVE;2.70;2.7 +96943-6;Thinking about your friends and family: I have people who will help me;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about your friends and family: I have people who will help me;;;ACTIVE;2.70;2.7 +96944-4;Thinking about your friends and family: I do things with others;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about your friends and family: I do things with others;;;ACTIVE;2.70;2.7 +96945-1;Health confidence panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Health confidence panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.72 +96946-9;Health confidence score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Health confidence score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +96947-7;How do you feel about caring for your health: I can look after my health;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How do you feel about caring for your health: I can look after my health;;;ACTIVE;2.70;2.7 +96948-5;How do you feel about caring for your health: I can get the right help if I need it;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How do you feel about caring for your health: I can get the right help if I need it;;;ACTIVE;2.70;2.7 +96949-3;How do you feel about caring for your health: I am involved in decisions about me;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How do you feel about caring for your health: I am involved in decisions about me;;;ACTIVE;2.70;2.7 +96950-1;How do you feel about caring for your health: I know enough about my health;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;How do you feel about caring for your health: I know enough about my health;;;ACTIVE;2.70;2.7 +96951-9;Social determinants of health panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Social determinants of health panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.72 +96952-7;Social determinants of health score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Social determinants of health score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +96953-5;Thinking about how you live: I have had a good education;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about how you live: I have had a good education;;;ACTIVE;2.70;2.7 +96954-3;Thinking about how you live: I am valued for what I do;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about how you live: I am valued for what I do;;;ACTIVE;2.70;2.7 +96955-0;Thinking about how you live: I am happy about where I live;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about how you live: I am happy about where I live;;;ACTIVE;2.70;2.7 +96956-8;Thinking about how you live: I have enough money to cope;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Thinking about how you live: I have enough money to cope;;;ACTIVE;2.70;2.7 +96957-6;SARS coronavirus 2 M gene;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) M gene [Presence] in Upper respiratory specimen by NAA with probe detection;SARS-CoV-2 M gene Upper resp Ql NAA+prb;;ACTIVE;2.70;2.7 +9695-8;3-Methoxy-4-Hydroxyphenylglycol;MRat;24H;Urine;Qn;;CHEM;1;3-Methoxy-4-Hydroxyphenylglycol [Mass/time] in 24 hour Urine;3Me4OH-phenylglycol 24h Ur-mRate;;ACTIVE;1.0i;2.73 +96958-4;SARS coronavirus 2 N gene;PrThr;Pt;Saliva;Ord;Probe.amp.tar.CDC primer-probe set N2;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N2;SARS-CoV-2 N gene Sal Ql NAA N2;;ACTIVE;2.70;2.7 +96959-2;Cholesterol.in LDL.small dense;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.in LDL.small dense [Moles/volume] in Serum or Plasma;Chol.in LDL.small dense SerPl-sCnc;;ACTIVE;2.70;2.7 +969-6;D little u Ab;ACnc;Pt;Ser;Ord;Aggl RBC;BLDBK;1;Deprecated D little u Ab;Deprecated Du Ab Ser Ql;;DEPRECATED;1.0;2.36 +96960-0;Varicella zoster virus Ab.IgM Index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Varicella zoster virus IgM Ab index [Units/volume] in Serum and CSF;VZV IgM Index Ser+CSF-aCnc;;ACTIVE;2.70;2.7 +96961-8;Varicella zoster virus Ab.IgG Index;ACnc;Pt;Ser+CSF;Qn;;MICRO;1;Varicella zoster virus IgG Ab index [Units/volume] in Serum and CSF;VZV IgG Index Ser+CSF-aCnc;;ACTIVE;2.70;2.7 +96962-6;Bordetella pertussis.pertussis toxin promoter region;PrThr;Pt;Respiratory.lower;Ord;Probe.amp.tar;MICRO;1;Bordetella pertussis.pertussis toxin promoter region [Presence] in Lower respiratory specimen by NAA with probe detection;B pert.PT Prmt Lower resp Ql NAA+probe;;ACTIVE;2.70;2.7 +96963-4;Grimontia holisae & Vibrio fluvialis & Vibrio harveyi DNA;Prid;Pt;XXX;Nom;Probe.amp.tar;MICRO;1;Grimontia holisae and Vibrio fluvialis and Vibrio harveyi DNA [Identifier] in Specimen by NAA with probe detection;G. hol + V. fluv + harv DNA Spec NAA+Prb;;ACTIVE;2.70;2.7 +96964-2;EZH2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;EZH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;EZH2 gene Mut Anl Bld/T;;ACTIVE;2.70;2.7 +96965-9;CARD11 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CARD11 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CARD11 Mut Anl Bld/T;;ACTIVE;2.70;2.7 +9696-6;8-Hydroxyloxapine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;8-Hydroxyloxapine [Mass/volume] in Serum or Plasma;8OH-Loxapine SerPl-mCnc;;ACTIVE;1.0i;2.73 +96966-7;CD79A gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CD79A gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CD79A Mut Anl Bld/T;;ACTIVE;2.70;2.7 +96967-5;CD79B gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;CD79B gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CD79B Mut Anl Bld/T;;ACTIVE;2.70;2.7 +96968-3;TNFAIP3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;TNFAIP3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TNFAIP3 Mut Anl Bld/T;;ACTIVE;2.70;2.7 +96969-1;MYD88 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;MYD88 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;MYD88 Mut Anl Bld/T;;ACTIVE;2.70;2.7 +96970-9;TP53 gene deletion+duplication;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DELDUP;1;TP53 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal;TP53 gene Del+Dup Bld/T;;ACTIVE;2.70;2.7 +96971-7;STK11 gene deletion+duplication;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DELDUP;1;STK11 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal;STK11 gene Del+Dup Bld/T;;ACTIVE;2.70;2.7 +96972-5;PTEN gene deletion+duplication;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DELDUP;1;PTEN gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PTEN gene Del+Dup Bld/T;;ACTIVE;2.70;2.7 +96973-3;CDH1 gene deletion+duplication;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DELDUP;1;CDH1 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal;CDH1 gene Del+Dup Bld/T;;ACTIVE;2.70;2.7 +9697-4;carBAMazepine 10,11-Epoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Deprecated carBAMazepine 10,11-Epoxide [Mass/volume] in Serum or Plasma;Deprecated carBAMazepine EP SerPl-mCnc;;DEPRECATED;1.0i;2.7 +96974-1;PALB2 gene deletion+duplication;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.DELDUP;1;PALB2 gene deletion and duplication mutation analysis [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PALB2 Del+Dup Bld/T;;ACTIVE;2.70;2.7 +96975-8;Sub-maximal exercise stress test study;Find;Pt;^Patient;Doc;{Role};CARDIO-PULM;2;Sub-maximal exercise stress test study;SubMax Ex Stress Test;;ACTIVE;2.70;2.72 +96976-6;Carbon dioxide^at end expiration-Carbon dioxide^at end expiration+W sub-maximal exercise;PPresDiff;Pt;Exhl gas;Qn;;CARDIO-PULM;2;Carbon dioxide end tidal baseline - sub-maximal exercise delta;pCO2 baseline-SubMx Exer delta;;ACTIVE;2.70;2.7 +96977-4;Noninvasive prenatal fetal aneuploidy panel;-;Pt;WBC.DNA+Plas.cfDNA;-;Dosage of chromosome specific cf DNA;PANEL.MOLPATH;1;Noninvasive prenatal fetal aneuploidy panel - Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;NIP fet aneu Pnl WBC.DNA+cfDNA;;ACTIVE;2.70;2.7 +96978-2;Noninvasive prenatal fetal aneuploidy & 22q11.2 deletion panel;-;Pt;WBC.DNA+Plas.cfDNA;-;Dosage of chromosome specific cf DNA;PANEL.MOLPATH;1;Noninvasive prenatal fetal aneuploidy and 22q11.2 deletion panel - Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA;NIP aneu + 22q11.2 Pnl WBC.DNA+cfDNA;;ACTIVE;2.70;2.7 +96979-0;Fetal trisomy 13+trisomy 18+triploidy risk;Imp;Pt;WBC.DNA+Plas.cfDNA;Ord;Calculated;MOLPATH;1;Trisomy 13, trisomy 18 or triploidy risk [Interpretation] in Plasma cell-free+WBC DNA Qualitative by calculation;T13+T18+Trip risk WBC.DNA+cfDNA Calc-Imp;;ACTIVE;2.70;2.7 +96980-8;Comment on overall fetal aneuploidy risk;Txt;Pt;WBC.DNA+Plas.cfDNA;Nar;Dosage of chromosome specific cf DNA;MOLPATH;1;Comment on overall fetal aneuploidy risk [Text] in Plasma cell-free+WBC DNA by Dosage of chromosome-specific cfDNA Narrative;Comment aneu risk WBC.DNA+cfDNA;;ACTIVE;2.70;2.7 +96981-6;Fetal trisomy 13+trisomy 18+triploidy risk;Likelihood;Pt;WBC.DNA+Plas.cfDNA;Qn;Calculated;MOLPATH;1;Trisomy 13, trisomy 18 or triploidy risk [Likelihood] in Plasma cell-free+WBC DNA by calculation;T13+T18+Trip risk WBC.DNA+cfDNA Calc;;ACTIVE;2.70;2.7 +9698-2;Desmethylclomipramine;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Deprecated Norclomipramine [Mass/volume] in Serum or Plasma;Deprecated Desmethylclomipramine Ser;;DEPRECATED;1.0i;2.7 +96982-4;Test result delivery method;Type;Pt;Referral lab test;Nom;;ADMIN;2;Referral lab test result delivery method;Ref lab result delivery method;;ACTIVE;2.70;2.7 +96983-2;Twin pregnancy;Find;Pt;^Patient;Ord;;CLIN;2;Twin pregnancy;Twin pregnancy;;ACTIVE;2.70;2.7 +96984-0;Chromosome analysis;Find;Pt;POC;Doc;Microarray;MOLPATH;1;Chromosome analysis in Products of Conception by Microarray;Chrom analy POC Microarray;;ACTIVE;2.70;2.7 +96985-7;Fetal sex;Type;Pt;POC;Nom;Molgen;MOLPATH;1;Sex [Type] in Products of Conception by Molecular genetics method;Sex POC;;ACTIVE;2.70;2.7 +96986-5;SARS coronavirus 2 N gene;PrThr;Pt;Nose;Ord;Non-probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with non-probe detection;SARS-CoV-2 N gene Nose Ql NAA+non-probe;;ACTIVE;2.70;2.7 +96987-3;Mass vaccination status;-;Pt;^Event;-;CDC.EOC;PANEL.SURVEY.CDC;4;Mass vaccination status [CDC Emergency Operations Centers];;;ACTIVE;2.70;2.7 +96988-1;CVX code;ID;Pt;Vaccine;Nom;;VACCIN;2;Vaccine CVX code;Vaccine CVX code;;ACTIVE;2.70;2.7 +96989-9;MVX code;ID;Pt;Vaccine;Nom;;VACCIN;2;Vaccine MVX code;Vaccine MVX code;;ACTIVE;2.70;2.7 +9699-0;PARoxetine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;PARoxetine [Mass/volume] in Serum or Plasma;PARoxetine SerPl-mCnc;;ACTIVE;1.0i;2.73 +96990-7;Vaccine administration location;Type;Pt;^Event;Nom;;VACCIN;2;Vaccine administration location;Vaccine administration loc;;ACTIVE;2.70;2.7 +96991-5;Vaccine administration county;Loc;Pt;^Event;Nom;;VACCIN;2;Vaccine administration county [Location];Vaccine administration county;;ACTIVE;2.70;2.7 +96992-3;Vaccine administration state;Loc;Pt;^Event;Nom;;VACCIN;2;State where vaccine was administered;Vaccine administration state;;ACTIVE;2.70;2.7 +96993-1;Federal agency code;ID;Pt;Agency;Nom;;ADMIN;2;Federal agency code;Federal agency code;;ACTIVE;2.70;2.7 +96994-9;Vaccine doses distributed;Num;Pt;^Event;Qn;;VACCIN;2;Vaccine doses distributed [#];Vaccine doses distributed;;ACTIVE;2.70;2.7 +96995-6;Vaccine doses distributed/100,000 population;NRto;Pt;^Event;Qn;;VACCIN;2;Total vaccine doses distributed per 100,000 population;Vac doses dist per 100,000;;ACTIVE;2.70;2.7 +96996-4;People who have received first dose of vaccine;Num;Pt;^Population;Qn;;VACCIN;2;People who have received first dose of vaccine [#] Population;People rcvd first dose of vaccine Pop;;ACTIVE;2.70;2.7 +96997-2;People who have received first dose of vaccine/100,000 population;NFr;Pt;^Population;Qn;;VACCIN;2;Count of people who initiated vaccination per 100,000 population;Rcvd first dose of vaccine/100,00 pop;;ACTIVE;2.70;2.7 +96998-0;People who are fully vaccinated;Num;Pt;^Population;Qn;;VACCIN;2;Count of people who are fully vaccinated in Population;People who fully vaccinated Pop;;ACTIVE;2.70;2.7 +96999-8;People who are fully vaccinated/100,000 population;NFr;Pt;^Population;Qn;;VACCIN;2;Count of people who are fully vaccinated per 100,000 population;People who fully vaccinated/100,000 pop;;ACTIVE;2.70;2.7 +97000-4;Vaccine doses distributed for use in long term care facilities;Num;Pt;^Event;Qn;;VACCIN;2;Vaccine doses distributed for use in long term care facilities [#];Vaccine doses distributed to LTCFs;;ACTIVE;2.70;2.7 +97001-2;Vaccine administration tier;Type;Pt;^Event;Nom;;VACCIN;2;Vaccine administration tier;Vaccine administration tier;;ACTIVE;2.70;2.7 +97002-0;People in long-term care facilities who have received first dose of vaccine;Num;Pt;^Population;Qn;;VACCIN;2;Number of people in long-term care facilities who have received first dose of vaccine;# People in LTCFs rcvd 1st dose vaccine;;ACTIVE;2.70;2.7 +97003-8;People in long-term care facilities who are fully vaccinated;Num;Pt;^Population;Qn;;VACCIN;2;Number of people in long-term care facilities who are fully vaccinated;# People in LTCFs fully vaccinated;;ACTIVE;2.70;2.7 +97004-6;Insulin type;Prid;Pt;Ser/Plas;Nom;LC/MS/MS;CHEM;1;Insulin type [Identifier] in Serum or Plasma by LC/MS/MS;Insulin Type SerPl LC/MS/MS;;ACTIVE;2.70;2.7 +97005-3;Maximum clot strength amplitude.kaolin+tissue factor induced;Len;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Maximum amplitude kaolin+tissue factor induced [Length] in Blood by Resonance TEG;MA kaolin+TF Bld Res TEG;;ACTIVE;2.70;2.7 +9700-6;Procaine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Procaine [Mass/volume] in Serum or Plasma;Procaine SerPl-mCnc;;ACTIVE;1.0i;2.73 +97006-1;Maximum clot strength amplitude.kaolin+tissue factor induced;Len;Pt;Bld;Qn;;COAG;1;Maximum amplitude kaolin+tissue factor induced [Length] in Blood;MA kaolin+TF Bld;;ACTIVE;2.70;2.7 +97007-9;Clot initiation.kaolin induced^post heparin neutralization;Time;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Clot initiation.kaolin induced [Time] in Blood by Resonance TEG --post heparin neutralization;Clot init kao ind p hep neut Bld Res TEG;;ACTIVE;2.70;2.7 +97008-7;Clot initiation.kaolin+tissue factor induced;Time;Pt;Bld;Qn;;COAG;1;Clot initiation.kaolin+tissue factor induced [Time] in Blood;Clot init kaolin+TF ind Bld;;ACTIVE;2.70;2.7 +97009-5;Activated clotting time.kaolin+tissue factor induced;Time;Pt;Bld;Qn;Calculated;COAG;1;Activated clotting time.kaolin+tissue factor induced of Blood by calculation;ACT Kaolin+TF Ind Bld Calc;;ACTIVE;2.70;2.7 +97010-3;Clot formation.kaolin+tissue factor induced;Time;Pt;Bld;Qn;;COAG;1;Clot formation kaolin+tissue factor induced [Time] in Blood;CFT kaolin+TF ind Bld;;ACTIVE;2.70;2.7 +97011-1;Clot angle.kaolin+tissue factor induced;Angle;Pt;Bld;Qn;;COAG;1;Clot angle kaolin+tissue factor induced in Blood;Clot angle kaolin+TF ind Bld;;ACTIVE;2.70;2.7 +97012-9;Reduction in clot strength.kaolin+tissue factor induced^30M post maximum clot amplitude;LenFr;Pt;Bld;Qn;;COAG;1;Reduction in kaolin+tissue factor induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude;Lysis kao+TF ind clot 30M p MA LenFr Bld;;ACTIVE;2.70;2.7 +97013-7;Reduction in clot strength.kaolin induced^30M post maximum clot amplitude;LenFr;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Reduction in kaolin induced clot strength [Length fraction] in Blood by Resonance TEG --30 minutes post maximum clot amplitude;Lys kao ind clt 30M p MA LenFr Bl ResTEG;;ACTIVE;2.70;2.7 +9701-4;sulfiSOXAZOLE;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;sulfiSOXAZOLE [Mass/volume] in Serum or Plasma;Sulfisoxaz SerPl-mCnc;;ACTIVE;1.0i;2.7 +97014-5;Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited;Len;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood by Resonance TEG;MA TF ind+IIb-IIIa inh Bld Res TEG;;ACTIVE;2.70;2.7 +97015-2;Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited;Len;Pt;Bld;Qn;;COAG;1;Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood;MA TF ind+IIb-IIIa inh Bld;;ACTIVE;2.70;2.7 +97016-0;Fibrinogen;MCnc;Pt;Bld;Qn;Calculated;COAG;1;Fibrinogen [Mass/volume] in Blood by calculation;Fibrinogen Bld Calc-mCnc;;ACTIVE;2.70;2.7 +97017-8;Maximum clot strength amplitude.kaolin induced^after addition of heparinase;Len;Pt;Bld;Qn;;COAG;1;Maximum amplitude kaolin induced [Length] in Blood --after addition of heparinase;MA kaolin P Hpase Bld;;ACTIVE;2.70;2.7 +97018-6;Maximum clot strength amplitude.activator F induced;Len;Pt;Bld;Qn;;COAG;1;Maximum amplitude activator F induced [Length] in Blood;MA ActF Bld;;ACTIVE;2.70;2.7 +97019-4;Maximum clot strength amplitude.adenosine diphosphate induced;Len;Pt;Bld;Qn;;COAG;1;Maximum amplitude ADP induced [Length] in Blood;MA ADP Bld;;ACTIVE;2.70;2.7 +97020-2;Maximum clot strength amplitude.arachidonate induced;Len;Pt;Bld;Qn;;COAG;1;Maximum amplitude arachidonate induced [Length] in Blood;MA AA Bld;;ACTIVE;2.70;2.7 +97021-0;Reduction in clot strength.kaolin induced^30M post maximum clot amplitude;LenFr;Pt;Bld;Qn;;COAG;1;Reduction in kaolin induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude;Lys of kao ind clot 30M p MA LenFr Bld;;ACTIVE;2.70;2.7 +9702-2;Terbutaline;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Terbutaline [Mass/volume] in Serum or Plasma;Terbutaline SerPl-mCnc;;ACTIVE;1.0i;2.7 +97022-8;Clot strength.arachidonate inhibited;LenFr;Pt;Bld;Qn;Calculated;COAG;1;Clot strength arachidonate inhibited [Length fraction] in Blood by calculation;Clot strength AA inhib LenFr Bld Calc;;ACTIVE;2.70;2.7 +97023-6;Accountable health communities health-related social needs supplemental questions;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Accountable health communities (AHC) health-related social needs (HRSN) supplemental questions;;;ACTIVE;2.70;2.7 +97024-4;aPTT mixing study panel;-;Pt;PPP;-;;PANEL.COAG;1;aPTT mixing study panel - Platelet poor plasma;aPTT Mix Pnl PPP;;ACTIVE;2.70;2.7 +97025-1;BRAF gene.p.Val600 mutations;Prid;Pt;Tiss;Nom;Molgen;MOLPATH.MUT;1;BRAF gene V600 mutations [Identifier] in Tissue by Molecular genetics method Nominal;BRAF p.V600 mutations Tiss;;ACTIVE;2.70;2.7 +97026-9;Phosphatidylserine-prothrombin complex Ab.IgG & IgM panel;-;Pt;Ser/Plas;-;;PANEL.COAG;1;Phosphatidylserine-prothrombin complex IgG and IgM panel - Serum or Plasma;PS-prothrom cmplx IgG IgM Pnl SerPl;;ACTIVE;2.70;2.7 +97027-7;Speaks a language other than English at home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Speaks a language other than English at home;;;ACTIVE;2.70;2.7 +97029-3;Spine Tango surgery follow-up 2017;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Spine Tango surgery follow-up 2017 Spine Tango;Spine Tango surgery f/u 2017 Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +9703-0;Trihexyphenidyl;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Trihexyphenidyl [Mass/volume] in Serum or Plasma;Trihexyphenidyl SerPl-mCnc;;ACTIVE;1.0i;2.7 +97030-1;Level of spine intervention;Find;Pt;^Patient;Nom;;SURG;2;Level of spine intervention;Level of spine intervention;;ACTIVE;2.70;2.7 +97031-9;Follow-up panel;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Follow-up panel Spine Tango;Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +97032-7;Postoperative follow-up interval;Find;Pt;^Patient;Nom;;H&P.HX;2;Postoperative follow-up interval;Postop follow-up interval;;ACTIVE;2.70;2.7 +97033-5;Postoperative work status;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Postoperative work status;;;ACTIVE;2.70;2.7 +97034-3;Postoperative therapeutic goals or measures that were achieved;Find;Pt;^Patient;Nom;;SURG;2;Postoperative therapeutic goals or measures that were achieved;Postop ther goals achieved;;ACTIVE;2.70;2.7 +97035-0;Postoperative therapeutic goals or measures that were partially achieved;Find;Pt;^Patient;Nom;;SURG;2;Postoperative therapeutic goals or measures that were partially achieved;Postop ther goals partially achieved;;ACTIVE;2.70;2.7 +97036-8;Postoperative therapeutic goals or measures that were not achieved;Find;Pt;^Patient;Nom;;SURG;2;Postoperative therapeutic goals or measures that were not achieved;Postop ther goals not achieved;;ACTIVE;2.70;2.7 +97037-6;Medication for spinal surgery or pathology;Find;Pt;^Patient;Nom;;SURG;2;Medication for spinal surgery or pathology;Meds spinal surgery/pathology;;ACTIVE;2.70;2.7 +97038-4;Postoperative rehabilitation;Find;Pt;^Patient;Nom;;SURG;2;Postoperative rehabilitation;Postop rehab;;ACTIVE;2.70;2.7 +97039-2;Overall outcome of spine surgery;Find;Pt;^Patient;Nom;;SURG;2;Overall outcome of spine surgery;Overall outcome of spine surgery;;ACTIVE;2.70;2.7 +970-4;Weak D Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Weak D Ag [Presence] on Red Blood Cells from Blood product unit;Weak D Ag RBC BPU Ql;;ACTIVE;1.0;2.7 +97040-0;Postoperative follow-up care decision;Find;Pt;^Patient;Nom;;SURG;2;Postoperative follow-up care decision;Postop follow-up care decision;;ACTIVE;2.70;2.7 +97041-8;Comments regarding postoperative follow-up;Find;Pt;^Patient;Nom;;SURG;2;Comments regarding postoperative follow-up;Comments re: postop follow-up;;ACTIVE;2.70;2.7 +97042-6;Complications panel;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Complications panel Spine Tango;Complications pnl Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +97043-4;Postoperative complication occurred;Find;Pt;^Patient;Ord;;SURG;2;Postoperative complication occurred;Postop comp occurred;;ACTIVE;2.70;2.7 +97044-2;Postoperative complication timing;Find;Pt;^Patient;Nom;;SURG;2;Postoperative complication timing;Postop complication timing;;ACTIVE;2.70;2.7 +97045-9;Postoperative complication type;Find;Pt;^Patient;Nom;;SURG;2;Postoperative complication type;Postop complication type;;ACTIVE;2.70;2.7 +97046-7;Postoperative complication treatment needed;Find;Pt;^Patient;Nom;;SURG;2;Postoperative complication treatment needed;Postop complication treatment;;ACTIVE;2.70;2.7 +97047-5;Postoperative complication effect on recovery;Find;Pt;^Patient;Nom;;SURG;2;Postoperative complication effect on recovery;Postop comp effect on recvry;;ACTIVE;2.70;2.7 +9704-8;Spermatozoa;Morph;Pt;Semen;Nom;;FERT;1;Spermatozoa [Morphology] in Semen;Sperm Smn;;ACTIVE;1.0i;2.73 +97048-3;Comments regarding postoperative complications;Find;Pt;^Patient;Nom;;SURG;2;Comments regarding postoperative complications;Comments re: postop complications;;ACTIVE;2.70;2.7 +97049-1;p53 Ab;MCnc;Pt;Ser/Plas;Qn;IA;SERO;1;p53 Ab [Mass/volume] in Serum or Plasma by Immunoassay;p53 Ab SerPl IA-mCnc;;ACTIVE;2.70;2.7 +97050-9;Acinetobacter calcoaceticus-baumannii complex DNA;PrThr;Pt;Bld.pos growth;Ord;Non-probe.amp.tar;MICRO;1;Acinetobacter calcoaceticus-baumannii complex DNA [Presence] by NAA with non-probe detection in Positive blood culture;ACB complex DNA Bld Pos Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97051-7;Interferon.beta;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interferon beta [Mass/volume] in Serum or Plasma;IFN-B SerPl-mCnc;;ACTIVE;2.70;2.7 +97052-5;Chemokine (C-C motif) ligand 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 2 [Mass/volume] in Serum or Plasma;CCL2 SerPl-mCnc;;ACTIVE;2.70;2.7 +97053-3;Macrophage inflammatory protein 1.alpha;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Macrophage inflammatory protein 1 alpha [Mass/volume] in Serum or Plasma;MIP-1 alpha SerPl-mCnc;;ACTIVE;2.70;2.71 +97054-1;Granulocyte macrophage colony stimulating factor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Granulocyte macrophage colony stimulating factor [Mass/volume] in Serum or Plasma;GM-CSF SerPl-mCnc;;ACTIVE;2.70;2.71 +9705-5;Coccidioides immitis Ab.IgA;ACnc;Pt;Ser;Qn;;MICRO;1;Coccidioides immitis IgA Ab [Units/volume] in Serum;C immitis IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +97055-8;Finnish diabetes risk score panel;-;Pt;^Patient;-;FINDRISC;PANEL.CLIN.RISK;2;Finnish diabetes risk score panel FINDRISC;FINDRISC pnl FINDRISC;;ACTIVE;2.70;2.7 +97057-4;BMI score for risk calculation;Score;Pt;^Patient;Ord;;H&P.HX;2;BMI score for risk calculation;BMI score for risk calc;;ACTIVE;2.70;2.7 +97058-2;Waist circumference score for risk calculation;Score;Pt;^Patient;Ord;;H&P.PX;2;Waist circumference score for risk calculation;Waist circ score for risk calc;;ACTIVE;2.70;2.7 +97059-0;Physical activity at least 30M per D;Find;Pt;^Patient;Ord;;H&P.HX;2;Physical activity at least 30 minutes per day;Physical activity min 30 M/day;;ACTIVE;2.70;2.7 +97060-8;Vegetable &or fruit frequency;NRat;Pt;^Patient;Ord;;H&P.HX;2;Vegetable AndOr fruit frequency;Vegetable AndOr fruit frequency;;ACTIVE;2.70;2.7 +97062-4;High blood glucose;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of High blood glucose;Hx of High blood glucose;;ACTIVE;2.70;2.7 +9706-3;Coxiella burnetii phase 1 Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 IgA Ab [Titer] in Serum;C burnet Ph1 IgA Titr Ser;;ACTIVE;1.0i;2.73 +97063-2;Diabetes;Hx;Pt;^Family member;Ord;;H&P.HX;2;Family history of Diabetes;Family hx of Diabetes;;ACTIVE;2.70;2.7 +97064-0;Total risk score;Score;Pt;^Patient;Qn;FINDRISC;CLIN.RISK;2;Total risk score FINDRISC;Total risk score FINDRISC;;ACTIVE;2.70;2.7 +97065-7;Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine;-;Pt;^Patient;-;;PANEL.VACCIN;2;Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine;Hx for COVID -19 vaccine;;ACTIVE;2.70;2.7 +97066-5;Acute illness with fever;Find;Pt;^Patient;Ord;;H&P.HX;2;Acute illness with fever;Acute ill w/fever;;ACTIVE;2.70;2.7 +97067-3;Allergic reaction to first COVID-19 vaccine dose;Find;Pt;^Patient;Ord;;VACCIN;2;Allergic reaction to first COVID-19 vaccine dose;Aller react 1st COVID-19 dose;;ACTIVE;2.70;2.7 +97068-1;Chronic diseases &or immunodeficiency;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Chronic diseases AndOr immunodeficiency;Hx chronic diseases/immunodeficiency;;ACTIVE;2.70;2.7 +97069-9;Coagulation disorder &or blood-thinning medication use;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Coagulation disorder AndOr blood-thinning medication use;Hx coag disorder &/or bld-thin med;;ACTIVE;2.70;2.7 +97070-7;Adverse event following prior vaccination;Find;Pt;^Patient;Ord;;VACCIN;2;Adverse event following prior vaccination;AE p vaccine;;ACTIVE;2.70;2.7 +9707-1;Coxiella burnetii phase 2 Ab.IgA;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 IgA Ab [Titer] in Serum;C burnet Ph2 IgA Titr Ser;;ACTIVE;1.0i;2.73 +97071-5;Pregnant or nursing;Find;Pt;^Patient;Ord;;H&P.HX;2;Pregnant or nursing;Pregnant/Nursing;;ACTIVE;2.70;2.7 +97072-3;Vaccinated in last 14 D;Find;14D;^Patient;Ord;;VACCIN;2;Vaccinated in last 14 days;Vacc last 14 D;;ACTIVE;2.70;2.7 +97073-1;Received COVID-19 vaccine;Find;Pt;^Patient;Ord;;VACCIN;2;Received COVID-19 vaccine;Rcvd COVID-19 vaccine;;ACTIVE;2.70;2.7 +97074-9;Mean score;Score;Pt;^Patient;Qn;CRBS;SURVEY.COVID;4;Mean score [CRBS];;Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.;ACTIVE;2.70;2.71 +97075-6;Total score;Score;Pt;^Patient;Qn;CAS;SURVEY.COVID;4;Total score [CAS];;;ACTIVE;2.70;2.71 +97076-4;Common news sources;Type;Pt;^Patient;Nom;;SURVEY.COVID;4;Common news sources;;;ACTIVE;2.70;2.71 +97077-2;Time spent per day getting information about COVID-19 &or its impact;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Time spent per day getting information about COVID-19 and/or its impact;;;ACTIVE;2.70;2.71 +97078-0;Effect of friends, family or neighbors as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of friends, family or neighbors as source of information on mental health;;;ACTIVE;2.70;2.71 +97079-8;Effect of local government officials as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of local government officials as source of information on mental health;;;ACTIVE;2.70;2.71 +97080-6;Effect of national government officials as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of national government officials as source of information on mental health;;;ACTIVE;2.70;2.71 +97081-4;Effect of national and international health officials as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of national and international health officials as source of information on mental health;;;ACTIVE;2.70;2.71 +97082-2;Effect of print or online news as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of print or online news as source of information on mental health;;;ACTIVE;2.70;2.71 +97083-0;Effect of radio or podcast as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of radio or podcast as source of information on mental health;;;ACTIVE;2.70;2.71 +97084-8;Effect of Facebook as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of Facebook as source of information on mental health;;;ACTIVE;2.70;2.71 +97085-5;Effect of Instagram or Snapchat as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of Instagram or Snapchat as source of information on mental health;;;ACTIVE;2.70;2.71 +97086-3;Effect of Twitter as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of Twitter as source of information on mental health;;;ACTIVE;2.70;2.71 +97087-1;Effect of social media (e.g., TikTok, Reddit) as source of information on mental health;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Effect of social media (e.g., TikTok, Reddit) as source of information on mental health;;;ACTIVE;2.70;2.71 +97088-9;How often friends, family or neighbors used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often friends, family or neighbors used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +9708-9;Coxiella burnetii phase 1 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 IgG Ab [Titer] in Serum;C burnet Ph1 IgG Titr Ser;;ACTIVE;1.0i;2.73 +97089-7;How often medical providers used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often medical providers used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +97090-5;How often local government officials used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often local government officials used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +97091-3;How often Federal Government used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often Federal Government used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +97092-1;How often medical or health websites used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often medical or health websites used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +97093-9;How often print or online news used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often print or online news used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +97094-7;How often TV or radio used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often TV or radio used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +97095-4;How often social media used as source of information for COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often social media used as source of information for COVID-19;;;ACTIVE;2.70;2.71 +97096-2;COVID-19 experiences - media use panel;-;Pt;^Patient;-;COVEX;PANEL.SURVEY.COVID;4;COVID-19 experiences - media use panel [COVEX];;;ACTIVE;2.70;2.71 +9709-7;Coxiella burnetii phase 2 Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 IgG Ab [Titer] in Serum;C burnet Ph2 IgG Titr Ser;;ACTIVE;1.0i;2.73 +97097-0;SARS coronavirus 2 Ag;PrThr;Pt;Respiratory.upper;Ord;IA.rapid;MICRO;1;SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay;SARS-CoV-2 Ag Upper resp Ql IA.rapid;;ACTIVE;2.70;2.7 +97098-8;SARS coronavirus 2 Nsp2 gene;PrThr;Pt;Respiratory.upper;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) Nsp2 gene [Presence] in Upper respiratory specimen by NAA with probe detection;SARS-CoV-2 Nsp2 Upper resp Ql NAA+probe;;ACTIVE;2.70;2.7 +97099-6;Influenza virus A & Influenza virus B & SARS coronavirus 2 Ag panel;-;Pt;Respiratory.upper;-;IA.rapid;PANEL.MICRO;1;Influenza virus A and B and SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay;FLUABV+SARS-CoV2 Ag Pnl Up resp IA.rapid;;ACTIVE;2.70;2.7 +97100-2;Colonoscopy and endoscopic ultrasound study;Find;Pt;Lower GI tract;Doc;Colonoscopy+US;ENDO.GI;2;Colonoscopy+US Study;Colonoscopy+US Study;;ACTIVE;2.70;2.72 +97101-0;Flexible sigmoidoscopy and endoscopic ultrasound study;Find;Pt;Lower GI tract;Doc;Flexible sigmoidoscopy+US;ENDO.GI;2;Flexible sigmoidoscopy+US Study;FSIG+US Study;;ACTIVE;2.70;2.72 +97102-8;Tau protein.phosphorylated 181/Amyloid beta 42 peptide;Ratio;Pt;CSF;Qn;;CHEM;1;Phosphorylated tau 181/Amyloid beta 42 peptide [Ratio] in Cerebral spinal fluid;p-tau181/AL beta42 CSF-Rto;;ACTIVE;2.70;2.7 +97103-6;Zygosity;Type;Pt;^Fetuses;Nom;Molgen;MOLPATH;1;Zygosity [Type] in Fetuses by Molecular genetics method;Zygosity in Fetuses;;ACTIVE;2.70;2.7 +97104-4;SARS coronavirus 2 ORF1ab region;ACnc;Pt;Respiratory.upper;Qn;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1ab region [Units/volume] (viral load) in Upper respiratory specimen by NAA with probe detection;SARS-CoV-2 ORF1ab U resp NAA+probe-aCnc;;ACTIVE;2.70;2.7 +9710-5;Coxiella burnetii phase 1 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 1 IgM Ab [Titer] in Serum;C burnet Ph1 IgM Titr Ser;;ACTIVE;1.0i;2.73 +97105-1;Chemokine (C-C motif) ligand 2;MCnc;Pt;Urine;Qn;IA;CHEM;1;Chemokine (C-C motif) ligand 2 [Mass/volume] in Urine by Immunoassay;CCL2 Ur IA-mCnc;;ACTIVE;2.70;2.7 +97106-9;Hepatitis A virus cellular receptor 1;MCnc;Pt;Urine;Qn;IA;CHEM;1;Hepatitis A virus cellular receptor 1 [Mass/volume] in Urine by Immunoassay;HAVcr-1 Ur IA-mCnc;;ACTIVE;2.70;2.7 +97107-7;Fibroblast growth factor 19;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Fibroblast growth factor 19 [Mass/volume] in Serum or Plasma by Immunoassay;FGF-19 SerPl IA-mCnc;;ACTIVE;2.70;2.7 +97108-5;Employment status in the 2W prior to COVID-19 outbreak;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Employment status in the 2 weeks prior to COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97109-3;New employment during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;New employment during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97110-1;Work setting in the 2W before the COVID-19 outbreak;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Work setting in the 2 weeks before the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97111-9;Job loss during the COVID-19 outbreak;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Job loss during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97112-7;Worked during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Worked during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +9711-3;Coxiella burnetii phase 2 Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Coxiella burnetii phase 2 IgM Ab [Titer] in Serum;C burnet Ph2 IgM Titr Ser;;ACTIVE;1.0i;2.73 +97113-5;Significant job changes during the COVID-19 outbreak;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Significant job changes during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97114-3;Work setting during the COVID-19 outbreak;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Work setting during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97115-0;Student in the few weeks before COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Student in the few weeks before COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97116-8;Student during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Student during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97117-6;School has offered classes remotely during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;School has offered classes remotely during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97118-4;Increase or decrease in schoolwork during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Increase or decrease in schoolwork during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97119-2;Difficulty getting work or schoolwork done because of other responsibilities at home during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Difficulty getting work or schoolwork done because of other responsibilities at home during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +971-2;Weak D Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Weak D Ag [Presence] on Red Blood Cells from Donor;Weak D Ag RBC Donr Ql;;ACTIVE;1.0;2.7 +97120-0;Difficulty getting work or schoolwork done because of your home environment during the COIVD-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Difficulty getting work or schoolwork done because of your home environment during the COIVD-19 outbreak;;;ACTIVE;2.70;2.71 +9712-1;Shigella boydii Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Shigella boydii Ab [Titer] in Serum by Complement fixation;S boydii Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97121-8;Household job or income loss due to the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Household job or income loss due to the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97122-6;Person who lost job or income due to COVID-19 outbreak;Find;Pt;^Household member;Nom;;SURVEY.COVID;4;Household member who lost job or income due to COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97123-4;COVID-19 experiences - employment and school changes panel;-;Pt;^Patient;-;COVEX;PANEL.SURVEY.COVID;4;COVID-19 experiences - employment and school changes panel [COVEX];;;ACTIVE;2.70;2.71 +97124-2;How helpful has texting, calling or video-calling family members or friends been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has texting, calling or video-calling family members or friends been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97125-9;How helpful has talking to a therapist been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has talking to a therapist been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97126-7;How helpful has exercising or walking been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has exercising or walking been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97127-5;How helpful has cooking or baking been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has cooking or baking been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97128-3;How helpful have arts and crafts projects been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful have arts and crafts projects been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97129-1;How helpful has cleaning or doing household chores been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has cleaning or doing household chores been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97130-9;How helpful has playing games with family members been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has playing games with family members been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97131-7;How helpful has playing online games been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has playing online games been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97132-5;How helpful has virtual entertainment been as a coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has virtual entertainment been as a coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97133-3;Helpful coping strategy used during the COVID-19 outbreak;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Helpful coping strategy used during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97134-1;How helpful was your coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful was your coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97135-8;Impact of COVID-19 outbreak on life;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Impact of COVID-19 outbreak on life;;;ACTIVE;2.70;2.71 +97136-6;How helpful has texting, calling or video-calling family members or friends been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has texting, calling or video-calling family members or friends been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97137-4;How helpful has virtual learning or school been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has virtual learning or school been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97138-2;How helpful has talking to a therapist been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has talking to a therapist been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +9713-9;Shigella dysenteriae Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Shigella dysenteriae Ab [Titer] in Serum by Complement fixation;S dysenter Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97139-0;How helpful has exercising or walking been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has exercising or walking been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97140-8;How helpful has cooking or baking been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has cooking or baking been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97141-6;How helpful have arts and crafts projects been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful have arts and crafts projects been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97142-4;How helpful has playing board games, cards with family members been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has playing board games, cards with family members been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97143-2;How helpful has playing online games been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has playing online games been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97144-0;How helpful has virtual entertainment been as a coping strategy to your child during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful has virtual entertainment been as a coping strategy to your child during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97145-7;Helpful coping strategy your child used during the COVID-19 outbreak;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Helpful coping strategy your child used during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +97146-5;How helpful was your child's coping strategy during the COVID-19 outbreak;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How helpful was your child's coping strategy during the COVID-19 outbreak;;;ACTIVE;2.70;2.71 +9714-7;Shigella flexneri Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Shigella flexneri Ab [Titer] in Serum by Complement fixation;S flexneri Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97147-3;COVID-19 experiences - coping panel;-;Pt;^Patient;-;COVEX;PANEL.SURVEY.COVID;4;COVID-19 experiences - coping panel [COVEX];;;ACTIVE;2.70;2.71 +97148-1;Guanidinoacetate;SCnc;Pt;Urine;Qn;;CHEM;1;Guanidinoacetate [Moles/volume] in Urine;Guanidinoacetate Ur-sCnc;;ACTIVE;2.70;2.7 +97149-9;Pro prostate specific Ag isoform 2;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;proPSA isoform 2 [Mass/volume] in Serum or Plasma by Immunoassay;proPSA isoform 2 SerPl IA-mCnc;;ACTIVE;2.70;2.7 +97150-7;Prostate health index;Score;Pt;Ser/Plas;Qn;Calculated;CHEM;1;Prostate health index in Serum or Plasma by calculation;PHI Score SerPl Calc;;ACTIVE;2.70;2.7 +97151-5;Enterovirus RNA;PrThr;Pt;Ser/Plas;Ord;Non-probe.amp.tar;MICRO;1;Enterovirus RNA [Presence] in Serum or Plasma by NAA with non-probe detection;EV RNA SerPl Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97152-3;Hepatitis B virus core+little e+p22cr Ag;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;HBc+HBe+p22cr Ag [Units/volume] in Serum or Plasma by Immunoassay;HBc+HBe+p22cr Ag SerPl IA-aCnc;;ACTIVE;2.70;2.7 +97153-1;Primidone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Primidone [Presence] in Urine by Confirmatory method;Primidone Ur Ql Cfm;;ACTIVE;2.70;2.7 +9715-4;Shigella sonnei Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Shigella sonnei Ab [Titer] in Serum by Complement fixation;S sonnei Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97154-9;Ecgonine methyl ester;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Ecgonine methyl ester [Presence] in Urine by Confirmatory method;EME Ur Ql Cfm;;ACTIVE;2.70;2.7 +97155-6;SARS coronavirus 2 immunization status;Hx;Pt;^Patient;Nom;;VACCIN;2;SARS coronavirus 2 (COVID-19) immunization status;SARS-CoV-2 immunization status;;ACTIVE;2.70;2.7 +97156-4;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA;PrThr;Pt;Genital;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Genital specimen by Probe with signal amplification;HPV I/H Risk DNA Genital Ql Prb+sig amp;;ACTIVE;2.70;2.7 +97157-2;Human papilloma virus 6+11+42+43+44 DNA;PrThr;Pt;Genital;Ord;Probe.amp.sig;MICRO;1;Human papilloma virus 6+11+42+43+44 DNA [Presence] in Genital specimen by Probe with signal amplification;HPV Low Risk DNA Genital Ql Prb+sig amp;;ACTIVE;2.70;2.7 +97158-0;Cytokeratin 8 Ag;PrThr;Pt;Tissue;Ord;Immune stain;PATH;1;Cytokeratin 8 Ag [Presence] in Tissue by Immune stain;CK8 Ag tiss Ql ImStn;;ACTIVE;2.70;2.7 +97159-8;2-Hydroxyethylflurazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;2-Hydroxyethylflurazepam [Mass/volume] in Urine by Confirmatory method;2-OH-Ethylfluraz Ur Cfm-mCnc;;ACTIVE;2.70;2.7 +97160-6;Norclobazam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Norclobazam [Mass/volume] in Urine by Confirmatory method;Norclobazam Ur Cfm-mCnc;;ACTIVE;2.70;2.7 +97161-4;Amphetamines panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;Amphetamines panel - Urine by Confirmatory method;Amphetamines Pnl Ur Cfm;;ACTIVE;2.70;2.7 +9716-2;Streptococcal hyaluronidase Ab;Titr;Pt;Ser;Qn;;MICRO;1;Streptococcal hyaluronidase Ab [Titer] in Serum;Str Hyaluronidase Ab Titr Ser;;ACTIVE;1.0i;2.7 +97162-2;Titin Ab;ACnc;Pt;CSF;Qn;Line blot;SERO;1;Titin Ab [Units/volume] in Cerebral spinal fluid by Line blot;Titin Ab CSF Line blot-aCnc;;ACTIVE;2.70;2.7 +97163-0;Theophylline^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Theophylline [Mass/volume] in Serum or Plasma --peak;Theophylline Peak SerPl-mCnc;;ACTIVE;2.70;2.7 +97164-8;Triiodothyronine;MRat;24H;Urine;Qn;;CHEM;1;Triiodothyronine (T3) [Mass/time] in 24 hour Urine;T3 24h Ur-mRate;;ACTIVE;2.70;2.7 +97165-5;Triiodothyronine;SRat;24H;Urine;Qn;;CHEM;1;Triiodothyronine (T3) [Moles/time] in 24 hour Urine;T3 24h Ur-sRate;;ACTIVE;2.70;2.7 +97166-3;Thyroxine;MRat;24H;Urine;Qn;;CHEM;1;Thyroxine (T4) [Mass/time] in 24 hour Urine;T4 24h Ur-mRate;;ACTIVE;2.70;2.7 +97167-1;Thyroxine;SRat;24H;Urine;Qn;;CHEM;1;Thyroxine (T4) [Moles/time] in 24 hour Urine;T4 24h Ur-sRate;;ACTIVE;2.70;2.7 +97168-9;Vasopressin;MRat;24H;Urine;Qn;;CHEM;1;Vasopressin [Mass/time] in 24 hour Urine;Vasopressin 24h Ur-mRate;;ACTIVE;2.70;2.7 +97169-7;Vasopressin;SRat;24H;Urine;Qn;;CHEM;1;Vasopressin [Moles/time] in 24 hour Urine;Vasopressin 24h Ur-sRate;;ACTIVE;2.70;2.7 +9717-0;Toxocara canis Ab.IgA;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxocara canis IgA Ab [Units/volume] in Serum by Immunoassay;T canis IgA Ser IA-aCnc;;ACTIVE;1.0i;2.68 +97170-5;Adalimumab^trough;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Adalimumab [Mass/volume] in Serum or Plasma --trough;Adalimumab Trough SerPl-mCnc;;ACTIVE;2.70;2.7 +97171-3;Hexacarboxylporphyrin/Creatinine;SRto;Pt;Urine;Qn;;CHEM;1;Hexacarboxylporphyrin/Creatinine [Molar ratio] in Urine;Hexa-CP/Creat Ur-sRto;;ACTIVE;2.70;2.7 +97172-1;Yersinia outer protein Ab panel;-;Pt;Ser;-;Line blot;PANEL.MICRO;1;Yersinia outer protein Ab panel - Serum by Line blot;Yop Ab Pnl Ser Line blot;;ACTIVE;2.70;2.7 +97173-9;Yersinia outer protein M Ab;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Yersinia outer protein M Ab [Presence] in Serum by Line blot;YopM Ab Ser Ql Line blot;;ACTIVE;2.70;2.7 +97174-7;Yersinia outer protein H Ab;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Yersinia outer protein H Ab [Presence] in Serum by Line blot;YopH Ab Ser Ql Line blot;;ACTIVE;2.70;2.7 +97175-4;Yersinia LcrV protein Ab;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Yersinia LcrV protein Ab [Presence] in Serum by Line blot;Yersinia LcrV Ab Ser Ql Line blot;;ACTIVE;2.70;2.7 +97176-2;Yersinia outer protein D Ab;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Yersinia outer protein D Ab [Presence] in Serum by Line blot;YopD Ab Ser Ql Line blot;;ACTIVE;2.70;2.7 +97177-0;Yersinia outer protein N Ab;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Yersinia outer protein N Ab [Presence] in Serum by Line blot;YopN Ab Ser Ql Line blot;;ACTIVE;2.70;2.7 +97178-8;Yersinia outer protein P Ab;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Yersinia outer protein P Ab [Presence] in Serum by Line blot;YopP Ab Ser Ql Line blot;;ACTIVE;2.70;2.7 +97179-6;Yersinia outer protein E Ab;PrThr;Pt;Ser;Ord;Line blot;MICRO;1;Yersinia outer protein E Ab [Presence] in Serum by Line blot;YopE Ab Ser Ql Line blot;;ACTIVE;2.70;2.7 +97180-4;Yersinia outer protein Ab band pattern;Imp;Pt;Ser;Nom;Line blot;MICRO;1;Yersinia outer protein Ab band pattern [Interpretation] in Serum by Line blot;Yop Ab Patrn Ser Line blot-Imp;;ACTIVE;2.70;2.7 +97181-2;Muscle relaxants;PrThr;Pt;Saliva;Ord;Confirm;DRUG/TOX;1;Muscle relaxants [Presence] in Saliva (oral fluid) by Confirmatory method;Muscle relaxants Sal Ql Cfm;;ACTIVE;2.70;2.7 +97182-0;Carnitine free & total & acylcarnitine panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Carnitine free and total and acylcarnitine panel - Serum or Plasma;Carnitine + acylcarnitine Pnl SerPl;;ACTIVE;2.70;2.7 +97183-8;Mephobarbital & PHENobarbital panel;-;Pt;Ser/Plas;Qn;;PANEL.DRUG/TOX;1;Mephobarbital and PHENobarbital panel - Serum or Plasma;Mephobarb + phenobarb Pnl SerPl;;ACTIVE;2.70;2.7 +97184-6;Ravulizumab;MCnc;Pt;Ser;Qn;;DRUG/TOX;1;Ravulizumab [Mass/volume] in Serum;Ravulizumab Ser-mCnc;;ACTIVE;2.70;2.7 +97185-3;West Nile virus RNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;West Nile virus RNA [Presence] in Urine by NAA with probe detection;WNV RNA Ur Ql NAA+probe;;ACTIVE;2.70;2.7 +97186-1;Bordetella parapertussis IS1001 DNA;PrThr;Pt;Respiratory.lower;Ord;Non-probe.amp.tar;MICRO;1;Bordetella parapertussis IS1001 DNA [Presence] in Lower respiratory specimen by NAA with non-probe detection;B para IS1001 DNA L resp Ql NAA+non-prb;;ACTIVE;2.70;2.7 +97187-9;Urea/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;Urea/Creatinine [Mass Ratio] in Urine;Urea/Creat Ur;;ACTIVE;2.70;2.7 +9718-8;Toxocara canis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxocara canis IgG Ab [Units/volume] in Serum by Immunoassay;T canis IgG Ser IA-aCnc;;ACTIVE;1.0i;2.68 +97188-7;Ryanodine receptor Ab;PrThr;Pt;Ser;Ord;IB;SERO;1;Ryanodine receptor Ab [Presence] in Serum by Immunoblot;RyR Ab Ser Ql IB;;ACTIVE;2.70;2.7 +97189-5;Alpha-2-Macroglobulin;MCnc;Pt;Urine;Qn;;CHEM;1;Alpha-2-Macroglobulin [Mass/volume] in Urine;A2 Macroglob Ur-mCnc;;ACTIVE;2.70;2.7 +97190-3;carBAMazepine^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine [Mass/volume] in Serum or Plasma --peak;carBAMazepine Peak SerPl-mCnc;;ACTIVE;2.70;2.7 +97191-1;carBAMazepine^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine [Moles/volume] in Serum or Plasma --peak;carBAMazepine Peak SerPl-sCnc;;ACTIVE;2.70;2.7 +97192-9;carBAMazepine^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;carBAMazepine [Moles/volume] in Serum or Plasma --trough;carBAMazepine Trough SerPl-sCnc;;ACTIVE;2.70;2.7 +97193-7;Phenytoin^peak;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin [Mass/volume] in Serum or Plasma --peak;Phenytoin Peak SerPl-mCnc;;ACTIVE;2.70;2.7 +97194-5;Phenytoin^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin [Moles/volume] in Serum or Plasma --peak;Phenytoin Peak SerPl-sCnc;;ACTIVE;2.70;2.7 +97195-2;Phenytoin^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenytoin [Moles/volume] in Serum or Plasma --trough;Phenytoin Trough SerPl-sCnc;;ACTIVE;2.70;2.7 +9719-6;Toxocara canis Ab.IgM;ACnc;Pt;Ser;Qn;IA;MICRO;1;Toxocara canis IgM Ab [Units/volume] in Serum by Immunoassay;T canis IgM Ser IA-aCnc;;ACTIVE;1.0i;2.68 +97196-0;quiNIDine^peak;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNIDine [Moles/volume] in Serum or Plasma --peak;quiNIDine Peak SerPl-sCnc;;ACTIVE;2.70;2.7 +97197-8;quiNIDine^trough;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNIDine [Moles/volume] in Serum or Plasma --trough;quiNIDine Trough SerPl-sCnc;;ACTIVE;2.70;2.7 +97198-6;Hemolysis interference index;ACnc;Pt;CSF;Qn;;SPEC;1;Hemolysis interference index of Cerebral spinal fluid;Hemolysis interf index CSF-aCnc;;ACTIVE;2.70;2.7 +97199-4;Icteric interference index;ACnc;Pt;CSF;Qn;;SPEC;1;Icteric interference index of Cerebral spinal fluid;Icteric interf index CSF-aCnc;;ACTIVE;2.70;2.7 +972-0;Weak D Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Weak D Ag [Presence] on Red Blood Cells;Weak D Ag RBC Ql;;ACTIVE;1.0;2.73 +97200-0;Lipemic interference index;ACnc;Pt;CSF;Qn;;SPEC;1;Lipemic interference index of Cerebral spinal fluid;Lipemic interf index CSF-aCnc;;ACTIVE;2.70;2.7 +97201-8;Hemolysis interference index;ACnc;Pt;Urine;Qn;;SPEC;1;Hemolysis interference index of Urine;Hemolysis interf index Ur-aCnc;;ACTIVE;2.70;2.7 +97202-6;Icteric interference index;ACnc;Pt;Urine;Qn;;SPEC;1;Icteric interference index of Urine;Icteric interf index Ur-aCnc;;ACTIVE;2.70;2.7 +97203-4;Lipemic interference index;ACnc;Pt;Urine;Qn;;SPEC;1;Lipemic interference index of Urine;Lipemic interf index Ur-aCnc;;ACTIVE;2.70;2.7 +9720-4;Reticulin Ab.IgA;Titr;Pt;Ser;Qn;;SERO;1;Reticulin IgA Ab [Titer] in Serum;Reticulin IgA Titr Ser;;ACTIVE;1.0i;2.73 +97204-2;Oxidants;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Oxidants [Mass/volume] in Urine;Oxidants Ur-mCnc;;ACTIVE;2.70;2.7 +97205-9;Tropheryma whipplei DNA;PrThr;Pt;Bld;Ord;Non-probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Blood by NAA with non-probe detection;T whipplei DNA Bld Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97206-7;Tropheryma whipplei DNA;PrThr;Pt;XXX;Ord;Non-probe.amp.tar;MICRO;1;Tropheryma whipplei DNA [Presence] in Specimen by NAA with non-probe detection;T whipplei DNA Spec Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97207-5;Purkinje cell cytoplasmic type Tr Ab;PrThr;Pt;Ser;Ord;;SERO;1;PCA-Tr Ab [Presence] in Serum;PCA-Tr Ab Ser Ql;;ACTIVE;2.70;2.7 +97208-3;Shipping date;Date;Pt;XXX;Qn;;ADMIN;2;Shipping date;Shipping date;;ACTIVE;2.70;2.7 +97209-1;Shipment tracking number;ID;Pt;XXX;Nom;;ADMIN;2;Shipment tracking number [Identifier];Shipment tracking #;;ACTIVE;2.70;2.7 +97210-9;6-Monoacetylmorphine.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;6-monoacetylmorphine free [Presence] in Cord tissue by Screen method;6MAM Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97211-7;6-Monoacetylmorphine.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;6-monoacetylmorphine free [Presence] in Cord tissue by Confirmatory method;6MAM Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +9721-2;Salivary gland Ab;Titr;Pt;Ser;Qn;;SERO;1;Salivary gland Ab [Titer] in Serum;Salivary Gland Ab Titr Ser;;ACTIVE;1.0i;2.7 +97212-5;7-Aminoclonazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Cord tissue by Screen method;7Aminoclonazepam TissCo Ql Scn;;ACTIVE;2.70;2.7 +97213-3;7-Aminoclonazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;7-Aminoclonazepam [Presence] in Cord tissue by Confirmatory method;7Aminoclonazepam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97214-1;Acetyl Fentanyl;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Acetyl fentanyl [Presence] in Cord tissue by Screen method;Acetyl fentanyl TissCo Ql Scn;;ACTIVE;2.70;2.7 +97215-8;Acetyl Fentanyl;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Acetyl fentanyl [Presence] in Cord tissue by Confirmatory method;Acetyl fentanyl TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97216-6;Alpha pyrrolidinovalerophenone;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Alpha pyrrolidinovalerophenone [Presence] in Cord tissue by Screen method;a-PVP TissCo Ql Scn;;ACTIVE;2.70;2.7 +97217-4;Alpha pyrrolidinovalerophenone;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Alpha pyrrolidinovalerophenone [Presence] in Cord tissue by Confirmatory method;a-PVP TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97218-2;Alprazolam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;ALPRAZolam [Presence] in Cord tissue by Screen method;Alpraz TissCo Ql Scn;;ACTIVE;2.70;2.7 +97219-0;Alprazolam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;ALPRAZolam [Presence] in Cord tissue by Confirmatory method;Alpraz TissCo Ql Cfm;;ACTIVE;2.70;2.7 +9722-0;Smith extractable nuclear Ab;Titr;Pt;Ser;Qn;;SERO;1;Smith extractable nuclear Ab [Titer] in Serum;ENA SM Ab Titr Ser;;ACTIVE;1.0i;2.73 +97220-8;Amphetamine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Amphetamine [Presence] in Cord tissue by Screen method;Amphet TissCo Ql Scn;;ACTIVE;2.70;2.7 +97221-6;Amphetamine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Amphetamine [Presence] in Cord tissue by Confirmatory method;Amphet TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97222-4;Benzoylecgonine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Benzoylecgonine [Presence] in Cord tissue by Screen method;BZE TissCo Ql Scn;;ACTIVE;2.70;2.7 +97223-2;Benzoylecgonine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Benzoylecgonine [Presence] in Cord tissue by Confirmatory method;BZE TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97224-0;Butalbital;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Butalbital [Presence] in Cord tissue by Screen method;Butalbital TissCo Ql Scn;;ACTIVE;2.70;2.7 +97225-7;Butalbital;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Butalbital [Presence] in Cord tissue by Confirmatory method;Butalbital TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97226-5;Carisoprodol;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Carisoprodol [Presence] in Cord tissue by Screen method;Carisoprodol TissCo Ql Scn;;ACTIVE;2.70;2.7 +97227-3;Carisoprodol;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Carisoprodol [Presence] in Cord tissue by Confirmatory method;Carisoprodol TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97228-1;Chlordiazepoxide;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;chlordiazePOXIDE [Presence] in Cord tissue by Screen method;Chlordiazep TissCo Ql Scn;;ACTIVE;2.70;2.7 +97229-9;Chlordiazepoxide;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;chlordiazePOXIDE [Presence] in Cord tissue by Confirmatory method;Chlordiazep TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97230-7;Clonazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;clonazePAM [Presence] in Cord tissue by Screen method;clonazePAM TissCo Ql Scn;;ACTIVE;2.70;2.7 +97231-5;Clonazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;clonazePAM [Presence] in Cord tissue by Confirmatory method;clonazePAM TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97232-3;Cocaethylene;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Cocaethylene [Presence] in Cord tissue by Screen method;Cocaethylene TissCo Ql Scn;;ACTIVE;2.70;2.7 +97233-1;Cocaethylene;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Cocaethylene [Presence] in Cord tissue by Confirmatory method;Cocaethylene TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97234-9;Cocaine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Cocaine [Presence] in Cord tissue by Screen method;Cocaine TissCo Ql Scn;;ACTIVE;2.70;2.7 +97235-6;Cocaine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Cocaine [Presence] in Cord tissue by Confirmatory method;Cocaine TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97236-4;Codeine.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Codeine Free [Presence] in Cord tissue by Screen method;Codeine Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97237-2;Codeine.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Codeine Free [Presence] in Cord tissue by Confirmatory method;Codeine Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +9723-8;Spermatozoa Ab.IgA;ACnc;Pt;Ser;Qn;;FERT;1;Spermatozoa IgA Ab [Units/volume] in Serum;Sperm IgA Ser-aCnc;;ACTIVE;1.0i;2.73 +97238-0;N-desalkylflurazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Cord tissue by Screen method;Desalkylfluraz TissCo Ql Scn;;ACTIVE;2.70;2.7 +97239-8;N-desalkylflurazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;N-desalkylflurazepam [Presence] in Cord tissue by Confirmatory method;Desalkylfluraz TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97240-6;Diazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;diazePAM [Presence] in Cord tissue by Screen method;diazePAM TissCo Ql Scn;;ACTIVE;2.70;2.7 +97241-4;Diazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;diazePAM [Presence] in Cord tissue by Confirmatory method;diazePAM TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97242-2;Dihydrocodeine.free+Hydrocodol.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Dihydrocodeine Free+Hydrocodol Free [Presence] in Cord tissue by Screen method;DHC+Hydrocodol Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97243-0;Dihydrocodeine.free+Hydrocodol.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Dihydrocodeine Free+Hydrocodol Free [Presence] in Cord tissue by Confirmatory method;DHC+Hydrocodol Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97244-8;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Cord tissue by Screen method;EDDP TissCo Ql Scn;;ACTIVE;2.70;2.7 +97245-5;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) [Presence] in Cord tissue by Confirmatory method;EDDP TissCo Ql Cfm;;ACTIVE;2.70;2.7 +9724-6;Spermatozoa Ab.IgG;ACnc;Pt;Ser;Qn;;FERT;1;Spermatozoa IgG Ab [Units/volume] in Serum;Sperm IgG Ser-aCnc;;ACTIVE;1.0i;2.73 +97246-3;Ethylone;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Ethylone [Presence] in Cord tissue by Screen method;bk-MDEA TissCo Ql Scn;;ACTIVE;2.70;2.7 +97247-1;Ethylone;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Ethylone [Presence] in Cord tissue by Confirmatory method;bk-MDEA TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97248-9;Fentanyl;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;fentaNYL [Presence] in Cord tissue by Screen method;fentaNYL TissCo Ql Scn;;ACTIVE;2.70;2.7 +97249-7;Fentanyl;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;fentaNYL [Presence] in Cord tissue by Confirmatory method;fentaNYL TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97250-5;Flunitrazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Flunitrazepam [Presence] in Cord tissue by Screen method;Flunitrazepam TissCo Ql Scn;;ACTIVE;2.70;2.7 +97251-3;Flunitrazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Flunitrazepam [Presence] in Cord tissue by Confirmatory method;Flunitrazepam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97252-1;Flurazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Flurazepam [Presence] in Cord tissue by Screen method;Flurazepam TissCo Ql Scn;;ACTIVE;2.70;2.7 +9725-3;Spermatozoa Ab.IgM;ACnc;Pt;Ser;Qn;;FERT;1;Spermatozoa IgM Ab [Units/volume] in Serum;Sperm IgM Ser-aCnc;;ACTIVE;1.0i;2.73 +97253-9;Flurazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Flurazepam [Presence] in Cord tissue by Confirmatory method;Flurazepam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97254-7;Hydrocodone.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;HYDROcodone Free [Presence] in Cord tissue by Screen method;HYDROcodone Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97255-4;Hydrocodone.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;HYDROcodone Free [Presence] in Cord tissue by Confirmatory method;HYDROcodone Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97256-2;Hydromorphone.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;HYDROmorphone Free [Presence] in Cord tissue by Screen method;HYDROmorphone Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97257-0;Hydromorphone.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;HYDROmorphone Free [Presence] in Cord tissue by Confirmatory method;HYDROmorphone Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97258-8;Hydroxytriazolam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Hydroxytriazolam [Presence] in Cord tissue by Screen method;OH-Triazolam TissCo Ql Scn;;ACTIVE;2.70;2.7 +97259-6;Hydroxytriazolam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Hydroxytriazolam [Presence] in Cord tissue by Confirmatory method;OH-Triazolam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97260-4;Lorazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;LORazepam [Presence] in Cord tissue by Screen method;LORazepam TissCo Ql Scn;;ACTIVE;2.70;2.7 +9726-1;Mescaline;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Mescaline [Mass/volume] in Urine;Mescaline Ur-mCnc;;ACTIVE;1.0i;2.73 +97261-2;Lorazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;LORazepam [Presence] in Cord tissue by Confirmatory method;LORazepam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97262-0;Methylenedioxyamphetamine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Cord tissue by Screen method;MDA TissCo Ql Scn;;ACTIVE;2.70;2.7 +97263-8;Methylenedioxyamphetamine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Methylenedioxyamphetamine [Presence] in Cord tissue by Confirmatory method;MDA TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97264-6;Methylenedioxyethylamphetamine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Cord tissue by Screen method;MDEA TissCo Ql Scn;;ACTIVE;2.70;2.7 +97265-3;Methylenedioxyethylamphetamine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Methylenedioxyethylamphetamine [Presence] in Cord tissue by Confirmatory method;MDEA TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97266-1;Methylenedioxymethamphetamine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Cord tissue by Screen method;MDMA TissCo Ql Scn;;ACTIVE;2.70;2.7 +97267-9;Methylenedioxymethamphetamine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Methylenedioxymethamphetamine [Presence] in Cord tissue by Confirmatory method;MDMA TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97268-7;Meperidine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Meperidine [Presence] in Cord tissue by Screen method;Meperidine TissCo Ql Scn;;ACTIVE;2.70;2.7 +97269-5;Meperidine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Meperidine [Presence] in Cord tissue by Confirmatory method;Meperidine TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97270-3;Meprobamate;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Meprobamate [Presence] in Cord tissue by Screen method;Meprobamate TissCo Ql Scn;;ACTIVE;2.70;2.7 +97271-1;Meprobamate;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Meprobamate [Presence] in Cord tissue by Confirmatory method;Meprobamate TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97272-9;Methadone;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Methadone [Presence] in Cord tissue by Screen method;Methadone TissCo Ql Scn;;ACTIVE;2.70;2.7 +97273-7;Methadone;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Methadone [Presence] in Cord tissue by Confirmatory method;Methadone TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97274-5;Methamphetamine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Methamphetamine [Presence] in Cord tissue by Screen method;Methamphet TissCo Ql Scn;;ACTIVE;2.70;2.7 +97275-2;Methamphetamine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Methamphetamine [Presence] in Cord tissue by Confirmatory method;Methamphet TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97276-0;Methylone;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Methylone [Presence] in Cord tissue by Screen method;Methylone TissCo Ql Scn;;ACTIVE;2.70;2.7 +97277-8;Methylone;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Methylone [Presence] in Cord tissue by Confirmatory method;Methylone TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97278-6;Midazolam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Midazolam [Presence] in Cord tissue by Screen method;Midazolam TissCo Ql Scn;;ACTIVE;2.70;2.7 +9727-9;Eosinophils/100 leukocytes;NFr;Pt;Nose;Qn;Manual count;HEM/BC;1;Eosinophils/100 leukocytes in Nose by Manual count;Eosinophil/leuk NFr Nose Manual;;ACTIVE;1.0i;2.73 +97279-4;Midazolam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Midazolam [Presence] in Cord tissue by Confirmatory method;Midazolam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97280-2;Morphine.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Morphine Free [Presence] in Cord tissue by Screen method;Morphine Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97281-0;Morphine.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Morphine Free [Presence] in Cord tissue by Confirmatory method;Morphine Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97282-8;Nordiazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Nordiazepam [Presence] in Cord tissue by Screen method;Nordiazepam TissCo Ql Scn;;ACTIVE;2.70;2.7 +97283-6;Nordiazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Nordiazepam [Presence] in Cord tissue by Confirmatory method;Nordiazepam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97284-4;Norfentanyl;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Norfentanyl [Presence] in Cord tissue by Screen method;Norfentanyl TissCo Ql Scn;;ACTIVE;2.70;2.7 +97285-1;Norfentanyl;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Norfentanyl [Presence] in Cord tissue by Confirmatory method;Norfentanyl TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97286-9;Norhydrocodone;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Norhydrocodone [Presence] in Cord tissue by Screen method;Norhydrocodone TissCo Ql Scn;;ACTIVE;2.70;2.7 +9728-7;Cells.CD3-CD16+CD56+;NCnc;Pt;Bld;Qn;;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood;CD3-CD16+CD56+ Cells # Bld;;ACTIVE;1.0i;2.73 +97287-7;Norhydrocodone;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Norhydrocodone [Presence] in Cord tissue by Confirmatory method;Norhydrocodone TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97288-5;Normeperidine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Normeperidine [Presence] in Cord tissue by Screen method;Normeperidine TissCo Ql Scn;;ACTIVE;2.70;2.7 +97289-3;Normeperidine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Normeperidine [Presence] in Cord tissue by Confirmatory method;Normeperidine TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97290-1;Noroxycodone;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Noroxycodone [Presence] in Cord tissue by Screen method;Noroxycodone TissCo Ql Scn;;ACTIVE;2.70;2.7 +97291-9;Noroxycodone;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Noroxycodone [Presence] in Cord tissue by Confirmatory method;Noroxycodone TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97292-7;O-Nortramadol;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;O-nortramadol [Presence] in Cord tissue by Screen method;O-nortramadol TissCo Ql Scn;;ACTIVE;2.70;2.72 +97293-5;O-Nortramadol;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;O-nortramadol [Presence] in Cord tissue by Confirmatory method;O-nortramadol TissCo Ql Cfm;;ACTIVE;2.70;2.72 +97294-3;Oxazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Oxazepam [Presence] in Cord tissue by Confirmatory method;Oxazepam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +9729-5;Canary serum proteins Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Canary serum proteins IgE Ab [Units/volume] in Serum;Canary Serum Prot IgE Qn;;ACTIVE;1.0i;2.42 +97295-0;Oxycodone.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;oxyCODONE Free [Presence] in Cord tissue by Screen method;oxyCODONE Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97296-8;Oxymorphone.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;oxyMORphone Free [Presence] in Cord tissue by Screen method;oxyMORphone Free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97297-6;Oxymorphone.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;oxyMORphone Free [Presence] in Cord tissue by Confirmatory method;oxyMORphone Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97298-4;Phencyclidine;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Phencyclidine [Presence] in Cord tissue by Screen method;PCP TissCo Ql Scn;;ACTIVE;2.70;2.7 +97299-2;Phencyclidine;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Phencyclidine [Presence] in Cord tissue by Confirmatory method;PCP TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97300-8;Phenobarbital;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;PHENobarbital [Presence] in Cord tissue by Screen method;Phenobarb TissCo Ql Scn;;ACTIVE;2.70;2.7 +97301-6;Phenobarbital;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;PHENobarbital [Presence] in Cord tissue by Confirmatory method;Phenobarb TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97302-4;Tapentadol;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Tapentadol [Presence] in Cord tissue by Screen method;Tapentadol TissCo Ql Scn;;ACTIVE;2.70;2.7 +9730-3;Pentacarboxylporphyrins;MRat;24H;Urine;Qn;;CHEM;1;Pentacarboxylporphyrins [Mass/time] in 24 hour Urine;Penta-CP 24h Ur-mRate;;ACTIVE;1.0i;2.73 +97303-2;Tapentadol;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Tapentadol [Presence] in Cord tissue by Confirmatory method;Tapentadol TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97304-0;Temazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Temazepam [Presence] in Cord tissue by Screen method;Temazepam TissCo Ql Scn;;ACTIVE;2.70;2.7 +97305-7;Temazepam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Temazepam [Presence] in Cord tissue by Confirmatory method;Temazepam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97306-5;Tramadol;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;traMADol [Presence] in Cord tissue by Screen method;traMADol TissCo Ql Scn;;ACTIVE;2.70;2.7 +97307-3;Tramadol;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;traMADol [Presence] in Cord tissue by Confirmatory method;traMADol TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97308-1;Triazolam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Triazolam [Presence] in Cord tissue by Screen method;Triazolam TissCo Ql Scn;;ACTIVE;2.70;2.7 +97309-9;Triazolam;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Triazolam [Presence] in Cord tissue by Confirmatory method;Triazolam TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97310-7;Zolpidem;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Zolpidem [Presence] in Cord tissue by Screen method;Zolpidem TissCo Ql Scn;;ACTIVE;2.70;2.7 +9731-1;Phosphoethanolamine;MRat;24H;Urine;Qn;;CHEM;1;Phosphoethanolamine [Mass/time] in 24 hour Urine;PETN 24h Ur-mRate;;ACTIVE;1.0i;2.73 +97311-5;Zolpidem;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Zolpidem [Presence] in Cord tissue by Confirmatory method;Zolpidem TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97312-3;Campylobacter coli+jejuni+upsaliensis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Campylobacter coli+jejuni+upsaliensis DNA [Presence] in Stool by NAA with probe detection;C coli+jej+upsa DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97313-1;Salmonella sp DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Salmonella sp DNA [Presence] in Stool by NAA with probe detection;Salmonella DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97314-9;Vibrio cholerae DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Vibrio cholerae DNA [Presence] in Stool by NAA with probe detection;V cholerae DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97315-6;Vibrio parahaemolyticus DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Vibrio parahaemolyticus DNA [Presence] in Stool by NAA with probe detection;V parahaem DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97316-4;Vibrio vulnificus DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Vibrio vulnificus DNA [Presence] in Stool by NAA with probe detection;V. vulnificus DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97317-2;Escherichia coli enteroaggregative DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enteroaggregative DNA [Presence] in Stool by NAA with probe detection;EAEC DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97318-0;Escherichia coli enteropathogenic DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enteropathogenic DNA [Presence] in Stool by NAA with probe detection;EPEC DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97319-8;Escherichia coli enterotoxigenic DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli enterotoxigenic DNA [Presence] in Stool by NAA with probe detection;ETEC DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97320-6;Escherichia coli O157 DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Escherichia coli O157 DNA [Presence] in Stool by NAA with probe detection;E coli O157 DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97321-4;Cyclospora cayetanensis DNA;PrThr;Pt;Stool;Ord;Probe.amp.tar;MICRO;1;Cyclospora cayetanensis DNA [Presence] in Stool by NAA with probe detection;C cayetanensis DNA Stl Ql NAA+probe;;ACTIVE;2.70;2.7 +97322-2;Oxazepam;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Oxazepam [Presence] in Cord tissue by Screen method;Oxazepam TissCo Ql Scn;;ACTIVE;2.70;2.7 +97323-0;Oxycodone.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;oxyCODONE Free [Presence] in Cord tissue by Confirmatory method;oxyCODONE Free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97324-8;Carbapenem resistant bacteria identification & resistance panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Carbapenem resistant bacteria identification and resistance panel by Molecular genetics method;CPR bact ID + resistance Pnl Islt/Spm;;ACTIVE;2.70;2.72 +97325-5;Staphylococcus aureus VNTR pattern;Type;Pt;Isolate/Specimen;Nom;Molgen;MICRO;1;Staphylococcus aureus VNTR pattern [Type] in Isolate or Specimen by Molecular genetics method;SA VNTR patt Islt/Spm;;ACTIVE;2.70;2.7 +97326-3;Staphylococcus aureus identification & resistance panel;-;Pt;Isolate/Specimen;-;Molgen;PANEL.ABXBACT;1;Staphylococcus aureus identification and resistance panel by Molecular genetics method;SA ID + resistance Pnl Islt/Spm;;ACTIVE;2.70;2.7 +97327-1;Core Outcome Measures Index for the Neck;-;Pt;^Patient;-;COMI;PANEL.SURVEY.GNHLTH;4;Core Outcome Measures Index for the Neck [COMI];;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +97328-9;Interval between surgery and examination;Find;Pt;^Patient;Ord;;H&P.HX;2;Interval between surgery and examination;Interval between surgery and examination;;ACTIVE;2.70;2.7 +9732-9;Phosphoserine;MRat;24H;Urine;Qn;;CHEM;1;Phosphoserine [Mass/time] in 24 hour Urine;Phosphoserine 24h Ur-mRate;;ACTIVE;1.0i;2.44 +97329-7;Which of the following problems related to your neck condition troubles you the most;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Which of the following problems related to your neck condition troubles you the most;;;ACTIVE;2.70;2.7 +97330-5;How much did health condition interfere with normal work in past W;Find;1W;^Patient;Ord;;H&P.HX;2;How much did health condition interfere with normal work in past week in the past week;Hlth cond interfere with normal work past W;;ACTIVE;2.70;2.7 +97331-3;If you had to spend the rest of your life with the symptoms you have right now how would you feel about it;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;If you had to spend the rest of your life with the symptoms you have right now how would you feel about it;;;ACTIVE;2.70;2.7 +97332-1;Quality of life in past W;Find;1W;^Patient;Ord;;H&P.HX;2;Quality of life in past week;Quality of life in past W;;ACTIVE;2.70;2.7 +97333-9;Number of D cut down on usual activities because of health condition in past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Number of days cut down on usual activities because of health condition in past 4 weeks;#D cut down activities hlt cond 4W;;ACTIVE;2.70;2.7 +97334-7;Number of D did not go to work because of health condition in past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Number of days did not go to work because of health condition in past 4 weeks;#D didn't go to work due to health cond;;ACTIVE;2.70;2.7 +97335-4;Type of postoperative complication;Prid;Pt;^Patient;Nom;;H&P.HX;2;Type of postoperative complication;Type of postoperative complication;;ACTIVE;2.70;2.7 +97336-2;Postoperative complication distress level;Find;Pt;^Patient;Ord;;H&P.HX;2;Postoperative complication distress level;Postop complication distress level;;ACTIVE;2.70;2.7 +9733-7;Porphyrins;MRat;24H;Stool;Qn;;CHEM;1;Porphyrins [Mass/time] in 24 hour Stool;Porphyrins 24h Stl-mRate;;ACTIVE;1.0i;2.42 +97337-0;Subsequent operation for same health condition;Find;Pt;^Patient;Ord;;H&P.HX;2;Subsequent operation for same health condition;Subsequent operation for same condition;;ACTIVE;2.70;2.7 +97338-8;Treatment effectiveness;Find;Pt;^Patient;Ord;;H&P.HX;2;Treatment effectiveness;Treatment effectiveness;;ACTIVE;2.70;2.7 +97339-6;Pain severity & Body site panel;-;Pt;^Patient;-;;PANEL.H&P;2;Pain severity and Body site panel;Pain severity + Body site Pnl;;ACTIVE;2.70;2.7 +97340-4;View AP;Find;Pt;Chest>Sternoclavicular joint.left;Doc;XR;RAD;2;XR Sternoclavicular joint - left AP;XR SC joint-L AP;;ACTIVE;2.70;2.7 +97341-2;View AP;Find;Pt;Upper extremity.right>Finger.second;Doc;XR;RAD;2;XR Finger second - right AP;XR Finger.2nd-R AP;;ACTIVE;2.70;2.7 +97342-0;View PA;Find;Pt;Upper extremity.right>Finger.second;Doc;XR;RAD;2;XR Finger second - right PA;XR Finger.2nd-R PA;;ACTIVE;2.70;2.7 +97343-8;View PA;Find;Pt;Chest>Sternoclavicular joint.left;Doc;XR;RAD;2;XR Sternoclavicular joint - left PA;XR SC joint-L PA;;ACTIVE;2.70;2.7 +97344-6;View PA;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left PA;XR Radius+Ulna-L PA;;ACTIVE;2.70;2.7 +9734-5;Alpha 1 globulin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Alpha 1 globulin [Mass/volume] in Urine by Electrophoresis;Alpha1 Glob Ur Elph-mCnc;;ACTIVE;1.0i;2.73 +97345-3;View lateral;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left Lateral;XR Radius+Ulna-L Lat;;ACTIVE;2.70;2.7 +97346-1;View AP;Find;Pt;Upper extremity.left>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - left AP;XR Radius+Ulna-L AP;;ACTIVE;2.70;2.7 +97347-9;View AP;Find;Pt;Chest>Clavicle.left;Doc;XR;RAD;2;XR Clavicle - left AP;XR Clavicle-L AP;;ACTIVE;2.70;2.7 +97348-7;View oblique;Find;Pt;Chest>Clavicle.left;Doc;XR;RAD;2;XR Clavicle - left Oblique;XR Clavicle-L Obl;;ACTIVE;2.70;2.7 +97349-5;View axial;Find;Pt;Chest>Clavicle.left;Doc;XR;RAD;2;XR Clavicle - left Axial;XR Clavicle-L Axial;;ACTIVE;2.70;2.7 +97350-3;View lateral;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right Lateral;XR Humerus-R Lat;;ACTIVE;2.70;2.7 +97351-1;View AP;Find;Pt;Upper extremity.right>Humerus;Doc;XR;RAD;2;XR Humerus - right AP;XR Humerus-R AP;;ACTIVE;2.70;2.7 +9735-2;Uroporphyrin/Porphyrins.total;MFr;24H;Stool;Qn;;CHEM;1;Uroporphyrin/Porphyrins.total in 24 hour Stool;Uropor 24h MFr Stl;;ACTIVE;1.0i;2.7 +97352-9;View lateral;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Lateral;XR Elbow-R Lat;;ACTIVE;2.70;2.7 +97353-7;View AP;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right AP;XR Elbow-R AP;;ACTIVE;2.70;2.7 +97354-5;View AP external rotation;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP external rotation;XR Should-R AP ER;;ACTIVE;2.70;2.7 +97355-2;View AP internal rotation;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right AP internal rotation;XR Should-R AP IR;;ACTIVE;2.70;2.7 +97356-0;View oblique;Find;Pt;Chest>Sternoclavicular joint.right;Doc;XR;RAD;2;XR Sternoclavicular joint - right Oblique;XR SC joint-R Obl;;ACTIVE;2.70;2.7 +97357-8;View AP;Find;Pt;Chest>Sternoclavicular joint.right;Doc;XR;RAD;2;XR Sternoclavicular joint - right AP;XR SC joint-R AP;;ACTIVE;2.70;2.7 +97358-6;View PA;Find;Pt;Chest>Sternoclavicular joint.right;Doc;XR;RAD;2;XR Sternoclavicular joint - right PA;XR SC joint-R PA;;ACTIVE;2.70;2.7 +97359-4;View PA;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right PA;XR Radius+Ulna-R PA;;ACTIVE;2.70;2.7 +9736-0;Allopurinol;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Allopurinol [Mass/volume] in Serum or Plasma;Allopurinol SerPl-mCnc;;ACTIVE;1.0i;2.73 +97360-2;View lateral;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right Lateral;XR Radius+Ulna-R Lat;;ACTIVE;2.70;2.7 +97361-0;View AP;Find;Pt;Upper extremity.right>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - right AP;XR Radius+Ulna-R AP;;ACTIVE;2.70;2.7 +97362-8;View AP;Find;Pt;Chest>Clavicle.right;Doc;XR;RAD;2;XR Clavicle - right AP;XR Clavicle-R AP;;ACTIVE;2.70;2.7 +97363-6;View oblique;Find;Pt;Chest>Clavicle.right;Doc;XR;RAD;2;XR Clavicle - right Oblique;XR Clavicle-R Obl;;ACTIVE;2.70;2.7 +97364-4;View axial;Find;Pt;Chest>Clavicle.right;Doc;XR;RAD;2;XR Clavicle - right Axial;XR Clavicle-R Axial;;ACTIVE;2.70;2.7 +97365-1;View oblique;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left Oblique;XR Ribs-L Obl;;ACTIVE;2.70;2.7 +97366-9;View PA;Find;Pt;Chest>Ribs.left;Doc;XR;RAD;2;XR Ribs - left PA;XR Ribs-L PA;;ACTIVE;2.70;2.7 +97367-7;View AP external rotation;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP external rotation;XR Should AP ER;;ACTIVE;2.70;2.7 +97368-5;View AP internal rotation;Find;Pt;Upper extremity>Shoulder;Doc;XR;RAD;2;XR Shoulder AP internal rotation;XR Should AP IR;;ACTIVE;2.70;2.7 +97369-3;View oblique;Find;Pt;Chest>Sternoclavicular joint.bilateral;Doc;XR;RAD;2;XR Sternoclavicular joint - bilateral Oblique;XR SC joint-Bl Obl;;ACTIVE;2.70;2.7 +97370-1;View PA;Find;Pt;Chest>Sternoclavicular joint.bilateral;Doc;XR;RAD;2;XR Sternoclavicular joint - bilateral PA;XR SC joint-Bl PA;;ACTIVE;2.70;2.7 +97371-9;View AP;Find;Pt;Chest>Sternoclavicular joint.bilateral;Doc;XR;RAD;2;XR Sternoclavicular joint - bilateral AP;XR SC joint-Bl AP;;ACTIVE;2.70;2.7 +97372-7;View AP;Find;Pt;Upper extremity.bilateral>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - bilateral AP;XR Radius+Ulna-Bl AP;;ACTIVE;2.70;2.7 +97373-5;View PA;Find;Pt;Upper extremity.bilateral>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - bilateral PA;XR Radius+Ulna-Bl PA;;ACTIVE;2.70;2.7 +97374-3;View lateral;Find;Pt;Upper extremity.bilateral>Radius+Ulna;Doc;XR;RAD;2;XR Radius and Ulna - bilateral Lateral;XR Radius+Ulna-Bl Lat;;ACTIVE;2.70;2.7 +97375-0;Views AP + oblique;Find;Pt;Chest>Clavicle.bilateral;Doc;XR;RAD;2;XR Clavicle - bilateral AP and Oblique;XR Clavicle-Bl AP+Obl;;ACTIVE;2.70;2.7 +97376-8;View AP;Find;Pt;Chest>Clavicle.bilateral;Doc;XR;RAD;2;XR Clavicle - bilateral AP;XR Clavicle-Bl AP;;ACTIVE;2.70;2.7 +97377-6;View oblique;Find;Pt;Chest>Clavicle.bilateral;Doc;XR;RAD;2;XR Clavicle - bilateral Oblique;XR Clavicle-Bl Obl;;ACTIVE;2.70;2.7 +9737-8;Propoxyphene;MCnc;Pt;Gast fld;Qn;;DRUG/TOX;1;Propoxyphene [Mass/volume] in Gastric fluid;Propoxyph Gast-mCnc;;ACTIVE;1.0i;2.34 +97378-4;View lateral;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left Lateral;XR Humerus-L Lat;;ACTIVE;2.70;2.7 +97379-2;View AP;Find;Pt;Upper extremity.left>Humerus;Doc;XR;RAD;2;XR Humerus - left AP;XR Humerus-L AP;;ACTIVE;2.70;2.7 +973-8;D Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;D Ab [Presence] in Serum or Plasma from Blood product unit;D Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +97380-0;View AP;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left AP;XR Elbow-L AP;;ACTIVE;2.70;2.7 +97381-8;View AP external rotation;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP external rotation;XR Should-L AP ER;;ACTIVE;2.70;2.7 +97382-6;View AP internal rotation;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left AP internal rotation;XR Should-L AP IR;;ACTIVE;2.70;2.7 +97383-4;View oblique;Find;Pt;Chest>Sternoclavicular joint.left;Doc;XR;RAD;2;XR Sternoclavicular joint - left Oblique;XR SC joint-L Obl;;ACTIVE;2.70;2.7 +97384-2;View lateral;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left Lateral;XR Tib+Fib-L Lat;;ACTIVE;2.70;2.7 +97385-9;View AP;Find;Pt;Lower extremity.left>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - left AP;XR Tib+Fib-L AP;;ACTIVE;2.70;2.7 +9738-6;Gabapentin;MCnc;Pt;Ser/Plas/Bld;Qn;;DRUG/TOX;1;Gabapentin [Mass/volume] in Serum, Plasma or Blood;Gabapentin SerPlBld-mCnc;;ACTIVE;1.0i;2.73 +97386-7;View lateral;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right Lateral;XR Tib+Fib-R Lat;;ACTIVE;2.70;2.7 +97387-5;View AP;Find;Pt;Lower extremity.right>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - right AP;XR Tib+Fib-R AP;;ACTIVE;2.70;2.7 +97388-3;Views lateral^W manual stress;Find;Pt;Upper extremity.bilateral>Elbow;Doc;XR;RAD;2;XR Elbow - bilateral Lateral Views W manual stress;XR Elbow-Bl Views Lat W man stress;;ACTIVE;2.70;2.71 +97389-1;Views lateral^W manual stress;Find;Pt;Upper extremity.left>Elbow;Doc;XR;RAD;2;XR Elbow - left Lateral Views W manual stress;XR Elbow-L Views Lat W man stress;;ACTIVE;2.70;2.71 +97390-9;Views lateral^W manual stress;Find;Pt;Upper extremity.right>Elbow;Doc;XR;RAD;2;XR Elbow - right Lateral Views W manual stress;XR Elbow-R Views Lat W man stress;;ACTIVE;2.70;2.71 +97391-7;Multisection^WO contrast;Find;Pt;Abdomen+Pelvis;Doc;MR;RAD;2;MR Abdomen and Pelvis WO contrast;MR Abd+Pelvis WO contr;;ACTIVE;2.70;2.7 +97392-5;Multisection^WO & W contrast IV;Find;Pt;Abdomen+Pelvis;Doc;MR;RAD;2;MR Abdomen and Pelvis WO and W contrast IV;MR Abd+Pelvis WO+W contr IV;;ACTIVE;2.70;2.7 +97393-3;Multisection^W contrast IV;Find;Pt;Abdomen+Pelvis;Doc;MR;RAD;2;MR Abdomen and Pelvis W contrast IV;MR Abd+Pelvis W contr IV;;ACTIVE;2.70;2.7 +9739-4;Morphine;ACnc;Pt;Gast fld;Ord;;DRUG/TOX;1;Deprecated Morphine [Presence] in Gastric fluid;Deprecated Morphine Gast Ql;;DEPRECATED;1.0i;2.36 +97394-1;Guidance for injection;Find;Pt;Upper extremity.left>Elbow;Doc;US;RAD;2;US Guidance for injection of Elbow - left;US Guided Elbow-L Inj;;ACTIVE;2.70;2.7 +97395-8;Guidance for injection;Find;Pt;Upper extremity.right>Elbow;Doc;US;RAD;2;US Guidance for injection of Elbow - right;US Guided Elbow-R Inj;;ACTIVE;2.70;2.7 +97396-6;Guidance for injection;Find;Pt;Upper extremity.bilateral>Elbow;Doc;US;RAD;2;US Guidance for injection of Elbow - bilateral;US Guided Elbow-Bl Inj;;ACTIVE;2.70;2.7 +97397-4;Views AP + lateral;Find;Pt;Upper extremity.left>Finger.third;Doc;XR;RAD;2;XR Finger third - left AP and Lateral;XR Finger.3rd-L AP+Lat;;ACTIVE;2.70;2.7 +97398-2;Views AP + lateral;Find;Pt;Upper extremity.left>Finger.second;Doc;XR;RAD;2;XR Finger second - left AP and Lateral;XR Finger.2nd-L AP+Lat;;ACTIVE;2.70;2.7 +97399-0;Views AP + lateral;Find;Pt;Upper extremity.left>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - left AP and Lateral;XR Finger.4th-L AP+Lat;;ACTIVE;2.70;2.7 +97400-6;Views AP + lateral;Find;Pt;Upper extremity.left>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - left AP and Lateral;XR Finger.5th-L AP+Lat;;ACTIVE;2.70;2.7 +97401-4;View PA;Find;Pt;Upper extremity.left>Finger.third;Doc;XR;RAD;2;XR Finger third - left PA;XR Finger.3rd-L PA;;ACTIVE;2.70;2.7 +9740-2;Neopterin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Neopterin [Moles/volume] in Serum or Plasma;Neopterin SerPl-sCnc;;ACTIVE;1.0i;2.73 +97402-2;Views AP + lateral;Find;Pt;Upper extremity.right>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - right AP and Lateral;XR Finger.4th-R AP+Lat;;ACTIVE;2.70;2.7 +97403-0;Views AP + lateral;Find;Pt;Upper extremity.right>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - right AP and Lateral;XR Finger.5th-R AP+Lat;;ACTIVE;2.70;2.7 +97404-8;Views AP + lateral;Find;Pt;Upper extremity.right>Finger.second;Doc;XR;RAD;2;XR Finger second - right AP and Lateral;XR Finger.2nd-R AP+Lat;;ACTIVE;2.70;2.7 +97405-5;Views AP + lateral;Find;Pt;Upper extremity.right>Finger.third;Doc;XR;RAD;2;XR Finger third - right AP and Lateral;XR Finger.3rd-R AP+Lat;;ACTIVE;2.70;2.7 +97406-3;View PA;Find;Pt;Upper extremity.right>Finger.third;Doc;XR;RAD;2;XR Finger third - right PA;XR Finger.3rd-R PA;;ACTIVE;2.70;2.7 +97407-1;View Bernageau;Find;Pt;Upper extremity.right>Shoulder;Doc;XR;RAD;2;XR Shoulder - right Bernageau;XR Should-R Bernageau;;ACTIVE;2.70;2.7 +97408-9;View Bernageau;Find;Pt;Upper extremity.left>Shoulder;Doc;XR;RAD;2;XR Shoulder - left Bernageau;XR Should-L Bernageau;;ACTIVE;2.70;2.7 +97409-7;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - left AP and Lateral and oblique;XR Toe 5th-L AP+Lat+Obl;;ACTIVE;2.70;2.7 +9741-0;Toxoplasma gondii Ab.IgG;ACnc;Pt;CSF;Qn;;MICRO;1;Toxoplasma gondii IgG Ab [Units/volume] in Cerebral spinal fluid;T gondii IgG CSF-aCnc;;ACTIVE;1.0i;2.73 +97410-5;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - left AP and Lateral and oblique;XR Toe 4th-L AP+Lat+Obl;;ACTIVE;2.70;2.7 +97411-3;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Toe.third;Doc;XR;RAD;2;XR Toe third - left AP and Lateral and oblique;XR Toe 3rd-L AP+Lat+Obl;;ACTIVE;2.70;2.7 +97412-1;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Toe.second;Doc;XR;RAD;2;XR Toe second - left AP and Lateral and oblique;XR Toe 2nd-L AP+Lat+Obl;;ACTIVE;2.70;2.7 +97413-9;Views AP + lateral + oblique;Find;Pt;Lower extremity.left>Great toe;Doc;XR;RAD;2;XR Great toe - left AP and Lateral and oblique;XR Great toe-L AP+Lat+Obl;;ACTIVE;2.70;2.7 +97414-7;Views AP + lateral;Find;Pt;Lower extremity.left>Toe.third;Doc;XR;RAD;2;XR Toe third - left AP and Lateral;XR Toe 3rd-L AP+Lat;;ACTIVE;2.70;2.7 +97415-4;Views AP + lateral;Find;Pt;Lower extremity.left>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - left AP and Lateral;XR Toe 4th-L AP+Lat;;ACTIVE;2.70;2.7 +97416-2;Views AP + lateral;Find;Pt;Lower extremity.left>Toe.second;Doc;XR;RAD;2;XR Toe second - left AP and Lateral;XR Toe 2nd-L AP+Lat;;ACTIVE;2.70;2.7 +97417-0;Views AP + lateral;Find;Pt;Lower extremity.left>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - left AP and Lateral;XR Toe 5th-L AP+Lat;;ACTIVE;2.70;2.7 +97418-8;Views AP + lateral;Find;Pt;Lower extremity.left>Great toe;Doc;XR;RAD;2;XR Great toe - left AP and Lateral;XR Great toe-L AP+Lat;;ACTIVE;2.70;2.7 +97419-6;Views AP + lateral + oblique;Find;Pt;Lower extremity.right>Toe.third;Doc;XR;RAD;2;XR Toe third - right AP and Lateral and oblique;XR Toe 3rd-R AP+Lat+Obl;;ACTIVE;2.70;2.7 +97420-4;Views AP + lateral + oblique;Find;Pt;Lower extremity.right>Toe.second;Doc;XR;RAD;2;XR Toe second - right AP and Lateral and oblique;XR Toe 2nd-R AP+Lat+Obl;;ACTIVE;2.70;2.7 +97421-2;View PA;Find;Pt;Upper extremity.left>Finger.second;Doc;XR;RAD;2;XR Finger second - left PA;XR Finger.2nd-L PA;;ACTIVE;2.70;2.7 +97422-0;View AP;Find;Pt;Upper extremity.left>Finger.second;Doc;XR;RAD;2;XR Finger second - left AP;XR Finger.2nd-L AP;;ACTIVE;2.70;2.7 +97423-8;View AP;Find;Pt;Upper extremity.bilateral>Finger.second;Doc;XR;RAD;2;XR Finger second - bilateral AP;XR Finger.2nd-Bl AP;;ACTIVE;2.70;2.7 +97424-6;View PA;Find;Pt;Upper extremity.bilateral>Finger.second;Doc;XR;RAD;2;XR Finger second - bilateral PA;XR Finger.2nd-Bl PA;;ACTIVE;2.70;2.7 +97425-3;View AP;Find;Pt;Upper extremity.right>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - right AP;XR Finger.5th-R AP;;ACTIVE;2.70;2.7 +97426-1;View AP;Find;Pt;Upper extremity.left>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - left AP;XR Finger.5th-L AP;;ACTIVE;2.70;2.7 +97427-9;View AP;Find;Pt;Upper extremity.left>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - left AP;XR Finger.4th-L AP;;ACTIVE;2.70;2.7 +9742-8;Chloride;SRat;24H;Stool;Qn;;CHEM;1;Chloride [Moles/time] in 24 hour Stool;Chloride 24h Stl-sRate;;ACTIVE;1.0i;2.73 +97428-7;View AP;Find;Pt;Upper extremity.right>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - right AP;XR Finger.4th-R AP;;ACTIVE;2.70;2.7 +97429-5;View AP;Find;Pt;Upper extremity.left>Finger.third;Doc;XR;RAD;2;XR Finger third - left AP;XR Finger.3rd-L AP;;ACTIVE;2.70;2.7 +97430-3;View AP;Find;Pt;Upper extremity.right>Finger.third;Doc;XR;RAD;2;XR Finger third - right AP;XR Finger.3rd-R AP;;ACTIVE;2.70;2.7 +97431-1;View lateral;Find;Pt;Upper extremity.left>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - left Lateral;XR Finger.5th-L Lat;;ACTIVE;2.70;2.7 +97432-9;View lateral;Find;Pt;Upper extremity.right>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - right Lateral;XR Finger.5th-R Lat;;ACTIVE;2.70;2.7 +97433-7;View lateral;Find;Pt;Upper extremity.right>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - right Lateral;XR Finger.4th-R Lat;;ACTIVE;2.70;2.7 +97434-5;View lateral;Find;Pt;Upper extremity.left>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - left Lateral;XR Finger.4th-L Lat;;ACTIVE;2.70;2.7 +97435-2;View lateral;Find;Pt;Upper extremity.right>Finger.second;Doc;XR;RAD;2;XR Finger second - right Lateral;XR Finger.2nd-R Lat;;ACTIVE;2.70;2.7 +9743-6;Isoleucine;MCnc;Pt;CSF;Qn;;CHEM;1;Isoleucine [Mass/volume] in Cerebral spinal fluid;Isoleucine CSF-mCnc;;ACTIVE;1.0i;2.42 +97436-0;View lateral;Find;Pt;Upper extremity.left>Finger.second;Doc;XR;RAD;2;XR Finger second - left Lateral;XR Finger.2nd-L Lat;;ACTIVE;2.70;2.7 +97437-8;View lateral;Find;Pt;Upper extremity.left>Finger.third;Doc;XR;RAD;2;XR Finger third - left Lateral;XR Finger.3rd-L Lat;;ACTIVE;2.70;2.7 +97438-6;View lateral;Find;Pt;Upper extremity.right>Finger.third;Doc;XR;RAD;2;XR Finger third - right Lateral;XR Finger.3rd-R Lat;;ACTIVE;2.70;2.7 +97439-4;View oblique;Find;Pt;Upper extremity.right>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - right Oblique;XR Finger.5th-R Obl;;ACTIVE;2.70;2.7 +97440-2;View oblique;Find;Pt;Upper extremity.left>Finger.fifth;Doc;XR;RAD;2;XR Finger fifth - left Oblique;XR Finger.5th-L Obl;;ACTIVE;2.70;2.7 +97441-0;View oblique;Find;Pt;Upper extremity.left>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - left Oblique;XR Finger.4th-L Obl;;ACTIVE;2.70;2.7 +97442-8;View oblique;Find;Pt;Upper extremity.right>Finger.fourth;Doc;XR;RAD;2;XR Finger fourth - right Oblique;XR Finger.4th-R Obl;;ACTIVE;2.70;2.7 +97443-6;View oblique;Find;Pt;Upper extremity.right>Finger.second;Doc;XR;RAD;2;XR Finger second - right Oblique;XR Finger.2nd-R Obl;;ACTIVE;2.70;2.7 +9744-4;Beta globulin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Beta globulin [Mass/volume] in Urine by Electrophoresis;B-Globulin Ur Elph-mCnc;;ACTIVE;1.0i;2.73 +97444-4;View oblique;Find;Pt;Upper extremity.left>Finger.second;Doc;XR;RAD;2;XR Finger second - left Oblique;XR Finger.2nd-L Obl;;ACTIVE;2.70;2.7 +97445-1;View oblique;Find;Pt;Upper extremity.right>Finger.third;Doc;XR;RAD;2;XR Finger third - right Oblique;XR Finger.3rd-R Obl;;ACTIVE;2.70;2.7 +97446-9;View oblique;Find;Pt;Upper extremity.left>Finger.third;Doc;XR;RAD;2;XR Finger third - left Oblique;XR Finger.3rd-L Obl;;ACTIVE;2.70;2.7 +97447-7;View oblique;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right Oblique;XR Ribs-R Obl;;ACTIVE;2.70;2.7 +97448-5;View PA;Find;Pt;Chest>Ribs.right;Doc;XR;RAD;2;XR Ribs - right PA;XR Ribs-R PA;;ACTIVE;2.70;2.7 +97449-3;View AP;Find;Pt;Lower extremity.bilateral>Great toe;Doc;XR;RAD;2;XR Great toe - bilateral AP;XR Great toe-Bl AP;;ACTIVE;2.70;2.7 +97450-1;View oblique;Find;Pt;Lower extremity.bilateral>Great toe;Doc;XR;RAD;2;XR Great toe - bilateral Oblique;XR Great toe-Bl Obl;;ACTIVE;2.70;2.7 +9745-1;Gamma globulin;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Gamma globulin [Mass/volume] in Urine by Electrophoresis;Gamma glob Ur Elph-mCnc;;ACTIVE;1.0i;2.73 +97451-9;View lateral;Find;Pt;Lower extremity.bilateral>Great toe;Doc;XR;RAD;2;XR Great toe - bilateral Lateral;XR Great toe-Bl Lat;;ACTIVE;2.70;2.7 +97452-7;View oblique;Find;Pt;Lower extremity.bilateral>Toe.second;Doc;XR;RAD;2;XR Toe second - bilateral Oblique;XR Toe 2nd-Bl Obl;;ACTIVE;2.70;2.7 +97453-5;View oblique;Find;Pt;Lower extremity.bilateral>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - bilateral Oblique;XR Toe 5th-Bl Obl;;ACTIVE;2.70;2.7 +97454-3;View oblique;Find;Pt;Lower extremity.bilateral>Toe.third;Doc;XR;RAD;2;XR Toe third - bilateral Oblique;XR Toe 3rd-Bl Obl;;ACTIVE;2.70;2.7 +97455-0;View AP;Find;Pt;Lower extremity.bilateral>Toe.third;Doc;XR;RAD;2;XR Toe third - bilateral AP;XR Toe 3rd-Bl AP;;ACTIVE;2.70;2.7 +97456-8;View oblique;Find;Pt;Lower extremity.bilateral>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - bilateral Oblique;XR Toe 4th-Bl Obl;;ACTIVE;2.70;2.7 +97457-6;View AP;Find;Pt;Lower extremity.bilateral>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - bilateral AP;XR Toe 5th-Bl AP;;ACTIVE;2.70;2.7 +97458-4;View AP;Find;Pt;Lower extremity.bilateral>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - bilateral AP;XR Toe 4th-Bl AP;;ACTIVE;2.70;2.7 +97459-2;View AP;Find;Pt;Lower extremity.bilateral>Toe.second;Doc;XR;RAD;2;XR Toe second - bilateral AP;XR Toe 2nd-Bl AP;;ACTIVE;2.70;2.7 +974-6;D Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;D Ab [Presence] in Serum or Plasma from Donor;D Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +97460-0;View oblique;Find;Pt;Lower extremity.left>Toe.third;Doc;XR;RAD;2;XR Toe third - left Oblique;XR Toe 3rd-L Obl;;ACTIVE;2.70;2.7 +97461-8;View AP;Find;Pt;Lower extremity.left>Toe.third;Doc;XR;RAD;2;XR Toe third - left AP;XR Toe 3rd-L AP;;ACTIVE;2.70;2.7 +97462-6;View lateral;Find;Pt;Lower extremity.left>Toe.third;Doc;XR;RAD;2;XR Toe third - left Lateral;XR Toe 3rd-L Lat;;ACTIVE;2.70;2.7 +97463-4;View lateral;Find;Pt;Lower extremity.left>Toe.second;Doc;XR;RAD;2;XR Toe second - left Lateral;XR Toe 2nd-L Lat;;ACTIVE;2.70;2.7 +97464-2;View AP;Find;Pt;Lower extremity.left>Toe.second;Doc;XR;RAD;2;XR Toe second - left AP;XR Toe 2nd-L AP;;ACTIVE;2.70;2.7 +97465-9;View oblique;Find;Pt;Lower extremity.left>Toe.second;Doc;XR;RAD;2;XR Toe second - left Oblique;XR Toe 2nd-L Obl;;ACTIVE;2.70;2.7 +97466-7;view oblique;Find;Pt;Lower extremity.left>Great toe;Doc;XR;RAD;2;XR Great toe - left Oblique;XR Great toe-L Obl;;ACTIVE;2.70;2.7 +97467-5;View lateral;Find;Pt;Lower extremity.left>Great toe;Doc;XR;RAD;2;XR Great toe - left Lateral;XR Great toe-L Lat;;ACTIVE;2.70;2.7 +97468-3;View AP;Find;Pt;Lower extremity.left>Great toe;Doc;XR;RAD;2;XR Great toe - left AP;XR Great toe-L AP;;ACTIVE;2.70;2.7 +9746-9;Dantrolene;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dantrolene [Mass/volume] in Serum or Plasma;Dantrolene SerPl-mCnc;;ACTIVE;1.0i;2.73 +97469-1;View AP;Find;Pt;Lower extremity.left>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - left AP;XR Toe 4th-L AP;;ACTIVE;2.70;2.7 +97470-9;View lateral;Find;Pt;Lower extremity.left>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - left Lateral;XR Toe 4th-L Lat;;ACTIVE;2.70;2.7 +97471-7;View oblique;Find;Pt;Lower extremity.left>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - left Oblique;XR Toe 4th-L Obl;;ACTIVE;2.70;2.7 +97472-5;View lateral;Find;Pt;Lower extremity.left>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - left Lateral;XR Toe 5th-L Lat;;ACTIVE;2.70;2.7 +97473-3;View oblique;Find;Pt;Lower extremity.left>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - left Oblique;XR Toe 5th-L Obl;;ACTIVE;2.70;2.7 +97474-1;View AP;Find;Pt;Lower extremity.left>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - left AP;XR Toe 5th-L AP;;ACTIVE;2.70;2.7 +97475-8;View AP;Find;Pt;Lower extremity.right>Great toe;Doc;XR;RAD;2;XR Great toe - right AP;XR Great toe-R AP;;ACTIVE;2.70;2.7 +97476-6;View lateral;Find;Pt;Lower extremity.right>Great toe;Doc;XR;RAD;2;XR Great toe - right Lateral;XR Great toe-R Lat;;ACTIVE;2.70;2.7 +9747-7;Dapsone;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dapsone [Mass/volume] in Serum or Plasma;DDS SerPl-mCnc;;ACTIVE;1.0i;2.73 +97477-4;View oblique;Find;Pt;Lower extremity.right>Great toe;Doc;XR;RAD;2;XR Great toe - right Oblique;XR Great toe-R Obl;;ACTIVE;2.70;2.7 +97478-2;View oblique;Find;Pt;Lower extremity.right>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - right Oblique;XR Toe 5th-R Obl;;ACTIVE;2.70;2.7 +97479-0;View AP;Find;Pt;Lower extremity.right>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - right AP;XR Toe 5th-R AP;;ACTIVE;2.70;2.7 +97480-8;View lateral;Find;Pt;Lower extremity.right>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - right Lateral;XR Toe 5th-R Lat;;ACTIVE;2.70;2.7 +97481-6;View lateral;Find;Pt;Lower extremity.right>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - right Lateral;XR Toe 4th-R Lat;;ACTIVE;2.70;2.7 +97482-4;View AP;Find;Pt;Lower extremity.right>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - right AP;XR Toe 4th-R AP;;ACTIVE;2.70;2.7 +97483-2;View oblique;Find;Pt;Lower extremity.right>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - right Oblique;XR Toe 4th-R Obl;;ACTIVE;2.70;2.7 +97484-0;View oblique;Find;Pt;Lower extremity.right>Toe.third;Doc;XR;RAD;2;XR Toe third - right Oblique;XR Toe 3rd-R Obl;;ACTIVE;2.70;2.7 +9748-5;Dipyridamole;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Dipyridamole [Mass/volume] in Specimen;Dipyridamole Spec-mCnc;;ACTIVE;1.0i;2.69 +97485-7;View lateral;Find;Pt;Lower extremity.right>Toe.third;Doc;XR;RAD;2;XR Toe third - right Lateral;XR Toe 3rd-R Lat;;ACTIVE;2.70;2.7 +97486-5;View AP;Find;Pt;Lower extremity.right>Toe.third;Doc;XR;RAD;2;XR Toe third - right AP;XR Toe 3rd-R AP;;ACTIVE;2.70;2.7 +97487-3;View oblique;Find;Pt;Lower extremity.right>Toe.second;Doc;XR;RAD;2;XR Toe second - right Oblique;XR Toe 2nd-R Obl;;ACTIVE;2.70;2.7 +97488-1;View lateral;Find;Pt;Lower extremity.right>Toe.second;Doc;XR;RAD;2;XR Toe second - right Lateral;XR Toe 2nd-R Lat;;ACTIVE;2.70;2.7 +97489-9;View AP;Find;Pt;Lower extremity.right>Toe.second;Doc;XR;RAD;2;XR Toe second - right AP;XR Toe 2nd-R AP;;ACTIVE;2.70;2.7 +97490-7;View AP;Find;Pt;Lower extremity.bilateral>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - bilateral AP;XR Tib+Fib-Bl AP;;ACTIVE;2.70;2.7 +97491-5;View lateral;Find;Pt;Lower extremity.bilateral>Tibia+Fibula;Doc;XR;RAD;2;XR Tibia and Fibula - bilateral Lateral;XR Tib+Fib-Bl Lat;;ACTIVE;2.70;2.7 +97492-3;Views AP + lateral + oblique;Find;Pt;Lower extremity.right>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - right AP and Lateral and oblique;XR Toe 5th-R AP+Lat+Obl;;ACTIVE;2.70;2.7 +9749-3;Hemoglobin F;ACnc;Pt;Bld;Qn;Electrophoresis;HEM/BC;1;Hemoglobin F [Units/volume] in Blood by Electrophoresis;Hgb F Bld Elph-aCnc;;ACTIVE;1.0i;2.73 +97493-1;Views AP + lateral + oblique;Find;Pt;Lower extremity.right>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - right AP and Lateral and oblique;XR Toe 4th-R AP+Lat+Obl;;ACTIVE;2.70;2.7 +97494-9;Views AP + lateral;Find;Pt;Lower extremity.right>Toe.third;Doc;XR;RAD;2;XR Toe third - right AP and Lateral;XR Toe 3rd-R AP+Lat;;ACTIVE;2.70;2.7 +97495-6;Views AP + lateral;Find;Pt;Lower extremity.right>Great toe;Doc;XR;RAD;2;XR Great toe - right AP and Lateral;XR Great toe-R AP+Lat;;ACTIVE;2.70;2.7 +97496-4;Views AP + lateral;Find;Pt;Lower extremity.right>Toe.second;Doc;XR;RAD;2;XR Toe second - right AP and Lateral;XR Toe 2nd-R AP+Lat;;ACTIVE;2.70;2.7 +97497-2;Views AP + lateral;Find;Pt;Lower extremity.right>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - right AP and Lateral;XR Toe 4th-R AP+Lat;;ACTIVE;2.70;2.7 +97498-0;Views AP + lateral;Find;Pt;Lower extremity.right>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - right AP and Lateral;XR Toe 5th-R AP+Lat;;ACTIVE;2.70;2.7 +97499-8;Proof of COVID-19 recovery certificate;Find;Pt;{Setting};Doc;{Role};DOC.ADMIN;2;Proof of COVID-19 recovery certificate;Proof of COVID-19 recovery Cert;;ACTIVE;2.70;2.7 +97500-3;Proof of COVID-19 immunization or negative status certificate;Find;Pt;{Setting};Doc;{Role};DOC.ADMIN;2;Proof of COVID-19 immunization or negative status certificate;COVID-19 Immunization or Neg Cert;;ACTIVE;2.70;2.7 +9750-1;Coxsackievirus A10 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A10 Ab [Titer] in Serum by Complement fixation;CV A10 Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97501-1;REVEAL 2.0;Score;Pt;^Patient;Qn;REVEAL;PULM;2;REVEAL 2.0 [Score];REVEAL 2.0 [Score];;ACTIVE;2.70;2.7 +97502-9;Prion disease biomarker panel;-;Pt;CSF;-;;PANEL.CHEM;1;Prion disease biomarker panel - Cerebral spinal fluid;Prion disease biomarker panel CSF;;ACTIVE;2.70;2.7 +97503-7;Prion protein.abnormal;PrThr;Pt;CSF;Ord;;MICRO;1;Abnormal Prion Protein [Presence] in Cerebral spinal fluid;Abn Prion Prot CSF Ql;;ACTIVE;2.70;2.71 +97504-5;Percent sensor usage;TimeFr;RptPeriod;^Patient;Qn;Calculated;H&P.HX;2;Percent sensor usage;Sensor usage %;;ACTIVE;2.70;2.7 +97505-2;Glucose standard deviation;MCnc;RptPeriod;Interstitial fluid;Qn;Calculated;CHEM;1;Glucose standard deviation Calculated;Glucose SD Calc;;ACTIVE;2.70;2.7 +97506-0;Glucose management indicator;NFr;RptPeriod;Interstitial fluid;Qn;Calculated;CHEM;1;Glucose management indicator;Glucose management indicator;;ACTIVE;2.70;2.7 +97507-8;Glucose;MCnc;RptPeriod^mean;Interstitial fluid;Qn;Calculated;CHEM;1;Average glucose [Mass/volume] in Interstitial fluid during Reporting Period;Ave Glucose Interstitial fld RptPeriod;;ACTIVE;2.70;2.7 +97508-6;Number of providers seen for condition of interest;Num;Pt;^Patient;Qn;;H&P.HX;2;Number of providers seen for condition of interest;Num providers seen;;ACTIVE;2.70;2.7 +97509-4;Cancer disease progression;Find;Pt;^Patient;Nom;;CLIN;2;Cancer disease progression;Cancer progression;;ACTIVE;2.70;2.7 +97510-2;Glucose measurements in range/Total glucose measurements;NFr;RptPeriod;Interstitial fluid;Qn;Calculated;CHEM;1;Glucose measurements in range out of Total glucose measurements during reporting period;% Glucose measurements in range;;ACTIVE;2.70;2.72 +97511-0;Fungal Ab panel;-;Pt;XXX;-;Immune diffusion;PANEL.MICRO;1;Fungal Ab panel - Specimen by Immune diffusion (ID);Fungal Ab Pnl Spec ID;;ACTIVE;2.70;2.7 +97512-8;Rabies virus Ab.IgM;PrThr;Pt;XXX;Ord;IF;MICRO;1;Rabies virus IgM Ab [Presence] in Specimen by Immunofluorescence;RABV IgM Spec Ql IF;;ACTIVE;2.70;2.7 +97513-6;Campylobacter sp;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Campylobacter sp [Presence] in Specimen by Organism specific culture;Campylobacter Spec Ql Cult;;ACTIVE;2.70;2.7 +97514-4;Entamoeba moshkovskii DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Entamoeba moshkovskii DNA [Presence] in Specimen by NAA with probe detection;E moshkovskii DNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97515-1;Entamoeba bangladeshi DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Entamoeba bangladeshi DNA [Presence] in Specimen by NAA with probe detection;E bangladeshi DNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97516-9;Acanthamoeba sp Ab;PrThr;Pt;XXX;Ord;IF;MICRO;1;Acanthamoeba sp Ab [Presence] in Specimen by Immunofluorescence;Acanthamoeba Ab Spec Ql IF;;ACTIVE;2.70;2.7 +97517-7;Rabies virus Ab.IgG;PrThr;Pt;XXX;Ord;IF;MICRO;1;Rabies virus IgG Ab [Presence] in Specimen by Immunofluorescence;RABV IgG Spec Ql IF;;ACTIVE;2.70;2.7 +97518-5;Paracoccidioides sp Ab band pattern;Prid;Pt;XXX;Nom;Immune diffusion;MICRO;1;Paracoccidioides sp Ab band pattern [Identifier] in Specimen by Immune diffusion (ID);Paracoccidioides Ab Patrn Spec ID;;ACTIVE;2.70;2.7 +9751-9;Coxsackievirus A10 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus A10 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV A10 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97519-3;Blastomyces sp Ab band pattern;Prid;Pt;XXX;Nom;Immune diffusion;MICRO;1;Blastomyces sp Ab band pattern [Identifier] in Specimen by Immune diffusion (ID);Blastomyces Ab Patrn Spec ID;;ACTIVE;2.70;2.7 +97520-1;Histoplasma capsulatum mycelial phase Ab band pattern;Prid;Pt;XXX;Nom;Immune diffusion;MICRO;1;Histoplasma capsulatum mycelial phase Ab band pattern [Identifier] in Specimen by Immune diffusion (ID);H capsul Myc Ab Patrn Spec ID;;ACTIVE;2.70;2.7 +97521-9;Coccidioides sp Ab band pattern;Prid;Pt;XXX;Nom;Immune diffusion;MICRO;1;Coccidioides sp Ab band pattern [Identifier] in Specimen by Immune diffusion (ID);Coccidioides Ab Patrn Spec ID;;ACTIVE;2.70;2.7 +97522-7;Giardia sp;PrThr;Pt;Water;Ord;IF;MICRO;1;Giardia sp [Presence] in Water by Immunofluorescence;Giardia Wat Ql IF;;ACTIVE;2.70;2.7 +97523-5;Hepatitis A virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Hepatitis A virus RNA [Presence] in Specimen by NAA with probe detection;HAV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97524-3;Cryptosporidium sp;PrThr;Pt;Water;Ord;IF;MICRO;1;Cryptosporidium sp [Presence] in Water by Immunofluorescence;Cryptosp Wat Ql IF;;ACTIVE;2.70;2.7 +97525-0;Norovirus genogroup I RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup I RNA [Presence] in Specimen by NAA with probe detection;Norovirus GI RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97526-8;Balamuthia mandrillaris Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Balamuthia mandrillaris Ag [Presence] in Specimen by Immunofluorescence;B mandrillaris Ag Spec Ql IF;;ACTIVE;2.70;2.7 +9752-7;Coxsackievirus A16 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus A16 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV A16 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97527-6;Acanthamoeba sp Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Acanthamoeba sp Ag [Presence] in Specimen by Immunofluorescence;Acanthamoeba Ag Spec Ql IF;;ACTIVE;2.70;2.7 +97528-4;Naegleria fowleri Ag;PrThr;Pt;XXX;Ord;IF;MICRO;1;Naegleria fowleri Ag [Presence] in Specimen by Immunofluorescence;N fowleri Ag Spec Ql IF;;ACTIVE;2.70;2.7 +97529-2;Naegleria fowleri;PrThr;Pt;XXX;Ord;Organism specific culture;MICRO;1;Naegleria fowleri [Presence] in Specimen by Organism specific culture;N fowleri Spec Ql Cult;;ACTIVE;2.70;2.7 +975-3;D Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;D Ab [Presence] in Serum or Plasma;D Ab SerPl Ql;;ACTIVE;1.0;2.73 +97530-0;Naegleria fowleri Ab;PrThr;Pt;XXX;Ord;IF;MICRO;1;Naegleria fowleri Ab [Presence] in Specimen by Immunofluorescence;N fowleri Ab Spec Ql IF;;ACTIVE;2.70;2.7 +97531-8;Balamuthia mandrillaris Ab;PrThr;Pt;XXX;Ord;IF;MICRO;1;Balamuthia mandrillaris Ab [Presence] in Specimen by Immunofluorescence;B mandrillaris Ab Spec Ql IF;;ACTIVE;2.70;2.7 +97532-6;Norovirus genogroup II RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Norovirus genogroup II RNA [Presence] in Specimen by NAA with probe detection;Norovirus GII RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97533-4;Somatotropin post glucose stimulation panel;-;Pt;Ser/Plas;-;;PANEL.CHAL;1;Somatotropin post glucose stimulation panel - Serum or Plasma;GH p glucose Pnl SerPl;;ACTIVE;2.70;2.7 +97534-2;Somatotropin^3H post dose glucose;MCnc;Pt;Ser/Plas;Qn;;CHAL;1;Somatotropin [Mass/volume] in Serum or Plasma --3 hours post dose glucose;GH 3h p Glc SerPl-mCnc;;ACTIVE;2.70;2.7 +9753-5;Coxsackievirus A2 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A2 Ab [Titer] in Serum by Complement fixation;CV A2 Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97535-9;Gas panel;-;Pt;BldCV;Qn;;PANEL.CHEM;1;Gas panel - Central venous blood;Gas Pnl BldCV;;ACTIVE;2.70;2.7 +97536-7;pH;LsCnc;Pt;BldCV;Qn;;CHEM;1;pH of Central venous blood;pH BldCV;;ACTIVE;2.70;2.7 +97537-5;pH^^adjusted to patient's actual temperature;LsCnc;Pt;BldCV;Qn;;CHEM;1;pH of Central venous blood adjusted to patient's actual temperature;pH temp adj BldCV;;ACTIVE;2.70;2.7 +97538-3;Carbon dioxide;PPres;Pt;BldCV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] in Central venous blood;pCO2 BldCV;;ACTIVE;2.70;2.7 +97539-1;Carbon dioxide^^adjusted to patient's actual temperature;PPres;Pt;BldCV;Qn;;CHEM;1;Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Central venous blood;pCO2 temp adj BldCV;;ACTIVE;2.70;2.7 +97540-9;Oxygen;PPres;Pt;BldCV;Qn;;CHEM;1;Oxygen [Partial pressure] in Central venous blood;pO2 BldCV;;ACTIVE;2.70;2.7 +97541-7;Oxygen^^adjusted to patient's actual temperature;PPres;Pt;BldCV;Qn;;CHEM;1;Oxygen [Partial pressure] adjusted to patient's actual temperature in Central venous blood;pO2 temp adj BldCV;;ACTIVE;2.70;2.7 +97542-5;Oxygen content;SCnc;Pt;BldCV;Qn;;CHEM;1;Oxygen content in Central venous blood;O2 Ct BldCV-sCnc;;ACTIVE;2.70;2.7 +9754-3;Coxsackievirus A4 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A4 Ab [Titer] in Serum by Complement fixation;CV A4 Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97543-3;Bicarbonate;SCnc;Pt;BldCV;Qn;;CHEM;1;Bicarbonate [Moles/volume] in Central venous blood;HCO3 BldCV-sCnc;;ACTIVE;2.70;2.7 +97544-1;Bicarbonate^^standard;SCnc;Pt;BldCV;Qn;;CHEM;1;Bicarbonate [Moles/volume] standard in Central venous blood;HCO3 std BldCV-sCnc;;ACTIVE;2.70;2.7 +97545-8;Carbon dioxide;SCnc;Pt;BldCV;Qn;;CHEM;1;Carbon dioxide, total [Moles/volume] in Central venous blood;CO2 BldCV-sCnc;;ACTIVE;2.70;2.7 +97546-6;Base excess;SCnc;Pt;BldCV;Qn;Calculated;CHEM;1;Base excess in Central venous blood by calculation;Base excess BldCV Calc-sCnc;;ACTIVE;2.70;2.7 +97547-4;Base excess^^standard;SCnc;Pt;BldCV;Qn;;CHEM;1;Base excess standard in Central venous blood;Base excess std BldCV-sCnc;;ACTIVE;2.70;2.7 +97548-2;Base deficit;SCnc;Pt;BldCV;Qn;;CHEM;1;Base deficit in Central venous blood;Base deficit BldCV-sCnc;;ACTIVE;2.70;2.7 +97549-0;Oxygen saturation;MFr;Pt;BldCV;Qn;;CHEM;1;Oxygen saturation in Central venous blood;SaO2 % BldCV;;ACTIVE;2.70;2.7 +9755-0;Coxsackievirus A7 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A7 Ab [Titer] in Serum by Complement fixation;CV A7 Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97550-8;Hemoglobin;MCnc;Pt;BldCV;Qn;Calculated;HEM/BC;1;Hemoglobin [Mass/volume] in Central venous blood by calculation;Hgb BldCV Calc-mCnc;;ACTIVE;2.70;2.7 +97551-6;Carboxyhemoglobin/Hemoglobin.total;MFr;Pt;BldCV;Qn;;CHEM;1;Carboxyhemoglobin/Hemoglobin.total in Central venous blood;COHgb MFr BldCV;;ACTIVE;2.70;2.7 +97552-4;Oxyhemoglobin/Hemoglobin.total;MFr;Pt;BldCV;Qn;;CHEM;1;Fractional oxyhemoglobin in Central venous blood;OxyHgb MFr BldCV;;ACTIVE;2.70;2.7 +97553-2;Deoxyhemoglobin/Hemoglobin.total;MFr;Pt;BldCV;Qn;;CHEM;1;Deoxyhemoglobin/Hemoglobin.total in Central venous blood;DO-Hgb MFr BldCV;;ACTIVE;2.70;2.7 +97554-0;Methemoglobin/Hemoglobin.total;MFr;Pt;BldCV;Qn;;CHEM;1;Methemoglobin/Hemoglobin.total in Central venous blood;MetHgb MFr BldCV;;ACTIVE;2.70;2.7 +97555-7;Hemoglobin;MCnc;Pt;BldCV;Qn;Oximetry;HEM/BC;1;Hemoglobin [Mass/volume] in Central venous blood by Oximetry;Hgb BldCV Oximetry-mCnc;;ACTIVE;2.70;2.7 +97556-5;Hemoglobin;MCnc;Pt;BldC;Qn;Oximetry;CHEM;1;Hemoglobin [Mass/volume] in Capillary blood by Oximetry;Hgb BldC Oximetry-mCnc;;ACTIVE;2.70;2.7 +97557-3;Gastrointestinal dysmotility autoimmune Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Gastrointestinal dysmotility autoimmune Ab panel - Serum;AGID Ab pnl Ser;;ACTIVE;2.70;2.7 +97558-1;Acetylcholine receptor binding Ab.IgG+IgM;SCnc;Pt;Ser;Qn;IA;SERO;1;Acetylcholine receptor binding IgG+IgM Ab [Moles/volume] in Serum by Immunoassay;AChR Bind IgG+IgM Ser IA-sCnc;;ACTIVE;2.70;2.7 +97559-9;Acetylcholine receptor ganglionic neuronal Ab.IgG+IgM;SCnc;Pt;Ser;Qn;IA;SERO;1;Acetylcholine receptor ganglionic neuronal IgG+IgM Ab [Moles/volume] in Serum by Immunoassay;nAChR IgG+IgM Ser IA-sCnc;;ACTIVE;2.70;2.7 +97560-7;Voltage-gated potassium channel Ab.IgG+IgM;SCnc;Pt;Ser;Qn;IA;SERO;1;Voltage-gated potassium channel IgG+IgM Ab [Moles/volume] in Serum by Immunoassay;VGKC IgG+IgM Ser IA-sCnc;;ACTIVE;2.70;2.7 +97561-5;Necrotizing myopathy autoimmune Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Necrotizing myopathy autoimmune Ab panel - Serum;Necrotizing myopathy Ab pnl Ser;;ACTIVE;2.70;2.7 +97562-3;Signal recognition particle Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IF;SERO;1;Signal Recognition Particle (SRP) IgG Ab [Presence] in Serum or Plasma by Immunofluorescence;SRP IgG SerPl Ql IF;;ACTIVE;2.70;2.7 +97563-1;Signal recognition particle Ab.IgG;Titr;Pt;Ser/Plas;Qn;IF;SERO;1;Signal Recognition Particle (SRP) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence;SRP IgG Titr SerPl IF;;ACTIVE;2.70;2.7 +97564-9;Nuclear antibody panel;-;Pt;Ser;-;;PANEL.SERO;1;Nuclear antibody panel - Serum;ANA pnl Ser;;ACTIVE;2.70;2.7 +97565-6;B-cell primary immunodeficiency multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;B-cell primary immunodeficiency multigene analysis in Blood or Tissue by Molecular genetics method;B-cell PI multigene Bld/T;;ACTIVE;2.70;2.7 +97566-4;Myasthenia gravis & Lambert-Eaton syndrome autoimmune Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Myasthenia gravis and Lambert-Eaton syndrome autoimmune Ab panel - Serum;MG and LES Ab Pnl Ser;;ACTIVE;2.70;2.7 +9756-8;Coxsackievirus A7 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus A7 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV A7 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97568-0;Owner of animal patient was exposed to;Type;Pt;^Patient;Nom;;H&P.HX;2;Owner of animal patient was exposed to;Animal owner;;ACTIVE;2.70;2.7 +97569-8;Note;Find;Pt;Telehealth;Doc;Eating disorders;DOC.ONTOLOGY;2;Eating disorders Telehealth Note;Eating disorders Telehealth Note;;ACTIVE;2.70;2.7 +97570-6;Progress note;Find;Pt;{Setting};Doc;Cardiovascular disease+Pulmonary disease;DOC.ONTOLOGY;2;Cardiopulmonary Progress note;Cardio+Pulm disease Prog note;;ACTIVE;2.70;2.73 +97571-4;Progress note;Find;Pt;{Setting};Doc;Cardiac surgery;DOC.ONTOLOGY;2;Cardiac surgery Progress note;Cardiac surgery Prog note;;ACTIVE;2.70;2.73 +97572-2;Progress note;Find;Pt;{Setting};Doc;Eating disorders;DOC.ONTOLOGY;2;Eating disorders Progress note;Eating disorders Prog note;;ACTIVE;2.70;2.73 +97573-0;Mechanical circulatory support+progress note;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Mechanical circulatory support Progress note;MCS+progress note;;ACTIVE;2.70;2.7 +97574-8;Progress note;Find;Pt;{Setting};Doc;Spinal surgery;DOC.ONTOLOGY;2;Spinal surgery Progress note;Spinal surgery Prog note;;ACTIVE;2.70;2.73 +97575-5;Progress note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Progress note;Col+rec surg Prog note;;ACTIVE;2.70;2.73 +9757-6;Coxsackievirus A9 Ab;Titr;Pt;Ser;Qn;Comp fix;MICRO;1;Coxsackievirus A9 Ab [Titer] in Serum by Complement fixation;CV A9 Ab Titr Ser CF;;ACTIVE;1.0i;2.73 +97576-3;Progress note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Progress note;Hand Surgery Prog note;;ACTIVE;2.70;2.73 +97577-1;Progress note;Find;Pt;{Setting};Doc;Heart failure+Transplant cardiology;DOC.ONTOLOGY;2;Heart failure+Transplant cardiology Progress note;HF+TC Prog note;;ACTIVE;2.70;2.73 +97578-9;Progress note;Find;Pt;{Setting};Doc;Internal medicine;DOC.ONTOLOGY;2;Internal medicine Progress note;Internal Med Prog note;;ACTIVE;2.70;2.73 +97579-7;Progress note;Find;Pt;{Setting};Doc;Orthotics prosthetics;DOC.ONTOLOGY;2;Orthotics prosthetics Progress note;Orthotics prosthetics Prog note;;ACTIVE;2.70;2.73 +97580-5;Progress note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Progress note;Radiology Prog note;;ACTIVE;2.70;2.73 +97582-1;Buprenorphine.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Buprenorphine free [Presence] in Cord tissue by Screen method;Buprenorphine free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97583-9;Buprenorphine.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Buprenorphine free [Presence] in Cord tissue by Confirmatory method;Buprenorphine free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +9758-4;Coxsackievirus A9 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus A9 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV A9 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97584-7;Carboxy tetrahydrocannabinol;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Cord tissue by Screen method;CarboxyTHC TissCo Ql Scn;;ACTIVE;2.70;2.7 +97585-4;Carboxy tetrahydrocannabinol;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Carboxy tetrahydrocannabinol [Presence] in Cord tissue by Confirmatory method;CarboxyTHC TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97586-2;Tetrahydrocannabinol;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Cord tissue by Screen method;THC TissCo Ql Scn;;ACTIVE;2.70;2.7 +97587-0;Tetrahydrocannabinol;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Tetrahydrocannabinol [Presence] in Cord tissue by Confirmatory method;THC TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97588-8;Dextromethorphan+Levomethorphan;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Dextromethorphan+Levomethorphan [Presence] in Cord tissue by Screen method;D+L-methorphan TissCo Ql Scn;;ACTIVE;2.70;2.7 +97589-6;Dextromethorphan+Levomethorphan;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Dextromethorphan+Levomethorphan [Presence] in Cord tissue by Confirmatory method;D+L-methorphan TissCo Ql Cfm;;ACTIVE;2.70;2.7 +97590-4;Norbuprenorphine.free;PrThr;Pt;TissCo;Ord;Screen;DRUG/TOX;1;Norbuprenorphine free [Presence] in Cord tissue by Screen method;Norbuprenorphine free TissCo Ql Scn;;ACTIVE;2.70;2.7 +97591-2;Norbuprenorphine.free;PrThr;Pt;TissCo;Ord;Confirm;DRUG/TOX;1;Norbuprenorphine free [Presence] in Cord tissue by Confirmatory method;Norbuprenorphine free TissCo Ql Cfm;;ACTIVE;2.70;2.7 +9759-2;Coxsackievirus B1 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus B1 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV B1 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97592-0;Predicted response to cancer treatment;Find;Pt;^Patient;Ord;Based on lab data;CLIN.RISK;2;Predicted response to cancer treatment based on lab data;Pred resp to cancer tx from lab data;;ACTIVE;2.70;2.7 +97593-8;Lymphocyte T-cell & B-cell & Natural killer subsets panel;-;Pt;Respiratory.lower;Qn;Flow cytometry;PANEL.CELLMARK;1;Lymphocyte T-cell and B-cell and Natural killer subsets panel - Lower respiratory specimen by Flow cytometry (FC);Lymph T + B-cell + NK subsets Pnl L Resp;;ACTIVE;2.70;2.7 +97594-6;Cells.CD3/100 lymphocytes;NFr;Pt;Respiratory.lower;Qn;Flow cytometry;CELLMARK;1;CD3 cells/100 lymphocytes in Lower respiratory specimen by Flow cytometry (FC);CD3 Cells/lymph NFr Lower resp FC;;ACTIVE;2.70;2.7 +97595-3;Cells.CD3+CD4+/100 lymphocytes;NFr;Pt;Respiratory.lower;Qn;Flow cytometry;CELLMARK;1;CD3+CD4+ (T4 helper) cells/100 lymphocytes in Lower respiratory specimen by Flow cytometry (FC);CD3+CD4+ Cells/lymph NFr Lower resp FC;;ACTIVE;2.70;2.7 +97596-1;Cells.CD3+CD8+/100 lymphocytes;NFr;Pt;Respiratory.lower;Qn;Flow cytometry;CELLMARK;1;CD3+CD8+ (T8 suppressor) cells/100 lymphocytes in Lower respiratory specimen by Flow cytometry (FC);CD3+CD8+ Cells/lymph NFr Lower resp FC;;ACTIVE;2.70;2.72 +97597-9;Cells.CD19/100 lymphocytes;NFr;Pt;Respiratory.lower;Qn;Flow cytometry;CELLMARK;1;CD19 cells/100 lymphocytes in Lower respiratory specimen by Flow cytometry (FC);CD19 Cells/lymph NFr Lower resp FC;;ACTIVE;2.70;2.7 +97598-7;Cells.CD3-CD16+CD56+/100 lymphocytes;NFr;Pt;Respiratory.lower;Qn;Flow cytometry;CELLMARK;1;CD3-CD16+CD56+ (Natural killer) cells/100 lymphocytes in Lower respiratory specimen by Flow cytometry (FC);CD3-CD16+CD56+ Cells/lymph NFr L resp FC;;ACTIVE;2.70;2.7 +97599-5;Cells.CD3+CD4+/Cells.CD3+CD8+;NRto;Pt;Respiratory.lower;Qn;Flow cytometry;CELLMARK;1;CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Lower respiratory specimen by Flow cytometry (FC);CD3+CD4+ Cells/CD3+CD8+ Cells L resp FC;;ACTIVE;2.70;2.7 +97-6;Cefonicid;Susc;Pt;Isolate;OrdQn;Agar diffusion;ABXBACT;1;Cefonicid [Susceptibility] by Disk diffusion (KB);Cefonocid Islt KB;;ACTIVE;1.0;2.73 +9760-0;Coxsackievirus B2 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus B2 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV B2 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97600-1;Cells.CD45;NCnc;Pt;Respiratory.lower;Qn;Flow cytometry;CELLMARK;1;CD45 (Lymphs) cells [#/volume] in Lower respiratory specimen by Flow cytometry (FC);CD45 Cells # Lower resp FC;;ACTIVE;2.70;2.7 +97601-9;Microorganism of interest sequence;PrThr;Pt;XXX;Ord;Sequencing;MICRO;1;Microorganism of interest sequence [Presence] in Specimen;Microorganism Sequence Ql;;ACTIVE;2.70;2.7 +97602-7;Glial fibrillary acidic protein & Ubiquitin carboxyl-terminal hydrolase-L1 panel;-;Pt;Plas;-;;PANEL.CHEM;1;Glial fibrillary acidic protein and Ubiquitin carboxyl-terminal hydrolase-L1 panel - Plasma;GFAP + UCH-L1 Pnl Plas;;ACTIVE;2.70;2.7 +97603-5;Glial fibrillary acidic protein+Ubiquitin carboxyl-terminal hydrolase-L1;Imp;Pt;Plas;Ord;;CHEM;1;Glial fibrillary acidic protein+Ubiquitin carboxyl-terminal hydrolase-L1 [Interpretation] in Plasma Qualitative;GFAP+UCH-L1 Plas-Imp;;ACTIVE;2.70;2.7 +97604-3;Glial fibrillary acidic protein;MCnc;Pt;Plas;Qn;IA;CHEM;1;Glial fibrillary acidic protein [Mass/volume] in Plasma by Immunoassay;GFAP Plas IA-mCnc;;ACTIVE;2.70;2.7 +97605-0;Ubiquitin carboxyl-terminal hydrolase-L1;MCnc;Pt;Plas;Qn;IA;CHEM;1;Ubiquitin carboxyl-terminal hydrolase-L1 [Mass/volume] in Plasma by Immunoassay;UCH-L1 Plas IA-mCnc;;ACTIVE;2.70;2.7 +97606-8;Phosphatidylethanol 16:0-18:2;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;PLPEth [Mass/volume] in Blood;PLPEth Bld-mCnc;;ACTIVE;2.70;2.7 +97607-6;Phosphatidylethanol 16:0-18:1;MCnc;Pt;Bld;Qn;;DRUG/TOX;1;POPEth [Mass/volume] in Blood;POPEth Bld-mCnc;;ACTIVE;2.70;2.7 +97608-4;Joint pathogens panel;-;Pt;Synv fld;-;Non-probe.amp.tar;PANEL.MICRO;1;Joint pathogens panel - Synovial fluid by NAA with non-probe detection;Joint pathogens Pnl Snv NAA+non-probe;;ACTIVE;2.70;2.7 +97609-2;Anaerococcus prevotii+vaginalis DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Anaerococcus prevotii+vaginalis DNA [Presence] in Synovial fluid by NAA with non-probe detection;A prev+vag DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +976-1;D Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;D Ag [Presence] on Red Blood Cells from Blood product unit;D Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +97610-0;Bacteroides fragilis DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Bacteroides fragilis DNA [Presence] in Synovial fluid by NAA with non-probe detection;B fragilis DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97611-8;Candida albicans DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Candida albicans DNA [Presence] in Synovial fluid by NAA with non-probe detection;C albicans DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97612-6;Candida sp DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Candida sp DNA [Presence] in Synovial fluid by NAA with non-probe detection;Candida DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97613-4;Citrobacter sp DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Citrobacter sp DNA [Presence] in Synovial fluid by NAA with non-probe detection;Citrobac sp DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97614-2;Clostridium perfringens;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Clostridium perfringens [Presence] in Synovial fluid by NAA with non-probe detection;C perfringens Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97615-9;Cutibacterium avidum+granulosum DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Cutibacterium avidum+granulosum DNA [Presence] in Synovial fluid by NAA with non-probe detection;C avid+granul DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97616-7;Enterobacter cloacae complex DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [Presence] in Synovial fluid by NAA with non-probe detection;E cloac comp DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97617-5;Enterococcus faecalis DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Enterococcus faecalis DNA [Presence] in Synovial fluid by NAA with non-probe detection;E faecalis DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +9761-8;Coxsackievirus B3 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus B3 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV B3 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97618-3;Enterococcus faecium DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Enterococcus faecium DNA [Presence] in Synovial fluid by NAA with non-probe detection;E faecium DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97619-1;Escherichia coli DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Escherichia coli DNA [Presence] in Synovial fluid by NAA with non-probe detection;E coli DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97620-9;Finegoldia magna DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Finegoldia magna DNA [Presence] in Synovial fluid by NAA with non-probe detection;F magna DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97621-7;Haemophilus influenzae DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] in Synovial fluid by NAA with non-probe detection;Haem influ DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97622-5;Kingella kingae DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Kingella kingae DNA [Presence] in Synovial fluid by NAA with non-probe detection;K kingae DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97623-3;Klebsiella aerogenes DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [Presence] in Synovial fluid by NAA with non-probe detection;K. aerogenes DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97624-1;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Klebsiella pneumoniae+Klebsiella variicola+Klebsiella quasipneumoniae DNA [Presence] in Synovial fluid by NAA with non-probe detection;K. pneumon group DNA Snv Ql NAA+non-prb;;ACTIVE;2.70;2.7 +97625-8;Morganella morganii DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Morganella morganii DNA [Presence] in Synovial fluid by NAA with non-probe detection;M. morganii DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +9762-6;Coxsackievirus B4 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus B4 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV B4 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97626-6;Neisseria gonorrhoeae DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Neisseria gonorrhoeae DNA [Presence] in Synovial fluid by NAA with non-probe detection;N gonorrhoea DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97627-4;Parvimonas micra DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Parvimonas micra DNA [Presence] in Synovial fluid by NAA with non-probe detection;P micra DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97628-2;Peptoniphilus sp DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Peptoniphilus sp DNA [Presence] in Synovial fluid by NAA with non-probe detection;Peptoniphilus sp DNA Snv Ql NAA+non-prb;;ACTIVE;2.70;2.7 +97629-0;Peptostreptococcus anaerobius DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Peptostreptococcus anaerobius DNA [Presence] in Synovial fluid by NAA with non-probe detection;P anaerobius DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97630-8;Proteus sp DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Proteus sp DNA [Presence] in Synovial fluid by NAA with non-probe detection;Proteus sp DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97631-6;Pseudomonas aeruginosa DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [Presence] in Synovial fluid by NAA with non-probe detection;P aeruginosa DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97632-4;Salmonella sp DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Salmonella sp DNA [Presence] in Synovial fluid by NAA with non-probe detection;Salmonella DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97633-2;Serratia marcescens DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Serratia marcescens DNA [Presence] in Synovial fluid by NAA with non-probe detection;S marcescens DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +9763-4;Coxsackievirus B5 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus B5 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV B5 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97634-0;Staphylococcus aureus DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [Presence] in Synovial fluid by NAA with non-probe detection;S aureus DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97635-7;Staphylococcus lugdunensis DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Staphylococcus lugdunensis DNA [Presence] in Synovial fluid by NAA with non-probe detection;S lugdunensis DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97636-5;Streptococcus agalactiae DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Synovial fluid by NAA with non-probe detection;Gp B Strep DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97637-3;Streptococcus pneumoniae DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] in Synovial fluid by NAA with non-probe detection;S pneum DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97638-1;Streptococcus pyogenes DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Presence] in Synovial fluid by NAA with non-probe detection;S pyo DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97639-9;Streptococcus sp DNA;PrThr;Pt;Synv fld;Ord;Non-probe.amp.tar;MICRO;1;Streptococcus sp DNA [Presence] in Synovial fluid by NAA with non-probe detection;Streptococcus DNA Snv Ql NAA+non-probe;;ACTIVE;2.70;2.7 +97640-7;Thyroglobulin;SCnc;Pt;Tiss.FNA;Qn;;CHEM;1;Thyroglobulin [Moles/volume] in Tissue fine needle aspirate;Thyroglob Tiss FNA-sCnc;;ACTIVE;2.70;2.7 +97641-5;Coagulation dilute Russell viper venom induced/Coagulation dilute Russell viper venom induced.excess phospholipid^post DOAC neutralization^normalized;Ratio;Pt;PPP;Qn;Coag;COAG;1;dRVVT/dRVVT.excess phospholipid [Ratio] normalized in Platelet poor plasma by Coagulation assay --post DOAC neutralization;dRVVT/dRVVT cfm p DOAC neut Norm PPP-Rto;;ACTIVE;2.70;2.7 +9764-2;Coxsackievirus B6 Ab;Titr;Pt;CSF;Qn;Comp fix;MICRO;1;Coxsackievirus B6 Ab [Titer] in Cerebral spinal fluid by Complement fixation;CV B6 Ab Titr CSF CF;;ACTIVE;1.0i;2.73 +97642-3;Coagulation dilute Russell viper venom induced/Coagulation dilute Russell viper venom induced.excess phospholipid^^normalized;Ratio;Pt;PPP;Qn;Coag;COAG;1;dRVVT/dRVVT.excess phospholipid [Ratio] normalized in Platelet poor plasma by Coagulation assay;dRVVT/dRVVT cfm Nrmlzd PPP-Rto;;ACTIVE;2.70;2.7 +97643-1;Barmah forest virus Ab.IgG;PrThr;Pt;CSF;Ord;IA;MICRO;1;Barmah forest virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay;BFV IgG CSF Ql IA;;ACTIVE;2.70;2.7 +97644-9;Barmah forest virus Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Barmah forest virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;BFV IgM CSF Ql IA;;ACTIVE;2.70;2.7 +97645-6;Parainfluenza virus 1+2+3+4 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Parainfluenza virus 1+2+3+4 RNA [Presence] in Specimen by NAA with probe detection;HPIV 1+2+3+4 RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97646-4;Lassa virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Lassa virus RNA [Presence] in Specimen by NAA with probe detection;LASV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97647-2;Asenapine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Asenapine [Presence] in Urine by Confirmatory method;Asenapine Ur Ql Cfm;;ACTIVE;2.70;2.7 +97648-0;Iloperidone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Iloperidone [Presence] in Urine by Confirmatory method;Iloperidone Ur Ql Cfm;;ACTIVE;2.70;2.7 +97649-8;2-Amino-5-chloropyridine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;2-Amino-5-chloropyridine [Presence] in Urine by Confirmatory method;ACP Ur Ql Cfm;;ACTIVE;2.70;2.7 +97650-6;Desmethylcyclobenzaprine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Desmethylcyclobenzaprine [Presence] in Urine by Confirmatory method;Desmethylcyclobenzaprine Ur Ql Cfm;;ACTIVE;2.70;2.7 +97651-4;Pigeon serum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pigeon serum IgG Ab [Mass/volume] in Serum;Pigeon Serum IgG-mCnc;;ACTIVE;2.70;2.7 +97652-2;(Alternaria alternata+Cladosporium herbarum+Mucor racemosus+Penicillium notatum) Ab.IgG;MCnc;Pt;Ser;Qn;Multidisk;ALLERGY;1;Mold Allergen Mix 6 (Alternaria alternata+Cladosporium herbarum+Mucor racemosus+Penicillium notatum) IgG Ab [Mass/volume] in Serum by Multidisk;Mold Allerg Mix6 IgG-mCnc;;ACTIVE;2.70;2.7 +97653-0;Vespa velutina Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Asian Hornet IgE Ab [Units/volume] in Serum;Asian Hornet IgE Qn;;ACTIVE;2.70;2.7 +97654-8;SMN2 gene copy number;EntNum;Pt;Bld/Tiss;Qn;Molgen;MOLPATH;1;SMN2 gene copy number in Blood or Tissue by Molecular genetics method;SMN2 copy num EntNum Bld/T;;ACTIVE;2.70;2.72 +97655-5;Hereditary breast & gynecologic cancer multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Hereditary breast and gynecologic cancer multigene analysis in Blood or Tissue by Molecular genetics method;Breast Gyn Multigene Bld/T;;ACTIVE;2.70;2.7 +97656-3;Hereditary cancer multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Hereditary cancer multigene analysis in Blood or Tissue by Molecular genetics method;Hereditary Cancer Multigene Anl Bld/T;;ACTIVE;2.70;2.7 +97657-1;Vancomycin^2H post dose;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Vancomycin [Mass/volume] in Serum or Plasma --2 hours post dose;Vancomycin 2h p SerPl-mCnc;;ACTIVE;2.70;2.7 +97658-9;2,3-dinor 11 beta-Prostaglandin F2 alpha/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;2,3-dinor 11 beta-Prostaglandin F2 alpha/Creatinine [Mass Ratio] in Urine;2,3-dinor 11B-PG F2a/Creat Ur;;ACTIVE;2.70;2.7 +9765-9;Lymphocytic choriomeningitis virus Ab.IgG;Titr;Pt;Ser;Qn;IF;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Titer] in Serum by Immunofluorescence;LCMV IgG Titr Ser IF;;ACTIVE;1.0i;2.73 +97659-7;Admission history and physical note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Admission history and physical note;Emergency med ED Admit H&P note;;ACTIVE;2.70;2.7 +97660-5;Evaluation note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Evaluation note;Emergency med ED Eval note;;ACTIVE;2.70;2.7 +97661-3;Checklist;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Checklist;Emergency med ED Checklist;;ACTIVE;2.70;2.7 +97662-1;Discharge instructions;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Discharge instructions;Emergency med ED Discharge instruct;;ACTIVE;2.70;2.7 +97663-9;Discharge summary note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Discharge summary;Emergency med ED D/C sum;;ACTIVE;2.70;2.73 +97664-7;Discharge teaching note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Discharge teaching note;Emergency med ED Discharge teach note;;ACTIVE;2.70;2.7 +97665-4;Education note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Education note;Emergency med ED Educ note;;ACTIVE;2.70;2.7 +97666-2;History and physical note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department History and physical note;Emergency med ED H&P note;;ACTIVE;2.70;2.7 +9766-7;Lymphocytic choriomeningitis virus Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Lymphocytic choriomeningitis virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;LCMV IgG Titr CSF IF;;ACTIVE;1.0i;2.73 +97667-0;Initial evaluation note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Initial evaluation note;Emergency med ED Initial eval note;;ACTIVE;2.70;2.7 +97668-8;Procedure note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department procedure note;Emergency med ED Procedure note;;ACTIVE;2.70;2.7 +97669-6;Progress note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Progress note;Emergency med ED Prog note;;ACTIVE;2.70;2.73 +97670-4;Transfer summary note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Transfer summary note;Emergency med ED Transfer sum note;;ACTIVE;2.70;2.7 +97671-2;Triage note;Find;Pt;Emergency department;Doc;Emergency medicine;DOC.ONTOLOGY;2;Emergency medicine Emergency department Triage note;Emergency med ED Triage note;;ACTIVE;2.70;2.7 +97672-0;History and physical note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology History and physical note;IC H&P note;;ACTIVE;2.70;2.7 +97673-8;History and physical note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology History and physical note;IR H&P note;;ACTIVE;2.70;2.7 +97674-6;History and physical note;Find;Pt;{Setting};Doc;Pulmonary disease;DOC.ONTOLOGY;2;Pulmonary History and physical note;Pulmonary disease H&P note;;ACTIVE;2.70;2.7 +9767-5;Lymphocytic choriomeningitis virus Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Titer] in Serum by Immunofluorescence;LCMV IgM Titr Ser IF;;ACTIVE;1.0i;2.73 +97675-3;History and physical note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery History and physical note;OMS H&P note;;ACTIVE;2.70;2.7 +97676-1;History and physical note;Find;Pt;{Setting};Doc;Anesthesiology;DOC.ONTOLOGY;2;Anesthesiology History and physical note;Anesthesiology H&P note;;ACTIVE;2.70;2.7 +97677-9;History and physical note;Find;Pt;{Setting};Doc;Burn management;DOC.ONTOLOGY;2;Burn management History and physical note;Burn H&P note;;ACTIVE;2.70;2.7 +97678-7;History and physical note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery History and physical note;Col+rec surg H&P note;;ACTIVE;2.70;2.7 +97679-5;History and physical note;Find;Pt;{Setting};Doc;Nutrition and dietetics;DOC.ONTOLOGY;2;Nutrition and dietetics History and physical note;Nutr+diet H&P note;;ACTIVE;2.70;2.7 +97680-3;History and physical note;Find;Pt;{Setting};Doc;Infectious disease;DOC.ONTOLOGY;2;Infectious disease History and physical note;Infectious disease H&P note;;ACTIVE;2.70;2.7 +97681-1;History and physical note;Find;Pt;{Setting};Doc;Nurse;DOC.ONTOLOGY;2;Nurse History and physical note;Nurse H&P note;;ACTIVE;2.70;2.7 +97682-9;History and physical note;Find;Pt;{Setting};Doc;Pharmacology;DOC.ONTOLOGY;2;Pharmacology History and physical note;Pharmacology H&P note;;ACTIVE;2.70;2.7 +9768-3;Lymphocytic choriomeningitis virus Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Lymphocytic choriomeningitis virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;LCMV IgM Titr CSF IF;;ACTIVE;1.0i;2.73 +97683-7;History and physical note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology History and physical note;Radiation Onc H&P note;;ACTIVE;2.70;2.7 +97684-5;History and physical note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology History and physical note;Radiology H&P note;;ACTIVE;2.70;2.7 +97685-2;History and physical note;Find;Pt;{Setting};Doc;Rheumatology;DOC.ONTOLOGY;2;Rheumatology History and physical note;Rheumatology H&P note;;ACTIVE;2.70;2.7 +97686-0;History and physical note;Find;Pt;{Setting};Doc;Trauma;DOC.ONTOLOGY;2;Trauma History and physical note;Trauma H&P note;;ACTIVE;2.70;2.7 +97687-8;Evaluation note;Find;Pt;{Setting};Doc;Burn management;DOC.ONTOLOGY;2;Burn management Evaluation note;Burn Eval note;;ACTIVE;2.70;2.7 +97688-6;Evaluation note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Evaluation note;Fam Med Eval note;;ACTIVE;2.70;2.7 +97689-4;Evaluation note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Evaluation note;IC Eval note;;ACTIVE;2.70;2.7 +97690-2;Discharge summary note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Discharge summary;IC D/C sum;;ACTIVE;2.70;2.73 +9769-1;Thermoactinomyces candidus Ab;ACnc;Pt;Ser;OrdQn;;MICRO;1;Deprecated Thermoactinomyces candidus Ab;Deprecated T candidus Ab Ser;;DEPRECATED;1.0i;2.36 +97691-0;Progress note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology Progress note;IC Prog note;;ACTIVE;2.70;2.73 +97692-8;Procedure note;Find;Pt;{Setting};Doc;Interventional cardiology;DOC.ONTOLOGY;2;Interventional cardiology procedure note;IC Procedure note;;ACTIVE;2.70;2.7 +97693-6;Surgical operation note;Find;Pt;{Setting};Doc;Interventional radiology;DOC.ONTOLOGY;2;Interventional radiology Surgical operation note;IR Operative note;;ACTIVE;2.70;2.7 +97694-4;Evaluation note;Find;Pt;{Setting};Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Evaluation note;Mat fetal med Eval note;;ACTIVE;2.70;2.73 +97695-1;Evaluation note;Find;Pt;{Setting};Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant Evaluation note;Solid Org Transplant Eval note;;ACTIVE;2.70;2.7 +97696-9;Evaluation note;Find;Pt;{Setting};Doc;Psychiatry;DOC.ONTOLOGY;2;Psychiatry Evaluation note;Psychiatric Eval note;;ACTIVE;2.70;2.7 +97697-7;Evaluation note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Evaluation note;Radiation Onc Eval note;;ACTIVE;2.70;2.7 +97698-5;Evaluation note;Find;Pt;{Setting};Doc;Radiology;DOC.ONTOLOGY;2;Radiology Evaluation note;Radiology Eval note;;ACTIVE;2.70;2.7 +97699-3;Evaluation note;Find;Pt;{Setting};Doc;Pastoral care;DOC.ONTOLOGY;2;Pastoral care Evaluation note;Pastoral Care Eval note;;ACTIVE;2.70;2.7 +97700-9;Discharge summary note;Find;Pt;{Setting};Doc;Burn management;DOC.ONTOLOGY;2;Burn management Discharge summary;Burn D/C sum;;ACTIVE;2.70;2.73 +97701-7;Discharge summary note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Discharge summary;Gyn Onc D/C sum;;ACTIVE;2.70;2.73 +97702-5;Discharge summary note;Find;Pt;{Setting};Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine Discharge summary;Mat fetal med D/C sum;;ACTIVE;2.70;2.73 +97703-3;Discharge summary note;Find;Pt;{Setting};Doc;Oral and maxillofacial surgery;DOC.ONTOLOGY;2;Oral and Maxillofacial Surgery Discharge summary;OMS D/C sum;;ACTIVE;2.70;2.73 +97704-1;Discharge summary note;Find;Pt;{Setting};Doc;Radiation oncology;DOC.ONTOLOGY;2;Radiation oncology Discharge summary;Radiation Onc D/C sum;;ACTIVE;2.70;2.73 +97705-8;Surgical operation note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology Surgical operation note;Gyn Onc Operative note;;ACTIVE;2.70;2.7 +97706-6;Procedure note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program procedure note;Multi-spec prog Procedure note;;ACTIVE;2.70;2.7 +97707-4;Procedure note;Find;Pt;{Setting};Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant procedure note;Solid Org Transplant Procedure note;;ACTIVE;2.70;2.7 +97708-2;Evaluation note;Find;Pt;{Setting};Doc;Multi-specialty program;DOC.ONTOLOGY;2;Multi-specialty program Evaluation note;Multi-spec prog Eval note;;ACTIVE;2.70;2.7 +9770-9;Thermoactinomyces sacchari Ab;ACnc;Pt;Ser;OrdQn;;MICRO;1;Deprecated Thermoactinomyces sacchari Ab;Deprecated T sacchari Ab Ser;;DEPRECATED;1.0i;2.36 +97709-0;Letter;Find;Pt;{Setting};Doc;Mental health;DOC.ONTOLOGY;2;Mental health Letter;Mental health Letter;;ACTIVE;2.70;2.7 +97710-8;Conference note;Find;Pt;{Setting};Doc;Cardiovascular disease.team;DOC.ONTOLOGY;2;Cardiology Team Conference note;Cardiology Team Conf eval note;;ACTIVE;2.70;2.7 +97711-6;Note;Find;Pt;Outpatient;Doc;Heart failure;DOC.ONTOLOGY;2;Heart failure Outpatient Note;Heart failure OP Note;;ACTIVE;2.70;2.7 +97712-4;Procedure note;Find;Pt;{Setting};Doc;Neuropsychology;DOC.ONTOLOGY;2;Neuropsychology procedure note;Neuropsych Procedure note;;ACTIVE;2.70;2.7 +97713-2;Evaluation note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Evaluation note;Hand Surgery Eval note;;ACTIVE;2.70;2.7 +97714-0;Discharge summary note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Discharge summary;Hand Surgery D/C sum;;ACTIVE;2.70;2.73 +97715-7;History and physical note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand History and physical note;Hand Surgery H&P note;;ACTIVE;2.70;2.7 +97716-5;Procedure note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand procedure note;Hand Surgery Procedure note;;ACTIVE;2.70;2.7 +9771-7;Cells.CD5+CD20+;NCnc;Pt;WBC;Qn;;CELLMARK;1;CD5+CD20+ cells [#/volume] in Leukocytes;CD5+CD20+ Cells # WBC;;ACTIVE;1.0i;2.42 +97717-3;Surgical operation note;Find;Pt;{Setting};Doc;Surgery of the hand;DOC.ONTOLOGY;2;Surgery of the hand Surgical operation note;Hand Surgery Operative note;;ACTIVE;2.70;2.7 +97718-1;Evaluation note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Evaluation note;Hepatology Eval note;;ACTIVE;2.70;2.7 +97719-9;Discharge summary note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Discharge summary;Hepatology D/C sum;;ACTIVE;2.70;2.73 +97720-7;History and physical note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology History and physical note;Hepatology H&P note;;ACTIVE;2.70;2.7 +97721-5;Surgical operation note;Find;Pt;{Setting};Doc;Hepatology;DOC.ONTOLOGY;2;Hepatology Surgical operation note;Hepatology Operative note;;ACTIVE;2.70;2.7 +97722-3;Evaluation note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology Evaluation note;Hematology Eval note;;ACTIVE;2.70;2.7 +97723-1;History and physical note;Find;Pt;{Setting};Doc;Hematology;DOC.ONTOLOGY;2;Hematology History and physical note;Hematology H&P note;;ACTIVE;2.70;2.7 +97724-9;Evaluation note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Evaluation note;Sleep med Eval note;;ACTIVE;2.70;2.7 +9772-5;Xylose^1H post 25 g xylose PO;MCnc;Pt;Bld;Qn;;CHAL;1;Xylose [Mass/volume] in Blood --1 hour post 25 g xylose PO;Xylose 1h p 25 g Xyl PO Bld-mCnc;;ACTIVE;1.0i;2.4 +97725-6;Discharge summary note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine Discharge summary;Sleep med D/C sum;;ACTIVE;2.70;2.73 +97726-4;History and physical note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine History and physical note;Sleep med H&P note;;ACTIVE;2.70;2.7 +97727-2;Procedure note;Find;Pt;{Setting};Doc;Sleep medicine;DOC.ONTOLOGY;2;Sleep medicine procedure note;Sleep med Procedure note;;ACTIVE;2.70;2.7 +97728-0;History and physical note;Find;Pt;{Setting};Doc;Occupational therapy;DOC.ONTOLOGY;2;Occupational therapy History and physical note;OT H&P note;;ACTIVE;2.70;2.7 +97729-8;History and physical note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy History and physical note;Rec therapy H&P note;;ACTIVE;2.70;2.7 +97730-6;History and physical note;Find;Pt;{Setting};Doc;Respiratory therapy;DOC.ONTOLOGY;2;Respiratory therapy History and physical note;Resp therapy H&P note;;ACTIVE;2.70;2.7 +97731-4;Stroke prevention note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Stroke prevention note;OP Stroke prevention note;;ACTIVE;2.70;2.7 +97732-2;Enterovirus VP1 gene;Seq;Pt;Isolate;Nom;Sequencing;MICRO;1;Enterovirus VP1 gene [Nucleotide sequence] in Isolate by Sequencing;EV VP1 gene Islt-Seq;;ACTIVE;2.70;2.7 +9773-3;Ergotamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Ergotamine [Mass/volume] in Serum or Plasma;Ergotamine SerPl-mCnc;;ACTIVE;1.0i;2.42 +97733-0;Influenza virus types A & B & subtypes RNA panel;-;Pt;XXX;-;Probe.amp.tar;PANEL.MICRO;1;Influenza virus types A and B and subtypes RNA panel - Specimen by NAA with probe detection;FLUAV + FLUBV + subtyp Pnl Spec NAA+prb;;ACTIVE;2.70;2.7 +97734-8;Inability to stop drinking once started;Find;1Y;^Patient;Ord;;SURVEY.GNHLTH;4;Inability to stop drinking once started;;;ACTIVE;2.70;2.7 +97735-5;Failed expectations due to drinking;Find;1Y;^Patient;Ord;;SURVEY.GNHLTH;4;Failed expectations due to drinking;;;ACTIVE;2.70;2.7 +97736-3;Drink needed in morning to begin activities after drinking session;Find;1Y;^Patient;Ord;;SURVEY.GNHLTH;4;Drink needed in morning to begin activities after drinking session;;;ACTIVE;2.70;2.7 +97737-1;Guilt or remorse after drinking;Find;1Y;^Patient;Ord;;SURVEY.GNHLTH;4;Guilt or remorse after drinking;;;ACTIVE;2.70;2.7 +97738-9;Inability to recall events from night before due to drinking;Find;1Y;^Patient;Ord;;SURVEY.GNHLTH;4;Inability to recall events from night before due to drinking;;;ACTIVE;2.70;2.7 +97739-7;Injury to you or someone else resulting from drinking;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Injury to you or someone else resulting from drinking;;;ACTIVE;2.70;2.7 +97740-5;Has anyone expressed concern about your drinking or suggested you cut down;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Has anyone expressed concern about your drinking or suggested you cut down;;;ACTIVE;2.70;2.7 +9774-1;Metoclopramide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Metoclopramide [Mass/volume] in Serum or Plasma;Metoclopramide SerPl-mCnc;;ACTIVE;1.0i;2.42 +97741-3;Estradiol;SCnc;Pt;Asp;Qn;;CHEM;1;Estradiol (E2) [Moles/volume] in Aspirate;Estradiol Aspirate-sCnc;;ACTIVE;2.70;2.7 +97742-1;Estradiol;MCnc;Pt;Asp;Qn;;CHEM;1;Estradiol (E2) [Mass/volume] in Aspirate;Estradiol Aspirate-mCnc;;ACTIVE;2.70;2.7 +97743-9;Cancer Ag 125;ACnc;Pt;Asp;Qn;;CHEM;1;Cancer Ag 125 [Units/volume] in Aspirate;Cancer Ag125 Aspirate-aCnc;;ACTIVE;2.70;2.7 +97744-7;Enolase.neuron specific;MCnc;Pt;Asp;Qn;;CHEM;1;Enolase.neuron specific [Mass/volume] in Aspirate;NSE Aspirate-mCnc;;ACTIVE;2.70;2.7 +97745-4;Alpha-1-Fetoprotein;ACnc;Pt;Asp;Qn;;CHEM;1;Alpha-1-Fetoprotein [Units/volume] in Aspirate;AFP Aspirate-aCnc;;ACTIVE;2.70;2.7 +97746-2;Alpha-1-Fetoprotein;MCnc;Pt;Asp;Qn;;CHEM;1;Alpha-1-Fetoprotein [Mass/volume] in Aspirate;AFP Aspirate-mCnc;;ACTIVE;2.70;2.7 +97747-0;Carcinoembryonic Ag;MCnc;Pt;Asp;Qn;;CHEM;1;Carcinoembryonic Ag [Mass/volume] in Aspirate;CEA Aspirate-mCnc;;ACTIVE;2.70;2.7 +97748-8;Cytokeratin 19;MCnc;Pt;Asp;Qn;;CHEM;1;Cytokeratin 19 [Mass/volume] in Aspirate;CK 19 Aspirate-mCnc;;ACTIVE;2.70;2.7 +97749-6;Cancer Ag 15-3;ACnc;Pt;Asp;Qn;;CHEM;1;Cancer Ag 15-3 [Units/volume] in Aspirate;Cancer Ag15-3 Aspirate-aCnc;;ACTIVE;2.70;2.7 +97750-4;Cancer Ag 19-9;ACnc;Pt;Asp;Qn;;CHEM;1;Cancer Ag 19-9 [Units/volume] in Aspirate;Cancer Ag19-9 Aspirate-aCnc;;ACTIVE;2.70;2.7 +97751-2;Amiodarone+Desethylamiodarone;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Amiodarone+Desethylamiodarone [Moles/volume] in Serum or Plasma;Amiodarone+Deseth SerPl-sCnc;;ACTIVE;2.70;2.7 +97752-0;Herpes virus 6 DNA;LnCnc;Pt;CSF;Qn;Probe.amp.tar;MICRO;1;Herpes virus 6 DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection;HHV6 DNA CSF NAA+probe-Log#;;ACTIVE;2.70;2.7 +97753-8;Ammonia;SCnt;Pt;Stool;Qn;;CHEM;1;Ammonia [Moles/mass] in Stool;Ammonia Stl-sCnt;;ACTIVE;2.70;2.7 +97754-6;Oxalate;SCnc;Pt;Body fld;Qn;;CHEM;1;Oxalate [Moles/volume] in Body fluid;Oxalate Fld-sCnc;;ACTIVE;2.70;2.7 +97755-3;Oxalate;MCnc;Pt;Body fld;Qn;;CHEM;1;Oxalate [Mass/volume] in Body fluid;Oxalate Fld-mCnc;;ACTIVE;2.70;2.7 +97756-1;Androstenedione;MCnc;Pt;Body fld;Qn;;CHEM;1;Androstenedione [Mass/volume] in Body fluid;Androst Fld-mCnc;;ACTIVE;2.70;2.7 +97757-9;Androstenedione;SCnc;Pt;Body fld;Qn;;CHEM;1;Androstenedione [Moles/volume] in Body fluid;Androst Fld-sCnc;;ACTIVE;2.70;2.7 +9775-8;Moricizine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Moricizine [Mass/volume] in Serum or Plasma;Moricizine SerPl-mCnc;;ACTIVE;1.0i;2.73 +97758-7;Fungus & Mycobacterium sp identified;Prid;Pt;Bld;Nom;Organism specific culture;MICRO;1;Fungus and Mycobacterium sp identified in Blood by Organism specific culture;Fung+Mycobact sp Bld Cult;;ACTIVE;2.70;2.7 +97759-5;Magnesium & phosphate & lactate panel;-;Pt;Ser/Plas;-;;PANEL.CHEM;1;Magnesium and phosphate and lactate panel - Serum or Plasma;Mg+Phos+Lact Pnl SerPl;;ACTIVE;2.70;2.7 +97760-3;MLH1 gene methylation analysis;Find;Pt;Bld;Doc;Molgen;MOLPATH;1;MLH1 gene methylation analysis in Blood by Molecular genetics method;MLH1 Methyl Anl Bld;;ACTIVE;2.70;2.7 +97761-1;MLH1 gene methylation analysis;Find;Pt;Tumor;Doc;Molgen;MOLPATH;1;MLH1 gene methylation analysis in Tumor by Molecular genetics method;MLH1 Methyl Anl Tumor;;ACTIVE;2.70;2.7 +97762-9;Parathyrin.intact;SCnc;Pt;Body fld;Qn;;CHEM;1;Parathyrin.intact [Moles/volume] in Body fluid;PTH-Intact Fld-sCnc;;ACTIVE;2.70;2.7 +97763-7;Beta 2 globulin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta 2 globulin/Protein.total in 24 hour Urine by Electrophoresis;Beta2 Glob 24h MFr Ur Elph;;ACTIVE;2.70;2.7 +97764-5;Beta 1 globulin/Protein.total;MFr;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta 1 globulin/Protein.total in 24 hour Urine by Electrophoresis;Beta1 Glob 24h MFr Ur Elph;;ACTIVE;2.70;2.7 +97765-2;Cortisol^post dose dexamethasone PO overnight;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Cortisol [Moles/volume] in Serum or Plasma --post dose dexamethasone PO overnight;Cortis p Dex overnight SerPl-sCnc;;ACTIVE;2.70;2.7 +9776-6;Norchlordiazepoxide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Norchlordiazepoxide [Mass/volume] in Serum or Plasma;Norchlordiazep SerPl-mCnc;;ACTIVE;1.0i;2.73 +97766-0;IgG subclass 2;MCnc;Pt;Body fld;Qn;;CHEM;1;IgG subclass 2 [Mass/volume] in Body fluid;IgG2 Fld-mCnc;;ACTIVE;2.70;2.7 +97767-8;IgG subclass 4;MCnc;Pt;Body fld;Qn;;CHEM;1;IgG subclass 4 [Mass/volume] in Body fluid;IgG4 Fld-mCnc;;ACTIVE;2.70;2.7 +97768-6;Artifact;Naric;Pt;Urine sed;Qn;Microscopy.light;UA;1;Artifact [#/area] in Urine sediment by Light microscopy;Artifact #/area UrnS Micro;;ACTIVE;2.70;2.7 +97769-4;Erythrocytes.nucleated;NCnc;Pt;BldCo;Qn;;HEM/BC;1;Nucleated erythrocytes [#/volume] in Cord blood;nRBC # BldCo;;ACTIVE;2.70;2.7 +97770-2;Bilirubin;SCnc;Pt;BldC;Qn;;CHEM;1;Bilirubin.total [Moles/volume] in Capillary blood;Bilirub BldC-sCnc;;ACTIVE;2.70;2.7 +97771-0;Protein.monoclonal band 1;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 1 [Mass/volume] in 24 hour Urine by Electrophoresis;M Protein 1 24h Ur Elph-mCnc;;ACTIVE;2.70;2.7 +97772-8;Protein.monoclonal band 1;MCnc;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 1 [Mass/volume] in Urine by Electrophoresis;M Protein 1 Ur Elph-mCnc;;ACTIVE;2.70;2.7 +97773-6;Base excess^^standard;SCnc;Pt;BldCoA;Qn;Calculated;CHEM;1;Base excess standard in Arterial cord blood by calculation;Base excess std BldCoA Calc-sCnc;;ACTIVE;2.70;2.7 +9777-4;Nalbuphine;MCnc;Pt;XXX;Qn;;DRUG/TOX;1;Nalbuphine [Mass/volume] in Specimen;Nalbuphine Spec-mCnc;;ACTIVE;1.0i;2.69 +97774-4;Base excess^^standard;SCnc;Pt;BldCoV;Qn;Calculated;CHEM;1;Base excess standard in Venous cord blood by calculation;Base excess std BldCoV Calc-sCnc;;ACTIVE;2.70;2.7 +97775-1;Base excess^^standard;SCnc;Pt;BldCo;Qn;Calculated;CHEM;1;Base excess standard in Cord blood by calculation;Base excess std BldCo Calc-sCnc;;ACTIVE;2.70;2.7 +97776-9;Urea^1H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Urea [Moles/volume] in Dialysis fluid --1 hour specimen;Urea 1h spec Dial fld-sCnc;;ACTIVE;2.70;2.7 +97777-7;Creatinine^1H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Creatinine [Moles/volume] in Dialysis fluid --1 hour specimen;Creat 1h spec Dial fld-sCnc;;ACTIVE;2.70;2.7 +97778-5;Glucose^1H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Glucose [Moles/volume] in Dialysis fluid --1 hour specimen;Glucose 1h spec Dial fld-sCnc;;ACTIVE;2.70;2.7 +97779-3;Sodium^1H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Sodium [Moles/volume] in Dialysis fluid --1 hour specimen;Sodium 1h spec Dial fld-sCnc;;ACTIVE;2.70;2.7 +97780-1;Sodium^2H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Sodium [Moles/volume] in Dialysis fluid --2 hour specimen;Sodium 2h spec Dial fld-sCnc;;ACTIVE;2.70;2.7 +97781-9;Sodium^4H specimen;SCnc;Pt;Dial fld;Qn;;CHEM;1;Sodium [Moles/volume] in Dialysis fluid --4 hour specimen;Sodium 4h spec Dial fld-sCnc;;ACTIVE;2.70;2.7 +9778-2;Phenelzine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Phenelzine [Mass/volume] in Serum or Plasma;Phenelzine SerPl-mCnc;;ACTIVE;1.0i;2.73 +97782-7;Spine Tango Surgery 2017;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Spine Tango Surgery 2017;Spine Tango Surgery 2017;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.72 +97783-5;Admission or pathology panel;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Admission or pathology panel Spine Tango;Admission/path pnl Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.72 +97784-3;Specification of main pathology panel;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Specification of main pathology panel Spine Tango;Main pathology pnl Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.72 +97785-0;Spine degeneration.primary;Type;Pt;^Patient;Nom;;SURG;2;Type of spine degeneration.primary;Primary spine degen type;;ACTIVE;2.70;2.7 +97786-8;Spine degeneration.secondary;Type;Pt;^Patient;Nom;;SURG;2;Type of spine degeneration.secondary;Second spine degen type;;ACTIVE;2.70;2.7 +97787-6;Spine deformity;Type;Pt;^Patient;Nom;;SURG;2;Type of spine deformity;Spine deformity type;;ACTIVE;2.70;2.7 +97788-4;Primary etiology of spine deformity;Find;Pt;^Patient;Nom;;SURG;2;Primary etiology of spine deformity;Prim etiology spine deform;;ACTIVE;2.70;2.7 +97789-2;Fracture or trauma;Type;Pt;^Patient;Nom;;SURG;2;Fracture or trauma;Fracture/trauma;;ACTIVE;2.70;2.7 +977-9;D Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;D Ag [Presence] on Red Blood Cells from Donor;D Ag RBC Donr Ql;;ACTIVE;1.0;2.73 +9779-0;quiNIDine.free;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;quiNIDine Free [Mass/volume] in Serum or Plasma;quiNIDine Free SerPl-mCnc;;ACTIVE;1.0i;2.4 +97790-0;Dens fracture;Type;Pt;^Patient;Nom;;SURG;2;Type of dens fracture;Dens fracture type;;ACTIVE;2.70;2.7 +97791-8;C3-L5 or S1 AO fracture;Type;Pt;^Patient;Nom;;SURG;2;Type of C3-L5 or S1 AO fracture;C3-L5 or S1 AO fracture type;;ACTIVE;2.70;2.7 +97792-6;AO neurologic injury;Type;Pt;^Patient;Nom;;SURG;2;AO neurologic injury;AO neurologic injury;;ACTIVE;2.70;2.7 +97793-4;AO modifiers;Type;Pt;^Patient;Nom;;SURG;2;AO modifiers;AO modifiers;;ACTIVE;2.70;2.7 +97794-2;Cause of pathological spine fracture;Find;Pt;^Patient;Nom;;SURG;2;Cause of pathological spine fracture;Path spine fracture cause;;ACTIVE;2.70;2.7 +97795-9;Fracture age;Find;Pt;^Patient;Nom;;SURG;2;Fracture age;Fracture age;;ACTIVE;2.70;2.7 +97796-7;Osteoporotic vertebral fractures classification;Type;Pt;^Patient;Nom;;SURG;2;Osteoporotic vertebral fractures classification;Osteo vertebral frac class;;ACTIVE;2.70;2.7 +97797-5;Spondylolisthesis;Type;Pt;^Patient;Nom;;SURG;2;Type of spondylolisthesis;Spondylolisthesis type;;ACTIVE;2.70;2.7 +97798-3;Spondylolisthesis grade;Find;Pt;^Patient;Nom;;SURG;2;Spondylolisthesis grade;Spondylolisthesis grade;;ACTIVE;2.70;2.7 +97799-1;Spine infection;Type;Pt;^Patient;Nom;;SURG;2;Type of spine infection;Spine infection type;;ACTIVE;2.70;2.7 +97800-7;Structure affected by spine infection;Find;Pt;^Patient;Nom;;SURG;2;Structure affected by spine infection;Structure affected;;ACTIVE;2.70;2.7 +97801-5;Spine tumor;Type;Pt;^Patient;Nom;;SURG;2;Type of spine tumor;Spine tumor type;;ACTIVE;2.70;2.7 +97802-3;Spine tumor localization;Find;Pt;^Patient;Nom;;SURG;2;Spine tumor localization;Spine tumor loc;;ACTIVE;2.70;2.7 +97803-1;Reason for repeat spine surgery;Find;Pt;^Patient;Nom;;SURG;2;Reason for repeat spine surgery;Repeat spine surg reason;;ACTIVE;2.70;2.7 +97804-9;Most severely affected spine segment or vertebral body;Find;Pt;^Patient;Nom;;SURG;2;Most severely affected spine segment or vertebral body;Most affected spine segment;;ACTIVE;2.70;2.7 +97805-6;Extent of spine segment or vertebral body lesion;Find;Pt;^Patient;Nom;;SURG;2;Extent of spine segment or vertebral body lesion;Extent of spine lesion;;ACTIVE;2.70;2.7 +97806-4;Additional spine pathology;Find;Pt;^Patient;Nom;;SURG;2;Additional spine pathology;Additional pathology;;ACTIVE;2.70;2.7 +97807-2;Number of previous spine surgeries at same or adjacent level;Num;Pt;^Patient;Qn;;SURG;2;Number of previous spine surgeries at same or adjacent level;Num prev surg at/near level;;ACTIVE;2.70;2.7 +9780-8;Spermatozoa;NCnc;Pt;Semen;Qn;;FERT;1;Spermatozoa [#/volume] in Semen;Sperm # Smn;;ACTIVE;1.0i;2.73 +97808-0;Number of previous spine surgeries at other level;Num;Pt;^Patient;Qn;;SURG;2;Number of previous spine surgeries at other level;Num prev surg at other level;;ACTIVE;2.70;2.7 +97809-8;Surgery panel;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Surgery panel Spine Tango;Surg pnl Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.72 +97810-6;Surgeon;Pn;Pt;Provider;Nom;;SURG;2;Surgeon;Surgeon Provider;;ACTIVE;2.70;2.7 +97811-4;Surgery assistant;Pn;Pt;Provider;Nom;;SURG;2;Surgery assistant;Surg assistant Provider;;ACTIVE;2.70;2.7 +97812-2;Therapeutic goals of spine surgery;Find;Pt;^Patient;Nom;;SURG;2;Therapeutic goals of spine surgery;Therapeutic goals;;ACTIVE;2.70;2.7 +97813-0;Implant component;Find;Pt;^Patient;Nom;;SURG;2;Implant component;Implant;;ACTIVE;2.70;2.7 +97814-8;Anterior surgical access;Type;Pt;^Patient;Nom;;SURG;2;Type of anterior access;Anterior access type;;ACTIVE;2.70;2.7 +97815-5;Posterior surgical access;Type;Pt;^Patient;Nom;;SURG;2;Posterior surgical access;Posterior access;;ACTIVE;2.70;2.7 +9781-6;Acanthamoeba sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Acanthamoeba sp identified in Specimen by Organism specific culture;Acanthamoeba Spec Cult;;ACTIVE;1.0i;2.73 +97816-3;American society of anesthesiologists morbidity state;Find;Pt;^Patient;Nom;;SURG;2;American society of anesthesiologists morbidity state;ASA morbidity state;;ACTIVE;2.70;2.7 +97817-1;Surgical technology used;Type;Pt;^Patient;Nom;;SURG;2;Type of surgical technology used;Surgical tech used type;;ACTIVE;2.70;2.7 +97818-9;Blood product volume &or cell saver;Find;Pt;^Patient;Nom;;SURG;2;Blood product volume and/or cell saver;Bld prod vol/cell saver;;ACTIVE;2.70;2.7 +97819-7;Surgical measures panel;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Surgical measures panel Spine Tango;Surgical measures panel Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +97820-5;Spine decompression;Type;Pt;^Patient;Nom;;SURG;2;Type of spine decompression;Spine decompression type;;ACTIVE;2.70;2.7 +97821-3;Level of spine decompression;Find;Pt;^Patient;Nom;;SURG;2;Level of spine decompression;Spine decomp lvl;;ACTIVE;2.70;2.7 +97822-1;Spine fusion;Type;Pt;^Patient;Nom;;SURG;2;Spine fusion;Spine fusion;;ACTIVE;2.70;2.7 +97823-9;Level of spine fusion;Find;Pt;^Patient;Nom;;SURG;2;Level of spine fusion;Spine fusion lvl;;ACTIVE;2.70;2.7 +9782-4;Adenovirus sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Adenovirus sp identified in Specimen by Organism specific culture;Adenovirus Spec Cult;;ACTIVE;1.0i;2.73 +97824-7;Spine fusion material;Find;Pt;^Patient;Nom;;SURG;2;Spine fusion material;Spine fusion material;;ACTIVE;2.70;2.7 +97825-4;Rigid spine stabilization;Type;Pt;^Patient;Nom;;SURG;2;Type of rigid spine stabilization;Rigid spine stabilization type;;ACTIVE;2.70;2.7 +97826-2;Level of rigid spine stabilization;Find;Pt;^Patient;Nom;;SURG;2;Level of rigid spine stabilization;Rigid stablization lvl;;ACTIVE;2.70;2.7 +97827-0;Spine deformity correction;Type;Pt;^Patient;Nom;;SURG;2;Spine deformity correction;Spine deformity correction;;ACTIVE;2.70;2.7 +97828-8;Level of deformity correction;Find;Pt;^Patient;Nom;;SURG;2;Level of deformity correction;Defomity correction lvl;;ACTIVE;2.70;2.7 +97829-6;Motion preserving spine stablization;Type;Pt;^Patient;Nom;;SURG;2;Type of motion preserving spine stablization;Motion preserv stabl type;;ACTIVE;2.70;2.7 +97830-4;Level of motion preserving spine stablization;Find;Pt;^Patient;Nom;;SURG;2;Level of motion preserving spine stablization;Motion preserv stabl lvl;;ACTIVE;2.70;2.7 +97831-2;Spine surgery measures;Find;Pt;^Patient;Nom;;SURG;2;Spine surgery measures;Spine surgery measures;;ACTIVE;2.70;2.7 +9783-2;Ehrlichia chaffeensis Ab.IgG;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia chaffeensis IgG Ab [Titer] in Serum;E chaffeensis IgG Titr Ser;;ACTIVE;1.0i;2.73 +97832-0;Level of spine surgery measures;Find;Pt;^Patient;Nom;;SURG;2;Level of spine surgery measures;Spine surg measures lvl;;ACTIVE;2.70;2.7 +97833-8;Surgical complication^during surgery;Find;Pt;^Patient;Nom;;SURG;2;Surgical complication --during surgery;Surg comp in Surg;;ACTIVE;2.70;2.7 +97834-6;Measures used during spine surgery;Find;Pt;^Patient;Nom;;SURG;2;Measures used during spine surgery;Surgical measures;;ACTIVE;2.70;2.7 +97835-3;Medical complication^during surgery;Find;Pt;^Patient;Nom;;SURG;2;Medical complication --during surgery;Medical complication in Surg;;ACTIVE;2.70;2.7 +97836-1;Hospital stay panel;-;Pt;^Patient;-;Spine Tango;PANEL.SURG;2;Hospital stay panel Spine Tango;Hospital stay pnl Spine Tango;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.72 +97837-9;Postoperative surgical complication before discharge;Find;Pt;^Patient;Nom;;SURG;2;Postoperative surgical complication before discharge;Postop surg comp before discharge;;ACTIVE;2.70;2.7 +97838-7;Postoperative medical complication before discharge;Find;Pt;^Patient;Nom;;SURG;2;Postoperative medical complication before discharge;Postop med compl before discharge;;ACTIVE;2.70;2.7 +97839-5;Additional procedure after spine surgery;Find;Pt;^Patient;Nom;;SURG;2;Additional procedure after spine surgery;Add procedure post surg;;ACTIVE;2.70;2.7 +9784-0;Ehrlichia chaffeensis Ab.IgM;Titr;Pt;Ser;Qn;;MICRO;1;Ehrlichia chaffeensis IgM Ab [Titer] in Serum;E chaffeensis IgM Titr Ser;;ACTIVE;1.0i;2.73 +97840-3;Hospital stay description;Find;Pt;^Patient;Nom;;SURG;2;Hospital stay description;Hospital stay description;;ACTIVE;2.70;2.7 +97841-1;Status of surgical &or medical complication at discharge;Find;Pt;^Patient;Nom;;SURG;2;Status of surgical and/or medical complication at discharge;Surg/med complication at discharge;;ACTIVE;2.70;2.7 +97842-9;Achievement of therapeutic goals by discharge;Find;Pt;^Patient;Nom;;SURG;2;Achievement of therapeutic goals by discharge;Achieve goals by discharge;;ACTIVE;2.70;2.7 +97843-7;ASIA impairment scale;Find;Pt;^Patient;Nom;;SURG;2;ASIA impairment scale;ASIA scale;"American Spinal Injury Association: International Standards for Neurological Classification of Spinal Cord Injury, revised 2019; Richmond, VA. Used with permission.";ACTIVE;2.70;2.71 +97844-5;Blood pressure panel;Pres;24H^mean;^Patient;Qn;;PANEL.BP;2;Blood pressure panel 24 hour mean;BP Pnl 24h Mean;;ACTIVE;2.70;2.7 +97845-2;Name panel;-;Pt;Person;-;;PANEL.ADMIN;2;Name panel Person;Name panel Person;;ACTIVE;2.70;2.7 +97846-0;Name use;Find;Pt;Person;Nom;;ADMIN;2;Name use Person;Name use Person;;ACTIVE;2.70;2.7 +97847-8;Last name;Pn;Pt;Person;Nom;;ADMIN;2;Last (Family) name Person;Last name Person;;ACTIVE;2.70;2.7 +97848-6;First name;Pn;Pt;Person;Nom;;ADMIN;2;First (Given) name Person;First name Person;;ACTIVE;2.70;2.7 +97849-4;Name prefix;Pn;Pt;Person;Nom;;ADMIN;2;Name prefix Person;Name prefix Person;;ACTIVE;2.70;2.7 +97850-2;Name suffix;Pn;Pt;Person;Nom;;ADMIN;2;Name suffix Person;Name suffix Person;;ACTIVE;2.70;2.7 +97851-0;Subject;Find;Pt;Person;Nom;;ADMIN;2;Subject of Person;Subject of Person;;ACTIVE;2.70;2.7 +97852-8;COVID-19 clinical status;Find;Pt;^Patient;Ord;WHO classification;H&P.HX;2;COVID-19 clinical status by WHO classification;COVID-19 clinical status WHO;;ACTIVE;2.70;2.7 +97853-6;Anticomplementary activity;Titr;Pt;XXX;Qn;Comp fix;MICRO;1;Anticomplementary activity [Titer] in Specimen by Complement fixation;Anticompl Act Titr Spec CF;;ACTIVE;2.70;2.7 +97854-4;Paracoccidioides sp Ab;Titr;Pt;XXX;Qn;Comp fix;MICRO;1;Paracoccidioides sp Ab [Titer] in Specimen by Complement fixation;Paracoccidioides Ab Titr Spec CF;;ACTIVE;2.70;2.7 +97855-1;Blastomyces sp Ab;Titr;Pt;XXX;Qn;Comp fix;MICRO;1;Blastomyces sp Ab [Titer] in Specimen by Complement fixation;Blastomyces Ab Titr Spec CF;;ACTIVE;2.70;2.7 +97856-9;Histoplasma capsulatum yeast phase Ab;Titr;Pt;XXX;Qn;Comp fix;MICRO;1;Histoplasma capsulatum yeast phase Ab [Titer] in Specimen by Complement fixation;H capsul Yst Ab Titr Spec CF;;ACTIVE;2.70;2.7 +9785-7;Microscopic observation;Prid;Pt;Stool;Nom;Ova and parasite preparation;MICRO;1;Deprecated Microscopic observation [Identifier] in Stool by Ova and Parasite Preparation;Deprecated O and P Prep Stl;;DEPRECATED;1.0i;2.5 +97857-7;Histoplasma capsulatum mycelial phase Ab;Titr;Pt;XXX;Qn;Comp fix;MICRO;1;Histoplasma capsulatum mycelial phase Ab [Titer] in Specimen by Complement fixation;H capsul Myc Ab Titr Spec CF;;ACTIVE;2.70;2.7 +97858-5;Coccidioides sp Ab;Titr;Pt;XXX;Qn;Comp fix;MICRO;1;Coccidioides sp Ab [Titer] in Specimen by Complement fixation;Coccidioides Ab Titr Spec CF;;ACTIVE;2.70;2.7 +97859-3;Fungal Ab panel;-;Pt;XXX;-;Comp fix;PANEL.MICRO;1;Fungal Ab panel - Specimen by Complement fixation;Fungal Ab Pnl Spec CF;;ACTIVE;2.70;2.7 +97860-1;HIV 1 Ab panel;-;Pt;Ser/Plas;-;IB;PANEL.MICRO;1;HIV 1 Ab panel - Serum or Plasma by Immunoblot;HIV 1 Ab Pnl SerPl IB;;ACTIVE;2.70;2.7 +97861-9;HIV 2 Ab panel;-;Pt;Ser/Plas;-;IB;PANEL.MICRO;1;HIV 2 Ab panel - Serum or Plasma by Immunoblot;HIV 2 Ab Pnl SerPl IB;;ACTIVE;2.70;2.7 +97862-7;Herpes virus 8 Ab.IgG & IgM panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Herpes virus 8 IgG and IgM panel - Serum or Plasma;HHV8 IgG+IgM Pnl SerPl;;ACTIVE;2.70;2.7 +97863-5;Herpes virus 8 Ab.IgM;PrThr;Pt;Ser/Plas;Ord;IF;MICRO;1;Herpes virus 8 IgM Ab [Presence] in Serum or Plasma by Immunofluorescence;HHV8 IgM SerPl Ql IF;;ACTIVE;2.70;2.7 +97864-3;Parainfluenza virus 1 & 2 & 3 Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Parainfluenza virus 1 and 2 and 3 Ab panel - Serum or Plasma;HPIV1+2+3 Ab Pnl SerPl;;ACTIVE;2.70;2.7 +9786-5;Microscopic observation;Prid;Pt;Bld/Bone mar;Nom;Periodic acid-Schiff stain;MICRO;1;Microscopic observation [Identifier] in Blood or Marrow by Periodic acid-Schiff stain;PAS Stn Bld/Mar;;ACTIVE;1.0i;2.73 +97865-0;Chikungunya virus Ab.IgM & IgG panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Deprecated Chikungunya virus Ab.IgM and IgG panel - Serum or Plasma;Deprecated CHIKV IgG+IgM Pnl SerPl;;DEPRECATED;2.70;2.72 +97866-8;Chikungunya virus Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Chikungunya virus IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;CHIKV IgG SerPl IA-aCnc;;ACTIVE;2.70;2.7 +97867-6;Chikungunya virus Ab.IgM;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Chikungunya virus IgM Ab [Units/volume] in Serum or Plasma by Immunoassay;CHIKV IgM SerPl IA-aCnc;;ACTIVE;2.70;2.7 +97868-4;Yellow fever virus Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Yellow fever virus Ab panel - Serum or Plasma;Yel Fev Ab Pnl SerPl;;ACTIVE;2.70;2.7 +97869-2;Zika virus Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Zika virus Ab panel - Serum or Plasma;ZIKV Ab Pnl SerPl;;ACTIVE;2.70;2.7 +978-7;D Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;D Ag [Presence] on Red Blood Cells;D Ag RBC Ql;;ACTIVE;1.0;2.73 +97870-0;Zika virus Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Zika virus IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;ZIKV IgG SerPl IA-aCnc;;ACTIVE;2.70;2.7 +97871-8;Hantavirus Ab.IgG & IgM panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Hantavirus IgG and IgM panel - Serum or Plasma;Hantavir IgG+IgM Pnl SerPl;;ACTIVE;2.70;2.7 +97872-6;Rabies virus Ab panel;-;Pt;Ser/Plas;-;;PANEL.MICRO;1;Rabies virus Ab panel - Serum or Plasma;Rabies Ab Pnl SerPl;;ACTIVE;2.70;2.7 +9787-3;Sarcoptes scabiei identified;Prid;Pt;Skin;Nom;Microscopy.light;MICRO;1;Sarcoptes scabiei identified in Skin by Light microscopy;S scabiei Skin Micro;;ACTIVE;1.0i;2.73 +97873-4;Herpes virus 8 Ab.IgM;PrThr;Pt;Ser/Plas;Ord;;MICRO;1;Herpes virus 8 IgM Ab [Presence] in Serum or Plasma;HHV8 IgM SerPl Ql;;ACTIVE;2.70;2.7 +97874-2;Stay Independent panel;-;Pt;^Patient;-;Stay Independent;PANEL.SURVEY.GNHLTH;4;Stay Independent panel [Stay Independent];;;ACTIVE;2.70;2.71 +97875-9;Use or advised to use cane or walker for safety;Find;Pt;^Patient;Ord;;H&P.HX;2;Use or advised to use cane or walker for safety;Use AndOr advised cane or walker;;ACTIVE;2.70;2.7 +97876-7;Sometimes feel unsteady when walking;Find;Pt;^Patient;Ord;;H&P.HX;2;Sometimes feel unsteady when walking;Sometimes feel unsteady when walking;;ACTIVE;2.70;2.7 +97877-5;Use furniture to steady when walking;Find;Pt;^Patient;Ord;;H&P.HX;2;Use furniture to steady when walking;Use furniture to steady when walking;;ACTIVE;2.70;2.7 +97878-3;Worried about falling;Find;Pt;^Patient;Ord;;H&P.HX;2;Worried about falling;Worried about falling;;ACTIVE;2.70;2.7 +97879-1;Push with hands to stand up from chair;Find;Pt;^Patient;Ord;;H&P.HX;2;Push with hands to stand up from chair;Push with hands to stand up from chair;;ACTIVE;2.70;2.7 +97880-9;Trouble stepping up onto curb;Find;Pt;^Patient;Ord;;H&P.HX;2;Trouble stepping up onto curb;Trouble stepping up onto curb;;ACTIVE;2.70;2.7 +9788-1;Streptolysin O Ab;PrThr;Pt;Ser;Ord;;MICRO;1;Streptolysin O Ab [Presence] in Serum;ASO Ab Ser Ql;;ACTIVE;1.0i;2.73 +97881-7;Often rush to toilet;Find;Pt;^Patient;Ord;;H&P.HX;2;Often rush to toilet;Often rush to toilet;;ACTIVE;2.70;2.7 +97882-5;Loss of feeling in feet;Find;Pt;^Patient;Ord;;H&P.HX;2;Loss of feeling in feet;Loss of feeling in feet;;ACTIVE;2.70;2.7 +97883-3;Medication causes light-headedness or fatigue;Find;Pt;^Patient;Ord;;H&P.HX;2;Medication causes light-headedness or fatigue;Med causes light-headedness or fatigue;;ACTIVE;2.70;2.7 +97884-1;Taking medicine for sleep or mood;Find;Pt;^Patient;Ord;;H&P.HX;2;Taking medicine for sleep or mood;Taking medicine for sleep or mood;;ACTIVE;2.70;2.7 +97885-8;Stay Independent total score;Score;Pt;^Patient;Qn;Stay Independent;SURVEY.GNHLTH;4;Stay Independent total score [Stay Independent];;;ACTIVE;2.70;2.7 +97886-6;Core Outcome Measures Index for the Neck score;Score;Pt;^Patient;Qn;COMI;SURVEY.GNHLTH;4;Core Outcome Measures Index for the Neck score [COMI];;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +97887-4;Core Outcome Measures Index for the Back;-;Pt;^Patient;-;COMI;PANEL.SURVEY.GNHLTH;4;Core Outcome Measures Index for the Back [COMI];;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +97888-2;Which of the following problems related to your back condition troubles you the most;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Which of the following problems related to your back condition troubles you the most;;;ACTIVE;2.70;2.7 +97889-0;Core Outcome Measures Index for the Back score;Score;Pt;^Patient;Qn;COMI;SURVEY.GNHLTH;4;Core Outcome Measures Index for the Back score [COMI];;Copyright © 2020 EUROSPINE. All rights reserved.;ACTIVE;2.70;2.7 +97890-8;Sleep Panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Sleep panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.71 +97891-6;Sleep total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Sleep score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +97892-4;Go to sleep at the same time;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Go to sleep at the same time;;;ACTIVE;2.70;2.72 +97893-2;Wake up at the same time;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Wake up at the same time;;;ACTIVE;2.70;2.72 +97894-0;Wake up feeling refreshed;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Wake up feeling refreshed;;;ACTIVE;2.70;2.72 +97895-7;Sleep well;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Sleep well;;;ACTIVE;2.70;2.72 +97896-5;Self-care panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Self-care panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.71 +97897-3;Self-care total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Self-care total score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +97898-1;Manage diet well;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Manage diet well;;;ACTIVE;2.70;2.72 +9789-9;Carbamate pesticides;Type;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Carbamate pesticides [Type] in Serum or Plasma;Carbamate pesticides SerPl;;ACTIVE;1.0i;2.15 +97899-9;Manage physical activity well;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Manage physical activity well;;;ACTIVE;2.70;2.72 +97900-5;Manage weight well;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Manage weight well;;;ACTIVE;2.70;2.72 +97901-3;Manage medication well;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Manage medication well;;;ACTIVE;2.70;2.72 +97902-1;Fatigue panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Fatigue panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.71 +97903-9;Fatigue total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Fatigue total score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.70;2.7 +97904-7;Usually have enough energy;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Usually have enough energy;;;ACTIVE;2.70;2.72 +97905-4;Do not tire too quickly;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Do not tire too quickly;;;ACTIVE;2.70;2.72 +97906-2;Usually concentrate well;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Usually concentrate well;;;ACTIVE;2.70;2.72 +9790-7;Methyl bromide;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methyl bromide [Mass/volume] in Serum or Plasma;Me- Bromide SerPl-mCnc;;ACTIVE;1.0i;2.73 +97907-0;Can keep going if needed;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Can keep going if needed;;;ACTIVE;2.70;2.72 +97908-8;Oswestry Disability Index;-;Pt;^Patient;-;ODI;PANEL.SURVEY.GNHLTH;4;Oswestry Disability Index;;ODI © Jeremy Fairbank, 1980. All Rights Reserved.;ACTIVE;2.70;2.7 +97909-6;Oswestry disability index score;Score;Pt;^Patient;Qn;ODI;CLIN;2;Oswestry disability index score ODI;ODI score;ODI © Jeremy Fairbank, 1980. All Rights Reserved.;ACTIVE;2.70;2.7 +97910-4;Endogenous thrombin potential;TmSCnc;Pt;PPP;Qn;Chromo;COAG;1;Endogenous thrombin potential [Area under the curve] in Platelet poor plasma by Chromogenic method;ETP PPP Chro-AUC;;ACTIVE;2.70;2.7 +97911-2;Endogenous thrombin potential^after addition of Factor VIII Ab;TmSCnc;Pt;PPP;Qn;Chromo;COAG;1;Endogenous thrombin potential [Area under the curve] in Platelet poor plasma by Chromogenic method --after addition of factor VIII Ab;ETP p FVIII Ab PPP Chro-AUC;;ACTIVE;2.70;2.7 +97912-0;Thrombin peak;Sub;Pt;PPP;Qn;Chromo;COAG;1;Thrombin peak [Molar amount] in Platelet poor plasma by Chromogenic method;Thrombin peak sub PPP Qn Chro;;ACTIVE;2.70;2.7 +97913-8;Thrombin peak^after addition of Factor VIII Ab;Sub;Pt;PPP;Qn;Chromo;COAG;1;Thrombin peak [Molar amount] in Platelet poor plasma by Chromogenic method --after addition of factor VIII Ab;Thrombin peak p FVIII Ab sub PPP Qn Chro;;ACTIVE;2.70;2.7 +97914-6;Time to thrombin peak;Time;Pt;PPP;Qn;Chromo;COAG;1;Time to thrombin peak in Platelet poor plasma by Chromogenic method;Time to thrombin peak PPP Chro;;ACTIVE;2.70;2.7 +9791-5;Organochlorine pesticides;Type;Pt;Ser/Plas;Nom;;DRUG/TOX;1;Organochlorine pesticides [Type] in Serum or Plasma;OC Pesticides SerPl;;ACTIVE;1.0i;2.73 +97915-3;Thrombin generation test panel;-;Pt;PPP;-;;PANEL.COAG;1;Thrombin generation test panel - Platelet poor plasma;TGT Pnl PPP;;ACTIVE;2.70;2.7 +97916-1;Coccidioides sp DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Coccidioides sp DNA [Presence] in Specimen by NAA with probe detection;Coccidioides DNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97917-9;Oropouche virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Oropouche virus RNA [Presence] in Specimen by NAA with probe detection;Oropouche virus RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97918-7;Rift valley fever virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rift valley fever virus RNA [Presence] in Specimen by NAA with probe detection;RVFV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97919-5;Bwamba virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bwamba virus RNA [Presence] in Specimen by NAA with probe detection;Bwamba virus RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97920-3;Tick-borne encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Tick-borne encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;TBEV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97921-1;Bunyamwera virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bunyamwera virus RNA [Presence] in Specimen by NAA with probe detection;Bunyamwera virus RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97922-9;California encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;California encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;CEV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +9792-3;Organophosphate pesticides;Prid;Pt;Bld;Nom;;DRUG/TOX;1;Organophosphate pesticides [Identifier] in Blood;OP Pesticides Bld;;ACTIVE;1.0i;2.07 +97923-7;Sandfly fever Naples virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Sandfly fever Naples virus RNA [Presence] in Specimen by NAA with probe detection;SFNV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97924-5;Jamestown canyon virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Jamestown canyon virus RNA [Presence] in Specimen by NAA with probe detection;JCV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97925-2;Barmah forest virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Barmah forest virus RNA [Presence] in Specimen by NAA with probe detection;BFV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97926-0;Snowshoe hare virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Snowshoe hare virus RNA [Presence] in Specimen by NAA with probe detection;SSHV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97927-8;Tahyna virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Tahyna virus RNA [Presence] in Specimen by NAA with probe detection;TAHV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97928-6;Highlands J virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Highlands J virus RNA [Presence] in Specimen by NAA with probe detection;HJV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97929-4;Ross River virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ross River virus RNA [Presence] in Specimen by NAA with probe detection;RRV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97930-2;Sindbis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Sindbis virus RNA [Presence] in Specimen by NAA with probe detection;SINV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +9793-1;Trichloroethylene;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Trichloroethylene [Mass/volume] in Urine;TCY Ur-mCnc;;ACTIVE;1.0i;2.42 +97931-0;Mayaro virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Mayaro virus RNA [Presence] in Specimen by NAA with probe detection;MAYV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97932-8;Colorado tick fever virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Colorado tick fever virus RNA [Presence] in Specimen by NAA with probe detection;CTFV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97933-6;Sandfly fever Sicilian virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Sandfly fever Sicilian virus RNA [Presence] in Specimen by NAA with probe detection;SFSV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97934-4;Toscana virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Toscana virus RNA [Presence] in Specimen by NAA with probe detection;TOSV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97935-1;Bourbon virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Bourbon virus RNA [Presence] in Specimen by NAA with probe detection;Bourbon virus RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97936-9;Candida auris DNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Candida auris DNA [Presence] in Specimen by NAA with probe detection;C auris DNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97937-7;Thermotolerance;Find;Pt;Isolate;Nom;Culture;MICRO;1;Thermotolerance in Isolate by Culture;Thermotol Islt Cult;;ACTIVE;2.70;2.7 +97938-5;Color.reverse pigment;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.reverse pigment [Type] in Isolate by Culture;Rev Pigmnt Color Islt Cult;;ACTIVE;2.70;2.7 +97939-3;Medium induced in vitro yeast conversion;Prid;Pt;Isolate;Nom;Culture;MICRO;1;Medium induced in vitro yeast conversion [Identifier] in Isolate by Culture;In Vitro Conversion Yst Islt Cult;;ACTIVE;2.70;2.7 +97940-1;Cryptococcus sp;PrThr;Pt;Isolate;Ord;Organism specific culture;MICRO;1;Cryptococcus sp [Presence] in Isolate by Organism specific culture;Cryptoc Islt Ql Cult;;ACTIVE;2.70;2.7 +97941-9;Cycloheximide;Susc;Pt;Isolate;Ord;;MICRO;1;Cycloheximide [Susceptibility] in Isolate Qualitative;Cycloheximide Islt Ql-Susc;;ACTIVE;2.70;2.7 +97942-7;Texture.yeast colony;Type;Pt;Isolate;Nom;Culture;MICRO;1;Texture.yeast colony [Type] in Isolate by Culture;Yeast Texture Islt Cult;;ACTIVE;2.70;2.7 +97943-5;Color.yeast colony;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.yeast colony [Type] in Isolate by Culture;Yeast Color Islt Cult;;ACTIVE;2.70;2.7 +97944-3;Color.yeast colony^with canavanine glycine+bromothymol blue;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.yeast colony [Type] in Isolate by Culture--with canavanine glycine+bromothymol blue;Yeast Color w CGB Islt Cult;;ACTIVE;2.70;2.7 +97945-0;Color.mold colony;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.mold colony [Type] in Isolate by Culture;Mold Color Islt Cult;;ACTIVE;2.70;2.7 +97946-8;Color.fungal colony^with Chromogenic agar;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.fungal colony [Type] in Isolate by Culture--with Chromogenic agar;Fungal Color w Chrom Agar Islt Cult;;ACTIVE;2.70;2.7 +97947-6;Rocio virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Rocio virus RNA [Presence] in Specimen by NAA with probe detection;Rocio virus RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97948-4;Ilheus virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Ilheus virus RNA [Presence] in Specimen by NAA with probe detection;ILHV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +9794-9;Cathepsin D;SCnt;Pt;Tiss;Qn;;CHEM;1;Cathepsin D [Moles/mass] in Tissue;Cathepsin D Tiss-sCnt;;ACTIVE;1.0i;2.42 +97949-2;Semliki Forest virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Semliki Forest virus RNA [Presence] in Specimen by NAA with probe detection;SFV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +979-5;D little i super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Di sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Di sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +97950-0;Onyong-nyong virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Onyong-nyong virus RNA [Presence] in Specimen by NAA with probe detection;ONN virus RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97951-8;Venezuelan equine encephalitis virus RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Venezuelan equine encephalitis virus RNA [Presence] in Specimen by NAA with probe detection;VEEV RNA Spec Ql NAA+probe;;ACTIVE;2.70;2.7 +97952-6;Glomerular filtration rate/Body surface area;ArVRat;Pt;Ser/Plas;Qn;Creatinine-based formula (CKD-EPI);CHEM;1;Deprecated Glomerular filtration rate/Body surface area [Volume Rate/Area] in Serum or Plasma by Creatinine-based formula (CKD-EPI);Deprecated GFR/BSA SerPl CKD-EPI-ArVRat;;DEPRECATED;2.70;2.72 +97953-4;Risk level of developing disease after exposure;Find;Pt;^Patient;Ord;;CLIN.RISK;2;Risk level of developing disease after exposure;Risk lvl devel dis exposure;;ACTIVE;2.70;2.7 +97954-2;Rhinovirus+Enterovirus A+B+C RNA;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;Rhinovirus+Enterovirus A+B+C RNA [Presence] in Respiratory specimen by NAA with probe detection;RV+EV-A+B+C RNA Resp Ql NAA+probe;;ACTIVE;2.70;2.7 +97955-9;Vespa crabro Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;European Hornet IgG4 Ab [Mass/volume] in Serum;European Hornet IgG4-mCnc;;ACTIVE;2.70;2.7 +9795-6;Composition;Type;Pt;Calculus;Nom;;PATH;1;Composition in Stone;Compn Stone;;ACTIVE;1.0i;2.73 +97956-7;Lysozyme Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Lysozyme IgG4 Ab [Mass/volume] in Serum;Lysozyme IgG4-mCnc;;ACTIVE;2.70;2.7 +97957-5;Anisakis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Anisakis IgG4 Ab [Mass/volume] in Serum;Anisakis IgG4-mCnc;;ACTIVE;2.70;2.7 +97958-3;Platanus acerifolia Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;London Plane IgG4 Ab [Mass/volume] in Serum;London Plane IgG4-mCnc;;ACTIVE;2.70;2.7 +97959-1;Betula verrucosa recombinant (rBet v) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 1 IgG4 Ab [Mass/volume] in Serum;Silver Birch (rBet v) 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97960-9;Olea europaea native (nOle e) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Olive pollen native (nOle e) 1 IgG4 Ab [Mass/volume] in Serum;Olive (nOle e) 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97961-7;Fraxinus excelsior Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;European Ash IgG4 Ab [Mass/volume] in Serum;European Ash IgG4-mCnc;;ACTIVE;2.70;2.7 +97962-5;Alnus incana Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grey Alder IgG4 Ab [Mass/volume] in Serum;Grey Alder IgG4-mCnc;;ACTIVE;2.70;2.7 +97963-3;Betula verrucosa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch IgG4 Ab [Mass/volume] in Serum;Silver Birch IgG4-mCnc;;ACTIVE;2.70;2.7 +9796-4;Color;Type;Pt;Calculus;Nom;;SPEC;1;Color of Stone;Color Stone;;ACTIVE;1.0i;2.73 +97964-1;Parietaria judaica Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pellitory (Parietaria judaica) IgG4 Ab [Mass/volume] in Serum;Pellitory (judaic) IgG4-mCnc;;ACTIVE;2.70;2.7 +97965-8;Dermatophagoides pteronyssinus recombinant (rDer p) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides pteronyssinus recombinant (rDer p) 1 IgG4 Ab [Mass/volume] in Serum;D pteronyss (rDer p) 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97966-6;Dermatophagoides pteronyssinus recombinant (rDer p) 2 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;European house dust mite recombinant (rDer p) 2 IgG4 Ab [Mass/volume] in Serum;D pteronyss (rDer p) 2 IgG4-mCnc;;ACTIVE;2.70;2.7 +97967-4;Chicken droppings Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken droppings IgG4 Ab [Mass/volume] in Serum;Chicken Drop IgG4-mCnc;;ACTIVE;2.70;2.7 +97968-2;Ovalbumin Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Ovalbumin IgG4 Ab [Mass/volume] in Serum;Ovalb IgG4-mCnc;;ACTIVE;2.70;2.7 +97969-0;Ovomucoid Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Ovomucoid IgG4 Ab [Mass/volume] in Serum;Ovomucoid IgG4-mCnc;;ACTIVE;2.70;2.7 +97970-8;Turkey meat Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Turkey meat IgG4 Ab [Mass/volume] in Serum;Turkey Meat IgG4-mCnc;;ACTIVE;2.70;2.7 +97971-6;Conalbumin Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Conalbumin IgG4 Ab [Mass/volume] in Serum;Conalb IgG4-mCnc;;ACTIVE;2.70;2.7 +9797-2;Consistency;Type;Pt;Calculus;Nom;;SPEC;1;Consistency of Stone;Consistency Stone;;ACTIVE;1.0i;2.73 +97972-4;Arachis hypogaea recombinant (rAra h) 8 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 8 IgG4 Ab [Mass/volume] in Serum;Peanut (rAra h) 8 IgG4-mCnc;;ACTIVE;2.70;2.7 +97973-2;Arachis hypogaea recombinant (rAra h) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 1 IgG4 Ab [Mass/volume] in Serum;Peanut (rAra h) 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97974-0;Arachis hypogaea recombinant (rAra h) 2 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 2 IgG4 Ab [Mass/volume] in Serum;Peanut (rAra h) 2 IgG4-mCnc;;ACTIVE;2.70;2.7 +97975-7;Arachis hypogaea recombinant (rAra h) 3 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 3 IgG4 Ab [Mass/volume] in Serum;Peanut (rAra h) 3 IgG4-mCnc;;ACTIVE;2.70;2.7 +97976-5;Gadus morhua recombinant (rGad c) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Codfish recombinant (rGad c) 1 IgG4 Ab [Mass/volume] in Serum;Codfish (rGad c) 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97977-3;Arachis hypogaea recombinant (rAra h) 9 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 9 IgG4 Ab [Mass/volume] in Serum;Peanut (rAra h) 9 IgG4-mCnc;;ACTIVE;2.70;2.7 +97978-1;Malus domestica recombinant (rMal d) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Apple recombinant (rMal d) 1 IgG4 Ab [Mass/volume] in Serum;Apple (rMal d) 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97979-9;Malus domestica recombinant (rMal d) 3 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Apple recombinant (rMal d) 3 IgG4 Ab [Mass/volume] in Serum;Apple (rMal d) 3 IgG4-mCnc;;ACTIVE;2.70;2.7 +9798-0;Depth;Len;Pt;Calculus;Qn;;PATH;1;Depth of Stone;Dpth Stone;;ACTIVE;1.0i;2.73 +97980-7;Corylus avellana recombinant (rCor a) 14 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut recombinant (rCor a) 14 IgG4 Ab [Mass/volume] in Serum;Hazelnut (rCor a) 14 IgG4-mCnc;;ACTIVE;2.70;2.7 +97981-5;Corylus avellana recombinant (rCor a) 9 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut recombinant (rCor a) 9 IgG4 Ab [Mass/volume] in Serum;Hazelnut (rCor a) 9 IgG4-mCnc;;ACTIVE;2.70;2.7 +97982-3;Zea mays pollen Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Corn IgG4 Ab [Mass/volume] in Serum;Cultivated Corn IgG4-mCnc;;ACTIVE;2.70;2.7 +97983-1;Phleum pratense recombinant (rPhl p) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 1 IgG4 Ab [Mass/volume] in Serum;Timothy (rPhl p) 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97984-9;Phleum pratense recombinant (rPhl p) 1+5b Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Timothy recombinant (rPhl p) 1 + 5b IgG4 Ab [Mass/volume] in Serum;Timothy (rPhl p) 1+5b IgG4-mCnc;;ACTIVE;2.70;2.7 +97985-6;Apis mellifera phospholipase A2 recombinant (rApi m) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee phospholipase A2 recombinant (rApi m) 1 IgG4 Ab [Mass/volume] in Serum;PLA2 rApi m 1 IgG4-mCnc;;ACTIVE;2.70;2.7 +97986-4;Vespula vulgaris recombinant (rVes v) 5 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common wasp recombinant (rVes v) 5 IgG4 Ab [Mass/volume] in Serum;Common wasp (rVes v) 5 IgG4-mCnc;;ACTIVE;2.70;2.7 +97987-2;Apis mellifera recombinant (rApi m) 10 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Honey bee recombinant (rApi m) 10 IgG4 Ab [Mass/volume] in Serum;Honey bee (rApi m) 10 IgG4-mCnc;;ACTIVE;2.70;2.7 +97988-0;Chicken meat Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken meat IgG4 Ab [Mass/volume] in Serum;Chicken Meat IgG4-mCnc;;ACTIVE;2.70;2.7 +97989-8;Culex pipiens Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Culex mosquito IgG4 Ab [Mass/volume] in Serum;Culex mosquito IgG4-mCnc;;ACTIVE;2.70;2.7 +97990-6;von Willebrand factor cleaving protease actual/normal;RelCCnc;Pt;PPP;Qn;IA;COAG;1;von Willebrand factor (vWf) cleaving protease actual/normal in Platelet poor plasma by Immunoassay;vWF Cp Act/Nor PPP IA;;ACTIVE;2.70;2.7 +97991-4;Herpes virus 6 Ab.IgG;ACnc;Pt;Ser;Qn;IF;MICRO;1;Herpes virus 6 IgG Ab [Units/volume] in Serum by Immunofluorescence;HHV6 IgG Ser IF-aCnc;;ACTIVE;2.70;2.7 +97992-2;Herpes virus 6 Ab.IgM;PrThr;Pt;Ser;Ord;IF;MICRO;1;Herpes virus 6 IgM Ab [Presence] in Serum by Immunofluorescence;HHV6 IgM Ser Ql IF;;ACTIVE;2.70;2.7 +97993-0;Epstein Barr virus early Ab.IgM;Titr;Pt;Ser;Qn;IF;MICRO;1;Epstein Barr virus early IgM Ab [Titer] in Serum by Immunofluorescence;EBV EA IgM Titr Ser IF;;ACTIVE;2.70;2.7 +97994-8;Platelets.large/Platelets;NFr;Pt;Bld;Qn;Automated count.optical;HEM/BC;1;Platelets Large/Platelets in Blood by Automated count.optical;Lg Platelets NFr Bld Auto Optical;;ACTIVE;2.70;2.7 +97995-5;Platelets;NCnc;Pt;Bld;Qn;Automated count.optical;HEM/BC;1;Platelets [#/volume] in Blood by Automated count.optical;Platelet # Bld Auto Optical;;ACTIVE;2.70;2.7 +97996-3;Myeloperoxidase Ab.IgG;ACnc;Pt;Ser/Plas;Qn;IA;SERO;1;Myeloperoxidase IgG Ab [Units/volume] in Serum or Plasma by Immunoassay;Myeloperoxidase IgG SerPl IA-aCnc;;ACTIVE;2.70;2.7 +97997-1;HPA & HLA Ab;Imp;Pt;Ser/Plas/Bld;Nar;;HLA;1;HPA and HLA Ab [Interpretation] in Serum, Plasma or Blood Narrative;HPA+HLA Ab SerPlBld-Imp;;ACTIVE;2.70;2.7 +9799-8;Length;Len;Pt;Calculus;Qn;;PATH;1;Length of Stone;Length Stone;;ACTIVE;1.0i;2.73 +97998-9;HPA Ab;Prid;Pt;Ser/Plas;Nom;;HLA;1;HPA Ab [Identifier] in Serum or Plasma;HPA Ab SerPl;;ACTIVE;2.70;2.7 +97999-7;HLA-DP & DQ & DR (class II) Ab.IgG donor specific;Prid;Pt;Ser/Plas;Nom;;HLA;1;HLA-DP and DQ and DR (class II) IgG donor specific [Identifier] in Serum or Plasma;HLA Class II Ab.IgG Don Spec SerPl;;ACTIVE;2.70;2.7 +98000-3;HLA-A & B & C (class I) & HLA-DP & DQ & DR (class II);Type;Pt;Bld/Tiss;Nom;High resolution;HLA;1;HLA-A and B and C (class I) and HLA-DP and DQ and DR (class II) [Type] by High resolution;HLA Class I & II High Res;;ACTIVE;2.70;2.7 +98001-1;HLA-DP & DQ & DR (class II);Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-DP and DQ and DR (class II) [Type] by Low resolution;HLA-DP+DQ+DR (class II) Low res;;ACTIVE;2.70;2.7 +98002-9;HLA-A & B & C (class I);Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-A and B and C (class I) [Type] by Low resolution;HLA-A+B+C (class I) Low res;;ACTIVE;2.70;2.7 +98003-7;HLA-A & B & C (class I) Ab.IgG donor specific;Prid;Pt;Ser/Plas;Nom;;HLA;1;HLA-A and B and C (class I) IgG donor specific [Identifier] in Serum or Plasma;HLA Class I Ab.IgG Don Spec SerPl;;ACTIVE;2.70;2.7 +9800-4;Number;Num;Pt;Calculus;Qn;;PATH;1;Number of Stones;Number Stone;;ACTIVE;1.0i;2.73 +98004-5;HLA-A & B & C (class I) & HLA-DP & DQ & DR (class II);Type;Pt;Bld/Tiss;Nom;;HLA;1;HLA-A and B and C (class I) and HLA-DP and DQ and DR (class II) [Type];HLA Class I & II;;ACTIVE;2.70;2.7 +98005-2;HLA-A & B & C (class I) & HLA-DP & DQ & DR (class II);Type;Pt;Bld/Tiss;Nom;Low resolution;HLA;1;HLA-A and B and C (class I) and HLA-DP and DQ and DR (class II) [Type] by Low resolution;HLA Class I & II Low res;;ACTIVE;2.70;2.7 +98006-0;HLA-A & B & C (class I) & HLA-DP & DQ & DR (class II) Ab;Prid;Pt;Ser/Plas;Nom;;HLA;1;HLA-A and B and C (class I) and HLA-DP and DQ and DR (class II) Ab [Identifier] in Serum or Plasma;HLA Class I & II Ab SerPl;;ACTIVE;2.70;2.7 +98007-8;B cell+T cell crossmatch;Imp;Pt;Ser+Bld;Nar;;HLA;1;B cell+T cell crossmatch [Interpretation] Narrative;B+T cell XM Ser+Bld-Imp;;ACTIVE;2.70;2.7 +98008-6;Neonatal infant pain scale panel;-;Pt;^Patient;-;NIPS;PANEL.NEONAT;2;Neonatal infant pain scale panel;NIPS;© 1989, Children's Hospital of Eastern Ontario. Used with permission.;DISCOURAGED;2.70;2.73 +98009-4;Pain &or agitation severity.breathing pattern;Find;Pt;^Patient;Ord;;H&P.HX;2;Pain/agitation severity.breathing pattern;Pain/agit severity breath patt;;ACTIVE;2.70;2.72 +98010-2;Pain &or agitation severity.arm rigidity;Find;Pt;^Patient;Ord;;H&P.HX;2;Pain/agitation severity.arm rigidity;Pain/agit severity arm rigid;;ACTIVE;2.70;2.72 +98011-0;Pain &or agitation severity.leg rigidity;Find;Pt;^Patient;Ord;;H&P.HX;2;Pain/agitation severity.leg rigidity;Pain/agit severity leg rigid;;ACTIVE;2.70;2.72 +9801-2;Shape;Type;Pt;Calculus;Nom;;PATH;1;Shape of Stone;Shape Stone;;ACTIVE;1.0i;2.73 +98012-8;Total score;Score;Pt;^Patient;Qn;NIPS;H&P.HX;2;Total score NIPS;Total score NIPS;© 1989, Children's Hospital of Eastern Ontario. Used with permission.;ACTIVE;2.70;2.7 +98013-6;Neonatal infant pain scale interpretation;Find;Pt;^Patient;Ord;NIPS;H&P.HX;2;Neonatal infant pain scale interpretation;NIPS interp;© 1989, Children's Hospital of Eastern Ontario. Used with permission.;ACTIVE;2.70;2.7 +98014-4;Plasma cell proliferation analysis;Find;Pt;Bone mar;Doc;FISH;MOLPATH;1;Plasma cell proliferation analysis in Bone marrow by FISH;PC prolif analysis Mar FISH;;ACTIVE;2.70;2.7 +98015-1;Triiodothyronine^1st specimen post XXX challenge;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Triiodothyronine (T3) [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge;T3 sp1 p chal SerPl-sCnc;;ACTIVE;2.70;2.7 +98016-9;Fat;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Fat [#/area] in Urine sediment by Microscopy high power field;Fat #/area UrnS HPF;;ACTIVE;2.70;2.7 +98017-7;Megakaryocytes;NCnc;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Megakaryocytes [#/volume] in Bone marrow by Manual count;Megakaryocytes # Mar Manual;;ACTIVE;2.70;2.7 +98018-5;Megakaryoblasts/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Megakaryoblasts/100 cells in Bone marrow by Manual count;Megakaryoblasts NFr Mar Manual;;ACTIVE;2.70;2.7 +98019-3;Promegakaryocytes/100 cells;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Promegakaryocytes/100 cells in Bone marrow by Manual count;Promegakaryocytes NFr Mar Manual;;ACTIVE;2.70;2.7 +9802-0;Size;EntVol;Pt;Calculus;Qn;;PATH;1;Size [Entitic volume] of Stone;Size Stone;;ACTIVE;1.0i;2.73 +98020-1;Leukocytes;NCnc;Pt;Respiratory.lower;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Lower respiratory specimen by Manual count;WBC # Lower resp Manual;;ACTIVE;2.70;2.7 +98021-9;Rivalta test;PrThr;Pt;Body fld;Ord;;CHEM;1;Rivalta test [Presence] in Body fluid;Rivalta test Fld Ql;;ACTIVE;2.70;2.7 +98022-7;Lymphocytes.abnormal;PrThr;Pt;Body fld;Ord;Manual count;HEM/BC;1;Abnormal lymphocytes [Presence] in Body fluid by Manual count;Lymph Abn Fld Ql Manual;;ACTIVE;2.70;2.7 +98023-5;Epithelial cells;Naric;Pt;Cvx/Vag;Qn;Microscopy.light;HEM/BC;1;Epithelial cells [#/area] in Cervical or vaginal smear or scraping by Light microscopy;Epi Cells #/area Cvx/Vag Micro;;ACTIVE;2.70;2.7 +98024-3;Lecithin;Naric;Pt;Prostatic fld;Qn;Manual count;FERT;1;Lecithin [#/area] in Prostatic fluid by Manual count;Lecithin #/area Prost fld Manual;;ACTIVE;2.70;2.7 +98025-0;Fungus;Prid;Pt;Prostatic fld;Nom;Fungus stain;MICRO;1;Fungus [Identifier] in Prostatic fluid by Fungus stain;Fungus Prost fld Fungus Stn;;ACTIVE;2.70;2.7 +98026-8;Parasite identified;Prid;Pt;Prostatic fld;Nom;Microscopy.light;MICRO;1;Parasite identified in Prostatic fluid by Light microscopy;Parasite Prost fld Micro;;ACTIVE;2.70;2.7 +98027-6;Lecithin;PrThr;Pt;Semen;Ord;Microscopy.light;CHEM;1;Lecithin [Presence] in Semen by Light microscopy;Lecithin Smn Ql Micro;;ACTIVE;2.70;2.7 +98028-4;Crystals;Prid;Pt;Semen;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Semen by Light microscopy;Crystals Smn Micro;;ACTIVE;2.70;2.7 +98029-2;Crystals;Prid;Pt;Stool;Nom;Microscopy.light;HEM/BC;1;Crystals [type] in Stool by Light microscopy;Crystals Stl Micro;;ACTIVE;2.70;2.7 +980-3;D little i super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Di sup(a) Ab [Presence] in Serum or Plasma from Donor;Di sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +98030-0;Natural killer cell cytotoxicity.IL-2 stimulated panel;-;Pt;Bld MC;-;Flow cytometry;PANEL.CELLMARK;1;Natural killer cell cytotoxicity.IL-2 stimulated panel - Blood mononuclear cells by Flow cytometry (FC);NK cyto IL2 Pnl Bld MC FC;;ACTIVE;2.70;2.7 +98031-8;Body weight discordance;MRto;Pt;^Fetuses;Qn;US+Calculated;OB.US;2;Body weight discordance in multiple fetuses US+Calculated;EFW discordance US+Calc;;ACTIVE;2.70;2.7 +98032-6;Body weight.current fetus/Body weight.heaviest fetus;MRto;Pt;^Fetuses;Qn;US+Calculated;OB.US;2;Fetal body weight/Heaviest fetus body weight US+Calculated;Fetal bdy wt/Heaviest fetus wt US+Calc;;ACTIVE;2.70;2.7 +98033-4;Multisection^W radionuclide IV;Find;Pt;Lower extremity;Doc;PT+CT;RAD;2;PET+CT Lower extremity;PET+CT LE W RNC IV;;ACTIVE;2.70;2.7 +98034-2;Views limited;Find;Pt;XXX;Doc;RF;RAD;2;RF Unspecified body region Limited Views;RF Views Ltd;;ACTIVE;2.70;2.7 +98035-9;Multisection;Find;Pt;Head>Eye;Doc;US;RAD;2;US Eye;US Eye;;ACTIVE;2.70;2.7 +98036-7;Views for therapy^W Tc-99m SC IV;Find;Pt;Abdomen;Doc;NM;RAD;2;NM Abdomen Views for therapy W Tc-99m SC IV;NM Abd Views for therapy W Tc99mSC IV;;ACTIVE;2.70;2.7 +98037-5;Jewish descent preconception &or prenatal carrier screening multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Jewish descent preconception AndOr prenatal carrier screening multigene analysis in Blood or Tissue by Molecular genetics method;Jewish Carrier Multigene Anl Bld/T;;ACTIVE;2.70;2.7 +9803-8;Texture;Type;Pt;Calculus;Nom;;PATH;1;Texture of Stone;Texture Stone;;ACTIVE;1.0i;2.73 +98038-3;CFTR gene & FMR1 gene CGG repeat & SMN1 gene mutation analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;CFTR and FMR1 (CGG repeat) and SMN1 gene mutation analysis in Blood or Tissue by Molecular genetics method;CFTR+FMR1+SMN1 Mut Anl Bld/T;;ACTIVE;2.70;2.7 +98039-1;Preconception &or prenatal carrier screening multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Preconception AndOr prenatal carrier screening multigene analysis in Blood or Tissue by Molecular genetics method;Reproductive Carrier Multigene Anl Bld/T;;ACTIVE;2.70;2.7 +98040-9;Urothelial carcinoma recurrence score;Score;Pt;Urine;Qn;Molgen;CLIN.RISK;2;Urothelial carcinoma recurrence score Urine Molecular genetics method;UC recurrence score Ur;;ACTIVE;2.70;2.72 +98041-7;Cortisone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cortisone IgE Ab [Units/volume] in Serum;Cortisone IgE Qn;;ACTIVE;2.70;2.7 +98042-5;Cantharellus cibarius Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Chanterelles IgE Ab [Units/volume] in Serum;Chanterelles IgE Qn;;ACTIVE;2.70;2.7 +98043-3;5-Aminosalicylate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;5-Aminosalicylate IgE Ab [Units/volume] in Serum;5-ASA IgE Qn;;ACTIVE;2.70;2.7 +98044-1;Benzoate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Benzoate IgE Ab [Units/volume] in Serum;Benzoate IgE Qn;;ACTIVE;2.70;2.7 +98045-8;Linum usitatissimum seed Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Flaxseed IgE Ab [Units/volume] in Serum;Flaxseed IgE Qn;;ACTIVE;2.70;2.7 +9804-6;Weight;Mass;Pt;Calculus;Qn;;PATH;1;Weight of Stone;Wt Stone;;ACTIVE;1.0i;2.73 +98046-6;Lincomycin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lincomycin IgE Ab [Units/volume] in Serum;Lincomycin IgE Qn;;ACTIVE;2.70;2.7 +98047-4;Lipoxygenase Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Lipoxygenase IgE Ab [Units/volume] in Serum;Lipoxygenase IgE Qn;;ACTIVE;2.70;2.7 +98048-2;Levothyroxine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Levothyroxine IgE Ab [Units/volume] in Serum;Levothyroxine IgE Qn;;ACTIVE;2.70;2.7 +98050-8;European roe venison Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;European roe venison IgE Ab [Units/volume] in Serum;European roe venison IgE Qn;;ACTIVE;2.71;2.71 +98051-6;Microsporum canis Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Microsporum canis IgE Ab [Units/volume] in Serum;M canis IgE Qn;;ACTIVE;2.70;2.7 +98052-4;Minocycline Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Minocycline IgE Ab [Units/volume] in Serum;Minocycline IgE Qn;;ACTIVE;2.70;2.7 +9805-3;Width;Len;Pt;Calculus;Qn;;PATH;1;Width of Stone;Width Stone;;ACTIVE;1.0i;2.73 +98053-2;Eriobotrya japonica Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Loquat IgE Ab [Units/volume] in Serum;Loquat IgE Qn;;ACTIVE;2.70;2.7 +98054-0;Mouse droppings Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Mouse droppings IgE Ab [Units/volume] in Serum;Mouse droppings IgE Qn;;ACTIVE;2.70;2.7 +98055-7;Nystatin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Nystatin IgE Ab [Units/volume] in Serum;Nystatin IgE Qn;;ACTIVE;2.70;2.7 +98056-5;Oxacillin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Oxacillin IgE Ab [Units/volume] in Serum;Oxacillin IgE Qn;;ACTIVE;2.70;2.7 +98057-3;Penicillium digitatum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium digitatum IgE Ab [Units/volume] in Serum;P. digitatum IgE Qn;;ACTIVE;2.70;2.7 +98058-1;Penicillium expansum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium expansum IgE Ab [Units/volume] in Serum;P. expansum IgE Qn;;ACTIVE;2.70;2.7 +98059-9;Sparus aurata Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Gilt-head bream IgE Ab [Units/volume] in Serum;Gilt-head bream IgE Qn;;ACTIVE;2.70;2.7 +98060-7;Penicillamine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Penicillamine IgE Ab [Units/volume] in Serum;Penicillamine IgE Qn;;ACTIVE;2.70;2.7 +9806-1;2,4-Dichlorophenoxyacetate;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;2,4-Dichlorophenoxyacetate [Mass/volume] in Urine;2,4D Ur-mCnc;;ACTIVE;1.0i;2.42 +98061-5;Allium ursinum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wild garlic (Allium ursinum) IgE Ab [Units/volume] in Serum;Wild garlic IgE Qn;;ACTIVE;2.70;2.7 +98062-3;Sequencing study identifier;ID;Pt;Specimen;Nom;;MICRO;1;Sequencing study identifier;Sequencing study ID;;ACTIVE;2.70;2.72 +98063-1;Bacterial beta-lactam resistance ESBL blaCTX-M-15 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaCTX-M-15 gene [Presence] by Molecular method;ESBL blaCTX-M-15 gene Islt/Spm Ql;;ACTIVE;2.70;2.72 +98064-9;Bacterial beta-lactam resistance ESBL blaCTX-M-14 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Beta-lactam resistance ESBL blaCTX-M-14 gene [Presence] by Molecular method;ESBL blaCTX-M-14 gene Islt/Spm Ql;;ACTIVE;2.70;2.72 +98065-6;Bacterial carbapenem resistance blaOXA-143 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Carbapenem resistance blaOXA-143 gene [Presence] by Molecular method;blaOXA-143 Islt/Spm Ql;;ACTIVE;2.70;2.72 +98066-4;Bacterial colistin resistance mcr-3+mcr-4+mcr-5 genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Colistin resistance mcr-3+mcr-4+mcr-5 genes [Presence] by Molecular method;Colistin res mcr-(3-5) Islt/Spm Ql;;ACTIVE;2.70;2.72 +98067-2;Patient-centered disability questionnaire;-;Pt;^Patient;-;;PANEL.SURVEY.GNHLTH;4;Patient-centered disability questionnaire;;;ACTIVE;2.71;2.71 +98068-0;Difficulty communicating in usual language;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Difficulty communicating in usual language;;;ACTIVE;2.71;2.71 +98069-8;SARS coronavirus 2 Ab;PrThr;Pt;Saliva;Ord;IA.rapid;MICRO;1;SARS-CoV-2 (COVID-19) Ab [Presence] in Saliva (oral fluid) by Rapid immunoassay;SARS-CoV-2 Ab Sal Ql IA.rapid;;ACTIVE;2.71;2.72 +98070-6;Medical Research Council breathlessness scale grade;Find;Pt;^Patient;Ord;MRC;PULM;2;Medical Research Council breathlessness scale grade;MRC breathlessness scale grade;Used with the permission of the Medical Research Council;ACTIVE;2.71;2.71 +98071-4;Post COVID-19 functional status scale;-;Pt;^Patient;-;PCFS;PANEL.SURVEY.COVID;4;Post COVID-19 functional status scale [PCFS];;;ACTIVE;2.71;2.71 +98072-2;Post COVID-19 functional status grade;Find;Pt;^Patient;Ord;PCFS;SURVEY.COVID;4;Post COVID-19 functional status grade [PCFS];;;ACTIVE;2.71;2.71 +98073-0;Natural killer & natural killer T cell subsets panel;-;Pt;Bld;-;;PANEL.CELLMARK;1;Natural killer and natural killer T cell subsets panel - Blood;NK + NK T-cell subsets Pnl Bld;;ACTIVE;2.71;2.71 +98074-8;Multisection^W contrast;Find;Pt;Head>Internal auditory canal.bilateral;Doc;CT;RAD;2;CT Internal auditory canal - bilateral W contrast;CT IAC-Bl W contr;;ACTIVE;2.71;2.71 +98075-5;Animal cells, tissues, and cell and tissue based product label;-;-;^FDA product label;Nar;;DOCUMENT.REGULATORY;2;FDA product label Animal cells, tissues, and cell and tissue based product label;FDA label ACTPs;;ACTIVE;2.71;2.71 +98076-3;Do you want to talk about contraception or pregnancy prevention during your visit today;Find;Pt;^Patient;Nom;;OBGYN;2;Do you want to talk about contraception or pregnancy prevention during your visit today;Wish to discuss contraception;;ACTIVE;2.71;2.71 +98077-1;Whether the patient previously met the case definition for condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Whether the patient previously met the case definition for condition of interest;Previous case condition of interest;;ACTIVE;2.71;2.71 +98078-9;Difficulty reading or writing;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Difficulty reading or writing;;;ACTIVE;2.71;2.71 +9807-9;Chlordane;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Chlordane [Mass/volume] in Serum or Plasma;Chlordane SerPl-mCnc;;ACTIVE;1.0i;2.42 +98079-7;Do you need any additional assistance or accommodations during your visit;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Do you need any additional assistance or accommodations during your visit;;;ACTIVE;2.71;2.71 +98080-5;SARS coronavirus 2 & SARS-related coronavirus RNA panel;-;Pt;Saliva;-;Probe.amp.tar;PANEL.MICRO;1;SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2+SARSr-CoV RNA pnl Sal NAA+prb;;ACTIVE;2.71;2.71 +98081-3;Cytomegalovirus DNA;NCnc;Pt;Saliva;Qn;Probe.amp.tar;MICRO;1;Cytomegalovirus DNA [#/volume] (viral load) in Saliva (oral fluid) by NAA with probe detection;CMV DNA # Sal NAA+probe;;ACTIVE;2.71;2.71 +98082-1;Specific resistance.airway^pre bronchodilation;FldResist;Stdy^mean;Respiratory system.airway;Qn;Plethysmograph.body box;PULM;2;Specific airway resistance mean by Plethysmograph body box --pre bronchodilation;Spec airway resist pre BD Mean Plethys;;ACTIVE;2.71;2.71 +98083-9;Specific resistance.airway^post bronchodilation;FldResist;Stdy^mean;Respiratory system.airway;Qn;Plethysmograph.body box;PULM;2;Specific airway resistance mean by Plethysmograph body box --post bronchodilation;Spec airway resist p BD Mean Plethys;;ACTIVE;2.71;2.71 +98084-7;Specific effective resistance.airway;FldResist;Stdy^mean;Respiratory system.airway;Qn;Calculated;PULM;2;Specific effective resistance.airway mean Calculated;sReff Mean Calc;;ACTIVE;2.71;2.71 +98085-4;Specific effective resistance.airway^pre bronchodilation;FldResist;Stdy^mean;Respiratory system.airway;Qn;Calculated;PULM;2;Specific effective resistance.airway mean Calculated --pre bronchodilation;sReff pre BD Mean Calc;;ACTIVE;2.71;2.71 +98086-2;Specific effective resistance.airway^post bronchodilation;FldResist;Stdy^mean;Respiratory system.airway;Qn;Calculated;PULM;2;Specific effective resistance.airway mean Calculated --post bronchodilation;sReff p BD Mean Calc;;ACTIVE;2.71;2.71 +9808-7;Phenothiazines;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Phenothiazines [Presence] in Gastric fluid;Phenothiaz Gast Ql;;ACTIVE;1.0i;2.56 +98087-0;Specific effective resistance.airway/predicted;RelFldResist;Stdy^mean;Respiratory system.airway;Qn;;PULM;2;Specific effective resistance.airway/Predicted mean;sReff/Predicted Mean;;ACTIVE;2.71;2.71 +98088-8;Vital capacity/Vital capacity.predicted;RelVol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Vital capacity/predicted VC Respiratory system by Spirometry;VC/predicted VC Respiratory Spirometry;;ACTIVE;2.71;2.71 +98089-6;Capacity.inspiratory^pre bronchodilation;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Inspiratory capacity by Spirometry --pre bronchodilation;IC pre BD Spirometry;;ACTIVE;2.71;2.71 +98090-4;Capacity.inspiratory^post bronchodilation;Vol;Pt;Respiratory system;Qn;Spirometry;PULM;2;Inspiratory capacity by Spirometry --post bronchodilation;IC p BD Spirometry;;ACTIVE;2.71;2.71 +98091-2;Diffusion capacity.carbon monoxide^pre bronchodilation;FldConduct;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity.carbon monoxide --pre bronchodilation;Diff cap.CO pre BD;;ACTIVE;2.71;2.71 +98092-0;Diffusion capacity.carbon monoxide^post bronchodilation;FldConduct;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity.carbon monoxide --post bronchodilation;Diff cap.CO p BD;;ACTIVE;2.71;2.71 +98093-8;Rowland Universal Dementia Assessment Scale;-;Pt;^Patient;-;RUDAS;PANEL.SURVEY.RUDAS;4;Rowland Universal Dementia Assessment Scale [RUDAS];;;ACTIVE;2.71;2.71 +98094-6;Total score;Score;Pt;^Patient;Qn;RUDAS;SURVEY.RUDAS;4;Total score [RUDAS];;;ACTIVE;2.71;2.71 +9809-5;Propoxyphene;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;Propoxyphene [Presence] in Gastric fluid;Propoxyph Gast Ql;;ACTIVE;1.0i;2.56 +98095-3;Cells.FOXP3 Ag/100 cells;NFr;Pt;Bld;Qn;;MICRO;1;Cells.FOXP3 Ag/100 cells in Blood;FOXP3 Ag Bld-NFr;;ACTIVE;2.71;2.72 +98096-1;Interleukin 33;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 33 [Mass/volume] in Serum or Plasma;IL-33 SerPl-mCnc;;ACTIVE;2.71;2.71 +98097-9;Thymic stromal lymphopoietin;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Thymic stromal lymphopoietin [Mass/volume] in Serum or Plasma;TSLP SerPl-mCnc;;ACTIVE;2.71;2.71 +98098-7;Interleukin 17F;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 17F [Mass/volume] in Serum or Plasma;IL-17F SerPl-mCnc;;ACTIVE;2.71;2.71 +98099-5;Interleukin 21;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 21 [Mass/volume] in Serum or Plasma;IL-21 SerPl-mCnc;;ACTIVE;2.71;2.71 +98100-1;Interleukin 22;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 22 [Mass/volume] in Serum or Plasma;IL-22 SerPl-mCnc;;ACTIVE;2.71;2.71 +98101-9;Interleukin 23;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 23 [Mass/volume] in Serum or Plasma;IL-23 SerPl-mCnc;;ACTIVE;2.71;2.71 +98102-7;Chemokine (C-X-C motif) ligand 10;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-X-C motif) ligand 10 [Mass/volume] in Serum or Plasma;CXCL10 SerPl-mCnc;;ACTIVE;2.71;2.71 +9810-3;quiNINE;PrThr;Pt;Gast fld;Ord;;DRUG/TOX;1;quiNINE [Presence] in Gastric fluid;quiNINE Gast Ql;;ACTIVE;1.0i;2.56 +98103-5;Interleukin 9;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 9 [Mass/volume] in Serum or Plasma;IL-9 SerPl-mCnc;;ACTIVE;2.71;2.71 +98104-3;Interleukin 15;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 15 [Mass/volume] in Serum or Plasma;IL-15 SerPl-mCnc;;ACTIVE;2.71;2.71 +98105-0;Interleukin 16;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Interleukin 16 [Mass/volume] in Serum or Plasma;IL-16 SerPl-mCnc;;ACTIVE;2.71;2.71 +98106-8;Brain-derived neurotrophic factor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Brain-derived neurotrophic factor [Mass/volume] in Serum or Plasma;BDNF SerPl-mCnc;;ACTIVE;2.71;2.71 +98107-6;Macrophage colony-stimulating factor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Macrophage colony-stimulating factor [Mass/volume] in Serum or Plasma;M-CSF SerPl-mCnc;;ACTIVE;2.71;2.71 +98108-4;Chemokine (C-C motif) ligand 11;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 11 [Mass/volume] in Serum or Plasma;CCL11 SerPl-mCnc;;ACTIVE;2.71;2.71 +98109-2;Chemokine (C-C motif) ligand 8;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 8 [Mass/volume] in Serum or Plasma;CCL8 SerPl-mCnc;;ACTIVE;2.71;2.71 +981-1;D little i super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Di sup(a) Ab [Presence] in Serum or Plasma;Di sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.56 +98110-0;Chemokine (C-C motif) ligand 7;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 7 [Mass/volume] in Serum or Plasma;CCL7 SerPl-mCnc;;ACTIVE;2.71;2.71 +9811-1;Chromogranin A;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chromogranin A [Mass/volume] in Serum or Plasma;CgA SerPl-mCnc;;ACTIVE;1.0i;2.73 +98111-8;Chemokine (C-C motif) ligand 4;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 4 [Mass/volume] in Serum or Plasma;CCL4 SerPl-mCnc;;ACTIVE;2.71;2.71 +98112-6;Chemokine (C-C motif) ligand 20;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 20 [Mass/volume] in Serum or Plasma;CCL20 SerPl-mCnc;;ACTIVE;2.71;2.71 +98113-4;Chemokine (C-C motif) ligand 5;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 5 [Mass/volume] in Serum or Plasma;CCL5 SerPl-mCnc;;ACTIVE;2.71;2.71 +98114-2;Chemokine (C-X3-C motif) ligand 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-X3-C motif) ligand 1 [Mass/volume] in Serum or Plasma;CX3CL1 SerPl-mCnc;;ACTIVE;2.71;2.71 +98115-9;Chemokine (C-X-C motif) ligand 9;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-X-C motif) ligand 9 [Mass/volume] in Serum or Plasma;CXCL9 SerPl-mCnc;;ACTIVE;2.71;2.71 +98116-7;Chemokine (C-C motif) ligand 27;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-C motif) ligand 27 [Mass/volume] in Serum or Plasma;CCL27 SerPl-mCnc;;ACTIVE;2.71;2.71 +98117-5;Fibroblast growth factor 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Fibroblast growth factor 2 [Mass/volume] in Serum or Plasma;FGF2 SerPl-mCnc;;ACTIVE;2.71;2.71 +98118-3;Vascular endothelial growth factor C;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Vascular endothelial growth factor C [Mass/volume] in Serum or Plasma;VEGF-C SerPl-mCnc;;ACTIVE;2.71;2.71 +98119-1;Angiopoietin 2 receptor;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Angiopoietin receptor 2 [Mass/volume] in Serum or Plasma;Angiopoietin 2 receptor SerPl-mCnc;;ACTIVE;2.71;2.71 +98120-9;Intercellular adhesion molecule 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Intercellular adhesion molecule 1 [Mass/volume] in Serum or Plasma;ICAM-1 SerPl-mCnc;;ACTIVE;2.71;2.71 +98121-7;Protein/Creatinine;PrThr;Pt;Urine;Ord;Test strip;CHEM;1;Protein/Creatinine Qualitative in Urine by Test strip;Prot/Creat Ur Ql Strip;;ACTIVE;2.71;2.71 +98122-5;Neutrophil.fMLP & PMA stimulated DHR panel;-;Pt;^Patient;-;Flow cytometry;PANEL.HEM/BC;1;Neutrophil.fMLP and PMA stimulated DHR panel by Flow cytometry (FC);Neut fMLP + PMA stim DHR Pnl Patient FC;;ACTIVE;2.71;2.72 +98123-3;Neutrophil.fMLP stimulated DHR panel;-;Pt;^Patient;-;Flow cytometry;PANEL.HEM/BC;1;Neutrophil.fMLP stimulated DHR panel by Flow cytometry (FC);Neut fMLP stim DHR Pnl Patient FC;;ACTIVE;2.71;2.71 +98124-1;Neutrophil.PMA stimulated DHR panel;-;Pt;^Patient;-;Flow cytometry;PANEL.HEM/BC;1;Neutrophil.PMA stimulated DHR panel by Flow cytometry (FC);Neut PMA stim DHR Pnl Patient FC;;ACTIVE;2.71;2.72 +98125-8;Intravascular coagulation and fibrinolysis panel;-;Pt;^Patient;-;;PANEL.COAG;1;Intravascular coagulation and fibrinolysis panel;Intravascular coag + fibrinolysis Pnl;;ACTIVE;2.71;2.71 +98126-6;Zimnitsky urine concentration panel;-;-;Urine;-;;PANEL.UA;1;Zimnitsky urine concentration panel - Urine;Zimnitsky Pnl Ur;;ACTIVE;2.71;2.71 +98127-4;Normoblasts.oxyphilic+polychromatophilic/Normoblasts.total;NFr;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Normoblasts oxyphilic+polychromatophilic/Normoblasts.total in Bone marrow by Manual count;Oxy+poly normoblasts/Tot NFr Mar Manual;;ACTIVE;2.71;2.71 +98128-2;Neutrophils.immature/Neutrophils.segmented;Ratio;Pt;Bone mar;Qn;Manual count;HEM/BC;1;Neutrophils.immature/Neutrophils.segmented [Ratio] in Bone marrow by Manual count;Neut.imm/Neut.segment Mar Manual - Rto;;ACTIVE;2.71;2.71 +9812-9;Cortisol^PM trough specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma --PM trough specimen;Cortis PM SerPl-mCnc;;ACTIVE;1.0i;2.73 +98129-0;Thymol turbidity test;Arb;Pt;Bld;Qn;;CHEM;1;Thymol turbidity test in Blood;Thymol turbidity test Bld;;ACTIVE;2.71;2.71 +98130-8;Diffusion capacity.carbon monoxide/predicted;RelFldConduct;Pt;Respiratory system;Qn;;PULM;2;Diffusion capacity.carbon monoxide/Predicted;Diff cap.CO/Predicted;;ACTIVE;2.71;2.71 +98131-6;SARS coronavirus 2 ORF1b region;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 ORF1b Resp Ql NAA+probe;;ACTIVE;2.71;2.71 +98132-4;SARS coronavirus 2 ORF1a region;PrThr;Pt;Respiratory;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Respiratory specimen by NAA with probe detection;SARS-CoV-2 ORF1a Resp Ql NAA+probe;;ACTIVE;2.71;2.71 +98133-2;Osteoporosis Index of Risk panel;-;Pt;^Patient;-;Osteoporosis Index of Risk;PANEL.CLIN.RISK;2;Osteoporosis Index of Risk panel;OSIRIS panel;;ACTIVE;2.71;2.71 +98134-0;Estrogen use;Find;Pt;^Patient;Ord;;H&P.HX;2;Estrogen use;Estrogen use;;ACTIVE;2.71;2.71 +98135-7;Low impact fracture;Hx;Pt;^Patient;Ord;;H&P.HX;2;History of Low impact fracture;Hx of Low impact fracture;;ACTIVE;2.71;2.71 +98136-5;Total score;Score;Pt;^Patient;Qn;Osteoporosis Index of Risk;CLIN.RISK;2;Total score Osteoporosis Index of Risk;Total score OSIRIS;;ACTIVE;2.71;2.71 +9813-7;Cortisol^AM peak specimen;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cortisol [Mass/volume] in Serum or Plasma --AM peak specimen;Cortis AM peak SerPl-mCnc;;ACTIVE;1.0i;2.73 +98137-3;Pain assessment report;Find;Pt;{Setting};Doc;{Role};DOC.ONTOLOGY;2;Pain assessment report;Pain assessment Rpt;;ACTIVE;2.71;2.71 +98138-1;Amyloid plaques probability score;Score;Pt;^Patient;Qn;Based on clinical+lab data;CLIN.RISK;2;Amyloid plaques probability score based on clinical and lab data;Amyloid plaques score from clin+lab data;;ACTIVE;2.71;2.72 +98139-9;Osteoporosis Risk Assessment Instrument;-;Pt;^Patient;-;Osteoporosis Risk Assessment Instrument;PANEL.CLIN.RISK;2;Osteoporosis Risk Assessment Instrument;ORAI;;ACTIVE;2.71;2.71 +98140-7;Total score;Score;Pt;^Patient;Qn;Osteoporosis Risk Assessment Instrument;CLIN.RISK;2;Total score Osteoporosis Risk Assessment Instrument;Total score ORAI;;ACTIVE;2.71;2.71 +98141-5;Admission notification note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Admission notification;ED Admission notification;;ACTIVE;2.71;2.71 +98142-3;Discharge notification note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Discharge notification;ED Discharge notification;;ACTIVE;2.71;2.71 +98143-1;Arrival notification note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Arrival notification;ED Arrival notification;;ACTIVE;2.71;2.72 +98144-9;Departure notification note;Find;Pt;Emergency department;Doc;{Role};DOC.ONTOLOGY;2;Emergency department Departure notification;ED Departure notification;;ACTIVE;2.71;2.72 +9814-5;Dextroamphetamine;MCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Dextroamphetamine [Mass/volume] in Serum or Plasma;D-amphet SerPl-mCnc;;ACTIVE;1.0i;2.73 +98145-6;Visit notification note;Find;Pt;Outpatient;Doc;{Role};DOC.ONTOLOGY;2;Outpatient Visit notification;OP Visit notification;;ACTIVE;2.71;2.71 +98146-4;Osteoporosis Self-Assessment Tool;-;Pt;^Patient;-;Osteoporosis Self-Assessment Tool;PANEL.CLIN.RISK;2;Osteoporosis Self-Assessment Tool;OST;;ACTIVE;2.71;2.71 +98147-2;Total score;Score;Pt;^Patient;Qn;Osteoporosis Self-Assessment Tool;CLIN.RISK;2;Total score Osteoporosis Self-Assessment Tool;Total score OST;;ACTIVE;2.71;2.71 +98148-0;Oxygen saturation;MFr;12H^mean;BldA;Qn;Pulse oximetry;PULM;2;Oxygen saturation in 12 hour mean Arterial blood by Pulse oximetry;SaO2 12h Mean % BldA PulseOx;;ACTIVE;2.71;2.71 +98149-8;Body temperature;Temp;12H^mean;Surface;Qn;;BDYTMP.MOLEC;2;Body temperature - 12 hour mean Surface;Bdy temp 12h Mean Surface;;ACTIVE;2.71;2.71 +98150-6;Encephalopathy grade;Find;Pt;^Patient;Ord;;SURVEY.CHILD-PUGH;4;Encephalopathy grade;;;ACTIVE;2.71;2.71 +98151-4;Degree of ascites;Find;Pt;^Patient;Ord;;SURVEY.CHILD-PUGH;4;Degree of ascites;;;ACTIVE;2.71;2.71 +9815-2;Lithium;MCnc;Pt;RBC;Qn;;DRUG/TOX;1;Lithium [Mass/volume] in Red Blood Cells;Lithium RBC-mCnc;;ACTIVE;1.0i;2.42 +98152-2;Total score;Score;Pt;^Patient;Qn;Child-Pugh;SURVEY.CHILD-PUGH;4;Total score [Child-Pugh];;;ACTIVE;2.71;2.71 +98153-0;Child-Pugh panel;-;Pt;^Patient;-;;PANEL.SURVEY.CHILD-PUGH;4;Child-Pugh panel;;;ACTIVE;2.71;2.71 +98154-8;SARS-CoV-2-related socioeconomic questionnaire for adults;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;SARS-CoV-2-related socioeconomic questionnaire for adults;;© 2021 E. Sicuri, I. Lopes, E. Tacconelli, M. Giannella. Used with permission.;ACTIVE;2.71;2.72 +98155-5;Number of children under the age of 14 living in household;Num;Pt;^Patient;Qn;;ADMIN.DEMOG;2;Number of children under the age of 14 living in household;Num household members <14Y;;ACTIVE;2.71;2.71 +98156-3;Routine doctor's visits &or check-ups cancelled since the beginning of the pandemic;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Routine doctor's visits AndOr check-ups cancelled since the beginning of the pandemic;;;ACTIVE;2.71;2.71 +98157-1;Routine doctor's visits &or check-ups postponed since the beginning of the pandemic;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Routine doctor's visits AndOr check-ups postponed since the beginning of the pandemic;;;ACTIVE;2.71;2.71 +98158-9;Problems accessing medication since the beginning of the pandemic;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Problems accessing medication since the beginning of the pandemic;;;ACTIVE;2.71;2.71 +98159-7;Treatment sessions postponed by doctor or patient since the beginning of the pandemic;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Treatment sessions postponed by doctor or patient since the beginning of the pandemic;;;ACTIVE;2.71;2.71 +9816-0;Actinomyces sp identified;Prid;Pt;XXX;Nom;Organism specific culture;MICRO;1;Actinomyces sp identified in Specimen by Organism specific culture;Actinomyces Spec Cult;;ACTIVE;1.0i;2.73 +98160-5;Treatment sessions cancelled by doctor or patient since the beginning of the pandemic;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Treatment sessions cancelled by doctor or patient since the beginning of the pandemic;;;ACTIVE;2.71;2.71 +98161-3;Monthly household net income;NRat;Pt;^Patient;Qn;;ADMIN.PATIENT.DEMOG;2;Monthly household net income;Monthly household net income nRate;;ACTIVE;2.71;2.71 +98162-1;Financial problems since the beginning of the pandemic;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Financial problems since the beginning of the pandemic;;;ACTIVE;2.71;2.71 +98163-9;Received any financial or material aid since the beginning of the pandemic;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Received any financial or material aid since the beginning of the pandemic;;;ACTIVE;2.71;2.71 +98164-7;How often have you recently looked for information on COVID-19;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often have you recently looked for information on COVID-19;;;ACTIVE;2.71;2.71 +98165-4;What do you think is your current risk of infection or re-infection;Score;Pt;^Patient;Qn;;SURVEY.COVID;4;What do you think is your current risk of infection or re-infection;;;ACTIVE;2.71;2.71 +98166-2;What do you think is your current risk that, in case of infection or re-infection, you will experience severe complications or even death;Score;Pt;^Patient;Qn;;SURVEY.COVID;4;What do you think is your current risk that, in case of infection or re-infection, you will experience severe complications or even death;;;ACTIVE;2.71;2.71 +98167-0;How often do you wash your hands with hand-soap or hydro-alcoholic solutions;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often do you wash your hands with hand-soap or hydro-alcoholic solutions;;;ACTIVE;2.71;2.71 +98168-8;How often do you keep a distance of at least 2 meters from others;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;How often do you keep a distance of at least 2 meters from others;;;ACTIVE;2.71;2.71 +98169-6;Stay at home to avoid social contact;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Stay at home to avoid social contact;;;ACTIVE;2.71;2.71 +98170-4;Wear face mask in public;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Wear face mask in public;;;ACTIVE;2.71;2.71 +98171-2;Has been offered COVID-19 vaccine;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Has been offered COVID-19 vaccine;;;ACTIVE;2.71;2.71 +98172-0;Accepted or will accept COVID-19 vaccination once offered;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Accepted or will accept COVID-19 vaccination once offered;;;ACTIVE;2.71;2.71 +98173-8;Reasons for not accepting COVID-19 vaccine;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Reasons for not accepting COVID-19 vaccine;;;ACTIVE;2.71;2.71 +98174-6;Routine doctor's visits &or check-ups cancelled in the last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Routine doctor's visits AndOr check-ups cancelled in the last 12 months;;;ACTIVE;2.71;2.71 +98175-3;Routine doctor's visits &or check-ups postponed in the last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Routine doctor's visits AndOr check-ups postponed in the last 12 months;;;ACTIVE;2.71;2.71 +98176-1;Problems accessing medication in last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Problems accessing medication in last 12 months;;;ACTIVE;2.71;2.71 +98177-9;Treatment sessions postponed by doctor or patient in the last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Treatment sessions postponed by doctor or patient in the last 12 months;;;ACTIVE;2.71;2.71 +9817-8;Cryptococcus sp Ag;Titr;Pt;CSF;Qn;IA;MICRO;1;Cryptococcus sp Ag [Titer] in Cerebral spinal fluid by Immunoassay;Cryptoc Ag Titr CSF IA;;ACTIVE;1.0i;2.73 +98178-7;Treatment sessions cancelled by doctor or patient in the last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Treatment sessions cancelled by doctor or patient in the last 12 months;;;ACTIVE;2.71;2.71 +98179-5;Financial problems in last 12 Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Financial problems in last 12 months;;;ACTIVE;2.71;2.71 +98180-3;Received any financial or material aid in last 12 Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Received any financial or material aid in last 12 months;;;ACTIVE;2.71;2.71 +98181-1;Medical equipment used;Type;Pt;^Patient;Nom;;H&P.HX;2;Medical equipment used;Medical equipment used;;ACTIVE;2.71;2.71 +98182-9;Thyroxine.free;SCnc;Pt;BldCo;Qn;;CHEM;1;Thyroxine (T4) free [Moles/volume] in Cord blood;T4 Free BldCo-sCnc;;ACTIVE;2.71;2.71 +98183-7;Wild boar dander Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wild boar dander IgE Ab [Units/volume] in Serum;Wild boar dander IgE Qn;;ACTIVE;2.71;2.71 +98184-5;Acetylcysteine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Acetylcysteine IgE Ab [Units/volume] in Serum;NAC IgE Qn;;ACTIVE;2.71;2.71 +98185-2;Ambroxol Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ambroxol IgE Ab [Units/volume] in Serum;Ambroxol IgE Qn;;ACTIVE;2.71;2.71 +9818-6;Cryptococcus sp Ag;Titr;Pt;Ser;Qn;IA;MICRO;1;Cryptococcus sp Ag [Titer] in Serum by Immunoassay;Cryptoc Ag Titr Ser IA;;ACTIVE;1.0i;2.73 +98186-0;Aspartame Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspartame IgE Ab [Units/volume] in Serum;Aspartame IgE Qn;;ACTIVE;2.71;2.71 +98187-8;Aspergillus repens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Aspergillus repens IgE Ab [Units/volume] in Serum;Aspergillus repens IgE Qn;;ACTIVE;2.71;2.71 +98188-6;Bacampicillin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bacampicillin IgE Ab [Units/volume] in Serum;Bacampicillin IgE Qn;;ACTIVE;2.71;2.71 +98189-4;Benzocaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Benzocaine IgE Ab [Units/volume] in Serum;Benzocaine IgE Qn;;ACTIVE;2.71;2.71 +98190-2;Bromhexine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Bromhexine IgE Ab [Units/volume] in Serum;Bromhexine IgE Qn;;ACTIVE;2.71;2.71 +98191-0;Azlocillin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Azlocillin IgE Ab [Units/volume] in Serum;Azlocillin IgE Qn;;ACTIVE;2.71;2.71 +98192-8;Cephalothin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cephalothin IgE Ab [Units/volume] in Serum;Cephalothin IgE Qn;;ACTIVE;2.71;2.71 +98193-6;Begonia semperflorens Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wax begonia IgE Ab [Units/volume] in Serum;Wax begonia IgE Qn;;ACTIVE;2.71;2.71 +9819-4;Cryptococcus sp Ag;Titr;Pt;CSF;Qn;LA;MICRO;1;Cryptococcus sp Ag [Titer] in Cerebral spinal fluid by Latex agglutination;Cryptoc Ag Titr CSF LA;;ACTIVE;1.0i;2.73 +98194-4;Hibiscus tea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Hibiscus tea IgE Ab [Units/volume] in Serum;Hibiscus tea IgE Qn;;ACTIVE;2.71;2.71 +98195-1;Diatrizoate Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Diatrizoate IgE Ab [Units/volume] in Serum;Diatrizoate IgE Qn;;ACTIVE;2.71;2.71 +98196-9;Echinacea Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Echinacea IgE Ab [Units/volume] in Serum;Echinacea IgE Qn;;ACTIVE;2.71;2.71 +98197-7;EPINEPHrine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;EPINEPHrine IgE Ab [Units/volume] in Serum;Epineph IgE Qn;;ACTIVE;2.71;2.71 +98198-5;Erythrosine B Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Erythrosine B IgE Ab [Units/volume] in Serum;Erythrosine B IgE Qn;;ACTIVE;2.71;2.71 +98199-3;Phenacetin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Phenacetin IgE Ab [Units/volume] in Serum;Phenac IgE Qn;;ACTIVE;2.71;2.71 +98200-9;Paraphenylenediamine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Paraphenylenediamine IgE Ab [Units/volume] in Serum;Paraphenylenediamine IgE Qn;;ACTIVE;2.71;2.71 +98201-7;Fuchsia spp Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Fuchsia spp IgE Ab [Units/volume] in Serum;Fuchsia spp IgE Qn;;ACTIVE;2.71;2.71 +9820-2;Cryptococcus sp Ag;Titr;Pt;Ser;Qn;LA;MICRO;1;Cryptococcus sp Ag [Titer] in Serum by Latex agglutination;Cryptoc Ag Titr Ser LA;;ACTIVE;1.0i;2.73 +98202-5;Ginkgo Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ginkgo IgE Ab [Units/volume] in Serum;Ginkgo IgE Qn;;ACTIVE;2.71;2.71 +98203-3;(Diffusion capacity/Alveolar volume)/predicted;RelInvVI;Pt;Respiratory system;Qn;;PULM;2;(Diffusion capacity/Alveolar volume)/predicted;(Diff cap/Alv vol)/predicted;;ACTIVE;2.71;2.71 +98204-1;Borrelia burgdorferi Ab.IgG & IgM bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Borrelia burgdorferi IgG and IgM bands panel - Serum by Immunoblot;B burgdor IgG+IgM bands Pnl Ser IB;;ACTIVE;2.71;2.71 +98205-8;Borrelia burgdorferi Ab.IgG & IgM & total panel;-;Pt;Ser;-;IA;PANEL.MICRO;1;Borrelia burgdorferi IgG and IgM and total panel - Serum by Immunoassay;B burgdor IgG + IgM + tot Pnl Ser IA;;ACTIVE;2.71;2.71 +98206-6;Borrelia burgdorferi 21kD Ab.IgG;PrThr;Pt;Ser;Ord;IB;MICRO;1;Borrelia burgdorferi 21kD IgG Ab [Presence] in Serum by Immunoblot;B burgdor21kD IgG Ser Ql IB;;ACTIVE;2.71;2.71 +98207-4;Borrelia burgdorferi Ab.IgG & IgM panel;-;Pt;CSF;-;IA;PANEL.MICRO;1;Borrelia burgdorferi IgG and IgM panel - Cerebral spinal fluid by Immunoassay;B burgdor IgG+IgM Pnl CSF IA;;ACTIVE;2.71;2.71 +98208-2;Borrelia burgdorferi Ab.IgM;PrThr;Pt;CSF;Ord;IA;MICRO;1;Borrelia burgdorferi IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay;B burgdor IgM CSF Ql IA;;ACTIVE;2.71;2.71 +98209-0;Legionella pneumophila Ab.IgG & IgM panel;-;Pt;Ser;-;;PANEL.MICRO;1;Legionella pneumophila IgG and IgM panel - Serum;L pneumophila IgG + IgM Pnl Ser;;ACTIVE;2.71;2.71 +9821-0;HIV 1 p24 Ag;PrThr;Pt;Ser;Ord;;MICRO;1;HIV 1 p24 Ag [Presence] in Serum;HIV1 p24 Ag Ser Ql;;ACTIVE;1.0i;2.73 +98210-8;Legionella pneumophila Ab.IgM;PrThr;Pt;Ser;Ord;IA;MICRO;1;Legionella pneumophila IgM Ab [Presence] in Serum by Immunoassay;L pneumo IgM Ser Ql IA;;ACTIVE;2.71;2.71 +98211-6;Salmonella spp Ab panel;-;Pt;Ser;-;Aggl;PANEL.MICRO;1;Salmonella species antibody panel - Serum by Agglutination;Salmonella spp Ab Pnl Ser Aggl;;ACTIVE;2.71;2.71 +98212-4;Reagin Ab & Treponema pallidum Ab.IgG & IgM & total panel;-;Pt;Ser;-;;PANEL.MICRO;1;Reagin Ab and Treponema pallidum IgG and IgM and total panel - Serum;Reag Ab + T pall IgG + IgM + tot Pnl Ser;;ACTIVE;2.71;2.71 +98213-2;Treponema pallidum Ab.IgG & IgM & bands panel;-;Pt;Ser;-;IB;PANEL.MICRO;1;Treponema pallidum IgG and IgM and bands panel - Serum by Immunoblot;T pall IgG + IgM + bands Pnl Ser IB;;ACTIVE;2.71;2.71 +98214-0;Reagin Ab & Treponema pallidum Ab.IgG & IgM & total panel;-;Pt;CSF;-;;PANEL.MICRO;1;Reagin Ab and Treponema pallidum IgG and IgM and total panel - Cerebral spinal fluid;Reag Ab + T pall IgG + IgM + tot Pnl CSF;;ACTIVE;2.71;2.71 +98215-7;Treponema pallidum Ab;PrThr;Pt;CSF;Ord;IA;MICRO;1;Treponema pallidum Ab [Presence] in Cerebral spinal fluid by Immunoassay;T pallidum Ab CSF Ql IA;;ACTIVE;2.71;2.71 +98216-5;Treponema pallidum Ab;ACnc;Pt;CSF;Qn;IA;MICRO;1;Treponema pallidum Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;T pallidum Ab CSF IA-aCnc;;ACTIVE;2.71;2.71 +98217-3;Treponema pallidum Ab.IgG;Titr;Pt;CSF;Qn;IF;MICRO;1;Treponema pallidum IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;T pallidum IgG Titr CSF IF;;ACTIVE;2.71;2.71 +98218-1;Treponema pallidum Ab.IgM;Titr;Pt;CSF;Qn;IF;MICRO;1;Treponema pallidum IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;T pallidum IgM Titr CSF IF;;ACTIVE;2.71;2.71 +98219-9;Treponema pallidum Ab.IgG & IgM & bands panel;-;Pt;CSF;-;IB;PANEL.MICRO;1;Treponema pallidum IgG and IgM and bands panel - Cerebral spinal fluid by Immunoblot;T pall IgG + IgM + bands Pnl CSF IB;;ACTIVE;2.71;2.71 +98220-7;Treponema pallidum Ab.IgG;PrThr;Pt;CSF;Ord;IB;MICRO;1;Treponema pallidum IgG Ab [Presence] in Cerebral spinal fluid by Immunoblot;T pallidum IgG CSF Ql IB;;ACTIVE;2.71;2.71 +98221-5;Treponema pallidum Ab.IgG bands;Prid;Pt;Ser;Nom;IB;MICRO;1;Treponema pallidum IgG bands [Identifier] in Serum by Immunoblot;T pallidum IgG bands Ser IB;;ACTIVE;2.71;2.71 +98222-3;Treponema pallidum Ab.IgG bands;Prid;Pt;CSF;Nom;IB;MICRO;1;Treponema pallidum IgG bands [Identifier] in Cerebral spinal fluid by Immunoblot;T pallidum IgG bands CSF IB;;ACTIVE;2.71;2.71 +98223-1;Treponema pallidum Ab.IgM bands;Prid;Pt;Ser;Nom;IB;MICRO;1;Treponema pallidum IgM bands [Identifier] in Serum by Immunoblot;T pallidum IgM bands Ser IB;;ACTIVE;2.71;2.71 +98224-9;Treponema pallidum Ab.IgM bands;Prid;Pt;CSF;Nom;IB;MICRO;1;Treponema pallidum IgM bands [Identifier] in Cerebral spinal fluid by Immunoblot;T pallidum IgM bands CSF IB;;ACTIVE;2.71;2.71 +98225-6;Piperacillin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Piperacillin IgE Ab [Units/volume] in Serum;Piperacillin IgE Qn;;ACTIVE;2.71;2.71 +98226-4;Prednisolone Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;prednisoLONE IgE Ab [Units/volume] in Serum;prednisoLONE IgE Qn;;ACTIVE;2.71;2.71 +98227-2;Prilocaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Prilocaine IgE Ab [Units/volume] in Serum;Prilocaine IgE Qn;;ACTIVE;2.71;2.71 +9822-8;Bacteria identified;Prid;Pt;Dial fld;Nom;Culture;MICRO;1;Bacteria identified in Dialysis fluid by Culture;Bacteria Dial fld Cult;;ACTIVE;1.0i;2.73 +98228-0;Procaine Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Deprecated Procaine IgE Ab [Units/volume] in Serum;Deprecated Procaine IgE Qn;;DEPRECATED;2.71;2.72 +98229-8;Ofloxacin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Ofloxacin IgE Ab [Units/volume] in Serum;Ofloxacin IgE Qn;;ACTIVE;2.71;2.71 +98230-6;Zea mays starch Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Corn starch IgE Ab [Units/volume] in Serum;Corn starch IgE Qn;;ACTIVE;2.71;2.71 +98231-4;Sorbic acid Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Sorbic acid IgE Ab [Units/volume] in Serum;Sorbic acid IgE Qn;;ACTIVE;2.71;2.71 +98232-2;Hypericum perforatum Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;St. John's wort IgE Ab [Units/volume] in Serum;St. John's wort IgE Qn;;ACTIVE;2.71;2.71 +98233-0;Physalis peruviana Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Cape gooseberry IgE Ab [Units/volume] in Serum;Cape gooseberry IgE Qn;;ACTIVE;2.71;2.71 +98234-8;Quail meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Quail meat IgE Ab [Units/volume] in Serum;Quail meat IgE Qn;;ACTIVE;2.71;2.71 +98235-5;Wild boar meat Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Wild boar meat IgE Ab [Units/volume] in Serum;Wild boar meat IgE Qn;;ACTIVE;2.71;2.71 +9823-6;Mycobacterium sp identified;Prid;Pt;Bronchial;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Bronchial specimen by Organism specific culture;Mycobacterium Bronch Cult;;ACTIVE;1.0i;2.73 +98236-3;Norfloxacin Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;Norfloxacin IgE Ab [Units/volume] in Serum;Norfloxacin IgE Qn;;ACTIVE;2.71;2.71 +98237-1;Chemokine (C-X-C motif) ligand 1;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Chemokine (C-X-C motif) ligand 1 [Mass/volume] in Serum or Plasma;CXCL1 SerPl-mCnc;;ACTIVE;2.71;2.71 +98238-9;Platelet-derived growth factor B+BB;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Platelet-derived growth factor B+BB [Mass/volume] in Serum or Plasma;PDGF B+BB SerPl-mCnc;;ACTIVE;2.71;2.71 +98239-7;CD154 expression & function panel;-;Pt;T cells;-;Flow cytometry;PANEL.CELLMARK;1;CD154 expression and function panel - T cells by Flow cytometry (FC);CD154 Expr+Func Pnl T cells FC;;ACTIVE;2.71;2.71 +98240-5;Cells.CD154;PrThr;Pt;T cells;Ord;;CELLMARK;1;CD154 cells [Presence] in T cells;CD154 cells T cells Ql;;ACTIVE;2.71;2.71 +98241-3;CD154 function (binding to CD40);PrThr;Pt;T cells;Ord;;CELLMARK;1;CD154 function (binding to CD40) [Presence] in T cells;CD154 Function T cells Ql;;ACTIVE;2.71;2.71 +98242-1;Spermatozoa.motile^post ejaculation;NCnc;Pt;Urine;Qn;Microscopy.light;FERT;1;Spermatozoa Motile [#/volume] in Urine by Light microscopy --post ejaculation;Sperm Motile p ejac # Ur Micro;;ACTIVE;2.71;2.71 +98243-9;Spermatozoa^post ejaculation;NCnc;Pt;Urine;Qn;Microscopy.light;FERT;1;Spermatozoa [#/volume] in Urine by Light microscopy --post ejaculation;Sperm p ejac # Ur Micro;;ACTIVE;2.71;2.71 +9824-4;Mycobacterium sp identified;Prid;Pt;Gast fld;Nom;Organism specific culture;MICRO;1;Mycobacterium sp identified in Gastric fluid by Organism specific culture;Mycobacterium Gast Cult;;ACTIVE;1.0i;2.19 +98244-7;Spermatozoa.motile/100 spermatozoa^post ejaculation;NFr;Pt;Urine;Qn;Microscopy.light;FERT;1;Spermatozoa Motile/100 spermatozoa in Urine by Light microscopy --post ejaculation;Sperm Motile p ejac NFr Ur Micro;;ACTIVE;2.71;2.71 +98245-4;Spermatozoa motility^post ejaculation;Score;Pt;Urine;Ord;Microscopy.light;FERT;1;Spermatozoa motility [Score] in Urine Qualitative by Light microscopy --post ejaculation;Sperm motility p ejac Ur Ql Micro;;ACTIVE;2.71;2.71 +98246-2;Spermatozoa.motile^post ejaculation;Num;Pt;Urine;Qn;Microscopy.light;FERT;1;Spermatozoa Motile [#] in Urine by Light microscopy --post ejaculation;Sperm Motile p ejac Ur Micro;;ACTIVE;2.71;2.71 +98247-0;Spermatozoa.agglutinated^post ejaculation;PrThr;Pt;Urine;Ord;;FERT;1;Spermatozoa Agglutinated [Presence] in Urine --post ejaculation;Sperm Agglutinated p ejac Ur Ql;;ACTIVE;2.71;2.71 +98248-8;Primary or recurrent or distant metastasis;Type;Pt;Tumor;Nom;;PATH;1;Primary or recurrent or distant metastasis [Type] in Tumor;Primary, recurrent or dist metastasis;;ACTIVE;2.71;2.71 +98249-6;Cancer pathology panel;-;Pt;Endometrial cancer specimen;-;;PANEL.PATH;1;Cancer pathology panel - Endometrial cancer specimen;Cancer Path Pnl EC spec;;ACTIVE;2.71;2.71 +98250-4;Neuroendocrine tumor;Type;Pt;Tumor;Nom;;PATH;1;Neuroendocrine tumor [Type] in Tumor;Neuroendocrine tumor;;ACTIVE;2.71;2.71 +9825-1;Mycobacterium sp identified;Prid;Pt;Isolate;Nom;;MICRO;1;Mycobacterium sp identified in Isolate;Mycobacterium Islt;;ACTIVE;1.0i;2.73 +98251-2;Stage;Type;Pt;Endometrial cancer specimen;Nom;FIGO;PATH;1;Stage [Type] in Endometrial cancer specimen by FIGO;Stage EC spec FIGO;;ACTIVE;2.71;2.71 +98252-0;Histologic grade;Find;Pt;Endometrial cancer specimen;Ord;;PATH;1;Histologic grade in Endometrial cancer specimen Qualitative;Histo grade EC spec Ql;;ACTIVE;2.71;2.71 +98253-8;Myometrial invasion;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Myometrial invasion [Presence] in Endometrial cancer specimen;Myometrial invasion EC spec Ql;;ACTIVE;2.71;2.71 +98254-6;Depth of myometrial invasion;Len;Pt;Endometrial cancer specimen;Qn;;PATH;1;Depth of myometrial invasion [Length] in Endometrial cancer specimen;Depth myometrial invasion EC spec;;ACTIVE;2.71;2.71 +98255-3;Depth of myometrial invasion/Myometrial thickness;LenFr;Pt;Endometrial cancer specimen;Qn;;PATH;1;Depth of myometrial invasion/Myometrial thickness [Length fraction] in Endometrial cancer specimen;Myometrial invasion/Myometrial LenFr;;ACTIVE;2.71;2.71 +98256-1;Extent of myometrial invasion;Find;Pt;Endometrial cancer specimen;Ord;;PATH;1;Extent of myometrial invasion in Endometrial cancer specimen Qualitative;Extent myometrial invasion EC spec Ql;;ACTIVE;2.71;2.71 +98257-9;Microcystic elongated and fragmented invasion pattern;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;MELF invasion pattern [Presence] in Endometrial cancer specimen;MELF invasion pattern EC spec Ql;;ACTIVE;2.71;2.71 +98258-7;Distance of myoinvasive tumor from serosa;Len;Pt;Endometrial cancer specimen;Qn;;PATH;1;Distance of myoinvasive tumor from serosa [Length] in Endometrial cancer specimen;Myoinvasive tumor from serosa EC spec;;ACTIVE;2.71;2.71 +98259-5;Vessels involved in lymphovascular invasion;Num;Pt;Cancer specimen;Qn;;PATH;1;Vessels involved in lymphovascular invasion [#] in Cancer specimen;Vessels involved LVI Ca spec;;ACTIVE;2.71;2.71 +98260-3;Lymphovascular invasion extent;Find;Pt;Cancer specimen;Ord;;PATH;1;Lymphovascular invasion extent in Cancer specimen Qualitative;LVI extent Ca spec Ql;;ACTIVE;2.71;2.71 +98261-1;Stromal invasion;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Stromal invasion [Presence] in Endometrial cancer specimen;Stromal invasion EC spec Ql;;ACTIVE;2.71;2.71 +98262-9;Distance of tumor from cervical resection margins;Len;Pt;Endometrial cancer specimen;Qn;;PATH;1;Distance of tumor from cervical resection margins [Length] in Endometrial cancer specimen;Tumor dist cerv resect margins EC;;ACTIVE;2.71;2.71 +98263-7;Vaginal involvement;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Vaginal involvement [Presence] in Endometrial cancer specimen;Vaginal involvement EC spec Ql;;ACTIVE;2.71;2.71 +98264-5;Omental involvement;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Omental involvement [Presence] in Endometrial cancer specimen;Omental involvement EC spec Ql;;ACTIVE;2.71;2.71 +98265-2;Involvement of peritoneal biopsy specimen;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Involvement of peritoneal biopsy specimen [Presence] in Endometrial cancer specimen;Peritoneal biopsy involvement EC spec Ql;;ACTIVE;2.71;2.71 +98266-0;Uterine serosa involvement;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Uterine serosa involvement [Presence] in Endometrial cancer specimen;Uterine serosa involvmnt EC spec Ql;;ACTIVE;2.71;2.71 +98267-8;Parametrial involvement;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Parametrial involvement [Presence] in Endometrial cancer specimen;Parametrial involvement EC spec Ql;;ACTIVE;2.71;2.71 +98268-6;Adnexal involvement;PrThr;Pt;Endometrial cancer specimen;Ord;;PATH;1;Adnexal involvement [Presence] in Endometrial cancer specimen;Adnexal involvement EC spec Ql;;ACTIVE;2.71;2.71 +9826-9;Treponema pallidum Ab;PrThr;Pt;CSF;Ord;IF;MICRO;1;Treponema pallidum Ab [Presence] in Cerebral spinal fluid by Immunofluorescence;T pallidum Ab CSF Ql IF;;ACTIVE;1.0i;2.73 +98269-4;Site of adnexal involvement;Anat;Pt;Endometrial cancer specimen;Nom;;PATH;1;Site of adnexal involvement [Anatomy] in Endometrial cancer specimen;Adnexal site EC spec;;ACTIVE;2.71;2.71 +98270-2;Background endometrium findings;Find;Pt;Endometrial cancer specimen;Nom;;PATH;1;Background endometrium findings in Endometrial cancer specimen;Background endometrium EC spec;;ACTIVE;2.71;2.71 +98271-0;Cyclic hormonal phase of endometrium;Type;Pt;Endometrial cancer specimen;Nom;;PATH;1;Cyclic hormonal phase of endometrium [Type] in Endometrial cancer specimen;Hormonal phase EC spec;;ACTIVE;2.71;2.71 +98272-8;Left pelvic lymph nodes examined;Num;Pt;Specimen;Qn;;PATH;1;Left pelvic lymph nodes examined [#] in Specimen;L Pelvic LN examined Spec;;ACTIVE;2.71;2.71 +98273-6;Left pelvic lymph nodes positive;Num;Pt;Specimen;Qn;;PATH;1;Left pelvic lymph nodes positive [#] in Specimen;L Pelvic LN positive Spec;;ACTIVE;2.71;2.71 +98274-4;Right pelvic lymph nodes examined;Num;Pt;Specimen;Qn;;PATH;1;Right pelvic lymph nodes examined [#] in Specimen;R Pelvic LN examined Spec;;ACTIVE;2.71;2.71 +98275-1;Right pelvic lymph nodes positive;Num;Pt;Specimen;Qn;;PATH;1;Right pelvic lymph nodes positive [#] in Specimen;R Pelvic LN positive Spec;;ACTIVE;2.71;2.71 +98276-9;Para-aortic lymph nodes examined;Num;Pt;Specimen;Qn;;PATH;1;Para-aortic lymph nodes examined [#] in Specimen;Para-aortic LN examined Spec;;ACTIVE;2.71;2.71 +9827-7;Paraquat;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;Paraquat [Mass/volume] in Urine;Paraquat Ur-mCnc;;ACTIVE;1.0i;2.42 +98277-7;Para-aortic lymph nodes positive;Num;Pt;Specimen;Qn;;PATH;1;Para-aortic lymph nodes positive [#] in Specimen;Para-aortic LN positive Spec;;ACTIVE;2.71;2.71 +98278-5;Protocol used for examination of sentinel lymph nodes;Type;Pt;Specimen;Nom;;PATH;1;Protocol used for examination of sentinel lymph nodes;Path protocol sentinel nodes;;ACTIVE;2.71;2.71 +98279-3;DNA mismatch repair;Find;Pt;Cancer specimen;Nar;Immune stain;PATH;1;DNA mismatch repair in Cancer specimen by Immune stain Narrative;DNA MMR Ca spec ImStn;;ACTIVE;2.71;2.71 +98280-1;Optimal tissue block;ID;Pt;Cancer specimen;Nom;;PATH;1;Optimal tissue block [Identifier] in Cancer specimen;Optimal tissue block Ca spec;;ACTIVE;2.71;2.71 +98281-9;Structured reporting protocol used;Type;Pt;Report;Nom;;PATH;1;Structured reporting protocol used;Reporting protocol used;;ACTIVE;2.71;2.71 +98282-7;Views;Find;Pt;Abdomen>Stomach+Duodenum;Doc;XR;RAD;2;XR Stomach and Duodenum Views;XR Stomach+Duodenum Views;;ACTIVE;2.71;2.71 +98283-5;Views;Find;Pt;Abdomen>Gastrointestinal tract.upper;Doc;XR;RAD;2;XR Gastrointestinal tract upper Views;XR UGI Views;;ACTIVE;2.71;2.71 +98284-3;Guidance for myelography;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for myelography of Thoracic and lumbar spine;Guided T+L-Spine Myelography;;ACTIVE;2.71;2.71 +9828-5;House dust Greer Ab.IgE;ACnc;Pt;Ser;Qn;;ALLERGY;1;House dust Greer IgE Ab [Units/volume] in Serum;House Dust Greer IgE Qn;;ACTIVE;1.0i;2.73 +98285-0;Guidance for myelography;Find;Pt;Neck>Spine.cervical & Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;{Imaging modality};RAD;2;Guidance for myelography of Cervical and thoracic and lumbar spine;Guided C+T+L-spine Myelography;;ACTIVE;2.71;2.71 +98286-8;Multisection;Find;Pt;Lower extremity.right>Foot vessels;Doc;US.doppler;RAD;2;US.doppler Foot vessels - right;DOP Ft ves-R;;ACTIVE;2.71;2.71 +98287-6;Multisection;Find;Pt;Lower extremity.bilateral>Foot vessels;Doc;US.doppler;RAD;2;US.doppler Foot vessels - bilateral;DOP Ft ves-Bl;;ACTIVE;2.71;2.71 +98288-4;Multisection;Find;Pt;Lower extremity.left>Foot vessels;Doc;US.doppler;RAD;2;US.doppler Foot vessels - left;DOP Ft ves-L;;ACTIVE;2.71;2.71 +98289-2;Multisection;Find;Pt;Upper extremity.left>Hand vessels;Doc;US.doppler;RAD;2;US.doppler Hand vessels - left;DOP Hand ves-L;;ACTIVE;2.71;2.71 +982-9;D little i super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Di sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Di sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +98290-0;Multisection;Find;Pt;Upper extremity.bilateral>Hand vessels;Doc;US.doppler;RAD;2;US.doppler Hand vessels - bilateral;DOP Hand ves-Bl;;ACTIVE;2.71;2.71 +98291-8;Multisection;Find;Pt;Upper extremity.right>Hand vessels;Doc;US.doppler;RAD;2;US.doppler Hand vessels - right;DOP Hand ves-R;;ACTIVE;2.71;2.71 +98292-6;Multisection;Find;Pt;Lower extremity.right>Femoral artery+Popliteal artery;Doc;US.doppler;RAD;2;US.doppler Femoral artery and Popliteal artery - right;DOP Fem a+Pop a-R;;ACTIVE;2.71;2.71 +9829-3;Beta globulin;MRat;24H;Urine;Qn;;CHEM;1;Beta globulin [Mass/time] in 24 hour Urine;B-Globulin 24h Ur-mRate;;ACTIVE;1.0i;2.73 +98293-4;Multisection;Find;Pt;Lower extremity.left>Femoral artery+Popliteal artery;Doc;US.doppler;RAD;2;US.doppler Femoral artery and Popliteal artery - left;DOP Fem a+Pop a-L;;ACTIVE;2.71;2.71 +98294-2;Views lateral^W manual stress;Find;Pt;Lower extremity.bilateral>Lower extremity joint;Doc;XR;RAD;2;XR Lower extremity joint - bilateral Lateral Views W manual stress;XR LE joint-Bl Views Lat W man stress;;ACTIVE;2.71;2.71 +98295-9;Views lateral^W manual stress;Find;Pt;Lower extremity.left>Lower extremity joint;Doc;XR;RAD;2;XR Lower extremity joint - left Lateral Views W manual stress;XR LE joint-L Views Lat W man stress;;ACTIVE;2.71;2.71 +98296-7;Views lateral^W manual stress;Find;Pt;Lower extremity.right>Lower extremity joint;Doc;XR;RAD;2;XR Lower extremity joint - right Lateral Views W manual stress;XR LE joint-R Views Lat W man stress;;ACTIVE;2.71;2.71 +98297-5;Views;Find;Pt;Lower extremity.right>Foot.cuneiform bones;Doc;XR;RAD;2;XR Foot cuneiform bones - right Views;XR Ft.Cuneiforms-R Views;;ACTIVE;2.71;2.71 +98298-3;Views;Find;Pt;Lower extremity.right>Forefoot;Doc;XR;RAD;2;XR Forefoot - right Views;XR Forefoot-R Views;;ACTIVE;2.71;2.71 +98299-1;View Mortise^W gravity stress;Find;Pt;Lower extremity.right>Ankle;Doc;XR;RAD;2;XR Ankle - right Mortise W gravity stress;XR Ankle-R Mortise W gravity stress;;ACTIVE;2.71;2.71 +98300-7;Views LE 3 Broden;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right LE 3 Broden Views;XR Heel-R LE 3V Broden;;ACTIVE;2.71;2.71 +9830-1;Cholesterol.total/Cholesterol.in HDL;MRto;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma;Cholest/HDLc SerPl;;ACTIVE;1.0i;2.73 +98301-5;View AP^W varus stress;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP W varus stress;XR Knee-R AP W varus stress;;ACTIVE;2.71;2.71 +98302-3;View AP^W valgus stress;Find;Pt;Lower extremity.right>Knee;Doc;XR;RAD;2;XR Knee - right AP W valgus stress;XR Knee-R AP W valgus stress;;ACTIVE;2.71;2.71 +98303-1;View lateral;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Lateral;XR Heel-R Lat;;ACTIVE;2.71;2.71 +98304-9;View Canale;Find;Pt;Lower extremity.right>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - right Canale;XR Heel-R Canale;;ACTIVE;2.71;2.71 +98305-6;Views;Find;Pt;Lower extremity.left>Foot.cuneiform bones;Doc;XR;RAD;2;XR Foot cuneiform bones - left Views;XR Ft.Cuneiforms-L Views;;ACTIVE;2.71;2.71 +98306-4;Views;Find;Pt;Lower extremity.left>Forefoot;Doc;XR;RAD;2;XR Forefoot - left Views;XR Forefoot-L Views;;ACTIVE;2.71;2.71 +98307-2;View Mortise^W gravity stress;Find;Pt;Lower extremity.left>Ankle;Doc;XR;RAD;2;XR Ankle - left Mortise W gravity stress;XR Ankle-L Mortise W gravity stress;;ACTIVE;2.71;2.71 +98308-0;Views LE 3 Broden;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left LE 3 Broden Views;XR Heel-L LE 3V Broden;;ACTIVE;2.71;2.71 +98309-8;View AP^W valgus stress;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP W valgus stress;XR Knee-L AP W valgus stress;;ACTIVE;2.71;2.71 +98310-6;View AP^W varus stress;Find;Pt;Lower extremity.left>Knee;Doc;XR;RAD;2;XR Knee - left AP W varus stress;XR Knee-L AP W varus stress;;ACTIVE;2.71;2.71 +98311-4;View lateral;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Lateral;XR Heel-L Lat;;ACTIVE;2.71;2.71 +98312-2;View Canale;Find;Pt;Lower extremity.left>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - left Canale;XR Heel-L Canale;;ACTIVE;2.71;2.71 +98313-0;Views;Find;Pt;Lower extremity.bilateral>Foot.cuneiform bones;Doc;XR;RAD;2;XR Foot cuneiform bones - bilateral Views;XR Ft.Cuneiforms-Bl Views;;ACTIVE;2.71;2.71 +98314-8;Views;Find;Pt;Lower extremity.bilateral>Forefoot;Doc;XR;RAD;2;XR Forefoot - bilateral Views;XR Forefoot-Bl Views;;ACTIVE;2.71;2.71 +98315-5;View lateral;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral Lateral;XR Heel-Bl Lat;;ACTIVE;2.71;2.71 +98316-3;View^W valgus stress;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral Single view W valgus stress;XR Knee-Bl 1V W valgus stress;;ACTIVE;2.71;2.71 +98317-1;View AP^W varus stress;Find;Pt;Lower extremity.bilateral>Knee;Doc;XR;RAD;2;XR Knee - bilateral AP W varus stress;XR Knee-Bl AP W varus stress;;ACTIVE;2.71;2.71 +98318-9;View Mortise^W gravity stress;Find;Pt;Lower extremity.bilateral>Ankle;Doc;XR;RAD;2;XR Ankle - bilateral Mortise W gravity stress;XR Ankle-Bl Mortise W gravity stress;;ACTIVE;2.71;2.71 +9831-9;Gamma globulin;MRat;24H;Urine;Qn;;CHEM;1;Gamma globulin [Mass/time] in 24 hour Urine;Gamma glob 24h Ur-mRate;;ACTIVE;1.0i;2.73 +98319-7;Views LE 3 Broden;Find;Pt;Lower extremity.bilateral>Calcaneus;Doc;XR;RAD;2;XR Calcaneus - bilateral LE 3 Broden Views;XR Heel-Bl LE 3V Broden;;ACTIVE;2.71;2.71 +98320-5;View lateral;Find;Pt;Lower extremity.bilateral>Toe.fourth;Doc;XR;RAD;2;XR Toe fourth - bilateral Lateral;XR Toe 4th-Bl Lat;;ACTIVE;2.71;2.71 +98321-3;View lateral;Find;Pt;Lower extremity.bilateral>Toe.second;Doc;XR;RAD;2;XR Toe second - bilateral Lateral;XR Toe 2nd-Bl Lat;;ACTIVE;2.71;2.71 +98322-1;View lateral;Find;Pt;Lower extremity.bilateral>Toe.third;Doc;XR;RAD;2;XR Toe third - bilateral Lateral;XR Toe 3rd-Bl Lat;;ACTIVE;2.71;2.71 +98323-9;View lateral;Find;Pt;Lower extremity.bilateral>Toe.fifth;Doc;XR;RAD;2;XR Toe fifth - bilateral Lateral;XR Toe 5th-Bl Lat;;ACTIVE;2.71;2.71 +98324-7;Views AP;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Sacrum and Coccyx Views AP;XR Sacrum+Coccyx Views AP;;ACTIVE;2.71;2.71 +98325-4;Views lateral;Find;Pt;Pelvis>Sacrum+Coccyx;Doc;XR;RAD;2;XR Sacrum and Coccyx Lateral Views;XR Sacrum+Coccyx Views Lat;;ACTIVE;2.71;2.71 +98326-2;Views PA for scoliosis^W standing;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine PA Views for scoliosis W standing;XR T+L-Spine Views PA for Scoli W Stand;;ACTIVE;2.71;2.71 +9832-7;Cholesterol.in HDL 2;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 2 [Mass/volume] in Serum or Plasma;HDL2c SerPl-mCnc;;ACTIVE;1.0i;2.73 +98327-0;Views AP for scoliosis^W standing;Find;Pt;Chest>Spine.thoracic & Abdomen>Spine.lumbar;Doc;XR;RAD;2;XR Thoracic and lumbar spine AP Views for scoliosis W standing;XR T+L-Spine Views AP for Scoli W Stand;;ACTIVE;2.71;2.71 +98328-8;View lateral;Find;Pt;Chest+Abdomen>Spine.thoracolumbar junction;Doc;XR;RAD;2;XR Spine thoracolumbar junction Lateral;XR TLJ Lat;;ACTIVE;2.71;2.71 +98329-6;View AP;Find;Pt;Chest+Abdomen>Spine.thoracolumbar junction;Doc;XR;RAD;2;XR Spine thoracolumbar junction AP;XR TLJ AP;;ACTIVE;2.71;2.71 +98330-4;Views PA;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum PA Views;XR Sternum Views PA;;ACTIVE;2.71;2.71 +98331-2;Views oblique;Find;Pt;Chest>Sternum;Doc;XR;RAD;2;XR Sternum Oblique Views;XR Sternum Views Obl;;ACTIVE;2.71;2.71 +98332-0;View reverse oblique;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Reverse oblique;XR Wrist-R Rev Oblique;;ACTIVE;2.71;2.71 +98333-8;View;Find;Pt;Upper extremity.right>Wrist.scaphoid+trapezium+trapezoid;Doc;XR;RAD;2;XR Scaphoid and Trapezium and Trapezoid - right Single view;XR STT-R 1V;;ACTIVE;2.71;2.71 +98334-6;View;Find;Pt;Upper extremity.right>Wrist.hamate;Doc;XR;RAD;2;XR Hamate - right Single view;XR Hamate-R 1V;;ACTIVE;2.71;2.71 +9833-5;Cholesterol.in HDL 3;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Cholesterol in HDL 3 [Mass/volume] in Serum or Plasma;HDL3c SerPl-mCnc;;ACTIVE;1.0i;2.73 +98335-3;View;Find;Pt;Upper extremity.right>Wrist.pisiform+triquetrum;Doc;XR;RAD;2;XR Pisiform and Triquetrum - right Single view;XR Pisiform+Triquetrum-R 1V;;ACTIVE;2.71;2.71 +98336-1;View AP;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right AP;XR Wrist-R AP;;ACTIVE;2.71;2.71 +98337-9;View lateral;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Lateral;XR Wrist-R Lat;;ACTIVE;2.71;2.71 +98338-7;View lateral;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Lateral;XR Wrist-L Lat;;ACTIVE;2.71;2.71 +98339-5;View AP;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left AP;XR Wrist-L AP;;ACTIVE;2.71;2.71 +98340-3;View reverse oblique;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Reverse oblique;XR Wrist-L Rev Oblique;;ACTIVE;2.71;2.71 +98341-1;View;Find;Pt;Upper extremity.left>Wrist.pisiform+triquetrum;Doc;XR;RAD;2;XR Pisiform and Triquetrum - left Single view;XR Pisiform+Triquetrum-L 1V;;ACTIVE;2.71;2.71 +98342-9;View;Find;Pt;Upper extremity.left>Wrist.hamate;Doc;XR;RAD;2;XR Hamate - left Single view;XR Hamate-L 1V;;ACTIVE;2.71;2.71 +9834-3;HYDROmorphone;PrThr;Pt;Urine;Ord;;DRUG/TOX;1;HYDROmorphone [Presence] in Urine;HYDROmorphone Ur Ql;;ACTIVE;1.0i;2.73 +98343-7;View;Find;Pt;Upper extremity.left>Wrist.scaphoid+trapezium+trapezoid;Doc;XR;RAD;2;XR Scaphoid and Trapezium and Trapezoid - left Single view;XR STT-L 1V;;ACTIVE;2.71;2.71 +98344-5;View AP;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral AP;XR Wrist-Bl AP;;ACTIVE;2.71;2.71 +98345-2;View lateral;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Lateral;XR Wrist-Bl Lat;;ACTIVE;2.71;2.71 +98346-0;Views;Find;Pt;Upper extremity.bilateral>Wrist.scaphoid+trapezium+trapezoid;Doc;XR;RAD;2;XR Scaphoid and Trapezium and Trapezoid - bilateral Views;XR STT-Bl Views;;ACTIVE;2.71;2.71 +98347-8;Views;Find;Pt;Upper extremity.bilateral>Wrist.hamate;Doc;XR;RAD;2;XR Hamate - bilateral Views;XR Hamate-Bl Views;;ACTIVE;2.71;2.71 +98348-6;Views;Find;Pt;Upper extremity.bilateral>Wrist.pisiform+triquetrum;Doc;XR;RAD;2;XR Pisiform and Triquetrum - bilateral Views;XR Pisiform+Triquetrum-Bl Views;;ACTIVE;2.71;2.71 +98349-4;Views ulnar deviation;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Ulnar deviation Views;XR Wrist-Bl Views ulnar dev;;ACTIVE;2.71;2.71 +9835-0;HYDROmorphone;MCnc;Pt;Urine;Qn;;DRUG/TOX;1;HYDROmorphone [Mass/volume] in Urine;HYDROmorphone Ur-mCnc;;ACTIVE;1.0i;2.73 +98350-2;Views radial deviation;Find;Pt;Upper extremity.bilateral>Wrist;Doc;XR;RAD;2;XR Wrist - bilateral Radial deviation;XR Wrist-Bl Radial deviation;;ACTIVE;2.71;2.71 +98351-0;Views radial deviation;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right Radial deviation;XR Thumb-R Radial deviation;;ACTIVE;2.71;2.71 +98352-8;View PA;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right PA;XR Thumb-R PA;;ACTIVE;2.71;2.71 +98353-6;View oblique;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left Oblique;XR Thumb-L Obl;;ACTIVE;2.71;2.71 +98354-4;View PA;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left PA;XR Thumb-L PA;;ACTIVE;2.71;2.71 +98355-1;View PA;Find;Pt;Upper extremity.bilateral>Thumb;Doc;XR;RAD;2;XR Thumb - bilateral PA;XR Thumb-Bl PA;;ACTIVE;2.71;2.71 +98356-9;View AP;Find;Pt;Pelvis>Coccyx;Doc;XR;RAD;2;XR Coccyx AP;XR Coccyx AP;;ACTIVE;2.71;2.71 +98357-7;View lateral;Find;Pt;Pelvis>Coccyx;Doc;XR;RAD;2;XR Coccyx Lateral;XR Coccyx Lat;;ACTIVE;2.71;2.71 +98358-5;View^W flexion;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Single view W flexion;XR C-spine 1V W Flx;;ACTIVE;2.71;2.71 +98359-3;View odontoid;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Odontoid;XR C-spine Odont;;ACTIVE;2.71;2.71 +98360-1;View^W extension;Find;Pt;Neck>Spine.cervical;Doc;XR;RAD;2;XR Cervical spine Single view W extension;XR C-spine 1V W Ext;;ACTIVE;2.71;2.71 +98361-9;Views radial deviation;Find;Pt;Upper extremity.left>Thumb;Doc;XR;RAD;2;XR Thumb - left Radial deviation;XR Thumb-L Radial deviation;;ACTIVE;2.71;2.71 +98362-7;View oblique;Find;Pt;Upper extremity.right>Thumb;Doc;XR;RAD;2;XR Thumb - right Oblique;XR Thumb-R Obl;;ACTIVE;2.71;2.71 +98363-5;Views AP + oblique;Find;Pt;Pelvis>Sacroiliac joint.left;Doc;XR;RAD;2;XR Sacroiliac joint - left AP and Oblique;XR SIJ-L AP+Obl;;ACTIVE;2.71;2.71 +98364-3;Views AP + oblique;Find;Pt;Pelvis>Sacroiliac joint.right;Doc;XR;RAD;2;XR Sacroiliac joint - right AP and Oblique;XR SIJ-R AP+Obl;;ACTIVE;2.71;2.71 +98365-0;View^W extension;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Single view W extension;XR T-spine 1V W Ext;;ACTIVE;2.71;2.71 +98366-8;View^W flexion;Find;Pt;Chest>Spine.thoracic;Doc;XR;RAD;2;XR Thoracic spine Single view W flexion;XR T-spine 1V W Flx;;ACTIVE;2.71;2.71 +98367-6;Refraction type;Type;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Phoropter Refraction type;Phoropter Refraction type;;ACTIVE;2.71;2.71 +9836-8;HIV proviral DNA;PrThr;Pt;Bld;Ord;Probe.amp;MICRO;1;HIV proviral DNA [Presence] in Blood by Probe with amplification;HIV proviral DNA Bld Ql Probe amp;;ACTIVE;1.0i;2.73 +98368-4;Corneal vertex distance;Len;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Corneal vertex distance by Phoropter;Corneal vertex by Phoropter;;ACTIVE;2.71;2.71 +98369-2;Vision distance being tested;Type;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Type of Vision distance being tested by by Phoropter;Vision dist tested by by Phoropter;;ACTIVE;2.71;2.71 +983-7;D little i super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Di sup(a) Ag [Presence] on Red Blood Cells from Donor;Di sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +98370-0;Viewing distance;Len;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Phoropter Viewing distance;Phoropter View dist;;ACTIVE;2.71;2.71 +98371-8;Cylinder mode far;Type;Pt;Eye;Ord;Phoropter;EYE.REFRACTION;2;Phoropter Cylinder mode far;Phoropter Cylinder mode far;;ACTIVE;2.71;2.71 +98372-6;Prism far;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism far by Phoropter;R eye Prism far by Phoropter;;ACTIVE;2.71;2.71 +98373-4;Prism far;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism far by Phoropter;L eye Prism far by Phoropter;;ACTIVE;2.71;2.71 +98374-2;Prism base direction far;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base direction far by Phoropter;R eye Prism base dir far by Phoropter;;ACTIVE;2.71;2.71 +98375-9;Prism base direction far;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction far by Phoropter;L eye Prism base dir far by Phoropter;;ACTIVE;2.71;2.71 +9837-6;HIV 1 proviral DNA;PrThr;Pt;Bld;Ord;Probe.amp;MICRO;1;HIV 1 proviral DNA [Presence] in Blood by Probe with amplification;HIV 1 pro DNA Bld Ql Probe amp;;ACTIVE;1.0i;2.73 +98376-7;Horizontal prism.out far;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out far by Phoropter;R eye H prism-out far by Phoropter;;ACTIVE;2.71;2.71 +98377-5;Horizontal prism.out far;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out far by Phoropter;L eye H prism-out far by Phoropter;;ACTIVE;2.71;2.71 +98378-3;Horizontal prism.in far;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in far by Phoropter;R eye H prism-in far by Phoropter;;ACTIVE;2.71;2.71 +98379-1;Horizontal prism.in far;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in far by Phoropter;L eye H prism-in far by Phoropter;;ACTIVE;2.71;2.71 +98380-9;Vertical prism.up far;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - up far by Phoropter;R eye V prism-up far by Phoropter;;ACTIVE;2.71;2.71 +98381-7;Vertical prism.up far;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - up far by Phoropter;L eye V prism-up far by Phoropter;;ACTIVE;2.71;2.71 +98382-5;Vertical prism.down far;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - down far by Phoropter;R eye V prism-down far by Phoropter;;ACTIVE;2.71;2.71 +98383-3;Vertical prism.down far;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - down far by Phoropter;L eye V prism-down far by Phoropter;;ACTIVE;2.71;2.71 +9838-4;Liver kidney microsomal Ab;Titr;Pt;Ser;Qn;IF;SERO;1;Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence;LKM Ab Titr Ser IF;;ACTIVE;1.0i;2.73 +98384-1;Visual acuity far testing condition;Type;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Visual acuity far testing condition by Phoropter;Far VA test cond by Phoropter;;ACTIVE;2.71;2.72 +98385-8;Contrast ratio for far visual acuity measurement;NFr;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Contrast ratio for far visual acuity measurement Phoropter;Contrast for far VA Phoropter;;ACTIVE;2.71;2.71 +98386-6;Pupillary distance.monocular far;Len;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Pupillary distance.monocular far by Phoropter;R eye PD monoc far by Phoropter;;ACTIVE;2.71;2.71 +98387-4;Pupillary distance.monocular far;Len;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Pupillary distance.monocular far by Phoropter;L eye PD monoc far by Phoropter;;ACTIVE;2.71;2.71 +98388-2;Pupillary distance.binocular far;Len;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Pupillary distance.binocular far by Phoropter;Eye PD binoc far by Phoropter;;ACTIVE;2.71;2.71 +98389-0;Depth of stromal invasion/Cervical thickness;LenFr;Pt;Endometrial cancer specimen;Qn;;PATH;1;Depth of stromal invasion/Cervical thickness [Length fraction] in Endometrial cancer specimen;Depth stromal invasion/Cervical LenFr;;ACTIVE;2.71;2.71 +98390-8;Epithelial component of carcinosarcoma;AFr;Pt;Tumor;Qn;;PATH;1;Percent epithelial component of carcinosarcoma;Epithelial comp carcinosarcoma %;;ACTIVE;2.71;2.71 +98391-6;Sarcomatous component of carcinosarcoma;AFr;Pt;Tumor;Qn;;PATH;1;Percent sarcomatous component of carcinosarcoma;Sarcoma comp carcinosarcoma %;;ACTIVE;2.71;2.71 +9839-2;Rheumatoid arthritis nuclear Ab;PrThr;Pt;Ser;Ord;Immune diffusion;SERO;1;Rheumatoid arthritis nuclear Ab [Presence] in Serum by Immune diffusion (ID);RA Nuc Ab Ser Ql ID;;ACTIVE;1.0i;2.73 +98392-4;Sarcomatous pattern in carcinosarcoma;Type;Pt;Tumor;Nom;;PATH;1;Sarcomatous pattern [Type] in carcinosarcoma;Sarcoma pattern carcinosarcoma;;ACTIVE;2.71;2.71 +98393-2;Candida sp;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Candida sp [Identifier] in Isolate by Sequencing;Candida Islt Seq;;ACTIVE;2.71;2.71 +98394-0;Candida sp;Prid;Pt;Isolate;Nom;MS.MALDI-TOF;MICRO;1;Candida sp [Identifier] in Isolate by MS.MALDI-TOF;Candida Islt MS.MALDI-TOF;;ACTIVE;2.71;2.71 +98395-7;Color.candida colony;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.candida colony [Type] in Isolate by Culture;Candida Color Islt Cult;;ACTIVE;2.71;2.71 +98396-5;Aspergillus sp CYP51 gene;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Aspergillus sp CYP51 gene [Identifier] in Isolate by Sequencing;Asperg sp CYP51 Islt Seq;;ACTIVE;2.71;2.71 +98397-3;Color.aspergillus colony;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.aspergillus colony [Type] in Isolate by Culture;Asperg Color Islt Cult;;ACTIVE;2.71;2.71 +98398-1;Fungus identified;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Fungus identified in Isolate by NAA with probe detection;Fungus Islt NAA+probe;;ACTIVE;2.71;2.71 +98399-9;Fungus identified;Prid;Pt;Isolate;Nom;MS.MALDI-TOF;MICRO;1;Fungus identified in Isolate by MS.MALDI-TOF;Fungus Islt MS.MALDI-TOF;;ACTIVE;2.71;2.71 +98-4;Cefonicid;Titr;Pt;Isolate+Ser;Qn;SBT;ABXBACT;1;Cefonicid [Susceptibility] by Serum bactericidal titer;Cefonocid Titr SBT;;ACTIVE;1.0;2.32 +9840-0;Cells.CD11+CD20+;NCnc;Pt;WBC;Qn;;CELLMARK;1;CD11+CD20+ cells [#/volume] in Leukocytes;CD11+CD20+ Cells # WBC;;ACTIVE;1.0i;2.42 +98400-5;Fungus identified;Prid;Pt;Isolate;Nom;Sequencing;MICRO;1;Fungus identified in Isolate by Sequencing;Fungus Islt Seq;;ACTIVE;2.71;2.71 +98401-3;Yeast;Morph;Pt;Isolate;Nom;Microscopy.light;MICRO;1;Yeast [Morphology] in Isolate by Light microscopy;Yeast Morph Islt Micro;;ACTIVE;2.71;2.71 +98402-1;Mold;Morph;Pt;Isolate;Nom;Microscopy.light;MICRO;1;Mold [Morphology] in Isolate by Light microscopy;Mold Islt Micro;;ACTIVE;2.71;2.71 +98403-9;Yeast identified;Prid;Pt;Isolate;Nom;MS.MALDI-TOF;MICRO;1;Yeast identified in Isolate by MS.MALDI-TOF;Yeast Islt MS.MALDI-TOF;;ACTIVE;2.71;2.71 +98404-7;Mold identified;Prid;Pt;Isolate;Nom;MS.MALDI-TOF;MICRO;1;Mold identified in Isolate by MS.MALDI-TOF;Mold Islt MS.MALDI-TOF;;ACTIVE;2.71;2.71 +98405-4;Malassezia sp identified;Prid;Pt;Isolate;Nom;MS.MALDI-TOF;MICRO;1;Malassezia sp identified in Isolate by MS.MALDI-TOF;Malassezia sp Islt MS.MALDI-TOF;;ACTIVE;2.71;2.71 +98406-2;Color.yeast colony^with Sabouraud Dextrose Agar;Type;Pt;Isolate;Nom;Culture;MICRO;1;Color.yeast colony [Type] in Isolate by Culture--with Sabouraud Dextrose Agar;Yeast Color w SDA Islt Cult;;ACTIVE;2.71;2.71 +98407-0;Conidia morphology;Imp;Pt;Isolate;Nom;Microscopy.light;MICRO;1;Conidia morphology [Interpretation] in Isolate by Light microscopy;Conidia morphology Islt Micro-Imp;;ACTIVE;2.71;2.71 +98408-8;Yeast identified;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Yeast identified in Isolate by NAA with probe detection;Yeast Islt NAA+probe;;ACTIVE;2.71;2.71 +98409-6;Mold identified;Prid;Pt;Isolate;Nom;Probe.amp.tar;MICRO;1;Mold identified in Isolate by NAA with probe detection;Mold Islt NAA+probe;;ACTIVE;2.71;2.71 +98410-4;Cryptococcus molecular type;Type;Pt;Isolate;Nom;Sequencing;MICRO;1;Cryptococcus molecular type in Isolate by Sequencing;Cryptoc Molec Typ Islt Seq;;ACTIVE;2.71;2.71 +98411-2;Cryptosporidium sp;Prid;Pt;Isolate;Nom;RFLP.rRNA;MICRO;1;Cryptosporidium sp [Identifier] in Isolate by RFLP.rRNA;Cryptosp Islt RFLP.rRNA;;ACTIVE;2.71;2.71 +98412-0;Retrograde ejaculation evaluation panel;-;Pt;Urine;-;;PANEL.FERT;1;Retrograde ejaculation evaluation panel - Urine;Retrogr Ejac Pnl Ur;;ACTIVE;2.71;2.71 +98413-8;lamoTRIgine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;lamoTRIgine [Mass/volume] in Urine by Confirmatory method;lamoTRIgine Ur Cfm-mCnc;;ACTIVE;2.71;2.71 +98414-6;lamoTRIgine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;lamoTRIgine [Presence] in Urine by Confirmatory method;lamoTRIgine Ur Ql Cfm;;ACTIVE;2.71;2.71 +98415-3;Sertraline/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Sertraline/Creatinine [Mass Ratio] in Urine by Confirmatory method;Sertraline/Creat Ur Cfm;;ACTIVE;2.71;2.71 +98416-1;traZODone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;traZODone/Creatinine [Mass Ratio] in Urine by Confirmatory method;traZODone/Creat Ur Cfm;;ACTIVE;2.71;2.71 +98417-9;Eutylone/Creatinine;MRto;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Eutylone/Creatinine [Mass Ratio] in Urine by Confirmatory method;Eutylone/Creat Ur Cfm;;ACTIVE;2.71;2.71 +9841-8;Casts;Naric;Pt;Urine sed;Qn;Microscopy.light.HPF;UA;1;Deprecated Casts [#/area] in Urine sediment by Microscopy high power field;Deprecated Casts UrnS Qn HPF;;DEPRECATED;1.0i;2.4 +98418-7;Diagnostic audiology results panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Diagnostic audiology results panel;Dx audio result pnl;;TRIAL;2.71;2.71 +98419-5;Diagnostic audiology test performed;Find;Pt;^Patient;Nom;;AUDIO;2;Diagnostic audiology test performed;Dx audio test performed;;TRIAL;2.71;2.71 +98420-3;Comment;Imp;Pt;^Patient;Nar;Audiology;AUDIO;2;Audiology Comment Narrative;Audiology Comment Nar;;TRIAL;2.71;2.71 +98421-1;Hearing loss type;Type;Pt;Ear.left;Nom;;AUDIO;2;Hearing loss type Ear - left;HL type Ear-L;;TRIAL;2.71;2.71 +98422-9;Hearing loss degree;Find;Pt;Ear.left;Ord;;AUDIO;2;Hearing loss degree Ear - left;HL degree Ear-L;;TRIAL;2.71;2.71 +98423-7;Hearing loss degree.min;Find;Pt;Ear.left;Ord;;AUDIO;2;Hearing loss degree.min Ear - left;HL degree.min Ear-L;;TRIAL;2.71;2.71 +98424-5;Hearing loss degree.max;Find;Pt;Ear.left;Ord;;AUDIO;2;Hearing loss degree.max Ear - left;HL degree.max Ear-L;;TRIAL;2.71;2.71 +98425-2;Hearing loss configuration;Type;Pt;Ear.left;Nom;;AUDIO;2;Hearing loss configuration Ear - left;HL config Ear-L;;TRIAL;2.71;2.71 +9842-6;Casts;Naric;Pt;Urine sed;Qn;Microscopy.light.LPF;UA;1;Casts [#/area] in Urine sediment by Microscopy low power field;Casts #/area UrnS LPF;;ACTIVE;1.0i;2.73 +98426-0;Hearing loss type;Type;Pt;Ear.right;Nom;;AUDIO;2;Hearing loss type Ear - right;HL type Ear-R;;TRIAL;2.71;2.71 +98427-8;Hearing loss degree;Find;Pt;Ear.right;Ord;;AUDIO;2;Hearing loss degree Ear - right;HL degree Ear-R;;TRIAL;2.71;2.71 +98428-6;Hearing loss degree.min;Find;Pt;Ear.right;Ord;;AUDIO;2;Hearing loss degree.min Ear - right;HL degree.min Ear-R;;TRIAL;2.71;2.71 +98429-4;Hearing loss degree.max;Find;Pt;Ear.right;Ord;;AUDIO;2;Hearing loss degree.max Ear - right;HL degree.max Ear-R;;TRIAL;2.71;2.71 +98430-2;Hearing loss configuration;Type;Pt;Ear.right;Nom;;AUDIO;2;Hearing loss configuration Ear - right;HL config Ear-R;;TRIAL;2.71;2.71 +98431-0;Diagnostic audiology follow-up recommendation;Find;Pt;^Patient;Nom;;AUDIO;2;Diagnostic audiology follow-up recommendation;Dx audio follow-up rec;;TRIAL;2.71;2.71 +98432-8;Reason diagnostic audiology assessment not performed;Find;Pt;^Patient;Nom;;AUDIO;2;Reason diagnostic audiology assessment not performed;Reason Dx audio not performed;;TRIAL;2.71;2.71 +98433-6;Cylinder mode intermediate;Type;Pt;Eye;Ord;Phoropter;EYE.REFRACTION;2;Phoropter Cylinder mode intermediate;Phoropter Cylinder mode inter;;ACTIVE;2.72;2.72 +9843-4;Circumference.occipital-frontal;Len;Pt;Head;Qn;;BDYCRC.MOLEC;2;Head Occipital-frontal circumference;Head Circumf OFC;;ACTIVE;1.0i;2.73 +98434-4;Sphere intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Sphere intermediate by Phoropter;R eye Sphere inter by Phoropter;;ACTIVE;2.72;2.72 +98435-1;Sphere intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Sphere intermediate by Phoropter;L eye Sphere inter by Phoropter;;ACTIVE;2.72;2.72 +98436-9;Cylinder intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Cylinder intermediate by Phoropter;R eye Cylinder inter by Phoropter;;ACTIVE;2.72;2.72 +98437-7;Cylinder intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Cylinder intermediate by Phoropter;L eye Cylinder inter by Phoropter;;ACTIVE;2.72;2.72 +98438-5;Axis intermediate;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Axis intermediate by Phoropter;R eye Axis inter by Phoropter;;ACTIVE;2.72;2.72 +98439-3;Axis intermediate;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Axis intermediate by Phoropter;L eye Axis inter by Phoropter;;ACTIVE;2.72;2.72 +98440-1;Add intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Add intermediate by Phoropter;R eye Add inter by Phoropter;;ACTIVE;2.72;2.72 +98441-9;Add intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Add intermediate by Phoropter;L eye Add inter by Phoropter;;ACTIVE;2.72;2.72 +9844-2;Circumference;Len;Pt;XXX;Qn;;BDYCRC.ATOM;2;Body region Circumference;Body reg Circumf;;ACTIVE;1.0i;2.73 +98442-7;Prism intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism intermediate by Phoropter;R eye Prism inter by Phoropter;;ACTIVE;2.72;2.72 +98443-5;Prism intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism intermediate by Phoropter;L eye Prism inter by Phoropter;;ACTIVE;2.72;2.72 +98444-3;Prism base direction intermediate;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base direction intermediate by Phoropter;R eye Prism base dir inter by Phoropter;;ACTIVE;2.72;2.72 +98445-0;Prism base direction intermediate;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction intermediate by Phoropter;L eye Prism base dir inter by Phoropter;;ACTIVE;2.72;2.72 +98446-8;Horizontal prism.out intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out intermediate by Phoropter;R eye H prism-out inter by Phoropter;;ACTIVE;2.72;2.72 +98447-6;Horizontal prism.out intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out intermediate by Phoropter;L eye H prism-out inter by Phoropter;;ACTIVE;2.72;2.72 +98448-4;Horizontal prism.in intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in intermediate by Phoropter;R eye H prism-in inter by Phoropter;;ACTIVE;2.72;2.72 +98449-2;Horizontal prism.in intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in intermediate by Phoropter;L eye H prism-in inter by Phoropter;;ACTIVE;2.72;2.72 +984-5;D little i super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Di sup(a) Ag [Presence] on Red Blood Cells;Di sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +98450-0;Vertical prism.up intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - up intermediate by Phoropter;R eye V prism-up inter by Phoropter;;ACTIVE;2.72;2.72 +98451-8;Vertical prism.up intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - up intermediate by Phoropter;L eye V prism-up inter by Phoropter;;ACTIVE;2.72;2.72 +98452-6;Vertical prism.down intermediate;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - down intermediate by Phoropter;R eye V prism-down inter by Phoropter;;ACTIVE;2.72;2.72 +98453-4;Vertical prism.down intermediate;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - down intermediate by Phoropter;L eye V prism-down inter by Phoropter;;ACTIVE;2.72;2.72 +98454-2;Visual acuity intermediate testing condition;Type;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Visual acuity intermediate testing condition by Phoropter;Inter VA test cond by Phoropter;;ACTIVE;2.72;2.72 +98455-9;Contrast ratio for intermediate visual acuity measurement;NFr;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Contrast ratio for intermediate visual acuity measurement by Phoropter;Contrast for inter VA by Phoropter;;ACTIVE;2.72;2.72 +98456-7;Visual acuity.intermediate;LenRto;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Visual acuity intermediate by Phoropter;R eye Inter VA by Phoropter;;ACTIVE;2.72;2.72 +98457-5;Visual acuity.intermediate;LenRto;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Visual acuity intermediate by Phoropter;L eye Inter VA by Phoropter;;ACTIVE;2.72;2.72 +98458-3;Visual acuity.intermediate;LenRto;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Visual acuity intermediate by Phoropter;Eye Inter VA by Phoropter;;ACTIVE;2.72;2.72 +9845-9;Circumference;Prctl;Pt;XXX;Qn;;BDYCRC.ATOM;2;Body region Circumference Percentile;Body reg Circumf Prctl;;ACTIVE;1.0i;2.69 +98459-1;Pupillary distance.monocular intermediate;Len;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Pupillary distance.monocular intermediate by Phoropter;R eye PD monoc inter by Phoropter;;ACTIVE;2.72;2.72 +98460-9;Pupillary distance.monocular intermediate;Len;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Pupillary distance.monocular intermediate by Phoropter;L eye PD monoc inter by Phoropter;;ACTIVE;2.72;2.72 +98461-7;Pupillary distance.binocular intermediate;Len;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Pupillary distance.binocular intermediate by Phoropter;Eye PD binoc inter by Phoropter;;ACTIVE;2.72;2.72 +98462-5;Cylinder mode near;Type;Pt;Eye;Ord;Phoropter;EYE.REFRACTION;2;Phoropter Cylinder mode near;Phoropter Cylinder mode near;;ACTIVE;2.71;2.71 +98463-3;Prism near;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism near by Phoropter;R eye Prism near by Phoropter;;ACTIVE;2.71;2.71 +98464-1;Prism near;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism near by Phoropter;L eye Prism near by Phoropter;;ACTIVE;2.71;2.71 +98465-8;Prism base direction near;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base direction near by Phoropter;R eye Prism base dir near by Phoropter;;ACTIVE;2.71;2.71 +98466-6;Prism base direction near;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction near by Phoropter;L eye Prism base dir near by Phoropter;;ACTIVE;2.71;2.71 +9846-7;Circumference method;Type;Pt;XXX;Nom;*;BDYCRC.ATOM;2;Body region Circumference method;Body reg Circumf method;;ACTIVE;1.0i;2.69 +98467-4;Horizontal prism.out near;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out near by Phoropter;R eye H prism-out near by Phoropter;;ACTIVE;2.71;2.71 +98468-2;Horizontal prism.out near;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out near by Phoropter;L eye H prism-out near by Phoropter;;ACTIVE;2.71;2.71 +98469-0;Horizontal prism.in near;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in near by Phoropter;R eye H prism-in near by Phoropter;;ACTIVE;2.71;2.71 +98470-8;Horizontal prism.in near;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in near by Phoropter;L eye H prism-in near by Phoropter;;ACTIVE;2.71;2.71 +98471-6;Vertical prism.up near;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - up near by Phoropter;R eye V prism-up near by Phoropter;;ACTIVE;2.71;2.71 +98472-4;Vertical prism.up near;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - up near by Phoropter;L eye V prism-up near by Phoropter;;ACTIVE;2.71;2.71 +98473-2;Vertical prism.down near;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - down near by Phoropter;R eye V prism-down near by Phoropter;;ACTIVE;2.71;2.71 +98474-0;Vertical prism.down near;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - down near by Phoropter;L eye V prism-down near by Phoropter;;ACTIVE;2.71;2.71 +9847-5;Circumference site;Anat;Pt;*;Nom;;BDYCRC.ATOM;2;Circumference site;Circumf site;;ACTIVE;1.0i;2.27 +98475-7;Visual acuity near testing condition;Type;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Visual acuity near testing condition by Phoropter;Near VA test cond by Phoropter;;ACTIVE;2.71;2.72 +98476-5;Contrast ratio for near visual acuity measurement;NFr;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Contrast ratio for near visual acuity measurement by Phoropter;Contrast for near VA by Phoropter;;ACTIVE;2.71;2.71 +98477-3;Pupillary distance.monocular near;Len;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Pupillary distance.monocular near by Phoropter;R eye PD monoc near by Phoropter;;ACTIVE;2.71;2.71 +98478-1;Pupillary distance.monocular near;Len;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Pupillary distance.monocular near by Phoropter;L eye PD monoc near by Phoropter;;ACTIVE;2.71;2.71 +98479-9;Pupillary distance.binocular near;Len;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Pupillary distance.binocular near by Phoropter;Eye PD binoc near by Phoropter;;ACTIVE;2.71;2.71 +98480-7;Auditory brainstem response panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Auditory brainstem response panel;ABR panel;;TRIAL;2.71;2.71 +98481-5;Auditory brainstem response threshold^click;RelSoundInt;Pt;Ear.left;Qn;;AUDIO;2;Auditory brainstem response threshold Ear - left --click;ABR threshold click Ear-L;;TRIAL;2.71;2.71 +98482-3;Auditory brainstem response threshold^click;RelSoundInt;Pt;Ear.right;Qn;;AUDIO;2;Auditory brainstem response threshold Ear - right --click;ABR threshold click Ear-R;;TRIAL;2.71;2.71 +9848-3;Body temperature special circumstances;Type;Pt;^Patient;Nom;;BDYTMP.ATOM;2;Body temperature special circumstances;Bdy temp special circumstances;;ACTIVE;1.0i;2.64 +98483-1;Apolipoprotein E phenotype;Prid;Pt;CSF;Nom;;CHEM;1;Apolipoprotein E phenotype [Identifier] in Cerebral spinal fluid;Apo E Phenotype CSF;;ACTIVE;2.71;2.71 +98484-9;Apolipoprotein E phenotype;Imp;Pt;CSF;Nar;;CHEM;1;Apolipoprotein E phenotype [Interpretation] in Cerebral spinal fluid Narrative;Apo E Phenotype CSF-Imp;;ACTIVE;2.71;2.71 +98485-6;Amyloid beta 42 peptide/Amyloid beta 40 peptide;MRto;Pt;CSF;Qn;;CHEM;1;Amyloid beta 42 peptide/Amyloid beta 40 peptide [Mass Ratio] in Cerebral spinal fluid;AL beta42/ABeta 40 CSF;;ACTIVE;2.71;2.74 +98486-4;Apolipoprotein E;MCnc;Pt;CSF;Qn;;CHEM;1;Apolipoprotein E [Mass/volume] in Cerebral spinal fluid;Apo E CSF-mCnc;;ACTIVE;2.71;2.71 +98487-2;Alzheimer's disease risk;Score;Pt;CSF;Qn;Calculated;CHEM;1;Alzheimer's disease risk [Score] in Cerebral spinal fluid by calculation;Alzheimer's risk Score CSF Calc;;ACTIVE;2.71;2.71 +98488-0;Liver fibrosis score;Score;Pt;Ser;Qn;Calculated.FIB4;CHEM;1;Liver fibrosis score in Serum Calculated by FIB4;Liver fibr score Ser Calc.FIB4;;ACTIVE;2.71;2.71 +98489-8;FLT3 gene internal tandem duplication length;Num;Pt;Bld/Tiss;Qn;Molgen;MOLPATH;1;FLT3 gene internal tandem duplication length [#] in Blood or Tissue by Molecular genetics method;FLT3 gene ITD length Bld/T;;ACTIVE;2.71;2.71 +98490-6;FLT3 gene.p.Asp835+Ile836 mutations/normal;NFr;Pt;Bld/Tiss;Qn;Molgen;MOLPATH;1;FLT3 gene.p.Asp835+Ile836 mutations/Normal in Blood or Tissue by Molecular genetics method;FLT3 p.D835+I836/Nor NFr Bld/T;;ACTIVE;2.71;2.71 +9849-1;Institution inventory number;ID;Pt;Body temperature device;Nom;;DEVICES;2;Body temperature device Institution inventory number;Bdy Temp Device Inventory #;;ACTIVE;1.0i;2.27 +98491-4;Liver fibrosis score panel;-;Pt;^Patient;-;Calculated.FIB4;PANEL.CHEM;1;Liver fibrosis score panel by Calculated by FIB4;Liver fibr score Pnl Patient Calc.FIB4;;ACTIVE;2.71;2.71 +98492-2;Apolipoprotein E & beta amyloid Alzheimer's risk panel;-;Pt;CSF;-;;PANEL.CHEM;1;Apolipoprotein E and beta amyloid Alzheimer's risk panel - Cerebral spinal fluid;APOE+ABeta Alz Risk Pnl CSF;;ACTIVE;2.71;2.71 +98493-0;SARS coronavirus 2 ORF1b region;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 ORF1b Sal Ql NAA+probe;;ACTIVE;2.71;2.72 +98494-8;SARS coronavirus 2 ORF1a region;PrThr;Pt;Saliva;Ord;Probe.amp.tar;MICRO;1;SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Saliva (oral fluid) by NAA with probe detection;SARS-CoV-2 ORF1a Sal Ql NAA+probe;;ACTIVE;2.71;2.72 +98495-5;Color vision panel;-;Pt;Eye;-;;PANEL.EYE;2;Color vision panel;Color vision Pnl;;ACTIVE;2.72;2.72 +98496-3;Color blindness;Type;Pt;Eye;Nom;;H&P.PX;2;Color blindness of Eye;Color blindness Eye;;ACTIVE;2.72;2.72 +98497-1;Visual acuity panel;-;Pt;Eye;-;;PANEL.EYE;2;Visual acuity panel;Visual acuity Pnl;;ACTIVE;2.72;2.72 +98498-9;Visual acuity^uncorrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION;2;Visual acuity uncorrected Left eye;L eye VA--uncorr;;ACTIVE;2.72;2.72 +98499-7;Visual acuity^uncorrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION;2;Visual acuity uncorrected Right eye;R eye VA--uncorr;;ACTIVE;2.72;2.72 +98500-2;Visual acuity.binocular^uncorrected;LenRto;Pt;Eye;Qn;;EYE.REFRACTION;2;Visual acuity.binocular uncorrected Eye;Eye VA.binoc--uncorr;;ACTIVE;2.72;2.72 +98501-0;Visual acuity.near^uncorrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION;2;Visual acuity near uncorrected Left eye;L eye Near VA--uncorr;;ACTIVE;2.72;2.72 +98502-8;Visual acuity.near^uncorrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION;2;Visual acuity near uncorrected Right eye;R eye Near VA--uncorr;;ACTIVE;2.72;2.72 +98503-6;Visual acuity.binocular near^uncorrected;LenRto;Pt;Eye;Qn;;EYE.REFRACTION;2;Visual acuity.binocular near uncorrected Eye;Eye Near VA.binoc--uncorr;;ACTIVE;2.72;2.72 +98504-4;Visual acuity.far^uncorrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION;2;Visual acuity far uncorrected Left eye;L eye Far VA--uncorr;;ACTIVE;2.72;2.72 +98505-1;Visual acuity.far^uncorrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION;2;Visual acuity far uncorrected Right eye;R eye Far VA--uncorr;;ACTIVE;2.72;2.72 +98506-9;Visual acuity.binocular far^uncorrected;LenRto;Pt;Eye;Qn;;EYE.REFRACTION;2;Visual acuity.binocular far uncorrected Eye;Eye Far VA.binoc--uncorr;;ACTIVE;2.72;2.72 +98507-7;Visual acuity.binocular^best corrected;LenRto;Pt;Eye;Qn;;EYE.REFRACTION;2;Visual acuity.binocular best corrected Eye;Eye VA.binoc--corr;;ACTIVE;2.72;2.72 +98508-5;Visual acuity.near^best corrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION;2;Visual acuity near best corrected Left eye;L eye Near VA--corr;;ACTIVE;2.72;2.72 +9850-9;Vendor model number;Prid;Pt;Body temperature device;Nom;;DEVICES;2;Body temperature device Vendor model number;Bdy Temp Device Model #;;ACTIVE;1.0i;2.27 +98509-3;Visual acuity.near^best corrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION;2;Visual acuity near best corrected Right eye;R eye Near VA--corr;;ACTIVE;2.72;2.72 +98510-1;Visual acuity.binocular near^best corrected;LenRto;Pt;Eye;Qn;;EYE.REFRACTION;2;Visual acuity.binocular near best corrected Eye;Eye Near VA.binoc--corr;;ACTIVE;2.72;2.72 +98511-9;Visual acuity.far^best corrected;LenRto;Pt;Eye.left;Qn;;EYE.REFRACTION;2;Visual acuity far best corrected Left eye;L eye Far VA--corr;;ACTIVE;2.72;2.72 +98512-7;Visual acuity.far^best corrected;LenRto;Pt;Eye.right;Qn;;EYE.REFRACTION;2;Visual acuity far best corrected Right eye;R eye Far VA--corr;;ACTIVE;2.72;2.72 +98513-5;Visual acuity.binocular far^best corrected;LenRto;Pt;Eye;Qn;;EYE.REFRACTION;2;Visual acuity.binocular far best corrected Eye;Eye Far VA.binoc--corr;;ACTIVE;2.72;2.72 +98514-3;Intensity of shortness of breath in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;Intensity of shortness of breath in past 7 days;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98515-0;PROMIS dyspnea characteristics - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS dyspnea characteristics - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98516-8;Frequency of shortness of breath in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;Frequency of shortness of breath in past 7 days;;;ACTIVE;2.72;2.72 +9851-7;Vendor serial number;ID;Pt;Body temperature device;Nom;;DEVICES;2;Body temperature device Vendor serial number;Bdy Temp Device Serial #;;ACTIVE;1.0i;2.27 +98517-6;Duration of shortness of breath in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;Duration of shortness of breath in past 7 days;;;ACTIVE;2.72;2.72 +98518-4;Shortness of breath in general in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;Shortness of breath in general in past 7 days;;;ACTIVE;2.72;2.72 +985-2;D little i super little b Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Di sup(b) Ab [Presence] in Serum or Plasma from Blood product unit;Di sup(b) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +98520-0;PROMIS item bank - dyspnea characteristics - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - dyspnea characteristics - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98521-8;I worry about becoming short of breath in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;I worry about becoming short of breath in past 7 days;;;ACTIVE;2.72;2.72 +98522-6;I become afraid when I have trouble catching my breath in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;I become afraid when I have trouble catching my breath in past 7 days;;;ACTIVE;2.72;2.72 +98523-4;Exercise seems unsafe for me in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;Exercise seems unsafe for me in past 7 days;;;ACTIVE;2.72;2.72 +98524-2;I am embarrassed by using my inhaled medication in public in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;I am embarrassed by using my inhaled medication in public in past 7 days;;;ACTIVE;2.72;2.72 +9852-5;Institution inventory number;ID;Pt;Weighing device;Nom;;DEVICES;2;Weighing device Institution inventory number;Weighing Device Inventory #;;ACTIVE;1.0i;2.27 +98525-9;I am embarrassed by using my oxygen in public in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;I am embarrassed by using my oxygen in public in past 7 days;;;ACTIVE;2.72;2.72 +98526-7;I am embarrassed by my shortness of breath in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;I am embarrassed by my shortness of breath in past 7 days;;;ACTIVE;2.72;2.72 +98527-5;Things are in the house that trigger breathing problems;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Things are in the house that trigger breathing problems;;;ACTIVE;2.72;2.72 +98528-3;Things are outside that trigger breathing problems;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Things are outside that trigger breathing problems;;;ACTIVE;2.72;2.72 +98529-1;Exposed to pesticides, household cleaning products or substances with irritating odors in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;Exposed to pesticides, household cleaning products or substances with irritating odors in past 7 days;;;ACTIVE;2.72;2.72 +98530-9;Regularly exposed to other people's smoke;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Regularly exposed to other people's smoke;;;ACTIVE;2.72;2.72 +98531-7;Lives in an environment with extreme changes in temperature;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Lives in an environment with extreme changes in temperature;;;ACTIVE;2.72;2.72 +98532-5;There are pets in the household;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;There are pets in the household;;;ACTIVE;2.72;2.72 +9853-3;Vendor model number;Prid;Pt;Weighing device;Nom;;DEVICES;2;Weighing device Vendor model number;Weighing Device Model #;;ACTIVE;1.0i;2.27 +98533-3;PROMIS item bank - dyspnea airborne exposure - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - dyspnea airborne exposure - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98534-1;PROMIS dyspnea airborne exposure - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS dyspnea airborne exposure - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98535-8;I get upset when I can't do something because of my shortness of breath in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROMIS;4;I get upset when I can't do something because of my shortness of breath in past 7 days;;;ACTIVE;2.72;2.72 +98536-6;PROMIS item bank - dyspnea emotional response - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - dyspnea emotional response - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98537-4;PROMIS dyspnea emotional response - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS dyspnea emotional response - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98538-2;Feel like a failure since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel like a failure since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98539-0;Felt like a failure before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt like a failure before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98540-8;Feel useless since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel useless since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +9854-1;Vendor serial number;ID;Pt;Weighing device;Nom;;DEVICES;2;Weighing device Vendor serial number;Weighing Device Serial #;;ACTIVE;1.0i;2.27 +98541-6;Felt useless before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt useless before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98542-4;Feel lack of respect since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel lack of respect since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98543-2;Felt lack of respect before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt lack of respect before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98544-0;Feel worthless since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel worthless since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98545-7;Felt worthless before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt worthless before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98546-5;Feel inferior to others since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel inferior to others since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98547-3;Felt inferior to others before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt inferior to others before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98548-1;Lack confidence since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Lack confidence since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98549-9;Lacked confidence before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Lacked confidence before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98550-7;Negative attitude toward self since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Negative attitude toward self since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98551-5;Negative attitude toward self before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Negative attitude toward self before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98552-3;Feel helpless since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel helpless since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98553-1;Felt helpless before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt helpless before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98554-9;Feel like a burden to family since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel like a burden to family since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98555-6;Felt like a burden to family before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt like a burden to family before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98556-4;Trouble asking others for help since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Trouble asking others for help since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98557-2;Trouble asking others for help before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Trouble asking others for help before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +9855-8;Blood pressure special circumstances;Type;Pt;^Patient;Nom;;BP.ATOM;2;Blood pressure special circumstances;BP special circumstances;;ACTIVE;1.0i;2.64 +98558-0;Feel isolated from others since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel isolated from others since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98559-8;Felt isolated from others before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt isolated from others before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98560-6;Feel disconnected from others since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel disconnected from others since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98561-4;Felt disconnected from others before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt disconnected from others before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98562-2;Feel like a burden to others since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel like a burden to others since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98563-0;Felt like a burden to others before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt like a burden to others before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98564-8;Lost some close relationships since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Lost some close relationships since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98565-5;Lost some close relationships before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Lost some close relationships before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +9856-6;Institution inventory number;ID;Pt;Blood pressure device;Nom;;DEVICES;2;Blood pressure device Institution inventory number;BP device Inventory #;;ACTIVE;1.0i;2.27 +98566-3;Feel avoided since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel avoided since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98567-1;Felt avoided before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt avoided before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98568-9;Feel guilty for being unavailable to family and friends since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel guilty for being unavailable to family and friends since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98569-7;Felt guilty for being unavailable to family and friends before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt guilty for being unavailable to family and friends before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98570-5;Hard to get close to people since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Hard to get close to people since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98571-3;Hard to get close to people before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Hard to get close to people before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98572-1;Trouble relating to others since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Trouble relating to others since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98573-9;Trouble relating to others before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Trouble relating to others before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +9857-4;Vendor model number;Prid;Pt;Blood pressure device;Nom;;DEVICES;2;Blood pressure device Vendor model number;BP device Model #;;ACTIVE;1.0i;2.27 +98574-7;Feel the need to hide true feelings since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel the need to hide true feelings since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98575-4;Felt the need to hide true feelings before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt the need to hide true feelings before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98576-2;Worry about the future since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Worry about the future since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98577-0;Worried about the future before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Worried about the future before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98578-8;Bothered by little things since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Bothered by little things since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98579-6;Bothered by little things before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Bothered by little things before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98580-4;Have difficulty accepting that things aren't always in my control since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Have difficulty accepting that things aren't always in my control since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98581-2;Had difficulty accepting that things weren't always in my control before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Had difficulty accepting that things weren't always in my control before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +9858-2;Vendor serial number;ID;Pt;Blood pressure device;Nom;;DEVICES;2;Blood pressure device Vendor serial number;BP device Serial #;;ACTIVE;1.0i;2.27 +98582-0;Upset by small changes in health since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Upset by small changes in health since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98583-8;Upset by small changes in health before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Upset by small changes in health before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98584-6;Worry about health interfering with life since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Worry about health interfering with life since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98585-3;Worried about health interfering with life before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Worried about health interfering with life before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98586-1;Fear what will happen in the future since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Fear what will happen in the future since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98587-9;Feared what would happen in the future before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feared what would happen in the future before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98588-7;Worry about health interfering with sleep since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Worry about health interfering with sleep since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98589-5;Worried about health interfering with sleep before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Worried about health interfering with sleep before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +9859-0;Class;Type;Pt;Pacemaker lead;Nom;EKG;EKG.ATOM;2;Type of Pacemaker lead by EKG;Pacemaker lead Class EKG;;ACTIVE;1.0i;2.72 +98590-3;Get nervous before going to the doctor since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Get nervous before going to the doctor since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98591-1;Got nervous before going to the doctor before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Got nervous before going to the doctor before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98592-9;Feel I have been given more than I can take since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Feel I have been given more than I can take since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98593-7;Felt I had been given more than I could take before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Felt I had been given more than I could take before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98594-5;Trouble feeling peace of mind since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Trouble feeling peace of mind since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98595-2;Trouble feeling peace of mind before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Trouble feeling peace of mind before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98596-0;Life lacks meaning since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Life lacks meaning since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98597-8;Life lacked meaning before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Life lacked meaning before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98598-6;Life lacks purpose since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Life lacks purpose since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98599-4;Life lacked purpose before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Life lacked purpose before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +986-0;D little i super little b Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Di sup(b) Ab [Presence] in Serum or Plasma from Donor;Di sup(b) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +98600-0;Question the purpose of life since illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Question the purpose of life since illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98601-8;Questioned the purpose of life before illness;Find;Pt;^Patient;Ord;;SURVEY.PROMIS;4;Questioned the purpose of life before illness;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98602-6;PROMIS item bank - psychosocial illness impact - negative - version 1.0;-;Pt;^Patient;-;PROMIS;PANEL.SURVEY.PROMIS;4;PROMIS item bank - psychosocial illness impact - negative - version 1.0;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98603-4;PROMIS psychosocial illness impact - negative - version 1.0 T-score;Tscore;Pt;^Patient;Qn;PROMIS;SURVEY.PROMIS;4;PROMIS psychosocial illness impact - negative - version 1.0 T-score;;Copyright © 2010 PROMIS Health Organization or other individuals/entities that have contributed information and materials to Assessment Center, and are being used with the permission of the copyright holders. Use of PROMIS instruments (e.g., item banks, short forms, profile measures) are subject to the PROMIS Terms and Conditions available at: http://www.assessmentcenter.net/TandC.aspx;ACTIVE;2.72;2.72 +98604-2;Nerve conduction study panel;-;Pt;Nerve;-;;PANEL.NEURO;2;Nerve conduction study panel Nerve;Nerve conduction study Pnl Nerve;;ACTIVE;2.72;2.72 +98605-9;Sensory nerve conduction panel;-;Pt;Radial nerve.left;-;;PANEL.NEURO;2;Sensory nerve conduction panel Left radial nerve;Sensory NC Pnl L radial n;;ACTIVE;2.72;2.72 +98606-7;Stimulation site;Anat;Pt;Nerve;Nom;;NEURO;2;Stimulation site Nerve;Stimulation site Nerve;;ACTIVE;2.72;2.72 +98607-5;Sensory nerve action potential amplitude;Elpot;Pt;Radial nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Left radial nerve;SNAP amplitude L radial n;;ACTIVE;2.72;2.72 +9860-8;Institution inventory number;ID;Pt;EKG device;Nom;;DEVICES;2;EKG device Institution inventory number;EKG Device Inventory #;;ACTIVE;1.0i;2.27 +98608-3;Peak sensory nerve conduction latency;Time;Pt;Radial nerve.left;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Left radial nerve;Peak Sensory NC latency Time L radial n;;ACTIVE;2.72;2.72 +98609-1;Sensory nerve conduction velocity;Vel;Pt;Radial nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Left radial nerve;Sensory NC velocity L radial n;;ACTIVE;2.72;2.72 +98610-9;Sensory nerve action potential area;TmElpot;Pt;Radial nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Left radial nerve;SNAP area AUC L radial n;;ACTIVE;2.72;2.72 +98611-7;Sensory nerve conduction panel;-;Pt;Radial nerve.right;-;;PANEL.NEURO;2;Sensory nerve conduction panel Right radial nerve;Sensory NC Pnl R radial n;;ACTIVE;2.72;2.72 +98612-5;Recording site;Anat;Pt;Nerve;Nom;;NEURO;2;Recording site Nerve;Recording site Nerve;;ACTIVE;2.72;2.72 +98613-3;Sensory nerve action potential amplitude;Elpot;Pt;Radial nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Right radial nerve;SNAP amplitude R radial n;;ACTIVE;2.72;2.72 +98614-1;Peak sensory nerve conduction latency;Time;Pt;Radial nerve.right;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Right radial nerve;Peak Sensory NC latency Time R radial n;;ACTIVE;2.72;2.72 +98615-8;Sensory nerve conduction velocity;Vel;Pt;Radial nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Right radial nerve;Sensory NC velocity R radial n;;ACTIVE;2.72;2.72 +9861-6;Style;Type;Pt;Pacemaker lead;Nom;EKG;EKG.ATOM;2;Style Pacemaker lead by EKG;Style Pacemaker lead EKG;;ACTIVE;1.0i;2.72 +98616-6;Sensory nerve action potential area;TmElpot;Pt;Radial nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Right radial nerve;SNAP area AUC R radial n;;ACTIVE;2.72;2.72 +98617-4;Sensory nerve conduction panel;-;Pt;Median nerve.left;-;;PANEL.NEURO;2;Sensory nerve conduction panel Left median nerve;Sensory NC Pnl L median n;;ACTIVE;2.72;2.72 +98618-2;Sensory nerve action potential amplitude;Elpot;Pt;Median nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Left median nerve;SNAP amplitude L median n;;ACTIVE;2.72;2.72 +98619-0;Peak sensory nerve conduction latency;Time;Pt;Median nerve.left;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Left median nerve;Peak Sensory NC latency Time L median n;;ACTIVE;2.72;2.72 +98620-8;Sensory nerve conduction velocity;Vel;Pt;Median nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Left median nerve;Sensory NC velocity L median n;;ACTIVE;2.72;2.72 +98621-6;Sensory nerve action potential area;TmElpot;Pt;Median nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Left median nerve;SNAP area AUC L median n;;ACTIVE;2.72;2.72 +98622-4;Sensory nerve conduction panel;-;Pt;Median nerve.right;-;;PANEL.NEURO;2;Sensory nerve conduction panel Right median nerve;Sensory NC Pnl R median n;;ACTIVE;2.72;2.72 +98623-2;Sensory nerve action potential amplitude;Elpot;Pt;Median nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Right median nerve;SNAP amplitude R median n;;ACTIVE;2.72;2.72 +9862-4;Vendor model number;Prid;Pt;Pacemaker lead;Nom;EKG;DEVICES;2;Pacemaker lead Vendor model number by EKG;Pacemaker lead Model # EKG;;ACTIVE;1.0i;2.72 +98624-0;Peak sensory nerve conduction latency;Time;Pt;Median nerve.right;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Right median nerve;Peak Sensory NC latency Time R median n;;ACTIVE;2.72;2.72 +98625-7;Sensory nerve conduction velocity;Vel;Pt;Median nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Right median nerve;Sensory NC velocity R median n;;ACTIVE;2.72;2.72 +98626-5;Sensory nerve action potential area;TmElpot;Pt;Median nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Right median nerve;SNAP area AUC R median n;;ACTIVE;2.72;2.72 +98627-3;Sensory nerve conduction panel;-;Pt;Ulnar nerve.left;-;;PANEL.NEURO;2;Sensory nerve conduction panel Left ulnar nerve;Sensory NC Pnl L ulnar n;;ACTIVE;2.72;2.72 +98628-1;Sensory nerve action potential amplitude;Elpot;Pt;Ulnar nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Left ulnar nerve;SNAP amplitude L ulnar n;;ACTIVE;2.72;2.72 +98629-9;Peak sensory nerve conduction latency;Time;Pt;Ulnar nerve.left;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Left ulnar nerve;Peak Sensory NC latency Time L ulnar n;;ACTIVE;2.72;2.72 +98630-7;Sensory nerve conduction velocity;Vel;Pt;Ulnar nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Left ulnar nerve;Sensory NC velocity L ulnar n;;ACTIVE;2.72;2.72 +98631-5;Sensory nerve action potential area;TmElpot;Pt;Ulnar nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Left ulnar nerve;SNAP area AUC L ulnar n;;ACTIVE;2.72;2.72 +9863-2;Vendor model number;Prid;Pt;EKG device;Nom;;DEVICES;2;EKG device Vendor model number;EKG Device Model #;;ACTIVE;1.0i;2.27 +98632-3;Sensory nerve conduction panel;-;Pt;Ulnar nerve.right;-;;PANEL.NEURO;2;Sensory nerve conduction panel Right ulnar nerve;Sensory NC Pnl R ulnar n;;ACTIVE;2.72;2.72 +98633-1;Sensory nerve action potential amplitude;Elpot;Pt;Ulnar nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Right ulnar nerve;SNAP amplitude R ulnar n;;ACTIVE;2.72;2.72 +98634-9;Peak sensory nerve conduction latency;Time;Pt;Ulnar nerve.right;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Right ulnar nerve;Peak Sensory NC latency Time R ulnar n;;ACTIVE;2.72;2.72 +98635-6;Sensory nerve conduction velocity;Vel;Pt;Ulnar nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Right ulnar nerve;Sensory NC velocity R ulnar n;;ACTIVE;2.72;2.72 +98636-4;Sensory nerve action potential area;TmElpot;Pt;Ulnar nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Right ulnar nerve;SNAP area AUC R ulnar n;;ACTIVE;2.72;2.72 +98637-2;Sensory nerve conduction panel;-;Pt;Medial antebrachial cutaneous nerve.left;-;;PANEL.NEURO;2;Sensory nerve conduction panel Left medial antebrachial cutaneous nerve;Sensory NC Pnl L MACN;;ACTIVE;2.72;2.72 +98638-0;Sensory nerve action potential amplitude;Elpot;Pt;Medial antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Left medial antebrachial cutaneous nerve;SNAP amplitude L MACN;;ACTIVE;2.72;2.72 +98639-8;Peak sensory nerve conduction latency;Time;Pt;Medial antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Left medial antebrachial cutaneous nerve;Peak Sensory NC latency Time L MACN;;ACTIVE;2.72;2.72 +9864-0;Vendor serial number;ID;Pt;Pacemaker lead;Nom;EKG;DEVICES;2;Pacemaker lead Vendor serial number by EKG;Pacemaker lead Serial # EKG;;ACTIVE;1.0i;2.72 +98640-6;Sensory nerve conduction velocity;Vel;Pt;Medial antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Left medial antebrachial cutaneous nerve;Sensory NC velocity L MACN;;ACTIVE;2.72;2.72 +98641-4;Sensory nerve action potential area;TmElpot;Pt;Medial antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Left medial antebrachial cutaneous nerve;SNAP area AUC L MACN;;ACTIVE;2.72;2.72 +98642-2;Sensory nerve conduction panel;-;Pt;Medial antebrachial cutaneous nerve.right;-;;PANEL.NEURO;2;Sensory nerve conduction panel Right medial antebrachial cutaneous nerve;Sensory NC Pnl R MACN;;ACTIVE;2.72;2.72 +98643-0;Sensory nerve action potential amplitude;Elpot;Pt;Medial antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Right medial antebrachial cutaneous nerve;SNAP amplitude R MACN;;ACTIVE;2.72;2.72 +98644-8;Peak sensory nerve conduction latency;Time;Pt;Medial antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Right medial antebrachial cutaneous nerve;Peak Sensory NC latency Time R MACN;;ACTIVE;2.72;2.72 +98645-5;Sensory nerve conduction velocity;Vel;Pt;Medial antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Right medial antebrachial cutaneous nerve;Sensory NC velocity R MACN;;ACTIVE;2.72;2.72 +98646-3;Sensory nerve action potential area;TmElpot;Pt;Medial antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Right medial antebrachial cutaneous nerve;SNAP area AUC R MACN;;ACTIVE;2.72;2.72 +98647-1;Sensory nerve conduction panel;-;Pt;Lateral antebrachial cutaneous nerve.left;-;;PANEL.NEURO;2;Sensory nerve conduction panel Left lateral antebrachial cutaneous nerve;Sensory NC Pnl L LACN;;ACTIVE;2.72;2.72 +98648-9;Sensory nerve action potential amplitude;Elpot;Pt;Lateral antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Left lateral antebrachial cutaneous nerve;SNAP amplitude L LACN;;ACTIVE;2.72;2.72 +98649-7;Peak sensory nerve conduction latency;Time;Pt;Lateral antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Left lateral antebrachial cutaneous nerve;Peak Sensory NC latency Time L LACN;;ACTIVE;2.72;2.72 +98650-5;Sensory nerve conduction velocity;Vel;Pt;Lateral antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Left lateral antebrachial cutaneous nerve;Sensory NC velocity L LACN;;ACTIVE;2.72;2.72 +98651-3;Sensory nerve action potential area;TmElpot;Pt;Lateral antebrachial cutaneous nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Left lateral antebrachial cutaneous nerve;SNAP area AUC L LACN;;ACTIVE;2.72;2.72 +98652-1;Sensory nerve conduction panel;-;Pt;Lateral antebrachial cutaneous nerve.right;-;;PANEL.NEURO;2;Sensory nerve conduction panel Right lateral antebrachial cutaneous nerve;Sensory NC Pnl R LACN;;ACTIVE;2.72;2.72 +98653-9;Sensory nerve action potential amplitude;Elpot;Pt;Lateral antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Right lateral antebrachial cutaneous nerve;SNAP amplitude R LACN;;ACTIVE;2.72;2.72 +98654-7;Peak sensory nerve conduction latency;Time;Pt;Lateral antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Right lateral antebrachial cutaneous nerve;Peak Sensory NC latency Time R LACN;;ACTIVE;2.72;2.72 +98655-4;Sensory nerve conduction velocity;Vel;Pt;Lateral antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Right lateral antebrachial cutaneous nerve;Sensory NC velocity R LACN;;ACTIVE;2.72;2.72 +98656-2;Sensory nerve action potential area;TmElpot;Pt;Lateral antebrachial cutaneous nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Right lateral antebrachial cutaneous nerve;SNAP area AUC R LACN;;ACTIVE;2.72;2.72 +9865-7;Vendor serial number;ID;Pt;EKG device;Nom;;DEVICES;2;EKG device Vendor serial number;EKG Device Serial #;;ACTIVE;1.0i;2.27 +98657-0;Body temperature;Temp;Pt;Surface.hand;Qn;;BDYTMP.MOLEC;2;Body temperature - Hand surface;Bdy temp Hand surface;;ACTIVE;2.72;2.72 +98658-8;Sensory nerve conduction panel;-;Pt;Sural nerve.left;-;;PANEL.NEURO;2;Sensory nerve conduction panel Left sural nerve;Sensory NC Pnl L sural n;;ACTIVE;2.72;2.72 +98659-6;Sensory nerve action potential amplitude;Elpot;Pt;Sural nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Left sural nerve;SNAP amplitude L sural n;;ACTIVE;2.72;2.72 +98660-4;Peak sensory nerve conduction latency;Time;Pt;Sural nerve.left;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Left sural nerve;Peak Sensory NC latency Time L sural n;;ACTIVE;2.72;2.72 +98661-2;Sensory nerve conduction velocity;Vel;Pt;Sural nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Left sural nerve;Sensory NC velocity L sural n;;ACTIVE;2.72;2.72 +98662-0;Sensory nerve action potential area;TmElpot;Pt;Sural nerve.left;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Left sural nerve;SNAP area AUC L sural n;;ACTIVE;2.72;2.72 +98663-8;Body temperature;Temp;Pt;Surface.foot;Qn;;BDYTMP.MOLEC;2;Body temperature - Foot surface;Bdy temp Foot surface;;ACTIVE;2.72;2.72 +98664-6;Sensory nerve conduction panel;-;Pt;Sural nerve.right;-;;PANEL.NEURO;2;Sensory nerve conduction panel Right sural nerve;Sensory NC Pnl R sural n;;ACTIVE;2.72;2.72 +9866-5;Axis;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Axis [Interpretation] Narrative by EKG;Axis Imp EKG;;ACTIVE;1.0i;2.5 +98665-3;Sensory nerve action potential amplitude;Elpot;Pt;Sural nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Right sural nerve;SNAP amplitude R sural n;;ACTIVE;2.72;2.72 +98666-1;Peak sensory nerve conduction latency;Time;Pt;Sural nerve.right;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Right sural nerve;Peak Sensory NC latency Time R sural n;;ACTIVE;2.72;2.72 +98667-9;Sensory nerve conduction velocity;Vel;Pt;Sural nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Right sural nerve;Sensory NC velocity R sural n;;ACTIVE;2.72;2.72 +98668-7;Sensory nerve action potential area;TmElpot;Pt;Sural nerve.right;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Right sural nerve;SNAP area AUC R sural n;;ACTIVE;2.72;2.72 +98669-5;Motor nerve conduction panel;-;Pt;Median nerve.left;-;;PANEL.NEURO;2;Motor nerve conduction panel Left median nerve;Motor NC Pnl L median n;;ACTIVE;2.72;2.72 +98670-3;Distance from nerve stimulation to muscle recording site;Len;Pt;Nerve+Muscle;Qn;;NEURO;2;Distance from nerve stimulation to muscle recording site;Dist nerve stim to muscle record site;;ACTIVE;2.72;2.72 +98671-1;Peak motor nerve conduction latency;Time;Pt;Median nerve.left;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Left median nerve;Peak motor NC latency Time L median n;;ACTIVE;2.72;2.72 +98672-9;Motor nerve conduction velocity;Vel;Pt;Median nerve.left;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Left median nerve;Motor NC velocity L median n;;ACTIVE;2.72;2.72 +9867-3;Cardiac pacemaker prosthetic;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Prosthetic cardiac pacemaker [Interpretation] Narrative by EKG;Pmkr Imp EKG;;ACTIVE;1.0i;2.5 +98673-7;Motor nerve conduction panel;-;Pt;Median nerve.right;-;;PANEL.NEURO;2;Motor nerve conduction panel Right median nerve;Motor NC Pnl R median n;;ACTIVE;2.72;2.72 +98674-5;Peak motor nerve conduction latency;Time;Pt;Median nerve.right;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Right median nerve;Peak motor NC latency Time R median n;;ACTIVE;2.72;2.72 +98675-2;Motor nerve conduction velocity;Vel;Pt;Median nerve.right;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Right median nerve;Motor NC velocity R median n;;ACTIVE;2.72;2.72 +98676-0;Nerve segment where motor conduction velocity measured;Anat;Pt;Nerve;Nom;;NEURO;2;Nerve segment where motor conduction velocity measured [Anatomy] Nerve;Nerve seg measured Nerve;;ACTIVE;2.72;2.72 +98677-8;Compound muscle action potential area;TmElpot;Pt;Muscle;Qn;Nerve conduction;NEURO;2;Compound muscle action potential area [Area under the curve] Muscle;CMAP area AUC Muscle;;ACTIVE;2.72;2.72 +98678-6;Motor nerve conduction panel;-;Pt;Ulnar nerve.left;-;;PANEL.NEURO;2;Motor nerve conduction panel Left ulnar nerve;Motor NC Pnl L ulnar n;;ACTIVE;2.72;2.72 +98679-4;Peak motor nerve conduction latency;Time;Pt;Ulnar nerve.left;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Left ulnar nerve;Peak motor NC latency Time L ulnar n;;ACTIVE;2.72;2.72 +98680-2;Motor nerve conduction velocity;Vel;Pt;Ulnar nerve.left;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Left ulnar nerve;Motor NC velocity L ulnar n;;ACTIVE;2.72;2.72 +9868-1;Conduction;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Conduction [Interpretation] Narrative by EKG;Conduction Imp EKG;;ACTIVE;1.0i;2.5 +98681-0;Motor nerve conduction panel;-;Pt;Ulnar nerve.right;-;;PANEL.NEURO;2;Motor nerve conduction panel Right ulnar nerve;Motor NC Pnl R ulnar n;;ACTIVE;2.72;2.72 +98682-8;Peak motor nerve conduction latency;Time;Pt;Ulnar nerve.right;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Right ulnar nerve;Peak motor NC latency Time R ulnar n;;ACTIVE;2.72;2.72 +98683-6;Motor nerve conduction velocity;Vel;Pt;Ulnar nerve.right;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Right ulnar nerve;Motor NC velocity R ulnar n;;ACTIVE;2.72;2.72 +98684-4;Motor nerve conduction panel;-;Pt;Fibular nerve.left;-;;PANEL.NEURO;2;Motor nerve conduction panel Left fibular nerve;Motor NC Pnl L fibular n;;ACTIVE;2.72;2.72 +98685-1;Peak motor nerve conduction latency;Time;Pt;Fibular nerve.left;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Left fibular nerve;Peak motor NC latency Time L fibular n;;ACTIVE;2.72;2.72 +98686-9;Motor nerve conduction velocity;Vel;Pt;Fibular nerve.left;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Left fibular nerve;Motor NC velocity L fibular n;;ACTIVE;2.72;2.72 +98687-7;Motor nerve conduction panel;-;Pt;Fibular nerve.right;-;;PANEL.NEURO;2;Motor nerve conduction panel Right fibular nerve;Motor NC Pnl R fibular n;;ACTIVE;2.72;2.72 +98688-5;Peak motor nerve conduction latency;Time;Pt;Fibular nerve.right;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Right fibular nerve;Peak motor NC latency Time R fibular n;;ACTIVE;2.72;2.72 +98689-3;Motor nerve conduction velocity;Vel;Pt;Fibular nerve.right;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Right fibular nerve;Motor NC velocity R fibular n;;ACTIVE;2.72;2.72 +98690-1;Motor nerve conduction panel;-;Pt;Tibial nerve.left;-;;PANEL.NEURO;2;Motor nerve conduction panel Left tibial nerve;Motor NC Pnl L tibial n;;ACTIVE;2.72;2.72 +98691-9;Peak motor nerve conduction latency;Time;Pt;Tibial nerve.left;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Left tibial nerve;Peak motor NC latency Time L tibial n;;ACTIVE;2.72;2.72 +98692-7;Motor nerve conduction velocity;Vel;Pt;Tibial nerve.left;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Left tibial nerve;Motor NC velocity L tibial n;;ACTIVE;2.72;2.72 +98693-5;Motor nerve conduction panel;-;Pt;Tibial nerve.right;-;;PANEL.NEURO;2;Motor nerve conduction panel Right tibial nerve;Motor NC Pnl R tibial n;;ACTIVE;2.72;2.72 +98694-3;Peak motor nerve conduction latency;Time;Pt;Tibial nerve.right;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Right tibial nerve;Peak motor NC latency Time R tibial n;;ACTIVE;2.72;2.72 +98695-0;Motor nerve conduction velocity;Vel;Pt;Tibial nerve.right;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Right tibial nerve;Motor NC velocity R tibial n;;ACTIVE;2.72;2.72 +98696-8;Sensory nerve conduction panel;-;Pt;Nerve;-;;PANEL.NEURO;2;Sensory nerve conduction panel Nerve;Sensory NC Pnl Nerve;;ACTIVE;2.72;2.72 +98697-6;Distance from nerve stimulation to recording site;Len;Pt;Nerve;Qn;;NEURO;2;Distance from nerve stimulation to recording site Nerve;Dist from nerve stim to record site;;ACTIVE;2.72;2.72 +98698-4;Sensory nerve action potential amplitude;Elpot;Pt;Nerve;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential amplitude Nerve;SNAP amplitude Nerve;;ACTIVE;2.72;2.72 +9869-9;Hypertrophy;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Hypertrophy [Interpretation] Narrative by EKG;Hypertrophy Imp EKG;;ACTIVE;1.0i;2.5 +98699-2;Peak sensory nerve conduction latency;Time;Pt;Nerve;Qn;Nerve conduction;NEURO;2;Peak sensory nerve conduction latency [Time] Nerve;Peak Sensory NC latency Time Nerve;;ACTIVE;2.72;2.72 +98700-8;Sensory nerve conduction velocity;Vel;Pt;Nerve;Qn;Nerve conduction;NEURO;2;Sensory nerve conduction velocity Nerve;Sensory NC velocity Nerve;;ACTIVE;2.72;2.72 +98701-6;Nerve segment where sensory conduction velocity measured;Anat;Pt;Nerve;Nom;;NEURO;2;Nerve segment where sensory conduction velocity measured [Anatomy];Nerve seg measured;;ACTIVE;2.72;2.72 +98702-4;Sensory nerve action potential area;TmElpot;Pt;Nerve;Qn;Nerve conduction;NEURO;2;Sensory nerve action potential area [Area under the curve] Nerve;SNAP area AUC Nerve;;ACTIVE;2.72;2.72 +98703-2;Motor nerve conduction panel;-;Pt;Nerve;-;;PANEL.NEURO;2;Motor nerve conduction panel Nerve;Motor NC Pnl Nerve;;ACTIVE;2.72;2.72 +98704-0;F-wave motor nerve conduction panel;-;Pt;Nerve;-;;PANEL.NEURO;2;F-wave motor nerve conduction panel Nerve;F-wave motor NC Pnl Nerve;;ACTIVE;2.72;2.72 +98705-7;Minimum F-wave latency;Time;Pt;Nerve;Qn;Nerve conduction;NEURO;2;Minimum F-wave latency [Time] Nerve;Min F-wave latency Time Nerve;;ACTIVE;2.72;2.72 +98706-5;Repetitive motor nerve stimulation panel;-;Pt;Nerve;-;;PANEL.NEURO;2;Repetitive motor nerve stimulation panel Nerve;RMNS Pnl Nerve;;ACTIVE;2.72;2.72 +9870-7;Intraventricular conduction;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Intraventricular conduction [Interpretation] Narrative by EKG;IV Conduction Imp EKG;;ACTIVE;1.0i;2.5 +98707-3;Nerve studied;Anat;Pt;*;Nom;;NEURO;2;Nerve studied [Anatomy];Nerve studied;;ACTIVE;2.72;2.72 +98708-1;Muscle state at time of nerve stimulation;Find;Pt;Muscle;Nom;;NEURO;2;Muscle state at time of nerve stimulation Muscle;Muscle state nerve stim Muscle;;ACTIVE;2.72;2.72 +98709-9;Duration of muscle exercise;Time;Pt;Muscle;Qn;;NEURO;2;Duration of muscle exercise;Duration muscle exercise;;ACTIVE;2.72;2.72 +98710-7;Time since muscle exercise;Time;Pt;Muscle;Qn;;NEURO;2;Time since muscle exercise;Time since muscle exercise;;ACTIVE;2.72;2.72 +98711-5;Number of stimuli;Num;Pt;Muscle;Qn;;NEURO;2;Number of stimuli Muscle;Num of stimuli Muscle;;ACTIVE;2.72;2.72 +98712-3;Rate of stimuli;NRat;Pt;Muscle;Qn;;NEURO;2;Rate of stimuli Muscle;Rate of stimuli Muscle;;ACTIVE;2.72;2.72 +98713-1;Compound muscle action potential amplitude;Elpot;Pt;Muscle;Qn;Nerve conduction;NEURO;2;Compound muscle action potential amplitude Muscle;CMAP amplitude Muscle;;ACTIVE;2.72;2.72 +98714-9;Percent change in action potential amplitude^post repetitive stimulation;Ratio;Pt;Muscle;Qn;;NEURO;2;Percent change in action potential amplitude [Ratio] Muscle --post repetitive stimulation;Prcnt chng AP amp p rptv stim Muscle;;ACTIVE;2.72;2.72 +9871-5;Intraventricular conduction;Imp;Pt;Heart;Nom;EKG;EKG.IMP;2;Intraventricular conduction [Interpretation] by EKG;IV Conduction Imp EKG;;ACTIVE;1.0i;2.5 +98715-6;Percent change in action potential area^post repetitive stimulation;Ratio;Pt;Muscle;Qn;;NEURO;2;Percent change in action potential area [Ratio] Muscle --post repetitive stimulation;Prcnt chng AP area p rptv stim Muscle;;ACTIVE;2.72;2.72 +98716-4;Electromyography panel;-;Pt;Muscle;-;EMG;PANEL.NEURO;2;Electromyography panel;EMG Pnl;;ACTIVE;2.72;2.72 +98717-2;Muscle studied;Anat;Pt;*;Nom;;NEURO;2;Muscle studied [Anatomy];Muscle studied;;ACTIVE;2.72;2.72 +98718-0;Insertional activity;Find;Pt;Muscle;Ord;EMG;NEURO;2;Insertional activity of Muscle on EMG;Insertional activity Muscle EMG;;ACTIVE;2.72;2.72 +98719-8;Spontaneous activity;Find;Pt;Muscle;Ord;EMG;NEURO;2;Spontaneous activity of Muscle on EMG;Spont activity Muscle EMG;;ACTIVE;2.72;2.72 +98720-6;Spontaneous activity.positive sharp waves;Find;Pt;Muscle;Ord;EMG;NEURO;2;Spontaneous activity.positive sharp waves of Muscle on EMG;Spont activity.PSWs Muscle EMG;;ACTIVE;2.72;2.72 +98721-4;Spontaneous activity.fibrillation;Find;Pt;Muscle;Ord;EMG;NEURO;2;Spontaneous activity.fibrillation of Muscle on EMG;Spont activity.fibrillation Muscle EMG;;ACTIVE;2.72;2.72 +98722-2;Spontaneous activity.fasciculation;Find;Pt;Muscle;Ord;EMG;NEURO;2;Spontaneous activity.fasciculation of Muscle on EMG;Spont activity.fasciculation Muscle EMG;;ACTIVE;2.72;2.72 +9872-3;Myocardial ischemia;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Myocardial ischemia [Interpretation] Narrative by EKG;Myocard Ischemia Imp EKG;;ACTIVE;1.0i;2.5 +98723-0;Voluntary activity.amplitude;Find;Pt;Muscle;Ord;EMG;NEURO;2;Voluntary activity.amplitude of Muscle on EMG;Volun activity.amplitude Muscle EMG;;ACTIVE;2.72;2.72 +98724-8;Voluntary activity.duration;Find;Pt;Muscle;Ord;EMG;NEURO;2;Voluntary activity.duration of Muscle on EMG;Volun activity.duration Muscle EMG;;ACTIVE;2.72;2.72 +98725-5;Voluntary activity.polyphasics;Find;Pt;Muscle;Ord;EMG;NEURO;2;Voluntary activity.polyphasics of Muscle on EMG;Volun activity.polyphasics Muscle EMG;;ACTIVE;2.72;2.72 +98726-3;Voluntary activity.recruitment;Find;Pt;Muscle;Nom;EMG;NEURO;2;Voluntary activity.recruitment of Muscle on EMG;Volun activity.recruitment Muscle EMG;;ACTIVE;2.72;2.72 +98727-1;Voluntary activity pattern;Find;Pt;Muscle;Nom;EMG;NEURO;2;Voluntary activity pattern of Muscle on EMG;Volun activity pattern Muscle EMG;;ACTIVE;2.72;2.72 +98728-9;Voluntary activity effort;Find;Pt;Muscle;Ord;EMG;NEURO;2;Voluntary activity effort of Muscle on EMG;Volun activity effort Muscle EMG;;ACTIVE;2.72;2.72 +98729-7;Recording site;Anat;Pt;Muscle;Nom;;NEURO;2;Recording site Muscle;Recording site Muscle;;ACTIVE;2.72;2.72 +98730-5;Peak motor nerve conduction latency;Time;Pt;Nerve;Qn;Nerve conduction;NEURO;2;Peak motor nerve conduction latency [Time] Nerve;Peak motor NC latency Time Nerve;;ACTIVE;2.72;2.72 +9873-1;QRS complex;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;QRS complex [Interpretation] Narrative by EKG;QRS Complex Imp EKG;;ACTIVE;1.0i;2.5 +98731-3;Motor nerve conduction velocity;Vel;Pt;Nerve;Qn;Nerve conduction;NEURO;2;Motor nerve conduction velocity Nerve;Motor NC velocity Nerve;;ACTIVE;2.72;2.72 +98732-1;SARS coronavirus 2 spike protein RBD Ab.neut;Titr;Pt;Ser/Plas;Qn;IA;MICRO;1;SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Titer] in Serum or Plasma by Immunoassay;SARS-CoV-2 S RBD NAb Titr SerPl IA;;ACTIVE;2.72;2.72 +98733-9;Percent neutralization by SARS coronavirus 2 spike protein RBD Ab.neut;AFr;Pt;Ser/Plas;Qn;IA;MICRO;1;Percent neutralization by SARS coronavirus 2 spike protein RBD neutralizing antibody in Serum or Plasma by Immunoassay;SARS-CoV-2 S RBD NAb SerPl IA-%;;ACTIVE;2.72;2.72 +98734-7;SARS coronavirus 2 spike protein RBD Ab.neut;ACnc;Pt;Ser/Plas;Qn;IA;MICRO;1;SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Units/volume] in Serum or Plasma by Immunoassay;SARS-CoV-2 S RBD NAb SerPl IA-aCnc;;ACTIVE;2.72;2.72 +98735-4;Worth 4 dot test far;Imp;Pt;Eye;Nom;;EYE.PX;2;Eye Worth 4 dot test far [Interpretation];Eye Worth 4 dot far [Imp];;ACTIVE;2.72;2.72 +98736-2;Eye that was covered with red lens during test;Find;Pt;Eye;Nom;;EYE.PX;2;Eye that was covered with red lens during test;Eye covered w red lens;;ACTIVE;2.72;2.72 +98737-0;Worth 4 dot test near;Imp;Pt;Eye;Nom;;EYE.PX;2;Eye Worth 4 dot test near [Interpretation];Eye Worth 4 dot near [Imp];;ACTIVE;2.72;2.72 +98738-8;Accommodative convergence to accommodation ratio;Type;Pt;Eye;Nom;Phoropter;EYE.REFRACTION;2;Type of AC/A ratio by by Phoropter;Type of AC/A ratio by by Phoropter;;ACTIVE;2.72;2.72 +98739-6;Accommodative convergence to accommodation ratio;Ratio;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye AC/A ratio by Phoropter;Eye AC/A ratio by Phoropter;;ACTIVE;2.72;2.72 +98740-4;Phoria exam method;Type;Pt;Eye;Nom;;EYE.PX;2;Type of Phoria exam method;Type of Phoria exam method;;ACTIVE;2.72;2.72 +98741-2;Lens used for testing;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Lens used for testing by Phoropter;Eye Lens used for testing by Phoropter;;ACTIVE;2.72;2.72 +98742-0;Prism for far phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism for far phoria by Phoropter;R eye Prism far phor by Phoropter;;ACTIVE;2.72;2.72 +98743-8;Prism for far phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism for far phoria by Phoropter;L eye Prism far phor by Phoropter;;ACTIVE;2.72;2.72 +98744-6;Prism base direction for far phoria;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base direction for far phoria by Phoropter;R eye Prism dir far phor by Phoropter;;ACTIVE;2.72;2.72 +98745-3;Prism base direction for far phoria;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction for far phoria by Phoropter;L eye Prism dir far phor by Phoropter;;ACTIVE;2.72;2.72 +98746-1;Horizontal prism.out for far phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out for far phoria by Phoropter;R eye H prism-out far phor by Phoropter;;ACTIVE;2.72;2.72 +98747-9;Horizontal prism.out for far phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out for far phoria by Phoropter;L eye H prism-out far phor by Phoropter;;ACTIVE;2.72;2.72 +98748-7;Horizontal prism.in for far phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in for far phoria by Phoropter;R eye H prism-in far phor by Phoropter;;ACTIVE;2.72;2.72 +9874-9;Rhythm segment;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Rhythm segment [Interpretation] Narrative by EKG;Rhythm Seg Imp EKG;;ACTIVE;1.0i;2.5 +98749-5;Horizontal prism.in for far phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in for far phoria by Phoropter;L eye H prism-in far phor by Phoropter;;ACTIVE;2.72;2.72 +98750-3;Vertical prism.up for far phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - up for far phoria by Phoropter;R eye V prism-up far phor by Phoropter;;ACTIVE;2.72;2.72 +98751-1;Vertical prism.up for far phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - up for far phoria by Phoropter;L eye V prism-up far phor by Phoropter;;ACTIVE;2.72;2.72 +98752-9;Vertical prism.down for far phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - down for far phoria by Phoropter;R eye V prism-down far phor by Phoropter;;ACTIVE;2.72;2.72 +98753-7;Vertical prism.down for far phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - down for far phoria by Phoropter;L eye V prism-down far phor by Phoropter;;ACTIVE;2.72;2.72 +98754-5;Prism for near phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism for near phoria by Phoropter;R eye Prism near phor by Phoropter;;ACTIVE;2.72;2.72 +98755-2;Prism for near phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism for near phoria by Phoropter;L eye Prism near phor by Phoropter;;ACTIVE;2.72;2.72 +9875-6;ST-T segment;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;ST-T segment [Interpretation] Narrative by EKG;ST-T seg Imp EKG;;ACTIVE;1.0i;2.5 +98756-0;Prism base direction for near phoria;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base direction for near phoria by Phoropter;R eye Prism dir near phor by Phoropter;;ACTIVE;2.72;2.72 +98757-8;Prism base direction for near phoria;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction for near phoria by Phoropter;L eye Prism dir near phor by Phoropter;;ACTIVE;2.72;2.72 +98758-6;Horizontal prism.out for near phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out for near phoria by Phoropter;R eye H prism-out near phor by Phoropter;;ACTIVE;2.72;2.72 +98759-4;Horizontal prism.out for near phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out for near phoria by Phoropter;L eye H prism-out near phor by Phoropter;;ACTIVE;2.72;2.72 +98760-2;Horizontal prism.in for near phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in for near phoria by Phoropter;R eye H prism-in near phor by Phoropter;;ACTIVE;2.72;2.72 +98761-0;Horizontal prism.in for near phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in for near phoria by Phoropter;L eye H prism-in near phor by Phoropter;;ACTIVE;2.72;2.72 +98762-8;Vertical prism.up for near phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - up for near phoria by Phoropter;R eye V prism-up near phor by Phoropter;;ACTIVE;2.72;2.72 +98763-6;Vertical prism.up for near phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - up for near phoria by Phoropter;L eye V prism-up near phor by Phoropter;;ACTIVE;2.72;2.72 +9876-4;Ventricular morphology;Imp;Pt;Heart;Nar;EKG;EKG.IMP;2;Ventricular morphology [Interpretation] Narrative by EKG;Ventricular morph Imp EKG;;ACTIVE;1.0i;2.5 +98764-4;Vertical prism.down for near phoria;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - down for near phoria by Phoropter;R eye V prism-down near phor Phoropter;;ACTIVE;2.72;2.72 +98765-1;Vertical prism.down for near phoria;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - down for near phoria by Phoropter;L eye V prism-down near phor Phoropter;;ACTIVE;2.72;2.72 +98766-9;Far divergence blur;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far divergence blur by Phoropter;Far div blur by Phoropter;;ACTIVE;2.72;2.72 +98767-7;Far divergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far divergence break by Phoropter;Far divergence break by Phoropter;;ACTIVE;2.72;2.72 +98768-5;Far divergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far divergence recovery by Phoropter;Far div recovery by Phoropter;;ACTIVE;2.72;2.72 +98769-3;Far convergence blur;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far convergence blur by Phoropter;Far con blur by Phoropter;;ACTIVE;2.72;2.72 +98770-1;Far convergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far convergence break by Phoropter;Far con break by Phoropter;;ACTIVE;2.72;2.72 +98771-9;Far convergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far convergence recovery by Phoropter;Far con recovery by Phoropter;;ACTIVE;2.72;2.72 +9877-2;J point depression.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead AVF;J Pnt Depr L-AVF;;ACTIVE;1.0i;2.48 +98772-7;Eye for far infravergence measurement;Find;Pt;^Patient;Nom;;EYE.REFRACTION;2;Eye for far infravergence measurement;Far infra measurement eye;;ACTIVE;2.72;2.72 +98773-5;Far infravergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far infravergence break by Phoropter;Far infravergence break by Phoropter;;ACTIVE;2.72;2.72 +98774-3;Far infravergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far infravergence recovery by Phoropter;Far infra recovery by Phoropter;;ACTIVE;2.72;2.72 +98775-0;Eye for far supravergence measurement;Find;Pt;^Patient;Nom;;EYE.REFRACTION;2;Eye for far supravergence measurement;Far supra measurement eye;;ACTIVE;2.72;2.72 +98776-8;Far supravergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far supravergence break by Phoropter;Far supravergence break by Phoropter;;ACTIVE;2.72;2.72 +98777-6;Far supravergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Far supravergence recovery by Phoropter;Far supra recovery by Phoropter;;ACTIVE;2.72;2.72 +98778-4;Near divergence blur;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near divergence blur by Phoropter;Near div blur by Phoropter;;ACTIVE;2.72;2.72 +98779-2;Near divergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near divergence break by Phoropter;Near divergence break by Phoropter;;ACTIVE;2.72;2.72 +987-8;D little i super little b Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Di sup(b) Ab [Presence] in Serum or Plasma;Di sup(b) Ab SerPl Ql;;ACTIVE;1.0;2.56 +9878-0;J point depression.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead AVL;J Pnt Depr L-AVL;;ACTIVE;1.0i;2.48 +98780-0;Near divergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near divergence recovery by Phoropter;Near div recovery by Phoropter;;ACTIVE;2.72;2.72 +98781-8;Near convergence blur;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near convergence blur by Phoropter;Near con blur by Phoropter;;ACTIVE;2.72;2.72 +98782-6;Near convergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near convergence recovery by Phoropter;Near con recovery by Phoropter;;ACTIVE;2.72;2.72 +98783-4;Eye for near infravergence measurement;Find;Pt;Eye;Nom;;EYE.REFRACTION;2;Eye for near infravergence measurement;Near infra measurement eye;;ACTIVE;2.72;2.72 +98784-2;Near infravergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near infravergence break by Phoropter;Near infravergence break by Phoropter;;ACTIVE;2.72;2.72 +98785-9;Near infravergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near infravergence recovery by Phoropter;Near infra recovery by Phoropter;;ACTIVE;2.72;2.72 +98786-7;Eye for near supravergence measurement;Find;Pt;Eye;Nom;;EYE.REFRACTION;2;Eye for near supravergence measurement;Near supra measurement eye;;ACTIVE;2.72;2.72 +98787-5;Near supravergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near supravergence break by Phoropter;Near supravergence break by Phoropter;;ACTIVE;2.72;2.72 +98788-3;Near supravergence recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near supravergence recovery by Phoropter;Near supra recovery by Phoropter;;ACTIVE;2.72;2.72 +98789-1;Horizontal prism.in far for Sheard;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - in far for Sheard by Phoropter;Eye H prism-in far Sheard by Phoropter;;ACTIVE;2.72;2.72 +98790-9;Horizontal prism.out far for Sheard;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - out far for Sheard by Phoropter;Eye H prism-out far Sheard by Phoropter;;ACTIVE;2.72;2.72 +98791-7;Sphere far for Sheard;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Sphere far for Sheard by Phoropter;Eye Sphere far Sheard by Phoropter;;ACTIVE;2.72;2.72 +98792-5;Horizontal prism.in near for Sheard;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - in near for Sheard by Phoropter;Eye H prism-in near Sheard by Phoropter;;ACTIVE;2.72;2.72 +98793-3;Horizontal prism.out near for Sheard;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - out near for Sheard by Phoropter;Eye H prism-out near Sheard by Phoropter;;ACTIVE;2.72;2.72 +98794-1;Sphere near for Sheard;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Sphere near for Sheard by Phoropter;Eye Sphere near Sheard by Phoropter;;ACTIVE;2.72;2.72 +98795-8;Horizontal prism.in far for Percival;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - in far for Percival by Phoropter;Eye H prism-in far Perc by Phoropter;;ACTIVE;2.72;2.72 +98796-6;Horizontal prism.out far for Percival;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - out far for Percival by Phoropter;Eye H prism-out far Perc by Phoropter;;ACTIVE;2.72;2.72 +98797-4;Sphere far for Percival;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Sphere far for Percival by Phoropter;Eye Sphere far Perc by Phoropter;;ACTIVE;2.72;2.72 +9879-8;J point depression.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead AVR;J Pnt Depr L-AVR;;ACTIVE;1.0i;2.48 +98798-2;Horizontal prism.in near for Percival;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - in near for Percival by Phoropter;Eye H prism-in near Perc by Phoropter;;ACTIVE;2.72;2.72 +98799-0;Horizontal prism.out near for Percival;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal prism - out near for Percival by Phoropter;Eye H prism-out near Perc by Phoropter;;ACTIVE;2.72;2.72 +98800-6;Sphere near for Percival;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Sphere near for Percival by Phoropter;Eye Sphere near Perc by Phoropter;;ACTIVE;2.72;2.72 +98801-4;Horizontal aniseikonia;PctDiff;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Horizontal aniseikonia by Phoropter;Eye Hor aniseikonia by Phoropter;;ACTIVE;2.72;2.72 +98802-2;Eye that sees the larger image in horizontal aniseikonia;Find;Pt;^Patient;Nom;;EYE.REFRACTION;2;Eye that sees the larger image in horizontal aniseikonia;Eye seeing larger in hor aniseikonia;;ACTIVE;2.72;2.72 +98803-0;Vertical aniseikonia;PctDiff;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Vertical aniseikonia by Phoropter;Eye Vert aniseikonia by Phoropter;;ACTIVE;2.72;2.72 +98804-8;Eye that sees the larger image in vertical aniseikonia;Find;Pt;^Patient;Nom;;EYE.REFRACTION;2;Eye that sees the larger image in vertical aniseikonia;Eye seeing larger in vert aniseikonia;;ACTIVE;2.72;2.72 +98805-5;Add for monocular accommodative lag;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Add for monocular accommodative lag by Phoropter;R eye Add mon accom lag by Phoropter;;ACTIVE;2.72;2.72 +9880-6;J point depression.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead I;J Pnt Depr L-I;;ACTIVE;1.0i;2.48 +98806-3;Add for monocular accommodative lag;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Add for monocular accommodative lag by Phoropter;L eye Add mon accom lag by Phoropter;;ACTIVE;2.72;2.72 +98807-1;Add for binocular accommodative lag;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Add for binocular accommodative lag by Phoropter;R eye Add bin accom lag by Phoropter;;ACTIVE;2.72;2.72 +98808-9;Add for binocular accommodative lag;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Add for binocular accommodative lag by Phoropter;L eye Add bin accom lag by Phoropter;;ACTIVE;2.72;2.72 +98809-7;Horizontal prism.out for monocular accommodative lag;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out for monocular accommodative lag by Phoropter;R eye H prism-out mon acc lag Phoropter;;ACTIVE;2.72;2.72 +98810-5;Horizontal prism.out for monocular accommodative lag;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out for monocular accommodative lag by Phoropter;L eye H prism-out mon acc lag Phoropter;;ACTIVE;2.72;2.72 +98811-3;Horizontal prism.in for monocular accommodative lag;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in for monocular accommodative lag by Phoropter;R eye H prism-in mon acc lag Phoropter;;ACTIVE;2.72;2.72 +98812-1;Horizontal prism.in for monocular accommodative lag;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in for monocular accommodative lag by Phoropter;L eye H prism-in mon acc lag Phoropter;;ACTIVE;2.72;2.72 +98813-9;Horizontal prism.in for binocular accommodative lag;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in for binocular accommodative lag by Phoropter;R eye H prism-in bin acc lag Phoropter;;ACTIVE;2.72;2.72 +9881-4;J point depression.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead II;J Pnt Depr L-II;;ACTIVE;1.0i;2.48 +98814-7;Horizontal prism.in for binocular accommodative lag;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in for binocular accommodative lag by Phoropter;L eye H prism-in bin acc lag Phoropter;;ACTIVE;2.72;2.72 +98815-4;Horizontal prism.out for binocular accommodative lag;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out for binocular accommodative lag by Phoropter;R eye H prism-out bin acc lag Phoropter;;ACTIVE;2.72;2.72 +98816-2;Horizontal prism.out for binocular accommodative lag;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out for binocular accommodative lag by Phoropter;L eye H prism-out bin acc lag Phoropter;;ACTIVE;2.72;2.72 +98817-0;Meter angle for near point convergence;Arb;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Meter angle for near point convergence by Phoropter;Eye MA for NPC by Phoropter;;ACTIVE;2.72;2.72 +98818-8;Prism for near point convergence;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Prism for near point convergence by Phoropter;Eye Prism for near pt converg Phoropter;;ACTIVE;2.72;2.72 +98819-6;Prism for near point accommodation;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism for near point accommodation by Phoropter;R eye Prism for near pt accom Phoropter;;ACTIVE;2.72;2.72 +98820-4;Prism for near point accommodation;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism for near point accommodation by Phoropter;L eye Prism for near pt accom Phoropter;;ACTIVE;2.72;2.72 +98821-2;Prism for near point accommodation;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Prism for near point accommodation by Phoropter;Eye Prism for near pt accom by Phoropter;;ACTIVE;2.72;2.72 +9882-2;J point depression.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead III;J Pnt Depr L-III;;ACTIVE;1.0i;2.48 +98822-0;Prism for far fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism for far fixation disparity by Phoropter;R eye Prism for far fix disparity Phor;;ACTIVE;2.72;2.72 +98823-8;Prism for far fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism for far fixation disparity by Phoropter;L eye Prism for far fix disparity Phor;;ACTIVE;2.72;2.72 +98824-6;Prism base direction for far fixation disparity;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base direction for far fixation disparity by Phoropter;R eye Prism dir for far fix disp Phor;;ACTIVE;2.72;2.72 +98825-3;Prism base direction for far fixation disparity;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction for far fixation disparity by Phoropter;L eye Prism dir for far fix disp Phor;;ACTIVE;2.72;2.72 +98826-1;Horizontal prism.out for far fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out for far fixation disparity by Phoropter;R eye H prism-out for far fix disp Phor;;ACTIVE;2.72;2.72 +98827-9;Horizontal prism.out for far fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out for far fixation disparity by Phoropter;L eye H prism-out for far fix disp Phor;;ACTIVE;2.72;2.72 +98828-7;Horizontal prism.in for far fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in for far fixation disparity by Phoropter;R eye H prism-in for far fix disp Phor;;ACTIVE;2.72;2.72 +98829-5;Horizontal prism.in for far fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in for far fixation disparity by Phoropter;L eye H prism-in for far fix disp Phor;;ACTIVE;2.72;2.72 +9883-0;J point depression.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead V1;J Pnt Depr L-V1;;ACTIVE;1.0i;2.48 +98830-3;Vertical prism.up for far fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - up for far fixation disparity by Phoropter;R eye V prism-up for far fix disp Phor;;ACTIVE;2.72;2.72 +98831-1;Vertical prism.up for far fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - up for far fixation disparity by Phoropter;L eye V prism-up for far fix disp Phor;;ACTIVE;2.72;2.72 +98832-9;Vertical prism.down for far fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - down for far fixation disparity by Phoropter;R eye V prism-down for far fix disp Phor;;ACTIVE;2.72;2.72 +98833-7;Vertical prism.down for far fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - down for far fixation disparity by Phoropter;L eye V prism-down for far fix disp Phor;;ACTIVE;2.72;2.72 +98834-5;Prism for near fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism for near fixation disparity by Phoropter;R eye Prism for near fix disparity Phor;;ACTIVE;2.72;2.72 +98835-2;Prism for near fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism for near fixation disparity by Phoropter;L eye Prism for near fix disparity Phor;;ACTIVE;2.72;2.72 +98836-0;Prism base direction for near fixation disparity;Angle;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Prism base direction for near fixation disparity by Phoropter;R eye Prism dir for near fix disp Phor;;ACTIVE;2.72;2.72 +98837-8;Prism base direction for near fixation disparity;Angle;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Prism base direction for near fixation disparity by Phoropter;L eye Prism dir for near fix disp Phor;;ACTIVE;2.72;2.72 +98838-6;Horizontal prism.out for near fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - out for near fixation disparity by Phoropter;R eye H prism-out for near fix disp Phor;;ACTIVE;2.72;2.72 +98839-4;Horizontal prism.out for near fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - out for near fixation disparity by Phoropter;L eye H prism-out for near fix disp Phor;;ACTIVE;2.72;2.72 +98840-2;Horizontal prism.in for near fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Horizontal prism - in for near fixation disparity by Phoropter;R eye H prism-in for near fix disp Phor;;ACTIVE;2.72;2.72 +98841-0;Horizontal prism.in for near fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Horizontal prism - in for near fixation disparity by Phoropter;L eye H prism-in for near fix disp Phor;;ACTIVE;2.72;2.72 +98842-8;Vertical prism.up for near fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - up for near fixation disparity by Phoropter;R eye V prism-up for near fix disp Phor;;ACTIVE;2.72;2.72 +98843-6;Vertical prism.up for near fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - up for near fixation disparity by Phoropter;L eye V prism-up for near fix disp Phor;;ACTIVE;2.72;2.72 +98844-4;Vertical prism.down for near fixation disparity;InvLen;Pt;Eye.right;Qn;Phoropter;EYE.REFRACTION;2;Right eye Vertical prism - down for near fixation disparity by Phoropter;R eye V prism-down - near fix disp Phor;;ACTIVE;2.72;2.72 +98845-1;Vertical prism.down for near fixation disparity;InvLen;Pt;Eye.left;Qn;Phoropter;EYE.REFRACTION;2;Left eye Vertical prism - down for near fixation disparity by Phoropter;L eye V prism-down - near fix disp Phor;;ACTIVE;2.72;2.72 +98846-9;SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+) T-cells^^corrected for background;ACnc;Pt;Bld;Qn;IA;MICRO;1;SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+) T-cells [Units/volume] corrected for background in Blood by Immunoassay;SARS-CoV-2 IFN-g CD4 cells Bld IA;;ACTIVE;2.72;2.72 +98847-7;SARS coronavirus 2 stimulated gamma interferon release by lymphocytes^^corrected for background;ACnc;Pt;Bld;Qn;IA;MICRO;1;SARS coronavirus 2 stimulated gamma interferon release by lymphocytes [Units/volume] corrected for background in Blood by Immunoassay;SARS-CoV-2 IFN-g Lymphs Bld IA;;ACTIVE;2.72;2.72 +9884-8;J point depression.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead V2;J Pnt Depr L-V2;;ACTIVE;1.0i;2.48 +98848-5;Minimum stereopsis angle;Angle;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Minimum stereopsis angle by Phoropter;Eye Min stereo angle by Phoropter;;ACTIVE;2.72;2.72 +98849-3;Depth perception;Find;Pt;Eye;Ord;Phoropter;EYE.REFRACTION;2;Eye Depth perception by Phoropter;Eye Depth perception by Phoropter;;ACTIVE;2.72;2.72 +98850-1;Threshold angle for measuring depth perception;Angle;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Threshold angle for measuring depth perception by Phoropter;Eye Angle for depth perc meas Phoropter;;ACTIVE;2.72;2.72 +98851-9;Accommodation using minus lens;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Eye Accommodation using minus lens by Phoropter;Eye Accom using minus lens by Phoropter;;ACTIVE;2.72;2.72 +98852-7;Physical intensity of work;Find;Pt;^Patient;Ord;;H&P.HX;2;Physical intensity of work;Physical intensity of work;;ACTIVE;2.72;2.72 +98853-5;Phoropter panel;-;Pt;Eye;-;Phoropter;PANEL.EYE;2;Phoropter panel;Phoropter Pnl;;ACTIVE;2.72;2.72 +98854-3;Urothelial carcinoma probability score;Score;Pt;Urine;Qn;Based on clinical+lab data;CLIN.RISK;2;Urothelial carcinoma probability score based on clinical and lab data;Urothelial Ca prob score clin+lab data;;ACTIVE;2.72;2.72 +9885-5;J point depression.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead V3;J Pnt Depr L-V3;;ACTIVE;1.0i;2.48 +98855-0;Type of therapeutic antibody administered;Type;Pt;^Patient;Nom;;H&P.HX;2;Type of therapeutic antibody administered;Type of therap Ab administered;;ACTIVE;2.72;2.72 +98856-8;Volume^post void;Vol;Pt;Urinary bladder;Qn;US;RAD;2;US Urinary bladder Volume post void;US Bladder Volume p vdg;;ACTIVE;2.72;2.72 +98857-6;Cardiac stress EKG study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Cardiac stress EKG study Document;Cardiac stress EKG study Doc;;ACTIVE;2.72;2.72 +98858-4;Esophageal pH monitoring study;Find;Pt;^Patient;Doc;;DOC.MISC;2;Esophageal pH monitoring study Document;Esophageal pH monitoring study Doc;;ACTIVE;2.72;2.72 +98859-2;Anorectal manometry study;Find;Pt;^Patient;Doc;;ENDO.GI;2;Anorectal manometry study;Anorectal manometry study;;ACTIVE;2.72;2.72 +988-6;D little i super little b Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Di sup(b) Ag [Presence] on Red Blood Cells from Blood product unit;Di sup(b) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +98860-0;Transforming growth factor beta.free;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transforming growth factor beta free [Mass/volume] in Serum or Plasma;TGF-beta free SerPl-mCnc;;ACTIVE;2.72;2.72 +98861-8;Transforming growth factor beta;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Transforming growth factor beta [Mass/volume] in Serum or Plasma;TGF-beta SerPl-mCnc;;ACTIVE;2.72;2.72 +98862-6;Taking medication for condition of interest;Find;Pt;^Patient;Ord;;H&P.HX;2;Taking medication for condition of interest;Taking meds for condition;;ACTIVE;2.72;2.72 +9886-3;J point depression.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead V4;J Pnt Depr L-V4;;ACTIVE;1.0i;2.48 +98864-2;Days' supply remaining;Num;Pt;Medication;Qn;;MEDS;2;Days' supply remaining [#] Medication;Days' remaining Medication;;ACTIVE;2.72;2.72 +98865-9;Made arrangements to get medication refilled;Find;Pt;^Patient;Nom;;H&P.HX;2;Made arrangements to get medication refilled;Made arrangment for refill;;ACTIVE;2.72;2.72 +98866-7;Postponed medical procedures since the beginning of the pandemic;Find;Pt;^Patient;Ord;;H&P.HX;2;Postponed medical procedures since the beginning of the pandemic;Procedure postponed since pandemic;;ACTIVE;2.72;2.72 +98867-5;Missed scheduled appointment with healthcare provider in past Mo;Find;1Mo;^Patient;Ord;;H&P.HX;2;Missed scheduled appointment with healthcare provider in past Mo;Missed appt past Mo;;ACTIVE;2.72;2.72 +98868-3;Reason for missed appointment with healthcare provider in past Mo;Find;1Mo;^Patient;Nom;;H&P.HX;2;Reason for missed appointment with healthcare provider in past month;Reason missed appt past Mo;;ACTIVE;2.72;2.72 +98869-1;Missed taking medication in past Mo;Find;1Mo;^Patient;Ord;;H&P.HX;2;Missed taking medication in past month;Missed med past Mo;;ACTIVE;2.72;2.72 +98870-9;Reason for missed medications in past Mo;Find;1Mo;^Patient;Nom;;H&P.HX;2;Reason for missed medications in past month;Reason missed meds past Mo;;ACTIVE;2.72;2.72 +9887-1;J point depression.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead V5;J Pnt Depr L-V5;;ACTIVE;1.0i;2.48 +98871-7;COVID-19 comorbidity and healthcare questionnaire;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;COVID-19 comorbidity and healthcare questionnaire;;;ACTIVE;2.72;2.72 +98872-5;SARS-CoV-2-related socioeconomic questionnaire for school-age children;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;SARS-CoV-2-related socioeconomic questionnaire for school-age children;;© 2021 E. Sicuri, I. Lopes, E. Tacconelli, M. Giannella. Used with permission.;ACTIVE;2.72;2.72 +98873-3;Were classes suspended;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Were classes suspended;;;ACTIVE;2.72;2.72 +98874-1;How long were classes suspended;Time;Pt;^Patient;Qn;;SURVEY.COVID;4;How long were classes suspended;;;ACTIVE;2.72;2.72 +98875-8;Able to participate in remote learning;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Able to participate in remote learning;;;ACTIVE;2.72;2.72 +98876-6;Reason for not participating in remote learning;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Reason for not participating in remote learning;;;ACTIVE;2.72;2.72 +98877-4;Amount of school lost;Time;Pt;^Patient;Qn;;SURVEY.COVID;4;Amount of school lost;;;ACTIVE;2.72;2.72 +98878-2;Received or applied for other assistance since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for other assistance since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98879-0;Received or applied for assistance from a food pantry since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for assistance from a food pantry since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98880-8;Received or applied for assistance from community organization since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for assistance from community organization since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98881-6;Received or applied for assistance from a religious organization since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for assistance from a religious organization since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98882-4;Received or applied for assistance from a union since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for assistance from a union since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98883-2;Received or applied for other government aid since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for other government aid since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98884-0;Received or applied for paycheck protection since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for paycheck protection since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98885-7;Received or applied for government health insurance since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for government health insurance since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98886-5;Received or applied for supplemental social security since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for supplemental social security since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98887-3;Received or applied for social security since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for social security since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98888-1;Received or applied for nutrition assistance since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for nutrition assistance since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +9888-9;J point depression.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;J point depression in lead V6;J Pnt Depr L-V6;;ACTIVE;1.0i;2.48 +98889-9;COVID-19 related household finances;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;COVID-19 related household finances;;;ACTIVE;2.72;2.72 +98890-7;Received or applied for unemployment insurance since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for unemployment insurance since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98891-5;Methods using or plan to use to cover expenses;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Methods using or plan to use to cover expenses;;;ACTIVE;2.72;2.72 +98892-3;Emergency expense payment method;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Emergency expense payment method;;;ACTIVE;2.72;2.72 +98893-1;Difficulty level of paying expenses in past Mo;Find;1Mo;^Patient;Nom;;SURVEY.COVID;4;Difficulty level of paying expenses in past month;;;ACTIVE;2.72;2.72 +98894-9;Level of worry that asset value has been or will be negatively impacted by COVID-19;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Level of worry that asset value has been or will be negatively impacted by COVID-19;;;ACTIVE;2.72;2.72 +98895-6;Level of worry that household income has been or will be negatively impacted by COVID-19;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Level of worry that household income has been or will be negatively impacted by COVID-19;;;ACTIVE;2.72;2.72 +98896-4;Household income changed significantly since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Household income changed significantly since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +9889-7;P wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead AVF;P wave Amp L-AVF;;ACTIVE;1.0i;2.48 +98897-2;Views abduction + internal rotation;Find;Pt;Pelvis & Lower extremity.left>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - left Abduction and Internal rotation;XR Pelvis and Hip-L V Abd+IR;;ACTIVE;2.72;2.72 +98898-0;Views abduction + internal rotation;Find;Pt;Pelvis & Lower extremity.right>Hip;Doc;XR;RAD;2;XR Pelvis and Hip - right Abduction and Internal rotation;XR Pelvis and Hip-R V Abd+IR;;ACTIVE;2.72;2.72 +98899-8;View pronated oblique;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right Pronated oblique;XR Wrist-R Prone Oblique;;ACTIVE;2.72;2.72 +98900-4;View pronated oblique;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left Pronated oblique;XR Wrist-L Prone Oblique;;ACTIVE;2.72;2.72 +98901-2;Received or applied for temporary assistance since the beginning of the pandemic;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Received or applied for temporary assistance since the beginning of the pandemic;;;ACTIVE;2.72;2.72 +98902-0;Methemoglobin & sulfhemoglobin panel;MFr;Pt;Bld;Qn;;PANEL.CHEM;1;Methemoglobin and sulfhemoglobin panel - Blood;Meth + SulfHgb Pnl MFr Bld;;ACTIVE;2.72;2.72 +98903-8;Hemolytic anemia panel;-;Pt;^Patient;-;;PANEL.HEM/BC;1;Hemolytic anemia panel;Hemolytic anemia Pnl Patient;;ACTIVE;2.72;2.72 +98904-6;Osmotic fragility panel;-;Pt;RBC;-;;PANEL.HEM/BC;1;Osmotic fragility panel of Red Blood Cells;OF Pnl RBC;;ACTIVE;2.72;2.72 +9890-5;P wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead AVL;P wave Amp L-AVL;;ACTIVE;1.0i;2.48 +98905-3;Red blood cell membrane evaluation panel;-;Pt;RBC;-;;PANEL.HEM/BC;1;Red blood cell membrane evaluation panel - Red Blood Cells;RBC membrane eval Pnl RBC;;ACTIVE;2.72;2.72 +98906-1;Band 3;PrThr;Pt;RBC;Ord;Flow cytometry;HEM/BC;1;Band 3 [Presence] in Red Blood Cells by Flow cytometry (FC);Band 3 RBC Ql FC;;ACTIVE;2.72;2.72 +98907-9;Hemoglobinopathy panel;-;Pt;^Patient;-;;PANEL.HEM/BC;1;Hemoglobinopathy panel;Hemoglobinopathy panel Patient;;ACTIVE;2.72;2.72 +98908-7;Room brightness level during testing;Type;Pt;Eye;Nom;;EYE.PX;2;Type of Room brightness level during testing;Type of Brightness during test;;ACTIVE;2.72;2.72 +98909-5;Shock index;Ratio;Pt;^Patient;Qn;Calculated;CLIN.RISK;2;Shock index Calculated;SI Calc;;ACTIVE;2.72;2.72 +98910-3;Modified shock index;Ratio;Pt;^Patient;Qn;Calculated;CLIN.RISK;2;Modified shock index Calculated;mSI Calc;;ACTIVE;2.72;2.72 +98911-1;Negative relative accommodation blur;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Negative relative accommodation blur by Phoropter;NRA blur by Phoropter;;ACTIVE;2.72;2.72 +98912-9;Positive relative accommodation blur;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Positive relative accommodation blur by Phoropter;PRA blur by Phoropter;;ACTIVE;2.72;2.72 +9891-3;P wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead AVR;P wave Amp L-AVR;;ACTIVE;1.0i;2.48 +98913-7;Negative relative accommodation recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Negative relative accommodation recovery by Phoropter;NRA recovery by Phoropter;;ACTIVE;2.72;2.72 +98914-5;Positive relative accommodation recovery;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Positive relative accommodation recovery by Phoropter;PRA recovery by Phoropter;;ACTIVE;2.72;2.72 +98915-2;Knee injury and osteoarthritis outcome score - physical function shortform panel;-;Pt;^Patient;-;KOOS-PS;PANEL.SURVEY.GNHLTH;4;Knee injury and osteoarthritis outcome score - physical function shortform panel [KOOS-PS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.72;2.72 +98916-0;Total score;Score;Pt;^Patient;Qn;KOOS-PS;SURVEY.GNHLTH;4;Total score [KOOS-PS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.72;2.72 +98917-8;WHO Quality of life-BREF;-;2W;^Patient;-;WHOQOL_BREF;PANEL.SURVEY.GNHLTH;4;WHO Quality of life-BREF [WHOQOL_BREF];;Reproduced with permission from WHOQOL-BREF Field Trial Version, Geneva, World Health Organization (WHO), 1996, https://www.who.int/publications/i/item/WHOQOL-BREF, accessed Sep 2021. WHO does not endorse any specific companies, products or services.;ACTIVE;2.72;2.72 +98918-6;Quality of life in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Quality of life in last 2 weeks;;;ACTIVE;2.72;2.72 +98919-4;Satisfaction with health in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with health in last 2 weeks;;;ACTIVE;2.72;2.72 +98920-2;Extent that physical pain prevents activity in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Extent that physical pain prevents activity in last 2 weeks;;;ACTIVE;2.72;2.72 +9892-1;P wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead I;P wave Amp L-I;;ACTIVE;1.0i;2.48 +98921-0;Dependency on medical treatment to function in daily life in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Dependency on medical treatment to function in daily life in last 2 weeks;;;ACTIVE;2.72;2.72 +98922-8;Enjoyment of life in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Enjoyment of life in last 2 weeks;;;ACTIVE;2.72;2.72 +98923-6;Extent to which life is meaningful in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Extent to which life is meaningful in last 2 weeks;;;ACTIVE;2.72;2.72 +98924-4;Ability to concentrate in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Ability to concentrate in last 2 weeks;;;ACTIVE;2.72;2.72 +98925-1;How safe do you feel in your daily life in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;How safe do you feel in your daily life in last 2 weeks;;;ACTIVE;2.72;2.72 +98926-9;Healthiness of physical environment in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Healthiness of physical environment in last 2 weeks;;;ACTIVE;2.72;2.72 +98927-7;Have enough energy for everyday life in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Have enough energy for everyday life in last 2 weeks;;;ACTIVE;2.72;2.72 +98928-5;Able to accept body appearance in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Able to accept body appearance in last 2 weeks;;;ACTIVE;2.72;2.72 +98929-3;Have enough money to meet needs in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Have enough money to meet needs in last 2 weeks;;;ACTIVE;2.72;2.72 +98930-1;Availability of information needed in daily life in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Availability of information needed in daily life in last 2 weeks;;;ACTIVE;2.72;2.72 +98931-9;Extent of opportunity for leisure activities in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Extent of opportunity for leisure activities in last 2 weeks;;;ACTIVE;2.72;2.72 +98932-7;Ability to get around in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Ability to get around in last 2 weeks;;;ACTIVE;2.72;2.72 +98933-5;Satisfaction with sleep in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with sleep in last 2 weeks;;;ACTIVE;2.72;2.72 +98934-3;Satisfaction with ability to perform daily living activities in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with ability to perform daily living activities in last 2 weeks;;;ACTIVE;2.72;2.72 +98935-0;Satisfaction with capacity for work in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with capacity for work in last 2 weeks;;;ACTIVE;2.72;2.72 +98936-8;Satisfaction with self in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with self in last 2 weeks;;;ACTIVE;2.72;2.72 +98937-6;Satisfaction with personal relationships in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with personal relationships in last 2 weeks;;;ACTIVE;2.72;2.72 +98938-4;Satisfaction with sex life in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with sex life in last 2 weeks;;;ACTIVE;2.72;2.72 +9893-9;P wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead II;P wave Amp L-II;;ACTIVE;1.0i;2.48 +98939-2;Satisfaction with support from friends in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with support from friends in last 2 weeks;;;ACTIVE;2.72;2.72 +989-4;D little i super little b Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Di sup(b) Ag [Presence] on Red Blood Cells from Donor;Di sup(b) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +98940-0;Satisfaction with condition of living place in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with condition of living place in last 2 weeks;;;ACTIVE;2.72;2.72 +98941-8;Satisfaction with access to health services in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with access to health services in last 2 weeks;;;ACTIVE;2.72;2.72 +98942-6;Satisfaction with access to transportation in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Satisfaction with access to transportation in last 2 weeks;;;ACTIVE;2.72;2.72 +98943-4;Frequency of negative feelings in last 2W;Find;2W;^Patient;Ord;;SURVEY.GNHLTH;4;Frequency of negative feelings in last 2 weeks;;;ACTIVE;2.72;2.72 +98944-2;Total Score;Score;2W;^Patient;Qn;WHOQOL_BREF;SURVEY.GNHLTH;4;Total score [WHOQOL_BREF];;Reproduced with permission from WHOQOL-BREF Field Trial Version, Geneva, World Health Organization (WHO), 1996, https://www.who.int/publications/i/item/WHOQOL-BREF, accessed Sep 2021. WHO does not endorse any specific companies, products or services.;ACTIVE;2.72;2.72 +98945-9;Hip disability and osteoarthritis outcome score - physical function shortform panel;-;Pt;^Patient;-;HOOS-PS;PANEL.SURVEY.GNHLTH;4;Hip disability and osteoarthritis outcome score - physical function shortform panel [HOOS-PS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.72;2.72 +98946-7;Total score;Score;Pt;^Patient;Qn;HOOS-PS;SURVEY.GNHLTH;4;Total score [HOOS-PS];;Copyright © 2012 Ewa Roos. Used with permission.;ACTIVE;2.72;2.72 +9894-7;P wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead III;P wave Amp L-III;;ACTIVE;1.0i;2.48 +98947-5;SARS-CoV-2-related socioeconomic questionnaire for school-age children intake questions;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;SARS-CoV-2-related socioeconomic questionnaire for school-age children intake questions;;;ACTIVE;2.72;2.72 +98948-3;SARS-CoV-2-related socioeconomic questionnaire for school-age children 12Mo follow-up;-;12Mo;^Patient;-;;PANEL.SURVEY.COVID;4;SARS-CoV-2-related socioeconomic questionnaire for school-age children 12 month follow-up;;;ACTIVE;2.72;2.72 +98949-1;Were classes suspended in last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Were classes suspended in last 12 months;;;ACTIVE;2.72;2.72 +98950-9;How long were classes suspended in last 12Mo;Time;12Mo;^Patient;Qn;;SURVEY.COVID;4;How long were classes suspended in last 12 months;;;ACTIVE;2.72;2.72 +98951-7;Amount of school lost in last 12Mo;Time;12Mo;^Patient;Qn;;SURVEY.COVID;4;Amount of school lost in last 12 months;;;ACTIVE;2.72;2.72 +98952-5;Reason for not participating in remote learning in last 12Mo;Find;12Mo;^Patient;Nom;;SURVEY.COVID;4;Reason for not participating in remote learning in last 12 months;;;ACTIVE;2.72;2.72 +98953-3;Able to participate in remote learning in last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.COVID;4;Able to participate in remote learning in last 12 months;;;ACTIVE;2.72;2.72 +9895-4;P wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead V1;P wave Amp L-V1;;ACTIVE;1.0i;2.48 +98954-1;KCNN4 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;KCNN4 gene full mutation analysis in Blood or Tissue by Sequencing;KCNN4 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +98955-8;Burkholderia pseudomallei Ab;Titr;Pt;XXX;Qn;HAI;MICRO;1;Burkholderia pseudomallei Ab [Titer] in Specimen by Hemagglutination inhibition;B pseudomal Ab Titr Spec HAI;;ACTIVE;2.72;2.72 +98956-6;Coccidioides immitis Ab.IgM;ACnc;Pt;XXX;Qn;IA;MICRO;1;Coccidioides immitis IgM Ab [Units/volume] in Specimen by Immunoassay;C immitis IgM Spec IA-aCnc;;ACTIVE;2.72;2.72 +98957-4;Coccidioides immitis Ab.IgG;ACnc;Pt;XXX;Qn;IA;MICRO;1;Coccidioides immitis IgG Ab [Units/volume] in Specimen by Immunoassay;C immitis IgG Spec IA-aCnc;;ACTIVE;2.72;2.72 +98958-2;Periostin;SCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Periostin [Moles/volume] in Serum or Plasma by Immunoassay;Periostin SerPl IA-sCnc;;ACTIVE;2.72;2.72 +98959-0;Aspergillus fumigatus;PrThr;Pt;Isolate;Ord;MS.MALDI-TOF;MICRO;1;Aspergillus fumigatus [Presence] in Isolate by MS.MALDI-TOF;A fumigatus Islt Ql MS.MALDI-TOF;;ACTIVE;2.72;2.72 +98960-8;Dehydroaripiprazole;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Dehydroaripiprazole [Presence] in Urine by Confirmatory method;Dehydroaripiprazole Ur Ql Cfm;;ACTIVE;2.72;2.72 +98961-6;Lurasidone;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Lurasidone [Presence] in Urine by Confirmatory method;Lurasidone Ur Ql Cfm;;ACTIVE;2.72;2.72 +9896-2;P wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead V2;P wave Amp L-V2;;ACTIVE;1.0i;2.48 +98962-4;Cariprazine;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Cariprazine [Presence] in Urine by Confirmatory method;Cariprazine Ur Ql Cfm;;ACTIVE;2.72;2.72 +98963-2;Cariprazine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Cariprazine [Mass/volume] in Urine by Confirmatory method;Cariprazine Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +98964-0;Brexpiprazole;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Brexpiprazole [Presence] in Urine by Confirmatory method;Brexpiprazole Ur Ql Cfm;;ACTIVE;2.72;2.72 +98965-7;Brexpiprazole;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Brexpiprazole [Mass/volume] in Urine by Confirmatory method;Brexpiprazole Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +98966-5;Antipsychotics drug panel;-;Pt;Urine;-;Confirm;PANEL.DRUG/TOX;1;Antipsychotics drug panel - Urine by Confirmatory method;Antipsychotics Pnl Ur Cfm;;ACTIVE;2.72;2.72 +98967-3;Nutritional Risk Screening 2002 panel;-;Pt;^Patient;-;NRS_2002;PANEL.CLIN.RISK;2;Nutritional Risk Screening 2002 panel;NRS 2002;;ACTIVE;2.72;2.72 +98968-1;Initial screening;-;Pt;^Patient;-;NRS_2002;PANEL.CLIN.RISK;2;Initial screening NRS_2002;Initial screening NRS_2002;;ACTIVE;2.72;2.72 +98969-9;Lost weight in last 3Mo;Find;3Mo;^Patient;Ord;;CLIN.RISK;2;Lost weight in last 3 months;Lost weight in last 3Mo;;ACTIVE;2.72;2.72 +9897-0;P wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead V3;P wave Amp L-V3;;ACTIVE;1.0i;2.48 +98970-7;Reduced nutritional intake in last W;Find;1W;^Patient;Ord;;CLIN.RISK;2;Reduced nutritional intake in last week in the past week;Reduced nutritio intake in last W;;ACTIVE;2.72;2.72 +98971-5;Severely ill;Find;Pt;^Patient;Ord;;CLIN.RISK;2;Severely ill;Severely ill;;ACTIVE;2.72;2.72 +98972-3;Final screening;-;Pt;^Patient;-;NRS_2002;PANEL.CLIN.RISK;2;Final screening NRS_2002;Final screening NRS_2002;;ACTIVE;2.72;2.72 +98973-1;Impaired nutritional status;Find;Pt;^Patient;Ord;;H&P.HX;2;Impaired nutritional status;Impaired nutrition status;;ACTIVE;2.72;2.72 +98974-9;Total score;Score;Pt;^Patient;Qn;NRS_2002;CLIN.RISK;2;Total score NRS_2002;Total score NRS_2002;;ACTIVE;2.72;2.72 +98975-6;Children's Health Watch Housing Stability Vital Signs panel;-;12Mo;^Patient;-;HSVS;PANEL.SURVEY.SDOH;4;Children's Health Watch Housing Stability Vital Signs;;© 2019 Children's HealthWatch, Boston Medical Center Used with permission.;ACTIVE;2.72;2.72 +98976-4;Behind on rent or mortgage in past 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.SDOH;4;Behind on rent or mortgage in past 12 months;;;ACTIVE;2.72;2.72 +98977-2;Number of residential moves in past 12Mo;Num;12Mo;^Patient;Qn;;SURVEY.SDOH;4;Number of residential moves in past 12 months;;;ACTIVE;2.72;2.72 +98978-0;Homeless in past 12Mo;NRat;12Mo;^Patient;Ord;;SURVEY.SDOH;4;Homeless in past 12 months;;;ACTIVE;2.72;2.72 +98979-8;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine-based formula (CKD-EPI 2021);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021);eGFRcr SerPlBld CKD-EPI 2021;;ACTIVE;2.72;2.72 +98980-6;Glomerular filtration rate/1.73 sq M.predicted;ArVRat;Pt;Ser/Plas/Bld;Qn;Creatinine and Cystatin C-based formula (CKD-EPI 2021);CHEM;1;Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI 2021);eGFRcr-cys SerPlBld CKD-EPI 2021;;ACTIVE;2.72;2.72 +98981-4;Urate;MCnc;Pt;Bld;Qn;;CHEM;1;Urate [Mass/volume] in Blood;Urate Bld-mCnc;;ACTIVE;2.72;2.72 +98982-2;6-Hydroxybuspirone;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;6-Hydroxybuspirone [Mass/volume] in Urine by Confirmatory method;6OH-buspirone Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +98983-0;Methocarbamol;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Methocarbamol [Mass/volume] in Urine by Confirmatory method;Methocarbamol Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +98984-8;OXcarbazepine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;OXcarbazepine [Mass/volume] in Urine by Confirmatory method;OXcarbazepine Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +98985-5;10-Hydroxycarbazepine;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;10-Hydroxycarbazepine [Mass/volume] in Urine by Confirmatory method;10OH-Carbazepine Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +98986-3;Chloride/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Chloride/Creatinine [Molar ratio] in 24 hour Urine;Chloride/Creat 24h Ur-sRto;;ACTIVE;2.72;2.72 +98987-1;C reactive protein;ACnc;Pt;Body fld;Qn;;CHEM;1;C reactive protein [Units/volume] in Body fluid;CRP Fld-aCnc;;ACTIVE;2.72;2.72 +9898-8;P wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead V4;P wave Amp L-V4;;ACTIVE;1.0i;2.48 +98988-9;Prolactin^45M post dose TRH IV;SCnc;Pt;Ser/Plas;Qn;;CHAL;1;Prolactin [Moles/volume] in Serum or Plasma --45 minutes post dose TRH IV;Prolactin 45M p TRH IV SerPl-sCnc;;ACTIVE;2.72;2.72 +98989-7;Neutrophils.band form/leukocytes;NFr.DF;Pt;Bld;Qn;Automated count;HEM/BC;1;Band form neutrophils/Leukocytes [Pure number fraction] in Blood by Automated count;Neuts Band NFr.DF Bld Auto;;ACTIVE;2.72;2.72 +98990-5;Methotrexate^18H post dose;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --18 hour post dose;MTX 18h p SerPl-sCnc;;ACTIVE;2.72;2.72 +98991-3;Methotrexate^5M post dose;SCnc;Pt;Ser/Plas;Qn;;DRUG/TOX;1;Methotrexate [Moles/volume] in Serum or Plasma --5 minutes post dose;MTX 5M p dose SerPl-sCnc;;ACTIVE;2.72;2.72 +98992-1;Alpha-1-Acid glycoprotein/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha-1-acid glycoprotein/Protein.total in Serum or Plasma by Electrophoresis;A1acid Glycoprotein MFr SerPl Elph;;ACTIVE;2.72;2.72 +98993-9;Alpha 1 antitrypsin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 1 antitrypsin/Protein.total in Serum or Plasma by Electrophoresis;A1AT MFr SerPl Elph;;ACTIVE;2.72;2.72 +98994-7;Alpha 1 antitrypsin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Electrophoresis;A1AT SerPl Elph-mCnc;;ACTIVE;2.72;2.72 +98995-4;Transferrin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Transferrin/Protein.total in Serum or Plasma by Electrophoresis;Transferrin MFr SerPl Elph;;ACTIVE;2.72;2.72 +9899-6;P wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in in lead V5;P wave Amp L-V5;;ACTIVE;1.0i;2.48 +98996-2;Transferrin;MCnc;Pt;Ser/Plas;Qn;Electrophoresis;CHEM;1;Transferrin [Mass/volume] in Serum or Plasma by Electrophoresis;Transferrin SerPl Elph-mCnc;;ACTIVE;2.72;2.72 +98997-0;Haptoglobin/Protein.total;MFr;Pt;Ser/Plas;Qn;Electrophoresis;HEM/BC;1;Haptoglobin/Protein.total in Serum or Plasma by Electrophoresis;Haptoglob MFr SerPl Elph;;ACTIVE;2.72;2.72 +98998-8;Hematocrit;VFr.DF;Pt;BldCo;Qn;Automated count;HEM/BC;1;Hematocrit [Pure volume fraction] of Cord blood by Automated count;Hct VFr.DF BldCo Auto;;ACTIVE;2.72;2.72 +98999-6;Nucleated cells;NCnc;Pt;Synv fld;Qn;Automated count;HEM/BC;1;Nucleated cells [#/volume] in Synovial fluid by Automated count;Nuc cell # Snv Auto;;ACTIVE;2.72;2.72 +99000-2;Dysautonomia autoimmune Ab panel;-;Pt;Ser;-;;PANEL.SERO;1;Dysautonomia autoimmune Ab panel - Serum;Dysauto autoimmune Ab pnl Ser;;ACTIVE;2.72;2.72 +99001-0;Leptospira weilii serovar Celledoni Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira weilii sv Celledoni Ab [Titer] in Serum by Agglutination;L weilii Celledoni Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +9900-2;P wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave amplitude in lead V6;P wave Amp L-V6;;ACTIVE;1.0i;2.48 +99002-8;Leptospira santarosai serovar Alexi Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira santarosai sv Alexi Ab [Titer] in Serum by Agglutination;L santarosai Alexi Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +99003-6;Leptospira santarosai serovar Georgia Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira santarosai sv Georgia Ab [Titer] in Serum by Agglutination;L santarosai Georgia Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +99004-4;Leptospira santarosai serovar Borincana Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira santarosai sv Borincana Ab [Titer] in Serum by Agglutination;L santarosai Borincana Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +99005-1;Leptospira kirschneri serovar Cynopteri Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira kirschneri sv Cynopteri Ab [Titer] in Serum by Agglutination;L kirschneri Cynopteri Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +99006-9;Leptospira interrogans serovar Wolffi Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Wolffi Ab [Titer] in Serum by Agglutination;L interrogans Wolffi Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +99007-7;Leptospira interrogans serovar Mankarso Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Mankarso Ab [Titer] in Serum by Agglutination;L interrogans Mankarso Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +99008-5;Leptospira interrogans serovar Djasiman Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira interrogans sv Djasiman Ab [Titer] in Serum by Agglutination;L inter Djasim Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +9901-0;P wave duration.lead AVF;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead AVF;P wave dur L-AVF;;ACTIVE;1.0i;2.48 +99010-1;Leptospira borgpetersenii serovar Javanica Ab;Titr;Pt;Ser;Qn;Aggl;MICRO;1;Leptospira borgpetersenii sv Javanica Ab [Titer] in Serum by Agglutination;L borgp Javanica Ab Titr Ser Aggl;;ACTIVE;2.72;2.72 +99011-9;Leptospira sp Ab panel;-;Pt;Ser;-;Aggl;PANEL.MICRO;1;Leptospira sp Ab panel - Serum by Agglutination;Leptospira sp Ab Pnl Ser Aggl;;ACTIVE;2.72;2.72 +99012-7;Urinary tract pathogens panel;-;Pt;Urine;-;Probe.amp.tar;PANEL.MICRO;1;Urinary tract pathogens panel - Urine by NAA with probe detection;UTI pathogens Pnl Ur NAA+probe;;ACTIVE;2.72;2.72 +99013-5;Acinetobacter baumannii DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Acinetobacter baumannii DNA [Presence] in Urine by NAA with probe detection;A baumannii DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99014-3;Citrobacter freundii DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Citrobacter freundii DNA [Presence] in Urine by NAA with probe detection;C freundii DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99015-0;Citrobacter koseri DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Citrobacter koseri DNA [Presence] in Urine by NAA with probe detection;C koseri DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99016-8;Enterobacter cloacae complex DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Enterobacter cloacae complex DNA [Presence] in Urine by NAA with probe detection;E cloac comp DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99017-6;Enterococcus faecalis DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecalis DNA [Presence] in Urine by NAA with probe detection;E faecalis DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99018-4;Enterococcus faecium DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Enterococcus faecium DNA [Presence] in Urine by NAA with probe detection;E faecium DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99019-2;Escherichia coli DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Escherichia coli DNA [Presence] in Urine by NAA with probe detection;E coli DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +990-2;D little i super little b Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Di sup(b) Ag [Presence] on Red Blood Cells;Di sup(b) Ag RBC Ql;;ACTIVE;1.0;2.56 +99020-0;Klebsiella aerogenes DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Klebsiella aerogenes DNA [Presence] in Urine by NAA with probe detection;K. aerogenes DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99021-8;Klebsiella oxytoca DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Klebsiella oxytoca DNA [Presence] in Urine by NAA with probe detection;K oxytoca DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99022-6;Klebsiella pneumoniae DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Klebsiella pneumoniae DNA [Presence] in Urine by NAA with probe detection;K pneumon DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99023-4;Morganella morganii DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Morganella morganii DNA [Presence] in Urine by NAA with probe detection;M. morganii DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99024-2;Proteus sp DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Proteus sp DNA [Presence] in Urine by NAA with probe detection;Proteus sp DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99025-9;Providencia rettgeri DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Providencia rettgeri DNA [Presence] in Urine by NAA with probe detection;P rettgeri DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99026-7;Providencia stuartii DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Providencia stuartii DNA [Presence] in Urine by NAA with probe detection;P stuartii DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99027-5;Pseudomonas aeruginosa DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Pseudomonas aeruginosa DNA [Presence] in Urine by NAA with probe detection;P aeruginosa DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +9902-8;P wave duration.lead AVL;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead AVL;P wave dur L-AVL;;ACTIVE;1.0i;2.48 +99028-3;Serratia marcescens DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Serratia marcescens DNA [Presence] in Urine by NAA with probe detection;S marcescens DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99029-1;Staphylococcus aureus DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Staphylococcus aureus DNA [Presence] in Urine by NAA with probe detection;S aureus DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99030-9;Staphylococcus epidermidis DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Staphylococcus epidermidis DNA [Presence] in Urine by NAA with probe detection;S epidermidis DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99031-7;Staphylococcus saprophyticus DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Staphylococcus saprophyticus DNA [Presence] in Urine by NAA with probe detection;S. saprophyticus DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99032-5;Streptococcus agalactiae DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Urine by NAA with probe detection;Gp B Strep DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99033-3;Candida albicans DNA;PrThr;Pt;Urine;Ord;Probe.amp.tar;MICRO;1;Candida albicans DNA [Presence] in Urine by NAA with probe detection;C albicans DNA Ur Ql NAA+probe;;ACTIVE;2.72;2.72 +99034-1;Bacterial trimethoprim resistance dfrA1 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Trimethoprim resistance dfrA1 gene [Presence] by Molecular method;dfrA1 Islt/Spm Ql;;ACTIVE;2.72;2.72 +99035-8;Bacterial trimethoprim resistance dfrA5 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Trimethoprim resistance dfrA5 gene [Presence] by Molecular method;dfrA5 Islt/Spm Ql;;ACTIVE;2.72;2.72 +9903-6;P wave duration.lead AVR;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead AVR;P wave dur L-AVR;;ACTIVE;1.0i;2.48 +99036-6;Bacterial trimethoprim resistance dfrA7+dfrA17 genes;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Trimethoprim resistance dfrA7+dfrA17 genes [Presence] by Molecular method;dfrA7+dfrA17 Islt/Spm Ql;;ACTIVE;2.72;2.72 +99037-4;Bacterial trimethoprim resistance dfrA12 gene;PrThr;Pt;Isolate/Specimen;Ord;Molgen;ABXBACT;1;Trimethoprim dfrA12 gene [Presence] by Molecular method;dfrA12 Islt/Spm Ql;;ACTIVE;2.72;2.72 +99041-6;Trajectory of foreign object at wound entry panel;-;Pt;Wound;-;;PANEL.H&P;2;Trajectory of foreign object at wound entry panel;Trajectory wound entry panel;;ACTIVE;2.72;2.72 +99042-4;Trajectory deviation.vertical;Find;Pt;Wound;Nom;;H&P.HX;2;Trajectory deviation.vertical of Wound;Trajectory deviation.vertical Wnd;;ACTIVE;2.72;2.72 +99043-2;Trajectory deviation.lateral;Find;Pt;Wound;Nom;;H&P.HX;2;Trajectory deviation.lateral of Wound;Trajectory deviation.lateral Wnd;;ACTIVE;2.72;2.72 +9904-4;P wave duration.lead I;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead I;P wave dur L-I;;ACTIVE;1.0i;2.48 +99044-0;Trajectory deviation.anterior-posterior;Find;Pt;Wound;Nom;;H&P.HX;2;Trajectory deviation.anterior-posterior of Wound;Trajectory deviation.AP Wnd;;ACTIVE;2.72;2.72 +99045-7;Donated organ;Find;Pt;^Patient;Nom;;H&P.HX;2;Donated organ;Donated organ;;ACTIVE;2.72;2.72 +99046-5;Total score;Score;Pt;^Patient;Qn;EPDS;SURVEY.EPDS;4;Total score [EPDS];;;ACTIVE;2.72;2.72 +99047-3;Metanephrine.free;SRat;24H;Urine;Qn;;CHEM;1;Metanephrine Free [Moles/time] in 24 hour Urine;Metaneph Free 24h Ur-sRate;;ACTIVE;2.72;2.72 +99048-1;Metanephrine.free;SCnc;Pt;Urine;Qn;;CHEM;1;Metanephrine Free [Moles/volume] in Urine;Metaneph Free Ur-sCnc;;ACTIVE;2.72;2.72 +99049-9;Acidity.titratable;SCnc;24H;Urine;Qn;;CHEM;1;Acidity.titratable [Moles/volume] in 24 hour Urine;Titratable Acidity 24h Ur-sCnc;;ACTIVE;2.72;2.72 +99050-7;Erythrocytes;NCnc;Pt;BAL;Qn;Manual count;HEM/BC;1;Erythrocytes [#/volume] in Bronchoalveolar lavage by Manual count;RBC # BAL Manual;;ACTIVE;2.72;2.72 +9905-1;P wave duration.lead II;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead II;P wave dur L-II;;ACTIVE;1.0i;2.48 +99051-5;Leukocytes;NCnc;Pt;BAL;Qn;Manual count;HEM/BC;1;Leukocytes [#/volume] in Bronchoalveolar lavage by Manual count;WBC # BAL Manual;;ACTIVE;2.72;2.72 +99052-3;Epithelial cells;PrThr;Pt;BAL;Ord;Microscopy.light;HEM/BC;1;Epithelial cells [Presence] in Bronchoalveolar lavage by Light microscopy;Epi Cells BAL Ql Micro;;ACTIVE;2.72;2.72 +99053-1;Cells counted.total;Num;Pt;BAL;Qn;;HEM/BC;1;Cells Counted Total [#] in Bronchoalveolar lavage;Total Cells Counted BAL;;ACTIVE;2.72;2.72 +99054-9;Manual differential comment;Imp;Pt;BAL;Nar;;HEM/BC;1;Manual differential comment [Interpretation] in Bronchoalveolar lavage Narrative;Manual dif comment BAL-Imp;;ACTIVE;2.72;2.72 +99055-6;Cardiovascular disease 10Y risk;Likelihood;Pt;^Patient;Qn;;CARD.RISK;2;Cardiovascular disease 10Y risk [Likelihood];CVD 10Y risk Qn;;ACTIVE;2.72;2.72 +99056-4;Cardiovascular disease 10Y risk;Find;Pt;^Patient;Ord;;CARD.RISK;2;Cardiovascular disease 10Y risk;CVD 10Y risk;;ACTIVE;2.72;2.72 +99057-2;SLC12A1 gene full mutation analysis;Find;Pt;Bld;Doc;Molgen;MOLPATH.MUT;1;SLC12A1 gene full mutation analysis in Blood by Molecular genetics method;SLC12A1 Full Mut Anl Bld;;ACTIVE;2.72;2.72 +99058-0;DHCR7 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH.MUT;1;DHCR7 gene full mutation analysis in Blood or Tissue by Sequencing;DHCR7 gene Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99059-8;n-Acetylglycine/Creatinine;MRto;Pt;Urine;Qn;;CHEM;1;N-acetylglycine/Creatinine [Mass Ratio] in Urine;N-acetylglycine/Creat Ur;;ACTIVE;2.72;2.72 +99060-6;Cerebroventricular lining cells/100 leukocytes;NFr;Pt;CSF;Qn;;HEM/BC;1;Cerebroventricular lining cells/100 leukocytes in Cerebral spinal fluid;Cerebrov Lin Cell/leuk NFr CSF;;ACTIVE;2.72;2.72 +99061-4;Cholesterol.esterified actual/normal;RelACnc;Pt;Fibroblasts;Qn;;CHEM;1;Cholesterol.esterified actual/normal in Fibroblast;Esterified Cholest Act/Nor Fib;;ACTIVE;2.72;2.72 +99062-2;Acetylcholine receptor modulation Ab;PrThr;Pt;Ser;Ord;Flow cytometry;SERO;1;Acetylcholine receptor modulation Ab [Presence] in Serum by Flow cytometry (FC);AChR Mod Ab Ser Ql FC;;ACTIVE;2.72;2.72 +99063-0;Free water clearance;VRat;Pt;Urine+Ser/Plas;Qn;;CHEM;1;Free water Clearance in Urine and Serum or Plasma;Free H2O Ur+SerPl-vRate;;ACTIVE;2.72;2.72 +99064-8;Programmed cell death ligand 1 by clone SP263;Find;Pt;Tiss;Doc;;PATH;1;PD-L1 by clone SP263 in Tissue Document;PD-L1 by SP263 Tiss Doc;;ACTIVE;2.72;2.72 +99065-5;EJ Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Ej Ab [Units/volume] in Serum by Line blot;Ej Ab Ser Line blot-aCnc;;ACTIVE;2.72;2.72 +99066-3;PL-12 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;PL-12 Ab [Units/volume] in Serum by Line blot;PL12 Ab Ser Line blot-aCnc;;ACTIVE;2.72;2.72 +99067-1;PL-7 Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;PL-7 Ab [Units/volume] in Serum by Line blot;PL7 Ab Ser Line blot-aCnc;;ACTIVE;2.72;2.72 +99068-9;Ku Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Ku Ab [Units/volume] in Serum by Line blot;Ku Ab Ser Line blot-aCnc;;ACTIVE;2.72;2.72 +9906-9;P wave duration.lead III;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead III;P wave dur L-III;;ACTIVE;1.0i;2.48 +99069-7;Jo-1 extractable nuclear Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Jo-1 extractable nuclear Ab [Units/volume] in Serum by Line blot;ENA Jo1 Ab Ser Line blot-aCnc;;ACTIVE;2.72;2.72 +99070-5;Kelch-like protein 11 Ab.IgG;Titr;Pt;Ser;Qn;IF;SERO;1;Kelch-like protein 11 IgG Ab [Titer] in Serum by Immunofluorescence;KLHL11 IgG Titr Ser IF;;ACTIVE;2.72;2.72 +99071-3;Kelch-like protein 11 Ab.IgG;Titr;Pt;CSF;Qn;IF;SERO;1;Kelch-like protein 11 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence;KLHL11 IgG Titr CSF IF;;ACTIVE;2.72;2.72 +99072-1;Kelch-like protein 11 Ab.IgG;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Kelch-like protein 11 IgG Ab [Presence] in Serum by Cell binding immunofluorescent assay;KLHL11 IgG Ser Ql CBA IFA;;ACTIVE;2.72;2.72 +99073-9;Kelch-like protein 11 Ab.IgG;PrThr;Pt;CSF;Ord;CBA IFA;SERO;1;Kelch-like protein 11 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay;KLHL11 IgG CSF Ql CBA IFA;;ACTIVE;2.72;2.72 +99074-7;Calcium/Creatinine;MRto;Pt;Urine^Fetus;Qn;;CHEM;1;Calcium/Creatinine [Mass Ratio] in Urine from Fetus;Calcium/Creat Ur Fetus;;ACTIVE;2.72;2.72 +99075-4;Alpha-1-Microglobulin/Creatinine;MRto;24H;Urine;Qn;;CHEM;1;Alpha-1-Microglobulin/Creatinine [Mass Ratio] in 24 hour Urine;A1 Microglob/Creat 24h Ur;;ACTIVE;2.72;2.72 +99076-2;Alpha-1-Microglobulin;MCnc;24H;Urine;Qn;;CHEM;1;Alpha-1-Microglobulin [Mass/volume] in 24 hour Urine;A1 Microglob 24h Ur-mCnc;;ACTIVE;2.72;2.72 +9907-7;P wave duration.lead V1;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead V1;P wave dur L-V1;;ACTIVE;1.0i;2.48 +99077-0;Alpha-1-Fetoprotein.L3;MCnc;Pt;Ser/Plas;Qn;IA;CHEM;1;Alpha-1-Fetoprotein L3 [Mass/volume] in Serum or Plasma by Immunoassay;AFP L3 SerPl IA-mCnc;;ACTIVE;2.72;2.72 +99078-8;Thyrotropin blocking Ab;PrThr;Pt;Ser;Ord;CBA IFA;SERO;1;Thyrotropin blocking Ab [Presence] in Serum by Cell binding immunofluorescent assay;TSH Block Ab Ser Ql CBA IFA;;ACTIVE;2.72;2.72 +99079-6;Acrylfentanyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Acrylfentanyl [Presence] in Urine by Confirmatory method;Acrylfentanyl Ur Ql Cfm;;ACTIVE;2.72;2.72 +99080-4;O-Nortramadol;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;O-nortramadol [Presence] in Urine by Confirmatory method;O-nortramadol Ur Ql Cfm;;ACTIVE;2.72;2.72 +99081-2;Furanylfentanyl;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Furanylfentanyl [Presence] in Urine by Confirmatory method;Furanylfentanyl Ur Ql Cfm;;ACTIVE;2.72;2.72 +99082-0;Coccidioides sp Ag;MCnc;Pt;Body fld;Qn;IA;MICRO;1;Coccidioides sp Ag [Mass/volume] in Body fluid by Immunoassay;Coccidioides Ag Fld IA-mCnc;;ACTIVE;2.72;2.72 +99083-8;Blastomyces sp Ag;MCnc;Pt;Body fld;Qn;IA;MICRO;1;Blastomyces sp Ag [Mass/volume] in Body fluid by Immunoassay;Blastomyces Ag Fld IA-mCnc;;ACTIVE;2.72;2.73 +99084-6;Aspergillus sp Ag;ACnc;Pt;Body fld;Qn;IA;MICRO;1;Aspergillus sp Ag [Units/volume] in Body fluid by Immunoassay;Aspergillus Ag Fld IA-aCnc;;ACTIVE;2.72;2.72 +9908-5;P wave duration.lead V2;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead V2;P wave dur L-V2;;ACTIVE;1.0i;2.48 +99085-3;Napsin A Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;Napsin A Ag [Presence] in Tissue by Immune stain;Napsin A Ag Tiss Ql ImStn;;ACTIVE;2.72;2.72 +99086-1;p40 Ag;PrThr;Pt;Tiss;Ord;Immune stain;PATH;1;p40 Ag [Presence] in Tissue by Immune stain;p40 Ag Tiss Ql ImStn;;ACTIVE;2.72;2.72 +99087-9;Meningitis+Encephalitis pathogens panel;-;Pt;CSF;-;Probe.amp.tar;PANEL.MICRO;1;Meningitis+Encephalitis pathogens panel - Cerebral spinal fluid by NAA with probe detection;Mening+Enc Pnl CSF NAA+probe;;ACTIVE;2.72;2.72 +99088-7;Cryptococcus gattii+neoformans DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Cryptococcus gattii+neoformans DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;C gattii+neofor DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99089-5;Escherichia coli K1 DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Escherichia coli K1 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;E coli K1 DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99090-3;Haemophilus influenzae DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Haemophilus influenzae DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Haem influ DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99091-1;Listeria monocytogenes DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Listeria monocytogenes DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;L monocytog DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99092-9;Neisseria meningitidis DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Neisseria meningitidis DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;N men DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +9909-3;P wave duration.lead V3;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead V3;P wave dur L-V3;;ACTIVE;1.0i;2.48 +99093-7;Streptococcus agalactiae DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Streptococcus agalactiae DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;Gp B Strep DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99094-5;Streptococcus pneumoniae DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Streptococcus pneumoniae DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;S pneum DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99095-2;Streptococcus pyogenes DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Streptococcus pyogenes DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;S pyo DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99096-0;Mycoplasma pneumoniae DNA;PrThr;Pt;CSF;Ord;Probe.amp.tar;MICRO;1;Mycoplasma pneumoniae DNA [Presence] in Cerebral spinal fluid by NAA with probe detection;M pneumo DNA CSF Ql NAA+probe;;ACTIVE;2.72;2.72 +99097-8;Blastomyces dermatitidis Ab.IgG;ACnc;Pt;CSF;Qn;IA;MICRO;1;Blastomyces dermatitidis IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay;B dermat IgG CSF IA-aCnc;;ACTIVE;2.72;2.72 +99098-6;Blastomyces dermatitidis Ab.IgG;ACnc;Pt;Ser;Qn;IA;MICRO;1;Blastomyces dermatitidis IgG Ab [Units/volume] in Serum by Immunoassay;B dermat IgG Ser IA-aCnc;;ACTIVE;2.72;2.72 +99099-4;Procalcitonin;SCnc;Pt;Ser/Plas;Qn;;CHEM;1;Procalcitonin [Moles/volume] in Serum or Plasma;Procalcitonin SerPl-sCnc;;ACTIVE;2.72;2.72 +991-0;D little o super little a Ab;PrThr;Pt;Ser/Plas^BPU;Ord;;BLDBK;1;Do sup(a) Ab [Presence] in Serum or Plasma from Blood product unit;Do sup(a) Ab SerPl BPU Ql;;ACTIVE;1.0;2.56 +99100-0;Norepinephrine;MCnc;Pt;Ser/Plas;Qn;;CHEM;1;Norepinephrine [Mass/volume] in Serum or Plasma;Norepineph SerPl-mCnc;;ACTIVE;2.72;2.72 +9910-1;P wave duration.lead V4;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead V4;P wave dur L-V4;;ACTIVE;1.0i;2.48 +99101-8;Cancer Ag 242;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Cancer Ag 242 [Units/volume] in Serum or Plasma;Cancer Ag242 SerPl-aCnc;;ACTIVE;2.72;2.72 +99102-6;Gastrin releasing polypeptide;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Gastrin releasing polypeptide [Units/volume] in Serum or Plasma;GRP SerPl-aCnc;;ACTIVE;2.72;2.72 +99103-4;Tumor necrosis factor.alpha;ACnc;Pt;Ser/Plas;Qn;;CHEM;1;Tumor necrosis factor.alpha [Units/volume] in Serum or Plasma;A-Tumor Necrosis Fact SerPl-aCnc;;ACTIVE;2.72;2.72 +99104-2;Choriogonadotropin;MCnc;Pt;Urine;Qn;;CHEM;1;Choriogonadotropin [Mass/volume] in Urine;HCG Ur-mCnc;;ACTIVE;2.72;2.72 +99105-9;Chlamydia trachomatis Ag;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;Chlamydia trachomatis Ag [Presence] in Serum or Plasma by Immunoassay;C trach Ag SerPl Ql IA;;ACTIVE;2.72;2.72 +99106-7;How often do you attend meetings of the clubs or organizations you belong to;NRat;Pt;^Patient;Qn;;SURVEY.NHANES;4;How often do you attend meetings of the clubs or organizations you belong to;;;ACTIVE;2.72;2.72 +99107-5;Stimulants drug panel;-;Pt;Urine;-;Screen;PANEL.DRUG/TOX;1;Stimulants drug panel - Urine by Screen method;Stimulants drug panel Ur Scn;;ACTIVE;2.72;2.72 +99108-3;ePHEDrine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;ePHEDrine [Presence] in Urine by Screen method;Ephedrin Ur Ql Scn;;ACTIVE;2.72;2.72 +99109-1;Pseudoephedrine;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Pseudoephedrine [Presence] in Urine by Screen method;Pseudoephedrine Ur Ql Scn;;ACTIVE;2.72;2.72 +99110-9;Alpha-Phenyl-2-Piperidine acetate;PrThr;Pt;Urine;Ord;Screen;DRUG/TOX;1;Alpha-Phenyl-2-Piperidine acetate [Presence] in Urine by Screen method;PPAA Ur Ql Scn;;ACTIVE;2.72;2.72 +99111-7;Dengue virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Dengue virus neutralizing antibody [Titer] in Specimen by Neutralization test;DENV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99112-5;Rocio virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Rocio virus neutralizing antibody [Titer] in Specimen by Neutralization test;Rocio virus NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99113-3;Ilheus virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Ilheus virus neutralizing antibody [Titer] in Specimen by Neutralization test;ILHV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99114-1;Semliki Forest virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Semliki Forest virus neutralizing antibody [Titer] in Specimen by Neutralization test;SFV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99115-8;Onyong-nyong virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Onyong-nyong virus neutralizing antibody [Titer] in Specimen by Neutralization test;ONN virus NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99116-6;Bourbon virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Bourbon virus neutralizing antibody [Titer] in Specimen by Neutralization test;Bourbon virus NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99117-4;Toscana virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Toscana virus neutralizing antibody [Titer] in Specimen by Neutralization test;TOSV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99118-2;Sandfly fever Sicilian virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Sandfly fever Sicilian virus neutralizing antibody [Titer] in Specimen by Neutralization test;SFSV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +9911-9;P wave duration.lead V5;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead V5;P wave dur L-V5;;ACTIVE;1.0i;2.48 +99119-0;Sandfly fever Naples virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Sandfly fever Naples virus neutralizing antibody [Titer] in Specimen by Neutralization test;SFNV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99120-8;Oropouche virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Oropouche virus neutralizing antibody [Titer] in Specimen by Neutralization test;Oropouche virus NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99121-6;Rift Valley fever virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Rift valley fever virus neutralizing antibody [Titer] in Specimen by Neutralization test;RVFV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99122-4;Bwamba virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Bwamba virus neutralizing antibody [Titer] in Specimen by Neutralization test;Bwamba virus NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99123-2;Heartland banyangvirus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Heartland banyangvirus neutralizing antibody [Titer] in Specimen by Neutralization test;HRTV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99124-0;Tick-borne encephalitis virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Tick-borne encephalitis virus neutralizing antibody [Titer] in Specimen by Neutralization test;TBEV NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99125-7;Bunyamwera virus Ab.Neut;Titr;Pt;XXX;Qn;Neut;MICRO;1;Bunyamwera virus neutralizing antibody [Titer] in Specimen by Neutralization test;Bunyamwera virus NAb Titr Spec Nt;;ACTIVE;2.72;2.72 +99126-5;NOTCH1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;NOTCH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;NOTCH1 Mut Anl Bld/T;;ACTIVE;2.72;2.72 +9912-7;P wave duration.lead V6;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;P wave duration in lead V6;P wave dur L-V6;;ACTIVE;1.0i;2.48 +99127-3;BIRC3 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;BIRC3 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;BIRC3 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +99128-1;PLCG2 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;PLCG2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;PLCG2 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +99129-9;SF3B1 gene targeted mutation analysis;Prid;Pt;Bld/Tiss;Nom;Molgen;MOLPATH.MUT;1;SF3B1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal;SF3B1 gene Mut Anl Bld/T;;ACTIVE;2.72;2.72 +99130-7;Outcome and assessment information set (OASIS) form - version E;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version E [CMS Assessment];;;ACTIVE;2.72;2.74 +99131-5;Outcome and assessment information set (OASIS) form - version E - Start of Care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version E - Start of Care [CMS Assessment];;;ACTIVE;2.72;2.74 +99132-3;OASIS E - Administrative information - SOC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Administrative information - SOC [CMS Assessment];;;ACTIVE;2.72;2.74 +99133-1;Near convergence break;InvLen;Pt;Eye;Qn;Phoropter;EYE.REFRACTION;2;Near convergence break by Phoropter;Near con break by Phoropter;;ACTIVE;2.72;2.72 +99134-9;You or your families' health is affected by environmental conditions at home;Find;Pt;^Patient;Ord;;SURVEY.SDOH;4;You or your families' health is affected by environmental conditions at home;;;ACTIVE;2.72;2.72 +9913-5;P' wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead AVF;P' wave Amp L-AVF;;ACTIVE;1.0i;2.48 +99135-6;Environmental conditions in the home that affect you or your families' health;Find;Pt;^Patient;Nom;;SURVEY.SDOH;4;Environmental conditions in the home that affect you or your families' health;;;ACTIVE;2.72;2.72 +99136-4;Rabies virus Ab.IgM;Titr;Pt;XXX;Qn;IF;MICRO;1;Rabies virus IgM Ab [Titer] in Specimen by Immunofluorescence;RABV IgM Titr Spec IF;;ACTIVE;2.72;2.72 +99137-2;Rabies virus Ab.IgG;Titr;Pt;XXX;Qn;IF;MICRO;1;Rabies virus IgG Ab [Titer] in Specimen by Immunofluorescence;RABV IgG Titr Spec IF;;ACTIVE;2.72;2.72 +99138-0;OASIS E - Hearing, speech, and vision - SOC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Hearing, speech, and vision - SOC [CMS Assessment];;;ACTIVE;2.72;2.72 +99139-8;Sjogrens syndrome-A extractable nuclear 52kD Ab;ACnc;Pt;Ser;Qn;Line blot;SERO;1;Sjogrens syndrome-A extractable nuclear 52kD Ab [Units/volume] in Serum by Line blot;ENA SS-A 52kD Ab Ser Line blot-aCnc;;ACTIVE;2.72;2.72 +99140-6;OASIS E - Cognitive Patterns - SOC, ROC, DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Cognitive Patterns - SOC, ROC, DC [CMS Assessment];;;ACTIVE;2.72;2.72 +99142-2;OASIS E - Health Conditions - SOC, ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Health Conditions - SOC, ROC [CMS Assessment];;;ACTIVE;2.72;2.72 +9914-3;P' wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead AVL;P' wave Amp L-AVL;;ACTIVE;1.0i;2.48 +99143-0;OASIS E - Special Treatment, Procedures, and Programs - SOC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Special Treatment, Procedures, and Programs - SOC [CMS Assessment];;;ACTIVE;2.72;2.72 +99144-8;OASIS E - Behavior - SOC, ROC, DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Behavior - SOC, ROC, DC [CMS Assessment];;;ACTIVE;2.72;2.72 +99146-3;OASIS E - Active Diagnoses - SOC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Active Diagnoses - SOC [CMS Assessment];;;ACTIVE;2.72;2.72 +99147-1;OASIS E - Preferences for Customary Routine Activities - SOC, ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Preferences for Customary Routine Activities - SOC, ROC [CMS Assessment];;;ACTIVE;2.72;2.72 +99148-9;OASIS E - Functional Status - SOC, ROC, DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Functional Status - SOC, ROC, DC [CMS Assessment];;;ACTIVE;2.72;2.72 +99149-7;OASIS E - Self-care - follow-up performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Self-care - follow-up performance during assessment period [CMS Assessment];;;ACTIVE;2.72;2.72 +9915-0;P' wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead AVR;P' wave Amp L-AVR;;ACTIVE;1.0i;2.48 +99150-5;OASIS E - Mobility - follow-up performance;-;RptPeriod;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Mobility - follow-up performance during assessment period [CMS Assessment];;;ACTIVE;2.72;2.72 +99151-3;OASIS E - Medications - SOC, ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Medications - SOC, ROC [CMS Assessment];;;ACTIVE;2.72;2.72 +99152-1;OASIS E - Swallowing And Or Nutritional Status - SOC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Swallowing And Or Nutritional Status - SOC [CMS Assessment];;;ACTIVE;2.72;2.72 +99153-9;Outcome and assessment information set (OASIS) form - version E - Follow Up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version E - Follow Up [CMS Assessment];;;ACTIVE;2.72;2.72 +99154-7;OASIS E - Functional abilities and goals - FU;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Functional abilities and goals - FU [CMS Assessment];;;ACTIVE;2.72;2.72 +99155-4;OASIS E - Functional Status - follow up;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Functional Status - follow up [CMS Assessment];;;ACTIVE;2.72;2.72 +99156-2;OASIS E - Health Conditions - FU;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Health Conditions - FU [CMS Assessment];;;ACTIVE;2.72;2.72 +99157-0;OASIS E - Skin Conditions - FU;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Skin Conditions - FU [CMS Assessment];;;ACTIVE;2.72;2.72 +99158-8;Outcome and assessment information set (OASIS) form - version E - Death at Home;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version E - Death at Home [CMS Assessment];;;ACTIVE;2.72;2.72 +99159-6;OASIS E - Administrative information - DAH;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Administrative information - DAH [CMS Assessment];;;ACTIVE;2.72;2.72 +99160-4;Outcome and assessment information set (OASIS) form - version E - Resumption of Care;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version E - Resumption of Care [CMS Assessment];;;ACTIVE;2.72;2.74 +99161-2;OASIS E - Administrative information - ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Administrative information - ROC [CMS Assessment];;;ACTIVE;2.72;2.74 +9916-8;P' wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead I;P' wave Amp L-I;;ACTIVE;1.0i;2.48 +99169-5;OASIS E - Active Diagnoses - ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Active Diagnoses - ROC [CMS Assessment];;;ACTIVE;2.72;2.72 +99170-3;OASIS E - Health Conditions - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Health Conditions - DC [CMS Assessment];;;ACTIVE;2.72;2.72 +99171-1;OASIS E - Swallowing And Or Nutritional Status - ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Swallowing And Or Nutritional Status - ROC [CMS Assessment];;;ACTIVE;2.72;2.72 +99173-7;OASIS E - Special Treatment, Procedures, and Programs - ROC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Special Treatment, Procedures, and Programs - ROC [CMS Assessment];;;ACTIVE;2.72;2.72 +99174-5;Outcome and assessment information set (OASIS) form - version E - Transfer to an Inpatient Facility;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version E - Transfer to an Inpatient Facility [CMS Assessment];;;ACTIVE;2.72;2.72 +99175-2;OASIS E - Administrative information - TRN;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Administrative information - TRN [CMS Assessment];;;ACTIVE;2.72;2.72 +9917-6;P' wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead II;P' wave Amp L-II;;ACTIVE;1.0i;2.48 +99176-0;OASIS E - Special Treatment, Procedures, and Programs - transfer to an inpatient facility;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Special Treatment, Procedures, and Programs - transfer to an inpatient facility [CMS Assessment];;;ACTIVE;2.72;2.72 +99177-8;OASIS E - Participation in Assessment and Goal Setting - TRN, DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Participation in Assessment and Goal Setting - TRN, DC [CMS Assessment];;;ACTIVE;2.72;2.72 +99178-6;Outcome and assessment information set (OASIS) form - version E - Discharge from Agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;Outcome and assessment information set (OASIS) form - version E - Discharge from Agency [CMS Assessment];;;ACTIVE;2.72;2.74 +99179-4;OASIS E - Administrative information - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Administrative information - DC [CMS Assessment];;;ACTIVE;2.72;2.74 +9918-4;P' wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead III;P' wave Amp L-III;;ACTIVE;1.0i;2.48 +99188-5;OASIS E - Swallowing And Or Nutritional Status - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Swallowing And Or Nutritional Status - DC [CMS Assessment];;;ACTIVE;2.72;2.72 +99189-3;OASIS E - Skin Conditions - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Skin Conditions - DC [CMS Assessment];;;ACTIVE;2.72;2.72 +99190-1;OASIS E - Special Treatment, Procedures, and Programs - discharge from agency;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Special Treatment, Procedures, and Programs - discharge from agency [CMS Assessment];;;ACTIVE;2.72;2.72 +99191-9;OASIS E - Medications - DC;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Medications - DC [CMS Assessment];;;ACTIVE;2.72;2.72 +9919-2;P' wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead V1;P' wave Amp L-V1;;ACTIVE;1.0i;2.48 +99192-7;Patient-reported outcomes with LASIK - pre-operative panel;-;Pt;^Patient;-;PROWL;PANEL.SURVEY.PROWL;4;Patient-reported outcomes with LASIK - pre-operative panel [Patient reported outcomes with LASIK];;;ACTIVE;2.72;2.72 +99193-5;Frequency of noticing or thinking about eyesight or vision;Find;Pt;^Patient;Ord;;EYE.HX;2;Frequency of noticing or thinking about eyesight or vision;Freq of thinking about eyesight/vision;;ACTIVE;2.72;2.72 +99194-3;Could accept less than perfect vision if able to see well enough to drive without corrective lenses;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Could accept less than perfect vision if able to see well enough to drive without corrective lenses;;;ACTIVE;2.72;2.72 +99195-0;Expected corrective lens use frequency after healing from LASIK.distance;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Expected corrective lens use frequency after healing from LASIK.distance;;;ACTIVE;2.72;2.72 +99196-8;Expected corrective lens use frequency after healing from LASIK.near;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Expected corrective lens use frequency after healing from LASIK.near;;;ACTIVE;2.72;2.72 +99197-6;Expect clear vision after healing from LASIK;Find;Pt;^Patient;Nom;;SURVEY.PROWL;4;Expect clear vision after healing from LASIK;;;ACTIVE;2.72;2.72 +99198-4;Expect perfect vision after healing from LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Expect perfect vision after healing from LASIK;;;ACTIVE;2.72;2.72 +99199-2;Could accept less than perfect vision without corrective lenses after healing from LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Could accept less than perfect vision without corrective lenses after healing from LASIK;;;ACTIVE;2.72;2.72 +99-2;Cefoperazone;Susc;Pt;Isolate;Qn;MLC;ABXBACT;1;Cefoperazone [Susceptibility] by Minimum lethal concentration (MLC);Cefoperazone Islt MLC;;ACTIVE;1.0;2.19 +9920-0;P' wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead V2;P' wave Amp L-V2;;ACTIVE;1.0i;2.48 +99200-8;Ever driven a car;Find;Pt;^Patient;Ord;;H&P.HX;2;Ever driven a car;Ever driven;;ACTIVE;2.72;2.72 +99202-4;Level of difficulty when driving at night because of vision;Find;Pt;^Patient;Ord;;EYE.HX;2;Level of difficulty when driving at night because of vision;Diff driving night due to vision;;ACTIVE;2.72;2.72 +99203-2;Level of difficulty with daily activities because of vision;Find;Pt;^Patient;Ord;;EYE.HX;2;Level of difficulty with daily activities because of vision;Diff w/ daily activities due to vision;;ACTIVE;2.72;2.72 +99204-0;Participate less in active sports or other outdoor activities because of vision;Find;Pt;^Patient;Ord;;EYE.HX;2;Participate less in active sports or other outdoor activities because of vision;Less active sports/outdoor due to vision;;ACTIVE;2.72;2.72 +99205-7;Were recreational or sports activities avoided because of vision;Find;Pt;^Patient;Ord;;EYE.HX;2;Were recreational or sports activities avoided because of vision;Avoid recreation/sports due to vision;;ACTIVE;2.72;2.72 +99206-5;Daily activities that are difficult because of vision;Find;Pt;^Patient;Nom;;EYE.HX;2;Daily activities that are difficult because of vision;Diff daily activities due to vision;;ACTIVE;2.72;2.72 +99207-3;Are daily activities not done because of vision;Find;Pt;^Patient;Ord;;EYE.HX;2;Are daily activities not done because of vision;Avoid daily activities due to vision;;ACTIVE;2.72;2.72 +99208-1;Level of difficulty judging distances;Find;Pt;^Patient;Ord;;EYE.HX;2;Level of difficulty judging distances;Diff level judge distances;;ACTIVE;2.72;2.72 +99209-9;Level of difficulty getting used to the dark when moving from a lighted area into a dark place;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Level of difficulty getting used to the dark when moving from a lighted area into a dark place;;;ACTIVE;2.72;2.72 +99210-7;Level of difficulty seeing because of changes in vision clarity during the course of the day;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Level of difficulty seeing because of changes in vision clarity during the course of the day;;;ACTIVE;2.72;2.72 +99211-5;Frequency of being bothered by changes in the clarity of vision over the course of the day;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Frequency of being bothered by changes in the clarity of vision over the course of the day;;;ACTIVE;2.72;2.72 +99212-3;Frequency of seeing starbursts or halos that are bothersome or make it difficult to see when around bright lights at night;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Frequency of seeing starbursts or halos that are bothersome or make it difficult to see when around bright lights at night;;;ACTIVE;2.72;2.72 +99213-1;Experienced glare in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Experienced glare in past 7 days;Experienced glare past 7D;;ACTIVE;2.72;2.72 +99214-9;How bothersome has glare been in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome has glare been in past 7 days;Level of bother glare 7D;;ACTIVE;2.72;2.72 +99215-6;Experienced distorted vision in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Experienced distorted vision in past 7 days;Exper distorted vision 7D;;ACTIVE;2.72;2.72 +99216-4;How bothersome has distorted vision been in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome has distorted vision been in past 7 days;Level of bother distorted vision 7D;;ACTIVE;2.72;2.72 +99217-2;Experienced blurry vision in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Experienced blurry vision in past 7 days;Blurry vision past 7D;;ACTIVE;2.72;2.72 +9921-8;P' wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead V3;P' wave Amp L-V3;;ACTIVE;1.0i;2.48 +99218-0;How bothersome has blurry vision been in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome has blurry vision been in past 7 days;Level of bother blurry vision 7D;;ACTIVE;2.72;2.72 +99219-8;Experienced trouble seeing in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Experienced trouble seeing in past 7 days;Trouble seeing in past 7D;;ACTIVE;2.72;2.72 +99220-6;How bothersome has trouble seeing been in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome has trouble seeing been in past 7 days;Level of bother trouble seeing 7D;;ACTIVE;2.72;2.72 +99221-4;Satisfaction level with present vision;Find;Pt;^Patient;Ord;;EYE.HX;2;Satisfaction level with present vision;Satisfaction level w/ vision;;ACTIVE;2.72;2.72 +99222-2;Employed;Find;Pt;^Patient;Ord;;H&P.HX;2;Employed;Employed;;ACTIVE;2.72;2.72 +99223-0;H missed from work because of eye problems in past 7D;Time;7D;^Patient;Qn;;EYE.HX;2;Hours missed from work because of eye problems in past 7 days [Time];H missed work b/c eye prob 7D [Time];;ACTIVE;2.72;2.72 +99224-8;H missed from work because of any non vision related reasons in past 7D;Time;7D;^Patient;Qn;;SURVEY.PROWL;4;Hours missed from work because of any non vision related reasons in past 7 days;;;ACTIVE;2.72;2.72 +99225-5;H worked in past 7D;Time;7D;^Patient;Qn;;H&P.HX;2;Hours worked in past 7 days [Time];H worked in past 7D Time;;ACTIVE;2.72;2.72 +9922-6;P' wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead V4;P' wave Amp L-V4;;ACTIVE;1.0i;2.48 +99226-3;Level that eye problems affected productivity while working in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Level that eye problems affected productivity while working in past 7 days;Eye prob affect prdctvty at work 7D;;ACTIVE;2.72;2.72 +99227-1;Level that eye problems affected ability to do regular daily activities, other than work at a job in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Level that eye problems affected ability to do regular daily activities, other than work at a job in past 7 days;Lvl eye prbs afct daily non wk activ 7D;;ACTIVE;2.72;2.72 +99228-9;Use of corrective lenses in a typical day;Find;Pt;^Patient;Ord;;EYE.HX;2;Use of corrective lenses in a typical day;Use of corr lens in typical day;;ACTIVE;2.72;2.72 +99229-7;Seen double images in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Seen double images in past 7 days;Seen double images in past 7D;;ACTIVE;2.72;2.72 +99230-5;Frequency of seeing double images when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Frequency of seeing double images when wearing best corrective lenses in past 7 days;Freq see dble imge w best corr lens p 7D;;ACTIVE;2.72;2.72 +99231-3;Frequency of seeing double images when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Frequency of seeing double images when not wearing corrective lenses in past 7 days;Freq double images w/o corr lens pst 7D;;ACTIVE;2.72;2.72 +99232-1;How bothersome have double images been when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome have double images been when wearing best corrective lenses in past 7 days;Bother lvl dble images w best corr p 7D;;ACTIVE;2.72;2.72 +99233-9;How bothersome have double images been when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome have double images been when not wearing corrective lenses in past 7 days;Bother lvl double images w/o corr pst 7D;;ACTIVE;2.72;2.72 +9923-4;P' wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead V5;P' wave Amp L-V5;;ACTIVE;1.0i;2.48 +99234-7;Level of difficulty doing usual activities because of double images when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Level of difficulty doing usual activities because of double images when wearing best corrective lenses in past 7 days;Diff lvl bc dbl image w best cor lens 7D;;ACTIVE;2.72;2.72 +99235-4;Level of difficulty doing usual activities because of double images when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Level of difficulty doing usual activities because of double images when not wearing corrective lenses in past 7 days;Dif lvl bc dbl image w/o corr lens p 7D;;ACTIVE;2.72;2.72 +99236-2;Impact of best corrective lenses on double images;Find;Pt;^Patient;Ord;;EYE.HX;2;Impact of best corrective lenses on double images;Best corr lens impact on double images;;ACTIVE;2.72;2.72 +99237-0;Frequency of noticing glare when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Frequency of noticing glare when wearing best corrective lenses in past 7 days;Freq notice glar w best corr lens p 7D;;ACTIVE;2.72;2.72 +99238-8;Frequency of noticing glare when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Frequency of noticing glare when not wearing corrective lenses in past 7 days;Freq notice glar w/o corr lens p 7D;;ACTIVE;2.72;2.72 +99239-6;How bothersome has glare been when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome has glare been when wearing best corrective lenses in past 7 days;Bother level glare w best corr pst 7D;;ACTIVE;2.72;2.72 +99240-4;How bothersome has glare been when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;How bothersome has glare been when not wearing corrective lenses in past 7 days;Bother level of glare w/o corr past 7D;;ACTIVE;2.72;2.72 +99241-2;Level of difficulty doing usual activities because of glare when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Level of difficulty doing usual activities because of glare when wearing best corrective lenses in past 7 days;Diff lvl b/c glare w best corr lens p 7D;;ACTIVE;2.72;2.72 +9924-2;P' wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;P' wave amplitude in lead V6;P' wave Amp L-V6;;ACTIVE;1.0i;2.48 +99242-0;Level of difficulty doing usual activities because of glare when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Level of difficulty doing usual activities because of glare when not wearing corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99243-8;Impact of best corrective lenses on glare;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Impact of best corrective lenses on glare;;;ACTIVE;2.72;2.72 +99244-6;Seen halos in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Seen halos in past 7 days;Seen halos in past 7D;;ACTIVE;2.72;2.72 +99245-3;Frequency of seeing halos when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Frequency of seeing halos when wearing best corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99246-1;Frequency of seeing halos when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Frequency of seeing halos when not wearing corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99247-9;How bothersome have halos been when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;How bothersome have halos been when wearing best corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99248-7;How bothersome have halos been when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;How bothersome have halos been when not wearing corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99249-5;Level of difficulty doing usual activities because of halos when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Level of difficulty doing usual activities because of halos when wearing best corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99250-3;Level of difficulty doing usual activities because of halos when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Level of difficulty doing usual activities because of halos when not wearing corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99251-1;Impact of best corrective lenses on halos;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Impact of best corrective lenses on halos;;;ACTIVE;2.72;2.72 +99252-9;Seen starbursts in past 7D;Find;7D;^Patient;Ord;;EYE.HX;2;Seen starbursts in past 7 days;Seen starbursts in past 7D;;ACTIVE;2.72;2.72 +99253-7;Frequency of seeing starbursts when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Frequency of seeing starbursts when wearing best corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99254-5;Frequency of seeing starbursts when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Frequency of seeing starbursts when not wearing corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99255-2;How bothersome have starbursts been when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;How bothersome have starbursts been when wearing best corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99256-0;How bothersome have starbursts been when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;How bothersome have starbursts been when not wearing corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99257-8;Level of difficulty doing usual activities because of starbursts when wearing best corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Level of difficulty doing usual activities because of starbursts when wearing best corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +99258-6;Level of difficulty doing usual activities because of starbursts when not wearing corrective lenses in past 7D;Find;7D;^Patient;Ord;;SURVEY.PROWL;4;Level of difficulty doing usual activities because of starbursts when not wearing corrective lenses in past 7 days;;;ACTIVE;2.72;2.72 +9925-9;Q wave depth.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead AVF;Q wave Dpth L-AVF;;ACTIVE;1.0i;2.48 +99259-4;Impact of best corrective lenses on starbursts;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Impact of best corrective lenses on starbursts;;;ACTIVE;2.72;2.72 +99260-2;Information source for medical procedure;Type;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Information source for medical procedure;;;ACTIVE;2.72;2.72 +99261-0;Told not to have LASIK by an eye care professional;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Told not to have LASIK by an eye care professional;;;ACTIVE;2.72;2.72 +99262-8;Designer benzodiazepines;PrThr;Pt;Urine;Ord;Confirm;DRUG/TOX;1;Designer benzodiazepines [Presence] in Urine by Confirmatory method;Designer benzodiazepines Ur Ql Cfm;;ACTIVE;2.72;2.72 +99263-6;Delorazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Delorazepam [Mass/volume] in Urine by Confirmatory method;Delorazepam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99264-4;Etizolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Etizolam [Mass/volume] in Urine by Confirmatory method;Etizolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99265-1;Alpha hydroxyetizolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha hydroxyetizolam [Mass/volume] in Urine by Confirmatory method;A-OH-etizolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99266-9;Deschloroetizolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Deschloroetizolam [Mass/volume] in Urine by Confirmatory method;Deschloroetizolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +9926-7;Q wave depth.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead AVL;Q wave Dpth L-AVL;;ACTIVE;1.0i;2.48 +99267-7;Nifoxipam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Nifoxipam [Mass/volume] in Urine by Confirmatory method;Nifoxipam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99268-5;Diclazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Diclazepam [Mass/volume] in Urine by Confirmatory method;Diclazepam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99269-3;Clonazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Clonazolam [Mass/volume] in Urine by Confirmatory method;Clonazolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99270-1;8-Aminoclonazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;8-Aminoclonazolam [Mass/volume] in Urine by Confirmatory method;8-Aminoclonazolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99271-9;Flualprazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flualprazolam [Mass/volume] in Urine by Confirmatory method;Flualprazolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99272-7;Alpha-hydroxy flualprazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha-hydroxy flualprazolam [Mass/volume] in Urine by Confirmatory method;A-OH flualprazolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99273-5;Meclonazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Meclonazepam [Mass/volume] in Urine by Confirmatory method;Meclonazepam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99274-3;Flubromazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flubromazepam [Mass/volume] in Urine by Confirmatory method;Flubromazepam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +9927-5;Q wave depth.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead AVR;Q wave Dpth L-AVR;;ACTIVE;1.0i;2.48 +99275-0;Phenazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Phenazepam [Mass/volume] in Urine by Confirmatory method;Phenazepam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99276-8;3-Hydroxyphenazepam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;3-Hydroxyphenazepam [Mass/volume] in Urine by Confirmatory method;3-OH-phenazepam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99277-6;Pyrazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Pyrazolam [Mass/volume] in Urine by Confirmatory method;Pyrazolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99278-4;Flubromazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Flubromazolam [Mass/volume] in Urine by Confirmatory method;Flubromazolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +99279-2;Alpha-hydroxy flubromazolam;MCnc;Pt;Urine;Qn;Confirm;DRUG/TOX;1;Alpha-hydroxy flubromazolam [Mass/volume] in Urine by Confirmatory method;A-OH flubromazolam Ur Cfm-mCnc;;ACTIVE;2.72;2.72 +992-8;D little o super little a Ab;PrThr;Pt;Ser/Plas^Donor;Ord;;BLDBK;1;Do sup(a) Ab [Presence] in Serum or Plasma from Donor;Do sup(a) Ab SerPl Donr Ql;;ACTIVE;1.0;2.56 +99280-0;Cefiderocol;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Cefiderocol [Susceptibility];Cefiderocol Susc Islt;;ACTIVE;2.72;2.72 +99281-8;Lefamulin;Susc;Pt;Isolate;OrdQn;;ABXBACT;1;Lefamulin [Susceptibility];Lefamulin Susc Islt;;ACTIVE;2.72;2.72 +99282-6;FDA-initiated compliance action drug registration and listing inactivation - animal drug;-;-;^FDA product label;Nar;;DOC.REF;2;FDA product label FDA-initiated compliance action drug registration and listing inactivation - animal drug;FDA animal drug+list inactivation;;ACTIVE;2.72;2.72 +9928-3;Q wave depth.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead I;Q wave Dpth L-I;;ACTIVE;1.0i;2.48 +99283-4;Tegner activity scale panel;-;Pt;^Patient;-;Tegner;PANEL.SURVEY.GNHLTH;4;Tegner Activity Scale panel [Tegner];;;ACTIVE;2.72;2.72 +99284-2;Activity level before injury;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Activity level before injury;;;ACTIVE;2.72;2.72 +99285-9;Current activity level;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Current activity level;;;ACTIVE;2.72;2.72 +99286-7;Provision of current reconciled medication list to subsequent provider at transfer;Find;Pt;^Patient;Ord;CMS Assessment;SURVEY.CMS;4;Provision of current reconciled medication list to subsequent provider at transfer [CMS Assessment];;;ACTIVE;2.72;2.72 +99287-5;Checklist of nonverbal pain indicators panel;-;Pt;^Patient;-;CNPI;PANEL.SURVEY.CNPI;4;Checklist of nonverbal pain indicators panel [CNPI];;Copyright. Karen S. Feldt, PhD, RN, GNP-BC Used with permission;ACTIVE;2.72;2.72 +99288-3;Checklist of nonverbal pain indicators with movement panel;-;Pt;^Patient;-;CNPI;PANEL.SURVEY.CNPI;4;Checklist of nonverbal pain indicators with movement panel [CNPI];;Copyright. Karen S. Feldt, PhD, RN, GNP-BC Used with permission;ACTIVE;2.72;2.72 +99289-1;Nonverbal vocal complaints during movement;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Nonverbal vocal complaints during movement;;;ACTIVE;2.72;2.72 +99290-9;Facial grimaces or winces during movement;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Facial grimaces or winces during movement;;;ACTIVE;2.72;2.72 +9929-1;Q wave depth.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead II;Q wave Dpth L-II;;ACTIVE;1.0i;2.48 +99291-7;Bracing during movement;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Bracing during movement;;;ACTIVE;2.72;2.72 +99292-5;Rubbing during movement;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Rubbing during movement;;;ACTIVE;2.72;2.72 +99293-3;Restlessness during movement;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Restlessness during movement;;;ACTIVE;2.72;2.72 +99294-1;Verbal complaints during movement;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Verbal complaints during movement;;;ACTIVE;2.72;2.72 +99295-8;With movement score;Score;Pt;^Patient;Qn;CNPI;SURVEY.CNPI;4;With movement score [CNPI];;Copyright. Karen S. Feldt, PhD, RN, GNP-BC Used with permission;ACTIVE;2.72;2.72 +99296-6;Checklist of nonverbal pain indicators at rest panel;-;Pt;^Patient;-;CNPI;PANEL.SURVEY.CNPI;4;Checklist of nonverbal pain indicators at rest panel [CNPI];;Copyright. Karen S. Feldt, PhD, RN, GNP-BC Used with permission;ACTIVE;2.72;2.72 +99297-4;Nonverbal vocal complaints while at rest;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Nonverbal vocal complaints while at rest;;;ACTIVE;2.72;2.72 +99298-2;Facial grimaces or winces while at rest;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Facial grimaces or winces while at rest;;;ACTIVE;2.72;2.72 +99299-0;Bracing while at rest;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Bracing while at rest;;;ACTIVE;2.72;2.72 +99300-6;Restlessness while at rest;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Restlessness while at rest;;;ACTIVE;2.72;2.72 +99301-4;Rubbing while at rest;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Rubbing while at rest;;;ACTIVE;2.72;2.72 +99302-2;Verbal complaints while at rest;Find;Pt;^Patient;Ord;;SURVEY.CNPI;4;Verbal complaints while at rest;;;ACTIVE;2.72;2.72 +99303-0;At rest score;Score;Pt;^Patient;Qn;CNPI;SURVEY.CNPI;4;At rest score [CNPI];;Copyright. Karen S. Feldt, PhD, RN, GNP-BC Used with permission;ACTIVE;2.72;2.72 +99304-8;Total score;Score;Pt;^Patient;Qn;CNPI;SURVEY.CNPI;4;Total score [CNPI];;Copyright. Karen S. Feldt, PhD, RN, GNP-BC Used with permission;ACTIVE;2.72;2.72 +99305-5;Checklist of nonverbal pain indicators assessment;Imp;Pt;^Patient;Nom;CNPI;SURVEY.CNPI;4;Checklist of nonverbal pain indicators assessment [CNPI];;Copyright. Karen S. Feldt, PhD, RN, GNP-BC Used with permission;ACTIVE;2.72;2.72 +99306-3;Choriogonadotropin.beta subunit heterophile Ab interference panel;-;Pt;Ser;-;;PANEL.CHEM;1;Choriogonadotropin.beta subunit heterophile Ab interference panel - Serum;B-HCG heterph Ab intrf Pnl Ser;;ACTIVE;2.72;2.72 +99307-1;Choriogonadotropin.beta subunit heterophile Ab interference;PrThr;Pt;Ser;Ord;;CHEM;1;Choriogonadotropin.beta subunit heterophile Ab interference [Presence] in Serum;B-HCG heterph Ab intrf Ser Ql;;ACTIVE;2.72;2.72 +99308-9;Acid alpha glucosidase cross-reactive immunologic material (CRIM);PrThr;Pt;WBC;Ord;IB;CHEM;1;Acid alpha glucosidase cross-reactive immunologic material (CRIM) [Presence] in Leukocytes by Immunoblot;AAG CRIM WBC Ql IB;;ACTIVE;2.72;2.72 +9930-9;Q wave depth.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead III;Q wave Dpth L-III;;ACTIVE;1.0i;2.48 +99309-7;Acid alpha glucosidase cross-reactive immunologic material (CRIM);PrThr;Pt;Tissue;Ord;IB;CHEM;1;Acid alpha glucosidase cross-reactive immunologic material (CRIM) [Presence] in Tissue by Immunoblot;AAG CRIM tiss Ql IB;;ACTIVE;2.72;2.72 +99310-5;Total score^^adjusted for age;Score;Pt;^Patient;Qn;;CLIN.RISK;2;Total score age adjusted;Total score age-adj;;ACTIVE;2.72;2.72 +99311-3;Seizure onset;Type;Pt;^Patient;Nom;;H&P.HX;2;Seizure onset;Seizure onset;;ACTIVE;2.72;2.72 +99312-1;Seizure frequency;Find;Pt;^Patient;Ord;;H&P.HX;2;Seizure frequency;Seizure frequency;;ACTIVE;2.72;2.72 +99313-9;Time since last seizure;Find;Pt;^Patient;Ord;;H&P.HX;2;Time since last seizure;Time since last seizure;;ACTIVE;2.72;2.72 +99314-7;SARS coronavirus 2 RdRp gene mutation detected;Prid;Pt;XXX;Nom;Molgen;MICRO;1;SARS-CoV-2 (COVID-19) RdRp gene mutation detected [Identifier] in Specimen by Molecular genetics method;SARS-CoV-2 RdRp mut Spec;;ACTIVE;2.72;2.72 +99315-4;OASIS E - Intervention synopsis - DC, TRN;-;Pt;^Patient;-;CMS Assessment;PANEL.SURVEY.CMS;4;OASIS E - Intervention synopsis - DC, TRN [CMS Assessment];;;ACTIVE;2.72;2.72 +9931-7;Q wave depth.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead V1;Q wave Dpth L-V1;;ACTIVE;1.0i;2.48 +9932-5;Q wave depth.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead V2;Q wave Dpth L-V2;;ACTIVE;1.0i;2.48 +9933-3;Q wave depth.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead V3;Q wave Dpth L-V3;;ACTIVE;1.0i;2.48 +9934-1;Q wave depth.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead V4;Q wave Dpth L-V4;;ACTIVE;1.0i;2.48 +99342-8;Days since symptom started;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Days since symptom started;;;ACTIVE;2.72;2.72 +99343-6;Days since symptom finished;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Days since symptom finished;;;ACTIVE;2.72;2.72 +99344-4;Sought medical attention for symptoms;Find;RptPeriod;^Patient;Nom;;SURVEY.GNHLTH;4;Sought medical attention for symptoms;;;ACTIVE;2.72;2.72 +99345-1;Type of medical attention accessed;Type;RptPeriod;^Patient;Nom;;SURVEY.GNHLTH;4;Type of medical attention accessed;;;ACTIVE;2.72;2.72 +99346-9;Temperature taken;Find;RptPeriod;^Patient;Ord;;H&P.HX;2;Temperature taken Reporting Period;Temperature taken RptPeriod;;ACTIVE;2.72;2.72 +99347-7;Body temperature.max;Temp;RptPeriod;^Patient;Qn;;H&P.HX;2;Maximum body temperature Reporting Period;Body temp.max RptPeriod;;ACTIVE;2.72;2.72 +99348-5;Close contact with COVID-19 in last 2W;Find;2W;^Patient;Nom;;SURVEY.COVID;4;Close contact with COVID-19 in last 2W;;;ACTIVE;2.72;2.72 +99349-3;Has or had COVID-19;Hx;Pt;^Patient;Ord;;SURVEY.COVID;4;Has or had COVID-19;;;ACTIVE;2.72;2.72 +99350-1;Date of first infection onset;Date;Pt;^Patient;Nom;;SURVEY.COVID;4;Date of first infection onset;;;ACTIVE;2.72;2.72 +99351-9;Informed of being at severe risk from COVID-19 due to an underlying health condition;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Informed of being at severe risk from COVID-19 due to an underlying health condition;;;ACTIVE;2.72;2.72 +99352-7;Has health problems that require activity limits;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Has health problems that require activity limits;;;ACTIVE;2.72;2.72 +99353-5;Has health problems that require staying at home;Find;Pt;^Patient;Ord;;H&P.HX;2;Has health problems that require staying at home;Health prob require stay home;;ACTIVE;2.72;2.72 +99354-3;Mobility device or aid is regularly used;Find;Pt;^Patient;Ord;;H&P.HX;2;Mobility device or aid is regularly used;Mobility device reg used;;ACTIVE;2.72;2.72 +99355-0;Takes routine medication;Find;Pt;^Patient;Nom;;H&P.HX;2;Takes routine medication;Takes routine med;;ACTIVE;2.72;2.72 +99356-8;Influenza virus vaccination received in last 12Mo;Find;12Mo;^Patient;Ord;;H&P.HX;2;Influenza virus vaccination received in last 12 months;Flu vacc last 12Mo;;ACTIVE;2.72;2.72 +99357-6;COVID-19 health questions panel;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;COVID-19 health questions panel;;;ACTIVE;2.72;2.72 +9935-8;Q wave depth.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead V5;Q wave Dpth L-V5;;ACTIVE;1.0i;2.48 +99359-2;Person who performed clinical measurement;Type;Pt;^Patient;Nom;;H&P.HX;2;Person who performed clinical measurement;Clinical measurement by;;ACTIVE;2.72;2.72 +993-6;D little o super little a Ab;PrThr;Pt;Ser/Plas;Ord;;BLDBK;1;Do sup(a) Ab [Presence] in Serum or Plasma;Do sup(a) Ab SerPl Ql;;ACTIVE;1.0;2.73 +99360-0;Bovine serum albumin Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bovine serum albumin (BSA) IgG Ab [Mass/volume] in Serum;BSA IgG-mCnc;;ACTIVE;2.72;2.72 +99361-8;Horse hair+Horse dander Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horse hair+Horse dander IgG Ab [Mass/volume] in Serum;Horse Hair+Dander IgG-mCnc;;ACTIVE;2.72;2.72 +99362-6;Euroglyphus maynei Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Euroglyphus maynei IgG Ab [Mass/volume] in Serum;E maynei IgG-mCnc;;ACTIVE;2.72;2.72 +99363-4;Triticum spelta Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Spelt IgG Ab [Mass/volume] in Serum;Spelt IgG-mCnc;;ACTIVE;2.72;2.72 +99364-2;Ovalbumin Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Ovalbumin IgG Ab [Mass/volume] in Serum;Ovalb IgG-mCnc;;ACTIVE;2.72;2.72 +99365-9;Sheep milk Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sheep milk IgG Ab [Mass/volume] in Serum;Sheep Milk IgG-mCnc;;ACTIVE;2.72;2.72 +9936-6;Q wave depth.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave depth in lead V6;Q wave Dpth L-V6;;ACTIVE;1.0i;2.48 +99366-7;Chicken meat Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Chicken meat IgG Ab [Mass/volume] in Serum;Chicken Meat IgG-mCnc;;ACTIVE;2.72;2.72 +99367-5;Theobroma cacao Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cocoa IgG Ab [Mass/volume] in Serum;Cocoa IgG-mCnc;;ACTIVE;2.72;2.72 +99368-3;Gliadin Ab.IgG;MCnc;Pt;Ser;Qn;;SERO;1;Gliadin IgG Ab [Mass/volume] in Serum;Gliadin IgG Ser-mCnc;;ACTIVE;2.72;2.72 +99369-1;Dactylis glomerata Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cocksfoot IgG Ab [Mass/volume] in Serum;Cocksfoot IgG-mCnc;;ACTIVE;2.72;2.72 +99370-9;Tabanus spp Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horse Fly IgG Ab [Mass/volume] in Serum;Horse Fly IgG-mCnc;;ACTIVE;2.72;2.72 +99371-7;Culex pipiens Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Culex mosquito IgG Ab [Mass/volume] in Serum;Culex mosquito IgG-mCnc;;ACTIVE;2.72;2.72 +99372-5;Platanus acerifolia Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;London Plane IgG Ab [Mass/volume] in Serum;London Plane IgG-mCnc;;ACTIVE;2.72;2.72 +99373-3;Alnus incana Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grey Alder IgG Ab [Mass/volume] in Serum;Grey Alder IgG-mCnc;;ACTIVE;2.72;2.72 +9937-4;Q wave duration.lead AVF;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead AVF;Q wave dur L-AVF;;ACTIVE;1.0i;2.48 +99374-1;Betula verrucosa Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch IgG Ab [Mass/volume] in Serum;Silver Birch IgG-mCnc;;ACTIVE;2.72;2.72 +99375-8;Corylus avellana pollen Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Hazelnut Pollen IgG Ab [Mass/volume] in Serum;Hazelnut Poln IgG-mCnc;;ACTIVE;2.72;2.72 +99376-6;Olea europaea pollen Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Olive Pollen IgG Ab [Mass/volume] in Serum;Olive Poln IgG-mCnc;;ACTIVE;2.72;2.72 +99377-4;Parietaria judaica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Pellitory (Parietaria judaica) IgG Ab [Mass/volume] in Serum;Pellitory (judaic) IgG-mCnc;;ACTIVE;2.72;2.72 +99378-2;Vasopressin;SCnc;Pt;Urine;Qn;;CHEM;1;Vasopressin [Moles/volume] in Urine;Vasopressin Ur-sCnc;;ACTIVE;2.72;2.72 +99379-0;Mercury;SCnc;Pt;Milk;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Milk;Mercury Mlk-sCnc;;ACTIVE;2.72;2.72 +99380-8;Mercury;SCnc;Pt;CSF;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Cerebral spinal fluid;Mercury CSF-sCnc;;ACTIVE;2.72;2.72 +99381-6;Mercury;SCnc;Pt;Dial fld;Qn;;DRUG/TOX;1;Mercury [Moles/volume] in Dialysis fluid;Mercury Dial fld-sCnc;;ACTIVE;2.72;2.72 +9938-2;Q wave duration.lead AVL;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead AVL;Q wave dur L-AVL;;ACTIVE;1.0i;2.48 +99382-4;Cancer Ag 50;ACnc;Pt;Body fld;Qn;;CHEM;1;Cancer Ag 50 [Units/volume] in Body fluid;Cancer Ag50 Fld-aCnc;;ACTIVE;2.72;2.72 +99383-2;Copper;SCnc;Pt;Water;Qn;;DRUG/TOX;1;Copper [Moles/volume] in Water;Copper Wat-sCnc;;ACTIVE;2.72;2.72 +99384-0;Creatinine;SRat;6H;Urine;Qn;;CHEM;1;Creatinine [Moles/time] in 6 hour Urine;Creat 6h Ur-sRate;;ACTIVE;2.72;2.72 +99385-7;Hepatitis B virus surface Ag;LaCnc;Pt;Ser/Plas;Qn;IA;MICRO;1;Hepatitis B virus surface Ag [log units/volume] in Serum or Plasma by Immunoassay;HBV surface Ag SerPl IA-Log IU;;ACTIVE;2.72;2.72 +99386-5;Adenovirus DNA;LnCnc;Pt;Cornea/Conjunctiva;Qn;Probe.amp.tar;MICRO;1;Adenovirus DNA [Log #/volume] (viral load) in Cornea or Conjunctiva by NAA with probe detection;HAdV DNA Corn/Cnjt NAA+probe-Log#;;ACTIVE;2.72;2.74 +99387-3;Carbon monoxide;SCnc;Pt;Bld;Qn;;CHEM;1;Carbon monoxide [Moles/volume] in Blood;CO Bld-sCnc;;ACTIVE;2.72;2.72 +99388-1;Choriogonadotropin.tumor marker;ACnc;Pt;Asp;Qn;;CHEM;1;Choriogonadotropin.tumor marker [Units/volume] in Aspirate;HCG-TM Aspirate-aCnc;;ACTIVE;2.72;2.72 +99389-9;Choriogonadotropin.tumor marker;ACnc;Pt;Plr fld;Qn;;CHEM;1;Choriogonadotropin.tumor marker [Units/volume] in Pleural fluid;HCG-TM Plr-aCnc;;ACTIVE;2.72;2.72 +9939-0;Q wave duration.lead AVR;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead AVR;Q wave dur L-AVR;;ACTIVE;1.0i;2.48 +99390-7;Progesterone;SCnc;Pt;Ovarian asp;Qn;;CHEM;1;Progesterone [Moles/volume] in Ovarian aspirate;Progest Ovarian asp-sCnc;;ACTIVE;2.72;2.72 +99391-5;Progesterone;MCnc;Pt;Ovarian asp;Qn;;CHEM;1;Progesterone [Mass/volume] in Ovarian aspirate;Progest Ovarian asp-mCnc;;ACTIVE;2.72;2.72 +99392-3;Sulfocysteine;SCnc;Pt;Urine;Qn;;CHEM;1;Sulfocysteine [Moles/volume] in Urine;Sulfocysteine Ur-sCnc;;ACTIVE;2.72;2.72 +99393-1;Siderocytes panel;-;Pt;Bld/Bone mar;-;Prussian blue stain;PANEL.HEM/BC;1;Siderocytes panel - Blood or Marrow by Prussian blue stain;Siderocytes Pnl Bld/Mar Prus Bl St;;ACTIVE;2.72;2.72 +99394-9;Siderocytes;PrThr;Pt;Bld/Bone mar;Ord;Prussian blue stain;HEM/BC;1;Siderocytes [Presence] in Blood or Marrow by Prussian blue stain;Siderocytes Bld/Mar Ql Prus Bl St;;ACTIVE;2.72;2.72 +99395-6;Siderocytes/100 Erythroblasts;NFr;Pt;Bld/Bone mar;Qn;Prussian blue stain;HEM/BC;1;Siderocytes/100 Erythroblasts in Blood or Marrow by Prussian blue stain;Siderocytes NFr Bld/Mar Prus Bl St;;ACTIVE;2.72;2.72 +99396-4;Siderocytes.Type 1/100 Erythroblasts;NFr;Pt;Bld/Bone mar;Qn;Prussian blue stain;HEM/BC;1;Siderocytes.Type 1/100 Erythroblasts in Blood or Marrow by Prussian blue stain;Siderocytes.Tp 1 NFr Bld/Mar Prus Bl St;;ACTIVE;2.72;2.72 +99397-2;Siderocytes.Type 2/100 Erythroblasts;NFr;Pt;Bld/Bone mar;Qn;Prussian blue stain;HEM/BC;1;Siderocytes.Type 2/100 Erythroblasts in Blood or Marrow by Prussian blue stain;Siderocytes.Tp 2 NFr Bld/Mar Prus Bl St;;ACTIVE;2.72;2.72 +99398-0;Siderocytes.Type 3/100 Erythroblasts;NFr;Pt;Bld/Bone mar;Qn;Prussian blue stain;HEM/BC;1;Siderocytes.Type 3/100 Erythroblasts in Blood or Marrow by Prussian blue stain;Siderocytes.Tp 3 NFr Bld/Mar Prus Bl St;;ACTIVE;2.72;2.72 +99399-8;Zonulin;MCnc;Pt;Stool;Qn;;CHEM;1;Zonulin [Mass/volume] in Stool;Zonulin Stl-mCnc;;ACTIVE;2.72;2.72 +99400-4;Cells.CD19+CD23+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19+CD23+ cells/100 cells in Bone marrow;CD19+CD23+ Cells NFr Mar;;ACTIVE;2.72;2.72 +99401-2;Cells.CD19+FMC7+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cells.CD19+FMC7+/100 cells in Bone marrow;Cells.CD19+FMC7+ NFr Mar;;ACTIVE;2.72;2.72 +99402-0;Cells.CD19+CD79b+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cells.CD19+CD79b+/100 cells in Bone marrow;Cells.CD19+CD79b+ NFr Mar;;ACTIVE;2.72;2.72 +99403-8;Cells.CD19+CD22+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;Cells.CD19+CD22+/100 cells in Bone marrow;Cells.CD19+CD22+ NFr Mar;;ACTIVE;2.72;2.72 +99404-6;Cells.CD19+CD38+/100 cells;NFr;Pt;Bone mar;Qn;;CELLMARK;1;CD19+CD38+ cells/100 cells in Bone marrow;CD19+CD38+ Cells NFr Mar;;ACTIVE;2.72;2.72 +99405-3;Cells.CD19+FMC7+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cells.CD19+FMC7+/100 cells in Blood;Cells.CD19+FMC7+ NFr Bld;;ACTIVE;2.72;2.72 +99406-1;Cells.CD19+CD79b+/100 cells;NFr;Pt;Bld;Qn;;CELLMARK;1;Cells.CD19+CD79b+/100 cells in Blood;Cells.CD19+CD79b+ NFr Bld;;ACTIVE;2.72;2.72 +99407-9;Myeloperoxidase;MCnc;Pt;Ser;Qn;IA;CHEM;1;Myeloperoxidase [Mass/volume] in Serum by Immunoassay;Myeloperoxidase Ser IA-mCnc;;ACTIVE;2.72;2.72 +9940-8;Q wave duration.lead I;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead I;Q wave dur L-I;;ACTIVE;1.0i;2.48 +99408-7;Matrix metallopeptidase 9;MCnc;Pt;Ser;Qn;IA;CHEM;1;Matrix metallopeptidase 9 [Mass/volume] in Serum by Immunoassay;MMP9 Ser IA-mCnc;;ACTIVE;2.72;2.72 +99409-5;Acetaminophen-cysteine adduct;SCnc;Pt;Ser/Plas;Qn;LC/MS/MS;DRUG/TOX;1;Acetaminophen-cysteine adduct [Moles/volume] in Serum or Plasma by LC/MS/MS;APAP-Cysteine SerPl LC/MS/MS-sCnc;;ACTIVE;2.72;2.72 +99410-3;Cupressus sempervirens Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Italian Cypress IgG Ab [Mass/volume] in Serum;Italian Cypress IgG-mCnc;;ACTIVE;2.72;2.72 +99411-1;Voltage-gated calcium channel Ab;SCnc;Pt;CSF;Qn;IA;SERO;1;Voltage-gated calcium channel Ab [Moles/volume] in Cerebral spinal fluid by Immunoassay;VGCC Ab CSF IA-sCnc;;ACTIVE;2.72;2.72 +99412-9;Beta globulin;MCnc;Pt;Ser/Plas;Qn;Immunofixation;CHEM;1;Beta globulin [Mass/volume] in Serum or Plasma by Immunofixation;B-Globulin SerPl IFE-mCnc;;ACTIVE;2.72;2.72 +99413-7;cycloSPORINE;TmMCnc;Pt;Bld;Qn;;DRUG/TOX;1;cycloSPORINE [AUC] in Blood;cycloSPORINE Bld-AUC;;ACTIVE;2.72;2.72 +99414-5;Gamma globulin;MCnc;Pt;Ser/Plas;Qn;Immunofixation;CHEM;1;Gamma globulin [Mass/volume] in Serum or Plasma by Immunofixation;Gamma glob SerPl IFE-mCnc;;ACTIVE;2.72;2.72 +99415-2;Protein.monoclonal band 1;MCnc;Pt;Ser/Plas;Qn;Immunofixation;CHEM;1;Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Immunofixation;M Protein 1 SerPl IFE-mCnc;;ACTIVE;2.72;2.72 +9941-6;Q wave duration.lead II;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead II;Q wave dur L-II;;ACTIVE;1.0i;2.48 +99416-0;Protein.monoclonal band 2;MCnc;Pt;Ser/Plas;Qn;Immunofixation;CHEM;1;Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Immunofixation;M Protein 2 SerPl IFE-mCnc;;ACTIVE;2.72;2.72 +99417-8;Shared decision making panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Shared decision making panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +99418-6;Shared decision making total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Shared decision making total score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +99419-4;Know possible benefits of treatment plan;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Know possible benefits of treatment plan;;;ACTIVE;2.72;2.72 +99420-2;Know possible downside of treatment plan;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Know possible downside of treatment plan;;;ACTIVE;2.72;2.72 +99421-0;Know available choices for treatment plan;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Know available choices for treatment plan;;;ACTIVE;2.72;2.72 +99422-8;Feel fully involved in treatment plan;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Feel fully involved in treatment plan;;;ACTIVE;2.72;2.72 +99423-6;Time to complete survey;Time;Pt;^Patient;Qn;;SURVEY.PROWL;4;Time to complete survey;;;ACTIVE;2.72;2.72 +9942-4;Q wave duration.lead III;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead III;Q wave dur L-III;;ACTIVE;1.0i;2.48 +99424-4;Penicillin G Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillin G IgG4 Ab [Mass/volume] in Serum;Penicillin G IgG4-mCnc;;ACTIVE;2.72;2.72 +99425-1;Penicillin V Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillin V IgG4 Ab [Mass/volume] in Serum;Penicillin V IgG4-mCnc;;ACTIVE;2.72;2.72 +99426-9;Amoxicillin Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Amoxicillin IgG4 Ab [Mass/volume] in Serum;Amoxicillin IgG4-mCnc;;ACTIVE;2.72;2.72 +99427-7;Blomia tropicalis Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blomia tropicalis IgG4 Ab [Mass/volume] in Serum;B tropicalis IgG4-mCnc;;ACTIVE;2.72;2.72 +99428-5;Dermatophagoides microceras Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Dermatophagoides microceras IgG4 Ab [Mass/volume] in Serum;D microceras IgG4-mCnc;;ACTIVE;2.72;2.72 +99429-3;Tyrophagus putrescentiae Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tyrophagus putrescentiae IgG4 Ab [Mass/volume] in Serum;T putrescentiae IgG4-mCnc;;ACTIVE;2.72;2.72 +99430-1;Euroglyphus maynei Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Euroglyphus maynei IgG4 Ab [Mass/volume] in Serum;E maynei IgG4-mCnc;;ACTIVE;2.72;2.72 +99431-9;Goat epithelium Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Goat epithelium IgG4 Ab [Mass/volume] in Serum;Goat Epith IgG4-mCnc;;ACTIVE;2.72;2.72 +9943-2;Q wave duration.lead V1;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead V1;Q wave dur L-V1;;ACTIVE;1.0i;2.48 +99432-7;Cat recombinant (rFel d) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cat recombinant (rFel d) 1 IgG4 Ab [Mass/volume] in Serum;Cat (rFel d) 1 IgG4-mCnc;;ACTIVE;2.72;2.72 +99433-5;Beta vulgaris seed Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Beet Seed (Beta vulgaris seed) IgG4 Ab [Mass/volume] in Serum;Sugar Beet Seed IgG4-mCnc;;ACTIVE;2.72;2.72 +99434-3;Chenopodium quinoa Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Quinoa IgG4 Ab [Mass/volume] in Serum;Quinoa IgG4-mCnc;;ACTIVE;2.72;2.72 +99435-0;Cyprinus carpio recombinant (rCyp c) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cyprinus carpio recombinant (rCyp c) 1 IgG4 Ab [Mass/volume] in Serum;Carp (rCyp c) 1 IgG4-mCnc;;ACTIVE;2.72;2.72 +99436-8;Prunus persica recombinant (rPru p) 3 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peach recombinant (rPru p) 3 IgG4 Ab [Mass/volume] in Serum;Peach (rPru p) 3 IgG4-mCnc;;ACTIVE;2.72;2.72 +99437-6;Juglans regia recombinant (rJug r) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;English walnut recombinant (rJug r) 1 IgG4 Ab [Mass/volume] in Serum;English walnut (rJug r) 1 IgG4-mCnc;;ACTIVE;2.72;2.72 +99438-4;Juglans regia recombinant (rJug r) 3 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;English walnut recombinant (rJug r) 3 IgG4 Ab [Mass/volume] in Serum;English walnut (rJug r) 3 IgG4-mCnc;;ACTIVE;2.72;2.72 +99439-2;Anacardium occidentale recombinant (rAna o) 3 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cashew nut recombinant (rAna o) 3 IgG4 Ab [Mass/volume] in Serum;Cashew nut (rAna o) 3 IgG4-mCnc;;ACTIVE;2.72;2.72 +994-4;D little o super little a Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;Do sup(a) Ag [Presence] on Red Blood Cells from Blood product unit;Do sup(a) Ag RBC BPU Ql;;ACTIVE;1.0;2.56 +9944-0;Q wave duration.lead V2;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead V2;Q wave dur L-V2;;ACTIVE;1.0i;2.48 +99440-0;Arachis hypogaea recombinant (rAra h) 6 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Peanut recombinant (rAra h) 6 IgG4 Ab [Mass/volume] in Serum;Peanut (rAra h) 6 IgG4-mCnc;;ACTIVE;2.72;2.72 +99441-8;Theobroma cacao Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cocoa IgG4 Ab [Mass/volume] in Serum;Cocoa IgG4-mCnc;;ACTIVE;2.72;2.72 +99442-6;Hordeum vulgare pollen Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Barley Pollen IgG4 Ab [Mass/volume] in Serum;Barley Poln IgG4-mCnc;;ACTIVE;2.72;2.72 +99443-4;(Dactylis glomerata+Festuca elatior+Lolium perenne+Phleum pratense+Poa pratensis) Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grass Allergen Mix 1 (Orchard grass+Meadow Fescue+Perennial rye grass+Timothy+Kentucky blue grass) IgG4 Ab [Mass/volume] in Serum;Grass Allerg Mix1 IgG4-mCnc;;ACTIVE;2.72;2.72 +99444-2;(Anthoxanthum odoratum+Lolium perenne+Phleum pratense+Secale cereale+Holcus lanatus) Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grass Allergen Mix 3 (Sweet vernal grass+Perennial rye grass+Timothy+Rye+Velvet grass) IgG4 Ab [Mass/volume] in Serum;Grass Allerg Mix3 IgG4-mCnc;;ACTIVE;2.72;2.72 +99445-9;Bombus terrestris Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Bumble Bee IgG4 Ab [Mass/volume] in Serum;Bumble Bee IgG4-mCnc;;ACTIVE;2.72;2.72 +99446-7;Polistes spp recombinant (rPol d) 5 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp recombinant (rPol d) 5 IgG4 Ab [Mass/volume] in Serum;Paper wasp (rPol d) 5 IgG4-mCnc;;ACTIVE;2.72;2.72 +99447-5;Vespula vulgaris recombinant (rVes v) 1 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common wasp recombinant (rVes v) 1 IgG4 Ab [Mass/volume] in Serum;Common wasp (rVes v) 1 IgG4-mCnc;;ACTIVE;2.72;2.72 +99448-3;Cladotanytarsus lewisi Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Green Nimitti IgG4 Ab [Mass/volume] in Serum;Green Nimitti IgG4-mCnc;;ACTIVE;2.72;2.72 +99449-1;Polistes dominulus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;European paper wasp IgG4 Ab [Mass/volume] in Serum;European paper wasp IgG4-mCnc;;ACTIVE;2.72;2.72 +99450-9;Botrytis cinerea Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Botrytis cinerea IgG4 Ab [Mass/volume] in Serum;B cinerea IgG4-mCnc;;ACTIVE;2.72;2.72 +99451-7;Carpinus betulus Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horn beam IgG4 Ab [Mass/volume] in Serum;Horn beam IgG4-mCnc;;ACTIVE;2.72;2.72 +99452-5;Betula verrucosa recombinant (rBet v) 2 Ab.IgG4;MCnc;Pt;Ser;Qn;;ALLERGY;1;Silver Birch recombinant (rBet v) 2 IgG4 Ab [Mass/volume] in Serum;Silver Birch (rBet v) 2 IgG4-mCnc;;ACTIVE;2.72;2.72 +99453-3;Penicillin V Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillin V IgG Ab [Mass/volume] in Serum;Penicillin V IgG-mCnc;;ACTIVE;2.72;2.72 +99454-1;Clostridium tetani toxoid Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Clostridium tetani toxoid IgG Ab [Mass/volume] in Serum;C tetani Toxoid IgG Ser-mCnc;;ACTIVE;2.72;2.72 +99455-8;Amoxicillin Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Amoxicillin IgG Ab [Mass/volume] in Serum;Amoxicillin IgG-mCnc;;ACTIVE;2.72;2.72 +99456-6;Blomia tropicalis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Blomia tropicalis IgG Ab [Mass/volume] in Serum;B tropicalis IgG-mCnc;;ACTIVE;2.72;2.72 +9945-7;Q wave duration.lead V3;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead V3;Q wave dur L-V3;;ACTIVE;1.0i;2.48 +99457-4;Tyrophagus putrescentiae Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Tyrophagus putrescentiae IgG Ab [Mass/volume] in Serum;T putrescentiae IgG-mCnc;;ACTIVE;2.72;2.72 +99458-2;Rabbit urine proteins Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit urine proteins IgG Ab [Mass/volume] in Serum;Rabbit Urine Prot IgG-mCnc;;ACTIVE;2.72;2.72 +99459-0;Budgerigar droppings Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Budgerigar droppings IgG Ab [Mass/volume] in Serum;Budgie Drop IgG-mCnc;;ACTIVE;2.72;2.72 +99460-8;Rabbit epithelium Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rabbit epithelium IgG Ab [Mass/volume] in Serum;Rabbit Epith IgG-mCnc;;ACTIVE;2.72;2.72 +99461-6;Rat epithelium+Serum proteins+Urine proteins Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Rat epithelium, serum proteins + urine proteins IgG Ab [Mass/volume] in Serum;Rat Epith+Ser+Ur IgG-mCnc;;ACTIVE;2.72;2.72 +99462-4;Beta vulgaris seed Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sugar Beet Seed (Beta vulgaris seed) IgG Ab [Mass/volume] in Serum;Sugar Beet Seed IgG-mCnc;;ACTIVE;2.72;2.72 +99463-2;(Anacardium occidentale+Carya illinoinensis+Juglans spp+Pistacia vera) Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Food Allergen Mix 22 (Cashew+Pecan or Hickory nut+Walnut+Pistachio) IgG Ab [Mass/volume] in Serum;Food Allerg Mix22 IgG-mCnc;;ACTIVE;2.72;2.72 +99464-0;Anthoxanthum odoratum Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sweet Vernal grass IgG Ab [Mass/volume] in Serum;Sw Vernal grass IgG-mCnc;;ACTIVE;2.72;2.72 +9946-5;Q wave duration.lead V4;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead V4;Q wave dur L-V4;;ACTIVE;1.0i;2.48 +99465-7;Holcus lanatus Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Velvet grass IgG Ab [Mass/volume] in Serum;Velvet grass IgG-mCnc;;ACTIVE;2.72;2.72 +99466-5;Avena sativa cultivated Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Oat pollen IgG Ab [Mass/volume] in Serum;Oat Poln IgG-mCnc;;ACTIVE;2.72;2.72 +99467-3;Zea mays pollen Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cultivated Corn IgG Ab [Mass/volume] in Serum;Cultivated Corn IgG-mCnc;;ACTIVE;2.72;2.72 +99468-1;(Dactylis glomerata+Festuca elatior+Lolium perenne+Phleum pratense+Poa pratensis) Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Grass Allergen Mix 1 (Orchard grass+Meadow Fescue+Perennial rye grass+Timothy+Kentucky blue grass) IgG Ab [Mass/volume] in Serum;Grass Allerg Mix1 IgG-mCnc;;ACTIVE;2.72;2.72 +99469-9;Gasterophilus intestinalis Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Horse Bot Fly IgG Ab [Mass/volume] in Serum;Horse Bot Fly IgG-mCnc;;ACTIVE;2.72;2.72 +99470-7;Polistes spp recombinant (rPol d) 5 Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Paper wasp recombinant (rPol d) 5 IgG Ab [Mass/volume] in Serum;Paper wasp (rPol d) 5 IgG-mCnc;;ACTIVE;2.72;2.72 +99471-5;Vespula vulgaris recombinant (rVes v) 1 Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Common wasp recombinant (rVes v) 1 IgG Ab [Mass/volume] in Serum;Common wasp (rVes v) 1 IgG-mCnc;;ACTIVE;2.72;2.72 +99472-3;Blatella germanica Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Cockroach IgG Ab [Mass/volume] in Serum;Roach IgG-mCnc;;ACTIVE;2.72;2.72 +9947-3;Q wave duration.lead V5;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead V5;Q wave dur L-V5;;ACTIVE;1.0i;2.48 +99473-1;Solenopsis invicta Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Red Imported Fire Ant IgG Ab [Mass/volume] in Serum;Red Imp Fire Ant IgG-mCnc;;ACTIVE;2.72;2.72 +99474-9;Amylase Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Amylase IgG Ab [Mass/volume] in Serum;Amylase IgG-mCnc;;ACTIVE;2.72;2.72 +99475-6;Penicillium frequentans Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Penicillium frequentans IgG Ab [Mass/volume] in Serum;P frequentans IgG-mCnc;;ACTIVE;2.72;2.72 +99476-4;Aspergillus flavus Ab.IgG;MCnc;Pt;Ser;Qn;;MICRO;1;Aspergillus flavus IgG Ab [Mass/volume] in Serum;A flavus IgG Ser-mCnc;;ACTIVE;2.72;2.72 +99477-2;Rumex acetosella Ab.IgG;MCnc;Pt;Ser;Qn;;ALLERGY;1;Sheep Sorrel IgG Ab [Mass/volume] in Serum;Sheep Sorrel IgG-mCnc;;ACTIVE;2.72;2.72 +99478-0;Cardiac loop monitor study;Find;Stdy;Heart;Doc;;CARD.PROC;2;Cardiac loop monitor study Document;Card loop study Doc;;ACTIVE;2.72;2.72 +99479-8;Note;Find;Pt;Telehealth;Doc;Physical therapy;DOC.ONTOLOGY;2;Physical therapy Telehealth Note;PT Telehealth Note;;ACTIVE;2.72;2.72 +99480-6;History and physical note;Find;Pt;{Setting};Doc;Solid organ transplant;DOC.ONTOLOGY;2;Solid Organ Transplant History and physical note;Solid Org Transplant H&P note;;ACTIVE;2.72;2.73 +9948-1;Q wave duration.lead V6;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;Q wave duration in lead V6;Q wave dur L-V6;;ACTIVE;1.0i;2.48 +99481-4;History and physical note;Find;Pt;{Setting};Doc;Thromboembolism;DOC.ONTOLOGY;2;Thromboembolism History and physical note;Thromboemb H&P note;;ACTIVE;2.72;2.72 +99482-2;History and physical note;Find;Pt;{Setting};Doc;Obstetrics.midwife;DOC.ONTOLOGY;2;Obstetrics Midwife History and physical note;OB Midwife H&P note;;ACTIVE;2.72;2.72 +99483-0;Discharge summary note;Find;Pt;{Setting};Doc;Obstetrics.midwife;DOC.ONTOLOGY;2;Obstetrics Midwife Discharge summary;OB Midwife D/C sum;;ACTIVE;2.72;2.73 +99484-8;Procedure note;Find;Pt;{Setting};Doc;Obstetrics.midwife;DOC.ONTOLOGY;2;Obstetrics Midwife procedure note;OB Midwife Procedure note;;ACTIVE;2.72;2.72 +99485-5;History and physical note;Find;Pt;{Setting};Doc;Maternal and fetal medicine;DOC.ONTOLOGY;2;Maternal and fetal medicine History and physical note;Mat fetal med H&P note;;ACTIVE;2.72;2.73 +99486-3;History and physical note;Find;Pt;{Setting};Doc;Gynecologic oncology;DOC.ONTOLOGY;2;Gynecologic oncology History and physical note;Gyn Onc H&P note;;ACTIVE;2.72;2.72 +99487-1;History and physical note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine History and physical note;Fam Med H&P note;;ACTIVE;2.72;2.72 +99488-9;Discharge summary note;Find;Pt;{Setting};Doc;Colon and rectal surgery;DOC.ONTOLOGY;2;Colon and rectal surgery Discharge summary;Col+rec surg D/C sum;;ACTIVE;2.72;2.73 +99489-7;Discharge summary note;Find;Pt;{Setting};Doc;Thoracic and cardiac surgery;DOC.ONTOLOGY;2;Cardiothoracic surgery Discharge summary;Cardiothor surg D/C sum;;ACTIVE;2.72;2.73 +99490-5;Discharge summary note;Find;Pt;{Setting};Doc;Family medicine;DOC.ONTOLOGY;2;Family medicine Discharge summary;Fam Med D/C sum;;ACTIVE;2.72;2.73 +99491-3;Procedure note;Find;Pt;{Setting};Doc;Recreational therapy;DOC.ONTOLOGY;2;Recreational therapy procedure note;Rec therapy Procedure note;;ACTIVE;2.72;2.72 +99492-1;Evaluation note;Find;Pt;Emergency department;Doc;Geriatric medicine;DOC.ONTOLOGY;2;Geriatric medicine Emergency department Evaluation note;Geri med ED Eval note;;ACTIVE;2.72;2.72 +99493-9;Condition clinical status;Find;Pt;^Patient;Nom;;H&P.HX;2;Condition clinical status;Condition clinical status;;ACTIVE;2.72;2.72 +99494-7;Diagnosis type;Type;Pt;^Patient;Nom;;H&P.HX;2;Diagnosis type;Diagnosis type;;ACTIVE;2.72;2.72 +99495-4;Speed of condition onset;Find;Pt;^Patient;Nom;;H&P.HX;2;Speed of condition onset;Speed of condition onset;;ACTIVE;2.72;2.72 +99496-2;Condition cause;Find;Pt;^Patient;Nom;;H&P.HX;2;Condition cause;Condition cause;;ACTIVE;2.72;2.72 +99498-8;Condition verification status;Find;Pt;^Patient;Nom;;H&P.HX;2;Condition verification status;Condition verification status;;ACTIVE;2.72;2.72 +9949-9;QRS duration.lead AVF;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead AVF;QRS dur L-AVF;;ACTIVE;1.0i;2.48 +99499-6;Condition severity;Find;Pt;^Patient;Nom;;H&P.HX;2;Condition severity;Condition severity;;ACTIVE;2.72;2.72 +99500-1;Clinical trial vaccine received;Find;Pt;^Patient;Ord;;VACCIN;2;Clinical trial vaccine received;Clin trial vaccine received;;ACTIVE;2.72;2.72 +99501-9;Sex for clinical use;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Sex for clinical use;SFCU;;TRIAL;2.72;2.73 +99502-7;Recorded sex or gender;Type;Pt;^Patient;Nom;;ADMIN.PATIENT.DEMOG;2;Recorded sex or gender;Recorded sex/gender;;TRIAL;2.72;2.72 +99503-5;Cefiderocol;Susc;Pt;Isolate;OrdQn;MIC;ABXBACT;1;Cefiderocol [Susceptibility] by Minimum inhibitory concentration (MIC);Cefiderocol Islt MIC;;ACTIVE;2.72;2.72 +99504-3;Glucose;MCnc;Pt;Interstitial fluid;Qn;;CHEM;1;Glucose [Mass/volume] in Interstitial fluid;Glucose Interstitial fld-mCnc;;ACTIVE;2.72;2.72 +99505-0;View PA;Find;Pt;Upper extremity.left>Wrist;Doc;XR;RAD;2;XR Wrist - left PA;XR Wrist-L PA;;ACTIVE;2.72;2.72 +99506-8;View PA;Find;Pt;Upper extremity.right>Wrist;Doc;XR;RAD;2;XR Wrist - right PA;XR Wrist-R PA;;ACTIVE;2.72;2.72 +9950-7;QRS duration.lead AVL;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead AVL;QRS dur L-AVL;;ACTIVE;1.0i;2.48 +99507-6;View Judet external oblique;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Judet external oblique;XR Hip-R Judet Ext Obl;;ACTIVE;2.72;2.72 +99508-4;View Judet external oblique;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Judet external oblique;XR Hip-L Judet Ext Obl;;ACTIVE;2.72;2.72 +99509-2;View Judet internal oblique;Find;Pt;Lower extremity.left>Hip;Doc;XR;RAD;2;XR Hip - left Judet internal oblique;XR Hip-L Judet Int Obl;;ACTIVE;2.72;2.72 +995-1;D little o super little a Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;Do sup(a) Ag [Presence] on Red Blood Cells from Donor;Do sup(a) Ag RBC Donr Ql;;ACTIVE;1.0;2.56 +99510-0;View Judet internal oblique;Find;Pt;Lower extremity.right>Hip;Doc;XR;RAD;2;XR Hip - right Judet internal oblique;XR Hip-R Judet Int Obl;;ACTIVE;2.72;2.72 +99511-8;Views;Find;Pt;XXX>Spinal cord;Doc;XR.slot radiography;RAD;2;XR.slot radiography Spinal cord Views;XR.slot radiography Spinal cord Views;;ACTIVE;2.72;2.72 +99512-6;Weight;Mass;Pt;Brain;Qn;;PATH;1;Weight of Brain;Wt Brain Qn;;ACTIVE;2.72;2.72 +99513-4;Weight;Mass;Pt;Lung.left;Qn;;PATH;1;Weight of Lung - left;Wt Lung-L Qn;;ACTIVE;2.72;2.72 +99514-2;Weight;Mass;Pt;Lung.right;Qn;;PATH;1;Weight of Lung - right;Wt Lung-R Qn;;ACTIVE;2.72;2.72 +9951-5;QRS duration.lead AVR;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead AVR;QRS dur L-AVR;;ACTIVE;1.0i;2.48 +99515-9;Weight;Mass;Pt;Heart;Qn;;PATH;1;Weight of Heart;Wt Hrt Qn;;ACTIVE;2.72;2.72 +99516-7;Weight;Mass;Pt;Spleen;Qn;;PATH;1;Weight of Spleen;Wt Spleen Qn;;ACTIVE;2.72;2.72 +99517-5;Weight;Mass;Pt;Liver;Qn;;PATH;1;Weight of Liver;Wt Liver Qn;;ACTIVE;2.72;2.72 +99518-3;Weight;Mass;Pt;Pancreas;Qn;;PATH;1;Weight of Pancreas;Wt Pancreas Qn;;ACTIVE;2.72;2.72 +99519-1;Volume;Vol;Pt;Gallbladder;Qn;;PATH;1;Volume of Gallbladder;Volume GB;;ACTIVE;2.72;2.72 +99520-9;Weight;Mass;Pt;Kidney.right;Qn;;PATH;1;Weight of Kidney - right;Wt Kidney-R Qn;;ACTIVE;2.72;2.72 +99521-7;Weight;Mass;Pt;Kidney.left;Qn;;PATH;1;Weight of Kidney - left;Wt Kidney-L Qn;;ACTIVE;2.72;2.72 +99522-5;Circumference;Len;Pt;Heart.valve.XXX;Qn;;PATH;1;Circumference [Length] of Heart valve;Circumf Valve;;ACTIVE;2.72;2.72 +9952-3;QRS duration.lead I;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead I;QRS dur L-I;;ACTIVE;1.0i;2.48 +99523-3;Circumference;Len;Pt;Pulmonary valve;Qn;;PATH;1;Circumference [Length] of Pulmonary valve;Circumf Pulm valve;;ACTIVE;2.72;2.72 +99524-1;Circumference;Len;Pt;Mitral valve;Qn;;PATH;1;Circumference [Length] of Mitral valve;Circumf MV;;ACTIVE;2.72;2.72 +99525-8;Circumference;Len;Pt;Aortic valve;Qn;;PATH;1;Circumference [Length] of Aortic valve;Circumf AV;;ACTIVE;2.72;2.72 +99526-6;Thickness;Len;Pt;Heart.ventricle.right;Qn;;PATH;1;Thickness [Length] of Right ventricle;Thickness RV;;ACTIVE;2.72;2.72 +99527-4;Thickness;Len;Pt;Heart.ventricle.left;Qn;;PATH;1;Thickness [Length] of Left ventricle;Thickness LV;;ACTIVE;2.72;2.72 +99528-2;Thickness;Len;Pt;Heart.interventricular septum;Qn;;PATH;1;Thickness [Length] of Interventricular septum;Thickness IVS;;ACTIVE;2.72;2.72 +99529-0;Volume;Vol;Pt;Pleural space.right;Qn;;PATH;1;Volume of Pleural space - right;Volume Pl space-R;;ACTIVE;2.72;2.72 +99530-8;Volume;Vol;Pt;Pleural space.left;Qn;;PATH;1;Volume of Pleural space - left;Volume Pl space-L;;ACTIVE;2.72;2.72 +9953-1;QRS duration.lead II;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead II;QRS dur L-II;;ACTIVE;1.0i;2.48 +99531-6;Volume;Vol;Pt;Pericardial space;Qn;;PATH;1;Volume of Pericardial space;Volume Pericardial space;;ACTIVE;2.72;2.72 +99532-4;Volume;Vol;Pt;Peritoneal space;Qn;;PATH;1;Volume of Peritoneal space;Volume Peritoneal space;;ACTIVE;2.72;2.72 +99533-2;Length.crown rump;Len;Pt;^Patient;Qn;Measured;H&P.PX;2;Crown Rump length Measured;CRL Measured;;ACTIVE;2.72;2.72 +99534-0;Length.crown heel;Len;Pt;^Patient;Qn;Measured;H&P.PX;2;Crown heel length Measured;CHL Measured;;ACTIVE;2.72;2.72 +99535-7;Length.palm;Len;Pt;Hand;Qn;Measured;H&P.PX;2;Palm length of Hand Measured;Palm length Hand Measured;;ACTIVE;2.72;2.72 +99536-5;Length.heel toe;Len;Pt;Foot;Qn;Measured;H&P.PX;2;Heel toe length of Foot Measured;Heel toe length Ft Measured;;ACTIVE;2.72;2.72 +99537-3;Stenosis degree;LenFr;Pt;Left main coronary artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Left main coronary artery by Autopsy;Sten deg LenFr LM Autopsy;;ACTIVE;2.72;2.72 +99538-1;Stenosis degree;LenFr;Pt;Proximal left anterior descending artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Proximal left anterior descending artery by Autopsy;Sten deg LenFr pLAD Autopsy;;ACTIVE;2.72;2.72 +99539-9;Stenosis degree;LenFr;Pt;Mid left anterior descending artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Mid left anterior descending artery by Autopsy;Sten deg LenFr mLAD Autopsy;;ACTIVE;2.72;2.72 +99540-7;Stenosis degree;LenFr;Pt;Distal left anterior descending artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Distal left anterior descending artery by Autopsy;Sten deg LenFr dLAD Autopsy;;ACTIVE;2.72;2.72 +99541-5;Stenosis degree;LenFr;Pt;Proximal left circumflex artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Proximal left circumflex artery by Autopsy;Sten deg LenFr pCx Autopsy;;ACTIVE;2.72;2.72 +99542-3;Stenosis degree;LenFr;Pt;Middle left circumflex artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Middle left circumflex artery by Autopsy;Sten deg LenFr mLCX Autopsy;;ACTIVE;2.72;2.72 +99543-1;Stenosis degree;LenFr;Pt;Distal left circumflex artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Distal left circumflex artery by Autopsy;Sten deg LenFr dLCX Autopsy;;ACTIVE;2.72;2.72 +99544-9;Stenosis degree;LenFr;Pt;Proximal right coronary artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Proximal right coronary artery by Autopsy;Sten deg LenFr pRCA Autopsy;;ACTIVE;2.72;2.72 +99545-6;Stenosis degree;LenFr;Pt;Mid right coronary artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Mid right coronary artery by Autopsy;Sten deg LenFr mRCA Autopsy;;ACTIVE;2.72;2.72 +99546-4;Circumference;Len;Pt;Lower extremity;Qn;;PATH;1;Circumference [Length] of Lower extremity;Circumf LE;;ACTIVE;2.72;2.72 +99547-2;Stenosis degree;LenFr;Pt;Distal right coronary artery;Qn;Autopsy;PATH;1;Stenosis degree [Length fraction] in Distal right coronary artery by Autopsy;Sten deg LenFr dRCA Autopsy;;ACTIVE;2.72;2.72 +99548-0;Gas & electrolytes panel;-;Pt;BldA;Qn;;PANEL.CHEM;1;Gas and electrolytes panel - Arterial blood;Gas + Electrolytes Pnl BldA;;ACTIVE;2.72;2.72 +9954-9;QRS duration.lead III;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead III;QRS dur L-III;;ACTIVE;1.0i;2.48 +99549-8;Health Leads screening panel;-;Pt;^Patient;-;;PANEL.SURVEY.SDOH;4;Health Leads screening panel;;;ACTIVE;2.72;2.72 +99550-6;Worried about housing stability in next 2Mo;Find;2Mo;^Patient;Ord;;SURVEY.SDOH;4;Worried about housing stability in next 2 months;;;ACTIVE;2.72;2.72 +99551-4;Problems getting child care make work or study difficult;Find;Pt;^Patient;Ord;;SURVEY.SDOH;4;Problems getting child care make work or study difficult;;;ACTIVE;2.72;2.72 +99552-2;Could not see doctor due to cost in past 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.SDOH;4;Could not see doctor due to cost in past 12Mo;;;ACTIVE;2.72;2.72 +99553-0;Went without health care due to lack of transportation in last 12Mo;Find;12Mo;^Patient;Ord;;SURVEY.SDOH;4;Went without health care due to lack of transportation in last 12 months;;;ACTIVE;2.72;2.72 +99554-8;Personal needs are urgent;Find;Pt;^Patient;Ord;;SURVEY.SDOH;4;Personal needs are urgent;;;ACTIVE;2.72;2.72 +99555-5;Want assistance with personal needs;Find;Pt;^Patient;Ord;;SURVEY.SDOH;4;Want assistance with personal needs;;;ACTIVE;2.72;2.72 +9955-6;QRS duration.lead V1;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead V1;QRS dur L-V1;;ACTIVE;1.0i;2.48 +99556-3;Behavior change panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Behavior change panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +99557-1;Behavior change total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Behavior change total score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +99558-9;Skills and tools to change behavior;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Skills and tools to change behavior;;;ACTIVE;2.72;2.72 +99559-7;Nothing prevents behavior change;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Nothing prevents behavior change;;;ACTIVE;2.72;2.72 +99560-5;Choose to change behavior;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Choose to change behavior;;;ACTIVE;2.72;2.72 +99561-3;Change behavior without thinking;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Change behavior without thinking;;;ACTIVE;2.72;2.72 +99562-1;Adherence panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Adherence panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +99563-9;Adherence total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Adherence total score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +9956-4;QRS duration.lead V2;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead V2;QRS dur L-V2;;ACTIVE;1.0i;2.48 +99564-7;Remember to follow treatment instructions;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Remember to follow treatment instructions;;;ACTIVE;2.72;2.72 +99565-4;Follow treatment instructions if feel bad;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Follow treatment instructions if feel bad;;;ACTIVE;2.72;2.72 +99566-2;Follow treatment instructions if feel better;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Follow treatment instructions if feel better;;;ACTIVE;2.72;2.72 +99567-0;Acceptance of loss panel;-;Pt;^Patient;-;R-Outcomes;PANEL.SURVEY.R-OUTCOMES;4;Acceptance of loss panel [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +99568-8;Acceptance of loss total score;Score;Pt;^Patient;Qn;R-Outcomes;SURVEY.R-OUTCOMES;4;Acceptance of loss total score [R-Outcomes];;Copyright © 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Tim Benson by email: tim.benson@r-outcomes.com Used with permission;ACTIVE;2.72;2.72 +99569-6;Know capabilities following loss;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Know capabilities following loss;;;ACTIVE;2.72;2.72 +99570-4;Recognize life changes following loss;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Recognize life changes following loss;;;ACTIVE;2.72;2.72 +99571-2;Activities done differently following loss;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Activities done differently following loss;;;ACTIVE;2.72;2.72 +9957-2;QRS duration.lead V3;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead V3;QRS dur L-V3;;ACTIVE;1.0i;2.48 +99572-0;Moved on following loss;Find;Pt;^Patient;Ord;;SURVEY.R-OUTCOMES;4;Moved on following loss;;;ACTIVE;2.72;2.72 +99573-8;Often feel lack of companionship;Find;Pt;^Patient;Ord;;SURVEY.SDOH;4;Often feel lack of companionship;;;ACTIVE;2.72;2.72 +99574-6;Roland Morris Disability Questionnaire panel;-;Pt;^Patient;-;RMDQ;PANEL.SURVEY.RMDQ;4;Roland Morris Disability Questionnaire panel [RMDQ];;;ACTIVE;2.72;2.72 +99575-3;Total Score;Score;Pt;^Patient;Qn;RMDQ;SURVEY.RMDQ;4;Total score [RMDQ];;;ACTIVE;2.72;2.72 +99576-1;Impact of back pain today;Find;Pt;^Patient;Nom;;SURVEY.RMDQ;4;Impact of back pain today;;;ACTIVE;2.72;2.72 +99577-9;Columbia Behavior Scale for Dementia panel;-;Pt;^Patient;-;CBS-8;PANEL.SURVEY.CBS-8;4;Columbia Behavior Scale for Dementia panel [CBS-8];;© 2020 Dr. William Mansbach. Used with permission;ACTIVE;2.72;2.72 +99578-7;Total score;Score;Pt;^Patient;Qn;CBS-8;SURVEY.CBS-8;4;Total score [CBS-8];;© 2020 Dr. William Mansbach. Used with permission;ACTIVE;2.72;2.72 +99579-5;Psychosis factor score;Score;Pt;^Patient;Qn;CBS-8;SURVEY.CBS-8;4;Psychosis factor score [CBS-8];;© 2020 Dr. William Mansbach. Used with permission;ACTIVE;2.72;2.72 +9958-0;QRS duration.lead V4;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead V4;QRS dur L-V4;;ACTIVE;1.0i;2.48 +99580-3;Aggression factor score;Score;Pt;^Patient;Qn;CBS-8;SURVEY.CBS-8;4;Aggression factor score [CBS-8];;© 2020 Dr. William Mansbach. Used with permission;ACTIVE;2.72;2.72 +99581-1;Motor disinhibition factor score;Score;Pt;^Patient;Qn;CBS-8;SURVEY.CBS-8;4;Motor disinhibition factor score [CBS-8];;© 2020 Dr. William Mansbach. Used with permission;ACTIVE;2.72;2.72 +99582-9;Symptom and timing panel;-;Pt;^Patient;-;;PANEL.H&P;2;Symptom and timing panel;Symptom and timing panel;;ACTIVE;2.72;2.72 +99583-7;Lysholm Knee Scoring Scale;-;Pt;^Patient;-;LKSS;PANEL.SURVEY.LKSS;4;Lysholm Knee Scoring Scale [LKSS];;;ACTIVE;2.72;2.72 +99584-5;Limp severity;Find;Pt;^Patient;Ord;;H&P.PX;2;Limp severity;Limp severity;;ACTIVE;2.72;2.72 +99585-2;Level of cane or crutch use;Find;Pt;^Patient;Ord;;H&P.PX;2;Level of cane or crutch use;Level of cane or crutch use;;ACTIVE;2.72;2.72 +99586-0;Knee locking frequency;Find;Pt;^Patient;Ord;;H&P.PX;2;Knee locking frequency;Knee locking frequency;;ACTIVE;2.72;2.72 +99587-8;Knee instability frequency;Find;Pt;^Patient;Ord;;H&P.PX;2;Knee instability frequency;Knee instability frequency;;ACTIVE;2.72;2.72 +99588-6;Knee pain severity;Find;Pt;^Patient;Ord;;H&P.PX;2;Knee pain severity;Knee pain severity;;ACTIVE;2.72;2.72 +99589-4;Knee swelling frequency;Find;Pt;^Patient;Ord;;H&P.PX;2;Knee swelling frequency;Knee swelling frequency;;ACTIVE;2.72;2.72 +99592-8;Total score;Score;Pt;^Patient;Qn;LKSS;SURVEY.LKSS;4;Total score [LKSS];;;ACTIVE;2.72;2.72 +99593-6;American Academy of Family Physicians Social Needs Screening Tool;-;Pt;^Patient;-;;PANEL.SURVEY.SDOH;4;American Academy of Family Physicians Social Needs Screening Tool;;©2018 American Academy of Family Physicians Used with permission.;ACTIVE;2.72;2.72 +99594-4;Delayed medical care due to distance or lack of transportation;Find;Pt;^Patient;Ord;;SURVEY.SDOH;4;Delayed medical care due to distance or lack of transportation;;;ACTIVE;2.72;2.72 +99595-1;American Academy of Family Physicians Social Needs Screening Tool - short form;-;Pt;^Patient;-;;PANEL.SURVEY.SDOH;4;American Academy of Family Physicians Social Needs Screening Tool - short form;;©2018 American Academy of Family Physicians Used with permission.;ACTIVE;2.72;2.72 +99596-9;SARS coronavirus 2 nucleocapsid protein Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) N protein IgG Ab [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 N IgG SerPl Ql IA;;ACTIVE;2.72;2.72 +99597-7;SARS coronavirus 2 spike protein Ab.IgG;PrThr;Pt;Ser/Plas;Ord;IA;MICRO;1;SARS-CoV-2 (COVID-19) S protein IgG Ab [Presence] in Serum or Plasma by Immunoassay;SARS-CoV-2 S IgG SerPl Ql IA;;ACTIVE;2.72;2.72 +9959-8;QRS duration.lead V5;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead V5;QRS dur L-V5;;ACTIVE;1.0i;2.48 +99598-5;Erythrocytes.dysmorphic/100 erythrocytes;NFr;Pt;Urine;Qn;Automated count;UA;1;Erythrocytes.dysmorphic/100 erythrocytes in Urine by Automated count;Dysmorphic RBC/100 RBC NFr Ur Auto;;ACTIVE;2.72;2.72 +99599-3;Protein.monoclonal band 1/Protein.total;MFr;Pt;Urine;Qn;Electrophoresis;CHEM;1;Protein.monoclonal band 1/Protein.total in Urine by Electrophoresis;M Protein 1 MFr Ur Elph;;ACTIVE;2.72;2.72 +99600-9;Beta 1 globulin;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta 1 globulin [Mass/volume] in 24 hour Urine by Electrophoresis;Beta1 Glob 24h Ur Elph-mCnc;;ACTIVE;2.72;2.72 +99601-7;Beta 2 globulin;MCnc;24H;Urine;Qn;Electrophoresis;CHEM;1;Beta 2 globulin [Mass/volume] in 24 hour Urine by Electrophoresis;Beta2 Glob 24h Ur Elph-mCnc;;ACTIVE;2.72;2.72 +99602-5;Glucose/Creatinine;SRto;24H;Urine;Qn;;CHEM;1;Glucose/Creatinine [Molar ratio] in 24 hour Urine;Glucose/Creat 24h Ur-sRto;;ACTIVE;2.72;2.72 +99603-3;Neutrophils.band form/100 leukocytes;NFr;Pt;Periton fld;Qn;Manual count;HEM/BC;1;Band form neutrophils/100 leukocytes in Peritoneal fluid by Manual count;Neuts Band/leuk NFr Prt Manual;;ACTIVE;2.72;2.72 +99604-1;Neutrophils.band form/100 leukocytes;NFr;Pt;Plr fld;Qn;Manual count;HEM/BC;1;Band form neutrophils/100 leukocytes in Pleural fluid by Manual count;Neuts Band/leuk NFr Plr Manual;;ACTIVE;2.72;2.72 +99605-8;Multisection for venous mapping;Find;Pt;Lower extremity.left>Lower extremity vein;Doc;US.doppler;RAD;2;US.doppler Lower extremity vein - left for venous mapping;DOP LE v-L for venous map;;ACTIVE;2.72;2.72 +9960-6;QRS duration.lead V6;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS duration in lead V6;QRS dur L-V6;;ACTIVE;1.0i;2.48 +99606-6;Multisection for venous mapping;Find;Pt;Lower extremity.right>Lower extremity vein;Doc;US.doppler;RAD;2;US.doppler Lower extremity vein - right for venous mapping;DOP LE v-R for venous map;;ACTIVE;2.72;2.72 +99607-4;Multisection for venous mapping;Find;Pt;Lower extremity.bilateral>Lower extremity vein;Doc;US.doppler;RAD;2;US.doppler Lower extremity vein - bilateral for venous mapping;DOP LE v-Bl for venous map;;ACTIVE;2.72;2.72 +99608-2;Multisection^WO & W contrast IV;Find;Pt;Chest>Subclavian vessels.bilateral;Doc;MR.angio;RAD;2;MRA Subclavian vessels - bilateral WO and W contrast IV;MRA Subclavian ves-Bl WO+W contr IV;;ACTIVE;2.72;2.72 +99609-0;Multisection^W contrast IV;Find;Pt;Chest>Aorta.thoracic;Doc;MR.angio;RAD;2;MRA Thoracic Aorta W contrast IV;MRA TA W contr IV;;ACTIVE;2.72;2.72 +99610-8;Multisection^W contrast PO;Find;Pt;Abdomen+Pelvis;Doc;CT;RAD;2;CT Abdomen and Pelvis W contrast PO;CT Abd+Pelvis W contr PO;;ACTIVE;2.72;2.72 +99611-6;Multisection^WO contrast;Find;Pt;Abdomen>Abdominal vessels & Pelvis>Pelvis vessels;Doc;MR.angio;RAD;2;MRA Abdominal vessels and Pelvis vessels WO contrast;MRA Abd ves+Pelvis ves WO contr;;ACTIVE;2.72;2.72 +99612-4;Multisection^WO contrast;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart WO contrast;CT Hrt WO contr;;ACTIVE;2.72;2.72 +99613-2;Multisection^WO & W contrast IV;Find;Pt;Chest>Heart;Doc;CT;RAD;2;CT Heart WO and W contrast IV;CT Hrt WO+W contr IV;;ACTIVE;2.72;2.72 +9961-4;QRS initial amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead AVF;QRS I-Amp L-AVF;;ACTIVE;1.0i;2.48 +99614-0;Emicizumab;MCnc;Pt;PPP;Qn;Coag;DRUG/TOX;1;Emicizumab [Mass/volume] in Platelet poor plasma by Coagulation assay;Emicizumab PPP-mCnc;;ACTIVE;2.72;2.72 +99615-7;Current anti-inflammatory drug use;Find;Pt;^Patient;Ord;;H&P.HX;2;Current anti-inflammatory drug use;Current anti-inflammatory drug use;;ACTIVE;2.72;2.72 +99616-5;Trienoate/Arachidonate;SRto;Pt;RBC.lysate;Qn;;CHEM;1;Trienoate (C20:3w9)/Arachidonate (C20:4w6) [Molar ratio] in RBC.lysate;Trienoate/AA RBC.lysate-sRto;;ACTIVE;2.72;2.72 +99617-3;Fatty acids.saturated;SCnc;Pt;RBC.lysate;Qn;;CHEM;1;Saturated fatty acids [Moles/volume] in RBC.lysate;Sat FA RBC.lysate-sCnc;;ACTIVE;2.72;2.72 +99618-1;Fatty acids.monounsaturated;SCnc;Pt;RBC.lysate;Qn;;CHEM;1;Monounsaturated fatty acids [Moles/volume] in RBC.lysate;Monounsat FA RBC.lysate-sCnc;;ACTIVE;2.72;2.72 +99619-9;Fatty acids.polyunsaturated;SCnc;Pt;RBC.lysate;Qn;;CHEM;1;Polyunsaturated fatty acids [Moles/volume] in RBC.lysate;Polyunsat FA RBC.lysate-sCnc;;ACTIVE;2.72;2.72 +99620-7;Fatty acids.omega 3;SCnc;Pt;RBC.lysate;Qn;;CHEM;1;Omega 3 fatty acids (w3) [Moles/volume] in RBC.lysate;w3 FA RBC.lysate-sCnc;;ACTIVE;2.72;2.72 +99621-5;Fatty acids.omega 6;SCnc;Pt;RBC.lysate;Qn;;CHEM;1;Omega 6 fatty acids (w6) [Moles/volume] in RBC.lysate;w6 FA RBC.lysate-sCnc;;ACTIVE;2.72;2.72 +9962-2;QRS initial amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead AVL;QRS I-Amp L-AVL;;ACTIVE;1.0i;2.48 +99622-3;Resource information for patient;Find;Pt;^Patient;Doc;;DOC.MISC;2;Resource information for patient;Patient resource info;;ACTIVE;2.72;2.72 +99623-1;Influenza virus A N1 RNA;PrThr;Pt;XXX;Ord;Probe.amp.tar;MICRO;1;Influenza virus A N1 RNA [Presence] in Specimen by NAA with probe detection;FLUAV N1 RNA Spec Ql NAA+probe;;ACTIVE;2.72;2.72 +99624-9;Japanese encephalitis virus Ab.IgG;PrThr;Pt;Ser;Ord;IA;MICRO;1;Japanese encephalitis virus IgG Ab [Presence] in Serum by Immunoassay;JEV IgG Ser Ql IA;;ACTIVE;2.72;2.72 +99625-6;Purkinje cell cytoplasmic type 2 Ab;PrThr;Pt;Ser;Ord;Line blot;SERO;1;PCA-2 Ab [Presence] in Serum by Line blot;PCA-2 Ab Ser Ql Line blot;;ACTIVE;2.72;2.72 +99626-4;Purkinje cell cytoplasmic type 2 Ab;PrThr;Pt;CSF;Ord;Line blot;SERO;1;PCA-2 Ab [Presence] in Cerebral spinal fluid by Line blot;PCA-2 Ab CSF Ql Line blot;;ACTIVE;2.72;2.72 +99627-2;How often does this describe you, I don't have enough money to pay my bills;Find;Pt;^Patient;Ord;;SURVEY.SDOH;4;How often does this describe you, I don't have enough money to pay my bills;;;ACTIVE;2.72;2.72 +99628-0;Multisection;Find;Pt;Neck+Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Neck+Chest+Abdomen+Pelvis;CT Neck to Pelvis;;ACTIVE;2.72;2.72 +99629-8;Multisection^WO contrast;Find;Pt;Neck+Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Neck+Chest+Abdomen+Pelvis WO contrast;CT Neck to Pelvis WO contr;;ACTIVE;2.72;2.72 +9963-0;QRS initial amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead AVR;QRS I-Amp L-AVR;;ACTIVE;1.0i;2.48 +99630-6;Multisection^WO & W contrast IV;Find;Pt;Neck+Chest+Abdomen+Pelvis;Doc;CT;RAD;2;CT Neck+Chest+Abdomen+Pelvis WO and W contrast IV;CT Neck to Pelvis WO+W contr IV;;ACTIVE;2.72;2.72 +99631-4;Multisection;Find;Pt;Head>Temporomandibular joint.bilateral;Doc;CT.cone beam;RAD;2;Cone beam CT Temporomandibular joint - bilateral;CBCT TMJ-Bl;;ACTIVE;2.72;2.72 +99632-2;Multisection^WO & W contrast IV;Find;Pt;Head>Temporomandibular joint;Doc;CT.cone beam;RAD;2;Cone beam CT Temporomandibular joint WO and W contrast IV;CBCT TMJ WO+W contr IV;;ACTIVE;2.72;2.72 +99633-0;Multisection;Find;Pt;Head>Teeth;Doc;CT.cone beam;RAD;2;Cone beam CT Teeth;CBCT Teeth;;ACTIVE;2.72;2.72 +99634-8;Federal, state, or local governments required limiting non-essential travel;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Federal, state, or local governments required limiting non-essential travel;;;ACTIVE;2.72;2.72 +99635-5;Main symptoms experienced by people infected with condition of interest;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Main symptoms experienced by people infected with condition of interest;;;ACTIVE;2.72;2.72 +99636-3;Activity related to possible exposure to condition of interest;Find;7D;^Patient;Nom;;SURVEY.GNHLTH;4;Activity related to possible exposure to condition of interest;;;ACTIVE;2.72;2.72 +99637-1;Measures taken to keep safe from condition of interest;Find;RptPeriod;^Patient;Nom;;SURVEY.GNHLTH;4;Measures taken to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99638-9;Federal, state, or local governments encouraged limiting non-essential travel;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Federal, state, or local governments encouraged limiting non-essential travel;;;ACTIVE;2.72;2.72 +99639-7;Effectiveness of wearing a face mask to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of wearing a face mask to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99640-5;Effectiveness of praying to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of praying to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99641-3;Effectiveness of washing your hands with soap or using hand sanitizer frequently to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of washing your hands with soap or using hand sanitizer frequently to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99642-1;Effectiveness of seeing a doctor if you feel sick to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of seeing a doctor if you feel sick to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99643-9;Effectiveness of seeing a doctor if you feel healthy but worry that you were exposed to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of seeing a doctor if you feel healthy but worry that you were exposed to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99644-7;Effectiveness of avoiding public spaces, gatherings, and crowds to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of avoiding public spaces, gatherings, and crowds to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99645-4;Effectiveness of avoiding contact with people who could be high-risk to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of avoiding contact with people who could be high-risk to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99646-2;Effectiveness of avoiding hospitals and clinics to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of avoiding hospitals and clinics to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99647-0;Effectiveness of avoiding restaurants to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of avoiding restaurants to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +9964-8;QRS initial amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead I;QRS I-Amp L-I;;ACTIVE;1.0i;2.48 +99648-8;Effectiveness of avoiding airplanes to keep safe from condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Effectiveness of avoiding airplanes to keep safe from condition of interest;;;ACTIVE;2.72;2.72 +99649-6;Safety of grocery shopping for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of grocery shopping for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99650-4;Safety of attending gatherings of more than 100 people for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of attending gatherings of more than 100 people for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99651-2;Safety of going to the hospital for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of going to the hospital for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99652-0;Safety of dining in at restaurants for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of dining in at restaurants for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99653-8;Safety of eating take-out meals from restaurants for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of eating take-out meals from restaurants for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99654-6;Safety of visiting with relatives or friends in their home for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of visiting with relatives or friends in their home for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +9965-5;QRS initial amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead II;QRS I-Amp L-II;;ACTIVE;1.0i;2.48 +99655-3;Safety of handling packages that have been delivered for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of handling packages that have been delivered for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99656-1;Safety of playing on playground equipment for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of playing on playground equipment for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99657-9;Safety of touching door knobs, countertops, and other surfaces in your home for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of touching door knobs, countertops, and other surfaces in your home for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99658-7;Safety of interacting closely with other members of your household for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of interacting closely with other members of your household for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99659-5;Safety of going outside to walk, hike, or exercise for avoiding exposure to condition of interest;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Safety of going outside to walk, hike, or exercise for avoiding exposure to condition of interest;;;ACTIVE;2.72;2.72 +99660-3;Number of family members or close friends;Num;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Number of family members or close friends;;;ACTIVE;2.72;2.73 +99661-1;Number of family members or close friends that have been infected with condition of interest;Num;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Number of family members or close friends that have been infected with condition of interest;;;ACTIVE;2.72;2.74 +99662-9;Percent chance of contracting condition of interest in next 3Mo;NFr;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Percent chance of contracting condition of interest in next 3 months;;;ACTIVE;2.72;2.72 +9966-3;QRS initial amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead III;QRS I-Amp L-III;;ACTIVE;1.0i;2.48 +99663-7;Percent chance of death from condition of interest if infected;NFr;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Percent chance of death from condition of interest if infected;;;ACTIVE;2.72;2.72 +99664-5;Agreement with statement: childhood vaccines have many known harmful side effects;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Agreement with statement: childhood vaccines have many known harmful side effects;;;ACTIVE;2.72;2.72 +99665-2;Agreement with statement: childhood vaccines provide important benefits to society;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Agreement with statement: childhood vaccines provide important benefits to society;;;ACTIVE;2.72;2.72 +99666-0;Agreement with statement: childhood vaccines may lead to illness and death;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Agreement with statement: childhood vaccines may lead to illness and death;;;ACTIVE;2.72;2.72 +99667-8;Agreement with statement: childhood vaccines are useful and effective;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Agreement with statement: childhood vaccines are useful and effective;;;ACTIVE;2.72;2.72 +99668-6;Likelihood of getting vaccinated for condition of interest when available;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Likelihood of getting vaccinated for condition of interest when available;;;ACTIVE;2.72;2.72 +99669-4;Agreement with statement: most people believe that people with condition of interest are dangerous;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Agreement with statement: most people believe that people with condition of interest are dangerous;;;ACTIVE;2.72;2.72 +99670-2;Agreement with statement: most people believe that people who used to have condition of interest are dangerous;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Agreement with statement: most people believe that people who used to have condition of interest are dangerous;;;ACTIVE;2.72;2.72 +9967-1;QRS initial amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead V1;QRS I-Amp L-V1;;ACTIVE;1.0i;2.48 +99671-0;Agreement with statement: most people believe that having condition of interest is a sign of personal weakness or failure;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Agreement with statement: most people believe that having condition of interest is a sign of personal weakness or failure;;;ACTIVE;2.72;2.72 +99672-8;Agreement with statement: if I caught condition of interest, I would consider it a sign of my personal weakness or failure;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Agreement with statement: if I caught condition of interest, I would consider it a sign of my personal weakness or failure;;;ACTIVE;2.72;2.72 +99673-6;COVID-19 Knowledge, Attitudes, and Avoidant Behaviors panel;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;COVID-19 Knowledge, Attitudes, and Avoidant Behaviors panel;;;ACTIVE;2.72;2.72 +99674-4;Temporary pacemaker panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Temporary pacemaker panel;Temporary pacemaker panel;;ACTIVE;2.72;2.72 +99675-1;Atrial electrical activity captured;Find;Pt;Pacemaker;Ord;;DEVICES;2;Pacemaker Atrial electrical activity captured;Pacemaker Atrial electric activity capt;;ACTIVE;2.72;2.72 +99676-9;Atrial electrical activity sensed;Find;Pt;Pacemaker;Ord;;DEVICES;2;Pacemaker Atrial electrical activity sensed;Pacemaker Atrial electric activity sensd;;ACTIVE;2.72;2.72 +99677-7;Atrial sensitivity setting;Elpot;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Atrial sensitivity setting;Pacemaker Atrial sensitivity setting;;ACTIVE;2.72;2.72 +99678-5;Atrial sensitivity threshold;Elpot;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Atrial sensitivity threshold;Pacemaker Atrial sensitivity threshold;;ACTIVE;2.72;2.72 +99679-3;Atrial stimulation setting;Elcur;Pt;Pacemaker.temporary;Qn;;DEVICES;2;Temporary pacemaker Atrial stimulation setting;Temp pacemaker Atrial stim setting;;ACTIVE;2.72;2.72 +99680-1;Atrial stimulation threshold;Elcur;Pt;Pacemaker.temporary;Qn;;DEVICES;2;Temporary pacemaker Atrial stimulation threshold;Temp pacemaker Atrial stim threshold;;ACTIVE;2.72;2.72 +99681-9;Atrial wire;Num;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Atrial wire;Pacemaker Atrial wire;;ACTIVE;2.72;2.72 +99682-7;Atrioventricular interval;Time;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Atrioventricular interval;Pacemaker AV interval;;ACTIVE;2.72;2.72 +99683-5;Ground wire;Num;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Ground wire;Pacemaker Ground wire;;ACTIVE;2.72;2.72 +99684-3;Pacemaker mode;Type;Pt;Pacemaker;Nom;;DEVICES;2;Pacemaker mode;Pacemaker mode;;ACTIVE;2.72;2.72 +99685-0;Pacemaker rate;NRat;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker rate;Pacemaker rate;;ACTIVE;2.72;2.72 +99686-8;Pacemaker type;Type;Pt;Pacemaker;Nom;;DEVICES;2;Pacemaker type;Pacemaker type;;ACTIVE;2.72;2.72 +99687-6;Pacing method;Type;Pt;Pacemaker.temporary;Nom;;DEVICES;2;Temporary pacemaker Pacing method;Temp pacemaker Pacing method;;ACTIVE;2.72;2.72 +99688-4;Post-ventricular atrial refractory period setting;Time;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Post-ventricular atrial refractory period setting;Pacemaker PVARP setting;;ACTIVE;2.72;2.72 +9968-9;QRS initial amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead V2;QRS I-Amp L-V2;;ACTIVE;1.0i;2.48 +99689-2;Ventricular electrical activity captured;Find;Pt;Pacemaker;Ord;;DEVICES;2;Pacemaker Ventricular electrical activity captured;Pacemaker Vent elec activ captured;;ACTIVE;2.72;2.72 +996-9;D little o super little a Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;Do sup(a) Ag [Presence] on Red Blood Cells;Do sup(a) Ag RBC Ql;;ACTIVE;1.0;2.56 +99690-0;Ventricular electrical activity sensed;Find;Pt;Pacemaker;Ord;;DEVICES;2;Pacemaker Ventricular electrical activity sensed;Pacemaker Vent elec activ sensed;;ACTIVE;2.72;2.72 +99691-8;Ventricular sensitivity setting;Elpot;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Ventricular sensitivity setting;Pacemaker Ventric sensitivity setting;;ACTIVE;2.72;2.72 +99692-6;Ventricular sensitivity threshold;Elpot;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Ventricular sensitivity threshold;Pacemaker Ventric sensitivity threshold;;ACTIVE;2.72;2.72 +99693-4;Ventricular stimulation setting;Elcur;Pt;Pacemaker.temporary;Qn;;DEVICES;2;Temporary pacemaker Ventricular stimulation setting;Temp pacemaker Ventric stim setting;;ACTIVE;2.72;2.72 +99694-2;Ventricular stimulation threshold;Elcur;Pt;Pacemaker.temporary;Qn;;DEVICES;2;Temporary pacemaker Ventricular stimulation threshold;Temp pacemaker Ventric stim threshold;;ACTIVE;2.72;2.72 +99695-9;Ventricular wire;Num;Pt;Pacemaker;Qn;;DEVICES;2;Pacemaker Ventricular wire;Pacemaker Ventricular wire;;ACTIVE;2.72;2.72 +99696-7;Wire status;Find;Pt;Pacemaker.temporary;Nom;;DEVICES;2;Temporary pacemaker Wire status;Temp pacemaker Wire status;;ACTIVE;2.72;2.72 +9969-7;QRS initial amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead V3;QRS I-Amp L-V3;;ACTIVE;1.0i;2.48 +99697-5;Permanent pacemaker panel;-;Pt;^Patient;-;;PANEL.DEVICES;2;Permanent pacemaker panel;Permanent pacemaker panel;;ACTIVE;2.72;2.72 +99698-3;Atrial stimulation setting;Elpot;Pt;Pacemaker.permanent;Qn;;DEVICES;2;Permanent pacemaker Atrial stimulation setting;Perm pacemaker Atrial stim setting;;ACTIVE;2.72;2.72 +99699-1;Atrial stimulation threshold;Elpot;Pt;Pacemaker.permanent;Qn;;DEVICES;2;Permanent pacemaker Atrial stimulation threshold;Perm pacemaker Atrial stim threshold;;ACTIVE;2.72;2.72 +99700-7;Ventricular stimulation setting;Elpot;Pt;Pacemaker.permanent;Qn;;DEVICES;2;Permanent pacemaker Ventricular stimulation setting;Perm pacemaker Ventric stim setting;;ACTIVE;2.72;2.72 +99701-5;Ventricular stimulation threshold;Elpot;Pt;Pacemaker.permanent;Qn;;DEVICES;2;Permanent pacemaker Ventricular stimulation threshold;Perm pacemaker Ventric stim threshold;;ACTIVE;2.72;2.72 +99702-3;Multisection;Find;Pt;Head>Brain;Doc;MR.tractography;RAD;2;MR tractography Brain;MR tractography Brain;;ACTIVE;2.72;2.72 +99703-1;Multisection;Find;Pt;Head>Brain;Doc;MR.perfusion;RAD;2;MR perfusion Brain;MR perfusion Brain;;ACTIVE;2.72;2.72 +99704-9;Multisection for stroke mapping;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain for stroke mapping;MR Brain for stroke mapping;;ACTIVE;2.72;2.72 +9970-5;QRS initial amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead V4;QRS I-Amp L-V4;;ACTIVE;1.0i;2.48 +99705-6;Multisection for seizure mapping;Find;Pt;Head>Brain;Doc;MR;RAD;2;MR Brain for seizure mapping;MR Brain for seizure mapping;;ACTIVE;2.72;2.72 +99706-4;Hepatocellular carcinoma screening;Imp;Pt;^Patient;Ord;Based on clinical+lab data;MOLPATH;1;Hepatocellular carcinoma screening [Interpretation] based on clinical and lab data;HCC screen clin+lab data - Imp;;ACTIVE;2.72;2.72 +99707-2;Continuous renal replacement therapy panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Continuous renal replacement therapy panel;CRRT panel;;ACTIVE;2.72;2.72 +99708-0;Continuous renal replacement therapy mode;Type;Pt;Renal replacement therapy circuit;Nom;;CLIN;2;Continuous renal replacement therapy mode Renal replacement therapy circuit;CRRT mode RRT circuit;;ACTIVE;2.72;2.72 +99709-8;Continuous renal replacement therapy fluid removal goal;Vol;1H;^Patient;Qn;;CLIN;2;Continuous renal replacement therapy fluid removal goal [Volume] 1 hour;CRRT fluid removal goal 1h Vol;;ACTIVE;2.72;2.72 +99710-6;Venous lumen volume;Vol;Pt;Dialysis catheter;Qn;;CLIN;2;Venous lumen volume Dialysis catheter;Venous lumen vol Dialysis catheter;;ACTIVE;2.72;2.72 +99711-4;Blood flow rate;VRat;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Blood flow rate Renal replacement therapy circuit;Bld flow rate RRT circuit;;ACTIVE;2.72;2.72 +99712-2;Dialysate flow rate;VRat;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Dialysate flow rate Renal replacement therapy circuit;Dialysate flow rate RRT circuit;;ACTIVE;2.72;2.72 +9971-3;QRS initial amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead V5;QRS I-Amp L-V5;;ACTIVE;1.0i;2.48 +99713-0;Post-filter replacement fluid rate;VRat;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Post-filter replacement fluid rate Renal replacement therapy circuit;Post-filter replace fld rate RRT circuit;;ACTIVE;2.72;2.72 +99714-8;Pre-filter replacement fluid rate;VRat;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Pre-filter replacement fluid rate Renal replacement therapy circuit;Pre-filter replace fld rate RRT circuit;;ACTIVE;2.72;2.72 +99715-5;Dialysis access site;Anat;Pt;^Patient;Nom;;CLIN;2;Dialysis access site;Dialysis access site;;ACTIVE;2.72;2.72 +99716-3;Dialysis access site appearance;Aper;Pt;^Patient;Nom;;CLIN;2;Dialysis access site appearance;Dialysis access site appearance;;ACTIVE;2.72;2.72 +99717-1;Access pressure;Pres;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Access pressure Renal replacement therapy circuit;Access pressure RRT circuit;;ACTIVE;2.72;2.72 +99718-9;Effluent pressure;Pres;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Effluent pressure Renal replacement therapy circuit;Effluent pressure RRT circuit;;ACTIVE;2.72;2.72 +99719-7;Filter pressure;Pres;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Filter pressure Renal replacement therapy circuit;Filter pressure RRT circuit;;ACTIVE;2.72;2.72 +99720-5;Transmembrane pressure;Pres;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Transmembrane pressure Renal replacement therapy circuit;Transmembrane pressure RRT circuit;;ACTIVE;2.72;2.72 +9972-1;QRS initial amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS initial amplitude in lead V6;QRS I-Amp L-V6;;ACTIVE;1.0i;2.48 +99721-3;Return pressure;Pres;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Return pressure Renal replacement therapy circuit;Return pressure RRT circuit;;ACTIVE;2.72;2.72 +99722-1;Medication added to peritoneal dialysis fluid;Type;Pt;Medication;Nom;;CLIN;2;Medication added to peritoneal dialysis fluid;Med [Type] add to peri dialysis fld;;ACTIVE;2.72;2.72 +99723-9;Medication added to peritoneal dialysis fluid;Vol;Pt;Medication;Qn;;CLIN;2;Medication added to peritoneal dialysis fluid [Volume];Med add to peri dialysis fld Vol;;ACTIVE;2.72;2.72 +99724-7;Peritoneal dialysis fluid infused;Vol;Pt;^Patient;Qn;;CLIN;2;Peritoneal dialysis fluid infused [Volume];Peritoneal dialysis fluid infused Vol;;ACTIVE;2.72;2.72 +99725-4;Peritoneal dialysis fluid drained;Vol;Pt;^Patient;Qn;;CLIN;2;Peritoneal dialysis fluid drained [Volume];Peritoneal dialysis fluid drained Vol;;ACTIVE;2.72;2.72 +99726-2;Peritoneal dialysis fluid;Type;Pt;^Patient;Nom;;CLIN;2;Peritoneal dialysis fluid;Peritoneal dialysis fluid;;ACTIVE;2.72;2.72 +99727-0;Peritoneal dialysis fluid infusion start time;ClockTime;Pt;^Patient;Qn;;CLIN;2;Peritoneal dialysis fluid infusion start time;Peri dialysis fld infu start time;;ACTIVE;2.72;2.72 +99728-8;Peritoneal dialysis fluid infusion stop time;ClockTime;Pt;^Patient;Qn;;CLIN;2;Peritoneal dialysis fluid infusion stop time;Peri dialysis fld infu stop time;;ACTIVE;2.72;2.72 +99729-6;Peritoneal dialysis fluid drainage start time;ClockTime;Pt;^Patient;Qn;;CLIN;2;Peritoneal dialysis fluid drainage start time;Peritoneal dialysis fld drain start tme;;ACTIVE;2.72;2.72 +99730-4;Peritoneal dialysis fluid drainage stop time;ClockTime;Pt;^Patient;Qn;;CLIN;2;Peritoneal dialysis fluid drainage stop time;Peritoneal dialysis fld drain stop time;;ACTIVE;2.72;2.72 +99731-2;Pressure drop;PressDiff;Pt;Renal replacement therapy circuit;Qn;;CLIN;2;Pressure drop Renal replacement therapy circuit;Pressure drop PressDiff RRT circuit;;ACTIVE;2.72;2.72 +99732-0;Dialysate fluid;Type;Pt;Renal replacement therapy circuit;Nom;;CLIN;2;Dialysate fluid Renal replacement therapy circuit;Dialysate fluid RRT circuit;;ACTIVE;2.72;2.72 +99733-8;Replacement fluid;Type;Pt;Renal replacement therapy circuit;Nom;;CLIN;2;Replacement fluid Renal replacement therapy circuit;Replacement fluid RRT circuit;;ACTIVE;2.72;2.72 +99734-6;Arterial lumen volume;Vol;Pt;Dialysis catheter;Qn;;CLIN;2;Arterial lumen volume Dialysis catheter;Arterial lumen vol Dialysis catheter;;ACTIVE;2.72;2.72 +99735-3;Ultrafiltrate volume removed;Vol;1H;^Patient;Qn;;CLIN;2;Ultrafiltrate volume removed 1 hour;Ultrafiltrate volume removed 1h;;ACTIVE;2.72;2.72 +99736-1;Reason for filter change;Find;Pt;Renal replacement therapy circuit;Nom;;CLIN;2;Reason for filter change Renal replacement therapy circuit;Reason for filter change RRT circuit;;ACTIVE;2.72;2.72 +99737-9;Intermittent hemodialysis panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Intermittent hemodialysis panel;Intermittent hemodialysis panel;;ACTIVE;2.72;2.72 +99738-7;Hemodialysis fluid removal goal;Vol;Procedure dur;^Patient;Qn;;CLIN;2;Hemodialysis fluid removal goal [Volume];Hemodialysis fluid removal goal Vol;;ACTIVE;2.72;2.72 +9973-9;QRS terminal amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead AVF;QRS T-Amp L-AVF;;ACTIVE;1.0i;2.48 +99739-5;Hemodialysis fluid removed;Vol;Procedure dur;^Patient;Qn;;CLIN;2;Hemodialysis fluid removed [Volume];Hemodialysis fluid removed Vol;;ACTIVE;2.72;2.72 +99740-3;Hemodialysis fluid removed;Vol;1H;^Patient;Qn;;CLIN;2;Hemodialysis fluid removed [Volume] 1 hour;Hemodialysis fluid removed 1h Vol;;ACTIVE;2.72;2.72 +99741-1;Ultrafiltrate volume removed;Vol;Procedure dur;^Patient;Qn;;CLIN;2;Ultrafiltrate volume removed;Ultrafiltrate volume removed;;ACTIVE;2.72;2.72 +99742-9;Peritoneal dialysis panel;-;Pt;^Patient;-;;PANEL.CLIN;2;Peritoneal dialysis panel;Peritoneal dialysis panel;;ACTIVE;2.72;2.72 +99743-7;Peritoneal dialysis dwell time;Time;Procedure dur;^Patient;Qn;;CLIN;2;Peritoneal dialysis dwell time;Peritoneal dialysis dwell time;;ACTIVE;2.72;2.72 +99744-5;Peritoneal dialysis catheter type;Type;Pt;^Patient;Nom;;CLIN;2;Peritoneal dialysis catheter type;Peritoneal dialysis catheter type;;ACTIVE;2.72;2.72 +99745-2;Patient reported outcomes with LASIK - post-operative panel;-;Pt;^Patient;-;PROWL;PANEL.SURVEY.PROWL;4;Patient reported outcomes with LASIK - post-operative panel [Patient reported outcomes with LASIK];;;ACTIVE;2.72;2.72 +99746-0;New problem or limitation after LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;New problem or limitation after LASIK;;;ACTIVE;2.72;2.72 +9974-7;QRS terminal amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead AVL;QRS T-Amp L-AVL;;ACTIVE;1.0i;2.48 +99747-8;Problem or limitation because of LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Problem or limitation because of LASIK;;;ACTIVE;2.72;2.72 +99748-6;Problem or limitation after LASIK affected quality of life;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Problem or limitation after LASIK affected quality of life;;;ACTIVE;2.72;2.72 +99749-4;Surgery provider explained what to expect during LASIK recovery period;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Surgery provider explained what to expect during LASIK recovery period;;;ACTIVE;2.72;2.72 +99750-2;Satisfaction level with LASIK result;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Satisfaction level with LASIK result;;;ACTIVE;2.72;2.72 +99751-0;Satisfaction level with length of time for vision improvement after LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Satisfaction level with length of time for vision improvement after LASIK;;;ACTIVE;2.72;2.72 +99752-8;Satisfaction level with length of time it took for improvement in post-operative discomfort after LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Satisfaction level with length of time it took for improvement in post-operative discomfort after LASIK;;;ACTIVE;2.72;2.72 +99753-6;Level of understanding risk and benefit of LASIK before treatment;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Level of understanding risk and benefit of LASIK before treatment;;;ACTIVE;2.72;2.72 +9975-4;QRS terminal amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead AVR;QRS T-Amp L-AVR;;ACTIVE;1.0i;2.48 +99754-4;When not wearing corrective lenses, distance vision is as good as anticipated after LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;When not wearing corrective lenses, distance vision is as good as anticipated after LASIK;;;ACTIVE;2.72;2.72 +99755-1;Wear corrective lenses to see in the distance;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Wear corrective lenses to see in the distance;;;ACTIVE;2.72;2.72 +99756-9;Goal for LASIK achieved;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Goal for LASIK achieved;;;ACTIVE;2.72;2.72 +99757-7;Happiness level of having LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Happiness level of having LASIK;;;ACTIVE;2.72;2.72 +99759-3;Would recommend LASIK to friend or family member;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Would recommend LASIK to friend or family member;;;ACTIVE;2.72;2.72 +99760-1;Reason not to have or recommend LASIK;Find;Pt;^Patient;Ord;;SURVEY.PROWL;4;Reason not to have or recommend LASIK;;;ACTIVE;2.72;2.72 +99761-9;Clot initiation.kaolin induced;Time;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Clot initiation.kaolin induced [Time] in Blood by Resonance TEG;Clot init kaolin ind Bld Res TEG;;ACTIVE;2.72;2.72 +9976-2;QRS terminal amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead I;QRS T-Amp L-I;;ACTIVE;1.0i;2.48 +99762-7;Clot angle.kaolin induced;Angle;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Clot angle.kaolin induced in Blood by Resonance TEG;Clot angle.kaolin induced Bld Res TEG;;ACTIVE;2.72;2.72 +99763-5;Clot formation.kaolin induced;Time;Pt;Bld;Qn;Thromboelastography.resonance;COAG;1;Clot formation.kaolin induced [Time] in Blood by Resonance TEG;CFT form kaolin ind Bld Res TEG;;ACTIVE;2.72;2.72 +99764-3;Interferon.gamma;MCnc;Pt;CSF;Qn;;HEM/BC;1;Interferon gamma [Mass/volume] in Cerebral spinal fluid;IGNF CSF-mCnc;;ACTIVE;2.72;2.72 +99765-0;Interleukin 12;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 12 [Mass/volume] in Cerebral spinal fluid;Il12 CSF-mCnc;;ACTIVE;2.72;2.72 +99766-8;Interleukin 17;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 17 [Mass/volume] in Cerebral spinal fluid;IL-17 CSF-mCnc;;ACTIVE;2.72;2.72 +99767-6;Interleukin 1 beta;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 1 beta [Mass/volume] in Cerebral spinal fluid;Il1Beta CSF-mCnc;;ACTIVE;2.72;2.72 +99768-4;Interleukin 2 receptor.soluble;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 2 Receptor Soluble [Mass/volume] in Cerebral spinal fluid;Sol Il2 Recep CSF-mCnc;;ACTIVE;2.72;2.72 +99769-2;Interleukin 8;MCnc;Pt;CSF;Qn;;CHEM;1;Interleukin 8 [Mass/volume] in Cerebral spinal fluid;Il8 CSF-mCnc;;ACTIVE;2.72;2.72 +997-7;DBG Ag;PrThr;Pt;RBC^BPU;Ord;;BLDBK;1;DBG Ag [Presence] on Red Blood Cells from Blood product unit;DBG Ag RBC BPU Ql;;ACTIVE;1.0;2.73 +9977-0;QRS terminal amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead II;QRS T-Amp L-II;;ACTIVE;1.0i;2.48 +99770-0;Tumor necrosis factor.alpha;MCnc;Pt;CSF;Qn;;CHEM;1;Tumor necrosis factor.alpha [Mass/volume] in Cerebral spinal fluid;A-Tumor Necrosis Fact CSF-mCnc;;ACTIVE;2.72;2.72 +99771-8;SARS coronavirus 2 spike & nucleocapsid protein stimulated gamma interferon panel;-;Pt;Bld;-;;PANEL.MICRO;1;SARS coronavirus 2 spike and nucleocapsid protein stimulated gamma interferon panel - Blood;SARS-CoV-2 IGRA Spk+Nuclcp Pnl Bld;;ACTIVE;2.72;2.72 +99772-6;SARS coronavirus 2 stimulated gamma interferon;Imp;Pt;Bld;Ord;;MICRO;1;SARS-CoV-2 stimulated gamma interferon [Interpretation] in Blood Qualitative;SARS-CoV-2 IFN-g Bld-Imp;;ACTIVE;2.72;2.72 +99773-4;SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count^^corrected for background;Num;Pt;Bld;Qn;;MICRO;1;SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count [#] corrected for background in Blood;SARSCoV2 IGRA Spike Ct bckgrd cor Bld;;ACTIVE;2.72;2.72 +99774-2;SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count^^corrected for background;Num;Pt;Bld;Qn;;MICRO;1;SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count [#] corrected for background in Blood;SARSCoV2 IGRA Nucpsid Ct bckgrd cor Bld;;ACTIVE;2.72;2.72 +99775-9;Leukocytes;NCnc;Pt;Dial fld prt;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Peritoneal dialysis fluid by Automated count;WBC # DiafP Auto;;ACTIVE;2.72;2.72 +99776-7;Leukocytes;NCnc;Pt;BAL;Qn;Automated count;HEM/BC;1;Leukocytes [#/volume] in Bronchoalveolar lavage by Automated count;WBC # BAL Auto;;ACTIVE;2.72;2.72 +99777-5;Erythrocytes;NCnc;Pt;BAL;Qn;Automated count;HEM/BC;1;Erythrocytes [#/volume] in Bronchoalveolar lavage by Automated count;RBC # BAL Auto;;ACTIVE;2.72;2.72 +99778-3;Chlamydia trachomatis rRNA;PrThr;Pt;Cnjt;Ord;Probe.amp.tar;MICRO;1;Chlamydia trachomatis rRNA [Presence] in Conjunctival specimen by NAA with probe detection;C trach rRNA Conjunct Ql NAA+probe;;ACTIVE;2.72;2.72 +99779-1;Neisseria gonorrhoeae rRNA;PrThr;Pt;Cnjt;Ord;Probe.amp.tar;MICRO;1;Neisseria gonorrhoeae rRNA [Presence] in Conjunctival specimen by NAA with probe detection;N gonorrhoea rRNA Conjunct Ql NAA+probe;;ACTIVE;2.72;2.72 +99780-9;Multidrug resistant gram-negative organism classification;Type;Pt;Isolate;Ord;;ABXBACT;1;Multidrug resistant gram-negative organism classification [Type];MRGN classification Islt Ql;;ACTIVE;2.72;2.72 +99781-7;Adalimumab & Adalimumab Ab panel;-;Pt;Ser/Plas;-;IA;PANEL.SERO;1;Adalimumab and Adalimumab Ab panel - Serum or Plasma by Immunoassay;Adalimumab + Adalimumab Ab Pnl SerPl IA;;ACTIVE;2.72;2.72 +99782-5;Months^post transplant;Time;Pt;^Patient;Qn;;TRNSPLNT.ORGAN;2;Months [Time] --post transplant;Mo p trnsplt Time;;ACTIVE;2.72;2.72 +99783-3;Negative predictive value;Likelihood;Pt;Laboratory device;Qn;;DEVICES;2;Laboratory device Negative predictive value;Lab Device NPV;;ACTIVE;2.72;2.72 +99784-1;Positive predictive value;Likelihood;Pt;Laboratory device;Qn;;DEVICES;2;Laboratory device Positive predictive value;Lab Device PPV;;ACTIVE;2.72;2.72 +99785-8;Cell-free DNA.donor/Cell-free DNA.total^post cardiac transplant;NFr;Pt;Plas.cfDNA;Qn;;MOLPATH;1;Cell-free DNA.donor/Cell-free DNA.total in Plasma cell-free DNA --post cardiac transplant;cfDNA.donor/cfDNA.total p card trnsplt;;ACTIVE;2.72;2.72 +99786-6;Cell-free DNA.donor/Cell-free DNA.total^post lung transplant;NFr;Pt;Plas.cfDNA;Qn;;MOLPATH;1;Cell-free DNA.donor/Cell-free DNA.total in Plasma cell-free DNA --post lung transplant;cfDNA.donor/cfDNA.total p lung trnsplt;;ACTIVE;2.72;2.72 +99787-4;Cell-free DNA.donor/Cell-free DNA.total^post kidney transplant;NFr;Pt;Plas.cfDNA;Qn;;MOLPATH;1;Cell-free DNA.donor/Cell-free DNA.total in Plasma cell-free DNA --post kidney transplant;cfDNA.donor/cfDNA.ttl p kid trnsplt;;ACTIVE;2.72;2.72 +9978-8;QRS terminal amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead III;QRS T-Amp L-III;;ACTIVE;1.0i;2.48 +99788-2;Functional Communication Measure - Cognition ages 6 or older panel;-;Pt;^Patient;-;ASHA NOMS;PANEL.SURVEY.SLP;4;Functional Communication Measure - Cognition ages 6 or older panel [ASHA NOMS];;;ACTIVE;2.72;2.72 +99789-0;Frequency of demonstrating cognitive-communication skills for completing rote &or simple routine living tasks;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of demonstrating cognitive-communication skills for completing rote AndOr simple routine living tasks;;;ACTIVE;2.72;2.72 +99790-8;Frequency of demonstrating cognitive-communication skills for completing age-appropriate common daily living tasks;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of demonstrating cognitive-communication skills for completing age-appropriate common daily living tasks;;;ACTIVE;2.72;2.72 +99791-6;Frequency of demonstrating cognitive-communication skills for completing age-appropriate complex living tasks;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of demonstrating cognitive-communication skills for completing age-appropriate complex living tasks;;;ACTIVE;2.72;2.72 +99792-4;Frequency of demonstrating cognitive-communication skills to independently function safely without supervision &or assistance;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of demonstrating cognitive-communication skills to independently function safely without supervision AndOr assistance;;;ACTIVE;2.72;2.72 +99793-2;Functional Communication Measure - Cognition ages 6 or older score;Score;Pt;^Patient;Qn;ASHA NOMS;SURVEY.SLP;4;Functional Communication Measure - Cognition ages 6 or older score [ASHA NOMS];;;ACTIVE;2.72;2.72 +99794-0;Number of household members enrolled in preschool or day care;Num;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Number of household members enrolled in preschool or day care;;;ACTIVE;2.72;2.72 +99795-7;Number of household members enrolled in elementary school;Num;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Number of household members enrolled in elementary school;;;ACTIVE;2.72;2.72 +9979-6;QRS terminal amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead V1;QRS T-Amp L-V1;;ACTIVE;1.0i;2.48 +99796-5;Number of household members enrolled in middle school or junior high;Num;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Number of household members enrolled in middle school or junior high;;;ACTIVE;2.72;2.72 +99797-3;Number of household members enrolled in high school;Num;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Number of household members enrolled in high school;;;ACTIVE;2.72;2.72 +99798-1;Number of household members enrolled in college or trade school, including four-year colleges, community colleges, technical institutes, and vocational schools;Num;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Number of household members enrolled in college or trade school, including four-year colleges, community colleges, technical institutes, and vocational schools;;;ACTIVE;2.72;2.72 +99799-9;Enrolled in college or trade school, including four-year colleges, community colleges;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Enrolled in college or trade school, including four-year colleges, community colleges;;;ACTIVE;2.72;2.72 +99800-5;Do children in this household have access to the internet during the day to support learning;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Do children in this household have access to the internet during the day to support learning;;;ACTIVE;2.72;2.72 +99801-3;Type of internet available to children in household to support learning;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Type of internet available to children in household to support learning;;;ACTIVE;2.72;2.72 +99802-1;Devices used in household to access the internet for learning;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Devices used in household to access the internet for learning;;;ACTIVE;2.72;2.72 +99803-9;Number of laptops or desktops used in household for learning;Num;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Number of laptops or desktops used in household for learning;;;ACTIVE;2.72;2.72 +9980-4;QRS terminal amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead V2;QRS T-Amp L-V2;;ACTIVE;1.0i;2.48 +99804-7;Number of tablets used in household for learning;Num;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Number of tablets used in household for learning;;;ACTIVE;2.72;2.72 +99805-4;Number of smartphones used in household use for learning;Num;Pt;^Patient;Qn;;SURVEY.GNHLTH;4;Number of smartphones used in household use for learning;;;ACTIVE;2.72;2.72 +99806-2;Number of household members enrolled in preschool or day care that had school suspended or canceled because of the condition of interest;Num;Pt;^Patient;Ord;;SURVEY.COVID;4;Number of household members enrolled in preschool or day care that had school suspended or canceled because of the condition of interest;;;ACTIVE;2.72;2.72 +99807-0;Number of household members enrolled in elementary school that had school suspended or canceled because of the condition of interest;Num;Pt;^Patient;Ord;;SURVEY.COVID;4;Number of household members enrolled in elementary school that had school suspended or canceled because of the condition of interest;;;ACTIVE;2.72;2.72 +99808-8;Household members in elementary school do educational activities at home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Household members in elementary school do educational activities at home;;;ACTIVE;2.72;2.72 +99809-6;Provider of educational activities;Find;Pt;^Patient;Nom;;SURVEY.GNHLTH;4;Provider of educational activities;;;ACTIVE;2.72;2.72 +99810-4;Number of household members enrolled in middle school or junior high that had school suspended or canceled because of the condition of interest;Num;Pt;^Patient;Ord;;SURVEY.COVID;4;Number of household members enrolled in middle school or junior high that had school suspended or canceled because of the condition of interest;;;ACTIVE;2.72;2.72 +99811-2;Household members in middle school or junior high do educational activities at home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Household members in middle school or junior high do educational activities at home;;;ACTIVE;2.72;2.72 +9981-2;QRS terminal amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead V3;QRS T-Amp L-V3;;ACTIVE;1.0i;2.48 +99812-0;Number of household members enrolled in high school that have had school suspended or canceled because of the condition of interest;Num;Pt;^Patient;Ord;;SURVEY.COVID;4;Number of household members enrolled in high school that have had school suspended or canceled because of the condition of interest;;;ACTIVE;2.72;2.72 +99813-8;Household members in high school do educational activities at home;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Household members in high school do educational activities at home;;;ACTIVE;2.72;2.72 +99814-6;Number of household members in grade 12;Num;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Number of household members in grade 12;;;ACTIVE;2.72;2.72 +99815-3;Name of the household member in grade 12;Find;Pt;^Household member;Nom;;SURVEY.GNHLTH;4;Name of the household member in grade 12 Household member;;;ACTIVE;2.72;2.72 +99816-1;Plans for after high school;Find;Pt;^Household member;Nom;;SURVEY.GNHLTH;4;Plans for after high school Household member;;;ACTIVE;2.72;2.72 +99817-9;Post high school plans changed due to condition of interest or school closures;Find;Pt;^Household member;Ord;;SURVEY.COVID;4;Post high school plans changed due to condition of interest or school closures Household member;;;ACTIVE;2.72;2.72 +99818-7;Previous plans for after high school;Find;Pt;^Household member;Nom;;SURVEY.GNHLTH;4;Previous plans for after high school Household member;;;ACTIVE;2.72;2.72 +99819-5;Primary child care provider while school is suspended or canceled;Find;Pt;^Patient;Nom;;SURVEY.COVID;4;Primary child care provider while school is suspended or canceled;;;ACTIVE;2.72;2.72 +9982-0;QRS terminal amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead V4;QRS T-Amp L-V4;;ACTIVE;1.0i;2.48 +99820-3;Level of difficulty finding affordable child care while school is suspended or canceled;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Level of difficulty finding affordable child care while school is suspended or canceled;;;ACTIVE;2.72;2.72 +99821-1;Agreement with statement: School closures made it difficult for me to work or do other household tasks;Find;Pt;^Patient;Ord;;SURVEY.COVID;4;Agreement with statement: School closures made it difficult for me to work or do other household tasks;;;ACTIVE;2.72;2.72 +99822-9;Agreement with statement: I am satisfied with the communication to support learning from my child's school;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Agreement with statement: I am satisfied with the communication to support learning from my child's school;;;ACTIVE;2.72;2.72 +99823-7;Agreement with statement: My child will be prepared for school in the next school year;Find;Pt;^Patient;Ord;;SURVEY.GNHLTH;4;Agreement with statement: My child will be prepared for school in the next school year;;;ACTIVE;2.72;2.72 +99824-5;Earliest date school will resume in person;Date;Pt;^Patient;Qn;;SURVEY.COVID;4;Earliest date school will resume in person;;;ACTIVE;2.72;2.72 +99825-2;Educational impact due to COVID-19 panel;-;Pt;^Patient;-;;PANEL.SURVEY.COVID;4;Educational impact due to COVID-19 panel;;;ACTIVE;2.72;2.72 +99826-0;Multisection;Find;Pt;Head>Eye;Doc;US.A-scan;RAD;2;US.A-scan Eye;US.A-scan Eye;;ACTIVE;2.72;2.72 +99827-8;Multisection;Find;Pt;Breast;Doc;US.elastography;RAD;2;US.elastography Breast;USE Brst;;ACTIVE;2.72;2.72 +99828-6;Functional Communication Measure - Multi-Modal Functional Communication panel;-;Pt;^Patient;-;ASHA NOMS;PANEL.SURVEY.SLP;4;Functional Communication Measure - Multi-Modal Functional Communication panel [ASHA NOMS];;;ACTIVE;2.72;2.73 +99829-4;Frequency of conveying meaningful simple messages in routine low demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of conveying meaningful simple messages in routine low demand situations;;;ACTIVE;2.72;2.72 +99830-2;Frequency of participating in meaningful short structured conversations in low demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of participating in meaningful short structured conversations in low demand situations;;;ACTIVE;2.72;2.72 +99831-0;Frequency of conveying meaningful complex messages in low demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of conveying meaningful complex messages in low demand situations;;;ACTIVE;2.72;2.72 +99832-8;Frequency of conveying meaningful simple messages in routine high demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of conveying meaningful simple messages in routine high demand situations;;;ACTIVE;2.72;2.72 +99833-6;Frequency of participating in meaningful short structured conversations in high demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of participating in meaningful short structured conversations in high demand situations;;;ACTIVE;2.72;2.72 +99834-4;Frequency of conveying meaningful complex messages in high demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of conveying meaningful complex messages in high demand situations;;;ACTIVE;2.72;2.72 +99835-1;Functional Communication Measure - Multi-Modal Functional Communication score;Score;Pt;^Patient;Qn;ASHA NOMS;SURVEY.SLP;4;Functional Communication Measure - Multi-Modal Functional Communication score [ASHA NOMS];;;ACTIVE;2.72;2.72 +99836-9;Functional Communication Measure - Spoken Language Comprehension ages 6 or older panel;-;Pt;^Patient;-;ASHA NOMS;PANEL.SURVEY.SLP;4;Functional Communication Measure - Spoken Language Comprehension ages 6 or older panel [ASHA NOMS];;;ACTIVE;2.72;2.72 +99837-7;Frequency of understanding simple messages in routine low demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of understanding simple messages in routine low demand situations;;;ACTIVE;2.72;2.72 +9983-8;QRS terminal amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead V5;QRS T-Amp L-V5;;ACTIVE;1.0i;2.48 +99838-5;Frequency of understanding complex messages in low demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of understanding complex messages in low demand situations;;;ACTIVE;2.72;2.72 +99839-3;Frequency of understanding simple messages in routine high demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of understanding simple messages in routine high demand situations;;;ACTIVE;2.72;2.72 +99840-1;Frequency of understanding complex messages in high demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of understanding complex messages in high demand situations;;;ACTIVE;2.72;2.72 +99841-9;Frequency of functioning without assistance due to comprehension deficit;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of functioning without assistance due to comprehension deficit;;;ACTIVE;2.72;2.72 +99842-7;Frequency of participating in spoken language comprehension communication without assistance;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of participating in spoken language comprehension communication without assistance;;;ACTIVE;2.72;2.73 +99843-5;Functional Communication Measure - Spoken Language Comprehension ages 6 or older score;Score;-;^Patient;Qn;ASHA NOMS;SURVEY.SLP;4;Functional Communication Measure - Spoken Language Comprehension ages 6 or older score [ASHA NOMS];;;ACTIVE;2.72;2.72 +99844-3;Functional Communication Measure - Spoken Language Expression ages 6 or older panel;-;Pt;^Patient;-;ASHA NOMS;PANEL.SURVEY.SLP;4;Functional Communication Measure - Spoken Language Expression ages 6 or older panel [ASHA NOMS];;;ACTIVE;2.72;2.73 +99845-0;Frequency of noticeable spoken language expression difficulties;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of noticeable spoken language expression difficulties;;;ACTIVE;2.72;2.72 +9984-6;QRS terminal amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;QRS terminal amplitude in lead V6;QRS T-Amp L-V6;;ACTIVE;1.0i;2.48 +99846-8;Frequency of simple meaningful word or phrase expression;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of simple meaningful word or phrase expression;;;ACTIVE;2.72;2.72 +99847-6;Frequency of producing verbal messages with appropriate form in low demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of producing verbal messages with appropriate form in low demand situations;;;ACTIVE;2.72;2.72 +99848-4;Frequency of producing verbal messages with appropriate content in low demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of producing verbal messages with appropriate content in low demand situations;;;ACTIVE;2.72;2.72 +99849-2;Frequency of producing verbal messages with appropriate form in high demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of producing verbal messages with appropriate form in high demand situations;;;ACTIVE;2.72;2.72 +998-5;DBG Ag;PrThr;Pt;RBC^Donor;Ord;;BLDBK;1;DBG Ag [Presence] on Red Blood Cells from Donor;DBG Ag RBC Donr Ql;;ACTIVE;1.0;2.73 +99850-0;Frequency of producing verbal messages with appropriate content in high demand situations;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of producing verbal messages with appropriate content in high demand situations;;;ACTIVE;2.72;2.72 +99851-8;Functional Communication Measure - Spoken Language Expression ages 6 or older score;Score;Pt;^Patient;Qn;ASHA NOMS;SURVEY.SLP;4;Functional Communication Measure - Spoken Language Expression ages 6 or older score [ASHA NOMS];;;ACTIVE;2.72;2.72 +99852-6;Functional Communication Measure - Swallowing panel;-;Pt;^Patient;-;ASHA NOMS;PANEL.SURVEY.SLP;4;Functional Communication Measure - Swallowing panel [ASHA NOMS];;;ACTIVE;2.72;2.72 +9985-3;R wave amplitude.lead AVF;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead AVF;R wave Amp L-AVF;;ACTIVE;1.0i;2.48 +99853-4;Recommended modified solids diet;Find;Pt;^Patient;Nom;;SURVEY.SLP;4;Recommended modified solids diet;;;ACTIVE;2.72;2.72 +99854-2;Recommended modified liquids diet;Find;Pt;^Patient;Nom;;SURVEY.SLP;4;Recommended modified liquids diet;;;ACTIVE;2.72;2.72 +99855-9;Percentage of daily diet delivered through non-oral means;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Percentage of daily diet delivered through non-oral means;;;ACTIVE;2.72;2.72 +99856-7;Frequency of difficulties with oral containment or secretion management;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of difficulties with oral containment or secretion management;;;ACTIVE;2.72;2.72 +99857-5;Frequency of required supervision or assistance for swallowing safety;Find;Pt;^Patient;Ord;;SURVEY.SLP;4;Frequency of required supervision or assistance for swallowing safety;;;ACTIVE;2.72;2.72 +99858-3;Functional Communication Measure - Swallowing score;Score;Pt;^Patient;Qn;ASHA NOMS;SURVEY.SLP;4;Functional Communication Measure - Swallowing score [ASHA NOMS];;;ACTIVE;2.72;2.72 +99859-1;Erythrocytes.non-dysmorphic;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Erythrocytes.non-dysmorphic [Presence] in Urine sediment by Computer assisted method;Non-dys RBC UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99860-9;Erythrocytes.non-dysmorphic;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Erythrocytes.non-dysmorphic [#/area] in Urine sediment by Computer assisted method;Non-dysmorphic RBC #/area UrnS AI Assis;;ACTIVE;2.72;2.72 +9986-1;R wave amplitude.lead AVL;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead AVL;R wave Amp L-AVL;;ACTIVE;1.0i;2.48 +99861-7;Erythrocytes.non-dysmorphic;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Erythrocytes.non-dysmorphic [#/volume] in Urine sediment by Computer assisted method;Non-dys RBC # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99862-5;Erythrocytes.dysmorphic;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Erythrocytes.dysmorphic [#/area] in Urine sediment by Computer assisted method;Dysmorphic RBC #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99863-3;Erythrocytes.dysmorphic;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Erythrocytes.dysmorphic [Presence] in Urine sediment by Computer assisted method;Dysmorphic RBC UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99864-1;Erythrocytes.dysmorphic;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Erythrocytes.dysmorphic [#/volume] in Urine sediment by Computer assisted method;Dysmorphic RBC # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99865-8;Acanthocytes;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Acanthocytes [Presence] in Urine sediment by Computer assisted method;Acanthocytes UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99866-6;Acanthocytes/100 erythrocytes;NFr;Pt;Urine sed;Qn;Computer assisted;UA;1;Acanthocytes/100 erythrocytes in Urine sediment by Computer assisted method;Acanthocytes/100 RBC NFr UrnS Com Assist;;ACTIVE;2.72;2.72 +99867-4;Acanthocytes;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Acanthocytes [#/area] in Urine sediment by Computer assisted method;Acanthocytes #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99868-2;Acanthocytes;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Acanthocytes [#/volume] in Urine sediment by Computer assisted method;Acanthocytes # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99869-0;Erythrocytes.ghost cells;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Erythrocytes.ghost cells [Presence] in Urine sediment by Computer assisted method;RBCGhost UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99870-8;Erythrocytes.ghost cells;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Erythrocytes.ghost cells [#/area] in Urine sediment by Computer assisted method;RBCGhost #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99871-6;Erythrocytes.ghost cells;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Erythrocytes.ghost cells [#/volume] in Urine sediment by Computer assisted method;RBCGhost # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99872-4;Transitional cells.superficial;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Superficial transitional cells [Presence] in Urine sediment by Computer assisted method;Superficial trans cells UrnS Ql AI Assis;;ACTIVE;2.72;2.72 +99873-2;Transitional cells.superficial;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Superficial transitional cells [#/area] in Urine sediment by Computer assisted method;Sup trans cells #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99874-0;Transitional cells.superficial;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Superficial transitional cells [#/volume] in Urine sediment by Computer assisted method;Superficial trans cells # UrnS AI Assis;;ACTIVE;2.72;2.72 +99875-7;Transitional cells.deep;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Deep transitional cells [Presence] in Urine sediment by Computer assisted method;Deep trans cells UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99876-5;Transitional cells.deep;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Deep transitional cells [#/area] in Urine sediment by Computer assisted method;Deep trans cells #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99877-3;Transitional cells.deep;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Deep transitional cells [#/volume] in Urine sediment by Computer assisted method;Deep trans cells # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99878-1;Lipids;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Lipids [Presence] in Urine sediment by Computer assisted method;Lipids UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +9987-9;R wave amplitude.lead AVR;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead AVR;R wave Amp L-AVR;;ACTIVE;1.0i;2.48 +99879-9;Lipids;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Lipids [#/area] in Urine sediment by Computer assisted method;Lipids #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99880-7;Lipids;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Lipids [#/volume] in Urine sediment by Computer assisted method;Lipids # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99881-5;Free lipid droplets;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Free lipid droplets [Presence] in Urine sediment by Computer assisted method;Lipid droplets UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99882-3;Free lipid droplets;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Free lipid droplets [#/area] in Urine sediment by Computer assisted method;Free lipid droplets #/area UrnS AI assis;;ACTIVE;2.72;2.72 +99883-1;Free lipid droplets;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Free lipid droplets [#/volume] in Urine sediment by Computer assisted method;Lipid droplets # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99884-9;Cholesterol crystals;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Cholesterol crystals [#/volume] in Urine sediment by Computer assisted method;Cholest Cry # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99885-6;Hyaline-granular casts;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Hyaline-granular casts [Presence] in Urine sediment by Computer assisted method;Hyln-grnlr casts UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99886-4;Hyaline-granular casts;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Hyaline-granular casts [#/area] in Urine sediment by Computer assisted method;Hyaline-grnlr casts #/area UrnS AI Assis;;ACTIVE;2.72;2.72 +9988-7;R wave amplitude.lead I;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead I;R wave Amp L-I;;ACTIVE;1.0i;2.48 +99887-2;Hyaline-granular casts;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Hyaline-granular casts [#/volume] in Urine sediment by Computer assisted method;Hyln-grnlr casts # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99888-0;Crystal casts;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Crystal casts [Presence] in Urine sediment by Computer assisted method;Crystal casts UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99889-8;Crystal casts;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Crystal casts [#/area] in Urine sediment by Computer assisted method;Crystal casts #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99890-6;Crystal casts;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Crystal casts [#/volume] in Urine sediment by Computer assisted method;Crystal casts # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99891-4;Microorganism casts;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Microorganism casts [Presence] in Urine sediment by Computer assisted method;Microorg casts UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99892-2;Microorganism casts;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Microorganism casts [#/area] in Urine sediment by Computer assisted method;Microorganism casts #/area UrnS AI Asst;;ACTIVE;2.72;2.72 +99893-0;Microorganism casts;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Microorganism casts [#/volume] in Urine sediment by Computer assisted method;Microorg casts # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99894-8;Calcium oxalate monohydrate crystals;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Calcium oxalate monohydrate crystals [Presence] in Urine sediment by Computer assisted method;COM Cry UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +9989-5;R wave amplitude.lead II;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead II;R wave Amp L-II;;ACTIVE;1.0i;2.48 +99895-5;Calcium oxalate monohydrate crystals;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Calcium oxalate monohydrate crystals [#/area] in Urine sediment by Computer assisted method;COM Cry #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99896-3;Calcium oxalate monohydrate crystals;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Calcium oxalate monohydrate crystals [#/volume] in Urine sediment by Computer assisted method;COM Cry # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99897-1;Calcium oxalate dihydrate crystals;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Calcium oxalate dihydrate crystals [Presence] in Urine sediment by Computer assisted method;COD Cry UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99898-9;Calcium oxalate dihydrate crystals;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Calcium oxalate dihydrate crystals [#/area] in Urine sediment by Computer assisted method;COD Cry #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99899-7;Calcium oxalate dihydrate crystals;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Calcium oxalate dihydrate crystals [#/volume] in Urine sediment by Computer assisted method;COD Cry # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99900-3;Triple phosphate crystals;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Triple phosphate crystals [Presence] in Urine sediment by Computer assisted method;Tri-Phos Cry UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99901-1;Triple phosphate crystals;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Triple phosphate crystals [#/area] in Urine sediment by Computer assisted method;Tri-Phos Cry #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99902-9;Triple phosphate crystals;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Triple phosphate crystals [#/volume] in Urine sediment by Computer assisted method;Tri-Phos Cry # UrnS Comp Assist;;ACTIVE;2.72;2.72 +9990-3;R wave amplitude.lead III;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead III;R wave Amp L-III;;ACTIVE;1.0i;2.48 +99903-7;Urate crystals;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Urate crystals [Presence] in Urine sediment by Computer assisted method;Urate Cry UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99904-5;Urate crystals;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Urate crystals [#/area] in Urine sediment by Computer assisted method;Urate Cry #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99905-2;Urate crystals;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Urate crystals [#/volume] in Urine sediment by Computer assisted method;Urate Cry # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99906-0;Urate crystals.amorphous;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Urate crystals amorphous [#/area] in Urine sediment by Computer assisted method;Amorph Urate Cry #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99907-8;Urate crystals.amorphous;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Urate crystals amorphous [#/volume] in Urine sediment by Computer assisted method;Amorph Urate Cry # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99908-6;Phosphate crystals.amorphous;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Phosphate crystals amorphous [#/volume] in Urine sediment by Computer assisted method;Amorph Phos Cry # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99909-4;Atypical crystals;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Atypical crystals [Presence] in Urine sediment by Computer assisted method;Atyp crystals UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99910-2;Atypical crystals;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Atypical crystals [#/area] in Urine sediment by Computer assisted method;Atypical crystals #/area UrnS Comp Asst;;ACTIVE;2.72;2.72 +9991-1;R wave amplitude.lead V1;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead V1;R wave Amp L-V1;;ACTIVE;1.0i;2.48 +99911-0;Atypical crystals;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Atypical crystals [#/volume] in Urine sediment by Computer assisted method;Atyp crystals # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99912-8;Bacilliform bacteria;PrThr;Pt;Urine sed;Ord;Automated;UA;1;Bacilliform bacteria [Presence] in Urine sediment by Automated;Bacilliform bact UrnS Ql Auto;;ACTIVE;2.72;2.72 +99913-6;Bacilliform bacteria;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Bacilliform bacteria [#/area] in Urine sediment by Automated count;Bacilliform bact #/area UrnS Auto;;ACTIVE;2.72;2.72 +99914-4;Bacilliform bacteria;NCnc;Pt;Urine sed;Qn;Automated count;UA;1;Bacilliform bacteria [#/volume] in Urine sediment by Automated count;Bacilliform bact # UrnS Auto;;ACTIVE;2.72;2.72 +99915-1;Cocci bacteria;PrThr;Pt;Urine sed;Ord;Automated;UA;1;Cocci bacteria [Presence] in Urine sediment by Automated;Cocci UrnS Ql Auto;;ACTIVE;2.72;2.72 +99916-9;Cocci bacteria;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Cocci bacteria [#/area] in Urine sediment by Automated count;Cocci #/area UrnS Auto;;ACTIVE;2.72;2.72 +99917-7;Cocci bacteria;NCnc;Pt;Urine sed;Qn;Automated count;UA;1;Cocci bacteria [#/volume] in Urine sediment by Automated count;Cocci # UrnS Auto;;ACTIVE;2.72;2.72 +99918-5;Amorphous sediment;PrThr;Pt;Urine sed;Ord;Automated;UA;1;Amorphous sediment [Presence] in Urine sediment by Automated;Amorph Sed UrnS Ql Auto;;ACTIVE;2.72;2.72 +99919-3;Amorphous sediment;Naric;Pt;Urine sed;Qn;Automated count;UA;1;Amorphous sediment [#/area] in Urine sediment by Automated count;Amorph Sed #/area UrnS Auto;;ACTIVE;2.72;2.72 +99920-1;Amorphous sediment;NCnc;Pt;Urine sed;Qn;Automated count;UA;1;Amorphous sediment [#/volume] in Urine sediment by Automated count;Amorph Sed # UrnS Auto;;ACTIVE;2.72;2.72 +99921-9;Schistosoma haematobium;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Schistosoma haematobium [Presence] in Urine sediment by Computer assisted method;S haematobium UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99922-7;Schistosoma haematobium;Naric;Pt;Urine sed;Qn;Computer assisted;UA;1;Schistosoma haematobium [#/area] in Urine sediment by Computer assisted method;S haematobium #/area UrnS Comp Assist;;ACTIVE;2.72;2.72 +99923-5;Schistosoma haematobium;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Schistosoma haematobium [#/volume] in Urine sediment by Computer assisted method;S haematobium # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99924-3;Artifact;PrThr;Pt;Urine sed;Ord;Computer assisted;UA;1;Artifact [Presence] in Urine sediment by Computer assisted method;Artifact UrnS Ql Comp Assist;;ACTIVE;2.72;2.72 +99925-0;Artifact;NCnc;Pt;Urine sed;Qn;Computer assisted;UA;1;Artifact [#/volume] in Urine sediment by Computer assisted method;Artifact # UrnS Comp Assist;;ACTIVE;2.72;2.72 +99926-8;Erythrocytes;PrThr;Pt;Body fld;Ord;Automated;HEM/BC;1;Erythrocytes [Presence] in Body fluid by Automated;RBC Fld Ql Auto;;ACTIVE;2.72;2.72 +99927-6;Erythrocytes;Naric;Pt;Body fld;Qn;Automated count;HEM/BC;1;Erythrocytes [#/area] in Body fluid by Automated count;RBC #/area Fld Auto;;ACTIVE;2.72;2.72 +99928-4;Leukocytes;PrThr;Pt;Body fld;Ord;Automated;HEM/BC;1;Leukocytes [Presence] in Body fluid by Automated;WBC Fld Ql Auto;;ACTIVE;2.72;2.72 +9992-9;R wave amplitude.lead V2;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead V2;R wave Amp L-V2;;ACTIVE;1.0i;2.48 +99929-2;Leukocytes;Naric;Pt;Body fld;Qn;Automated count;HEM/BC;1;Leukocytes [#/area] in Body fluid by Automated count;WBC #/area Fld Auto;;ACTIVE;2.72;2.72 +999-3;DBG Ag;PrThr;Pt;RBC;Ord;;BLDBK;1;DBG Ag [Presence] on Red Blood Cells;DBG Ag RBC Ql;;ACTIVE;1.0;2.56 +99930-0;Nucleated cells;PrThr;Pt;Body fld;Ord;Automated;HEM/BC;1;Nucleated cells [Presence] in Body fluid by Automated;Nuc cell Fld Ql Auto;;ACTIVE;2.72;2.72 +99931-8;Nucleated cells;Naric;Pt;Body fld;Qn;Automated count;HEM/BC;1;Nucleated cells [#/area] in Body fluid by Automated count;Nuc cell #/area Fld Auto;;ACTIVE;2.72;2.72 +99932-6;Bacteria;PrThr;Pt;Body fld;Ord;Automated;MICRO;1;Bacteria [Presence] in Body fluid by Automated;Bacteria Fld Ql Auto;;ACTIVE;2.72;2.72 +99933-4;Leukocyte clumps;PrThr;Pt;Body fld;Ord;Automated;HEM/BC;1;Leukocyte clumps [Presence] in Body fluid by Automated;WBC clumps Fld Ql Auto;;ACTIVE;2.72;2.72 +99934-2;Mainz pain staging system panel;-;Pt;^Patient;-;Mainz Pain Staging System;PANEL.SURVEY.GNHLTH;4;Mainz pain staging system panel [Mainz Pain Staging System];;© 1999 H.U. Gerbershagen, J. Korb, B. Nagel, P. Nilges. Used with permission.;ACTIVE;2.72;2.72 +99935-9;Average frequency of primary pain in past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Average frequency of primary pain in past 4 weeks;Avg freq primary pain past 4W;;ACTIVE;2.72;2.72 +99936-7;Average duration of primary pain in past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Average duration of primary pain in past 4 weeks;Avg duration primary pain past 4W;;ACTIVE;2.72;2.72 +9993-7;R wave amplitude.lead V3;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead V3;R wave Amp L-V3;;ACTIVE;1.0i;2.48 +99937-5;Fluctuation of primary pain intensity in past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Fluctuation of primary pain intensity in past 4 weeks;Fluct of primary pain intensity past 4W;;ACTIVE;2.72;2.72 +99938-3;Variation of episodic pain intensity in past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Variation of episodic pain intensity in past 4 weeks;Var of episodic pain intensity past 4W;;ACTIVE;2.72;2.72 +99939-1;Pain distribution in past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Pain distribution in past 4 weeks;Pain distribution in past 4W;;ACTIVE;2.72;2.72 +99940-9;Pain medication in the past 4W;Find;4W;^Patient;Ord;;H&P.HX;2;Pain medication in the past 4 weeks;Pain medication in the past 4W;;ACTIVE;2.72;2.72 +99941-7;Withdrawn from or reduced dose of pain medication;Find;Pt;^Patient;Ord;;H&P.HX;2;Withdrawn from or reduced dose of pain medication;Withdrawn or reduced dose of pain med;;ACTIVE;2.72;2.72 +99942-5;Change of physician responsible for pain treatment;Find;Pt;^Patient;Ord;;H&P.HX;2;Change of physician responsible for pain treatment;Change physician responsible for pain tx;;ACTIVE;2.72;2.72 +99943-3;Frequency of pain related hospitalizations;Find;Pt;^Patient;Ord;;H&P.HX;2;Frequency of pain related hospitalizations;Freq of pain related hospitalizations;;ACTIVE;2.72;2.72 +99944-1;Number of surgical procedures for pain;Find;Pt;^Patient;Ord;;H&P.HX;2;Number of surgical procedures for pain;Num surgical procedures for pain;;ACTIVE;2.72;2.72 +9994-5;R wave amplitude.lead V4;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead V4;R wave Amp L-V4;;ACTIVE;1.0i;2.48 +99945-8;Number of pain related stays at treatment facility;Find;Pt;^Patient;Ord;;H&P.HX;2;Number of pain related stays at treatment facility;Num of pain related stays at tx facility;;ACTIVE;2.72;2.72 +99946-6;Total score;Score;Pt;^Patient;Qn;Mainz Pain Staging System;SURVEY.GNHLTH;4;Total score [Mainz Pain Staging System];;© 1999 H.U. Gerbershagen, J. Korb, B. Nagel, P. Nilges. Used with permission.;ACTIVE;2.72;2.72 +99947-4;Telecommunication type;Type;Pt;^Entity;Nom;;ADMIN;2;Entity Telecommunication type;Entity Telecom type;;ACTIVE;2.72;2.72 +99948-2;Telecommunication panel;-;Pt;^Entity;-;;PANEL.ADMIN;2;Entity Telecommunication panel;Entity Telecom panel;;ACTIVE;2.72;2.72 +99949-0;Telecommunication mode;Type;Pt;^Entity;Nom;;ADMIN;2;Entity Telecommunication mode;Entity Telecom mode;;ACTIVE;2.72;2.72 +99950-8;State;Loc;Pt;^Entity;Nom;;ADMIN;2;Entity State;Entity State;;ACTIVE;2.72;2.72 +99951-6;Postal code;Loc;Pt;^Entity;Nom;;ADMIN;2;Entity Postal code;Entity Postal code;;ACTIVE;2.72;2.72 +9995-2;R wave amplitude.lead V5;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead V5;R wave Amp L-V5;;ACTIVE;1.0i;2.48 +99952-4;Address panel;-;Pt;^Entity;-;;PANEL.ADMIN;2;Entity Address panel;Entity Address panel;;ACTIVE;2.72;2.72 +99953-2;Address;Addr;Pt;^Entity;Nom;;ADMIN;2;Entity Address;Entity Address;;ACTIVE;2.72;2.72 +99954-0;City;Loc;Pt;^Entity;Nom;;ADMIN;2;Entity City;Entity City;;ACTIVE;2.72;2.72 +99955-7;Country;Loc;Pt;^Entity;Nom;;ADMIN;2;Entity Country;Entity Country;;ACTIVE;2.72;2.72 +99956-5;Complete address;Addr;Pt;^Entity;Nom;;ADMIN;2;Entity Complete address;Entity Complete address;;ACTIVE;2.72;2.72 +99957-3;Address type;Type;Pt;^Entity;Nom;;ADMIN;2;Entity Address type;Entity Addr type;;ACTIVE;2.72;2.72 +99958-1;Address use;Type;Pt;^Entity;Nom;;ADMIN;2;Entity Address use;Entity Address use;;ACTIVE;2.72;2.72 +99959-9;Urothelial carcinoma gene expression score;Score;Pt;Urine;Qn;Molgen;MOLPATH;1;Urothelial carcinoma gene expression score in Urine by Molecular genetics method;UC gene expression score Ur;;ACTIVE;2.72;2.72 +9996-0;R wave amplitude.lead V6;Elpot;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave amplitude in lead V6;R wave Amp L-V6;;ACTIVE;1.0i;2.48 +99960-7;ADAMTS13 gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;ADAMTS13 gene full mutation analysis in Blood or Tissue by Sequencing;ADAMTS13 Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99961-5;Myeloproliferative neoplasm multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Myeloproliferative neoplasm multigene analysis in Blood or Tissue by Molecular genetics method;MPN multigene analysis Bld/T;;ACTIVE;2.72;2.72 +99962-3;JAK2 gene exon 12 full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;JAK2 gene exon 12 full mutation analysis in Blood or Tissue by Sequencing;JAK2 exon 12 Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99963-1;JAK2 gene exon 14 full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;JAK2 gene exon 14 full mutation analysis in Blood or Tissue by Sequencing;JAK2 exon 14 Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99964-9;MPL gene exon 10 full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;MPL gene exon 10 full mutation analysis in Blood or Tissue by Sequencing;MPL exon 10 Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99965-6;ASXL1 gene exon 13 full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;ASXL1 gene exon 13 full mutation analysis in Blood or Tissue by Sequencing;ASXL1 exon 13 Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99966-4;KIT gene exon 17 full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;KIT gene exon 17 full mutation analysis in Blood or Tissue by Sequencing;KIT Exon 17 Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99967-2;Atypical hemolytic uremic syndrome multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Atypical hemolytic uremic syndrome multigene analysis in Blood or Tissue by Molecular genetics method;aHUS multigene analysis Bld/T;;ACTIVE;2.72;2.72 +99968-0;Thrombotic microangiopathy multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Thrombotic microangiopathy multigene analysis in Blood or Tissue by Molecular genetics method;TMA multigene analysis Bld/T;;ACTIVE;2.72;2.72 +99969-8;PLG gene full mutation analysis;Find;Pt;Bld/Tiss;Doc;Sequencing;MOLPATH;1;PLG gene full mutation analysis in Blood or Tissue by Sequencing;PLG Full Mut Anl Bld/T Seq;;ACTIVE;2.72;2.72 +99970-6;Hereditary thrombocytopenia multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Hereditary thrombocytopenia multigene analysis in Blood or Tissue by Molecular genetics method;IT multigene analysis Bld/T;;ACTIVE;2.72;2.72 +99971-4;Hemophagocytic lymphohistiocytosis multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Hemophagocytic lymphohistiocytosis multigene analysis in Blood or Tissue by Molecular genetics method;HLH multigene analysis Bld/T;;ACTIVE;2.72;2.72 +99972-2;Hearing loss multigene analysis;Find;Pt;Bld/Tiss;Doc;Molgen;MOLPATH;1;Hearing loss multigene analysis in Blood or Tissue by Molecular genetics method;Hearing loss multigene analy Bld/T;;ACTIVE;2.72;2.72 +99974-8;No injury due to a thermal source;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No risk of injury due to a thermal source;;;ACTIVE;2.72;2.72 +99975-5;No injury related to a chemical source;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to a chemical source;;;ACTIVE;2.72;2.72 +99976-3;No injury related to a radiation source;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to a radiation source;;;ACTIVE;2.72;2.72 +99977-1;No injury related to transfer &or transport during care;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to transfer AndOr transport during care;;;ACTIVE;2.72;2.72 +9997-8;R wave axis;Angle;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave axis;R wave axis;;ACTIVE;1.0i;2.48 +99978-9;No harm related to medications administered;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No harm related to medications administered;;;ACTIVE;2.72;2.72 +99979-7;No injury related to unintended retained surgical item;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to unintended retained surgical item;;;ACTIVE;2.72;2.72 +99980-5;Wound is healing or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Wound is healing or improved from baseline levels;;;ACTIVE;2.72;2.72 +99981-3;Culture and demographics incorporated into plan of care;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Culture and demographics incorporated into plan of care;;;ACTIVE;2.72;2.72 +99982-1;Care provided is consistent with established plan of care;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Care provided is consistent with established plan of care;;;ACTIVE;2.72;2.72 +99983-9;Patient's right to privacy is maintained;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Patient's right to privacy is maintained;;;ACTIVE;2.72;2.72 +99984-7;Patient receives competent and ethical care within legal standards of practice;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Patient receives competent and ethical care within legal standards of practice;;;ACTIVE;2.72;2.72 +99985-4;Patient receives consistent and comparable care regardless of the setting;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Patient receives consistent and comparable care regardless of the setting;;;ACTIVE;2.72;2.72 +9998-6;R wave duration.lead AVF;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead AVF;R wave dur L-AVF;;ACTIVE;1.0i;2.48 +99986-2;Tissue perfusion is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Tissue perfusion is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99987-0;Gastrointestinal status is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Gastrointestinal status is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99988-8;Genitourinary status is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Genitourinary status is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99989-6;Musculoskeletal status is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Musculoskeletal status is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99990-4;Endocrine status is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Endocrine status is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99991-2;No signs and symptoms of infection;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No signs and symptoms of infection;;;ACTIVE;2.72;2.72 +99992-0;Thermoregulation maintained core body temperature at desired range;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Thermoregulation maintained core body temperature at desired range;;;ACTIVE;2.72;2.72 +99993-8;No injury related to an incorrect procedure performed;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;No injury related to an incorrect procedure performed;;;ACTIVE;2.72;2.72 +9999-4;R wave duration.lead AVL;Time;Pt;Heart;Qn;EKG;EKG.MEAS;2;R wave duration in lead AVL;R wave dur L-AVL;;ACTIVE;1.0i;2.48 +99994-6;Fluid, electrolyte, and acid-base balances are maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Fluid, electrolyte, and acid-base balances are maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99995-3;Respiratory status is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Respiratory status is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99996-1;Cardiovascular status is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Cardiovascular status is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 +99997-9;Demonstrates &or reports adequate pain control;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Demonstrates AndOr reports adequate pain control;;;ACTIVE;2.72;2.72 +99998-7;Neurological status is maintained at or improved from baseline levels;Find;Pt;^Patient;Ord;;SURVEY.PNDS;4;Neurological status is maintained at or improved from baseline levels;;;ACTIVE;2.72;2.72 diff --git a/database/seeders/csv/loinc_answer.csv.stub b/database/seeders/csv/loinc_answer.csv.stub new file mode 100644 index 0000000..82e5f70 --- /dev/null +++ b/database/seeders/csv/loinc_answer.csv.stub @@ -0,0 +1,126515 @@ +LoincNumber;AnswerListId;AnswerListName;AnswerStringId;SequenceNumber;DisplayText;ExtCodeId;ExtCodeDisplayName;ExtCodeSystem +100002-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100002-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100002-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100002-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100003-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100003-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100003-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100003-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100004-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100004-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100004-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100004-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100005-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100005-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100005-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100005-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100006-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100006-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100006-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100006-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100007-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100007-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100007-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100007-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100008-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100008-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100008-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100008-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100009-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100009-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100009-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100009-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100010-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100010-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100010-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100010-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100011-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100011-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100011-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100011-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100012-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100012-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100012-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100012-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100013-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100013-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100013-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100013-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100014-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100014-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100014-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100014-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100015-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100015-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100015-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100015-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100016-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +100016-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +100016-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +100016-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99974-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99974-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99974-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99974-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99975-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99975-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99975-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99975-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99976-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99976-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99976-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99976-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99977-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99977-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99977-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99977-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99978-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99978-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99978-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99978-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99979-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99979-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99979-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99979-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99980-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99980-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99980-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99980-5;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99981-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99981-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99981-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99981-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99982-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99982-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99982-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99982-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99983-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99983-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99983-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99983-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99984-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99984-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99984-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99984-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99985-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99985-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99985-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99985-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99986-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99986-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99986-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99986-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99987-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99987-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99987-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99987-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99988-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99988-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99988-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99988-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99989-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99989-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99989-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99989-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99990-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99990-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99990-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99990-4;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99991-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99991-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99991-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99991-2;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99992-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99992-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99992-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99992-0;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99993-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99993-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99993-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99993-8;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99994-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99994-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99994-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99994-6;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99995-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99995-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99995-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99995-3;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99996-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99996-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99996-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99996-1;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99997-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99997-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99997-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99997-9;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +99998-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32971-6;1;Met;;; +99998-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA32972-4;2;Not met;;; +99998-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA9040-2;3;Ongoing;;; +99998-7;LL6136-7;Met/Not met/Ongoing/Unable to assess;LA10105-7;4;Unable to assess;;; +100019-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100019-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100020-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100020-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100021-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100021-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100022-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100022-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100023-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100023-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100024-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100024-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100025-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100025-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100026-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100026-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100027-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100027-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100028-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100028-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100305-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100305-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100306-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100306-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100671-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100671-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100672-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100672-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100673-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100673-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100694-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100694-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100717-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100717-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100762-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100762-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100897-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100897-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100908-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100908-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100909-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100909-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100911-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100911-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100980-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100980-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100981-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100981-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100982-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100982-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100995-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +100995-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101120-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101120-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101121-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101121-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101123-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101123-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101124-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101124-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101125-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101125-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101126-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101126-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101127-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101127-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101207-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101207-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101208-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101208-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101210-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101210-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101211-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101211-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101212-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101212-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101213-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101213-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101215-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101215-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101216-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101216-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101217-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101217-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101218-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101218-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101219-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101219-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101250-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101250-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101282-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101282-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101283-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101283-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101302-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101302-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101303-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101303-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101304-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101304-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101305-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101305-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101306-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101306-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101307-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101307-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101335-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101335-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101340-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101340-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101345-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101345-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101353-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101353-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101400-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101400-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101401-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101401-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101402-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101402-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101419-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101419-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101420-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101420-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101421-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101421-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101422-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101422-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101423-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101423-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101424-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101424-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101425-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101425-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101426-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101426-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101427-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101427-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101428-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101428-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101469-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101469-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101470-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101470-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101545-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101545-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101546-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101546-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101547-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101547-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101548-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101548-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101552-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101552-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101553-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101553-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101554-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101554-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101555-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101555-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101556-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101556-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101557-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101557-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101558-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101558-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101559-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101559-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101560-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101560-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101561-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101561-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101562-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101562-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101563-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101563-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +101571-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +101571-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +19106-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +19106-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +19140-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +19140-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +21560-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +21560-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +21561-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +21561-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +29529-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +29529-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +29530-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +29530-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +29531-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +29531-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +30333-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +30333-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +30334-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +30334-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +30335-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +30335-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +30336-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +30336-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +30337-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +30337-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +33633-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +33633-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +33978-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +33978-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +33985-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +33985-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +33986-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +33986-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +33989-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +33989-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +34487-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +34487-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +34489-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +34489-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35318-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35318-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35362-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35362-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35389-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35389-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35686-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35686-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35687-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35687-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35688-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35688-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35689-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35689-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +35690-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +35690-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +36902-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +36902-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +43279-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +43279-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +46999-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +46999-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +47000-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +47000-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +48175-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +48175-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +48176-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +48176-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +49514-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +49514-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +49530-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +49530-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +49535-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +49535-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +49579-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +49579-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +49629-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +49629-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +49633-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +49633-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +49671-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +49671-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +50703-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +50703-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +51669-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +51669-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +51760-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +51760-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +53817-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +53817-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +53941-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +53941-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +54033-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +54033-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +54034-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +54034-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +54035-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +54035-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +54036-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +54036-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +55143-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +55143-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +55464-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +55464-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +55465-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +55465-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +56748-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +56748-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +58465-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +58465-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +59420-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +59420-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +60521-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +60521-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +60525-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +60525-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61360-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61360-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61361-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61361-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61362-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61362-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61363-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61363-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61364-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61364-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61365-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61365-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61366-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61366-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61367-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61367-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61368-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61368-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61369-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61369-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61370-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61370-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61371-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61371-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61372-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61372-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61373-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61373-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61374-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61374-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61375-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61375-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61376-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61376-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61377-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61377-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61378-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61378-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61379-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61379-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61380-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61380-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61381-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61381-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61382-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61382-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61383-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61383-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61384-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61384-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61385-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61385-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61386-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61386-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61387-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61387-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61388-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61388-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61389-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61389-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61390-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61390-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61391-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61391-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61392-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61392-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61393-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61393-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61394-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61394-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61395-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61395-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61396-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61396-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61397-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61397-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61398-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61398-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61399-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61399-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61400-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61400-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61401-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61401-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61402-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61402-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61403-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61403-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61404-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61404-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +61405-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +61405-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +62256-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +62256-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +62257-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +62257-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +62258-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +62258-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +62259-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +62259-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +62260-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +62260-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +62261-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +62261-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +63072-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +63072-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +63574-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +63574-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +64233-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +64233-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +67126-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +67126-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +67838-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +67838-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68369-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68369-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68370-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68370-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68371-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68371-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68372-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68372-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68377-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68377-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68380-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68380-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68385-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68385-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68386-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68386-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68901-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68901-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68954-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68954-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68964-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68964-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68965-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68965-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68966-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68966-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68967-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68967-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68968-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68968-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68986-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68986-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68987-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68987-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +68993-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +68993-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69353-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69353-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69369-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69369-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69370-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69370-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69371-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69371-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69373-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69373-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69575-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69575-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69576-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69576-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +69577-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +69577-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72268-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72268-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72421-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72421-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72607-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72607-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72836-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72836-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72837-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72837-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72863-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72863-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72864-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72864-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72865-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72865-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72866-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72866-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72867-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72867-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72868-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72868-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72869-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72869-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +72870-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +72870-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +73732-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +73732-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +73754-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +73754-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +73755-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +73755-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74472-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74472-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74473-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74473-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74474-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74474-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74732-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74732-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74736-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74736-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74737-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74737-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74738-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74738-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74739-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74739-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74740-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74740-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74741-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74741-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74742-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74742-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74743-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74743-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74744-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74744-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74745-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74745-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74746-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74746-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74747-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74747-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74748-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74748-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74763-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74763-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +74853-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +74853-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75674-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75674-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75675-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75675-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75676-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75676-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75677-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75677-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75678-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75678-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75679-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75679-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75681-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75681-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75682-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75682-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75683-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75683-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75684-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75684-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75685-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75685-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75686-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75686-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75687-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75687-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75690-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75690-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75753-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75753-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75754-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75754-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +75755-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +75755-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +76072-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +76072-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +76705-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +76705-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +77021-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +77021-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +77682-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +77682-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +77924-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +77924-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78202-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78202-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78203-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78203-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78204-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78204-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78205-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78205-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78215-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78215-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78216-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78216-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78217-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78217-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78218-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78218-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78219-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78219-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78220-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78220-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78221-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78221-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78245-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78245-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78357-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78357-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78876-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78876-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +78915-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +78915-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79209-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79209-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79210-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79210-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79334-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79334-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79335-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79335-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79336-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79336-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79337-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79337-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79338-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79338-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79379-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79379-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79380-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79380-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79382-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79382-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79383-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79383-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79384-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79384-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79385-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79385-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79386-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79386-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79387-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79387-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79388-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79388-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +79389-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +79389-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80348-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80348-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80349-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80349-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80350-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80350-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80351-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80351-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80353-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80353-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80355-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80355-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80360-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80360-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80361-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80361-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80362-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80362-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80363-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80363-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80364-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80364-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80365-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80365-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80366-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80366-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80367-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80367-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80368-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80368-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80373-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80373-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80375-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80375-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80382-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80382-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80383-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80383-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80386-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80386-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80387-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80387-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80518-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80518-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80586-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80586-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80587-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80587-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80588-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80588-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80589-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80589-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80590-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80590-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80591-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80591-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80592-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80592-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80593-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80593-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80594-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80594-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80595-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80595-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80596-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80596-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80597-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80597-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80598-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80598-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80599-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80599-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80600-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80600-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80601-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80601-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80825-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80825-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +80826-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +80826-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81096-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81096-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81097-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81097-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81111-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81111-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81113-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81113-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81116-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81116-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81117-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81117-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81118-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81118-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81121-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81121-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81148-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81148-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81149-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81149-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81150-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81150-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81151-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81151-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81152-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81152-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81153-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81153-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81428-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81428-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81649-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81649-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81650-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81650-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81651-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81651-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81656-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81656-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81657-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81657-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81688-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81688-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +81689-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +81689-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82160-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82160-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82161-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82161-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82162-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82162-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82163-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82163-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82164-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82164-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82165-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82165-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82166-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82166-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82167-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82167-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82168-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82168-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82169-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82169-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82170-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82170-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82171-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82171-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82172-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82172-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82173-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82173-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82174-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82174-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82175-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82175-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82176-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82176-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82177-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82177-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82178-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82178-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82179-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82179-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82181-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82181-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82182-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82182-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82183-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82183-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82184-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82184-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82185-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82185-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82186-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82186-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82187-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82187-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82188-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82188-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82189-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82189-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82190-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82190-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82191-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82191-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82192-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82192-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82193-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82193-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82194-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82194-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82196-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82196-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82197-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82197-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82198-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82198-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82199-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82199-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82200-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82200-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82201-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82201-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82202-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82202-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82203-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82203-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82204-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82204-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82205-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82205-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82206-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82206-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82207-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82207-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82208-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82208-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82209-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82209-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82210-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82210-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82211-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82211-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82212-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82212-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82213-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82213-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82306-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82306-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82383-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82383-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82384-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82384-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82513-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82513-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82731-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82731-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82780-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82780-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +82781-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +82781-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83066-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83066-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83080-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83080-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83081-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83081-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83087-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83087-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83095-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83095-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83100-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83100-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83123-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83123-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +83128-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +83128-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85043-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85043-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85046-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85046-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85047-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85047-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85049-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85049-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85050-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85050-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85053-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85053-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85100-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85100-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85101-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85101-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85296-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85296-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85299-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85299-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85761-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85761-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85763-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85763-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85764-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85764-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85765-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85765-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85766-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85766-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85767-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85767-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85768-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85768-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85769-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85769-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85770-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85770-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85771-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85771-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85772-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85772-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85773-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85773-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85774-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85774-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85775-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85775-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85776-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85776-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85777-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85777-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85778-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85778-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85779-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85779-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85780-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85780-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85781-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85781-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85782-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85782-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85783-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85783-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85784-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85784-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85785-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85785-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +85973-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +85973-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86143-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86143-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86144-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86144-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86162-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86162-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86165-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86165-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86318-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86318-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86581-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86581-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86590-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86590-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86712-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86712-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86713-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86713-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86714-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86714-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86722-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86722-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86724-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86724-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86725-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86725-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86733-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86733-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86737-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86737-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86738-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86738-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +86740-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +86740-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87445-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87445-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87621-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87621-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87755-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87755-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87758-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87758-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87816-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87816-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87827-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87827-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87828-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87828-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87831-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87831-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87923-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87923-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87924-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87924-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87948-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87948-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87949-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87949-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87950-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87950-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87951-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87951-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87952-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87952-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87953-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87953-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87958-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87958-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87959-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87959-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87960-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87960-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87961-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87961-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87982-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87982-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87983-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87983-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87984-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87984-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87985-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87985-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87988-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87988-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87989-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87989-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87992-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87992-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87993-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87993-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87994-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87994-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +87997-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +87997-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88022-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88022-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88023-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88023-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88038-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88038-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88039-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88039-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88041-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88041-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88042-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88042-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88043-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88043-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88044-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88044-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88045-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88045-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88046-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88046-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88047-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88047-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88048-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88048-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88049-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88049-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88050-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88050-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88051-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88051-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88059-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88059-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88128-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88128-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88131-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88131-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88132-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88132-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88133-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88133-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88134-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88134-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88135-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88135-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88136-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88136-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88138-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88138-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88140-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88140-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88160-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88160-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88161-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88161-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88163-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88163-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88164-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88164-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88165-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88165-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88166-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88166-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88179-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88179-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88180-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88180-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88181-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88181-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88182-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88182-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88193-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88193-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88195-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88195-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88196-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88196-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88197-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88197-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88198-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88198-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88199-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88199-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88202-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88202-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88204-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88204-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88208-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88208-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88209-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88209-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88210-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88210-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88211-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88211-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88213-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88213-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88215-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88215-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88217-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88217-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88218-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88218-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88219-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88219-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88221-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88221-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88222-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88222-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88223-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88223-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88224-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88224-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88225-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88225-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88226-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88226-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88227-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88227-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88228-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88228-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88229-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88229-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88230-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88230-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88232-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88232-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88233-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88233-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88244-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88244-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88245-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88245-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88246-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88246-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88247-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88247-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88248-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88248-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88249-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88249-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88250-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88250-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88251-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88251-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88252-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88252-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88253-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88253-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88254-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88254-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88255-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88255-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88256-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88256-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88257-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88257-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88258-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88258-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88263-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88263-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88264-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88264-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88265-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88265-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88267-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88267-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88268-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88268-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88269-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88269-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88270-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88270-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88271-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88271-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88272-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88272-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88273-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88273-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88274-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88274-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88275-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88275-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88276-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88276-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88277-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88277-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88301-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88301-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88302-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88302-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88303-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88303-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88304-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88304-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88519-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88519-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88527-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88527-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88528-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88528-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88529-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88529-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88530-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88530-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88533-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88533-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88534-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88534-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88535-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88535-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88536-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88536-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88538-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88538-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88539-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88539-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88540-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88540-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88541-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88541-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88546-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88546-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88547-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88547-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88548-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88548-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88549-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88549-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88550-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88550-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88551-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88551-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88552-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88552-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88553-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88553-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88554-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88554-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88555-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88555-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88556-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88556-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88557-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88557-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88558-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88558-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88559-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88559-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88560-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88560-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88561-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88561-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88562-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88562-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88563-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88563-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88565-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88565-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88570-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88570-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88573-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88573-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88574-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88574-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88575-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88575-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88576-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88576-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88577-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88577-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88579-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88579-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88584-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88584-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88590-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88590-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88591-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88591-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88592-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88592-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88593-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88593-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88594-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88594-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88595-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88595-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88596-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88596-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88597-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88597-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88599-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88599-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88600-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88600-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88602-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88602-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88603-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88603-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88604-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88604-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88605-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88605-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88607-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88607-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88608-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88608-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88609-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88609-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88610-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88610-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88611-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88611-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88612-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88612-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88613-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88613-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88614-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88614-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88615-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88615-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88616-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88616-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88617-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88617-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88618-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88618-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88619-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88619-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88620-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88620-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88621-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88621-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88622-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88622-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88625-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88625-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88626-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88626-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88627-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88627-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88628-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88628-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88678-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88678-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88679-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88679-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88680-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88680-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88681-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88681-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88689-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88689-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88690-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88690-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88691-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88691-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88744-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88744-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88873-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88873-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88874-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88874-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88889-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88889-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88890-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88890-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88891-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88891-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88897-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88897-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88898-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88898-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88899-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88899-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88900-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88900-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88901-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88901-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88902-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88902-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88904-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88904-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88905-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88905-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88906-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88906-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88907-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88907-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88908-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88908-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88909-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88909-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88910-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88910-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88911-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88911-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88912-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88912-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88913-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88913-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88914-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88914-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88915-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88915-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88918-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88918-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88919-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88919-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88920-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88920-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88924-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88924-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88925-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88925-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88926-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88926-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88927-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88927-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +88928-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +88928-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89300-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89300-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89301-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89301-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89302-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89302-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89303-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89303-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89304-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89304-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89305-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89305-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89306-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89306-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89307-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89307-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89308-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89308-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89309-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89309-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89310-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89310-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89314-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89314-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89342-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89342-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89359-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89359-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89372-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89372-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89500-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89500-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89501-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89501-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89504-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89504-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89505-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89505-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89506-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89506-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89507-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89507-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89508-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89508-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89509-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89509-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89510-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89510-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89511-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89511-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89512-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89512-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89513-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89513-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89514-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89514-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89515-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89515-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89516-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89516-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89517-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89517-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89518-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89518-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89519-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89519-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89520-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89520-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89521-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89521-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89522-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89522-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89523-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89523-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89524-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89524-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89525-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89525-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89526-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89526-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89527-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89527-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89528-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89528-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89529-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89529-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89530-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89530-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89531-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89531-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89532-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89532-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89533-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89533-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89534-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89534-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89535-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89535-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89536-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89536-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89537-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89537-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89538-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89538-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89539-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89539-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89540-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89540-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89541-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89541-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89542-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89542-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89584-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89584-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89585-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89585-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89587-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89587-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89592-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89592-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89593-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89593-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89594-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89594-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89595-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89595-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89596-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89596-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89597-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89597-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89598-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89598-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89599-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89599-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89632-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89632-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89635-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89635-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89640-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89640-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89641-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89641-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89642-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89642-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89645-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89645-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89646-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89646-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89647-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89647-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89648-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89648-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89649-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89649-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89650-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89650-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89651-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89651-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89861-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89861-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +89996-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +89996-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90002-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90002-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90042-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90042-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90272-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90272-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90275-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90275-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90285-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90285-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90286-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90286-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90287-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90287-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90288-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90288-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90289-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90289-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90297-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90297-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90299-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90299-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90301-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90301-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90302-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90302-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90303-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90303-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90337-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90337-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90338-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90338-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90339-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90339-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90340-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90340-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90450-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90450-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90451-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90451-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90452-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90452-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90453-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90453-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90454-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90454-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90463-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90463-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90806-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90806-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90807-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90807-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90808-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90808-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90809-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90809-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +90810-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +90810-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91057-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91057-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91058-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91058-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91059-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91059-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91060-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91060-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91061-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91061-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91066-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91066-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91067-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91067-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91068-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91068-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91070-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91070-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91071-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91071-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91075-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91075-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91076-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91076-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91079-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91079-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91081-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91081-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91082-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91082-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91083-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91083-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91084-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91084-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91085-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91085-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91086-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91086-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91087-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91087-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91088-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91088-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91089-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91089-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91090-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91090-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91091-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91091-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91092-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91092-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91093-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91093-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91130-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91130-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91131-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91131-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91132-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91132-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91133-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91133-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91763-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91763-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91766-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91766-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91767-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91767-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91769-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91769-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91774-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91774-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91780-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91780-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91781-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91781-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91782-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91782-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91783-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91783-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91784-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91784-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91785-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91785-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91786-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91786-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91787-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91787-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91788-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91788-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91789-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91789-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91790-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91790-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91791-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91791-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91792-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91792-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91793-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91793-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91794-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91794-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91795-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91795-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91796-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91796-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91798-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91798-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91799-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91799-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91800-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91800-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91801-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91801-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91802-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91802-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91803-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91803-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91804-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91804-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91805-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91805-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91806-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91806-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91807-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91807-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91809-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91809-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91810-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91810-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91811-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91811-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91814-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91814-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91815-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91815-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91816-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91816-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91817-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91817-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91820-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91820-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91821-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91821-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91822-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91822-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91823-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91823-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91824-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91824-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91825-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91825-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91827-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91827-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91828-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91828-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91829-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91829-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91830-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91830-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91831-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91831-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91832-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91832-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91833-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91833-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91834-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91834-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91835-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91835-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91836-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91836-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91837-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91837-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91839-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91839-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91840-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91840-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91841-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91841-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91842-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91842-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91843-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91843-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91844-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91844-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91845-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91845-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91846-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91846-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91847-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91847-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91848-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91848-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91849-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91849-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91852-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91852-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91853-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91853-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91854-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91854-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91855-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91855-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91856-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91856-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91857-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91857-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91858-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91858-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91859-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91859-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91860-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91860-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91861-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91861-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91862-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91862-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91863-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91863-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91864-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91864-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91865-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91865-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91867-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91867-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91868-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91868-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91869-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91869-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91870-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91870-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91873-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91873-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91874-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91874-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +91875-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +91875-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92645-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92645-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92646-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92646-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92647-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92647-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92648-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92648-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92649-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92649-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92650-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92650-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92651-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92651-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92652-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92652-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92653-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92653-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92767-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92767-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92768-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92768-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92769-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92769-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92770-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92770-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92771-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92771-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92772-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92772-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92773-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92773-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92774-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92774-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92775-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92775-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92776-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92776-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92777-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92777-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92778-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92778-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92779-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92779-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92780-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92780-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92781-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92781-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92782-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92782-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92783-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92783-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92784-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92784-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92785-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92785-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92786-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92786-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92787-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92787-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92788-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92788-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92790-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92790-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92791-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92791-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92792-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92792-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92793-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92793-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92794-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92794-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92795-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92795-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92796-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92796-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92797-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92797-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92798-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92798-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92799-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92799-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92800-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92800-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92801-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92801-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92802-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92802-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92803-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92803-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92804-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92804-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92828-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92828-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92843-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92843-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92956-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92956-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92957-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92957-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92963-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92963-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92964-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92964-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92967-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92967-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92968-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92968-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92969-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92969-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92976-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92976-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92977-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92977-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92978-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92978-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92979-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92979-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92986-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92986-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +92987-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +92987-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93384-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93384-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93385-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93385-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93386-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93386-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93387-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93387-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93388-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93388-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93389-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93389-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93390-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93390-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93391-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93391-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93392-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93392-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93393-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93393-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93394-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93394-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93395-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93395-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93396-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93396-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93397-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93397-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93398-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93398-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93399-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93399-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93400-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93400-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93401-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93401-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93402-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93402-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93403-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93403-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93404-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93404-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93405-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93405-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93406-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93406-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93418-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93418-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93504-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93504-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93777-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93777-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93778-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93778-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93786-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93786-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93787-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93787-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +93875-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +93875-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94100-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94100-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94101-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94101-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94289-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94289-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94290-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94290-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94307-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94307-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94308-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94308-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94310-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94310-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94314-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94314-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94315-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94315-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94316-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94316-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94365-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94365-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94366-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94366-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94367-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94367-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94368-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94368-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94369-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94369-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94370-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94370-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94371-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94371-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94372-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94372-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94373-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94373-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94374-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94374-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94375-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94375-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94376-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94376-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94377-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94377-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94378-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94378-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94379-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94379-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94380-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94380-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94382-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94382-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94383-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94383-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94384-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94384-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94385-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94385-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94386-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94386-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94387-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94387-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94388-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94388-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94389-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94389-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94390-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94390-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94392-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94392-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94394-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94394-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94395-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94395-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94396-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94396-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94419-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94419-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94478-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94478-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94479-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94479-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94480-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94480-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94481-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94481-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94482-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94482-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94483-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94483-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94484-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94484-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94485-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94485-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94486-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94486-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94660-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94660-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94756-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94756-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94757-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94757-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +94758-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +94758-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95416-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95416-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95540-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95540-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95554-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95554-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95658-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95658-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95659-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95659-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95717-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95717-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95719-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95719-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95797-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95797-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95798-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95798-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95799-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95799-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95807-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95807-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +95809-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +95809-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96056-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96056-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96119-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96119-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96301-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96301-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96302-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96302-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96303-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96303-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96304-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96304-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96305-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96305-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96306-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96306-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96307-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96307-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96308-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96308-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96309-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96309-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96310-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96310-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96311-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96311-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96312-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96312-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96313-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96313-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96420-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96420-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96599-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96599-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96752-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96752-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96756-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96756-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96757-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96757-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +96829-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +96829-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97050-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97050-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97097-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97097-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97098-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97098-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97156-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97156-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97157-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97157-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97158-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97158-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97186-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97186-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97188-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97188-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97210-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97210-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97211-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97211-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97212-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97212-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97213-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97213-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97214-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97214-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97215-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97215-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97216-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97216-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97217-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97217-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97218-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97218-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97219-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97219-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97220-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97220-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97221-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97221-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97222-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97222-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97223-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97223-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97224-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97224-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97225-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97225-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97226-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97226-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97227-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97227-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97228-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97228-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97229-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97229-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97230-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97230-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97231-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97231-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97232-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97232-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97233-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97233-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97234-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97234-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97235-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97235-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97236-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97236-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97237-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97237-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97238-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97238-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97239-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97239-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97240-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97240-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97241-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97241-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97242-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97242-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97243-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97243-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97244-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97244-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97245-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97245-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97246-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97246-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97247-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97247-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97248-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97248-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97249-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97249-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97250-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97250-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97251-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97251-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97252-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97252-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97253-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97253-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97254-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97254-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97255-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97255-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97256-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97256-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97257-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97257-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97258-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97258-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97259-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97259-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97260-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97260-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97261-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97261-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97262-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97262-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97263-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97263-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97264-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97264-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97265-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97265-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97266-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97266-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97267-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97267-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97268-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97268-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97269-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97269-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97270-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97270-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97271-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97271-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97272-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97272-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97273-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97273-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97274-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97274-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97275-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97275-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97276-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97276-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97277-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97277-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97278-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97278-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97279-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97279-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97280-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97280-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97281-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97281-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97282-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97282-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97283-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97283-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97284-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97284-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97285-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97285-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97286-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97286-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97287-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97287-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97288-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97288-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97289-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97289-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97290-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97290-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97291-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97291-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97292-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97292-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97293-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97293-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97294-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97294-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97295-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97295-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97296-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97296-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97297-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97297-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97298-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97298-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97299-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97299-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97300-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97300-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97301-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97301-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97302-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97302-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97303-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97303-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97304-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97304-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97305-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97305-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97306-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97306-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97307-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97307-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97308-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97308-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97309-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97309-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97310-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97310-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97311-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97311-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97322-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97322-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97323-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97323-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97582-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97582-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97583-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97583-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97584-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97584-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97585-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97585-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97586-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97586-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97587-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97587-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97588-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97588-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97589-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97589-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97590-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97590-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97591-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97591-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97601-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97601-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97609-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97609-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97610-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97610-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97611-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97611-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97612-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97612-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97613-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97613-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97614-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97614-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97615-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97615-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97616-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97616-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97617-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97617-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97618-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97618-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97619-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97619-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97620-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97620-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97621-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97621-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97622-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97622-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97623-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97623-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97624-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97624-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97625-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97625-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97626-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97626-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97627-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97627-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97628-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97628-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97629-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97629-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97630-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97630-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97631-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97631-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97632-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97632-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97633-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97633-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97634-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97634-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97635-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97635-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97636-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97636-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97637-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97637-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97638-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97638-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97639-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97639-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97647-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97647-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97648-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97648-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97649-8;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97649-8;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97650-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97650-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +97936-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +97936-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +98022-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +98022-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +98027-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +98027-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +98414-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +98414-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +98849-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +98849-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +98959-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +98959-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99079-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99079-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99080-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99080-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99081-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99081-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99085-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99085-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99086-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99086-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99088-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99088-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99089-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99089-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99090-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99090-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99091-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99091-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99092-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99092-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99093-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99093-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99094-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99094-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99095-2;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99095-2;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99096-0;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99096-0;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99107-5;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99107-5;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99108-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99108-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99109-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99109-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99110-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99110-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99307-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99307-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99596-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99596-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99597-7;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99597-7;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99623-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99623-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99624-9;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99624-9;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99625-6;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99625-6;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99626-4;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99626-4;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99778-3;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99778-3;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +99779-1;LL744-4;Detected|Not det;LA11882-0;1;Detected;;; +99779-1;LL744-4;Detected|Not det;LA11883-8;2;Not detected;;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA9277-0;1;Family member;;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA9405-7;2;Bystander;;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33278-5;3;Healthcare Provider (non-911 Responder);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33279-3;4;First Responder (EMS);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33280-1;5;First Responder (Law Enforcement);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33281-9;6;First Responder (non-EMS Fire);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33282-7;7;EMS Responder (transport EMS);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA9277-0;1;Family member;;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA9405-7;2;Bystander;;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33278-5;3;Healthcare Provider (non-911 Responder);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33279-3;4;First Responder (EMS);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33280-1;5;First Responder (Law Enforcement);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33281-9;6;First Responder (non-EMS Fire);;; +100034-8;LL6214-2;NEMSIS_Provider of AED or CPR;LA33282-7;7;EMS Responder (transport EMS);;; +88102-9;LL6214-2;NEMSIS_Provider of AED or CPR;LA9277-0;1;Family member;;; +88102-9;LL6214-2;NEMSIS_Provider of AED or CPR;LA9405-7;2;Bystander;;; +88102-9;LL6214-2;NEMSIS_Provider of AED or CPR;LA33278-5;3;Healthcare Provider (non-911 Responder);;; +88102-9;LL6214-2;NEMSIS_Provider of AED or CPR;LA33279-3;4;First Responder (EMS);;; +88102-9;LL6214-2;NEMSIS_Provider of AED or CPR;LA33280-1;5;First Responder (Law Enforcement);;; +88102-9;LL6214-2;NEMSIS_Provider of AED or CPR;LA33281-9;6;First Responder (non-EMS Fire);;; +88102-9;LL6214-2;NEMSIS_Provider of AED or CPR;LA33282-7;7;EMS Responder (transport EMS);;; +88663-0;LL6214-2;NEMSIS_Provider of AED or CPR;LA9277-0;1;Family member;;; +88663-0;LL6214-2;NEMSIS_Provider of AED or CPR;LA9405-7;2;Bystander;;; +88663-0;LL6214-2;NEMSIS_Provider of AED or CPR;LA33278-5;3;Healthcare Provider (non-911 Responder);;; +88663-0;LL6214-2;NEMSIS_Provider of AED or CPR;LA33279-3;4;First Responder (EMS);;; +88663-0;LL6214-2;NEMSIS_Provider of AED or CPR;LA33280-1;5;First Responder (Law Enforcement);;; +88663-0;LL6214-2;NEMSIS_Provider of AED or CPR;LA33281-9;6;First Responder (non-EMS Fire);;; +88663-0;LL6214-2;NEMSIS_Provider of AED or CPR;LA33282-7;7;EMS Responder (transport EMS);;; +100035-5;LL6218-3;Chest exam finding location;LA33301-5;1;Left - Anterior;;; +100035-5;LL6218-3;Chest exam finding location;LA33300-7;2;Left - Posterior;;; +100035-5;LL6218-3;Chest exam finding location;LA33299-1;3;Right - Anterior;;; +100035-5;LL6218-3;Chest exam finding location;LA33295-9;4;Right - Posterior;;; +100035-5;LL6218-3;Chest exam finding location;LA33297-5;5;General - Anterior;;; +100035-5;LL6218-3;Chest exam finding location;LA33302-3;6;General - Posterior;;; +100035-5;LL6218-3;Chest exam finding location;LA33296-7;7;Left - Side;;; +100035-5;LL6218-3;Chest exam finding location;LA33298-3;8;Right - Side;;; +100036-3;LL6215-9;NEMSIS_Lung exam finding location;LA4585-1;1;Left;;; +100036-3;LL6215-9;NEMSIS_Lung exam finding location;LA4306-2;2;Right;;; +100036-3;LL6215-9;NEMSIS_Lung exam finding location;LA25377-5;3;Bilateral;;; +100037-1;LL6219-1;NEMSIS_Unit Disposition;LA33303-1;4;Patient contact made;;; +100037-1;LL6219-1;NEMSIS_Unit Disposition;LA33304-9;5;Cancelled on scene;;; +100037-1;LL6219-1;NEMSIS_Unit Disposition;LA33305-6;6;Cancelled prior to arrival at scene;;; +100037-1;LL6219-1;NEMSIS_Unit Disposition;LA33306-4;7;No patient contact;;; +100037-1;LL6219-1;NEMSIS_Unit Disposition;LA33307-2;8;No patient found;;; +100037-1;LL6219-1;NEMSIS_Unit Disposition;LA33308-0;9;Non-patient incident (not otherwise listed);;; +100038-9;LL6220-9;NEMSIS_Patient evaluation disposition;LA33309-8;1;Patient evaluated and care provided;;; +100038-9;LL6220-9;NEMSIS_Patient evaluation disposition;LA33310-6;2;Patient evaluated and refused care;;; +100038-9;LL6220-9;NEMSIS_Patient evaluation disposition;LA33311-4;3;Patient evaluated, no care required;;; +100038-9;LL6220-9;NEMSIS_Patient evaluation disposition;LA33312-2;4;Patient refused evaluation/care;;; +100038-9;LL6220-9;NEMSIS_Patient evaluation disposition;LA33313-0;5;Patient support services provided;;; +100039-7;LL6221-7;NEMSIS_Crew disposition for patient care;LA33314-8;1;Initiated and continued primary care;;; +100039-7;LL6221-7;NEMSIS_Crew disposition for patient care;LA33315-5;2;Initiated primary care and transferred to another EMS crew;;; +100039-7;LL6221-7;NEMSIS_Crew disposition for patient care;LA33316-3;3;Provided care supporting primary EMS crew;;; +100039-7;LL6221-7;NEMSIS_Crew disposition for patient care;LA33317-1;4;Assumed primary care from another EMS crew;;; +100039-7;LL6221-7;NEMSIS_Crew disposition for patient care;LA33318-9;5;Incident support services provided (including standby);;; +100039-7;LL6221-7;NEMSIS_Crew disposition for patient care;LA33319-7;6;Back in service, no care/support services required;;; +100039-7;LL6221-7;NEMSIS_Crew disposition for patient care;LA33320-5;7;Back in service, care/support services refused;;; +100040-5;LL6222-5;NEMSIS_Patient transport disposition;LA33321-3;1;Transport by this EMS unit (this crew only);;; +100040-5;LL6222-5;NEMSIS_Patient transport disposition;LA33322-1;2;Transport by this EMS unit, with a member of another crew;;; +100040-5;LL6222-5;NEMSIS_Patient transport disposition;LA33323-9;3;Transport by another EMS unit;;; +100040-5;LL6222-5;NEMSIS_Patient transport disposition;LA33324-7;4;Transport by another EMS unit, with a member of this crew;;; +100040-5;LL6222-5;NEMSIS_Patient transport disposition;LA29248-4;5;Patient refused transport;;; +100040-5;LL6222-5;NEMSIS_Patient transport disposition;LA33326-2;6;Non-patient transport (not otherwise listed);;; +100040-5;LL6222-5;NEMSIS_Patient transport disposition;LA33327-0;7;No transport;;; +100041-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100041-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100042-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100042-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100043-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100043-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100044-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100044-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100045-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100045-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100046-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100046-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100047-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100047-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100048-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100048-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100049-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100049-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100050-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100050-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100051-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100051-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100052-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100052-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100053-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100053-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100054-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100054-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100055-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100055-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100056-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100056-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100057-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100057-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100058-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100058-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100059-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100059-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100060-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100060-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100061-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100061-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100351-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100351-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100352-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100352-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100383-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100383-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100654-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100654-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100696-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100696-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100845-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100845-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100865-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100865-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100872-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100872-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100979-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100979-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101060-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101060-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101061-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101061-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101062-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101062-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101063-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101063-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101064-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101064-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101065-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101065-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101066-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101066-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101067-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101067-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101068-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101068-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101069-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101069-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101070-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101070-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101071-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101071-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101072-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101072-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101073-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101073-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101074-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101074-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101075-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101075-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101076-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101076-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101077-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101077-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101078-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101078-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101079-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101079-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101080-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101080-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101081-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101081-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101082-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101082-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101083-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101083-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101084-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101084-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101085-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101085-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101086-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101086-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101087-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101087-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101088-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101088-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101089-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101089-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101090-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101090-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101091-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101091-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101092-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101092-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101093-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101093-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101094-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101094-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101095-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101095-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101096-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101096-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101097-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101097-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101098-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101098-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101099-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101099-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101100-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101100-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101101-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101101-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101102-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101102-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101103-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101103-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101116-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101116-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101137-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101137-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101138-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101138-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101139-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101139-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101156-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101156-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101158-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101158-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101160-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101160-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101162-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101162-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101165-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101165-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101168-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101168-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101180-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101180-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101183-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101183-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101186-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101186-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101189-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101189-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101192-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101192-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101226-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101226-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101227-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101227-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101228-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101228-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101229-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101229-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101230-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101230-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101231-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101231-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101232-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101232-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101233-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101233-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101234-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101234-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101235-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101235-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101236-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101236-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101237-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101237-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101240-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101240-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101241-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101241-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101242-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101242-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101243-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101243-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101244-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101244-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101245-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101245-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101246-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101246-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101247-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101247-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101251-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101251-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101284-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101284-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101286-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101286-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101287-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101287-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101288-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101288-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101289-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101289-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101290-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101290-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101291-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101291-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101292-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101292-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101293-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101293-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101294-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101294-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101295-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101295-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101296-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101296-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101297-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101297-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101298-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101298-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101299-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101299-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101300-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101300-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101336-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101336-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101448-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101448-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101449-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101449-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101450-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101450-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101451-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101451-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101452-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101452-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101460-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101460-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101461-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101461-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101462-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101462-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101463-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101463-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101464-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101464-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101465-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101465-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101466-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101466-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101467-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101467-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101472-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101472-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101508-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101508-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101517-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101517-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101518-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101518-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +10331-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +10331-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +10675-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +10675-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13946-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13946-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13947-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13947-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13948-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13948-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13949-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13949-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13950-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13950-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13951-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13951-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13952-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13952-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13953-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13953-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13954-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13954-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13955-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13955-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13956-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13956-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13957-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13957-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13958-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13958-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13960-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13960-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +13961-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +13961-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +14019-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +14019-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +14020-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +14020-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +14021-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +14021-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +14027-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +14027-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15130-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15130-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15131-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15131-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15132-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15132-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15133-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15133-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15134-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15134-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15135-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15135-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15136-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15136-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15137-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15137-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15138-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15138-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15139-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15139-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15140-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15140-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15141-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15141-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15142-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15142-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15143-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15143-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15144-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15144-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15145-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15145-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15213-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15213-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15214-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15214-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15215-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15215-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15216-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15216-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15217-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15217-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15218-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15218-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15219-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15219-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15220-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15220-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15221-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15221-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15222-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15222-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15223-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15223-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15224-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15224-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15225-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15225-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15226-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15226-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15227-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15227-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15228-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15228-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15229-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15229-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15230-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15230-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15231-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15231-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15232-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15232-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15233-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15233-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15234-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15234-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15235-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15235-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15236-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15236-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15237-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15237-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15238-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15238-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15239-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15239-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15240-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15240-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15241-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15241-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15242-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15242-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15243-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15243-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15244-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15244-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15245-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15245-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15246-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15246-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15247-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15247-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15248-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15248-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15249-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15249-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15250-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15250-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15251-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15251-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15252-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15252-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15253-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15253-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15254-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15254-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15255-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15255-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15256-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15256-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15257-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15257-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15258-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15258-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15259-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15259-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15260-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15260-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15261-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15261-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15262-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15262-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15263-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15263-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15264-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15264-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15265-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15265-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15266-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15266-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15267-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15267-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15268-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15268-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15269-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15269-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15270-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15270-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15271-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15271-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15272-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15272-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15273-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15273-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15274-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15274-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15275-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15275-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15276-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15276-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15433-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15433-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15434-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15434-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15435-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15435-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15437-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15437-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15443-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15443-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15444-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15444-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15451-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15451-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15452-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15452-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15455-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15455-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15456-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15456-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15460-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15460-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15461-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15461-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15464-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15464-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15465-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15465-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15466-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15466-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15468-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15468-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15472-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15472-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15474-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15474-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15482-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15482-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15486-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15486-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15490-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15490-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15491-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15491-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15495-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15495-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15496-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15496-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15497-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15497-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15498-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15498-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15500-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15500-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15501-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15501-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15502-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15502-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15503-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15503-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15504-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15504-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15505-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15505-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +19110-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +19110-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +19129-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +19129-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +19133-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +19133-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +19134-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +19134-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +19162-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +19162-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +19259-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +19259-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +19260-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +19260-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +21191-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +21191-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +21262-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +21262-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +21415-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +21415-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +21424-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +21424-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +21436-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +21436-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +21440-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +21440-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +21441-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +21441-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +22239-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +22239-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +22239-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +22239-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +24102-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +24102-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +24385-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +24385-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +24386-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +24386-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +24387-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +24387-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +24388-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +24388-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +24396-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +24396-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +24397-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +24397-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +27817-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +27817-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +28008-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +28008-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29496-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29496-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29497-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29497-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29498-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29498-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29566-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29566-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29567-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29567-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29569-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29569-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29641-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29641-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29642-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29642-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29645-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29645-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29646-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29646-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29647-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29647-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29649-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29649-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29651-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29651-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29657-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29657-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29658-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29658-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29659-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29659-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29660-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29660-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29661-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29661-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29662-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29662-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29663-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29663-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29664-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29664-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29666-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29666-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29667-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29667-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29669-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29669-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29671-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29671-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29672-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29672-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29673-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29673-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29674-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29674-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29675-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29675-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29676-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29676-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29677-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29677-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29681-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29681-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29683-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29683-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29685-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29685-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29687-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29687-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29689-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29689-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29691-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29691-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29693-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29693-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29694-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29694-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29695-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29695-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29696-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29696-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29697-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29697-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29698-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29698-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29699-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29699-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29700-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29700-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29701-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29701-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29702-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29702-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29704-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29704-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29706-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29706-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29708-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29708-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29710-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29710-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29712-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29712-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29714-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29714-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29716-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29716-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29718-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29718-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29720-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29720-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29722-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29722-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29724-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29724-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29725-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29725-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29726-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29726-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29727-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29727-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29728-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29728-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29729-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29729-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29730-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29730-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29731-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29731-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29732-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29732-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29733-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29733-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29734-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29734-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29735-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29735-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29736-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29736-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29738-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29738-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29739-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29739-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29740-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29740-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29741-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29741-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29778-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29778-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29780-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29780-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29860-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29860-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29888-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29888-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +29890-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +29890-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30086-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30086-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30094-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30094-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30095-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30095-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30096-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30096-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30097-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30097-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30098-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30098-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30106-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30106-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30176-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30176-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30324-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30324-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30326-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30326-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30339-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30339-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30340-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30340-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30360-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30360-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30470-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30470-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30500-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30500-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30535-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30535-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30538-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30538-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30539-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30539-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30545-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30545-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30546-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30546-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30547-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30547-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30548-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30548-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30555-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30555-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30910-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30910-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +31023-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +31023-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +31152-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +31152-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +31153-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +31153-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +31154-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +31154-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +31185-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +31185-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +31186-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +31186-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +3206-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +3206-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32370-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32370-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32371-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32371-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32571-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32571-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32575-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32575-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32576-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32576-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32577-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32577-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32578-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32578-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32628-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32628-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32644-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32644-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32645-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32645-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32819-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32819-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32854-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32854-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32999-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +32999-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33000-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33000-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33001-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33001-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33008-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33008-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33052-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33052-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33204-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33204-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33267-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33267-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33272-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33272-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33461-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33461-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33462-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33462-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33468-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33468-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33469-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33469-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33549-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33549-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33572-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33572-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33594-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33594-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33615-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33615-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33616-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33616-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33660-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33660-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33676-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33676-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33677-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33677-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33678-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33678-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33679-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33679-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33680-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33680-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33681-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33681-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33682-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33682-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33685-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33685-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33686-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33686-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33687-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33687-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33688-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33688-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33689-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33689-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33691-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33691-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33692-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33692-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33693-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33693-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33694-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33694-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33695-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33695-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33696-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33696-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33697-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33697-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33698-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33698-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33701-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33701-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33702-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33702-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33703-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33703-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33704-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33704-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33705-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33705-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33706-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33706-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33708-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33708-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33709-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33709-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33710-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33710-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33711-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33711-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33712-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33712-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33713-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33713-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33714-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33714-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33715-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33715-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33766-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33766-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33779-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33779-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33896-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33896-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33897-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33897-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33921-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33921-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33923-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33923-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33940-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33940-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33941-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33941-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33942-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33942-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33943-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33943-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33981-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33981-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34142-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34142-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34150-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34150-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34159-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34159-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34485-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34485-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34486-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34486-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34568-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34568-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34586-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34586-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34591-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34591-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34664-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34664-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34743-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34743-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +35134-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +35134-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +35471-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +35471-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +35503-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +35503-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +37982-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +37982-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +38270-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +38270-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +38271-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +38271-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +38272-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +38272-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +38372-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +38372-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +38440-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +38440-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +38553-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +38553-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39019-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39019-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39311-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39311-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39312-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39312-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39313-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39313-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39314-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39314-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39315-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39315-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39316-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39316-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39317-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39317-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39318-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39318-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39319-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39319-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39320-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39320-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39556-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39556-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40453-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40453-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40454-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40454-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40466-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40466-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40798-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40798-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40799-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40799-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40800-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40800-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40801-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40801-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40802-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40802-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40803-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40803-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40804-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40804-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40807-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40807-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40808-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40808-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40863-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40863-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +40958-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +40958-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41412-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41412-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41416-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41416-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41418-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41418-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41421-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41421-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41422-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41422-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41423-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41423-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41424-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41424-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41427-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41427-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41429-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41429-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41430-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41430-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41431-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41431-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41432-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41432-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41433-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41433-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41434-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41434-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41435-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41435-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41436-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41436-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41437-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41437-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41438-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41438-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41439-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41439-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41440-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41440-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41441-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41441-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41442-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41442-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41443-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41443-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41444-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41444-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41447-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41447-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41448-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41448-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41449-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41449-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41450-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41450-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41459-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41459-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41462-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41462-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41463-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41463-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41476-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41476-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41621-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41621-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41623-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41623-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41624-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41624-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41626-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41626-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41627-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41627-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41628-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41628-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41630-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41630-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41631-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41631-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41632-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41632-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41633-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41633-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41634-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41634-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41635-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41635-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41636-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41636-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41637-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41637-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41638-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41638-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41639-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41639-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41640-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41640-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41641-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41641-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41642-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41642-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41643-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41643-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41853-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41853-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41854-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41854-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41855-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41855-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41856-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41856-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41857-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41857-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41876-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41876-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42256-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42256-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42257-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42257-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42258-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42258-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42259-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42259-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42358-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42358-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42481-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42481-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42630-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42630-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42641-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42641-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42662-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42662-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +42721-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +42721-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +43335-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +43335-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +43376-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +43376-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +43377-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +43377-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +43799-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +43799-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44099-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44099-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44269-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44269-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44270-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44270-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44800-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44800-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44961-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44961-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44962-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44962-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +45335-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +45335-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +46154-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +46154-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +46722-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +46722-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +46987-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +46987-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47008-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47008-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47363-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47363-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47387-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47387-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47430-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47430-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47430-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47430-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48387-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48387-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48501-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48501-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48502-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48502-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48503-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48503-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48504-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48504-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48505-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48505-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48506-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48506-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48813-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48813-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48814-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48814-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48981-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48981-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48982-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48982-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49000-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49000-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49055-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49055-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49525-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49525-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49529-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49529-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49533-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49533-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49534-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49534-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49598-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49598-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49617-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49617-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49891-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49891-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49896-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49896-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49963-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49963-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50005-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50005-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50006-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50006-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50022-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50022-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50313-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50313-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50343-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50343-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50387-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50387-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50388-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50388-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50558-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50558-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50637-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50637-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50666-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50666-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50679-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50679-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50687-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50687-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50689-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50689-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50701-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50701-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50956-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50956-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50960-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50960-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51523-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51523-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51525-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51525-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51526-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51526-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51527-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51527-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51528-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51528-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51529-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51529-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51530-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51530-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51531-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51531-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51532-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51532-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51533-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51533-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51534-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51534-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51535-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51535-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51536-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51536-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51538-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51538-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51539-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51539-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51540-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51540-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51541-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51541-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51542-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51542-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51543-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51543-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51544-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51544-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51545-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51545-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51546-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51546-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51547-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51547-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51548-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51548-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51549-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51549-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51587-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51587-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51589-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51589-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51640-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51640-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51645-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51645-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51858-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51858-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51859-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51859-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51860-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51860-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51861-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51861-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51862-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51862-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51866-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51866-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51976-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51976-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +52107-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +52107-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +52750-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +52750-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +52821-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +52821-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +52822-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +52822-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +52823-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +52823-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +52824-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +52824-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +52825-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +52825-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53004-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53004-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53005-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53005-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53007-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53007-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53009-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53009-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53010-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53010-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53013-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53013-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53016-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53016-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53018-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53018-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53020-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53020-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53024-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53024-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53028-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53028-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53029-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53029-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53030-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53030-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53032-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53032-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53248-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53248-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53260-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53260-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53618-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53618-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53619-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53619-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53632-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53632-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53633-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53633-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53637-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53637-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53638-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53638-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53639-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53639-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53641-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53641-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53787-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53787-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53942-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53942-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53943-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53943-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53956-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53956-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53963-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53963-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53965-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53965-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53969-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53969-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53975-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53975-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53977-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53977-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53979-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53979-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53981-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53981-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53984-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53984-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53986-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53986-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53988-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53988-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53990-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53990-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53992-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53992-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53994-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53994-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53996-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53996-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53997-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53997-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53999-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53999-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54007-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54007-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54009-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54009-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54013-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54013-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54015-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54015-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54016-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54016-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54017-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54017-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54018-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54018-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54019-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54019-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54020-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54020-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54023-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54023-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54024-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54024-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54025-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54025-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54027-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54027-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54030-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54030-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54031-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54031-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54032-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54032-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54067-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54067-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54149-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54149-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54156-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54156-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54158-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54158-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +54160-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +54160-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55095-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55095-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55097-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55097-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55098-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55098-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55099-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55099-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55100-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55100-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55296-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55296-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55345-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55345-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +56129-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +56129-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +56131-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +56131-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +56141-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +56141-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +56142-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +56142-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +57287-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +57287-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +57760-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +57760-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +57901-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +57901-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +57945-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +57945-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +57979-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +57979-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +5802-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +5802-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +58714-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +58714-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59262-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59262-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59263-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59263-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59264-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59264-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59585-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59585-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59586-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59586-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59838-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59838-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59839-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59839-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +59844-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +59844-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61029-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61029-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61030-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61030-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61031-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61031-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61032-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61032-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61033-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61033-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61034-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61034-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61035-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61035-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61036-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61036-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61037-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61037-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61038-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61038-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61039-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61039-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61040-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61040-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61041-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61041-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61042-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61042-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61043-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61043-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61044-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61044-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61045-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61045-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61046-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61046-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61047-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61047-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61048-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61048-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61049-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61049-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61050-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61050-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61051-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61051-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61052-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61052-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61053-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61053-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61054-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61054-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61055-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61055-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61056-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61056-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61057-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61057-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61058-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61058-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61059-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61059-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61060-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61060-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61061-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61061-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61062-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61062-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61063-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61063-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61064-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61064-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61065-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61065-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61066-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61066-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61067-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61067-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61070-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61070-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61071-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61071-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61072-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61072-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61073-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61073-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61074-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61074-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61075-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61075-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61076-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61076-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61077-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61077-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61078-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61078-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61079-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61079-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61080-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61080-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61081-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61081-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61082-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61082-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61083-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61083-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61084-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61084-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61085-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61085-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61086-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61086-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61087-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61087-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61088-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61088-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61089-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61089-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61090-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61090-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61091-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61091-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61092-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61092-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61093-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61093-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61094-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61094-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61095-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61095-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61096-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61096-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61098-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61098-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +61197-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +61197-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +62859-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +62859-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +62860-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +62860-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +62861-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +62861-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63376-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +63376-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63379-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +63379-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63420-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +63420-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63422-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +63422-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +64412-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +64412-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65318-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65318-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65319-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65319-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65320-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65320-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65321-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65321-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65322-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65322-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65323-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65323-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65324-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65324-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65325-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65325-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65326-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65326-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65327-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65327-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65328-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65328-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65329-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65329-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65330-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65330-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65331-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65331-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65332-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65332-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65333-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65333-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65334-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65334-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65335-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65335-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65336-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65336-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65337-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65337-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65338-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65338-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65339-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65339-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +6565-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +6565-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65762-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65762-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65763-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65763-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +66453-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66453-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +66491-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66491-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +66492-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66492-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +66563-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66563-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +66881-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66881-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +66882-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66882-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67805-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67805-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67806-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67806-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67807-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67807-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67808-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67808-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67809-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67809-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67810-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67810-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67811-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67811-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67812-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67812-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68439-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +68439-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68460-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +68460-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68466-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +68466-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68546-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +68546-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68547-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +68547-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68549-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +68549-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68960-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +68960-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69002-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69002-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69030-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69030-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69031-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69031-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69032-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69032-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69356-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69356-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69358-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69358-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69362-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69362-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69366-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69366-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69367-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69367-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69368-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69368-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69556-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69556-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69557-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69557-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69558-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69558-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69559-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69559-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69562-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69562-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69563-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69563-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69572-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69572-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69798-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69798-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69933-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69933-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69934-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69934-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69935-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69935-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69936-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69936-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69937-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69937-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69938-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69938-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69939-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69939-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69945-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69945-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69949-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69949-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69952-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69952-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69953-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69953-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69954-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69954-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69955-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69955-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69956-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69956-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69957-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69957-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70015-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70015-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70016-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70016-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70018-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70018-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70019-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70019-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70020-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70020-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70021-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70021-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70022-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70022-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70023-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70023-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70024-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70024-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70025-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70025-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70026-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70026-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70027-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70027-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70061-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70061-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70065-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70065-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70178-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70178-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70242-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70242-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70252-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70252-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70275-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70275-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70276-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70276-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70277-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70277-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70278-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70278-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70279-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70279-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70280-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70280-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70281-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70281-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70282-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70282-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70283-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70283-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70284-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70284-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70285-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70285-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70286-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70286-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70287-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70287-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70288-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70288-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70289-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70289-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70291-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70291-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70292-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70292-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70293-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70293-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70295-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70295-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70296-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70296-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70568-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70568-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70665-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70665-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70666-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70666-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70667-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70667-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70671-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70671-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70850-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70850-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70851-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70851-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70852-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70852-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70853-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70853-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70854-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70854-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70855-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70855-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70857-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70857-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70858-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70858-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70859-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70859-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70860-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70860-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70861-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70861-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70862-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70862-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70863-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70863-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70908-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70908-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70909-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70909-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70910-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70910-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70911-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70911-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70970-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70970-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71429-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71429-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71430-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71430-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71699-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71699-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71707-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71707-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71708-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71708-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71712-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71712-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71714-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71714-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71715-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71715-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71762-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71762-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71765-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71765-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71768-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71768-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71769-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71769-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71770-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71770-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71771-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71771-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71778-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71778-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71780-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71780-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71781-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71781-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71782-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71782-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72321-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72321-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72322-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72322-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72323-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72323-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72328-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72328-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72333-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72333-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72379-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72379-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72383-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72383-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72384-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72384-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72386-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72386-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72387-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72387-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72389-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72389-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72390-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72390-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72391-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72391-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72400-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72400-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72401-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72401-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72402-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72402-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72407-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72407-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72451-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72451-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72456-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72456-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72457-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72457-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72458-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72458-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72459-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72459-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72460-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72460-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72461-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72461-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72462-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72462-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72463-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72463-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72464-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72464-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72465-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72465-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72466-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72466-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72467-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72467-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72468-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72468-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72469-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72469-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72470-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72470-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72471-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72471-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72472-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72472-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72473-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72473-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72474-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72474-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72475-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72475-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72485-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72485-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72495-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72495-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72520-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72520-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72521-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72521-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72522-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72522-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72609-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72609-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72611-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72611-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72612-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72612-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72614-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72614-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72615-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72615-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72616-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72616-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72617-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72617-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72618-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72618-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72620-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72620-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72622-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72622-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72626-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72626-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72627-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72627-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72628-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72628-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72629-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72629-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72630-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72630-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72631-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72631-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72632-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72632-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72633-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72633-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72634-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72634-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72885-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72885-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72887-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72887-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72891-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72891-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72920-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72920-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72929-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72929-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72930-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72930-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72931-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72931-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72932-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72932-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72933-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72933-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72934-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72934-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72935-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72935-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72936-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72936-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72937-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72937-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72938-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72938-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72939-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72939-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72940-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72940-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72941-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72941-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72942-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72942-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72943-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72943-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72944-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72944-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72945-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72945-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72946-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72946-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72947-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72947-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72948-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72948-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72949-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72949-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72950-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72950-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72951-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72951-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72952-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72952-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72953-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72953-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72954-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72954-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72955-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72955-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72956-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72956-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72957-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72957-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72958-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72958-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72959-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72959-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72960-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72960-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72961-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72961-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72962-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72962-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72963-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72963-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72964-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72964-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72965-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72965-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72966-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72966-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72967-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72967-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72968-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72968-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72969-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72969-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72970-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72970-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72971-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72971-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72972-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72972-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72973-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72973-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72974-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72974-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72975-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72975-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72976-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72976-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72977-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72977-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72978-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72978-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72979-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72979-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72980-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72980-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72981-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72981-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72982-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72982-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72983-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72983-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72984-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72984-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72985-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72985-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72986-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72986-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72987-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72987-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72988-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72988-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72989-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72989-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72990-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72990-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72991-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72991-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72992-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72992-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72993-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72993-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72994-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72994-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72995-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72995-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72996-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72996-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72997-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72997-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72998-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72998-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72999-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72999-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73000-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73000-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73001-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73001-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73002-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73002-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73003-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73003-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73004-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73004-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73005-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73005-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73006-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73006-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73007-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73007-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73008-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73008-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73009-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73009-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73010-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73010-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73011-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73011-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73012-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73012-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73013-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73013-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73014-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73014-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73015-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73015-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73016-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73016-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73017-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73017-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73018-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73018-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73019-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73019-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73020-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73020-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73021-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73021-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73022-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73022-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73023-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73023-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73024-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73024-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73025-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73025-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73026-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73026-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73027-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73027-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73028-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73028-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73029-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73029-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73030-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73030-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73031-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73031-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73032-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73032-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73033-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73033-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73034-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73034-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73035-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73035-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73036-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73036-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73037-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73037-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73038-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73038-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73039-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73039-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73040-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73040-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73041-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73041-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73042-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73042-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73043-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73043-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73044-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73044-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73045-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73045-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73046-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73046-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73047-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73047-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73048-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73048-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73049-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73049-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73050-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73050-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73051-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73051-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73052-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73052-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73053-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73053-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73054-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73054-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73055-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73055-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73056-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73056-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73057-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73057-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73058-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73058-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73059-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73059-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73060-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73060-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73061-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73061-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73062-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73062-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73063-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73063-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73064-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73064-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73065-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73065-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73066-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73066-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73067-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73067-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73068-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73068-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73069-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73069-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73070-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73070-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73071-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73071-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73072-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73072-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73073-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73073-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73074-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73074-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73076-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73076-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73077-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73077-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73078-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73078-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73079-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73079-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73080-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73080-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73081-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73081-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73082-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73082-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73083-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73083-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73084-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73084-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73085-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73085-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73086-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73086-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73087-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73087-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73088-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73088-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73089-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73089-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73090-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73090-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73091-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73091-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73092-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73092-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73093-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73093-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73094-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73094-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73095-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73095-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73096-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73096-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73097-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73097-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73098-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73098-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73099-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73099-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73100-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73100-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73101-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73101-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73102-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73102-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73103-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73103-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73104-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73104-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73105-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73105-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73106-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73106-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73107-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73107-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73108-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73108-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73109-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73109-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73110-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73110-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73111-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73111-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73112-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73112-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73113-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73113-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73114-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73114-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73115-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73115-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73116-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73116-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73117-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73117-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73118-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73118-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73119-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73119-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73120-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73120-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73121-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73121-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73122-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73122-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73123-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73123-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73124-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73124-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73125-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73125-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73126-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73126-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73127-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73127-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73128-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73128-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73129-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73129-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73130-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73130-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73131-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73131-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73132-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73132-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73133-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73133-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73134-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73134-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73135-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73135-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73136-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73136-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73137-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73137-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73138-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73138-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73139-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73139-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73140-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73140-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73141-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73141-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73142-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73142-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73143-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73143-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73144-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73144-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73145-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73145-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73146-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73146-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73147-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73147-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73148-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73148-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73149-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73149-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73150-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73150-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73151-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73151-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73152-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73152-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73153-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73153-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73154-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73154-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73155-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73155-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73156-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73156-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73157-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73157-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73158-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73158-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73159-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73159-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73160-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73160-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73161-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73161-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73162-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73162-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73163-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73163-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73164-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73164-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73165-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73165-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73166-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73166-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73167-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73167-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73168-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73168-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73169-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73169-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73170-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73170-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73171-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73171-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73172-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73172-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73173-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73173-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73174-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73174-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73175-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73175-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73176-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73176-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73177-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73177-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73178-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73178-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73179-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73179-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73180-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73180-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73181-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73181-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73182-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73182-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73183-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73183-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73184-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73184-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73185-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73185-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73186-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73186-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73187-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73187-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73188-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73188-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73189-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73189-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73190-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73190-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73191-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73191-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73192-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73192-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73193-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73193-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73194-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73194-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73195-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73195-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73196-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73196-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73197-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73197-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73198-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73198-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73199-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73199-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73200-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73200-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73201-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73201-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73202-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73202-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73203-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73203-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73204-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73204-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73205-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73205-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73206-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73206-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73207-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73207-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73208-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73208-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73209-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73209-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73210-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73210-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73211-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73211-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73212-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73212-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73213-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73213-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73214-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73214-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73215-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73215-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73216-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73216-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73217-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73217-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73218-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73218-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73219-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73219-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73220-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73220-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73221-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73221-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73222-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73222-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73223-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73223-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73224-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73224-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73225-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73225-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73226-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73226-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73227-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73227-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73228-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73228-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73229-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73229-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73230-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73230-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73231-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73231-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73232-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73232-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73233-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73233-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73234-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73234-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73235-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73235-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73236-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73236-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73237-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73237-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73238-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73238-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73239-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73239-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73240-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73240-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73241-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73241-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73242-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73242-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73243-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73243-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73244-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73244-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73245-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73245-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73246-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73246-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73247-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73247-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73248-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73248-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73249-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73249-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73250-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73250-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73251-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73251-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73252-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73252-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73253-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73253-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73254-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73254-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73255-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73255-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73256-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73256-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73257-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73257-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73258-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73258-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73259-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73259-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73260-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73260-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73261-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73261-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73262-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73262-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73263-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73263-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73264-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73264-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73265-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73265-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73266-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73266-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73267-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73267-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73268-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73268-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73269-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73269-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73270-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73270-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73271-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73271-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73272-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73272-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73273-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73273-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73274-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73274-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73275-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73275-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73276-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73276-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73277-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73277-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73278-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73278-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73279-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73279-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73280-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73280-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73281-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73281-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73282-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73282-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73283-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73283-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73284-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73284-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73285-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73285-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73286-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73286-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73287-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73287-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73288-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73288-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73289-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73289-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73290-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73290-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73291-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73291-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73292-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73292-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73293-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73293-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73294-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73294-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73295-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73295-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73296-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73296-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73297-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73297-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73298-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73298-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73299-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73299-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73300-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73300-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73301-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73301-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73302-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73302-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73303-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73303-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73304-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73304-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73305-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73305-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73306-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73306-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73307-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73307-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73308-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73308-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73309-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73309-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73310-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73310-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73311-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73311-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73312-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73312-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73313-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73313-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73314-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73314-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73315-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73315-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73316-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73316-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73317-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73317-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73318-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73318-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73319-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73319-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73320-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73320-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73321-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73321-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73322-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73322-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73323-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73323-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73324-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73324-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73325-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73325-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73326-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73326-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73327-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73327-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73328-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73328-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73329-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73329-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73330-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73330-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73331-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73331-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73332-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73332-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73333-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73333-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73334-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73334-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73335-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73335-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73336-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73336-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73337-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73337-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73338-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73338-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73339-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73339-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73340-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73340-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73341-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73341-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73342-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73342-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73343-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73343-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73344-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73344-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73345-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73345-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73346-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73346-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73347-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73347-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73348-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73348-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73349-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73349-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73350-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73350-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73351-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73351-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73352-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73352-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73353-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73353-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73354-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73354-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73355-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73355-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73356-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73356-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73357-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73357-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73358-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73358-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73359-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73359-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73360-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73360-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73361-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73361-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73362-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73362-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73363-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73363-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73364-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73364-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73365-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73365-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73366-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73366-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73367-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73367-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73368-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73368-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73369-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73369-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73370-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73370-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73371-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73371-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73372-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73372-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73373-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73373-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73374-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73374-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73375-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73375-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73376-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73376-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73377-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73377-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73378-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73378-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73379-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73379-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73380-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73380-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73381-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73381-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73382-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73382-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73383-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73383-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73384-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73384-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73385-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73385-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73386-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73386-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73387-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73387-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73388-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73388-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73389-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73389-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73390-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73390-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73391-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73391-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73392-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73392-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73393-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73393-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73394-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73394-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73395-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73395-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73396-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73396-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73397-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73397-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73398-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73398-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73399-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73399-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73400-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73400-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73401-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73401-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73402-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73402-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73403-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73403-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73404-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73404-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73405-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73405-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73406-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73406-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73407-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73407-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73408-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73408-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73409-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73409-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73410-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73410-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73411-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73411-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73412-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73412-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73413-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73413-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73414-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73414-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73415-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73415-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73416-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73416-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73417-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73417-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73418-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73418-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73419-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73419-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73420-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73420-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73421-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73421-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73422-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73422-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73423-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73423-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73424-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73424-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73425-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73425-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73426-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73426-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73427-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73427-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73428-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73428-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73429-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73429-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73430-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73430-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73431-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73431-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73432-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73432-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73433-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73433-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73434-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73434-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73435-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73435-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73436-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73436-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73437-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73437-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73438-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73438-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73439-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73439-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73440-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73440-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73441-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73441-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73442-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73442-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73443-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73443-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73444-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73444-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73445-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73445-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73446-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73446-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73447-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73447-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73448-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73448-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73449-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73449-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73450-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73450-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73451-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73451-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73452-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73452-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73453-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73453-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73454-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73454-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73455-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73455-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73456-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73456-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73457-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73457-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73458-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73458-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73459-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73459-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73460-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73460-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73461-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73461-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73462-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73462-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73463-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73463-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73464-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73464-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73465-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73465-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73466-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73466-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73467-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73467-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73468-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73468-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73469-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73469-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73470-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73470-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73471-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73471-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73472-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73472-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73473-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73473-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73474-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73474-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73475-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73475-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73476-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73476-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73477-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73477-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73478-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73478-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73479-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73479-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73480-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73480-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73481-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73481-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73482-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73482-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73483-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73483-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73484-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73484-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73485-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73485-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73486-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73486-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73487-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73487-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73488-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73488-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73489-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73489-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73490-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73490-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73491-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73491-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73492-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73492-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73493-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73493-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73494-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73494-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73495-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73495-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73496-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73496-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73497-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73497-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73498-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73498-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73499-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73499-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73500-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73500-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73501-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73501-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73502-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73502-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73503-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73503-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73504-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73504-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73505-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73505-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73506-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73506-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73507-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73507-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73508-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73508-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73509-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73509-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73510-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73510-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73511-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73511-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73512-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73512-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73513-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73513-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73514-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73514-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73515-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73515-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73516-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73516-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73517-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73517-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73518-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73518-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73519-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73519-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73520-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73520-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73521-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73521-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73522-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73522-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73523-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73523-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73524-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73524-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73525-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73525-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73526-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73526-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73527-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73527-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73528-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73528-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73529-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73529-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73530-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73530-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73531-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73531-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73532-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73532-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73533-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73533-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73534-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73534-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73535-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73535-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73536-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73536-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73537-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73537-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73538-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73538-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73539-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73539-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73540-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73540-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73541-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73541-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73542-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73542-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73543-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73543-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73544-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73544-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73545-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73545-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73546-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73546-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73547-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73547-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73548-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73548-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73549-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73549-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73550-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73550-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73551-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73551-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73554-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73554-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73555-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73555-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73556-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73556-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73567-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73567-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73664-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73664-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73667-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73667-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73668-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73668-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73669-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73669-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73670-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73670-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73686-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73686-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73687-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73687-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73688-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73688-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73726-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73726-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73727-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73727-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73728-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73728-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73729-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73729-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73730-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73730-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73753-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73753-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73819-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73819-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73823-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73823-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73830-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73830-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73831-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73831-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73832-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73832-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73909-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73909-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73910-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73910-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73911-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73911-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73912-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73912-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73914-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73914-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73915-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73915-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73917-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73917-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73918-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73918-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73919-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73919-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73920-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73920-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73921-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73921-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73922-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73922-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73923-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73923-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73924-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73924-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73925-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73925-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73926-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73926-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73927-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73927-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73928-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73928-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73929-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73929-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73930-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73930-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73936-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73936-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73942-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73942-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73943-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73943-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73944-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73944-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73945-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73945-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73946-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73946-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73947-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73947-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73948-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73948-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73949-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73949-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73950-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73950-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73951-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73951-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73952-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73952-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73953-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73953-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73954-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73954-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73955-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73955-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73956-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73956-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73957-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73957-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73959-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73959-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73971-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73971-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73982-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73982-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73993-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73993-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73994-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73994-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73995-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73995-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73996-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73996-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73998-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73998-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73999-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73999-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74000-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74000-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74001-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74001-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74108-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74108-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74109-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74109-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74110-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74110-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74118-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74118-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74119-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74119-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74120-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74120-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74121-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74121-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74122-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74122-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74123-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74123-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74124-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74124-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74125-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74125-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74126-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74126-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74127-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74127-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74128-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74128-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74129-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74129-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74132-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74132-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74133-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74133-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74157-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74157-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74184-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74184-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74305-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74305-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74312-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74312-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74316-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74316-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74319-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74319-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74320-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74320-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74321-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74321-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74322-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74322-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74323-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74323-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74324-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74324-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74325-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74325-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74326-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74326-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74327-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74327-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74328-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74328-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74329-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74329-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74330-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74330-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74331-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74331-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74332-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74332-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74333-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74333-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74334-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74334-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74335-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74335-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74336-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74336-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74337-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74337-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74338-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74338-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74339-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74339-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74340-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74340-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74341-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74341-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74342-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74342-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74343-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74343-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74344-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74344-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74345-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74345-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74346-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74346-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74370-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74370-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74415-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74415-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74417-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74417-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74422-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74422-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74632-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74632-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74643-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74643-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74644-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74644-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74645-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74645-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74646-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74646-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74648-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74648-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74650-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74650-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74653-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74653-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74654-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74654-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74656-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74656-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74657-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74657-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74658-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74658-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74659-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74659-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74660-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74660-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74670-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74670-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74671-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74671-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74673-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74673-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74674-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74674-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74675-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74675-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74677-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74677-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74678-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74678-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74679-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74679-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74680-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74680-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74681-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74681-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74683-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74683-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74690-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74690-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74729-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74729-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74758-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74758-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74815-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74815-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74821-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74821-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74823-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74823-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74824-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74824-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74825-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74825-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74826-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74826-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74827-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74827-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74828-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74828-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74829-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74829-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74830-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74830-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74843-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74843-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74844-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74844-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74845-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74845-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74846-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74846-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74847-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74847-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74967-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74967-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75010-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75010-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75011-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75011-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75012-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75012-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75013-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75013-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75014-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75014-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75015-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75015-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75016-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75016-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75017-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75017-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75018-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75018-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75019-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75019-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75242-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75242-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75263-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75263-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75264-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75264-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75265-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75265-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75369-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75369-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75404-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75404-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75643-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75643-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75644-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75644-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75646-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75646-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75647-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75647-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75648-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75648-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75649-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75649-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75664-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75664-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75694-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75694-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75695-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75695-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75696-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75696-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75757-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75757-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75811-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75811-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75812-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75812-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76070-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76070-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76071-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76071-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76074-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76074-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76076-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76076-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76077-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76077-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76078-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76078-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76079-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76079-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76080-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76080-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76084-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76084-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76085-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76085-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76086-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76086-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76087-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76087-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76088-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76088-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76089-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76089-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76338-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76338-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76339-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76339-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76399-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76399-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76766-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76766-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77008-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77008-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77170-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77170-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77173-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77173-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77201-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77201-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77204-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77204-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77205-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77205-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77206-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77206-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77345-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77345-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77346-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77346-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77350-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77350-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77368-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77368-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77369-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77369-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77382-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77382-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77383-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77383-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77384-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77384-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77385-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77385-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77386-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77386-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77387-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77387-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77388-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77388-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77389-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77389-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77390-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77390-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77391-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77391-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77392-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77392-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77452-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77452-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77666-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77666-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77731-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77731-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77732-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77732-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77745-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77745-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77746-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77746-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77747-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77747-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77954-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77954-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77955-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77955-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77956-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77956-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77957-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77957-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77959-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77959-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78035-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78035-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78036-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78036-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78363-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78363-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78433-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78433-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78514-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78514-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78752-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78752-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78753-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78753-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78754-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78754-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78756-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78756-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78757-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78757-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78759-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78759-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78760-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78760-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78778-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78778-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78790-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78790-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78808-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78808-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78816-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78816-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78823-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78823-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78831-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78831-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78859-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78859-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78889-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78889-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78891-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78891-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78893-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78893-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79206-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79206-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79222-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79222-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79447-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79447-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79708-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79708-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79709-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79709-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79711-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79711-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79712-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79712-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80136-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80136-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80137-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80137-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80144-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80144-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80146-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80146-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80147-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80147-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80148-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80148-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80149-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80149-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80162-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80162-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80196-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80196-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80197-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80197-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80198-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80198-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80199-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80199-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80200-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80200-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80205-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80205-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80206-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80206-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80212-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80212-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80213-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80213-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80214-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80214-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80215-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80215-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80217-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80217-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80384-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80384-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80385-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80385-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80603-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80603-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80660-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80660-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80674-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80674-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80675-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80675-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80676-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80676-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80677-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80677-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80678-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80678-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80679-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80679-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80680-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80680-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80681-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80681-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80682-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80682-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80683-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80683-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80684-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80684-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80685-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80685-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80823-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80823-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80824-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80824-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81123-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81123-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81124-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81124-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81125-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81125-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81310-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81310-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81328-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81328-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81421-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81421-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81439-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81439-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81629-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81629-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81712-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81712-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81713-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81713-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81714-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81714-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81715-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81715-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81716-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81716-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81717-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81717-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81718-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81718-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81719-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81719-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81720-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81720-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81721-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81721-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81722-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81722-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81723-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81723-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81724-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81724-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81725-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81725-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81726-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81726-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81727-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81727-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81728-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81728-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81729-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81729-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81730-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81730-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81731-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81731-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81732-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81732-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81733-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81733-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81734-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81734-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81735-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81735-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81736-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81736-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81737-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81737-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81738-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81738-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81739-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81739-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81740-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81740-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81741-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81741-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81743-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81743-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81771-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81771-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81774-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81774-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81787-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81787-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82299-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82299-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82369-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82369-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82370-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82370-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82371-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82371-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82372-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82372-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82373-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82373-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82374-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82374-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82375-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82375-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82389-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82389-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82392-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82392-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82394-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82394-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82395-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82395-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82396-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82396-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82397-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82397-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82398-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82398-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82399-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82399-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82400-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82400-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82401-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82401-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82402-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82402-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82403-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82403-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82404-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82404-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82405-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82405-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82406-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82406-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82407-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82407-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82408-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82408-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82409-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82409-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82410-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82410-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82411-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82411-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82412-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82412-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82413-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82413-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82415-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82415-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82416-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82416-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82418-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82418-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82419-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82419-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82420-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82420-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82422-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82422-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82423-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82423-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82424-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82424-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82426-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82426-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82427-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82427-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82428-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82428-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82429-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82429-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82432-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82432-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82433-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82433-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82434-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82434-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82437-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82437-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82438-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82438-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82440-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82440-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82442-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82442-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82443-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82443-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82444-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82444-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82445-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82445-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82446-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82446-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82447-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82447-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82448-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82448-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82449-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82449-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82450-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82450-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82451-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82451-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82452-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82452-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82453-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82453-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82456-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82456-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82471-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82471-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82472-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82472-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82473-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82473-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82474-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82474-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82475-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82475-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82476-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82476-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82547-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82547-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82550-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82550-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82553-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82553-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82557-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82557-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82560-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82560-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82563-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82563-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82566-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82566-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82577-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82577-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82580-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82580-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82658-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82658-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82659-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82659-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82660-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82660-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82723-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82723-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82732-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82732-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82733-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82733-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82734-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82734-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82735-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82735-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82747-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82747-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82840-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82840-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82842-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82842-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82870-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82870-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82872-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82872-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82913-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82913-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82915-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82915-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82918-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82918-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82919-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82919-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82921-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82921-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82926-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82926-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82928-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82928-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82931-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82931-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82975-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82975-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82976-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82976-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82977-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82977-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82978-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82978-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82979-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82979-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82980-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82980-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82981-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82981-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82982-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82982-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82983-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82983-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82984-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82984-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82985-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82985-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82986-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82986-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82987-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82987-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82988-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82988-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82989-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82989-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82990-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82990-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82991-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82991-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82992-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82992-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82993-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82993-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82994-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82994-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82995-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82995-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82996-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82996-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82997-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82997-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82998-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82998-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82999-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82999-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83000-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83000-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83001-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83001-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83002-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83002-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83003-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83003-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83004-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83004-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83052-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83052-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83055-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83055-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83137-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83137-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84871-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84871-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84872-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84872-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84924-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84924-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84925-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84925-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84926-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84926-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84927-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84927-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84928-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84928-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84929-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84929-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84930-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84930-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +84931-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +84931-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85086-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85086-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85360-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85360-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85365-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85365-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85366-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85366-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85367-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85367-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85485-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85485-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85486-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85486-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85487-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85487-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85488-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85488-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85553-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85553-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85621-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85621-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85622-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85622-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85623-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85623-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85737-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85737-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85738-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85738-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85739-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85739-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85822-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85822-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85823-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85823-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85824-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85824-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85825-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85825-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85826-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85826-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85827-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85827-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85828-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85828-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85829-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85829-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85830-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85830-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85831-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85831-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85832-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85832-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85833-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85833-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85834-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85834-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85835-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85835-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85836-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85836-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85837-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85837-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85838-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85838-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85839-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85839-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85840-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85840-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85841-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85841-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85842-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85842-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85843-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85843-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85844-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85844-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86199-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86199-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86200-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86200-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86202-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86202-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86203-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86203-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86204-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86204-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86217-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86217-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86228-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86228-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86319-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86319-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86453-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86453-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86454-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86454-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86455-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86455-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86456-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86456-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86457-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86457-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86688-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86688-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86689-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86689-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86690-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86690-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86691-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86691-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86692-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86692-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86925-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86925-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87243-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87243-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87277-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87277-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87318-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87318-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87319-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87319-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87320-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87320-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87321-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87321-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87322-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87322-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87324-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87324-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87328-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87328-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87332-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87332-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87336-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87336-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87341-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87341-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87345-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87345-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87348-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87348-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87370-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87370-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87371-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87371-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87372-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87372-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87373-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87373-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87374-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87374-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87375-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87375-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87376-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87376-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87377-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87377-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87380-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87380-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87387-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87387-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87390-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87390-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87392-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87392-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87402-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87402-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87484-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87484-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87485-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87485-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87486-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87486-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87487-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87487-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87488-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87488-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87489-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87489-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87490-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87490-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87491-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87491-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87492-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87492-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87493-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87493-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87494-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87494-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87495-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87495-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87496-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87496-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87497-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87497-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87558-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87558-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87559-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87559-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87560-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87560-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87561-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87561-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87622-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87622-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87757-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87757-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87805-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87805-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87810-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87810-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87811-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87811-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87815-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87815-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87818-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87818-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87820-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87820-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87822-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87822-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88450-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88450-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88451-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88451-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88452-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88452-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88457-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88457-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88881-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88881-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88882-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88882-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89040-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89040-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89964-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89964-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89965-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89965-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89967-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89967-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89969-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89969-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89970-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89970-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89971-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89971-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89974-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89974-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89977-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89977-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89978-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89978-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89979-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89979-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89980-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89980-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89981-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89981-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89982-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89982-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89983-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89983-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89984-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89984-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89985-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89985-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89987-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89987-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89989-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89989-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89991-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89991-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89992-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89992-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89994-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89994-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89995-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +89995-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90001-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90001-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90247-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90247-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90248-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90248-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90440-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90440-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90442-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90442-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90443-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90443-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90466-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90466-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90468-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90468-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90470-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90470-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90471-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90471-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90881-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90881-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90893-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90893-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90907-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90907-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91135-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91135-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91543-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91543-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91545-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91545-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92125-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92125-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92126-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92126-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92127-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92127-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92128-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92128-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92129-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92129-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92130-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92130-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92131-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92131-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92132-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92132-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92133-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92133-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92134-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92134-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92135-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92135-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92136-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92136-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92137-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92137-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92138-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92138-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92139-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92139-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92140-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92140-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92141-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92141-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92142-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92142-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92144-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92144-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92145-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92145-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92146-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92146-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92147-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92147-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92723-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92723-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92814-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92814-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92899-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92899-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92900-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92900-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92902-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92902-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92903-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92903-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93085-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93085-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93233-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93233-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93339-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93339-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93422-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93422-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93424-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93424-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93426-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93426-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93428-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93428-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93438-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93438-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93439-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93439-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93489-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93489-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93491-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93491-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93494-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93494-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93495-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93495-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93496-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93496-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93498-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93498-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +9350-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +9350-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93500-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93500-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93502-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93502-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93503-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93503-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +9351-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +9351-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93699-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93699-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93700-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93700-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93701-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93701-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93712-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93712-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93713-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93713-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93714-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93714-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93716-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93716-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93717-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93717-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93719-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93719-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93745-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93745-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93747-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93747-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93795-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93795-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93856-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93856-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93867-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93867-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93868-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93868-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93869-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93869-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93870-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93870-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93907-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93907-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93908-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93908-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93909-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93909-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93910-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93910-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93911-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93911-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93912-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93912-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93913-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93913-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93950-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93950-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94040-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94040-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94096-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94096-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94097-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94097-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94098-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94098-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94099-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94099-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94149-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94149-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94247-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94247-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94248-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94248-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94249-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94249-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94250-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94250-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94251-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94251-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94252-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94252-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94271-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94271-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94272-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94272-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94283-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94283-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94285-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94285-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94286-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94286-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94287-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94287-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94288-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94288-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94291-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94291-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94292-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94292-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94294-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94294-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94295-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94295-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94296-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94296-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94298-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94298-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94299-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94299-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94301-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94301-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94333-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94333-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94334-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94334-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94346-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94346-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94347-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94347-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94360-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94360-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94361-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94361-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94400-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94400-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94420-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94420-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94424-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94424-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94501-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94501-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94502-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94502-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94584-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94584-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94611-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94611-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94612-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94612-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94613-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94613-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94676-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94676-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94730-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94730-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94731-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94731-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94732-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94732-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94733-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94733-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94868-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94868-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94870-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94870-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95156-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95156-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95157-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95157-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95269-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95269-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95272-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95272-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95533-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95533-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95534-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95534-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95535-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95535-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95536-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95536-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95537-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95537-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95538-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95538-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95539-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95539-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95543-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95543-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95550-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95550-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95660-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95660-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95661-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95661-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95662-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95662-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95663-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95663-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95664-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95664-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95665-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95665-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95666-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95666-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95667-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95667-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95668-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95668-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95669-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95669-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95670-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95670-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95671-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95671-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95672-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95672-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95673-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95673-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95674-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95674-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95675-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95675-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95676-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95676-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95677-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95677-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95678-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95678-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95679-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95679-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95680-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95680-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95681-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95681-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95682-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95682-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95683-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95683-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95684-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95684-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95685-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95685-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95686-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95686-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95687-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95687-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95688-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95688-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95689-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95689-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95690-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95690-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95691-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95691-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95692-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95692-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95693-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95693-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95694-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95694-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95695-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95695-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95696-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95696-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95697-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95697-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95698-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95698-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95699-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95699-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95700-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95700-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95701-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95701-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95702-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95702-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95703-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95703-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95704-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95704-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95705-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95705-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95706-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95706-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95707-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95707-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95708-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95708-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95709-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95709-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95710-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95710-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95711-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95711-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95712-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95712-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95713-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95713-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95764-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95764-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95765-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95765-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95766-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95766-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96047-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96047-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96049-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96049-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96057-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96057-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96058-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96058-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96282-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96282-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96358-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96358-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96359-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96359-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96361-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96361-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96363-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96363-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96364-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96364-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96365-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96365-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96366-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96366-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96368-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96368-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96369-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96369-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96370-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96370-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96371-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96371-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96454-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96454-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96464-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96464-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96466-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96466-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96467-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96467-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96468-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96468-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96471-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96471-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96472-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96472-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96473-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96473-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96475-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96475-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96476-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96476-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96478-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96478-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96479-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96479-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96481-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96481-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96482-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96482-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96483-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96483-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96484-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96484-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96485-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96485-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96486-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96486-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96488-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96488-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96489-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96489-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96490-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96490-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96496-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96496-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96497-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96497-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96503-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96503-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96505-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96505-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96506-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96506-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96507-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96507-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96508-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96508-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96509-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96509-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96510-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96510-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96511-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96511-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96512-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96512-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96513-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96513-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96514-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96514-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96515-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96515-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96516-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96516-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96517-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96517-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96518-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96518-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96519-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96519-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96520-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96520-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96521-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96521-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96522-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96522-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96523-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96523-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96524-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96524-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96525-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96525-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96526-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96526-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96527-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96527-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96528-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96528-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96529-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96529-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96530-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96530-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96531-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96531-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96532-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96532-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96533-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96533-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96534-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96534-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96535-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96535-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96536-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96536-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96537-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96537-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96538-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96538-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96552-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96552-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96555-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96555-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96567-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96567-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96568-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96568-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96763-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96763-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96765-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96765-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96962-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96962-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97151-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97151-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97153-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97153-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97154-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97154-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97173-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97173-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97174-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97174-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97175-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97175-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97176-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97176-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97177-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97177-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97178-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97178-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97179-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97179-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97181-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97181-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97185-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97185-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97205-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97205-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97206-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97206-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97207-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97207-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97522-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97522-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97523-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97523-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97524-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97524-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97525-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97525-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97532-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97532-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97562-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97562-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97863-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97863-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97873-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97873-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97917-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97917-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97918-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97918-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97919-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97919-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97920-3;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97920-3;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97921-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97921-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97922-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97922-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97923-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97923-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97924-5;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97924-5;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97925-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97925-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97926-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97926-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97927-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97927-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97928-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97928-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97929-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97929-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97930-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97930-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97931-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97931-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97932-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97932-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97933-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97933-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97934-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97934-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97935-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97935-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97940-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97940-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97947-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97947-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97948-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97948-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97949-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97949-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97950-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97950-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97951-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97951-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97992-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97992-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98021-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98021-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98063-1;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98063-1;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98064-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98064-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98065-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98065-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98131-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98131-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98132-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98132-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98206-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98206-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98220-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98220-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98493-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98493-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98494-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98494-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98960-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98960-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98961-6;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98961-6;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98962-4;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98962-4;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98964-0;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98964-0;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99062-2;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99062-2;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99078-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99078-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99262-8;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99262-8;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99308-9;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99308-9;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99309-7;LL360-9;Pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99309-7;LL360-9;Pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100063-7;LL6216-7;Skin concerns;LA33283-5;1;I have a skin lesion (spot) or lesions that worry me and I want them checked;;; +100063-7;LL6216-7;Skin concerns;LA33284-3;2;I want a general skin exam to check for skin cancer. I have no specific areas of concern.;;; +100063-7;LL6216-7;Skin concerns;LA33285-0;3;Problem with rash or follow up on previously treated skin condition.;;; +100063-7;LL6216-7;Skin concerns;LA33286-8;4;Problem with skin, like itching;;; +100063-7;LL6216-7;Skin concerns;LA33287-6;5;Problem with acne;;; +100063-7;LL6216-7;Skin concerns;LA33288-4;6;Problem with hair;;; +100063-7;LL6216-7;Skin concerns;LA33289-2;7;Problem with nails;;; +100063-7;LL6216-7;Skin concerns;LA33290-0;8;Problem with skin coloring;;; +100063-7;LL6216-7;Skin concerns;LA33291-8;9;Problem with birthmark or hemangioma;;; +100063-7;LL6216-7;Skin concerns;LA33292-6;10;Other problems;;; +100064-5;LL6217-5;Itch severity 0-10;LA33293-4;1;0 = No itch;;; +100064-5;LL6217-5;Itch severity 0-10;LA6112-2;2;1;;; +100064-5;LL6217-5;Itch severity 0-10;LA6113-0;3;2;;; +100064-5;LL6217-5;Itch severity 0-10;LA6114-8;4;3;;; +100064-5;LL6217-5;Itch severity 0-10;LA6115-5;5;4;;; +100064-5;LL6217-5;Itch severity 0-10;LA10137-0;6;5;;; +100064-5;LL6217-5;Itch severity 0-10;LA10138-8;7;6;;; +100064-5;LL6217-5;Itch severity 0-10;LA10139-6;8;7;;; +100064-5;LL6217-5;Itch severity 0-10;LA10140-4;9;8;;; +100064-5;LL6217-5;Itch severity 0-10;LA10141-2;10;9;;; +100064-5;LL6217-5;Itch severity 0-10;LA33294-2;11;10 = Worst itch imaginable;;; +100065-2;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA19732-9;1;Clear;;; +100065-2;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29528-9;2;Almost clear;;; +100065-2;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29529-7;3;Mild disease;;; +100065-2;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29530-5;4;Moderate disease;;; +100065-2;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29531-3;5;Severe disease;;; +90775-8;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA19732-9;1;Clear;;; +90775-8;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29528-9;2;Almost clear;;; +90775-8;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29529-7;3;Mild disease;;; +90775-8;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29530-5;4;Moderate disease;;; +90775-8;LL5146-7;Clear|Almost clear|Mild|Moderate|Severe disease;LA29531-3;5;Severe disease;;; +100086-8;LL6226-6;Specular Microscopy Analysis Method;LA33379-1;1;Auto;;; +100086-8;LL6226-6;Specular Microscopy Analysis Method;LA19016-7;2;Manual;;; +100086-8;LL6226-6;Specular Microscopy Analysis Method;LA14198-8;3;Center;;; +100086-8;LL6226-6;Specular Microscopy Analysis Method;LA33380-9;4;Flex center;;; +100086-8;LL6226-6;Specular Microscopy Analysis Method;LA46-8;5;Other;;; +100155-1;LL6226-6;Specular Microscopy Analysis Method;LA33379-1;1;Auto;;; +100155-1;LL6226-6;Specular Microscopy Analysis Method;LA19016-7;2;Manual;;; +100155-1;LL6226-6;Specular Microscopy Analysis Method;LA14198-8;3;Center;;; +100155-1;LL6226-6;Specular Microscopy Analysis Method;LA33380-9;4;Flex center;;; +100155-1;LL6226-6;Specular Microscopy Analysis Method;LA46-8;5;Other;;; +100114-8;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100114-8;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100114-8;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100115-5;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100115-5;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100115-5;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100116-3;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100116-3;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100116-3;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100117-1;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100117-1;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100117-1;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100118-9;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100118-9;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100118-9;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100119-7;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100119-7;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100119-7;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +44795-3;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44795-3;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44795-3;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +44797-9;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44797-9;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44797-9;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +44799-5;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44799-5;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44799-5;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +83065-3;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +83065-3;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +83065-3;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86207-8;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86207-8;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86207-8;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +88184-7;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88184-7;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88184-7;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +88185-4;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +88185-4;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88185-4;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +97512-8;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97512-8;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97512-8;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +97513-6;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97513-6;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97513-6;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +97517-7;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97517-7;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97517-7;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +97529-2;LL2431-6;Pos|Neg|Inconcl;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97529-2;LL2431-6;Pos|Neg|Inconcl;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97529-2;LL2431-6;Pos|Neg|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100154-4;LL6225-8;Specimen collection supervision level;LA33375-9;1;Collected by healthcare professional unsupervised;;; +100154-4;LL6225-8;Specimen collection supervision level;LA33376-7;2;In-person supervision by healthcare professional;;; +100154-4;LL6225-8;Specimen collection supervision level;LA33377-5;3;Virtual supervision by healthcare professional;;; +100154-4;LL6225-8;Specimen collection supervision level;LA33378-3;4;Unsupervised by healthcare professional;;; +100156-9;LL5768-8;SARS-CoV-2 variants;LA31569-9;1;SARS-CoV-2 Alpha variant (WHO);;; +100156-9;LL5768-8;SARS-CoV-2 variants;LA31570-7;2;SARS-CoV-2 Beta variant (WHO);;; +100156-9;LL5768-8;SARS-CoV-2 variants;LA31621-8;3;SARS-CoV-2 Gamma variant (WHO);;; +100156-9;LL5768-8;SARS-CoV-2 variants;LA32552-4;6;SARS-CoV-2 Delta variant (WHO);;; +100156-9;LL5768-8;SARS-CoV-2 variants;LA33381-7;7;SARS-CoV-2 Omicron variant (WHO);;; +96741-4;LL5768-8;SARS-CoV-2 variants;LA31569-9;1;SARS-CoV-2 Alpha variant (WHO);;; +96741-4;LL5768-8;SARS-CoV-2 variants;LA31570-7;2;SARS-CoV-2 Beta variant (WHO);;; +96741-4;LL5768-8;SARS-CoV-2 variants;LA31621-8;3;SARS-CoV-2 Gamma variant (WHO);;; +96741-4;LL5768-8;SARS-CoV-2 variants;LA32552-4;6;SARS-CoV-2 Delta variant (WHO);;; +96741-4;LL5768-8;SARS-CoV-2 variants;LA33381-7;7;SARS-CoV-2 Omicron variant (WHO);;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA31701-8;1;SARS-CoV-2 A.1.1 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA31620-0;2;SARS-CoV-2 B.1.1.238 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA31703-4;3;SARS-CoV-2 B.1.2 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA31704-2;4;SARS-CoV-2 B.1.1 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA31705-9;5;SARS-CoV-2 B.1.1.7 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA31706-7;6;SARS-CoV-2 B.1.29 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA31702-6;7;SARS-CoV-2 B.2.4 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA32553-2;8;SARS-CoV-2 B.1.351 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA32555-7;9;SARS-CoV-2 P.1 lineage;;; +100157-7;LL5807-4;SARS-CoV-2 lineages;LA32556-5;10;SARS-CoV-2 B.1.617.2 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA31701-8;1;SARS-CoV-2 A.1.1 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA31620-0;2;SARS-CoV-2 B.1.1.238 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA31703-4;3;SARS-CoV-2 B.1.2 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA31704-2;4;SARS-CoV-2 B.1.1 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA31705-9;5;SARS-CoV-2 B.1.1.7 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA31706-7;6;SARS-CoV-2 B.1.29 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA31702-6;7;SARS-CoV-2 B.2.4 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA32553-2;8;SARS-CoV-2 B.1.351 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA32555-7;9;SARS-CoV-2 P.1 lineage;;; +96895-8;LL5807-4;SARS-CoV-2 lineages;LA32556-5;10;SARS-CoV-2 B.1.617.2 lineage;;; +100160-1;LL6236-5;Primary/Revision;LA21208-6;1;Primary;;; +100160-1;LL6236-5;Primary/Revision;LA32684-5;2;Revision;;; +100160-1;LL6236-5;Primary/Revision;LA21208-6;1;Primary;;; +100160-1;LL6236-5;Primary/Revision;LA32684-5;2;Revision;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32779-3;1;Unilateral knee arthritis;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32780-1;2;Unilateral TKA, opposite knee arthritic;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32781-9;3;Bilateral TKA;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32782-7;4;TKR, but remote arthritis affecting ambulation;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32783-5;5;TKR, but medical condition affecting ambulation;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32784-3;6;Unilateral or Bilateral TKA with Unilateral or Bilateral THR;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32779-3;1;Unilateral knee arthritis;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32780-1;2;Unilateral TKA, opposite knee arthritic;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32781-9;3;Bilateral TKA;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32782-7;4;TKR, but remote arthritis affecting ambulation;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32783-5;5;TKR, but medical condition affecting ambulation;;; +100161-9;LL6104-5;Charnley Functional Classification;LA32784-3;6;Unilateral or Bilateral TKA with Unilateral or Bilateral THR;;; +100162-7;LL6238-1;Alignment;LA32685-2;1;Neutral: 2-10 degrees valgus;;; +100162-7;LL6238-1;Alignment;LA32686-0;2;Varus: <2 degrees valgus;;; +100162-7;LL6238-1;Alignment;LA32687-8;3;Valgus: >10 degrees valgus;;; +100162-7;LL6238-1;Alignment;LA32685-2;1;Neutral: 2-10 degrees valgus;;; +100162-7;LL6238-1;Alignment;LA32686-0;2;Varus: <2 degrees valgus;;; +100162-7;LL6238-1;Alignment;LA32687-8;3;Valgus: >10 degrees valgus;;; +100163-5;LL6239-9;Medial / Lateral Instability;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +100163-5;LL6239-9;Medial / Lateral Instability;LA33166-2;2;Little or < 5 mm;;; +100163-5;LL6239-9;Medial / Lateral Instability;LA33167-0;3;Moderate or 5 mm;;; +100163-5;LL6239-9;Medial / Lateral Instability;LA33168-8;4;Severe or > 5 mm;;; +100163-5;LL6239-9;Medial / Lateral Instability;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +100163-5;LL6239-9;Medial / Lateral Instability;LA33166-2;2;Little or < 5 mm;;; +100163-5;LL6239-9;Medial / Lateral Instability;LA33167-0;3;Moderate or 5 mm;;; +100163-5;LL6239-9;Medial / Lateral Instability;LA33168-8;4;Severe or > 5 mm;;; +100164-3;LL6240-7;Anterior / Posterior Instability;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +100164-3;LL6240-7;Anterior / Posterior Instability;LA33169-6;2;Moderate < 5 mm;;; +100164-3;LL6240-7;Anterior / Posterior Instability;LA33170-4;3;Severe > 5 mm;;; +100164-3;LL6240-7;Anterior / Posterior Instability;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +100164-3;LL6240-7;Anterior / Posterior Instability;LA33169-6;2;Moderate < 5 mm;;; +100164-3;LL6240-7;Anterior / Posterior Instability;LA33170-4;3;Severe > 5 mm;;; +100166-8;LL6105-2;Flexion Contracture;LA32785-0;1;1-5 degrees;;; +100166-8;LL6105-2;Flexion Contracture;LA32786-8;2;6-10 degrees;;; +100166-8;LL6105-2;Flexion Contracture;LA32787-6;3;11-15 degrees;;; +100166-8;LL6105-2;Flexion Contracture;LA32788-4;4;> 15 degrees;;; +100166-8;LL6105-2;Flexion Contracture;LA32785-0;1;1-5 degrees;;; +100166-8;LL6105-2;Flexion Contracture;LA32786-8;2;6-10 degrees;;; +100166-8;LL6105-2;Flexion Contracture;LA32787-6;3;11-15 degrees;;; +100166-8;LL6105-2;Flexion Contracture;LA32788-4;4;> 15 degrees;;; +100167-6;LL6106-0;Extensor Lag;LA32789-2;1;<10 degrees;;; +100167-6;LL6106-0;Extensor Lag;LA32790-0;2;10-20 degrees;;; +100167-6;LL6106-0;Extensor Lag;LA32791-8;3;> 20 degrees;;; +100167-6;LL6106-0;Extensor Lag;LA32789-2;1;<10 degrees;;; +100167-6;LL6106-0;Extensor Lag;LA32790-0;2;10-20 degrees;;; +100167-6;LL6106-0;Extensor Lag;LA32791-8;3;> 20 degrees;;; +100168-4;LL6108-6;0-10 None Severe;LA32838-7;1;0 = None;;; +100168-4;LL6108-6;0-10 None Severe;LA6112-2;2;1;;; +100168-4;LL6108-6;0-10 None Severe;LA6113-0;3;2;;; +100168-4;LL6108-6;0-10 None Severe;LA6114-8;4;3;;; +100168-4;LL6108-6;0-10 None Severe;LA6115-5;5;4;;; +100168-4;LL6108-6;0-10 None Severe;LA10137-0;6;5;;; +100168-4;LL6108-6;0-10 None Severe;LA10138-8;7;6;;; +100168-4;LL6108-6;0-10 None Severe;LA10140-4;8;8;;; +100168-4;LL6108-6;0-10 None Severe;LA10141-2;9;9;;; +100168-4;LL6108-6;0-10 None Severe;LA32839-5;10;10 = Severe;;; +100168-4;LL6108-6;0-10 None Severe;LA32838-7;1;0 = None;;; +100168-4;LL6108-6;0-10 None Severe;LA6112-2;2;1;;; +100168-4;LL6108-6;0-10 None Severe;LA6113-0;3;2;;; +100168-4;LL6108-6;0-10 None Severe;LA6114-8;4;3;;; +100168-4;LL6108-6;0-10 None Severe;LA6115-5;5;4;;; +100168-4;LL6108-6;0-10 None Severe;LA10137-0;6;5;;; +100168-4;LL6108-6;0-10 None Severe;LA10138-8;7;6;;; +100168-4;LL6108-6;0-10 None Severe;LA10140-4;8;8;;; +100168-4;LL6108-6;0-10 None Severe;LA10141-2;9;9;;; +100168-4;LL6108-6;0-10 None Severe;LA32839-5;10;10 = Severe;;; +100169-2;LL6108-6;0-10 None Severe;LA32838-7;1;0 = None;;; +100169-2;LL6108-6;0-10 None Severe;LA6112-2;2;1;;; +100169-2;LL6108-6;0-10 None Severe;LA6113-0;3;2;;; +100169-2;LL6108-6;0-10 None Severe;LA6114-8;4;3;;; +100169-2;LL6108-6;0-10 None Severe;LA6115-5;5;4;;; +100169-2;LL6108-6;0-10 None Severe;LA10137-0;6;5;;; +100169-2;LL6108-6;0-10 None Severe;LA10138-8;7;6;;; +100169-2;LL6108-6;0-10 None Severe;LA10140-4;8;8;;; +100169-2;LL6108-6;0-10 None Severe;LA10141-2;9;9;;; +100169-2;LL6108-6;0-10 None Severe;LA32839-5;10;10 = Severe;;; +100169-2;LL6108-6;0-10 None Severe;LA32838-7;1;0 = None;;; +100169-2;LL6108-6;0-10 None Severe;LA6112-2;2;1;;; +100169-2;LL6108-6;0-10 None Severe;LA6113-0;3;2;;; +100169-2;LL6108-6;0-10 None Severe;LA6114-8;4;3;;; +100169-2;LL6108-6;0-10 None Severe;LA6115-5;5;4;;; +100169-2;LL6108-6;0-10 None Severe;LA10137-0;6;5;;; +100169-2;LL6108-6;0-10 None Severe;LA10138-8;7;6;;; +100169-2;LL6108-6;0-10 None Severe;LA10140-4;8;8;;; +100169-2;LL6108-6;0-10 None Severe;LA10141-2;9;9;;; +100169-2;LL6108-6;0-10 None Severe;LA32839-5;10;10 = Severe;;; +100170-0;LL6115-1;Always/Sometimes/Never Scored;LA9933-8;1;Always;;; +100170-0;LL6115-1;Always/Sometimes/Never Scored;LA10082-8;2;Sometimes;;; +100170-0;LL6115-1;Always/Sometimes/Never Scored;LA6270-8;3;Never;;; +100170-0;LL6115-1;Always/Sometimes/Never Scored;LA9933-8;1;Always;;; +100170-0;LL6115-1;Always/Sometimes/Never Scored;LA10082-8;2;Sometimes;;; +100170-0;LL6115-1;Always/Sometimes/Never Scored;LA6270-8;3;Never;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100171-8;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100172-6;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100173-4;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100174-2;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA14642-5;1;Very satisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA29495-1;2;Satisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA14786-0;3;Neutral;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA29496-9;4;Dissatisfied;;; +100175-9;LL6124-3;Very satisfied to very dissatisfied Scored;LA14638-3;5;Very dissatisfied;;; +100176-7;LL6181-3;No not at all/Yes alot;LA18387-3;1;No, not at all;;; +100176-7;LL6181-3;No not at all/Yes alot;LA33171-2;2;Yes, a little bit;;; +100176-7;LL6181-3;No not at all/Yes alot;LA33172-0;3;Yes, somewhat;;; +100176-7;LL6181-3;No not at all/Yes alot;LA33173-8;4;Yes, a moderate amount;;; +100176-7;LL6181-3;No not at all/Yes alot;LA33174-6;5;Yes, a lot;;; +100177-5;LL6181-3;No not at all/Yes alot;LA18387-3;1;No, not at all;;; +100177-5;LL6181-3;No not at all/Yes alot;LA33171-2;2;Yes, a little bit;;; +100177-5;LL6181-3;No not at all/Yes alot;LA33172-0;3;Yes, somewhat;;; +100177-5;LL6181-3;No not at all/Yes alot;LA33173-8;4;Yes, a moderate amount;;; +100177-5;LL6181-3;No not at all/Yes alot;LA33174-6;5;Yes, a lot;;; +100178-3;LL6181-3;No not at all/Yes alot;LA18387-3;1;No, not at all;;; +100178-3;LL6181-3;No not at all/Yes alot;LA33171-2;2;Yes, a little bit;;; +100178-3;LL6181-3;No not at all/Yes alot;LA33172-0;3;Yes, somewhat;;; +100178-3;LL6181-3;No not at all/Yes alot;LA33173-8;4;Yes, a moderate amount;;; +100178-3;LL6181-3;No not at all/Yes alot;LA33174-6;5;Yes, a lot;;; +100179-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100179-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100179-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100179-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100181-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100181-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100181-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100181-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100256-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100256-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100257-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100257-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100258-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100258-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +34524-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +34524-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +34525-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +34525-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +44250-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +44250-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +44255-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +44255-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +45249-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45249-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +45344-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45344-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +45675-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45675-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +46694-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46694-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +47224-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +47224-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48614-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48614-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +49898-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +49898-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +50957-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +50957-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +51855-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +51855-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +52574-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52574-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +54118-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54118-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +54122-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54122-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +54128-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54128-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +54135-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54135-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +54411-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54411-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +55211-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55211-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +55212-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55212-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +55216-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55216-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +55217-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55217-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +55748-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55748-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58254-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58254-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58255-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58255-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58256-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58256-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58266-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58266-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58267-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58267-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58287-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58287-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58289-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58289-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58298-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58298-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58324-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58324-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58325-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58325-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58333-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58333-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +59781-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +59781-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +62363-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +62363-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63611-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63611-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63633-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63633-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63694-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63694-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63704-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63704-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63705-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63705-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63709-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63709-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63714-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63714-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63732-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63732-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63734-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63734-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63737-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63737-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63765-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63765-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63777-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63777-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63800-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63800-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63801-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63801-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63803-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63803-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63804-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63804-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63806-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63806-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63823-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63823-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63824-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63824-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63825-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63825-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63826-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63826-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63836-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63836-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63837-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63837-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63889-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63889-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63892-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63892-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63899-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63899-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63901-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63901-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63908-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63908-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63923-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63923-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63928-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63928-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63956-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63956-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63970-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63970-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63975-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63975-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63991-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63991-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64000-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64000-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64001-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64001-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64007-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64007-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64024-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64024-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64104-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64104-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64145-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64145-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64146-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64146-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64147-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64147-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64148-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64148-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64151-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64151-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64152-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64152-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64153-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64153-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64154-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64154-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64157-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64157-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64159-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64159-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64160-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64160-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64161-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64161-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64163-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64163-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64168-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64168-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64174-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64174-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64177-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64177-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64178-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64178-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64181-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64181-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64184-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64184-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64187-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64187-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64191-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64191-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64195-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64195-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64200-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64200-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64202-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64202-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64204-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64204-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64207-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64207-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64216-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64216-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64221-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64221-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64227-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64227-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64234-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64234-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64236-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64236-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64244-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64244-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64246-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64246-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64247-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64247-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64248-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64248-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64249-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64249-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64250-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64250-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64251-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64251-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64252-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64252-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64253-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64253-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64254-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64254-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64256-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64256-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64257-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64257-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64259-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64259-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64261-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64261-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64263-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64263-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64264-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64264-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64267-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64267-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64268-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64268-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64269-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64269-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64270-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64270-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64271-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64271-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64272-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64272-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64275-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64275-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64276-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64276-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64277-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64277-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64278-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64278-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64280-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64280-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64281-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64281-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64282-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64282-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64398-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64398-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64399-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64399-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64400-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64400-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64401-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64401-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64402-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64402-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64403-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64403-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64404-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64404-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64406-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64406-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64407-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64407-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64408-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64408-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64411-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64411-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64437-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64437-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64483-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64483-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64494-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64494-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64537-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64537-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64541-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64541-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64542-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64542-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64587-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64587-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64595-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64595-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64596-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64596-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64599-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64599-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64718-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64718-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64719-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64719-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64722-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64722-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64724-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64724-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64728-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64728-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64735-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64735-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64736-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64736-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64749-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64749-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64849-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64860-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64860-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64861-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64861-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64862-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64862-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65100-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65100-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65101-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65101-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65102-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65102-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65103-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65103-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65104-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65104-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65105-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65105-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65106-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65106-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65107-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65107-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65108-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65108-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65109-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65109-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65110-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65110-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65111-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65111-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65112-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65112-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65113-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65113-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65114-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65114-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65115-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65115-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65116-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65116-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65117-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65117-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65118-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65118-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65119-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65119-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65120-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65120-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65121-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65121-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65122-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65122-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65123-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65123-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65124-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65124-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65125-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65125-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65126-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65126-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65127-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65127-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65128-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65128-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65129-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65129-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65130-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65130-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65131-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65131-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65132-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65132-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65133-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65133-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65134-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65134-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65135-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65135-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65136-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65136-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65137-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65137-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65140-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65140-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65141-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65141-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65142-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65142-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65143-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65143-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65144-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65144-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65374-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65374-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65387-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65387-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65389-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65389-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65392-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65392-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65395-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65395-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65396-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65396-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65397-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65397-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65398-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65398-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65399-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65399-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65400-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65400-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65405-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65405-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65406-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65406-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65461-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65461-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65522-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65522-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65523-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65523-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65718-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65718-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65721-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65721-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65722-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65722-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65725-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65725-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65730-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65730-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65734-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65734-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65741-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65741-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65744-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65744-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65748-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65748-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65816-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65816-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65829-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65829-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65845-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65845-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65870-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65870-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65889-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65889-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65909-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65909-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65911-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65911-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65913-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65913-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65915-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65915-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65919-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65919-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65920-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65920-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65921-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65921-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65922-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65922-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65923-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65923-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65924-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65924-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65925-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65925-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65931-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65931-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66047-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66047-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66065-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66065-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66090-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66090-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66091-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66091-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66092-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66092-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66093-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66093-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66094-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66094-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66095-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66095-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66096-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66096-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66097-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66097-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66098-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66098-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66099-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66099-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66100-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66100-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66101-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66101-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66102-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66102-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66103-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66103-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66104-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66104-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66166-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66166-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66168-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66168-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66170-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66170-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66172-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66172-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66180-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66180-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66181-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66181-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66182-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66182-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66202-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66202-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66225-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66225-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66233-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66233-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66234-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66234-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66235-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66235-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66236-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66236-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66237-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66237-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66238-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66238-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66239-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66239-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66243-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66243-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66260-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66260-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66261-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66261-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66262-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66262-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66263-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66263-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66264-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66264-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66284-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66284-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66295-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66295-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66300-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66300-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66301-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66301-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66303-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66303-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66304-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66304-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66305-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66305-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66306-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66306-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66307-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66307-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66308-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66308-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66309-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66309-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66310-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66310-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66312-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66312-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66315-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66315-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66319-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66319-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66320-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66320-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66321-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66321-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66322-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66322-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66323-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66323-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66324-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66324-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66325-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66325-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66326-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66326-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66400-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66400-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66401-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66401-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66402-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66402-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66403-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66403-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66404-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66404-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66405-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66405-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66406-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66406-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66407-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66407-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66408-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66408-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66409-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66409-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66410-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66410-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66411-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66411-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66420-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66420-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66421-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66421-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66478-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66478-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66535-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66535-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66536-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66536-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66538-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66538-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66539-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66539-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66540-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66540-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66545-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66545-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66546-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66546-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66558-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66558-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66559-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66559-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66560-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66560-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66562-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66562-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66564-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66564-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66565-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66565-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66759-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66759-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66886-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66886-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66888-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66888-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66889-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66889-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66890-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66890-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66891-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66891-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66892-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66892-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66893-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66893-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66894-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66894-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66895-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66895-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66896-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66896-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66899-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66899-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66900-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66900-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66901-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66901-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66902-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66902-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66904-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66904-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66905-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66905-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66906-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66906-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66909-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66909-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66910-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66910-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66911-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66911-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66912-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66912-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66913-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66913-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66914-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66914-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66915-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66915-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66916-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66916-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66917-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66917-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66918-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66918-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66919-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66919-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66920-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66920-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66922-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66922-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66923-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66923-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66924-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66924-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66926-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66926-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66927-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66927-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66928-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66928-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66929-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66929-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66930-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66930-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66932-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66932-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66933-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66933-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66934-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66934-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66935-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66935-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66982-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66982-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67093-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67093-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67105-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67105-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67106-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67106-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67107-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67107-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67108-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67108-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67109-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67109-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67110-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67110-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67111-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67111-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67112-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67112-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67113-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67113-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67114-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67114-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67115-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67115-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67116-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67116-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67117-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67117-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67118-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67118-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67119-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67119-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67120-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67120-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67121-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67121-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67122-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67122-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67123-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67123-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67124-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67124-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67133-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67133-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67137-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67137-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67158-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67158-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67159-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67159-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67185-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67185-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67204-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67204-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67208-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67208-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67212-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67212-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67227-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67227-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67235-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67235-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67481-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67481-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67490-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67490-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67506-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67506-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67511-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67511-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67518-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67518-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67539-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67539-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67542-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67542-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67544-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67544-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67579-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67579-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67581-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67581-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67582-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67582-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67583-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67583-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67584-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67584-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67585-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67585-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67671-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67671-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67672-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67672-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67673-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67673-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67674-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67674-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67677-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67677-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67678-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67678-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67679-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67679-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67680-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67680-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67681-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67681-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67682-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67682-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67683-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67683-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67684-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67684-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67685-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67685-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67686-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67686-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67687-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67687-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67688-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67688-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67689-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67689-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67690-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67690-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67691-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67691-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67692-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67692-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67693-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67693-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67694-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67694-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67695-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67695-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67696-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67696-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67697-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67697-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67698-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67698-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67699-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67699-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67700-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67700-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67722-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67722-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67791-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67791-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67792-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67792-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67793-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67793-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67794-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67794-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67797-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67797-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67798-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67798-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67872-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67872-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68338-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68338-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68344-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68344-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68347-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68347-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68360-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68360-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68507-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68507-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68509-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68509-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68525-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68525-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68526-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68526-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68527-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68527-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68528-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68528-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68529-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68529-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68530-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68530-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68531-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68531-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68532-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68532-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68533-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68533-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68534-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68534-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68535-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68535-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68536-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68536-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68537-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68537-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68538-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68538-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68539-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68539-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68540-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68540-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69436-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69436-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69444-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69444-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69448-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69448-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69725-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69725-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69747-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69747-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69749-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69749-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69757-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69757-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69856-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69856-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69856-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69856-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69856-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69856-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69857-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69857-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69857-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69857-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69857-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69857-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69858-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69859-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69859-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69859-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69859-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69859-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69859-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69860-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69861-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69861-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +70844-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70844-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +70914-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70914-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +70950-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70950-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +70954-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70954-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +70955-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70955-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +70957-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70957-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71458-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71458-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71460-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71460-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71475-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71475-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71476-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71476-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71477-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71477-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71478-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71478-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71481-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71481-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71520-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71520-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71756-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71756-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +71785-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71785-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72031-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72031-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72033-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72033-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72036-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72036-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72038-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72038-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72040-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72040-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72041-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72041-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72043-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72043-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72045-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72045-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72056-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72056-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72058-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72058-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72064-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72064-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72066-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72066-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72067-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72067-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72069-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72069-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72070-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72070-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72073-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72073-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72075-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72075-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72077-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72077-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72080-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72080-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72082-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72082-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72083-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72083-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +72151-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72151-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75250-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75250-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75251-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75251-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75252-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75252-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75253-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75253-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75254-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75254-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75530-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75530-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75607-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75607-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75855-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75855-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76398-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76398-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76517-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76517-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76749-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76749-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76749-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76749-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77239-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77239-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77241-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77241-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77318-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77318-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +80290-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80290-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +80291-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80291-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +80292-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80292-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82814-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82814-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82815-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82815-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82816-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82816-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82817-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82817-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82818-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82818-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82819-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82819-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82820-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82820-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82821-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82821-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82822-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82822-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82823-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82823-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88096-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88096-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88381-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88381-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89014-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89014-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89062-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89062-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89069-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89069-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89074-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89074-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89076-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89076-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89078-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89078-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89174-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89174-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +91388-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +91388-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +91390-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +91390-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93030-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93030-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93030-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93030-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93246-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93246-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93247-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93247-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93248-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93248-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93249-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93249-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93250-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93250-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93257-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93257-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93258-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93258-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93267-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93267-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93269-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93269-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93486-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93486-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93487-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93487-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93668-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93668-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93669-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93669-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93670-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93670-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93671-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93671-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93672-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93672-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93673-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93673-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93674-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93674-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93675-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93675-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93676-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93676-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93677-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93677-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93678-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93678-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93680-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93680-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93680-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93680-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93682-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93682-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93683-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93683-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95251-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95251-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95369-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95369-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95371-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95371-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95373-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95373-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95385-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95385-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95389-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95389-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95390-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95390-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95390-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95390-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95391-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95391-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95392-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95392-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95393-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95393-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95394-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95394-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95395-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95395-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95396-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95396-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95397-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95397-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95398-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95398-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95399-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95399-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95400-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95400-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95401-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95401-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95402-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95402-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95492-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95492-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95937-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95937-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96434-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96434-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96434-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96434-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96435-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96435-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96435-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96435-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96436-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96436-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96436-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96436-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96437-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96437-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96437-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96437-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96439-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96439-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96439-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96439-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96441-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96441-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96441-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96441-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96442-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96442-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96442-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96442-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96444-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96444-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96444-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96444-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96444-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96444-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96446-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96446-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96446-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96446-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96446-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96446-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96539-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96539-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96540-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96540-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96541-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96541-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96542-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96542-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96543-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96543-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96544-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96544-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96548-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96548-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96743-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96743-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96743-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96743-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96747-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96747-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96747-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96747-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96779-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96779-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96779-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96779-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96780-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96780-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96782-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96782-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96782-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96782-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96846-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96846-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96846-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96846-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96847-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96847-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96847-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96847-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96848-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96848-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96848-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96848-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96849-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96849-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96849-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96849-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96850-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96850-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96850-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96850-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96851-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96851-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96851-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96851-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96852-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96852-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96852-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96852-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96853-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96853-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96853-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96853-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96854-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96854-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96854-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96854-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96855-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96855-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96855-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96855-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96856-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96856-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96856-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96856-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96857-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96857-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96857-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96857-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96858-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96858-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96858-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96858-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96859-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96859-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96859-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96859-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96860-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96860-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96860-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96860-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96861-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96861-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96861-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96861-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96862-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96862-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96862-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96862-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96863-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96863-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96863-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96863-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96864-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96864-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96864-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96864-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96865-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96865-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96865-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96865-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96866-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96866-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96866-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96866-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96867-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96867-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96867-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96867-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96868-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96868-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96868-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96868-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96869-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96869-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96869-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96869-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96870-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96870-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96870-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96870-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96871-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96871-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96871-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96871-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96872-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96872-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96872-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96872-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97027-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97027-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97027-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97027-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97043-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97043-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97043-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97043-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97057-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97057-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97059-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97059-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97062-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97062-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97063-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97063-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97066-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97066-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97066-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97066-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97067-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97067-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97067-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97067-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97068-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97068-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97068-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97068-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97069-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97069-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97069-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97069-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97070-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97070-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97070-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97070-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97071-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97071-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97071-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97071-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97072-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97072-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97072-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97072-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97073-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97073-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97073-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97073-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97109-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97109-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97109-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97109-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97112-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97112-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97112-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97112-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97115-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97115-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97116-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97116-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97117-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97117-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97117-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97117-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97119-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97119-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97119-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97119-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97120-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97120-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97120-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97120-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97121-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97121-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97121-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97121-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98068-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98068-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98068-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98068-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98077-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98077-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98078-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98078-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98079-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98079-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98162-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98162-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98162-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98162-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98163-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98163-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98163-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98163-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98179-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98179-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98180-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98180-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98527-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98527-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98528-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98528-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98529-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98529-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98530-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98530-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98531-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98531-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98532-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98532-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98862-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98862-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98866-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98866-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98867-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98867-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98868-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98868-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98869-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98869-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98873-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98873-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98875-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98875-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98878-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98878-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98879-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98879-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98880-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98880-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98881-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98881-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98882-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98882-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98883-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98883-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98884-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98884-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98885-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98885-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98886-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98886-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98887-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98887-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98888-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98888-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98890-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98890-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98896-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98896-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98901-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98901-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98949-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98949-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98953-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98953-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98969-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98969-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98969-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98969-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98970-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98970-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98970-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98970-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98971-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98971-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98971-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98971-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98976-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98976-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98978-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98978-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99105-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99105-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99134-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99134-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99134-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99134-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99200-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99200-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99200-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99200-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99200-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99200-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99204-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99204-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99204-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99204-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99204-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99204-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99205-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99205-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99205-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99205-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99213-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99213-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99213-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99213-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99213-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99213-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99215-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99215-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99215-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99215-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99215-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99215-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99217-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99217-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99217-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99217-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99217-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99217-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99219-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99219-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99219-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99219-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99219-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99219-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99222-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99222-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99222-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99222-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99222-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99222-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99261-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99261-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99261-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99261-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99289-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99289-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99290-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99290-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99291-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99291-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99292-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99292-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99293-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99293-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99294-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99294-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99297-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99297-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99298-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99298-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99299-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99299-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99300-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99300-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99301-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99301-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99302-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99302-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99344-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99344-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99344-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99344-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99346-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99346-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99346-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99346-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99348-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99348-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99349-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99349-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99351-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99351-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99351-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99351-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99352-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99352-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99352-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99352-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99353-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99353-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99353-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99353-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99354-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99354-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99354-3;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99354-3;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99355-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99355-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99355-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99355-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99356-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99356-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99356-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99356-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99500-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99500-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99550-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99550-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99550-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99550-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99550-6;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99550-6;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99551-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99551-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99551-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99551-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99551-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99551-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99552-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99552-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99552-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99552-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99553-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99553-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99553-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99553-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99554-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99554-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99554-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99554-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99555-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99555-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99555-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99555-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99555-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99555-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99573-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99573-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99573-8;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99573-8;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99594-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99594-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99594-4;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99594-4;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99615-7;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99615-7;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99675-1;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99675-1;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99676-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99676-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99689-2;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99689-2;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99690-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99690-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99746-0;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99746-0;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99799-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99799-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99800-5;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99800-5;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99817-9;LL361-7;Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99817-9;LL361-7;Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100180-9;LL6242-3;Assisted mobility devices;LA21662-4;1;Wheelchair;;; +100180-9;LL6242-3;Assisted mobility devices;LA10117-2;2;Walker;;; +100180-9;LL6242-3;Assisted mobility devices;LA21660-8;3;Crutches;;; +100180-9;LL6242-3;Assisted mobility devices;LA33391-6;4;Two canes;;; +100180-9;LL6242-3;Assisted mobility devices;LA33390-8;5;One crutch;;; +100180-9;LL6242-3;Assisted mobility devices;LA33416-1;6;One cane;;; +100180-9;LL6242-3;Assisted mobility devices;LA33417-9;7;Knee sleeve/brace;;; +100180-9;LL6242-3;Assisted mobility devices;LA46-8;8;Other;;; +100180-9;LL6242-3;Assisted mobility devices;LA21662-4;1;Wheelchair;;; +100180-9;LL6242-3;Assisted mobility devices;LA10117-2;2;Walker;;; +100180-9;LL6242-3;Assisted mobility devices;LA21660-8;3;Crutches;;; +100180-9;LL6242-3;Assisted mobility devices;LA33391-6;4;Two canes;;; +100180-9;LL6242-3;Assisted mobility devices;LA33390-8;5;One crutch;;; +100180-9;LL6242-3;Assisted mobility devices;LA33416-1;6;One cane;;; +100180-9;LL6242-3;Assisted mobility devices;LA33417-9;7;Knee sleeve/brace;;; +100180-9;LL6242-3;Assisted mobility devices;LA46-8;8;Other;;; +100182-5;LL6243-1;Stand time before discomfort;LA33418-7;1;Cannot stand;;; +100182-5;LL6243-1;Stand time before discomfort;LA33419-5;2;0-5 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA33420-3;3;6-15 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA176-0;4;16-30 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA33422-9;5;31-60 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA33423-7;6;More than an hour;;; +100182-5;LL6243-1;Stand time before discomfort;LA33418-7;1;Cannot stand;;; +100182-5;LL6243-1;Stand time before discomfort;LA33419-5;2;0-5 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA33420-3;3;6-15 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA176-0;4;16-30 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA33422-9;5;31-60 minutes;;; +100182-5;LL6243-1;Stand time before discomfort;LA33423-7;6;More than an hour;;; +100183-3;LL6244-9;Walk time before discomfort;LA15026-0;1;Cannot walk;;; +100183-3;LL6244-9;Walk time before discomfort;LA33419-5;2;0-5 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA33420-3;3;6-15 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA176-0;4;16-30 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA33422-9;5;31-60 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA33423-7;6;More than an hour;;; +100183-3;LL6244-9;Walk time before discomfort;LA15026-0;1;Cannot walk;;; +100183-3;LL6244-9;Walk time before discomfort;LA33419-5;2;0-5 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA33420-3;3;6-15 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA176-0;4;16-30 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA33422-9;5;31-60 minutes;;; +100183-3;LL6244-9;Walk time before discomfort;LA33423-7;6;More than an hour;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100184-1;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100185-8;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100186-6;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100187-4;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100188-2;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100189-0;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100190-8;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100191-6;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100192-4;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100193-2;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA33424-5;1;No bother;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA11910-9;2;Slight;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA6751-7;3;Moderate;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA6750-9;4;Severe;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA13958-6;5;Very severe;;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA33425-2;6;Cannot do (because of knee);;; +100194-0;LL6245-6;No bother/Cannot do/Never;LA33426-0;7;I never do this;;; +100195-7;LL6246-4;No bother/Cannot do;LA33424-5;1;No bother;;; +100195-7;LL6246-4;No bother/Cannot do;LA11910-9;2;Slight;;; +100195-7;LL6246-4;No bother/Cannot do;LA6751-7;3;Moderate;;; +100195-7;LL6246-4;No bother/Cannot do;LA6750-9;4;Severe;;; +100195-7;LL6246-4;No bother/Cannot do;LA13958-6;5;Very severe;;; +100195-7;LL6246-4;No bother/Cannot do;LA33425-2;6;Cannot do (because of knee);;; +100195-7;LL6246-4;No bother/Cannot do;LA33424-5;1;No bother;;; +100195-7;LL6246-4;No bother/Cannot do;LA11910-9;2;Slight;;; +100195-7;LL6246-4;No bother/Cannot do;LA6751-7;3;Moderate;;; +100195-7;LL6246-4;No bother/Cannot do;LA6750-9;4;Severe;;; +100195-7;LL6246-4;No bother/Cannot do;LA13958-6;5;Very severe;;; +100195-7;LL6246-4;No bother/Cannot do;LA33425-2;6;Cannot do (because of knee);;; +100204-7;LL6254-8;Too High/Too Low;LA33450-0;6;"Too High- ""I'm a lot worse than I thought""";;; +100204-7;LL6254-8;Too High/Too Low;LA33451-8;7;"Too High- ""I'm somewhat worse than I thought""";;; +100204-7;LL6254-8;Too High/Too Low;LA33452-6;8;"Just Right- ""My expectations were met""";;; +100204-7;LL6254-8;Too High/Too Low;LA33453-4;9;"Too Low- ""I'm somewhat better than I thought""";;; +100204-7;LL6254-8;Too High/Too Low;LA33454-2;10;"Too Low- ""I'm a lot better than I thought""";;; +100205-4;LL6254-8;Too High/Too Low;LA33450-0;6;"Too High- ""I'm a lot worse than I thought""";;; +100205-4;LL6254-8;Too High/Too Low;LA33451-8;7;"Too High- ""I'm somewhat worse than I thought""";;; +100205-4;LL6254-8;Too High/Too Low;LA33452-6;8;"Just Right- ""My expectations were met""";;; +100205-4;LL6254-8;Too High/Too Low;LA33453-4;9;"Too Low- ""I'm somewhat better than I thought""";;; +100205-4;LL6254-8;Too High/Too Low;LA33454-2;10;"Too Low- ""I'm a lot better than I thought""";;; +100206-2;LL6254-8;Too High/Too Low;LA33450-0;6;"Too High- ""I'm a lot worse than I thought""";;; +100206-2;LL6254-8;Too High/Too Low;LA33451-8;7;"Too High- ""I'm somewhat worse than I thought""";;; +100206-2;LL6254-8;Too High/Too Low;LA33452-6;8;"Just Right- ""My expectations were met""";;; +100206-2;LL6254-8;Too High/Too Low;LA33453-4;9;"Too Low- ""I'm somewhat better than I thought""";;; +100206-2;LL6254-8;Too High/Too Low;LA33454-2;10;"Too Low- ""I'm a lot better than I thought""";;; +100282-3;LL4353-0;Reason vaccine not received;LA20564-3;1;Foreign visitor;;; +100282-3;LL4353-0;Reason vaccine not received;LA27161-1;2;Immigrant;;; +100282-3;LL4353-0;Reason vaccine not received;LA27162-9;3;Lab evidence of previous disease;;; +100282-3;LL4353-0;Reason vaccine not received;LA27163-7;4;MD diagnosis of previous disease;;; +100282-3;LL4353-0;Reason vaccine not received;LA27164-5;5;Medical contraindication;;; +100282-3;LL4353-0;Reason vaccine not received;LA27165-2;6;Missed opportunity in medical setting;;; +100282-3;LL4353-0;Reason vaccine not received;LA27166-0;7;Parent/Patient forgot to vaccinate;;; +100282-3;LL4353-0;Reason vaccine not received;LA27167-8;8;Parent/Patient refusal;;; +100282-3;LL4353-0;Reason vaccine not received;LA27168-6;9;Parent/Patient report of previous disease;;; +100282-3;LL4353-0;Reason vaccine not received;LA27169-4;10;Parent/Patient unaware of recommendation;;; +100282-3;LL4353-0;Reason vaccine not received;LA27170-2;11;Philosophical objection;;; +100282-3;LL4353-0;Reason vaccine not received;LA27171-0;12;Religious exemption;;; +100282-3;LL4353-0;Reason vaccine not received;LA27172-8;13;Too young;;; +100282-3;LL4353-0;Reason vaccine not received;LA27173-6;14;Vaccine record incomplete/unavailable;;; +100282-3;LL4353-0;Reason vaccine not received;LA46-8;15;Other;;; +100282-3;LL4353-0;Reason vaccine not received;LA4489-6;16;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85714-4;LL4353-0;Reason vaccine not received;LA20564-3;1;Foreign visitor;;; +85714-4;LL4353-0;Reason vaccine not received;LA27161-1;2;Immigrant;;; +85714-4;LL4353-0;Reason vaccine not received;LA27162-9;3;Lab evidence of previous disease;;; +85714-4;LL4353-0;Reason vaccine not received;LA27163-7;4;MD diagnosis of previous disease;;; +85714-4;LL4353-0;Reason vaccine not received;LA27164-5;5;Medical contraindication;;; +85714-4;LL4353-0;Reason vaccine not received;LA27165-2;6;Missed opportunity in medical setting;;; +85714-4;LL4353-0;Reason vaccine not received;LA27166-0;7;Parent/Patient forgot to vaccinate;;; +85714-4;LL4353-0;Reason vaccine not received;LA27167-8;8;Parent/Patient refusal;;; +85714-4;LL4353-0;Reason vaccine not received;LA27168-6;9;Parent/Patient report of previous disease;;; +85714-4;LL4353-0;Reason vaccine not received;LA27169-4;10;Parent/Patient unaware of recommendation;;; +85714-4;LL4353-0;Reason vaccine not received;LA27170-2;11;Philosophical objection;;; +85714-4;LL4353-0;Reason vaccine not received;LA27171-0;12;Religious exemption;;; +85714-4;LL4353-0;Reason vaccine not received;LA27172-8;13;Too young;;; +85714-4;LL4353-0;Reason vaccine not received;LA27173-6;14;Vaccine record incomplete/unavailable;;; +85714-4;LL4353-0;Reason vaccine not received;LA46-8;15;Other;;; +85714-4;LL4353-0;Reason vaccine not received;LA4489-6;16;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +100293-0;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33410-4;1;211° - 300°;;; +100293-0;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33411-2;2;161° - 210°;;; +100293-0;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33412-0;3;101° - 160°;;; +100293-0;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33413-8;4;61° - 100°;;; +100293-0;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33414-6;5;31° - 60°;;; +100293-0;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33415-3;6;0° - 30°;;; +100294-8;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33410-4;1;211° - 300°;;; +100294-8;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33411-2;2;161° - 210°;;; +100294-8;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33412-0;3;101° - 160°;;; +100294-8;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33413-8;4;61° - 100°;;; +100294-8;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33414-6;5;31° - 60°;;; +100294-8;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33415-3;6;0° - 30°;;; +100295-5;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33410-4;1;211° - 300°;;; +100295-5;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33411-2;2;161° - 210°;;; +100295-5;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33412-0;3;101° - 160°;;; +100295-5;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33413-8;4;61° - 100°;;; +100295-5;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33414-6;5;31° - 60°;;; +100295-5;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33415-3;6;0° - 30°;;; +100296-3;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33410-4;1;211° - 300°;;; +100296-3;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33411-2;2;161° - 210°;;; +100296-3;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33412-0;3;101° - 160°;;; +100296-3;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33413-8;4;61° - 100°;;; +100296-3;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33414-6;5;31° - 60°;;; +100296-3;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33415-3;6;0° - 30°;;; +100297-1;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33410-4;1;211° - 300°;;; +100297-1;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33411-2;2;161° - 210°;;; +100297-1;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33412-0;3;101° - 160°;;; +100297-1;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33413-8;4;61° - 100°;;; +100297-1;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33414-6;5;31° - 60°;;; +100297-1;LL6234-0;Harris Hip Score - Range of Motion Scale;LA33415-3;6;0° - 30°;;; +100308-6;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100308-6;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100308-6;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100308-6;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100311-0;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100311-0;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100311-0;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100311-0;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100313-6;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100313-6;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100313-6;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100313-6;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100314-4;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100314-4;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100314-4;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100314-4;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100315-1;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100315-1;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100315-1;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100315-1;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100316-9;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100316-9;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100316-9;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100316-9;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100318-5;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100318-5;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100318-5;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100318-5;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100320-1;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100320-1;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100320-1;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100320-1;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100321-9;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100321-9;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100321-9;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100321-9;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100322-7;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100322-7;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100322-7;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100322-7;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100323-5;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100323-5;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100323-5;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100323-5;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100324-3;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100324-3;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100324-3;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100324-3;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100325-0;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100325-0;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100325-0;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100325-0;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100326-8;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100326-8;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100326-8;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100326-8;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100327-6;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100327-6;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100327-6;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100327-6;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100328-4;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100328-4;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100328-4;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100328-4;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100329-2;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100329-2;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100329-2;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100329-2;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100330-0;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100330-0;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100330-0;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100330-0;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100331-8;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100331-8;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100331-8;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100331-8;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100332-6;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100332-6;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100332-6;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100332-6;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100333-4;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100333-4;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100333-4;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100333-4;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100334-2;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100334-2;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100334-2;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100334-2;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100335-9;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100335-9;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100335-9;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100335-9;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100336-7;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100336-7;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100336-7;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100336-7;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100337-5;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100337-5;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100337-5;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100337-5;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100338-3;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100338-3;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100338-3;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100338-3;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100339-1;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +100339-1;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +100339-1;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +100339-1;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82141-3;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82141-3;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82141-3;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +82141-3;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82142-1;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82142-1;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82142-1;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +82142-1;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82143-9;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82143-9;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82143-9;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +82143-9;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82144-7;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82144-7;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82144-7;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +82144-7;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +91568-6;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +91568-6;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +91568-6;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +91568-6;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +91572-8;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +91572-8;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +91572-8;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +91572-8;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +92278-1;LL4027-0;Yes | No | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +92278-1;LL4027-0;Yes | No | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +92278-1;LL4027-0;Yes | No | DK/NS | Refused;LA14619-3;3;Don't know/not sure;;; +92278-1;LL4027-0;Yes | No | DK/NS | Refused;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100309-4;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA33444-3;1;Yes, one person;;; +100309-4;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA33445-0;2;Yes, more than one person;;; +100309-4;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +100309-4;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +100309-4;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100312-8;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA33444-3;1;Yes, one person;;; +100312-8;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA33445-0;2;Yes, more than one person;;; +100312-8;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +100312-8;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +100312-8;LL6250-6;Yes 1 person|Yes >1 person|No|DK|Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100310-2;LL6249-8;Not at all |Somewhat |Vey |Completely |DK|Refused;LA33440-1;1;Not at all reliable;;; +100310-2;LL6249-8;Not at all |Somewhat |Vey |Completely |DK|Refused;LA33441-9;2;Somewhat reliable;;; +100310-2;LL6249-8;Not at all |Somewhat |Vey |Completely |DK|Refused;LA33442-7;3;Very reliable;;; +100310-2;LL6249-8;Not at all |Somewhat |Vey |Completely |DK|Refused;LA33443-5;4;Completely reliable;;; +100310-2;LL6249-8;Not at all |Somewhat |Vey |Completely |DK|Refused;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +100310-2;LL6249-8;Not at all |Somewhat |Vey |Completely |DK|Refused;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100317-7;LL6252-2;Relationship;LA33221-5;1;Your spouse or partner;;; +100317-7;LL6252-2;Relationship;LA33447-6;2;Ex spouse or partner;;; +100317-7;LL6252-2;Relationship;LA33448-4;3;Parent or step-parent;;; +100317-7;LL6252-2;Relationship;LA15645-7;4;Brother or sister;;; +100317-7;LL6252-2;Relationship;LA9949-4;5;Child;;; +100317-7;LL6252-2;Relationship;LA15640-8;6;Other relative;;; +100317-7;LL6252-2;Relationship;LA33449-2;7;Co-worker;;; +100317-7;LL6252-2;Relationship;LA27179-3;8;Neighbor;;; +100317-7;LL6252-2;Relationship;LA6656-8;9;Friend;;; +100317-7;LL6252-2;Relationship;LA15649-9;10;Other nonrelative;;; +100317-7;LL6252-2;Relationship;LA12688-0;13;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +100317-7;LL6252-2;Relationship;LA4389-8;14;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100319-3;LL6252-2;Relationship;LA33221-5;1;Your spouse or partner;;; +100319-3;LL6252-2;Relationship;LA33447-6;2;Ex spouse or partner;;; +100319-3;LL6252-2;Relationship;LA33448-4;3;Parent or step-parent;;; +100319-3;LL6252-2;Relationship;LA15645-7;4;Brother or sister;;; +100319-3;LL6252-2;Relationship;LA9949-4;5;Child;;; +100319-3;LL6252-2;Relationship;LA15640-8;6;Other relative;;; +100319-3;LL6252-2;Relationship;LA33449-2;7;Co-worker;;; +100319-3;LL6252-2;Relationship;LA27179-3;8;Neighbor;;; +100319-3;LL6252-2;Relationship;LA6656-8;9;Friend;;; +100319-3;LL6252-2;Relationship;LA15649-9;10;Other nonrelative;;; +100319-3;LL6252-2;Relationship;LA12688-0;13;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +100319-3;LL6252-2;Relationship;LA4389-8;14;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +100354-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +100354-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +100354-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +100354-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +100354-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +100355-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +100355-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +100355-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +100355-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +100355-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99789-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99789-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99789-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99789-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99789-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99790-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99790-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99790-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99790-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99790-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99791-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99791-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99791-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99791-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99791-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99792-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99792-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99792-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99792-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99792-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99829-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99829-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99829-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99829-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99829-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99830-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99830-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99830-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99830-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99830-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99831-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99831-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99831-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99831-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99831-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99832-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99832-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99832-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99832-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99832-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99833-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99833-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99833-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99833-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99833-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99834-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99834-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99834-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99834-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99834-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99837-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99837-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99837-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99837-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99837-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99838-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99838-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99838-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99838-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99838-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99839-3;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99839-3;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99839-3;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99839-3;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99839-3;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99840-1;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99840-1;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99840-1;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99840-1;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99840-1;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99841-9;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99841-9;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99841-9;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99841-9;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99841-9;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99842-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99842-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99842-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99842-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99842-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99845-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99845-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99845-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99845-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99845-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99846-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99846-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99846-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99846-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99846-8;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99847-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99847-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99847-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99847-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99847-6;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99848-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99848-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99848-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99848-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99848-4;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99849-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99849-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99849-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99849-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99849-2;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99850-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99850-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99850-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99850-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99850-0;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99856-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99856-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99856-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99856-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99856-7;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +99857-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33175-3;1;0-25% of the time (rarely);;; +99857-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33176-1;2;26-49% of the time (sometimes);;; +99857-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33177-9;3;50-75% of the time (often);;; +99857-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33178-7;4;76-90% of the time (most of the time);;; +99857-5;LL6183-9;NOMS Functional Communication Measures scoring;LA33179-5;5;91-100% of the time (always);;; +100356-5;LL6259-7;CT&GC&TV;LA16153-1;1;Chlamydia trachomatis detected;;; +100356-5;LL6259-7;CT&GC&TV;LA16154-9;2;Chlamydia trachomatis not detected;;; +100356-5;LL6259-7;CT&GC&TV;LA16155-6;3;Chlamydia trachomatis inconclusive;;; +100356-5;LL6259-7;CT&GC&TV;LA16157-2;4;Chlamydia trachomatis equivocal;;; +100356-5;LL6259-7;CT&GC&TV;LA16150-7;5;Neisseria gonorrhoeae detected;;; +100356-5;LL6259-7;CT&GC&TV;LA16151-5;6;Neisseria gonorrhoeae not detected;;; +100356-5;LL6259-7;CT&GC&TV;LA16152-3;7;Neisseria gonorrhoeae inconclusive;;; +100356-5;LL6259-7;CT&GC&TV;LA16156-4;8;Neisseria gonorrhoeae equivocal;;; +100356-5;LL6259-7;CT&GC&TV;LA26252-9;9;Trichomonas vaginalis present;;; +100356-5;LL6259-7;CT&GC&TV;LA26253-7;10;Trichomonas vaginalis not present;;; +100357-3;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +100357-3;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100358-1;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +100358-1;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +74812-9;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +74812-9;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +74822-8;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +74822-8;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75226-1;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75226-1;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75229-5;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75229-5;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75230-3;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75230-3;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75231-1;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75231-1;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75232-9;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75232-9;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75233-7;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75233-7;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75234-5;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75234-5;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +75235-2;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +75235-2;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +77022-2;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +77022-2;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +77023-0;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +77023-0;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +77024-8;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +77024-8;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +77025-5;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +77025-5;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +77026-3;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +77026-3;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +77027-1;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +77027-1;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +77028-9;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +77028-9;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +81142-2;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +81142-2;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84919-0;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +84919-0;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +87241-6;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +87241-6;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +87242-4;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +87242-4;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +92838-2;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +92838-2;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93121-2;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +93121-2;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98253-8;LL2872-1;pres/not detected;LA11883-8;0;Not detected;;; +98253-8;LL2872-1;pres/not detected;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100361-5;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15236-5;1;Strongly disagree;;; +100361-5;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15773-7;2;Disagree;;; +100361-5;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA14786-0;3;Neutral;;; +100361-5;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15774-5;4;Agree;;; +100361-5;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15237-3;5;Strongly agree;;; +100363-1;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15236-5;1;Strongly disagree;;; +100363-1;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15773-7;2;Disagree;;; +100363-1;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA14786-0;3;Neutral;;; +100363-1;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15774-5;4;Agree;;; +100363-1;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15237-3;5;Strongly agree;;; +100365-6;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15236-5;1;Strongly disagree;;; +100365-6;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15773-7;2;Disagree;;; +100365-6;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA14786-0;3;Neutral;;; +100365-6;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15774-5;4;Agree;;; +100365-6;LL6255-5;Strong disagree/Disagree/Neut/Agree/ Strong agree;LA15237-3;5;Strongly agree;;; +100362-3;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15236-5;1;Strongly disagree;;; +100362-3;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15773-7;2;Disagree;;; +100362-3;LL6256-3;SD/Disagree/Neut/Agree/SA;LA14786-0;3;Neutral;;; +100362-3;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15774-5;4;Agree;;; +100362-3;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15237-3;5;Strongly agree;;; +100364-9;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15236-5;1;Strongly disagree;;; +100364-9;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15773-7;2;Disagree;;; +100364-9;LL6256-3;SD/Disagree/Neut/Agree/SA;LA14786-0;3;Neutral;;; +100364-9;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15774-5;4;Agree;;; +100364-9;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15237-3;5;Strongly agree;;; +100366-4;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15236-5;1;Strongly disagree;;; +100366-4;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15773-7;2;Disagree;;; +100366-4;LL6256-3;SD/Disagree/Neut/Agree/SA;LA14786-0;3;Neutral;;; +100366-4;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15774-5;4;Agree;;; +100366-4;LL6256-3;SD/Disagree/Neut/Agree/SA;LA15237-3;5;Strongly agree;;; +100370-6;LL6260-5;Orthopoxvirus;LA33460-9;1;Presumptive positive identification of Variola virus;;; +100370-6;LL6260-5;Orthopoxvirus;LA33461-7;2;Presumptive positive identification of Varicella virus;;; +100370-6;LL6260-5;Orthopoxvirus;LA33462-5;3;Presumptive positive identification of Non-Variola virus;;; +100370-6;LL6260-5;Orthopoxvirus;LA33463-3;4;Presumptive positive identification of Orthopoxvirus;;; +100370-6;LL6260-5;Orthopoxvirus;LA33464-1;5;Unable to rule out Variola virus;;; +100370-6;LL6260-5;Orthopoxvirus;LA33465-8;6;Viral testing inconclusive;;; +100370-6;LL6260-5;Orthopoxvirus;LA33466-6;7;No Orthopoxvirus;;; +100370-6;LL6260-5;Orthopoxvirus;LA13546-9;8;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +100434-0;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA11882-0;0;Detected;;; +100434-0;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA11883-8;1;Not detected;;; +100434-0;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100434-0;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100434-0;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA13538-6;4;Not tested;;; +79190-5;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA11882-0;0;Detected;;; +79190-5;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA11883-8;1;Not detected;;; +79190-5;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +79190-5;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +79190-5;LL3698-9;Detected|Not Det|Equiv|Inconcl|Not test;LA13538-6;4;Not tested;;; +10061-0;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +10061-0;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +33232-0;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +33232-0;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +53319-0;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +53319-0;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +65948-2;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +65948-2;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +65949-0;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +65949-0;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +66024-1;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +66024-1;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +66029-0;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +66029-0;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +67848-2;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +67848-2;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +71355-2;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +71355-2;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +71431-1;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +71431-1;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72223-1;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72223-1;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72224-9;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72224-9;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72277-7;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72277-7;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72295-9;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72295-9;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72298-3;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72298-3;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72338-7;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72338-7;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72339-5;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72339-5;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72340-3;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72340-3;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +72341-1;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +72341-1;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +74347-6;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +74347-6;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +74357-5;LL1311-1;PhenX12_44;LA14895-9;1;Not present;;; +74357-5;LL1311-1;PhenX12_44;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +100663-4;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +100663-4;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +100663-4;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +100664-2;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +100664-2;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +100664-2;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +100665-9;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +100665-9;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +100665-9;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +100666-7;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +100666-7;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +100666-7;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +100667-5;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +100667-5;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +100667-5;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +100668-3;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +100668-3;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +100668-3;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +100669-1;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +100669-1;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +100669-1;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +70041-9;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +70041-9;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +70041-9;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +70243-1;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +70243-1;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +70243-1;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +70244-9;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +70244-9;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +70244-9;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +70245-6;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +70245-6;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +70245-6;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +70246-4;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +70246-4;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +70246-4;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +70247-2;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +70247-2;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +70247-2;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +70248-0;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +70248-0;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +70248-0;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +72506-9;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +72506-9;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +72506-9;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +72507-7;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +72507-7;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +72507-7;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +72508-5;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +72508-5;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +72508-5;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +72697-6;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +72697-6;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +72697-6;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +74692-5;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +74692-5;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +74692-5;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +94717-6;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +94717-6;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +94717-6;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +95555-9;LL2014-0;Wild type-Hetero-Homo;LA9658-1;1;Wild type;;; +95555-9;LL2014-0;Wild type-Hetero-Homo;LA6706-1;2;Heterozygous;;; +95555-9;LL2014-0;Wild type-Hetero-Homo;LA6705-3;3;Homozygous;;; +100670-9;LL3288-9;RHD genotype;LA22747-2;1;RhD positive;;; +100670-9;LL3288-9;RHD genotype;LA22748-0;2;RhD negative;;; +100670-9;LL3288-9;RHD genotype;LA22749-8;3;Psi(+)/RhD variant;;; +100670-9;LL3288-9;RHD genotype;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +100670-9;LL3288-9;RHD genotype;LA13546-9;5;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +35465-4;LL3288-9;RHD genotype;LA22747-2;1;RhD positive;;; +35465-4;LL3288-9;RHD genotype;LA22748-0;2;RhD negative;;; +35465-4;LL3288-9;RHD genotype;LA22749-8;3;Psi(+)/RhD variant;;; +35465-4;LL3288-9;RHD genotype;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +35465-4;LL3288-9;RHD genotype;LA13546-9;5;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +42316-0;LL3288-9;RHD genotype;LA22747-2;1;RhD positive;;; +42316-0;LL3288-9;RHD genotype;LA22748-0;2;RhD negative;;; +42316-0;LL3288-9;RHD genotype;LA22749-8;3;Psi(+)/RhD variant;;; +42316-0;LL3288-9;RHD genotype;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +42316-0;LL3288-9;RHD genotype;LA13546-9;5;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +77016-4;LL3288-9;RHD genotype;LA22747-2;1;RhD positive;;; +77016-4;LL3288-9;RHD genotype;LA22748-0;2;RhD negative;;; +77016-4;LL3288-9;RHD genotype;LA22749-8;3;Psi(+)/RhD variant;;; +77016-4;LL3288-9;RHD genotype;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +77016-4;LL3288-9;RHD genotype;LA13546-9;5;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +100737-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100737-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100738-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100738-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100739-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100739-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100740-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100740-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100741-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100741-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100742-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100742-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100743-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100743-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100764-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100764-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +18265-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +18265-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +20502-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +20502-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +32825-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +32825-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +33009-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +33009-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +33508-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +33508-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +34680-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +34680-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +35301-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +35301-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +40744-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +40744-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +41277-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +41277-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +41293-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +41293-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +43154-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +43154-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49973-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49973-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49974-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49974-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49975-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49975-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49976-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49976-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49977-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49977-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49978-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49978-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49979-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49979-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49980-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49980-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49981-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49981-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49982-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49982-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49983-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49983-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49984-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49984-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49991-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49991-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49992-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49992-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49993-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49993-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49994-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49994-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49995-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49995-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49996-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49996-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49997-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49997-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +49998-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +49998-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +50390-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +50390-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +50391-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +50391-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +60277-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +60277-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +60278-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +60278-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64413-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64413-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64414-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64414-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64415-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64415-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64416-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64416-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64419-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64419-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64420-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64420-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64421-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64421-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64422-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64422-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64423-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64423-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64424-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64424-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64425-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64425-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64426-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64426-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64427-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64427-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64428-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64428-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64429-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64429-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64430-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64430-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64431-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64431-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +64432-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +64432-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +6676-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +6676-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +675-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +675-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +69428-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +69428-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +71488-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +71488-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +71489-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +71489-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +74138-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +74138-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +78355-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +78355-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +80372-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +80372-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +80610-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +80610-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +80612-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +80612-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86510-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86510-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86511-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86511-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86512-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86512-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86513-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86513-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86514-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86514-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86515-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86515-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86517-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86517-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86518-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86518-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86519-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86519-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86520-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86520-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86536-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86536-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86537-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86537-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86538-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86538-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86539-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86539-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86540-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86540-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86541-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86541-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86542-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86542-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86543-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86543-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86544-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86544-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86545-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86545-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86546-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86546-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86550-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86550-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86559-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86559-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86560-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86560-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86561-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86561-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86562-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86562-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86563-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86563-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86564-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86564-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86565-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86565-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86566-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86566-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86567-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86567-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86568-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86568-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86569-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86569-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86570-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86570-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86571-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86571-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86572-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86572-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86573-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86573-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86574-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86574-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86575-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86575-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86576-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86576-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86577-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86577-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86578-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86578-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86579-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86579-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86580-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86580-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86582-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86582-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86586-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86586-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86587-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86587-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86588-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86588-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86589-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86589-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86591-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86591-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86592-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86592-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86593-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86593-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86594-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86594-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +86954-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +86954-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88188-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88188-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88189-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88189-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88190-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88190-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88191-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88191-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88192-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88192-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88194-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88194-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88201-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88201-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88205-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88205-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88206-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88206-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88207-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88207-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88212-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88212-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88214-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88214-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88216-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88216-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88220-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88220-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88564-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88564-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88566-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88566-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88567-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88567-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88598-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88598-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88623-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88623-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88624-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88624-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88629-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88629-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88630-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88630-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88903-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88903-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88979-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +88979-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +89259-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +89259-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +89583-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +89583-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +89586-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +89586-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +89588-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +89588-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +89589-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +89589-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +90459-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +90459-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +90460-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +90460-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +90461-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +90461-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +90462-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +90462-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +90464-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +90464-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +91064-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +91064-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +91065-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +91065-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +91069-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +91069-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +91074-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +91074-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +91077-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +91077-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +91078-6;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +91078-6;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +91080-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +91080-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +92837-4;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +92837-4;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93801-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93801-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93803-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93803-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93866-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93866-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93953-8;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93953-8;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94665-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94665-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94666-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94666-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94827-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94827-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94837-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94837-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94838-0;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94838-0;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +95127-7;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +95127-7;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +95559-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +95559-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +96426-2;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +96426-2;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +96710-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +96710-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +96732-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +96732-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +96733-1;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +96733-1;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +96734-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +96734-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98240-5;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98240-5;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98241-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98241-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98257-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98257-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +99052-3;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +99052-3;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +99394-9;LL1937-3;Present|Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +99394-9;LL1937-3;Present|Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100748-3;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +100748-3;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +100748-3;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +100749-1;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +100749-1;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +100749-1;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +100750-9;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +100750-9;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +100750-9;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81644-7;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +81644-7;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +81644-7;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81645-4;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +81645-4;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +81645-4;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81646-2;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +81646-2;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +81646-2;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81647-0;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +81647-0;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +81647-0;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +87620-1;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +87620-1;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +87620-1;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92577-6;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +92577-6;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +92577-6;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92807-7;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +92807-7;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +92807-7;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92808-5;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +92808-5;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +92808-5;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92809-3;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +92809-3;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +92809-3;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +94184-9;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +94184-9;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +94184-9;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +94185-6;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +94185-6;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +94185-6;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +95912-2;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +95912-2;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +95912-2;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +95913-0;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +95913-0;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +95913-0;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +95914-8;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +95914-8;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +95914-8;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +95915-5;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +95915-5;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +95915-5;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +95916-3;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +95916-3;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +95916-3;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +95917-1;LL3987-6;Detected|Not Det|Indeterm;LA11882-0;1;Detected;;; +95917-1;LL3987-6;Detected|Not Det|Indeterm;LA11883-8;2;Not detected;;; +95917-1;LL3987-6;Detected|Not Det|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33512-7;1;Activities of daily living;282260003;Activity of daily living procedures and interventions (procedure);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33513-5;2;Coughing;49727002;Cough (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33514-3;3;Deep breathing;289123006;Deep breathing (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33515-0;4;Dressing change;18949003;Change of dressing (procedure);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33516-8;5;Environmental stimulation;255710008;Environmental stimuli (event);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33517-6;6;Exercising;226029000;Exercises (regime/therapy);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33518-4;7;Feeling anxious;48694002;Anxiety (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33519-2;8;Feeling fatigued;84229001;Fatigue (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33520-0;9;Immobility;102491009;Immobile (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33521-8;10;Kneeling;277773003;Kneeling position (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33523-4;11;Palpating;113011001;Palpation (procedure);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33522-6;12;Presence of indwelling tubes;397578001;Device in situ (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33524-2;13;Resting;128975004;Resting state (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA11868-9;14;Sitting;33586001;Sitting position (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33098-7;15;Sneezing;76067001;Sneezing (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33525-9;16;Squatting;408797004;Squatting body position (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA11870-5;17;Standing;10904000;Orthostatic body position (finding);http://snomed.info/sct +100752-5;LL6278-7;Exacerbating factors;LA33526-7;18;Stretching;122546009;Stretching procedure (procedure);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33527-5;1;Acupuncture therapy;44868003;Acupuncture (procedure);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33528-3;2;Acupressure;231107005;Acupressure (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA25339-5;3;Aromatherapy;394615007;Aromatherapy (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33529-1;4;Bedrest;225316001;Bedrest (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33530-9;5;Stabilizing appliance;7704007;Stabilizing appliance, device (physical object);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33531-7;6;Chiropractic therapy;182548004;Chiropraxy (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA25341-1;7;Cold therapy;182660006;Cold therapy (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33532-5;8;Mobility aid;183135000;Mobility aid (physical object);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33533-3;9;Distraction activities;414039005;Distraction (procedure);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA25349-4;10;Elevation;;; +100753-3;LL6279-5;Alleviating factors;LA33534-1;11;Environment adjustment;719078002;Adjustment of physical environment (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33535-8;12;Exercises;226029000;Exercises (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA9494-1;13;Physical Therapy;91251008;Physical therapy procedure (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33536-6;14;Emotional support;133921002;Emotional support (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA25351-0;15;Guided Imagery;228565006;Imagery technique (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA25340-3;16;Heat therapy;266694003;Heat therapy (procedure);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33537-4;17;Hypnotherapy;19997007;Hypnotherapy (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33538-2;18;Immobilization;266686005;Procedures relating to splintage and immobilization (procedure);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA25338-7;19;Massage;387854002;Massage physiotherapy (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA22650-8;20;Medication;416608005;Drug therapy (procedure);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33539-0;21;Music Therapy;21065008;Music therapy (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33540-8;22;Non-nutritive sucking;386370001;Provision of non-nutritive sucking (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA9495-8;23;Occupational Therapy;84478008;Occupational therapy (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33541-6;24;Relaxation techniques;11609002;Relaxation exercise (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33542-4;25;Repositioning;308739004;Repositioning (procedure);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33524-2;26;Resting;128975004;Resting state (finding);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA11868-9;27;Sitting;33586001;Sitting position (finding);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33543-2;28;Skin-to-skin contact;386342003;Kangaroo care (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33544-0;29;Specialty bed;311767007;Special bed (physical object);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33545-7;30;Touch;386476006;Touch (regime/therapy);http://snomed.info/sct +100753-3;LL6279-5;Alleviating factors;LA33546-5;31;Application of transcutaneous electric nerve stimulator;229559001;Transcutaneous electrical nerve stimulation (regime/therapy);http://snomed.info/sct +100761-6;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100761-6;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100761-6;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +100846-5;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100846-5;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100846-5;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +100964-6;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +100964-6;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +100964-6;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +41453-2;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41453-2;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41453-2;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +41458-1;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41458-1;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41458-1;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +48056-6;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48056-6;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48056-6;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55764-5;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55764-5;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55764-5;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55765-2;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55765-2;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55765-2;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55766-0;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55766-0;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55766-0;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55767-8;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55767-8;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55767-8;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55768-6;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55768-6;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55768-6;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55769-4;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55769-4;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55769-4;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55770-2;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55770-2;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +55770-2;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +69420-8;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69420-8;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69420-8;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +69568-4;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69568-4;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69568-4;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +70068-2;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70068-2;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70068-2;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +70069-0;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70069-0;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70069-0;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +70070-8;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70070-8;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70070-8;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +70071-6;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70071-6;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70071-6;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +71773-6;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +71773-6;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +71773-6;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +93812-6;LL759-2;Neg|Pos|Indeterm;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93812-6;LL759-2;Neg|Pos|Indeterm;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93812-6;LL759-2;Neg|Pos|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +100767-3;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100767-3;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100767-3;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100767-3;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100768-1;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100768-1;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100768-1;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100768-1;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100769-9;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100769-9;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100769-9;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100769-9;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100770-7;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100770-7;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100770-7;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100770-7;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100771-5;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100771-5;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100771-5;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100771-5;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100772-3;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100772-3;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100772-3;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100772-3;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100773-1;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100773-1;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100773-1;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100773-1;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100774-9;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100774-9;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100774-9;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100774-9;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100775-6;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100775-6;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100775-6;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100775-6;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100776-4;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100776-4;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100776-4;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100776-4;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100777-2;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100777-2;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100777-2;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100777-2;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100778-0;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100778-0;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100778-0;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100778-0;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100779-8;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100779-8;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100779-8;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100779-8;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100780-6;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100780-6;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100780-6;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100780-6;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100781-4;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100781-4;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100781-4;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100781-4;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100782-2;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100782-2;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100782-2;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100782-2;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100783-0;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100783-0;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100783-0;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100783-0;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100784-8;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100784-8;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100784-8;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100784-8;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100785-5;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100785-5;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100785-5;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100785-5;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100786-3;LL6277-9;Rare or Never|Some|Occas|Most;LA15665-5;1;Rarely or never;;; +100786-3;LL6277-9;Rare or Never|Some|Occas|Most;LA14733-2;2;Some of the time;;; +100786-3;LL6277-9;Rare or Never|Some|Occas|Most;LA6483-7;3;Occasionally;;; +100786-3;LL6277-9;Rare or Never|Some|Occas|Most;LA14734-0;4;Most of the time;;; +100822-6;LL6263-9;POLST CPR;LA33470-8;1;Yes CPR;;; +100822-6;LL6263-9;POLST CPR;LA33471-6;2;No CPR: Do Not Attempt Resuscitation.;;; +100822-6;LL6263-9;POLST CPR;LA33470-8;1;Yes CPR;;; +100822-6;LL6263-9;POLST CPR;LA33471-6;2;No CPR: Do Not Attempt Resuscitation.;;; +100823-4;LL6264-7;POLST Initial Tx;LA33473-2;1;Full treatments;;; +100823-4;LL6264-7;POLST Initial Tx;LA33474-0;2;Selective treatments;;; +100823-4;LL6264-7;POLST Initial Tx;LA33475-7;3;Comfort-focused treatments;;; +100823-4;LL6264-7;POLST Initial Tx;LA33473-2;1;Full treatments;;; +100823-4;LL6264-7;POLST Initial Tx;LA33474-0;2;Selective treatments;;; +100823-4;LL6264-7;POLST Initial Tx;LA33475-7;3;Comfort-focused treatments;;; +100825-9;LL6267-0;POLST Med assist nutr;LA33489-8;1;Provide feeding through new or existing surgically-placed tubes;;; +100825-9;LL6267-0;POLST Med assist nutr;LA33490-6;2;Trial period for artificial nutrition but no surgically-placed tubes;;; +100825-9;LL6267-0;POLST Med assist nutr;LA33491-4;3;No artificial means of nutrition desired;;; +100825-9;LL6267-0;POLST Med assist nutr;LA33492-2;4;Not discussed or no decision made (provide standard of care);;; +100825-9;LL6267-0;POLST Med assist nutr;LA33489-8;1;Provide feeding through new or existing surgically-placed tubes;;; +100825-9;LL6267-0;POLST Med assist nutr;LA33490-6;2;Trial period for artificial nutrition but no surgically-placed tubes;;; +100825-9;LL6267-0;POLST Med assist nutr;LA33491-4;3;No artificial means of nutrition desired;;; +100825-9;LL6267-0;POLST Med assist nutr;LA33492-2;4;Not discussed or no decision made (provide standard of care);;; +100826-7;LL6265-4;POLST review;LA33476-5;1;Yes the document was reviewed;;; +100826-7;LL6265-4;POLST review;LA33478-1;2;Conflict exists, notified patient;;; +100826-7;LL6265-4;POLST review;LA33479-9;3;Advance directive not available;;; +100826-7;LL6265-4;POLST review;LA33481-5;4;No advance directive exists;;; +100826-7;LL6265-4;POLST review;LA33476-5;1;Yes the document was reviewed;;; +100826-7;LL6265-4;POLST review;LA33478-1;2;Conflict exists, notified patient;;; +100826-7;LL6265-4;POLST review;LA33479-9;3;Advance directive not available;;; +100826-7;LL6265-4;POLST review;LA33481-5;4;No advance directive exists;;; +100827-5;LL6266-2;POLST discuss part;LA33482-3;1;Patient with decision-making capacity;;; +100827-5;LL6266-2;POLST discuss part;LA33483-1;2;Court appointed guardian;;; +100827-5;LL6266-2;POLST discuss part;LA33485-6;3;Parent of minor;;; +100827-5;LL6266-2;POLST discuss part;LA33487-2;4;Legal surrogate/health care agent;;; +100827-5;LL6266-2;POLST discuss part;LA46-8;5;Other;;; +100827-5;LL6266-2;POLST discuss part;LA33482-3;1;Patient with decision-making capacity;;; +100827-5;LL6266-2;POLST discuss part;LA33483-1;2;Court appointed guardian;;; +100827-5;LL6266-2;POLST discuss part;LA33485-6;3;Parent of minor;;; +100827-5;LL6266-2;POLST discuss part;LA33487-2;4;Legal surrogate/health care agent;;; +100827-5;LL6266-2;POLST discuss part;LA46-8;5;Other;;; +100841-6;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100841-6;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93619-5;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93619-5;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93623-7;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93623-7;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93629-4;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93629-4;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93634-4;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93634-4;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +93664-1;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +93664-1;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94147-6;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94147-6;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94148-4;LL5435-4;Present-1 or Absent-0;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94148-4;LL5435-4;Present-1 or Absent-0;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100868-9;LL5997-3;Cryptosporidium species;LA15840-4;1;Cryptosporidium parvum;51504002;Cryptosporidium parvum (organism);http://snomed.info/sct +100868-9;LL5997-3;Cryptosporidium species;LA32413-9;2;Cryptosporidium hominis;;; +100868-9;LL5997-3;Cryptosporidium species;LA46-8;3;Other;;; +100870-5;LL5997-3;Cryptosporidium species;LA15840-4;1;Cryptosporidium parvum;51504002;Cryptosporidium parvum (organism);http://snomed.info/sct +100870-5;LL5997-3;Cryptosporidium species;LA32413-9;2;Cryptosporidium hominis;;; +100870-5;LL5997-3;Cryptosporidium species;LA46-8;3;Other;;; +98411-2;LL5997-3;Cryptosporidium species;LA15840-4;1;Cryptosporidium parvum;51504002;Cryptosporidium parvum (organism);http://snomed.info/sct +98411-2;LL5997-3;Cryptosporidium species;LA32413-9;2;Cryptosporidium hominis;;; +98411-2;LL5997-3;Cryptosporidium species;LA46-8;3;Other;;; +100869-7;LL6268-8;Cryptospordium species subtypes;LA33493-0;1;IaA17R2;;; +100869-7;LL6268-8;Cryptospordium species subtypes;LA33494-8;2;IbA10G2;;; +100869-7;LL6268-8;Cryptospordium species subtypes;LA33495-5;3;IeA11G3T3;;; +100869-7;LL6268-8;Cryptospordium species subtypes;LA33496-3;4;IeA13G3T1;;; +100869-7;LL6268-8;Cryptospordium species subtypes;LA33497-1;5;IIaA15G3;;; +100869-7;LL6268-8;Cryptospordium species subtypes;LA33498-9;6;IIdA15G1;;; +100871-3;LL6269-6;Giardia lamblia genotypes;LA33499-7;1;G. lamblia AII;;; +100871-3;LL6269-6;Giardia lamblia genotypes;LA33500-2;2;G.lamblia BIII;;; +100871-3;LL6269-6;Giardia lamblia genotypes;LA33501-0;3;G. lamblia BIV;;; +100873-9;LL6269-6;Giardia lamblia genotypes;LA33499-7;1;G. lamblia AII;;; +100873-9;LL6269-6;Giardia lamblia genotypes;LA33500-2;2;G.lamblia BIII;;; +100873-9;LL6269-6;Giardia lamblia genotypes;LA33501-0;3;G. lamblia BIV;;; +100874-7;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +100874-7;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +81181-0;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +81181-0;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +82137-1;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +82137-1;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +82904-4;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +82904-4;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84874-7;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84874-7;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84876-2;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84876-2;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84879-6;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84879-6;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84881-2;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84881-2;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84886-1;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84886-1;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84890-3;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84890-3;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84895-2;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84895-2;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84896-0;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84896-0;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84899-4;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84899-4;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84917-4;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84917-4;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +84918-2;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +84918-2;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +85091-7;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +85091-7;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +94737-4;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +94737-4;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98208-2;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98208-2;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98210-8;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98210-8;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98215-7;LL3950-4;Present | Absent;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98215-7;LL3950-4;Present | Absent;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +100885-3;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +100885-3;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +100885-3;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100885-3;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +100886-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +100886-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +100886-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100886-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +100887-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +100887-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +100887-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100887-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +100888-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +100888-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +100888-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100888-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +100889-5;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +100889-5;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +100889-5;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100889-5;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +100891-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +100891-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +100891-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100891-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +100892-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +100892-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +100892-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +100892-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +86220-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +86220-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +86220-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86220-1;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +86620-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +86620-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +86620-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86620-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88454-4;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +88454-4;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +88454-4;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88454-4;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88716-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +88716-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +88716-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88716-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88718-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +88718-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +88718-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88718-2;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88719-0;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +88719-0;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +88719-0;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88719-0;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88720-8;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +88720-8;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +88720-8;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88720-8;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88721-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +88721-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +88721-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88721-6;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94565-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +94565-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +94565-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94565-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94768-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +94768-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +94768-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94768-9;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95542-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA11882-0;0;Detected;;; +95542-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA11883-8;1;Not detected;;; +95542-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +95542-7;LL3713-6;Detected|Not det||Equiv|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +100899-4;LL6272-0;ESBL enterobacter;LA33506-9;1;E. coli ESBL;;; +100899-4;LL6272-0;ESBL enterobacter;LA33507-7;2;K. pneumoniae ESBL;;; +100901-8;LL6273-8;Carbapenemase bacteria detected;LA33508-5;1;E. coli carbapenemase producing;;; +100901-8;LL6273-8;Carbapenemase bacteria detected;LA33509-3;2;K. pneumoniae carbapenemase producing;;; +100902-6;LL6274-6;OXA-48 carbapenemase bacteria;LA33510-1;1;K.pneumoniae OXA-48 carbapenemase producing;;; +100902-6;LL6274-6;OXA-48 carbapenemase bacteria;LA33511-9;2;E. coli OXA-48 carbapenemase producing;;; +100905-9;LL6275-3;Fastidious gram positive;LA20988-4;1;Streptococcus species;;; +100905-9;LL6275-3;Fastidious gram positive;LA20993-4;2;Listeria species;;; +100907-5;LL6270-4;VRE species;LA33502-8;1;Enterococcus faecium (vanA);;; +100907-5;LL6270-4;VRE species;LA33503-6;2;Enterococcus faecalis (vanB);;; +100910-9;LL6271-2;Colistin Resistant;LA33504-4;1;E. coli colistin resistant;;; +100910-9;LL6271-2;Colistin Resistant;LA33505-1;2;K. pneumoniae colistin resistant;;; +100917-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100917-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100917-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100917-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100918-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100918-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100918-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100918-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100919-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100919-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100919-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100919-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100920-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100920-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100920-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100920-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100924-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100924-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100924-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100924-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100925-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100925-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100925-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100925-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100926-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100926-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100926-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100926-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100927-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100927-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100927-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100927-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100930-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100931-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100931-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100931-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100931-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100932-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100932-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100932-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100932-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100933-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100936-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100936-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100936-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100936-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100937-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100937-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100937-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100937-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100938-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100938-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100938-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100938-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100939-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100939-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100939-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100939-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100942-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100942-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100942-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100942-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100943-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100943-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100943-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100943-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100944-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100944-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100944-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100944-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100945-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100945-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100945-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100945-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100954-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100954-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100954-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100954-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100955-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100955-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100955-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100955-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100956-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100956-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100956-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100956-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100957-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100957-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100957-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100957-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100960-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100960-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100960-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100960-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100961-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +100961-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +100961-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +100961-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +90020-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +90020-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +90020-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +90020-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96773-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96774-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96775-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96776-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96931-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96932-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96933-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96934-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96941-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96942-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96943-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96944-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96947-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96948-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96949-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96950-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96953-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96954-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96955-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +96956-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97892-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97893-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97894-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97895-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97898-1;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97899-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97900-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97901-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97904-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97905-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97906-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +97907-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99419-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99420-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99421-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99422-8;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99558-9;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99559-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99560-5;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99561-3;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99564-7;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99565-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99566-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99569-6;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99570-4;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99571-2;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15237-3;1;Strongly agree;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15774-5;2;Agree;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA14786-0;3;Neutral;;; +99572-0;LL5780-3;Strongly agree/Agree/Neutral/Disagree;LA15773-7;4;Disagree;;; +100947-1;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA14751-4;1;Hardly ever;;; +100947-1;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA6483-7;2;Occasionally;;; +100947-1;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA10082-8;3;Sometimes;;; +100947-1;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA9933-8;4;Always;;; +100948-9;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA14751-4;1;Hardly ever;;; +100948-9;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA6483-7;2;Occasionally;;; +100948-9;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA10082-8;3;Sometimes;;; +100948-9;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA9933-8;4;Always;;; +100949-7;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA14751-4;1;Hardly ever;;; +100949-7;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA6483-7;2;Occasionally;;; +100949-7;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA10082-8;3;Sometimes;;; +100949-7;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA9933-8;4;Always;;; +100950-5;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA14751-4;1;Hardly ever;;; +100950-5;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA6483-7;2;Occasionally;;; +100950-5;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA10082-8;3;Sometimes;;; +100950-5;LL6276-1;Hardly ever/Occasionally/Sometimes/Always;LA9933-8;4;Always;;; +100973-7;LL6280-3;Flu A;LA33547-3;1;Flu A positive;;; +100973-7;LL6280-3;Flu A;LA33548-1;2;Flu A negative;;; +100973-7;LL6280-3;Flu A;LA13548-5;3;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +100974-5;LL6281-1;Flu B;LA33549-9;1;Flu B positive;;; +100974-5;LL6281-1;Flu B;LA33550-7;2;Flu B negative;;; +100974-5;LL6281-1;Flu B;LA13548-5;3;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +100975-2;LL6283-7;Induced abortion methods;LA33553-1;1;Hysterotomy and termination of pregnancy;;; +100975-2;LL6283-7;Induced abortion methods;LA33554-9;2;Injection of substance into amniotic cavity for termination of pregnancy;;; +100975-2;LL6283-7;Induced abortion methods;LA33555-6;3;Dilation of cervix uteri and curettage for termination of pregnancy;;; +101003-2;LL6290-2;Monkeypox virus clade;LA33581-2;1;Clade I;;; +101003-2;LL6290-2;Monkeypox virus clade;LA33582-0;2;Clade IIa;;; +101003-2;LL6290-2;Monkeypox virus clade;LA33583-8;3;Clade IIb;;; +101003-2;LL6290-2;Monkeypox virus clade;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101003-2;LL6290-2;Monkeypox virus clade;LA20552-8;5;Unsatisfactory;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA13487-6;1;A;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33584-6;2;A.1;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33585-3;3;A.1.1;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33586-1;4;A.2;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33587-9;5;B.1;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33588-7;6;B.1.1;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33589-5;7;B.1.2;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33590-3;8;B.1.3;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33591-1;9;B.1.4;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33592-9;10;B.1.5;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33593-7;11;B.1.6;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33594-5;12;B.1.7;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA33595-2;13;B.1.8;;; +101004-0;LL6291-0;Monkeypox virus lineage;LA15841-2;14;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101004-0;LL6291-0;Monkeypox virus lineage;LA20552-8;15;Unsatisfactory;;; +101140-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101140-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101140-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +6556-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +6556-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +6556-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +70165-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70165-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70165-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +70166-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70166-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70166-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +70167-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70167-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70167-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +72174-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72174-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72174-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +72367-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72367-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72367-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75377-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75377-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75377-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75378-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75378-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75378-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75407-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75407-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75407-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75408-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75408-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75408-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75409-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75409-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75409-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75410-1;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75410-1;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75410-1;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +76772-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +76772-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76772-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +77684-9;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77684-9;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77684-9;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +77949-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77949-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77949-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +77952-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77952-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77952-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +78012-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78012-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78012-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +78529-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78529-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78529-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +82510-9;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82510-9;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82510-9;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +82675-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82675-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82675-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85362-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85362-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85362-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85477-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85477-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85477-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85478-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85478-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85478-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85479-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85479-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85479-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85581-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85581-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85581-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +91027-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91027-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91027-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +91676-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91676-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91676-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +91677-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91677-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91677-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +91761-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91761-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91761-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92855-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92855-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92855-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92856-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92856-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92856-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92857-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92857-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92857-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92858-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92858-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92858-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92870-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92870-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92870-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92871-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92871-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92871-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92872-1;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92872-1;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92872-1;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92873-9;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92873-9;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92873-9;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92874-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92874-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92874-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92875-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92875-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92875-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92878-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92878-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92878-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92879-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92879-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92879-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92883-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92883-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92883-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92884-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92884-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92884-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92885-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92885-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92885-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +92888-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92888-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92888-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94421-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94421-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94421-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94422-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94422-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94422-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94426-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94426-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94426-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94427-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94427-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94427-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94500-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94500-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94500-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94532-9;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94532-9;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94532-9;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94558-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94558-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94558-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94559-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94559-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94559-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94639-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94639-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94639-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94640-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94640-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94640-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94641-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94641-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94641-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94647-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94647-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94647-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94718-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94718-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94718-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94822-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94822-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94822-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94845-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94845-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94845-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95209-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95209-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95209-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95970-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95970-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95970-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96120-1;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96120-1;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96120-1;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96121-9;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96121-9;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96121-9;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96122-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96122-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96122-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96123-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96123-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96123-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96448-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96448-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96448-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96797-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96797-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96797-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96957-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96957-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96957-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +97954-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97954-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97954-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +98066-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98066-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98066-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +98069-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +98069-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98069-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99013-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99013-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99013-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99014-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99014-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99014-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99015-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99015-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99015-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99016-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99016-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99016-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99017-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99017-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99017-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99018-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99018-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99018-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99019-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99019-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99019-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99020-0;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99020-0;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99020-0;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99021-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99021-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99021-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99022-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99022-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99022-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99023-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99023-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99023-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99024-2;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99024-2;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99024-2;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99025-9;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99025-9;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99025-9;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99026-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99026-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99026-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99027-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99027-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99027-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99028-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99028-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99028-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99029-1;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99029-1;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99029-1;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99030-9;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99030-9;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99030-9;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99031-7;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99031-7;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99031-7;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99032-5;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99032-5;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99032-5;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99033-3;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99033-3;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99033-3;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99034-1;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99034-1;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99034-1;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99035-8;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99035-8;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99035-8;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99036-6;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99036-6;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99036-6;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99037-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99037-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99037-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99706-4;LL2021-5;Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +99706-4;LL2021-5;Pos|Neg|Invalid;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99706-4;LL2021-5;Pos|Neg|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101141-0;LL6293-6;NAT2 genotype results;LA33596-0;1;NAT 2*4/*4;;; +101141-0;LL6293-6;NAT2 genotype results;LA33597-8;2;NAT 2*4/*5;;; +101141-0;LL6293-6;NAT2 genotype results;LA33598-6;3;NAT2*4/*6;;; +101141-0;LL6293-6;NAT2 genotype results;LA33599-4;4;NAT2*4/*7;;; +101141-0;LL6293-6;NAT2 genotype results;LA33600-0;5;NAT2*4/*10;;; +101141-0;LL6293-6;NAT2 genotype results;LA33601-8;6;NAT2*4/*12D;;; +101141-0;LL6293-6;NAT2 genotype results;LA33602-6;7;NAT2*4/*14;;; +101141-0;LL6293-6;NAT2 genotype results;LA33603-4;8;NAT2*4/*17;;; +101141-0;LL6293-6;NAT2 genotype results;LA33604-2;9;NAT2*4/*19;;; +101142-8;LL6292-8;Slow|Intermediate|Rapid;LA24898-1;1;Slow;;; +101142-8;LL6292-8;Slow|Intermediate|Rapid;LA16550-8;2;Intermediate;;; +101142-8;LL6292-8;Slow|Intermediate|Rapid;LA24868-4;3;Rapid;;; +101143-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +101143-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +101143-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +101143-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +101143-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +51971-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +51971-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +51971-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +51971-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +51971-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +53040-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +53040-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +53040-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +53040-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +53040-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +72878-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +72878-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +72878-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +72878-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +72878-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79713-4;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79713-4;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79713-4;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79713-4;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79713-4;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79714-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79714-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79714-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79714-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79714-2;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79715-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79715-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79715-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79715-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79715-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79716-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79716-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79716-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79716-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79716-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79717-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79717-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79717-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79717-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79717-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79718-3;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79718-3;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79718-3;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79718-3;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79718-3;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79719-1;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79719-1;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79719-1;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79719-1;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79719-1;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79720-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79720-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79720-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79720-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79720-9;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +79721-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +79721-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +79721-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +79721-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +79721-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +81145-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +81145-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +81145-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +81145-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +81145-5;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +93195-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +93195-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +93195-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +93195-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +93195-6;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +93411-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +93411-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +93411-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +93411-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +93411-7;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +94254-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10315-2;1;Ultrarapid metabolizer;;; +94254-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25390-8;2;Rapid metabolizer;;; +94254-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA25391-6;3;Normal metabolizer;;; +94254-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA10317-8;4;Intermediate metabolizer;;; +94254-0;LL3856-3;[CPIC metab act] Ultrarapid|Rapid|Nl|Interm|Poor;LA9657-3;5;Poor metabolizer;;; +101193-1;LL6284-5;Abdominoperineal excision for low rectal cancer;LA33556-4;1;Extralevator plane;;; +101193-1;LL6284-5;Abdominoperineal excision for low rectal cancer;LA33557-2;2;Sphincteric plane;;; +101193-1;LL6284-5;Abdominoperineal excision for low rectal cancer;LA33558-0;3;Intrasphincteric plane;;; +101194-9;LL6285-2;Colorectal cancer excision planes;LA33559-8;1;Mesocolic plane;;; +101194-9;LL6285-2;Colorectal cancer excision planes;LA33560-6;2;Intramesocolic plane;;; +101194-9;LL6285-2;Colorectal cancer excision planes;LA33561-4;3;Muscularis propria plane;;; +101196-4;LL6294-4;Tumor lymphocytes;LA33605-9;1;Tumor-infiltrating lymphocytes;;; +101196-4;LL6294-4;Tumor lymphocytes;LA33606-7;2;Peritumoral lymphocyte infiltration;;; +101196-4;LL6294-4;Tumor lymphocytes;LA33607-5;3;Peritumoral lymphoid aggregates;;; +101225-1;LL6041-9;Increased|Normal|Decreased;LA24377-6;1;Increased;;; +101225-1;LL6041-9;Increased|Normal|Decreased;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +101225-1;LL6041-9;Increased|Normal|Decreased;LA24378-4;3;Decreased;;; +98718-0;LL6041-9;Increased|Normal|Decreased;LA24377-6;1;Increased;;; +98718-0;LL6041-9;Increased|Normal|Decreased;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98718-0;LL6041-9;Increased|Normal|Decreased;LA24378-4;3;Decreased;;; +98724-8;LL6041-9;Increased|Normal|Decreased;LA24377-6;1;Increased;;; +98724-8;LL6041-9;Increased|Normal|Decreased;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98724-8;LL6041-9;Increased|Normal|Decreased;LA24378-4;3;Decreased;;; +101248-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +101248-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +101248-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +101248-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +101248-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +12178-0;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +12178-0;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +12178-0;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +12178-0;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +12178-0;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +16290-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +16290-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +16290-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +16290-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +16290-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +25145-4;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +25145-4;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +25145-4;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +25145-4;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +25145-4;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +25156-1;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +25156-1;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +25156-1;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +25156-1;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +25156-1;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +25157-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +25157-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +25157-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +25157-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +25157-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +25158-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +25158-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +25158-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +25158-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +25158-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +25159-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +25159-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +25159-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +25159-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +25159-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +25160-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +25160-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +25160-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +25160-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +25160-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +25162-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +25162-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +25162-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +25162-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +25162-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32240-4;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32240-4;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32240-4;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32240-4;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32240-4;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32268-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32268-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32268-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32268-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32268-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32280-0;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32280-0;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32280-0;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32280-0;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32280-0;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32282-6;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32282-6;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32282-6;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32282-6;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32282-6;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32761-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32761-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32761-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32761-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32761-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32762-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32762-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32762-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32762-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32762-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32763-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32763-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32763-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32763-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32763-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32764-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32764-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32764-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32764-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32764-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32765-0;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32765-0;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32765-0;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32765-0;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32765-0;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +32766-8;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32766-8;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +32766-8;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +32766-8;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +32766-8;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33233-8;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33233-8;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33233-8;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33233-8;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33233-8;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33234-6;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33234-6;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33234-6;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33234-6;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33234-6;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33235-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33235-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33235-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33235-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33235-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33236-1;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33236-1;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33236-1;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33236-1;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33236-1;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33237-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33237-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33237-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33237-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33237-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33238-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33238-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33238-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33238-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33238-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33239-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33239-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33239-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33239-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33239-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33240-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33240-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33240-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33240-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33240-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33241-1;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33241-1;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33241-1;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33241-1;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33241-1;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33242-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33242-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33242-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33242-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33242-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +33243-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +33243-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +33243-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +33243-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +33243-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +34445-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +34445-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +34445-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +34445-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +34445-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +34446-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +34446-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +34446-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +34446-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +34446-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50222-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50222-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50222-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50222-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50222-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50223-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50223-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50223-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50223-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50223-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50224-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50224-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50224-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50224-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50224-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50225-2;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50225-2;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50225-2;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50225-2;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50225-2;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50229-4;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50229-4;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50229-4;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50229-4;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50229-4;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50230-2;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50230-2;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50230-2;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50230-2;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50230-2;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50231-0;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50231-0;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50231-0;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50231-0;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50231-0;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50232-8;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50232-8;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50232-8;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50232-8;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50232-8;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50234-4;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50234-4;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50234-4;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50234-4;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50234-4;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50236-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50236-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50236-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50236-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50236-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50237-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50237-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50237-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50237-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50237-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50238-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50238-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50238-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50238-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50238-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50239-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50239-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50239-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50239-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50239-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50240-1;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50240-1;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50240-1;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50240-1;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50240-1;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50260-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50260-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50260-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50260-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50260-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50340-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50340-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50340-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50340-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50340-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +50341-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +50341-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +50341-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +50341-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +50341-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +63487-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +63487-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +63487-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +63487-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +63487-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +63488-1;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +63488-1;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +63488-1;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +63488-1;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +63488-1;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +70122-7;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +70122-7;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +70122-7;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +70122-7;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +70122-7;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +70123-5;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +70123-5;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +70123-5;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +70123-5;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +70123-5;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +70124-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +70124-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +70124-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +70124-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +70124-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +70125-0;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +70125-0;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +70125-0;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +70125-0;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +70125-0;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +72161-3;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +72161-3;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +72161-3;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +72161-3;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +72161-3;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +72162-1;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +72162-1;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +72162-1;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +72162-1;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +72162-1;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +72163-9;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +72163-9;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +72163-9;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +72163-9;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +72163-9;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +74759-2;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +74759-2;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +74759-2;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +74759-2;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +74759-2;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +74783-2;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +74783-2;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +74783-2;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +74783-2;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +74783-2;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +88113-6;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88113-6;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +88113-6;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +88113-6;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +88113-6;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +88114-4;LL1162-8;Quantity (5 answers, ord);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88114-4;LL1162-8;Quantity (5 answers, ord);LA15679-6;2;Rare;89292003;Rare (qualifier value);http://snomed.info/sct +88114-4;LL1162-8;Quantity (5 answers, ord);LA15680-4;3;Few;57176003;Few (qualifier value);http://snomed.info/sct +88114-4;LL1162-8;Quantity (5 answers, ord);LA6751-7;4;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +88114-4;LL1162-8;Quantity (5 answers, ord);LA15681-2;5;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +101325-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +45606-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83187-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83189-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83191-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83193-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83195-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83197-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83199-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83201-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83203-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83205-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83207-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83209-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83211-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83213-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83215-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83217-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83219-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83221-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83223-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83225-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83227-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83229-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83231-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83236-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89375-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89377-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89379-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89387-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89396-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89400-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89402-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89406-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89412-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89416-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89418-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89420-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27993-7;1;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27994-5;2;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28870-6;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27996-0;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27998-6;6;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA27999-4;7;Resident refused;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28871-4;8;Not applicable - Not attempted and the resident did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4971-9;CMS MDS 1.16.1 Functional goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +101327-5;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +101328-3;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18604-1;1;Parenteral/IV feeding;;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA30294-5;2;Feeding tube (e.g., nasogastric or abdominal (PEG));;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +93178-2;LL5387-7;CMS IRF_PAI v4.0 - Nutritional Approaches (K0520);LA9-3;5;None of the above;;; +101329-1;LL6299-3;Assessment participants;LA11019-9;1;Resident;;; +101329-1;LL6299-3;Assessment participants;LA12068-5;2;Family;;; +101329-1;LL6299-3;Assessment participants;LA30381-0;3;Significant other;;; +101329-1;LL6299-3;Assessment participants;LA30382-8;4;Legal guardian;;; +101329-1;LL6299-3;Assessment participants;LA30383-6;5;Other legally authorized representative;;; +101329-1;LL6299-3;Assessment participants;LA9-3;6;None of the above;;; +55058-2;LL6299-3;Assessment participants;LA11019-9;1;Resident;;; +55058-2;LL6299-3;Assessment participants;LA12068-5;2;Family;;; +55058-2;LL6299-3;Assessment participants;LA30381-0;3;Significant other;;; +55058-2;LL6299-3;Assessment participants;LA30382-8;4;Legal guardian;;; +55058-2;LL6299-3;Assessment participants;LA30383-6;5;Other legally authorized representative;;; +55058-2;LL6299-3;Assessment participants;LA9-3;6;None of the above;;; +86798-6;LL6299-3;Assessment participants;LA11019-9;1;Resident;;; +86798-6;LL6299-3;Assessment participants;LA12068-5;2;Family;;; +86798-6;LL6299-3;Assessment participants;LA30381-0;3;Significant other;;; +86798-6;LL6299-3;Assessment participants;LA30382-8;4;Legal guardian;;; +86798-6;LL6299-3;Assessment participants;LA30383-6;5;Other legally authorized representative;;; +86798-6;LL6299-3;Assessment participants;LA9-3;6;None of the above;;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +101331-7;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +86747-3;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27943-2;0;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27944-0;1;Diabetic foot ulcer(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27945-7;2;Other open lesion(s) on the foot;;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27946-5;3;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27947-3;4;Surgical wound(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27948-1;5;Burn(s) (second or third degree);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA18608-2;6;Skin tear(s);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27950-7;7;Moisture associated skin damage (MASD) (e.g., incontinence-associated dermatitis [IAD], perspiration, drainage);;; +88696-0;LL4583-2;CMS_MDS Ulcers, wounds, and skin problems;LA27939-0;8;None of the above were present;;; +101332-5;LL6302-5;***** CLONED FROM - LL5442-0 *****;LA33610-9;1;Local contact agency (LCA) unknown;;; +101332-5;LL6302-5;***** CLONED FROM - LL5442-0 *****;LA33611-7;2;Referral previously made;;; +101332-5;LL6302-5;***** CLONED FROM - LL5442-0 *****;LA33614-1;3;Referral not wanted;;; +101332-5;LL6302-5;***** CLONED FROM - LL5442-0 *****;LA33612-5;4;Discharge date 3 or fewer months away;;; +101332-5;LL6302-5;***** CLONED FROM - LL5442-0 *****;LA33613-3;5;Discharge date more than 3 months away;;; +101333-3;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +101333-3;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +101333-3;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +101333-3;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA28887-0;1;Resident has a pressure ulcer/injury, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27941-6;2;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA27942-4;3;Clinical assessment;;; +86708-5;LL4975-0;CMS MDS Pressure injury risk;LA9-3;4;None of the above;;; +101349-9;LL6313-2;Jurisdiction;;0;;;; +101351-5;LL6295-1;Lack of Transportation;LA30133-5;1;Yes, it has kept me from medical appointments or from getting my medications;;; +101351-5;LL6295-1;Lack of Transportation;LA30134-3;2;Yes, it has kept me from non-medical meetings, appointments, work, or from getting things that I need;;; +101351-5;LL6295-1;Lack of Transportation;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +101351-5;LL6295-1;Lack of Transportation;LA30435-4;4;Resident unable to respond;;; +101351-5;LL6295-1;Lack of Transportation;LA33608-3;5;Resident declines to respond;;; +101354-9;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101354-9;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101354-9;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +101355-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101355-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101355-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +101356-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101356-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101356-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +101357-2;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101357-2;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101357-2;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +101403-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +101403-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +101403-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +30325-5;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30325-5;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30325-5;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +33459-9;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +33459-9;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33459-9;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +41475-5;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +41475-5;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41475-5;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +47383-5;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47383-5;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47383-5;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +49580-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49580-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49580-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +50018-1;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +50018-1;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +50018-1;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +60524-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +60524-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +60524-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +69753-2;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69753-2;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69753-2;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +69754-0;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69754-0;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69754-0;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +69755-7;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69755-7;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69755-7;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +74765-9;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74765-9;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74765-9;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +74766-7;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74766-7;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74766-7;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +75710-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75710-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75710-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +77953-8;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77953-8;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77953-8;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +80821-2;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80821-2;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80821-2;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +80822-0;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +80822-0;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80822-0;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +85318-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85318-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85318-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +85628-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85628-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85628-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86320-9;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86320-9;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86320-9;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86857-0;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86857-0;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86857-0;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86862-0;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86862-0;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86862-0;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86863-8;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86863-8;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86863-8;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86864-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86864-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86864-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86865-3;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86865-3;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86865-3;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87275-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87275-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87275-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87284-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87284-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87284-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87285-3;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87285-3;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87285-3;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87400-8;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87400-8;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87400-8;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87401-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87401-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87401-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87411-5;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87411-5;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87411-5;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87725-8;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87725-8;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87725-8;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +87726-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87726-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87726-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +93859-7;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93859-7;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93859-7;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94533-7;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94533-7;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94533-7;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94534-5;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94534-5;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94534-5;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94547-7;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94547-7;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94547-7;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94562-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94562-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94562-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94563-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94563-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94563-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94564-2;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94564-2;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94564-2;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94662-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94662-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94662-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94663-2;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94663-2;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94663-2;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +95125-1;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95125-1;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95125-1;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +95411-5;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95411-5;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95411-5;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +95527-8;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95527-8;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95527-8;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +96603-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96603-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96603-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97514-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97514-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97514-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97515-1;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97515-1;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97515-1;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97516-9;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97516-9;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97516-9;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97526-8;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97526-8;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97526-8;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97527-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97527-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97527-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97528-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97528-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97528-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97530-0;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97530-0;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97530-0;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97531-8;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97531-8;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97531-8;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97643-1;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97643-1;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97643-1;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97644-9;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97644-9;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97644-9;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97645-6;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97645-6;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97645-6;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +97646-4;LL2009-0;Pos|Neg|Equiv;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97646-4;LL2009-0;Pos|Neg|Equiv;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97646-4;LL2009-0;Pos|Neg|Equiv;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +101358-0;LL6315-7;Lymes MTTT Imp;LA33615-8;1;IgG- and IgM-;;; +101358-0;LL6315-7;Lymes MTTT Imp;LA33616-6;2;IgG- and IgM+;;; +101358-0;LL6315-7;Lymes MTTT Imp;LA33617-4;3;IgG+ and IgM-;;; +101358-0;LL6315-7;Lymes MTTT Imp;LA33618-2;4;IgG+ and IgM+;;; +101360-6;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101360-6;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101360-6;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101361-4;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101361-4;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101361-4;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101362-2;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101362-2;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101362-2;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101363-0;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101363-0;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101363-0;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101364-8;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101364-8;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101364-8;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101365-5;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101365-5;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101365-5;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101366-3;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101366-3;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101366-3;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101367-1;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101367-1;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101367-1;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101368-9;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101368-9;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101368-9;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101369-7;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101369-7;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101369-7;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101370-5;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101370-5;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101370-5;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101371-3;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101371-3;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101371-3;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101372-1;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101372-1;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101372-1;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101373-9;LL6314-0;Detected|Not det|Invalid;LA11882-0;1;Detected;;; +101373-9;LL6314-0;Detected|Not det|Invalid;LA11883-8;2;Not detected;;; +101373-9;LL6314-0;Detected|Not det|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +101374-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +101374-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45421-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45421-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45422-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45422-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45423-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45423-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45424-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45424-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45425-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45425-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45426-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45426-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45482-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45482-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45612-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45612-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45613-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45613-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45696-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45696-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45701-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45701-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45703-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45703-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45708-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45708-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46506-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46506-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46533-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46533-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46534-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46534-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46535-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46535-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46540-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46540-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46543-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46543-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46545-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46545-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46547-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46547-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46549-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46549-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46593-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46593-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52501-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52501-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52540-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52540-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52553-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52553-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52555-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52555-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52557-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52557-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52558-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52558-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52560-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52560-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52561-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52561-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52562-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52562-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52563-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52563-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52570-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52570-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52572-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52572-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52585-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52585-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52594-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52594-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52598-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52598-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52599-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52599-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52600-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52600-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52601-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52601-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52603-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52603-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52608-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52608-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52609-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52609-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52610-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52610-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52613-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52613-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52614-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52614-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52617-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52617-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52621-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52621-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52626-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52626-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52631-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52631-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52634-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52634-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52637-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52637-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52652-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52652-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52690-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52690-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52701-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52701-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52713-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52713-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52716-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52716-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52719-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52719-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52727-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52727-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52798-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52798-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54066-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54066-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54586-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54586-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54587-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54587-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54594-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54594-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54597-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54597-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54599-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54599-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54604-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54604-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54619-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54619-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54620-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54620-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54621-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54621-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54622-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54622-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54623-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54623-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54632-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54632-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54655-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54655-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54658-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54658-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54660-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54660-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54662-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54662-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54664-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54664-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54666-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54666-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54668-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54668-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54670-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54670-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54672-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54672-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54673-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54673-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54675-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54675-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54678-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54678-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54679-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54679-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54680-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54680-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54681-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54681-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54685-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54685-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54686-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54686-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54687-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54687-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54688-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54688-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54689-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54689-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54690-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54690-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54691-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54691-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54694-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54694-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54695-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54695-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54716-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54716-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54717-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54717-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54718-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54718-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54719-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54719-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54720-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54720-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54721-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54721-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54722-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54722-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54723-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54723-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54724-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54724-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54725-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54725-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54726-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54726-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54727-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54727-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54728-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54728-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54729-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54729-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54730-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54730-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54731-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54731-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54732-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54732-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54733-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54733-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54734-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54734-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54735-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54735-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54736-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54736-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54756-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54756-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54757-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54757-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54758-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54758-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54759-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54759-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54760-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54760-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54761-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54761-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54762-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54762-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54763-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54763-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54764-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54764-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54765-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54765-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54766-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54766-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54769-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54769-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54772-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54772-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54773-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54773-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54774-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54774-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54775-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54775-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54776-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54776-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54777-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54777-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54778-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54778-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54779-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54779-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54780-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54780-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54781-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54781-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54782-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54782-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54783-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54783-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54784-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54784-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54785-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54785-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54786-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54786-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54787-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54787-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54788-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54788-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54789-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54789-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54790-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54790-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54791-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54791-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54792-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54792-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54793-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54793-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54794-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54794-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54795-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54795-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54796-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54796-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54797-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54797-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54798-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54798-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54799-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54799-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54800-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54800-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54801-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54801-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54802-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54802-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54803-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54803-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54804-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54804-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54805-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54805-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54806-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54806-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54807-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54807-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54808-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54808-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54809-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54809-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54810-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54810-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54811-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54811-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54812-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54812-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54813-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54813-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54814-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54814-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54815-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54815-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54816-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54816-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54817-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54817-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54818-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54818-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54819-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54819-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54820-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54820-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54821-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54821-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54822-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54822-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54823-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54823-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54824-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54824-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54825-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54825-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54826-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54826-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54827-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54827-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54835-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54835-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54836-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54836-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54837-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54837-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54838-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54838-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54839-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54839-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54841-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54841-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54842-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54842-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54843-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54843-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54844-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54844-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54845-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54845-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54846-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54846-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54848-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54848-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54853-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54853-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54858-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54858-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54859-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54859-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54860-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54860-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54861-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54861-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54862-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54862-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54864-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54864-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54865-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54865-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54866-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54866-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54867-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54867-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54868-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54868-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54870-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54870-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54871-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54871-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54872-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54872-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54873-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54873-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54874-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54874-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54875-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54875-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54876-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54876-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54877-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54877-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54878-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54878-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54879-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54879-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54880-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54880-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54881-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54881-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54882-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54882-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54885-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54885-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54957-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54957-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54962-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54962-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54963-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54963-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54964-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54964-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54965-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54965-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54966-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54966-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54967-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54967-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54968-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54968-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54969-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54969-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54972-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54972-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54973-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54973-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54974-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54974-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54975-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54975-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54976-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54976-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54977-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54977-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54978-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54978-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54979-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54979-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54980-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54980-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54981-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54981-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54984-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54984-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54985-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54985-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54986-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54986-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54987-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54987-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54988-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54988-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54989-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54989-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54992-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54992-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54993-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54993-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54994-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54994-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54995-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54995-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54996-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54996-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54997-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54997-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54998-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54998-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54999-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54999-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55000-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55000-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55001-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55001-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55002-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55002-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55003-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55003-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55004-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55004-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55005-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55005-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55006-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55006-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55007-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55007-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55008-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55008-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55009-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55009-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55010-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55010-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55011-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55011-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55012-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55012-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55013-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55013-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55014-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55014-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55015-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55015-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55016-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55016-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55017-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55017-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55019-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55019-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55022-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55022-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55054-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55054-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55061-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55061-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55062-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55062-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57210-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57210-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57280-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57280-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57281-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57281-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57307-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57307-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58107-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58107-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58109-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58109-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58111-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58111-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58113-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58113-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58114-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58114-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58116-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58116-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58119-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58119-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58129-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58129-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58146-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58146-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58201-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58201-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58202-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58202-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58203-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58203-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58204-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58204-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58207-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58207-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58208-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58208-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58214-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58214-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58227-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58227-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58421-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58421-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63874-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63874-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63910-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63910-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63911-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63911-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63912-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63912-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63914-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63914-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63916-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63916-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63917-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63917-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63918-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63918-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63958-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63958-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63960-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63960-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63981-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63981-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63982-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63982-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63993-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63993-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64446-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64446-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64628-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64628-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64645-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64645-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64649-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64649-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64651-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64651-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64653-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64653-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64812-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64812-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65573-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65573-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65631-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65631-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65675-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65675-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65677-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65677-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65679-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65679-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65877-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65877-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66271-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66271-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66287-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66287-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66289-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66289-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66606-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66606-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66608-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66608-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66609-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66609-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66610-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66610-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66611-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66611-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66613-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66613-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66614-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66614-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66615-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66615-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66616-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66616-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66617-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66617-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66618-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66618-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66619-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66619-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66620-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66620-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66621-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66621-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66622-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66622-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66623-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66623-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66625-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66625-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66626-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66626-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66627-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66627-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66628-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66628-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66662-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66662-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66664-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66664-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66665-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66665-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66666-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66666-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66667-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66667-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66668-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66668-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66669-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66669-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66670-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66670-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66671-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66671-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66673-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66673-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66674-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66674-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66675-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66675-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66676-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66676-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66677-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66677-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66678-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66678-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67173-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67173-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67181-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67181-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67190-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67190-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67219-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67219-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67220-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67220-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67221-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67221-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67222-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67222-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67225-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67225-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67308-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67308-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67309-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67309-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67310-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67310-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67311-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67311-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67312-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67312-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67313-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67313-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67314-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67314-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67315-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67315-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67316-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67316-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67317-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67317-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67318-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67318-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67319-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67319-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67400-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67400-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67404-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67404-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67405-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67405-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67407-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67407-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67408-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67408-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67412-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67412-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67415-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67415-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67416-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67416-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67418-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67418-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67420-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67420-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67423-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67423-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67428-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67428-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67429-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67429-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67433-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67433-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67436-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67436-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67440-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67440-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67442-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67442-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67444-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67444-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67446-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67446-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67447-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67447-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67450-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67450-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67454-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67454-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67459-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67459-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67463-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67463-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67465-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67465-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67554-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67554-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67728-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67728-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67733-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67733-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67739-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67739-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67743-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67743-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69690-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69690-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69691-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69691-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69692-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69692-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69693-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69693-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69694-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69694-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69695-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69695-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69696-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69696-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69697-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69697-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69698-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69698-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69699-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69699-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69700-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69700-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69701-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69701-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69702-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69702-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69703-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69703-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69704-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69704-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69705-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69705-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69706-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69706-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69707-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69707-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69708-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69708-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69709-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69709-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69710-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69710-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69711-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69711-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69712-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69712-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69713-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69713-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69714-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69714-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69715-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69715-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69716-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69716-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69720-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69720-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69721-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69721-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70482-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +70482-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70483-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +70483-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70710-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +70710-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +70712-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +70712-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71447-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71447-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71448-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71448-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71449-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71449-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71450-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71450-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71451-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71451-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71452-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71452-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71453-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71453-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71455-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71455-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83271-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +83271-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83280-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +83280-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85407-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85407-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85411-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85411-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85412-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85412-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85415-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85415-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85629-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85629-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85630-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85630-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85631-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85634-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85634-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85646-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85646-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85651-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85655-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85655-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85918-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85918-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86525-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +86525-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86772-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +86772-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86795-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +86795-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87538-5;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +87538-5;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87540-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +87540-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87541-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +87541-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87542-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +87542-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88297-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +88297-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88695-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +88695-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88871-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +88871-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89411-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89411-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89437-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89437-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89438-6;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89438-6;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89439-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89439-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90525-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90525-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90549-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90549-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +91387-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +91387-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +94912-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +94912-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95021-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95021-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95021-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95021-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95022-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95022-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95022-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95022-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95042-8;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95042-8;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95738-1;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95738-1;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95812-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95812-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95812-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95812-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95812-4;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95812-4;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95813-2;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95813-2;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95814-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95814-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95814-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95814-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95814-0;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95814-0;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95855-3;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95855-3;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95857-9;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95857-9;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95858-7;LL251-0;OASIS_M0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95858-7;LL251-0;OASIS_M0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +101394-5;LL1-9;Gender_M/F;LA2-8;1;Male;;; +101394-5;LL1-9;Gender_M/F;LA3-6;2;Female;;; +46098-0;LL1-9;Gender_M/F;LA2-8;1;Male;;; +46098-0;LL1-9;Gender_M/F;LA3-6;2;Female;;; +46098-0;LL1-9;Gender_M/F;LA2-8;1;Male;;; +46098-0;LL1-9;Gender_M/F;LA3-6;2;Female;;; +46098-0;LL1-9;Gender_M/F;LA2-8;1;Male;;; +46098-0;LL1-9;Gender_M/F;LA3-6;2;Female;;; +46607-8;LL1-9;Gender_M/F;LA2-8;1;Male;;; +46607-8;LL1-9;Gender_M/F;LA3-6;2;Female;;; +54123-5;LL1-9;Gender_M/F;LA2-8;1;Male;;; +54123-5;LL1-9;Gender_M/F;LA3-6;2;Female;;; +60478-5;LL1-9;Gender_M/F;LA2-8;1;Male;;; +60478-5;LL1-9;Gender_M/F;LA3-6;2;Female;;; +63781-9;LL1-9;Gender_M/F;LA2-8;1;Male;;; +63781-9;LL1-9;Gender_M/F;LA3-6;2;Female;;; +63898-1;LL1-9;Gender_M/F;LA2-8;1;Male;;; +63898-1;LL1-9;Gender_M/F;LA3-6;2;Female;;; +101399-4;LL6316-5;Monkeypox virus & Orthopoxvirus.non-variola;LA33619-0;1;Non-variola orthopoxvirus detected;;; +101399-4;LL6316-5;Monkeypox virus & Orthopoxvirus.non-variola;LA33620-8;2;Non-variola orthopoxvirus and Monkeypox virus detected;;; +101399-4;LL6316-5;Monkeypox virus & Orthopoxvirus.non-variola;LA33621-6;3;Monkeypox virus detected;;; +101399-4;LL6316-5;Monkeypox virus & Orthopoxvirus.non-variola;LA11883-8;4;Not detected;;; +101399-4;LL6316-5;Monkeypox virus & Orthopoxvirus.non-variola;LA33622-4;5;Invalid result/Retest;;; +101399-4;LL6316-5;Monkeypox virus & Orthopoxvirus.non-variola;LA13548-5;6;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +101406-7;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +101406-7;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +101406-7;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +101406-7;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +76626-1;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +76626-1;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +76626-1;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +76626-1;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +76632-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +76632-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +76632-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +76632-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +77495-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +77495-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +77495-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +77495-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +77496-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +77496-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +77496-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +77496-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +85684-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +85684-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +85684-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85684-9;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +86328-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +86328-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +86328-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86328-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +86329-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +86329-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +86329-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86329-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +86330-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +86330-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +86330-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86330-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +86331-6;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +86331-6;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +86331-6;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86331-6;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +86332-4;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +86332-4;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +86332-4;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86332-4;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +86333-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +86333-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +86333-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86333-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +86334-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +86334-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +86334-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86334-0;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +94309-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +94309-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +94309-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94309-2;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +95424-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +95424-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +95424-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95424-8;LL3250-9;Detected|Not det|Inconcl|Spec unsat for eval;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +101408-3;LL1927-4;RAST;LA6111-4;1;0;;; +101408-3;LL1927-4;RAST;LA6112-2;2;1;;; +101408-3;LL1927-4;RAST;LA6113-0;3;2;;; +101408-3;LL1927-4;RAST;LA6114-8;4;3;;; +101408-3;LL1927-4;RAST;LA6115-5;5;4;;; +101408-3;LL1927-4;RAST;LA10137-0;6;5;;; +101408-3;LL1927-4;RAST;LA10138-8;7;6;;; +15518-4;LL1927-4;RAST;LA6111-4;1;0;;; +15518-4;LL1927-4;RAST;LA6112-2;2;1;;; +15518-4;LL1927-4;RAST;LA6113-0;3;2;;; +15518-4;LL1927-4;RAST;LA6114-8;4;3;;; +15518-4;LL1927-4;RAST;LA6115-5;5;4;;; +15518-4;LL1927-4;RAST;LA10137-0;6;5;;; +15518-4;LL1927-4;RAST;LA10138-8;7;6;;; +15519-2;LL1927-4;RAST;LA6111-4;1;0;;; +15519-2;LL1927-4;RAST;LA6112-2;2;1;;; +15519-2;LL1927-4;RAST;LA6113-0;3;2;;; +15519-2;LL1927-4;RAST;LA6114-8;4;3;;; +15519-2;LL1927-4;RAST;LA6115-5;5;4;;; +15519-2;LL1927-4;RAST;LA10137-0;6;5;;; +15519-2;LL1927-4;RAST;LA10138-8;7;6;;; +15520-0;LL1927-4;RAST;LA6111-4;1;0;;; +15520-0;LL1927-4;RAST;LA6112-2;2;1;;; +15520-0;LL1927-4;RAST;LA6113-0;3;2;;; +15520-0;LL1927-4;RAST;LA6114-8;4;3;;; +15520-0;LL1927-4;RAST;LA6115-5;5;4;;; +15520-0;LL1927-4;RAST;LA10137-0;6;5;;; +15520-0;LL1927-4;RAST;LA10138-8;7;6;;; +15521-8;LL1927-4;RAST;LA6111-4;1;0;;; +15521-8;LL1927-4;RAST;LA6112-2;2;1;;; +15521-8;LL1927-4;RAST;LA6113-0;3;2;;; +15521-8;LL1927-4;RAST;LA6114-8;4;3;;; +15521-8;LL1927-4;RAST;LA6115-5;5;4;;; +15521-8;LL1927-4;RAST;LA10137-0;6;5;;; +15521-8;LL1927-4;RAST;LA10138-8;7;6;;; +15523-4;LL1927-4;RAST;LA6111-4;1;0;;; +15523-4;LL1927-4;RAST;LA6112-2;2;1;;; +15523-4;LL1927-4;RAST;LA6113-0;3;2;;; +15523-4;LL1927-4;RAST;LA6114-8;4;3;;; +15523-4;LL1927-4;RAST;LA6115-5;5;4;;; +15523-4;LL1927-4;RAST;LA10137-0;6;5;;; +15523-4;LL1927-4;RAST;LA10138-8;7;6;;; +15524-2;LL1927-4;RAST;LA6111-4;1;0;;; +15524-2;LL1927-4;RAST;LA6112-2;2;1;;; +15524-2;LL1927-4;RAST;LA6113-0;3;2;;; +15524-2;LL1927-4;RAST;LA6114-8;4;3;;; +15524-2;LL1927-4;RAST;LA6115-5;5;4;;; +15524-2;LL1927-4;RAST;LA10137-0;6;5;;; +15524-2;LL1927-4;RAST;LA10138-8;7;6;;; +15525-9;LL1927-4;RAST;LA6111-4;1;0;;; +15525-9;LL1927-4;RAST;LA6112-2;2;1;;; +15525-9;LL1927-4;RAST;LA6113-0;3;2;;; +15525-9;LL1927-4;RAST;LA6114-8;4;3;;; +15525-9;LL1927-4;RAST;LA6115-5;5;4;;; +15525-9;LL1927-4;RAST;LA10137-0;6;5;;; +15525-9;LL1927-4;RAST;LA10138-8;7;6;;; +15526-7;LL1927-4;RAST;LA6111-4;1;0;;; +15526-7;LL1927-4;RAST;LA6112-2;2;1;;; +15526-7;LL1927-4;RAST;LA6113-0;3;2;;; +15526-7;LL1927-4;RAST;LA6114-8;4;3;;; +15526-7;LL1927-4;RAST;LA6115-5;5;4;;; +15526-7;LL1927-4;RAST;LA10137-0;6;5;;; +15526-7;LL1927-4;RAST;LA10138-8;7;6;;; +15527-5;LL1927-4;RAST;LA6111-4;1;0;;; +15527-5;LL1927-4;RAST;LA6112-2;2;1;;; +15527-5;LL1927-4;RAST;LA6113-0;3;2;;; +15527-5;LL1927-4;RAST;LA6114-8;4;3;;; +15527-5;LL1927-4;RAST;LA6115-5;5;4;;; +15527-5;LL1927-4;RAST;LA10137-0;6;5;;; +15527-5;LL1927-4;RAST;LA10138-8;7;6;;; +15528-3;LL1927-4;RAST;LA6111-4;1;0;;; +15528-3;LL1927-4;RAST;LA6112-2;2;1;;; +15528-3;LL1927-4;RAST;LA6113-0;3;2;;; +15528-3;LL1927-4;RAST;LA6114-8;4;3;;; +15528-3;LL1927-4;RAST;LA6115-5;5;4;;; +15528-3;LL1927-4;RAST;LA10137-0;6;5;;; +15528-3;LL1927-4;RAST;LA10138-8;7;6;;; +15529-1;LL1927-4;RAST;LA6111-4;1;0;;; +15529-1;LL1927-4;RAST;LA6112-2;2;1;;; +15529-1;LL1927-4;RAST;LA6113-0;3;2;;; +15529-1;LL1927-4;RAST;LA6114-8;4;3;;; +15529-1;LL1927-4;RAST;LA6115-5;5;4;;; +15529-1;LL1927-4;RAST;LA10137-0;6;5;;; +15529-1;LL1927-4;RAST;LA10138-8;7;6;;; +15530-9;LL1927-4;RAST;LA6111-4;1;0;;; +15530-9;LL1927-4;RAST;LA6112-2;2;1;;; +15530-9;LL1927-4;RAST;LA6113-0;3;2;;; +15530-9;LL1927-4;RAST;LA6114-8;4;3;;; +15530-9;LL1927-4;RAST;LA6115-5;5;4;;; +15530-9;LL1927-4;RAST;LA10137-0;6;5;;; +15530-9;LL1927-4;RAST;LA10138-8;7;6;;; +15532-5;LL1927-4;RAST;LA6111-4;1;0;;; +15532-5;LL1927-4;RAST;LA6112-2;2;1;;; +15532-5;LL1927-4;RAST;LA6113-0;3;2;;; +15532-5;LL1927-4;RAST;LA6114-8;4;3;;; +15532-5;LL1927-4;RAST;LA6115-5;5;4;;; +15532-5;LL1927-4;RAST;LA10137-0;6;5;;; +15532-5;LL1927-4;RAST;LA10138-8;7;6;;; +15533-3;LL1927-4;RAST;LA6111-4;1;0;;; +15533-3;LL1927-4;RAST;LA6112-2;2;1;;; +15533-3;LL1927-4;RAST;LA6113-0;3;2;;; +15533-3;LL1927-4;RAST;LA6114-8;4;3;;; +15533-3;LL1927-4;RAST;LA6115-5;5;4;;; +15533-3;LL1927-4;RAST;LA10137-0;6;5;;; +15533-3;LL1927-4;RAST;LA10138-8;7;6;;; +15534-1;LL1927-4;RAST;LA6111-4;1;0;;; +15534-1;LL1927-4;RAST;LA6112-2;2;1;;; +15534-1;LL1927-4;RAST;LA6113-0;3;2;;; +15534-1;LL1927-4;RAST;LA6114-8;4;3;;; +15534-1;LL1927-4;RAST;LA6115-5;5;4;;; +15534-1;LL1927-4;RAST;LA10137-0;6;5;;; +15534-1;LL1927-4;RAST;LA10138-8;7;6;;; +15535-8;LL1927-4;RAST;LA6111-4;1;0;;; +15535-8;LL1927-4;RAST;LA6112-2;2;1;;; +15535-8;LL1927-4;RAST;LA6113-0;3;2;;; +15535-8;LL1927-4;RAST;LA6114-8;4;3;;; +15535-8;LL1927-4;RAST;LA6115-5;5;4;;; +15535-8;LL1927-4;RAST;LA10137-0;6;5;;; +15535-8;LL1927-4;RAST;LA10138-8;7;6;;; +15536-6;LL1927-4;RAST;LA6111-4;1;0;;; +15536-6;LL1927-4;RAST;LA6112-2;2;1;;; +15536-6;LL1927-4;RAST;LA6113-0;3;2;;; +15536-6;LL1927-4;RAST;LA6114-8;4;3;;; +15536-6;LL1927-4;RAST;LA6115-5;5;4;;; +15536-6;LL1927-4;RAST;LA10137-0;6;5;;; +15536-6;LL1927-4;RAST;LA10138-8;7;6;;; +15537-4;LL1927-4;RAST;LA6111-4;1;0;;; +15537-4;LL1927-4;RAST;LA6112-2;2;1;;; +15537-4;LL1927-4;RAST;LA6113-0;3;2;;; +15537-4;LL1927-4;RAST;LA6114-8;4;3;;; +15537-4;LL1927-4;RAST;LA6115-5;5;4;;; +15537-4;LL1927-4;RAST;LA10137-0;6;5;;; +15537-4;LL1927-4;RAST;LA10138-8;7;6;;; +15539-0;LL1927-4;RAST;LA6111-4;1;0;;; +15539-0;LL1927-4;RAST;LA6112-2;2;1;;; +15539-0;LL1927-4;RAST;LA6113-0;3;2;;; +15539-0;LL1927-4;RAST;LA6114-8;4;3;;; +15539-0;LL1927-4;RAST;LA6115-5;5;4;;; +15539-0;LL1927-4;RAST;LA10137-0;6;5;;; +15539-0;LL1927-4;RAST;LA10138-8;7;6;;; +15540-8;LL1927-4;RAST;LA6111-4;1;0;;; +15540-8;LL1927-4;RAST;LA6112-2;2;1;;; +15540-8;LL1927-4;RAST;LA6113-0;3;2;;; +15540-8;LL1927-4;RAST;LA6114-8;4;3;;; +15540-8;LL1927-4;RAST;LA6115-5;5;4;;; +15540-8;LL1927-4;RAST;LA10137-0;6;5;;; +15540-8;LL1927-4;RAST;LA10138-8;7;6;;; +15541-6;LL1927-4;RAST;LA6111-4;1;0;;; +15541-6;LL1927-4;RAST;LA6112-2;2;1;;; +15541-6;LL1927-4;RAST;LA6113-0;3;2;;; +15541-6;LL1927-4;RAST;LA6114-8;4;3;;; +15541-6;LL1927-4;RAST;LA6115-5;5;4;;; +15541-6;LL1927-4;RAST;LA10137-0;6;5;;; +15541-6;LL1927-4;RAST;LA10138-8;7;6;;; +15542-4;LL1927-4;RAST;LA6111-4;1;0;;; +15542-4;LL1927-4;RAST;LA6112-2;2;1;;; +15542-4;LL1927-4;RAST;LA6113-0;3;2;;; +15542-4;LL1927-4;RAST;LA6114-8;4;3;;; +15542-4;LL1927-4;RAST;LA6115-5;5;4;;; +15542-4;LL1927-4;RAST;LA10137-0;6;5;;; +15542-4;LL1927-4;RAST;LA10138-8;7;6;;; +15543-2;LL1927-4;RAST;LA6111-4;1;0;;; +15543-2;LL1927-4;RAST;LA6112-2;2;1;;; +15543-2;LL1927-4;RAST;LA6113-0;3;2;;; +15543-2;LL1927-4;RAST;LA6114-8;4;3;;; +15543-2;LL1927-4;RAST;LA6115-5;5;4;;; +15543-2;LL1927-4;RAST;LA10137-0;6;5;;; +15543-2;LL1927-4;RAST;LA10138-8;7;6;;; +15544-0;LL1927-4;RAST;LA6111-4;1;0;;; +15544-0;LL1927-4;RAST;LA6112-2;2;1;;; +15544-0;LL1927-4;RAST;LA6113-0;3;2;;; +15544-0;LL1927-4;RAST;LA6114-8;4;3;;; +15544-0;LL1927-4;RAST;LA6115-5;5;4;;; +15544-0;LL1927-4;RAST;LA10137-0;6;5;;; +15544-0;LL1927-4;RAST;LA10138-8;7;6;;; +15545-7;LL1927-4;RAST;LA6111-4;1;0;;; +15545-7;LL1927-4;RAST;LA6112-2;2;1;;; +15545-7;LL1927-4;RAST;LA6113-0;3;2;;; +15545-7;LL1927-4;RAST;LA6114-8;4;3;;; +15545-7;LL1927-4;RAST;LA6115-5;5;4;;; +15545-7;LL1927-4;RAST;LA10137-0;6;5;;; +15545-7;LL1927-4;RAST;LA10138-8;7;6;;; +15546-5;LL1927-4;RAST;LA6111-4;1;0;;; +15546-5;LL1927-4;RAST;LA6112-2;2;1;;; +15546-5;LL1927-4;RAST;LA6113-0;3;2;;; +15546-5;LL1927-4;RAST;LA6114-8;4;3;;; +15546-5;LL1927-4;RAST;LA6115-5;5;4;;; +15546-5;LL1927-4;RAST;LA10137-0;6;5;;; +15546-5;LL1927-4;RAST;LA10138-8;7;6;;; +15547-3;LL1927-4;RAST;LA6111-4;1;0;;; +15547-3;LL1927-4;RAST;LA6112-2;2;1;;; +15547-3;LL1927-4;RAST;LA6113-0;3;2;;; +15547-3;LL1927-4;RAST;LA6114-8;4;3;;; +15547-3;LL1927-4;RAST;LA6115-5;5;4;;; +15547-3;LL1927-4;RAST;LA10137-0;6;5;;; +15547-3;LL1927-4;RAST;LA10138-8;7;6;;; +15548-1;LL1927-4;RAST;LA6111-4;1;0;;; +15548-1;LL1927-4;RAST;LA6112-2;2;1;;; +15548-1;LL1927-4;RAST;LA6113-0;3;2;;; +15548-1;LL1927-4;RAST;LA6114-8;4;3;;; +15548-1;LL1927-4;RAST;LA6115-5;5;4;;; +15548-1;LL1927-4;RAST;LA10137-0;6;5;;; +15548-1;LL1927-4;RAST;LA10138-8;7;6;;; +15549-9;LL1927-4;RAST;LA6111-4;1;0;;; +15549-9;LL1927-4;RAST;LA6112-2;2;1;;; +15549-9;LL1927-4;RAST;LA6113-0;3;2;;; +15549-9;LL1927-4;RAST;LA6114-8;4;3;;; +15549-9;LL1927-4;RAST;LA6115-5;5;4;;; +15549-9;LL1927-4;RAST;LA10137-0;6;5;;; +15549-9;LL1927-4;RAST;LA10138-8;7;6;;; +15550-7;LL1927-4;RAST;LA6111-4;1;0;;; +15550-7;LL1927-4;RAST;LA6112-2;2;1;;; +15550-7;LL1927-4;RAST;LA6113-0;3;2;;; +15550-7;LL1927-4;RAST;LA6114-8;4;3;;; +15550-7;LL1927-4;RAST;LA6115-5;5;4;;; +15550-7;LL1927-4;RAST;LA10137-0;6;5;;; +15550-7;LL1927-4;RAST;LA10138-8;7;6;;; +15551-5;LL1927-4;RAST;LA6111-4;1;0;;; +15551-5;LL1927-4;RAST;LA6112-2;2;1;;; +15551-5;LL1927-4;RAST;LA6113-0;3;2;;; +15551-5;LL1927-4;RAST;LA6114-8;4;3;;; +15551-5;LL1927-4;RAST;LA6115-5;5;4;;; +15551-5;LL1927-4;RAST;LA10137-0;6;5;;; +15551-5;LL1927-4;RAST;LA10138-8;7;6;;; +15552-3;LL1927-4;RAST;LA6111-4;1;0;;; +15552-3;LL1927-4;RAST;LA6112-2;2;1;;; +15552-3;LL1927-4;RAST;LA6113-0;3;2;;; +15552-3;LL1927-4;RAST;LA6114-8;4;3;;; +15552-3;LL1927-4;RAST;LA6115-5;5;4;;; +15552-3;LL1927-4;RAST;LA10137-0;6;5;;; +15552-3;LL1927-4;RAST;LA10138-8;7;6;;; +15553-1;LL1927-4;RAST;LA6111-4;1;0;;; +15553-1;LL1927-4;RAST;LA6112-2;2;1;;; +15553-1;LL1927-4;RAST;LA6113-0;3;2;;; +15553-1;LL1927-4;RAST;LA6114-8;4;3;;; +15553-1;LL1927-4;RAST;LA6115-5;5;4;;; +15553-1;LL1927-4;RAST;LA10137-0;6;5;;; +15553-1;LL1927-4;RAST;LA10138-8;7;6;;; +15554-9;LL1927-4;RAST;LA6111-4;1;0;;; +15554-9;LL1927-4;RAST;LA6112-2;2;1;;; +15554-9;LL1927-4;RAST;LA6113-0;3;2;;; +15554-9;LL1927-4;RAST;LA6114-8;4;3;;; +15554-9;LL1927-4;RAST;LA6115-5;5;4;;; +15554-9;LL1927-4;RAST;LA10137-0;6;5;;; +15554-9;LL1927-4;RAST;LA10138-8;7;6;;; +15555-6;LL1927-4;RAST;LA6111-4;1;0;;; +15555-6;LL1927-4;RAST;LA6112-2;2;1;;; +15555-6;LL1927-4;RAST;LA6113-0;3;2;;; +15555-6;LL1927-4;RAST;LA6114-8;4;3;;; +15555-6;LL1927-4;RAST;LA6115-5;5;4;;; +15555-6;LL1927-4;RAST;LA10137-0;6;5;;; +15555-6;LL1927-4;RAST;LA10138-8;7;6;;; +15556-4;LL1927-4;RAST;LA6111-4;1;0;;; +15556-4;LL1927-4;RAST;LA6112-2;2;1;;; +15556-4;LL1927-4;RAST;LA6113-0;3;2;;; +15556-4;LL1927-4;RAST;LA6114-8;4;3;;; +15556-4;LL1927-4;RAST;LA6115-5;5;4;;; +15556-4;LL1927-4;RAST;LA10137-0;6;5;;; +15556-4;LL1927-4;RAST;LA10138-8;7;6;;; +15557-2;LL1927-4;RAST;LA6111-4;1;0;;; +15557-2;LL1927-4;RAST;LA6112-2;2;1;;; +15557-2;LL1927-4;RAST;LA6113-0;3;2;;; +15557-2;LL1927-4;RAST;LA6114-8;4;3;;; +15557-2;LL1927-4;RAST;LA6115-5;5;4;;; +15557-2;LL1927-4;RAST;LA10137-0;6;5;;; +15557-2;LL1927-4;RAST;LA10138-8;7;6;;; +15558-0;LL1927-4;RAST;LA6111-4;1;0;;; +15558-0;LL1927-4;RAST;LA6112-2;2;1;;; +15558-0;LL1927-4;RAST;LA6113-0;3;2;;; +15558-0;LL1927-4;RAST;LA6114-8;4;3;;; +15558-0;LL1927-4;RAST;LA6115-5;5;4;;; +15558-0;LL1927-4;RAST;LA10137-0;6;5;;; +15558-0;LL1927-4;RAST;LA10138-8;7;6;;; +15559-8;LL1927-4;RAST;LA6111-4;1;0;;; +15559-8;LL1927-4;RAST;LA6112-2;2;1;;; +15559-8;LL1927-4;RAST;LA6113-0;3;2;;; +15559-8;LL1927-4;RAST;LA6114-8;4;3;;; +15559-8;LL1927-4;RAST;LA6115-5;5;4;;; +15559-8;LL1927-4;RAST;LA10137-0;6;5;;; +15559-8;LL1927-4;RAST;LA10138-8;7;6;;; +15560-6;LL1927-4;RAST;LA6111-4;1;0;;; +15560-6;LL1927-4;RAST;LA6112-2;2;1;;; +15560-6;LL1927-4;RAST;LA6113-0;3;2;;; +15560-6;LL1927-4;RAST;LA6114-8;4;3;;; +15560-6;LL1927-4;RAST;LA6115-5;5;4;;; +15560-6;LL1927-4;RAST;LA10137-0;6;5;;; +15560-6;LL1927-4;RAST;LA10138-8;7;6;;; +15561-4;LL1927-4;RAST;LA6111-4;1;0;;; +15561-4;LL1927-4;RAST;LA6112-2;2;1;;; +15561-4;LL1927-4;RAST;LA6113-0;3;2;;; +15561-4;LL1927-4;RAST;LA6114-8;4;3;;; +15561-4;LL1927-4;RAST;LA6115-5;5;4;;; +15561-4;LL1927-4;RAST;LA10137-0;6;5;;; +15561-4;LL1927-4;RAST;LA10138-8;7;6;;; +15562-2;LL1927-4;RAST;LA6111-4;1;0;;; +15562-2;LL1927-4;RAST;LA6112-2;2;1;;; +15562-2;LL1927-4;RAST;LA6113-0;3;2;;; +15562-2;LL1927-4;RAST;LA6114-8;4;3;;; +15562-2;LL1927-4;RAST;LA6115-5;5;4;;; +15562-2;LL1927-4;RAST;LA10137-0;6;5;;; +15562-2;LL1927-4;RAST;LA10138-8;7;6;;; +15563-0;LL1927-4;RAST;LA6111-4;1;0;;; +15563-0;LL1927-4;RAST;LA6112-2;2;1;;; +15563-0;LL1927-4;RAST;LA6113-0;3;2;;; +15563-0;LL1927-4;RAST;LA6114-8;4;3;;; +15563-0;LL1927-4;RAST;LA6115-5;5;4;;; +15563-0;LL1927-4;RAST;LA10137-0;6;5;;; +15563-0;LL1927-4;RAST;LA10138-8;7;6;;; +15564-8;LL1927-4;RAST;LA6111-4;1;0;;; +15564-8;LL1927-4;RAST;LA6112-2;2;1;;; +15564-8;LL1927-4;RAST;LA6113-0;3;2;;; +15564-8;LL1927-4;RAST;LA6114-8;4;3;;; +15564-8;LL1927-4;RAST;LA6115-5;5;4;;; +15564-8;LL1927-4;RAST;LA10137-0;6;5;;; +15564-8;LL1927-4;RAST;LA10138-8;7;6;;; +15565-5;LL1927-4;RAST;LA6111-4;1;0;;; +15565-5;LL1927-4;RAST;LA6112-2;2;1;;; +15565-5;LL1927-4;RAST;LA6113-0;3;2;;; +15565-5;LL1927-4;RAST;LA6114-8;4;3;;; +15565-5;LL1927-4;RAST;LA6115-5;5;4;;; +15565-5;LL1927-4;RAST;LA10137-0;6;5;;; +15565-5;LL1927-4;RAST;LA10138-8;7;6;;; +15566-3;LL1927-4;RAST;LA6111-4;1;0;;; +15566-3;LL1927-4;RAST;LA6112-2;2;1;;; +15566-3;LL1927-4;RAST;LA6113-0;3;2;;; +15566-3;LL1927-4;RAST;LA6114-8;4;3;;; +15566-3;LL1927-4;RAST;LA6115-5;5;4;;; +15566-3;LL1927-4;RAST;LA10137-0;6;5;;; +15566-3;LL1927-4;RAST;LA10138-8;7;6;;; +15567-1;LL1927-4;RAST;LA6111-4;1;0;;; +15567-1;LL1927-4;RAST;LA6112-2;2;1;;; +15567-1;LL1927-4;RAST;LA6113-0;3;2;;; +15567-1;LL1927-4;RAST;LA6114-8;4;3;;; +15567-1;LL1927-4;RAST;LA6115-5;5;4;;; +15567-1;LL1927-4;RAST;LA10137-0;6;5;;; +15567-1;LL1927-4;RAST;LA10138-8;7;6;;; +15568-9;LL1927-4;RAST;LA6111-4;1;0;;; +15568-9;LL1927-4;RAST;LA6112-2;2;1;;; +15568-9;LL1927-4;RAST;LA6113-0;3;2;;; +15568-9;LL1927-4;RAST;LA6114-8;4;3;;; +15568-9;LL1927-4;RAST;LA6115-5;5;4;;; +15568-9;LL1927-4;RAST;LA10137-0;6;5;;; +15568-9;LL1927-4;RAST;LA10138-8;7;6;;; +15569-7;LL1927-4;RAST;LA6111-4;1;0;;; +15569-7;LL1927-4;RAST;LA6112-2;2;1;;; +15569-7;LL1927-4;RAST;LA6113-0;3;2;;; +15569-7;LL1927-4;RAST;LA6114-8;4;3;;; +15569-7;LL1927-4;RAST;LA6115-5;5;4;;; +15569-7;LL1927-4;RAST;LA10137-0;6;5;;; +15569-7;LL1927-4;RAST;LA10138-8;7;6;;; +15570-5;LL1927-4;RAST;LA6111-4;1;0;;; +15570-5;LL1927-4;RAST;LA6112-2;2;1;;; +15570-5;LL1927-4;RAST;LA6113-0;3;2;;; +15570-5;LL1927-4;RAST;LA6114-8;4;3;;; +15570-5;LL1927-4;RAST;LA6115-5;5;4;;; +15570-5;LL1927-4;RAST;LA10137-0;6;5;;; +15570-5;LL1927-4;RAST;LA10138-8;7;6;;; +15571-3;LL1927-4;RAST;LA6111-4;1;0;;; +15571-3;LL1927-4;RAST;LA6112-2;2;1;;; +15571-3;LL1927-4;RAST;LA6113-0;3;2;;; +15571-3;LL1927-4;RAST;LA6114-8;4;3;;; +15571-3;LL1927-4;RAST;LA6115-5;5;4;;; +15571-3;LL1927-4;RAST;LA10137-0;6;5;;; +15571-3;LL1927-4;RAST;LA10138-8;7;6;;; +15572-1;LL1927-4;RAST;LA6111-4;1;0;;; +15572-1;LL1927-4;RAST;LA6112-2;2;1;;; +15572-1;LL1927-4;RAST;LA6113-0;3;2;;; +15572-1;LL1927-4;RAST;LA6114-8;4;3;;; +15572-1;LL1927-4;RAST;LA6115-5;5;4;;; +15572-1;LL1927-4;RAST;LA10137-0;6;5;;; +15572-1;LL1927-4;RAST;LA10138-8;7;6;;; +15573-9;LL1927-4;RAST;LA6111-4;1;0;;; +15573-9;LL1927-4;RAST;LA6112-2;2;1;;; +15573-9;LL1927-4;RAST;LA6113-0;3;2;;; +15573-9;LL1927-4;RAST;LA6114-8;4;3;;; +15573-9;LL1927-4;RAST;LA6115-5;5;4;;; +15573-9;LL1927-4;RAST;LA10137-0;6;5;;; +15573-9;LL1927-4;RAST;LA10138-8;7;6;;; +15574-7;LL1927-4;RAST;LA6111-4;1;0;;; +15574-7;LL1927-4;RAST;LA6112-2;2;1;;; +15574-7;LL1927-4;RAST;LA6113-0;3;2;;; +15574-7;LL1927-4;RAST;LA6114-8;4;3;;; +15574-7;LL1927-4;RAST;LA6115-5;5;4;;; +15574-7;LL1927-4;RAST;LA10137-0;6;5;;; +15574-7;LL1927-4;RAST;LA10138-8;7;6;;; +15575-4;LL1927-4;RAST;LA6111-4;1;0;;; +15575-4;LL1927-4;RAST;LA6112-2;2;1;;; +15575-4;LL1927-4;RAST;LA6113-0;3;2;;; +15575-4;LL1927-4;RAST;LA6114-8;4;3;;; +15575-4;LL1927-4;RAST;LA6115-5;5;4;;; +15575-4;LL1927-4;RAST;LA10137-0;6;5;;; +15575-4;LL1927-4;RAST;LA10138-8;7;6;;; +15576-2;LL1927-4;RAST;LA6111-4;1;0;;; +15576-2;LL1927-4;RAST;LA6112-2;2;1;;; +15576-2;LL1927-4;RAST;LA6113-0;3;2;;; +15576-2;LL1927-4;RAST;LA6114-8;4;3;;; +15576-2;LL1927-4;RAST;LA6115-5;5;4;;; +15576-2;LL1927-4;RAST;LA10137-0;6;5;;; +15576-2;LL1927-4;RAST;LA10138-8;7;6;;; +15577-0;LL1927-4;RAST;LA6111-4;1;0;;; +15577-0;LL1927-4;RAST;LA6112-2;2;1;;; +15577-0;LL1927-4;RAST;LA6113-0;3;2;;; +15577-0;LL1927-4;RAST;LA6114-8;4;3;;; +15577-0;LL1927-4;RAST;LA6115-5;5;4;;; +15577-0;LL1927-4;RAST;LA10137-0;6;5;;; +15577-0;LL1927-4;RAST;LA10138-8;7;6;;; +15579-6;LL1927-4;RAST;LA6111-4;1;0;;; +15579-6;LL1927-4;RAST;LA6112-2;2;1;;; +15579-6;LL1927-4;RAST;LA6113-0;3;2;;; +15579-6;LL1927-4;RAST;LA6114-8;4;3;;; +15579-6;LL1927-4;RAST;LA6115-5;5;4;;; +15579-6;LL1927-4;RAST;LA10137-0;6;5;;; +15579-6;LL1927-4;RAST;LA10138-8;7;6;;; +15580-4;LL1927-4;RAST;LA6111-4;1;0;;; +15580-4;LL1927-4;RAST;LA6112-2;2;1;;; +15580-4;LL1927-4;RAST;LA6113-0;3;2;;; +15580-4;LL1927-4;RAST;LA6114-8;4;3;;; +15580-4;LL1927-4;RAST;LA6115-5;5;4;;; +15580-4;LL1927-4;RAST;LA10137-0;6;5;;; +15580-4;LL1927-4;RAST;LA10138-8;7;6;;; +15581-2;LL1927-4;RAST;LA6111-4;1;0;;; +15581-2;LL1927-4;RAST;LA6112-2;2;1;;; +15581-2;LL1927-4;RAST;LA6113-0;3;2;;; +15581-2;LL1927-4;RAST;LA6114-8;4;3;;; +15581-2;LL1927-4;RAST;LA6115-5;5;4;;; +15581-2;LL1927-4;RAST;LA10137-0;6;5;;; +15581-2;LL1927-4;RAST;LA10138-8;7;6;;; +15582-0;LL1927-4;RAST;LA6111-4;1;0;;; +15582-0;LL1927-4;RAST;LA6112-2;2;1;;; +15582-0;LL1927-4;RAST;LA6113-0;3;2;;; +15582-0;LL1927-4;RAST;LA6114-8;4;3;;; +15582-0;LL1927-4;RAST;LA6115-5;5;4;;; +15582-0;LL1927-4;RAST;LA10137-0;6;5;;; +15582-0;LL1927-4;RAST;LA10138-8;7;6;;; +15583-8;LL1927-4;RAST;LA6111-4;1;0;;; +15583-8;LL1927-4;RAST;LA6112-2;2;1;;; +15583-8;LL1927-4;RAST;LA6113-0;3;2;;; +15583-8;LL1927-4;RAST;LA6114-8;4;3;;; +15583-8;LL1927-4;RAST;LA6115-5;5;4;;; +15583-8;LL1927-4;RAST;LA10137-0;6;5;;; +15583-8;LL1927-4;RAST;LA10138-8;7;6;;; +15584-6;LL1927-4;RAST;LA6111-4;1;0;;; +15584-6;LL1927-4;RAST;LA6112-2;2;1;;; +15584-6;LL1927-4;RAST;LA6113-0;3;2;;; +15584-6;LL1927-4;RAST;LA6114-8;4;3;;; +15584-6;LL1927-4;RAST;LA6115-5;5;4;;; +15584-6;LL1927-4;RAST;LA10137-0;6;5;;; +15584-6;LL1927-4;RAST;LA10138-8;7;6;;; +15585-3;LL1927-4;RAST;LA6111-4;1;0;;; +15585-3;LL1927-4;RAST;LA6112-2;2;1;;; +15585-3;LL1927-4;RAST;LA6113-0;3;2;;; +15585-3;LL1927-4;RAST;LA6114-8;4;3;;; +15585-3;LL1927-4;RAST;LA6115-5;5;4;;; +15585-3;LL1927-4;RAST;LA10137-0;6;5;;; +15585-3;LL1927-4;RAST;LA10138-8;7;6;;; +15586-1;LL1927-4;RAST;LA6111-4;1;0;;; +15586-1;LL1927-4;RAST;LA6112-2;2;1;;; +15586-1;LL1927-4;RAST;LA6113-0;3;2;;; +15586-1;LL1927-4;RAST;LA6114-8;4;3;;; +15586-1;LL1927-4;RAST;LA6115-5;5;4;;; +15586-1;LL1927-4;RAST;LA10137-0;6;5;;; +15586-1;LL1927-4;RAST;LA10138-8;7;6;;; +15587-9;LL1927-4;RAST;LA6111-4;1;0;;; +15587-9;LL1927-4;RAST;LA6112-2;2;1;;; +15587-9;LL1927-4;RAST;LA6113-0;3;2;;; +15587-9;LL1927-4;RAST;LA6114-8;4;3;;; +15587-9;LL1927-4;RAST;LA6115-5;5;4;;; +15587-9;LL1927-4;RAST;LA10137-0;6;5;;; +15587-9;LL1927-4;RAST;LA10138-8;7;6;;; +15588-7;LL1927-4;RAST;LA6111-4;1;0;;; +15588-7;LL1927-4;RAST;LA6112-2;2;1;;; +15588-7;LL1927-4;RAST;LA6113-0;3;2;;; +15588-7;LL1927-4;RAST;LA6114-8;4;3;;; +15588-7;LL1927-4;RAST;LA6115-5;5;4;;; +15588-7;LL1927-4;RAST;LA10137-0;6;5;;; +15588-7;LL1927-4;RAST;LA10138-8;7;6;;; +15589-5;LL1927-4;RAST;LA6111-4;1;0;;; +15589-5;LL1927-4;RAST;LA6112-2;2;1;;; +15589-5;LL1927-4;RAST;LA6113-0;3;2;;; +15589-5;LL1927-4;RAST;LA6114-8;4;3;;; +15589-5;LL1927-4;RAST;LA6115-5;5;4;;; +15589-5;LL1927-4;RAST;LA10137-0;6;5;;; +15589-5;LL1927-4;RAST;LA10138-8;7;6;;; +15590-3;LL1927-4;RAST;LA6111-4;1;0;;; +15590-3;LL1927-4;RAST;LA6112-2;2;1;;; +15590-3;LL1927-4;RAST;LA6113-0;3;2;;; +15590-3;LL1927-4;RAST;LA6114-8;4;3;;; +15590-3;LL1927-4;RAST;LA6115-5;5;4;;; +15590-3;LL1927-4;RAST;LA10137-0;6;5;;; +15590-3;LL1927-4;RAST;LA10138-8;7;6;;; +15591-1;LL1927-4;RAST;LA6111-4;1;0;;; +15591-1;LL1927-4;RAST;LA6112-2;2;1;;; +15591-1;LL1927-4;RAST;LA6113-0;3;2;;; +15591-1;LL1927-4;RAST;LA6114-8;4;3;;; +15591-1;LL1927-4;RAST;LA6115-5;5;4;;; +15591-1;LL1927-4;RAST;LA10137-0;6;5;;; +15591-1;LL1927-4;RAST;LA10138-8;7;6;;; +15592-9;LL1927-4;RAST;LA6111-4;1;0;;; +15592-9;LL1927-4;RAST;LA6112-2;2;1;;; +15592-9;LL1927-4;RAST;LA6113-0;3;2;;; +15592-9;LL1927-4;RAST;LA6114-8;4;3;;; +15592-9;LL1927-4;RAST;LA6115-5;5;4;;; +15592-9;LL1927-4;RAST;LA10137-0;6;5;;; +15592-9;LL1927-4;RAST;LA10138-8;7;6;;; +15593-7;LL1927-4;RAST;LA6111-4;1;0;;; +15593-7;LL1927-4;RAST;LA6112-2;2;1;;; +15593-7;LL1927-4;RAST;LA6113-0;3;2;;; +15593-7;LL1927-4;RAST;LA6114-8;4;3;;; +15593-7;LL1927-4;RAST;LA6115-5;5;4;;; +15593-7;LL1927-4;RAST;LA10137-0;6;5;;; +15593-7;LL1927-4;RAST;LA10138-8;7;6;;; +15594-5;LL1927-4;RAST;LA6111-4;1;0;;; +15594-5;LL1927-4;RAST;LA6112-2;2;1;;; +15594-5;LL1927-4;RAST;LA6113-0;3;2;;; +15594-5;LL1927-4;RAST;LA6114-8;4;3;;; +15594-5;LL1927-4;RAST;LA6115-5;5;4;;; +15594-5;LL1927-4;RAST;LA10137-0;6;5;;; +15594-5;LL1927-4;RAST;LA10138-8;7;6;;; +15595-2;LL1927-4;RAST;LA6111-4;1;0;;; +15595-2;LL1927-4;RAST;LA6112-2;2;1;;; +15595-2;LL1927-4;RAST;LA6113-0;3;2;;; +15595-2;LL1927-4;RAST;LA6114-8;4;3;;; +15595-2;LL1927-4;RAST;LA6115-5;5;4;;; +15595-2;LL1927-4;RAST;LA10137-0;6;5;;; +15595-2;LL1927-4;RAST;LA10138-8;7;6;;; +15596-0;LL1927-4;RAST;LA6111-4;1;0;;; +15596-0;LL1927-4;RAST;LA6112-2;2;1;;; +15596-0;LL1927-4;RAST;LA6113-0;3;2;;; +15596-0;LL1927-4;RAST;LA6114-8;4;3;;; +15596-0;LL1927-4;RAST;LA6115-5;5;4;;; +15596-0;LL1927-4;RAST;LA10137-0;6;5;;; +15596-0;LL1927-4;RAST;LA10138-8;7;6;;; +15597-8;LL1927-4;RAST;LA6111-4;1;0;;; +15597-8;LL1927-4;RAST;LA6112-2;2;1;;; +15597-8;LL1927-4;RAST;LA6113-0;3;2;;; +15597-8;LL1927-4;RAST;LA6114-8;4;3;;; +15597-8;LL1927-4;RAST;LA6115-5;5;4;;; +15597-8;LL1927-4;RAST;LA10137-0;6;5;;; +15597-8;LL1927-4;RAST;LA10138-8;7;6;;; +15598-6;LL1927-4;RAST;LA6111-4;1;0;;; +15598-6;LL1927-4;RAST;LA6112-2;2;1;;; +15598-6;LL1927-4;RAST;LA6113-0;3;2;;; +15598-6;LL1927-4;RAST;LA6114-8;4;3;;; +15598-6;LL1927-4;RAST;LA6115-5;5;4;;; +15598-6;LL1927-4;RAST;LA10137-0;6;5;;; +15598-6;LL1927-4;RAST;LA10138-8;7;6;;; +15599-4;LL1927-4;RAST;LA6111-4;1;0;;; +15599-4;LL1927-4;RAST;LA6112-2;2;1;;; +15599-4;LL1927-4;RAST;LA6113-0;3;2;;; +15599-4;LL1927-4;RAST;LA6114-8;4;3;;; +15599-4;LL1927-4;RAST;LA6115-5;5;4;;; +15599-4;LL1927-4;RAST;LA10137-0;6;5;;; +15599-4;LL1927-4;RAST;LA10138-8;7;6;;; +15601-8;LL1927-4;RAST;LA6111-4;1;0;;; +15601-8;LL1927-4;RAST;LA6112-2;2;1;;; +15601-8;LL1927-4;RAST;LA6113-0;3;2;;; +15601-8;LL1927-4;RAST;LA6114-8;4;3;;; +15601-8;LL1927-4;RAST;LA6115-5;5;4;;; +15601-8;LL1927-4;RAST;LA10137-0;6;5;;; +15601-8;LL1927-4;RAST;LA10138-8;7;6;;; +15602-6;LL1927-4;RAST;LA6111-4;1;0;;; +15602-6;LL1927-4;RAST;LA6112-2;2;1;;; +15602-6;LL1927-4;RAST;LA6113-0;3;2;;; +15602-6;LL1927-4;RAST;LA6114-8;4;3;;; +15602-6;LL1927-4;RAST;LA6115-5;5;4;;; +15602-6;LL1927-4;RAST;LA10137-0;6;5;;; +15602-6;LL1927-4;RAST;LA10138-8;7;6;;; +15603-4;LL1927-4;RAST;LA6111-4;1;0;;; +15603-4;LL1927-4;RAST;LA6112-2;2;1;;; +15603-4;LL1927-4;RAST;LA6113-0;3;2;;; +15603-4;LL1927-4;RAST;LA6114-8;4;3;;; +15603-4;LL1927-4;RAST;LA6115-5;5;4;;; +15603-4;LL1927-4;RAST;LA10137-0;6;5;;; +15603-4;LL1927-4;RAST;LA10138-8;7;6;;; +15604-2;LL1927-4;RAST;LA6111-4;1;0;;; +15604-2;LL1927-4;RAST;LA6112-2;2;1;;; +15604-2;LL1927-4;RAST;LA6113-0;3;2;;; +15604-2;LL1927-4;RAST;LA6114-8;4;3;;; +15604-2;LL1927-4;RAST;LA6115-5;5;4;;; +15604-2;LL1927-4;RAST;LA10137-0;6;5;;; +15604-2;LL1927-4;RAST;LA10138-8;7;6;;; +15605-9;LL1927-4;RAST;LA6111-4;1;0;;; +15605-9;LL1927-4;RAST;LA6112-2;2;1;;; +15605-9;LL1927-4;RAST;LA6113-0;3;2;;; +15605-9;LL1927-4;RAST;LA6114-8;4;3;;; +15605-9;LL1927-4;RAST;LA6115-5;5;4;;; +15605-9;LL1927-4;RAST;LA10137-0;6;5;;; +15605-9;LL1927-4;RAST;LA10138-8;7;6;;; +15606-7;LL1927-4;RAST;LA6111-4;1;0;;; +15606-7;LL1927-4;RAST;LA6112-2;2;1;;; +15606-7;LL1927-4;RAST;LA6113-0;3;2;;; +15606-7;LL1927-4;RAST;LA6114-8;4;3;;; +15606-7;LL1927-4;RAST;LA6115-5;5;4;;; +15606-7;LL1927-4;RAST;LA10137-0;6;5;;; +15606-7;LL1927-4;RAST;LA10138-8;7;6;;; +15607-5;LL1927-4;RAST;LA6111-4;1;0;;; +15607-5;LL1927-4;RAST;LA6112-2;2;1;;; +15607-5;LL1927-4;RAST;LA6113-0;3;2;;; +15607-5;LL1927-4;RAST;LA6114-8;4;3;;; +15607-5;LL1927-4;RAST;LA6115-5;5;4;;; +15607-5;LL1927-4;RAST;LA10137-0;6;5;;; +15607-5;LL1927-4;RAST;LA10138-8;7;6;;; +15609-1;LL1927-4;RAST;LA6111-4;1;0;;; +15609-1;LL1927-4;RAST;LA6112-2;2;1;;; +15609-1;LL1927-4;RAST;LA6113-0;3;2;;; +15609-1;LL1927-4;RAST;LA6114-8;4;3;;; +15609-1;LL1927-4;RAST;LA6115-5;5;4;;; +15609-1;LL1927-4;RAST;LA10137-0;6;5;;; +15609-1;LL1927-4;RAST;LA10138-8;7;6;;; +15611-7;LL1927-4;RAST;LA6111-4;1;0;;; +15611-7;LL1927-4;RAST;LA6112-2;2;1;;; +15611-7;LL1927-4;RAST;LA6113-0;3;2;;; +15611-7;LL1927-4;RAST;LA6114-8;4;3;;; +15611-7;LL1927-4;RAST;LA6115-5;5;4;;; +15611-7;LL1927-4;RAST;LA10137-0;6;5;;; +15611-7;LL1927-4;RAST;LA10138-8;7;6;;; +15612-5;LL1927-4;RAST;LA6111-4;1;0;;; +15612-5;LL1927-4;RAST;LA6112-2;2;1;;; +15612-5;LL1927-4;RAST;LA6113-0;3;2;;; +15612-5;LL1927-4;RAST;LA6114-8;4;3;;; +15612-5;LL1927-4;RAST;LA6115-5;5;4;;; +15612-5;LL1927-4;RAST;LA10137-0;6;5;;; +15612-5;LL1927-4;RAST;LA10138-8;7;6;;; +15613-3;LL1927-4;RAST;LA6111-4;1;0;;; +15613-3;LL1927-4;RAST;LA6112-2;2;1;;; +15613-3;LL1927-4;RAST;LA6113-0;3;2;;; +15613-3;LL1927-4;RAST;LA6114-8;4;3;;; +15613-3;LL1927-4;RAST;LA6115-5;5;4;;; +15613-3;LL1927-4;RAST;LA10137-0;6;5;;; +15613-3;LL1927-4;RAST;LA10138-8;7;6;;; +15614-1;LL1927-4;RAST;LA6111-4;1;0;;; +15614-1;LL1927-4;RAST;LA6112-2;2;1;;; +15614-1;LL1927-4;RAST;LA6113-0;3;2;;; +15614-1;LL1927-4;RAST;LA6114-8;4;3;;; +15614-1;LL1927-4;RAST;LA6115-5;5;4;;; +15614-1;LL1927-4;RAST;LA10137-0;6;5;;; +15614-1;LL1927-4;RAST;LA10138-8;7;6;;; +15615-8;LL1927-4;RAST;LA6111-4;1;0;;; +15615-8;LL1927-4;RAST;LA6112-2;2;1;;; +15615-8;LL1927-4;RAST;LA6113-0;3;2;;; +15615-8;LL1927-4;RAST;LA6114-8;4;3;;; +15615-8;LL1927-4;RAST;LA6115-5;5;4;;; +15615-8;LL1927-4;RAST;LA10137-0;6;5;;; +15615-8;LL1927-4;RAST;LA10138-8;7;6;;; +15616-6;LL1927-4;RAST;LA6111-4;1;0;;; +15616-6;LL1927-4;RAST;LA6112-2;2;1;;; +15616-6;LL1927-4;RAST;LA6113-0;3;2;;; +15616-6;LL1927-4;RAST;LA6114-8;4;3;;; +15616-6;LL1927-4;RAST;LA6115-5;5;4;;; +15616-6;LL1927-4;RAST;LA10137-0;6;5;;; +15616-6;LL1927-4;RAST;LA10138-8;7;6;;; +15617-4;LL1927-4;RAST;LA6111-4;1;0;;; +15617-4;LL1927-4;RAST;LA6112-2;2;1;;; +15617-4;LL1927-4;RAST;LA6113-0;3;2;;; +15617-4;LL1927-4;RAST;LA6114-8;4;3;;; +15617-4;LL1927-4;RAST;LA6115-5;5;4;;; +15617-4;LL1927-4;RAST;LA10137-0;6;5;;; +15617-4;LL1927-4;RAST;LA10138-8;7;6;;; +15618-2;LL1927-4;RAST;LA6111-4;1;0;;; +15618-2;LL1927-4;RAST;LA6112-2;2;1;;; +15618-2;LL1927-4;RAST;LA6113-0;3;2;;; +15618-2;LL1927-4;RAST;LA6114-8;4;3;;; +15618-2;LL1927-4;RAST;LA6115-5;5;4;;; +15618-2;LL1927-4;RAST;LA10137-0;6;5;;; +15618-2;LL1927-4;RAST;LA10138-8;7;6;;; +15619-0;LL1927-4;RAST;LA6111-4;1;0;;; +15619-0;LL1927-4;RAST;LA6112-2;2;1;;; +15619-0;LL1927-4;RAST;LA6113-0;3;2;;; +15619-0;LL1927-4;RAST;LA6114-8;4;3;;; +15619-0;LL1927-4;RAST;LA6115-5;5;4;;; +15619-0;LL1927-4;RAST;LA10137-0;6;5;;; +15619-0;LL1927-4;RAST;LA10138-8;7;6;;; +15620-8;LL1927-4;RAST;LA6111-4;1;0;;; +15620-8;LL1927-4;RAST;LA6112-2;2;1;;; +15620-8;LL1927-4;RAST;LA6113-0;3;2;;; +15620-8;LL1927-4;RAST;LA6114-8;4;3;;; +15620-8;LL1927-4;RAST;LA6115-5;5;4;;; +15620-8;LL1927-4;RAST;LA10137-0;6;5;;; +15620-8;LL1927-4;RAST;LA10138-8;7;6;;; +15621-6;LL1927-4;RAST;LA6111-4;1;0;;; +15621-6;LL1927-4;RAST;LA6112-2;2;1;;; +15621-6;LL1927-4;RAST;LA6113-0;3;2;;; +15621-6;LL1927-4;RAST;LA6114-8;4;3;;; +15621-6;LL1927-4;RAST;LA6115-5;5;4;;; +15621-6;LL1927-4;RAST;LA10137-0;6;5;;; +15621-6;LL1927-4;RAST;LA10138-8;7;6;;; +15622-4;LL1927-4;RAST;LA6111-4;1;0;;; +15622-4;LL1927-4;RAST;LA6112-2;2;1;;; +15622-4;LL1927-4;RAST;LA6113-0;3;2;;; +15622-4;LL1927-4;RAST;LA6114-8;4;3;;; +15622-4;LL1927-4;RAST;LA6115-5;5;4;;; +15622-4;LL1927-4;RAST;LA10137-0;6;5;;; +15622-4;LL1927-4;RAST;LA10138-8;7;6;;; +15623-2;LL1927-4;RAST;LA6111-4;1;0;;; +15623-2;LL1927-4;RAST;LA6112-2;2;1;;; +15623-2;LL1927-4;RAST;LA6113-0;3;2;;; +15623-2;LL1927-4;RAST;LA6114-8;4;3;;; +15623-2;LL1927-4;RAST;LA6115-5;5;4;;; +15623-2;LL1927-4;RAST;LA10137-0;6;5;;; +15623-2;LL1927-4;RAST;LA10138-8;7;6;;; +15624-0;LL1927-4;RAST;LA6111-4;1;0;;; +15624-0;LL1927-4;RAST;LA6112-2;2;1;;; +15624-0;LL1927-4;RAST;LA6113-0;3;2;;; +15624-0;LL1927-4;RAST;LA6114-8;4;3;;; +15624-0;LL1927-4;RAST;LA6115-5;5;4;;; +15624-0;LL1927-4;RAST;LA10137-0;6;5;;; +15624-0;LL1927-4;RAST;LA10138-8;7;6;;; +15625-7;LL1927-4;RAST;LA6111-4;1;0;;; +15625-7;LL1927-4;RAST;LA6112-2;2;1;;; +15625-7;LL1927-4;RAST;LA6113-0;3;2;;; +15625-7;LL1927-4;RAST;LA6114-8;4;3;;; +15625-7;LL1927-4;RAST;LA6115-5;5;4;;; +15625-7;LL1927-4;RAST;LA10137-0;6;5;;; +15625-7;LL1927-4;RAST;LA10138-8;7;6;;; +15626-5;LL1927-4;RAST;LA6111-4;1;0;;; +15626-5;LL1927-4;RAST;LA6112-2;2;1;;; +15626-5;LL1927-4;RAST;LA6113-0;3;2;;; +15626-5;LL1927-4;RAST;LA6114-8;4;3;;; +15626-5;LL1927-4;RAST;LA6115-5;5;4;;; +15626-5;LL1927-4;RAST;LA10137-0;6;5;;; +15626-5;LL1927-4;RAST;LA10138-8;7;6;;; +15627-3;LL1927-4;RAST;LA6111-4;1;0;;; +15627-3;LL1927-4;RAST;LA6112-2;2;1;;; +15627-3;LL1927-4;RAST;LA6113-0;3;2;;; +15627-3;LL1927-4;RAST;LA6114-8;4;3;;; +15627-3;LL1927-4;RAST;LA6115-5;5;4;;; +15627-3;LL1927-4;RAST;LA10137-0;6;5;;; +15627-3;LL1927-4;RAST;LA10138-8;7;6;;; +15628-1;LL1927-4;RAST;LA6111-4;1;0;;; +15628-1;LL1927-4;RAST;LA6112-2;2;1;;; +15628-1;LL1927-4;RAST;LA6113-0;3;2;;; +15628-1;LL1927-4;RAST;LA6114-8;4;3;;; +15628-1;LL1927-4;RAST;LA6115-5;5;4;;; +15628-1;LL1927-4;RAST;LA10137-0;6;5;;; +15628-1;LL1927-4;RAST;LA10138-8;7;6;;; +15629-9;LL1927-4;RAST;LA6111-4;1;0;;; +15629-9;LL1927-4;RAST;LA6112-2;2;1;;; +15629-9;LL1927-4;RAST;LA6113-0;3;2;;; +15629-9;LL1927-4;RAST;LA6114-8;4;3;;; +15629-9;LL1927-4;RAST;LA6115-5;5;4;;; +15629-9;LL1927-4;RAST;LA10137-0;6;5;;; +15629-9;LL1927-4;RAST;LA10138-8;7;6;;; +15630-7;LL1927-4;RAST;LA6111-4;1;0;;; +15630-7;LL1927-4;RAST;LA6112-2;2;1;;; +15630-7;LL1927-4;RAST;LA6113-0;3;2;;; +15630-7;LL1927-4;RAST;LA6114-8;4;3;;; +15630-7;LL1927-4;RAST;LA6115-5;5;4;;; +15630-7;LL1927-4;RAST;LA10137-0;6;5;;; +15630-7;LL1927-4;RAST;LA10138-8;7;6;;; +15632-3;LL1927-4;RAST;LA6111-4;1;0;;; +15632-3;LL1927-4;RAST;LA6112-2;2;1;;; +15632-3;LL1927-4;RAST;LA6113-0;3;2;;; +15632-3;LL1927-4;RAST;LA6114-8;4;3;;; +15632-3;LL1927-4;RAST;LA6115-5;5;4;;; +15632-3;LL1927-4;RAST;LA10137-0;6;5;;; +15632-3;LL1927-4;RAST;LA10138-8;7;6;;; +15633-1;LL1927-4;RAST;LA6111-4;1;0;;; +15633-1;LL1927-4;RAST;LA6112-2;2;1;;; +15633-1;LL1927-4;RAST;LA6113-0;3;2;;; +15633-1;LL1927-4;RAST;LA6114-8;4;3;;; +15633-1;LL1927-4;RAST;LA6115-5;5;4;;; +15633-1;LL1927-4;RAST;LA10137-0;6;5;;; +15633-1;LL1927-4;RAST;LA10138-8;7;6;;; +15634-9;LL1927-4;RAST;LA6111-4;1;0;;; +15634-9;LL1927-4;RAST;LA6112-2;2;1;;; +15634-9;LL1927-4;RAST;LA6113-0;3;2;;; +15634-9;LL1927-4;RAST;LA6114-8;4;3;;; +15634-9;LL1927-4;RAST;LA6115-5;5;4;;; +15634-9;LL1927-4;RAST;LA10137-0;6;5;;; +15634-9;LL1927-4;RAST;LA10138-8;7;6;;; +15635-6;LL1927-4;RAST;LA6111-4;1;0;;; +15635-6;LL1927-4;RAST;LA6112-2;2;1;;; +15635-6;LL1927-4;RAST;LA6113-0;3;2;;; +15635-6;LL1927-4;RAST;LA6114-8;4;3;;; +15635-6;LL1927-4;RAST;LA6115-5;5;4;;; +15635-6;LL1927-4;RAST;LA10137-0;6;5;;; +15635-6;LL1927-4;RAST;LA10138-8;7;6;;; +15636-4;LL1927-4;RAST;LA6111-4;1;0;;; +15636-4;LL1927-4;RAST;LA6112-2;2;1;;; +15636-4;LL1927-4;RAST;LA6113-0;3;2;;; +15636-4;LL1927-4;RAST;LA6114-8;4;3;;; +15636-4;LL1927-4;RAST;LA6115-5;5;4;;; +15636-4;LL1927-4;RAST;LA10137-0;6;5;;; +15636-4;LL1927-4;RAST;LA10138-8;7;6;;; +15637-2;LL1927-4;RAST;LA6111-4;1;0;;; +15637-2;LL1927-4;RAST;LA6112-2;2;1;;; +15637-2;LL1927-4;RAST;LA6113-0;3;2;;; +15637-2;LL1927-4;RAST;LA6114-8;4;3;;; +15637-2;LL1927-4;RAST;LA6115-5;5;4;;; +15637-2;LL1927-4;RAST;LA10137-0;6;5;;; +15637-2;LL1927-4;RAST;LA10138-8;7;6;;; +15638-0;LL1927-4;RAST;LA6111-4;1;0;;; +15638-0;LL1927-4;RAST;LA6112-2;2;1;;; +15638-0;LL1927-4;RAST;LA6113-0;3;2;;; +15638-0;LL1927-4;RAST;LA6114-8;4;3;;; +15638-0;LL1927-4;RAST;LA6115-5;5;4;;; +15638-0;LL1927-4;RAST;LA10137-0;6;5;;; +15638-0;LL1927-4;RAST;LA10138-8;7;6;;; +15640-6;LL1927-4;RAST;LA6111-4;1;0;;; +15640-6;LL1927-4;RAST;LA6112-2;2;1;;; +15640-6;LL1927-4;RAST;LA6113-0;3;2;;; +15640-6;LL1927-4;RAST;LA6114-8;4;3;;; +15640-6;LL1927-4;RAST;LA6115-5;5;4;;; +15640-6;LL1927-4;RAST;LA10137-0;6;5;;; +15640-6;LL1927-4;RAST;LA10138-8;7;6;;; +15641-4;LL1927-4;RAST;LA6111-4;1;0;;; +15641-4;LL1927-4;RAST;LA6112-2;2;1;;; +15641-4;LL1927-4;RAST;LA6113-0;3;2;;; +15641-4;LL1927-4;RAST;LA6114-8;4;3;;; +15641-4;LL1927-4;RAST;LA6115-5;5;4;;; +15641-4;LL1927-4;RAST;LA10137-0;6;5;;; +15641-4;LL1927-4;RAST;LA10138-8;7;6;;; +15642-2;LL1927-4;RAST;LA6111-4;1;0;;; +15642-2;LL1927-4;RAST;LA6112-2;2;1;;; +15642-2;LL1927-4;RAST;LA6113-0;3;2;;; +15642-2;LL1927-4;RAST;LA6114-8;4;3;;; +15642-2;LL1927-4;RAST;LA6115-5;5;4;;; +15642-2;LL1927-4;RAST;LA10137-0;6;5;;; +15642-2;LL1927-4;RAST;LA10138-8;7;6;;; +15643-0;LL1927-4;RAST;LA6111-4;1;0;;; +15643-0;LL1927-4;RAST;LA6112-2;2;1;;; +15643-0;LL1927-4;RAST;LA6113-0;3;2;;; +15643-0;LL1927-4;RAST;LA6114-8;4;3;;; +15643-0;LL1927-4;RAST;LA6115-5;5;4;;; +15643-0;LL1927-4;RAST;LA10137-0;6;5;;; +15643-0;LL1927-4;RAST;LA10138-8;7;6;;; +15644-8;LL1927-4;RAST;LA6111-4;1;0;;; +15644-8;LL1927-4;RAST;LA6112-2;2;1;;; +15644-8;LL1927-4;RAST;LA6113-0;3;2;;; +15644-8;LL1927-4;RAST;LA6114-8;4;3;;; +15644-8;LL1927-4;RAST;LA6115-5;5;4;;; +15644-8;LL1927-4;RAST;LA10137-0;6;5;;; +15644-8;LL1927-4;RAST;LA10138-8;7;6;;; +15645-5;LL1927-4;RAST;LA6111-4;1;0;;; +15645-5;LL1927-4;RAST;LA6112-2;2;1;;; +15645-5;LL1927-4;RAST;LA6113-0;3;2;;; +15645-5;LL1927-4;RAST;LA6114-8;4;3;;; +15645-5;LL1927-4;RAST;LA6115-5;5;4;;; +15645-5;LL1927-4;RAST;LA10137-0;6;5;;; +15645-5;LL1927-4;RAST;LA10138-8;7;6;;; +15646-3;LL1927-4;RAST;LA6111-4;1;0;;; +15646-3;LL1927-4;RAST;LA6112-2;2;1;;; +15646-3;LL1927-4;RAST;LA6113-0;3;2;;; +15646-3;LL1927-4;RAST;LA6114-8;4;3;;; +15646-3;LL1927-4;RAST;LA6115-5;5;4;;; +15646-3;LL1927-4;RAST;LA10137-0;6;5;;; +15646-3;LL1927-4;RAST;LA10138-8;7;6;;; +15647-1;LL1927-4;RAST;LA6111-4;1;0;;; +15647-1;LL1927-4;RAST;LA6112-2;2;1;;; +15647-1;LL1927-4;RAST;LA6113-0;3;2;;; +15647-1;LL1927-4;RAST;LA6114-8;4;3;;; +15647-1;LL1927-4;RAST;LA6115-5;5;4;;; +15647-1;LL1927-4;RAST;LA10137-0;6;5;;; +15647-1;LL1927-4;RAST;LA10138-8;7;6;;; +15649-7;LL1927-4;RAST;LA6111-4;1;0;;; +15649-7;LL1927-4;RAST;LA6112-2;2;1;;; +15649-7;LL1927-4;RAST;LA6113-0;3;2;;; +15649-7;LL1927-4;RAST;LA6114-8;4;3;;; +15649-7;LL1927-4;RAST;LA6115-5;5;4;;; +15649-7;LL1927-4;RAST;LA10137-0;6;5;;; +15649-7;LL1927-4;RAST;LA10138-8;7;6;;; +15650-5;LL1927-4;RAST;LA6111-4;1;0;;; +15650-5;LL1927-4;RAST;LA6112-2;2;1;;; +15650-5;LL1927-4;RAST;LA6113-0;3;2;;; +15650-5;LL1927-4;RAST;LA6114-8;4;3;;; +15650-5;LL1927-4;RAST;LA6115-5;5;4;;; +15650-5;LL1927-4;RAST;LA10137-0;6;5;;; +15650-5;LL1927-4;RAST;LA10138-8;7;6;;; +15651-3;LL1927-4;RAST;LA6111-4;1;0;;; +15651-3;LL1927-4;RAST;LA6112-2;2;1;;; +15651-3;LL1927-4;RAST;LA6113-0;3;2;;; +15651-3;LL1927-4;RAST;LA6114-8;4;3;;; +15651-3;LL1927-4;RAST;LA6115-5;5;4;;; +15651-3;LL1927-4;RAST;LA10137-0;6;5;;; +15651-3;LL1927-4;RAST;LA10138-8;7;6;;; +15652-1;LL1927-4;RAST;LA6111-4;1;0;;; +15652-1;LL1927-4;RAST;LA6112-2;2;1;;; +15652-1;LL1927-4;RAST;LA6113-0;3;2;;; +15652-1;LL1927-4;RAST;LA6114-8;4;3;;; +15652-1;LL1927-4;RAST;LA6115-5;5;4;;; +15652-1;LL1927-4;RAST;LA10137-0;6;5;;; +15652-1;LL1927-4;RAST;LA10138-8;7;6;;; +15653-9;LL1927-4;RAST;LA6111-4;1;0;;; +15653-9;LL1927-4;RAST;LA6112-2;2;1;;; +15653-9;LL1927-4;RAST;LA6113-0;3;2;;; +15653-9;LL1927-4;RAST;LA6114-8;4;3;;; +15653-9;LL1927-4;RAST;LA6115-5;5;4;;; +15653-9;LL1927-4;RAST;LA10137-0;6;5;;; +15653-9;LL1927-4;RAST;LA10138-8;7;6;;; +15654-7;LL1927-4;RAST;LA6111-4;1;0;;; +15654-7;LL1927-4;RAST;LA6112-2;2;1;;; +15654-7;LL1927-4;RAST;LA6113-0;3;2;;; +15654-7;LL1927-4;RAST;LA6114-8;4;3;;; +15654-7;LL1927-4;RAST;LA6115-5;5;4;;; +15654-7;LL1927-4;RAST;LA10137-0;6;5;;; +15654-7;LL1927-4;RAST;LA10138-8;7;6;;; +15655-4;LL1927-4;RAST;LA6111-4;1;0;;; +15655-4;LL1927-4;RAST;LA6112-2;2;1;;; +15655-4;LL1927-4;RAST;LA6113-0;3;2;;; +15655-4;LL1927-4;RAST;LA6114-8;4;3;;; +15655-4;LL1927-4;RAST;LA6115-5;5;4;;; +15655-4;LL1927-4;RAST;LA10137-0;6;5;;; +15655-4;LL1927-4;RAST;LA10138-8;7;6;;; +15656-2;LL1927-4;RAST;LA6111-4;1;0;;; +15656-2;LL1927-4;RAST;LA6112-2;2;1;;; +15656-2;LL1927-4;RAST;LA6113-0;3;2;;; +15656-2;LL1927-4;RAST;LA6114-8;4;3;;; +15656-2;LL1927-4;RAST;LA6115-5;5;4;;; +15656-2;LL1927-4;RAST;LA10137-0;6;5;;; +15656-2;LL1927-4;RAST;LA10138-8;7;6;;; +15657-0;LL1927-4;RAST;LA6111-4;1;0;;; +15657-0;LL1927-4;RAST;LA6112-2;2;1;;; +15657-0;LL1927-4;RAST;LA6113-0;3;2;;; +15657-0;LL1927-4;RAST;LA6114-8;4;3;;; +15657-0;LL1927-4;RAST;LA6115-5;5;4;;; +15657-0;LL1927-4;RAST;LA10137-0;6;5;;; +15657-0;LL1927-4;RAST;LA10138-8;7;6;;; +15658-8;LL1927-4;RAST;LA6111-4;1;0;;; +15658-8;LL1927-4;RAST;LA6112-2;2;1;;; +15658-8;LL1927-4;RAST;LA6113-0;3;2;;; +15658-8;LL1927-4;RAST;LA6114-8;4;3;;; +15658-8;LL1927-4;RAST;LA6115-5;5;4;;; +15658-8;LL1927-4;RAST;LA10137-0;6;5;;; +15658-8;LL1927-4;RAST;LA10138-8;7;6;;; +15659-6;LL1927-4;RAST;LA6111-4;1;0;;; +15659-6;LL1927-4;RAST;LA6112-2;2;1;;; +15659-6;LL1927-4;RAST;LA6113-0;3;2;;; +15659-6;LL1927-4;RAST;LA6114-8;4;3;;; +15659-6;LL1927-4;RAST;LA6115-5;5;4;;; +15659-6;LL1927-4;RAST;LA10137-0;6;5;;; +15659-6;LL1927-4;RAST;LA10138-8;7;6;;; +15660-4;LL1927-4;RAST;LA6111-4;1;0;;; +15660-4;LL1927-4;RAST;LA6112-2;2;1;;; +15660-4;LL1927-4;RAST;LA6113-0;3;2;;; +15660-4;LL1927-4;RAST;LA6114-8;4;3;;; +15660-4;LL1927-4;RAST;LA6115-5;5;4;;; +15660-4;LL1927-4;RAST;LA10137-0;6;5;;; +15660-4;LL1927-4;RAST;LA10138-8;7;6;;; +15661-2;LL1927-4;RAST;LA6111-4;1;0;;; +15661-2;LL1927-4;RAST;LA6112-2;2;1;;; +15661-2;LL1927-4;RAST;LA6113-0;3;2;;; +15661-2;LL1927-4;RAST;LA6114-8;4;3;;; +15661-2;LL1927-4;RAST;LA6115-5;5;4;;; +15661-2;LL1927-4;RAST;LA10137-0;6;5;;; +15661-2;LL1927-4;RAST;LA10138-8;7;6;;; +15662-0;LL1927-4;RAST;LA6111-4;1;0;;; +15662-0;LL1927-4;RAST;LA6112-2;2;1;;; +15662-0;LL1927-4;RAST;LA6113-0;3;2;;; +15662-0;LL1927-4;RAST;LA6114-8;4;3;;; +15662-0;LL1927-4;RAST;LA6115-5;5;4;;; +15662-0;LL1927-4;RAST;LA10137-0;6;5;;; +15662-0;LL1927-4;RAST;LA10138-8;7;6;;; +15663-8;LL1927-4;RAST;LA6111-4;1;0;;; +15663-8;LL1927-4;RAST;LA6112-2;2;1;;; +15663-8;LL1927-4;RAST;LA6113-0;3;2;;; +15663-8;LL1927-4;RAST;LA6114-8;4;3;;; +15663-8;LL1927-4;RAST;LA6115-5;5;4;;; +15663-8;LL1927-4;RAST;LA10137-0;6;5;;; +15663-8;LL1927-4;RAST;LA10138-8;7;6;;; +15664-6;LL1927-4;RAST;LA6111-4;1;0;;; +15664-6;LL1927-4;RAST;LA6112-2;2;1;;; +15664-6;LL1927-4;RAST;LA6113-0;3;2;;; +15664-6;LL1927-4;RAST;LA6114-8;4;3;;; +15664-6;LL1927-4;RAST;LA6115-5;5;4;;; +15664-6;LL1927-4;RAST;LA10137-0;6;5;;; +15664-6;LL1927-4;RAST;LA10138-8;7;6;;; +15665-3;LL1927-4;RAST;LA6111-4;1;0;;; +15665-3;LL1927-4;RAST;LA6112-2;2;1;;; +15665-3;LL1927-4;RAST;LA6113-0;3;2;;; +15665-3;LL1927-4;RAST;LA6114-8;4;3;;; +15665-3;LL1927-4;RAST;LA6115-5;5;4;;; +15665-3;LL1927-4;RAST;LA10137-0;6;5;;; +15665-3;LL1927-4;RAST;LA10138-8;7;6;;; +15666-1;LL1927-4;RAST;LA6111-4;1;0;;; +15666-1;LL1927-4;RAST;LA6112-2;2;1;;; +15666-1;LL1927-4;RAST;LA6113-0;3;2;;; +15666-1;LL1927-4;RAST;LA6114-8;4;3;;; +15666-1;LL1927-4;RAST;LA6115-5;5;4;;; +15666-1;LL1927-4;RAST;LA10137-0;6;5;;; +15666-1;LL1927-4;RAST;LA10138-8;7;6;;; +15667-9;LL1927-4;RAST;LA6111-4;1;0;;; +15667-9;LL1927-4;RAST;LA6112-2;2;1;;; +15667-9;LL1927-4;RAST;LA6113-0;3;2;;; +15667-9;LL1927-4;RAST;LA6114-8;4;3;;; +15667-9;LL1927-4;RAST;LA6115-5;5;4;;; +15667-9;LL1927-4;RAST;LA10137-0;6;5;;; +15667-9;LL1927-4;RAST;LA10138-8;7;6;;; +15668-7;LL1927-4;RAST;LA6111-4;1;0;;; +15668-7;LL1927-4;RAST;LA6112-2;2;1;;; +15668-7;LL1927-4;RAST;LA6113-0;3;2;;; +15668-7;LL1927-4;RAST;LA6114-8;4;3;;; +15668-7;LL1927-4;RAST;LA6115-5;5;4;;; +15668-7;LL1927-4;RAST;LA10137-0;6;5;;; +15668-7;LL1927-4;RAST;LA10138-8;7;6;;; +15669-5;LL1927-4;RAST;LA6111-4;1;0;;; +15669-5;LL1927-4;RAST;LA6112-2;2;1;;; +15669-5;LL1927-4;RAST;LA6113-0;3;2;;; +15669-5;LL1927-4;RAST;LA6114-8;4;3;;; +15669-5;LL1927-4;RAST;LA6115-5;5;4;;; +15669-5;LL1927-4;RAST;LA10137-0;6;5;;; +15669-5;LL1927-4;RAST;LA10138-8;7;6;;; +15670-3;LL1927-4;RAST;LA6111-4;1;0;;; +15670-3;LL1927-4;RAST;LA6112-2;2;1;;; +15670-3;LL1927-4;RAST;LA6113-0;3;2;;; +15670-3;LL1927-4;RAST;LA6114-8;4;3;;; +15670-3;LL1927-4;RAST;LA6115-5;5;4;;; +15670-3;LL1927-4;RAST;LA10137-0;6;5;;; +15670-3;LL1927-4;RAST;LA10138-8;7;6;;; +15671-1;LL1927-4;RAST;LA6111-4;1;0;;; +15671-1;LL1927-4;RAST;LA6112-2;2;1;;; +15671-1;LL1927-4;RAST;LA6113-0;3;2;;; +15671-1;LL1927-4;RAST;LA6114-8;4;3;;; +15671-1;LL1927-4;RAST;LA6115-5;5;4;;; +15671-1;LL1927-4;RAST;LA10137-0;6;5;;; +15671-1;LL1927-4;RAST;LA10138-8;7;6;;; +15672-9;LL1927-4;RAST;LA6111-4;1;0;;; +15672-9;LL1927-4;RAST;LA6112-2;2;1;;; +15672-9;LL1927-4;RAST;LA6113-0;3;2;;; +15672-9;LL1927-4;RAST;LA6114-8;4;3;;; +15672-9;LL1927-4;RAST;LA6115-5;5;4;;; +15672-9;LL1927-4;RAST;LA10137-0;6;5;;; +15672-9;LL1927-4;RAST;LA10138-8;7;6;;; +15673-7;LL1927-4;RAST;LA6111-4;1;0;;; +15673-7;LL1927-4;RAST;LA6112-2;2;1;;; +15673-7;LL1927-4;RAST;LA6113-0;3;2;;; +15673-7;LL1927-4;RAST;LA6114-8;4;3;;; +15673-7;LL1927-4;RAST;LA6115-5;5;4;;; +15673-7;LL1927-4;RAST;LA10137-0;6;5;;; +15673-7;LL1927-4;RAST;LA10138-8;7;6;;; +15674-5;LL1927-4;RAST;LA6111-4;1;0;;; +15674-5;LL1927-4;RAST;LA6112-2;2;1;;; +15674-5;LL1927-4;RAST;LA6113-0;3;2;;; +15674-5;LL1927-4;RAST;LA6114-8;4;3;;; +15674-5;LL1927-4;RAST;LA6115-5;5;4;;; +15674-5;LL1927-4;RAST;LA10137-0;6;5;;; +15674-5;LL1927-4;RAST;LA10138-8;7;6;;; +15675-2;LL1927-4;RAST;LA6111-4;1;0;;; +15675-2;LL1927-4;RAST;LA6112-2;2;1;;; +15675-2;LL1927-4;RAST;LA6113-0;3;2;;; +15675-2;LL1927-4;RAST;LA6114-8;4;3;;; +15675-2;LL1927-4;RAST;LA6115-5;5;4;;; +15675-2;LL1927-4;RAST;LA10137-0;6;5;;; +15675-2;LL1927-4;RAST;LA10138-8;7;6;;; +15676-0;LL1927-4;RAST;LA6111-4;1;0;;; +15676-0;LL1927-4;RAST;LA6112-2;2;1;;; +15676-0;LL1927-4;RAST;LA6113-0;3;2;;; +15676-0;LL1927-4;RAST;LA6114-8;4;3;;; +15676-0;LL1927-4;RAST;LA6115-5;5;4;;; +15676-0;LL1927-4;RAST;LA10137-0;6;5;;; +15676-0;LL1927-4;RAST;LA10138-8;7;6;;; +15677-8;LL1927-4;RAST;LA6111-4;1;0;;; +15677-8;LL1927-4;RAST;LA6112-2;2;1;;; +15677-8;LL1927-4;RAST;LA6113-0;3;2;;; +15677-8;LL1927-4;RAST;LA6114-8;4;3;;; +15677-8;LL1927-4;RAST;LA6115-5;5;4;;; +15677-8;LL1927-4;RAST;LA10137-0;6;5;;; +15677-8;LL1927-4;RAST;LA10138-8;7;6;;; +15678-6;LL1927-4;RAST;LA6111-4;1;0;;; +15678-6;LL1927-4;RAST;LA6112-2;2;1;;; +15678-6;LL1927-4;RAST;LA6113-0;3;2;;; +15678-6;LL1927-4;RAST;LA6114-8;4;3;;; +15678-6;LL1927-4;RAST;LA6115-5;5;4;;; +15678-6;LL1927-4;RAST;LA10137-0;6;5;;; +15678-6;LL1927-4;RAST;LA10138-8;7;6;;; +15679-4;LL1927-4;RAST;LA6111-4;1;0;;; +15679-4;LL1927-4;RAST;LA6112-2;2;1;;; +15679-4;LL1927-4;RAST;LA6113-0;3;2;;; +15679-4;LL1927-4;RAST;LA6114-8;4;3;;; +15679-4;LL1927-4;RAST;LA6115-5;5;4;;; +15679-4;LL1927-4;RAST;LA10137-0;6;5;;; +15679-4;LL1927-4;RAST;LA10138-8;7;6;;; +15680-2;LL1927-4;RAST;LA6111-4;1;0;;; +15680-2;LL1927-4;RAST;LA6112-2;2;1;;; +15680-2;LL1927-4;RAST;LA6113-0;3;2;;; +15680-2;LL1927-4;RAST;LA6114-8;4;3;;; +15680-2;LL1927-4;RAST;LA6115-5;5;4;;; +15680-2;LL1927-4;RAST;LA10137-0;6;5;;; +15680-2;LL1927-4;RAST;LA10138-8;7;6;;; +15681-0;LL1927-4;RAST;LA6111-4;1;0;;; +15681-0;LL1927-4;RAST;LA6112-2;2;1;;; +15681-0;LL1927-4;RAST;LA6113-0;3;2;;; +15681-0;LL1927-4;RAST;LA6114-8;4;3;;; +15681-0;LL1927-4;RAST;LA6115-5;5;4;;; +15681-0;LL1927-4;RAST;LA10137-0;6;5;;; +15681-0;LL1927-4;RAST;LA10138-8;7;6;;; +15682-8;LL1927-4;RAST;LA6111-4;1;0;;; +15682-8;LL1927-4;RAST;LA6112-2;2;1;;; +15682-8;LL1927-4;RAST;LA6113-0;3;2;;; +15682-8;LL1927-4;RAST;LA6114-8;4;3;;; +15682-8;LL1927-4;RAST;LA6115-5;5;4;;; +15682-8;LL1927-4;RAST;LA10137-0;6;5;;; +15682-8;LL1927-4;RAST;LA10138-8;7;6;;; +15683-6;LL1927-4;RAST;LA6111-4;1;0;;; +15683-6;LL1927-4;RAST;LA6112-2;2;1;;; +15683-6;LL1927-4;RAST;LA6113-0;3;2;;; +15683-6;LL1927-4;RAST;LA6114-8;4;3;;; +15683-6;LL1927-4;RAST;LA6115-5;5;4;;; +15683-6;LL1927-4;RAST;LA10137-0;6;5;;; +15683-6;LL1927-4;RAST;LA10138-8;7;6;;; +15684-4;LL1927-4;RAST;LA6111-4;1;0;;; +15684-4;LL1927-4;RAST;LA6112-2;2;1;;; +15684-4;LL1927-4;RAST;LA6113-0;3;2;;; +15684-4;LL1927-4;RAST;LA6114-8;4;3;;; +15684-4;LL1927-4;RAST;LA6115-5;5;4;;; +15684-4;LL1927-4;RAST;LA10137-0;6;5;;; +15684-4;LL1927-4;RAST;LA10138-8;7;6;;; +15685-1;LL1927-4;RAST;LA6111-4;1;0;;; +15685-1;LL1927-4;RAST;LA6112-2;2;1;;; +15685-1;LL1927-4;RAST;LA6113-0;3;2;;; +15685-1;LL1927-4;RAST;LA6114-8;4;3;;; +15685-1;LL1927-4;RAST;LA6115-5;5;4;;; +15685-1;LL1927-4;RAST;LA10137-0;6;5;;; +15685-1;LL1927-4;RAST;LA10138-8;7;6;;; +15686-9;LL1927-4;RAST;LA6111-4;1;0;;; +15686-9;LL1927-4;RAST;LA6112-2;2;1;;; +15686-9;LL1927-4;RAST;LA6113-0;3;2;;; +15686-9;LL1927-4;RAST;LA6114-8;4;3;;; +15686-9;LL1927-4;RAST;LA6115-5;5;4;;; +15686-9;LL1927-4;RAST;LA10137-0;6;5;;; +15686-9;LL1927-4;RAST;LA10138-8;7;6;;; +15687-7;LL1927-4;RAST;LA6111-4;1;0;;; +15687-7;LL1927-4;RAST;LA6112-2;2;1;;; +15687-7;LL1927-4;RAST;LA6113-0;3;2;;; +15687-7;LL1927-4;RAST;LA6114-8;4;3;;; +15687-7;LL1927-4;RAST;LA6115-5;5;4;;; +15687-7;LL1927-4;RAST;LA10137-0;6;5;;; +15687-7;LL1927-4;RAST;LA10138-8;7;6;;; +15688-5;LL1927-4;RAST;LA6111-4;1;0;;; +15688-5;LL1927-4;RAST;LA6112-2;2;1;;; +15688-5;LL1927-4;RAST;LA6113-0;3;2;;; +15688-5;LL1927-4;RAST;LA6114-8;4;3;;; +15688-5;LL1927-4;RAST;LA6115-5;5;4;;; +15688-5;LL1927-4;RAST;LA10137-0;6;5;;; +15688-5;LL1927-4;RAST;LA10138-8;7;6;;; +15689-3;LL1927-4;RAST;LA6111-4;1;0;;; +15689-3;LL1927-4;RAST;LA6112-2;2;1;;; +15689-3;LL1927-4;RAST;LA6113-0;3;2;;; +15689-3;LL1927-4;RAST;LA6114-8;4;3;;; +15689-3;LL1927-4;RAST;LA6115-5;5;4;;; +15689-3;LL1927-4;RAST;LA10137-0;6;5;;; +15689-3;LL1927-4;RAST;LA10138-8;7;6;;; +15690-1;LL1927-4;RAST;LA6111-4;1;0;;; +15690-1;LL1927-4;RAST;LA6112-2;2;1;;; +15690-1;LL1927-4;RAST;LA6113-0;3;2;;; +15690-1;LL1927-4;RAST;LA6114-8;4;3;;; +15690-1;LL1927-4;RAST;LA6115-5;5;4;;; +15690-1;LL1927-4;RAST;LA10137-0;6;5;;; +15690-1;LL1927-4;RAST;LA10138-8;7;6;;; +15691-9;LL1927-4;RAST;LA6111-4;1;0;;; +15691-9;LL1927-4;RAST;LA6112-2;2;1;;; +15691-9;LL1927-4;RAST;LA6113-0;3;2;;; +15691-9;LL1927-4;RAST;LA6114-8;4;3;;; +15691-9;LL1927-4;RAST;LA6115-5;5;4;;; +15691-9;LL1927-4;RAST;LA10137-0;6;5;;; +15691-9;LL1927-4;RAST;LA10138-8;7;6;;; +15692-7;LL1927-4;RAST;LA6111-4;1;0;;; +15692-7;LL1927-4;RAST;LA6112-2;2;1;;; +15692-7;LL1927-4;RAST;LA6113-0;3;2;;; +15692-7;LL1927-4;RAST;LA6114-8;4;3;;; +15692-7;LL1927-4;RAST;LA6115-5;5;4;;; +15692-7;LL1927-4;RAST;LA10137-0;6;5;;; +15692-7;LL1927-4;RAST;LA10138-8;7;6;;; +15693-5;LL1927-4;RAST;LA6111-4;1;0;;; +15693-5;LL1927-4;RAST;LA6112-2;2;1;;; +15693-5;LL1927-4;RAST;LA6113-0;3;2;;; +15693-5;LL1927-4;RAST;LA6114-8;4;3;;; +15693-5;LL1927-4;RAST;LA6115-5;5;4;;; +15693-5;LL1927-4;RAST;LA10137-0;6;5;;; +15693-5;LL1927-4;RAST;LA10138-8;7;6;;; +15694-3;LL1927-4;RAST;LA6111-4;1;0;;; +15694-3;LL1927-4;RAST;LA6112-2;2;1;;; +15694-3;LL1927-4;RAST;LA6113-0;3;2;;; +15694-3;LL1927-4;RAST;LA6114-8;4;3;;; +15694-3;LL1927-4;RAST;LA6115-5;5;4;;; +15694-3;LL1927-4;RAST;LA10137-0;6;5;;; +15694-3;LL1927-4;RAST;LA10138-8;7;6;;; +15696-8;LL1927-4;RAST;LA6111-4;1;0;;; +15696-8;LL1927-4;RAST;LA6112-2;2;1;;; +15696-8;LL1927-4;RAST;LA6113-0;3;2;;; +15696-8;LL1927-4;RAST;LA6114-8;4;3;;; +15696-8;LL1927-4;RAST;LA6115-5;5;4;;; +15696-8;LL1927-4;RAST;LA10137-0;6;5;;; +15696-8;LL1927-4;RAST;LA10138-8;7;6;;; +15697-6;LL1927-4;RAST;LA6111-4;1;0;;; +15697-6;LL1927-4;RAST;LA6112-2;2;1;;; +15697-6;LL1927-4;RAST;LA6113-0;3;2;;; +15697-6;LL1927-4;RAST;LA6114-8;4;3;;; +15697-6;LL1927-4;RAST;LA6115-5;5;4;;; +15697-6;LL1927-4;RAST;LA10137-0;6;5;;; +15697-6;LL1927-4;RAST;LA10138-8;7;6;;; +15698-4;LL1927-4;RAST;LA6111-4;1;0;;; +15698-4;LL1927-4;RAST;LA6112-2;2;1;;; +15698-4;LL1927-4;RAST;LA6113-0;3;2;;; +15698-4;LL1927-4;RAST;LA6114-8;4;3;;; +15698-4;LL1927-4;RAST;LA6115-5;5;4;;; +15698-4;LL1927-4;RAST;LA10137-0;6;5;;; +15698-4;LL1927-4;RAST;LA10138-8;7;6;;; +15699-2;LL1927-4;RAST;LA6111-4;1;0;;; +15699-2;LL1927-4;RAST;LA6112-2;2;1;;; +15699-2;LL1927-4;RAST;LA6113-0;3;2;;; +15699-2;LL1927-4;RAST;LA6114-8;4;3;;; +15699-2;LL1927-4;RAST;LA6115-5;5;4;;; +15699-2;LL1927-4;RAST;LA10137-0;6;5;;; +15699-2;LL1927-4;RAST;LA10138-8;7;6;;; +15700-8;LL1927-4;RAST;LA6111-4;1;0;;; +15700-8;LL1927-4;RAST;LA6112-2;2;1;;; +15700-8;LL1927-4;RAST;LA6113-0;3;2;;; +15700-8;LL1927-4;RAST;LA6114-8;4;3;;; +15700-8;LL1927-4;RAST;LA6115-5;5;4;;; +15700-8;LL1927-4;RAST;LA10137-0;6;5;;; +15700-8;LL1927-4;RAST;LA10138-8;7;6;;; +15701-6;LL1927-4;RAST;LA6111-4;1;0;;; +15701-6;LL1927-4;RAST;LA6112-2;2;1;;; +15701-6;LL1927-4;RAST;LA6113-0;3;2;;; +15701-6;LL1927-4;RAST;LA6114-8;4;3;;; +15701-6;LL1927-4;RAST;LA6115-5;5;4;;; +15701-6;LL1927-4;RAST;LA10137-0;6;5;;; +15701-6;LL1927-4;RAST;LA10138-8;7;6;;; +15702-4;LL1927-4;RAST;LA6111-4;1;0;;; +15702-4;LL1927-4;RAST;LA6112-2;2;1;;; +15702-4;LL1927-4;RAST;LA6113-0;3;2;;; +15702-4;LL1927-4;RAST;LA6114-8;4;3;;; +15702-4;LL1927-4;RAST;LA6115-5;5;4;;; +15702-4;LL1927-4;RAST;LA10137-0;6;5;;; +15702-4;LL1927-4;RAST;LA10138-8;7;6;;; +15703-2;LL1927-4;RAST;LA6111-4;1;0;;; +15703-2;LL1927-4;RAST;LA6112-2;2;1;;; +15703-2;LL1927-4;RAST;LA6113-0;3;2;;; +15703-2;LL1927-4;RAST;LA6114-8;4;3;;; +15703-2;LL1927-4;RAST;LA6115-5;5;4;;; +15703-2;LL1927-4;RAST;LA10137-0;6;5;;; +15703-2;LL1927-4;RAST;LA10138-8;7;6;;; +15704-0;LL1927-4;RAST;LA6111-4;1;0;;; +15704-0;LL1927-4;RAST;LA6112-2;2;1;;; +15704-0;LL1927-4;RAST;LA6113-0;3;2;;; +15704-0;LL1927-4;RAST;LA6114-8;4;3;;; +15704-0;LL1927-4;RAST;LA6115-5;5;4;;; +15704-0;LL1927-4;RAST;LA10137-0;6;5;;; +15704-0;LL1927-4;RAST;LA10138-8;7;6;;; +15705-7;LL1927-4;RAST;LA6111-4;1;0;;; +15705-7;LL1927-4;RAST;LA6112-2;2;1;;; +15705-7;LL1927-4;RAST;LA6113-0;3;2;;; +15705-7;LL1927-4;RAST;LA6114-8;4;3;;; +15705-7;LL1927-4;RAST;LA6115-5;5;4;;; +15705-7;LL1927-4;RAST;LA10137-0;6;5;;; +15705-7;LL1927-4;RAST;LA10138-8;7;6;;; +15706-5;LL1927-4;RAST;LA6111-4;1;0;;; +15706-5;LL1927-4;RAST;LA6112-2;2;1;;; +15706-5;LL1927-4;RAST;LA6113-0;3;2;;; +15706-5;LL1927-4;RAST;LA6114-8;4;3;;; +15706-5;LL1927-4;RAST;LA6115-5;5;4;;; +15706-5;LL1927-4;RAST;LA10137-0;6;5;;; +15706-5;LL1927-4;RAST;LA10138-8;7;6;;; +15707-3;LL1927-4;RAST;LA6111-4;1;0;;; +15707-3;LL1927-4;RAST;LA6112-2;2;1;;; +15707-3;LL1927-4;RAST;LA6113-0;3;2;;; +15707-3;LL1927-4;RAST;LA6114-8;4;3;;; +15707-3;LL1927-4;RAST;LA6115-5;5;4;;; +15707-3;LL1927-4;RAST;LA10137-0;6;5;;; +15707-3;LL1927-4;RAST;LA10138-8;7;6;;; +15708-1;LL1927-4;RAST;LA6111-4;1;0;;; +15708-1;LL1927-4;RAST;LA6112-2;2;1;;; +15708-1;LL1927-4;RAST;LA6113-0;3;2;;; +15708-1;LL1927-4;RAST;LA6114-8;4;3;;; +15708-1;LL1927-4;RAST;LA6115-5;5;4;;; +15708-1;LL1927-4;RAST;LA10137-0;6;5;;; +15708-1;LL1927-4;RAST;LA10138-8;7;6;;; +15709-9;LL1927-4;RAST;LA6111-4;1;0;;; +15709-9;LL1927-4;RAST;LA6112-2;2;1;;; +15709-9;LL1927-4;RAST;LA6113-0;3;2;;; +15709-9;LL1927-4;RAST;LA6114-8;4;3;;; +15709-9;LL1927-4;RAST;LA6115-5;5;4;;; +15709-9;LL1927-4;RAST;LA10137-0;6;5;;; +15709-9;LL1927-4;RAST;LA10138-8;7;6;;; +15710-7;LL1927-4;RAST;LA6111-4;1;0;;; +15710-7;LL1927-4;RAST;LA6112-2;2;1;;; +15710-7;LL1927-4;RAST;LA6113-0;3;2;;; +15710-7;LL1927-4;RAST;LA6114-8;4;3;;; +15710-7;LL1927-4;RAST;LA6115-5;5;4;;; +15710-7;LL1927-4;RAST;LA10137-0;6;5;;; +15710-7;LL1927-4;RAST;LA10138-8;7;6;;; +15711-5;LL1927-4;RAST;LA6111-4;1;0;;; +15711-5;LL1927-4;RAST;LA6112-2;2;1;;; +15711-5;LL1927-4;RAST;LA6113-0;3;2;;; +15711-5;LL1927-4;RAST;LA6114-8;4;3;;; +15711-5;LL1927-4;RAST;LA6115-5;5;4;;; +15711-5;LL1927-4;RAST;LA10137-0;6;5;;; +15711-5;LL1927-4;RAST;LA10138-8;7;6;;; +15712-3;LL1927-4;RAST;LA6111-4;1;0;;; +15712-3;LL1927-4;RAST;LA6112-2;2;1;;; +15712-3;LL1927-4;RAST;LA6113-0;3;2;;; +15712-3;LL1927-4;RAST;LA6114-8;4;3;;; +15712-3;LL1927-4;RAST;LA6115-5;5;4;;; +15712-3;LL1927-4;RAST;LA10137-0;6;5;;; +15712-3;LL1927-4;RAST;LA10138-8;7;6;;; +15713-1;LL1927-4;RAST;LA6111-4;1;0;;; +15713-1;LL1927-4;RAST;LA6112-2;2;1;;; +15713-1;LL1927-4;RAST;LA6113-0;3;2;;; +15713-1;LL1927-4;RAST;LA6114-8;4;3;;; +15713-1;LL1927-4;RAST;LA6115-5;5;4;;; +15713-1;LL1927-4;RAST;LA10137-0;6;5;;; +15713-1;LL1927-4;RAST;LA10138-8;7;6;;; +15714-9;LL1927-4;RAST;LA6111-4;1;0;;; +15714-9;LL1927-4;RAST;LA6112-2;2;1;;; +15714-9;LL1927-4;RAST;LA6113-0;3;2;;; +15714-9;LL1927-4;RAST;LA6114-8;4;3;;; +15714-9;LL1927-4;RAST;LA6115-5;5;4;;; +15714-9;LL1927-4;RAST;LA10137-0;6;5;;; +15714-9;LL1927-4;RAST;LA10138-8;7;6;;; +15715-6;LL1927-4;RAST;LA6111-4;1;0;;; +15715-6;LL1927-4;RAST;LA6112-2;2;1;;; +15715-6;LL1927-4;RAST;LA6113-0;3;2;;; +15715-6;LL1927-4;RAST;LA6114-8;4;3;;; +15715-6;LL1927-4;RAST;LA6115-5;5;4;;; +15715-6;LL1927-4;RAST;LA10137-0;6;5;;; +15715-6;LL1927-4;RAST;LA10138-8;7;6;;; +15716-4;LL1927-4;RAST;LA6111-4;1;0;;; +15716-4;LL1927-4;RAST;LA6112-2;2;1;;; +15716-4;LL1927-4;RAST;LA6113-0;3;2;;; +15716-4;LL1927-4;RAST;LA6114-8;4;3;;; +15716-4;LL1927-4;RAST;LA6115-5;5;4;;; +15716-4;LL1927-4;RAST;LA10137-0;6;5;;; +15716-4;LL1927-4;RAST;LA10138-8;7;6;;; +15717-2;LL1927-4;RAST;LA6111-4;1;0;;; +15717-2;LL1927-4;RAST;LA6112-2;2;1;;; +15717-2;LL1927-4;RAST;LA6113-0;3;2;;; +15717-2;LL1927-4;RAST;LA6114-8;4;3;;; +15717-2;LL1927-4;RAST;LA6115-5;5;4;;; +15717-2;LL1927-4;RAST;LA10137-0;6;5;;; +15717-2;LL1927-4;RAST;LA10138-8;7;6;;; +15718-0;LL1927-4;RAST;LA6111-4;1;0;;; +15718-0;LL1927-4;RAST;LA6112-2;2;1;;; +15718-0;LL1927-4;RAST;LA6113-0;3;2;;; +15718-0;LL1927-4;RAST;LA6114-8;4;3;;; +15718-0;LL1927-4;RAST;LA6115-5;5;4;;; +15718-0;LL1927-4;RAST;LA10137-0;6;5;;; +15718-0;LL1927-4;RAST;LA10138-8;7;6;;; +15719-8;LL1927-4;RAST;LA6111-4;1;0;;; +15719-8;LL1927-4;RAST;LA6112-2;2;1;;; +15719-8;LL1927-4;RAST;LA6113-0;3;2;;; +15719-8;LL1927-4;RAST;LA6114-8;4;3;;; +15719-8;LL1927-4;RAST;LA6115-5;5;4;;; +15719-8;LL1927-4;RAST;LA10137-0;6;5;;; +15719-8;LL1927-4;RAST;LA10138-8;7;6;;; +15720-6;LL1927-4;RAST;LA6111-4;1;0;;; +15720-6;LL1927-4;RAST;LA6112-2;2;1;;; +15720-6;LL1927-4;RAST;LA6113-0;3;2;;; +15720-6;LL1927-4;RAST;LA6114-8;4;3;;; +15720-6;LL1927-4;RAST;LA6115-5;5;4;;; +15720-6;LL1927-4;RAST;LA10137-0;6;5;;; +15720-6;LL1927-4;RAST;LA10138-8;7;6;;; +15721-4;LL1927-4;RAST;LA6111-4;1;0;;; +15721-4;LL1927-4;RAST;LA6112-2;2;1;;; +15721-4;LL1927-4;RAST;LA6113-0;3;2;;; +15721-4;LL1927-4;RAST;LA6114-8;4;3;;; +15721-4;LL1927-4;RAST;LA6115-5;5;4;;; +15721-4;LL1927-4;RAST;LA10137-0;6;5;;; +15721-4;LL1927-4;RAST;LA10138-8;7;6;;; +15722-2;LL1927-4;RAST;LA6111-4;1;0;;; +15722-2;LL1927-4;RAST;LA6112-2;2;1;;; +15722-2;LL1927-4;RAST;LA6113-0;3;2;;; +15722-2;LL1927-4;RAST;LA6114-8;4;3;;; +15722-2;LL1927-4;RAST;LA6115-5;5;4;;; +15722-2;LL1927-4;RAST;LA10137-0;6;5;;; +15722-2;LL1927-4;RAST;LA10138-8;7;6;;; +15723-0;LL1927-4;RAST;LA6111-4;1;0;;; +15723-0;LL1927-4;RAST;LA6112-2;2;1;;; +15723-0;LL1927-4;RAST;LA6113-0;3;2;;; +15723-0;LL1927-4;RAST;LA6114-8;4;3;;; +15723-0;LL1927-4;RAST;LA6115-5;5;4;;; +15723-0;LL1927-4;RAST;LA10137-0;6;5;;; +15723-0;LL1927-4;RAST;LA10138-8;7;6;;; +15724-8;LL1927-4;RAST;LA6111-4;1;0;;; +15724-8;LL1927-4;RAST;LA6112-2;2;1;;; +15724-8;LL1927-4;RAST;LA6113-0;3;2;;; +15724-8;LL1927-4;RAST;LA6114-8;4;3;;; +15724-8;LL1927-4;RAST;LA6115-5;5;4;;; +15724-8;LL1927-4;RAST;LA10137-0;6;5;;; +15724-8;LL1927-4;RAST;LA10138-8;7;6;;; +15725-5;LL1927-4;RAST;LA6111-4;1;0;;; +15725-5;LL1927-4;RAST;LA6112-2;2;1;;; +15725-5;LL1927-4;RAST;LA6113-0;3;2;;; +15725-5;LL1927-4;RAST;LA6114-8;4;3;;; +15725-5;LL1927-4;RAST;LA6115-5;5;4;;; +15725-5;LL1927-4;RAST;LA10137-0;6;5;;; +15725-5;LL1927-4;RAST;LA10138-8;7;6;;; +15726-3;LL1927-4;RAST;LA6111-4;1;0;;; +15726-3;LL1927-4;RAST;LA6112-2;2;1;;; +15726-3;LL1927-4;RAST;LA6113-0;3;2;;; +15726-3;LL1927-4;RAST;LA6114-8;4;3;;; +15726-3;LL1927-4;RAST;LA6115-5;5;4;;; +15726-3;LL1927-4;RAST;LA10137-0;6;5;;; +15726-3;LL1927-4;RAST;LA10138-8;7;6;;; +15727-1;LL1927-4;RAST;LA6111-4;1;0;;; +15727-1;LL1927-4;RAST;LA6112-2;2;1;;; +15727-1;LL1927-4;RAST;LA6113-0;3;2;;; +15727-1;LL1927-4;RAST;LA6114-8;4;3;;; +15727-1;LL1927-4;RAST;LA6115-5;5;4;;; +15727-1;LL1927-4;RAST;LA10137-0;6;5;;; +15727-1;LL1927-4;RAST;LA10138-8;7;6;;; +15728-9;LL1927-4;RAST;LA6111-4;1;0;;; +15728-9;LL1927-4;RAST;LA6112-2;2;1;;; +15728-9;LL1927-4;RAST;LA6113-0;3;2;;; +15728-9;LL1927-4;RAST;LA6114-8;4;3;;; +15728-9;LL1927-4;RAST;LA6115-5;5;4;;; +15728-9;LL1927-4;RAST;LA10137-0;6;5;;; +15728-9;LL1927-4;RAST;LA10138-8;7;6;;; +15729-7;LL1927-4;RAST;LA6111-4;1;0;;; +15729-7;LL1927-4;RAST;LA6112-2;2;1;;; +15729-7;LL1927-4;RAST;LA6113-0;3;2;;; +15729-7;LL1927-4;RAST;LA6114-8;4;3;;; +15729-7;LL1927-4;RAST;LA6115-5;5;4;;; +15729-7;LL1927-4;RAST;LA10137-0;6;5;;; +15729-7;LL1927-4;RAST;LA10138-8;7;6;;; +15730-5;LL1927-4;RAST;LA6111-4;1;0;;; +15730-5;LL1927-4;RAST;LA6112-2;2;1;;; +15730-5;LL1927-4;RAST;LA6113-0;3;2;;; +15730-5;LL1927-4;RAST;LA6114-8;4;3;;; +15730-5;LL1927-4;RAST;LA6115-5;5;4;;; +15730-5;LL1927-4;RAST;LA10137-0;6;5;;; +15730-5;LL1927-4;RAST;LA10138-8;7;6;;; +15731-3;LL1927-4;RAST;LA6111-4;1;0;;; +15731-3;LL1927-4;RAST;LA6112-2;2;1;;; +15731-3;LL1927-4;RAST;LA6113-0;3;2;;; +15731-3;LL1927-4;RAST;LA6114-8;4;3;;; +15731-3;LL1927-4;RAST;LA6115-5;5;4;;; +15731-3;LL1927-4;RAST;LA10137-0;6;5;;; +15731-3;LL1927-4;RAST;LA10138-8;7;6;;; +15732-1;LL1927-4;RAST;LA6111-4;1;0;;; +15732-1;LL1927-4;RAST;LA6112-2;2;1;;; +15732-1;LL1927-4;RAST;LA6113-0;3;2;;; +15732-1;LL1927-4;RAST;LA6114-8;4;3;;; +15732-1;LL1927-4;RAST;LA6115-5;5;4;;; +15732-1;LL1927-4;RAST;LA10137-0;6;5;;; +15732-1;LL1927-4;RAST;LA10138-8;7;6;;; +15733-9;LL1927-4;RAST;LA6111-4;1;0;;; +15733-9;LL1927-4;RAST;LA6112-2;2;1;;; +15733-9;LL1927-4;RAST;LA6113-0;3;2;;; +15733-9;LL1927-4;RAST;LA6114-8;4;3;;; +15733-9;LL1927-4;RAST;LA6115-5;5;4;;; +15733-9;LL1927-4;RAST;LA10137-0;6;5;;; +15733-9;LL1927-4;RAST;LA10138-8;7;6;;; +15734-7;LL1927-4;RAST;LA6111-4;1;0;;; +15734-7;LL1927-4;RAST;LA6112-2;2;1;;; +15734-7;LL1927-4;RAST;LA6113-0;3;2;;; +15734-7;LL1927-4;RAST;LA6114-8;4;3;;; +15734-7;LL1927-4;RAST;LA6115-5;5;4;;; +15734-7;LL1927-4;RAST;LA10137-0;6;5;;; +15734-7;LL1927-4;RAST;LA10138-8;7;6;;; +15735-4;LL1927-4;RAST;LA6111-4;1;0;;; +15735-4;LL1927-4;RAST;LA6112-2;2;1;;; +15735-4;LL1927-4;RAST;LA6113-0;3;2;;; +15735-4;LL1927-4;RAST;LA6114-8;4;3;;; +15735-4;LL1927-4;RAST;LA6115-5;5;4;;; +15735-4;LL1927-4;RAST;LA10137-0;6;5;;; +15735-4;LL1927-4;RAST;LA10138-8;7;6;;; +15736-2;LL1927-4;RAST;LA6111-4;1;0;;; +15736-2;LL1927-4;RAST;LA6112-2;2;1;;; +15736-2;LL1927-4;RAST;LA6113-0;3;2;;; +15736-2;LL1927-4;RAST;LA6114-8;4;3;;; +15736-2;LL1927-4;RAST;LA6115-5;5;4;;; +15736-2;LL1927-4;RAST;LA10137-0;6;5;;; +15736-2;LL1927-4;RAST;LA10138-8;7;6;;; +15737-0;LL1927-4;RAST;LA6111-4;1;0;;; +15737-0;LL1927-4;RAST;LA6112-2;2;1;;; +15737-0;LL1927-4;RAST;LA6113-0;3;2;;; +15737-0;LL1927-4;RAST;LA6114-8;4;3;;; +15737-0;LL1927-4;RAST;LA6115-5;5;4;;; +15737-0;LL1927-4;RAST;LA10137-0;6;5;;; +15737-0;LL1927-4;RAST;LA10138-8;7;6;;; +15738-8;LL1927-4;RAST;LA6111-4;1;0;;; +15738-8;LL1927-4;RAST;LA6112-2;2;1;;; +15738-8;LL1927-4;RAST;LA6113-0;3;2;;; +15738-8;LL1927-4;RAST;LA6114-8;4;3;;; +15738-8;LL1927-4;RAST;LA6115-5;5;4;;; +15738-8;LL1927-4;RAST;LA10137-0;6;5;;; +15738-8;LL1927-4;RAST;LA10138-8;7;6;;; +15739-6;LL1927-4;RAST;LA6111-4;1;0;;; +15739-6;LL1927-4;RAST;LA6112-2;2;1;;; +15739-6;LL1927-4;RAST;LA6113-0;3;2;;; +15739-6;LL1927-4;RAST;LA6114-8;4;3;;; +15739-6;LL1927-4;RAST;LA6115-5;5;4;;; +15739-6;LL1927-4;RAST;LA10137-0;6;5;;; +15739-6;LL1927-4;RAST;LA10138-8;7;6;;; +15740-4;LL1927-4;RAST;LA6111-4;1;0;;; +15740-4;LL1927-4;RAST;LA6112-2;2;1;;; +15740-4;LL1927-4;RAST;LA6113-0;3;2;;; +15740-4;LL1927-4;RAST;LA6114-8;4;3;;; +15740-4;LL1927-4;RAST;LA6115-5;5;4;;; +15740-4;LL1927-4;RAST;LA10137-0;6;5;;; +15740-4;LL1927-4;RAST;LA10138-8;7;6;;; +15741-2;LL1927-4;RAST;LA6111-4;1;0;;; +15741-2;LL1927-4;RAST;LA6112-2;2;1;;; +15741-2;LL1927-4;RAST;LA6113-0;3;2;;; +15741-2;LL1927-4;RAST;LA6114-8;4;3;;; +15741-2;LL1927-4;RAST;LA6115-5;5;4;;; +15741-2;LL1927-4;RAST;LA10137-0;6;5;;; +15741-2;LL1927-4;RAST;LA10138-8;7;6;;; +15742-0;LL1927-4;RAST;LA6111-4;1;0;;; +15742-0;LL1927-4;RAST;LA6112-2;2;1;;; +15742-0;LL1927-4;RAST;LA6113-0;3;2;;; +15742-0;LL1927-4;RAST;LA6114-8;4;3;;; +15742-0;LL1927-4;RAST;LA6115-5;5;4;;; +15742-0;LL1927-4;RAST;LA10137-0;6;5;;; +15742-0;LL1927-4;RAST;LA10138-8;7;6;;; +15743-8;LL1927-4;RAST;LA6111-4;1;0;;; +15743-8;LL1927-4;RAST;LA6112-2;2;1;;; +15743-8;LL1927-4;RAST;LA6113-0;3;2;;; +15743-8;LL1927-4;RAST;LA6114-8;4;3;;; +15743-8;LL1927-4;RAST;LA6115-5;5;4;;; +15743-8;LL1927-4;RAST;LA10137-0;6;5;;; +15743-8;LL1927-4;RAST;LA10138-8;7;6;;; +15744-6;LL1927-4;RAST;LA6111-4;1;0;;; +15744-6;LL1927-4;RAST;LA6112-2;2;1;;; +15744-6;LL1927-4;RAST;LA6113-0;3;2;;; +15744-6;LL1927-4;RAST;LA6114-8;4;3;;; +15744-6;LL1927-4;RAST;LA6115-5;5;4;;; +15744-6;LL1927-4;RAST;LA10137-0;6;5;;; +15744-6;LL1927-4;RAST;LA10138-8;7;6;;; +15745-3;LL1927-4;RAST;LA6111-4;1;0;;; +15745-3;LL1927-4;RAST;LA6112-2;2;1;;; +15745-3;LL1927-4;RAST;LA6113-0;3;2;;; +15745-3;LL1927-4;RAST;LA6114-8;4;3;;; +15745-3;LL1927-4;RAST;LA6115-5;5;4;;; +15745-3;LL1927-4;RAST;LA10137-0;6;5;;; +15745-3;LL1927-4;RAST;LA10138-8;7;6;;; +15746-1;LL1927-4;RAST;LA6111-4;1;0;;; +15746-1;LL1927-4;RAST;LA6112-2;2;1;;; +15746-1;LL1927-4;RAST;LA6113-0;3;2;;; +15746-1;LL1927-4;RAST;LA6114-8;4;3;;; +15746-1;LL1927-4;RAST;LA6115-5;5;4;;; +15746-1;LL1927-4;RAST;LA10137-0;6;5;;; +15746-1;LL1927-4;RAST;LA10138-8;7;6;;; +15747-9;LL1927-4;RAST;LA6111-4;1;0;;; +15747-9;LL1927-4;RAST;LA6112-2;2;1;;; +15747-9;LL1927-4;RAST;LA6113-0;3;2;;; +15747-9;LL1927-4;RAST;LA6114-8;4;3;;; +15747-9;LL1927-4;RAST;LA6115-5;5;4;;; +15747-9;LL1927-4;RAST;LA10137-0;6;5;;; +15747-9;LL1927-4;RAST;LA10138-8;7;6;;; +15748-7;LL1927-4;RAST;LA6111-4;1;0;;; +15748-7;LL1927-4;RAST;LA6112-2;2;1;;; +15748-7;LL1927-4;RAST;LA6113-0;3;2;;; +15748-7;LL1927-4;RAST;LA6114-8;4;3;;; +15748-7;LL1927-4;RAST;LA6115-5;5;4;;; +15748-7;LL1927-4;RAST;LA10137-0;6;5;;; +15748-7;LL1927-4;RAST;LA10138-8;7;6;;; +15749-5;LL1927-4;RAST;LA6111-4;1;0;;; +15749-5;LL1927-4;RAST;LA6112-2;2;1;;; +15749-5;LL1927-4;RAST;LA6113-0;3;2;;; +15749-5;LL1927-4;RAST;LA6114-8;4;3;;; +15749-5;LL1927-4;RAST;LA6115-5;5;4;;; +15749-5;LL1927-4;RAST;LA10137-0;6;5;;; +15749-5;LL1927-4;RAST;LA10138-8;7;6;;; +15751-1;LL1927-4;RAST;LA6111-4;1;0;;; +15751-1;LL1927-4;RAST;LA6112-2;2;1;;; +15751-1;LL1927-4;RAST;LA6113-0;3;2;;; +15751-1;LL1927-4;RAST;LA6114-8;4;3;;; +15751-1;LL1927-4;RAST;LA6115-5;5;4;;; +15751-1;LL1927-4;RAST;LA10137-0;6;5;;; +15751-1;LL1927-4;RAST;LA10138-8;7;6;;; +15752-9;LL1927-4;RAST;LA6111-4;1;0;;; +15752-9;LL1927-4;RAST;LA6112-2;2;1;;; +15752-9;LL1927-4;RAST;LA6113-0;3;2;;; +15752-9;LL1927-4;RAST;LA6114-8;4;3;;; +15752-9;LL1927-4;RAST;LA6115-5;5;4;;; +15752-9;LL1927-4;RAST;LA10137-0;6;5;;; +15752-9;LL1927-4;RAST;LA10138-8;7;6;;; +15753-7;LL1927-4;RAST;LA6111-4;1;0;;; +15753-7;LL1927-4;RAST;LA6112-2;2;1;;; +15753-7;LL1927-4;RAST;LA6113-0;3;2;;; +15753-7;LL1927-4;RAST;LA6114-8;4;3;;; +15753-7;LL1927-4;RAST;LA6115-5;5;4;;; +15753-7;LL1927-4;RAST;LA10137-0;6;5;;; +15753-7;LL1927-4;RAST;LA10138-8;7;6;;; +15754-5;LL1927-4;RAST;LA6111-4;1;0;;; +15754-5;LL1927-4;RAST;LA6112-2;2;1;;; +15754-5;LL1927-4;RAST;LA6113-0;3;2;;; +15754-5;LL1927-4;RAST;LA6114-8;4;3;;; +15754-5;LL1927-4;RAST;LA6115-5;5;4;;; +15754-5;LL1927-4;RAST;LA10137-0;6;5;;; +15754-5;LL1927-4;RAST;LA10138-8;7;6;;; +15755-2;LL1927-4;RAST;LA6111-4;1;0;;; +15755-2;LL1927-4;RAST;LA6112-2;2;1;;; +15755-2;LL1927-4;RAST;LA6113-0;3;2;;; +15755-2;LL1927-4;RAST;LA6114-8;4;3;;; +15755-2;LL1927-4;RAST;LA6115-5;5;4;;; +15755-2;LL1927-4;RAST;LA10137-0;6;5;;; +15755-2;LL1927-4;RAST;LA10138-8;7;6;;; +15756-0;LL1927-4;RAST;LA6111-4;1;0;;; +15756-0;LL1927-4;RAST;LA6112-2;2;1;;; +15756-0;LL1927-4;RAST;LA6113-0;3;2;;; +15756-0;LL1927-4;RAST;LA6114-8;4;3;;; +15756-0;LL1927-4;RAST;LA6115-5;5;4;;; +15756-0;LL1927-4;RAST;LA10137-0;6;5;;; +15756-0;LL1927-4;RAST;LA10138-8;7;6;;; +15757-8;LL1927-4;RAST;LA6111-4;1;0;;; +15757-8;LL1927-4;RAST;LA6112-2;2;1;;; +15757-8;LL1927-4;RAST;LA6113-0;3;2;;; +15757-8;LL1927-4;RAST;LA6114-8;4;3;;; +15757-8;LL1927-4;RAST;LA6115-5;5;4;;; +15757-8;LL1927-4;RAST;LA10137-0;6;5;;; +15757-8;LL1927-4;RAST;LA10138-8;7;6;;; +15758-6;LL1927-4;RAST;LA6111-4;1;0;;; +15758-6;LL1927-4;RAST;LA6112-2;2;1;;; +15758-6;LL1927-4;RAST;LA6113-0;3;2;;; +15758-6;LL1927-4;RAST;LA6114-8;4;3;;; +15758-6;LL1927-4;RAST;LA6115-5;5;4;;; +15758-6;LL1927-4;RAST;LA10137-0;6;5;;; +15758-6;LL1927-4;RAST;LA10138-8;7;6;;; +15759-4;LL1927-4;RAST;LA6111-4;1;0;;; +15759-4;LL1927-4;RAST;LA6112-2;2;1;;; +15759-4;LL1927-4;RAST;LA6113-0;3;2;;; +15759-4;LL1927-4;RAST;LA6114-8;4;3;;; +15759-4;LL1927-4;RAST;LA6115-5;5;4;;; +15759-4;LL1927-4;RAST;LA10137-0;6;5;;; +15759-4;LL1927-4;RAST;LA10138-8;7;6;;; +15760-2;LL1927-4;RAST;LA6111-4;1;0;;; +15760-2;LL1927-4;RAST;LA6112-2;2;1;;; +15760-2;LL1927-4;RAST;LA6113-0;3;2;;; +15760-2;LL1927-4;RAST;LA6114-8;4;3;;; +15760-2;LL1927-4;RAST;LA6115-5;5;4;;; +15760-2;LL1927-4;RAST;LA10137-0;6;5;;; +15760-2;LL1927-4;RAST;LA10138-8;7;6;;; +15761-0;LL1927-4;RAST;LA6111-4;1;0;;; +15761-0;LL1927-4;RAST;LA6112-2;2;1;;; +15761-0;LL1927-4;RAST;LA6113-0;3;2;;; +15761-0;LL1927-4;RAST;LA6114-8;4;3;;; +15761-0;LL1927-4;RAST;LA6115-5;5;4;;; +15761-0;LL1927-4;RAST;LA10137-0;6;5;;; +15761-0;LL1927-4;RAST;LA10138-8;7;6;;; +15762-8;LL1927-4;RAST;LA6111-4;1;0;;; +15762-8;LL1927-4;RAST;LA6112-2;2;1;;; +15762-8;LL1927-4;RAST;LA6113-0;3;2;;; +15762-8;LL1927-4;RAST;LA6114-8;4;3;;; +15762-8;LL1927-4;RAST;LA6115-5;5;4;;; +15762-8;LL1927-4;RAST;LA10137-0;6;5;;; +15762-8;LL1927-4;RAST;LA10138-8;7;6;;; +15763-6;LL1927-4;RAST;LA6111-4;1;0;;; +15763-6;LL1927-4;RAST;LA6112-2;2;1;;; +15763-6;LL1927-4;RAST;LA6113-0;3;2;;; +15763-6;LL1927-4;RAST;LA6114-8;4;3;;; +15763-6;LL1927-4;RAST;LA6115-5;5;4;;; +15763-6;LL1927-4;RAST;LA10137-0;6;5;;; +15763-6;LL1927-4;RAST;LA10138-8;7;6;;; +15764-4;LL1927-4;RAST;LA6111-4;1;0;;; +15764-4;LL1927-4;RAST;LA6112-2;2;1;;; +15764-4;LL1927-4;RAST;LA6113-0;3;2;;; +15764-4;LL1927-4;RAST;LA6114-8;4;3;;; +15764-4;LL1927-4;RAST;LA6115-5;5;4;;; +15764-4;LL1927-4;RAST;LA10137-0;6;5;;; +15764-4;LL1927-4;RAST;LA10138-8;7;6;;; +15765-1;LL1927-4;RAST;LA6111-4;1;0;;; +15765-1;LL1927-4;RAST;LA6112-2;2;1;;; +15765-1;LL1927-4;RAST;LA6113-0;3;2;;; +15765-1;LL1927-4;RAST;LA6114-8;4;3;;; +15765-1;LL1927-4;RAST;LA6115-5;5;4;;; +15765-1;LL1927-4;RAST;LA10137-0;6;5;;; +15765-1;LL1927-4;RAST;LA10138-8;7;6;;; +15766-9;LL1927-4;RAST;LA6111-4;1;0;;; +15766-9;LL1927-4;RAST;LA6112-2;2;1;;; +15766-9;LL1927-4;RAST;LA6113-0;3;2;;; +15766-9;LL1927-4;RAST;LA6114-8;4;3;;; +15766-9;LL1927-4;RAST;LA6115-5;5;4;;; +15766-9;LL1927-4;RAST;LA10137-0;6;5;;; +15766-9;LL1927-4;RAST;LA10138-8;7;6;;; +15767-7;LL1927-4;RAST;LA6111-4;1;0;;; +15767-7;LL1927-4;RAST;LA6112-2;2;1;;; +15767-7;LL1927-4;RAST;LA6113-0;3;2;;; +15767-7;LL1927-4;RAST;LA6114-8;4;3;;; +15767-7;LL1927-4;RAST;LA6115-5;5;4;;; +15767-7;LL1927-4;RAST;LA10137-0;6;5;;; +15767-7;LL1927-4;RAST;LA10138-8;7;6;;; +15768-5;LL1927-4;RAST;LA6111-4;1;0;;; +15768-5;LL1927-4;RAST;LA6112-2;2;1;;; +15768-5;LL1927-4;RAST;LA6113-0;3;2;;; +15768-5;LL1927-4;RAST;LA6114-8;4;3;;; +15768-5;LL1927-4;RAST;LA6115-5;5;4;;; +15768-5;LL1927-4;RAST;LA10137-0;6;5;;; +15768-5;LL1927-4;RAST;LA10138-8;7;6;;; +15769-3;LL1927-4;RAST;LA6111-4;1;0;;; +15769-3;LL1927-4;RAST;LA6112-2;2;1;;; +15769-3;LL1927-4;RAST;LA6113-0;3;2;;; +15769-3;LL1927-4;RAST;LA6114-8;4;3;;; +15769-3;LL1927-4;RAST;LA6115-5;5;4;;; +15769-3;LL1927-4;RAST;LA10137-0;6;5;;; +15769-3;LL1927-4;RAST;LA10138-8;7;6;;; +15770-1;LL1927-4;RAST;LA6111-4;1;0;;; +15770-1;LL1927-4;RAST;LA6112-2;2;1;;; +15770-1;LL1927-4;RAST;LA6113-0;3;2;;; +15770-1;LL1927-4;RAST;LA6114-8;4;3;;; +15770-1;LL1927-4;RAST;LA6115-5;5;4;;; +15770-1;LL1927-4;RAST;LA10137-0;6;5;;; +15770-1;LL1927-4;RAST;LA10138-8;7;6;;; +15771-9;LL1927-4;RAST;LA6111-4;1;0;;; +15771-9;LL1927-4;RAST;LA6112-2;2;1;;; +15771-9;LL1927-4;RAST;LA6113-0;3;2;;; +15771-9;LL1927-4;RAST;LA6114-8;4;3;;; +15771-9;LL1927-4;RAST;LA6115-5;5;4;;; +15771-9;LL1927-4;RAST;LA10137-0;6;5;;; +15771-9;LL1927-4;RAST;LA10138-8;7;6;;; +15772-7;LL1927-4;RAST;LA6111-4;1;0;;; +15772-7;LL1927-4;RAST;LA6112-2;2;1;;; +15772-7;LL1927-4;RAST;LA6113-0;3;2;;; +15772-7;LL1927-4;RAST;LA6114-8;4;3;;; +15772-7;LL1927-4;RAST;LA6115-5;5;4;;; +15772-7;LL1927-4;RAST;LA10137-0;6;5;;; +15772-7;LL1927-4;RAST;LA10138-8;7;6;;; +15773-5;LL1927-4;RAST;LA6111-4;1;0;;; +15773-5;LL1927-4;RAST;LA6112-2;2;1;;; +15773-5;LL1927-4;RAST;LA6113-0;3;2;;; +15773-5;LL1927-4;RAST;LA6114-8;4;3;;; +15773-5;LL1927-4;RAST;LA6115-5;5;4;;; +15773-5;LL1927-4;RAST;LA10137-0;6;5;;; +15773-5;LL1927-4;RAST;LA10138-8;7;6;;; +15774-3;LL1927-4;RAST;LA6111-4;1;0;;; +15774-3;LL1927-4;RAST;LA6112-2;2;1;;; +15774-3;LL1927-4;RAST;LA6113-0;3;2;;; +15774-3;LL1927-4;RAST;LA6114-8;4;3;;; +15774-3;LL1927-4;RAST;LA6115-5;5;4;;; +15774-3;LL1927-4;RAST;LA10137-0;6;5;;; +15774-3;LL1927-4;RAST;LA10138-8;7;6;;; +15775-0;LL1927-4;RAST;LA6111-4;1;0;;; +15775-0;LL1927-4;RAST;LA6112-2;2;1;;; +15775-0;LL1927-4;RAST;LA6113-0;3;2;;; +15775-0;LL1927-4;RAST;LA6114-8;4;3;;; +15775-0;LL1927-4;RAST;LA6115-5;5;4;;; +15775-0;LL1927-4;RAST;LA10137-0;6;5;;; +15775-0;LL1927-4;RAST;LA10138-8;7;6;;; +15776-8;LL1927-4;RAST;LA6111-4;1;0;;; +15776-8;LL1927-4;RAST;LA6112-2;2;1;;; +15776-8;LL1927-4;RAST;LA6113-0;3;2;;; +15776-8;LL1927-4;RAST;LA6114-8;4;3;;; +15776-8;LL1927-4;RAST;LA6115-5;5;4;;; +15776-8;LL1927-4;RAST;LA10137-0;6;5;;; +15776-8;LL1927-4;RAST;LA10138-8;7;6;;; +15777-6;LL1927-4;RAST;LA6111-4;1;0;;; +15777-6;LL1927-4;RAST;LA6112-2;2;1;;; +15777-6;LL1927-4;RAST;LA6113-0;3;2;;; +15777-6;LL1927-4;RAST;LA6114-8;4;3;;; +15777-6;LL1927-4;RAST;LA6115-5;5;4;;; +15777-6;LL1927-4;RAST;LA10137-0;6;5;;; +15777-6;LL1927-4;RAST;LA10138-8;7;6;;; +15778-4;LL1927-4;RAST;LA6111-4;1;0;;; +15778-4;LL1927-4;RAST;LA6112-2;2;1;;; +15778-4;LL1927-4;RAST;LA6113-0;3;2;;; +15778-4;LL1927-4;RAST;LA6114-8;4;3;;; +15778-4;LL1927-4;RAST;LA6115-5;5;4;;; +15778-4;LL1927-4;RAST;LA10137-0;6;5;;; +15778-4;LL1927-4;RAST;LA10138-8;7;6;;; +15779-2;LL1927-4;RAST;LA6111-4;1;0;;; +15779-2;LL1927-4;RAST;LA6112-2;2;1;;; +15779-2;LL1927-4;RAST;LA6113-0;3;2;;; +15779-2;LL1927-4;RAST;LA6114-8;4;3;;; +15779-2;LL1927-4;RAST;LA6115-5;5;4;;; +15779-2;LL1927-4;RAST;LA10137-0;6;5;;; +15779-2;LL1927-4;RAST;LA10138-8;7;6;;; +15780-0;LL1927-4;RAST;LA6111-4;1;0;;; +15780-0;LL1927-4;RAST;LA6112-2;2;1;;; +15780-0;LL1927-4;RAST;LA6113-0;3;2;;; +15780-0;LL1927-4;RAST;LA6114-8;4;3;;; +15780-0;LL1927-4;RAST;LA6115-5;5;4;;; +15780-0;LL1927-4;RAST;LA10137-0;6;5;;; +15780-0;LL1927-4;RAST;LA10138-8;7;6;;; +15781-8;LL1927-4;RAST;LA6111-4;1;0;;; +15781-8;LL1927-4;RAST;LA6112-2;2;1;;; +15781-8;LL1927-4;RAST;LA6113-0;3;2;;; +15781-8;LL1927-4;RAST;LA6114-8;4;3;;; +15781-8;LL1927-4;RAST;LA6115-5;5;4;;; +15781-8;LL1927-4;RAST;LA10137-0;6;5;;; +15781-8;LL1927-4;RAST;LA10138-8;7;6;;; +15782-6;LL1927-4;RAST;LA6111-4;1;0;;; +15782-6;LL1927-4;RAST;LA6112-2;2;1;;; +15782-6;LL1927-4;RAST;LA6113-0;3;2;;; +15782-6;LL1927-4;RAST;LA6114-8;4;3;;; +15782-6;LL1927-4;RAST;LA6115-5;5;4;;; +15782-6;LL1927-4;RAST;LA10137-0;6;5;;; +15782-6;LL1927-4;RAST;LA10138-8;7;6;;; +15783-4;LL1927-4;RAST;LA6111-4;1;0;;; +15783-4;LL1927-4;RAST;LA6112-2;2;1;;; +15783-4;LL1927-4;RAST;LA6113-0;3;2;;; +15783-4;LL1927-4;RAST;LA6114-8;4;3;;; +15783-4;LL1927-4;RAST;LA6115-5;5;4;;; +15783-4;LL1927-4;RAST;LA10137-0;6;5;;; +15783-4;LL1927-4;RAST;LA10138-8;7;6;;; +15784-2;LL1927-4;RAST;LA6111-4;1;0;;; +15784-2;LL1927-4;RAST;LA6112-2;2;1;;; +15784-2;LL1927-4;RAST;LA6113-0;3;2;;; +15784-2;LL1927-4;RAST;LA6114-8;4;3;;; +15784-2;LL1927-4;RAST;LA6115-5;5;4;;; +15784-2;LL1927-4;RAST;LA10137-0;6;5;;; +15784-2;LL1927-4;RAST;LA10138-8;7;6;;; +15785-9;LL1927-4;RAST;LA6111-4;1;0;;; +15785-9;LL1927-4;RAST;LA6112-2;2;1;;; +15785-9;LL1927-4;RAST;LA6113-0;3;2;;; +15785-9;LL1927-4;RAST;LA6114-8;4;3;;; +15785-9;LL1927-4;RAST;LA6115-5;5;4;;; +15785-9;LL1927-4;RAST;LA10137-0;6;5;;; +15785-9;LL1927-4;RAST;LA10138-8;7;6;;; +15786-7;LL1927-4;RAST;LA6111-4;1;0;;; +15786-7;LL1927-4;RAST;LA6112-2;2;1;;; +15786-7;LL1927-4;RAST;LA6113-0;3;2;;; +15786-7;LL1927-4;RAST;LA6114-8;4;3;;; +15786-7;LL1927-4;RAST;LA6115-5;5;4;;; +15786-7;LL1927-4;RAST;LA10137-0;6;5;;; +15786-7;LL1927-4;RAST;LA10138-8;7;6;;; +15787-5;LL1927-4;RAST;LA6111-4;1;0;;; +15787-5;LL1927-4;RAST;LA6112-2;2;1;;; +15787-5;LL1927-4;RAST;LA6113-0;3;2;;; +15787-5;LL1927-4;RAST;LA6114-8;4;3;;; +15787-5;LL1927-4;RAST;LA6115-5;5;4;;; +15787-5;LL1927-4;RAST;LA10137-0;6;5;;; +15787-5;LL1927-4;RAST;LA10138-8;7;6;;; +15788-3;LL1927-4;RAST;LA6111-4;1;0;;; +15788-3;LL1927-4;RAST;LA6112-2;2;1;;; +15788-3;LL1927-4;RAST;LA6113-0;3;2;;; +15788-3;LL1927-4;RAST;LA6114-8;4;3;;; +15788-3;LL1927-4;RAST;LA6115-5;5;4;;; +15788-3;LL1927-4;RAST;LA10137-0;6;5;;; +15788-3;LL1927-4;RAST;LA10138-8;7;6;;; +15789-1;LL1927-4;RAST;LA6111-4;1;0;;; +15789-1;LL1927-4;RAST;LA6112-2;2;1;;; +15789-1;LL1927-4;RAST;LA6113-0;3;2;;; +15789-1;LL1927-4;RAST;LA6114-8;4;3;;; +15789-1;LL1927-4;RAST;LA6115-5;5;4;;; +15789-1;LL1927-4;RAST;LA10137-0;6;5;;; +15789-1;LL1927-4;RAST;LA10138-8;7;6;;; +15790-9;LL1927-4;RAST;LA6111-4;1;0;;; +15790-9;LL1927-4;RAST;LA6112-2;2;1;;; +15790-9;LL1927-4;RAST;LA6113-0;3;2;;; +15790-9;LL1927-4;RAST;LA6114-8;4;3;;; +15790-9;LL1927-4;RAST;LA6115-5;5;4;;; +15790-9;LL1927-4;RAST;LA10137-0;6;5;;; +15790-9;LL1927-4;RAST;LA10138-8;7;6;;; +15791-7;LL1927-4;RAST;LA6111-4;1;0;;; +15791-7;LL1927-4;RAST;LA6112-2;2;1;;; +15791-7;LL1927-4;RAST;LA6113-0;3;2;;; +15791-7;LL1927-4;RAST;LA6114-8;4;3;;; +15791-7;LL1927-4;RAST;LA6115-5;5;4;;; +15791-7;LL1927-4;RAST;LA10137-0;6;5;;; +15791-7;LL1927-4;RAST;LA10138-8;7;6;;; +15792-5;LL1927-4;RAST;LA6111-4;1;0;;; +15792-5;LL1927-4;RAST;LA6112-2;2;1;;; +15792-5;LL1927-4;RAST;LA6113-0;3;2;;; +15792-5;LL1927-4;RAST;LA6114-8;4;3;;; +15792-5;LL1927-4;RAST;LA6115-5;5;4;;; +15792-5;LL1927-4;RAST;LA10137-0;6;5;;; +15792-5;LL1927-4;RAST;LA10138-8;7;6;;; +15793-3;LL1927-4;RAST;LA6111-4;1;0;;; +15793-3;LL1927-4;RAST;LA6112-2;2;1;;; +15793-3;LL1927-4;RAST;LA6113-0;3;2;;; +15793-3;LL1927-4;RAST;LA6114-8;4;3;;; +15793-3;LL1927-4;RAST;LA6115-5;5;4;;; +15793-3;LL1927-4;RAST;LA10137-0;6;5;;; +15793-3;LL1927-4;RAST;LA10138-8;7;6;;; +15794-1;LL1927-4;RAST;LA6111-4;1;0;;; +15794-1;LL1927-4;RAST;LA6112-2;2;1;;; +15794-1;LL1927-4;RAST;LA6113-0;3;2;;; +15794-1;LL1927-4;RAST;LA6114-8;4;3;;; +15794-1;LL1927-4;RAST;LA6115-5;5;4;;; +15794-1;LL1927-4;RAST;LA10137-0;6;5;;; +15794-1;LL1927-4;RAST;LA10138-8;7;6;;; +15795-8;LL1927-4;RAST;LA6111-4;1;0;;; +15795-8;LL1927-4;RAST;LA6112-2;2;1;;; +15795-8;LL1927-4;RAST;LA6113-0;3;2;;; +15795-8;LL1927-4;RAST;LA6114-8;4;3;;; +15795-8;LL1927-4;RAST;LA6115-5;5;4;;; +15795-8;LL1927-4;RAST;LA10137-0;6;5;;; +15795-8;LL1927-4;RAST;LA10138-8;7;6;;; +15796-6;LL1927-4;RAST;LA6111-4;1;0;;; +15796-6;LL1927-4;RAST;LA6112-2;2;1;;; +15796-6;LL1927-4;RAST;LA6113-0;3;2;;; +15796-6;LL1927-4;RAST;LA6114-8;4;3;;; +15796-6;LL1927-4;RAST;LA6115-5;5;4;;; +15796-6;LL1927-4;RAST;LA10137-0;6;5;;; +15796-6;LL1927-4;RAST;LA10138-8;7;6;;; +15797-4;LL1927-4;RAST;LA6111-4;1;0;;; +15797-4;LL1927-4;RAST;LA6112-2;2;1;;; +15797-4;LL1927-4;RAST;LA6113-0;3;2;;; +15797-4;LL1927-4;RAST;LA6114-8;4;3;;; +15797-4;LL1927-4;RAST;LA6115-5;5;4;;; +15797-4;LL1927-4;RAST;LA10137-0;6;5;;; +15797-4;LL1927-4;RAST;LA10138-8;7;6;;; +15798-2;LL1927-4;RAST;LA6111-4;1;0;;; +15798-2;LL1927-4;RAST;LA6112-2;2;1;;; +15798-2;LL1927-4;RAST;LA6113-0;3;2;;; +15798-2;LL1927-4;RAST;LA6114-8;4;3;;; +15798-2;LL1927-4;RAST;LA6115-5;5;4;;; +15798-2;LL1927-4;RAST;LA10137-0;6;5;;; +15798-2;LL1927-4;RAST;LA10138-8;7;6;;; +15799-0;LL1927-4;RAST;LA6111-4;1;0;;; +15799-0;LL1927-4;RAST;LA6112-2;2;1;;; +15799-0;LL1927-4;RAST;LA6113-0;3;2;;; +15799-0;LL1927-4;RAST;LA6114-8;4;3;;; +15799-0;LL1927-4;RAST;LA6115-5;5;4;;; +15799-0;LL1927-4;RAST;LA10137-0;6;5;;; +15799-0;LL1927-4;RAST;LA10138-8;7;6;;; +15800-6;LL1927-4;RAST;LA6111-4;1;0;;; +15800-6;LL1927-4;RAST;LA6112-2;2;1;;; +15800-6;LL1927-4;RAST;LA6113-0;3;2;;; +15800-6;LL1927-4;RAST;LA6114-8;4;3;;; +15800-6;LL1927-4;RAST;LA6115-5;5;4;;; +15800-6;LL1927-4;RAST;LA10137-0;6;5;;; +15800-6;LL1927-4;RAST;LA10138-8;7;6;;; +15801-4;LL1927-4;RAST;LA6111-4;1;0;;; +15801-4;LL1927-4;RAST;LA6112-2;2;1;;; +15801-4;LL1927-4;RAST;LA6113-0;3;2;;; +15801-4;LL1927-4;RAST;LA6114-8;4;3;;; +15801-4;LL1927-4;RAST;LA6115-5;5;4;;; +15801-4;LL1927-4;RAST;LA10137-0;6;5;;; +15801-4;LL1927-4;RAST;LA10138-8;7;6;;; +15802-2;LL1927-4;RAST;LA6111-4;1;0;;; +15802-2;LL1927-4;RAST;LA6112-2;2;1;;; +15802-2;LL1927-4;RAST;LA6113-0;3;2;;; +15802-2;LL1927-4;RAST;LA6114-8;4;3;;; +15802-2;LL1927-4;RAST;LA6115-5;5;4;;; +15802-2;LL1927-4;RAST;LA10137-0;6;5;;; +15802-2;LL1927-4;RAST;LA10138-8;7;6;;; +15803-0;LL1927-4;RAST;LA6111-4;1;0;;; +15803-0;LL1927-4;RAST;LA6112-2;2;1;;; +15803-0;LL1927-4;RAST;LA6113-0;3;2;;; +15803-0;LL1927-4;RAST;LA6114-8;4;3;;; +15803-0;LL1927-4;RAST;LA6115-5;5;4;;; +15803-0;LL1927-4;RAST;LA10137-0;6;5;;; +15803-0;LL1927-4;RAST;LA10138-8;7;6;;; +15805-5;LL1927-4;RAST;LA6111-4;1;0;;; +15805-5;LL1927-4;RAST;LA6112-2;2;1;;; +15805-5;LL1927-4;RAST;LA6113-0;3;2;;; +15805-5;LL1927-4;RAST;LA6114-8;4;3;;; +15805-5;LL1927-4;RAST;LA6115-5;5;4;;; +15805-5;LL1927-4;RAST;LA10137-0;6;5;;; +15805-5;LL1927-4;RAST;LA10138-8;7;6;;; +15806-3;LL1927-4;RAST;LA6111-4;1;0;;; +15806-3;LL1927-4;RAST;LA6112-2;2;1;;; +15806-3;LL1927-4;RAST;LA6113-0;3;2;;; +15806-3;LL1927-4;RAST;LA6114-8;4;3;;; +15806-3;LL1927-4;RAST;LA6115-5;5;4;;; +15806-3;LL1927-4;RAST;LA10137-0;6;5;;; +15806-3;LL1927-4;RAST;LA10138-8;7;6;;; +15807-1;LL1927-4;RAST;LA6111-4;1;0;;; +15807-1;LL1927-4;RAST;LA6112-2;2;1;;; +15807-1;LL1927-4;RAST;LA6113-0;3;2;;; +15807-1;LL1927-4;RAST;LA6114-8;4;3;;; +15807-1;LL1927-4;RAST;LA6115-5;5;4;;; +15807-1;LL1927-4;RAST;LA10137-0;6;5;;; +15807-1;LL1927-4;RAST;LA10138-8;7;6;;; +15808-9;LL1927-4;RAST;LA6111-4;1;0;;; +15808-9;LL1927-4;RAST;LA6112-2;2;1;;; +15808-9;LL1927-4;RAST;LA6113-0;3;2;;; +15808-9;LL1927-4;RAST;LA6114-8;4;3;;; +15808-9;LL1927-4;RAST;LA6115-5;5;4;;; +15808-9;LL1927-4;RAST;LA10137-0;6;5;;; +15808-9;LL1927-4;RAST;LA10138-8;7;6;;; +15809-7;LL1927-4;RAST;LA6111-4;1;0;;; +15809-7;LL1927-4;RAST;LA6112-2;2;1;;; +15809-7;LL1927-4;RAST;LA6113-0;3;2;;; +15809-7;LL1927-4;RAST;LA6114-8;4;3;;; +15809-7;LL1927-4;RAST;LA6115-5;5;4;;; +15809-7;LL1927-4;RAST;LA10137-0;6;5;;; +15809-7;LL1927-4;RAST;LA10138-8;7;6;;; +15810-5;LL1927-4;RAST;LA6111-4;1;0;;; +15810-5;LL1927-4;RAST;LA6112-2;2;1;;; +15810-5;LL1927-4;RAST;LA6113-0;3;2;;; +15810-5;LL1927-4;RAST;LA6114-8;4;3;;; +15810-5;LL1927-4;RAST;LA6115-5;5;4;;; +15810-5;LL1927-4;RAST;LA10137-0;6;5;;; +15810-5;LL1927-4;RAST;LA10138-8;7;6;;; +15811-3;LL1927-4;RAST;LA6111-4;1;0;;; +15811-3;LL1927-4;RAST;LA6112-2;2;1;;; +15811-3;LL1927-4;RAST;LA6113-0;3;2;;; +15811-3;LL1927-4;RAST;LA6114-8;4;3;;; +15811-3;LL1927-4;RAST;LA6115-5;5;4;;; +15811-3;LL1927-4;RAST;LA10137-0;6;5;;; +15811-3;LL1927-4;RAST;LA10138-8;7;6;;; +15812-1;LL1927-4;RAST;LA6111-4;1;0;;; +15812-1;LL1927-4;RAST;LA6112-2;2;1;;; +15812-1;LL1927-4;RAST;LA6113-0;3;2;;; +15812-1;LL1927-4;RAST;LA6114-8;4;3;;; +15812-1;LL1927-4;RAST;LA6115-5;5;4;;; +15812-1;LL1927-4;RAST;LA10137-0;6;5;;; +15812-1;LL1927-4;RAST;LA10138-8;7;6;;; +15813-9;LL1927-4;RAST;LA6111-4;1;0;;; +15813-9;LL1927-4;RAST;LA6112-2;2;1;;; +15813-9;LL1927-4;RAST;LA6113-0;3;2;;; +15813-9;LL1927-4;RAST;LA6114-8;4;3;;; +15813-9;LL1927-4;RAST;LA6115-5;5;4;;; +15813-9;LL1927-4;RAST;LA10137-0;6;5;;; +15813-9;LL1927-4;RAST;LA10138-8;7;6;;; +15814-7;LL1927-4;RAST;LA6111-4;1;0;;; +15814-7;LL1927-4;RAST;LA6112-2;2;1;;; +15814-7;LL1927-4;RAST;LA6113-0;3;2;;; +15814-7;LL1927-4;RAST;LA6114-8;4;3;;; +15814-7;LL1927-4;RAST;LA6115-5;5;4;;; +15814-7;LL1927-4;RAST;LA10137-0;6;5;;; +15814-7;LL1927-4;RAST;LA10138-8;7;6;;; +15815-4;LL1927-4;RAST;LA6111-4;1;0;;; +15815-4;LL1927-4;RAST;LA6112-2;2;1;;; +15815-4;LL1927-4;RAST;LA6113-0;3;2;;; +15815-4;LL1927-4;RAST;LA6114-8;4;3;;; +15815-4;LL1927-4;RAST;LA6115-5;5;4;;; +15815-4;LL1927-4;RAST;LA10137-0;6;5;;; +15815-4;LL1927-4;RAST;LA10138-8;7;6;;; +15816-2;LL1927-4;RAST;LA6111-4;1;0;;; +15816-2;LL1927-4;RAST;LA6112-2;2;1;;; +15816-2;LL1927-4;RAST;LA6113-0;3;2;;; +15816-2;LL1927-4;RAST;LA6114-8;4;3;;; +15816-2;LL1927-4;RAST;LA6115-5;5;4;;; +15816-2;LL1927-4;RAST;LA10137-0;6;5;;; +15816-2;LL1927-4;RAST;LA10138-8;7;6;;; +15817-0;LL1927-4;RAST;LA6111-4;1;0;;; +15817-0;LL1927-4;RAST;LA6112-2;2;1;;; +15817-0;LL1927-4;RAST;LA6113-0;3;2;;; +15817-0;LL1927-4;RAST;LA6114-8;4;3;;; +15817-0;LL1927-4;RAST;LA6115-5;5;4;;; +15817-0;LL1927-4;RAST;LA10137-0;6;5;;; +15817-0;LL1927-4;RAST;LA10138-8;7;6;;; +15818-8;LL1927-4;RAST;LA6111-4;1;0;;; +15818-8;LL1927-4;RAST;LA6112-2;2;1;;; +15818-8;LL1927-4;RAST;LA6113-0;3;2;;; +15818-8;LL1927-4;RAST;LA6114-8;4;3;;; +15818-8;LL1927-4;RAST;LA6115-5;5;4;;; +15818-8;LL1927-4;RAST;LA10137-0;6;5;;; +15818-8;LL1927-4;RAST;LA10138-8;7;6;;; +15819-6;LL1927-4;RAST;LA6111-4;1;0;;; +15819-6;LL1927-4;RAST;LA6112-2;2;1;;; +15819-6;LL1927-4;RAST;LA6113-0;3;2;;; +15819-6;LL1927-4;RAST;LA6114-8;4;3;;; +15819-6;LL1927-4;RAST;LA6115-5;5;4;;; +15819-6;LL1927-4;RAST;LA10137-0;6;5;;; +15819-6;LL1927-4;RAST;LA10138-8;7;6;;; +15820-4;LL1927-4;RAST;LA6111-4;1;0;;; +15820-4;LL1927-4;RAST;LA6112-2;2;1;;; +15820-4;LL1927-4;RAST;LA6113-0;3;2;;; +15820-4;LL1927-4;RAST;LA6114-8;4;3;;; +15820-4;LL1927-4;RAST;LA6115-5;5;4;;; +15820-4;LL1927-4;RAST;LA10137-0;6;5;;; +15820-4;LL1927-4;RAST;LA10138-8;7;6;;; +15821-2;LL1927-4;RAST;LA6111-4;1;0;;; +15821-2;LL1927-4;RAST;LA6112-2;2;1;;; +15821-2;LL1927-4;RAST;LA6113-0;3;2;;; +15821-2;LL1927-4;RAST;LA6114-8;4;3;;; +15821-2;LL1927-4;RAST;LA6115-5;5;4;;; +15821-2;LL1927-4;RAST;LA10137-0;6;5;;; +15821-2;LL1927-4;RAST;LA10138-8;7;6;;; +15822-0;LL1927-4;RAST;LA6111-4;1;0;;; +15822-0;LL1927-4;RAST;LA6112-2;2;1;;; +15822-0;LL1927-4;RAST;LA6113-0;3;2;;; +15822-0;LL1927-4;RAST;LA6114-8;4;3;;; +15822-0;LL1927-4;RAST;LA6115-5;5;4;;; +15822-0;LL1927-4;RAST;LA10137-0;6;5;;; +15822-0;LL1927-4;RAST;LA10138-8;7;6;;; +15823-8;LL1927-4;RAST;LA6111-4;1;0;;; +15823-8;LL1927-4;RAST;LA6112-2;2;1;;; +15823-8;LL1927-4;RAST;LA6113-0;3;2;;; +15823-8;LL1927-4;RAST;LA6114-8;4;3;;; +15823-8;LL1927-4;RAST;LA6115-5;5;4;;; +15823-8;LL1927-4;RAST;LA10137-0;6;5;;; +15823-8;LL1927-4;RAST;LA10138-8;7;6;;; +15824-6;LL1927-4;RAST;LA6111-4;1;0;;; +15824-6;LL1927-4;RAST;LA6112-2;2;1;;; +15824-6;LL1927-4;RAST;LA6113-0;3;2;;; +15824-6;LL1927-4;RAST;LA6114-8;4;3;;; +15824-6;LL1927-4;RAST;LA6115-5;5;4;;; +15824-6;LL1927-4;RAST;LA10137-0;6;5;;; +15824-6;LL1927-4;RAST;LA10138-8;7;6;;; +15825-3;LL1927-4;RAST;LA6111-4;1;0;;; +15825-3;LL1927-4;RAST;LA6112-2;2;1;;; +15825-3;LL1927-4;RAST;LA6113-0;3;2;;; +15825-3;LL1927-4;RAST;LA6114-8;4;3;;; +15825-3;LL1927-4;RAST;LA6115-5;5;4;;; +15825-3;LL1927-4;RAST;LA10137-0;6;5;;; +15825-3;LL1927-4;RAST;LA10138-8;7;6;;; +15826-1;LL1927-4;RAST;LA6111-4;1;0;;; +15826-1;LL1927-4;RAST;LA6112-2;2;1;;; +15826-1;LL1927-4;RAST;LA6113-0;3;2;;; +15826-1;LL1927-4;RAST;LA6114-8;4;3;;; +15826-1;LL1927-4;RAST;LA6115-5;5;4;;; +15826-1;LL1927-4;RAST;LA10137-0;6;5;;; +15826-1;LL1927-4;RAST;LA10138-8;7;6;;; +15827-9;LL1927-4;RAST;LA6111-4;1;0;;; +15827-9;LL1927-4;RAST;LA6112-2;2;1;;; +15827-9;LL1927-4;RAST;LA6113-0;3;2;;; +15827-9;LL1927-4;RAST;LA6114-8;4;3;;; +15827-9;LL1927-4;RAST;LA6115-5;5;4;;; +15827-9;LL1927-4;RAST;LA10137-0;6;5;;; +15827-9;LL1927-4;RAST;LA10138-8;7;6;;; +15828-7;LL1927-4;RAST;LA6111-4;1;0;;; +15828-7;LL1927-4;RAST;LA6112-2;2;1;;; +15828-7;LL1927-4;RAST;LA6113-0;3;2;;; +15828-7;LL1927-4;RAST;LA6114-8;4;3;;; +15828-7;LL1927-4;RAST;LA6115-5;5;4;;; +15828-7;LL1927-4;RAST;LA10137-0;6;5;;; +15828-7;LL1927-4;RAST;LA10138-8;7;6;;; +15829-5;LL1927-4;RAST;LA6111-4;1;0;;; +15829-5;LL1927-4;RAST;LA6112-2;2;1;;; +15829-5;LL1927-4;RAST;LA6113-0;3;2;;; +15829-5;LL1927-4;RAST;LA6114-8;4;3;;; +15829-5;LL1927-4;RAST;LA6115-5;5;4;;; +15829-5;LL1927-4;RAST;LA10137-0;6;5;;; +15829-5;LL1927-4;RAST;LA10138-8;7;6;;; +15831-1;LL1927-4;RAST;LA6111-4;1;0;;; +15831-1;LL1927-4;RAST;LA6112-2;2;1;;; +15831-1;LL1927-4;RAST;LA6113-0;3;2;;; +15831-1;LL1927-4;RAST;LA6114-8;4;3;;; +15831-1;LL1927-4;RAST;LA6115-5;5;4;;; +15831-1;LL1927-4;RAST;LA10137-0;6;5;;; +15831-1;LL1927-4;RAST;LA10138-8;7;6;;; +15832-9;LL1927-4;RAST;LA6111-4;1;0;;; +15832-9;LL1927-4;RAST;LA6112-2;2;1;;; +15832-9;LL1927-4;RAST;LA6113-0;3;2;;; +15832-9;LL1927-4;RAST;LA6114-8;4;3;;; +15832-9;LL1927-4;RAST;LA6115-5;5;4;;; +15832-9;LL1927-4;RAST;LA10137-0;6;5;;; +15832-9;LL1927-4;RAST;LA10138-8;7;6;;; +15833-7;LL1927-4;RAST;LA6111-4;1;0;;; +15833-7;LL1927-4;RAST;LA6112-2;2;1;;; +15833-7;LL1927-4;RAST;LA6113-0;3;2;;; +15833-7;LL1927-4;RAST;LA6114-8;4;3;;; +15833-7;LL1927-4;RAST;LA6115-5;5;4;;; +15833-7;LL1927-4;RAST;LA10137-0;6;5;;; +15833-7;LL1927-4;RAST;LA10138-8;7;6;;; +15834-5;LL1927-4;RAST;LA6111-4;1;0;;; +15834-5;LL1927-4;RAST;LA6112-2;2;1;;; +15834-5;LL1927-4;RAST;LA6113-0;3;2;;; +15834-5;LL1927-4;RAST;LA6114-8;4;3;;; +15834-5;LL1927-4;RAST;LA6115-5;5;4;;; +15834-5;LL1927-4;RAST;LA10137-0;6;5;;; +15834-5;LL1927-4;RAST;LA10138-8;7;6;;; +15835-2;LL1927-4;RAST;LA6111-4;1;0;;; +15835-2;LL1927-4;RAST;LA6112-2;2;1;;; +15835-2;LL1927-4;RAST;LA6113-0;3;2;;; +15835-2;LL1927-4;RAST;LA6114-8;4;3;;; +15835-2;LL1927-4;RAST;LA6115-5;5;4;;; +15835-2;LL1927-4;RAST;LA10137-0;6;5;;; +15835-2;LL1927-4;RAST;LA10138-8;7;6;;; +15836-0;LL1927-4;RAST;LA6111-4;1;0;;; +15836-0;LL1927-4;RAST;LA6112-2;2;1;;; +15836-0;LL1927-4;RAST;LA6113-0;3;2;;; +15836-0;LL1927-4;RAST;LA6114-8;4;3;;; +15836-0;LL1927-4;RAST;LA6115-5;5;4;;; +15836-0;LL1927-4;RAST;LA10137-0;6;5;;; +15836-0;LL1927-4;RAST;LA10138-8;7;6;;; +15837-8;LL1927-4;RAST;LA6111-4;1;0;;; +15837-8;LL1927-4;RAST;LA6112-2;2;1;;; +15837-8;LL1927-4;RAST;LA6113-0;3;2;;; +15837-8;LL1927-4;RAST;LA6114-8;4;3;;; +15837-8;LL1927-4;RAST;LA6115-5;5;4;;; +15837-8;LL1927-4;RAST;LA10137-0;6;5;;; +15837-8;LL1927-4;RAST;LA10138-8;7;6;;; +15838-6;LL1927-4;RAST;LA6111-4;1;0;;; +15838-6;LL1927-4;RAST;LA6112-2;2;1;;; +15838-6;LL1927-4;RAST;LA6113-0;3;2;;; +15838-6;LL1927-4;RAST;LA6114-8;4;3;;; +15838-6;LL1927-4;RAST;LA6115-5;5;4;;; +15838-6;LL1927-4;RAST;LA10137-0;6;5;;; +15838-6;LL1927-4;RAST;LA10138-8;7;6;;; +15839-4;LL1927-4;RAST;LA6111-4;1;0;;; +15839-4;LL1927-4;RAST;LA6112-2;2;1;;; +15839-4;LL1927-4;RAST;LA6113-0;3;2;;; +15839-4;LL1927-4;RAST;LA6114-8;4;3;;; +15839-4;LL1927-4;RAST;LA6115-5;5;4;;; +15839-4;LL1927-4;RAST;LA10137-0;6;5;;; +15839-4;LL1927-4;RAST;LA10138-8;7;6;;; +15840-2;LL1927-4;RAST;LA6111-4;1;0;;; +15840-2;LL1927-4;RAST;LA6112-2;2;1;;; +15840-2;LL1927-4;RAST;LA6113-0;3;2;;; +15840-2;LL1927-4;RAST;LA6114-8;4;3;;; +15840-2;LL1927-4;RAST;LA6115-5;5;4;;; +15840-2;LL1927-4;RAST;LA10137-0;6;5;;; +15840-2;LL1927-4;RAST;LA10138-8;7;6;;; +15841-0;LL1927-4;RAST;LA6111-4;1;0;;; +15841-0;LL1927-4;RAST;LA6112-2;2;1;;; +15841-0;LL1927-4;RAST;LA6113-0;3;2;;; +15841-0;LL1927-4;RAST;LA6114-8;4;3;;; +15841-0;LL1927-4;RAST;LA6115-5;5;4;;; +15841-0;LL1927-4;RAST;LA10137-0;6;5;;; +15841-0;LL1927-4;RAST;LA10138-8;7;6;;; +15843-6;LL1927-4;RAST;LA6111-4;1;0;;; +15843-6;LL1927-4;RAST;LA6112-2;2;1;;; +15843-6;LL1927-4;RAST;LA6113-0;3;2;;; +15843-6;LL1927-4;RAST;LA6114-8;4;3;;; +15843-6;LL1927-4;RAST;LA6115-5;5;4;;; +15843-6;LL1927-4;RAST;LA10137-0;6;5;;; +15843-6;LL1927-4;RAST;LA10138-8;7;6;;; +15844-4;LL1927-4;RAST;LA6111-4;1;0;;; +15844-4;LL1927-4;RAST;LA6112-2;2;1;;; +15844-4;LL1927-4;RAST;LA6113-0;3;2;;; +15844-4;LL1927-4;RAST;LA6114-8;4;3;;; +15844-4;LL1927-4;RAST;LA6115-5;5;4;;; +15844-4;LL1927-4;RAST;LA10137-0;6;5;;; +15844-4;LL1927-4;RAST;LA10138-8;7;6;;; +15845-1;LL1927-4;RAST;LA6111-4;1;0;;; +15845-1;LL1927-4;RAST;LA6112-2;2;1;;; +15845-1;LL1927-4;RAST;LA6113-0;3;2;;; +15845-1;LL1927-4;RAST;LA6114-8;4;3;;; +15845-1;LL1927-4;RAST;LA6115-5;5;4;;; +15845-1;LL1927-4;RAST;LA10137-0;6;5;;; +15845-1;LL1927-4;RAST;LA10138-8;7;6;;; +15846-9;LL1927-4;RAST;LA6111-4;1;0;;; +15846-9;LL1927-4;RAST;LA6112-2;2;1;;; +15846-9;LL1927-4;RAST;LA6113-0;3;2;;; +15846-9;LL1927-4;RAST;LA6114-8;4;3;;; +15846-9;LL1927-4;RAST;LA6115-5;5;4;;; +15846-9;LL1927-4;RAST;LA10137-0;6;5;;; +15846-9;LL1927-4;RAST;LA10138-8;7;6;;; +15847-7;LL1927-4;RAST;LA6111-4;1;0;;; +15847-7;LL1927-4;RAST;LA6112-2;2;1;;; +15847-7;LL1927-4;RAST;LA6113-0;3;2;;; +15847-7;LL1927-4;RAST;LA6114-8;4;3;;; +15847-7;LL1927-4;RAST;LA6115-5;5;4;;; +15847-7;LL1927-4;RAST;LA10137-0;6;5;;; +15847-7;LL1927-4;RAST;LA10138-8;7;6;;; +15848-5;LL1927-4;RAST;LA6111-4;1;0;;; +15848-5;LL1927-4;RAST;LA6112-2;2;1;;; +15848-5;LL1927-4;RAST;LA6113-0;3;2;;; +15848-5;LL1927-4;RAST;LA6114-8;4;3;;; +15848-5;LL1927-4;RAST;LA6115-5;5;4;;; +15848-5;LL1927-4;RAST;LA10137-0;6;5;;; +15848-5;LL1927-4;RAST;LA10138-8;7;6;;; +15849-3;LL1927-4;RAST;LA6111-4;1;0;;; +15849-3;LL1927-4;RAST;LA6112-2;2;1;;; +15849-3;LL1927-4;RAST;LA6113-0;3;2;;; +15849-3;LL1927-4;RAST;LA6114-8;4;3;;; +15849-3;LL1927-4;RAST;LA6115-5;5;4;;; +15849-3;LL1927-4;RAST;LA10137-0;6;5;;; +15849-3;LL1927-4;RAST;LA10138-8;7;6;;; +15850-1;LL1927-4;RAST;LA6111-4;1;0;;; +15850-1;LL1927-4;RAST;LA6112-2;2;1;;; +15850-1;LL1927-4;RAST;LA6113-0;3;2;;; +15850-1;LL1927-4;RAST;LA6114-8;4;3;;; +15850-1;LL1927-4;RAST;LA6115-5;5;4;;; +15850-1;LL1927-4;RAST;LA10137-0;6;5;;; +15850-1;LL1927-4;RAST;LA10138-8;7;6;;; +15851-9;LL1927-4;RAST;LA6111-4;1;0;;; +15851-9;LL1927-4;RAST;LA6112-2;2;1;;; +15851-9;LL1927-4;RAST;LA6113-0;3;2;;; +15851-9;LL1927-4;RAST;LA6114-8;4;3;;; +15851-9;LL1927-4;RAST;LA6115-5;5;4;;; +15851-9;LL1927-4;RAST;LA10137-0;6;5;;; +15851-9;LL1927-4;RAST;LA10138-8;7;6;;; +15852-7;LL1927-4;RAST;LA6111-4;1;0;;; +15852-7;LL1927-4;RAST;LA6112-2;2;1;;; +15852-7;LL1927-4;RAST;LA6113-0;3;2;;; +15852-7;LL1927-4;RAST;LA6114-8;4;3;;; +15852-7;LL1927-4;RAST;LA6115-5;5;4;;; +15852-7;LL1927-4;RAST;LA10137-0;6;5;;; +15852-7;LL1927-4;RAST;LA10138-8;7;6;;; +15853-5;LL1927-4;RAST;LA6111-4;1;0;;; +15853-5;LL1927-4;RAST;LA6112-2;2;1;;; +15853-5;LL1927-4;RAST;LA6113-0;3;2;;; +15853-5;LL1927-4;RAST;LA6114-8;4;3;;; +15853-5;LL1927-4;RAST;LA6115-5;5;4;;; +15853-5;LL1927-4;RAST;LA10137-0;6;5;;; +15853-5;LL1927-4;RAST;LA10138-8;7;6;;; +15854-3;LL1927-4;RAST;LA6111-4;1;0;;; +15854-3;LL1927-4;RAST;LA6112-2;2;1;;; +15854-3;LL1927-4;RAST;LA6113-0;3;2;;; +15854-3;LL1927-4;RAST;LA6114-8;4;3;;; +15854-3;LL1927-4;RAST;LA6115-5;5;4;;; +15854-3;LL1927-4;RAST;LA10137-0;6;5;;; +15854-3;LL1927-4;RAST;LA10138-8;7;6;;; +15855-0;LL1927-4;RAST;LA6111-4;1;0;;; +15855-0;LL1927-4;RAST;LA6112-2;2;1;;; +15855-0;LL1927-4;RAST;LA6113-0;3;2;;; +15855-0;LL1927-4;RAST;LA6114-8;4;3;;; +15855-0;LL1927-4;RAST;LA6115-5;5;4;;; +15855-0;LL1927-4;RAST;LA10137-0;6;5;;; +15855-0;LL1927-4;RAST;LA10138-8;7;6;;; +15856-8;LL1927-4;RAST;LA6111-4;1;0;;; +15856-8;LL1927-4;RAST;LA6112-2;2;1;;; +15856-8;LL1927-4;RAST;LA6113-0;3;2;;; +15856-8;LL1927-4;RAST;LA6114-8;4;3;;; +15856-8;LL1927-4;RAST;LA6115-5;5;4;;; +15856-8;LL1927-4;RAST;LA10137-0;6;5;;; +15856-8;LL1927-4;RAST;LA10138-8;7;6;;; +15857-6;LL1927-4;RAST;LA6111-4;1;0;;; +15857-6;LL1927-4;RAST;LA6112-2;2;1;;; +15857-6;LL1927-4;RAST;LA6113-0;3;2;;; +15857-6;LL1927-4;RAST;LA6114-8;4;3;;; +15857-6;LL1927-4;RAST;LA6115-5;5;4;;; +15857-6;LL1927-4;RAST;LA10137-0;6;5;;; +15857-6;LL1927-4;RAST;LA10138-8;7;6;;; +15858-4;LL1927-4;RAST;LA6111-4;1;0;;; +15858-4;LL1927-4;RAST;LA6112-2;2;1;;; +15858-4;LL1927-4;RAST;LA6113-0;3;2;;; +15858-4;LL1927-4;RAST;LA6114-8;4;3;;; +15858-4;LL1927-4;RAST;LA6115-5;5;4;;; +15858-4;LL1927-4;RAST;LA10137-0;6;5;;; +15858-4;LL1927-4;RAST;LA10138-8;7;6;;; +15859-2;LL1927-4;RAST;LA6111-4;1;0;;; +15859-2;LL1927-4;RAST;LA6112-2;2;1;;; +15859-2;LL1927-4;RAST;LA6113-0;3;2;;; +15859-2;LL1927-4;RAST;LA6114-8;4;3;;; +15859-2;LL1927-4;RAST;LA6115-5;5;4;;; +15859-2;LL1927-4;RAST;LA10137-0;6;5;;; +15859-2;LL1927-4;RAST;LA10138-8;7;6;;; +15860-0;LL1927-4;RAST;LA6111-4;1;0;;; +15860-0;LL1927-4;RAST;LA6112-2;2;1;;; +15860-0;LL1927-4;RAST;LA6113-0;3;2;;; +15860-0;LL1927-4;RAST;LA6114-8;4;3;;; +15860-0;LL1927-4;RAST;LA6115-5;5;4;;; +15860-0;LL1927-4;RAST;LA10137-0;6;5;;; +15860-0;LL1927-4;RAST;LA10138-8;7;6;;; +15861-8;LL1927-4;RAST;LA6111-4;1;0;;; +15861-8;LL1927-4;RAST;LA6112-2;2;1;;; +15861-8;LL1927-4;RAST;LA6113-0;3;2;;; +15861-8;LL1927-4;RAST;LA6114-8;4;3;;; +15861-8;LL1927-4;RAST;LA6115-5;5;4;;; +15861-8;LL1927-4;RAST;LA10137-0;6;5;;; +15861-8;LL1927-4;RAST;LA10138-8;7;6;;; +15862-6;LL1927-4;RAST;LA6111-4;1;0;;; +15862-6;LL1927-4;RAST;LA6112-2;2;1;;; +15862-6;LL1927-4;RAST;LA6113-0;3;2;;; +15862-6;LL1927-4;RAST;LA6114-8;4;3;;; +15862-6;LL1927-4;RAST;LA6115-5;5;4;;; +15862-6;LL1927-4;RAST;LA10137-0;6;5;;; +15862-6;LL1927-4;RAST;LA10138-8;7;6;;; +15863-4;LL1927-4;RAST;LA6111-4;1;0;;; +15863-4;LL1927-4;RAST;LA6112-2;2;1;;; +15863-4;LL1927-4;RAST;LA6113-0;3;2;;; +15863-4;LL1927-4;RAST;LA6114-8;4;3;;; +15863-4;LL1927-4;RAST;LA6115-5;5;4;;; +15863-4;LL1927-4;RAST;LA10137-0;6;5;;; +15863-4;LL1927-4;RAST;LA10138-8;7;6;;; +15864-2;LL1927-4;RAST;LA6111-4;1;0;;; +15864-2;LL1927-4;RAST;LA6112-2;2;1;;; +15864-2;LL1927-4;RAST;LA6113-0;3;2;;; +15864-2;LL1927-4;RAST;LA6114-8;4;3;;; +15864-2;LL1927-4;RAST;LA6115-5;5;4;;; +15864-2;LL1927-4;RAST;LA10137-0;6;5;;; +15864-2;LL1927-4;RAST;LA10138-8;7;6;;; +15866-7;LL1927-4;RAST;LA6111-4;1;0;;; +15866-7;LL1927-4;RAST;LA6112-2;2;1;;; +15866-7;LL1927-4;RAST;LA6113-0;3;2;;; +15866-7;LL1927-4;RAST;LA6114-8;4;3;;; +15866-7;LL1927-4;RAST;LA6115-5;5;4;;; +15866-7;LL1927-4;RAST;LA10137-0;6;5;;; +15866-7;LL1927-4;RAST;LA10138-8;7;6;;; +15869-1;LL1927-4;RAST;LA6111-4;1;0;;; +15869-1;LL1927-4;RAST;LA6112-2;2;1;;; +15869-1;LL1927-4;RAST;LA6113-0;3;2;;; +15869-1;LL1927-4;RAST;LA6114-8;4;3;;; +15869-1;LL1927-4;RAST;LA6115-5;5;4;;; +15869-1;LL1927-4;RAST;LA10137-0;6;5;;; +15869-1;LL1927-4;RAST;LA10138-8;7;6;;; +15870-9;LL1927-4;RAST;LA6111-4;1;0;;; +15870-9;LL1927-4;RAST;LA6112-2;2;1;;; +15870-9;LL1927-4;RAST;LA6113-0;3;2;;; +15870-9;LL1927-4;RAST;LA6114-8;4;3;;; +15870-9;LL1927-4;RAST;LA6115-5;5;4;;; +15870-9;LL1927-4;RAST;LA10137-0;6;5;;; +15870-9;LL1927-4;RAST;LA10138-8;7;6;;; +15871-7;LL1927-4;RAST;LA6111-4;1;0;;; +15871-7;LL1927-4;RAST;LA6112-2;2;1;;; +15871-7;LL1927-4;RAST;LA6113-0;3;2;;; +15871-7;LL1927-4;RAST;LA6114-8;4;3;;; +15871-7;LL1927-4;RAST;LA6115-5;5;4;;; +15871-7;LL1927-4;RAST;LA10137-0;6;5;;; +15871-7;LL1927-4;RAST;LA10138-8;7;6;;; +15872-5;LL1927-4;RAST;LA6111-4;1;0;;; +15872-5;LL1927-4;RAST;LA6112-2;2;1;;; +15872-5;LL1927-4;RAST;LA6113-0;3;2;;; +15872-5;LL1927-4;RAST;LA6114-8;4;3;;; +15872-5;LL1927-4;RAST;LA6115-5;5;4;;; +15872-5;LL1927-4;RAST;LA10137-0;6;5;;; +15872-5;LL1927-4;RAST;LA10138-8;7;6;;; +15873-3;LL1927-4;RAST;LA6111-4;1;0;;; +15873-3;LL1927-4;RAST;LA6112-2;2;1;;; +15873-3;LL1927-4;RAST;LA6113-0;3;2;;; +15873-3;LL1927-4;RAST;LA6114-8;4;3;;; +15873-3;LL1927-4;RAST;LA6115-5;5;4;;; +15873-3;LL1927-4;RAST;LA10137-0;6;5;;; +15873-3;LL1927-4;RAST;LA10138-8;7;6;;; +15874-1;LL1927-4;RAST;LA6111-4;1;0;;; +15874-1;LL1927-4;RAST;LA6112-2;2;1;;; +15874-1;LL1927-4;RAST;LA6113-0;3;2;;; +15874-1;LL1927-4;RAST;LA6114-8;4;3;;; +15874-1;LL1927-4;RAST;LA6115-5;5;4;;; +15874-1;LL1927-4;RAST;LA10137-0;6;5;;; +15874-1;LL1927-4;RAST;LA10138-8;7;6;;; +15875-8;LL1927-4;RAST;LA6111-4;1;0;;; +15875-8;LL1927-4;RAST;LA6112-2;2;1;;; +15875-8;LL1927-4;RAST;LA6113-0;3;2;;; +15875-8;LL1927-4;RAST;LA6114-8;4;3;;; +15875-8;LL1927-4;RAST;LA6115-5;5;4;;; +15875-8;LL1927-4;RAST;LA10137-0;6;5;;; +15875-8;LL1927-4;RAST;LA10138-8;7;6;;; +15876-6;LL1927-4;RAST;LA6111-4;1;0;;; +15876-6;LL1927-4;RAST;LA6112-2;2;1;;; +15876-6;LL1927-4;RAST;LA6113-0;3;2;;; +15876-6;LL1927-4;RAST;LA6114-8;4;3;;; +15876-6;LL1927-4;RAST;LA6115-5;5;4;;; +15876-6;LL1927-4;RAST;LA10137-0;6;5;;; +15876-6;LL1927-4;RAST;LA10138-8;7;6;;; +15877-4;LL1927-4;RAST;LA6111-4;1;0;;; +15877-4;LL1927-4;RAST;LA6112-2;2;1;;; +15877-4;LL1927-4;RAST;LA6113-0;3;2;;; +15877-4;LL1927-4;RAST;LA6114-8;4;3;;; +15877-4;LL1927-4;RAST;LA6115-5;5;4;;; +15877-4;LL1927-4;RAST;LA10137-0;6;5;;; +15877-4;LL1927-4;RAST;LA10138-8;7;6;;; +15878-2;LL1927-4;RAST;LA6111-4;1;0;;; +15878-2;LL1927-4;RAST;LA6112-2;2;1;;; +15878-2;LL1927-4;RAST;LA6113-0;3;2;;; +15878-2;LL1927-4;RAST;LA6114-8;4;3;;; +15878-2;LL1927-4;RAST;LA6115-5;5;4;;; +15878-2;LL1927-4;RAST;LA10137-0;6;5;;; +15878-2;LL1927-4;RAST;LA10138-8;7;6;;; +15879-0;LL1927-4;RAST;LA6111-4;1;0;;; +15879-0;LL1927-4;RAST;LA6112-2;2;1;;; +15879-0;LL1927-4;RAST;LA6113-0;3;2;;; +15879-0;LL1927-4;RAST;LA6114-8;4;3;;; +15879-0;LL1927-4;RAST;LA6115-5;5;4;;; +15879-0;LL1927-4;RAST;LA10137-0;6;5;;; +15879-0;LL1927-4;RAST;LA10138-8;7;6;;; +15880-8;LL1927-4;RAST;LA6111-4;1;0;;; +15880-8;LL1927-4;RAST;LA6112-2;2;1;;; +15880-8;LL1927-4;RAST;LA6113-0;3;2;;; +15880-8;LL1927-4;RAST;LA6114-8;4;3;;; +15880-8;LL1927-4;RAST;LA6115-5;5;4;;; +15880-8;LL1927-4;RAST;LA10137-0;6;5;;; +15880-8;LL1927-4;RAST;LA10138-8;7;6;;; +15881-6;LL1927-4;RAST;LA6111-4;1;0;;; +15881-6;LL1927-4;RAST;LA6112-2;2;1;;; +15881-6;LL1927-4;RAST;LA6113-0;3;2;;; +15881-6;LL1927-4;RAST;LA6114-8;4;3;;; +15881-6;LL1927-4;RAST;LA6115-5;5;4;;; +15881-6;LL1927-4;RAST;LA10137-0;6;5;;; +15881-6;LL1927-4;RAST;LA10138-8;7;6;;; +15882-4;LL1927-4;RAST;LA6111-4;1;0;;; +15882-4;LL1927-4;RAST;LA6112-2;2;1;;; +15882-4;LL1927-4;RAST;LA6113-0;3;2;;; +15882-4;LL1927-4;RAST;LA6114-8;4;3;;; +15882-4;LL1927-4;RAST;LA6115-5;5;4;;; +15882-4;LL1927-4;RAST;LA10137-0;6;5;;; +15882-4;LL1927-4;RAST;LA10138-8;7;6;;; +15885-7;LL1927-4;RAST;LA6111-4;1;0;;; +15885-7;LL1927-4;RAST;LA6112-2;2;1;;; +15885-7;LL1927-4;RAST;LA6113-0;3;2;;; +15885-7;LL1927-4;RAST;LA6114-8;4;3;;; +15885-7;LL1927-4;RAST;LA6115-5;5;4;;; +15885-7;LL1927-4;RAST;LA10137-0;6;5;;; +15885-7;LL1927-4;RAST;LA10138-8;7;6;;; +15886-5;LL1927-4;RAST;LA6111-4;1;0;;; +15886-5;LL1927-4;RAST;LA6112-2;2;1;;; +15886-5;LL1927-4;RAST;LA6113-0;3;2;;; +15886-5;LL1927-4;RAST;LA6114-8;4;3;;; +15886-5;LL1927-4;RAST;LA6115-5;5;4;;; +15886-5;LL1927-4;RAST;LA10137-0;6;5;;; +15886-5;LL1927-4;RAST;LA10138-8;7;6;;; +15888-1;LL1927-4;RAST;LA6111-4;1;0;;; +15888-1;LL1927-4;RAST;LA6112-2;2;1;;; +15888-1;LL1927-4;RAST;LA6113-0;3;2;;; +15888-1;LL1927-4;RAST;LA6114-8;4;3;;; +15888-1;LL1927-4;RAST;LA6115-5;5;4;;; +15888-1;LL1927-4;RAST;LA10137-0;6;5;;; +15888-1;LL1927-4;RAST;LA10138-8;7;6;;; +15889-9;LL1927-4;RAST;LA6111-4;1;0;;; +15889-9;LL1927-4;RAST;LA6112-2;2;1;;; +15889-9;LL1927-4;RAST;LA6113-0;3;2;;; +15889-9;LL1927-4;RAST;LA6114-8;4;3;;; +15889-9;LL1927-4;RAST;LA6115-5;5;4;;; +15889-9;LL1927-4;RAST;LA10137-0;6;5;;; +15889-9;LL1927-4;RAST;LA10138-8;7;6;;; +15890-7;LL1927-4;RAST;LA6111-4;1;0;;; +15890-7;LL1927-4;RAST;LA6112-2;2;1;;; +15890-7;LL1927-4;RAST;LA6113-0;3;2;;; +15890-7;LL1927-4;RAST;LA6114-8;4;3;;; +15890-7;LL1927-4;RAST;LA6115-5;5;4;;; +15890-7;LL1927-4;RAST;LA10137-0;6;5;;; +15890-7;LL1927-4;RAST;LA10138-8;7;6;;; +15891-5;LL1927-4;RAST;LA6111-4;1;0;;; +15891-5;LL1927-4;RAST;LA6112-2;2;1;;; +15891-5;LL1927-4;RAST;LA6113-0;3;2;;; +15891-5;LL1927-4;RAST;LA6114-8;4;3;;; +15891-5;LL1927-4;RAST;LA6115-5;5;4;;; +15891-5;LL1927-4;RAST;LA10137-0;6;5;;; +15891-5;LL1927-4;RAST;LA10138-8;7;6;;; +15892-3;LL1927-4;RAST;LA6111-4;1;0;;; +15892-3;LL1927-4;RAST;LA6112-2;2;1;;; +15892-3;LL1927-4;RAST;LA6113-0;3;2;;; +15892-3;LL1927-4;RAST;LA6114-8;4;3;;; +15892-3;LL1927-4;RAST;LA6115-5;5;4;;; +15892-3;LL1927-4;RAST;LA10137-0;6;5;;; +15892-3;LL1927-4;RAST;LA10138-8;7;6;;; +15893-1;LL1927-4;RAST;LA6111-4;1;0;;; +15893-1;LL1927-4;RAST;LA6112-2;2;1;;; +15893-1;LL1927-4;RAST;LA6113-0;3;2;;; +15893-1;LL1927-4;RAST;LA6114-8;4;3;;; +15893-1;LL1927-4;RAST;LA6115-5;5;4;;; +15893-1;LL1927-4;RAST;LA10137-0;6;5;;; +15893-1;LL1927-4;RAST;LA10138-8;7;6;;; +15894-9;LL1927-4;RAST;LA6111-4;1;0;;; +15894-9;LL1927-4;RAST;LA6112-2;2;1;;; +15894-9;LL1927-4;RAST;LA6113-0;3;2;;; +15894-9;LL1927-4;RAST;LA6114-8;4;3;;; +15894-9;LL1927-4;RAST;LA6115-5;5;4;;; +15894-9;LL1927-4;RAST;LA10137-0;6;5;;; +15894-9;LL1927-4;RAST;LA10138-8;7;6;;; +15895-6;LL1927-4;RAST;LA6111-4;1;0;;; +15895-6;LL1927-4;RAST;LA6112-2;2;1;;; +15895-6;LL1927-4;RAST;LA6113-0;3;2;;; +15895-6;LL1927-4;RAST;LA6114-8;4;3;;; +15895-6;LL1927-4;RAST;LA6115-5;5;4;;; +15895-6;LL1927-4;RAST;LA10137-0;6;5;;; +15895-6;LL1927-4;RAST;LA10138-8;7;6;;; +15896-4;LL1927-4;RAST;LA6111-4;1;0;;; +15896-4;LL1927-4;RAST;LA6112-2;2;1;;; +15896-4;LL1927-4;RAST;LA6113-0;3;2;;; +15896-4;LL1927-4;RAST;LA6114-8;4;3;;; +15896-4;LL1927-4;RAST;LA6115-5;5;4;;; +15896-4;LL1927-4;RAST;LA10137-0;6;5;;; +15896-4;LL1927-4;RAST;LA10138-8;7;6;;; +15897-2;LL1927-4;RAST;LA6111-4;1;0;;; +15897-2;LL1927-4;RAST;LA6112-2;2;1;;; +15897-2;LL1927-4;RAST;LA6113-0;3;2;;; +15897-2;LL1927-4;RAST;LA6114-8;4;3;;; +15897-2;LL1927-4;RAST;LA6115-5;5;4;;; +15897-2;LL1927-4;RAST;LA10137-0;6;5;;; +15897-2;LL1927-4;RAST;LA10138-8;7;6;;; +15898-0;LL1927-4;RAST;LA6111-4;1;0;;; +15898-0;LL1927-4;RAST;LA6112-2;2;1;;; +15898-0;LL1927-4;RAST;LA6113-0;3;2;;; +15898-0;LL1927-4;RAST;LA6114-8;4;3;;; +15898-0;LL1927-4;RAST;LA6115-5;5;4;;; +15898-0;LL1927-4;RAST;LA10137-0;6;5;;; +15898-0;LL1927-4;RAST;LA10138-8;7;6;;; +15899-8;LL1927-4;RAST;LA6111-4;1;0;;; +15899-8;LL1927-4;RAST;LA6112-2;2;1;;; +15899-8;LL1927-4;RAST;LA6113-0;3;2;;; +15899-8;LL1927-4;RAST;LA6114-8;4;3;;; +15899-8;LL1927-4;RAST;LA6115-5;5;4;;; +15899-8;LL1927-4;RAST;LA10137-0;6;5;;; +15899-8;LL1927-4;RAST;LA10138-8;7;6;;; +15900-4;LL1927-4;RAST;LA6111-4;1;0;;; +15900-4;LL1927-4;RAST;LA6112-2;2;1;;; +15900-4;LL1927-4;RAST;LA6113-0;3;2;;; +15900-4;LL1927-4;RAST;LA6114-8;4;3;;; +15900-4;LL1927-4;RAST;LA6115-5;5;4;;; +15900-4;LL1927-4;RAST;LA10137-0;6;5;;; +15900-4;LL1927-4;RAST;LA10138-8;7;6;;; +15901-2;LL1927-4;RAST;LA6111-4;1;0;;; +15901-2;LL1927-4;RAST;LA6112-2;2;1;;; +15901-2;LL1927-4;RAST;LA6113-0;3;2;;; +15901-2;LL1927-4;RAST;LA6114-8;4;3;;; +15901-2;LL1927-4;RAST;LA6115-5;5;4;;; +15901-2;LL1927-4;RAST;LA10137-0;6;5;;; +15901-2;LL1927-4;RAST;LA10138-8;7;6;;; +15902-0;LL1927-4;RAST;LA6111-4;1;0;;; +15902-0;LL1927-4;RAST;LA6112-2;2;1;;; +15902-0;LL1927-4;RAST;LA6113-0;3;2;;; +15902-0;LL1927-4;RAST;LA6114-8;4;3;;; +15902-0;LL1927-4;RAST;LA6115-5;5;4;;; +15902-0;LL1927-4;RAST;LA10137-0;6;5;;; +15902-0;LL1927-4;RAST;LA10138-8;7;6;;; +15903-8;LL1927-4;RAST;LA6111-4;1;0;;; +15903-8;LL1927-4;RAST;LA6112-2;2;1;;; +15903-8;LL1927-4;RAST;LA6113-0;3;2;;; +15903-8;LL1927-4;RAST;LA6114-8;4;3;;; +15903-8;LL1927-4;RAST;LA6115-5;5;4;;; +15903-8;LL1927-4;RAST;LA10137-0;6;5;;; +15903-8;LL1927-4;RAST;LA10138-8;7;6;;; +15904-6;LL1927-4;RAST;LA6111-4;1;0;;; +15904-6;LL1927-4;RAST;LA6112-2;2;1;;; +15904-6;LL1927-4;RAST;LA6113-0;3;2;;; +15904-6;LL1927-4;RAST;LA6114-8;4;3;;; +15904-6;LL1927-4;RAST;LA6115-5;5;4;;; +15904-6;LL1927-4;RAST;LA10137-0;6;5;;; +15904-6;LL1927-4;RAST;LA10138-8;7;6;;; +15906-1;LL1927-4;RAST;LA6111-4;1;0;;; +15906-1;LL1927-4;RAST;LA6112-2;2;1;;; +15906-1;LL1927-4;RAST;LA6113-0;3;2;;; +15906-1;LL1927-4;RAST;LA6114-8;4;3;;; +15906-1;LL1927-4;RAST;LA6115-5;5;4;;; +15906-1;LL1927-4;RAST;LA10137-0;6;5;;; +15906-1;LL1927-4;RAST;LA10138-8;7;6;;; +15907-9;LL1927-4;RAST;LA6111-4;1;0;;; +15907-9;LL1927-4;RAST;LA6112-2;2;1;;; +15907-9;LL1927-4;RAST;LA6113-0;3;2;;; +15907-9;LL1927-4;RAST;LA6114-8;4;3;;; +15907-9;LL1927-4;RAST;LA6115-5;5;4;;; +15907-9;LL1927-4;RAST;LA10137-0;6;5;;; +15907-9;LL1927-4;RAST;LA10138-8;7;6;;; +15908-7;LL1927-4;RAST;LA6111-4;1;0;;; +15908-7;LL1927-4;RAST;LA6112-2;2;1;;; +15908-7;LL1927-4;RAST;LA6113-0;3;2;;; +15908-7;LL1927-4;RAST;LA6114-8;4;3;;; +15908-7;LL1927-4;RAST;LA6115-5;5;4;;; +15908-7;LL1927-4;RAST;LA10137-0;6;5;;; +15908-7;LL1927-4;RAST;LA10138-8;7;6;;; +15909-5;LL1927-4;RAST;LA6111-4;1;0;;; +15909-5;LL1927-4;RAST;LA6112-2;2;1;;; +15909-5;LL1927-4;RAST;LA6113-0;3;2;;; +15909-5;LL1927-4;RAST;LA6114-8;4;3;;; +15909-5;LL1927-4;RAST;LA6115-5;5;4;;; +15909-5;LL1927-4;RAST;LA10137-0;6;5;;; +15909-5;LL1927-4;RAST;LA10138-8;7;6;;; +15910-3;LL1927-4;RAST;LA6111-4;1;0;;; +15910-3;LL1927-4;RAST;LA6112-2;2;1;;; +15910-3;LL1927-4;RAST;LA6113-0;3;2;;; +15910-3;LL1927-4;RAST;LA6114-8;4;3;;; +15910-3;LL1927-4;RAST;LA6115-5;5;4;;; +15910-3;LL1927-4;RAST;LA10137-0;6;5;;; +15910-3;LL1927-4;RAST;LA10138-8;7;6;;; +15911-1;LL1927-4;RAST;LA6111-4;1;0;;; +15911-1;LL1927-4;RAST;LA6112-2;2;1;;; +15911-1;LL1927-4;RAST;LA6113-0;3;2;;; +15911-1;LL1927-4;RAST;LA6114-8;4;3;;; +15911-1;LL1927-4;RAST;LA6115-5;5;4;;; +15911-1;LL1927-4;RAST;LA10137-0;6;5;;; +15911-1;LL1927-4;RAST;LA10138-8;7;6;;; +15912-9;LL1927-4;RAST;LA6111-4;1;0;;; +15912-9;LL1927-4;RAST;LA6112-2;2;1;;; +15912-9;LL1927-4;RAST;LA6113-0;3;2;;; +15912-9;LL1927-4;RAST;LA6114-8;4;3;;; +15912-9;LL1927-4;RAST;LA6115-5;5;4;;; +15912-9;LL1927-4;RAST;LA10137-0;6;5;;; +15912-9;LL1927-4;RAST;LA10138-8;7;6;;; +15913-7;LL1927-4;RAST;LA6111-4;1;0;;; +15913-7;LL1927-4;RAST;LA6112-2;2;1;;; +15913-7;LL1927-4;RAST;LA6113-0;3;2;;; +15913-7;LL1927-4;RAST;LA6114-8;4;3;;; +15913-7;LL1927-4;RAST;LA6115-5;5;4;;; +15913-7;LL1927-4;RAST;LA10137-0;6;5;;; +15913-7;LL1927-4;RAST;LA10138-8;7;6;;; +15914-5;LL1927-4;RAST;LA6111-4;1;0;;; +15914-5;LL1927-4;RAST;LA6112-2;2;1;;; +15914-5;LL1927-4;RAST;LA6113-0;3;2;;; +15914-5;LL1927-4;RAST;LA6114-8;4;3;;; +15914-5;LL1927-4;RAST;LA6115-5;5;4;;; +15914-5;LL1927-4;RAST;LA10137-0;6;5;;; +15914-5;LL1927-4;RAST;LA10138-8;7;6;;; +15915-2;LL1927-4;RAST;LA6111-4;1;0;;; +15915-2;LL1927-4;RAST;LA6112-2;2;1;;; +15915-2;LL1927-4;RAST;LA6113-0;3;2;;; +15915-2;LL1927-4;RAST;LA6114-8;4;3;;; +15915-2;LL1927-4;RAST;LA6115-5;5;4;;; +15915-2;LL1927-4;RAST;LA10137-0;6;5;;; +15915-2;LL1927-4;RAST;LA10138-8;7;6;;; +15916-0;LL1927-4;RAST;LA6111-4;1;0;;; +15916-0;LL1927-4;RAST;LA6112-2;2;1;;; +15916-0;LL1927-4;RAST;LA6113-0;3;2;;; +15916-0;LL1927-4;RAST;LA6114-8;4;3;;; +15916-0;LL1927-4;RAST;LA6115-5;5;4;;; +15916-0;LL1927-4;RAST;LA10137-0;6;5;;; +15916-0;LL1927-4;RAST;LA10138-8;7;6;;; +15917-8;LL1927-4;RAST;LA6111-4;1;0;;; +15917-8;LL1927-4;RAST;LA6112-2;2;1;;; +15917-8;LL1927-4;RAST;LA6113-0;3;2;;; +15917-8;LL1927-4;RAST;LA6114-8;4;3;;; +15917-8;LL1927-4;RAST;LA6115-5;5;4;;; +15917-8;LL1927-4;RAST;LA10137-0;6;5;;; +15917-8;LL1927-4;RAST;LA10138-8;7;6;;; +15918-6;LL1927-4;RAST;LA6111-4;1;0;;; +15918-6;LL1927-4;RAST;LA6112-2;2;1;;; +15918-6;LL1927-4;RAST;LA6113-0;3;2;;; +15918-6;LL1927-4;RAST;LA6114-8;4;3;;; +15918-6;LL1927-4;RAST;LA6115-5;5;4;;; +15918-6;LL1927-4;RAST;LA10137-0;6;5;;; +15918-6;LL1927-4;RAST;LA10138-8;7;6;;; +15921-0;LL1927-4;RAST;LA6111-4;1;0;;; +15921-0;LL1927-4;RAST;LA6112-2;2;1;;; +15921-0;LL1927-4;RAST;LA6113-0;3;2;;; +15921-0;LL1927-4;RAST;LA6114-8;4;3;;; +15921-0;LL1927-4;RAST;LA6115-5;5;4;;; +15921-0;LL1927-4;RAST;LA10137-0;6;5;;; +15921-0;LL1927-4;RAST;LA10138-8;7;6;;; +15922-8;LL1927-4;RAST;LA6111-4;1;0;;; +15922-8;LL1927-4;RAST;LA6112-2;2;1;;; +15922-8;LL1927-4;RAST;LA6113-0;3;2;;; +15922-8;LL1927-4;RAST;LA6114-8;4;3;;; +15922-8;LL1927-4;RAST;LA6115-5;5;4;;; +15922-8;LL1927-4;RAST;LA10137-0;6;5;;; +15922-8;LL1927-4;RAST;LA10138-8;7;6;;; +15923-6;LL1927-4;RAST;LA6111-4;1;0;;; +15923-6;LL1927-4;RAST;LA6112-2;2;1;;; +15923-6;LL1927-4;RAST;LA6113-0;3;2;;; +15923-6;LL1927-4;RAST;LA6114-8;4;3;;; +15923-6;LL1927-4;RAST;LA6115-5;5;4;;; +15923-6;LL1927-4;RAST;LA10137-0;6;5;;; +15923-6;LL1927-4;RAST;LA10138-8;7;6;;; +15924-4;LL1927-4;RAST;LA6111-4;1;0;;; +15924-4;LL1927-4;RAST;LA6112-2;2;1;;; +15924-4;LL1927-4;RAST;LA6113-0;3;2;;; +15924-4;LL1927-4;RAST;LA6114-8;4;3;;; +15924-4;LL1927-4;RAST;LA6115-5;5;4;;; +15924-4;LL1927-4;RAST;LA10137-0;6;5;;; +15924-4;LL1927-4;RAST;LA10138-8;7;6;;; +15925-1;LL1927-4;RAST;LA6111-4;1;0;;; +15925-1;LL1927-4;RAST;LA6112-2;2;1;;; +15925-1;LL1927-4;RAST;LA6113-0;3;2;;; +15925-1;LL1927-4;RAST;LA6114-8;4;3;;; +15925-1;LL1927-4;RAST;LA6115-5;5;4;;; +15925-1;LL1927-4;RAST;LA10137-0;6;5;;; +15925-1;LL1927-4;RAST;LA10138-8;7;6;;; +15926-9;LL1927-4;RAST;LA6111-4;1;0;;; +15926-9;LL1927-4;RAST;LA6112-2;2;1;;; +15926-9;LL1927-4;RAST;LA6113-0;3;2;;; +15926-9;LL1927-4;RAST;LA6114-8;4;3;;; +15926-9;LL1927-4;RAST;LA6115-5;5;4;;; +15926-9;LL1927-4;RAST;LA10137-0;6;5;;; +15926-9;LL1927-4;RAST;LA10138-8;7;6;;; +15927-7;LL1927-4;RAST;LA6111-4;1;0;;; +15927-7;LL1927-4;RAST;LA6112-2;2;1;;; +15927-7;LL1927-4;RAST;LA6113-0;3;2;;; +15927-7;LL1927-4;RAST;LA6114-8;4;3;;; +15927-7;LL1927-4;RAST;LA6115-5;5;4;;; +15927-7;LL1927-4;RAST;LA10137-0;6;5;;; +15927-7;LL1927-4;RAST;LA10138-8;7;6;;; +15928-5;LL1927-4;RAST;LA6111-4;1;0;;; +15928-5;LL1927-4;RAST;LA6112-2;2;1;;; +15928-5;LL1927-4;RAST;LA6113-0;3;2;;; +15928-5;LL1927-4;RAST;LA6114-8;4;3;;; +15928-5;LL1927-4;RAST;LA6115-5;5;4;;; +15928-5;LL1927-4;RAST;LA10137-0;6;5;;; +15928-5;LL1927-4;RAST;LA10138-8;7;6;;; +15929-3;LL1927-4;RAST;LA6111-4;1;0;;; +15929-3;LL1927-4;RAST;LA6112-2;2;1;;; +15929-3;LL1927-4;RAST;LA6113-0;3;2;;; +15929-3;LL1927-4;RAST;LA6114-8;4;3;;; +15929-3;LL1927-4;RAST;LA6115-5;5;4;;; +15929-3;LL1927-4;RAST;LA10137-0;6;5;;; +15929-3;LL1927-4;RAST;LA10138-8;7;6;;; +15930-1;LL1927-4;RAST;LA6111-4;1;0;;; +15930-1;LL1927-4;RAST;LA6112-2;2;1;;; +15930-1;LL1927-4;RAST;LA6113-0;3;2;;; +15930-1;LL1927-4;RAST;LA6114-8;4;3;;; +15930-1;LL1927-4;RAST;LA6115-5;5;4;;; +15930-1;LL1927-4;RAST;LA10137-0;6;5;;; +15930-1;LL1927-4;RAST;LA10138-8;7;6;;; +15931-9;LL1927-4;RAST;LA6111-4;1;0;;; +15931-9;LL1927-4;RAST;LA6112-2;2;1;;; +15931-9;LL1927-4;RAST;LA6113-0;3;2;;; +15931-9;LL1927-4;RAST;LA6114-8;4;3;;; +15931-9;LL1927-4;RAST;LA6115-5;5;4;;; +15931-9;LL1927-4;RAST;LA10137-0;6;5;;; +15931-9;LL1927-4;RAST;LA10138-8;7;6;;; +15932-7;LL1927-4;RAST;LA6111-4;1;0;;; +15932-7;LL1927-4;RAST;LA6112-2;2;1;;; +15932-7;LL1927-4;RAST;LA6113-0;3;2;;; +15932-7;LL1927-4;RAST;LA6114-8;4;3;;; +15932-7;LL1927-4;RAST;LA6115-5;5;4;;; +15932-7;LL1927-4;RAST;LA10137-0;6;5;;; +15932-7;LL1927-4;RAST;LA10138-8;7;6;;; +15933-5;LL1927-4;RAST;LA6111-4;1;0;;; +15933-5;LL1927-4;RAST;LA6112-2;2;1;;; +15933-5;LL1927-4;RAST;LA6113-0;3;2;;; +15933-5;LL1927-4;RAST;LA6114-8;4;3;;; +15933-5;LL1927-4;RAST;LA6115-5;5;4;;; +15933-5;LL1927-4;RAST;LA10137-0;6;5;;; +15933-5;LL1927-4;RAST;LA10138-8;7;6;;; +15934-3;LL1927-4;RAST;LA6111-4;1;0;;; +15934-3;LL1927-4;RAST;LA6112-2;2;1;;; +15934-3;LL1927-4;RAST;LA6113-0;3;2;;; +15934-3;LL1927-4;RAST;LA6114-8;4;3;;; +15934-3;LL1927-4;RAST;LA6115-5;5;4;;; +15934-3;LL1927-4;RAST;LA10137-0;6;5;;; +15934-3;LL1927-4;RAST;LA10138-8;7;6;;; +15935-0;LL1927-4;RAST;LA6111-4;1;0;;; +15935-0;LL1927-4;RAST;LA6112-2;2;1;;; +15935-0;LL1927-4;RAST;LA6113-0;3;2;;; +15935-0;LL1927-4;RAST;LA6114-8;4;3;;; +15935-0;LL1927-4;RAST;LA6115-5;5;4;;; +15935-0;LL1927-4;RAST;LA10137-0;6;5;;; +15935-0;LL1927-4;RAST;LA10138-8;7;6;;; +15936-8;LL1927-4;RAST;LA6111-4;1;0;;; +15936-8;LL1927-4;RAST;LA6112-2;2;1;;; +15936-8;LL1927-4;RAST;LA6113-0;3;2;;; +15936-8;LL1927-4;RAST;LA6114-8;4;3;;; +15936-8;LL1927-4;RAST;LA6115-5;5;4;;; +15936-8;LL1927-4;RAST;LA10137-0;6;5;;; +15936-8;LL1927-4;RAST;LA10138-8;7;6;;; +15937-6;LL1927-4;RAST;LA6111-4;1;0;;; +15937-6;LL1927-4;RAST;LA6112-2;2;1;;; +15937-6;LL1927-4;RAST;LA6113-0;3;2;;; +15937-6;LL1927-4;RAST;LA6114-8;4;3;;; +15937-6;LL1927-4;RAST;LA6115-5;5;4;;; +15937-6;LL1927-4;RAST;LA10137-0;6;5;;; +15937-6;LL1927-4;RAST;LA10138-8;7;6;;; +15938-4;LL1927-4;RAST;LA6111-4;1;0;;; +15938-4;LL1927-4;RAST;LA6112-2;2;1;;; +15938-4;LL1927-4;RAST;LA6113-0;3;2;;; +15938-4;LL1927-4;RAST;LA6114-8;4;3;;; +15938-4;LL1927-4;RAST;LA6115-5;5;4;;; +15938-4;LL1927-4;RAST;LA10137-0;6;5;;; +15938-4;LL1927-4;RAST;LA10138-8;7;6;;; +15939-2;LL1927-4;RAST;LA6111-4;1;0;;; +15939-2;LL1927-4;RAST;LA6112-2;2;1;;; +15939-2;LL1927-4;RAST;LA6113-0;3;2;;; +15939-2;LL1927-4;RAST;LA6114-8;4;3;;; +15939-2;LL1927-4;RAST;LA6115-5;5;4;;; +15939-2;LL1927-4;RAST;LA10137-0;6;5;;; +15939-2;LL1927-4;RAST;LA10138-8;7;6;;; +15940-0;LL1927-4;RAST;LA6111-4;1;0;;; +15940-0;LL1927-4;RAST;LA6112-2;2;1;;; +15940-0;LL1927-4;RAST;LA6113-0;3;2;;; +15940-0;LL1927-4;RAST;LA6114-8;4;3;;; +15940-0;LL1927-4;RAST;LA6115-5;5;4;;; +15940-0;LL1927-4;RAST;LA10137-0;6;5;;; +15940-0;LL1927-4;RAST;LA10138-8;7;6;;; +15941-8;LL1927-4;RAST;LA6111-4;1;0;;; +15941-8;LL1927-4;RAST;LA6112-2;2;1;;; +15941-8;LL1927-4;RAST;LA6113-0;3;2;;; +15941-8;LL1927-4;RAST;LA6114-8;4;3;;; +15941-8;LL1927-4;RAST;LA6115-5;5;4;;; +15941-8;LL1927-4;RAST;LA10137-0;6;5;;; +15941-8;LL1927-4;RAST;LA10138-8;7;6;;; +15942-6;LL1927-4;RAST;LA6111-4;1;0;;; +15942-6;LL1927-4;RAST;LA6112-2;2;1;;; +15942-6;LL1927-4;RAST;LA6113-0;3;2;;; +15942-6;LL1927-4;RAST;LA6114-8;4;3;;; +15942-6;LL1927-4;RAST;LA6115-5;5;4;;; +15942-6;LL1927-4;RAST;LA10137-0;6;5;;; +15942-6;LL1927-4;RAST;LA10138-8;7;6;;; +15943-4;LL1927-4;RAST;LA6111-4;1;0;;; +15943-4;LL1927-4;RAST;LA6112-2;2;1;;; +15943-4;LL1927-4;RAST;LA6113-0;3;2;;; +15943-4;LL1927-4;RAST;LA6114-8;4;3;;; +15943-4;LL1927-4;RAST;LA6115-5;5;4;;; +15943-4;LL1927-4;RAST;LA10137-0;6;5;;; +15943-4;LL1927-4;RAST;LA10138-8;7;6;;; +15944-2;LL1927-4;RAST;LA6111-4;1;0;;; +15944-2;LL1927-4;RAST;LA6112-2;2;1;;; +15944-2;LL1927-4;RAST;LA6113-0;3;2;;; +15944-2;LL1927-4;RAST;LA6114-8;4;3;;; +15944-2;LL1927-4;RAST;LA6115-5;5;4;;; +15944-2;LL1927-4;RAST;LA10137-0;6;5;;; +15944-2;LL1927-4;RAST;LA10138-8;7;6;;; +15945-9;LL1927-4;RAST;LA6111-4;1;0;;; +15945-9;LL1927-4;RAST;LA6112-2;2;1;;; +15945-9;LL1927-4;RAST;LA6113-0;3;2;;; +15945-9;LL1927-4;RAST;LA6114-8;4;3;;; +15945-9;LL1927-4;RAST;LA6115-5;5;4;;; +15945-9;LL1927-4;RAST;LA10137-0;6;5;;; +15945-9;LL1927-4;RAST;LA10138-8;7;6;;; +15946-7;LL1927-4;RAST;LA6111-4;1;0;;; +15946-7;LL1927-4;RAST;LA6112-2;2;1;;; +15946-7;LL1927-4;RAST;LA6113-0;3;2;;; +15946-7;LL1927-4;RAST;LA6114-8;4;3;;; +15946-7;LL1927-4;RAST;LA6115-5;5;4;;; +15946-7;LL1927-4;RAST;LA10137-0;6;5;;; +15946-7;LL1927-4;RAST;LA10138-8;7;6;;; +15947-5;LL1927-4;RAST;LA6111-4;1;0;;; +15947-5;LL1927-4;RAST;LA6112-2;2;1;;; +15947-5;LL1927-4;RAST;LA6113-0;3;2;;; +15947-5;LL1927-4;RAST;LA6114-8;4;3;;; +15947-5;LL1927-4;RAST;LA6115-5;5;4;;; +15947-5;LL1927-4;RAST;LA10137-0;6;5;;; +15947-5;LL1927-4;RAST;LA10138-8;7;6;;; +15948-3;LL1927-4;RAST;LA6111-4;1;0;;; +15948-3;LL1927-4;RAST;LA6112-2;2;1;;; +15948-3;LL1927-4;RAST;LA6113-0;3;2;;; +15948-3;LL1927-4;RAST;LA6114-8;4;3;;; +15948-3;LL1927-4;RAST;LA6115-5;5;4;;; +15948-3;LL1927-4;RAST;LA10137-0;6;5;;; +15948-3;LL1927-4;RAST;LA10138-8;7;6;;; +15949-1;LL1927-4;RAST;LA6111-4;1;0;;; +15949-1;LL1927-4;RAST;LA6112-2;2;1;;; +15949-1;LL1927-4;RAST;LA6113-0;3;2;;; +15949-1;LL1927-4;RAST;LA6114-8;4;3;;; +15949-1;LL1927-4;RAST;LA6115-5;5;4;;; +15949-1;LL1927-4;RAST;LA10137-0;6;5;;; +15949-1;LL1927-4;RAST;LA10138-8;7;6;;; +15950-9;LL1927-4;RAST;LA6111-4;1;0;;; +15950-9;LL1927-4;RAST;LA6112-2;2;1;;; +15950-9;LL1927-4;RAST;LA6113-0;3;2;;; +15950-9;LL1927-4;RAST;LA6114-8;4;3;;; +15950-9;LL1927-4;RAST;LA6115-5;5;4;;; +15950-9;LL1927-4;RAST;LA10137-0;6;5;;; +15950-9;LL1927-4;RAST;LA10138-8;7;6;;; +15951-7;LL1927-4;RAST;LA6111-4;1;0;;; +15951-7;LL1927-4;RAST;LA6112-2;2;1;;; +15951-7;LL1927-4;RAST;LA6113-0;3;2;;; +15951-7;LL1927-4;RAST;LA6114-8;4;3;;; +15951-7;LL1927-4;RAST;LA6115-5;5;4;;; +15951-7;LL1927-4;RAST;LA10137-0;6;5;;; +15951-7;LL1927-4;RAST;LA10138-8;7;6;;; +15952-5;LL1927-4;RAST;LA6111-4;1;0;;; +15952-5;LL1927-4;RAST;LA6112-2;2;1;;; +15952-5;LL1927-4;RAST;LA6113-0;3;2;;; +15952-5;LL1927-4;RAST;LA6114-8;4;3;;; +15952-5;LL1927-4;RAST;LA6115-5;5;4;;; +15952-5;LL1927-4;RAST;LA10137-0;6;5;;; +15952-5;LL1927-4;RAST;LA10138-8;7;6;;; +15953-3;LL1927-4;RAST;LA6111-4;1;0;;; +15953-3;LL1927-4;RAST;LA6112-2;2;1;;; +15953-3;LL1927-4;RAST;LA6113-0;3;2;;; +15953-3;LL1927-4;RAST;LA6114-8;4;3;;; +15953-3;LL1927-4;RAST;LA6115-5;5;4;;; +15953-3;LL1927-4;RAST;LA10137-0;6;5;;; +15953-3;LL1927-4;RAST;LA10138-8;7;6;;; +15954-1;LL1927-4;RAST;LA6111-4;1;0;;; +15954-1;LL1927-4;RAST;LA6112-2;2;1;;; +15954-1;LL1927-4;RAST;LA6113-0;3;2;;; +15954-1;LL1927-4;RAST;LA6114-8;4;3;;; +15954-1;LL1927-4;RAST;LA6115-5;5;4;;; +15954-1;LL1927-4;RAST;LA10137-0;6;5;;; +15954-1;LL1927-4;RAST;LA10138-8;7;6;;; +15955-8;LL1927-4;RAST;LA6111-4;1;0;;; +15955-8;LL1927-4;RAST;LA6112-2;2;1;;; +15955-8;LL1927-4;RAST;LA6113-0;3;2;;; +15955-8;LL1927-4;RAST;LA6114-8;4;3;;; +15955-8;LL1927-4;RAST;LA6115-5;5;4;;; +15955-8;LL1927-4;RAST;LA10137-0;6;5;;; +15955-8;LL1927-4;RAST;LA10138-8;7;6;;; +15956-6;LL1927-4;RAST;LA6111-4;1;0;;; +15956-6;LL1927-4;RAST;LA6112-2;2;1;;; +15956-6;LL1927-4;RAST;LA6113-0;3;2;;; +15956-6;LL1927-4;RAST;LA6114-8;4;3;;; +15956-6;LL1927-4;RAST;LA6115-5;5;4;;; +15956-6;LL1927-4;RAST;LA10137-0;6;5;;; +15956-6;LL1927-4;RAST;LA10138-8;7;6;;; +15957-4;LL1927-4;RAST;LA6111-4;1;0;;; +15957-4;LL1927-4;RAST;LA6112-2;2;1;;; +15957-4;LL1927-4;RAST;LA6113-0;3;2;;; +15957-4;LL1927-4;RAST;LA6114-8;4;3;;; +15957-4;LL1927-4;RAST;LA6115-5;5;4;;; +15957-4;LL1927-4;RAST;LA10137-0;6;5;;; +15957-4;LL1927-4;RAST;LA10138-8;7;6;;; +15958-2;LL1927-4;RAST;LA6111-4;1;0;;; +15958-2;LL1927-4;RAST;LA6112-2;2;1;;; +15958-2;LL1927-4;RAST;LA6113-0;3;2;;; +15958-2;LL1927-4;RAST;LA6114-8;4;3;;; +15958-2;LL1927-4;RAST;LA6115-5;5;4;;; +15958-2;LL1927-4;RAST;LA10137-0;6;5;;; +15958-2;LL1927-4;RAST;LA10138-8;7;6;;; +15959-0;LL1927-4;RAST;LA6111-4;1;0;;; +15959-0;LL1927-4;RAST;LA6112-2;2;1;;; +15959-0;LL1927-4;RAST;LA6113-0;3;2;;; +15959-0;LL1927-4;RAST;LA6114-8;4;3;;; +15959-0;LL1927-4;RAST;LA6115-5;5;4;;; +15959-0;LL1927-4;RAST;LA10137-0;6;5;;; +15959-0;LL1927-4;RAST;LA10138-8;7;6;;; +15960-8;LL1927-4;RAST;LA6111-4;1;0;;; +15960-8;LL1927-4;RAST;LA6112-2;2;1;;; +15960-8;LL1927-4;RAST;LA6113-0;3;2;;; +15960-8;LL1927-4;RAST;LA6114-8;4;3;;; +15960-8;LL1927-4;RAST;LA6115-5;5;4;;; +15960-8;LL1927-4;RAST;LA10137-0;6;5;;; +15960-8;LL1927-4;RAST;LA10138-8;7;6;;; +15961-6;LL1927-4;RAST;LA6111-4;1;0;;; +15961-6;LL1927-4;RAST;LA6112-2;2;1;;; +15961-6;LL1927-4;RAST;LA6113-0;3;2;;; +15961-6;LL1927-4;RAST;LA6114-8;4;3;;; +15961-6;LL1927-4;RAST;LA6115-5;5;4;;; +15961-6;LL1927-4;RAST;LA10137-0;6;5;;; +15961-6;LL1927-4;RAST;LA10138-8;7;6;;; +15962-4;LL1927-4;RAST;LA6111-4;1;0;;; +15962-4;LL1927-4;RAST;LA6112-2;2;1;;; +15962-4;LL1927-4;RAST;LA6113-0;3;2;;; +15962-4;LL1927-4;RAST;LA6114-8;4;3;;; +15962-4;LL1927-4;RAST;LA6115-5;5;4;;; +15962-4;LL1927-4;RAST;LA10137-0;6;5;;; +15962-4;LL1927-4;RAST;LA10138-8;7;6;;; +15963-2;LL1927-4;RAST;LA6111-4;1;0;;; +15963-2;LL1927-4;RAST;LA6112-2;2;1;;; +15963-2;LL1927-4;RAST;LA6113-0;3;2;;; +15963-2;LL1927-4;RAST;LA6114-8;4;3;;; +15963-2;LL1927-4;RAST;LA6115-5;5;4;;; +15963-2;LL1927-4;RAST;LA10137-0;6;5;;; +15963-2;LL1927-4;RAST;LA10138-8;7;6;;; +15964-0;LL1927-4;RAST;LA6111-4;1;0;;; +15964-0;LL1927-4;RAST;LA6112-2;2;1;;; +15964-0;LL1927-4;RAST;LA6113-0;3;2;;; +15964-0;LL1927-4;RAST;LA6114-8;4;3;;; +15964-0;LL1927-4;RAST;LA6115-5;5;4;;; +15964-0;LL1927-4;RAST;LA10137-0;6;5;;; +15964-0;LL1927-4;RAST;LA10138-8;7;6;;; +15966-5;LL1927-4;RAST;LA6111-4;1;0;;; +15966-5;LL1927-4;RAST;LA6112-2;2;1;;; +15966-5;LL1927-4;RAST;LA6113-0;3;2;;; +15966-5;LL1927-4;RAST;LA6114-8;4;3;;; +15966-5;LL1927-4;RAST;LA6115-5;5;4;;; +15966-5;LL1927-4;RAST;LA10137-0;6;5;;; +15966-5;LL1927-4;RAST;LA10138-8;7;6;;; +15967-3;LL1927-4;RAST;LA6111-4;1;0;;; +15967-3;LL1927-4;RAST;LA6112-2;2;1;;; +15967-3;LL1927-4;RAST;LA6113-0;3;2;;; +15967-3;LL1927-4;RAST;LA6114-8;4;3;;; +15967-3;LL1927-4;RAST;LA6115-5;5;4;;; +15967-3;LL1927-4;RAST;LA10137-0;6;5;;; +15967-3;LL1927-4;RAST;LA10138-8;7;6;;; +15968-1;LL1927-4;RAST;LA6111-4;1;0;;; +15968-1;LL1927-4;RAST;LA6112-2;2;1;;; +15968-1;LL1927-4;RAST;LA6113-0;3;2;;; +15968-1;LL1927-4;RAST;LA6114-8;4;3;;; +15968-1;LL1927-4;RAST;LA6115-5;5;4;;; +15968-1;LL1927-4;RAST;LA10137-0;6;5;;; +15968-1;LL1927-4;RAST;LA10138-8;7;6;;; +15969-9;LL1927-4;RAST;LA6111-4;1;0;;; +15969-9;LL1927-4;RAST;LA6112-2;2;1;;; +15969-9;LL1927-4;RAST;LA6113-0;3;2;;; +15969-9;LL1927-4;RAST;LA6114-8;4;3;;; +15969-9;LL1927-4;RAST;LA6115-5;5;4;;; +15969-9;LL1927-4;RAST;LA10137-0;6;5;;; +15969-9;LL1927-4;RAST;LA10138-8;7;6;;; +15970-7;LL1927-4;RAST;LA6111-4;1;0;;; +15970-7;LL1927-4;RAST;LA6112-2;2;1;;; +15970-7;LL1927-4;RAST;LA6113-0;3;2;;; +15970-7;LL1927-4;RAST;LA6114-8;4;3;;; +15970-7;LL1927-4;RAST;LA6115-5;5;4;;; +15970-7;LL1927-4;RAST;LA10137-0;6;5;;; +15970-7;LL1927-4;RAST;LA10138-8;7;6;;; +15971-5;LL1927-4;RAST;LA6111-4;1;0;;; +15971-5;LL1927-4;RAST;LA6112-2;2;1;;; +15971-5;LL1927-4;RAST;LA6113-0;3;2;;; +15971-5;LL1927-4;RAST;LA6114-8;4;3;;; +15971-5;LL1927-4;RAST;LA6115-5;5;4;;; +15971-5;LL1927-4;RAST;LA10137-0;6;5;;; +15971-5;LL1927-4;RAST;LA10138-8;7;6;;; +15972-3;LL1927-4;RAST;LA6111-4;1;0;;; +15972-3;LL1927-4;RAST;LA6112-2;2;1;;; +15972-3;LL1927-4;RAST;LA6113-0;3;2;;; +15972-3;LL1927-4;RAST;LA6114-8;4;3;;; +15972-3;LL1927-4;RAST;LA6115-5;5;4;;; +15972-3;LL1927-4;RAST;LA10137-0;6;5;;; +15972-3;LL1927-4;RAST;LA10138-8;7;6;;; +15973-1;LL1927-4;RAST;LA6111-4;1;0;;; +15973-1;LL1927-4;RAST;LA6112-2;2;1;;; +15973-1;LL1927-4;RAST;LA6113-0;3;2;;; +15973-1;LL1927-4;RAST;LA6114-8;4;3;;; +15973-1;LL1927-4;RAST;LA6115-5;5;4;;; +15973-1;LL1927-4;RAST;LA10137-0;6;5;;; +15973-1;LL1927-4;RAST;LA10138-8;7;6;;; +15974-9;LL1927-4;RAST;LA6111-4;1;0;;; +15974-9;LL1927-4;RAST;LA6112-2;2;1;;; +15974-9;LL1927-4;RAST;LA6113-0;3;2;;; +15974-9;LL1927-4;RAST;LA6114-8;4;3;;; +15974-9;LL1927-4;RAST;LA6115-5;5;4;;; +15974-9;LL1927-4;RAST;LA10137-0;6;5;;; +15974-9;LL1927-4;RAST;LA10138-8;7;6;;; +15975-6;LL1927-4;RAST;LA6111-4;1;0;;; +15975-6;LL1927-4;RAST;LA6112-2;2;1;;; +15975-6;LL1927-4;RAST;LA6113-0;3;2;;; +15975-6;LL1927-4;RAST;LA6114-8;4;3;;; +15975-6;LL1927-4;RAST;LA6115-5;5;4;;; +15975-6;LL1927-4;RAST;LA10137-0;6;5;;; +15975-6;LL1927-4;RAST;LA10138-8;7;6;;; +15976-4;LL1927-4;RAST;LA6111-4;1;0;;; +15976-4;LL1927-4;RAST;LA6112-2;2;1;;; +15976-4;LL1927-4;RAST;LA6113-0;3;2;;; +15976-4;LL1927-4;RAST;LA6114-8;4;3;;; +15976-4;LL1927-4;RAST;LA6115-5;5;4;;; +15976-4;LL1927-4;RAST;LA10137-0;6;5;;; +15976-4;LL1927-4;RAST;LA10138-8;7;6;;; +15977-2;LL1927-4;RAST;LA6111-4;1;0;;; +15977-2;LL1927-4;RAST;LA6112-2;2;1;;; +15977-2;LL1927-4;RAST;LA6113-0;3;2;;; +15977-2;LL1927-4;RAST;LA6114-8;4;3;;; +15977-2;LL1927-4;RAST;LA6115-5;5;4;;; +15977-2;LL1927-4;RAST;LA10137-0;6;5;;; +15977-2;LL1927-4;RAST;LA10138-8;7;6;;; +15978-0;LL1927-4;RAST;LA6111-4;1;0;;; +15978-0;LL1927-4;RAST;LA6112-2;2;1;;; +15978-0;LL1927-4;RAST;LA6113-0;3;2;;; +15978-0;LL1927-4;RAST;LA6114-8;4;3;;; +15978-0;LL1927-4;RAST;LA6115-5;5;4;;; +15978-0;LL1927-4;RAST;LA10137-0;6;5;;; +15978-0;LL1927-4;RAST;LA10138-8;7;6;;; +15980-6;LL1927-4;RAST;LA6111-4;1;0;;; +15980-6;LL1927-4;RAST;LA6112-2;2;1;;; +15980-6;LL1927-4;RAST;LA6113-0;3;2;;; +15980-6;LL1927-4;RAST;LA6114-8;4;3;;; +15980-6;LL1927-4;RAST;LA6115-5;5;4;;; +15980-6;LL1927-4;RAST;LA10137-0;6;5;;; +15980-6;LL1927-4;RAST;LA10138-8;7;6;;; +15981-4;LL1927-4;RAST;LA6111-4;1;0;;; +15981-4;LL1927-4;RAST;LA6112-2;2;1;;; +15981-4;LL1927-4;RAST;LA6113-0;3;2;;; +15981-4;LL1927-4;RAST;LA6114-8;4;3;;; +15981-4;LL1927-4;RAST;LA6115-5;5;4;;; +15981-4;LL1927-4;RAST;LA10137-0;6;5;;; +15981-4;LL1927-4;RAST;LA10138-8;7;6;;; +15982-2;LL1927-4;RAST;LA6111-4;1;0;;; +15982-2;LL1927-4;RAST;LA6112-2;2;1;;; +15982-2;LL1927-4;RAST;LA6113-0;3;2;;; +15982-2;LL1927-4;RAST;LA6114-8;4;3;;; +15982-2;LL1927-4;RAST;LA6115-5;5;4;;; +15982-2;LL1927-4;RAST;LA10137-0;6;5;;; +15982-2;LL1927-4;RAST;LA10138-8;7;6;;; +15983-0;LL1927-4;RAST;LA6111-4;1;0;;; +15983-0;LL1927-4;RAST;LA6112-2;2;1;;; +15983-0;LL1927-4;RAST;LA6113-0;3;2;;; +15983-0;LL1927-4;RAST;LA6114-8;4;3;;; +15983-0;LL1927-4;RAST;LA6115-5;5;4;;; +15983-0;LL1927-4;RAST;LA10137-0;6;5;;; +15983-0;LL1927-4;RAST;LA10138-8;7;6;;; +15984-8;LL1927-4;RAST;LA6111-4;1;0;;; +15984-8;LL1927-4;RAST;LA6112-2;2;1;;; +15984-8;LL1927-4;RAST;LA6113-0;3;2;;; +15984-8;LL1927-4;RAST;LA6114-8;4;3;;; +15984-8;LL1927-4;RAST;LA6115-5;5;4;;; +15984-8;LL1927-4;RAST;LA10137-0;6;5;;; +15984-8;LL1927-4;RAST;LA10138-8;7;6;;; +15985-5;LL1927-4;RAST;LA6111-4;1;0;;; +15985-5;LL1927-4;RAST;LA6112-2;2;1;;; +15985-5;LL1927-4;RAST;LA6113-0;3;2;;; +15985-5;LL1927-4;RAST;LA6114-8;4;3;;; +15985-5;LL1927-4;RAST;LA6115-5;5;4;;; +15985-5;LL1927-4;RAST;LA10137-0;6;5;;; +15985-5;LL1927-4;RAST;LA10138-8;7;6;;; +15986-3;LL1927-4;RAST;LA6111-4;1;0;;; +15986-3;LL1927-4;RAST;LA6112-2;2;1;;; +15986-3;LL1927-4;RAST;LA6113-0;3;2;;; +15986-3;LL1927-4;RAST;LA6114-8;4;3;;; +15986-3;LL1927-4;RAST;LA6115-5;5;4;;; +15986-3;LL1927-4;RAST;LA10137-0;6;5;;; +15986-3;LL1927-4;RAST;LA10138-8;7;6;;; +15987-1;LL1927-4;RAST;LA6111-4;1;0;;; +15987-1;LL1927-4;RAST;LA6112-2;2;1;;; +15987-1;LL1927-4;RAST;LA6113-0;3;2;;; +15987-1;LL1927-4;RAST;LA6114-8;4;3;;; +15987-1;LL1927-4;RAST;LA6115-5;5;4;;; +15987-1;LL1927-4;RAST;LA10137-0;6;5;;; +15987-1;LL1927-4;RAST;LA10138-8;7;6;;; +15988-9;LL1927-4;RAST;LA6111-4;1;0;;; +15988-9;LL1927-4;RAST;LA6112-2;2;1;;; +15988-9;LL1927-4;RAST;LA6113-0;3;2;;; +15988-9;LL1927-4;RAST;LA6114-8;4;3;;; +15988-9;LL1927-4;RAST;LA6115-5;5;4;;; +15988-9;LL1927-4;RAST;LA10137-0;6;5;;; +15988-9;LL1927-4;RAST;LA10138-8;7;6;;; +15989-7;LL1927-4;RAST;LA6111-4;1;0;;; +15989-7;LL1927-4;RAST;LA6112-2;2;1;;; +15989-7;LL1927-4;RAST;LA6113-0;3;2;;; +15989-7;LL1927-4;RAST;LA6114-8;4;3;;; +15989-7;LL1927-4;RAST;LA6115-5;5;4;;; +15989-7;LL1927-4;RAST;LA10137-0;6;5;;; +15989-7;LL1927-4;RAST;LA10138-8;7;6;;; +15990-5;LL1927-4;RAST;LA6111-4;1;0;;; +15990-5;LL1927-4;RAST;LA6112-2;2;1;;; +15990-5;LL1927-4;RAST;LA6113-0;3;2;;; +15990-5;LL1927-4;RAST;LA6114-8;4;3;;; +15990-5;LL1927-4;RAST;LA6115-5;5;4;;; +15990-5;LL1927-4;RAST;LA10137-0;6;5;;; +15990-5;LL1927-4;RAST;LA10138-8;7;6;;; +15991-3;LL1927-4;RAST;LA6111-4;1;0;;; +15991-3;LL1927-4;RAST;LA6112-2;2;1;;; +15991-3;LL1927-4;RAST;LA6113-0;3;2;;; +15991-3;LL1927-4;RAST;LA6114-8;4;3;;; +15991-3;LL1927-4;RAST;LA6115-5;5;4;;; +15991-3;LL1927-4;RAST;LA10137-0;6;5;;; +15991-3;LL1927-4;RAST;LA10138-8;7;6;;; +15992-1;LL1927-4;RAST;LA6111-4;1;0;;; +15992-1;LL1927-4;RAST;LA6112-2;2;1;;; +15992-1;LL1927-4;RAST;LA6113-0;3;2;;; +15992-1;LL1927-4;RAST;LA6114-8;4;3;;; +15992-1;LL1927-4;RAST;LA6115-5;5;4;;; +15992-1;LL1927-4;RAST;LA10137-0;6;5;;; +15992-1;LL1927-4;RAST;LA10138-8;7;6;;; +15993-9;LL1927-4;RAST;LA6111-4;1;0;;; +15993-9;LL1927-4;RAST;LA6112-2;2;1;;; +15993-9;LL1927-4;RAST;LA6113-0;3;2;;; +15993-9;LL1927-4;RAST;LA6114-8;4;3;;; +15993-9;LL1927-4;RAST;LA6115-5;5;4;;; +15993-9;LL1927-4;RAST;LA10137-0;6;5;;; +15993-9;LL1927-4;RAST;LA10138-8;7;6;;; +15994-7;LL1927-4;RAST;LA6111-4;1;0;;; +15994-7;LL1927-4;RAST;LA6112-2;2;1;;; +15994-7;LL1927-4;RAST;LA6113-0;3;2;;; +15994-7;LL1927-4;RAST;LA6114-8;4;3;;; +15994-7;LL1927-4;RAST;LA6115-5;5;4;;; +15994-7;LL1927-4;RAST;LA10137-0;6;5;;; +15994-7;LL1927-4;RAST;LA10138-8;7;6;;; +15995-4;LL1927-4;RAST;LA6111-4;1;0;;; +15995-4;LL1927-4;RAST;LA6112-2;2;1;;; +15995-4;LL1927-4;RAST;LA6113-0;3;2;;; +15995-4;LL1927-4;RAST;LA6114-8;4;3;;; +15995-4;LL1927-4;RAST;LA6115-5;5;4;;; +15995-4;LL1927-4;RAST;LA10137-0;6;5;;; +15995-4;LL1927-4;RAST;LA10138-8;7;6;;; +15996-2;LL1927-4;RAST;LA6111-4;1;0;;; +15996-2;LL1927-4;RAST;LA6112-2;2;1;;; +15996-2;LL1927-4;RAST;LA6113-0;3;2;;; +15996-2;LL1927-4;RAST;LA6114-8;4;3;;; +15996-2;LL1927-4;RAST;LA6115-5;5;4;;; +15996-2;LL1927-4;RAST;LA10137-0;6;5;;; +15996-2;LL1927-4;RAST;LA10138-8;7;6;;; +15997-0;LL1927-4;RAST;LA6111-4;1;0;;; +15997-0;LL1927-4;RAST;LA6112-2;2;1;;; +15997-0;LL1927-4;RAST;LA6113-0;3;2;;; +15997-0;LL1927-4;RAST;LA6114-8;4;3;;; +15997-0;LL1927-4;RAST;LA6115-5;5;4;;; +15997-0;LL1927-4;RAST;LA10137-0;6;5;;; +15997-0;LL1927-4;RAST;LA10138-8;7;6;;; +15998-8;LL1927-4;RAST;LA6111-4;1;0;;; +15998-8;LL1927-4;RAST;LA6112-2;2;1;;; +15998-8;LL1927-4;RAST;LA6113-0;3;2;;; +15998-8;LL1927-4;RAST;LA6114-8;4;3;;; +15998-8;LL1927-4;RAST;LA6115-5;5;4;;; +15998-8;LL1927-4;RAST;LA10137-0;6;5;;; +15998-8;LL1927-4;RAST;LA10138-8;7;6;;; +16001-0;LL1927-4;RAST;LA6111-4;1;0;;; +16001-0;LL1927-4;RAST;LA6112-2;2;1;;; +16001-0;LL1927-4;RAST;LA6113-0;3;2;;; +16001-0;LL1927-4;RAST;LA6114-8;4;3;;; +16001-0;LL1927-4;RAST;LA6115-5;5;4;;; +16001-0;LL1927-4;RAST;LA10137-0;6;5;;; +16001-0;LL1927-4;RAST;LA10138-8;7;6;;; +16002-8;LL1927-4;RAST;LA6111-4;1;0;;; +16002-8;LL1927-4;RAST;LA6112-2;2;1;;; +16002-8;LL1927-4;RAST;LA6113-0;3;2;;; +16002-8;LL1927-4;RAST;LA6114-8;4;3;;; +16002-8;LL1927-4;RAST;LA6115-5;5;4;;; +16002-8;LL1927-4;RAST;LA10137-0;6;5;;; +16002-8;LL1927-4;RAST;LA10138-8;7;6;;; +16003-6;LL1927-4;RAST;LA6111-4;1;0;;; +16003-6;LL1927-4;RAST;LA6112-2;2;1;;; +16003-6;LL1927-4;RAST;LA6113-0;3;2;;; +16003-6;LL1927-4;RAST;LA6114-8;4;3;;; +16003-6;LL1927-4;RAST;LA6115-5;5;4;;; +16003-6;LL1927-4;RAST;LA10137-0;6;5;;; +16003-6;LL1927-4;RAST;LA10138-8;7;6;;; +16005-1;LL1927-4;RAST;LA6111-4;1;0;;; +16005-1;LL1927-4;RAST;LA6112-2;2;1;;; +16005-1;LL1927-4;RAST;LA6113-0;3;2;;; +16005-1;LL1927-4;RAST;LA6114-8;4;3;;; +16005-1;LL1927-4;RAST;LA6115-5;5;4;;; +16005-1;LL1927-4;RAST;LA10137-0;6;5;;; +16005-1;LL1927-4;RAST;LA10138-8;7;6;;; +16006-9;LL1927-4;RAST;LA6111-4;1;0;;; +16006-9;LL1927-4;RAST;LA6112-2;2;1;;; +16006-9;LL1927-4;RAST;LA6113-0;3;2;;; +16006-9;LL1927-4;RAST;LA6114-8;4;3;;; +16006-9;LL1927-4;RAST;LA6115-5;5;4;;; +16006-9;LL1927-4;RAST;LA10137-0;6;5;;; +16006-9;LL1927-4;RAST;LA10138-8;7;6;;; +16007-7;LL1927-4;RAST;LA6111-4;1;0;;; +16007-7;LL1927-4;RAST;LA6112-2;2;1;;; +16007-7;LL1927-4;RAST;LA6113-0;3;2;;; +16007-7;LL1927-4;RAST;LA6114-8;4;3;;; +16007-7;LL1927-4;RAST;LA6115-5;5;4;;; +16007-7;LL1927-4;RAST;LA10137-0;6;5;;; +16007-7;LL1927-4;RAST;LA10138-8;7;6;;; +16008-5;LL1927-4;RAST;LA6111-4;1;0;;; +16008-5;LL1927-4;RAST;LA6112-2;2;1;;; +16008-5;LL1927-4;RAST;LA6113-0;3;2;;; +16008-5;LL1927-4;RAST;LA6114-8;4;3;;; +16008-5;LL1927-4;RAST;LA6115-5;5;4;;; +16008-5;LL1927-4;RAST;LA10137-0;6;5;;; +16008-5;LL1927-4;RAST;LA10138-8;7;6;;; +16009-3;LL1927-4;RAST;LA6111-4;1;0;;; +16009-3;LL1927-4;RAST;LA6112-2;2;1;;; +16009-3;LL1927-4;RAST;LA6113-0;3;2;;; +16009-3;LL1927-4;RAST;LA6114-8;4;3;;; +16009-3;LL1927-4;RAST;LA6115-5;5;4;;; +16009-3;LL1927-4;RAST;LA10137-0;6;5;;; +16009-3;LL1927-4;RAST;LA10138-8;7;6;;; +16011-9;LL1927-4;RAST;LA6111-4;1;0;;; +16011-9;LL1927-4;RAST;LA6112-2;2;1;;; +16011-9;LL1927-4;RAST;LA6113-0;3;2;;; +16011-9;LL1927-4;RAST;LA6114-8;4;3;;; +16011-9;LL1927-4;RAST;LA6115-5;5;4;;; +16011-9;LL1927-4;RAST;LA10137-0;6;5;;; +16011-9;LL1927-4;RAST;LA10138-8;7;6;;; +16012-7;LL1927-4;RAST;LA6111-4;1;0;;; +16012-7;LL1927-4;RAST;LA6112-2;2;1;;; +16012-7;LL1927-4;RAST;LA6113-0;3;2;;; +16012-7;LL1927-4;RAST;LA6114-8;4;3;;; +16012-7;LL1927-4;RAST;LA6115-5;5;4;;; +16012-7;LL1927-4;RAST;LA10137-0;6;5;;; +16012-7;LL1927-4;RAST;LA10138-8;7;6;;; +16013-5;LL1927-4;RAST;LA6111-4;1;0;;; +16013-5;LL1927-4;RAST;LA6112-2;2;1;;; +16013-5;LL1927-4;RAST;LA6113-0;3;2;;; +16013-5;LL1927-4;RAST;LA6114-8;4;3;;; +16013-5;LL1927-4;RAST;LA6115-5;5;4;;; +16013-5;LL1927-4;RAST;LA10137-0;6;5;;; +16013-5;LL1927-4;RAST;LA10138-8;7;6;;; +16014-3;LL1927-4;RAST;LA6111-4;1;0;;; +16014-3;LL1927-4;RAST;LA6112-2;2;1;;; +16014-3;LL1927-4;RAST;LA6113-0;3;2;;; +16014-3;LL1927-4;RAST;LA6114-8;4;3;;; +16014-3;LL1927-4;RAST;LA6115-5;5;4;;; +16014-3;LL1927-4;RAST;LA10137-0;6;5;;; +16014-3;LL1927-4;RAST;LA10138-8;7;6;;; +16015-0;LL1927-4;RAST;LA6111-4;1;0;;; +16015-0;LL1927-4;RAST;LA6112-2;2;1;;; +16015-0;LL1927-4;RAST;LA6113-0;3;2;;; +16015-0;LL1927-4;RAST;LA6114-8;4;3;;; +16015-0;LL1927-4;RAST;LA6115-5;5;4;;; +16015-0;LL1927-4;RAST;LA10137-0;6;5;;; +16015-0;LL1927-4;RAST;LA10138-8;7;6;;; +16016-8;LL1927-4;RAST;LA6111-4;1;0;;; +16016-8;LL1927-4;RAST;LA6112-2;2;1;;; +16016-8;LL1927-4;RAST;LA6113-0;3;2;;; +16016-8;LL1927-4;RAST;LA6114-8;4;3;;; +16016-8;LL1927-4;RAST;LA6115-5;5;4;;; +16016-8;LL1927-4;RAST;LA10137-0;6;5;;; +16016-8;LL1927-4;RAST;LA10138-8;7;6;;; +16017-6;LL1927-4;RAST;LA6111-4;1;0;;; +16017-6;LL1927-4;RAST;LA6112-2;2;1;;; +16017-6;LL1927-4;RAST;LA6113-0;3;2;;; +16017-6;LL1927-4;RAST;LA6114-8;4;3;;; +16017-6;LL1927-4;RAST;LA6115-5;5;4;;; +16017-6;LL1927-4;RAST;LA10137-0;6;5;;; +16017-6;LL1927-4;RAST;LA10138-8;7;6;;; +16018-4;LL1927-4;RAST;LA6111-4;1;0;;; +16018-4;LL1927-4;RAST;LA6112-2;2;1;;; +16018-4;LL1927-4;RAST;LA6113-0;3;2;;; +16018-4;LL1927-4;RAST;LA6114-8;4;3;;; +16018-4;LL1927-4;RAST;LA6115-5;5;4;;; +16018-4;LL1927-4;RAST;LA10137-0;6;5;;; +16018-4;LL1927-4;RAST;LA10138-8;7;6;;; +16019-2;LL1927-4;RAST;LA6111-4;1;0;;; +16019-2;LL1927-4;RAST;LA6112-2;2;1;;; +16019-2;LL1927-4;RAST;LA6113-0;3;2;;; +16019-2;LL1927-4;RAST;LA6114-8;4;3;;; +16019-2;LL1927-4;RAST;LA6115-5;5;4;;; +16019-2;LL1927-4;RAST;LA10137-0;6;5;;; +16019-2;LL1927-4;RAST;LA10138-8;7;6;;; +16020-0;LL1927-4;RAST;LA6111-4;1;0;;; +16020-0;LL1927-4;RAST;LA6112-2;2;1;;; +16020-0;LL1927-4;RAST;LA6113-0;3;2;;; +16020-0;LL1927-4;RAST;LA6114-8;4;3;;; +16020-0;LL1927-4;RAST;LA6115-5;5;4;;; +16020-0;LL1927-4;RAST;LA10137-0;6;5;;; +16020-0;LL1927-4;RAST;LA10138-8;7;6;;; +16021-8;LL1927-4;RAST;LA6111-4;1;0;;; +16021-8;LL1927-4;RAST;LA6112-2;2;1;;; +16021-8;LL1927-4;RAST;LA6113-0;3;2;;; +16021-8;LL1927-4;RAST;LA6114-8;4;3;;; +16021-8;LL1927-4;RAST;LA6115-5;5;4;;; +16021-8;LL1927-4;RAST;LA10137-0;6;5;;; +16021-8;LL1927-4;RAST;LA10138-8;7;6;;; +16022-6;LL1927-4;RAST;LA6111-4;1;0;;; +16022-6;LL1927-4;RAST;LA6112-2;2;1;;; +16022-6;LL1927-4;RAST;LA6113-0;3;2;;; +16022-6;LL1927-4;RAST;LA6114-8;4;3;;; +16022-6;LL1927-4;RAST;LA6115-5;5;4;;; +16022-6;LL1927-4;RAST;LA10137-0;6;5;;; +16022-6;LL1927-4;RAST;LA10138-8;7;6;;; +16023-4;LL1927-4;RAST;LA6111-4;1;0;;; +16023-4;LL1927-4;RAST;LA6112-2;2;1;;; +16023-4;LL1927-4;RAST;LA6113-0;3;2;;; +16023-4;LL1927-4;RAST;LA6114-8;4;3;;; +16023-4;LL1927-4;RAST;LA6115-5;5;4;;; +16023-4;LL1927-4;RAST;LA10137-0;6;5;;; +16023-4;LL1927-4;RAST;LA10138-8;7;6;;; +16024-2;LL1927-4;RAST;LA6111-4;1;0;;; +16024-2;LL1927-4;RAST;LA6112-2;2;1;;; +16024-2;LL1927-4;RAST;LA6113-0;3;2;;; +16024-2;LL1927-4;RAST;LA6114-8;4;3;;; +16024-2;LL1927-4;RAST;LA6115-5;5;4;;; +16024-2;LL1927-4;RAST;LA10137-0;6;5;;; +16024-2;LL1927-4;RAST;LA10138-8;7;6;;; +16025-9;LL1927-4;RAST;LA6111-4;1;0;;; +16025-9;LL1927-4;RAST;LA6112-2;2;1;;; +16025-9;LL1927-4;RAST;LA6113-0;3;2;;; +16025-9;LL1927-4;RAST;LA6114-8;4;3;;; +16025-9;LL1927-4;RAST;LA6115-5;5;4;;; +16025-9;LL1927-4;RAST;LA10137-0;6;5;;; +16025-9;LL1927-4;RAST;LA10138-8;7;6;;; +16026-7;LL1927-4;RAST;LA6111-4;1;0;;; +16026-7;LL1927-4;RAST;LA6112-2;2;1;;; +16026-7;LL1927-4;RAST;LA6113-0;3;2;;; +16026-7;LL1927-4;RAST;LA6114-8;4;3;;; +16026-7;LL1927-4;RAST;LA6115-5;5;4;;; +16026-7;LL1927-4;RAST;LA10137-0;6;5;;; +16026-7;LL1927-4;RAST;LA10138-8;7;6;;; +16027-5;LL1927-4;RAST;LA6111-4;1;0;;; +16027-5;LL1927-4;RAST;LA6112-2;2;1;;; +16027-5;LL1927-4;RAST;LA6113-0;3;2;;; +16027-5;LL1927-4;RAST;LA6114-8;4;3;;; +16027-5;LL1927-4;RAST;LA6115-5;5;4;;; +16027-5;LL1927-4;RAST;LA10137-0;6;5;;; +16027-5;LL1927-4;RAST;LA10138-8;7;6;;; +16028-3;LL1927-4;RAST;LA6111-4;1;0;;; +16028-3;LL1927-4;RAST;LA6112-2;2;1;;; +16028-3;LL1927-4;RAST;LA6113-0;3;2;;; +16028-3;LL1927-4;RAST;LA6114-8;4;3;;; +16028-3;LL1927-4;RAST;LA6115-5;5;4;;; +16028-3;LL1927-4;RAST;LA10137-0;6;5;;; +16028-3;LL1927-4;RAST;LA10138-8;7;6;;; +16029-1;LL1927-4;RAST;LA6111-4;1;0;;; +16029-1;LL1927-4;RAST;LA6112-2;2;1;;; +16029-1;LL1927-4;RAST;LA6113-0;3;2;;; +16029-1;LL1927-4;RAST;LA6114-8;4;3;;; +16029-1;LL1927-4;RAST;LA6115-5;5;4;;; +16029-1;LL1927-4;RAST;LA10137-0;6;5;;; +16029-1;LL1927-4;RAST;LA10138-8;7;6;;; +16030-9;LL1927-4;RAST;LA6111-4;1;0;;; +16030-9;LL1927-4;RAST;LA6112-2;2;1;;; +16030-9;LL1927-4;RAST;LA6113-0;3;2;;; +16030-9;LL1927-4;RAST;LA6114-8;4;3;;; +16030-9;LL1927-4;RAST;LA6115-5;5;4;;; +16030-9;LL1927-4;RAST;LA10137-0;6;5;;; +16030-9;LL1927-4;RAST;LA10138-8;7;6;;; +16031-7;LL1927-4;RAST;LA6111-4;1;0;;; +16031-7;LL1927-4;RAST;LA6112-2;2;1;;; +16031-7;LL1927-4;RAST;LA6113-0;3;2;;; +16031-7;LL1927-4;RAST;LA6114-8;4;3;;; +16031-7;LL1927-4;RAST;LA6115-5;5;4;;; +16031-7;LL1927-4;RAST;LA10137-0;6;5;;; +16031-7;LL1927-4;RAST;LA10138-8;7;6;;; +16032-5;LL1927-4;RAST;LA6111-4;1;0;;; +16032-5;LL1927-4;RAST;LA6112-2;2;1;;; +16032-5;LL1927-4;RAST;LA6113-0;3;2;;; +16032-5;LL1927-4;RAST;LA6114-8;4;3;;; +16032-5;LL1927-4;RAST;LA6115-5;5;4;;; +16032-5;LL1927-4;RAST;LA10137-0;6;5;;; +16032-5;LL1927-4;RAST;LA10138-8;7;6;;; +16033-3;LL1927-4;RAST;LA6111-4;1;0;;; +16033-3;LL1927-4;RAST;LA6112-2;2;1;;; +16033-3;LL1927-4;RAST;LA6113-0;3;2;;; +16033-3;LL1927-4;RAST;LA6114-8;4;3;;; +16033-3;LL1927-4;RAST;LA6115-5;5;4;;; +16033-3;LL1927-4;RAST;LA10137-0;6;5;;; +16033-3;LL1927-4;RAST;LA10138-8;7;6;;; +16034-1;LL1927-4;RAST;LA6111-4;1;0;;; +16034-1;LL1927-4;RAST;LA6112-2;2;1;;; +16034-1;LL1927-4;RAST;LA6113-0;3;2;;; +16034-1;LL1927-4;RAST;LA6114-8;4;3;;; +16034-1;LL1927-4;RAST;LA6115-5;5;4;;; +16034-1;LL1927-4;RAST;LA10137-0;6;5;;; +16034-1;LL1927-4;RAST;LA10138-8;7;6;;; +16035-8;LL1927-4;RAST;LA6111-4;1;0;;; +16035-8;LL1927-4;RAST;LA6112-2;2;1;;; +16035-8;LL1927-4;RAST;LA6113-0;3;2;;; +16035-8;LL1927-4;RAST;LA6114-8;4;3;;; +16035-8;LL1927-4;RAST;LA6115-5;5;4;;; +16035-8;LL1927-4;RAST;LA10137-0;6;5;;; +16035-8;LL1927-4;RAST;LA10138-8;7;6;;; +16037-4;LL1927-4;RAST;LA6111-4;1;0;;; +16037-4;LL1927-4;RAST;LA6112-2;2;1;;; +16037-4;LL1927-4;RAST;LA6113-0;3;2;;; +16037-4;LL1927-4;RAST;LA6114-8;4;3;;; +16037-4;LL1927-4;RAST;LA6115-5;5;4;;; +16037-4;LL1927-4;RAST;LA10137-0;6;5;;; +16037-4;LL1927-4;RAST;LA10138-8;7;6;;; +16038-2;LL1927-4;RAST;LA6111-4;1;0;;; +16038-2;LL1927-4;RAST;LA6112-2;2;1;;; +16038-2;LL1927-4;RAST;LA6113-0;3;2;;; +16038-2;LL1927-4;RAST;LA6114-8;4;3;;; +16038-2;LL1927-4;RAST;LA6115-5;5;4;;; +16038-2;LL1927-4;RAST;LA10137-0;6;5;;; +16038-2;LL1927-4;RAST;LA10138-8;7;6;;; +16039-0;LL1927-4;RAST;LA6111-4;1;0;;; +16039-0;LL1927-4;RAST;LA6112-2;2;1;;; +16039-0;LL1927-4;RAST;LA6113-0;3;2;;; +16039-0;LL1927-4;RAST;LA6114-8;4;3;;; +16039-0;LL1927-4;RAST;LA6115-5;5;4;;; +16039-0;LL1927-4;RAST;LA10137-0;6;5;;; +16039-0;LL1927-4;RAST;LA10138-8;7;6;;; +16040-8;LL1927-4;RAST;LA6111-4;1;0;;; +16040-8;LL1927-4;RAST;LA6112-2;2;1;;; +16040-8;LL1927-4;RAST;LA6113-0;3;2;;; +16040-8;LL1927-4;RAST;LA6114-8;4;3;;; +16040-8;LL1927-4;RAST;LA6115-5;5;4;;; +16040-8;LL1927-4;RAST;LA10137-0;6;5;;; +16040-8;LL1927-4;RAST;LA10138-8;7;6;;; +16041-6;LL1927-4;RAST;LA6111-4;1;0;;; +16041-6;LL1927-4;RAST;LA6112-2;2;1;;; +16041-6;LL1927-4;RAST;LA6113-0;3;2;;; +16041-6;LL1927-4;RAST;LA6114-8;4;3;;; +16041-6;LL1927-4;RAST;LA6115-5;5;4;;; +16041-6;LL1927-4;RAST;LA10137-0;6;5;;; +16041-6;LL1927-4;RAST;LA10138-8;7;6;;; +16042-4;LL1927-4;RAST;LA6111-4;1;0;;; +16042-4;LL1927-4;RAST;LA6112-2;2;1;;; +16042-4;LL1927-4;RAST;LA6113-0;3;2;;; +16042-4;LL1927-4;RAST;LA6114-8;4;3;;; +16042-4;LL1927-4;RAST;LA6115-5;5;4;;; +16042-4;LL1927-4;RAST;LA10137-0;6;5;;; +16042-4;LL1927-4;RAST;LA10138-8;7;6;;; +16043-2;LL1927-4;RAST;LA6111-4;1;0;;; +16043-2;LL1927-4;RAST;LA6112-2;2;1;;; +16043-2;LL1927-4;RAST;LA6113-0;3;2;;; +16043-2;LL1927-4;RAST;LA6114-8;4;3;;; +16043-2;LL1927-4;RAST;LA6115-5;5;4;;; +16043-2;LL1927-4;RAST;LA10137-0;6;5;;; +16043-2;LL1927-4;RAST;LA10138-8;7;6;;; +16044-0;LL1927-4;RAST;LA6111-4;1;0;;; +16044-0;LL1927-4;RAST;LA6112-2;2;1;;; +16044-0;LL1927-4;RAST;LA6113-0;3;2;;; +16044-0;LL1927-4;RAST;LA6114-8;4;3;;; +16044-0;LL1927-4;RAST;LA6115-5;5;4;;; +16044-0;LL1927-4;RAST;LA10137-0;6;5;;; +16044-0;LL1927-4;RAST;LA10138-8;7;6;;; +16045-7;LL1927-4;RAST;LA6111-4;1;0;;; +16045-7;LL1927-4;RAST;LA6112-2;2;1;;; +16045-7;LL1927-4;RAST;LA6113-0;3;2;;; +16045-7;LL1927-4;RAST;LA6114-8;4;3;;; +16045-7;LL1927-4;RAST;LA6115-5;5;4;;; +16045-7;LL1927-4;RAST;LA10137-0;6;5;;; +16045-7;LL1927-4;RAST;LA10138-8;7;6;;; +16046-5;LL1927-4;RAST;LA6111-4;1;0;;; +16046-5;LL1927-4;RAST;LA6112-2;2;1;;; +16046-5;LL1927-4;RAST;LA6113-0;3;2;;; +16046-5;LL1927-4;RAST;LA6114-8;4;3;;; +16046-5;LL1927-4;RAST;LA6115-5;5;4;;; +16046-5;LL1927-4;RAST;LA10137-0;6;5;;; +16046-5;LL1927-4;RAST;LA10138-8;7;6;;; +16047-3;LL1927-4;RAST;LA6111-4;1;0;;; +16047-3;LL1927-4;RAST;LA6112-2;2;1;;; +16047-3;LL1927-4;RAST;LA6113-0;3;2;;; +16047-3;LL1927-4;RAST;LA6114-8;4;3;;; +16047-3;LL1927-4;RAST;LA6115-5;5;4;;; +16047-3;LL1927-4;RAST;LA10137-0;6;5;;; +16047-3;LL1927-4;RAST;LA10138-8;7;6;;; +16048-1;LL1927-4;RAST;LA6111-4;1;0;;; +16048-1;LL1927-4;RAST;LA6112-2;2;1;;; +16048-1;LL1927-4;RAST;LA6113-0;3;2;;; +16048-1;LL1927-4;RAST;LA6114-8;4;3;;; +16048-1;LL1927-4;RAST;LA6115-5;5;4;;; +16048-1;LL1927-4;RAST;LA10137-0;6;5;;; +16048-1;LL1927-4;RAST;LA10138-8;7;6;;; +16049-9;LL1927-4;RAST;LA6111-4;1;0;;; +16049-9;LL1927-4;RAST;LA6112-2;2;1;;; +16049-9;LL1927-4;RAST;LA6113-0;3;2;;; +16049-9;LL1927-4;RAST;LA6114-8;4;3;;; +16049-9;LL1927-4;RAST;LA6115-5;5;4;;; +16049-9;LL1927-4;RAST;LA10137-0;6;5;;; +16049-9;LL1927-4;RAST;LA10138-8;7;6;;; +16050-7;LL1927-4;RAST;LA6111-4;1;0;;; +16050-7;LL1927-4;RAST;LA6112-2;2;1;;; +16050-7;LL1927-4;RAST;LA6113-0;3;2;;; +16050-7;LL1927-4;RAST;LA6114-8;4;3;;; +16050-7;LL1927-4;RAST;LA6115-5;5;4;;; +16050-7;LL1927-4;RAST;LA10137-0;6;5;;; +16050-7;LL1927-4;RAST;LA10138-8;7;6;;; +16051-5;LL1927-4;RAST;LA6111-4;1;0;;; +16051-5;LL1927-4;RAST;LA6112-2;2;1;;; +16051-5;LL1927-4;RAST;LA6113-0;3;2;;; +16051-5;LL1927-4;RAST;LA6114-8;4;3;;; +16051-5;LL1927-4;RAST;LA6115-5;5;4;;; +16051-5;LL1927-4;RAST;LA10137-0;6;5;;; +16051-5;LL1927-4;RAST;LA10138-8;7;6;;; +16052-3;LL1927-4;RAST;LA6111-4;1;0;;; +16052-3;LL1927-4;RAST;LA6112-2;2;1;;; +16052-3;LL1927-4;RAST;LA6113-0;3;2;;; +16052-3;LL1927-4;RAST;LA6114-8;4;3;;; +16052-3;LL1927-4;RAST;LA6115-5;5;4;;; +16052-3;LL1927-4;RAST;LA10137-0;6;5;;; +16052-3;LL1927-4;RAST;LA10138-8;7;6;;; +16053-1;LL1927-4;RAST;LA6111-4;1;0;;; +16053-1;LL1927-4;RAST;LA6112-2;2;1;;; +16053-1;LL1927-4;RAST;LA6113-0;3;2;;; +16053-1;LL1927-4;RAST;LA6114-8;4;3;;; +16053-1;LL1927-4;RAST;LA6115-5;5;4;;; +16053-1;LL1927-4;RAST;LA10137-0;6;5;;; +16053-1;LL1927-4;RAST;LA10138-8;7;6;;; +16054-9;LL1927-4;RAST;LA6111-4;1;0;;; +16054-9;LL1927-4;RAST;LA6112-2;2;1;;; +16054-9;LL1927-4;RAST;LA6113-0;3;2;;; +16054-9;LL1927-4;RAST;LA6114-8;4;3;;; +16054-9;LL1927-4;RAST;LA6115-5;5;4;;; +16054-9;LL1927-4;RAST;LA10137-0;6;5;;; +16054-9;LL1927-4;RAST;LA10138-8;7;6;;; +16056-4;LL1927-4;RAST;LA6111-4;1;0;;; +16056-4;LL1927-4;RAST;LA6112-2;2;1;;; +16056-4;LL1927-4;RAST;LA6113-0;3;2;;; +16056-4;LL1927-4;RAST;LA6114-8;4;3;;; +16056-4;LL1927-4;RAST;LA6115-5;5;4;;; +16056-4;LL1927-4;RAST;LA10137-0;6;5;;; +16056-4;LL1927-4;RAST;LA10138-8;7;6;;; +16057-2;LL1927-4;RAST;LA6111-4;1;0;;; +16057-2;LL1927-4;RAST;LA6112-2;2;1;;; +16057-2;LL1927-4;RAST;LA6113-0;3;2;;; +16057-2;LL1927-4;RAST;LA6114-8;4;3;;; +16057-2;LL1927-4;RAST;LA6115-5;5;4;;; +16057-2;LL1927-4;RAST;LA10137-0;6;5;;; +16057-2;LL1927-4;RAST;LA10138-8;7;6;;; +16058-0;LL1927-4;RAST;LA6111-4;1;0;;; +16058-0;LL1927-4;RAST;LA6112-2;2;1;;; +16058-0;LL1927-4;RAST;LA6113-0;3;2;;; +16058-0;LL1927-4;RAST;LA6114-8;4;3;;; +16058-0;LL1927-4;RAST;LA6115-5;5;4;;; +16058-0;LL1927-4;RAST;LA10137-0;6;5;;; +16058-0;LL1927-4;RAST;LA10138-8;7;6;;; +16059-8;LL1927-4;RAST;LA6111-4;1;0;;; +16059-8;LL1927-4;RAST;LA6112-2;2;1;;; +16059-8;LL1927-4;RAST;LA6113-0;3;2;;; +16059-8;LL1927-4;RAST;LA6114-8;4;3;;; +16059-8;LL1927-4;RAST;LA6115-5;5;4;;; +16059-8;LL1927-4;RAST;LA10137-0;6;5;;; +16059-8;LL1927-4;RAST;LA10138-8;7;6;;; +16060-6;LL1927-4;RAST;LA6111-4;1;0;;; +16060-6;LL1927-4;RAST;LA6112-2;2;1;;; +16060-6;LL1927-4;RAST;LA6113-0;3;2;;; +16060-6;LL1927-4;RAST;LA6114-8;4;3;;; +16060-6;LL1927-4;RAST;LA6115-5;5;4;;; +16060-6;LL1927-4;RAST;LA10137-0;6;5;;; +16060-6;LL1927-4;RAST;LA10138-8;7;6;;; +16061-4;LL1927-4;RAST;LA6111-4;1;0;;; +16061-4;LL1927-4;RAST;LA6112-2;2;1;;; +16061-4;LL1927-4;RAST;LA6113-0;3;2;;; +16061-4;LL1927-4;RAST;LA6114-8;4;3;;; +16061-4;LL1927-4;RAST;LA6115-5;5;4;;; +16061-4;LL1927-4;RAST;LA10137-0;6;5;;; +16061-4;LL1927-4;RAST;LA10138-8;7;6;;; +16062-2;LL1927-4;RAST;LA6111-4;1;0;;; +16062-2;LL1927-4;RAST;LA6112-2;2;1;;; +16062-2;LL1927-4;RAST;LA6113-0;3;2;;; +16062-2;LL1927-4;RAST;LA6114-8;4;3;;; +16062-2;LL1927-4;RAST;LA6115-5;5;4;;; +16062-2;LL1927-4;RAST;LA10137-0;6;5;;; +16062-2;LL1927-4;RAST;LA10138-8;7;6;;; +16063-0;LL1927-4;RAST;LA6111-4;1;0;;; +16063-0;LL1927-4;RAST;LA6112-2;2;1;;; +16063-0;LL1927-4;RAST;LA6113-0;3;2;;; +16063-0;LL1927-4;RAST;LA6114-8;4;3;;; +16063-0;LL1927-4;RAST;LA6115-5;5;4;;; +16063-0;LL1927-4;RAST;LA10137-0;6;5;;; +16063-0;LL1927-4;RAST;LA10138-8;7;6;;; +16064-8;LL1927-4;RAST;LA6111-4;1;0;;; +16064-8;LL1927-4;RAST;LA6112-2;2;1;;; +16064-8;LL1927-4;RAST;LA6113-0;3;2;;; +16064-8;LL1927-4;RAST;LA6114-8;4;3;;; +16064-8;LL1927-4;RAST;LA6115-5;5;4;;; +16064-8;LL1927-4;RAST;LA10137-0;6;5;;; +16064-8;LL1927-4;RAST;LA10138-8;7;6;;; +16065-5;LL1927-4;RAST;LA6111-4;1;0;;; +16065-5;LL1927-4;RAST;LA6112-2;2;1;;; +16065-5;LL1927-4;RAST;LA6113-0;3;2;;; +16065-5;LL1927-4;RAST;LA6114-8;4;3;;; +16065-5;LL1927-4;RAST;LA6115-5;5;4;;; +16065-5;LL1927-4;RAST;LA10137-0;6;5;;; +16065-5;LL1927-4;RAST;LA10138-8;7;6;;; +16066-3;LL1927-4;RAST;LA6111-4;1;0;;; +16066-3;LL1927-4;RAST;LA6112-2;2;1;;; +16066-3;LL1927-4;RAST;LA6113-0;3;2;;; +16066-3;LL1927-4;RAST;LA6114-8;4;3;;; +16066-3;LL1927-4;RAST;LA6115-5;5;4;;; +16066-3;LL1927-4;RAST;LA10137-0;6;5;;; +16066-3;LL1927-4;RAST;LA10138-8;7;6;;; +16067-1;LL1927-4;RAST;LA6111-4;1;0;;; +16067-1;LL1927-4;RAST;LA6112-2;2;1;;; +16067-1;LL1927-4;RAST;LA6113-0;3;2;;; +16067-1;LL1927-4;RAST;LA6114-8;4;3;;; +16067-1;LL1927-4;RAST;LA6115-5;5;4;;; +16067-1;LL1927-4;RAST;LA10137-0;6;5;;; +16067-1;LL1927-4;RAST;LA10138-8;7;6;;; +16069-7;LL1927-4;RAST;LA6111-4;1;0;;; +16069-7;LL1927-4;RAST;LA6112-2;2;1;;; +16069-7;LL1927-4;RAST;LA6113-0;3;2;;; +16069-7;LL1927-4;RAST;LA6114-8;4;3;;; +16069-7;LL1927-4;RAST;LA6115-5;5;4;;; +16069-7;LL1927-4;RAST;LA10137-0;6;5;;; +16069-7;LL1927-4;RAST;LA10138-8;7;6;;; +16070-5;LL1927-4;RAST;LA6111-4;1;0;;; +16070-5;LL1927-4;RAST;LA6112-2;2;1;;; +16070-5;LL1927-4;RAST;LA6113-0;3;2;;; +16070-5;LL1927-4;RAST;LA6114-8;4;3;;; +16070-5;LL1927-4;RAST;LA6115-5;5;4;;; +16070-5;LL1927-4;RAST;LA10137-0;6;5;;; +16070-5;LL1927-4;RAST;LA10138-8;7;6;;; +16071-3;LL1927-4;RAST;LA6111-4;1;0;;; +16071-3;LL1927-4;RAST;LA6112-2;2;1;;; +16071-3;LL1927-4;RAST;LA6113-0;3;2;;; +16071-3;LL1927-4;RAST;LA6114-8;4;3;;; +16071-3;LL1927-4;RAST;LA6115-5;5;4;;; +16071-3;LL1927-4;RAST;LA10137-0;6;5;;; +16071-3;LL1927-4;RAST;LA10138-8;7;6;;; +16072-1;LL1927-4;RAST;LA6111-4;1;0;;; +16072-1;LL1927-4;RAST;LA6112-2;2;1;;; +16072-1;LL1927-4;RAST;LA6113-0;3;2;;; +16072-1;LL1927-4;RAST;LA6114-8;4;3;;; +16072-1;LL1927-4;RAST;LA6115-5;5;4;;; +16072-1;LL1927-4;RAST;LA10137-0;6;5;;; +16072-1;LL1927-4;RAST;LA10138-8;7;6;;; +16073-9;LL1927-4;RAST;LA6111-4;1;0;;; +16073-9;LL1927-4;RAST;LA6112-2;2;1;;; +16073-9;LL1927-4;RAST;LA6113-0;3;2;;; +16073-9;LL1927-4;RAST;LA6114-8;4;3;;; +16073-9;LL1927-4;RAST;LA6115-5;5;4;;; +16073-9;LL1927-4;RAST;LA10137-0;6;5;;; +16073-9;LL1927-4;RAST;LA10138-8;7;6;;; +16074-7;LL1927-4;RAST;LA6111-4;1;0;;; +16074-7;LL1927-4;RAST;LA6112-2;2;1;;; +16074-7;LL1927-4;RAST;LA6113-0;3;2;;; +16074-7;LL1927-4;RAST;LA6114-8;4;3;;; +16074-7;LL1927-4;RAST;LA6115-5;5;4;;; +16074-7;LL1927-4;RAST;LA10137-0;6;5;;; +16074-7;LL1927-4;RAST;LA10138-8;7;6;;; +16075-4;LL1927-4;RAST;LA6111-4;1;0;;; +16075-4;LL1927-4;RAST;LA6112-2;2;1;;; +16075-4;LL1927-4;RAST;LA6113-0;3;2;;; +16075-4;LL1927-4;RAST;LA6114-8;4;3;;; +16075-4;LL1927-4;RAST;LA6115-5;5;4;;; +16075-4;LL1927-4;RAST;LA10137-0;6;5;;; +16075-4;LL1927-4;RAST;LA10138-8;7;6;;; +16076-2;LL1927-4;RAST;LA6111-4;1;0;;; +16076-2;LL1927-4;RAST;LA6112-2;2;1;;; +16076-2;LL1927-4;RAST;LA6113-0;3;2;;; +16076-2;LL1927-4;RAST;LA6114-8;4;3;;; +16076-2;LL1927-4;RAST;LA6115-5;5;4;;; +16076-2;LL1927-4;RAST;LA10137-0;6;5;;; +16076-2;LL1927-4;RAST;LA10138-8;7;6;;; +16077-0;LL1927-4;RAST;LA6111-4;1;0;;; +16077-0;LL1927-4;RAST;LA6112-2;2;1;;; +16077-0;LL1927-4;RAST;LA6113-0;3;2;;; +16077-0;LL1927-4;RAST;LA6114-8;4;3;;; +16077-0;LL1927-4;RAST;LA6115-5;5;4;;; +16077-0;LL1927-4;RAST;LA10137-0;6;5;;; +16077-0;LL1927-4;RAST;LA10138-8;7;6;;; +16078-8;LL1927-4;RAST;LA6111-4;1;0;;; +16078-8;LL1927-4;RAST;LA6112-2;2;1;;; +16078-8;LL1927-4;RAST;LA6113-0;3;2;;; +16078-8;LL1927-4;RAST;LA6114-8;4;3;;; +16078-8;LL1927-4;RAST;LA6115-5;5;4;;; +16078-8;LL1927-4;RAST;LA10137-0;6;5;;; +16078-8;LL1927-4;RAST;LA10138-8;7;6;;; +16080-4;LL1927-4;RAST;LA6111-4;1;0;;; +16080-4;LL1927-4;RAST;LA6112-2;2;1;;; +16080-4;LL1927-4;RAST;LA6113-0;3;2;;; +16080-4;LL1927-4;RAST;LA6114-8;4;3;;; +16080-4;LL1927-4;RAST;LA6115-5;5;4;;; +16080-4;LL1927-4;RAST;LA10137-0;6;5;;; +16080-4;LL1927-4;RAST;LA10138-8;7;6;;; +16082-0;LL1927-4;RAST;LA6111-4;1;0;;; +16082-0;LL1927-4;RAST;LA6112-2;2;1;;; +16082-0;LL1927-4;RAST;LA6113-0;3;2;;; +16082-0;LL1927-4;RAST;LA6114-8;4;3;;; +16082-0;LL1927-4;RAST;LA6115-5;5;4;;; +16082-0;LL1927-4;RAST;LA10137-0;6;5;;; +16082-0;LL1927-4;RAST;LA10138-8;7;6;;; +16083-8;LL1927-4;RAST;LA6111-4;1;0;;; +16083-8;LL1927-4;RAST;LA6112-2;2;1;;; +16083-8;LL1927-4;RAST;LA6113-0;3;2;;; +16083-8;LL1927-4;RAST;LA6114-8;4;3;;; +16083-8;LL1927-4;RAST;LA6115-5;5;4;;; +16083-8;LL1927-4;RAST;LA10137-0;6;5;;; +16083-8;LL1927-4;RAST;LA10138-8;7;6;;; +16084-6;LL1927-4;RAST;LA6111-4;1;0;;; +16084-6;LL1927-4;RAST;LA6112-2;2;1;;; +16084-6;LL1927-4;RAST;LA6113-0;3;2;;; +16084-6;LL1927-4;RAST;LA6114-8;4;3;;; +16084-6;LL1927-4;RAST;LA6115-5;5;4;;; +16084-6;LL1927-4;RAST;LA10137-0;6;5;;; +16084-6;LL1927-4;RAST;LA10138-8;7;6;;; +16085-3;LL1927-4;RAST;LA6111-4;1;0;;; +16085-3;LL1927-4;RAST;LA6112-2;2;1;;; +16085-3;LL1927-4;RAST;LA6113-0;3;2;;; +16085-3;LL1927-4;RAST;LA6114-8;4;3;;; +16085-3;LL1927-4;RAST;LA6115-5;5;4;;; +16085-3;LL1927-4;RAST;LA10137-0;6;5;;; +16085-3;LL1927-4;RAST;LA10138-8;7;6;;; +16086-1;LL1927-4;RAST;LA6111-4;1;0;;; +16086-1;LL1927-4;RAST;LA6112-2;2;1;;; +16086-1;LL1927-4;RAST;LA6113-0;3;2;;; +16086-1;LL1927-4;RAST;LA6114-8;4;3;;; +16086-1;LL1927-4;RAST;LA6115-5;5;4;;; +16086-1;LL1927-4;RAST;LA10137-0;6;5;;; +16086-1;LL1927-4;RAST;LA10138-8;7;6;;; +16088-7;LL1927-4;RAST;LA6111-4;1;0;;; +16088-7;LL1927-4;RAST;LA6112-2;2;1;;; +16088-7;LL1927-4;RAST;LA6113-0;3;2;;; +16088-7;LL1927-4;RAST;LA6114-8;4;3;;; +16088-7;LL1927-4;RAST;LA6115-5;5;4;;; +16088-7;LL1927-4;RAST;LA10137-0;6;5;;; +16088-7;LL1927-4;RAST;LA10138-8;7;6;;; +16089-5;LL1927-4;RAST;LA6111-4;1;0;;; +16089-5;LL1927-4;RAST;LA6112-2;2;1;;; +16089-5;LL1927-4;RAST;LA6113-0;3;2;;; +16089-5;LL1927-4;RAST;LA6114-8;4;3;;; +16089-5;LL1927-4;RAST;LA6115-5;5;4;;; +16089-5;LL1927-4;RAST;LA10137-0;6;5;;; +16089-5;LL1927-4;RAST;LA10138-8;7;6;;; +16090-3;LL1927-4;RAST;LA6111-4;1;0;;; +16090-3;LL1927-4;RAST;LA6112-2;2;1;;; +16090-3;LL1927-4;RAST;LA6113-0;3;2;;; +16090-3;LL1927-4;RAST;LA6114-8;4;3;;; +16090-3;LL1927-4;RAST;LA6115-5;5;4;;; +16090-3;LL1927-4;RAST;LA10137-0;6;5;;; +16090-3;LL1927-4;RAST;LA10138-8;7;6;;; +16091-1;LL1927-4;RAST;LA6111-4;1;0;;; +16091-1;LL1927-4;RAST;LA6112-2;2;1;;; +16091-1;LL1927-4;RAST;LA6113-0;3;2;;; +16091-1;LL1927-4;RAST;LA6114-8;4;3;;; +16091-1;LL1927-4;RAST;LA6115-5;5;4;;; +16091-1;LL1927-4;RAST;LA10137-0;6;5;;; +16091-1;LL1927-4;RAST;LA10138-8;7;6;;; +16092-9;LL1927-4;RAST;LA6111-4;1;0;;; +16092-9;LL1927-4;RAST;LA6112-2;2;1;;; +16092-9;LL1927-4;RAST;LA6113-0;3;2;;; +16092-9;LL1927-4;RAST;LA6114-8;4;3;;; +16092-9;LL1927-4;RAST;LA6115-5;5;4;;; +16092-9;LL1927-4;RAST;LA10137-0;6;5;;; +16092-9;LL1927-4;RAST;LA10138-8;7;6;;; +16093-7;LL1927-4;RAST;LA6111-4;1;0;;; +16093-7;LL1927-4;RAST;LA6112-2;2;1;;; +16093-7;LL1927-4;RAST;LA6113-0;3;2;;; +16093-7;LL1927-4;RAST;LA6114-8;4;3;;; +16093-7;LL1927-4;RAST;LA6115-5;5;4;;; +16093-7;LL1927-4;RAST;LA10137-0;6;5;;; +16093-7;LL1927-4;RAST;LA10138-8;7;6;;; +16094-5;LL1927-4;RAST;LA6111-4;1;0;;; +16094-5;LL1927-4;RAST;LA6112-2;2;1;;; +16094-5;LL1927-4;RAST;LA6113-0;3;2;;; +16094-5;LL1927-4;RAST;LA6114-8;4;3;;; +16094-5;LL1927-4;RAST;LA6115-5;5;4;;; +16094-5;LL1927-4;RAST;LA10137-0;6;5;;; +16094-5;LL1927-4;RAST;LA10138-8;7;6;;; +16095-2;LL1927-4;RAST;LA6111-4;1;0;;; +16095-2;LL1927-4;RAST;LA6112-2;2;1;;; +16095-2;LL1927-4;RAST;LA6113-0;3;2;;; +16095-2;LL1927-4;RAST;LA6114-8;4;3;;; +16095-2;LL1927-4;RAST;LA6115-5;5;4;;; +16095-2;LL1927-4;RAST;LA10137-0;6;5;;; +16095-2;LL1927-4;RAST;LA10138-8;7;6;;; +16096-0;LL1927-4;RAST;LA6111-4;1;0;;; +16096-0;LL1927-4;RAST;LA6112-2;2;1;;; +16096-0;LL1927-4;RAST;LA6113-0;3;2;;; +16096-0;LL1927-4;RAST;LA6114-8;4;3;;; +16096-0;LL1927-4;RAST;LA6115-5;5;4;;; +16096-0;LL1927-4;RAST;LA10137-0;6;5;;; +16096-0;LL1927-4;RAST;LA10138-8;7;6;;; +16098-6;LL1927-4;RAST;LA6111-4;1;0;;; +16098-6;LL1927-4;RAST;LA6112-2;2;1;;; +16098-6;LL1927-4;RAST;LA6113-0;3;2;;; +16098-6;LL1927-4;RAST;LA6114-8;4;3;;; +16098-6;LL1927-4;RAST;LA6115-5;5;4;;; +16098-6;LL1927-4;RAST;LA10137-0;6;5;;; +16098-6;LL1927-4;RAST;LA10138-8;7;6;;; +19044-7;LL1927-4;RAST;LA6111-4;1;0;;; +19044-7;LL1927-4;RAST;LA6112-2;2;1;;; +19044-7;LL1927-4;RAST;LA6113-0;3;2;;; +19044-7;LL1927-4;RAST;LA6114-8;4;3;;; +19044-7;LL1927-4;RAST;LA6115-5;5;4;;; +19044-7;LL1927-4;RAST;LA10137-0;6;5;;; +19044-7;LL1927-4;RAST;LA10138-8;7;6;;; +19045-4;LL1927-4;RAST;LA6111-4;1;0;;; +19045-4;LL1927-4;RAST;LA6112-2;2;1;;; +19045-4;LL1927-4;RAST;LA6113-0;3;2;;; +19045-4;LL1927-4;RAST;LA6114-8;4;3;;; +19045-4;LL1927-4;RAST;LA6115-5;5;4;;; +19045-4;LL1927-4;RAST;LA10137-0;6;5;;; +19045-4;LL1927-4;RAST;LA10138-8;7;6;;; +19047-0;LL1927-4;RAST;LA6111-4;1;0;;; +19047-0;LL1927-4;RAST;LA6112-2;2;1;;; +19047-0;LL1927-4;RAST;LA6113-0;3;2;;; +19047-0;LL1927-4;RAST;LA6114-8;4;3;;; +19047-0;LL1927-4;RAST;LA6115-5;5;4;;; +19047-0;LL1927-4;RAST;LA10137-0;6;5;;; +19047-0;LL1927-4;RAST;LA10138-8;7;6;;; +21060-9;LL1927-4;RAST;LA6111-4;1;0;;; +21060-9;LL1927-4;RAST;LA6112-2;2;1;;; +21060-9;LL1927-4;RAST;LA6113-0;3;2;;; +21060-9;LL1927-4;RAST;LA6114-8;4;3;;; +21060-9;LL1927-4;RAST;LA6115-5;5;4;;; +21060-9;LL1927-4;RAST;LA10137-0;6;5;;; +21060-9;LL1927-4;RAST;LA10138-8;7;6;;; +21061-7;LL1927-4;RAST;LA6111-4;1;0;;; +21061-7;LL1927-4;RAST;LA6112-2;2;1;;; +21061-7;LL1927-4;RAST;LA6113-0;3;2;;; +21061-7;LL1927-4;RAST;LA6114-8;4;3;;; +21061-7;LL1927-4;RAST;LA6115-5;5;4;;; +21061-7;LL1927-4;RAST;LA10137-0;6;5;;; +21061-7;LL1927-4;RAST;LA10138-8;7;6;;; +21063-3;LL1927-4;RAST;LA6111-4;1;0;;; +21063-3;LL1927-4;RAST;LA6112-2;2;1;;; +21063-3;LL1927-4;RAST;LA6113-0;3;2;;; +21063-3;LL1927-4;RAST;LA6114-8;4;3;;; +21063-3;LL1927-4;RAST;LA6115-5;5;4;;; +21063-3;LL1927-4;RAST;LA10137-0;6;5;;; +21063-3;LL1927-4;RAST;LA10138-8;7;6;;; +21065-8;LL1927-4;RAST;LA6111-4;1;0;;; +21065-8;LL1927-4;RAST;LA6112-2;2;1;;; +21065-8;LL1927-4;RAST;LA6113-0;3;2;;; +21065-8;LL1927-4;RAST;LA6114-8;4;3;;; +21065-8;LL1927-4;RAST;LA6115-5;5;4;;; +21065-8;LL1927-4;RAST;LA10137-0;6;5;;; +21065-8;LL1927-4;RAST;LA10138-8;7;6;;; +21067-4;LL1927-4;RAST;LA6111-4;1;0;;; +21067-4;LL1927-4;RAST;LA6112-2;2;1;;; +21067-4;LL1927-4;RAST;LA6113-0;3;2;;; +21067-4;LL1927-4;RAST;LA6114-8;4;3;;; +21067-4;LL1927-4;RAST;LA6115-5;5;4;;; +21067-4;LL1927-4;RAST;LA10137-0;6;5;;; +21067-4;LL1927-4;RAST;LA10138-8;7;6;;; +21068-2;LL1927-4;RAST;LA6111-4;1;0;;; +21068-2;LL1927-4;RAST;LA6112-2;2;1;;; +21068-2;LL1927-4;RAST;LA6113-0;3;2;;; +21068-2;LL1927-4;RAST;LA6114-8;4;3;;; +21068-2;LL1927-4;RAST;LA6115-5;5;4;;; +21068-2;LL1927-4;RAST;LA10137-0;6;5;;; +21068-2;LL1927-4;RAST;LA10138-8;7;6;;; +21072-4;LL1927-4;RAST;LA6111-4;1;0;;; +21072-4;LL1927-4;RAST;LA6112-2;2;1;;; +21072-4;LL1927-4;RAST;LA6113-0;3;2;;; +21072-4;LL1927-4;RAST;LA6114-8;4;3;;; +21072-4;LL1927-4;RAST;LA6115-5;5;4;;; +21072-4;LL1927-4;RAST;LA10137-0;6;5;;; +21072-4;LL1927-4;RAST;LA10138-8;7;6;;; +21073-2;LL1927-4;RAST;LA6111-4;1;0;;; +21073-2;LL1927-4;RAST;LA6112-2;2;1;;; +21073-2;LL1927-4;RAST;LA6113-0;3;2;;; +21073-2;LL1927-4;RAST;LA6114-8;4;3;;; +21073-2;LL1927-4;RAST;LA6115-5;5;4;;; +21073-2;LL1927-4;RAST;LA10137-0;6;5;;; +21073-2;LL1927-4;RAST;LA10138-8;7;6;;; +21076-5;LL1927-4;RAST;LA6111-4;1;0;;; +21076-5;LL1927-4;RAST;LA6112-2;2;1;;; +21076-5;LL1927-4;RAST;LA6113-0;3;2;;; +21076-5;LL1927-4;RAST;LA6114-8;4;3;;; +21076-5;LL1927-4;RAST;LA6115-5;5;4;;; +21076-5;LL1927-4;RAST;LA10137-0;6;5;;; +21076-5;LL1927-4;RAST;LA10138-8;7;6;;; +21079-9;LL1927-4;RAST;LA6111-4;1;0;;; +21079-9;LL1927-4;RAST;LA6112-2;2;1;;; +21079-9;LL1927-4;RAST;LA6113-0;3;2;;; +21079-9;LL1927-4;RAST;LA6114-8;4;3;;; +21079-9;LL1927-4;RAST;LA6115-5;5;4;;; +21079-9;LL1927-4;RAST;LA10137-0;6;5;;; +21079-9;LL1927-4;RAST;LA10138-8;7;6;;; +21082-3;LL1927-4;RAST;LA6111-4;1;0;;; +21082-3;LL1927-4;RAST;LA6112-2;2;1;;; +21082-3;LL1927-4;RAST;LA6113-0;3;2;;; +21082-3;LL1927-4;RAST;LA6114-8;4;3;;; +21082-3;LL1927-4;RAST;LA6115-5;5;4;;; +21082-3;LL1927-4;RAST;LA10137-0;6;5;;; +21082-3;LL1927-4;RAST;LA10138-8;7;6;;; +21087-2;LL1927-4;RAST;LA6111-4;1;0;;; +21087-2;LL1927-4;RAST;LA6112-2;2;1;;; +21087-2;LL1927-4;RAST;LA6113-0;3;2;;; +21087-2;LL1927-4;RAST;LA6114-8;4;3;;; +21087-2;LL1927-4;RAST;LA6115-5;5;4;;; +21087-2;LL1927-4;RAST;LA10137-0;6;5;;; +21087-2;LL1927-4;RAST;LA10138-8;7;6;;; +21090-6;LL1927-4;RAST;LA6111-4;1;0;;; +21090-6;LL1927-4;RAST;LA6112-2;2;1;;; +21090-6;LL1927-4;RAST;LA6113-0;3;2;;; +21090-6;LL1927-4;RAST;LA6114-8;4;3;;; +21090-6;LL1927-4;RAST;LA6115-5;5;4;;; +21090-6;LL1927-4;RAST;LA10137-0;6;5;;; +21090-6;LL1927-4;RAST;LA10138-8;7;6;;; +21092-2;LL1927-4;RAST;LA6111-4;1;0;;; +21092-2;LL1927-4;RAST;LA6112-2;2;1;;; +21092-2;LL1927-4;RAST;LA6113-0;3;2;;; +21092-2;LL1927-4;RAST;LA6114-8;4;3;;; +21092-2;LL1927-4;RAST;LA6115-5;5;4;;; +21092-2;LL1927-4;RAST;LA10137-0;6;5;;; +21092-2;LL1927-4;RAST;LA10138-8;7;6;;; +21097-1;LL1927-4;RAST;LA6111-4;1;0;;; +21097-1;LL1927-4;RAST;LA6112-2;2;1;;; +21097-1;LL1927-4;RAST;LA6113-0;3;2;;; +21097-1;LL1927-4;RAST;LA6114-8;4;3;;; +21097-1;LL1927-4;RAST;LA6115-5;5;4;;; +21097-1;LL1927-4;RAST;LA10137-0;6;5;;; +21097-1;LL1927-4;RAST;LA10138-8;7;6;;; +21098-9;LL1927-4;RAST;LA6111-4;1;0;;; +21098-9;LL1927-4;RAST;LA6112-2;2;1;;; +21098-9;LL1927-4;RAST;LA6113-0;3;2;;; +21098-9;LL1927-4;RAST;LA6114-8;4;3;;; +21098-9;LL1927-4;RAST;LA6115-5;5;4;;; +21098-9;LL1927-4;RAST;LA10137-0;6;5;;; +21098-9;LL1927-4;RAST;LA10138-8;7;6;;; +21099-7;LL1927-4;RAST;LA6111-4;1;0;;; +21099-7;LL1927-4;RAST;LA6112-2;2;1;;; +21099-7;LL1927-4;RAST;LA6113-0;3;2;;; +21099-7;LL1927-4;RAST;LA6114-8;4;3;;; +21099-7;LL1927-4;RAST;LA6115-5;5;4;;; +21099-7;LL1927-4;RAST;LA10137-0;6;5;;; +21099-7;LL1927-4;RAST;LA10138-8;7;6;;; +21100-3;LL1927-4;RAST;LA6111-4;1;0;;; +21100-3;LL1927-4;RAST;LA6112-2;2;1;;; +21100-3;LL1927-4;RAST;LA6113-0;3;2;;; +21100-3;LL1927-4;RAST;LA6114-8;4;3;;; +21100-3;LL1927-4;RAST;LA6115-5;5;4;;; +21100-3;LL1927-4;RAST;LA10137-0;6;5;;; +21100-3;LL1927-4;RAST;LA10138-8;7;6;;; +21101-1;LL1927-4;RAST;LA6111-4;1;0;;; +21101-1;LL1927-4;RAST;LA6112-2;2;1;;; +21101-1;LL1927-4;RAST;LA6113-0;3;2;;; +21101-1;LL1927-4;RAST;LA6114-8;4;3;;; +21101-1;LL1927-4;RAST;LA6115-5;5;4;;; +21101-1;LL1927-4;RAST;LA10137-0;6;5;;; +21101-1;LL1927-4;RAST;LA10138-8;7;6;;; +21102-9;LL1927-4;RAST;LA6111-4;1;0;;; +21102-9;LL1927-4;RAST;LA6112-2;2;1;;; +21102-9;LL1927-4;RAST;LA6113-0;3;2;;; +21102-9;LL1927-4;RAST;LA6114-8;4;3;;; +21102-9;LL1927-4;RAST;LA6115-5;5;4;;; +21102-9;LL1927-4;RAST;LA10137-0;6;5;;; +21102-9;LL1927-4;RAST;LA10138-8;7;6;;; +21104-5;LL1927-4;RAST;LA6111-4;1;0;;; +21104-5;LL1927-4;RAST;LA6112-2;2;1;;; +21104-5;LL1927-4;RAST;LA6113-0;3;2;;; +21104-5;LL1927-4;RAST;LA6114-8;4;3;;; +21104-5;LL1927-4;RAST;LA6115-5;5;4;;; +21104-5;LL1927-4;RAST;LA10137-0;6;5;;; +21104-5;LL1927-4;RAST;LA10138-8;7;6;;; +21105-2;LL1927-4;RAST;LA6111-4;1;0;;; +21105-2;LL1927-4;RAST;LA6112-2;2;1;;; +21105-2;LL1927-4;RAST;LA6113-0;3;2;;; +21105-2;LL1927-4;RAST;LA6114-8;4;3;;; +21105-2;LL1927-4;RAST;LA6115-5;5;4;;; +21105-2;LL1927-4;RAST;LA10137-0;6;5;;; +21105-2;LL1927-4;RAST;LA10138-8;7;6;;; +21106-0;LL1927-4;RAST;LA6111-4;1;0;;; +21106-0;LL1927-4;RAST;LA6112-2;2;1;;; +21106-0;LL1927-4;RAST;LA6113-0;3;2;;; +21106-0;LL1927-4;RAST;LA6114-8;4;3;;; +21106-0;LL1927-4;RAST;LA6115-5;5;4;;; +21106-0;LL1927-4;RAST;LA10137-0;6;5;;; +21106-0;LL1927-4;RAST;LA10138-8;7;6;;; +21109-4;LL1927-4;RAST;LA6111-4;1;0;;; +21109-4;LL1927-4;RAST;LA6112-2;2;1;;; +21109-4;LL1927-4;RAST;LA6113-0;3;2;;; +21109-4;LL1927-4;RAST;LA6114-8;4;3;;; +21109-4;LL1927-4;RAST;LA6115-5;5;4;;; +21109-4;LL1927-4;RAST;LA10137-0;6;5;;; +21109-4;LL1927-4;RAST;LA10138-8;7;6;;; +21115-1;LL1927-4;RAST;LA6111-4;1;0;;; +21115-1;LL1927-4;RAST;LA6112-2;2;1;;; +21115-1;LL1927-4;RAST;LA6113-0;3;2;;; +21115-1;LL1927-4;RAST;LA6114-8;4;3;;; +21115-1;LL1927-4;RAST;LA6115-5;5;4;;; +21115-1;LL1927-4;RAST;LA10137-0;6;5;;; +21115-1;LL1927-4;RAST;LA10138-8;7;6;;; +21123-5;LL1927-4;RAST;LA6111-4;1;0;;; +21123-5;LL1927-4;RAST;LA6112-2;2;1;;; +21123-5;LL1927-4;RAST;LA6113-0;3;2;;; +21123-5;LL1927-4;RAST;LA6114-8;4;3;;; +21123-5;LL1927-4;RAST;LA6115-5;5;4;;; +21123-5;LL1927-4;RAST;LA10137-0;6;5;;; +21123-5;LL1927-4;RAST;LA10138-8;7;6;;; +21124-3;LL1927-4;RAST;LA6111-4;1;0;;; +21124-3;LL1927-4;RAST;LA6112-2;2;1;;; +21124-3;LL1927-4;RAST;LA6113-0;3;2;;; +21124-3;LL1927-4;RAST;LA6114-8;4;3;;; +21124-3;LL1927-4;RAST;LA6115-5;5;4;;; +21124-3;LL1927-4;RAST;LA10137-0;6;5;;; +21124-3;LL1927-4;RAST;LA10138-8;7;6;;; +21126-8;LL1927-4;RAST;LA6111-4;1;0;;; +21126-8;LL1927-4;RAST;LA6112-2;2;1;;; +21126-8;LL1927-4;RAST;LA6113-0;3;2;;; +21126-8;LL1927-4;RAST;LA6114-8;4;3;;; +21126-8;LL1927-4;RAST;LA6115-5;5;4;;; +21126-8;LL1927-4;RAST;LA10137-0;6;5;;; +21126-8;LL1927-4;RAST;LA10138-8;7;6;;; +21127-6;LL1927-4;RAST;LA6111-4;1;0;;; +21127-6;LL1927-4;RAST;LA6112-2;2;1;;; +21127-6;LL1927-4;RAST;LA6113-0;3;2;;; +21127-6;LL1927-4;RAST;LA6114-8;4;3;;; +21127-6;LL1927-4;RAST;LA6115-5;5;4;;; +21127-6;LL1927-4;RAST;LA10137-0;6;5;;; +21127-6;LL1927-4;RAST;LA10138-8;7;6;;; +21137-5;LL1927-4;RAST;LA6111-4;1;0;;; +21137-5;LL1927-4;RAST;LA6112-2;2;1;;; +21137-5;LL1927-4;RAST;LA6113-0;3;2;;; +21137-5;LL1927-4;RAST;LA6114-8;4;3;;; +21137-5;LL1927-4;RAST;LA6115-5;5;4;;; +21137-5;LL1927-4;RAST;LA10137-0;6;5;;; +21137-5;LL1927-4;RAST;LA10138-8;7;6;;; +21141-7;LL1927-4;RAST;LA6111-4;1;0;;; +21141-7;LL1927-4;RAST;LA6112-2;2;1;;; +21141-7;LL1927-4;RAST;LA6113-0;3;2;;; +21141-7;LL1927-4;RAST;LA6114-8;4;3;;; +21141-7;LL1927-4;RAST;LA6115-5;5;4;;; +21141-7;LL1927-4;RAST;LA10137-0;6;5;;; +21141-7;LL1927-4;RAST;LA10138-8;7;6;;; +21144-1;LL1927-4;RAST;LA6111-4;1;0;;; +21144-1;LL1927-4;RAST;LA6112-2;2;1;;; +21144-1;LL1927-4;RAST;LA6113-0;3;2;;; +21144-1;LL1927-4;RAST;LA6114-8;4;3;;; +21144-1;LL1927-4;RAST;LA6115-5;5;4;;; +21144-1;LL1927-4;RAST;LA10137-0;6;5;;; +21144-1;LL1927-4;RAST;LA10138-8;7;6;;; +21145-8;LL1927-4;RAST;LA6111-4;1;0;;; +21145-8;LL1927-4;RAST;LA6112-2;2;1;;; +21145-8;LL1927-4;RAST;LA6113-0;3;2;;; +21145-8;LL1927-4;RAST;LA6114-8;4;3;;; +21145-8;LL1927-4;RAST;LA6115-5;5;4;;; +21145-8;LL1927-4;RAST;LA10137-0;6;5;;; +21145-8;LL1927-4;RAST;LA10138-8;7;6;;; +21146-6;LL1927-4;RAST;LA6111-4;1;0;;; +21146-6;LL1927-4;RAST;LA6112-2;2;1;;; +21146-6;LL1927-4;RAST;LA6113-0;3;2;;; +21146-6;LL1927-4;RAST;LA6114-8;4;3;;; +21146-6;LL1927-4;RAST;LA6115-5;5;4;;; +21146-6;LL1927-4;RAST;LA10137-0;6;5;;; +21146-6;LL1927-4;RAST;LA10138-8;7;6;;; +21147-4;LL1927-4;RAST;LA6111-4;1;0;;; +21147-4;LL1927-4;RAST;LA6112-2;2;1;;; +21147-4;LL1927-4;RAST;LA6113-0;3;2;;; +21147-4;LL1927-4;RAST;LA6114-8;4;3;;; +21147-4;LL1927-4;RAST;LA6115-5;5;4;;; +21147-4;LL1927-4;RAST;LA10137-0;6;5;;; +21147-4;LL1927-4;RAST;LA10138-8;7;6;;; +21150-8;LL1927-4;RAST;LA6111-4;1;0;;; +21150-8;LL1927-4;RAST;LA6112-2;2;1;;; +21150-8;LL1927-4;RAST;LA6113-0;3;2;;; +21150-8;LL1927-4;RAST;LA6114-8;4;3;;; +21150-8;LL1927-4;RAST;LA6115-5;5;4;;; +21150-8;LL1927-4;RAST;LA10137-0;6;5;;; +21150-8;LL1927-4;RAST;LA10138-8;7;6;;; +21152-4;LL1927-4;RAST;LA6111-4;1;0;;; +21152-4;LL1927-4;RAST;LA6112-2;2;1;;; +21152-4;LL1927-4;RAST;LA6113-0;3;2;;; +21152-4;LL1927-4;RAST;LA6114-8;4;3;;; +21152-4;LL1927-4;RAST;LA6115-5;5;4;;; +21152-4;LL1927-4;RAST;LA10137-0;6;5;;; +21152-4;LL1927-4;RAST;LA10138-8;7;6;;; +21178-9;LL1927-4;RAST;LA6111-4;1;0;;; +21178-9;LL1927-4;RAST;LA6112-2;2;1;;; +21178-9;LL1927-4;RAST;LA6113-0;3;2;;; +21178-9;LL1927-4;RAST;LA6114-8;4;3;;; +21178-9;LL1927-4;RAST;LA6115-5;5;4;;; +21178-9;LL1927-4;RAST;LA10137-0;6;5;;; +21178-9;LL1927-4;RAST;LA10138-8;7;6;;; +21179-7;LL1927-4;RAST;LA6111-4;1;0;;; +21179-7;LL1927-4;RAST;LA6112-2;2;1;;; +21179-7;LL1927-4;RAST;LA6113-0;3;2;;; +21179-7;LL1927-4;RAST;LA6114-8;4;3;;; +21179-7;LL1927-4;RAST;LA6115-5;5;4;;; +21179-7;LL1927-4;RAST;LA10137-0;6;5;;; +21179-7;LL1927-4;RAST;LA10138-8;7;6;;; +21180-5;LL1927-4;RAST;LA6111-4;1;0;;; +21180-5;LL1927-4;RAST;LA6112-2;2;1;;; +21180-5;LL1927-4;RAST;LA6113-0;3;2;;; +21180-5;LL1927-4;RAST;LA6114-8;4;3;;; +21180-5;LL1927-4;RAST;LA6115-5;5;4;;; +21180-5;LL1927-4;RAST;LA10137-0;6;5;;; +21180-5;LL1927-4;RAST;LA10138-8;7;6;;; +21181-3;LL1927-4;RAST;LA6111-4;1;0;;; +21181-3;LL1927-4;RAST;LA6112-2;2;1;;; +21181-3;LL1927-4;RAST;LA6113-0;3;2;;; +21181-3;LL1927-4;RAST;LA6114-8;4;3;;; +21181-3;LL1927-4;RAST;LA6115-5;5;4;;; +21181-3;LL1927-4;RAST;LA10137-0;6;5;;; +21181-3;LL1927-4;RAST;LA10138-8;7;6;;; +21182-1;LL1927-4;RAST;LA6111-4;1;0;;; +21182-1;LL1927-4;RAST;LA6112-2;2;1;;; +21182-1;LL1927-4;RAST;LA6113-0;3;2;;; +21182-1;LL1927-4;RAST;LA6114-8;4;3;;; +21182-1;LL1927-4;RAST;LA6115-5;5;4;;; +21182-1;LL1927-4;RAST;LA10137-0;6;5;;; +21182-1;LL1927-4;RAST;LA10138-8;7;6;;; +21183-9;LL1927-4;RAST;LA6111-4;1;0;;; +21183-9;LL1927-4;RAST;LA6112-2;2;1;;; +21183-9;LL1927-4;RAST;LA6113-0;3;2;;; +21183-9;LL1927-4;RAST;LA6114-8;4;3;;; +21183-9;LL1927-4;RAST;LA6115-5;5;4;;; +21183-9;LL1927-4;RAST;LA10137-0;6;5;;; +21183-9;LL1927-4;RAST;LA10138-8;7;6;;; +21196-1;LL1927-4;RAST;LA6111-4;1;0;;; +21196-1;LL1927-4;RAST;LA6112-2;2;1;;; +21196-1;LL1927-4;RAST;LA6113-0;3;2;;; +21196-1;LL1927-4;RAST;LA6114-8;4;3;;; +21196-1;LL1927-4;RAST;LA6115-5;5;4;;; +21196-1;LL1927-4;RAST;LA10137-0;6;5;;; +21196-1;LL1927-4;RAST;LA10138-8;7;6;;; +21202-7;LL1927-4;RAST;LA6111-4;1;0;;; +21202-7;LL1927-4;RAST;LA6112-2;2;1;;; +21202-7;LL1927-4;RAST;LA6113-0;3;2;;; +21202-7;LL1927-4;RAST;LA6114-8;4;3;;; +21202-7;LL1927-4;RAST;LA6115-5;5;4;;; +21202-7;LL1927-4;RAST;LA10137-0;6;5;;; +21202-7;LL1927-4;RAST;LA10138-8;7;6;;; +21204-3;LL1927-4;RAST;LA6111-4;1;0;;; +21204-3;LL1927-4;RAST;LA6112-2;2;1;;; +21204-3;LL1927-4;RAST;LA6113-0;3;2;;; +21204-3;LL1927-4;RAST;LA6114-8;4;3;;; +21204-3;LL1927-4;RAST;LA6115-5;5;4;;; +21204-3;LL1927-4;RAST;LA10137-0;6;5;;; +21204-3;LL1927-4;RAST;LA10138-8;7;6;;; +21205-0;LL1927-4;RAST;LA6111-4;1;0;;; +21205-0;LL1927-4;RAST;LA6112-2;2;1;;; +21205-0;LL1927-4;RAST;LA6113-0;3;2;;; +21205-0;LL1927-4;RAST;LA6114-8;4;3;;; +21205-0;LL1927-4;RAST;LA6115-5;5;4;;; +21205-0;LL1927-4;RAST;LA10137-0;6;5;;; +21205-0;LL1927-4;RAST;LA10138-8;7;6;;; +21210-0;LL1927-4;RAST;LA6111-4;1;0;;; +21210-0;LL1927-4;RAST;LA6112-2;2;1;;; +21210-0;LL1927-4;RAST;LA6113-0;3;2;;; +21210-0;LL1927-4;RAST;LA6114-8;4;3;;; +21210-0;LL1927-4;RAST;LA6115-5;5;4;;; +21210-0;LL1927-4;RAST;LA10137-0;6;5;;; +21210-0;LL1927-4;RAST;LA10138-8;7;6;;; +21211-8;LL1927-4;RAST;LA6111-4;1;0;;; +21211-8;LL1927-4;RAST;LA6112-2;2;1;;; +21211-8;LL1927-4;RAST;LA6113-0;3;2;;; +21211-8;LL1927-4;RAST;LA6114-8;4;3;;; +21211-8;LL1927-4;RAST;LA6115-5;5;4;;; +21211-8;LL1927-4;RAST;LA10137-0;6;5;;; +21211-8;LL1927-4;RAST;LA10138-8;7;6;;; +21212-6;LL1927-4;RAST;LA6111-4;1;0;;; +21212-6;LL1927-4;RAST;LA6112-2;2;1;;; +21212-6;LL1927-4;RAST;LA6113-0;3;2;;; +21212-6;LL1927-4;RAST;LA6114-8;4;3;;; +21212-6;LL1927-4;RAST;LA6115-5;5;4;;; +21212-6;LL1927-4;RAST;LA10137-0;6;5;;; +21212-6;LL1927-4;RAST;LA10138-8;7;6;;; +21213-4;LL1927-4;RAST;LA6111-4;1;0;;; +21213-4;LL1927-4;RAST;LA6112-2;2;1;;; +21213-4;LL1927-4;RAST;LA6113-0;3;2;;; +21213-4;LL1927-4;RAST;LA6114-8;4;3;;; +21213-4;LL1927-4;RAST;LA6115-5;5;4;;; +21213-4;LL1927-4;RAST;LA10137-0;6;5;;; +21213-4;LL1927-4;RAST;LA10138-8;7;6;;; +21214-2;LL1927-4;RAST;LA6111-4;1;0;;; +21214-2;LL1927-4;RAST;LA6112-2;2;1;;; +21214-2;LL1927-4;RAST;LA6113-0;3;2;;; +21214-2;LL1927-4;RAST;LA6114-8;4;3;;; +21214-2;LL1927-4;RAST;LA6115-5;5;4;;; +21214-2;LL1927-4;RAST;LA10137-0;6;5;;; +21214-2;LL1927-4;RAST;LA10138-8;7;6;;; +21220-9;LL1927-4;RAST;LA6111-4;1;0;;; +21220-9;LL1927-4;RAST;LA6112-2;2;1;;; +21220-9;LL1927-4;RAST;LA6113-0;3;2;;; +21220-9;LL1927-4;RAST;LA6114-8;4;3;;; +21220-9;LL1927-4;RAST;LA6115-5;5;4;;; +21220-9;LL1927-4;RAST;LA10137-0;6;5;;; +21220-9;LL1927-4;RAST;LA10138-8;7;6;;; +21221-7;LL1927-4;RAST;LA6111-4;1;0;;; +21221-7;LL1927-4;RAST;LA6112-2;2;1;;; +21221-7;LL1927-4;RAST;LA6113-0;3;2;;; +21221-7;LL1927-4;RAST;LA6114-8;4;3;;; +21221-7;LL1927-4;RAST;LA6115-5;5;4;;; +21221-7;LL1927-4;RAST;LA10137-0;6;5;;; +21221-7;LL1927-4;RAST;LA10138-8;7;6;;; +21227-4;LL1927-4;RAST;LA6111-4;1;0;;; +21227-4;LL1927-4;RAST;LA6112-2;2;1;;; +21227-4;LL1927-4;RAST;LA6113-0;3;2;;; +21227-4;LL1927-4;RAST;LA6114-8;4;3;;; +21227-4;LL1927-4;RAST;LA6115-5;5;4;;; +21227-4;LL1927-4;RAST;LA10137-0;6;5;;; +21227-4;LL1927-4;RAST;LA10138-8;7;6;;; +21228-2;LL1927-4;RAST;LA6111-4;1;0;;; +21228-2;LL1927-4;RAST;LA6112-2;2;1;;; +21228-2;LL1927-4;RAST;LA6113-0;3;2;;; +21228-2;LL1927-4;RAST;LA6114-8;4;3;;; +21228-2;LL1927-4;RAST;LA6115-5;5;4;;; +21228-2;LL1927-4;RAST;LA10137-0;6;5;;; +21228-2;LL1927-4;RAST;LA10138-8;7;6;;; +21230-8;LL1927-4;RAST;LA6111-4;1;0;;; +21230-8;LL1927-4;RAST;LA6112-2;2;1;;; +21230-8;LL1927-4;RAST;LA6113-0;3;2;;; +21230-8;LL1927-4;RAST;LA6114-8;4;3;;; +21230-8;LL1927-4;RAST;LA6115-5;5;4;;; +21230-8;LL1927-4;RAST;LA10137-0;6;5;;; +21230-8;LL1927-4;RAST;LA10138-8;7;6;;; +21231-6;LL1927-4;RAST;LA6111-4;1;0;;; +21231-6;LL1927-4;RAST;LA6112-2;2;1;;; +21231-6;LL1927-4;RAST;LA6113-0;3;2;;; +21231-6;LL1927-4;RAST;LA6114-8;4;3;;; +21231-6;LL1927-4;RAST;LA6115-5;5;4;;; +21231-6;LL1927-4;RAST;LA10137-0;6;5;;; +21231-6;LL1927-4;RAST;LA10138-8;7;6;;; +21234-0;LL1927-4;RAST;LA6111-4;1;0;;; +21234-0;LL1927-4;RAST;LA6112-2;2;1;;; +21234-0;LL1927-4;RAST;LA6113-0;3;2;;; +21234-0;LL1927-4;RAST;LA6114-8;4;3;;; +21234-0;LL1927-4;RAST;LA6115-5;5;4;;; +21234-0;LL1927-4;RAST;LA10137-0;6;5;;; +21234-0;LL1927-4;RAST;LA10138-8;7;6;;; +21235-7;LL1927-4;RAST;LA6111-4;1;0;;; +21235-7;LL1927-4;RAST;LA6112-2;2;1;;; +21235-7;LL1927-4;RAST;LA6113-0;3;2;;; +21235-7;LL1927-4;RAST;LA6114-8;4;3;;; +21235-7;LL1927-4;RAST;LA6115-5;5;4;;; +21235-7;LL1927-4;RAST;LA10137-0;6;5;;; +21235-7;LL1927-4;RAST;LA10138-8;7;6;;; +21238-1;LL1927-4;RAST;LA6111-4;1;0;;; +21238-1;LL1927-4;RAST;LA6112-2;2;1;;; +21238-1;LL1927-4;RAST;LA6113-0;3;2;;; +21238-1;LL1927-4;RAST;LA6114-8;4;3;;; +21238-1;LL1927-4;RAST;LA6115-5;5;4;;; +21238-1;LL1927-4;RAST;LA10137-0;6;5;;; +21238-1;LL1927-4;RAST;LA10138-8;7;6;;; +21251-4;LL1927-4;RAST;LA6111-4;1;0;;; +21251-4;LL1927-4;RAST;LA6112-2;2;1;;; +21251-4;LL1927-4;RAST;LA6113-0;3;2;;; +21251-4;LL1927-4;RAST;LA6114-8;4;3;;; +21251-4;LL1927-4;RAST;LA6115-5;5;4;;; +21251-4;LL1927-4;RAST;LA10137-0;6;5;;; +21251-4;LL1927-4;RAST;LA10138-8;7;6;;; +21253-0;LL1927-4;RAST;LA6111-4;1;0;;; +21253-0;LL1927-4;RAST;LA6112-2;2;1;;; +21253-0;LL1927-4;RAST;LA6113-0;3;2;;; +21253-0;LL1927-4;RAST;LA6114-8;4;3;;; +21253-0;LL1927-4;RAST;LA6115-5;5;4;;; +21253-0;LL1927-4;RAST;LA10137-0;6;5;;; +21253-0;LL1927-4;RAST;LA10138-8;7;6;;; +21254-8;LL1927-4;RAST;LA6111-4;1;0;;; +21254-8;LL1927-4;RAST;LA6112-2;2;1;;; +21254-8;LL1927-4;RAST;LA6113-0;3;2;;; +21254-8;LL1927-4;RAST;LA6114-8;4;3;;; +21254-8;LL1927-4;RAST;LA6115-5;5;4;;; +21254-8;LL1927-4;RAST;LA10137-0;6;5;;; +21254-8;LL1927-4;RAST;LA10138-8;7;6;;; +21255-5;LL1927-4;RAST;LA6111-4;1;0;;; +21255-5;LL1927-4;RAST;LA6112-2;2;1;;; +21255-5;LL1927-4;RAST;LA6113-0;3;2;;; +21255-5;LL1927-4;RAST;LA6114-8;4;3;;; +21255-5;LL1927-4;RAST;LA6115-5;5;4;;; +21255-5;LL1927-4;RAST;LA10137-0;6;5;;; +21255-5;LL1927-4;RAST;LA10138-8;7;6;;; +21258-9;LL1927-4;RAST;LA6111-4;1;0;;; +21258-9;LL1927-4;RAST;LA6112-2;2;1;;; +21258-9;LL1927-4;RAST;LA6113-0;3;2;;; +21258-9;LL1927-4;RAST;LA6114-8;4;3;;; +21258-9;LL1927-4;RAST;LA6115-5;5;4;;; +21258-9;LL1927-4;RAST;LA10137-0;6;5;;; +21258-9;LL1927-4;RAST;LA10138-8;7;6;;; +21261-3;LL1927-4;RAST;LA6111-4;1;0;;; +21261-3;LL1927-4;RAST;LA6112-2;2;1;;; +21261-3;LL1927-4;RAST;LA6113-0;3;2;;; +21261-3;LL1927-4;RAST;LA6114-8;4;3;;; +21261-3;LL1927-4;RAST;LA6115-5;5;4;;; +21261-3;LL1927-4;RAST;LA10137-0;6;5;;; +21261-3;LL1927-4;RAST;LA10138-8;7;6;;; +21270-4;LL1927-4;RAST;LA6111-4;1;0;;; +21270-4;LL1927-4;RAST;LA6112-2;2;1;;; +21270-4;LL1927-4;RAST;LA6113-0;3;2;;; +21270-4;LL1927-4;RAST;LA6114-8;4;3;;; +21270-4;LL1927-4;RAST;LA6115-5;5;4;;; +21270-4;LL1927-4;RAST;LA10137-0;6;5;;; +21270-4;LL1927-4;RAST;LA10138-8;7;6;;; +21272-0;LL1927-4;RAST;LA6111-4;1;0;;; +21272-0;LL1927-4;RAST;LA6112-2;2;1;;; +21272-0;LL1927-4;RAST;LA6113-0;3;2;;; +21272-0;LL1927-4;RAST;LA6114-8;4;3;;; +21272-0;LL1927-4;RAST;LA6115-5;5;4;;; +21272-0;LL1927-4;RAST;LA10137-0;6;5;;; +21272-0;LL1927-4;RAST;LA10138-8;7;6;;; +21273-8;LL1927-4;RAST;LA6111-4;1;0;;; +21273-8;LL1927-4;RAST;LA6112-2;2;1;;; +21273-8;LL1927-4;RAST;LA6113-0;3;2;;; +21273-8;LL1927-4;RAST;LA6114-8;4;3;;; +21273-8;LL1927-4;RAST;LA6115-5;5;4;;; +21273-8;LL1927-4;RAST;LA10137-0;6;5;;; +21273-8;LL1927-4;RAST;LA10138-8;7;6;;; +21274-6;LL1927-4;RAST;LA6111-4;1;0;;; +21274-6;LL1927-4;RAST;LA6112-2;2;1;;; +21274-6;LL1927-4;RAST;LA6113-0;3;2;;; +21274-6;LL1927-4;RAST;LA6114-8;4;3;;; +21274-6;LL1927-4;RAST;LA6115-5;5;4;;; +21274-6;LL1927-4;RAST;LA10137-0;6;5;;; +21274-6;LL1927-4;RAST;LA10138-8;7;6;;; +21281-1;LL1927-4;RAST;LA6111-4;1;0;;; +21281-1;LL1927-4;RAST;LA6112-2;2;1;;; +21281-1;LL1927-4;RAST;LA6113-0;3;2;;; +21281-1;LL1927-4;RAST;LA6114-8;4;3;;; +21281-1;LL1927-4;RAST;LA6115-5;5;4;;; +21281-1;LL1927-4;RAST;LA10137-0;6;5;;; +21281-1;LL1927-4;RAST;LA10138-8;7;6;;; +21285-2;LL1927-4;RAST;LA6111-4;1;0;;; +21285-2;LL1927-4;RAST;LA6112-2;2;1;;; +21285-2;LL1927-4;RAST;LA6113-0;3;2;;; +21285-2;LL1927-4;RAST;LA6114-8;4;3;;; +21285-2;LL1927-4;RAST;LA6115-5;5;4;;; +21285-2;LL1927-4;RAST;LA10137-0;6;5;;; +21285-2;LL1927-4;RAST;LA10138-8;7;6;;; +21297-7;LL1927-4;RAST;LA6111-4;1;0;;; +21297-7;LL1927-4;RAST;LA6112-2;2;1;;; +21297-7;LL1927-4;RAST;LA6113-0;3;2;;; +21297-7;LL1927-4;RAST;LA6114-8;4;3;;; +21297-7;LL1927-4;RAST;LA6115-5;5;4;;; +21297-7;LL1927-4;RAST;LA10137-0;6;5;;; +21297-7;LL1927-4;RAST;LA10138-8;7;6;;; +21298-5;LL1927-4;RAST;LA6111-4;1;0;;; +21298-5;LL1927-4;RAST;LA6112-2;2;1;;; +21298-5;LL1927-4;RAST;LA6113-0;3;2;;; +21298-5;LL1927-4;RAST;LA6114-8;4;3;;; +21298-5;LL1927-4;RAST;LA6115-5;5;4;;; +21298-5;LL1927-4;RAST;LA10137-0;6;5;;; +21298-5;LL1927-4;RAST;LA10138-8;7;6;;; +21304-1;LL1927-4;RAST;LA6111-4;1;0;;; +21304-1;LL1927-4;RAST;LA6112-2;2;1;;; +21304-1;LL1927-4;RAST;LA6113-0;3;2;;; +21304-1;LL1927-4;RAST;LA6114-8;4;3;;; +21304-1;LL1927-4;RAST;LA6115-5;5;4;;; +21304-1;LL1927-4;RAST;LA10137-0;6;5;;; +21304-1;LL1927-4;RAST;LA10138-8;7;6;;; +21311-6;LL1927-4;RAST;LA6111-4;1;0;;; +21311-6;LL1927-4;RAST;LA6112-2;2;1;;; +21311-6;LL1927-4;RAST;LA6113-0;3;2;;; +21311-6;LL1927-4;RAST;LA6114-8;4;3;;; +21311-6;LL1927-4;RAST;LA6115-5;5;4;;; +21311-6;LL1927-4;RAST;LA10137-0;6;5;;; +21311-6;LL1927-4;RAST;LA10138-8;7;6;;; +21313-2;LL1927-4;RAST;LA6111-4;1;0;;; +21313-2;LL1927-4;RAST;LA6112-2;2;1;;; +21313-2;LL1927-4;RAST;LA6113-0;3;2;;; +21313-2;LL1927-4;RAST;LA6114-8;4;3;;; +21313-2;LL1927-4;RAST;LA6115-5;5;4;;; +21313-2;LL1927-4;RAST;LA10137-0;6;5;;; +21313-2;LL1927-4;RAST;LA10138-8;7;6;;; +21314-0;LL1927-4;RAST;LA6111-4;1;0;;; +21314-0;LL1927-4;RAST;LA6112-2;2;1;;; +21314-0;LL1927-4;RAST;LA6113-0;3;2;;; +21314-0;LL1927-4;RAST;LA6114-8;4;3;;; +21314-0;LL1927-4;RAST;LA6115-5;5;4;;; +21314-0;LL1927-4;RAST;LA10137-0;6;5;;; +21314-0;LL1927-4;RAST;LA10138-8;7;6;;; +21315-7;LL1927-4;RAST;LA6111-4;1;0;;; +21315-7;LL1927-4;RAST;LA6112-2;2;1;;; +21315-7;LL1927-4;RAST;LA6113-0;3;2;;; +21315-7;LL1927-4;RAST;LA6114-8;4;3;;; +21315-7;LL1927-4;RAST;LA6115-5;5;4;;; +21315-7;LL1927-4;RAST;LA10137-0;6;5;;; +21315-7;LL1927-4;RAST;LA10138-8;7;6;;; +21319-9;LL1927-4;RAST;LA6111-4;1;0;;; +21319-9;LL1927-4;RAST;LA6112-2;2;1;;; +21319-9;LL1927-4;RAST;LA6113-0;3;2;;; +21319-9;LL1927-4;RAST;LA6114-8;4;3;;; +21319-9;LL1927-4;RAST;LA6115-5;5;4;;; +21319-9;LL1927-4;RAST;LA10137-0;6;5;;; +21319-9;LL1927-4;RAST;LA10138-8;7;6;;; +21321-5;LL1927-4;RAST;LA6111-4;1;0;;; +21321-5;LL1927-4;RAST;LA6112-2;2;1;;; +21321-5;LL1927-4;RAST;LA6113-0;3;2;;; +21321-5;LL1927-4;RAST;LA6114-8;4;3;;; +21321-5;LL1927-4;RAST;LA6115-5;5;4;;; +21321-5;LL1927-4;RAST;LA10137-0;6;5;;; +21321-5;LL1927-4;RAST;LA10138-8;7;6;;; +21324-9;LL1927-4;RAST;LA6111-4;1;0;;; +21324-9;LL1927-4;RAST;LA6112-2;2;1;;; +21324-9;LL1927-4;RAST;LA6113-0;3;2;;; +21324-9;LL1927-4;RAST;LA6114-8;4;3;;; +21324-9;LL1927-4;RAST;LA6115-5;5;4;;; +21324-9;LL1927-4;RAST;LA10137-0;6;5;;; +21324-9;LL1927-4;RAST;LA10138-8;7;6;;; +21329-8;LL1927-4;RAST;LA6111-4;1;0;;; +21329-8;LL1927-4;RAST;LA6112-2;2;1;;; +21329-8;LL1927-4;RAST;LA6113-0;3;2;;; +21329-8;LL1927-4;RAST;LA6114-8;4;3;;; +21329-8;LL1927-4;RAST;LA6115-5;5;4;;; +21329-8;LL1927-4;RAST;LA10137-0;6;5;;; +21329-8;LL1927-4;RAST;LA10138-8;7;6;;; +21344-7;LL1927-4;RAST;LA6111-4;1;0;;; +21344-7;LL1927-4;RAST;LA6112-2;2;1;;; +21344-7;LL1927-4;RAST;LA6113-0;3;2;;; +21344-7;LL1927-4;RAST;LA6114-8;4;3;;; +21344-7;LL1927-4;RAST;LA6115-5;5;4;;; +21344-7;LL1927-4;RAST;LA10137-0;6;5;;; +21344-7;LL1927-4;RAST;LA10138-8;7;6;;; +21353-8;LL1927-4;RAST;LA6111-4;1;0;;; +21353-8;LL1927-4;RAST;LA6112-2;2;1;;; +21353-8;LL1927-4;RAST;LA6113-0;3;2;;; +21353-8;LL1927-4;RAST;LA6114-8;4;3;;; +21353-8;LL1927-4;RAST;LA6115-5;5;4;;; +21353-8;LL1927-4;RAST;LA10137-0;6;5;;; +21353-8;LL1927-4;RAST;LA10138-8;7;6;;; +21354-6;LL1927-4;RAST;LA6111-4;1;0;;; +21354-6;LL1927-4;RAST;LA6112-2;2;1;;; +21354-6;LL1927-4;RAST;LA6113-0;3;2;;; +21354-6;LL1927-4;RAST;LA6114-8;4;3;;; +21354-6;LL1927-4;RAST;LA6115-5;5;4;;; +21354-6;LL1927-4;RAST;LA10137-0;6;5;;; +21354-6;LL1927-4;RAST;LA10138-8;7;6;;; +21358-7;LL1927-4;RAST;LA6111-4;1;0;;; +21358-7;LL1927-4;RAST;LA6112-2;2;1;;; +21358-7;LL1927-4;RAST;LA6113-0;3;2;;; +21358-7;LL1927-4;RAST;LA6114-8;4;3;;; +21358-7;LL1927-4;RAST;LA6115-5;5;4;;; +21358-7;LL1927-4;RAST;LA10137-0;6;5;;; +21358-7;LL1927-4;RAST;LA10138-8;7;6;;; +21359-5;LL1927-4;RAST;LA6111-4;1;0;;; +21359-5;LL1927-4;RAST;LA6112-2;2;1;;; +21359-5;LL1927-4;RAST;LA6113-0;3;2;;; +21359-5;LL1927-4;RAST;LA6114-8;4;3;;; +21359-5;LL1927-4;RAST;LA6115-5;5;4;;; +21359-5;LL1927-4;RAST;LA10137-0;6;5;;; +21359-5;LL1927-4;RAST;LA10138-8;7;6;;; +21360-3;LL1927-4;RAST;LA6111-4;1;0;;; +21360-3;LL1927-4;RAST;LA6112-2;2;1;;; +21360-3;LL1927-4;RAST;LA6113-0;3;2;;; +21360-3;LL1927-4;RAST;LA6114-8;4;3;;; +21360-3;LL1927-4;RAST;LA6115-5;5;4;;; +21360-3;LL1927-4;RAST;LA10137-0;6;5;;; +21360-3;LL1927-4;RAST;LA10138-8;7;6;;; +21364-5;LL1927-4;RAST;LA6111-4;1;0;;; +21364-5;LL1927-4;RAST;LA6112-2;2;1;;; +21364-5;LL1927-4;RAST;LA6113-0;3;2;;; +21364-5;LL1927-4;RAST;LA6114-8;4;3;;; +21364-5;LL1927-4;RAST;LA6115-5;5;4;;; +21364-5;LL1927-4;RAST;LA10137-0;6;5;;; +21364-5;LL1927-4;RAST;LA10138-8;7;6;;; +21366-0;LL1927-4;RAST;LA6111-4;1;0;;; +21366-0;LL1927-4;RAST;LA6112-2;2;1;;; +21366-0;LL1927-4;RAST;LA6113-0;3;2;;; +21366-0;LL1927-4;RAST;LA6114-8;4;3;;; +21366-0;LL1927-4;RAST;LA6115-5;5;4;;; +21366-0;LL1927-4;RAST;LA10137-0;6;5;;; +21366-0;LL1927-4;RAST;LA10138-8;7;6;;; +21369-4;LL1927-4;RAST;LA6111-4;1;0;;; +21369-4;LL1927-4;RAST;LA6112-2;2;1;;; +21369-4;LL1927-4;RAST;LA6113-0;3;2;;; +21369-4;LL1927-4;RAST;LA6114-8;4;3;;; +21369-4;LL1927-4;RAST;LA6115-5;5;4;;; +21369-4;LL1927-4;RAST;LA10137-0;6;5;;; +21369-4;LL1927-4;RAST;LA10138-8;7;6;;; +21370-2;LL1927-4;RAST;LA6111-4;1;0;;; +21370-2;LL1927-4;RAST;LA6112-2;2;1;;; +21370-2;LL1927-4;RAST;LA6113-0;3;2;;; +21370-2;LL1927-4;RAST;LA6114-8;4;3;;; +21370-2;LL1927-4;RAST;LA6115-5;5;4;;; +21370-2;LL1927-4;RAST;LA10137-0;6;5;;; +21370-2;LL1927-4;RAST;LA10138-8;7;6;;; +21371-0;LL1927-4;RAST;LA6111-4;1;0;;; +21371-0;LL1927-4;RAST;LA6112-2;2;1;;; +21371-0;LL1927-4;RAST;LA6113-0;3;2;;; +21371-0;LL1927-4;RAST;LA6114-8;4;3;;; +21371-0;LL1927-4;RAST;LA6115-5;5;4;;; +21371-0;LL1927-4;RAST;LA10137-0;6;5;;; +21371-0;LL1927-4;RAST;LA10138-8;7;6;;; +21376-9;LL1927-4;RAST;LA6111-4;1;0;;; +21376-9;LL1927-4;RAST;LA6112-2;2;1;;; +21376-9;LL1927-4;RAST;LA6113-0;3;2;;; +21376-9;LL1927-4;RAST;LA6114-8;4;3;;; +21376-9;LL1927-4;RAST;LA6115-5;5;4;;; +21376-9;LL1927-4;RAST;LA10137-0;6;5;;; +21376-9;LL1927-4;RAST;LA10138-8;7;6;;; +21379-3;LL1927-4;RAST;LA6111-4;1;0;;; +21379-3;LL1927-4;RAST;LA6112-2;2;1;;; +21379-3;LL1927-4;RAST;LA6113-0;3;2;;; +21379-3;LL1927-4;RAST;LA6114-8;4;3;;; +21379-3;LL1927-4;RAST;LA6115-5;5;4;;; +21379-3;LL1927-4;RAST;LA10137-0;6;5;;; +21379-3;LL1927-4;RAST;LA10138-8;7;6;;; +21390-0;LL1927-4;RAST;LA6111-4;1;0;;; +21390-0;LL1927-4;RAST;LA6112-2;2;1;;; +21390-0;LL1927-4;RAST;LA6113-0;3;2;;; +21390-0;LL1927-4;RAST;LA6114-8;4;3;;; +21390-0;LL1927-4;RAST;LA6115-5;5;4;;; +21390-0;LL1927-4;RAST;LA10137-0;6;5;;; +21390-0;LL1927-4;RAST;LA10138-8;7;6;;; +21393-4;LL1927-4;RAST;LA6111-4;1;0;;; +21393-4;LL1927-4;RAST;LA6112-2;2;1;;; +21393-4;LL1927-4;RAST;LA6113-0;3;2;;; +21393-4;LL1927-4;RAST;LA6114-8;4;3;;; +21393-4;LL1927-4;RAST;LA6115-5;5;4;;; +21393-4;LL1927-4;RAST;LA10137-0;6;5;;; +21393-4;LL1927-4;RAST;LA10138-8;7;6;;; +21399-1;LL1927-4;RAST;LA6111-4;1;0;;; +21399-1;LL1927-4;RAST;LA6112-2;2;1;;; +21399-1;LL1927-4;RAST;LA6113-0;3;2;;; +21399-1;LL1927-4;RAST;LA6114-8;4;3;;; +21399-1;LL1927-4;RAST;LA6115-5;5;4;;; +21399-1;LL1927-4;RAST;LA10137-0;6;5;;; +21399-1;LL1927-4;RAST;LA10138-8;7;6;;; +21400-7;LL1927-4;RAST;LA6111-4;1;0;;; +21400-7;LL1927-4;RAST;LA6112-2;2;1;;; +21400-7;LL1927-4;RAST;LA6113-0;3;2;;; +21400-7;LL1927-4;RAST;LA6114-8;4;3;;; +21400-7;LL1927-4;RAST;LA6115-5;5;4;;; +21400-7;LL1927-4;RAST;LA10137-0;6;5;;; +21400-7;LL1927-4;RAST;LA10138-8;7;6;;; +21403-1;LL1927-4;RAST;LA6111-4;1;0;;; +21403-1;LL1927-4;RAST;LA6112-2;2;1;;; +21403-1;LL1927-4;RAST;LA6113-0;3;2;;; +21403-1;LL1927-4;RAST;LA6114-8;4;3;;; +21403-1;LL1927-4;RAST;LA6115-5;5;4;;; +21403-1;LL1927-4;RAST;LA10137-0;6;5;;; +21403-1;LL1927-4;RAST;LA10138-8;7;6;;; +21404-9;LL1927-4;RAST;LA6111-4;1;0;;; +21404-9;LL1927-4;RAST;LA6112-2;2;1;;; +21404-9;LL1927-4;RAST;LA6113-0;3;2;;; +21404-9;LL1927-4;RAST;LA6114-8;4;3;;; +21404-9;LL1927-4;RAST;LA6115-5;5;4;;; +21404-9;LL1927-4;RAST;LA10137-0;6;5;;; +21404-9;LL1927-4;RAST;LA10138-8;7;6;;; +21425-4;LL1927-4;RAST;LA6111-4;1;0;;; +21425-4;LL1927-4;RAST;LA6112-2;2;1;;; +21425-4;LL1927-4;RAST;LA6113-0;3;2;;; +21425-4;LL1927-4;RAST;LA6114-8;4;3;;; +21425-4;LL1927-4;RAST;LA6115-5;5;4;;; +21425-4;LL1927-4;RAST;LA10137-0;6;5;;; +21425-4;LL1927-4;RAST;LA10138-8;7;6;;; +21426-2;LL1927-4;RAST;LA6111-4;1;0;;; +21426-2;LL1927-4;RAST;LA6112-2;2;1;;; +21426-2;LL1927-4;RAST;LA6113-0;3;2;;; +21426-2;LL1927-4;RAST;LA6114-8;4;3;;; +21426-2;LL1927-4;RAST;LA6115-5;5;4;;; +21426-2;LL1927-4;RAST;LA10137-0;6;5;;; +21426-2;LL1927-4;RAST;LA10138-8;7;6;;; +21429-6;LL1927-4;RAST;LA6111-4;1;0;;; +21429-6;LL1927-4;RAST;LA6112-2;2;1;;; +21429-6;LL1927-4;RAST;LA6113-0;3;2;;; +21429-6;LL1927-4;RAST;LA6114-8;4;3;;; +21429-6;LL1927-4;RAST;LA6115-5;5;4;;; +21429-6;LL1927-4;RAST;LA10137-0;6;5;;; +21429-6;LL1927-4;RAST;LA10138-8;7;6;;; +21430-4;LL1927-4;RAST;LA6111-4;1;0;;; +21430-4;LL1927-4;RAST;LA6112-2;2;1;;; +21430-4;LL1927-4;RAST;LA6113-0;3;2;;; +21430-4;LL1927-4;RAST;LA6114-8;4;3;;; +21430-4;LL1927-4;RAST;LA6115-5;5;4;;; +21430-4;LL1927-4;RAST;LA10137-0;6;5;;; +21430-4;LL1927-4;RAST;LA10138-8;7;6;;; +21432-0;LL1927-4;RAST;LA6111-4;1;0;;; +21432-0;LL1927-4;RAST;LA6112-2;2;1;;; +21432-0;LL1927-4;RAST;LA6113-0;3;2;;; +21432-0;LL1927-4;RAST;LA6114-8;4;3;;; +21432-0;LL1927-4;RAST;LA6115-5;5;4;;; +21432-0;LL1927-4;RAST;LA10137-0;6;5;;; +21432-0;LL1927-4;RAST;LA10138-8;7;6;;; +21433-8;LL1927-4;RAST;LA6111-4;1;0;;; +21433-8;LL1927-4;RAST;LA6112-2;2;1;;; +21433-8;LL1927-4;RAST;LA6113-0;3;2;;; +21433-8;LL1927-4;RAST;LA6114-8;4;3;;; +21433-8;LL1927-4;RAST;LA6115-5;5;4;;; +21433-8;LL1927-4;RAST;LA10137-0;6;5;;; +21433-8;LL1927-4;RAST;LA10138-8;7;6;;; +21434-6;LL1927-4;RAST;LA6111-4;1;0;;; +21434-6;LL1927-4;RAST;LA6112-2;2;1;;; +21434-6;LL1927-4;RAST;LA6113-0;3;2;;; +21434-6;LL1927-4;RAST;LA6114-8;4;3;;; +21434-6;LL1927-4;RAST;LA6115-5;5;4;;; +21434-6;LL1927-4;RAST;LA10137-0;6;5;;; +21434-6;LL1927-4;RAST;LA10138-8;7;6;;; +21438-7;LL1927-4;RAST;LA6111-4;1;0;;; +21438-7;LL1927-4;RAST;LA6112-2;2;1;;; +21438-7;LL1927-4;RAST;LA6113-0;3;2;;; +21438-7;LL1927-4;RAST;LA6114-8;4;3;;; +21438-7;LL1927-4;RAST;LA6115-5;5;4;;; +21438-7;LL1927-4;RAST;LA10137-0;6;5;;; +21438-7;LL1927-4;RAST;LA10138-8;7;6;;; +21439-5;LL1927-4;RAST;LA6111-4;1;0;;; +21439-5;LL1927-4;RAST;LA6112-2;2;1;;; +21439-5;LL1927-4;RAST;LA6113-0;3;2;;; +21439-5;LL1927-4;RAST;LA6114-8;4;3;;; +21439-5;LL1927-4;RAST;LA6115-5;5;4;;; +21439-5;LL1927-4;RAST;LA10137-0;6;5;;; +21439-5;LL1927-4;RAST;LA10138-8;7;6;;; +21444-5;LL1927-4;RAST;LA6111-4;1;0;;; +21444-5;LL1927-4;RAST;LA6112-2;2;1;;; +21444-5;LL1927-4;RAST;LA6113-0;3;2;;; +21444-5;LL1927-4;RAST;LA6114-8;4;3;;; +21444-5;LL1927-4;RAST;LA6115-5;5;4;;; +21444-5;LL1927-4;RAST;LA10137-0;6;5;;; +21444-5;LL1927-4;RAST;LA10138-8;7;6;;; +21445-2;LL1927-4;RAST;LA6111-4;1;0;;; +21445-2;LL1927-4;RAST;LA6112-2;2;1;;; +21445-2;LL1927-4;RAST;LA6113-0;3;2;;; +21445-2;LL1927-4;RAST;LA6114-8;4;3;;; +21445-2;LL1927-4;RAST;LA6115-5;5;4;;; +21445-2;LL1927-4;RAST;LA10137-0;6;5;;; +21445-2;LL1927-4;RAST;LA10138-8;7;6;;; +21446-0;LL1927-4;RAST;LA6111-4;1;0;;; +21446-0;LL1927-4;RAST;LA6112-2;2;1;;; +21446-0;LL1927-4;RAST;LA6113-0;3;2;;; +21446-0;LL1927-4;RAST;LA6114-8;4;3;;; +21446-0;LL1927-4;RAST;LA6115-5;5;4;;; +21446-0;LL1927-4;RAST;LA10137-0;6;5;;; +21446-0;LL1927-4;RAST;LA10138-8;7;6;;; +21447-8;LL1927-4;RAST;LA6111-4;1;0;;; +21447-8;LL1927-4;RAST;LA6112-2;2;1;;; +21447-8;LL1927-4;RAST;LA6113-0;3;2;;; +21447-8;LL1927-4;RAST;LA6114-8;4;3;;; +21447-8;LL1927-4;RAST;LA6115-5;5;4;;; +21447-8;LL1927-4;RAST;LA10137-0;6;5;;; +21447-8;LL1927-4;RAST;LA10138-8;7;6;;; +21448-6;LL1927-4;RAST;LA6111-4;1;0;;; +21448-6;LL1927-4;RAST;LA6112-2;2;1;;; +21448-6;LL1927-4;RAST;LA6113-0;3;2;;; +21448-6;LL1927-4;RAST;LA6114-8;4;3;;; +21448-6;LL1927-4;RAST;LA6115-5;5;4;;; +21448-6;LL1927-4;RAST;LA10137-0;6;5;;; +21448-6;LL1927-4;RAST;LA10138-8;7;6;;; +21449-4;LL1927-4;RAST;LA6111-4;1;0;;; +21449-4;LL1927-4;RAST;LA6112-2;2;1;;; +21449-4;LL1927-4;RAST;LA6113-0;3;2;;; +21449-4;LL1927-4;RAST;LA6114-8;4;3;;; +21449-4;LL1927-4;RAST;LA6115-5;5;4;;; +21449-4;LL1927-4;RAST;LA10137-0;6;5;;; +21449-4;LL1927-4;RAST;LA10138-8;7;6;;; +21450-2;LL1927-4;RAST;LA6111-4;1;0;;; +21450-2;LL1927-4;RAST;LA6112-2;2;1;;; +21450-2;LL1927-4;RAST;LA6113-0;3;2;;; +21450-2;LL1927-4;RAST;LA6114-8;4;3;;; +21450-2;LL1927-4;RAST;LA6115-5;5;4;;; +21450-2;LL1927-4;RAST;LA10137-0;6;5;;; +21450-2;LL1927-4;RAST;LA10138-8;7;6;;; +21451-0;LL1927-4;RAST;LA6111-4;1;0;;; +21451-0;LL1927-4;RAST;LA6112-2;2;1;;; +21451-0;LL1927-4;RAST;LA6113-0;3;2;;; +21451-0;LL1927-4;RAST;LA6114-8;4;3;;; +21451-0;LL1927-4;RAST;LA6115-5;5;4;;; +21451-0;LL1927-4;RAST;LA10137-0;6;5;;; +21451-0;LL1927-4;RAST;LA10138-8;7;6;;; +21452-8;LL1927-4;RAST;LA6111-4;1;0;;; +21452-8;LL1927-4;RAST;LA6112-2;2;1;;; +21452-8;LL1927-4;RAST;LA6113-0;3;2;;; +21452-8;LL1927-4;RAST;LA6114-8;4;3;;; +21452-8;LL1927-4;RAST;LA6115-5;5;4;;; +21452-8;LL1927-4;RAST;LA10137-0;6;5;;; +21452-8;LL1927-4;RAST;LA10138-8;7;6;;; +21453-6;LL1927-4;RAST;LA6111-4;1;0;;; +21453-6;LL1927-4;RAST;LA6112-2;2;1;;; +21453-6;LL1927-4;RAST;LA6113-0;3;2;;; +21453-6;LL1927-4;RAST;LA6114-8;4;3;;; +21453-6;LL1927-4;RAST;LA6115-5;5;4;;; +21453-6;LL1927-4;RAST;LA10137-0;6;5;;; +21453-6;LL1927-4;RAST;LA10138-8;7;6;;; +21454-4;LL1927-4;RAST;LA6111-4;1;0;;; +21454-4;LL1927-4;RAST;LA6112-2;2;1;;; +21454-4;LL1927-4;RAST;LA6113-0;3;2;;; +21454-4;LL1927-4;RAST;LA6114-8;4;3;;; +21454-4;LL1927-4;RAST;LA6115-5;5;4;;; +21454-4;LL1927-4;RAST;LA10137-0;6;5;;; +21454-4;LL1927-4;RAST;LA10138-8;7;6;;; +21456-9;LL1927-4;RAST;LA6111-4;1;0;;; +21456-9;LL1927-4;RAST;LA6112-2;2;1;;; +21456-9;LL1927-4;RAST;LA6113-0;3;2;;; +21456-9;LL1927-4;RAST;LA6114-8;4;3;;; +21456-9;LL1927-4;RAST;LA6115-5;5;4;;; +21456-9;LL1927-4;RAST;LA10137-0;6;5;;; +21456-9;LL1927-4;RAST;LA10138-8;7;6;;; +21459-3;LL1927-4;RAST;LA6111-4;1;0;;; +21459-3;LL1927-4;RAST;LA6112-2;2;1;;; +21459-3;LL1927-4;RAST;LA6113-0;3;2;;; +21459-3;LL1927-4;RAST;LA6114-8;4;3;;; +21459-3;LL1927-4;RAST;LA6115-5;5;4;;; +21459-3;LL1927-4;RAST;LA10137-0;6;5;;; +21459-3;LL1927-4;RAST;LA10138-8;7;6;;; +21460-1;LL1927-4;RAST;LA6111-4;1;0;;; +21460-1;LL1927-4;RAST;LA6112-2;2;1;;; +21460-1;LL1927-4;RAST;LA6113-0;3;2;;; +21460-1;LL1927-4;RAST;LA6114-8;4;3;;; +21460-1;LL1927-4;RAST;LA6115-5;5;4;;; +21460-1;LL1927-4;RAST;LA10137-0;6;5;;; +21460-1;LL1927-4;RAST;LA10138-8;7;6;;; +21462-7;LL1927-4;RAST;LA6111-4;1;0;;; +21462-7;LL1927-4;RAST;LA6112-2;2;1;;; +21462-7;LL1927-4;RAST;LA6113-0;3;2;;; +21462-7;LL1927-4;RAST;LA6114-8;4;3;;; +21462-7;LL1927-4;RAST;LA6115-5;5;4;;; +21462-7;LL1927-4;RAST;LA10137-0;6;5;;; +21462-7;LL1927-4;RAST;LA10138-8;7;6;;; +21463-5;LL1927-4;RAST;LA6111-4;1;0;;; +21463-5;LL1927-4;RAST;LA6112-2;2;1;;; +21463-5;LL1927-4;RAST;LA6113-0;3;2;;; +21463-5;LL1927-4;RAST;LA6114-8;4;3;;; +21463-5;LL1927-4;RAST;LA6115-5;5;4;;; +21463-5;LL1927-4;RAST;LA10137-0;6;5;;; +21463-5;LL1927-4;RAST;LA10138-8;7;6;;; +21469-2;LL1927-4;RAST;LA6111-4;1;0;;; +21469-2;LL1927-4;RAST;LA6112-2;2;1;;; +21469-2;LL1927-4;RAST;LA6113-0;3;2;;; +21469-2;LL1927-4;RAST;LA6114-8;4;3;;; +21469-2;LL1927-4;RAST;LA6115-5;5;4;;; +21469-2;LL1927-4;RAST;LA10137-0;6;5;;; +21469-2;LL1927-4;RAST;LA10138-8;7;6;;; +21470-0;LL1927-4;RAST;LA6111-4;1;0;;; +21470-0;LL1927-4;RAST;LA6112-2;2;1;;; +21470-0;LL1927-4;RAST;LA6113-0;3;2;;; +21470-0;LL1927-4;RAST;LA6114-8;4;3;;; +21470-0;LL1927-4;RAST;LA6115-5;5;4;;; +21470-0;LL1927-4;RAST;LA10137-0;6;5;;; +21470-0;LL1927-4;RAST;LA10138-8;7;6;;; +21472-6;LL1927-4;RAST;LA6111-4;1;0;;; +21472-6;LL1927-4;RAST;LA6112-2;2;1;;; +21472-6;LL1927-4;RAST;LA6113-0;3;2;;; +21472-6;LL1927-4;RAST;LA6114-8;4;3;;; +21472-6;LL1927-4;RAST;LA6115-5;5;4;;; +21472-6;LL1927-4;RAST;LA10137-0;6;5;;; +21472-6;LL1927-4;RAST;LA10138-8;7;6;;; +21474-2;LL1927-4;RAST;LA6111-4;1;0;;; +21474-2;LL1927-4;RAST;LA6112-2;2;1;;; +21474-2;LL1927-4;RAST;LA6113-0;3;2;;; +21474-2;LL1927-4;RAST;LA6114-8;4;3;;; +21474-2;LL1927-4;RAST;LA6115-5;5;4;;; +21474-2;LL1927-4;RAST;LA10137-0;6;5;;; +21474-2;LL1927-4;RAST;LA10138-8;7;6;;; +21475-9;LL1927-4;RAST;LA6111-4;1;0;;; +21475-9;LL1927-4;RAST;LA6112-2;2;1;;; +21475-9;LL1927-4;RAST;LA6113-0;3;2;;; +21475-9;LL1927-4;RAST;LA6114-8;4;3;;; +21475-9;LL1927-4;RAST;LA6115-5;5;4;;; +21475-9;LL1927-4;RAST;LA10137-0;6;5;;; +21475-9;LL1927-4;RAST;LA10138-8;7;6;;; +21479-1;LL1927-4;RAST;LA6111-4;1;0;;; +21479-1;LL1927-4;RAST;LA6112-2;2;1;;; +21479-1;LL1927-4;RAST;LA6113-0;3;2;;; +21479-1;LL1927-4;RAST;LA6114-8;4;3;;; +21479-1;LL1927-4;RAST;LA6115-5;5;4;;; +21479-1;LL1927-4;RAST;LA10137-0;6;5;;; +21479-1;LL1927-4;RAST;LA10138-8;7;6;;; +21485-8;LL1927-4;RAST;LA6111-4;1;0;;; +21485-8;LL1927-4;RAST;LA6112-2;2;1;;; +21485-8;LL1927-4;RAST;LA6113-0;3;2;;; +21485-8;LL1927-4;RAST;LA6114-8;4;3;;; +21485-8;LL1927-4;RAST;LA6115-5;5;4;;; +21485-8;LL1927-4;RAST;LA10137-0;6;5;;; +21485-8;LL1927-4;RAST;LA10138-8;7;6;;; +21486-6;LL1927-4;RAST;LA6111-4;1;0;;; +21486-6;LL1927-4;RAST;LA6112-2;2;1;;; +21486-6;LL1927-4;RAST;LA6113-0;3;2;;; +21486-6;LL1927-4;RAST;LA6114-8;4;3;;; +21486-6;LL1927-4;RAST;LA6115-5;5;4;;; +21486-6;LL1927-4;RAST;LA10137-0;6;5;;; +21486-6;LL1927-4;RAST;LA10138-8;7;6;;; +21488-2;LL1927-4;RAST;LA6111-4;1;0;;; +21488-2;LL1927-4;RAST;LA6112-2;2;1;;; +21488-2;LL1927-4;RAST;LA6113-0;3;2;;; +21488-2;LL1927-4;RAST;LA6114-8;4;3;;; +21488-2;LL1927-4;RAST;LA6115-5;5;4;;; +21488-2;LL1927-4;RAST;LA10137-0;6;5;;; +21488-2;LL1927-4;RAST;LA10138-8;7;6;;; +21499-9;LL1927-4;RAST;LA6111-4;1;0;;; +21499-9;LL1927-4;RAST;LA6112-2;2;1;;; +21499-9;LL1927-4;RAST;LA6113-0;3;2;;; +21499-9;LL1927-4;RAST;LA6114-8;4;3;;; +21499-9;LL1927-4;RAST;LA6115-5;5;4;;; +21499-9;LL1927-4;RAST;LA10137-0;6;5;;; +21499-9;LL1927-4;RAST;LA10138-8;7;6;;; +21505-3;LL1927-4;RAST;LA6111-4;1;0;;; +21505-3;LL1927-4;RAST;LA6112-2;2;1;;; +21505-3;LL1927-4;RAST;LA6113-0;3;2;;; +21505-3;LL1927-4;RAST;LA6114-8;4;3;;; +21505-3;LL1927-4;RAST;LA6115-5;5;4;;; +21505-3;LL1927-4;RAST;LA10137-0;6;5;;; +21505-3;LL1927-4;RAST;LA10138-8;7;6;;; +21506-1;LL1927-4;RAST;LA6111-4;1;0;;; +21506-1;LL1927-4;RAST;LA6112-2;2;1;;; +21506-1;LL1927-4;RAST;LA6113-0;3;2;;; +21506-1;LL1927-4;RAST;LA6114-8;4;3;;; +21506-1;LL1927-4;RAST;LA6115-5;5;4;;; +21506-1;LL1927-4;RAST;LA10137-0;6;5;;; +21506-1;LL1927-4;RAST;LA10138-8;7;6;;; +21507-9;LL1927-4;RAST;LA6111-4;1;0;;; +21507-9;LL1927-4;RAST;LA6112-2;2;1;;; +21507-9;LL1927-4;RAST;LA6113-0;3;2;;; +21507-9;LL1927-4;RAST;LA6114-8;4;3;;; +21507-9;LL1927-4;RAST;LA6115-5;5;4;;; +21507-9;LL1927-4;RAST;LA10137-0;6;5;;; +21507-9;LL1927-4;RAST;LA10138-8;7;6;;; +21508-7;LL1927-4;RAST;LA6111-4;1;0;;; +21508-7;LL1927-4;RAST;LA6112-2;2;1;;; +21508-7;LL1927-4;RAST;LA6113-0;3;2;;; +21508-7;LL1927-4;RAST;LA6114-8;4;3;;; +21508-7;LL1927-4;RAST;LA6115-5;5;4;;; +21508-7;LL1927-4;RAST;LA10137-0;6;5;;; +21508-7;LL1927-4;RAST;LA10138-8;7;6;;; +21515-2;LL1927-4;RAST;LA6111-4;1;0;;; +21515-2;LL1927-4;RAST;LA6112-2;2;1;;; +21515-2;LL1927-4;RAST;LA6113-0;3;2;;; +21515-2;LL1927-4;RAST;LA6114-8;4;3;;; +21515-2;LL1927-4;RAST;LA6115-5;5;4;;; +21515-2;LL1927-4;RAST;LA10137-0;6;5;;; +21515-2;LL1927-4;RAST;LA10138-8;7;6;;; +21516-0;LL1927-4;RAST;LA6111-4;1;0;;; +21516-0;LL1927-4;RAST;LA6112-2;2;1;;; +21516-0;LL1927-4;RAST;LA6113-0;3;2;;; +21516-0;LL1927-4;RAST;LA6114-8;4;3;;; +21516-0;LL1927-4;RAST;LA6115-5;5;4;;; +21516-0;LL1927-4;RAST;LA10137-0;6;5;;; +21516-0;LL1927-4;RAST;LA10138-8;7;6;;; +21517-8;LL1927-4;RAST;LA6111-4;1;0;;; +21517-8;LL1927-4;RAST;LA6112-2;2;1;;; +21517-8;LL1927-4;RAST;LA6113-0;3;2;;; +21517-8;LL1927-4;RAST;LA6114-8;4;3;;; +21517-8;LL1927-4;RAST;LA6115-5;5;4;;; +21517-8;LL1927-4;RAST;LA10137-0;6;5;;; +21517-8;LL1927-4;RAST;LA10138-8;7;6;;; +21519-4;LL1927-4;RAST;LA6111-4;1;0;;; +21519-4;LL1927-4;RAST;LA6112-2;2;1;;; +21519-4;LL1927-4;RAST;LA6113-0;3;2;;; +21519-4;LL1927-4;RAST;LA6114-8;4;3;;; +21519-4;LL1927-4;RAST;LA6115-5;5;4;;; +21519-4;LL1927-4;RAST;LA10137-0;6;5;;; +21519-4;LL1927-4;RAST;LA10138-8;7;6;;; +21520-2;LL1927-4;RAST;LA6111-4;1;0;;; +21520-2;LL1927-4;RAST;LA6112-2;2;1;;; +21520-2;LL1927-4;RAST;LA6113-0;3;2;;; +21520-2;LL1927-4;RAST;LA6114-8;4;3;;; +21520-2;LL1927-4;RAST;LA6115-5;5;4;;; +21520-2;LL1927-4;RAST;LA10137-0;6;5;;; +21520-2;LL1927-4;RAST;LA10138-8;7;6;;; +21521-0;LL1927-4;RAST;LA6111-4;1;0;;; +21521-0;LL1927-4;RAST;LA6112-2;2;1;;; +21521-0;LL1927-4;RAST;LA6113-0;3;2;;; +21521-0;LL1927-4;RAST;LA6114-8;4;3;;; +21521-0;LL1927-4;RAST;LA6115-5;5;4;;; +21521-0;LL1927-4;RAST;LA10137-0;6;5;;; +21521-0;LL1927-4;RAST;LA10138-8;7;6;;; +21524-4;LL1927-4;RAST;LA6111-4;1;0;;; +21524-4;LL1927-4;RAST;LA6112-2;2;1;;; +21524-4;LL1927-4;RAST;LA6113-0;3;2;;; +21524-4;LL1927-4;RAST;LA6114-8;4;3;;; +21524-4;LL1927-4;RAST;LA6115-5;5;4;;; +21524-4;LL1927-4;RAST;LA10137-0;6;5;;; +21524-4;LL1927-4;RAST;LA10138-8;7;6;;; +21528-5;LL1927-4;RAST;LA6111-4;1;0;;; +21528-5;LL1927-4;RAST;LA6112-2;2;1;;; +21528-5;LL1927-4;RAST;LA6113-0;3;2;;; +21528-5;LL1927-4;RAST;LA6114-8;4;3;;; +21528-5;LL1927-4;RAST;LA6115-5;5;4;;; +21528-5;LL1927-4;RAST;LA10137-0;6;5;;; +21528-5;LL1927-4;RAST;LA10138-8;7;6;;; +21537-6;LL1927-4;RAST;LA6111-4;1;0;;; +21537-6;LL1927-4;RAST;LA6112-2;2;1;;; +21537-6;LL1927-4;RAST;LA6113-0;3;2;;; +21537-6;LL1927-4;RAST;LA6114-8;4;3;;; +21537-6;LL1927-4;RAST;LA6115-5;5;4;;; +21537-6;LL1927-4;RAST;LA10137-0;6;5;;; +21537-6;LL1927-4;RAST;LA10138-8;7;6;;; +21538-4;LL1927-4;RAST;LA6111-4;1;0;;; +21538-4;LL1927-4;RAST;LA6112-2;2;1;;; +21538-4;LL1927-4;RAST;LA6113-0;3;2;;; +21538-4;LL1927-4;RAST;LA6114-8;4;3;;; +21538-4;LL1927-4;RAST;LA6115-5;5;4;;; +21538-4;LL1927-4;RAST;LA10137-0;6;5;;; +21538-4;LL1927-4;RAST;LA10138-8;7;6;;; +21539-2;LL1927-4;RAST;LA6111-4;1;0;;; +21539-2;LL1927-4;RAST;LA6112-2;2;1;;; +21539-2;LL1927-4;RAST;LA6113-0;3;2;;; +21539-2;LL1927-4;RAST;LA6114-8;4;3;;; +21539-2;LL1927-4;RAST;LA6115-5;5;4;;; +21539-2;LL1927-4;RAST;LA10137-0;6;5;;; +21539-2;LL1927-4;RAST;LA10138-8;7;6;;; +21540-0;LL1927-4;RAST;LA6111-4;1;0;;; +21540-0;LL1927-4;RAST;LA6112-2;2;1;;; +21540-0;LL1927-4;RAST;LA6113-0;3;2;;; +21540-0;LL1927-4;RAST;LA6114-8;4;3;;; +21540-0;LL1927-4;RAST;LA6115-5;5;4;;; +21540-0;LL1927-4;RAST;LA10137-0;6;5;;; +21540-0;LL1927-4;RAST;LA10138-8;7;6;;; +21541-8;LL1927-4;RAST;LA6111-4;1;0;;; +21541-8;LL1927-4;RAST;LA6112-2;2;1;;; +21541-8;LL1927-4;RAST;LA6113-0;3;2;;; +21541-8;LL1927-4;RAST;LA6114-8;4;3;;; +21541-8;LL1927-4;RAST;LA6115-5;5;4;;; +21541-8;LL1927-4;RAST;LA10137-0;6;5;;; +21541-8;LL1927-4;RAST;LA10138-8;7;6;;; +21542-6;LL1927-4;RAST;LA6111-4;1;0;;; +21542-6;LL1927-4;RAST;LA6112-2;2;1;;; +21542-6;LL1927-4;RAST;LA6113-0;3;2;;; +21542-6;LL1927-4;RAST;LA6114-8;4;3;;; +21542-6;LL1927-4;RAST;LA6115-5;5;4;;; +21542-6;LL1927-4;RAST;LA10137-0;6;5;;; +21542-6;LL1927-4;RAST;LA10138-8;7;6;;; +21543-4;LL1927-4;RAST;LA6111-4;1;0;;; +21543-4;LL1927-4;RAST;LA6112-2;2;1;;; +21543-4;LL1927-4;RAST;LA6113-0;3;2;;; +21543-4;LL1927-4;RAST;LA6114-8;4;3;;; +21543-4;LL1927-4;RAST;LA6115-5;5;4;;; +21543-4;LL1927-4;RAST;LA10137-0;6;5;;; +21543-4;LL1927-4;RAST;LA10138-8;7;6;;; +21544-2;LL1927-4;RAST;LA6111-4;1;0;;; +21544-2;LL1927-4;RAST;LA6112-2;2;1;;; +21544-2;LL1927-4;RAST;LA6113-0;3;2;;; +21544-2;LL1927-4;RAST;LA6114-8;4;3;;; +21544-2;LL1927-4;RAST;LA6115-5;5;4;;; +21544-2;LL1927-4;RAST;LA10137-0;6;5;;; +21544-2;LL1927-4;RAST;LA10138-8;7;6;;; +21547-5;LL1927-4;RAST;LA6111-4;1;0;;; +21547-5;LL1927-4;RAST;LA6112-2;2;1;;; +21547-5;LL1927-4;RAST;LA6113-0;3;2;;; +21547-5;LL1927-4;RAST;LA6114-8;4;3;;; +21547-5;LL1927-4;RAST;LA6115-5;5;4;;; +21547-5;LL1927-4;RAST;LA10137-0;6;5;;; +21547-5;LL1927-4;RAST;LA10138-8;7;6;;; +21548-3;LL1927-4;RAST;LA6111-4;1;0;;; +21548-3;LL1927-4;RAST;LA6112-2;2;1;;; +21548-3;LL1927-4;RAST;LA6113-0;3;2;;; +21548-3;LL1927-4;RAST;LA6114-8;4;3;;; +21548-3;LL1927-4;RAST;LA6115-5;5;4;;; +21548-3;LL1927-4;RAST;LA10137-0;6;5;;; +21548-3;LL1927-4;RAST;LA10138-8;7;6;;; +21552-5;LL1927-4;RAST;LA6111-4;1;0;;; +21552-5;LL1927-4;RAST;LA6112-2;2;1;;; +21552-5;LL1927-4;RAST;LA6113-0;3;2;;; +21552-5;LL1927-4;RAST;LA6114-8;4;3;;; +21552-5;LL1927-4;RAST;LA6115-5;5;4;;; +21552-5;LL1927-4;RAST;LA10137-0;6;5;;; +21552-5;LL1927-4;RAST;LA10138-8;7;6;;; +21553-3;LL1927-4;RAST;LA6111-4;1;0;;; +21553-3;LL1927-4;RAST;LA6112-2;2;1;;; +21553-3;LL1927-4;RAST;LA6113-0;3;2;;; +21553-3;LL1927-4;RAST;LA6114-8;4;3;;; +21553-3;LL1927-4;RAST;LA6115-5;5;4;;; +21553-3;LL1927-4;RAST;LA10137-0;6;5;;; +21553-3;LL1927-4;RAST;LA10138-8;7;6;;; +21568-1;LL1927-4;RAST;LA6111-4;1;0;;; +21568-1;LL1927-4;RAST;LA6112-2;2;1;;; +21568-1;LL1927-4;RAST;LA6113-0;3;2;;; +21568-1;LL1927-4;RAST;LA6114-8;4;3;;; +21568-1;LL1927-4;RAST;LA6115-5;5;4;;; +21568-1;LL1927-4;RAST;LA10137-0;6;5;;; +21568-1;LL1927-4;RAST;LA10138-8;7;6;;; +21578-0;LL1927-4;RAST;LA6111-4;1;0;;; +21578-0;LL1927-4;RAST;LA6112-2;2;1;;; +21578-0;LL1927-4;RAST;LA6113-0;3;2;;; +21578-0;LL1927-4;RAST;LA6114-8;4;3;;; +21578-0;LL1927-4;RAST;LA6115-5;5;4;;; +21578-0;LL1927-4;RAST;LA10137-0;6;5;;; +21578-0;LL1927-4;RAST;LA10138-8;7;6;;; +21581-4;LL1927-4;RAST;LA6111-4;1;0;;; +21581-4;LL1927-4;RAST;LA6112-2;2;1;;; +21581-4;LL1927-4;RAST;LA6113-0;3;2;;; +21581-4;LL1927-4;RAST;LA6114-8;4;3;;; +21581-4;LL1927-4;RAST;LA6115-5;5;4;;; +21581-4;LL1927-4;RAST;LA10137-0;6;5;;; +21581-4;LL1927-4;RAST;LA10138-8;7;6;;; +21583-0;LL1927-4;RAST;LA6111-4;1;0;;; +21583-0;LL1927-4;RAST;LA6112-2;2;1;;; +21583-0;LL1927-4;RAST;LA6113-0;3;2;;; +21583-0;LL1927-4;RAST;LA6114-8;4;3;;; +21583-0;LL1927-4;RAST;LA6115-5;5;4;;; +21583-0;LL1927-4;RAST;LA10137-0;6;5;;; +21583-0;LL1927-4;RAST;LA10138-8;7;6;;; +21584-8;LL1927-4;RAST;LA6111-4;1;0;;; +21584-8;LL1927-4;RAST;LA6112-2;2;1;;; +21584-8;LL1927-4;RAST;LA6113-0;3;2;;; +21584-8;LL1927-4;RAST;LA6114-8;4;3;;; +21584-8;LL1927-4;RAST;LA6115-5;5;4;;; +21584-8;LL1927-4;RAST;LA10137-0;6;5;;; +21584-8;LL1927-4;RAST;LA10138-8;7;6;;; +21589-7;LL1927-4;RAST;LA6111-4;1;0;;; +21589-7;LL1927-4;RAST;LA6112-2;2;1;;; +21589-7;LL1927-4;RAST;LA6113-0;3;2;;; +21589-7;LL1927-4;RAST;LA6114-8;4;3;;; +21589-7;LL1927-4;RAST;LA6115-5;5;4;;; +21589-7;LL1927-4;RAST;LA10137-0;6;5;;; +21589-7;LL1927-4;RAST;LA10138-8;7;6;;; +21591-3;LL1927-4;RAST;LA6111-4;1;0;;; +21591-3;LL1927-4;RAST;LA6112-2;2;1;;; +21591-3;LL1927-4;RAST;LA6113-0;3;2;;; +21591-3;LL1927-4;RAST;LA6114-8;4;3;;; +21591-3;LL1927-4;RAST;LA6115-5;5;4;;; +21591-3;LL1927-4;RAST;LA10137-0;6;5;;; +21591-3;LL1927-4;RAST;LA10138-8;7;6;;; +21599-6;LL1927-4;RAST;LA6111-4;1;0;;; +21599-6;LL1927-4;RAST;LA6112-2;2;1;;; +21599-6;LL1927-4;RAST;LA6113-0;3;2;;; +21599-6;LL1927-4;RAST;LA6114-8;4;3;;; +21599-6;LL1927-4;RAST;LA6115-5;5;4;;; +21599-6;LL1927-4;RAST;LA10137-0;6;5;;; +21599-6;LL1927-4;RAST;LA10138-8;7;6;;; +21600-2;LL1927-4;RAST;LA6111-4;1;0;;; +21600-2;LL1927-4;RAST;LA6112-2;2;1;;; +21600-2;LL1927-4;RAST;LA6113-0;3;2;;; +21600-2;LL1927-4;RAST;LA6114-8;4;3;;; +21600-2;LL1927-4;RAST;LA6115-5;5;4;;; +21600-2;LL1927-4;RAST;LA10137-0;6;5;;; +21600-2;LL1927-4;RAST;LA10138-8;7;6;;; +21601-0;LL1927-4;RAST;LA6111-4;1;0;;; +21601-0;LL1927-4;RAST;LA6112-2;2;1;;; +21601-0;LL1927-4;RAST;LA6113-0;3;2;;; +21601-0;LL1927-4;RAST;LA6114-8;4;3;;; +21601-0;LL1927-4;RAST;LA6115-5;5;4;;; +21601-0;LL1927-4;RAST;LA10137-0;6;5;;; +21601-0;LL1927-4;RAST;LA10138-8;7;6;;; +21602-8;LL1927-4;RAST;LA6111-4;1;0;;; +21602-8;LL1927-4;RAST;LA6112-2;2;1;;; +21602-8;LL1927-4;RAST;LA6113-0;3;2;;; +21602-8;LL1927-4;RAST;LA6114-8;4;3;;; +21602-8;LL1927-4;RAST;LA6115-5;5;4;;; +21602-8;LL1927-4;RAST;LA10137-0;6;5;;; +21602-8;LL1927-4;RAST;LA10138-8;7;6;;; +21604-4;LL1927-4;RAST;LA6111-4;1;0;;; +21604-4;LL1927-4;RAST;LA6112-2;2;1;;; +21604-4;LL1927-4;RAST;LA6113-0;3;2;;; +21604-4;LL1927-4;RAST;LA6114-8;4;3;;; +21604-4;LL1927-4;RAST;LA6115-5;5;4;;; +21604-4;LL1927-4;RAST;LA10137-0;6;5;;; +21604-4;LL1927-4;RAST;LA10138-8;7;6;;; +21605-1;LL1927-4;RAST;LA6111-4;1;0;;; +21605-1;LL1927-4;RAST;LA6112-2;2;1;;; +21605-1;LL1927-4;RAST;LA6113-0;3;2;;; +21605-1;LL1927-4;RAST;LA6114-8;4;3;;; +21605-1;LL1927-4;RAST;LA6115-5;5;4;;; +21605-1;LL1927-4;RAST;LA10137-0;6;5;;; +21605-1;LL1927-4;RAST;LA10138-8;7;6;;; +21607-7;LL1927-4;RAST;LA6111-4;1;0;;; +21607-7;LL1927-4;RAST;LA6112-2;2;1;;; +21607-7;LL1927-4;RAST;LA6113-0;3;2;;; +21607-7;LL1927-4;RAST;LA6114-8;4;3;;; +21607-7;LL1927-4;RAST;LA6115-5;5;4;;; +21607-7;LL1927-4;RAST;LA10137-0;6;5;;; +21607-7;LL1927-4;RAST;LA10138-8;7;6;;; +21608-5;LL1927-4;RAST;LA6111-4;1;0;;; +21608-5;LL1927-4;RAST;LA6112-2;2;1;;; +21608-5;LL1927-4;RAST;LA6113-0;3;2;;; +21608-5;LL1927-4;RAST;LA6114-8;4;3;;; +21608-5;LL1927-4;RAST;LA6115-5;5;4;;; +21608-5;LL1927-4;RAST;LA10137-0;6;5;;; +21608-5;LL1927-4;RAST;LA10138-8;7;6;;; +21609-3;LL1927-4;RAST;LA6111-4;1;0;;; +21609-3;LL1927-4;RAST;LA6112-2;2;1;;; +21609-3;LL1927-4;RAST;LA6113-0;3;2;;; +21609-3;LL1927-4;RAST;LA6114-8;4;3;;; +21609-3;LL1927-4;RAST;LA6115-5;5;4;;; +21609-3;LL1927-4;RAST;LA10137-0;6;5;;; +21609-3;LL1927-4;RAST;LA10138-8;7;6;;; +23813-9;LL1927-4;RAST;LA6111-4;1;0;;; +23813-9;LL1927-4;RAST;LA6112-2;2;1;;; +23813-9;LL1927-4;RAST;LA6113-0;3;2;;; +23813-9;LL1927-4;RAST;LA6114-8;4;3;;; +23813-9;LL1927-4;RAST;LA6115-5;5;4;;; +23813-9;LL1927-4;RAST;LA10137-0;6;5;;; +23813-9;LL1927-4;RAST;LA10138-8;7;6;;; +23834-5;LL1927-4;RAST;LA6111-4;1;0;;; +23834-5;LL1927-4;RAST;LA6112-2;2;1;;; +23834-5;LL1927-4;RAST;LA6113-0;3;2;;; +23834-5;LL1927-4;RAST;LA6114-8;4;3;;; +23834-5;LL1927-4;RAST;LA6115-5;5;4;;; +23834-5;LL1927-4;RAST;LA10137-0;6;5;;; +23834-5;LL1927-4;RAST;LA10138-8;7;6;;; +23837-8;LL1927-4;RAST;LA6111-4;1;0;;; +23837-8;LL1927-4;RAST;LA6112-2;2;1;;; +23837-8;LL1927-4;RAST;LA6113-0;3;2;;; +23837-8;LL1927-4;RAST;LA6114-8;4;3;;; +23837-8;LL1927-4;RAST;LA6115-5;5;4;;; +23837-8;LL1927-4;RAST;LA10137-0;6;5;;; +23837-8;LL1927-4;RAST;LA10138-8;7;6;;; +23863-4;LL1927-4;RAST;LA6111-4;1;0;;; +23863-4;LL1927-4;RAST;LA6112-2;2;1;;; +23863-4;LL1927-4;RAST;LA6113-0;3;2;;; +23863-4;LL1927-4;RAST;LA6114-8;4;3;;; +23863-4;LL1927-4;RAST;LA6115-5;5;4;;; +23863-4;LL1927-4;RAST;LA10137-0;6;5;;; +23863-4;LL1927-4;RAST;LA10138-8;7;6;;; +23894-9;LL1927-4;RAST;LA6111-4;1;0;;; +23894-9;LL1927-4;RAST;LA6112-2;2;1;;; +23894-9;LL1927-4;RAST;LA6113-0;3;2;;; +23894-9;LL1927-4;RAST;LA6114-8;4;3;;; +23894-9;LL1927-4;RAST;LA6115-5;5;4;;; +23894-9;LL1927-4;RAST;LA10137-0;6;5;;; +23894-9;LL1927-4;RAST;LA10138-8;7;6;;; +23895-6;LL1927-4;RAST;LA6111-4;1;0;;; +23895-6;LL1927-4;RAST;LA6112-2;2;1;;; +23895-6;LL1927-4;RAST;LA6113-0;3;2;;; +23895-6;LL1927-4;RAST;LA6114-8;4;3;;; +23895-6;LL1927-4;RAST;LA6115-5;5;4;;; +23895-6;LL1927-4;RAST;LA10137-0;6;5;;; +23895-6;LL1927-4;RAST;LA10138-8;7;6;;; +23909-5;LL1927-4;RAST;LA6111-4;1;0;;; +23909-5;LL1927-4;RAST;LA6112-2;2;1;;; +23909-5;LL1927-4;RAST;LA6113-0;3;2;;; +23909-5;LL1927-4;RAST;LA6114-8;4;3;;; +23909-5;LL1927-4;RAST;LA6115-5;5;4;;; +23909-5;LL1927-4;RAST;LA10137-0;6;5;;; +23909-5;LL1927-4;RAST;LA10138-8;7;6;;; +23923-6;LL1927-4;RAST;LA6111-4;1;0;;; +23923-6;LL1927-4;RAST;LA6112-2;2;1;;; +23923-6;LL1927-4;RAST;LA6113-0;3;2;;; +23923-6;LL1927-4;RAST;LA6114-8;4;3;;; +23923-6;LL1927-4;RAST;LA6115-5;5;4;;; +23923-6;LL1927-4;RAST;LA10137-0;6;5;;; +23923-6;LL1927-4;RAST;LA10138-8;7;6;;; +23924-4;LL1927-4;RAST;LA6111-4;1;0;;; +23924-4;LL1927-4;RAST;LA6112-2;2;1;;; +23924-4;LL1927-4;RAST;LA6113-0;3;2;;; +23924-4;LL1927-4;RAST;LA6114-8;4;3;;; +23924-4;LL1927-4;RAST;LA6115-5;5;4;;; +23924-4;LL1927-4;RAST;LA10137-0;6;5;;; +23924-4;LL1927-4;RAST;LA10138-8;7;6;;; +23926-9;LL1927-4;RAST;LA6111-4;1;0;;; +23926-9;LL1927-4;RAST;LA6112-2;2;1;;; +23926-9;LL1927-4;RAST;LA6113-0;3;2;;; +23926-9;LL1927-4;RAST;LA6114-8;4;3;;; +23926-9;LL1927-4;RAST;LA6115-5;5;4;;; +23926-9;LL1927-4;RAST;LA10137-0;6;5;;; +23926-9;LL1927-4;RAST;LA10138-8;7;6;;; +23927-7;LL1927-4;RAST;LA6111-4;1;0;;; +23927-7;LL1927-4;RAST;LA6112-2;2;1;;; +23927-7;LL1927-4;RAST;LA6113-0;3;2;;; +23927-7;LL1927-4;RAST;LA6114-8;4;3;;; +23927-7;LL1927-4;RAST;LA6115-5;5;4;;; +23927-7;LL1927-4;RAST;LA10137-0;6;5;;; +23927-7;LL1927-4;RAST;LA10138-8;7;6;;; +23938-4;LL1927-4;RAST;LA6111-4;1;0;;; +23938-4;LL1927-4;RAST;LA6112-2;2;1;;; +23938-4;LL1927-4;RAST;LA6113-0;3;2;;; +23938-4;LL1927-4;RAST;LA6114-8;4;3;;; +23938-4;LL1927-4;RAST;LA6115-5;5;4;;; +23938-4;LL1927-4;RAST;LA10137-0;6;5;;; +23938-4;LL1927-4;RAST;LA10138-8;7;6;;; +24162-0;LL1927-4;RAST;LA6111-4;1;0;;; +24162-0;LL1927-4;RAST;LA6112-2;2;1;;; +24162-0;LL1927-4;RAST;LA6113-0;3;2;;; +24162-0;LL1927-4;RAST;LA6114-8;4;3;;; +24162-0;LL1927-4;RAST;LA6115-5;5;4;;; +24162-0;LL1927-4;RAST;LA10137-0;6;5;;; +24162-0;LL1927-4;RAST;LA10138-8;7;6;;; +24478-0;LL1927-4;RAST;LA6111-4;1;0;;; +24478-0;LL1927-4;RAST;LA6112-2;2;1;;; +24478-0;LL1927-4;RAST;LA6113-0;3;2;;; +24478-0;LL1927-4;RAST;LA6114-8;4;3;;; +24478-0;LL1927-4;RAST;LA6115-5;5;4;;; +24478-0;LL1927-4;RAST;LA10137-0;6;5;;; +24478-0;LL1927-4;RAST;LA10138-8;7;6;;; +24479-8;LL1927-4;RAST;LA6111-4;1;0;;; +24479-8;LL1927-4;RAST;LA6112-2;2;1;;; +24479-8;LL1927-4;RAST;LA6113-0;3;2;;; +24479-8;LL1927-4;RAST;LA6114-8;4;3;;; +24479-8;LL1927-4;RAST;LA6115-5;5;4;;; +24479-8;LL1927-4;RAST;LA10137-0;6;5;;; +24479-8;LL1927-4;RAST;LA10138-8;7;6;;; +24481-4;LL1927-4;RAST;LA6111-4;1;0;;; +24481-4;LL1927-4;RAST;LA6112-2;2;1;;; +24481-4;LL1927-4;RAST;LA6113-0;3;2;;; +24481-4;LL1927-4;RAST;LA6114-8;4;3;;; +24481-4;LL1927-4;RAST;LA6115-5;5;4;;; +24481-4;LL1927-4;RAST;LA10137-0;6;5;;; +24481-4;LL1927-4;RAST;LA10138-8;7;6;;; +24482-2;LL1927-4;RAST;LA6111-4;1;0;;; +24482-2;LL1927-4;RAST;LA6112-2;2;1;;; +24482-2;LL1927-4;RAST;LA6113-0;3;2;;; +24482-2;LL1927-4;RAST;LA6114-8;4;3;;; +24482-2;LL1927-4;RAST;LA6115-5;5;4;;; +24482-2;LL1927-4;RAST;LA10137-0;6;5;;; +24482-2;LL1927-4;RAST;LA10138-8;7;6;;; +24483-0;LL1927-4;RAST;LA6111-4;1;0;;; +24483-0;LL1927-4;RAST;LA6112-2;2;1;;; +24483-0;LL1927-4;RAST;LA6113-0;3;2;;; +24483-0;LL1927-4;RAST;LA6114-8;4;3;;; +24483-0;LL1927-4;RAST;LA6115-5;5;4;;; +24483-0;LL1927-4;RAST;LA10137-0;6;5;;; +24483-0;LL1927-4;RAST;LA10138-8;7;6;;; +24484-8;LL1927-4;RAST;LA6111-4;1;0;;; +24484-8;LL1927-4;RAST;LA6112-2;2;1;;; +24484-8;LL1927-4;RAST;LA6113-0;3;2;;; +24484-8;LL1927-4;RAST;LA6114-8;4;3;;; +24484-8;LL1927-4;RAST;LA6115-5;5;4;;; +24484-8;LL1927-4;RAST;LA10137-0;6;5;;; +24484-8;LL1927-4;RAST;LA10138-8;7;6;;; +24485-5;LL1927-4;RAST;LA6111-4;1;0;;; +24485-5;LL1927-4;RAST;LA6112-2;2;1;;; +24485-5;LL1927-4;RAST;LA6113-0;3;2;;; +24485-5;LL1927-4;RAST;LA6114-8;4;3;;; +24485-5;LL1927-4;RAST;LA6115-5;5;4;;; +24485-5;LL1927-4;RAST;LA10137-0;6;5;;; +24485-5;LL1927-4;RAST;LA10138-8;7;6;;; +24486-3;LL1927-4;RAST;LA6111-4;1;0;;; +24486-3;LL1927-4;RAST;LA6112-2;2;1;;; +24486-3;LL1927-4;RAST;LA6113-0;3;2;;; +24486-3;LL1927-4;RAST;LA6114-8;4;3;;; +24486-3;LL1927-4;RAST;LA6115-5;5;4;;; +24486-3;LL1927-4;RAST;LA10137-0;6;5;;; +24486-3;LL1927-4;RAST;LA10138-8;7;6;;; +24487-1;LL1927-4;RAST;LA6111-4;1;0;;; +24487-1;LL1927-4;RAST;LA6112-2;2;1;;; +24487-1;LL1927-4;RAST;LA6113-0;3;2;;; +24487-1;LL1927-4;RAST;LA6114-8;4;3;;; +24487-1;LL1927-4;RAST;LA6115-5;5;4;;; +24487-1;LL1927-4;RAST;LA10137-0;6;5;;; +24487-1;LL1927-4;RAST;LA10138-8;7;6;;; +24488-9;LL1927-4;RAST;LA6111-4;1;0;;; +24488-9;LL1927-4;RAST;LA6112-2;2;1;;; +24488-9;LL1927-4;RAST;LA6113-0;3;2;;; +24488-9;LL1927-4;RAST;LA6114-8;4;3;;; +24488-9;LL1927-4;RAST;LA6115-5;5;4;;; +24488-9;LL1927-4;RAST;LA10137-0;6;5;;; +24488-9;LL1927-4;RAST;LA10138-8;7;6;;; +24489-7;LL1927-4;RAST;LA6111-4;1;0;;; +24489-7;LL1927-4;RAST;LA6112-2;2;1;;; +24489-7;LL1927-4;RAST;LA6113-0;3;2;;; +24489-7;LL1927-4;RAST;LA6114-8;4;3;;; +24489-7;LL1927-4;RAST;LA6115-5;5;4;;; +24489-7;LL1927-4;RAST;LA10137-0;6;5;;; +24489-7;LL1927-4;RAST;LA10138-8;7;6;;; +24490-5;LL1927-4;RAST;LA6111-4;1;0;;; +24490-5;LL1927-4;RAST;LA6112-2;2;1;;; +24490-5;LL1927-4;RAST;LA6113-0;3;2;;; +24490-5;LL1927-4;RAST;LA6114-8;4;3;;; +24490-5;LL1927-4;RAST;LA6115-5;5;4;;; +24490-5;LL1927-4;RAST;LA10137-0;6;5;;; +24490-5;LL1927-4;RAST;LA10138-8;7;6;;; +24492-1;LL1927-4;RAST;LA6111-4;1;0;;; +24492-1;LL1927-4;RAST;LA6112-2;2;1;;; +24492-1;LL1927-4;RAST;LA6113-0;3;2;;; +24492-1;LL1927-4;RAST;LA6114-8;4;3;;; +24492-1;LL1927-4;RAST;LA6115-5;5;4;;; +24492-1;LL1927-4;RAST;LA10137-0;6;5;;; +24492-1;LL1927-4;RAST;LA10138-8;7;6;;; +24494-7;LL1927-4;RAST;LA6111-4;1;0;;; +24494-7;LL1927-4;RAST;LA6112-2;2;1;;; +24494-7;LL1927-4;RAST;LA6113-0;3;2;;; +24494-7;LL1927-4;RAST;LA6114-8;4;3;;; +24494-7;LL1927-4;RAST;LA6115-5;5;4;;; +24494-7;LL1927-4;RAST;LA10137-0;6;5;;; +24494-7;LL1927-4;RAST;LA10138-8;7;6;;; +24495-4;LL1927-4;RAST;LA6111-4;1;0;;; +24495-4;LL1927-4;RAST;LA6112-2;2;1;;; +24495-4;LL1927-4;RAST;LA6113-0;3;2;;; +24495-4;LL1927-4;RAST;LA6114-8;4;3;;; +24495-4;LL1927-4;RAST;LA6115-5;5;4;;; +24495-4;LL1927-4;RAST;LA10137-0;6;5;;; +24495-4;LL1927-4;RAST;LA10138-8;7;6;;; +24496-2;LL1927-4;RAST;LA6111-4;1;0;;; +24496-2;LL1927-4;RAST;LA6112-2;2;1;;; +24496-2;LL1927-4;RAST;LA6113-0;3;2;;; +24496-2;LL1927-4;RAST;LA6114-8;4;3;;; +24496-2;LL1927-4;RAST;LA6115-5;5;4;;; +24496-2;LL1927-4;RAST;LA10137-0;6;5;;; +24496-2;LL1927-4;RAST;LA10138-8;7;6;;; +24506-8;LL1927-4;RAST;LA6111-4;1;0;;; +24506-8;LL1927-4;RAST;LA6112-2;2;1;;; +24506-8;LL1927-4;RAST;LA6113-0;3;2;;; +24506-8;LL1927-4;RAST;LA6114-8;4;3;;; +24506-8;LL1927-4;RAST;LA6115-5;5;4;;; +24506-8;LL1927-4;RAST;LA10137-0;6;5;;; +24506-8;LL1927-4;RAST;LA10138-8;7;6;;; +24510-0;LL1927-4;RAST;LA6111-4;1;0;;; +24510-0;LL1927-4;RAST;LA6112-2;2;1;;; +24510-0;LL1927-4;RAST;LA6113-0;3;2;;; +24510-0;LL1927-4;RAST;LA6114-8;4;3;;; +24510-0;LL1927-4;RAST;LA6115-5;5;4;;; +24510-0;LL1927-4;RAST;LA10137-0;6;5;;; +24510-0;LL1927-4;RAST;LA10138-8;7;6;;; +24513-4;LL1927-4;RAST;LA6111-4;1;0;;; +24513-4;LL1927-4;RAST;LA6112-2;2;1;;; +24513-4;LL1927-4;RAST;LA6113-0;3;2;;; +24513-4;LL1927-4;RAST;LA6114-8;4;3;;; +24513-4;LL1927-4;RAST;LA6115-5;5;4;;; +24513-4;LL1927-4;RAST;LA10137-0;6;5;;; +24513-4;LL1927-4;RAST;LA10138-8;7;6;;; +24514-2;LL1927-4;RAST;LA6111-4;1;0;;; +24514-2;LL1927-4;RAST;LA6112-2;2;1;;; +24514-2;LL1927-4;RAST;LA6113-0;3;2;;; +24514-2;LL1927-4;RAST;LA6114-8;4;3;;; +24514-2;LL1927-4;RAST;LA6115-5;5;4;;; +24514-2;LL1927-4;RAST;LA10137-0;6;5;;; +24514-2;LL1927-4;RAST;LA10138-8;7;6;;; +24516-7;LL1927-4;RAST;LA6111-4;1;0;;; +24516-7;LL1927-4;RAST;LA6112-2;2;1;;; +24516-7;LL1927-4;RAST;LA6113-0;3;2;;; +24516-7;LL1927-4;RAST;LA6114-8;4;3;;; +24516-7;LL1927-4;RAST;LA6115-5;5;4;;; +24516-7;LL1927-4;RAST;LA10137-0;6;5;;; +24516-7;LL1927-4;RAST;LA10138-8;7;6;;; +25328-6;LL1927-4;RAST;LA6111-4;1;0;;; +25328-6;LL1927-4;RAST;LA6112-2;2;1;;; +25328-6;LL1927-4;RAST;LA6113-0;3;2;;; +25328-6;LL1927-4;RAST;LA6114-8;4;3;;; +25328-6;LL1927-4;RAST;LA6115-5;5;4;;; +25328-6;LL1927-4;RAST;LA10137-0;6;5;;; +25328-6;LL1927-4;RAST;LA10138-8;7;6;;; +25345-0;LL1927-4;RAST;LA6111-4;1;0;;; +25345-0;LL1927-4;RAST;LA6112-2;2;1;;; +25345-0;LL1927-4;RAST;LA6113-0;3;2;;; +25345-0;LL1927-4;RAST;LA6114-8;4;3;;; +25345-0;LL1927-4;RAST;LA6115-5;5;4;;; +25345-0;LL1927-4;RAST;LA10137-0;6;5;;; +25345-0;LL1927-4;RAST;LA10138-8;7;6;;; +25350-0;LL1927-4;RAST;LA6111-4;1;0;;; +25350-0;LL1927-4;RAST;LA6112-2;2;1;;; +25350-0;LL1927-4;RAST;LA6113-0;3;2;;; +25350-0;LL1927-4;RAST;LA6114-8;4;3;;; +25350-0;LL1927-4;RAST;LA6115-5;5;4;;; +25350-0;LL1927-4;RAST;LA10137-0;6;5;;; +25350-0;LL1927-4;RAST;LA10138-8;7;6;;; +25355-9;LL1927-4;RAST;LA6111-4;1;0;;; +25355-9;LL1927-4;RAST;LA6112-2;2;1;;; +25355-9;LL1927-4;RAST;LA6113-0;3;2;;; +25355-9;LL1927-4;RAST;LA6114-8;4;3;;; +25355-9;LL1927-4;RAST;LA6115-5;5;4;;; +25355-9;LL1927-4;RAST;LA10137-0;6;5;;; +25355-9;LL1927-4;RAST;LA10138-8;7;6;;; +25368-2;LL1927-4;RAST;LA6111-4;1;0;;; +25368-2;LL1927-4;RAST;LA6112-2;2;1;;; +25368-2;LL1927-4;RAST;LA6113-0;3;2;;; +25368-2;LL1927-4;RAST;LA6114-8;4;3;;; +25368-2;LL1927-4;RAST;LA6115-5;5;4;;; +25368-2;LL1927-4;RAST;LA10137-0;6;5;;; +25368-2;LL1927-4;RAST;LA10138-8;7;6;;; +25370-8;LL1927-4;RAST;LA6111-4;1;0;;; +25370-8;LL1927-4;RAST;LA6112-2;2;1;;; +25370-8;LL1927-4;RAST;LA6113-0;3;2;;; +25370-8;LL1927-4;RAST;LA6114-8;4;3;;; +25370-8;LL1927-4;RAST;LA6115-5;5;4;;; +25370-8;LL1927-4;RAST;LA10137-0;6;5;;; +25370-8;LL1927-4;RAST;LA10138-8;7;6;;; +25383-1;LL1927-4;RAST;LA6111-4;1;0;;; +25383-1;LL1927-4;RAST;LA6112-2;2;1;;; +25383-1;LL1927-4;RAST;LA6113-0;3;2;;; +25383-1;LL1927-4;RAST;LA6114-8;4;3;;; +25383-1;LL1927-4;RAST;LA6115-5;5;4;;; +25383-1;LL1927-4;RAST;LA10137-0;6;5;;; +25383-1;LL1927-4;RAST;LA10138-8;7;6;;; +25395-5;LL1927-4;RAST;LA6111-4;1;0;;; +25395-5;LL1927-4;RAST;LA6112-2;2;1;;; +25395-5;LL1927-4;RAST;LA6113-0;3;2;;; +25395-5;LL1927-4;RAST;LA6114-8;4;3;;; +25395-5;LL1927-4;RAST;LA6115-5;5;4;;; +25395-5;LL1927-4;RAST;LA10137-0;6;5;;; +25395-5;LL1927-4;RAST;LA10138-8;7;6;;; +25396-3;LL1927-4;RAST;LA6111-4;1;0;;; +25396-3;LL1927-4;RAST;LA6112-2;2;1;;; +25396-3;LL1927-4;RAST;LA6113-0;3;2;;; +25396-3;LL1927-4;RAST;LA6114-8;4;3;;; +25396-3;LL1927-4;RAST;LA6115-5;5;4;;; +25396-3;LL1927-4;RAST;LA10137-0;6;5;;; +25396-3;LL1927-4;RAST;LA10138-8;7;6;;; +25408-6;LL1927-4;RAST;LA6111-4;1;0;;; +25408-6;LL1927-4;RAST;LA6112-2;2;1;;; +25408-6;LL1927-4;RAST;LA6113-0;3;2;;; +25408-6;LL1927-4;RAST;LA6114-8;4;3;;; +25408-6;LL1927-4;RAST;LA6115-5;5;4;;; +25408-6;LL1927-4;RAST;LA10137-0;6;5;;; +25408-6;LL1927-4;RAST;LA10138-8;7;6;;; +25414-4;LL1927-4;RAST;LA6111-4;1;0;;; +25414-4;LL1927-4;RAST;LA6112-2;2;1;;; +25414-4;LL1927-4;RAST;LA6113-0;3;2;;; +25414-4;LL1927-4;RAST;LA6114-8;4;3;;; +25414-4;LL1927-4;RAST;LA6115-5;5;4;;; +25414-4;LL1927-4;RAST;LA10137-0;6;5;;; +25414-4;LL1927-4;RAST;LA10138-8;7;6;;; +25442-5;LL1927-4;RAST;LA6111-4;1;0;;; +25442-5;LL1927-4;RAST;LA6112-2;2;1;;; +25442-5;LL1927-4;RAST;LA6113-0;3;2;;; +25442-5;LL1927-4;RAST;LA6114-8;4;3;;; +25442-5;LL1927-4;RAST;LA6115-5;5;4;;; +25442-5;LL1927-4;RAST;LA10137-0;6;5;;; +25442-5;LL1927-4;RAST;LA10138-8;7;6;;; +25454-0;LL1927-4;RAST;LA6111-4;1;0;;; +25454-0;LL1927-4;RAST;LA6112-2;2;1;;; +25454-0;LL1927-4;RAST;LA6113-0;3;2;;; +25454-0;LL1927-4;RAST;LA6114-8;4;3;;; +25454-0;LL1927-4;RAST;LA6115-5;5;4;;; +25454-0;LL1927-4;RAST;LA10137-0;6;5;;; +25454-0;LL1927-4;RAST;LA10138-8;7;6;;; +25456-5;LL1927-4;RAST;LA6111-4;1;0;;; +25456-5;LL1927-4;RAST;LA6112-2;2;1;;; +25456-5;LL1927-4;RAST;LA6113-0;3;2;;; +25456-5;LL1927-4;RAST;LA6114-8;4;3;;; +25456-5;LL1927-4;RAST;LA6115-5;5;4;;; +25456-5;LL1927-4;RAST;LA10137-0;6;5;;; +25456-5;LL1927-4;RAST;LA10138-8;7;6;;; +25457-3;LL1927-4;RAST;LA6111-4;1;0;;; +25457-3;LL1927-4;RAST;LA6112-2;2;1;;; +25457-3;LL1927-4;RAST;LA6113-0;3;2;;; +25457-3;LL1927-4;RAST;LA6114-8;4;3;;; +25457-3;LL1927-4;RAST;LA6115-5;5;4;;; +25457-3;LL1927-4;RAST;LA10137-0;6;5;;; +25457-3;LL1927-4;RAST;LA10138-8;7;6;;; +25465-6;LL1927-4;RAST;LA6111-4;1;0;;; +25465-6;LL1927-4;RAST;LA6112-2;2;1;;; +25465-6;LL1927-4;RAST;LA6113-0;3;2;;; +25465-6;LL1927-4;RAST;LA6114-8;4;3;;; +25465-6;LL1927-4;RAST;LA6115-5;5;4;;; +25465-6;LL1927-4;RAST;LA10137-0;6;5;;; +25465-6;LL1927-4;RAST;LA10138-8;7;6;;; +25480-5;LL1927-4;RAST;LA6111-4;1;0;;; +25480-5;LL1927-4;RAST;LA6112-2;2;1;;; +25480-5;LL1927-4;RAST;LA6113-0;3;2;;; +25480-5;LL1927-4;RAST;LA6114-8;4;3;;; +25480-5;LL1927-4;RAST;LA6115-5;5;4;;; +25480-5;LL1927-4;RAST;LA10137-0;6;5;;; +25480-5;LL1927-4;RAST;LA10138-8;7;6;;; +25485-4;LL1927-4;RAST;LA6111-4;1;0;;; +25485-4;LL1927-4;RAST;LA6112-2;2;1;;; +25485-4;LL1927-4;RAST;LA6113-0;3;2;;; +25485-4;LL1927-4;RAST;LA6114-8;4;3;;; +25485-4;LL1927-4;RAST;LA6115-5;5;4;;; +25485-4;LL1927-4;RAST;LA10137-0;6;5;;; +25485-4;LL1927-4;RAST;LA10138-8;7;6;;; +25490-4;LL1927-4;RAST;LA6111-4;1;0;;; +25490-4;LL1927-4;RAST;LA6112-2;2;1;;; +25490-4;LL1927-4;RAST;LA6113-0;3;2;;; +25490-4;LL1927-4;RAST;LA6114-8;4;3;;; +25490-4;LL1927-4;RAST;LA6115-5;5;4;;; +25490-4;LL1927-4;RAST;LA10137-0;6;5;;; +25490-4;LL1927-4;RAST;LA10138-8;7;6;;; +25493-8;LL1927-4;RAST;LA6111-4;1;0;;; +25493-8;LL1927-4;RAST;LA6112-2;2;1;;; +25493-8;LL1927-4;RAST;LA6113-0;3;2;;; +25493-8;LL1927-4;RAST;LA6114-8;4;3;;; +25493-8;LL1927-4;RAST;LA6115-5;5;4;;; +25493-8;LL1927-4;RAST;LA10137-0;6;5;;; +25493-8;LL1927-4;RAST;LA10138-8;7;6;;; +25496-1;LL1927-4;RAST;LA6111-4;1;0;;; +25496-1;LL1927-4;RAST;LA6112-2;2;1;;; +25496-1;LL1927-4;RAST;LA6113-0;3;2;;; +25496-1;LL1927-4;RAST;LA6114-8;4;3;;; +25496-1;LL1927-4;RAST;LA6115-5;5;4;;; +25496-1;LL1927-4;RAST;LA10137-0;6;5;;; +25496-1;LL1927-4;RAST;LA10138-8;7;6;;; +25517-4;LL1927-4;RAST;LA6111-4;1;0;;; +25517-4;LL1927-4;RAST;LA6112-2;2;1;;; +25517-4;LL1927-4;RAST;LA6113-0;3;2;;; +25517-4;LL1927-4;RAST;LA6114-8;4;3;;; +25517-4;LL1927-4;RAST;LA6115-5;5;4;;; +25517-4;LL1927-4;RAST;LA10137-0;6;5;;; +25517-4;LL1927-4;RAST;LA10138-8;7;6;;; +25522-4;LL1927-4;RAST;LA6111-4;1;0;;; +25522-4;LL1927-4;RAST;LA6112-2;2;1;;; +25522-4;LL1927-4;RAST;LA6113-0;3;2;;; +25522-4;LL1927-4;RAST;LA6114-8;4;3;;; +25522-4;LL1927-4;RAST;LA6115-5;5;4;;; +25522-4;LL1927-4;RAST;LA10137-0;6;5;;; +25522-4;LL1927-4;RAST;LA10138-8;7;6;;; +25525-7;LL1927-4;RAST;LA6111-4;1;0;;; +25525-7;LL1927-4;RAST;LA6112-2;2;1;;; +25525-7;LL1927-4;RAST;LA6113-0;3;2;;; +25525-7;LL1927-4;RAST;LA6114-8;4;3;;; +25525-7;LL1927-4;RAST;LA6115-5;5;4;;; +25525-7;LL1927-4;RAST;LA10137-0;6;5;;; +25525-7;LL1927-4;RAST;LA10138-8;7;6;;; +25532-3;LL1927-4;RAST;LA6111-4;1;0;;; +25532-3;LL1927-4;RAST;LA6112-2;2;1;;; +25532-3;LL1927-4;RAST;LA6113-0;3;2;;; +25532-3;LL1927-4;RAST;LA6114-8;4;3;;; +25532-3;LL1927-4;RAST;LA6115-5;5;4;;; +25532-3;LL1927-4;RAST;LA10137-0;6;5;;; +25532-3;LL1927-4;RAST;LA10138-8;7;6;;; +25536-4;LL1927-4;RAST;LA6111-4;1;0;;; +25536-4;LL1927-4;RAST;LA6112-2;2;1;;; +25536-4;LL1927-4;RAST;LA6113-0;3;2;;; +25536-4;LL1927-4;RAST;LA6114-8;4;3;;; +25536-4;LL1927-4;RAST;LA6115-5;5;4;;; +25536-4;LL1927-4;RAST;LA10137-0;6;5;;; +25536-4;LL1927-4;RAST;LA10138-8;7;6;;; +25539-8;LL1927-4;RAST;LA6111-4;1;0;;; +25539-8;LL1927-4;RAST;LA6112-2;2;1;;; +25539-8;LL1927-4;RAST;LA6113-0;3;2;;; +25539-8;LL1927-4;RAST;LA6114-8;4;3;;; +25539-8;LL1927-4;RAST;LA6115-5;5;4;;; +25539-8;LL1927-4;RAST;LA10137-0;6;5;;; +25539-8;LL1927-4;RAST;LA10138-8;7;6;;; +25554-7;LL1927-4;RAST;LA6111-4;1;0;;; +25554-7;LL1927-4;RAST;LA6112-2;2;1;;; +25554-7;LL1927-4;RAST;LA6113-0;3;2;;; +25554-7;LL1927-4;RAST;LA6114-8;4;3;;; +25554-7;LL1927-4;RAST;LA6115-5;5;4;;; +25554-7;LL1927-4;RAST;LA10137-0;6;5;;; +25554-7;LL1927-4;RAST;LA10138-8;7;6;;; +25566-1;LL1927-4;RAST;LA6111-4;1;0;;; +25566-1;LL1927-4;RAST;LA6112-2;2;1;;; +25566-1;LL1927-4;RAST;LA6113-0;3;2;;; +25566-1;LL1927-4;RAST;LA6114-8;4;3;;; +25566-1;LL1927-4;RAST;LA6115-5;5;4;;; +25566-1;LL1927-4;RAST;LA10137-0;6;5;;; +25566-1;LL1927-4;RAST;LA10138-8;7;6;;; +25585-1;LL1927-4;RAST;LA6111-4;1;0;;; +25585-1;LL1927-4;RAST;LA6112-2;2;1;;; +25585-1;LL1927-4;RAST;LA6113-0;3;2;;; +25585-1;LL1927-4;RAST;LA6114-8;4;3;;; +25585-1;LL1927-4;RAST;LA6115-5;5;4;;; +25585-1;LL1927-4;RAST;LA10137-0;6;5;;; +25585-1;LL1927-4;RAST;LA10138-8;7;6;;; +25586-9;LL1927-4;RAST;LA6111-4;1;0;;; +25586-9;LL1927-4;RAST;LA6112-2;2;1;;; +25586-9;LL1927-4;RAST;LA6113-0;3;2;;; +25586-9;LL1927-4;RAST;LA6114-8;4;3;;; +25586-9;LL1927-4;RAST;LA6115-5;5;4;;; +25586-9;LL1927-4;RAST;LA10137-0;6;5;;; +25586-9;LL1927-4;RAST;LA10138-8;7;6;;; +25610-7;LL1927-4;RAST;LA6111-4;1;0;;; +25610-7;LL1927-4;RAST;LA6112-2;2;1;;; +25610-7;LL1927-4;RAST;LA6113-0;3;2;;; +25610-7;LL1927-4;RAST;LA6114-8;4;3;;; +25610-7;LL1927-4;RAST;LA6115-5;5;4;;; +25610-7;LL1927-4;RAST;LA10137-0;6;5;;; +25610-7;LL1927-4;RAST;LA10138-8;7;6;;; +25612-3;LL1927-4;RAST;LA6111-4;1;0;;; +25612-3;LL1927-4;RAST;LA6112-2;2;1;;; +25612-3;LL1927-4;RAST;LA6113-0;3;2;;; +25612-3;LL1927-4;RAST;LA6114-8;4;3;;; +25612-3;LL1927-4;RAST;LA6115-5;5;4;;; +25612-3;LL1927-4;RAST;LA10137-0;6;5;;; +25612-3;LL1927-4;RAST;LA10138-8;7;6;;; +25614-9;LL1927-4;RAST;LA6111-4;1;0;;; +25614-9;LL1927-4;RAST;LA6112-2;2;1;;; +25614-9;LL1927-4;RAST;LA6113-0;3;2;;; +25614-9;LL1927-4;RAST;LA6114-8;4;3;;; +25614-9;LL1927-4;RAST;LA6115-5;5;4;;; +25614-9;LL1927-4;RAST;LA10137-0;6;5;;; +25614-9;LL1927-4;RAST;LA10138-8;7;6;;; +25616-4;LL1927-4;RAST;LA6111-4;1;0;;; +25616-4;LL1927-4;RAST;LA6112-2;2;1;;; +25616-4;LL1927-4;RAST;LA6113-0;3;2;;; +25616-4;LL1927-4;RAST;LA6114-8;4;3;;; +25616-4;LL1927-4;RAST;LA6115-5;5;4;;; +25616-4;LL1927-4;RAST;LA10137-0;6;5;;; +25616-4;LL1927-4;RAST;LA10138-8;7;6;;; +25634-7;LL1927-4;RAST;LA6111-4;1;0;;; +25634-7;LL1927-4;RAST;LA6112-2;2;1;;; +25634-7;LL1927-4;RAST;LA6113-0;3;2;;; +25634-7;LL1927-4;RAST;LA6114-8;4;3;;; +25634-7;LL1927-4;RAST;LA6115-5;5;4;;; +25634-7;LL1927-4;RAST;LA10137-0;6;5;;; +25634-7;LL1927-4;RAST;LA10138-8;7;6;;; +25701-4;LL1927-4;RAST;LA6111-4;1;0;;; +25701-4;LL1927-4;RAST;LA6112-2;2;1;;; +25701-4;LL1927-4;RAST;LA6113-0;3;2;;; +25701-4;LL1927-4;RAST;LA6114-8;4;3;;; +25701-4;LL1927-4;RAST;LA6115-5;5;4;;; +25701-4;LL1927-4;RAST;LA10137-0;6;5;;; +25701-4;LL1927-4;RAST;LA10138-8;7;6;;; +25704-8;LL1927-4;RAST;LA6111-4;1;0;;; +25704-8;LL1927-4;RAST;LA6112-2;2;1;;; +25704-8;LL1927-4;RAST;LA6113-0;3;2;;; +25704-8;LL1927-4;RAST;LA6114-8;4;3;;; +25704-8;LL1927-4;RAST;LA6115-5;5;4;;; +25704-8;LL1927-4;RAST;LA10137-0;6;5;;; +25704-8;LL1927-4;RAST;LA10138-8;7;6;;; +25715-4;LL1927-4;RAST;LA6111-4;1;0;;; +25715-4;LL1927-4;RAST;LA6112-2;2;1;;; +25715-4;LL1927-4;RAST;LA6113-0;3;2;;; +25715-4;LL1927-4;RAST;LA6114-8;4;3;;; +25715-4;LL1927-4;RAST;LA6115-5;5;4;;; +25715-4;LL1927-4;RAST;LA10137-0;6;5;;; +25715-4;LL1927-4;RAST;LA10138-8;7;6;;; +25728-7;LL1927-4;RAST;LA6111-4;1;0;;; +25728-7;LL1927-4;RAST;LA6112-2;2;1;;; +25728-7;LL1927-4;RAST;LA6113-0;3;2;;; +25728-7;LL1927-4;RAST;LA6114-8;4;3;;; +25728-7;LL1927-4;RAST;LA6115-5;5;4;;; +25728-7;LL1927-4;RAST;LA10137-0;6;5;;; +25728-7;LL1927-4;RAST;LA10138-8;7;6;;; +25744-4;LL1927-4;RAST;LA6111-4;1;0;;; +25744-4;LL1927-4;RAST;LA6112-2;2;1;;; +25744-4;LL1927-4;RAST;LA6113-0;3;2;;; +25744-4;LL1927-4;RAST;LA6114-8;4;3;;; +25744-4;LL1927-4;RAST;LA6115-5;5;4;;; +25744-4;LL1927-4;RAST;LA10137-0;6;5;;; +25744-4;LL1927-4;RAST;LA10138-8;7;6;;; +25780-8;LL1927-4;RAST;LA6111-4;1;0;;; +25780-8;LL1927-4;RAST;LA6112-2;2;1;;; +25780-8;LL1927-4;RAST;LA6113-0;3;2;;; +25780-8;LL1927-4;RAST;LA6114-8;4;3;;; +25780-8;LL1927-4;RAST;LA6115-5;5;4;;; +25780-8;LL1927-4;RAST;LA10137-0;6;5;;; +25780-8;LL1927-4;RAST;LA10138-8;7;6;;; +25802-0;LL1927-4;RAST;LA6111-4;1;0;;; +25802-0;LL1927-4;RAST;LA6112-2;2;1;;; +25802-0;LL1927-4;RAST;LA6113-0;3;2;;; +25802-0;LL1927-4;RAST;LA6114-8;4;3;;; +25802-0;LL1927-4;RAST;LA6115-5;5;4;;; +25802-0;LL1927-4;RAST;LA10137-0;6;5;;; +25802-0;LL1927-4;RAST;LA10138-8;7;6;;; +25815-2;LL1927-4;RAST;LA6111-4;1;0;;; +25815-2;LL1927-4;RAST;LA6112-2;2;1;;; +25815-2;LL1927-4;RAST;LA6113-0;3;2;;; +25815-2;LL1927-4;RAST;LA6114-8;4;3;;; +25815-2;LL1927-4;RAST;LA6115-5;5;4;;; +25815-2;LL1927-4;RAST;LA10137-0;6;5;;; +25815-2;LL1927-4;RAST;LA10138-8;7;6;;; +25823-6;LL1927-4;RAST;LA6111-4;1;0;;; +25823-6;LL1927-4;RAST;LA6112-2;2;1;;; +25823-6;LL1927-4;RAST;LA6113-0;3;2;;; +25823-6;LL1927-4;RAST;LA6114-8;4;3;;; +25823-6;LL1927-4;RAST;LA6115-5;5;4;;; +25823-6;LL1927-4;RAST;LA10137-0;6;5;;; +25823-6;LL1927-4;RAST;LA10138-8;7;6;;; +25825-1;LL1927-4;RAST;LA6111-4;1;0;;; +25825-1;LL1927-4;RAST;LA6112-2;2;1;;; +25825-1;LL1927-4;RAST;LA6113-0;3;2;;; +25825-1;LL1927-4;RAST;LA6114-8;4;3;;; +25825-1;LL1927-4;RAST;LA6115-5;5;4;;; +25825-1;LL1927-4;RAST;LA10137-0;6;5;;; +25825-1;LL1927-4;RAST;LA10138-8;7;6;;; +25827-7;LL1927-4;RAST;LA6111-4;1;0;;; +25827-7;LL1927-4;RAST;LA6112-2;2;1;;; +25827-7;LL1927-4;RAST;LA6113-0;3;2;;; +25827-7;LL1927-4;RAST;LA6114-8;4;3;;; +25827-7;LL1927-4;RAST;LA6115-5;5;4;;; +25827-7;LL1927-4;RAST;LA10137-0;6;5;;; +25827-7;LL1927-4;RAST;LA10138-8;7;6;;; +25960-6;LL1927-4;RAST;LA6111-4;1;0;;; +25960-6;LL1927-4;RAST;LA6112-2;2;1;;; +25960-6;LL1927-4;RAST;LA6113-0;3;2;;; +25960-6;LL1927-4;RAST;LA6114-8;4;3;;; +25960-6;LL1927-4;RAST;LA6115-5;5;4;;; +25960-6;LL1927-4;RAST;LA10137-0;6;5;;; +25960-6;LL1927-4;RAST;LA10138-8;7;6;;; +25967-1;LL1927-4;RAST;LA6111-4;1;0;;; +25967-1;LL1927-4;RAST;LA6112-2;2;1;;; +25967-1;LL1927-4;RAST;LA6113-0;3;2;;; +25967-1;LL1927-4;RAST;LA6114-8;4;3;;; +25967-1;LL1927-4;RAST;LA6115-5;5;4;;; +25967-1;LL1927-4;RAST;LA10137-0;6;5;;; +25967-1;LL1927-4;RAST;LA10138-8;7;6;;; +25982-0;LL1927-4;RAST;LA6111-4;1;0;;; +25982-0;LL1927-4;RAST;LA6112-2;2;1;;; +25982-0;LL1927-4;RAST;LA6113-0;3;2;;; +25982-0;LL1927-4;RAST;LA6114-8;4;3;;; +25982-0;LL1927-4;RAST;LA6115-5;5;4;;; +25982-0;LL1927-4;RAST;LA10137-0;6;5;;; +25982-0;LL1927-4;RAST;LA10138-8;7;6;;; +25983-8;LL1927-4;RAST;LA6111-4;1;0;;; +25983-8;LL1927-4;RAST;LA6112-2;2;1;;; +25983-8;LL1927-4;RAST;LA6113-0;3;2;;; +25983-8;LL1927-4;RAST;LA6114-8;4;3;;; +25983-8;LL1927-4;RAST;LA6115-5;5;4;;; +25983-8;LL1927-4;RAST;LA10137-0;6;5;;; +25983-8;LL1927-4;RAST;LA10138-8;7;6;;; +26018-2;LL1927-4;RAST;LA6111-4;1;0;;; +26018-2;LL1927-4;RAST;LA6112-2;2;1;;; +26018-2;LL1927-4;RAST;LA6113-0;3;2;;; +26018-2;LL1927-4;RAST;LA6114-8;4;3;;; +26018-2;LL1927-4;RAST;LA6115-5;5;4;;; +26018-2;LL1927-4;RAST;LA10137-0;6;5;;; +26018-2;LL1927-4;RAST;LA10138-8;7;6;;; +26026-5;LL1927-4;RAST;LA6111-4;1;0;;; +26026-5;LL1927-4;RAST;LA6112-2;2;1;;; +26026-5;LL1927-4;RAST;LA6113-0;3;2;;; +26026-5;LL1927-4;RAST;LA6114-8;4;3;;; +26026-5;LL1927-4;RAST;LA6115-5;5;4;;; +26026-5;LL1927-4;RAST;LA10137-0;6;5;;; +26026-5;LL1927-4;RAST;LA10138-8;7;6;;; +26030-7;LL1927-4;RAST;LA6111-4;1;0;;; +26030-7;LL1927-4;RAST;LA6112-2;2;1;;; +26030-7;LL1927-4;RAST;LA6113-0;3;2;;; +26030-7;LL1927-4;RAST;LA6114-8;4;3;;; +26030-7;LL1927-4;RAST;LA6115-5;5;4;;; +26030-7;LL1927-4;RAST;LA10137-0;6;5;;; +26030-7;LL1927-4;RAST;LA10138-8;7;6;;; +26032-3;LL1927-4;RAST;LA6111-4;1;0;;; +26032-3;LL1927-4;RAST;LA6112-2;2;1;;; +26032-3;LL1927-4;RAST;LA6113-0;3;2;;; +26032-3;LL1927-4;RAST;LA6114-8;4;3;;; +26032-3;LL1927-4;RAST;LA6115-5;5;4;;; +26032-3;LL1927-4;RAST;LA10137-0;6;5;;; +26032-3;LL1927-4;RAST;LA10138-8;7;6;;; +26036-4;LL1927-4;RAST;LA6111-4;1;0;;; +26036-4;LL1927-4;RAST;LA6112-2;2;1;;; +26036-4;LL1927-4;RAST;LA6113-0;3;2;;; +26036-4;LL1927-4;RAST;LA6114-8;4;3;;; +26036-4;LL1927-4;RAST;LA6115-5;5;4;;; +26036-4;LL1927-4;RAST;LA10137-0;6;5;;; +26036-4;LL1927-4;RAST;LA10138-8;7;6;;; +26038-0;LL1927-4;RAST;LA6111-4;1;0;;; +26038-0;LL1927-4;RAST;LA6112-2;2;1;;; +26038-0;LL1927-4;RAST;LA6113-0;3;2;;; +26038-0;LL1927-4;RAST;LA6114-8;4;3;;; +26038-0;LL1927-4;RAST;LA6115-5;5;4;;; +26038-0;LL1927-4;RAST;LA10137-0;6;5;;; +26038-0;LL1927-4;RAST;LA10138-8;7;6;;; +26048-9;LL1927-4;RAST;LA6111-4;1;0;;; +26048-9;LL1927-4;RAST;LA6112-2;2;1;;; +26048-9;LL1927-4;RAST;LA6113-0;3;2;;; +26048-9;LL1927-4;RAST;LA6114-8;4;3;;; +26048-9;LL1927-4;RAST;LA6115-5;5;4;;; +26048-9;LL1927-4;RAST;LA10137-0;6;5;;; +26048-9;LL1927-4;RAST;LA10138-8;7;6;;; +26050-5;LL1927-4;RAST;LA6111-4;1;0;;; +26050-5;LL1927-4;RAST;LA6112-2;2;1;;; +26050-5;LL1927-4;RAST;LA6113-0;3;2;;; +26050-5;LL1927-4;RAST;LA6114-8;4;3;;; +26050-5;LL1927-4;RAST;LA6115-5;5;4;;; +26050-5;LL1927-4;RAST;LA10137-0;6;5;;; +26050-5;LL1927-4;RAST;LA10138-8;7;6;;; +26404-4;LL1927-4;RAST;LA6111-4;1;0;;; +26404-4;LL1927-4;RAST;LA6112-2;2;1;;; +26404-4;LL1927-4;RAST;LA6113-0;3;2;;; +26404-4;LL1927-4;RAST;LA6114-8;4;3;;; +26404-4;LL1927-4;RAST;LA6115-5;5;4;;; +26404-4;LL1927-4;RAST;LA10137-0;6;5;;; +26404-4;LL1927-4;RAST;LA10138-8;7;6;;; +26406-9;LL1927-4;RAST;LA6111-4;1;0;;; +26406-9;LL1927-4;RAST;LA6112-2;2;1;;; +26406-9;LL1927-4;RAST;LA6113-0;3;2;;; +26406-9;LL1927-4;RAST;LA6114-8;4;3;;; +26406-9;LL1927-4;RAST;LA6115-5;5;4;;; +26406-9;LL1927-4;RAST;LA10137-0;6;5;;; +26406-9;LL1927-4;RAST;LA10138-8;7;6;;; +26408-5;LL1927-4;RAST;LA6111-4;1;0;;; +26408-5;LL1927-4;RAST;LA6112-2;2;1;;; +26408-5;LL1927-4;RAST;LA6113-0;3;2;;; +26408-5;LL1927-4;RAST;LA6114-8;4;3;;; +26408-5;LL1927-4;RAST;LA6115-5;5;4;;; +26408-5;LL1927-4;RAST;LA10137-0;6;5;;; +26408-5;LL1927-4;RAST;LA10138-8;7;6;;; +26410-1;LL1927-4;RAST;LA6111-4;1;0;;; +26410-1;LL1927-4;RAST;LA6112-2;2;1;;; +26410-1;LL1927-4;RAST;LA6113-0;3;2;;; +26410-1;LL1927-4;RAST;LA6114-8;4;3;;; +26410-1;LL1927-4;RAST;LA6115-5;5;4;;; +26410-1;LL1927-4;RAST;LA10137-0;6;5;;; +26410-1;LL1927-4;RAST;LA10138-8;7;6;;; +26412-7;LL1927-4;RAST;LA6111-4;1;0;;; +26412-7;LL1927-4;RAST;LA6112-2;2;1;;; +26412-7;LL1927-4;RAST;LA6113-0;3;2;;; +26412-7;LL1927-4;RAST;LA6114-8;4;3;;; +26412-7;LL1927-4;RAST;LA6115-5;5;4;;; +26412-7;LL1927-4;RAST;LA10137-0;6;5;;; +26412-7;LL1927-4;RAST;LA10138-8;7;6;;; +26414-3;LL1927-4;RAST;LA6111-4;1;0;;; +26414-3;LL1927-4;RAST;LA6112-2;2;1;;; +26414-3;LL1927-4;RAST;LA6113-0;3;2;;; +26414-3;LL1927-4;RAST;LA6114-8;4;3;;; +26414-3;LL1927-4;RAST;LA6115-5;5;4;;; +26414-3;LL1927-4;RAST;LA10137-0;6;5;;; +26414-3;LL1927-4;RAST;LA10138-8;7;6;;; +26416-8;LL1927-4;RAST;LA6111-4;1;0;;; +26416-8;LL1927-4;RAST;LA6112-2;2;1;;; +26416-8;LL1927-4;RAST;LA6113-0;3;2;;; +26416-8;LL1927-4;RAST;LA6114-8;4;3;;; +26416-8;LL1927-4;RAST;LA6115-5;5;4;;; +26416-8;LL1927-4;RAST;LA10137-0;6;5;;; +26416-8;LL1927-4;RAST;LA10138-8;7;6;;; +26418-4;LL1927-4;RAST;LA6111-4;1;0;;; +26418-4;LL1927-4;RAST;LA6112-2;2;1;;; +26418-4;LL1927-4;RAST;LA6113-0;3;2;;; +26418-4;LL1927-4;RAST;LA6114-8;4;3;;; +26418-4;LL1927-4;RAST;LA6115-5;5;4;;; +26418-4;LL1927-4;RAST;LA10137-0;6;5;;; +26418-4;LL1927-4;RAST;LA10138-8;7;6;;; +26420-0;LL1927-4;RAST;LA6111-4;1;0;;; +26420-0;LL1927-4;RAST;LA6112-2;2;1;;; +26420-0;LL1927-4;RAST;LA6113-0;3;2;;; +26420-0;LL1927-4;RAST;LA6114-8;4;3;;; +26420-0;LL1927-4;RAST;LA6115-5;5;4;;; +26420-0;LL1927-4;RAST;LA10137-0;6;5;;; +26420-0;LL1927-4;RAST;LA10138-8;7;6;;; +26422-6;LL1927-4;RAST;LA6111-4;1;0;;; +26422-6;LL1927-4;RAST;LA6112-2;2;1;;; +26422-6;LL1927-4;RAST;LA6113-0;3;2;;; +26422-6;LL1927-4;RAST;LA6114-8;4;3;;; +26422-6;LL1927-4;RAST;LA6115-5;5;4;;; +26422-6;LL1927-4;RAST;LA10137-0;6;5;;; +26422-6;LL1927-4;RAST;LA10138-8;7;6;;; +26424-2;LL1927-4;RAST;LA6111-4;1;0;;; +26424-2;LL1927-4;RAST;LA6112-2;2;1;;; +26424-2;LL1927-4;RAST;LA6113-0;3;2;;; +26424-2;LL1927-4;RAST;LA6114-8;4;3;;; +26424-2;LL1927-4;RAST;LA6115-5;5;4;;; +26424-2;LL1927-4;RAST;LA10137-0;6;5;;; +26424-2;LL1927-4;RAST;LA10138-8;7;6;;; +26426-7;LL1927-4;RAST;LA6111-4;1;0;;; +26426-7;LL1927-4;RAST;LA6112-2;2;1;;; +26426-7;LL1927-4;RAST;LA6113-0;3;2;;; +26426-7;LL1927-4;RAST;LA6114-8;4;3;;; +26426-7;LL1927-4;RAST;LA6115-5;5;4;;; +26426-7;LL1927-4;RAST;LA10137-0;6;5;;; +26426-7;LL1927-4;RAST;LA10138-8;7;6;;; +26429-1;LL1927-4;RAST;LA6111-4;1;0;;; +26429-1;LL1927-4;RAST;LA6112-2;2;1;;; +26429-1;LL1927-4;RAST;LA6113-0;3;2;;; +26429-1;LL1927-4;RAST;LA6114-8;4;3;;; +26429-1;LL1927-4;RAST;LA6115-5;5;4;;; +26429-1;LL1927-4;RAST;LA10137-0;6;5;;; +26429-1;LL1927-4;RAST;LA10138-8;7;6;;; +26431-7;LL1927-4;RAST;LA6111-4;1;0;;; +26431-7;LL1927-4;RAST;LA6112-2;2;1;;; +26431-7;LL1927-4;RAST;LA6113-0;3;2;;; +26431-7;LL1927-4;RAST;LA6114-8;4;3;;; +26431-7;LL1927-4;RAST;LA6115-5;5;4;;; +26431-7;LL1927-4;RAST;LA10137-0;6;5;;; +26431-7;LL1927-4;RAST;LA10138-8;7;6;;; +26433-3;LL1927-4;RAST;LA6111-4;1;0;;; +26433-3;LL1927-4;RAST;LA6112-2;2;1;;; +26433-3;LL1927-4;RAST;LA6113-0;3;2;;; +26433-3;LL1927-4;RAST;LA6114-8;4;3;;; +26433-3;LL1927-4;RAST;LA6115-5;5;4;;; +26433-3;LL1927-4;RAST;LA10137-0;6;5;;; +26433-3;LL1927-4;RAST;LA10138-8;7;6;;; +26434-1;LL1927-4;RAST;LA6111-4;1;0;;; +26434-1;LL1927-4;RAST;LA6112-2;2;1;;; +26434-1;LL1927-4;RAST;LA6113-0;3;2;;; +26434-1;LL1927-4;RAST;LA6114-8;4;3;;; +26434-1;LL1927-4;RAST;LA6115-5;5;4;;; +26434-1;LL1927-4;RAST;LA10137-0;6;5;;; +26434-1;LL1927-4;RAST;LA10138-8;7;6;;; +29534-5;LL1927-4;RAST;LA6111-4;1;0;;; +29534-5;LL1927-4;RAST;LA6112-2;2;1;;; +29534-5;LL1927-4;RAST;LA6113-0;3;2;;; +29534-5;LL1927-4;RAST;LA6114-8;4;3;;; +29534-5;LL1927-4;RAST;LA6115-5;5;4;;; +29534-5;LL1927-4;RAST;LA10137-0;6;5;;; +29534-5;LL1927-4;RAST;LA10138-8;7;6;;; +29618-6;LL1927-4;RAST;LA6111-4;1;0;;; +29618-6;LL1927-4;RAST;LA6112-2;2;1;;; +29618-6;LL1927-4;RAST;LA6113-0;3;2;;; +29618-6;LL1927-4;RAST;LA6114-8;4;3;;; +29618-6;LL1927-4;RAST;LA6115-5;5;4;;; +29618-6;LL1927-4;RAST;LA10137-0;6;5;;; +29618-6;LL1927-4;RAST;LA10138-8;7;6;;; +29861-2;LL1927-4;RAST;LA6111-4;1;0;;; +29861-2;LL1927-4;RAST;LA6112-2;2;1;;; +29861-2;LL1927-4;RAST;LA6113-0;3;2;;; +29861-2;LL1927-4;RAST;LA6114-8;4;3;;; +29861-2;LL1927-4;RAST;LA6115-5;5;4;;; +29861-2;LL1927-4;RAST;LA10137-0;6;5;;; +29861-2;LL1927-4;RAST;LA10138-8;7;6;;; +29862-0;LL1927-4;RAST;LA6111-4;1;0;;; +29862-0;LL1927-4;RAST;LA6112-2;2;1;;; +29862-0;LL1927-4;RAST;LA6113-0;3;2;;; +29862-0;LL1927-4;RAST;LA6114-8;4;3;;; +29862-0;LL1927-4;RAST;LA6115-5;5;4;;; +29862-0;LL1927-4;RAST;LA10137-0;6;5;;; +29862-0;LL1927-4;RAST;LA10138-8;7;6;;; +30125-9;LL1927-4;RAST;LA6111-4;1;0;;; +30125-9;LL1927-4;RAST;LA6112-2;2;1;;; +30125-9;LL1927-4;RAST;LA6113-0;3;2;;; +30125-9;LL1927-4;RAST;LA6114-8;4;3;;; +30125-9;LL1927-4;RAST;LA6115-5;5;4;;; +30125-9;LL1927-4;RAST;LA10137-0;6;5;;; +30125-9;LL1927-4;RAST;LA10138-8;7;6;;; +30126-7;LL1927-4;RAST;LA6111-4;1;0;;; +30126-7;LL1927-4;RAST;LA6112-2;2;1;;; +30126-7;LL1927-4;RAST;LA6113-0;3;2;;; +30126-7;LL1927-4;RAST;LA6114-8;4;3;;; +30126-7;LL1927-4;RAST;LA6115-5;5;4;;; +30126-7;LL1927-4;RAST;LA10137-0;6;5;;; +30126-7;LL1927-4;RAST;LA10138-8;7;6;;; +31001-1;LL1927-4;RAST;LA6111-4;1;0;;; +31001-1;LL1927-4;RAST;LA6112-2;2;1;;; +31001-1;LL1927-4;RAST;LA6113-0;3;2;;; +31001-1;LL1927-4;RAST;LA6114-8;4;3;;; +31001-1;LL1927-4;RAST;LA6115-5;5;4;;; +31001-1;LL1927-4;RAST;LA10137-0;6;5;;; +31001-1;LL1927-4;RAST;LA10138-8;7;6;;; +31011-0;LL1927-4;RAST;LA6111-4;1;0;;; +31011-0;LL1927-4;RAST;LA6112-2;2;1;;; +31011-0;LL1927-4;RAST;LA6113-0;3;2;;; +31011-0;LL1927-4;RAST;LA6114-8;4;3;;; +31011-0;LL1927-4;RAST;LA6115-5;5;4;;; +31011-0;LL1927-4;RAST;LA10137-0;6;5;;; +31011-0;LL1927-4;RAST;LA10138-8;7;6;;; +31078-9;LL1927-4;RAST;LA6111-4;1;0;;; +31078-9;LL1927-4;RAST;LA6112-2;2;1;;; +31078-9;LL1927-4;RAST;LA6113-0;3;2;;; +31078-9;LL1927-4;RAST;LA6114-8;4;3;;; +31078-9;LL1927-4;RAST;LA6115-5;5;4;;; +31078-9;LL1927-4;RAST;LA10137-0;6;5;;; +31078-9;LL1927-4;RAST;LA10138-8;7;6;;; +31079-7;LL1927-4;RAST;LA6111-4;1;0;;; +31079-7;LL1927-4;RAST;LA6112-2;2;1;;; +31079-7;LL1927-4;RAST;LA6113-0;3;2;;; +31079-7;LL1927-4;RAST;LA6114-8;4;3;;; +31079-7;LL1927-4;RAST;LA6115-5;5;4;;; +31079-7;LL1927-4;RAST;LA10137-0;6;5;;; +31079-7;LL1927-4;RAST;LA10138-8;7;6;;; +32573-8;LL1927-4;RAST;LA6111-4;1;0;;; +32573-8;LL1927-4;RAST;LA6112-2;2;1;;; +32573-8;LL1927-4;RAST;LA6113-0;3;2;;; +32573-8;LL1927-4;RAST;LA6114-8;4;3;;; +32573-8;LL1927-4;RAST;LA6115-5;5;4;;; +32573-8;LL1927-4;RAST;LA10137-0;6;5;;; +32573-8;LL1927-4;RAST;LA10138-8;7;6;;; +33003-5;LL1927-4;RAST;LA6111-4;1;0;;; +33003-5;LL1927-4;RAST;LA6112-2;2;1;;; +33003-5;LL1927-4;RAST;LA6113-0;3;2;;; +33003-5;LL1927-4;RAST;LA6114-8;4;3;;; +33003-5;LL1927-4;RAST;LA6115-5;5;4;;; +33003-5;LL1927-4;RAST;LA10137-0;6;5;;; +33003-5;LL1927-4;RAST;LA10138-8;7;6;;; +33005-0;LL1927-4;RAST;LA6111-4;1;0;;; +33005-0;LL1927-4;RAST;LA6112-2;2;1;;; +33005-0;LL1927-4;RAST;LA6113-0;3;2;;; +33005-0;LL1927-4;RAST;LA6114-8;4;3;;; +33005-0;LL1927-4;RAST;LA6115-5;5;4;;; +33005-0;LL1927-4;RAST;LA10137-0;6;5;;; +33005-0;LL1927-4;RAST;LA10138-8;7;6;;; +33011-8;LL1927-4;RAST;LA6111-4;1;0;;; +33011-8;LL1927-4;RAST;LA6112-2;2;1;;; +33011-8;LL1927-4;RAST;LA6113-0;3;2;;; +33011-8;LL1927-4;RAST;LA6114-8;4;3;;; +33011-8;LL1927-4;RAST;LA6115-5;5;4;;; +33011-8;LL1927-4;RAST;LA10137-0;6;5;;; +33011-8;LL1927-4;RAST;LA10138-8;7;6;;; +33013-4;LL1927-4;RAST;LA6111-4;1;0;;; +33013-4;LL1927-4;RAST;LA6112-2;2;1;;; +33013-4;LL1927-4;RAST;LA6113-0;3;2;;; +33013-4;LL1927-4;RAST;LA6114-8;4;3;;; +33013-4;LL1927-4;RAST;LA6115-5;5;4;;; +33013-4;LL1927-4;RAST;LA10137-0;6;5;;; +33013-4;LL1927-4;RAST;LA10138-8;7;6;;; +33015-9;LL1927-4;RAST;LA6111-4;1;0;;; +33015-9;LL1927-4;RAST;LA6112-2;2;1;;; +33015-9;LL1927-4;RAST;LA6113-0;3;2;;; +33015-9;LL1927-4;RAST;LA6114-8;4;3;;; +33015-9;LL1927-4;RAST;LA6115-5;5;4;;; +33015-9;LL1927-4;RAST;LA10137-0;6;5;;; +33015-9;LL1927-4;RAST;LA10138-8;7;6;;; +33276-7;LL1927-4;RAST;LA6111-4;1;0;;; +33276-7;LL1927-4;RAST;LA6112-2;2;1;;; +33276-7;LL1927-4;RAST;LA6113-0;3;2;;; +33276-7;LL1927-4;RAST;LA6114-8;4;3;;; +33276-7;LL1927-4;RAST;LA6115-5;5;4;;; +33276-7;LL1927-4;RAST;LA10137-0;6;5;;; +33276-7;LL1927-4;RAST;LA10138-8;7;6;;; +33281-7;LL1927-4;RAST;LA6111-4;1;0;;; +33281-7;LL1927-4;RAST;LA6112-2;2;1;;; +33281-7;LL1927-4;RAST;LA6113-0;3;2;;; +33281-7;LL1927-4;RAST;LA6114-8;4;3;;; +33281-7;LL1927-4;RAST;LA6115-5;5;4;;; +33281-7;LL1927-4;RAST;LA10137-0;6;5;;; +33281-7;LL1927-4;RAST;LA10138-8;7;6;;; +33283-3;LL1927-4;RAST;LA6111-4;1;0;;; +33283-3;LL1927-4;RAST;LA6112-2;2;1;;; +33283-3;LL1927-4;RAST;LA6113-0;3;2;;; +33283-3;LL1927-4;RAST;LA6114-8;4;3;;; +33283-3;LL1927-4;RAST;LA6115-5;5;4;;; +33283-3;LL1927-4;RAST;LA10137-0;6;5;;; +33283-3;LL1927-4;RAST;LA10138-8;7;6;;; +33286-6;LL1927-4;RAST;LA6111-4;1;0;;; +33286-6;LL1927-4;RAST;LA6112-2;2;1;;; +33286-6;LL1927-4;RAST;LA6113-0;3;2;;; +33286-6;LL1927-4;RAST;LA6114-8;4;3;;; +33286-6;LL1927-4;RAST;LA6115-5;5;4;;; +33286-6;LL1927-4;RAST;LA10137-0;6;5;;; +33286-6;LL1927-4;RAST;LA10138-8;7;6;;; +33289-0;LL1927-4;RAST;LA6111-4;1;0;;; +33289-0;LL1927-4;RAST;LA6112-2;2;1;;; +33289-0;LL1927-4;RAST;LA6113-0;3;2;;; +33289-0;LL1927-4;RAST;LA6114-8;4;3;;; +33289-0;LL1927-4;RAST;LA6115-5;5;4;;; +33289-0;LL1927-4;RAST;LA10137-0;6;5;;; +33289-0;LL1927-4;RAST;LA10138-8;7;6;;; +33296-5;LL1927-4;RAST;LA6111-4;1;0;;; +33296-5;LL1927-4;RAST;LA6112-2;2;1;;; +33296-5;LL1927-4;RAST;LA6113-0;3;2;;; +33296-5;LL1927-4;RAST;LA6114-8;4;3;;; +33296-5;LL1927-4;RAST;LA6115-5;5;4;;; +33296-5;LL1927-4;RAST;LA10137-0;6;5;;; +33296-5;LL1927-4;RAST;LA10138-8;7;6;;; +33297-3;LL1927-4;RAST;LA6111-4;1;0;;; +33297-3;LL1927-4;RAST;LA6112-2;2;1;;; +33297-3;LL1927-4;RAST;LA6113-0;3;2;;; +33297-3;LL1927-4;RAST;LA6114-8;4;3;;; +33297-3;LL1927-4;RAST;LA6115-5;5;4;;; +33297-3;LL1927-4;RAST;LA10137-0;6;5;;; +33297-3;LL1927-4;RAST;LA10138-8;7;6;;; +33302-1;LL1927-4;RAST;LA6111-4;1;0;;; +33302-1;LL1927-4;RAST;LA6112-2;2;1;;; +33302-1;LL1927-4;RAST;LA6113-0;3;2;;; +33302-1;LL1927-4;RAST;LA6114-8;4;3;;; +33302-1;LL1927-4;RAST;LA6115-5;5;4;;; +33302-1;LL1927-4;RAST;LA10137-0;6;5;;; +33302-1;LL1927-4;RAST;LA10138-8;7;6;;; +33303-9;LL1927-4;RAST;LA6111-4;1;0;;; +33303-9;LL1927-4;RAST;LA6112-2;2;1;;; +33303-9;LL1927-4;RAST;LA6113-0;3;2;;; +33303-9;LL1927-4;RAST;LA6114-8;4;3;;; +33303-9;LL1927-4;RAST;LA6115-5;5;4;;; +33303-9;LL1927-4;RAST;LA10137-0;6;5;;; +33303-9;LL1927-4;RAST;LA10138-8;7;6;;; +33304-7;LL1927-4;RAST;LA6111-4;1;0;;; +33304-7;LL1927-4;RAST;LA6112-2;2;1;;; +33304-7;LL1927-4;RAST;LA6113-0;3;2;;; +33304-7;LL1927-4;RAST;LA6114-8;4;3;;; +33304-7;LL1927-4;RAST;LA6115-5;5;4;;; +33304-7;LL1927-4;RAST;LA10137-0;6;5;;; +33304-7;LL1927-4;RAST;LA10138-8;7;6;;; +33305-4;LL1927-4;RAST;LA6111-4;1;0;;; +33305-4;LL1927-4;RAST;LA6112-2;2;1;;; +33305-4;LL1927-4;RAST;LA6113-0;3;2;;; +33305-4;LL1927-4;RAST;LA6114-8;4;3;;; +33305-4;LL1927-4;RAST;LA6115-5;5;4;;; +33305-4;LL1927-4;RAST;LA10137-0;6;5;;; +33305-4;LL1927-4;RAST;LA10138-8;7;6;;; +33312-0;LL1927-4;RAST;LA6111-4;1;0;;; +33312-0;LL1927-4;RAST;LA6112-2;2;1;;; +33312-0;LL1927-4;RAST;LA6113-0;3;2;;; +33312-0;LL1927-4;RAST;LA6114-8;4;3;;; +33312-0;LL1927-4;RAST;LA6115-5;5;4;;; +33312-0;LL1927-4;RAST;LA10137-0;6;5;;; +33312-0;LL1927-4;RAST;LA10138-8;7;6;;; +33315-3;LL1927-4;RAST;LA6111-4;1;0;;; +33315-3;LL1927-4;RAST;LA6112-2;2;1;;; +33315-3;LL1927-4;RAST;LA6113-0;3;2;;; +33315-3;LL1927-4;RAST;LA6114-8;4;3;;; +33315-3;LL1927-4;RAST;LA6115-5;5;4;;; +33315-3;LL1927-4;RAST;LA10137-0;6;5;;; +33315-3;LL1927-4;RAST;LA10138-8;7;6;;; +33324-5;LL1927-4;RAST;LA6111-4;1;0;;; +33324-5;LL1927-4;RAST;LA6112-2;2;1;;; +33324-5;LL1927-4;RAST;LA6113-0;3;2;;; +33324-5;LL1927-4;RAST;LA6114-8;4;3;;; +33324-5;LL1927-4;RAST;LA6115-5;5;4;;; +33324-5;LL1927-4;RAST;LA10137-0;6;5;;; +33324-5;LL1927-4;RAST;LA10138-8;7;6;;; +33536-4;LL1927-4;RAST;LA6111-4;1;0;;; +33536-4;LL1927-4;RAST;LA6112-2;2;1;;; +33536-4;LL1927-4;RAST;LA6113-0;3;2;;; +33536-4;LL1927-4;RAST;LA6114-8;4;3;;; +33536-4;LL1927-4;RAST;LA6115-5;5;4;;; +33536-4;LL1927-4;RAST;LA10137-0;6;5;;; +33536-4;LL1927-4;RAST;LA10138-8;7;6;;; +33922-6;LL1927-4;RAST;LA6111-4;1;0;;; +33922-6;LL1927-4;RAST;LA6112-2;2;1;;; +33922-6;LL1927-4;RAST;LA6113-0;3;2;;; +33922-6;LL1927-4;RAST;LA6114-8;4;3;;; +33922-6;LL1927-4;RAST;LA6115-5;5;4;;; +33922-6;LL1927-4;RAST;LA10137-0;6;5;;; +33922-6;LL1927-4;RAST;LA10138-8;7;6;;; +35731-9;LL1927-4;RAST;LA6111-4;1;0;;; +35731-9;LL1927-4;RAST;LA6112-2;2;1;;; +35731-9;LL1927-4;RAST;LA6113-0;3;2;;; +35731-9;LL1927-4;RAST;LA6114-8;4;3;;; +35731-9;LL1927-4;RAST;LA6115-5;5;4;;; +35731-9;LL1927-4;RAST;LA10137-0;6;5;;; +35731-9;LL1927-4;RAST;LA10138-8;7;6;;; +41272-6;LL1927-4;RAST;LA6111-4;1;0;;; +41272-6;LL1927-4;RAST;LA6112-2;2;1;;; +41272-6;LL1927-4;RAST;LA6113-0;3;2;;; +41272-6;LL1927-4;RAST;LA6114-8;4;3;;; +41272-6;LL1927-4;RAST;LA6115-5;5;4;;; +41272-6;LL1927-4;RAST;LA10137-0;6;5;;; +41272-6;LL1927-4;RAST;LA10138-8;7;6;;; +42583-5;LL1927-4;RAST;LA6111-4;1;0;;; +42583-5;LL1927-4;RAST;LA6112-2;2;1;;; +42583-5;LL1927-4;RAST;LA6113-0;3;2;;; +42583-5;LL1927-4;RAST;LA6114-8;4;3;;; +42583-5;LL1927-4;RAST;LA6115-5;5;4;;; +42583-5;LL1927-4;RAST;LA10137-0;6;5;;; +42583-5;LL1927-4;RAST;LA10138-8;7;6;;; +43276-5;LL1927-4;RAST;LA6111-4;1;0;;; +43276-5;LL1927-4;RAST;LA6112-2;2;1;;; +43276-5;LL1927-4;RAST;LA6113-0;3;2;;; +43276-5;LL1927-4;RAST;LA6114-8;4;3;;; +43276-5;LL1927-4;RAST;LA6115-5;5;4;;; +43276-5;LL1927-4;RAST;LA10137-0;6;5;;; +43276-5;LL1927-4;RAST;LA10138-8;7;6;;; +43373-0;LL1927-4;RAST;LA6111-4;1;0;;; +43373-0;LL1927-4;RAST;LA6112-2;2;1;;; +43373-0;LL1927-4;RAST;LA6113-0;3;2;;; +43373-0;LL1927-4;RAST;LA6114-8;4;3;;; +43373-0;LL1927-4;RAST;LA6115-5;5;4;;; +43373-0;LL1927-4;RAST;LA10137-0;6;5;;; +43373-0;LL1927-4;RAST;LA10138-8;7;6;;; +43374-8;LL1927-4;RAST;LA6111-4;1;0;;; +43374-8;LL1927-4;RAST;LA6112-2;2;1;;; +43374-8;LL1927-4;RAST;LA6113-0;3;2;;; +43374-8;LL1927-4;RAST;LA6114-8;4;3;;; +43374-8;LL1927-4;RAST;LA6115-5;5;4;;; +43374-8;LL1927-4;RAST;LA10137-0;6;5;;; +43374-8;LL1927-4;RAST;LA10138-8;7;6;;; +43375-5;LL1927-4;RAST;LA6111-4;1;0;;; +43375-5;LL1927-4;RAST;LA6112-2;2;1;;; +43375-5;LL1927-4;RAST;LA6113-0;3;2;;; +43375-5;LL1927-4;RAST;LA6114-8;4;3;;; +43375-5;LL1927-4;RAST;LA6115-5;5;4;;; +43375-5;LL1927-4;RAST;LA10137-0;6;5;;; +43375-5;LL1927-4;RAST;LA10138-8;7;6;;; +43692-3;LL1927-4;RAST;LA6111-4;1;0;;; +43692-3;LL1927-4;RAST;LA6112-2;2;1;;; +43692-3;LL1927-4;RAST;LA6113-0;3;2;;; +43692-3;LL1927-4;RAST;LA6114-8;4;3;;; +43692-3;LL1927-4;RAST;LA6115-5;5;4;;; +43692-3;LL1927-4;RAST;LA10137-0;6;5;;; +43692-3;LL1927-4;RAST;LA10138-8;7;6;;; +43841-6;LL1927-4;RAST;LA6111-4;1;0;;; +43841-6;LL1927-4;RAST;LA6112-2;2;1;;; +43841-6;LL1927-4;RAST;LA6113-0;3;2;;; +43841-6;LL1927-4;RAST;LA6114-8;4;3;;; +43841-6;LL1927-4;RAST;LA6115-5;5;4;;; +43841-6;LL1927-4;RAST;LA10137-0;6;5;;; +43841-6;LL1927-4;RAST;LA10138-8;7;6;;; +43862-2;LL1927-4;RAST;LA6111-4;1;0;;; +43862-2;LL1927-4;RAST;LA6112-2;2;1;;; +43862-2;LL1927-4;RAST;LA6113-0;3;2;;; +43862-2;LL1927-4;RAST;LA6114-8;4;3;;; +43862-2;LL1927-4;RAST;LA6115-5;5;4;;; +43862-2;LL1927-4;RAST;LA10137-0;6;5;;; +43862-2;LL1927-4;RAST;LA10138-8;7;6;;; +44298-8;LL1927-4;RAST;LA6111-4;1;0;;; +44298-8;LL1927-4;RAST;LA6112-2;2;1;;; +44298-8;LL1927-4;RAST;LA6113-0;3;2;;; +44298-8;LL1927-4;RAST;LA6114-8;4;3;;; +44298-8;LL1927-4;RAST;LA6115-5;5;4;;; +44298-8;LL1927-4;RAST;LA10137-0;6;5;;; +44298-8;LL1927-4;RAST;LA10138-8;7;6;;; +44315-0;LL1927-4;RAST;LA6111-4;1;0;;; +44315-0;LL1927-4;RAST;LA6112-2;2;1;;; +44315-0;LL1927-4;RAST;LA6113-0;3;2;;; +44315-0;LL1927-4;RAST;LA6114-8;4;3;;; +44315-0;LL1927-4;RAST;LA6115-5;5;4;;; +44315-0;LL1927-4;RAST;LA10137-0;6;5;;; +44315-0;LL1927-4;RAST;LA10138-8;7;6;;; +44379-6;LL1927-4;RAST;LA6111-4;1;0;;; +44379-6;LL1927-4;RAST;LA6112-2;2;1;;; +44379-6;LL1927-4;RAST;LA6113-0;3;2;;; +44379-6;LL1927-4;RAST;LA6114-8;4;3;;; +44379-6;LL1927-4;RAST;LA6115-5;5;4;;; +44379-6;LL1927-4;RAST;LA10137-0;6;5;;; +44379-6;LL1927-4;RAST;LA10138-8;7;6;;; +44380-4;LL1927-4;RAST;LA6111-4;1;0;;; +44380-4;LL1927-4;RAST;LA6112-2;2;1;;; +44380-4;LL1927-4;RAST;LA6113-0;3;2;;; +44380-4;LL1927-4;RAST;LA6114-8;4;3;;; +44380-4;LL1927-4;RAST;LA6115-5;5;4;;; +44380-4;LL1927-4;RAST;LA10137-0;6;5;;; +44380-4;LL1927-4;RAST;LA10138-8;7;6;;; +44381-2;LL1927-4;RAST;LA6111-4;1;0;;; +44381-2;LL1927-4;RAST;LA6112-2;2;1;;; +44381-2;LL1927-4;RAST;LA6113-0;3;2;;; +44381-2;LL1927-4;RAST;LA6114-8;4;3;;; +44381-2;LL1927-4;RAST;LA6115-5;5;4;;; +44381-2;LL1927-4;RAST;LA10137-0;6;5;;; +44381-2;LL1927-4;RAST;LA10138-8;7;6;;; +44554-4;LL1927-4;RAST;LA6111-4;1;0;;; +44554-4;LL1927-4;RAST;LA6112-2;2;1;;; +44554-4;LL1927-4;RAST;LA6113-0;3;2;;; +44554-4;LL1927-4;RAST;LA6114-8;4;3;;; +44554-4;LL1927-4;RAST;LA6115-5;5;4;;; +44554-4;LL1927-4;RAST;LA10137-0;6;5;;; +44554-4;LL1927-4;RAST;LA10138-8;7;6;;; +44829-0;LL1927-4;RAST;LA6111-4;1;0;;; +44829-0;LL1927-4;RAST;LA6112-2;2;1;;; +44829-0;LL1927-4;RAST;LA6113-0;3;2;;; +44829-0;LL1927-4;RAST;LA6114-8;4;3;;; +44829-0;LL1927-4;RAST;LA6115-5;5;4;;; +44829-0;LL1927-4;RAST;LA10137-0;6;5;;; +44829-0;LL1927-4;RAST;LA10138-8;7;6;;; +47384-3;LL1927-4;RAST;LA6111-4;1;0;;; +47384-3;LL1927-4;RAST;LA6112-2;2;1;;; +47384-3;LL1927-4;RAST;LA6113-0;3;2;;; +47384-3;LL1927-4;RAST;LA6114-8;4;3;;; +47384-3;LL1927-4;RAST;LA6115-5;5;4;;; +47384-3;LL1927-4;RAST;LA10137-0;6;5;;; +47384-3;LL1927-4;RAST;LA10138-8;7;6;;; +47417-1;LL1927-4;RAST;LA6111-4;1;0;;; +47417-1;LL1927-4;RAST;LA6112-2;2;1;;; +47417-1;LL1927-4;RAST;LA6113-0;3;2;;; +47417-1;LL1927-4;RAST;LA6114-8;4;3;;; +47417-1;LL1927-4;RAST;LA6115-5;5;4;;; +47417-1;LL1927-4;RAST;LA10137-0;6;5;;; +47417-1;LL1927-4;RAST;LA10138-8;7;6;;; +48604-3;LL1927-4;RAST;LA6111-4;1;0;;; +48604-3;LL1927-4;RAST;LA6112-2;2;1;;; +48604-3;LL1927-4;RAST;LA6113-0;3;2;;; +48604-3;LL1927-4;RAST;LA6114-8;4;3;;; +48604-3;LL1927-4;RAST;LA6115-5;5;4;;; +48604-3;LL1927-4;RAST;LA10137-0;6;5;;; +48604-3;LL1927-4;RAST;LA10138-8;7;6;;; +48782-7;LL1927-4;RAST;LA6111-4;1;0;;; +48782-7;LL1927-4;RAST;LA6112-2;2;1;;; +48782-7;LL1927-4;RAST;LA6113-0;3;2;;; +48782-7;LL1927-4;RAST;LA6114-8;4;3;;; +48782-7;LL1927-4;RAST;LA6115-5;5;4;;; +48782-7;LL1927-4;RAST;LA10137-0;6;5;;; +48782-7;LL1927-4;RAST;LA10138-8;7;6;;; +49079-7;LL1927-4;RAST;LA6111-4;1;0;;; +49079-7;LL1927-4;RAST;LA6112-2;2;1;;; +49079-7;LL1927-4;RAST;LA6113-0;3;2;;; +49079-7;LL1927-4;RAST;LA6114-8;4;3;;; +49079-7;LL1927-4;RAST;LA6115-5;5;4;;; +49079-7;LL1927-4;RAST;LA10137-0;6;5;;; +49079-7;LL1927-4;RAST;LA10138-8;7;6;;; +50678-2;LL1927-4;RAST;LA6111-4;1;0;;; +50678-2;LL1927-4;RAST;LA6112-2;2;1;;; +50678-2;LL1927-4;RAST;LA6113-0;3;2;;; +50678-2;LL1927-4;RAST;LA6114-8;4;3;;; +50678-2;LL1927-4;RAST;LA6115-5;5;4;;; +50678-2;LL1927-4;RAST;LA10137-0;6;5;;; +50678-2;LL1927-4;RAST;LA10138-8;7;6;;; +51550-2;LL1927-4;RAST;LA6111-4;1;0;;; +51550-2;LL1927-4;RAST;LA6112-2;2;1;;; +51550-2;LL1927-4;RAST;LA6113-0;3;2;;; +51550-2;LL1927-4;RAST;LA6114-8;4;3;;; +51550-2;LL1927-4;RAST;LA6115-5;5;4;;; +51550-2;LL1927-4;RAST;LA10137-0;6;5;;; +51550-2;LL1927-4;RAST;LA10138-8;7;6;;; +51551-0;LL1927-4;RAST;LA6111-4;1;0;;; +51551-0;LL1927-4;RAST;LA6112-2;2;1;;; +51551-0;LL1927-4;RAST;LA6113-0;3;2;;; +51551-0;LL1927-4;RAST;LA6114-8;4;3;;; +51551-0;LL1927-4;RAST;LA6115-5;5;4;;; +51551-0;LL1927-4;RAST;LA10137-0;6;5;;; +51551-0;LL1927-4;RAST;LA10138-8;7;6;;; +51552-8;LL1927-4;RAST;LA6111-4;1;0;;; +51552-8;LL1927-4;RAST;LA6112-2;2;1;;; +51552-8;LL1927-4;RAST;LA6113-0;3;2;;; +51552-8;LL1927-4;RAST;LA6114-8;4;3;;; +51552-8;LL1927-4;RAST;LA6115-5;5;4;;; +51552-8;LL1927-4;RAST;LA10137-0;6;5;;; +51552-8;LL1927-4;RAST;LA10138-8;7;6;;; +51553-6;LL1927-4;RAST;LA6111-4;1;0;;; +51553-6;LL1927-4;RAST;LA6112-2;2;1;;; +51553-6;LL1927-4;RAST;LA6113-0;3;2;;; +51553-6;LL1927-4;RAST;LA6114-8;4;3;;; +51553-6;LL1927-4;RAST;LA6115-5;5;4;;; +51553-6;LL1927-4;RAST;LA10137-0;6;5;;; +51553-6;LL1927-4;RAST;LA10138-8;7;6;;; +51554-4;LL1927-4;RAST;LA6111-4;1;0;;; +51554-4;LL1927-4;RAST;LA6112-2;2;1;;; +51554-4;LL1927-4;RAST;LA6113-0;3;2;;; +51554-4;LL1927-4;RAST;LA6114-8;4;3;;; +51554-4;LL1927-4;RAST;LA6115-5;5;4;;; +51554-4;LL1927-4;RAST;LA10137-0;6;5;;; +51554-4;LL1927-4;RAST;LA10138-8;7;6;;; +51555-1;LL1927-4;RAST;LA6111-4;1;0;;; +51555-1;LL1927-4;RAST;LA6112-2;2;1;;; +51555-1;LL1927-4;RAST;LA6113-0;3;2;;; +51555-1;LL1927-4;RAST;LA6114-8;4;3;;; +51555-1;LL1927-4;RAST;LA6115-5;5;4;;; +51555-1;LL1927-4;RAST;LA10137-0;6;5;;; +51555-1;LL1927-4;RAST;LA10138-8;7;6;;; +51556-9;LL1927-4;RAST;LA6111-4;1;0;;; +51556-9;LL1927-4;RAST;LA6112-2;2;1;;; +51556-9;LL1927-4;RAST;LA6113-0;3;2;;; +51556-9;LL1927-4;RAST;LA6114-8;4;3;;; +51556-9;LL1927-4;RAST;LA6115-5;5;4;;; +51556-9;LL1927-4;RAST;LA10137-0;6;5;;; +51556-9;LL1927-4;RAST;LA10138-8;7;6;;; +51557-7;LL1927-4;RAST;LA6111-4;1;0;;; +51557-7;LL1927-4;RAST;LA6112-2;2;1;;; +51557-7;LL1927-4;RAST;LA6113-0;3;2;;; +51557-7;LL1927-4;RAST;LA6114-8;4;3;;; +51557-7;LL1927-4;RAST;LA6115-5;5;4;;; +51557-7;LL1927-4;RAST;LA10137-0;6;5;;; +51557-7;LL1927-4;RAST;LA10138-8;7;6;;; +51558-5;LL1927-4;RAST;LA6111-4;1;0;;; +51558-5;LL1927-4;RAST;LA6112-2;2;1;;; +51558-5;LL1927-4;RAST;LA6113-0;3;2;;; +51558-5;LL1927-4;RAST;LA6114-8;4;3;;; +51558-5;LL1927-4;RAST;LA6115-5;5;4;;; +51558-5;LL1927-4;RAST;LA10137-0;6;5;;; +51558-5;LL1927-4;RAST;LA10138-8;7;6;;; +51559-3;LL1927-4;RAST;LA6111-4;1;0;;; +51559-3;LL1927-4;RAST;LA6112-2;2;1;;; +51559-3;LL1927-4;RAST;LA6113-0;3;2;;; +51559-3;LL1927-4;RAST;LA6114-8;4;3;;; +51559-3;LL1927-4;RAST;LA6115-5;5;4;;; +51559-3;LL1927-4;RAST;LA10137-0;6;5;;; +51559-3;LL1927-4;RAST;LA10138-8;7;6;;; +51560-1;LL1927-4;RAST;LA6111-4;1;0;;; +51560-1;LL1927-4;RAST;LA6112-2;2;1;;; +51560-1;LL1927-4;RAST;LA6113-0;3;2;;; +51560-1;LL1927-4;RAST;LA6114-8;4;3;;; +51560-1;LL1927-4;RAST;LA6115-5;5;4;;; +51560-1;LL1927-4;RAST;LA10137-0;6;5;;; +51560-1;LL1927-4;RAST;LA10138-8;7;6;;; +51561-9;LL1927-4;RAST;LA6111-4;1;0;;; +51561-9;LL1927-4;RAST;LA6112-2;2;1;;; +51561-9;LL1927-4;RAST;LA6113-0;3;2;;; +51561-9;LL1927-4;RAST;LA6114-8;4;3;;; +51561-9;LL1927-4;RAST;LA6115-5;5;4;;; +51561-9;LL1927-4;RAST;LA10137-0;6;5;;; +51561-9;LL1927-4;RAST;LA10138-8;7;6;;; +51562-7;LL1927-4;RAST;LA6111-4;1;0;;; +51562-7;LL1927-4;RAST;LA6112-2;2;1;;; +51562-7;LL1927-4;RAST;LA6113-0;3;2;;; +51562-7;LL1927-4;RAST;LA6114-8;4;3;;; +51562-7;LL1927-4;RAST;LA6115-5;5;4;;; +51562-7;LL1927-4;RAST;LA10137-0;6;5;;; +51562-7;LL1927-4;RAST;LA10138-8;7;6;;; +51563-5;LL1927-4;RAST;LA6111-4;1;0;;; +51563-5;LL1927-4;RAST;LA6112-2;2;1;;; +51563-5;LL1927-4;RAST;LA6113-0;3;2;;; +51563-5;LL1927-4;RAST;LA6114-8;4;3;;; +51563-5;LL1927-4;RAST;LA6115-5;5;4;;; +51563-5;LL1927-4;RAST;LA10137-0;6;5;;; +51563-5;LL1927-4;RAST;LA10138-8;7;6;;; +51564-3;LL1927-4;RAST;LA6111-4;1;0;;; +51564-3;LL1927-4;RAST;LA6112-2;2;1;;; +51564-3;LL1927-4;RAST;LA6113-0;3;2;;; +51564-3;LL1927-4;RAST;LA6114-8;4;3;;; +51564-3;LL1927-4;RAST;LA6115-5;5;4;;; +51564-3;LL1927-4;RAST;LA10137-0;6;5;;; +51564-3;LL1927-4;RAST;LA10138-8;7;6;;; +51565-0;LL1927-4;RAST;LA6111-4;1;0;;; +51565-0;LL1927-4;RAST;LA6112-2;2;1;;; +51565-0;LL1927-4;RAST;LA6113-0;3;2;;; +51565-0;LL1927-4;RAST;LA6114-8;4;3;;; +51565-0;LL1927-4;RAST;LA6115-5;5;4;;; +51565-0;LL1927-4;RAST;LA10137-0;6;5;;; +51565-0;LL1927-4;RAST;LA10138-8;7;6;;; +51566-8;LL1927-4;RAST;LA6111-4;1;0;;; +51566-8;LL1927-4;RAST;LA6112-2;2;1;;; +51566-8;LL1927-4;RAST;LA6113-0;3;2;;; +51566-8;LL1927-4;RAST;LA6114-8;4;3;;; +51566-8;LL1927-4;RAST;LA6115-5;5;4;;; +51566-8;LL1927-4;RAST;LA10137-0;6;5;;; +51566-8;LL1927-4;RAST;LA10138-8;7;6;;; +51567-6;LL1927-4;RAST;LA6111-4;1;0;;; +51567-6;LL1927-4;RAST;LA6112-2;2;1;;; +51567-6;LL1927-4;RAST;LA6113-0;3;2;;; +51567-6;LL1927-4;RAST;LA6114-8;4;3;;; +51567-6;LL1927-4;RAST;LA6115-5;5;4;;; +51567-6;LL1927-4;RAST;LA10137-0;6;5;;; +51567-6;LL1927-4;RAST;LA10138-8;7;6;;; +51568-4;LL1927-4;RAST;LA6111-4;1;0;;; +51568-4;LL1927-4;RAST;LA6112-2;2;1;;; +51568-4;LL1927-4;RAST;LA6113-0;3;2;;; +51568-4;LL1927-4;RAST;LA6114-8;4;3;;; +51568-4;LL1927-4;RAST;LA6115-5;5;4;;; +51568-4;LL1927-4;RAST;LA10137-0;6;5;;; +51568-4;LL1927-4;RAST;LA10138-8;7;6;;; +51569-2;LL1927-4;RAST;LA6111-4;1;0;;; +51569-2;LL1927-4;RAST;LA6112-2;2;1;;; +51569-2;LL1927-4;RAST;LA6113-0;3;2;;; +51569-2;LL1927-4;RAST;LA6114-8;4;3;;; +51569-2;LL1927-4;RAST;LA6115-5;5;4;;; +51569-2;LL1927-4;RAST;LA10137-0;6;5;;; +51569-2;LL1927-4;RAST;LA10138-8;7;6;;; +51570-0;LL1927-4;RAST;LA6111-4;1;0;;; +51570-0;LL1927-4;RAST;LA6112-2;2;1;;; +51570-0;LL1927-4;RAST;LA6113-0;3;2;;; +51570-0;LL1927-4;RAST;LA6114-8;4;3;;; +51570-0;LL1927-4;RAST;LA6115-5;5;4;;; +51570-0;LL1927-4;RAST;LA10137-0;6;5;;; +51570-0;LL1927-4;RAST;LA10138-8;7;6;;; +51571-8;LL1927-4;RAST;LA6111-4;1;0;;; +51571-8;LL1927-4;RAST;LA6112-2;2;1;;; +51571-8;LL1927-4;RAST;LA6113-0;3;2;;; +51571-8;LL1927-4;RAST;LA6114-8;4;3;;; +51571-8;LL1927-4;RAST;LA6115-5;5;4;;; +51571-8;LL1927-4;RAST;LA10137-0;6;5;;; +51571-8;LL1927-4;RAST;LA10138-8;7;6;;; +51572-6;LL1927-4;RAST;LA6111-4;1;0;;; +51572-6;LL1927-4;RAST;LA6112-2;2;1;;; +51572-6;LL1927-4;RAST;LA6113-0;3;2;;; +51572-6;LL1927-4;RAST;LA6114-8;4;3;;; +51572-6;LL1927-4;RAST;LA6115-5;5;4;;; +51572-6;LL1927-4;RAST;LA10137-0;6;5;;; +51572-6;LL1927-4;RAST;LA10138-8;7;6;;; +51573-4;LL1927-4;RAST;LA6111-4;1;0;;; +51573-4;LL1927-4;RAST;LA6112-2;2;1;;; +51573-4;LL1927-4;RAST;LA6113-0;3;2;;; +51573-4;LL1927-4;RAST;LA6114-8;4;3;;; +51573-4;LL1927-4;RAST;LA6115-5;5;4;;; +51573-4;LL1927-4;RAST;LA10137-0;6;5;;; +51573-4;LL1927-4;RAST;LA10138-8;7;6;;; +51574-2;LL1927-4;RAST;LA6111-4;1;0;;; +51574-2;LL1927-4;RAST;LA6112-2;2;1;;; +51574-2;LL1927-4;RAST;LA6113-0;3;2;;; +51574-2;LL1927-4;RAST;LA6114-8;4;3;;; +51574-2;LL1927-4;RAST;LA6115-5;5;4;;; +51574-2;LL1927-4;RAST;LA10137-0;6;5;;; +51574-2;LL1927-4;RAST;LA10138-8;7;6;;; +51575-9;LL1927-4;RAST;LA6111-4;1;0;;; +51575-9;LL1927-4;RAST;LA6112-2;2;1;;; +51575-9;LL1927-4;RAST;LA6113-0;3;2;;; +51575-9;LL1927-4;RAST;LA6114-8;4;3;;; +51575-9;LL1927-4;RAST;LA6115-5;5;4;;; +51575-9;LL1927-4;RAST;LA10137-0;6;5;;; +51575-9;LL1927-4;RAST;LA10138-8;7;6;;; +51576-7;LL1927-4;RAST;LA6111-4;1;0;;; +51576-7;LL1927-4;RAST;LA6112-2;2;1;;; +51576-7;LL1927-4;RAST;LA6113-0;3;2;;; +51576-7;LL1927-4;RAST;LA6114-8;4;3;;; +51576-7;LL1927-4;RAST;LA6115-5;5;4;;; +51576-7;LL1927-4;RAST;LA10137-0;6;5;;; +51576-7;LL1927-4;RAST;LA10138-8;7;6;;; +51577-5;LL1927-4;RAST;LA6111-4;1;0;;; +51577-5;LL1927-4;RAST;LA6112-2;2;1;;; +51577-5;LL1927-4;RAST;LA6113-0;3;2;;; +51577-5;LL1927-4;RAST;LA6114-8;4;3;;; +51577-5;LL1927-4;RAST;LA6115-5;5;4;;; +51577-5;LL1927-4;RAST;LA10137-0;6;5;;; +51577-5;LL1927-4;RAST;LA10138-8;7;6;;; +51863-9;LL1927-4;RAST;LA6111-4;1;0;;; +51863-9;LL1927-4;RAST;LA6112-2;2;1;;; +51863-9;LL1927-4;RAST;LA6113-0;3;2;;; +51863-9;LL1927-4;RAST;LA6114-8;4;3;;; +51863-9;LL1927-4;RAST;LA6115-5;5;4;;; +51863-9;LL1927-4;RAST;LA10137-0;6;5;;; +51863-9;LL1927-4;RAST;LA10138-8;7;6;;; +51864-7;LL1927-4;RAST;LA6111-4;1;0;;; +51864-7;LL1927-4;RAST;LA6112-2;2;1;;; +51864-7;LL1927-4;RAST;LA6113-0;3;2;;; +51864-7;LL1927-4;RAST;LA6114-8;4;3;;; +51864-7;LL1927-4;RAST;LA6115-5;5;4;;; +51864-7;LL1927-4;RAST;LA10137-0;6;5;;; +51864-7;LL1927-4;RAST;LA10138-8;7;6;;; +53258-0;LL1927-4;RAST;LA6111-4;1;0;;; +53258-0;LL1927-4;RAST;LA6112-2;2;1;;; +53258-0;LL1927-4;RAST;LA6113-0;3;2;;; +53258-0;LL1927-4;RAST;LA6114-8;4;3;;; +53258-0;LL1927-4;RAST;LA6115-5;5;4;;; +53258-0;LL1927-4;RAST;LA10137-0;6;5;;; +53258-0;LL1927-4;RAST;LA10138-8;7;6;;; +57877-3;LL1927-4;RAST;LA6111-4;1;0;;; +57877-3;LL1927-4;RAST;LA6112-2;2;1;;; +57877-3;LL1927-4;RAST;LA6113-0;3;2;;; +57877-3;LL1927-4;RAST;LA6114-8;4;3;;; +57877-3;LL1927-4;RAST;LA6115-5;5;4;;; +57877-3;LL1927-4;RAST;LA10137-0;6;5;;; +57877-3;LL1927-4;RAST;LA10138-8;7;6;;; +57878-1;LL1927-4;RAST;LA6111-4;1;0;;; +57878-1;LL1927-4;RAST;LA6112-2;2;1;;; +57878-1;LL1927-4;RAST;LA6113-0;3;2;;; +57878-1;LL1927-4;RAST;LA6114-8;4;3;;; +57878-1;LL1927-4;RAST;LA6115-5;5;4;;; +57878-1;LL1927-4;RAST;LA10137-0;6;5;;; +57878-1;LL1927-4;RAST;LA10138-8;7;6;;; +57881-5;LL1927-4;RAST;LA6111-4;1;0;;; +57881-5;LL1927-4;RAST;LA6112-2;2;1;;; +57881-5;LL1927-4;RAST;LA6113-0;3;2;;; +57881-5;LL1927-4;RAST;LA6114-8;4;3;;; +57881-5;LL1927-4;RAST;LA6115-5;5;4;;; +57881-5;LL1927-4;RAST;LA10137-0;6;5;;; +57881-5;LL1927-4;RAST;LA10138-8;7;6;;; +57882-3;LL1927-4;RAST;LA6111-4;1;0;;; +57882-3;LL1927-4;RAST;LA6112-2;2;1;;; +57882-3;LL1927-4;RAST;LA6113-0;3;2;;; +57882-3;LL1927-4;RAST;LA6114-8;4;3;;; +57882-3;LL1927-4;RAST;LA6115-5;5;4;;; +57882-3;LL1927-4;RAST;LA10137-0;6;5;;; +57882-3;LL1927-4;RAST;LA10138-8;7;6;;; +57947-4;LL1927-4;RAST;LA6111-4;1;0;;; +57947-4;LL1927-4;RAST;LA6112-2;2;1;;; +57947-4;LL1927-4;RAST;LA6113-0;3;2;;; +57947-4;LL1927-4;RAST;LA6114-8;4;3;;; +57947-4;LL1927-4;RAST;LA6115-5;5;4;;; +57947-4;LL1927-4;RAST;LA10137-0;6;5;;; +57947-4;LL1927-4;RAST;LA10138-8;7;6;;; +58008-4;LL1927-4;RAST;LA6111-4;1;0;;; +58008-4;LL1927-4;RAST;LA6112-2;2;1;;; +58008-4;LL1927-4;RAST;LA6113-0;3;2;;; +58008-4;LL1927-4;RAST;LA6114-8;4;3;;; +58008-4;LL1927-4;RAST;LA6115-5;5;4;;; +58008-4;LL1927-4;RAST;LA10137-0;6;5;;; +58008-4;LL1927-4;RAST;LA10138-8;7;6;;; +58021-7;LL1927-4;RAST;LA6111-4;1;0;;; +58021-7;LL1927-4;RAST;LA6112-2;2;1;;; +58021-7;LL1927-4;RAST;LA6113-0;3;2;;; +58021-7;LL1927-4;RAST;LA6114-8;4;3;;; +58021-7;LL1927-4;RAST;LA6115-5;5;4;;; +58021-7;LL1927-4;RAST;LA10137-0;6;5;;; +58021-7;LL1927-4;RAST;LA10138-8;7;6;;; +60236-7;LL1927-4;RAST;LA6111-4;1;0;;; +60236-7;LL1927-4;RAST;LA6112-2;2;1;;; +60236-7;LL1927-4;RAST;LA6113-0;3;2;;; +60236-7;LL1927-4;RAST;LA6114-8;4;3;;; +60236-7;LL1927-4;RAST;LA6115-5;5;4;;; +60236-7;LL1927-4;RAST;LA10137-0;6;5;;; +60236-7;LL1927-4;RAST;LA10138-8;7;6;;; +60237-5;LL1927-4;RAST;LA6111-4;1;0;;; +60237-5;LL1927-4;RAST;LA6112-2;2;1;;; +60237-5;LL1927-4;RAST;LA6113-0;3;2;;; +60237-5;LL1927-4;RAST;LA6114-8;4;3;;; +60237-5;LL1927-4;RAST;LA6115-5;5;4;;; +60237-5;LL1927-4;RAST;LA10137-0;6;5;;; +60237-5;LL1927-4;RAST;LA10138-8;7;6;;; +60239-1;LL1927-4;RAST;LA6111-4;1;0;;; +60239-1;LL1927-4;RAST;LA6112-2;2;1;;; +60239-1;LL1927-4;RAST;LA6113-0;3;2;;; +60239-1;LL1927-4;RAST;LA6114-8;4;3;;; +60239-1;LL1927-4;RAST;LA6115-5;5;4;;; +60239-1;LL1927-4;RAST;LA10137-0;6;5;;; +60239-1;LL1927-4;RAST;LA10138-8;7;6;;; +60241-7;LL1927-4;RAST;LA6111-4;1;0;;; +60241-7;LL1927-4;RAST;LA6112-2;2;1;;; +60241-7;LL1927-4;RAST;LA6113-0;3;2;;; +60241-7;LL1927-4;RAST;LA6114-8;4;3;;; +60241-7;LL1927-4;RAST;LA6115-5;5;4;;; +60241-7;LL1927-4;RAST;LA10137-0;6;5;;; +60241-7;LL1927-4;RAST;LA10138-8;7;6;;; +60454-6;LL1927-4;RAST;LA6111-4;1;0;;; +60454-6;LL1927-4;RAST;LA6112-2;2;1;;; +60454-6;LL1927-4;RAST;LA6113-0;3;2;;; +60454-6;LL1927-4;RAST;LA6114-8;4;3;;; +60454-6;LL1927-4;RAST;LA6115-5;5;4;;; +60454-6;LL1927-4;RAST;LA10137-0;6;5;;; +60454-6;LL1927-4;RAST;LA10138-8;7;6;;; +60464-5;LL1927-4;RAST;LA6111-4;1;0;;; +60464-5;LL1927-4;RAST;LA6112-2;2;1;;; +60464-5;LL1927-4;RAST;LA6113-0;3;2;;; +60464-5;LL1927-4;RAST;LA6114-8;4;3;;; +60464-5;LL1927-4;RAST;LA6115-5;5;4;;; +60464-5;LL1927-4;RAST;LA10137-0;6;5;;; +60464-5;LL1927-4;RAST;LA10138-8;7;6;;; +64037-5;LL1927-4;RAST;LA6111-4;1;0;;; +64037-5;LL1927-4;RAST;LA6112-2;2;1;;; +64037-5;LL1927-4;RAST;LA6113-0;3;2;;; +64037-5;LL1927-4;RAST;LA6114-8;4;3;;; +64037-5;LL1927-4;RAST;LA6115-5;5;4;;; +64037-5;LL1927-4;RAST;LA10137-0;6;5;;; +64037-5;LL1927-4;RAST;LA10138-8;7;6;;; +66715-4;LL1927-4;RAST;LA6111-4;1;0;;; +66715-4;LL1927-4;RAST;LA6112-2;2;1;;; +66715-4;LL1927-4;RAST;LA6113-0;3;2;;; +66715-4;LL1927-4;RAST;LA6114-8;4;3;;; +66715-4;LL1927-4;RAST;LA6115-5;5;4;;; +66715-4;LL1927-4;RAST;LA10137-0;6;5;;; +66715-4;LL1927-4;RAST;LA10138-8;7;6;;; +66716-2;LL1927-4;RAST;LA6111-4;1;0;;; +66716-2;LL1927-4;RAST;LA6112-2;2;1;;; +66716-2;LL1927-4;RAST;LA6113-0;3;2;;; +66716-2;LL1927-4;RAST;LA6114-8;4;3;;; +66716-2;LL1927-4;RAST;LA6115-5;5;4;;; +66716-2;LL1927-4;RAST;LA10137-0;6;5;;; +66716-2;LL1927-4;RAST;LA10138-8;7;6;;; +68972-9;LL1927-4;RAST;LA6111-4;1;0;;; +68972-9;LL1927-4;RAST;LA6112-2;2;1;;; +68972-9;LL1927-4;RAST;LA6113-0;3;2;;; +68972-9;LL1927-4;RAST;LA6114-8;4;3;;; +68972-9;LL1927-4;RAST;LA6115-5;5;4;;; +68972-9;LL1927-4;RAST;LA10137-0;6;5;;; +68972-9;LL1927-4;RAST;LA10138-8;7;6;;; +6934-4;LL1927-4;RAST;LA6111-4;1;0;;; +6934-4;LL1927-4;RAST;LA6112-2;2;1;;; +6934-4;LL1927-4;RAST;LA6113-0;3;2;;; +6934-4;LL1927-4;RAST;LA6114-8;4;3;;; +6934-4;LL1927-4;RAST;LA6115-5;5;4;;; +6934-4;LL1927-4;RAST;LA10137-0;6;5;;; +6934-4;LL1927-4;RAST;LA10138-8;7;6;;; +81960-7;LL1927-4;RAST;LA6111-4;1;0;;; +81960-7;LL1927-4;RAST;LA6112-2;2;1;;; +81960-7;LL1927-4;RAST;LA6113-0;3;2;;; +81960-7;LL1927-4;RAST;LA6114-8;4;3;;; +81960-7;LL1927-4;RAST;LA6115-5;5;4;;; +81960-7;LL1927-4;RAST;LA10137-0;6;5;;; +81960-7;LL1927-4;RAST;LA10138-8;7;6;;; +81961-5;LL1927-4;RAST;LA6111-4;1;0;;; +81961-5;LL1927-4;RAST;LA6112-2;2;1;;; +81961-5;LL1927-4;RAST;LA6113-0;3;2;;; +81961-5;LL1927-4;RAST;LA6114-8;4;3;;; +81961-5;LL1927-4;RAST;LA6115-5;5;4;;; +81961-5;LL1927-4;RAST;LA10137-0;6;5;;; +81961-5;LL1927-4;RAST;LA10138-8;7;6;;; +81962-3;LL1927-4;RAST;LA6111-4;1;0;;; +81962-3;LL1927-4;RAST;LA6112-2;2;1;;; +81962-3;LL1927-4;RAST;LA6113-0;3;2;;; +81962-3;LL1927-4;RAST;LA6114-8;4;3;;; +81962-3;LL1927-4;RAST;LA6115-5;5;4;;; +81962-3;LL1927-4;RAST;LA10137-0;6;5;;; +81962-3;LL1927-4;RAST;LA10138-8;7;6;;; +81963-1;LL1927-4;RAST;LA6111-4;1;0;;; +81963-1;LL1927-4;RAST;LA6112-2;2;1;;; +81963-1;LL1927-4;RAST;LA6113-0;3;2;;; +81963-1;LL1927-4;RAST;LA6114-8;4;3;;; +81963-1;LL1927-4;RAST;LA6115-5;5;4;;; +81963-1;LL1927-4;RAST;LA10137-0;6;5;;; +81963-1;LL1927-4;RAST;LA10138-8;7;6;;; +81964-9;LL1927-4;RAST;LA6111-4;1;0;;; +81964-9;LL1927-4;RAST;LA6112-2;2;1;;; +81964-9;LL1927-4;RAST;LA6113-0;3;2;;; +81964-9;LL1927-4;RAST;LA6114-8;4;3;;; +81964-9;LL1927-4;RAST;LA6115-5;5;4;;; +81964-9;LL1927-4;RAST;LA10137-0;6;5;;; +81964-9;LL1927-4;RAST;LA10138-8;7;6;;; +81965-6;LL1927-4;RAST;LA6111-4;1;0;;; +81965-6;LL1927-4;RAST;LA6112-2;2;1;;; +81965-6;LL1927-4;RAST;LA6113-0;3;2;;; +81965-6;LL1927-4;RAST;LA6114-8;4;3;;; +81965-6;LL1927-4;RAST;LA6115-5;5;4;;; +81965-6;LL1927-4;RAST;LA10137-0;6;5;;; +81965-6;LL1927-4;RAST;LA10138-8;7;6;;; +81966-4;LL1927-4;RAST;LA6111-4;1;0;;; +81966-4;LL1927-4;RAST;LA6112-2;2;1;;; +81966-4;LL1927-4;RAST;LA6113-0;3;2;;; +81966-4;LL1927-4;RAST;LA6114-8;4;3;;; +81966-4;LL1927-4;RAST;LA6115-5;5;4;;; +81966-4;LL1927-4;RAST;LA10137-0;6;5;;; +81966-4;LL1927-4;RAST;LA10138-8;7;6;;; +81967-2;LL1927-4;RAST;LA6111-4;1;0;;; +81967-2;LL1927-4;RAST;LA6112-2;2;1;;; +81967-2;LL1927-4;RAST;LA6113-0;3;2;;; +81967-2;LL1927-4;RAST;LA6114-8;4;3;;; +81967-2;LL1927-4;RAST;LA6115-5;5;4;;; +81967-2;LL1927-4;RAST;LA10137-0;6;5;;; +81967-2;LL1927-4;RAST;LA10138-8;7;6;;; +81968-0;LL1927-4;RAST;LA6111-4;1;0;;; +81968-0;LL1927-4;RAST;LA6112-2;2;1;;; +81968-0;LL1927-4;RAST;LA6113-0;3;2;;; +81968-0;LL1927-4;RAST;LA6114-8;4;3;;; +81968-0;LL1927-4;RAST;LA6115-5;5;4;;; +81968-0;LL1927-4;RAST;LA10137-0;6;5;;; +81968-0;LL1927-4;RAST;LA10138-8;7;6;;; +81969-8;LL1927-4;RAST;LA6111-4;1;0;;; +81969-8;LL1927-4;RAST;LA6112-2;2;1;;; +81969-8;LL1927-4;RAST;LA6113-0;3;2;;; +81969-8;LL1927-4;RAST;LA6114-8;4;3;;; +81969-8;LL1927-4;RAST;LA6115-5;5;4;;; +81969-8;LL1927-4;RAST;LA10137-0;6;5;;; +81969-8;LL1927-4;RAST;LA10138-8;7;6;;; +81970-6;LL1927-4;RAST;LA6111-4;1;0;;; +81970-6;LL1927-4;RAST;LA6112-2;2;1;;; +81970-6;LL1927-4;RAST;LA6113-0;3;2;;; +81970-6;LL1927-4;RAST;LA6114-8;4;3;;; +81970-6;LL1927-4;RAST;LA6115-5;5;4;;; +81970-6;LL1927-4;RAST;LA10137-0;6;5;;; +81970-6;LL1927-4;RAST;LA10138-8;7;6;;; +81971-4;LL1927-4;RAST;LA6111-4;1;0;;; +81971-4;LL1927-4;RAST;LA6112-2;2;1;;; +81971-4;LL1927-4;RAST;LA6113-0;3;2;;; +81971-4;LL1927-4;RAST;LA6114-8;4;3;;; +81971-4;LL1927-4;RAST;LA6115-5;5;4;;; +81971-4;LL1927-4;RAST;LA10137-0;6;5;;; +81971-4;LL1927-4;RAST;LA10138-8;7;6;;; +81972-2;LL1927-4;RAST;LA6111-4;1;0;;; +81972-2;LL1927-4;RAST;LA6112-2;2;1;;; +81972-2;LL1927-4;RAST;LA6113-0;3;2;;; +81972-2;LL1927-4;RAST;LA6114-8;4;3;;; +81972-2;LL1927-4;RAST;LA6115-5;5;4;;; +81972-2;LL1927-4;RAST;LA10137-0;6;5;;; +81972-2;LL1927-4;RAST;LA10138-8;7;6;;; +81973-0;LL1927-4;RAST;LA6111-4;1;0;;; +81973-0;LL1927-4;RAST;LA6112-2;2;1;;; +81973-0;LL1927-4;RAST;LA6113-0;3;2;;; +81973-0;LL1927-4;RAST;LA6114-8;4;3;;; +81973-0;LL1927-4;RAST;LA6115-5;5;4;;; +81973-0;LL1927-4;RAST;LA10137-0;6;5;;; +81973-0;LL1927-4;RAST;LA10138-8;7;6;;; +81974-8;LL1927-4;RAST;LA6111-4;1;0;;; +81974-8;LL1927-4;RAST;LA6112-2;2;1;;; +81974-8;LL1927-4;RAST;LA6113-0;3;2;;; +81974-8;LL1927-4;RAST;LA6114-8;4;3;;; +81974-8;LL1927-4;RAST;LA6115-5;5;4;;; +81974-8;LL1927-4;RAST;LA10137-0;6;5;;; +81974-8;LL1927-4;RAST;LA10138-8;7;6;;; +81975-5;LL1927-4;RAST;LA6111-4;1;0;;; +81975-5;LL1927-4;RAST;LA6112-2;2;1;;; +81975-5;LL1927-4;RAST;LA6113-0;3;2;;; +81975-5;LL1927-4;RAST;LA6114-8;4;3;;; +81975-5;LL1927-4;RAST;LA6115-5;5;4;;; +81975-5;LL1927-4;RAST;LA10137-0;6;5;;; +81975-5;LL1927-4;RAST;LA10138-8;7;6;;; +81976-3;LL1927-4;RAST;LA6111-4;1;0;;; +81976-3;LL1927-4;RAST;LA6112-2;2;1;;; +81976-3;LL1927-4;RAST;LA6113-0;3;2;;; +81976-3;LL1927-4;RAST;LA6114-8;4;3;;; +81976-3;LL1927-4;RAST;LA6115-5;5;4;;; +81976-3;LL1927-4;RAST;LA10137-0;6;5;;; +81976-3;LL1927-4;RAST;LA10138-8;7;6;;; +81977-1;LL1927-4;RAST;LA6111-4;1;0;;; +81977-1;LL1927-4;RAST;LA6112-2;2;1;;; +81977-1;LL1927-4;RAST;LA6113-0;3;2;;; +81977-1;LL1927-4;RAST;LA6114-8;4;3;;; +81977-1;LL1927-4;RAST;LA6115-5;5;4;;; +81977-1;LL1927-4;RAST;LA10137-0;6;5;;; +81977-1;LL1927-4;RAST;LA10138-8;7;6;;; +81978-9;LL1927-4;RAST;LA6111-4;1;0;;; +81978-9;LL1927-4;RAST;LA6112-2;2;1;;; +81978-9;LL1927-4;RAST;LA6113-0;3;2;;; +81978-9;LL1927-4;RAST;LA6114-8;4;3;;; +81978-9;LL1927-4;RAST;LA6115-5;5;4;;; +81978-9;LL1927-4;RAST;LA10137-0;6;5;;; +81978-9;LL1927-4;RAST;LA10138-8;7;6;;; +81979-7;LL1927-4;RAST;LA6111-4;1;0;;; +81979-7;LL1927-4;RAST;LA6112-2;2;1;;; +81979-7;LL1927-4;RAST;LA6113-0;3;2;;; +81979-7;LL1927-4;RAST;LA6114-8;4;3;;; +81979-7;LL1927-4;RAST;LA6115-5;5;4;;; +81979-7;LL1927-4;RAST;LA10137-0;6;5;;; +81979-7;LL1927-4;RAST;LA10138-8;7;6;;; +81980-5;LL1927-4;RAST;LA6111-4;1;0;;; +81980-5;LL1927-4;RAST;LA6112-2;2;1;;; +81980-5;LL1927-4;RAST;LA6113-0;3;2;;; +81980-5;LL1927-4;RAST;LA6114-8;4;3;;; +81980-5;LL1927-4;RAST;LA6115-5;5;4;;; +81980-5;LL1927-4;RAST;LA10137-0;6;5;;; +81980-5;LL1927-4;RAST;LA10138-8;7;6;;; +81981-3;LL1927-4;RAST;LA6111-4;1;0;;; +81981-3;LL1927-4;RAST;LA6112-2;2;1;;; +81981-3;LL1927-4;RAST;LA6113-0;3;2;;; +81981-3;LL1927-4;RAST;LA6114-8;4;3;;; +81981-3;LL1927-4;RAST;LA6115-5;5;4;;; +81981-3;LL1927-4;RAST;LA10137-0;6;5;;; +81981-3;LL1927-4;RAST;LA10138-8;7;6;;; +81982-1;LL1927-4;RAST;LA6111-4;1;0;;; +81982-1;LL1927-4;RAST;LA6112-2;2;1;;; +81982-1;LL1927-4;RAST;LA6113-0;3;2;;; +81982-1;LL1927-4;RAST;LA6114-8;4;3;;; +81982-1;LL1927-4;RAST;LA6115-5;5;4;;; +81982-1;LL1927-4;RAST;LA10137-0;6;5;;; +81982-1;LL1927-4;RAST;LA10138-8;7;6;;; +81983-9;LL1927-4;RAST;LA6111-4;1;0;;; +81983-9;LL1927-4;RAST;LA6112-2;2;1;;; +81983-9;LL1927-4;RAST;LA6113-0;3;2;;; +81983-9;LL1927-4;RAST;LA6114-8;4;3;;; +81983-9;LL1927-4;RAST;LA6115-5;5;4;;; +81983-9;LL1927-4;RAST;LA10137-0;6;5;;; +81983-9;LL1927-4;RAST;LA10138-8;7;6;;; +81984-7;LL1927-4;RAST;LA6111-4;1;0;;; +81984-7;LL1927-4;RAST;LA6112-2;2;1;;; +81984-7;LL1927-4;RAST;LA6113-0;3;2;;; +81984-7;LL1927-4;RAST;LA6114-8;4;3;;; +81984-7;LL1927-4;RAST;LA6115-5;5;4;;; +81984-7;LL1927-4;RAST;LA10137-0;6;5;;; +81984-7;LL1927-4;RAST;LA10138-8;7;6;;; +81985-4;LL1927-4;RAST;LA6111-4;1;0;;; +81985-4;LL1927-4;RAST;LA6112-2;2;1;;; +81985-4;LL1927-4;RAST;LA6113-0;3;2;;; +81985-4;LL1927-4;RAST;LA6114-8;4;3;;; +81985-4;LL1927-4;RAST;LA6115-5;5;4;;; +81985-4;LL1927-4;RAST;LA10137-0;6;5;;; +81985-4;LL1927-4;RAST;LA10138-8;7;6;;; +81986-2;LL1927-4;RAST;LA6111-4;1;0;;; +81986-2;LL1927-4;RAST;LA6112-2;2;1;;; +81986-2;LL1927-4;RAST;LA6113-0;3;2;;; +81986-2;LL1927-4;RAST;LA6114-8;4;3;;; +81986-2;LL1927-4;RAST;LA6115-5;5;4;;; +81986-2;LL1927-4;RAST;LA10137-0;6;5;;; +81986-2;LL1927-4;RAST;LA10138-8;7;6;;; +81987-0;LL1927-4;RAST;LA6111-4;1;0;;; +81987-0;LL1927-4;RAST;LA6112-2;2;1;;; +81987-0;LL1927-4;RAST;LA6113-0;3;2;;; +81987-0;LL1927-4;RAST;LA6114-8;4;3;;; +81987-0;LL1927-4;RAST;LA6115-5;5;4;;; +81987-0;LL1927-4;RAST;LA10137-0;6;5;;; +81987-0;LL1927-4;RAST;LA10138-8;7;6;;; +81988-8;LL1927-4;RAST;LA6111-4;1;0;;; +81988-8;LL1927-4;RAST;LA6112-2;2;1;;; +81988-8;LL1927-4;RAST;LA6113-0;3;2;;; +81988-8;LL1927-4;RAST;LA6114-8;4;3;;; +81988-8;LL1927-4;RAST;LA6115-5;5;4;;; +81988-8;LL1927-4;RAST;LA10137-0;6;5;;; +81988-8;LL1927-4;RAST;LA10138-8;7;6;;; +81989-6;LL1927-4;RAST;LA6111-4;1;0;;; +81989-6;LL1927-4;RAST;LA6112-2;2;1;;; +81989-6;LL1927-4;RAST;LA6113-0;3;2;;; +81989-6;LL1927-4;RAST;LA6114-8;4;3;;; +81989-6;LL1927-4;RAST;LA6115-5;5;4;;; +81989-6;LL1927-4;RAST;LA10137-0;6;5;;; +81989-6;LL1927-4;RAST;LA10138-8;7;6;;; +81990-4;LL1927-4;RAST;LA6111-4;1;0;;; +81990-4;LL1927-4;RAST;LA6112-2;2;1;;; +81990-4;LL1927-4;RAST;LA6113-0;3;2;;; +81990-4;LL1927-4;RAST;LA6114-8;4;3;;; +81990-4;LL1927-4;RAST;LA6115-5;5;4;;; +81990-4;LL1927-4;RAST;LA10137-0;6;5;;; +81990-4;LL1927-4;RAST;LA10138-8;7;6;;; +81991-2;LL1927-4;RAST;LA6111-4;1;0;;; +81991-2;LL1927-4;RAST;LA6112-2;2;1;;; +81991-2;LL1927-4;RAST;LA6113-0;3;2;;; +81991-2;LL1927-4;RAST;LA6114-8;4;3;;; +81991-2;LL1927-4;RAST;LA6115-5;5;4;;; +81991-2;LL1927-4;RAST;LA10137-0;6;5;;; +81991-2;LL1927-4;RAST;LA10138-8;7;6;;; +81992-0;LL1927-4;RAST;LA6111-4;1;0;;; +81992-0;LL1927-4;RAST;LA6112-2;2;1;;; +81992-0;LL1927-4;RAST;LA6113-0;3;2;;; +81992-0;LL1927-4;RAST;LA6114-8;4;3;;; +81992-0;LL1927-4;RAST;LA6115-5;5;4;;; +81992-0;LL1927-4;RAST;LA10137-0;6;5;;; +81992-0;LL1927-4;RAST;LA10138-8;7;6;;; +81993-8;LL1927-4;RAST;LA6111-4;1;0;;; +81993-8;LL1927-4;RAST;LA6112-2;2;1;;; +81993-8;LL1927-4;RAST;LA6113-0;3;2;;; +81993-8;LL1927-4;RAST;LA6114-8;4;3;;; +81993-8;LL1927-4;RAST;LA6115-5;5;4;;; +81993-8;LL1927-4;RAST;LA10137-0;6;5;;; +81993-8;LL1927-4;RAST;LA10138-8;7;6;;; +81994-6;LL1927-4;RAST;LA6111-4;1;0;;; +81994-6;LL1927-4;RAST;LA6112-2;2;1;;; +81994-6;LL1927-4;RAST;LA6113-0;3;2;;; +81994-6;LL1927-4;RAST;LA6114-8;4;3;;; +81994-6;LL1927-4;RAST;LA6115-5;5;4;;; +81994-6;LL1927-4;RAST;LA10137-0;6;5;;; +81994-6;LL1927-4;RAST;LA10138-8;7;6;;; +81995-3;LL1927-4;RAST;LA6111-4;1;0;;; +81995-3;LL1927-4;RAST;LA6112-2;2;1;;; +81995-3;LL1927-4;RAST;LA6113-0;3;2;;; +81995-3;LL1927-4;RAST;LA6114-8;4;3;;; +81995-3;LL1927-4;RAST;LA6115-5;5;4;;; +81995-3;LL1927-4;RAST;LA10137-0;6;5;;; +81995-3;LL1927-4;RAST;LA10138-8;7;6;;; +81996-1;LL1927-4;RAST;LA6111-4;1;0;;; +81996-1;LL1927-4;RAST;LA6112-2;2;1;;; +81996-1;LL1927-4;RAST;LA6113-0;3;2;;; +81996-1;LL1927-4;RAST;LA6114-8;4;3;;; +81996-1;LL1927-4;RAST;LA6115-5;5;4;;; +81996-1;LL1927-4;RAST;LA10137-0;6;5;;; +81996-1;LL1927-4;RAST;LA10138-8;7;6;;; +81997-9;LL1927-4;RAST;LA6111-4;1;0;;; +81997-9;LL1927-4;RAST;LA6112-2;2;1;;; +81997-9;LL1927-4;RAST;LA6113-0;3;2;;; +81997-9;LL1927-4;RAST;LA6114-8;4;3;;; +81997-9;LL1927-4;RAST;LA6115-5;5;4;;; +81997-9;LL1927-4;RAST;LA10137-0;6;5;;; +81997-9;LL1927-4;RAST;LA10138-8;7;6;;; +81998-7;LL1927-4;RAST;LA6111-4;1;0;;; +81998-7;LL1927-4;RAST;LA6112-2;2;1;;; +81998-7;LL1927-4;RAST;LA6113-0;3;2;;; +81998-7;LL1927-4;RAST;LA6114-8;4;3;;; +81998-7;LL1927-4;RAST;LA6115-5;5;4;;; +81998-7;LL1927-4;RAST;LA10137-0;6;5;;; +81998-7;LL1927-4;RAST;LA10138-8;7;6;;; +81999-5;LL1927-4;RAST;LA6111-4;1;0;;; +81999-5;LL1927-4;RAST;LA6112-2;2;1;;; +81999-5;LL1927-4;RAST;LA6113-0;3;2;;; +81999-5;LL1927-4;RAST;LA6114-8;4;3;;; +81999-5;LL1927-4;RAST;LA6115-5;5;4;;; +81999-5;LL1927-4;RAST;LA10137-0;6;5;;; +81999-5;LL1927-4;RAST;LA10138-8;7;6;;; +82000-1;LL1927-4;RAST;LA6111-4;1;0;;; +82000-1;LL1927-4;RAST;LA6112-2;2;1;;; +82000-1;LL1927-4;RAST;LA6113-0;3;2;;; +82000-1;LL1927-4;RAST;LA6114-8;4;3;;; +82000-1;LL1927-4;RAST;LA6115-5;5;4;;; +82000-1;LL1927-4;RAST;LA10137-0;6;5;;; +82000-1;LL1927-4;RAST;LA10138-8;7;6;;; +82001-9;LL1927-4;RAST;LA6111-4;1;0;;; +82001-9;LL1927-4;RAST;LA6112-2;2;1;;; +82001-9;LL1927-4;RAST;LA6113-0;3;2;;; +82001-9;LL1927-4;RAST;LA6114-8;4;3;;; +82001-9;LL1927-4;RAST;LA6115-5;5;4;;; +82001-9;LL1927-4;RAST;LA10137-0;6;5;;; +82001-9;LL1927-4;RAST;LA10138-8;7;6;;; +82002-7;LL1927-4;RAST;LA6111-4;1;0;;; +82002-7;LL1927-4;RAST;LA6112-2;2;1;;; +82002-7;LL1927-4;RAST;LA6113-0;3;2;;; +82002-7;LL1927-4;RAST;LA6114-8;4;3;;; +82002-7;LL1927-4;RAST;LA6115-5;5;4;;; +82002-7;LL1927-4;RAST;LA10137-0;6;5;;; +82002-7;LL1927-4;RAST;LA10138-8;7;6;;; +82003-5;LL1927-4;RAST;LA6111-4;1;0;;; +82003-5;LL1927-4;RAST;LA6112-2;2;1;;; +82003-5;LL1927-4;RAST;LA6113-0;3;2;;; +82003-5;LL1927-4;RAST;LA6114-8;4;3;;; +82003-5;LL1927-4;RAST;LA6115-5;5;4;;; +82003-5;LL1927-4;RAST;LA10137-0;6;5;;; +82003-5;LL1927-4;RAST;LA10138-8;7;6;;; +82004-3;LL1927-4;RAST;LA6111-4;1;0;;; +82004-3;LL1927-4;RAST;LA6112-2;2;1;;; +82004-3;LL1927-4;RAST;LA6113-0;3;2;;; +82004-3;LL1927-4;RAST;LA6114-8;4;3;;; +82004-3;LL1927-4;RAST;LA6115-5;5;4;;; +82004-3;LL1927-4;RAST;LA10137-0;6;5;;; +82004-3;LL1927-4;RAST;LA10138-8;7;6;;; +82005-0;LL1927-4;RAST;LA6111-4;1;0;;; +82005-0;LL1927-4;RAST;LA6112-2;2;1;;; +82005-0;LL1927-4;RAST;LA6113-0;3;2;;; +82005-0;LL1927-4;RAST;LA6114-8;4;3;;; +82005-0;LL1927-4;RAST;LA6115-5;5;4;;; +82005-0;LL1927-4;RAST;LA10137-0;6;5;;; +82005-0;LL1927-4;RAST;LA10138-8;7;6;;; +82006-8;LL1927-4;RAST;LA6111-4;1;0;;; +82006-8;LL1927-4;RAST;LA6112-2;2;1;;; +82006-8;LL1927-4;RAST;LA6113-0;3;2;;; +82006-8;LL1927-4;RAST;LA6114-8;4;3;;; +82006-8;LL1927-4;RAST;LA6115-5;5;4;;; +82006-8;LL1927-4;RAST;LA10137-0;6;5;;; +82006-8;LL1927-4;RAST;LA10138-8;7;6;;; +82007-6;LL1927-4;RAST;LA6111-4;1;0;;; +82007-6;LL1927-4;RAST;LA6112-2;2;1;;; +82007-6;LL1927-4;RAST;LA6113-0;3;2;;; +82007-6;LL1927-4;RAST;LA6114-8;4;3;;; +82007-6;LL1927-4;RAST;LA6115-5;5;4;;; +82007-6;LL1927-4;RAST;LA10137-0;6;5;;; +82007-6;LL1927-4;RAST;LA10138-8;7;6;;; +82008-4;LL1927-4;RAST;LA6111-4;1;0;;; +82008-4;LL1927-4;RAST;LA6112-2;2;1;;; +82008-4;LL1927-4;RAST;LA6113-0;3;2;;; +82008-4;LL1927-4;RAST;LA6114-8;4;3;;; +82008-4;LL1927-4;RAST;LA6115-5;5;4;;; +82008-4;LL1927-4;RAST;LA10137-0;6;5;;; +82008-4;LL1927-4;RAST;LA10138-8;7;6;;; +82009-2;LL1927-4;RAST;LA6111-4;1;0;;; +82009-2;LL1927-4;RAST;LA6112-2;2;1;;; +82009-2;LL1927-4;RAST;LA6113-0;3;2;;; +82009-2;LL1927-4;RAST;LA6114-8;4;3;;; +82009-2;LL1927-4;RAST;LA6115-5;5;4;;; +82009-2;LL1927-4;RAST;LA10137-0;6;5;;; +82009-2;LL1927-4;RAST;LA10138-8;7;6;;; +82010-0;LL1927-4;RAST;LA6111-4;1;0;;; +82010-0;LL1927-4;RAST;LA6112-2;2;1;;; +82010-0;LL1927-4;RAST;LA6113-0;3;2;;; +82010-0;LL1927-4;RAST;LA6114-8;4;3;;; +82010-0;LL1927-4;RAST;LA6115-5;5;4;;; +82010-0;LL1927-4;RAST;LA10137-0;6;5;;; +82010-0;LL1927-4;RAST;LA10138-8;7;6;;; +82011-8;LL1927-4;RAST;LA6111-4;1;0;;; +82011-8;LL1927-4;RAST;LA6112-2;2;1;;; +82011-8;LL1927-4;RAST;LA6113-0;3;2;;; +82011-8;LL1927-4;RAST;LA6114-8;4;3;;; +82011-8;LL1927-4;RAST;LA6115-5;5;4;;; +82011-8;LL1927-4;RAST;LA10137-0;6;5;;; +82011-8;LL1927-4;RAST;LA10138-8;7;6;;; +82012-6;LL1927-4;RAST;LA6111-4;1;0;;; +82012-6;LL1927-4;RAST;LA6112-2;2;1;;; +82012-6;LL1927-4;RAST;LA6113-0;3;2;;; +82012-6;LL1927-4;RAST;LA6114-8;4;3;;; +82012-6;LL1927-4;RAST;LA6115-5;5;4;;; +82012-6;LL1927-4;RAST;LA10137-0;6;5;;; +82012-6;LL1927-4;RAST;LA10138-8;7;6;;; +82013-4;LL1927-4;RAST;LA6111-4;1;0;;; +82013-4;LL1927-4;RAST;LA6112-2;2;1;;; +82013-4;LL1927-4;RAST;LA6113-0;3;2;;; +82013-4;LL1927-4;RAST;LA6114-8;4;3;;; +82013-4;LL1927-4;RAST;LA6115-5;5;4;;; +82013-4;LL1927-4;RAST;LA10137-0;6;5;;; +82013-4;LL1927-4;RAST;LA10138-8;7;6;;; +82014-2;LL1927-4;RAST;LA6111-4;1;0;;; +82014-2;LL1927-4;RAST;LA6112-2;2;1;;; +82014-2;LL1927-4;RAST;LA6113-0;3;2;;; +82014-2;LL1927-4;RAST;LA6114-8;4;3;;; +82014-2;LL1927-4;RAST;LA6115-5;5;4;;; +82014-2;LL1927-4;RAST;LA10137-0;6;5;;; +82014-2;LL1927-4;RAST;LA10138-8;7;6;;; +82015-9;LL1927-4;RAST;LA6111-4;1;0;;; +82015-9;LL1927-4;RAST;LA6112-2;2;1;;; +82015-9;LL1927-4;RAST;LA6113-0;3;2;;; +82015-9;LL1927-4;RAST;LA6114-8;4;3;;; +82015-9;LL1927-4;RAST;LA6115-5;5;4;;; +82015-9;LL1927-4;RAST;LA10137-0;6;5;;; +82015-9;LL1927-4;RAST;LA10138-8;7;6;;; +82016-7;LL1927-4;RAST;LA6111-4;1;0;;; +82016-7;LL1927-4;RAST;LA6112-2;2;1;;; +82016-7;LL1927-4;RAST;LA6113-0;3;2;;; +82016-7;LL1927-4;RAST;LA6114-8;4;3;;; +82016-7;LL1927-4;RAST;LA6115-5;5;4;;; +82016-7;LL1927-4;RAST;LA10137-0;6;5;;; +82016-7;LL1927-4;RAST;LA10138-8;7;6;;; +82017-5;LL1927-4;RAST;LA6111-4;1;0;;; +82017-5;LL1927-4;RAST;LA6112-2;2;1;;; +82017-5;LL1927-4;RAST;LA6113-0;3;2;;; +82017-5;LL1927-4;RAST;LA6114-8;4;3;;; +82017-5;LL1927-4;RAST;LA6115-5;5;4;;; +82017-5;LL1927-4;RAST;LA10137-0;6;5;;; +82017-5;LL1927-4;RAST;LA10138-8;7;6;;; +82018-3;LL1927-4;RAST;LA6111-4;1;0;;; +82018-3;LL1927-4;RAST;LA6112-2;2;1;;; +82018-3;LL1927-4;RAST;LA6113-0;3;2;;; +82018-3;LL1927-4;RAST;LA6114-8;4;3;;; +82018-3;LL1927-4;RAST;LA6115-5;5;4;;; +82018-3;LL1927-4;RAST;LA10137-0;6;5;;; +82018-3;LL1927-4;RAST;LA10138-8;7;6;;; +82019-1;LL1927-4;RAST;LA6111-4;1;0;;; +82019-1;LL1927-4;RAST;LA6112-2;2;1;;; +82019-1;LL1927-4;RAST;LA6113-0;3;2;;; +82019-1;LL1927-4;RAST;LA6114-8;4;3;;; +82019-1;LL1927-4;RAST;LA6115-5;5;4;;; +82019-1;LL1927-4;RAST;LA10137-0;6;5;;; +82019-1;LL1927-4;RAST;LA10138-8;7;6;;; +82020-9;LL1927-4;RAST;LA6111-4;1;0;;; +82020-9;LL1927-4;RAST;LA6112-2;2;1;;; +82020-9;LL1927-4;RAST;LA6113-0;3;2;;; +82020-9;LL1927-4;RAST;LA6114-8;4;3;;; +82020-9;LL1927-4;RAST;LA6115-5;5;4;;; +82020-9;LL1927-4;RAST;LA10137-0;6;5;;; +82020-9;LL1927-4;RAST;LA10138-8;7;6;;; +82021-7;LL1927-4;RAST;LA6111-4;1;0;;; +82021-7;LL1927-4;RAST;LA6112-2;2;1;;; +82021-7;LL1927-4;RAST;LA6113-0;3;2;;; +82021-7;LL1927-4;RAST;LA6114-8;4;3;;; +82021-7;LL1927-4;RAST;LA6115-5;5;4;;; +82021-7;LL1927-4;RAST;LA10137-0;6;5;;; +82021-7;LL1927-4;RAST;LA10138-8;7;6;;; +82022-5;LL1927-4;RAST;LA6111-4;1;0;;; +82022-5;LL1927-4;RAST;LA6112-2;2;1;;; +82022-5;LL1927-4;RAST;LA6113-0;3;2;;; +82022-5;LL1927-4;RAST;LA6114-8;4;3;;; +82022-5;LL1927-4;RAST;LA6115-5;5;4;;; +82022-5;LL1927-4;RAST;LA10137-0;6;5;;; +82022-5;LL1927-4;RAST;LA10138-8;7;6;;; +82023-3;LL1927-4;RAST;LA6111-4;1;0;;; +82023-3;LL1927-4;RAST;LA6112-2;2;1;;; +82023-3;LL1927-4;RAST;LA6113-0;3;2;;; +82023-3;LL1927-4;RAST;LA6114-8;4;3;;; +82023-3;LL1927-4;RAST;LA6115-5;5;4;;; +82023-3;LL1927-4;RAST;LA10137-0;6;5;;; +82023-3;LL1927-4;RAST;LA10138-8;7;6;;; +82024-1;LL1927-4;RAST;LA6111-4;1;0;;; +82024-1;LL1927-4;RAST;LA6112-2;2;1;;; +82024-1;LL1927-4;RAST;LA6113-0;3;2;;; +82024-1;LL1927-4;RAST;LA6114-8;4;3;;; +82024-1;LL1927-4;RAST;LA6115-5;5;4;;; +82024-1;LL1927-4;RAST;LA10137-0;6;5;;; +82024-1;LL1927-4;RAST;LA10138-8;7;6;;; +82025-8;LL1927-4;RAST;LA6111-4;1;0;;; +82025-8;LL1927-4;RAST;LA6112-2;2;1;;; +82025-8;LL1927-4;RAST;LA6113-0;3;2;;; +82025-8;LL1927-4;RAST;LA6114-8;4;3;;; +82025-8;LL1927-4;RAST;LA6115-5;5;4;;; +82025-8;LL1927-4;RAST;LA10137-0;6;5;;; +82025-8;LL1927-4;RAST;LA10138-8;7;6;;; +82026-6;LL1927-4;RAST;LA6111-4;1;0;;; +82026-6;LL1927-4;RAST;LA6112-2;2;1;;; +82026-6;LL1927-4;RAST;LA6113-0;3;2;;; +82026-6;LL1927-4;RAST;LA6114-8;4;3;;; +82026-6;LL1927-4;RAST;LA6115-5;5;4;;; +82026-6;LL1927-4;RAST;LA10137-0;6;5;;; +82026-6;LL1927-4;RAST;LA10138-8;7;6;;; +82027-4;LL1927-4;RAST;LA6111-4;1;0;;; +82027-4;LL1927-4;RAST;LA6112-2;2;1;;; +82027-4;LL1927-4;RAST;LA6113-0;3;2;;; +82027-4;LL1927-4;RAST;LA6114-8;4;3;;; +82027-4;LL1927-4;RAST;LA6115-5;5;4;;; +82027-4;LL1927-4;RAST;LA10137-0;6;5;;; +82027-4;LL1927-4;RAST;LA10138-8;7;6;;; +82028-2;LL1927-4;RAST;LA6111-4;1;0;;; +82028-2;LL1927-4;RAST;LA6112-2;2;1;;; +82028-2;LL1927-4;RAST;LA6113-0;3;2;;; +82028-2;LL1927-4;RAST;LA6114-8;4;3;;; +82028-2;LL1927-4;RAST;LA6115-5;5;4;;; +82028-2;LL1927-4;RAST;LA10137-0;6;5;;; +82028-2;LL1927-4;RAST;LA10138-8;7;6;;; +82029-0;LL1927-4;RAST;LA6111-4;1;0;;; +82029-0;LL1927-4;RAST;LA6112-2;2;1;;; +82029-0;LL1927-4;RAST;LA6113-0;3;2;;; +82029-0;LL1927-4;RAST;LA6114-8;4;3;;; +82029-0;LL1927-4;RAST;LA6115-5;5;4;;; +82029-0;LL1927-4;RAST;LA10137-0;6;5;;; +82029-0;LL1927-4;RAST;LA10138-8;7;6;;; +82030-8;LL1927-4;RAST;LA6111-4;1;0;;; +82030-8;LL1927-4;RAST;LA6112-2;2;1;;; +82030-8;LL1927-4;RAST;LA6113-0;3;2;;; +82030-8;LL1927-4;RAST;LA6114-8;4;3;;; +82030-8;LL1927-4;RAST;LA6115-5;5;4;;; +82030-8;LL1927-4;RAST;LA10137-0;6;5;;; +82030-8;LL1927-4;RAST;LA10138-8;7;6;;; +82033-2;LL1927-4;RAST;LA6111-4;1;0;;; +82033-2;LL1927-4;RAST;LA6112-2;2;1;;; +82033-2;LL1927-4;RAST;LA6113-0;3;2;;; +82033-2;LL1927-4;RAST;LA6114-8;4;3;;; +82033-2;LL1927-4;RAST;LA6115-5;5;4;;; +82033-2;LL1927-4;RAST;LA10137-0;6;5;;; +82033-2;LL1927-4;RAST;LA10138-8;7;6;;; +82034-0;LL1927-4;RAST;LA6111-4;1;0;;; +82034-0;LL1927-4;RAST;LA6112-2;2;1;;; +82034-0;LL1927-4;RAST;LA6113-0;3;2;;; +82034-0;LL1927-4;RAST;LA6114-8;4;3;;; +82034-0;LL1927-4;RAST;LA6115-5;5;4;;; +82034-0;LL1927-4;RAST;LA10137-0;6;5;;; +82034-0;LL1927-4;RAST;LA10138-8;7;6;;; +82036-5;LL1927-4;RAST;LA6111-4;1;0;;; +82036-5;LL1927-4;RAST;LA6112-2;2;1;;; +82036-5;LL1927-4;RAST;LA6113-0;3;2;;; +82036-5;LL1927-4;RAST;LA6114-8;4;3;;; +82036-5;LL1927-4;RAST;LA6115-5;5;4;;; +82036-5;LL1927-4;RAST;LA10137-0;6;5;;; +82036-5;LL1927-4;RAST;LA10138-8;7;6;;; +82037-3;LL1927-4;RAST;LA6111-4;1;0;;; +82037-3;LL1927-4;RAST;LA6112-2;2;1;;; +82037-3;LL1927-4;RAST;LA6113-0;3;2;;; +82037-3;LL1927-4;RAST;LA6114-8;4;3;;; +82037-3;LL1927-4;RAST;LA6115-5;5;4;;; +82037-3;LL1927-4;RAST;LA10137-0;6;5;;; +82037-3;LL1927-4;RAST;LA10138-8;7;6;;; +82038-1;LL1927-4;RAST;LA6111-4;1;0;;; +82038-1;LL1927-4;RAST;LA6112-2;2;1;;; +82038-1;LL1927-4;RAST;LA6113-0;3;2;;; +82038-1;LL1927-4;RAST;LA6114-8;4;3;;; +82038-1;LL1927-4;RAST;LA6115-5;5;4;;; +82038-1;LL1927-4;RAST;LA10137-0;6;5;;; +82038-1;LL1927-4;RAST;LA10138-8;7;6;;; +82039-9;LL1927-4;RAST;LA6111-4;1;0;;; +82039-9;LL1927-4;RAST;LA6112-2;2;1;;; +82039-9;LL1927-4;RAST;LA6113-0;3;2;;; +82039-9;LL1927-4;RAST;LA6114-8;4;3;;; +82039-9;LL1927-4;RAST;LA6115-5;5;4;;; +82039-9;LL1927-4;RAST;LA10137-0;6;5;;; +82039-9;LL1927-4;RAST;LA10138-8;7;6;;; +82040-7;LL1927-4;RAST;LA6111-4;1;0;;; +82040-7;LL1927-4;RAST;LA6112-2;2;1;;; +82040-7;LL1927-4;RAST;LA6113-0;3;2;;; +82040-7;LL1927-4;RAST;LA6114-8;4;3;;; +82040-7;LL1927-4;RAST;LA6115-5;5;4;;; +82040-7;LL1927-4;RAST;LA10137-0;6;5;;; +82040-7;LL1927-4;RAST;LA10138-8;7;6;;; +82042-3;LL1927-4;RAST;LA6111-4;1;0;;; +82042-3;LL1927-4;RAST;LA6112-2;2;1;;; +82042-3;LL1927-4;RAST;LA6113-0;3;2;;; +82042-3;LL1927-4;RAST;LA6114-8;4;3;;; +82042-3;LL1927-4;RAST;LA6115-5;5;4;;; +82042-3;LL1927-4;RAST;LA10137-0;6;5;;; +82042-3;LL1927-4;RAST;LA10138-8;7;6;;; +82043-1;LL1927-4;RAST;LA6111-4;1;0;;; +82043-1;LL1927-4;RAST;LA6112-2;2;1;;; +82043-1;LL1927-4;RAST;LA6113-0;3;2;;; +82043-1;LL1927-4;RAST;LA6114-8;4;3;;; +82043-1;LL1927-4;RAST;LA6115-5;5;4;;; +82043-1;LL1927-4;RAST;LA10137-0;6;5;;; +82043-1;LL1927-4;RAST;LA10138-8;7;6;;; +82044-9;LL1927-4;RAST;LA6111-4;1;0;;; +82044-9;LL1927-4;RAST;LA6112-2;2;1;;; +82044-9;LL1927-4;RAST;LA6113-0;3;2;;; +82044-9;LL1927-4;RAST;LA6114-8;4;3;;; +82044-9;LL1927-4;RAST;LA6115-5;5;4;;; +82044-9;LL1927-4;RAST;LA10137-0;6;5;;; +82044-9;LL1927-4;RAST;LA10138-8;7;6;;; +82046-4;LL1927-4;RAST;LA6111-4;1;0;;; +82046-4;LL1927-4;RAST;LA6112-2;2;1;;; +82046-4;LL1927-4;RAST;LA6113-0;3;2;;; +82046-4;LL1927-4;RAST;LA6114-8;4;3;;; +82046-4;LL1927-4;RAST;LA6115-5;5;4;;; +82046-4;LL1927-4;RAST;LA10137-0;6;5;;; +82046-4;LL1927-4;RAST;LA10138-8;7;6;;; +82048-0;LL1927-4;RAST;LA6111-4;1;0;;; +82048-0;LL1927-4;RAST;LA6112-2;2;1;;; +82048-0;LL1927-4;RAST;LA6113-0;3;2;;; +82048-0;LL1927-4;RAST;LA6114-8;4;3;;; +82048-0;LL1927-4;RAST;LA6115-5;5;4;;; +82048-0;LL1927-4;RAST;LA10137-0;6;5;;; +82048-0;LL1927-4;RAST;LA10138-8;7;6;;; +82049-8;LL1927-4;RAST;LA6111-4;1;0;;; +82049-8;LL1927-4;RAST;LA6112-2;2;1;;; +82049-8;LL1927-4;RAST;LA6113-0;3;2;;; +82049-8;LL1927-4;RAST;LA6114-8;4;3;;; +82049-8;LL1927-4;RAST;LA6115-5;5;4;;; +82049-8;LL1927-4;RAST;LA10137-0;6;5;;; +82049-8;LL1927-4;RAST;LA10138-8;7;6;;; +82050-6;LL1927-4;RAST;LA6111-4;1;0;;; +82050-6;LL1927-4;RAST;LA6112-2;2;1;;; +82050-6;LL1927-4;RAST;LA6113-0;3;2;;; +82050-6;LL1927-4;RAST;LA6114-8;4;3;;; +82050-6;LL1927-4;RAST;LA6115-5;5;4;;; +82050-6;LL1927-4;RAST;LA10137-0;6;5;;; +82050-6;LL1927-4;RAST;LA10138-8;7;6;;; +82051-4;LL1927-4;RAST;LA6111-4;1;0;;; +82051-4;LL1927-4;RAST;LA6112-2;2;1;;; +82051-4;LL1927-4;RAST;LA6113-0;3;2;;; +82051-4;LL1927-4;RAST;LA6114-8;4;3;;; +82051-4;LL1927-4;RAST;LA6115-5;5;4;;; +82051-4;LL1927-4;RAST;LA10137-0;6;5;;; +82051-4;LL1927-4;RAST;LA10138-8;7;6;;; +82053-0;LL1927-4;RAST;LA6111-4;1;0;;; +82053-0;LL1927-4;RAST;LA6112-2;2;1;;; +82053-0;LL1927-4;RAST;LA6113-0;3;2;;; +82053-0;LL1927-4;RAST;LA6114-8;4;3;;; +82053-0;LL1927-4;RAST;LA6115-5;5;4;;; +82053-0;LL1927-4;RAST;LA10137-0;6;5;;; +82053-0;LL1927-4;RAST;LA10138-8;7;6;;; +82055-5;LL1927-4;RAST;LA6111-4;1;0;;; +82055-5;LL1927-4;RAST;LA6112-2;2;1;;; +82055-5;LL1927-4;RAST;LA6113-0;3;2;;; +82055-5;LL1927-4;RAST;LA6114-8;4;3;;; +82055-5;LL1927-4;RAST;LA6115-5;5;4;;; +82055-5;LL1927-4;RAST;LA10137-0;6;5;;; +82055-5;LL1927-4;RAST;LA10138-8;7;6;;; +82056-3;LL1927-4;RAST;LA6111-4;1;0;;; +82056-3;LL1927-4;RAST;LA6112-2;2;1;;; +82056-3;LL1927-4;RAST;LA6113-0;3;2;;; +82056-3;LL1927-4;RAST;LA6114-8;4;3;;; +82056-3;LL1927-4;RAST;LA6115-5;5;4;;; +82056-3;LL1927-4;RAST;LA10137-0;6;5;;; +82056-3;LL1927-4;RAST;LA10138-8;7;6;;; +82057-1;LL1927-4;RAST;LA6111-4;1;0;;; +82057-1;LL1927-4;RAST;LA6112-2;2;1;;; +82057-1;LL1927-4;RAST;LA6113-0;3;2;;; +82057-1;LL1927-4;RAST;LA6114-8;4;3;;; +82057-1;LL1927-4;RAST;LA6115-5;5;4;;; +82057-1;LL1927-4;RAST;LA10137-0;6;5;;; +82057-1;LL1927-4;RAST;LA10138-8;7;6;;; +82058-9;LL1927-4;RAST;LA6111-4;1;0;;; +82058-9;LL1927-4;RAST;LA6112-2;2;1;;; +82058-9;LL1927-4;RAST;LA6113-0;3;2;;; +82058-9;LL1927-4;RAST;LA6114-8;4;3;;; +82058-9;LL1927-4;RAST;LA6115-5;5;4;;; +82058-9;LL1927-4;RAST;LA10137-0;6;5;;; +82058-9;LL1927-4;RAST;LA10138-8;7;6;;; +82060-5;LL1927-4;RAST;LA6111-4;1;0;;; +82060-5;LL1927-4;RAST;LA6112-2;2;1;;; +82060-5;LL1927-4;RAST;LA6113-0;3;2;;; +82060-5;LL1927-4;RAST;LA6114-8;4;3;;; +82060-5;LL1927-4;RAST;LA6115-5;5;4;;; +82060-5;LL1927-4;RAST;LA10137-0;6;5;;; +82060-5;LL1927-4;RAST;LA10138-8;7;6;;; +82061-3;LL1927-4;RAST;LA6111-4;1;0;;; +82061-3;LL1927-4;RAST;LA6112-2;2;1;;; +82061-3;LL1927-4;RAST;LA6113-0;3;2;;; +82061-3;LL1927-4;RAST;LA6114-8;4;3;;; +82061-3;LL1927-4;RAST;LA6115-5;5;4;;; +82061-3;LL1927-4;RAST;LA10137-0;6;5;;; +82061-3;LL1927-4;RAST;LA10138-8;7;6;;; +82062-1;LL1927-4;RAST;LA6111-4;1;0;;; +82062-1;LL1927-4;RAST;LA6112-2;2;1;;; +82062-1;LL1927-4;RAST;LA6113-0;3;2;;; +82062-1;LL1927-4;RAST;LA6114-8;4;3;;; +82062-1;LL1927-4;RAST;LA6115-5;5;4;;; +82062-1;LL1927-4;RAST;LA10137-0;6;5;;; +82062-1;LL1927-4;RAST;LA10138-8;7;6;;; +82063-9;LL1927-4;RAST;LA6111-4;1;0;;; +82063-9;LL1927-4;RAST;LA6112-2;2;1;;; +82063-9;LL1927-4;RAST;LA6113-0;3;2;;; +82063-9;LL1927-4;RAST;LA6114-8;4;3;;; +82063-9;LL1927-4;RAST;LA6115-5;5;4;;; +82063-9;LL1927-4;RAST;LA10137-0;6;5;;; +82063-9;LL1927-4;RAST;LA10138-8;7;6;;; +82064-7;LL1927-4;RAST;LA6111-4;1;0;;; +82064-7;LL1927-4;RAST;LA6112-2;2;1;;; +82064-7;LL1927-4;RAST;LA6113-0;3;2;;; +82064-7;LL1927-4;RAST;LA6114-8;4;3;;; +82064-7;LL1927-4;RAST;LA6115-5;5;4;;; +82064-7;LL1927-4;RAST;LA10137-0;6;5;;; +82064-7;LL1927-4;RAST;LA10138-8;7;6;;; +82065-4;LL1927-4;RAST;LA6111-4;1;0;;; +82065-4;LL1927-4;RAST;LA6112-2;2;1;;; +82065-4;LL1927-4;RAST;LA6113-0;3;2;;; +82065-4;LL1927-4;RAST;LA6114-8;4;3;;; +82065-4;LL1927-4;RAST;LA6115-5;5;4;;; +82065-4;LL1927-4;RAST;LA10137-0;6;5;;; +82065-4;LL1927-4;RAST;LA10138-8;7;6;;; +82066-2;LL1927-4;RAST;LA6111-4;1;0;;; +82066-2;LL1927-4;RAST;LA6112-2;2;1;;; +82066-2;LL1927-4;RAST;LA6113-0;3;2;;; +82066-2;LL1927-4;RAST;LA6114-8;4;3;;; +82066-2;LL1927-4;RAST;LA6115-5;5;4;;; +82066-2;LL1927-4;RAST;LA10137-0;6;5;;; +82066-2;LL1927-4;RAST;LA10138-8;7;6;;; +82067-0;LL1927-4;RAST;LA6111-4;1;0;;; +82067-0;LL1927-4;RAST;LA6112-2;2;1;;; +82067-0;LL1927-4;RAST;LA6113-0;3;2;;; +82067-0;LL1927-4;RAST;LA6114-8;4;3;;; +82067-0;LL1927-4;RAST;LA6115-5;5;4;;; +82067-0;LL1927-4;RAST;LA10137-0;6;5;;; +82067-0;LL1927-4;RAST;LA10138-8;7;6;;; +82069-6;LL1927-4;RAST;LA6111-4;1;0;;; +82069-6;LL1927-4;RAST;LA6112-2;2;1;;; +82069-6;LL1927-4;RAST;LA6113-0;3;2;;; +82069-6;LL1927-4;RAST;LA6114-8;4;3;;; +82069-6;LL1927-4;RAST;LA6115-5;5;4;;; +82069-6;LL1927-4;RAST;LA10137-0;6;5;;; +82069-6;LL1927-4;RAST;LA10138-8;7;6;;; +82070-4;LL1927-4;RAST;LA6111-4;1;0;;; +82070-4;LL1927-4;RAST;LA6112-2;2;1;;; +82070-4;LL1927-4;RAST;LA6113-0;3;2;;; +82070-4;LL1927-4;RAST;LA6114-8;4;3;;; +82070-4;LL1927-4;RAST;LA6115-5;5;4;;; +82070-4;LL1927-4;RAST;LA10137-0;6;5;;; +82070-4;LL1927-4;RAST;LA10138-8;7;6;;; +82071-2;LL1927-4;RAST;LA6111-4;1;0;;; +82071-2;LL1927-4;RAST;LA6112-2;2;1;;; +82071-2;LL1927-4;RAST;LA6113-0;3;2;;; +82071-2;LL1927-4;RAST;LA6114-8;4;3;;; +82071-2;LL1927-4;RAST;LA6115-5;5;4;;; +82071-2;LL1927-4;RAST;LA10137-0;6;5;;; +82071-2;LL1927-4;RAST;LA10138-8;7;6;;; +82072-0;LL1927-4;RAST;LA6111-4;1;0;;; +82072-0;LL1927-4;RAST;LA6112-2;2;1;;; +82072-0;LL1927-4;RAST;LA6113-0;3;2;;; +82072-0;LL1927-4;RAST;LA6114-8;4;3;;; +82072-0;LL1927-4;RAST;LA6115-5;5;4;;; +82072-0;LL1927-4;RAST;LA10137-0;6;5;;; +82072-0;LL1927-4;RAST;LA10138-8;7;6;;; +82073-8;LL1927-4;RAST;LA6111-4;1;0;;; +82073-8;LL1927-4;RAST;LA6112-2;2;1;;; +82073-8;LL1927-4;RAST;LA6113-0;3;2;;; +82073-8;LL1927-4;RAST;LA6114-8;4;3;;; +82073-8;LL1927-4;RAST;LA6115-5;5;4;;; +82073-8;LL1927-4;RAST;LA10137-0;6;5;;; +82073-8;LL1927-4;RAST;LA10138-8;7;6;;; +82075-3;LL1927-4;RAST;LA6111-4;1;0;;; +82075-3;LL1927-4;RAST;LA6112-2;2;1;;; +82075-3;LL1927-4;RAST;LA6113-0;3;2;;; +82075-3;LL1927-4;RAST;LA6114-8;4;3;;; +82075-3;LL1927-4;RAST;LA6115-5;5;4;;; +82075-3;LL1927-4;RAST;LA10137-0;6;5;;; +82075-3;LL1927-4;RAST;LA10138-8;7;6;;; +82076-1;LL1927-4;RAST;LA6111-4;1;0;;; +82076-1;LL1927-4;RAST;LA6112-2;2;1;;; +82076-1;LL1927-4;RAST;LA6113-0;3;2;;; +82076-1;LL1927-4;RAST;LA6114-8;4;3;;; +82076-1;LL1927-4;RAST;LA6115-5;5;4;;; +82076-1;LL1927-4;RAST;LA10137-0;6;5;;; +82076-1;LL1927-4;RAST;LA10138-8;7;6;;; +82077-9;LL1927-4;RAST;LA6111-4;1;0;;; +82077-9;LL1927-4;RAST;LA6112-2;2;1;;; +82077-9;LL1927-4;RAST;LA6113-0;3;2;;; +82077-9;LL1927-4;RAST;LA6114-8;4;3;;; +82077-9;LL1927-4;RAST;LA6115-5;5;4;;; +82077-9;LL1927-4;RAST;LA10137-0;6;5;;; +82077-9;LL1927-4;RAST;LA10138-8;7;6;;; +82079-5;LL1927-4;RAST;LA6111-4;1;0;;; +82079-5;LL1927-4;RAST;LA6112-2;2;1;;; +82079-5;LL1927-4;RAST;LA6113-0;3;2;;; +82079-5;LL1927-4;RAST;LA6114-8;4;3;;; +82079-5;LL1927-4;RAST;LA6115-5;5;4;;; +82079-5;LL1927-4;RAST;LA10137-0;6;5;;; +82079-5;LL1927-4;RAST;LA10138-8;7;6;;; +82081-1;LL1927-4;RAST;LA6111-4;1;0;;; +82081-1;LL1927-4;RAST;LA6112-2;2;1;;; +82081-1;LL1927-4;RAST;LA6113-0;3;2;;; +82081-1;LL1927-4;RAST;LA6114-8;4;3;;; +82081-1;LL1927-4;RAST;LA6115-5;5;4;;; +82081-1;LL1927-4;RAST;LA10137-0;6;5;;; +82081-1;LL1927-4;RAST;LA10138-8;7;6;;; +82082-9;LL1927-4;RAST;LA6111-4;1;0;;; +82082-9;LL1927-4;RAST;LA6112-2;2;1;;; +82082-9;LL1927-4;RAST;LA6113-0;3;2;;; +82082-9;LL1927-4;RAST;LA6114-8;4;3;;; +82082-9;LL1927-4;RAST;LA6115-5;5;4;;; +82082-9;LL1927-4;RAST;LA10137-0;6;5;;; +82082-9;LL1927-4;RAST;LA10138-8;7;6;;; +82083-7;LL1927-4;RAST;LA6111-4;1;0;;; +82083-7;LL1927-4;RAST;LA6112-2;2;1;;; +82083-7;LL1927-4;RAST;LA6113-0;3;2;;; +82083-7;LL1927-4;RAST;LA6114-8;4;3;;; +82083-7;LL1927-4;RAST;LA6115-5;5;4;;; +82083-7;LL1927-4;RAST;LA10137-0;6;5;;; +82083-7;LL1927-4;RAST;LA10138-8;7;6;;; +82084-5;LL1927-4;RAST;LA6111-4;1;0;;; +82084-5;LL1927-4;RAST;LA6112-2;2;1;;; +82084-5;LL1927-4;RAST;LA6113-0;3;2;;; +82084-5;LL1927-4;RAST;LA6114-8;4;3;;; +82084-5;LL1927-4;RAST;LA6115-5;5;4;;; +82084-5;LL1927-4;RAST;LA10137-0;6;5;;; +82084-5;LL1927-4;RAST;LA10138-8;7;6;;; +82086-0;LL1927-4;RAST;LA6111-4;1;0;;; +82086-0;LL1927-4;RAST;LA6112-2;2;1;;; +82086-0;LL1927-4;RAST;LA6113-0;3;2;;; +82086-0;LL1927-4;RAST;LA6114-8;4;3;;; +82086-0;LL1927-4;RAST;LA6115-5;5;4;;; +82086-0;LL1927-4;RAST;LA10137-0;6;5;;; +82086-0;LL1927-4;RAST;LA10138-8;7;6;;; +82087-8;LL1927-4;RAST;LA6111-4;1;0;;; +82087-8;LL1927-4;RAST;LA6112-2;2;1;;; +82087-8;LL1927-4;RAST;LA6113-0;3;2;;; +82087-8;LL1927-4;RAST;LA6114-8;4;3;;; +82087-8;LL1927-4;RAST;LA6115-5;5;4;;; +82087-8;LL1927-4;RAST;LA10137-0;6;5;;; +82087-8;LL1927-4;RAST;LA10138-8;7;6;;; +82089-4;LL1927-4;RAST;LA6111-4;1;0;;; +82089-4;LL1927-4;RAST;LA6112-2;2;1;;; +82089-4;LL1927-4;RAST;LA6113-0;3;2;;; +82089-4;LL1927-4;RAST;LA6114-8;4;3;;; +82089-4;LL1927-4;RAST;LA6115-5;5;4;;; +82089-4;LL1927-4;RAST;LA10137-0;6;5;;; +82089-4;LL1927-4;RAST;LA10138-8;7;6;;; +82091-0;LL1927-4;RAST;LA6111-4;1;0;;; +82091-0;LL1927-4;RAST;LA6112-2;2;1;;; +82091-0;LL1927-4;RAST;LA6113-0;3;2;;; +82091-0;LL1927-4;RAST;LA6114-8;4;3;;; +82091-0;LL1927-4;RAST;LA6115-5;5;4;;; +82091-0;LL1927-4;RAST;LA10137-0;6;5;;; +82091-0;LL1927-4;RAST;LA10138-8;7;6;;; +82093-6;LL1927-4;RAST;LA6111-4;1;0;;; +82093-6;LL1927-4;RAST;LA6112-2;2;1;;; +82093-6;LL1927-4;RAST;LA6113-0;3;2;;; +82093-6;LL1927-4;RAST;LA6114-8;4;3;;; +82093-6;LL1927-4;RAST;LA6115-5;5;4;;; +82093-6;LL1927-4;RAST;LA10137-0;6;5;;; +82093-6;LL1927-4;RAST;LA10138-8;7;6;;; +82094-4;LL1927-4;RAST;LA6111-4;1;0;;; +82094-4;LL1927-4;RAST;LA6112-2;2;1;;; +82094-4;LL1927-4;RAST;LA6113-0;3;2;;; +82094-4;LL1927-4;RAST;LA6114-8;4;3;;; +82094-4;LL1927-4;RAST;LA6115-5;5;4;;; +82094-4;LL1927-4;RAST;LA10137-0;6;5;;; +82094-4;LL1927-4;RAST;LA10138-8;7;6;;; +82095-1;LL1927-4;RAST;LA6111-4;1;0;;; +82095-1;LL1927-4;RAST;LA6112-2;2;1;;; +82095-1;LL1927-4;RAST;LA6113-0;3;2;;; +82095-1;LL1927-4;RAST;LA6114-8;4;3;;; +82095-1;LL1927-4;RAST;LA6115-5;5;4;;; +82095-1;LL1927-4;RAST;LA10137-0;6;5;;; +82095-1;LL1927-4;RAST;LA10138-8;7;6;;; +82096-9;LL1927-4;RAST;LA6111-4;1;0;;; +82096-9;LL1927-4;RAST;LA6112-2;2;1;;; +82096-9;LL1927-4;RAST;LA6113-0;3;2;;; +82096-9;LL1927-4;RAST;LA6114-8;4;3;;; +82096-9;LL1927-4;RAST;LA6115-5;5;4;;; +82096-9;LL1927-4;RAST;LA10137-0;6;5;;; +82096-9;LL1927-4;RAST;LA10138-8;7;6;;; +82097-7;LL1927-4;RAST;LA6111-4;1;0;;; +82097-7;LL1927-4;RAST;LA6112-2;2;1;;; +82097-7;LL1927-4;RAST;LA6113-0;3;2;;; +82097-7;LL1927-4;RAST;LA6114-8;4;3;;; +82097-7;LL1927-4;RAST;LA6115-5;5;4;;; +82097-7;LL1927-4;RAST;LA10137-0;6;5;;; +82097-7;LL1927-4;RAST;LA10138-8;7;6;;; +82099-3;LL1927-4;RAST;LA6111-4;1;0;;; +82099-3;LL1927-4;RAST;LA6112-2;2;1;;; +82099-3;LL1927-4;RAST;LA6113-0;3;2;;; +82099-3;LL1927-4;RAST;LA6114-8;4;3;;; +82099-3;LL1927-4;RAST;LA6115-5;5;4;;; +82099-3;LL1927-4;RAST;LA10137-0;6;5;;; +82099-3;LL1927-4;RAST;LA10138-8;7;6;;; +82100-9;LL1927-4;RAST;LA6111-4;1;0;;; +82100-9;LL1927-4;RAST;LA6112-2;2;1;;; +82100-9;LL1927-4;RAST;LA6113-0;3;2;;; +82100-9;LL1927-4;RAST;LA6114-8;4;3;;; +82100-9;LL1927-4;RAST;LA6115-5;5;4;;; +82100-9;LL1927-4;RAST;LA10137-0;6;5;;; +82100-9;LL1927-4;RAST;LA10138-8;7;6;;; +82102-5;LL1927-4;RAST;LA6111-4;1;0;;; +82102-5;LL1927-4;RAST;LA6112-2;2;1;;; +82102-5;LL1927-4;RAST;LA6113-0;3;2;;; +82102-5;LL1927-4;RAST;LA6114-8;4;3;;; +82102-5;LL1927-4;RAST;LA6115-5;5;4;;; +82102-5;LL1927-4;RAST;LA10137-0;6;5;;; +82102-5;LL1927-4;RAST;LA10138-8;7;6;;; +82104-1;LL1927-4;RAST;LA6111-4;1;0;;; +82104-1;LL1927-4;RAST;LA6112-2;2;1;;; +82104-1;LL1927-4;RAST;LA6113-0;3;2;;; +82104-1;LL1927-4;RAST;LA6114-8;4;3;;; +82104-1;LL1927-4;RAST;LA6115-5;5;4;;; +82104-1;LL1927-4;RAST;LA10137-0;6;5;;; +82104-1;LL1927-4;RAST;LA10138-8;7;6;;; +82106-6;LL1927-4;RAST;LA6111-4;1;0;;; +82106-6;LL1927-4;RAST;LA6112-2;2;1;;; +82106-6;LL1927-4;RAST;LA6113-0;3;2;;; +82106-6;LL1927-4;RAST;LA6114-8;4;3;;; +82106-6;LL1927-4;RAST;LA6115-5;5;4;;; +82106-6;LL1927-4;RAST;LA10137-0;6;5;;; +82106-6;LL1927-4;RAST;LA10138-8;7;6;;; +82108-2;LL1927-4;RAST;LA6111-4;1;0;;; +82108-2;LL1927-4;RAST;LA6112-2;2;1;;; +82108-2;LL1927-4;RAST;LA6113-0;3;2;;; +82108-2;LL1927-4;RAST;LA6114-8;4;3;;; +82108-2;LL1927-4;RAST;LA6115-5;5;4;;; +82108-2;LL1927-4;RAST;LA10137-0;6;5;;; +82108-2;LL1927-4;RAST;LA10138-8;7;6;;; +82110-8;LL1927-4;RAST;LA6111-4;1;0;;; +82110-8;LL1927-4;RAST;LA6112-2;2;1;;; +82110-8;LL1927-4;RAST;LA6113-0;3;2;;; +82110-8;LL1927-4;RAST;LA6114-8;4;3;;; +82110-8;LL1927-4;RAST;LA6115-5;5;4;;; +82110-8;LL1927-4;RAST;LA10137-0;6;5;;; +82110-8;LL1927-4;RAST;LA10138-8;7;6;;; +82112-4;LL1927-4;RAST;LA6111-4;1;0;;; +82112-4;LL1927-4;RAST;LA6112-2;2;1;;; +82112-4;LL1927-4;RAST;LA6113-0;3;2;;; +82112-4;LL1927-4;RAST;LA6114-8;4;3;;; +82112-4;LL1927-4;RAST;LA6115-5;5;4;;; +82112-4;LL1927-4;RAST;LA10137-0;6;5;;; +82112-4;LL1927-4;RAST;LA10138-8;7;6;;; +82113-2;LL1927-4;RAST;LA6111-4;1;0;;; +82113-2;LL1927-4;RAST;LA6112-2;2;1;;; +82113-2;LL1927-4;RAST;LA6113-0;3;2;;; +82113-2;LL1927-4;RAST;LA6114-8;4;3;;; +82113-2;LL1927-4;RAST;LA6115-5;5;4;;; +82113-2;LL1927-4;RAST;LA10137-0;6;5;;; +82113-2;LL1927-4;RAST;LA10138-8;7;6;;; +82459-9;LL1927-4;RAST;LA6111-4;1;0;;; +82459-9;LL1927-4;RAST;LA6112-2;2;1;;; +82459-9;LL1927-4;RAST;LA6113-0;3;2;;; +82459-9;LL1927-4;RAST;LA6114-8;4;3;;; +82459-9;LL1927-4;RAST;LA6115-5;5;4;;; +82459-9;LL1927-4;RAST;LA10137-0;6;5;;; +82459-9;LL1927-4;RAST;LA10138-8;7;6;;; +82460-7;LL1927-4;RAST;LA6111-4;1;0;;; +82460-7;LL1927-4;RAST;LA6112-2;2;1;;; +82460-7;LL1927-4;RAST;LA6113-0;3;2;;; +82460-7;LL1927-4;RAST;LA6114-8;4;3;;; +82460-7;LL1927-4;RAST;LA6115-5;5;4;;; +82460-7;LL1927-4;RAST;LA10137-0;6;5;;; +82460-7;LL1927-4;RAST;LA10138-8;7;6;;; +82540-6;LL1927-4;RAST;LA6111-4;1;0;;; +82540-6;LL1927-4;RAST;LA6112-2;2;1;;; +82540-6;LL1927-4;RAST;LA6113-0;3;2;;; +82540-6;LL1927-4;RAST;LA6114-8;4;3;;; +82540-6;LL1927-4;RAST;LA6115-5;5;4;;; +82540-6;LL1927-4;RAST;LA10137-0;6;5;;; +82540-6;LL1927-4;RAST;LA10138-8;7;6;;; +82542-2;LL1927-4;RAST;LA6111-4;1;0;;; +82542-2;LL1927-4;RAST;LA6112-2;2;1;;; +82542-2;LL1927-4;RAST;LA6113-0;3;2;;; +82542-2;LL1927-4;RAST;LA6114-8;4;3;;; +82542-2;LL1927-4;RAST;LA6115-5;5;4;;; +82542-2;LL1927-4;RAST;LA10137-0;6;5;;; +82542-2;LL1927-4;RAST;LA10138-8;7;6;;; +82544-8;LL1927-4;RAST;LA6111-4;1;0;;; +82544-8;LL1927-4;RAST;LA6112-2;2;1;;; +82544-8;LL1927-4;RAST;LA6113-0;3;2;;; +82544-8;LL1927-4;RAST;LA6114-8;4;3;;; +82544-8;LL1927-4;RAST;LA6115-5;5;4;;; +82544-8;LL1927-4;RAST;LA10137-0;6;5;;; +82544-8;LL1927-4;RAST;LA10138-8;7;6;;; +82545-5;LL1927-4;RAST;LA6111-4;1;0;;; +82545-5;LL1927-4;RAST;LA6112-2;2;1;;; +82545-5;LL1927-4;RAST;LA6113-0;3;2;;; +82545-5;LL1927-4;RAST;LA6114-8;4;3;;; +82545-5;LL1927-4;RAST;LA6115-5;5;4;;; +82545-5;LL1927-4;RAST;LA10137-0;6;5;;; +82545-5;LL1927-4;RAST;LA10138-8;7;6;;; +82546-3;LL1927-4;RAST;LA6111-4;1;0;;; +82546-3;LL1927-4;RAST;LA6112-2;2;1;;; +82546-3;LL1927-4;RAST;LA6113-0;3;2;;; +82546-3;LL1927-4;RAST;LA6114-8;4;3;;; +82546-3;LL1927-4;RAST;LA6115-5;5;4;;; +82546-3;LL1927-4;RAST;LA10137-0;6;5;;; +82546-3;LL1927-4;RAST;LA10138-8;7;6;;; +82548-9;LL1927-4;RAST;LA6111-4;1;0;;; +82548-9;LL1927-4;RAST;LA6112-2;2;1;;; +82548-9;LL1927-4;RAST;LA6113-0;3;2;;; +82548-9;LL1927-4;RAST;LA6114-8;4;3;;; +82548-9;LL1927-4;RAST;LA6115-5;5;4;;; +82548-9;LL1927-4;RAST;LA10137-0;6;5;;; +82548-9;LL1927-4;RAST;LA10138-8;7;6;;; +82551-3;LL1927-4;RAST;LA6111-4;1;0;;; +82551-3;LL1927-4;RAST;LA6112-2;2;1;;; +82551-3;LL1927-4;RAST;LA6113-0;3;2;;; +82551-3;LL1927-4;RAST;LA6114-8;4;3;;; +82551-3;LL1927-4;RAST;LA6115-5;5;4;;; +82551-3;LL1927-4;RAST;LA10137-0;6;5;;; +82551-3;LL1927-4;RAST;LA10138-8;7;6;;; +82554-7;LL1927-4;RAST;LA6111-4;1;0;;; +82554-7;LL1927-4;RAST;LA6112-2;2;1;;; +82554-7;LL1927-4;RAST;LA6113-0;3;2;;; +82554-7;LL1927-4;RAST;LA6114-8;4;3;;; +82554-7;LL1927-4;RAST;LA6115-5;5;4;;; +82554-7;LL1927-4;RAST;LA10137-0;6;5;;; +82554-7;LL1927-4;RAST;LA10138-8;7;6;;; +82556-2;LL1927-4;RAST;LA6111-4;1;0;;; +82556-2;LL1927-4;RAST;LA6112-2;2;1;;; +82556-2;LL1927-4;RAST;LA6113-0;3;2;;; +82556-2;LL1927-4;RAST;LA6114-8;4;3;;; +82556-2;LL1927-4;RAST;LA6115-5;5;4;;; +82556-2;LL1927-4;RAST;LA10137-0;6;5;;; +82556-2;LL1927-4;RAST;LA10138-8;7;6;;; +82558-8;LL1927-4;RAST;LA6111-4;1;0;;; +82558-8;LL1927-4;RAST;LA6112-2;2;1;;; +82558-8;LL1927-4;RAST;LA6113-0;3;2;;; +82558-8;LL1927-4;RAST;LA6114-8;4;3;;; +82558-8;LL1927-4;RAST;LA6115-5;5;4;;; +82558-8;LL1927-4;RAST;LA10137-0;6;5;;; +82558-8;LL1927-4;RAST;LA10138-8;7;6;;; +82561-2;LL1927-4;RAST;LA6111-4;1;0;;; +82561-2;LL1927-4;RAST;LA6112-2;2;1;;; +82561-2;LL1927-4;RAST;LA6113-0;3;2;;; +82561-2;LL1927-4;RAST;LA6114-8;4;3;;; +82561-2;LL1927-4;RAST;LA6115-5;5;4;;; +82561-2;LL1927-4;RAST;LA10137-0;6;5;;; +82561-2;LL1927-4;RAST;LA10138-8;7;6;;; +82564-6;LL1927-4;RAST;LA6111-4;1;0;;; +82564-6;LL1927-4;RAST;LA6112-2;2;1;;; +82564-6;LL1927-4;RAST;LA6113-0;3;2;;; +82564-6;LL1927-4;RAST;LA6114-8;4;3;;; +82564-6;LL1927-4;RAST;LA6115-5;5;4;;; +82564-6;LL1927-4;RAST;LA10137-0;6;5;;; +82564-6;LL1927-4;RAST;LA10138-8;7;6;;; +82567-9;LL1927-4;RAST;LA6111-4;1;0;;; +82567-9;LL1927-4;RAST;LA6112-2;2;1;;; +82567-9;LL1927-4;RAST;LA6113-0;3;2;;; +82567-9;LL1927-4;RAST;LA6114-8;4;3;;; +82567-9;LL1927-4;RAST;LA6115-5;5;4;;; +82567-9;LL1927-4;RAST;LA10137-0;6;5;;; +82567-9;LL1927-4;RAST;LA10138-8;7;6;;; +82569-5;LL1927-4;RAST;LA6111-4;1;0;;; +82569-5;LL1927-4;RAST;LA6112-2;2;1;;; +82569-5;LL1927-4;RAST;LA6113-0;3;2;;; +82569-5;LL1927-4;RAST;LA6114-8;4;3;;; +82569-5;LL1927-4;RAST;LA6115-5;5;4;;; +82569-5;LL1927-4;RAST;LA10137-0;6;5;;; +82569-5;LL1927-4;RAST;LA10138-8;7;6;;; +82571-1;LL1927-4;RAST;LA6111-4;1;0;;; +82571-1;LL1927-4;RAST;LA6112-2;2;1;;; +82571-1;LL1927-4;RAST;LA6113-0;3;2;;; +82571-1;LL1927-4;RAST;LA6114-8;4;3;;; +82571-1;LL1927-4;RAST;LA6115-5;5;4;;; +82571-1;LL1927-4;RAST;LA10137-0;6;5;;; +82571-1;LL1927-4;RAST;LA10138-8;7;6;;; +82573-7;LL1927-4;RAST;LA6111-4;1;0;;; +82573-7;LL1927-4;RAST;LA6112-2;2;1;;; +82573-7;LL1927-4;RAST;LA6113-0;3;2;;; +82573-7;LL1927-4;RAST;LA6114-8;4;3;;; +82573-7;LL1927-4;RAST;LA6115-5;5;4;;; +82573-7;LL1927-4;RAST;LA10137-0;6;5;;; +82573-7;LL1927-4;RAST;LA10138-8;7;6;;; +82578-6;LL1927-4;RAST;LA6111-4;1;0;;; +82578-6;LL1927-4;RAST;LA6112-2;2;1;;; +82578-6;LL1927-4;RAST;LA6113-0;3;2;;; +82578-6;LL1927-4;RAST;LA6114-8;4;3;;; +82578-6;LL1927-4;RAST;LA6115-5;5;4;;; +82578-6;LL1927-4;RAST;LA10137-0;6;5;;; +82578-6;LL1927-4;RAST;LA10138-8;7;6;;; +82581-0;LL1927-4;RAST;LA6111-4;1;0;;; +82581-0;LL1927-4;RAST;LA6112-2;2;1;;; +82581-0;LL1927-4;RAST;LA6113-0;3;2;;; +82581-0;LL1927-4;RAST;LA6114-8;4;3;;; +82581-0;LL1927-4;RAST;LA6115-5;5;4;;; +82581-0;LL1927-4;RAST;LA10137-0;6;5;;; +82581-0;LL1927-4;RAST;LA10138-8;7;6;;; +82600-8;LL1927-4;RAST;LA6111-4;1;0;;; +82600-8;LL1927-4;RAST;LA6112-2;2;1;;; +82600-8;LL1927-4;RAST;LA6113-0;3;2;;; +82600-8;LL1927-4;RAST;LA6114-8;4;3;;; +82600-8;LL1927-4;RAST;LA6115-5;5;4;;; +82600-8;LL1927-4;RAST;LA10137-0;6;5;;; +82600-8;LL1927-4;RAST;LA10138-8;7;6;;; +82602-4;LL1927-4;RAST;LA6111-4;1;0;;; +82602-4;LL1927-4;RAST;LA6112-2;2;1;;; +82602-4;LL1927-4;RAST;LA6113-0;3;2;;; +82602-4;LL1927-4;RAST;LA6114-8;4;3;;; +82602-4;LL1927-4;RAST;LA6115-5;5;4;;; +82602-4;LL1927-4;RAST;LA10137-0;6;5;;; +82602-4;LL1927-4;RAST;LA10138-8;7;6;;; +82604-0;LL1927-4;RAST;LA6111-4;1;0;;; +82604-0;LL1927-4;RAST;LA6112-2;2;1;;; +82604-0;LL1927-4;RAST;LA6113-0;3;2;;; +82604-0;LL1927-4;RAST;LA6114-8;4;3;;; +82604-0;LL1927-4;RAST;LA6115-5;5;4;;; +82604-0;LL1927-4;RAST;LA10137-0;6;5;;; +82604-0;LL1927-4;RAST;LA10138-8;7;6;;; +82605-7;LL1927-4;RAST;LA6111-4;1;0;;; +82605-7;LL1927-4;RAST;LA6112-2;2;1;;; +82605-7;LL1927-4;RAST;LA6113-0;3;2;;; +82605-7;LL1927-4;RAST;LA6114-8;4;3;;; +82605-7;LL1927-4;RAST;LA6115-5;5;4;;; +82605-7;LL1927-4;RAST;LA10137-0;6;5;;; +82605-7;LL1927-4;RAST;LA10138-8;7;6;;; +82614-9;LL1927-4;RAST;LA6111-4;1;0;;; +82614-9;LL1927-4;RAST;LA6112-2;2;1;;; +82614-9;LL1927-4;RAST;LA6113-0;3;2;;; +82614-9;LL1927-4;RAST;LA6114-8;4;3;;; +82614-9;LL1927-4;RAST;LA6115-5;5;4;;; +82614-9;LL1927-4;RAST;LA10137-0;6;5;;; +82614-9;LL1927-4;RAST;LA10138-8;7;6;;; +87717-5;LL1927-4;RAST;LA6111-4;1;0;;; +87717-5;LL1927-4;RAST;LA6112-2;2;1;;; +87717-5;LL1927-4;RAST;LA6113-0;3;2;;; +87717-5;LL1927-4;RAST;LA6114-8;4;3;;; +87717-5;LL1927-4;RAST;LA6115-5;5;4;;; +87717-5;LL1927-4;RAST;LA10137-0;6;5;;; +87717-5;LL1927-4;RAST;LA10138-8;7;6;;; +87718-3;LL1927-4;RAST;LA6111-4;1;0;;; +87718-3;LL1927-4;RAST;LA6112-2;2;1;;; +87718-3;LL1927-4;RAST;LA6113-0;3;2;;; +87718-3;LL1927-4;RAST;LA6114-8;4;3;;; +87718-3;LL1927-4;RAST;LA6115-5;5;4;;; +87718-3;LL1927-4;RAST;LA10137-0;6;5;;; +87718-3;LL1927-4;RAST;LA10138-8;7;6;;; +87719-1;LL1927-4;RAST;LA6111-4;1;0;;; +87719-1;LL1927-4;RAST;LA6112-2;2;1;;; +87719-1;LL1927-4;RAST;LA6113-0;3;2;;; +87719-1;LL1927-4;RAST;LA6114-8;4;3;;; +87719-1;LL1927-4;RAST;LA6115-5;5;4;;; +87719-1;LL1927-4;RAST;LA10137-0;6;5;;; +87719-1;LL1927-4;RAST;LA10138-8;7;6;;; +90882-2;LL1927-4;RAST;LA6111-4;1;0;;; +90882-2;LL1927-4;RAST;LA6112-2;2;1;;; +90882-2;LL1927-4;RAST;LA6113-0;3;2;;; +90882-2;LL1927-4;RAST;LA6114-8;4;3;;; +90882-2;LL1927-4;RAST;LA6115-5;5;4;;; +90882-2;LL1927-4;RAST;LA10137-0;6;5;;; +90882-2;LL1927-4;RAST;LA10138-8;7;6;;; +91121-4;LL1927-4;RAST;LA6111-4;1;0;;; +91121-4;LL1927-4;RAST;LA6112-2;2;1;;; +91121-4;LL1927-4;RAST;LA6113-0;3;2;;; +91121-4;LL1927-4;RAST;LA6114-8;4;3;;; +91121-4;LL1927-4;RAST;LA6115-5;5;4;;; +91121-4;LL1927-4;RAST;LA10137-0;6;5;;; +91121-4;LL1927-4;RAST;LA10138-8;7;6;;; +91123-0;LL1927-4;RAST;LA6111-4;1;0;;; +91123-0;LL1927-4;RAST;LA6112-2;2;1;;; +91123-0;LL1927-4;RAST;LA6113-0;3;2;;; +91123-0;LL1927-4;RAST;LA6114-8;4;3;;; +91123-0;LL1927-4;RAST;LA6115-5;5;4;;; +91123-0;LL1927-4;RAST;LA10137-0;6;5;;; +91123-0;LL1927-4;RAST;LA10138-8;7;6;;; +91666-8;LL1927-4;RAST;LA6111-4;1;0;;; +91666-8;LL1927-4;RAST;LA6112-2;2;1;;; +91666-8;LL1927-4;RAST;LA6113-0;3;2;;; +91666-8;LL1927-4;RAST;LA6114-8;4;3;;; +91666-8;LL1927-4;RAST;LA6115-5;5;4;;; +91666-8;LL1927-4;RAST;LA10137-0;6;5;;; +91666-8;LL1927-4;RAST;LA10138-8;7;6;;; +94279-7;LL1927-4;RAST;LA6111-4;1;0;;; +94279-7;LL1927-4;RAST;LA6112-2;2;1;;; +94279-7;LL1927-4;RAST;LA6113-0;3;2;;; +94279-7;LL1927-4;RAST;LA6114-8;4;3;;; +94279-7;LL1927-4;RAST;LA6115-5;5;4;;; +94279-7;LL1927-4;RAST;LA10137-0;6;5;;; +94279-7;LL1927-4;RAST;LA10138-8;7;6;;; +94280-5;LL1927-4;RAST;LA6111-4;1;0;;; +94280-5;LL1927-4;RAST;LA6112-2;2;1;;; +94280-5;LL1927-4;RAST;LA6113-0;3;2;;; +94280-5;LL1927-4;RAST;LA6114-8;4;3;;; +94280-5;LL1927-4;RAST;LA6115-5;5;4;;; +94280-5;LL1927-4;RAST;LA10137-0;6;5;;; +94280-5;LL1927-4;RAST;LA10138-8;7;6;;; +94281-3;LL1927-4;RAST;LA6111-4;1;0;;; +94281-3;LL1927-4;RAST;LA6112-2;2;1;;; +94281-3;LL1927-4;RAST;LA6113-0;3;2;;; +94281-3;LL1927-4;RAST;LA6114-8;4;3;;; +94281-3;LL1927-4;RAST;LA6115-5;5;4;;; +94281-3;LL1927-4;RAST;LA10137-0;6;5;;; +94281-3;LL1927-4;RAST;LA10138-8;7;6;;; +94282-1;LL1927-4;RAST;LA6111-4;1;0;;; +94282-1;LL1927-4;RAST;LA6112-2;2;1;;; +94282-1;LL1927-4;RAST;LA6113-0;3;2;;; +94282-1;LL1927-4;RAST;LA6114-8;4;3;;; +94282-1;LL1927-4;RAST;LA6115-5;5;4;;; +94282-1;LL1927-4;RAST;LA10137-0;6;5;;; +94282-1;LL1927-4;RAST;LA10138-8;7;6;;; +101439-8;LL6318-1;Observed|Not observed;LA19655-2;1;Not observed;;; +101439-8;LL6318-1;Observed|Not observed;LA33635-6;2;Observed;;; +101440-6;LL6318-1;Observed|Not observed;LA19655-2;1;Not observed;;; +101440-6;LL6318-1;Observed|Not observed;LA33635-6;2;Observed;;; +101439-8;LL6320-7;Champs Mental status;LA33631-5;1;Change in mental status not observed;;; +101439-8;LL6320-7;Champs Mental status;LA33632-3;2;Change in mental status observed;;; +101440-6;LL6324-9;Champs Fall Hx;LA33640-6;3;History of falls not observed;;; +101440-6;LL6324-9;Champs Fall Hx;LA33641-4;4;History of falls observed;;; +101440-6;LL6329-8;Schmid fall;LA33655-4;13;Yes, Before admission (Home or previous inpatient care);;; +101440-6;LL6329-8;Schmid fall;LA33656-2;14;Yes, During this admission;;; +101440-6;LL6329-8;Schmid fall;LA32-8;15;No;373067005;No (qualifier value);http://snomed.info/sct +101440-6;LL6329-8;Schmid fall;LA4489-6;16;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +101441-4;LL6332-2;Champs Imp;LA33659-6;1;Lower risk;;; +101441-4;LL6332-2;Champs Imp;LA19541-4;2;High risk;;; +101444-8;LL3198-0;High risk|Intermediate risk|Low risk;LA19541-4;1;High risk;;; +101444-8;LL3198-0;High risk|Intermediate risk|Low risk;LA22380-2;2;Intermediate risk;;; +101444-8;LL3198-0;High risk|Intermediate risk|Low risk;LA19542-2;3;Low risk;;; +101445-5;LL3198-0;High risk|Intermediate risk|Low risk;LA19541-4;1;High risk;;; +101445-5;LL3198-0;High risk|Intermediate risk|Low risk;LA22380-2;2;Intermediate risk;;; +101445-5;LL3198-0;High risk|Intermediate risk|Low risk;LA19542-2;3;Low risk;;; +76545-3;LL3198-0;High risk|Intermediate risk|Low risk;LA19541-4;1;High risk;;; +76545-3;LL3198-0;High risk|Intermediate risk|Low risk;LA22380-2;2;Intermediate risk;;; +76545-3;LL3198-0;High risk|Intermediate risk|Low risk;LA19542-2;3;Low risk;;; +97953-4;LL3198-0;High risk|Intermediate risk|Low risk;LA19541-4;1;High risk;;; +97953-4;LL3198-0;High risk|Intermediate risk|Low risk;LA22380-2;2;Intermediate risk;;; +97953-4;LL3198-0;High risk|Intermediate risk|Low risk;LA19542-2;3;Low risk;;; +101551-0;LL6321-5;Schmid score interp;LA33633-1;1;Score of 3 or above;;; +101551-0;LL6321-5;Schmid score interp;LA33634-9;2;Score of less than 3;;; +101572-6;LL6289-4;Prenatal visits;LA33575-4;1;0=None;;; +101572-6;LL6289-4;Prenatal visits;LA33576-2;2;1=1 to 3 visits;;; +101572-6;LL6289-4;Prenatal visits;LA33577-0;3;2= >= 4 visits;;; +101572-6;LL6289-4;Prenatal visits;LA33573-9;4;9=Unknown;;; +101573-4;LL6288-6;Diet at discharge;LA33568-9;1;0= None;;; +101573-4;LL6288-6;Diet at discharge;LA33574-7;2;1=Human milk only;;; +101573-4;LL6288-6;Diet at discharge;LA33570-5;3;2=Fortified human Milk;;; +101573-4;LL6288-6;Diet at discharge;LA33571-3;4;3=Formula only;;; +101573-4;LL6288-6;Diet at discharge;LA33572-1;5;4=Combination;;; +101573-4;LL6288-6;Diet at discharge;LA33573-9;6;9=Unknown;;; +101575-9;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +101575-9;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +101575-9;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +98134-0;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98134-0;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98134-0;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +98135-7;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98135-7;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98135-7;LL5981-7;Yes 2 / No 0 / Don't Know 0;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +10389-5;LL2413-4;Othr bld prod;LA19693-3;1;C1 esterase;;; +10389-5;LL2413-4;Othr bld prod;LA19694-1;2;Protein C;25525005;Protein C (substance);http://snomed.info/sct +10390-3;LL2422-5;Blood prod treatment;LA19715-4;1;Irradiated;;; +10390-3;LL2422-5;Blood prod treatment;LA19716-2;2;Washed;;; +10390-3;LL2422-5;Blood prod treatment;LA19717-0;3;Reconstituted;;; +10390-3;LL2422-5;Blood prod treatment;LA19718-8;4;Leukoreduced;;; +10390-3;LL2422-5;Blood prod treatment;LA19719-6;5;Directed donation;;; +10393-7;LL2420-9;Human/Recomb;LA19711-3;1;Human;;; +10393-7;LL2420-9;Human/Recomb;LA19712-1;2;Recombinant;;; +10395-2;LL2420-9;Human/Recomb;LA19711-3;1;Human;;; +10395-2;LL2420-9;Human/Recomb;LA19712-1;2;Recombinant;;; +10401-8;LL2421-7;IM/IV;LA19713-9;1;IM;;; +10401-8;LL2421-7;IM/IV;LA15460-1;2;IV;;; +10410-9;LL2417-5;Plasma type;LA19701-4;1;Fresh frozen;;; +10410-9;LL2417-5;Plasma type;LA19702-2;2;Frozen;;; +10410-9;LL2417-5;Plasma type;LA19703-0;3;Cryosupernatant poor;;; +10410-9;LL2417-5;Plasma type;LA19704-8;4;Apheresis;;; +10568-4;LL2427-4;Clear/Opales/Milky;LA19732-9;1;Clear;;; +10568-4;LL2427-4;Clear/Opales/Milky;LA19734-5;2;Opalescent;;; +10568-4;LL2427-4;Clear/Opales/Milky;LA19735-2;3;Milky;;; +10570-0;LL2446-4;Viscosity;LA19069-6;1;Viscous;;; +10570-0;LL2446-4;Viscosity;LA19790-7;2;Mildly viscous;;; +10570-0;LL2446-4;Viscosity;LA19789-9;3;Slightly viscous;;; +10570-0;LL2446-4;Viscosity;LA19782-4;4;Watery;;; +10570-0;LL2446-4;Viscosity;LA19791-5;5;Liquified;;; +10571-8;LL2446-4;Viscosity;LA19069-6;1;Viscous;;; +10571-8;LL2446-4;Viscosity;LA19790-7;2;Mildly viscous;;; +10571-8;LL2446-4;Viscosity;LA19789-9;3;Slightly viscous;;; +10571-8;LL2446-4;Viscosity;LA19782-4;4;Watery;;; +10571-8;LL2446-4;Viscosity;LA19791-5;5;Liquified;;; +38509-6;LL2446-4;Viscosity;LA19069-6;1;Viscous;;; +38509-6;LL2446-4;Viscosity;LA19790-7;2;Mildly viscous;;; +38509-6;LL2446-4;Viscosity;LA19789-9;3;Slightly viscous;;; +38509-6;LL2446-4;Viscosity;LA19782-4;4;Watery;;; +38509-6;LL2446-4;Viscosity;LA19791-5;5;Liquified;;; +79333-1;LL2446-4;Viscosity;LA19069-6;1;Viscous;;; +79333-1;LL2446-4;Viscosity;LA19790-7;2;Mildly viscous;;; +79333-1;LL2446-4;Viscosity;LA19789-9;3;Slightly viscous;;; +79333-1;LL2446-4;Viscosity;LA19782-4;4;Watery;;; +79333-1;LL2446-4;Viscosity;LA19791-5;5;Liquified;;; +10635-1;LL4724-2;Acanthamoeba species;LA28378-0;1;Acanthamoeba astronyxis;;; +10635-1;LL4724-2;Acanthamoeba species;LA28377-2;2;Acanthamoeba castellanii;;; +10635-1;LL4724-2;Acanthamoeba species;LA28375-6;3;Acanthamoeba culbertsoni;;; +10635-1;LL4724-2;Acanthamoeba species;LA28380-6;4;Acanthamoeba lugdunensis;;; +10635-1;LL4724-2;Acanthamoeba species;LA28376-4;5;Acanthamoeba polyphaga;;; +10635-1;LL4724-2;Acanthamoeba species;LA28379-8;6;Acanthamoeba hatchetti;;; +10636-9;LL4724-2;Acanthamoeba species;LA28378-0;1;Acanthamoeba astronyxis;;; +10636-9;LL4724-2;Acanthamoeba species;LA28377-2;2;Acanthamoeba castellanii;;; +10636-9;LL4724-2;Acanthamoeba species;LA28375-6;3;Acanthamoeba culbertsoni;;; +10636-9;LL4724-2;Acanthamoeba species;LA28380-6;4;Acanthamoeba lugdunensis;;; +10636-9;LL4724-2;Acanthamoeba species;LA28376-4;5;Acanthamoeba polyphaga;;; +10636-9;LL4724-2;Acanthamoeba species;LA28379-8;6;Acanthamoeba hatchetti;;; +87990-8;LL4724-2;Acanthamoeba species;LA28378-0;1;Acanthamoeba astronyxis;;; +87990-8;LL4724-2;Acanthamoeba species;LA28377-2;2;Acanthamoeba castellanii;;; +87990-8;LL4724-2;Acanthamoeba species;LA28375-6;3;Acanthamoeba culbertsoni;;; +87990-8;LL4724-2;Acanthamoeba species;LA28380-6;4;Acanthamoeba lugdunensis;;; +87990-8;LL4724-2;Acanthamoeba species;LA28376-4;5;Acanthamoeba polyphaga;;; +87990-8;LL4724-2;Acanthamoeba species;LA28379-8;6;Acanthamoeba hatchetti;;; +87991-6;LL4724-2;Acanthamoeba species;LA28378-0;1;Acanthamoeba astronyxis;;; +87991-6;LL4724-2;Acanthamoeba species;LA28377-2;2;Acanthamoeba castellanii;;; +87991-6;LL4724-2;Acanthamoeba species;LA28375-6;3;Acanthamoeba culbertsoni;;; +87991-6;LL4724-2;Acanthamoeba species;LA28380-6;4;Acanthamoeba lugdunensis;;; +87991-6;LL4724-2;Acanthamoeba species;LA28376-4;5;Acanthamoeba polyphaga;;; +87991-6;LL4724-2;Acanthamoeba species;LA28379-8;6;Acanthamoeba hatchetti;;; +88162-3;LL4724-2;Acanthamoeba species;LA28378-0;1;Acanthamoeba astronyxis;;; +88162-3;LL4724-2;Acanthamoeba species;LA28377-2;2;Acanthamoeba castellanii;;; +88162-3;LL4724-2;Acanthamoeba species;LA28375-6;3;Acanthamoeba culbertsoni;;; +88162-3;LL4724-2;Acanthamoeba species;LA28380-6;4;Acanthamoeba lugdunensis;;; +88162-3;LL4724-2;Acanthamoeba species;LA28376-4;5;Acanthamoeba polyphaga;;; +88162-3;LL4724-2;Acanthamoeba species;LA28379-8;6;Acanthamoeba hatchetti;;; +9781-6;LL4724-2;Acanthamoeba species;LA28378-0;1;Acanthamoeba astronyxis;;; +9781-6;LL4724-2;Acanthamoeba species;LA28377-2;2;Acanthamoeba castellanii;;; +9781-6;LL4724-2;Acanthamoeba species;LA28375-6;3;Acanthamoeba culbertsoni;;; +9781-6;LL4724-2;Acanthamoeba species;LA28380-6;4;Acanthamoeba lugdunensis;;; +9781-6;LL4724-2;Acanthamoeba species;LA28376-4;5;Acanthamoeba polyphaga;;; +9781-6;LL4724-2;Acanthamoeba species;LA28379-8;6;Acanthamoeba hatchetti;;; +10639-3;LL2262-5;Thermophilic actino;LA19192-6;1;Thermoactinomyces vulgaris;;; +10639-3;LL2262-5;Thermophilic actino;LA19193-4;2;Saccharopolyspora rectivirgula;;; +10641-9;LL2284-9;Amoeba;LA19274-2;1;Blastocystis hominis;;; +10641-9;LL2284-9;Amoeba;LA19275-9;2;Endolimax nana;;; +10641-9;LL2284-9;Amoeba;LA19276-7;3;Entamoeba coli;;; +10641-9;LL2284-9;Amoeba;LA19277-5;4;Entamoeba hartmanni;;; +10641-9;LL2284-9;Amoeba;LA15839-6;5;Entamoeba histolytica/dispar;;; +10641-9;LL2284-9;Amoeba;LA19278-3;6;Entamoeba histolytica;4716008;Entamoeba histolytica (organism);http://snomed.info/sct +10641-9;LL2284-9;Amoeba;LA19279-1;7;Iodamoeba butshlii;;; +10642-7;LL2284-9;Amoeba;LA19274-2;1;Blastocystis hominis;;; +10642-7;LL2284-9;Amoeba;LA19275-9;2;Endolimax nana;;; +10642-7;LL2284-9;Amoeba;LA19276-7;3;Entamoeba coli;;; +10642-7;LL2284-9;Amoeba;LA19277-5;4;Entamoeba hartmanni;;; +10642-7;LL2284-9;Amoeba;LA15839-6;5;Entamoeba histolytica/dispar;;; +10642-7;LL2284-9;Amoeba;LA19278-3;6;Entamoeba histolytica;4716008;Entamoeba histolytica (organism);http://snomed.info/sct +10642-7;LL2284-9;Amoeba;LA19279-1;7;Iodamoeba butshlii;;; +10643-5;LL2284-9;Amoeba;LA19274-2;1;Blastocystis hominis;;; +10643-5;LL2284-9;Amoeba;LA19275-9;2;Endolimax nana;;; +10643-5;LL2284-9;Amoeba;LA19276-7;3;Entamoeba coli;;; +10643-5;LL2284-9;Amoeba;LA19277-5;4;Entamoeba hartmanni;;; +10643-5;LL2284-9;Amoeba;LA15839-6;5;Entamoeba histolytica/dispar;;; +10643-5;LL2284-9;Amoeba;LA19278-3;6;Entamoeba histolytica;4716008;Entamoeba histolytica (organism);http://snomed.info/sct +10643-5;LL2284-9;Amoeba;LA19279-1;7;Iodamoeba butshlii;;; +18305-3;LL2284-9;Amoeba;LA19274-2;1;Blastocystis hominis;;; +18305-3;LL2284-9;Amoeba;LA19275-9;2;Endolimax nana;;; +18305-3;LL2284-9;Amoeba;LA19276-7;3;Entamoeba coli;;; +18305-3;LL2284-9;Amoeba;LA19277-5;4;Entamoeba hartmanni;;; +18305-3;LL2284-9;Amoeba;LA15839-6;5;Entamoeba histolytica/dispar;;; +18305-3;LL2284-9;Amoeba;LA19278-3;6;Entamoeba histolytica;4716008;Entamoeba histolytica (organism);http://snomed.info/sct +18305-3;LL2284-9;Amoeba;LA19279-1;7;Iodamoeba butshlii;;; +6594-6;LL2284-9;Amoeba;LA19274-2;1;Blastocystis hominis;;; +6594-6;LL2284-9;Amoeba;LA19275-9;2;Endolimax nana;;; +6594-6;LL2284-9;Amoeba;LA19276-7;3;Entamoeba coli;;; +6594-6;LL2284-9;Amoeba;LA19277-5;4;Entamoeba hartmanni;;; +6594-6;LL2284-9;Amoeba;LA15839-6;5;Entamoeba histolytica/dispar;;; +6594-6;LL2284-9;Amoeba;LA19278-3;6;Entamoeba histolytica;4716008;Entamoeba histolytica (organism);http://snomed.info/sct +6594-6;LL2284-9;Amoeba;LA19279-1;7;Iodamoeba butshlii;;; +87998-1;LL2284-9;Amoeba;LA19274-2;1;Blastocystis hominis;;; +87998-1;LL2284-9;Amoeba;LA19275-9;2;Endolimax nana;;; +87998-1;LL2284-9;Amoeba;LA19276-7;3;Entamoeba coli;;; +87998-1;LL2284-9;Amoeba;LA19277-5;4;Entamoeba hartmanni;;; +87998-1;LL2284-9;Amoeba;LA15839-6;5;Entamoeba histolytica/dispar;;; +87998-1;LL2284-9;Amoeba;LA19278-3;6;Entamoeba histolytica;4716008;Entamoeba histolytica (organism);http://snomed.info/sct +87998-1;LL2284-9;Amoeba;LA19279-1;7;Iodamoeba butshlii;;; +10686-4;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +10686-4;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +10686-4;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +10686-4;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +10686-4;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +10687-2;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +10687-2;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +10687-2;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +10687-2;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +10687-2;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +23160-5;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +23160-5;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +23160-5;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +23160-5;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +23160-5;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +23161-3;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +23161-3;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +23161-3;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +23161-3;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +23161-3;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +23162-1;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +23162-1;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +23162-1;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +23162-1;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +23162-1;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +51709-4;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +51709-4;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +51709-4;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +51709-4;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +51709-4;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +51710-2;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +51710-2;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +51710-2;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +51710-2;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +51710-2;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +53625-0;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +53625-0;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +53625-0;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +53625-0;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +53625-0;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +87986-6;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +87986-6;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +87986-6;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +87986-6;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +87986-6;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +87987-4;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +87987-4;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +87987-4;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +87987-4;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +87987-4;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +88916-2;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +88916-2;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +88916-2;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +88916-2;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +88916-2;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +88917-0;LL4725-9;Leishmania species;LA28384-8;1;Leishmania braziliensis;;; +88917-0;LL4725-9;Leishmania species;LA28385-5;2;Leishmania chagasi;;; +88917-0;LL4725-9;Leishmania species;LA28383-0;3;Leishmania donovani;;; +88917-0;LL4725-9;Leishmania species;LA28382-2;4;Leishmania mexicana;;; +88917-0;LL4725-9;Leishmania species;LA28381-4;5;Leishmania tropica;;; +10710-2;LL2041-3;Malaria;LA18496-2;1;Plasmodium falciparum;;; +10710-2;LL2041-3;Malaria;LA18497-0;2;Plasmodium falciparum + Plasmodium vivax;;; +10710-2;LL2041-3;Malaria;LA18498-8;3;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp (not P. vivax);;; +10710-2;LL2041-3;Malaria;LA18499-6;4;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp;;; +10710-2;LL2041-3;Malaria;LA18500-1;5;Plasmodium falciparum + Plasmodium vivax or Plasmodium falciparum + Plasmodium vivax + Plasmodium sp;;; +10710-2;LL2041-3;Malaria;LA18501-9;6;Plasmodium vivax;;; +10710-2;LL2041-3;Malaria;LA18502-7;7;Plasmodium vivax or Plasmodium vivax + Plasmodium sp;;; +10710-2;LL2041-3;Malaria;LA18503-5;8;Plasmodium sp (not P. falciparum);;; +10710-2;LL2041-3;Malaria;LA18504-3;9;Plasmodium sp (not P. vivax or P. falciparum);;; +10710-2;LL2041-3;Malaria;LA6577-6;10;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +10710-2;LL2041-3;Malaria;LA15841-2;11;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +32206-5;LL2041-3;Malaria;LA18496-2;1;Plasmodium falciparum;;; +32206-5;LL2041-3;Malaria;LA18497-0;2;Plasmodium falciparum + Plasmodium vivax;;; +32206-5;LL2041-3;Malaria;LA18498-8;3;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp (not P. vivax);;; +32206-5;LL2041-3;Malaria;LA18499-6;4;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp;;; +32206-5;LL2041-3;Malaria;LA18500-1;5;Plasmodium falciparum + Plasmodium vivax or Plasmodium falciparum + Plasmodium vivax + Plasmodium sp;;; +32206-5;LL2041-3;Malaria;LA18501-9;6;Plasmodium vivax;;; +32206-5;LL2041-3;Malaria;LA18502-7;7;Plasmodium vivax or Plasmodium vivax + Plasmodium sp;;; +32206-5;LL2041-3;Malaria;LA18503-5;8;Plasmodium sp (not P. falciparum);;; +32206-5;LL2041-3;Malaria;LA18504-3;9;Plasmodium sp (not P. vivax or P. falciparum);;; +32206-5;LL2041-3;Malaria;LA6577-6;10;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +32206-5;LL2041-3;Malaria;LA15841-2;11;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +47260-5;LL2041-3;Malaria;LA18496-2;1;Plasmodium falciparum;;; +47260-5;LL2041-3;Malaria;LA18497-0;2;Plasmodium falciparum + Plasmodium vivax;;; +47260-5;LL2041-3;Malaria;LA18498-8;3;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp (not P. vivax);;; +47260-5;LL2041-3;Malaria;LA18499-6;4;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp;;; +47260-5;LL2041-3;Malaria;LA18500-1;5;Plasmodium falciparum + Plasmodium vivax or Plasmodium falciparum + Plasmodium vivax + Plasmodium sp;;; +47260-5;LL2041-3;Malaria;LA18501-9;6;Plasmodium vivax;;; +47260-5;LL2041-3;Malaria;LA18502-7;7;Plasmodium vivax or Plasmodium vivax + Plasmodium sp;;; +47260-5;LL2041-3;Malaria;LA18503-5;8;Plasmodium sp (not P. falciparum);;; +47260-5;LL2041-3;Malaria;LA18504-3;9;Plasmodium sp (not P. vivax or P. falciparum);;; +47260-5;LL2041-3;Malaria;LA6577-6;10;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47260-5;LL2041-3;Malaria;LA15841-2;11;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +51865-4;LL2041-3;Malaria;LA18496-2;1;Plasmodium falciparum;;; +51865-4;LL2041-3;Malaria;LA18497-0;2;Plasmodium falciparum + Plasmodium vivax;;; +51865-4;LL2041-3;Malaria;LA18498-8;3;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp (not P. vivax);;; +51865-4;LL2041-3;Malaria;LA18499-6;4;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp;;; +51865-4;LL2041-3;Malaria;LA18500-1;5;Plasmodium falciparum + Plasmodium vivax or Plasmodium falciparum + Plasmodium vivax + Plasmodium sp;;; +51865-4;LL2041-3;Malaria;LA18501-9;6;Plasmodium vivax;;; +51865-4;LL2041-3;Malaria;LA18502-7;7;Plasmodium vivax or Plasmodium vivax + Plasmodium sp;;; +51865-4;LL2041-3;Malaria;LA18503-5;8;Plasmodium sp (not P. falciparum);;; +51865-4;LL2041-3;Malaria;LA18504-3;9;Plasmodium sp (not P. vivax or P. falciparum);;; +51865-4;LL2041-3;Malaria;LA6577-6;10;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51865-4;LL2041-3;Malaria;LA15841-2;11;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +70569-9;LL2041-3;Malaria;LA18496-2;1;Plasmodium falciparum;;; +70569-9;LL2041-3;Malaria;LA18497-0;2;Plasmodium falciparum + Plasmodium vivax;;; +70569-9;LL2041-3;Malaria;LA18498-8;3;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp (not P. vivax);;; +70569-9;LL2041-3;Malaria;LA18499-6;4;Plasmodium falciparum or Plasmodium falciparum + Plasmodium sp;;; +70569-9;LL2041-3;Malaria;LA18500-1;5;Plasmodium falciparum + Plasmodium vivax or Plasmodium falciparum + Plasmodium vivax + Plasmodium sp;;; +70569-9;LL2041-3;Malaria;LA18501-9;6;Plasmodium vivax;;; +70569-9;LL2041-3;Malaria;LA18502-7;7;Plasmodium vivax or Plasmodium vivax + Plasmodium sp;;; +70569-9;LL2041-3;Malaria;LA18503-5;8;Plasmodium sp (not P. falciparum);;; +70569-9;LL2041-3;Malaria;LA18504-3;9;Plasmodium sp (not P. vivax or P. falciparum);;; +70569-9;LL2041-3;Malaria;LA6577-6;10;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70569-9;LL2041-3;Malaria;LA15841-2;11;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +10715-1;LL2290-6;Schistosoma spp;LA19297-3;1;Schistosoma hematobium;;; +10715-1;LL2290-6;Schistosoma spp;LA19296-5;3;Schistosoma mansoni;;; +10715-1;LL2290-6;Schistosoma spp;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +10716-9;LL2290-6;Schistosoma spp;LA19297-3;1;Schistosoma hematobium;;; +10716-9;LL2290-6;Schistosoma spp;LA19296-5;3;Schistosoma mansoni;;; +10716-9;LL2290-6;Schistosoma spp;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +11085-8;LL2290-6;Schistosoma spp;LA19297-3;1;Schistosoma hematobium;;; +11085-8;LL2290-6;Schistosoma spp;LA19296-5;3;Schistosoma mansoni;;; +11085-8;LL2290-6;Schistosoma spp;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76767-3;LL2290-6;Schistosoma spp;LA19297-3;1;Schistosoma hematobium;;; +76767-3;LL2290-6;Schistosoma spp;LA19296-5;3;Schistosoma mansoni;;; +76767-3;LL2290-6;Schistosoma spp;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +11029-6;LL3815-9;Stool consistency;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +11029-6;LL3815-9;Stool consistency;LA14744-9;2;Soft;;; +11029-6;LL3815-9;Stool consistency;LA25074-8;3;Clots present;;; +11029-6;LL3815-9;Stool consistency;LA25075-5;4;Creamy;;; +11029-6;LL3815-9;Stool consistency;LA17199-3;5;Dry;;; +11029-6;LL3815-9;Stool consistency;LA25078-9;6;Frothy;;; +11029-6;LL3815-9;Stool consistency;LA14745-6;7;Hard;;; +11029-6;LL3815-9;Stool consistency;LA25011-0;8;Liquid;;; +11029-6;LL3815-9;Stool consistency;LA25012-8;9;Loose;;; +11029-6;LL3815-9;Stool consistency;LA25082-1;10;Mucoid;;; +11029-6;LL3815-9;Stool consistency;LA25083-9;11;Seedy;;; +11029-6;LL3815-9;Stool consistency;LA25084-7;12;Tarry;269899009;Feces color: tarry (finding);http://snomed.info/sct +11125-2;LL715-4;Platelet morph;LA11165-0;1;Platelet anisocytosis;;; +11125-2;LL715-4;Platelet morph;LA11168-4;2;Platelet clump;;; +11125-2;LL715-4;Platelet morph;LA11167-6;3;Platelet large fragments;;; +11125-2;LL715-4;Platelet morph;LA11166-8;4;Platelet satellitism;;; +11125-2;LL715-4;Platelet morph;LA11169-2;5;Platelets.agranular;;; +11125-2;LL715-4;Platelet morph;LA11170-0;6;Platelets.giant;;; +11125-2;LL715-4;Platelet morph;LA11172-6;7;Platelets.large;;; +11125-2;LL715-4;Platelet morph;LA11171-8;8;Platelets.small;;; +11156-7;LL716-2;WBC morph;LA11178-3;1;Auer rods;;; +11156-7;LL716-2;WBC morph;LA11179-1;2;Barr bodies;;; +11156-7;LL716-2;WBC morph;LA11180-9;3;Dohle body;;; +11156-7;LL716-2;WBC morph;LA11186-6;4;Hairy cells;;; +11156-7;LL716-2;WBC morph;LA11187-4;5;Neutrophils.agranular;;; +11156-7;LL716-2;WBC morph;LA11188-2;6;Neutrophils.hypersegmented;;; +11156-7;LL716-2;WBC morph;LA11189-0;7;Neutrophils.vacuolated;;; +11156-7;LL716-2;WBC morph;LA11184-1;8;Sezary cells;;; +11156-7;LL716-2;WBC morph;LA11183-3;9;Smudge cells;;; +11156-7;LL716-2;WBC morph;LA11182-5;10;Toxic granules;;; +11156-7;LL716-2;WBC morph;LA11181-7;11;Toxic vacuoles;;; +11283-9;LL486-2;DEEDS4.08_1st Acuity Assessment;LA9336-4;0;Requires immediate evaluation or treatment;;; +11283-9;LL486-2;DEEDS4.08_1st Acuity Assessment;LA9337-2;1;Requires prompt evaluation or treatment;;; +11283-9;LL486-2;DEEDS4.08_1st Acuity Assessment;LA9338-0;2;Time to evaluation or treatment not critical;;; +11283-9;LL486-2;DEEDS4.08_1st Acuity Assessment;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +11290-4;LL494-6;DEEDS4.27_1st temp site;LA9367-9;0;Oral;;; +11290-4;LL494-6;DEEDS4.27_1st temp site;LA9368-7;1;Tympanic membrane;;; +11290-4;LL494-6;DEEDS4.27_1st temp site;LA9369-5;2;Rectal;;; +11290-4;LL494-6;DEEDS4.27_1st temp site;LA9370-3;3;Axillary;;; +11290-4;LL494-6;DEEDS4.27_1st temp site;LA9371-1;4;Urinary bladder;;; +11290-4;LL494-6;DEEDS4.27_1st temp site;LA46-8;5;Other;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA9325-7;0;Self-referral;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA9326-5;1;EMS transport decision;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA9327-3;2;Practitioner or health care facility referral;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA9328-1;3;Internal facility referral or transfer;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA9329-9;4;Law enforcement referral;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA9330-7;5;Acute care hospital transfer;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA9331-5;6;Other health care facility transfer;;; +11293-8;LL484-7;DEEDS4.05_Source of Referral;LA46-8;7;Other;;; +11298-7;LL512-5;NPI;;0;;;; +11489-2;LL512-5;NPI;;0;;;; +11513-9;LL512-5;NPI;;0;;;; +11531-1;LL512-5;NPI;;0;;;; +11532-9;LL512-5;NPI;;0;;;; +18600-7;LL512-5;NPI;;0;;;; +18602-3;LL512-5;NPI;;0;;;; +18706-2;LL512-5;NPI;;0;;;; +18730-2;LL512-5;NPI;;0;;;; +18775-7;LL512-5;NPI;;0;;;; +18780-7;LL512-5;NPI;;0;;;; +18812-8;LL512-5;NPI;;0;;;; +27456-3;LL512-5;NPI;;0;;;; +27514-9;LL512-5;NPI;;0;;;; +27583-4;LL512-5;NPI;;0;;;; +27634-5;LL512-5;NPI;;0;;;; +27697-2;LL512-5;NPI;;0;;;; +27736-8;LL512-5;NPI;;0;;;; +27787-1;LL512-5;NPI;;0;;;; +29188-0;LL512-5;NPI;;0;;;; +52145-0;LL512-5;NPI;;0;;;; +67879-7;LL512-5;NPI;;0;;;; +67880-5;LL512-5;NPI;;0;;;; +67881-3;LL512-5;NPI;;0;;;; +68357-3;LL512-5;NPI;;0;;;; +68456-3;LL512-5;NPI;;0;;;; +68468-8;LL512-5;NPI;;0;;;; +87286-1;LL512-5;NPI;;0;;;; +87287-9;LL512-5;NPI;;0;;;; +11302-7;LL1053-9;ED dispo;LA14102-0;1;Discharged;;; +11302-7;LL1053-9;ED dispo;LA14103-8;2;Transferred;;; +11302-7;LL1053-9;ED dispo;LA14104-6;3;Eloped;;; +11302-7;LL1053-9;ED dispo;LA14105-3;4;Left AMA;;; +11302-7;LL1053-9;ED dispo;LA14106-1;5;Admitted;;; +11302-7;LL1053-9;ED dispo;LA10325-1;6;Expired;;; +11302-7;LL1053-9;ED dispo;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20587-4;1;Floor bed (general admission, non-specialty unit bed);;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20588-2;2;Observation unit (unit that provides < 24 hour stays);;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20589-0;3;Telemetry/step-down unit (less acuity than ICU);;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20590-8;4;Home with services;;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20591-6;5;Died/Expired;;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20592-4;6;Other (jail, institutional care, mental health, etc.);;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA7222-8;7;Operating room;;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20596-5;8;Intensive care unit (ICU);;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20594-0;9;Home without services;;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20595-7;10;Left against medical advice;;; +11302-7;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20597-3;11;Transferred to another hospital;;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20587-4;1;Floor bed (general admission, non-specialty unit bed);;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20588-2;2;Observation unit (unit that provides < 24 hour stays);;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20589-0;3;Telemetry/step-down unit (less acuity than ICU);;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20590-8;4;Home with services;;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20591-6;5;Died/Expired;;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20592-4;6;Other (jail, institutional care, mental health, etc.);;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA7222-8;7;Operating room;;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20596-5;8;Intensive care unit (ICU);;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20594-0;9;Home without services;;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20595-7;10;Left against medical advice;;; +74285-8;LL2760-8;NTDS_ED_19_ED Discharge Disposition;LA20597-3;11;Transferred to another hospital;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24304-0;1;No follow-up planned;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24286-9;2;Return to ED;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24287-7;3;Return/refer to physician/clinic for outpatient mental health treatment;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24288-5;4;Return/refer to physician/clinic for substance abuse treatment;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24289-3;5;Return/refer to physician/clinic for follow-up;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24301-6;6;Left without being seen;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24300-8;7;Left before treatment was complete;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA20595-7;8;Left against medical advice;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24302-4;9;Dead on arrival;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24303-2;10;Died in ED;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24290-1;11;Return/transfer to nursing home;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24291-9;12;Return/transfer to jail/prison/law enforcement;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24292-7;13;Transfer to psychiatric inpatient treatment - involuntary status;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24293-5;14;Transfer to psychiatric inpatient treatment - voluntary status;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24294-3;15;Transfer to psychiatric inpatient treatment - status not documented;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24295-0;16;Transfer to substance abuse treatment facility;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24296-8;17;Transfer to inpatient behavioral healthcare facility - type unknown;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24297-6;18;Transfer to other non-psychiatric hospital;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24305-7;19;Admit to this hospital;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24306-5;20;Admit to observation unit then hospitalized;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA24307-3;21;Admit to observation unit then discharged;;; +11302-7;LL3677-3;[NHCS] ED discharge disposition;LA46-8;22;Other;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24304-0;1;No follow-up planned;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24286-9;2;Return to ED;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24287-7;3;Return/refer to physician/clinic for outpatient mental health treatment;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24288-5;4;Return/refer to physician/clinic for substance abuse treatment;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24289-3;5;Return/refer to physician/clinic for follow-up;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24301-6;6;Left without being seen;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24300-8;7;Left before treatment was complete;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA20595-7;8;Left against medical advice;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24302-4;9;Dead on arrival;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24303-2;10;Died in ED;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24290-1;11;Return/transfer to nursing home;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24291-9;12;Return/transfer to jail/prison/law enforcement;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24292-7;13;Transfer to psychiatric inpatient treatment - involuntary status;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24293-5;14;Transfer to psychiatric inpatient treatment - voluntary status;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24294-3;15;Transfer to psychiatric inpatient treatment - status not documented;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24295-0;16;Transfer to substance abuse treatment facility;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24296-8;17;Transfer to inpatient behavioral healthcare facility - type unknown;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24297-6;18;Transfer to other non-psychiatric hospital;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24305-7;19;Admit to this hospital;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24306-5;20;Admit to observation unit then hospitalized;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA24307-3;21;Admit to observation unit then discharged;;; +78024-7;LL3677-3;[NHCS] ED discharge disposition;LA46-8;22;Other;;; +11314-2;LL510-9;LNProcResult;LA9585-6;0;Numerous codes in the LOINC system that identify procedure results;;; +11324-1;LL488-8;DEEDS4.14_1st GCS-eye;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +11324-1;LL488-8;DEEDS4.14_1st GCS-eye;LA9345-5;1;Opens eyes in response to painful stimulation;;; +11324-1;LL488-8;DEEDS4.14_1st GCS-eye;LA9346-3;2;Opens eyes in response to verbal stimulation;;; +11324-1;LL488-8;DEEDS4.14_1st GCS-eye;LA9347-1;3;Opens eyes spontaneously;;; +11324-1;LL488-8;DEEDS4.14_1st GCS-eye;LA9348-9;4;Not assessed;;; +11325-8;LL490-4;DEEDS4.16_1st GCS-motor;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +11325-8;LL490-4;DEEDS4.16_1st GCS-motor;LA9355-4;1;"Adult: Extensor posturing in response to painful stimulation; infant or child: Abnormal extension (decerebrate)";;; +11325-8;LL490-4;DEEDS4.16_1st GCS-motor;LA9356-2;2;"Adult: Flexor posturing in response to painful stimulation; infant or child: Abnormal flexion (decorticate)";;; +11325-8;LL490-4;DEEDS4.16_1st GCS-motor;LA9357-0;3;"Adult: General withdrawal in response to painful stimulation; infant or child: Withdraws to pain";;; +11325-8;LL490-4;DEEDS4.16_1st GCS-motor;LA9358-8;4;"Adult: Localization of painful stimulation; infant or child: Withdraws to touch";;; +11325-8;LL490-4;DEEDS4.16_1st GCS-motor;LA9359-6;5;"Adult: Obeys commands with appropriate motor response; infant or child: Normal spontaneous movement";;; +11326-6;LL489-6;DEEDS4.15_1st GCS-verbal;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +11326-6;LL489-6;DEEDS4.15_1st GCS-verbal;LA9350-5;1;Nonspecific sounds;;; +11326-6;LL489-6;DEEDS4.15_1st GCS-verbal;LA9351-3;2;"non-infant: Inappropriate words; non-verbal infant: Cries to pain, screams to pain";;; +11326-6;LL489-6;DEEDS4.15_1st GCS-verbal;LA9352-1;3;"non-infant: Confused conversation or speech; non-verbal infant: Irritable cries";;; +11326-6;LL489-6;DEEDS4.15_1st GCS-verbal;LA9353-9;4;"non-infant: Oriented and appropriate speech; non-verbal infant: Coos and babbles";;; +11327-4;LL492-0;DEEDS4.22_1st HR method;LA9361-2;0;Pulse rate measured by palpation;;; +11327-4;LL492-0;DEEDS4.22_1st HR method;LA9362-0;1;Pulse rate measured by automated device;;; +11327-4;LL492-0;DEEDS4.22_1st HR method;LA9363-8;2;Heart rate measured by palpation or auscultation;;; +11327-4;LL492-0;DEEDS4.22_1st HR method;LA9364-6;3;Heart rate measured by automated device;;; +11333-2;LL2963-8;SNOMED CT;;0;;;; +75275-8;LL2963-8;SNOMED CT;;0;;;; +75276-6;LL2963-8;SNOMED CT;;0;;;; +75281-6;LL2963-8;SNOMED CT;;0;;;; +75313-7;LL2963-8;SNOMED CT;;0;;;; +75314-5;LL2963-8;SNOMED CT;;0;;;; +75315-2;LL2963-8;SNOMED CT;;0;;;; +75316-0;LL2963-8;SNOMED CT;;0;;;; +75317-8;LL2963-8;SNOMED CT;;0;;;; +75319-4;LL2963-8;SNOMED CT;;0;;;; +75322-8;LL2963-8;SNOMED CT;;0;;;; +75323-6;LL2963-8;SNOMED CT;;0;;;; +75325-1;LL2963-8;SNOMED CT;;0;;;; +8671-0;LL2963-8;SNOMED CT;;0;;;; +11371-2;LL485-4;DEEDS4.07_Initial Encounter;LA33-6;0;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +11371-2;LL485-4;DEEDS4.07_Initial Encounter;LA9334-9;1;No (chief complaint attributable to illness or injury, but this is not the initial encounter);;; +11371-2;LL485-4;DEEDS4.07_Initial Encounter;LA9335-6;2;Other (chief complaint not attributable to illness or injury);;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9373-7;0;Sports;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9374-5;1;Leisure;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9375-2;2;Paid work;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9376-0;3;Unpaid work;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9377-8;4;Educational activity;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9378-6;5;Vital activity;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9379-4;6;Other specified activity;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9380-2;7;Unknown activity;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9373-7;0;Sports;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9374-5;1;Leisure;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9375-2;2;Paid work;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9376-0;3;Unpaid work;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9377-8;4;Educational activity;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9378-6;5;Vital activity;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9379-4;6;Other specified activity;;; +11372-0;LL495-3;DEEDS5.06_Injury Activity;LA9380-2;7;Unknown activity;;; +11372-0;LL5970-0;Injury associated activity;LA9373-7;1;Sports;;; +11372-0;LL5970-0;Injury associated activity;LA9374-5;2;Leisure;;; +11372-0;LL5970-0;Injury associated activity;LA16501-1;3;Work;;; +11372-0;LL5970-0;Injury associated activity;LA9375-2;4;Paid work;;; +11372-0;LL5970-0;Injury associated activity;LA9376-0;5;Unpaid work;;; +11372-0;LL5970-0;Injury associated activity;LA9377-8;6;Educational activity;;; +11372-0;LL5970-0;Injury associated activity;LA9378-6;7;Vital activity;;; +11372-0;LL5970-0;Injury associated activity;LA46-8;8;Other;;; +11372-0;LL5970-0;Injury associated activity;LA9380-2;9;Unknown activity;;; +11373-8;LL4936-2;Wound etiology;LA17118-3;0;Animal bite;;; +11373-8;LL4936-2;Wound etiology;LA28743-5;1;Device related;;; +11373-8;LL4936-2;Wound etiology;LA28744-3;2;Disease related;;; +11373-8;LL4936-2;Wound etiology;LA28745-0;3;Human bite;;; +11373-8;LL4936-2;Wound etiology;LA28746-8;4;Insect bite;;; +11373-8;LL4936-2;Wound etiology;LA28747-6;5;Moisture related;;; +11373-8;LL4936-2;Wound etiology;LA28748-4;6;Pressure point related;;; +11373-8;LL4936-2;Wound etiology;LA28749-2;7;Self inflicted;;; +11373-8;LL4936-2;Wound etiology;LA28750-0;8;Shearing force injury;;; +11373-8;LL4936-2;Wound etiology;LA17058-1;9;Trauma;;; +11375-3;LL1052-1;Injury intent;LA14094-9;1;Unintentional;;; +11375-3;LL1052-1;Injury intent;LA14095-6;2;Intentional self-inflicted confirmed;;; +11375-3;LL1052-1;Injury intent;LA14096-4;3;Intentional self-inflicted suspected;;; +11375-3;LL1052-1;Injury intent;LA14097-2;4;Assault confirmed;;; +11375-3;LL1052-1;Injury intent;LA14098-0;5;Assault suspected;;; +11375-3;LL1052-1;Injury intent;LA14099-8;6;Legal intervention;;; +11375-3;LL1052-1;Injury intent;LA14100-4;7;Undetermined;;; +11375-3;LL1052-1;Injury intent;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +11376-1;LL1051-3;Inj Location;LA14084-0;1;Home;;; +11376-1;LL1051-3;Inj Location;LA14085-7;2;Residential institution;;; +11376-1;LL1051-3;Inj Location;LA14086-5;3;School;;; +11376-1;LL1051-3;Inj Location;LA14087-3;4;Public institution;;; +11376-1;LL1051-3;Inj Location;LA14088-1;5;Sports or recreational area;;; +11376-1;LL1051-3;Inj Location;LA14089-9;6;Street or highway;;; +11376-1;LL1051-3;Inj Location;LA14090-7;7;Trade or service area;;; +11376-1;LL1051-3;Inj Location;LA14091-5;8;Industrial or construction area;;; +11376-1;LL1051-3;Inj Location;LA14092-3;9;Farm;;; +11376-1;LL1051-3;Inj Location;LA14093-1;10;Unspecified;;; +11379-5;LL7-6;MDS_143_Education;LA35-1;1;No schooling;;; +11379-5;LL7-6;MDS_143_Education;LA36-9;2;8th grade/less;;; +11379-5;LL7-6;MDS_143_Education;LA37-7;3;9-11 grades;;; +11379-5;LL7-6;MDS_143_Education;LA38-5;4;High school;;; +11379-5;LL7-6;MDS_143_Education;LA39-3;5;Technical or trade school;;; +11379-5;LL7-6;MDS_143_Education;LA40-1;6;Some college;;; +11379-5;LL7-6;MDS_143_Education;LA41-9;7;Bachelor's degree;;; +11379-5;LL7-6;MDS_143_Education;LA42-7;8;Graduate degree;;; +82589-3;LL7-6;MDS_143_Education;LA35-1;1;No schooling;;; +82589-3;LL7-6;MDS_143_Education;LA36-9;2;8th grade/less;;; +82589-3;LL7-6;MDS_143_Education;LA37-7;3;9-11 grades;;; +82589-3;LL7-6;MDS_143_Education;LA38-5;4;High school;;; +82589-3;LL7-6;MDS_143_Education;LA39-3;5;Technical or trade school;;; +82589-3;LL7-6;MDS_143_Education;LA40-1;6;Some college;;; +82589-3;LL7-6;MDS_143_Education;LA41-9;7;Bachelor's degree;;; +82589-3;LL7-6;MDS_143_Education;LA42-7;8;Graduate degree;;; +82589-3;LL7-6;MDS_143_Education;LA35-1;1;No schooling;;; +82589-3;LL7-6;MDS_143_Education;LA36-9;2;8th grade/less;;; +82589-3;LL7-6;MDS_143_Education;LA37-7;3;9-11 grades;;; +82589-3;LL7-6;MDS_143_Education;LA38-5;4;High school;;; +82589-3;LL7-6;MDS_143_Education;LA39-3;5;Technical or trade school;;; +82589-3;LL7-6;MDS_143_Education;LA40-1;6;Some college;;; +82589-3;LL7-6;MDS_143_Education;LA41-9;7;Bachelor's degree;;; +82589-3;LL7-6;MDS_143_Education;LA42-7;8;Graduate degree;;; +82589-3;LL7-6;MDS_143_Education;LA35-1;1;No schooling;;; +82589-3;LL7-6;MDS_143_Education;LA36-9;2;8th grade/less;;; +82589-3;LL7-6;MDS_143_Education;LA37-7;3;9-11 grades;;; +82589-3;LL7-6;MDS_143_Education;LA38-5;4;High school;;; +82589-3;LL7-6;MDS_143_Education;LA39-3;5;Technical or trade school;;; +82589-3;LL7-6;MDS_143_Education;LA40-1;6;Some college;;; +82589-3;LL7-6;MDS_143_Education;LA41-9;7;Bachelor's degree;;; +82589-3;LL7-6;MDS_143_Education;LA42-7;8;Graduate degree;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA22693-8;1;Unmarried;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA22694-6;2;Annulled;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA51-8;3;Divorced;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA22696-1;4;Interlocutory;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA22697-9;5;Legally separated;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA48-4;6;Married;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA22698-7;7;Polygamous;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA47-6;8;Never married;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA22700-1;9;Domestic partner;;; +11381-1;LL3271-5;HL7_FHIR_Marital Status;LA49-2;10;Widowed;;; +11382-9;LL4991-7;Aspirin;LA26702-3;0;Aspirin;;; +11382-9;LL5328-1;Medication allergy examples;LA26702-3;1;Aspirin;;; +11382-9;LL5328-1;Medication allergy examples;LA30119-4;2;Iodine;;; +11382-9;LL5328-1;Medication allergy examples;LA14348-9;3;Naproxen, ketoprofen or other non-steroidal;;; +11382-9;LL5328-1;Medication allergy examples;LA28487-9;4;Penicillin;;; +11382-9;LL5328-1;Medication allergy examples;LA30118-6;5;Sulfa drugs;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA7410-9;1;Abrasion;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA18220-6;2;Avulsion;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA17222-3;3;Accessory muscles used with breathing;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA17209-0;4;Bleeding uncontrolled;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA33338-7;5;Burn-blistering;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA33346-0;6;Burn-charing;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA33353-6;7;Burn-redness;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA33345-2;8;Burn-white/waxy;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA17229-8;9;Crush injury;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA18225-5;10;Deformity;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA33342-9;11;Flail segment;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA18236-2;12;Implanted device;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA7452-1;13;Laceration;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA6626-1;14;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +11422-3;LL6224-1;NEMSIS_Chest assessment;LA6630-3;15;Not done;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA7460-4;16;Pain;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA33332-0;17;Pain with inspiration/expiration;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA17214-0;18;Puncture/stab wound;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA18231-3;19;Retraction;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA17709-9;20;Tenderness;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA17212-4;21;Gunshot wound;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA22440-4;22;Swelling;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA7423-2;23;Contusion;;; +11422-3;LL6224-1;NEMSIS_Chest assessment;LA23810-7;24;Tenderness-General;;; +11449-6;LL4129-4;Pregnant|Not pregnant|Unknown;LA15173-0;1;Pregnant;;; +11449-6;LL4129-4;Pregnant|Not pregnant|Unknown;LA26683-5;2;Not pregnant;;; +11449-6;LL4129-4;Pregnant|Not pregnant|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82810-3;LL4129-4;Pregnant|Not pregnant|Unknown;LA15173-0;1;Pregnant;;; +82810-3;LL4129-4;Pregnant|Not pregnant|Unknown;LA26683-5;2;Not pregnant;;; +82810-3;LL4129-4;Pregnant|Not pregnant|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +11454-6;LL487-0;DEEDS4.12_1st Responsiveness Assess;LA9340-6;0;Alert;;; +11454-6;LL487-0;DEEDS4.12_1st Responsiveness Assess;LA9341-4;1;Verbal response;;; +11454-6;LL487-0;DEEDS4.12_1st Responsiveness Assess;LA9342-2;2;Painful response;;; +11454-6;LL487-0;DEEDS4.12_1st Responsiveness Assess;LA9343-0;3;Unresponsive;422768004;unresponsive (finding);http://snomed.info/sct +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9381-0;0;Shoulder belt;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9382-8;1;Lap belt;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9383-6;2;Seat belt, not otherwise specified;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9384-4;3;Driver's front air bag;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9385-1;4;Passenger's front air bag;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9386-9;5;Front air bag, not otherwise specified;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9387-7;6;Side air bag;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9388-5;7;Air bag, not otherwise specified;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9389-3;8;Child safety seat;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9390-1;9;Helmet;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9391-9;10;Eye protection;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9392-7;11;Protective clothing;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9393-5;12;Personal flotation device;;; +11457-9;LL496-1;DEEDS5.08_Safety Equipment Use;LA9394-3;13;Other protective gear;;; +11458-7;LL940-8;Imm_status;LA13421-5;1;Complete - all required doses have been received to meet the requirements for a particular vaccine group.;;; +11458-7;LL940-8;Imm_status;LA13422-3;2;On schedule - person is not overdue for a given dose in the series. Includes a person too young to start the series.;;; +11458-7;LL940-8;Imm_status;LA13423-1;3;Overdue - person is late getting the next dose in the series.;;; +11458-7;LL940-8;Imm_status;LA13424-9;4;Too old - cannot complete the series because the latest age for receiving dose has passed.;;; +11458-7;LL940-8;Imm_status;LA27183-5;5;Immune;;; +11458-7;LL940-8;Imm_status;LA4216-3;6;Contraindicated;;; +11458-7;LL940-8;Imm_status;LA4695-8;7;Not Recommended;;; +59783-1;LL940-8;Imm_status;LA13421-5;1;Complete - all required doses have been received to meet the requirements for a particular vaccine group.;;; +59783-1;LL940-8;Imm_status;LA13422-3;2;On schedule - person is not overdue for a given dose in the series. Includes a person too young to start the series.;;; +59783-1;LL940-8;Imm_status;LA13423-1;3;Overdue - person is late getting the next dose in the series.;;; +59783-1;LL940-8;Imm_status;LA13424-9;4;Too old - cannot complete the series because the latest age for receiving dose has passed.;;; +59783-1;LL940-8;Imm_status;LA27183-5;5;Immune;;; +59783-1;LL940-8;Imm_status;LA4216-3;6;Contraindicated;;; +59783-1;LL940-8;Imm_status;LA4695-8;7;Not Recommended;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9315-8;0;Ground ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9316-6;1;Helicopter ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9317-4;2;Fixed-wing air ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9318-2;3;Ambulance, not otherwise specified;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9319-0;4;Walk-in following transport via private transportation;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9320-8;5;Walk-in following transport via public transportation;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9321-6;6;Walk-in following nonambulance, law enforcement transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9322-4;7;Walk-in, not otherwise specified;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9323-2;8;Other mode of transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9324-0;9;Unknown mode of transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9315-8;0;Ground ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9316-6;1;Helicopter ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9317-4;2;Fixed-wing air ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9318-2;3;Ambulance, not otherwise specified;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9319-0;4;Walk-in following transport via private transportation;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9320-8;5;Walk-in following transport via public transportation;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9321-6;6;Walk-in following nonambulance, law enforcement transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9322-4;7;Walk-in, not otherwise specified;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9323-2;8;Other mode of transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9324-0;9;Unknown mode of transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9315-8;0;Ground ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9316-6;1;Helicopter ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9317-4;2;Fixed-wing air ambulance;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9318-2;3;Ambulance, not otherwise specified;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9319-0;4;Walk-in following transport via private transportation;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9320-8;5;Walk-in following transport via public transportation;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9321-6;6;Walk-in following nonambulance, law enforcement transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9322-4;7;Walk-in, not otherwise specified;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9323-2;8;Other mode of transport;;; +11459-5;LL483-9;DEEDS4.02_Mode of Transport;LA9324-0;9;Unknown mode of transport;;; +11619-4;LL2388-8;Heart valve defects;LA19655-2;1;Not observed;;; +11619-4;LL2388-8;Heart valve defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +11619-4;LL2388-8;Heart valve defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +11619-4;LL2388-8;Heart valve defects;LA19574-5;4;More specific code;;; +11621-0;LL2388-8;Heart valve defects;LA19655-2;1;Not observed;;; +11621-0;LL2388-8;Heart valve defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +11621-0;LL2388-8;Heart valve defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +11621-0;LL2388-8;Heart valve defects;LA19574-5;4;More specific code;;; +12086-5;LL2388-8;Heart valve defects;LA19655-2;1;Not observed;;; +12086-5;LL2388-8;Heart valve defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12086-5;LL2388-8;Heart valve defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12086-5;LL2388-8;Heart valve defects;LA19574-5;4;More specific code;;; +11630-1;LL531-5;BP;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +11630-1;LL531-5;BP;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +11631-9;LL531-5;BP;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +11631-9;LL531-5;BP;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +11632-7;LL531-5;BP;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +11632-7;LL531-5;BP;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +11635-0;LL531-5;BP;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +11635-0;LL531-5;BP;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +58259-3;LL531-5;BP;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +58259-3;LL531-5;BP;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +11633-5;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +11633-5;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +89374-3;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +89374-3;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +92813-5;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +92813-5;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +94762-2;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +94762-2;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +95825-6;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +95825-6;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +96273-8;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +96273-8;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +99072-1;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +99072-1;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +99073-9;LL4994-1;Reactive|Nonreactive;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +99073-9;LL4994-1;Reactive|Nonreactive;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +11882-8;LL2903-4;Male/Female Fetus;LA21135-1;1;Female fetus;;; +11882-8;LL2903-4;Male/Female Fetus;LA21134-4;2;Male fetus;;; +11882-8;LL2903-4;Male/Female Fetus;LA21136-9;3;No result;;; +75604-9;LL2903-4;Male/Female Fetus;LA21135-1;1;Female fetus;;; +75604-9;LL2903-4;Male/Female Fetus;LA21134-4;2;Male fetus;;; +75604-9;LL2903-4;Male/Female Fetus;LA21136-9;3;No result;;; +75693-2;LL2903-4;Male/Female Fetus;LA21135-1;1;Female fetus;;; +75693-2;LL2903-4;Male/Female Fetus;LA21134-4;2;Male fetus;;; +75693-2;LL2903-4;Male/Female Fetus;LA21136-9;3;No result;;; +96985-7;LL2903-4;Male/Female Fetus;LA21135-1;1;Female fetus;;; +96985-7;LL2903-4;Male/Female Fetus;LA21134-4;2;Male fetus;;; +96985-7;LL2903-4;Male/Female Fetus;LA21136-9;3;No result;;; +11946-1;LL530-7;OB_Grade;LA9628-4;1;Grade 0;;; +11946-1;LL530-7;OB_Grade;LA9629-2;2;Grade 1;;; +11946-1;LL530-7;OB_Grade;LA9630-0;3;Grade 2;;; +11946-1;LL530-7;OB_Grade;LA9631-8;4;Grade 3;;; +11946-1;LL530-7;OB_Grade;LA9632-6;5;Not visualized;;; +12028-7;LL2366-4;Abdomen defects;LA9632-6;1;Not visualized;;; +12028-7;LL2366-4;Abdomen defects;LA18997-9;2;Suboptimally visualized;;; +12028-7;LL2366-4;Abdomen defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12028-7;LL2366-4;Abdomen defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12028-7;LL2366-4;Abdomen defects;LA19589-3;5;Distended;;; +12028-7;LL2366-4;Abdomen defects;LA17637-2;6;Ascites;;; +12028-7;LL2366-4;Abdomen defects;LA19574-5;7;More specific code;;; +12030-3;LL2367-2;Abdomen wall defects;LA9632-6;1;Not visualized;;; +12030-3;LL2367-2;Abdomen wall defects;LA18997-9;2;Suboptimally visualized;;; +12030-3;LL2367-2;Abdomen wall defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12030-3;LL2367-2;Abdomen wall defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12030-3;LL2367-2;Abdomen wall defects;LA19590-1;5;Gastroschisis;;; +12030-3;LL2367-2;Abdomen wall defects;LA20082-6;6;Omphalocele;;; +12030-3;LL2367-2;Abdomen wall defects;LA19592-7;7;Body wall disrupion;;; +12030-3;LL2367-2;Abdomen wall defects;LA19593-5;8;Pentalogy of Cantrell;;; +12030-3;LL2367-2;Abdomen wall defects;LA19574-5;9;More specific code;;; +12032-9;LL2368-0;Asc aorta defects;LA9632-6;1;Not visualized;;; +12032-9;LL2368-0;Asc aorta defects;LA18997-9;2;Suboptimally visualized;;; +12032-9;LL2368-0;Asc aorta defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12032-9;LL2368-0;Asc aorta defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12032-9;LL2368-0;Asc aorta defects;LA19594-3;5;Hypoplastic;;; +12032-9;LL2368-0;Asc aorta defects;LA19576-0;6;Dilated;;; +12032-9;LL2368-0;Asc aorta defects;LA19595-0;7;Truncus abnormality;;; +12032-9;LL2368-0;Asc aorta defects;LA19574-5;8;More specific code;;; +12034-5;LL2369-8;Desc aorta defects;LA9632-6;1;Not visualized;;; +12034-5;LL2369-8;Desc aorta defects;LA18997-9;2;Suboptimally visualized;;; +12034-5;LL2369-8;Desc aorta defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12034-5;LL2369-8;Desc aorta defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12034-5;LL2369-8;Desc aorta defects;LA19594-3;5;Hypoplastic;;; +12034-5;LL2369-8;Desc aorta defects;LA19596-8;6;Hypoplastic segment;;; +12034-5;LL2369-8;Desc aorta defects;LA19597-6;7;Coarctation;;; +12034-5;LL2369-8;Desc aorta defects;LA19574-5;8;More specific code;;; +12036-0;LL2208-8;Not visual, sub visual, norm, abnorm;LA9632-6;1;Not visualized;;; +12036-0;LL2208-8;Not visual, sub visual, norm, abnorm;LA18997-9;2;Suboptimally visualized;;; +12036-0;LL2208-8;Not visual, sub visual, norm, abnorm;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12036-0;LL2208-8;Not visual, sub visual, norm, abnorm;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +72221-5;LL2208-8;Not visual, sub visual, norm, abnorm;LA9632-6;1;Not visualized;;; +72221-5;LL2208-8;Not visual, sub visual, norm, abnorm;LA18997-9;2;Suboptimally visualized;;; +72221-5;LL2208-8;Not visual, sub visual, norm, abnorm;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +72221-5;LL2208-8;Not visual, sub visual, norm, abnorm;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12038-6;LL2370-6;Aortic arch defects;LA9632-6;1;Not visualized;;; +12038-6;LL2370-6;Aortic arch defects;LA18997-9;2;Suboptimally visualized;;; +12038-6;LL2370-6;Aortic arch defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12038-6;LL2370-6;Aortic arch defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12038-6;LL2370-6;Aortic arch defects;LA19654-5;5;Interrupted;;; +12038-6;LL2370-6;Aortic arch defects;LA19594-3;6;Hypoplastic;;; +12038-6;LL2370-6;Aortic arch defects;LA19598-4;7;Right arch;;; +12038-6;LL2370-6;Aortic arch defects;LA19599-2;8;Left arch;;; +12038-6;LL2370-6;Aortic arch defects;LA19600-8;9;Double arch;;; +12038-6;LL2370-6;Aortic arch defects;LA19601-6;10;Normal branching;;; +12038-6;LL2370-6;Aortic arch defects;LA19602-4;11;Branching not visualized;;; +12038-6;LL2370-6;Aortic arch defects;LA19603-2;12;Branching suboptimally visualized;;; +12038-6;LL2370-6;Aortic arch defects;LA19604-0;13;Retrograde flow;;; +12038-6;LL2370-6;Aortic arch defects;LA19574-5;14;More specific code;;; +12040-2;LL2372-2;Cerebellum defects;LA19655-2;1;Not observed;;; +12040-2;LL2372-2;Cerebellum defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12040-2;LL2372-2;Cerebellum defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12040-2;LL2372-2;Cerebellum defects;LA19656-0;4;Cerebellar vermis;;; +12040-2;LL2372-2;Cerebellum defects;LA19574-5;5;More specific code;;; +12042-8;LL2373-0;Cerebrum defects;LA19655-2;1;Not observed;;; +12042-8;LL2373-0;Cerebrum defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12042-8;LL2373-0;Cerebrum defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12042-8;LL2373-0;Cerebrum defects;LA19657-8;4;Hydrocephaly;;; +12042-8;LL2373-0;Cerebrum defects;LA19658-6;5;Holoprosencephaly;;; +12042-8;LL2373-0;Cerebrum defects;LA19659-4;6;Hydranencephaly;;; +12042-8;LL2373-0;Cerebrum defects;LA19660-2;7;Porecephaly;;; +12042-8;LL2373-0;Cerebrum defects;LA19661-0;8;Cebocephaly;;; +12042-8;LL2373-0;Cerebrum defects;LA19574-5;9;More specific code;;; +12047-7;LL2374-8;Colon defects;LA9632-6;1;Not visualized;;; +12047-7;LL2374-8;Colon defects;LA18997-9;2;Suboptimally visualized;;; +12047-7;LL2374-8;Colon defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12047-7;LL2374-8;Colon defects;LA19576-0;4;Dilated;;; +12047-7;LL2374-8;Colon defects;LA19574-5;5;More specific code;;; +12049-3;LL2375-5;Cranium defects;LA19655-2;1;Not observed;;; +12049-3;LL2375-5;Cranium defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12049-3;LL2375-5;Cranium defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12049-3;LL2375-5;Cranium defects;LA19663-6;4;Microcephalic;;; +12049-3;LL2375-5;Cranium defects;LA19664-4;5;Macrocephalic;;; +12049-3;LL2375-5;Cranium defects;LA19665-1;6;Anencephalic;;; +12049-3;LL2375-5;Cranium defects;LA19666-9;7;Dolichocephalic;;; +12049-3;LL2375-5;Cranium defects;LA19667-7;8;Brachycephalic;;; +12049-3;LL2375-5;Cranium defects;LA19636-2;9;Hypocalcified;;; +12049-3;LL2375-5;Cranium defects;LA19668-5;10;Lemon sign;;; +12049-3;LL2375-5;Cranium defects;LA19669-3;11;Cloverleaf skull;;; +12049-3;LL2375-5;Cranium defects;LA19670-1;12;Synostosis;;; +12049-3;LL2375-5;Cranium defects;LA19574-5;13;More specific code;;; +12051-9;LL2376-3;Diaphragm defects;LA19655-2;1;Not observed;;; +12051-9;LL2376-3;Diaphragm defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12051-9;LL2376-3;Diaphragm defects;LA19671-9;3;Abnormal intact;;; +12051-9;LL2376-3;Diaphragm defects;LA19672-7;4;Diaphragmatic hernia;;; +12051-9;LL2376-3;Diaphragm defects;LA19574-5;5;More specific code;;; +12053-5;LL2377-1;Ductal arch defects;LA9632-6;1;Not visualized;;; +12053-5;LL2377-1;Ductal arch defects;LA18997-9;2;Suboptimally visualized;;; +12053-5;LL2377-1;Ductal arch defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12053-5;LL2377-1;Ductal arch defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12053-5;LL2377-1;Ductal arch defects;LA19605-7;5;Constricted;;; +12053-5;LL2377-1;Ductal arch defects;LA19576-0;6;Dilated;;; +12053-5;LL2377-1;Ductal arch defects;LA19604-0;7;Retrograde flow;;; +12053-5;LL2377-1;Ductal arch defects;LA19574-5;8;More specific code;;; +12055-0;LL2378-9;Facial defects;LA9632-6;1;Not visualized;;; +12055-0;LL2378-9;Facial defects;LA18997-9;2;Suboptimally visualized;;; +12055-0;LL2378-9;Facial defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12055-0;LL2378-9;Facial defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12055-0;LL2378-9;Facial defects;LA14411-5;5;Cleft lip;;; +12055-0;LL2378-9;Facial defects;LA14412-3;6;Cleft palate;;; +12055-0;LL2378-9;Facial defects;LA19573-7;7;Micrognathia;;; +12055-0;LL2378-9;Facial defects;LA19572-9;8;Macroglossia;;; +12055-0;LL2378-9;Facial defects;LA19574-5;9;More specific code;;; +12057-6;LL2379-7;Choroid plexus defects;LA19655-2;1;Not observed;;; +12057-6;LL2379-7;Choroid plexus defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12057-6;LL2379-7;Choroid plexus defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12057-6;LL2379-7;Choroid plexus defects;LA19575-2;4;Enlarged;;; +12057-6;LL2379-7;Choroid plexus defects;LA19674-3;5;Cystic;;; +12057-6;LL2379-7;Choroid plexus defects;LA19675-0;6;Bilateraly cystic;;; +12057-6;LL2379-7;Choroid plexus defects;LA19676-8;7;Laterally deviated;;; +12057-6;LL2379-7;Choroid plexus defects;LA19574-5;8;More specific code;;; +12059-2;LL2380-5;4th ventricle defects;LA19574-5;0;More specific code;;; +12059-2;LL2380-5;4th ventricle defects;LA9632-6;1;Not visualized;;; +12059-2;LL2380-5;4th ventricle defects;LA18997-9;2;Suboptimally visualized;;; +12059-2;LL2380-5;4th ventricle defects;LA19575-2;3;Enlarged;;; +12059-2;LL2380-5;4th ventricle defects;LA19576-0;4;Dilated;;; +12059-2;LL2380-5;4th ventricle defects;LA19577-8;5;Hydrocephalus;;; +12063-4;LL2381-3;Cerebral LV defects;LA19655-2;1;Not observed;;; +12063-4;LL2381-3;Cerebral LV defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12063-4;LL2381-3;Cerebral LV defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12063-4;LL2381-3;Cerebral LV defects;LA19576-0;4;Dilated;;; +12063-4;LL2381-3;Cerebral LV defects;LA19577-8;5;Hydrocephalus;;; +12063-4;LL2381-3;Cerebral LV defects;LA19574-5;6;More specific code;;; +12065-9;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA9632-6;1;Not visualized;;; +12065-9;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA19578-6;2;Inadequately visualized;;; +12065-9;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA19575-2;3;Enlarged;;; +12065-9;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA19574-5;4;More specific code;;; +12067-5;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA9632-6;1;Not visualized;;; +12067-5;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA19578-6;2;Inadequately visualized;;; +12067-5;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA19575-2;3;Enlarged;;; +12067-5;LL2396-1;Not vis-Inadeq vis-Enlarged-more spec code;LA19574-5;4;More specific code;;; +12071-7;LL2371-4;Aortic valve defects;LA9632-6;1;Not visualized;;; +12071-7;LL2371-4;Aortic valve defects;LA18997-9;2;Suboptimally visualized;;; +12071-7;LL2371-4;Aortic valve defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12071-7;LL2371-4;Aortic valve defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12071-7;LL2371-4;Aortic valve defects;LA19606-5;5;Stenoic;;; +12071-7;LL2371-4;Aortic valve defects;LA19607-3;6;Atretic;;; +12071-7;LL2371-4;Aortic valve defects;LA14110-3;7;Thickened;;; +12071-7;LL2371-4;Aortic valve defects;LA19608-1;8;Regurgitant;;; +12071-7;LL2371-4;Aortic valve defects;LA19574-5;9;More specific code;;; +12073-3;LL2383-9;Atrial defects;LA9632-6;1;Not visualized;;; +12073-3;LL2383-9;Atrial defects;LA18997-9;2;Suboptimally visualized;;; +12073-3;LL2383-9;Atrial defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12073-3;LL2383-9;Atrial defects;LA6626-1;4;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12073-3;LL2383-9;Atrial defects;LA19677-6;5;Situs solitus;;; +12073-3;LL2383-9;Atrial defects;LA19610-7;6;Situs inversus;;; +12073-3;LL2383-9;Atrial defects;LA19574-5;7;More specific code;;; +12075-8;LL2384-7;Chamber defects;LA9632-6;1;Not visualized;;; +12075-8;LL2384-7;Chamber defects;LA18997-9;2;Suboptimally visualized;;; +12075-8;LL2384-7;Chamber defects;LA19611-5;3;Normal chamber sizes;;; +12075-8;LL2384-7;Chamber defects;LA19612-3;4;Normal segmental relationships;;; +12075-8;LL2384-7;Chamber defects;LA12748-2;5;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12075-8;LL2384-7;Chamber defects;LA19574-5;6;More specific code;;; +12077-4;LL2385-4;Great vessels defects;LA9632-6;1;Not visualized;;; +12077-4;LL2385-4;Great vessels defects;LA18997-9;2;Suboptimally visualized;;; +12077-4;LL2385-4;Great vessels defects;LA19613-1;3;Normally related;;; +12077-4;LL2385-4;Great vessels defects;LA19614-9;4;Malposed;;; +12077-4;LL2385-4;Great vessels defects;LA19615-6;5;Transposed;;; +12077-4;LL2385-4;Great vessels defects;LA19616-4;6;Double outlet;;; +12077-4;LL2385-4;Great vessels defects;LA19574-5;7;More specific code;;; +12079-0;LL2387-0;IV septum defects;LA9632-6;1;Not visualized;;; +12079-0;LL2387-0;IV septum defects;LA18997-9;2;Suboptimally visualized;;; +12079-0;LL2387-0;IV septum defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12079-0;LL2387-0;IV septum defects;LA6626-1;4;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12079-0;LL2387-0;IV septum defects;LA19617-2;5;Hypertrophied;;; +12079-0;LL2387-0;IV septum defects;LA19618-0;6;Septal defect;;; +12079-0;LL2387-0;IV septum defects;LA19574-5;7;More specific code;;; +12081-6;LL2394-6;Mitral valve defects;LA9632-6;1;Not visualized;;; +12081-6;LL2394-6;Mitral valve defects;LA18997-9;2;Suboptimally visualized;;; +12081-6;LL2394-6;Mitral valve defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12081-6;LL2394-6;Mitral valve defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12081-6;LL2394-6;Mitral valve defects;LA19594-3;5;Hypoplastic;;; +12081-6;LL2394-6;Mitral valve defects;LA19607-3;6;Atretic;;; +12081-6;LL2394-6;Mitral valve defects;LA19608-1;7;Regurgitant;;; +12081-6;LL2394-6;Mitral valve defects;LA19679-2;8;Stenotic;;; +12081-6;LL2394-6;Mitral valve defects;LA19619-8;9;Parachute;;; +12081-6;LL2394-6;Mitral valve defects;LA19574-5;10;More specific code;;; +12083-2;LL2398-7;Pulm valve defects;LA9632-6;1;Not visualized;;; +12083-2;LL2398-7;Pulm valve defects;LA18997-9;2;Suboptimally visualized;;; +12083-2;LL2398-7;Pulm valve defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12083-2;LL2398-7;Pulm valve defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12083-2;LL2398-7;Pulm valve defects;LA19594-3;5;Hypoplastic;;; +12083-2;LL2398-7;Pulm valve defects;LA19679-2;6;Stenotic;;; +12083-2;LL2398-7;Pulm valve defects;LA19576-0;7;Dilated;;; +12083-2;LL2398-7;Pulm valve defects;LA9634-2;8;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +12083-2;LL2398-7;Pulm valve defects;LA19608-1;9;Regurgitant;;; +12083-2;LL2398-7;Pulm valve defects;LA19574-5;10;More specific code;;; +12084-0;LL2404-3;Tricusp valve defects;LA9632-6;1;Not visualized;;; +12084-0;LL2404-3;Tricusp valve defects;LA18997-9;2;Suboptimally visualized;;; +12084-0;LL2404-3;Tricusp valve defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12084-0;LL2404-3;Tricusp valve defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12084-0;LL2404-3;Tricusp valve defects;LA19594-3;5;Hypoplastic;;; +12084-0;LL2404-3;Tricusp valve defects;LA19679-2;6;Stenotic;;; +12084-0;LL2404-3;Tricusp valve defects;LA19608-1;7;Regurgitant;;; +12084-0;LL2404-3;Tricusp valve defects;LA14110-3;8;Thickened;;; +12084-0;LL2404-3;Tricusp valve defects;LA19620-6;9;Myxomatous;;; +12084-0;LL2404-3;Tricusp valve defects;LA19621-4;10;Ebstein anomaly;;; +12084-0;LL2404-3;Tricusp valve defects;LA19574-5;11;More specific code;;; +12088-1;LL2389-6;L outflow;LA9632-6;1;Not visualized;;; +12088-1;LL2389-6;L outflow;LA18997-9;2;Suboptimally visualized;;; +12088-1;LL2389-6;L outflow;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12088-1;LL2389-6;L outflow;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12088-1;LL2389-6;L outflow;LA19606-5;5;Stenoic;;; +12088-1;LL2389-6;L outflow;LA19622-2;6;Obstructed;;; +12088-1;LL2389-6;L outflow;LA19574-5;7;More specific code;;; +12090-7;LL2390-4;R outflow;LA9632-6;1;Not visualized;;; +12090-7;LL2390-4;R outflow;LA18997-9;2;Suboptimally visualized;;; +12090-7;LL2390-4;R outflow;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12090-7;LL2390-4;R outflow;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12090-7;LL2390-4;R outflow;LA19606-5;5;Stenoic;;; +12090-7;LL2390-4;R outflow;LA19622-2;6;Obstructed;;; +12090-7;LL2390-4;R outflow;LA19623-0;7;Tetralogy of Fallot;;; +12090-7;LL2390-4;R outflow;LA19574-5;8;More specific code;;; +12092-3;LL2391-2;Intestinal defects;LA9632-6;1;Not visualized;;; +12092-3;LL2391-2;Intestinal defects;LA18997-9;2;Suboptimally visualized;;; +12092-3;LL2391-2;Intestinal defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12092-3;LL2391-2;Intestinal defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12092-3;LL2391-2;Intestinal defects;LA19624-8;5;Hyperechoic;;; +12092-3;LL2391-2;Intestinal defects;LA19625-5;6;Echogenic;;; +12092-3;LL2391-2;Intestinal defects;LA19574-5;7;More specific code;;; +12094-9;LL2392-0;Kidney defects;LA9632-6;1;Not visualized;;; +12094-9;LL2392-0;Kidney defects;LA18997-9;2;Suboptimally visualized;;; +12094-9;LL2392-0;Kidney defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12094-9;LL2392-0;Kidney defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12094-9;LL2392-0;Kidney defects;LA19626-3;5;Multicystic;;; +12094-9;LL2392-0;Kidney defects;LA19627-1;6;Polycystic;;; +12094-9;LL2392-0;Kidney defects;LA9634-2;7;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +12094-9;LL2392-0;Kidney defects;LA19622-2;8;Obstructed;;; +12094-9;LL2392-0;Kidney defects;LA19628-9;9;Hydronephrotic;;; +12094-9;LL2392-0;Kidney defects;LA19629-7;10;Good corticomedullary differentiation;;; +12094-9;LL2392-0;Kidney defects;LA19630-5;11;Poor corticomedullary differentiation;;; +12094-9;LL2392-0;Kidney defects;LA19625-5;12;Echogenic;;; +12094-9;LL2392-0;Kidney defects;LA19574-5;13;More specific code;;; +12096-4;LL2392-0;Kidney defects;LA9632-6;1;Not visualized;;; +12096-4;LL2392-0;Kidney defects;LA18997-9;2;Suboptimally visualized;;; +12096-4;LL2392-0;Kidney defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12096-4;LL2392-0;Kidney defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12096-4;LL2392-0;Kidney defects;LA19626-3;5;Multicystic;;; +12096-4;LL2392-0;Kidney defects;LA19627-1;6;Polycystic;;; +12096-4;LL2392-0;Kidney defects;LA9634-2;7;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +12096-4;LL2392-0;Kidney defects;LA19622-2;8;Obstructed;;; +12096-4;LL2392-0;Kidney defects;LA19628-9;9;Hydronephrotic;;; +12096-4;LL2392-0;Kidney defects;LA19629-7;10;Good corticomedullary differentiation;;; +12096-4;LL2392-0;Kidney defects;LA19630-5;11;Poor corticomedullary differentiation;;; +12096-4;LL2392-0;Kidney defects;LA19625-5;12;Echogenic;;; +12096-4;LL2392-0;Kidney defects;LA19574-5;13;More specific code;;; +12098-0;LL2392-0;Kidney defects;LA9632-6;1;Not visualized;;; +12098-0;LL2392-0;Kidney defects;LA18997-9;2;Suboptimally visualized;;; +12098-0;LL2392-0;Kidney defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12098-0;LL2392-0;Kidney defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12098-0;LL2392-0;Kidney defects;LA19626-3;5;Multicystic;;; +12098-0;LL2392-0;Kidney defects;LA19627-1;6;Polycystic;;; +12098-0;LL2392-0;Kidney defects;LA9634-2;7;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +12098-0;LL2392-0;Kidney defects;LA19622-2;8;Obstructed;;; +12098-0;LL2392-0;Kidney defects;LA19628-9;9;Hydronephrotic;;; +12098-0;LL2392-0;Kidney defects;LA19629-7;10;Good corticomedullary differentiation;;; +12098-0;LL2392-0;Kidney defects;LA19630-5;11;Poor corticomedullary differentiation;;; +12098-0;LL2392-0;Kidney defects;LA19625-5;12;Echogenic;;; +12098-0;LL2392-0;Kidney defects;LA19574-5;13;More specific code;;; +12100-4;LL2393-8;Limb defects;LA9632-6;1;Not visualized;;; +12100-4;LL2393-8;Limb defects;LA18997-9;2;Suboptimally visualized;;; +12100-4;LL2393-8;Limb defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12100-4;LL2393-8;Limb defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12100-4;LL2393-8;Limb defects;LA19631-3;5;Short;;; +12100-4;LL2393-8;Limb defects;LA19632-1;6;Phocomelic;;; +12100-4;LL2393-8;Limb defects;LA19633-9;7;Mesomelic;;; +12100-4;LL2393-8;Limb defects;LA19634-7;8;Camptomelic;;; +12100-4;LL2393-8;Limb defects;LA19635-4;9;Fractured;;; +12100-4;LL2393-8;Limb defects;LA19636-2;10;Hypocalcified;;; +12100-4;LL2393-8;Limb defects;LA19574-5;11;More specific code;;; +12102-0;LL2395-3;Nuchal fold defects;LA9632-6;1;Not visualized;;; +12102-0;LL2395-3;Nuchal fold defects;LA18997-9;2;Suboptimally visualized;;; +12102-0;LL2395-3;Nuchal fold defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12102-0;LL2395-3;Nuchal fold defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12102-0;LL2395-3;Nuchal fold defects;LA14110-3;5;Thickened;;; +12102-0;LL2395-3;Nuchal fold defects;LA19574-5;6;More specific code;;; +12104-6;LL2397-9;Pulm art defects;LA19574-5;0;More specific code;;; +12104-6;LL2397-9;Pulm art defects;LA9632-6;1;Not visualized;;; +12104-6;LL2397-9;Pulm art defects;LA18997-9;2;Suboptimally visualized;;; +12104-6;LL2397-9;Pulm art defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12104-6;LL2397-9;Pulm art defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12104-6;LL2397-9;Pulm art defects;LA19576-0;5;Dilated;;; +12104-6;LL2397-9;Pulm art defects;LA19594-3;6;Hypoplastic;;; +12104-6;LL2397-9;Pulm art defects;LA19637-0;7;Confluent;;; +12104-6;LL2397-9;Pulm art defects;LA19638-8;8;Non-confluent;;; +12106-1;LL2399-5;Pulm vein defects;LA9632-6;1;Not visualized;;; +12106-1;LL2399-5;Pulm vein defects;LA18997-9;2;Suboptimally visualized;;; +12106-1;LL2399-5;Pulm vein defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12106-1;LL2399-5;Pulm vein defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12106-1;LL2399-5;Pulm vein defects;LA19622-2;5;Obstructed;;; +12106-1;LL2399-5;Pulm vein defects;LA19639-6;6;Partial anomalous return;;; +12106-1;LL2399-5;Pulm vein defects;LA19640-4;7;Total anomalous return;;; +12106-1;LL2399-5;Pulm vein defects;LA19574-5;8;More specific code;;; +12108-7;LL2400-1;Sm bowel defects;LA9632-6;1;Not visualized;;; +12108-7;LL2400-1;Sm bowel defects;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12108-7;LL2400-1;Sm bowel defects;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12108-7;LL2400-1;Sm bowel defects;LA19641-2;4;High obstruction (double bubble);;; +12108-7;LL2400-1;Sm bowel defects;LA19642-0;5;Dilated loops;;; +12108-7;LL2400-1;Sm bowel defects;LA19624-8;6;Hyperechoic;;; +12108-7;LL2400-1;Sm bowel defects;LA19625-5;7;Echogenic;;; +12108-7;LL2400-1;Sm bowel defects;LA19574-5;8;More specific code;;; +12110-3;LL2401-9;Spine defects;LA9632-6;1;Not visualized;;; +12110-3;LL2401-9;Spine defects;LA18997-9;2;Suboptimally visualized;;; +12110-3;LL2401-9;Spine defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12110-3;LL2401-9;Spine defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12110-3;LL2401-9;Spine defects;LA19643-8;5;Spina bifida;;; +12110-3;LL2401-9;Spine defects;LA19644-6;6;Meningocele;;; +12110-3;LL2401-9;Spine defects;LA19645-3;7;Meningomyelocele;;; +12110-3;LL2401-9;Spine defects;LA19646-1;8;Rachischisis;;; +12110-3;LL2401-9;Spine defects;LA19647-9;9;Separation of posterior ossification centers;;; +12110-3;LL2401-9;Spine defects;LA19648-7;10;Disruption;;; +12110-3;LL2401-9;Spine defects;LA19649-5;11;Hemivertebra;;; +12110-3;LL2401-9;Spine defects;LA19574-5;12;More specific code;;; +12112-9;LL2402-7;Stomach defects;LA9632-6;1;Not visualized;;; +12112-9;LL2402-7;Stomach defects;LA18997-9;2;Suboptimally visualized;;; +12112-9;LL2402-7;Stomach defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12112-9;LL2402-7;Stomach defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12112-9;LL2402-7;Stomach defects;LA19576-0;5;Dilated;;; +12112-9;LL2402-7;Stomach defects;LA19574-5;6;More specific code;;; +12114-5;LL2403-5;Thorax defects;LA9632-6;1;Not visualized;;; +12114-5;LL2403-5;Thorax defects;LA18997-9;2;Suboptimally visualized;;; +12114-5;LL2403-5;Thorax defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12114-5;LL2403-5;Thorax defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12114-5;LL2403-5;Thorax defects;LA19650-3;5;Hydrothorax;;; +12114-5;LL2403-5;Thorax defects;LA19651-1;6;Cystic adenomatoid malformation;;; +12114-5;LL2403-5;Thorax defects;LA19574-5;7;More specific code;;; +12116-0;LL2405-0;Umb cord defects;LA19655-2;1;Not observed;;; +12116-0;LL2405-0;Umb cord defects;LA19680-0;2;Three vessels;;; +12116-0;LL2405-0;Umb cord defects;LA19681-8;3;Two vessels;;; +12116-0;LL2405-0;Umb cord defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12116-0;LL2405-0;Umb cord defects;LA19574-5;5;More specific code;;; +12118-6;LL2406-8;Bladder updates;LA19655-2;1;Not observed;;; +12118-6;LL2406-8;Bladder updates;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12118-6;LL2406-8;Bladder updates;LA12748-2;3;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12118-6;LL2406-8;Bladder updates;LA19682-6;4;Full;;; +12118-6;LL2406-8;Bladder updates;LA19683-4;5;Empty;;; +12118-6;LL2406-8;Bladder updates;LA19589-3;6;Distended;;; +12118-6;LL2406-8;Bladder updates;LA19684-2;7;Thick-walled;;; +12118-6;LL2406-8;Bladder updates;LA19574-5;8;More specific code;;; +12120-2;LL2407-6;IVC defects;LA9632-6;1;Not visualized;;; +12120-2;LL2407-6;IVC defects;LA18997-9;2;Suboptimally visualized;;; +12120-2;LL2407-6;IVC defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12120-2;LL2407-6;IVC defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12120-2;LL2407-6;IVC defects;LA19652-9;5;Interrupted IVC;;; +12120-2;LL2407-6;IVC defects;LA19574-5;6;More specific code;;; +12122-8;LL2408-4;SVC defects;LA9632-6;1;Not visualized;;; +12122-8;LL2408-4;SVC defects;LA18997-9;2;Suboptimally visualized;;; +12122-8;LL2408-4;SVC defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12122-8;LL2408-4;SVC defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12122-8;LL2408-4;SVC defects;LA19653-7;5;Left SVC;;; +12122-8;LL2408-4;SVC defects;LA19574-5;6;More specific code;;; +12124-4;LL2409-2;VC defects;LA9632-6;1;Not visualized;;; +12124-4;LL2409-2;VC defects;LA18997-9;2;Suboptimally visualized;;; +12124-4;LL2409-2;VC defects;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +12124-4;LL2409-2;VC defects;LA12748-2;4;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +12124-4;LL2409-2;VC defects;LA19652-9;5;Interrupted IVC;;; +12124-4;LL2409-2;VC defects;LA19653-7;6;Left SVC;;; +12124-4;LL2409-2;VC defects;LA19574-5;7;More specific code;;; +12158-2;LL2442-3;US device class;LA19769-1;1;2-D;;; +12158-2;LL2442-3;US device class;LA19770-9;2;3-D;;; +12158-2;LL2442-3;US device class;LA19771-7;3;Doppler;;; +12158-2;LL2442-3;US device class;LA19772-5;4;Color doppler;;; +12245-7;LL2987-7;Pres/Not demon;LA9633-4;0;Present;52101004;Present (qualifier value);http://snomed.info/sct +12245-7;LL2987-7;Pres/Not demon;LA21362-1;1;Not demonstrated;;; +2809-2;LL2987-7;Pres/Not demon;LA9633-4;0;Present;52101004;Present (qualifier value);http://snomed.info/sct +2809-2;LL2987-7;Pres/Not demon;LA21362-1;1;Not demonstrated;;; +13532-7;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +13532-7;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +13532-7;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +77734-2;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +77734-2;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +77734-2;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +77735-9;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +77735-9;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +77735-9;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85549-4;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +85549-4;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +85549-4;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85550-2;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +85550-2;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +85550-2;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +88875-0;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +88875-0;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +88875-0;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +92834-1;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +92834-1;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +92834-1;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +92835-8;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +92835-8;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +92835-8;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +93979-3;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +93979-3;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +93979-3;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95406-5;LL3596-5;Detected|Not det|Inconcl;LA11882-0;1;Detected;;; +95406-5;LL3596-5;Detected|Not det|Inconcl;LA11883-8;2;Not detected;;; +95406-5;LL3596-5;Detected|Not det|Inconcl;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +14226-5;LL2287-2;Nocardia spp;LA19289-0;1;Nocardia asteroides;;; +14226-5;LL2287-2;Nocardia spp;LA19290-8;2;Nocardia brasiliensis;;; +14226-5;LL2287-2;Nocardia spp;LA19291-6;3;Nocardia caviae;;; +55096-2;LL2287-2;Nocardia spp;LA19289-0;1;Nocardia asteroides;;; +55096-2;LL2287-2;Nocardia spp;LA19290-8;2;Nocardia brasiliensis;;; +55096-2;LL2287-2;Nocardia spp;LA19291-6;3;Nocardia caviae;;; +14484-0;LL2108-0;Mycop/Urea;LA18629-8;1;Mycoplasma hominis;1290001;Mycoplasma hominis (organism);http://snomed.info/sct +14484-0;LL2108-0;Mycop/Urea;LA18630-6;2;Ureaplasma urealyticum;12006007;Ureaplasma urealyticum (organism);http://snomed.info/sct +14484-0;LL2108-0;Mycop/Urea;LA18631-4;3;Negative for Mycoplasma and Ureaplasma;;; +14485-7;LL2108-0;Mycop/Urea;LA18629-8;1;Mycoplasma hominis;1290001;Mycoplasma hominis (organism);http://snomed.info/sct +14485-7;LL2108-0;Mycop/Urea;LA18630-6;2;Ureaplasma urealyticum;12006007;Ureaplasma urealyticum (organism);http://snomed.info/sct +14485-7;LL2108-0;Mycop/Urea;LA18631-4;3;Negative for Mycoplasma and Ureaplasma;;; +14486-5;LL2108-0;Mycop/Urea;LA18629-8;1;Mycoplasma hominis;1290001;Mycoplasma hominis (organism);http://snomed.info/sct +14486-5;LL2108-0;Mycop/Urea;LA18630-6;2;Ureaplasma urealyticum;12006007;Ureaplasma urealyticum (organism);http://snomed.info/sct +14486-5;LL2108-0;Mycop/Urea;LA18631-4;3;Negative for Mycoplasma and Ureaplasma;;; +14487-3;LL2108-0;Mycop/Urea;LA18629-8;1;Mycoplasma hominis;1290001;Mycoplasma hominis (organism);http://snomed.info/sct +14487-3;LL2108-0;Mycop/Urea;LA18630-6;2;Ureaplasma urealyticum;12006007;Ureaplasma urealyticum (organism);http://snomed.info/sct +14487-3;LL2108-0;Mycop/Urea;LA18631-4;3;Negative for Mycoplasma and Ureaplasma;;; +687-4;LL2108-0;Mycop/Urea;LA18629-8;1;Mycoplasma hominis;1290001;Mycoplasma hominis (organism);http://snomed.info/sct +687-4;LL2108-0;Mycop/Urea;LA18630-6;2;Ureaplasma urealyticum;12006007;Ureaplasma urealyticum (organism);http://snomed.info/sct +687-4;LL2108-0;Mycop/Urea;LA18631-4;3;Negative for Mycoplasma and Ureaplasma;;; +14577-1;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +14577-1;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +14577-1;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +14577-1;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +14577-1;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +14577-1;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +14577-1;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +14577-1;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +19057-9;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +34474-7;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +44086-7;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +46268-9;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +50773-1;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +54417-1;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +77397-8;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +881-3;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +882-1;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +884-7;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +90039-9;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +90905-1;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +90906-9;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +93906-6;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21321-7;0;O Pos;278147001;Blood group O Rh(D) positive (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21322-5;1;O Neg;278148006;Blood group O Rh(D) negative (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21327-4;2;B Pos;278150003;Blood group B Rh(D) positive (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21328-2;3;B Neg;278153001;Blood group B Rh(D) negative (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21323-3;4;AB Pos;278151004;Blood group AB Rh(D) positive (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21324-1;5;AB Neg;278154007;Blood group AB Rh(D) negative (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21325-8;6;A Pos;278149003;Blood group A Rh(D) positive (finding);http://snomed.info/sct +93932-2;LL2972-9;ABORh;LA21326-6;7;A Neg;278152006;Blood group A Rh(D) negative (finding);http://snomed.info/sct +14578-9;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +14578-9;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +14578-9;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +14578-9;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +14579-7;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +14579-7;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +14579-7;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +14579-7;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +14580-5;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +14580-5;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +14580-5;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +14580-5;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +46270-5;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +46270-5;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +46270-5;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +46270-5;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +51892-8;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +51892-8;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +51892-8;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +51892-8;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +52793-7;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +52793-7;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +52793-7;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +52793-7;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +57743-7;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +57743-7;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +57743-7;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +57743-7;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +85504-9;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +85504-9;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +85504-9;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +85504-9;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +883-9;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +883-9;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +883-9;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +883-9;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +93905-8;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +93905-8;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +93905-8;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +93905-8;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +93931-4;LL2419-1;ABO group;LA19710-5;1;Group A;112144000;Blood group A (finding);http://snomed.info/sct +93931-4;LL2419-1;ABO group;LA19709-7;2;Group B;112149005;Blood group B (finding);http://snomed.info/sct +93931-4;LL2419-1;ABO group;LA19708-9;3;Group O;58460004;Blood group O (finding);http://snomed.info/sct +93931-4;LL2419-1;ABO group;LA28449-9;4;Group AB;;; +14725-6;LL943-2;Fluid type;LA13476-9;1;Pericardial fluid;;; +14725-6;LL943-2;Fluid type;LA13475-1;2;Peritoneal fluid;;; +14725-6;LL943-2;Fluid type;LA13478-5;3;Pleural fluid;;; +14725-6;LL943-2;Fluid type;LA13477-7;4;Synovial fluid;;; +14908-8;LL4424-9;Rh+|Rh-;LA27326-0;1;Rh+;;; +14908-8;LL4424-9;Rh+|Rh-;LA27325-2;2;Rh-;;; +85505-6;LL4424-9;Rh+|Rh-;LA27326-0;1;Rh+;;; +85505-6;LL4424-9;Rh+|Rh-;LA27325-2;2;Rh-;;; +14977-3;LL2432-4;Kappa/Lambda;LA19741-0;1;Kappa;;; +14977-3;LL2432-4;Kappa/Lambda;LA19742-8;2;Lambda;;; +74638-8;LL2432-4;Kappa/Lambda;LA19741-0;1;Kappa;;; +74638-8;LL2432-4;Kappa/Lambda;LA19742-8;2;Lambda;;; +74639-6;LL2432-4;Kappa/Lambda;LA19741-0;1;Kappa;;; +74639-6;LL2432-4;Kappa/Lambda;LA19742-8;2;Lambda;;; +74640-4;LL2432-4;Kappa/Lambda;LA19741-0;1;Kappa;;; +74640-4;LL2432-4;Kappa/Lambda;LA19742-8;2;Lambda;;; +74641-2;LL2432-4;Kappa/Lambda;LA19741-0;1;Kappa;;; +74641-2;LL2432-4;Kappa/Lambda;LA19742-8;2;Lambda;;; +74665-1;LL2432-4;Kappa/Lambda;LA19741-0;1;Kappa;;; +74665-1;LL2432-4;Kappa/Lambda;LA19742-8;2;Lambda;;; +74666-9;LL2432-4;Kappa/Lambda;LA19741-0;1;Kappa;;; +74666-9;LL2432-4;Kappa/Lambda;LA19742-8;2;Lambda;;; +15360-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +15360-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +15360-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +15360-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47393-4;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +47393-4;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47393-4;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +47393-4;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +47394-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +47394-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +47394-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +47394-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63375-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +63375-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +63375-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +63375-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72910-3;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72910-3;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72910-3;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72910-3;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72911-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72911-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72911-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72911-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72912-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72912-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72912-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72912-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72913-7;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72913-7;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72913-7;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72913-7;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72914-5;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72914-5;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72914-5;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72914-5;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72915-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72915-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72915-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72915-2;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72916-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72916-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72916-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72916-0;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72922-8;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +72922-8;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72922-8;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +72922-8;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81312-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +81312-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81312-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +81312-1;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81313-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA18996-1;1;Strong positive;;; +81313-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81313-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA19422-7;3;Weak positive;;; +81313-9;LL2329-2;Strong Pos|Pos|Weak Pos|Neg;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +15509-3;LL507-5;HL79008_Destination rationale;LA9522-9;0;Patient was transported to nearest facility for care of symptoms, complaints or both;;; +15509-3;LL507-5;HL79008_Destination rationale;LA9523-7;1;Patient was transported for the benefit of a preferred physician;;; +15509-3;LL507-5;HL79008_Destination rationale;LA9524-5;2;Patient was transported for the nearness of family members;;; +15509-3;LL507-5;HL79008_Destination rationale;LA9525-2;3;Patient was transported for the care of a specialist or for availability of specialized equipment;;; +15509-3;LL507-5;HL79008_Destination rationale;LA9526-0;4;Patient was transported due to the lack of appropriate facilities/specialist;;; +15509-3;LL507-5;HL79008_Destination rationale;LA9527-8;5;Patient was transported for the care of a trauma center;;; +15509-3;LL507-5;HL79008_Destination rationale;LA9528-6;6;Patient was transported for the care of a burn center;;; +15509-3;LL507-5;HL79008_Destination rationale;LA9529-4;7;Patient was transported for a special care unit NOS;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9530-2;0;abdominal pain / problems;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9531-0;1;airway obstruction;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9532-8;2;Allergic reaction;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9533-6;3;altered level of consciousness;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9534-4;4;Behavioral / psychiatric disorder;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9535-1;5;Cardiac arrest;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9536-9;6;cardiac rhythm disturbance;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9537-7;7;chest pain / discomfort;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9538-5;8;diabetic symptoms (hypoglycemia);;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9539-3;9;Electrocution;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9540-1;10;Hyperthermia;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9541-9;11;Hypothermia;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9542-7;12;hypovolemia / shock;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9543-5;13;inhalation injury (toxic gas);;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9544-3;14;obvious death;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9545-0;15;poisoning / drug ingestion;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9546-8;16;pregnancy / OB delivery;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9547-6;17;Respiratory arrest;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9548-4;18;Respiratory distress;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA7472-9;19;Seizure;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9550-0;20;sexual assault / rape;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9551-8;21;smoke inhalation;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9552-6;22;stings / venomous bites;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9553-4;23;Stroke/CVA;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9554-2;24;syncope / fainting;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9555-9;25;Traumatic injury;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9556-7;26;vaginal hemorrhage;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9557-5;27;unconsciousness or shock;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9558-3;28;severe hemorrhage;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9559-1;29;spinal injury;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9560-9;30;DOA;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9561-7;31;acute respiratory distress;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9562-5;32;restraining psychiatric patient;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9563-3;33;vehicle accident;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9564-1;34;cardiac incident;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9565-8;35;trauma other than vehicle;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9566-6;36;overdose/poisoning;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9567-4;37;bedbound;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9568-2;38;Burns;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9569-0;39;acute metabolic or endocrine;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9570-8;40;acute surgical emergency non-trauma;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9571-6;41;hemodynamic instability;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9572-4;42;acute infectious process;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9573-2;43;neurological/neurovascular;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9574-0;44;organ procurement;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA9575-7;45;accident, possible injury;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA4720-4;46;Not applicable;;; +15515-0;LL508-3;HL79010_Med reason-unsched trip;LA4489-6;47;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +15517-6;LL506-7;HL79007_Ambulance Trip Type;LA9518-7;0;initial trip;;; +15517-6;LL506-7;HL79007_Ambulance Trip Type;LA9519-5;1;return trip;;; +15517-6;LL506-7;HL79007_Ambulance Trip Type;LA9520-3;2;transfer trip;;; +15517-6;LL506-7;HL79007_Ambulance Trip Type;LA9521-1;3;round trip;;; +17576-0;LL2291-4;Shigella spp;LA19301-3;1;Shigella boydii;;; +17576-0;LL2291-4;Shigella spp;LA19300-5;2;Shigella flexneri;;; +17576-0;LL2291-4;Shigella spp;LA19299-9;3;Shigella dysenteriae;;; +17576-0;LL2291-4;Shigella spp;LA19302-1;4;Shigella sonnei;;; +20964-3;LL2291-4;Shigella spp;LA19301-3;1;Shigella boydii;;; +20964-3;LL2291-4;Shigella spp;LA19300-5;2;Shigella flexneri;;; +20964-3;LL2291-4;Shigella spp;LA19299-9;3;Shigella dysenteriae;;; +20964-3;LL2291-4;Shigella spp;LA19302-1;4;Shigella sonnei;;; +88586-3;LL2291-4;Shigella spp;LA19301-3;1;Shigella boydii;;; +88586-3;LL2291-4;Shigella spp;LA19300-5;2;Shigella flexneri;;; +88586-3;LL2291-4;Shigella spp;LA19299-9;3;Shigella dysenteriae;;; +88586-3;LL2291-4;Shigella spp;LA19302-1;4;Shigella sonnei;;; +18107-3;LL2443-1;Stress method;LA19773-3;1;Dobutamine stress;;; +18107-3;LL2443-1;Stress method;LA19774-1;2;Persantine;;; +18107-3;LL2443-1;Stress method;LA19775-8;3;Bicycle;;; +18107-3;LL2443-1;Stress method;LA19776-6;4;Hand ergonometer;;; +18107-3;LL2443-1;Stress method;LA19777-4;5;Treadmill;;; +18107-3;LL2443-1;Stress method;LA19778-2;6;Isopril;;; +18108-1;LL2434-0;Prosthetic valve type;LA19743-6;1;Mechanical;;; +18108-1;LL2434-0;Prosthetic valve type;LA19744-4;2;Bioprosthetic;;; +18108-1;LL2434-0;Prosthetic valve type;LA19745-1;3;Porcine;;; +18108-1;LL2434-0;Prosthetic valve type;LA19746-9;4;Bovine;;; +18109-9;LL2434-0;Prosthetic valve type;LA19743-6;1;Mechanical;;; +18109-9;LL2434-0;Prosthetic valve type;LA19744-4;2;Bioprosthetic;;; +18109-9;LL2434-0;Prosthetic valve type;LA19745-1;3;Porcine;;; +18109-9;LL2434-0;Prosthetic valve type;LA19746-9;4;Bovine;;; +18110-7;LL2434-0;Prosthetic valve type;LA19743-6;1;Mechanical;;; +18110-7;LL2434-0;Prosthetic valve type;LA19744-4;2;Bioprosthetic;;; +18110-7;LL2434-0;Prosthetic valve type;LA19745-1;3;Porcine;;; +18110-7;LL2434-0;Prosthetic valve type;LA19746-9;4;Bovine;;; +18111-5;LL2434-0;Prosthetic valve type;LA19743-6;1;Mechanical;;; +18111-5;LL2434-0;Prosthetic valve type;LA19744-4;2;Bioprosthetic;;; +18111-5;LL2434-0;Prosthetic valve type;LA19745-1;3;Porcine;;; +18111-5;LL2434-0;Prosthetic valve type;LA19746-9;4;Bovine;;; +18112-3;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +18112-3;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +18112-3;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +18112-3;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +18113-1;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +18113-1;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +18113-1;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +18113-1;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +18114-9;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +18114-9;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +18114-9;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +18114-9;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +18115-6;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +18115-6;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +18115-6;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +18115-6;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +32389-9;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32389-9;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +32389-9;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +32389-9;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +32390-7;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32390-7;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +32390-7;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +32390-7;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +32391-5;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32391-5;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +32391-5;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +32391-5;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +32392-3;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32392-3;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +32392-3;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +32392-3;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +32393-1;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32393-1;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +32393-1;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +32393-1;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +32491-3;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +32491-3;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +32491-3;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +32491-3;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +44974-4;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +44974-4;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +44974-4;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +44974-4;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +71369-3;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +71369-3;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +71369-3;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +71369-3;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +72357-7;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +72357-7;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +72357-7;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +72357-7;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +81431-9;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +81431-9;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +81431-9;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +81431-9;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +81432-7;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +81432-7;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +81432-7;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +81432-7;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +85093-3;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +85093-3;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +85093-3;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +85093-3;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +85096-6;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +85096-6;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +85096-6;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +85096-6;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +91900-1;LL2089-2;None|1+|2+|3+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +91900-1;LL2089-2;None|1+|2+|3+;LA11841-6;2;1+;;; +91900-1;LL2089-2;None|1+|2+|3+;LA11842-4;3;2+;;; +91900-1;LL2089-2;None|1+|2+|3+;LA11843-2;4;3+;;; +18116-4;LL1054-7;SWA;LA14108-7;1;Thinned;;; +18116-4;LL1054-7;SWA;LA14109-5;2;Fibrotic;;; +18116-4;LL1054-7;SWA;LA14110-3;3;Thickened;;; +18116-4;LL1054-7;SWA;LA14111-1;4;Ground glass;;; +18117-2;LL481-3;SWM;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +18117-2;LL481-3;SWM;LA9282-0;2;Mildly hypokinetic;;; +18117-2;LL481-3;SWM;LA9283-8;3;Hypokinetic;;; +18117-2;LL481-3;SWM;LA9284-6;4;Akinetic;;; +18117-2;LL481-3;SWM;LA9285-3;5;Dyskinetic;;; +18117-2;LL481-3;SWM;LA9286-1;6;Not scored;;; +18119-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18119-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18119-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18119-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18119-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18119-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18119-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18120-6;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18120-6;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18120-6;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18120-6;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18120-6;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18120-6;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18120-6;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18121-4;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18121-4;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18121-4;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18121-4;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18121-4;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18121-4;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18121-4;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18122-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18122-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18122-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18122-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18122-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18122-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18122-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18123-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18123-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18123-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18123-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18123-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18123-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18123-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18124-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18124-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18124-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18124-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18124-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18124-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18124-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18125-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18125-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18125-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18125-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18125-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18125-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18125-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18126-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18126-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18126-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18126-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18126-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18126-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18126-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18127-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18127-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18127-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18127-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18127-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18127-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18127-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18128-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18128-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18128-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18128-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18128-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18128-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18128-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18129-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18129-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18129-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18129-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18129-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18129-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18129-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18130-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18130-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18130-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18130-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18130-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18130-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18130-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18131-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18131-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18131-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18131-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18131-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18131-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18131-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18132-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18132-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18132-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18132-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18132-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18132-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18132-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18133-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18133-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18133-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18133-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18133-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18133-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18133-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18134-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +18134-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +18134-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +18134-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +18134-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +18134-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +18134-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78192-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78192-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78192-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78192-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78192-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78192-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78192-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78193-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78193-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78193-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78193-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78193-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78193-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78193-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78194-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78194-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78194-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78194-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78194-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78194-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78194-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78195-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78195-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78195-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78195-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78195-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78195-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78195-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78196-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78196-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78196-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78196-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78196-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78196-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78196-3;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78197-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78197-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78197-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78197-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78197-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78197-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78197-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78198-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78198-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78198-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78198-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78198-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78198-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78198-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78951-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78951-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78951-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78951-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78951-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78951-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78951-1;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78952-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78952-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78952-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78952-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78952-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78952-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78952-9;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78953-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78953-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78953-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78953-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78953-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78953-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78953-7;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78954-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78954-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78954-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78954-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78954-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78954-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78954-5;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78955-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78955-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78955-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78955-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78955-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78955-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78955-2;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78956-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78956-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78956-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78956-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78956-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78956-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78956-0;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +78957-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA24346-1;1;Normal or hyperkinetic;;; +78957-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9283-8;2;Hypokinetic;;; +78957-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9282-0;3;Mildly hypokinetic;;; +78957-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA28647-8;4;Severely hypokinetic;;; +78957-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9284-6;5;Akinetic;;; +78957-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA9285-3;6;Dyskinetic;;; +78957-8;LL3681-5;[ASE 2015] Nl or hyperkinetic|Hypo|Akin|Dyskin;LA11137-9;7;Unable to determine;;; +18289-9;LL717-0;RBC morph;LA11190-8;1;Acanthocytes;;; +18289-9;LL717-0;RBC morph;LA11220-3;2;Anisochromasia;;; +18289-9;LL717-0;RBC morph;LA11191-6;3;Anisocytosis;57241006;Anisocytosis (morphologic abnormality);http://snomed.info/sct +18289-9;LL717-0;RBC morph;LA11221-1;4;Anulocytes;;; +18289-9;LL717-0;RBC morph;LA11226-0;5;Basophilic stippling;;; +18289-9;LL717-0;RBC morph;LA11227-8;6;Basophilic stippling coarse;;; +18289-9;LL717-0;RBC morph;LA11228-6;7;Basophilic stippling fine;;; +18289-9;LL717-0;RBC morph;LA11192-4;8;Bite cells;;; +18289-9;LL717-0;RBC morph;LA11193-2;9;Bizarre cells;;; +18289-9;LL717-0;RBC morph;LA11194-0;10;Blister cells;;; +18289-9;LL717-0;RBC morph;LA11195-7;11;Burr cells;;; +18289-9;LL717-0;RBC morph;LA11229-4;12;Cabot rings;;; +18289-9;LL717-0;RBC morph;LA11196-5;13;Dacrocytes;;; +18289-9;LL717-0;RBC morph;LA11197-3;14;Dyserythropoieisis;;; +18289-9;LL717-0;RBC morph;LA11198-1;15;Elliptocytes;;; +18289-9;LL717-0;RBC morph;LA11200-5;16;Erythrocytes.filamented;;; +18289-9;LL717-0;RBC morph;LA11201-3;17;Fragments;;; +18289-9;LL717-0;RBC morph;LA11230-2;18;Heinz bodies;;; +18289-9;LL717-0;RBC morph;LA11202-1;19;Helmet cells;;; +18289-9;LL717-0;RBC morph;LA11231-0;20;Hemoglobin C crystals;;; +18289-9;LL717-0;RBC morph;LA11232-8;21;Howell-Jolly bodies;;; +18289-9;LL717-0;RBC morph;LA11222-9;22;Hyperchromic;;; +18289-9;LL717-0;RBC morph;LA11223-7;23;Hypochromia;;; +18289-9;LL717-0;RBC morph;LA11203-9;24;Irregularly contracted cells;;; +18289-9;LL717-0;RBC morph;LA11216-1;25;Macrocytes;;; +18289-9;LL717-0;RBC morph;LA11217-9;26;Macrocytes.oval;;; +18289-9;LL717-0;RBC morph;LA11218-7;27;Microcytes;;; +18289-9;LL717-0;RBC morph;LA11224-5;28;Normochromic;;; +18289-9;LL717-0;RBC morph;LA11219-5;29;Normocytic;;; +18289-9;LL717-0;RBC morph;LA11199-9;30;Ovalocytes;;; +18289-9;LL717-0;RBC morph;LA11233-6;31;Pappenheimer bodies;;; +18289-9;LL717-0;RBC morph;LA11204-7;32;Pencil cells;;; +18289-9;LL717-0;RBC morph;LA11205-4;33;Poikilocytosis;;; +18289-9;LL717-0;RBC morph;LA11225-2;34;Polychromasia;;; +18289-9;LL717-0;RBC morph;LA11206-2;35;Prekeratocytes;;; +18289-9;LL717-0;RBC morph;LA11207-0;36;Pyknosis;;; +18289-9;LL717-0;RBC morph;LA11208-8;37;Rouleaux;;; +18289-9;LL717-0;RBC morph;LA11209-6;38;Schistocytes;;; +18289-9;LL717-0;RBC morph;LA11210-4;39;Sickle cells;;; +18289-9;LL717-0;RBC morph;LA11211-2;40;Siderocytes;;; +18289-9;LL717-0;RBC morph;LA11212-0;41;Spherocytes;;; +18289-9;LL717-0;RBC morph;LA11213-8;42;Spherocytes.micro;;; +18289-9;LL717-0;RBC morph;LA11214-6;43;Stomatocytes;;; +18289-9;LL717-0;RBC morph;LA11215-3;44;Target cells;;; +18290-7;LL717-0;RBC morph;LA11190-8;1;Acanthocytes;;; +18290-7;LL717-0;RBC morph;LA11220-3;2;Anisochromasia;;; +18290-7;LL717-0;RBC morph;LA11191-6;3;Anisocytosis;57241006;Anisocytosis (morphologic abnormality);http://snomed.info/sct +18290-7;LL717-0;RBC morph;LA11221-1;4;Anulocytes;;; +18290-7;LL717-0;RBC morph;LA11226-0;5;Basophilic stippling;;; +18290-7;LL717-0;RBC morph;LA11227-8;6;Basophilic stippling coarse;;; +18290-7;LL717-0;RBC morph;LA11228-6;7;Basophilic stippling fine;;; +18290-7;LL717-0;RBC morph;LA11192-4;8;Bite cells;;; +18290-7;LL717-0;RBC morph;LA11193-2;9;Bizarre cells;;; +18290-7;LL717-0;RBC morph;LA11194-0;10;Blister cells;;; +18290-7;LL717-0;RBC morph;LA11195-7;11;Burr cells;;; +18290-7;LL717-0;RBC morph;LA11229-4;12;Cabot rings;;; +18290-7;LL717-0;RBC morph;LA11196-5;13;Dacrocytes;;; +18290-7;LL717-0;RBC morph;LA11197-3;14;Dyserythropoieisis;;; +18290-7;LL717-0;RBC morph;LA11198-1;15;Elliptocytes;;; +18290-7;LL717-0;RBC morph;LA11200-5;16;Erythrocytes.filamented;;; +18290-7;LL717-0;RBC morph;LA11201-3;17;Fragments;;; +18290-7;LL717-0;RBC morph;LA11230-2;18;Heinz bodies;;; +18290-7;LL717-0;RBC morph;LA11202-1;19;Helmet cells;;; +18290-7;LL717-0;RBC morph;LA11231-0;20;Hemoglobin C crystals;;; +18290-7;LL717-0;RBC morph;LA11232-8;21;Howell-Jolly bodies;;; +18290-7;LL717-0;RBC morph;LA11222-9;22;Hyperchromic;;; +18290-7;LL717-0;RBC morph;LA11223-7;23;Hypochromia;;; +18290-7;LL717-0;RBC morph;LA11203-9;24;Irregularly contracted cells;;; +18290-7;LL717-0;RBC morph;LA11216-1;25;Macrocytes;;; +18290-7;LL717-0;RBC morph;LA11217-9;26;Macrocytes.oval;;; +18290-7;LL717-0;RBC morph;LA11218-7;27;Microcytes;;; +18290-7;LL717-0;RBC morph;LA11224-5;28;Normochromic;;; +18290-7;LL717-0;RBC morph;LA11219-5;29;Normocytic;;; +18290-7;LL717-0;RBC morph;LA11199-9;30;Ovalocytes;;; +18290-7;LL717-0;RBC morph;LA11233-6;31;Pappenheimer bodies;;; +18290-7;LL717-0;RBC morph;LA11204-7;32;Pencil cells;;; +18290-7;LL717-0;RBC morph;LA11205-4;33;Poikilocytosis;;; +18290-7;LL717-0;RBC morph;LA11225-2;34;Polychromasia;;; +18290-7;LL717-0;RBC morph;LA11206-2;35;Prekeratocytes;;; +18290-7;LL717-0;RBC morph;LA11207-0;36;Pyknosis;;; +18290-7;LL717-0;RBC morph;LA11208-8;37;Rouleaux;;; +18290-7;LL717-0;RBC morph;LA11209-6;38;Schistocytes;;; +18290-7;LL717-0;RBC morph;LA11210-4;39;Sickle cells;;; +18290-7;LL717-0;RBC morph;LA11211-2;40;Siderocytes;;; +18290-7;LL717-0;RBC morph;LA11212-0;41;Spherocytes;;; +18290-7;LL717-0;RBC morph;LA11213-8;42;Spherocytes.micro;;; +18290-7;LL717-0;RBC morph;LA11214-6;43;Stomatocytes;;; +18290-7;LL717-0;RBC morph;LA11215-3;44;Target cells;;; +57960-7;LL717-0;RBC morph;LA11190-8;1;Acanthocytes;;; +57960-7;LL717-0;RBC morph;LA11220-3;2;Anisochromasia;;; +57960-7;LL717-0;RBC morph;LA11191-6;3;Anisocytosis;57241006;Anisocytosis (morphologic abnormality);http://snomed.info/sct +57960-7;LL717-0;RBC morph;LA11221-1;4;Anulocytes;;; +57960-7;LL717-0;RBC morph;LA11226-0;5;Basophilic stippling;;; +57960-7;LL717-0;RBC morph;LA11227-8;6;Basophilic stippling coarse;;; +57960-7;LL717-0;RBC morph;LA11228-6;7;Basophilic stippling fine;;; +57960-7;LL717-0;RBC morph;LA11192-4;8;Bite cells;;; +57960-7;LL717-0;RBC morph;LA11193-2;9;Bizarre cells;;; +57960-7;LL717-0;RBC morph;LA11194-0;10;Blister cells;;; +57960-7;LL717-0;RBC morph;LA11195-7;11;Burr cells;;; +57960-7;LL717-0;RBC morph;LA11229-4;12;Cabot rings;;; +57960-7;LL717-0;RBC morph;LA11196-5;13;Dacrocytes;;; +57960-7;LL717-0;RBC morph;LA11197-3;14;Dyserythropoieisis;;; +57960-7;LL717-0;RBC morph;LA11198-1;15;Elliptocytes;;; +57960-7;LL717-0;RBC morph;LA11200-5;16;Erythrocytes.filamented;;; +57960-7;LL717-0;RBC morph;LA11201-3;17;Fragments;;; +57960-7;LL717-0;RBC morph;LA11230-2;18;Heinz bodies;;; +57960-7;LL717-0;RBC morph;LA11202-1;19;Helmet cells;;; +57960-7;LL717-0;RBC morph;LA11231-0;20;Hemoglobin C crystals;;; +57960-7;LL717-0;RBC morph;LA11232-8;21;Howell-Jolly bodies;;; +57960-7;LL717-0;RBC morph;LA11222-9;22;Hyperchromic;;; +57960-7;LL717-0;RBC morph;LA11223-7;23;Hypochromia;;; +57960-7;LL717-0;RBC morph;LA11203-9;24;Irregularly contracted cells;;; +57960-7;LL717-0;RBC morph;LA11216-1;25;Macrocytes;;; +57960-7;LL717-0;RBC morph;LA11217-9;26;Macrocytes.oval;;; +57960-7;LL717-0;RBC morph;LA11218-7;27;Microcytes;;; +57960-7;LL717-0;RBC morph;LA11224-5;28;Normochromic;;; +57960-7;LL717-0;RBC morph;LA11219-5;29;Normocytic;;; +57960-7;LL717-0;RBC morph;LA11199-9;30;Ovalocytes;;; +57960-7;LL717-0;RBC morph;LA11233-6;31;Pappenheimer bodies;;; +57960-7;LL717-0;RBC morph;LA11204-7;32;Pencil cells;;; +57960-7;LL717-0;RBC morph;LA11205-4;33;Poikilocytosis;;; +57960-7;LL717-0;RBC morph;LA11225-2;34;Polychromasia;;; +57960-7;LL717-0;RBC morph;LA11206-2;35;Prekeratocytes;;; +57960-7;LL717-0;RBC morph;LA11207-0;36;Pyknosis;;; +57960-7;LL717-0;RBC morph;LA11208-8;37;Rouleaux;;; +57960-7;LL717-0;RBC morph;LA11209-6;38;Schistocytes;;; +57960-7;LL717-0;RBC morph;LA11210-4;39;Sickle cells;;; +57960-7;LL717-0;RBC morph;LA11211-2;40;Siderocytes;;; +57960-7;LL717-0;RBC morph;LA11212-0;41;Spherocytes;;; +57960-7;LL717-0;RBC morph;LA11213-8;42;Spherocytes.micro;;; +57960-7;LL717-0;RBC morph;LA11214-6;43;Stomatocytes;;; +57960-7;LL717-0;RBC morph;LA11215-3;44;Target cells;;; +6742-1;LL717-0;RBC morph;LA11190-8;1;Acanthocytes;;; +6742-1;LL717-0;RBC morph;LA11220-3;2;Anisochromasia;;; +6742-1;LL717-0;RBC morph;LA11191-6;3;Anisocytosis;57241006;Anisocytosis (morphologic abnormality);http://snomed.info/sct +6742-1;LL717-0;RBC morph;LA11221-1;4;Anulocytes;;; +6742-1;LL717-0;RBC morph;LA11226-0;5;Basophilic stippling;;; +6742-1;LL717-0;RBC morph;LA11227-8;6;Basophilic stippling coarse;;; +6742-1;LL717-0;RBC morph;LA11228-6;7;Basophilic stippling fine;;; +6742-1;LL717-0;RBC morph;LA11192-4;8;Bite cells;;; +6742-1;LL717-0;RBC morph;LA11193-2;9;Bizarre cells;;; +6742-1;LL717-0;RBC morph;LA11194-0;10;Blister cells;;; +6742-1;LL717-0;RBC morph;LA11195-7;11;Burr cells;;; +6742-1;LL717-0;RBC morph;LA11229-4;12;Cabot rings;;; +6742-1;LL717-0;RBC morph;LA11196-5;13;Dacrocytes;;; +6742-1;LL717-0;RBC morph;LA11197-3;14;Dyserythropoieisis;;; +6742-1;LL717-0;RBC morph;LA11198-1;15;Elliptocytes;;; +6742-1;LL717-0;RBC morph;LA11200-5;16;Erythrocytes.filamented;;; +6742-1;LL717-0;RBC morph;LA11201-3;17;Fragments;;; +6742-1;LL717-0;RBC morph;LA11230-2;18;Heinz bodies;;; +6742-1;LL717-0;RBC morph;LA11202-1;19;Helmet cells;;; +6742-1;LL717-0;RBC morph;LA11231-0;20;Hemoglobin C crystals;;; +6742-1;LL717-0;RBC morph;LA11232-8;21;Howell-Jolly bodies;;; +6742-1;LL717-0;RBC morph;LA11222-9;22;Hyperchromic;;; +6742-1;LL717-0;RBC morph;LA11223-7;23;Hypochromia;;; +6742-1;LL717-0;RBC morph;LA11203-9;24;Irregularly contracted cells;;; +6742-1;LL717-0;RBC morph;LA11216-1;25;Macrocytes;;; +6742-1;LL717-0;RBC morph;LA11217-9;26;Macrocytes.oval;;; +6742-1;LL717-0;RBC morph;LA11218-7;27;Microcytes;;; +6742-1;LL717-0;RBC morph;LA11224-5;28;Normochromic;;; +6742-1;LL717-0;RBC morph;LA11219-5;29;Normocytic;;; +6742-1;LL717-0;RBC morph;LA11199-9;30;Ovalocytes;;; +6742-1;LL717-0;RBC morph;LA11233-6;31;Pappenheimer bodies;;; +6742-1;LL717-0;RBC morph;LA11204-7;32;Pencil cells;;; +6742-1;LL717-0;RBC morph;LA11205-4;33;Poikilocytosis;;; +6742-1;LL717-0;RBC morph;LA11225-2;34;Polychromasia;;; +6742-1;LL717-0;RBC morph;LA11206-2;35;Prekeratocytes;;; +6742-1;LL717-0;RBC morph;LA11207-0;36;Pyknosis;;; +6742-1;LL717-0;RBC morph;LA11208-8;37;Rouleaux;;; +6742-1;LL717-0;RBC morph;LA11209-6;38;Schistocytes;;; +6742-1;LL717-0;RBC morph;LA11210-4;39;Sickle cells;;; +6742-1;LL717-0;RBC morph;LA11211-2;40;Siderocytes;;; +6742-1;LL717-0;RBC morph;LA11212-0;41;Spherocytes;;; +6742-1;LL717-0;RBC morph;LA11213-8;42;Spherocytes.micro;;; +6742-1;LL717-0;RBC morph;LA11214-6;43;Stomatocytes;;; +6742-1;LL717-0;RBC morph;LA11215-3;44;Target cells;;; +18396-2;LL3207-9;Reac/Non-reac/Indet;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +18396-2;LL3207-9;Reac/Non-reac/Indet;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +18396-2;LL3207-9;Reac/Non-reac/Indet;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +24116-6;LL3207-9;Reac/Non-reac/Indet;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +24116-6;LL3207-9;Reac/Non-reac/Indet;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +24116-6;LL3207-9;Reac/Non-reac/Indet;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +24119-0;LL3207-9;Reac/Non-reac/Indet;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +24119-0;LL3207-9;Reac/Non-reac/Indet;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +24119-0;LL3207-9;Reac/Non-reac/Indet;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +40678-5;LL3207-9;Reac/Non-reac/Indet;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +40678-5;LL3207-9;Reac/Non-reac/Indet;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +40678-5;LL3207-9;Reac/Non-reac/Indet;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +77741-7;LL3207-9;Reac/Non-reac/Indet;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +77741-7;LL3207-9;Reac/Non-reac/Indet;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +77741-7;LL3207-9;Reac/Non-reac/Indet;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +88453-6;LL3207-9;Reac/Non-reac/Indet;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +88453-6;LL3207-9;Reac/Non-reac/Indet;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +88453-6;LL3207-9;Reac/Non-reac/Indet;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +18589-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +18589-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +18591-8;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +18591-8;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +18592-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +18592-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +18593-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +18593-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +18649-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +18649-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +18650-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +18650-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +18672-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +18672-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27495-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27495-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27496-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27496-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27543-8;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27543-8;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27544-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27544-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27565-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27565-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27566-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27566-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27616-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27616-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27617-0;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27617-0;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27679-0;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27679-0;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27680-8;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27680-8;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27718-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27718-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27719-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27719-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27769-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27769-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +27770-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +27770-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +29174-0;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +29174-0;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +29176-5;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +29176-5;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +30977-3;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +30977-3;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39158-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39158-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39160-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39160-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39238-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39238-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39240-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39240-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39241-5;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39241-5;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39242-3;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39242-3;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39243-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39243-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39244-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39244-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39246-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39246-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39247-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39247-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39248-0;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39248-0;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39252-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39252-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39253-0;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39253-0;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39254-8;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39254-8;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39278-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39278-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39279-5;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39279-5;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39288-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39288-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +73776-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +73776-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74041-5;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74041-5;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74186-8;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74186-8;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74199-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74199-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79726-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79726-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79727-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79727-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +80985-5;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80985-5;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83847-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83847-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83848-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83848-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84296-3;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84296-3;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84297-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84297-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84298-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84298-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84301-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84301-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85272-3;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85272-3;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +86371-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86371-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +86646-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86646-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +86654-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86654-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +86655-8;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86655-8;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +87295-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87295-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +87516-1;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87516-1;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +87517-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87517-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +87518-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87518-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +87519-5;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87519-5;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88073-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88073-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88075-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88075-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88087-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88087-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88091-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88091-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88103-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88103-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88108-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88108-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88239-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88239-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88669-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88669-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89013-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89013-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +92256-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +92256-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +92277-3;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +92277-3;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93257-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93257-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93257-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93257-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93258-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93258-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93258-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93258-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93486-9;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93486-9;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93487-7;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93487-7;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +94034-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +94034-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +94035-3;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +94035-3;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +94069-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +94069-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +94072-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +94072-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95044-4;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95044-4;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95415-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95415-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95547-6;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95547-6;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96770-3;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96770-3;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96983-2;LL365-8;[HL7-0136] Yes|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96983-2;LL365-8;[HL7-0136] Yes|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +18609-8;LL696-6;HL7_route;LA11235-1;1;Chew, oral;;; +18609-8;LL696-6;HL7_route;LA11236-9;2;Diffusion, extracorporeal;;; +18609-8;LL696-6;HL7_route;LA11237-7;3;Diffusion, hemodialysis;;; +18609-8;LL696-6;HL7_route;LA11238-5;4;Diffusion, transdermal;;; +18609-8;LL696-6;HL7_route;LA11239-3;5;Dissolve, oral;;; +18609-8;LL696-6;HL7_route;LA11240-1;6;Dissolve, sublingual;;; +18609-8;LL696-6;HL7_route;LA11241-9;7;Douche, vaginal;;; +18609-8;LL696-6;HL7_route;LA11242-7;8;Electro-osmosis;;; +18609-8;LL696-6;HL7_route;LA11243-5;9;Enema, rectal;;; +18609-8;LL696-6;HL7_route;LA11244-3;10;Enema, rectal retention;;; +18609-8;LL696-6;HL7_route;LA11245-0;11;Flush, intravenous catheter;;; +18609-8;LL696-6;HL7_route;LA11246-8;12;Gargle;;; +18609-8;LL696-6;HL7_route;LA11247-6;13;Immersion (soak);;; +18609-8;LL696-6;HL7_route;LA11248-4;14;Implantation, intradermal;;; +18609-8;LL696-6;HL7_route;LA11249-2;15;Implantation, intravitreal;;; +18609-8;LL696-6;HL7_route;LA11250-0;16;Implantation, subcutaneous;;; +18609-8;LL696-6;HL7_route;LA11251-8;17;Infusion, epidural;;; +18609-8;LL696-6;HL7_route;LA11252-6;18;Infusion, intraarterial catheter;;; +18609-8;LL696-6;HL7_route;LA11253-4;19;Infusion, intracardiac;;; +18609-8;LL696-6;HL7_route;LA11254-2;20;Infusion, intracoronary;;; +18609-8;LL696-6;HL7_route;LA11255-9;21;Infusion, intraosseous, continuous;;; +18609-8;LL696-6;HL7_route;LA11256-7;22;Infusion, intrathecal;;; +18609-8;LL696-6;HL7_route;LA11257-5;23;Infusion, intravascular;;; +18609-8;LL696-6;HL7_route;LA11258-3;24;Infusion, intravenous;;; +18609-8;LL696-6;HL7_route;LA11259-1;25;Infusion, intravenous catheter;;; +18609-8;LL696-6;HL7_route;LA11260-9;26;Infusion, intravenous catheter, continuous;;; +18609-8;LL696-6;HL7_route;LA11261-7;27;Infusion, intravenous catheter, intermittent;;; +18609-8;LL696-6;HL7_route;LA11262-5;28;Infusion, intravenous catheter, pca pump;;; +18609-8;LL696-6;HL7_route;LA11263-3;29;Infusion, subcutaneous;;; +18609-8;LL696-6;HL7_route;LA11264-1;30;Inhalation, intermittent positive pressure breathing (ippb);;; +18609-8;LL696-6;HL7_route;LA11265-8;31;Inhalation, nasal;;; +18609-8;LL696-6;HL7_route;LA11266-6;32;Inhalation, nasal cannula;;; +18609-8;LL696-6;HL7_route;LA11268-2;34;Inhalation, nebulization;;; +18609-8;LL696-6;HL7_route;LA11269-0;35;Inhalation, nebulization, nasal;;; +18609-8;LL696-6;HL7_route;LA11270-8;36;Inhalation, nebulization, oral;;; +18609-8;LL696-6;HL7_route;LA11271-6;37;Inhalation, oral intermittent flow;;; +18609-8;LL696-6;HL7_route;LA11272-4;38;Inhalation, oral rebreather mask;;; +18609-8;LL696-6;HL7_route;LA11273-2;39;Inhalation, respiratory;;; +18609-8;LL696-6;HL7_route;LA11274-0;40;Inhalation, tracheostomy;;; +18609-8;LL696-6;HL7_route;LA11275-7;41;Inhalation, ventilator;;; +18609-8;LL696-6;HL7_route;LA11276-5;42;Inhalation, ventimask;;; +18609-8;LL696-6;HL7_route;LA11277-3;43;Injection, amniotic fluid;;; +18609-8;LL696-6;HL7_route;LA11278-1;44;Injection, biliary tract;;; +18609-8;LL696-6;HL7_route;LA11279-9;45;Injection, cervical;;; +18609-8;LL696-6;HL7_route;LA11280-7;46;Injection, endosinusial;;; +18609-8;LL696-6;HL7_route;LA11281-5;47;Injection, epidural;;; +18609-8;LL696-6;HL7_route;LA11282-3;48;Injection, epidural, push;;; +18609-8;LL696-6;HL7_route;LA11283-1;49;Injection, epidural, slow push;;; +18609-8;LL696-6;HL7_route;LA11284-9;50;Injection, extra-amniotic;;; +18609-8;LL696-6;HL7_route;LA11285-6;51;Injection, extracorporeal;;; +18609-8;LL696-6;HL7_route;LA11286-4;52;Injection, for cholangiography;;; +18609-8;LL696-6;HL7_route;LA11287-2;53;Injection, gastric button;;; +18609-8;LL696-6;HL7_route;LA11288-0;54;Injection, gingival;;; +18609-8;LL696-6;HL7_route;LA11289-8;55;Injection, hemodialysis port;;; +18609-8;LL696-6;HL7_route;LA11290-6;56;Injection, insulin pump;;; +18609-8;LL696-6;HL7_route;LA11291-4;57;Injection, interameningeal;;; +18609-8;LL696-6;HL7_route;LA11292-2;58;Injection, interstitial;;; +18609-8;LL696-6;HL7_route;LA11293-0;59;Injection, intra-abdominal;;; +18609-8;LL696-6;HL7_route;LA11294-8;60;Injection, intraarterial;;; +18609-8;LL696-6;HL7_route;LA11295-5;61;Injection, intraarterial, push;;; +18609-8;LL696-6;HL7_route;LA11296-3;62;Injection, intraarterial, slow push;;; +18609-8;LL696-6;HL7_route;LA11297-1;63;Injection, intraarticular;;; +18609-8;LL696-6;HL7_route;LA11298-9;64;Injection, intrabursal;;; +18609-8;LL696-6;HL7_route;LA11299-7;65;Injection, intracardiac;;; +18609-8;LL696-6;HL7_route;LA11300-3;66;Injection, intracardiac, push;;; +18609-8;LL696-6;HL7_route;LA11301-1;67;Injection, intracardiac, rapid push;;; +18609-8;LL696-6;HL7_route;LA11302-9;68;Injection, intracardiac, slow push;;; +18609-8;LL696-6;HL7_route;LA11303-7;69;Injection, intracartilaginous;;; +18609-8;LL696-6;HL7_route;LA11304-5;70;Injection, intracaudal;;; +18609-8;LL696-6;HL7_route;LA11305-2;71;Injection, intracavernous;;; +18609-8;LL696-6;HL7_route;LA11306-0;72;Injection, intracavitary;;; +18609-8;LL696-6;HL7_route;LA11307-8;73;Injection, intracerebral;;; +18609-8;LL696-6;HL7_route;LA11308-6;74;Injection, intracervical (uterus);;; +18609-8;LL696-6;HL7_route;LA11309-4;75;Injection, intracisternal;;; +18609-8;LL696-6;HL7_route;LA11310-2;76;Injection, intracoronary;;; +18609-8;LL696-6;HL7_route;LA11311-0;77;Injection, intracoronary, push;;; +18609-8;LL696-6;HL7_route;LA11312-8;78;Injection, intracorpus cavernosum;;; +18609-8;LL696-6;HL7_route;LA11313-6;79;Injection, intradermal;;; +18609-8;LL696-6;HL7_route;LA11314-4;80;Injection, intradiscal;;; +18609-8;LL696-6;HL7_route;LA11315-1;81;Injection, intraductal;;; +18609-8;LL696-6;HL7_route;LA11316-9;82;Injection, intradural;;; +18609-8;LL696-6;HL7_route;LA11317-7;83;Injection, intraepidermal;;; +18609-8;LL696-6;HL7_route;LA11318-5;84;Injection, intraepithelial;;; +18609-8;LL696-6;HL7_route;LA11319-3;85;Injection, intralesional;;; +18609-8;LL696-6;HL7_route;LA11320-1;86;Injection, intraluminal;;; +18609-8;LL696-6;HL7_route;LA11321-9;87;Injection, intralymphatic;;; +18609-8;LL696-6;HL7_route;LA11322-7;88;Injection, intramedullary;;; +18609-8;LL696-6;HL7_route;LA11323-5;89;Injection, intramuscular;;; +18609-8;LL696-6;HL7_route;LA11324-3;90;Injection, intramuscular, deep;;; +18609-8;LL696-6;HL7_route;LA11325-0;91;Injection, intramuscular, z track;;; +18609-8;LL696-6;HL7_route;LA11326-8;92;Injection, intraocular;;; +18609-8;LL696-6;HL7_route;LA11327-6;93;Injection, intraosseous;;; +18609-8;LL696-6;HL7_route;LA11328-4;94;Injection, intraovarian;;; +18609-8;LL696-6;HL7_route;LA11329-2;95;Injection, intrapericardial;;; +18609-8;LL696-6;HL7_route;LA11330-0;96;Injection, intraperitoneal;;; +18609-8;LL696-6;HL7_route;LA11331-8;97;Injection, intrapleural;;; +18609-8;LL696-6;HL7_route;LA11332-6;98;Injection, intraprostatic;;; +18609-8;LL696-6;HL7_route;LA11333-4;99;Injection, intrapulmonary;;; +18609-8;LL696-6;HL7_route;LA11334-2;100;Injection, intraspinal;;; +18609-8;LL696-6;HL7_route;LA11335-9;101;Injection, intrasternal;;; +18609-8;LL696-6;HL7_route;LA11336-7;102;Injection, intrasynovial;;; +18609-8;LL696-6;HL7_route;LA11337-5;103;Injection, intratendinous;;; +18609-8;LL696-6;HL7_route;LA11338-3;104;Injection, intratesticular;;; +18609-8;LL696-6;HL7_route;LA11339-1;105;Injection, intrathecal;;; +18609-8;LL696-6;HL7_route;LA11340-9;106;Injection, intrathoracic;;; +18609-8;LL696-6;HL7_route;LA11341-7;107;Injection, intratubular;;; +18609-8;LL696-6;HL7_route;LA11342-5;108;Injection, intratumor;;; +18609-8;LL696-6;HL7_route;LA11343-3;109;Injection, intratympanic;;; +18609-8;LL696-6;HL7_route;LA11344-1;110;Injection, intraureteral, retrograde;;; +18609-8;LL696-6;HL7_route;LA11345-8;111;Injection, intrauterine;;; +18609-8;LL696-6;HL7_route;LA11346-6;112;Injection, intravascular;;; +18609-8;LL696-6;HL7_route;LA11347-4;113;Injection, intravenous;;; +18609-8;LL696-6;HL7_route;LA11348-2;114;Injection, intravenous, bolus;;; +18609-8;LL696-6;HL7_route;LA11349-0;115;Injection, intravenous, push;;; +18609-8;LL696-6;HL7_route;LA11350-8;116;Injection, intravenous, rapid push;;; +18609-8;LL696-6;HL7_route;LA11351-6;117;Injection, intravenous, slow push;;; +18609-8;LL696-6;HL7_route;LA11352-4;118;Injection, intraventricular (heart);;; +18609-8;LL696-6;HL7_route;LA11353-2;119;Injection, intravesicle;;; +18609-8;LL696-6;HL7_route;LA11354-0;120;Injection, intravitreal;;; +18609-8;LL696-6;HL7_route;LA11355-7;121;Injection, paranasal sinuses;;; +18609-8;LL696-6;HL7_route;LA11356-5;122;Injection, parenteral;;; +18609-8;LL696-6;HL7_route;LA11357-3;123;Injection, periarticular;;; +18609-8;LL696-6;HL7_route;LA11358-1;124;Injection, peridural;;; +18609-8;LL696-6;HL7_route;LA11359-9;125;Injection, perineural;;; +18609-8;LL696-6;HL7_route;LA11360-7;126;Injection, periodontal;;; +18609-8;LL696-6;HL7_route;LA11361-5;127;Injection, peritoneal dialysis port;;; +18609-8;LL696-6;HL7_route;LA11362-3;128;Injection, retrobulbar;;; +18609-8;LL696-6;HL7_route;LA11363-1;129;Injection, soft tissue;;; +18609-8;LL696-6;HL7_route;LA11364-9;130;Injection, subarachnoid;;; +18609-8;LL696-6;HL7_route;LA11365-6;131;Injection, subconjunctival;;; +18609-8;LL696-6;HL7_route;LA11366-4;132;Injection, subcutaneous;;; +18609-8;LL696-6;HL7_route;LA11367-2;133;Injection, sublesional;;; +18609-8;LL696-6;HL7_route;LA11368-0;134;Injection, submucosal;;; +18609-8;LL696-6;HL7_route;LA11369-8;135;Injection, transplacental;;; +18609-8;LL696-6;HL7_route;LA11370-6;136;Injection, transtracheal;;; +18609-8;LL696-6;HL7_route;LA11371-4;137;Injection, ureteral;;; +18609-8;LL696-6;HL7_route;LA11372-2;138;Injection, urethral;;; +18609-8;LL696-6;HL7_route;LA11373-0;139;Injection, urinary bladder;;; +18609-8;LL696-6;HL7_route;LA11374-8;140;Insertion, cervical (uterine);;; +18609-8;LL696-6;HL7_route;LA11375-5;141;Insertion, intraocular, surgical;;; +18609-8;LL696-6;HL7_route;LA11376-3;142;Insertion, intrauterine;;; +18609-8;LL696-6;HL7_route;LA11377-1;143;Insertion, lacrimal puncta;;; +18609-8;LL696-6;HL7_route;LA11378-9;144;Insertion, rectal;;; +18609-8;LL696-6;HL7_route;LA11379-7;145;Insertion, subcutaneous, surgical;;; +18609-8;LL696-6;HL7_route;LA11380-5;146;Insertion, urethral;;; +18609-8;LL696-6;HL7_route;LA11381-3;147;Insertion, vaginal;;; +18609-8;LL696-6;HL7_route;LA11382-1;148;Instillation, cecostomy;;; +18609-8;LL696-6;HL7_route;LA11383-9;149;Instillation, chest tube;;; +18609-8;LL696-6;HL7_route;LA11384-7;150;Instillation, continuous ambulatory peritoneal dialysis port;;; +18609-8;LL696-6;HL7_route;LA11385-4;151;Instillation, endotracheal tube;;; +18609-8;LL696-6;HL7_route;LA11386-2;152;Instillation, enteral;;; +18609-8;LL696-6;HL7_route;LA11387-0;153;Instillation, enteral feeding tube;;; +18609-8;LL696-6;HL7_route;LA11388-8;154;Instillation, gastro-jejunostomy tube;;; +18609-8;LL696-6;HL7_route;LA11389-6;155;Instillation, gastrostomy tube;;; +18609-8;LL696-6;HL7_route;LA11390-4;156;Instillation, intrabronchial;;; +18609-8;LL696-6;HL7_route;LA11391-2;157;Instillation, intraduodenal;;; +18609-8;LL696-6;HL7_route;LA11392-0;158;Instillation, intraesophageal;;; +18609-8;LL696-6;HL7_route;LA11393-8;159;Instillation, intragastric;;; +18609-8;LL696-6;HL7_route;LA11394-6;160;Instillation, intraileal;;; +18609-8;LL696-6;HL7_route;LA11395-3;161;Instillation, intraocular;;; +18609-8;LL696-6;HL7_route;LA11396-1;162;Instillation, intrasinal;;; +18609-8;LL696-6;HL7_route;LA11397-9;163;Instillation, intratracheal;;; +18609-8;LL696-6;HL7_route;LA11398-7;164;Instillation, intrauterine;;; +18609-8;LL696-6;HL7_route;LA11399-5;165;Instillation, jejunostomy tube;;; +18609-8;LL696-6;HL7_route;LA11400-1;166;Instillation, laryngeal;;; +18609-8;LL696-6;HL7_route;LA11401-9;167;Instillation, nasal;;; +18609-8;LL696-6;HL7_route;LA11402-7;168;Instillation, nasogastric;;; +18609-8;LL696-6;HL7_route;LA11403-5;169;Instillation, nasogastric tube;;; +18609-8;LL696-6;HL7_route;LA11404-3;170;Instillation, nasotracheal tube;;; +18609-8;LL696-6;HL7_route;LA11405-0;171;Instillation, orogastric tube;;; +18609-8;LL696-6;HL7_route;LA11406-8;172;Instillation, orojejunum tube;;; +18609-8;LL696-6;HL7_route;LA11407-6;173;Instillation, otic;;; +18609-8;LL696-6;HL7_route;LA11408-4;174;Instillation, paranasal sinuses;;; +18609-8;LL696-6;HL7_route;LA11409-2;175;Instillation, peritoneal dialysis port;;; +18609-8;LL696-6;HL7_route;LA11410-0;176;Instillation, rectal;;; +18609-8;LL696-6;HL7_route;LA11411-8;177;Instillation, rectal tube;;; +18609-8;LL696-6;HL7_route;LA11412-6;178;Instillation, sinus, unspecified;;; +18609-8;LL696-6;HL7_route;LA11413-4;179;Instillation, soft tissue;;; +18609-8;LL696-6;HL7_route;LA11414-2;180;Instillation, tracheostomy;;; +18609-8;LL696-6;HL7_route;LA11415-9;181;Instillation, transtympanic;;; +18609-8;LL696-6;HL7_route;LA11416-7;182;instillation, urethral;;; +18609-8;LL696-6;HL7_route;LA11417-5;183;Instillation, urinary catheter;;; +18609-8;LL696-6;HL7_route;LA11418-3;184;Insufflation;;; +18609-8;LL696-6;HL7_route;LA11419-1;185;Irrigation, genitourinary;;; +18609-8;LL696-6;HL7_route;LA11420-9;186;Irrigation, intragastric;;; +18609-8;LL696-6;HL7_route;LA11421-7;187;Irrigation, intralesional;;; +18609-8;LL696-6;HL7_route;LA11422-5;188;Irrigation, intraocular;;; +18609-8;LL696-6;HL7_route;LA11423-3;189;Irrigation, rectal;;; +18609-8;LL696-6;HL7_route;LA11424-1;190;Irrigation, urinary bladder;;; +18609-8;LL696-6;HL7_route;LA11425-8;191;Irrigation, urinary bladder, continuous;;; +18609-8;LL696-6;HL7_route;LA11426-6;192;Irrigation, urinary bladder, tidal;;; +18609-8;LL696-6;HL7_route;LA11427-4;193;Lavage, intragastric;;; +18609-8;LL696-6;HL7_route;LA11428-2;194;Mucosal absorption, intraduodenal;;; +18609-8;LL696-6;HL7_route;LA11429-0;195;Mucosal absorption, intratracheal;;; +18609-8;LL696-6;HL7_route;LA11430-8;196;Mucosal absorption, submucosal;;; +18609-8;LL696-6;HL7_route;LA11431-6;197;Nebulization, endotracheal tube;;; +18609-8;LL696-6;HL7_route;LA11432-4;198;Occlusive dressing technique;;; +18609-8;LL696-6;HL7_route;LA11433-2;199;Rinse, dental;;; +18609-8;LL696-6;HL7_route;LA11434-0;200;Rinse, oral;;; +18609-8;LL696-6;HL7_route;LA11435-7;201;Shampoo;;; +18609-8;LL696-6;HL7_route;LA11436-5;202;Subconjunctival;;; +18609-8;LL696-6;HL7_route;LA11437-3;203;Suck, oromucosal;;; +18609-8;LL696-6;HL7_route;LA11438-1;204;Suppository, urethral;;; +18609-8;LL696-6;HL7_route;LA11439-9;205;Swallow, oral;;; +18609-8;LL696-6;HL7_route;LA11440-7;206;Swish and spit out, oromucosal;;; +18609-8;LL696-6;HL7_route;LA11441-5;207;Swish and swallow, oromucosal;;; +18609-8;LL696-6;HL7_route;LA9456-0;208;Topical;;; +18609-8;LL696-6;HL7_route;LA11443-1;209;Topical absorption, transtympanic;;; +18609-8;LL696-6;HL7_route;LA11444-9;210;Topical application, buccal;;; +18609-8;LL696-6;HL7_route;LA11445-6;211;Topical application, cervical;;; +18609-8;LL696-6;HL7_route;LA11446-4;212;Topical application, dental;;; +18609-8;LL696-6;HL7_route;LA11447-2;213;Topical application, gingival;;; +18609-8;LL696-6;HL7_route;LA11448-0;214;Topical application, hair;;; +18609-8;LL696-6;HL7_route;LA11449-8;215;Topical application, intracorneal;;; +18609-8;LL696-6;HL7_route;LA11450-6;216;Topical application, intracoronal (dental);;; +18609-8;LL696-6;HL7_route;LA11451-4;217;Topical application, intraesophageal;;; +18609-8;LL696-6;HL7_route;LA11452-2;218;Topical application, intraileal;;; +18609-8;LL696-6;HL7_route;LA11453-0;219;Topical application, intralesional;;; +18609-8;LL696-6;HL7_route;LA11454-8;220;Topical application, intraluminal;;; +18609-8;LL696-6;HL7_route;LA11455-5;221;Topical application, intraocular;;; +18609-8;LL696-6;HL7_route;LA11456-3;222;Topical application, iontophoresis;;; +18609-8;LL696-6;HL7_route;LA11457-1;223;Topical application, laryngeal;;; +18609-8;LL696-6;HL7_route;LA11458-9;224;Topical application, mucous membrane;;; +18609-8;LL696-6;HL7_route;LA11459-7;225;Topical application, nail;;; +18609-8;LL696-6;HL7_route;LA11460-5;226;Topical application, nasal;;; +18609-8;LL696-6;HL7_route;LA11461-3;227;Topical application, ophthalmic;;; +18609-8;LL696-6;HL7_route;LA11462-1;228;Topical application, oral;;; +18609-8;LL696-6;HL7_route;LA11463-9;229;Topical application, oromucosal;;; +18609-8;LL696-6;HL7_route;LA11464-7;230;Topical application, oropharyngeal;;; +18609-8;LL696-6;HL7_route;LA11465-4;231;Topical application, perianal;;; +18609-8;LL696-6;HL7_route;LA11466-2;232;Topical application, perineal;;; +18609-8;LL696-6;HL7_route;LA11467-0;233;Topical application, periodontal;;; +18609-8;LL696-6;HL7_route;LA11468-8;234;Topical application, rectal;;; +18609-8;LL696-6;HL7_route;LA11469-6;235;Topical application, scalp;;; +18609-8;LL696-6;HL7_route;LA11470-4;236;Topical application, skin;;; +18609-8;LL696-6;HL7_route;LA11471-2;237;Topical application, soaked dressing;;; +18609-8;LL696-6;HL7_route;LA11472-0;238;Topical application, swab;;; +18609-8;LL696-6;HL7_route;LA11473-8;239;Topical application, transmucosal;;; +18609-8;LL696-6;HL7_route;LA11474-6;240;Topical application, vaginal;;; +18609-8;LL696-6;HL7_route;LA9454-5;241;Transdermal;;; +18609-8;LL696-6;HL7_route;LA9455-2;242;Translingual;;; +18612-2;LL696-6;HL7_route;LA11235-1;1;Chew, oral;;; +18612-2;LL696-6;HL7_route;LA11236-9;2;Diffusion, extracorporeal;;; +18612-2;LL696-6;HL7_route;LA11237-7;3;Diffusion, hemodialysis;;; +18612-2;LL696-6;HL7_route;LA11238-5;4;Diffusion, transdermal;;; +18612-2;LL696-6;HL7_route;LA11239-3;5;Dissolve, oral;;; +18612-2;LL696-6;HL7_route;LA11240-1;6;Dissolve, sublingual;;; +18612-2;LL696-6;HL7_route;LA11241-9;7;Douche, vaginal;;; +18612-2;LL696-6;HL7_route;LA11242-7;8;Electro-osmosis;;; +18612-2;LL696-6;HL7_route;LA11243-5;9;Enema, rectal;;; +18612-2;LL696-6;HL7_route;LA11244-3;10;Enema, rectal retention;;; +18612-2;LL696-6;HL7_route;LA11245-0;11;Flush, intravenous catheter;;; +18612-2;LL696-6;HL7_route;LA11246-8;12;Gargle;;; +18612-2;LL696-6;HL7_route;LA11247-6;13;Immersion (soak);;; +18612-2;LL696-6;HL7_route;LA11248-4;14;Implantation, intradermal;;; +18612-2;LL696-6;HL7_route;LA11249-2;15;Implantation, intravitreal;;; +18612-2;LL696-6;HL7_route;LA11250-0;16;Implantation, subcutaneous;;; +18612-2;LL696-6;HL7_route;LA11251-8;17;Infusion, epidural;;; +18612-2;LL696-6;HL7_route;LA11252-6;18;Infusion, intraarterial catheter;;; +18612-2;LL696-6;HL7_route;LA11253-4;19;Infusion, intracardiac;;; +18612-2;LL696-6;HL7_route;LA11254-2;20;Infusion, intracoronary;;; +18612-2;LL696-6;HL7_route;LA11255-9;21;Infusion, intraosseous, continuous;;; +18612-2;LL696-6;HL7_route;LA11256-7;22;Infusion, intrathecal;;; +18612-2;LL696-6;HL7_route;LA11257-5;23;Infusion, intravascular;;; +18612-2;LL696-6;HL7_route;LA11258-3;24;Infusion, intravenous;;; +18612-2;LL696-6;HL7_route;LA11259-1;25;Infusion, intravenous catheter;;; +18612-2;LL696-6;HL7_route;LA11260-9;26;Infusion, intravenous catheter, continuous;;; +18612-2;LL696-6;HL7_route;LA11261-7;27;Infusion, intravenous catheter, intermittent;;; +18612-2;LL696-6;HL7_route;LA11262-5;28;Infusion, intravenous catheter, pca pump;;; +18612-2;LL696-6;HL7_route;LA11263-3;29;Infusion, subcutaneous;;; +18612-2;LL696-6;HL7_route;LA11264-1;30;Inhalation, intermittent positive pressure breathing (ippb);;; +18612-2;LL696-6;HL7_route;LA11265-8;31;Inhalation, nasal;;; +18612-2;LL696-6;HL7_route;LA11266-6;32;Inhalation, nasal cannula;;; +18612-2;LL696-6;HL7_route;LA11268-2;34;Inhalation, nebulization;;; +18612-2;LL696-6;HL7_route;LA11269-0;35;Inhalation, nebulization, nasal;;; +18612-2;LL696-6;HL7_route;LA11270-8;36;Inhalation, nebulization, oral;;; +18612-2;LL696-6;HL7_route;LA11271-6;37;Inhalation, oral intermittent flow;;; +18612-2;LL696-6;HL7_route;LA11272-4;38;Inhalation, oral rebreather mask;;; +18612-2;LL696-6;HL7_route;LA11273-2;39;Inhalation, respiratory;;; +18612-2;LL696-6;HL7_route;LA11274-0;40;Inhalation, tracheostomy;;; +18612-2;LL696-6;HL7_route;LA11275-7;41;Inhalation, ventilator;;; +18612-2;LL696-6;HL7_route;LA11276-5;42;Inhalation, ventimask;;; +18612-2;LL696-6;HL7_route;LA11277-3;43;Injection, amniotic fluid;;; +18612-2;LL696-6;HL7_route;LA11278-1;44;Injection, biliary tract;;; +18612-2;LL696-6;HL7_route;LA11279-9;45;Injection, cervical;;; +18612-2;LL696-6;HL7_route;LA11280-7;46;Injection, endosinusial;;; +18612-2;LL696-6;HL7_route;LA11281-5;47;Injection, epidural;;; +18612-2;LL696-6;HL7_route;LA11282-3;48;Injection, epidural, push;;; +18612-2;LL696-6;HL7_route;LA11283-1;49;Injection, epidural, slow push;;; +18612-2;LL696-6;HL7_route;LA11284-9;50;Injection, extra-amniotic;;; +18612-2;LL696-6;HL7_route;LA11285-6;51;Injection, extracorporeal;;; +18612-2;LL696-6;HL7_route;LA11286-4;52;Injection, for cholangiography;;; +18612-2;LL696-6;HL7_route;LA11287-2;53;Injection, gastric button;;; +18612-2;LL696-6;HL7_route;LA11288-0;54;Injection, gingival;;; +18612-2;LL696-6;HL7_route;LA11289-8;55;Injection, hemodialysis port;;; +18612-2;LL696-6;HL7_route;LA11290-6;56;Injection, insulin pump;;; +18612-2;LL696-6;HL7_route;LA11291-4;57;Injection, interameningeal;;; +18612-2;LL696-6;HL7_route;LA11292-2;58;Injection, interstitial;;; +18612-2;LL696-6;HL7_route;LA11293-0;59;Injection, intra-abdominal;;; +18612-2;LL696-6;HL7_route;LA11294-8;60;Injection, intraarterial;;; +18612-2;LL696-6;HL7_route;LA11295-5;61;Injection, intraarterial, push;;; +18612-2;LL696-6;HL7_route;LA11296-3;62;Injection, intraarterial, slow push;;; +18612-2;LL696-6;HL7_route;LA11297-1;63;Injection, intraarticular;;; +18612-2;LL696-6;HL7_route;LA11298-9;64;Injection, intrabursal;;; +18612-2;LL696-6;HL7_route;LA11299-7;65;Injection, intracardiac;;; +18612-2;LL696-6;HL7_route;LA11300-3;66;Injection, intracardiac, push;;; +18612-2;LL696-6;HL7_route;LA11301-1;67;Injection, intracardiac, rapid push;;; +18612-2;LL696-6;HL7_route;LA11302-9;68;Injection, intracardiac, slow push;;; +18612-2;LL696-6;HL7_route;LA11303-7;69;Injection, intracartilaginous;;; +18612-2;LL696-6;HL7_route;LA11304-5;70;Injection, intracaudal;;; +18612-2;LL696-6;HL7_route;LA11305-2;71;Injection, intracavernous;;; +18612-2;LL696-6;HL7_route;LA11306-0;72;Injection, intracavitary;;; +18612-2;LL696-6;HL7_route;LA11307-8;73;Injection, intracerebral;;; +18612-2;LL696-6;HL7_route;LA11308-6;74;Injection, intracervical (uterus);;; +18612-2;LL696-6;HL7_route;LA11309-4;75;Injection, intracisternal;;; +18612-2;LL696-6;HL7_route;LA11310-2;76;Injection, intracoronary;;; +18612-2;LL696-6;HL7_route;LA11311-0;77;Injection, intracoronary, push;;; +18612-2;LL696-6;HL7_route;LA11312-8;78;Injection, intracorpus cavernosum;;; +18612-2;LL696-6;HL7_route;LA11313-6;79;Injection, intradermal;;; +18612-2;LL696-6;HL7_route;LA11314-4;80;Injection, intradiscal;;; +18612-2;LL696-6;HL7_route;LA11315-1;81;Injection, intraductal;;; +18612-2;LL696-6;HL7_route;LA11316-9;82;Injection, intradural;;; +18612-2;LL696-6;HL7_route;LA11317-7;83;Injection, intraepidermal;;; +18612-2;LL696-6;HL7_route;LA11318-5;84;Injection, intraepithelial;;; +18612-2;LL696-6;HL7_route;LA11319-3;85;Injection, intralesional;;; +18612-2;LL696-6;HL7_route;LA11320-1;86;Injection, intraluminal;;; +18612-2;LL696-6;HL7_route;LA11321-9;87;Injection, intralymphatic;;; +18612-2;LL696-6;HL7_route;LA11322-7;88;Injection, intramedullary;;; +18612-2;LL696-6;HL7_route;LA11323-5;89;Injection, intramuscular;;; +18612-2;LL696-6;HL7_route;LA11324-3;90;Injection, intramuscular, deep;;; +18612-2;LL696-6;HL7_route;LA11325-0;91;Injection, intramuscular, z track;;; +18612-2;LL696-6;HL7_route;LA11326-8;92;Injection, intraocular;;; +18612-2;LL696-6;HL7_route;LA11327-6;93;Injection, intraosseous;;; +18612-2;LL696-6;HL7_route;LA11328-4;94;Injection, intraovarian;;; +18612-2;LL696-6;HL7_route;LA11329-2;95;Injection, intrapericardial;;; +18612-2;LL696-6;HL7_route;LA11330-0;96;Injection, intraperitoneal;;; +18612-2;LL696-6;HL7_route;LA11331-8;97;Injection, intrapleural;;; +18612-2;LL696-6;HL7_route;LA11332-6;98;Injection, intraprostatic;;; +18612-2;LL696-6;HL7_route;LA11333-4;99;Injection, intrapulmonary;;; +18612-2;LL696-6;HL7_route;LA11334-2;100;Injection, intraspinal;;; +18612-2;LL696-6;HL7_route;LA11335-9;101;Injection, intrasternal;;; +18612-2;LL696-6;HL7_route;LA11336-7;102;Injection, intrasynovial;;; +18612-2;LL696-6;HL7_route;LA11337-5;103;Injection, intratendinous;;; +18612-2;LL696-6;HL7_route;LA11338-3;104;Injection, intratesticular;;; +18612-2;LL696-6;HL7_route;LA11339-1;105;Injection, intrathecal;;; +18612-2;LL696-6;HL7_route;LA11340-9;106;Injection, intrathoracic;;; +18612-2;LL696-6;HL7_route;LA11341-7;107;Injection, intratubular;;; +18612-2;LL696-6;HL7_route;LA11342-5;108;Injection, intratumor;;; +18612-2;LL696-6;HL7_route;LA11343-3;109;Injection, intratympanic;;; +18612-2;LL696-6;HL7_route;LA11344-1;110;Injection, intraureteral, retrograde;;; +18612-2;LL696-6;HL7_route;LA11345-8;111;Injection, intrauterine;;; +18612-2;LL696-6;HL7_route;LA11346-6;112;Injection, intravascular;;; +18612-2;LL696-6;HL7_route;LA11347-4;113;Injection, intravenous;;; +18612-2;LL696-6;HL7_route;LA11348-2;114;Injection, intravenous, bolus;;; +18612-2;LL696-6;HL7_route;LA11349-0;115;Injection, intravenous, push;;; +18612-2;LL696-6;HL7_route;LA11350-8;116;Injection, intravenous, rapid push;;; +18612-2;LL696-6;HL7_route;LA11351-6;117;Injection, intravenous, slow push;;; +18612-2;LL696-6;HL7_route;LA11352-4;118;Injection, intraventricular (heart);;; +18612-2;LL696-6;HL7_route;LA11353-2;119;Injection, intravesicle;;; +18612-2;LL696-6;HL7_route;LA11354-0;120;Injection, intravitreal;;; +18612-2;LL696-6;HL7_route;LA11355-7;121;Injection, paranasal sinuses;;; +18612-2;LL696-6;HL7_route;LA11356-5;122;Injection, parenteral;;; +18612-2;LL696-6;HL7_route;LA11357-3;123;Injection, periarticular;;; +18612-2;LL696-6;HL7_route;LA11358-1;124;Injection, peridural;;; +18612-2;LL696-6;HL7_route;LA11359-9;125;Injection, perineural;;; +18612-2;LL696-6;HL7_route;LA11360-7;126;Injection, periodontal;;; +18612-2;LL696-6;HL7_route;LA11361-5;127;Injection, peritoneal dialysis port;;; +18612-2;LL696-6;HL7_route;LA11362-3;128;Injection, retrobulbar;;; +18612-2;LL696-6;HL7_route;LA11363-1;129;Injection, soft tissue;;; +18612-2;LL696-6;HL7_route;LA11364-9;130;Injection, subarachnoid;;; +18612-2;LL696-6;HL7_route;LA11365-6;131;Injection, subconjunctival;;; +18612-2;LL696-6;HL7_route;LA11366-4;132;Injection, subcutaneous;;; +18612-2;LL696-6;HL7_route;LA11367-2;133;Injection, sublesional;;; +18612-2;LL696-6;HL7_route;LA11368-0;134;Injection, submucosal;;; +18612-2;LL696-6;HL7_route;LA11369-8;135;Injection, transplacental;;; +18612-2;LL696-6;HL7_route;LA11370-6;136;Injection, transtracheal;;; +18612-2;LL696-6;HL7_route;LA11371-4;137;Injection, ureteral;;; +18612-2;LL696-6;HL7_route;LA11372-2;138;Injection, urethral;;; +18612-2;LL696-6;HL7_route;LA11373-0;139;Injection, urinary bladder;;; +18612-2;LL696-6;HL7_route;LA11374-8;140;Insertion, cervical (uterine);;; +18612-2;LL696-6;HL7_route;LA11375-5;141;Insertion, intraocular, surgical;;; +18612-2;LL696-6;HL7_route;LA11376-3;142;Insertion, intrauterine;;; +18612-2;LL696-6;HL7_route;LA11377-1;143;Insertion, lacrimal puncta;;; +18612-2;LL696-6;HL7_route;LA11378-9;144;Insertion, rectal;;; +18612-2;LL696-6;HL7_route;LA11379-7;145;Insertion, subcutaneous, surgical;;; +18612-2;LL696-6;HL7_route;LA11380-5;146;Insertion, urethral;;; +18612-2;LL696-6;HL7_route;LA11381-3;147;Insertion, vaginal;;; +18612-2;LL696-6;HL7_route;LA11382-1;148;Instillation, cecostomy;;; +18612-2;LL696-6;HL7_route;LA11383-9;149;Instillation, chest tube;;; +18612-2;LL696-6;HL7_route;LA11384-7;150;Instillation, continuous ambulatory peritoneal dialysis port;;; +18612-2;LL696-6;HL7_route;LA11385-4;151;Instillation, endotracheal tube;;; +18612-2;LL696-6;HL7_route;LA11386-2;152;Instillation, enteral;;; +18612-2;LL696-6;HL7_route;LA11387-0;153;Instillation, enteral feeding tube;;; +18612-2;LL696-6;HL7_route;LA11388-8;154;Instillation, gastro-jejunostomy tube;;; +18612-2;LL696-6;HL7_route;LA11389-6;155;Instillation, gastrostomy tube;;; +18612-2;LL696-6;HL7_route;LA11390-4;156;Instillation, intrabronchial;;; +18612-2;LL696-6;HL7_route;LA11391-2;157;Instillation, intraduodenal;;; +18612-2;LL696-6;HL7_route;LA11392-0;158;Instillation, intraesophageal;;; +18612-2;LL696-6;HL7_route;LA11393-8;159;Instillation, intragastric;;; +18612-2;LL696-6;HL7_route;LA11394-6;160;Instillation, intraileal;;; +18612-2;LL696-6;HL7_route;LA11395-3;161;Instillation, intraocular;;; +18612-2;LL696-6;HL7_route;LA11396-1;162;Instillation, intrasinal;;; +18612-2;LL696-6;HL7_route;LA11397-9;163;Instillation, intratracheal;;; +18612-2;LL696-6;HL7_route;LA11398-7;164;Instillation, intrauterine;;; +18612-2;LL696-6;HL7_route;LA11399-5;165;Instillation, jejunostomy tube;;; +18612-2;LL696-6;HL7_route;LA11400-1;166;Instillation, laryngeal;;; +18612-2;LL696-6;HL7_route;LA11401-9;167;Instillation, nasal;;; +18612-2;LL696-6;HL7_route;LA11402-7;168;Instillation, nasogastric;;; +18612-2;LL696-6;HL7_route;LA11403-5;169;Instillation, nasogastric tube;;; +18612-2;LL696-6;HL7_route;LA11404-3;170;Instillation, nasotracheal tube;;; +18612-2;LL696-6;HL7_route;LA11405-0;171;Instillation, orogastric tube;;; +18612-2;LL696-6;HL7_route;LA11406-8;172;Instillation, orojejunum tube;;; +18612-2;LL696-6;HL7_route;LA11407-6;173;Instillation, otic;;; +18612-2;LL696-6;HL7_route;LA11408-4;174;Instillation, paranasal sinuses;;; +18612-2;LL696-6;HL7_route;LA11409-2;175;Instillation, peritoneal dialysis port;;; +18612-2;LL696-6;HL7_route;LA11410-0;176;Instillation, rectal;;; +18612-2;LL696-6;HL7_route;LA11411-8;177;Instillation, rectal tube;;; +18612-2;LL696-6;HL7_route;LA11412-6;178;Instillation, sinus, unspecified;;; +18612-2;LL696-6;HL7_route;LA11413-4;179;Instillation, soft tissue;;; +18612-2;LL696-6;HL7_route;LA11414-2;180;Instillation, tracheostomy;;; +18612-2;LL696-6;HL7_route;LA11415-9;181;Instillation, transtympanic;;; +18612-2;LL696-6;HL7_route;LA11416-7;182;instillation, urethral;;; +18612-2;LL696-6;HL7_route;LA11417-5;183;Instillation, urinary catheter;;; +18612-2;LL696-6;HL7_route;LA11418-3;184;Insufflation;;; +18612-2;LL696-6;HL7_route;LA11419-1;185;Irrigation, genitourinary;;; +18612-2;LL696-6;HL7_route;LA11420-9;186;Irrigation, intragastric;;; +18612-2;LL696-6;HL7_route;LA11421-7;187;Irrigation, intralesional;;; +18612-2;LL696-6;HL7_route;LA11422-5;188;Irrigation, intraocular;;; +18612-2;LL696-6;HL7_route;LA11423-3;189;Irrigation, rectal;;; +18612-2;LL696-6;HL7_route;LA11424-1;190;Irrigation, urinary bladder;;; +18612-2;LL696-6;HL7_route;LA11425-8;191;Irrigation, urinary bladder, continuous;;; +18612-2;LL696-6;HL7_route;LA11426-6;192;Irrigation, urinary bladder, tidal;;; +18612-2;LL696-6;HL7_route;LA11427-4;193;Lavage, intragastric;;; +18612-2;LL696-6;HL7_route;LA11428-2;194;Mucosal absorption, intraduodenal;;; +18612-2;LL696-6;HL7_route;LA11429-0;195;Mucosal absorption, intratracheal;;; +18612-2;LL696-6;HL7_route;LA11430-8;196;Mucosal absorption, submucosal;;; +18612-2;LL696-6;HL7_route;LA11431-6;197;Nebulization, endotracheal tube;;; +18612-2;LL696-6;HL7_route;LA11432-4;198;Occlusive dressing technique;;; +18612-2;LL696-6;HL7_route;LA11433-2;199;Rinse, dental;;; +18612-2;LL696-6;HL7_route;LA11434-0;200;Rinse, oral;;; +18612-2;LL696-6;HL7_route;LA11435-7;201;Shampoo;;; +18612-2;LL696-6;HL7_route;LA11436-5;202;Subconjunctival;;; +18612-2;LL696-6;HL7_route;LA11437-3;203;Suck, oromucosal;;; +18612-2;LL696-6;HL7_route;LA11438-1;204;Suppository, urethral;;; +18612-2;LL696-6;HL7_route;LA11439-9;205;Swallow, oral;;; +18612-2;LL696-6;HL7_route;LA11440-7;206;Swish and spit out, oromucosal;;; +18612-2;LL696-6;HL7_route;LA11441-5;207;Swish and swallow, oromucosal;;; +18612-2;LL696-6;HL7_route;LA9456-0;208;Topical;;; +18612-2;LL696-6;HL7_route;LA11443-1;209;Topical absorption, transtympanic;;; +18612-2;LL696-6;HL7_route;LA11444-9;210;Topical application, buccal;;; +18612-2;LL696-6;HL7_route;LA11445-6;211;Topical application, cervical;;; +18612-2;LL696-6;HL7_route;LA11446-4;212;Topical application, dental;;; +18612-2;LL696-6;HL7_route;LA11447-2;213;Topical application, gingival;;; +18612-2;LL696-6;HL7_route;LA11448-0;214;Topical application, hair;;; +18612-2;LL696-6;HL7_route;LA11449-8;215;Topical application, intracorneal;;; +18612-2;LL696-6;HL7_route;LA11450-6;216;Topical application, intracoronal (dental);;; +18612-2;LL696-6;HL7_route;LA11451-4;217;Topical application, intraesophageal;;; +18612-2;LL696-6;HL7_route;LA11452-2;218;Topical application, intraileal;;; +18612-2;LL696-6;HL7_route;LA11453-0;219;Topical application, intralesional;;; +18612-2;LL696-6;HL7_route;LA11454-8;220;Topical application, intraluminal;;; +18612-2;LL696-6;HL7_route;LA11455-5;221;Topical application, intraocular;;; +18612-2;LL696-6;HL7_route;LA11456-3;222;Topical application, iontophoresis;;; +18612-2;LL696-6;HL7_route;LA11457-1;223;Topical application, laryngeal;;; +18612-2;LL696-6;HL7_route;LA11458-9;224;Topical application, mucous membrane;;; +18612-2;LL696-6;HL7_route;LA11459-7;225;Topical application, nail;;; +18612-2;LL696-6;HL7_route;LA11460-5;226;Topical application, nasal;;; +18612-2;LL696-6;HL7_route;LA11461-3;227;Topical application, ophthalmic;;; +18612-2;LL696-6;HL7_route;LA11462-1;228;Topical application, oral;;; +18612-2;LL696-6;HL7_route;LA11463-9;229;Topical application, oromucosal;;; +18612-2;LL696-6;HL7_route;LA11464-7;230;Topical application, oropharyngeal;;; +18612-2;LL696-6;HL7_route;LA11465-4;231;Topical application, perianal;;; +18612-2;LL696-6;HL7_route;LA11466-2;232;Topical application, perineal;;; +18612-2;LL696-6;HL7_route;LA11467-0;233;Topical application, periodontal;;; +18612-2;LL696-6;HL7_route;LA11468-8;234;Topical application, rectal;;; +18612-2;LL696-6;HL7_route;LA11469-6;235;Topical application, scalp;;; +18612-2;LL696-6;HL7_route;LA11470-4;236;Topical application, skin;;; +18612-2;LL696-6;HL7_route;LA11471-2;237;Topical application, soaked dressing;;; +18612-2;LL696-6;HL7_route;LA11472-0;238;Topical application, swab;;; +18612-2;LL696-6;HL7_route;LA11473-8;239;Topical application, transmucosal;;; +18612-2;LL696-6;HL7_route;LA11474-6;240;Topical application, vaginal;;; +18612-2;LL696-6;HL7_route;LA9454-5;241;Transdermal;;; +18612-2;LL696-6;HL7_route;LA9455-2;242;Translingual;;; +18621-3;LL696-6;HL7_route;LA11235-1;1;Chew, oral;;; +18621-3;LL696-6;HL7_route;LA11236-9;2;Diffusion, extracorporeal;;; +18621-3;LL696-6;HL7_route;LA11237-7;3;Diffusion, hemodialysis;;; +18621-3;LL696-6;HL7_route;LA11238-5;4;Diffusion, transdermal;;; +18621-3;LL696-6;HL7_route;LA11239-3;5;Dissolve, oral;;; +18621-3;LL696-6;HL7_route;LA11240-1;6;Dissolve, sublingual;;; +18621-3;LL696-6;HL7_route;LA11241-9;7;Douche, vaginal;;; +18621-3;LL696-6;HL7_route;LA11242-7;8;Electro-osmosis;;; +18621-3;LL696-6;HL7_route;LA11243-5;9;Enema, rectal;;; +18621-3;LL696-6;HL7_route;LA11244-3;10;Enema, rectal retention;;; +18621-3;LL696-6;HL7_route;LA11245-0;11;Flush, intravenous catheter;;; +18621-3;LL696-6;HL7_route;LA11246-8;12;Gargle;;; +18621-3;LL696-6;HL7_route;LA11247-6;13;Immersion (soak);;; +18621-3;LL696-6;HL7_route;LA11248-4;14;Implantation, intradermal;;; +18621-3;LL696-6;HL7_route;LA11249-2;15;Implantation, intravitreal;;; +18621-3;LL696-6;HL7_route;LA11250-0;16;Implantation, subcutaneous;;; +18621-3;LL696-6;HL7_route;LA11251-8;17;Infusion, epidural;;; +18621-3;LL696-6;HL7_route;LA11252-6;18;Infusion, intraarterial catheter;;; +18621-3;LL696-6;HL7_route;LA11253-4;19;Infusion, intracardiac;;; +18621-3;LL696-6;HL7_route;LA11254-2;20;Infusion, intracoronary;;; +18621-3;LL696-6;HL7_route;LA11255-9;21;Infusion, intraosseous, continuous;;; +18621-3;LL696-6;HL7_route;LA11256-7;22;Infusion, intrathecal;;; +18621-3;LL696-6;HL7_route;LA11257-5;23;Infusion, intravascular;;; +18621-3;LL696-6;HL7_route;LA11258-3;24;Infusion, intravenous;;; +18621-3;LL696-6;HL7_route;LA11259-1;25;Infusion, intravenous catheter;;; +18621-3;LL696-6;HL7_route;LA11260-9;26;Infusion, intravenous catheter, continuous;;; +18621-3;LL696-6;HL7_route;LA11261-7;27;Infusion, intravenous catheter, intermittent;;; +18621-3;LL696-6;HL7_route;LA11262-5;28;Infusion, intravenous catheter, pca pump;;; +18621-3;LL696-6;HL7_route;LA11263-3;29;Infusion, subcutaneous;;; +18621-3;LL696-6;HL7_route;LA11264-1;30;Inhalation, intermittent positive pressure breathing (ippb);;; +18621-3;LL696-6;HL7_route;LA11265-8;31;Inhalation, nasal;;; +18621-3;LL696-6;HL7_route;LA11266-6;32;Inhalation, nasal cannula;;; +18621-3;LL696-6;HL7_route;LA11268-2;34;Inhalation, nebulization;;; +18621-3;LL696-6;HL7_route;LA11269-0;35;Inhalation, nebulization, nasal;;; +18621-3;LL696-6;HL7_route;LA11270-8;36;Inhalation, nebulization, oral;;; +18621-3;LL696-6;HL7_route;LA11271-6;37;Inhalation, oral intermittent flow;;; +18621-3;LL696-6;HL7_route;LA11272-4;38;Inhalation, oral rebreather mask;;; +18621-3;LL696-6;HL7_route;LA11273-2;39;Inhalation, respiratory;;; +18621-3;LL696-6;HL7_route;LA11274-0;40;Inhalation, tracheostomy;;; +18621-3;LL696-6;HL7_route;LA11275-7;41;Inhalation, ventilator;;; +18621-3;LL696-6;HL7_route;LA11276-5;42;Inhalation, ventimask;;; +18621-3;LL696-6;HL7_route;LA11277-3;43;Injection, amniotic fluid;;; +18621-3;LL696-6;HL7_route;LA11278-1;44;Injection, biliary tract;;; +18621-3;LL696-6;HL7_route;LA11279-9;45;Injection, cervical;;; +18621-3;LL696-6;HL7_route;LA11280-7;46;Injection, endosinusial;;; +18621-3;LL696-6;HL7_route;LA11281-5;47;Injection, epidural;;; +18621-3;LL696-6;HL7_route;LA11282-3;48;Injection, epidural, push;;; +18621-3;LL696-6;HL7_route;LA11283-1;49;Injection, epidural, slow push;;; +18621-3;LL696-6;HL7_route;LA11284-9;50;Injection, extra-amniotic;;; +18621-3;LL696-6;HL7_route;LA11285-6;51;Injection, extracorporeal;;; +18621-3;LL696-6;HL7_route;LA11286-4;52;Injection, for cholangiography;;; +18621-3;LL696-6;HL7_route;LA11287-2;53;Injection, gastric button;;; +18621-3;LL696-6;HL7_route;LA11288-0;54;Injection, gingival;;; +18621-3;LL696-6;HL7_route;LA11289-8;55;Injection, hemodialysis port;;; +18621-3;LL696-6;HL7_route;LA11290-6;56;Injection, insulin pump;;; +18621-3;LL696-6;HL7_route;LA11291-4;57;Injection, interameningeal;;; +18621-3;LL696-6;HL7_route;LA11292-2;58;Injection, interstitial;;; +18621-3;LL696-6;HL7_route;LA11293-0;59;Injection, intra-abdominal;;; +18621-3;LL696-6;HL7_route;LA11294-8;60;Injection, intraarterial;;; +18621-3;LL696-6;HL7_route;LA11295-5;61;Injection, intraarterial, push;;; +18621-3;LL696-6;HL7_route;LA11296-3;62;Injection, intraarterial, slow push;;; +18621-3;LL696-6;HL7_route;LA11297-1;63;Injection, intraarticular;;; +18621-3;LL696-6;HL7_route;LA11298-9;64;Injection, intrabursal;;; +18621-3;LL696-6;HL7_route;LA11299-7;65;Injection, intracardiac;;; +18621-3;LL696-6;HL7_route;LA11300-3;66;Injection, intracardiac, push;;; +18621-3;LL696-6;HL7_route;LA11301-1;67;Injection, intracardiac, rapid push;;; +18621-3;LL696-6;HL7_route;LA11302-9;68;Injection, intracardiac, slow push;;; +18621-3;LL696-6;HL7_route;LA11303-7;69;Injection, intracartilaginous;;; +18621-3;LL696-6;HL7_route;LA11304-5;70;Injection, intracaudal;;; +18621-3;LL696-6;HL7_route;LA11305-2;71;Injection, intracavernous;;; +18621-3;LL696-6;HL7_route;LA11306-0;72;Injection, intracavitary;;; +18621-3;LL696-6;HL7_route;LA11307-8;73;Injection, intracerebral;;; +18621-3;LL696-6;HL7_route;LA11308-6;74;Injection, intracervical (uterus);;; +18621-3;LL696-6;HL7_route;LA11309-4;75;Injection, intracisternal;;; +18621-3;LL696-6;HL7_route;LA11310-2;76;Injection, intracoronary;;; +18621-3;LL696-6;HL7_route;LA11311-0;77;Injection, intracoronary, push;;; +18621-3;LL696-6;HL7_route;LA11312-8;78;Injection, intracorpus cavernosum;;; +18621-3;LL696-6;HL7_route;LA11313-6;79;Injection, intradermal;;; +18621-3;LL696-6;HL7_route;LA11314-4;80;Injection, intradiscal;;; +18621-3;LL696-6;HL7_route;LA11315-1;81;Injection, intraductal;;; +18621-3;LL696-6;HL7_route;LA11316-9;82;Injection, intradural;;; +18621-3;LL696-6;HL7_route;LA11317-7;83;Injection, intraepidermal;;; +18621-3;LL696-6;HL7_route;LA11318-5;84;Injection, intraepithelial;;; +18621-3;LL696-6;HL7_route;LA11319-3;85;Injection, intralesional;;; +18621-3;LL696-6;HL7_route;LA11320-1;86;Injection, intraluminal;;; +18621-3;LL696-6;HL7_route;LA11321-9;87;Injection, intralymphatic;;; +18621-3;LL696-6;HL7_route;LA11322-7;88;Injection, intramedullary;;; +18621-3;LL696-6;HL7_route;LA11323-5;89;Injection, intramuscular;;; +18621-3;LL696-6;HL7_route;LA11324-3;90;Injection, intramuscular, deep;;; +18621-3;LL696-6;HL7_route;LA11325-0;91;Injection, intramuscular, z track;;; +18621-3;LL696-6;HL7_route;LA11326-8;92;Injection, intraocular;;; +18621-3;LL696-6;HL7_route;LA11327-6;93;Injection, intraosseous;;; +18621-3;LL696-6;HL7_route;LA11328-4;94;Injection, intraovarian;;; +18621-3;LL696-6;HL7_route;LA11329-2;95;Injection, intrapericardial;;; +18621-3;LL696-6;HL7_route;LA11330-0;96;Injection, intraperitoneal;;; +18621-3;LL696-6;HL7_route;LA11331-8;97;Injection, intrapleural;;; +18621-3;LL696-6;HL7_route;LA11332-6;98;Injection, intraprostatic;;; +18621-3;LL696-6;HL7_route;LA11333-4;99;Injection, intrapulmonary;;; +18621-3;LL696-6;HL7_route;LA11334-2;100;Injection, intraspinal;;; +18621-3;LL696-6;HL7_route;LA11335-9;101;Injection, intrasternal;;; +18621-3;LL696-6;HL7_route;LA11336-7;102;Injection, intrasynovial;;; +18621-3;LL696-6;HL7_route;LA11337-5;103;Injection, intratendinous;;; +18621-3;LL696-6;HL7_route;LA11338-3;104;Injection, intratesticular;;; +18621-3;LL696-6;HL7_route;LA11339-1;105;Injection, intrathecal;;; +18621-3;LL696-6;HL7_route;LA11340-9;106;Injection, intrathoracic;;; +18621-3;LL696-6;HL7_route;LA11341-7;107;Injection, intratubular;;; +18621-3;LL696-6;HL7_route;LA11342-5;108;Injection, intratumor;;; +18621-3;LL696-6;HL7_route;LA11343-3;109;Injection, intratympanic;;; +18621-3;LL696-6;HL7_route;LA11344-1;110;Injection, intraureteral, retrograde;;; +18621-3;LL696-6;HL7_route;LA11345-8;111;Injection, intrauterine;;; +18621-3;LL696-6;HL7_route;LA11346-6;112;Injection, intravascular;;; +18621-3;LL696-6;HL7_route;LA11347-4;113;Injection, intravenous;;; +18621-3;LL696-6;HL7_route;LA11348-2;114;Injection, intravenous, bolus;;; +18621-3;LL696-6;HL7_route;LA11349-0;115;Injection, intravenous, push;;; +18621-3;LL696-6;HL7_route;LA11350-8;116;Injection, intravenous, rapid push;;; +18621-3;LL696-6;HL7_route;LA11351-6;117;Injection, intravenous, slow push;;; +18621-3;LL696-6;HL7_route;LA11352-4;118;Injection, intraventricular (heart);;; +18621-3;LL696-6;HL7_route;LA11353-2;119;Injection, intravesicle;;; +18621-3;LL696-6;HL7_route;LA11354-0;120;Injection, intravitreal;;; +18621-3;LL696-6;HL7_route;LA11355-7;121;Injection, paranasal sinuses;;; +18621-3;LL696-6;HL7_route;LA11356-5;122;Injection, parenteral;;; +18621-3;LL696-6;HL7_route;LA11357-3;123;Injection, periarticular;;; +18621-3;LL696-6;HL7_route;LA11358-1;124;Injection, peridural;;; +18621-3;LL696-6;HL7_route;LA11359-9;125;Injection, perineural;;; +18621-3;LL696-6;HL7_route;LA11360-7;126;Injection, periodontal;;; +18621-3;LL696-6;HL7_route;LA11361-5;127;Injection, peritoneal dialysis port;;; +18621-3;LL696-6;HL7_route;LA11362-3;128;Injection, retrobulbar;;; +18621-3;LL696-6;HL7_route;LA11363-1;129;Injection, soft tissue;;; +18621-3;LL696-6;HL7_route;LA11364-9;130;Injection, subarachnoid;;; +18621-3;LL696-6;HL7_route;LA11365-6;131;Injection, subconjunctival;;; +18621-3;LL696-6;HL7_route;LA11366-4;132;Injection, subcutaneous;;; +18621-3;LL696-6;HL7_route;LA11367-2;133;Injection, sublesional;;; +18621-3;LL696-6;HL7_route;LA11368-0;134;Injection, submucosal;;; +18621-3;LL696-6;HL7_route;LA11369-8;135;Injection, transplacental;;; +18621-3;LL696-6;HL7_route;LA11370-6;136;Injection, transtracheal;;; +18621-3;LL696-6;HL7_route;LA11371-4;137;Injection, ureteral;;; +18621-3;LL696-6;HL7_route;LA11372-2;138;Injection, urethral;;; +18621-3;LL696-6;HL7_route;LA11373-0;139;Injection, urinary bladder;;; +18621-3;LL696-6;HL7_route;LA11374-8;140;Insertion, cervical (uterine);;; +18621-3;LL696-6;HL7_route;LA11375-5;141;Insertion, intraocular, surgical;;; +18621-3;LL696-6;HL7_route;LA11376-3;142;Insertion, intrauterine;;; +18621-3;LL696-6;HL7_route;LA11377-1;143;Insertion, lacrimal puncta;;; +18621-3;LL696-6;HL7_route;LA11378-9;144;Insertion, rectal;;; +18621-3;LL696-6;HL7_route;LA11379-7;145;Insertion, subcutaneous, surgical;;; +18621-3;LL696-6;HL7_route;LA11380-5;146;Insertion, urethral;;; +18621-3;LL696-6;HL7_route;LA11381-3;147;Insertion, vaginal;;; +18621-3;LL696-6;HL7_route;LA11382-1;148;Instillation, cecostomy;;; +18621-3;LL696-6;HL7_route;LA11383-9;149;Instillation, chest tube;;; +18621-3;LL696-6;HL7_route;LA11384-7;150;Instillation, continuous ambulatory peritoneal dialysis port;;; +18621-3;LL696-6;HL7_route;LA11385-4;151;Instillation, endotracheal tube;;; +18621-3;LL696-6;HL7_route;LA11386-2;152;Instillation, enteral;;; +18621-3;LL696-6;HL7_route;LA11387-0;153;Instillation, enteral feeding tube;;; +18621-3;LL696-6;HL7_route;LA11388-8;154;Instillation, gastro-jejunostomy tube;;; +18621-3;LL696-6;HL7_route;LA11389-6;155;Instillation, gastrostomy tube;;; +18621-3;LL696-6;HL7_route;LA11390-4;156;Instillation, intrabronchial;;; +18621-3;LL696-6;HL7_route;LA11391-2;157;Instillation, intraduodenal;;; +18621-3;LL696-6;HL7_route;LA11392-0;158;Instillation, intraesophageal;;; +18621-3;LL696-6;HL7_route;LA11393-8;159;Instillation, intragastric;;; +18621-3;LL696-6;HL7_route;LA11394-6;160;Instillation, intraileal;;; +18621-3;LL696-6;HL7_route;LA11395-3;161;Instillation, intraocular;;; +18621-3;LL696-6;HL7_route;LA11396-1;162;Instillation, intrasinal;;; +18621-3;LL696-6;HL7_route;LA11397-9;163;Instillation, intratracheal;;; +18621-3;LL696-6;HL7_route;LA11398-7;164;Instillation, intrauterine;;; +18621-3;LL696-6;HL7_route;LA11399-5;165;Instillation, jejunostomy tube;;; +18621-3;LL696-6;HL7_route;LA11400-1;166;Instillation, laryngeal;;; +18621-3;LL696-6;HL7_route;LA11401-9;167;Instillation, nasal;;; +18621-3;LL696-6;HL7_route;LA11402-7;168;Instillation, nasogastric;;; +18621-3;LL696-6;HL7_route;LA11403-5;169;Instillation, nasogastric tube;;; +18621-3;LL696-6;HL7_route;LA11404-3;170;Instillation, nasotracheal tube;;; +18621-3;LL696-6;HL7_route;LA11405-0;171;Instillation, orogastric tube;;; +18621-3;LL696-6;HL7_route;LA11406-8;172;Instillation, orojejunum tube;;; +18621-3;LL696-6;HL7_route;LA11407-6;173;Instillation, otic;;; +18621-3;LL696-6;HL7_route;LA11408-4;174;Instillation, paranasal sinuses;;; +18621-3;LL696-6;HL7_route;LA11409-2;175;Instillation, peritoneal dialysis port;;; +18621-3;LL696-6;HL7_route;LA11410-0;176;Instillation, rectal;;; +18621-3;LL696-6;HL7_route;LA11411-8;177;Instillation, rectal tube;;; +18621-3;LL696-6;HL7_route;LA11412-6;178;Instillation, sinus, unspecified;;; +18621-3;LL696-6;HL7_route;LA11413-4;179;Instillation, soft tissue;;; +18621-3;LL696-6;HL7_route;LA11414-2;180;Instillation, tracheostomy;;; +18621-3;LL696-6;HL7_route;LA11415-9;181;Instillation, transtympanic;;; +18621-3;LL696-6;HL7_route;LA11416-7;182;instillation, urethral;;; +18621-3;LL696-6;HL7_route;LA11417-5;183;Instillation, urinary catheter;;; +18621-3;LL696-6;HL7_route;LA11418-3;184;Insufflation;;; +18621-3;LL696-6;HL7_route;LA11419-1;185;Irrigation, genitourinary;;; +18621-3;LL696-6;HL7_route;LA11420-9;186;Irrigation, intragastric;;; +18621-3;LL696-6;HL7_route;LA11421-7;187;Irrigation, intralesional;;; +18621-3;LL696-6;HL7_route;LA11422-5;188;Irrigation, intraocular;;; +18621-3;LL696-6;HL7_route;LA11423-3;189;Irrigation, rectal;;; +18621-3;LL696-6;HL7_route;LA11424-1;190;Irrigation, urinary bladder;;; +18621-3;LL696-6;HL7_route;LA11425-8;191;Irrigation, urinary bladder, continuous;;; +18621-3;LL696-6;HL7_route;LA11426-6;192;Irrigation, urinary bladder, tidal;;; +18621-3;LL696-6;HL7_route;LA11427-4;193;Lavage, intragastric;;; +18621-3;LL696-6;HL7_route;LA11428-2;194;Mucosal absorption, intraduodenal;;; +18621-3;LL696-6;HL7_route;LA11429-0;195;Mucosal absorption, intratracheal;;; +18621-3;LL696-6;HL7_route;LA11430-8;196;Mucosal absorption, submucosal;;; +18621-3;LL696-6;HL7_route;LA11431-6;197;Nebulization, endotracheal tube;;; +18621-3;LL696-6;HL7_route;LA11432-4;198;Occlusive dressing technique;;; +18621-3;LL696-6;HL7_route;LA11433-2;199;Rinse, dental;;; +18621-3;LL696-6;HL7_route;LA11434-0;200;Rinse, oral;;; +18621-3;LL696-6;HL7_route;LA11435-7;201;Shampoo;;; +18621-3;LL696-6;HL7_route;LA11436-5;202;Subconjunctival;;; +18621-3;LL696-6;HL7_route;LA11437-3;203;Suck, oromucosal;;; +18621-3;LL696-6;HL7_route;LA11438-1;204;Suppository, urethral;;; +18621-3;LL696-6;HL7_route;LA11439-9;205;Swallow, oral;;; +18621-3;LL696-6;HL7_route;LA11440-7;206;Swish and spit out, oromucosal;;; +18621-3;LL696-6;HL7_route;LA11441-5;207;Swish and swallow, oromucosal;;; +18621-3;LL696-6;HL7_route;LA9456-0;208;Topical;;; +18621-3;LL696-6;HL7_route;LA11443-1;209;Topical absorption, transtympanic;;; +18621-3;LL696-6;HL7_route;LA11444-9;210;Topical application, buccal;;; +18621-3;LL696-6;HL7_route;LA11445-6;211;Topical application, cervical;;; +18621-3;LL696-6;HL7_route;LA11446-4;212;Topical application, dental;;; +18621-3;LL696-6;HL7_route;LA11447-2;213;Topical application, gingival;;; +18621-3;LL696-6;HL7_route;LA11448-0;214;Topical application, hair;;; +18621-3;LL696-6;HL7_route;LA11449-8;215;Topical application, intracorneal;;; +18621-3;LL696-6;HL7_route;LA11450-6;216;Topical application, intracoronal (dental);;; +18621-3;LL696-6;HL7_route;LA11451-4;217;Topical application, intraesophageal;;; +18621-3;LL696-6;HL7_route;LA11452-2;218;Topical application, intraileal;;; +18621-3;LL696-6;HL7_route;LA11453-0;219;Topical application, intralesional;;; +18621-3;LL696-6;HL7_route;LA11454-8;220;Topical application, intraluminal;;; +18621-3;LL696-6;HL7_route;LA11455-5;221;Topical application, intraocular;;; +18621-3;LL696-6;HL7_route;LA11456-3;222;Topical application, iontophoresis;;; +18621-3;LL696-6;HL7_route;LA11457-1;223;Topical application, laryngeal;;; +18621-3;LL696-6;HL7_route;LA11458-9;224;Topical application, mucous membrane;;; +18621-3;LL696-6;HL7_route;LA11459-7;225;Topical application, nail;;; +18621-3;LL696-6;HL7_route;LA11460-5;226;Topical application, nasal;;; +18621-3;LL696-6;HL7_route;LA11461-3;227;Topical application, ophthalmic;;; +18621-3;LL696-6;HL7_route;LA11462-1;228;Topical application, oral;;; +18621-3;LL696-6;HL7_route;LA11463-9;229;Topical application, oromucosal;;; +18621-3;LL696-6;HL7_route;LA11464-7;230;Topical application, oropharyngeal;;; +18621-3;LL696-6;HL7_route;LA11465-4;231;Topical application, perianal;;; +18621-3;LL696-6;HL7_route;LA11466-2;232;Topical application, perineal;;; +18621-3;LL696-6;HL7_route;LA11467-0;233;Topical application, periodontal;;; +18621-3;LL696-6;HL7_route;LA11468-8;234;Topical application, rectal;;; +18621-3;LL696-6;HL7_route;LA11469-6;235;Topical application, scalp;;; +18621-3;LL696-6;HL7_route;LA11470-4;236;Topical application, skin;;; +18621-3;LL696-6;HL7_route;LA11471-2;237;Topical application, soaked dressing;;; +18621-3;LL696-6;HL7_route;LA11472-0;238;Topical application, swab;;; +18621-3;LL696-6;HL7_route;LA11473-8;239;Topical application, transmucosal;;; +18621-3;LL696-6;HL7_route;LA11474-6;240;Topical application, vaginal;;; +18621-3;LL696-6;HL7_route;LA9454-5;241;Transdermal;;; +18621-3;LL696-6;HL7_route;LA9455-2;242;Translingual;;; +71468-3;LL696-6;HL7_route;LA11235-1;1;Chew, oral;;; +71468-3;LL696-6;HL7_route;LA11236-9;2;Diffusion, extracorporeal;;; +71468-3;LL696-6;HL7_route;LA11237-7;3;Diffusion, hemodialysis;;; +71468-3;LL696-6;HL7_route;LA11238-5;4;Diffusion, transdermal;;; +71468-3;LL696-6;HL7_route;LA11239-3;5;Dissolve, oral;;; +71468-3;LL696-6;HL7_route;LA11240-1;6;Dissolve, sublingual;;; +71468-3;LL696-6;HL7_route;LA11241-9;7;Douche, vaginal;;; +71468-3;LL696-6;HL7_route;LA11242-7;8;Electro-osmosis;;; +71468-3;LL696-6;HL7_route;LA11243-5;9;Enema, rectal;;; +71468-3;LL696-6;HL7_route;LA11244-3;10;Enema, rectal retention;;; +71468-3;LL696-6;HL7_route;LA11245-0;11;Flush, intravenous catheter;;; +71468-3;LL696-6;HL7_route;LA11246-8;12;Gargle;;; +71468-3;LL696-6;HL7_route;LA11247-6;13;Immersion (soak);;; +71468-3;LL696-6;HL7_route;LA11248-4;14;Implantation, intradermal;;; +71468-3;LL696-6;HL7_route;LA11249-2;15;Implantation, intravitreal;;; +71468-3;LL696-6;HL7_route;LA11250-0;16;Implantation, subcutaneous;;; +71468-3;LL696-6;HL7_route;LA11251-8;17;Infusion, epidural;;; +71468-3;LL696-6;HL7_route;LA11252-6;18;Infusion, intraarterial catheter;;; +71468-3;LL696-6;HL7_route;LA11253-4;19;Infusion, intracardiac;;; +71468-3;LL696-6;HL7_route;LA11254-2;20;Infusion, intracoronary;;; +71468-3;LL696-6;HL7_route;LA11255-9;21;Infusion, intraosseous, continuous;;; +71468-3;LL696-6;HL7_route;LA11256-7;22;Infusion, intrathecal;;; +71468-3;LL696-6;HL7_route;LA11257-5;23;Infusion, intravascular;;; +71468-3;LL696-6;HL7_route;LA11258-3;24;Infusion, intravenous;;; +71468-3;LL696-6;HL7_route;LA11259-1;25;Infusion, intravenous catheter;;; +71468-3;LL696-6;HL7_route;LA11260-9;26;Infusion, intravenous catheter, continuous;;; +71468-3;LL696-6;HL7_route;LA11261-7;27;Infusion, intravenous catheter, intermittent;;; +71468-3;LL696-6;HL7_route;LA11262-5;28;Infusion, intravenous catheter, pca pump;;; +71468-3;LL696-6;HL7_route;LA11263-3;29;Infusion, subcutaneous;;; +71468-3;LL696-6;HL7_route;LA11264-1;30;Inhalation, intermittent positive pressure breathing (ippb);;; +71468-3;LL696-6;HL7_route;LA11265-8;31;Inhalation, nasal;;; +71468-3;LL696-6;HL7_route;LA11266-6;32;Inhalation, nasal cannula;;; +71468-3;LL696-6;HL7_route;LA11268-2;34;Inhalation, nebulization;;; +71468-3;LL696-6;HL7_route;LA11269-0;35;Inhalation, nebulization, nasal;;; +71468-3;LL696-6;HL7_route;LA11270-8;36;Inhalation, nebulization, oral;;; +71468-3;LL696-6;HL7_route;LA11271-6;37;Inhalation, oral intermittent flow;;; +71468-3;LL696-6;HL7_route;LA11272-4;38;Inhalation, oral rebreather mask;;; +71468-3;LL696-6;HL7_route;LA11273-2;39;Inhalation, respiratory;;; +71468-3;LL696-6;HL7_route;LA11274-0;40;Inhalation, tracheostomy;;; +71468-3;LL696-6;HL7_route;LA11275-7;41;Inhalation, ventilator;;; +71468-3;LL696-6;HL7_route;LA11276-5;42;Inhalation, ventimask;;; +71468-3;LL696-6;HL7_route;LA11277-3;43;Injection, amniotic fluid;;; +71468-3;LL696-6;HL7_route;LA11278-1;44;Injection, biliary tract;;; +71468-3;LL696-6;HL7_route;LA11279-9;45;Injection, cervical;;; +71468-3;LL696-6;HL7_route;LA11280-7;46;Injection, endosinusial;;; +71468-3;LL696-6;HL7_route;LA11281-5;47;Injection, epidural;;; +71468-3;LL696-6;HL7_route;LA11282-3;48;Injection, epidural, push;;; +71468-3;LL696-6;HL7_route;LA11283-1;49;Injection, epidural, slow push;;; +71468-3;LL696-6;HL7_route;LA11284-9;50;Injection, extra-amniotic;;; +71468-3;LL696-6;HL7_route;LA11285-6;51;Injection, extracorporeal;;; +71468-3;LL696-6;HL7_route;LA11286-4;52;Injection, for cholangiography;;; +71468-3;LL696-6;HL7_route;LA11287-2;53;Injection, gastric button;;; +71468-3;LL696-6;HL7_route;LA11288-0;54;Injection, gingival;;; +71468-3;LL696-6;HL7_route;LA11289-8;55;Injection, hemodialysis port;;; +71468-3;LL696-6;HL7_route;LA11290-6;56;Injection, insulin pump;;; +71468-3;LL696-6;HL7_route;LA11291-4;57;Injection, interameningeal;;; +71468-3;LL696-6;HL7_route;LA11292-2;58;Injection, interstitial;;; +71468-3;LL696-6;HL7_route;LA11293-0;59;Injection, intra-abdominal;;; +71468-3;LL696-6;HL7_route;LA11294-8;60;Injection, intraarterial;;; +71468-3;LL696-6;HL7_route;LA11295-5;61;Injection, intraarterial, push;;; +71468-3;LL696-6;HL7_route;LA11296-3;62;Injection, intraarterial, slow push;;; +71468-3;LL696-6;HL7_route;LA11297-1;63;Injection, intraarticular;;; +71468-3;LL696-6;HL7_route;LA11298-9;64;Injection, intrabursal;;; +71468-3;LL696-6;HL7_route;LA11299-7;65;Injection, intracardiac;;; +71468-3;LL696-6;HL7_route;LA11300-3;66;Injection, intracardiac, push;;; +71468-3;LL696-6;HL7_route;LA11301-1;67;Injection, intracardiac, rapid push;;; +71468-3;LL696-6;HL7_route;LA11302-9;68;Injection, intracardiac, slow push;;; +71468-3;LL696-6;HL7_route;LA11303-7;69;Injection, intracartilaginous;;; +71468-3;LL696-6;HL7_route;LA11304-5;70;Injection, intracaudal;;; +71468-3;LL696-6;HL7_route;LA11305-2;71;Injection, intracavernous;;; +71468-3;LL696-6;HL7_route;LA11306-0;72;Injection, intracavitary;;; +71468-3;LL696-6;HL7_route;LA11307-8;73;Injection, intracerebral;;; +71468-3;LL696-6;HL7_route;LA11308-6;74;Injection, intracervical (uterus);;; +71468-3;LL696-6;HL7_route;LA11309-4;75;Injection, intracisternal;;; +71468-3;LL696-6;HL7_route;LA11310-2;76;Injection, intracoronary;;; +71468-3;LL696-6;HL7_route;LA11311-0;77;Injection, intracoronary, push;;; +71468-3;LL696-6;HL7_route;LA11312-8;78;Injection, intracorpus cavernosum;;; +71468-3;LL696-6;HL7_route;LA11313-6;79;Injection, intradermal;;; +71468-3;LL696-6;HL7_route;LA11314-4;80;Injection, intradiscal;;; +71468-3;LL696-6;HL7_route;LA11315-1;81;Injection, intraductal;;; +71468-3;LL696-6;HL7_route;LA11316-9;82;Injection, intradural;;; +71468-3;LL696-6;HL7_route;LA11317-7;83;Injection, intraepidermal;;; +71468-3;LL696-6;HL7_route;LA11318-5;84;Injection, intraepithelial;;; +71468-3;LL696-6;HL7_route;LA11319-3;85;Injection, intralesional;;; +71468-3;LL696-6;HL7_route;LA11320-1;86;Injection, intraluminal;;; +71468-3;LL696-6;HL7_route;LA11321-9;87;Injection, intralymphatic;;; +71468-3;LL696-6;HL7_route;LA11322-7;88;Injection, intramedullary;;; +71468-3;LL696-6;HL7_route;LA11323-5;89;Injection, intramuscular;;; +71468-3;LL696-6;HL7_route;LA11324-3;90;Injection, intramuscular, deep;;; +71468-3;LL696-6;HL7_route;LA11325-0;91;Injection, intramuscular, z track;;; +71468-3;LL696-6;HL7_route;LA11326-8;92;Injection, intraocular;;; +71468-3;LL696-6;HL7_route;LA11327-6;93;Injection, intraosseous;;; +71468-3;LL696-6;HL7_route;LA11328-4;94;Injection, intraovarian;;; +71468-3;LL696-6;HL7_route;LA11329-2;95;Injection, intrapericardial;;; +71468-3;LL696-6;HL7_route;LA11330-0;96;Injection, intraperitoneal;;; +71468-3;LL696-6;HL7_route;LA11331-8;97;Injection, intrapleural;;; +71468-3;LL696-6;HL7_route;LA11332-6;98;Injection, intraprostatic;;; +71468-3;LL696-6;HL7_route;LA11333-4;99;Injection, intrapulmonary;;; +71468-3;LL696-6;HL7_route;LA11334-2;100;Injection, intraspinal;;; +71468-3;LL696-6;HL7_route;LA11335-9;101;Injection, intrasternal;;; +71468-3;LL696-6;HL7_route;LA11336-7;102;Injection, intrasynovial;;; +71468-3;LL696-6;HL7_route;LA11337-5;103;Injection, intratendinous;;; +71468-3;LL696-6;HL7_route;LA11338-3;104;Injection, intratesticular;;; +71468-3;LL696-6;HL7_route;LA11339-1;105;Injection, intrathecal;;; +71468-3;LL696-6;HL7_route;LA11340-9;106;Injection, intrathoracic;;; +71468-3;LL696-6;HL7_route;LA11341-7;107;Injection, intratubular;;; +71468-3;LL696-6;HL7_route;LA11342-5;108;Injection, intratumor;;; +71468-3;LL696-6;HL7_route;LA11343-3;109;Injection, intratympanic;;; +71468-3;LL696-6;HL7_route;LA11344-1;110;Injection, intraureteral, retrograde;;; +71468-3;LL696-6;HL7_route;LA11345-8;111;Injection, intrauterine;;; +71468-3;LL696-6;HL7_route;LA11346-6;112;Injection, intravascular;;; +71468-3;LL696-6;HL7_route;LA11347-4;113;Injection, intravenous;;; +71468-3;LL696-6;HL7_route;LA11348-2;114;Injection, intravenous, bolus;;; +71468-3;LL696-6;HL7_route;LA11349-0;115;Injection, intravenous, push;;; +71468-3;LL696-6;HL7_route;LA11350-8;116;Injection, intravenous, rapid push;;; +71468-3;LL696-6;HL7_route;LA11351-6;117;Injection, intravenous, slow push;;; +71468-3;LL696-6;HL7_route;LA11352-4;118;Injection, intraventricular (heart);;; +71468-3;LL696-6;HL7_route;LA11353-2;119;Injection, intravesicle;;; +71468-3;LL696-6;HL7_route;LA11354-0;120;Injection, intravitreal;;; +71468-3;LL696-6;HL7_route;LA11355-7;121;Injection, paranasal sinuses;;; +71468-3;LL696-6;HL7_route;LA11356-5;122;Injection, parenteral;;; +71468-3;LL696-6;HL7_route;LA11357-3;123;Injection, periarticular;;; +71468-3;LL696-6;HL7_route;LA11358-1;124;Injection, peridural;;; +71468-3;LL696-6;HL7_route;LA11359-9;125;Injection, perineural;;; +71468-3;LL696-6;HL7_route;LA11360-7;126;Injection, periodontal;;; +71468-3;LL696-6;HL7_route;LA11361-5;127;Injection, peritoneal dialysis port;;; +71468-3;LL696-6;HL7_route;LA11362-3;128;Injection, retrobulbar;;; +71468-3;LL696-6;HL7_route;LA11363-1;129;Injection, soft tissue;;; +71468-3;LL696-6;HL7_route;LA11364-9;130;Injection, subarachnoid;;; +71468-3;LL696-6;HL7_route;LA11365-6;131;Injection, subconjunctival;;; +71468-3;LL696-6;HL7_route;LA11366-4;132;Injection, subcutaneous;;; +71468-3;LL696-6;HL7_route;LA11367-2;133;Injection, sublesional;;; +71468-3;LL696-6;HL7_route;LA11368-0;134;Injection, submucosal;;; +71468-3;LL696-6;HL7_route;LA11369-8;135;Injection, transplacental;;; +71468-3;LL696-6;HL7_route;LA11370-6;136;Injection, transtracheal;;; +71468-3;LL696-6;HL7_route;LA11371-4;137;Injection, ureteral;;; +71468-3;LL696-6;HL7_route;LA11372-2;138;Injection, urethral;;; +71468-3;LL696-6;HL7_route;LA11373-0;139;Injection, urinary bladder;;; +71468-3;LL696-6;HL7_route;LA11374-8;140;Insertion, cervical (uterine);;; +71468-3;LL696-6;HL7_route;LA11375-5;141;Insertion, intraocular, surgical;;; +71468-3;LL696-6;HL7_route;LA11376-3;142;Insertion, intrauterine;;; +71468-3;LL696-6;HL7_route;LA11377-1;143;Insertion, lacrimal puncta;;; +71468-3;LL696-6;HL7_route;LA11378-9;144;Insertion, rectal;;; +71468-3;LL696-6;HL7_route;LA11379-7;145;Insertion, subcutaneous, surgical;;; +71468-3;LL696-6;HL7_route;LA11380-5;146;Insertion, urethral;;; +71468-3;LL696-6;HL7_route;LA11381-3;147;Insertion, vaginal;;; +71468-3;LL696-6;HL7_route;LA11382-1;148;Instillation, cecostomy;;; +71468-3;LL696-6;HL7_route;LA11383-9;149;Instillation, chest tube;;; +71468-3;LL696-6;HL7_route;LA11384-7;150;Instillation, continuous ambulatory peritoneal dialysis port;;; +71468-3;LL696-6;HL7_route;LA11385-4;151;Instillation, endotracheal tube;;; +71468-3;LL696-6;HL7_route;LA11386-2;152;Instillation, enteral;;; +71468-3;LL696-6;HL7_route;LA11387-0;153;Instillation, enteral feeding tube;;; +71468-3;LL696-6;HL7_route;LA11388-8;154;Instillation, gastro-jejunostomy tube;;; +71468-3;LL696-6;HL7_route;LA11389-6;155;Instillation, gastrostomy tube;;; +71468-3;LL696-6;HL7_route;LA11390-4;156;Instillation, intrabronchial;;; +71468-3;LL696-6;HL7_route;LA11391-2;157;Instillation, intraduodenal;;; +71468-3;LL696-6;HL7_route;LA11392-0;158;Instillation, intraesophageal;;; +71468-3;LL696-6;HL7_route;LA11393-8;159;Instillation, intragastric;;; +71468-3;LL696-6;HL7_route;LA11394-6;160;Instillation, intraileal;;; +71468-3;LL696-6;HL7_route;LA11395-3;161;Instillation, intraocular;;; +71468-3;LL696-6;HL7_route;LA11396-1;162;Instillation, intrasinal;;; +71468-3;LL696-6;HL7_route;LA11397-9;163;Instillation, intratracheal;;; +71468-3;LL696-6;HL7_route;LA11398-7;164;Instillation, intrauterine;;; +71468-3;LL696-6;HL7_route;LA11399-5;165;Instillation, jejunostomy tube;;; +71468-3;LL696-6;HL7_route;LA11400-1;166;Instillation, laryngeal;;; +71468-3;LL696-6;HL7_route;LA11401-9;167;Instillation, nasal;;; +71468-3;LL696-6;HL7_route;LA11402-7;168;Instillation, nasogastric;;; +71468-3;LL696-6;HL7_route;LA11403-5;169;Instillation, nasogastric tube;;; +71468-3;LL696-6;HL7_route;LA11404-3;170;Instillation, nasotracheal tube;;; +71468-3;LL696-6;HL7_route;LA11405-0;171;Instillation, orogastric tube;;; +71468-3;LL696-6;HL7_route;LA11406-8;172;Instillation, orojejunum tube;;; +71468-3;LL696-6;HL7_route;LA11407-6;173;Instillation, otic;;; +71468-3;LL696-6;HL7_route;LA11408-4;174;Instillation, paranasal sinuses;;; +71468-3;LL696-6;HL7_route;LA11409-2;175;Instillation, peritoneal dialysis port;;; +71468-3;LL696-6;HL7_route;LA11410-0;176;Instillation, rectal;;; +71468-3;LL696-6;HL7_route;LA11411-8;177;Instillation, rectal tube;;; +71468-3;LL696-6;HL7_route;LA11412-6;178;Instillation, sinus, unspecified;;; +71468-3;LL696-6;HL7_route;LA11413-4;179;Instillation, soft tissue;;; +71468-3;LL696-6;HL7_route;LA11414-2;180;Instillation, tracheostomy;;; +71468-3;LL696-6;HL7_route;LA11415-9;181;Instillation, transtympanic;;; +71468-3;LL696-6;HL7_route;LA11416-7;182;instillation, urethral;;; +71468-3;LL696-6;HL7_route;LA11417-5;183;Instillation, urinary catheter;;; +71468-3;LL696-6;HL7_route;LA11418-3;184;Insufflation;;; +71468-3;LL696-6;HL7_route;LA11419-1;185;Irrigation, genitourinary;;; +71468-3;LL696-6;HL7_route;LA11420-9;186;Irrigation, intragastric;;; +71468-3;LL696-6;HL7_route;LA11421-7;187;Irrigation, intralesional;;; +71468-3;LL696-6;HL7_route;LA11422-5;188;Irrigation, intraocular;;; +71468-3;LL696-6;HL7_route;LA11423-3;189;Irrigation, rectal;;; +71468-3;LL696-6;HL7_route;LA11424-1;190;Irrigation, urinary bladder;;; +71468-3;LL696-6;HL7_route;LA11425-8;191;Irrigation, urinary bladder, continuous;;; +71468-3;LL696-6;HL7_route;LA11426-6;192;Irrigation, urinary bladder, tidal;;; +71468-3;LL696-6;HL7_route;LA11427-4;193;Lavage, intragastric;;; +71468-3;LL696-6;HL7_route;LA11428-2;194;Mucosal absorption, intraduodenal;;; +71468-3;LL696-6;HL7_route;LA11429-0;195;Mucosal absorption, intratracheal;;; +71468-3;LL696-6;HL7_route;LA11430-8;196;Mucosal absorption, submucosal;;; +71468-3;LL696-6;HL7_route;LA11431-6;197;Nebulization, endotracheal tube;;; +71468-3;LL696-6;HL7_route;LA11432-4;198;Occlusive dressing technique;;; +71468-3;LL696-6;HL7_route;LA11433-2;199;Rinse, dental;;; +71468-3;LL696-6;HL7_route;LA11434-0;200;Rinse, oral;;; +71468-3;LL696-6;HL7_route;LA11435-7;201;Shampoo;;; +71468-3;LL696-6;HL7_route;LA11436-5;202;Subconjunctival;;; +71468-3;LL696-6;HL7_route;LA11437-3;203;Suck, oromucosal;;; +71468-3;LL696-6;HL7_route;LA11438-1;204;Suppository, urethral;;; +71468-3;LL696-6;HL7_route;LA11439-9;205;Swallow, oral;;; +71468-3;LL696-6;HL7_route;LA11440-7;206;Swish and spit out, oromucosal;;; +71468-3;LL696-6;HL7_route;LA11441-5;207;Swish and swallow, oromucosal;;; +71468-3;LL696-6;HL7_route;LA9456-0;208;Topical;;; +71468-3;LL696-6;HL7_route;LA11443-1;209;Topical absorption, transtympanic;;; +71468-3;LL696-6;HL7_route;LA11444-9;210;Topical application, buccal;;; +71468-3;LL696-6;HL7_route;LA11445-6;211;Topical application, cervical;;; +71468-3;LL696-6;HL7_route;LA11446-4;212;Topical application, dental;;; +71468-3;LL696-6;HL7_route;LA11447-2;213;Topical application, gingival;;; +71468-3;LL696-6;HL7_route;LA11448-0;214;Topical application, hair;;; +71468-3;LL696-6;HL7_route;LA11449-8;215;Topical application, intracorneal;;; +71468-3;LL696-6;HL7_route;LA11450-6;216;Topical application, intracoronal (dental);;; +71468-3;LL696-6;HL7_route;LA11451-4;217;Topical application, intraesophageal;;; +71468-3;LL696-6;HL7_route;LA11452-2;218;Topical application, intraileal;;; +71468-3;LL696-6;HL7_route;LA11453-0;219;Topical application, intralesional;;; +71468-3;LL696-6;HL7_route;LA11454-8;220;Topical application, intraluminal;;; +71468-3;LL696-6;HL7_route;LA11455-5;221;Topical application, intraocular;;; +71468-3;LL696-6;HL7_route;LA11456-3;222;Topical application, iontophoresis;;; +71468-3;LL696-6;HL7_route;LA11457-1;223;Topical application, laryngeal;;; +71468-3;LL696-6;HL7_route;LA11458-9;224;Topical application, mucous membrane;;; +71468-3;LL696-6;HL7_route;LA11459-7;225;Topical application, nail;;; +71468-3;LL696-6;HL7_route;LA11460-5;226;Topical application, nasal;;; +71468-3;LL696-6;HL7_route;LA11461-3;227;Topical application, ophthalmic;;; +71468-3;LL696-6;HL7_route;LA11462-1;228;Topical application, oral;;; +71468-3;LL696-6;HL7_route;LA11463-9;229;Topical application, oromucosal;;; +71468-3;LL696-6;HL7_route;LA11464-7;230;Topical application, oropharyngeal;;; +71468-3;LL696-6;HL7_route;LA11465-4;231;Topical application, perianal;;; +71468-3;LL696-6;HL7_route;LA11466-2;232;Topical application, perineal;;; +71468-3;LL696-6;HL7_route;LA11467-0;233;Topical application, periodontal;;; +71468-3;LL696-6;HL7_route;LA11468-8;234;Topical application, rectal;;; +71468-3;LL696-6;HL7_route;LA11469-6;235;Topical application, scalp;;; +71468-3;LL696-6;HL7_route;LA11470-4;236;Topical application, skin;;; +71468-3;LL696-6;HL7_route;LA11471-2;237;Topical application, soaked dressing;;; +71468-3;LL696-6;HL7_route;LA11472-0;238;Topical application, swab;;; +71468-3;LL696-6;HL7_route;LA11473-8;239;Topical application, transmucosal;;; +71468-3;LL696-6;HL7_route;LA11474-6;240;Topical application, vaginal;;; +71468-3;LL696-6;HL7_route;LA9454-5;241;Transdermal;;; +71468-3;LL696-6;HL7_route;LA9455-2;242;Translingual;;; +18626-2;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +18626-2;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +27470-4;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +27470-4;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +27474-6;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +27474-6;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +27483-7;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +27483-7;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +27597-4;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +27597-4;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +27660-0;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +27660-0;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +27699-8;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +27699-8;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +27750-9;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +27750-9;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +29162-5;LL502-6;[HL7-9002] Original|Updated;LA9505-4;0;Original;;; +29162-5;LL502-6;[HL7-9002] Original|Updated;LA9506-2;1;Updated;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA46-8;1;Other;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20350-7;2;Alcoholism;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20352-3;3;Bleeding disorder;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20353-1;4;Currently receiving chemotherapy for cancer;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20354-9;5;Congenital anomalies;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA12740-9;6;Congestive heart failure (CHF);;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20356-4;7;Current smoker;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20357-2;8;Chronic renal failure;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA22244-0;9;Cerebrovascular accident;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA14291-1;10;Diabetes mellitus;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20360-6;11;Disseminated cancer;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20361-4;12;Advanced directive limiting care;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20363-0;13;Functionally dependent health status;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA7444-8;14;Hypertension;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20368-9;15;Prematurity;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28200-6;16;Chronic obstructive pulmonary disease;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20370-5;17;Steroid use;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA9639-1;18;Cirrhosis;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20372-1;19;Dementia;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28412-7;20;Attention deficit disorder/Attention deficit hyperactivity disorder (ADD/ADHD);;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28199-0;21;Anticoagulant therapy;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA14275-4;22;Angina pectoris;194828000;Angina (disorder);http://snomed.info/sct +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28198-2;23;Mental/personality disorder;;; +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA14274-7;24;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28197-4;25;Peripheral arterial disease;399957001;Peripheral arterial occlusive disease (disorder);http://snomed.info/sct +18630-4;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28195-8;26;Substance abuse disorder;66214007;Substance abuse (disorder);http://snomed.info/sct +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA46-8;1;Other;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20350-7;2;Alcoholism;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20352-3;3;Bleeding disorder;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20353-1;4;Currently receiving chemotherapy for cancer;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20354-9;5;Congenital anomalies;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA12740-9;6;Congestive heart failure (CHF);;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20356-4;7;Current smoker;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20357-2;8;Chronic renal failure;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA22244-0;9;Cerebrovascular accident;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA14291-1;10;Diabetes mellitus;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20360-6;11;Disseminated cancer;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20361-4;12;Advanced directive limiting care;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20363-0;13;Functionally dependent health status;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA7444-8;14;Hypertension;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20368-9;15;Prematurity;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28200-6;16;Chronic obstructive pulmonary disease;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20370-5;17;Steroid use;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA9639-1;18;Cirrhosis;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA20372-1;19;Dementia;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28412-7;20;Attention deficit disorder/Attention deficit hyperactivity disorder (ADD/ADHD);;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28199-0;21;Anticoagulant therapy;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA14275-4;22;Angina pectoris;194828000;Angina (disorder);http://snomed.info/sct +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28198-2;23;Mental/personality disorder;;; +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA14274-7;24;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28197-4;25;Peripheral arterial disease;399957001;Peripheral arterial occlusive disease (disorder);http://snomed.info/sct +74291-6;LL4747-3;NTDS_DG_01_Co-morbid Conditions_v2018;LA28195-8;26;Substance abuse disorder;66214007;Substance abuse (disorder);http://snomed.info/sct +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32303-2;1;Degenerative disease;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32304-0;2;Non-degenerative deformity;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32103-6;3;Fracture/trauma;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32104-4;4;Pathological fracture;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32105-1;5;Spondylolisthesis (non-degenerative);;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32106-9;6;Chiari;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA7446-3;7;Infection;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA16304-0;8;Tumor;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32107-7;9;Repeat surgery;;; +18630-4;LL5960-1;Spine Tango - Main Pathology;LA32305-7;11;Other: specify;;; +18637-9;LL1048-9;Days|Months|Weeks|Quarter|As needed;LA8999-0;1;Days;;; +18637-9;LL1048-9;Days|Months|Weeks|Quarter|As needed;LA9001-4;2;Months;;; +18637-9;LL1048-9;Days|Months|Weeks|Quarter|As needed;LA9000-6;3;Weeks;;; +18637-9;LL1048-9;Days|Months|Weeks|Quarter|As needed;LA14059-2;4;Quarter;;; +18637-9;LL1048-9;Days|Months|Weeks|Quarter|As needed;LA14060-0;5;As needed;;; +18645-2;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +18645-2;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +27491-0;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +27491-0;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +27539-6;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +27539-6;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +27561-0;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +27561-0;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +27612-1;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +27612-1;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +27675-8;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +27675-8;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +27714-5;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +27714-5;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +27765-7;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +27765-7;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +29171-6;LL503-4;[HL7-9003] Continue|Discontinue;LA9507-0;0;Continue;;; +29171-6;LL503-4;[HL7-9003] Continue|Discontinue;LA9508-8;1;Discontinue;;; +18652-8;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +18652-8;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +18652-8;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +18652-8;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +18652-8;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +27499-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +27499-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +27499-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +27499-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +27499-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +27546-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +27546-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +27546-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +27546-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +27546-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +27568-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +27568-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +27568-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +27568-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +27568-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +27619-6;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +27619-6;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +27619-6;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +27619-6;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +27619-6;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +27682-4;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +27682-4;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +27682-4;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +27682-4;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +27682-4;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +27721-0;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +27721-0;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +27721-0;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +27721-0;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +27721-0;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +27772-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +27772-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +27772-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +27772-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +27772-3;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +29178-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +29178-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +29178-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +29178-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +29178-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +75328-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +75328-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +75328-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +75328-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +75328-5;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +92725-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8969-3;0;Poor;;; +92725-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9510-4;1;Guarded;;; +92725-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8968-5;2;Fair;;; +92725-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA8967-7;3;Good;;; +92725-1;LL504-2;[HL7-9005] Poor|Guarded|Fair|Good|Excellent;LA9206-9;4;Excellent;;; +18668-4;LL509-1;HL79015_Frequency Base Period;LA9578-1;0;per second;;; +18668-4;LL509-1;HL79015_Frequency Base Period;LA9579-9;1;per minute;;; +18668-4;LL509-1;HL79015_Frequency Base Period;LA9580-7;2;per hour;;; +18668-4;LL509-1;HL79015_Frequency Base Period;LA9581-5;3;per day;;; +18668-4;LL509-1;HL79015_Frequency Base Period;LA9582-3;4;per week;;; +18668-4;LL509-1;HL79015_Frequency Base Period;LA9583-1;5;per month;;; +18668-4;LL509-1;HL79015_Frequency Base Period;LA9584-9;6;per year;;; +18673-4;LL505-9;HL79006_Rehab serv remission;LA9514-6;0;Early Full Remission;;; +18673-4;LL505-9;HL79006_Rehab serv remission;LA9515-3;1;Early Partial Remission;;; +18673-4;LL505-9;HL79006_Rehab serv remission;LA9516-1;2;Sustained Full Remission;;; +18673-4;LL505-9;HL79006_Rehab serv remission;LA9517-9;3;Sustained Partial Remission;;; +18676-7;LL1047-1;Days|Months|Weeks;LA8999-0;1;Days;;; +18676-7;LL1047-1;Days|Months|Weeks;LA9001-4;2;Months;;; +18676-7;LL1047-1;Days|Months|Weeks;LA9000-6;3;Weeks;;; +18685-8;LL491-2;DEEDS4.18_1st B/P;LA9360-4;0;Not measurable, but pulse palpable;;; +18687-4;LL493-8;DEEDS4.24_1st resp rate;LA9365-3;0;Agonal respirations;;; +18687-4;LL493-8;DEEDS4.24_1st resp rate;LA9366-1;1;Respiratory assistance with manual or mechanical ventilation;;; +18689-0;LL527-3;DEEDS4.26_1st Temp;LA9620-1;1;Not measured;;; +18689-0;LL527-3;DEEDS4.26_1st Temp;LA4489-6;2;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +18692-4;LL528-1;DEEDS4.29_Measured weight;LA9620-1;1;Not measured;;; +18692-4;LL528-1;DEEDS4.29_Measured weight;LA4489-6;2;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA4634-7;0;Patient;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9396-8;1;Paramedic/emergency medical technician;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA6654-3;2;Parent;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9398-4;3;Spouse/partner;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA6311-0;4;Other family member;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9400-8;5;Caretaker;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9401-6;6;Nurse;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA4687-5;7;Physician;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9403-2;8;Other practitioner;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9404-0;9;Acquaintance;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9405-7;10;Bystander;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9406-5;11;Law enforcement personnel;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA9407-3;12;Existing medical records;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA4723-8;13;Other Source;;; +18697-3;LL497-9;DEEDS5.19_Clin finding data source;LA4413-6;14;Unknown Source;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9287-9;0;ED attending or staff physician;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9288-7;1;ED resident (includes interns, house staff at all postgraduate levels, and fellows);;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9289-5;2;Non-ED-based attending or staff physician (includes primary care physicians and other attending or staff physicians called to the ED once the patient arrives);;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9290-3;3;Non-ED-based resident (includes interns, house staff at all postgraduate levels, and fellows working on the service of a non- ED-based attending or staff physician);;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9291-1;4;Registered nurse;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9292-9;5;Nurse practitioner;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9293-7;6;Attending nurse practitioner;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9294-5;7;Other advanced practice nurse (clinical nurse specialist, nurse anesthetist, or nurse midwife);;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9295-2;8;Licensed practical nurse or licensed vocational nurse;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9296-0;9;Physician assistant;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9297-8;10;Respiratory therapist;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9298-6;11;Nurse's aide;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9299-4;12;ED technician;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9300-0;13;Phlebotomy technician;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9301-8;14;ECG technician;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9302-6;15;Radiologic technologist or technician;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9303-4;16;Other technician or technologist;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA6657-6;17;Social worker;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9305-9;18;Medical student;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9306-7;19;Registered nurse student;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9307-5;20;Nurse practitioner student;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9308-3;21;Other advanced practice nurse student (clinical nurse specialist, Nurse anesthetist, or nurse midwife);;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9309-1;22;Licensed practical nurse or licensed vocational nurse student;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9310-9;23;Physician assistant student;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9311-7;24;Nurse's aide, technician, or technologist student;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9312-5;25;Other student practitioner;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9313-3;26;Other role;;; +18702-1;LL482-1;DEEDS2.10_ED Practitioner Role;LA9314-1;27;Unknown role;;; +18709-6;LL526-5;DEEDS4.21_1st HR;LA9620-1;1;Not measured;;; +18709-6;LL526-5;DEEDS4.21_1st HR;LA4489-6;2;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9462-8;0;Evaluation and Management;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9463-6;1;Endoscopy;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9464-4;2;Trach Tube/GI Tube Insertion/Placement;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9465-1;3;No one at home to receive the patient;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9466-9;4;Pre-Surgical Testing;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9467-7;5;Nerve Blocks;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9468-5;6;Cast Application/Removal;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA7214-5;7;Cardiac catheterization;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9470-1;8;Cataract Surgery;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9471-9;9;Other Ambulatory Surgery: Debridement Decubitis Ulcer;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9472-7;10;Other Ambulatory Surgery: Shunt declotting;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9473-5;11;Other Ambulatory Surgery: Shunt Maintenance;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9474-3;12;Other Ambulatory Surgery: Lithotripsy;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9475-0;13;Other Ambulatory Surgery: Biopsy;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9476-8;14;Radiation Therapy (Cobalt Therapy);;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9477-6;15;CAT Scans;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9478-4;16;MRI Scans;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9479-2;17;PET Scans;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9480-0;18;Bone Scans;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9481-8;19;X-Rays;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9482-6;20;Ultrasounds;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9483-4;21;Diagnostic Mammography;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9484-2;22;Nuclear Medicine Tests;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA6172-6;23;Chemotherapy;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9486-7;24;Other Intravenous Therapy: Antibiotic;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9487-5;25;Other Intravenous Therapy: Hydration;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9488-3;26;Arterial Blood Gases;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9489-1;27;Other Laboratory Testing (Specify Type of Lab Test);;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9490-9;28;Blood Transfusions;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9491-7;29;Respiratory Therapy;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9492-5;30;Whole Body Hyperbaric Therapy;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9493-3;31;Other Hyperbaric Therapy;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9494-1;32;Physical Therapy;91251008;Physical therapy procedure (regime/therapy);http://snomed.info/sct +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9495-8;33;Occupational Therapy;84478008;Occupational therapy (regime/therapy);http://snomed.info/sct +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9496-6;34;Speech-Language Pathology;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9497-4;35;Pulmonary Function Testing;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9498-2;36;Cardiac Stress Testing;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9499-0;37;EKG/ECG/EEG;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9500-5;38;Renal Dialysis;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9501-3;39;Electroconvulsive Therapy (ECT);;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9502-1;40;Other Psychiatric/Psychological Services (Specify Type of Service);;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA7200-4;41;Rehabilitation;;; +18814-4;LL501-8;HL79000_Med reason-unsched trip;LA9504-7;42;Detoxification;;; +18816-9;LL511-7;NDC;;0;;;; +27461-3;LL511-7;NDC;;0;;;; +27524-8;LL511-7;NDC;;0;;;; +27588-3;LL511-7;NDC;;0;;;; +27639-4;LL511-7;NDC;;0;;;; +27651-9;LL511-7;NDC;;0;;;; +27741-8;LL511-7;NDC;;0;;;; +27792-1;LL511-7;NDC;;0;;;; +29196-3;LL511-7;NDC;;0;;;; +52424-9;LL511-7;NDC;;0;;;; +52428-0;LL511-7;NDC;;0;;;; +18819-3;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +18819-3;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +18819-3;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +18819-3;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +18819-3;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +18819-3;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +18819-3;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +18819-3;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +18819-3;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +18819-3;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +18819-3;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +18819-3;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +18819-3;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +18819-3;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +18819-3;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +18819-3;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +18819-3;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +18819-3;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +18819-3;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +18819-3;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +18819-3;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +18819-3;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +18819-3;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +18819-3;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +18819-3;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +18819-3;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +18819-3;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +18819-3;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +18819-3;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +18819-3;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +18819-3;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +18819-3;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +18819-3;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +18819-3;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +18819-3;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +18819-3;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +18819-3;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +18819-3;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +27468-8;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +27468-8;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +27468-8;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +27468-8;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +27468-8;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +27468-8;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +27468-8;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +27468-8;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +27468-8;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +27468-8;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +27468-8;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +27468-8;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +27468-8;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +27468-8;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +27468-8;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +27468-8;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +27468-8;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +27468-8;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +27468-8;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +27468-8;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +27468-8;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +27468-8;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +27468-8;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +27468-8;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +27468-8;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +27468-8;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +27468-8;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +27468-8;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +27468-8;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +27468-8;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +27468-8;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +27468-8;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +27468-8;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +27468-8;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +27468-8;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +27468-8;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +27468-8;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +27468-8;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +27537-0;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +27537-0;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +27537-0;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +27537-0;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +27537-0;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +27537-0;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +27537-0;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +27537-0;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +27537-0;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +27537-0;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +27537-0;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +27537-0;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +27537-0;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +27537-0;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +27537-0;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +27537-0;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +27537-0;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +27537-0;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +27537-0;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +27537-0;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +27537-0;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +27537-0;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +27537-0;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +27537-0;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +27537-0;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +27537-0;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +27537-0;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +27537-0;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +27537-0;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +27537-0;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +27537-0;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +27537-0;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +27537-0;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +27537-0;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +27537-0;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +27537-0;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +27537-0;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +27537-0;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +27595-8;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +27595-8;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +27595-8;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +27595-8;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +27595-8;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +27595-8;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +27595-8;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +27595-8;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +27595-8;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +27595-8;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +27595-8;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +27595-8;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +27595-8;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +27595-8;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +27595-8;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +27595-8;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +27595-8;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +27595-8;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +27595-8;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +27595-8;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +27595-8;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +27595-8;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +27595-8;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +27595-8;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +27595-8;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +27595-8;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +27595-8;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +27595-8;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +27595-8;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +27595-8;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +27595-8;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +27595-8;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +27595-8;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +27595-8;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +27595-8;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +27595-8;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +27595-8;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +27595-8;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +27646-9;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +27646-9;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +27646-9;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +27646-9;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +27646-9;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +27646-9;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +27646-9;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +27646-9;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +27646-9;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +27646-9;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +27646-9;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +27646-9;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +27646-9;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +27646-9;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +27646-9;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +27646-9;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +27646-9;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +27646-9;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +27646-9;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +27646-9;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +27646-9;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +27646-9;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +27646-9;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +27646-9;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +27646-9;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +27646-9;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +27646-9;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +27646-9;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +27646-9;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +27646-9;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +27646-9;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +27646-9;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +27646-9;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +27646-9;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +27646-9;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +27646-9;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +27646-9;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +27646-9;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +27658-4;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +27658-4;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +27658-4;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +27658-4;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +27658-4;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +27658-4;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +27658-4;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +27658-4;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +27658-4;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +27658-4;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +27658-4;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +27658-4;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +27658-4;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +27658-4;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +27658-4;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +27658-4;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +27658-4;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +27658-4;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +27658-4;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +27658-4;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +27658-4;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +27658-4;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +27658-4;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +27658-4;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +27658-4;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +27658-4;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +27658-4;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +27658-4;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +27658-4;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +27658-4;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +27658-4;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +27658-4;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +27658-4;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +27658-4;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +27658-4;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +27658-4;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +27658-4;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +27658-4;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +27748-3;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +27748-3;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +27748-3;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +27748-3;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +27748-3;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +27748-3;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +27748-3;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +27748-3;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +27748-3;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +27748-3;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +27748-3;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +27748-3;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +27748-3;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +27748-3;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +27748-3;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +27748-3;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +27748-3;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +27748-3;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +27748-3;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +27748-3;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +27748-3;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +27748-3;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +27748-3;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +27748-3;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +27748-3;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +27748-3;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +27748-3;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +27748-3;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +27748-3;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +27748-3;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +27748-3;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +27748-3;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +27748-3;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +27748-3;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +27748-3;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +27748-3;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +27748-3;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +27748-3;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +27799-6;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +27799-6;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +27799-6;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +27799-6;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +27799-6;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +27799-6;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +27799-6;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +27799-6;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +27799-6;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +27799-6;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +27799-6;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +27799-6;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +27799-6;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +27799-6;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +27799-6;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +27799-6;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +27799-6;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +27799-6;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +27799-6;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +27799-6;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +27799-6;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +27799-6;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +27799-6;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +27799-6;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +27799-6;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +27799-6;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +27799-6;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +27799-6;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +27799-6;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +27799-6;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +27799-6;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +27799-6;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +27799-6;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +27799-6;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +27799-6;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +27799-6;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +27799-6;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +27799-6;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +29197-1;LL500-0;HL70162_Route of administration;LA9415-6;0;Apply Externally;;; +29197-1;LL500-0;HL70162_Route of administration;LA9416-4;1;Buccal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9417-2;2;Dental;;; +29197-1;LL500-0;HL70162_Route of administration;LA9418-0;3;Epidural;;; +29197-1;LL500-0;HL70162_Route of administration;LA9419-8;4;Endotrachial Tube*;;; +29197-1;LL500-0;HL70162_Route of administration;LA9420-6;5;Gastronomy Tube;;; +29197-1;LL500-0;HL70162_Route of administration;LA9421-4;6;GU Irrigant;;; +29197-1;LL500-0;HL70162_Route of administration;LA9422-2;7;Intra-arterial;;; +29197-1;LL500-0;HL70162_Route of administration;LA9423-0;8;Intrabursal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9424-8;9;Intracardiac;;; +29197-1;LL500-0;HL70162_Route of administration;LA9425-5;10;Intracervical (uterus);;; +29197-1;LL500-0;HL70162_Route of administration;LA9426-3;11;Intradermal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9427-1;12;Inhalation;;; +29197-1;LL500-0;HL70162_Route of administration;LA9428-9;13;Intrahepatic artery;;; +29197-1;LL500-0;HL70162_Route of administration;LA9429-7;14;Intramuscular;;; +29197-1;LL500-0;HL70162_Route of administration;LA9430-5;15;Immerse (Soak) Body Part;;; +29197-1;LL500-0;HL70162_Route of administration;LA9431-3;16;Intranasal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9432-1;17;Intraocular;;; +29197-1;LL500-0;HL70162_Route of administration;LA9433-9;18;Intraperitoneal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9434-7;19;Intrasynovial;;; +29197-1;LL500-0;HL70162_Route of administration;LA9435-4;20;Intrathecal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9436-2;21;Intrauterine;;; +29197-1;LL500-0;HL70162_Route of administration;LA9437-0;22;Intravenous;;; +29197-1;LL500-0;HL70162_Route of administration;LA9438-8;23;Mucous Membrane;;; +29197-1;LL500-0;HL70162_Route of administration;LA9439-6;24;Mouth/Throat;;; +29197-1;LL500-0;HL70162_Route of administration;LA9440-4;25;Nasogastric;;; +29197-1;LL500-0;HL70162_Route of administration;LA9441-2;26;Nasal Prongs*;;; +29197-1;LL500-0;HL70162_Route of administration;LA9263-0;27;Nasal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9443-8;28;Nasotrachial Tube;;; +29197-1;LL500-0;HL70162_Route of administration;LA9444-6;29;Ophthalmic;;; +29197-1;LL500-0;HL70162_Route of administration;LA9445-3;30;Otic;;; +29197-1;LL500-0;HL70162_Route of administration;LA9446-1;31;Other/Miscellaneous;;; +29197-1;LL500-0;HL70162_Route of administration;LA9447-9;32;Perfusion;;; +29197-1;LL500-0;HL70162_Route of administration;LA9367-9;33;Oral;;; +29197-1;LL500-0;HL70162_Route of administration;LA9369-5;34;Rectal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9450-3;35;Rebreather Mask*;;; +29197-1;LL500-0;HL70162_Route of administration;LA9451-1;36;Subcutaneous;;; +29197-1;LL500-0;HL70162_Route of administration;LA9452-9;37;Soaked Dressing;;; +29197-1;LL500-0;HL70162_Route of administration;LA9453-7;38;Sublingual;;; +29197-1;LL500-0;HL70162_Route of administration;LA9454-5;39;Transdermal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9455-2;40;Translingual;;; +29197-1;LL500-0;HL70162_Route of administration;LA9456-0;41;Topical;;; +29197-1;LL500-0;HL70162_Route of administration;LA9457-8;42;Tracheostomy*;;; +29197-1;LL500-0;HL70162_Route of administration;LA9458-6;43;Urethral;;; +29197-1;LL500-0;HL70162_Route of administration;LA9459-4;44;Vaginal;;; +29197-1;LL500-0;HL70162_Route of administration;LA9460-2;45;Ventimask;;; +29197-1;LL500-0;HL70162_Route of administration;LA9461-0;46;Wound;;; +19012-4;LL697-4;HL7_subs;LA9412-3;1;Allow generic substitutions;;; +19012-4;LL697-4;HL7_subs;LA9413-1;2;Substitutions are NOT authorized;;; +19012-4;LL697-4;HL7_subs;LA9414-9;3;Allow therapeutic substitutions;;; +19012-4;LL697-4;HL7_subs;LA11478-7;4;All formulary substitutions;;; +19779-8;LL5535-1;Endoscopy procedures;LA30756-3;1;Esophagogastroduodenoscopy;;; +19779-8;LL5535-1;Endoscopy procedures;LA30757-1;2;Enteroscopy;;; +19779-8;LL5535-1;Endoscopy procedures;LA15380-1;3;Colonoscopy;;; +19779-8;LL5535-1;Endoscopy procedures;LA30759-7;4;Endoscopic biopsy;;; +19779-8;LL5535-1;Endoscopy procedures;LA30760-5;5;Aspiration biopsy;;; +19779-8;LL5535-1;Endoscopy procedures;LA30761-3;6;Needle biopsy;;; +19779-8;LL5535-1;Endoscopy procedures;LA30762-1;7;Endoscopic retrograde cholangiopancreatography;;; +19779-8;LL5535-1;Endoscopy procedures;LA30763-9;8;Endoscopic ultrasonography;;; +19779-8;LL5535-1;Endoscopy procedures;LA30764-7;9;Treatment for esophageal, gastric or esophago-gastric varices;;; +19779-8;LL5535-1;Endoscopy procedures;LA17735-4;10;Polypectomy;;; +19779-8;LL5535-1;Endoscopy procedures;LA30766-2;11;Endoscopic mucosal resection;;; +19779-8;LL5535-1;Endoscopy procedures;LA30767-0;12;Endoscopic submucosal dissection;;; +19779-8;LL5535-1;Endoscopy procedures;LA30768-8;13;Endoscopic variceal ligation;;; +19826-7;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +19826-7;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +19826-7;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +54139-1;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54139-1;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +54139-1;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +64234-8;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64234-8;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64234-8;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +64234-8;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64234-8;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64234-8;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73756-9;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +73756-9;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +73756-9;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73758-5;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +73758-5;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +73758-5;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73760-1;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +73760-1;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +73760-1;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73763-5;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +73763-5;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +73763-5;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +87301-8;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87301-8;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +87301-8;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +87303-4;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +87303-4;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +87303-4;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +89088-9;LL624-8;Yes|No|Unknown;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89088-9;LL624-8;Yes|No|Unknown;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89088-9;LL624-8;Yes|No|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +19827-5;LL2213-8;Microscopic method;LA19016-7;1;Manual;;; +19827-5;LL2213-8;Microscopic method;LA19015-9;2;Automated;;; +72375-9;LL2213-8;Microscopic method;LA19016-7;1;Manual;;; +72375-9;LL2213-8;Microscopic method;LA19015-9;2;Automated;;; +19979-4;LL756-8;Cannula_Types;LA11913-3;1;Neonatal nasal cannula;;; +19979-4;LL756-8;Cannula_Types;LA11914-1;2;Pediatric nasal cannula;;; +19979-4;LL756-8;Cannula_Types;LA11915-8;3;Infant nasal cannula;;; +19979-4;LL756-8;Cannula_Types;LA11916-6;4;Adult nasal cannula;;; +20081-6;LL739-4;Oxim_site;LA11862-2;1;Finger;;; +20081-6;LL739-4;Oxim_site;LA11863-0;2;Ear lobe;;; +20124-4;LL5054-3;Manual|Assist|Ctrl|Assist-Ctrl|MMV|Other;LA19016-7;1;Manual;;; +20124-4;LL5054-3;Manual|Assist|Ctrl|Assist-Ctrl|MMV|Other;LA12671-6;2;Assisted ventilation;;; +20124-4;LL5054-3;Manual|Assist|Ctrl|Assist-Ctrl|MMV|Other;LA29246-8;3;Controlled ventilation;;; +20124-4;LL5054-3;Manual|Assist|Ctrl|Assist-Ctrl|MMV|Other;LA29247-6;4;Assist-control ventilation;;; +20124-4;LL5054-3;Manual|Assist|Ctrl|Assist-Ctrl|MMV|Other;LA29245-0;5;Mandatory minute ventilation;;; +20124-4;LL5054-3;Manual|Assist|Ctrl|Assist-Ctrl|MMV|Other;LA46-8;6;Other;;; +20228-3;LL3803-5;Left|Right|Bilateral|Unilateral;LA4585-1;1;Left;;; +20228-3;LL3803-5;Left|Right|Bilateral|Unilateral;LA4306-2;2;Right;;; +20228-3;LL3803-5;Left|Right|Bilateral|Unilateral;LA25377-5;3;Bilateral;;; +20228-3;LL3803-5;Left|Right|Bilateral|Unilateral;LA25378-3;4;Unilateral;;; +20627-6;LL2426-6;Clear|Cloudy;LA19732-9;1;Clear;;; +20627-6;LL2426-6;Clear|Cloudy;LA19733-7;2;Cloudy;;; +33511-7;LL2426-6;Clear|Cloudy;LA19732-9;1;Clear;;; +33511-7;LL2426-6;Clear|Cloudy;LA19733-7;2;Cloudy;;; +76675-8;LL2426-6;Clear|Cloudy;LA19732-9;1;Clear;;; +76675-8;LL2426-6;Clear|Cloudy;LA19733-7;2;Cloudy;;; +76676-6;LL2426-6;Clear|Cloudy;LA19732-9;1;Clear;;; +76676-6;LL2426-6;Clear|Cloudy;LA19733-7;2;Cloudy;;; +76677-4;LL2426-6;Clear|Cloudy;LA19732-9;1;Clear;;; +76677-4;LL2426-6;Clear|Cloudy;LA19733-7;2;Cloudy;;; +76678-2;LL2426-6;Clear|Cloudy;LA19732-9;1;Clear;;; +76678-2;LL2426-6;Clear|Cloudy;LA19733-7;2;Cloudy;;; +9374-0;LL2426-6;Clear|Cloudy;LA19732-9;1;Clear;;; +9374-0;LL2426-6;Clear|Cloudy;LA19733-7;2;Cloudy;;; +20672-2;LL2258-3;A pleuro;LA6112-2;1;1;;; +20672-2;LL2258-3;A pleuro;LA10137-0;2;5;;; +20672-2;LL2258-3;A pleuro;LA10139-6;3;7;;; +20672-2;LL2258-3;A pleuro;LA6113-0;4;2;;; +20672-2;LL2258-3;A pleuro;LA6114-8;5;3;;; +20672-2;LL2258-3;A pleuro;LA6115-5;6;4;;; +20672-2;LL2258-3;A pleuro;LA10138-8;7;6;;; +20672-2;LL2258-3;A pleuro;LA10140-4;8;8;;; +20672-2;LL2258-3;A pleuro;LA10141-2;9;9;;; +20672-2;LL2258-3;A pleuro;LA13942-0;10;10;;; +20672-2;LL2258-3;A pleuro;LA14557-5;11;11;;; +20672-2;LL2258-3;A pleuro;LA14558-3;12;12;;; +20672-2;LL2258-3;A pleuro;LA14559-1;13;13;;; +20672-2;LL2258-3;A pleuro;LA14560-9;14;14;;; +20672-2;LL2258-3;A pleuro;LA14561-7;15;15;;; +23650-5;LL2258-3;A pleuro;LA6112-2;1;1;;; +23650-5;LL2258-3;A pleuro;LA10137-0;2;5;;; +23650-5;LL2258-3;A pleuro;LA10139-6;3;7;;; +23650-5;LL2258-3;A pleuro;LA6113-0;4;2;;; +23650-5;LL2258-3;A pleuro;LA6114-8;5;3;;; +23650-5;LL2258-3;A pleuro;LA6115-5;6;4;;; +23650-5;LL2258-3;A pleuro;LA10138-8;7;6;;; +23650-5;LL2258-3;A pleuro;LA10140-4;8;8;;; +23650-5;LL2258-3;A pleuro;LA10141-2;9;9;;; +23650-5;LL2258-3;A pleuro;LA13942-0;10;10;;; +23650-5;LL2258-3;A pleuro;LA14557-5;11;11;;; +23650-5;LL2258-3;A pleuro;LA14558-3;12;12;;; +23650-5;LL2258-3;A pleuro;LA14559-1;13;13;;; +23650-5;LL2258-3;A pleuro;LA14560-9;14;14;;; +23650-5;LL2258-3;A pleuro;LA14561-7;15;15;;; +20688-8;LL2296-3;Aspergillus spp;LA19332-8;1;Aspergillus flavis;;; +20688-8;LL2296-3;Aspergillus spp;LA19329-4;2;Aspergillus fumigatus;;; +20688-8;LL2296-3;Aspergillus spp;LA19331-0;3;Aspergillus terreus;;; +20688-8;LL2296-3;Aspergillus spp;LA19330-2;4;Aspergillus versicolor;;; +43979-4;LL2296-3;Aspergillus spp;LA19332-8;1;Aspergillus flavis;;; +43979-4;LL2296-3;Aspergillus spp;LA19329-4;2;Aspergillus fumigatus;;; +43979-4;LL2296-3;Aspergillus spp;LA19331-0;3;Aspergillus terreus;;; +43979-4;LL2296-3;Aspergillus spp;LA19330-2;4;Aspergillus versicolor;;; +98396-5;LL2296-3;Aspergillus spp;LA19332-8;1;Aspergillus flavis;;; +98396-5;LL2296-3;Aspergillus spp;LA19329-4;2;Aspergillus fumigatus;;; +98396-5;LL2296-3;Aspergillus spp;LA19331-0;3;Aspergillus terreus;;; +98396-5;LL2296-3;Aspergillus spp;LA19330-2;4;Aspergillus versicolor;;; +20698-7;LL2285-6;BTV serotype;LA6112-2;1;1;;; +20698-7;LL2285-6;BTV serotype;LA6113-0;2;2;;; +20698-7;LL2285-6;BTV serotype;LA6114-8;3;3;;; +20698-7;LL2285-6;BTV serotype;LA10137-0;4;5;;; +20698-7;LL2285-6;BTV serotype;LA13942-0;5;10;;; +20698-7;LL2285-6;BTV serotype;LA19282-5;6;20;;; +20698-7;LL2285-6;BTV serotype;LA19281-7;7;25;;; +20698-7;LL2285-6;BTV serotype;LA19280-9;8;26;;; +22874-2;LL2285-6;BTV serotype;LA6112-2;1;1;;; +22874-2;LL2285-6;BTV serotype;LA6113-0;2;2;;; +22874-2;LL2285-6;BTV serotype;LA6114-8;3;3;;; +22874-2;LL2285-6;BTV serotype;LA10137-0;4;5;;; +22874-2;LL2285-6;BTV serotype;LA13942-0;5;10;;; +22874-2;LL2285-6;BTV serotype;LA19282-5;6;20;;; +22874-2;LL2285-6;BTV serotype;LA19281-7;7;25;;; +22874-2;LL2285-6;BTV serotype;LA19280-9;8;26;;; +20734-0;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +20734-0;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +20734-0;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +20734-0;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +20734-0;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +20734-0;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +20734-0;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +20735-7;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +20735-7;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +20735-7;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +20735-7;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +20735-7;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +20735-7;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +20735-7;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +23594-5;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +23594-5;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +23594-5;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +23594-5;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +23594-5;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +23594-5;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +23594-5;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +24003-6;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +24003-6;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +24003-6;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +24003-6;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +24003-6;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +24003-6;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +24003-6;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +41625-5;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +41625-5;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +41625-5;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +41625-5;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +41625-5;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +41625-5;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +41625-5;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +53604-5;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +53604-5;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +53604-5;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +53604-5;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +53604-5;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +53604-5;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +53604-5;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +551-2;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +551-2;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +551-2;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +551-2;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +551-2;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +551-2;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +551-2;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +552-0;LL2264-1;Brucella;LA19197-5;1;Brucella abortus;;; +552-0;LL2264-1;Brucella;LA19198-3;2;Brucella canis;;; +552-0;LL2264-1;Brucella;LA19199-1;3;Brucella maris;;; +552-0;LL2264-1;Brucella;LA19200-7;4;Brucella melitensis;;; +552-0;LL2264-1;Brucella;LA19201-5;5;Brucella neotomae;;; +552-0;LL2264-1;Brucella;LA19202-3;6;Brucella ovis;;; +552-0;LL2264-1;Brucella;LA19203-1;7;Brucella suis;;; +20764-7;LL4642-6;Clostridium perfringens genotype;LA28068-7;1;Clostridium perfringens genotype A;;; +20764-7;LL4642-6;Clostridium perfringens genotype;LA28069-5;2;Clostridium perfringens genotype B;;; +20764-7;LL4642-6;Clostridium perfringens genotype;LA28070-3;3;Clostridium perfringens genotype C;;; +20764-7;LL4642-6;Clostridium perfringens genotype;LA28071-1;4;Clostridium perfringens genotype D;;; +20764-7;LL4642-6;Clostridium perfringens genotype;LA28072-9;5;Clostridium perfringens genotype E;;; +20833-0;LL2282-3;H paragallinarum serotype;LA6112-2;1;1;;; +20833-0;LL2282-3;H paragallinarum serotype;LA6113-0;2;2;;; +20833-0;LL2282-3;H paragallinarum serotype;LA13487-6;3;A;;; +20833-0;LL2282-3;H paragallinarum serotype;LA14518-7;4;B;;; +20833-0;LL2282-3;H paragallinarum serotype;LA14519-5;5;C;;; +20833-0;LL2282-3;H paragallinarum serotype;LA15167-2;6;N;;; +20935-3;LL2288-0;P mult serotype;LA6112-2;1;1;;; +20935-3;LL2288-0;P mult serotype;LA6114-8;2;3;;; +20935-3;LL2288-0;P mult serotype;LA6115-5;3;4;;; +20935-3;LL2288-0;P mult serotype;LA14558-3;4;12;;; +20935-3;LL2288-0;P mult serotype;LA14561-7;5;15;;; +20935-3;LL2288-0;P mult serotype;LA13487-6;6;A;;; +20935-3;LL2288-0;P mult serotype;LA14520-3;7;D;;; +23345-2;LL2288-0;P mult serotype;LA6112-2;1;1;;; +23345-2;LL2288-0;P mult serotype;LA6114-8;2;3;;; +23345-2;LL2288-0;P mult serotype;LA6115-5;3;4;;; +23345-2;LL2288-0;P mult serotype;LA14558-3;4;12;;; +23345-2;LL2288-0;P mult serotype;LA14561-7;5;15;;; +23345-2;LL2288-0;P mult serotype;LA13487-6;6;A;;; +23345-2;LL2288-0;P mult serotype;LA14520-3;7;D;;; +23346-0;LL2288-0;P mult serotype;LA6112-2;1;1;;; +23346-0;LL2288-0;P mult serotype;LA6114-8;2;3;;; +23346-0;LL2288-0;P mult serotype;LA6115-5;3;4;;; +23346-0;LL2288-0;P mult serotype;LA14558-3;4;12;;; +23346-0;LL2288-0;P mult serotype;LA14561-7;5;15;;; +23346-0;LL2288-0;P mult serotype;LA13487-6;6;A;;; +23346-0;LL2288-0;P mult serotype;LA14520-3;7;D;;; +23347-8;LL2288-0;P mult serotype;LA6112-2;1;1;;; +23347-8;LL2288-0;P mult serotype;LA6114-8;2;3;;; +23347-8;LL2288-0;P mult serotype;LA6115-5;3;4;;; +23347-8;LL2288-0;P mult serotype;LA14558-3;4;12;;; +23347-8;LL2288-0;P mult serotype;LA14561-7;5;15;;; +23347-8;LL2288-0;P mult serotype;LA13487-6;6;A;;; +23347-8;LL2288-0;P mult serotype;LA14520-3;7;D;;; +23763-6;LL2288-0;P mult serotype;LA6112-2;1;1;;; +23763-6;LL2288-0;P mult serotype;LA6114-8;2;3;;; +23763-6;LL2288-0;P mult serotype;LA6115-5;3;4;;; +23763-6;LL2288-0;P mult serotype;LA14558-3;4;12;;; +23763-6;LL2288-0;P mult serotype;LA14561-7;5;15;;; +23763-6;LL2288-0;P mult serotype;LA13487-6;6;A;;; +23763-6;LL2288-0;P mult serotype;LA14520-3;7;D;;; +20966-8;LL2275-7;Staph spp;LA19246-0;1;Staphylococcus aureus;;; +20966-8;LL2275-7;Staph spp;LA19247-8;2;Staphylococcus epidermidis;;; +20966-8;LL2275-7;Staph spp;LA19249-4;3;Staphylococcus equorum;;; +20966-8;LL2275-7;Staph spp;LA19248-6;4;Staphylococcus xylosus;;; +20967-6;LL2275-7;Staph spp;LA19246-0;1;Staphylococcus aureus;;; +20967-6;LL2275-7;Staph spp;LA19247-8;2;Staphylococcus epidermidis;;; +20967-6;LL2275-7;Staph spp;LA19249-4;3;Staphylococcus equorum;;; +20967-6;LL2275-7;Staph spp;LA19248-6;4;Staphylococcus xylosus;;; +20968-4;LL2275-7;Staph spp;LA19246-0;1;Staphylococcus aureus;;; +20968-4;LL2275-7;Staph spp;LA19247-8;2;Staphylococcus epidermidis;;; +20968-4;LL2275-7;Staph spp;LA19249-4;3;Staphylococcus equorum;;; +20968-4;LL2275-7;Staph spp;LA19248-6;4;Staphylococcus xylosus;;; +20987-4;LL2294-8;Yersinia spp;LA19324-5;1;Yersinia enterocolitica;65255000;Yersinia enterocolitica (organism);http://snomed.info/sct +20987-4;LL2294-8;Yersinia spp;LA19325-2;2;Yersinia frederiksenii;;; +20987-4;LL2294-8;Yersinia spp;LA19326-0;3;Yersinia intermedia;;; +20987-4;LL2294-8;Yersinia spp;LA19327-8;4;Yersinia kristensenii;;; +28549-4;LL2294-8;Yersinia spp;LA19324-5;1;Yersinia enterocolitica;65255000;Yersinia enterocolitica (organism);http://snomed.info/sct +28549-4;LL2294-8;Yersinia spp;LA19325-2;2;Yersinia frederiksenii;;; +28549-4;LL2294-8;Yersinia spp;LA19326-0;3;Yersinia intermedia;;; +28549-4;LL2294-8;Yersinia spp;LA19327-8;4;Yersinia kristensenii;;; +701-3;LL2294-8;Yersinia spp;LA19324-5;1;Yersinia enterocolitica;65255000;Yersinia enterocolitica (organism);http://snomed.info/sct +701-3;LL2294-8;Yersinia spp;LA19325-2;2;Yersinia frederiksenii;;; +701-3;LL2294-8;Yersinia spp;LA19326-0;3;Yersinia intermedia;;; +701-3;LL2294-8;Yersinia spp;LA19327-8;4;Yersinia kristensenii;;; +21093-0;LL2430-8;Dermal/Epidermal;LA19739-4;1;Dermal pattern;;; +21093-0;LL2430-8;Dermal/Epidermal;LA19740-2;2;Epidermal pattern;;; +21352-0;LL2430-8;Dermal/Epidermal;LA19739-4;1;Dermal pattern;;; +21352-0;LL2430-8;Dermal/Epidermal;LA19740-2;2;Epidermal pattern;;; +21442-9;LL2270-8;HPIV type;LA6112-2;1;1;;; +21442-9;LL2270-8;HPIV type;LA6113-0;2;2;;; +21442-9;LL2270-8;HPIV type;LA6114-8;3;3;;; +21442-9;LL2270-8;HPIV type;LA11883-8;4;Not detected;;; +40436-8;LL2270-8;HPIV type;LA6112-2;1;1;;; +40436-8;LL2270-8;HPIV type;LA6113-0;2;2;;; +40436-8;LL2270-8;HPIV type;LA6114-8;3;3;;; +40436-8;LL2270-8;HPIV type;LA11883-8;4;Not detected;;; +43366-4;LL2270-8;HPIV type;LA6112-2;1;1;;; +43366-4;LL2270-8;HPIV type;LA6113-0;2;2;;; +43366-4;LL2270-8;HPIV type;LA6114-8;3;3;;; +43366-4;LL2270-8;HPIV type;LA11883-8;4;Not detected;;; +88531-9;LL2270-8;HPIV type;LA6112-2;1;1;;; +88531-9;LL2270-8;HPIV type;LA6113-0;2;2;;; +88531-9;LL2270-8;HPIV type;LA6114-8;3;3;;; +88531-9;LL2270-8;HPIV type;LA11883-8;4;Not detected;;; +89653-0;LL2270-8;HPIV type;LA6112-2;1;1;;; +89653-0;LL2270-8;HPIV type;LA6113-0;2;2;;; +89653-0;LL2270-8;HPIV type;LA6114-8;3;3;;; +89653-0;LL2270-8;HPIV type;LA11883-8;4;Not detected;;; +89654-8;LL2270-8;HPIV type;LA6112-2;1;1;;; +89654-8;LL2270-8;HPIV type;LA6113-0;2;2;;; +89654-8;LL2270-8;HPIV type;LA6114-8;3;3;;; +89654-8;LL2270-8;HPIV type;LA11883-8;4;Not detected;;; +21484-1;LL2858-0;Race or Unknown;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +21484-1;LL2858-0;Race or Unknown;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +21484-1;LL2858-0;Race or Unknown;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +21484-1;LL2858-0;Race or Unknown;LA10611-4;4;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +21484-1;LL2858-0;Race or Unknown;LA4457-3;5;White;2106-3;White;https://www.cdc.gov/phin +21484-1;LL2858-0;Race or Unknown;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +32624-9;LL2858-0;Race or Unknown;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +32624-9;LL2858-0;Race or Unknown;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +32624-9;LL2858-0;Race or Unknown;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +32624-9;LL2858-0;Race or Unknown;LA10611-4;4;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +32624-9;LL2858-0;Race or Unknown;LA4457-3;5;White;2106-3;White;https://www.cdc.gov/phin +32624-9;LL2858-0;Race or Unknown;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21619-2;LL2986-9;APOE genotypes;LA21356-3;1;APOE e2/e2;;; +21619-2;LL2986-9;APOE genotypes;LA21357-1;2;APOE e2/e3;;; +21619-2;LL2986-9;APOE genotypes;LA21361-3;3;APOE e2/e4;;; +21619-2;LL2986-9;APOE genotypes;LA21358-9;4;APOE e3/e3 (wild type);;; +21619-2;LL2986-9;APOE genotypes;LA21359-7;5;APOE e3/e4;;; +21619-2;LL2986-9;APOE genotypes;LA21360-5;6;APOE e4/e4;;; +42315-2;LL2986-9;APOE genotypes;LA21356-3;1;APOE e2/e2;;; +42315-2;LL2986-9;APOE genotypes;LA21357-1;2;APOE e2/e3;;; +42315-2;LL2986-9;APOE genotypes;LA21361-3;3;APOE e2/e4;;; +42315-2;LL2986-9;APOE genotypes;LA21358-9;4;APOE e3/e3 (wild type);;; +42315-2;LL2986-9;APOE genotypes;LA21359-7;5;APOE e3/e4;;; +42315-2;LL2986-9;APOE genotypes;LA21360-5;6;APOE e4/e4;;; +21757-0;LL2303-7;Triplet repeat genetic results;LA19353-4;1;Not Expanded;;; +21757-0;LL2303-7;Triplet repeat genetic results;LA16550-8;2;Intermediate;;; +21757-0;LL2303-7;Triplet repeat genetic results;LA19354-2;3;Reduced penetrance;;; +21757-0;LL2303-7;Triplet repeat genetic results;LA19352-6;4;Expanded;;; +21763-8;LL2303-7;Triplet repeat genetic results;LA19353-4;1;Not Expanded;;; +21763-8;LL2303-7;Triplet repeat genetic results;LA16550-8;2;Intermediate;;; +21763-8;LL2303-7;Triplet repeat genetic results;LA19354-2;3;Reduced penetrance;;; +21763-8;LL2303-7;Triplet repeat genetic results;LA19352-6;4;Expanded;;; +35374-8;LL2303-7;Triplet repeat genetic results;LA19353-4;1;Not Expanded;;; +35374-8;LL2303-7;Triplet repeat genetic results;LA16550-8;2;Intermediate;;; +35374-8;LL2303-7;Triplet repeat genetic results;LA19354-2;3;Reduced penetrance;;; +35374-8;LL2303-7;Triplet repeat genetic results;LA19352-6;4;Expanded;;; +35375-5;LL2303-7;Triplet repeat genetic results;LA19353-4;1;Not Expanded;;; +35375-5;LL2303-7;Triplet repeat genetic results;LA16550-8;2;Intermediate;;; +35375-5;LL2303-7;Triplet repeat genetic results;LA19354-2;3;Reduced penetrance;;; +35375-5;LL2303-7;Triplet repeat genetic results;LA19352-6;4;Expanded;;; +75393-9;LL2303-7;Triplet repeat genetic results;LA19353-4;1;Not Expanded;;; +75393-9;LL2303-7;Triplet repeat genetic results;LA16550-8;2;Intermediate;;; +75393-9;LL2303-7;Triplet repeat genetic results;LA19354-2;3;Reduced penetrance;;; +75393-9;LL2303-7;Triplet repeat genetic results;LA19352-6;4;Expanded;;; +21827-1;LL51-4;CR_10_Record type;LA3938-3;1;Incidence-only;;; +21827-1;LL51-4;CR_10_Record type;LA3960-7;2;Full Case Abstract;;; +21827-1;LL51-4;CR_10_Record type;LA4213-0;3;Confidential;;; +21827-1;LL51-4;CR_10_Record type;LA4218-9;4;Correction/Update;;; +21827-1;LL51-4;CR_10_Record type;LA4233-8;5;Analysis/research;;; +21828-9;LL201-5;CR_30_Registry type;LA4176-9;1;Central Reg - pop based;;; +21828-9;LL201-5;CR_30_Registry type;LA4175-1;2;Central Reg - non-pop based;;; +21828-9;LL201-5;CR_30_Registry type;LA4338-5;3;Single Hospital;;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4123-1;1;1992-1994 version;;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4146-2;2;1995 version (v4.0);;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4148-8;3;1996 version (v5.0, 5.1);;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4429-2;4;Version 6 - 1998;;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4151-2;5;1999 Version (v.7);;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4131-4;6;2000 Version (v.8);;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4127-2;7;2001 and 2002 Version (v.9 and 9.1);;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4128-0;8;2003 Version (Version 10 and 10.1);;; +21830-5;LL219-7;CR_50_NAACCR record version;LA4287-4;9;September 1989 version;;; +21832-1;LL71-2;CR_120_Census tract-coding;LA4734-5;1;Not Tracted;;; +21832-1;LL71-2;CR_120_Census tract-coding;LA4117-3;2;1970 Census (1973-77);;; +21832-1;LL71-2;CR_120_Census tract-coding;LA4106-6;3;1980 Census (1978-87);;; +21832-1;LL71-2;CR_120_Census tract-coding;LA4097-7;4;1990 Census (1988+);;; +21832-1;LL71-2;CR_120_Census tract-coding;LA4155-3;5;2000 Census;;; +21833-9;LL85-2;CR_130_Alternate census tract;LA4224-7;1;Area not census-tracted;;; +21833-9;LL85-2;CR_130_Alternate census tract;LA4225-4;2;Area census-tracted, but census tract is not available;;; +21834-7;LL95-1;CR_140_Census tract coding;LA4734-5;1;Not Tracted;;; +21834-7;LL95-1;CR_140_Census tract coding;LA4115-7;2;1970 Census Tract Definitions;;; +21834-7;LL95-1;CR_140_Census tract coding;LA4104-1;3;1980 Census Tract Definitions;;; +21834-7;LL95-1;CR_140_Census tract coding;LA4095-1;4;1990 Census Tract Definitions;;; +21834-7;LL95-1;CR_140_Census tract coding;LA4133-0;5;2000 Census Tract Definitions;;; +21835-4;LL127-2;CR_170_Race coding system;LA4445-8;1;Value coding: 1=white, 2=black, 3=other, 9=unk;;; +21835-4;LL127-2;CR_170_Race coding system;LA4294-0;2;SEER < 1988;;; +21835-4;LL127-2;CR_170_Race coding system;LA4100-9;3;1988+ SEER & COC;;; +21835-4;LL127-2;CR_170_Race coding system;LA4149-6;4;1991+ SEER & COC;;; +21835-4;LL127-2;CR_170_Race coding system;LA4145-4;5;1994+ SEER & COC;;; +21835-4;LL127-2;CR_170_Race coding system;LA4147-0;6;2000+ SEER & COC;;; +21835-4;LL127-2;CR_170_Race coding system;LA46-8;7;Other;;; +21836-2;LL127-2;CR_170_Race coding system;LA4445-8;1;Value coding: 1=white, 2=black, 3=other, 9=unk;;; +21836-2;LL127-2;CR_170_Race coding system;LA4294-0;2;SEER < 1988;;; +21836-2;LL127-2;CR_170_Race coding system;LA4100-9;3;1988+ SEER & COC;;; +21836-2;LL127-2;CR_170_Race coding system;LA4149-6;4;1991+ SEER & COC;;; +21836-2;LL127-2;CR_170_Race coding system;LA4145-4;5;1994+ SEER & COC;;; +21836-2;LL127-2;CR_170_Race coding system;LA4147-0;6;2000+ SEER & COC;;; +21836-2;LL127-2;CR_170_Race coding system;LA46-8;7;Other;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4719-6;1;Non Spanish, Non-Hispanic;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4611-5;2;Mexican;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4364-1;3;Puerto Rican;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4190-0;4;Cuban;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4328-6;5;South or Central American;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4678-4;6;Other Specified Spanish;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4326-0;7;"Spanish,NOS; Hispanic,NOS";;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4312-0;8;Spanish Surname only;;; +21837-0;LL146-2;CR_190_Hispanic origin;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21838-8;LL162-9;CR_200_Computed ethnicity;LA4546-3;1;No match run, 1994+ cases;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA4710-5;2;Non-Hispan last & maiden;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA4712-1;3;Non-Hisp last-no maid chk;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA4711-3;4;Non-Hisp last-no maid nam;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA4143-9;5;1993 & earlier cases;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA4026-6;6;Hisp-last,non-hisp maiden;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA4015-9;7;Hisp-last, no check maid;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA3965-6;8;Hisp-last, missing maiden;;; +21838-8;LL162-9;CR_200_Computed ethnicity;LA3968-0;9;Hispanic maiden name;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4562-0;1;No match run, 1994+;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4234-6;2;Census Spanish List;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4105-8;3;1980 Census List;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4096-9;4;1990 Census List;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA3985-4;5;GUESS Program;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4204-9;6;Combo List w/S. Florida;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4171-0;7;Census + local;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4076-1;8;Census + GUESS + ?;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4749-3;9;Other Type of Match;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4415-1;10;Unknown Type of Match;;; +21839-6;LL175-1;CR_210_Computed ethnicity source;LA4560-4;11;No match-1993 and earlier;;; +21840-4;LL183-5;CR_220_Sex-gender;LA2-8;1;Male;;; +21840-4;LL183-5;CR_220_Sex-gender;LA3-6;2;Female;;; +21840-4;LL183-5;CR_220_Sex-gender;LA4732-9;3;Other (hermaphrodite);;; +21840-4;LL183-5;CR_220_Sex-gender;LA4512-5;4;Transsexual;;; +21840-4;LL183-5;CR_220_Sex-gender;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21841-2;LL184-3;CR_230;LA4427-6;1;Unknown age;;; +21842-0;LL197-5;CR_250_Birthplace;LA3597-7;1;United States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3752-8;2;New England and New Jersey;;; +21842-0;LL197-5;CR_250_Birthplace;LA3782-5;3;Maine;;; +21842-0;LL197-5;CR_250_Birthplace;LA3751-0;4;New Hampshire;;; +21842-0;LL197-5;CR_250_Birthplace;LA3585-2;5;Vermont;;; +21842-0;LL197-5;CR_250_Birthplace;LA33036-7;6;Massachusetts;;; +21842-0;LL197-5;CR_250_Birthplace;LA3692-6;7;Rhode Island;;; +21842-0;LL197-5;CR_250_Birthplace;LA3859-1;8;Connecticut;;; +21842-0;LL197-5;CR_250_Birthplace;LA3750-2;9;New Jersey;;; +21842-0;LL197-5;CR_250_Birthplace;LA3733-8;10;North Mid-Atlantic States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3748-6;11;New York;;; +21842-0;LL197-5;CR_250_Birthplace;LA3708-0;12;Pennsylvania;;; +21842-0;LL197-5;CR_250_Birthplace;LA3851-8;13;Delaware;;; +21842-0;LL197-5;CR_250_Birthplace;LA3675-1;14;South Mid-Atlantic States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3775-9;15;Maryland;;; +21842-0;LL197-5;CR_250_Birthplace;LA3849-2;16;District of Columbia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3583-7;17;Virginia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3578-7;18;West Virginia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3736-1;19;North Carolina;;; +21842-0;LL197-5;CR_250_Birthplace;LA3677-7;20;South Carolina;;; +21842-0;LL197-5;CR_250_Birthplace;LA3673-6;21;Southeastern States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3612-4;22;Tennessee;;; +21842-0;LL197-5;CR_250_Birthplace;LA3830-2;23;Georgia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3834-4;24;Florida;;; +21842-0;LL197-5;CR_250_Birthplace;LA3904-5;25;Alabama;;; +21842-0;LL197-5;CR_250_Birthplace;LA3765-0;26;Mississippi;;; +21842-0;LL197-5;CR_250_Birthplace;LA3735-3;27;North Central States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3771-8;28;Michigan;;; +21842-0;LL197-5;CR_250_Birthplace;LA3726-2;29;Ohio;;; +21842-0;LL197-5;CR_250_Birthplace;LA3812-0;30;Indiana;;; +21842-0;LL197-5;CR_250_Birthplace;LA3798-1;31;Kentucky;;; +21842-0;LL197-5;CR_250_Birthplace;LA3731-2;32;Northern Midwest States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3577-9;33;Wisconsin;;; +21842-0;LL197-5;CR_250_Birthplace;LA3766-8;34;Minnesota;;; +21842-0;LL197-5;CR_250_Birthplace;LA3809-6;35;Iowa;;; +21842-0;LL197-5;CR_250_Birthplace;LA3734-6;36;North Dakota;;; +21842-0;LL197-5;CR_250_Birthplace;LA3676-9;37;South Dakota;;; +21842-0;LL197-5;CR_250_Birthplace;LA3762-7;38;Montana;;; +21842-0;LL197-5;CR_250_Birthplace;LA3868-2;39;Central Midwest States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3814-6;40;Illinois;;; +21842-0;LL197-5;CR_250_Birthplace;LA3764-3;41;Missouri;;; +21842-0;LL197-5;CR_250_Birthplace;LA3799-9;42;Kansas;;; +21842-0;LL197-5;CR_250_Birthplace;LA3756-9;43;Nebraska;;; +21842-0;LL197-5;CR_250_Birthplace;LA3672-8;44;Southern Midwest States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3894-8;45;Arkansas;;; +21842-0;LL197-5;CR_250_Birthplace;LA3786-6;46;Louisiana;;; +21842-0;LL197-5;CR_250_Birthplace;LA3725-4;47;Oklahoma;;; +21842-0;LL197-5;CR_250_Birthplace;LA3611-6;48;Texas;;; +21842-0;LL197-5;CR_250_Birthplace;LA3760-1;49;Mountain States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3815-3;50;Idaho;;; +21842-0;LL197-5;CR_250_Birthplace;LA3576-1;51;Wyoming;;; +21842-0;LL197-5;CR_250_Birthplace;LA3862-5;52;Colorado;;; +21842-0;LL197-5;CR_250_Birthplace;LA3587-8;53;Utah;;; +21842-0;LL197-5;CR_250_Birthplace;LA3753-6;54;Nevada;;; +21842-0;LL197-5;CR_250_Birthplace;LA3749-4;55;New Mexico;;; +21842-0;LL197-5;CR_250_Birthplace;LA3895-5;56;Arizona;;; +21842-0;LL197-5;CR_250_Birthplace;LA3714-8;57;Pacific Coast States;;; +21842-0;LL197-5;CR_250_Birthplace;LA3903-7;58;Alaska;;; +21842-0;LL197-5;CR_250_Birthplace;LA3580-3;59;Washington;;; +21842-0;LL197-5;CR_250_Birthplace;LA3722-1;60;Oregon;;; +21842-0;LL197-5;CR_250_Birthplace;LA3875-7;61;California;;; +21842-0;LL197-5;CR_250_Birthplace;LA3820-3;62;Hawaii;;; +21842-0;LL197-5;CR_250_Birthplace;LA3891-4;63;Atlantic/Caribbean Area;;; +21842-0;LL197-5;CR_250_Birthplace;LA3700-7;64;Puerto Rico;;; +21842-0;LL197-5;CR_250_Birthplace;LA3588-6;65;US Virgin Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3720-5;66;Other Atlantic/Caribbean Area;;; +21842-0;LL197-5;CR_250_Birthplace;LA3872-4;67;Canal Zone;;; +21842-0;LL197-5;CR_250_Birthplace;LA3715-5;68;Pacific Area;;; +21842-0;LL197-5;CR_250_Birthplace;LA3900-3;69;American Samoa;;; +21842-0;LL197-5;CR_250_Birthplace;LA3796-5;70;Kiribati (Canton, Enderbury, Gilbert, S Lines, Phoenix);;; +21842-0;LL197-5;CR_250_Birthplace;LA3770-0;71;Micronesia (Fed States of) (Caroline, Trust Terr of Pacific);;; +21842-0;LL197-5;CR_250_Birthplace;LA3858-3;72;Cook Islands (New Zealand);;; +21842-0;LL197-5;CR_250_Birthplace;LA3602-5;73;Tuvalu (Ellice Islands);;; +21842-0;LL197-5;CR_250_Birthplace;LA3824-5;74;Guam;;; +21842-0;LL197-5;CR_250_Birthplace;LA3801-3;75;Johnston Atoll;;; +21842-0;LL197-5;CR_250_Birthplace;LA3778-3;76;Mariana Islands (Trust Territory of Pacific Islands);;; +21842-0;LL197-5;CR_250_Birthplace;LA3776-7;77;Marshall Islands (Trust Territory Pacific Islands);;; +21842-0;LL197-5;CR_250_Birthplace;LA3767-6;78;Midway Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3758-5;79;Nampo-Shoto, Southern;;; +21842-0;LL197-5;CR_250_Birthplace;LA3687-6;80;Ryukyu Islands (Japan);;; +21842-0;LL197-5;CR_250_Birthplace;LA3642-1;81;Swan Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3605-8;82;Tokelau Islands (New Zealand);;; +21842-0;LL197-5;CR_250_Birthplace;LA3582-9;83;Wake Island;;; +21842-0;LL197-5;CR_250_Birthplace;LA3711-4;84;Palau (Trust Territory of Pacific Islands);;; +21842-0;LL197-5;CR_250_Birthplace;LA3825-2;85;Greenland;;; +21842-0;LL197-5;CR_250_Birthplace;LA3873-2;86;Canada;;; +21842-0;LL197-5;CR_250_Birthplace;LA3777-5;87;Maritime Provinces (New Brunsw, Newfound, Nova Scotia, PE);;; +21842-0;LL197-5;CR_250_Birthplace;LA3699-1;88;Quebec;;; +21842-0;LL197-5;CR_250_Birthplace;LA3724-7;89;Ontario;;; +21842-0;LL197-5;CR_250_Birthplace;LA3702-3;90;Prairie Provinces (Alberta Manitoba, Saskatchewan);;; +21842-0;LL197-5;CR_250_Birthplace;LA3730-4;91;Northwest Territories, Yukon Territory;;; +21842-0;LL197-5;CR_250_Birthplace;LA3880-7;92;British Columbia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3772-6;93;Mexico;;; +21842-0;LL197-5;CR_250_Birthplace;LA3737-9;94;North American Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3854-2;95;Cuba;;; +21842-0;LL197-5;CR_250_Birthplace;LA3821-1;96;Haiti;;; +21842-0;LL197-5;CR_250_Birthplace;LA3847-6;97;Dominican Republic;;; +21842-0;LL197-5;CR_250_Birthplace;LA3803-9;98;Jamaica;;; +21842-0;LL197-5;CR_250_Birthplace;LA3719-7;99;Other Caribbean Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3883-1;100;Bermuda;;; +21842-0;LL197-5;CR_250_Birthplace;LA3888-0;101;Bahamas;;; +21842-0;LL197-5;CR_250_Birthplace;LA3670-2;102;St Pierre and Miquelon;;; +21842-0;LL197-5;CR_250_Birthplace;LA3870-8;103;Central America;;; +21842-0;LL197-5;CR_250_Birthplace;LA3823-7;104;Guatemala;;; +21842-0;LL197-5;CR_250_Birthplace;LA3884-9;105;Belize (British Honduras);;; +21842-0;LL197-5;CR_250_Birthplace;LA3819-5;106;Honduras;;; +21842-0;LL197-5;CR_250_Birthplace;LA3842-7;107;El Salvador;;; +21842-0;LL197-5;CR_250_Birthplace;LA3746-0;108;Nicaragua;;; +21842-0;LL197-5;CR_250_Birthplace;LA3857-5;109;Costa Rica;;; +21842-0;LL197-5;CR_250_Birthplace;LA3710-6;110;Panama;;; +21842-0;LL197-5;CR_250_Birthplace;LA3738-7;111;North America, NOS;;; +21842-0;LL197-5;CR_250_Birthplace;LA3793-2;112;Latin America, NOS;;; +21842-0;LL197-5;CR_250_Birthplace;LA3679-3;113;South America;;; +21842-0;LL197-5;CR_250_Birthplace;LA3863-3;114;Colombia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3586-0;115;Venezuela;;; +21842-0;LL197-5;CR_250_Birthplace;LA3822-9;116;Guyana (British Guiana);;; +21842-0;LL197-5;CR_250_Birthplace;LA3643-9;117;Suriname (Dutch Guiana);;; +21842-0;LL197-5;CR_250_Birthplace;LA3832-8;118;French Guiana;;; +21842-0;LL197-5;CR_250_Birthplace;LA3881-5;119;Brazil;;; +21842-0;LL197-5;CR_250_Birthplace;LA3844-3;120;Ecuador;;; +21842-0;LL197-5;CR_250_Birthplace;LA3707-2;121;Peru;;; +21842-0;LL197-5;CR_250_Birthplace;LA3882-3;122;Bolivia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3866-6;123;Chile;;; +21842-0;LL197-5;CR_250_Birthplace;LA3896-3;124;Argentina;;; +21842-0;LL197-5;CR_250_Birthplace;LA3709-8;125;Paraguay;;; +21842-0;LL197-5;CR_250_Birthplace;LA3589-4;126;Uruguay;;; +21842-0;LL197-5;CR_250_Birthplace;LA3678-5;127;South American Island;;; +21842-0;LL197-5;CR_250_Birthplace;LA3836-9;128;Falkland Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3598-5;129;United Kingdom;;; +21842-0;LL197-5;CR_250_Birthplace;LA3840-1;130;England, Channel Islands, Isle of Man;;; +21842-0;LL197-5;CR_250_Birthplace;LA3581-1;131;Wales;;; +21842-0;LL197-5;CR_250_Birthplace;LA3685-0;132;Scotland;;; +21842-0;LL197-5;CR_250_Birthplace;LA3732-0;133;Northern Ireland (Ulster);;; +21842-0;LL197-5;CR_250_Birthplace;LA3806-2;134;Ireland (Eire) (Ireland NOS, Republic of Ireland);;; +21842-0;LL197-5;CR_250_Birthplace;LA3686-8;135;Scandinavia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3816-1;136;Iceland;;; +21842-0;LL197-5;CR_250_Birthplace;LA3729-6;137;Norway (Svalbard, Jan Mayen);;; +21842-0;LL197-5;CR_250_Birthplace;LA3850-0;138;Denmark, Faroe Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3641-3;139;Sweden;;; +21842-0;LL197-5;CR_250_Birthplace;LA3835-1;140;Finland;;; +21842-0;LL197-5;CR_250_Birthplace;LA3829-4;141;Germanic Countries;;; +21842-0;LL197-5;CR_250_Birthplace;LA3828-6;142;Germany (East and West);;; +21842-0;LL197-5;CR_250_Birthplace;LA3754-4;143;Netherlands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3885-6;144;Belgium;;; +21842-0;LL197-5;CR_250_Birthplace;LA3785-8;145;Luxembourg;;; +21842-0;LL197-5;CR_250_Birthplace;LA3640-5;146;Switzerland;;; +21842-0;LL197-5;CR_250_Birthplace;LA3889-8;147;Austria;;; +21842-0;LL197-5;CR_250_Birthplace;LA3789-0;148;Liechtenstein;;; +21842-0;LL197-5;CR_250_Birthplace;LA3691-8;149;Romance-Language Countries;;; +21842-0;LL197-5;CR_250_Birthplace;LA3833-6;150;France, Corsica, Monaco;;; +21842-0;LL197-5;CR_250_Birthplace;LA3671-0;151;Spain (Canary Islands, Balearic Islands), Andorra;;; +21842-0;LL197-5;CR_250_Birthplace;LA3703-1;152;Portugal (Madeira Islands, Azores, Cape Verde Islands);;; +21842-0;LL197-5;CR_250_Birthplace;LA3804-7;153;Italy (Sardinia, Sicily), San Marino, Vatican City;;; +21842-0;LL197-5;CR_250_Birthplace;LA3690-0;154;Romania;;; +21842-0;LL197-5;CR_250_Birthplace;LA3682-7;155;Slavic Countries;;; +21842-0;LL197-5;CR_250_Birthplace;LA3705-6;156;Poland;;; +21842-0;LL197-5;CR_250_Birthplace;LA3852-6;157;Czechoslovakia (former);;; +21842-0;LL197-5;CR_250_Birthplace;LA3575-3;158;Yugoslavia (former);;; +21842-0;LL197-5;CR_250_Birthplace;LA3879-9;159;Bulgaria;;; +21842-0;LL197-5;CR_250_Birthplace;LA3689-2;160;Russian SFSR (Russia);;; +21842-0;LL197-5;CR_250_Birthplace;LA3599-3;161;Ukraine and Moldavia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3876-5;162;Byelorus (Byelorussian SSR, White Russia);;; +21842-0;LL197-5;CR_250_Birthplace;LA3839-3;163;Estonian SSR (Estonia);;; +21842-0;LL197-5;CR_250_Birthplace;LA3792-4;164;Latvian SSR (Estonia);;; +21842-0;LL197-5;CR_250_Birthplace;LA3788-2;165;Lithuania (Lithuanian SSR);;; +21842-0;LL197-5;CR_250_Birthplace;LA3887-2;166;Baltic Republic(s), NOS (Baltic States, NOS);;; +21842-0;LL197-5;CR_250_Birthplace;LA3718-9;167;Other Mainland Europe;;; +21842-0;LL197-5;CR_250_Birthplace;LA3826-0;168;Greece;;; +21842-0;LL197-5;CR_250_Birthplace;LA3817-9;169;Hungary;;; +21842-0;LL197-5;CR_250_Birthplace;LA3902-9;170;Albania;;; +21842-0;LL197-5;CR_250_Birthplace;LA3827-8;171;Gibraltar;;; +21842-0;LL197-5;CR_250_Birthplace;LA3717-1;172;Other Mediterranean Isles;;; +21842-0;LL197-5;CR_250_Birthplace;LA3779-1;173;Malta;;; +21842-0;LL197-5;CR_250_Birthplace;LA3853-4;174;Cyprus;;; +21842-0;LL197-5;CR_250_Birthplace;LA3837-7;175;Europe, NOS (Central, Eastern, Northern, Southern, Western);;; +21842-0;LL197-5;CR_250_Birthplace;LA3906-0;176;Africa, NOS (Central, Equatorial);;; +21842-0;LL197-5;CR_250_Birthplace;LA3739-5;177;North Africa;;; +21842-0;LL197-5;CR_250_Birthplace;LA3761-9;178;Morocco;;; +21842-0;LL197-5;CR_250_Birthplace;LA3901-1;179;Algeria;;; +21842-0;LL197-5;CR_250_Birthplace;LA3604-1;180;Tunisia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3790-8;181;Libya (Tripoli, Tripolitania, Cyrenaica);;; +21842-0;LL197-5;CR_250_Birthplace;LA3843-5;182;Egypt (United Arab Republic);;; +21842-0;LL197-5;CR_250_Birthplace;LA3646-2;183;Sudanese Countries;;; +21842-0;LL197-5;CR_250_Birthplace;LA3579-5;184;West Africa, NOS (French Africa, NOS);;; +21842-0;LL197-5;CR_250_Birthplace;LA3745-2;185;Nigeria;;; +21842-0;LL197-5;CR_250_Birthplace;LA3716-3;186;Other West African Countries;;; +21842-0;LL197-5;CR_250_Birthplace;LA3680-1;187;South Africa, NOS;;; +21842-0;LL197-5;CR_250_Birthplace;LA3574-6;188;Zaire (Congo-Leopoldville, Belgian Congo, Congo/Kinshasa);;; +21842-0;LL197-5;CR_250_Birthplace;LA3899-7;189;Angola (Sao Tome, Principe, Cabinda);;; +21842-0;LL197-5;CR_250_Birthplace;LA3693-4;190;Republic of South Africa;;; +21842-0;LL197-5;CR_250_Birthplace;LA3572-0;191;Zimbabwe (Rhodesia, Southern Rhodesia);;; +21842-0;LL197-5;CR_250_Birthplace;LA3573-8;192;Zambia (Northern Rhodesia);;; +21842-0;LL197-5;CR_250_Birthplace;LA3780-9;193;Malawi (Nyasaland);;; +21842-0;LL197-5;CR_250_Birthplace;LA3759-3;194;Mozambique;;; +21842-0;LL197-5;CR_250_Birthplace;LA3783-3;195;Madagascar (Malagasy Republic);;; +21842-0;LL197-5;CR_250_Birthplace;LA3846-8;196;East Africa;;; +21842-0;LL197-5;CR_250_Birthplace;LA3613-2;197;Tanzania (Tanganyika, Zanzibar);;; +21842-0;LL197-5;CR_250_Birthplace;LA3600-9;198;Uganda;;; +21842-0;LL197-5;CR_250_Birthplace;LA3797-3;199;Kenya;;; +21842-0;LL197-5;CR_250_Birthplace;LA3688-4;200;Rwanda (Ruanda);;; +21842-0;LL197-5;CR_250_Birthplace;LA3877-3;201;Burundi (Urundi);;; +21842-0;LL197-5;CR_250_Birthplace;LA3905-2;202;African Coastal Islands (previously in South Africa, NOS);;; +21842-0;LL197-5;CR_250_Birthplace;LA3681-9;203;Somalia (Somali Republic, Somaliland);;; +21842-0;LL197-5;CR_250_Birthplace;LA3848-4;204;Djibouti;;; +21842-0;LL197-5;CR_250_Birthplace;LA3838-5;205;Ethiopia (Abyssinia), Eritrea;;; +21842-0;LL197-5;CR_250_Birthplace;LA3893-0;206;Asia, NOS;;; +21842-0;LL197-5;CR_250_Birthplace;LA3757-7;207;Near East;;; +21842-0;LL197-5;CR_250_Birthplace;LA3603-3;208;Turkey;;; +21842-0;LL197-5;CR_250_Birthplace;LA3892-2;209;Asian and Arab Countries;;; +21842-0;LL197-5;CR_250_Birthplace;LA3639-7;210;Syria;;; +21842-0;LL197-5;CR_250_Birthplace;LA3791-6;211;Lebanon;;; +21842-0;LL197-5;CR_250_Birthplace;LA3800-5;212;Jordan (Transjordan) and former Arab Palestine;;; +21842-0;LL197-5;CR_250_Birthplace;LA3807-0;213;Iraq;;; +21842-0;LL197-5;CR_250_Birthplace;LA3897-1;214;Arabian Peninsula;;; +21842-0;LL197-5;CR_250_Birthplace;LA3805-4;215;Israel and former Jewish Palestine;;; +21842-0;LL197-5;CR_250_Birthplace;LA3871-6;216;Caucasian Republics of the USSR;;; +21842-0;LL197-5;CR_250_Birthplace;LA3721-3;217;Other Asian Republics of the USSR;;; +21842-0;LL197-5;CR_250_Birthplace;LA3808-8;218;Iran (Persia);;; +21842-0;LL197-5;CR_250_Birthplace;LA3907-8;219;Afghanistan;;; +21842-0;LL197-5;CR_250_Birthplace;LA3712-2;220;Pakistan (West Pakistan);;; +21842-0;LL197-5;CR_250_Birthplace;LA3768-4;221;Mid-East Asia, NOS;;; +21842-0;LL197-5;CR_250_Birthplace;LA3813-8;222;India;;; +21842-0;LL197-5;CR_250_Birthplace;LA3755-1;223;Nepal, Bhutan, Sikkim;;; +21842-0;LL197-5;CR_250_Birthplace;LA3886-4;224;Bangladesh (East Pakistan);;; +21842-0;LL197-5;CR_250_Birthplace;LA3867-4;225;Ceylon (Sri Lanka);;; +21842-0;LL197-5;CR_250_Birthplace;LA3878-1;226;Burma;;; +21842-0;LL197-5;CR_250_Birthplace;LA3674-4;227;Southeast Asia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3610-8;228;Thailand (Siam);;; +21842-0;LL197-5;CR_250_Birthplace;LA3811-2;229;Indochina;;; +21842-0;LL197-5;CR_250_Birthplace;LA3794-0;230;Laos;;; +21842-0;LL197-5;CR_250_Birthplace;LA3874-0;231;Cambodia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3584-5;232;Vietnam (Tonkin, Annam, Cochin China);;; +21842-0;LL197-5;CR_250_Birthplace;LA3781-7;233;Malaysia, Singapore, Brunei;;; +21842-0;LL197-5;CR_250_Birthplace;LA3810-4;234;Indonesia (Dutch East Indies);;; +21842-0;LL197-5;CR_250_Birthplace;LA3706-4;235;Philippines (Philippine Islands);;; +21842-0;LL197-5;CR_250_Birthplace;LA3845-0;236;East Asia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3864-1;237;China, NOS;;; +21842-0;LL197-5;CR_250_Birthplace;LA3865-8;238;China (Peoples Republic of China);;; +21842-0;LL197-5;CR_250_Birthplace;LA3818-7;239;Hong Kong;;; +21842-0;LL197-5;CR_250_Birthplace;LA3614-0;240;Taiwan (Formosa) (Republic of China);;; +21842-0;LL197-5;CR_250_Birthplace;LA3609-0;241;Tibet;;; +21842-0;LL197-5;CR_250_Birthplace;LA3784-1;242;Macao (Macau);;; +21842-0;LL197-5;CR_250_Birthplace;LA3763-5;243;Mongolia;;; +21842-0;LL197-5;CR_250_Birthplace;LA3802-1;244;Japan;;; +21842-0;LL197-5;CR_250_Birthplace;LA3795-7;245;Korea (North and South);;; +21842-0;LL197-5;CR_250_Birthplace;LA3890-6;246;Australia and Australian New Guinea;;; +21842-0;LL197-5;CR_250_Birthplace;LA3747-8;247;New Zealand;;; +21842-0;LL197-5;CR_250_Birthplace;LA3713-0;248;Pacific Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3773-4;249;Melanesian Islands, Solomon Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3769-2;250;Micronesian Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3704-9;251;Polynesian Islands;;; +21842-0;LL197-5;CR_250_Birthplace;LA3898-9;252;Antarctica;;; +21842-0;LL197-5;CR_250_Birthplace;LA4683-4;253;Place of birth stated not to be in United States, but no other information available;;; +21842-0;LL197-5;CR_250_Birthplace;LA4682-6;254;Place of birth unknown;;; +63492-3;LL197-5;CR_250_Birthplace;LA3597-7;1;United States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3752-8;2;New England and New Jersey;;; +63492-3;LL197-5;CR_250_Birthplace;LA3782-5;3;Maine;;; +63492-3;LL197-5;CR_250_Birthplace;LA3751-0;4;New Hampshire;;; +63492-3;LL197-5;CR_250_Birthplace;LA3585-2;5;Vermont;;; +63492-3;LL197-5;CR_250_Birthplace;LA33036-7;6;Massachusetts;;; +63492-3;LL197-5;CR_250_Birthplace;LA3692-6;7;Rhode Island;;; +63492-3;LL197-5;CR_250_Birthplace;LA3859-1;8;Connecticut;;; +63492-3;LL197-5;CR_250_Birthplace;LA3750-2;9;New Jersey;;; +63492-3;LL197-5;CR_250_Birthplace;LA3733-8;10;North Mid-Atlantic States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3748-6;11;New York;;; +63492-3;LL197-5;CR_250_Birthplace;LA3708-0;12;Pennsylvania;;; +63492-3;LL197-5;CR_250_Birthplace;LA3851-8;13;Delaware;;; +63492-3;LL197-5;CR_250_Birthplace;LA3675-1;14;South Mid-Atlantic States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3775-9;15;Maryland;;; +63492-3;LL197-5;CR_250_Birthplace;LA3849-2;16;District of Columbia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3583-7;17;Virginia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3578-7;18;West Virginia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3736-1;19;North Carolina;;; +63492-3;LL197-5;CR_250_Birthplace;LA3677-7;20;South Carolina;;; +63492-3;LL197-5;CR_250_Birthplace;LA3673-6;21;Southeastern States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3612-4;22;Tennessee;;; +63492-3;LL197-5;CR_250_Birthplace;LA3830-2;23;Georgia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3834-4;24;Florida;;; +63492-3;LL197-5;CR_250_Birthplace;LA3904-5;25;Alabama;;; +63492-3;LL197-5;CR_250_Birthplace;LA3765-0;26;Mississippi;;; +63492-3;LL197-5;CR_250_Birthplace;LA3735-3;27;North Central States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3771-8;28;Michigan;;; +63492-3;LL197-5;CR_250_Birthplace;LA3726-2;29;Ohio;;; +63492-3;LL197-5;CR_250_Birthplace;LA3812-0;30;Indiana;;; +63492-3;LL197-5;CR_250_Birthplace;LA3798-1;31;Kentucky;;; +63492-3;LL197-5;CR_250_Birthplace;LA3731-2;32;Northern Midwest States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3577-9;33;Wisconsin;;; +63492-3;LL197-5;CR_250_Birthplace;LA3766-8;34;Minnesota;;; +63492-3;LL197-5;CR_250_Birthplace;LA3809-6;35;Iowa;;; +63492-3;LL197-5;CR_250_Birthplace;LA3734-6;36;North Dakota;;; +63492-3;LL197-5;CR_250_Birthplace;LA3676-9;37;South Dakota;;; +63492-3;LL197-5;CR_250_Birthplace;LA3762-7;38;Montana;;; +63492-3;LL197-5;CR_250_Birthplace;LA3868-2;39;Central Midwest States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3814-6;40;Illinois;;; +63492-3;LL197-5;CR_250_Birthplace;LA3764-3;41;Missouri;;; +63492-3;LL197-5;CR_250_Birthplace;LA3799-9;42;Kansas;;; +63492-3;LL197-5;CR_250_Birthplace;LA3756-9;43;Nebraska;;; +63492-3;LL197-5;CR_250_Birthplace;LA3672-8;44;Southern Midwest States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3894-8;45;Arkansas;;; +63492-3;LL197-5;CR_250_Birthplace;LA3786-6;46;Louisiana;;; +63492-3;LL197-5;CR_250_Birthplace;LA3725-4;47;Oklahoma;;; +63492-3;LL197-5;CR_250_Birthplace;LA3611-6;48;Texas;;; +63492-3;LL197-5;CR_250_Birthplace;LA3760-1;49;Mountain States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3815-3;50;Idaho;;; +63492-3;LL197-5;CR_250_Birthplace;LA3576-1;51;Wyoming;;; +63492-3;LL197-5;CR_250_Birthplace;LA3862-5;52;Colorado;;; +63492-3;LL197-5;CR_250_Birthplace;LA3587-8;53;Utah;;; +63492-3;LL197-5;CR_250_Birthplace;LA3753-6;54;Nevada;;; +63492-3;LL197-5;CR_250_Birthplace;LA3749-4;55;New Mexico;;; +63492-3;LL197-5;CR_250_Birthplace;LA3895-5;56;Arizona;;; +63492-3;LL197-5;CR_250_Birthplace;LA3714-8;57;Pacific Coast States;;; +63492-3;LL197-5;CR_250_Birthplace;LA3903-7;58;Alaska;;; +63492-3;LL197-5;CR_250_Birthplace;LA3580-3;59;Washington;;; +63492-3;LL197-5;CR_250_Birthplace;LA3722-1;60;Oregon;;; +63492-3;LL197-5;CR_250_Birthplace;LA3875-7;61;California;;; +63492-3;LL197-5;CR_250_Birthplace;LA3820-3;62;Hawaii;;; +63492-3;LL197-5;CR_250_Birthplace;LA3891-4;63;Atlantic/Caribbean Area;;; +63492-3;LL197-5;CR_250_Birthplace;LA3700-7;64;Puerto Rico;;; +63492-3;LL197-5;CR_250_Birthplace;LA3588-6;65;US Virgin Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3720-5;66;Other Atlantic/Caribbean Area;;; +63492-3;LL197-5;CR_250_Birthplace;LA3872-4;67;Canal Zone;;; +63492-3;LL197-5;CR_250_Birthplace;LA3715-5;68;Pacific Area;;; +63492-3;LL197-5;CR_250_Birthplace;LA3900-3;69;American Samoa;;; +63492-3;LL197-5;CR_250_Birthplace;LA3796-5;70;Kiribati (Canton, Enderbury, Gilbert, S Lines, Phoenix);;; +63492-3;LL197-5;CR_250_Birthplace;LA3770-0;71;Micronesia (Fed States of) (Caroline, Trust Terr of Pacific);;; +63492-3;LL197-5;CR_250_Birthplace;LA3858-3;72;Cook Islands (New Zealand);;; +63492-3;LL197-5;CR_250_Birthplace;LA3602-5;73;Tuvalu (Ellice Islands);;; +63492-3;LL197-5;CR_250_Birthplace;LA3824-5;74;Guam;;; +63492-3;LL197-5;CR_250_Birthplace;LA3801-3;75;Johnston Atoll;;; +63492-3;LL197-5;CR_250_Birthplace;LA3778-3;76;Mariana Islands (Trust Territory of Pacific Islands);;; +63492-3;LL197-5;CR_250_Birthplace;LA3776-7;77;Marshall Islands (Trust Territory Pacific Islands);;; +63492-3;LL197-5;CR_250_Birthplace;LA3767-6;78;Midway Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3758-5;79;Nampo-Shoto, Southern;;; +63492-3;LL197-5;CR_250_Birthplace;LA3687-6;80;Ryukyu Islands (Japan);;; +63492-3;LL197-5;CR_250_Birthplace;LA3642-1;81;Swan Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3605-8;82;Tokelau Islands (New Zealand);;; +63492-3;LL197-5;CR_250_Birthplace;LA3582-9;83;Wake Island;;; +63492-3;LL197-5;CR_250_Birthplace;LA3711-4;84;Palau (Trust Territory of Pacific Islands);;; +63492-3;LL197-5;CR_250_Birthplace;LA3825-2;85;Greenland;;; +63492-3;LL197-5;CR_250_Birthplace;LA3873-2;86;Canada;;; +63492-3;LL197-5;CR_250_Birthplace;LA3777-5;87;Maritime Provinces (New Brunsw, Newfound, Nova Scotia, PE);;; +63492-3;LL197-5;CR_250_Birthplace;LA3699-1;88;Quebec;;; +63492-3;LL197-5;CR_250_Birthplace;LA3724-7;89;Ontario;;; +63492-3;LL197-5;CR_250_Birthplace;LA3702-3;90;Prairie Provinces (Alberta Manitoba, Saskatchewan);;; +63492-3;LL197-5;CR_250_Birthplace;LA3730-4;91;Northwest Territories, Yukon Territory;;; +63492-3;LL197-5;CR_250_Birthplace;LA3880-7;92;British Columbia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3772-6;93;Mexico;;; +63492-3;LL197-5;CR_250_Birthplace;LA3737-9;94;North American Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3854-2;95;Cuba;;; +63492-3;LL197-5;CR_250_Birthplace;LA3821-1;96;Haiti;;; +63492-3;LL197-5;CR_250_Birthplace;LA3847-6;97;Dominican Republic;;; +63492-3;LL197-5;CR_250_Birthplace;LA3803-9;98;Jamaica;;; +63492-3;LL197-5;CR_250_Birthplace;LA3719-7;99;Other Caribbean Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3883-1;100;Bermuda;;; +63492-3;LL197-5;CR_250_Birthplace;LA3888-0;101;Bahamas;;; +63492-3;LL197-5;CR_250_Birthplace;LA3670-2;102;St Pierre and Miquelon;;; +63492-3;LL197-5;CR_250_Birthplace;LA3870-8;103;Central America;;; +63492-3;LL197-5;CR_250_Birthplace;LA3823-7;104;Guatemala;;; +63492-3;LL197-5;CR_250_Birthplace;LA3884-9;105;Belize (British Honduras);;; +63492-3;LL197-5;CR_250_Birthplace;LA3819-5;106;Honduras;;; +63492-3;LL197-5;CR_250_Birthplace;LA3842-7;107;El Salvador;;; +63492-3;LL197-5;CR_250_Birthplace;LA3746-0;108;Nicaragua;;; +63492-3;LL197-5;CR_250_Birthplace;LA3857-5;109;Costa Rica;;; +63492-3;LL197-5;CR_250_Birthplace;LA3710-6;110;Panama;;; +63492-3;LL197-5;CR_250_Birthplace;LA3738-7;111;North America, NOS;;; +63492-3;LL197-5;CR_250_Birthplace;LA3793-2;112;Latin America, NOS;;; +63492-3;LL197-5;CR_250_Birthplace;LA3679-3;113;South America;;; +63492-3;LL197-5;CR_250_Birthplace;LA3863-3;114;Colombia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3586-0;115;Venezuela;;; +63492-3;LL197-5;CR_250_Birthplace;LA3822-9;116;Guyana (British Guiana);;; +63492-3;LL197-5;CR_250_Birthplace;LA3643-9;117;Suriname (Dutch Guiana);;; +63492-3;LL197-5;CR_250_Birthplace;LA3832-8;118;French Guiana;;; +63492-3;LL197-5;CR_250_Birthplace;LA3881-5;119;Brazil;;; +63492-3;LL197-5;CR_250_Birthplace;LA3844-3;120;Ecuador;;; +63492-3;LL197-5;CR_250_Birthplace;LA3707-2;121;Peru;;; +63492-3;LL197-5;CR_250_Birthplace;LA3882-3;122;Bolivia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3866-6;123;Chile;;; +63492-3;LL197-5;CR_250_Birthplace;LA3896-3;124;Argentina;;; +63492-3;LL197-5;CR_250_Birthplace;LA3709-8;125;Paraguay;;; +63492-3;LL197-5;CR_250_Birthplace;LA3589-4;126;Uruguay;;; +63492-3;LL197-5;CR_250_Birthplace;LA3678-5;127;South American Island;;; +63492-3;LL197-5;CR_250_Birthplace;LA3836-9;128;Falkland Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3598-5;129;United Kingdom;;; +63492-3;LL197-5;CR_250_Birthplace;LA3840-1;130;England, Channel Islands, Isle of Man;;; +63492-3;LL197-5;CR_250_Birthplace;LA3581-1;131;Wales;;; +63492-3;LL197-5;CR_250_Birthplace;LA3685-0;132;Scotland;;; +63492-3;LL197-5;CR_250_Birthplace;LA3732-0;133;Northern Ireland (Ulster);;; +63492-3;LL197-5;CR_250_Birthplace;LA3806-2;134;Ireland (Eire) (Ireland NOS, Republic of Ireland);;; +63492-3;LL197-5;CR_250_Birthplace;LA3686-8;135;Scandinavia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3816-1;136;Iceland;;; +63492-3;LL197-5;CR_250_Birthplace;LA3729-6;137;Norway (Svalbard, Jan Mayen);;; +63492-3;LL197-5;CR_250_Birthplace;LA3850-0;138;Denmark, Faroe Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3641-3;139;Sweden;;; +63492-3;LL197-5;CR_250_Birthplace;LA3835-1;140;Finland;;; +63492-3;LL197-5;CR_250_Birthplace;LA3829-4;141;Germanic Countries;;; +63492-3;LL197-5;CR_250_Birthplace;LA3828-6;142;Germany (East and West);;; +63492-3;LL197-5;CR_250_Birthplace;LA3754-4;143;Netherlands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3885-6;144;Belgium;;; +63492-3;LL197-5;CR_250_Birthplace;LA3785-8;145;Luxembourg;;; +63492-3;LL197-5;CR_250_Birthplace;LA3640-5;146;Switzerland;;; +63492-3;LL197-5;CR_250_Birthplace;LA3889-8;147;Austria;;; +63492-3;LL197-5;CR_250_Birthplace;LA3789-0;148;Liechtenstein;;; +63492-3;LL197-5;CR_250_Birthplace;LA3691-8;149;Romance-Language Countries;;; +63492-3;LL197-5;CR_250_Birthplace;LA3833-6;150;France, Corsica, Monaco;;; +63492-3;LL197-5;CR_250_Birthplace;LA3671-0;151;Spain (Canary Islands, Balearic Islands), Andorra;;; +63492-3;LL197-5;CR_250_Birthplace;LA3703-1;152;Portugal (Madeira Islands, Azores, Cape Verde Islands);;; +63492-3;LL197-5;CR_250_Birthplace;LA3804-7;153;Italy (Sardinia, Sicily), San Marino, Vatican City;;; +63492-3;LL197-5;CR_250_Birthplace;LA3690-0;154;Romania;;; +63492-3;LL197-5;CR_250_Birthplace;LA3682-7;155;Slavic Countries;;; +63492-3;LL197-5;CR_250_Birthplace;LA3705-6;156;Poland;;; +63492-3;LL197-5;CR_250_Birthplace;LA3852-6;157;Czechoslovakia (former);;; +63492-3;LL197-5;CR_250_Birthplace;LA3575-3;158;Yugoslavia (former);;; +63492-3;LL197-5;CR_250_Birthplace;LA3879-9;159;Bulgaria;;; +63492-3;LL197-5;CR_250_Birthplace;LA3689-2;160;Russian SFSR (Russia);;; +63492-3;LL197-5;CR_250_Birthplace;LA3599-3;161;Ukraine and Moldavia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3876-5;162;Byelorus (Byelorussian SSR, White Russia);;; +63492-3;LL197-5;CR_250_Birthplace;LA3839-3;163;Estonian SSR (Estonia);;; +63492-3;LL197-5;CR_250_Birthplace;LA3792-4;164;Latvian SSR (Estonia);;; +63492-3;LL197-5;CR_250_Birthplace;LA3788-2;165;Lithuania (Lithuanian SSR);;; +63492-3;LL197-5;CR_250_Birthplace;LA3887-2;166;Baltic Republic(s), NOS (Baltic States, NOS);;; +63492-3;LL197-5;CR_250_Birthplace;LA3718-9;167;Other Mainland Europe;;; +63492-3;LL197-5;CR_250_Birthplace;LA3826-0;168;Greece;;; +63492-3;LL197-5;CR_250_Birthplace;LA3817-9;169;Hungary;;; +63492-3;LL197-5;CR_250_Birthplace;LA3902-9;170;Albania;;; +63492-3;LL197-5;CR_250_Birthplace;LA3827-8;171;Gibraltar;;; +63492-3;LL197-5;CR_250_Birthplace;LA3717-1;172;Other Mediterranean Isles;;; +63492-3;LL197-5;CR_250_Birthplace;LA3779-1;173;Malta;;; +63492-3;LL197-5;CR_250_Birthplace;LA3853-4;174;Cyprus;;; +63492-3;LL197-5;CR_250_Birthplace;LA3837-7;175;Europe, NOS (Central, Eastern, Northern, Southern, Western);;; +63492-3;LL197-5;CR_250_Birthplace;LA3906-0;176;Africa, NOS (Central, Equatorial);;; +63492-3;LL197-5;CR_250_Birthplace;LA3739-5;177;North Africa;;; +63492-3;LL197-5;CR_250_Birthplace;LA3761-9;178;Morocco;;; +63492-3;LL197-5;CR_250_Birthplace;LA3901-1;179;Algeria;;; +63492-3;LL197-5;CR_250_Birthplace;LA3604-1;180;Tunisia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3790-8;181;Libya (Tripoli, Tripolitania, Cyrenaica);;; +63492-3;LL197-5;CR_250_Birthplace;LA3843-5;182;Egypt (United Arab Republic);;; +63492-3;LL197-5;CR_250_Birthplace;LA3646-2;183;Sudanese Countries;;; +63492-3;LL197-5;CR_250_Birthplace;LA3579-5;184;West Africa, NOS (French Africa, NOS);;; +63492-3;LL197-5;CR_250_Birthplace;LA3745-2;185;Nigeria;;; +63492-3;LL197-5;CR_250_Birthplace;LA3716-3;186;Other West African Countries;;; +63492-3;LL197-5;CR_250_Birthplace;LA3680-1;187;South Africa, NOS;;; +63492-3;LL197-5;CR_250_Birthplace;LA3574-6;188;Zaire (Congo-Leopoldville, Belgian Congo, Congo/Kinshasa);;; +63492-3;LL197-5;CR_250_Birthplace;LA3899-7;189;Angola (Sao Tome, Principe, Cabinda);;; +63492-3;LL197-5;CR_250_Birthplace;LA3693-4;190;Republic of South Africa;;; +63492-3;LL197-5;CR_250_Birthplace;LA3572-0;191;Zimbabwe (Rhodesia, Southern Rhodesia);;; +63492-3;LL197-5;CR_250_Birthplace;LA3573-8;192;Zambia (Northern Rhodesia);;; +63492-3;LL197-5;CR_250_Birthplace;LA3780-9;193;Malawi (Nyasaland);;; +63492-3;LL197-5;CR_250_Birthplace;LA3759-3;194;Mozambique;;; +63492-3;LL197-5;CR_250_Birthplace;LA3783-3;195;Madagascar (Malagasy Republic);;; +63492-3;LL197-5;CR_250_Birthplace;LA3846-8;196;East Africa;;; +63492-3;LL197-5;CR_250_Birthplace;LA3613-2;197;Tanzania (Tanganyika, Zanzibar);;; +63492-3;LL197-5;CR_250_Birthplace;LA3600-9;198;Uganda;;; +63492-3;LL197-5;CR_250_Birthplace;LA3797-3;199;Kenya;;; +63492-3;LL197-5;CR_250_Birthplace;LA3688-4;200;Rwanda (Ruanda);;; +63492-3;LL197-5;CR_250_Birthplace;LA3877-3;201;Burundi (Urundi);;; +63492-3;LL197-5;CR_250_Birthplace;LA3905-2;202;African Coastal Islands (previously in South Africa, NOS);;; +63492-3;LL197-5;CR_250_Birthplace;LA3681-9;203;Somalia (Somali Republic, Somaliland);;; +63492-3;LL197-5;CR_250_Birthplace;LA3848-4;204;Djibouti;;; +63492-3;LL197-5;CR_250_Birthplace;LA3838-5;205;Ethiopia (Abyssinia), Eritrea;;; +63492-3;LL197-5;CR_250_Birthplace;LA3893-0;206;Asia, NOS;;; +63492-3;LL197-5;CR_250_Birthplace;LA3757-7;207;Near East;;; +63492-3;LL197-5;CR_250_Birthplace;LA3603-3;208;Turkey;;; +63492-3;LL197-5;CR_250_Birthplace;LA3892-2;209;Asian and Arab Countries;;; +63492-3;LL197-5;CR_250_Birthplace;LA3639-7;210;Syria;;; +63492-3;LL197-5;CR_250_Birthplace;LA3791-6;211;Lebanon;;; +63492-3;LL197-5;CR_250_Birthplace;LA3800-5;212;Jordan (Transjordan) and former Arab Palestine;;; +63492-3;LL197-5;CR_250_Birthplace;LA3807-0;213;Iraq;;; +63492-3;LL197-5;CR_250_Birthplace;LA3897-1;214;Arabian Peninsula;;; +63492-3;LL197-5;CR_250_Birthplace;LA3805-4;215;Israel and former Jewish Palestine;;; +63492-3;LL197-5;CR_250_Birthplace;LA3871-6;216;Caucasian Republics of the USSR;;; +63492-3;LL197-5;CR_250_Birthplace;LA3721-3;217;Other Asian Republics of the USSR;;; +63492-3;LL197-5;CR_250_Birthplace;LA3808-8;218;Iran (Persia);;; +63492-3;LL197-5;CR_250_Birthplace;LA3907-8;219;Afghanistan;;; +63492-3;LL197-5;CR_250_Birthplace;LA3712-2;220;Pakistan (West Pakistan);;; +63492-3;LL197-5;CR_250_Birthplace;LA3768-4;221;Mid-East Asia, NOS;;; +63492-3;LL197-5;CR_250_Birthplace;LA3813-8;222;India;;; +63492-3;LL197-5;CR_250_Birthplace;LA3755-1;223;Nepal, Bhutan, Sikkim;;; +63492-3;LL197-5;CR_250_Birthplace;LA3886-4;224;Bangladesh (East Pakistan);;; +63492-3;LL197-5;CR_250_Birthplace;LA3867-4;225;Ceylon (Sri Lanka);;; +63492-3;LL197-5;CR_250_Birthplace;LA3878-1;226;Burma;;; +63492-3;LL197-5;CR_250_Birthplace;LA3674-4;227;Southeast Asia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3610-8;228;Thailand (Siam);;; +63492-3;LL197-5;CR_250_Birthplace;LA3811-2;229;Indochina;;; +63492-3;LL197-5;CR_250_Birthplace;LA3794-0;230;Laos;;; +63492-3;LL197-5;CR_250_Birthplace;LA3874-0;231;Cambodia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3584-5;232;Vietnam (Tonkin, Annam, Cochin China);;; +63492-3;LL197-5;CR_250_Birthplace;LA3781-7;233;Malaysia, Singapore, Brunei;;; +63492-3;LL197-5;CR_250_Birthplace;LA3810-4;234;Indonesia (Dutch East Indies);;; +63492-3;LL197-5;CR_250_Birthplace;LA3706-4;235;Philippines (Philippine Islands);;; +63492-3;LL197-5;CR_250_Birthplace;LA3845-0;236;East Asia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3864-1;237;China, NOS;;; +63492-3;LL197-5;CR_250_Birthplace;LA3865-8;238;China (Peoples Republic of China);;; +63492-3;LL197-5;CR_250_Birthplace;LA3818-7;239;Hong Kong;;; +63492-3;LL197-5;CR_250_Birthplace;LA3614-0;240;Taiwan (Formosa) (Republic of China);;; +63492-3;LL197-5;CR_250_Birthplace;LA3609-0;241;Tibet;;; +63492-3;LL197-5;CR_250_Birthplace;LA3784-1;242;Macao (Macau);;; +63492-3;LL197-5;CR_250_Birthplace;LA3763-5;243;Mongolia;;; +63492-3;LL197-5;CR_250_Birthplace;LA3802-1;244;Japan;;; +63492-3;LL197-5;CR_250_Birthplace;LA3795-7;245;Korea (North and South);;; +63492-3;LL197-5;CR_250_Birthplace;LA3890-6;246;Australia and Australian New Guinea;;; +63492-3;LL197-5;CR_250_Birthplace;LA3747-8;247;New Zealand;;; +63492-3;LL197-5;CR_250_Birthplace;LA3713-0;248;Pacific Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3773-4;249;Melanesian Islands, Solomon Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3769-2;250;Micronesian Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3704-9;251;Polynesian Islands;;; +63492-3;LL197-5;CR_250_Birthplace;LA3898-9;252;Antarctica;;; +63492-3;LL197-5;CR_250_Birthplace;LA4683-4;253;Place of birth stated not to be in United States, but no other information available;;; +63492-3;LL197-5;CR_250_Birthplace;LA4682-6;254;Place of birth unknown;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31572-3;1;US;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3713-0;2;Pacific Islands;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3865-8;3;China (Peoples Republic of China);;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3614-0;4;Taiwan (Formosa) (Republic of China);;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3802-1;5;Japan;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3795-7;6;Korea (North and South);;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3874-0;7;Cambodia;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3794-0;8;Laos;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3706-4;9;Philippines (Philippine Islands);;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31573-1;10;South Asia;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3610-8;11;Thailand (Siam);;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA3584-5;12;Vietnam (Tonkin, Annam, Cochin China);;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31574-9;13;Other Asian Country;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31575-6;14;Europe;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31576-4;15;Africa;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31577-2;16;Latin, Central, or South America;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31578-0;17;Other place of Birth;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA30122-8;18;I choose not to answer this question;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31369-4;19;Question not administered;;; +21842-0;LL5771-2;AAPCHO - Birthplace;LA31370-2;20;Skipped question;;; +21843-8;LL3926-4;PHVS_Occupation_CDC_Census2010;;0;;;; +85658-3;LL3926-4;PHVS_Occupation_CDC_Census2010;;0;;;; +85659-1;LL3926-4;PHVS_Occupation_CDC_Census2010;;0;;;; +21844-6;LL3925-6;PHVS_Industry_CDC_Census2010;;0;;;; +85078-4;LL3925-6;PHVS_Industry_CDC_Census2010;;0;;;; +85657-5;LL3925-6;PHVS_Industry_CDC_Census2010;;0;;;; +86188-0;LL3925-6;PHVS_Industry_CDC_Census2010;;0;;;; +21845-3;LL200-7;CR_290_Occupation source;LA4404-5;1;Unknown occupation;;; +21845-3;LL200-7;CR_290_Occupation source;LA4377-3;2;Reporting facility record;;; +21845-3;LL200-7;CR_290_Occupation source;LA4188-4;3;Death Certificate;;; +21845-3;LL200-7;CR_290_Occupation source;LA4601-6;4;Interview;;; +21845-3;LL200-7;CR_290_Occupation source;LA4723-8;5;Other Source;;; +21845-3;LL200-7;CR_290_Occupation source;LA4702-2;6;Not Applicable <14yr old;;; +21845-3;LL200-7;CR_290_Occupation source;LA4413-6;7;Unknown Source;;; +21845-3;LL200-7;CR_290_Occupation source;LA4700-6;8;Not Collected;;; +21846-1;LL202-3;CR_300_Industry source;LA4405-2;1;Unknown Industry;;; +21846-1;LL202-3;CR_300_Industry source;LA4377-3;2;Reporting facility record;;; +21846-1;LL202-3;CR_300_Industry source;LA4188-4;3;Death Certificate;;; +21846-1;LL202-3;CR_300_Industry source;LA4601-6;4;Interview;;; +21846-1;LL202-3;CR_300_Industry source;LA4723-8;5;Other Source;;; +21846-1;LL202-3;CR_300_Industry source;LA4702-2;6;Not Applicable <14yr old;;; +21846-1;LL202-3;CR_300_Industry source;LA4413-6;7;Unknown Source;;; +21846-1;LL202-3;CR_300_Industry source;LA4700-6;8;Not Collected;;; +21849-5;LL203-1;CR_330_Occupation coding system;LA4094-4;1;1970 Census;;; +21849-5;LL203-1;CR_330_Occupation coding system;LA4107-4;2;1980 Census;;; +21849-5;LL203-1;CR_330_Occupation coding system;LA4098-5;3;1990 Census;;; +21849-5;LL203-1;CR_330_Occupation coding system;LA4155-3;4;2000 Census;;; +21849-5;LL203-1;CR_330_Occupation coding system;LA4727-9;5;Other Coding System;;; +21849-5;LL203-1;CR_330_Occupation coding system;LA4426-8;6;Unknown Coding System;;; +21850-3;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +21850-3;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +21850-3;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52615-2;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52615-2;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52615-2;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52616-0;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52616-0;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52616-0;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58252-8;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58252-8;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58252-8;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58253-6;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58253-6;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58253-6;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58257-7;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58257-7;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58257-7;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58340-1;LL208-0;CR_360_Fam hx of cancer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58340-1;LL208-0;CR_360_Fam hx of cancer;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58340-1;LL208-0;CR_360_Fam hx of cancer;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21852-9;LL209-8;CR_364_Census tract certainty;LA4446-6;1;Valid Street Address;;; +21852-9;LL209-8;CR_364_Census tract certainty;LA4375-7;2;Residence Zip +4;;; +21852-9;LL209-8;CR_364_Census tract certainty;LA4376-5;3;Residence Zip +2;;; +21852-9;LL209-8;CR_364_Census tract certainty;LA4374-0;4;Residence Zip only;;; +21852-9;LL209-8;CR_364_Census tract certainty;LA4536-4;5;Zip or P.O. Box;;; +21852-9;LL209-8;CR_364_Census tract certainty;LA4490-4;6;Unable to Assign;;; +21853-7;LL210-6;CR_380_Cancer sequence number;LA4740-2;1;One primary only;;; +21853-7;LL210-6;CR_380_Cancer sequence number;LA3988-8;2;First of one or more primaries;;; +21853-7;LL210-6;CR_380_Cancer sequence number;LA4311-2;3;Second of two or more primaries;;; +21853-7;LL210-6;CR_380_Cancer sequence number;LA4262-7;4;Case of carcinoma in situ of the cervix diagnosed on January;;; +21853-7;LL210-6;CR_380_Cancer sequence number;LA4449-0;5;Unspecified sequence number;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA3967-2;1;Grade I;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA3992-0;2;Grade II;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA4027-4;3;Grade III;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA3982-1;4;Grade IV;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA4470-6;5;T-cell;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA4275-9;6;B-cell;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA4748-5;7;Null cell;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA4573-7;8;NK (natural killer) cell;;; +21857-8;LL212-2;CR_430_Cancer behavior;LA3983-9;9;Grade/differentiation unknown, not stated, or not applicable;;; +21858-6;LL213-0;CR_440_Cancer grade;LA4158-7;1;Code - not defined in code system;;; +21858-6;LL213-0;CR_440_Cancer grade;LA3967-2;2;Grade I;;; +21858-6;LL213-0;CR_440_Cancer grade;LA3992-0;3;Grade II;;; +21858-6;LL213-0;CR_440_Cancer grade;LA4027-4;4;Grade III;;; +21858-6;LL213-0;CR_440_Cancer grade;LA3982-1;5;Grade IV;;; +21858-6;LL213-0;CR_440_Cancer grade;LA4470-6;6;T-cell;;; +21858-6;LL213-0;CR_440_Cancer grade;LA4275-9;7;B-cell;;; +21858-6;LL213-0;CR_440_Cancer grade;LA4748-5;8;Null cell;;; +21858-6;LL213-0;CR_440_Cancer grade;LA4573-7;9;NK (natural killer) cell;;; +21858-6;LL213-0;CR_440_Cancer grade;LA3983-9;10;Grade/differentiation unknown, not stated, or not applicable;;; +21859-4;LL214-8;CR_450_Site coding system;LA3913-6;1;ICD-8;;; +21859-4;LL214-8;CR_450_Site coding system;LA3926-8;2;ICD-9;;; +21859-4;LL214-8;CR_450_Site coding system;LA4008-4;3;ICD-0 1st Ed.;;; +21859-4;LL214-8;CR_450_Site coding system;LA4009-2;4;ICD-0 2nd Ed.;;; +21859-4;LL214-8;CR_450_Site coding system;LA3951-6;5;ICD-O, Third Edition;;; +21859-4;LL214-8;CR_450_Site coding system;LA4012-6;6;ICD-10;;; +21859-4;LL214-8;CR_450_Site coding system;LA46-8;7;Other;;; +42129-7;LL214-8;CR_450_Site coding system;LA3913-6;1;ICD-8;;; +42129-7;LL214-8;CR_450_Site coding system;LA3926-8;2;ICD-9;;; +42129-7;LL214-8;CR_450_Site coding system;LA4008-4;3;ICD-0 1st Ed.;;; +42129-7;LL214-8;CR_450_Site coding system;LA4009-2;4;ICD-0 2nd Ed.;;; +42129-7;LL214-8;CR_450_Site coding system;LA3951-6;5;ICD-O, Third Edition;;; +42129-7;LL214-8;CR_450_Site coding system;LA4012-6;6;ICD-10;;; +42129-7;LL214-8;CR_450_Site coding system;LA46-8;7;Other;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA4008-4;1;ICD-0 1st Ed.;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA3998-7;2;ICD-0 1986 Field Trial;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA4007-6;3;ICD-0 1988 Field Trial;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA4009-2;4;ICD-0 2nd Ed.;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA4010-0;5;ICD-0 2nd Ed.+ 1995 mods;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA4011-8;6;ICD-0 2nd Ed.+ 1998 mods;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA3958-1;7;ICD-O-3;;; +21860-2;LL216-3;CR_470_Morphology coding system;LA46-8;8;Other;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA4008-4;1;ICD-0 1st Ed.;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA3998-7;2;ICD-0 1986 Field Trial;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA4007-6;3;ICD-0 1988 Field Trial;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA4009-2;4;ICD-0 2nd Ed.;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA4010-0;5;ICD-0 2nd Ed.+ 1995 mods;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA4011-8;6;ICD-0 2nd Ed.+ 1998 mods;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA3958-1;7;ICD-O-3;;; +42034-9;LL216-3;CR_470_Morphology coding system;LA46-8;8;Other;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4674-3;2;Positive Histology;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4675-0;3;Positive Cytology;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4610-7;4;Micro Confirmation, NOS;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4673-5;5;Positive Lab/Marker Study;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4199-1;6;Direct Visualization;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4383-1;7;Radiography/Imaging Only;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4163-7;8;Clinical Dx Only;;; +21861-0;LL218-9;CR_490_Diagnostic confirmation;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21862-8;LL220-5;CR_500_Type of reporting source;LA4005-0;1;Hospital or Clinic;;; +21862-8;LL220-5;CR_500_Type of reporting source;LA4587-7;2;Laboratory Only;;; +21862-8;LL220-5;CR_500_Type of reporting source;LA4685-9;3;Physician's Office;;; +21862-8;LL220-5;CR_500_Type of reporting source;LA4746-9;4;Nursing/Conv home/Hospice;;; +21862-8;LL220-5;CR_500_Type of reporting source;LA4222-1;5;Autopsy Only;;; +21862-8;LL220-5;CR_500_Type of reporting source;LA4197-5;6;Death Certificate Only;;; +21863-6;LL221-3;CR_510_Screening date;LA4638-8;1;Patient participated in screening program related to this pr;;; +21863-6;LL221-3;CR_510_Screening date;LA4646-1;2;Patient did not participate in screening program related to;;; +21864-4;LL222-1;CR_520_Screening result;LA4439-1;1;Within Normal Limits;;; +21864-4;LL222-1;CR_520_Screening result;LA4239-5;2;Abnormal/not suggest Ca;;; +21864-4;LL222-1;CR_520_Screening result;LA4240-3;3;Abnormal/suggest Ca;;; +21864-4;LL222-1;CR_520_Screening result;LA4019-1;4;Equivocal/no follow-up req;;; +21864-4;LL222-1;CR_520_Screening result;LA4020-9;5;Equivocal/eval recommend;;; +21864-4;LL222-1;CR_520_Screening result;LA4720-4;6;Not applicable;;; +21864-4;LL222-1;CR_520_Screening result;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21867-7;LL223-9;CR_560_Hospital sequence number;LA4740-2;1;One primary only;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3993-8;2;First of two or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4311-2;3;Second of two or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4464-9;4;Third of three or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3924-3;5;Fourth of four or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3980-5;6;Fifth of five or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4333-6;7;Sixth of six or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4325-2;8;Seventh of seven or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3979-7;9;Eighth of eight or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4532-3;11;Ninth of nine or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4468-0;12;Tenth of ten or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4025-8;13;Eleventh of eleven or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4504-2;14;Twelfth of twelve or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4463-1;20;Thirteenth of thirteen or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3987-0;21;Fourteenth of fourteen or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3974-8;22;Fifteenth of fifteen or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4335-1;25;Sixteenth of sixteen or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4285-8;26;Seventeenth of seventeen or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4023-3;27;Eighteenth of eighteen or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4530-7;28;Nineteenth of nineteen or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4503-4;30;Twentieth of twenty or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4516-6;31;Twenty-first of twenty-one or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4497-9;32;Twenty-second of twenty-two or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4494-6;33;Twenty-third of twenty-three or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4499-5;34;Twenty-fourth of twenty-four or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4501-8;35;Twenty-fifth of twenty-five or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4495-3;36;Twenty-sixth of twenty-six or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4496-1;37;Twenty-seventh of twenty-seven or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4487-0;38;Twenty-eighth of twenty-eight or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4498-7;39;Twenty-ninth of twenty-nine or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4462-3;40;Thirtieth of thirty or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4460-7;41;Thirty-first of thirty-one or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4500-0;42;Thirty-second of thirty-two or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4502-6;43;Thirty-third of thirty-three or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4459-9;44;Thirty-fourth of thirty-four or more primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4461-5;45;Thirty-fifth of thirty-five primaries;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4738-6;46;Only one neoplasm required by the state or the hospital cancer committee but not by COC;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3990-4;47;First of two or more neoplasms in this category;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4297-3;48;Second of two or more neoplasms in this category;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4449-0;49;Unspecified sequence number;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4742-8;50;One benign tumor only, or the first of more than one benign;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4283-3;51;Second of two or more benign tumors;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4465-6;52;Third of three or more benign tumors;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA3914-4;53;Fourth of four or more benign tumors;;; +21867-7;LL223-9;CR_560_Hospital sequence number;LA4450-8;54;Unspecified number of benign tumors;;; +21870-1;LL224-7;CR_590_ Inpatient admit date;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21870-1;LL224-7;CR_590_ Inpatient admit date;LA4636-2;2;Patient was never an inpatient at the reporting facility;;; +21871-9;LL225-4;CR_600_Inpatient discharge date;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21871-9;LL225-4;CR_600_Inpatient discharge date;LA4676-8;2;Patient was never an inpatient at the reporting hospital;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3925-0;1;Dx here, Rx elsewhere;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3963-1;2;Dx and Rx here;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3935-9;3;Dx elsewhere, Rx here;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3929-2;4;Dx, Rx elsewhere;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3931-8;5;Dx, Rx prior to ref date;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3934-2;6;Dx at Autopsy;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3927-6;7;Dx&Rx in staff MDs office;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA4650-3;8;Pathology report only. Patient does not enter the reporting facility at any time for diagnosis or treatment. This category excludes tumors diagnosed at autopsy.;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA3920-1;9;Dx by death Certificate;;; +21872-7;LL226-2;CR_610_Hospital-cancer relationship;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21874-3;LL460-7;CR_650_ CA presentation status;LA9170-7;1;Not presented;;; +21874-3;LL460-7;CR_650_ CA presentation status;LA9171-5;2;Prospective presentation (diagnostic);;; +21874-3;LL460-7;CR_650_ CA presentation status;LA9172-3;3;Prospective presentation (treatment);;; +21874-3;LL460-7;CR_650_ CA presentation status;LA9173-1;4;Prospective presentation (follow-up care);;; +21874-3;LL460-7;CR_650_ CA presentation status;LA9174-9;5;Prospective presentation (combinations of 1, 2, or 3);;; +21874-3;LL460-7;CR_650_ CA presentation status;LA9175-6;6;Prospective, NOS;;; +21874-3;LL460-7;CR_650_ CA presentation status;LA9176-4;7;Retrospective presentation;;; +21874-3;LL460-7;CR_650_ CA presentation status;LA9177-2;8;Follow-up;;; +21876-8;LL227-0;CR_670_Surgical protocol;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21876-8;LL227-0;CR_670_Surgical protocol;LA3644-7;2;Surgery, NOS;;; +21876-8;LL227-0;CR_670_Surgical protocol;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21880-0;LL456-5;CR_690_Radiation treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21880-0;LL456-5;CR_690_Radiation treatment;LA4269-2;2;Beam Radiation;;; +21880-0;LL456-5;CR_690_Radiation treatment;LA4342-7;3;Radioactive Implants;;; +21880-0;LL456-5;CR_690_Radiation treatment;LA4385-6;4;Radioisotopes;;; +21880-0;LL456-5;CR_690_Radiation treatment;LA9149-1;5;Combination of 1 with 2 or 3;;; +21880-0;LL456-5;CR_690_Radiation treatment;LA9150-9;6;Radiation, NOS method or source not specified;;; +21880-0;LL456-5;CR_690_Radiation treatment;LA9151-7;7;Unknown if radiation therapy administered;;; +21881-8;LL458-1;CR_700_Chemo treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21881-8;LL458-1;CR_700_Chemo treatment;LA4157-9;2;Chemotherapy, NOS;;; +21881-8;LL458-1;CR_700_Chemo treatment;LA9162-4;3;Chemotherapy, single agent;;; +21881-8;LL458-1;CR_700_Chemo treatment;LA9163-2;4;Chemotherapy, multiple agents (combination regimen);;; +21881-8;LL458-1;CR_700_Chemo treatment;LA9181-4;5;Unknown if any chemotherapy administered;;; +21882-6;LL459-9;CR_710_Hormone treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21882-6;LL459-9;CR_710_Hormone treatment;LA9166-5;2;Hormones (including NOS and antihormones);;; +21882-6;LL459-9;CR_710_Hormone treatment;LA9167-3;3;Endocrine surgery and/or endocrine radiation (if cancer is of another site);;; +21882-6;LL459-9;CR_710_Hormone treatment;LA4189-2;4;Combination of 1 & 2;;; +21882-6;LL459-9;CR_710_Hormone treatment;LA9169-9;5;Unknown if hormone therapy administered;;; +21883-4;LL457-3;CR_720_Transplant treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21883-4;LL457-3;CR_720_Transplant treatment;LA4272-6;2;Biological response modifier (BRM);;; +21883-4;LL457-3;CR_720_Transplant treatment;LA9154-1;3;Bone marrow transplant--autologous;;; +21883-4;LL457-3;CR_720_Transplant treatment;LA9155-8;4;Bone marrow transplant--allogenic;;; +21883-4;LL457-3;CR_720_Transplant treatment;LA4278-3;5;Bone marrow transplant, NOS;;; +21883-4;LL457-3;CR_720_Transplant treatment;LA4478-9;6;Stem Cell Transplant;;; +21883-4;LL457-3;CR_720_Transplant treatment;LA4212-2;7;Combination of 1 and any 2, 3, 4, or 5;;; +21883-4;LL457-3;CR_720_Transplant treatment;LA9159-0;8;Patient or patient’s guardian refused;;; +21884-2;LL454-0;CR_730_Other treatment;LA4558-8;1;No other cancer-directed therapy except as coded elsewhere;;; +21884-2;LL454-0;CR_730_Other treatment;LA4730-3;2;Other cancer-directed therapy;;; +21884-2;LL454-0;CR_730_Other treatment;LA9128-5;3;Other experimental cancer-directed therapy (not included elsewhere);;; +21884-2;LL454-0;CR_730_Other treatment;LA3962-3;4;Double-blind study, code not yet broken;;; +21884-2;LL454-0;CR_730_Other treatment;LA4451-6;5;Unproven therapy (including laetrile, krebiozen, etc.);;; +21884-2;LL454-0;CR_730_Other treatment;LA9131-9;6;Patient or patient's guardian refused therapy which would have been coded 1-3 above;;; +21884-2;LL454-0;CR_730_Other treatment;LA9132-7;7;Other cancer-directed therapy recommended, unknown if administered;;; +21884-2;LL454-0;CR_730_Other treatment;LA4411-0;8;Unknown if other cancer-directed therapy administered;;; +21885-9;LL461-5;CR_740_Surgical treatment;LA4518-2;1;No surgical procedure;;; +21885-9;LL461-5;CR_740_Surgical treatment;LA9179-8;2;Incisional biopsy of other than primary site,Needle biopsy of other than primary site,Aspiration biopsy of other than primary site;;; +21885-9;LL461-5;CR_740_Surgical treatment;LA3949-0;3;"Incisional biopsy of primary site; needle biopsy of primary";;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA3944-1;1;In Situ;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA3787-4;2;Localized;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA3695-9;3;Regional, direct extension only;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA3694-2;4;Regional, regional lymph nodes only;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA3696-7;5;Regional, direct extension and regional lymph nodes;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA4380-7;6;Regional, NOS;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA4200-7;7;Distant;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA4720-4;8;Not applicable;;; +21887-5;LL228-8;CR_759_SEER stage 2000;LA3595-1;9;Unstaged;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA3944-1;1;In Situ;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA3787-4;2;Localized;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA3695-9;3;Regional, direct extension only;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA3694-2;4;Regional, regional lymph nodes only;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA3696-7;5;Regional, direct extension and regional lymph nodes;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA4380-7;6;Regional, NOS;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA4200-7;7;Distant;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA4720-4;8;Not applicable;;; +39806-5;LL228-8;CR_759_SEER stage 2000;LA3595-1;9;Unstaged;;; +21888-3;LL230-4;CR_770_Stage at diagnosis;LA3944-1;1;In Situ;;; +21888-3;LL230-4;CR_770_Stage at diagnosis;LA4583-6;2;Local;;; +21888-3;LL230-4;CR_770_Stage at diagnosis;LA3697-5;3;Regional;;; +21888-3;LL230-4;CR_770_Stage at diagnosis;LA4200-7;4;Distant;;; +21888-3;LL230-4;CR_770_Stage at diagnosis;LA3595-1;5;Unstaged;;; +21898-2;LL453-2;CR_870_EOD version used;LA9121-0;1;2-Digit Nonspecific Extent of Disease (1973-82);;; +21898-2;LL453-2;CR_870_EOD version used;LA9122-8;2;2-Digit Site-Specific Extent of Disease (1973-82);;; +21898-2;LL453-2;CR_870_EOD version used;LA9123-6;3;13-Digit (Expanded) Site-Specific Extent of Disease (1973-82);;; +21898-2;LL453-2;CR_870_EOD version used;LA9124-4;4;4-Digit Extent of Disease (1983-87);;; +21898-2;LL453-2;CR_870_EOD version used;LA9125-1;5;10-Digit Extent of Disease, 1988 (1988+);;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3601-7;1;TX;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3606-6;2;Tispu;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3607-4;3;Tispd;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3608-2;4;Tis;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3615-7;5;Ta;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3616-5;6;T4d;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3617-3;7;T4c;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3618-1;8;T4b;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3619-9;9;T4a;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3620-7;10;T4;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3621-5;11;T3c;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3622-3;12;T3b;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3623-1;13;T3a;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3624-9;14;T3;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3625-6;15;T2c;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3626-4;16;T2b;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3627-2;17;T2a;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3628-0;18;T2;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3629-8;19;T1mic;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3630-6;20;T1c;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3631-4;21;T1b2;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3632-2;22;T1b1;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3633-0;23;T1b;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3634-8;24;T1a2;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3635-5;25;T1a1;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3636-3;26;T1a;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3637-1;27;T1;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA3638-9;28;T0;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA4703-0;29;Not applicable (no AJCC staging scheme);;; +21899-0;LL232-0;CR_880_Tumor pathology;LA21805-9;30;T1d;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA21806-7;31;T2a1;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA21807-5;32;T2a2;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA21808-3;33;T2d;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA21810-9;34;T3d;;; +21899-0;LL232-0;CR_880_Tumor pathology;LA21811-7;35;T4e;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4745-1;1;NX;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4368-2;2;N0;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21814-1;3;N0I-;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21815-8;4;N0I+;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21816-6;5;N0M-;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21817-4;6;N0M+;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21818-2;7;N0a;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21819-0;8;N0b;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4537-2;9;N1;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4264-3;10;N1a;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4535-6;11;N1b;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21866-1;12;N1c;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21821-6;13;N1m;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21822-4;14;N1mi;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4534-9;15;N2;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4533-1;16;N2a;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4517-4;17;N2b;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4531-5;18;N2c;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4545-5;19;N3;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4529-9;20;N3a;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4528-1;21;N3b;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4527-3;22;N3c;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA4703-0;23;Not applicable (no AJCC staging scheme);;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21830-7;24;NI-;;; +21900-6;LL3136-0;Regional lymph nodes pathology;LA21831-5;25;NI+;;; +21901-4;LL3137-8;Distant metastases pathology;LA21832-3;1;PX;;; +21901-4;LL3137-8;Distant metastases pathology;LA21833-1;2;P0;;; +21901-4;LL3137-8;Distant metastases pathology;LA21834-9;3;P1;;; +21901-4;LL3137-8;Distant metastases pathology;LA21835-6;4;P1a;;; +21901-4;LL3137-8;Distant metastases pathology;LA21836-4;5;P1b;;; +21901-4;LL3137-8;Distant metastases pathology;LA21837-2;6;P1c;;; +21901-4;LL3137-8;Distant metastases pathology;LA21838-0;7;P1d;;; +21901-4;LL3137-8;Distant metastases pathology;LA21839-8;8;P1e;;; +21901-4;LL3137-8;Distant metastases pathology;LA21840-6;9;P1m;;; +21901-4;LL3137-8;Distant metastases pathology;LA21841-4;10;P1m1;;; +21901-4;LL3137-8;Distant metastases pathology;LA4703-0;11;Not applicable (no AJCC staging scheme);;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3649-6;1;Stage IVB;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3650-4;2;Stage IVA;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3651-2;3;Stage IV;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3654-6;4;Stage IIIC;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3655-3;5;Stage IIIB;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3656-1;6;Stage IIIA;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3657-9;7;Stage III;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3658-7;8;Stage IIC;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3659-5;9;Stage IIB;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3660-3;10;Stage IIA;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3661-1;11;Stage II;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3662-9;12;Stage IB;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3663-7;13;Stage IA;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3664-5;14;Stage I;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4314-6;15;Stage IVC;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4315-3;16;Stage IS;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4317-9;17;Stage IB2;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4318-7;18;Stage IB1;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4319-5;19;Stage IA2;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4320-3;20;Stage IA1;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4321-1;21;Stage 0is;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4322-9;22;Stage 0A;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4323-7;23;Stage 0;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4489-6;24;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21902-2;LL234-6;CR_910_Tumor stage group;LA4703-0;25;Not applicable (no AJCC staging scheme);;; +21902-2;LL234-6;CR_910_Tumor stage group;LA4316-1;26;Stage IC;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21791-1;27;Stage IE;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21792-9;28;Stage 2A1;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21793-7;29;Stage 2A2;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21794-5;30;Stage IIE;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21847-1;31;Stage IIS;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21795-2;32;Stage 3C1;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21796-0;33;Stage 3C2;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3652-0;34;Stage IIIE;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21800-0;35;Stage IIIS;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA21802-6;36;Stage IVE;;; +21902-2;LL234-6;CR_910_Tumor stage group;LA3648-8;37;Stage IVS;;; +21903-0;LL235-3;CR_920_Pathology descriptor;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21903-0;LL235-3;CR_920_Pathology descriptor;LA3930-0;2;E (extranodal lymphoma);;; +21903-0;LL235-3;CR_920_Pathology descriptor;LA4301-3;3;S (spleen, lymphomas);;; +21903-0;LL235-3;CR_920_Pathology descriptor;LA4619-8;4;M (multiple primaries);;; +21903-0;LL235-3;CR_920_Pathology descriptor;LA4431-8;5;Y (multi-modality);;; +21903-0;LL235-3;CR_920_Pathology descriptor;LA3921-9;6;E & S;;; +21903-0;LL235-3;CR_920_Pathology descriptor;LA4576-0;7;M & Y;;; +21903-0;LL235-3;CR_920_Pathology descriptor;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21904-8;LL236-1;CR_930_Pathology stager;LA4693-3;1;Not staged;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4622-2;2;Managing physician;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4651-1;3;Pathologist;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4724-6;4;Other physician;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4219-7;5;Combo 1, 2, or 3;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4379-9;6;Registrar;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4211-4;7;Combo 5 + 1, 2, or 3;;; +21904-8;LL236-1;CR_930_Pathology stager;LA46-8;8;Other;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4482-1;9;Staged, NOS;;; +21904-8;LL236-1;CR_930_Pathology stager;LA4406-0;10;Unknown if Staged;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3601-7;1;TX;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3608-2;2;Tis;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3615-7;3;Ta;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3616-5;4;T4d;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3617-3;5;T4c;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3618-1;6;T4b;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3619-9;7;T4a;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3620-7;8;T4;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3621-5;9;T3c;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3622-3;10;T3b;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3623-1;11;T3a;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3624-9;12;T3;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3625-6;13;T2c;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3626-4;14;T2b;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3627-2;15;T2a;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3628-0;16;T2;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3629-8;17;T1mic;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3630-6;18;T1c;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3631-4;19;T1b2;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3632-2;20;T1b1;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3633-0;21;T1b;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3634-8;22;T1a2;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3635-5;23;T1a1;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3636-3;24;T1a;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3637-1;25;T1;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA3638-9;26;T0;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA4473-0;27;Tid pd;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA4514-1;28;Tis pu;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA4703-0;29;Not applicable (no AJCC staging scheme);;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA21805-9;30;T1d;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA21854-7;31;T1mi;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA21806-7;32;T2a1;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA21807-5;33;T2a2;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA21808-3;34;T2d;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA21810-9;35;T3d;;; +21905-5;LL237-9;CR_940_Clinical tumor staging;LA21811-7;36;T4e;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA15167-2;0;N;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4264-3;1;N1a;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4368-2;2;N0;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4517-4;3;N2b;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4527-3;4;N3c;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4528-1;5;N3b;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4529-9;6;N3a;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4531-5;7;N2c;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4533-1;8;N2a;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4534-9;9;N2;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4535-6;10;N1b;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4537-2;11;N1;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4545-5;12;N3;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4703-0;13;Not applicable (no AJCC staging scheme);;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA4745-1;14;NX;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21814-1;15;N0I-;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21815-8;16;N0I+;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21816-6;17;N0M-;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21817-4;18;N0M+;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21818-2;19;N0a;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21819-0;20;N0b;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21866-1;21;N1c;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21822-4;22;N1mi;;; +21906-3;LL238-7;CR_950_Clinical lymph node staging;LA21874-5;23;N4;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA4544-8;1;MX;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA4625-5;2;M1C;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA4626-3;3;M1B;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA4627-1;4;M1A;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA4628-9;5;M1;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA4629-7;6;M0;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA4703-0;7;Not applicable (no AJCC staging scheme);;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA21875-2;8;M0+;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA21876-0;9;M0I+;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA21877-8;10;M1d;;; +21907-1;LL239-5;CR_960_Clinical metastasis staging;LA21878-6;11;M1e;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3649-6;1;Stage IVB;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3650-4;2;Stage IVA;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3651-2;3;Stage IV;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3654-6;4;Stage IIIC;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3655-3;5;Stage IIIB;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3656-1;6;Stage IIIA;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3657-9;7;Stage III;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3658-7;8;Stage IIC;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3659-5;9;Stage IIB;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3660-3;10;Stage IIA;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3661-1;11;Stage II;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3663-7;12;Stage IA;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3664-5;13;Stage I;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4284-1;14;Stage T1A2;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4314-6;15;Stage IVC;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4316-1;16;Stage IC;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4321-1;17;Stage 0is;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4322-9;18;Stage 0A;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4323-7;19;Stage 0;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4371-6;20;Stage T1B;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4391-4;21;Recurrent, unstaged, unknown, Stage X;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4401-1;22;Stage T1A1;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4484-7;23;Stage T1B2;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4485-4;24;Stage T1B1;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4703-0;25;Not applicable (no AJCC staging scheme);;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4744-4;26;Occult;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21791-1;27;Stage IE;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA4315-3;28;Stage IS;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21844-8;29;Stage IIA1;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21845-5;30;Stage IIA2;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21794-5;31;Stage IIE;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21847-1;32;Stage IIS;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21848-9;33;Stage IIIC1;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21871-1;34;Stage IIIC2;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3652-0;35;Stage IIIE;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21800-0;36;Stage IIIS;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21872-9;37;Stage IVA1;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21850-5;38;Stage IVA2;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA21802-6;39;Stage IVE;;; +21908-9;LL240-3;CR_970_Clinical staging group;LA3648-8;40;Stage IVS;;; +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA3928-4;2;E (Extranodal, lymphomas only);;; +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA3932-6;3;E & S (Extranodal and spleen);;; +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA4302-1;4;S (Spleen, lymphomas only);;; +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA4432-6;5;Y (Classification during or after initial multimodality ther;;; +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA4590-1;7;M (Multiple primary tumors in a single site);;; +21909-7;LL241-1;CR_980_Clincial staging descriptor;LA4617-2;8;M & Y (Multiple primary tumors and initial multimodality the;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4693-3;1;Not staged;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4622-2;2;Managing physician;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4651-1;3;Pathologist;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4724-6;4;Other physician;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4230-4;5;Any combination of 1, 2, or 3;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4379-9;6;Registrar;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4228-8;7;Any combination of 5 with 1, 2, or 3;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA46-8;8;Other;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4483-9;9;Staged, individual not specified;;; +21910-5;LL57-1;CR_1040_Cancer stager;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21915-4;LL57-1;CR_1040_Cancer stager;LA4693-3;1;Not staged;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4622-2;2;Managing physician;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4651-1;3;Pathologist;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4724-6;4;Other physician;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4230-4;5;Any combination of 1, 2, or 3;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4379-9;6;Registrar;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4228-8;7;Any combination of 5 with 1, 2, or 3;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA46-8;8;Other;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4483-9;9;Staged, individual not specified;;; +21915-4;LL57-1;CR_1040_Cancer stager;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21911-3;LL53-0;CR_1000;LA4543-0;1;;;; +21912-1;LL53-0;CR_1000;LA4543-0;1;;;; +21913-9;LL53-0;CR_1000;LA4543-0;1;;;; +21914-7;LL56-3;CR_1030;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21914-7;LL56-3;CR_1030;LA4543-0;2;;;; +21916-2;LL58-9;CR_1050_Descriptor stage;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21916-2;LL58-9;CR_1050_Descriptor stage;LA3928-4;2;E (Extranodal, lymphomas only);;; +21916-2;LL58-9;CR_1050_Descriptor stage;LA4302-1;3;S (Spleen, lymphomas only);;; +21916-2;LL58-9;CR_1050_Descriptor stage;LA4590-1;4;M (Multiple primary tumors in a single site);;; +21916-2;LL58-9;CR_1050_Descriptor stage;LA4432-6;5;Y (Classification during or after initial multimodality ther;;; +21916-2;LL58-9;CR_1050_Descriptor stage;LA3932-6;6;E & S (Extranodal and spleen);;; +21916-2;LL58-9;CR_1050_Descriptor stage;LA4617-2;7;M & Y (Multiple primary tumors and initial multimodality the;;; +21916-2;LL58-9;CR_1050_Descriptor stage;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21917-0;LL59-7;CR_1060_Edition TNM classification;LA4693-3;1;Not staged;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA3966-4;2;First Edition;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA4299-9;3;Second Edition;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA4466-4;4;Third Edition;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA4028-2;5;Fourth Edition;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA3972-2;6;Fifth Edition;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA4334-4;7;Sixth Edition;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA4720-4;8;Not applicable;;; +21917-0;LL59-7;CR_1060_Edition TNM classification;LA4029-0;9;Edition Unknown;;; +21919-6;LL60-5;CR_1080_Pos bx date;LA4691-7;1;Positive biopsy never obtained;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21920-4;LL61-3;CR_1090_Metastasis site;LA4689-1;2;Peritoneum;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4579-4;3;Lung;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4680-0;4;Pleura;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4584-4;5;Liver;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4277-5;6;Bone;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4174-4;7;Central Nervous System;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4332-8;8;Skin;;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4577-8;9;Lymph Nodes (distant);;; +21920-4;LL61-3;CR_1090_Metastasis site;LA4708-9;10;NOS, unknown;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +44667-4;LL61-3;CR_1090_Metastasis site;LA4689-1;2;Peritoneum;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4579-4;3;Lung;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4680-0;4;Pleura;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4584-4;5;Liver;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4277-5;6;Bone;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4174-4;7;Central Nervous System;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4332-8;8;Skin;;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4577-8;9;Lymph Nodes (distant);;; +44667-4;LL61-3;CR_1090_Metastasis site;LA4708-9;10;NOS, unknown;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3594-4;1;Unstaged, unknown;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3647-0;2;Stage V;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3648-8;3;Stage IVS;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3649-6;4;Stage IVB;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3650-4;5;Stage IVA;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3651-2;6;Stage IV;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3652-0;7;Stage IIIE;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3653-8;8;Stage IIID;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3654-6;9;Stage IIIC;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3655-3;10;Stage IIIB;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3656-1;11;Stage IIIA;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3657-9;12;Stage III;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3658-7;13;Stage IIC;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3659-5;14;Stage IIB;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3660-3;15;Stage IIA;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3661-1;16;Stage II;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3662-9;17;Stage IB;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3663-7;18;Stage IA;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3664-5;19;Stage I;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3665-2;20;Stage DS;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3666-0;21;Stage D;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3667-8;22;Stage C;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3668-6;23;Stage B;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3669-4;24;Stage A;;; +21921-2;LL65-4;CR_1120_Pediatric staging;LA3728-8;25;Not Applicable (Not Pediatric Case);;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4245-2;2;AJCC;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4232-0;3;Ann Arbor;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4169-4;4;Children's Cancer Group;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA3996-1;5;Evans;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4030-8;6;General Summary;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA3918-5;7;Intergroup Ewings;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA3919-3;8;Intergroup Hepatoblastoma;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA3923-5;9;Intergroup Rhabdomyosarc;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4205-6;10;International System;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4588-5;11;Murphy;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4523-2;12;NCI (Pediatric Oncology);;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4525-7;13;Natl Wilms Tumor Study;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4647-9;14;Pediatric Oncology Group;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4390-6;15;Reese-Ellsworth;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4292-4;16;SEER Extent of Disease;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4704-8;17;Not Applicable - Non-Ped;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA46-8;18;Other;;; +21922-0;LL66-2;CR_1130_Peds staging coding system;LA4489-6;19;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21923-8;LL67-0;CR_1140_Peds stager;LA4693-3;1;Not staged;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4622-2;2;Managing physician;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4651-1;3;Pathologist;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4724-6;4;Other physician;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4229-6;5;Any Combination of 1-3;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4379-9;6;Registrar;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4227-0;7;Any Combination of 5 with 1-3;;; +21923-8;LL67-0;CR_1140_Peds stager;LA46-8;8;Other;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4483-9;9;Staged, individual not specified;;; +21923-8;LL67-0;CR_1140_Peds stager;LA4406-0;10;Unknown if Staged;;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4716-2;1;None Done (SX);;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4677-6;2;Positive / Elevated;;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4522-4;3;Negative / Normal (SO);;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4259-3;4;Borderline;;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4356-7;5;Range 1 (S1);;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4397-1;6;Range 2 (S2);;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4396-3;7;Range 3 (S3);;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4721-2;8;Ordered, results not in Chart;;; +21924-6;LL68-8;CR_1150_Tumor marker;LA4471-4;9;Unknown / Not Applicable;;; +21925-3;LL72-0;CR_1200_Treatment date-surgery;LA4424-3;1;"Unknown if any cancer-directed surgery performed; date unkno";;; +21925-3;LL72-0;CR_1200_Treatment date-surgery;LA4570-3;2;"No cancer-directed surgery performed; autopsy-only case";;; +21926-1;LL73-8;CR_1210_Radiation date;LA4417-7;1;"Unknown if any radiation therapy administered; date unknown,";;; +21926-1;LL73-8;CR_1210_Radiation date;LA4552-1;2;"No radiation therapy adminstered; autopsy-only case";;; +21927-9;LL74-6;CR_1220_Chemo date;LA4422-7;1;"Unknown if any chemotherapy administered; date unknown, or d";;; +21927-9;LL74-6;CR_1220_Chemo date;LA4568-7;2;"No chemotherapy administered; autopsy-only case";;; +21928-7;LL75-3;CR_1230_Hormone treatment date;LA4421-9;1;"Unknown if any hormone therapy administered; date unknown, o";;; +21928-7;LL75-3;CR_1230_Hormone treatment date;LA4564-6;2;"No hormone therapy adminstered; autopsy-only case";;; +21929-5;LL76-1;CR_1240_BRM treatment date;LA4420-1;1;"Unknown if any immunotherapy administered; date unknown, or";;; +21929-5;LL76-1;CR_1240_BRM treatment date;LA4563-8;2;"No immunotherapy administered; autopsy-only case";;; +21930-3;LL77-9;CR_1250_Other treatment date;LA4418-5;1;"Unknown if any other treatment adminsted; date unknown, or d";;; +21930-3;LL77-9;CR_1250_Other treatment date;LA4557-0;2;"No other treatment adminstered; autopsy-only case";;; +21931-1;LL78-7;CR_1260_1st treatment date;LA4423-5;1;Unknown if any cancer-directed therapy was administered;;; +21931-1;LL78-7;CR_1260_1st treatment date;LA4569-5;2;No cancer-directed therapy;;; +21932-9;LL79-5;CR_1270_CoC treatment date;LA4455-7;1;"Unknown whether treatement given; death certificate only";;; +21933-7;LL80-3;CR_1280_Non CDS treatment date;LA4419-3;1;"Unknown if any noncancer-directed surgery performed; date un";;; +21933-7;LL80-3;CR_1280_Non CDS treatment date;LA4574-5;2;"No noncancer-directed surgery performed; autopsy-only case";;; +21934-5;LL81-1;CR_1290_Surgery site-primary;LA4410-2;1;Unknown if primary site surgery performed;;; +21934-5;LL81-1;CR_1290_Surgery site-primary;LA4556-2;2;No primary site surgery performed;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA3742-9;1;No regional lymph nodes removed;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4274-2;2;Biopsy or aspiration of regional lymph node, NOS;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4291-6;3;Sentinel lymph node biopsy;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4747-7;4;"Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS";;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4111-6;5;1 to 3 regional lymph nodes removed;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4046-4;6;4 or more regional lymph nodes removed;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4289-0;7;Sentinel node biopsy and code 3, 4, or 5 at same time or timing not stated;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4290-8;8;Sentinel node biopsy and code 3, 4, or 5 at different times;;; +21935-2;LL82-9;CR_1292_Lymph node surgery-scope;LA4403-7;9;Unknown or not applicable;;; +21936-0;LL83-7;CR_1294_Other regional site surgery;LA9648-2;1;"None; diagnosed at autopsy";;; +21936-0;LL83-7;CR_1294_Other regional site surgery;LA9649-0;2;Non-primary surgical procedure performed;;; +21936-0;LL83-7;CR_1294_Other regional site surgery;LA9650-8;3;Non-primary surgical procedure to other regional sites;;; +21936-0;LL83-7;CR_1294_Other regional site surgery;LA9651-6;4;Non-primary surgical procedure to distant lymph node(s);;; +21936-0;LL83-7;CR_1294_Other regional site surgery;LA9652-4;5;Non-primary surgical procedure to distant site;;; +21936-0;LL83-7;CR_1294_Other regional site surgery;LA9653-2;6;Any combination of codes 2, 3, or 4;;; +21936-0;LL83-7;CR_1294_Other regional site surgery;LA9654-0;7;"Unknown; death certificate only";;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4549-7;1;No regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4739-4;2;One regional lymph node examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4493-8;3;Two regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4138-9;4;3 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4055-5;5;4 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4041-5;6;5 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4086-0;7;6 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4089-4;8;7 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4077-9;9;8 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4236-1;10;9 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4112-4;11;10 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4113-2;12;11 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4114-0;13;12 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4124-9;14;13 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4116-5;15;14 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4109-0;16;15 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4119-9;17;16 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4120-7;18;17 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4121-5;19;18 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4122-3;20;19 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4154-6;21;20 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4129-8;22;21 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4130-6;23;22 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4140-5;24;23 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4132-2;25;24 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4125-6;26;25 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4134-8;27;26 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4135-5;28;27 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4136-3;29;28 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4137-1;30;29 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4139-7;31;30 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4079-5;32;31 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4045-6;33;32 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4108-2;34;33 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4048-0;35;34 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4049-8;36;35 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4050-6;37;36 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4051-4;38;37 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4061-3;39;38 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4053-0;40;39 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4056-3;41;40 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4057-1;42;41 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4058-9;43;42 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4059-7;44;43 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4031-6;45;44 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4054-8;46;45 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4052-2;47;46 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4044-9;48;47 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4043-1;49;48 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4042-3;50;49 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4040-7;51;50 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4039-9;52;51 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4038-1;53;52 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4037-3;54;53 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4036-5;55;54 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4035-7;56;55 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4034-0;57;56 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4033-2;58;57 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4032-4;59;58 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4063-9;60;59 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4060-5;61;60 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4080-3;62;61 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4081-1;63;62 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4082-9;64;63 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4083-7;65;64 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4093-6;66;65 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4085-2;67;66 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4078-7;68;67 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4087-8;69;68 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4088-6;70;69 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4090-2;71;70 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4091-0;72;71 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4092-8;73;72 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4070-4;74;73 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4068-8;75;74 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4084-5;76;75 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4064-7;77;76 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4065-4;78;77 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4066-2;79;78 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4067-0;80;79 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4069-6;81;80 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4062-1;82;81 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4071-2;83;82 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4072-0;84;83 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4073-8;85;84 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4074-6;86;85 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4075-3;87;86 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4173-6;88;87 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4047-2;89;88 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4142-1;90;89 regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4237-9;95;90 or more regional lymph nodes examined;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4550-5;96;No regional lymph node(s) removed, but aspiration of regiona;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4386-4;97;Regional lymph node removal documented as sampling, and numb;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4387-2;98;Regional lymph node removal documented as a dissection, and;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA4384-9;99;Regional lymph nodes surgically removed, but number of lymph;;; +21937-8;LL84-5;CR_1296_Regional nodes examined;LA3596-9;100;"Unknown; not stated; death certificate ONLY";;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4248-6;1;All margins negative;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4604-0;2;Margins Involved, NOS;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4608-1;3;Microscopic Involvement;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4337-7;4;Single Margin;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4632-1;5;Multiple Margins;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4624-8;7;Macroscopic Involvement;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4618-0;8;Margins Not Evaluated;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4605-7;9;No-Ca dir surgery of primary site;;; +21939-4;LL87-8;CR_1320_Surgical margins involved;LA4515-8;10;Unknown (Death Cert Only);;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4260-1;1;CA Directed Surgery Performed;;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4251-0;2;CA Dir Surg Not Recommended;;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4216-3;5;Contraindicated;;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4474-8;6;Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery;;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4442-5;7;Unknown reason for No Surg;;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4388-0;8;Refused Surgery;;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4475-5;9;Surg recommended - Unknown if Done;;; +21941-0;LL89-4;CR_1340_Reason no surgery;LA4408-6;10;Unknown if Recommended or Performed;;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA4518-2;1;No surgical procedure;;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA3956-5;2;"Incisional biopsy of other than primary site; needle biopsy";;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA3949-0;3;"Incisional biopsy of primary site; needle biopsy of primary";;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA4004-3;4;Exploratory ONLY (no biopsy);;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA4266-8;5;"Bypass surgery (no biopsy); -ostomy ONLY (no biopsy)";;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA3978-9;6;Exploratory ONLY and incisional or needle biopsy of primary;;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA4258-5;7;Bypass surgery and incisional or needle biopsy of primary si;;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA4718-8;8;Noncancer-directed surgery, NOS;;; +21942-8;LL90-2;CR_1350_Non CDS summary;LA4428-4;9;Unknown if noncancer-directed surgery done;;; +21943-6;LL91-0;CR_1360_Radiation summary;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21943-6;LL91-0;CR_1360_Radiation summary;LA4269-2;2;Beam Radiation;;; +21943-6;LL91-0;CR_1360_Radiation summary;LA4342-7;3;Radioactive Implants;;; +21943-6;LL91-0;CR_1360_Radiation summary;LA4385-6;4;Radioisotopes;;; +21943-6;LL91-0;CR_1360_Radiation summary;LA4249-4;5;Beam Rad + 2 or 3;;; +21943-6;LL91-0;CR_1360_Radiation summary;LA4352-6;7;Radiatio, NOS;;; +21943-6;LL91-0;CR_1360_Radiation summary;LA4389-8;8;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +21943-6;LL91-0;CR_1360_Radiation summary;LA4350-0;9;Radiation Recommend;;; +21943-6;LL91-0;CR_1360_Radiation summary;LA4425-0;10;Unknown if Administered;;; +21944-4;LL92-8;CR_1370_Lung-leukemia radiation;LA4425-0;0;Unknown if Administered;;; +21944-4;LL92-8;CR_1370_Lung-leukemia radiation;LA4714-7;1;None to Brain / CNS;;; +21944-4;LL92-8;CR_1370_Lung-leukemia radiation;LA4351-8;7;Radiation;;; +21944-4;LL92-8;CR_1370_Lung-leukemia radiation;LA4389-8;8;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +21944-4;LL92-8;CR_1370_Lung-leukemia radiation;LA4349-2;9;Radiation Recommended;;; +21945-1;LL93-6;CR_1380_Radiation sequence;LA4555-4;2;No Rad &/or CA-dir Surg;;; +21945-1;LL93-6;CR_1380_Radiation sequence;LA4361-7;3;Rad Before Surgery;;; +21945-1;LL93-6;CR_1380_Radiation sequence;LA4363-3;4;Rad After Surgery;;; +21945-1;LL93-6;CR_1380_Radiation sequence;LA4362-5;5;Rad Before & After Surgery;;; +21945-1;LL93-6;CR_1380_Radiation sequence;LA4602-4;6;Interoperative Radiation;;; +21945-1;LL93-6;CR_1380_Radiation sequence;LA4722-0;7;Interop + before or after;;; +21945-1;LL93-6;CR_1380_Radiation sequence;LA4286-6;8;Sequence Unknown;;; +21946-9;LL94-4;CR_1390_Chemo;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21946-9;LL94-4;CR_1390_Chemo;LA4157-9;2;Chemotherapy, NOS;;; +21946-9;LL94-4;CR_1390_Chemo;LA4183-5;3;Chemo - Single Agent;;; +21946-9;LL94-4;CR_1390_Chemo;LA4182-7;4;Chemo - Multiple Agent;;; +21946-9;LL94-4;CR_1390_Chemo;LA4695-8;5;Not Recommended;;; +21946-9;LL94-4;CR_1390_Chemo;LA4645-3;6;Patient Died Before Therapy;;; +21946-9;LL94-4;CR_1390_Chemo;LA4706-3;7;Not Administered, Unknown Reason;;; +21946-9;LL94-4;CR_1390_Chemo;LA4389-8;8;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +21946-9;LL94-4;CR_1390_Chemo;LA4172-8;9;Chem recommended;;; +21946-9;LL94-4;CR_1390_Chemo;LA4454-0;10;Unknown, Death Cert Only;;; +21947-7;LL96-9;CR_1400_Hormone treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21947-7;LL96-9;CR_1400_Hormone treatment;LA4003-5;2;Hormones;;; +21947-7;LL96-9;CR_1400_Hormone treatment;LA4216-3;3;Contraindicated;;; +21947-7;LL96-9;CR_1400_Hormone treatment;LA4645-3;4;Patient Died Before Therapy;;; +21947-7;LL96-9;CR_1400_Hormone treatment;LA4013-4;5;"Hormones Recommended but Not Administered; Unknown Reason";;; +21947-7;LL96-9;CR_1400_Hormone treatment;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +21947-7;LL96-9;CR_1400_Hormone treatment;LA4001-9;7;Hormone Rx Recommended;;; +21947-7;LL96-9;CR_1400_Hormone treatment;LA4454-0;8;Unknown, Death Cert Only;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +21948-5;LL98-5;CR_1410_BRM treatment;LA3936-7;2;Immunotherapy was not administered because the patient died prior to planned or recommended therapy;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA3947-4;3;Immunotherapy was recommended, but it is unknown if it was administered;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA3948-2;4;Immunotherapy was recommended by the physician, but was refused by patient/family member/guardian;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA3952-4;5;Immunotherapy not recommended/administered due to patient risks (comorbid conditions, advanced age);;; +21948-5;LL98-5;CR_1410_BRM treatment;LA3957-3;6;Immunotherapy administered as first-course therapy;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA3964-9;7;"Immunotherapy was recommended by the physician, but was not administered; no reason was stated";;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4212-2;8;Combination of 1 and any 2, 3, 4, or 5;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4272-6;9;Biological response modifier (BRM);;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4278-3;10;Bone marrow transplant, NOS;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4279-1;11;Bone marrow transplant?allogeneic;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4280-9;12;Bone marrow transplant?autologous;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4282-5;13;Biological response modifier recommended, unknown if adminis;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4400-3;14;Unknown if BRM administered;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4414-4;15;"Unknown if immunotherapy recommended/administered (not in pat. record); death certificate-only cases";;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4478-9;16;Stem Cell Transplant;;; +21948-5;LL98-5;CR_1410_BRM treatment;LA4489-6;17;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21948-5;LL98-5;CR_1410_BRM treatment;LA4640-4;18;Patient or patient's guardian refused;;; +21949-3;LL99-3;CR_1420_Other treatment;LA4558-8;1;No other cancer-directed therapy except as coded elsewhere;;; +21949-3;LL99-3;CR_1420_Other treatment;LA4730-3;2;Other cancer-directed therapy;;; +21949-3;LL99-3;CR_1420_Other treatment;LA4726-1;3;Other experimental cancer-directed therapy (not included els;;; +21949-3;LL99-3;CR_1420_Other treatment;LA3962-3;4;Double-blind study, code not yet broken;;; +21949-3;LL99-3;CR_1420_Other treatment;LA4451-6;5;Unproven therapy (including laetrile, krebiozen, etc.);;; +21949-3;LL99-3;CR_1420_Other treatment;LA4639-6;6;Patient or patient's guardian refused therapy which would ha;;; +21949-3;LL99-3;CR_1420_Other treatment;LA4729-5;7;Other cancer-directed therapy recommended, unknown if admini;;; +21949-3;LL99-3;CR_1420_Other treatment;LA4411-0;8;Unknown if other cancer-directed therapy administered;;; +21950-1;LL100-9;CR_1430_Reason no radiation;LA4347-6;1;Radiation Rx Performed;;; +21950-1;LL100-9;CR_1430_Reason no radiation;LA4348-4;2;Radiation Rx not recommended;;; +21950-1;LL100-9;CR_1430_Reason no radiation;LA4217-1;3;Contraindicated, Autopsy Only;;; +21950-1;LL100-9;CR_1430_Reason no radiation;LA4644-6;4;Patient Died Prior to Treatment;;; +21950-1;LL100-9;CR_1430_Reason no radiation;LA4393-0;5;Reason Unknown for Rad Rx;;; +21950-1;LL100-9;CR_1430_Reason no radiation;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +21950-1;LL100-9;CR_1430_Reason no radiation;LA4353-4;7;Rad Rx Recommend but unknown of Admin;;; +21950-1;LL100-9;CR_1430_Reason no radiation;LA4444-1;8;Unknown - Death Cert Only;;; +21951-9;LL101-7;CR_1440_Reason no chemo;LA4184-3;1;Chemo Not Recommended;;; +21951-9;LL101-7;CR_1440_Reason no chemo;LA4179-3;2;Chem Contraindicated;;; +21951-9;LL101-7;CR_1440_Reason no chemo;LA4394-8;3;Reason unknown;;; +21951-9;LL101-7;CR_1440_Reason no chemo;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +21951-9;LL101-7;CR_1440_Reason no chemo;LA4181-9;5;Chem recommended - Unknown if Admin;;; +21951-9;LL101-7;CR_1440_Reason no chemo;LA4409-4;6;Unknown if Recommended;;; +21951-9;LL101-7;CR_1440_Reason no chemo;LA4185-0;9;Chemotherapy Administered;;; +21952-7;LL102-5;CR_1450_Reason no hormones;LA4002-7;1;Hormone Therapy Administered;;; +21952-7;LL102-5;CR_1450_Reason no hormones;LA4000-1;2;Hormone Rx Not Recommended;;; +21952-7;LL102-5;CR_1450_Reason no hormones;LA3999-5;3;Hormone RX Contraindicated;;; +21952-7;LL102-5;CR_1450_Reason no hormones;LA4394-8;4;Reason unknown;;; +21952-7;LL102-5;CR_1450_Reason no hormones;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +21952-7;LL102-5;CR_1450_Reason no hormones;LA4001-9;6;Hormone Rx Recommended;;; +21952-7;LL102-5;CR_1450_Reason no hormones;LA4444-1;7;Unknown - Death Cert Only;;; +21953-5;LL103-3;CR_1460_Coding system;LA4510-9;1;Treatment Data Not Coded;;; +21953-5;LL103-3;CR_1460_Coding system;LA4153-8;2;1-Digit Surgery Codes;;; +21953-5;LL103-3;CR_1460_Coding system;LA4103-3;3;1983-1992 SEER;;; +21953-5;LL103-3;CR_1460_Coding system;LA4156-1;4;1996 ROADS;;; +21953-5;LL103-3;CR_1460_Coding system;LA4141-3;5;1998 ROADS Supplement;;; +21953-5;LL103-3;CR_1460_Coding system;LA4150-4;6;1998 SEER Manual;;; +21953-5;LL103-3;CR_1460_Coding system;LA3989-6;7;FORDS Manual;;; +21953-5;LL103-3;CR_1460_Coding system;LA4728-7;8;Other Coding;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4667-7;1;Protocol Not Available;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4743-6;2;On Protocol;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4642-0;3;Patient Ineligible - age, stage;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4365-8;4;Pt. Ineligible - Comorbidity;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4006-8;5;Entered but Withdrawn;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4024-1;6;Eligible but Not Entered, not specified;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4014-2;7;Eligible but Refused;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4666-9;8;Protocol Not Recommended;;; +21954-3;LL104-1;CR_1470_Protocol eligibility;LA4412-8;9;Unknown if on Protocol;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4697-4;1;Not on /Not Applicable;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4707-1;2;NSABP;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4016-7;3;GOG;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4303-9;4;RTOG;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4458-1;5;SWOG;;; +21955-0;LL105-8;CR_1480_Protocol source;LA3915-1;6;ECOG;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4679-2;7;POG;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4265-0;8;CCG;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4261-9;9;CALGB;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4524-0;10;NCI;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4242-9;11;ACS;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4526-5;12;National Protocol, NOS;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4250-2;13;ACOS-OG;;; +21955-0;LL105-8;CR_1480_Protocol source;LA4489-6;14;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21956-8;LL106-6;CR_1490_Support referral;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +21956-8;LL106-6;CR_1490_Support referral;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +21956-8;LL106-6;CR_1490_Support referral;LA4453-2;3;Unknown, not specified;;; +21957-6;LL108-2;CR_1500_Calculation method;LA4160-3;1;COC definitions;;; +21957-6;LL108-2;CR_1500_Calculation method;LA4293-2;2;SEER definitions;;; +21957-6;LL108-2;CR_1500_Calculation method;LA4659-4;3;Other, Unknown;;; +21958-4;LL109-0;CR_1510_Radiation dose;LA4344-3;1;"Radiation therapy administered; dosage unknown; unknown if r";;; +21958-4;LL109-0;CR_1510_Radiation dose;LA4553-9;2;No radiation therapy administered;;; +21959-2;LL110-8;CR_1520_No. radiation treatments;LA4345-0;1;Radiation therapy administered, but number of treatments is;;; +21959-2;LL110-8;CR_1520_No. radiation treatments;LA4553-9;2;No radiation therapy administered;;; +21960-0;LL111-6;CR_1530_Radiation duration;LA4346-8;1;Radiation therapy administered, but number of treatment days;;; +21960-0;LL111-6;CR_1530_Radiation duration;LA4553-9;2;No radiation therapy administered;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4214-8;1;Consult Only - No Rad;;; +21961-8;LL112-4;CR_1540_Radiation target;LA3976-3;2;Eye/Orbit;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4684-2;3;Pituitary;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4254-4;4;Brain, NOS;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4253-6;5;Brain, Limited;;; +21961-8;LL112-4;CR_1540_Radiation target;LA3994-6;6;Head and Neck, NOS;;; +21961-8;LL112-4;CR_1540_Radiation target;LA3991-2;7;Head and Neck, Limited;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4017-5;8;Glottis;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4336-9;9;Sinuses;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4653-7;10;Parotid;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4180-1;11;Chest / Lung, NOS;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4578-6;12;Lung, Limited;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4018-3;13;Esophagus;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4476-3;14;Stomach;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4584-4;15;Liver;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4654-5;16;Pancreas;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4591-9;17;Kidney;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4238-7;18;Abdomen, NOS;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4255-1;19;Breast;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4256-9;20;Breast / Lymph Nodes;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4178-5;21;Chest Wall;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4170-2;22;Chest Wall / Lymph Nodes;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4620-6;23;Mantle;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4580-2;24;Lower Extended Field;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4340-1;25;Spine;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4331-0;26;Skull;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4307-0;27;Ribs;;; +21961-8;LL112-4;CR_1540_Radiation target;LA3973-0;28;Hip;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4649-5;29;Pelvic Bones;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4690-9;30;Pelvis, NOS;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4332-8;31;Skin;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4329-4;32;Soft Tissue;;; +21961-8;LL112-4;CR_1540_Radiation target;LA3995-3;33;Hemibody;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4441-7;34;Whole Body;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4276-7;35;Bladder and Pelvis;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4669-3;36;Prostate and Pelvis;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4447-4;37;Uterus;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4298-1;38;Shoulder;;; +21961-8;LL112-4;CR_1540_Radiation target;LA3977-1;39;Extremities;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4599-2;40;Inverted Y;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4705-5;41;Other Volume;;; +21961-8;LL112-4;CR_1540_Radiation target;LA4456-5;42;"Unknown Volume; unknown if radiation treatment given";;; +21962-6;LL113-2;CR_1550_Radiation treatment location;LA4551-3;1;No radiation treatment;;; +21962-6;LL113-2;CR_1550_Radiation treatment location;LA4220-5;2;All Rad Rx at this Facility;;; +21962-6;LL113-2;CR_1550_Radiation treatment location;LA4382-3;3;Regional Rx at this Facility;;; +21962-6;LL113-2;CR_1550_Radiation treatment location;LA4281-7;4;Boost Rad at this Facility;;; +21962-6;LL113-2;CR_1550_Radiation treatment location;LA4243-7;5;All Radiation Elsewhere;;; +21962-6;LL113-2;CR_1550_Radiation treatment location;LA4660-2;6;Other, NOS;;; +21962-6;LL113-2;CR_1550_Radiation treatment location;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21963-4;LL114-0;CR_1560_Radiation intent;LA4551-3;1;No radiation treatment;;; +21963-4;LL114-0;CR_1560_Radiation intent;LA4192-6;2;Curative (Primary);;; +21963-4;LL114-0;CR_1560_Radiation intent;LA4191-8;3;Curative (Adjuvant);;; +21963-4;LL114-0;CR_1560_Radiation intent;LA4655-2;4;Palliative (Pain Control);;; +21963-4;LL114-0;CR_1560_Radiation intent;LA4656-0;5;Palliative (Other, Cosmetic);;; +21963-4;LL114-0;CR_1560_Radiation intent;LA4670-1;6;Prophylactic (No Symptoms);;; +21963-4;LL114-0;CR_1560_Radiation intent;LA4660-2;7;Other, NOS;;; +21963-4;LL114-0;CR_1560_Radiation intent;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21964-2;LL115-7;CR_1570_Radiation modality;LA3953-2;1;Electrons;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4162-9;2;Cobalt 60, Cesium 137;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4257-7;3;Brachytherapy, High Dose rate (HDR);;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4273-4;4;Brachytherapy, Standard;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4433-4;5;X-Rays Mixed Energies;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4434-2;6;X-Rays and Electrons (mixed);;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4435-9;7;X-Rays 6-10 MV;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4436-7;8;X-Rays 2-5 MV;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4437-5;9;X-Rays 11-19 MV;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4438-3;10;X-Rays > 19 MV;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4477-1;11;Stereotactic Radiosurgery;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21964-2;LL115-7;CR_1570_Radiation modality;LA4521-6;13;Neutrons (w or w/o X-Rays, electrons);;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4554-7;14;No radiation therapy;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4600-8;15;Intraoperative Rad Rx (IORT);;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4613-1;16;Megavoltage, NOS;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4660-2;17;Other, NOS;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4665-1;18;Protons;;; +21964-2;LL115-7;CR_1570_Radiation modality;LA4750-1;19;Orthovoltage;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4551-3;1;No radiation treatment;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4511-7;2;Treatment Completed;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4369-0;3;Rad Not Complete, Pt Health;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4355-9;4;Rad Not Complete, Pt Expired;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4341-9;5;Rad Not Complete, Pt Choice;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4358-3;6;Rad Not Complete, Family Choice;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4360-9;7;Rad Not Complete, Complications;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4359-1;8;Rad Not Complete, Cytopenia;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4357-5;9;Rad Not Complete, Other Reason;;; +21965-9;LL116-5;CR_1580_Radiation completion;LA4699-0;10;Not Complete, Unknown;;; +21966-7;LL117-3;CR_1590_Radiation outcome;LA4551-3;1;No radiation treatment;;; +21966-7;LL117-3;CR_1590_Radiation outcome;LA4479-7;2;Status Not Evaluable;;; +21966-7;LL117-3;CR_1590_Radiation outcome;LA4507-5;3;Tumor/Symptoms Controlled;;; +21966-7;LL117-3;CR_1590_Radiation outcome;LA4506-7;4;Tumor/Symptoms Returned;;; +21966-7;LL117-3;CR_1590_Radiation outcome;LA4505-9;5;Tumor/Symptoms Never Controlled;;; +21966-7;LL117-3;CR_1590_Radiation outcome;LA4660-2;6;Other, NOS;;; +21966-7;LL117-3;CR_1590_Radiation outcome;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21969-1;LL120-7;CR_1642_Staging procedure;LA3744-5;1;Not done/Not applicable;;; +21969-1;LL120-7;CR_1642_Staging procedure;LA3911-0;2;Biopsy, nos;;; +21969-1;LL120-7;CR_1642_Staging procedure;LA3909-4;3;Fine needle aspiration (cytology);;; +21969-1;LL120-7;CR_1642_Staging procedure;LA3910-2;4;Core biopsy (histology);;; +21969-1;LL120-7;CR_1642_Staging procedure;LA3912-8;5;Sextant biopsy;;; +21969-1;LL120-7;CR_1642_Staging procedure;LA3908-6;6;Excision of major duct;;; +21969-1;LL120-7;CR_1642_Staging procedure;LA4454-0;7;Unknown, Death Cert Only;;; +21970-9;LL125-6;CR_1660;LA4416-9;1;Unknown if any subsequent therapy;;; +21970-9;LL125-6;CR_1660;LA4635-4;2;No subsequent therapy;;; +21974-1;LL452-4;CR_1741_Surgery reconstruction;LA9115-2;1;no reconstruction;;; +21974-1;LL452-4;CR_1741_Surgery reconstruction;LA9116-0;2;immediate reconstruction without implant/prosthesis;;; +21974-1;LL452-4;CR_1741_Surgery reconstruction;LA9117-8;3;immediate reconstruction with implant/prosthesis;;; +21974-1;LL452-4;CR_1741_Surgery reconstruction;LA9118-6;4;delayed reconstruction without implant/prosthesis;;; +21974-1;LL452-4;CR_1741_Surgery reconstruction;LA9119-4;5;delayed reconstruction with implant/prosthesis;;; +21974-1;LL452-4;CR_1741_Surgery reconstruction;LA9120-2;6;reconstruction;;; +21976-6;LL131-4;CR_1770_Cancer status follow up;LA4566-1;1;No Evidence of this Cancer;;; +21976-6;LL131-4;CR_1770_Cancer status follow up;LA3971-4;2;Evidence of this Cancer;;; +21976-6;LL131-4;CR_1770_Cancer status follow up;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21977-4;LL132-2;CR_1780_Survival quality;LA4709-7;1;Normal Activity;;; +21977-4;LL132-2;CR_1780_Survival quality;LA4472-2;2;Symptomatic & Ambulatory;;; +21977-4;LL132-2;CR_1780_Survival quality;LA4110-8;3;> 50% Ambulatory;;; +21977-4;LL132-2;CR_1780_Survival quality;LA4538-0;4;< 50% Ambulatory;;; +21977-4;LL132-2;CR_1780_Survival quality;LA4270-0;5;Bedridden;;; +21977-4;LL132-2;CR_1780_Survival quality;LA4541-4;6;N/A, Dead;;; +21977-4;LL132-2;CR_1780_Survival quality;LA4452-4;7;Unknown, Unspecified;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4378-1;1;Reported Hospitalization;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4395-5;2;Readmission;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4687-5;3;Physician;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4634-7;4;Patient;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4198-3;5;Dept of Motor Vehicles;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4614-9;6;Medicare/Medicaid Files;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4188-4;7;Death Certificate;;; +21978-2;LL133-0;CR_1790_Follow up source;LA46-8;8;Other;;; +21978-2;LL133-0;CR_1790_Follow up source;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +21979-0;LL135-5;CR_1800_Next follow up;LA4187-6;1;Chart Requisition;;; +21979-0;LL135-5;CR_1800_Next follow up;LA4686-7;2;Physician Letter;;; +21979-0;LL135-5;CR_1800_Next follow up;LA4215-5;3;Contact Letter;;; +21979-0;LL135-5;CR_1800_Next follow up;LA4688-3;4;Phone Call;;; +21979-0;LL135-5;CR_1800_Next follow up;LA4725-3;5;Other Hospital Contact;;; +21979-0;LL135-5;CR_1800_Next follow up;LA4660-2;6;Other, NOS;;; +21979-0;LL135-5;CR_1800_Next follow up;LA3997-9;7;Foreign Residents-Not Followed;;; +21979-0;LL135-5;CR_1800_Next follow up;LA4698-2;8;Not Followed;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA9134-3;1;None or none known;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4689-1;2;Peritoneum;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4579-4;3;Lung;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4680-0;4;Pleura;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4584-4;5;Liver;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4277-5;6;Bone;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4174-4;7;Central Nervous System;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4332-8;8;Skin;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4577-8;9;Lymph Nodes (distant);;; +21982-4;LL455-7;CR_1870_Recurrence site;LA4661-0;10;Other, generalized, NOS, carcinomatosis;;; +21982-4;LL455-7;CR_1870_Recurrence site;LA9144-2;11;Carcinomatosis;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4713-9;1;None, Disease Free;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3944-1;2;In Situ;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3939-1;3;In situ recurrence of an invasive tumor;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3942-5;4;In situ recurrence following diagnosis of an in situ lesion;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4583-6;5;Local;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4508-3;6;Trochar Site;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4581-0;7;Local recurrence of an invasive tumor;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4509-1;8;Trocar recurrence of an invasive tumor;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4186-8;9;Combination of 10 & 11;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4582-8;11;Local recurrence following an in situ lesion of the same sit;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4206-4;12;Combination of 16 with 10, 11, and/or 15;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4380-7;13;Regional, NOS;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4381-5;14;Regional Tissue;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4370-8;20;Regional Lymph Nodes;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4207-2;21;Combination of 21 & 22;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4399-7;22;Regional recurrence following an in situ lesion of the same;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4208-0;25;Combination of 26 with 21, 22, and/or 25;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4231-2;26;Any Comb 10,11,20,21, or 22;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4226-2;27;Any combination of recurrence following an in situ lesion of;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4200-7;28;Distant;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4201-5;30;Distant recurrence following an in situ lesion of the same s;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3937-5;31;Distant recurrence of an invasive tumor in the peritoneum only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3954-0;32;Distant recurrence of an invasive tumor in the lung only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3940-9;33;Distant recurrence of an invasive tumor in the pleura only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3955-7;34;Distant recurrence of an invasive tumor in the liver only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4202-3;35;Distant recurrence of an invasive tumor in bone only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3959-9;36;Distant recurrence of an invasive tumor in the CNS only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3941-7;37;Distant recurrence of an invasive tumor in the skin only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4268-4;38;Distant recurrence of an invasive tumor in lymph node only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3945-8;39;Distant systemic recurrence of an invasive tumor only;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3961-5;40;Distant recurrence of an invasive tumor in single distant site and local/trocar/regional recurrence;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA3922-7;41;Distant recurrence of an invasive tumor in multiple sites;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4520-8;42;Never Disease Free;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4392-2;43;Recurred, Site Unknown;;; +21983-2;LL144-7;CR_1880_Cancer recurrence type;LA4407-8;44;Unknown if Recurred;;; +21984-0;LL147-0;CR_1910_Cause of death;LA4480-5;1;State death certificate not available;;; +21984-0;LL147-0;CR_1910_Cause of death;LA4481-3;2;State death certificate available but underlying cause of de;;; +21984-0;LL147-0;CR_1910_Cause of death;LA4648-7;3;Patient alive at last contact;;; +21985-7;LL148-8;CR_1920_ICD revision;LA4662-8;1;Patient Alive at Last Follow-up;;; +21985-7;LL148-8;CR_1920_ICD revision;LA3916-9;2;ICD-10 (not yet used in US);;; +21985-7;LL148-8;CR_1920_ICD revision;LA3917-7;3;ICD-7;;; +21985-7;LL148-8;CR_1920_ICD revision;LA3933-4;4;ICDA-8;;; +21985-7;LL148-8;CR_1920_ICD revision;LA3926-8;5;ICD-9;;; +21986-5;LL149-6;CR_1930_Autopsy;LA4542-2;1;N/A - Patient Alive;;; +21986-5;LL149-6;CR_1930_Autopsy;LA4221-3;2;Autopsy Performed;;; +21986-5;LL149-6;CR_1930_Autopsy;LA4571-1;3;No Autopsy Performed;;; +21986-5;LL149-6;CR_1930_Autopsy;LA4366-6;4;Pt Expired, Unknown if Autopsy Performed;;; +21987-3;LL150-4;CR_1940_Place of death;LA3597-7;1;United States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3752-8;2;New England and New Jersey;;; +21987-3;LL150-4;CR_1940_Place of death;LA3782-5;3;Maine;;; +21987-3;LL150-4;CR_1940_Place of death;LA3751-0;4;New Hampshire;;; +21987-3;LL150-4;CR_1940_Place of death;LA3585-2;5;Vermont;;; +21987-3;LL150-4;CR_1940_Place of death;LA33036-7;7;Massachusetts;;; +21987-3;LL150-4;CR_1940_Place of death;LA3692-6;8;Rhode Island;;; +21987-3;LL150-4;CR_1940_Place of death;LA3859-1;9;Connecticut;;; +21987-3;LL150-4;CR_1940_Place of death;LA3750-2;10;New Jersey;;; +21987-3;LL150-4;CR_1940_Place of death;LA3733-8;11;North Mid-Atlantic States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3748-6;12;New York;;; +21987-3;LL150-4;CR_1940_Place of death;LA3708-0;13;Pennsylvania;;; +21987-3;LL150-4;CR_1940_Place of death;LA3851-8;14;Delaware;;; +21987-3;LL150-4;CR_1940_Place of death;LA3675-1;15;South Mid-Atlantic States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3775-9;16;Maryland;;; +21987-3;LL150-4;CR_1940_Place of death;LA3849-2;17;District of Columbia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3583-7;18;Virginia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3578-7;19;West Virginia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3736-1;20;North Carolina;;; +21987-3;LL150-4;CR_1940_Place of death;LA3677-7;21;South Carolina;;; +21987-3;LL150-4;CR_1940_Place of death;LA3673-6;22;Southeastern States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3612-4;23;Tennessee;;; +21987-3;LL150-4;CR_1940_Place of death;LA3830-2;24;Georgia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3834-4;25;Florida;;; +21987-3;LL150-4;CR_1940_Place of death;LA3904-5;26;Alabama;;; +21987-3;LL150-4;CR_1940_Place of death;LA3765-0;27;Mississippi;;; +21987-3;LL150-4;CR_1940_Place of death;LA3735-3;28;North Central States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3771-8;29;Michigan;;; +21987-3;LL150-4;CR_1940_Place of death;LA3726-2;30;Ohio;;; +21987-3;LL150-4;CR_1940_Place of death;LA3812-0;31;Indiana;;; +21987-3;LL150-4;CR_1940_Place of death;LA3798-1;32;Kentucky;;; +21987-3;LL150-4;CR_1940_Place of death;LA3731-2;33;Northern Midwest States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3577-9;34;Wisconsin;;; +21987-3;LL150-4;CR_1940_Place of death;LA3766-8;35;Minnesota;;; +21987-3;LL150-4;CR_1940_Place of death;LA3809-6;36;Iowa;;; +21987-3;LL150-4;CR_1940_Place of death;LA3734-6;37;North Dakota;;; +21987-3;LL150-4;CR_1940_Place of death;LA3676-9;38;South Dakota;;; +21987-3;LL150-4;CR_1940_Place of death;LA3762-7;39;Montana;;; +21987-3;LL150-4;CR_1940_Place of death;LA3868-2;40;Central Midwest States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3814-6;41;Illinois;;; +21987-3;LL150-4;CR_1940_Place of death;LA3764-3;42;Missouri;;; +21987-3;LL150-4;CR_1940_Place of death;LA3799-9;43;Kansas;;; +21987-3;LL150-4;CR_1940_Place of death;LA3756-9;44;Nebraska;;; +21987-3;LL150-4;CR_1940_Place of death;LA3672-8;45;Southern Midwest States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3894-8;46;Arkansas;;; +21987-3;LL150-4;CR_1940_Place of death;LA3786-6;47;Louisiana;;; +21987-3;LL150-4;CR_1940_Place of death;LA3725-4;48;Oklahoma;;; +21987-3;LL150-4;CR_1940_Place of death;LA3611-6;49;Texas;;; +21987-3;LL150-4;CR_1940_Place of death;LA3760-1;50;Mountain States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3815-3;51;Idaho;;; +21987-3;LL150-4;CR_1940_Place of death;LA3576-1;52;Wyoming;;; +21987-3;LL150-4;CR_1940_Place of death;LA3862-5;53;Colorado;;; +21987-3;LL150-4;CR_1940_Place of death;LA3587-8;54;Utah;;; +21987-3;LL150-4;CR_1940_Place of death;LA3753-6;55;Nevada;;; +21987-3;LL150-4;CR_1940_Place of death;LA3749-4;56;New Mexico;;; +21987-3;LL150-4;CR_1940_Place of death;LA3895-5;57;Arizona;;; +21987-3;LL150-4;CR_1940_Place of death;LA3714-8;58;Pacific Coast States;;; +21987-3;LL150-4;CR_1940_Place of death;LA3903-7;59;Alaska;;; +21987-3;LL150-4;CR_1940_Place of death;LA3580-3;60;Washington;;; +21987-3;LL150-4;CR_1940_Place of death;LA3722-1;61;Oregon;;; +21987-3;LL150-4;CR_1940_Place of death;LA3875-7;62;California;;; +21987-3;LL150-4;CR_1940_Place of death;LA3820-3;63;Hawaii;;; +21987-3;LL150-4;CR_1940_Place of death;LA3891-4;64;Atlantic/Caribbean Area;;; +21987-3;LL150-4;CR_1940_Place of death;LA3700-7;65;Puerto Rico;;; +21987-3;LL150-4;CR_1940_Place of death;LA3588-6;66;US Virgin Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3720-5;67;Other Atlantic/Caribbean Area;;; +21987-3;LL150-4;CR_1940_Place of death;LA3872-4;68;Canal Zone;;; +21987-3;LL150-4;CR_1940_Place of death;LA3715-5;69;Pacific Area;;; +21987-3;LL150-4;CR_1940_Place of death;LA3900-3;70;American Samoa;;; +21987-3;LL150-4;CR_1940_Place of death;LA3796-5;71;Kiribati (Canton, Enderbury, Gilbert, S Lines, Phoenix);;; +21987-3;LL150-4;CR_1940_Place of death;LA3770-0;72;Micronesia (Fed States of) (Caroline, Trust Terr of Pacific);;; +21987-3;LL150-4;CR_1940_Place of death;LA3858-3;73;Cook Islands (New Zealand);;; +21987-3;LL150-4;CR_1940_Place of death;LA3602-5;74;Tuvalu (Ellice Islands);;; +21987-3;LL150-4;CR_1940_Place of death;LA3824-5;75;Guam;;; +21987-3;LL150-4;CR_1940_Place of death;LA3801-3;76;Johnston Atoll;;; +21987-3;LL150-4;CR_1940_Place of death;LA3778-3;77;Mariana Islands (Trust Territory of Pacific Islands);;; +21987-3;LL150-4;CR_1940_Place of death;LA3776-7;78;Marshall Islands (Trust Territory Pacific Islands);;; +21987-3;LL150-4;CR_1940_Place of death;LA3767-6;79;Midway Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3758-5;80;Nampo-Shoto, Southern;;; +21987-3;LL150-4;CR_1940_Place of death;LA3687-6;81;Ryukyu Islands (Japan);;; +21987-3;LL150-4;CR_1940_Place of death;LA3642-1;82;Swan Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3605-8;83;Tokelau Islands (New Zealand);;; +21987-3;LL150-4;CR_1940_Place of death;LA3582-9;84;Wake Island;;; +21987-3;LL150-4;CR_1940_Place of death;LA3711-4;85;Palau (Trust Territory of Pacific Islands);;; +21987-3;LL150-4;CR_1940_Place of death;LA3825-2;86;Greenland;;; +21987-3;LL150-4;CR_1940_Place of death;LA3873-2;87;Canada;;; +21987-3;LL150-4;CR_1940_Place of death;LA3777-5;88;Maritime Provinces (New Brunsw, Newfound, Nova Scotia, PE);;; +21987-3;LL150-4;CR_1940_Place of death;LA3699-1;89;Quebec;;; +21987-3;LL150-4;CR_1940_Place of death;LA3724-7;90;Ontario;;; +21987-3;LL150-4;CR_1940_Place of death;LA3702-3;91;Prairie Provinces (Alberta Manitoba, Saskatchewan);;; +21987-3;LL150-4;CR_1940_Place of death;LA3730-4;92;Northwest Territories, Yukon Territory;;; +21987-3;LL150-4;CR_1940_Place of death;LA3880-7;93;British Columbia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3772-6;94;Mexico;;; +21987-3;LL150-4;CR_1940_Place of death;LA3737-9;95;North American Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3854-2;96;Cuba;;; +21987-3;LL150-4;CR_1940_Place of death;LA3821-1;97;Haiti;;; +21987-3;LL150-4;CR_1940_Place of death;LA3847-6;98;Dominican Republic;;; +21987-3;LL150-4;CR_1940_Place of death;LA3803-9;99;Jamaica;;; +21987-3;LL150-4;CR_1940_Place of death;LA3719-7;100;Other Caribbean Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3883-1;101;Bermuda;;; +21987-3;LL150-4;CR_1940_Place of death;LA3888-0;102;Bahamas;;; +21987-3;LL150-4;CR_1940_Place of death;LA3670-2;103;St Pierre and Miquelon;;; +21987-3;LL150-4;CR_1940_Place of death;LA3870-8;104;Central America;;; +21987-3;LL150-4;CR_1940_Place of death;LA3823-7;105;Guatemala;;; +21987-3;LL150-4;CR_1940_Place of death;LA3884-9;106;Belize (British Honduras);;; +21987-3;LL150-4;CR_1940_Place of death;LA3819-5;107;Honduras;;; +21987-3;LL150-4;CR_1940_Place of death;LA3842-7;108;El Salvador;;; +21987-3;LL150-4;CR_1940_Place of death;LA3746-0;109;Nicaragua;;; +21987-3;LL150-4;CR_1940_Place of death;LA3857-5;110;Costa Rica;;; +21987-3;LL150-4;CR_1940_Place of death;LA3710-6;111;Panama;;; +21987-3;LL150-4;CR_1940_Place of death;LA3738-7;112;North America, NOS;;; +21987-3;LL150-4;CR_1940_Place of death;LA3793-2;113;Latin America, NOS;;; +21987-3;LL150-4;CR_1940_Place of death;LA3679-3;114;South America;;; +21987-3;LL150-4;CR_1940_Place of death;LA3863-3;115;Colombia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3586-0;116;Venezuela;;; +21987-3;LL150-4;CR_1940_Place of death;LA3822-9;117;Guyana (British Guiana);;; +21987-3;LL150-4;CR_1940_Place of death;LA3643-9;118;Suriname (Dutch Guiana);;; +21987-3;LL150-4;CR_1940_Place of death;LA3832-8;119;French Guiana;;; +21987-3;LL150-4;CR_1940_Place of death;LA3881-5;120;Brazil;;; +21987-3;LL150-4;CR_1940_Place of death;LA3844-3;121;Ecuador;;; +21987-3;LL150-4;CR_1940_Place of death;LA3707-2;122;Peru;;; +21987-3;LL150-4;CR_1940_Place of death;LA3882-3;123;Bolivia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3866-6;124;Chile;;; +21987-3;LL150-4;CR_1940_Place of death;LA3896-3;125;Argentina;;; +21987-3;LL150-4;CR_1940_Place of death;LA3709-8;126;Paraguay;;; +21987-3;LL150-4;CR_1940_Place of death;LA3589-4;127;Uruguay;;; +21987-3;LL150-4;CR_1940_Place of death;LA3678-5;128;South American Island;;; +21987-3;LL150-4;CR_1940_Place of death;LA3836-9;129;Falkland Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3598-5;130;United Kingdom;;; +21987-3;LL150-4;CR_1940_Place of death;LA3840-1;131;England, Channel Islands, Isle of Man;;; +21987-3;LL150-4;CR_1940_Place of death;LA3581-1;132;Wales;;; +21987-3;LL150-4;CR_1940_Place of death;LA3685-0;133;Scotland;;; +21987-3;LL150-4;CR_1940_Place of death;LA3732-0;134;Northern Ireland (Ulster);;; +21987-3;LL150-4;CR_1940_Place of death;LA3806-2;135;Ireland (Eire) (Ireland NOS, Republic of Ireland);;; +21987-3;LL150-4;CR_1940_Place of death;LA3686-8;136;Scandinavia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3816-1;137;Iceland;;; +21987-3;LL150-4;CR_1940_Place of death;LA3729-6;138;Norway (Svalbard, Jan Mayen);;; +21987-3;LL150-4;CR_1940_Place of death;LA3850-0;139;Denmark, Faroe Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3641-3;140;Sweden;;; +21987-3;LL150-4;CR_1940_Place of death;LA3835-1;141;Finland;;; +21987-3;LL150-4;CR_1940_Place of death;LA3829-4;142;Germanic Countries;;; +21987-3;LL150-4;CR_1940_Place of death;LA3828-6;143;Germany (East and West);;; +21987-3;LL150-4;CR_1940_Place of death;LA3754-4;144;Netherlands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3885-6;145;Belgium;;; +21987-3;LL150-4;CR_1940_Place of death;LA3785-8;146;Luxembourg;;; +21987-3;LL150-4;CR_1940_Place of death;LA3640-5;147;Switzerland;;; +21987-3;LL150-4;CR_1940_Place of death;LA3889-8;148;Austria;;; +21987-3;LL150-4;CR_1940_Place of death;LA3789-0;149;Liechtenstein;;; +21987-3;LL150-4;CR_1940_Place of death;LA3691-8;150;Romance-Language Countries;;; +21987-3;LL150-4;CR_1940_Place of death;LA3833-6;151;France, Corsica, Monaco;;; +21987-3;LL150-4;CR_1940_Place of death;LA3671-0;152;Spain (Canary Islands, Balearic Islands), Andorra;;; +21987-3;LL150-4;CR_1940_Place of death;LA3703-1;153;Portugal (Madeira Islands, Azores, Cape Verde Islands);;; +21987-3;LL150-4;CR_1940_Place of death;LA3804-7;154;Italy (Sardinia, Sicily), San Marino, Vatican City;;; +21987-3;LL150-4;CR_1940_Place of death;LA3690-0;155;Romania;;; +21987-3;LL150-4;CR_1940_Place of death;LA3682-7;156;Slavic Countries;;; +21987-3;LL150-4;CR_1940_Place of death;LA3705-6;157;Poland;;; +21987-3;LL150-4;CR_1940_Place of death;LA3852-6;158;Czechoslovakia (former);;; +21987-3;LL150-4;CR_1940_Place of death;LA3575-3;159;Yugoslavia (former);;; +21987-3;LL150-4;CR_1940_Place of death;LA3879-9;160;Bulgaria;;; +21987-3;LL150-4;CR_1940_Place of death;LA3689-2;161;Russian SFSR (Russia);;; +21987-3;LL150-4;CR_1940_Place of death;LA3599-3;162;Ukraine and Moldavia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3876-5;163;Byelorus (Byelorussian SSR, White Russia);;; +21987-3;LL150-4;CR_1940_Place of death;LA3839-3;164;Estonian SSR (Estonia);;; +21987-3;LL150-4;CR_1940_Place of death;LA3792-4;165;Latvian SSR (Estonia);;; +21987-3;LL150-4;CR_1940_Place of death;LA3788-2;166;Lithuania (Lithuanian SSR);;; +21987-3;LL150-4;CR_1940_Place of death;LA3887-2;167;Baltic Republic(s), NOS (Baltic States, NOS);;; +21987-3;LL150-4;CR_1940_Place of death;LA3718-9;168;Other Mainland Europe;;; +21987-3;LL150-4;CR_1940_Place of death;LA3826-0;169;Greece;;; +21987-3;LL150-4;CR_1940_Place of death;LA3817-9;170;Hungary;;; +21987-3;LL150-4;CR_1940_Place of death;LA3902-9;171;Albania;;; +21987-3;LL150-4;CR_1940_Place of death;LA3827-8;172;Gibraltar;;; +21987-3;LL150-4;CR_1940_Place of death;LA3717-1;173;Other Mediterranean Isles;;; +21987-3;LL150-4;CR_1940_Place of death;LA3779-1;174;Malta;;; +21987-3;LL150-4;CR_1940_Place of death;LA3853-4;175;Cyprus;;; +21987-3;LL150-4;CR_1940_Place of death;LA3837-7;176;Europe, NOS (Central, Eastern, Northern, Southern, Western);;; +21987-3;LL150-4;CR_1940_Place of death;LA3906-0;177;Africa, NOS (Central, Equatorial);;; +21987-3;LL150-4;CR_1940_Place of death;LA3739-5;178;North Africa;;; +21987-3;LL150-4;CR_1940_Place of death;LA3761-9;179;Morocco;;; +21987-3;LL150-4;CR_1940_Place of death;LA3901-1;180;Algeria;;; +21987-3;LL150-4;CR_1940_Place of death;LA3604-1;181;Tunisia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3790-8;182;Libya (Tripoli, Tripolitania, Cyrenaica);;; +21987-3;LL150-4;CR_1940_Place of death;LA3843-5;183;Egypt (United Arab Republic);;; +21987-3;LL150-4;CR_1940_Place of death;LA3646-2;184;Sudanese Countries;;; +21987-3;LL150-4;CR_1940_Place of death;LA3579-5;185;West Africa, NOS (French Africa, NOS);;; +21987-3;LL150-4;CR_1940_Place of death;LA3745-2;186;Nigeria;;; +21987-3;LL150-4;CR_1940_Place of death;LA3716-3;187;Other West African Countries;;; +21987-3;LL150-4;CR_1940_Place of death;LA3680-1;188;South Africa, NOS;;; +21987-3;LL150-4;CR_1940_Place of death;LA3574-6;189;Zaire (Congo-Leopoldville, Belgian Congo, Congo/Kinshasa);;; +21987-3;LL150-4;CR_1940_Place of death;LA3899-7;190;Angola (Sao Tome, Principe, Cabinda);;; +21987-3;LL150-4;CR_1940_Place of death;LA3693-4;191;Republic of South Africa;;; +21987-3;LL150-4;CR_1940_Place of death;LA3572-0;192;Zimbabwe (Rhodesia, Southern Rhodesia);;; +21987-3;LL150-4;CR_1940_Place of death;LA3573-8;193;Zambia (Northern Rhodesia);;; +21987-3;LL150-4;CR_1940_Place of death;LA3780-9;194;Malawi (Nyasaland);;; +21987-3;LL150-4;CR_1940_Place of death;LA3759-3;195;Mozambique;;; +21987-3;LL150-4;CR_1940_Place of death;LA3783-3;196;Madagascar (Malagasy Republic);;; +21987-3;LL150-4;CR_1940_Place of death;LA3846-8;197;East Africa;;; +21987-3;LL150-4;CR_1940_Place of death;LA3613-2;198;Tanzania (Tanganyika, Zanzibar);;; +21987-3;LL150-4;CR_1940_Place of death;LA3600-9;199;Uganda;;; +21987-3;LL150-4;CR_1940_Place of death;LA3797-3;200;Kenya;;; +21987-3;LL150-4;CR_1940_Place of death;LA3688-4;201;Rwanda (Ruanda);;; +21987-3;LL150-4;CR_1940_Place of death;LA3877-3;202;Burundi (Urundi);;; +21987-3;LL150-4;CR_1940_Place of death;LA3905-2;203;African Coastal Islands (previously in South Africa, NOS);;; +21987-3;LL150-4;CR_1940_Place of death;LA3681-9;204;Somalia (Somali Republic, Somaliland);;; +21987-3;LL150-4;CR_1940_Place of death;LA3848-4;205;Djibouti;;; +21987-3;LL150-4;CR_1940_Place of death;LA3838-5;206;Ethiopia (Abyssinia), Eritrea;;; +21987-3;LL150-4;CR_1940_Place of death;LA3893-0;207;Asia, NOS;;; +21987-3;LL150-4;CR_1940_Place of death;LA3757-7;208;Near East;;; +21987-3;LL150-4;CR_1940_Place of death;LA3603-3;209;Turkey;;; +21987-3;LL150-4;CR_1940_Place of death;LA3892-2;210;Asian and Arab Countries;;; +21987-3;LL150-4;CR_1940_Place of death;LA3639-7;211;Syria;;; +21987-3;LL150-4;CR_1940_Place of death;LA3791-6;212;Lebanon;;; +21987-3;LL150-4;CR_1940_Place of death;LA3800-5;213;Jordan (Transjordan) and former Arab Palestine;;; +21987-3;LL150-4;CR_1940_Place of death;LA3807-0;214;Iraq;;; +21987-3;LL150-4;CR_1940_Place of death;LA3897-1;215;Arabian Peninsula;;; +21987-3;LL150-4;CR_1940_Place of death;LA3805-4;216;Israel and former Jewish Palestine;;; +21987-3;LL150-4;CR_1940_Place of death;LA3871-6;217;Caucasian Republics of the USSR;;; +21987-3;LL150-4;CR_1940_Place of death;LA3721-3;218;Other Asian Republics of the USSR;;; +21987-3;LL150-4;CR_1940_Place of death;LA3808-8;219;Iran (Persia);;; +21987-3;LL150-4;CR_1940_Place of death;LA3907-8;220;Afghanistan;;; +21987-3;LL150-4;CR_1940_Place of death;LA3712-2;221;Pakistan (West Pakistan);;; +21987-3;LL150-4;CR_1940_Place of death;LA3768-4;222;Mid-East Asia, NOS;;; +21987-3;LL150-4;CR_1940_Place of death;LA3813-8;223;India;;; +21987-3;LL150-4;CR_1940_Place of death;LA3755-1;224;Nepal, Bhutan, Sikkim;;; +21987-3;LL150-4;CR_1940_Place of death;LA3886-4;225;Bangladesh (East Pakistan);;; +21987-3;LL150-4;CR_1940_Place of death;LA3867-4;226;Ceylon (Sri Lanka);;; +21987-3;LL150-4;CR_1940_Place of death;LA3878-1;227;Burma;;; +21987-3;LL150-4;CR_1940_Place of death;LA3674-4;228;Southeast Asia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3610-8;229;Thailand (Siam);;; +21987-3;LL150-4;CR_1940_Place of death;LA3811-2;230;Indochina;;; +21987-3;LL150-4;CR_1940_Place of death;LA3794-0;231;Laos;;; +21987-3;LL150-4;CR_1940_Place of death;LA3874-0;232;Cambodia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3584-5;233;Vietnam (Tonkin, Annam, Cochin China);;; +21987-3;LL150-4;CR_1940_Place of death;LA3781-7;234;Malaysia, Singapore, Brunei;;; +21987-3;LL150-4;CR_1940_Place of death;LA3810-4;235;Indonesia (Dutch East Indies);;; +21987-3;LL150-4;CR_1940_Place of death;LA3706-4;236;Philippines (Philippine Islands);;; +21987-3;LL150-4;CR_1940_Place of death;LA3845-0;237;East Asia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3864-1;238;China, NOS;;; +21987-3;LL150-4;CR_1940_Place of death;LA3865-8;239;China (Peoples Republic of China);;; +21987-3;LL150-4;CR_1940_Place of death;LA3818-7;240;Hong Kong;;; +21987-3;LL150-4;CR_1940_Place of death;LA3614-0;241;Taiwan (Formosa) (Republic of China);;; +21987-3;LL150-4;CR_1940_Place of death;LA3609-0;242;Tibet;;; +21987-3;LL150-4;CR_1940_Place of death;LA3784-1;243;Macao (Macau);;; +21987-3;LL150-4;CR_1940_Place of death;LA3763-5;244;Mongolia;;; +21987-3;LL150-4;CR_1940_Place of death;LA3802-1;245;Japan;;; +21987-3;LL150-4;CR_1940_Place of death;LA3795-7;246;Korea (North and South);;; +21987-3;LL150-4;CR_1940_Place of death;LA3890-6;247;Australia and Australian New Guinea;;; +21987-3;LL150-4;CR_1940_Place of death;LA3747-8;248;New Zealand;;; +21987-3;LL150-4;CR_1940_Place of death;LA3713-0;249;Pacific Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3773-4;250;Melanesian Islands, Solomon Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3769-2;251;Micronesian Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3704-9;252;Polynesian Islands;;; +21987-3;LL150-4;CR_1940_Place of death;LA3898-9;253;Antarctica;;; +21987-3;LL150-4;CR_1940_Place of death;LA4539-8;254;N/A, patient alive;;; +21987-3;LL150-4;CR_1940_Place of death;LA3727-0;255;Not US, but no other information;;; +21987-3;LL150-4;CR_1940_Place of death;LA4681-8;256;Place of death unknown;;; +21990-7;LL151-2;CR_1980_ICD conversion;LA4547-1;1;PS & M orig in ICD-0-2;;; +21990-7;LL151-2;CR_1980_ICD conversion;LA4488-8;2;PS & M Converted w/o Review;;; +21990-7;LL151-2;CR_1980_ICD conversion;LA4664-4;3;PS w/Review, M mach converted w/o Review;;; +21990-7;LL151-2;CR_1980_ICD conversion;LA4367-4;4;PS w/o Review, M w/Review;;; +21990-7;LL151-2;CR_1980_ICD conversion;LA4313-8;5;PS & M Converted w/Review;;; +21990-7;LL151-2;CR_1980_ICD conversion;LA4630-5;6;M converted from ICD-O-3 w/o review;;; +21990-7;LL151-2;CR_1980_ICD conversion;LA4631-3;7;M converted from ICD-O-3 w/ review;;; +21991-5;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21991-5;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21992-3;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21992-3;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21993-1;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21993-1;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21994-9;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21994-9;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21995-6;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21995-6;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21997-2;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21997-2;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21998-0;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21998-0;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21999-8;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +21999-8;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +22000-4;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +22000-4;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +22001-2;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +22001-2;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +22002-0;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +22002-0;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +22003-8;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +22003-8;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42067-9;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42067-9;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42068-7;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42068-7;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42069-5;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42069-5;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42070-3;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42070-3;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42071-1;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42071-1;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42072-9;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42072-9;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42073-7;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42073-7;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42074-5;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42074-5;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +42075-2;LL152-0;CR_1981_Cancer case reviewed;LA4354-2;1;Reviewed;;; +42075-2;LL152-0;CR_1981_Cancer case reviewed;LA4694-1;2;Not reviewed;;; +21996-4;LL167-8;CR_2040_Histology reviewed;LA4308-8;1;Reviewed: Cases 1 and 2 both apply;;; +21996-4;LL167-8;CR_2040_Histology reviewed;LA4309-6;2;"Reviewed: Behavior code indicates ""benign"" or ""uncertain"" but the pathologist states the primary to be ""in situ"" or ""malignant""";;; +21996-4;LL167-8;CR_2040_Histology reviewed;LA4310-4;3;"Reviewed: Behavior code indicates ""in situ"" but the case is not microscopically confirmed";;; +21996-4;LL167-8;CR_2040_Histology reviewed;LA4694-1;4;Not reviewed;;; +22011-1;LL177-7;CR_2120_SEER coding system;LA4548-9;1;No SEER Coding;;; +22011-1;LL177-7;CR_2120_SEER coding system;LA4102-5;2;1987 SEER Coding Manual;;; +22011-1;LL177-7;CR_2120_SEER coding system;LA4616-4;3;May 1988 SEER Coding;;; +22011-1;LL177-7;CR_2120_SEER coding system;LA4598-4;4;Jan 1989 SEER Coding;;; +22011-1;LL177-7;CR_2120_SEER coding system;LA4597-6;5;Jan 1992 SEER Coding;;; +22011-1;LL177-7;CR_2120_SEER coding system;LA4596-8;6;Jan 1998 SEER Coding;;; +22012-9;LL177-7;CR_2120_SEER coding system;LA4548-9;1;No SEER Coding;;; +22012-9;LL177-7;CR_2120_SEER coding system;LA4102-5;2;1987 SEER Coding Manual;;; +22012-9;LL177-7;CR_2120_SEER coding system;LA4616-4;3;May 1988 SEER Coding;;; +22012-9;LL177-7;CR_2120_SEER coding system;LA4598-4;4;Jan 1989 SEER Coding;;; +22012-9;LL177-7;CR_2120_SEER coding system;LA4597-6;5;Jan 1992 SEER Coding;;; +22012-9;LL177-7;CR_2120_SEER coding system;LA4596-8;6;Jan 1998 SEER Coding;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4567-9;1;No COC Coding System;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4672-7;2;Pre-1988 COC Manual Supp;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4101-7;3;1988 Data Acquisition Man;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4099-3;4;1989 DAM Revisions;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4126-4;5;1990 DAM Revisions;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4144-7;6;1994 DAM Revisions;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4305-4;7;ROADS;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4304-7;8;ROADS + 1998 Supplement;;; +22013-7;LL179-3;CR_2140_CoC coding system;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +22014-5;LL179-3;CR_2140_CoC coding system;LA4567-9;1;No COC Coding System;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4672-7;2;Pre-1988 COC Manual Supp;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4101-7;3;1988 Data Acquisition Man;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4099-3;4;1989 DAM Revisions;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4126-4;5;1990 DAM Revisions;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4144-7;6;1994 DAM Revisions;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4305-4;7;ROADS;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4304-7;8;ROADS + 1998 Supplement;;; +22014-5;LL179-3;CR_2140_CoC coding system;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +22015-2;LL181-9;CR_2180_Follow up expectation;LA4252-8;1;Autopsy/Death Cert Only;;; +22015-2;LL181-9;CR_2180_Follow up expectation;LA4235-3;2;Active Follow-up Case;;; +22015-2;LL181-9;CR_2180_Follow up expectation;LA3943-3;3;In Situ Cancer Cervix Uteri Only;;; +22015-2;LL181-9;CR_2180_Follow up expectation;LA4696-6;4;Not orig Follow-up - but Now;;; +22016-0;LL182-7;CR_2190_SEER record;LA4741-0;1;One or first of more than one record for person;;; +22016-0;LL182-7;CR_2190_SEER record;LA4295-7;2;Second record for person;;; +22018-6;LL186-8;CR_2310_military record;LA4164-5;1;Civilian emergency;;; +22018-6;LL186-8;CR_2310_military record;LA4324-5;2;Sponsor;;; +22018-6;LL186-8;CR_2310_military record;LA4540-6;3;N/A, medical record not from a military hospital;;; +22018-6;LL186-8;CR_2310_military record;LA4701-4;4;Not classified elsewhere/stillborn;;; +22021-0;LL189-2;CR_2410_Referring institution;LA4637-0;1;Patient referred but referring institution's ID number unk;;; +22021-0;LL189-2;CR_2410_Referring institution;LA4641-2;2;Patient not referred from another institution;;; +22022-8;LL189-2;CR_2410_Referring institution;LA4637-0;1;Patient referred but referring institution's ID number unk;;; +22022-8;LL189-2;CR_2410_Referring institution;LA4641-2;2;Patient not referred from another institution;;; +22023-6;LL189-2;CR_2410_Referring institution;LA4637-0;1;Patient referred but referring institution's ID number unk;;; +22023-6;LL189-2;CR_2410_Referring institution;LA4641-2;2;Patient not referred from another institution;;; +22024-4;LL192-6;CR_2440_Following registry hospital;LA3981-3;1;Following registry's ID number unknown;;; +22025-1;LL193-4;CR_2460_Physician ID;LA4621-4;1;Managing physician unknown or ID number not assigned;;; +22026-9;LL193-4;CR_2460_Physician ID;LA4621-4;1;Managing physician unknown or ID number not assigned;;; +22027-7;LL193-4;CR_2460_Physician ID;LA4621-4;1;Managing physician unknown or ID number not assigned;;; +22028-5;LL193-4;CR_2460_Physician ID;LA4621-4;1;Managing physician unknown or ID number not assigned;;; +22775-1;LL2283-1;AHSV serotyp;LA6112-2;1;1;;; +22775-1;LL2283-1;AHSV serotyp;LA6113-0;2;2;;; +22775-1;LL2283-1;AHSV serotyp;LA6114-8;3;3;;; +22775-1;LL2283-1;AHSV serotyp;LA6115-5;5;4;;; +22775-1;LL2283-1;AHSV serotyp;LA10138-8;6;6;;; +22775-1;LL2283-1;AHSV serotyp;LA10139-6;7;7;;; +22775-1;LL2283-1;AHSV serotyp;LA10140-4;8;8;;; +22775-1;LL2283-1;AHSV serotyp;LA10141-2;9;9;;; +22776-9;LL2283-1;AHSV serotyp;LA6112-2;1;1;;; +22776-9;LL2283-1;AHSV serotyp;LA6113-0;2;2;;; +22776-9;LL2283-1;AHSV serotyp;LA6114-8;3;3;;; +22776-9;LL2283-1;AHSV serotyp;LA6115-5;5;4;;; +22776-9;LL2283-1;AHSV serotyp;LA10138-8;6;6;;; +22776-9;LL2283-1;AHSV serotyp;LA10139-6;7;7;;; +22776-9;LL2283-1;AHSV serotyp;LA10140-4;8;8;;; +22776-9;LL2283-1;AHSV serotyp;LA10141-2;9;9;;; +22827-0;LL898-8;FLUA typing;LA13023-9;1;Influenza A (H1);;; +22827-0;LL898-8;FLUA typing;LA13024-7;2;Influenza A (H3);;; +22827-0;LL898-8;FLUA typing;LA13025-4;3;Influenza A (H5);;; +22827-0;LL898-8;FLUA typing;LA13026-2;4;Inconclusive for Influenza A (H1) 2009 pandemic;;; +22827-0;LL898-8;FLUA typing;LA13027-0;5;Influenza A (H1) 2009 pandemic detected;;; +22827-0;LL898-8;FLUA typing;LA13028-8;6;Inconclusive for Influenza A (H5) asian lineage;;; +22827-0;LL898-8;FLUA typing;LA13029-6;7;Influenza A (unsubtypable);;; +22827-0;LL898-8;FLUA typing;LA11919-0;8;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +22828-8;LL898-8;FLUA typing;LA13023-9;1;Influenza A (H1);;; +22828-8;LL898-8;FLUA typing;LA13024-7;2;Influenza A (H3);;; +22828-8;LL898-8;FLUA typing;LA13025-4;3;Influenza A (H5);;; +22828-8;LL898-8;FLUA typing;LA13026-2;4;Inconclusive for Influenza A (H1) 2009 pandemic;;; +22828-8;LL898-8;FLUA typing;LA13027-0;5;Influenza A (H1) 2009 pandemic detected;;; +22828-8;LL898-8;FLUA typing;LA13028-8;6;Inconclusive for Influenza A (H5) asian lineage;;; +22828-8;LL898-8;FLUA typing;LA13029-6;7;Influenza A (unsubtypable);;; +22828-8;LL898-8;FLUA typing;LA11919-0;8;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +59423-4;LL898-8;FLUA typing;LA13023-9;1;Influenza A (H1);;; +59423-4;LL898-8;FLUA typing;LA13024-7;2;Influenza A (H3);;; +59423-4;LL898-8;FLUA typing;LA13025-4;3;Influenza A (H5);;; +59423-4;LL898-8;FLUA typing;LA13026-2;4;Inconclusive for Influenza A (H1) 2009 pandemic;;; +59423-4;LL898-8;FLUA typing;LA13027-0;5;Influenza A (H1) 2009 pandemic detected;;; +59423-4;LL898-8;FLUA typing;LA13028-8;6;Inconclusive for Influenza A (H5) asian lineage;;; +59423-4;LL898-8;FLUA typing;LA13029-6;7;Influenza A (unsubtypable);;; +59423-4;LL898-8;FLUA typing;LA11919-0;8;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +59424-2;LL898-8;FLUA typing;LA13023-9;1;Influenza A (H1);;; +59424-2;LL898-8;FLUA typing;LA13024-7;2;Influenza A (H3);;; +59424-2;LL898-8;FLUA typing;LA13025-4;3;Influenza A (H5);;; +59424-2;LL898-8;FLUA typing;LA13026-2;4;Inconclusive for Influenza A (H1) 2009 pandemic;;; +59424-2;LL898-8;FLUA typing;LA13027-0;5;Influenza A (H1) 2009 pandemic detected;;; +59424-2;LL898-8;FLUA typing;LA13028-8;6;Inconclusive for Influenza A (H5) asian lineage;;; +59424-2;LL898-8;FLUA typing;LA13029-6;7;Influenza A (unsubtypable);;; +59424-2;LL898-8;FLUA typing;LA11919-0;8;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +88187-0;LL898-8;FLUA typing;LA13023-9;1;Influenza A (H1);;; +88187-0;LL898-8;FLUA typing;LA13024-7;2;Influenza A (H3);;; +88187-0;LL898-8;FLUA typing;LA13025-4;3;Influenza A (H5);;; +88187-0;LL898-8;FLUA typing;LA13026-2;4;Inconclusive for Influenza A (H1) 2009 pandemic;;; +88187-0;LL898-8;FLUA typing;LA13027-0;5;Influenza A (H1) 2009 pandemic detected;;; +88187-0;LL898-8;FLUA typing;LA13028-8;6;Inconclusive for Influenza A (H5) asian lineage;;; +88187-0;LL898-8;FLUA typing;LA13029-6;7;Influenza A (unsubtypable);;; +88187-0;LL898-8;FLUA typing;LA11919-0;8;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +91072-9;LL898-8;FLUA typing;LA13023-9;1;Influenza A (H1);;; +91072-9;LL898-8;FLUA typing;LA13024-7;2;Influenza A (H3);;; +91072-9;LL898-8;FLUA typing;LA13025-4;3;Influenza A (H5);;; +91072-9;LL898-8;FLUA typing;LA13026-2;4;Inconclusive for Influenza A (H1) 2009 pandemic;;; +91072-9;LL898-8;FLUA typing;LA13027-0;5;Influenza A (H1) 2009 pandemic detected;;; +91072-9;LL898-8;FLUA typing;LA13028-8;6;Inconclusive for Influenza A (H5) asian lineage;;; +91072-9;LL898-8;FLUA typing;LA13029-6;7;Influenza A (unsubtypable);;; +91072-9;LL898-8;FLUA typing;LA11919-0;8;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +91771-6;LL898-8;FLUA typing;LA13023-9;1;Influenza A (H1);;; +91771-6;LL898-8;FLUA typing;LA13024-7;2;Influenza A (H3);;; +91771-6;LL898-8;FLUA typing;LA13025-4;3;Influenza A (H5);;; +91771-6;LL898-8;FLUA typing;LA13026-2;4;Inconclusive for Influenza A (H1) 2009 pandemic;;; +91771-6;LL898-8;FLUA typing;LA13027-0;5;Influenza A (H1) 2009 pandemic detected;;; +91771-6;LL898-8;FLUA typing;LA13028-8;6;Inconclusive for Influenza A (H5) asian lineage;;; +91771-6;LL898-8;FLUA typing;LA13029-6;7;Influenza A (unsubtypable);;; +91771-6;LL898-8;FLUA typing;LA11919-0;8;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +23115-9;LL2281-5;FMDV serotype (nom);LA13487-6;1;A;;; +23115-9;LL2281-5;FMDV serotype (nom);LA14519-5;2;C;;; +23115-9;LL2281-5;FMDV serotype (nom);LA19268-4;3;O;;; +23115-9;LL2281-5;FMDV serotype (nom);LA19269-2;4;Asia 1;;; +23115-9;LL2281-5;FMDV serotype (nom);LA19270-0;5;SAT 1;;; +23115-9;LL2281-5;FMDV serotype (nom);LA19271-8;6;SAT 2;;; +23115-9;LL2281-5;FMDV serotype (nom);LA19272-6;7;SAT 3;;; +23116-7;LL2281-5;FMDV serotype (nom);LA13487-6;1;A;;; +23116-7;LL2281-5;FMDV serotype (nom);LA14519-5;2;C;;; +23116-7;LL2281-5;FMDV serotype (nom);LA19268-4;3;O;;; +23116-7;LL2281-5;FMDV serotype (nom);LA19269-2;4;Asia 1;;; +23116-7;LL2281-5;FMDV serotype (nom);LA19270-0;5;SAT 1;;; +23116-7;LL2281-5;FMDV serotype (nom);LA19271-8;6;SAT 2;;; +23116-7;LL2281-5;FMDV serotype (nom);LA19272-6;7;SAT 3;;; +23117-5;LL2281-5;FMDV serotype (nom);LA13487-6;1;A;;; +23117-5;LL2281-5;FMDV serotype (nom);LA14519-5;2;C;;; +23117-5;LL2281-5;FMDV serotype (nom);LA19268-4;3;O;;; +23117-5;LL2281-5;FMDV serotype (nom);LA19269-2;4;Asia 1;;; +23117-5;LL2281-5;FMDV serotype (nom);LA19270-0;5;SAT 1;;; +23117-5;LL2281-5;FMDV serotype (nom);LA19271-8;6;SAT 2;;; +23117-5;LL2281-5;FMDV serotype (nom);LA19272-6;7;SAT 3;;; +23118-3;LL2281-5;FMDV serotype (nom);LA13487-6;1;A;;; +23118-3;LL2281-5;FMDV serotype (nom);LA14519-5;2;C;;; +23118-3;LL2281-5;FMDV serotype (nom);LA19268-4;3;O;;; +23118-3;LL2281-5;FMDV serotype (nom);LA19269-2;4;Asia 1;;; +23118-3;LL2281-5;FMDV serotype (nom);LA19270-0;5;SAT 1;;; +23118-3;LL2281-5;FMDV serotype (nom);LA19271-8;6;SAT 2;;; +23118-3;LL2281-5;FMDV serotype (nom);LA19272-6;7;SAT 3;;; +23119-1;LL2281-5;FMDV serotype (nom);LA13487-6;1;A;;; +23119-1;LL2281-5;FMDV serotype (nom);LA14519-5;2;C;;; +23119-1;LL2281-5;FMDV serotype (nom);LA19268-4;3;O;;; +23119-1;LL2281-5;FMDV serotype (nom);LA19269-2;4;Asia 1;;; +23119-1;LL2281-5;FMDV serotype (nom);LA19270-0;5;SAT 1;;; +23119-1;LL2281-5;FMDV serotype (nom);LA19271-8;6;SAT 2;;; +23119-1;LL2281-5;FMDV serotype (nom);LA19272-6;7;SAT 3;;; +23120-9;LL2281-5;FMDV serotype (nom);LA13487-6;1;A;;; +23120-9;LL2281-5;FMDV serotype (nom);LA14519-5;2;C;;; +23120-9;LL2281-5;FMDV serotype (nom);LA19268-4;3;O;;; +23120-9;LL2281-5;FMDV serotype (nom);LA19269-2;4;Asia 1;;; +23120-9;LL2281-5;FMDV serotype (nom);LA19270-0;5;SAT 1;;; +23120-9;LL2281-5;FMDV serotype (nom);LA19271-8;6;SAT 2;;; +23120-9;LL2281-5;FMDV serotype (nom);LA19272-6;7;SAT 3;;; +23121-7;LL2281-5;FMDV serotype (nom);LA13487-6;1;A;;; +23121-7;LL2281-5;FMDV serotype (nom);LA14519-5;2;C;;; +23121-7;LL2281-5;FMDV serotype (nom);LA19268-4;3;O;;; +23121-7;LL2281-5;FMDV serotype (nom);LA19269-2;4;Asia 1;;; +23121-7;LL2281-5;FMDV serotype (nom);LA19270-0;5;SAT 1;;; +23121-7;LL2281-5;FMDV serotype (nom);LA19271-8;6;SAT 2;;; +23121-7;LL2281-5;FMDV serotype (nom);LA19272-6;7;SAT 3;;; +23552-3;LL2277-3;VEEV;LA19254-4;1;IAB;;; +23552-3;LL2277-3;VEEV;LA19255-1;2;IC;;; +23552-3;LL2277-3;VEEV;LA19256-9;3;ID;;; +23552-3;LL2277-3;VEEV;LA19257-7;4;IE;;; +23552-3;LL2277-3;VEEV;LA19258-5;5;IIIA;;; +23553-1;LL2277-3;VEEV;LA19254-4;1;IAB;;; +23553-1;LL2277-3;VEEV;LA19255-1;2;IC;;; +23553-1;LL2277-3;VEEV;LA19256-9;3;ID;;; +23553-1;LL2277-3;VEEV;LA19257-7;4;IE;;; +23553-1;LL2277-3;VEEV;LA19258-5;5;IIIA;;; +23554-9;LL2277-3;VEEV;LA19254-4;1;IAB;;; +23554-9;LL2277-3;VEEV;LA19255-1;2;IC;;; +23554-9;LL2277-3;VEEV;LA19256-9;3;ID;;; +23554-9;LL2277-3;VEEV;LA19257-7;4;IE;;; +23554-9;LL2277-3;VEEV;LA19258-5;5;IIIA;;; +23569-7;LL2278-1;VSIV serotype;LA3750-2;1;New Jersey;;; +23569-7;LL2278-1;VSIV serotype;LA3812-0;2;Indiana;;; +23569-7;LL2278-1;VSIV serotype;LA19259-3;3;Alagoas;;; +23570-5;LL2278-1;VSIV serotype;LA3750-2;1;New Jersey;;; +23570-5;LL2278-1;VSIV serotype;LA3812-0;2;Indiana;;; +23570-5;LL2278-1;VSIV serotype;LA19259-3;3;Alagoas;;; +23571-3;LL2278-1;VSIV serotype;LA3750-2;1;New Jersey;;; +23571-3;LL2278-1;VSIV serotype;LA3812-0;2;Indiana;;; +23571-3;LL2278-1;VSIV serotype;LA19259-3;3;Alagoas;;; +23572-1;LL2278-1;VSIV serotype;LA3750-2;1;New Jersey;;; +23572-1;LL2278-1;VSIV serotype;LA3812-0;2;Indiana;;; +23572-1;LL2278-1;VSIV serotype;LA19259-3;3;Alagoas;;; +23599-4;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +23599-4;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +23599-4;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +23600-0;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +23600-0;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +23600-0;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +594-2;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +594-2;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +594-2;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +6453-5;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +6453-5;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +6453-5;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +6454-3;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +6454-3;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +6454-3;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +6455-0;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +6455-0;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +6455-0;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +71378-4;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +71378-4;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +71378-4;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +86732-5;LL2090-0;Leptospira sp;LA18543-1;1;Leptospira biflexa;;; +86732-5;LL2090-0;Leptospira sp;LA18544-9;2;Leptospira interrogans;;; +86732-5;LL2090-0;Leptospira sp;LA18545-6;3;Leptospira kirschneri;;; +23649-7;LL2257-5;A pleuro bv2;LA14559-1;1;13;;; +23649-7;LL2257-5;A pleuro bv2;LA14560-9;2;14;;; +23649-7;LL2257-5;A pleuro bv2;LA6113-0;3;2;;; +23649-7;LL2257-5;A pleuro bv2;LA6115-5;4;4;;; +23649-7;LL2257-5;A pleuro bv2;LA10139-6;5;7;;; +23649-7;LL2257-5;A pleuro bv2;LA10141-2;6;9;;; +23651-3;LL2260-9;A suis;LA19185-0;1;O1/K1;;; +23651-3;LL2260-9;A suis;LA19186-8;2;O1/K2;;; +23651-3;LL2260-9;A suis;LA19187-6;3;O2/K2;;; +23826-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +23826-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +23826-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +23826-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +29723-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +29723-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +29723-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +29723-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +37983-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +37983-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +37983-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +37983-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +37984-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +37984-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +37984-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +37984-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +37985-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +37985-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +37985-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +37985-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +37986-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +37986-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +37986-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +37986-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +41003-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +41003-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +41003-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +41003-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +41005-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +41005-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +41005-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +41005-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +41009-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +41009-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +41009-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +41009-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +43304-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +43304-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +43304-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +43304-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +43305-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +43305-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +43305-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +43305-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +44878-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +44878-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +44878-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +44878-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +44879-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +44879-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +44879-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +44879-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +44880-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +44880-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +44880-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +44880-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +45294-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +45294-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +45294-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +45294-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +50702-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +50702-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +50702-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +50702-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +50706-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +50706-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +50706-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +50706-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +50707-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +50707-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +50707-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +50707-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +50708-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +50708-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +50708-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +50708-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +60494-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +60494-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +60494-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +60494-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +62423-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +62423-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +62423-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +62423-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63423-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63423-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63423-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63423-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63424-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63424-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63424-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63424-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63425-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63425-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63425-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63425-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63426-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63426-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63426-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63426-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63427-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63427-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63427-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63427-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63428-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63428-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63428-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63428-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63429-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63429-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63429-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63429-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +63431-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +63431-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +63431-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63431-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +67561-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +67561-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +67561-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +67561-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +67562-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +67562-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +67562-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +67562-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +67563-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +67563-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +67563-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +67563-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +69765-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +69765-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +69765-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +69765-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +69766-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +69766-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +69766-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +69766-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +69767-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +69767-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +69767-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +69767-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +71718-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +71718-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +71718-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +71718-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +71719-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +71719-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +71719-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +71719-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +71786-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +71786-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +71786-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +71786-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +71787-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +71787-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +71787-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +71787-6;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +72111-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +72111-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +72111-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +72111-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +72822-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +72822-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +72822-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +72822-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +72823-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +72823-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +72823-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +72823-8;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85498-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +85498-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +85498-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +85498-4;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85499-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +85499-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +85499-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +85499-2;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85500-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +85500-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +85500-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +85500-7;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85501-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +85501-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +85501-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +85501-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85503-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +85503-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +85503-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +85503-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86221-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +86221-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +86221-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86221-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86621-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +86621-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +86621-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86621-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86930-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +86930-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +86930-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +86930-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94183-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +94183-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +94183-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94183-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94763-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +94763-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +94763-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94763-0;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94765-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +94765-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +94765-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94765-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94766-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +94766-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +94766-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94766-3;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94767-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +94767-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +94767-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94767-1;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95409-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +95409-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +95409-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +95409-9;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +96986-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11882-0;1;Detected;;; +96986-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11883-8;2;Not detected;;; +96986-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +96986-5;LL956-4;Detected|Not det|Equiv|Inconcl;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +24126-5;LL2239-3;Adenovirus;LA19141-3;1;Ad7a;;; +24126-5;LL2239-3;Adenovirus;LA19142-1;2;Ad7b;;; +24126-5;LL2239-3;Adenovirus;LA19143-9;3;Ad7c;;; +24126-5;LL2239-3;Adenovirus;LA19144-7;4;Ad7d;;; +24126-5;LL2239-3;Adenovirus;LA19145-4;5;Ad7e;;; +24126-5;LL2239-3;Adenovirus;LA19140-5;6;Ad7p;;; +24126-5;LL2239-3;Adenovirus;LA11884-6;7;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +24126-5;LL2239-3;Adenovirus;LA13538-6;8;Not tested;;; +24126-5;LL2239-3;Adenovirus;LA46-8;9;Other;;; +40975-5;LL2239-3;Adenovirus;LA19141-3;1;Ad7a;;; +40975-5;LL2239-3;Adenovirus;LA19142-1;2;Ad7b;;; +40975-5;LL2239-3;Adenovirus;LA19143-9;3;Ad7c;;; +40975-5;LL2239-3;Adenovirus;LA19144-7;4;Ad7d;;; +40975-5;LL2239-3;Adenovirus;LA19145-4;5;Ad7e;;; +40975-5;LL2239-3;Adenovirus;LA19140-5;6;Ad7p;;; +40975-5;LL2239-3;Adenovirus;LA11884-6;7;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +40975-5;LL2239-3;Adenovirus;LA13538-6;8;Not tested;;; +40975-5;LL2239-3;Adenovirus;LA46-8;9;Other;;; +24430-1;LL2293-0;S suis serotype;LA19315-3;0;34;;; +24430-1;LL2293-0;S suis serotype;LA6112-2;1;1;;; +24430-1;LL2293-0;S suis serotype;LA6113-0;2;2;;; +24430-1;LL2293-0;S suis serotype;LA10141-2;3;9;;; +24430-1;LL2293-0;S suis serotype;LA19317-9;4;32;;; +24430-1;LL2293-0;S suis serotype;LA19316-1;5;33;;; +24475-6;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +24475-6;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +24475-6;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +74511-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +74511-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +74511-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +75715-3;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +75715-3;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +75715-3;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +75717-9;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +75717-9;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +75717-9;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +75718-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +75718-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +75718-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +75719-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +75719-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +75719-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +75721-1;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +75721-1;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +75721-1;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +75723-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +75723-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +75723-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +75726-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +75726-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +75726-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +78378-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +78378-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +78378-7;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +79164-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +79164-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +79164-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +93198-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +93198-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +93198-0;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +94402-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +94402-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +94402-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +94416-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19932-5;1;G/G (wild type);;; +94416-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19933-3;2;G/A (heterozygous);;; +94416-5;LL2478-7;Genotypes G/G, G/A, A/A;LA19934-1;3;A/A (homozygous);;; +2514-8;LL733-7;Neg|Trace|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +2514-8;LL733-7;Neg|Trace|Small|Mod|Large;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +2514-8;LL733-7;Neg|Trace|Small|Mod|Large;LA8983-4;3;Small;255507004;Small (qualifier value);http://snomed.info/sct +2514-8;LL733-7;Neg|Trace|Small|Mod|Large;LA6751-7;4;Moderate;;; +2514-8;LL733-7;Neg|Trace|Small|Mod|Large;LA8981-8;5;Large;255509001;Large (qualifier value);http://snomed.info/sct +57796-5;LL733-7;Neg|Trace|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +57796-5;LL733-7;Neg|Trace|Small|Mod|Large;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +57796-5;LL733-7;Neg|Trace|Small|Mod|Large;LA8983-4;3;Small;255507004;Small (qualifier value);http://snomed.info/sct +57796-5;LL733-7;Neg|Trace|Small|Mod|Large;LA6751-7;4;Moderate;;; +57796-5;LL733-7;Neg|Trace|Small|Mod|Large;LA8981-8;5;Large;255509001;Large (qualifier value);http://snomed.info/sct +63371-9;LL733-7;Neg|Trace|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63371-9;LL733-7;Neg|Trace|Small|Mod|Large;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +63371-9;LL733-7;Neg|Trace|Small|Mod|Large;LA8983-4;3;Small;255507004;Small (qualifier value);http://snomed.info/sct +63371-9;LL733-7;Neg|Trace|Small|Mod|Large;LA6751-7;4;Moderate;;; +63371-9;LL733-7;Neg|Trace|Small|Mod|Large;LA8981-8;5;Large;255509001;Large (qualifier value);http://snomed.info/sct +63372-7;LL733-7;Neg|Trace|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63372-7;LL733-7;Neg|Trace|Small|Mod|Large;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +63372-7;LL733-7;Neg|Trace|Small|Mod|Large;LA8983-4;3;Small;255507004;Small (qualifier value);http://snomed.info/sct +63372-7;LL733-7;Neg|Trace|Small|Mod|Large;LA6751-7;4;Moderate;;; +63372-7;LL733-7;Neg|Trace|Small|Mod|Large;LA8981-8;5;Large;255509001;Large (qualifier value);http://snomed.info/sct +63373-5;LL733-7;Neg|Trace|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63373-5;LL733-7;Neg|Trace|Small|Mod|Large;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +63373-5;LL733-7;Neg|Trace|Small|Mod|Large;LA8983-4;3;Small;255507004;Small (qualifier value);http://snomed.info/sct +63373-5;LL733-7;Neg|Trace|Small|Mod|Large;LA6751-7;4;Moderate;;; +63373-5;LL733-7;Neg|Trace|Small|Mod|Large;LA8981-8;5;Large;255509001;Large (qualifier value);http://snomed.info/sct +26615-5;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +26615-5;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +26616-3;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +26616-3;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +33664-4;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +33664-4;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +34589-2;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +34589-2;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +34598-3;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +34598-3;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +35468-8;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +35468-8;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +38479-2;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +38479-2;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +38486-7;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +38486-7;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +49599-4;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +49599-4;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +49625-7;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +49625-7;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +58400-3;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +58400-3;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +71895-7;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +71895-7;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +72072-2;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +72072-2;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +73570-4;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +73570-4;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +94265-6;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +94265-6;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +94267-2;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +94267-2;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +94268-0;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +94268-0;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +98719-8;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98719-8;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +98723-0;LL2354-0;Normal|Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98723-0;LL2354-0;Normal|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +27482-9;LL2433-2;Visit frequency;LA15804-0;1;Day;;; +27482-9;LL2433-2;Visit frequency;LA14216-8;2;Week;;; +27482-9;LL2433-2;Visit frequency;LA14217-6;3;Month;;; +27482-9;LL2433-2;Visit frequency;LA14059-2;4;Quarter;;; +27482-9;LL2433-2;Visit frequency;LA14060-0;5;As needed;;; +27531-3;LL2433-2;Visit frequency;LA15804-0;1;Day;;; +27531-3;LL2433-2;Visit frequency;LA14216-8;2;Week;;; +27531-3;LL2433-2;Visit frequency;LA14217-6;3;Month;;; +27531-3;LL2433-2;Visit frequency;LA14059-2;4;Quarter;;; +27531-3;LL2433-2;Visit frequency;LA14060-0;5;As needed;;; +27555-2;LL2433-2;Visit frequency;LA15804-0;1;Day;;; +27555-2;LL2433-2;Visit frequency;LA14216-8;2;Week;;; +27555-2;LL2433-2;Visit frequency;LA14217-6;3;Month;;; +27555-2;LL2433-2;Visit frequency;LA14059-2;4;Quarter;;; +27555-2;LL2433-2;Visit frequency;LA14060-0;5;As needed;;; +27606-3;LL2433-2;Visit frequency;LA15804-0;1;Day;;; +27606-3;LL2433-2;Visit frequency;LA14216-8;2;Week;;; +27606-3;LL2433-2;Visit frequency;LA14217-6;3;Month;;; +27606-3;LL2433-2;Visit frequency;LA14059-2;4;Quarter;;; +27606-3;LL2433-2;Visit frequency;LA14060-0;5;As needed;;; +27669-1;LL2433-2;Visit frequency;LA15804-0;1;Day;;; +27669-1;LL2433-2;Visit frequency;LA14216-8;2;Week;;; +27669-1;LL2433-2;Visit frequency;LA14217-6;3;Month;;; +27669-1;LL2433-2;Visit frequency;LA14059-2;4;Quarter;;; +27669-1;LL2433-2;Visit frequency;LA14060-0;5;As needed;;; +27708-7;LL2433-2;Visit frequency;LA15804-0;1;Day;;; +27708-7;LL2433-2;Visit frequency;LA14216-8;2;Week;;; +27708-7;LL2433-2;Visit frequency;LA14217-6;3;Month;;; +27708-7;LL2433-2;Visit frequency;LA14059-2;4;Quarter;;; +27708-7;LL2433-2;Visit frequency;LA14060-0;5;As needed;;; +27759-0;LL2433-2;Visit frequency;LA15804-0;1;Day;;; +27759-0;LL2433-2;Visit frequency;LA14216-8;2;Week;;; +27759-0;LL2433-2;Visit frequency;LA14217-6;3;Month;;; +27759-0;LL2433-2;Visit frequency;LA14059-2;4;Quarter;;; +27759-0;LL2433-2;Visit frequency;LA14060-0;5;As needed;;; +28005-7;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +28005-7;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +28005-7;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +60279-7;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +60279-7;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +60279-7;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +75720-3;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +75720-3;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +75720-3;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +75725-2;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +75725-2;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +75725-2;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +75729-4;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +75729-4;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +75729-4;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +75732-8;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +75732-8;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +75732-8;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +77748-2;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +77748-2;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +77748-2;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +92936-4;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +92936-4;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +92936-4;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +93191-5;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +93191-5;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +93191-5;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +94403-3;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +94403-3;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +94403-3;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +94414-0;LL951-5;Genotypes C/C, C/T, T/T;LA13521-2;1;C/C (wild type);;; +94414-0;LL951-5;Genotypes C/C, C/T, T/T;LA13522-0;2;C/T (heterozygous);;; +94414-0;LL951-5;Genotypes C/C, C/T, T/T;LA13523-8;3;T/T (homozygous);;; +28060-2;LL5128-5;Genotypes A/A,A/C, C/C;LA21537-8;1;A/A (wild type);;; +28060-2;LL5128-5;Genotypes A/A,A/C, C/C;LA29485-2;2;A/C (heterozygous);;; +28060-2;LL5128-5;Genotypes A/A,A/C, C/C;LA21506-3;3;C/C (homozygous);;; +91138-8;LL5128-5;Genotypes A/A,A/C, C/C;LA21537-8;1;A/A (wild type);;; +91138-8;LL5128-5;Genotypes A/A,A/C, C/C;LA29485-2;2;A/C (heterozygous);;; +91138-8;LL5128-5;Genotypes A/A,A/C, C/C;LA21506-3;3;C/C (homozygous);;; +94716-8;LL5128-5;Genotypes A/A,A/C, C/C;LA21537-8;1;A/A (wild type);;; +94716-8;LL5128-5;Genotypes A/A,A/C, C/C;LA29485-2;2;A/C (heterozygous);;; +94716-8;LL5128-5;Genotypes A/A,A/C, C/C;LA21506-3;3;C/C (homozygous);;; +28079-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28079-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28079-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28080-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28080-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28080-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28081-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28081-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28081-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28082-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28082-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28082-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28083-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28083-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28083-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28084-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28084-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28084-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28085-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28085-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28085-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28086-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28086-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28086-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28087-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28087-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28087-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28088-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28088-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28088-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28089-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28089-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28089-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28090-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28090-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28090-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28091-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28091-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28091-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28092-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28092-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28092-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28093-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28093-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28093-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28094-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28094-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28094-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28095-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28095-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28095-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28096-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28096-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28096-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28097-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28097-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28097-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28098-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28098-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28098-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28099-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28099-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28099-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28100-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28100-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28100-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28101-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28101-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28101-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28102-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28102-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28102-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28103-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28103-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28103-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28104-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28104-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28104-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28105-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28105-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28105-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28106-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28106-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28106-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28107-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28107-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28107-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28108-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28108-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28108-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28109-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28109-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28109-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28110-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28110-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28110-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28111-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28111-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28111-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28112-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28112-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28112-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28113-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28113-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28113-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28114-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28114-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28114-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28115-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28115-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28115-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28116-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28116-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28116-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28117-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28117-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28117-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28118-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28118-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28118-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28119-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28119-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28119-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28120-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28120-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28120-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28121-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28121-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28121-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28122-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28122-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28122-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28123-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28123-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28123-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28124-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28124-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28124-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28125-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28125-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28125-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28126-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28126-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28126-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28127-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28127-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28127-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28128-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28128-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28128-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28129-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28129-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28129-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28130-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28130-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28130-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28131-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28131-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28131-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28132-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28132-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28132-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28133-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28133-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28133-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28134-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28134-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28134-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28135-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28135-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28135-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28136-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28136-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28136-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28137-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28137-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28137-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28138-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28138-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28138-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28139-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28139-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28139-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28140-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28140-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28140-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28141-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28141-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28141-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28142-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28142-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28142-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28143-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28143-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28143-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28144-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28144-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28144-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28145-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28145-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28145-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28146-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28146-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28146-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28147-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28147-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28147-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28148-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28148-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28148-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28149-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28149-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28149-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28150-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28150-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28150-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28151-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28151-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28151-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28152-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28152-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28152-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28153-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28153-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28153-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28154-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28154-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28154-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28155-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28155-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28155-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28156-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28156-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28156-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28157-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28157-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28157-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28171-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28171-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28171-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28172-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28172-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28172-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28173-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28173-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28173-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28174-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28174-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28174-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28175-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28175-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28175-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28176-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28176-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28176-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28177-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28177-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28177-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28178-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28178-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28178-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28179-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28179-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28179-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28180-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28180-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28180-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28181-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28181-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28181-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28182-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28182-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28182-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28183-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28183-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28183-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28184-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28184-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28184-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28185-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28185-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28185-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28186-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28186-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28186-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28187-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28187-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28187-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28188-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28188-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28188-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28189-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28189-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28189-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28190-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28190-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28190-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28191-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28191-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28191-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28192-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28192-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28192-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28193-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28193-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28193-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28194-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28194-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28194-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28195-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28195-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28195-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28196-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28196-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28196-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28197-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28197-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28197-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28198-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28198-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28198-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28199-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28199-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28199-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28200-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28200-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28200-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28201-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28201-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28201-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28202-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28202-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28202-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28203-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28203-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28203-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28204-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28204-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28204-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28205-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28205-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28205-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28206-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28206-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28206-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28207-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28207-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28207-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28208-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28208-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28208-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28209-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28209-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28209-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28210-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28210-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28210-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28211-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28211-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28211-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28212-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28212-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28212-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28213-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28213-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28213-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28214-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28214-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28214-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28215-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28215-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28215-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28216-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28216-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28216-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28226-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28226-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28226-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28227-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28227-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28227-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28228-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28228-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28228-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28229-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28229-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28229-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28230-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28230-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28230-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28231-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28231-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28231-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28232-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28232-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28232-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28233-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28233-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28233-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28234-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28234-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28234-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28235-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28235-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28235-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28236-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28236-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28236-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28237-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28237-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28237-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28238-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28238-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28238-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28239-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28239-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28239-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28240-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28240-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28240-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28241-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28241-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28241-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28242-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28242-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28242-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28523-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28523-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28523-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28524-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28524-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28524-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28525-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28525-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28525-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28526-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +28526-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +28526-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42819-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42819-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42819-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42820-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42820-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42820-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42821-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42821-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42821-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42822-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42822-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42822-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42823-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42823-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42823-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42824-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42824-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42824-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42825-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42825-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42825-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42826-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42826-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42826-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42827-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42827-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42827-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42828-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42828-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42828-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42829-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42829-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42829-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42830-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42830-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42830-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42831-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42831-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42831-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42832-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42832-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42832-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42833-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42833-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42833-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42834-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42834-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42834-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42835-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42835-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42835-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42836-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42836-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42836-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42837-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42837-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42837-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42838-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42838-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42838-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42839-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42839-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42839-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42840-9;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42840-9;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42840-9;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42841-7;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42841-7;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42841-7;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42842-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42842-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42842-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42843-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42843-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42843-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42844-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42844-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42844-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42845-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42845-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42845-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42846-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42846-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42846-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42847-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42847-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42847-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42848-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42848-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42848-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42849-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42849-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42849-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42850-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42850-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42850-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42851-6;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42851-6;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42851-6;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42852-4;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42852-4;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42852-4;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42853-2;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42853-2;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42853-2;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +42854-0;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +42854-0;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +42854-0;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +81224-8;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +81224-8;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +81224-8;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +81225-5;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +81225-5;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +81225-5;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +81226-3;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +81226-3;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +81226-3;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +81227-1;LL2751-7;Improved-Deteriorated-Stabilized;LA65-8;1;Improved;;; +81227-1;LL2751-7;Improved-Deteriorated-Stabilized;LA66-6;2;Deteriorated;;; +81227-1;LL2751-7;Improved-Deteriorated-Stabilized;LA6635-2;3;Stabilized;;; +28158-4;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28158-4;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28158-4;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28158-4;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28158-4;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28159-2;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28159-2;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28159-2;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28159-2;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28159-2;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28160-0;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28160-0;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28160-0;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28160-0;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28160-0;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28161-8;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28161-8;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28161-8;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28161-8;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28161-8;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28162-6;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28162-6;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28162-6;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28162-6;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28162-6;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28163-4;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28163-4;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28163-4;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28163-4;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28163-4;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28164-2;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28164-2;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28164-2;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28164-2;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28164-2;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28165-9;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28165-9;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28165-9;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28165-9;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28165-9;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28166-7;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28166-7;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28166-7;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28166-7;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28166-7;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28167-5;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28167-5;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28167-5;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28167-5;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28167-5;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28168-3;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28168-3;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28168-3;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28168-3;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28168-3;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28169-1;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28169-1;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28169-1;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28169-1;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28169-1;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28170-9;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28170-9;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28170-9;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28170-9;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28170-9;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28364-8;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28364-8;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28364-8;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28364-8;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28364-8;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28365-5;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28365-5;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28365-5;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28365-5;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28365-5;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28366-3;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28366-3;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28366-3;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28366-3;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28366-3;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28367-1;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28367-1;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28367-1;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28367-1;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28367-1;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28368-9;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28368-9;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28368-9;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28368-9;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28368-9;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28369-7;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28369-7;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28369-7;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28369-7;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28369-7;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28370-5;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28370-5;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28370-5;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28370-5;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28370-5;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28371-3;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28371-3;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28371-3;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28371-3;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28371-3;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28372-1;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28372-1;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28372-1;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28372-1;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28372-1;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28373-9;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28373-9;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28373-9;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28373-9;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28373-9;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28374-7;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28374-7;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28374-7;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28374-7;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28374-7;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28400-0;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28400-0;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28400-0;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28400-0;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28400-0;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28401-8;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28401-8;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28401-8;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28401-8;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28401-8;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28402-6;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28402-6;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28402-6;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28402-6;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28402-6;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28403-4;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28403-4;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28403-4;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28403-4;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28403-4;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28404-2;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28404-2;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28404-2;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28404-2;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28404-2;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28405-9;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28405-9;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28405-9;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28405-9;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28405-9;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28406-7;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28406-7;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28406-7;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28406-7;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28406-7;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28407-5;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28407-5;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28407-5;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28407-5;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28407-5;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28527-0;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28527-0;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28527-0;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28527-0;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28527-0;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28528-8;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28528-8;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28528-8;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28528-8;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28528-8;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28529-6;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28529-6;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28529-6;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28529-6;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28529-6;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28530-4;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28530-4;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28530-4;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28530-4;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28530-4;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28531-2;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28531-2;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28531-2;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28531-2;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28531-2;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28532-0;LL389-8;LIV.HIV;LA6728-5;1;Never/not true;;; +28532-0;LL389-8;LIV.HIV;LA6729-3;2;Sometimes true;;; +28532-0;LL389-8;LIV.HIV;LA6730-1;3;Usually true;;; +28532-0;LL389-8;LIV.HIV;LA6731-9;4;Always true;;; +28532-0;LL389-8;LIV.HIV;LA6732-7;5;No experience/Not applicable;;; +28217-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28217-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28217-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28217-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28217-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28220-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28220-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28220-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28220-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28220-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28223-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28223-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28223-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28223-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28223-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28243-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28243-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28243-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28243-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28243-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28246-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28246-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28246-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28246-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28246-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28248-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28248-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28248-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28248-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28248-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28251-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28251-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28251-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28251-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28251-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28254-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28254-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28254-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28254-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28254-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28257-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28257-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28257-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28257-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28257-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28260-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28260-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28260-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28260-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28260-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28263-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28263-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28263-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28263-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28263-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28266-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28266-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28266-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28266-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28266-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28269-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28269-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28269-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28269-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28269-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28272-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28272-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28272-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28272-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28272-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28275-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28275-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28275-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28275-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28275-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28278-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28278-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28278-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28278-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28278-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28281-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28281-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28281-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28281-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28281-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28284-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28284-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28284-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28284-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28284-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28287-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28287-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28287-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28287-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28287-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28290-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28290-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28290-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28290-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28290-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28293-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28293-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28293-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28293-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28293-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28296-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28296-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28296-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28296-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28296-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28299-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28299-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28299-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28299-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28299-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28302-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28302-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28302-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28302-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28302-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28305-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28305-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28305-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28305-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28305-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28308-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28308-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28308-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28308-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28308-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28311-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28311-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28311-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28311-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28311-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28314-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28314-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28314-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28314-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28314-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28317-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28317-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28317-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28317-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28317-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28320-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28320-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28320-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28320-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28320-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28323-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28323-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28323-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28323-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28323-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28326-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28326-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28326-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28326-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28326-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28329-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28329-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28329-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28329-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28329-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28332-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28332-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28332-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28332-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28332-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28335-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28335-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28335-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28335-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28335-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28338-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28338-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28338-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28338-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28338-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28341-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28341-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28341-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28341-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28341-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28344-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28344-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28344-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28344-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28344-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28347-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28347-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28347-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28347-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28347-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28350-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28350-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28350-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28350-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28350-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28353-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28353-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28353-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28353-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28353-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28356-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28356-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28356-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28356-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28356-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28359-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28359-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28359-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28359-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28359-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28415-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28415-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28415-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28415-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28415-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28418-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28418-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28418-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28418-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28418-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28421-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28421-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28421-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28421-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28421-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28426-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28426-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28426-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28426-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28426-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28427-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28427-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28427-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28427-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28427-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28430-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28430-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28430-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28430-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28430-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28433-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28433-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28433-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28433-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28433-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28436-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28436-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28436-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28436-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28436-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28439-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28439-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28439-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28439-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28439-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28440-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28440-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28440-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28440-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28440-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28445-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28445-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28445-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28445-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28445-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28448-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28448-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28448-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28448-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28448-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28451-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28451-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28451-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28451-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28451-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28453-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28453-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28453-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28453-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28453-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28456-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28456-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28456-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28456-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28456-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28459-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28459-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28459-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28459-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28459-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28462-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28462-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28462-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28462-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28462-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28465-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28465-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28465-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28465-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28465-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28468-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28468-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28468-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28468-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28468-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28471-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28471-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28471-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28471-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28471-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28474-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28474-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28474-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28474-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28474-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28477-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28477-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28477-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28477-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28477-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28480-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28480-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28480-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28480-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28480-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28483-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28483-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28483-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28483-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28483-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28486-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28486-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28486-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28486-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28486-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28489-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28489-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28489-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28489-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28489-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28492-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28492-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28492-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28492-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28492-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28495-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28495-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28495-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28495-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28495-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28498-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28498-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28498-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28498-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28498-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28501-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28501-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28501-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28501-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28501-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28504-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28504-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28504-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28504-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28504-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28507-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28507-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28507-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28507-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28507-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28510-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28510-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28510-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28510-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28510-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28513-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28513-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28513-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28513-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28513-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28516-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28516-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28516-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28516-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28516-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28519-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28519-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28519-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28519-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28519-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28536-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +28536-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +28536-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +28536-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +28536-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46783-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46783-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46783-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46783-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46783-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46786-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46786-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46786-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46786-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46786-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46789-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46789-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46789-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46789-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46789-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46792-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46792-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46792-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46792-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46792-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46795-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46795-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46795-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46795-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46795-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46798-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46798-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46798-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46798-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46798-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46801-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46801-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46801-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46801-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46801-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46804-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46804-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46804-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46804-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46804-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46807-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46807-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46807-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46807-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46807-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46810-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46810-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46810-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46810-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46810-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46813-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46813-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46813-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46813-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46813-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46816-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46816-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46816-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46816-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46816-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46819-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46819-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46819-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46819-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46819-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46822-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46822-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46822-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46822-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46822-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46825-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46825-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46825-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46825-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46825-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46828-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46828-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46828-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46828-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46828-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46831-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46831-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46831-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46831-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46831-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46834-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46834-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46834-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46834-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46834-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46837-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46837-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46837-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46837-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46837-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46840-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46840-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46840-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46840-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46840-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46843-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46843-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46843-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46843-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46843-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46846-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46846-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46846-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46846-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46846-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46849-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46849-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46849-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46849-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46849-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46852-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46852-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46852-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46852-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46852-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46855-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46855-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46855-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46855-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46855-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46858-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46858-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46858-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46858-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46858-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46861-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46861-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46861-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46861-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46861-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46864-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46864-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46864-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46864-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46864-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46867-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46867-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46867-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46867-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46867-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46870-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46870-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46870-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46870-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46870-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46873-6;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46873-6;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46873-6;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46873-6;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46873-6;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46876-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46876-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46876-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46876-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46876-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46879-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46879-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46879-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46879-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46879-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46882-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46882-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46882-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46882-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46882-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46885-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46885-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46885-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46885-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46885-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46888-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46888-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46888-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46888-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46888-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46891-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46891-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46891-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46891-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46891-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46894-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46894-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46894-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46894-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46894-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46897-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46897-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46897-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46897-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46897-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46900-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46900-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46900-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46900-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46900-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46903-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46903-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46903-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46903-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46903-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46906-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46906-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46906-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46906-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46906-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46909-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46909-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46909-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46909-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46909-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46912-2;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46912-2;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46912-2;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46912-2;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46912-2;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46915-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46915-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46915-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46915-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46915-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46918-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46918-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46918-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46918-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46918-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46921-3;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46921-3;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46921-3;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46921-3;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46921-3;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46924-7;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46924-7;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46924-7;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46924-7;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46924-7;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46927-0;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46927-0;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46927-0;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46927-0;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46927-0;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46930-4;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46930-4;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46930-4;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46930-4;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46930-4;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46933-8;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46933-8;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46933-8;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46933-8;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46933-8;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46936-1;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46936-1;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46936-1;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46936-1;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46936-1;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46939-5;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46939-5;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46939-5;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46939-5;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46939-5;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +46942-9;LL346-8;OMAHA_3_Behavior;LA6500-8;1;Not appropriate behavior;;; +46942-9;LL346-8;OMAHA_3_Behavior;LA6501-6;2;Rarely appropriate behavior;;; +46942-9;LL346-8;OMAHA_3_Behavior;LA6502-4;3;Inconsistently appropriate behavior;;; +46942-9;LL346-8;OMAHA_3_Behavior;LA6503-2;4;Usually appropriate behavior;;; +46942-9;LL346-8;OMAHA_3_Behavior;LA6504-0;5;Consistently appropriate behavior;;; +28218-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28218-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28218-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28218-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28218-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28221-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28221-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28221-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28221-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28221-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28224-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28224-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28224-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28224-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28224-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28244-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28244-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28244-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28244-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28244-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28249-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28249-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28249-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28249-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28249-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28252-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28252-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28252-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28252-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28252-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28255-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28255-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28255-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28255-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28255-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28258-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28258-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28258-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28258-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28258-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28261-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28261-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28261-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28261-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28261-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28264-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28264-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28264-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28264-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28264-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28267-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28267-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28267-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28267-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28267-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28270-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28270-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28270-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28270-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28270-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28273-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28273-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28273-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28273-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28273-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28276-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28276-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28276-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28276-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28276-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28279-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28279-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28279-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28279-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28279-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28282-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28282-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28282-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28282-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28282-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28285-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28285-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28285-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28285-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28285-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28288-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28288-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28288-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28288-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28288-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28291-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28291-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28291-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28291-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28291-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28294-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28294-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28294-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28294-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28294-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28297-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28297-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28297-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28297-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28297-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28300-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28300-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28300-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28300-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28300-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28303-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28303-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28303-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28303-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28303-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28306-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28306-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28306-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28306-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28306-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28309-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28309-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28309-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28309-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28309-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28312-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28312-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28312-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28312-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28312-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28315-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28315-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28315-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28315-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28315-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28318-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28318-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28318-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28318-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28318-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28321-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28321-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28321-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28321-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28321-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28324-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28324-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28324-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28324-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28324-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28327-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28327-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28327-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28327-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28327-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28330-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28330-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28330-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28330-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28330-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28333-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28333-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28333-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28333-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28333-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28336-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28336-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28336-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28336-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28336-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28339-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28339-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28339-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28339-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28339-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28342-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28342-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28342-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28342-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28342-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28345-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28345-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28345-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28345-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28345-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28348-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28348-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28348-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28348-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28348-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28351-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28351-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28351-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28351-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28351-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28354-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28354-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28354-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28354-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28354-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28357-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28357-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28357-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28357-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28357-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28360-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28360-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28360-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28360-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28360-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28416-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28416-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28416-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28416-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28416-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28419-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28419-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28419-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28419-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28419-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28422-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28422-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28422-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28422-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28422-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28424-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28424-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28424-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28424-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28424-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28428-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28428-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28428-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28428-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28428-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28431-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28431-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28431-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28431-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28431-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28434-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28434-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28434-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28434-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28434-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28437-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28437-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28437-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28437-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28437-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28441-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28441-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28441-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28441-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28441-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28443-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28443-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28443-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28443-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28443-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28446-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28446-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28446-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28446-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28446-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28449-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28449-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28449-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28449-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28449-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28454-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28454-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28454-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28454-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28454-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28457-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28457-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28457-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28457-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28457-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28460-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28460-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28460-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28460-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28460-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28463-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28463-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28463-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28463-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28463-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28466-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28466-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28466-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28466-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28466-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28469-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28469-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28469-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28469-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28469-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28472-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28472-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28472-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28472-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28472-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28475-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28475-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28475-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28475-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28475-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28478-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28478-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28478-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28478-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28478-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28481-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28481-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28481-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28481-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28481-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28484-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28484-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28484-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28484-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28484-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28487-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28487-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28487-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28487-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28487-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28490-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28490-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28490-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28490-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28490-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28494-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28494-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28494-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28494-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28494-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28496-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28496-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28496-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28496-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28496-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28499-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28499-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28499-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28499-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28499-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28502-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28502-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28502-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28502-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28502-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28505-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28505-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28505-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28505-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28505-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28508-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28508-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28508-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28508-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28508-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28511-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28511-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28511-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28511-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28511-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28514-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28514-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28514-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28514-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28514-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28517-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28517-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28517-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28517-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28517-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28520-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28520-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28520-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28520-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28520-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28533-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28533-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28533-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28533-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28533-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28535-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28535-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28535-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28535-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28535-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28537-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +28537-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +28537-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +28537-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +28537-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46784-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46784-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46784-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46784-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46784-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46787-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46787-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46787-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46787-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46787-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46790-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46790-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46790-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46790-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46790-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46793-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46793-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46793-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46793-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46793-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46796-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46796-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46796-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46796-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46796-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46799-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46799-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46799-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46799-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46799-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46802-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46802-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46802-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46802-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46802-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46805-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46805-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46805-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46805-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46805-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46808-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46808-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46808-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46808-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46808-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46811-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46811-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46811-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46811-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46811-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46814-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46814-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46814-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46814-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46814-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46817-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46817-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46817-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46817-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46817-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46820-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46820-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46820-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46820-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46820-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46823-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46823-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46823-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46823-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46823-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46826-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46826-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46826-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46826-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46826-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46829-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46829-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46829-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46829-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46829-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46832-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46832-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46832-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46832-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46832-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46835-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46835-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46835-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46835-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46835-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46838-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46838-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46838-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46838-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46838-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46841-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46841-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46841-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46841-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46841-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46844-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46844-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46844-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46844-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46844-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46847-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46847-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46847-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46847-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46847-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46850-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46850-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46850-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46850-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46850-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46853-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46853-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46853-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46853-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46853-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46856-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46856-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46856-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46856-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46856-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46859-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46859-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46859-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46859-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46859-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46862-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46862-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46862-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46862-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46862-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46865-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46865-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46865-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46865-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46865-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46868-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46868-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46868-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46868-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46868-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46871-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46871-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46871-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46871-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46871-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46874-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46874-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46874-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46874-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46874-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46877-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46877-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46877-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46877-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46877-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46880-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46880-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46880-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46880-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46880-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46883-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46883-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46883-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46883-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46883-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46886-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46886-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46886-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46886-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46886-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46889-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46889-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46889-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46889-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46889-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46892-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46892-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46892-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46892-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46892-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46895-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46895-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46895-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46895-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46895-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46898-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46898-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46898-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46898-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46898-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46901-5;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46901-5;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46901-5;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46901-5;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46901-5;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46904-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46904-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46904-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46904-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46904-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46907-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46907-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46907-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46907-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46907-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46910-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46910-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46910-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46910-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46910-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46913-0;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46913-0;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46913-0;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46913-0;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46913-0;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46916-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46916-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46916-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46916-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46916-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46919-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46919-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46919-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46919-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46919-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46922-1;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46922-1;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46922-1;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46922-1;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46922-1;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46925-4;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46925-4;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46925-4;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46925-4;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46925-4;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46928-8;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46928-8;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46928-8;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46928-8;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46928-8;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46931-2;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46931-2;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46931-2;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46931-2;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46931-2;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46934-6;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46934-6;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46934-6;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46934-6;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46934-6;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46937-9;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46937-9;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46937-9;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46937-9;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46937-9;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46940-3;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46940-3;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46940-3;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46940-3;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46940-3;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +46943-7;LL345-0;OMAHA_2_Knowledge;LA6495-1;1;No knowledge;;; +46943-7;LL345-0;OMAHA_2_Knowledge;LA6496-9;2;Minimal knowledge;;; +46943-7;LL345-0;OMAHA_2_Knowledge;LA6497-7;3;Basic knowledge;;; +46943-7;LL345-0;OMAHA_2_Knowledge;LA6498-5;4;Adequate knowledge;;; +46943-7;LL345-0;OMAHA_2_Knowledge;LA6499-3;5;Superior knowledge;;; +28219-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28219-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28219-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28219-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28219-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28222-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28222-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28222-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28222-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28222-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28225-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28225-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28225-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28225-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28225-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28245-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28245-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28245-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28245-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28245-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28247-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28247-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28247-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28247-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28247-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28250-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28250-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28250-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28250-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28250-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28253-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28253-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28253-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28253-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28253-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28256-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28256-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28256-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28256-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28256-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28259-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28259-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28259-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28259-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28259-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28262-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28262-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28262-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28262-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28262-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28265-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28265-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28265-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28265-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28265-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28268-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28268-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28268-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28268-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28268-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28271-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28271-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28271-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28271-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28271-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28274-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28274-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28274-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28274-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28274-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28277-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28277-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28277-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28277-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28277-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28280-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28280-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28280-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28280-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28280-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28283-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28283-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28283-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28283-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28283-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28286-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28286-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28286-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28286-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28286-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28289-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28289-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28289-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28289-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28289-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28292-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28292-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28292-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28292-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28292-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28295-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28295-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28295-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28295-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28295-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28298-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28298-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28298-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28298-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28298-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28301-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28301-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28301-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28301-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28301-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28304-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28304-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28304-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28304-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28304-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28307-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28307-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28307-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28307-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28307-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28310-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28310-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28310-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28310-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28310-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28313-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28313-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28313-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28313-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28313-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28316-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28316-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28316-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28316-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28316-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28319-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28319-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28319-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28319-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28319-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28322-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28322-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28322-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28322-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28322-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28325-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28325-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28325-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28325-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28325-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28328-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28328-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28328-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28328-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28328-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28331-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28331-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28331-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28331-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28331-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28334-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28334-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28334-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28334-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28334-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28337-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28337-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28337-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28337-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28337-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28340-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28340-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28340-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28340-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28340-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28343-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28343-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28343-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28343-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28343-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28346-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28346-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28346-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28346-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28346-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28349-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28349-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28349-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28349-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28349-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28352-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28352-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28352-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28352-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28352-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28355-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28355-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28355-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28355-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28355-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28358-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28358-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28358-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28358-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28358-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28361-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28361-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28361-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28361-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28361-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28417-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28417-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28417-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28417-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28417-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28420-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28420-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28420-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28420-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28420-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28423-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28423-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28423-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28423-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28423-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28425-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28425-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28425-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28425-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28425-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28429-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28429-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28429-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28429-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28429-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28432-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28432-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28432-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28432-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28432-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28435-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28435-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28435-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28435-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28435-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28438-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28438-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28438-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28438-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28438-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28442-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28442-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28442-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28442-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28442-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28444-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28444-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28444-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28444-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28444-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28447-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28447-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28447-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28447-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28447-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28450-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28450-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28450-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28450-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28450-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28452-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28452-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28452-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28452-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28452-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28455-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28455-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28455-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28455-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28455-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28458-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28458-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28458-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28458-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28458-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28461-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28461-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28461-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28461-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28461-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28464-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28464-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28464-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28464-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28464-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28467-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28467-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28467-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28467-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28467-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28470-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28470-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28470-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28470-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28470-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28473-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28473-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28473-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28473-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28473-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28476-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28476-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28476-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28476-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28476-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28479-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28479-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28479-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28479-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28479-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28482-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28482-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28482-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28482-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28482-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28485-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28485-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28485-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28485-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28485-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28488-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28488-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28488-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28488-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28488-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28491-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28491-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28491-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28491-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28491-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28493-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28493-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28493-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28493-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28493-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28497-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28497-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28497-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28497-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28497-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28500-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28500-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28500-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28500-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28500-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28503-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28503-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28503-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28503-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28503-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28506-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28506-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28506-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28506-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28506-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28509-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28509-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28509-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28509-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28509-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28512-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28512-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28512-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28512-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28512-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28515-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28515-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28515-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28515-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28515-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28518-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28518-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28518-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28518-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28518-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28521-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28521-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28521-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28521-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28521-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28522-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +28522-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +28522-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +28522-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +28522-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46785-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46785-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46785-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46785-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46785-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46788-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46788-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46788-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46788-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46788-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46791-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46791-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46791-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46791-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46791-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46794-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46794-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46794-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46794-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46794-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46797-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46797-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46797-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46797-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46797-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46800-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46800-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46800-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46800-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46800-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46803-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46803-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46803-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46803-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46803-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46806-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46806-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46806-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46806-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46806-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46809-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46809-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46809-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46809-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46809-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46812-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46812-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46812-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46812-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46812-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46815-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46815-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46815-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46815-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46815-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46818-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46818-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46818-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46818-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46818-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46821-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46821-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46821-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46821-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46821-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46824-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46824-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46824-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46824-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46824-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46827-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46827-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46827-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46827-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46827-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46830-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46830-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46830-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46830-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46830-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46833-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46833-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46833-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46833-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46833-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46836-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46836-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46836-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46836-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46836-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46839-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46839-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46839-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46839-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46839-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46842-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46842-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46842-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46842-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46842-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46845-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46845-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46845-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46845-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46845-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46848-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46848-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46848-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46848-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46848-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46851-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46851-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46851-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46851-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46851-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46854-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46854-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46854-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46854-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46854-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46857-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46857-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46857-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46857-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46857-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46860-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46860-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46860-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46860-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46860-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46863-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46863-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46863-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46863-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46863-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46866-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46866-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46866-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46866-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46866-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46869-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46869-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46869-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46869-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46869-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46872-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46872-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46872-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46872-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46872-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46875-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46875-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46875-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46875-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46875-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46878-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46878-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46878-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46878-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46878-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46881-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46881-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46881-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46881-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46881-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46884-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46884-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46884-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46884-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46884-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46887-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46887-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46887-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46887-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46887-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46890-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46890-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46890-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46890-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46890-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46893-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46893-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46893-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46893-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46893-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46896-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46896-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46896-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46896-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46896-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46899-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46899-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46899-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46899-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46899-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46902-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46902-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46902-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46902-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46902-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46905-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46905-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46905-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46905-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46905-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46908-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46908-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46908-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46908-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46908-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46911-4;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46911-4;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46911-4;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46911-4;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46911-4;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46914-8;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46914-8;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46914-8;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46914-8;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46914-8;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46917-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46917-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46917-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46917-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46917-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46920-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46920-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46920-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46920-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46920-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46923-9;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46923-9;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46923-9;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46923-9;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46923-9;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46926-2;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46926-2;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46926-2;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46926-2;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46926-2;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46929-6;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46929-6;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46929-6;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46929-6;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46929-6;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46932-0;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46932-0;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46932-0;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46932-0;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46932-0;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46935-3;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46935-3;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46935-3;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46935-3;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46935-3;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46938-7;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46938-7;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46938-7;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46938-7;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46938-7;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46941-1;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46941-1;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46941-1;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46941-1;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46941-1;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +46944-5;LL344-3;OMAHA_1_Status;LA6490-2;1;Extreme signs/symptoms;;; +46944-5;LL344-3;OMAHA_1_Status;LA6491-0;2;Severe signs/symptoms;;; +46944-5;LL344-3;OMAHA_1_Status;LA6492-8;3;Moderate signs/symptoms;;; +46944-5;LL344-3;OMAHA_1_Status;LA6493-6;4;Minimal signs/symptoms;;; +46944-5;LL344-3;OMAHA_1_Status;LA6494-4;5;No signs/symptoms;;; +28362-2;LL395-5;QAM_6_Fear-anxiety;LA6750-9;1;Severe;;; +28362-2;LL395-5;QAM_6_Fear-anxiety;LA6751-7;2;Moderate;;; +28362-2;LL395-5;QAM_6_Fear-anxiety;LA6752-5;3;Mild;;; +28362-2;LL395-5;QAM_6_Fear-anxiety;LA137-2;4;None;260413007;None (qualifier value);http://snomed.info/sct +28363-0;LL395-5;QAM_6_Fear-anxiety;LA6750-9;1;Severe;;; +28363-0;LL395-5;QAM_6_Fear-anxiety;LA6751-7;2;Moderate;;; +28363-0;LL395-5;QAM_6_Fear-anxiety;LA6752-5;3;Mild;;; +28363-0;LL395-5;QAM_6_Fear-anxiety;LA137-2;4;None;260413007;None (qualifier value);http://snomed.info/sct +28375-4;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28375-4;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28375-4;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28376-2;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28376-2;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28376-2;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28377-0;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28377-0;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28377-0;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28378-8;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28378-8;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28378-8;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28379-6;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28379-6;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28379-6;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28380-4;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28380-4;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28380-4;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28381-2;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28381-2;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28381-2;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28382-0;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28382-0;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28382-0;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28383-8;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28383-8;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28383-8;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28384-6;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28384-6;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28384-6;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28385-3;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28385-3;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28385-3;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28386-1;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28386-1;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28386-1;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28387-9;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28387-9;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28387-9;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28388-7;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28388-7;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28388-7;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28389-5;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28389-5;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28389-5;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28390-3;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28390-3;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28390-3;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28391-1;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28391-1;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28391-1;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28392-9;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28392-9;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28392-9;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28393-7;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28393-7;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28393-7;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28394-5;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28394-5;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28394-5;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28395-2;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28395-2;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28395-2;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28396-0;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28396-0;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28396-0;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28397-8;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28397-8;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28397-8;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28398-6;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28398-6;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28398-6;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28399-4;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28399-4;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28399-4;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28538-7;LL396-3;HIV-SSC_Severity;LA6752-5;1;Mild;;; +28538-7;LL396-3;HIV-SSC_Severity;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +28538-7;LL396-3;HIV-SSC_Severity;LA6750-9;3;Severe;;; +28408-3;LL390-6;QAM_1_Self care;LA6746-7;1;Dependent/does not participate;;; +28408-3;LL390-6;QAM_1_Self care;LA6747-5;2;Requires assistance or supervision from another person;;; +28408-3;LL390-6;QAM_1_Self care;LA6748-3;3;Requires use of equipment or device;;; +28408-3;LL390-6;QAM_1_Self care;LA6749-1;4;Full self-care;;; +28409-1;LL390-6;QAM_1_Self care;LA6746-7;1;Dependent/does not participate;;; +28409-1;LL390-6;QAM_1_Self care;LA6747-5;2;Requires assistance or supervision from another person;;; +28409-1;LL390-6;QAM_1_Self care;LA6748-3;3;Requires use of equipment or device;;; +28409-1;LL390-6;QAM_1_Self care;LA6749-1;4;Full self-care;;; +28410-9;LL390-6;QAM_1_Self care;LA6746-7;1;Dependent/does not participate;;; +28410-9;LL390-6;QAM_1_Self care;LA6747-5;2;Requires assistance or supervision from another person;;; +28410-9;LL390-6;QAM_1_Self care;LA6748-3;3;Requires use of equipment or device;;; +28410-9;LL390-6;QAM_1_Self care;LA6749-1;4;Full self-care;;; +28534-6;LL390-6;QAM_1_Self care;LA6746-7;1;Dependent/does not participate;;; +28534-6;LL390-6;QAM_1_Self care;LA6747-5;2;Requires assistance or supervision from another person;;; +28534-6;LL390-6;QAM_1_Self care;LA6748-3;3;Requires use of equipment or device;;; +28534-6;LL390-6;QAM_1_Self care;LA6749-1;4;Full self-care;;; +28411-7;LL391-4;QAM_2_Personal hygiene;LA6754-1;1;Total care required;;; +28411-7;LL391-4;QAM_2_Personal hygiene;LA6755-8;2;Bed bath required;;; +28411-7;LL391-4;QAM_2_Personal hygiene;LA6756-6;3;Bathes with assistance;;; +28411-7;LL391-4;QAM_2_Personal hygiene;LA6757-4;4;ADLS no assistance;;; +28412-5;LL392-2;QAM_3_Physical performance;LA4270-0;1;Bedridden;;; +28412-5;LL392-2;QAM_3_Physical performance;LA6734-3;2;Symptomatic, in bed >50% day;;; +28412-5;LL392-2;QAM_3_Physical performance;LA6735-0;3;Symptomatic, in bed <50% day;;; +28412-5;LL392-2;QAM_3_Physical performance;LA6736-8;4;Symptomatic, full ADLS;;; +28412-5;LL392-2;QAM_3_Physical performance;LA6737-6;5;Asymptomatic;;; +28413-3;LL393-0;QAM_4_Ambulation;LA6742-6;1;Bedfast;;; +28413-3;LL393-0;QAM_4_Ambulation;LA6743-4;2;Chairbound;;; +28413-3;LL393-0;QAM_4_Ambulation;LA6744-2;3;Walk help;;; +28413-3;LL393-0;QAM_4_Ambulation;LA6745-9;4;Ambulate;;; +28414-1;LL394-8;QAM_5_Activity;LA6738-4;1;Bed rest, can't turn self;;; +28414-1;LL394-8;QAM_5_Activity;LA6739-2;2;Bed rest, turns self;;; +28414-1;LL394-8;QAM_5_Activity;LA6740-0;3;Needs one person to assist;;; +28414-1;LL394-8;QAM_5_Activity;LA6741-8;4;Up ad lib;;; +29885-1;LL2259-1;Actinobacillus;LA19182-7;1;Actinobacillus suis;112272003;Actinobacillus suis (organism);http://snomed.info/sct +29885-1;LL2259-1;Actinobacillus;LA19183-5;2;Actinobacillus pleuropneumoniae;116382001;Actinobacillus pleuropneumoniae (organism);http://snomed.info/sct +29885-1;LL2259-1;Actinobacillus;LA19184-3;3;Actinobacillus porcinus;;; +29887-7;LL2271-6;P mult type;LA13487-6;1;A;;; +29887-7;LL2271-6;P mult type;LA14518-7;2;B;;; +29887-7;LL2271-6;P mult type;LA14520-3;3;D;;; +29887-7;LL2271-6;P mult type;LA13503-0;4;E;;; +29887-7;LL2271-6;P mult type;LA13504-8;5;F;;; +30045-9;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +30045-9;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +30045-9;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +30045-9;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +30045-9;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +30045-9;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +40699-1;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +40699-1;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +40699-1;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +40699-1;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +40699-1;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +40699-1;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +44851-4;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +44851-4;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +44851-4;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +44851-4;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +44851-4;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +44851-4;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +44852-2;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +44852-2;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +44852-2;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +44852-2;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +44852-2;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +44852-2;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +44854-8;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +44854-8;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +44854-8;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +44854-8;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +44854-8;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +44854-8;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +44855-5;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +44855-5;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +44855-5;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +44855-5;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +44855-5;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +44855-5;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +532-2;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +532-2;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +532-2;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +532-2;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +532-2;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +532-2;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +533-0;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +533-0;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +533-0;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +533-0;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +533-0;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +533-0;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +534-8;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +534-8;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +534-8;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +534-8;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +534-8;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +534-8;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +535-5;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +535-5;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +535-5;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +535-5;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +535-5;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +535-5;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +536-3;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +536-3;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +536-3;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +536-3;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +536-3;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +536-3;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +537-1;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +537-1;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +537-1;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +537-1;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +537-1;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +537-1;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +538-9;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +538-9;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +538-9;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +538-9;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +538-9;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +538-9;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +53909-8;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +53909-8;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +53909-8;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +53909-8;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +53909-8;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +53909-8;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +539-7;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +539-7;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +539-7;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +539-7;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +539-7;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +539-7;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +540-5;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +540-5;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +540-5;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +540-5;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +540-5;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +540-5;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +541-3;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +541-3;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +541-3;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +541-3;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +541-3;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +541-3;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +542-1;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +542-1;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +542-1;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +542-1;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +542-1;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +542-1;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +543-9;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +543-9;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +543-9;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +543-9;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +543-9;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +543-9;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +9823-6;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +9823-6;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +9823-6;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +9823-6;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +9823-6;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +9823-6;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +9824-4;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +9824-4;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +9824-4;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +9824-4;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +9824-4;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +9824-4;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +9825-1;LL2286-4;Mycobacteria spp;LA16933-6;1;Mycobacterium abscessus;;; +9825-1;LL2286-4;Mycobacteria spp;LA16934-4;2;Mycobacterium avium/intracellulare;;; +9825-1;LL2286-4;Mycobacteria spp;LA19286-6;3;Mycobacterium bovis;;; +9825-1;LL2286-4;Mycobacteria spp;LA19288-2;4;Mycobacterium chelonae;;; +9825-1;LL2286-4;Mycobacteria spp;LA19287-4;5;Mycobacterium kansasii;;; +9825-1;LL2286-4;Mycobacteria spp;LA16935-1;6;Mycobacterium tuberculosis complex;;; +30361-0;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +30361-0;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +30361-0;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +34147-9;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +34147-9;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +34147-9;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +34597-5;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +34597-5;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +34597-5;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +38998-1;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +38998-1;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +38998-1;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +42600-7;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +42600-7;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +42600-7;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +43180-9;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +43180-9;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +43180-9;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +43238-5;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +43238-5;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +43238-5;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +47358-7;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +47358-7;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +47358-7;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +47359-5;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +47359-5;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +47359-5;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +47360-3;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +47360-3;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +47360-3;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +47361-1;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +47361-1;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +47361-1;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +47364-5;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +47364-5;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +47364-5;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +47365-2;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +47365-2;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +47365-2;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +48345-3;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +48345-3;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +48345-3;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +51916-5;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +51916-5;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +51916-5;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +59052-1;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +59052-1;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +59052-1;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +70051-8;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +70051-8;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +70051-8;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +72376-7;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +72376-7;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +72376-7;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +73905-2;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +73905-2;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +73905-2;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +73906-0;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +73906-0;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +73906-0;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +79189-7;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +79189-7;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +79189-7;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +87439-6;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +87439-6;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +87439-6;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +87440-4;LL2017-3;Reactive w indet (3 answers, ord);LA11884-6;1;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +87440-4;LL2017-3;Reactive w indet (3 answers, ord);LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +87440-4;LL2017-3;Reactive w indet (3 answers, ord);LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +30530-0;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +30530-0;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +30530-0;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +34592-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +34592-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +34592-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +37425-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +37425-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +37425-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +38274-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +38274-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +38274-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +39021-1;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39021-1;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39021-1;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +39023-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39023-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39023-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +39024-5;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +39024-5;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +39024-5;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +44275-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +44275-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +44275-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +48039-2;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48039-2;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +48039-2;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49522-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +49522-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +49522-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +70173-0;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70173-0;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70173-0;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +73685-0;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73685-0;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73685-0;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81705-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81705-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81705-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81706-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81706-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81706-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81710-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +81710-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81710-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +85337-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85337-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85337-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +85339-0;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85339-0;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85339-0;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +85686-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85686-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85686-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +86233-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86233-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86233-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +86323-3;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86323-3;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86323-3;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +87398-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87398-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87398-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90811-1;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90811-1;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90811-1;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90813-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90813-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90813-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90815-2;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90815-2;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90815-2;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90817-8;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90817-8;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90817-8;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90818-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90818-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90818-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90820-2;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90820-2;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90820-2;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90823-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90823-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90823-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90825-1;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90825-1;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90825-1;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90827-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90827-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90827-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90830-1;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90830-1;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90830-1;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90832-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90832-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90832-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90835-0;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90835-0;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90835-0;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90836-8;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90836-8;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90836-8;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90839-2;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90839-2;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90839-2;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90841-8;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90841-8;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90841-8;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90843-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90843-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90843-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90844-2;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90844-2;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90844-2;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90845-9;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90845-9;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90845-9;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92685-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92685-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92685-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92686-5;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92686-5;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92686-5;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92687-3;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92687-3;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92687-3;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92688-1;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92688-1;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92688-1;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92689-9;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92689-9;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92689-9;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92690-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92690-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92690-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92691-5;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92691-5;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92691-5;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92692-3;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92692-3;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92692-3;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92693-1;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92693-1;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92693-1;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92694-9;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92694-9;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92694-9;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92698-0;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92698-0;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92698-0;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92699-8;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92699-8;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92699-8;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92700-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92700-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92700-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92701-2;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +92701-2;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92701-2;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +94425-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94425-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94425-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +94581-6;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94581-6;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94581-6;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +94582-4;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94582-4;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94582-4;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +95971-8;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95971-8;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95971-8;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +97135-8;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97135-8;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97135-8;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +97503-7;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97503-7;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97503-7;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +97916-1;LL2038-9;Pos|Neg|Indeterm;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97916-1;LL2038-9;Pos|Neg|Indeterm;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97916-1;LL2038-9;Pos|Neg|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +30949-2;LL2345-8;Vaccination adverse event outcome;LA19515-8;1;Patient died (date MM/DD/YY);;; +30949-2;LL2345-8;Vaccination adverse event outcome;LA19516-6;2;Life threatening illness;;; +30949-2;LL2345-8;Vaccination adverse event outcome;LA19517-4;3;Required emergency room/doctor visit;;; +30949-2;LL2345-8;Vaccination adverse event outcome;LA19518-2;4;Required hospitalization (____ days);;; +30949-2;LL2345-8;Vaccination adverse event outcome;LA19519-0;5;Resulted in prolongation of hospitalization;;; +30949-2;LL2345-8;Vaccination adverse event outcome;LA19520-8;6;Resulted in permanent disability;;; +30949-2;LL2345-8;Vaccination adverse event outcome;LA9-3;7;None of the above;;; +30971-6;LL2345-8;Vaccination adverse event outcome;LA19515-8;1;Patient died (date MM/DD/YY);;; +30971-6;LL2345-8;Vaccination adverse event outcome;LA19516-6;2;Life threatening illness;;; +30971-6;LL2345-8;Vaccination adverse event outcome;LA19517-4;3;Required emergency room/doctor visit;;; +30971-6;LL2345-8;Vaccination adverse event outcome;LA19518-2;4;Required hospitalization (____ days);;; +30971-6;LL2345-8;Vaccination adverse event outcome;LA19519-0;5;Resulted in prolongation of hospitalization;;; +30971-6;LL2345-8;Vaccination adverse event outcome;LA19520-8;6;Resulted in permanent disability;;; +30971-6;LL2345-8;Vaccination adverse event outcome;LA9-3;7;None of the above;;; +30951-8;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +30951-8;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +30951-8;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66161-1;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66161-1;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66161-1;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +68350-8;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68350-8;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68350-8;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +68352-4;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68352-4;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68352-4;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +68353-2;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68353-2;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68353-2;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +68354-0;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +68354-0;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +68354-0;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75610-6;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75610-6;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75610-6;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75611-4;LL1362-4;PhenX12_83;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75611-4;LL1362-4;PhenX12_83;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75611-4;LL1362-4;PhenX12_83;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +30962-5;LL2347-4;Site vaccine administered;LA19523-2;1;Private doctor's office/hospital;;; +30962-5;LL2347-4;Site vaccine administered;LA19524-0;2;Public health clinic/hospital;;; +30962-5;LL2347-4;Site vaccine administered;LA19525-7;3;Military clinic/hospital;;; +30962-5;LL2347-4;Site vaccine administered;LA19526-5;4;Other/Unknown;;; +30963-3;LL2348-2;Funds vaccine purchased with;LA19527-3;1;Private funds;;; +30963-3;LL2348-2;Funds vaccine purchased with;LA19528-1;2;Public funds;;; +30963-3;LL2348-2;Funds vaccine purchased with;LA19529-9;3;Military funds;;; +30963-3;LL2348-2;Funds vaccine purchased with;LA19526-5;4;Other/Unknown;;; +30967-4;LL2349-0;Reported event previously;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +30967-4;LL2349-0;Reported event previously;LA19530-7;2;To doctor;;; +30967-4;LL2349-0;Reported event previously;LA19531-5;3;To health department;;; +30967-4;LL2349-0;Reported event previously;LA19532-3;4;To manufacturer;;; +30978-1;LL2350-8;Report type;LA6662-6;1;Initial;;; +30978-1;LL2350-8;Report type;LA9177-2;2;Follow-up;;; +80245-4;LL2350-8;Report type;LA6662-6;1;Initial;;; +80245-4;LL2350-8;Report type;LA9177-2;2;Follow-up;;; +31034-2;LL5864-5;Body sites for vaccination;LA29192-4;2;Upper Extremity-Left;;; +31034-2;LL5864-5;Body sites for vaccination;LA29191-6;3;Upper Extremity-Right;;; +31034-2;LL5864-5;Body sites for vaccination;LA24413-9;4;Lower Extremity-Left;;; +31034-2;LL5864-5;Body sites for vaccination;LA24414-7;5;Lower Extremity-Right;;; +31044-1;LL3209-5;Immunization reactions;LA7460-4;0;Pain;;; +31044-1;LL3209-5;Immunization reactions;LA22435-4;1;Hypotonic;;; +31044-1;LL3209-5;Immunization reactions;LA7435-6;2;Fever;;; +31044-1;LL3209-5;Immunization reactions;LA22437-0;3;Encephalopathy, disorder of the brain;;; +31044-1;LL3209-5;Immunization reactions;LA22438-8;4;Anaphylaxis within 24 hours;;; +31044-1;LL3209-5;Immunization reactions;LA22439-6;5;Redness;;; +31044-1;LL3209-5;Immunization reactions;LA22440-4;6;Swelling;;; +31210-8;LL130-6;CR_1760_Vital status follow up;LA4203-1;1;Dead (COC);;; +31210-8;LL130-6;CR_1760_Vital status follow up;LA4247-8;2;Alive;;; +31210-8;LL130-6;CR_1760_Vital status follow up;LA4195-9;3;Dead (SEER);;; +3143-5;LL5704-3;Related|Unrelated|Cord blood;LA31343-9;1;Related;;; +3143-5;LL5704-3;Related|Unrelated|Cord blood;LA31345-4;2;Unrelated;;; +3143-5;LL5704-3;Related|Unrelated|Cord blood;LA31344-7;3;Cord blood;;; +3143-5;LL5704-3;Related|Unrelated|Cord blood;LA31343-9;1;Related;;; +3143-5;LL5704-3;Related|Unrelated|Cord blood;LA31345-4;2;Unrelated;;; +3143-5;LL5704-3;Related|Unrelated|Cord blood;LA31344-7;3;Cord blood;;; +3150-0;LL738-6;O2_mask;LA11849-9;1;Room air;;; +3150-0;LL738-6;O2_mask;LA11856-4;2;24% mask;;; +3150-0;LL738-6;O2_mask;LA11857-2;3;28% mask;;; +3150-0;LL738-6;O2_mask;LA11858-0;4;31% mask;;; +3150-0;LL738-6;O2_mask;LA11859-8;5;35% mask;;; +3150-0;LL738-6;O2_mask;LA11860-6;6;40% mask;;; +3150-0;LL738-6;O2_mask;LA11861-4;7;50% mask;;; +3151-8;LL737-8;O2_nasal;LA11849-9;1;Room air;;; +3151-8;LL737-8;O2_nasal;LA11850-7;2;1 liter/min;;; +3151-8;LL737-8;O2_nasal;LA11851-5;3;2 liters/min;;; +3151-8;LL737-8;O2_nasal;LA11852-3;4;3 liters/min;;; +3151-8;LL737-8;O2_nasal;LA11853-1;5;4 liters/min;;; +3151-8;LL737-8;O2_nasal;LA11854-9;6;5 liters/min;;; +3151-8;LL737-8;O2_nasal;LA11855-6;7;6 liters/min;;; +32286-7;LL2254-2;HCV genotype;LA6112-2;1;1;;; +32286-7;LL2254-2;HCV genotype;LA6113-0;2;2;;; +32286-7;LL2254-2;HCV genotype;LA6114-8;3;3;;; +32286-7;LL2254-2;HCV genotype;LA6115-5;4;4;;; +32286-7;LL2254-2;HCV genotype;LA10137-0;5;5;;; +32286-7;LL2254-2;HCV genotype;LA10138-8;6;6;;; +32286-7;LL2254-2;HCV genotype;LA11883-8;7;Not detected;;; +48574-8;LL2254-2;HCV genotype;LA6112-2;1;1;;; +48574-8;LL2254-2;HCV genotype;LA6113-0;2;2;;; +48574-8;LL2254-2;HCV genotype;LA6114-8;3;3;;; +48574-8;LL2254-2;HCV genotype;LA6115-5;4;4;;; +48574-8;LL2254-2;HCV genotype;LA10137-0;5;5;;; +48574-8;LL2254-2;HCV genotype;LA10138-8;6;6;;; +48574-8;LL2254-2;HCV genotype;LA11883-8;7;Not detected;;; +48575-5;LL2254-2;HCV genotype;LA6112-2;1;1;;; +48575-5;LL2254-2;HCV genotype;LA6113-0;2;2;;; +48575-5;LL2254-2;HCV genotype;LA6114-8;3;3;;; +48575-5;LL2254-2;HCV genotype;LA6115-5;4;4;;; +48575-5;LL2254-2;HCV genotype;LA10137-0;5;5;;; +48575-5;LL2254-2;HCV genotype;LA10138-8;6;6;;; +48575-5;LL2254-2;HCV genotype;LA11883-8;7;Not detected;;; +49607-5;LL2254-2;HCV genotype;LA6112-2;1;1;;; +49607-5;LL2254-2;HCV genotype;LA6113-0;2;2;;; +49607-5;LL2254-2;HCV genotype;LA6114-8;3;3;;; +49607-5;LL2254-2;HCV genotype;LA6115-5;4;4;;; +49607-5;LL2254-2;HCV genotype;LA10137-0;5;5;;; +49607-5;LL2254-2;HCV genotype;LA10138-8;6;6;;; +49607-5;LL2254-2;HCV genotype;LA11883-8;7;Not detected;;; +92731-9;LL2254-2;HCV genotype;LA6112-2;1;1;;; +92731-9;LL2254-2;HCV genotype;LA6113-0;2;2;;; +92731-9;LL2254-2;HCV genotype;LA6114-8;3;3;;; +92731-9;LL2254-2;HCV genotype;LA6115-5;4;4;;; +92731-9;LL2254-2;HCV genotype;LA10137-0;5;5;;; +92731-9;LL2254-2;HCV genotype;LA10138-8;6;6;;; +92731-9;LL2254-2;HCV genotype;LA11883-8;7;Not detected;;; +32366-7;LL2253-4;HBV genotype;LA13487-6;1;A;;; +32366-7;LL2253-4;HBV genotype;LA14518-7;2;B;;; +32366-7;LL2253-4;HBV genotype;LA14519-5;3;C;;; +32366-7;LL2253-4;HBV genotype;LA14520-3;4;D;;; +32366-7;LL2253-4;HBV genotype;LA13503-0;5;E;;; +32366-7;LL2253-4;HBV genotype;LA13504-8;6;F;;; +32366-7;LL2253-4;HBV genotype;LA19150-4;7;G;;; +32366-7;LL2253-4;HBV genotype;LA19174-4;8;H;;; +32368-3;LL2238-5;Ureaplasma;LA18630-6;1;Ureaplasma urealyticum;12006007;Ureaplasma urealyticum (organism);http://snomed.info/sct +32368-3;LL2238-5;Ureaplasma;LA19123-1;2;Ureaplasma cati;;; +32368-3;LL2238-5;Ureaplasma;LA19124-9;3;Ureaplasma gallorale;;; +32368-3;LL2238-5;Ureaplasma;LA19122-3;4;Ureaplasma parvum;;; +32369-1;LL2251-8;enterotoxin - Staph/Clost;LA13487-6;1;A;;; +32369-1;LL2251-8;enterotoxin - Staph/Clost;LA14518-7;2;B;;; +32369-1;LL2251-8;enterotoxin - Staph/Clost;LA14519-5;3;C;;; +32369-1;LL2251-8;enterotoxin - Staph/Clost;LA14520-3;4;D;;; +32369-1;LL2251-8;enterotoxin - Staph/Clost;LA13503-0;5;E;;; +33865-7;LL2251-8;enterotoxin - Staph/Clost;LA13487-6;1;A;;; +33865-7;LL2251-8;enterotoxin - Staph/Clost;LA14518-7;2;B;;; +33865-7;LL2251-8;enterotoxin - Staph/Clost;LA14519-5;3;C;;; +33865-7;LL2251-8;enterotoxin - Staph/Clost;LA14520-3;4;D;;; +33865-7;LL2251-8;enterotoxin - Staph/Clost;LA13503-0;5;E;;; +32401-2;LL384-9;Apgar_1_Color;LA6722-8;1;The baby's whole body is completely bluish-gray or pale;;; +32401-2;LL384-9;Apgar_1_Color;LA6723-6;2;Good color in body with bluish hands or feet;;; +32401-2;LL384-9;Apgar_1_Color;LA6724-4;3;Good color all over;;; +32406-1;LL384-9;Apgar_1_Color;LA6722-8;1;The baby's whole body is completely bluish-gray or pale;;; +32406-1;LL384-9;Apgar_1_Color;LA6723-6;2;Good color in body with bluish hands or feet;;; +32406-1;LL384-9;Apgar_1_Color;LA6724-4;3;Good color all over;;; +32411-1;LL384-9;Apgar_1_Color;LA6722-8;1;The baby's whole body is completely bluish-gray or pale;;; +32411-1;LL384-9;Apgar_1_Color;LA6723-6;2;Good color in body with bluish hands or feet;;; +32411-1;LL384-9;Apgar_1_Color;LA6724-4;3;Good color all over;;; +32402-0;LL385-6;Apgar_2_Pulse;LA6716-0;1;No heart rate;;; +32402-0;LL385-6;Apgar_2_Pulse;LA6717-8;2;Fewer than 100 beats per minute;;; +32402-0;LL385-6;Apgar_2_Pulse;LA6718-6;3;At least 100 beats per minute;;; +32407-9;LL385-6;Apgar_2_Pulse;LA6716-0;1;No heart rate;;; +32407-9;LL385-6;Apgar_2_Pulse;LA6717-8;2;Fewer than 100 beats per minute;;; +32407-9;LL385-6;Apgar_2_Pulse;LA6718-6;3;At least 100 beats per minute;;; +32412-9;LL385-6;Apgar_2_Pulse;LA6716-0;1;No heart rate;;; +32412-9;LL385-6;Apgar_2_Pulse;LA6717-8;2;Fewer than 100 beats per minute;;; +32412-9;LL385-6;Apgar_2_Pulse;LA6718-6;3;At least 100 beats per minute;;; +32403-8;LL387-2;Apgar_4_Activity;LA6713-7;1;"Limp; no movement";;; +32403-8;LL387-2;Apgar_4_Activity;LA6714-5;2;Some flexion of arms and legs;;; +32403-8;LL387-2;Apgar_4_Activity;LA6715-2;3;Active motion;;; +32408-7;LL387-2;Apgar_4_Activity;LA6713-7;1;"Limp; no movement";;; +32408-7;LL387-2;Apgar_4_Activity;LA6714-5;2;Some flexion of arms and legs;;; +32408-7;LL387-2;Apgar_4_Activity;LA6715-2;3;Active motion;;; +32413-7;LL387-2;Apgar_4_Activity;LA6713-7;1;"Limp; no movement";;; +32413-7;LL387-2;Apgar_4_Activity;LA6714-5;2;Some flexion of arms and legs;;; +32413-7;LL387-2;Apgar_4_Activity;LA6715-2;3;Active motion;;; +32404-6;LL386-4;Apgar_3_Grimace;LA6719-4;1;No response to airways being suctioned;;; +32404-6;LL386-4;Apgar_3_Grimace;LA6720-2;2;Grimace during suctioning;;; +32404-6;LL386-4;Apgar_3_Grimace;LA6721-0;3;Grimace and pulling away, cough, or sneeze during suctioning;;; +32409-5;LL386-4;Apgar_3_Grimace;LA6719-4;1;No response to airways being suctioned;;; +32409-5;LL386-4;Apgar_3_Grimace;LA6720-2;2;Grimace during suctioning;;; +32409-5;LL386-4;Apgar_3_Grimace;LA6721-0;3;Grimace and pulling away, cough, or sneeze during suctioning;;; +32414-5;LL386-4;Apgar_3_Grimace;LA6719-4;1;No response to airways being suctioned;;; +32414-5;LL386-4;Apgar_3_Grimace;LA6720-2;2;Grimace during suctioning;;; +32414-5;LL386-4;Apgar_3_Grimace;LA6721-0;3;Grimace and pulling away, cough, or sneeze during suctioning;;; +32405-3;LL388-0;Apgar_5_Respiration;LA6725-1;1;Not breathing;;; +32405-3;LL388-0;Apgar_5_Respiration;LA6726-9;2;"Weak cry; may sound like whimpering, slow or irregular breathing";;; +32405-3;LL388-0;Apgar_5_Respiration;LA6727-7;3;"Good, strong cry; normal rate and effort of breathing";;; +32410-3;LL388-0;Apgar_5_Respiration;LA6725-1;1;Not breathing;;; +32410-3;LL388-0;Apgar_5_Respiration;LA6726-9;2;"Weak cry; may sound like whimpering, slow or irregular breathing";;; +32410-3;LL388-0;Apgar_5_Respiration;LA6727-7;3;"Good, strong cry; normal rate and effort of breathing";;; +32415-2;LL388-0;Apgar_5_Respiration;LA6725-1;1;Not breathing;;; +32415-2;LL388-0;Apgar_5_Respiration;LA6726-9;2;"Weak cry; may sound like whimpering, slow or irregular breathing";;; +32415-2;LL388-0;Apgar_5_Respiration;LA6727-7;3;"Good, strong cry; normal rate and effort of breathing";;; +32419-4;LL4459-5;Pain quality;LA27491-2;1;Ache;;; +32419-4;LL4459-5;Pain quality;LA25279-3;2;Burning;;; +32419-4;LL4459-5;Pain quality;LA27492-0;3;Cramping;;; +32419-4;LL4459-5;Pain quality;LA27493-8;4;Crushing pain;;; +32419-4;LL4459-5;Pain quality;LA12709-4;5;Dull;;; +32419-4;LL4459-5;Pain quality;LA24760-3;6;Intermittent;;; +32419-4;LL4459-5;Pain quality;LA27496-1;7;Phantom limb;;; +32419-4;LL4459-5;Pain quality;LA27497-9;8;Piercing;;; +32419-4;LL4459-5;Pain quality;LA27498-7;9;Pressure;;; +32419-4;LL4459-5;Pain quality;LA27499-5;10;Pruritus;;; +32419-4;LL4459-5;Pain quality;LA12708-6;11;Sharp;;; +32419-4;LL4459-5;Pain quality;LA27501-8;12;Shock-like electrical pain;;; +32419-4;LL4459-5;Pain quality;LA27502-6;13;Stabbing;;; +32419-4;LL4459-5;Pain quality;LA27503-4;14;Tearing pain;;; +32419-4;LL4459-5;Pain quality;LA27505-9;15;Throbbing;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33360-1;1;Breath sounds-absent;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33354-4;2;Breath sounds-decreased;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA18402-0;3;Breath sounds-equal;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33362-7;4;Breath sounds-normal;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA18226-3;5;Foreign body;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA17232-2;6;Increased respiratory effort;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA6626-1;7;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +32449-1;LL6223-3;NEMSIS_Lung assessment;LA6630-3;8;Not done;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA7460-4;9;Pain;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33356-9;10;Pain with inspiraton/expiration;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33355-1;11;Rales;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33363-5;12;Rhonchi;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA17236-3;13;Rhonchi/wheezing;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA17612-5;14;Stridor;70407001;stridor (finding);http://snomed.info/sct +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33364-3;15;Wheezing-expiratory;;; +32449-1;LL6223-3;NEMSIS_Lung assessment;LA33365-0;16;Wheezing-inspiratory;;; +32455-8;LL3843-1;Muscle tone;LA25259-5;1;Muscle tone asymmetric;406146007;Asymmetric muscle tone (finding);http://snomed.info/sct +32455-8;LL3843-1;Muscle tone;LA25260-3;2;Decreased muscle tone;398151007;decreased muscle tone (finding);http://snomed.info/sct +32455-8;LL3843-1;Muscle tone;LA25261-1;3;Flaccid muscle;186611004;Flaccidity of muscle (finding);http://snomed.info/sct +32455-8;LL3843-1;Muscle tone;LA25262-9;4;Fluctuating muscle tone;250076001;fluctuating muscle tone (finding);http://snomed.info/sct +32455-8;LL3843-1;Muscle tone;LA25263-7;5;Rigor;;; +32624-9;LL4960-2;ADAPTABLE Race list;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +32624-9;LL4960-2;ADAPTABLE Race list;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +32624-9;LL4960-2;ADAPTABLE Race list;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +32624-9;LL4960-2;ADAPTABLE Race list;LA4457-3;4;White;2106-3;White;https://www.cdc.gov/phin +32624-9;LL4960-2;ADAPTABLE Race list;LA28802-9;5;Multiple races;;; +32624-9;LL4960-2;ADAPTABLE Race list;LA46-8;6;Other;2131-1;Other Race;https://www.cdc.gov/phin +32624-9;LL4960-2;ADAPTABLE Race list;LA28803-7;7;Prefer not to say;;; +32624-9;LL5348-9;PRAPARE_Race;LA6156-9;1;Asian;2028-9;Asian;https://www.cdc.gov/phin +32624-9;LL5348-9;PRAPARE_Race;LA14045-1;2;Native Hawaiian;;; +32624-9;LL5348-9;PRAPARE_Race;LA30187-1;3;Pacific Islander;;; +32624-9;LL5348-9;PRAPARE_Race;LA14042-8;4;Black/African American;2054-5;Black or African American;https://www.cdc.gov/phin +32624-9;LL5348-9;PRAPARE_Race;LA4457-3;5;White;2106-3;White;https://www.cdc.gov/phin +32624-9;LL5348-9;PRAPARE_Race;LA4-4;6;American Indian/Alaskan Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +32624-9;LL5348-9;PRAPARE_Race;LA46-8;7;Other;2131-1;Other Race;https://www.cdc.gov/phin +32624-9;LL5348-9;PRAPARE_Race;LA30122-8;8;I choose not to answer this question;;; +32624-9;LL6100-3;NEI Race List;LA4457-3;1;White;;; +32624-9;LL6100-3;NEI Race List;LA10610-6;2;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +32624-9;LL6100-3;NEI Race List;LA6155-1;3;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +32624-9;LL6100-3;NEI Race List;LA14048-5;4;Asian Indian;;; +32624-9;LL6100-3;NEI Race List;LA6156-9;5;Asian;2028-9;Asian;https://www.cdc.gov/phin +32624-9;LL6100-3;NEI Race List;LA32763-7;6;Samoan or Native Hawaiian;;; +32624-9;LL6100-3;NEI Race List;LA14047-7;7;Other Pacific Islander;;; +32624-9;LL6100-3;NEI Race List;LA46-8;8;Other;;; +32870-8;LL476-3;D40_Facial land mark;LA9245-7;1;Trichion;;; +32870-8;LL476-3;D40_Facial land mark;LA9246-5;2;Gnathion;;; +32870-8;LL476-3;D40_Facial land mark;LA9247-3;3;Menton;;; +32870-8;LL476-3;D40_Facial land mark;LA9248-1;4;Subnasale;;; +32870-8;LL476-3;D40_Facial land mark;LA9251-5;5;Pronasale;;; +32870-8;LL476-3;D40_Facial land mark;LA9252-3;6;Alar base (nasal base);;; +32870-8;LL476-3;D40_Facial land mark;LA9253-1;7;Nasal tip;;; +32870-8;LL476-3;D40_Facial land mark;LA9254-9;8;Infrarbital rim;;; +32870-8;LL476-3;D40_Facial land mark;LA9255-6;9;Anterior globe;;; +32870-8;LL476-3;D40_Facial land mark;LA9256-4;10;Supraorbital rim;;; +32870-8;LL476-3;D40_Facial land mark;LA9257-2;11;Sub-pupil;;; +32870-8;LL476-3;D40_Facial land mark;LA9258-0;12;Cheek bone;;; +32870-8;LL476-3;D40_Facial land mark;LA9259-8;13;Chin midline;;; +32870-8;LL476-3;D40_Facial land mark;LA9260-6;14;Maxillary midline;;; +32870-8;LL476-3;D40_Facial land mark;LA9261-4;15;Mandibular midline;;; +32870-8;LL476-3;D40_Facial land mark;LA9262-2;16;Philtrum;;; +32870-8;LL476-3;D40_Facial land mark;LA9263-0;17;Nasal;;; +32871-6;LL476-3;D40_Facial land mark;LA9245-7;1;Trichion;;; +32871-6;LL476-3;D40_Facial land mark;LA9246-5;2;Gnathion;;; +32871-6;LL476-3;D40_Facial land mark;LA9247-3;3;Menton;;; +32871-6;LL476-3;D40_Facial land mark;LA9248-1;4;Subnasale;;; +32871-6;LL476-3;D40_Facial land mark;LA9251-5;5;Pronasale;;; +32871-6;LL476-3;D40_Facial land mark;LA9252-3;6;Alar base (nasal base);;; +32871-6;LL476-3;D40_Facial land mark;LA9253-1;7;Nasal tip;;; +32871-6;LL476-3;D40_Facial land mark;LA9254-9;8;Infrarbital rim;;; +32871-6;LL476-3;D40_Facial land mark;LA9255-6;9;Anterior globe;;; +32871-6;LL476-3;D40_Facial land mark;LA9256-4;10;Supraorbital rim;;; +32871-6;LL476-3;D40_Facial land mark;LA9257-2;11;Sub-pupil;;; +32871-6;LL476-3;D40_Facial land mark;LA9258-0;12;Cheek bone;;; +32871-6;LL476-3;D40_Facial land mark;LA9259-8;13;Chin midline;;; +32871-6;LL476-3;D40_Facial land mark;LA9260-6;14;Maxillary midline;;; +32871-6;LL476-3;D40_Facial land mark;LA9261-4;15;Mandibular midline;;; +32871-6;LL476-3;D40_Facial land mark;LA9262-2;16;Philtrum;;; +32871-6;LL476-3;D40_Facial land mark;LA9263-0;17;Nasal;;; +32881-5;LL477-1;D41_Dental probing response;LA9264-8;1;Bleeding on probing;;; +32881-5;LL477-1;D41_Dental probing response;LA9265-5;2;Pus on probing;;; +32882-3;LL480-5;D44_Reason for dental eval;LA9275-4;1;Accession;;; +32882-3;LL480-5;D44_Reason for dental eval;LA9276-2;2;Lost paper record;;; +32882-3;LL480-5;D44_Reason for dental eval;LA9277-0;3;Family member;;; +32882-3;LL480-5;D44_Reason for dental eval;LA9278-8;4;Overseas screening;;; +32882-3;LL480-5;D44_Reason for dental eval;LA9279-6;5;Checkup;;; +32882-3;LL480-5;D44_Reason for dental eval;LA9280-4;6;Patient required comprehensive oral evaluation;;; +32882-3;LL480-5;D44_Reason for dental eval;LA6484-5;7;Limited;;; +32883-1;LL478-9;D42_Dental arch;LA9267-1;1;Maxilla;;; +32883-1;LL478-9;D42_Dental arch;LA9268-9;2;Mandible;;; +32888-0;LL479-7;D43_Probe site;LA9269-7;1;Facial;;; +32888-0;LL479-7;D43_Probe site;LA9270-5;2;Mesiofacial;;; +32888-0;LL479-7;D43_Probe site;LA9271-3;3;Distofacial;;; +32888-0;LL479-7;D43_Probe site;LA9272-1;4;Lingual;;; +32888-0;LL479-7;D43_Probe site;LA9273-9;5;Distolingual;;; +32888-0;LL479-7;D43_Probe site;LA9274-7;6;Mesiolingual;;; +32948-2;LL472-2;D36_Ear size;LA9230-9;1;Anotia;;; +32948-2;LL472-2;D36_Ear size;LA9231-7;2;Microtia;;; +32948-2;LL472-2;D36_Ear size;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +32948-2;LL472-2;D36_Ear size;LA9232-5;4;Macrotia;;; +32949-0;LL472-2;D36_Ear size;LA9230-9;1;Anotia;;; +32949-0;LL472-2;D36_Ear size;LA9231-7;2;Microtia;;; +32949-0;LL472-2;D36_Ear size;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +32949-0;LL472-2;D36_Ear size;LA9232-5;4;Macrotia;;; +32956-5;LL462-3;D27_Dental shape;LA9189-7;1;U shape;;; +32956-5;LL462-3;D27_Dental shape;LA9190-5;2;V shape;;; +32956-5;LL462-3;D27_Dental shape;LA9191-3;3;Narrow;;; +32956-5;LL462-3;D27_Dental shape;LA9192-1;4;broad;;; +32956-5;LL462-3;D27_Dental shape;LA9193-9;5;High;;; +32956-5;LL462-3;D27_Dental shape;LA9194-7;6;Low;;; +32956-5;LL462-3;D27_Dental shape;LA8933-9;7;Under contour;;; +32956-5;LL462-3;D27_Dental shape;LA9196-2;8;knife edge;;; +32957-3;LL469-8;D33_Palate shape;LA9211-9;1;Curved;;; +32957-3;LL469-8;D33_Palate shape;LA9212-7;2;Flat;;; +32957-3;LL469-8;D33_Palate shape;LA9213-5;3;Vaulted;;; +32958-1;LL466-4;D30_Crown shape;LA9203-6;1;Square;;; +32958-1;LL466-4;D30_Crown shape;LA9204-4;2;Tapering;;; +32958-1;LL466-4;D30_Crown shape;LA9205-1;3;Ovoid;;; +32959-9;LL470-6;D34_Root shape;LA9214-3;1;Taper root;;; +32959-9;LL470-6;D34_Root shape;LA9215-0;2;Multi-root;;; +32959-9;LL470-6;D34_Root shape;LA9216-8;3;Tripod root;;; +32959-9;LL470-6;D34_Root shape;LA9217-6;4;Curved root;;; +32959-9;LL470-6;D34_Root shape;LA9218-4;5;Dilacerated root;;; +32959-9;LL470-6;D34_Root shape;LA9219-2;6;Straight root;;; +32959-9;LL470-6;D34_Root shape;LA9220-0;7;Thin (spindled) root;;; +32959-9;LL470-6;D34_Root shape;LA9221-8;8;Thick root;;; +32959-9;LL470-6;D34_Root shape;LA9222-6;9;Single root;;; +32959-9;LL470-6;D34_Root shape;LA9223-4;10;Bayonet;;; +32959-9;LL470-6;D34_Root shape;LA9224-2;11;Fused;;; +32959-9;LL470-6;D34_Root shape;LA9225-9;12;C-shaped;;; +32959-9;LL470-6;D34_Root shape;LA9226-7;13;Conical;;; +32960-7;LL474-8;D38_Transverse section shape;LA9234-1;1;Tapered arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9235-8;2;Ovoid arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9236-6;3;Mid-buccal constricted (hour glass shape) arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9200-2;4;Square anterior arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9201-0;5;V-Shaped anterior arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9239-0;6;U-shaped (broad) arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9240-8;7;Tapered-ovoid arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9241-6;8;Constricted arch form;;; +32960-7;LL474-8;D38_Transverse section shape;LA9202-8;9;Mutilated anterior arch form;;; +32961-5;LL463-1;D28_Anterior segment shape;LA9197-0;1;Tapered anterior arch form;;; +32961-5;LL463-1;D28_Anterior segment shape;LA9199-6;2;Ovoid anterior arch form;;; +32961-5;LL463-1;D28_Anterior segment shape;LA9200-2;3;Square anterior arch form;;; +32961-5;LL463-1;D28_Anterior segment shape;LA9201-0;4;V-Shaped anterior arch form;;; +32961-5;LL463-1;D28_Anterior segment shape;LA9202-8;5;Mutilated anterior arch form;;; +32962-3;LL465-6;D29_Risk;LA9194-7;1;Low;;; +32962-3;LL465-6;D29_Risk;LA6751-7;2;Moderate;;; +32962-3;LL465-6;D29_Risk;LA9193-9;3;High;;; +32963-1;LL465-6;D29_Risk;LA9194-7;1;Low;;; +32963-1;LL465-6;D29_Risk;LA6751-7;2;Moderate;;; +32963-1;LL465-6;D29_Risk;LA9193-9;3;High;;; +79900-7;LL465-6;D29_Risk;LA9194-7;1;Low;;; +79900-7;LL465-6;D29_Risk;LA6751-7;2;Moderate;;; +79900-7;LL465-6;D29_Risk;LA9193-9;3;High;;; +93374-7;LL465-6;D29_Risk;LA9194-7;1;Low;;; +93374-7;LL465-6;D29_Risk;LA6751-7;2;Moderate;;; +93374-7;LL465-6;D29_Risk;LA9193-9;3;High;;; +99056-4;LL465-6;D29_Risk;LA9194-7;1;Low;;; +99056-4;LL465-6;D29_Risk;LA6751-7;2;Moderate;;; +99056-4;LL465-6;D29_Risk;LA9193-9;3;High;;; +32964-9;LL467-2;D31_Prognosis;LA9206-9;1;Excellent;;; +32964-9;LL467-2;D31_Prognosis;LA8967-7;2;Good;;; +32964-9;LL467-2;D31_Prognosis;LA8968-5;3;Fair;;; +32964-9;LL467-2;D31_Prognosis;LA9207-7;4;Questionable;;; +32964-9;LL467-2;D31_Prognosis;LA8969-3;5;Poor;;; +32964-9;LL467-2;D31_Prognosis;LA9208-5;6;Hopeless;;; +32965-6;LL467-2;D31_Prognosis;LA9206-9;1;Excellent;;; +32965-6;LL467-2;D31_Prognosis;LA8967-7;2;Good;;; +32965-6;LL467-2;D31_Prognosis;LA8968-5;3;Fair;;; +32965-6;LL467-2;D31_Prognosis;LA9207-7;4;Questionable;;; +32965-6;LL467-2;D31_Prognosis;LA8969-3;5;Poor;;; +32965-6;LL467-2;D31_Prognosis;LA9208-5;6;Hopeless;;; +32966-4;LL467-2;D31_Prognosis;LA9206-9;1;Excellent;;; +32966-4;LL467-2;D31_Prognosis;LA8967-7;2;Good;;; +32966-4;LL467-2;D31_Prognosis;LA8968-5;3;Fair;;; +32966-4;LL467-2;D31_Prognosis;LA9207-7;4;Questionable;;; +32966-4;LL467-2;D31_Prognosis;LA8969-3;5;Poor;;; +32966-4;LL467-2;D31_Prognosis;LA9208-5;6;Hopeless;;; +32967-2;LL471-4;D35_Root apex develop;LA9227-5;1;Open;;; +32967-2;LL471-4;D35_Root apex develop;LA9228-3;2;Closed;;; +32967-2;LL471-4;D35_Root apex develop;LA9229-1;3;Blunderbuss;;; +32968-0;LL468-0;D32_Eruption-exfoliation;LA9209-3;1;Premature;;; +32968-0;LL468-0;D32_Eruption-exfoliation;LA4439-1;2;Within Normal Limits;;; +32968-0;LL468-0;D32_Eruption-exfoliation;LA7305-1;3;Delayed;;; +32969-8;LL468-0;D32_Eruption-exfoliation;LA9209-3;1;Premature;;; +32969-8;LL468-0;D32_Eruption-exfoliation;LA4439-1;2;Within Normal Limits;;; +32969-8;LL468-0;D32_Eruption-exfoliation;LA7305-1;3;Delayed;;; +32970-6;LL468-0;D32_Eruption-exfoliation;LA9209-3;1;Premature;;; +32970-6;LL468-0;D32_Eruption-exfoliation;LA4439-1;2;Within Normal Limits;;; +32970-6;LL468-0;D32_Eruption-exfoliation;LA7305-1;3;Delayed;;; +32971-4;LL468-0;D32_Eruption-exfoliation;LA9209-3;1;Premature;;; +32971-4;LL468-0;D32_Eruption-exfoliation;LA4439-1;2;Within Normal Limits;;; +32971-4;LL468-0;D32_Eruption-exfoliation;LA7305-1;3;Delayed;;; +32972-2;LL468-0;D32_Eruption-exfoliation;LA9209-3;1;Premature;;; +32972-2;LL468-0;D32_Eruption-exfoliation;LA4439-1;2;Within Normal Limits;;; +32972-2;LL468-0;D32_Eruption-exfoliation;LA7305-1;3;Delayed;;; +32974-8;LL473-0;D37_Dental arch size;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +32974-8;LL473-0;D37_Dental arch size;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +32974-8;LL473-0;D37_Dental arch size;LA8982-6;3;Medium;;; +32974-8;LL473-0;D37_Dental arch size;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +32975-5;LL475-5;D39_Vertical displacement;LA9243-2;1;Superior displacement;;; +32975-5;LL475-5;D39_Vertical displacement;LA4439-1;2;Within Normal Limits;;; +32975-5;LL475-5;D39_Vertical displacement;LA9244-0;3;Inferior displacement;;; +32976-3;LL475-5;D39_Vertical displacement;LA9243-2;1;Superior displacement;;; +32976-3;LL475-5;D39_Vertical displacement;LA4439-1;2;Within Normal Limits;;; +32976-3;LL475-5;D39_Vertical displacement;LA9244-0;3;Inferior displacement;;; +32977-1;LL475-5;D39_Vertical displacement;LA9243-2;1;Superior displacement;;; +32977-1;LL475-5;D39_Vertical displacement;LA4439-1;2;Within Normal Limits;;; +32977-1;LL475-5;D39_Vertical displacement;LA9244-0;3;Inferior displacement;;; +32978-9;LL475-5;D39_Vertical displacement;LA9243-2;1;Superior displacement;;; +32978-9;LL475-5;D39_Vertical displacement;LA4439-1;2;Within Normal Limits;;; +32978-9;LL475-5;D39_Vertical displacement;LA9244-0;3;Inferior displacement;;; +32979-7;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32979-7;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32979-7;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32980-5;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32980-5;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32980-5;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32981-3;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32981-3;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32981-3;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32982-1;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32982-1;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32982-1;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32983-9;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32983-9;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32983-9;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32984-7;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32984-7;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32984-7;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32985-4;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32985-4;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32985-4;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32986-2;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32986-2;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32986-2;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32987-0;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32987-0;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32987-0;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32988-8;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32988-8;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32988-8;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32989-6;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32989-6;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32989-6;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32990-4;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32990-4;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32990-4;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32991-2;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32991-2;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32991-2;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32992-0;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32992-0;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32992-0;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32993-8;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32993-8;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32993-8;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +32994-6;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +32994-6;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +32994-6;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +33769-1;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +33769-1;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +33769-1;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +33770-9;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +33770-9;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +33770-9;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +34031-5;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +34031-5;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +34031-5;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +34032-3;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +34032-3;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +34032-3;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +73574-6;LL438-3;Good|Fair|Poor;LA8967-7;1;Good;;; +73574-6;LL438-3;Good|Fair|Poor;LA8968-5;2;Fair;;; +73574-6;LL438-3;Good|Fair|Poor;LA8969-3;3;Poor;;; +33035-7;LL2449-8;Semen analysis reason;LA19798-0;1;Fertility;;; +33035-7;LL2449-8;Semen analysis reason;LA19799-8;2;Post vasectomy;;; +33035-7;LL2449-8;Semen analysis reason;LA19800-4;3;Reanastomosis;;; +33443-3;LL2444-9;Type intubation tube;LA19779-0;1;Endotracheal tube;;; +33443-3;LL2444-9;Type intubation tube;LA19780-8;2;Nasalendotracheal tube;;; +33443-3;LL2444-9;Type intubation tube;LA19781-6;3;Oralendotracheal tube;;; +33443-3;LL2444-9;Type intubation tube;LA18004-4;4;Tracheostomy tube;;; +33443-3;LL5542-7;Intubation tube types;LA30792-8;1;Supraglottic airway device;;; +33443-3;LL5542-7;Intubation tube types;LA18662-9;2;Supraglottic airway device-LMA;;; +33443-3;LL5542-7;Intubation tube types;LA30793-6;3;Supraglottic airway device - Laryngeal tube;;; +33443-3;LL5542-7;Intubation tube types;LA18663-7;4;Supraglottic airway device-other;;; +33443-3;LL5542-7;Intubation tube types;LA19779-0;5;Endotracheal tube;;; +33443-3;LL5542-7;Intubation tube types;LA19780-8;6;Nasalendotracheal tube;;; +33443-3;LL5542-7;Intubation tube types;LA19781-6;7;Oralendotracheal tube;;; +33443-3;LL5542-7;Intubation tube types;LA18004-4;8;Tracheostomy tube;;; +33443-3;LL5542-7;Intubation tube types;LA30791-0;9;Coniotomy tube;;; +33443-3;LL5542-7;Intubation tube types;LA46-8;10;Other;;; +33557-0;LL1049-7;Completion;LA14061-8;1;None (0%);;; +33557-0;LL1049-7;Completion;LA14062-6;2;Minimal extent (about 1-20%);;; +33557-0;LL1049-7;Completion;LA14063-4;3;Some extent (about 21-40%);;; +33557-0;LL1049-7;Completion;LA14064-2;4;Medium extent (about 41-60%);;; +33557-0;LL1049-7;Completion;LA14065-9;5;Large extent (about 61-80%);;; +33557-0;LL1049-7;Completion;LA14066-7;6;Great extent (about 81-99%);;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16833-8;1;Cecum;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16834-6;2;Ascending colon;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16835-3;3;Hepatic flexure;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16836-1;4;Transverse colon;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16837-9;5;Splenic flexure;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16838-7;6;Descending colon;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16839-5;7;Sigmoid colon;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA26985-4;8;Rectosigmoid junction;;; +33725-3;LL4310-0;Colorectal cancer tumor sites;LA16840-3;9;Rectum;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16833-8;1;Cecum;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16834-6;2;Ascending colon;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16835-3;3;Hepatic flexure;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16836-1;4;Transverse colon;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16837-9;5;Splenic flexure;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16838-7;6;Descending colon;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16839-5;7;Sigmoid colon;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA26985-4;8;Rectosigmoid junction;;; +85298-8;LL4310-0;Colorectal cancer tumor sites;LA16840-3;9;Rectum;;; +33726-1;LL1675-9;PhenX19_21_colorectal gross morphology;LA15437-9;1;Exophytic;;; +33726-1;LL1675-9;PhenX19_21_colorectal gross morphology;LA15438-7;2;Endophytic;;; +33726-1;LL1675-9;PhenX19_21_colorectal gross morphology;LA15439-5;3;Annular;;; +33726-1;LL1675-9;PhenX19_21_colorectal gross morphology;LA15440-3;4;Diffusely infiltrative;;; +33726-1;LL1675-9;PhenX19_21_colorectal gross morphology;LA7338-2;5;Not available;;; +67193-3;LL1675-9;PhenX19_21_colorectal gross morphology;LA15437-9;1;Exophytic;;; +67193-3;LL1675-9;PhenX19_21_colorectal gross morphology;LA15438-7;2;Endophytic;;; +67193-3;LL1675-9;PhenX19_21_colorectal gross morphology;LA15439-5;3;Annular;;; +67193-3;LL1675-9;PhenX19_21_colorectal gross morphology;LA15440-3;4;Diffusely infiltrative;;; +67193-3;LL1675-9;PhenX19_21_colorectal gross morphology;LA7338-2;5;Not available;;; +33730-3;LL4568-3;Complete|Near complete|Incomplete;LA4720-4;1;Not applicable;;; +33730-3;LL4568-3;Complete|Near complete|Incomplete;LA26032-5;2;Complete;;; +33730-3;LL4568-3;Complete|Near complete|Incomplete;LA27882-2;3;Near complete;;; +33730-3;LL4568-3;Complete|Near complete|Incomplete;LA7341-6;4;Incomplete;;; +33730-3;LL4568-3;Complete|Near complete|Incomplete;LA11899-4;5;Cannot be determined;;; +33738-6;LL4348-0;Surgical margin types;LA27145-4;1;Proximal margin;;; +33738-6;LL4348-0;Surgical margin types;LA27149-6;2;Distal margin;;; +33738-6;LL4348-0;Surgical margin types;LA27146-2;3;Deep margin;;; +33738-6;LL4348-0;Surgical margin types;LA27147-0;4;Circumferential margin;;; +33738-6;LL4348-0;Surgical margin types;LA27150-4;5;Mucosal margin;;; +33738-6;LL4348-0;Surgical margin types;LA27148-8;6;Mesenteric margin;;; +33738-6;LL4348-0;Surgical margin types;LA46-8;7;Other;;; +85276-4;LL4348-0;Surgical margin types;LA27145-4;1;Proximal margin;;; +85276-4;LL4348-0;Surgical margin types;LA27149-6;2;Distal margin;;; +85276-4;LL4348-0;Surgical margin types;LA27146-2;3;Deep margin;;; +85276-4;LL4348-0;Surgical margin types;LA27147-0;4;Circumferential margin;;; +85276-4;LL4348-0;Surgical margin types;LA27150-4;5;Mucosal margin;;; +85276-4;LL4348-0;Surgical margin types;LA27148-8;6;Mesenteric margin;;; +85276-4;LL4348-0;Surgical margin types;LA46-8;7;Other;;; +33739-4;LL750-1;Absent|Present|Indeterm;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +33739-4;LL750-1;Absent|Present|Indeterm;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +33739-4;LL750-1;Absent|Present|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +42669-2;LL750-1;Absent|Present|Indeterm;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +42669-2;LL750-1;Absent|Present|Indeterm;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +42669-2;LL750-1;Absent|Present|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +80325-4;LL750-1;Absent|Present|Indeterm;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +80325-4;LL750-1;Absent|Present|Indeterm;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +80325-4;LL750-1;Absent|Present|Indeterm;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +33741-0;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +33741-0;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +44625-2;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +44625-2;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +44626-0;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +44626-0;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +84888-7;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +84888-7;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +84889-5;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +84889-5;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +85338-2;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +85338-2;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +85350-7;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +85350-7;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +92830-9;LL748-5;CAP_invasion_1;LA11902-6;1;Not identified;;; +92830-9;LL748-5;CAP_invasion_1;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +33764-2;LL1498-6;STX;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +33764-2;LL1498-6;STX;LA16137-4;2;Shiga toxin 1;;; +33764-2;LL1498-6;STX;LA16138-2;3;Shiga toxin 2;;; +33764-2;LL1498-6;STX;LA16139-0;4;Shiga toxin 1+2;;; +53946-0;LL1498-6;STX;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53946-0;LL1498-6;STX;LA16137-4;2;Shiga toxin 1;;; +53946-0;LL1498-6;STX;LA16138-2;3;Shiga toxin 2;;; +53946-0;LL1498-6;STX;LA16139-0;4;Shiga toxin 1+2;;; +64013-6;LL1498-6;STX;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +64013-6;LL1498-6;STX;LA16137-4;2;Shiga toxin 1;;; +64013-6;LL1498-6;STX;LA16138-2;3;Shiga toxin 2;;; +64013-6;LL1498-6;STX;LA16139-0;4;Shiga toxin 1+2;;; +81285-9;LL1498-6;STX;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81285-9;LL1498-6;STX;LA16137-4;2;Shiga toxin 1;;; +81285-9;LL1498-6;STX;LA16138-2;3;Shiga toxin 2;;; +81285-9;LL1498-6;STX;LA16139-0;4;Shiga toxin 1+2;;; +33893-9;LL5706-8;PAM Revised - Cyotgenetic abnormalities;LA31354-6;1;Complex karyotype (>4 abnormalities);;; +33893-9;LL5706-8;PAM Revised - Cyotgenetic abnormalities;LA31355-3;2;inv(16) without complex karyotype;;; +33893-9;LL5706-8;PAM Revised - Cyotgenetic abnormalities;LA31357-9;3;>3 cytogeneic abnormalities or monosomal karyotype;;; +33893-9;LL5706-8;PAM Revised - Cyotgenetic abnormalities;LA31356-1;4;All other;;; +33930-9;LL2429-0;Confirmed|Not confirmed;LA15290-2;1;Confirmed;;; +33930-9;LL2429-0;Confirmed|Not confirmed;LA19738-6;2;Not confirmed;;; +33999-4;LL451-6;D26_Diagnosis status;LA9039-4;1;New;;; +33999-4;LL451-6;D26_Diagnosis status;LA9040-2;2;Ongoing;;; +33999-4;LL451-6;D26_Diagnosis status;LA9041-0;3;Resolved;;; +33999-4;LL451-6;D26_Diagnosis status;LA9042-8;4;Finding;;; +33999-4;LL451-6;D26_Diagnosis status;LA9043-6;5;Observe;;; +33999-4;LL451-6;D26_Diagnosis status;LA9044-4;6;Provisional;;; +33999-4;LL451-6;D26_Diagnosis status;LA9045-1;7;Confirm negative;;; +33999-4;LL451-6;D26_Diagnosis status;LA9046-9;8;Unable to Confirm;;; +33999-4;LL451-6;D26_Diagnosis status;LA9047-7;9;Deleted;;; +34000-0;LL449-0;D24_Treatment urgency;LA9035-2;1;Routine;;; +34000-0;LL449-0;D24_Treatment urgency;LA9036-0;2;Priority;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8927-1;1;Bacterial plaque;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8928-9;2;Smoking;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8929-7;3;Calculus (calcified plaque);;; +34001-8;LL433-4;D8_Dental etiol factors;LA8930-5;4;Food impaction;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8931-3;5;Traumatogenic occlusion;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8932-1;6;Over contour;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8933-9;7;Under contour;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8934-7;8;Plunger cusp;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8935-4;9;Open contact;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8936-2;10;Overhang restoration;;; +34001-8;LL433-4;D8_Dental etiol factors;LA8937-0;11;Toothbrush abrasion.;;; +34003-4;LL436-7;D11_Tooth impaction;LA8955-2;1;Full bony impacted;;; +34003-4;LL436-7;D11_Tooth impaction;LA8956-0;2;Partial bony impacted;;; +34003-4;LL436-7;D11_Tooth impaction;LA8957-8;3;Soft tissue impacted;;; +34003-4;LL436-7;D11_Tooth impaction;LA8958-6;4;Tooth eruption probable;;; +34003-4;LL436-7;D11_Tooth impaction;LA8959-4;5;Tooth eruption possible;;; +34004-2;LL444-1;D19_Tooth impaction position;LA8991-7;1;Mesioangular;;; +34004-2;LL444-1;D19_Tooth impaction position;LA8992-5;2;Distoangular;;; +34004-2;LL444-1;D19_Tooth impaction position;LA8993-3;3;Horizontal;;; +34004-2;LL444-1;D19_Tooth impaction position;LA8994-1;4;Vertical;;; +34004-2;LL444-1;D19_Tooth impaction position;LA8995-8;5;Inverted;;; +34004-2;LL444-1;D19_Tooth impaction position;LA8996-6;6;Transverse;;; +34005-9;LL427-6;D2_Tooth mobility;LA8906-5;1;Mobility subjectively above expected physiologic movement;;; +34005-9;LL427-6;D2_Tooth mobility;LA8907-3;2;Mobility up to 1 mm in a single lateral direction;;; +34005-9;LL427-6;D2_Tooth mobility;LA8908-1;3;Mobility greater than 1 mm in a single lateral direction or depressible in the socket.;;; +34006-7;LL439-1;D14_Orthodontic tx;LA8973-5;1;Interceptive;;; +34006-7;LL439-1;D14_Orthodontic tx;LA6484-5;2;Limited;;; +34006-7;LL439-1;D14_Orthodontic tx;LA8975-0;3;Comprehensive;;; +34006-7;LL439-1;D14_Orthodontic tx;LA8976-8;4;Minor Treatment to Control Harmful Habits;;; +34007-5;LL447-4;D22_Type of dentition;LA9028-7;1;Primary dentition;;; +34007-5;LL447-4;D22_Type of dentition;LA9029-5;2;Transitional dentition (mixed dentition);;; +34007-5;LL447-4;D22_Type of dentition;LA9030-3;3;Adolescent dentition;;; +34007-5;LL447-4;D22_Type of dentition;LA9031-1;4;Permanent dentition;;; +34008-3;LL448-2;D23_Treatment status;LA9032-9;1;Retention;;; +34008-3;LL448-2;D23_Treatment status;LA9033-7;2;No retention;;; +34008-3;LL448-2;D23_Treatment status;LA9034-5;3;Active Appliances;;; +34013-3;LL426-8;D1_Periodontal eval;LA8901-6;1;No bleeding on probing, probing depth less than 3.5 mm;;; +34013-3;LL426-8;D1_Periodontal eval;LA8902-4;2;Bleeding on probing, probing depth less than 3.5 mm;;; +34013-3;LL426-8;D1_Periodontal eval;LA8903-2;3;Bleeding on probing, probing depth less than 3.5 mm, plaque retaining factors (calculus restoration);;; +34013-3;LL426-8;D1_Periodontal eval;LA8904-0;4;Depth greater than 3.5 mm but less than 5.5 mm;;; +34013-3;LL426-8;D1_Periodontal eval;LA8905-7;5;Depth greater than 5.5 mm.;;; +34014-1;LL437-5;D12_Periodontal special finding;LA8960-2;1;Gingival recession;;; +34014-1;LL437-5;D12_Periodontal special finding;LA8961-0;2;Furcation invasion;;; +34014-1;LL437-5;D12_Periodontal special finding;LA8962-8;3;Tooth mobility;;; +34014-1;LL437-5;D12_Periodontal special finding;LA8963-6;4;Inadequate attached gingiva;;; +34014-1;LL437-5;D12_Periodontal special finding;LA8930-5;5;Food impaction;;; +34014-1;LL437-5;D12_Periodontal special finding;LA8965-1;6;High frenum attachment;;; +34014-1;LL437-5;D12_Periodontal special finding;LA8920-6;7;Etc.;;; +34015-8;LL428-4;D3_Furcation class;LA8909-9;1;No horizontal component to the bone loss;;; +34015-8;LL428-4;D3_Furcation class;LA8910-7;2;"Partial horizontal component to the bone loss but no ""through and ""through""";;; +34015-8;LL428-4;D3_Furcation class;LA8911-5;3;"Complete horizontal component to the bone loss (""through and through"")";;; +34015-8;LL428-4;D3_Furcation class;LA8912-3;4;Complete horizontal component to the bone loss;;; +34023-2;LL442-5;D17_Bone resorption pattern;LA8984-2;1;Lekholm & Zarb class A;;; +34023-2;LL442-5;D17_Bone resorption pattern;LA8985-9;2;Lekholm & Zarb class B;;; +34023-2;LL442-5;D17_Bone resorption pattern;LA8986-7;3;Lekholm & Zarb class C;;; +34023-2;LL442-5;D17_Bone resorption pattern;LA8987-5;4;Lekholm & Zarb class D;;; +34023-2;LL442-5;D17_Bone resorption pattern;LA8988-3;5;Lekholm & Zarb class E;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8947-9;1;External trauma;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8948-7;2;Caries;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8949-5;3;Occlusal trauma;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8950-3;4;Periodontal disease;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8951-1;5;Resection;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8952-9;6;Impacted;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8953-7;7;Medical necessity;;; +34024-0;LL435-9;D10_Tooth loss reason;LA8954-5;8;Strategic extraction;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8938-8;1;Complete denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8939-6;2;Fixed partial denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8940-4;3;Removable partial denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8941-2;4;Over denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8942-0;5;Temporary treatment partial denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8943-8;6;Immediate complete denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8944-6;7;Immediate partial denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8945-3;8;Interim fixed partial denture;;; +34026-5;LL434-2;D9_Dental prosthesis;LA8946-1;9;Resin retained fixed partial denture;;; +34030-7;LL430-0;D5_Reason-prosthesis complaint;LA8915-6;1;Aesthetics;;; +34030-7;LL430-0;D5_Reason-prosthesis complaint;LA8916-4;2;Function;;; +34030-7;LL430-0;D5_Reason-prosthesis complaint;LA8917-2;3;Fit;;; +34033-1;LL445-8;D20_Denture occlusion;LA9010-5;1;Monoplane;;; +34033-1;LL445-8;D20_Denture occlusion;LA9011-3;2;Balanced monoplane;;; +34033-1;LL445-8;D20_Denture occlusion;LA9012-1;3;Lingualized;;; +34033-1;LL445-8;D20_Denture occlusion;LA9013-9;4;Cross tooth;;; +34033-1;LL445-8;D20_Denture occlusion;LA9014-7;5;Cross arch balance;;; +34033-1;LL445-8;D20_Denture occlusion;LA9015-4;6;Nonspecific occlusion;;; +34036-4;LL429-2;D4_Keratinized gingiva;LA8913-1;1;Adequate;;; +34036-4;LL429-2;D4_Keratinized gingiva;LA8914-9;2;Inadequate;;; +34037-2;LL441-7;D16;LA8981-8;1;Large;255509001;Large (qualifier value);http://snomed.info/sct +34037-2;LL441-7;D16;LA8982-6;2;Medium;;; +34037-2;LL441-7;D16;LA8983-4;3;Small;255507004;Small (qualifier value);http://snomed.info/sct +34039-8;LL446-6;D21_Edentulous ridge relat;LA9016-2;1;Orthognathic;;; +34039-8;LL446-6;D21_Edentulous ridge relat;LA9017-0;2;Retrognathic;;; +34039-8;LL446-6;D21_Edentulous ridge relat;LA9018-8;3;Prognathic;;; +34039-8;LL446-6;D21_Edentulous ridge relat;LA9019-6;4;Posterior crossbite;;; +34039-8;LL446-6;D21_Edentulous ridge relat;LA9020-4;5;Parallel;;; +34039-8;LL446-6;D21_Edentulous ridge relat;LA9021-2;6;Not parallel;;; +34040-6;LL446-6;D21_Edentulous ridge relat;LA9016-2;1;Orthognathic;;; +34040-6;LL446-6;D21_Edentulous ridge relat;LA9017-0;2;Retrognathic;;; +34040-6;LL446-6;D21_Edentulous ridge relat;LA9018-8;3;Prognathic;;; +34040-6;LL446-6;D21_Edentulous ridge relat;LA9019-6;4;Posterior crossbite;;; +34040-6;LL446-6;D21_Edentulous ridge relat;LA9020-4;5;Parallel;;; +34040-6;LL446-6;D21_Edentulous ridge relat;LA9021-2;6;Not parallel;;; +34041-4;LL440-9;D15_Edentulism class;LA8977-6;1;Kennedy Class I (bilateral distal extension);;; +34041-4;LL440-9;D15_Edentulism class;LA8978-4;2;Kennedy Class II (unilateral distal extension);;; +34041-4;LL440-9;D15_Edentulism class;LA8979-2;3;Kennedy Class III (posterior tooth-borne);;; +34041-4;LL440-9;D15_Edentulism class;LA8980-0;4;Kennedy Class IV (anterior tooth-borne);;; +34042-2;LL432-6;D7_Endentulous maxillectomy class;LA8921-4;1;Aramany Class I (midline resection);;; +34042-2;LL432-6;D7_Endentulous maxillectomy class;LA8922-2;2;Aramany Class II (unilateral resection);;; +34042-2;LL432-6;D7_Endentulous maxillectomy class;LA8923-0;3;Aramany Class III (central resection);;; +34042-2;LL432-6;D7_Endentulous maxillectomy class;LA8924-8;4;Aramany Class IV (bilateral anterior-posterior resection);;; +34042-2;LL432-6;D7_Endentulous maxillectomy class;LA8925-5;5;Aramany Class V (posterior resection);;; +34042-2;LL432-6;D7_Endentulous maxillectomy class;LA8926-3;6;Aramany Class VI;;; +34043-0;LL450-8;D25_Dental exam method;LA9037-8;1;Transillumination;;; +34043-0;LL450-8;D25_Dental exam method;LA9038-6;2;Magnification;;; +34044-8;LL443-3;D18_Magnification instrument;LA8989-1;1;Loupes;;; +34044-8;LL443-3;D18_Magnification instrument;LA8990-9;2;Microscope;;; +34048-9;LL431-8;D6_Dental material;LA8918-0;1;Amalgam materials;;; +34048-9;LL431-8;D6_Dental material;LA8919-8;2;Impression materials;;; +34048-9;LL431-8;D6_Dental material;LA8920-6;3;Etc.;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28413-5;1;Amphetamine;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28414-3;2;Barbiturate;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28415-0;3;Benzodiazepines;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA15257-1;4;Cocaine;387085005;Cocaine (substance);http://snomed.info/sct +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA15259-7;5;Methamphetamine;387499002;Metamfetamine (substance);http://snomed.info/sct +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28418-4;6;Ecstasy;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28419-2;7;Methadone;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28420-0;8;Opioid;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28421-8;9;Oxycodone;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28422-6;10;Phencyclidine;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28423-4;11;Tricyclic Antidepressant;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28424-2;12;Cannabinoid;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA46-8;13;Other;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA137-2;14;None;260413007;None (qualifier value);http://snomed.info/sct +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA13538-6;15;Not tested;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28413-5;1;Amphetamine;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28414-3;2;Barbiturate;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28415-0;3;Benzodiazepines;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA15257-1;4;Cocaine;387085005;Cocaine (substance);http://snomed.info/sct +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA15259-7;5;Methamphetamine;387499002;Metamfetamine (substance);http://snomed.info/sct +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28418-4;6;Ecstasy;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28419-2;7;Methadone;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28420-0;8;Opioid;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28421-8;9;Oxycodone;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28422-6;10;Phencyclidine;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28423-4;11;Tricyclic Antidepressant;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA28424-2;12;Cannabinoid;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA46-8;13;Other;;; +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA137-2;14;None;260413007;None (qualifier value);http://snomed.info/sct +34601-5;LL4748-1;NTDS_ED_17_Drug Screen;LA13538-6;15;Not tested;;; +34731-0;LL2984-4;APOE alleles;LA21353-0;1;APOE e2;;; +34731-0;LL2984-4;APOE alleles;LA21354-8;2;APOE e3 (wild type);;; +34731-0;LL2984-4;APOE alleles;LA21355-5;3;APOE e4;;; +34732-8;LL2984-4;APOE alleles;LA21353-0;1;APOE e2;;; +34732-8;LL2984-4;APOE alleles;LA21354-8;2;APOE e3 (wild type);;; +34732-8;LL2984-4;APOE alleles;LA21355-5;3;APOE e4;;; +36903-3;LL1501-7;CT&GC probe;LA16153-1;1;Chlamydia trachomatis detected;;; +36903-3;LL1501-7;CT&GC probe;LA16154-9;2;Chlamydia trachomatis not detected;;; +36903-3;LL1501-7;CT&GC probe;LA16155-6;3;Chlamydia trachomatis inconclusive;;; +36903-3;LL1501-7;CT&GC probe;LA16157-2;4;Chlamydia trachomatis equivocal;;; +36903-3;LL1501-7;CT&GC probe;LA16150-7;5;Neisseria gonorrhoeae detected;;; +36903-3;LL1501-7;CT&GC probe;LA16151-5;6;Neisseria gonorrhoeae not detected;;; +36903-3;LL1501-7;CT&GC probe;LA16152-3;7;Neisseria gonorrhoeae inconclusive;;; +36903-3;LL1501-7;CT&GC probe;LA16156-4;8;Neisseria gonorrhoeae equivocal;;; +43405-0;LL1501-7;CT&GC probe;LA16153-1;1;Chlamydia trachomatis detected;;; +43405-0;LL1501-7;CT&GC probe;LA16154-9;2;Chlamydia trachomatis not detected;;; +43405-0;LL1501-7;CT&GC probe;LA16155-6;3;Chlamydia trachomatis inconclusive;;; +43405-0;LL1501-7;CT&GC probe;LA16157-2;4;Chlamydia trachomatis equivocal;;; +43405-0;LL1501-7;CT&GC probe;LA16150-7;5;Neisseria gonorrhoeae detected;;; +43405-0;LL1501-7;CT&GC probe;LA16151-5;6;Neisseria gonorrhoeae not detected;;; +43405-0;LL1501-7;CT&GC probe;LA16152-3;7;Neisseria gonorrhoeae inconclusive;;; +43405-0;LL1501-7;CT&GC probe;LA16156-4;8;Neisseria gonorrhoeae equivocal;;; +38167-3;LL2414-2;Compatible/Incompatible;LA19695-8;1;Compatible;;; +38167-3;LL2414-2;Compatible/Incompatible;LA19696-6;2;Incompatible;;; +38168-1;LL2414-2;Compatible/Incompatible;LA19695-8;1;Compatible;;; +38168-1;LL2414-2;Compatible/Incompatible;LA19696-6;2;Incompatible;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA19102-5;1;0 - no pain;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6112-2;2;1;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6113-0;3;2;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6114-8;4;3;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6115-5;5;4;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10137-0;6;5;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10138-8;7;6;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10139-6;8;7;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10140-4;9;8;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10141-2;10;9;;; +38208-5;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA21948-7;11;10 - worst imaginable pain;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA19102-5;1;0 - no pain;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6112-2;2;1;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6113-0;3;2;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6114-8;4;3;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA6115-5;5;4;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10137-0;6;5;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10138-8;7;6;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10139-6;8;7;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10140-4;9;8;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA10141-2;10;9;;; +61583-1;LL1014-1;[PROMIS] 0-no pain|1|2|3|4|5|6|7|8|9|10-worst imag;LA21948-7;11;10 - worst imaginable pain;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA31728-1;1;0 = No pain;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6112-2;2;1;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6113-0;3;2;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6114-8;4;3;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6115-5;5;4;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10137-0;6;5;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10138-8;7;6;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10139-6;8;7;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10140-4;9;8;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10141-2;10;9;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA31727-3;11;10 = Worst pain that I can imagine;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA31728-1;1;0 = No pain;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6112-2;2;1;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6113-0;3;2;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6114-8;4;3;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA6115-5;5;4;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10137-0;6;5;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10138-8;7;6;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10139-6;8;7;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10140-4;9;8;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA10141-2;10;9;;; +38208-5;LL5812-4;Pain scale 0 to 10;LA31727-3;11;10 = Worst pain that I can imagine;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA31728-1;1;0 = No pain;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA6112-2;2;1;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA6113-0;3;2;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA6114-8;4;3;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA6115-5;5;4;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA10137-0;6;5;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA10138-8;7;6;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA10139-6;8;7;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA10140-4;9;8;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA10141-2;10;9;;; +75893-8;LL5812-4;Pain scale 0 to 10;LA31727-3;11;10 = Worst pain that I can imagine;;; +38216-8;LL513-3;FLACC-F;LA9588-0;1;No particular expression or smile;;; +38216-8;LL513-3;FLACC-F;LA9589-8;2;"Occasional grimace/frown, withdrawn or disinterested, appears sad or worried; or parent-identified expression";;; +38216-8;LL513-3;FLACC-F;LA9590-6;3;"Constant grimace or frown, frequent / constant quivering chin, clenched jaw, distressed-looking face, expression of fright or panic; or parent-identified expression";;; +38217-6;LL514-1;FLACC-L;LA9591-4;1;"Normal position or relaxed; usual tone and motion to limbs";;; +38217-6;LL514-1;FLACC-L;LA9592-2;2;"Uneasy, restless, tense, occasional tremors; or parent-identified behavior";;; +38217-6;LL514-1;FLACC-L;LA9593-0;3;"Kicking or legs drawn up, marked increase in spasticity, constant tremors or jerking; or parent-identified behavior";;; +38218-4;LL515-8;FLACC-A;LA9594-8;1;"Lying quietly, normal position, moves easily; regular, rhythmic respirations";;; +38218-4;LL515-8;FLACC-A;LA9595-5;2;"Squirming, shifting back and forth, tense or guarded movements; mildly agitated (e.g., head back and forth, aggression), shallow; splinting respirations, intermittent sighs; or parent-identified behavior";;; +38218-4;LL515-8;FLACC-A;LA9596-3;3;"Arched, rigid, or jerking; severe agitation; head banging; shivering (not rigors); breath holding, gasping or sharp intake of breaths, severe splinting; or parent-identified behavior";;; +38219-2;LL516-6;FLACC-Cr;LA9597-1;1;No cry/verbalization;;; +38219-2;LL516-6;FLACC-Cr;LA9598-9;2;"Moans or whimpers; occasional complaint; occasional verbal outburst or grunt; or parent-identified vocalization";;; +38219-2;LL516-6;FLACC-Cr;LA9599-7;3;"Crying steadily, screams or sobs; frequent complaints; repeated outbursts, constant grunting; or parent-identified vocalization";;; +38220-0;LL517-4;FLACC-Co;LA9600-3;1;Content and relaxed;;; +38220-0;LL517-4;FLACC-Co;LA9601-1;2;"Reassured by occasional touching, hugging, or being talked to; distractible; or parent-identified behavior";;; +38220-0;LL517-4;FLACC-Co;LA9602-9;3;"Difficult to console or comfort; pushing away caregiver, resisting care or comfort measures; or parent-identified behavior";;; +38222-6;LL520-8;BS_1_Sensory perception;LA9603-7;1;Completely limited;;; +38222-6;LL520-8;BS_1_Sensory perception;LA9604-5;2;Very limited;;; +38222-6;LL520-8;BS_1_Sensory perception;LA9605-2;3;Slightly limited;;; +38222-6;LL520-8;BS_1_Sensory perception;LA9606-0;4;No impairment;;; +38223-4;LL522-4;BS_3_Activity;LA6742-6;1;Bedfast;;; +38223-4;LL522-4;BS_3_Activity;LA9611-0;2;Chairfast;;; +38223-4;LL522-4;BS_3_Activity;LA9612-8;3;Walks occasionally;;; +38223-4;LL522-4;BS_3_Activity;LA9613-6;4;Walks frequently;;; +38224-2;LL523-2;BS_4_Mobility;LA9614-4;1;Completely immobile;;; +38224-2;LL523-2;BS_4_Mobility;LA9604-5;2;Very limited;;; +38224-2;LL523-2;BS_4_Mobility;LA9605-2;3;Slightly limited;;; +38224-2;LL523-2;BS_4_Mobility;LA120-8;4;No limitation;;; +38225-9;LL525-7;BS_5_Nutrition;LA9615-1;1;Very poor;;; +38225-9;LL525-7;BS_5_Nutrition;LA9616-9;2;Probably inadequate;;; +38225-9;LL525-7;BS_5_Nutrition;LA8913-1;3;Adequate;;; +38225-9;LL525-7;BS_5_Nutrition;LA9206-9;4;Excellent;;; +38226-7;LL524-0;BS_6_Friction-shear;LA9617-7;1;Problem;;; +38226-7;LL524-0;BS_6_Friction-shear;LA9618-5;2;Potential problem;;; +38226-7;LL524-0;BS_6_Friction-shear;LA9619-3;3;No apparent problem;;; +38229-1;LL521-6;BS_2_Moisture;LA9607-8;1;Constantly moist;;; +38229-1;LL521-6;BS_2_Moisture;LA9608-6;2;Very moist;;; +38229-1;LL521-6;BS_2_Moisture;LA9609-4;3;Occasionally moist;;; +38229-1;LL521-6;BS_2_Moisture;LA9610-2;4;Rarely moist;;; +38347-1;LL1031-5;PCR_HK;LA13959-4;1;PCR for Chlamydia pneumoniae - Negative;;; +38347-1;LL1031-5;PCR_HK;LA13960-2;2;PCR for Chlamydia pneumoniae - Positive;;; +38347-1;LL1031-5;PCR_HK;LA13961-0;3;PCR for Chlamydia psittaci - Negative;;; +38347-1;LL1031-5;PCR_HK;LA13962-8;4;PCR for Chlamydia psittaci - Positive;;; +38347-1;LL1031-5;PCR_HK;LA13963-6;5;PCR for Coxiella burnetii - Negative;;; +38347-1;LL1031-5;PCR_HK;LA13964-4;6;PCR for Coxiella burnetii - Positive;;; +38347-1;LL1031-5;PCR_HK;LA13965-1;7;PCR for Cytomegalovirus - Negative;;; +38347-1;LL1031-5;PCR_HK;LA13966-9;8;PCR for Cytomegalovirus - Positive;;; +62201-9;LL1031-5;PCR_HK;LA13959-4;1;PCR for Chlamydia pneumoniae - Negative;;; +62201-9;LL1031-5;PCR_HK;LA13960-2;2;PCR for Chlamydia pneumoniae - Positive;;; +62201-9;LL1031-5;PCR_HK;LA13961-0;3;PCR for Chlamydia psittaci - Negative;;; +62201-9;LL1031-5;PCR_HK;LA13962-8;4;PCR for Chlamydia psittaci - Positive;;; +62201-9;LL1031-5;PCR_HK;LA13963-6;5;PCR for Coxiella burnetii - Negative;;; +62201-9;LL1031-5;PCR_HK;LA13964-4;6;PCR for Coxiella burnetii - Positive;;; +62201-9;LL1031-5;PCR_HK;LA13965-1;7;PCR for Cytomegalovirus - Negative;;; +62201-9;LL1031-5;PCR_HK;LA13966-9;8;PCR for Cytomegalovirus - Positive;;; +62202-7;LL1031-5;PCR_HK;LA13959-4;1;PCR for Chlamydia pneumoniae - Negative;;; +62202-7;LL1031-5;PCR_HK;LA13960-2;2;PCR for Chlamydia pneumoniae - Positive;;; +62202-7;LL1031-5;PCR_HK;LA13961-0;3;PCR for Chlamydia psittaci - Negative;;; +62202-7;LL1031-5;PCR_HK;LA13962-8;4;PCR for Chlamydia psittaci - Positive;;; +62202-7;LL1031-5;PCR_HK;LA13963-6;5;PCR for Coxiella burnetii - Negative;;; +62202-7;LL1031-5;PCR_HK;LA13964-4;6;PCR for Coxiella burnetii - Positive;;; +62202-7;LL1031-5;PCR_HK;LA13965-1;7;PCR for Cytomegalovirus - Negative;;; +62202-7;LL1031-5;PCR_HK;LA13966-9;8;PCR for Cytomegalovirus - Positive;;; +38348-9;LL2255-9;HHV6 DNA;LA13487-6;1;A;;; +38348-9;LL2255-9;HHV6 DNA;LA14518-7;2;B;;; +38348-9;LL2255-9;HHV6 DNA;LA19175-1;3;A & B;;; +47410-6;LL2255-9;HHV6 DNA;LA13487-6;1;A;;; +47410-6;LL2255-9;HHV6 DNA;LA14518-7;2;B;;; +47410-6;LL2255-9;HHV6 DNA;LA19175-1;3;A & B;;; +38376-0;LL2068-6;Cryptococcus sp;LA18527-4;1;C neoformans;;; +38376-0;LL2068-6;Cryptococcus sp;LA18528-2;2;C gattii;;; +38376-0;LL2068-6;Cryptococcus sp;LA18529-0;3;C grubii;;; +70907-1;LL2068-6;Cryptococcus sp;LA18527-4;1;C neoformans;;; +70907-1;LL2068-6;Cryptococcus sp;LA18528-2;2;C gattii;;; +70907-1;LL2068-6;Cryptococcus sp;LA18529-0;3;C grubii;;; +38393-5;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +38393-5;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +38393-5;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +38394-3;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +38394-3;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +38394-3;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +49616-6;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +49616-6;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +49616-6;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +589-2;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +589-2;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +589-2;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +590-0;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +590-0;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +590-0;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +593-4;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +593-4;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +593-4;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +71377-6;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +71377-6;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +71377-6;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +87956-9;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +87956-9;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +87956-9;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +87957-7;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +87957-7;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +87957-7;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +88585-5;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +88585-5;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +88585-5;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +88587-1;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +88587-1;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +88587-1;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +88588-9;LL2091-8;Legionella sp;LA18546-4;1;Legionella adelaidensis;;; +88588-9;LL2091-8;Legionella sp;LA18547-2;2;Legionella drancourtii;;; +88588-9;LL2091-8;Legionella sp;LA18548-0;3;Legionella pneumophila;80897008;Legionella pneumophila (organism);http://snomed.info/sct +38883-5;LL2437-3;Urgency;LA19759-2;1;Emergent;;; +38883-5;LL2437-3;Urgency;LA19760-0;2;Elective;;; +38885-0;LL2437-3;Urgency;LA19759-2;1;Emergent;;; +38885-0;LL2437-3;Urgency;LA19760-0;2;Elective;;; +78927-1;LL2437-3;Urgency;LA19759-2;1;Emergent;;; +78927-1;LL2437-3;Urgency;LA19760-0;2;Elective;;; +38918-9;LL3632-8;Example ABCC8 gene variants;LA24050-9;1;c.4160_4162delTCT;;; +38918-9;LL3632-8;Example ABCC8 gene variants;LA24051-7;2;c.3989-9G>A;;; +38918-9;LL3632-8;Example ABCC8 gene variants;LA24057-4;3;c.2147G>T;;; +38918-9;LL3632-8;Example ABCC8 gene variants;LA24056-6;4;c.4307G>A;;; +39025-2;LL2269-0;FLUAV hemaggl;LA13508-9;1;H1;;; +39025-2;LL2269-0;FLUAV hemaggl;LA13509-7;2;H2;;; +39025-2;LL2269-0;FLUAV hemaggl;LA19220-5;3;H3;;; +39025-2;LL2269-0;FLUAV hemaggl;LA19221-3;4;H5;;; +39025-2;LL2269-0;FLUAV hemaggl;LA19222-1;5;H7;;; +39025-2;LL2269-0;FLUAV hemaggl;LA19223-9;6;H9;;; +39102-9;LL2269-0;FLUAV hemaggl;LA13508-9;1;H1;;; +39102-9;LL2269-0;FLUAV hemaggl;LA13509-7;2;H2;;; +39102-9;LL2269-0;FLUAV hemaggl;LA19220-5;3;H3;;; +39102-9;LL2269-0;FLUAV hemaggl;LA19221-3;4;H5;;; +39102-9;LL2269-0;FLUAV hemaggl;LA19222-1;5;H7;;; +39102-9;LL2269-0;FLUAV hemaggl;LA19223-9;6;H9;;; +50697-2;LL2269-0;FLUAV hemaggl;LA13508-9;1;H1;;; +50697-2;LL2269-0;FLUAV hemaggl;LA13509-7;2;H2;;; +50697-2;LL2269-0;FLUAV hemaggl;LA19220-5;3;H3;;; +50697-2;LL2269-0;FLUAV hemaggl;LA19221-3;4;H5;;; +50697-2;LL2269-0;FLUAV hemaggl;LA19222-1;5;H7;;; +50697-2;LL2269-0;FLUAV hemaggl;LA19223-9;6;H9;;; +55133-3;LL2269-0;FLUAV hemaggl;LA13508-9;1;H1;;; +55133-3;LL2269-0;FLUAV hemaggl;LA13509-7;2;H2;;; +55133-3;LL2269-0;FLUAV hemaggl;LA19220-5;3;H3;;; +55133-3;LL2269-0;FLUAV hemaggl;LA19221-3;4;H5;;; +55133-3;LL2269-0;FLUAV hemaggl;LA19222-1;5;H7;;; +55133-3;LL2269-0;FLUAV hemaggl;LA19223-9;6;H9;;; +39103-7;LL957-2;FLUAV cDNA;LA13541-0;1;Influenza A (N1);;; +39103-7;LL957-2;FLUAV cDNA;LA13542-8;2;Influenza A (N2);;; +39103-7;LL957-2;FLUAV cDNA;LA11137-9;3;Unable to determine;;; +50696-4;LL957-2;FLUAV cDNA;LA13541-0;1;Influenza A (N1);;; +50696-4;LL957-2;FLUAV cDNA;LA13542-8;2;Influenza A (N2);;; +50696-4;LL957-2;FLUAV cDNA;LA11137-9;3;Unable to determine;;; +53381-0;LL957-2;FLUAV cDNA;LA13541-0;1;Influenza A (N1);;; +53381-0;LL957-2;FLUAV cDNA;LA13542-8;2;Influenza A (N2);;; +53381-0;LL957-2;FLUAV cDNA;LA11137-9;3;Unable to determine;;; +61101-2;LL957-2;FLUAV cDNA;LA13541-0;1;Influenza A (N1);;; +61101-2;LL957-2;FLUAV cDNA;LA13542-8;2;Influenza A (N2);;; +61101-2;LL957-2;FLUAV cDNA;LA11137-9;3;Unable to determine;;; +39106-0;LL3920-7;Skin temperature;LA15475-9;1;Cold;;; +39106-0;LL3920-7;Skin temperature;LA17202-5;2;Hot;;; +39106-0;LL3920-7;Skin temperature;LA17207-4;3;Warm;;; +81673-6;LL3920-7;Skin temperature;LA15475-9;1;Cold;;; +81673-6;LL3920-7;Skin temperature;LA17202-5;2;Hot;;; +81673-6;LL3920-7;Skin temperature;LA17207-4;3;Warm;;; +39107-8;LL3918-1;Skin color;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39107-8;LL3918-1;Skin color;LA17200-9;2;Red (erythematous);;; +39107-8;LL3918-1;Skin color;LA17205-8;3;Mottled;;; +39107-8;LL3918-1;Skin color;LA17198-5;4;Cyanotic;;; +39107-8;LL3918-1;Skin color;LA17206-6;5;Pale;;; +39107-8;LL3918-1;Skin color;LA17204-1;6;Lividity;;; +39107-8;LL3918-1;Skin color;LA7450-5;7;Jaundice;;; +39107-8;LL3918-1;Skin color;LA17201-7;8;Flushed;;; +39109-4;LL3921-5;Skin turgor;LA18219-8;1;Tenting;;; +39109-4;LL3921-5;Skin turgor;LA18218-0;2;Poor turgor;;; +39109-4;LL3921-5;Skin turgor;LA25964-0;3;Good turgor;;; +39109-4;LL3921-5;Skin turgor;LA25963-2;4;Doughy skin;;; +39109-4;LL3921-5;Skin turgor;LA25965-7;5;Decreased turgor;;; +39109-4;LL3921-5;Skin turgor;LA25012-8;6;Loose;;; +39109-4;LL3921-5;Skin turgor;LA25058-1;7;Shiny;;; +39109-4;LL3921-5;Skin turgor;LA25968-1;8;Tight;;; +39109-4;LL3921-5;Skin turgor;LA25962-4;9;Zosteriform;;; +39111-0;LL5026-1;UE-R|LE-R|UE-L|LE-L;LA29191-6;1;Upper Extremity-Right;;; +39111-0;LL5026-1;UE-R|LE-R|UE-L|LE-L;LA24414-7;2;Lower Extremity-Right;;; +39111-0;LL5026-1;UE-R|LE-R|UE-L|LE-L;LA29192-4;3;Upper Extremity-Left;;; +39111-0;LL5026-1;UE-R|LE-R|UE-L|LE-L;LA24413-9;4;Lower Extremity-Left;;; +39111-0;LL5065-9;Body site;LA12706-0;1;Abdomen;;; +39111-0;LL5065-9;Body site;LA29192-4;2;Upper Extremity-Left;;; +39111-0;LL5065-9;Body site;LA29191-6;3;Upper Extremity-Right;;; +39111-0;LL5065-9;Body site;LA24413-9;4;Lower Extremity-Left;;; +39111-0;LL5065-9;Body site;LA24414-7;5;Lower Extremity-Right;;; +39111-0;LL5065-9;Body site;LA18111-7;6;Chest;;; +39111-0;LL5065-9;Body site;LA18116-6;7;Head;;; +39111-0;LL5065-9;Body site;LA16744-7;8;Pelvis;;; +39111-0;LL5065-9;Body site;LA4476-3;9;Stomach;;; +39111-0;LL5065-9;Body site;LA18788-2;10;Eye-left;;; +39111-0;LL5065-9;Body site;LA18789-0;11;Eye-right;;; +39111-0;LL5065-9;Body site;LA4584-4;12;Liver;;; +39111-0;LL5065-9;Body site;LA4654-5;13;Pancreas;;; +39111-0;LL5065-9;Body site;LA4591-9;14;Kidney;;; +39111-0;LL5065-9;Body site;LA4255-1;15;Breast;;; +39111-0;LL5065-9;Body site;LA4340-1;16;Spine;;; +39111-0;LL5065-9;Body site;LA4331-0;17;Skull;;; +39111-0;LL5969-2;COMI body site;LA12705-2;1;Back;;; +39111-0;LL5969-2;COMI body site;LA32330-5;2;Leg (sciatica)/buttock;;; +39111-0;LL5969-2;COMI body site;LA12703-7;3;Neck;;; +39111-0;LL5969-2;COMI body site;LA32329-7;4;Arm/shoulder;;; +39111-0;LL5969-2;COMI body site;LA12705-2;1;Back;;; +39111-0;LL5969-2;COMI body site;LA32330-5;2;Leg (sciatica)/buttock;;; +39111-0;LL5969-2;COMI body site;LA12703-7;3;Neck;;; +39111-0;LL5969-2;COMI body site;LA32329-7;4;Arm/shoulder;;; +39112-8;LL3804-3;Body location qualifier;LA25151-4;1;Apical;;; +39112-8;LL3804-3;Body location qualifier;LA16059-0;2;Anterior;;; +39112-8;LL3804-3;Body location qualifier;LA25384-1;3;Caudal;;; +39112-8;LL3804-3;Body location qualifier;LA11875-4;4;Deep;;; +39112-8;LL3804-3;Body location qualifier;LA25386-6;5;Distal;;; +39112-8;LL3804-3;Body location qualifier;LA25387-4;6;Dorsal;;; +39112-8;LL3804-3;Body location qualifier;LA11877-0;7;External;;; +39112-8;LL3804-3;Body location qualifier;LA11878-8;8;Internal;;; +39112-8;LL3804-3;Body location qualifier;LA25379-1;9;Anterolateral;;; +39112-8;LL3804-3;Body location qualifier;LA25380-9;10;Mediolateral;;; +39112-8;LL3804-3;Body location qualifier;LA25381-7;11;Median;;; +39112-8;LL3804-3;Body location qualifier;LA24844-5;12;Peripheral;;; +39112-8;LL3804-3;Body location qualifier;LA16060-8;13;Posterior;;; +39112-8;LL3804-3;Body location qualifier;LA8994-1;14;Vertical;;; +39114-4;LL743-6;WndDepth;LA11875-4;1;Deep;;; +39114-4;LL743-6;WndDepth;LA11876-2;2;Exterior;;; +39114-4;LL743-6;WndDepth;LA11877-0;3;External;;; +39114-4;LL743-6;WndDepth;LA11878-8;4;Internal;;; +39114-4;LL743-6;WndDepth;LA11879-6;5;Shallow;;; +39114-4;LL743-6;WndDepth;LA11880-4;6;Superficial;;; +39116-9;LL2222-9;Amount - scant,mod,large,copious;LA19074-6;1;Scant;;; +39116-9;LL2222-9;Amount - scant,mod,large,copious;LA6751-7;2;Moderate;;; +39116-9;LL2222-9;Amount - scant,mod,large,copious;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +39116-9;LL2222-9;Amount - scant,mod,large,copious;LA19075-3;4;Copious;;; +39116-9;LL5200-2;[PUSH 3.0] Exudate amount;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +39116-9;LL5200-2;[PUSH 3.0] Exudate amount;LA15831-3;1;Light;;; +39116-9;LL5200-2;[PUSH 3.0] Exudate amount;LA6751-7;2;Moderate;;; +39116-9;LL5200-2;[PUSH 3.0] Exudate amount;LA29665-9;3;Heavy;;; +39121-9;LL2339-1;Dressing for wound;LA19455-7;1;Gauze;;; +39121-9;LL2339-1;Dressing for wound;LA19456-5;2;Hydrocolloid;;; +39121-9;LL2339-1;Dressing for wound;LA19457-3;3;Semi-permeable membrane;;; +39121-9;LL2339-1;Dressing for wound;LA19458-1;4;Wet-dry;;; +39121-9;LL2339-1;Dressing for wound;LA19459-9;5;Packed;;; +39121-9;LL2339-1;Dressing for wound;LA19460-7;6;Carbon-impregnated;;; +39121-9;LL2339-1;Dressing for wound;LA19461-5;7;Hydrogels;;; +39121-9;LL2339-1;Dressing for wound;LA19462-3;8;Absorptive wound filters;;; +39121-9;LL2339-1;Dressing for wound;LA19463-1;9;Alginates;;; +39121-9;LL2339-1;Dressing for wound;LA19464-9;10;Biosynthetic;;; +39121-9;LL2339-1;Dressing for wound;LA19465-6;11;Nonionic surfactant;;; +39121-9;LL2339-1;Dressing for wound;LA19466-4;12;Enzymatic debriders;;; +39121-9;LL2339-1;Dressing for wound;LA16576-3;13;Foam;;; +39121-9;LL2339-1;Dressing for wound;LA19467-2;14;Non-adherents;;; +39121-9;LL2339-1;Dressing for wound;LA19468-0;15;Steri-strips;;; +39121-9;LL2339-1;Dressing for wound;LA19469-8;16;Hydrofiber;;; +39121-9;LL2339-1;Dressing for wound;LA19470-6;17;Transparent film;;; +39121-9;LL2339-1;Dressing for wound;LA19471-4;18;Superabsorbant;;; +39121-9;LL2339-1;Dressing for wound;LA19472-2;19;Absorptive;;; +39121-9;LL2339-1;Dressing for wound;LA19473-0;20;Alginate with Collagen;;; +39129-2;LL3919-9;Skin moisture;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39129-2;LL3919-9;Skin moisture;LA17197-7;2;Clammy;;; +39129-2;LL3919-9;Skin moisture;LA17199-3;3;Dry;;; +39129-2;LL3919-9;Skin moisture;LA18217-2;4;Diaphoretic;;; +39129-2;LL3919-9;Skin moisture;LA19044-9;5;Moist;;; +39130-0;LL2228-6;Normal (firm) - Spongy;LA20139-4;1;Normal to palpation (firm);;; +39130-0;LL2228-6;Normal (firm) - Spongy;LA20138-6;2;Spongy to palpation;;; +39132-6;LL2338-3;Color of Wound Base;LA19449-0;1;Red/Healthy;;; +39132-6;LL2338-3;Color of Wound Base;LA19450-8;2;Pink/Pale;;; +39132-6;LL2338-3;Color of Wound Base;LA19451-6;3;Red/Hyperemic;;; +39132-6;LL2338-3;Color of Wound Base;LA17195-1;4;Yellow;;; +39132-6;LL2338-3;Color of Wound Base;LA4267-6;5;Black;;; +39132-6;LL2338-3;Color of Wound Base;LA19058-9;6;Brown;;; +39132-6;LL2338-3;Color of Wound Base;LA19452-4;7;Gray;;; +39133-4;LL2338-3;Color of Wound Base;LA19449-0;1;Red/Healthy;;; +39133-4;LL2338-3;Color of Wound Base;LA19450-8;2;Pink/Pale;;; +39133-4;LL2338-3;Color of Wound Base;LA19451-6;3;Red/Hyperemic;;; +39133-4;LL2338-3;Color of Wound Base;LA17195-1;4;Yellow;;; +39133-4;LL2338-3;Color of Wound Base;LA4267-6;5;Black;;; +39133-4;LL2338-3;Color of Wound Base;LA19058-9;6;Brown;;; +39133-4;LL2338-3;Color of Wound Base;LA19452-4;7;Gray;;; +39134-2;LL2216-1;Periwound description;LA19030-8;1;Boggy;;; +39134-2;LL2216-1;Periwound description;LA19031-6;2;Blanched;;; +39134-2;LL2216-1;Periwound description;LA19032-4;3;Blistered;;; +39134-2;LL2216-1;Periwound description;LA19033-2;4;Calloused;;; +39134-2;LL2216-1;Periwound description;LA17199-3;5;Dry;;; +39134-2;LL2216-1;Periwound description;LA19034-0;6;Ecchymotic;;; +39134-2;LL2216-1;Periwound description;LA19035-7;7;Edematous;;; +39134-2;LL2216-1;Periwound description;LA19036-5;8;Erythematous;;; +39134-2;LL2216-1;Periwound description;LA19037-3;9;Excoriated;;; +39134-2;LL2216-1;Periwound description;LA19038-1;10;Fluctuant;;; +39134-2;LL2216-1;Periwound description;LA19039-9;11;Friable;;; +39134-2;LL2216-1;Periwound description;LA19040-7;12;Hemorrhagic;;; +39134-2;LL2216-1;Periwound description;LA19041-5;13;Indurated;;; +39134-2;LL2216-1;Periwound description;LA19042-3;14;Lacerated;;; +39134-2;LL2216-1;Periwound description;LA19043-1;15;Macerated;;; +39134-2;LL2216-1;Periwound description;LA19044-9;16;Moist;;; +39134-2;LL2216-1;Periwound description;LA19045-6;17;Purpuric;;; +39134-2;LL2216-1;Periwound description;LA7469-5;18;Rash;;; +39134-2;LL2216-1;Periwound description;LA7470-3;19;Rupture;;; +39134-2;LL2216-1;Periwound description;LA19047-2;20;Scarred;;; +39134-2;LL2216-1;Periwound description;LA19048-0;21;Swollen (inflammed);;; +72301-5;LL2216-1;Periwound description;LA19030-8;1;Boggy;;; +72301-5;LL2216-1;Periwound description;LA19031-6;2;Blanched;;; +72301-5;LL2216-1;Periwound description;LA19032-4;3;Blistered;;; +72301-5;LL2216-1;Periwound description;LA19033-2;4;Calloused;;; +72301-5;LL2216-1;Periwound description;LA17199-3;5;Dry;;; +72301-5;LL2216-1;Periwound description;LA19034-0;6;Ecchymotic;;; +72301-5;LL2216-1;Periwound description;LA19035-7;7;Edematous;;; +72301-5;LL2216-1;Periwound description;LA19036-5;8;Erythematous;;; +72301-5;LL2216-1;Periwound description;LA19037-3;9;Excoriated;;; +72301-5;LL2216-1;Periwound description;LA19038-1;10;Fluctuant;;; +72301-5;LL2216-1;Periwound description;LA19039-9;11;Friable;;; +72301-5;LL2216-1;Periwound description;LA19040-7;12;Hemorrhagic;;; +72301-5;LL2216-1;Periwound description;LA19041-5;13;Indurated;;; +72301-5;LL2216-1;Periwound description;LA19042-3;14;Lacerated;;; +72301-5;LL2216-1;Periwound description;LA19043-1;15;Macerated;;; +72301-5;LL2216-1;Periwound description;LA19044-9;16;Moist;;; +72301-5;LL2216-1;Periwound description;LA19045-6;17;Purpuric;;; +72301-5;LL2216-1;Periwound description;LA7469-5;18;Rash;;; +72301-5;LL2216-1;Periwound description;LA7470-3;19;Rupture;;; +72301-5;LL2216-1;Periwound description;LA19047-2;20;Scarred;;; +72301-5;LL2216-1;Periwound description;LA19048-0;21;Swollen (inflammed);;; +39155-7;LL369-0;[HL7-9022] Yes 1 cond|Yes 2-3 cond|Yes >3 cond|No;LA6639-4;1;Yes, 1 condition;;; +39155-7;LL369-0;[HL7-9022] Yes 1 cond|Yes 2-3 cond|Yes >3 cond|No;LA6640-2;2;Yes, 2-3 conditions;;; +39155-7;LL369-0;[HL7-9022] Yes 1 cond|Yes 2-3 cond|Yes >3 cond|No;LA6641-0;3;Yes, more than 3 conditions;;; +39155-7;LL369-0;[HL7-9022] Yes 1 cond|Yes 2-3 cond|Yes >3 cond|No;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +39157-3;LL375-7;HL79020_ Screen type;LA6662-6;1;Initial;;; +39157-3;LL375-7;HL79020_ Screen type;LA6663-4;2;Periodic;;; +39157-3;LL375-7;HL79020_ Screen type;LA11153-6;3;Interperiodic;;; +39159-9;LL374-0;[HL7-9021] Partial|Total;LA6660-0;1;Partial;;; +39159-9;LL374-0;[HL7-9021] Partial|Total;LA6661-8;2;Total;;; +39162-3;LL376-5;HL79023_Referred;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39162-3;LL376-5;HL79023_Referred;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39162-3;LL376-5;HL79023_Referred;LA6624-6;3;Referred;;; +39245-6;LL376-5;HL79023_Referred;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +39245-6;LL376-5;HL79023_Referred;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +39245-6;LL376-5;HL79023_Referred;LA6624-6;3;Referred;;; +39163-1;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39163-1;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39163-1;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39163-1;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39163-1;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39163-1;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39163-1;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39167-2;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39167-2;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39167-2;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39167-2;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39167-2;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39167-2;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39167-2;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39170-6;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39170-6;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39170-6;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39170-6;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39170-6;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39170-6;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39170-6;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39174-8;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39174-8;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39174-8;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39174-8;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39174-8;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39174-8;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39174-8;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39177-1;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39177-1;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39177-1;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39177-1;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39177-1;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39177-1;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39177-1;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39178-9;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39178-9;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39178-9;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39178-9;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39178-9;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39178-9;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39178-9;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39182-1;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39182-1;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39182-1;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39182-1;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39182-1;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39182-1;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39182-1;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39186-2;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39186-2;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39186-2;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39186-2;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39186-2;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39186-2;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39186-2;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39190-4;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39190-4;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39190-4;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39190-4;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39190-4;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39190-4;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39190-4;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39194-6;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39194-6;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39194-6;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39194-6;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39194-6;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39194-6;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39194-6;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39197-9;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39197-9;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39197-9;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39197-9;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39197-9;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39197-9;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39197-9;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39201-9;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39201-9;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39201-9;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39201-9;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39201-9;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39201-9;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39201-9;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39205-0;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39205-0;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39205-0;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39205-0;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39205-0;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39205-0;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39205-0;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39209-2;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39209-2;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39209-2;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39209-2;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39209-2;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39209-2;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39209-2;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39210-0;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39210-0;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39210-0;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39210-0;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39210-0;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39210-0;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39210-0;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39213-4;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39213-4;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39213-4;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39213-4;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39213-4;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39213-4;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39213-4;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39214-2;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39214-2;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39214-2;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39214-2;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39214-2;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39214-2;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39214-2;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39218-3;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39218-3;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39218-3;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39218-3;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39218-3;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39218-3;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39218-3;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39219-1;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39219-1;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39219-1;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39219-1;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39219-1;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39219-1;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39219-1;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39259-7;LL366-6;HL79025_Screen assessment result;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +39259-7;LL366-6;HL79025_Screen assessment result;LA6627-9;2;Normal, not under care;;; +39259-7;LL366-6;HL79025_Screen assessment result;LA6628-7;3;Abnormal, no treatment required;;; +39259-7;LL366-6;HL79025_Screen assessment result;LA6629-5;4;Abnormal, under care;;; +39259-7;LL366-6;HL79025_Screen assessment result;LA6630-3;5;Not done;;; +39259-7;LL366-6;HL79025_Screen assessment result;LA6631-1;6;Results pending;;; +39259-7;LL366-6;HL79025_Screen assessment result;LA6632-9;7;Refused, contraindicated or not needed;;; +39164-9;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39164-9;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39164-9;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39164-9;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39164-9;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39168-0;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39168-0;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39168-0;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39168-0;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39168-0;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39171-4;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39171-4;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39171-4;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39171-4;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39171-4;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39175-5;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39175-5;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39175-5;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39175-5;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39175-5;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39179-7;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39179-7;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39179-7;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39179-7;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39179-7;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39183-9;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39183-9;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39183-9;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39183-9;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39183-9;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39187-0;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39187-0;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39187-0;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39187-0;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39187-0;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39191-2;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39191-2;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39191-2;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39191-2;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39191-2;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39195-3;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39195-3;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39195-3;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39195-3;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39195-3;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39198-7;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39198-7;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39198-7;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39198-7;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39198-7;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39202-7;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39202-7;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39202-7;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39202-7;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39202-7;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39206-8;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39206-8;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39206-8;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39206-8;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39206-8;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39260-5;LL364-1;HL79026_Follow up;LA6621-2;1;Questionable result, re-check scheduled;;; +39260-5;LL364-1;HL79026_Follow up;LA6622-0;2;Diagnosis made and treatment started;;; +39260-5;LL364-1;HL79026_Follow up;LA6623-8;3;Diagnosis pending/return visit scheduled;;; +39260-5;LL364-1;HL79026_Follow up;LA6624-6;4;Referred;;; +39260-5;LL364-1;HL79026_Follow up;LA6625-3;5;Referral refused;;; +39165-6;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39165-6;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39169-8;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39169-8;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39172-2;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39172-2;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39176-3;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39176-3;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39180-5;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39180-5;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39184-7;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39184-7;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39188-8;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39188-8;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39192-0;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39192-0;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39196-1;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39196-1;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39199-5;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39199-5;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39203-5;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39203-5;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39207-6;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39207-6;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39211-8;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39211-8;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39215-9;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39215-9;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39220-9;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39220-9;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39261-3;LL367-4;HL79027_Dx discovery;LA6633-7;1;Newly discovered;;; +39261-3;LL367-4;HL79027_Dx discovery;LA6634-5;2;Previously discovered;;; +39224-1;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39224-1;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39224-1;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39224-1;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39225-8;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39225-8;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39225-8;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39225-8;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39226-6;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39226-6;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39226-6;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39226-6;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39227-4;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39227-4;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39227-4;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39227-4;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39228-2;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39228-2;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39228-2;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39228-2;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39229-0;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39229-0;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39229-0;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39229-0;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39230-8;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39230-8;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39230-8;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39230-8;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39231-6;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39231-6;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39231-6;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39231-6;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39234-0;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39234-0;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39234-0;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39234-0;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39263-9;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39263-9;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39263-9;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39263-9;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39264-7;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39264-7;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39264-7;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39264-7;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39265-4;LL368-2;HL79029_Screen test status;LA11157-7;0;Not ordered;;; +39265-4;LL368-2;HL79029_Screen test status;LA11154-4;1;Ordered - Positive;;; +39265-4;LL368-2;HL79029_Screen test status;LA11155-1;2;Ordered - Negative;;; +39265-4;LL368-2;HL79029_Screen test status;LA11156-9;3;Ordered - No results;;; +39237-3;LL370-8;HL79031_Immunizsation;LA6642-8;1;Now up to date for age;;; +39237-3;LL370-8;HL79031_Immunizsation;LA6643-6;2;Still not up to date for age;;; +39237-3;LL370-8;HL79031_Immunizsation;LA6644-4;3;Parental refusal;609589008;Refused by parents of subject (qualifier value);http://snomed.info/sct +39237-3;LL370-8;HL79031_Immunizsation;LA6645-1;4;Medically contraindicated;;; +39237-3;LL370-8;HL79031_Immunizsation;LA6646-9;5;Vaccine not available;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6607-1;1;Childbirth;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6608-9;2;Communicable disease;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6609-7;3;Crisis intervention;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6610-5;4;Developmental/behavioral;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6611-3;5;Drug/alcohol/inhalants;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6612-1;6;Family involvement;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6613-9;7;Infant care;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6614-7;8;Nutrition activity;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6615-4;9;Oral health;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6616-2;10;Parenting;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6617-0;11;Safety/injury prevention;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6618-8;12;Sexual activity/family planning;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6619-6;13;Signs of illness;;; +39239-9;LL363-3;HL79032_Pt guidance type;LA6620-4;14;Social/peer skills;;; +39250-6;LL371-6;HL79033_Program name;LA6647-7;1;Children with special needs;;; +39250-6;LL371-6;HL79033_Program name;LA6648-5;2;Early intervention program;;; +39250-6;LL371-6;HL79033_Program name;LA6649-3;3;Head start;;; +39250-6;LL371-6;HL79033_Program name;LA6650-1;4;Women infants and children;;; +39250-6;LL371-6;HL79033_Program name;LA46-8;5;Other;;; +39272-0;LL372-4;HL79030_Network;LA6652-7;1;In-network;;; +39272-0;LL372-4;HL79030_Network;LA6653-5;2;Out-of-network;;; +39286-0;LL373-2;HL79034_Pt escort;LA6654-3;1;Parent;;; +39286-0;LL373-2;HL79034_Pt escort;LA6655-0;2;Relative;;; +39286-0;LL373-2;HL79034_Pt escort;LA6656-8;3;Friend;;; +39286-0;LL373-2;HL79034_Pt escort;LA6657-6;4;Social worker;;; +39286-0;LL373-2;HL79034_Pt escort;LA46-8;5;Other;;; +39286-0;LL373-2;HL79034_Pt escort;LA6654-3;1;Parent;;; +39286-0;LL373-2;HL79034_Pt escort;LA6655-0;2;Relative;;; +39286-0;LL373-2;HL79034_Pt escort;LA6656-8;3;Friend;;; +39286-0;LL373-2;HL79034_Pt escort;LA6657-6;4;Social worker;;; +39286-0;LL373-2;HL79034_Pt escort;LA46-8;5;Other;;; +39807-3;LL124-9;CR_1646_Surgery site;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +39807-3;LL124-9;CR_1646_Surgery site;LA4489-6;2;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +42040-6;LL124-9;CR_1646_Surgery site;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +42040-6;LL124-9;CR_1646_Surgery site;LA4489-6;2;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3869-0;1;Metropolitan central county, 1 million population or more;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3831-0;2;Metropolitan fringe county, 1 million population or more;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3856-7;3;Metropolitan county, 250,000-1,000,000 population;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3855-9;4;Metropolitan county, less than 250,000 population;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3591-0;5;Urban, adjacent to metropolitan area, 20,000 population or more;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3590-2;6;Urban, not adjacent to metropolitan area, 20,000 population or more;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3593-6;7;Urban, adjacent to metropolitan area, 2,500-19,999 population;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3592-8;8;Urban, not adjacent to metropolitan area, 2,500-19,999 population;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3861-7;9;Rural, adjacent to metropolitan area, less than 2,500 population;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3860-9;11;Rural, not adjacent to metropolitan area, less than 2,500 population;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA3701-5;12;Area not in rural-urban continuum code table or resident outside reporting institution state;;; +39810-7;LL204-9;CR_3300_Rural-urban 1993;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +40425-1;LL5517-9;CYP2D6 genotypes;LA30687-0;1;CYP2D6*1A/*4X2;;; +40425-1;LL5517-9;CYP2D6 genotypes;LA30688-8;2;CYP2D6*1A/*1B;;; +40425-1;LL5517-9;CYP2D6 genotypes;LA30689-6;3;CYP2D6*1A/*1C;;; +40425-1;LL5517-9;CYP2D6 genotypes;LA30690-4;4;CYP2D6*1C/*6B;;; +40684-3;LL2256-7;Acinetobacter MDR;LA19180-1;1;No drug resistant Acinetobacter isolated;;; +40684-3;LL2256-7;Acinetobacter MDR;LA19179-3;2;Acinetobacter baumanii;;; +40978-9;LL2267-4;hMPV genotype;LA19212-2;1;A1;;; +40978-9;LL2267-4;hMPV genotype;LA19213-0;2;A2;;; +40978-9;LL2267-4;hMPV genotype;LA13488-4;3;B1;;; +40978-9;LL2267-4;hMPV genotype;LA13489-2;4;B2;;; +40978-9;LL2267-4;hMPV genotype;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +40978-9;LL2267-4;hMPV genotype;LA46-8;6;Other;;; +88532-7;LL2267-4;hMPV genotype;LA19212-2;1;A1;;; +88532-7;LL2267-4;hMPV genotype;LA19213-0;2;A2;;; +88532-7;LL2267-4;hMPV genotype;LA13488-4;3;B1;;; +88532-7;LL2267-4;hMPV genotype;LA13489-2;4;B2;;; +88532-7;LL2267-4;hMPV genotype;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +88532-7;LL2267-4;hMPV genotype;LA46-8;6;Other;;; +89652-2;LL2267-4;hMPV genotype;LA19212-2;1;A1;;; +89652-2;LL2267-4;hMPV genotype;LA19213-0;2;A2;;; +89652-2;LL2267-4;hMPV genotype;LA13488-4;3;B1;;; +89652-2;LL2267-4;hMPV genotype;LA13489-2;4;B2;;; +89652-2;LL2267-4;hMPV genotype;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +89652-2;LL2267-4;hMPV genotype;LA46-8;6;Other;;; +91778-1;LL2267-4;hMPV genotype;LA19212-2;1;A1;;; +91778-1;LL2267-4;hMPV genotype;LA19213-0;2;A2;;; +91778-1;LL2267-4;hMPV genotype;LA13488-4;3;B1;;; +91778-1;LL2267-4;hMPV genotype;LA13489-2;4;B2;;; +91778-1;LL2267-4;hMPV genotype;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +91778-1;LL2267-4;hMPV genotype;LA46-8;6;Other;;; +40987-0;LL2272-4;RSV type;LA19232-0;1;GA1;;; +40987-0;LL2272-4;RSV type;LA19233-8;2;GA2;;; +40987-0;LL2272-4;RSV type;LA19234-6;3;GA3;;; +40987-0;LL2272-4;RSV type;LA19235-3;4;GA4;;; +40987-0;LL2272-4;RSV type;LA19225-4;5;GA5;;; +40987-0;LL2272-4;RSV type;LA19228-8;6;gB1;;; +40987-0;LL2272-4;RSV type;LA19229-6;7;gB2;;; +40987-0;LL2272-4;RSV type;LA19230-4;8;gB3;;; +40987-0;LL2272-4;RSV type;LA19231-2;9;gB4;;; +40987-0;LL2272-4;RSV type;LA46-8;10;Other;;; +40990-4;LL2274-0;Rhinovirus;LA19241-1;1;1A;;; +40990-4;LL2274-0;Rhinovirus;LA19242-9;2;1B;;; +40990-4;LL2274-0;Rhinovirus;LA6113-0;3;2;;; +40990-4;LL2274-0;Rhinovirus;LA6114-8;4;3;;; +40990-4;LL2274-0;Rhinovirus;LA13942-0;5;10;;; +40990-4;LL2274-0;Rhinovirus;LA19243-7;6;29;;; +40990-4;LL2274-0;Rhinovirus;LA19244-5;7;100;;; +40990-4;LL2274-0;Rhinovirus;LA19245-2;8;101;;; +40990-4;LL2274-0;Rhinovirus;LA46-8;9;Other;;; +40993-8;LL2274-0;Rhinovirus;LA19241-1;1;1A;;; +40993-8;LL2274-0;Rhinovirus;LA19242-9;2;1B;;; +40993-8;LL2274-0;Rhinovirus;LA6113-0;3;2;;; +40993-8;LL2274-0;Rhinovirus;LA6114-8;4;3;;; +40993-8;LL2274-0;Rhinovirus;LA13942-0;5;10;;; +40993-8;LL2274-0;Rhinovirus;LA19243-7;6;29;;; +40993-8;LL2274-0;Rhinovirus;LA19244-5;7;100;;; +40993-8;LL2274-0;Rhinovirus;LA19245-2;8;101;;; +40993-8;LL2274-0;Rhinovirus;LA46-8;9;Other;;; +41000-1;LL2266-6;HCoV;LA19207-2;1;229E;;; +41000-1;LL2266-6;HCoV;LA19208-0;2;OC43;;; +41000-1;LL2266-6;HCoV;LA19209-8;3;NL63;;; +41000-1;LL2266-6;HCoV;LA19210-6;4;HK1;;; +41000-1;LL2266-6;HCoV;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +41000-1;LL2266-6;HCoV;LA13538-6;6;Not tested;;; +41000-1;LL2266-6;HCoV;LA46-8;7;Other;;; +41454-0;LL2266-6;HCoV;LA19207-2;1;229E;;; +41454-0;LL2266-6;HCoV;LA19208-0;2;OC43;;; +41454-0;LL2266-6;HCoV;LA19209-8;3;NL63;;; +41454-0;LL2266-6;HCoV;LA19210-6;4;HK1;;; +41454-0;LL2266-6;HCoV;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +41454-0;LL2266-6;HCoV;LA13538-6;6;Not tested;;; +41454-0;LL2266-6;HCoV;LA46-8;7;Other;;; +41096-9;LL5518-7;KEL allele genotypes;LA30883-5;1;KEL*01.01 /02 (K/k or K+k+);;; +41096-9;LL5518-7;KEL allele genotypes;LA30884-3;2;KEL*02/02 (k/k or K-k+);;; +41096-9;LL5518-7;KEL allele genotypes;LA30885-0;3;KEL*01.01/01.01 (K/K or K+k-);;; +41451-6;LL2289-8;Plasmodium stages;LA19292-4;1;Gametocytes;;; +41451-6;LL2289-8;Plasmodium stages;LA19293-2;2;Rings;;; +41451-6;LL2289-8;Plasmodium stages;LA19294-0;3;Schizonts;;; +41451-6;LL2289-8;Plasmodium stages;LA19295-7;4;Trophozoites;;; +41622-2;LL2263-3;B anthracis;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +41622-2;LL2263-3;B anthracis;LA19194-2;2;Pasteur strain;;; +41622-2;LL2263-3;B anthracis;LA19195-9;3;Sterne strain;;; +41622-2;LL2263-3;B anthracis;LA19196-7;4;Virulent strain;;; +41901-0;LL3624-5;Blood pressure measurement devices;LA24017-8;0;Mercury sphygmomanometer;;; +41901-0;LL3624-5;Blood pressure measurement devices;LA24018-6;1;Aneroid (mechanical) sphygmomanometer;;; +41901-0;LL3624-5;Blood pressure measurement devices;LA24019-4;2;Ambulatory oscillometric device;;; +41901-0;LL3624-5;Blood pressure measurement devices;LA24020-2;3;Home oscillometric device;;; +41901-0;LL3624-5;Blood pressure measurement devices;LA24021-0;4;Continuous noninvasive arterial pressure (CNAP) device;;; +41901-0;LL3624-5;Blood pressure measurement devices;LA24022-8;5;Invasive arterial blood pressure device;;; +41904-4;LL718-8;BP site;LA11158-5;1;Biceps left;;; +41904-4;LL718-8;BP site;LA11159-3;2;Biceps right;;; +41904-4;LL718-8;BP site;LA11160-1;3;Wrist left;;; +41904-4;LL718-8;BP site;LA11161-9;4;Wrist right;;; +41904-4;LL718-8;BP site;LA21901-6;5;Thigh left;;; +41904-4;LL718-8;BP site;LA21900-8;6;Thigh right;;; +41904-4;LL718-8;BP site;LA21903-2;7;Ankle left;;; +41904-4;LL718-8;BP site;LA21902-4;8;Ankle right;;; +41904-4;LL718-8;BP site;LA11862-2;9;Finger;;; +42023-2;LL206-4;CR_35_FIN coding system;LA4161-1;1;COC 6-digit codes;;; +42023-2;LL206-4;CR_35_FIN coding system;LA4159-5;2;COC FIN 10-digit codes;;; +42023-2;LL206-4;CR_35_FIN coding system;LA4736-0;3;NPI 8-digit codes;;; +42023-2;LL206-4;CR_35_FIN coding system;LA4118-1;4;15-digit codes;;; +42023-2;LL206-4;CR_35_FIN coding system;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +42062-0;LL138-9;CR_1840_Country;LA4210-6;1;County unknown;;; +42062-0;LL138-9;CR_1840_Country;LA4589-3;2;"Known place of residence, county code not available; non-US";;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4715-4;1;None or not known;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4689-1;2;Peritoneum;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4579-4;3;Lung;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4680-0;4;Pleura;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4584-4;5;Liver;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4277-5;6;Bone;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4174-4;7;Central Nervous System;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4332-8;8;Skin;;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4577-8;9;Lymph Nodes (distant);;; +42063-8;LL141-3;CR_1871_Cancer recurrance site;LA4661-0;11;Other, generalized, NOS, carcinomatosis;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4715-4;1;None or not known;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4689-1;2;Peritoneum;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4579-4;3;Lung;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4680-0;4;Pleura;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4584-4;5;Liver;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4277-5;6;Bone;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4174-4;7;Central Nervous System;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4332-8;8;Skin;;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4577-8;9;Lymph Nodes (distant);;; +42064-6;LL141-3;CR_1871_Cancer recurrance site;LA4661-0;11;Other, generalized, NOS, carcinomatosis;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4715-4;1;None or not known;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4689-1;2;Peritoneum;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4579-4;3;Lung;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4680-0;4;Pleura;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4584-4;5;Liver;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4277-5;6;Bone;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4174-4;7;Central Nervous System;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4332-8;8;Skin;;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4577-8;9;Lymph Nodes (distant);;; +42065-3;LL141-3;CR_1871_Cancer recurrance site;LA4661-0;11;Other, generalized, NOS, carcinomatosis;;; +42076-0;LL176-9;CR_2116_Morphology conversion method;LA4561-2;1;Morphology (Morph--Type&Behav ICD-O-3 [521] originally coded in ICD-O-3;;; +42076-0;LL176-9;CR_2116_Morphology conversion method;LA4606-5;2;Morphology (Morph--Type&Behav ICD-O-3 [521] converted from (Morph--Type&Behav ICD-O-2 [419] without review;;; +42076-0;LL176-9;CR_2116_Morphology conversion method;LA9655-7;3;Morphology (Morph--Type&Behav ICD-O-3 [521] converted from (Morph--Type&Behav ICD-O-2 [419] with review;;; +42325-1;LL5570-8;RHD & RHCE allele genotypes;LA30906-4;1;DCe/-cE;;; +42325-1;LL5570-8;RHD & RHCE allele genotypes;LA30907-2;2;DCE/DCe;;; +42325-1;LL5570-8;RHD & RHCE allele genotypes;LA30908-0;3;-ce/Dce;;; +42540-5;LL421-9;MERS_TH_21_Environ contributing factor;LA7524-7;1;Lighting;;; +42540-5;LL421-9;MERS_TH_21_Environ contributing factor;LA7525-4;2;Noise level;;; +42540-5;LL421-9;MERS_TH_21_Environ contributing factor;LA7526-2;3;Emergency situation;;; +42540-5;LL421-9;MERS_TH_21_Environ contributing factor;LA7527-0;4;Wet/slippery floor/surface;;; +42540-5;LL421-9;MERS_TH_21_Environ contributing factor;LA7528-8;5;Night, weekend, or holiday;;; +42540-5;LL421-9;MERS_TH_21_Environ contributing factor;LA46-8;6;Other;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7530-4;1;Confusion;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7531-2;2;Frail/unsteady;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7532-0;3;Medicated;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7533-8;4;Drugs/alcohol;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7534-6;5;Psychosis;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7535-3;6;Physical impairment;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7536-1;7;Known allergy;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7537-9;8;Line/cath. removed;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7538-7;9;Self-administration;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7539-5;10;Non-compliant;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA7540-3;11;Language barrier;;; +42541-3;LL422-7;MERS_TH_22_Pt contibuting factor;LA46-8;12;Other;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7542-9;1;Fatigue;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7543-7;2;Distractions/interruptions;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7544-5;3;Inexperience;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7545-2;4;Stress;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7546-0;5;Inattention;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7547-8;6;Clinical decision/assessment;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7548-6;7;Technical performance/administration;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7549-4;8;Wristband check incorrect/not done;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA7550-2;9;Slow/no response to situation;;; +42542-1;LL423-5;MERS_TH_23_Staff contributing factor;LA46-8;10;Other;;; +42543-9;LL424-3;MERS_TH_24_Delay-premature factor;LA7552-8;1;Treatment/administration;;; +42543-9;LL424-3;MERS_TH_24_Delay-premature factor;LA7553-6;2;Consultation;;; +42543-9;LL424-3;MERS_TH_24_Delay-premature factor;LA7554-4;3;Execution;;; +42543-9;LL424-3;MERS_TH_24_Delay-premature factor;LA7555-1;4;Delivery;;; +42543-9;LL424-3;MERS_TH_24_Delay-premature factor;LA7556-9;5;Test;;; +42543-9;LL424-3;MERS_TH_24_Delay-premature factor;LA46-8;6;Other;;; +42545-4;LL425-0;MERS_TH_25_Event outcome;LA7558-5;1;No recovery, harm;;; +42545-4;LL425-0;MERS_TH_25_Event outcome;LA7559-3;2;No recovery, no harm;;; +42545-4;LL425-0;MERS_TH_25_Event outcome;LA7560-1;3;Near miss, unplanned recovery;;; +42545-4;LL425-0;MERS_TH_25_Event outcome;LA7561-9;4;Near miss, planned recovery;;; +42547-0;LL401-1;MERS_TH_1;LA7165-9;1;Consequent;;; +42547-0;LL401-1;MERS_TH_1;LA7166-7;2;First antecedent;;; +42547-0;LL401-1;MERS_TH_1;LA7167-5;3;Most significant antecedent;;; +42547-0;LL401-1;MERS_TH_1;LA7168-3;4;Other antecedent;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7169-1;1;Anesthesia;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7170-9;2;Dentistry;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7171-7;3;Dermatology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7172-5;4;Emergency room;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7173-3;5;Family medicine;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7174-1;6;ICU.coronary care;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7175-8;7;ICU.general;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7176-6;8;ICU.medical;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7177-4;9;ICU.neurological;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7178-2;10;ICU.surgical;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7179-0;11;Medicine.cardiology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7180-8;12;Medicine.endocrinology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7181-6;13;Medicine.gastroenterology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7182-4;14;Medicine.general medicine;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7183-2;15;Medicine.hematology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7184-0;16;Medicine.infectious disease;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7185-7;17;Medicine.nephrology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7186-5;18;Medicine.oncology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7188-1;19;Medicine.pulmonary;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7189-9;20;Medicine.rhematology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7190-7;21;Neurology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7191-5;22;Neurosurgery;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7193-1;23;Obstetrics/gynecology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7194-9;24;Opthalmology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7195-6;25;Orthopedics;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7196-4;26;Otolaryngology/ENT;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7197-2;27;Pediatrics;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7198-0;28;Psychiatry;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7199-8;29;Radiation oncology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7200-4;30;Rehabilitation;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7201-2;31;Surgery.breast;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7202-0;32;Surgery.cardiothoracic;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7203-8;33;Surgery.colorectal;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7204-6;34;Surgery.endocrine;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7205-3;35;Surgery.general;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7206-1;36;Surgery.pediatric;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7207-9;37;Surgery.plastic;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7208-7;38;Surgery.oncologic;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7209-5;39;Surgery.transplant;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7210-3;40;Surgery.trauma;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7211-1;41;Surgery.vascular;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7212-9;42;Surgery.urology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7213-7;43;Ambulatory care;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7214-5;44;Cardiac catheterization;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7215-2;45;Echocardiography;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7216-0;46;Dialysis;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7217-8;47;Laboratory.chemistry;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7218-6;48;Laboratory.hematology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7219-4;49;Laboratory.microbiology;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7221-0;51;Laboratory.other;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7222-8;52;Operating room;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7223-6;53;Pharmacy;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7224-4;54;Radiology/imaging;;; +42548-8;LL402-9;MERS_TH_2_Service;LA7225-1;55;Recovery room;;; +42548-8;LL402-9;MERS_TH_2_Service;LA46-8;56;Other;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7227-7;1;Medication.prescribing;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7228-5;2;Medication.ordering/documenting;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7229-3;3;Medication.preparation/dispensing;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7230-1;4;Medication.administering;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7231-9;5;Medication.monitoring;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7232-7;6;Procedure/treatment/surgery.anesthesia;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7233-5;7;Procedure/treatment/surgery.radiology;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7234-3;8;Procedure/treatment/surgery.surgery;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7235-0;9;Procedure/treatment/surgery.diagnostic procedure;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7236-8;10;Procedure/treatment/surgery.therapy;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7237-6;11;Food/nutrition;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7238-4;12;Fall;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7239-2;13;Accident.nonfall;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7240-0;14;General nursing care;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7241-8;15;Equipment/device;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7242-6;16;Laboratory.test request;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7243-4;17;Laboratory.order entry;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7244-2;18;Laboratory.sample collection;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7245-9;19;Laboratory.sample labeling;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7246-7;20;Laboratory.sample testing;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7247-5;21;Laboratory.results interpretation;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7248-3;22;Laboratory.results entry;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7249-1;23;Laboratory.product/reagent/sample storage/manipulation;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7250-9;24;Transfusion service.product check-in;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7251-7;25;Transfusion service.product testing;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7252-5;26;Transfusion service.product/test request;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7253-3;27;Transfusion service.product order entry;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7254-1;28;Transfusion service.sample collection;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7255-8;29;Transfusion service.labeling/handling;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7256-6;30;Transfusion service.sample testing;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7257-4;31;Transfusion service.product storage;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7258-2;32;Transfusion service.product manipulation;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7259-0;33;Transfusion service.product selection;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7260-8;34;Transfusion service.product issue;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7261-6;35;Transfusion service.product administration;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7262-4;36;Administrative;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7263-2;37;Complaint;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7264-0;38;Environmental hazard/safety;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7265-7;39;Crime/intentional harm/patient disappearance;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA7266-5;40;Adverse event;;; +42549-6;LL403-7;MERS_TH_3_Event type;LA46-8;41;Other;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7268-1;1;Not prescribed;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7269-9;2;Wrong prescription;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7270-7;3;Dose omission;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7271-5;4;Extra dose;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7272-3;5;Wrong frequency;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7273-1;6;Wrong duration;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7274-9;7;Wrong strength/concentration;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7275-6;8;Wrong drug;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7276-4;9;Wrong dosage form;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7277-2;10;Wrong diluent;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7278-0;11;Wrong technique;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7279-8;12;Wrong administration route;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7280-6;13;Wrong rate of administration;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7378-8;14;Computer issue incorrect/not done;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7282-2;15;Expired drug;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7283-0;16;Contraindicated drug;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7284-8;17;Confusing/similar drug names;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7285-5;18;Labeled incorrectly;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7286-3;19;Delivered to wrong location;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA7287-1;20;Unavailable;;; +42550-4;LL404-5;MERS_TH_4_Med event;LA46-8;21;Other;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7289-7;1;Wrong patient;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7290-5;2;Wrong laterality;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7291-3;3;Wrong site;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7292-1;4;Wrong procedure;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7293-9;5;Failure in sterile precautions;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7294-7;6;Unintended laceration/puncture;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7295-4;7;Foreign body retained;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7296-2;8;Unplanned extubation;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7297-0;9;Intubation problem;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7298-8;10;Suture/ligature problem;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7299-6;11;Incorrect sponge count;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7300-2;12;Incorrect needle count;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7301-0;13;Incorrect instrument count;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7302-8;14;Incorrect contrast/dye;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7303-6;15;Problem with consent;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7304-4;16;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA7305-1;17;Delayed;;; +42551-2;LL405-2;MERS_TH_5_Proc-tx-surg event;LA46-8;18;Other;;; +42552-0;LL406-0;MERS_TH_6_Food-nutrition event;LA7307-7;1;Incorrect diet ordered;;; +42552-0;LL406-0;MERS_TH_6_Food-nutrition event;LA7308-5;2;Incorrect diet served;;; +42552-0;LL406-0;MERS_TH_6_Food-nutrition event;LA7309-3;3;Food/liquids given despite NPO;;; +42552-0;LL406-0;MERS_TH_6_Food-nutrition event;LA46-8;4;Other;;; +42553-8;LL407-8;MERS_TH_7_Fall event;LA7311-9;1;Fall from bed/table/stretcher;;; +42553-8;LL407-8;MERS_TH_7_Fall event;LA7312-7;2;Fall from chair;;; +42553-8;LL407-8;MERS_TH_7_Fall event;LA7313-5;3;Fall from wheelchair;;; +42553-8;LL407-8;MERS_TH_7_Fall event;LA7314-3;4;Fall during transfer;;; +42553-8;LL407-8;MERS_TH_7_Fall event;LA7315-0;5;Fall while walking;;; +42553-8;LL407-8;MERS_TH_7_Fall event;LA7316-8;6;Fall in bathroom/shower;;; +42553-8;LL407-8;MERS_TH_7_Fall event;LA7317-6;7;Found on floor;;; +42554-6;LL408-6;MERS_TH_8_Accident event;LA7318-4;1;Burn;;; +42554-6;LL408-6;MERS_TH_8_Accident event;LA7319-2;2;Collision;;; +42554-6;LL408-6;MERS_TH_8_Accident event;LA7320-0;3;Cut/abrasion/puncture;;; +42554-6;LL408-6;MERS_TH_8_Accident event;LA7321-8;4;Poisoning;;; +42554-6;LL408-6;MERS_TH_8_Accident event;LA7322-6;5;Electrical shock;;; +42554-6;LL408-6;MERS_TH_8_Accident event;LA7323-4;6;Needle stick;;; +42554-6;LL408-6;MERS_TH_8_Accident event;LA46-8;7;Other;;; +42555-3;LL409-4;MERS_TH_9_Nursing care event;LA7289-7;1;Wrong patient;;; +42555-3;LL409-4;MERS_TH_9_Nursing care event;LA7326-7;2;Inadequate monitoring;;; +42555-3;LL409-4;MERS_TH_9_Nursing care event;LA7327-5;3;Improper bedrail position;;; +42555-3;LL409-4;MERS_TH_9_Nursing care event;LA7328-3;4;Improper restraint;;; +42555-3;LL409-4;MERS_TH_9_Nursing care event;LA7329-1;5;Inadequate patient turning;;; +42555-3;LL409-4;MERS_TH_9_Nursing care event;LA7330-9;6;Wristband not checked;;; +42555-3;LL409-4;MERS_TH_9_Nursing care event;LA46-8;7;Other;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7332-5;1;Not functioning properly;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7333-3;2;Not properly maintained;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7334-1;3;Used/set incorrectly;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7335-8;4;Used inappropriately;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7336-6;5;Electrical malfunction;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7337-4;6;Disconnected;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7338-2;7;Not available;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA7339-0;8;Operator problem;;; +42556-1;LL410-2;MERS_TH_10_Equip-device event;LA46-8;9;Other;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7341-6;1;Incomplete;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7342-4;2;Incorrect;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7343-2;3;Delay;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7344-0;4;Not performed/received;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7289-7;5;Wrong patient;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7346-5;6;Computer problem;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7347-3;7;Sample tube mix-up;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7348-1;8;Lost sample;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7349-9;9;Papers and sample don't match;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7350-7;10;Computer warning overridden;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7351-5;11;Special processing needs not checked/not understood/ misinterpreted/ not done;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7352-3;12;Reagent/equipment issue;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7353-1;13;Treated/stored under inappropriate conditions;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7354-9;14;Administrative check not done/ incorrect;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA7355-6;15;No/incorrect check of patient information;;; +42557-9;LL411-0;MERS_TH_11_Lab event;LA46-8;16;Other;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7341-6;1;Incomplete;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7342-4;2;Incorrect;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7343-2;3;Delay;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7344-0;4;Not performed/received;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7289-7;5;Wrong patient;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7346-5;6;Computer problem;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7347-3;7;Sample tube mix-up;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7348-1;8;Lost sample;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7365-5;9;Shipped/stored under inappropriate conditions;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7366-3;10;Special needs not indicated (e.g. auto, CMV negative);;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7367-1;11;Paperwork and sample/product discrepancy;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7350-7;12;Computer warning overridden;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7369-7;13;Test method/interpretation incorrect;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7352-3;14;Reagent/equipment issue;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7371-3;15;Record review incomplete/incorrect;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7372-1;16;Historical file misinterpreted/not checked;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7373-9;17;Mismatch between current and historical type;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7374-7;18;Administrative/2nd check not done/incorrect;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7351-5;19;Special processing needs not checked/not understood/ misinterpreted/ not done;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7376-2;20;No check/incorrect check of product and/or patient information;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7377-0;21;Pick-up slip did not match patient information;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7378-8;22;Computer issue incorrect/not done;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7379-6;23;Subsequent check (review/audit after the fact);;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7286-3;24;Delivered to wrong location;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7381-2;25;Administered with wrong IV fluid;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7382-0;26;Administered in wrong order;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA7383-8;27;Autologous/directed issue;;; +42558-7;LL412-8;MERS_TH_12_Transfusion event;LA46-8;28;Other;;; +42559-5;LL413-6;MERS_TH_13_Admin event;LA7385-3;1;Admission problem/error;;; +42559-5;LL413-6;MERS_TH_13_Admin event;LA7386-1;2;Discharge problem/error;;; +42559-5;LL413-6;MERS_TH_13_Admin event;LA7387-9;3;Unavailable/incorrect record;;; +42559-5;LL413-6;MERS_TH_13_Admin event;LA7388-7;4;Patient identification issue;;; +42559-5;LL413-6;MERS_TH_13_Admin event;LA46-8;5;Other;;; +42560-3;LL414-4;MERS_TH_14_Complaint event;LA7390-3;1;Inappropriate staff/MD behavior;;; +42560-3;LL414-4;MERS_TH_14_Complaint event;LA7391-1;2;Inappropriate patient behavior;;; +42560-3;LL414-4;MERS_TH_14_Complaint event;LA46-8;3;Other;;; +42561-1;LL415-1;MERS_TH_15_Eviron-safety event;LA7393-7;1;Body fluid exposure;;; +42561-1;LL415-1;MERS_TH_15_Eviron-safety event;LA7394-5;2;Chemical exposure;;; +42561-1;LL415-1;MERS_TH_15_Eviron-safety event;LA7395-2;3;Chemotherapy spill;;; +42561-1;LL415-1;MERS_TH_15_Eviron-safety event;LA7396-0;4;Hazardous material spill;;; +42561-1;LL415-1;MERS_TH_15_Eviron-safety event;LA46-8;5;Other;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7398-6;1;Abduction;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7399-4;2;Sexual assault/rape;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7321-8;3;Poisoning;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7401-8;4;Assault/altercation;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7402-6;5;Suicide/attempt;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7403-4;6;Self-harm;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7404-2;7;Threats;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7405-9;8;Elopement;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7406-7;9;Missing child/infant;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7407-5;10;Confidentiality breach;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA7408-3;11;Theft;;; +42562-9;LL416-9;MERS_TH_16_Crime-harm-disappear event;LA46-8;12;Other;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7410-9;1;Abrasion;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7411-7;2;Abscess;44132006;Abscess (morphologic abnormality);http://snomed.info/sct +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7412-5;3;Acute MI;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7413-3;4;Anaphylaxis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7414-1;5;Arrhythmia;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7415-8;6;Aspiration pneumonia;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7416-6;7;Atelectasis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7417-4;8;Birth-related injury;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7418-2;9;Bleeding;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7318-4;10;Burn;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7420-8;11;Cardiac occurrence;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7421-6;12;Cardiac/respiratory arrest;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7422-4;13;Concussion;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7423-2;14;Contusion;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7424-0;15;Death;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7425-7;16;Deep vein thrombosis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7426-5;17;Delirium;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7427-3;18;Dehiscence;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7428-1;19;Dizziness;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7429-9;20;Drug reaction;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7430-7;21;Ecchymosis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7431-5;22;Emotional;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7432-3;23;Endocarditis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7433-1;24;Erythema;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7434-9;25;Extravasation;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7435-6;26;Fever;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7436-4;27;Fistula;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7437-2;28;Fracture;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7438-0;29;Hallucinations;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7439-8;30;Hematoma;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7440-6;31;Hematologic complication;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7441-4;32;Hemorrhage;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7442-2;33;Hepatitis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7443-0;34;Hypotension;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7444-8;35;Hypertension;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7445-5;36;Incontinence;48340000;incontinence (finding);http://snomed.info/sct +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7446-3;37;Infection;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7447-1;38;Inflammation;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7448-9;39;Internal trauma;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7449-7;40;Irritation;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7450-5;41;Jaundice;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7451-3;42;Laboratory finding;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7452-1;43;Laceration;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7453-9;44;Loss of consciousness;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7454-7;45;Meningitis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7455-4;46;Mental status change;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7456-2;47;Necrosis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7457-0;48;Non-healing;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7458-8;49;Neurological impairment;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7459-6;50;Neuropothy;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7460-4;51;Pain;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7461-2;52;Perforation;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7462-0;53;Pericarditis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7463-8;54;Peritonitis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7464-6;55;Phlebitis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7465-3;56;Pneumonia;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7466-1;57;Pneumothorax;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7467-9;58;Pulmonary edema;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7468-7;59;Pulmonary embolism;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7469-5;60;Rash;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7470-3;61;Rupture;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7471-1;62;Scarring;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7472-9;63;Seizure;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7473-7;64;Shock;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7474-5;65;Sprain/strain;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7475-2;66;Thrombophlebitis;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7476-0;67;Transfusion reaction;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA7477-8;68;Ulceration;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA6437-3;69;Urinary tract infection;;; +42563-7;LL417-7;MERS_TH_17_Adverse event;LA46-8;70;Other;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7480-2;1;Computer error;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7272-3;2;Wrong frequency;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7482-8;3;Drug names similar/confusing;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7387-9;4;Unavailable/incorrect record;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7484-4;5;Unavailable/incorrect test;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7485-1;6;Unavailable/incorrect equipment;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7486-9;7;Unavailable/incorrect drug/blood product;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7487-7;8;Unavailable/incorrect wristband;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7488-5;9;Unavailable/incorrect prescription;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7489-3;10;Unavailable/incorrect supplies;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7490-1;11;Incorrect infusion rate;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7491-9;12;Incorrect dose;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7492-7;13;Omission;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7493-5;14;Incorrect medication route;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7494-3;15;Incorrect diluent/concentration;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7495-0;16;Failure in dispensing;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7496-8;17;Wrong/ambiguous labeling/packaging;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7497-6;18;Equipment failure;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7498-4;19;Miscalculation;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA7499-2;20;Expiration date issue;;; +42564-5;LL418-5;MERS_TH_18_Tech contributing factor;LA46-8;21;Other;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7501-5;1;Procedure wrong/ambiguous/lacking;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7502-3;2;Training inadequate/not done;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7503-1;3;Insufficient/inappropriate supervision;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7504-9;4;Inappropriate workload;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7505-6;5;Staffing level;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7506-4;6;Inappropriate/no policy;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7507-2;7;Cross-coverage inadequate;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA7508-0;8;Culture;;; +42565-2;LL419-3;MERS_TH_19_Org contributing factor;LA46-8;9;Other;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7510-6;1;Confusing abbreviation(s) used;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7511-4;2;Illegible documentation;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7512-2;3;Transcription error;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7513-0;4;Verbal miscommunication;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7514-8;5;Written communication;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7515-5;6;Lack of communication;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7516-3;7;Hand-off/ teamwork/cross-coverage;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7517-1;8;Shift change;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7518-9;9;Name confusion;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7519-7;10;Fax problem;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7520-5;11;Lack of/inadequate documentation;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7521-3;12;Record incomplete/unavail./incorrect;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA7522-1;13;Poor/inadequate/no instructions;;; +42566-0;LL420-1;MERS_TH_20_Comm-documentation factor;LA46-8;14;Other;;; +42800-3;LL529-9;ECOG_Performance status;LA9622-7;1;Fully active, able to carry on all pre-disease performance without restriction;;; +42800-3;LL529-9;ECOG_Performance status;LA9623-5;2;Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work;;; +42800-3;LL529-9;ECOG_Performance status;LA9624-3;3;Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours;;; +42800-3;LL529-9;ECOG_Performance status;LA9625-0;4;Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours;;; +42800-3;LL529-9;ECOG_Performance status;LA9626-8;5;Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair;;; +42800-3;LL529-9;ECOG_Performance status;LA9627-6;6;Dead;;; +89262-0;LL529-9;ECOG_Performance status;LA9622-7;1;Fully active, able to carry on all pre-disease performance without restriction;;; +89262-0;LL529-9;ECOG_Performance status;LA9623-5;2;Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work;;; +89262-0;LL529-9;ECOG_Performance status;LA9624-3;3;Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours;;; +89262-0;LL529-9;ECOG_Performance status;LA9625-0;4;Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours;;; +89262-0;LL529-9;ECOG_Performance status;LA9626-8;5;Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair;;; +89262-0;LL529-9;ECOG_Performance status;LA9627-6;6;Dead;;; +44093-3;LL2022-3;N meningitidis culture;LA16626-6;1;Neisseria meningitidis;17872004;Neisseria meningitidis (organism);http://snomed.info/sct +44093-3;LL2022-3;N meningitidis culture;LA18421-0;2;Neisseria meningitidis serogroup A;;; +44093-3;LL2022-3;N meningitidis culture;LA18431-9;3;Neisseria meningitidis serogroup B;;; +44093-3;LL2022-3;N meningitidis culture;LA18422-8;4;Neisseria meningitidis serogroup C;;; +44093-3;LL2022-3;N meningitidis culture;LA18425-1;5;Neisseria meningitidis serogroup Z;;; +44093-3;LL2022-3;N meningitidis culture;LA18420-2;6;Neisseria meningitidis serogroup Z';;; +44093-3;LL2022-3;N meningitidis culture;LA18423-6;7;Neisseria meningitidis serogroup W135;;; +44093-3;LL2022-3;N meningitidis culture;LA18429-3;8;Neisseria mucosa;;; +44093-3;LL2022-3;N meningitidis culture;LA18430-1;9;No Neisseria meningitidis isolated;;; +44093-3;LL2022-3;N meningitidis culture;LA18426-9;10;Sent to CDC;;; +44093-3;LL2022-3;N meningitidis culture;LA18427-7;11;Organism not viable;;; +44093-3;LL2022-3;N meningitidis culture;LA16390-9;12;Rejected;;; +44093-3;LL2022-3;N meningitidis culture;LA18428-5;13;Culture contaminated;;; +70172-2;LL2022-3;N meningitidis culture;LA16626-6;1;Neisseria meningitidis;17872004;Neisseria meningitidis (organism);http://snomed.info/sct +70172-2;LL2022-3;N meningitidis culture;LA18421-0;2;Neisseria meningitidis serogroup A;;; +70172-2;LL2022-3;N meningitidis culture;LA18431-9;3;Neisseria meningitidis serogroup B;;; +70172-2;LL2022-3;N meningitidis culture;LA18422-8;4;Neisseria meningitidis serogroup C;;; +70172-2;LL2022-3;N meningitidis culture;LA18425-1;5;Neisseria meningitidis serogroup Z;;; +70172-2;LL2022-3;N meningitidis culture;LA18420-2;6;Neisseria meningitidis serogroup Z';;; +70172-2;LL2022-3;N meningitidis culture;LA18423-6;7;Neisseria meningitidis serogroup W135;;; +70172-2;LL2022-3;N meningitidis culture;LA18429-3;8;Neisseria mucosa;;; +70172-2;LL2022-3;N meningitidis culture;LA18430-1;9;No Neisseria meningitidis isolated;;; +70172-2;LL2022-3;N meningitidis culture;LA18426-9;10;Sent to CDC;;; +70172-2;LL2022-3;N meningitidis culture;LA18427-7;11;Organism not viable;;; +70172-2;LL2022-3;N meningitidis culture;LA16390-9;12;Rejected;;; +70172-2;LL2022-3;N meningitidis culture;LA18428-5;13;Culture contaminated;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44250-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +44250-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44250-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44251-7;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44251-7;LL358-3;PHQ;LA6569-3;2;Several days;;; +44251-7;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44251-7;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44252-5;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44252-5;LL358-3;PHQ;LA6569-3;2;Several days;;; +44252-5;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44252-5;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44253-3;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44253-3;LL358-3;PHQ;LA6569-3;2;Several days;;; +44253-3;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44253-3;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44254-1;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44254-1;LL358-3;PHQ;LA6569-3;2;Several days;;; +44254-1;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44254-1;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44255-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44255-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44255-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44255-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44258-2;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44258-2;LL358-3;PHQ;LA6569-3;2;Several days;;; +44258-2;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44258-2;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44259-0;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44259-0;LL358-3;PHQ;LA6569-3;2;Several days;;; +44259-0;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44259-0;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44260-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +44260-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +44260-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +44260-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69683-1;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69683-1;LL358-3;PHQ;LA6569-3;2;Several days;;; +69683-1;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69683-1;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69684-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69684-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +69684-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69684-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69685-6;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69685-6;LL358-3;PHQ;LA6569-3;2;Several days;;; +69685-6;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69685-6;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69686-4;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69686-4;LL358-3;PHQ;LA6569-3;2;Several days;;; +69686-4;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69686-4;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69687-2;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69687-2;LL358-3;PHQ;LA6569-3;2;Several days;;; +69687-2;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69687-2;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69688-0;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69688-0;LL358-3;PHQ;LA6569-3;2;Several days;;; +69688-0;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69688-0;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69689-8;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69689-8;LL358-3;PHQ;LA6569-3;2;Several days;;; +69689-8;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69689-8;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69725-0;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69725-0;LL358-3;PHQ;LA6569-3;2;Several days;;; +69725-0;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69725-0;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69725-0;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69725-0;LL358-3;PHQ;LA6569-3;2;Several days;;; +69725-0;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69725-0;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69725-0;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69725-0;LL358-3;PHQ;LA6569-3;2;Several days;;; +69725-0;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69725-0;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69733-4;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69733-4;LL358-3;PHQ;LA6569-3;2;Several days;;; +69733-4;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69733-4;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69734-2;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69734-2;LL358-3;PHQ;LA6569-3;2;Several days;;; +69734-2;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69734-2;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69735-9;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69735-9;LL358-3;PHQ;LA6569-3;2;Several days;;; +69735-9;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69735-9;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +69736-7;LL358-3;PHQ;LA6568-5;1;Not at all;;; +69736-7;LL358-3;PHQ;LA6569-3;2;Several days;;; +69736-7;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +69736-7;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +95393-5;LL358-3;PHQ;LA6568-5;1;Not at all;;; +95393-5;LL358-3;PHQ;LA6569-3;2;Several days;;; +95393-5;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +95393-5;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +95394-3;LL358-3;PHQ;LA6568-5;1;Not at all;;; +95394-3;LL358-3;PHQ;LA6569-3;2;Several days;;; +95394-3;LL358-3;PHQ;LA6570-1;3;More than half the days;;; +95394-3;LL358-3;PHQ;LA6571-9;4;Nearly every day;;; +44250-9;LL5871-0;Frequency: Not at all --> Nearly every day;LA6568-5;1;Not at all;;; +44250-9;LL5871-0;Frequency: Not at all --> Nearly every day;LA6569-3;2;Several days;;; +44250-9;LL5871-0;Frequency: Not at all --> Nearly every day;LA6570-1;3;More than half the days;;; +44250-9;LL5871-0;Frequency: Not at all --> Nearly every day;LA6571-9;4;Nearly every day;;; +44255-8;LL5871-0;Frequency: Not at all --> Nearly every day;LA6568-5;1;Not at all;;; +44255-8;LL5871-0;Frequency: Not at all --> Nearly every day;LA6569-3;2;Several days;;; +44255-8;LL5871-0;Frequency: Not at all --> Nearly every day;LA6570-1;3;More than half the days;;; +44255-8;LL5871-0;Frequency: Not at all --> Nearly every day;LA6571-9;4;Nearly every day;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +44250-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +44255-8;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +68509-9;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6568-5;1;Not at all;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6569-3;2;Several days;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6570-1;3;More than half the days;;; +69725-0;LL6099-7;Freq: Not at all to near evry day w/o score;LA6571-9;4;Nearly every day;;; +44256-6;LL359-1;PHQ.10;LA6572-7;1;Not difficult at all;;; +44256-6;LL359-1;PHQ.10;LA6573-5;2;Somewhat difficult;;; +44256-6;LL359-1;PHQ.10;LA6575-0;3;Very difficult;;; +44256-6;LL359-1;PHQ.10;LA6574-3;4;Extremely difficult;;; +69722-7;LL359-1;PHQ.10;LA6572-7;1;Not difficult at all;;; +69722-7;LL359-1;PHQ.10;LA6573-5;2;Somewhat difficult;;; +69722-7;LL359-1;PHQ.10;LA6575-0;3;Very difficult;;; +69722-7;LL359-1;PHQ.10;LA6574-3;4;Extremely difficult;;; +44262-4;LL382-3;PHQ-9 Interp-score;LA6708-7;1;0-4 = None;;; +44262-4;LL382-3;PHQ-9 Interp-score;LA6709-5;2;5-9 = Mild depression;;; +44262-4;LL382-3;PHQ-9 Interp-score;LA6710-3;3;10-14 = Moderate depression;;; +44262-4;LL382-3;PHQ-9 Interp-score;LA6711-1;4;15-19 = Moderately severe depression;;; +44262-4;LL382-3;PHQ-9 Interp-score;LA6712-9;5;20-27 = Severe depression;;; +44274-9;LL2241-9;Botulinum toxin;LA11883-8;0;Not detected;;; +44274-9;LL2241-9;Botulinum toxin;LA13487-6;1;A;;; +44274-9;LL2241-9;Botulinum toxin;LA14518-7;2;B;;; +44274-9;LL2241-9;Botulinum toxin;LA14519-5;3;C;;; +44274-9;LL2241-9;Botulinum toxin;LA14520-3;4;D;;; +44274-9;LL2241-9;Botulinum toxin;LA13503-0;5;E;;; +44274-9;LL2241-9;Botulinum toxin;LA13504-8;6;F;;; +44274-9;LL2241-9;Botulinum toxin;LA19150-4;7;G;;; +44796-1;LL2241-9;Botulinum toxin;LA11883-8;0;Not detected;;; +44796-1;LL2241-9;Botulinum toxin;LA13487-6;1;A;;; +44796-1;LL2241-9;Botulinum toxin;LA14518-7;2;B;;; +44796-1;LL2241-9;Botulinum toxin;LA14519-5;3;C;;; +44796-1;LL2241-9;Botulinum toxin;LA14520-3;4;D;;; +44796-1;LL2241-9;Botulinum toxin;LA13503-0;5;E;;; +44796-1;LL2241-9;Botulinum toxin;LA13504-8;6;F;;; +44796-1;LL2241-9;Botulinum toxin;LA19150-4;7;G;;; +46705-0;LL2241-9;Botulinum toxin;LA11883-8;0;Not detected;;; +46705-0;LL2241-9;Botulinum toxin;LA13487-6;1;A;;; +46705-0;LL2241-9;Botulinum toxin;LA14518-7;2;B;;; +46705-0;LL2241-9;Botulinum toxin;LA14519-5;3;C;;; +46705-0;LL2241-9;Botulinum toxin;LA14520-3;4;D;;; +46705-0;LL2241-9;Botulinum toxin;LA13503-0;5;E;;; +46705-0;LL2241-9;Botulinum toxin;LA13504-8;6;F;;; +46705-0;LL2241-9;Botulinum toxin;LA19150-4;7;G;;; +88578-0;LL2241-9;Botulinum toxin;LA11883-8;0;Not detected;;; +88578-0;LL2241-9;Botulinum toxin;LA13487-6;1;A;;; +88578-0;LL2241-9;Botulinum toxin;LA14518-7;2;B;;; +88578-0;LL2241-9;Botulinum toxin;LA14519-5;3;C;;; +88578-0;LL2241-9;Botulinum toxin;LA14520-3;4;D;;; +88578-0;LL2241-9;Botulinum toxin;LA13503-0;5;E;;; +88578-0;LL2241-9;Botulinum toxin;LA13504-8;6;F;;; +88578-0;LL2241-9;Botulinum toxin;LA19150-4;7;G;;; +88589-7;LL2241-9;Botulinum toxin;LA11883-8;0;Not detected;;; +88589-7;LL2241-9;Botulinum toxin;LA13487-6;1;A;;; +88589-7;LL2241-9;Botulinum toxin;LA14518-7;2;B;;; +88589-7;LL2241-9;Botulinum toxin;LA14519-5;3;C;;; +88589-7;LL2241-9;Botulinum toxin;LA14520-3;4;D;;; +88589-7;LL2241-9;Botulinum toxin;LA13503-0;5;E;;; +88589-7;LL2241-9;Botulinum toxin;LA13504-8;6;F;;; +88589-7;LL2241-9;Botulinum toxin;LA19150-4;7;G;;; +44633-6;LL4566-7;[CAP] Tumor pigmentation;LA27878-0;1;No pigmentation;;; +44633-6;LL4566-7;[CAP] Tumor pigmentation;LA27879-8;2;Diffuse pigmentation;;; +44633-6;LL4566-7;[CAP] Tumor pigmentation;LA27880-6;3;Patchy or focal pigmentation;;; +44633-6;LL4566-7;[CAP] Tumor pigmentation;LA11899-4;4;Cannot be determined;;; +44639-3;LL747-7;Histo_Prost;LA11899-4;1;Cannot be determined;;; +44639-3;LL747-7;Histo_Prost;LA11900-0;2;Adenocarcinoma;;; +44639-3;LL747-7;Histo_Prost;LA6310-2;3;Other (specify);;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27883-0;1;Superficial spreading melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27884-8;2;Nodular melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27885-5;3;Lentigo maligna melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27886-3;4;Acral lentiginous melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27887-1;5;Mucosal-lentiginous melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27888-9;6;Desmoplastic/neurotropic melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27889-7;7;Melanoma arising from blue nevus;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27890-5;8;Melanoma arising from a giant congenital nevus;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27891-3;9;Melanoma of childhood;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27892-1;10;Nevoid melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27893-9;11;Persistent melanoma;;; +44640-1;LL4569-1;[CAP] Histologic types for melanoma;LA27894-7;12;Melanoma, not otherwise classified;;; +44641-9;LL746-9;Gleason;LA9629-2;1;Grade 1;;; +44641-9;LL746-9;Gleason;LA9630-0;2;Grade 2;;; +44641-9;LL746-9;Gleason;LA9631-8;3;Grade 3;;; +44641-9;LL746-9;Gleason;LA11897-8;4;Grade 4;;; +44641-9;LL746-9;Gleason;LA11898-6;5;Grade 5;;; +44642-7;LL746-9;Gleason;LA9629-2;1;Grade 1;;; +44642-7;LL746-9;Gleason;LA9630-0;2;Grade 2;;; +44642-7;LL746-9;Gleason;LA9631-8;3;Grade 3;;; +44642-7;LL746-9;Gleason;LA11897-8;4;Grade 4;;; +44642-7;LL746-9;Gleason;LA11898-6;5;Grade 5;;; +44643-5;LL746-9;Gleason;LA9629-2;1;Grade 1;;; +44643-5;LL746-9;Gleason;LA9630-0;2;Grade 2;;; +44643-5;LL746-9;Gleason;LA9631-8;3;Grade 3;;; +44643-5;LL746-9;Gleason;LA11897-8;4;Grade 4;;; +44643-5;LL746-9;Gleason;LA11898-6;5;Grade 5;;; +84904-2;LL746-9;Gleason;LA9629-2;1;Grade 1;;; +84904-2;LL746-9;Gleason;LA9630-0;2;Grade 2;;; +84904-2;LL746-9;Gleason;LA9631-8;3;Grade 3;;; +84904-2;LL746-9;Gleason;LA11897-8;4;Grade 4;;; +84904-2;LL746-9;Gleason;LA11898-6;5;Grade 5;;; +44645-0;LL4382-9;[CAP] Nuclear Pleomorphism;LA27222-1;1;Nuclei small with little increase in size in comparison with normal outlines, uniform clear chromatin, little variation in size;;; +44645-0;LL4382-9;[CAP] Nuclear Pleomorphism;LA27223-9;2;Cells larger than normal with open vesicular nuclei, visible nucleo size and shape;;; +44645-0;LL4382-9;[CAP] Nuclear Pleomorphism;LA27224-7;3;Vesicular nuclei, often with prominent nucleoli, exhibited marked occasionally with very large and bizzare forms;;; +44645-0;LL4382-9;[CAP] Nuclear Pleomorphism;LA27219-7;4;Only microinvasion present (not graded);;; +44645-0;LL4382-9;[CAP] Nuclear Pleomorphism;LA27220-5;5;No residual invasive carcinoma after presurgical (neoadjuvant) therapy;;; +44645-0;LL4382-9;[CAP] Nuclear Pleomorphism;LA27221-3;6;Score cannot be determined;;; +44648-4;LL4561-8;[CAP] Nottingham breast cancer histology score;LA27823-6;1;Nottingham grade 1;;; +44648-4;LL4561-8;[CAP] Nottingham breast cancer histology score;LA27824-4;2;Nottingham grade 2;;; +44648-4;LL4561-8;[CAP] Nottingham breast cancer histology score;LA27825-1;3;Nottingham grade 3;;; +44648-4;LL4561-8;[CAP] Nottingham breast cancer histology score;LA27219-7;4;Only microinvasion present (not graded);;; +44648-4;LL4561-8;[CAP] Nottingham breast cancer histology score;LA27220-5;5;No residual invasive carcinoma after presurgical (neoadjuvant) therapy;;; +44648-4;LL4561-8;[CAP] Nottingham breast cancer histology score;LA27221-3;6;Score cannot be determined;;; +44669-0;LL4350-6;Mucosal margin involvement type;LA27144-7;1;Cannot be assessed;;; +44669-0;LL4350-6;Mucosal margin involvement type;LA27151-2;2;Uninvolved by invasive carcinoma;;; +44669-0;LL4350-6;Mucosal margin involvement type;LA27152-0;3;Involved by invasive carcinoma;;; +44669-0;LL4350-6;Mucosal margin involvement type;LA27153-8;4;Uninvolved by adenoma;;; +44669-0;LL4350-6;Mucosal margin involvement type;LA27154-6;5;Involved by adenoma;;; +85294-7;LL4350-6;Mucosal margin involvement type;LA27144-7;1;Cannot be assessed;;; +85294-7;LL4350-6;Mucosal margin involvement type;LA27151-2;2;Uninvolved by invasive carcinoma;;; +85294-7;LL4350-6;Mucosal margin involvement type;LA27152-0;3;Involved by invasive carcinoma;;; +85294-7;LL4350-6;Mucosal margin involvement type;LA27153-8;4;Uninvolved by adenoma;;; +85294-7;LL4350-6;Mucosal margin involvement type;LA27154-6;5;Involved by adenoma;;; +44674-0;LL4564-2;[CAP] Margins;LA27830-1;1;Anterior margin;;; +44674-0;LL4564-2;[CAP] Margins;LA27831-9;2;Posterior margin;;; +44674-0;LL4564-2;[CAP] Margins;LA27832-7;3;Superior margin;;; +44674-0;LL4564-2;[CAP] Margins;LA27833-5;4;Inferior margin;;; +44674-0;LL4564-2;[CAP] Margins;LA27835-0;5;Lateral margin;;; +44674-0;LL4564-2;[CAP] Margins;LA27834-3;6;Medial margin;;; +44674-0;LL4564-2;[CAP] Margins;LA46-8;7;Other;;; +44675-7;LL4564-2;[CAP] Margins;LA27830-1;1;Anterior margin;;; +44675-7;LL4564-2;[CAP] Margins;LA27831-9;2;Posterior margin;;; +44675-7;LL4564-2;[CAP] Margins;LA27832-7;3;Superior margin;;; +44675-7;LL4564-2;[CAP] Margins;LA27833-5;4;Inferior margin;;; +44675-7;LL4564-2;[CAP] Margins;LA27835-0;5;Lateral margin;;; +44675-7;LL4564-2;[CAP] Margins;LA27834-3;6;Medial margin;;; +44675-7;LL4564-2;[CAP] Margins;LA46-8;7;Other;;; +44676-5;LL4564-2;[CAP] Margins;LA27830-1;1;Anterior margin;;; +44676-5;LL4564-2;[CAP] Margins;LA27831-9;2;Posterior margin;;; +44676-5;LL4564-2;[CAP] Margins;LA27832-7;3;Superior margin;;; +44676-5;LL4564-2;[CAP] Margins;LA27833-5;4;Inferior margin;;; +44676-5;LL4564-2;[CAP] Margins;LA27835-0;5;Lateral margin;;; +44676-5;LL4564-2;[CAP] Margins;LA27834-3;6;Medial margin;;; +44676-5;LL4564-2;[CAP] Margins;LA46-8;7;Other;;; +44677-3;LL4564-2;[CAP] Margins;LA27830-1;1;Anterior margin;;; +44677-3;LL4564-2;[CAP] Margins;LA27831-9;2;Posterior margin;;; +44677-3;LL4564-2;[CAP] Margins;LA27832-7;3;Superior margin;;; +44677-3;LL4564-2;[CAP] Margins;LA27833-5;4;Inferior margin;;; +44677-3;LL4564-2;[CAP] Margins;LA27835-0;5;Lateral margin;;; +44677-3;LL4564-2;[CAP] Margins;LA27834-3;6;Medial margin;;; +44677-3;LL4564-2;[CAP] Margins;LA46-8;7;Other;;; +44678-1;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA25151-4;1;Apical;;; +44678-1;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA26552-2;2;Bladder neck;;; +44678-1;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA16059-0;3;Anterior;;; +44678-1;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA26553-0;4;Lateral;;; +44678-1;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA26554-8;5;Posterolateral;;; +44678-1;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA16060-8;6;Posterior;;; +44678-1;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA46-8;7;Other;;; +84902-6;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA25151-4;1;Apical;;; +84902-6;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA26552-2;2;Bladder neck;;; +84902-6;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA16059-0;3;Anterior;;; +84902-6;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA26553-0;4;Lateral;;; +84902-6;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA26554-8;5;Posterolateral;;; +84902-6;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA16060-8;6;Posterior;;; +84902-6;LL4081-7;Apical|Bladder neck|Ant|Post|Post-lat|Post|Other;LA46-8;7;Other;;; +44679-9;LL4572-5;[CAP] Melanoma margins;LA27835-0;1;Lateral margin;;; +44679-9;LL4572-5;[CAP] Melanoma margins;LA27146-2;2;Deep margin;;; +44679-9;LL4572-5;[CAP] Melanoma margins;LA46-8;3;Other;;; +44680-7;LL4572-5;[CAP] Melanoma margins;LA27835-0;1;Lateral margin;;; +44680-7;LL4572-5;[CAP] Melanoma margins;LA27146-2;2;Deep margin;;; +44680-7;LL4572-5;[CAP] Melanoma margins;LA46-8;3;Other;;; +44681-5;LL4572-5;[CAP] Melanoma margins;LA27835-0;1;Lateral margin;;; +44681-5;LL4572-5;[CAP] Melanoma margins;LA27146-2;2;Deep margin;;; +44681-5;LL4572-5;[CAP] Melanoma margins;LA46-8;3;Other;;; +44682-3;LL4572-5;[CAP] Melanoma margins;LA27835-0;1;Lateral margin;;; +44682-3;LL4572-5;[CAP] Melanoma margins;LA27146-2;2;Deep margin;;; +44682-3;LL4572-5;[CAP] Melanoma margins;LA46-8;3;Other;;; +44692-2;LL4562-6;[CAP] Microcalcifications in breast cancer;LA46-8;0;Other;;; +44692-2;LL4562-6;[CAP] Microcalcifications in breast cancer;LA27829-3;1;Microcalcifications not identified;;; +44692-2;LL4562-6;[CAP] Microcalcifications in breast cancer;LA27826-9;2;Microcalcifications present in DCIS;;; +44692-2;LL4562-6;[CAP] Microcalcifications in breast cancer;LA27827-7;3;Microcalcifications present in invasive carcinoma;;; +44692-2;LL4562-6;[CAP] Microcalcifications in breast cancer;LA27828-5;4;Microcalcifications present in nonneoplastic tissue;;; +44693-0;LL4451-2;[CAP] Tumor-Infiltrating Lymphocytes;LA11902-6;1;Not identified;;; +44693-0;LL4451-2;[CAP] Tumor-Infiltrating Lymphocytes;LA27474-8;2;Present, nonbrisk;;; +44693-0;LL4451-2;[CAP] Tumor-Infiltrating Lymphocytes;LA27475-5;3;Present, brisk;;; +45183-1;LL1610-6;N men serogroup;LA18421-0;1;Neisseria meningitidis serogroup A;;; +45183-1;LL1610-6;N men serogroup;LA18431-9;2;Neisseria meningitidis serogroup B;;; +45183-1;LL1610-6;N men serogroup;LA18422-8;3;Neisseria meningitidis serogroup C;;; +45183-1;LL1610-6;N men serogroup;LA18423-6;4;Neisseria meningitidis serogroup W135;;; +45183-1;LL1610-6;N men serogroup;LA16629-0;5;Neisseria meningitidis serogroup Y;;; +71788-4;LL1610-6;N men serogroup;LA18421-0;1;Neisseria meningitidis serogroup A;;; +71788-4;LL1610-6;N men serogroup;LA18431-9;2;Neisseria meningitidis serogroup B;;; +71788-4;LL1610-6;N men serogroup;LA18422-8;3;Neisseria meningitidis serogroup C;;; +71788-4;LL1610-6;N men serogroup;LA18423-6;4;Neisseria meningitidis serogroup W135;;; +71788-4;LL1610-6;N men serogroup;LA16629-0;5;Neisseria meningitidis serogroup Y;;; +45231-8;LL351-8;ART_2_Prior;LA6517-2;1;Currently being treated and transferred in with treatment records from within system.;;; +45231-8;LL351-8;ART_2_Prior;LA6518-0;2;PMTCT only;;; +45231-8;LL351-8;ART_2_Prior;LA6519-8;3;Prior ARV treatment, but not transfer in with records, or client not abel to provide information.;;; +45231-8;LL351-8;ART_2_Prior;LA137-2;4;None;260413007;None (qualifier value);http://snomed.info/sct +45232-6;LL352-6;ART_3_Medical eligibility;LA6520-6;1;Clinical Criteria Only;;; +45232-6;LL352-6;ART_3_Medical eligibility;LA6521-4;2;CD4 With Or Without Clinical Criteria;;; +45232-6;LL352-6;ART_3_Medical eligibility;LA6522-2;3;Clinical Plus TLC;;; +45241-7;LL399-7;ART_7_TB status;LA6758-2;1;No signs or symptoms suggesting TB;;; +45241-7;LL399-7;ART_7_TB status;LA6759-0;2;Currently on INH prophylaxis dose, adherence;;; +45241-7;LL399-7;ART_7_TB status;LA6760-8;3;Suspected TB, referred for evaluation (include referral date);;; +45241-7;LL399-7;ART_7_TB status;LA6761-6;4;Sputum sample sent - date, sputum results and date received;;; +45241-7;LL399-7;ART_7_TB status;LA6762-4;5;Currently on TB treatment;;; +45243-3;LL354-2;ART_5_Reason med discontinued;LA6529-7;1;Toxicity/Side Effects;;; +45243-3;LL354-2;ART_5_Reason med discontinued;LA6530-5;2;Pregnancy;;; +45243-3;LL354-2;ART_5_Reason med discontinued;LA6531-3;3;Risk of Pregnancy;;; +45243-3;LL354-2;ART_5_Reason med discontinued;LA6532-1;4;Newly Diagnosed TB;;; +45243-3;LL354-2;ART_5_Reason med discontinued;LA6533-9;5;New Drug Available;;; +45243-3;LL354-2;ART_5_Reason med discontinued;LA6534-7;6;Drug Out of Stock;;; +45243-3;LL354-2;ART_5_Reason med discontinued;LA6535-4;7;Other Reason;;; +45245-8;LL398-9;ART_6_TB status;LA6763-2;1;Good = 95% adherence;;; +45245-8;LL398-9;ART_6_TB status;LA6764-0;2;Fair 85-954% adherence;;; +45245-8;LL398-9;ART_6_TB status;LA6765-7;3;Poor <85% adherence;;; +45246-6;LL398-9;ART_6_TB status;LA6763-2;1;Good = 95% adherence;;; +45246-6;LL398-9;ART_6_TB status;LA6764-0;2;Fair 85-954% adherence;;; +45246-6;LL398-9;ART_6_TB status;LA6765-7;3;Poor <85% adherence;;; +45252-4;LL350-0;ART_1_Entry point;LA6505-7;1;PMTCT;;; +45252-4;LL350-0;ART_1_Entry point;LA6506-5;2;Medical Outpatient;;; +45252-4;LL350-0;ART_1_Entry point;LA6507-3;3;Outpatient – under 5/paediatric;;; +45252-4;LL350-0;ART_1_Entry point;LA6508-1;4;STI Outpatient;;; +45252-4;LL350-0;ART_1_Entry point;LA6509-9;5;TB Outpatient;;; +45252-4;LL350-0;ART_1_Entry point;LA6510-7;6;Private/co-private provider or company/business;;; +45252-4;LL350-0;ART_1_Entry point;LA6511-5;7;Inpatient;;; +45252-4;LL350-0;ART_1_Entry point;LA6512-3;8;IDU Outreach/special services - IDU;;; +45252-4;LL350-0;ART_1_Entry point;LA6513-1;9;Sex Outreach/special services – sex worker;;; +45252-4;LL350-0;ART_1_Entry point;LA6514-9;10;Outreach/special services – Adolescent;;; +45252-4;LL350-0;ART_1_Entry point;LA6515-6;11;Self-referred (via VCT);;; +45252-4;LL350-0;ART_1_Entry point;LA6516-4;12;CBO referred (referred from a community-based organization via VCT);;; +45252-4;LL350-0;ART_1_Entry point;LA46-8;13;Other;;; +45336-5;LL2425-8;Hemolysis;LA19729-5;1;Alpha hemolytic;;; +45336-5;LL2425-8;Hemolysis;LA19730-3;2;Beta hemolytic;;; +45336-5;LL2425-8;Hemolysis;LA19731-1;3;Gamma hemolytic (none);;; +45339-9;LL2276-5;Tick;LA19251-0;1;Ixodes cookei;;; +45339-9;LL2276-5;Tick;LA19252-8;2;Ixodes pacifcus;;; +45339-9;LL2276-5;Tick;LA19253-6;3;Ixodes ricinus;;; +45339-9;LL2276-5;Tick;LA19250-2;4;Ixodes scapularis;;; +45340-7;LL2276-5;Tick;LA19251-0;1;Ixodes cookei;;; +45340-7;LL2276-5;Tick;LA19252-8;2;Ixodes pacifcus;;; +45340-7;LL2276-5;Tick;LA19253-6;3;Ixodes ricinus;;; +45340-7;LL2276-5;Tick;LA19250-2;4;Ixodes scapularis;;; +45341-5;LL2276-5;Tick;LA19251-0;1;Ixodes cookei;;; +45341-5;LL2276-5;Tick;LA19252-8;2;Ixodes pacifcus;;; +45341-5;LL2276-5;Tick;LA19253-6;3;Ixodes ricinus;;; +45341-5;LL2276-5;Tick;LA19250-2;4;Ixodes scapularis;;; +45342-3;LL2276-5;Tick;LA19251-0;1;Ixodes cookei;;; +45342-3;LL2276-5;Tick;LA19252-8;2;Ixodes pacifcus;;; +45342-3;LL2276-5;Tick;LA19253-6;3;Ixodes ricinus;;; +45342-3;LL2276-5;Tick;LA19250-2;4;Ixodes scapularis;;; +45373-8;LL2105-6;ESRD-medication route;LA9367-9;1;Oral;;; +45373-8;LL2105-6;ESRD-medication route;LA9437-0;2;Intravenous;;; +45373-8;LL2105-6;ESRD-medication route;LA18623-1;3;Intravenous push;;; +45373-8;LL2105-6;ESRD-medication route;LA9429-7;4;Intramuscular;;; +45373-8;LL2105-6;ESRD-medication route;LA9451-1;5;Subcutaneous;;; +45373-8;LL2105-6;ESRD-medication route;LA46-8;6;Other;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA43-5;1;English;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA31371-0;2;Cantonese;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4021-7;3;Hmong;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4595-0;4;Japanese;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA31372-8;5;Khmer;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4603-2;6;Korean;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4586-9;7;Laotian;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA31373-6;8;Mandarin;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4300-5;9;Samoan;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA44-3;10;Spanish;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA15353-8;11;Tagalog;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA31374-4;12;Tibetan;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4467-2;13;Thai;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4513-3;14;Tongan;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA4443-3;15;Vietnamese;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA31375-1;16;Visayan;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA30122-8;17;I choose not to answer this question;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA31369-4;18;Question not administered;;; +45402-5;LL5710-0;AAPCHO - Primary Language;LA31370-2;19;Skipped question;;; +45402-5;LL8-4;MDS_156_Primary language;LA43-5;1;English;;; +45402-5;LL8-4;MDS_156_Primary language;LA45-0;2;French;;; +45402-5;LL8-4;MDS_156_Primary language;LA31373-6;3;Mandarin;;; +45402-5;LL8-4;MDS_156_Primary language;LA44-3;4;Spanish;;; +45402-5;LL8-4;MDS_156_Primary language;LA15353-8;5;Tagalog;;; +45402-5;LL8-4;MDS_156_Primary language;LA4443-3;6;Vietnamese;;; +45402-5;LL8-4;MDS_156_Primary language;LA46-8;7;Other;;; +45404-1;LL6025-2;Marital status + cohabitating;LA17717-2;1;Single;;; +45404-1;LL6025-2;Marital status + cohabitating;LA48-4;2;Married;;; +45404-1;LL6025-2;Marital status + cohabitating;LA49-2;3;Widowed;;; +45404-1;LL6025-2;Marital status + cohabitating;LA32569-8;4;Separated or divorced;;; +45404-1;LL6025-2;Marital status + cohabitating;LA32570-6;5;Cohabitating;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45404-1;LL9-2;MDS_293_Marital status;LA47-6;1;Never married;;; +45404-1;LL9-2;MDS_293_Marital status;LA48-4;2;Married;;; +45404-1;LL9-2;MDS_293_Marital status;LA49-2;3;Widowed;;; +45404-1;LL9-2;MDS_293_Marital status;LA4288-2;4;Separated;;; +45404-1;LL9-2;MDS_293_Marital status;LA51-8;5;Divorced;;; +45405-8;LL18-3;MDS_539_Understand others;LA78-1;1;UNDERSTANDS;;; +45405-8;LL18-3;MDS_539_Understand others;LA79-9;2;USUALLY UNDERSTANDS- may miss some part/intent of message;;; +45405-8;LL18-3;MDS_539_Understand others;LA80-7;3;SOMETIMES UNDERSTANDS- responds adequately to simple, direct communication;;; +45405-8;LL18-3;MDS_539_Understand others;LA81-5;4;Rarely/never understands;;; +45406-6;LL14-2;MDS_464_Change in status;LA64-1;1;No change;;; +45406-6;LL14-2;MDS_464_Change in status;LA65-8;2;Improved;;; +45406-6;LL14-2;MDS_464_Change in status;LA66-6;3;Deteriorated;;; +45497-5;LL14-2;MDS_464_Change in status;LA64-1;1;No change;;; +45497-5;LL14-2;MDS_464_Change in status;LA65-8;2;Improved;;; +45497-5;LL14-2;MDS_464_Change in status;LA66-6;3;Deteriorated;;; +45557-6;LL14-2;MDS_464_Change in status;LA64-1;1;No change;;; +45557-6;LL14-2;MDS_464_Change in status;LA65-8;2;Improved;;; +45557-6;LL14-2;MDS_464_Change in status;LA66-6;3;Deteriorated;;; +45568-3;LL14-2;MDS_464_Change in status;LA64-1;1;No change;;; +45568-3;LL14-2;MDS_464_Change in status;LA65-8;2;Improved;;; +45568-3;LL14-2;MDS_464_Change in status;LA66-6;3;Deteriorated;;; +45617-8;LL14-2;MDS_464_Change in status;LA64-1;1;No change;;; +45617-8;LL14-2;MDS_464_Change in status;LA65-8;2;Improved;;; +45617-8;LL14-2;MDS_464_Change in status;LA66-6;3;Deteriorated;;; +45635-0;LL14-2;MDS_464_Change in status;LA64-1;1;No change;;; +45635-0;LL14-2;MDS_464_Change in status;LA65-8;2;Improved;;; +45635-0;LL14-2;MDS_464_Change in status;LA66-6;3;Deteriorated;;; +45407-4;LL19-1;MDS_554_Vision;LA82-3;1;ADEQUATE- sees fine detail, including regular print in newspaper/books;;; +45407-4;LL19-1;MDS_554_Vision;LA10957-1;2;Impaired - sees large print, but not regular print in newspapers/books;;; +45407-4;LL19-1;MDS_554_Vision;LA84-9;3;"MODERATELY IMPAIRED- limited vision; not able to see newspaper headlines, but can identify objects";;; +45407-4;LL19-1;MDS_554_Vision;LA9644-1;4;HIGHLY IMPAIRED-object identification in question, but eyes appear to follow objects;;; +45407-4;LL19-1;MDS_554_Vision;LA85-6;5;"SEVERELY IMPAIRED- no vision or sees only light color, or shapes; eyes do not appear to follow objects";;; +45408-2;LL3-5;MDS_57_Reason for assessment-primary;LA10-4;1;Admission assessment (required by day 14);;; +45408-2;LL3-5;MDS_57_Reason for assessment-primary;LA12-0;2;Annual assessment;;; +45408-2;LL3-5;MDS_57_Reason for assessment-primary;LA13-8;3;Significant change in status assessment;;; +45408-2;LL3-5;MDS_57_Reason for assessment-primary;LA14-6;4;Significant correction of prior full assessment;;; +45408-2;LL3-5;MDS_57_Reason for assessment-primary;LA15-3;5;Quarterly review assessment;;; +45408-2;LL3-5;MDS_57_Reason for assessment-primary;LA11-2;6;Significant correction of prior quarterly assessment;;; +45408-2;LL3-5;MDS_57_Reason for assessment-primary;LA9-3;7;None of the above;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA16-1;1;Medicare 5 day assessment;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA17-9;2;Medicare 30 day assessment;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA18-7;3;Medicare 60 day assessment;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA19-5;4;Medicare 90 day assessment;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA20-3;5;Medicare readmission/return assessment;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA21-1;6;Other state required assessment;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA22-9;7;Medicare 14 Day assessment;;; +45409-0;LL4-3;MDS_71_Reason for assessment-special;LA23-7;8;Other Medicare required assessment;;; +45410-8;LL5-0;MDS_90_Admitted from;LA24-5;1;Private home/apt. with no home health services;;; +45410-8;LL5-0;MDS_90_Admitted from;LA25-2;2;Private home/apt. with home health services;;; +45410-8;LL5-0;MDS_90_Admitted from;LA26-0;3;Board and care/assisted living group home;;; +45410-8;LL5-0;MDS_90_Admitted from;LA27-8;4;Nursing Home;;; +45410-8;LL5-0;MDS_90_Admitted from;LA28-6;5;Acute care hospital;;; +45410-8;LL5-0;MDS_90_Admitted from;LA29-4;6;Psychiatric hospital, MR/DD facility;;; +45410-8;LL5-0;MDS_90_Admitted from;LA30-2;7;Rehabilitation hospital;;; +45410-8;LL5-0;MDS_90_Admitted from;LA46-8;8;Other;;; +45411-6;LL6-8;MDS_104_Lived alone;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45411-6;LL6-8;MDS_104_Lived alone;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45411-6;LL6-8;MDS_104_Lived alone;LA34-4;3;In other facility;;; +45412-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45412-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45412-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45413-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45413-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45413-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45414-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45414-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45414-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45415-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45415-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45415-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45416-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45416-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45416-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45417-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45417-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45417-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45420-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45420-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45420-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45428-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45428-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45428-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45429-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45429-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45429-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45430-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45430-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45430-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45431-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45431-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45431-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45432-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45432-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45432-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45433-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45433-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45433-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45434-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45434-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45434-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45435-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45435-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45435-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45436-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45436-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45436-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45437-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45437-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45437-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45438-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45438-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45438-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45439-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45439-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45439-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45440-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45440-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45440-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45441-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45441-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45441-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45442-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45442-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45442-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45443-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45443-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45443-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45444-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45444-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45444-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45445-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45445-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45445-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45446-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45446-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45446-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45447-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45447-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45447-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45448-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45448-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45448-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45449-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45449-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45449-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45450-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45450-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45450-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45451-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45451-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45451-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45452-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45452-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45452-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45456-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45456-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45456-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45457-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45457-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45457-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45458-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45458-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45458-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45459-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45459-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45459-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45460-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45460-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45460-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45461-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45461-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45461-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45462-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45462-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45462-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45463-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45463-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45463-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45464-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45464-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45464-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45465-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45465-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45465-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45466-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45466-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45466-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45467-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45467-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45467-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45468-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45468-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45468-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45469-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45469-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45469-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45470-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45470-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45470-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45471-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45471-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45471-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45472-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45472-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45472-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45473-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45473-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45473-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45474-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45474-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45474-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45475-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45475-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45475-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45476-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45476-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45476-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45477-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45477-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45477-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45478-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45478-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45478-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45479-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45479-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45479-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45480-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45480-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45480-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45481-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45481-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45481-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45485-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45485-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45485-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45486-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45486-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45486-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45487-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45487-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45487-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45488-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45488-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45488-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45489-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45489-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45489-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45499-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45499-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45499-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45500-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45500-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45500-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45501-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45501-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45501-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45502-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45502-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45502-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45503-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45503-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45503-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45504-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45504-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45504-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45505-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45505-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45505-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45506-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45506-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45506-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45507-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45507-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45507-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45508-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45508-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45508-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45509-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45509-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45509-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45512-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45512-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45512-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45513-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45513-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45513-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45514-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45514-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45514-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45515-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45515-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45515-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45536-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45536-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45536-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45537-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45537-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45537-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45538-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45538-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45538-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45539-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45539-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45539-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45540-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45540-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45540-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45541-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45541-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45541-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45542-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45542-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45542-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45543-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45543-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45543-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45544-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45544-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45544-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45545-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45545-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45545-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45546-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45546-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45546-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45569-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45569-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45569-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45570-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45570-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45570-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45571-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45571-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45571-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45572-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45572-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45572-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45573-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45573-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45573-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45574-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45574-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45574-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45575-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45575-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45575-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45576-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45576-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45576-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45577-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45577-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45577-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45578-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45578-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45578-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45579-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45579-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45579-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45580-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45580-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45580-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45581-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45581-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45581-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45582-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45582-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45582-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45583-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45583-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45583-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45584-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45584-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45584-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45585-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45585-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45585-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45586-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45586-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45586-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45587-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45587-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45587-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45611-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45611-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45611-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45614-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45614-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45614-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45615-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45615-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45615-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45616-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45616-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45616-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45620-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45620-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45620-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45621-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45621-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45621-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45622-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45622-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45622-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45623-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45623-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45623-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45624-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45624-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45624-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45625-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45625-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45625-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45626-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45626-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45626-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45627-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45627-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45627-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45628-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45628-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45628-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45629-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45629-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45629-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45630-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45630-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45630-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45631-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45631-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45631-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45632-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45632-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45632-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45633-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45633-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45633-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45634-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45634-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45634-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45636-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45636-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45636-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45637-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45637-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45637-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45638-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45638-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45638-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45639-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45639-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45639-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45640-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45640-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45640-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45641-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45641-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45641-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45642-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45642-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45642-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45643-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45643-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45643-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45644-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45644-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45644-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45645-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45645-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45645-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45646-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45646-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45646-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45647-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45647-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45647-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45648-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45648-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45648-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45649-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45649-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45649-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45650-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45650-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45650-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45651-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45651-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45651-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45652-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45652-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45652-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45653-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45653-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45653-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45654-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45654-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45654-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45655-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45655-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45655-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45656-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45656-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45656-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45657-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45657-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45657-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45658-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45658-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45658-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45659-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45659-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45659-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45660-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45660-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45660-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45661-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45661-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45661-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45662-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45662-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45662-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45663-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45663-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45663-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45664-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45664-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45664-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45665-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45665-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45665-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45666-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45666-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45666-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45667-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45667-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45667-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45668-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45668-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45668-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45669-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45669-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45669-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45670-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45670-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45670-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45671-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45671-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45671-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45672-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45672-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45672-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45673-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45673-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45673-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45674-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45674-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45674-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45675-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45675-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45675-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45675-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45675-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45675-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45676-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45676-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45676-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45677-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45677-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45677-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45678-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45678-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45678-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45679-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45679-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45679-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45680-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45680-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45680-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45681-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45681-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45681-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45682-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45682-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45682-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45683-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45683-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45683-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45684-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45684-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45684-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45685-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45685-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45685-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45686-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45686-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45686-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45687-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45687-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45687-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45688-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45688-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45688-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45689-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45689-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45689-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45690-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45690-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45690-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45691-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45691-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45691-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45692-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45692-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45692-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45694-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45694-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45694-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45695-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45695-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45695-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45697-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45697-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45697-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45698-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45698-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45698-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45699-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45699-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45699-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45700-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45700-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45700-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45702-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45702-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45702-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45704-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45704-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45704-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45705-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45705-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45705-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45706-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45706-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45706-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45707-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45707-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45707-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45709-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45709-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45709-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45712-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45712-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45712-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45713-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45713-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45713-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45714-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45714-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45714-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45715-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45715-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45715-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45717-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45717-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45717-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45718-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45718-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45718-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45719-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45719-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45719-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45720-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45720-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45720-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45721-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45721-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45721-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45722-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45722-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45722-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45723-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45723-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45723-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45724-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45724-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45724-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45725-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45725-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45725-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45726-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45726-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45726-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45727-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45727-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45727-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45728-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45728-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45728-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45729-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45729-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45729-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45730-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45730-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45730-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45731-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45731-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45731-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45732-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45732-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45732-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45733-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45733-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45733-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45734-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45734-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45734-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45735-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45735-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45735-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45736-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45736-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45736-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45737-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45737-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45737-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45738-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45738-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45738-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45739-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45739-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45739-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45740-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45740-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45740-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45741-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45741-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45741-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45742-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45742-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45742-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45743-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45743-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45743-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45744-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45744-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45744-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45745-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45745-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45745-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45746-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45746-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45746-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45747-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45747-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45747-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45748-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45748-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45748-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45749-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45749-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45749-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45752-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45752-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45752-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45753-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45753-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45753-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45753-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45753-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45754-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45754-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45754-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45755-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45755-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45755-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45756-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45756-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45756-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45757-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45757-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45757-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45758-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45758-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45758-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45759-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45759-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45759-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45769-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45769-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45769-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45770-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45770-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45770-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45771-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45771-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45771-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45772-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45772-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45772-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45773-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45773-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45773-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45774-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45774-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45774-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45775-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45775-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45775-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45782-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45782-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45782-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45783-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45783-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45783-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45784-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45784-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45784-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45785-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45785-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45785-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45786-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45786-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45786-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45787-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45787-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45787-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45788-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45788-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45788-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45789-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45789-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45789-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45790-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45790-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45790-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45791-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45791-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45791-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45792-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45792-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45792-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45793-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45793-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45793-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45794-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45794-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45794-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45795-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45795-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45795-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45796-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45796-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45796-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45797-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45797-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45797-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45798-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45798-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45798-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45799-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45799-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45799-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45800-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45800-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45800-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45801-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45801-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45801-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45802-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45802-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45802-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45803-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45803-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45803-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45804-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45804-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45804-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45805-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45805-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45805-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45806-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45806-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45806-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45807-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45807-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45807-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45808-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45808-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45808-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45809-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45809-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45809-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45810-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45810-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45810-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45811-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45811-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45811-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45813-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45813-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45813-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45814-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45814-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45814-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45815-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45815-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45815-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45816-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45816-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45816-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45817-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45817-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45817-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45818-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45818-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45818-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45819-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45819-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45819-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45820-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45820-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45820-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45821-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45821-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45821-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45822-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45822-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45822-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45823-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45823-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45823-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45824-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45824-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45824-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45825-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45825-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45825-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45826-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45826-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45826-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45827-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45827-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45827-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45828-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45828-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45828-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45829-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45829-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45829-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45830-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45830-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45830-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45834-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45834-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45834-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45841-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45841-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45841-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45842-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45842-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45842-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45843-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45843-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45843-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45844-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45844-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45844-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45845-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45845-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45845-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45846-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45846-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45846-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45847-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45847-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45847-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45848-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45848-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45848-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45849-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45849-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45849-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45850-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45850-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45850-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45851-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45851-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45851-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45853-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45853-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45853-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45854-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45854-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45854-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45855-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45855-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45855-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45856-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45856-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45856-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45857-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45857-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45857-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45858-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45858-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45858-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45879-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45879-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45879-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45880-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45880-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45880-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45881-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45881-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45881-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45884-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45884-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45884-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45888-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45888-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45888-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45895-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45895-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45895-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45917-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45917-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45917-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45919-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45919-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45919-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45921-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45921-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45921-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45923-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45923-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45923-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45925-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45925-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45925-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45927-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45927-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45927-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45929-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45929-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45929-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45931-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45931-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45931-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45933-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45933-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45933-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45935-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45935-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45935-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45937-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45937-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45937-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +45939-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45939-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45939-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +45941-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45941-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45941-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +45943-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45943-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45943-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +45945-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45945-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45945-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +45947-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45947-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45947-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +45949-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45949-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45949-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +45951-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45951-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45951-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +45953-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45953-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45953-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +45955-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45955-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45955-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +80246-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80246-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80246-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +80247-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80247-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80247-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +80248-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80248-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80248-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +80249-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80249-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80249-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +80250-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80250-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80250-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +80251-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80251-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80251-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +80252-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80252-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80252-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +80253-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80253-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80253-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +80254-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80254-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80254-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +80255-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80255-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80255-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +80256-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80256-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80256-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +80257-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80257-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80257-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +80922-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80922-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80922-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +80986-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80986-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80986-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +80987-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80987-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80987-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +80988-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80988-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80988-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +80994-7;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80994-7;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80994-7;LL50-6;MDS_117;LA1-0;3;UTD;;; +80995-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80995-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80995-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +80996-2;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80996-2;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80996-2;LL50-6;MDS_117;LA1-0;3;UTD;;; +80997-0;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80997-0;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80997-0;LL50-6;MDS_117;LA1-0;3;UTD;;; +80998-8;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +80998-8;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80998-8;LL50-6;MDS_117;LA1-0;3;UTD;;; +81433-5;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +81433-5;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81433-5;LL50-6;MDS_117;LA1-0;3;UTD;;; +81434-3;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +81434-3;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81434-3;LL50-6;MDS_117;LA1-0;3;UTD;;; +88653-1;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +88653-1;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88653-1;LL50-6;MDS_117;LA1-0;3;UTD;;; +88654-9;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +88654-9;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88654-9;LL50-6;MDS_117;LA1-0;3;UTD;;; +88655-6;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +88655-6;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88655-6;LL50-6;MDS_117;LA1-0;3;UTD;;; +88656-4;LL50-6;MDS_117;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +88656-4;LL50-6;MDS_117;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88656-4;LL50-6;MDS_117;LA1-0;3;UTD;;; +45483-5;LL11-8;MDS_399_Memory;LA55-9;1;Memory OK;;; +45483-5;LL11-8;MDS_399_Memory;LA56-7;2;Memory problem;;; +45484-3;LL11-8;MDS_399_Memory;LA55-9;1;Memory OK;;; +45484-3;LL11-8;MDS_399_Memory;LA56-7;2;Memory problem;;; +54616-8;LL11-8;MDS_399_Memory;LA55-9;1;Memory OK;;; +54616-8;LL11-8;MDS_399_Memory;LA56-7;2;Memory problem;;; +54617-6;LL11-8;MDS_399_Memory;LA55-9;1;Memory OK;;; +54617-6;LL11-8;MDS_399_Memory;LA56-7;2;Memory problem;;; +45490-0;LL12-6;MDS_428_Decision of ADLs;LA57-5;1;INDEPENDENT-decisions consistent/reasonable;;; +45490-0;LL12-6;MDS_428_Decision of ADLs;LA58-3;2;MODIFIED INDEPENDENCE-some difficulty in new situations only;;; +45490-0;LL12-6;MDS_428_Decision of ADLs;LA59-1;3;"MODERATELY IMPAIRED-decisions poor; cues/supervision required";;; +45490-0;LL12-6;MDS_428_Decision of ADLs;LA60-9;4;SEVERELY IMPAIRED-never/rarely made decisions;;; +45491-8;LL13-4;MDS_439_Delirium indicators;LA61-7;1;Behavior not present;;; +45491-8;LL13-4;MDS_439_Delirium indicators;LA62-5;2;Behavior present, not of recent onset;;; +45491-8;LL13-4;MDS_439_Delirium indicators;LA63-3;3;Behavior present over last 7 days appears different from resident's usual functioning (e.g., new onset or worsening);;; +45492-6;LL13-4;MDS_439_Delirium indicators;LA61-7;1;Behavior not present;;; +45492-6;LL13-4;MDS_439_Delirium indicators;LA62-5;2;Behavior present, not of recent onset;;; +45492-6;LL13-4;MDS_439_Delirium indicators;LA63-3;3;Behavior present over last 7 days appears different from resident's usual functioning (e.g., new onset or worsening);;; +45493-4;LL13-4;MDS_439_Delirium indicators;LA61-7;1;Behavior not present;;; +45493-4;LL13-4;MDS_439_Delirium indicators;LA62-5;2;Behavior present, not of recent onset;;; +45493-4;LL13-4;MDS_439_Delirium indicators;LA63-3;3;Behavior present over last 7 days appears different from resident's usual functioning (e.g., new onset or worsening);;; +45494-2;LL13-4;MDS_439_Delirium indicators;LA61-7;1;Behavior not present;;; +45494-2;LL13-4;MDS_439_Delirium indicators;LA62-5;2;Behavior present, not of recent onset;;; +45494-2;LL13-4;MDS_439_Delirium indicators;LA63-3;3;Behavior present over last 7 days appears different from resident's usual functioning (e.g., new onset or worsening);;; +45495-9;LL13-4;MDS_439_Delirium indicators;LA61-7;1;Behavior not present;;; +45495-9;LL13-4;MDS_439_Delirium indicators;LA62-5;2;Behavior present, not of recent onset;;; +45495-9;LL13-4;MDS_439_Delirium indicators;LA63-3;3;Behavior present over last 7 days appears different from resident's usual functioning (e.g., new onset or worsening);;; +45496-7;LL13-4;MDS_439_Delirium indicators;LA61-7;1;Behavior not present;;; +45496-7;LL13-4;MDS_439_Delirium indicators;LA62-5;2;Behavior present, not of recent onset;;; +45496-7;LL13-4;MDS_439_Delirium indicators;LA63-3;3;Behavior present over last 7 days appears different from resident's usual functioning (e.g., new onset or worsening);;; +45498-3;LL15-9;MDS_473_Hearing;LA67-4;1;HEARS ADEQUATELY-normal talk, TV, phone;;; +45498-3;LL15-9;MDS_473_Hearing;LA68-2;2;MINIMAL DIFFICULTY when not in quiet setting;;; +45498-3;LL15-9;MDS_473_Hearing;LA69-0;3;HEARS IN SPECIAL SITUATIONS ONLY- speaker has to adjust tonal quality and speak distinctly;;; +45498-3;LL15-9;MDS_473_Hearing;LA70-8;4;HIGHLY IMPAIRED-absence of useful hearing;;; +45510-5;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +45510-5;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +45510-5;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +45510-5;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA71-6;1;Understood;;; +95737-3;LL16-7;MDS_519_Making self understood;LA72-4;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA73-2;3;Sometimes understood - ability is limited to making concrete requests.;;; +95737-3;LL16-7;MDS_519_Making self understood;LA74-0;4;Rarely/never understood;;; +45511-3;LL17-5;MDS_529_Speech clarity;LA75-7;1;CLEAR SPEECH- distinct, intelligible words;;; +45511-3;LL17-5;MDS_529_Speech clarity;LA76-5;2;UNCLEAR SPEECH- slurred, mumbled words;;; +45511-3;LL17-5;MDS_529_Speech clarity;LA77-3;3;NO SPEECH- absence of spoken words;;; +45516-2;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45516-2;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45516-2;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45517-0;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45517-0;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45517-0;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45518-8;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45518-8;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45518-8;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45519-6;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45519-6;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45519-6;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45520-4;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45520-4;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45520-4;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45521-2;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45521-2;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45521-2;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45522-0;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45522-0;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45522-0;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45547-7;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45547-7;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45547-7;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45548-5;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45548-5;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45548-5;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45549-3;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45549-3;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45549-3;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45550-1;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45550-1;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45550-1;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45551-9;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45551-9;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45551-9;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45552-7;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45552-7;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45552-7;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45553-5;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45553-5;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45553-5;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45554-3;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45554-3;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45554-3;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45555-0;LL20-9;MDS_579_Depression, anxiety, mood;LA86-4;1;Indicator not exhibited in last 30 days;;; +45555-0;LL20-9;MDS_579_Depression, anxiety, mood;LA87-2;2;Indicator of this type exhibited up to five days a week;;; +45555-0;LL20-9;MDS_579_Depression, anxiety, mood;LA88-0;3;Indicator of this type exhibited daily or almost daily (6, 7 days a week);;; +45523-8;LL28-2;MDS_876_Balance test;LA116-6;1;Maintained position as required in test;;; +45523-8;LL28-2;MDS_876_Balance test;LA117-4;2;Unsteady, but able to rebalance self without physical support;;; +45523-8;LL28-2;MDS_876_Balance test;LA118-2;3;"Partial physical support during test; or stands (sits) but does not follow directions for test";;; +45523-8;LL28-2;MDS_876_Balance test;LA119-0;4;Not able to attempt test without physical help;;; +45610-3;LL28-2;MDS_876_Balance test;LA116-6;1;Maintained position as required in test;;; +45610-3;LL28-2;MDS_876_Balance test;LA117-4;2;Unsteady, but able to rebalance self without physical support;;; +45610-3;LL28-2;MDS_876_Balance test;LA118-2;3;"Partial physical support during test; or stands (sits) but does not follow directions for test";;; +45610-3;LL28-2;MDS_876_Balance test;LA119-0;4;Not able to attempt test without physical help;;; +45524-6;LL29-0;MDS_889_Range of motion;LA120-8;1;No limitation;;; +45524-6;LL29-0;MDS_889_Range of motion;LA121-6;2;Limitation on one side;;; +45524-6;LL29-0;MDS_889_Range of motion;LA122-4;3;Limitation on both sides;;; +45526-1;LL29-0;MDS_889_Range of motion;LA120-8;1;No limitation;;; +45526-1;LL29-0;MDS_889_Range of motion;LA121-6;2;Limitation on one side;;; +45526-1;LL29-0;MDS_889_Range of motion;LA122-4;3;Limitation on both sides;;; +45528-7;LL29-0;MDS_889_Range of motion;LA120-8;1;No limitation;;; +45528-7;LL29-0;MDS_889_Range of motion;LA121-6;2;Limitation on one side;;; +45528-7;LL29-0;MDS_889_Range of motion;LA122-4;3;Limitation on both sides;;; +45530-3;LL29-0;MDS_889_Range of motion;LA120-8;1;No limitation;;; +45530-3;LL29-0;MDS_889_Range of motion;LA121-6;2;Limitation on one side;;; +45530-3;LL29-0;MDS_889_Range of motion;LA122-4;3;Limitation on both sides;;; +45532-9;LL29-0;MDS_889_Range of motion;LA120-8;1;No limitation;;; +45532-9;LL29-0;MDS_889_Range of motion;LA121-6;2;Limitation on one side;;; +45532-9;LL29-0;MDS_889_Range of motion;LA122-4;3;Limitation on both sides;;; +45534-5;LL29-0;MDS_889_Range of motion;LA120-8;1;No limitation;;; +45534-5;LL29-0;MDS_889_Range of motion;LA121-6;2;Limitation on one side;;; +45534-5;LL29-0;MDS_889_Range of motion;LA122-4;3;Limitation on both sides;;; +45525-3;LL30-8;MDS_898_Voluntary movement;LA123-2;1;No loss;;; +45525-3;LL30-8;MDS_898_Voluntary movement;LA124-0;2;Partial loss;;; +45525-3;LL30-8;MDS_898_Voluntary movement;LA125-7;3;Full loss;;; +45527-9;LL30-8;MDS_898_Voluntary movement;LA123-2;1;No loss;;; +45527-9;LL30-8;MDS_898_Voluntary movement;LA124-0;2;Partial loss;;; +45527-9;LL30-8;MDS_898_Voluntary movement;LA125-7;3;Full loss;;; +45529-5;LL30-8;MDS_898_Voluntary movement;LA123-2;1;No loss;;; +45529-5;LL30-8;MDS_898_Voluntary movement;LA124-0;2;Partial loss;;; +45529-5;LL30-8;MDS_898_Voluntary movement;LA125-7;3;Full loss;;; +45531-1;LL30-8;MDS_898_Voluntary movement;LA123-2;1;No loss;;; +45531-1;LL30-8;MDS_898_Voluntary movement;LA124-0;2;Partial loss;;; +45531-1;LL30-8;MDS_898_Voluntary movement;LA125-7;3;Full loss;;; +45533-7;LL30-8;MDS_898_Voluntary movement;LA123-2;1;No loss;;; +45533-7;LL30-8;MDS_898_Voluntary movement;LA124-0;2;Partial loss;;; +45533-7;LL30-8;MDS_898_Voluntary movement;LA125-7;3;Full loss;;; +45535-2;LL30-8;MDS_898_Voluntary movement;LA123-2;1;No loss;;; +45535-2;LL30-8;MDS_898_Voluntary movement;LA124-0;2;Partial loss;;; +45535-2;LL30-8;MDS_898_Voluntary movement;LA125-7;3;Full loss;;; +45556-8;LL21-7;MDS_637_Mood persistance;LA89-8;1;No mood indicators;;; +45556-8;LL21-7;MDS_637_Mood persistance;LA90-6;2;Indicators present, easily altered;;; +45556-8;LL21-7;MDS_637_Mood persistance;LA91-4;3;Indicators present, not easily altered;;; +45558-4;LL22-5;MDS_651_Behavioral symptoms;LA92-2;1;Behavior not exhibited in last 7 days;;; +45558-4;LL22-5;MDS_651_Behavioral symptoms;LA93-0;2;Behavior of this type occurred 1 to 3 days in last 7 days;;; +45558-4;LL22-5;MDS_651_Behavioral symptoms;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +45558-4;LL22-5;MDS_651_Behavioral symptoms;LA95-5;4;Behavior of this type occurred daily;;; +45560-0;LL22-5;MDS_651_Behavioral symptoms;LA92-2;1;Behavior not exhibited in last 7 days;;; +45560-0;LL22-5;MDS_651_Behavioral symptoms;LA93-0;2;Behavior of this type occurred 1 to 3 days in last 7 days;;; +45560-0;LL22-5;MDS_651_Behavioral symptoms;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +45560-0;LL22-5;MDS_651_Behavioral symptoms;LA95-5;4;Behavior of this type occurred daily;;; +45562-6;LL22-5;MDS_651_Behavioral symptoms;LA92-2;1;Behavior not exhibited in last 7 days;;; +45562-6;LL22-5;MDS_651_Behavioral symptoms;LA93-0;2;Behavior of this type occurred 1 to 3 days in last 7 days;;; +45562-6;LL22-5;MDS_651_Behavioral symptoms;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +45562-6;LL22-5;MDS_651_Behavioral symptoms;LA95-5;4;Behavior of this type occurred daily;;; +45564-2;LL22-5;MDS_651_Behavioral symptoms;LA92-2;1;Behavior not exhibited in last 7 days;;; +45564-2;LL22-5;MDS_651_Behavioral symptoms;LA93-0;2;Behavior of this type occurred 1 to 3 days in last 7 days;;; +45564-2;LL22-5;MDS_651_Behavioral symptoms;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +45564-2;LL22-5;MDS_651_Behavioral symptoms;LA95-5;4;Behavior of this type occurred daily;;; +45566-7;LL22-5;MDS_651_Behavioral symptoms;LA92-2;1;Behavior not exhibited in last 7 days;;; +45566-7;LL22-5;MDS_651_Behavioral symptoms;LA93-0;2;Behavior of this type occurred 1 to 3 days in last 7 days;;; +45566-7;LL22-5;MDS_651_Behavioral symptoms;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +45566-7;LL22-5;MDS_651_Behavioral symptoms;LA95-5;4;Behavior of this type occurred daily;;; +45559-2;LL23-3;MDS_661_Behavior alterability;LA96-3;1;Behavior not present OR behavior was easily altered;;; +45559-2;LL23-3;MDS_661_Behavior alterability;LA97-1;2;Behavior was not easily altered;;; +45561-8;LL23-3;MDS_661_Behavior alterability;LA96-3;1;Behavior not present OR behavior was easily altered;;; +45561-8;LL23-3;MDS_661_Behavior alterability;LA97-1;2;Behavior was not easily altered;;; +45563-4;LL23-3;MDS_661_Behavior alterability;LA96-3;1;Behavior not present OR behavior was easily altered;;; +45563-4;LL23-3;MDS_661_Behavior alterability;LA97-1;2;Behavior was not easily altered;;; +45565-9;LL23-3;MDS_661_Behavior alterability;LA96-3;1;Behavior not present OR behavior was easily altered;;; +45565-9;LL23-3;MDS_661_Behavior alterability;LA97-1;2;Behavior was not easily altered;;; +45567-5;LL23-3;MDS_661_Behavior alterability;LA96-3;1;Behavior not present OR behavior was easily altered;;; +45567-5;LL23-3;MDS_661_Behavior alterability;LA97-1;2;Behavior was not easily altered;;; +45588-1;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45588-1;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45588-1;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45588-1;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45588-1;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45588-1;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45588-1;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45590-7;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45590-7;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45590-7;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45590-7;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45590-7;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45590-7;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45590-7;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45592-3;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45592-3;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45592-3;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45592-3;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45592-3;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45592-3;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45592-3;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45594-9;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45594-9;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45594-9;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45594-9;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45594-9;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45594-9;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45594-9;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45596-4;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45596-4;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45596-4;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45596-4;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45596-4;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45596-4;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45596-4;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45598-0;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45598-0;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45598-0;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45598-0;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45598-0;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45598-0;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45598-0;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45600-4;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45600-4;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45600-4;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45600-4;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45600-4;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45600-4;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45600-4;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45602-0;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45602-0;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45602-0;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45602-0;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45602-0;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45602-0;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45602-0;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45604-6;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45604-6;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45604-6;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45604-6;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45604-6;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45604-6;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45604-6;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45606-1;LL850-9;MDSv3_G0110;LA12637-7;1;Independent - no help or staff oversight at any time;;; +45606-1;LL850-9;MDSv3_G0110;LA12638-5;2;Supervision - oversight, encouragement or cueing;;; +45606-1;LL850-9;MDSv3_G0110;LA12639-3;3;"Limited assistance - resident highly involved in activity; staff provide guided maneuvering of limbs or other non-weight-bearing assistance";;; +45606-1;LL850-9;MDSv3_G0110;LA12640-1;4;Extensive assistance - resident involved in activity, staff provide weight-bearing support;;; +45606-1;LL850-9;MDSv3_G0110;LA12641-9;5;Total dependence - full staff performance every time during entire 7-day period;;; +45606-1;LL850-9;MDSv3_G0110;LA12642-7;6;Activity occurred only once or twice - activity did occur but only once or twice;;; +45606-1;LL850-9;MDSv3_G0110;LA18614-0;7;Activity did not occur - activity did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45589-9;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45589-9;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45589-9;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45589-9;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45589-9;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45591-5;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45591-5;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45591-5;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45591-5;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45591-5;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45593-1;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45593-1;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45593-1;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45593-1;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45593-1;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45595-6;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45595-6;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45595-6;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45595-6;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45595-6;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45597-2;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45597-2;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45597-2;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45597-2;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45597-2;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45599-8;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45599-8;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45599-8;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45599-8;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45599-8;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45601-2;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45601-2;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45601-2;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45601-2;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45601-2;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45603-8;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45603-8;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45603-8;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45603-8;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45603-8;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45605-3;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45605-3;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45605-3;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45605-3;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45605-3;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45607-9;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45607-9;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45607-9;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45607-9;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45607-9;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45609-5;LL26-6;MDS_768_ADL support;LA105-9;1;No setup or physical help from staff;;; +45609-5;LL26-6;MDS_768_ADL support;LA106-7;2;Setup help only;;; +45609-5;LL26-6;MDS_768_ADL support;LA107-5;3;One person physical assist;;; +45609-5;LL26-6;MDS_768_ADL support;LA108-3;4;Two+ persons physical assist;;; +45609-5;LL26-6;MDS_768_ADL support;LA109-1;5;ADL activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45608-7;LL27-4;MDS_860_Bathing self performance;LA110-9;1;Independent - no help provided;;; +45608-7;LL27-4;MDS_860_Bathing self performance;LA111-7;2;Supervision - oversight help only;;; +45608-7;LL27-4;MDS_860_Bathing self performance;LA112-5;3;Physical help limited to transfer only;;; +45608-7;LL27-4;MDS_860_Bathing self performance;LA113-3;4;Physical help in part of bathing activity;;; +45608-7;LL27-4;MDS_860_Bathing self performance;LA114-1;5;Total dependence;;; +45608-7;LL27-4;MDS_860_Bathing self performance;LA115-8;6;Activity itself did not occur or family and/or non-facility staff provided care 100% of the time for that activity over the entire 7-day period;;; +45618-6;LL31-6;MDS_990_Continence;LA126-5;1;CONTINENT-Complete control [includes use of indwelling urinary catheter or ostomy device that does not leak urine or stool];;; +45618-6;LL31-6;MDS_990_Continence;LA127-3;2;"USUALLY CONTINENT-BLADDER, incontinent episodes once a week or less; BOWEL, less than weekly";;; +45618-6;LL31-6;MDS_990_Continence;LA128-1;3;"OCCASIONALLY INCONTINENT-BLADDER, 2 or more times a week but not daily; BOWEL, once a week";;; +45618-6;LL31-6;MDS_990_Continence;LA129-9;4;"FREQUENTLY INCONTINENT-BLADDER, tended to be incontinent daily, but some control present (e.g., on day shift); BOWEL, 2-3 times a week";;; +45618-6;LL31-6;MDS_990_Continence;LA130-7;5;"INCONTINENT-Had inadequate control BLADDER, multiple daily episodes; BOWEL, all (or almost all) of the time";;; +45619-4;LL31-6;MDS_990_Continence;LA126-5;1;CONTINENT-Complete control [includes use of indwelling urinary catheter or ostomy device that does not leak urine or stool];;; +45619-4;LL31-6;MDS_990_Continence;LA127-3;2;"USUALLY CONTINENT-BLADDER, incontinent episodes once a week or less; BOWEL, less than weekly";;; +45619-4;LL31-6;MDS_990_Continence;LA128-1;3;"OCCASIONALLY INCONTINENT-BLADDER, 2 or more times a week but not daily; BOWEL, once a week";;; +45619-4;LL31-6;MDS_990_Continence;LA129-9;4;"FREQUENTLY INCONTINENT-BLADDER, tended to be incontinent daily, but some control present (e.g., on day shift); BOWEL, 2-3 times a week";;; +45619-4;LL31-6;MDS_990_Continence;LA130-7;5;"INCONTINENT-Had inadequate control BLADDER, multiple daily episodes; BOWEL, all (or almost all) of the time";;; +45693-9;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +45958-6;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +45959-4;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +45960-2;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +45961-0;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46504-7;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46504-7;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46504-7;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46504-7;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46504-7;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46505-4;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46507-0;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46507-0;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46507-0;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46507-0;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46507-0;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46508-8;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46509-6;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46510-4;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46511-2;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46513-8;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46515-3;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46517-9;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46519-5;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46521-1;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46584-9;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +46585-6;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +49561-4;LL343-5;ICD-9CM (diagnosis codes);;0;;;; +45710-1;LL32-4;MDS_1291_Pain frequency;LA131-5;1;No pain;;; +45710-1;LL32-4;MDS_1291_Pain frequency;LA132-3;2;Pain less than daily;;; +45710-1;LL32-4;MDS_1291_Pain frequency;LA133-1;3;Pain daily;;; +45711-9;LL33-2;MDS_1301_Pain intensity;LA134-9;1;Mild intensity;;; +45711-9;LL33-2;MDS_1301_Pain intensity;LA135-6;2;Moderate pain;;; +45711-9;LL33-2;MDS_1301_Pain intensity;LA136-4;3;Times when pain is horrible or excruciating;;; +45750-7;LL34-0;MDS_1441_MDS proportion;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +45750-7;LL34-0;MDS_1441_MDS proportion;LA138-0;2;1% to 25%;;; +45750-7;LL34-0;MDS_1441_MDS proportion;LA139-8;3;26% to 50%;;; +45750-7;LL34-0;MDS_1441_MDS proportion;LA140-6;4;51% to 75%;;; +45750-7;LL34-0;MDS_1441_MDS proportion;LA141-4;5;76% to 100%;;; +45751-5;LL35-7;MDS_1453_Fluid intake;LA142-2;2;1 to 500 cc/day;;; +45751-5;LL35-7;MDS_1453_Fluid intake;LA143-0;3;501 to 1000 cc/day;;; +45751-5;LL35-7;MDS_1453_Fluid intake;LA144-8;4;1001 to 1500 cc/day;;; +45751-5;LL35-7;MDS_1453_Fluid intake;LA145-5;5;1501 to 2000 cc/day;;; +45751-5;LL35-7;MDS_1453_Fluid intake;LA146-3;6;2001 or more cc/day;;; +45780-4;LL36-5;MDS_1503_Ulcer stage;LA147-1;2;Stage 1. A persistent area of skin redness (without a break in the skin) that does not disappear when pressure is relieved.;;; +45780-4;LL36-5;MDS_1503_Ulcer stage;LA148-9;3;Stage 2. A partial thickness loss of skin layers that presents clinically as an abrasion, blister, or shallow crater.;;; +45780-4;LL36-5;MDS_1503_Ulcer stage;LA149-7;4;Stage 3. A full thickness of skin is lost, exposing the subcutaneous tissues - presents as a deep crater with or without undermining adjacent tissue.;;; +45780-4;LL36-5;MDS_1503_Ulcer stage;LA150-5;5;Stage 4. A full thickness of skin and subcutaneous tissue is lost, exposing muscle or bone.;;; +45781-2;LL36-5;MDS_1503_Ulcer stage;LA147-1;2;Stage 1. A persistent area of skin redness (without a break in the skin) that does not disappear when pressure is relieved.;;; +45781-2;LL36-5;MDS_1503_Ulcer stage;LA148-9;3;Stage 2. A partial thickness loss of skin layers that presents clinically as an abrasion, blister, or shallow crater.;;; +45781-2;LL36-5;MDS_1503_Ulcer stage;LA149-7;4;Stage 3. A full thickness of skin is lost, exposing the subcutaneous tissues - presents as a deep crater with or without undermining adjacent tissue.;;; +45781-2;LL36-5;MDS_1503_Ulcer stage;LA150-5;5;Stage 4. A full thickness of skin and subcutaneous tissue is lost, exposing muscle or bone.;;; +45812-5;LL37-3;MDS_1612_Avg time in activities;LA151-3;1;Most-more than 2/3 of time;;; +45812-5;LL37-3;MDS_1612_Avg time in activities;LA152-1;2;Some-from 1/3 to 2/3 of time;;; +45812-5;LL37-3;MDS_1612_Avg time in activities;LA153-9;3;Little-less than 1/3 of time;;; +45812-5;LL37-3;MDS_1612_Avg time in activities;LA137-2;4;None;260413007;None (qualifier value);http://snomed.info/sct +45831-5;LL38-1;CARE_Chg in daily routine;LA64-1;1;No change;;; +45831-5;LL38-1;CARE_Chg in daily routine;LA155-4;2;Slight change;;; +45831-5;LL38-1;CARE_Chg in daily routine;LA156-2;3;Major change;;; +45832-3;LL38-1;CARE_Chg in daily routine;LA64-1;1;No change;;; +45832-3;LL38-1;CARE_Chg in daily routine;LA155-4;2;Slight change;;; +45832-3;LL38-1;CARE_Chg in daily routine;LA156-2;3;Major change;;; +45870-3;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +45870-3;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +45870-3;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +45871-1;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +45871-1;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +45871-1;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +45872-9;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +45872-9;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +45872-9;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +45873-7;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +45873-7;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +45873-7;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +45874-5;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +45874-5;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +45874-5;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55044-2;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55044-2;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55044-2;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55045-9;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55045-9;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55045-9;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55046-7;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55046-7;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55046-7;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55047-5;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55047-5;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55047-5;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55048-3;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55048-3;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55048-3;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55049-1;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55049-1;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55049-1;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55050-9;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55050-9;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55050-9;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +55051-7;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +55051-7;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +55051-7;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86786-1;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86786-1;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86786-1;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86787-9;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86787-9;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86787-9;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86788-7;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86788-7;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86788-7;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86789-5;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86789-5;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86789-5;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86790-3;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86790-3;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86790-3;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86791-1;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86791-1;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86791-1;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86792-9;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86792-9;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86792-9;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +86793-7;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +86793-7;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +86793-7;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +88308-2;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +88308-2;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +88308-2;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +88310-8;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +88310-8;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +88310-8;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +88311-6;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +88311-6;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +88311-6;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +88312-4;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +88312-4;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +88312-4;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +88313-2;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +88313-2;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +88313-2;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +88314-0;LL39-9;MDS_1868_Device-restraint use;LA157-0;1;Not used;;; +88314-0;LL39-9;MDS_1868_Device-restraint use;LA158-8;2;Used less than daily;;; +88314-0;LL39-9;MDS_1868_Device-restraint use;LA159-6;3;Used daily;;; +45882-8;LL40-7;MDS_1916_Discharge projection;LA160-4;2;Within 30 days;;; +45882-8;LL40-7;MDS_1916_Discharge projection;LA161-2;3;Within 31-90 days;;; +45882-8;LL40-7;MDS_1916_Discharge projection;LA162-0;4;Discharge status uncertain;;; +45883-6;LL41-5;MDS_1924_Care change needs;LA64-1;1;No change;;; +45883-6;LL41-5;MDS_1924_Care change needs;LA163-8;2;Improved-receives fewer supports, needs less restrictive level of care;;; +45883-6;LL41-5;MDS_1924_Care change needs;LA164-6;3;Deteriorated-receives more support;;; +45885-1;LL42-3;MDS_1936_Family participation;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45885-1;LL42-3;MDS_1936_Family participation;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45885-1;LL42-3;MDS_1936_Family participation;LA165-3;3;No family;;; +45891-9;LL44-9;MDS_1966_Distance walked;LA167-9;1;150+ feet;;; +45891-9;LL44-9;MDS_1966_Distance walked;LA168-7;2;51-149 feet;;; +45891-9;LL44-9;MDS_1966_Distance walked;LA169-5;3;26-50 feet;;; +45891-9;LL44-9;MDS_1966_Distance walked;LA170-3;4;10-25 feet;;; +45891-9;LL44-9;MDS_1966_Distance walked;LA171-1;5;less than 10 feet;;; +45892-7;LL45-6;MDS_1977_Time walked;LA172-9;1;1-2 minutes;;; +45892-7;LL45-6;MDS_1977_Time walked;LA173-7;2;3-4 minutes;;; +45892-7;LL45-6;MDS_1977_Time walked;LA174-5;3;5-10 minutes;;; +45892-7;LL45-6;MDS_1977_Time walked;LA175-2;4;11-15 minutes;;; +45892-7;LL45-6;MDS_1977_Time walked;LA176-0;5;16-30 minutes;;; +45892-7;LL45-6;MDS_1977_Time walked;LA177-8;6;31+ minutes;;; +45893-5;LL46-4;MDS_1988_Walking self performance;LA178-6;1;INDEPENDENT--No help or oversight;;; +45893-5;LL46-4;MDS_1988_Walking self performance;LA179-4;2;SUPERVISION--Oversight, encouragement or cueing provided;;; +45893-5;LL46-4;MDS_1988_Walking self performance;LA180-2;3;"LIMITED ASSISTANCE--Resident highly involved in walking; received physical help in guided maneuvering of limbs or other nonweight bearing assistance";;; +45893-5;LL46-4;MDS_1988_Walking self performance;LA181-0;4;EXTENSIVE ASSISTANCE--Resident received weight bearing assistance while walking;;; +45894-3;LL47-2;MDS_1997_Walking support;LA105-9;1;No setup or physical help from staff;;; +45894-3;LL47-2;MDS_1997_Walking support;LA106-7;2;Setup help only;;; +45894-3;LL47-2;MDS_1997_Walking support;LA107-5;3;One person physical assist;;; +45894-3;LL47-2;MDS_1997_Walking support;LA108-3;4;Two+ persons physical assist;;; +45954-5;LL48-0;MDS_2167_Reason no vaccine-flu;LA183-6;1;Not in facility during this year's flu season;;; +45954-5;LL48-0;MDS_2167_Reason no vaccine-flu;LA184-4;2;Received outside of this facility;;; +45954-5;LL48-0;MDS_2167_Reason no vaccine-flu;LA185-1;3;Not eligible;;; +45954-5;LL48-0;MDS_2167_Reason no vaccine-flu;LA186-9;4;Offered and declined;;; +45954-5;LL48-0;MDS_2167_Reason no vaccine-flu;LA187-7;5;Not offered;;; +45954-5;LL48-0;MDS_2167_Reason no vaccine-flu;LA188-5;6;Inability to obtain vaccine;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA186-9;1;Offered and declined;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA12154-3;2;Assessed and determined to have medical contraindication(s);;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA27632-1;3;"Not indicated; patient does not meet age/condition guidelines for Pneumococcal Vaccine";;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA9-3;4;None of the above;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA186-9;1;Offered and declined;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA12154-3;2;Assessed and determined to have medical contraindication(s);;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA27632-1;3;"Not indicated; patient does not meet age/condition guidelines for Pneumococcal Vaccine";;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA9-3;4;None of the above;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA186-9;1;Offered and declined;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA12154-3;2;Assessed and determined to have medical contraindication(s);;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA27632-1;3;"Not indicated; patient does not meet age/condition guidelines for Pneumococcal Vaccine";;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA9-3;4;None of the above;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA186-9;1;Offered and declined;;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA12154-3;2;Assessed and determined to have medical contraindication(s);;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA27632-1;3;"Not indicated; patient does not meet age/condition guidelines for Pneumococcal Vaccine";;; +45956-0;LL4497-5;CMS_OASIS Reason pneumococcal vaccine not received;LA9-3;4;None of the above;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA185-1;1;Not eligible;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA186-9;2;Offered and declined;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA187-7;3;Not offered;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA185-1;1;Not eligible;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA186-9;2;Offered and declined;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA187-7;3;Not offered;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA185-1;1;Not eligible;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA186-9;2;Offered and declined;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA187-7;3;Not offered;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA185-1;1;Not eligible;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA186-9;2;Offered and declined;;; +45956-0;LL49-8;MDS_2183_Reason no vaccine-pneumococcal;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45956-0;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +45956-0;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +45956-0;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +55023-6;LL677-6;MDSv3_O0300B;LA11091-8;1;Not eligible - medical contraindication;;; +55023-6;LL677-6;MDSv3_O0300B;LA186-9;2;Offered and declined;;; +55023-6;LL677-6;MDSv3_O0300B;LA187-7;3;Not offered;;; +45957-8;LL43-1;MDS_1942_Significant other participation;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +45957-8;LL43-1;MDS_1942_Significant other participation;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +45957-8;LL43-1;MDS_1942_Significant other participation;LA137-2;3;None;260413007;None (qualifier value);http://snomed.info/sct +46251-5;LL2435-7;Age group;LA19747-7;1;Infant;;; +46251-5;LL2435-7;Age group;LA10403-6;2;Newborn;;; +46251-5;LL2435-7;Age group;LA9949-4;3;Child;;; +46251-5;LL2435-7;Age group;LA19748-5;4;Pre-school;;; +46251-5;LL2435-7;Age group;LA19749-3;5;Adolescent;;; +46251-5;LL2435-7;Age group;LA13524-6;6;Adult;;; +46251-5;LL2435-7;Age group;LA19750-1;7;Middle aged;;; +46251-5;LL2435-7;Age group;LA19751-9;8;Aged;;; +46251-5;LL5591-4;PAM Revised Age Score;LA31019-5;2;<65 years;;; +46251-5;LL5591-4;PAM Revised Age Score;LA31342-1;3;> or equal to 65 years;;; +46457-8;LL249-4;OASIS_M0175_Discharged from;LA6218-7;1;Hospital;;; +46457-8;LL249-4;OASIS_M0175_Discharged from;LA6357-3;2;Rehabilitation facility;;; +46457-8;LL249-4;OASIS_M0175_Discharged from;LA6376-3;3;Skilled Nursing Facility;;; +46457-8;LL249-4;OASIS_M0175_Discharged from;LA6314-4;4;Other nursing home;;; +46457-8;LL249-4;OASIS_M0175_Discharged from;LA6310-2;5;Other (specify);;; +46457-8;LL249-4;OASIS_M0175_Discharged from;LA6342-5;6;Patient was not discharged from an inpatient facility;;; +46461-0;LL324-5;OASIS_M0830_OP emergent care;LA6275-7;1;No emergent care services;;; +46461-0;LL324-5;OASIS_M0830_OP emergent care;LA6219-5;2;Hospital emergency room (includes 23-hour holding);;; +46461-0;LL324-5;OASIS_M0830_OP emergent care;LA6188-2;3;Doctor's office emergency visit/house call;;; +46461-0;LL324-5;OASIS_M0830_OP emergent care;LA6318-5;4;Outpatient department/clinic emergency (includes urgicenter sites);;; +46461-0;LL324-5;OASIS_M0830_OP emergent care;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6162-7;3;Black or African-American;;; +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6214-6;4;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6266-6;5;Native Hawaiian or Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4457-3;6;White;2106-3;White;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6162-7;3;Black or African-American;;; +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6214-6;4;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6266-6;5;Native Hawaiian or Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4457-3;6;White;2106-3;White;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6162-7;3;Black or African-American;;; +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6214-6;4;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6266-6;5;Native Hawaiian or Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4457-3;6;White;2106-3;White;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6162-7;3;Black or African-American;;; +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6214-6;4;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6266-6;5;Native Hawaiian or Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4457-3;6;White;2106-3;White;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6162-7;3;Black or African-American;;; +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6214-6;4;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA6266-6;5;Native Hawaiian or Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4457-3;6;White;2106-3;White;https://www.cdc.gov/phin +46463-6;LL247-8;OASIS_M0140_Race-ethnicity;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA31367-8;1;Asian Indian/South Asian;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA4168-6;2;Chinese;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA3969-8;3;Filipino;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA4595-0;4;Japanese;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA4603-2;5;Korean;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA4443-3;6;Vietnamese;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA14049-3;7;Other Asian;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA14045-1;8;Native Hawaiian;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA18375-8;9;Guamanian or Chamorro;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA4300-5;10;Samoan;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA14047-7;11;Other Pacific Islander;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA4-4;12;American Indian/Alaskan Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA4457-3;13;White;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA31368-6;14;Hispanic/Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA14042-8;15;Black/African American;2054-5;Black or African American;https://www.cdc.gov/phin +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA30122-8;16;I choose not to answer this question;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA31369-4;17;Question not administered;;; +46463-6;LL5709-2;AAPCHO - Race/Ethnicity;LA31370-2;18;Skipped question;;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6298-9;1;None, no charge for current services;;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6259-1;2;Medicare (traditional fee-for-service);;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6258-3;3;Medicare (HMO/managed care);;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6257-5;4;Medicaid (traditional fee-for-service);;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6256-7;5;Medicaid (HMO/managed care);;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6452-2;6;Workers' compensation;;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6313-6;8;Other government (e.g., CHAMPUS, VA, etc.);;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6350-8;9;Private insurance;;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6349-0;10;Private HMO/managed care;;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6369-8;11;Self-pay;;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA6310-2;12;Other (specify);;; +46464-4;LL248-6;OASIS_M0150_Payment sources;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46465-1;LL252-8;OASIS_M0220_Prior condition;LA6436-5;1;Urinary incontinence;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA6240-1;2;Indwelling/suprapubic catheter;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA6243-5;3;Intractable pain;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA6227-8;4;Impaired decision-making;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA27596-8;5;Disruptive or socially inappropriate behavior;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA6261-7;6;Memory loss to the extent that supervision required;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA9-3;7;None of the above;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA6282-3;8;No inpatient facility discharge and no change in medical/treatment regimen in past 14 days;;; +46465-1;LL252-8;OASIS_M0220_Prior condition;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +86469-4;LL252-8;OASIS_M0220_Prior condition;LA6436-5;1;Urinary incontinence;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA6240-1;2;Indwelling/suprapubic catheter;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA6243-5;3;Intractable pain;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA6227-8;4;Impaired decision-making;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA27596-8;5;Disruptive or socially inappropriate behavior;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA6261-7;6;Memory loss to the extent that supervision required;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA9-3;7;None of the above;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA6282-3;8;No inpatient facility discharge and no change in medical/treatment regimen in past 14 days;;; +86469-4;LL252-8;OASIS_M0220_Prior condition;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46466-9;LL254-4;OASIS_M0250_M1030_Home therapy;LA6244-3;1;Intravenous or infusion therapy (excludes TPN);;; +46466-9;LL254-4;OASIS_M0250_M1030_Home therapy;LA6321-9;2;Parenteral nutrition (TPN or lipids);;; +46466-9;LL254-4;OASIS_M0250_M1030_Home therapy;LA6194-0;3;Enteral nutrition (nasogastric, gastrostomy, jejunostomy, or any other artificial entry into the alimentary canal);;; +46466-9;LL254-4;OASIS_M0250_M1030_Home therapy;LA9-3;4;None of the above;;; +46467-7;LL258-5;OASIS_M0290_High risk factors;LA6213-8;1;Heavy smoking;;; +46467-7;LL258-5;OASIS_M0290_High risk factors;LA6301-1;2;Obesity;;; +46467-7;LL258-5;OASIS_M0290_High risk factors;LA6152-8;3;Alcohol dependency;;; +46467-7;LL258-5;OASIS_M0290_High risk factors;LA6189-0;4;Drug dependency;;; +46467-7;LL258-5;OASIS_M0290_High risk factors;LA9-3;5;None of the above;;; +46467-7;LL258-5;OASIS_M0290_High risk factors;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46468-5;LL260-1;OASIS_M0340_Lives with;LA6255-9;1;Lives alone;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6450-6;2;With spouse or significant other;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6447-2;3;With other family member;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6444-9;4;With a friend;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6449-8;5;With paid help (other than home care agency staff);;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6448-0;6;With other than above;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6255-9;1;Lives alone;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6450-6;2;With spouse or significant other;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6447-2;3;With other family member;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6444-9;4;With a friend;;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6449-8;5;With paid help (other than home care agency staff);;; +46468-5;LL260-1;OASIS_M0340_Lives with;LA6448-0;6;With other than above;;; +46469-3;LL261-9;OASIS_M0350_Assisting person;LA6358-1;1;Relatives, friends, or neighbors living outside the home;;; +46469-3;LL261-9;OASIS_M0350_Assisting person;LA6346-6;2;Person residing in the home (EXCLUDING paid help);;; +46469-3;LL261-9;OASIS_M0350_Assisting person;LA6320-1;3;Paid help;;; +46469-3;LL261-9;OASIS_M0350_Assisting person;LA9-3;4;None of the above;;; +46469-3;LL261-9;OASIS_M0350_Assisting person;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46470-1;LL264-3;OASIS_M0380_Assistance type;LA6148-6;1;ADL assistance (e.g., bathing, dressing, toileting, bowel/bladder, eating/feeding);;; +46470-1;LL264-3;OASIS_M0380_Assistance type;LA6224-5;2;IADL assistance (e.g., meds, meals, housekeeping, laundry, phone, shopping, finances);;; +46470-1;LL264-3;OASIS_M0380_Assistance type;LA6195-7;3;Environmental support (e.g., housing, home maintenance);;; +46470-1;LL264-3;OASIS_M0380_Assistance type;LA6351-6;4;Psychosocial support (e.g., socialization, companionship, recreation);;; +46470-1;LL264-3;OASIS_M0380_Assistance type;LA6149-4;5;Advocates or facilitates patient's participation in appropriate medical care;;; +46470-1;LL264-3;OASIS_M0380_Assistance type;LA6199-9;6;Financial agent, power of attorney, or conservator of finance;;; +46470-1;LL264-3;OASIS_M0380_Assistance type;LA6212-0;7;Health care agent, conservator of person, or medical power of attorney;;; +46470-1;LL264-3;OASIS_M0380_Assistance type;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46471-9;LL275-9;OASIS_M0500_Resp treatments;LA6319-3;1;Oxygen (intermittent or continuous);;; +46471-9;LL275-9;OASIS_M0500_Resp treatments;LA6438-1;2;Ventilator (continually or at night);;; +46471-9;LL275-9;OASIS_M0500_Resp treatments;LA6176-7;3;Continuous positive airway pressure;;; +46471-9;LL275-9;OASIS_M0500_Resp treatments;LA9-3;4;None of the above;;; +46472-7;LL284-1;OASIS_M0590_Depression;LA6182-5;1;Depressed mood (e.g., feeling sad, tearful);;; +46472-7;LL284-1;OASIS_M0590_Depression;LA6370-6;2;Sense of failure or self reproach;;; +46472-7;LL284-1;OASIS_M0590_Depression;LA6215-3;3;Hopelessness;;; +46472-7;LL284-1;OASIS_M0590_Depression;LA6356-5;4;Recurrent thoughts of death;;; +46472-7;LL284-1;OASIS_M0590_Depression;LA6394-6;5;Thoughts of suicide;;; +46472-7;LL284-1;OASIS_M0590_Depression;LA6296-3;6;None of the above feelings observed or reported;;; +46473-5;LL285-8;OASIS_M0610_Demonstrated delusions;LA12257-4;1;Memory deficit: failure to recognize familiar persons/places, inability to recall events of past 24 hours, significant memory loss so that supervision is required;;; +46473-5;LL285-8;OASIS_M0610_Demonstrated delusions;LA6228-6;2;Impaired decision-making: failure to perform usual ADLs or IADLs, inability to appropriately stop activities, jeopardizes safety through actions;;; +46473-5;LL285-8;OASIS_M0610_Demonstrated delusions;LA6439-9;3;Verbal disruption: yelling, threatening, excessive profanity, sexual references, etc.;;; +46473-5;LL285-8;OASIS_M0610_Demonstrated delusions;LA12260-8;4;Physical aggression: aggressive or combative to self and others (for example, hits self, throws objects, punches, dangerous maneuvers with wheelchair or other objects);;; +46473-5;LL285-8;OASIS_M0610_Demonstrated delusions;LA6187-4;5;Disruptive, infantile, or socially inappropriate behavior (excludes verbal actions);;; +46473-5;LL285-8;OASIS_M0610_Demonstrated delusions;LA6181-7;6;Delusional, hallucinatory, or paranoid behavior;;; +46473-5;LL285-8;OASIS_M0610_Demonstrated delusions;LA6294-8;7;None of the above behaviors demonstrated;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6229-4;1;Improper medication administration, medication side effects, toxicity, anaphylaxis;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6267-4;2;Nausea, dehydration, malnutrition, constipation, impaction;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6241-9;3;Injury caused by fall or accident at home;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6363-1;4;Respiratory problems (e.g., shortness of breath, respiratory infection, tracheobronchial obstruction);;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6453-0;5;Wound infection, deteriorating wound status, new lesion/ulcer;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6165-0;6;Cardiac problems (e.g., fluid overload, exacerbation of CHF, chest pain);;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6223-7;7;Hypo/hyperglycemia, diabetes out of control;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6204-7;8;GI bleeding, obstruction;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA6315-1;9;Other than above reasons;;; +46474-3;LL325-2;OASIS_M0840_Reason emergent care;LA4394-8;10;Reason unknown;;; +46475-0;LL328-6;OASIS_M0880_Family assist post D/C;LA6272-4;1;No assistance or services received;;; +46475-0;LL328-6;OASIS_M0880_Family assist post D/C;LA6456-3;2;Yes, assistance or services provided by family or friends;;; +46475-0;LL328-6;OASIS_M0880_Family assist post D/C;LA6457-1;3;Yes, assistance or services provided by other community resources (e.g., meals-on-wheels, home health, homemaker assistnc, transportation assistnc);;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6229-4;1;Improper medication administration, medication side effects, toxicity, anaphylaxis;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6241-9;2;Injury caused by fall or accident at home;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6364-9;3;Respiratory problems (SOB, infection, obstruction);;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6454-8;4;Wound or tube site infection, deteriorating wound status, new lesion/ulcer;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6223-7;5;Hypo/hyperglycemia, diabetes out of control;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6204-7;6;GI bleeding, obstruction;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6196-5;7;Exacerbation of CHF, fluid overload, heart failure;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6264-1;8;Myocardial infarction, stroke;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6172-6;9;Chemotherapy;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6368-0;10;Scheduled surgical procedure;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6437-3;11;Urinary tract infection;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6246-8;12;IV catheter-related infection;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6180-9;13;Deep vein thrombosis, pulmonary embolus;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6430-8;14;Uncontrolled pain;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6352-4;15;Psychotic episode;;; +46476-8;LL330-2;OASIS_M0895_Reason hospitalized;LA6315-1;16;Other than above reasons;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6229-4;1;Improper medication administration, medication side effects, toxicity, anaphylaxis;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6241-9;2;Injury caused by fall or accident at home;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6364-9;3;Respiratory problems (SOB, infection, obstruction);;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6454-8;4;Wound or tube site infection, deteriorating wound status, new lesion/ulcer;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6223-7;5;Hypo/hyperglycemia, diabetes out of control;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6204-7;6;GI bleeding, obstruction;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6196-5;7;Exacerbation of CHF, fluid overload, heart failure;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6264-1;8;Myocardial infarction, stroke;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6172-6;9;Chemotherapy;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6368-0;10;Scheduled surgical procedure;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6437-3;11;Urinary tract infection;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6246-8;12;IV catheter-related infection;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6180-9;13;Deep vein thrombosis, pulmonary embolus;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6430-8;14;Uncontrolled pain;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6352-4;15;Psychotic episode;;; +86947-9;LL330-2;OASIS_M0895_Reason hospitalized;LA6315-1;16;Other than above reasons;;; +46477-6;LL331-0;OASIS_M0900_Nursing home admission;LA6393-8;1;Therapy services;;; +46477-6;LL331-0;OASIS_M0900_Nursing home admission;LA6365-6;2;Respite care;;; +46477-6;LL331-0;OASIS_M0900_Nursing home admission;LA6217-9;3;Hospice care;;; +46477-6;LL331-0;OASIS_M0900_Nursing home admission;LA6345-8;4;Permanent placement;;; +46477-6;LL331-0;OASIS_M0900_Nursing home admission;LA6434-0;5;Unsafe for care at home;;; +46477-6;LL331-0;OASIS_M0900_Nursing home admission;LA46-8;6;Other;;; +46477-6;LL331-0;OASIS_M0900_Nursing home admission;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46494-1;LL3661-7;PHVS_State_FIPS_5-2;;0;;;; +46499-0;LL3661-7;PHVS_State_FIPS_5-2;;0;;;; +77985-0;LL3661-7;PHVS_State_FIPS_5-2;;0;;;; +91516-5;LL3661-7;PHVS_State_FIPS_5-2;;0;;;; +46500-5;LL245-2;OASIS_M0080_Assessor discipline;LA6367-2;1;RN;;; +46500-5;LL245-2;OASIS_M0080_Assessor discipline;LA6353-2;2;PT;;; +46500-5;LL245-2;OASIS_M0080_Assessor discipline;LA6378-9;3;SLP/ST;;; +46500-5;LL245-2;OASIS_M0080_Assessor discipline;LA6309-4;4;OT;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6390-4;1;Start of care - further visits planned;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6391-2;2;Start of care - no further visits planned;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6366-4;3;Resumption of care (after inpatient stay);;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6355-7;4;Recertification (follow-up) reassessment;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6312-8;5;Other follow-up;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6402-7;6;Transferred to an inpatient facility - patient not discharged from agency;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6401-9;7;Transferred to an inpatient facility - patient discharged from agency;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6179-1;8;Death at home;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6184-1;9;Discharge from agency;;; +46502-1;LL246-0;OASIS_M0100_Reason for assessment;LA6185-8;10;Discharge from agency - no visits completed after start/resumption of care assessment;;; +46504-7;LL3174-1;ICD-10CM;;0;;;; +46504-7;LL3174-1;ICD-10CM;;0;;;; +46507-0;LL3174-1;ICD-10CM;;0;;;; +46507-0;LL3174-1;ICD-10CM;;0;;;; +81892-2;LL3174-1;ICD-10CM;;0;;;; +85914-0;LL3174-1;ICD-10CM;;0;;;; +85914-0;LL3174-1;ICD-10CM;;0;;;; +85914-0;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +86255-7;LL3174-1;ICD-10CM;;0;;;; +46512-0;LL253-6;OASIS_M0230_Primary dx severity;LA6111-4;1;0;;; +46512-0;LL253-6;OASIS_M0230_Primary dx severity;LA6112-2;2;1;;; +46512-0;LL253-6;OASIS_M0230_Primary dx severity;LA6113-0;3;2;;; +46512-0;LL253-6;OASIS_M0230_Primary dx severity;LA6114-8;4;3;;; +46512-0;LL253-6;OASIS_M0230_Primary dx severity;LA6115-5;5;4;;; +46514-6;LL253-6;OASIS_M0230_Primary dx severity;LA6111-4;1;0;;; +46514-6;LL253-6;OASIS_M0230_Primary dx severity;LA6112-2;2;1;;; +46514-6;LL253-6;OASIS_M0230_Primary dx severity;LA6113-0;3;2;;; +46514-6;LL253-6;OASIS_M0230_Primary dx severity;LA6114-8;4;3;;; +46514-6;LL253-6;OASIS_M0230_Primary dx severity;LA6115-5;5;4;;; +46516-1;LL253-6;OASIS_M0230_Primary dx severity;LA6111-4;1;0;;; +46516-1;LL253-6;OASIS_M0230_Primary dx severity;LA6112-2;2;1;;; +46516-1;LL253-6;OASIS_M0230_Primary dx severity;LA6113-0;3;2;;; +46516-1;LL253-6;OASIS_M0230_Primary dx severity;LA6114-8;4;3;;; +46516-1;LL253-6;OASIS_M0230_Primary dx severity;LA6115-5;5;4;;; +46518-7;LL253-6;OASIS_M0230_Primary dx severity;LA6111-4;1;0;;; +46518-7;LL253-6;OASIS_M0230_Primary dx severity;LA6112-2;2;1;;; +46518-7;LL253-6;OASIS_M0230_Primary dx severity;LA6113-0;3;2;;; +46518-7;LL253-6;OASIS_M0230_Primary dx severity;LA6114-8;4;3;;; +46518-7;LL253-6;OASIS_M0230_Primary dx severity;LA6115-5;5;4;;; +46520-3;LL253-6;OASIS_M0230_Primary dx severity;LA6111-4;1;0;;; +46520-3;LL253-6;OASIS_M0230_Primary dx severity;LA6112-2;2;1;;; +46520-3;LL253-6;OASIS_M0230_Primary dx severity;LA6113-0;3;2;;; +46520-3;LL253-6;OASIS_M0230_Primary dx severity;LA6114-8;4;3;;; +46520-3;LL253-6;OASIS_M0230_Primary dx severity;LA6115-5;5;4;;; +46522-9;LL253-6;OASIS_M0230_Primary dx severity;LA6111-4;1;0;;; +46522-9;LL253-6;OASIS_M0230_Primary dx severity;LA6112-2;2;1;;; +46522-9;LL253-6;OASIS_M0230_Primary dx severity;LA6113-0;3;2;;; +46522-9;LL253-6;OASIS_M0230_Primary dx severity;LA6114-8;4;3;;; +46522-9;LL253-6;OASIS_M0230_Primary dx severity;LA6115-5;5;4;;; +46523-7;LL255-1;OASIS_M0260_Prognosis for recovery;LA6348-2;1;Poor: little or no recovery is expected and/or further decline is imminent;;; +46523-7;LL255-1;OASIS_M0260_Prognosis for recovery;LA6205-4;2;Good/Fair: partial to full recovery is expected;;; +46523-7;LL255-1;OASIS_M0260_Prognosis for recovery;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46524-5;LL256-9;OASIS_M0270_Rehab prognosis;LA6208-8;1;Guarded: minimal improvement in functional status is expected, decline is possible;;; +46524-5;LL256-9;OASIS_M0270_Rehab prognosis;LA6206-2;2;Good: marked improvement in functional status is expected;;; +46524-5;LL256-9;OASIS_M0270_Rehab prognosis;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46525-2;LL257-7;OASIS_M0280_Life expectancy;LA6254-2;1;Life expectancy is greater than 6 months;;; +46525-2;LL257-7;OASIS_M0280_Life expectancy;LA6253-4;2;Life expectancy is 6 months or fewer;;; +46526-0;LL259-3;OASIS_M0300_Current residence;LA6344-1;1;Patient's owned or rented residence (house, apartment, or mobile home owned or rented by patient/couple/significant other);;; +46526-0;LL259-3;OASIS_M0300_Current residence;LA6198-1;2;Family member's residence;;; +46526-0;LL259-3;OASIS_M0300_Current residence;LA6164-3;3;Boarding home or rented room;;; +46526-0;LL259-3;OASIS_M0300_Current residence;LA6163-5;4;Board and care or assisted living facility;;; +46526-0;LL259-3;OASIS_M0300_Current residence;LA46-8;5;Other;;; +46527-8;LL262-7;OASIS_M0360_Primary caregiver;LA6289-8;1;No one person;;; +46527-8;LL262-7;OASIS_M0360_Primary caregiver;LA6382-1;2;Spouse or significant other;;; +46527-8;LL262-7;OASIS_M0360_Primary caregiver;LA6178-3;3;Daughter or son;;; +46527-8;LL262-7;OASIS_M0360_Primary caregiver;LA6311-0;4;Other family member;;; +46527-8;LL262-7;OASIS_M0360_Primary caregiver;LA6202-1;5;Friend or neighbor or community or church member;;; +46527-8;LL262-7;OASIS_M0360_Primary caregiver;LA6320-1;6;Paid help;;; +46527-8;LL262-7;OASIS_M0360_Primary caregiver;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46528-6;LL263-5;OASIS_M0370_PCG assistance freq;LA6373-0;1;Several times during day and night;;; +46528-6;LL263-5;OASIS_M0370_PCG assistance freq;LA6372-2;2;Several times during day;;; +46528-6;LL263-5;OASIS_M0370_PCG assistance freq;LA6305-2;3;Once daily;;; +46528-6;LL263-5;OASIS_M0370_PCG assistance freq;LA6396-1;4;Three or more times per week;;; +46528-6;LL263-5;OASIS_M0370_PCG assistance freq;LA6308-6;5;One to two times per week;;; +46528-6;LL263-5;OASIS_M0370_PCG assistance freq;LA6250-0;6;Less often than weekly;;; +46528-6;LL263-5;OASIS_M0370_PCG assistance freq;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46529-4;LL265-0;OASIS_M0390_Vision;LA6299-7;1;Normal vision: sees adequately in most situations, can see medication labels, newsprint.;;; +46529-4;LL265-0;OASIS_M0390_Vision;LA6322-7;2;Partially impaired: cannot see medication labels/newsprint, but CAN see obstacles in path, and surrounding layout, can count fingers at arm's length.;;; +46529-4;LL265-0;OASIS_M0390_Vision;LA6375-5;3;Severely impaired: cannot locate objects without hearing or touching them or patient nonresponsive.;;; +46530-2;LL266-8;OASIS_M0400_Hearing;LA6285-6;1;No observable impairment. Able to hear and understand complex or detailed instructions and extended or abstract conversation.;;; +46530-2;LL266-8;OASIS_M0400_Hearing;LA6441-5;2;W/ min difficulty, able to hear and understand most multi-step instructns and ordinary conversatn. May need occasional repetition, xtra time or louder voice.;;; +46530-2;LL266-8;OASIS_M0400_Hearing;LA6209-6;3;Has moderate difficulty hearing and understanding simple, one-step instructions and brief conversation, needs frequent prompting or assistance.;;; +46530-2;LL266-8;OASIS_M0400_Hearing;LA6211-2;4;Has severe difficulty hearing and understanding simple greetings and short comments. Requires mult repetitions, restatements, demonstrations, addtl time.;;; +46530-2;LL266-8;OASIS_M0400_Hearing;LA6418-3;5;UNABLE to hear and understand familiar words or common expressions consistently, OR patient nonresponsive.;;; +46531-0;LL267-6;OASIS_M0410_Speech;LA6197-3;1;Expresses complex ideas, feelings, and needs clearly, completely, and easily in all situations with no observable impairment.;;; +46531-0;LL267-6;OASIS_M0410_Speech;LA6262-5;2;Min diff in xpressing ideas/needs (may take xtra time, occasional errors in word choice/grammar/speech intelligibility, needs min prompting or assist).;;; +46531-0;LL267-6;OASIS_M0410_Speech;LA6455-5;3;Xpresses simple ideas/needs w/moderate diff (needs prompting or assist, errors in word choice, org. or speech intell). Speaks in phrases/short sentcs.;;; +46531-0;LL267-6;OASIS_M0410_Speech;LA6210-4;4;Has severe difficulty expressing basic ideas or needs and requires max assistance or guessing by listener. Speech limited to single words or short phrases.;;; +46531-0;LL267-6;OASIS_M0410_Speech;LA6429-0;5;UNABLE to xpress basic needs even w/maximal prompting or assist but is not comatose/unresponsive (e.g., speech is nonsensical/unintelligible).;;; +46531-0;LL267-6;OASIS_M0410_Speech;LA6336-7;6;Patient nonresponsive or unable to speak.;;; +46532-8;LL268-4;OASIS_M0420_Pain freq;LA6329-2;1;Patient has no pain or pain does not interfere with activity or movement;;; +46532-8;LL268-4;OASIS_M0420_Pain freq;LA6249-2;2;Less often than daily;;; +46532-8;LL268-4;OASIS_M0420_Pain freq;LA6177-5;3;Daily, but not constantly;;; +46532-8;LL268-4;OASIS_M0420_Pain freq;LA6154-4;4;All of the time;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46536-9;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46537-7;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46537-7;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46537-7;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46537-7;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46537-7;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46538-5;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46538-5;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46538-5;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46538-5;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46538-5;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46539-3;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46539-3;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46539-3;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46539-3;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46539-3;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46544-3;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46544-3;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46544-3;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46544-3;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46544-3;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46548-4;LL269-2;OASIS_M0450_Surgical wounds;LA6458-9;1;Zero;;; +46548-4;LL269-2;OASIS_M0450_Surgical wounds;LA6306-0;2;One;;; +46548-4;LL269-2;OASIS_M0450_Surgical wounds;LA6404-3;3;Two;;; +46548-4;LL269-2;OASIS_M0450_Surgical wounds;LA6395-3;4;Three;;; +46548-4;LL269-2;OASIS_M0450_Surgical wounds;LA6200-5;5;Four or more;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6111-4;1;0;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6112-2;2;1;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6113-0;3;2;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6114-8;4;3;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA12206-1;5;4 or more;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6111-4;1;0;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6112-2;2;1;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6113-0;3;2;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6114-8;4;3;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA12206-1;5;4 or more;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6111-4;1;0;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6112-2;2;1;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6113-0;3;2;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6114-8;4;3;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA12206-1;5;4 or more;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6111-4;1;0;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6112-2;2;1;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6113-0;3;2;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6114-8;4;3;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA12206-1;5;4 or more;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6111-4;1;0;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6112-2;2;1;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6113-0;3;2;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6114-8;4;3;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA12206-1;5;4 or more;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6111-4;1;0;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6112-2;2;1;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6113-0;3;2;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA6114-8;4;3;;; +46536-9;LL5031-1;0 | 1 | 2 | 3 | 4 or more;LA12206-1;5;4 or more;;; +46536-9;LL792-3;OASIS-C_M1322;LA6111-4;1;0;;; +46536-9;LL792-3;OASIS-C_M1322;LA6112-2;2;1;;; +46536-9;LL792-3;OASIS-C_M1322;LA6113-0;3;2;;; +46536-9;LL792-3;OASIS-C_M1322;LA6114-8;4;3;;; +46536-9;LL792-3;OASIS-C_M1322;LA12206-1;5;4 or more;;; +46536-9;LL792-3;OASIS-C_M1322;LA6111-4;1;0;;; +46536-9;LL792-3;OASIS-C_M1322;LA6112-2;2;1;;; +46536-9;LL792-3;OASIS-C_M1322;LA6113-0;3;2;;; +46536-9;LL792-3;OASIS-C_M1322;LA6114-8;4;3;;; +46536-9;LL792-3;OASIS-C_M1322;LA12206-1;5;4 or more;;; +46536-9;LL792-3;OASIS-C_M1322;LA6111-4;1;0;;; +46536-9;LL792-3;OASIS-C_M1322;LA6112-2;2;1;;; +46536-9;LL792-3;OASIS-C_M1322;LA6113-0;3;2;;; +46536-9;LL792-3;OASIS-C_M1322;LA6114-8;4;3;;; +46536-9;LL792-3;OASIS-C_M1322;LA12206-1;5;4 or more;;; +46536-9;LL792-3;OASIS-C_M1322;LA6111-4;1;0;;; +46536-9;LL792-3;OASIS-C_M1322;LA6112-2;2;1;;; +46536-9;LL792-3;OASIS-C_M1322;LA6113-0;3;2;;; +46536-9;LL792-3;OASIS-C_M1322;LA6114-8;4;3;;; +46536-9;LL792-3;OASIS-C_M1322;LA12206-1;5;4 or more;;; +57230-5;LL792-3;OASIS-C_M1322;LA6111-4;1;0;;; +57230-5;LL792-3;OASIS-C_M1322;LA6112-2;2;1;;; +57230-5;LL792-3;OASIS-C_M1322;LA6113-0;3;2;;; +57230-5;LL792-3;OASIS-C_M1322;LA6114-8;4;3;;; +57230-5;LL792-3;OASIS-C_M1322;LA12206-1;5;4 or more;;; +46541-9;LL270-0;OASIS_M0460_Ulcer stage;LA6383-9;1;Stage 1;;; +46541-9;LL270-0;OASIS_M0460_Ulcer stage;LA6384-7;2;Stage 2;;; +46541-9;LL270-0;OASIS_M0460_Ulcer stage;LA6385-4;3;Stage 3;;; +46541-9;LL270-0;OASIS_M0460_Ulcer stage;LA6386-2;4;Stage 4;;; +46541-9;LL270-0;OASIS_M0460_Ulcer stage;LA6286-4;5;No observable pressure ulcer;;; +46542-7;LL271-8;OASIS_M0464_Pressure ulcer status;LA6203-9;1;Fully granulating;;; +46542-7;LL271-8;OASIS_M0464_Pressure ulcer status;LA6193-2;2;Early/partial granulation;;; +46542-7;LL271-8;OASIS_M0464_Pressure ulcer status;LA6300-3;3;Not healing;;; +46542-7;LL271-8;OASIS_M0464_Pressure ulcer status;LA6286-4;4;No observable pressure ulcer;;; +46546-8;LL272-6;OASIS_M0476_Stasis ulcer status;LA6203-9;1;Fully granulating;;; +46546-8;LL272-6;OASIS_M0476_Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +46546-8;LL272-6;OASIS_M0476_Stasis ulcer status;LA6300-3;3;Not healing;;; +46546-8;LL272-6;OASIS_M0476_Stasis ulcer status;LA6287-2;4;No observable stasis ulcer;;; +46550-0;LL273-4;OASIS_M0488_Surgical wound status;LA6203-9;1;Fully granulating;;; +46550-0;LL273-4;OASIS_M0488_Surgical wound status;LA6193-2;2;Early/partial granulation;;; +46550-0;LL273-4;OASIS_M0488_Surgical wound status;LA6300-3;3;Not healing;;; +46550-0;LL273-4;OASIS_M0488_Surgical wound status;LA6288-0;4;No observable surgical wound;;; +46551-8;LL274-2;OASIS_M0490_Dyspnea;LA6271-6;1;Never, patient is not short of breath;;; +46551-8;LL274-2;OASIS_M0490_Dyspnea;LA6443-1;2;When walking more than 20 feet, climbing stairs;;; +46551-8;LL274-2;OASIS_M0490_Dyspnea;LA6446-4;3;With moderate exertion (for example, while dressing, using commode or bedpan, walking distances less than 20 feet);;; +46551-8;LL274-2;OASIS_M0490_Dyspnea;LA6445-6;4;With minimal exertion (for example, while eating, talking, or performing other ADLs) or with agitation;;; +46551-8;LL274-2;OASIS_M0490_Dyspnea;LA6158-5;5;At rest (during day or night);;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL276-7;OASIS_M0510_UTI treatment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA6337-5;3;Patient on prophylactic treatment;;; +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46552-6;LL4528-7;CMS_OASIS UTI minus UK option;LA6337-5;3;Patient on prophylactic treatment;;; +46553-4;LL277-5;OASIS_M0520_Urinary incontinance-catheter;LA6278-1;1;No incontinence or catheter (includes anuria or ostomy for urinary drainage);;; +46553-4;LL277-5;OASIS_M0520_Urinary incontinance-catheter;LA6332-6;2;Patient is incontinent;;; +46553-4;LL277-5;OASIS_M0520_Urinary incontinance-catheter;LA6339-1;3;Patient requires a urinary catheter (specifically: external, indwelling, intermittent, or suprapubic);;; +46554-2;LL300-5;OASIS_M0700_Prior ambulation;LA6137-9;1;Able to independently walk on even/uneven surfaces and climb stairs with or without railings (i.e., needs no human assist or assist device).;;; +46554-2;LL300-5;OASIS_M0700_Prior ambulation;LA6361-5;2;Requires device (e.g., cane, walker) to walk alone OR requires human supervision/assistance to negotiate stairs/steps/uneven surfaces.;;; +46554-2;LL300-5;OASIS_M0700_Prior ambulation;LA6147-8;3;Able to walk only with the supervision or assistance of another person at all times.;;; +46554-2;LL300-5;OASIS_M0700_Prior ambulation;LA6171-8;4;Chairfast, unable to ambulate but is able to wheel self independently.;;; +46554-2;LL300-5;OASIS_M0700_Prior ambulation;LA6170-0;5;Chairfast, unable to ambulate and is unable to wheel self.;;; +46554-2;LL300-5;OASIS_M0700_Prior ambulation;LA6159-3;6;Bedfast, unable to ambulate or be up in a chair.;;; +46554-2;LL300-5;OASIS_M0700_Prior ambulation;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46555-9;LL299-9;OASIS_M0700_Ambulation;LA6137-9;1;Able to independently walk on even/uneven surfaces and climb stairs with or without railings (i.e., needs no human assist or assist device).;;; +46555-9;LL299-9;OASIS_M0700_Ambulation;LA6361-5;2;Requires device (e.g., cane, walker) to walk alone OR requires human supervision/assistance to negotiate stairs/steps/uneven surfaces.;;; +46555-9;LL299-9;OASIS_M0700_Ambulation;LA6147-8;3;Able to walk only with the supervision or assistance of another person at all times.;;; +46555-9;LL299-9;OASIS_M0700_Ambulation;LA6171-8;4;Chairfast, unable to ambulate but is able to wheel self independently.;;; +46555-9;LL299-9;OASIS_M0700_Ambulation;LA6170-0;5;Chairfast, unable to ambulate and is unable to wheel self.;;; +46555-9;LL299-9;OASIS_M0700_Ambulation;LA6159-3;6;Bedfast, unable to ambulate or be up in a chair.;;; +46556-7;LL302-1;OASIS_M0710_Prior feeding;LA6133-8;1;Able to independently feed self.;;; +46556-7;LL302-1;OASIS_M0710_Prior feeding;LA6128-8;2;Able to feed self independently but requires: a) meal set-up OR b) intermittent aid/supervision OR c) liquid/pureed/ground meat diet.;;; +46556-7;LL302-1;OASIS_M0710_Prior feeding;LA6414-2;3;Unable to feed self and must be assisted or supervised throughout the meal/snack.;;; +46556-7;LL302-1;OASIS_M0710_Prior feeding;LA6142-9;4;Able to take in nutrients orally AND receives supplemental nutrients through a nasogastric tube or gastrostomy.;;; +46556-7;LL302-1;OASIS_M0710_Prior feeding;LA6422-5;5;Unable to take in nutrients orally and is fed nutrients through a nasogastric tube or gastrostomy.;;; +46556-7;LL302-1;OASIS_M0710_Prior feeding;LA6423-3;6;Unable to take in nutrients orally or by tube feeding.;;; +46556-7;LL302-1;OASIS_M0710_Prior feeding;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46557-5;LL301-3;OASIS_M0710_Feeding;LA6133-8;1;Able to independently feed self.;;; +46557-5;LL301-3;OASIS_M0710_Feeding;LA6128-8;2;Able to feed self independently but requires: a) meal set-up OR b) intermittent aid/supervision OR c) liquid/pureed/ground meat diet.;;; +46557-5;LL301-3;OASIS_M0710_Feeding;LA6414-2;3;Unable to feed self and must be assisted or supervised throughout the meal/snack.;;; +46557-5;LL301-3;OASIS_M0710_Feeding;LA6142-9;4;Able to take in nutrients orally AND receives supplemental nutrients through a nasogastric tube or gastrostomy.;;; +46557-5;LL301-3;OASIS_M0710_Feeding;LA6422-5;5;Unable to take in nutrients orally and is fed nutrients through a nasogastric tube or gastrostomy.;;; +46557-5;LL301-3;OASIS_M0710_Feeding;LA6423-3;6;Unable to take in nutrients orally or by tube feeding.;;; +46558-3;LL304-7;OASIS_M0720_Prior light meals;LA6117-1;1;a) Able to indep plan and prep all lt meals for self or reheat delivered meals OR b) Physically/cognitively/mentally able to prepare lt meals.;;; +46558-3;LL304-7;OASIS_M0720_Prior light meals;LA6420-9;2;Unable to prepare light meals on a regular basis due to physical, cognitive, or mental limitations.;;; +46558-3;LL304-7;OASIS_M0720_Prior light meals;LA6419-1;3;Unable to prepare any light meals or reheat any delivered meals.;;; +46558-3;LL304-7;OASIS_M0720_Prior light meals;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46559-1;LL303-9;OASIS_M0720_Light meals;LA6117-1;1;a) Able to indep plan and prep all lt meals for self or reheat delivered meals OR b) Physically/cognitively/mentally able to prepare lt meals.;;; +46559-1;LL303-9;OASIS_M0720_Light meals;LA6420-9;2;Unable to prepare light meals on a regular basis due to physical, cognitive, or mental limitations.;;; +46559-1;LL303-9;OASIS_M0720_Light meals;LA6419-1;3;Unable to prepare any light meals or reheat any delivered meals.;;; +46560-9;LL306-2;OASIS_M0730_Priot transportation;LA6132-0;1;Able to independently drive a regular or adapted car, OR uses a regular or handicap-accessible public bus.;;; +46560-9;LL306-2;OASIS_M0730_Priot transportation;LA6141-1;2;Able to ride in car only when driven by another person OR able to use bus/handicap van only when assisted/accompanied by another person.;;; +46560-9;LL306-2;OASIS_M0730_Priot transportation;LA6421-7;3;UNABLE to ride in a car, taxi, bus, or van, and requires transportation by ambulance.;;; +46560-9;LL306-2;OASIS_M0730_Priot transportation;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46561-7;LL305-4;OASIS_M0730_Transportion;LA6132-0;1;Able to independently drive a regular or adapted car, OR uses a regular or handicap-accessible public bus.;;; +46561-7;LL305-4;OASIS_M0730_Transportion;LA6141-1;2;Able to ride in car only when driven by another person OR able to use bus/handicap van only when assisted/accompanied by another person.;;; +46561-7;LL305-4;OASIS_M0730_Transportion;LA6421-7;3;UNABLE to ride in a car, taxi, bus, or van, and requires transportation by ambulance.;;; +46562-5;LL308-8;OASIS_M0740_Prior laundry;LA6119-7;1;a) Able to independently take care of all laundry tasks OR b) Physically, cognitively, and mentally able to do laundry and access facilities.;;; +46562-5;LL308-8;OASIS_M0740_Prior laundry;LA6125-4;2;Able to do only light laundry, (minor hand wash or light loads). Due to physical/cognitive/mental limitations, needs assist with heavy laundry.;;; +46562-5;LL308-8;OASIS_M0740_Prior laundry;LA6411-8;3;UNABLE to do any laundry due to physical limitation or needs continual supervision and assistance due to cognitive or mental limitation.;;; +46562-5;LL308-8;OASIS_M0740_Prior laundry;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46563-3;LL307-0;OASIS_M0740_Laundry;LA6119-7;1;a) Able to independently take care of all laundry tasks OR b) Physically, cognitively, and mentally able to do laundry and access facilities.;;; +46563-3;LL307-0;OASIS_M0740_Laundry;LA6125-4;2;Able to do only light laundry, (minor hand wash or light loads). Due to physical/cognitive/mental limitations, needs assist with heavy laundry.;;; +46563-3;LL307-0;OASIS_M0740_Laundry;LA6411-8;3;UNABLE to do any laundry due to physical limitation or needs continual supervision and assistance due to cognitive or mental limitation.;;; +46564-1;LL310-4;OASIS_M0750_Prior housekeeping;LA6118-9;1;a) Able to independently perform all housekeeping tasks OR b) Physically, cognitively, and mentally able to perform all housekeeping tasks .;;; +46564-1;LL310-4;OASIS_M0750_Prior housekeeping;LA6140-3;2;Able to perform only LIGHT housekeeping (e.g., dusting, wiping kitchen counters) tasks independently.;;; +46564-1;LL310-4;OASIS_M0750_Prior housekeeping;LA6139-5;3;Able to perform housekeeping tasks with intermittent assistance or supervision from another person.;;; +46564-1;LL310-4;OASIS_M0750_Prior housekeeping;LA6410-0;4;UNABLE to consistently perform any housekeeping tasks unless assisted by another person throughout the process.;;; +46564-1;LL310-4;OASIS_M0750_Prior housekeeping;LA6412-6;5;Unable to effectively participate in any housekeeping tasks.;;; +46564-1;LL310-4;OASIS_M0750_Prior housekeeping;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46565-8;LL309-6;OASIS_M0750_Housekeeping;LA6118-9;1;a) Able to independently perform all housekeeping tasks OR b) Physically, cognitively, and mentally able to perform all housekeeping tasks .;;; +46565-8;LL309-6;OASIS_M0750_Housekeeping;LA6140-3;2;Able to perform only LIGHT housekeeping (e.g., dusting, wiping kitchen counters) tasks independently.;;; +46565-8;LL309-6;OASIS_M0750_Housekeeping;LA6139-5;3;Able to perform housekeeping tasks with intermittent assistance or supervision from another person.;;; +46565-8;LL309-6;OASIS_M0750_Housekeeping;LA6410-0;4;UNABLE to consistently perform any housekeeping tasks unless assisted by another person throughout the process.;;; +46565-8;LL309-6;OASIS_M0750_Housekeeping;LA6412-6;5;Unable to effectively participate in any housekeeping tasks.;;; +46566-6;LL312-0;OASIS_M0760_Prior shopping;LA6120-5;1;a) Able to plan for shopping needs and indep perform shopping tasks OR b) Physically/cognitively/mentally able to take care of shopping;;; +46566-6;LL312-0;OASIS_M0760_Prior shopping;LA6268-2;2;Needs some assistance: a) By self is able to do only light shopping and carry small packages OR b) UNABLE to go shopping alone;;; +46566-6;LL312-0;OASIS_M0760_Prior shopping;LA6417-5;3;UNABLE to go shopping, but is able to identify items needed, place orders, and arrange home delivery.;;; +46566-6;LL312-0;OASIS_M0760_Prior shopping;LA6269-0;4;Needs someone to do all shopping and errands.;;; +46566-6;LL312-0;OASIS_M0760_Prior shopping;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46567-4;LL311-2;OASIS_M0760_Shopping;LA6120-5;1;a) Able to plan for shopping needs and indep perform shopping tasks OR b) Physically/cognitively/mentally able to take care of shopping;;; +46567-4;LL311-2;OASIS_M0760_Shopping;LA6268-2;2;Needs some assistance: a) By self is able to do only light shopping and carry small packages OR b) UNABLE to go shopping alone;;; +46567-4;LL311-2;OASIS_M0760_Shopping;LA6417-5;3;UNABLE to go shopping, but is able to identify items needed, place orders, and arrange home delivery.;;; +46567-4;LL311-2;OASIS_M0760_Shopping;LA6269-0;4;Needs someone to do all shopping and errands.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA6124-7;1;Able to dial numbers and answer calls appropriately and as desired.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA6146-0;2;Able to use a specially adapted telephone (for example, large numbers on the dial, teletype phone for the deaf) and call essential numbers.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA6121-3;3;Able to answer the telephone and carry on a normal conversation but has difficulty with placing calls.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA6122-1;4;Able to answer the telephone only some of the time or is able to carry on only a limited conversation.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA6409-2;5;Unable to answer the telephone at all but can listen if assisted with equipment.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA6400-1;6;Totally unable to use the telephone.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA6327-6;7;Patient does not have a telephone.;;; +46568-2;LL314-6;OASIS_M0770_Prior telephone use;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46569-0;LL313-8;OASIS_M0770_Telephone use;LA6124-7;1;Able to dial numbers and answer calls appropriately and as desired.;;; +46569-0;LL313-8;OASIS_M0770_Telephone use;LA6146-0;2;Able to use a specially adapted telephone (for example, large numbers on the dial, teletype phone for the deaf) and call essential numbers.;;; +46569-0;LL313-8;OASIS_M0770_Telephone use;LA6121-3;3;Able to answer the telephone and carry on a normal conversation but has difficulty with placing calls.;;; +46569-0;LL313-8;OASIS_M0770_Telephone use;LA6122-1;4;Able to answer the telephone only some of the time or is able to carry on only a limited conversation.;;; +46569-0;LL313-8;OASIS_M0770_Telephone use;LA6409-2;5;Unable to answer the telephone at all but can listen if assisted with equipment.;;; +46569-0;LL313-8;OASIS_M0770_Telephone use;LA6400-1;6;Totally unable to use the telephone.;;; +46569-0;LL313-8;OASIS_M0770_Telephone use;LA6327-6;7;Patient does not have a telephone.;;; +46570-8;LL316-1;OASIS_M0780_Prior oral med mgmnt;LA6135-3;1;Able to independently take the correct oral medication(s) and proper dosage(s) at the correct times.;;; +46570-8;LL316-1;OASIS_M0780_Prior oral med mgmnt;LA6145-2;2;Able to take medication(s) at correct times if: a) indiv dosages prep in advance OR b) given daily reminders OR c) uses drug diary or chart.;;; +46570-8;LL316-1;OASIS_M0780_Prior oral med mgmnt;LA6425-8;3;UNABLE to take medication unless administered by someone else.;;; +46570-8;LL316-1;OASIS_M0780_Prior oral med mgmnt;LA6290-6;4;No oral medications prescribed.;;; +46570-8;LL316-1;OASIS_M0780_Prior oral med mgmnt;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46571-6;LL315-3;OASIS_M0780_Oral med management;LA6135-3;1;Able to independently take the correct oral medication(s) and proper dosage(s) at the correct times.;;; +46571-6;LL315-3;OASIS_M0780_Oral med management;LA6145-2;2;Able to take medication(s) at correct times if: a) indiv dosages prep in advance OR b) given daily reminders OR c) uses drug diary or chart.;;; +46571-6;LL315-3;OASIS_M0780_Oral med management;LA6425-8;3;UNABLE to take medication unless administered by someone else.;;; +46571-6;LL315-3;OASIS_M0780_Oral med management;LA6290-6;4;No oral medications prescribed.;;; +46572-4;LL318-7;OASIS_M0790_Prior inhaled med mgmnt;LA6134-6;1;Able to independently take the correct medication and proper dosage at the correct times.;;; +46572-4;LL318-7;OASIS_M0790_Prior inhaled med mgmnt;LA6144-5;2;Able to take medication at the correct times if: a) indiv dosages are prep in advance by another person OR b) given daily reminders.;;; +46572-4;LL318-7;OASIS_M0790_Prior inhaled med mgmnt;LA6425-8;3;UNABLE to take medication unless administered by someone else.;;; +46572-4;LL318-7;OASIS_M0790_Prior inhaled med mgmnt;LA6279-9;4;No inhalant/mist medications prescribed.;;; +46572-4;LL318-7;OASIS_M0790_Prior inhaled med mgmnt;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46573-2;LL317-9;OASIS_M0790_Inhaled med mgmnt;LA6134-6;1;Able to independently take the correct medication and proper dosage at the correct times.;;; +46573-2;LL317-9;OASIS_M0790_Inhaled med mgmnt;LA6144-5;2;Able to take medication at the correct times if: a) indiv dosages are prep in advance by another person OR b) given daily reminders.;;; +46573-2;LL317-9;OASIS_M0790_Inhaled med mgmnt;LA6425-8;3;UNABLE to take medication unless administered by someone else.;;; +46573-2;LL317-9;OASIS_M0790_Inhaled med mgmnt;LA6279-9;4;No inhalant/mist medications prescribed.;;; +46574-0;LL320-3;OASIS_M0800_Prior inject med mgmnt;LA6134-6;1;Able to independently take the correct medication and proper dosage at the correct times.;;; +46574-0;LL320-3;OASIS_M0800_Prior inject med mgmnt;LA6143-7;2;Able to take injectable medication at correct times if: a) indiv syringes are prep in advance by another person OR b) given daily reminders.;;; +46574-0;LL320-3;OASIS_M0800_Prior inject med mgmnt;LA6424-1;3;UNABLE to take injectable medications unless administered by someone else.;;; +46574-0;LL320-3;OASIS_M0800_Prior inject med mgmnt;LA6280-7;4;No injectable medications prescribed.;;; +46574-0;LL320-3;OASIS_M0800_Prior inject med mgmnt;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46575-7;LL319-5;OASIS_M0800_Inject med mgmnt;LA6134-6;1;Able to independently take the correct medication and proper dosage at the correct times.;;; +46575-7;LL319-5;OASIS_M0800_Inject med mgmnt;LA6143-7;2;Able to take injectable medication at correct times if: a) indiv syringes are prep in advance by another person OR b) given daily reminders.;;; +46575-7;LL319-5;OASIS_M0800_Inject med mgmnt;LA6424-1;3;UNABLE to take injectable medications unless administered by someone else.;;; +46575-7;LL319-5;OASIS_M0800_Inject med mgmnt;LA6280-7;4;No injectable medications prescribed.;;; +46576-5;LL321-1;OASIS_M0810_Pt equip mgmnt;LA6334-2;1;Patient manages all tasks related to equipment completely independently.;;; +46576-5;LL321-1;OASIS_M0810_Pt equip mgmnt;LA6225-2;2;If someone else sets up equipment (i.e. fills portable oxygen tank, provides patient w/prep solns), patient able to manage all other aspects of equipment.;;; +46576-5;LL321-1;OASIS_M0810_Pt equip mgmnt;LA6340-9;3;Patient requires considerable assistance from another person to manage equipment, but independently completes portions of the task.;;; +46576-5;LL321-1;OASIS_M0810_Pt equip mgmnt;LA6333-4;4;Patient is only able to monitor equipment (e.g., liter flow, fluid in bag) and must call someone else to manage the equipment.;;; +46576-5;LL321-1;OASIS_M0810_Pt equip mgmnt;LA6331-8;5;Patient is completely dependent on someone else to manage all equipment.;;; +46576-5;LL321-1;OASIS_M0810_Pt equip mgmnt;LA6276-5;6;No equipment of this type used in care.;;; +46577-3;LL322-9;OASIS_M0820_PCG equip mgmnt;LA6168-4;1;Caregiver manages all tasks related to equipment completely independently.;;; +46577-3;LL322-9;OASIS_M0820_PCG equip mgmnt;LA6226-0;2;If someone else sets up equipment, caregiver is able to manage all other aspects.;;; +46577-3;LL322-9;OASIS_M0820_PCG equip mgmnt;LA6169-2;3;Caregiver requires considerable assistance from another person to manage equipment, but independently completes significant portions of task.;;; +46577-3;LL322-9;OASIS_M0820_PCG equip mgmnt;LA6167-6;4;Caregiver is only able to complete small portions of task (e.g., administer nebulizer treatment, clean/store/dispose of equipment or supplies).;;; +46577-3;LL322-9;OASIS_M0820_PCG equip mgmnt;LA6166-8;5;Caregiver is completely dependent on someone else to manage all equipment.;;; +46577-3;LL322-9;OASIS_M0820_PCG equip mgmnt;LA6273-2;6;No caregiver;;; +46577-3;LL322-9;OASIS_M0820_PCG equip mgmnt;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6218-7;1;Hospital;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6357-3;2;Rehabilitation facility;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA27-8;3;Nursing Home;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6216-1;4;Hospice;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6281-5;5;No inpatient facility admission;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6218-7;1;Hospital;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6357-3;2;Rehabilitation facility;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA27-8;3;Nursing Home;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6216-1;4;Hospice;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6281-5;5;No inpatient facility admission;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6218-7;1;Hospital;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6357-3;2;Rehabilitation facility;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA27-8;3;Nursing Home;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6216-1;4;Hospice;;; +46578-1;LL326-0;OASIS_M0855_Inpatient facility;LA6281-5;5;No inpatient facility admission;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6218-7;1;Hospital;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6357-3;2;Rehabilitation facility;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA27-8;3;Nursing Home;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6216-1;4;Hospice;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6218-7;1;Hospital;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6357-3;2;Rehabilitation facility;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA27-8;3;Nursing Home;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6216-1;4;Hospice;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6218-7;1;Hospital;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6357-3;2;Rehabilitation facility;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA27-8;3;Nursing Home;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6216-1;4;Hospice;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6218-7;1;Hospital;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6357-3;2;Rehabilitation facility;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA27-8;3;Nursing Home;;; +46578-1;LL4546-9;CMS_OASIS Inpatient Facilty Admission -transfer;LA6216-1;4;Hospice;;; +46579-9;LL327-8;OASIS_M0870_Discharge disposition;LA6338-3;1;Patient remained in the community (not in hospital, nursing home, or rehab facility);;; +46579-9;LL327-8;OASIS_M0870_Discharge disposition;LA6341-7;2;Patient transferred to a noninstitutional hospice;;; +46579-9;LL327-8;OASIS_M0870_Discharge disposition;LA6431-6;3;Unknown because patient moved to a geographic location not served by this agency;;; +46579-9;LL327-8;OASIS_M0870_Discharge disposition;LA6316-9;4;Other unknown;;; +46580-7;LL329-4;OASIS_M0890_Reason acute hospitalization;LA6221-1;1;Hospitalization for EMERGENT (unscheduled) care;;; +46580-7;LL329-4;OASIS_M0890_Reason acute hospitalization;LA6222-9;2;Hospitalization for URGENT (scheduled within 24 hours of admisson) care;;; +46580-7;LL329-4;OASIS_M0890_Reason acute hospitalization;LA6220-3;3;Hospitalization for ELECTIVE (scheduled more than 24 hours before admission) care;;; +46580-7;LL329-4;OASIS_M0890_Reason acute hospitalization;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46583-1;LL323-7;OASIS_M0825_Therapy need;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +46583-1;LL323-7;OASIS_M0825_Therapy need;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46583-1;LL323-7;OASIS_M0825_Therapy need;LA4720-4;3;Not applicable;;; +46586-4;LL278-3;OASIS_M0530_Urinary incontinence-time;LA6397-9;1;Timed-voiding defers incontinence;;; +46586-4;LL278-3;OASIS_M0530_Urinary incontinence-time;LA6192-4;2;During the night only;;; +46586-4;LL278-3;OASIS_M0530_Urinary incontinence-time;LA6191-6;3;During the day and night;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6252-6;2;Less than once weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6307-8;3;One to three times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6201-3;4;Four to six times weekly;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6302-9;5;On a daily basis;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6263-3;6;More often than once daily;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL279-1;OASIS_M0540_Bowel incontinence freq;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6252-6;2;Less than once weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6307-8;3;One to three times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6201-3;4;Four to six times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6302-9;5;On a daily basis;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6263-3;6;More often than once daily;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6252-6;2;Less than once weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6307-8;3;One to three times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6201-3;4;Four to six times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6302-9;5;On a daily basis;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6263-3;6;More often than once daily;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6252-6;2;Less than once weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6307-8;3;One to three times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6201-3;4;Four to six times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6302-9;5;On a daily basis;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6263-3;6;More often than once daily;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6252-6;2;Less than once weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6307-8;3;One to three times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6201-3;4;Four to six times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6302-9;5;On a daily basis;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6263-3;6;More often than once daily;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6252-6;2;Less than once weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6307-8;3;One to three times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6201-3;4;Four to six times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6302-9;5;On a daily basis;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6263-3;6;More often than once daily;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6440-7;1;Very rarely or never has bowel incontinence;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6252-6;2;Less than once weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6307-8;3;One to three times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6201-3;4;Four to six times weekly;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6302-9;5;On a daily basis;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6263-3;6;More often than once daily;;; +46587-2;LL4529-5;CMS_OASIS Bowel frequency minus UK option;LA6330-0;7;Patient has ostomy for bowel elimination;;; +46588-0;LL280-9;OASIS_M0550_Ostomy;LA6328-4;1;Patient does not have an ostomy for bowel elimination.;;; +46588-0;LL280-9;OASIS_M0550_Ostomy;LA6343-3;2;Patient's ostomy was not related to an inpatient stay and did not necessitate change in medical or treatment regimen.;;; +46588-0;LL280-9;OASIS_M0550_Ostomy;LA6392-0;3;The ostomy was related to an inpatient stay or did necessitate change in medical or treatment regimen.;;; +86471-0;LL280-9;OASIS_M0550_Ostomy;LA6328-4;1;Patient does not have an ostomy for bowel elimination.;;; +86471-0;LL280-9;OASIS_M0550_Ostomy;LA6343-3;2;Patient's ostomy was not related to an inpatient stay and did not necessitate change in medical or treatment regimen.;;; +86471-0;LL280-9;OASIS_M0550_Ostomy;LA6392-0;3;The ostomy was related to an inpatient stay or did necessitate change in medical or treatment regimen.;;; +46589-8;LL281-7;OASIS_M0560_Cognitive functioning;LA6153-6;1;Alert/oriented, able to focus and shift attention, comprehends and recalls task directions independently.;;; +46589-8;LL281-7;OASIS_M0560_Cognitive functioning;LA6362-3;2;Requires prompting (cueing, repetition, reminders) only under stressful or unfamiliar conditions.;;; +46589-8;LL281-7;OASIS_M0560_Cognitive functioning;LA6359-9;3;Requires assistance and some direction in specific situations (for example, all tasks involving shifting of attention) or consistently requires low stimulus environment due to distractibility.;;; +46589-8;LL281-7;OASIS_M0560_Cognitive functioning;LA12251-7;4;Requires considerable assistance in routine situations. Is not alert and oriented or is unable to shift attention and recall directions more than half the time.;;; +46589-8;LL281-7;OASIS_M0560_Cognitive functioning;LA6399-5;5;Totally dependent due to disturbances such as constant disorientation, coma, persistent vegetative state, or delirium.;;; +46590-6;LL282-5;OASIS_M0570_Confusion;LA6270-8;1;Never;;; +46590-6;LL282-5;OASIS_M0570_Confusion;LA6231-0;2;In new or complex situations only;;; +46590-6;LL282-5;OASIS_M0570_Confusion;LA6303-7;3;On awakening or at night only;;; +46590-6;LL282-5;OASIS_M0570_Confusion;LA6190-8;4;During the day and evening, but not constantly;;; +46590-6;LL282-5;OASIS_M0570_Confusion;LA6174-2;5;Constantly;;; +46590-6;LL282-5;OASIS_M0570_Confusion;LA6335-9;6;Patient nonresponsive;;; +58104-1;LL282-5;OASIS_M0570_Confusion;LA6270-8;1;Never;;; +58104-1;LL282-5;OASIS_M0570_Confusion;LA6231-0;2;In new or complex situations only;;; +58104-1;LL282-5;OASIS_M0570_Confusion;LA6303-7;3;On awakening or at night only;;; +58104-1;LL282-5;OASIS_M0570_Confusion;LA6190-8;4;During the day and evening, but not constantly;;; +58104-1;LL282-5;OASIS_M0570_Confusion;LA6174-2;5;Constantly;;; +58104-1;LL282-5;OASIS_M0570_Confusion;LA6335-9;6;Patient nonresponsive;;; +46591-4;LL283-3;OASIS_M0580_Anxiety;LA6297-1;1;None of the time;;; +46591-4;LL283-3;OASIS_M0580_Anxiety;LA6249-2;2;Less often than daily;;; +46591-4;LL283-3;OASIS_M0580_Anxiety;LA6177-5;3;Daily, but not constantly;;; +46591-4;LL283-3;OASIS_M0580_Anxiety;LA6154-4;4;All of the time;;; +46591-4;LL283-3;OASIS_M0580_Anxiety;LA6335-9;5;Patient nonresponsive;;; +86495-9;LL283-3;OASIS_M0580_Anxiety;LA6297-1;1;None of the time;;; +86495-9;LL283-3;OASIS_M0580_Anxiety;LA6249-2;2;Less often than daily;;; +86495-9;LL283-3;OASIS_M0580_Anxiety;LA6177-5;3;Daily, but not constantly;;; +86495-9;LL283-3;OASIS_M0580_Anxiety;LA6154-4;4;All of the time;;; +86495-9;LL283-3;OASIS_M0580_Anxiety;LA6335-9;5;Patient nonresponsive;;; +46592-2;LL286-6;OASIS_M0620_Behavior probs freq;LA6270-8;1;Never;;; +46592-2;LL286-6;OASIS_M0620_Behavior probs freq;LA6251-8;2;Less than once a month;;; +46592-2;LL286-6;OASIS_M0620_Behavior probs freq;LA6304-5;3;Once a month;;; +46592-2;LL286-6;OASIS_M0620_Behavior probs freq;LA6374-8;4;Several times each month;;; +46592-2;LL286-6;OASIS_M0620_Behavior probs freq;LA6371-4;5;Several times a week;;; +46592-2;LL286-6;OASIS_M0620_Behavior probs freq;LA6157-7;6;At least daily;;; +46594-8;LL288-2;OASIS_M0640_Prior grooming;LA6131-2;1;Able to groom self unaided, with or without the use of assistive devices or adapted methods.;;; +46594-8;LL288-2;OASIS_M0640_Prior grooming;LA6207-0;2;Grooming utensils must be placed within reach before able to complete grooming activities.;;; +46594-8;LL288-2;OASIS_M0640_Prior grooming;LA6379-7;3;Someone must assist the patient to groom self.;;; +46594-8;LL288-2;OASIS_M0640_Prior grooming;LA6326-8;4;Patient depends entirely upon someone else for grooming needs.;;; +46594-8;LL288-2;OASIS_M0640_Prior grooming;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46595-5;LL287-4;OASIS_M0640_Grooming;LA6131-2;1;Able to groom self unaided, with or without the use of assistive devices or adapted methods.;;; +46595-5;LL287-4;OASIS_M0640_Grooming;LA6207-0;2;Grooming utensils must be placed within reach before able to complete grooming activities.;;; +46595-5;LL287-4;OASIS_M0640_Grooming;LA6379-7;3;Someone must assist the patient to groom self.;;; +46595-5;LL287-4;OASIS_M0640_Grooming;LA6326-8;4;Patient depends entirely upon someone else for grooming needs.;;; +46596-3;LL290-8;OASIS_M0650_Prior dress upper body;LA6129-6;1;Able to get clothes out of closets and drawers, put them on and remove them from the upper body without assistance.;;; +46596-3;LL290-8;OASIS_M0650_Prior dress upper body;LA6127-0;2;Able to dress upper body without assistance if clothing is laid out or handed to the patient.;;; +46596-3;LL290-8;OASIS_M0650_Prior dress upper body;LA6381-3;3;Someone must help the patient put on upper body clothing.;;; +46596-3;LL290-8;OASIS_M0650_Prior dress upper body;LA6325-0;4;Patient depends entirely upon another person to dress the upper body.;;; +46596-3;LL290-8;OASIS_M0650_Prior dress upper body;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46597-1;LL289-0;OASIS_M0650_Dress upper body;LA6129-6;1;Able to get clothes out of closets and drawers, put them on and remove them from the upper body without assistance.;;; +46597-1;LL289-0;OASIS_M0650_Dress upper body;LA6127-0;2;Able to dress upper body without assistance if clothing is laid out or handed to the patient.;;; +46597-1;LL289-0;OASIS_M0650_Dress upper body;LA6381-3;3;Someone must help the patient put on upper body clothing.;;; +46597-1;LL289-0;OASIS_M0650_Dress upper body;LA6325-0;4;Patient depends entirely upon another person to dress the upper body.;;; +46598-9;LL292-4;OASIS_M0660_Prior dress lower body;LA6138-7;1;Able to obtain, put on, and remove clothing and shoes without assistance.;;; +46598-9;LL292-4;OASIS_M0660_Prior dress lower body;LA6126-2;2;Able to dress lower body without assistance if clothing and shoes are laid out or handed to the patient.;;; +46598-9;LL292-4;OASIS_M0660_Prior dress lower body;LA6380-5;3;Someone must help the patient put on undergarments, slacks, socks or nylons, and shoes.;;; +46598-9;LL292-4;OASIS_M0660_Prior dress lower body;LA6324-3;4;Patient depends entirely upon another person to dress lower body.;;; +46598-9;LL292-4;OASIS_M0660_Prior dress lower body;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46599-7;LL291-6;OASIS_M0660_Dress lower body;LA6138-7;1;Able to obtain, put on, and remove clothing and shoes without assistance.;;; +46599-7;LL291-6;OASIS_M0660_Dress lower body;LA6126-2;2;Able to dress lower body without assistance if clothing and shoes are laid out or handed to the patient.;;; +46599-7;LL291-6;OASIS_M0660_Dress lower body;LA6380-5;3;Someone must help the patient put on undergarments, slacks, socks or nylons, and shoes.;;; +46599-7;LL291-6;OASIS_M0660_Dress lower body;LA6324-3;4;Patient depends entirely upon another person to dress lower body.;;; +46600-3;LL294-0;OASIS_M0670_Prior bathing;LA6123-9;1;Able to bathe self in SHOWER OR TUB independently.;;; +46600-3;LL294-0;OASIS_M0670_Prior bathing;LA6451-4;2;With the use of devices, is able to bathe self in shower or tub independently.;;; +46600-3;LL294-0;OASIS_M0670_Prior bathing;LA6151-0;3;Aid: a) for intermittent supervision/encouragement/reminders, OR b) to get in/out of shower/tub, OR c) for washing difficult to reach areas.;;; +46600-3;LL294-0;OASIS_M0670_Prior bathing;LA6323-5;4;Participates in bathing self in shower or tub, BUT requires presence of another person throughout the bath for assistance or supervision.;;; +46600-3;LL294-0;OASIS_M0670_Prior bathing;LA6428-2;5;UNABLE to use the shower or tub and is bathed in BED OR BEDSIDE CHAIR.;;; +46600-3;LL294-0;OASIS_M0670_Prior bathing;LA6413-4;6;Unable to effectively participate in bathing and is totally bathed by another person.;;; +46600-3;LL294-0;OASIS_M0670_Prior bathing;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46601-1;LL293-2;OASIS_M0670_Bathing;LA6123-9;1;Able to bathe self in SHOWER OR TUB independently.;;; +46601-1;LL293-2;OASIS_M0670_Bathing;LA6451-4;2;With the use of devices, is able to bathe self in shower or tub independently.;;; +46601-1;LL293-2;OASIS_M0670_Bathing;LA6151-0;3;Aid: a) for intermittent supervision/encouragement/reminders, OR b) to get in/out of shower/tub, OR c) for washing difficult to reach areas.;;; +46601-1;LL293-2;OASIS_M0670_Bathing;LA6323-5;4;Participates in bathing self in shower or tub, BUT requires presence of another person throughout the bath for assistance or supervision.;;; +46601-1;LL293-2;OASIS_M0670_Bathing;LA6428-2;5;UNABLE to use the shower or tub and is bathed in BED OR BEDSIDE CHAIR.;;; +46601-1;LL293-2;OASIS_M0670_Bathing;LA6413-4;6;Unable to effectively participate in bathing and is totally bathed by another person.;;; +46602-9;LL296-5;OASIS_M0680_Prior toileting;LA6130-4;1;Able to get to and from the toilet independently with or without a device.;;; +46602-9;LL296-5;OASIS_M0680_Prior toileting;LA6442-3;2;When reminded, assisted, or supervised by another person, able to get to and from the toilet.;;; +46602-9;LL296-5;OASIS_M0680_Prior toileting;LA6415-9;3;Unable to get to and from the toilet but is able to use a bedside commode (with or without assistance).;;; +46602-9;LL296-5;OASIS_M0680_Prior toileting;LA6416-7;4;Unable to get to and from the toilet or bedside commode but is able to use a bedpan/urinal independently.;;; +46602-9;LL296-5;OASIS_M0680_Prior toileting;LA6245-0;5;Is totally dependent in toileting.;;; +46602-9;LL296-5;OASIS_M0680_Prior toileting;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46603-7;LL295-7;OASIS_M0680_Toileting;LA6130-4;1;Able to get to and from the toilet independently with or without a device.;;; +46603-7;LL295-7;OASIS_M0680_Toileting;LA6442-3;2;When reminded, assisted, or supervised by another person, able to get to and from the toilet.;;; +46603-7;LL295-7;OASIS_M0680_Toileting;LA6415-9;3;Unable to get to and from the toilet but is able to use a bedside commode (with or without assistance).;;; +46603-7;LL295-7;OASIS_M0680_Toileting;LA6416-7;4;Unable to get to and from the toilet or bedside commode but is able to use a bedpan/urinal independently.;;; +46603-7;LL295-7;OASIS_M0680_Toileting;LA6245-0;5;Is totally dependent in toileting.;;; +46604-5;LL298-1;OASIS_M0690_Prior transferring;LA6136-1;1;Able to independently transfer.;;; +46604-5;LL298-1;OASIS_M0690_Prior transferring;LA6403-5;2;Transfers with minimal human assistance or with use of an assistive device.;;; +46604-5;LL298-1;OASIS_M0690_Prior transferring;LA6427-4;3;UNABLE to transfer self but is able to bear weight and pivot during the transfer process.;;; +46604-5;LL298-1;OASIS_M0690_Prior transferring;LA6426-6;4;Unable to transfer self and is unable to bear weight or pivot when transferred by another person.;;; +46604-5;LL298-1;OASIS_M0690_Prior transferring;LA6161-9;5;Bedfast, unable to transfer but is able to turn and position self in bed.;;; +46604-5;LL298-1;OASIS_M0690_Prior transferring;LA6160-1;6;Bedfast, unable to transfer and is unable to turn and position self.;;; +46604-5;LL298-1;OASIS_M0690_Prior transferring;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +46605-2;LL297-3;OASIS_M0690_Transferring;LA6136-1;1;Able to independently transfer.;;; +46605-2;LL297-3;OASIS_M0690_Transferring;LA6403-5;2;Transfers with minimal human assistance or with use of an assistive device.;;; +46605-2;LL297-3;OASIS_M0690_Transferring;LA6427-4;3;UNABLE to transfer self but is able to bear weight and pivot during the transfer process.;;; +46605-2;LL297-3;OASIS_M0690_Transferring;LA6426-6;4;Unable to transfer self and is unable to bear weight or pivot when transferred by another person.;;; +46605-2;LL297-3;OASIS_M0690_Transferring;LA6161-9;5;Bedfast, unable to transfer but is able to turn and position self in bed.;;; +46605-2;LL297-3;OASIS_M0690_Transferring;LA6160-1;6;Bedfast, unable to transfer and is unable to turn and position self.;;; +46613-6;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46613-6;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46613-6;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46613-6;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46613-6;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46614-4;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46614-4;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46614-4;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46614-4;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46614-4;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46615-1;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46615-1;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46615-1;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46615-1;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46615-1;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46616-9;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46616-9;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46616-9;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46616-9;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46616-9;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46617-7;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46617-7;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46617-7;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46617-7;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46617-7;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46618-5;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46618-5;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46618-5;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46618-5;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46618-5;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46619-3;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46619-3;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46619-3;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46619-3;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46619-3;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46620-1;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46620-1;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46620-1;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46620-1;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46620-1;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46621-9;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46621-9;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46621-9;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46621-9;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46621-9;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46622-7;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46622-7;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46622-7;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46622-7;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46622-7;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46623-5;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46623-5;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46623-5;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46623-5;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46623-5;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46624-3;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46624-3;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46624-3;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46624-3;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46624-3;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46625-0;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46625-0;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46625-0;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46625-0;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46625-0;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46626-8;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46626-8;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46626-8;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46626-8;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46626-8;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46627-6;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46627-6;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46627-6;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46627-6;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46627-6;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46628-4;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46628-4;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46628-4;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46628-4;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46628-4;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46629-2;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46629-2;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46629-2;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46629-2;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46629-2;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46630-0;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46630-0;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46630-0;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46630-0;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46630-0;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46631-8;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46631-8;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46631-8;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46631-8;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46631-8;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46632-6;LL332-8;RFC_Mental summary;LA6459-7;1;Not significantly limited;;; +46632-6;LL332-8;RFC_Mental summary;LA6460-5;2;Moderately limited;;; +46632-6;LL332-8;RFC_Mental summary;LA6461-3;3;Markedly limited;;; +46632-6;LL332-8;RFC_Mental summary;LA6462-1;4;No evidence of limitation in this category;;; +46632-6;LL332-8;RFC_Mental summary;LA6463-9;5;Not ratable on available evidence;;; +46645-8;LL333-6;RFC A-1_Physical exertion;LA6464-7;1;less than 10 pounds;;; +46645-8;LL333-6;RFC A-1_Physical exertion;LA6469-6;2;10 pounds;;; +46645-8;LL333-6;RFC A-1_Physical exertion;LA6465-4;3;20 pounds;;; +46645-8;LL333-6;RFC A-1_Physical exertion;LA6466-2;4;50 pounds;;; +46645-8;LL333-6;RFC A-1_Physical exertion;LA6467-0;5;100 pounds or more;;; +46646-6;LL334-4;RFC A-2_Physical exertion limitations;LA6464-7;1;less than 10 pounds;;; +46646-6;LL334-4;RFC A-2_Physical exertion limitations;LA6469-6;2;10 pounds;;; +46646-6;LL334-4;RFC A-2_Physical exertion limitations;LA6470-4;3;25 pounds;;; +46646-6;LL334-4;RFC A-2_Physical exertion limitations;LA6471-2;4;50 pounds or more;;; +46647-4;LL335-1;RFC A-3_Physical exertion limitations;LA6472-0;1;Less than 2 hours in an 8-hour workday;;; +46647-4;LL335-1;RFC A-3_Physical exertion limitations;LA6474-6;2;at least 2 hours in an 8-hour workday;;; +46647-4;LL335-1;RFC A-3_Physical exertion limitations;LA6475-3;3;about 6 hours in an 8-hour workday;;; +46647-4;LL335-1;RFC A-3_Physical exertion limitations;LA6476-1;4;medically required hand-held assistive device is necessary for ambulation;;; +46648-2;LL336-9;RFC A-4_Physical exertion freq;LA6477-9;1;Less than about 6 hours in an 8-hour workday;;; +46648-2;LL336-9;RFC A-4_Physical exertion freq;LA6475-3;2;about 6 hours in an 8-hour workday;;; +46648-2;LL336-9;RFC A-4_Physical exertion freq;LA6479-5;3;must periodically alternate sitting and standing to relieve pain or discomfort. (If checked, explain in 6.);;; +46649-0;LL337-7;RFC A-5_Physical exertion limitations;LA6478-7;1;Unlimited, other than as shown for lift and/or carry;;; +46649-0;LL337-7;RFC A-5_Physical exertion limitations;LA6480-3;2;limited in upper extremities (describe nature and degree);;; +46649-0;LL337-7;RFC A-5_Physical exertion limitations;LA6481-1;3;limited in lower extremities (describe nature and degree);;; +46653-2;LL338-5;RFC B_Postural limitations;LA6482-9;1;Frequently;;; +46653-2;LL338-5;RFC B_Postural limitations;LA6483-7;2;Occasionally;;; +46653-2;LL338-5;RFC B_Postural limitations;LA6270-8;3;Never;;; +46654-0;LL338-5;RFC B_Postural limitations;LA6482-9;1;Frequently;;; +46654-0;LL338-5;RFC B_Postural limitations;LA6483-7;2;Occasionally;;; +46654-0;LL338-5;RFC B_Postural limitations;LA6270-8;3;Never;;; +46655-7;LL338-5;RFC B_Postural limitations;LA6482-9;1;Frequently;;; +46655-7;LL338-5;RFC B_Postural limitations;LA6483-7;2;Occasionally;;; +46655-7;LL338-5;RFC B_Postural limitations;LA6270-8;3;Never;;; +46656-5;LL338-5;RFC B_Postural limitations;LA6482-9;1;Frequently;;; +46656-5;LL338-5;RFC B_Postural limitations;LA6483-7;2;Occasionally;;; +46656-5;LL338-5;RFC B_Postural limitations;LA6270-8;3;Never;;; +46657-3;LL338-5;RFC B_Postural limitations;LA6482-9;1;Frequently;;; +46657-3;LL338-5;RFC B_Postural limitations;LA6483-7;2;Occasionally;;; +46657-3;LL338-5;RFC B_Postural limitations;LA6270-8;3;Never;;; +46658-1;LL338-5;RFC B_Postural limitations;LA6482-9;1;Frequently;;; +46658-1;LL338-5;RFC B_Postural limitations;LA6483-7;2;Occasionally;;; +46658-1;LL338-5;RFC B_Postural limitations;LA6270-8;3;Never;;; +46662-3;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46662-3;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46663-1;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46663-1;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46664-9;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46664-9;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46665-6;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46665-6;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46669-8;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46669-8;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46670-6;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46670-6;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46671-4;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46671-4;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46672-2;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46672-2;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46673-0;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46673-0;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46674-8;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46674-8;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46678-9;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46678-9;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46679-7;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6484-5;1;Limited;;; +46679-7;LL339-3;RFC CDE_Manip-Visual-Commun limitations;LA6485-2;2;Unlimited;;; +46682-1;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46682-1;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46682-1;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46682-1;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46683-9;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46683-9;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46683-9;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46683-9;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46684-7;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46684-7;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46684-7;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46684-7;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46685-4;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46685-4;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46685-4;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46685-4;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46686-2;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46686-2;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46686-2;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46686-2;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46687-0;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46687-0;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46687-0;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46687-0;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46688-8;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46688-8;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46688-8;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46688-8;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46689-6;LL340-1;RFC F_Environ limitations;LA6485-2;1;Unlimited;;; +46689-6;LL340-1;RFC F_Environ limitations;LA6486-0;2;Avoid concentrated exposure;;; +46689-6;LL340-1;RFC F_Environ limitations;LA6487-8;3;Avoid even moderate exposure;;; +46689-6;LL340-1;RFC F_Environ limitations;LA6488-6;4;Avoid all exposure;;; +46693-8;LL342-7;RFC IIIA_Treating statement;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +46693-8;LL342-7;RFC IIIA_Treating statement;LA6489-4;2;No (Includes situations in which there was no source or when the source(s) did not provide a statement regarding the claimant's physical capacities.);;; +46706-8;LL2242-7;C perf toxin genes;LA19151-2;1;Alpha toxin DNA detected;;; +46706-8;LL2242-7;C perf toxin genes;LA19152-0;2;Epsilon toxin DNA detected;;; +46724-1;LL5510-4;CYP2C9 allele genotype;LA30670-6;9;CYP2C9 *1/*2;;; +46724-1;LL5510-4;CYP2C9 allele genotype;LA30671-4;10;CYP2C9 *1/*6;;; +46724-1;LL5510-4;CYP2C9 allele genotype;LA30672-2;11;CYP2C9 *6/*11;;; +46731-6;LL5568-2;RHCE gene allele Cc genotypes;LA30900-7;4;RHCE*2/*4 (C/c);;; +46731-6;LL5568-2;RHCE gene allele Cc genotypes;LA30901-5;5;RHCE*2/*2 (C/C);;; +46731-6;LL5568-2;RHCE gene allele Cc genotypes;LA30902-3;6;RHCE*4/*4 (c/c);;; +94752-3;LL5568-2;RHCE gene allele Cc genotypes;LA30900-7;4;RHCE*2/*4 (C/c);;; +94752-3;LL5568-2;RHCE gene allele Cc genotypes;LA30901-5;5;RHCE*2/*2 (C/C);;; +94752-3;LL5568-2;RHCE gene allele Cc genotypes;LA30902-3;6;RHCE*4/*4 (c/c);;; +46732-4;LL2243-5;F tularensis subtype;LA19153-8;1;Francisella tularensis subspecies tularensis;;; +46732-4;LL2243-5;F tularensis subtype;LA19154-6;2;Francisella tularensis subspecies holartica;;; +46732-4;LL2243-5;F tularensis subtype;LA19155-3;3;Francisella tularensis subspecies novicida;;; +46732-4;LL2243-5;F tularensis subtype;LA19156-1;4;Francisella tularensis subspecies novicida-like;;; +46732-4;LL2243-5;F tularensis subtype;LA19157-9;5;Francisella tularensis subspecies mediasiatica;;; +46732-4;LL2243-5;F tularensis subtype;LA19158-7;6;Francisella tularensis subspecies japonica;;; +46733-2;LL840-0;NBS interp;LA18592-8;1;In range;;; +46733-2;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46733-2;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46733-2;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46733-2;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46733-2;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46733-2;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46733-2;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46733-2;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46733-2;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46736-5;LL840-0;NBS interp;LA18592-8;1;In range;;; +46736-5;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46736-5;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46736-5;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46736-5;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46736-5;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46736-5;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46736-5;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46736-5;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46736-5;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46737-3;LL840-0;NBS interp;LA18592-8;1;In range;;; +46737-3;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46737-3;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46737-3;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46737-3;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46737-3;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46737-3;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46737-3;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46737-3;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46737-3;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46740-7;LL840-0;NBS interp;LA18592-8;1;In range;;; +46740-7;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46740-7;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46740-7;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46740-7;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46740-7;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46740-7;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46740-7;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46740-7;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46740-7;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46743-1;LL840-0;NBS interp;LA18592-8;1;In range;;; +46743-1;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46743-1;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46743-1;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46743-1;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46743-1;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46743-1;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46743-1;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46743-1;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46743-1;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46744-9;LL840-0;NBS interp;LA18592-8;1;In range;;; +46744-9;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46744-9;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46744-9;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46744-9;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46744-9;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46744-9;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46744-9;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46744-9;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46744-9;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46746-4;LL840-0;NBS interp;LA18592-8;1;In range;;; +46746-4;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46746-4;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46746-4;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46746-4;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46746-4;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46746-4;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46746-4;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46746-4;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46746-4;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46758-9;LL840-0;NBS interp;LA18592-8;1;In range;;; +46758-9;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46758-9;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46758-9;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46758-9;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46758-9;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46758-9;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46758-9;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46758-9;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46758-9;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46761-3;LL840-0;NBS interp;LA18592-8;1;In range;;; +46761-3;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46761-3;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46761-3;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46761-3;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46761-3;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46761-3;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46761-3;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46761-3;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46761-3;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46762-1;LL840-0;NBS interp;LA18592-8;1;In range;;; +46762-1;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46762-1;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46762-1;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46762-1;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46762-1;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46762-1;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46762-1;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46762-1;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46762-1;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46769-6;LL840-0;NBS interp;LA18592-8;1;In range;;; +46769-6;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +46769-6;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +46769-6;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +46769-6;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +46769-6;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +46769-6;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +46769-6;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +46769-6;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +46769-6;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +58088-6;LL840-0;NBS interp;LA18592-8;1;In range;;; +58088-6;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +58088-6;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +58088-6;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +58088-6;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +58088-6;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +58088-6;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +58088-6;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +58088-6;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +58088-6;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +58089-4;LL840-0;NBS interp;LA18592-8;1;In range;;; +58089-4;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +58089-4;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +58089-4;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +58089-4;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +58089-4;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +58089-4;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +58089-4;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +58089-4;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +58089-4;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +62301-7;LL840-0;NBS interp;LA18592-8;1;In range;;; +62301-7;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +62301-7;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +62301-7;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +62301-7;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +62301-7;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +62301-7;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +62301-7;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +62301-7;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +62301-7;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +62305-8;LL840-0;NBS interp;LA18592-8;1;In range;;; +62305-8;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +62305-8;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +62305-8;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +62305-8;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +62305-8;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +62305-8;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +62305-8;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +62305-8;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +62305-8;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +62308-2;LL840-0;NBS interp;LA18592-8;1;In range;;; +62308-2;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +62308-2;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +62308-2;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +62308-2;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +62308-2;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +62308-2;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +62308-2;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +62308-2;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +62308-2;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +62312-4;LL840-0;NBS interp;LA18592-8;1;In range;;; +62312-4;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +62312-4;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +62312-4;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +62312-4;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +62312-4;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +62312-4;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +62312-4;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +62312-4;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +62312-4;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +62318-1;LL840-0;NBS interp;LA18592-8;1;In range;;; +62318-1;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +62318-1;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +62318-1;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +62318-1;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +62318-1;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +62318-1;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +62318-1;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +62318-1;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +62318-1;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +62321-5;LL840-0;NBS interp;LA18592-8;1;In range;;; +62321-5;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +62321-5;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +62321-5;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +62321-5;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +62321-5;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +62321-5;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +62321-5;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +62321-5;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +62321-5;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +63415-4;LL840-0;NBS interp;LA18592-8;1;In range;;; +63415-4;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +63415-4;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +63415-4;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +63415-4;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +63415-4;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +63415-4;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +63415-4;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +63415-4;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +63415-4;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +73701-5;LL840-0;NBS interp;LA18592-8;1;In range;;; +73701-5;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +73701-5;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +73701-5;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +73701-5;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +73701-5;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +73701-5;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +73701-5;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +73701-5;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +73701-5;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +79564-1;LL840-0;NBS interp;LA18592-8;1;In range;;; +79564-1;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +79564-1;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +79564-1;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +79564-1;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +79564-1;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +79564-1;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +79564-1;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +79564-1;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +79564-1;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +85269-9;LL840-0;NBS interp;LA18592-8;1;In range;;; +85269-9;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +85269-9;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +85269-9;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +85269-9;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +85269-9;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +85269-9;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +85269-9;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +85269-9;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +85269-9;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +92004-1;LL840-0;NBS interp;LA18592-8;1;In range;;; +92004-1;LL840-0;NBS interp;LA4259-3;2;Borderline;;; +92004-1;LL840-0;NBS interp;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +92004-1;LL840-0;NBS interp;LA18593-6;4;Out of range;;; +92004-1;LL840-0;NBS interp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +92004-1;LL840-0;NBS interp;LA25817-0;6;Out of range requiring immediate referral;;; +92004-1;LL840-0;NBS interp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +92004-1;LL840-0;NBS interp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +92004-1;LL840-0;NBS interp;LA16204-2;9;One or more tests pending;;; +92004-1;LL840-0;NBS interp;LA16205-9;10;Specimen unsatisfactory for at least one condition;;; +46770-4;LL834-3;NBS hearing interp;LA12448-9;1;Pass both ears;164059009;On examination - hearing normal (finding);http://snomed.info/sct +46770-4;LL834-3;NBS hearing interp;LA12449-7;2;Pass R –refer L;;; +46770-4;LL834-3;NBS hearing interp;LA12450-5;3;Pass L- refer R;;; +46770-4;LL834-3;NBS hearing interp;LA12451-3;4;Refer L and R;;; +47212-6;LL2240-1;C trach sv;LA19147-0;1;Serovar D;;; +47212-6;LL2240-1;C trach sv;LA19148-8;2;Serovar E;;; +47212-6;LL2240-1;C trach sv;LA19149-6;3;Serovar F;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6668-3;1;Pathogenic;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6669-1;2;Presumed Pathogenic;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6670-9;3;Novel Presumed Pathogenic;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6671-7;4;Novel Unknown Significance;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6672-5;5;Novel Presumed Benign;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6673-3;6;Novel;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6674-1;7;Presumed Benign;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6675-8;8;Benign;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6676-6;9;Resistant;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6677-4;10;Responsive;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6678-2;11;Novel Presumed Non-Responsive;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6679-0;12;Novel Presumed Responsive;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6680-8;13;Unclassified;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6681-6;14;Polymorphism;;; +47997-2;LL377-3;MG_1_Genetic variant;LA6682-4;15;Unknown Significance;;; +48000-4;LL2938-0;List of human chromosomes;LA21254-0;1;Chromosome 1;;; +48000-4;LL2938-0;List of human chromosomes;LA21255-7;2;Chromosome 2;;; +48000-4;LL2938-0;List of human chromosomes;LA21256-5;3;Chromosome 3;;; +48000-4;LL2938-0;List of human chromosomes;LA21257-3;4;Chromosome 4;;; +48000-4;LL2938-0;List of human chromosomes;LA21258-1;5;Chromosome 5;;; +48000-4;LL2938-0;List of human chromosomes;LA21259-9;6;Chromosome 6;;; +48000-4;LL2938-0;List of human chromosomes;LA21260-7;7;Chromosome 7;;; +48000-4;LL2938-0;List of human chromosomes;LA21261-5;8;Chromosome 8;;; +48000-4;LL2938-0;List of human chromosomes;LA21262-3;9;Chromosome 9;;; +48000-4;LL2938-0;List of human chromosomes;LA21263-1;10;Chromosome 10;;; +48000-4;LL2938-0;List of human chromosomes;LA21264-9;11;Chromosome 11;;; +48000-4;LL2938-0;List of human chromosomes;LA21265-6;12;Chromosome 12;;; +48000-4;LL2938-0;List of human chromosomes;LA21266-4;13;Chromosome 13;;; +48000-4;LL2938-0;List of human chromosomes;LA21267-2;14;Chromosome 14;;; +48000-4;LL2938-0;List of human chromosomes;LA21268-0;15;Chromosome 15;;; +48000-4;LL2938-0;List of human chromosomes;LA21269-8;16;Chromosome 16;;; +48000-4;LL2938-0;List of human chromosomes;LA21270-6;17;Chromosome 17;;; +48000-4;LL2938-0;List of human chromosomes;LA21271-4;18;Chromosome 18;;; +48000-4;LL2938-0;List of human chromosomes;LA21272-2;19;Chromosome 19;;; +48000-4;LL2938-0;List of human chromosomes;LA21273-0;20;Chromosome 20;;; +48000-4;LL2938-0;List of human chromosomes;LA21274-8;21;Chromosome 21;;; +48000-4;LL2938-0;List of human chromosomes;LA21275-5;22;Chromosome 22;;; +48000-4;LL2938-0;List of human chromosomes;LA21276-3;23;Chromosome X;;; +48000-4;LL2938-0;List of human chromosomes;LA21277-1;24;Chromosome Y;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA6683-2;1;Germline;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA6684-0;2;Somatic;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA10429-1;3;Fetal;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA18194-3;4;Likely germline;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA18195-0;5;Likely somatic;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA18196-8;6;Likely fetal;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA18197-6;7;Unknown genomic origin;;; +48002-0;LL378-1;MG_2_Genetic variant source;LA26807-0;8;De novo;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA9658-1;1;Wild type;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6692-3;2;Deletion;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6686-5;3;Duplication;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6694-9;4;Frameshift;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6695-6;5;Initiating Methionine;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6687-3;6;Insertion;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA9659-9;7;Insertion and Deletion;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6698-0;8;Missense;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6699-8;9;Nonsense;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6700-4;10;Silent;;; +48006-1;LL380-7;MG_4_Amino acid change type;LA6701-2;11;Stop Codon Mutation;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA9658-1;1;Wild type;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6692-3;2;Deletion;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6686-5;3;Duplication;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6694-9;4;Frameshift;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6695-6;5;Initiating Methionine;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6687-3;6;Insertion;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA9659-9;7;Insertion and Deletion;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6698-0;8;Missense;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6699-8;9;Nonsense;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6700-4;10;Silent;;; +92247-6;LL380-7;MG_4_Amino acid change type;LA6701-2;11;Stop Codon Mutation;;; +48007-9;LL381-5;MG_5_Genetic variant allelic state;LA6703-8;1;Heteroplasmic;;; +48007-9;LL381-5;MG_5_Genetic variant allelic state;LA6704-6;2;Homoplasmic;;; +48007-9;LL381-5;MG_5_Genetic variant allelic state;LA6705-3;3;Homozygous;;; +48007-9;LL381-5;MG_5_Genetic variant allelic state;LA6706-1;4;Heterozygous;;; +48007-9;LL381-5;MG_5_Genetic variant allelic state;LA6707-9;5;Hemizygous;;; +53034-5;LL381-5;MG_5_Genetic variant allelic state;LA6703-8;1;Heteroplasmic;;; +53034-5;LL381-5;MG_5_Genetic variant allelic state;LA6704-6;2;Homoplasmic;;; +53034-5;LL381-5;MG_5_Genetic variant allelic state;LA6705-3;3;Homozygous;;; +53034-5;LL381-5;MG_5_Genetic variant allelic state;LA6706-1;4;Heterozygous;;; +53034-5;LL381-5;MG_5_Genetic variant allelic state;LA6707-9;5;Hemizygous;;; +48019-4;LL379-9;MG_3_DNA change type;LA9658-1;1;Wild type;;; +48019-4;LL379-9;MG_3_DNA change type;LA6692-3;2;Deletion;;; +48019-4;LL379-9;MG_3_DNA change type;LA6686-5;3;Duplication;;; +48019-4;LL379-9;MG_3_DNA change type;LA6687-3;4;Insertion;;; +48019-4;LL379-9;MG_3_DNA change type;LA6688-1;5;Insertion/Deletion;;; +48019-4;LL379-9;MG_3_DNA change type;LA6689-9;6;Inversion;;; +48019-4;LL379-9;MG_3_DNA change type;LA6690-7;7;Substitution;;; +92244-3;LL379-9;MG_3_DNA change type;LA9658-1;1;Wild type;;; +92244-3;LL379-9;MG_3_DNA change type;LA6692-3;2;Deletion;;; +92244-3;LL379-9;MG_3_DNA change type;LA6686-5;3;Duplication;;; +92244-3;LL379-9;MG_3_DNA change type;LA6687-3;4;Insertion;;; +92244-3;LL379-9;MG_3_DNA change type;LA6688-1;5;Insertion/Deletion;;; +92244-3;LL379-9;MG_3_DNA change type;LA6689-9;6;Inversion;;; +92244-3;LL379-9;MG_3_DNA change type;LA6690-7;7;Substitution;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA9658-1;1;Wild type;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA6692-3;2;Deletion;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA6686-5;3;Duplication;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA6687-3;4;Insertion;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA6688-1;5;Insertion/Deletion;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA6689-9;6;Inversion;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA6690-7;7;Substitution;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA14033-7;8;Copy number gain;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA14034-5;9;Copy number loss;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26324-6;10;Mobile element insertion;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26325-3;11;Novel sequence insertion;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26326-1;12;Tandem duplication;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26327-9;13;Intrachromosomal breakpoint;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26328-7;14;Interchromosomal breakpoint;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26331-1;15;Translocation;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26330-3;16;Complex;;; +48019-4;LL4033-8;Simple and Chromosome struct variant types;LA26329-5;17;Sequence alteration;;; +48020-2;LL2236-9;Example primer sequence;LA19110-8;1;tagttagtgtgaaagaagc;;; +48020-2;LL2236-9;Example primer sequence;LA19111-6;2;cctcattagtcgtt;;; +48021-0;LL2236-9;Example primer sequence;LA19110-8;1;tagttagtgtgaaagaagc;;; +48021-0;LL2236-9;Example primer sequence;LA19111-6;2;cctcattagtcgtt;;; +48030-1;LL5569-0;RHCE allele Ee genotypes;LA30903-1;7;RHCE*3/*5 (E/e);;; +48030-1;LL5569-0;RHCE allele Ee genotypes;LA30904-9;8;RHCE*3/*3 (E/E);;; +48030-1;LL5569-0;RHCE allele Ee genotypes;LA30905-6;9;RHCE*5/*5 (e/e);;; +94751-5;LL5569-0;RHCE allele Ee genotypes;LA30903-1;7;RHCE*3/*5 (E/e);;; +94751-5;LL5569-0;RHCE allele Ee genotypes;LA30904-9;8;RHCE*3/*3 (E/E);;; +94751-5;LL5569-0;RHCE allele Ee genotypes;LA30905-6;9;RHCE*5/*5 (e/e);;; +48327-1;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48327-1;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +48328-9;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48328-9;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +48329-7;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +48329-7;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +64137-3;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +64137-3;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +66127-2;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66127-2;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +66129-8;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66129-8;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +66130-6;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66130-6;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +66131-4;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +66131-4;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +73565-4;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73565-4;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +75680-9;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75680-9;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +79138-4;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79138-4;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +79145-9;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79145-9;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +79147-5;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +79147-5;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91028-1;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91028-1;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91029-9;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91029-9;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91030-7;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91030-7;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91031-5;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91031-5;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91032-3;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91032-3;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91033-1;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91033-1;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91034-9;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91034-9;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91035-6;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91035-6;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91036-4;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91036-4;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91037-2;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91037-2;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91038-0;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91038-0;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91039-8;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91039-8;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91040-6;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91040-6;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91041-4;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91041-4;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91042-2;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91042-2;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91043-0;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91043-0;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91044-8;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91044-8;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91045-5;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91045-5;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91046-3;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91046-3;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91047-1;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91047-1;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91048-9;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91048-9;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91049-7;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91049-7;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91050-5;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91050-5;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91051-3;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91051-3;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91052-1;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91052-1;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +91053-9;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91053-9;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +96427-0;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96427-0;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +96428-8;LL2355-7;Pos|None detected;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96428-8;LL2355-7;Pos|None detected;LA19544-8;2;None detected;;; +48509-4;LL958-0;FLUAV+FLUBV;LA13549-3;1;Not detected/negative;;; +48509-4;LL958-0;FLUAV+FLUBV;LA11919-0;2;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +48509-4;LL958-0;FLUAV+FLUBV;LA13543-6;3;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +48509-4;LL958-0;FLUAV+FLUBV;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +48509-4;LL958-0;FLUAV+FLUBV;LA13544-4;5;Influenza A virus not detected, Influenza B virus inconclusive;;; +48509-4;LL958-0;FLUAV+FLUBV;LA13545-1;6;Influenza B virus not detected, Influenza A virus inconclusive;;; +48509-4;LL958-0;FLUAV+FLUBV;LA13548-5;7;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +48509-4;LL958-0;FLUAV+FLUBV;LA13546-9;8;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +49537-4;LL958-0;FLUAV+FLUBV;LA13549-3;1;Not detected/negative;;; +49537-4;LL958-0;FLUAV+FLUBV;LA11919-0;2;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +49537-4;LL958-0;FLUAV+FLUBV;LA13543-6;3;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +49537-4;LL958-0;FLUAV+FLUBV;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +49537-4;LL958-0;FLUAV+FLUBV;LA13544-4;5;Influenza A virus not detected, Influenza B virus inconclusive;;; +49537-4;LL958-0;FLUAV+FLUBV;LA13545-1;6;Influenza B virus not detected, Influenza A virus inconclusive;;; +49537-4;LL958-0;FLUAV+FLUBV;LA13548-5;7;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +49537-4;LL958-0;FLUAV+FLUBV;LA13546-9;8;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +61102-0;LL958-0;FLUAV+FLUBV;LA13549-3;1;Not detected/negative;;; +61102-0;LL958-0;FLUAV+FLUBV;LA11919-0;2;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +61102-0;LL958-0;FLUAV+FLUBV;LA13543-6;3;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +61102-0;LL958-0;FLUAV+FLUBV;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +61102-0;LL958-0;FLUAV+FLUBV;LA13544-4;5;Influenza A virus not detected, Influenza B virus inconclusive;;; +61102-0;LL958-0;FLUAV+FLUBV;LA13545-1;6;Influenza B virus not detected, Influenza A virus inconclusive;;; +61102-0;LL958-0;FLUAV+FLUBV;LA13548-5;7;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +61102-0;LL958-0;FLUAV+FLUBV;LA13546-9;8;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +48512-8;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48512-8;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48516-9;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48516-9;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48518-5;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48518-5;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48520-1;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48520-1;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48526-8;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48526-8;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48530-0;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48530-0;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48532-6;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48532-6;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48538-3;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48538-3;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48540-9;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48540-9;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48541-7;LL518-2;GDS_1;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48541-7;LL518-2;GDS_1;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48513-6;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48513-6;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48514-4;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48514-4;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48515-1;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48515-1;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48517-7;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48517-7;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48519-3;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48519-3;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48521-9;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48521-9;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48522-7;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48522-7;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48523-5;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48523-5;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48524-3;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48524-3;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48525-0;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48525-0;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48527-6;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48527-6;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48528-4;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48528-4;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48529-2;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48529-2;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48531-8;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48531-8;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48533-4;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48533-4;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48534-2;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48534-2;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48535-9;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48535-9;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48536-7;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48536-7;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48537-5;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48537-5;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48539-1;LL519-0;GDS_2;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48539-1;LL519-0;GDS_2;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48527-6;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +48527-6;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65390-7;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65390-7;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97876-7;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97876-7;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97876-7;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97876-7;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97877-5;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97877-5;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97877-5;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97877-5;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97878-3;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97878-3;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97878-3;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97878-3;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97879-1;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97879-1;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97879-1;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97879-1;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97880-9;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97880-9;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97880-9;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97880-9;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97881-7;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97881-7;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97881-7;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97881-7;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97882-5;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97882-5;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97882-5;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97882-5;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97883-3;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97883-3;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97883-3;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97883-3;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97884-1;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97884-1;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97884-1;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97884-1;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98862-6;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98862-6;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98866-7;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98866-7;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98867-5;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98867-5;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98869-1;LL5955-1;Yes 1/ No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98869-1;LL5955-1;Yes 1/ No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +48560-7;LL2268-2;HPV genotype;LA10138-8;1;6;;; +48560-7;LL2268-2;HPV genotype;LA14557-5;2;11;;; +48560-7;LL2268-2;HPV genotype;LA19218-9;3;6+11;;; +48560-7;LL2268-2;HPV genotype;LA19216-3;4;6+11+42+43+44;;; +48560-7;LL2268-2;HPV genotype;LA19215-5;5;16+18+31+33+35+39+45+51+52+56+58+59+68;;; +48560-7;LL2268-2;HPV genotype;LA19217-1;6;16+18+31+33+35+45+51+52+56;;; +91073-7;LL2268-2;HPV genotype;LA10138-8;1;6;;; +91073-7;LL2268-2;HPV genotype;LA14557-5;2;11;;; +91073-7;LL2268-2;HPV genotype;LA19218-9;3;6+11;;; +91073-7;LL2268-2;HPV genotype;LA19216-3;4;6+11+42+43+44;;; +91073-7;LL2268-2;HPV genotype;LA19215-5;5;16+18+31+33+35+39+45+51+52+56+58+59+68;;; +91073-7;LL2268-2;HPV genotype;LA19217-1;6;16+18+31+33+35+45+51+52+56;;; +91851-6;LL2268-2;HPV genotype;LA10138-8;1;6;;; +91851-6;LL2268-2;HPV genotype;LA14557-5;2;11;;; +91851-6;LL2268-2;HPV genotype;LA19218-9;3;6+11;;; +91851-6;LL2268-2;HPV genotype;LA19216-3;4;6+11+42+43+44;;; +91851-6;LL2268-2;HPV genotype;LA19215-5;5;16+18+31+33+35+39+45+51+52+56+58+59+68;;; +91851-6;LL2268-2;HPV genotype;LA19217-1;6;16+18+31+33+35+45+51+52+56;;; +48646-4;LL2301-1;Yersinia pestis/sp;LA19346-8;1;Yersinia sp;;; +48646-4;LL2301-1;Yersinia pestis/sp;LA19347-6;2;Yersinia pestis;54365000;Yersinia pestis (organism);http://snomed.info/sct +48766-0;LL3678-1;PHVS_ReportingSourceType_NND;;0;;;; +48793-4;LL534-9;FibroSURE_2_Activity;LA9640-9;1;No activity;;; +48793-4;LL534-9;FibroSURE_2_Activity;LA9641-7;2;Minimal activity;;; +48793-4;LL534-9;FibroSURE_2_Activity;LA9642-5;3;Moderate activity;;; +48793-4;LL534-9;FibroSURE_2_Activity;LA9643-3;4;Severe activity;;; +48794-2;LL533-1;FibroSURE_1_Fibrosis stage;LA9635-9;1;No fibrosis;;; +48794-2;LL533-1;FibroSURE_1_Fibrosis stage;LA9636-7;2;Portal fibrosis;;; +48794-2;LL533-1;FibroSURE_1_Fibrosis stage;LA9637-5;3;Bridging with fibrosis with few septa;;; +48794-2;LL533-1;FibroSURE_1_Fibrosis stage;LA9638-3;4;Bridging fibrosis with many septa;;; +48794-2;LL533-1;FibroSURE_1_Fibrosis stage;LA9639-1;5;Cirrhosis;;; +48873-4;LL2280-7;Ehrlichia spp;LA19264-3;1;Ehrlichia canis;;; +48873-4;LL2280-7;Ehrlichia spp;LA19265-0;2;Ehrlichia chaffeensis;;; +48873-4;LL2280-7;Ehrlichia spp;LA19266-8;3;Ehrlichia ewingii;;; +48873-4;LL2280-7;Ehrlichia spp;LA19267-6;4;Ehrlichia risticii;;; +49024-3;LL3893-6;Differential methods;LA25818-8;1;Human read;;; +49024-3;LL3893-6;Differential methods;LA25819-6;2;Computer imaging assisted;;; +49024-3;LL3893-6;Differential methods;LA25820-4;3;Automated flow cytometry;;; +49520-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +49520-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +49520-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +49520-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49521-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +49521-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +49521-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +49521-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49523-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +49523-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +49523-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +49523-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49524-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +49524-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +49524-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +49524-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49527-5;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +49527-5;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +49527-5;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +49527-5;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49528-3;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +49528-3;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +49528-3;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +49528-3;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49531-7;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +49531-7;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +49531-7;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +49531-7;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +55148-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +55148-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +55148-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +55148-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +60544-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +60544-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +60544-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +60544-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +60545-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +60545-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +60545-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +60545-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +72505-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +72505-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +72505-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +72505-1;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +74534-9;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +74534-9;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +74534-9;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +74534-9;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +74535-6;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +74535-6;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +74535-6;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +74535-6;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +74536-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +74536-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +74536-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +74536-4;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +74537-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +74537-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +74537-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +74537-2;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +74538-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +74538-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +74538-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +74538-0;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +74539-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +74539-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +74539-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +74539-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81648-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11882-0;1;Detected;;; +81648-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11883-8;2;Not detected;;; +81648-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA13538-6;3;Not tested;;; +81648-8;LL955-6;Detected|Not det|Not tested|Indeterm;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +49609-1;LL2279-9;Vibrio spp;LA19345-0;0;Vibrio furnissi;;; +49609-1;LL2279-9;Vibrio spp;LA19260-1;1;Vibrio cholerae;;; +49609-1;LL2279-9;Vibrio spp;LA19261-9;2;Vibrio cincinnatiensis;;; +49609-1;LL2279-9;Vibrio spp;LA19262-7;3;Vibrio damsela;;; +49609-1;LL2279-9;Vibrio spp;LA19263-5;4;Vibrio parahemolyticus;;; +49609-1;LL2279-9;Vibrio spp;LA19343-5;5;Vibrio mimicus;;; +49609-1;LL2279-9;Vibrio spp;LA19344-3;6;Vibrio fluvialis;;; +6578-9;LL2279-9;Vibrio spp;LA19345-0;0;Vibrio furnissi;;; +6578-9;LL2279-9;Vibrio spp;LA19260-1;1;Vibrio cholerae;;; +6578-9;LL2279-9;Vibrio spp;LA19261-9;2;Vibrio cincinnatiensis;;; +6578-9;LL2279-9;Vibrio spp;LA19262-7;3;Vibrio damsela;;; +6578-9;LL2279-9;Vibrio spp;LA19263-5;4;Vibrio parahemolyticus;;; +6578-9;LL2279-9;Vibrio spp;LA19343-5;5;Vibrio mimicus;;; +6578-9;LL2279-9;Vibrio spp;LA19344-3;6;Vibrio fluvialis;;; +6579-7;LL2279-9;Vibrio spp;LA19345-0;0;Vibrio furnissi;;; +6579-7;LL2279-9;Vibrio spp;LA19260-1;1;Vibrio cholerae;;; +6579-7;LL2279-9;Vibrio spp;LA19261-9;2;Vibrio cincinnatiensis;;; +6579-7;LL2279-9;Vibrio spp;LA19262-7;3;Vibrio damsela;;; +6579-7;LL2279-9;Vibrio spp;LA19263-5;4;Vibrio parahemolyticus;;; +6579-7;LL2279-9;Vibrio spp;LA19343-5;5;Vibrio mimicus;;; +6579-7;LL2279-9;Vibrio spp;LA19344-3;6;Vibrio fluvialis;;; +6580-5;LL2279-9;Vibrio spp;LA19345-0;0;Vibrio furnissi;;; +6580-5;LL2279-9;Vibrio spp;LA19260-1;1;Vibrio cholerae;;; +6580-5;LL2279-9;Vibrio spp;LA19261-9;2;Vibrio cincinnatiensis;;; +6580-5;LL2279-9;Vibrio spp;LA19262-7;3;Vibrio damsela;;; +6580-5;LL2279-9;Vibrio spp;LA19263-5;4;Vibrio parahemolyticus;;; +6580-5;LL2279-9;Vibrio spp;LA19343-5;5;Vibrio mimicus;;; +6580-5;LL2279-9;Vibrio spp;LA19344-3;6;Vibrio fluvialis;;; +6581-3;LL2279-9;Vibrio spp;LA19345-0;0;Vibrio furnissi;;; +6581-3;LL2279-9;Vibrio spp;LA19260-1;1;Vibrio cholerae;;; +6581-3;LL2279-9;Vibrio spp;LA19261-9;2;Vibrio cincinnatiensis;;; +6581-3;LL2279-9;Vibrio spp;LA19262-7;3;Vibrio damsela;;; +6581-3;LL2279-9;Vibrio spp;LA19263-5;4;Vibrio parahemolyticus;;; +6581-3;LL2279-9;Vibrio spp;LA19343-5;5;Vibrio mimicus;;; +6581-3;LL2279-9;Vibrio spp;LA19344-3;6;Vibrio fluvialis;;; +49614-1;LL2298-9;Campy spp;LA19336-9;1;Campylobacter coli;;; +49614-1;LL2298-9;Campy spp;LA19338-5;2;Campylobacter fetus;;; +49614-1;LL2298-9;Campy spp;LA19337-7;3;Campylobacter jejuni;;; +49614-1;LL2298-9;Campy spp;LA19335-1;4;Campylobacter species;;; +49615-8;LL2297-1;Borrelia spp;LA19334-4;1;Borrelia burgdorferi;76327009;Borrelia burgdorferi (organism);http://snomed.info/sct +49615-8;LL2297-1;Borrelia spp;LA19333-6;2;Borrelia species;;; +49615-8;LL2297-1;Borrelia spp;LA11883-8;3;Not detected;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18049-9;1;Haemophilus influenzae;44470000;Haemophilus influenzae (organism);http://snomed.info/sct +49721-4;LL1932-4;Haemophilus influenzae;LA18050-7;2;Haemophilus influenzae type A;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18051-5;3;Haemophilus influenzae type B;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18052-3;4;Haemophilus influenzae type C;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18053-1;5;Haemophilus influenzae type D;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18054-9;6;Haemophilus influenzae type E;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18055-6;7;Haemophilus influenzae type F;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18056-4;8;Haemophilus influenzae, biotype I;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18057-2;9;Haemophilus influenzae, biotype II;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18058-0;10;Haemophilus influenzae, biotype III;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18059-8;11;Haemophilus influenzae, biotype IV;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18060-6;12;Haemophilus influenzae, biotype V;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18061-4;13;Haemophilus influenzae, biotype VI;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18062-2;14;Haemophilus influenzae, biotype VII;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18063-0;15;Haemophilus influenzae, biotype VIII;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18064-8;16;Haemophilus influenzae, non-typable;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18065-5;17;Haemophilus influenzae, not B;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18373-3;18;Test not done;373121007;Test not done (qualifier value);http://snomed.info/sct +49721-4;LL1932-4;Haemophilus influenzae;LA18372-5;19;Not isolated;;; +49721-4;LL1932-4;Haemophilus influenzae;LA18374-1;20;Specimen unsatisfactory for diagnosis;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18049-9;1;Haemophilus influenzae;44470000;Haemophilus influenzae (organism);http://snomed.info/sct +58473-0;LL1932-4;Haemophilus influenzae;LA18050-7;2;Haemophilus influenzae type A;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18051-5;3;Haemophilus influenzae type B;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18052-3;4;Haemophilus influenzae type C;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18053-1;5;Haemophilus influenzae type D;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18054-9;6;Haemophilus influenzae type E;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18055-6;7;Haemophilus influenzae type F;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18056-4;8;Haemophilus influenzae, biotype I;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18057-2;9;Haemophilus influenzae, biotype II;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18058-0;10;Haemophilus influenzae, biotype III;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18059-8;11;Haemophilus influenzae, biotype IV;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18060-6;12;Haemophilus influenzae, biotype V;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18061-4;13;Haemophilus influenzae, biotype VI;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18062-2;14;Haemophilus influenzae, biotype VII;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18063-0;15;Haemophilus influenzae, biotype VIII;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18064-8;16;Haemophilus influenzae, non-typable;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18065-5;17;Haemophilus influenzae, not B;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18373-3;18;Test not done;373121007;Test not done (qualifier value);http://snomed.info/sct +58473-0;LL1932-4;Haemophilus influenzae;LA18372-5;19;Not isolated;;; +58473-0;LL1932-4;Haemophilus influenzae;LA18374-1;20;Specimen unsatisfactory for diagnosis;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18049-9;1;Haemophilus influenzae;44470000;Haemophilus influenzae (organism);http://snomed.info/sct +58739-4;LL1932-4;Haemophilus influenzae;LA18050-7;2;Haemophilus influenzae type A;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18051-5;3;Haemophilus influenzae type B;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18052-3;4;Haemophilus influenzae type C;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18053-1;5;Haemophilus influenzae type D;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18054-9;6;Haemophilus influenzae type E;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18055-6;7;Haemophilus influenzae type F;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18056-4;8;Haemophilus influenzae, biotype I;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18057-2;9;Haemophilus influenzae, biotype II;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18058-0;10;Haemophilus influenzae, biotype III;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18059-8;11;Haemophilus influenzae, biotype IV;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18060-6;12;Haemophilus influenzae, biotype V;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18061-4;13;Haemophilus influenzae, biotype VI;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18062-2;14;Haemophilus influenzae, biotype VII;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18063-0;15;Haemophilus influenzae, biotype VIII;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18064-8;16;Haemophilus influenzae, non-typable;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18065-5;17;Haemophilus influenzae, not B;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18373-3;18;Test not done;373121007;Test not done (qualifier value);http://snomed.info/sct +58739-4;LL1932-4;Haemophilus influenzae;LA18372-5;19;Not isolated;;; +58739-4;LL1932-4;Haemophilus influenzae;LA18374-1;20;Specimen unsatisfactory for diagnosis;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18049-9;1;Haemophilus influenzae;44470000;Haemophilus influenzae (organism);http://snomed.info/sct +69410-9;LL1932-4;Haemophilus influenzae;LA18050-7;2;Haemophilus influenzae type A;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18051-5;3;Haemophilus influenzae type B;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18052-3;4;Haemophilus influenzae type C;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18053-1;5;Haemophilus influenzae type D;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18054-9;6;Haemophilus influenzae type E;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18055-6;7;Haemophilus influenzae type F;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18056-4;8;Haemophilus influenzae, biotype I;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18057-2;9;Haemophilus influenzae, biotype II;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18058-0;10;Haemophilus influenzae, biotype III;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18059-8;11;Haemophilus influenzae, biotype IV;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18060-6;12;Haemophilus influenzae, biotype V;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18061-4;13;Haemophilus influenzae, biotype VI;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18062-2;14;Haemophilus influenzae, biotype VII;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18063-0;15;Haemophilus influenzae, biotype VIII;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18064-8;16;Haemophilus influenzae, non-typable;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18065-5;17;Haemophilus influenzae, not B;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18373-3;18;Test not done;373121007;Test not done (qualifier value);http://snomed.info/sct +69410-9;LL1932-4;Haemophilus influenzae;LA18372-5;19;Not isolated;;; +69410-9;LL1932-4;Haemophilus influenzae;LA18374-1;20;Specimen unsatisfactory for diagnosis;;; +49877-4;LL2307-8;HBV codon 173;LA19360-9;1;V173;;; +49877-4;LL2307-8;HBV codon 173;LA19361-7;2;L173;;; +49877-4;LL2307-8;HBV codon 173;LA19362-5;3;G173;;; +49878-2;LL2308-6;HBV codon 180;LA19363-3;1;L180;;; +49878-2;LL2308-6;HBV codon 180;LA19364-1;2;M180;;; +49879-0;LL2309-4;HBV codon 181;LA19365-8;1;A181;;; +49879-0;LL2309-4;HBV codon 181;LA19366-6;2;T181;;; +49879-0;LL2309-4;HBV codon 181;LA19367-4;3;V181;;; +49880-8;LL2313-6;HBV codon 204;LA19378-1;1;M204;;; +49880-8;LL2313-6;HBV codon 204;LA19379-9;2;I204;;; +49880-8;LL2313-6;HBV codon 204;LA19380-7;3;S204;;; +49880-8;LL2313-6;HBV codon 204;LA19381-5;4;V204;;; +49881-6;LL2316-9;HBV codon 236;LA19388-0;1;N236;;; +49881-6;LL2316-9;HBV codon 236;LA19389-8;2;T236;;; +49882-4;LL2305-2;HBV codon 80;LA19355-9;1;L80;;; +49882-4;LL2305-2;HBV codon 80;LA19356-7;2;I80;;; +49882-4;LL2305-2;HBV codon 80;LA19357-5;3;V80;;; +50401-9;LL2411-8;Bld group Ab;LA19685-9;1;Anti-B;;; +50401-9;LL2411-8;Bld group Ab;LA19686-7;2;Anti-C;;; +50401-9;LL2411-8;Bld group Ab;LA19687-5;3;Anti-D;;; +50401-9;LL2411-8;Bld group Ab;LA19688-3;4;Anti-Cw;;; +50401-9;LL2411-8;Bld group Ab;LA19689-1;5;Anti-E;;; +50548-7;LL2273-2;Resp viruses;LA19236-1;1;Parainfluenza virus 1;;; +50548-7;LL2273-2;Resp viruses;LA19237-9;2;Parainfluenza virus 2;;; +50548-7;LL2273-2;Resp viruses;LA19238-7;3;Parainfluenza virus 3;;; +50548-7;LL2273-2;Resp viruses;LA19239-5;4;Respiratory syncytial virus;;; +50548-7;LL2273-2;Resp viruses;LA19240-3;5;Metapneumovirus;;; +50548-7;LL2273-2;Resp viruses;LA137-2;6;None;260413007;None (qualifier value);http://snomed.info/sct +54245-6;LL2273-2;Resp viruses;LA19236-1;1;Parainfluenza virus 1;;; +54245-6;LL2273-2;Resp viruses;LA19237-9;2;Parainfluenza virus 2;;; +54245-6;LL2273-2;Resp viruses;LA19238-7;3;Parainfluenza virus 3;;; +54245-6;LL2273-2;Resp viruses;LA19239-5;4;Respiratory syncytial virus;;; +54245-6;LL2273-2;Resp viruses;LA19240-3;5;Metapneumovirus;;; +54245-6;LL2273-2;Resp viruses;LA137-2;6;None;260413007;None (qualifier value);http://snomed.info/sct +87709-2;LL2273-2;Resp viruses;LA19236-1;1;Parainfluenza virus 1;;; +87709-2;LL2273-2;Resp viruses;LA19237-9;2;Parainfluenza virus 2;;; +87709-2;LL2273-2;Resp viruses;LA19238-7;3;Parainfluenza virus 3;;; +87709-2;LL2273-2;Resp viruses;LA19239-5;4;Respiratory syncytial virus;;; +87709-2;LL2273-2;Resp viruses;LA19240-3;5;Metapneumovirus;;; +87709-2;LL2273-2;Resp viruses;LA137-2;6;None;260413007;None (qualifier value);http://snomed.info/sct +50552-9;LL2428-2;Cloudy/Clear/ Bloody;LA19733-7;1;Cloudy;;; +50552-9;LL2428-2;Cloudy/Clear/ Bloody;LA19732-9;2;Clear;;; +50552-9;LL2428-2;Cloudy/Clear/ Bloody;LA19736-0;3;Bloody;;; +94127-8;LL2428-2;Cloudy/Clear/ Bloody;LA19733-7;1;Cloudy;;; +94127-8;LL2428-2;Cloudy/Clear/ Bloody;LA19732-9;2;Clear;;; +94127-8;LL2428-2;Cloudy/Clear/ Bloody;LA19736-0;3;Bloody;;; +50704-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +50704-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +50704-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +50704-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +50704-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +50705-3;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +50705-3;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +50705-3;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +50705-3;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +50705-3;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +62427-0;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +62427-0;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +62427-0;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +62427-0;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +62427-0;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +74475-5;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +74475-5;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +74475-5;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +74475-5;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +74475-5;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +94759-8;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +94759-8;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +94759-8;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94759-8;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94759-8;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +94760-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11882-0;1;Detected;;; +94760-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11883-8;2;Not detected;;; +94760-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +94760-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +94760-6;LL1055-4;Detected|Not det|Equiv|Inconcl|Spec unsat for eval;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA10-4;1;Admission assessment (required by day 14);;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA12-0;2;Annual assessment;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA13-8;3;Significant change in status assessment;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA14-6;4;Significant correction of prior full assessment;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA15-3;5;Quarterly review assessment;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA52-6;6;Discharged-return not anticipated;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA53-4;7;Discharged-return anticipated;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA9656-5;8;Discharged prior to completing initial assessment;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA54-2;9;Reentry;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA11-2;12;Significant correction of prior quarterly assessment;;; +50787-1;LL536-4;MDS_57b_Reason For Assessment (full);LA9-3;13;None of the above;;; +50790-5;LL2265-8;HIV1 tropism;LA19204-9;1;R5;;; +50790-5;LL2265-8;HIV1 tropism;LA19205-6;2;X4;;; +50790-5;LL2265-8;HIV1 tropism;LA19206-4;3;D/M;;; +53923-9;LL2265-8;HIV1 tropism;LA19204-9;1;R5;;; +53923-9;LL2265-8;HIV1 tropism;LA19205-6;2;X4;;; +53923-9;LL2265-8;HIV1 tropism;LA19206-4;3;D/M;;; +57182-8;LL2265-8;HIV1 tropism;LA19204-9;1;R5;;; +57182-8;LL2265-8;HIV1 tropism;LA19205-6;2;X4;;; +57182-8;LL2265-8;HIV1 tropism;LA19206-4;3;D/M;;; +79155-8;LL2265-8;HIV1 tropism;LA19204-9;1;R5;;; +79155-8;LL2265-8;HIV1 tropism;LA19205-6;2;X4;;; +79155-8;LL2265-8;HIV1 tropism;LA19206-4;3;D/M;;; +80688-5;LL2265-8;HIV1 tropism;LA19204-9;1;R5;;; +80688-5;LL2265-8;HIV1 tropism;LA19205-6;2;X4;;; +80688-5;LL2265-8;HIV1 tropism;LA19206-4;3;D/M;;; +80690-1;LL2265-8;HIV1 tropism;LA19204-9;1;R5;;; +80690-1;LL2265-8;HIV1 tropism;LA19205-6;2;X4;;; +80690-1;LL2265-8;HIV1 tropism;LA19206-4;3;D/M;;; +87963-5;LL2265-8;HIV1 tropism;LA19204-9;1;R5;;; +87963-5;LL2265-8;HIV1 tropism;LA19205-6;2;X4;;; +87963-5;LL2265-8;HIV1 tropism;LA19206-4;3;D/M;;; +50944-8;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +50944-8;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +50944-8;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +50945-5;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +50945-5;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +50945-5;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +50946-3;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +50946-3;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +50946-3;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +50947-1;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +50947-1;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +50947-1;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96187-0;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96187-0;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96187-0;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96188-8;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96188-8;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96188-8;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96189-6;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96189-6;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96189-6;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96190-4;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96190-4;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96190-4;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96191-2;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96191-2;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96191-2;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96192-0;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96192-0;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96192-0;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96193-8;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96193-8;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96193-8;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96194-6;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96194-6;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96194-6;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96195-3;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96195-3;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96195-3;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96196-1;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96196-1;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96196-1;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96197-9;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96197-9;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96197-9;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96198-7;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96198-7;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96198-7;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96199-5;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96199-5;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96199-5;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96200-1;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96200-1;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96200-1;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96201-9;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96201-9;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96201-9;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +96202-7;LL2439-9;Normal|Abnormal|Borderline;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +96202-7;LL2439-9;Normal|Abnormal|Borderline;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +96202-7;LL2439-9;Normal|Abnormal|Borderline;LA4259-3;3;Borderline;;; +51391-1;LL2441-5;Medical device;LA19764-2;1;C-Pap;;; +51391-1;LL2441-5;Medical device;LA19765-9;2;Brace;;; +51391-1;LL2441-5;Medical device;LA19766-7;3;Glucose monitor;;; +51391-1;LL2441-5;Medical device;LA19767-5;4;Pacemaker;;; +51391-1;LL2441-5;Medical device;LA19768-3;5;Pin;;; +51668-2;LL2299-7;Haem/Pseud/S pneumo;LA19339-3;1;Haemophilus influenza;;; +51668-2;LL2299-7;Haem/Pseud/S pneumo;LA19340-1;2;Pseudomonas aeruginosa;;; +51668-2;LL2299-7;Haem/Pseud/S pneumo;LA19341-9;3;Streptococcus pneumoniae;9861002;Streptococcus pneumoniae (organism);http://snomed.info/sct +51961-1;LL539-8;MG_6;LA6676-6;1;Resistant;;; +51961-1;LL539-8;MG_6;LA6677-4;2;Responsive;;; +51961-1;LL539-8;MG_6;LA9660-7;3;Presumed resistant;;; +51961-1;LL539-8;MG_6;LA9661-5;4;Presumed responsive;;; +51961-1;LL539-8;MG_6;LA6682-4;5;Unknown Significance;;; +51961-1;LL539-8;MG_6;LA6675-8;6;Benign;;; +51961-1;LL539-8;MG_6;LA6674-1;7;Presumed Benign;;; +51961-1;LL539-8;MG_6;LA9662-3;8;Presumed non-responsive;;; +51964-5;LL540-6;MG_7;LA6677-4;1;Responsive;;; +51964-5;LL540-6;MG_7;LA6676-6;2;Resistant;;; +51964-5;LL540-6;MG_7;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51964-5;LL540-6;MG_7;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +51964-5;LL540-6;MG_7;LA9664-9;5;Failure;;; +51968-6;LL541-4;MG_8;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +51968-6;LL541-4;MG_8;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +51968-6;LL541-4;MG_8;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +51968-6;LL541-4;MG_8;LA9664-9;4;Failure;;; +53038-6;LL541-4;MG_8;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +53038-6;LL541-4;MG_8;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53038-6;LL541-4;MG_8;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +53038-6;LL541-4;MG_8;LA9664-9;4;Failure;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +52454-6;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +69418-2;LL1934-0;CARE_LTCH-reason for assessment;LA10922-5;1;Admission;;; +69418-2;LL1934-0;CARE_LTCH-reason for assessment;LA18067-1;2;Planned discharge;;; +69418-2;LL1934-0;CARE_LTCH-reason for assessment;LA18068-9;3;Unplanned discharge;;; +69418-2;LL1934-0;CARE_LTCH-reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18418-6;1;Admit;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10324-4;2;Interim;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18419-4;3;Discharge;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18418-6;1;Admit;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10324-4;2;Interim;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18419-4;3;Discharge;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18418-6;1;Admit;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10324-4;2;Interim;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18419-4;3;Discharge;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18418-6;1;Admit;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10324-4;2;Interim;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18419-4;3;Discharge;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18418-6;1;Admit;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10324-4;2;Interim;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18419-4;3;Discharge;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10325-1;4;Expired;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18418-6;1;Admit;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10324-4;2;Interim;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA18419-4;3;Discharge;;; +52454-6;LL2019-9;CARE_1_A1_Reason for assessment;LA10325-1;4;Expired;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52517-0;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52518-8;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52642-6;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52643-4;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52644-2;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52645-9;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52646-7;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52647-5;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52648-3;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52649-1;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52650-9;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52651-7;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52653-3;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52654-1;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52655-8;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52656-6;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52657-4;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52658-2;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52659-0;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA10039-8;7;Not attempted due to medical condition;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA10040-6;8;Not attempted due to safety concerns;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA10092-7;9;Task attempted but not completed;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA4720-4;10;Not applicable;;; +52660-8;LL586-9;CARE_6_a01_Core Self Care;LA10058-8;11;Patient refused;;; +52532-9;LL3178-2;US state or other_specify;LA21991-7;1;AL;;; +52532-9;LL3178-2;US state or other_specify;LA21992-5;2;AK;;; +52532-9;LL3178-2;US state or other_specify;LA21993-3;3;AZ;;; +52532-9;LL3178-2;US state or other_specify;LA21994-1;4;AR;;; +52532-9;LL3178-2;US state or other_specify;LA21995-8;5;CA;;; +52532-9;LL3178-2;US state or other_specify;LA21996-6;6;CO;;; +52532-9;LL3178-2;US state or other_specify;LA21997-4;7;CT;;; +52532-9;LL3178-2;US state or other_specify;LA21998-2;8;DC;;; +52532-9;LL3178-2;US state or other_specify;LA21999-0;9;DE;;; +52532-9;LL3178-2;US state or other_specify;LA22000-6;10;FL;;; +52532-9;LL3178-2;US state or other_specify;LA22001-4;11;GA;;; +52532-9;LL3178-2;US state or other_specify;LA22002-2;12;HI;;; +52532-9;LL3178-2;US state or other_specify;LA19256-9;13;ID;;; +52532-9;LL3178-2;US state or other_specify;LA22003-0;14;IL;;; +52532-9;LL3178-2;US state or other_specify;LA22004-8;15;IN;;; +52532-9;LL3178-2;US state or other_specify;LA22005-5;16;IA;;; +52532-9;LL3178-2;US state or other_specify;LA22006-3;17;KS;;; +52532-9;LL3178-2;US state or other_specify;LA22007-1;18;KY;;; +52532-9;LL3178-2;US state or other_specify;LA22008-9;19;LA;;; +52532-9;LL3178-2;US state or other_specify;LA22009-7;20;ME;;; +52532-9;LL3178-2;US state or other_specify;LA20036-2;21;MD;;; +52532-9;LL3178-2;US state or other_specify;LA22010-5;22;MA;;; +52532-9;LL3178-2;US state or other_specify;LA22011-3;23;MI;;; +52532-9;LL3178-2;US state or other_specify;LA22012-1;24;MN;;; +52532-9;LL3178-2;US state or other_specify;LA22013-9;25;MS;;; +52532-9;LL3178-2;US state or other_specify;LA22014-7;26;MO;;; +52532-9;LL3178-2;US state or other_specify;LA22015-4;27;MT;;; +52532-9;LL3178-2;US state or other_specify;LA22016-2;28;NE;;; +52532-9;LL3178-2;US state or other_specify;LA22017-0;29;NV;;; +52532-9;LL3178-2;US state or other_specify;LA21453-8;30;NH;;; +52532-9;LL3178-2;US state or other_specify;LA22018-8;31;NJ;;; +52532-9;LL3178-2;US state or other_specify;LA22019-6;32;NM;;; +52532-9;LL3178-2;US state or other_specify;LA22020-4;33;NY;;; +52532-9;LL3178-2;US state or other_specify;LA22021-2;34;NC;;; +52532-9;LL3178-2;US state or other_specify;LA22022-0;35;ND;;; +52532-9;LL3178-2;US state or other_specify;LA22023-8;36;OH;;; +52532-9;LL3178-2;US state or other_specify;LA22024-6;37;OK;;; +52532-9;LL3178-2;US state or other_specify;LA22025-3;38;OR;;; +52532-9;LL3178-2;US state or other_specify;LA22026-1;39;PA;;; +52532-9;LL3178-2;US state or other_specify;LA21403-3;40;PR;;; +52532-9;LL3178-2;US state or other_specify;LA22027-9;41;RI;;; +52532-9;LL3178-2;US state or other_specify;LA22028-7;42;SC;;; +52532-9;LL3178-2;US state or other_specify;LA22029-5;43;SD;;; +52532-9;LL3178-2;US state or other_specify;LA22030-3;44;TN;;; +52532-9;LL3178-2;US state or other_specify;LA3601-7;45;TX;;; +52532-9;LL3178-2;US state or other_specify;LA22031-1;46;UT;;; +52532-9;LL3178-2;US state or other_specify;LA22032-9;47;VT;;; +52532-9;LL3178-2;US state or other_specify;LA18827-8;48;VA;;; +52532-9;LL3178-2;US state or other_specify;LA22033-7;49;WA;;; +52532-9;LL3178-2;US state or other_specify;LA22034-5;50;WV;;; +52532-9;LL3178-2;US state or other_specify;LA22035-2;51;WI;;; +52532-9;LL3178-2;US state or other_specify;LA22036-0;52;WY;;; +52532-9;LL3178-2;US state or other_specify;LA46-8;53;Other;;; +77966-0;LL3178-2;US state or other_specify;LA21991-7;1;AL;;; +77966-0;LL3178-2;US state or other_specify;LA21992-5;2;AK;;; +77966-0;LL3178-2;US state or other_specify;LA21993-3;3;AZ;;; +77966-0;LL3178-2;US state or other_specify;LA21994-1;4;AR;;; +77966-0;LL3178-2;US state or other_specify;LA21995-8;5;CA;;; +77966-0;LL3178-2;US state or other_specify;LA21996-6;6;CO;;; +77966-0;LL3178-2;US state or other_specify;LA21997-4;7;CT;;; +77966-0;LL3178-2;US state or other_specify;LA21998-2;8;DC;;; +77966-0;LL3178-2;US state or other_specify;LA21999-0;9;DE;;; +77966-0;LL3178-2;US state or other_specify;LA22000-6;10;FL;;; +77966-0;LL3178-2;US state or other_specify;LA22001-4;11;GA;;; +77966-0;LL3178-2;US state or other_specify;LA22002-2;12;HI;;; +77966-0;LL3178-2;US state or other_specify;LA19256-9;13;ID;;; +77966-0;LL3178-2;US state or other_specify;LA22003-0;14;IL;;; +77966-0;LL3178-2;US state or other_specify;LA22004-8;15;IN;;; +77966-0;LL3178-2;US state or other_specify;LA22005-5;16;IA;;; +77966-0;LL3178-2;US state or other_specify;LA22006-3;17;KS;;; +77966-0;LL3178-2;US state or other_specify;LA22007-1;18;KY;;; +77966-0;LL3178-2;US state or other_specify;LA22008-9;19;LA;;; +77966-0;LL3178-2;US state or other_specify;LA22009-7;20;ME;;; +77966-0;LL3178-2;US state or other_specify;LA20036-2;21;MD;;; +77966-0;LL3178-2;US state or other_specify;LA22010-5;22;MA;;; +77966-0;LL3178-2;US state or other_specify;LA22011-3;23;MI;;; +77966-0;LL3178-2;US state or other_specify;LA22012-1;24;MN;;; +77966-0;LL3178-2;US state or other_specify;LA22013-9;25;MS;;; +77966-0;LL3178-2;US state or other_specify;LA22014-7;26;MO;;; +77966-0;LL3178-2;US state or other_specify;LA22015-4;27;MT;;; +77966-0;LL3178-2;US state or other_specify;LA22016-2;28;NE;;; +77966-0;LL3178-2;US state or other_specify;LA22017-0;29;NV;;; +77966-0;LL3178-2;US state or other_specify;LA21453-8;30;NH;;; +77966-0;LL3178-2;US state or other_specify;LA22018-8;31;NJ;;; +77966-0;LL3178-2;US state or other_specify;LA22019-6;32;NM;;; +77966-0;LL3178-2;US state or other_specify;LA22020-4;33;NY;;; +77966-0;LL3178-2;US state or other_specify;LA22021-2;34;NC;;; +77966-0;LL3178-2;US state or other_specify;LA22022-0;35;ND;;; +77966-0;LL3178-2;US state or other_specify;LA22023-8;36;OH;;; +77966-0;LL3178-2;US state or other_specify;LA22024-6;37;OK;;; +77966-0;LL3178-2;US state or other_specify;LA22025-3;38;OR;;; +77966-0;LL3178-2;US state or other_specify;LA22026-1;39;PA;;; +77966-0;LL3178-2;US state or other_specify;LA21403-3;40;PR;;; +77966-0;LL3178-2;US state or other_specify;LA22027-9;41;RI;;; +77966-0;LL3178-2;US state or other_specify;LA22028-7;42;SC;;; +77966-0;LL3178-2;US state or other_specify;LA22029-5;43;SD;;; +77966-0;LL3178-2;US state or other_specify;LA22030-3;44;TN;;; +77966-0;LL3178-2;US state or other_specify;LA3601-7;45;TX;;; +77966-0;LL3178-2;US state or other_specify;LA22031-1;46;UT;;; +77966-0;LL3178-2;US state or other_specify;LA22032-9;47;VT;;; +77966-0;LL3178-2;US state or other_specify;LA18827-8;48;VA;;; +77966-0;LL3178-2;US state or other_specify;LA22033-7;49;WA;;; +77966-0;LL3178-2;US state or other_specify;LA22034-5;50;WV;;; +77966-0;LL3178-2;US state or other_specify;LA22035-2;51;WI;;; +77966-0;LL3178-2;US state or other_specify;LA22036-0;52;WY;;; +77966-0;LL3178-2;US state or other_specify;LA46-8;53;Other;;; +82158-7;LL3178-2;US state or other_specify;LA21991-7;1;AL;;; +82158-7;LL3178-2;US state or other_specify;LA21992-5;2;AK;;; +82158-7;LL3178-2;US state or other_specify;LA21993-3;3;AZ;;; +82158-7;LL3178-2;US state or other_specify;LA21994-1;4;AR;;; +82158-7;LL3178-2;US state or other_specify;LA21995-8;5;CA;;; +82158-7;LL3178-2;US state or other_specify;LA21996-6;6;CO;;; +82158-7;LL3178-2;US state or other_specify;LA21997-4;7;CT;;; +82158-7;LL3178-2;US state or other_specify;LA21998-2;8;DC;;; +82158-7;LL3178-2;US state or other_specify;LA21999-0;9;DE;;; +82158-7;LL3178-2;US state or other_specify;LA22000-6;10;FL;;; +82158-7;LL3178-2;US state or other_specify;LA22001-4;11;GA;;; +82158-7;LL3178-2;US state or other_specify;LA22002-2;12;HI;;; +82158-7;LL3178-2;US state or other_specify;LA19256-9;13;ID;;; +82158-7;LL3178-2;US state or other_specify;LA22003-0;14;IL;;; +82158-7;LL3178-2;US state or other_specify;LA22004-8;15;IN;;; +82158-7;LL3178-2;US state or other_specify;LA22005-5;16;IA;;; +82158-7;LL3178-2;US state or other_specify;LA22006-3;17;KS;;; +82158-7;LL3178-2;US state or other_specify;LA22007-1;18;KY;;; +82158-7;LL3178-2;US state or other_specify;LA22008-9;19;LA;;; +82158-7;LL3178-2;US state or other_specify;LA22009-7;20;ME;;; +82158-7;LL3178-2;US state or other_specify;LA20036-2;21;MD;;; +82158-7;LL3178-2;US state or other_specify;LA22010-5;22;MA;;; +82158-7;LL3178-2;US state or other_specify;LA22011-3;23;MI;;; +82158-7;LL3178-2;US state or other_specify;LA22012-1;24;MN;;; +82158-7;LL3178-2;US state or other_specify;LA22013-9;25;MS;;; +82158-7;LL3178-2;US state or other_specify;LA22014-7;26;MO;;; +82158-7;LL3178-2;US state or other_specify;LA22015-4;27;MT;;; +82158-7;LL3178-2;US state or other_specify;LA22016-2;28;NE;;; +82158-7;LL3178-2;US state or other_specify;LA22017-0;29;NV;;; +82158-7;LL3178-2;US state or other_specify;LA21453-8;30;NH;;; +82158-7;LL3178-2;US state or other_specify;LA22018-8;31;NJ;;; +82158-7;LL3178-2;US state or other_specify;LA22019-6;32;NM;;; +82158-7;LL3178-2;US state or other_specify;LA22020-4;33;NY;;; +82158-7;LL3178-2;US state or other_specify;LA22021-2;34;NC;;; +82158-7;LL3178-2;US state or other_specify;LA22022-0;35;ND;;; +82158-7;LL3178-2;US state or other_specify;LA22023-8;36;OH;;; +82158-7;LL3178-2;US state or other_specify;LA22024-6;37;OK;;; +82158-7;LL3178-2;US state or other_specify;LA22025-3;38;OR;;; +82158-7;LL3178-2;US state or other_specify;LA22026-1;39;PA;;; +82158-7;LL3178-2;US state or other_specify;LA21403-3;40;PR;;; +82158-7;LL3178-2;US state or other_specify;LA22027-9;41;RI;;; +82158-7;LL3178-2;US state or other_specify;LA22028-7;42;SC;;; +82158-7;LL3178-2;US state or other_specify;LA22029-5;43;SD;;; +82158-7;LL3178-2;US state or other_specify;LA22030-3;44;TN;;; +82158-7;LL3178-2;US state or other_specify;LA3601-7;45;TX;;; +82158-7;LL3178-2;US state or other_specify;LA22031-1;46;UT;;; +82158-7;LL3178-2;US state or other_specify;LA22032-9;47;VT;;; +82158-7;LL3178-2;US state or other_specify;LA18827-8;48;VA;;; +82158-7;LL3178-2;US state or other_specify;LA22033-7;49;WA;;; +82158-7;LL3178-2;US state or other_specify;LA22034-5;50;WV;;; +82158-7;LL3178-2;US state or other_specify;LA22035-2;51;WI;;; +82158-7;LL3178-2;US state or other_specify;LA22036-0;52;WY;;; +82158-7;LL3178-2;US state or other_specify;LA46-8;53;Other;;; +52541-0;LL548-9;CARE_2_B3_Community assistance;LA10022-4;1;No help received or no help necessary;;; +52541-0;LL548-9;CARE_2_B3_Community assistance;LA10111-5;2;Unpaid Assistance;;; +52541-0;LL548-9;CARE_2_B3_Community assistance;LA10054-7;3;Paid Assistance;;; +52541-0;LL548-9;CARE_2_B3_Community assistance;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52542-8;LL549-7;CARE_2_B3a_Living situation;LA6255-9;1;Lives alone;;; +52542-8;LL549-7;CARE_2_B3a_Living situation;LA9997-3;2;Lives with paid helper;;; +52542-8;LL549-7;CARE_2_B3a_Living situation;LA9996-5;3;Lives with other(s);;; +52542-8;LL549-7;CARE_2_B3a_Living situation;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52693-9;LL549-7;CARE_2_B3a_Living situation;LA6255-9;1;Lives alone;;; +52693-9;LL549-7;CARE_2_B3a_Living situation;LA9997-3;2;Lives with paid helper;;; +52693-9;LL549-7;CARE_2_B3a_Living situation;LA9996-5;3;Lives with other(s);;; +52693-9;LL549-7;CARE_2_B3a_Living situation;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +55756-1;LL549-7;CARE_2_B3a_Living situation;LA6255-9;1;Lives alone;;; +55756-1;LL549-7;CARE_2_B3a_Living situation;LA9997-3;2;Lives with paid helper;;; +55756-1;LL549-7;CARE_2_B3a_Living situation;LA9996-5;3;Lives with other(s);;; +55756-1;LL549-7;CARE_2_B3a_Living situation;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52543-6;LL550-5;CARE_2_B4_Structural barriers;LA10089-3;1;Structural barriers are not an issue.;;; +52543-6;LL550-5;CARE_2_B4_Structural barriers;LA10086-9;2;Stairs inside the living setting that must be used by patient (e.g., to get to toileting, sleeping, eating areas).;;; +52543-6;LL550-5;CARE_2_B4_Structural barriers;LA10087-7;3;Stairs leading from inside to outside of living setting.;;; +52543-6;LL550-5;CARE_2_B4_Structural barriers;LA10016-6;4;Narrow or obstructed doorways for patients using wheelchairs or walkers.;;; +52543-6;LL550-5;CARE_2_B4_Structural barriers;LA9987-4;5;Insufficient space to accommodate extra equipment (e.g., hospital bed, vent equipment).;;; +52543-6;LL550-5;CARE_2_B4_Structural barriers;LA6310-2;6;Other (specify);;; +52543-6;LL550-5;CARE_2_B4_Structural barriers;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52545-1;LL546-3;CARE_2_b05a_Prior Functioning;LA9982-5;1;Independent – Patient completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +52545-1;LL546-3;CARE_2_b05a_Prior Functioning;LA10018-2;2;Needed partial assistance – Patient needed partial assistance from another person to complete activities.;;; +52545-1;LL546-3;CARE_2_b05a_Prior Functioning;LA9963-5;3;Dependent – A helper completed the activity for the patient.;;; +52545-1;LL546-3;CARE_2_b05a_Prior Functioning;LA4720-4;4;Not applicable;;; +52545-1;LL546-3;CARE_2_b05a_Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52546-9;LL546-3;CARE_2_b05a_Prior Functioning;LA9982-5;1;Independent – Patient completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +52546-9;LL546-3;CARE_2_b05a_Prior Functioning;LA10018-2;2;Needed partial assistance – Patient needed partial assistance from another person to complete activities.;;; +52546-9;LL546-3;CARE_2_b05a_Prior Functioning;LA9963-5;3;Dependent – A helper completed the activity for the patient.;;; +52546-9;LL546-3;CARE_2_b05a_Prior Functioning;LA4720-4;4;Not applicable;;; +52546-9;LL546-3;CARE_2_b05a_Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52547-7;LL546-3;CARE_2_b05a_Prior Functioning;LA9982-5;1;Independent – Patient completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +52547-7;LL546-3;CARE_2_b05a_Prior Functioning;LA10018-2;2;Needed partial assistance – Patient needed partial assistance from another person to complete activities.;;; +52547-7;LL546-3;CARE_2_b05a_Prior Functioning;LA9963-5;3;Dependent – A helper completed the activity for the patient.;;; +52547-7;LL546-3;CARE_2_b05a_Prior Functioning;LA4720-4;4;Not applicable;;; +52547-7;LL546-3;CARE_2_b05a_Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52548-5;LL546-3;CARE_2_b05a_Prior Functioning;LA9982-5;1;Independent – Patient completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +52548-5;LL546-3;CARE_2_b05a_Prior Functioning;LA10018-2;2;Needed partial assistance – Patient needed partial assistance from another person to complete activities.;;; +52548-5;LL546-3;CARE_2_b05a_Prior Functioning;LA9963-5;3;Dependent – A helper completed the activity for the patient.;;; +52548-5;LL546-3;CARE_2_b05a_Prior Functioning;LA4720-4;4;Not applicable;;; +52548-5;LL546-3;CARE_2_b05a_Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52549-3;LL546-3;CARE_2_b05a_Prior Functioning;LA9982-5;1;Independent – Patient completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +52549-3;LL546-3;CARE_2_b05a_Prior Functioning;LA10018-2;2;Needed partial assistance – Patient needed partial assistance from another person to complete activities.;;; +52549-3;LL546-3;CARE_2_b05a_Prior Functioning;LA9963-5;3;Dependent – A helper completed the activity for the patient.;;; +52549-3;LL546-3;CARE_2_b05a_Prior Functioning;LA4720-4;4;Not applicable;;; +52549-3;LL546-3;CARE_2_b05a_Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA9941-1;1;Cane/crutch;;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA10117-2;2;Walker;;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA10046-3;3;Orthotics/Prosthetics;;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA10119-8;4;Wheelchair/scooter full time;;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA10120-6;5;Wheelchair/scooter part time;;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA10003-4;6;Mechanical lift required;;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA6310-2;7;Other (specify);;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA10029-9;8;None apply;;; +52550-1;LL551-3;CARE_2_B6_Mobility devices;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL4184-9;No | Yes | Unknown 8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +83274-1;LL4184-9;No | Yes | Unknown 8;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +83274-1;LL4184-9;No | Yes | Unknown 8;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83274-1;LL4184-9;No | Yes | Unknown 8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +90542-2;LL4184-9;No | Yes | Unknown 8;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90542-2;LL4184-9;No | Yes | Unknown 8;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90542-2;LL4184-9;No | Yes | Unknown 8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52552-7;LL5954-4;Yes 2 / No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52552-7;LL5954-4;Yes 2 / No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97875-9;LL5954-4;Yes 2 / No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97875-9;LL5954-4;Yes 2 / No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +97875-9;LL5954-4;Yes 2 / No 0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97875-9;LL5954-4;Yes 2 / No 0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6259-1;1;Medicare (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27554-7;2;Medicare (managed care/Part C/Medicare Advantage);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6257-5;3;Medicaid (traditional fee-for-service);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27556-2;4;Medicaid (managed care);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6452-2;5;Workers' compensation;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6398-7;6;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10049-7;7;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA10061-2;8;Private insurance/Medigap;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA27561-2;9;Private managed care;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA6369-8;10;Self-pay;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA18995-3;11;No payer source;;; +52556-8;LL4470-2;CMS_LCDS Payer information;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL4470-2;CMS_LCDS Payer information;LA46-8;13;Other;;; +52556-8;LL4688-9;PHDSC_Source of Payment Typology;;0;;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52556-8;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +52556-8;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +76437-3;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +76437-3;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +76438-1;LL544-8;CARE_1_D_Payor Information;LA10028-1;1;None (no charge for current services);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6259-1;2;Medicare (traditional fee-for-service);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6258-3;3;Medicare (HMO/managed care);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6257-5;4;Medicaid (traditional fee-for-service);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6256-7;5;Medicaid (HMO/managed care);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA10123-0;6;Workers’ compensation;;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6398-7;7;Title programs (e.g., Title III, V, or XX);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA10049-7;8;Other government (e.g., TRICARE, VA, etc.);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA10061-2;9;Private insurance/Medigap;;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6349-0;10;Private HMO/managed care;;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6369-8;11;Self-pay;;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA6310-2;12;Other (specify);;; +76438-1;LL544-8;CARE_1_D_Payor Information;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9988-2;2;Insulin Drip;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10101-6;3;Total parenteral nutrition;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9943-7;4;Central Line Management;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9940-3;5;Blood Transfusion(s);;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9959-3;6;Controlled Parenteral Analgesia – Peripheral;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9958-5;7;Controlled Parenteral Analgesia – Epidural;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9994-0;8;Left Ventricular Assistive Device (LVAD);;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9957-7;9;Continuous Cardiac Monitoring;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9948-6;10;Chest Tube(s);;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10102-4;11;Trach Tube with Suctioning;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9976-7;12;High O2 Concentration Delivery System with FiO2 > 40%;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10033-1;13;Non-invasive ventilation (CPAP);;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10115-6;14;Ventilator – Weaning;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10114-9;15;Ventilator – Non-Weaning;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9975-9;16;Hemodialysis;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10059-6;17;Peritoneal Dialysis;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9971-8;18;Fistula or Other Drain Management;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10019-0;19;Negative Pressure Wound Therapy;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9954-4;20;Complex Wound Management with positioning and skin separation/traction that requires at least two persons or extensive & complex wound management by one person;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9974-2;21;Halo;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9953-6;22;Complex External Fixators (e.g., Ilizarov);;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA11601-4;23;One-on-One 24-Hour Staff Supervision;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10084-4;24;Specialty Surface or Bed (i.e., air fluidized, bariatric, low air loss, or rotation bed);;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA11603-0;25;Multiple Types of IV Antibiotic Administration;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9992-4;26;IV Vaso-actors (e.g., pressors, dilators, medication for pulmonary edema);;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9990-8;27;IV Anti-coagulants;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9991-6;28;IV Chemotherapy;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA9984-1;29;Indwelling Bowel Catheter Management System;;; +52564-2;LL552-1;CARE_3_Da_Current Medical Information;LA10050-5;30;Other Major Treatments, e.g. isolation, hypothermia blanket;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9988-2;2;Insulin Drip;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10101-6;3;Total parenteral nutrition;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9943-7;4;Central Line Management;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9940-3;5;Blood Transfusion(s);;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9959-3;6;Controlled Parenteral Analgesia – Peripheral;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9958-5;7;Controlled Parenteral Analgesia – Epidural;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9994-0;8;Left Ventricular Assistive Device (LVAD);;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9957-7;9;Continuous Cardiac Monitoring;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9948-6;10;Chest Tube(s);;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10102-4;11;Trach Tube with Suctioning;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9976-7;12;High O2 Concentration Delivery System with FiO2 > 40%;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10033-1;13;Non-invasive ventilation (CPAP);;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10115-6;14;Ventilator – Weaning;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10114-9;15;Ventilator – Non-Weaning;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9975-9;16;Hemodialysis;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10059-6;17;Peritoneal Dialysis;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9971-8;18;Fistula or Other Drain Management;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10019-0;19;Negative Pressure Wound Therapy;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9954-4;20;Complex Wound Management with positioning and skin separation/traction that requires at least two persons or extensive & complex wound management by one person;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9974-2;21;Halo;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9953-6;22;Complex External Fixators (e.g., Ilizarov);;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA11601-4;23;One-on-One 24-Hour Staff Supervision;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10084-4;24;Specialty Surface or Bed (i.e., air fluidized, bariatric, low air loss, or rotation bed);;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA11603-0;25;Multiple Types of IV Antibiotic Administration;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9992-4;26;IV Vaso-actors (e.g., pressors, dilators, medication for pulmonary edema);;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9990-8;27;IV Anti-coagulants;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9991-6;28;IV Chemotherapy;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA9984-1;29;Indwelling Bowel Catheter Management System;;; +52569-1;LL552-1;CARE_3_Da_Current Medical Information;LA10050-5;30;Other Major Treatments, e.g. isolation, hypothermia blanket;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9988-2;2;Insulin Drip;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10101-6;3;Total parenteral nutrition;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9943-7;4;Central Line Management;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9940-3;5;Blood Transfusion(s);;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9959-3;6;Controlled Parenteral Analgesia – Peripheral;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9958-5;7;Controlled Parenteral Analgesia – Epidural;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9994-0;8;Left Ventricular Assistive Device (LVAD);;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9957-7;9;Continuous Cardiac Monitoring;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9948-6;10;Chest Tube(s);;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10102-4;11;Trach Tube with Suctioning;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9976-7;12;High O2 Concentration Delivery System with FiO2 > 40%;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10033-1;13;Non-invasive ventilation (CPAP);;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10115-6;14;Ventilator – Weaning;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10114-9;15;Ventilator – Non-Weaning;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9975-9;16;Hemodialysis;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10059-6;17;Peritoneal Dialysis;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9971-8;18;Fistula or Other Drain Management;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10019-0;19;Negative Pressure Wound Therapy;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9954-4;20;Complex Wound Management with positioning and skin separation/traction that requires at least two persons or extensive & complex wound management by one person;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9974-2;21;Halo;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9953-6;22;Complex External Fixators (e.g., Ilizarov);;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA11601-4;23;One-on-One 24-Hour Staff Supervision;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10084-4;24;Specialty Surface or Bed (i.e., air fluidized, bariatric, low air loss, or rotation bed);;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA11603-0;25;Multiple Types of IV Antibiotic Administration;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9992-4;26;IV Vaso-actors (e.g., pressors, dilators, medication for pulmonary edema);;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9990-8;27;IV Anti-coagulants;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9991-6;28;IV Chemotherapy;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA9984-1;29;Indwelling Bowel Catheter Management System;;; +52800-0;LL552-1;CARE_3_Da_Current Medical Information;LA10050-5;30;Other Major Treatments, e.g. isolation, hypothermia blanket;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9988-2;2;Insulin Drip;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10101-6;3;Total parenteral nutrition;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9943-7;4;Central Line Management;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9940-3;5;Blood Transfusion(s);;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9959-3;6;Controlled Parenteral Analgesia – Peripheral;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9958-5;7;Controlled Parenteral Analgesia – Epidural;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9994-0;8;Left Ventricular Assistive Device (LVAD);;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9957-7;9;Continuous Cardiac Monitoring;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9948-6;10;Chest Tube(s);;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10102-4;11;Trach Tube with Suctioning;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9976-7;12;High O2 Concentration Delivery System with FiO2 > 40%;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10033-1;13;Non-invasive ventilation (CPAP);;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10115-6;14;Ventilator – Weaning;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10114-9;15;Ventilator – Non-Weaning;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9975-9;16;Hemodialysis;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10059-6;17;Peritoneal Dialysis;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9971-8;18;Fistula or Other Drain Management;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10019-0;19;Negative Pressure Wound Therapy;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9954-4;20;Complex Wound Management with positioning and skin separation/traction that requires at least two persons or extensive & complex wound management by one person;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9974-2;21;Halo;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9953-6;22;Complex External Fixators (e.g., Ilizarov);;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA11601-4;23;One-on-One 24-Hour Staff Supervision;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10084-4;24;Specialty Surface or Bed (i.e., air fluidized, bariatric, low air loss, or rotation bed);;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA11603-0;25;Multiple Types of IV Antibiotic Administration;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9992-4;26;IV Vaso-actors (e.g., pressors, dilators, medication for pulmonary edema);;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9990-8;27;IV Anti-coagulants;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9991-6;28;IV Chemotherapy;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA9984-1;29;Indwelling Bowel Catheter Management System;;; +52802-6;LL552-1;CARE_3_Da_Current Medical Information;LA10050-5;30;Other Major Treatments, e.g. isolation, hypothermia blanket;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9988-2;2;Insulin Drip;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10101-6;3;Total parenteral nutrition;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9943-7;4;Central Line Management;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9940-3;5;Blood Transfusion(s);;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9959-3;6;Controlled Parenteral Analgesia – Peripheral;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9958-5;7;Controlled Parenteral Analgesia – Epidural;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9994-0;8;Left Ventricular Assistive Device (LVAD);;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9957-7;9;Continuous Cardiac Monitoring;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9948-6;10;Chest Tube(s);;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10102-4;11;Trach Tube with Suctioning;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9976-7;12;High O2 Concentration Delivery System with FiO2 > 40%;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10033-1;13;Non-invasive ventilation (CPAP);;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10115-6;14;Ventilator – Weaning;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10114-9;15;Ventilator – Non-Weaning;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9975-9;16;Hemodialysis;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10059-6;17;Peritoneal Dialysis;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9971-8;18;Fistula or Other Drain Management;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10019-0;19;Negative Pressure Wound Therapy;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9954-4;20;Complex Wound Management with positioning and skin separation/traction that requires at least two persons or extensive & complex wound management by one person;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9974-2;21;Halo;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9953-6;22;Complex External Fixators (e.g., Ilizarov);;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA11601-4;23;One-on-One 24-Hour Staff Supervision;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10084-4;24;Specialty Surface or Bed (i.e., air fluidized, bariatric, low air loss, or rotation bed);;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA11603-0;25;Multiple Types of IV Antibiotic Administration;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9992-4;26;IV Vaso-actors (e.g., pressors, dilators, medication for pulmonary edema);;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9990-8;27;IV Anti-coagulants;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9991-6;28;IV Chemotherapy;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA9984-1;29;Indwelling Bowel Catheter Management System;;; +52804-2;LL552-1;CARE_3_Da_Current Medical Information;LA10050-5;30;Other Major Treatments, e.g. isolation, hypothermia blanket;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9988-2;2;Insulin Drip;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10101-6;3;Total parenteral nutrition;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9943-7;4;Central Line Management;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9940-3;5;Blood Transfusion(s);;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9959-3;6;Controlled Parenteral Analgesia – Peripheral;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9958-5;7;Controlled Parenteral Analgesia – Epidural;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9994-0;8;Left Ventricular Assistive Device (LVAD);;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9957-7;9;Continuous Cardiac Monitoring;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9948-6;10;Chest Tube(s);;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10102-4;11;Trach Tube with Suctioning;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9976-7;12;High O2 Concentration Delivery System with FiO2 > 40%;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10033-1;13;Non-invasive ventilation (CPAP);;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10115-6;14;Ventilator – Weaning;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10114-9;15;Ventilator – Non-Weaning;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9975-9;16;Hemodialysis;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10059-6;17;Peritoneal Dialysis;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9971-8;18;Fistula or Other Drain Management;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10019-0;19;Negative Pressure Wound Therapy;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9954-4;20;Complex Wound Management with positioning and skin separation/traction that requires at least two persons or extensive & complex wound management by one person;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9974-2;21;Halo;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9953-6;22;Complex External Fixators (e.g., Ilizarov);;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA11601-4;23;One-on-One 24-Hour Staff Supervision;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10084-4;24;Specialty Surface or Bed (i.e., air fluidized, bariatric, low air loss, or rotation bed);;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA11603-0;25;Multiple Types of IV Antibiotic Administration;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9992-4;26;IV Vaso-actors (e.g., pressors, dilators, medication for pulmonary edema);;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9990-8;27;IV Anti-coagulants;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9991-6;28;IV Chemotherapy;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA9984-1;29;Indwelling Bowel Catheter Management System;;; +52806-7;LL552-1;CARE_3_Da_Current Medical Information;LA10050-5;30;Other Major Treatments, e.g. isolation, hypothermia blanket;;; +52571-7;LL553-9;CARE_3_f01_known allergies;LA10030-7;1;None known;;; +52571-7;LL553-9;CARE_3_f01_known allergies;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52573-3;LL723-8;CARE_3_G1_Risk of developing ulcer;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52573-3;LL723-8;CARE_3_G1_Risk of developing ulcer;LA11612-1;2;Yes, indicated by clinical judgement;;; +52573-3;LL723-8;CARE_3_G1_Risk of developing ulcer;LA11613-9;3;Yes, indicated by high risk by formal assessment (e.g., on Braden or Norton tools) or the patient has a stage I or greater ulcer, a scar over a bony prominence, or a non-removable dressing, device, or cast.;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52575-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52576-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52577-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52578-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52579-0;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52580-8;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52581-6;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52582-4;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9916-3;1;0 ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9917-1;2;1 ulcer;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9918-9;3;2 ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9920-5;4;3 ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9921-3;5;4 ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9922-1;6;5 ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9923-9;7;6 ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9924-7;8;7 ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA9925-4;9;8 or more ulcers;;; +52583-2;LL555-4;CARE_3_g02a1_Number of pressure ulcers;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52592-3;LL557-0;CARE_3_G6_Turning surfaces;LA10081-0;1;Skin for all turning surfaces is intact;;; +52592-3;LL557-0;CARE_3_G6_Turning surfaces;LA10071-1;2;Right hip not intact;;; +52592-3;LL557-0;CARE_3_G6_Turning surfaces;LA9993-2;3;Left hip not intact;;; +52592-3;LL557-0;CARE_3_G6_Turning surfaces;LA9935-3;4;Back/buttocks not intact;;; +52592-3;LL557-0;CARE_3_G6_Turning surfaces;LA10051-3;5;Other turning surface(s) not intact;;; +52595-6;LL558-8;CARE_4_b01b_Unable to perform Cognitive Status;LA10112-3;1;Unresponsive or minimally conscious;;; +52595-6;LL558-8;CARE_4_b01b_Unable to perform Cognitive Status;LA9950-2;2;Communication disorder;;; +52595-6;LL558-8;CARE_4_b01b_Unable to perform Cognitive Status;LA10023-2;3;No interpreter available;;; +52596-4;LL566-1;CARE_4_C1_Memory/Recall ability;LA9962-7;1;Current season;;; +52596-4;LL566-1;CARE_4_C1_Memory/Recall ability;LA9998-1;2;Location of own room;;; +52596-4;LL566-1;CARE_4_C1_Memory/Recall ability;LA10085-1;3;Staff names and faces;;; +52596-4;LL566-1;CARE_4_C1_Memory/Recall ability;LA10093-5;4;That he or she is in a hospital, nursing home, or home;;; +52596-4;LL566-1;CARE_4_C1_Memory/Recall ability;LA10031-5;5;None of the above are recalled;;; +52596-4;LL566-1;CARE_4_C1_Memory/Recall ability;LA10106-5;6;Unable to assess. Specify reason;;; +52602-0;LL568-7;CARE_4_f03_Feeling sad;LA6270-8;1;Never;;; +52602-0;LL568-7;CARE_4_f03_Feeling sad;LA10066-1;2;Rarely;;; +52602-0;LL568-7;CARE_4_f03_Feeling sad;LA10082-8;3;Sometimes;;; +52602-0;LL568-7;CARE_4_f03_Feeling sad;LA10044-8;4;Often;;; +52602-0;LL568-7;CARE_4_f03_Feeling sad;LA9933-8;5;Always;;; +52602-0;LL568-7;CARE_4_f03_Feeling sad;LA10107-3;6;Unable to respond;;; +52604-6;LL569-5;CARE_4_g01_Pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52604-6;LL569-5;CARE_4_g01_Pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52604-6;LL569-5;CARE_4_g01_Pain;LA10104-0;3;Unable to answer or no response;;; +52605-3;LL569-5;CARE_4_g01_Pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52605-3;LL569-5;CARE_4_g01_Pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52605-3;LL569-5;CARE_4_g01_Pain;LA10104-0;3;Unable to answer or no response;;; +52606-1;LL569-5;CARE_4_g01_Pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52606-1;LL569-5;CARE_4_g01_Pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52606-1;LL569-5;CARE_4_g01_Pain;LA10104-0;3;Unable to answer or no response;;; +52607-9;LL572-9;CARE_4_G6_Pain Observation;LA10034-9;1;Non-verbal sounds (e.g., crying, whining, gasping, moaning, or groaning);;; +52607-9;LL572-9;CARE_4_G6_Pain Observation;LA10116-4;2;Vocal complaints of pain (e.g., that hurts, ouch, stop);;; +52607-9;LL572-9;CARE_4_G6_Pain Observation;LA9968-4;3;Facial Expressions (e.g., grimaces, winces, wrinkled forehead, furrowed brow, clenched teeth or jaw);;; +52607-9;LL572-9;CARE_4_G6_Pain Observation;LA10063-8;4;Protective body movements or postures (e.g., bracing, guarding, rubbing or massaging a body part/area, clutching or holding a body part during movement);;; +52607-9;LL572-9;CARE_4_G6_Pain Observation;LA10032-3;5;None of these signs observed or documented;;; +52611-1;LL724-6;CARE_5_A3_ incontinence freq;LA9956-9;1;Continent (no documented incontinence);;; +52611-1;LL724-6;CARE_5_A3_ incontinence freq;LA10088-5;2;Stress incontinence only (bladder only);;; +52611-1;LL724-6;CARE_5_A3_ incontinence freq;LA11689-9;3;Incontinence less than daily;;; +52611-1;LL724-6;CARE_5_A3_ incontinence freq;LA11690-7;4;Incontinence daily (at least once a day);;; +52611-1;LL724-6;CARE_5_A3_ incontinence freq;LA11042-1;5;Always continent;;; +52611-1;LL724-6;CARE_5_A3_ incontinence freq;LA10024-0;6;No urine/bowel output (e.g., renal failure);;; +52611-1;LL724-6;CARE_5_A3_ incontinence freq;LA11693-1;7;Not applicable (e.g., indwelling catheter);;; +52612-9;LL724-6;CARE_5_A3_ incontinence freq;LA9956-9;1;Continent (no documented incontinence);;; +52612-9;LL724-6;CARE_5_A3_ incontinence freq;LA10088-5;2;Stress incontinence only (bladder only);;; +52612-9;LL724-6;CARE_5_A3_ incontinence freq;LA11689-9;3;Incontinence less than daily;;; +52612-9;LL724-6;CARE_5_A3_ incontinence freq;LA11690-7;4;Incontinence daily (at least once a day);;; +52612-9;LL724-6;CARE_5_A3_ incontinence freq;LA11042-1;5;Always continent;;; +52612-9;LL724-6;CARE_5_A3_ incontinence freq;LA10024-0;6;No urine/bowel output (e.g., renal failure);;; +52612-9;LL724-6;CARE_5_A3_ incontinence freq;LA11693-1;7;Not applicable (e.g., indwelling catheter);;; +52618-6;LL574-5;CARE_5_B1_Swallowing Disorder;LA9952-8;1;Complaints of difficulty or pain with swallowing;;; +52618-6;LL574-5;CARE_5_B1_Swallowing Disorder;LA9961-9;2;Coughing or choking during meals or when swallowing medications;;; +52618-6;LL574-5;CARE_5_B1_Swallowing Disorder;LA9977-5;3;Holding food in mouth/cheeks or residual food in mouth after meals;;; +52618-6;LL574-5;CARE_5_B1_Swallowing Disorder;LA10001-8;4;Loss of liquids/solids from mouth when eating or drinking;;; +52618-6;LL574-5;CARE_5_B1_Swallowing Disorder;LA10043-0;5;NPO: intake not by mouth;;; +52618-6;LL574-5;CARE_5_B1_Swallowing Disorder;LA6310-2;6;Other (specify);;; +52618-6;LL574-5;CARE_5_B1_Swallowing Disorder;LA137-2;7;None;260413007;None (qualifier value);http://snomed.info/sct +52620-2;LL575-2;CARE_5_B2_Swallowing Ability;LA10070-3;1;Regular food: solids and liquids swallowed safely without supervision and without modified food or liquid consistency.;;; +52620-2;LL575-2;CARE_5_B2_Swallowing Ability;LA10013-3;2;Modified food consistency/supervision: Patient requires modified food or liquid consistency and/or needs supervision during eating for safety.;;; +52620-2;LL575-2;CARE_5_B2_Swallowing Ability;LA10103-2;3;Tube/parenteral feeding: Tube/parenteral feeding used wholly or partially as a means of sustenance.;;; +83245-1;LL575-2;CARE_5_B2_Swallowing Ability;LA10070-3;1;Regular food: solids and liquids swallowed safely without supervision and without modified food or liquid consistency.;;; +83245-1;LL575-2;CARE_5_B2_Swallowing Ability;LA10013-3;2;Modified food consistency/supervision: Patient requires modified food or liquid consistency and/or needs supervision during eating for safety.;;; +83245-1;LL575-2;CARE_5_B2_Swallowing Ability;LA10103-2;3;Tube/parenteral feeding: Tube/parenteral feeding used wholly or partially as a means of sustenance.;;; +95946-0;LL575-2;CARE_5_B2_Swallowing Ability;LA10070-3;1;Regular food: solids and liquids swallowed safely without supervision and without modified food or liquid consistency.;;; +95946-0;LL575-2;CARE_5_B2_Swallowing Ability;LA10013-3;2;Modified food consistency/supervision: Patient requires modified food or liquid consistency and/or needs supervision during eating for safety.;;; +95946-0;LL575-2;CARE_5_B2_Swallowing Ability;LA10103-2;3;Tube/parenteral feeding: Tube/parenteral feeding used wholly or partially as a means of sustenance.;;; +52622-8;LL576-0;CARE_5_c01a_Understanding Verbal Content;LA10110-7;1;Understands: clear comprehension without cues or repetitions;;; +52622-8;LL576-0;CARE_5_c01a_Understanding Verbal Content;LA10113-1;2;Usually understands: understands most conversations, but misses some part/intent of message. Requires cues at times to understand;;; +52622-8;LL576-0;CARE_5_c01a_Understanding Verbal Content;LA10083-6;3;Sometimes understands: understands only basic conversations or simple, direct phrases. Frequently requires cues to understand;;; +52622-8;LL576-0;CARE_5_c01a_Understanding Verbal Content;LA81-5;4;Rarely/never understands;;; +52622-8;LL576-0;CARE_5_c01a_Understanding Verbal Content;LA10105-7;5;Unable to assess;;; +52622-8;LL576-0;CARE_5_c01a_Understanding Verbal Content;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52623-6;LL577-8;CARE_5_c01b_Expression of Ideas/Wants;LA9967-6;1;Expresses complex messages without difficulty and with speech that is clear and easy to understand;;; +52623-6;LL577-8;CARE_5_c01b_Expression of Ideas/Wants;LA9966-8;2;Exhibits some difficulty with expressing needs and ideas (e.g., some words or finishing thoughts) or speech is not clear;;; +52623-6;LL577-8;CARE_5_c01b_Expression of Ideas/Wants;LA9972-6;3;Frequently exhibits difficulty with expressing needs and ideas;;; +52623-6;LL577-8;CARE_5_c01b_Expression of Ideas/Wants;LA10067-9;4;Rarely/Never expresses self or speech is very difficult to understand.;;; +52623-6;LL577-8;CARE_5_c01b_Expression of Ideas/Wants;LA10105-7;5;Unable to assess;;; +52623-6;LL577-8;CARE_5_c01b_Expression of Ideas/Wants;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52624-4;LL578-6;CARE_5_c01c_Vision;LA9930-4;1;Adequate: Sees fine detail, including regular print in newspapers/books;;; +52624-4;LL578-6;CARE_5_c01c_Vision;LA10006-7;2;"Mildly to Moderately Impaired: Can identify objects; may see large print";;; +52624-4;LL578-6;CARE_5_c01c_Vision;LA10077-8;3;Severely Impaired: No vision or object identification questionable;;; +52624-4;LL578-6;CARE_5_c01c_Vision;LA10105-7;4;Unable to assess;;; +52624-4;LL578-6;CARE_5_c01c_Vision;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52625-1;LL579-4;CARE_5_c01d_Ability to Hear;LA9929-6;1;Adequate: Hears normal conversation and TV without difficulty;;; +52625-1;LL579-4;CARE_5_c01d_Ability to Hear;LA10007-5;2;Mildly to Moderately Impaired: Difficulty hearing in some environments or speaker may need to increase volume or speak distinctly;;; +52625-1;LL579-4;CARE_5_c01d_Ability to Hear;LA10076-0;3;Severely Impaired: Absence of useful hearing;;; +52625-1;LL579-4;CARE_5_c01d_Ability to Hear;LA10105-7;4;Unable to assess;;; +52625-1;LL579-4;CARE_5_c01d_Ability to Hear;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52627-7;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA9973-4;1;Fully weight-bearing: No clinician ordered restrictions;;; +52627-7;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA10042-2;2;Not fully weight-bearing: Patient has clinician ordered restrictions;;; +52628-5;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA9973-4;1;Fully weight-bearing: No clinician ordered restrictions;;; +52628-5;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA10042-2;2;Not fully weight-bearing: Patient has clinician ordered restrictions;;; +52629-3;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA9973-4;1;Fully weight-bearing: No clinician ordered restrictions;;; +52629-3;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA10042-2;2;Not fully weight-bearing: Patient has clinician ordered restrictions;;; +52630-1;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA9973-4;1;Fully weight-bearing: No clinician ordered restrictions;;; +52630-1;LL580-2;CARE_5_d01a_Weight Bearing Ability;LA10042-2;2;Not fully weight-bearing: Patient has clinician ordered restrictions;;; +52632-7;LL581-0;CARE_5_e01a_Grip Strength;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +52632-7;LL581-0;CARE_5_e01a_Grip Strength;LA10068-7;2;Reduced/Limited;;; +52632-7;LL581-0;CARE_5_e01a_Grip Strength;LA9634-2;3;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +52633-5;LL581-0;CARE_5_e01a_Grip Strength;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +52633-5;LL581-0;CARE_5_e01a_Grip Strength;LA10068-7;2;Reduced/Limited;;; +52633-5;LL581-0;CARE_5_e01a_Grip Strength;LA9634-2;3;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA10075-2;1;Severe, with evidence the patient is struggling to breathe at rest;;; +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA10005-9;2;Mild at rest (during day or night);;; +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA6445-6;3;With minimal exertion (for example, while eating, talking, or performing other ADLs) or with agitation;;; +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA10122-2;4;With moderate exertion (e.g., while dressing, using commode or bedpan, walking between rooms);;; +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA10121-4;5;When climbing stairs;;; +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA10020-8;6;Never, patient was not short of breath;;; +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA10035-6;7;Not assessed (e.g., on ventilator);;; +52635-0;LL582-8;CARE_5_f01a_Respiratory status;LA4720-4;8;Not applicable;;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA10075-2;1;Severe, with evidence the patient is struggling to breathe at rest;;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA10005-9;2;Mild at rest (during day or night);;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA6445-6;3;With minimal exertion (for example, while eating, talking, or performing other ADLs) or with agitation;;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA10122-2;4;With moderate exertion (e.g., while dressing, using commode or bedpan, walking between rooms);;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA10121-4;5;When climbing stairs;;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA10020-8;6;Never, patient was not short of breath;;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA10035-6;7;Not assessed (e.g., on ventilator);;; +52636-8;LL582-8;CARE_5_f01a_Respiratory status;LA4720-4;8;Not applicable;;; +52638-4;LL583-6;CARE_5_g01a_Mobility Endurance;LA10026-5;1;No, could not do;;; +52638-4;LL583-6;CARE_5_g01a_Mobility Endurance;LA10128-9;2;Yes, can do with rest;;; +52638-4;LL583-6;CARE_5_g01a_Mobility Endurance;LA10129-7;3;Yes, can do without rest;;; +52638-4;LL583-6;CARE_5_g01a_Mobility Endurance;LA10036-4;4;Not assessed due to medical restriction;;; +52639-2;LL584-4;CARE_5_g01b_Sitting Endurance;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52639-2;LL584-4;CARE_5_g01b_Sitting Endurance;LA10135-4;2;Yes, with support;;; +52639-2;LL584-4;CARE_5_g01b_Sitting Endurance;LA10136-2;3;Yes, without support;;; +52639-2;LL584-4;CARE_5_g01b_Sitting Endurance;LA10036-4;4;Not assessed due to medical restriction;;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA9942-9;1;Canes/crutch;;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA10117-2;2;Walker;;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA10046-3;3;Orthotics/Prosthetics;;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA10119-8;4;Wheelchair/scooter full time;;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA10120-6;5;Wheelchair/scooter part time;;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA11549-5;6;Mechanical lift;;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA6310-2;7;Other (specify);;; +52640-0;LL585-1;CARE_5_H1_Mobility devices and aids;LA10029-9;8;None apply;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52661-6;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52662-4;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52663-2;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52664-0;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52665-7;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52666-5;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52667-3;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52668-1;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52669-9;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52670-7;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52671-5;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52672-3;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52673-1;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52674-9;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52675-6;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52676-4;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52677-2;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52678-0;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52679-8;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52680-6;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52681-4;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52682-2;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52683-0;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10090-1;5;Substantial/maximal assistance – Helper does MORE THAN HALF the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA9964-3;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the task.;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10039-8;7;Not attempted due to medical condition;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10040-6;8;Not attempted due to safety concerns;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10038-0;9;Not attempted due to environmental constraints;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10092-7;10;Task attempted but not completed;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA4720-4;11;Not applicable;;; +52684-8;LL587-7;CARE_6_c01_Core Functional Status;LA10058-8;12;Patient refused;;; +52685-5;LL588-5;CARE_7_a01_Care Plan Goals;LA10025-7;1;No, but this work is in process;;; +52685-5;LL588-5;CARE_7_a01_Care Plan Goals;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52685-5;LL588-5;CARE_7_a01_Care Plan Goals;LA10109-9;3;Unclear or unknown;;; +52686-3;LL589-3;CARE_7_a02_Overall Status Prognosis;LA10098-4;1;The patient is stable with no risk for serious complications and death (beyond those typical of the patient’s age).;;; +52686-3;LL589-3;CARE_7_a02_Overall Status Prognosis;LA10099-2;2;The patient is temporarily facing high health risks but likely to return to being stable without risk for serious complications and death (beyond those typical of the patient's age).;;; +52686-3;LL589-3;CARE_7_a02_Overall Status Prognosis;LA10097-6;3;The patient is likely to remain in fragile health and have ongoing high risks of serious complications and death.;;; +52686-3;LL589-3;CARE_7_a02_Overall Status Prognosis;LA10096-8;4;The patient has serious progressive conditions that could lead to death within a year.;;; +52686-3;LL589-3;CARE_7_a02_Overall Status Prognosis;LA10100-8;5;The patient's situation is unknown or unclear to the respondent.;;; +52687-1;LL590-1;CARE_7_A3_Advance Care Directive;LA11786-3;1;The patient has designated a decision-maker (if the patient is unable to make decisions) which is documented in the medical record.;;; +52687-1;LL590-1;CARE_7_A3_Advance Care Directive;LA11787-1;2;The patient (or surrogate) has made a decision to forgo resuscitation which is documented in the medical record.;;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA10062-0;1;Private residence;;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA10048-9;2;Other community-based residential setting (e.g., assisted living residents, group home, adult foster care);;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA9999-9;3;Long-term care facility/nursing home;;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA10080-2;4;Skilled nursing facility (SNF/TCU);;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA10078-6;5;Short-stay acute hospital (IPPS);;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA10000-0;6;Long-term care hospital (LTCH);;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA9986-6;7;Inpatient rehabilitation hospital or unit (IRF);;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA10065-3;8;Psychiatric hospital or unit;;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA9969-2;9;Facility-based hospice;;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA10047-1;10;Other (e.g., shelter, jail, no known address);;; +52688-9;LL591-9;CARE_8_a03_Discharge Location;LA9965-0;11;Discharged against medical advice;;; +52689-7;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA10057-0;1;Patient does not require assistance;;; +52689-7;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA10118-0;2;Weekly or less (e.g., requires help with grocery shopping or errands, etc.);;; +52689-7;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9995-7;3;Less than daily but more often than weekly;;; +52689-7;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9989-0;4;Intermittently and predictably during the day or night;;; +52689-7;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9932-0;5;All night but not during the day;;; +52689-7;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9931-2;6;All day but not at night;;; +52689-7;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9919-7;7;24 hours per day, or standby services;;; +55754-6;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA10057-0;1;Patient does not require assistance;;; +55754-6;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA10118-0;2;Weekly or less (e.g., requires help with grocery shopping or errands, etc.);;; +55754-6;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9995-7;3;Less than daily but more often than weekly;;; +55754-6;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9989-0;4;Intermittently and predictably during the day or night;;; +55754-6;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9932-0;5;All night but not during the day;;; +55754-6;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9931-2;6;All day but not at night;;; +55754-6;LL592-7;CARE_8_a04_Assistance at Discharge freq;LA9919-7;7;24 hours per day, or standby services;;; +52691-3;LL593-5;CARE_8_a06_Willing Caregiver;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52691-3;LL593-5;CARE_8_a06_Willing Caregiver;LA10130-5;2;Yes, confirmed by caregiver;;; +52691-3;LL593-5;CARE_8_a06_Willing Caregiver;LA10131-3;3;Yes, confirmed only by patient;;; +52691-3;LL593-5;CARE_8_a06_Willing Caregiver;LA10108-1;4;"Unclear from patient; no confirmation from caregiver";;; +52692-1;LL594-3;CARE_8_A7_Relationship to caregiver;LA6382-1;1;Spouse or significant other;;; +52692-1;LL594-3;CARE_8_A7_Relationship to caregiver;LA9949-4;2;Child;;; +52692-1;LL594-3;CARE_8_A7_Relationship to caregiver;LA10052-1;3;Other unpaid family member or friend;;; +52692-1;LL594-3;CARE_8_A7_Relationship to caregiver;LA6320-1;4;Paid help;;; +52694-7;LL595-0;CARE_8_c01a_support needs;LA9945-2;1;CG able;;; +52694-7;LL595-0;CARE_8_c01a_support needs;LA9947-8;2;CG will need training and/or other supportive services;;; +52694-7;LL595-0;CARE_8_c01a_support needs;LA9946-0;3;CG not likely to be able;;; +52694-7;LL595-0;CARE_8_c01a_support needs;LA9944-5;4;CG ability unclear;;; +52695-4;LL595-0;CARE_8_c01a_support needs;LA9945-2;1;CG able;;; +52695-4;LL595-0;CARE_8_c01a_support needs;LA9947-8;2;CG will need training and/or other supportive services;;; +52695-4;LL595-0;CARE_8_c01a_support needs;LA9946-0;3;CG not likely to be able;;; +52695-4;LL595-0;CARE_8_c01a_support needs;LA9944-5;4;CG ability unclear;;; +52696-2;LL595-0;CARE_8_c01a_support needs;LA9945-2;1;CG able;;; +52696-2;LL595-0;CARE_8_c01a_support needs;LA9947-8;2;CG will need training and/or other supportive services;;; +52696-2;LL595-0;CARE_8_c01a_support needs;LA9946-0;3;CG not likely to be able;;; +52696-2;LL595-0;CARE_8_c01a_support needs;LA9944-5;4;CG ability unclear;;; +52697-0;LL595-0;CARE_8_c01a_support needs;LA9945-2;1;CG able;;; +52697-0;LL595-0;CARE_8_c01a_support needs;LA9947-8;2;CG will need training and/or other supportive services;;; +52697-0;LL595-0;CARE_8_c01a_support needs;LA9946-0;3;CG not likely to be able;;; +52697-0;LL595-0;CARE_8_c01a_support needs;LA9944-5;4;CG ability unclear;;; +52698-8;LL595-0;CARE_8_c01a_support needs;LA9945-2;1;CG able;;; +52698-8;LL595-0;CARE_8_c01a_support needs;LA9947-8;2;CG will need training and/or other supportive services;;; +52698-8;LL595-0;CARE_8_c01a_support needs;LA9946-0;3;CG not likely to be able;;; +52698-8;LL595-0;CARE_8_c01a_support needs;LA9944-5;4;CG ability unclear;;; +52699-6;LL595-0;CARE_8_c01a_support needs;LA9945-2;1;CG able;;; +52699-6;LL595-0;CARE_8_c01a_support needs;LA9947-8;2;CG will need training and/or other supportive services;;; +52699-6;LL595-0;CARE_8_c01a_support needs;LA9946-0;3;CG not likely to be able;;; +52699-6;LL595-0;CARE_8_c01a_support needs;LA9944-5;4;CG ability unclear;;; +52700-2;LL595-0;CARE_8_c01a_support needs;LA9945-2;1;CG able;;; +52700-2;LL595-0;CARE_8_c01a_support needs;LA9947-8;2;CG will need training and/or other supportive services;;; +52700-2;LL595-0;CARE_8_c01a_support needs;LA9946-0;3;CG not likely to be able;;; +52700-2;LL595-0;CARE_8_c01a_support needs;LA9944-5;4;CG ability unclear;;; +52702-8;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52702-8;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52702-8;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52702-8;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52703-6;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52703-6;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52703-6;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52703-6;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52704-4;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52704-4;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52704-4;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52704-4;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52705-1;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52705-1;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52705-1;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52705-1;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52706-9;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52706-9;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52706-9;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52706-9;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52707-7;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52707-7;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52707-7;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52707-7;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52708-5;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52708-5;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52708-5;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52708-5;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52709-3;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52709-3;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52709-3;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52709-3;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52710-1;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52710-1;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52710-1;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52710-1;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52711-9;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52711-9;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52711-9;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52711-9;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52712-7;LL596-8;CARE_8_d01_Discharge Care Options;LA9955-1;1;Considered Appropriate by the Provider;;; +52712-7;LL596-8;CARE_8_d01_Discharge Care Options;LA11804-4;2;No Bed/Services Available;;; +52712-7;LL596-8;CARE_8_d01_Discharge Care Options;LA10069-5;3;Refused by Patient/Family;;; +52712-7;LL596-8;CARE_8_d01_Discharge Care Options;LA10041-4;4;Not Covered by Insurance;;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA9978-3;1;Home Health Care (HHA);;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA10080-2;2;Skilled nursing facility (SNF/TCU);;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA9986-6;3;Inpatient rehabilitation hospital or unit (IRF);;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA10000-0;4;Long-term care hospital (LTCH);;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA10065-3;5;Psychiatric hospital or unit;;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA10053-9;6;Outpatient Services;;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA10078-6;7;Short-stay acute hospital (IPPS);;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA6216-1;8;Hospice;;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA11502-4;9;Long-term nursing facility;;; +52714-3;LL729-5;CARE_8_D3_Type of discharge provider;LA6310-2;10;Other (specify);;; +52717-6;LL598-4;CARE_8_e08_Reason for Discharge Delay;LA10021-6;1;No bed available;;; +52717-6;LL598-4;CARE_8_e08_Reason for Discharge Delay;LA10072-9;2;Services, equipment or medications not available (e.g., home health care, durable medical equipment, IV medications);;; +52717-6;LL598-4;CARE_8_e08_Reason for Discharge Delay;LA9970-0;3;Family/support (e.g., family could not pick patient up);;; +52717-6;LL598-4;CARE_8_e08_Reason for Discharge Delay;LA10004-2;4;Medical (patient condition changed);;; +52717-6;LL598-4;CARE_8_e08_Reason for Discharge Delay;LA6310-2;5;Other (specify);;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA11501-6;1;Community residential setting (e.g., private home, assisted living, group home, adult foster care);;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA11502-4;2;Long-term nursing facility;;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA10080-2;3;Skilled nursing facility (SNF/TCU);;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA11504-0;4;Hospital emergency department;;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA10078-6;5;Short-stay acute hospital (IPPS);;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA10000-0;6;Long-term care hospital (LTCH);;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA9986-6;7;Inpatient rehabilitation hospital or unit (IRF);;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA10065-3;8;Psychiatric hospital or unit;;; +52722-6;LL730-3;CARE_1_A1-2_Admitted from;LA6310-2;9;Other (specify);;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA10080-2;1;Skilled nursing facility (SNF/TCU);;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA10078-6;2;Short-stay acute hospital (IPPS);;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA10000-0;3;Long-term care hospital (LTCH);;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA9986-6;4;Inpatient rehabilitation hospital or unit (IRF);;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA10065-3;5;Psychiatric hospital or unit;;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA9978-3;6;Home Health Care (HHA);;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA6216-1;7;Hospice;;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA10053-9;8;Outpatient Services;;; +52725-9;LL722-0;CARE_1_A3_Other medical services;LA137-2;9;None;260413007;None (qualifier value);http://snomed.info/sct +52726-7;LL545-5;CARE_2_b01_Prior residence type;LA10062-0;1;Private residence;;; +52726-7;LL545-5;CARE_2_b01_Prior residence type;LA9951-0;2;Community based residence (e.g., assisted living residence, group home, adult foster care);;; +52726-7;LL545-5;CARE_2_b01_Prior residence type;LA11521-4;3;Long-term care facility (e.g., nursing home);;; +52726-7;LL545-5;CARE_2_b01_Prior residence type;LA10047-1;4;Other (e.g., shelter, jail, no known address);;; +52726-7;LL545-5;CARE_2_b01_Prior residence type;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +52730-9;LL556-2;CARE_3_g04_Stage 3/4 unhealed ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +52730-9;LL556-2;CARE_3_g04_Stage 3/4 unhealed ulcers;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +52730-9;LL556-2;CARE_3_g04_Stage 3/4 unhealed ulcers;LA10105-7;3;Unable to assess;;; +52731-7;LL687-5;MDSv3_C0200;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +52731-7;LL687-5;MDSv3_C0200;LA6306-0;2;One;;; +52731-7;LL687-5;MDSv3_C0200;LA6404-3;3;Two;;; +52731-7;LL687-5;MDSv3_C0200;LA6395-3;4;Three;;; +54606-9;LL687-5;MDSv3_C0200;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +54606-9;LL687-5;MDSv3_C0200;LA6306-0;2;One;;; +54606-9;LL687-5;MDSv3_C0200;LA6404-3;3;Two;;; +54606-9;LL687-5;MDSv3_C0200;LA6395-3;4;Three;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA9960-1;1;Correct;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA10008-3;2;Missed by 1 year;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA10009-1;3;Missed by 2 to 5 years;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA10012-5;4;Missed by more than 5 years or no answer;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA9960-1;1;Correct;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA10008-3;2;Missed by 1 year;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA10009-1;3;Missed by 2 to 5 years;;; +52732-5;LL560-4;CARE_4_b03b1_Year answer accuracy;LA10012-5;4;Missed by more than 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52732-5;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +52732-5;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +52732-5;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +52732-5;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +54607-7;LL643-8;MDSv3_C0300A;LA10965-4;1;Missed by > 5 years or no answer;;; +54607-7;LL643-8;MDSv3_C0300A;LA10966-2;2;Missed by 2-5 years;;; +54607-7;LL643-8;MDSv3_C0300A;LA10008-3;3;Missed by 1 year;;; +54607-7;LL643-8;MDSv3_C0300A;LA9960-1;4;Correct;;; +52733-3;LL644-6;MDSv3_C0300B;LA10969-6;1;Missed by > 1 month or no answer;;; +52733-3;LL644-6;MDSv3_C0300B;LA10010-9;2;Missed by 6 days to 1 month;;; +52733-3;LL644-6;MDSv3_C0300B;LA9927-0;3;Accurate within 5 days;;; +54608-5;LL644-6;MDSv3_C0300B;LA10969-6;1;Missed by > 1 month or no answer;;; +54608-5;LL644-6;MDSv3_C0300B;LA10010-9;2;Missed by 6 days to 1 month;;; +54608-5;LL644-6;MDSv3_C0300B;LA9927-0;3;Accurate within 5 days;;; +52734-1;LL562-0;CARE_4_b03b3_Week day question;LA9926-2;1;Accurate;;; +52734-1;LL562-0;CARE_4_b03b3_Week day question;LA9981-7;2;Incorrect or no answer;;; +52735-8;LL646-1;MDSv3_C0400A;LA10974-6;1;No - could not recall;;; +52735-8;LL646-1;MDSv3_C0400A;LA10126-3;2;"Yes, after cueing (""something to wear"")";;; +52735-8;LL646-1;MDSv3_C0400A;LA10134-7;3;Yes, no cue required;;; +54611-9;LL646-1;MDSv3_C0400A;LA10974-6;1;No - could not recall;;; +54611-9;LL646-1;MDSv3_C0400A;LA10126-3;2;"Yes, after cueing (""something to wear"")";;; +54611-9;LL646-1;MDSv3_C0400A;LA10134-7;3;Yes, no cue required;;; +52736-6;LL647-9;MDSv3_C0400B;LA10974-6;1;No - could not recall;;; +52736-6;LL647-9;MDSv3_C0400B;LA10978-7;2;"Yes, after cueing (""a color"")";;; +52736-6;LL647-9;MDSv3_C0400B;LA10134-7;3;Yes, no cue required;;; +54612-7;LL647-9;MDSv3_C0400B;LA10974-6;1;No - could not recall;;; +54612-7;LL647-9;MDSv3_C0400B;LA10978-7;2;"Yes, after cueing (""a color"")";;; +54612-7;LL647-9;MDSv3_C0400B;LA10134-7;3;Yes, no cue required;;; +52737-4;LL648-7;MDSv3_C0400C;LA10974-6;1;No - could not recall;;; +52737-4;LL648-7;MDSv3_C0400C;LA10125-5;2;"Yes, after cueing (""a piece of furniture"")";;; +52737-4;LL648-7;MDSv3_C0400C;LA10134-7;3;Yes, no cue required;;; +54613-5;LL648-7;MDSv3_C0400C;LA10974-6;1;No - could not recall;;; +54613-5;LL648-7;MDSv3_C0400C;LA10125-5;2;"Yes, after cueing (""a piece of furniture"")";;; +54613-5;LL648-7;MDSv3_C0400C;LA10134-7;3;Yes, no cue required;;; +52738-2;LL567-9;CARE_4_d01_Confusion Assessment;LA9938-7;1;Behavior is not present.;;; +52738-2;LL567-9;CARE_4_d01_Confusion Assessment;LA9937-9;2;Behavior continuously present does not fluctuate.;;; +52738-2;LL567-9;CARE_4_d01_Confusion Assessment;LA9939-5;3;Behavior present, fluctuates (e.g., comes and goes, changes in severity).;;; +52739-0;LL567-9;CARE_4_d01_Confusion Assessment;LA9938-7;1;Behavior is not present.;;; +52739-0;LL567-9;CARE_4_d01_Confusion Assessment;LA9937-9;2;Behavior continuously present does not fluctuate.;;; +52739-0;LL567-9;CARE_4_d01_Confusion Assessment;LA9939-5;3;Behavior present, fluctuates (e.g., comes and goes, changes in severity).;;; +52740-8;LL567-9;CARE_4_d01_Confusion Assessment;LA9938-7;1;Behavior is not present.;;; +52740-8;LL567-9;CARE_4_d01_Confusion Assessment;LA9937-9;2;Behavior continuously present does not fluctuate.;;; +52740-8;LL567-9;CARE_4_d01_Confusion Assessment;LA9939-5;3;Behavior present, fluctuates (e.g., comes and goes, changes in severity).;;; +52741-6;LL567-9;CARE_4_d01_Confusion Assessment;LA9938-7;1;Behavior is not present.;;; +52741-6;LL567-9;CARE_4_d01_Confusion Assessment;LA9937-9;2;Behavior continuously present does not fluctuate.;;; +52741-6;LL567-9;CARE_4_d01_Confusion Assessment;LA9939-5;3;Behavior present, fluctuates (e.g., comes and goes, changes in severity).;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA6111-4;1;0;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA6112-2;2;1;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA6113-0;3;2;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA6114-8;4;3;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA6115-5;5;4;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA10137-0;6;5;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA10138-8;7;6;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA10139-6;8;7;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA10140-4;9;8;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA10141-2;10;9;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA13942-0;11;10;;; +52742-4;LL571-1;CARE_4_g03_Pain severity;LA10056-2;12;Patient does not answer or is unable to respond;;; +52797-8;LL1892-0;ICD-9_ICD-10;;0;;;; +52797-8;LL1892-0;ICD-9_ICD-10;;0;;;; +52797-8;LL1892-0;ICD-9_ICD-10;;0;;;; +67492-9;LL1892-0;ICD-9_ICD-10;;0;;;; +67774-0;LL1892-0;ICD-9_ICD-10;;0;;;; +67776-5;LL1892-0;ICD-9_ICD-10;;0;;;; +67873-0;LL1892-0;ICD-9_ICD-10;;0;;;; +67876-3;LL1892-0;ICD-9_ICD-10;;0;;;; +68343-3;LL1892-0;ICD-9_ICD-10;;0;;;; +68345-8;LL1892-0;ICD-9_ICD-10;;0;;;; +68346-6;LL1892-0;ICD-9_ICD-10;;0;;;; +69542-9;LL1892-0;ICD-9_ICD-10;;0;;;; +69543-7;LL1892-0;ICD-9_ICD-10;;0;;;; +69544-5;LL1892-0;ICD-9_ICD-10;;0;;;; +74292-4;LL1892-0;ICD-9_ICD-10;;0;;;; +75618-9;LL1892-0;ICD-9_ICD-10;;0;;;; +75618-9;LL1892-0;ICD-9_ICD-10;;0;;;; +75618-9;LL1892-0;ICD-9_ICD-10;;0;;;; +75618-9;LL1892-0;ICD-9_ICD-10;;0;;;; +75618-9;LL1892-0;ICD-9_ICD-10;;0;;;; +76540-4;LL1892-0;ICD-9_ICD-10;;0;;;; +76541-2;LL1892-0;ICD-9_ICD-10;;0;;;; +80356-9;LL1892-0;ICD-9_ICD-10;;0;;;; +80357-7;LL1892-0;ICD-9_ICD-10;;0;;;; +80358-5;LL1892-0;ICD-9_ICD-10;;0;;;; +80359-3;LL1892-0;ICD-9_ICD-10;;0;;;; +85418-2;LL1892-0;ICD-9_ICD-10;;0;;;; +85419-0;LL1892-0;ICD-9_ICD-10;;0;;;; +52797-8;LL4547-7;ICD any version;;0;;;; +85914-0;LL4547-7;ICD any version;;0;;;; +86255-7;LL4547-7;ICD any version;;0;;;; +89498-0;LL4547-7;ICD any version;;0;;;; +52809-1;LL3146-9;Dosage forms;LA16247-1;1;Pill;;; +52809-1;LL3146-9;Dosage forms;LA21908-1;2;Tablet;;; +52809-1;LL3146-9;Dosage forms;LA21907-3;3;Capsule;;; +52809-1;LL3146-9;Dosage forms;LA21911-5;4;Extended-release capsule;;; +52809-1;LL3146-9;Dosage forms;LA21912-3;5;Granules;;; +52809-1;LL3146-9;Dosage forms;LA21913-1;6;Suspension;;; +52809-1;LL3146-9;Dosage forms;LA21914-9;7;Elixir;;; +52809-1;LL3146-9;Dosage forms;LA21915-6;8;Cream;;; +52809-1;LL3146-9;Dosage forms;LA21916-4;9;Ointment;;; +52809-1;LL3146-9;Dosage forms;LA21917-2;10;Injectable solution;;; +52809-1;LL3146-9;Dosage forms;LA21918-0;11;Patch;;; +52809-1;LL3146-9;Dosage forms;LA21919-8;12;Spray;;; +74055-5;LL3146-9;Dosage forms;LA16247-1;1;Pill;;; +74055-5;LL3146-9;Dosage forms;LA21908-1;2;Tablet;;; +74055-5;LL3146-9;Dosage forms;LA21907-3;3;Capsule;;; +74055-5;LL3146-9;Dosage forms;LA21911-5;4;Extended-release capsule;;; +74055-5;LL3146-9;Dosage forms;LA21912-3;5;Granules;;; +74055-5;LL3146-9;Dosage forms;LA21913-1;6;Suspension;;; +74055-5;LL3146-9;Dosage forms;LA21914-9;7;Elixir;;; +74055-5;LL3146-9;Dosage forms;LA21915-6;8;Cream;;; +74055-5;LL3146-9;Dosage forms;LA21916-4;9;Ointment;;; +74055-5;LL3146-9;Dosage forms;LA21917-2;10;Injectable solution;;; +74055-5;LL3146-9;Dosage forms;LA21918-0;11;Patch;;; +74055-5;LL3146-9;Dosage forms;LA21919-8;12;Spray;;; +52829-9;LL5063-4;CMS place of service;;0;;;; +52837-2;LL599-2;NDNQI list;LA10142-0;1;Adult Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10143-8;2;Adult Burn Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10144-6;3;Adult Cardiothoracic Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10145-3;4;Adult Coronary Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10146-1;5;Adult Medical Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10147-9;6;Adult Neurology Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10148-7;7;Adult Pulmonary Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10149-5;8;Adult Surgical Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10150-3;9;Adult Trauma Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10151-1;10;Adult Step-down Unit;;; +52837-2;LL599-2;NDNQI list;LA10152-9;11;Adult Med-Surg Step-down Unit;;; +52837-2;LL599-2;NDNQI list;LA10153-7;12;Adult Medical Step-down Unit;;; +52837-2;LL599-2;NDNQI list;LA10154-5;13;Adult Surgical Step-down Unit;;; +52837-2;LL599-2;NDNQI list;LA10155-2;14;Adult Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10156-0;15;Adult Bone Marrow Transplant Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10157-8;16;Adult Cardiac Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10158-6;17;Adult Gastrointestinal Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10159-4;18;Adult Infectious Disease Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10160-2;19;Adult Neurology Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10161-0;20;Adult Oncology Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10162-8;21;Adult Renal Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10163-6;22;Adult Respiratory Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10164-4;23;Adult Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10165-1;24;Adult Bariatric Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10166-9;25;Adult Cardiothoracic Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10167-7;26;Adult Gynecology Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10168-5;27;Adult Neurosurgery Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10169-3;28;Adult Orthopedic Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10170-1;29;Adult Plastics Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10171-9;30;Adult Transplant Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10172-7;31;Adult Trauma Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10173-5;32;Adult Med-Surg Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10174-3;33;Adult Cardiac Med-Surg Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10175-0;34;Adult Neuro/Neurosurgery Med-Surg Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10176-8;35;Adult Oncology Med-Surg Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10177-6;36;Adult Obstetrics Unit;;; +52837-2;LL599-2;NDNQI list;LA10178-4;37;Adult Obstetrics Ante-Partum Unit;;; +52837-2;LL599-2;NDNQI list;LA10179-2;38;Adult Obstetrics Labor & Delivery Unit;;; +52837-2;LL599-2;NDNQI list;LA10180-0;39;Adult Obstetrics Mother/Baby Combined Unit;;; +52837-2;LL599-2;NDNQI list;LA10181-8;40;Adult Obstetrics Post-Partum Unit;;; +52837-2;LL599-2;NDNQI list;LA10182-6;41;Other Adult Skilled Nursing Unit;;; +52837-2;LL599-2;NDNQI list;LA10183-4;42;Other Adult Mixed Acuity Unit;;; +52837-2;LL599-2;NDNQI list;LA10184-2;43;Neonatal Level I Neonate-Continuing Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10185-9;44;Neonatal Level II Neonate-Intermediate Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10186-7;45;Neonatal Level III/IV Neonatal Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10187-5;46;Neonatal Well Baby Nursery Unit;;; +52837-2;LL599-2;NDNQI list;LA10188-3;47;Neonatal Mixed Acuity Unit;;; +52837-2;LL599-2;NDNQI list;LA10189-1;48;Adult Rehabilitation Unit;;; +52837-2;LL599-2;NDNQI list;LA10190-9;49;Adult Brain Injury/Spinal Cord Injury Rehabilitation Unit;;; +52837-2;LL599-2;NDNQI list;LA10191-7;50;Adult Cardiopulmonary Rehabilitation Unit;;; +52837-2;LL599-2;NDNQI list;LA10192-5;51;Adult Neurology/Stroke Rehabilitation Unit;;; +52837-2;LL599-2;NDNQI list;LA10193-3;52;Adult Orthopedic/Amputee Rehabilitation Unit;;; +52837-2;LL599-2;NDNQI list;LA10194-1;53;Pediatric Rehabilitation Unit;;; +52837-2;LL599-2;NDNQI list;LA10195-8;54;Mixed Acuity Rehabilitation Unit;;; +52837-2;LL599-2;NDNQI list;LA10196-6;55;Pediatric Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10197-4;56;Pediatric Burn Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10198-2;57;Pediatric Cardiothoracic Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10199-0;58;Pediatric Coronary Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10200-6;59;Pediatric Medical Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10201-4;60;Pediatric Neurology Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10202-2;61;Pediatric Pulmonary Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10203-0;62;Pediatric Surgical Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10204-8;63;Pediatric Trauma Critical Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10205-5;64;Pediatric Step Down Unit;;; +52837-2;LL599-2;NDNQI list;LA10206-3;65;Pediatric Med-Surg Step-down Unit;;; +52837-2;LL599-2;NDNQI list;LA10207-1;66;Pediatric Medical Step-down Unit;;; +52837-2;LL599-2;NDNQI list;LA10208-9;67;Pediatric Surgical Step-down Unit;;; +52837-2;LL599-2;NDNQI list;LA10209-7;68;Pediatric Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10210-5;69;Pediatric Bone Marrow Transplant Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10211-3;70;Pediatric Cardiac Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10212-1;71;Pediatric Gastrointestinal Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10213-9;72;Pediatric Infectious Disease Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10214-7;73;Pediatric Neurology Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10215-4;74;Pediatric Oncology Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10216-2;75;Pediatric Renal Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10217-0;76;Pediatric Respiratory Medical Unit;;; +52837-2;LL599-2;NDNQI list;LA10218-8;77;Pediatric Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10219-6;78;Pediatric Bariatric Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10220-4;79;Pediatric Cardiothoracic Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10221-2;80;Pediatric Gynecology Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10222-0;81;Pediatric Neurosurgery Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10223-8;82;Pediatric Orthopedic Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10224-6;83;Pediatric Plastics Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10225-3;84;Pediatric Transplant Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10226-1;85;Pediatric Trauma Surgical Unit;;; +52837-2;LL599-2;NDNQI list;LA10227-9;86;Pediatric Med-Surg Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10228-7;87;Pediatric Cardiac Med-Surg Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10229-5;88;Pediatric Neurology/Neurosurgery Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10230-3;89;Pediatric Oncology Med-Surg Combination Unit;;; +52837-2;LL599-2;NDNQI list;LA10231-1;90;Pediatric Mixed Acuity Unit;;; +52837-2;LL599-2;NDNQI list;LA10232-9;91;Adult Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10233-7;92;Adult General Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10234-5;93;Adult Intensive Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10235-2;94;Adult Mixed Acuity Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10236-0;95;Adolescent Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10237-8;96;Adolescent General Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10238-6;97;Adolescent Intensive Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10239-4;98;Adolescent Mixed Acuity Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10240-2;99;Child Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10241-0;100;Child General Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10242-8;101;Child Intensive Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10243-6;102;Child Mixed Acuity Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10244-4;103;Child-Adolescent Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10245-1;104;Child-Adolescent General Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10246-9;105;Child-Adolescent Intensive Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10247-7;106;Child-Adolescent Mixed Acuity Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10248-5;107;Geripsych Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10249-3;108;Geripsych General Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10250-1;109;Geripsych Intensive Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10251-9;110;Geripsych Mixed Acuity Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10252-7;111;Behavioral Health Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10253-5;112;Behavioral Health General Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10254-3;113;Behavioral Health Intensive Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10255-0;114;Behavioral Health Mixed Acuity Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10256-8;115;Specialty Psychiatric Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10257-6;116;Specialty Psychiatric General Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10258-4;117;Specialty Psychiatric Intensive Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10259-2;118;Specialty Psychiatric Mixed Acuity Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10260-0;119;Multiple Psychiatric Unit Types Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10261-8;120;Multiple Psychiatric Unit Types General Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10262-6;121;Multiple Psychiatric Unit Types Intensive Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10263-4;122;Multiple Psychiatric Unit Types Mixed Acuity Inpatient Unit;;; +52837-2;LL599-2;NDNQI list;LA10264-2;123;Other Psychiatric Inpatient or Outpatient Units;;; +52837-2;LL599-2;NDNQI list;LA10265-9;124;Psychiatric Day Hospital;;; +52837-2;LL599-2;NDNQI list;LA10266-7;125;Outpatient Psychiatric Clinics;;; +52837-2;LL599-2;NDNQI list;LA10267-5;126;Psychiatric Residential Unit (no 24/7 nurse);;; +52837-2;LL599-2;NDNQI list;LA10268-3;127;Emergency Department;;; +52837-2;LL599-2;NDNQI list;LA10269-1;128;General Emergency Department;;; +52837-2;LL599-2;NDNQI list;LA10270-9;129;Obstetrics Emergency Department;;; +52837-2;LL599-2;NDNQI list;LA10271-7;130;Pediatric Emergency Department;;; +52837-2;LL599-2;NDNQI list;LA10272-5;131;Urgent Care Emergency Department;;; +52837-2;LL599-2;NDNQI list;LA10273-3;132;Peri-operative Unit;;; +52837-2;LL599-2;NDNQI list;LA10274-1;133;Post Anesthesia Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10275-8;134;Pre-Op Holding;;; +52837-2;LL599-2;NDNQI list;LA7222-8;135;Operating room;;; +52837-2;LL599-2;NDNQI list;LA10277-4;136;Same Day/Ambulatory Surgery;;; +52837-2;LL599-2;NDNQI list;LA10278-2;137;General Ambulatory Care;;; +52837-2;LL599-2;NDNQI list;LA10279-0;138;Cardiac Rehabilitation Clinic;;; +52837-2;LL599-2;NDNQI list;LA10280-8;139;Outpatient Clinics;;; +52837-2;LL599-2;NDNQI list;LA10281-6;140;Outpatient Rehabilitation Clinic;;; +52837-2;LL599-2;NDNQI list;LA10282-4;141;Radiation Therapy Clinic;;; +52837-2;LL599-2;NDNQI list;LA10283-2;142;Wound Care Clinic;;; +52837-2;LL599-2;NDNQI list;LA10284-0;143;Interventional Unit;;; +52837-2;LL599-2;NDNQI list;LA10285-7;144;Bronchoscopy Unit;;; +52837-2;LL599-2;NDNQI list;LA10286-5;145;Catheterization Lab Unit;;; +52837-2;LL599-2;NDNQI list;LA10287-3;146;Dialysis unit;;; +52837-2;LL599-2;NDNQI list;LA10288-1;147;Gastrointestinal Clinic;;; +52837-2;LL599-2;NDNQI list;LA10289-9;148;Infusion Unit;;; +52837-2;LL599-2;NDNQI list;LA10290-7;149;Pain Management Unit;;; +52837-2;LL599-2;NDNQI list;LA10291-5;150;Radiology Unit;;; +52837-2;LL599-2;NDNQI list;LA10292-3;151;Short Stay Unit;;; +52837-2;LL599-2;NDNQI list;LA10293-1;152;Other Unit or Clinic;;; +52837-2;LL599-2;NDNQI list;LA10294-9;153;Home Health Clinic;;; +52837-2;LL599-2;NDNQI list;LA10295-6;154;Hospice/Palliative Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10296-4;155;Long Term Care Unit;;; +52837-2;LL599-2;NDNQI list;LA10297-2;156;Patient Preparation/Education Clinic;;; +52837-2;LL599-2;NDNQI list;LA10298-0;157;Work Group Clinic;;; +52837-2;LL599-2;NDNQI list;LA10299-8;158;Public Health Clinic;;; +52837-2;LL599-2;NDNQI list;LA10300-4;159;School Health Clinic;;; +52837-2;LL599-2;NDNQI list;LA10301-2;160;Aerospace Clinic;;; +52837-2;LL599-2;NDNQI list;LA10302-0;161;Continence Care Clinic;;; +52837-2;LL599-2;NDNQI list;LA10303-8;162;Flight Clinic;;; +52837-2;LL599-2;NDNQI list;LA10304-6;163;Genetics/Genetics Counseling Clinic;;; +52837-2;LL599-2;NDNQI list;LA10305-3;164;Health Promotion Clinic;;; +52837-2;LL599-2;NDNQI list;LA10306-1;165;Infection Control Clinic;;; +52837-2;LL599-2;NDNQI list;LA10307-9;166;Nutrition Support Clinic;;; +52837-2;LL599-2;NDNQI list;LA10308-7;167;Occupational Health Clinic;;; +52837-2;LL599-2;NDNQI list;LA10309-5;168;Ophthalmic Clinic;;; +52837-2;LL599-2;NDNQI list;LA10310-3;169;Ostomy Care Clinic;;; +52837-2;LL599-2;NDNQI list;LA10311-1;170;Reproductive Endocrinology/Infertility Clinic;;; +52837-2;LL599-2;NDNQI list;LA10312-9;171;Women's Health Care, Ambulatory Clinic;;; +53037-8;LL4034-6;ACMG_Clinical significance of genetic variation;LA6668-3;1;Pathogenic;;; +53037-8;LL4034-6;ACMG_Clinical significance of genetic variation;LA26332-9;2;Likely pathogenic;;; +53037-8;LL4034-6;ACMG_Clinical significance of genetic variation;LA26333-7;3;Uncertain significance;;; +53037-8;LL4034-6;ACMG_Clinical significance of genetic variation;LA26334-5;4;Likely benign;;; +53037-8;LL4034-6;ACMG_Clinical significance of genetic variation;LA6675-8;5;Benign;;; +53039-4;LL604-0;MG_10;LA10314-5;1;Carrier;;; +53039-4;LL604-0;MG_10;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +53039-4;LL604-0;MG_10;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +53039-4;LL604-0;MG_10;LA9664-9;4;Failure;;; +53719-1;LL612-3;CR_1755;LA10328-5;1;Patient still alive;;; +53719-1;LL612-3;CR_1755;LA10329-3;2;Patient deceased, unknown date of death;;; +53720-9;LL613-1;CR_193;LA4457-3;1;White;;; +53720-9;LL613-1;CR_193;LA4267-6;2;Black;;; +53720-9;LL613-1;CR_193;LA10326-9;3;American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere);;; +53720-9;LL613-1;CR_193;LA4168-6;4;Chinese;;; +53720-9;LL613-1;CR_193;LA4595-0;5;Japanese;;; +53720-9;LL613-1;CR_193;LA3969-8;6;Filipino;;; +53720-9;LL613-1;CR_193;LA3986-2;7;Hawaiian;;; +53720-9;LL613-1;CR_193;LA4603-2;8;Korean;;; +53720-9;LL613-1;CR_193;LA4223-9;9;Asian Indian, Pakistani;;; +53720-9;LL613-1;CR_193;LA4443-3;10;Vietnamese;;; +53720-9;LL613-1;CR_193;LA4586-9;11;Laotian;;; +53720-9;LL613-1;CR_193;LA4021-7;12;Hmong;;; +53720-9;LL613-1;CR_193;LA4592-7;13;Kampuchean;;; +53720-9;LL613-1;CR_193;LA4467-2;14;Thai;;; +53720-9;LL613-1;CR_193;LA4609-9;15;Micronesian, NOS;;; +53720-9;LL613-1;CR_193;LA4177-7;16;Chamorran;;; +53720-9;LL613-1;CR_193;LA3984-7;17;Guamanian, NOS;;; +53720-9;LL613-1;CR_193;LA4663-6;18;Polynesian, NOS;;; +53720-9;LL613-1;CR_193;LA4486-2;19;Tahitian;;; +53720-9;LL613-1;CR_193;LA4300-5;20;Samoan;;; +53720-9;LL613-1;CR_193;LA4513-3;21;Tongan;;; +53720-9;LL613-1;CR_193;LA4612-3;22;Melanesian, NOS;;; +53720-9;LL613-1;CR_193;LA3970-6;23;Fiji Islander;;; +53720-9;LL613-1;CR_193;LA4559-6;24;New Guinean;;; +53720-9;LL613-1;CR_193;LA10327-7;25;Other Asian, including Asian , NOS and Oriental, NOS;;; +53720-9;LL613-1;CR_193;LA4658-6;26;Pacific islander, NOS;;; +53720-9;LL613-1;CR_193;LA46-8;27;Other;;; +53720-9;LL613-1;CR_193;LA4489-6;28;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +53720-9;LL613-1;CR_193;LA10330-1;29;Algorithm was not run;;; +53796-9;LL941-6;B-INF;LA13472-8;1;Avonex;;; +53796-9;LL941-6;B-INF;LA13473-6;2;Rebif;;; +53796-9;LL941-6;B-INF;LA13474-4;3;Betaseron;;; +59181-8;LL941-6;B-INF;LA13472-8;1;Avonex;;; +59181-8;LL941-6;B-INF;LA13473-6;2;Rebif;;; +59181-8;LL941-6;B-INF;LA13474-4;3;Betaseron;;; +53826-4;LL2438-1;Y/N/ Not Given;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +53826-4;LL2438-1;Y/N/ Not Given;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +53826-4;LL2438-1;Y/N/ Not Given;LA19761-8;3;Not given;;; +53827-2;LL2438-1;Y/N/ Not Given;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +53827-2;LL2438-1;Y/N/ Not Given;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +53827-2;LL2438-1;Y/N/ Not Given;LA19761-8;3;Not given;;; +53945-2;LL2246-8;E.coli adherence;LA19159-5;1;Diffuse adherence;;; +53945-2;LL2246-8;E.coli adherence;LA19160-3;2;Local adherence;;; +53945-2;LL2246-8;E.coli adherence;LA19161-1;3;Aggregative adherence;;; +53945-2;LL2246-8;E.coli adherence;LA19162-9;4;No adherence;;; +54103-7;LL765-9;Hb band;LA11974-5;1;Hb F,A (normal);;; +54103-7;LL765-9;Hb band;LA11976-0;2;Hb F,A,C;;; +54103-7;LL765-9;Hb band;LA11977-8;3;Hb F,A,D;;; +54103-7;LL765-9;Hb band;LA11978-6;4;Hb F,A,E;;; +54103-7;LL765-9;Hb band;LA12060-2;5;Hb F,A,O-Arab;;; +54103-7;LL765-9;Hb band;LA11979-4;6;Hb F,A,S;;; +54103-7;LL765-9;Hb band;LA11980-2;7;Hb F,C;;; +54103-7;LL765-9;Hb band;LA11981-0;8;Hb F,C,A;;; +54103-7;LL765-9;Hb band;LA11982-8;9;Hb F,D;;; +54103-7;LL765-9;Hb band;LA11983-6;10;Hb F,D,A;;; +54103-7;LL765-9;Hb band;LA11984-4;11;Hb F Only;;; +54103-7;LL765-9;Hb band;LA11985-1;12;Hb F,E;;; +54103-7;LL765-9;Hb band;LA11986-9;13;Hb F,E,A;;; +54103-7;LL765-9;Hb band;LA11987-7;14;Hb F,S;;; +54103-7;LL765-9;Hb band;LA11988-5;15;Hb F,S,A;;; +54103-7;LL765-9;Hb band;LA11989-3;16;Hb F,S,C;;; +54103-7;LL765-9;Hb band;LA11990-1;17;Hb F,S,D;;; +54103-7;LL765-9;Hb band;LA11991-9;18;Hb F,S,E;;; +54103-7;LL765-9;Hb band;LA11992-7;19;Hb F,S,O-Arab;;; +54103-7;LL765-9;Hb band;LA11993-5;20;Hb F,S and other than A,C,D, E, O-Arab;;; +54103-7;LL765-9;Hb band;LA11994-3;21;Hb F, and other than A,C,D,E, S,O-Arab;;; +54103-7;LL765-9;Hb band;LA12057-8;22;Hb F,A and other than C,D, E, S, O-Arab;;; +54103-7;LL765-9;Hb band;LA12968-6;23;Hb F,A, C and other than D, E, S, O-Arab;;; +54103-7;LL765-9;Hb band;LA12970-2;24;Hb F,A, D and other than C, E, S, O-Arab;;; +54103-7;LL765-9;Hb band;LA12971-0;25;Hb F,A, E and other than C,D, S, O-Arab;;; +54103-7;LL765-9;Hb band;LA12972-8;26;Hb F,A, S and other than C,D, E, O-Arab;;; +54103-7;LL765-9;Hb band;LA12973-6;27;Hb F,A, O-Arab and other than C,D, E, S;;; +54103-7;LL765-9;Hb band;LA12974-4;28;Hb F,A, Barts;;; +54103-7;LL765-9;Hb band;LA12975-1;29;Hb Barts, F, A;;; +54103-7;LL765-9;Hb band;LA12976-9;30;Hb Barts, F, A, plus any other band(s);;; +54103-7;LL765-9;Hb band;LA12977-7;31;Hb F,A,C, Barts;;; +54103-7;LL765-9;Hb band;LA12978-5;32;Hb F,A,D, Barts;;; +54103-7;LL765-9;Hb band;LA12979-3;33;Hb F,A,E, Barts;;; +54103-7;LL765-9;Hb band;LA12980-1;34;Hb F,A,O-Arab, Barts;;; +54103-7;LL765-9;Hb band;LA12981-9;35;Hb F,A,S, Barts;;; +54103-7;LL765-9;Hb band;LA12982-7;36;Hb F,C, Barts;;; +54103-7;LL765-9;Hb band;LA12983-5;37;Hb F,C,A, Barts;;; +54103-7;LL765-9;Hb band;LA12984-3;38;Hb F,D, Barts;;; +54103-7;LL765-9;Hb band;LA12985-0;39;Hb F,D,A , Barts;;; +54103-7;LL765-9;Hb band;LA12986-8;40;Hb F Only, Barts;;; +54103-7;LL765-9;Hb band;LA13017-1;41;Hb F,E,Barts;;; +54103-7;LL765-9;Hb band;LA13018-9;42;Hb F,S,Barts;;; +54103-7;LL765-9;Hb band;LA13019-7;43;Hb F,S,C,Barts;;; +54103-7;LL765-9;Hb band;LA12990-0;44;Hb F,S,D, Barts;;; +54103-7;LL765-9;Hb band;LA12991-8;45;Hb F,S,E, Barts;;; +54103-7;LL765-9;Hb band;LA12992-6;46;Hb F,S,O-Arab, Barts;;; +54103-7;LL765-9;Hb band;LA12993-4;47;Hb F,S and other than A,C,D, E,O-Arab plus Barts;;; +54103-7;LL765-9;Hb band;LA12994-2;48;Hb F, and other than A,C,D,E,O-Arab,S plus Barts;;; +54103-7;LL765-9;Hb band;LA12995-9;49;Hb F,A and other than C,D, E, S, O-Arab plus Barts;;; +54103-7;LL765-9;Hb band;LA12996-7;59;Hb A (normal);;; +54103-7;LL765-9;Hb band;LA12997-5;60;Hb A,C;;; +54103-7;LL765-9;Hb band;LA12998-3;61;Hb A,D;;; +54103-7;LL765-9;Hb band;LA12999-1;62;Hb A,E;;; +54103-7;LL765-9;Hb band;LA13000-7;63;Hb A,O-Arab;;; +54103-7;LL765-9;Hb band;LA13001-5;64;Hb A,S;;; +54103-7;LL765-9;Hb band;LA13002-3;65;Hb C;;; +54103-7;LL765-9;Hb band;LA13003-1;66;Hb D;;; +54103-7;LL765-9;Hb band;LA13004-9;67;Hb D,A;;; +54103-7;LL765-9;Hb band;LA13005-6;68;Hb E;;; +54103-7;LL765-9;Hb band;LA13006-4;69;Hb E,A;;; +54103-7;LL765-9;Hb band;LA13007-2;70;Hb S;;; +54103-7;LL765-9;Hb band;LA13008-0;71;Hb S,A;;; +54103-7;LL765-9;Hb band;LA13009-8;72;Hb S,C;;; +54103-7;LL765-9;Hb band;LA13010-6;73;Hb S,D;;; +54103-7;LL765-9;Hb band;LA13011-4;74;Hb S,E;;; +54103-7;LL765-9;Hb band;LA13012-2;75;Hb S,O-Arab;;; +54103-7;LL765-9;Hb band;LA13013-0;76;Hb S and other than A,C,D, E,O-Arab;;; +54103-7;LL765-9;Hb band;LA13014-8;77;Variant other than A,C,D,E,O-Arab,S;;; +54103-7;LL765-9;Hb band;LA13015-5;78;Hb A and other than C,D, E, S, O-Arab;;; +54103-7;LL765-9;Hb band;LA13016-3;79;Other pattern (not described above);;; +54103-7;LL765-9;Hb band;LA26200-8;80;Hb F,C,E;;; +54103-7;LL765-9;Hb band;LA26201-6;81;Hb F,A,S, Barts and other than C,D, E, O-Arab;;; +54103-7;LL765-9;Hb band;LA26204-0;82;Hb F,C and other than A,C,D, E, O-Arab;;; +54103-7;LL765-9;Hb band;LA26205-7;83;Hb F,S,A, Barts;;; +54104-5;LL765-9;Hb band;LA11974-5;1;Hb F,A (normal);;; +54104-5;LL765-9;Hb band;LA11976-0;2;Hb F,A,C;;; +54104-5;LL765-9;Hb band;LA11977-8;3;Hb F,A,D;;; +54104-5;LL765-9;Hb band;LA11978-6;4;Hb F,A,E;;; +54104-5;LL765-9;Hb band;LA12060-2;5;Hb F,A,O-Arab;;; +54104-5;LL765-9;Hb band;LA11979-4;6;Hb F,A,S;;; +54104-5;LL765-9;Hb band;LA11980-2;7;Hb F,C;;; +54104-5;LL765-9;Hb band;LA11981-0;8;Hb F,C,A;;; +54104-5;LL765-9;Hb band;LA11982-8;9;Hb F,D;;; +54104-5;LL765-9;Hb band;LA11983-6;10;Hb F,D,A;;; +54104-5;LL765-9;Hb band;LA11984-4;11;Hb F Only;;; +54104-5;LL765-9;Hb band;LA11985-1;12;Hb F,E;;; +54104-5;LL765-9;Hb band;LA11986-9;13;Hb F,E,A;;; +54104-5;LL765-9;Hb band;LA11987-7;14;Hb F,S;;; +54104-5;LL765-9;Hb band;LA11988-5;15;Hb F,S,A;;; +54104-5;LL765-9;Hb band;LA11989-3;16;Hb F,S,C;;; +54104-5;LL765-9;Hb band;LA11990-1;17;Hb F,S,D;;; +54104-5;LL765-9;Hb band;LA11991-9;18;Hb F,S,E;;; +54104-5;LL765-9;Hb band;LA11992-7;19;Hb F,S,O-Arab;;; +54104-5;LL765-9;Hb band;LA11993-5;20;Hb F,S and other than A,C,D, E, O-Arab;;; +54104-5;LL765-9;Hb band;LA11994-3;21;Hb F, and other than A,C,D,E, S,O-Arab;;; +54104-5;LL765-9;Hb band;LA12057-8;22;Hb F,A and other than C,D, E, S, O-Arab;;; +54104-5;LL765-9;Hb band;LA12968-6;23;Hb F,A, C and other than D, E, S, O-Arab;;; +54104-5;LL765-9;Hb band;LA12970-2;24;Hb F,A, D and other than C, E, S, O-Arab;;; +54104-5;LL765-9;Hb band;LA12971-0;25;Hb F,A, E and other than C,D, S, O-Arab;;; +54104-5;LL765-9;Hb band;LA12972-8;26;Hb F,A, S and other than C,D, E, O-Arab;;; +54104-5;LL765-9;Hb band;LA12973-6;27;Hb F,A, O-Arab and other than C,D, E, S;;; +54104-5;LL765-9;Hb band;LA12974-4;28;Hb F,A, Barts;;; +54104-5;LL765-9;Hb band;LA12975-1;29;Hb Barts, F, A;;; +54104-5;LL765-9;Hb band;LA12976-9;30;Hb Barts, F, A, plus any other band(s);;; +54104-5;LL765-9;Hb band;LA12977-7;31;Hb F,A,C, Barts;;; +54104-5;LL765-9;Hb band;LA12978-5;32;Hb F,A,D, Barts;;; +54104-5;LL765-9;Hb band;LA12979-3;33;Hb F,A,E, Barts;;; +54104-5;LL765-9;Hb band;LA12980-1;34;Hb F,A,O-Arab, Barts;;; +54104-5;LL765-9;Hb band;LA12981-9;35;Hb F,A,S, Barts;;; +54104-5;LL765-9;Hb band;LA12982-7;36;Hb F,C, Barts;;; +54104-5;LL765-9;Hb band;LA12983-5;37;Hb F,C,A, Barts;;; +54104-5;LL765-9;Hb band;LA12984-3;38;Hb F,D, Barts;;; +54104-5;LL765-9;Hb band;LA12985-0;39;Hb F,D,A , Barts;;; +54104-5;LL765-9;Hb band;LA12986-8;40;Hb F Only, Barts;;; +54104-5;LL765-9;Hb band;LA13017-1;41;Hb F,E,Barts;;; +54104-5;LL765-9;Hb band;LA13018-9;42;Hb F,S,Barts;;; +54104-5;LL765-9;Hb band;LA13019-7;43;Hb F,S,C,Barts;;; +54104-5;LL765-9;Hb band;LA12990-0;44;Hb F,S,D, Barts;;; +54104-5;LL765-9;Hb band;LA12991-8;45;Hb F,S,E, Barts;;; +54104-5;LL765-9;Hb band;LA12992-6;46;Hb F,S,O-Arab, Barts;;; +54104-5;LL765-9;Hb band;LA12993-4;47;Hb F,S and other than A,C,D, E,O-Arab plus Barts;;; +54104-5;LL765-9;Hb band;LA12994-2;48;Hb F, and other than A,C,D,E,O-Arab,S plus Barts;;; +54104-5;LL765-9;Hb band;LA12995-9;49;Hb F,A and other than C,D, E, S, O-Arab plus Barts;;; +54104-5;LL765-9;Hb band;LA12996-7;59;Hb A (normal);;; +54104-5;LL765-9;Hb band;LA12997-5;60;Hb A,C;;; +54104-5;LL765-9;Hb band;LA12998-3;61;Hb A,D;;; +54104-5;LL765-9;Hb band;LA12999-1;62;Hb A,E;;; +54104-5;LL765-9;Hb band;LA13000-7;63;Hb A,O-Arab;;; +54104-5;LL765-9;Hb band;LA13001-5;64;Hb A,S;;; +54104-5;LL765-9;Hb band;LA13002-3;65;Hb C;;; +54104-5;LL765-9;Hb band;LA13003-1;66;Hb D;;; +54104-5;LL765-9;Hb band;LA13004-9;67;Hb D,A;;; +54104-5;LL765-9;Hb band;LA13005-6;68;Hb E;;; +54104-5;LL765-9;Hb band;LA13006-4;69;Hb E,A;;; +54104-5;LL765-9;Hb band;LA13007-2;70;Hb S;;; +54104-5;LL765-9;Hb band;LA13008-0;71;Hb S,A;;; +54104-5;LL765-9;Hb band;LA13009-8;72;Hb S,C;;; +54104-5;LL765-9;Hb band;LA13010-6;73;Hb S,D;;; +54104-5;LL765-9;Hb band;LA13011-4;74;Hb S,E;;; +54104-5;LL765-9;Hb band;LA13012-2;75;Hb S,O-Arab;;; +54104-5;LL765-9;Hb band;LA13013-0;76;Hb S and other than A,C,D, E,O-Arab;;; +54104-5;LL765-9;Hb band;LA13014-8;77;Variant other than A,C,D,E,O-Arab,S;;; +54104-5;LL765-9;Hb band;LA13015-5;78;Hb A and other than C,D, E, S, O-Arab;;; +54104-5;LL765-9;Hb band;LA13016-3;79;Other pattern (not described above);;; +54104-5;LL765-9;Hb band;LA26200-8;80;Hb F,C,E;;; +54104-5;LL765-9;Hb band;LA26201-6;81;Hb F,A,S, Barts and other than C,D, E, O-Arab;;; +54104-5;LL765-9;Hb band;LA26204-0;82;Hb F,C and other than A,C,D, E, O-Arab;;; +54104-5;LL765-9;Hb band;LA26205-7;83;Hb F,S,A, Barts;;; +54105-2;LL765-9;Hb band;LA11974-5;1;Hb F,A (normal);;; +54105-2;LL765-9;Hb band;LA11976-0;2;Hb F,A,C;;; +54105-2;LL765-9;Hb band;LA11977-8;3;Hb F,A,D;;; +54105-2;LL765-9;Hb band;LA11978-6;4;Hb F,A,E;;; +54105-2;LL765-9;Hb band;LA12060-2;5;Hb F,A,O-Arab;;; +54105-2;LL765-9;Hb band;LA11979-4;6;Hb F,A,S;;; +54105-2;LL765-9;Hb band;LA11980-2;7;Hb F,C;;; +54105-2;LL765-9;Hb band;LA11981-0;8;Hb F,C,A;;; +54105-2;LL765-9;Hb band;LA11982-8;9;Hb F,D;;; +54105-2;LL765-9;Hb band;LA11983-6;10;Hb F,D,A;;; +54105-2;LL765-9;Hb band;LA11984-4;11;Hb F Only;;; +54105-2;LL765-9;Hb band;LA11985-1;12;Hb F,E;;; +54105-2;LL765-9;Hb band;LA11986-9;13;Hb F,E,A;;; +54105-2;LL765-9;Hb band;LA11987-7;14;Hb F,S;;; +54105-2;LL765-9;Hb band;LA11988-5;15;Hb F,S,A;;; +54105-2;LL765-9;Hb band;LA11989-3;16;Hb F,S,C;;; +54105-2;LL765-9;Hb band;LA11990-1;17;Hb F,S,D;;; +54105-2;LL765-9;Hb band;LA11991-9;18;Hb F,S,E;;; +54105-2;LL765-9;Hb band;LA11992-7;19;Hb F,S,O-Arab;;; +54105-2;LL765-9;Hb band;LA11993-5;20;Hb F,S and other than A,C,D, E, O-Arab;;; +54105-2;LL765-9;Hb band;LA11994-3;21;Hb F, and other than A,C,D,E, S,O-Arab;;; +54105-2;LL765-9;Hb band;LA12057-8;22;Hb F,A and other than C,D, E, S, O-Arab;;; +54105-2;LL765-9;Hb band;LA12968-6;23;Hb F,A, C and other than D, E, S, O-Arab;;; +54105-2;LL765-9;Hb band;LA12970-2;24;Hb F,A, D and other than C, E, S, O-Arab;;; +54105-2;LL765-9;Hb band;LA12971-0;25;Hb F,A, E and other than C,D, S, O-Arab;;; +54105-2;LL765-9;Hb band;LA12972-8;26;Hb F,A, S and other than C,D, E, O-Arab;;; +54105-2;LL765-9;Hb band;LA12973-6;27;Hb F,A, O-Arab and other than C,D, E, S;;; +54105-2;LL765-9;Hb band;LA12974-4;28;Hb F,A, Barts;;; +54105-2;LL765-9;Hb band;LA12975-1;29;Hb Barts, F, A;;; +54105-2;LL765-9;Hb band;LA12976-9;30;Hb Barts, F, A, plus any other band(s);;; +54105-2;LL765-9;Hb band;LA12977-7;31;Hb F,A,C, Barts;;; +54105-2;LL765-9;Hb band;LA12978-5;32;Hb F,A,D, Barts;;; +54105-2;LL765-9;Hb band;LA12979-3;33;Hb F,A,E, Barts;;; +54105-2;LL765-9;Hb band;LA12980-1;34;Hb F,A,O-Arab, Barts;;; +54105-2;LL765-9;Hb band;LA12981-9;35;Hb F,A,S, Barts;;; +54105-2;LL765-9;Hb band;LA12982-7;36;Hb F,C, Barts;;; +54105-2;LL765-9;Hb band;LA12983-5;37;Hb F,C,A, Barts;;; +54105-2;LL765-9;Hb band;LA12984-3;38;Hb F,D, Barts;;; +54105-2;LL765-9;Hb band;LA12985-0;39;Hb F,D,A , Barts;;; +54105-2;LL765-9;Hb band;LA12986-8;40;Hb F Only, Barts;;; +54105-2;LL765-9;Hb band;LA13017-1;41;Hb F,E,Barts;;; +54105-2;LL765-9;Hb band;LA13018-9;42;Hb F,S,Barts;;; +54105-2;LL765-9;Hb band;LA13019-7;43;Hb F,S,C,Barts;;; +54105-2;LL765-9;Hb band;LA12990-0;44;Hb F,S,D, Barts;;; +54105-2;LL765-9;Hb band;LA12991-8;45;Hb F,S,E, Barts;;; +54105-2;LL765-9;Hb band;LA12992-6;46;Hb F,S,O-Arab, Barts;;; +54105-2;LL765-9;Hb band;LA12993-4;47;Hb F,S and other than A,C,D, E,O-Arab plus Barts;;; +54105-2;LL765-9;Hb band;LA12994-2;48;Hb F, and other than A,C,D,E,O-Arab,S plus Barts;;; +54105-2;LL765-9;Hb band;LA12995-9;49;Hb F,A and other than C,D, E, S, O-Arab plus Barts;;; +54105-2;LL765-9;Hb band;LA12996-7;59;Hb A (normal);;; +54105-2;LL765-9;Hb band;LA12997-5;60;Hb A,C;;; +54105-2;LL765-9;Hb band;LA12998-3;61;Hb A,D;;; +54105-2;LL765-9;Hb band;LA12999-1;62;Hb A,E;;; +54105-2;LL765-9;Hb band;LA13000-7;63;Hb A,O-Arab;;; +54105-2;LL765-9;Hb band;LA13001-5;64;Hb A,S;;; +54105-2;LL765-9;Hb band;LA13002-3;65;Hb C;;; +54105-2;LL765-9;Hb band;LA13003-1;66;Hb D;;; +54105-2;LL765-9;Hb band;LA13004-9;67;Hb D,A;;; +54105-2;LL765-9;Hb band;LA13005-6;68;Hb E;;; +54105-2;LL765-9;Hb band;LA13006-4;69;Hb E,A;;; +54105-2;LL765-9;Hb band;LA13007-2;70;Hb S;;; +54105-2;LL765-9;Hb band;LA13008-0;71;Hb S,A;;; +54105-2;LL765-9;Hb band;LA13009-8;72;Hb S,C;;; +54105-2;LL765-9;Hb band;LA13010-6;73;Hb S,D;;; +54105-2;LL765-9;Hb band;LA13011-4;74;Hb S,E;;; +54105-2;LL765-9;Hb band;LA13012-2;75;Hb S,O-Arab;;; +54105-2;LL765-9;Hb band;LA13013-0;76;Hb S and other than A,C,D, E,O-Arab;;; +54105-2;LL765-9;Hb band;LA13014-8;77;Variant other than A,C,D,E,O-Arab,S;;; +54105-2;LL765-9;Hb band;LA13015-5;78;Hb A and other than C,D, E, S, O-Arab;;; +54105-2;LL765-9;Hb band;LA13016-3;79;Other pattern (not described above);;; +54105-2;LL765-9;Hb band;LA26200-8;80;Hb F,C,E;;; +54105-2;LL765-9;Hb band;LA26201-6;81;Hb F,A,S, Barts and other than C,D, E, O-Arab;;; +54105-2;LL765-9;Hb band;LA26204-0;82;Hb F,C and other than A,C,D, E, O-Arab;;; +54105-2;LL765-9;Hb band;LA26205-7;83;Hb F,S,A, Barts;;; +54106-0;LL617-2;NB_hearing method;LA10387-1;1;Automated auditory brainstem response;;; +54106-0;LL617-2;NB_hearing method;LA10388-9;2;Auditory brain stem response;;; +54106-0;LL617-2;NB_hearing method;LA10389-7;3;Otoacoustic emissions;;; +54106-0;LL617-2;NB_hearing method;LA10390-5;4;Distortion product otoacoustic emissions;;; +54106-0;LL617-2;NB_hearing method;LA10391-3;5;Transient otoacoustic emissions;;; +54106-0;LL617-2;NB_hearing method;LA12406-7;6;Methodology unknown;;; +54107-8;LL618-0;NB_hearing;LA10392-1;1;Pass;;; +54107-8;LL618-0;NB_hearing;LA10393-9;2;Refer;183924009;Referral needed (finding);http://snomed.info/sct +54107-8;LL618-0;NB_hearing;LA6644-4;3;Parental refusal;609589008;Refused by parents of subject (qualifier value);http://snomed.info/sct +54107-8;LL618-0;NB_hearing;LA12408-3;4;Attempted, but unsuccessful - technical fail;103709008;Failed attempted procedure (situation);http://snomed.info/sct +54107-8;LL618-0;NB_hearing;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +54107-8;LL618-0;NB_hearing;LA12409-1;6;Not performed, medical exclusion - not indicated;410534003;Not indicated (qualifier value);http://snomed.info/sct +54108-6;LL618-0;NB_hearing;LA10392-1;1;Pass;;; +54108-6;LL618-0;NB_hearing;LA10393-9;2;Refer;183924009;Referral needed (finding);http://snomed.info/sct +54108-6;LL618-0;NB_hearing;LA6644-4;3;Parental refusal;609589008;Refused by parents of subject (qualifier value);http://snomed.info/sct +54108-6;LL618-0;NB_hearing;LA12408-3;4;Attempted, but unsuccessful - technical fail;103709008;Failed attempted procedure (situation);http://snomed.info/sct +54108-6;LL618-0;NB_hearing;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +54108-6;LL618-0;NB_hearing;LA12409-1;6;Not performed, medical exclusion - not indicated;410534003;Not indicated (qualifier value);http://snomed.info/sct +54109-4;LL618-0;NB_hearing;LA10392-1;1;Pass;;; +54109-4;LL618-0;NB_hearing;LA10393-9;2;Refer;183924009;Referral needed (finding);http://snomed.info/sct +54109-4;LL618-0;NB_hearing;LA6644-4;3;Parental refusal;609589008;Refused by parents of subject (qualifier value);http://snomed.info/sct +54109-4;LL618-0;NB_hearing;LA12408-3;4;Attempted, but unsuccessful - technical fail;103709008;Failed attempted procedure (situation);http://snomed.info/sct +54109-4;LL618-0;NB_hearing;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +54109-4;LL618-0;NB_hearing;LA12409-1;6;Not performed, medical exclusion - not indicated;410534003;Not indicated (qualifier value);http://snomed.info/sct +54110-2;LL618-0;NB_hearing;LA10392-1;1;Pass;;; +54110-2;LL618-0;NB_hearing;LA10393-9;2;Refer;183924009;Referral needed (finding);http://snomed.info/sct +54110-2;LL618-0;NB_hearing;LA6644-4;3;Parental refusal;609589008;Refused by parents of subject (qualifier value);http://snomed.info/sct +54110-2;LL618-0;NB_hearing;LA12408-3;4;Attempted, but unsuccessful - technical fail;103709008;Failed attempted procedure (situation);http://snomed.info/sct +54110-2;LL618-0;NB_hearing;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +54110-2;LL618-0;NB_hearing;LA12409-1;6;Not performed, medical exclusion - not indicated;410534003;Not indicated (qualifier value);http://snomed.info/sct +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10533-0;1;Blood Clots;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10572-8;2;Blood Clot in Leg;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10573-6;3;Blood Clot in Lungs;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10524-9;4;Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10549-6;5;Bone Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA14283-8;6;Breast cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10537-1;7;Colon Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10548-8;8;Esophageal Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10547-0;9;Gastric Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10541-3;10;Kidney Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10545-4;11;Leukemia;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA15687-9;12;Lung cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10546-2;13;Muscle Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA15682-0;14;Ovarian cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA15688-7;15;Prostate cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10543-9;16;Skin Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA15690-3;17;Thyroid cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10544-7;18;Uterine Cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA14284-6;19;Other cancer;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10529-8;20;Diabetes;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10551-2;21;Diabetes Type 1;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10552-0;22;Diabetes Type 2;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10553-8;23;Gestational Diabetes;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10532-2;24;Gastrointestinal Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10554-6;25;Crohn's Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10555-3;26;Irritable Bowel Syndrome;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10556-1;27;Ulceritive Colitis;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10557-9;28;Colon Polyps;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10523-1;29;Heart Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA16286-9;30;Heart attack;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10526-4;31;High Cholesterol/Hyperlipidemia;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA7444-8;32;Hypertension;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10528-0;33;Kidney Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10565-2;34;Cystic Kidney Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10566-0;35;Kidney Disease Present From Birth;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10567-8;36;Nephrosis;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA17784-2;37;Nephritis;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10569-4;38;Nephrotic Syndrome;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10570-2;39;Diabetic Kidney Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA19526-5;40;Other/Unknown;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10531-4;41;Lung Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10559-5;42;COPD;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10560-3;43;Chronic Bronchitis;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10561-1;44;Emphysema;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10562-9;45;Chronic Lower Respiratory Disease;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10563-7;46;Influenza/Pneumonia;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA16982-3;47;Asthma;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10590-0;48;Neurological Disorders;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10527-2;49;Osteoporosis;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10535-5;50;Psychological Disorders;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10574-4;51;Anxiety;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10575-1;52;Bipolar/Manic Depressive Disorder;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10576-9;53;Depression;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10577-7;54;Attention Deficit Hyper Activity;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA24638-1;55;Autism;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10579-3;56;Personality Disorder;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10580-1;57;Eating Disorder;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10581-9;58;Obsessive Compulsive Disorder;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10582-7;59;Panic Disorder;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10583-5;60;Post Traumatic Stress Disorder;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10584-3;61;Schizophrenia;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10585-0;62;Social Phobia;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA20372-1;63;Dementia;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10591-8;64;Septicemia;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10522-3;65;Stroke/Brain Attack;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10530-6;66;Sudden Infant Death Syndrome;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10595-9;67;Cause of Death;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA18036-6;68;Suicide;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10588-4;69;Accidental Death;;; +54112-8;LL627-1;USSG-FHT diseases & cause of death;LA10589-2;70;Other/Unexpected;;; +54113-6;LL619-8;USSG-FHT age;LA10402-8;1;Pre-Birth;;; +54113-6;LL619-8;USSG-FHT age;LA10403-6;2;Newborn;;; +54113-6;LL619-8;USSG-FHT age;LA10394-7;3;Infancy;;; +54113-6;LL619-8;USSG-FHT age;LA10395-4;4;Childhood;;; +54113-6;LL619-8;USSG-FHT age;LA10404-4;5;Adolescence;;; +54113-6;LL619-8;USSG-FHT age;LA10396-2;6;20-29;;; +54113-6;LL619-8;USSG-FHT age;LA10397-0;7;30-39;;; +54113-6;LL619-8;USSG-FHT age;LA10398-8;8;40-49;;; +54113-6;LL619-8;USSG-FHT age;LA10399-6;9;50-59;;; +54113-6;LL619-8;USSG-FHT age;LA10400-2;10;OVER 60;;; +54113-6;LL619-8;USSG-FHT age;LA4489-6;11;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +54115-1;LL619-8;USSG-FHT age;LA10402-8;1;Pre-Birth;;; +54115-1;LL619-8;USSG-FHT age;LA10403-6;2;Newborn;;; +54115-1;LL619-8;USSG-FHT age;LA10394-7;3;Infancy;;; +54115-1;LL619-8;USSG-FHT age;LA10395-4;4;Childhood;;; +54115-1;LL619-8;USSG-FHT age;LA10404-4;5;Adolescence;;; +54115-1;LL619-8;USSG-FHT age;LA10396-2;6;20-29;;; +54115-1;LL619-8;USSG-FHT age;LA10397-0;7;30-39;;; +54115-1;LL619-8;USSG-FHT age;LA10398-8;8;40-49;;; +54115-1;LL619-8;USSG-FHT age;LA10399-6;9;50-59;;; +54115-1;LL619-8;USSG-FHT age;LA10400-2;10;OVER 60;;; +54115-1;LL619-8;USSG-FHT age;LA4489-6;11;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +54129-2;LL619-8;USSG-FHT age;LA10402-8;1;Pre-Birth;;; +54129-2;LL619-8;USSG-FHT age;LA10403-6;2;Newborn;;; +54129-2;LL619-8;USSG-FHT age;LA10394-7;3;Infancy;;; +54129-2;LL619-8;USSG-FHT age;LA10395-4;4;Childhood;;; +54129-2;LL619-8;USSG-FHT age;LA10404-4;5;Adolescence;;; +54129-2;LL619-8;USSG-FHT age;LA10396-2;6;20-29;;; +54129-2;LL619-8;USSG-FHT age;LA10397-0;7;30-39;;; +54129-2;LL619-8;USSG-FHT age;LA10398-8;8;40-49;;; +54129-2;LL619-8;USSG-FHT age;LA10399-6;9;50-59;;; +54129-2;LL619-8;USSG-FHT age;LA10400-2;10;OVER 60;;; +54129-2;LL619-8;USSG-FHT age;LA4489-6;11;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +54130-0;LL619-8;USSG-FHT age;LA10402-8;1;Pre-Birth;;; +54130-0;LL619-8;USSG-FHT age;LA10403-6;2;Newborn;;; +54130-0;LL619-8;USSG-FHT age;LA10394-7;3;Infancy;;; +54130-0;LL619-8;USSG-FHT age;LA10395-4;4;Childhood;;; +54130-0;LL619-8;USSG-FHT age;LA10404-4;5;Adolescence;;; +54130-0;LL619-8;USSG-FHT age;LA10396-2;6;20-29;;; +54130-0;LL619-8;USSG-FHT age;LA10397-0;7;30-39;;; +54130-0;LL619-8;USSG-FHT age;LA10398-8;8;40-49;;; +54130-0;LL619-8;USSG-FHT age;LA10399-6;9;50-59;;; +54130-0;LL619-8;USSG-FHT age;LA10400-2;10;OVER 60;;; +54130-0;LL619-8;USSG-FHT age;LA4489-6;11;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +54116-9;LL626-3;USSG-FHT diseases;LA10533-0;1;Blood Clots;;; +54116-9;LL626-3;USSG-FHT diseases;LA10572-8;2;Blood Clot in Leg;;; +54116-9;LL626-3;USSG-FHT diseases;LA10573-6;3;Blood Clot in Lungs;;; +54116-9;LL626-3;USSG-FHT diseases;LA10524-9;4;Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10549-6;5;Bone Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA14283-8;6;Breast cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10537-1;7;Colon Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10548-8;8;Esophageal Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10547-0;9;Gastric Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10541-3;10;Kidney Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10545-4;11;Leukemia;;; +54116-9;LL626-3;USSG-FHT diseases;LA15687-9;12;Lung cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10546-2;13;Muscle Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA15682-0;14;Ovarian cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA15688-7;15;Prostate cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10543-9;16;Skin Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA15690-3;17;Thyroid cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10544-7;18;Uterine Cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA14284-6;19;Other cancer;;; +54116-9;LL626-3;USSG-FHT diseases;LA10529-8;20;Diabetes;;; +54116-9;LL626-3;USSG-FHT diseases;LA10551-2;21;Diabetes Type 1;;; +54116-9;LL626-3;USSG-FHT diseases;LA10552-0;22;Diabetes Type 2;;; +54116-9;LL626-3;USSG-FHT diseases;LA10553-8;23;Gestational Diabetes;;; +54116-9;LL626-3;USSG-FHT diseases;LA10532-2;24;Gastrointestinal Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA10554-6;25;Crohn's Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA10555-3;26;Irritable Bowel Syndrome;;; +54116-9;LL626-3;USSG-FHT diseases;LA10556-1;27;Ulceritive Colitis;;; +54116-9;LL626-3;USSG-FHT diseases;LA10557-9;28;Colon Polyps;;; +54116-9;LL626-3;USSG-FHT diseases;LA10523-1;29;Heart Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA16286-9;30;Heart attack;;; +54116-9;LL626-3;USSG-FHT diseases;LA10526-4;31;High Cholesterol/Hyperlipidemia;;; +54116-9;LL626-3;USSG-FHT diseases;LA7444-8;32;Hypertension;;; +54116-9;LL626-3;USSG-FHT diseases;LA10528-0;33;Kidney Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA10565-2;34;Cystic Kidney Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA10566-0;35;Kidney Disease Present From Birth;;; +54116-9;LL626-3;USSG-FHT diseases;LA10567-8;36;Nephrosis;;; +54116-9;LL626-3;USSG-FHT diseases;LA17784-2;37;Nephritis;;; +54116-9;LL626-3;USSG-FHT diseases;LA10569-4;38;Nephrotic Syndrome;;; +54116-9;LL626-3;USSG-FHT diseases;LA10570-2;39;Diabetic Kidney Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA19526-5;40;Other/Unknown;;; +54116-9;LL626-3;USSG-FHT diseases;LA10531-4;41;Lung Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA10559-5;42;COPD;;; +54116-9;LL626-3;USSG-FHT diseases;LA10560-3;43;Chronic Bronchitis;;; +54116-9;LL626-3;USSG-FHT diseases;LA10561-1;44;Emphysema;;; +54116-9;LL626-3;USSG-FHT diseases;LA10562-9;45;Chronic Lower Respiratory Disease;;; +54116-9;LL626-3;USSG-FHT diseases;LA10563-7;46;Influenza/Pneumonia;;; +54116-9;LL626-3;USSG-FHT diseases;LA16982-3;47;Asthma;;; +54116-9;LL626-3;USSG-FHT diseases;LA10590-0;48;Neurological Disorders;;; +54116-9;LL626-3;USSG-FHT diseases;LA10527-2;49;Osteoporosis;;; +54116-9;LL626-3;USSG-FHT diseases;LA10535-5;50;Psychological Disorders;;; +54116-9;LL626-3;USSG-FHT diseases;LA10574-4;51;Anxiety;;; +54116-9;LL626-3;USSG-FHT diseases;LA10575-1;52;Bipolar/Manic Depressive Disorder;;; +54116-9;LL626-3;USSG-FHT diseases;LA10576-9;53;Depression;;; +54116-9;LL626-3;USSG-FHT diseases;LA10577-7;54;Attention Deficit Hyper Activity;;; +54116-9;LL626-3;USSG-FHT diseases;LA24638-1;55;Autism;;; +54116-9;LL626-3;USSG-FHT diseases;LA10579-3;56;Personality Disorder;;; +54116-9;LL626-3;USSG-FHT diseases;LA10580-1;57;Eating Disorder;;; +54116-9;LL626-3;USSG-FHT diseases;LA10581-9;58;Obsessive Compulsive Disorder;;; +54116-9;LL626-3;USSG-FHT diseases;LA10582-7;59;Panic Disorder;;; +54116-9;LL626-3;USSG-FHT diseases;LA10583-5;60;Post Traumatic Stress Disorder;;; +54116-9;LL626-3;USSG-FHT diseases;LA10584-3;61;Schizophrenia;;; +54116-9;LL626-3;USSG-FHT diseases;LA10585-0;62;Social Phobia;;; +54116-9;LL626-3;USSG-FHT diseases;LA20372-1;63;Dementia;;; +54116-9;LL626-3;USSG-FHT diseases;LA10591-8;64;Septicemia;;; +54116-9;LL626-3;USSG-FHT diseases;LA10522-3;65;Stroke/Brain Attack;;; +54116-9;LL626-3;USSG-FHT diseases;LA10530-6;66;Sudden Infant Death Syndrome;;; +54140-9;LL626-3;USSG-FHT diseases;LA10533-0;1;Blood Clots;;; +54140-9;LL626-3;USSG-FHT diseases;LA10572-8;2;Blood Clot in Leg;;; +54140-9;LL626-3;USSG-FHT diseases;LA10573-6;3;Blood Clot in Lungs;;; +54140-9;LL626-3;USSG-FHT diseases;LA10524-9;4;Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10549-6;5;Bone Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA14283-8;6;Breast cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10537-1;7;Colon Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10548-8;8;Esophageal Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10547-0;9;Gastric Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10541-3;10;Kidney Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10545-4;11;Leukemia;;; +54140-9;LL626-3;USSG-FHT diseases;LA15687-9;12;Lung cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10546-2;13;Muscle Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA15682-0;14;Ovarian cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA15688-7;15;Prostate cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10543-9;16;Skin Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA15690-3;17;Thyroid cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10544-7;18;Uterine Cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA14284-6;19;Other cancer;;; +54140-9;LL626-3;USSG-FHT diseases;LA10529-8;20;Diabetes;;; +54140-9;LL626-3;USSG-FHT diseases;LA10551-2;21;Diabetes Type 1;;; +54140-9;LL626-3;USSG-FHT diseases;LA10552-0;22;Diabetes Type 2;;; +54140-9;LL626-3;USSG-FHT diseases;LA10553-8;23;Gestational Diabetes;;; +54140-9;LL626-3;USSG-FHT diseases;LA10532-2;24;Gastrointestinal Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA10554-6;25;Crohn's Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA10555-3;26;Irritable Bowel Syndrome;;; +54140-9;LL626-3;USSG-FHT diseases;LA10556-1;27;Ulceritive Colitis;;; +54140-9;LL626-3;USSG-FHT diseases;LA10557-9;28;Colon Polyps;;; +54140-9;LL626-3;USSG-FHT diseases;LA10523-1;29;Heart Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA16286-9;30;Heart attack;;; +54140-9;LL626-3;USSG-FHT diseases;LA10526-4;31;High Cholesterol/Hyperlipidemia;;; +54140-9;LL626-3;USSG-FHT diseases;LA7444-8;32;Hypertension;;; +54140-9;LL626-3;USSG-FHT diseases;LA10528-0;33;Kidney Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA10565-2;34;Cystic Kidney Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA10566-0;35;Kidney Disease Present From Birth;;; +54140-9;LL626-3;USSG-FHT diseases;LA10567-8;36;Nephrosis;;; +54140-9;LL626-3;USSG-FHT diseases;LA17784-2;37;Nephritis;;; +54140-9;LL626-3;USSG-FHT diseases;LA10569-4;38;Nephrotic Syndrome;;; +54140-9;LL626-3;USSG-FHT diseases;LA10570-2;39;Diabetic Kidney Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA19526-5;40;Other/Unknown;;; +54140-9;LL626-3;USSG-FHT diseases;LA10531-4;41;Lung Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA10559-5;42;COPD;;; +54140-9;LL626-3;USSG-FHT diseases;LA10560-3;43;Chronic Bronchitis;;; +54140-9;LL626-3;USSG-FHT diseases;LA10561-1;44;Emphysema;;; +54140-9;LL626-3;USSG-FHT diseases;LA10562-9;45;Chronic Lower Respiratory Disease;;; +54140-9;LL626-3;USSG-FHT diseases;LA10563-7;46;Influenza/Pneumonia;;; +54140-9;LL626-3;USSG-FHT diseases;LA16982-3;47;Asthma;;; +54140-9;LL626-3;USSG-FHT diseases;LA10590-0;48;Neurological Disorders;;; +54140-9;LL626-3;USSG-FHT diseases;LA10527-2;49;Osteoporosis;;; +54140-9;LL626-3;USSG-FHT diseases;LA10535-5;50;Psychological Disorders;;; +54140-9;LL626-3;USSG-FHT diseases;LA10574-4;51;Anxiety;;; +54140-9;LL626-3;USSG-FHT diseases;LA10575-1;52;Bipolar/Manic Depressive Disorder;;; +54140-9;LL626-3;USSG-FHT diseases;LA10576-9;53;Depression;;; +54140-9;LL626-3;USSG-FHT diseases;LA10577-7;54;Attention Deficit Hyper Activity;;; +54140-9;LL626-3;USSG-FHT diseases;LA24638-1;55;Autism;;; +54140-9;LL626-3;USSG-FHT diseases;LA10579-3;56;Personality Disorder;;; +54140-9;LL626-3;USSG-FHT diseases;LA10580-1;57;Eating Disorder;;; +54140-9;LL626-3;USSG-FHT diseases;LA10581-9;58;Obsessive Compulsive Disorder;;; +54140-9;LL626-3;USSG-FHT diseases;LA10582-7;59;Panic Disorder;;; +54140-9;LL626-3;USSG-FHT diseases;LA10583-5;60;Post Traumatic Stress Disorder;;; +54140-9;LL626-3;USSG-FHT diseases;LA10584-3;61;Schizophrenia;;; +54140-9;LL626-3;USSG-FHT diseases;LA10585-0;62;Social Phobia;;; +54140-9;LL626-3;USSG-FHT diseases;LA20372-1;63;Dementia;;; +54140-9;LL626-3;USSG-FHT diseases;LA10591-8;64;Septicemia;;; +54140-9;LL626-3;USSG-FHT diseases;LA10522-3;65;Stroke/Brain Attack;;; +54140-9;LL626-3;USSG-FHT diseases;LA10530-6;66;Sudden Infant Death Syndrome;;; +54119-3;LL629-7;USSG-FHT race;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +54119-3;LL629-7;USSG-FHT race;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +54119-3;LL629-7;USSG-FHT race;LA14048-5;3;Asian Indian;;; +54119-3;LL629-7;USSG-FHT race;LA4168-6;4;Chinese;;; +54119-3;LL629-7;USSG-FHT race;LA3969-8;5;Filipino;;; +54119-3;LL629-7;USSG-FHT race;LA4595-0;6;Japanese;;; +54119-3;LL629-7;USSG-FHT race;LA4603-2;7;Korean;;; +54119-3;LL629-7;USSG-FHT race;LA4443-3;8;Vietnamese;;; +54119-3;LL629-7;USSG-FHT race;LA14049-3;9;Other Asian;;; +54119-3;LL629-7;USSG-FHT race;LA10610-6;10;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +54119-3;LL629-7;USSG-FHT race;LA10611-4;11;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +54119-3;LL629-7;USSG-FHT race;LA14045-1;12;Native Hawaiian;;; +54119-3;LL629-7;USSG-FHT race;LA14046-9;13;Guamanian;;; +54119-3;LL629-7;USSG-FHT race;LA10621-3;14;Chamorro;;; +54119-3;LL629-7;USSG-FHT race;LA4300-5;15;Samoan;;; +54119-3;LL629-7;USSG-FHT race;LA14047-7;16;Other Pacific Islander;;; +54119-3;LL629-7;USSG-FHT race;LA4457-3;17;White;2106-3;White;https://www.cdc.gov/phin +54119-3;LL629-7;USSG-FHT race;LA10613-0;18;Other/Unknown/Refuse To Answer;;; +54134-2;LL629-7;USSG-FHT race;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +54134-2;LL629-7;USSG-FHT race;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +54134-2;LL629-7;USSG-FHT race;LA14048-5;3;Asian Indian;;; +54134-2;LL629-7;USSG-FHT race;LA4168-6;4;Chinese;;; +54134-2;LL629-7;USSG-FHT race;LA3969-8;5;Filipino;;; +54134-2;LL629-7;USSG-FHT race;LA4595-0;6;Japanese;;; +54134-2;LL629-7;USSG-FHT race;LA4603-2;7;Korean;;; +54134-2;LL629-7;USSG-FHT race;LA4443-3;8;Vietnamese;;; +54134-2;LL629-7;USSG-FHT race;LA14049-3;9;Other Asian;;; +54134-2;LL629-7;USSG-FHT race;LA10610-6;10;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +54134-2;LL629-7;USSG-FHT race;LA10611-4;11;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +54134-2;LL629-7;USSG-FHT race;LA14045-1;12;Native Hawaiian;;; +54134-2;LL629-7;USSG-FHT race;LA14046-9;13;Guamanian;;; +54134-2;LL629-7;USSG-FHT race;LA10621-3;14;Chamorro;;; +54134-2;LL629-7;USSG-FHT race;LA4300-5;15;Samoan;;; +54134-2;LL629-7;USSG-FHT race;LA14047-7;16;Other Pacific Islander;;; +54134-2;LL629-7;USSG-FHT race;LA4457-3;17;White;2106-3;White;https://www.cdc.gov/phin +54134-2;LL629-7;USSG-FHT race;LA10613-0;18;Other/Unknown/Refuse To Answer;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA6214-6;1;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +54120-1;LL628-9;USSG-FHT ethnicity;LA10599-1;2;Central American;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA4190-0;3;Cuban;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA10601-5;4;Dominican(Republic);;; +54120-1;LL628-9;USSG-FHT ethnicity;LA4611-5;5;Mexican;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA4364-1;6;Puerto Rican;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA10606-4;7;South American;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA14055-0;8;Other Latin American;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA10603-1;9;Other Hispanic/Latino/Spanish;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA10597-5;10;Non-Hispanic or Latino;2186-5;Not Hispanic or Latino;https://www.cdc.gov/phin +54120-1;LL628-9;USSG-FHT ethnicity;LA10598-3;11;Ashkenazi Jewish;;; +54120-1;LL628-9;USSG-FHT ethnicity;LA10607-2;12;Unknown/No answer;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA6214-6;1;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +54133-4;LL628-9;USSG-FHT ethnicity;LA10599-1;2;Central American;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA4190-0;3;Cuban;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA10601-5;4;Dominican(Republic);;; +54133-4;LL628-9;USSG-FHT ethnicity;LA4611-5;5;Mexican;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA4364-1;6;Puerto Rican;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA10606-4;7;South American;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA14055-0;8;Other Latin American;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA10603-1;9;Other Hispanic/Latino/Spanish;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA10597-5;10;Non-Hispanic or Latino;2186-5;Not Hispanic or Latino;https://www.cdc.gov/phin +54133-4;LL628-9;USSG-FHT ethnicity;LA10598-3;11;Ashkenazi Jewish;;; +54133-4;LL628-9;USSG-FHT ethnicity;LA10607-2;12;Unknown/No answer;;; +54121-9;LL623-0;USSG-FHT twin;LA10427-5;1;Yes - Identical (Same);;; +54121-9;LL623-0;USSG-FHT twin;LA10428-3;2;Yes - Fraternal (Different);;; +54121-9;LL623-0;USSG-FHT twin;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +54132-6;LL623-0;USSG-FHT twin;LA10427-5;1;Yes - Identical (Same);;; +54132-6;LL623-0;USSG-FHT twin;LA10428-3;2;Yes - Fraternal (Different);;; +54132-6;LL623-0;USSG-FHT twin;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +54123-5;LL622-2;USSG-FHT gender;LA2-8;1;Male;;; +54123-5;LL622-2;USSG-FHT gender;LA3-6;2;Female;;; +54123-5;LL622-2;USSG-FHT gender;LA46-8;3;Other;;; +54123-5;LL622-2;USSG-FHT gender;LA2-8;1;Male;;; +54123-5;LL622-2;USSG-FHT gender;LA3-6;2;Female;;; +54123-5;LL622-2;USSG-FHT gender;LA46-8;3;Other;;; +54131-8;LL622-2;USSG-FHT gender;LA2-8;1;Male;;; +54131-8;LL622-2;USSG-FHT gender;LA3-6;2;Female;;; +54131-8;LL622-2;USSG-FHT gender;LA46-8;3;Other;;; +54136-7;LL621-4;USSG-FHT relationship;LA10405-1;1;Daughter;;; +54136-7;LL621-4;USSG-FHT relationship;LA10406-9;2;Granddaughter;;; +54136-7;LL621-4;USSG-FHT relationship;LA10407-7;3;Grandson;;; +54136-7;LL621-4;USSG-FHT relationship;LA10408-5;4;Half-brother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10409-3;5;Half-sister;;; +54136-7;LL621-4;USSG-FHT relationship;LA10410-1;6;Maternal Aunt;;; +54136-7;LL621-4;USSG-FHT relationship;LA10411-9;7;Maternal Cousin;;; +54136-7;LL621-4;USSG-FHT relationship;LA10412-7;8;Maternal Grandfather;;; +54136-7;LL621-4;USSG-FHT relationship;LA10413-5;9;Maternal Grandmother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10414-3;10;Maternal Uncle;;; +54136-7;LL621-4;USSG-FHT relationship;LA10415-0;11;Brother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10416-8;12;Father;;; +54136-7;LL621-4;USSG-FHT relationship;LA10417-6;13;Mother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10418-4;14;Sister;;; +54136-7;LL621-4;USSG-FHT relationship;LA10419-2;15;Nephew;;; +54136-7;LL621-4;USSG-FHT relationship;LA10420-0;16;Niece;;; +54136-7;LL621-4;USSG-FHT relationship;LA10421-8;17;Paternal Aunt;;; +54136-7;LL621-4;USSG-FHT relationship;LA10422-6;18;Paternal Cousin;;; +54136-7;LL621-4;USSG-FHT relationship;LA10423-4;19;Paternal Grandfather;;; +54136-7;LL621-4;USSG-FHT relationship;LA10424-2;20;Paternal Grandmother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10425-9;21;Paternal Uncle;;; +54136-7;LL621-4;USSG-FHT relationship;LA10426-7;22;Son;;; +54136-7;LL621-4;USSG-FHT relationship;LA10405-1;1;Daughter;;; +54136-7;LL621-4;USSG-FHT relationship;LA10406-9;2;Granddaughter;;; +54136-7;LL621-4;USSG-FHT relationship;LA10407-7;3;Grandson;;; +54136-7;LL621-4;USSG-FHT relationship;LA10408-5;4;Half-brother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10409-3;5;Half-sister;;; +54136-7;LL621-4;USSG-FHT relationship;LA10410-1;6;Maternal Aunt;;; +54136-7;LL621-4;USSG-FHT relationship;LA10411-9;7;Maternal Cousin;;; +54136-7;LL621-4;USSG-FHT relationship;LA10412-7;8;Maternal Grandfather;;; +54136-7;LL621-4;USSG-FHT relationship;LA10413-5;9;Maternal Grandmother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10414-3;10;Maternal Uncle;;; +54136-7;LL621-4;USSG-FHT relationship;LA10415-0;11;Brother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10416-8;12;Father;;; +54136-7;LL621-4;USSG-FHT relationship;LA10417-6;13;Mother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10418-4;14;Sister;;; +54136-7;LL621-4;USSG-FHT relationship;LA10419-2;15;Nephew;;; +54136-7;LL621-4;USSG-FHT relationship;LA10420-0;16;Niece;;; +54136-7;LL621-4;USSG-FHT relationship;LA10421-8;17;Paternal Aunt;;; +54136-7;LL621-4;USSG-FHT relationship;LA10422-6;18;Paternal Cousin;;; +54136-7;LL621-4;USSG-FHT relationship;LA10423-4;19;Paternal Grandfather;;; +54136-7;LL621-4;USSG-FHT relationship;LA10424-2;20;Paternal Grandmother;;; +54136-7;LL621-4;USSG-FHT relationship;LA10425-9;21;Paternal Uncle;;; +54136-7;LL621-4;USSG-FHT relationship;LA10426-7;22;Son;;; +54210-0;LL2252-6;HBV BCP;LA19169-4;1;G1757A;;; +54210-0;LL2252-6;HBV BCP;LA19170-2;2;G1764T;;; +54210-0;LL2252-6;HBV BCP;LA19171-0;3;C1766G;;; +54210-0;LL2252-6;HBV BCP;LA19172-8;4;G1764T/C1766G;;; +54210-0;LL2252-6;HBV BCP;LA19173-6;5;A1762T/G1764A;;; +54217-5;LL625-5;Notifiable Condition;LA10430-9;1;AIDS;;; +54217-5;LL625-5;Notifiable Condition;LA10431-7;2;Amebiasis;;; +54217-5;LL625-5;Notifiable Condition;LA10432-5;3;Anthrax;;; +54217-5;LL625-5;Notifiable Condition;LA10433-3;4;Arbovirus infection;;; +54217-5;LL625-5;Notifiable Condition;LA10434-1;5;Babesiosis;;; +54217-5;LL625-5;Notifiable Condition;LA10435-8;6;Blastomyces infection of central nervous system;;; +54217-5;LL625-5;Notifiable Condition;LA10436-6;7;Blastomycosis;;; +54217-5;LL625-5;Notifiable Condition;LA10437-4;8;Botulism, other unspecified;;; +54217-5;LL625-5;Notifiable Condition;LA10438-2;9;Brucellosis;;; +54217-5;LL625-5;Notifiable Condition;LA10439-0;10;Campylobacteriosis;;; +54217-5;LL625-5;Notifiable Condition;LA10440-8;11;Cat scratch disease;;; +54217-5;LL625-5;Notifiable Condition;LA10441-6;12;Chancroid;;; +54217-5;LL625-5;Notifiable Condition;LA10442-4;13;Chlamydia trachomatis genital infection;;; +54217-5;LL625-5;Notifiable Condition;LA10443-2;14;Cholera (toxigenic Vibrio cholerae 01 or 0139);;; +54217-5;LL625-5;Notifiable Condition;LA10444-0;15;Coccidioidomycosis;;; +54217-5;LL625-5;Notifiable Condition;LA10445-7;16;Colorado tick fever;;; +54217-5;LL625-5;Notifiable Condition;LA10446-5;17;Cryptococcosis;;; +54217-5;LL625-5;Notifiable Condition;LA10447-3;18;Cryptococcus infection of central nervous system;;; +54217-5;LL625-5;Notifiable Condition;LA10448-1;19;Cryptosporidiosis;;; +54217-5;LL625-5;Notifiable Condition;LA10449-9;20;Cyclosporiasis;;; +54217-5;LL625-5;Notifiable Condition;LA10450-7;21;Cysticercosis;;; +54217-5;LL625-5;Notifiable Condition;LA10451-5;22;Dengue Fever;;; +54217-5;LL625-5;Notifiable Condition;LA10452-3;23;Diphtheria;;; +54217-5;LL625-5;Notifiable Condition;LA10453-1;24;Ebola virus infection;;; +54217-5;LL625-5;Notifiable Condition;LA10454-9;25;Ehrlichiosis human, other or unspecified agent;;; +54217-5;LL625-5;Notifiable Condition;LA10455-6;26;Ehrlichiosis, human granulocytic (HGE);;; +54217-5;LL625-5;Notifiable Condition;LA10456-4;27;Ehrlichiosis, human monocytic (HME);;; +54217-5;LL625-5;Notifiable Condition;LA10457-2;28;Encephalitis/meningitis, California serogroup viral;;; +54217-5;LL625-5;Notifiable Condition;LA10458-0;29;Encephalitis/meningitis, eastern equine (EEE);;; +54217-5;LL625-5;Notifiable Condition;LA10459-8;30;Encephalitis/meningitis, Powassan;;; +54217-5;LL625-5;Notifiable Condition;LA10460-6;31;Encephalitis/meningitis, St. Louis;;; +54217-5;LL625-5;Notifiable Condition;LA10461-4;32;Encephalitis/meningitis, Venezuelan equine (VEE);;; +54217-5;LL625-5;Notifiable Condition;LA10462-2;33;Encephalitis/meningitis, West Nile;;; +54217-5;LL625-5;Notifiable Condition;LA10463-0;34;Encephalitis/meningitis, western equine (WEE);;; +54217-5;LL625-5;Notifiable Condition;LA10464-8;35;Enterohemorrhagic Escherichia coli (EHEC) O157:H7;;; +54217-5;LL625-5;Notifiable Condition;LA10465-5;36;Enterohemorrhagic Escherichia coli (EHEC) shiga toxin+ (not serogrouped);;; +54217-5;LL625-5;Notifiable Condition;LA10466-3;37;Giardiasis;;; +54217-5;LL625-5;Notifiable Condition;LA10467-1;38;Gonorrhea;;; +54217-5;LL625-5;Notifiable Condition;LA10468-9;39;Haemophilus influenzae, invasive disease;;; +54217-5;LL625-5;Notifiable Condition;LA10469-7;40;Hantavirus Pulmonary Syndrome;;; +54217-5;LL625-5;Notifiable Condition;LA10470-5;41;Heavy metal poisoning;;; +54217-5;LL625-5;Notifiable Condition;LA10471-3;42;Hepatitis A, acute;;; +54217-5;LL625-5;Notifiable Condition;LA10472-1;43;Hepatitis B, acute;;; +54217-5;LL625-5;Notifiable Condition;LA10473-9;44;Hepatitis C virus infection, past or present;;; +54217-5;LL625-5;Notifiable Condition;LA10474-7;45;Hepatitis C, acute;;; +54217-5;LL625-5;Notifiable Condition;LA10475-4;46;Hepatitis E, acute;;; +54217-5;LL625-5;Notifiable Condition;LA10476-2;47;Histoplasma infection of central nervous system;;; +54217-5;LL625-5;Notifiable Condition;LA10477-0;48;Histoplasmosis;;; +54217-5;LL625-5;Notifiable Condition;LA10478-8;49;Influenza (laboratory-confirmed);;; +54217-5;LL625-5;Notifiable Condition;LA10479-6;50;Isosporiasis;;; +54217-5;LL625-5;Notifiable Condition;LA10480-4;51;Japanese encephalitis virus infection of central nervous system;;; +54217-5;LL625-5;Notifiable Condition;LA10481-2;52;Lassa fever;;; +54217-5;LL625-5;Notifiable Condition;LA10482-0;53;Lead poisoning;;; +54217-5;LL625-5;Notifiable Condition;LA10483-8;54;Legionellosis;;; +54217-5;LL625-5;Notifiable Condition;LA10484-6;55;Leptospirosis;;; +54217-5;LL625-5;Notifiable Condition;LA10485-3;56;Listeriosis;;; +54217-5;LL625-5;Notifiable Condition;LA10486-1;57;Louse-borne (epidemic) typhus;;; +54217-5;LL625-5;Notifiable Condition;LA10487-9;58;Lyme disease;;; +54217-5;LL625-5;Notifiable Condition;LA10488-7;59;Malaria;;; +54217-5;LL625-5;Notifiable Condition;LA10489-5;60;Measles (rubeola);;; +54217-5;LL625-5;Notifiable Condition;LA10490-3;61;Meningococcal disease (Neisseria meningitidis);;; +54217-5;LL625-5;Notifiable Condition;LA10491-1;62;Mumps;;; +54217-5;LL625-5;Notifiable Condition;LA10492-9;63;Neurosyphilis;;; +54217-5;LL625-5;Notifiable Condition;LA10493-7;64;Pertussis;;; +54217-5;LL625-5;Notifiable Condition;LA10494-5;65;Pesticide poisoning;;; +54217-5;LL625-5;Notifiable Condition;LA10495-2;66;Plague;;; +54217-5;LL625-5;Notifiable Condition;LA10496-0;67;Poliomyelitis, paralytic;;; +54217-5;LL625-5;Notifiable Condition;LA10497-8;68;Psittacosis (Ornithosis);;; +54217-5;LL625-5;Notifiable Condition;LA10498-6;69;Q fever;;; +54217-5;LL625-5;Notifiable Condition;LA10499-4;70;Rabies, human;;; +54217-5;LL625-5;Notifiable Condition;LA10500-9;71;Relapsing fever;;; +54217-5;LL625-5;Notifiable Condition;LA10501-7;72;Rocky Mountain spotted fever;;; +54217-5;LL625-5;Notifiable Condition;LA10502-5;73;Rubella;;; +54217-5;LL625-5;Notifiable Condition;LA10503-3;74;Salmonellosis;;; +54217-5;LL625-5;Notifiable Condition;LA10504-1;75;SARS;;; +54217-5;LL625-5;Notifiable Condition;LA10505-8;76;Shigellosis;;; +54217-5;LL625-5;Notifiable Condition;LA10506-6;77;Streptococcal disease, invasive, Group A;;; +54217-5;LL625-5;Notifiable Condition;LA10507-4;78;Streptococcal disease, invasive, Group B;;; +54217-5;LL625-5;Notifiable Condition;LA10508-2;79;Streptococcus pneumoniae, invasive disease;;; +54217-5;LL625-5;Notifiable Condition;LA10509-0;80;Syphilis, primary;;; +54217-5;LL625-5;Notifiable Condition;LA10510-8;81;Tetanus;;; +54217-5;LL625-5;Notifiable Condition;LA10511-6;82;Toxoplasmosis;;; +54217-5;LL625-5;Notifiable Condition;LA10512-4;83;Trichinosis;;; +54217-5;LL625-5;Notifiable Condition;LA10513-2;84;Tuberculosis;;; +54217-5;LL625-5;Notifiable Condition;LA10514-0;85;Tularemia;;; +54217-5;LL625-5;Notifiable Condition;LA10515-7;86;Typhoid fever (caused by Salmonella typhi);;; +54217-5;LL625-5;Notifiable Condition;LA10516-5;87;Typhus Fever, (endemic fleaborne, Murine);;; +54217-5;LL625-5;Notifiable Condition;LA10517-3;88;Varicella (Chickenpox);;; +54217-5;LL625-5;Notifiable Condition;LA10518-1;89;Vibrio spp., non-toxigenic, other or unspecified;;; +54217-5;LL625-5;Notifiable Condition;LA10519-9;90;West Nile Fever;;; +54217-5;LL625-5;Notifiable Condition;LA10520-7;91;Yellow fever;;; +54217-5;LL625-5;Notifiable Condition;LA10521-5;92;Yersiniosis;;; +54453-6;LL2448-0;Wet mount/Cent;LA19796-4;1;Direct wet mount;;; +54453-6;LL2448-0;Wet mount/Cent;LA19797-2;2;Centrifuged;;; +54582-2;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +54582-2;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +85632-8;LL630-5;MDSv3_A0200;LA10882-1;1;Nursing home (SNF/NF);;; +85632-8;LL630-5;MDSv3_A0200;LA10883-9;2;Swing bed;;; +54583-0;LL631-3;MDSv3_A0300;LA10-4;1;Admission assessment (required by day 14);;; +54583-0;LL631-3;MDSv3_A0300;LA15-3;2;Quarterly review assessment;;; +54583-0;LL631-3;MDSv3_A0300;LA12-0;3;Annual assessment;;; +54583-0;LL631-3;MDSv3_A0300;LA13-8;4;Significant change in status assessment;;; +54583-0;LL631-3;MDSv3_A0300;LA10888-8;5;Significant correction to prior comprehensive assessment;;; +54583-0;LL631-3;MDSv3_A0300;LA10889-6;6;Significant correction to prior quarterly assessment;;; +54583-0;LL631-3;MDSv3_A0300;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA10900-1;6;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL4610-3;CMS_MDSv3_A0310;LA9-3;7;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA29577-6;2;IPA - Interim Payment Assessment;;; +54584-8;LL5154-1;CMS_MDSv17_A0310;LA9-3;3;None of the above;;; +54584-8;LL632-1;MDSv3_A0300A;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10899-5;6;Readmission/return assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10900-1;7;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL632-1;MDSv3_A0300A;LA9-3;8;None of the above;;; +54584-8;LL632-1;MDSv3_A0300A;LA10894-6;1;5-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10895-3;2;14-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10896-1;3;30-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10897-9;4;60-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10898-7;5;90-day scheduled assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10899-5;6;Readmission/return assessment;;; +54584-8;LL632-1;MDSv3_A0300A;LA10900-1;7;Unscheduled assessment used for PPS (OMRA, significant or clinical change, or significant correction assessment);;; +54584-8;LL632-1;MDSv3_A0300A;LA9-3;8;None of the above;;; +54585-5;LL843-4;MDSv3.0_A0310A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54585-5;LL843-4;MDSv3.0_A0310A;LA12624-5;2;Start of therapy assessment;;; +54585-5;LL843-4;MDSv3.0_A0310A;LA12625-2;3;End of therapy assessment;;; +54585-5;LL843-4;MDSv3.0_A0310A;LA12626-0;4;Both Start and End of therapy assessment;;; +54585-5;LL843-4;MDSv3.0_A0310A;LA18612-4;5;Change of therapy assessment;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54767-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54767-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54767-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54850-3;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54850-3;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54850-3;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54851-1;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54851-1;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54851-1;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54852-9;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54852-9;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54852-9;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +55123-4;LL1502-5;MDSv3_J1700A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55123-4;LL1502-5;MDSv3_J1700A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55123-4;LL1502-5;MDSv3_J1700A;LA11137-9;3;Unable to determine;;; +54588-9;LL633-9;MDSv3_A1100A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL633-9;MDSv3_A1100A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL633-9;MDSv3_A1100A;LA11137-9;3;Unable to determine;;; +54588-9;LL633-9;MDSv3_A1100A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL633-9;MDSv3_A1100A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL633-9;MDSv3_A1100A;LA11137-9;3;Unable to determine;;; +54588-9;LL633-9;MDSv3_A1100A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54588-9;LL633-9;MDSv3_A1100A;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54588-9;LL633-9;MDSv3_A1100A;LA11137-9;3;Unable to determine;;; +54589-7;LL634-7;MDSv3_A1500;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54589-7;LL634-7;MDSv3_A1500;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54589-7;LL634-7;MDSv3_A1500;LA10921-7;3;Not a Medicaid-certified unit;;; +54590-5;LL635-4;MDSv3_A1700;LA10922-5;1;Admission;;; +54590-5;LL635-4;MDSv3_A1700;LA54-2;2;Reentry;;; +54591-3;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +54591-3;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +54591-3;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +54591-3;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +54591-3;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +54591-3;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +54591-3;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +54591-3;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +54591-3;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +85398-6;LL636-2;MDSv3_A0800;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +85398-6;LL636-2;MDSv3_A0800;LA10925-8;2;Another nursing home or swing bed;;; +85398-6;LL636-2;MDSv3_A0800;LA9928-8;3;Acute hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10064-6;4;Psychiatric hospital;;; +85398-6;LL636-2;MDSv3_A0800;LA10928-2;5;Inpatient rehabilitation facility;;; +85398-6;LL636-2;MDSv3_A0800;LA10929-0;6;ID/DD facility;;; +85398-6;LL636-2;MDSv3_A0800;LA6216-1;7;Hospice;;; +85398-6;LL636-2;MDSv3_A0800;LA10000-0;8;Long-term care hospital (LTCH);;; +85398-6;LL636-2;MDSv3_A0800;LA46-8;9;Other;;; +54598-8;LL638-8;MDSv3_B0200;LA10941-5;1;Adequate - no difficulty in normal conversation, social interaction, listening to TV;;; +54598-8;LL638-8;MDSv3_B0200;LA10942-3;2;Minimal difficulty - difficulty in some environments (e.g. when person speaks softly or setting is noisy);;; +54598-8;LL638-8;MDSv3_B0200;LA10943-1;3;Moderate difficulty - speaker has to increase volume and speak distinctly;;; +54598-8;LL638-8;MDSv3_B0200;LA10944-9;4;Highly impaired - absence of useful hearing;;; +93309-3;LL638-8;MDSv3_B0200;LA10941-5;1;Adequate - no difficulty in normal conversation, social interaction, listening to TV;;; +93309-3;LL638-8;MDSv3_B0200;LA10942-3;2;Minimal difficulty - difficulty in some environments (e.g. when person speaks softly or setting is noisy);;; +93309-3;LL638-8;MDSv3_B0200;LA10943-1;3;Moderate difficulty - speaker has to increase volume and speak distinctly;;; +93309-3;LL638-8;MDSv3_B0200;LA10944-9;4;Highly impaired - absence of useful hearing;;; +95744-9;LL638-8;MDSv3_B0200;LA10941-5;1;Adequate - no difficulty in normal conversation, social interaction, listening to TV;;; +95744-9;LL638-8;MDSv3_B0200;LA10942-3;2;Minimal difficulty - difficulty in some environments (e.g. when person speaks softly or setting is noisy);;; +95744-9;LL638-8;MDSv3_B0200;LA10943-1;3;Moderate difficulty - speaker has to increase volume and speak distinctly;;; +95744-9;LL638-8;MDSv3_B0200;LA10944-9;4;Highly impaired - absence of useful hearing;;; +54600-2;LL639-6;MDSv3_B0600;LA10945-6;1;Clear speech - distinct intelligible words;;; +54600-2;LL639-6;MDSv3_B0600;LA10946-4;2;Unclear speech - slurred or mumbled words;;; +54600-2;LL639-6;MDSv3_B0600;LA10947-2;3;No speech - absence of spoken words;;; +54601-0;LL640-4;MDSv3_B0700;LA71-6;1;Understood;;; +54601-0;LL640-4;MDSv3_B0700;LA10949-8;2;Usually understood - difficulty communicating some words or finishing thoughts but is able if prompted or given time;;; +54601-0;LL640-4;MDSv3_B0700;LA10950-6;3;Sometimes understood - ability is limited to making concrete requests;;; +54601-0;LL640-4;MDSv3_B0700;LA74-0;4;Rarely/never understood;;; +54602-8;LL641-2;MDSv3_B0800;LA10952-2;1;Understands - clear comprehension;;; +54602-8;LL641-2;MDSv3_B0800;LA10953-0;2;Usually understands - misses some part/intent of message but comprehends most conversation;;; +54602-8;LL641-2;MDSv3_B0800;LA10954-8;3;Sometimes understands - responds adequately to simple, direct communication only;;; +54602-8;LL641-2;MDSv3_B0800;LA81-5;4;Rarely/never understands;;; +54603-6;LL642-0;MDSv3_B1000;LA10956-3;1;Adequate - sees fine detail, such as regular print in newspapers/books;;; +54603-6;LL642-0;MDSv3_B1000;LA10957-1;2;Impaired - sees large print, but not regular print in newspapers/books;;; +54603-6;LL642-0;MDSv3_B1000;LA10958-9;3;"Moderately impaired - limited vision; not able to see newspaper headlines but can identify objects";;; +54603-6;LL642-0;MDSv3_B1000;LA10959-7;4;Highly impaired - object identification in question, but eyes appear to follow objects;;; +54603-6;LL642-0;MDSv3_B1000;LA10960-5;5;"Severely impaired - no vision or sees only light, colors or shapes; eyes do not appear to follow objects";;; +93310-1;LL642-0;MDSv3_B1000;LA10956-3;1;Adequate - sees fine detail, such as regular print in newspapers/books;;; +93310-1;LL642-0;MDSv3_B1000;LA10957-1;2;Impaired - sees large print, but not regular print in newspapers/books;;; +93310-1;LL642-0;MDSv3_B1000;LA10958-9;3;"Moderately impaired - limited vision; not able to see newspaper headlines but can identify objects";;; +93310-1;LL642-0;MDSv3_B1000;LA10959-7;4;Highly impaired - object identification in question, but eyes appear to follow objects;;; +93310-1;LL642-0;MDSv3_B1000;LA10960-5;5;"Severely impaired - no vision or sees only light, colors or shapes; eyes do not appear to follow objects";;; +95745-6;LL642-0;MDSv3_B1000;LA10956-3;1;Adequate - sees fine detail, such as regular print in newspapers/books;;; +95745-6;LL642-0;MDSv3_B1000;LA10957-1;2;Impaired - sees large print, but not regular print in newspapers/books;;; +95745-6;LL642-0;MDSv3_B1000;LA10958-9;3;"Moderately impaired - limited vision; not able to see newspaper headlines but can identify objects";;; +95745-6;LL642-0;MDSv3_B1000;LA10959-7;4;Highly impaired - object identification in question, but eyes appear to follow objects;;; +95745-6;LL642-0;MDSv3_B1000;LA10960-5;5;"Severely impaired - no vision or sees only light, colors or shapes; eyes do not appear to follow objects";;; +54605-1;LL691-7;MDSv3_D0100;LA11150-2;1;No (resident is rarely/never understood);;; +54605-1;LL691-7;MDSv3_D0100;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54634-1;LL691-7;MDSv3_D0100;LA11150-2;1;No (resident is rarely/never understood);;; +54634-1;LL691-7;MDSv3_D0100;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54828-9;LL691-7;MDSv3_D0100;LA11150-2;1;No (resident is rarely/never understood);;; +54828-9;LL691-7;MDSv3_D0100;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54609-3;LL645-3;MDSv3_C0300C;LA9981-7;1;Incorrect or no answer;;; +54609-3;LL645-3;MDSv3_C0300C;LA9960-1;2;Correct;;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26843-5;1;No (patient was able to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26844-3;2;Yes (patient was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26843-5;1;No (patient was able to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26844-3;2;Yes (patient was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26843-5;1;No (patient was able to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26844-3;2;Yes (patient was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26843-5;1;No (patient was able to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26844-3;2;Yes (patient was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26843-5;1;No (patient was able to complete Brief Interview for Mental Status);;; +54615-0;LL4180-7;CMS IRFPAI_C0900 Staff assess for mental status;LA26844-3;2;Yes (patient was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28146-1;1;No (resident was able to complete Brief Interview for Mental Status);;; +54615-0;LL4658-2;CMS_MDS Staff assess for mental status;LA28147-9;2;Yes (resident was unable to complete Brief Interview for Mental Status);;; +54615-0;LL688-3;MDSv3_C0600;LA11145-2;1;No (resident was able to complete interview);;; +54615-0;LL688-3;MDSv3_C0600;LA11146-0;2;Yes (resident was unable to complete interview);;; +54615-0;LL688-3;MDSv3_C0600;LA11145-2;1;No (resident was able to complete interview);;; +54615-0;LL688-3;MDSv3_C0600;LA11146-0;2;Yes (resident was unable to complete interview);;; +54624-2;LL650-3;MDSv3_C0100;LA10985-2;1;Independent - decisions consistent/reasonable;;; +54624-2;LL650-3;MDSv3_C0100;LA10986-0;2;Modified independence - some difficulty in new situations only;;; +54624-2;LL650-3;MDSv3_C0100;LA10987-8;3;"Moderately impaired - decisions poor; cues/supervision required";;; +54624-2;LL650-3;MDSv3_C0100;LA10988-6;4;Severely impaired - never/rarely made decisions;;; +54625-9;LL651-1;MDSv3_C1100;LA10989-4;1;Yes, Memory OK;;; +54625-9;LL651-1;MDSv3_C1100;LA56-7;2;Memory problem;;; +54628-3;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +54628-3;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +54628-3;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +54629-1;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +54629-1;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +54629-1;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +54630-9;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +54630-9;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +54630-9;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +54631-7;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +54631-7;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +54631-7;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +93414-1;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +93414-1;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +93414-1;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95812-4;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95812-4;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95812-4;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95814-0;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95814-0;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95814-0;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +95815-7;LL652-9;MDSv3_C1300A;LA61-7;1;Behavior not present;;; +95815-7;LL652-9;MDSv3_C1300A;LA10992-8;2;Behavior continuously present, does not fluctuate;;; +95815-7;LL652-9;MDSv3_C1300A;LA10993-6;3;Behavior present, fluctuates (comes and goes, changes in severity);;; +54636-6;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54636-6;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54636-6;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54638-2;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54638-2;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54638-2;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54640-8;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54640-8;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54640-8;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54642-4;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54642-4;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54642-4;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54644-0;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54644-0;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54644-0;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54646-5;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54646-5;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54646-5;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54648-1;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54648-1;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54648-1;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54650-7;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54650-7;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54650-7;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54652-3;LL653-7;MDSv3_D0200A1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54652-3;LL653-7;MDSv3_D0200A1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54652-3;LL653-7;MDSv3_D0200A1;LA10996-9;3;No response;;; +54637-4;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54637-4;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54637-4;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54637-4;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54639-0;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54639-0;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54639-0;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54639-0;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54641-6;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54641-6;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54641-6;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54641-6;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54643-2;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54643-2;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54643-2;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54643-2;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54645-7;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54645-7;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54645-7;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54645-7;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54647-3;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54647-3;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54647-3;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54647-3;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54649-9;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54649-9;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54649-9;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54649-9;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54651-5;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54651-5;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54651-5;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54651-5;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54653-1;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54653-1;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54653-1;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54653-1;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54659-8;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54659-8;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54659-8;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54659-8;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54661-4;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54661-4;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54661-4;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54661-4;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54663-0;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54663-0;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54663-0;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54663-0;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54665-5;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54665-5;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54665-5;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54665-5;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54667-1;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54667-1;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54667-1;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54667-1;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54669-7;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54669-7;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54669-7;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54669-7;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54671-3;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54671-3;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54671-3;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54671-3;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54674-7;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54674-7;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54674-7;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54674-7;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54676-2;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54676-2;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54676-2;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54676-2;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54904-8;LL654-5;MDSv3_D0200A2;LA10997-7;1;Never or 1 day;;; +54904-8;LL654-5;MDSv3_D0200A2;LA10998-5;2;2-6 days (several days);;; +54904-8;LL654-5;MDSv3_D0200A2;LA10999-3;3;7-11 days (half or more of the days);;; +54904-8;LL654-5;MDSv3_D0200A2;LA11000-9;4;12-14 days (nearly every day);;; +54656-4;LL689-1;MDSv3_D0500;LA11147-8;1;No (because Resident Mood Interview was completed);;; +54656-4;LL689-1;MDSv3_D0500;LA11148-6;2;Yes (because 3 or more items in Resident Mood Interview not completed);;; +54682-0;LL657-8;MDSv3_D0200I2;LA11005-8;1;Behavior not exhibited;;; +54682-0;LL657-8;MDSv3_D0200I2;LA11006-6;2;Behavior of this type occurred 1 to 3 days;;; +54682-0;LL657-8;MDSv3_D0200I2;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +54682-0;LL657-8;MDSv3_D0200I2;LA95-5;4;Behavior of this type occurred daily;;; +54683-8;LL657-8;MDSv3_D0200I2;LA11005-8;1;Behavior not exhibited;;; +54683-8;LL657-8;MDSv3_D0200I2;LA11006-6;2;Behavior of this type occurred 1 to 3 days;;; +54683-8;LL657-8;MDSv3_D0200I2;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +54683-8;LL657-8;MDSv3_D0200I2;LA95-5;4;Behavior of this type occurred daily;;; +54684-6;LL657-8;MDSv3_D0200I2;LA11005-8;1;Behavior not exhibited;;; +54684-6;LL657-8;MDSv3_D0200I2;LA11006-6;2;Behavior of this type occurred 1 to 3 days;;; +54684-6;LL657-8;MDSv3_D0200I2;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +54684-6;LL657-8;MDSv3_D0200I2;LA95-5;4;Behavior of this type occurred daily;;; +54692-9;LL657-8;MDSv3_D0200I2;LA11005-8;1;Behavior not exhibited;;; +54692-9;LL657-8;MDSv3_D0200I2;LA11006-6;2;Behavior of this type occurred 1 to 3 days;;; +54692-9;LL657-8;MDSv3_D0200I2;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +54692-9;LL657-8;MDSv3_D0200I2;LA95-5;4;Behavior of this type occurred daily;;; +54693-7;LL657-8;MDSv3_D0200I2;LA11005-8;1;Behavior not exhibited;;; +54693-7;LL657-8;MDSv3_D0200I2;LA11006-6;2;Behavior of this type occurred 1 to 3 days;;; +54693-7;LL657-8;MDSv3_D0200I2;LA94-8;3;Behavior of this type occurred 4 to 6 days, but less than daily;;; +54693-7;LL657-8;MDSv3_D0200I2;LA95-5;4;Behavior of this type occurred daily;;; +54696-0;LL658-6;MDSv3_E1100;LA11009-0;1;Same;;; +54696-0;LL658-6;MDSv3_E1100;LA65-8;2;Improved;;; +54696-0;LL658-6;MDSv3_E1100;LA11011-6;3;Worse;;; +54696-0;LL658-6;MDSv3_E1100;LA11012-4;4;N/A because no prior MDS assessment;;; +54697-8;LL1503-3;MDSv3_F0300v2;LA16158-0;1;No (resident is rarely/never understood and family/significant other not available);;; +54697-8;LL1503-3;MDSv3_F0300v2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54698-6;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54698-6;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54698-6;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54698-6;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54698-6;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54698-6;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54699-4;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54699-4;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54699-4;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54699-4;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54699-4;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54699-4;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54700-0;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54700-0;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54700-0;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54700-0;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54700-0;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54700-0;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54701-8;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54701-8;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54701-8;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54701-8;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54701-8;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54701-8;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54702-6;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54702-6;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54702-6;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54702-6;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54702-6;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54702-6;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54703-4;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54703-4;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54703-4;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54703-4;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54703-4;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54703-4;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54704-2;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54704-2;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54704-2;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54704-2;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54704-2;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54704-2;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54705-9;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54705-9;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54705-9;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54705-9;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54705-9;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54705-9;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54706-7;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54706-7;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54706-7;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54706-7;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54706-7;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54706-7;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54707-5;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54707-5;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54707-5;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54707-5;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54707-5;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54707-5;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54708-3;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54708-3;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54708-3;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54708-3;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54708-3;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54708-3;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54709-1;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54709-1;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54709-1;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54709-1;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54709-1;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54709-1;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54710-9;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54710-9;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54710-9;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54710-9;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54710-9;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54710-9;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54711-7;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54711-7;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54711-7;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54711-7;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54711-7;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54711-7;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54712-5;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54712-5;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54712-5;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54712-5;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54712-5;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54712-5;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54713-3;LL659-4;MDSv3_F0400A;LA11013-2;1;Very important;;; +54713-3;LL659-4;MDSv3_F0400A;LA11014-0;2;Somewhat important;;; +54713-3;LL659-4;MDSv3_F0400A;LA11015-7;3;Not very important;;; +54713-3;LL659-4;MDSv3_F0400A;LA11016-5;4;Not important at all;;; +54713-3;LL659-4;MDSv3_F0400A;LA11017-3;5;Important, but can't do or no choice;;; +54713-3;LL659-4;MDSv3_F0400A;LA11018-1;6;No response or non-responsive;;; +54714-1;LL686-7;MDSv3_F0600;LA11019-9;1;Resident;;; +54714-1;LL686-7;MDSv3_F0600;LA11020-7;2;Family or significant other (close friend or other representative);;; +54714-1;LL686-7;MDSv3_F0600;LA11021-5;3;"Interview could not be completed by resident or family/significant other (""No response"" to 3 or more items)";;; +54715-8;LL692-5;MDS_F0700;LA11151-0;1;No (because Interview for Daily and Activity Preferences (F0400 and F0500) was completed by resident or family/significant other);;; +54715-8;LL692-5;MDS_F0700;LA11152-8;2;Yes (because 3 or more items in Interview for Daily and Activity Preferences (F0400 and F0500) were not completed by resident or family/significant other);;; +54737-2;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54737-2;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54737-2;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54737-2;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54737-2;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54737-2;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54737-2;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54737-2;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54737-2;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54738-0;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54738-0;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54738-0;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54738-0;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54738-0;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54738-0;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54738-0;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54738-0;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54738-0;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54739-8;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54739-8;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54739-8;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54739-8;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54739-8;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54739-8;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54739-8;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54739-8;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54739-8;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54740-6;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54740-6;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54740-6;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54740-6;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54740-6;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54740-6;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54740-6;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54740-6;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54740-6;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54741-4;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54741-4;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54741-4;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54741-4;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54741-4;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54741-4;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54741-4;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54741-4;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54741-4;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54742-2;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54742-2;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54742-2;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54742-2;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54742-2;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54742-2;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54742-2;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54742-2;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54742-2;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54743-0;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54743-0;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54743-0;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54743-0;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54743-0;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54743-0;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54743-0;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54743-0;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54743-0;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54744-8;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54744-8;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54744-8;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54744-8;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54744-8;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54744-8;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54744-8;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54744-8;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54744-8;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54745-5;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54745-5;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54745-5;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54745-5;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54745-5;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54745-5;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54745-5;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54745-5;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54745-5;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54746-3;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54746-3;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54746-3;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54746-3;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54746-3;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54746-3;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54746-3;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54746-3;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54746-3;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54747-1;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54747-1;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54747-1;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54747-1;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54747-1;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54747-1;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54747-1;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54747-1;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54747-1;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54748-9;LL660-2;MDSv3_G0100A;LA11022-3;1;Independent - resident completes activity with no help or oversight;;; +54748-9;LL660-2;MDSv3_G0100A;LA11023-1;2;Set up assistance;;; +54748-9;LL660-2;MDSv3_G0100A;LA11024-9;3;Supervision - oversight, encouragement or cueing provided throughout the activity;;; +54748-9;LL660-2;MDSv3_G0100A;LA11025-6;4;Limited assistance - guided maneuvering of limbs or other non-weight bearing assistance provided at least once;;; +54748-9;LL660-2;MDSv3_G0100A;LA11026-4;5;Extensive assistance, 1 person assist - resident performed part of the activity while one staff member provided weight-bearing support or completed part of the activity at least once;;; +54748-9;LL660-2;MDSv3_G0100A;LA11027-2;6;Extensive assistance, 2 + person assist - resident performed part of the activity while two or more staff members provided weight-bearing support or completed part of the activity at least once;;; +54748-9;LL660-2;MDSv3_G0100A;LA11028-0;7;Total dependence, 1 person assist - full staff performance of activity (requiring only 1 person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54748-9;LL660-2;MDSv3_G0100A;LA11029-8;8;Total dependence, 2 + person assist - full staff performance of activity (requiring 2 or more person assistance) at least once. The resident must be unable or unwilling to perform any part of the activity.;;; +54748-9;LL660-2;MDSv3_G0100A;LA11030-6;9;Activity did not occur during entire period;;; +54749-7;LL661-0;MDSv3_G0300A;LA11031-4;1;Steady at all times;;; +54749-7;LL661-0;MDSv3_G0300A;LA11032-2;2;Not steady, but able to stabilize without staff assistance;;; +54749-7;LL661-0;MDSv3_G0300A;LA11033-0;3;Not steady, only able to stabilize with staff assistance;;; +54749-7;LL661-0;MDSv3_G0300A;LA11034-8;4;Activity did not occur;;; +54750-5;LL661-0;MDSv3_G0300A;LA11031-4;1;Steady at all times;;; +54750-5;LL661-0;MDSv3_G0300A;LA11032-2;2;Not steady, but able to stabilize without staff assistance;;; +54750-5;LL661-0;MDSv3_G0300A;LA11033-0;3;Not steady, only able to stabilize with staff assistance;;; +54750-5;LL661-0;MDSv3_G0300A;LA11034-8;4;Activity did not occur;;; +54751-3;LL661-0;MDSv3_G0300A;LA11031-4;1;Steady at all times;;; +54751-3;LL661-0;MDSv3_G0300A;LA11032-2;2;Not steady, but able to stabilize without staff assistance;;; +54751-3;LL661-0;MDSv3_G0300A;LA11033-0;3;Not steady, only able to stabilize with staff assistance;;; +54751-3;LL661-0;MDSv3_G0300A;LA11034-8;4;Activity did not occur;;; +54752-1;LL661-0;MDSv3_G0300A;LA11031-4;1;Steady at all times;;; +54752-1;LL661-0;MDSv3_G0300A;LA11032-2;2;Not steady, but able to stabilize without staff assistance;;; +54752-1;LL661-0;MDSv3_G0300A;LA11033-0;3;Not steady, only able to stabilize with staff assistance;;; +54752-1;LL661-0;MDSv3_G0300A;LA11034-8;4;Activity did not occur;;; +54753-9;LL661-0;MDSv3_G0300A;LA11031-4;1;Steady at all times;;; +54753-9;LL661-0;MDSv3_G0300A;LA11032-2;2;Not steady, but able to stabilize without staff assistance;;; +54753-9;LL661-0;MDSv3_G0300A;LA11033-0;3;Not steady, only able to stabilize with staff assistance;;; +54753-9;LL661-0;MDSv3_G0300A;LA11034-8;4;Activity did not occur;;; +54754-7;LL655-2;MDSv3_G0400A;LA9606-0;1;No impairment;;; +54754-7;LL655-2;MDSv3_G0400A;LA11036-3;2;Impairment on one side;;; +54754-7;LL655-2;MDSv3_G0400A;LA11037-1;3;Impairment on both sides;;; +54755-4;LL655-2;MDSv3_G0400A;LA9606-0;1;No impairment;;; +54755-4;LL655-2;MDSv3_G0400A;LA11036-3;2;Impairment on one side;;; +54755-4;LL655-2;MDSv3_G0400A;LA11037-1;3;Impairment on both sides;;; +92850-7;LL655-2;MDSv3_G0400A;LA9606-0;1;No impairment;;; +92850-7;LL655-2;MDSv3_G0400A;LA11036-3;2;Impairment on one side;;; +92850-7;LL655-2;MDSv3_G0400A;LA11037-1;3;Impairment on both sides;;; +92851-5;LL655-2;MDSv3_G0400A;LA9606-0;1;No impairment;;; +92851-5;LL655-2;MDSv3_G0400A;LA11036-3;2;Impairment on one side;;; +92851-5;LL655-2;MDSv3_G0400A;LA11037-1;3;Impairment on both sides;;; +54768-7;LL662-8;MDSv3_H0200B;LA11038-9;1;No improvement;;; +54768-7;LL662-8;MDSv3_H0200B;LA11039-7;2;Decreased wetness;;; +54768-7;LL662-8;MDSv3_H0200B;LA11040-5;3;Completely dry (continent);;; +54768-7;LL662-8;MDSv3_H0200B;LA11041-3;4;Unable to determine or trial in progress;;; +54770-3;LL663-6;MDSv3_H0300;LA11042-1;1;Always continent;;; +54770-3;LL663-6;MDSv3_H0300;LA11043-9;2;Occasionally incontinent (less than 7 episodes of incontinence);;; +54770-3;LL663-6;MDSv3_H0300;LA11044-7;3;Frequently incontinent (7 or more episodes of urinary incontinence, but with at least one episode of continent voiding);;; +54770-3;LL663-6;MDSv3_H0300;LA11045-4;4;Always incontinent (no episodes of continent voiding);;; +54770-3;LL663-6;MDSv3_H0300;LA11046-2;5;Not rated, resident had a catheter (indwelling, condom), urinary ostomy, or no urine output for the entire 7 days;;; +54771-1;LL664-4;MDSv3_H0400;LA11042-1;1;Always continent;;; +54771-1;LL664-4;MDSv3_H0400;LA11048-8;2;Occasionally incontinent (one episode of bowel incontinence);;; +54771-1;LL664-4;MDSv3_H0400;LA11049-6;3;Frequently incontinent (2 or more episodes of bowel incontinence, but at least one continent bowel movement);;; +54771-1;LL664-4;MDSv3_H0400;LA11050-4;4;Always incontinent (no episodes of continent bowel movements);;; +54771-1;LL664-4;MDSv3_H0400;LA11051-2;5;Not rated, resident had an ostomy or did not have a bowel movement for the entire 7 days;;; +54829-7;LL665-1;MDSv3_J0300;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54829-7;LL665-1;MDSv3_J0300;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54829-7;LL665-1;MDSv3_J0300;LA11054-6;3;Unable to answer;;; +54831-3;LL665-1;MDSv3_J0300;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54831-3;LL665-1;MDSv3_J0300;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54831-3;LL665-1;MDSv3_J0300;LA11054-6;3;Unable to answer;;; +54832-1;LL665-1;MDSv3_J0300;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +54832-1;LL665-1;MDSv3_J0300;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +54832-1;LL665-1;MDSv3_J0300;LA11054-6;3;Unable to answer;;; +54830-5;LL5497-4;Rarely | Almost constantly w/code;LA30273-9;1;Rarely or not at all;;; +54830-5;LL5497-4;Rarely | Almost constantly w/code;LA6483-7;2;Occasionally;;; +54830-5;LL5497-4;Rarely | Almost constantly w/code;LA6482-9;3;Frequently;;; +54830-5;LL5497-4;Rarely | Almost constantly w/code;LA11055-3;4;Almost constantly;;; +54830-5;LL5497-4;Rarely | Almost constantly w/code;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54830-5;LL666-9;MDSv3_0400;LA11055-3;1;Almost constantly;;; +54830-5;LL666-9;MDSv3_0400;LA6482-9;2;Frequently;;; +54830-5;LL666-9;MDSv3_0400;LA6483-7;3;Occasionally;;; +54830-5;LL666-9;MDSv3_0400;LA10066-1;4;Rarely;;; +54830-5;LL666-9;MDSv3_0400;LA11054-6;5;Unable to answer;;; +54834-7;LL667-7;MDSv3_J0600B;LA6752-5;1;Mild;;; +54834-7;LL667-7;MDSv3_J0600B;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +54834-7;LL667-7;MDSv3_J0600B;LA6750-9;3;Severe;;; +54834-7;LL667-7;MDSv3_J0600B;LA11063-7;4;Very severe, horrible;;; +54834-7;LL667-7;MDSv3_J0600B;LA11054-6;5;Unable to answer;;; +54840-4;LL668-5;MDSv3_J0900;LA11065-2;1;No issue of pain;;; +54840-4;LL668-5;MDSv3_J0900;LA11066-0;2;Pain intensity acceptable to resident, no treatment regimen or change in regimen required;;; +54840-4;LL668-5;MDSv3_J0900;LA11067-8;3;Controlled adequately by therapeutic regimen;;; +54840-4;LL668-5;MDSv3_J0900;LA11068-6;4;Controlled when therapeutic regimen followed, but not always followed as ordered;;; +54840-4;LL668-5;MDSv3_J0900;LA11069-4;5;Therapeutic regimen followed, but pain control not adequate;;; +54840-4;LL668-5;MDSv3_J0900;LA11070-2;6;"No therapeutic regimen being followed for pain; pain not adequately controlled";;; +54855-2;LL670-1;MDSv3_J1900A;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +54855-2;LL670-1;MDSv3_J1900A;LA6306-0;2;One;;; +54855-2;LL670-1;MDSv3_J1900A;LA11073-6;3;Two or more;;; +54856-0;LL670-1;MDSv3_J1900A;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +54856-0;LL670-1;MDSv3_J1900A;LA6306-0;2;One;;; +54856-0;LL670-1;MDSv3_J1900A;LA11073-6;3;Two or more;;; +54857-8;LL670-1;MDSv3_J1900A;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +54857-8;LL670-1;MDSv3_J1900A;LA6306-0;2;One;;; +54857-8;LL670-1;MDSv3_J1900A;LA11073-6;3;Two or more;;; +54863-6;LL671-9;MDSv3_K0300;LA11074-4;1;No or unknown;;; +54863-6;LL671-9;MDSv3_K0300;LA11075-1;2;Yes, on physician-prescribed weight-loss regimen;;; +54863-6;LL671-9;MDSv3_K0300;LA11076-9;3;Yes, not on physician-prescribed weight-loss regimen;;; +54869-3;LL673-5;MDSv3_K0700B;LA11080-1;1;500 cc/day or less;;; +54869-3;LL673-5;MDSv3_K0700B;LA11081-9;2;501 cc/day or more;;; +86682-2;LL673-5;MDSv3_K0700B;LA11080-1;1;500 cc/day or less;;; +86682-2;LL673-5;MDSv3_K0700B;LA11081-9;2;501 cc/day or more;;; +86683-0;LL673-5;MDSv3_K0700B;LA11080-1;1;500 cc/day or less;;; +86683-0;LL673-5;MDSv3_K0700B;LA11081-9;2;501 cc/day or more;;; +86684-8;LL673-5;MDSv3_K0700B;LA11080-1;1;500 cc/day or less;;; +86684-8;LL673-5;MDSv3_K0700B;LA11081-9;2;501 cc/day or more;;; +54896-6;LL669-3;MDSv3_A0400;LA10908-4;1;Neither federal nor state required submission;;; +54896-6;LL669-3;MDSv3_A0400;LA10907-6;2;State but not federal required submission (FOR NURSING HOMES ONLY);;; +54896-6;LL669-3;MDSv3_A0400;LA10906-8;3;Federal required submission;;; +54897-4;LL672-7;MDSv3_K0700A;LA11077-7;1;25% or less;;; +54897-4;LL672-7;MDSv3_K0700A;LA11078-5;2;26-50%;;; +54897-4;LL672-7;MDSv3_K0700A;LA11079-3;3;51% or more;;; +86680-6;LL672-7;MDSv3_K0700A;LA11077-7;1;25% or less;;; +86680-6;LL672-7;MDSv3_K0700A;LA11078-5;2;26-50%;;; +86680-6;LL672-7;MDSv3_K0700A;LA11079-3;3;51% or more;;; +86681-4;LL672-7;MDSv3_K0700A;LA11077-7;1;25% or less;;; +86681-4;LL672-7;MDSv3_K0700A;LA11078-5;2;26-50%;;; +86681-4;LL672-7;MDSv3_K0700A;LA11079-3;3;51% or more;;; +86687-1;LL672-7;MDSv3_K0700A;LA11077-7;1;25% or less;;; +86687-1;LL672-7;MDSv3_K0700A;LA11078-5;2;26-50%;;; +86687-1;LL672-7;MDSv3_K0700A;LA11079-3;3;51% or more;;; +54899-0;LL1628-8;PhenX18_11_languages;LA43-5;1;English;;; +54899-0;LL1628-8;PhenX18_11_languages;LA44-3;2;Spanish;;; +54899-0;LL1628-8;PhenX18_11_languages;LA4168-6;3;Chinese;;; +54899-0;LL1628-8;PhenX18_11_languages;LA4443-3;4;Vietnamese;;; +54899-0;LL1628-8;PhenX18_11_languages;LA15353-8;5;Tagalog;;; +54899-0;LL1628-8;PhenX18_11_languages;LA46-8;6;Other;;; +66948-1;LL1628-8;PhenX18_11_languages;LA43-5;1;English;;; +66948-1;LL1628-8;PhenX18_11_languages;LA44-3;2;Spanish;;; +66948-1;LL1628-8;PhenX18_11_languages;LA4168-6;3;Chinese;;; +66948-1;LL1628-8;PhenX18_11_languages;LA4443-3;4;Vietnamese;;; +66948-1;LL1628-8;PhenX18_11_languages;LA15353-8;5;Tagalog;;; +66948-1;LL1628-8;PhenX18_11_languages;LA46-8;6;Other;;; +54899-0;LL5349-7;PRAPARE_Primary Language;LA43-5;0;English;;; +54899-0;LL5349-7;PRAPARE_Primary Language;LA30188-9;1;Language other than English;;; +54899-0;LL5349-7;PRAPARE_Primary Language;LA30122-8;2;I choose not to answer this question;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26745-2;1;Patient not in this facility during this year's influenza vaccination season;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4488-4;CMS_IRF-PAI Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA28194-1;1;Resident not in this facility during this year's influenza vaccination season;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA184-4;2;Received outside of this facility;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA186-9;4;Offered and declined;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA187-7;5;Not offered;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA26746-0;6;Inability to obtain influenza vaccine due to a declared shortage;;; +55020-2;LL4672-3;CMS_MDS Reason influenza vaccine not received;LA9-3;7;None of the above;;; +55020-2;LL676-8;MDSv3_O0200B;LA12666-6;1;Resident not in facility during this year's flu season;;; +55020-2;LL676-8;MDSv3_O0200B;LA184-4;2;Received outside of this facility;;; +55020-2;LL676-8;MDSv3_O0200B;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL676-8;MDSv3_O0200B;LA186-9;4;Offered and declined;;; +55020-2;LL676-8;MDSv3_O0200B;LA187-7;5;Not offered;;; +55020-2;LL676-8;MDSv3_O0200B;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +55020-2;LL676-8;MDSv3_O0200B;LA9-3;7;None of the above;;; +55020-2;LL676-8;MDSv3_O0200B;LA12666-6;1;Resident not in facility during this year's flu season;;; +55020-2;LL676-8;MDSv3_O0200B;LA184-4;2;Received outside of this facility;;; +55020-2;LL676-8;MDSv3_O0200B;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL676-8;MDSv3_O0200B;LA186-9;4;Offered and declined;;; +55020-2;LL676-8;MDSv3_O0200B;LA187-7;5;Not offered;;; +55020-2;LL676-8;MDSv3_O0200B;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +55020-2;LL676-8;MDSv3_O0200B;LA9-3;7;None of the above;;; +55020-2;LL676-8;MDSv3_O0200B;LA12666-6;1;Resident not in facility during this year's flu season;;; +55020-2;LL676-8;MDSv3_O0200B;LA184-4;2;Received outside of this facility;;; +55020-2;LL676-8;MDSv3_O0200B;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL676-8;MDSv3_O0200B;LA186-9;4;Offered and declined;;; +55020-2;LL676-8;MDSv3_O0200B;LA187-7;5;Not offered;;; +55020-2;LL676-8;MDSv3_O0200B;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +55020-2;LL676-8;MDSv3_O0200B;LA9-3;7;None of the above;;; +55020-2;LL676-8;MDSv3_O0200B;LA12666-6;1;Resident not in facility during this year's flu season;;; +55020-2;LL676-8;MDSv3_O0200B;LA184-4;2;Received outside of this facility;;; +55020-2;LL676-8;MDSv3_O0200B;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL676-8;MDSv3_O0200B;LA186-9;4;Offered and declined;;; +55020-2;LL676-8;MDSv3_O0200B;LA187-7;5;Not offered;;; +55020-2;LL676-8;MDSv3_O0200B;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +55020-2;LL676-8;MDSv3_O0200B;LA9-3;7;None of the above;;; +55020-2;LL676-8;MDSv3_O0200B;LA12666-6;1;Resident not in facility during this year's flu season;;; +55020-2;LL676-8;MDSv3_O0200B;LA184-4;2;Received outside of this facility;;; +55020-2;LL676-8;MDSv3_O0200B;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL676-8;MDSv3_O0200B;LA186-9;4;Offered and declined;;; +55020-2;LL676-8;MDSv3_O0200B;LA187-7;5;Not offered;;; +55020-2;LL676-8;MDSv3_O0200B;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +55020-2;LL676-8;MDSv3_O0200B;LA9-3;7;None of the above;;; +55020-2;LL676-8;MDSv3_O0200B;LA12666-6;1;Resident not in facility during this year's flu season;;; +55020-2;LL676-8;MDSv3_O0200B;LA184-4;2;Received outside of this facility;;; +55020-2;LL676-8;MDSv3_O0200B;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL676-8;MDSv3_O0200B;LA186-9;4;Offered and declined;;; +55020-2;LL676-8;MDSv3_O0200B;LA187-7;5;Not offered;;; +55020-2;LL676-8;MDSv3_O0200B;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +55020-2;LL676-8;MDSv3_O0200B;LA9-3;7;None of the above;;; +55020-2;LL676-8;MDSv3_O0200B;LA12666-6;1;Resident not in facility during this year's flu season;;; +55020-2;LL676-8;MDSv3_O0200B;LA184-4;2;Received outside of this facility;;; +55020-2;LL676-8;MDSv3_O0200B;LA11091-8;3;Not eligible - medical contraindication;;; +55020-2;LL676-8;MDSv3_O0200B;LA186-9;4;Offered and declined;;; +55020-2;LL676-8;MDSv3_O0200B;LA187-7;5;Not offered;;; +55020-2;LL676-8;MDSv3_O0200B;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +55020-2;LL676-8;MDSv3_O0200B;LA9-3;7;None of the above;;; +55055-8;LL680-0;MDSv3_Q0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55055-8;LL680-0;MDSv3_Q0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55055-8;LL680-0;MDSv3_Q0200;LA11107-2;3;Unknown or uncertain;;; +58149-6;LL680-0;MDSv3_Q0200;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58149-6;LL680-0;MDSv3_Q0200;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58149-6;LL680-0;MDSv3_Q0200;LA11107-2;3;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30462-8;1;Discharge to the community;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30463-6;2;Remain in this facility;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA30464-4;3;Discharge to another facility/institution;;; +55057-4;LL853-3;MDSv3_Q0300_A;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11019-9;1;Resident;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL4673-1;CMS_MDS Information source for goals;LA11107-2;4;Unknown or uncertain;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA11019-9;1;Resident;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA18613-2;4;No information source available;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA11019-9;1;Resident;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA11116-3;2;If not resident, then family or significant other;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +55058-2;LL855-8;MDSv3_Q0300_B;LA18613-2;4;No information source available;;; +55073-1;LL674-3;MDSv3_M0700;LA11082-7;1;Epithelial tissue - new skin growing in superficial ulcer. It can be light pink and shiny, even in persons with darkly pigmented skin.;;; +55073-1;LL674-3;MDSv3_M0700;LA11083-5;2;Granulation tissue - pink or red tissue with shiny, moist, granular appearance;;; +55073-1;LL674-3;MDSv3_M0700;LA11084-3;3;Slough - yellow or white tissue that adheres to the ulcer bed in strings or thick clumps, or is mucinous;;; +55073-1;LL674-3;MDSv3_M0700;LA11085-0;4;Necrotic Tissue (Eschar) - black, brown, or tan tissue that adheres firmly to the wound bed or ulcer edges, may be softer or harder than surrounding skin.;;; +55073-1;LL674-3;MDSv3_M0700;LA9-3;5;None of the above;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL4587-3;CMS_MDS Ax participation-family;LA27973-9;3;Resident has no family or significant other;;; +55074-9;LL679-2;MDSv3_Q0100B;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL679-2;MDSv3_Q0100B;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL679-2;MDSv3_Q0100B;LA11104-9;3;No family or significant other available;;; +55074-9;LL679-2;MDSv3_Q0100B;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +55074-9;LL679-2;MDSv3_Q0100B;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +55074-9;LL679-2;MDSv3_Q0100B;LA11104-9;3;No family or significant other available;;; +55076-4;LL685-9;MDSv3_Z0600F;LA11135-3;1;Product submission;;; +55076-4;LL685-9;MDSv3_Z0600F;LA11136-1;2;Test submission;;; +55082-2;LL684-2;MDSv3_Z0600E;LA11132-0;1;Addition;;; +55082-2;LL684-2;MDSv3_Z0600E;LA11133-8;2;Modification;;; +55082-2;LL684-2;MDSv3_Z0600E;LA11134-6;3;Inactivation;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11118-9;1;Nursing home comprehensive assessment coupled with PPS assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11119-7;2;Nursing home comprehensive assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11120-5;3;Nursing home quarterly assessment coupled with PPS assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11121-3;4;Nursing home quarterly assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11122-1;5;Nursing home discharge coupled with EMCA;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11138-7;6;Nursing home discharge;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11123-9;7;Nursing home entry;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11124-7;8;Nursing home PPS assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11125-4;9;Nursing home EMCA;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11142-9;10;Nursing home not OMBRA and not PPS assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11126-2;11;Swing bed discharge coupled with EMCA;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11127-0;12;Swing bed discharge;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11139-5;13;Swing bed entry;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11128-8;14;Swing bed PPS assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA10901-9;15;Swing bed clinical change assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11130-4;16;Swing bed EMCA;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11141-1;17;Swing bed not a PPS assessment;;; +55083-0;LL683-4;MDSv3_Z0100B;LA11131-2;18;Inactivation transaction;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +55128-3;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +55128-3;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +55128-3;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +55128-3;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +55128-3;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +55128-3;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +55128-3;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +85398-6;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +85398-6;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +85398-6;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +85398-6;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +85398-6;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +85398-6;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +85398-6;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +85398-6;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +85399-4;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +85399-4;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +85399-4;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +85399-4;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +85399-4;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +85399-4;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +85399-4;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +85399-4;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +85399-4;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85399-4;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +85399-4;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +85399-4;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +85399-4;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +85399-4;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +85416-6;LL4427-2;CMS Living/residence settings;LA27336-9;1;Home (private home/apt., board/care, assisted living, group home, transistional living);;; +85416-6;LL4427-2;CMS Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +85416-6;LL4427-2;CMS Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +85416-6;LL4427-2;CMS Living/residence settings;LA27339-3;4;Intermediate care;;; +85416-6;LL4427-2;CMS Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +85416-6;LL4427-2;CMS Living/residence settings;LA27341-9;6;Hospice (home);;; +85416-6;LL4427-2;CMS Living/residence settings;LA27342-7;7;Hospice (institutional facility);;; +85416-6;LL4427-2;CMS Living/residence settings;LA10883-9;8;Swing bed;;; +85416-6;LL4427-2;CMS Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85416-6;LL4427-2;CMS Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +85416-6;LL4427-2;CMS Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +85416-6;LL4427-2;CMS Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +85416-6;LL4427-2;CMS Living/residence settings;LA22835-5;13;Critical Access Hospital;;; +85416-6;LL4427-2;CMS Living/residence settings;LA27349-2;14;Not listed;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA11501-6;2;Community residential setting (e.g., private home, assisted living, group home, adult foster care);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA18066-3;3;Long-term care facility;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA27338-5;4;Skilled nursing facility (SNF);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA11504-0;5;Hospital emergency department;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA10078-6;6;Short-stay acute hospital (IPPS);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA10000-0;7;Long-term care hospital (LTCH);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA27548-9;8;Inpatient rehabilitation facility or unit (IRF);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA10065-3;9;Psychiatric hospital or unit;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA28224-6;10;Intellectually disabled/developmentally disabled (ID/DD) facility;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA6216-1;11;Hospice;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA9965-0;12;Discharged against medical advice;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA46-8;13;Other;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA11501-6;2;Community residential setting (e.g., private home, assisted living, group home, adult foster care);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA18066-3;3;Long-term care facility;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA27338-5;4;Skilled nursing facility (SNF);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA11504-0;5;Hospital emergency department;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA10078-6;6;Short-stay acute hospital (IPPS);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA10000-0;7;Long-term care hospital (LTCH);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA27548-9;8;Inpatient rehabilitation facility or unit (IRF);;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA10065-3;9;Psychiatric hospital or unit;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA28224-6;10;Intellectually disabled/developmentally disabled (ID/DD) facility;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA6216-1;11;Hospice;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA9965-0;12;Discharged against medical advice;;; +55128-3;LL4472-8;CMS_LCDS Discharge location;LA46-8;13;Other;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA30313-3;1;Home (e.g., private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements);;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27337-7;2;Short-term General Hospital;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27338-5;3;Skilled nursing facility (SNF);;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27339-3;4;Intermediate care;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27340-1;5;Home under care of organized home health service organization;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27341-9;6;Hospice (home);;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA30259-8;7;Hospice (medical facility);;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA10883-9;8;Swing bed;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA10000-0;10;Long-term care hospital (LTCH);;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27346-8;11;Medicaid Nursing Facility;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27347-6;12;Inpatient Psychiatric Facility;;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA30261-4;13;Critical Access Hospital (CAH);;; +55128-3;LL5393-5;CMS IRF-PAI v4.0 Living/residence settings;LA27349-2;14;Not listed;;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30344-8;1;Home/Community (e.g., private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements;;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30345-5;2;Nursing Home (long-term care facility);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30346-3;3;Skilled Nursing Facility (SNF, swing bed);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30347-1;4;Short-Term General Hospital (acute hospital, IPPS);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA10000-0;5;Long-term care hospital (LTCH);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30348-9;6;Inpatient Rehabilitation Facility (IRF, free standing facility or unit);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30349-7;7;Inpatient Psychiatric Facility (psychiatric hospital or unit);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30350-5;8;Intermediate Care Facility (ID/DD facility);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30351-3;9;Hospice (home/non-institutional);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27342-7;10;Hospice (institutional facility);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30261-4;11;Critical Access Hospital (CAH);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27340-1;12;Home under care of organized home health service organization;;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27349-2;13;Not listed;;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30344-8;1;Home/Community (e.g., private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements;;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30345-5;2;Nursing Home (long-term care facility);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30346-3;3;Skilled Nursing Facility (SNF, swing bed);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30347-1;4;Short-Term General Hospital (acute hospital, IPPS);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA10000-0;5;Long-term care hospital (LTCH);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30348-9;6;Inpatient Rehabilitation Facility (IRF, free standing facility or unit);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30349-7;7;Inpatient Psychiatric Facility (psychiatric hospital or unit);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30350-5;8;Intermediate Care Facility (ID/DD facility);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30351-3;9;Hospice (home/non-institutional);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27342-7;10;Hospice (institutional facility);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30261-4;11;Critical Access Hospital (CAH);;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27340-1;12;Home under care of organized home health service organization;;; +55128-3;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27349-2;13;Not listed;;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30344-8;1;Home/Community (e.g., private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements;;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30345-5;2;Nursing Home (long-term care facility);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30346-3;3;Skilled Nursing Facility (SNF, swing bed);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30347-1;4;Short-Term General Hospital (acute hospital, IPPS);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA10000-0;5;Long-term care hospital (LTCH);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30348-9;6;Inpatient Rehabilitation Facility (IRF, free standing facility or unit);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30349-7;7;Inpatient Psychiatric Facility (psychiatric hospital or unit);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30350-5;8;Intermediate Care Facility (ID/DD facility);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30351-3;9;Hospice (home/non-institutional);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27342-7;10;Hospice (institutional facility);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30261-4;11;Critical Access Hospital (CAH);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27340-1;12;Home under care of organized home health service organization;;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27349-2;13;Not listed;;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30344-8;1;Home/Community (e.g., private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements;;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30345-5;2;Nursing Home (long-term care facility);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30346-3;3;Skilled Nursing Facility (SNF, swing bed);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30347-1;4;Short-Term General Hospital (acute hospital, IPPS);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA10000-0;5;Long-term care hospital (LTCH);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30348-9;6;Inpatient Rehabilitation Facility (IRF, free standing facility or unit);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30349-7;7;Inpatient Psychiatric Facility (psychiatric hospital or unit);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30350-5;8;Intermediate Care Facility (ID/DD facility);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30351-3;9;Hospice (home/non-institutional);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27342-7;10;Hospice (institutional facility);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA30261-4;11;Critical Access Hospital (CAH);;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27340-1;12;Home under care of organized home health service organization;;; +85398-6;LL5400-8;CMS_LCDS v5.0 - Admitted from (A1805);LA27349-2;13;Not listed;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA27543-0;1;Community residential setting (e.g., private home/apt., board/care, assisted living, group home, adult foster care);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA18066-3;3;Long-term care facility;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA27338-5;4;Skilled nursing facility (SNF);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA11504-0;5;Hospital emergency department;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA10078-6;6;Short-stay acute hospital (IPPS);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA10000-0;7;Long-term care hospital (LTCH);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA27548-9;8;Inpatient rehabilitation facility or unit (IRF);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA10065-3;9;Psychiatric hospital or unit;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA28224-6;10;Intellectually disabled/developmentally disabled (ID/DD) facility;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA6216-1;11;Hospice;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA9965-0;12;Discharged against medical advice;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA46-8;13;Other;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA27543-0;1;Community residential setting (e.g., private home/apt., board/care, assisted living, group home, adult foster care);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA18066-3;3;Long-term care facility;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA27338-5;4;Skilled nursing facility (SNF);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA11504-0;5;Hospital emergency department;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA10078-6;6;Short-stay acute hospital (IPPS);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA10000-0;7;Long-term care hospital (LTCH);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA27548-9;8;Inpatient rehabilitation facility or unit (IRF);;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA10065-3;9;Psychiatric hospital or unit;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA28224-6;10;Intellectually disabled/developmentally disabled (ID/DD) facility;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA6216-1;11;Hospice;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA9965-0;12;Discharged against medical advice;;; +55128-3;LL5739-9;CMS_LCDSv4 Discharge location;LA46-8;13;Other;;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30344-8;1;Home/Community (e.g., private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements;;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30345-5;2;Nursing Home (long-term care facility);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30346-3;3;Skilled Nursing Facility (SNF, swing bed);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30347-1;4;Short-Term General Hospital (acute hospital, IPPS);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA10000-0;5;Long-term care hospital (LTCH);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30348-9;6;Inpatient Rehabilitation Facility (IRF, free standing facility or unit);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30349-7;7;Inpatient Psychiatric Facility (psychiatric hospital or unit);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30350-5;8;Intermediate Care Facility (ID/DD facility);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30351-3;9;Hospice (home/non-institutional);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA27342-7;10;Hospice (institutional facility);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA30261-4;11;Critical Access Hospital (CAH);;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA27340-1;12;Home under care of organized home health service organization;;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA10939-9;13;Deceased;;; +55128-3;LL6296-9;***** CLONED FROM - LL5400-8 *****;LA27349-2;14;Not listed;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL637-0;MDSv3_A2100;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +55128-3;LL637-0;MDSv3_A2100;LA10925-8;2;Another nursing home or swing bed;;; +55128-3;LL637-0;MDSv3_A2100;LA9928-8;3;Acute hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10064-6;4;Psychiatric hospital;;; +55128-3;LL637-0;MDSv3_A2100;LA10928-2;5;Inpatient rehabilitation facility;;; +55128-3;LL637-0;MDSv3_A2100;LA10929-0;6;ID/DD facility;;; +55128-3;LL637-0;MDSv3_A2100;LA6216-1;7;Hospice;;; +55128-3;LL637-0;MDSv3_A2100;LA10939-9;8;Deceased;;; +55128-3;LL637-0;MDSv3_A2100;LA10000-0;9;Long-term care hospital (LTCH);;; +55128-3;LL637-0;MDSv3_A2100;LA46-8;10;Other;;; +55128-3;LL826-9;OASIS-C_M2420;LA12374-7;1;Patient remained in the community (without formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12375-4;2;Patient remained in the community (with formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12376-2;3;Patient transferred to a non-institutional hospice;;; +55128-3;LL826-9;OASIS-C_M2420;LA6431-6;4;Unknown because patient moved to a geographic location not served by this agency;;; +55128-3;LL826-9;OASIS-C_M2420;LA6316-9;5;Other unknown;;; +55128-3;LL826-9;OASIS-C_M2420;LA12374-7;1;Patient remained in the community (without formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12375-4;2;Patient remained in the community (with formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12376-2;3;Patient transferred to a non-institutional hospice;;; +55128-3;LL826-9;OASIS-C_M2420;LA6431-6;4;Unknown because patient moved to a geographic location not served by this agency;;; +55128-3;LL826-9;OASIS-C_M2420;LA6316-9;5;Other unknown;;; +55128-3;LL826-9;OASIS-C_M2420;LA12374-7;1;Patient remained in the community (without formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12375-4;2;Patient remained in the community (with formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12376-2;3;Patient transferred to a non-institutional hospice;;; +55128-3;LL826-9;OASIS-C_M2420;LA6431-6;4;Unknown because patient moved to a geographic location not served by this agency;;; +55128-3;LL826-9;OASIS-C_M2420;LA6316-9;5;Other unknown;;; +55128-3;LL826-9;OASIS-C_M2420;LA12374-7;1;Patient remained in the community (without formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12375-4;2;Patient remained in the community (with formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12376-2;3;Patient transferred to a non-institutional hospice;;; +55128-3;LL826-9;OASIS-C_M2420;LA6431-6;4;Unknown because patient moved to a geographic location not served by this agency;;; +55128-3;LL826-9;OASIS-C_M2420;LA6316-9;5;Other unknown;;; +55128-3;LL826-9;OASIS-C_M2420;LA12374-7;1;Patient remained in the community (without formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12375-4;2;Patient remained in the community (with formal assistive services);;; +55128-3;LL826-9;OASIS-C_M2420;LA12376-2;3;Patient transferred to a non-institutional hospice;;; +55128-3;LL826-9;OASIS-C_M2420;LA6431-6;4;Unknown because patient moved to a geographic location not served by this agency;;; +55128-3;LL826-9;OASIS-C_M2420;LA6316-9;5;Other unknown;;; +57278-4;LL826-9;OASIS-C_M2420;LA12374-7;1;Patient remained in the community (without formal assistive services);;; +57278-4;LL826-9;OASIS-C_M2420;LA12375-4;2;Patient remained in the community (with formal assistive services);;; +57278-4;LL826-9;OASIS-C_M2420;LA12376-2;3;Patient transferred to a non-institutional hospice;;; +57278-4;LL826-9;OASIS-C_M2420;LA6431-6;4;Unknown because patient moved to a geographic location not served by this agency;;; +57278-4;LL826-9;OASIS-C_M2420;LA6316-9;5;Other unknown;;; +55198-6;LL2186-6;Zygosity;LA18941-7;1;Twin X and Twin Y are dizygotic (fraternal);;; +55198-6;LL2186-6;Zygosity;LA18940-9;2;Twin X and Twin Y are monozygotic (identical);;; +97103-6;LL2186-6;Zygosity;LA18941-7;1;Twin X and Twin Y are dizygotic (fraternal);;; +97103-6;LL2186-6;Zygosity;LA18940-9;2;Twin X and Twin Y are monozygotic (identical);;; +55285-1;LL1852-4;NEMSIS_65_GCS qualifier;LA17102-7;1;Initial GCS has legitimate values without interventions such as intubation and sedation;;; +55285-1;LL1852-4;NEMSIS_65_GCS qualifier;LA17103-5;2;Eye obstruction prevents eye assessment;;; +55285-1;LL1852-4;NEMSIS_65_GCS qualifier;LA17104-3;3;Patient chemically sedated;;; +55285-1;LL1852-4;NEMSIS_65_GCS qualifier;LA17105-0;4;Patient chemically paralyzed;;; +55285-1;LL1852-4;NEMSIS_65_GCS qualifier;LA17106-8;5;Patient intubated;;; +55406-3;LL736-0;EF_meth;LA11845-7;1;Cardiac echo;;; +55406-3;LL736-0;EF_meth;LA11846-5;2;MUGA scan;;; +55406-3;LL736-0;EF_meth;LA11847-3;3;Catheterization;;; +55406-3;LL736-0;EF_meth;LA11848-1;4;Gated cardiac CT;;; +55407-1;LL735-2;Edema;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +55407-1;LL735-2;Edema;LA11841-6;2;1+;;; +55407-1;LL735-2;Edema;LA11842-4;3;2+;;; +55407-1;LL735-2;Edema;LA11843-2;4;3+;;; +55407-1;LL735-2;Edema;LA11844-0;5;4+;;; +55410-5;LL734-5;Exercise;LA11837-4;1;Bicycling;;; +55410-5;LL734-5;Exercise;LA11835-8;2;Jogging;;; +55410-5;LL734-5;Exercise;LA11836-6;3;Running;;; +55410-5;LL734-5;Exercise;LA11838-2;4;Swimming;;; +55410-5;LL734-5;Exercise;LA11834-1;5;Walking;;; +55410-5;LL734-5;Exercise;LA11839-0;6;Weights;;; +55410-5;LL734-5;Exercise;LA11840-8;7;Mixed;;; +73985-4;LL734-5;Exercise;LA11837-4;1;Bicycling;;; +73985-4;LL734-5;Exercise;LA11835-8;2;Jogging;;; +73985-4;LL734-5;Exercise;LA11836-6;3;Running;;; +73985-4;LL734-5;Exercise;LA11838-2;4;Swimming;;; +73985-4;LL734-5;Exercise;LA11834-1;5;Walking;;; +73985-4;LL734-5;Exercise;LA11839-0;6;Weights;;; +73985-4;LL734-5;Exercise;LA11840-8;7;Mixed;;; +55416-2;LL740-2;Special circumstances;LA11864-8;1;Sleeping;;; +55416-2;LL740-2;Special circumstances;LA11865-5;2;Post exercise;;; +55416-2;LL740-2;Special circumstances;LA11866-3;3;Pre exercise;;; +55416-2;LL740-2;Special circumstances;LA11867-1;4;Post inhalation Rx;;; +55416-2;LL740-2;Special circumstances;LA7460-4;5;Pain;;; +55416-2;LL740-2;Special circumstances;LA17393-2;6;Apnea;1023001;Apnea (finding);http://snomed.info/sct +55416-2;LL740-2;Special circumstances;LA7435-6;7;Fever;;; +55416-2;LL740-2;Special circumstances;LA29193-2;8;Crying;;; +55416-2;LL740-2;Special circumstances;LA46-8;9;Other;;; +9278-3;LL740-2;Special circumstances;LA11864-8;1;Sleeping;;; +9278-3;LL740-2;Special circumstances;LA11865-5;2;Post exercise;;; +9278-3;LL740-2;Special circumstances;LA11866-3;3;Pre exercise;;; +9278-3;LL740-2;Special circumstances;LA11867-1;4;Post inhalation Rx;;; +9278-3;LL740-2;Special circumstances;LA7460-4;5;Pain;;; +9278-3;LL740-2;Special circumstances;LA17393-2;6;Apnea;1023001;Apnea (finding);http://snomed.info/sct +9278-3;LL740-2;Special circumstances;LA7435-6;7;Fever;;; +9278-3;LL740-2;Special circumstances;LA29193-2;8;Crying;;; +9278-3;LL740-2;Special circumstances;LA46-8;9;Other;;; +9848-3;LL740-2;Special circumstances;LA11864-8;1;Sleeping;;; +9848-3;LL740-2;Special circumstances;LA11865-5;2;Post exercise;;; +9848-3;LL740-2;Special circumstances;LA11866-3;3;Pre exercise;;; +9848-3;LL740-2;Special circumstances;LA11867-1;4;Post inhalation Rx;;; +9848-3;LL740-2;Special circumstances;LA7460-4;5;Pain;;; +9848-3;LL740-2;Special circumstances;LA17393-2;6;Apnea;1023001;Apnea (finding);http://snomed.info/sct +9848-3;LL740-2;Special circumstances;LA7435-6;7;Fever;;; +9848-3;LL740-2;Special circumstances;LA29193-2;8;Crying;;; +9848-3;LL740-2;Special circumstances;LA46-8;9;Other;;; +9855-8;LL740-2;Special circumstances;LA11864-8;1;Sleeping;;; +9855-8;LL740-2;Special circumstances;LA11865-5;2;Post exercise;;; +9855-8;LL740-2;Special circumstances;LA11866-3;3;Pre exercise;;; +9855-8;LL740-2;Special circumstances;LA11867-1;4;Post inhalation Rx;;; +9855-8;LL740-2;Special circumstances;LA7460-4;5;Pain;;; +9855-8;LL740-2;Special circumstances;LA17393-2;6;Apnea;1023001;Apnea (finding);http://snomed.info/sct +9855-8;LL740-2;Special circumstances;LA7435-6;7;Fever;;; +9855-8;LL740-2;Special circumstances;LA29193-2;8;Crying;;; +9855-8;LL740-2;Special circumstances;LA46-8;9;Other;;; +55420-4;LL732-9;Cfast;LA11828-3;1;1 hour;;; +55420-4;LL732-9;Cfast;LA11829-1;2;2 hours;123030002;2 hours (qualifier value);http://snomed.info/sct +55420-4;LL732-9;Cfast;LA11830-9;3;3 hours;;; +55420-4;LL732-9;Cfast;LA11831-7;4;Fasting;;; +55463-4;LL745-1;H1N1(swine);LA11918-2;1;Influenzavirus, type A (H1), swine-like;;; +55463-4;LL745-1;H1N1(swine);LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +55463-4;LL745-1;H1N1(swine);LA11883-8;3;Not detected;;; +55463-4;LL745-1;H1N1(swine);LA11919-0;4;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +55745-4;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55745-4;LL755-0;howRU;LA13940-4;2;A little;;; +55745-4;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55745-4;LL755-0;howRU;LA11912-5;5;Extreme;;; +55745-4;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55745-4;LL755-0;howRU;LA13940-4;2;A little;;; +55745-4;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55745-4;LL755-0;howRU;LA11912-5;5;Extreme;;; +55746-2;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55746-2;LL755-0;howRU;LA13940-4;2;A little;;; +55746-2;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55746-2;LL755-0;howRU;LA11912-5;5;Extreme;;; +55746-2;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55746-2;LL755-0;howRU;LA13940-4;2;A little;;; +55746-2;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55746-2;LL755-0;howRU;LA11912-5;5;Extreme;;; +55747-0;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55747-0;LL755-0;howRU;LA13940-4;2;A little;;; +55747-0;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55747-0;LL755-0;howRU;LA11912-5;5;Extreme;;; +55747-0;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55747-0;LL755-0;howRU;LA13940-4;2;A little;;; +55747-0;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55747-0;LL755-0;howRU;LA11912-5;5;Extreme;;; +55748-8;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55748-8;LL755-0;howRU;LA13940-4;2;A little;;; +55748-8;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55748-8;LL755-0;howRU;LA11912-5;5;Extreme;;; +55748-8;LL755-0;howRU;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +55748-8;LL755-0;howRU;LA13940-4;2;A little;;; +55748-8;LL755-0;howRU;LA11911-7;4;Quite a lot;;; +55748-8;LL755-0;howRU;LA11912-5;5;Extreme;;; +56003-7;LL2440-7;Secreted|Not secreted;LA19762-6;1;Secreted;;; +56003-7;LL2440-7;Secreted|Not secreted;LA19763-4;2;Not secreted;;; +56004-5;LL2440-7;Secreted|Not secreted;LA19762-6;1;Secreted;;; +56004-5;LL2440-7;Secreted|Not secreted;LA19763-4;2;Not secreted;;; +56012-8;LL2440-7;Secreted|Not secreted;LA19762-6;1;Secreted;;; +56012-8;LL2440-7;Secreted|Not secreted;LA19763-4;2;Not secreted;;; +56016-9;LL2440-7;Secreted|Not secreted;LA19762-6;1;Secreted;;; +56016-9;LL2440-7;Secreted|Not secreted;LA19763-4;2;Not secreted;;; +56017-7;LL2440-7;Secreted|Not secreted;LA19762-6;1;Secreted;;; +56017-7;LL2440-7;Secreted|Not secreted;LA19763-4;2;Not secreted;;; +56018-5;LL2440-7;Secreted|Not secreted;LA19762-6;1;Secreted;;; +56018-5;LL2440-7;Secreted|Not secreted;LA19763-4;2;Not secreted;;; +56021-9;LL2440-7;Secreted|Not secreted;LA19762-6;1;Secreted;;; +56021-9;LL2440-7;Secreted|Not secreted;LA19763-4;2;Not secreted;;; +56051-6;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +56051-6;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +56051-6;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56051-6;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65424-4;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65424-4;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65424-4;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65424-4;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65425-1;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65425-1;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65425-1;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65425-1;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65426-9;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65426-9;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65426-9;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65426-9;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65427-7;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65427-7;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65427-7;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65427-7;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65428-5;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65428-5;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65428-5;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65428-5;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65429-3;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65429-3;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65429-3;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65429-3;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65430-1;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65430-1;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65430-1;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65430-1;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65432-7;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65432-7;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65432-7;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65432-7;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65433-5;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65433-5;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65433-5;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65433-5;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65435-0;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65435-0;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65435-0;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65435-0;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65436-8;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65436-8;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65436-8;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65436-8;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65437-6;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65437-6;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65437-6;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65437-6;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65438-4;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65438-4;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65438-4;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65438-4;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65439-2;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65439-2;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65439-2;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65439-2;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65440-0;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65440-0;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65440-0;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65440-0;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65441-8;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65441-8;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65441-8;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65441-8;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65442-6;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65442-6;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65442-6;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65442-6;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65443-4;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65443-4;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65443-4;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65443-4;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65444-2;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65444-2;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65444-2;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65444-2;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65445-9;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65445-9;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65445-9;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65445-9;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65446-7;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65446-7;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65446-7;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65446-7;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65447-5;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65447-5;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65447-5;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65447-5;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65483-0;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65483-0;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65483-0;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65483-0;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65484-8;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65484-8;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65484-8;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65484-8;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65487-1;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65487-1;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65487-1;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65487-1;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65491-3;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65491-3;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65491-3;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65491-3;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65492-1;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65492-1;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65492-1;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65492-1;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65493-9;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65493-9;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65493-9;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65493-9;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65494-7;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65494-7;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65494-7;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65494-7;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65495-4;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65495-4;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65495-4;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65495-4;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65499-6;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65499-6;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65499-6;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65499-6;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65500-1;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65500-1;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65500-1;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65500-1;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65531-6;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65531-6;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65531-6;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65531-6;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65532-4;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65532-4;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65532-4;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65532-4;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65534-0;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65534-0;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65534-0;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65534-0;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65535-7;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65535-7;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65535-7;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65535-7;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65538-1;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65538-1;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65538-1;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65538-1;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65543-1;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65543-1;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65543-1;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65543-1;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65635-5;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65635-5;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65635-5;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65635-5;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65832-8;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65832-8;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65832-8;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65832-8;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65886-4;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65886-4;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65886-4;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65886-4;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +65887-2;LL1270-9;PhenX12_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65887-2;LL1270-9;PhenX12_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65887-2;LL1270-9;PhenX12_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65887-2;LL1270-9;PhenX12_02;LA14761-3;4;Not asked;;; +56051-6;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +56051-6;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +56051-6;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93027-1;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93027-1;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93027-1;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93027-1;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93027-1;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93027-1;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93028-9;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93028-9;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93028-9;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93033-9;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93033-9;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93033-9;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93033-9;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93033-9;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93033-9;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93034-7;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93034-7;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93034-7;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93034-7;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93034-7;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93034-7;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +93035-4;LL5332-3;Y|N|Choose Not to Answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93035-4;LL5332-3;Y|N|Choose Not to Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93035-4;LL5332-3;Y|N|Choose Not to Answer;LA30122-8;3;I choose not to answer this question;;; +56051-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56051-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61434-7;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +61434-7;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +61434-7;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61434-7;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63513-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63513-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63513-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63513-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63717-3;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63717-3;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63717-3;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63717-3;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63723-1;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63723-1;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63723-1;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63723-1;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63740-5;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63740-5;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63740-5;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63740-5;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63771-0;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63771-0;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63771-0;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63771-0;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63843-7;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63843-7;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63843-7;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63843-7;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63844-5;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63844-5;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63844-5;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63844-5;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64751-1;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64751-1;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64751-1;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64751-1;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64753-7;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64753-7;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64753-7;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64753-7;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64754-5;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64754-5;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64754-5;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64754-5;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64755-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64755-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64755-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64755-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64758-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64758-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64758-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64758-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64759-4;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64759-4;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64759-4;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64759-4;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64760-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64760-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64760-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64760-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64767-7;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64767-7;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64767-7;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64767-7;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64774-3;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64774-3;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64774-3;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64774-3;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64782-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64782-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64782-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64782-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64784-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64784-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64784-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64784-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64785-9;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64785-9;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64785-9;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64785-9;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64789-1;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64789-1;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64789-1;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64789-1;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64816-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64816-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64816-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64816-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64817-0;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64817-0;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64817-0;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64817-0;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64818-8;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64818-8;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64818-8;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64818-8;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64819-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64819-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64819-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64819-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64820-4;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64820-4;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64820-4;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64820-4;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64988-9;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64988-9;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64988-9;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64988-9;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65668-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65668-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65668-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65668-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65672-8;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65672-8;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65672-8;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65672-8;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65673-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65673-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65673-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65673-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65871-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65871-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65871-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65871-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65873-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65873-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65873-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65873-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65874-0;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65874-0;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65874-0;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65874-0;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65878-1;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65878-1;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65878-1;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65878-1;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66164-5;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66164-5;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66164-5;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66164-5;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66175-1;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66175-1;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66175-1;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66175-1;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66176-9;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66176-9;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66176-9;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66176-9;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66177-7;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66177-7;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66177-7;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66177-7;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66178-5;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66178-5;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66178-5;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66178-5;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66467-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66467-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66467-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66467-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66474-8;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66474-8;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66474-8;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66474-8;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67238-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67238-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67238-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67238-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67240-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67240-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67240-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67240-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67259-2;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67259-2;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67259-2;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67259-2;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67260-0;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67260-0;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67260-0;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67260-0;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +94741-6;LL988-7;PhenX05_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +94741-6;LL988-7;PhenX05_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +94741-6;LL988-7;PhenX05_01;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +94741-6;LL988-7;PhenX05_01;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +56057-3;LL760-0;PhenX02_01_body weight;LA11926-5;1;More than 5 1/2 pounds (2500 g);;; +56057-3;LL760-0;PhenX02_01_body weight;LA11927-3;2;Less than 5 1/2 pounds (2500 g);;; +56057-3;LL760-0;PhenX02_01_body weight;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56057-3;LL760-0;PhenX02_01_body weight;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4364-1;1;Puerto Rican;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA3847-6;2;Dominican Republic;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14051-9;3;Mexican/Mexicano;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14057-6;4;Mexican American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14052-7;5;Chicano;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4190-0;6;Cuban;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14053-5;7;Cuban American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14054-3;8;Central or South American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14055-0;9;Other Latin American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14056-8;10;Other Hispanic;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4364-1;1;Puerto Rican;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA3847-6;2;Dominican Republic;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14051-9;3;Mexican/Mexicano;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14057-6;4;Mexican American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14052-7;5;Chicano;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4190-0;6;Cuban;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14053-5;7;Cuban American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14054-3;8;Central or South American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14055-0;9;Other Latin American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14056-8;10;Other Hispanic;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4364-1;1;Puerto Rican;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA3847-6;2;Dominican Republic;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14051-9;3;Mexican/Mexicano;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14057-6;4;Mexican American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14052-7;5;Chicano;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4190-0;6;Cuban;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14053-5;7;Cuban American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14054-3;8;Central or South American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14055-0;9;Other Latin American;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA14056-8;10;Other Hispanic;;; +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56090-4;LL1045-5;PhenX01_02_hispanic origin;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +56091-2;LL1044-8;PhenX01_01_race;LA4457-3;1;White;;; +56091-2;LL1044-8;PhenX01_01_race;LA10610-6;2;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +56091-2;LL1044-8;PhenX01_01_race;LA14043-6;3;Indian (American);;; +56091-2;LL1044-8;PhenX01_01_race;LA14044-4;4;Alaska Native;;; +56091-2;LL1044-8;PhenX01_01_race;LA14045-1;5;Native Hawaiian;;; +56091-2;LL1044-8;PhenX01_01_race;LA14046-9;6;Guamanian;;; +56091-2;LL1044-8;PhenX01_01_race;LA4300-5;7;Samoan;;; +56091-2;LL1044-8;PhenX01_01_race;LA14047-7;8;Other Pacific Islander;;; +56091-2;LL1044-8;PhenX01_01_race;LA14048-5;9;Asian Indian;;; +56091-2;LL1044-8;PhenX01_01_race;LA4168-6;10;Chinese;;; +56091-2;LL1044-8;PhenX01_01_race;LA3969-8;11;Filipino;;; +56091-2;LL1044-8;PhenX01_01_race;LA4595-0;12;Japanese;;; +56091-2;LL1044-8;PhenX01_01_race;LA4603-2;13;Korean;;; +56091-2;LL1044-8;PhenX01_01_race;LA4443-3;14;Vietnamese;;; +56091-2;LL1044-8;PhenX01_01_race;LA14049-3;15;Other Asian;;; +56091-2;LL1044-8;PhenX01_01_race;LA14050-1;16;Some Other Race (specify);;; +56091-2;LL1044-8;PhenX01_01_race;LA4389-8;17;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56091-2;LL1044-8;PhenX01_01_race;LA12688-0;18;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +56095-3;LL761-8;PhenX02_02_wt <9lbs at birth;LA11929-9;1;More than 9 pounds (2500 g);;; +56095-3;LL761-8;PhenX02_02_wt <9lbs at birth;LA11928-1;2;Less than 9 pounds (2500 g);;; +56095-3;LL761-8;PhenX02_02_wt <9lbs at birth;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +56095-3;LL761-8;PhenX02_02_wt <9lbs at birth;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +56097-9;LL762-6;ALSPAC_Hand dominance;LA4306-2;1;Right;;; +56097-9;LL762-6;ALSPAC_Hand dominance;LA4585-1;2;Left;;; +56097-9;LL762-6;ALSPAC_Hand dominance;LA11930-7;3;Either;;; +56098-7;LL762-6;ALSPAC_Hand dominance;LA4306-2;1;Right;;; +56098-7;LL762-6;ALSPAC_Hand dominance;LA4585-1;2;Left;;; +56098-7;LL762-6;ALSPAC_Hand dominance;LA11930-7;3;Either;;; +56099-5;LL762-6;ALSPAC_Hand dominance;LA4306-2;1;Right;;; +56099-5;LL762-6;ALSPAC_Hand dominance;LA4585-1;2;Left;;; +56099-5;LL762-6;ALSPAC_Hand dominance;LA11930-7;3;Either;;; +56100-1;LL762-6;ALSPAC_Hand dominance;LA4306-2;1;Right;;; +56100-1;LL762-6;ALSPAC_Hand dominance;LA4585-1;2;Left;;; +56100-1;LL762-6;ALSPAC_Hand dominance;LA11930-7;3;Either;;; +56102-7;LL763-4;EHI;LA4306-2;1;Right;;; +56102-7;LL763-4;EHI;LA4585-1;2;Left;;; +56102-7;LL763-4;EHI;LA11931-5;3;Both hands;;; +56103-5;LL763-4;EHI;LA4306-2;1;Right;;; +56103-5;LL763-4;EHI;LA4585-1;2;Left;;; +56103-5;LL763-4;EHI;LA11931-5;3;Both hands;;; +56104-3;LL763-4;EHI;LA4306-2;1;Right;;; +56104-3;LL763-4;EHI;LA4585-1;2;Left;;; +56104-3;LL763-4;EHI;LA11931-5;3;Both hands;;; +56105-0;LL763-4;EHI;LA4306-2;1;Right;;; +56105-0;LL763-4;EHI;LA4585-1;2;Left;;; +56105-0;LL763-4;EHI;LA11931-5;3;Both hands;;; +56106-8;LL763-4;EHI;LA4306-2;1;Right;;; +56106-8;LL763-4;EHI;LA4585-1;2;Left;;; +56106-8;LL763-4;EHI;LA11931-5;3;Both hands;;; +56107-6;LL763-4;EHI;LA4306-2;1;Right;;; +56107-6;LL763-4;EHI;LA4585-1;2;Left;;; +56107-6;LL763-4;EHI;LA11931-5;3;Both hands;;; +56108-4;LL763-4;EHI;LA4306-2;1;Right;;; +56108-4;LL763-4;EHI;LA4585-1;2;Left;;; +56108-4;LL763-4;EHI;LA11931-5;3;Both hands;;; +56109-2;LL763-4;EHI;LA4306-2;1;Right;;; +56109-2;LL763-4;EHI;LA4585-1;2;Left;;; +56109-2;LL763-4;EHI;LA11931-5;3;Both hands;;; +56110-0;LL763-4;EHI;LA4306-2;1;Right;;; +56110-0;LL763-4;EHI;LA4585-1;2;Left;;; +56110-0;LL763-4;EHI;LA11931-5;3;Both hands;;; +56111-8;LL763-4;EHI;LA4306-2;1;Right;;; +56111-8;LL763-4;EHI;LA4585-1;2;Left;;; +56111-8;LL763-4;EHI;LA11931-5;3;Both hands;;; +56112-6;LL763-4;EHI;LA4306-2;1;Right;;; +56112-6;LL763-4;EHI;LA4585-1;2;Left;;; +56112-6;LL763-4;EHI;LA11931-5;3;Both hands;;; +56832-9;LL5221-8;Opioid Risk Tool question 2;LA28139-6;1;Alcohol;;; +56832-9;LL5221-8;Opioid Risk Tool question 2;LA29718-6;2;Illegal drugs;;; +56832-9;LL5221-8;Opioid Risk Tool question 2;LA29719-4;3;Prescription drugs;;; +56832-9;LL5221-8;Opioid Risk Tool question 2;LA28139-6;1;Alcohol;;; +56832-9;LL5221-8;Opioid Risk Tool question 2;LA29718-6;2;Illegal drugs;;; +56832-9;LL5221-8;Opioid Risk Tool question 2;LA29719-4;3;Prescription drugs;;; +56865-9;LL5155-8;Geneva score for PE clinical findings;LA29585-9;1;Prior PE or DVT;;; +56865-9;LL5155-8;Geneva score for PE clinical findings;LA29592-5;2;Active malignant condition;;; +56865-9;LL5155-8;Geneva score for PE clinical findings;LA29593-3;3;Unilateral lower limb pain;;; +56865-9;LL5155-8;Geneva score for PE clinical findings;LA29583-4;4;Hemoptysis;;; +56865-9;LL5155-8;Geneva score for PE clinical findings;LA29594-1;5;Pain on limb palpation;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29587-5;1;Clinical signs and symptoms of DVT;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29588-3;2;Alternative diagnosis less likely than pulmonary embolism;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29589-1;3;Immobilization at least 3 days OR surgery in the previous 4 weeks;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29585-9;4;Prior PE or DVT;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29583-4;5;Hemoptysis;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29590-9;6;Malignancy with treatment within 6 months or palliative;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29587-5;1;Clinical signs and symptoms of DVT;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29588-3;2;Alternative diagnosis less likely than pulmonary embolism;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29589-1;3;Immobilization at least 3 days OR surgery in the previous 4 weeks;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29585-9;4;Prior PE or DVT;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29583-4;5;Hemoptysis;;; +56865-9;LL5156-6;Wells score for PE clinical findings;LA29590-9;6;Malignancy with treatment within 6 months or palliative;;; +56865-9;LL5157-4;PERC rule for PE clinical findings;LA29582-6;1;Unilateral leg swelling;;; +56865-9;LL5157-4;PERC rule for PE clinical findings;LA29583-4;2;Hemoptysis;;; +56865-9;LL5157-4;PERC rule for PE clinical findings;LA29584-2;3;Recent surgery or trauma;;; +56865-9;LL5157-4;PERC rule for PE clinical findings;LA29585-9;4;Prior PE or DVT;;; +56865-9;LL5157-4;PERC rule for PE clinical findings;LA29586-7;5;Hormone use;;; +56865-9;LL5158-2;PESI score for PE clinical findings;LA29578-4;1;History of cancer;;; +56865-9;LL5158-2;PESI score for PE clinical findings;LA29579-2;2;History of heart failure;;; +56865-9;LL5158-2;PESI score for PE clinical findings;LA29580-0;3;History of chronic lung disease;;; +56865-9;LL5158-2;PESI score for PE clinical findings;LA29581-8;4;Altered mental status (disorientation, lethargy, stupor, or coma);;; +56991-3;LL3257-4;High avidity|Gray-zone|Low avidity;LA22673-0;0;High avidity;;; +56991-3;LL3257-4;High avidity|Gray-zone|Low avidity;LA22672-2;1;Gray-zone;;; +56991-3;LL3257-4;High avidity|Gray-zone|Low avidity;LA22671-4;2;Low avidity;;; +78445-4;LL3257-4;High avidity|Gray-zone|Low avidity;LA22673-0;0;High avidity;;; +78445-4;LL3257-4;High avidity|Gray-zone|Low avidity;LA22672-2;1;Gray-zone;;; +78445-4;LL3257-4;High avidity|Gray-zone|Low avidity;LA22671-4;2;Low avidity;;; +57120-8;LL767-5;Type nursing provider;LA12063-6;1;APN;;; +57120-8;LL767-5;Type nursing provider;LA6367-2;2;RN;;; +57120-8;LL767-5;Type nursing provider;LA12071-9;3;LPN/ LVN;;; +57120-8;LL767-5;Type nursing provider;LA12085-9;4;UAP;;; +57120-8;LL767-5;Type nursing provider;LA12083-4;5;Total nursing personnel;;; +57121-6;LL768-3;Type client;LA12070-1;1;Individual;;; +57121-6;LL768-3;Type client;LA12068-5;2;Family;;; +57121-6;LL768-3;Type client;LA12078-4;3;Population;;; +57122-4;LL769-1;Type encounter;LA12073-5;1;Patient days – method 1;;; +57122-4;LL769-1;Type encounter;LA12074-3;2;Patient days – method 2;;; +57122-4;LL769-1;Type encounter;LA12075-0;3;Patient days – method 3;;; +57122-4;LL769-1;Type encounter;LA12076-8;4;Patient days – method 4;;; +57122-4;LL769-1;Type encounter;LA12077-6;5;Patient days – method 5;;; +57122-4;LL769-1;Type encounter;LA12086-7;6;Visits;;; +57122-4;LL769-1;Type encounter;LA12066-9;7;Consults;;; +57122-4;LL769-1;Type encounter;LA12067-7;8;Contacts;;; +57122-4;LL769-1;Type encounter;LA12080-0;9;Programs;;; +57122-4;LL769-1;Type encounter;LA12065-1;10;Classes;;; +57127-3;LL770-9;Method of care delivery;LA12069-3;1;Functional;;; +57127-3;LL770-9;Method of care delivery;LA12082-6;2;Team;;; +57127-3;LL770-9;Method of care delivery;LA12084-2;3;Total patient care;;; +57127-3;LL770-9;Method of care delivery;LA12079-2;4;Primary nursing;;; +57127-3;LL770-9;Method of care delivery;LA12064-4;5;Case management;;; +57127-3;LL770-9;Method of care delivery;LA12072-7;6;Managed care;;; +57127-3;LL770-9;Method of care delivery;LA12062-8;7;Advanced practice nursing;;; +57130-7;LL771-7;NBS_imp;LA12428-1;1;All screening is in range for the conditions tested;;; +57130-7;LL771-7;NBS_imp;LA12429-9;2;Screen is borderline for at least one condition;;; +57130-7;LL771-7;NBS_imp;LA18943-3;3;Screen is indeterminate for at least one condition;;; +57130-7;LL771-7;NBS_imp;LA18944-1;4;Screen is out of range for at least one condition;;; +57130-7;LL771-7;NBS_imp;LA12430-7;5;Out of range requiring further dried blood spot testing for at least one condition;;; +57130-7;LL771-7;NBS_imp;LA25817-0;6;Out of range requiring immediate referral;;; +57130-7;LL771-7;NBS_imp;LA12431-5;7;Out of range requiring immediate second-tier testing for at least one condition;;; +57130-7;LL771-7;NBS_imp;LA18594-4;8;Out of range requiring deferred follow-up for at least one condition;;; +57130-7;LL771-7;NBS_imp;LA14133-5;9;Screening not done due to parental refusal;;; +57130-7;LL771-7;NBS_imp;LA16204-2;10;One or more tests pending;;; +57130-7;LL771-7;NBS_imp;LA16205-9;11;Specimen unsatisfactory for at least one condition;;; +57131-5;LL835-0;NBS conditions;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA24366-9;1;Hearing loss;15188001;Hearing loss (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12464-6;2;2-Methyl-3-hydroxybutyric aciduria;791000124107;2-methyl-3-hydroxybutyric aciduria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12465-3;3;2-Methylbutyrylglycinuria;445596006;2-methylbutyrylglycinuria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12466-1;4;3-Methylcrotonyl-CoA carboxylase deficiency;13144005;Methylcrotonyl-coenzyme A carboxylase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12467-9;5;3-Methylcrotonyl-CoA carboxylase deficiency (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12468-7;6;3-Methylglutaconic aciduria;237950009;3-Methylglutaconic aciduria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12469-5;7;Pyroglutamic acidemia;39112005;Glutathione synthase deficiency with 5-oxoprolinuria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA21161-7;8;Argininemia;;; +57131-5;LL835-0;NBS conditions;LA21162-5;9;Argininosuccinic aciduria;;; +57131-5;LL835-0;NBS conditions;LA12472-9;10;Biopterin defect in cofactor biosynthesis;237914002;6-Pyruvoyl-tetrahydrobiopterin synthase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12473-7;11;Biopterin defect in cofactor regeneration;58256000;Dihydropteridine reductase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12474-5;12;Beta-ketothiolase deficiency;237953006;Mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency - potassium stimulated (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12475-2;13;Carnitine acylcarnitine translocase deficiency;238003000;Carnitine acylcarnitine translocase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12476-0;14;Cobalamin A disease;73843004;Cobalamin A disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12477-8;15;Cobalamin B disease;82245003;Cobalamin B disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12478-6;16;Cobalamin C disease;74653006;Cobalamin C disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12479-4;17;Cobalamin D disease;31220004;Cobalamin D disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12480-2;18;Cobalamin E disease;360373000;Homocystinuria vitamin B12-responsive type III (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12481-0;19;CBL G type Methylcobalamin deficiency;721187005;Methylcobalamin deficiency type cbl G (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12482-8;20;Citrullinemia, type I;398680004;Citrullinemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12483-6;21;Citrullinemia, type II;716863007;Citrullinemia type II (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12484-4;22;Carbamoyl-phosphate synthase deficiency;62522004;Congenital hyperammonemia, type I (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12485-1;23;Carnitine palmitoyltransferase type I deficiency;238001003;Carnitine palmitoyltransferase I deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12486-9;24;Carnitine palmitoyltransferase type II deficiency;238002005;Carnitine palmitoyltransferase II deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12487-7;25;Carnitine uptake deficiency/carnitine transport defect;21764004;Renal carnitine transport defect (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12488-5;26;Carnitine uptake deficiency/carnitine transport defect (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12489-3;27;2,4-Dienoyl-CoA reductase deficiency;444944006;Deficiency of 2,4-dienoyl-coenzyme A reductase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12490-1;28;Dihydrolipoamide dehydrogenase deficiency;29914000;Dihydrolipoamide dehydrogenase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12491-9;29;Ethylmalonic encephalopathy;723307008;Ethylmalonic encephalopathy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12492-7;30;Formiminoglutamic acidemia;59761008;Glutamate formiminotransferase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12493-5;31;Glutaric acidemia type I;76175005;Glutaric aciduria, type 1 (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12494-3;32;Glutaric acidemia (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12495-0;33;Glutaric acidemia type II;22886006;Glutaric aciduria, type 2 (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12496-8;34;Homocystinuria;11282001;Homocystinuria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12497-6;35;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome;30287008;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12498-4;36;Histidinemia;410058007;Histidinemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12499-2;37;3-Hydroxy-3-methylglutaric aciduria;410059004;Hydroxymethylglutaric aciduria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12500-7;38;Hyperphenylalaninemia (variant, benign);68528007;Hyperphenylalaninemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12501-5;39;Hyperlysinemia;58558003;Hyperlysinemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12502-3;40;Girate atrophy of the retina;314467007;Gyrate atrophy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12503-1;41;Valinemia;47719001;Hypervalinemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12504-9;42;Isobutyrylglycinuria;445571008;Isobutyrylglycinuria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12505-6;43;Isovaleric acidemia;87827003;Isovaleryl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12506-4;44;Primary lactic acidemia;190882007;Lactic acidemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12507-2;45;Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency;307127004;Isolated long chain hydroxyacyl-CoA dehydrogenase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12508-0;46;Malonic acidemia;124594007;Deficiency of malonyl-coenzyme A decarboxylase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12509-8;47;Medium-chain acyl-CoA dehydrogenase deficiency;128596003;Medium-chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12510-6;48;Holoocarboxylase synthase deficiency;360369003;Holocarboxylase synthase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12511-4;49;Medium-chain ketoacyl-CoA thiolase deficiency;124265004;Deficiency of acetyl-coenzyme A acyltransferase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12512-2;50;Hypermethioninemia;43123004;Hypermethioninemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA21168-2;51;Maple syrup urine disease;27718001;Maple syrup urine disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12514-8;52;Methylene tetrahydrofolate reductase deficiency;41797007;5,10-Methylenetetrahydrofolate reductase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12515-5;53;Methylmalonic acidemia;124680001;Deficiency of methylmalonyl-coenzyme A mutase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12516-3;54;Nonketotic hyperglycinemia (glycine encephalopathy);237939006;Non-ketotic hyperglycinemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12517-1;55;Hydroxyprolinemia;25739007;Hyperhydroxyprolinemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12518-9;56;Ornithine transcarbamylase deficiency;80908008;Ornithine carbamoyltransferase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12519-7;57;Pyruvate carboxylase deficiency;87694001;Pyruvate carboxylase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12520-5;58;Classic phenylketonuria;7573000;Classical phenylketonuria (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12521-3;59;Hyperprolinemia type I;61071003;Proline dehydrogenase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12522-1;60;Hyperprolinemia type II;717181004;Hyperprolinemia type 2 (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12523-9;61;Propionic acidemia;69080001;Propionic acidemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12524-7;62;Short-chain acyl-CoA dehydrogenase deficiency;124166007;Deficiency of butyryl-CoA dehydrogenase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12525-4;63;Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency;237998000;Short chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12526-2;64;Succinyl-CoA ligase deficiency;445275003;Deficiency of succinate-coenzyme A ligase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12527-0;65;Trifunctional protein deficiency;237999008;Mitochondrial trifunctional protein deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12528-8;66;Tyrosinemia, type I;410056006;Tyrosinemia type I (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12529-6;67;Tyrosinemia, type II;4887000;Hypertyrosinemia, Richner-Hanhart type (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12530-4;68;Tyrosinemia, type III;415764005;Tyrosinemia type III (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12531-2;69;Very long-chain acyl-CoA dehydrogenase deficiency;237997005;Very long chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12532-0;70;Biotinidase deficiency;8808004;Biotinidase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12533-8;71;Congenital adrenal hyperplasia;237751000;Congenital adrenal hyperplasia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA22202-8;72;Cystic fibrosis;190905008;Cystic fibrosis (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12538-7;73;Primary congenital hypothyroidism;190268003;Congenital hypothyroidism (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12539-5;74;Secondary congenital hypothyroidism;82598004;Secondary hypothyroidism (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12540-3;75;Glucose-6-phosphate dehydrogenase deficiency;124134002;Deficiency of glucose-6-phosphate dehydrogenase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12541-1;76;Galactoepimerase deficiency;8849004;Uridine diphosphate glucose-4-epimerase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12542-9;77;Galactokinase deficiency;124302001;Deficiency of galactokinase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA21165-8;78;Classical galactosemia;;; +57131-5;LL835-0;NBS conditions;LA12602-1;79;Hb C-carrier;76050008;Hemoglobin C trait (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12603-9;80;Hb D-carrier;7391009;Hemoglobin D trait (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12604-7;81;Hb E-carrier;46248003;Hemoglobin E trait (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12605-4;82;Hb O-Arab carrier;;; +57131-5;LL835-0;NBS conditions;LA12606-2;83;Hb S (sickle)-carrier;16402000;Sickle cell trait (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12607-0;84;Hb C-disease;51053007;Hemoglobin C disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12608-8;85;Hb C beta-thalassemia;119691000119106;Hemoglobin C/beta thalassemia disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12609-6;86;Hb D-disease;;; +57131-5;LL835-0;NBS conditions;LA12610-4;87;Hb D beta-thalassemia;119701000119106;Hemoglobin D/beta thalassemia disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12611-2;88;Hb beta zero-thalassemia;86715000;Beta zero thalassemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12612-0;89;Hb E-disease;25065001;Hemoglobin E disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12613-8;90;Hb E beta-thalassemia;234392002;Hemoglobin E/beta thalassemia disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12614-6;91;Hb SS-disease (sickle cell anemia);127040003;Sickle cell-hemoglobin SS disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12615-3;92;Hb S beta-thalassemia;127041004;Sickle cell-beta-thalassemia (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12616-1;93;Hb SC-disease;35434009;Sickle cell-hemoglobin C disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12617-9;94;Hb SD-disease;25472008;Sickle cell-hemoglobin D disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12618-7;95;Hb SE-disease;47024008;Sickle cell-hemoglobin E disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12619-5;96;Hb S O-Arab disease;127048005;Sickle cell-Hemoglobin O Arab disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12620-3;97;Hb S plus Hb other than A,C,D,E,O-Arab disease;23269001;Double heterozygous sickling disorder (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12621-1;98;Hb disease other than A, C, D, E, H,O-Arab, S;80141007;Hemoglobinopathy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12622-9;99;Hb carrier other than C, D, E, S ,O-Arab;;; +57131-5;LL835-0;NBS conditions;LA12565-0;100;Congenital HIV;52079000;Congenital human immunodeficiency virus infection (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12566-8;101;Severe combined immunodeficiency;31323000;Severe combined immunodeficiency disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12567-6;102;Thyroid-binding globulin deficiency;237544006;Thyroid-binding globulin deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12568-4;103;Congenital toxoplasmosis;73893000;Congenital toxoplasmosis (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA12569-2;104;CIT-I or CIT-II or ASA;;; +57131-5;LL835-0;NBS conditions;LA12570-0;105;HCY or MET or CBL C;;; +57131-5;LL835-0;NBS conditions;LA12571-8;106;PKU or BIPT-BS or BIOPT-REG or H-PHE;;; +57131-5;LL835-0;NBS conditions;LA12572-6;107;TYR-1 or TYR-II or TYR-III;;; +57131-5;LL835-0;NBS conditions;LA12573-4;108;CPT-II or CACT;;; +57131-5;LL835-0;NBS conditions;LA12574-2;109;LCHAD or TFP;;; +57131-5;LL835-0;NBS conditions;LA12575-9;110;MCAD or SCAD or GA-2(MADD);;; +57131-5;LL835-0;NBS conditions;LA12576-7;111;SCAD or EMA or IBG or GA-2 (MADD);;; +57131-5;LL835-0;NBS conditions;LA12577-5;112;2M3HBA or BKT-2;;; +57131-5;LL835-0;NBS conditions;LA12578-3;113;IVA or 2MBG or GA-2 or EMA;;; +57131-5;LL835-0;NBS conditions;LA12579-1;114;PROP or CBL A or CBL B or MUT or CBL C or MCD;;; +57131-5;LL835-0;NBS conditions;LA12915-7;115;3-MCC or 3-MCC (mat) or 3MGA or BKT or HMG or MCD or BIO;;; +57131-5;LL835-0;NBS conditions;LA12916-5;116;CUD or CUD (mat) or CPT-Ia;;; +57131-5;LL835-0;NBS conditions;LA12917-3;117;GA-1 or GA-2;;; +57131-5;LL835-0;NBS conditions;LA14036-0;118;Fabry disease;16652001;Fabry's disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA14037-8;119;Pompe disease;274864009;Glycogen storage disease, type II (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA14038-6;120;Krabbe disease;192782005;Galactosylceramide beta-galactosidase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA14039-4;121;Gaucher disease;190794006;Glucosylceramide beta-glucosidase deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA14040-2;122;Niemann Pick disease A/B;58459009;Sphingomyelin/cholesterol lipidosis (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA16007-9;123;Hb H-disease;48553001;Hemoglobin H disease (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA16207-5;124;Hemoglobinopathies;80141007;Hemoglobinopathy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA20349-9;125;Critical congenital heart disease;;; +57131-5;LL835-0;NBS conditions;LA25796-6;126;X-linked adrenoleukodystrophy;65389002;Adrenoleukodystrophy (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA25797-4;127;Mucopolysaccharidosis type I;75610003;Mucopolysaccharidosis type I (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA30113-7;128;Guanidinoacetate N-methyltransferase deficiency;124239003;Deficiency of guanidinoacetate methyltransferase (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA30114-5;129;L-arginine:glycine amidinotransferase deficiency;702440000;Cerebral creatine deficiency syndrome 3 (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA30492-5;130;X-linked creatine transporter (CRTR) deficiency;698290008;X-linked creatine deficiency (disorder);http://snomed.info/sct +57131-5;LL835-0;NBS conditions;LA22279-6;131;Spinal muscular atrophy;5262007;Spinal muscular atrophy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA24366-9;1;Hearing loss;15188001;Hearing loss (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12464-6;2;2-Methyl-3-hydroxybutyric aciduria;791000124107;2-methyl-3-hydroxybutyric aciduria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12465-3;3;2-Methylbutyrylglycinuria;445596006;2-methylbutyrylglycinuria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12466-1;4;3-Methylcrotonyl-CoA carboxylase deficiency;13144005;Methylcrotonyl-coenzyme A carboxylase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12467-9;5;3-Methylcrotonyl-CoA carboxylase deficiency (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12468-7;6;3-Methylglutaconic aciduria;237950009;3-Methylglutaconic aciduria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12469-5;7;Pyroglutamic acidemia;39112005;Glutathione synthase deficiency with 5-oxoprolinuria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA21161-7;8;Argininemia;;; +57720-5;LL835-0;NBS conditions;LA21162-5;9;Argininosuccinic aciduria;;; +57720-5;LL835-0;NBS conditions;LA12472-9;10;Biopterin defect in cofactor biosynthesis;237914002;6-Pyruvoyl-tetrahydrobiopterin synthase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12473-7;11;Biopterin defect in cofactor regeneration;58256000;Dihydropteridine reductase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12474-5;12;Beta-ketothiolase deficiency;237953006;Mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency - potassium stimulated (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12475-2;13;Carnitine acylcarnitine translocase deficiency;238003000;Carnitine acylcarnitine translocase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12476-0;14;Cobalamin A disease;73843004;Cobalamin A disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12477-8;15;Cobalamin B disease;82245003;Cobalamin B disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12478-6;16;Cobalamin C disease;74653006;Cobalamin C disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12479-4;17;Cobalamin D disease;31220004;Cobalamin D disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12480-2;18;Cobalamin E disease;360373000;Homocystinuria vitamin B12-responsive type III (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12481-0;19;CBL G type Methylcobalamin deficiency;721187005;Methylcobalamin deficiency type cbl G (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12482-8;20;Citrullinemia, type I;398680004;Citrullinemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12483-6;21;Citrullinemia, type II;716863007;Citrullinemia type II (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12484-4;22;Carbamoyl-phosphate synthase deficiency;62522004;Congenital hyperammonemia, type I (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12485-1;23;Carnitine palmitoyltransferase type I deficiency;238001003;Carnitine palmitoyltransferase I deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12486-9;24;Carnitine palmitoyltransferase type II deficiency;238002005;Carnitine palmitoyltransferase II deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12487-7;25;Carnitine uptake deficiency/carnitine transport defect;21764004;Renal carnitine transport defect (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12488-5;26;Carnitine uptake deficiency/carnitine transport defect (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12489-3;27;2,4-Dienoyl-CoA reductase deficiency;444944006;Deficiency of 2,4-dienoyl-coenzyme A reductase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12490-1;28;Dihydrolipoamide dehydrogenase deficiency;29914000;Dihydrolipoamide dehydrogenase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12491-9;29;Ethylmalonic encephalopathy;723307008;Ethylmalonic encephalopathy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12492-7;30;Formiminoglutamic acidemia;59761008;Glutamate formiminotransferase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12493-5;31;Glutaric acidemia type I;76175005;Glutaric aciduria, type 1 (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12494-3;32;Glutaric acidemia (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12495-0;33;Glutaric acidemia type II;22886006;Glutaric aciduria, type 2 (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12496-8;34;Homocystinuria;11282001;Homocystinuria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12497-6;35;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome;30287008;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12498-4;36;Histidinemia;410058007;Histidinemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12499-2;37;3-Hydroxy-3-methylglutaric aciduria;410059004;Hydroxymethylglutaric aciduria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12500-7;38;Hyperphenylalaninemia (variant, benign);68528007;Hyperphenylalaninemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12501-5;39;Hyperlysinemia;58558003;Hyperlysinemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12502-3;40;Girate atrophy of the retina;314467007;Gyrate atrophy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12503-1;41;Valinemia;47719001;Hypervalinemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12504-9;42;Isobutyrylglycinuria;445571008;Isobutyrylglycinuria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12505-6;43;Isovaleric acidemia;87827003;Isovaleryl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12506-4;44;Primary lactic acidemia;190882007;Lactic acidemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12507-2;45;Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency;307127004;Isolated long chain hydroxyacyl-CoA dehydrogenase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12508-0;46;Malonic acidemia;124594007;Deficiency of malonyl-coenzyme A decarboxylase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12509-8;47;Medium-chain acyl-CoA dehydrogenase deficiency;128596003;Medium-chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12510-6;48;Holoocarboxylase synthase deficiency;360369003;Holocarboxylase synthase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12511-4;49;Medium-chain ketoacyl-CoA thiolase deficiency;124265004;Deficiency of acetyl-coenzyme A acyltransferase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12512-2;50;Hypermethioninemia;43123004;Hypermethioninemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA21168-2;51;Maple syrup urine disease;27718001;Maple syrup urine disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12514-8;52;Methylene tetrahydrofolate reductase deficiency;41797007;5,10-Methylenetetrahydrofolate reductase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12515-5;53;Methylmalonic acidemia;124680001;Deficiency of methylmalonyl-coenzyme A mutase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12516-3;54;Nonketotic hyperglycinemia (glycine encephalopathy);237939006;Non-ketotic hyperglycinemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12517-1;55;Hydroxyprolinemia;25739007;Hyperhydroxyprolinemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12518-9;56;Ornithine transcarbamylase deficiency;80908008;Ornithine carbamoyltransferase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12519-7;57;Pyruvate carboxylase deficiency;87694001;Pyruvate carboxylase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12520-5;58;Classic phenylketonuria;7573000;Classical phenylketonuria (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12521-3;59;Hyperprolinemia type I;61071003;Proline dehydrogenase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12522-1;60;Hyperprolinemia type II;717181004;Hyperprolinemia type 2 (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12523-9;61;Propionic acidemia;69080001;Propionic acidemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12524-7;62;Short-chain acyl-CoA dehydrogenase deficiency;124166007;Deficiency of butyryl-CoA dehydrogenase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12525-4;63;Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency;237998000;Short chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12526-2;64;Succinyl-CoA ligase deficiency;445275003;Deficiency of succinate-coenzyme A ligase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12527-0;65;Trifunctional protein deficiency;237999008;Mitochondrial trifunctional protein deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12528-8;66;Tyrosinemia, type I;410056006;Tyrosinemia type I (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12529-6;67;Tyrosinemia, type II;4887000;Hypertyrosinemia, Richner-Hanhart type (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12530-4;68;Tyrosinemia, type III;415764005;Tyrosinemia type III (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12531-2;69;Very long-chain acyl-CoA dehydrogenase deficiency;237997005;Very long chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12532-0;70;Biotinidase deficiency;8808004;Biotinidase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12533-8;71;Congenital adrenal hyperplasia;237751000;Congenital adrenal hyperplasia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA22202-8;72;Cystic fibrosis;190905008;Cystic fibrosis (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12538-7;73;Primary congenital hypothyroidism;190268003;Congenital hypothyroidism (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12539-5;74;Secondary congenital hypothyroidism;82598004;Secondary hypothyroidism (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12540-3;75;Glucose-6-phosphate dehydrogenase deficiency;124134002;Deficiency of glucose-6-phosphate dehydrogenase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12541-1;76;Galactoepimerase deficiency;8849004;Uridine diphosphate glucose-4-epimerase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12542-9;77;Galactokinase deficiency;124302001;Deficiency of galactokinase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA21165-8;78;Classical galactosemia;;; +57720-5;LL835-0;NBS conditions;LA12602-1;79;Hb C-carrier;76050008;Hemoglobin C trait (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12603-9;80;Hb D-carrier;7391009;Hemoglobin D trait (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12604-7;81;Hb E-carrier;46248003;Hemoglobin E trait (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12605-4;82;Hb O-Arab carrier;;; +57720-5;LL835-0;NBS conditions;LA12606-2;83;Hb S (sickle)-carrier;16402000;Sickle cell trait (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12607-0;84;Hb C-disease;51053007;Hemoglobin C disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12608-8;85;Hb C beta-thalassemia;119691000119106;Hemoglobin C/beta thalassemia disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12609-6;86;Hb D-disease;;; +57720-5;LL835-0;NBS conditions;LA12610-4;87;Hb D beta-thalassemia;119701000119106;Hemoglobin D/beta thalassemia disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12611-2;88;Hb beta zero-thalassemia;86715000;Beta zero thalassemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12612-0;89;Hb E-disease;25065001;Hemoglobin E disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12613-8;90;Hb E beta-thalassemia;234392002;Hemoglobin E/beta thalassemia disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12614-6;91;Hb SS-disease (sickle cell anemia);127040003;Sickle cell-hemoglobin SS disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12615-3;92;Hb S beta-thalassemia;127041004;Sickle cell-beta-thalassemia (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12616-1;93;Hb SC-disease;35434009;Sickle cell-hemoglobin C disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12617-9;94;Hb SD-disease;25472008;Sickle cell-hemoglobin D disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12618-7;95;Hb SE-disease;47024008;Sickle cell-hemoglobin E disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12619-5;96;Hb S O-Arab disease;127048005;Sickle cell-Hemoglobin O Arab disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12620-3;97;Hb S plus Hb other than A,C,D,E,O-Arab disease;23269001;Double heterozygous sickling disorder (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12621-1;98;Hb disease other than A, C, D, E, H,O-Arab, S;80141007;Hemoglobinopathy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12622-9;99;Hb carrier other than C, D, E, S ,O-Arab;;; +57720-5;LL835-0;NBS conditions;LA12565-0;100;Congenital HIV;52079000;Congenital human immunodeficiency virus infection (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12566-8;101;Severe combined immunodeficiency;31323000;Severe combined immunodeficiency disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12567-6;102;Thyroid-binding globulin deficiency;237544006;Thyroid-binding globulin deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12568-4;103;Congenital toxoplasmosis;73893000;Congenital toxoplasmosis (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA12569-2;104;CIT-I or CIT-II or ASA;;; +57720-5;LL835-0;NBS conditions;LA12570-0;105;HCY or MET or CBL C;;; +57720-5;LL835-0;NBS conditions;LA12571-8;106;PKU or BIPT-BS or BIOPT-REG or H-PHE;;; +57720-5;LL835-0;NBS conditions;LA12572-6;107;TYR-1 or TYR-II or TYR-III;;; +57720-5;LL835-0;NBS conditions;LA12573-4;108;CPT-II or CACT;;; +57720-5;LL835-0;NBS conditions;LA12574-2;109;LCHAD or TFP;;; +57720-5;LL835-0;NBS conditions;LA12575-9;110;MCAD or SCAD or GA-2(MADD);;; +57720-5;LL835-0;NBS conditions;LA12576-7;111;SCAD or EMA or IBG or GA-2 (MADD);;; +57720-5;LL835-0;NBS conditions;LA12577-5;112;2M3HBA or BKT-2;;; +57720-5;LL835-0;NBS conditions;LA12578-3;113;IVA or 2MBG or GA-2 or EMA;;; +57720-5;LL835-0;NBS conditions;LA12579-1;114;PROP or CBL A or CBL B or MUT or CBL C or MCD;;; +57720-5;LL835-0;NBS conditions;LA12915-7;115;3-MCC or 3-MCC (mat) or 3MGA or BKT or HMG or MCD or BIO;;; +57720-5;LL835-0;NBS conditions;LA12916-5;116;CUD or CUD (mat) or CPT-Ia;;; +57720-5;LL835-0;NBS conditions;LA12917-3;117;GA-1 or GA-2;;; +57720-5;LL835-0;NBS conditions;LA14036-0;118;Fabry disease;16652001;Fabry's disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA14037-8;119;Pompe disease;274864009;Glycogen storage disease, type II (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA14038-6;120;Krabbe disease;192782005;Galactosylceramide beta-galactosidase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA14039-4;121;Gaucher disease;190794006;Glucosylceramide beta-glucosidase deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA14040-2;122;Niemann Pick disease A/B;58459009;Sphingomyelin/cholesterol lipidosis (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA16007-9;123;Hb H-disease;48553001;Hemoglobin H disease (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA16207-5;124;Hemoglobinopathies;80141007;Hemoglobinopathy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA20349-9;125;Critical congenital heart disease;;; +57720-5;LL835-0;NBS conditions;LA25796-6;126;X-linked adrenoleukodystrophy;65389002;Adrenoleukodystrophy (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA25797-4;127;Mucopolysaccharidosis type I;75610003;Mucopolysaccharidosis type I (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA30113-7;128;Guanidinoacetate N-methyltransferase deficiency;124239003;Deficiency of guanidinoacetate methyltransferase (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA30114-5;129;L-arginine:glycine amidinotransferase deficiency;702440000;Cerebral creatine deficiency syndrome 3 (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA30492-5;130;X-linked creatine transporter (CRTR) deficiency;698290008;X-linked creatine deficiency (disorder);http://snomed.info/sct +57720-5;LL835-0;NBS conditions;LA22279-6;131;Spinal muscular atrophy;5262007;Spinal muscular atrophy (disorder);http://snomed.info/sct +57132-3;LL950-7;CYP2C19 example genotypes;LA13515-4;1;CYP2C19*1/*1;;; +57132-3;LL950-7;CYP2C19 example genotypes;LA13516-2;2;CYP2C19*1/*2;;; +57132-3;LL950-7;CYP2C19 example genotypes;LA13517-0;3;CYP2C19*1/*3;;; +57132-3;LL950-7;CYP2C19 example genotypes;LA13518-8;4;CYP2C19*2/*2;;; +57132-3;LL950-7;CYP2C19 example genotypes;LA13519-6;5;CYP2C19*2/*3;;; +57132-3;LL950-7;CYP2C19 example genotypes;LA13520-4;6;CYP2C19*3/*3;;; +57195-0;LL817-8;OASIS-C_M2015;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57195-0;LL817-8;OASIS-C_M2015;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57195-0;LL817-8;OASIS-C_M2015;LA12320-0;3;Patient not taking any drugs;;; +57199-2;LL772-5;OASIS-C_M0150;LA12090-9;1;"None; no charge for current services";;; +57199-2;LL772-5;OASIS-C_M0150;LA6259-1;2;Medicare (traditional fee-for-service);;; +57199-2;LL772-5;OASIS-C_M0150;LA12092-5;3;Medicare (HMO/managed care/Advantage plan);;; +57199-2;LL772-5;OASIS-C_M0150;LA6257-5;4;Medicaid (traditional fee-for-service);;; +57199-2;LL772-5;OASIS-C_M0150;LA6256-7;5;Medicaid (HMO/managed care);;; +57199-2;LL772-5;OASIS-C_M0150;LA6452-2;6;Workers' compensation;;; +57199-2;LL772-5;OASIS-C_M0150;LA27774-1;7;Title programs (for example, Title III, V, or XX);;; +57199-2;LL772-5;OASIS-C_M0150;LA27775-8;8;Other government (for example, Tricare, VA);;; +57199-2;LL772-5;OASIS-C_M0150;LA6350-8;9;Private insurance;;; +57199-2;LL772-5;OASIS-C_M0150;LA6349-0;10;Private HMO/managed care;;; +57199-2;LL772-5;OASIS-C_M0150;LA6369-8;11;Self-pay;;; +57199-2;LL772-5;OASIS-C_M0150;LA6310-2;12;Other (specify);;; +57199-2;LL772-5;OASIS-C_M0150;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57200-8;LL773-3;OASIS-C_M0100;LA6390-4;1;Start of care - further visits planned;;; +57200-8;LL773-3;OASIS-C_M0100;LA6366-4;2;Resumption of care (after inpatient stay);;; +57200-8;LL773-3;OASIS-C_M0100;LA6355-7;3;Recertification (follow-up) reassessment;;; +57200-8;LL773-3;OASIS-C_M0100;LA6312-8;4;Other follow-up;;; +57200-8;LL773-3;OASIS-C_M0100;LA6402-7;5;Transferred to an inpatient facility - patient not discharged from agency;;; +57200-8;LL773-3;OASIS-C_M0100;LA6401-9;6;Transferred to an inpatient facility - patient discharged from agency;;; +57200-8;LL773-3;OASIS-C_M0100;LA6179-1;7;Death at home;;; +57200-8;LL773-3;OASIS-C_M0100;LA6184-1;8;Discharge from agency;;; +57203-2;LL774-1;OASIS-C_M0110;LA12111-3;1;Early;;; +57203-2;LL774-1;OASIS-C_M0110;LA12112-1;2;Later;;; +57203-2;LL774-1;OASIS-C_M0110;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57203-2;LL774-1;OASIS-C_M0110;LA12114-7;4;Not Applicable: No Medicare case mix group to be defined by this assessment.;;; +57204-0;LL775-8;OASIS-C_M1000;LA12115-4;1;Long-term nursing facility (NF);;; +57204-0;LL775-8;OASIS-C_M1000;LA10080-2;2;Skilled nursing facility (SNF/TCU);;; +57204-0;LL775-8;OASIS-C_M1000;LA10078-6;3;Short-stay acute hospital (IPPS);;; +57204-0;LL775-8;OASIS-C_M1000;LA10000-0;4;Long-term care hospital (LTCH);;; +57204-0;LL775-8;OASIS-C_M1000;LA9986-6;5;Inpatient rehabilitation hospital or unit (IRF);;; +57204-0;LL775-8;OASIS-C_M1000;LA10065-3;6;Psychiatric hospital or unit;;; +57204-0;LL775-8;OASIS-C_M1000;LA6310-2;7;Other (specify);;; +57204-0;LL775-8;OASIS-C_M1000;LA6342-5;8;Patient was not discharged from an inpatient facility;;; +57206-5;LL778-2;OASIS-C_M1034;LA12137-8;1;The patient is stable with no heightened risk(s) for serious complications and death (beyond those typical of the patient's age).;;; +57206-5;LL778-2;OASIS-C_M1034;LA12138-6;2;The patient is temporarily facing high health risk(s) but is likely to return to being stable without heightened risk(s) for serious complications and death (beyond those typical of the patient's age).;;; +57206-5;LL778-2;OASIS-C_M1034;LA12139-4;3;The patient is likely to remain in fragile health and have ongoing high risk(s) of serious complications and death.;;; +57206-5;LL778-2;OASIS-C_M1034;LA10096-8;4;The patient has serious progressive conditions that could lead to death within a year.;;; +57206-5;LL778-2;OASIS-C_M1034;LA12141-0;5;The patient's situation is unknown or unclear.;;; +57207-3;LL779-0;OASIS-C_M1036;LA8928-9;1;Smoking;;; +57207-3;LL779-0;OASIS-C_M1036;LA6301-1;2;Obesity;;; +57207-3;LL779-0;OASIS-C_M1036;LA6152-8;3;Alcohol dependency;;; +57207-3;LL779-0;OASIS-C_M1036;LA6189-0;4;Drug dependency;;; +57207-3;LL779-0;OASIS-C_M1036;LA9-3;5;None of the above;;; +57207-3;LL779-0;OASIS-C_M1036;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27623-0;1;"Yes; received from your agency during this episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27624-8;2;"Yes; received from your agency during a prior episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27625-5;3;"Yes; received from another health care provider (for example, physician, pharmacist)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27626-3;4;"No; patient offered and declined";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27627-1;5;"No; patient assessed and determined to have medical contraindication(s)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27628-9;6;"No; not indicated - patient does not meet age/condition guidelines for influenza vaccine";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27629-7;7;"No; inability to obtain vaccine due to declared shortage";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27630-5;8;"No; patient did not receive the vaccine due to reasons other than those listed in responses 4-7.";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27623-0;1;"Yes; received from your agency during this episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27624-8;2;"Yes; received from your agency during a prior episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27625-5;3;"Yes; received from another health care provider (for example, physician, pharmacist)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27626-3;4;"No; patient offered and declined";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27627-1;5;"No; patient assessed and determined to have medical contraindication(s)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27628-9;6;"No; not indicated - patient does not meet age/condition guidelines for influenza vaccine";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27629-7;7;"No; inability to obtain vaccine due to declared shortage";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27630-5;8;"No; patient did not receive the vaccine due to reasons other than those listed in responses 4-7.";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27623-0;1;"Yes; received from your agency during this episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27624-8;2;"Yes; received from your agency during a prior episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27625-5;3;"Yes; received from another health care provider (for example, physician, pharmacist)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27626-3;4;"No; patient offered and declined";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27627-1;5;"No; patient assessed and determined to have medical contraindication(s)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27628-9;6;"No; not indicated - patient does not meet age/condition guidelines for influenza vaccine";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27629-7;7;"No; inability to obtain vaccine due to declared shortage";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27630-5;8;"No; patient did not receive the vaccine due to reasons other than those listed in responses 4-7.";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27623-0;1;"Yes; received from your agency during this episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27624-8;2;"Yes; received from your agency during a prior episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27625-5;3;"Yes; received from another health care provider (for example, physician, pharmacist)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27626-3;4;"No; patient offered and declined";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27627-1;5;"No; patient assessed and determined to have medical contraindication(s)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27628-9;6;"No; not indicated - patient does not meet age/condition guidelines for influenza vaccine";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27629-7;7;"No; inability to obtain vaccine due to declared shortage";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27630-5;8;"No; patient did not receive the vaccine due to reasons other than those listed in responses 4-7.";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27623-0;1;"Yes; received from your agency during this episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27624-8;2;"Yes; received from your agency during a prior episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27625-5;3;"Yes; received from another health care provider (for example, physician, pharmacist)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27626-3;4;"No; patient offered and declined";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27627-1;5;"No; patient assessed and determined to have medical contraindication(s)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27628-9;6;"No; not indicated - patient does not meet age/condition guidelines for influenza vaccine";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27629-7;7;"No; inability to obtain vaccine due to declared shortage";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27630-5;8;"No; patient did not receive the vaccine due to reasons other than those listed in responses 4-7.";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27623-0;1;"Yes; received from your agency during this episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27624-8;2;"Yes; received from your agency during a prior episode of care (SOC/ROC to Transfer/Discharge)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27625-5;3;"Yes; received from another health care provider (for example, physician, pharmacist)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27626-3;4;"No; patient offered and declined";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27627-1;5;"No; patient assessed and determined to have medical contraindication(s)";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27628-9;6;"No; not indicated - patient does not meet age/condition guidelines for influenza vaccine";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27629-7;7;"No; inability to obtain vaccine due to declared shortage";;; +57208-1;LL4495-9;CMS_OASIS Influenza vaccine received;LA27630-5;8;"No; patient did not receive the vaccine due to reasons other than those listed in responses 4-7.";;; +57208-1;LL780-8;OASIS-C_M1040;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA12150-1;3;Does not apply because entire episode of care (SOC/ROC to Transfer/Discharge) is outside this influenza season.;;; +57208-1;LL780-8;OASIS-C_M1040;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA12150-1;3;Does not apply because entire episode of care (SOC/ROC to Transfer/Discharge) is outside this influenza season.;;; +57208-1;LL780-8;OASIS-C_M1040;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA12150-1;3;Does not apply because entire episode of care (SOC/ROC to Transfer/Discharge) is outside this influenza season.;;; +57208-1;LL780-8;OASIS-C_M1040;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57208-1;LL780-8;OASIS-C_M1040;LA12150-1;3;Does not apply because entire episode of care (SOC/ROC to Transfer/Discharge) is outside this influenza season.;;; +57209-9;LL781-6;OASIS-C_M1045;LA12151-9;1;Received from another health care provider (e.g., physician);;; +57209-9;LL781-6;OASIS-C_M1045;LA12152-7;2;Received from your agency previously during this year's flu season;;; +57209-9;LL781-6;OASIS-C_M1045;LA186-9;3;Offered and declined;;; +57209-9;LL781-6;OASIS-C_M1045;LA12154-3;4;Assessed and determined to have medical contraindication(s);;; +57209-9;LL781-6;OASIS-C_M1045;LA12155-0;5;"Not indicated; patient does not meet age/condition guidelines for influenza vaccine";;; +57209-9;LL781-6;OASIS-C_M1045;LA12156-8;6;Inability to obtain vaccine due to declared shortage;;; +57209-9;LL781-6;OASIS-C_M1045;LA9-3;7;None of the above;;; +57211-5;LL782-4;OASIS-C_M1055;LA12158-4;1;Patient has received PPV in the past;;; +57211-5;LL782-4;OASIS-C_M1055;LA186-9;2;Offered and declined;;; +57211-5;LL782-4;OASIS-C_M1055;LA12154-3;3;Assessed and determined to have medical contraindication(s);;; +57211-5;LL782-4;OASIS-C_M1055;LA12161-8;4;"Not indicated; patient does not meet age/condition guidelines for PPV";;; +57211-5;LL782-4;OASIS-C_M1055;LA9-3;5;None of the above;;; +57212-3;LL783-2;OASIS-C_M1100a;LA12163-4;1;Around the clock;;; +57212-3;LL783-2;OASIS-C_M1100a;LA12164-2;2;Regular daytime;;; +57212-3;LL783-2;OASIS-C_M1100a;LA12165-9;3;Regular nighttime;;; +57212-3;LL783-2;OASIS-C_M1100a;LA12166-7;4;Occasional / short-term assistance;;; +57212-3;LL783-2;OASIS-C_M1100a;LA12167-5;5;No assistance available;;; +57213-1;LL845-9;OASIS-C_M1100b;LA12163-4;1;Around the clock;;; +57213-1;LL845-9;OASIS-C_M1100b;LA12164-2;2;Regular daytime;;; +57213-1;LL845-9;OASIS-C_M1100b;LA12165-9;3;Regular nighttime;;; +57213-1;LL845-9;OASIS-C_M1100b;LA12166-7;4;Occasional / short-term assistance;;; +57213-1;LL845-9;OASIS-C_M1100b;LA12167-5;5;No assistance available;;; +57214-9;LL848-3;OASIS-C_M1100c;LA12163-4;1;Around the clock;;; +57214-9;LL848-3;OASIS-C_M1100c;LA12164-2;2;Regular daytime;;; +57214-9;LL848-3;OASIS-C_M1100c;LA12165-9;3;Regular nighttime;;; +57214-9;LL848-3;OASIS-C_M1100c;LA12166-7;4;Occasional / short-term assistance;;; +57214-9;LL848-3;OASIS-C_M1100c;LA12167-5;5;No assistance available;;; +57215-6;LL784-0;OASIS-C_M1200;LA12168-3;1;"Normal vision: sees adequately in most situations; can see medication labels, newsprint.";;; +57215-6;LL784-0;OASIS-C_M1200;LA12169-1;2;"Partially impaired: cannot see medication labels or newsprint, but can see obstacles in path, and the surrounding layout; can count fingers at arm's length.";;; +57215-6;LL784-0;OASIS-C_M1200;LA6375-5;3;Severely impaired: cannot locate objects without hearing or touching them or patient nonresponsive.;;; +57216-4;LL785-7;OASIS-C_M1210;LA12123-8;1;Adequate: hears normal conversation without difficulty.;;; +57216-4;LL785-7;OASIS-C_M1210;LA12124-6;2;Mildly to Moderately Impaired: difficulty hearing in some environments or speaker may need to increase volume or speak distinctly.;;; +57216-4;LL785-7;OASIS-C_M1210;LA12125-3;3;Severely Impaired: absence of useful hearing.;;; +57216-4;LL785-7;OASIS-C_M1210;LA12174-1;4;Unable to assess hearing.;;; +57217-2;LL786-5;OASIS-C_M1220;LA12175-8;1;Understands: clear comprehension without cues or repetitions.;;; +57217-2;LL786-5;OASIS-C_M1220;LA12176-6;2;Usually understands: understands most conversations, but misses some part/intent of message. Requires cues at times to understand.;;; +57217-2;LL786-5;OASIS-C_M1220;LA12177-4;3;Sometimes understands: understands only basic conversations or simple, direct phrases. Frequently requires cues to understand.;;; +57217-2;LL786-5;OASIS-C_M1220;LA27670-1;4;Rarely/never understands.;;; +57217-2;LL786-5;OASIS-C_M1220;LA12179-0;5;Unable to assess understanding.;;; +57218-0;LL787-3;OASIS-C_M1230;LA6197-3;1;Expresses complex ideas, feelings, and needs clearly, completely, and easily in all situations with no observable impairment.;;; +57218-0;LL787-3;OASIS-C_M1230;LA12181-6;2;"Minimal difficulty in expressing ideas and needs (may take extra time; makes occasional errors in word choice, grammar or speech intelligibility; needs minimal prompting or assistance).";;; +57218-0;LL787-3;OASIS-C_M1230;LA12182-4;3;Expresses simple ideas or needs with moderate difficulty (needs prompting or assistance, errors in word choice, organization or speech intelligibility). Speaks in phrases or short sentences.;;; +57218-0;LL787-3;OASIS-C_M1230;LA12183-2;4;Has severe difficulty expressing basic ideas or needs and requires maximal assistance or guessing by listener. Speech limited to single words or short phrases.;;; +57218-0;LL787-3;OASIS-C_M1230;LA12184-0;5;Unable to express basic needs even with maximal prompting or assistance but is not comatose or unresponsive (for example, speech is nonsensical or unintelligible).;;; +57218-0;LL787-3;OASIS-C_M1230;LA6336-7;6;Patient nonresponsive or unable to speak.;;; +57219-8;LL788-1;OASIS-C_M1240;LA27671-9;1;No standardized, validated assessment conducted;;; +57219-8;LL788-1;OASIS-C_M1240;LA12187-3;2;Yes, and it does not indicate severe pain;;; +57219-8;LL788-1;OASIS-C_M1240;LA12188-1;3;Yes, and it indicates severe pain;;; +57220-6;LL789-9;OASIS-C_M1242;LA12189-9;0;Patient has no pain;;; +57220-6;LL789-9;OASIS-C_M1242;LA12190-7;1;Patient has pain that does not interfere with activity or movement;;; +57220-6;LL789-9;OASIS-C_M1242;LA6249-2;2;Less often than daily;;; +57220-6;LL789-9;OASIS-C_M1242;LA6177-5;3;Daily, but not constantly;;; +57220-6;LL789-9;OASIS-C_M1242;LA6154-4;4;All of the time;;; +57221-4;LL790-7;OASIS-C_M1300;LA12194-9;1;No assessment conducted;;; +57221-4;LL790-7;OASIS-C_M1300;LA27673-5;2;Yes, based on an evaluation of clinical factors (for example, mobility, incontinence, nutrition) without use of standardized tool;;; +57221-4;LL790-7;OASIS-C_M1300;LA27672-7;3;Yes, using a standardized, validated tool (for example, Braden Scale, Norton Scale);;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA12403-4;1;Was present at the most recent SOC/ROC assessment;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA28343-4;2;Developed since the most recent SOC/ROC assessment;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA28342-6;3;No stage 2 pressure ulcers are present at discharge;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA12403-4;1;Was present at the most recent SOC/ROC assessment;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA28343-4;2;Developed since the most recent SOC/ROC assessment;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA28342-6;3;No stage 2 pressure ulcers are present at discharge;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA12403-4;1;Was present at the most recent SOC/ROC assessment;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA28343-4;2;Developed since the most recent SOC/ROC assessment;;; +57222-2;LL4716-8;CMS_OASIS Oldest Stage 2 pressure injury;LA28342-6;3;No stage 2 pressure ulcers are present at discharge;;; +57222-2;LL828-5;OASIS-C_M1307;LA12403-4;1;Was present at the most recent SOC/ROC assessment;;; +57222-2;LL828-5;OASIS-C_M1307;LA12404-2;2;Developed since the most recent SOC/ROC assessment: record date pressure ulcer first identified: __ __ /__ __ /____ __ __;;; +57222-2;LL828-5;OASIS-C_M1307;LA12405-9;3;No non-epithelialized Stage II pressure ulcers are present at discharge;;; +57222-2;LL828-5;OASIS-C_M1307;LA12403-4;1;Was present at the most recent SOC/ROC assessment;;; +57222-2;LL828-5;OASIS-C_M1307;LA12404-2;2;Developed since the most recent SOC/ROC assessment: record date pressure ulcer first identified: __ __ /__ __ /____ __ __;;; +57222-2;LL828-5;OASIS-C_M1307;LA12405-9;3;No non-epithelialized Stage II pressure ulcers are present at discharge;;; +57222-2;LL828-5;OASIS-C_M1307;LA12403-4;1;Was present at the most recent SOC/ROC assessment;;; +57222-2;LL828-5;OASIS-C_M1307;LA12404-2;2;Developed since the most recent SOC/ROC assessment: record date pressure ulcer first identified: __ __ /__ __ /____ __ __;;; +57222-2;LL828-5;OASIS-C_M1307;LA12405-9;3;No non-epithelialized Stage II pressure ulcers are present at discharge;;; +57229-7;LL791-5;OASIS-C_M1320;LA12197-2;1;Newly epithelialized;;; +57229-7;LL791-5;OASIS-C_M1320;LA6203-9;2;Fully granulating;;; +57229-7;LL791-5;OASIS-C_M1320;LA6193-2;3;Early/partial granulation;;; +57229-7;LL791-5;OASIS-C_M1320;LA6300-3;4;Not healing;;; +57229-7;LL791-5;OASIS-C_M1320;LA6286-4;5;No observable pressure ulcer;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA27644-6;5;Patient has no pressure ulcers or no stageable pressure ulcers;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA27644-6;5;Patient has no pressure ulcers or no stageable pressure ulcers;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA27644-6;5;Patient has no pressure ulcers or no stageable pressure ulcers;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL4511-3;CMS_Pressure ulcer stage;LA27644-6;5;Patient has no pressure ulcers or no stageable pressure ulcers;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6383-9;1;Stage 1;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6384-7;2;Stage 2;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6385-4;3;Stage 3;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA6386-2;4;Stage 4;;; +57231-3;LL5032-9;CMS_OASIS D_Pressure ulcer stage;LA29202-1;5;Patient has no pressure ulcers/injuries or no stageable pressure ulcers/injuries;;; +57231-3;LL793-1;OASIS-C_M1324;LA3664-5;1;Stage I;;; +57231-3;LL793-1;OASIS-C_M1324;LA3661-1;2;Stage II;;; +57231-3;LL793-1;OASIS-C_M1324;LA3657-9;3;Stage III;;; +57231-3;LL793-1;OASIS-C_M1324;LA3651-2;4;Stage IV;;; +57231-3;LL793-1;OASIS-C_M1324;LA12211-1;5;No observable pressure ulcer or unhealed pressure ulcer;;; +57231-3;LL793-1;OASIS-C_M1324;LA3664-5;1;Stage I;;; +57231-3;LL793-1;OASIS-C_M1324;LA3661-1;2;Stage II;;; +57231-3;LL793-1;OASIS-C_M1324;LA3657-9;3;Stage III;;; +57231-3;LL793-1;OASIS-C_M1324;LA3651-2;4;Stage IV;;; +57231-3;LL793-1;OASIS-C_M1324;LA12211-1;5;No observable pressure ulcer or unhealed pressure ulcer;;; +57231-3;LL793-1;OASIS-C_M1324;LA3664-5;1;Stage I;;; +57231-3;LL793-1;OASIS-C_M1324;LA3661-1;2;Stage II;;; +57231-3;LL793-1;OASIS-C_M1324;LA3657-9;3;Stage III;;; +57231-3;LL793-1;OASIS-C_M1324;LA3651-2;4;Stage IV;;; +57231-3;LL793-1;OASIS-C_M1324;LA12211-1;5;No observable pressure ulcer or unhealed pressure ulcer;;; +57231-3;LL793-1;OASIS-C_M1324;LA3664-5;1;Stage I;;; +57231-3;LL793-1;OASIS-C_M1324;LA3661-1;2;Stage II;;; +57231-3;LL793-1;OASIS-C_M1324;LA3657-9;3;Stage III;;; +57231-3;LL793-1;OASIS-C_M1324;LA3651-2;4;Stage IV;;; +57231-3;LL793-1;OASIS-C_M1324;LA12211-1;5;No observable pressure ulcer or unhealed pressure ulcer;;; +57231-3;LL793-1;OASIS-C_M1324;LA3664-5;1;Stage I;;; +57231-3;LL793-1;OASIS-C_M1324;LA3661-1;2;Stage II;;; +57231-3;LL793-1;OASIS-C_M1324;LA3657-9;3;Stage III;;; +57231-3;LL793-1;OASIS-C_M1324;LA3651-2;4;Stage IV;;; +57231-3;LL793-1;OASIS-C_M1324;LA12211-1;5;No observable pressure ulcer or unhealed pressure ulcer;;; +57231-3;LL793-1;OASIS-C_M1324;LA3664-5;1;Stage I;;; +57231-3;LL793-1;OASIS-C_M1324;LA3661-1;2;Stage II;;; +57231-3;LL793-1;OASIS-C_M1324;LA3657-9;3;Stage III;;; +57231-3;LL793-1;OASIS-C_M1324;LA3651-2;4;Stage IV;;; +57231-3;LL793-1;OASIS-C_M1324;LA12211-1;5;No observable pressure ulcer or unhealed pressure ulcer;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL4512-1;CMS_Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL4512-1;CMS_Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12402-6;2;Yes, patient has BOTH observable and unobservable stasis ulcers;;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12400-0;3;Yes, patient has observable stasis ulcers ONLY;;; +57232-1;LL6127-6;CMS_OASIS Stasis ulcers;LA12401-8;4;Yes, patient has unobservable stasis ulcers ONLY (known but not observable due to non-removable dressing/device);;; +57232-1;LL794-9;OASIS-C_M1330;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL794-9;OASIS-C_M1330;LA12213-7;2;Yes, patient has one or more (observable) stasis ulcers;;; +57232-1;LL794-9;OASIS-C_M1330;LA12214-5;3;Stasis ulcer known but not observable due to non-removable dressing;;; +57232-1;LL794-9;OASIS-C_M1330;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL794-9;OASIS-C_M1330;LA12213-7;2;Yes, patient has one or more (observable) stasis ulcers;;; +57232-1;LL794-9;OASIS-C_M1330;LA12214-5;3;Stasis ulcer known but not observable due to non-removable dressing;;; +57232-1;LL794-9;OASIS-C_M1330;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL794-9;OASIS-C_M1330;LA12213-7;2;Yes, patient has one or more (observable) stasis ulcers;;; +57232-1;LL794-9;OASIS-C_M1330;LA12214-5;3;Stasis ulcer known but not observable due to non-removable dressing;;; +57232-1;LL794-9;OASIS-C_M1330;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL794-9;OASIS-C_M1330;LA12213-7;2;Yes, patient has one or more (observable) stasis ulcers;;; +57232-1;LL794-9;OASIS-C_M1330;LA12214-5;3;Stasis ulcer known but not observable due to non-removable dressing;;; +57232-1;LL794-9;OASIS-C_M1330;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL794-9;OASIS-C_M1330;LA12213-7;2;Yes, patient has one or more (observable) stasis ulcers;;; +57232-1;LL794-9;OASIS-C_M1330;LA12214-5;3;Stasis ulcer known but not observable due to non-removable dressing;;; +57232-1;LL794-9;OASIS-C_M1330;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57232-1;LL794-9;OASIS-C_M1330;LA12213-7;2;Yes, patient has one or more (observable) stasis ulcers;;; +57232-1;LL794-9;OASIS-C_M1330;LA12214-5;3;Stasis ulcer known but not observable due to non-removable dressing;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA6306-0;1;One;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA6404-3;2;Two;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA6395-3;3;Three;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA33103-5;5;Four;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA6306-0;1;One;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA6404-3;2;Two;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA6395-3;3;Three;;; +57233-9;LL6158-1;One (1)|Two(2)|Three(3)|Four(4);LA33103-5;5;Four;;; +57233-9;LL795-6;OASIS-C_M1332;LA6306-0;1;One;;; +57233-9;LL795-6;OASIS-C_M1332;LA6404-3;2;Two;;; +57233-9;LL795-6;OASIS-C_M1332;LA6395-3;3;Three;;; +57233-9;LL795-6;OASIS-C_M1332;LA6200-5;4;Four or more;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6203-9;1;Fully granulating;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6193-2;2;Early/partial granulation;;; +57234-7;LL4513-9;CMS_OASIS Stasis ulcer status;LA6300-3;3;Not healing;;; +57234-7;LL796-4;OASIS-C_M1334;LA12197-2;1;Newly epithelialized;;; +57234-7;LL796-4;OASIS-C_M1334;LA6203-9;2;Fully granulating;;; +57234-7;LL796-4;OASIS-C_M1334;LA6193-2;3;Early/partial granulation;;; +57234-7;LL796-4;OASIS-C_M1334;LA6300-3;4;Not healing;;; +57234-7;LL796-4;OASIS-C_M1334;LA12197-2;1;Newly epithelialized;;; +57234-7;LL796-4;OASIS-C_M1334;LA6203-9;2;Fully granulating;;; +57234-7;LL796-4;OASIS-C_M1334;LA6193-2;3;Early/partial granulation;;; +57234-7;LL796-4;OASIS-C_M1334;LA6300-3;4;Not healing;;; +57234-7;LL796-4;OASIS-C_M1334;LA12197-2;1;Newly epithelialized;;; +57234-7;LL796-4;OASIS-C_M1334;LA6203-9;2;Fully granulating;;; +57234-7;LL796-4;OASIS-C_M1334;LA6193-2;3;Early/partial granulation;;; +57234-7;LL796-4;OASIS-C_M1334;LA6300-3;4;Not healing;;; +57234-7;LL796-4;OASIS-C_M1334;LA12197-2;1;Newly epithelialized;;; +57234-7;LL796-4;OASIS-C_M1334;LA6203-9;2;Fully granulating;;; +57234-7;LL796-4;OASIS-C_M1334;LA6193-2;3;Early/partial granulation;;; +57234-7;LL796-4;OASIS-C_M1334;LA6300-3;4;Not healing;;; +57234-7;LL796-4;OASIS-C_M1334;LA12197-2;1;Newly epithelialized;;; +57234-7;LL796-4;OASIS-C_M1334;LA6203-9;2;Fully granulating;;; +57234-7;LL796-4;OASIS-C_M1334;LA6193-2;3;Early/partial granulation;;; +57234-7;LL796-4;OASIS-C_M1334;LA6300-3;4;Not healing;;; +57234-7;LL796-4;OASIS-C_M1334;LA12197-2;1;Newly epithelialized;;; +57234-7;LL796-4;OASIS-C_M1334;LA6203-9;2;Fully granulating;;; +57234-7;LL796-4;OASIS-C_M1334;LA6193-2;3;Early/partial granulation;;; +57234-7;LL796-4;OASIS-C_M1334;LA6300-3;4;Not healing;;; +57236-2;LL796-4;OASIS-C_M1334;LA12197-2;1;Newly epithelialized;;; +57236-2;LL796-4;OASIS-C_M1334;LA6203-9;2;Fully granulating;;; +57236-2;LL796-4;OASIS-C_M1334;LA6193-2;3;Early/partial granulation;;; +57236-2;LL796-4;OASIS-C_M1334;LA6300-3;4;Not healing;;; +57235-4;LL849-1;OASIS_M1340;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57235-4;LL849-1;OASIS_M1340;LA12633-6;2;Yes, patient has at least one observable surgical wound;;; +57235-4;LL849-1;OASIS_M1340;LA12634-4;3;Surgical wound known but not observable due to non-removable dressing/device;;; +57237-0;LL797-2;OASIS-C_M1400;LA12224-4;1;Patient is not short of breath;;; +57237-0;LL797-2;OASIS-C_M1400;LA6443-1;2;When walking more than 20 feet, climbing stairs;;; +57237-0;LL797-2;OASIS-C_M1400;LA6446-4;3;With moderate exertion (for example, while dressing, using commode or bedpan, walking distances less than 20 feet);;; +57237-0;LL797-2;OASIS-C_M1400;LA6445-6;4;With minimal exertion (for example, while eating, talking, or performing other ADLs) or with agitation;;; +57237-0;LL797-2;OASIS-C_M1400;LA6158-5;5;At rest (during day or night);;; +57238-8;LL798-0;OASIS-C_M1410;LA6319-3;1;Oxygen (intermittent or continuous);;; +57238-8;LL798-0;OASIS-C_M1410;LA6438-1;2;Ventilator (continually or at night);;; +57238-8;LL798-0;OASIS-C_M1410;LA12231-9;3;Continuous / Bi-level positive airway pressure;;; +57238-8;LL798-0;OASIS-C_M1410;LA9-3;4;None of the above;;; +57239-6;LL799-8;OASIS-C_M1500;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57239-6;LL799-8;OASIS-C_M1500;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57239-6;LL799-8;OASIS-C_M1500;LA9348-9;3;Not assessed;;; +57239-6;LL799-8;OASIS-C_M1500;LA12236-8;4;Patient does not have diagnosis of heart failure;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12237-6;1;No action taken;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12238-4;2;Patient's physician (or other primary care practitioner) contacted the same day;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12239-2;3;Patient advised to get emergency treatment (for example, call 911 or go to emergency room);;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12240-0;4;Implemented physician-ordered patient-specific established parameters for treatment;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12241-8;5;Patient education or other clinical interventions;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA28023-2;6;Obtained change in care plan orders (for example, increased monitoring by agency, change in visit frequency, telehealth);;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12237-6;1;No action taken;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12238-4;2;Patient's physician (or other primary care practitioner) contacted the same day;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12239-2;3;Patient advised to get emergency treatment (for example, call 911 or go to emergency room);;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12240-0;4;Implemented physician-ordered patient-specific established parameters for treatment;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA12241-8;5;Patient education or other clinical interventions;;; +57240-4;LL4628-5;CMS_OASIS Heart failure follow-up;LA28023-2;6;Obtained change in care plan orders (for example, increased monitoring by agency, change in visit frequency, telehealth);;; +57240-4;LL800-4;OASIS-C_M1510;LA12237-6;1;No action taken;;; +57240-4;LL800-4;OASIS-C_M1510;LA12238-4;2;Patient's physician (or other primary care practitioner) contacted the same day;;; +57240-4;LL800-4;OASIS-C_M1510;LA12239-2;3;Patient advised to get emergency treatment (for example, call 911 or go to emergency room);;; +57240-4;LL800-4;OASIS-C_M1510;LA12240-0;4;Implemented physician-ordered patient-specific established parameters for treatment;;; +57240-4;LL800-4;OASIS-C_M1510;LA12241-8;5;Patient education or other clinical interventions;;; +57240-4;LL800-4;OASIS-C_M1510;LA12242-6;6;Obtained change in care plan orders (for example, increased monitoring by agency, change in visit frequency, telehealth, etc.);;; +57240-4;LL800-4;OASIS-C_M1510;LA12237-6;1;No action taken;;; +57240-4;LL800-4;OASIS-C_M1510;LA12238-4;2;Patient's physician (or other primary care practitioner) contacted the same day;;; +57240-4;LL800-4;OASIS-C_M1510;LA12239-2;3;Patient advised to get emergency treatment (for example, call 911 or go to emergency room);;; +57240-4;LL800-4;OASIS-C_M1510;LA12240-0;4;Implemented physician-ordered patient-specific established parameters for treatment;;; +57240-4;LL800-4;OASIS-C_M1510;LA12241-8;5;Patient education or other clinical interventions;;; +57240-4;LL800-4;OASIS-C_M1510;LA12242-6;6;Obtained change in care plan orders (for example, increased monitoring by agency, change in visit frequency, telehealth, etc.);;; +57240-4;LL800-4;OASIS-C_M1510;LA12237-6;1;No action taken;;; +57240-4;LL800-4;OASIS-C_M1510;LA12238-4;2;Patient's physician (or other primary care practitioner) contacted the same day;;; +57240-4;LL800-4;OASIS-C_M1510;LA12239-2;3;Patient advised to get emergency treatment (for example, call 911 or go to emergency room);;; +57240-4;LL800-4;OASIS-C_M1510;LA12240-0;4;Implemented physician-ordered patient-specific established parameters for treatment;;; +57240-4;LL800-4;OASIS-C_M1510;LA12241-8;5;Patient education or other clinical interventions;;; +57240-4;LL800-4;OASIS-C_M1510;LA12242-6;6;Obtained change in care plan orders (for example, increased monitoring by agency, change in visit frequency, telehealth, etc.);;; +57240-4;LL800-4;OASIS-C_M1510;LA12237-6;1;No action taken;;; +57240-4;LL800-4;OASIS-C_M1510;LA12238-4;2;Patient's physician (or other primary care practitioner) contacted the same day;;; +57240-4;LL800-4;OASIS-C_M1510;LA12239-2;3;Patient advised to get emergency treatment (for example, call 911 or go to emergency room);;; +57240-4;LL800-4;OASIS-C_M1510;LA12240-0;4;Implemented physician-ordered patient-specific established parameters for treatment;;; +57240-4;LL800-4;OASIS-C_M1510;LA12241-8;5;Patient education or other clinical interventions;;; +57240-4;LL800-4;OASIS-C_M1510;LA12242-6;6;Obtained change in care plan orders (for example, increased monitoring by agency, change in visit frequency, telehealth, etc.);;; +57241-2;LL801-2;OASIS-C_M1615;LA6397-9;1;Timed-voiding defers incontinence;;; +57241-2;LL801-2;OASIS-C_M1615;LA12244-2;2;Occasional stress incontinence;;; +57241-2;LL801-2;OASIS-C_M1615;LA6192-4;3;During the night only;;; +57241-2;LL801-2;OASIS-C_M1615;LA12246-7;4;During the day only;;; +57241-2;LL801-2;OASIS-C_M1615;LA6191-6;5;During the day and night;;; +57242-0;LL803-8;OASIS-C_M1730;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57242-0;LL803-8;OASIS-C_M1730;LA12254-1;2;Yes, patient was screened using the PHQ-2© scale.;;; +57242-0;LL803-8;OASIS-C_M1730;LA12255-8;3;Yes, patient was screened with a different standardized, validated assessment and the patient meets criteria for further evaluation for depression.;;; +57242-0;LL803-8;OASIS-C_M1730;LA12256-6;4;Yes, patient was screened with a different standardized, validated assessment and the patient does not meet criteria for further evaluation for depression.;;; +57243-8;LL805-3;OASIS-C_M1830;LA12264-0;1;Able to bathe self in shower or tub independently, including getting in and out of tub/shower.;;; +57243-8;LL805-3;OASIS-C_M1830;LA12265-7;2;With the use of devices, is able to bathe self in shower or tub independently, including getting in and out of the tub/shower.;;; +57243-8;LL805-3;OASIS-C_M1830;LA12266-5;3;Able to bathe in shower or tub with the intermittent assistance of another person: (a) for intermittent supervision or encouragement or reminders, OR (b) to get in and out of the shower or tub, OR (c) for washing difficult to reach areas.;;; +57243-8;LL805-3;OASIS-C_M1830;LA12267-3;4;Able to participate in bathing self in shower or tub, but requires presence of another person throughout the bath for assistance or supervision.;;; +57243-8;LL805-3;OASIS-C_M1830;LA12268-1;5;Unable to use the shower or tub, but able to bathe self independently with or without the use of devices at the sink, in chair, or on commode.;;; +57243-8;LL805-3;OASIS-C_M1830;LA12269-9;6;Unable to use the shower or tub, but able to participate in bathing self in bed, at the sink, in bedside chair, or on commode, with the assistance or supervision of another person.;;; +57243-8;LL805-3;OASIS-C_M1830;LA12270-7;7;Unable to participate effectively in bathing and is bathed totally by another person.;;; +57244-6;LL806-1;OASIS-C_M1840;LA12271-5;1;Able to get to and from the toilet and transfer independently with or without a device.;;; +57244-6;LL806-1;OASIS-C_M1840;LA12272-3;2;When reminded, assisted, or supervised by another person, able to get to and from the toilet and transfer.;;; +57244-6;LL806-1;OASIS-C_M1840;LA6415-9;3;Unable to get to and from the toilet but is able to use a bedside commode (with or without assistance).;;; +57244-6;LL806-1;OASIS-C_M1840;LA6416-7;4;Unable to get to and from the toilet or bedside commode but is able to use a bedpan/urinal independently.;;; +57244-6;LL806-1;OASIS-C_M1840;LA6245-0;5;Is totally dependent in toileting.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +57245-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83187-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83188-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83189-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83190-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83191-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83192-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83193-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83194-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83195-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83196-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83197-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83198-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83199-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83200-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83201-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83202-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83203-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83204-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83205-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83206-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83207-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83208-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83209-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83210-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83211-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83212-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83213-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83214-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83215-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83216-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83217-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83218-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83219-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83220-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83221-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83222-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83223-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83224-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83225-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83226-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83227-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83228-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83229-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83230-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83231-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83232-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83235-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +83236-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +85927-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89375-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89376-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89377-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89378-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89379-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89380-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89381-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89382-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89383-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89384-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89385-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89386-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89387-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89388-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89389-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89390-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89392-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89393-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89394-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89395-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89396-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89397-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89398-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89399-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89400-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89401-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89402-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89403-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89404-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89405-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89406-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89407-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89409-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89410-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89412-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89413-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89414-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89415-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89416-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89417-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89418-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89419-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89420-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +89421-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94991-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94992-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94997-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94998-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +94999-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95000-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95001-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95002-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95003-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95004-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95005-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95006-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95007-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95008-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95009-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95010-5;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95011-3;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95012-1;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95013-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95014-7;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95015-4;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95016-2;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95017-0;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95018-8;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +95019-6;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28225-3;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA10058-8;7;Patient refused;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28226-1;8;Not applicable - Not attempted and the patient did not perform this activity prior to the current illness, exacerbation, or injury.;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA28227-9;9;Not attempted due to environmental limitations (e.g., lack of equipment, weather constraints).;;; +96098-9;LL4681-4;CMS_LCDS v4 Functional abilities & goals;LA26735-3;10;Not attempted due to medical condition or safety concerns;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12276-4;1;Able to manage toileting hygiene and clothing management without assistance.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12277-2;2;Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12278-0;3;Someone must help the patient to maintain toileting hygiene and/or adjust clothing.;;; +57245-3;LL807-9;OASIS-C_M1845;LA12279-8;4;Patient depends entirely upon another person to maintain toileting hygiene.;;; +57246-1;LL808-7;OASIS-C_M1850;LA6136-1;1;Able to independently transfer.;;; +57246-1;LL808-7;OASIS-C_M1850;LA12281-4;2;Able to transfer with minimal human assistance or with use of an assistive device.;;; +57246-1;LL808-7;OASIS-C_M1850;LA12282-2;3;Able to bear weight and pivot during the transfer process but unable to transfer self.;;; +57246-1;LL808-7;OASIS-C_M1850;LA6426-6;4;Unable to transfer self and is unable to bear weight or pivot when transferred by another person.;;; +57246-1;LL808-7;OASIS-C_M1850;LA6161-9;5;Bedfast, unable to transfer but is able to turn and position self in bed.;;; +57246-1;LL808-7;OASIS-C_M1850;LA6160-1;6;Bedfast, unable to transfer and is unable to turn and position self.;;; +57247-9;LL809-5;OASIS-C_M1860;LA12286-3;1;Able to independently walk on even and uneven surfaces and negotiate stairs with or without railings (specifically: needs no human assistance or assistive device).;;; +57247-9;LL809-5;OASIS-C_M1860;LA12287-1;2;With the use of a one-handed device (for example, cane, single crutch, hemi-walker), able to independently walk on even and uneven surfaces and negotiate stairs with or without railings.;;; +57247-9;LL809-5;OASIS-C_M1860;LA12288-9;3;Requires use of a two-handed device (for example, walker or crutches) to walk alone on a level surface and/or requires human supervision or assistance to negotiate stairs or steps or uneven surfaces.;;; +57247-9;LL809-5;OASIS-C_M1860;LA6147-8;4;Able to walk only with the supervision or assistance of another person at all times.;;; +57247-9;LL809-5;OASIS-C_M1860;LA6171-8;5;Chairfast, unable to ambulate but is able to wheel self independently.;;; +57247-9;LL809-5;OASIS-C_M1860;LA6170-0;6;Chairfast, unable to ambulate and is unable to wheel self.;;; +57247-9;LL809-5;OASIS-C_M1860;LA6159-3;7;Bedfast, unable to ambulate or be up in a chair.;;; +57248-7;LL810-3;OASIS-C_M1870;LA6133-8;1;Able to independently feed self.;;; +57248-7;LL810-3;OASIS-C_M1870;LA12294-7;2;"Able to feed self independently but requires: (a) meal set-up; OR (b) intermittent assistance or supervision from another person; OR (c) a liquid, pureed or ground meat diet.";;; +57248-7;LL810-3;OASIS-C_M1870;LA6414-2;3;Unable to feed self and must be assisted or supervised throughout the meal/snack.;;; +57248-7;LL810-3;OASIS-C_M1870;LA6142-9;4;Able to take in nutrients orally AND receives supplemental nutrients through a nasogastric tube or gastrostomy.;;; +57248-7;LL810-3;OASIS-C_M1870;LA6422-5;5;Unable to take in nutrients orally and is fed nutrients through a nasogastric tube or gastrostomy.;;; +57248-7;LL810-3;OASIS-C_M1870;LA6423-3;6;Unable to take in nutrients orally or by tube feeding.;;; +57249-5;LL811-1;OASIS-C_M1880;LA12299-6;1;"Able to independently plan and prepare all light meals for self or reheat delivered meals; or Is physically, cognitively, and mentally able to prepare light meals on a regular basis but has not routinely performed light meal preparation in the past.";;; +57249-5;LL811-1;OASIS-C_M1880;LA6420-9;2;Unable to prepare light meals on a regular basis due to physical, cognitive, or mental limitations.;;; +57249-5;LL811-1;OASIS-C_M1880;LA6419-1;3;Unable to prepare any light meals or reheat any delivered meals.;;; +57250-3;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +57250-3;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +57250-3;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +57251-1;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +57251-1;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +57251-1;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +57252-9;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +57252-9;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +57252-9;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +57253-7;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +57253-7;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +57253-7;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +83181-8;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +83181-8;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +83181-8;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +83182-6;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +83182-6;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +83182-6;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +83183-4;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +83183-4;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +83183-4;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +83184-2;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +83184-2;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +83184-2;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +83185-9;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +83185-9;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +83185-9;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +83186-7;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +83186-7;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +83186-7;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +85070-1;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +85070-1;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +85070-1;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +85070-1;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +85070-1;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +85070-1;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +86185-6;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +86185-6;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +86185-6;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +86186-4;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +86186-4;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +86186-4;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +86187-2;LL812-9;OASIS-C_M1900;LA12302-8;1;Independent;;; +86187-2;LL812-9;OASIS-C_M1900;LA12303-6;2;Needed some help;;; +86187-2;LL812-9;OASIS-C_M1900;LA12304-4;3;Dependent;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA27633-9;3;Yes, and it does indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA27633-9;3;Yes, and it does indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA27633-9;3;Yes, and it does indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA27633-9;3;Yes, and it does indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL4498-3;CMS_OASIS C2 Fall Risk Assessment;LA27633-9;3;Yes, and it does indicate a risk for falls.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12305-1;1;No multi-factor falls risk assessment conducted.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12307-7;3;Yes, and it indicates a risk for falls.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12305-1;1;No multi-factor falls risk assessment conducted.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12307-7;3;Yes, and it indicates a risk for falls.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12305-1;1;No multi-factor falls risk assessment conducted.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12306-9;2;Yes, and it does not indicate a risk for falls.;;; +57254-5;LL813-7;OASIS-C_M1910;LA12307-7;3;Yes, and it indicates a risk for falls.;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +88870-1;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +88870-1;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +88870-1;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +88870-1;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27634-7;1;No - No issues found during review;;; +88870-1;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +88870-1;LL4499-1;CMS_OASIS C2 Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL5418-0;CMS_Medication Review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL5418-0;CMS_Medication Review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL5418-0;CMS_Medication Review;LA30361-2;3;Not applicable - Patient is not taking any medications;;; +57255-2;LL5418-0;CMS_Medication Review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL5418-0;CMS_Medication Review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL5418-0;CMS_Medication Review;LA30361-2;3;Not applicable - Patient is not taking any medications;;; +57255-2;LL6126-8;CMS_OASIS Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL6126-8;CMS_OASIS Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL6126-8;CMS_OASIS Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL6126-8;CMS_OASIS Drug regimen review;LA27634-7;1;No - No issues found during review;;; +57255-2;LL6126-8;CMS_OASIS Drug regimen review;LA27635-4;2;Yes - Issues found during review;;; +57255-2;LL6126-8;CMS_OASIS Drug regimen review;LA27636-2;3;NA - Patient is not taking any medications;;; +57255-2;LL814-5;OASIS-C_M2000;LA12308-5;1;Not assessed/reviewed;;; +57255-2;LL814-5;OASIS-C_M2000;LA12309-3;2;No problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12310-1;3;Problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12311-9;4;Patient is not taking any medications;;; +57255-2;LL814-5;OASIS-C_M2000;LA12308-5;1;Not assessed/reviewed;;; +57255-2;LL814-5;OASIS-C_M2000;LA12309-3;2;No problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12310-1;3;Problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12311-9;4;Patient is not taking any medications;;; +57255-2;LL814-5;OASIS-C_M2000;LA12308-5;1;Not assessed/reviewed;;; +57255-2;LL814-5;OASIS-C_M2000;LA12309-3;2;No problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12310-1;3;Problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12311-9;4;Patient is not taking any medications;;; +57255-2;LL814-5;OASIS-C_M2000;LA12308-5;1;Not assessed/reviewed;;; +57255-2;LL814-5;OASIS-C_M2000;LA12309-3;2;No problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12310-1;3;Problems found during review;;; +57255-2;LL814-5;OASIS-C_M2000;LA12311-9;4;Patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4520-4;CMS_OASIS Medication Intervention;LA27681-8;3;NA-There were no potential clinically significant medication issues identified since SOC/ROC or patient is not taking any medications;;; +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA28270-9;3;NA - There were no potential clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA28270-9;3;NA - There were no potential clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA28270-9;3;NA - There were no potential clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA28270-9;3;NA - There were no potential clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA28270-9;3;NA - There were no potential clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4698-8;CMS_LCDS Medication intervention;LA28270-9;3;NA - There were no potential clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL4996-6;CMS_MDS Meddication intervention;LA28935-7;3;NA - There were no potential clinically significant medication issues identified since admission or resident is not taking any medications;;; +57256-0;LL5404-0;CMS_LCDS v5 - Medication Intervention (N2005);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL5404-0;CMS_LCDS v5 - Medication Intervention (N2005);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL5404-0;CMS_LCDS v5 - Medication Intervention (N2005);LA30352-1;3;Not applicable - There were no potential clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL5419-8;CMS_IRF-PAI - Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL5419-8;CMS_IRF-PAI - Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL5419-8;CMS_IRF-PAI - Medication Intervention;LA30362-0;3;Not applicable - There were no potentially clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL5419-8;CMS_IRF-PAI - Medication Intervention;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL5419-8;CMS_IRF-PAI - Medication Intervention;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL5419-8;CMS_IRF-PAI - Medication Intervention;LA30362-0;3;Not applicable - There were no potentially clinically significant medication issues identified since admission or patient is not taking any medications;;; +57256-0;LL815-2;OASIS-C_M2004;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA12314-3;3;No clinically significant medication issues identified since the previous OASIS assessment;;; +57256-0;LL815-2;OASIS-C_M2004;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA12314-3;3;No clinically significant medication issues identified since the previous OASIS assessment;;; +57256-0;LL815-2;OASIS-C_M2004;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA12314-3;3;No clinically significant medication issues identified since the previous OASIS assessment;;; +57256-0;LL815-2;OASIS-C_M2004;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57256-0;LL815-2;OASIS-C_M2004;LA12314-3;3;No clinically significant medication issues identified since the previous OASIS assessment;;; +57257-8;LL816-0;OASIS-C_M2010;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57257-8;LL816-0;OASIS-C_M2010;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57257-8;LL816-0;OASIS-C_M2010;LA12317-6;3;Patient not taking any high risk drugs OR patient/caregiver fully knowledgeable about special precautions associated with all high-risk medications;;; +57258-6;LL820-2;OASIS-C_M2040;LA12302-8;1;Independent;;; +57258-6;LL820-2;OASIS-C_M2040;LA12303-6;2;Needed some help;;; +57258-6;LL820-2;OASIS-C_M2040;LA12304-4;3;Dependent;;; +57258-6;LL820-2;OASIS-C_M2040;LA4720-4;4;Not applicable;;; +57259-4;LL820-2;OASIS-C_M2040;LA12302-8;1;Independent;;; +57259-4;LL820-2;OASIS-C_M2040;LA12303-6;2;Needed some help;;; +57259-4;LL820-2;OASIS-C_M2040;LA12304-4;3;Dependent;;; +57259-4;LL820-2;OASIS-C_M2040;LA4720-4;4;Not applicable;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57260-2;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57261-0;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57262-8;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57263-6;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57264-4;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57265-1;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27608-1;1;No assistance needed -patient is independent or does not have needs in this area;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27610-7;2;Non-agency caregiver(s) currently provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27611-5;3;Non-agency caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27612-3;4;Non-agency caregiver(s) are not likely to provide assistance OR it is unclear if they will provide assistance;;; +57266-9;LL4492-6;CMS_Types and sources of assisstance;LA27613-1;5;Assistance needed, but no non-agency caregiver(s) available;;; +57260-2;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57260-2;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57260-2;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57260-2;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57260-2;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57260-2;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57260-2;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57260-2;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57260-2;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57260-2;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57260-2;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57261-0;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57261-0;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57261-0;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57261-0;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57261-0;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57261-0;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57261-0;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57261-0;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57261-0;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57261-0;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57261-0;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57262-8;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57262-8;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57262-8;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57262-8;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57262-8;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57262-8;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57262-8;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57262-8;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57262-8;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57262-8;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57262-8;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57263-6;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57263-6;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57263-6;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57263-6;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57263-6;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57263-6;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57263-6;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57263-6;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57263-6;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57263-6;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57263-6;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57264-4;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57264-4;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57264-4;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57264-4;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57264-4;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57264-4;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57264-4;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57264-4;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57264-4;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57264-4;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57264-4;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57265-1;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57265-1;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57265-1;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57265-1;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57265-1;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57265-1;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57265-1;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57265-1;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57265-1;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57265-1;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57265-1;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57266-9;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57266-9;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57266-9;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57266-9;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57266-9;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57266-9;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57266-9;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57266-9;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57266-9;LL821-0;OASIS-C_M2100;LA12335-8;1;No assistance needed in this area;;; +57266-9;LL821-0;OASIS-C_M2100;LA12336-6;2;Caregiver(s) currently provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12337-4;3;Caregiver(s) need training/ supportive services to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12338-2;4;Caregiver(s) not likely to provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12339-0;5;Unclear if caregiver(s) will provide assistance;;; +57266-9;LL821-0;OASIS-C_M2100;LA12340-8;6;Assistance needed, but no caregiver(s) available;;; +57267-7;LL822-8;OASIS-C_M2110;LA6157-7;1;At least daily;;; +57267-7;LL822-8;OASIS-C_M2110;LA6396-1;2;Three or more times per week;;; +57267-7;LL822-8;OASIS-C_M2110;LA6308-6;3;One to two times per week;;; +57267-7;LL822-8;OASIS-C_M2110;LA12344-0;4;Received, but less often than weekly;;; +57267-7;LL822-8;OASIS-C_M2110;LA12345-7;5;No assistance received;;; +57267-7;LL822-8;OASIS-C_M2110;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57269-3;LL4500-6;CMS_Plan of care-notifying physician of changes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57269-3;LL4500-6;CMS_Plan of care-notifying physician of changes;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57269-3;LL4500-6;CMS_Plan of care-notifying physician of changes;LA27637-0;3;NA-Physician has chosen not to establish patient-specific parameters for this patient. Agency will use standardized clinical guidelines accessible for all care providers to reference.;;; +57269-3;LL4500-6;CMS_Plan of care-notifying physician of changes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57269-3;LL4500-6;CMS_Plan of care-notifying physician of changes;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57269-3;LL4500-6;CMS_Plan of care-notifying physician of changes;LA27637-0;3;NA-Physician has chosen not to establish patient-specific parameters for this patient. Agency will use standardized clinical guidelines accessible for all care providers to reference.;;; +57269-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57269-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57269-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57269-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57269-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57270-1;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57270-1;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57270-1;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57270-1;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57271-9;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57272-7;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57272-7;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57272-7;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57272-7;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57272-7;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57272-7;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57273-5;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57273-5;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57273-5;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57273-5;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57273-5;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57273-5;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57274-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57274-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57274-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57274-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57274-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57274-3;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57275-0;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57275-0;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57275-0;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57275-0;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57275-0;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57275-0;LL823-6;OASIS-C_M2250;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL823-6;OASIS-C_M2250;LA4720-4;3;Not applicable;;; +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA27638-8;3;NA-Patient is not diabetic or is missing lower legs due to congenital or acquired condition (bilateral amputee).;;; +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA27638-8;3;NA-Patient is not diabetic or is missing lower legs due to congenital or acquired condition (bilateral amputee).;;; +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA27638-8;3;NA-Patient is not diabetic or is missing lower legs due to congenital or acquired condition (bilateral amputee).;;; +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA27638-8;3;NA-Patient is not diabetic or is missing lower legs due to congenital or acquired condition (bilateral amputee).;;; +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA27638-8;3;NA-Patient is not diabetic or is missing lower legs due to congenital or acquired condition (bilateral amputee).;;; +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57270-1;LL4502-2;CMS_Plan of care-diabetic foot care;LA27638-8;3;NA-Patient is not diabetic or is missing lower legs due to congenital or acquired condition (bilateral amputee).;;; +57271-9;LL4506-3;CMS_Plan of care-fall prevention interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL4506-3;CMS_Plan of care-fall prevention interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL4506-3;CMS_Plan of care-fall prevention interventions;LA27639-6;3;NA-Falls risk assessment indicates patient has no risk for falls.;;; +57271-9;LL4506-3;CMS_Plan of care-fall prevention interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL4506-3;CMS_Plan of care-fall prevention interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL4506-3;CMS_Plan of care-fall prevention interventions;LA27639-6;3;NA-Falls risk assessment indicates patient has no risk for falls.;;; +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA27694-1;3;NA-Every standardized, validated multifactor fall risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no risk for falls.;;; +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA27694-1;3;NA-Every standardized, validated multifactor fall risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no risk for falls.;;; +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA27694-1;3;NA-Every standardized, validated multifactor fall risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no risk for falls.;;; +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57271-9;LL4522-0;CMS_OASIS Intervention Synopsis;LA27694-1;3;NA-Every standardized, validated multifactor fall risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no risk for falls.;;; +57272-7;LL4507-1;CMS_Plan of care-depression interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL4507-1;CMS_Plan of care-depression interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL4507-1;CMS_Plan of care-depression interventions;LA27640-4;3;"NA-Patient has no diagnosis of depression AND depression screening indicates patient has: 1) no symptoms of depression; or 2) has some symptoms of depression but does not meet criteria for further evaluation of depression based on screening tool used";;; +57272-7;LL4507-1;CMS_Plan of care-depression interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL4507-1;CMS_Plan of care-depression interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL4507-1;CMS_Plan of care-depression interventions;LA27640-4;3;"NA-Patient has no diagnosis of depression AND depression screening indicates patient has: 1) no symptoms of depression; or 2) has some symptoms of depression but does not meet criteria for further evaluation of depression based on screening tool used";;; +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA27695-8;3;"NA-Patient has no diagnosis of depression AND every standardized, validated depression screening conducted at or since the most recent SOC/ROC assessment indicates the patient has: 1) no symptoms of depression; or 2) has some symptoms of depression";;; +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA27695-8;3;"NA-Patient has no diagnosis of depression AND every standardized, validated depression screening conducted at or since the most recent SOC/ROC assessment indicates the patient has: 1) no symptoms of depression; or 2) has some symptoms of depression";;; +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA27695-8;3;"NA-Patient has no diagnosis of depression AND every standardized, validated depression screening conducted at or since the most recent SOC/ROC assessment indicates the patient has: 1) no symptoms of depression; or 2) has some symptoms of depression";;; +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57272-7;LL4523-8;CMS_OASIS-transfer Depression interventions;LA27695-8;3;"NA-Patient has no diagnosis of depression AND every standardized, validated depression screening conducted at or since the most recent SOC/ROC assessment indicates the patient has: 1) no symptoms of depression; or 2) has some symptoms of depression";;; +57273-5;LL4508-9;CMS_Plan of care-monitor and mitigate pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL4508-9;CMS_Plan of care-monitor and mitigate pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL4508-9;CMS_Plan of care-monitor and mitigate pain;LA27641-2;3;NA-Pain assessment indicates patient has no pain.;;; +57273-5;LL4508-9;CMS_Plan of care-monitor and mitigate pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL4508-9;CMS_Plan of care-monitor and mitigate pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL4508-9;CMS_Plan of care-monitor and mitigate pain;LA27641-2;3;NA-Pain assessment indicates patient has no pain.;;; +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA27696-6;3;NA-Every standardized, validated pain assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no pain.;;; +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA27696-6;3;NA-Every standardized, validated pain assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no pain.;;; +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA27696-6;3;NA-Every standardized, validated pain assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no pain.;;; +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57273-5;LL4524-6;CMS_OASIS-transfer Intervention-pain;LA27696-6;3;NA-Every standardized, validated pain assessment conducted at or since the most recent SOC/ROC assessment indicates the patient has no pain.;;; +57274-3;LL4509-7;CMS_Plan of care-prevent pressure ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL4509-7;CMS_Plan of care-prevent pressure ulcers;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL4509-7;CMS_Plan of care-prevent pressure ulcers;LA27642-0;3;NA-Pressure ulcer risk assessment (clinical or formal) indicates patient is not at risk of developing pressure ulcers.;;; +57274-3;LL4509-7;CMS_Plan of care-prevent pressure ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL4509-7;CMS_Plan of care-prevent pressure ulcers;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL4509-7;CMS_Plan of care-prevent pressure ulcers;LA27642-0;3;NA-Pressure ulcer risk assessment (clinical or formal) indicates patient is not at risk of developing pressure ulcers.;;; +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA27697-4;3;NA-Every standardized, validated pressure ulcer risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient is not at risk of developing pressure ulcers.;;; +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA27697-4;3;NA-Every standardized, validated pressure ulcer risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient is not at risk of developing pressure ulcers.;;; +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA27697-4;3;NA-Every standardized, validated pressure ulcer risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient is not at risk of developing pressure ulcers.;;; +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57274-3;LL4525-3;CMS_OASIS-transfer Intervention-pressure ulcers;LA27697-4;3;NA-Every standardized, validated pressure ulcer risk assessment conducted at or since the most recent SOC/ROC assessment indicates the patient is not at risk of developing pressure ulcers.;;; +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA27643-8;3;NA-Patient has no pressure ulcers OR has no pressure ulcers for which moist wound healing is indicated.;;; +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA27643-8;3;NA-Patient has no pressure ulcers OR has no pressure ulcers for which moist wound healing is indicated.;;; +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA27643-8;3;NA-Patient has no pressure ulcers OR has no pressure ulcers for which moist wound healing is indicated.;;; +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA27643-8;3;NA-Patient has no pressure ulcers OR has no pressure ulcers for which moist wound healing is indicated.;;; +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA27643-8;3;NA-Patient has no pressure ulcers OR has no pressure ulcers for which moist wound healing is indicated.;;; +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +57275-0;LL4510-5;CMS_Plan of care-moist wound healing;LA27643-8;3;NA-Patient has no pressure ulcers OR has no pressure ulcers for which moist wound healing is indicated.;;; +57276-8;LL824-4;OASIS-C_M2300;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +57276-8;LL824-4;OASIS-C_M2300;LA12351-5;2;Yes, used hospital emergency department WITHOUT hospital admission;;; +57276-8;LL824-4;OASIS-C_M2300;LA12352-3;3;Yes, used hospital emergency department WITH hospital admission;;; +57276-8;LL824-4;OASIS-C_M2300;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6223-7;2;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6315-1;3;Other than above reasons;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA4394-8;4;Reason unknown;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6223-7;2;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6315-1;3;Other than above reasons;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA4394-8;4;Reason unknown;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6223-7;2;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6315-1;3;Other than above reasons;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA4394-8;4;Reason unknown;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6223-7;2;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA6315-1;3;Other than above reasons;;; +57277-6;LL4874-5;CMS_OASIS D_Reason for emergent care;LA4394-8;4;Reason unknown;;; +57277-6;LL825-1;OASIS-C_M2310;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL825-1;OASIS-C_M2310;LA12355-6;2;Injury caused by fall;;; +57277-6;LL825-1;OASIS-C_M2310;LA12356-4;3;Respiratory infection (for example, pneumonia, bronchitis);;; +57277-6;LL825-1;OASIS-C_M2310;LA12357-2;4;Other respiratory problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA12358-0;5;Heart failure (for example, fluid overload);;; +57277-6;LL825-1;OASIS-C_M2310;LA12359-8;6;Cardiac dysrhythmia (irregular heartbeat);;; +57277-6;LL825-1;OASIS-C_M2310;LA12360-6;7;Myocardial infarction or chest pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12361-4;8;Other heart disease;;; +57277-6;LL825-1;OASIS-C_M2310;LA12362-2;9;Stroke (CVA) or TIA;;; +57277-6;LL825-1;OASIS-C_M2310;LA6223-7;10;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL825-1;OASIS-C_M2310;LA12364-8;11;GI bleeding, obstruction, constipation, impaction;;; +57277-6;LL825-1;OASIS-C_M2310;LA12365-5;12;Dehydration, malnutrition;;; +57277-6;LL825-1;OASIS-C_M2310;LA6437-3;13;Urinary tract infection;;; +57277-6;LL825-1;OASIS-C_M2310;LA12367-1;14;IV catheter-related infection or complication;;; +57277-6;LL825-1;OASIS-C_M2310;LA12368-9;15;Wound infection or deterioration;;; +57277-6;LL825-1;OASIS-C_M2310;LA6430-8;16;Uncontrolled pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12370-5;17;Acute mental/behavioral health problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA6180-9;18;Deep vein thrombosis, pulmonary embolus;;; +57277-6;LL825-1;OASIS-C_M2310;LA6315-1;19;Other than above reasons;;; +57277-6;LL825-1;OASIS-C_M2310;LA4394-8;20;Reason unknown;;; +57277-6;LL825-1;OASIS-C_M2310;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL825-1;OASIS-C_M2310;LA12355-6;2;Injury caused by fall;;; +57277-6;LL825-1;OASIS-C_M2310;LA12356-4;3;Respiratory infection (for example, pneumonia, bronchitis);;; +57277-6;LL825-1;OASIS-C_M2310;LA12357-2;4;Other respiratory problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA12358-0;5;Heart failure (for example, fluid overload);;; +57277-6;LL825-1;OASIS-C_M2310;LA12359-8;6;Cardiac dysrhythmia (irregular heartbeat);;; +57277-6;LL825-1;OASIS-C_M2310;LA12360-6;7;Myocardial infarction or chest pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12361-4;8;Other heart disease;;; +57277-6;LL825-1;OASIS-C_M2310;LA12362-2;9;Stroke (CVA) or TIA;;; +57277-6;LL825-1;OASIS-C_M2310;LA6223-7;10;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL825-1;OASIS-C_M2310;LA12364-8;11;GI bleeding, obstruction, constipation, impaction;;; +57277-6;LL825-1;OASIS-C_M2310;LA12365-5;12;Dehydration, malnutrition;;; +57277-6;LL825-1;OASIS-C_M2310;LA6437-3;13;Urinary tract infection;;; +57277-6;LL825-1;OASIS-C_M2310;LA12367-1;14;IV catheter-related infection or complication;;; +57277-6;LL825-1;OASIS-C_M2310;LA12368-9;15;Wound infection or deterioration;;; +57277-6;LL825-1;OASIS-C_M2310;LA6430-8;16;Uncontrolled pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12370-5;17;Acute mental/behavioral health problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA6180-9;18;Deep vein thrombosis, pulmonary embolus;;; +57277-6;LL825-1;OASIS-C_M2310;LA6315-1;19;Other than above reasons;;; +57277-6;LL825-1;OASIS-C_M2310;LA4394-8;20;Reason unknown;;; +57277-6;LL825-1;OASIS-C_M2310;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL825-1;OASIS-C_M2310;LA12355-6;2;Injury caused by fall;;; +57277-6;LL825-1;OASIS-C_M2310;LA12356-4;3;Respiratory infection (for example, pneumonia, bronchitis);;; +57277-6;LL825-1;OASIS-C_M2310;LA12357-2;4;Other respiratory problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA12358-0;5;Heart failure (for example, fluid overload);;; +57277-6;LL825-1;OASIS-C_M2310;LA12359-8;6;Cardiac dysrhythmia (irregular heartbeat);;; +57277-6;LL825-1;OASIS-C_M2310;LA12360-6;7;Myocardial infarction or chest pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12361-4;8;Other heart disease;;; +57277-6;LL825-1;OASIS-C_M2310;LA12362-2;9;Stroke (CVA) or TIA;;; +57277-6;LL825-1;OASIS-C_M2310;LA6223-7;10;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL825-1;OASIS-C_M2310;LA12364-8;11;GI bleeding, obstruction, constipation, impaction;;; +57277-6;LL825-1;OASIS-C_M2310;LA12365-5;12;Dehydration, malnutrition;;; +57277-6;LL825-1;OASIS-C_M2310;LA6437-3;13;Urinary tract infection;;; +57277-6;LL825-1;OASIS-C_M2310;LA12367-1;14;IV catheter-related infection or complication;;; +57277-6;LL825-1;OASIS-C_M2310;LA12368-9;15;Wound infection or deterioration;;; +57277-6;LL825-1;OASIS-C_M2310;LA6430-8;16;Uncontrolled pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12370-5;17;Acute mental/behavioral health problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA6180-9;18;Deep vein thrombosis, pulmonary embolus;;; +57277-6;LL825-1;OASIS-C_M2310;LA6315-1;19;Other than above reasons;;; +57277-6;LL825-1;OASIS-C_M2310;LA4394-8;20;Reason unknown;;; +57277-6;LL825-1;OASIS-C_M2310;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL825-1;OASIS-C_M2310;LA12355-6;2;Injury caused by fall;;; +57277-6;LL825-1;OASIS-C_M2310;LA12356-4;3;Respiratory infection (for example, pneumonia, bronchitis);;; +57277-6;LL825-1;OASIS-C_M2310;LA12357-2;4;Other respiratory problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA12358-0;5;Heart failure (for example, fluid overload);;; +57277-6;LL825-1;OASIS-C_M2310;LA12359-8;6;Cardiac dysrhythmia (irregular heartbeat);;; +57277-6;LL825-1;OASIS-C_M2310;LA12360-6;7;Myocardial infarction or chest pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12361-4;8;Other heart disease;;; +57277-6;LL825-1;OASIS-C_M2310;LA12362-2;9;Stroke (CVA) or TIA;;; +57277-6;LL825-1;OASIS-C_M2310;LA6223-7;10;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL825-1;OASIS-C_M2310;LA12364-8;11;GI bleeding, obstruction, constipation, impaction;;; +57277-6;LL825-1;OASIS-C_M2310;LA12365-5;12;Dehydration, malnutrition;;; +57277-6;LL825-1;OASIS-C_M2310;LA6437-3;13;Urinary tract infection;;; +57277-6;LL825-1;OASIS-C_M2310;LA12367-1;14;IV catheter-related infection or complication;;; +57277-6;LL825-1;OASIS-C_M2310;LA12368-9;15;Wound infection or deterioration;;; +57277-6;LL825-1;OASIS-C_M2310;LA6430-8;16;Uncontrolled pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12370-5;17;Acute mental/behavioral health problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA6180-9;18;Deep vein thrombosis, pulmonary embolus;;; +57277-6;LL825-1;OASIS-C_M2310;LA6315-1;19;Other than above reasons;;; +57277-6;LL825-1;OASIS-C_M2310;LA4394-8;20;Reason unknown;;; +57277-6;LL825-1;OASIS-C_M2310;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL825-1;OASIS-C_M2310;LA12355-6;2;Injury caused by fall;;; +57277-6;LL825-1;OASIS-C_M2310;LA12356-4;3;Respiratory infection (for example, pneumonia, bronchitis);;; +57277-6;LL825-1;OASIS-C_M2310;LA12357-2;4;Other respiratory problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA12358-0;5;Heart failure (for example, fluid overload);;; +57277-6;LL825-1;OASIS-C_M2310;LA12359-8;6;Cardiac dysrhythmia (irregular heartbeat);;; +57277-6;LL825-1;OASIS-C_M2310;LA12360-6;7;Myocardial infarction or chest pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12361-4;8;Other heart disease;;; +57277-6;LL825-1;OASIS-C_M2310;LA12362-2;9;Stroke (CVA) or TIA;;; +57277-6;LL825-1;OASIS-C_M2310;LA6223-7;10;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL825-1;OASIS-C_M2310;LA12364-8;11;GI bleeding, obstruction, constipation, impaction;;; +57277-6;LL825-1;OASIS-C_M2310;LA12365-5;12;Dehydration, malnutrition;;; +57277-6;LL825-1;OASIS-C_M2310;LA6437-3;13;Urinary tract infection;;; +57277-6;LL825-1;OASIS-C_M2310;LA12367-1;14;IV catheter-related infection or complication;;; +57277-6;LL825-1;OASIS-C_M2310;LA12368-9;15;Wound infection or deterioration;;; +57277-6;LL825-1;OASIS-C_M2310;LA6430-8;16;Uncontrolled pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12370-5;17;Acute mental/behavioral health problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA6180-9;18;Deep vein thrombosis, pulmonary embolus;;; +57277-6;LL825-1;OASIS-C_M2310;LA6315-1;19;Other than above reasons;;; +57277-6;LL825-1;OASIS-C_M2310;LA4394-8;20;Reason unknown;;; +57277-6;LL825-1;OASIS-C_M2310;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57277-6;LL825-1;OASIS-C_M2310;LA12355-6;2;Injury caused by fall;;; +57277-6;LL825-1;OASIS-C_M2310;LA12356-4;3;Respiratory infection (for example, pneumonia, bronchitis);;; +57277-6;LL825-1;OASIS-C_M2310;LA12357-2;4;Other respiratory problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA12358-0;5;Heart failure (for example, fluid overload);;; +57277-6;LL825-1;OASIS-C_M2310;LA12359-8;6;Cardiac dysrhythmia (irregular heartbeat);;; +57277-6;LL825-1;OASIS-C_M2310;LA12360-6;7;Myocardial infarction or chest pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12361-4;8;Other heart disease;;; +57277-6;LL825-1;OASIS-C_M2310;LA12362-2;9;Stroke (CVA) or TIA;;; +57277-6;LL825-1;OASIS-C_M2310;LA6223-7;10;Hypo/hyperglycemia, diabetes out of control;;; +57277-6;LL825-1;OASIS-C_M2310;LA12364-8;11;GI bleeding, obstruction, constipation, impaction;;; +57277-6;LL825-1;OASIS-C_M2310;LA12365-5;12;Dehydration, malnutrition;;; +57277-6;LL825-1;OASIS-C_M2310;LA6437-3;13;Urinary tract infection;;; +57277-6;LL825-1;OASIS-C_M2310;LA12367-1;14;IV catheter-related infection or complication;;; +57277-6;LL825-1;OASIS-C_M2310;LA12368-9;15;Wound infection or deterioration;;; +57277-6;LL825-1;OASIS-C_M2310;LA6430-8;16;Uncontrolled pain;;; +57277-6;LL825-1;OASIS-C_M2310;LA12370-5;17;Acute mental/behavioral health problem;;; +57277-6;LL825-1;OASIS-C_M2310;LA6180-9;18;Deep vein thrombosis, pulmonary embolus;;; +57277-6;LL825-1;OASIS-C_M2310;LA6315-1;19;Other than above reasons;;; +57277-6;LL825-1;OASIS-C_M2310;LA4394-8;20;Reason unknown;;; +57279-2;LL827-7;OASIS-C_M2430;LA27773-3;1;Improper medication administration, adverse drug reactions, medication side effects, toxicity, anaphylaxis;;; +57279-2;LL827-7;OASIS-C_M2430;LA12355-6;2;Injury caused by fall;;; +57279-2;LL827-7;OASIS-C_M2430;LA12356-4;3;Respiratory infection (for example, pneumonia, bronchitis);;; +57279-2;LL827-7;OASIS-C_M2430;LA12357-2;4;Other respiratory problem;;; +57279-2;LL827-7;OASIS-C_M2430;LA12358-0;5;Heart failure (for example, fluid overload);;; +57279-2;LL827-7;OASIS-C_M2430;LA12359-8;6;Cardiac dysrhythmia (irregular heartbeat);;; +57279-2;LL827-7;OASIS-C_M2430;LA12360-6;7;Myocardial infarction or chest pain;;; +57279-2;LL827-7;OASIS-C_M2430;LA12361-4;8;Other heart disease;;; +57279-2;LL827-7;OASIS-C_M2430;LA12362-2;9;Stroke (CVA) or TIA;;; +57279-2;LL827-7;OASIS-C_M2430;LA6223-7;10;Hypo/hyperglycemia, diabetes out of control;;; +57279-2;LL827-7;OASIS-C_M2430;LA12364-8;11;GI bleeding, obstruction, constipation, impaction;;; +57279-2;LL827-7;OASIS-C_M2430;LA12365-5;12;Dehydration, malnutrition;;; +57279-2;LL827-7;OASIS-C_M2430;LA6437-3;13;Urinary tract infection;;; +57279-2;LL827-7;OASIS-C_M2430;LA12367-1;14;IV catheter-related infection or complication;;; +57279-2;LL827-7;OASIS-C_M2430;LA12368-9;15;Wound infection or deterioration;;; +57279-2;LL827-7;OASIS-C_M2430;LA6430-8;16;Uncontrolled pain;;; +57279-2;LL827-7;OASIS-C_M2430;LA12370-5;17;Acute mental/behavioral health problem;;; +57279-2;LL827-7;OASIS-C_M2430;LA6180-9;18;Deep vein thrombosis, pulmonary embolus;;; +57279-2;LL827-7;OASIS-C_M2430;LA12397-8;19;Scheduled treatment or procedure;;; +57279-2;LL827-7;OASIS-C_M2430;LA6315-1;20;Other than above reasons;;; +57279-2;LL827-7;OASIS-C_M2430;LA4394-8;21;Reason unknown;;; +57283-4;LL802-0;OASIS-C_M1700;LA6153-6;1;Alert/oriented, able to focus and shift attention, comprehends and recalls task directions independently.;;; +57283-4;LL802-0;OASIS-C_M1700;LA12249-1;2;Requires prompting (cuing, repetition, reminders) only under stressful or unfamiliar conditions.;;; +57283-4;LL802-0;OASIS-C_M1700;LA12250-9;3;Requires assistance and some direction in specific situations (e.g., on all tasks involving shifting of attention), or consistently requires low stimulus environment due to distractibility.;;; +57283-4;LL802-0;OASIS-C_M1700;LA12251-7;4;Requires considerable assistance in routine situations. Is not alert and oriented or is unable to shift attention and recall directions more than half the time.;;; +57283-4;LL802-0;OASIS-C_M1700;LA6399-5;5;Totally dependent due to disturbances such as constant disorientation, coma, persistent vegetative state, or delirium.;;; +57284-2;LL819-4;OASIS-C_M2030;LA12326-7;1;Able to independently take the correct medication(s) and proper dosage(s) at the correct times.;;; +57284-2;LL819-4;OASIS-C_M2030;LA12327-5;2;"Able to take injectable medication(s) at the correct times if: (a) individual syringes are prepared in advance by another person; OR (b) another person develops a drug diary or chart.";;; +57284-2;LL819-4;OASIS-C_M2030;LA12328-3;3;Able to take medication(s) at the correct times if given reminders by another person based on the frequency of the injection;;; +57284-2;LL819-4;OASIS-C_M2030;LA12329-1;4;Unable to take injectable medication unless administered by another person.;;; +57284-2;LL819-4;OASIS-C_M2030;LA6280-7;5;No injectable medications prescribed.;;; +57285-9;LL818-6;OASIS-C_M2020;LA6135-3;1;Able to independently take the correct oral medication(s) and proper dosage(s) at the correct times.;;; +57285-9;LL818-6;OASIS-C_M2020;LA12322-6;2;"Able to take medication(s) at the correct times if: (a) individual dosages are prepared in advance by another person; OR (b) another person develops a drug diary or chart.";;; +57285-9;LL818-6;OASIS-C_M2020;LA12323-4;3;Able to take medication(s) at the correct times if given reminders by another person at the appropriate times;;; +57285-9;LL818-6;OASIS-C_M2020;LA12324-2;4;Unable to take medication unless administered by another person.;;; +57285-9;LL818-6;OASIS-C_M2020;LA6290-6;5;No oral medications prescribed.;;; +57286-7;LL804-6;OASIS-C_M1740;LA12257-4;1;Memory deficit: failure to recognize familiar persons/places, inability to recall events of past 24 hours, significant memory loss so that supervision is required;;; +57286-7;LL804-6;OASIS-C_M1740;LA6228-6;2;Impaired decision-making: failure to perform usual ADLs or IADLs, inability to appropriately stop activities, jeopardizes safety through actions;;; +57286-7;LL804-6;OASIS-C_M1740;LA6439-9;3;Verbal disruption: yelling, threatening, excessive profanity, sexual references, etc.;;; +57286-7;LL804-6;OASIS-C_M1740;LA12260-8;4;Physical aggression: aggressive or combative to self and others (for example, hits self, throws objects, punches, dangerous maneuvers with wheelchair or other objects);;; +57286-7;LL804-6;OASIS-C_M1740;LA6187-4;5;Disruptive, infantile, or socially inappropriate behavior (excludes verbal actions);;; +57286-7;LL804-6;OASIS-C_M1740;LA6181-7;6;Delusional, hallucinatory, or paranoid behavior;;; +57286-7;LL804-6;OASIS-C_M1740;LA6294-8;7;None of the above behaviors demonstrated;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27614-9;1;History of falls (2 or more falls - or any fall with an injury - in the past 12 months);;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27615-6;2;Unintentional weight loss of a total of 10 pounds or more in the past 12 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27616-4;3;Multiple hospitalizations (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27617-2;4;Multiple emergency department visits (2 or more) in the past 6 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27618-0;5;Decline in mental, emotional, or behavioral status in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27619-8;6;Reported or observed history of difficulty complying with any medical instructions (for example, medications, diet, exercise) in the past 3 months;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27620-6;7;Currently taking 5 or more medications;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27621-4;8;Currently reports exhaustion;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA27622-2;9;Other risk(s) not listed in 1 - 8;;; +57319-6;LL4494-2;CMS_Risk for hospitalization;LA9-3;10;None of the above;;; +57319-6;LL777-4;OASIS-C_M1032;LA12130-3;1;Recent decline in mental, emotional, or behavioral status;;; +57319-6;LL777-4;OASIS-C_M1032;LA12131-1;2;Multiple hospitalizations (2 or more) in the past 12 months;;; +57319-6;LL777-4;OASIS-C_M1032;LA12132-9;3;History of falls (2 or more falls - or any fall with an injury - in the past year);;; +57319-6;LL777-4;OASIS-C_M1032;LA12133-7;4;Taking five or more medications;;; +57319-6;LL777-4;OASIS-C_M1032;LA12134-5;5;Frailty indicators, e.g., weight loss, self-reported exhaustion;;; +57319-6;LL777-4;OASIS-C_M1032;LA46-8;6;Other;;; +57319-6;LL777-4;OASIS-C_M1032;LA9-3;7;None of the above;;; +57319-6;LL777-4;OASIS-C_M1032;LA12130-3;1;Recent decline in mental, emotional, or behavioral status;;; +57319-6;LL777-4;OASIS-C_M1032;LA12131-1;2;Multiple hospitalizations (2 or more) in the past 12 months;;; +57319-6;LL777-4;OASIS-C_M1032;LA12132-9;3;History of falls (2 or more falls - or any fall with an injury - in the past year);;; +57319-6;LL777-4;OASIS-C_M1032;LA12133-7;4;Taking five or more medications;;; +57319-6;LL777-4;OASIS-C_M1032;LA12134-5;5;Frailty indicators, e.g., weight loss, self-reported exhaustion;;; +57319-6;LL777-4;OASIS-C_M1032;LA46-8;6;Other;;; +57319-6;LL777-4;OASIS-C_M1032;LA9-3;7;None of the above;;; +57319-6;LL777-4;OASIS-C_M1032;LA12130-3;1;Recent decline in mental, emotional, or behavioral status;;; +57319-6;LL777-4;OASIS-C_M1032;LA12131-1;2;Multiple hospitalizations (2 or more) in the past 12 months;;; +57319-6;LL777-4;OASIS-C_M1032;LA12132-9;3;History of falls (2 or more falls - or any fall with an injury - in the past year);;; +57319-6;LL777-4;OASIS-C_M1032;LA12133-7;4;Taking five or more medications;;; +57319-6;LL777-4;OASIS-C_M1032;LA12134-5;5;Frailty indicators, e.g., weight loss, self-reported exhaustion;;; +57319-6;LL777-4;OASIS-C_M1032;LA46-8;6;Other;;; +57319-6;LL777-4;OASIS-C_M1032;LA9-3;7;None of the above;;; +57319-6;LL777-4;OASIS-C_M1032;LA12130-3;1;Recent decline in mental, emotional, or behavioral status;;; +57319-6;LL777-4;OASIS-C_M1032;LA12131-1;2;Multiple hospitalizations (2 or more) in the past 12 months;;; +57319-6;LL777-4;OASIS-C_M1032;LA12132-9;3;History of falls (2 or more falls - or any fall with an injury - in the past year);;; +57319-6;LL777-4;OASIS-C_M1032;LA12133-7;4;Taking five or more medications;;; +57319-6;LL777-4;OASIS-C_M1032;LA12134-5;5;Frailty indicators, e.g., weight loss, self-reported exhaustion;;; +57319-6;LL777-4;OASIS-C_M1032;LA46-8;6;Other;;; +57319-6;LL777-4;OASIS-C_M1032;LA9-3;7;None of the above;;; +57702-3;LL833-5;NBS Inf interp;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +57702-3;LL833-5;NBS Inf interp;LA4259-3;2;Borderline;;; +57702-3;LL833-5;NBS Inf interp;LA12446-3;3;Suspect HIV;;; +57702-3;LL833-5;NBS Inf interp;LA12447-1;4;Suspect TOXO;;; +57712-2;LL836-8;Education;LA36-9;1;8th grade/less;;; +57712-2;LL836-8;Education;LA12456-2;2;9th - 12th grade, no diploma;;; +57712-2;LL836-8;Education;LA12457-0;3;High school graduate or GED completed;;; +57712-2;LL836-8;Education;LA12458-8;4;Some college credit but no degree;;; +57712-2;LL836-8;Education;LA12459-6;5;Associate degree (e.g., AA, AS);;; +57712-2;LL836-8;Education;LA12460-4;6;Bachelor's degree (e.g., BA, AB, BS);;; +57712-2;LL836-8;Education;LA12461-2;7;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +57712-2;LL836-8;Education;LA12462-0;8;Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD);;; +57712-2;LL836-8;Education;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57712-2;LL836-8;Education;LA36-9;1;8th grade/less;;; +57712-2;LL836-8;Education;LA12456-2;2;9th - 12th grade, no diploma;;; +57712-2;LL836-8;Education;LA12457-0;3;High school graduate or GED completed;;; +57712-2;LL836-8;Education;LA12458-8;4;Some college credit but no degree;;; +57712-2;LL836-8;Education;LA12459-6;5;Associate degree (e.g., AA, AS);;; +57712-2;LL836-8;Education;LA12460-4;6;Bachelor's degree (e.g., BA, AB, BS);;; +57712-2;LL836-8;Education;LA12461-2;7;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +57712-2;LL836-8;Education;LA12462-0;8;Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD);;; +57712-2;LL836-8;Education;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57712-2;LL836-8;Education;LA36-9;1;8th grade/less;;; +57712-2;LL836-8;Education;LA12456-2;2;9th - 12th grade, no diploma;;; +57712-2;LL836-8;Education;LA12457-0;3;High school graduate or GED completed;;; +57712-2;LL836-8;Education;LA12458-8;4;Some college credit but no degree;;; +57712-2;LL836-8;Education;LA12459-6;5;Associate degree (e.g., AA, AS);;; +57712-2;LL836-8;Education;LA12460-4;6;Bachelor's degree (e.g., BA, AB, BS);;; +57712-2;LL836-8;Education;LA12461-2;7;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +57712-2;LL836-8;Education;LA12462-0;8;Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD);;; +57712-2;LL836-8;Education;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +80913-7;LL836-8;Education;LA36-9;1;8th grade/less;;; +80913-7;LL836-8;Education;LA12456-2;2;9th - 12th grade, no diploma;;; +80913-7;LL836-8;Education;LA12457-0;3;High school graduate or GED completed;;; +80913-7;LL836-8;Education;LA12458-8;4;Some college credit but no degree;;; +80913-7;LL836-8;Education;LA12459-6;5;Associate degree (e.g., AA, AS);;; +80913-7;LL836-8;Education;LA12460-4;6;Bachelor's degree (e.g., BA, AB, BS);;; +80913-7;LL836-8;Education;LA12461-2;7;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +80913-7;LL836-8;Education;LA12462-0;8;Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD);;; +80913-7;LL836-8;Education;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +87300-0;LL836-8;Education;LA36-9;1;8th grade/less;;; +87300-0;LL836-8;Education;LA12456-2;2;9th - 12th grade, no diploma;;; +87300-0;LL836-8;Education;LA12457-0;3;High school graduate or GED completed;;; +87300-0;LL836-8;Education;LA12458-8;4;Some college credit but no degree;;; +87300-0;LL836-8;Education;LA12459-6;5;Associate degree (e.g., AA, AS);;; +87300-0;LL836-8;Education;LA12460-4;6;Bachelor's degree (e.g., BA, AB, BS);;; +87300-0;LL836-8;Education;LA12461-2;7;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +87300-0;LL836-8;Education;LA12462-0;8;Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD);;; +87300-0;LL836-8;Education;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +91694-0;LL836-8;Education;LA36-9;1;8th grade/less;;; +91694-0;LL836-8;Education;LA12456-2;2;9th - 12th grade, no diploma;;; +91694-0;LL836-8;Education;LA12457-0;3;High school graduate or GED completed;;; +91694-0;LL836-8;Education;LA12458-8;4;Some college credit but no degree;;; +91694-0;LL836-8;Education;LA12459-6;5;Associate degree (e.g., AA, AS);;; +91694-0;LL836-8;Education;LA12460-4;6;Bachelor's degree (e.g., BA, AB, BS);;; +91694-0;LL836-8;Education;LA12461-2;7;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +91694-0;LL836-8;Education;LA12462-0;8;Doctorate (e.g., PhD, EdD) or Professional degree (e.g., MD, DDS, DVM, LLB, JD);;; +91694-0;LL836-8;Education;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +57713-0;LL830-1;NBS events;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +57713-0;LL830-1;NBS events;LA12419-0;2;Infant in NICU at time of specimen collection;;; +57713-0;LL830-1;NBS events;LA25801-4;3;Infant in special care setting (other than ICU) at time of specimen collection;;; +57713-0;LL830-1;NBS events;LA25802-2;4;Preterm/Low birth weight (LBW);;; +57713-0;LL830-1;NBS events;LA12417-4;5;Any blood product transfusion (including ECLS/ECMO);;; +57713-0;LL830-1;NBS events;LA16923-7;6;Dopamine;412383006;Dopamine (substance);http://snomed.info/sct +57713-0;LL830-1;NBS events;LA16924-5;7;Topical iodine;;; +57713-0;LL830-1;NBS events;LA25803-0;8;Acute illness;;; +57713-0;LL830-1;NBS events;LA25804-8;9;Hypothyroxinemia of preterm birth;;; +57713-0;LL830-1;NBS events;LA25812-1;10;Significant hypoxia;;; +57713-0;LL830-1;NBS events;LA25805-5;11;Immature hypothalamic/pituitary axis;;; +57713-0;LL830-1;NBS events;LA25806-3;12;Immature liver enzymes;;; +57713-0;LL830-1;NBS events;LA25807-1;13;Immature renal system;;; +57713-0;LL830-1;NBS events;LA25809-7;14;Iodine deficiency;;; +57713-0;LL830-1;NBS events;LA25810-5;15;Liver disease;;; +57713-0;LL830-1;NBS events;LA25811-3;16;Other conditions, such as biliary atresia, intestinal perforation, abdominal wall defects, septicemia, CMV, renal failure, T21, T18, T13;;; +57713-0;LL830-1;NBS events;LA16925-2;17;Parenteral steroid treatment;;; +57713-0;LL830-1;NBS events;LA12420-8;18;Systemic antibiotics before newborn screening;;; +57713-0;LL830-1;NBS events;LA16927-8;19;Meconium ileus or other bowel obstruction;;; +57713-0;LL830-1;NBS events;LA25815-4;20;Thoracic surgery involving thymectomy;;; +57713-0;LL830-1;NBS events;LA25808-9;21;Immunosuppressive therapy of baby or mother;;; +57713-0;LL830-1;NBS events;LA25816-2;22;Total parenteral nutrition (TPN) or similar feeding;;; +57713-0;LL830-1;NBS events;LA25813-9;23;Special lactose-free diet;;; +57713-0;LL830-1;NBS events;LA25814-7;24;Special low protein diet;;; +57713-0;LL830-1;NBS events;LA46-8;25;Other;;; +57718-9;LL832-7;NBS quality;LA12432-3;1;Acceptable;;; +57718-9;LL832-7;NBS quality;LA12433-1;2;No sample received;;; +57718-9;LL832-7;NBS quality;LA20623-7;3;Specimen damaged during transport;;; +57718-9;LL832-7;NBS quality;LA20624-5;4;Specimen received in sealed plastic container;;; +57718-9;LL832-7;NBS quality;LA20625-2;5;Specimen quantity insufficient due to incomplete saturation (blood did not soak through paper);281268007;Insufficient sample (finding);http://snomed.info/sct +57718-9;LL832-7;NBS quality;LA20626-0;6;Specimen quantity insufficient because blood did not completely fill specimen circles;281268007;Insufficient sample (finding);http://snomed.info/sct +57718-9;LL832-7;NBS quality;LA20627-8;7;Specimen has uneven saturation;;; +57718-9;LL832-7;NBS quality;LA12682-3;8;Specimen appears scratched or abraded;;; +57718-9;LL832-7;NBS quality;LA12683-1;9;Specimen not dry before mailing;;; +57718-9;LL832-7;NBS quality;LA12684-9;10;Specimen appears supersaturated;;; +57718-9;LL832-7;NBS quality;LA12685-6;11;Specimen appears diluted, discolored or contaminated;;; +57718-9;LL832-7;NBS quality;LA12686-4;12;Specimen exhibits serum rings;;; +57718-9;LL832-7;NBS quality;LA12435-6;13;Specimen appears clotted or layered;;; +57718-9;LL832-7;NBS quality;LA20628-6;14;Specimen not eluting;;; +57718-9;LL832-7;NBS quality;LA12687-2;15;No blood;;; +57718-9;LL832-7;NBS quality;LA12441-4;16;Sample too old;;; +57718-9;LL832-7;NBS quality;LA20630-2;17;Testing of this specimen indicates more than one source of blood is present on the filter paper card;;; +57718-9;LL832-7;NBS quality;LA20629-4;18;Unsuitable for other reasons;;; +57719-7;LL841-8;NBS conditions tested;LA11231-0;0;Hemoglobin C crystals;;; +57719-7;LL841-8;NBS conditions tested;LA24366-9;1;Hearing loss;15188001;Hearing loss (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12464-6;2;2-Methyl-3-hydroxybutyric aciduria;791000124107;2-methyl-3-hydroxybutyric aciduria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12465-3;3;2-Methylbutyrylglycinuria;445596006;2-methylbutyrylglycinuria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12466-1;4;3-Methylcrotonyl-CoA carboxylase deficiency;13144005;Methylcrotonyl-coenzyme A carboxylase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12467-9;5;3-Methylcrotonyl-CoA carboxylase deficiency (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12468-7;6;3-Methylglutaconic aciduria;237950009;3-Methylglutaconic aciduria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12469-5;7;Pyroglutamic acidemia;39112005;Glutathione synthase deficiency with 5-oxoprolinuria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA21161-7;8;Argininemia;;; +57719-7;LL841-8;NBS conditions tested;LA21162-5;9;Argininosuccinic aciduria;;; +57719-7;LL841-8;NBS conditions tested;LA12472-9;10;Biopterin defect in cofactor biosynthesis;237914002;6-Pyruvoyl-tetrahydrobiopterin synthase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12473-7;11;Biopterin defect in cofactor regeneration;58256000;Dihydropteridine reductase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12474-5;12;Beta-ketothiolase deficiency;237953006;Mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency - potassium stimulated (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12475-2;13;Carnitine acylcarnitine translocase deficiency;238003000;Carnitine acylcarnitine translocase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12476-0;14;Cobalamin A disease;73843004;Cobalamin A disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12477-8;15;Cobalamin B disease;82245003;Cobalamin B disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12478-6;16;Cobalamin C disease;74653006;Cobalamin C disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12479-4;17;Cobalamin D disease;31220004;Cobalamin D disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12480-2;18;Cobalamin E disease;360373000;Homocystinuria vitamin B12-responsive type III (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12481-0;19;CBL G type Methylcobalamin deficiency;721187005;Methylcobalamin deficiency type cbl G (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12482-8;20;Citrullinemia, type I;398680004;Citrullinemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12483-6;21;Citrullinemia, type II;716863007;Citrullinemia type II (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12484-4;22;Carbamoyl-phosphate synthase deficiency;62522004;Congenital hyperammonemia, type I (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12485-1;23;Carnitine palmitoyltransferase type I deficiency;238001003;Carnitine palmitoyltransferase I deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12486-9;24;Carnitine palmitoyltransferase type II deficiency;238002005;Carnitine palmitoyltransferase II deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12487-7;25;Carnitine uptake deficiency/carnitine transport defect;21764004;Renal carnitine transport defect (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12488-5;26;Carnitine uptake deficiency/carnitine transport defect (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12489-3;27;2,4-Dienoyl-CoA reductase deficiency;444944006;Deficiency of 2,4-dienoyl-coenzyme A reductase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12490-1;28;Dihydrolipoamide dehydrogenase deficiency;29914000;Dihydrolipoamide dehydrogenase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12491-9;29;Ethylmalonic encephalopathy;723307008;Ethylmalonic encephalopathy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12492-7;30;Formiminoglutamic acidemia;59761008;Glutamate formiminotransferase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12493-5;31;Glutaric acidemia type I;76175005;Glutaric aciduria, type 1 (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12494-3;32;Glutaric acidemia (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12495-0;33;Glutaric acidemia type II;22886006;Glutaric aciduria, type 2 (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12496-8;34;Homocystinuria;11282001;Homocystinuria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12497-6;35;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome;30287008;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12498-4;36;Histidinemia;410058007;Histidinemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12499-2;37;3-Hydroxy-3-methylglutaric aciduria;410059004;Hydroxymethylglutaric aciduria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12500-7;38;Hyperphenylalaninemia (variant, benign);68528007;Hyperphenylalaninemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12501-5;39;Hyperlysinemia;58558003;Hyperlysinemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12502-3;40;Girate atrophy of the retina;314467007;Gyrate atrophy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12503-1;41;Valinemia;47719001;Hypervalinemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12504-9;42;Isobutyrylglycinuria;445571008;Isobutyrylglycinuria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12505-6;43;Isovaleric acidemia;87827003;Isovaleryl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12506-4;44;Primary lactic acidemia;190882007;Lactic acidemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12507-2;45;Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency;307127004;Isolated long chain hydroxyacyl-CoA dehydrogenase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12508-0;46;Malonic acidemia;124594007;Deficiency of malonyl-coenzyme A decarboxylase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12509-8;47;Medium-chain acyl-CoA dehydrogenase deficiency;128596003;Medium-chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12510-6;48;Holoocarboxylase synthase deficiency;360369003;Holocarboxylase synthase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12511-4;49;Medium-chain ketoacyl-CoA thiolase deficiency;124265004;Deficiency of acetyl-coenzyme A acyltransferase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12512-2;50;Hypermethioninemia;43123004;Hypermethioninemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA21168-2;51;Maple syrup urine disease;27718001;Maple syrup urine disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12514-8;52;Methylene tetrahydrofolate reductase deficiency;41797007;5,10-Methylenetetrahydrofolate reductase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12515-5;53;Methylmalonic acidemia;124680001;Deficiency of methylmalonyl-coenzyme A mutase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12516-3;54;Nonketotic hyperglycinemia (glycine encephalopathy);237939006;Non-ketotic hyperglycinemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12517-1;55;Hydroxyprolinemia;25739007;Hyperhydroxyprolinemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12518-9;56;Ornithine transcarbamylase deficiency;80908008;Ornithine carbamoyltransferase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12519-7;57;Pyruvate carboxylase deficiency;87694001;Pyruvate carboxylase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12520-5;58;Classic phenylketonuria;7573000;Classical phenylketonuria (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12521-3;59;Hyperprolinemia type I;61071003;Proline dehydrogenase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12522-1;60;Hyperprolinemia type II;717181004;Hyperprolinemia type 2 (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12523-9;61;Propionic acidemia;69080001;Propionic acidemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12524-7;62;Short-chain acyl-CoA dehydrogenase deficiency;124166007;Deficiency of butyryl-CoA dehydrogenase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12525-4;63;Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency;237998000;Short chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12526-2;64;Succinyl-CoA ligase deficiency;445275003;Deficiency of succinate-coenzyme A ligase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12527-0;65;Trifunctional protein deficiency;237999008;Mitochondrial trifunctional protein deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12528-8;66;Tyrosinemia, type I;410056006;Tyrosinemia type I (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12529-6;67;Tyrosinemia, type II;4887000;Hypertyrosinemia, Richner-Hanhart type (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12530-4;68;Tyrosinemia, type III;415764005;Tyrosinemia type III (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12531-2;69;Very long-chain acyl-CoA dehydrogenase deficiency;237997005;Very long chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12532-0;70;Biotinidase deficiency;8808004;Biotinidase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12533-8;71;Congenital adrenal hyperplasia;237751000;Congenital adrenal hyperplasia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA22202-8;72;Cystic fibrosis;190905008;Cystic fibrosis (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12538-7;73;Primary congenital hypothyroidism;190268003;Congenital hypothyroidism (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12539-5;74;Secondary congenital hypothyroidism;82598004;Secondary hypothyroidism (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12540-3;75;Glucose-6-phosphate dehydrogenase deficiency;124134002;Deficiency of glucose-6-phosphate dehydrogenase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12541-1;76;Galactoepimerase deficiency;8849004;Uridine diphosphate glucose-4-epimerase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12542-9;77;Galactokinase deficiency;124302001;Deficiency of galactokinase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA21165-8;78;Classical galactosemia;;; +57719-7;LL841-8;NBS conditions tested;LA12602-1;79;Hb C-carrier;76050008;Hemoglobin C trait (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12603-9;80;Hb D-carrier;7391009;Hemoglobin D trait (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12604-7;81;Hb E-carrier;46248003;Hemoglobin E trait (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12605-4;82;Hb O-Arab carrier;;; +57719-7;LL841-8;NBS conditions tested;LA12606-2;83;Hb S (sickle)-carrier;16402000;Sickle cell trait (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12607-0;84;Hb C-disease;51053007;Hemoglobin C disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12608-8;85;Hb C beta-thalassemia;119691000119106;Hemoglobin C/beta thalassemia disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12609-6;86;Hb D-disease;;; +57719-7;LL841-8;NBS conditions tested;LA12610-4;87;Hb D beta-thalassemia;119701000119106;Hemoglobin D/beta thalassemia disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12611-2;88;Hb beta zero-thalassemia;86715000;Beta zero thalassemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12612-0;89;Hb E-disease;25065001;Hemoglobin E disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12613-8;90;Hb E beta-thalassemia;234392002;Hemoglobin E/beta thalassemia disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12614-6;91;Hb SS-disease (sickle cell anemia);127040003;Sickle cell-hemoglobin SS disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12615-3;92;Hb S beta-thalassemia;127041004;Sickle cell-beta-thalassemia (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12616-1;93;Hb SC-disease;35434009;Sickle cell-hemoglobin C disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12617-9;94;Hb SD-disease;25472008;Sickle cell-hemoglobin D disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12618-7;95;Hb SE-disease;47024008;Sickle cell-hemoglobin E disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12619-5;96;Hb S O-Arab disease;127048005;Sickle cell-Hemoglobin O Arab disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12620-3;97;Hb S plus Hb other than A,C,D,E,O-Arab disease;23269001;Double heterozygous sickling disorder (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12621-1;98;Hb disease other than A, C, D, E, H,O-Arab, S;80141007;Hemoglobinopathy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12622-9;99;Hb carrier other than C, D, E, S ,O-Arab;;; +57719-7;LL841-8;NBS conditions tested;LA12565-0;100;Congenital HIV;52079000;Congenital human immunodeficiency virus infection (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12566-8;101;Severe combined immunodeficiency;31323000;Severe combined immunodeficiency disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12567-6;102;Thyroid-binding globulin deficiency;237544006;Thyroid-binding globulin deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA12568-4;103;Congenital toxoplasmosis;73893000;Congenital toxoplasmosis (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA14036-0;104;Fabry disease;16652001;Fabry's disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA14037-8;105;Pompe disease;274864009;Glycogen storage disease, type II (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA14038-6;106;Krabbe disease;192782005;Galactosylceramide beta-galactosidase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA14039-4;107;Gaucher disease;190794006;Glucosylceramide beta-glucosidase deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA14040-2;108;Niemann Pick disease A/B;58459009;Sphingomyelin/cholesterol lipidosis (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA16007-9;109;Hb H-disease;48553001;Hemoglobin H disease (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA16207-5;110;Hemoglobinopathies;80141007;Hemoglobinopathy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA20349-9;111;Critical congenital heart disease;;; +57719-7;LL841-8;NBS conditions tested;LA25796-6;112;X-linked adrenoleukodystrophy;65389002;Adrenoleukodystrophy (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA25797-4;113;Mucopolysaccharidosis type I;75610003;Mucopolysaccharidosis type I (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA30113-7;114;Guanidinoacetate N-methyltransferase deficiency;124239003;Deficiency of guanidinoacetate methyltransferase (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA30114-5;115;L-arginine:glycine amidinotransferase deficiency;702440000;Cerebral creatine deficiency syndrome 3 (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA30492-5;116;X-linked creatine transporter (CRTR) deficiency;698290008;X-linked creatine deficiency (disorder);http://snomed.info/sct +57719-7;LL841-8;NBS conditions tested;LA22279-6;117;Spinal muscular atrophy;5262007;Spinal muscular atrophy (disorder);http://snomed.info/sct +57721-3;LL831-9;NBS reason;LA12421-6;1;Initial screen;;; +57721-3;LL831-9;NBS reason;LA12425-7;2;Subsequent screen - required by law;;; +57721-3;LL831-9;NBS reason;LA12426-5;3;Subsequent screen - required by protocol;;; +57721-3;LL831-9;NBS reason;LA12427-3;4;Subsequent screen - for clarification of initial results (not by law or protocol);;; +57721-3;LL831-9;NBS reason;LA16473-3;5;Subsequent screen - reason unknown;;; +57721-3;LL831-9;NBS reason;LA14132-7;6;No sample collected due to parental refusal;;; +57722-1;LL829-3;Plurality;LA6112-2;1;1;;; +57722-1;LL829-3;Plurality;LA6113-0;2;2;;; +57722-1;LL829-3;Plurality;LA6114-8;3;3;;; +57722-1;LL829-3;Plurality;LA6115-5;4;4;;; +57722-1;LL829-3;Plurality;LA10137-0;5;5;;; +57722-1;LL829-3;Plurality;LA10138-8;6;6;;; +57722-1;LL829-3;Plurality;LA10139-6;7;7;;; +57722-1;LL829-3;Plurality;LA10140-4;8;8;;; +57722-1;LL829-3;Plurality;LA10141-2;9;9;;; +57722-1;LL829-3;Plurality;LA13942-0;10;10;;; +57722-1;LL829-3;Plurality;LA14557-5;11;11;;; +57722-1;LL829-3;Plurality;LA14558-3;12;12;;; +57722-1;LL829-3;Plurality;LA12914-0;13;Unknown plurality;;; +57791-6;LL839-2;NBS OA susc;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12577-5;2;2M3HBA or BKT-2;;; +57791-6;LL839-2;NBS OA susc;LA12493-5;3;Glutaric acidemia type I;76175005;Glutaric aciduria, type 1 (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12578-3;4;IVA or 2MBG or GA-2 or EMA;;; +57791-6;LL839-2;NBS OA susc;LA12508-0;5;Malonic acidemia;124594007;Deficiency of malonyl-coenzyme A decarboxylase (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12579-1;6;PROP or CBL A or CBL B or MUT or CBL C or MCD;;; +57791-6;LL839-2;NBS OA susc;LA12464-6;7;2-Methyl-3-hydroxybutyric aciduria;791000124107;2-methyl-3-hydroxybutyric aciduria (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12465-3;8;2-Methylbutyrylglycinuria;445596006;2-methylbutyrylglycinuria (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12499-2;9;3-Hydroxy-3-methylglutaric aciduria;410059004;Hydroxymethylglutaric aciduria (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12466-1;10;3-Methylcrotonyl-CoA carboxylase deficiency;13144005;Methylcrotonyl-coenzyme A carboxylase deficiency (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12474-5;11;Beta-ketothiolase deficiency;237953006;Mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency - potassium stimulated (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12491-9;12;Ethylmalonic encephalopathy;723307008;Ethylmalonic encephalopathy (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12492-7;13;Formiminoglutamic acidemia;59761008;Glutamate formiminotransferase deficiency (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12504-9;14;Isobutyrylglycinuria;445571008;Isobutyrylglycinuria (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12505-6;15;Isovaleric acidemia;87827003;Isovaleryl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12467-9;16;3-Methylcrotonyl-CoA carboxylase deficiency (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12476-0;17;Cobalamin A disease;73843004;Cobalamin A disease (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12477-8;18;Cobalamin B disease;82245003;Cobalamin B disease (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12515-5;19;Methylmalonic acidemia;124680001;Deficiency of methylmalonyl-coenzyme A mutase (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12478-6;20;Cobalamin C disease;74653006;Cobalamin C disease (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12479-4;21;Cobalamin D disease;31220004;Cobalamin D disease (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12510-6;22;Holoocarboxylase synthase deficiency;360369003;Holocarboxylase synthase deficiency (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12506-4;23;Primary lactic acidemia;190882007;Lactic acidemia (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12523-9;24;Propionic acidemia;69080001;Propionic acidemia (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12526-2;25;Succinyl-CoA ligase deficiency;445275003;Deficiency of succinate-coenzyme A ligase (disorder);http://snomed.info/sct +57791-6;LL839-2;NBS OA susc;LA12915-7;26;3-MCC or 3-MCC (mat) or 3MGA or BKT or HMG or MCD or BIO;;; +57791-6;LL839-2;NBS OA susc;LA12917-3;27;GA-1 or GA-2;;; +57792-4;LL838-4;NBS FA susc;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12485-1;2;Carnitine palmitoyltransferase type I deficiency;238001003;Carnitine palmitoyltransferase I deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12487-7;3;Carnitine uptake deficiency/carnitine transport defect;21764004;Renal carnitine transport defect (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12573-4;4;CPT-II or CACT;;; +57792-4;LL838-4;NBS FA susc;LA12574-2;5;LCHAD or TFP;;; +57792-4;LL838-4;NBS FA susc;LA12509-8;6;Medium-chain acyl-CoA dehydrogenase deficiency;128596003;Medium-chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12575-9;7;MCAD or SCAD or GA-2(MADD);;; +57792-4;LL838-4;NBS FA susc;LA12576-7;8;SCAD or EMA or IBG or GA-2 (MADD);;; +57792-4;LL838-4;NBS FA susc;LA12531-2;9;Very long-chain acyl-CoA dehydrogenase deficiency;237997005;Very long chain acyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12489-3;10;2,4-Dienoyl-CoA reductase deficiency;444944006;Deficiency of 2,4-dienoyl-coenzyme A reductase (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12475-2;11;Carnitine acylcarnitine translocase deficiency;238003000;Carnitine acylcarnitine translocase deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12486-9;12;Carnitine palmitoyltransferase type II deficiency;238002005;Carnitine palmitoyltransferase II deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12495-0;13;Glutaric acidemia type II;22886006;Glutaric aciduria, type 2 (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12507-2;14;Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency;307127004;Isolated long chain hydroxyacyl-CoA dehydrogenase deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12488-5;15;Carnitine uptake deficiency/carnitine transport defect (maternal);206001006;Fetal or neonatal effect of maternal problem unrelated to pregnancy (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12511-4;16;Medium-chain ketoacyl-CoA thiolase deficiency;124265004;Deficiency of acetyl-coenzyme A acyltransferase (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12524-7;17;Short-chain acyl-CoA dehydrogenase deficiency;124166007;Deficiency of butyryl-CoA dehydrogenase (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12525-4;18;Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency;237998000;Short chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12527-0;19;Trifunctional protein deficiency;237999008;Mitochondrial trifunctional protein deficiency (disorder);http://snomed.info/sct +57792-4;LL838-4;NBS FA susc;LA12916-5;20;CUD or CUD (mat) or CPT-Ia;;; +57792-4;LL838-4;NBS FA susc;LA12917-3;21;GA-1 or GA-2;;; +57792-4;LL838-4;NBS FA susc;LA25796-6;22;X-linked adrenoleukodystrophy;65389002;Adrenoleukodystrophy (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12569-2;2;CIT-I or CIT-II or ASA;;; +57793-2;LL837-6;NBS AA susc;LA12570-0;3;HCY or MET or CBL C;;; +57793-2;LL837-6;NBS AA susc;LA12571-8;4;PKU or BIPT-BS or BIOPT-REG or H-PHE;;; +57793-2;LL837-6;NBS AA susc;LA12572-6;5;TYR-1 or TYR-II or TYR-III;;; +57793-2;LL837-6;NBS AA susc;LA21168-2;6;Maple syrup urine disease;27718001;Maple syrup urine disease (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA21161-7;7;Argininemia;;; +57793-2;LL837-6;NBS AA susc;LA21162-5;8;Argininosuccinic aciduria;;; +57793-2;LL837-6;NBS AA susc;LA12484-4;9;Carbamoyl-phosphate synthase deficiency;62522004;Congenital hyperammonemia, type I (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12482-8;10;Citrullinemia, type I;398680004;Citrullinemia (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12483-6;11;Citrullinemia, type II;716863007;Citrullinemia type II (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12490-1;12;Dihydrolipoamide dehydrogenase deficiency;29914000;Dihydrolipoamide dehydrogenase deficiency (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12472-9;13;Biopterin defect in cofactor biosynthesis;237914002;6-Pyruvoyl-tetrahydrobiopterin synthase deficiency (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12473-7;14;Biopterin defect in cofactor regeneration;58256000;Dihydropteridine reductase deficiency (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12502-3;15;Girate atrophy of the retina;314467007;Gyrate atrophy (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12512-2;16;Hypermethioninemia;43123004;Hypermethioninemia (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12497-6;17;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome;30287008;Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12500-7;18;Hyperphenylalaninemia (variant, benign);68528007;Hyperphenylalaninemia (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12521-3;19;Hyperprolinemia type I;61071003;Proline dehydrogenase deficiency (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12522-1;20;Hyperprolinemia type II;717181004;Hyperprolinemia type 2 (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12480-2;21;Cobalamin E disease;360373000;Homocystinuria vitamin B12-responsive type III (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA30113-7;22;Guanidinoacetate N-methyltransferase deficiency;124239003;Deficiency of guanidinoacetate methyltransferase (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA30114-5;23;L-arginine:glycine amidinotransferase deficiency;702440000;Cerebral creatine deficiency syndrome 3 (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12514-8;24;Methylene tetrahydrofolate reductase deficiency;41797007;5,10-Methylenetetrahydrofolate reductase deficiency (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12516-3;25;Nonketotic hyperglycinemia (glycine encephalopathy);237939006;Non-ketotic hyperglycinemia (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12518-9;26;Ornithine transcarbamylase deficiency;80908008;Ornithine carbamoyltransferase deficiency (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12520-5;27;Classic phenylketonuria;7573000;Classical phenylketonuria (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12469-5;28;Pyroglutamic acidemia;39112005;Glutathione synthase deficiency with 5-oxoprolinuria (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12519-7;29;Pyruvate carboxylase deficiency;87694001;Pyruvate carboxylase deficiency (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12528-8;30;Tyrosinemia, type I;410056006;Tyrosinemia type I (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12529-6;31;Tyrosinemia, type II;4887000;Hypertyrosinemia, Richner-Hanhart type (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12530-4;32;Tyrosinemia, type III;415764005;Tyrosinemia type III (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA12503-1;33;Valinemia;47719001;Hypervalinemia (disorder);http://snomed.info/sct +57793-2;LL837-6;NBS AA susc;LA30492-5;34;X-linked creatine transporter (CRTR) deficiency;698290008;X-linked creatine deficiency (disorder);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12812-6;1;Acetaminophen crystals;;; +5782-8;LL891-3;UA_crystals;LA12813-4;2;Ammonium urate crystals;707966003;Ammonium urate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12814-2;3;Bilirubin crystals;707965004;Bilirubin crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12815-9;4;Calcium carbonate crystals;707964000;Calcium carbonate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12816-7;5;Calcium hydrogen phosphate dihydrate crystals;707963006;Calcium hydrogen phosphate dihydrate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12817-5;6;Calcium oxalate crystals;312281007;Calcium oxalate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12818-3;7;Calcium oxalate dihydrate crystals;707961008;Calcium oxalate dihydrate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12819-1;8;Calcium phosphate crystals;707959004;Calcium phosphate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12820-9;9;Calcium sulfate crystals;707958007;Calcium sulfate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12821-7;10;Cholesterol crystals;250452002;Cholesterol crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12822-5;11;Crystals.amorphous;;; +5782-8;LL891-3;UA_crystals;LA12823-3;12;Crystals.unidentified;;; +5782-8;LL891-3;UA_crystals;LA12824-1;13;Cystine crystals;707957002;Cystine crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12825-8;14;Dimagnesium phosphate crystals;;; +5782-8;LL891-3;UA_crystals;LA12826-6;15;Drug crystals;;; +5782-8;LL891-3;UA_crystals;LA12827-4;16;Hippurate crystals;707956006;Hippurate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12828-2;17;Leucine crystals;312282000;Leucine crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12830-8;18;Phosphate crystals.amorphous;;; +5782-8;LL891-3;UA_crystals;LA12831-6;19;Pyrophosphate crystals;;; +5782-8;LL891-3;UA_crystals;LA12832-4;20;Sodium urate crystals;707954009;Sodium urate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12833-2;21;Sulfonamide crystals;707953003;Sulfonamide crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12834-0;22;Triple phosphate crystals;;; +5782-8;LL891-3;UA_crystals;LA12835-7;23;Tyrosine crystals;312283005;Tyrosine crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12836-5;24;Urate crystals;250456004;Urate crystal (substance);http://snomed.info/sct +5782-8;LL891-3;UA_crystals;LA12837-3;25;Urate crystals.amorphous;;; +98028-4;LL891-3;UA_crystals;LA12812-6;1;Acetaminophen crystals;;; +98028-4;LL891-3;UA_crystals;LA12813-4;2;Ammonium urate crystals;707966003;Ammonium urate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12814-2;3;Bilirubin crystals;707965004;Bilirubin crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12815-9;4;Calcium carbonate crystals;707964000;Calcium carbonate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12816-7;5;Calcium hydrogen phosphate dihydrate crystals;707963006;Calcium hydrogen phosphate dihydrate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12817-5;6;Calcium oxalate crystals;312281007;Calcium oxalate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12818-3;7;Calcium oxalate dihydrate crystals;707961008;Calcium oxalate dihydrate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12819-1;8;Calcium phosphate crystals;707959004;Calcium phosphate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12820-9;9;Calcium sulfate crystals;707958007;Calcium sulfate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12821-7;10;Cholesterol crystals;250452002;Cholesterol crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12822-5;11;Crystals.amorphous;;; +98028-4;LL891-3;UA_crystals;LA12823-3;12;Crystals.unidentified;;; +98028-4;LL891-3;UA_crystals;LA12824-1;13;Cystine crystals;707957002;Cystine crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12825-8;14;Dimagnesium phosphate crystals;;; +98028-4;LL891-3;UA_crystals;LA12826-6;15;Drug crystals;;; +98028-4;LL891-3;UA_crystals;LA12827-4;16;Hippurate crystals;707956006;Hippurate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12828-2;17;Leucine crystals;312282000;Leucine crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12830-8;18;Phosphate crystals.amorphous;;; +98028-4;LL891-3;UA_crystals;LA12831-6;19;Pyrophosphate crystals;;; +98028-4;LL891-3;UA_crystals;LA12832-4;20;Sodium urate crystals;707954009;Sodium urate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12833-2;21;Sulfonamide crystals;707953003;Sulfonamide crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12834-0;22;Triple phosphate crystals;;; +98028-4;LL891-3;UA_crystals;LA12835-7;23;Tyrosine crystals;312283005;Tyrosine crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12836-5;24;Urate crystals;250456004;Urate crystal (substance);http://snomed.info/sct +98028-4;LL891-3;UA_crystals;LA12837-3;25;Urate crystals.amorphous;;; +98029-2;LL891-3;UA_crystals;LA12812-6;1;Acetaminophen crystals;;; +98029-2;LL891-3;UA_crystals;LA12813-4;2;Ammonium urate crystals;707966003;Ammonium urate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12814-2;3;Bilirubin crystals;707965004;Bilirubin crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12815-9;4;Calcium carbonate crystals;707964000;Calcium carbonate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12816-7;5;Calcium hydrogen phosphate dihydrate crystals;707963006;Calcium hydrogen phosphate dihydrate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12817-5;6;Calcium oxalate crystals;312281007;Calcium oxalate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12818-3;7;Calcium oxalate dihydrate crystals;707961008;Calcium oxalate dihydrate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12819-1;8;Calcium phosphate crystals;707959004;Calcium phosphate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12820-9;9;Calcium sulfate crystals;707958007;Calcium sulfate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12821-7;10;Cholesterol crystals;250452002;Cholesterol crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12822-5;11;Crystals.amorphous;;; +98029-2;LL891-3;UA_crystals;LA12823-3;12;Crystals.unidentified;;; +98029-2;LL891-3;UA_crystals;LA12824-1;13;Cystine crystals;707957002;Cystine crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12825-8;14;Dimagnesium phosphate crystals;;; +98029-2;LL891-3;UA_crystals;LA12826-6;15;Drug crystals;;; +98029-2;LL891-3;UA_crystals;LA12827-4;16;Hippurate crystals;707956006;Hippurate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12828-2;17;Leucine crystals;312282000;Leucine crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12830-8;18;Phosphate crystals.amorphous;;; +98029-2;LL891-3;UA_crystals;LA12831-6;19;Pyrophosphate crystals;;; +98029-2;LL891-3;UA_crystals;LA12832-4;20;Sodium urate crystals;707954009;Sodium urate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12833-2;21;Sulfonamide crystals;707953003;Sulfonamide crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12834-0;22;Triple phosphate crystals;;; +98029-2;LL891-3;UA_crystals;LA12835-7;23;Tyrosine crystals;312283005;Tyrosine crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12836-5;24;Urate crystals;250456004;Urate crystal (substance);http://snomed.info/sct +98029-2;LL891-3;UA_crystals;LA12837-3;25;Urate crystals.amorphous;;; +58050-6;LL842-6;ICD-9CM (procedure codes);;0;;;; +58108-2;LL844-2;MDSv3_A0310F;LA12627-8;1;Entry tracking record;;; +58108-2;LL844-2;MDSv3_A0310F;LA12628-6;2;Discharge assessment - return not anticipated;;; +58108-2;LL844-2;MDSv3_A0310F;LA12629-4;3;Discharge assessment - return anticipated;;; +58108-2;LL844-2;MDSv3_A0310F;LA12630-2;4;Death in facility tracking record;;; +58108-2;LL844-2;MDSv3_A0310F;LA9-3;5;None of the above;;; +58117-3;LL4624-4;CMS_MDS No(J0400=1thru4),Yes(J0400-9);LA32-8;0;No;373067005;No (qualifier value);http://snomed.info/sct +58117-3;LL4624-4;CMS_MDS No(J0400=1thru4),Yes(J0400-9);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58118-1;LL851-7;MDSv3_J0850;LA12645-0;1;Indicators of pain or possible pain observed 1 to 2 days;;; +58118-1;LL851-7;MDSv3_J0850;LA12646-8;2;Indicators of pain or possible pain observed 3 to 4 days;;; +58118-1;LL851-7;MDSv3_J0850;LA12647-6;3;Indicators of pain or possible pain observed daily;;; +58147-0;LL856-6;MDSv3_Q0400B;LA12653-4;1;Determination not made;;; +58147-0;LL856-6;MDSv3_Q0400B;LA12654-2;2;Discharge to community determined to be feasible;;; +58147-0;LL856-6;MDSv3_Q0400B;LA12655-9;3;Discharge to community determined to be not feasible;;; +58148-8;LL857-4;MDSv3_Q0500A;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58148-8;LL857-4;MDSv3_Q0500A;LA12656-7;2;"Yes - previous response was ""no""";;; +58148-8;LL857-4;MDSv3_Q0500A;LA12657-5;3;"Yes - previous response was ""yes""";;; +58148-8;LL857-4;MDSv3_Q0500A;LA12658-3;4;"Yes - previous response was ""unknown""";;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA12660-9;1;No - referral not needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18611-6;2;No - referral is or may be needed;;; +58150-4;LL859-0;MDSv3_Q0600-Referral to local contact agency;LA18610-8;3;Yes - referral made;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA27573-7;1;Add new assessment/record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12664-1;2;Modify existing record;;; +58198-3;LL4482-7;CMS_LCDS Type of Record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12663-3;1;Add new record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12664-1;2;Modify existing record;;; +58198-3;LL861-6;MDSv3-A0050-Type of record;LA12665-8;3;Inactivate existing record;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL4588-1;CMS_MDS Ax participation-guardian;LA27974-7;3;Resident has no guardian or legally authorized representative;;; +58221-3;LL860-8;MDSv3_Q0100C;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL860-8;MDSv3_Q0100C;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL860-8;MDSv3_Q0100C;LA12662-5;3;No guardian or legally authorized representative available;;; +58221-3;LL860-8;MDSv3_Q0100C;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58221-3;LL860-8;MDSv3_Q0100C;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58221-3;LL860-8;MDSv3_Q0100C;LA12662-5;3;No guardian or legally authorized representative available;;; +58232-0;LL862-4;NBS_hear_risk;LA12668-2;1;Family Hx of hearing loss;;; +58232-0;LL862-4;NBS_hear_risk;LA12669-0;2;ICU stay > 5 days;;; +58232-0;LL862-4;NBS_hear_risk;LA12673-2;3;Hyperbilirubinemia with exchange transfusion;;; +58232-0;LL862-4;NBS_hear_risk;LA12672-4;4;Aminoglycoside administration for more than 5 days;;; +58232-0;LL862-4;NBS_hear_risk;LA31563-2;5;Asphyxia or Hypoxic Ischemic Encephalopathy;;; +58232-0;LL862-4;NBS_hear_risk;LA12670-8;6;ECMO;;; +58232-0;LL862-4;NBS_hear_risk;LA12674-0;7;In utero infection(s) such as herpes, rubella, syphilis, and toxoplasmosis;;; +58232-0;LL862-4;NBS_hear_risk;LA31564-0;8;In utero infection with cytomegalovirus (CMV);;; +58232-0;LL862-4;NBS_hear_risk;LA31565-7;9;Mother + Zika and infant with no laboratory evidence and no clinical findings;;; +58232-0;LL862-4;NBS_hear_risk;LA31566-5;10;Mother + Zika and infant with laboratory evidence of Zika;;; +58232-0;LL862-4;NBS_hear_risk;LA31852-9;12;Craniofacial malformations: Other (e.g., ear dysplasia, oral facial clefting, white forelock, microphthalmia);;; +58232-0;LL862-4;NBS_hear_risk;LA31853-7;13;Craniofacial malformations: microtia/atresia;;; +58232-0;LL862-4;NBS_hear_risk;LA31567-3;14;Congenital microcephaly, congenital or acquired hydrocephalus;;; +58232-0;LL862-4;NBS_hear_risk;LA31855-2;15;Temporal bone ablornalities;;; +58232-0;LL862-4;NBS_hear_risk;LA12676-5;16;Syndromes associated with atypical hearing thresholds;;; +58232-0;LL862-4;NBS_hear_risk;LA12678-1;17;Culture-positive infections associated with sensorineural hearing loss;;; +58232-0;LL862-4;NBS_hear_risk;LA12679-9;18;Significant head trauma;;; +58232-0;LL862-4;NBS_hear_risk;LA6172-6;19;Chemotherapy;;; +58232-0;LL862-4;NBS_hear_risk;LA12667-4;20;Caregiver concern about hearing;;; +58232-0;LL862-4;NBS_hear_risk;LA137-2;21;None;260413007;None (qualifier value);http://snomed.info/sct +58233-8;LL864-0;Heart attack age;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58233-8;LL864-0;Heart attack age;LA12689-8;2;Less than 55;;; +58233-8;LL864-0;Heart attack age;LA12690-6;3;55-64;;; +58233-8;LL864-0;Heart attack age;LA12691-4;4;65 or older;;; +58233-8;LL864-0;Heart attack age;LA12692-2;5;Don't know if he or she had a heart attack;;; +58342-7;LL864-0;Heart attack age;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58342-7;LL864-0;Heart attack age;LA12689-8;2;Less than 55;;; +58342-7;LL864-0;Heart attack age;LA12690-6;3;55-64;;; +58342-7;LL864-0;Heart attack age;LA12691-4;4;65 or older;;; +58342-7;LL864-0;Heart attack age;LA12692-2;5;Don't know if he or she had a heart attack;;; +58344-3;LL864-0;Heart attack age;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58344-3;LL864-0;Heart attack age;LA12689-8;2;Less than 55;;; +58344-3;LL864-0;Heart attack age;LA12690-6;3;55-64;;; +58344-3;LL864-0;Heart attack age;LA12691-4;4;65 or older;;; +58344-3;LL864-0;Heart attack age;LA12692-2;5;Don't know if he or she had a heart attack;;; +58345-0;LL864-0;Heart attack age;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58345-0;LL864-0;Heart attack age;LA12689-8;2;Less than 55;;; +58345-0;LL864-0;Heart attack age;LA12690-6;3;55-64;;; +58345-0;LL864-0;Heart attack age;LA12691-4;4;65 or older;;; +58345-0;LL864-0;Heart attack age;LA12692-2;5;Don't know if he or she had a heart attack;;; +58346-8;LL864-0;Heart attack age;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58346-8;LL864-0;Heart attack age;LA12689-8;2;Less than 55;;; +58346-8;LL864-0;Heart attack age;LA12690-6;3;55-64;;; +58346-8;LL864-0;Heart attack age;LA12691-4;4;65 or older;;; +58346-8;LL864-0;Heart attack age;LA12692-2;5;Don't know if he or she had a heart attack;;; +58347-6;LL864-0;Heart attack age;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58347-6;LL864-0;Heart attack age;LA12689-8;2;Less than 55;;; +58347-6;LL864-0;Heart attack age;LA12690-6;3;55-64;;; +58347-6;LL864-0;Heart attack age;LA12691-4;4;65 or older;;; +58347-6;LL864-0;Heart attack age;LA12692-2;5;Don't know if he or she had a heart attack;;; +58258-5;LL881-4;MI;LA12745-8;1;Definite;;; +58258-5;LL881-4;MI;LA12746-6;2;Probable;;; +58258-5;LL881-4;MI;LA12747-4;3;No MI (skip to end);;; +58260-1;LL882-2;CardEnz;LA12748-2;1;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +58260-1;LL882-2;CardEnz;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +58260-1;LL882-2;CardEnz;LA7341-6;3;Incomplete;;; +58260-1;LL882-2;CardEnz;LA6626-1;4;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +58261-9;LL883-0;ECG;LA12749-0;1;Evolution of Major Q-Wave;;; +58261-9;LL883-0;ECG;LA12750-8;2;Evolution of ST-T Elevation with or without Q-Wave;;; +58261-9;LL883-0;ECG;LA12751-6;3;New LBBB;;; +58261-9;LL883-0;ECG;LA12752-4;4;Evolution of ST-Depression/Inversion alone;;; +58261-9;LL883-0;ECG;LA12753-2;5;Evolution of Minor Q-Wave alone;;; +58261-9;LL883-0;ECG;LA12754-0;6;Single ECG with Major Q-Wave;;; +58261-9;LL883-0;ECG;LA12755-7;7;Single ECG with LBBB, described as new;;; +58261-9;LL883-0;ECG;LA12756-5;8;Absent, Uncodable or Other ECG;;; +58262-7;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58262-7;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58263-5;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58263-5;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58264-3;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58264-3;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58265-0;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58265-0;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58276-7;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58276-7;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58277-5;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58277-5;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58297-3;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58297-3;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58339-3;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58339-3;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58341-9;LL867-3;N/Y 1/2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58341-9;LL867-3;N/Y 1/2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58268-4;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58268-4;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58268-4;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58268-4;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58271-8;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58271-8;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58271-8;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58271-8;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58273-4;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58273-4;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58273-4;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58273-4;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58274-2;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58274-2;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58274-2;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58274-2;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58319-5;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58319-5;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58319-5;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58319-5;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58320-3;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58320-3;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58320-3;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58320-3;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58321-1;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58321-1;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58321-1;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58321-1;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58322-9;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58322-9;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58322-9;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58322-9;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58323-7;LL873-1;N/Y/M/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58323-7;LL873-1;N/Y/M/U;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58323-7;LL873-1;N/Y/M/U;LA12696-3;3;Maybe;;; +58323-7;LL873-1;N/Y/M/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58270-0;LL890-5;Hosp/MD;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58270-0;LL890-5;Hosp/MD;LA12759-9;2;Hosp/ER;;; +58270-0;LL890-5;Hosp/MD;LA12760-7;3;Saw M.D.;;; +58270-0;LL890-5;Hosp/MD;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58275-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58275-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58275-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58282-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58282-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58282-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58288-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58288-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58288-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58291-6;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58291-6;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58291-6;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58302-1;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58302-1;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58302-1;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58303-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58303-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58303-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58338-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58338-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58338-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63706-6;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63706-6;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63706-6;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63707-4;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63707-4;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63707-4;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63708-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63708-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63708-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63789-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63789-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63789-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63790-0;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63790-0;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63790-0;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63793-4;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63793-4;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63793-4;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63797-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63797-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63797-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63811-4;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63811-4;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63811-4;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63812-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63812-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63812-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63845-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63845-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63845-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63989-8;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63989-8;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63989-8;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63992-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63992-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63992-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64239-7;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64239-7;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64239-7;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64240-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64240-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64240-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64241-3;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64241-3;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64241-3;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64242-1;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64242-1;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64242-1;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64243-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64243-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64243-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64496-3;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64496-3;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64496-3;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64873-3;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64873-3;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64873-3;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64874-1;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64874-1;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64874-1;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64875-8;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64875-8;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64875-8;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64876-6;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64876-6;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64876-6;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65720-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65720-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65720-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65728-8;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65728-8;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65728-8;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65731-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65731-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65731-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65732-0;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65732-0;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65732-0;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65735-3;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65735-3;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65735-3;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65736-1;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65736-1;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65736-1;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65738-7;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65738-7;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65738-7;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65742-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65742-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65742-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65745-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65745-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65745-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65746-0;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65746-0;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65746-0;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66152-0;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66152-0;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66152-0;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66153-8;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66153-8;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66153-8;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66156-1;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66156-1;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66156-1;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66157-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66157-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66157-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66158-7;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66158-7;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66158-7;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66159-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66159-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66159-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66162-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66162-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66162-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66373-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66373-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66373-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66374-0;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66374-0;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66374-0;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66375-7;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66375-7;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66375-7;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66376-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66376-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66376-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66377-3;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66377-3;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66377-3;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66378-1;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66378-1;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66378-1;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66379-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66379-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66379-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66380-7;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66380-7;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66380-7;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66381-5;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66381-5;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66381-5;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66382-3;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66382-3;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66382-3;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66383-1;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66383-1;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66383-1;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66384-9;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66384-9;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66384-9;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66385-6;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66385-6;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66385-6;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66386-4;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66386-4;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66386-4;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66387-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66387-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66387-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66388-0;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66388-0;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66388-0;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66389-8;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66389-8;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66389-8;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66390-6;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66390-6;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66390-6;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66391-4;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66391-4;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66391-4;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66561-2;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66561-2;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66561-2;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +89908-8;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89908-8;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89908-8;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +89909-6;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89909-6;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89909-6;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +92272-4;LL863-2;Y/N/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +92272-4;LL863-2;Y/N/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +92272-4;LL863-2;Y/N/Dk;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58279-1;LL885-5;PEDxCat;LA12776-3;1;Pulmonary embolism not resulting from a procedure within 60 days;;; +58279-1;LL885-5;PEDxCat;LA12777-1;2;Pulmonary embolism during or following a procedure within 60 days;;; +58280-9;LL888-9;DVTDxbase;LA12764-9;1;Hospital discharge summary with a diagnosis of deep vein thrombosis;;; +58280-9;LL888-9;DVTDxbase;LA12765-6;2;Positive findings on a venogram;;; +58280-9;LL888-9;DVTDxbase;LA12766-4;3;Positive findings using a impedance plethysmography;;; +58280-9;LL888-9;DVTDxbase;LA12767-2;4;Positive findings on doppler duplex, ultrasound, sonogram, or other non-invasive test examination;;; +58280-9;LL888-9;DVTDxbase;LA12768-0;5;Positive findings on isotope scan;;; +58281-7;LL889-7;DVTDxSource;LA12769-8;1;Hospital inpatient;;; +58281-7;LL889-7;DVTDxSource;LA12770-6;2;Hospital outpatient facility or clinic;;; +58281-7;LL889-7;DVTDxSource;LA12771-4;3;Radiology or imaging facility;;; +58281-7;LL889-7;DVTDxSource;LA12772-2;4;Physician's office/private medical practitioner;;; +58281-7;LL889-7;DVTDxSource;LA12773-0;5;Nursing/convalescent home/hospice;;; +58281-7;LL889-7;DVTDxSource;LA4222-1;6;Autopsy Only;;; +58281-7;LL889-7;DVTDxSource;LA4197-5;7;Death Certificate Only;;; +58281-7;LL889-7;DVTDxSource;LA46-8;8;Other;;; +58349-2;LL889-7;DVTDxSource;LA12769-8;1;Hospital inpatient;;; +58349-2;LL889-7;DVTDxSource;LA12770-6;2;Hospital outpatient facility or clinic;;; +58349-2;LL889-7;DVTDxSource;LA12771-4;3;Radiology or imaging facility;;; +58349-2;LL889-7;DVTDxSource;LA12772-2;4;Physician's office/private medical practitioner;;; +58349-2;LL889-7;DVTDxSource;LA12773-0;5;Nursing/convalescent home/hospice;;; +58349-2;LL889-7;DVTDxSource;LA4222-1;6;Autopsy Only;;; +58349-2;LL889-7;DVTDxSource;LA4197-5;7;Death Certificate Only;;; +58349-2;LL889-7;DVTDxSource;LA46-8;8;Other;;; +58285-8;LL887-1;DVTDxCat;LA12762-3;1;Deep vein thrombosis of lower extremities not resulting from a procedure within 60 days;;; +58285-8;LL887-1;DVTDxCat;LA12763-1;2;Deep vein thrombosis of lower extremities during or following a procedure within 60 days;;; +58286-6;LL886-3;PEDxbase;LA12764-9;1;Hospital discharge summary with a diagnosis of deep vein thrombosis;;; +58286-6;LL886-3;PEDxbase;LA12779-7;2;High probability orn ventilation-perfusion lung scan (exclude moderate, intermediate, or low probability on ventilation-perfusion lung scan);;; +58286-6;LL886-3;PEDxbase;LA12780-5;3;Positive findings on pulmonary angiogram or spiral CAT scan (CT);;; +58286-6;LL886-3;PEDxbase;LA12781-3;4;"Diagnosis of deep vein thrombosis (DVT) based on >= 1 deep vein thrombosis (DVT) criteria in question 1.3 (link to Form 126 in ""Source"" section below) plus signs and symptoms suggestive of pulmonary embolism (PE) (e.g., acute chest pain, dyspnea, ....)";;; +58286-6;LL886-3;PEDxbase;LA12782-1;5;Other, including autopsy;;; +58292-4;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58292-4;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58292-4;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +58295-7;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58295-7;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58295-7;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +58300-5;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58300-5;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58300-5;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +58301-3;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58301-3;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58301-3;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +63934-4;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63934-4;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63934-4;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +63941-9;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63941-9;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63941-9;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +63943-5;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63943-5;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63943-5;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64823-8;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64823-8;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64823-8;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64824-6;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64824-6;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64824-6;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64825-3;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64825-3;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64825-3;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64826-1;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64826-1;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64826-1;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64827-9;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64827-9;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64827-9;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64828-7;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64828-7;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64828-7;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64830-3;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64830-3;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64830-3;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64831-1;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64831-1;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64831-1;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64832-9;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64832-9;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64832-9;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64833-7;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64833-7;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64833-7;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64834-5;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64834-5;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64834-5;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64835-2;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64835-2;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64835-2;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +64839-4;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64839-4;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64839-4;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72152-2;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72152-2;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72152-2;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72175-3;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72175-3;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72175-3;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72177-9;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72177-9;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72177-9;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72178-7;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72178-7;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72178-7;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72179-5;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72179-5;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72179-5;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72180-3;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72180-3;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72180-3;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72181-1;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72181-1;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72181-1;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72182-9;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72182-9;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72182-9;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72183-7;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72183-7;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72183-7;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +72184-5;LL865-7;Y/N/Ns;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +72184-5;LL865-7;Y/N/Ns;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +72184-5;LL865-7;Y/N/Ns;LA12693-0;3;Not sure;;; +58293-2;LL866-5;N/Yn/Ynn/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58293-2;LL866-5;N/Yn/Ynn/U;LA12694-8;2;Yes, now;;; +58293-2;LL866-5;N/Yn/Ynn/U;LA12695-5;3;Yes, not now;;; +58293-2;LL866-5;N/Yn/Ynn/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58298-1;LL866-5;N/Yn/Ynn/U;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58298-1;LL866-5;N/Yn/Ynn/U;LA12694-8;2;Yes, now;;; +58298-1;LL866-5;N/Yn/Ynn/U;LA12695-5;3;Yes, not now;;; +58298-1;LL866-5;N/Yn/Ynn/U;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58298-1;LL5856-1;No (0)/Yes (2);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58298-1;LL5856-1;No (0)/Yes (2);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97059-0;LL5856-1;No (0)/Yes (2);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97059-0;LL5856-1;No (0)/Yes (2);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58304-7;LL868-1;N/Y/M/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58304-7;LL868-1;N/Y/M/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58304-7;LL868-1;N/Y/M/Dk;LA12696-3;3;Maybe;;; +58304-7;LL868-1;N/Y/M/Dk;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58305-4;LL868-1;N/Y/M/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58305-4;LL868-1;N/Y/M/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58305-4;LL868-1;N/Y/M/Dk;LA12696-3;3;Maybe;;; +58305-4;LL868-1;N/Y/M/Dk;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58306-2;LL868-1;N/Y/M/Dk;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58306-2;LL868-1;N/Y/M/Dk;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58306-2;LL868-1;N/Y/M/Dk;LA12696-3;3;Maybe;;; +58306-2;LL868-1;N/Y/M/Dk;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +58310-4;LL869-9;AnginaLoc;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58310-4;LL869-9;AnginaLoc;LA12697-1;2;Central sternum and upper chest;;; +58310-4;LL869-9;AnginaLoc;LA12698-9;3;Left upper quadrant;;; +58310-4;LL869-9;AnginaLoc;LA12699-7;4;Left lower ribcage;;; +58310-4;LL869-9;AnginaLoc;LA12700-3;5;Right chest;;; +58310-4;LL869-9;AnginaLoc;LA46-8;6;Other;;; +58310-4;LL869-9;AnginaLoc;LA12701-1;7;Combination;;; +58310-4;LL869-9;AnginaLoc;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58311-2;LL870-7;AnginaRad;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58311-2;LL870-7;AnginaRad;LA12702-9;2;Left shoulder or left arm;;; +58311-2;LL870-7;AnginaRad;LA12703-7;3;Neck;;; +58311-2;LL870-7;AnginaRad;LA12704-5;4;Right shoulder or arm;;; +58311-2;LL870-7;AnginaRad;LA12705-2;5;Back;;; +58311-2;LL870-7;AnginaRad;LA12706-0;6;Abdomen;;; +58311-2;LL870-7;AnginaRad;LA46-8;7;Other;;; +58311-2;LL870-7;AnginaRad;LA12701-1;8;Combination;;; +58311-2;LL870-7;AnginaRad;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58314-6;LL871-5;AnginaType;LA12707-8;1;Pressure, heavy, vise;;; +58314-6;LL871-5;AnginaType;LA12708-6;2;Sharp;;; +58314-6;LL871-5;AnginaType;LA12709-4;3;Dull;;; +58314-6;LL871-5;AnginaType;LA46-8;4;Other;;; +58314-6;LL871-5;AnginaType;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58315-3;LL872-3;AnginaRelief;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58315-3;LL872-3;AnginaRelief;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58315-3;LL872-3;AnginaRelief;LA12710-2;3;Not tried;;; +58315-3;LL872-3;AnginaRelief;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58316-1;LL872-3;AnginaRelief;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58316-1;LL872-3;AnginaRelief;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58316-1;LL872-3;AnginaRelief;LA12710-2;3;Not tried;;; +58316-1;LL872-3;AnginaRelief;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58317-9;LL872-3;AnginaRelief;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58317-9;LL872-3;AnginaRelief;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58317-9;LL872-3;AnginaRelief;LA12710-2;3;Not tried;;; +58317-9;LL872-3;AnginaRelief;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58318-7;LL872-3;AnginaRelief;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +58318-7;LL872-3;AnginaRelief;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58318-7;LL872-3;AnginaRelief;LA12710-2;3;Not tried;;; +58318-7;LL872-3;AnginaRelief;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58326-0;LL874-9;Y/N/Unc;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58326-0;LL874-9;Y/N/Unc;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58326-0;LL874-9;Y/N/Unc;LA12719-3;3;Uncertain;;; +58327-8;LL874-9;Y/N/Unc;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58327-8;LL874-9;Y/N/Unc;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58327-8;LL874-9;Y/N/Unc;LA12719-3;3;Uncertain;;; +58328-6;LL874-9;Y/N/Unc;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58328-6;LL874-9;Y/N/Unc;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58328-6;LL874-9;Y/N/Unc;LA12719-3;3;Uncertain;;; +58329-4;LL874-9;Y/N/Unc;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58329-4;LL874-9;Y/N/Unc;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58329-4;LL874-9;Y/N/Unc;LA12719-3;3;Uncertain;;; +58331-0;LL874-9;Y/N/Unc;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +58331-0;LL874-9;Y/N/Unc;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +58331-0;LL874-9;Y/N/Unc;LA12719-3;3;Uncertain;;; +58330-2;LL875-6;DeathOnset;LA12711-0;1;More than three days;;; +58330-2;LL875-6;DeathOnset;LA12712-8;2;Two - three days;;; +58330-2;LL875-6;DeathOnset;LA12713-6;3;One day;;; +58330-2;LL875-6;DeathOnset;LA12714-4;4;At least 12 hours, but less than 24 hours;;; +58330-2;LL875-6;DeathOnset;LA12715-1;5;At least 4 hours, but less than 12 hours;;; +58330-2;LL875-6;DeathOnset;LA12716-9;6;At least 1 hour, but less than 4 hours;;; +58330-2;LL875-6;DeathOnset;LA12717-7;7;Less than 1 hour;;; +58330-2;LL875-6;DeathOnset;LA12718-5;8;Death instantaneous, no symptoms;;; +58330-2;LL875-6;DeathOnset;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58332-8;LL876-4;DeathLoc;LA12720-1;1;Out-of-Hospital;;; +58332-8;LL876-4;DeathLoc;LA12721-9;2;Emergency Room (not dead on arrival - DOA);;; +58332-8;LL876-4;DeathLoc;LA12722-7;3;In Hospital;;; +58332-8;LL876-4;DeathLoc;LA12723-5;4;Nursing Home, Skilled Nursing Facility (SNF), or Extended Care Facility (ECF);;; +58332-8;LL876-4;DeathLoc;LA12724-3;5;Other, specify;;; +58334-4;LL877-2;MESA;LA12725-0;1;Atherosclerotic coronary heart disease (complete questions 10, 11 and 12 only);;; +58334-4;LL877-2;MESA;LA12783-9;2;Stroke (skip to end);;; +58334-4;LL877-2;MESA;LA12727-6;3;Atherosclerotic disease other than coronary disease or stroke (specify) (complete question 12 only);;; +58334-4;LL877-2;MESA;LA12728-4;4;Other cardiovascular disease, not defined above (specify) (complete question 12 only);;; +58334-4;LL877-2;MESA;LA12729-2;5;Non-cardiovascular disease (specify) (skip to end);;; +58334-4;LL877-2;MESA;LA12730-0;6;Unknown because death certificate unavailable (skip to end);;; +58335-1;LL878-0;CHDtype;LA12731-8;1;Definite fatal myocardial infaction (MI) (no known non-artherosclerotic cause and definite myocardial infarction within 4 weeks of death);;; +58335-1;LL878-0;CHDtype;LA12732-6;2;Definite fatal coronary heart disease (CHD) (no known non-atherosclerotic cause, and one or both of the following: chest pain within 72 hours of death or a history of chronic ischemic heart disease);;; +58335-1;LL878-0;CHDtype;LA12733-4;3;Possible fatal coronary heart disease (CHD) (no known non-atherosclerotic cause, and death certificate underlying cause: 120-25, 146, 151.6, R96 or R98-99);;; +58336-9;LL879-8;TimeCHDdeath;LA12734-2;1;Less than five minutes;;; +58336-9;LL879-8;TimeCHDdeath;LA12735-9;2;five minutes to one hour;;; +58336-9;LL879-8;TimeCHDdeath;LA12736-7;3;one hour to 24 hours;;; +58336-9;LL879-8;TimeCHDdeath;LA12737-5;4;more than 24 hours;;; +58336-9;LL879-8;TimeCHDdeath;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +58337-7;LL880-6;MechDeath;LA12738-3;1;Primary arrhythmic death;;; +58337-7;LL880-6;MechDeath;LA12739-1;2;Secondary arrhythmic/mechanical death;;; +58337-7;LL880-6;MechDeath;LA12740-9;3;Congestive heart failure (CHF);;; +58337-7;LL880-6;MechDeath;LA12741-7;4;Cardiac procedure such as coronary artery bypass graft (CABG) or angioplasty;;; +58337-7;LL880-6;MechDeath;LA12742-5;5;Hemorrhage from thrombolytic therapy;;; +58337-7;LL880-6;MechDeath;LA6310-2;6;Other (specify);;; +58337-7;LL880-6;MechDeath;LA11107-2;7;Unknown or uncertain;;; +58436-7;LL892-1;UA_casts;LA12859-7;1;Bacterial casts;;; +58436-7;LL892-1;UA_casts;LA12861-3;2;Bilirubin casts;;; +58436-7;LL892-1;UA_casts;LA12862-1;3;Broad casts;;; +58436-7;LL892-1;UA_casts;LA12863-9;4;Epithelial casts;;; +58436-7;LL892-1;UA_casts;LA12864-7;5;Erythrocyte casts;;; +58436-7;LL892-1;UA_casts;LA12865-4;7;Fatty casts;;; +58436-7;LL892-1;UA_casts;LA12866-2;8;Granular casts;;; +58436-7;LL892-1;UA_casts;LA12867-0;9;Granular casts.coarse;;; +58436-7;LL892-1;UA_casts;LA12868-8;10;Granular casts.fine;;; +58436-7;LL892-1;UA_casts;LA12869-6;11;Hemoglobin casts;;; +58436-7;LL892-1;UA_casts;LA12870-4;12;Hyaline casts;;; +58436-7;LL892-1;UA_casts;LA12871-2;13;Hyaline casts.broad;;; +58436-7;LL892-1;UA_casts;LA12872-0;14;Leukocyte casts;;; +58436-7;LL892-1;UA_casts;LA12873-8;15;Mixed cellular casts;;; +58436-7;LL892-1;UA_casts;LA12874-6;16;Waxy casts;;; +58436-7;LL892-1;UA_casts;LA12878-7;17;Waxy casts.broad;;; +58436-7;LL892-1;UA_casts;LA12906-6;18;Pseudocasts;;; +58437-5;LL893-9;UA_microorg;LA12886-0;1;Bacteria;;; +58437-5;LL893-9;UA_microorg;LA12879-5;2;Parasites (other);;; +58437-5;LL893-9;UA_microorg;LA12880-3;3;Trichomonas sp;;; +58437-5;LL893-9;UA_microorg;LA12882-9;4;Fungi.filamentous;;; +58437-5;LL893-9;UA_microorg;LA12883-7;5;Fungi.yeastlike;;; +58437-5;LL893-9;UA_microorg;LA12884-5;6;Yeast;62093005;Yeast (organism);http://snomed.info/sct +58437-5;LL893-9;UA_microorg;LA12885-2;7;Yeast.budding;;; +58437-5;LL893-9;UA_microorg;LA12907-4;8;Yeast.hyphae;;; +58437-5;LL893-9;UA_microorg;LA12908-2;9;Yeast.pseudohyphae;;; +58438-3;LL894-7;UA_cells;LA12890-2;1;Bladder cells;;; +58438-3;LL894-7;UA_cells;LA11195-7;2;Burr cells;;; +58438-3;LL894-7;UA_cells;LA12895-1;3;Eosinophils;;; +58438-3;LL894-7;UA_cells;LA12887-8;4;Epithelial cells;;; +58438-3;LL894-7;UA_cells;LA12888-6;5;Epithelial cells.extrarenal;;; +58438-3;LL894-7;UA_cells;LA12909-0;6;Epithelial cells.non-squamous;;; +58438-3;LL894-7;UA_cells;LA12889-4;7;Epithelial cells.renal;;; +58438-3;LL894-7;UA_cells;LA12891-0;8;Epithelial cells.squamous;;; +58438-3;LL894-7;UA_cells;LA12896-9;9;Erythrocytes;;; +58438-3;LL894-7;UA_cells;LA12911-6;10;Erythrocytes ghosts;;; +58438-3;LL894-7;UA_cells;LA12910-8;11;Erythrocytes.non-dysmorphic;;; +58438-3;LL894-7;UA_cells;LA12897-7;12;Histiocytes;;; +58438-3;LL894-7;UA_cells;LA12894-4;13;Leukocytes;;; +58438-3;LL894-7;UA_cells;LA12898-5;14;Spermatozoa;6789008;Spermatozoa (cell);http://snomed.info/sct +58438-3;LL894-7;UA_cells;LA12892-8;15;Transitional cells;;; +58438-3;LL894-7;UA_cells;LA12893-6;16;Tubular cells;;; +58442-5;LL895-4;UA_other;LA12899-3;1;Amorphous sediment;712616009;Amorphous sediment (substance);http://snomed.info/sct +58442-5;LL895-4;UA_other;LA12904-1;2;Artifact;;; +58442-5;LL895-4;UA_other;LA12905-8;3;Charcoal;;; +58442-5;LL895-4;UA_other;LA12902-5;4;Fat bodies.oval;;; +58442-5;LL895-4;UA_other;LA12903-3;5;Lipids;;; +58442-5;LL895-4;UA_other;LA12900-9;6;Mucus;49909006;Mucus (substance);http://snomed.info/sct +58442-5;LL895-4;UA_other;LA12901-7;7;Starch granules;;; +59060-4;LL896-2;IBD7;LA13020-5;1;Pattern consistent with IBD: Crohn's disease;;; +59060-4;LL896-2;IBD7;LA13021-3;2;Pattern consistent with IBD: Ulcerative colitis;;; +59060-4;LL896-2;IBD7;LA13022-1;3;Pattern not consistent with IBD;;; +59362-4;LL897-0;Race ethnicity combined OMB.1997;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +59362-4;LL897-0;Race ethnicity combined OMB.1997;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +59362-4;LL897-0;Race ethnicity combined OMB.1997;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +59362-4;LL897-0;Race ethnicity combined OMB.1997;LA6214-6;4;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +59362-4;LL897-0;Race ethnicity combined OMB.1997;LA10611-4;5;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +59362-4;LL897-0;Race ethnicity combined OMB.1997;LA4457-3;6;White;2106-3;White;https://www.cdc.gov/phin +59454-9;LL899-6;MFS_1;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +59454-9;LL899-6;MFS_1;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +59455-6;LL900-2;MFS_2;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +59455-6;LL900-2;MFS_2;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +59456-4;LL901-0;MFS_3;LA13030-4;1;Bed rest/nurse assist;;; +59456-4;LL901-0;MFS_3;LA13031-2;2;Crutches/cane/walker;;; +59456-4;LL901-0;MFS_3;LA13032-0;3;Furniture;;; +59457-2;LL902-8;MFS_4;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +59457-2;LL902-8;MFS_4;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +59458-0;LL903-6;MFS_5;LA13033-8;1;Normal/bedrest/immobile;;; +59458-0;LL903-6;MFS_5;LA13034-6;2;Weak;;; +59458-0;LL903-6;MFS_5;LA13035-3;3;Impaired;;; +59459-8;LL904-4;MFS_6;LA13036-1;1;Oriented to own ability;;; +59459-8;LL904-4;MFS_6;LA13037-9;2;Forgets limitations;;; +59461-4;LL905-1;MFS_Risk Level;LA13038-7;1;Low Risk (MFS Score 0 - 24);;; +59461-4;LL905-1;MFS_Risk Level;LA13039-5;2;Moderate Risk (MFS Score 25 - 45);;; +59461-4;LL905-1;MFS_Risk Level;LA13040-3;3;High Risk (MFS Score 50+);;; +59511-6;LL932-5;NAACCR_448;LA13356-3;1;No information whatsoever can be inferred from this exceptional value. (e.g., unknown if the diagnosis was initially based on ambiguous terminology).;;; +59511-6;LL932-5;NAACCR_448;LA13378-7;2;"No proper value is applicable in this context. (e.g., accessioned based on ambiguous terminology only [Code 1 in data item Ambiguous Terminology DX]; not applicable, initial diagnosis made by unambiguous terminology [Code 0 in data item Ambiguous Terminol";;; +59511-6;LL932-5;NAACCR_448;LA13234-2;3;A proper value is applicable but not known (e.g., the initial ambiguous diagnosis was followed by a conclusive term, but the date of the conclusive term is unknown).;;; +59511-6;LL932-5;NAACCR_448;LA13258-1;4;A valid date value is provided in item Date of Conclusive DX [443], or the date was not expected to have been transmitted.;;; +59545-4;LL932-5;NAACCR_448;LA13356-3;1;No information whatsoever can be inferred from this exceptional value. (e.g., unknown if the diagnosis was initially based on ambiguous terminology).;;; +59545-4;LL932-5;NAACCR_448;LA13378-7;2;"No proper value is applicable in this context. (e.g., accessioned based on ambiguous terminology only [Code 1 in data item Ambiguous Terminology DX]; not applicable, initial diagnosis made by unambiguous terminology [Code 0 in data item Ambiguous Terminol";;; +59545-4;LL932-5;NAACCR_448;LA13234-2;3;A proper value is applicable but not known (e.g., the initial ambiguous diagnosis was followed by a conclusive term, but the date of the conclusive term is unknown).;;; +59545-4;LL932-5;NAACCR_448;LA13258-1;4;A valid date value is provided in item Date of Conclusive DX [443], or the date was not expected to have been transmitted.;;; +59512-4;LL934-1;NAACCR_581;LA13232-6;1;A proper value is applicable but not known (e.g., date of 1st contact is unknown);;; +59512-4;LL934-1;NAACCR_581;LA13255-7;2;A valid date value is provided in item Date of 1st Contact [580], or the date was not expected to have been transmitted;;; +59513-2;LL914-3;NAACCR_1271;LA13344-9;1;No information whatsoever can be inferred from this exceptional value (e.g, unknown whether treatment was administered);;; +59513-2;LL914-3;NAACCR_1271;LA13358-9;2;No proper value is applicable in this context (e.g., autopsy only case);;; +59513-2;LL914-3;NAACCR_1271;LA13236-7;3;A proper value is applicable but not known (e.g., treatment administered but date is unknown);;; +59513-2;LL914-3;NAACCR_1271;LA13256-5;4;A valid date value is provided in item Date of 1st Crs RX [1270], or the date was not expected to have been transmitted;;; +59514-0;LL923-4;NAACCR_241;LA13237-5;1;A proper value is applicable but not known (i.e., birth date is unknown);;; +59514-0;LL923-4;NAACCR_241;LA13257-3;2;A valid date value is provided in item Date of Birth [240], or the date was not expected to have been transmitted;;; +59515-7;LL921-8;NAACCR_1756;LA13336-5;1;No information whatsoever can be inferred from this exceptional value (e.g, patient is not known to be deceased);;; +59515-7;LL921-8;NAACCR_1756;LA13357-1;2;No proper value is applicable in this context (e.g. patient is alive);;; +59515-7;LL921-8;NAACCR_1756;LA13233-4;3;A proper value is applicable but not known (e.g., date of death is unknown);;; +59515-7;LL921-8;NAACCR_1756;LA13259-9;4;A valid date value is provided in item Date of Death—Canada [1755], or the date was not expected to have been transmitted;;; +59516-5;LL929-1;NAACCR_391;LA13238-3;1;A proper value is applicable but not known. (e.g., date of diagnosis is unknown);;; +59516-5;LL929-1;NAACCR_391;LA13260-7;2;A valid date value is provided in item Date of Diagnosis [390], or the date was not expected to have been transmitted;;; +59517-3;LL913-5;NAACCR_1261;LA13343-1;1;No information whatsoever can be inferred from this exceptional value (e.g, unknown if therapy was administered);;; +59517-3;LL913-5;NAACCR_1261;LA13377-9;2;No proper value is applicable in this context (e.g., therapy was not administered);;; +59517-3;LL913-5;NAACCR_1261;LA13236-7;3;A proper value is applicable but not known (e.g., treatment administered but date is unknown);;; +59517-3;LL913-5;NAACCR_1261;LA13261-5;4;A valid date value is provided in item Date of Initial RX-SEER [1260], or the date was not expected to have been transmitted;;; +59518-1;LL935-8;NAACCR_591;LA13340-7;1;No information whatsoever can be inferred from this exceptional value (e.g, unknown if patient was an inpatient).;;; +59518-1;LL935-8;NAACCR_591;LA13373-8;2;No proper value is applicable in this context (e.g., patient was never an inpatient at the reporting facility).;;; +59518-1;LL935-8;NAACCR_591;LA13252-4;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., the patient was an inpatient but the date is unknown).;;; +59518-1;LL935-8;NAACCR_591;LA13262-3;4;A valid date value is provided in item Date of Inpatient Adm [590], or the date was not expected to have been transmitted.;;; +59519-9;LL936-6;NAACCR_601;LA13340-7;1;No information whatsoever can be inferred from this exceptional value (e.g, unknown if patient was an inpatient).;;; +59519-9;LL936-6;NAACCR_601;LA13373-8;2;No proper value is applicable in this context (e.g., patient was never an inpatient at the reporting facility).;;; +59519-9;LL936-6;NAACCR_601;LA13252-4;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., the patient was an inpatient but the date is unknown).;;; +59519-9;LL936-6;NAACCR_601;LA13263-1;4;A valid date value is provided in item Date of Inpatient Disch [600], or the date was not expected to have been transmitted.;;; +59520-7;LL920-0;NAACCR_1751;LA13240-9;1;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., date of last contact is unknown).;;; +59520-7;LL920-0;NAACCR_1751;LA13264-9;2;A valid date value is provided in item Date of Last Contact [1750], or the date was not expected to have been transmitted.;;; +59521-5;LL930-9;NAACCR_439;LA13376-1;1;"No proper value is applicable in this context (e.g., single tumor; information on multiple tumors not collected/not applicable for this site).";;; +59521-5;LL930-9;NAACCR_439;LA13246-6;2;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., patient was diagnosed with multiple tumors and the date is unknown).;;; +59521-5;LL930-9;NAACCR_439;LA13254-0;3;A valid date value is provided in item Date Multiple Tumors [445], or the date was not expected to have been transmitted.;;; +59529-8;LL928-3;NAACCR_3600;LA13335-7;1;Neoadjuvant therapy was not administered as part of the first course of therapy;;; +59529-8;LL928-3;NAACCR_3600;LA13334-0;2;Neoadjuvant therapy was administered as part of the first course of therapy;;; +59529-8;LL928-3;NAACCR_3600;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +59541-3;LL933-3;NAACCR_449;LA13411-6;1;Two-Grade System;;; +59541-3;LL933-3;NAACCR_449;LA13404-1;2;Three-Grade System;;; +59541-3;LL933-3;NAACCR_449;LA13308-4;3;Four-Grade System;;; +59541-3;LL933-3;NAACCR_449;LA13382-9;4;"Not a two, three or four grade system; unknown";;; +59542-1;LL931-7;NAACCR_441;LA13398-5;1;Recorded as Grade I or 1;;; +59542-1;LL931-7;NAACCR_441;LA13399-3;2;Recorded as Grade II or 2;;; +59542-1;LL931-7;NAACCR_441;LA13400-9;3;Recorded as Grade III or 3;;; +59542-1;LL931-7;NAACCR_441;LA13401-7;4;Recorded as Grade IV or 4;;; +59543-9;LL937-4;NAACCR_605;LA13397-7;1;Patient was never an inpatient;;; +59543-9;LL937-4;NAACCR_605;LA13396-9;2;Patient was inpatient;;; +59543-9;LL937-4;NAACCR_605;LA13418-1;3;Unknown if patient was an inpatient (only used for consolidated cases);;; +59544-7;LL906-9;NAACCR_1182;LA13327-4;1;Lymph-vascular Invasion Not Present (absent)/Not Identified;;; +59544-7;LL906-9;NAACCR_1182;LA13328-2;2;Lymph-vascular Invasion Present/Identified;;; +59544-7;LL906-9;NAACCR_1182;LA4720-4;3;Not applicable;;; +59544-7;LL906-9;NAACCR_1182;LA13420-7;9;Unknown/Indeterminate;;; +59546-2;LL924-2;NAACCR_3171;LA13349-8;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown if any surgical procedure of the primary site was performed).;;; +59546-2;LL924-2;NAACCR_3171;LA13369-6;2;No proper value is applicable in this context (e.g., no surgical resection of the primary site was performed and for cases diagnosed at autopsy).;;; +59546-2;LL924-2;NAACCR_3171;LA13249-0;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., surgical procedure of the primary site was performed but the date is unknown).;;; +59547-0;LL926-7;NAACCR_3221;LA13351-4;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown if radiation therapy administered).;;; +59547-0;LL926-7;NAACCR_3221;LA13375-3;2;"No proper value is applicable in this context (e.g., radiation therapy was not administered; diagnosed at autopsy).";;; +59547-0;LL926-7;NAACCR_3221;LA13241-7;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., date radiation ended is unknown).;;; +59547-0;LL926-7;NAACCR_3221;LA13323-3;4;Information is not available at this time, but it is expected that it will be available later (e.g., radiation was administered and was ongoing at the time of most recent follow-up).;;; +59547-0;LL926-7;NAACCR_3221;LA13271-4;5;A valid date value is provided in item RX Date-Radiation Ended [3220], or the date was not expected to have been transmitted.;;; +59548-8;LL925-9;NAACCR_3181;LA13354-8;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown whether surgical treatment was performed).;;; +59548-8;LL925-9;NAACCR_3181;LA13370-4;2;"No proper value is applicable in this context (e.g., no surgical treatment of the primary site was performed; autopsy only case).";;; +59548-8;LL925-9;NAACCR_3181;LA13250-8;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., surgical treatment performed but the date of discharge is unknown).;;; +59548-8;LL925-9;NAACCR_3181;LA13272-2;4;A valid date value is provided in item RX Date-Surgical Disch [3180], or the date was not expected to have been transmitted.;;; +59550-4;LL911-9;NAACCR_1241;LA13338-1;1;No information whatsoever can be inferred from this exceptional value (e.g, unknown if immunotherapy administered).;;; +59550-4;LL911-9;NAACCR_1241;LA13362-1;2;"No proper value is applicable in this context (e.g., no immunotherapy administered; autopsy only case).";;; +59550-4;LL911-9;NAACCR_1241;LA13244-1;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., immunotherapy administered but date is unknown).;;; +59550-4;LL911-9;NAACCR_1241;LA13321-7;4;Information is not available at this time, but it is expected that it will be available later (e.g., immune therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).;;; +59551-2;LL909-3;NAACCR_1221;LA13350-6;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown if chemotherapy administered).;;; +59551-2;LL909-3;NAACCR_1221;LA13359-7;2;"No proper value is applicable in this context (e.g., no chemotherapy administered; autopsy only case).";;; +59551-2;LL909-3;NAACCR_1221;LA13239-1;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., chemotherapy administered but date is unknown).;;; +59551-2;LL909-3;NAACCR_1221;LA13319-1;4;Information is not available at this time, but it is expected that it will be available later (e.g., chemotherapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).;;; +59552-0;LL915-0;NAACCR_1281;LA13337-3;1;No information whatsoever can be inferred from this exceptional value (e.g, unknown if any diagnostic or staging procedure performed).;;; +59552-0;LL915-0;NAACCR_1281;LA13360-5;2;"No proper value is applicable in this context (e.g., no diagnostic or staging procedure performed; autopsy only case).";;; +59552-0;LL915-0;NAACCR_1281;LA13242-5;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., diagnostic or staging procedure performed but date is unknown).;;; +59552-0;LL915-0;NAACCR_1281;LA13268-0;4;A valid date value is provided in item RX Date-DX/Stg Proc [1280], or the date was not expected to have been transmitted.;;; +59553-8;LL910-1;NAACCR_1231;LA13345-6;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown if any hormone therapy administered).;;; +59553-8;LL910-1;NAACCR_1231;LA13361-3;2;"No proper value is applicable in this context (e.g., no hormone therapy administered; autopsy only cases).";;; +59553-8;LL910-1;NAACCR_1231;LA13243-3;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., hormone therapy administered but date is unknown).;;; +59553-8;LL910-1;NAACCR_1231;LA13320-9;4;Information is not available at this time, but it is expected that it will be available later (e.g., hormone therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).;;; +59554-6;LL912-7;NAACCR_1251;LA13339-9;1;No information whatsoever can be inferred from this exceptional value (e.g, unknown if other therapy administered).;;; +59554-6;LL912-7;NAACCR_1251;LA13363-9;2;"No proper value is applicable in this context (e.g., no other treatment administered; autopsy only case).";;; +59554-6;LL912-7;NAACCR_1251;LA13245-8;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., other therapy administered but the date is unknown).;;; +59554-6;LL912-7;NAACCR_1251;LA13270-6;4;A valid date value is provided in item RX Date-Other [1250], or the date was not expected to have been transmitted.;;; +59555-3;LL908-5;NAACCR_1211;LA13353-0;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown whether any radiation therapy administered).;;; +59555-3;LL908-5;NAACCR_1211;LA13364-7;2;"No proper value is applicable in this context (e.g., no radiation therapy administered; autopsy only case).";;; +59555-3;LL908-5;NAACCR_1211;LA13247-4;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., radiation therapy administered but date is unknown).;;; +59555-3;LL908-5;NAACCR_1211;LA13322-5;4;Information is not available at this time, but it is expected that it will be available later (e.g., radiation therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).;;; +59556-1;LL907-7;NAACCR_1201;LA13349-8;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown if any surgical procedure of the primary site was performed).;;; +59556-1;LL907-7;NAACCR_1201;LA13368-8;2;"No proper value is applicable in this context (e.g., no surgical procedure was performed; autopsy only case).";;; +59556-1;LL907-7;NAACCR_1201;LA13248-2;3;A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., surgery of the primary site was performed but the date is unknown).;;; +59556-1;LL907-7;NAACCR_1201;LA13254-0;4;A valid date value is provided in item Date Multiple Tumors [445], or the date was not expected to have been transmitted.;;; +59557-9;LL916-8;NAACCR_1285;LA13380-3;1;No treatment given;;; +59557-9;LL916-8;NAACCR_1285;LA13405-8;2;Treatment given;;; +59557-9;LL916-8;NAACCR_1285;LA13277-1;3;Active surveillance (watchful waiting);;; +59557-9;LL916-8;NAACCR_1285;LA13419-9;4;Unknown if treatment was given;;; +59558-7;LL917-6;NAACCR_1661;LA13346-4;1;No information whatsoever can be inferred from this exceptional value (e.g., unknown if any subsequent therapy);;; +59558-7;LL917-6;NAACCR_1661;LA13365-4;2;No proper value is applicable in this context (e.g., no subsequent therapy);;; +59558-7;LL917-6;NAACCR_1661;LA13274-8;3;A valid date value is provided in item Subsq RX 2nd Course Date [1660], or the date was not expected to have been transmitted;;; +59560-3;LL938-2;NAACCR_668;LA13379-5;1;No surgical procedure of primary site at this facility. Diagnosed at autopsy.;;; +59560-3;LL938-2;NAACCR_668;LA13402-5;2;Robotic assisted.;;; +59560-3;LL938-2;NAACCR_668;LA13403-3;3;Robotic converted to open.;;; +59560-3;LL938-2;NAACCR_668;LA13326-6;4;Laparoscopic.;;; +59560-3;LL938-2;NAACCR_668;LA13325-8;5;Laparoscopic converted to open.;;; +59560-3;LL938-2;NAACCR_668;LA13384-5;6;Open. Approach, NOS.;;; +59560-3;LL938-2;NAACCR_668;LA13395-1;7;Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only.;;; +59846-6;LL944-0;Salm sp;LA13479-3;1;Salmonella subspecies I;;; +59846-6;LL944-0;Salm sp;LA13480-1;2;Salmonella enterica subsp. II;;; +59846-6;LL944-0;Salm sp;LA13481-9;3;Salmonella enterica subsp. IIb;;; +59846-6;LL944-0;Salm sp;LA13482-7;4;Salmonella enterica subsp. IV;;; +59846-6;LL944-0;Salm sp;LA13483-5;5;Salmonella enterica subsp. VI;;; +60033-8;LL945-7;PIK3CA gene mut;LA13484-3;1;Negative. No PIK3CA mutation was identified in the provided specimen of this individual.;;; +60033-8;LL945-7;PIK3CA gene mut;LA13485-0;2;Positive. PIK3CA mutation was identified in the provided specimen of this individual.;;; +60033-8;LL945-7;PIK3CA gene mut;LA13486-8;3;See interpretation.;;; +60422-3;LL946-5;MV genotype;LA13487-6;1;A;;; +60422-3;LL946-5;MV genotype;LA13488-4;2;B1;;; +60422-3;LL946-5;MV genotype;LA13489-2;3;B2;;; +60422-3;LL946-5;MV genotype;LA13490-0;4;B3;;; +60422-3;LL946-5;MV genotype;LA13491-8;5;C1;;; +60422-3;LL946-5;MV genotype;LA13492-6;6;C2;;; +60422-3;LL946-5;MV genotype;LA13493-4;7;D1;;; +60422-3;LL946-5;MV genotype;LA13494-2;8;D2;;; +60422-3;LL946-5;MV genotype;LA13495-9;9;D3;;; +60422-3;LL946-5;MV genotype;LA13496-7;10;D4;;; +60422-3;LL946-5;MV genotype;LA13497-5;11;D5;;; +60422-3;LL946-5;MV genotype;LA13498-3;12;D6;;; +60422-3;LL946-5;MV genotype;LA13499-1;13;D7;;; +60422-3;LL946-5;MV genotype;LA13500-6;14;D8;;; +60422-3;LL946-5;MV genotype;LA13501-4;15;D9;;; +60422-3;LL946-5;MV genotype;LA13502-2;16;D10;;; +60422-3;LL946-5;MV genotype;LA13503-0;17;E;;; +60422-3;LL946-5;MV genotype;LA13504-8;18;F;;; +60422-3;LL946-5;MV genotype;LA13505-5;19;G1;;; +60422-3;LL946-5;MV genotype;LA13506-3;20;G2;;; +60422-3;LL946-5;MV genotype;LA13507-1;21;G3;;; +60422-3;LL946-5;MV genotype;LA13508-9;22;H1;;; +60422-3;LL946-5;MV genotype;LA13509-7;23;H2;;; +60423-1;LL947-3;MVstrains;LA13510-5;1;MVi/NewYork.USA/03.98/2 [D2];;; +60423-1;LL947-3;MVstrains;LA13511-3;2;MVs/London.UNK/17.97 [G3] SSPE;;; +60430-6;LL948-1;HEV genotype;LA13512-1;1;Genotype 1;;; +60430-6;LL948-1;HEV genotype;LA13513-9;2;Genotype 2;;; +60430-6;LL948-1;HEV genotype;LA13514-7;3;Genotype 3;;; +60430-6;LL948-1;HEV genotype;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +60476-9;LL952-3;TickStage;LA13527-9;1;Egg;;; +60476-9;LL952-3;TickStage;LA13525-3;2;6-legged larva;;; +60476-9;LL952-3;TickStage;LA13526-1;3;8-legged larva;;; +60476-9;LL952-3;TickStage;LA13524-6;4;Adult;;; +60516-2;LL5319-0;Hormone treatments;LA14596-3;1;Oral Premarin® or conjugated estrogens;;; +60516-2;LL5319-0;Hormone treatments;LA14597-1;2;Patch estrogen;;; +60516-2;LL5319-0;Hormone treatments;LA14598-9;3;Vaginal estrogen;;; +60516-2;LL5319-0;Hormone treatments;LA14599-7;4;Estrace®;;; +60516-2;LL5319-0;Hormone treatments;LA14600-3;5;Estrogen gels, creams, or sprays on skin;;; +60516-2;LL5319-0;Hormone treatments;LA14601-1;6;Estratest®;;; +60516-2;LL5319-0;Hormone treatments;LA14602-9;7;Ogen®;;; +60516-2;LL5319-0;Hormone treatments;LA14603-7;8;Other estrogen;;; +60516-2;LL5319-0;Hormone treatments;LA14604-5;9;Provera®/Cycrin®/MPA;;; +60516-2;LL5319-0;Hormone treatments;LA9459-4;10;Vaginal;;; +60516-2;LL5319-0;Hormone treatments;LA14605-2;11;Micronized (e.g. Prometrium®);;; +60516-2;LL5319-0;Hormone treatments;LA14606-0;12;Other progesterone;;; +60516-2;LL5319-0;Hormone treatments;LA14589-8;13;Prempro® (Beige);;; +60516-2;LL5319-0;Hormone treatments;LA14590-6;14;Prempro® (Gold);;; +60516-2;LL5319-0;Hormone treatments;LA14591-4;15;Prempro® (Peach);;; +60516-2;LL5319-0;Hormone treatments;LA14592-2;16;Prempro® (Light Blue);;; +60516-2;LL5319-0;Hormone treatments;LA14593-0;17;Premphase;;; +60516-2;LL5319-0;Hormone treatments;LA14594-8;18;Combipatch;;; +60516-2;LL5319-0;Hormone treatments;LA14595-5;19;FemHRT;;; +60528-7;LL953-1;EVseq;LA13528-7;1;Human echovirus 1;;; +60528-7;LL953-1;EVseq;LA13529-5;2;Human entervirus 70;;; +60528-7;LL953-1;EVseq;LA13530-3;3;Human coxsachievirus A6;;; +60528-7;LL953-1;EVseq;LA13531-1;4;Untypeable enterovirus;;; +88537-6;LL953-1;EVseq;LA13528-7;1;Human echovirus 1;;; +88537-6;LL953-1;EVseq;LA13529-5;2;Human entervirus 70;;; +88537-6;LL953-1;EVseq;LA13530-3;3;Human coxsachievirus A6;;; +88537-6;LL953-1;EVseq;LA13531-1;4;Untypeable enterovirus;;; +91770-8;LL953-1;EVseq;LA13528-7;1;Human echovirus 1;;; +91770-8;LL953-1;EVseq;LA13529-5;2;Human entervirus 70;;; +91770-8;LL953-1;EVseq;LA13530-3;3;Human coxsachievirus A6;;; +91770-8;LL953-1;EVseq;LA13531-1;4;Untypeable enterovirus;;; +60546-9;LL954-9;PVtype;LA13532-9;1;Poliovirus type 1 (NON SABIN-LIKE);;; +60546-9;LL954-9;PVtype;LA13533-7;2;Poliovirus type 1 (SABIN-LIKE);;; +60546-9;LL954-9;PVtype;LA13535-2;3;Poliovirus type 2 (NON SABIN-LIKE);;; +60546-9;LL954-9;PVtype;LA13534-5;4;Poliovirus type 2 (SABIN-LIKE);;; +60546-9;LL954-9;PVtype;LA13536-0;5;Poliovirus type 3 (NON SABIN-LIKE);;; +60546-9;LL954-9;PVtype;LA13537-8;6;Poliovirus type 3 (SABIN-LIKE);;; +60691-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60691-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60692-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60692-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60693-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60693-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60694-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60694-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60695-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60695-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60696-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60696-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60697-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60697-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60698-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60698-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60699-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60699-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60700-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60700-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60701-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60701-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60702-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60702-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60736-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +60736-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67094-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67094-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76500-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76500-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76500-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76500-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76501-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76501-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76501-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76501-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76502-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76502-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76502-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76502-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76503-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76503-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76503-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76503-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76511-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76511-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77706-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77706-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77707-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77707-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77708-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77708-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77709-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77709-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77711-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77711-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77712-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77712-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77713-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77713-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84458-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84458-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84459-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84459-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84460-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84460-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84461-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84461-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84462-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84462-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84469-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84469-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84470-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84470-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84482-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84482-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84488-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84488-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84489-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84489-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84490-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84490-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84491-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84491-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84492-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84492-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84493-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84493-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84494-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84494-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84495-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84495-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84496-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84496-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84497-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84497-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84498-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84498-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84499-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84499-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84500-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84500-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84501-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84501-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84502-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84502-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84503-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84503-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84504-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84504-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84505-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84505-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84506-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84506-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84507-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84507-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84508-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84508-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84509-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84509-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84510-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84510-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84511-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84511-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84512-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84512-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84513-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84513-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84514-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84514-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84515-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84515-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84516-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84516-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84517-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84517-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84518-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84518-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84519-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84519-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84520-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84520-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84521-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84521-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84522-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84522-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84523-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84523-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84524-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84524-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84525-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84525-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84526-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84526-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84527-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84527-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84528-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84528-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84529-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84529-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84530-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84530-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84531-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84531-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84532-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84532-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84533-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84533-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84534-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84534-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84535-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84535-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84536-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84536-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84537-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84537-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84538-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84538-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84539-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84539-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84540-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84540-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84541-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84541-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84542-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84542-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84543-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84543-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84544-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84544-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84545-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84545-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84546-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84546-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84547-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84547-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84548-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84548-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84549-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84549-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84550-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84550-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84551-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84551-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84552-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84552-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84553-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84553-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84554-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84554-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84555-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84555-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84556-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84556-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84557-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84557-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84558-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84558-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84559-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84559-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84560-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84560-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84561-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84561-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84562-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84562-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84563-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84563-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84564-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84564-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84565-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84565-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84566-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84566-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84567-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84567-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84568-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84568-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84569-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84569-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84570-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84570-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84571-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84571-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84572-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84572-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84573-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84573-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84574-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84574-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84575-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84575-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84576-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84576-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84577-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84577-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84578-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84578-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84579-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84579-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84580-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84580-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84581-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84581-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84582-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84582-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84583-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84583-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84584-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84584-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84585-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84585-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84586-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84586-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84587-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84587-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84588-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84588-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84589-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84589-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84590-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84590-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84591-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84591-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84592-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84592-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84593-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84593-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84594-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84594-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84595-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84595-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84596-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84596-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84597-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84597-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84598-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84598-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84599-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84599-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84600-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84600-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84601-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84601-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84602-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84602-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84603-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84603-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84604-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84604-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84605-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84605-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84606-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84606-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84607-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84607-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84608-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84608-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84609-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84609-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84610-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84610-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84611-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84611-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84612-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84612-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84613-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84613-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84614-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84614-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84615-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84615-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84616-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84616-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84617-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84617-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84618-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84618-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84619-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84619-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84620-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84620-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84621-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84621-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84622-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84622-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84623-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84623-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84624-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84624-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84625-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84625-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84626-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84626-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84627-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84627-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84628-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84628-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84629-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84629-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84630-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84630-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84631-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84631-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84632-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84632-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84633-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84633-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84634-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84634-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84635-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84635-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84636-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84636-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84637-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84637-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84638-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84638-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84639-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84639-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84640-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84640-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84641-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84641-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84642-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84642-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84643-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84643-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84644-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84644-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84645-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84645-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84646-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84646-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84647-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84647-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84648-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84648-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84649-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84649-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84650-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84650-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84651-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84651-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84652-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84652-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84653-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84653-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84654-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84654-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84655-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84655-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84656-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84656-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84657-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84657-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84658-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84658-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84659-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84659-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84660-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84660-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84661-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84661-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84662-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84662-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84663-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84663-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84664-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84664-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84665-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84665-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84666-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84666-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84667-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84667-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84668-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84668-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84669-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84669-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84670-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84670-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84671-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84671-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84672-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84672-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84673-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84673-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84674-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84674-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84675-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84675-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84676-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84676-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84677-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84677-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84678-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84678-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84679-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84679-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84680-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84680-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84681-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84681-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84682-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84682-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84683-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84683-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84684-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84684-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84685-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84685-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84686-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84686-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84687-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84687-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84688-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84688-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84689-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84689-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84690-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84690-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84691-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84691-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84692-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84692-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84693-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84693-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84694-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84694-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84695-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84695-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84696-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84696-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84697-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84697-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84698-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84698-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84699-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84699-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84700-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84700-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84701-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84701-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84702-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84702-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84703-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84703-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84704-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84704-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84705-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84705-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84706-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84706-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84707-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84707-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84708-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84708-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84709-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84709-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84710-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84710-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84711-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84711-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84712-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84712-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84713-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84713-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84714-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84714-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84715-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84715-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84716-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84716-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84717-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84717-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84718-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84718-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84719-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84719-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84720-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84720-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84721-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84721-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84722-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84722-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84723-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84723-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84724-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84724-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84725-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84725-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84726-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84726-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84727-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84727-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84728-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84728-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84729-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84729-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84730-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84730-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84731-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84731-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84732-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84732-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84733-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84733-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84734-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84734-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84735-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84735-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84736-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84736-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84737-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84737-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84738-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84738-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84739-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84739-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84740-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84740-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84741-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84741-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84742-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84742-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84743-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84743-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84744-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84744-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84745-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84745-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84746-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84746-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84747-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84747-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84748-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84748-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84749-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84749-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84750-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84750-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84751-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84751-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84752-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84752-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84753-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84753-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84754-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84754-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84755-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84755-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84756-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84756-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84757-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84757-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84758-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84758-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84759-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84759-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84760-8;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84760-8;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84761-6;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84761-6;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84762-4;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84762-4;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84763-2;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84763-2;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84764-0;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84764-0;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84765-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84765-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84766-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84766-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84767-3;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84767-3;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84768-1;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84768-1;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84769-9;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84769-9;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84770-7;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84770-7;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +84771-5;LL963-0;Y1/N0;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +84771-5;LL963-0;Y1/N0;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +60704-4;LL961-4;TIMP_1_Head rotation;LA13785-3;1;No response or unable to achieve state 4 during testing.;;; +60704-4;LL961-4;TIMP_1_Head rotation;LA13816-6;2;Visually attends to examiner in midline without turning or turns head 15 degrees or less.;;; +60704-4;LL961-4;TIMP_1_Head rotation;LA13700-2;3;Attends and turns head at least 15 degrees to each side from midline.;;; +60704-4;LL961-4;TIMP_1_Head rotation;LA13701-0;4;Attends and turns head at least 45 degrees to each side, crossing midline for a total of at least 90 degrees.;;; +60704-4;LL961-4;TIMP_1_Head rotation;LA13817-4;5;Visually fixates while holding head upright independently and turns head at least 45 degrees to each side, crossing midline while following for a total of at least 90 degrees. If less than 90 degrees total, give a score of 3.;;; +60705-1;LL962-2;TIMP_2_Head control;LA13788-7;1;No response, head hangs.;;; +60705-1;LL962-2;TIMP_2_Head control;LA13699-6;2;Attempts to lift head twice within 15 seconds.;;; +60705-1;LL962-2;TIMP_2_Head control;LA13697-0;3;Attains upright head position at least once but sustains for less than 15 seconds.;;; +60705-1;LL962-2;TIMP_2_Head control;LA13767-1;4;Maintains head in midline with the head tipped in up to but no more than 30 degrees of forward flexion for at least 15 seconds.;;; +60705-1;LL962-2;TIMP_2_Head control;LA13770-5;5;Maintains head upright in midline for 15 to 30 seconds.;;; +60705-1;LL962-2;TIMP_2_Head control;LA13769-7;6;Maintains head upright for greater than 30 seconds, moving the head freely with control.;;; +60706-9;LL964-8;TIMP_3_Head control, post neck muscles;LA13775-4;1;Makes no attempt to raise head.;;; +60706-9;LL964-8;TIMP_3_Head control, post neck muscles;LA13756-4;2;Lifts head less than 45 degrees.;;; +60706-9;LL964-8;TIMP_3_Head control, post neck muscles;LA13752-3;3;Lifts head 45 degrees or more, but does not achieve full upright position.;;; +60706-9;LL964-8;TIMP_3_Head control, post neck muscles;LA13759-8;4;Lifts head to upright and sustains for 5 to 15 seconds.;;; +60706-9;LL964-8;TIMP_3_Head control, post neck muscles;LA13761-4;5;Lifts head to upright position and sustains for more than 15 seconds.;;; +60706-9;LL964-8;TIMP_3_Head control, post neck muscles;LA13744-0;6;Holds head upright independently when positioned and maintains position for greater than 30 seconds, moving the head freely with control.;;; +60707-7;LL965-5;TIMP_4_Head control, ant neck muscles;LA13774-7;1;Makes no attempt to raise head or lifts less than 45 degrees.;;; +60707-7;LL965-5;TIMP_4_Head control, ant neck muscles;LA13751-5;2;Lifts head 45 degrees or more, but does not achieve full upright position, OR lifts head passing through upright into forward flexion.;;; +60707-7;LL965-5;TIMP_4_Head control, ant neck muscles;LA13762-2;3;"Lifts head to upright position; sustains the position for at least 1 but less than 5 seconds.";;; +60707-7;LL965-5;TIMP_4_Head control, ant neck muscles;LA13759-8;4;Lifts head to upright and sustains for 5 to 15 seconds.;;; +60707-7;LL965-5;TIMP_4_Head control, ant neck muscles;LA13743-2;5;"Holds head independently with control when positioned; maintains for more than 15 seconds.";;; +60708-5;LL966-3;TIMP_5_Head control, lowered from sitting;LA13815-8;1;Unable to hold head vertically.;;; +60708-5;LL966-3;TIMP_5_Head control, lowered from sitting;LA13768-9;2;Maintains head in vertical position while upright but immediately loses control when movement begins.;;; +60708-5;LL966-3;TIMP_5_Head control, lowered from sitting;LA13772-1;3;Maintains head vertically while upright and maintains control for less than 15 degrees of backward movement.;;; +60708-5;LL966-3;TIMP_5_Head control, lowered from sitting;LA13771-3;4;Maintains head vertically while upright and maintains control for 15-45 degrees of backward movement, head in midline.;;; +60708-5;LL966-3;TIMP_5_Head control, lowered from sitting;LA13773-9;5;Maintains head vertically while upright and maintains control for more than 45 degrees of backward movement with chin tucked and head in midline.;;; +60709-3;LL967-1;TIMP_6_Inhibition of neck righting;LA13787-9;1;No response, body limp and inactive.;;; +60709-3;LL967-1;TIMP_6_Inhibition of neck righting;LA13763-0;2;Lifts only shoulder and scapula off the support surface.;;; +60709-3;LL967-1;TIMP_6_Inhibition of neck righting;LA13764-8;3;Lifts shoulder, scapula and pelvis off support, but does not roll onto side.;;; +60709-3;LL967-1;TIMP_6_Inhibition of neck righting;LA13804-2;4;Rolls onto side without rotation of the trunk.;;; +60709-3;LL967-1;TIMP_6_Inhibition of neck righting;LA13806-7;5;Rolls partially or completely to side but then returns trunk to supine actively while head is being held.;;; +60709-3;LL967-1;TIMP_6_Inhibition of neck righting;LA13777-0;6;May lift shoulder and/or pelvis briefly off support surface but then uses arms and/or legs to actively resist rolling.;;; +60710-1;LL967-1;TIMP_6_Inhibition of neck righting;LA13787-9;1;No response, body limp and inactive.;;; +60710-1;LL967-1;TIMP_6_Inhibition of neck righting;LA13763-0;2;Lifts only shoulder and scapula off the support surface.;;; +60710-1;LL967-1;TIMP_6_Inhibition of neck righting;LA13764-8;3;Lifts shoulder, scapula and pelvis off support, but does not roll onto side.;;; +60710-1;LL967-1;TIMP_6_Inhibition of neck righting;LA13804-2;4;Rolls onto side without rotation of the trunk.;;; +60710-1;LL967-1;TIMP_6_Inhibition of neck righting;LA13806-7;5;Rolls partially or completely to side but then returns trunk to supine actively while head is being held.;;; +60710-1;LL967-1;TIMP_6_Inhibition of neck righting;LA13777-0;6;May lift shoulder and/or pelvis briefly off support surface but then uses arms and/or legs to actively resist rolling.;;; +60711-9;LL968-9;TIMP_7_Head midline WO vis stim;LA13714-3;1;Head falls immediately to side, with chin resting on shoulder.;;; +60711-9;LL968-9;TIMP_7_Head midline WO vis stim;LA13716-8;2;Head falls to shoulder, but attempts to lift chin from shoulder are observed.;;; +60711-9;LL968-9;TIMP_7_Head midline WO vis stim;LA13726-7;3;Head moves out of midline but attempts to regain midline.;;; +60711-9;LL968-9;TIMP_7_Head midline WO vis stim;LA13765-5;4;Maintains head in midline for 5 to 15 seconds.;;; +60711-9;LL968-9;TIMP_7_Head midline WO vis stim;LA13766-3;5;Maintains head in midline for more than 15 seconds with or without hands being held.;;; +60712-7;LL969-7;TIMP_8_Head midlin W vis stim;LA13714-3;1;Head falls immediately to side, with chin resting on shoulder.;;; +60712-7;LL969-7;TIMP_8_Head midlin W vis stim;LA13726-7;2;Head moves out of midline but attempts to regain midline.;;; +60712-7;LL969-7;TIMP_8_Head midlin W vis stim;LA13729-1;3;Head remains in midline for up to 15 seconds.;;; +60712-7;LL969-7;TIMP_8_Head midlin W vis stim;LA13728-3;4;Head remains in midline for more than 15 seconds.;;; +60712-7;LL969-7;TIMP_8_Head midlin W vis stim;LA13707-7;5;Child is able to maintain head in midline for more than 15 seconds without hands being held.;;; +60713-5;LL970-5;TIMP_9_Supine neck rotation;LA13785-3;1;No response or unable to achieve state 4 during testing.;;; +60713-5;LL970-5;TIMP_9_Supine neck rotation;LA13742-4;2;Head turns toward the right less than 15 degrees.;;; +60713-5;LL970-5;TIMP_9_Supine neck rotation;LA13739-0;3;Head turns toward the right for 16 to 45 degrees.;;; +60713-5;LL970-5;TIMP_9_Supine neck rotation;LA13740-8;4;Head turns toward the right for 46 to 90 degrees.;;; +60713-5;LL970-5;TIMP_9_Supine neck rotation;LA13741-6;5;Head turns toward the right for 91 to 180 degrees.;;; +60714-3;LL971-3;TIMP_10_Neck rotation;LA13785-3;1;No response or unable to achieve state 4 during testing.;;; +60714-3;LL971-3;TIMP_10_Neck rotation;LA13738-2;2;Head turns toward the left less than 15 degrees.;;; +60714-3;LL971-3;TIMP_10_Neck rotation;LA13735-8;3;Head turns toward the left for 16 to 45 degrees.;;; +60714-3;LL971-3;TIMP_10_Neck rotation;LA13736-6;4;Head turns toward the left for 46 to 90 degrees.;;; +60714-3;LL971-3;TIMP_10_Neck rotation;LA13737-4;5;Head turns toward the left for 91 to 180 degrees.;;; +60715-0;LL972-1;TIMP_11_Defence head;LA13786-1;1;No response within 30 seconds.;;; +60715-0;LL972-1;TIMP_11_Defence head;LA13779-6;2;Neck stretch and head turn to the side in 15 to 29 seconds.;;; +60715-0;LL972-1;TIMP_11_Defence head;LA13780-4;3;Neck stretch and head turn to the side in 5-14 seconds.;;; +60715-0;LL972-1;TIMP_11_Defence head;LA13781-2;4;Neck stretch and head turn to the side in less than 5 seconds.;;; +60716-8;LL973-9;TIMP_12_Defence arm;LA13810-9;1;Scoring: Score based on movement of either or both arms.;;; +60716-8;LL973-9;TIMP_12_Defence arm;LA13696-2;2;Arm movement directed toward the head with head turned to one side.;;; +60716-8;LL973-9;TIMP_12_Defence arm;LA13695-4;3;Arm movement directed toward midline of face or body, head in the midline.;;; +60716-8;LL973-9;TIMP_12_Defence arm;LA13694-7;4;Arm and hand movements that grasp cloth, head in the midline.;;; +60716-8;LL973-9;TIMP_12_Defence arm;LA13693-9;5;Arm and hand movements that grasp cloth and uncover partially at least one eye, head in the midline.;;; +60717-6;LL974-7;TIMP_13_Hip-knee flexion;LA13706-9;1;Both thighs, knees and feet fall immediately to support surface.;;; +60717-6;LL974-7;TIMP_13_Hip-knee flexion;LA13704-4;2;Both feet fall to support surface, but thighs and knees remain off the surface.;;; +60717-6;LL974-7;TIMP_13_Hip-knee flexion;LA13794-5;3;One foot falls to the support surface, but knee remains off the support surface. The other foot and leg remain off the support surface.;;; +60717-6;LL974-7;TIMP_13_Hip-knee flexion;LA13703-6;4;Both feet and legs remain off the support surface for at least 5 seconds making kicking movements and occasionally touching the support surface. If both knees remain extended in the air, score 2.;;; +60717-6;LL974-7;TIMP_13_Hip-knee flexion;LA13705-1;5;Both feet return to support surface, followed by heel pounding by lifting and lowering one or both legs with knee extended OR bridging against the surface by pushing with heels and lifting bottom.;;; +60718-4;LL975-4;TIMP_14_Rolling-legs;LA13799-4;1;Pelvis lifted passively off support surface.;;; +60718-4;LL975-4;TIMP_14_Rolling-legs;LA13798-6;2;Pelvis and trunk lift from support surface and head turns to side. Arm remains behind trunk.;;; +60718-4;LL975-4;TIMP_14_Rolling-legs;LA13800-0;3;Pelvis, trunk and arm lift from support surface, and head turns to side. Rolls part way but not onto side.;;; +60718-4;LL975-4;TIMP_14_Rolling-legs;LA13801-8;4;Pelvis, trunk and arm lift from support surface, head turns and rolls onto side.;;; +60718-4;LL975-4;TIMP_14_Rolling-legs;LA13807-5;5;Rolls through sidelying into prone without lateral head righting.;;; +60718-4;LL975-4;TIMP_14_Rolling-legs;LA13818-2;6;When traction is applied at the end of the maneuver, rolls to prone with lateral head righting.;;; +60719-2;LL975-4;TIMP_14_Rolling-legs;LA13799-4;1;Pelvis lifted passively off support surface.;;; +60719-2;LL975-4;TIMP_14_Rolling-legs;LA13798-6;2;Pelvis and trunk lift from support surface and head turns to side. Arm remains behind trunk.;;; +60719-2;LL975-4;TIMP_14_Rolling-legs;LA13800-0;3;Pelvis, trunk and arm lift from support surface, and head turns to side. Rolls part way but not onto side.;;; +60719-2;LL975-4;TIMP_14_Rolling-legs;LA13801-8;4;Pelvis, trunk and arm lift from support surface, head turns and rolls onto side.;;; +60719-2;LL975-4;TIMP_14_Rolling-legs;LA13807-5;5;Rolls through sidelying into prone without lateral head righting.;;; +60719-2;LL975-4;TIMP_14_Rolling-legs;LA13818-2;6;When traction is applied at the end of the maneuver, rolls to prone with lateral head righting.;;; +60720-0;LL976-2;TIMP_15_Rolling-arms;LA13734-1;1;"Head turns to side; body remains limp or shoulder lifts slightly from support surface.";;; +60720-0;LL976-2;TIMP_15_Rolling-arms;LA13732-5;2;Head turns to side and shoulder and trunk lift from support surface.;;; +60720-0;LL976-2;TIMP_15_Rolling-arms;LA13733-3;3;Head turns to side and shoulder, trunk and pelvis lift from support surface. Rolls part way but not onto side.;;; +60720-0;LL976-2;TIMP_15_Rolling-arms;LA13805-9;4;Rolls onto side.;;; +60720-0;LL976-2;TIMP_15_Rolling-arms;LA13809-1;5;Rolls with active pelvic rotation through sidelying into prone without lateral head righting.;;; +60720-0;LL976-2;TIMP_15_Rolling-arms;LA13808-3;6;Rolls to prone with lateral head righting.;;; +60721-8;LL976-2;TIMP_15_Rolling-arms;LA13734-1;1;"Head turns to side; body remains limp or shoulder lifts slightly from support surface.";;; +60721-8;LL976-2;TIMP_15_Rolling-arms;LA13732-5;2;Head turns to side and shoulder and trunk lift from support surface.;;; +60721-8;LL976-2;TIMP_15_Rolling-arms;LA13733-3;3;Head turns to side and shoulder, trunk and pelvis lift from support surface. Rolls part way but not onto side.;;; +60721-8;LL976-2;TIMP_15_Rolling-arms;LA13805-9;4;Rolls onto side.;;; +60721-8;LL976-2;TIMP_15_Rolling-arms;LA13809-1;5;Rolls with active pelvic rotation through sidelying into prone without lateral head righting.;;; +60721-8;LL976-2;TIMP_15_Rolling-arms;LA13808-3;6;Rolls to prone with lateral head righting.;;; +60722-6;LL977-0;TIMP_16_Pull to sit;LA13783-8;1;No attempt to assist with head or arms during maneuver, head lags behind trunk.;;; +60722-6;LL977-0;TIMP_16_Pull to sit;LA13814-1;2;"Tension in arms with or without shoulder shrugging during maneuver; head lags behind trunk.";;; +60722-6;LL977-0;TIMP_16_Pull to sit;LA13811-7;3;Slight elbow flexion (with or without shoulder shrugging) and attempts to lift head during maneuver.;;; +60722-6;LL977-0;TIMP_16_Pull to sit;LA13708-5;4;"Elbow flexion with or without shoulder shrugging; head in line with trunk during the last 15 degrees of the maneuver.";;; +60722-6;LL977-0;TIMP_16_Pull to sit;LA13719-2;5;Head in line with trunk during the last 30 degrees of the maneuver.;;; +60722-6;LL977-0;TIMP_16_Pull to sit;LA13720-0;6;Head in midline and in line with trunk during last 45 degrees of the maneuver.;;; +60723-4;LL978-8;TIMP_17_Lateral straightening;LA13776-2;1;Makes no attempt to right head or abduct shoulder for weight bearing.;;; +60723-4;LL978-8;TIMP_17_Lateral straightening;LA13746-5;2;Initiates head righting, raises shoulder off the support surface briefly (less than 5 seconds), but does not achieve weight bearing on forearm.;;; +60723-4;LL978-8;TIMP_17_Lateral straightening;LA13686-3;3;Abducts shoulder for weight bearing and bears weight on forearm with elbow flexed more than 90 degrees.;;; +60723-4;LL978-8;TIMP_17_Lateral straightening;LA13688-9;4;Abducts shoulder for weight bearing, places hand and obtains weight bearing on forearm with 90 degree angle at the elbow.;;; +60723-4;LL978-8;TIMP_17_Lateral straightening;LA13687-1;5;Abducts shoulder for weight bearing, places hand and obtains greater than 90 degrees extension of the elbow while weight bearing on the hand.;;; +60724-2;LL979-6;TIMP_18_Hip abduction;LA13784-6;1;No head, trunk, or leg response.;;; +60724-2;LL979-6;TIMP_18_Hip abduction;LA13692-1;2;Active contraction of the lateral muscles of the neck.;;; +60724-2;LL979-6;TIMP_18_Hip abduction;LA13691-3;3;Active contraction of the lateral muscles of the neck and trunk.;;; +60724-2;LL979-6;TIMP_18_Hip abduction;LA13690-5;4;Active contraction of the lateral muscles of the neck and trunk with brief unsustained abduction of the uppermost lower extremity with dorsiflexion of the foot.;;; +60724-2;LL979-6;TIMP_18_Hip abduction;LA13689-7;5;Active contraction of the lateral muscles of the neck and trunk with abduction of the uppermost lower extremity and dorsiflexion of the foot sustained for at least 1-2 seconds.;;; +60725-9;LL980-4;TIMP_19_Prone suspension;LA13803-4;1;Remains flexed over examiner's hands. Little or no muscle activity noted in neck and trunk.;;; +60725-9;LL980-4;TIMP_19_Prone suspension;LA13812-5;2;Slight head lifting and tension in trunk muscles.;;; +60725-9;LL980-4;TIMP_19_Prone suspension;LA13778-8;3;"Neck extension, head aligns with trunk; cervical and upper thoracic muscle activity.";;; +60725-9;LL980-4;TIMP_19_Prone suspension;LA13711-9;4;"Head above line of trunk; muscle activity to thoraco-lumbar junction.";;; +60725-9;LL980-4;TIMP_19_Prone suspension;LA13710-1;5;"Head above line of trunk; muscle activity to lumbo-sacral area.";;; +60726-7;LL981-2;TIMP_20_Head lift;LA13717-6;1;"Head falls to side; no attempts to lift head.";;; +60726-7;LL981-2;TIMP_20_Head lift;LA13698-8;2;Attempts to lift head (muscle contraction observed) before it falls or is actively turned to one side.;;; +60726-7;LL981-2;TIMP_20_Head lift;LA13758-0;3;Lifts head off support surface so that chin just clears surface and turns to one side.;;; +60726-7;LL981-2;TIMP_20_Head lift;LA13757-2;4;Lifts head off support surface completely for more than 2 and less than 30 seconds (any position).;;; +60726-7;LL981-2;TIMP_20_Head lift;LA13754-9;5;Lifts head in midline to 45 degrees for up to 30 seconds.;;; +60726-7;LL981-2;TIMP_20_Head lift;LA13755-6;6;Lifts head in midline to greater than 45 degrees for more than 30 seconds.;;; +60727-5;LL982-0;TIMP_21_Crawling;LA13718-4;1;"Head falls to side; no response in legs.";;; +60727-5;LL982-0;TIMP_21_Crawling;LA13715-0;2;"Head falls or is turned to side; legs extend and/or one or both legs complete one flexion/extension cycle or one leg cycles twice.";;; +60727-5;LL982-0;TIMP_21_Crawling;LA13723-4;3;"Head is turned to side; legs cycle reciprocally 2 times or one leg cycles 3 times. If head moves only or legs cycle only, score a 1.";;; +60727-5;LL982-0;TIMP_21_Crawling;LA13724-2;4;"Head lifts from surface or lifts and turns to one side; legs cycle reciprocally 3 or more times. If head moves only or legs cycle only, score a 2.";;; +60727-5;LL982-0;TIMP_21_Crawling;LA13725-9;5;"Head lifts in midline to at least 45 degrees; legs cycle reciprocally 3 or more times or flex and extend together at least once before maintaining an extended position with hip abduction. If head lifts only or legs move only score 3.";;; +60728-3;LL983-8;TIMP_22_Head turn to sound;LA10996-9;1;No response;;; +60728-3;LL983-8;TIMP_22_Head turn to sound;LA13802-6;2;Quieting and/or brightening with no movement OR movements of extremities or trunk with no attempt to lift or turn head.;;; +60728-3;LL983-8;TIMP_22_Head turn to sound;LA13745-7;3;Initiates head lift or turn but does not turn head completely to midline.;;; +60728-3;LL983-8;TIMP_22_Head turn to sound;LA13749-9;4;Lifts and turns head, but only to midline.;;; +60728-3;LL983-8;TIMP_22_Head turn to sound;LA13748-1;5;Lifts and turns head to opposite side.;;; +60728-3;LL983-8;TIMP_22_Head turn to sound;LA13753-1;6;Lifts head 45 to 90 degrees and attempts to localize sound with eyes but cannot turn head.;;; +60728-3;LL983-8;TIMP_22_Head turn to sound;LA13750-7;7;Lifts and turns head, maintaining head in upright to turn 45 degrees toward the source of sound.;;; +60729-1;LL983-8;TIMP_22_Head turn to sound;LA10996-9;1;No response;;; +60729-1;LL983-8;TIMP_22_Head turn to sound;LA13802-6;2;Quieting and/or brightening with no movement OR movements of extremities or trunk with no attempt to lift or turn head.;;; +60729-1;LL983-8;TIMP_22_Head turn to sound;LA13745-7;3;Initiates head lift or turn but does not turn head completely to midline.;;; +60729-1;LL983-8;TIMP_22_Head turn to sound;LA13749-9;4;Lifts and turns head, but only to midline.;;; +60729-1;LL983-8;TIMP_22_Head turn to sound;LA13748-1;5;Lifts and turns head to opposite side.;;; +60729-1;LL983-8;TIMP_22_Head turn to sound;LA13753-1;6;Lifts head 45 to 90 degrees and attempts to localize sound with eyes but cannot turn head.;;; +60729-1;LL983-8;TIMP_22_Head turn to sound;LA13750-7;7;Lifts and turns head, maintaining head in upright to turn 45 degrees toward the source of sound.;;; +60730-9;LL984-6;TIMP_23_Standing;LA13791-1;1;"No upright head control; head and trunk forward-flexed. Unable to bear weight through legs.";;; +60730-9;LL984-6;TIMP_23_Standing;LA13797-8;2;Partial or full weight bearing for less than 5 seconds regardless of head and trunk alignment.;;; +60730-9;LL984-6;TIMP_23_Standing;LA13713-5;3;"Head and trunk upright; partial or full weight bearing for less than 5 seconds.";;; +60730-9;LL984-6;TIMP_23_Standing;LA13712-7;4;"Head and trunk upright; full weight bearing with feet flat for more than 5 seconds. May bounce, weight shift,or take steps.";;; +60730-9;LL984-6;TIMP_23_Standing;LA13709-3;5;Has enough head and trunk control to be held at the wrists only. Full weight bearing with feet flat for more than 5 seconds. May bounce, weight shift, or take steps.;;; +60731-7;LL985-3;TIMP_24_Head righting;LA13790-3;1;"No response; head hangs laterally or in flexion.";;; +60731-7;LL985-3;TIMP_24_Head righting;LA13722-6;2;Head is maintained partially upright by tension in lateral neck muscles with face down or facing forward.;;; +60731-7;LL985-3;TIMP_24_Head righting;LA13721-8;3;Head is maintained partially upright by tension in lateral neck muscles and face turns up.;;; +60731-7;LL985-3;TIMP_24_Head righting;LA13730-9;4;Head remains upright initially with face forward but then falls part way to the side.;;; +60731-7;LL985-3;TIMP_24_Head righting;LA13731-7;5;Head remains upright with face forward throughout tilt.;;; +60732-5;LL985-3;TIMP_24_Head righting;LA13790-3;1;"No response; head hangs laterally or in flexion.";;; +60732-5;LL985-3;TIMP_24_Head righting;LA13722-6;2;Head is maintained partially upright by tension in lateral neck muscles with face down or facing forward.;;; +60732-5;LL985-3;TIMP_24_Head righting;LA13721-8;3;Head is maintained partially upright by tension in lateral neck muscles and face turns up.;;; +60732-5;LL985-3;TIMP_24_Head righting;LA13730-9;4;Head remains upright initially with face forward but then falls part way to the side.;;; +60732-5;LL985-3;TIMP_24_Head righting;LA13731-7;5;Head remains upright with face forward throughout tilt.;;; +61112-9;LL959-8;HTLVtype;LA13550-1;1;HTLV-1;;; +61112-9;LL959-8;HTLVtype;LA13551-9;2;HTLV-2;;; +93743-3;LL959-8;HTLVtype;LA13550-1;1;HTLV-1;;; +93743-3;LL959-8;HTLVtype;LA13551-9;2;HTLV-2;;; +61133-5;LL986-1;TIMP_26_Clinical impression;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +61133-5;LL986-1;TIMP_26_Clinical impression;LA13813-3;2;Suspicious;;; +61133-5;LL986-1;TIMP_26_Clinical impression;LA13702-8;3;Atypical;;; +61134-3;LL987-9;TIMP_27_Environment;LA13747-3;1;Isolette;;; +61134-3;LL987-9;TIMP_27_Environment;LA13795-2;2;Open Crib;;; +61134-3;LL987-9;TIMP_27_Environment;LA13793-7;3;O sub 2;;; +61134-3;LL987-9;TIMP_27_Environment;LA46-8;4;Other;;; +61154-1;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61154-1;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61154-1;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61155-8;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61155-8;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61155-8;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61156-6;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61156-6;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61156-6;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61157-4;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61157-4;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61157-4;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61158-2;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61158-2;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61158-2;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61159-0;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61159-0;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61159-0;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61160-8;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61160-8;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61160-8;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61161-6;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61161-6;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61161-6;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61162-4;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61162-4;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61162-4;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61163-2;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61163-2;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61163-2;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61164-0;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61164-0;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61164-0;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61165-7;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61165-7;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61165-7;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61166-5;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61166-5;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61166-5;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61167-3;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61167-3;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61167-3;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61168-1;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61168-1;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61168-1;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61169-9;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61169-9;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61169-9;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61170-7;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61170-7;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61170-7;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61171-5;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61171-5;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61171-5;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61172-3;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61172-3;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61172-3;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61173-1;LL2410-0;Absent|Present|Mixed;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +61173-1;LL2410-0;Absent|Present|Mixed;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +61173-1;LL2410-0;Absent|Present|Mixed;LA11840-8;3;Mixed;;; +61199-6;LL2323-5;HIV1 Integrase;LA19405-2;1;N155S;;; +61199-6;LL2323-5;HIV1 Integrase;LA19406-0;2;F121Y;;; +61432-1;LL989-5;PhenX05_02_age other than breastfed;LA6270-8;1;Never;;; +61432-1;LL989-5;PhenX05_02_age other than breastfed;LA4389-8;2;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61432-1;LL989-5;PhenX05_02_age other than breastfed;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61433-9;LL991-1;PhenX05_04-age stopped breastfeeding;LA13911-5;1;Still breastfeeding;;; +61433-9;LL991-1;PhenX05_04-age stopped breastfeeding;LA4389-8;2;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61433-9;LL991-1;PhenX05_04-age stopped breastfeeding;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61437-0;LL992-9;PhenX05_05_food freq;LA13894-3;1;Never or less than 1 time per month;;; +61437-0;LL992-9;PhenX05_05_food freq;LA13828-1;2;1 time per month;;; +61437-0;LL992-9;PhenX05_05_food freq;LA13845-5;3;2-3 times per month;;; +61437-0;LL992-9;PhenX05_05_food freq;LA13834-9;4;1-2 times per week;;; +61437-0;LL992-9;PhenX05_05_food freq;LA13853-9;5;3-4 times per week;;; +61437-0;LL992-9;PhenX05_05_food freq;LA13860-4;6;5-6 times per week;;; +61437-0;LL992-9;PhenX05_05_food freq;LA13827-3;7;1 time per day;;; +61437-0;LL992-9;PhenX05_05_food freq;LA13837-2;8;2 or more times per day;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13894-3;1;Never or less than 1 time per month;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13828-1;2;1 time per month;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13845-5;3;2-3 times per month;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13834-9;4;1-2 times per week;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13853-9;5;3-4 times per week;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13860-4;6;5-6 times per week;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13827-3;7;1 time per day;;; +61439-6;LL992-9;PhenX05_05_food freq;LA13837-2;8;2 or more times per day;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13894-3;1;Never or less than 1 time per month;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13828-1;2;1 time per month;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13845-5;3;2-3 times per month;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13834-9;4;1-2 times per week;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13853-9;5;3-4 times per week;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13860-4;6;5-6 times per week;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13827-3;7;1 time per day;;; +61453-7;LL992-9;PhenX05_05_food freq;LA13837-2;8;2 or more times per day;;; +61438-8;LL1000-0;PhenX05_13_30D bread amt;LA13825-7;1;1 slice or 1 dinner roll;;; +61438-8;LL1000-0;PhenX05_13_30D bread amt;LA13838-0;2;2 slices or 2 dinner rolls;;; +61438-8;LL1000-0;PhenX05_13_30D bread amt;LA13892-7;3;More than 2 slices or 2 dinner rolls;;; +61441-2;LL996-0;PhenX05_09_30D food freq;LA13894-3;1;Never or less than 1 time per month;;; +61441-2;LL996-0;PhenX05_09_30D food freq;LA13828-1;2;1 time per month;;; +61441-2;LL996-0;PhenX05_09_30D food freq;LA13845-5;3;2-3 times per month;;; +61441-2;LL996-0;PhenX05_09_30D food freq;LA13834-9;4;1-2 times per week;;; +61441-2;LL996-0;PhenX05_09_30D food freq;LA13853-9;5;3-4 times per week;;; +61441-2;LL996-0;PhenX05_09_30D food freq;LA13860-4;6;5-6 times per week;;; +61441-2;LL996-0;PhenX05_09_30D food freq;LA13928-9;7;1 or more times per day;;; +61443-8;LL996-0;PhenX05_09_30D food freq;LA13894-3;1;Never or less than 1 time per month;;; +61443-8;LL996-0;PhenX05_09_30D food freq;LA13828-1;2;1 time per month;;; +61443-8;LL996-0;PhenX05_09_30D food freq;LA13845-5;3;2-3 times per month;;; +61443-8;LL996-0;PhenX05_09_30D food freq;LA13834-9;4;1-2 times per week;;; +61443-8;LL996-0;PhenX05_09_30D food freq;LA13853-9;5;3-4 times per week;;; +61443-8;LL996-0;PhenX05_09_30D food freq;LA13860-4;6;5-6 times per week;;; +61443-8;LL996-0;PhenX05_09_30D food freq;LA13928-9;7;1 or more times per day;;; +61445-3;LL996-0;PhenX05_09_30D food freq;LA13894-3;1;Never or less than 1 time per month;;; +61445-3;LL996-0;PhenX05_09_30D food freq;LA13828-1;2;1 time per month;;; +61445-3;LL996-0;PhenX05_09_30D food freq;LA13845-5;3;2-3 times per month;;; +61445-3;LL996-0;PhenX05_09_30D food freq;LA13834-9;4;1-2 times per week;;; +61445-3;LL996-0;PhenX05_09_30D food freq;LA13853-9;5;3-4 times per week;;; +61445-3;LL996-0;PhenX05_09_30D food freq;LA13860-4;6;5-6 times per week;;; +61445-3;LL996-0;PhenX05_09_30D food freq;LA13928-9;7;1 or more times per day;;; +61447-9;LL996-0;PhenX05_09_30D food freq;LA13894-3;1;Never or less than 1 time per month;;; +61447-9;LL996-0;PhenX05_09_30D food freq;LA13828-1;2;1 time per month;;; +61447-9;LL996-0;PhenX05_09_30D food freq;LA13845-5;3;2-3 times per month;;; +61447-9;LL996-0;PhenX05_09_30D food freq;LA13834-9;4;1-2 times per week;;; +61447-9;LL996-0;PhenX05_09_30D food freq;LA13853-9;5;3-4 times per week;;; +61447-9;LL996-0;PhenX05_09_30D food freq;LA13860-4;6;5-6 times per week;;; +61447-9;LL996-0;PhenX05_09_30D food freq;LA13928-9;7;1 or more times per day;;; +61455-2;LL996-0;PhenX05_09_30D food freq;LA13894-3;1;Never or less than 1 time per month;;; +61455-2;LL996-0;PhenX05_09_30D food freq;LA13828-1;2;1 time per month;;; +61455-2;LL996-0;PhenX05_09_30D food freq;LA13845-5;3;2-3 times per month;;; +61455-2;LL996-0;PhenX05_09_30D food freq;LA13834-9;4;1-2 times per week;;; +61455-2;LL996-0;PhenX05_09_30D food freq;LA13853-9;5;3-4 times per week;;; +61455-2;LL996-0;PhenX05_09_30D food freq;LA13860-4;6;5-6 times per week;;; +61455-2;LL996-0;PhenX05_09_30D food freq;LA13928-9;7;1 or more times per day;;; +61457-8;LL996-0;PhenX05_09_30D food freq;LA13894-3;1;Never or less than 1 time per month;;; +61457-8;LL996-0;PhenX05_09_30D food freq;LA13828-1;2;1 time per month;;; +61457-8;LL996-0;PhenX05_09_30D food freq;LA13845-5;3;2-3 times per month;;; +61457-8;LL996-0;PhenX05_09_30D food freq;LA13834-9;4;1-2 times per week;;; +61457-8;LL996-0;PhenX05_09_30D food freq;LA13853-9;5;3-4 times per week;;; +61457-8;LL996-0;PhenX05_09_30D food freq;LA13860-4;6;5-6 times per week;;; +61457-8;LL996-0;PhenX05_09_30D food freq;LA13928-9;7;1 or more times per day;;; +61442-0;LL999-4;PhenX05_12_30D cheese amt;LA13882-8;1;Less than 1 slice;;; +61442-0;LL999-4;PhenX05_12_30D cheese amt;LA13824-0;2;1 slice;;; +61442-0;LL999-4;PhenX05_12_30D cheese amt;LA13888-5;3;More than 1 slice;;; +61444-6;LL1029-9;PhenX05_27_30D ice cream amt;LA13923-0;1;Less than 1 cup;;; +61444-6;LL1029-9;PhenX05_27_30D ice cream amt;LA13932-1;2;1 cup (2 scoops);;; +61444-6;LL1029-9;PhenX05_27_30D ice cream amt;LA13925-5;3;More than 1 cup;;; +61446-1;LL993-7;PhenX05_06_food amt;LA13923-0;1;Less than 1 cup;;; +61446-1;LL993-7;PhenX05_06_food amt;LA13924-8;2;1 cup (8 ounces);;; +61446-1;LL993-7;PhenX05_06_food amt;LA13925-5;3;More than 1 cup;;; +61450-3;LL993-7;PhenX05_06_food amt;LA13923-0;1;Less than 1 cup;;; +61450-3;LL993-7;PhenX05_06_food amt;LA13924-8;2;1 cup (8 ounces);;; +61450-3;LL993-7;PhenX05_06_food amt;LA13925-5;3;More than 1 cup;;; +61454-5;LL993-7;PhenX05_06_food amt;LA13923-0;1;Less than 1 cup;;; +61454-5;LL993-7;PhenX05_06_food amt;LA13924-8;2;1 cup (8 ounces);;; +61454-5;LL993-7;PhenX05_06_food amt;LA13925-5;3;More than 1 cup;;; +61448-7;LL997-8;PhenX05_10_30D Mex food;LA13883-6;1;Less than 1 taco or burrito;;; +61448-7;LL997-8;PhenX05_10_30D Mex food;LA13826-5;2;1 taco or burrito;;; +61448-7;LL997-8;PhenX05_10_30D Mex food;LA13889-3;3;More than 1 taco or burrito;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13894-3;1;Never or less than 1 time per month;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13828-1;2;1 time per month;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13845-5;3;2-3 times per month;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13834-9;4;1-2 times per week;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13853-9;5;3-4 times per week;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13860-4;6;5-6 times per week;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13827-3;7;1 time per day;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13840-6;8;2 times per day;;; +61449-5;LL995-2;PhenX05_08_milk freq;LA13850-5;9;3 or more times per day;;; +61451-1;LL994-5;PhenX05_07_milk type;LA13917-2;1;Whole milk;;; +61451-1;LL994-5;PhenX05_07_milk type;LA13842-2;2;2% fat milk;;; +61451-1;LL994-5;PhenX05_07_milk type;LA13832-3;3;1% fat milk;;; +61451-1;LL994-5;PhenX05_07_milk type;LA13906-5;4;Skim or nonfat milk;;; +61451-1;LL994-5;PhenX05_07_milk type;LA13871-1;5;Chocolate milk;;; +61451-1;LL994-5;PhenX05_07_milk type;LA13910-7;6;Soy or rice milk;;; +61451-1;LL994-5;PhenX05_07_milk type;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61452-9;LL1028-1;PhenX05_26_30D calcium OJ freq;LA13926-3;1;Almost never or never;;; +61452-9;LL1028-1;PhenX05_26_30D calcium OJ freq;LA10082-8;2;Sometimes;;; +61452-9;LL1028-1;PhenX05_26_30D calcium OJ freq;LA13927-1;3;Almost always or always;;; +61452-9;LL1028-1;PhenX05_26_30D calcium OJ freq;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61456-0;LL998-6;PhenX05_11_30D pizza amt;LA13824-0;1;1 slice;;; +61456-0;LL998-6;PhenX05_11_30D pizza amt;LA13839-8;2;2 slices or one mini pizza;;; +61456-0;LL998-6;PhenX05_11_30D pizza amt;LA13849-7;3;3 or more slices;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61459-4;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61460-2;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61462-8;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61463-6;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61464-4;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61465-1;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61466-9;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61467-7;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61468-5;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61470-1;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61471-9;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61472-7;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61473-5;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61474-3;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61475-0;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61476-8;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61506-2;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61507-0;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61508-8;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61549-2;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61550-0;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61551-8;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61552-6;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61553-4;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61554-2;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA6270-8;1;Never;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13836-4;2;1-3 times per month;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13834-9;3;1-2 times per week;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13853-9;4;3-4 times per week;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13860-4;5;5-6 times per week;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13827-3;6;1 time per day;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13840-6;7;2 times per day;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13851-3;8;3 times per day;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13854-7;9;4 times per day;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA13858-8;10;5 or more times per day;;; +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA4389-8;11;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61555-9;LL1001-8;PhenX05_14_30D freq amts;LA12688-0;12;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61461-0;LL1002-6;PhenX05_15_30D cereal amt;LA13872-9;1;Cooked cereals (such as oatmeal, cream of wheat, grits);;; +61461-0;LL1002-6;PhenX05_15_30D cereal amt;LA13864-6;2;All bran cereals (such as All Bran®, Fiber One®, 100% Bran®, or Bran Buds®);;; +61461-0;LL1002-6;PhenX05_15_30D cereal amt;LA13870-3;3;Cereals with some bran or fiber (such as Cheerios®, Raisin Bran®, Shredded Wheat®, Total®, Wheaties®, 40% Bran flakes®, Granola, Grape Nuts®, Muselix®, etc.);;; +61461-0;LL1002-6;PhenX05_15_30D cereal amt;LA13869-5;4;Cereals with little bran or fiber (such as Corn Flakes®, Honey Nut Cheerios®, Froot Loops®, Rice Krispies®, Kix®, Frosted Flakes®, Special K®, Cap'n Crunch®, Blueberry Morning®, Product 19®, etc.);;; +61461-0;LL1002-6;PhenX05_15_30D cereal amt;LA46-8;5;Other;;; +61461-0;LL1002-6;PhenX05_15_30D cereal amt;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61461-0;LL1002-6;PhenX05_15_30D cereal amt;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61575-7;LL1002-6;PhenX05_15_30D cereal amt;LA13872-9;1;Cooked cereals (such as oatmeal, cream of wheat, grits);;; +61575-7;LL1002-6;PhenX05_15_30D cereal amt;LA13864-6;2;All bran cereals (such as All Bran®, Fiber One®, 100% Bran®, or Bran Buds®);;; +61575-7;LL1002-6;PhenX05_15_30D cereal amt;LA13870-3;3;Cereals with some bran or fiber (such as Cheerios®, Raisin Bran®, Shredded Wheat®, Total®, Wheaties®, 40% Bran flakes®, Granola, Grape Nuts®, Muselix®, etc.);;; +61575-7;LL1002-6;PhenX05_15_30D cereal amt;LA13869-5;4;Cereals with little bran or fiber (such as Corn Flakes®, Honey Nut Cheerios®, Froot Loops®, Rice Krispies®, Kix®, Frosted Flakes®, Special K®, Cap'n Crunch®, Blueberry Morning®, Product 19®, etc.);;; +61575-7;LL1002-6;PhenX05_15_30D cereal amt;LA46-8;5;Other;;; +61575-7;LL1002-6;PhenX05_15_30D cereal amt;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +61575-7;LL1002-6;PhenX05_15_30D cereal amt;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +61469-3;LL1027-3;PhenX05_25_30D cereal freq;LA13929-7;1;Less than 2 cups;;; +61469-3;LL1027-3;PhenX05_25_30D cereal freq;LA13930-5;2;2 cups;;; +61469-3;LL1027-3;PhenX05_25_30D cereal freq;LA13931-3;3;More than 2 cups;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61478-4;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61480-0;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61482-6;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61484-2;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61486-7;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61488-3;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61490-9;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61492-5;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61494-1;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61496-6;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61498-2;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61500-5;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13894-3;1;Never or less than 1 time per month;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13836-4;2;1-3 times per month;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13829-9;3;1 time per week;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13846-3;4;2-4 times per week;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13860-4;5;5-6 times per week;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13827-3;6;1 time per day;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13844-8;7;2-3 times per day;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13856-2;8;4-5 times per day;;; +61502-1;LL1003-4;PhenX05_16_beverage amts;LA13861-2;9;6 or more times per day;;; +61479-2;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61479-2;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61479-2;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61481-8;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61481-8;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61481-8;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61483-4;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61483-4;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61483-4;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61485-9;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61485-9;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61485-9;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61487-5;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61487-5;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61487-5;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61489-1;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61489-1;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61489-1;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61491-7;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61491-7;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61491-7;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61493-3;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61493-3;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61493-3;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61495-8;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61495-8;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61495-8;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61497-4;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61497-4;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61497-4;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61499-0;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61499-0;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61499-0;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61501-3;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61501-3;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61501-3;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61503-9;LL1004-2;PhenX05_17_serving size;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +61503-9;LL1004-2;PhenX05_17_serving size;LA8982-6;2;Medium;;; +61503-9;LL1004-2;PhenX05_17_serving size;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +61505-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61505-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61505-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61505-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61511-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61511-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61511-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61511-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61513-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61513-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61513-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61513-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61516-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61516-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61516-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61516-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61519-5;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61519-5;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61519-5;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61519-5;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61521-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61521-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61521-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61521-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61523-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61523-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61523-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61523-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61525-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61525-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61525-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61525-2;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61527-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61527-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61527-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61527-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61529-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61529-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61529-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61529-4;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61531-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61531-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61531-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61531-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61533-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61533-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61533-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61533-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61535-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61535-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61535-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61535-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61537-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61537-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61537-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61537-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61540-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61540-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61540-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61540-1;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61542-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61542-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61542-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61542-7;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61545-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61545-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61545-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61545-0;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61546-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61546-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61546-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61546-8;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61547-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13831-5;1;1 year or less;;; +61547-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13841-4;2;2 to 4 years;;; +61547-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13859-6;3;5 to 9 years;;; +61547-6;LL1007-5;PhenX05_20_Ys vitamin use;LA13833-1;4;10 years or more;;; +61510-4;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61510-4;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61510-4;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61512-0;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61512-0;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61512-0;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61515-3;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61515-3;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61515-3;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61517-9;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61517-9;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61517-9;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61518-7;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61518-7;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61518-7;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61520-3;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61520-3;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61520-3;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61522-9;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61522-9;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61522-9;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61524-5;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61524-5;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61524-5;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61526-0;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61526-0;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61526-0;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61528-6;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61528-6;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61528-6;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61530-2;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61530-2;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61530-2;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61532-8;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61532-8;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61532-8;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61534-4;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61534-4;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61534-4;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61536-9;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61536-9;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61536-9;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61538-5;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61538-5;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61538-5;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61541-9;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61541-9;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61541-9;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61543-5;LL1006-7;PhenX05_19_vitamin freq;LA13830-7;1;1 to 3 times a week;;; +61543-5;LL1006-7;PhenX05_19_vitamin freq;LA13855-4;2;4 to 6 times a week;;; +61543-5;LL1006-7;PhenX05_19_vitamin freq;LA13897-6;3;Once a day;;; +61514-6;LL1005-9;PhenX05_18_dietary supplements;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +61514-6;LL1005-9;PhenX05_18_dietary supplements;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +81949-0;LL1005-9;PhenX05_18_dietary supplements;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81949-0;LL1005-9;PhenX05_18_dietary supplements;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +81950-8;LL1005-9;PhenX05_18_dietary supplements;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81950-8;LL1005-9;PhenX05_18_dietary supplements;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +92658-4;LL1005-9;PhenX05_18_dietary supplements;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +92658-4;LL1005-9;PhenX05_18_dietary supplements;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +61539-3;LL1008-3;PhenX05_21_vit C amt;LA13847-1;1;250 mg or less;;; +61539-3;LL1008-3;PhenX05_21_vit C amt;LA13852-1;2;300 to 500 mg;;; +61539-3;LL1008-3;PhenX05_21_vit C amt;LA13862-0;3;600 to 1000 mg;;; +61539-3;LL1008-3;PhenX05_21_vit C amt;LA13891-9;4;More than 1000 mg;;; +61544-3;LL1009-1;PhenX05_22_vit E amt;LA13843-0;1;200 IU or less;;; +61544-3;LL1009-1;PhenX05_22_vit E amt;LA13848-9;2;250 to 400 IU;;; +61544-3;LL1009-1;PhenX05_22_vit E amt;LA13857-0;3;450 to 1000 IU;;; +61544-3;LL1009-1;PhenX05_22_vit E amt;LA13890-1;4;More than 1000 IU;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61558-3;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61559-1;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61560-9;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61561-7;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61562-5;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61563-3;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61564-1;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61565-8;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61566-6;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61567-4;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61568-2;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61569-0;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61570-8;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61571-6;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA6270-8;1;Never;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA6251-8;2;Less than once a month;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA13836-4;3;1-3 times per month;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA13834-9;4;1-2 times per week;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA13853-9;5;3-4 times per week;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA13860-4;6;5-6 times per week;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA13827-3;7;1 time per day;;; +61572-4;LL1010-9;PhenX05_23_food freq;LA13837-2;8;2 or more times per day;;; +61573-2;LL1011-7;PhenX05_24_margarine freq;LA13933-9;1;Didn't use margarine;;; +61573-2;LL1011-7;PhenX05_24_margarine freq;LA13866-1;2;Almost never;;; +61573-2;LL1011-7;PhenX05_24_margarine freq;LA13934-7;3;About 1/4 of the time;;; +61573-2;LL1011-7;PhenX05_24_margarine freq;LA13935-4;4;About 1/2 of the time;;; +61573-2;LL1011-7;PhenX05_24_margarine freq;LA13936-2;5;About 3/4 of the time;;; +61573-2;LL1011-7;PhenX05_24_margarine freq;LA13927-1;6;Almost always or always;;; +61574-0;LL1030-7;PhenX05_28_12Mo fat amt;LA9193-9;1;High;;; +61574-0;LL1030-7;PhenX05_28_12Mo fat amt;LA8982-6;2;Medium;;; +61574-0;LL1030-7;PhenX05_28_12Mo fat amt;LA9194-7;3;Low;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61577-3;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61578-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61578-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61578-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61578-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61578-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61579-9;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61579-9;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61579-9;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61579-9;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61579-9;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61580-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61580-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61580-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61580-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61580-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61581-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61581-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61581-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61581-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61581-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61585-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +61585-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +61585-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +61585-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +61585-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +64438-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +64438-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +64438-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +64438-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +64438-5;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +64845-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +64845-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +64845-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +64845-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +64845-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +75898-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +75898-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +75898-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +75898-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +75898-7;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +75900-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +75900-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +75900-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +75900-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +75900-1;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +75907-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +75907-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +75907-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +75907-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +75907-6;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +75908-4;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA9206-9;1;Excellent;;; +75908-4;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA13913-1;2;Very Good;;; +75908-4;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8967-7;3;Good;;; +75908-4;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8968-5;4;Fair;;; +75908-4;LL1012-5;[PROMIS] Excellent|Very good|Good|Fair|Poor;LA8969-3;5;Poor;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA9206-9;1;Excellent;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA13913-1;2;Very Good;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8967-7;3;Good;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8968-5;4;Fair;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8969-3;5;Poor;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA9206-9;1;Excellent;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA13913-1;2;Very Good;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8967-7;3;Good;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8968-5;4;Fair;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8969-3;5;Poor;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA9206-9;1;Excellent;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA13913-1;2;Very Good;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8967-7;3;Good;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8968-5;4;Fair;;; +61577-3;LL3193-1;20150106-APTASet1_16;LA8969-3;5;Poor;;; +64846-9;LL3193-1;20150106-APTASet1_16;LA9206-9;1;Excellent;;; +64846-9;LL3193-1;20150106-APTASet1_16;LA13913-1;2;Very Good;;; +64846-9;LL3193-1;20150106-APTASet1_16;LA8967-7;3;Good;;; +64846-9;LL3193-1;20150106-APTASet1_16;LA8968-5;4;Fair;;; +64846-9;LL3193-1;20150106-APTASet1_16;LA8969-3;5;Poor;;; +76447-2;LL3193-1;20150106-APTASet1_16;LA9206-9;1;Excellent;;; +76447-2;LL3193-1;20150106-APTASet1_16;LA13913-1;2;Very Good;;; +76447-2;LL3193-1;20150106-APTASet1_16;LA8967-7;3;Good;;; +76447-2;LL3193-1;20150106-APTASet1_16;LA8968-5;4;Fair;;; +76447-2;LL3193-1;20150106-APTASet1_16;LA8969-3;5;Poor;;; +98918-6;LL3193-1;20150106-APTASet1_16;LA9206-9;1;Excellent;;; +98918-6;LL3193-1;20150106-APTASet1_16;LA13913-1;2;Very Good;;; +98918-6;LL3193-1;20150106-APTASet1_16;LA8967-7;3;Good;;; +98918-6;LL3193-1;20150106-APTASet1_16;LA8968-5;4;Fair;;; +98918-6;LL3193-1;20150106-APTASet1_16;LA8969-3;5;Poor;;; +98932-7;LL3193-1;20150106-APTASet1_16;LA9206-9;1;Excellent;;; +98932-7;LL3193-1;20150106-APTASet1_16;LA13913-1;2;Very Good;;; +98932-7;LL3193-1;20150106-APTASet1_16;LA8967-7;3;Good;;; +98932-7;LL3193-1;20150106-APTASet1_16;LA8968-5;4;Fair;;; +98932-7;LL3193-1;20150106-APTASet1_16;LA8969-3;5;Poor;;; +61577-3;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA9206-9;1;Excellent;;; +61577-3;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA13913-1;2;Very Good;;; +61577-3;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8967-7;3;Good;;; +61577-3;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8968-5;4;Fair;;; +61577-3;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8969-3;5;Poor;;; +61578-1;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA9206-9;1;Excellent;;; +61578-1;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA13913-1;2;Very Good;;; +61578-1;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8967-7;3;Good;;; +61578-1;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8968-5;4;Fair;;; +61578-1;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8969-3;5;Poor;;; +61579-9;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA9206-9;1;Excellent;;; +61579-9;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA13913-1;2;Very Good;;; +61579-9;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8967-7;3;Good;;; +61579-9;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8968-5;4;Fair;;; +61579-9;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8969-3;5;Poor;;; +61580-7;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA9206-9;1;Excellent;;; +61580-7;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA13913-1;2;Very Good;;; +61580-7;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8967-7;3;Good;;; +61580-7;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8968-5;4;Fair;;; +61580-7;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8969-3;5;Poor;;; +61581-5;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA9206-9;1;Excellent;;; +61581-5;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA13913-1;2;Very Good;;; +61581-5;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8967-7;3;Good;;; +61581-5;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8968-5;4;Fair;;; +61581-5;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8969-3;5;Poor;;; +61585-6;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA9206-9;1;Excellent;;; +61585-6;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA13913-1;2;Very Good;;; +61585-6;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8967-7;3;Good;;; +61585-6;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8968-5;4;Fair;;; +61585-6;LL4280-5;[PROMIS]Excel-5|Very good-4|Good-3|Fair-2|Poor-1;LA8969-3;5;Poor;;; +61582-3;LL1013-3;[PROMIS] Completely|Mostly|Mod|A little|Not at all;LA13937-0;1;Completely;;; +61582-3;LL1013-3;[PROMIS] Completely|Mostly|Mod|A little|Not at all;LA13938-8;2;Mostly;;; +61582-3;LL1013-3;[PROMIS] Completely|Mostly|Mod|A little|Not at all;LA13939-6;3;Moderately;;; +61582-3;LL1013-3;[PROMIS] Completely|Mostly|Mod|A little|Not at all;LA13940-4;4;A little;;; +61582-3;LL1013-3;[PROMIS] Completely|Mostly|Mod|A little|Not at all;LA6568-5;5;Not at all;;; +61583-1;LL4258-1;[NIH] Pain scale;LA26951-6;1;"0:""No pain""";;; +61583-1;LL4258-1;[NIH] Pain scale;LA6112-2;2;1;;; +61583-1;LL4258-1;[NIH] Pain scale;LA6113-0;3;2;;; +61583-1;LL4258-1;[NIH] Pain scale;LA6114-8;4;3;;; +61583-1;LL4258-1;[NIH] Pain scale;LA6115-5;5;4;;; +61583-1;LL4258-1;[NIH] Pain scale;LA10137-0;6;5;;; +61583-1;LL4258-1;[NIH] Pain scale;LA10138-8;7;6;;; +61583-1;LL4258-1;[NIH] Pain scale;LA10139-6;8;7;;; +61583-1;LL4258-1;[NIH] Pain scale;LA10140-4;9;8;;; +61583-1;LL4258-1;[NIH] Pain scale;LA10141-2;10;9;;; +61583-1;LL4258-1;[NIH] Pain scale;LA26952-4;11;10 - worst pain imaginable;;; +61584-9;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +61584-9;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6752-5;2;Mild;;; +61584-9;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +61584-9;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6750-9;4;Severe;;; +61584-9;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA13958-6;5;Very severe;;; +61877-7;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +61877-7;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6752-5;2;Mild;;; +61877-7;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +61877-7;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6750-9;4;Severe;;; +61877-7;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA13958-6;5;Very severe;;; +64848-5;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +64848-5;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6752-5;2;Mild;;; +64848-5;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +64848-5;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA6750-9;4;Severe;;; +64848-5;LL1015-8;[PROMIS] None|Mild|Moderate|Severe|Very severe;LA13958-6;5;Very severe;;; +61584-9;LL4478-5;None|Mild|Moderate|Severe|Very Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +61584-9;LL4478-5;None|Mild|Moderate|Severe|Very Severe;LA6752-5;2;Mild;;; +61584-9;LL4478-5;None|Mild|Moderate|Severe|Very Severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +61584-9;LL4478-5;None|Mild|Moderate|Severe|Very Severe;LA6750-9;4;Severe;;; +61584-9;LL4478-5;None|Mild|Moderate|Severe|Very Severe;LA13958-6;5;Very severe;;; +61586-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61586-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61586-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61586-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61586-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61764-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61764-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61764-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61764-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61764-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61770-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61770-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61770-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61770-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61770-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61771-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61771-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61771-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61771-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61771-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61772-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61772-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61772-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61772-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61772-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61774-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61774-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61774-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61774-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61774-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61778-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61778-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61778-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61778-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61778-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61779-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61779-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61779-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61779-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61779-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61780-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61780-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61780-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61780-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61780-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61781-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61781-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61781-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61781-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61781-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61782-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61782-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61782-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61782-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61782-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61783-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61783-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61783-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61783-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61783-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61784-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61784-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61784-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61784-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61784-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61787-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61787-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61787-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61787-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61787-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61788-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61788-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61788-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61788-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61788-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61789-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61789-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61789-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61789-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61789-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61790-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61790-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61790-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61790-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61790-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61792-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61792-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61792-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61792-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61792-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61798-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61798-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61798-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61798-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61798-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61799-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61799-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61799-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61799-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61799-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61800-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61800-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61800-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61800-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61800-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61801-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61801-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61801-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61801-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61801-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61802-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61802-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61802-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61802-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61802-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61803-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61803-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61803-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61803-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61803-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61804-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61804-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61804-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61804-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61804-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61805-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61805-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61805-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61805-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61805-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61806-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61806-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61806-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61806-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61806-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61807-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61807-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61807-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61807-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61807-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61808-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61808-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61808-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61808-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61808-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61809-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61809-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61809-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61809-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61809-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61810-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61810-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61810-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61810-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61810-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61811-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61811-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61811-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61811-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61811-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61812-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61812-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61812-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61812-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61812-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61813-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61813-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61813-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61813-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61813-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61814-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61814-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61814-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61814-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61814-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61815-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61815-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61815-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61815-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61815-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61816-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61816-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61816-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61816-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61816-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61817-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61817-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61817-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61817-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61817-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61818-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61818-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61818-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61818-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61818-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61821-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61821-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61821-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61821-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61821-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61822-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61822-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61822-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61822-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61822-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61823-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61823-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61823-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61823-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61823-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61830-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61830-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61830-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61830-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61830-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61840-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61840-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61840-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61840-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61840-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61841-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61841-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61841-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61841-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61841-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61842-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61842-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61842-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61842-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61842-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61843-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61843-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61843-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61843-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61843-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61844-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61844-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61844-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61844-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61844-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61845-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61845-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61845-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61845-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61845-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61846-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61846-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61846-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61846-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61846-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61849-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61849-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61849-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61849-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61849-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61850-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61850-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61850-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61850-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61850-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61851-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61851-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61851-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61851-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61851-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61852-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61852-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61852-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61852-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61852-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61854-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61854-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61854-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61854-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61854-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61856-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61856-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61856-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61856-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61856-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61857-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61857-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61857-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61857-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61857-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61858-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61858-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61858-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61858-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61858-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61871-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61871-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61871-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61871-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61871-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61872-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61872-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61872-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61872-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61872-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61876-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61876-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61876-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61876-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61876-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61893-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61893-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61893-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61893-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61893-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61894-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61894-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61894-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61894-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61894-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61895-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61895-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61895-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61895-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61895-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61896-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61896-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61896-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61896-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61896-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61897-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61897-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61897-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61897-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61897-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61898-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61898-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61898-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61898-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61898-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61899-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61899-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61899-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61899-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61899-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61900-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61900-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61900-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61900-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61900-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61901-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61901-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61901-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61901-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61901-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61902-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61902-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61902-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61902-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61902-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61903-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61903-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61903-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61903-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61903-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61904-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61904-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61904-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61904-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61904-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61905-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61905-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61905-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61905-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61905-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61906-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61906-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61906-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61906-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61906-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61907-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61907-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61907-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61907-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61907-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61908-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61908-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61908-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61908-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61908-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61909-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61909-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61909-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61909-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61909-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61910-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61910-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61910-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61910-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61910-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61911-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61911-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61911-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61911-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61911-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61912-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61912-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61912-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61912-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61912-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61913-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61913-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61913-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61913-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61913-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61914-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61914-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61914-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61914-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61914-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61915-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61915-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61915-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61915-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61915-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61916-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61916-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61916-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61916-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61916-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61917-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61917-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61917-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61917-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61917-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61918-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61918-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61918-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61918-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61918-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61919-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61919-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61919-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61919-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61919-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61920-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61920-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61920-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61920-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61920-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61923-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61923-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61923-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61923-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61923-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61924-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61924-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61924-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61924-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61924-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61925-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61925-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61925-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61925-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61925-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61926-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61926-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61926-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61926-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61926-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61927-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61927-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61927-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61927-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61927-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61928-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61928-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61928-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61928-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61928-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61929-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61929-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61929-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61929-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61929-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61930-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61930-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61930-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61930-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61930-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61931-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61931-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61931-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61931-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61931-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61932-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61932-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61932-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61932-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61932-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61933-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61933-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61933-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61933-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61933-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61934-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61934-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61934-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61934-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61934-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61935-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61935-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61935-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61935-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61935-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61936-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61936-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61936-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61936-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61936-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61937-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61937-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61937-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61937-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61937-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61938-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61938-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61938-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61938-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61938-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61939-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61939-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61939-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61939-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61939-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61940-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61940-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61940-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61940-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61940-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61941-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61941-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61941-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61941-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61941-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61942-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61942-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61942-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61942-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61942-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61943-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61943-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61943-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61943-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61943-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61944-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61944-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61944-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61944-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61944-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61945-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61945-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61945-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61945-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61945-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61946-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61946-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61946-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61946-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61946-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61947-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61947-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61947-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61947-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61947-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61948-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61948-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61948-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61948-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61948-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61949-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61949-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61949-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61949-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61949-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61950-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61950-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61950-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61950-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61950-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61951-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61951-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61951-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61951-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61951-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61953-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61953-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61953-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61953-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61953-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61954-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61954-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61954-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61954-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61954-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61955-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61955-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61955-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61955-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61955-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61956-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61956-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61956-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61956-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61956-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61957-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61957-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61957-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61957-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61957-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61958-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61958-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61958-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61958-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61958-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61959-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61959-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61959-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61959-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61959-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61960-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61960-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61960-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61960-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61960-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61961-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61961-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61961-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61961-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61961-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61962-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61962-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61962-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61962-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61962-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61963-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61963-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61963-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61963-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61963-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61964-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61964-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61964-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61964-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61964-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61965-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61965-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61965-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61965-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61965-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61966-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61966-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61966-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61966-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61966-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61967-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61967-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61967-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61967-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61967-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61968-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61968-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61968-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61968-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61968-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61969-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61969-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61969-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61969-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61969-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61970-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61970-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61970-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61970-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61970-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61971-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61972-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61972-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61972-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61972-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61972-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61973-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61973-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61973-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61973-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61973-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61974-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61974-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61974-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61974-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61974-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61975-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61975-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61975-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61975-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61975-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61976-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61976-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61976-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61976-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61976-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61977-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61977-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61977-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61977-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61977-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61978-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61978-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61978-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61978-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61978-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61979-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61979-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61979-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61979-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61979-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61980-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61980-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61980-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61980-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61980-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61989-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61989-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61989-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61989-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61989-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61990-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61990-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61990-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61990-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61990-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61991-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61991-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61991-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61991-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61991-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61992-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61992-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61992-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61992-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61992-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61993-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61993-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61993-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61993-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61993-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61994-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +61994-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +61994-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +61994-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +61994-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +62011-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +62011-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +62011-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +62011-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +62011-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +62012-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +62012-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +62012-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +62012-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +62012-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +62095-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +62095-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +62095-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +62095-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +62095-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67915-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67915-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67915-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67915-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67915-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67916-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67916-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67916-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67916-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67916-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67917-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67917-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67917-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67917-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67917-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67918-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67918-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67918-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67918-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67918-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67919-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67919-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67919-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67919-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67919-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67920-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67920-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67920-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67920-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67920-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67921-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67921-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67921-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67921-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67921-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67922-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67922-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67922-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67922-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67922-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67923-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67923-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67923-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67923-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67923-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67924-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67924-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67924-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67924-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67924-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67925-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67925-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67925-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67925-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67925-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67926-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67926-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67926-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67926-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67926-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67927-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67927-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67927-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67927-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67927-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67928-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67928-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67928-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67928-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67928-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67929-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67929-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67929-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67929-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67929-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67930-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67930-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67930-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67930-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67930-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67931-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67931-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67931-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67931-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67931-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67932-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67932-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67932-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67932-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67932-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67933-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67933-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67933-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67933-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67933-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67934-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67934-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67934-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67934-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67934-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67935-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67935-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67935-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67935-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67935-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67984-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67984-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67984-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67984-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67984-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67985-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67985-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67985-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67985-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67985-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67986-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67986-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67986-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67986-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67986-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67987-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67987-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67987-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67987-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67987-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67988-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67988-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67988-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67988-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67988-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67989-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67989-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67989-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67989-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67989-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67990-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67990-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67990-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67990-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67990-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67991-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67991-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67991-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67991-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67991-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67992-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67992-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67992-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67992-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67992-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67993-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67993-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67993-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67993-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67993-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67994-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67994-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67994-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67994-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67994-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67995-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67995-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67995-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67995-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67995-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67996-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67996-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67996-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67996-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67996-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67997-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67997-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67997-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67997-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67997-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67998-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67998-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67998-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67998-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67998-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +67999-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +67999-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +67999-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +67999-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +67999-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68000-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68000-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68000-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68000-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68000-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68001-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68001-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68001-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68001-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68001-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68002-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68002-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68002-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68002-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68002-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68003-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68003-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68003-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68003-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68003-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68004-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68004-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68004-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68004-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68004-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68005-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68005-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68005-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68005-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68005-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68006-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68006-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68006-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68006-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68006-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68007-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68007-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68007-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68007-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68007-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68008-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68008-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68008-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68008-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68008-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68009-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68009-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68009-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68009-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68009-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68010-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68010-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68010-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68010-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68010-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68011-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68011-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68011-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68011-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68011-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68012-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68012-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68012-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68012-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68012-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68013-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68013-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68013-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68013-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68013-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68014-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68014-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68014-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68014-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68014-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68015-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68015-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68015-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68015-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68015-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68016-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68016-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68016-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68016-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68016-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68017-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68017-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68017-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68017-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68017-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68018-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68018-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68018-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68018-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68018-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68019-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68019-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68019-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68019-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68019-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68020-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68020-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68020-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68020-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68020-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68021-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68021-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68021-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68021-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68021-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68022-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68022-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68022-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68022-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68022-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68023-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68023-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68023-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68023-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68023-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68024-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68024-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68024-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68024-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68024-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68025-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68025-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68025-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68025-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68025-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68026-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68026-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68026-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68026-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68026-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68027-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68027-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68027-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68027-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68027-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68028-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68028-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68028-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68028-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68028-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68029-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68029-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68029-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68029-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68029-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68030-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68030-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68030-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68030-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68030-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68031-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68031-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68031-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68031-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68031-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68032-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68032-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68032-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68032-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68032-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68033-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68033-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68033-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68033-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68033-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68034-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68034-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68034-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68034-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68034-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68035-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68035-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68035-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68035-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68035-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68036-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68036-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68036-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68036-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68036-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68037-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68037-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68037-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68037-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68037-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68038-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68038-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68038-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68038-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68038-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68039-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68039-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68039-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68039-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68039-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68040-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68040-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68040-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68040-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68040-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68041-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68041-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68041-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68041-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68041-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68042-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68042-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68042-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68042-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68042-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68043-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68043-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68043-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68043-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68043-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68044-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68044-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68044-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68044-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68044-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68045-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68045-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68045-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68045-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68045-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68046-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68046-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68046-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68046-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68046-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68047-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68047-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68047-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68047-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68047-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68048-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68048-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68048-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68048-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68048-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68049-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68049-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68049-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68049-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68049-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68050-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68050-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68050-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68050-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68050-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68094-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68094-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68094-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68094-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68094-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68095-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68095-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68095-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68095-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68095-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68096-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68096-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68096-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68096-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68096-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68097-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68097-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68097-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68097-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68097-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68098-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68098-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68098-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68098-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68098-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68099-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68099-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68099-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68099-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68099-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68100-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68100-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68100-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68100-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68100-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68101-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68101-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68101-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68101-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68101-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68102-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68102-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68102-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68102-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68102-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68103-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68103-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68103-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68103-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68103-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68104-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68104-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68104-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68104-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68104-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68105-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68105-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68105-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68105-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68105-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68106-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68106-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68106-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68106-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68106-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68107-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68107-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68107-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68107-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68107-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68108-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68108-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68108-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68108-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68108-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68109-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68109-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68109-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68109-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68109-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68110-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68110-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68110-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68110-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68110-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68111-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68111-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68111-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68111-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68111-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68112-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68112-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68112-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68112-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68112-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68113-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68113-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68113-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68113-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68113-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68114-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68114-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68114-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68114-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68114-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68115-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68115-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68115-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68115-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68115-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68116-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68116-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68116-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68116-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68116-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68117-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68117-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68117-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68117-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68117-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68142-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68142-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68142-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68142-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68142-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68143-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68143-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68143-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68143-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68143-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68144-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68144-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68144-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68144-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68144-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68145-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68145-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68145-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68145-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68145-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68146-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68146-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68146-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68146-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68146-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68147-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68147-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68147-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68147-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68147-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68148-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68148-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68148-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68148-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68148-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68149-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68149-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68149-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68149-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68149-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68150-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68150-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68150-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68150-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68150-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68151-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68151-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68151-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68151-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68151-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68152-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68152-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68152-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68152-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68152-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68153-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68153-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68153-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68153-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68153-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68154-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68154-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68154-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68154-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68154-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68155-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68155-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68155-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68155-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68155-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68156-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68156-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68156-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68156-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68156-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68157-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68157-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68157-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68157-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68157-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68158-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68158-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68158-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68158-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68158-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68159-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68159-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68159-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68159-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68159-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68228-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68228-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68228-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68228-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68228-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68229-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68229-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68229-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68229-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68229-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68230-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68230-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68230-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68230-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68230-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68231-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68231-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68231-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68231-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68231-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68232-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68232-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68232-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68232-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68232-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68233-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68233-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68233-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68233-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68233-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68235-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68235-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68235-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68235-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68235-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68236-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68236-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68236-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68236-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68236-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68237-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68237-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68237-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68237-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68237-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68238-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68238-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68238-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68238-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68238-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68239-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68239-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68239-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68239-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68239-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68240-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68240-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68240-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68240-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68240-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +68321-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +68321-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +68321-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +68321-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +68321-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +75416-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +75416-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +75416-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +75416-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +75416-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +75895-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +75895-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +75895-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +75895-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +75895-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +75905-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +75905-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +75905-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +75905-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +75905-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78083-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78083-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78083-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78083-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78083-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78084-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78084-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78084-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78084-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78084-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78085-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78085-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78085-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78085-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78085-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78086-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78086-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78086-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78086-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78086-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78087-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78087-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78087-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78087-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78087-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78088-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78088-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78088-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78088-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78088-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78089-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78089-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78089-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78089-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78089-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78090-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78090-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78090-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78090-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78090-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78091-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78091-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78091-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78091-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78091-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78092-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78092-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78092-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78092-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78092-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78093-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78093-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78093-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78093-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78093-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78094-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78094-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78094-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78094-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78094-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78095-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78095-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78095-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78095-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78095-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78096-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78096-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78096-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78096-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78096-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78097-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78097-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78097-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78097-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78097-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78098-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78098-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78098-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78098-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78098-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78099-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78099-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78099-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78099-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78099-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78100-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78100-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78100-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78100-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78100-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78101-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78101-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78101-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78101-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78101-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78102-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78102-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78102-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78102-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78102-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78103-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78103-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78103-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78103-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78103-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78104-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78104-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78104-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78104-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78104-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78105-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78105-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78105-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78105-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78105-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78106-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78106-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78106-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78106-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78106-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78107-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78107-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78107-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78107-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78107-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78108-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78108-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78108-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78108-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78108-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78109-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78109-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78109-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78109-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78109-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78110-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78110-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78110-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78110-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78110-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78111-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78111-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78111-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78111-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78111-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78112-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78112-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78112-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78112-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78112-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78113-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78113-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78113-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78113-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78113-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78114-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78114-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78114-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78114-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78114-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78115-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78115-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78115-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78115-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78115-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78116-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78116-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78116-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78116-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78116-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78117-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78117-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78117-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78117-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78117-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78118-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78118-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78118-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78118-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78118-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78119-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78119-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78119-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78119-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78119-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78120-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78120-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78120-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78120-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78120-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78123-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78123-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78123-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78123-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78123-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78124-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78124-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78124-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78124-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78124-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78125-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78125-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78125-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78125-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78125-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78126-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78126-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78126-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78126-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78126-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78127-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78127-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78127-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78127-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78127-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78128-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78128-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78128-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78128-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78128-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78129-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78129-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78129-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78129-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78129-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78130-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78130-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78130-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78130-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78130-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78131-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78131-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78131-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78131-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78131-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78132-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78132-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78132-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78132-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78132-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78133-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78133-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78133-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78133-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78133-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78134-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78134-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78134-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78134-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78134-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78135-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78135-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78135-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78135-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78135-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78136-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78136-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78136-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78136-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78136-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78137-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78137-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78137-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78137-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78137-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78138-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78138-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78138-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78138-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78138-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78139-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78139-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78139-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78139-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78139-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78140-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78140-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78140-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78140-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78140-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78141-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78141-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78141-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78141-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78141-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78142-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78142-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78142-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78142-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78142-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78143-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78143-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78143-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78143-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78143-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78144-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78144-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78144-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78144-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78144-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78145-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78145-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78145-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78145-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78145-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78146-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78146-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78146-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78146-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78146-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78147-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78147-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78147-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78147-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78147-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78148-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78148-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78148-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78148-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78148-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78149-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78149-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78149-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78149-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78149-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78150-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78150-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78150-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78150-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78150-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78151-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78151-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78151-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78151-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78151-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78152-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78152-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78152-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78152-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78152-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78153-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78153-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78153-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78153-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78153-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78154-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78154-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78154-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78154-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78154-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78155-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78155-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78155-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78155-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78155-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78156-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78156-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78156-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78156-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78156-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78157-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78157-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78157-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78157-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78157-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78158-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78158-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78158-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78158-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78158-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78159-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78159-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78159-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78159-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78159-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +78160-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +78160-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +78160-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +78160-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +78160-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89663-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89663-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89663-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89663-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89663-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89664-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89664-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89664-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89664-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89664-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89665-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89665-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89665-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89665-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89665-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89666-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89666-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89666-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89666-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89666-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89667-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89667-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89667-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89667-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89667-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89668-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89668-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89668-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89668-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89668-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89672-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89672-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89672-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89672-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89672-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89678-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89678-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89678-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89678-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89678-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +89922-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +89922-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +89922-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +89922-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +89922-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91229-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91229-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91229-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91229-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91229-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91230-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91230-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91230-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91230-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91230-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91231-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91231-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91231-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91231-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91231-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91232-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91232-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91232-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91232-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91232-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91233-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91233-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91233-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91233-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91233-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91234-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91234-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91234-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91234-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91234-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91235-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91235-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91235-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91235-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91235-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91236-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91236-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91236-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91236-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91236-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91237-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91237-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91237-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91237-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91237-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91238-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91238-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91238-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91238-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91238-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91239-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91239-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91239-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91239-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91239-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91240-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91240-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91240-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91240-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91240-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91241-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91241-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91241-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91241-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91241-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91242-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91242-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91242-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91242-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91242-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91243-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91243-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91243-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91243-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91243-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91244-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91244-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91244-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91244-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91244-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91245-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91245-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91245-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91245-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91245-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91246-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91246-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91246-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91246-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91246-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91247-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91247-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91247-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91247-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91247-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91248-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91248-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91248-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91248-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91248-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91249-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91249-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91249-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91249-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91249-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91250-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91250-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91250-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91250-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91250-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91251-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91251-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91251-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91251-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91251-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91252-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91252-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91252-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91252-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91252-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91253-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91253-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91253-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91253-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91253-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91254-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91254-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91254-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91254-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91254-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91255-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91255-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91255-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91255-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91255-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91256-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91256-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91256-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91256-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91256-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91257-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91257-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91257-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91257-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91257-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91258-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91258-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91258-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91258-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91258-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91259-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91259-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91259-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91259-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91259-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91260-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91260-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91260-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91260-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91260-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91261-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91261-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91261-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91261-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91261-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91262-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91262-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91262-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91262-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91262-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91263-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91263-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91263-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91263-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91263-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91264-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91264-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91264-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91264-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91264-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91265-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91265-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91265-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91265-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91265-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91266-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91266-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91266-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91266-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91266-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91267-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91267-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91267-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91267-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91267-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91268-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91268-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91268-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91268-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91268-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91269-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91269-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91269-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91269-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91269-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91270-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91270-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91270-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91270-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91270-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91271-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91271-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91271-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91271-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91271-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91272-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91272-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91272-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91272-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91272-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91273-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91273-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91273-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91273-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91273-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91274-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91274-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91274-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91274-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91274-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91275-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91275-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91275-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91275-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91275-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91276-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91276-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91276-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91276-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91276-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91277-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91277-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91277-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91277-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91277-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91278-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91278-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91278-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91278-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91278-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91279-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91279-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91279-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91279-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91279-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91280-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91280-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91280-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91280-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91280-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91281-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91281-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91281-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91281-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91281-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91282-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91282-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91282-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91282-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91282-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91283-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91283-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91283-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91283-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91283-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91284-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91284-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91284-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91284-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91284-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91285-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91285-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91285-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91285-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91285-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91286-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91286-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91286-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91286-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91286-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91287-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91287-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91287-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91287-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91287-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91288-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91288-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91288-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91288-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91288-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91289-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91289-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91289-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91289-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91289-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91290-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91290-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91290-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91290-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91290-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91291-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91291-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91291-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91291-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91291-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91292-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91292-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91292-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91292-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91292-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91293-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91293-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91293-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91293-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91293-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91294-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91294-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91294-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91294-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91294-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91295-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91295-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91295-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91295-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91295-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91296-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91296-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91296-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91296-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91296-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91297-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91297-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91297-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91297-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91297-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91298-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91298-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91298-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91298-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91298-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91299-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91299-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91299-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91299-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91299-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91300-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91300-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91300-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91300-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91300-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91301-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91301-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91301-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91301-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91301-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91302-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91302-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91302-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91302-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91302-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91303-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91303-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91303-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91303-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91303-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91304-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91304-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91304-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91304-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91304-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91305-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91305-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91305-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91305-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91305-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91308-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91308-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91308-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91308-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91308-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91309-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91309-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91309-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91309-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91309-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91310-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91310-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91310-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91310-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91310-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91311-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91311-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91311-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91311-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91311-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91312-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91312-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91312-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91312-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91312-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91313-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91313-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91313-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91313-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91313-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91314-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91314-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91314-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91314-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91314-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91315-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91315-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91315-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91315-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91315-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91316-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91316-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91316-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91316-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91316-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91317-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91317-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91317-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91317-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91317-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91318-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91318-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91318-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91318-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91318-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91319-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91319-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91319-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91319-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91319-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91320-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91320-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91320-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91320-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91320-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91321-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91321-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91321-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91321-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91321-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91322-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91322-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91322-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91322-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91322-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91323-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91323-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91323-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91323-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91323-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91353-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91353-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91353-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91353-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91353-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91356-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91356-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91356-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91356-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91356-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91357-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91357-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91357-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91357-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91357-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91358-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91358-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91358-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91358-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91358-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91359-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91359-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91359-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91359-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91359-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91360-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91360-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91360-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91360-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91360-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91361-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91361-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91361-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91361-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91361-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91362-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91362-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91362-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91362-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91362-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91363-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91363-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91363-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91363-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91363-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91364-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91364-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91364-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91364-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91364-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91365-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91365-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91365-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91365-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91365-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91366-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91366-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91366-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91366-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91366-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91369-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91369-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91369-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91369-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91369-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91427-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91427-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91427-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91427-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91427-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91428-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91428-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91428-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91428-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91428-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91429-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91429-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91429-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91429-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91429-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91430-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91430-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91430-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91430-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91430-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91431-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91431-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91431-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91431-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91431-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91432-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91432-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91432-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91432-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91432-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91433-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91433-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91433-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91433-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91433-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91434-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91434-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91434-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91434-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91434-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91435-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91435-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91435-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91435-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91435-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91436-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91436-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91436-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91436-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91436-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91437-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91437-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91437-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91437-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91437-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91438-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91438-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91438-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91438-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91438-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91439-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91439-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91439-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91439-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91439-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91440-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91440-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91440-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91440-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91440-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91441-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91441-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91441-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91441-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91441-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91442-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91442-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91442-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91442-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91442-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91443-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91443-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91443-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91443-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91443-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91444-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91444-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91444-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91444-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91444-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91445-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91445-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91445-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91445-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91445-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91446-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91446-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91446-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91446-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91446-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91447-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91447-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91447-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91447-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91447-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91448-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91448-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91448-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91448-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91448-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91449-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91449-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91449-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91449-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91449-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91450-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91450-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91450-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91450-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91450-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +91451-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +91451-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +91451-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +91451-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +91451-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92051-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92052-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92053-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92054-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92055-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92056-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92057-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92058-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92059-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92060-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92061-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92062-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92063-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92064-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92065-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92066-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92067-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92068-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92069-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92070-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92071-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92071-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92071-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92071-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92071-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92072-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92072-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92072-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92072-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92072-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92073-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92073-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92073-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92073-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92073-6;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92074-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92074-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92074-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92074-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92074-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92075-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92075-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92075-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92075-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92075-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92076-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92076-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92076-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92076-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92076-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92206-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92206-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92206-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92206-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92206-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92207-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92207-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92207-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92207-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92207-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92208-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92208-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92208-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92208-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92208-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92216-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92216-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92216-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92216-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92216-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92217-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92217-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92217-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92217-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92217-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92234-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92296-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92296-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92296-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92296-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92296-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92298-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92298-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92298-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92298-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92298-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92299-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92299-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92299-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92299-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92299-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92300-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92300-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92300-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92300-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92300-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92302-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92302-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92302-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92302-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92302-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92303-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92303-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92303-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92303-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92303-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92310-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92310-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92310-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92310-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92310-2;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92311-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92311-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92311-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92311-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92311-0;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92312-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92312-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92312-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92312-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92312-8;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92314-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92314-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92314-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92314-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92314-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92315-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92315-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92315-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92315-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92315-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92317-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92317-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92317-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92317-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92317-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +92319-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +92319-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +92319-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +92319-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +92319-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97088-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97089-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97090-5;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97091-3;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97092-1;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97093-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97093-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97093-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97093-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97093-9;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97094-7;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA6270-8;1;Never;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10066-1;2;Rarely;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10082-8;3;Sometimes;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA10044-8;4;Often;;; +97095-4;LL1016-6;[PROMIS] Never|Rarely|Sometimes|Often|Always;LA9933-8;5;Always;;; +61586-4;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA6270-8;1;Never;;; +61586-4;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10066-1;2;Rarely;;; +61586-4;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10082-8;3;Sometimes;;; +61586-4;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10044-8;4;Often;;; +61586-4;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA9933-8;5;Always;;; +61829-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA6270-8;1;Never;;; +61829-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10066-1;2;Rarely;;; +61829-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10082-8;3;Sometimes;;; +61829-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10044-8;4;Often;;; +61829-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA9933-8;5;Always;;; +61855-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA6270-8;1;Never;;; +61855-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10066-1;2;Rarely;;; +61855-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10082-8;3;Sometimes;;; +61855-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10044-8;4;Often;;; +61855-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA9933-8;5;Always;;; +61866-0;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA6270-8;1;Never;;; +61866-0;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10066-1;2;Rarely;;; +61866-0;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10082-8;3;Sometimes;;; +61866-0;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10044-8;4;Often;;; +61866-0;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA9933-8;5;Always;;; +75416-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA6270-8;1;Never;;; +75416-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10066-1;2;Rarely;;; +75416-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10082-8;3;Sometimes;;; +75416-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10044-8;4;Often;;; +75416-8;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA9933-8;5;Always;;; +75904-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA6270-8;1;Never;;; +75904-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10066-1;2;Rarely;;; +75904-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10082-8;3;Sometimes;;; +75904-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA10044-8;4;Often;;; +75904-3;LL3122-0;Never(5)|Rarely(4)|Sometimes{3)|Often(2)|Always(1);LA9933-8;5;Always;;; +61588-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61588-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61588-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61588-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61588-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61589-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61589-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61589-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61589-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61589-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61590-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61590-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61590-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61590-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61590-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61591-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61591-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61591-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61591-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61591-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61592-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61592-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61592-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61592-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61592-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61593-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61593-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61593-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61593-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61593-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61639-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61639-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61639-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61639-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61639-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61640-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61640-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61640-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61640-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61640-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61641-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61641-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61641-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61641-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61641-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61642-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61642-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61642-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61642-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61642-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61676-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61676-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61676-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61676-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61676-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61677-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61677-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61677-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61677-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61677-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61678-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61678-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61678-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61678-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61678-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61679-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61679-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61679-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61679-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61679-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61681-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61681-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61681-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61681-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61681-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61682-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61682-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61682-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61682-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61682-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61687-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61687-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61687-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61687-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61687-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61688-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61688-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61688-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61688-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61688-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61690-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61690-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61690-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61690-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61690-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61695-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61695-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61695-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61695-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61695-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61696-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61696-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61696-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61696-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61696-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61697-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61697-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61697-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61697-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61697-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61698-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61698-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61698-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61698-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61698-7;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61711-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61711-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61711-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61711-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61711-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61712-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +61712-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +61712-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +61712-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +61712-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78052-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78052-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78052-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78052-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78052-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78059-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78059-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78059-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78059-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78059-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78060-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78060-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78060-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78060-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78060-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78063-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78063-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78063-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78063-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78063-5;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78064-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78064-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78064-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78064-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78064-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78065-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78065-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78065-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78065-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78065-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78067-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78067-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78067-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78067-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78067-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +78068-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +78068-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +78068-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +78068-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +78068-4;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +89681-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +89681-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +89681-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +89681-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +89681-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +89685-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +89685-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +89685-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +89685-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +89685-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +89686-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +89686-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +89686-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +89686-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +89686-0;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +89687-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +89687-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +89687-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +89687-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +89687-8;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +89688-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +89688-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +89688-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +89688-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +89688-6;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +91607-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +91607-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +91607-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +91607-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +91607-2;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +91758-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +91758-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +91758-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +91758-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +91758-3;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +91759-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +91759-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +91759-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +91759-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +91759-1;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +91760-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA6568-5;1;Not at all;;; +91760-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13947-9;2;Very little;;; +91760-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13909-9;3;Somewhat;;; +91760-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA11911-7;4;Quite a lot;;; +91760-9;LL1021-6;[PROMIS] Not at all|Ver litt|Some|Qte lot|Can't do;LA13868-7;5;Cannot do;;; +61594-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61594-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61594-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61594-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61594-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61595-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61595-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61595-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61595-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61595-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61596-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61596-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61596-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61596-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61596-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61597-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61597-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61597-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61597-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61597-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61598-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61598-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61598-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61598-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61598-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61599-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61599-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61599-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61599-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61599-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61600-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61600-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61600-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61600-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61600-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61601-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61601-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61601-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61601-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61601-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61602-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61602-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61602-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61602-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61602-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61603-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61603-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61603-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61603-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61603-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61604-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61604-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61604-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61604-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61604-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61605-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61605-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61605-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61605-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61605-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61606-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61606-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61606-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61606-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61606-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61607-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61607-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61607-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61607-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61607-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61608-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61608-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61608-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61608-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61608-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61609-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61609-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61609-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61609-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61609-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61610-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61610-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61610-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61610-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61610-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61611-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61611-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61611-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61611-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61611-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61612-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61612-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61612-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61612-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61612-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61613-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61613-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61613-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61613-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61613-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61614-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61614-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61614-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61614-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61614-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61615-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61615-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61615-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61615-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61615-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61616-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61616-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61616-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61616-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61616-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61617-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61617-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61617-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61617-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61617-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61618-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61618-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61618-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61618-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61618-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61619-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61619-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61619-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61619-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61619-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61620-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61620-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61620-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61620-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61620-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61621-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61621-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61621-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61621-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61621-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61622-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61622-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61622-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61622-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61622-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61623-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61623-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61623-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61623-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61623-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61624-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61624-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61624-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61624-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61624-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61625-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61625-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61625-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61625-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61625-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61626-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61626-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61626-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61626-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61626-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61627-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61627-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61627-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61627-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61627-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61628-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61628-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61628-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61628-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61628-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61629-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61629-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61629-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61629-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61629-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61630-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61630-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61630-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61630-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61630-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61631-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61631-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61631-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61631-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61631-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61632-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61632-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61632-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61632-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61632-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61633-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61633-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61633-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61633-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61633-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61634-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61634-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61634-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61634-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61634-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61635-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61635-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61635-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61635-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61635-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61636-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61636-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61636-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61636-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61636-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61637-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61637-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61637-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61637-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61637-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61638-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61638-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61638-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61638-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61638-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61643-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61643-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61643-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61643-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61643-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61644-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61644-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61644-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61644-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61644-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61645-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61645-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61645-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61645-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61645-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61646-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61646-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61646-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61646-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61646-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61647-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61647-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61647-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61647-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61647-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61648-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61648-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61648-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61648-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61648-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61649-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61649-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61649-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61649-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61649-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61650-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61650-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61650-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61650-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61650-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61651-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61651-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61651-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61651-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61651-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61652-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61652-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61652-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61652-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61652-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61653-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61653-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61653-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61653-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61653-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61654-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61654-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61654-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61654-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61654-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61655-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61655-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61655-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61655-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61655-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61656-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61656-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61656-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61656-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61656-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61657-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61657-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61657-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61657-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61657-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61658-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61658-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61658-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61658-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61658-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61659-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61659-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61659-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61659-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61659-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61660-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61660-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61660-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61660-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61660-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61661-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61661-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61661-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61661-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61661-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61662-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61662-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61662-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61662-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61662-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61663-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61663-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61663-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61663-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61663-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61664-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61664-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61664-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61664-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61664-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61665-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61665-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61665-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61665-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61665-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61666-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61666-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61666-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61666-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61666-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61667-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61667-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61667-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61667-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61667-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61668-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61668-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61668-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61668-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61668-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61669-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61669-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61669-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61669-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61669-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61670-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61670-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61670-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61670-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61670-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61671-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61671-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61671-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61671-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61671-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61672-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61672-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61672-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61672-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61672-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61673-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61673-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61673-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61673-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61673-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61674-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61674-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61674-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61674-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61674-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61675-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61675-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61675-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61675-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61675-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61683-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61683-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61683-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61683-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61683-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61685-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61685-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61685-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61685-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61685-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61686-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61686-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61686-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61686-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61686-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61689-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61689-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61689-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61689-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61689-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61691-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61691-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61691-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61691-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61691-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61692-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61692-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61692-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61692-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61692-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61693-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61693-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61693-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61693-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61693-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61694-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61694-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61694-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61694-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61694-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61699-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61699-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61699-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61699-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61699-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61700-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61700-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61700-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61700-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61700-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61701-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61701-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61701-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61701-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61701-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61702-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61702-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61702-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61702-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61702-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61703-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61703-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61703-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61703-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61703-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61704-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61704-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61704-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61704-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61704-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61705-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61705-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61705-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61705-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61705-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61706-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61706-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61706-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61706-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61706-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61707-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61707-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61707-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61707-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61707-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61708-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61708-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61708-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61708-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61708-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61709-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61709-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61709-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61709-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61709-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61710-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +61710-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +61710-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +61710-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +61710-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +67936-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +67936-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +67936-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +67936-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +67936-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +75909-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +75909-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +75909-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +75909-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +75909-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78048-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78048-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78048-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78048-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78048-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78049-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78049-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78049-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78049-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78049-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78050-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78050-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78050-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78050-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78050-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78051-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78051-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78051-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78051-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78051-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78052-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78052-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78052-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78052-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78052-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78053-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78053-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78053-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78053-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78053-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78054-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78054-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78054-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78054-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78054-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78055-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78055-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78055-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78055-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78055-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78056-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78056-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78056-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78056-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78056-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78057-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78057-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78057-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78057-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78057-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78058-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78058-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78058-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78058-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78058-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78061-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78061-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78061-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78061-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78061-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78062-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78062-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78062-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78062-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78062-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78066-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78066-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78066-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78066-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78066-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78081-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78081-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78081-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78081-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78081-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78082-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78082-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78082-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78082-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78082-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78997-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78997-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78997-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78997-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78997-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78998-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78998-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78998-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78998-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78998-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +78999-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +78999-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +78999-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +78999-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +78999-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79000-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79000-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79000-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79000-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79000-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79001-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79001-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79001-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79001-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79001-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79002-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79002-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79002-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79002-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79002-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79003-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79003-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79003-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79003-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79003-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79004-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79004-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79004-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79004-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79004-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79005-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79005-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79005-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79005-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79005-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79006-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79006-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79006-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79006-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79006-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79007-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79007-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79007-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79007-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79007-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79008-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79008-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79008-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79008-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79008-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79009-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79009-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79009-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79009-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79009-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79010-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79010-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79010-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79010-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79010-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79011-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79011-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79011-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79011-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79011-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79012-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79012-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79012-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79012-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79012-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79013-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79013-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79013-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79013-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79013-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79014-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79015-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79015-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79015-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79015-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79015-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79016-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79016-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79016-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79016-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79016-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79017-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79017-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79017-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79017-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79017-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79018-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79018-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79018-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79018-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79018-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79019-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79019-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79019-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79019-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79019-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79021-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79021-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79021-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79021-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79021-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79022-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79022-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79022-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79022-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79022-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79023-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79023-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79023-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79023-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79023-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79024-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79024-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79024-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79024-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79024-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79025-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79025-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79025-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79025-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79025-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79026-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79026-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79026-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79026-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79026-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79027-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79027-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79027-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79027-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79027-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79028-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79028-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79028-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79028-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79028-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79029-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79029-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79029-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79029-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79029-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79030-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79030-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79030-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79030-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79030-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79031-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79031-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79031-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79031-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79031-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79032-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79032-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79032-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79032-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79032-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79033-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79033-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79033-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79033-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79033-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79034-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79034-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79034-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79034-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79034-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79035-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79035-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79035-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79035-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79035-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79036-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79036-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79036-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79036-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79036-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79037-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79037-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79037-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79037-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79037-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79038-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79038-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79038-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79038-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79038-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79039-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79039-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79039-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79039-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79039-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79040-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79040-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79040-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79040-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79040-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79041-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79041-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79041-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79041-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79041-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79042-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79042-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79042-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79042-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79042-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79043-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79043-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79043-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79043-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79043-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79044-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79044-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79044-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79044-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79044-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79045-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79045-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79045-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79045-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79045-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79046-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79046-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79046-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79046-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79046-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79047-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79047-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79047-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79047-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79047-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79048-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79048-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79048-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79048-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79048-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79049-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79049-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79049-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79049-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79049-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79050-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79050-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79050-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79050-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79050-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79051-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79051-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79051-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79051-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79051-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79052-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79052-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79052-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79052-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79052-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79053-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79053-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79053-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79053-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79053-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79054-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79054-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79054-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79054-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79054-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79055-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79055-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79055-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79055-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79055-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79056-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79056-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79056-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79056-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79056-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79057-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79057-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79057-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79057-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79057-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79058-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79058-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79058-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79058-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79058-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79059-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79059-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79059-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79059-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79059-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79060-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79060-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79060-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79060-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79060-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +79061-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +79061-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +79061-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +79061-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +79061-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +89682-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +89682-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +89682-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +89682-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +89682-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +89683-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +89683-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +89683-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +89683-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +89683-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +89684-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +89684-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +89684-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +89684-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +89684-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91608-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91608-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91608-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91608-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91608-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91609-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91609-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91609-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91609-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91609-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91610-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91610-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91610-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91610-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91610-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91723-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91723-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91723-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91723-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91723-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91724-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91724-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91724-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91724-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91724-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91725-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91725-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91725-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91725-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91725-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91726-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91726-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91726-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91726-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91726-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91727-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91727-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91727-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91727-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91727-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91728-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91728-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91728-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91728-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91728-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91729-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91729-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91729-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91729-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91729-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91730-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91730-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91730-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91730-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91730-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91731-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91731-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91731-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91731-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91731-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91732-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91732-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91732-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91732-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91732-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91733-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91733-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91733-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91733-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91733-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91734-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91734-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91734-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91734-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91734-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91735-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91735-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91735-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91735-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91735-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91736-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91736-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91736-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91736-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91736-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91737-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91737-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91737-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91737-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91737-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91738-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91738-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91738-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91738-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91738-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91739-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91739-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91739-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91739-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91739-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91740-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91740-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91740-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91740-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91740-1;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91741-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91741-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91741-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91741-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91741-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91742-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91742-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91742-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91742-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91742-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91743-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91743-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91743-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91743-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91743-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91744-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91744-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91744-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91744-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91744-3;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91745-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91745-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91745-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91745-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91745-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91746-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91746-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91746-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91746-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91746-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91747-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91747-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91747-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91747-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91747-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91748-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91748-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91748-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91748-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91748-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91749-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91749-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91749-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91749-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91749-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91750-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91750-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91750-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91750-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91750-0;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91751-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91751-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91751-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91751-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91751-8;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91752-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91752-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91752-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91752-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91752-6;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91753-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91753-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91753-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91753-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91753-4;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91754-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91754-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91754-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91754-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91754-2;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91755-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91755-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91755-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91755-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91755-9;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91756-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91756-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91756-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91756-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91756-7;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +91757-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13921-4;1;Without any difficulty;;; +91757-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13918-0;2;With a little difficulty;;; +91757-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13920-6;3;With some difficulty;;; +91757-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13919-8;4;With much difficulty;;; +91757-5;LL1022-4;[PROMIS] Diffic: WO|W lit|W some|W much|Unab to do;LA13912-3;5;Unable to do;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61626-8;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61651-6;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61654-0;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61655-7;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61656-5;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61658-1;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61664-9;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61664-9;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61664-9;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61664-9;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61664-9;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61666-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61671-4;LL5290-3;PROMIS - WO(4)|W lil(3)|W Som(2)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13921-4;1;Without any difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13918-0;2;With a little difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13920-6;3;With some difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13919-8;4;With much difficulty;;; +61650-8;LL5291-1;PROMIS - WO(3)|W lil(2)|W Som(1)|W Muc(1)|Unab(1);LA13912-3;5;Unable to do;;; +61680-5;LL1026-5;[PROMIS] Diffic:No|A lit|Some|Lot|Can't do bc hlth;LA13948-7;1;No difficulty at all;;; +61680-5;LL1026-5;[PROMIS] Diffic:No|A lit|Some|Lot|Can't do bc hlth;LA13949-5;2;A little bit of difficulty;;; +61680-5;LL1026-5;[PROMIS] Diffic:No|A lit|Some|Lot|Can't do bc hlth;LA13950-3;3;Some difficulty;;; +61680-5;LL1026-5;[PROMIS] Diffic:No|A lit|Some|Lot|Can't do bc hlth;LA13951-1;4;A lot of difficulty;;; +61680-5;LL1026-5;[PROMIS] Diffic:No|A lit|Some|Lot|Can't do bc hlth;LA13952-9;5;Can't do because of health;;; +61714-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61714-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61714-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61714-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61714-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61714-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61715-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61715-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61715-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61715-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61715-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61715-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61716-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61716-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61716-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61716-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61716-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61716-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61717-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61717-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61717-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61717-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61717-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61717-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61718-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61718-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61718-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61718-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61718-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61718-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61719-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61719-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61719-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61719-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61719-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61719-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61720-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61720-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61720-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61720-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61720-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61720-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61721-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61721-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61721-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61721-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61721-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61721-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61722-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61722-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61722-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61722-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61722-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61722-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61723-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61723-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61723-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61723-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61723-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61723-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61724-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61724-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61724-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61724-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61724-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61724-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61725-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61725-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61725-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61725-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61725-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61725-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61726-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61726-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61726-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61726-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61726-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61726-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61727-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61727-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61727-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61727-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61727-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61727-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61728-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61728-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61728-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61728-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61728-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61728-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61729-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61729-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61729-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61729-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61729-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61729-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61730-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61730-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61730-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61730-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61730-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61730-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61731-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61731-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61731-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61731-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61731-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61731-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61732-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61732-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61732-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61732-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61732-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61732-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61733-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61733-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61733-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61733-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61733-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61733-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61734-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61734-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61734-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61734-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61734-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61734-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61735-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61735-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61735-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61735-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61735-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61735-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61736-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61736-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61736-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61736-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61736-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61736-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61737-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61737-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61737-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61737-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61737-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61737-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61738-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61738-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61738-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61738-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61738-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61738-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61739-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61739-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61739-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61739-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61739-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61739-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61740-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61740-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61740-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61740-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61740-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61740-7;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61741-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61741-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61741-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61741-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61741-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61741-5;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61742-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61742-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61742-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61742-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61742-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61742-3;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61743-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61743-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61743-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61743-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61743-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61743-1;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61744-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61744-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61744-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61744-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61744-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61744-9;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61745-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61745-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61745-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61745-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61745-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61745-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61746-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61746-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61746-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61746-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61746-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61746-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61747-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61747-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61747-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61747-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61747-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61747-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61748-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61748-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61748-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61748-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61748-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61748-0;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61749-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61749-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61749-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61749-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61749-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61749-8;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61750-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61750-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61750-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61750-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61750-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61750-6;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61751-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61751-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61751-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61751-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61751-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61751-4;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61752-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA13879-4;1;Had no pain;;; +61752-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA6270-8;2;Never;;; +61752-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10066-1;3;Rarely;;; +61752-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10082-8;4;Sometimes;;; +61752-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA10044-8;5;Often;;; +61752-2;LL1019-0;[PROMIS] Had no pain|Nev|Rare|Sometim|Oft|Alw;LA9933-8;6;Always;;; +61727-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +61727-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +61727-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +61727-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +61727-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +61727-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +61737-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +61737-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +61737-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +61737-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +61737-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +61737-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +61742-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +61742-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +61742-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +61742-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +61742-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +61742-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91152-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91152-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91152-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91152-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91152-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91152-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91153-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91153-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91153-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91153-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91153-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91153-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91154-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91154-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91154-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91154-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91154-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91154-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91155-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91155-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91155-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91155-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91155-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91155-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91156-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91156-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91156-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91156-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91156-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91156-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91157-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91157-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91157-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91157-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91157-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91157-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91158-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91158-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91158-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91158-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91158-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91158-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91159-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91159-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91159-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91159-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91159-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91159-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91160-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91160-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91160-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91160-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91160-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91160-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91161-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91161-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91161-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91161-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91161-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91161-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91162-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91162-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91162-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91162-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91162-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91162-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91163-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91163-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91163-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91163-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91163-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91163-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91164-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91164-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91164-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91164-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91164-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91164-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91165-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91165-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91165-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91165-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91165-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91165-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91166-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91166-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91166-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91166-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91166-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91166-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91167-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91167-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91167-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91167-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91167-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91167-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91168-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91168-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91168-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91168-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91168-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91168-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91169-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91169-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91169-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91169-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91169-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91169-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91170-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91170-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91170-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91170-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91170-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91170-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91171-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91171-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91171-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91171-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91171-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91171-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91172-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91172-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91172-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91172-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91172-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91172-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91173-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91173-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91173-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91173-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91173-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91173-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91174-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91174-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91174-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91174-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91174-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91174-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91175-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91175-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91175-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91175-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91175-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91175-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91176-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91176-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91176-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91176-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91176-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91176-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91177-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91177-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91177-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91177-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91177-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91177-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91178-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91178-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91178-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91178-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91178-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91178-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91179-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91179-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91179-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91179-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91179-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91179-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91180-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91180-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91180-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91180-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91180-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91180-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91181-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91181-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91181-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91181-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91181-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91181-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91182-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91182-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91182-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91182-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91182-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91182-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91183-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91183-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91183-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91183-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91183-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91183-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91184-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91184-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91184-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91184-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91184-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91184-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91185-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91185-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91185-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91185-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91185-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91185-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91186-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91186-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91186-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91186-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91186-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91186-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91187-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91187-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91187-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91187-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91187-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91187-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91188-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91188-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91188-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91188-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91188-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91188-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91189-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91189-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91189-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91189-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91189-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91189-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91190-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91190-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91190-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91190-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91190-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91190-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91191-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91191-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91191-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91191-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91191-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91191-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91192-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91192-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91192-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91192-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91192-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91192-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91193-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91193-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91193-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91193-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91193-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91193-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91194-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91194-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91194-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91194-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91194-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91194-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91195-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91195-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91195-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91195-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91195-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91195-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91196-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91196-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91196-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91196-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91196-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91196-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91197-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91197-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91197-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91197-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91197-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91197-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91198-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91198-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91198-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91198-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91198-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91198-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91199-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91199-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91199-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91199-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91199-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91199-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91200-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91200-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91200-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91200-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91200-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91200-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91201-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91201-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91201-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91201-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91201-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91201-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91202-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91202-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91202-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91202-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91202-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91202-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91937-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91937-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91937-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91937-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91937-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91937-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91938-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91938-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91938-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91938-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91938-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91938-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91939-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91939-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91939-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91939-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91939-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91939-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91940-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91940-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91940-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91940-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91940-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91940-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91941-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91941-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91941-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91941-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91941-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91941-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91942-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91942-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91942-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91942-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91942-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91942-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91943-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91943-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91943-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91943-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91943-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91943-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91944-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91944-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91944-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91944-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91944-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91944-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91945-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91945-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91945-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91945-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91945-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91945-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91946-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91946-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91946-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91946-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91946-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91946-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91947-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91947-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91947-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91947-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91947-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91947-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91948-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91948-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91948-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91948-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91948-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91948-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91949-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91949-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91949-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91949-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91949-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91949-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91950-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91950-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91950-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91950-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91950-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91950-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91951-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91951-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91951-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91951-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91951-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91951-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91952-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91952-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91952-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91952-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91952-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91952-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91953-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91953-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91953-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91953-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91953-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91953-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91954-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91954-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91954-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91954-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91954-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91954-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91955-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91955-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91955-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91955-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91955-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91955-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91956-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91956-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91956-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91956-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91956-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91956-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91957-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91957-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91957-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91957-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91957-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91957-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91958-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91958-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91958-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91958-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91958-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91958-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91959-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91959-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91959-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91959-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91959-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91959-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91960-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91960-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91960-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91960-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91960-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91960-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91961-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91961-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91961-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91961-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91961-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91961-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91962-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91962-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91962-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91962-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91962-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91962-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91963-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91963-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91963-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91963-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91963-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91963-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91964-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91964-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91964-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91964-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91964-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91964-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91965-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91965-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91965-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91965-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91965-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91965-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91966-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91966-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91966-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91966-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91966-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91966-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91967-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91967-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91967-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91967-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91967-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91967-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91968-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91968-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91968-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91968-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91968-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91968-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91969-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91969-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91969-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91969-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91969-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91969-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91970-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91970-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91970-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91970-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91970-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91970-4;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91971-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91971-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91971-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91971-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91971-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91971-2;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91972-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91972-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91972-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91972-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91972-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91972-0;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91973-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91973-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91973-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91973-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91973-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91973-8;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91974-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91974-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91974-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91974-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91974-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91974-6;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91975-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91975-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91975-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91975-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91975-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91975-3;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91976-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91976-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91976-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91976-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91976-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91976-1;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91977-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91977-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91977-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91977-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91977-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91977-9;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91978-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91978-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91978-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91978-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91978-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91978-7;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +91979-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13879-4;1;Had no pain;;; +91979-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA6270-8;2;Never;;; +91979-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13866-1;3;Almost never;;; +91979-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10082-8;4;Sometimes;;; +91979-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA10044-8;5;Often;;; +91979-5;LL5207-7;HadNoPain(1),Nev,AlmNev,Sometimes,Oft,Al Always(6);LA13865-3;6;Almost always;;; +61754-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61754-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61754-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61754-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61754-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61755-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61755-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61755-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61755-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61755-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61756-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61756-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61756-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61756-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61756-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61757-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61757-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61757-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61757-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61757-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61758-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61758-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61758-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61758-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61758-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61759-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61759-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61759-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61759-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61759-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61760-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61760-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61760-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61760-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61760-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61761-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61761-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61761-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61761-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61761-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61762-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61762-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61762-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61762-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61762-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61763-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61763-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61763-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61763-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61763-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61765-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61765-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61765-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61765-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61765-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61766-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61766-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61766-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61766-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61766-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61767-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61767-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61767-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61767-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61767-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61768-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61768-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61768-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61768-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61768-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61769-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61769-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61769-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61769-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61769-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61773-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61773-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61773-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61773-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61773-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61775-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61775-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61775-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61775-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61775-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61776-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61776-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61776-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61776-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61776-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61777-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61777-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61777-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61777-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61777-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61785-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61785-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61785-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61785-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61785-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61786-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61786-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61786-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61786-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61786-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61793-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61793-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61793-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61793-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61793-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61794-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61794-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61794-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61794-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61794-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61796-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61796-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61796-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61796-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61796-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61797-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61797-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61797-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61797-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61797-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61819-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61819-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61819-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61819-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61819-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61820-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61820-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61820-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61820-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61820-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61824-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61824-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61824-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61824-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61824-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61825-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61825-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61825-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61825-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61825-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61826-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61826-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61826-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61826-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61826-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61827-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61827-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61827-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61827-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61827-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61828-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61828-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61828-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61828-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61828-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61831-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61831-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61831-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61831-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61831-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61832-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61832-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61832-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61832-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61832-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61833-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61833-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61833-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61833-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61833-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61834-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61834-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61834-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61834-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61834-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61835-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61835-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61835-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61835-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61835-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61836-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61836-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61836-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61836-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61836-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61837-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61837-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61837-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61837-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61837-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61838-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61838-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61838-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61838-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61838-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61839-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61839-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61839-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61839-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61839-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61847-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61847-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61847-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61847-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61847-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61848-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61848-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61848-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61848-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61848-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61853-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61853-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61853-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61853-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61853-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61860-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61860-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61860-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61860-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61860-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61861-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61861-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61861-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61861-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61861-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61862-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61862-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61862-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61862-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61862-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61863-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61863-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61863-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61863-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61863-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61864-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61864-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61864-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61864-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61864-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61865-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61865-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61865-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61865-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61865-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61867-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61867-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61867-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61867-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61867-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61868-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61868-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61868-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61868-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61868-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61869-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61869-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61869-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61869-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61869-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61873-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61873-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61873-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61873-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61873-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61874-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61874-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61874-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61874-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61874-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61875-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61875-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61875-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61875-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61875-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61878-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61878-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61878-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61878-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61878-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61879-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61879-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61879-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61879-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61879-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61880-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61880-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61880-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61880-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61880-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61881-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61881-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61881-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61881-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61881-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61882-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61882-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61882-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61882-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61882-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61883-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61883-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61883-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61883-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61883-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61884-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61884-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61884-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61884-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61884-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61885-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61885-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61885-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61885-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61885-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61886-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61886-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61886-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61886-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61886-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61887-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61887-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61887-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61887-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61887-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61888-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61888-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61888-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61888-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61888-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61889-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61889-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61889-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61889-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61889-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61890-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61890-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61890-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61890-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61890-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61921-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61921-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61921-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61921-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61921-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61983-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61983-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61983-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61983-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61983-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61984-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61984-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61984-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61984-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61984-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61995-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61995-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61995-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61995-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61995-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61996-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61996-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61996-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61996-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61996-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61997-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61997-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61997-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61997-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61997-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61998-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61998-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61998-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61998-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61998-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61999-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +61999-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +61999-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +61999-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +61999-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62000-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62000-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62000-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62000-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62000-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62001-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62001-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62001-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62001-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62001-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62002-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62002-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62002-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62002-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62002-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62003-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62003-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62003-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62003-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62003-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62004-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62004-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62004-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62004-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62004-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62005-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62005-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62005-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62005-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62005-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62006-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62006-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62006-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62006-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62006-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62007-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62007-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62007-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62007-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62007-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62008-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62008-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62008-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62008-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62008-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62009-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62009-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62009-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62009-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62009-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62013-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62013-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62013-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62013-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62013-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62014-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62014-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62014-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62014-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62014-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62015-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62015-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62015-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62015-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62015-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62016-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62016-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62016-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62016-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62016-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62017-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62017-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62017-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62017-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62017-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62018-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62018-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62018-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62018-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62018-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62019-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62019-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62019-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62019-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62019-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62020-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62020-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62020-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62020-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62020-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62021-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62021-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62021-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62021-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62021-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62022-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62022-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62022-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62022-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62022-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62023-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62023-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62023-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62023-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62023-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62024-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62024-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62024-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62024-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62024-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62025-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62025-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62025-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62025-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62025-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62027-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62027-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62027-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62027-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62027-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62028-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62028-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62028-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62028-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62028-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62029-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62029-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62029-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62029-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62029-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62030-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62030-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62030-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62030-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62030-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62031-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62031-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62031-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62031-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62031-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62032-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62032-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62032-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62032-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62032-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62033-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62033-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62033-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62033-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62033-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62034-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62034-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62034-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62034-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62034-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62035-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62035-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62035-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62035-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62035-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62036-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62036-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62036-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62036-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62036-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62037-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62037-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62037-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62037-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62037-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62038-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62038-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62038-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62038-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62038-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62040-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62040-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62040-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62040-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62040-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62041-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62041-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62041-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62041-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62041-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62042-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62042-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62042-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62042-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62042-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62043-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62043-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62043-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62043-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62043-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62044-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62044-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62044-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62044-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62044-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62045-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62045-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62045-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62045-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62045-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62046-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62046-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62046-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62046-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62046-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62047-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62047-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62047-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62047-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62047-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62048-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62048-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62048-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62048-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62048-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62049-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62049-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62049-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62049-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62049-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62050-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62050-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62050-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62050-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62050-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62051-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62051-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62051-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62051-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62051-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62052-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62052-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62052-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62052-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62052-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +62053-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +62053-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +62053-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +62053-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +62053-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +67966-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +67966-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +67966-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +67966-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +67966-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68071-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68071-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68071-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68071-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68071-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68072-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68072-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68072-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68072-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68072-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68073-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68073-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68073-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68073-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68073-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68074-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68074-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68074-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68074-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68074-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68075-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68075-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68075-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68075-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68075-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68076-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68076-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68076-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68076-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68076-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68077-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68077-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68077-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68077-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68077-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68078-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68078-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68078-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68078-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68078-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68079-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68079-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68079-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68079-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68079-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68080-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68080-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68080-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68080-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68080-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68165-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68165-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68165-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68165-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68165-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68174-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68174-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68174-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68174-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68174-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68175-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68175-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68175-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68175-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68175-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68176-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68176-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68176-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68176-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68176-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68177-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68177-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68177-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68177-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68177-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68178-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68178-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68178-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68178-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68178-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68179-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68179-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68179-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68179-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68179-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68180-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68180-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68180-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68180-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68180-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68184-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68184-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68184-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68184-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68184-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68185-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68185-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68185-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68185-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68185-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68214-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68214-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68214-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68214-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68214-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68216-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68216-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68216-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68216-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68216-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68217-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68217-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68217-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68217-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68217-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68225-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68225-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68225-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68225-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68225-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68226-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68226-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68226-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68226-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68226-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +68227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +68227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +68227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +68227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +68227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76345-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76345-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76345-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76345-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76345-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76737-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76737-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76737-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76737-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76737-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76738-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76738-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76738-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76738-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76738-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76739-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76739-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76739-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76739-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76739-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76740-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76740-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76740-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76740-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76740-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76741-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76741-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76741-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76741-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76741-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76742-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76742-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76742-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76742-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76742-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76743-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76743-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76743-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76743-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76743-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76744-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76744-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76744-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76744-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76744-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76775-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76775-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76775-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76775-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76775-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76776-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76776-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76776-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76776-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76776-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76777-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76777-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76777-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76777-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76777-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76778-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76778-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76778-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76778-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76778-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76779-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76779-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76779-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76779-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76779-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76780-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76780-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76780-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76780-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76780-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76781-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76781-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76781-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76781-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76781-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76782-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76782-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76782-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76782-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76782-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76783-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76783-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76783-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76783-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76783-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76784-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76784-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76784-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76784-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76784-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76785-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76785-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76785-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76785-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76785-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76786-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76786-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76786-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76786-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76786-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76807-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76807-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76807-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76807-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76807-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76808-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76808-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76808-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76808-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76808-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76809-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76809-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76809-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76809-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76809-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76810-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76810-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76810-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76810-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76810-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76811-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76811-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76811-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76811-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76811-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76812-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76812-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76812-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76812-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76812-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76813-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76813-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76813-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76813-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76813-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76814-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76814-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76814-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76814-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76814-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76815-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76815-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76815-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76815-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76815-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76816-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76816-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76816-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76816-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76816-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76817-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76817-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76817-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76817-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76817-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76818-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76818-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76818-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76818-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76818-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76819-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76819-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76819-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76819-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76819-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76820-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76820-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76820-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76820-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76820-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76821-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76821-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76821-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76821-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76821-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76822-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76822-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76822-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76822-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76822-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76823-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76823-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76823-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76823-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76823-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76824-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76824-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76824-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76824-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76824-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76825-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76825-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76825-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76825-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76825-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76826-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76826-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76826-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76826-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76826-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76827-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76827-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76827-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76827-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76827-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76828-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76828-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76828-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76828-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76828-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76829-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76829-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76829-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76829-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76829-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76830-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76830-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76830-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76830-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76830-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76890-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76890-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76890-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76890-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76890-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76891-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76891-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76891-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76891-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76891-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76892-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76892-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76892-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76892-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76892-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76893-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76893-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76893-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76893-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76893-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76894-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76894-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76894-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76894-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76894-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76895-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76895-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76895-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76895-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76895-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76896-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76896-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76896-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76896-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76896-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76897-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76897-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76897-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76897-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76897-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76898-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76898-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76898-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76898-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76898-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76941-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76941-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76941-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76941-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76941-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76942-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76942-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76942-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76942-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76942-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76943-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76943-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76943-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76943-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76943-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76944-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76944-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76944-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76944-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76944-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76945-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76945-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76945-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76945-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76945-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76946-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76946-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76946-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76946-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76946-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76947-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76947-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76947-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76947-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76947-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76948-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76948-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76948-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76948-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76948-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76949-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76949-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76949-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76949-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76949-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76950-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76950-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76950-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76950-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76950-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +76951-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +76951-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +76951-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +76951-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +76951-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81493-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81493-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81493-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81493-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81493-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81494-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81494-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81494-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81494-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81494-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81495-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81495-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81495-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81495-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81495-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81496-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81496-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81496-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81496-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81496-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81497-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81497-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81497-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81497-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81497-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81498-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81498-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81498-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81498-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81498-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81499-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81499-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81499-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81499-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81499-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81500-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81500-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81500-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81500-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81500-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81501-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81501-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81501-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81501-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81501-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81502-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81502-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81502-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81502-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81502-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81503-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81503-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81503-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81503-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81503-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81504-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81504-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81504-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81504-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81504-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81505-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81505-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81505-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81505-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81505-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81506-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81506-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81506-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81506-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81506-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81507-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81507-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81507-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81507-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81507-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81508-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81508-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81508-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81508-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81508-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81509-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81509-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81509-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81509-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81509-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81510-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81510-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81510-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81510-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81510-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81511-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81511-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81511-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81511-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81511-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81512-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81512-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81512-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81512-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81512-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81513-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81513-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81513-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81513-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81513-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81514-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81514-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81514-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81514-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81514-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81515-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81515-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81515-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81515-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81515-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81516-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81516-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81516-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81516-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81516-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81517-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81517-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81517-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81517-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81517-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81518-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81518-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81518-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81518-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81518-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81519-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81519-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81519-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81519-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81519-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81520-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81520-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81520-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81520-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81520-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81521-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81521-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81521-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81521-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81521-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81522-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81522-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81522-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81522-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81522-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +81523-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +81523-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +81523-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +81523-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +81523-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +88853-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +88853-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +88853-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +88853-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +88853-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +88854-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +88854-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +88854-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +88854-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +88854-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +89671-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +89671-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +89671-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +89671-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +89671-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +89673-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +89673-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +89673-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +89673-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +89673-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90573-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90573-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90573-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90573-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90573-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90574-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90574-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90574-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90574-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90574-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90575-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90575-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90575-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90575-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90575-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90576-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90576-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90576-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90576-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90576-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90577-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90577-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90577-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90577-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90577-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90578-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90578-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90578-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90578-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90578-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90579-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90579-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90579-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90579-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90579-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90580-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90580-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90580-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90580-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90580-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90581-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90581-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90581-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90581-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90581-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90582-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90582-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90582-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90582-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90582-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90583-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90583-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90583-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90583-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90583-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90584-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90584-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90584-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90584-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90584-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90585-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90585-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90585-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90585-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90585-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90586-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90586-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90586-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90586-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90586-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90587-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90587-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90587-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90587-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90587-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90588-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90588-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90588-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90588-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90588-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90589-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90589-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90589-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90589-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90589-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90590-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90590-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90590-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90590-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90590-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90591-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90591-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90591-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90591-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90591-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90592-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90592-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90592-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90592-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90592-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90593-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90593-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90593-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90593-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90593-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90594-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90594-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90594-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90594-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90594-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90595-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90595-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90595-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90595-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90595-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90596-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90596-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90596-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90596-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90596-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90597-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90597-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90597-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90597-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90597-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90598-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90598-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90598-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90598-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90598-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90599-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90599-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90599-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90599-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90599-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90600-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90600-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90600-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90600-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90600-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90601-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90601-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90601-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90601-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90601-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90602-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90602-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90602-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90602-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90602-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90603-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90603-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90603-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90603-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90603-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90604-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90604-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90604-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90604-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90604-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90605-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90605-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90605-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90605-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90605-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90606-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90606-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90606-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90606-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90606-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90607-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90607-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90607-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90607-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90607-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90608-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90608-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90608-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90608-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90608-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90609-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90609-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90609-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90609-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90609-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90610-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90610-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90610-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90610-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90610-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90611-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90611-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90611-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90611-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90611-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90612-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90612-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90612-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90612-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90612-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90613-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90613-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90613-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90613-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90613-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90614-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90614-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90614-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90614-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90614-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90618-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90618-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90618-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90618-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90618-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90619-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90619-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90619-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90619-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90619-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90620-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90620-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90620-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90620-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90620-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90621-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90621-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90621-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90621-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90621-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90622-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90622-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90622-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90622-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90622-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90623-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90623-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90623-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90623-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90623-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90624-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90624-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90624-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90624-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90624-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90625-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90625-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90625-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90625-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90625-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90626-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90626-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90626-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90626-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90626-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90627-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90627-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90627-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90627-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90627-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90628-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90628-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90628-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90628-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90628-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90629-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90629-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90629-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90629-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90629-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90630-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90630-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90630-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90630-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90630-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90631-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90631-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90631-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90631-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90631-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90632-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90632-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90632-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90632-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90632-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90633-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90633-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90633-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90633-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90633-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90634-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90634-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90634-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90634-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90634-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90635-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90635-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90635-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90635-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90635-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90636-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90636-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90636-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90636-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90636-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90637-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90637-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90637-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90637-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90637-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90638-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90638-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90638-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90638-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90638-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90639-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90639-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90639-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90639-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90639-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90640-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90640-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90640-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90640-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90640-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90641-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90641-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90641-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90641-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90641-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90642-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90642-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90642-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90642-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90642-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90643-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90643-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90643-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90643-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90643-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90644-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90644-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90644-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90644-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90644-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90645-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90645-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90645-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90645-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90645-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90646-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90646-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90646-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90646-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90646-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90647-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90647-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90647-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90647-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90647-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90648-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90648-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90648-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90648-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90648-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90649-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90649-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90649-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90649-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90649-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90650-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90650-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90650-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90650-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90650-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90651-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90651-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90651-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90651-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90651-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90652-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90652-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90652-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90652-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90652-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90653-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90653-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90653-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90653-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90653-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90654-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90654-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90654-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90654-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90654-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90655-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90655-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90655-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90655-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90655-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90656-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90656-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90656-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90656-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90656-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90657-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90657-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90657-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90657-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90657-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90658-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90658-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90658-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90658-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90658-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +90659-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +90659-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +90659-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +90659-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +90659-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91208-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91208-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91208-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91208-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91208-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91220-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91220-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91220-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91220-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91220-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91456-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91456-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91456-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91456-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91456-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91457-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91457-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91457-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91457-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91457-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91458-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91458-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91458-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91458-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91458-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91459-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91459-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91459-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91459-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91459-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91460-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91460-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91460-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91460-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91460-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91461-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91461-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91461-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91461-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91461-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91462-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91462-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91462-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91462-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91462-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91463-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91463-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91463-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91463-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91463-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91464-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91464-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91464-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91464-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91464-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91465-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91465-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91465-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91465-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91465-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91466-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91466-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91466-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91466-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91466-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91467-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91467-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91467-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91467-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91467-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91468-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91468-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91468-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91468-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91468-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91469-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91469-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91469-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91469-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91469-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91470-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91470-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91470-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91470-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91470-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91471-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91471-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91471-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91471-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91471-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91472-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91472-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91472-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91472-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91472-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91473-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91473-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91473-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91473-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91473-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91474-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91474-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91474-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91474-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91474-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91475-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91475-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91475-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91475-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91475-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91476-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91476-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91476-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91476-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91476-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91477-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91477-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91477-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91477-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91477-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91478-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91478-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91478-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91478-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91478-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91479-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91479-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91479-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91479-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91479-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91480-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91480-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91480-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91480-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91480-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91481-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91481-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91481-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91481-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91481-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91482-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91482-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91482-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91482-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91482-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91483-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91483-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91483-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91483-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91483-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91484-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91484-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91484-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91484-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91484-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91485-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91485-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91485-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91485-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91485-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91486-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91486-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91486-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91486-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91486-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91487-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91487-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91487-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91487-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91487-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91488-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91488-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91488-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91488-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91488-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91489-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91489-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91489-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91489-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91489-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91490-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91490-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91490-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91490-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91490-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91491-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91491-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91491-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91491-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91491-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91492-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91492-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91492-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91492-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91492-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91493-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91493-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91493-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91493-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91493-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91494-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91494-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91494-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91494-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91494-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91495-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91495-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91495-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91495-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91495-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91496-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91496-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91496-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91496-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91496-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91497-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91497-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91497-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91497-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91497-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91498-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91498-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91498-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91498-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91498-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +91499-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +91499-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +91499-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +91499-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +91499-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92081-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92082-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92083-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92084-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92085-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92086-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92087-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92088-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92089-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92090-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92091-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92092-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92093-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92094-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92094-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92094-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92094-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92094-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92095-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92095-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92095-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92095-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92095-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92096-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92096-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92096-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92096-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92096-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92098-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92098-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92098-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92098-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92098-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92099-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92099-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92099-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92099-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92099-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92100-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92100-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92100-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92100-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92100-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92101-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92101-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92101-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92101-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92101-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92102-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92102-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92102-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92102-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92102-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92103-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92103-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92103-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92103-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92103-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92104-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92104-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92104-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92104-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92104-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92105-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92105-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92105-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92105-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92105-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92106-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92106-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92106-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92106-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92106-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92107-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92107-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92107-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92107-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92107-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92108-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92108-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92108-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92108-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92108-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92109-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92109-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92109-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92109-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92109-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92110-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92110-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92110-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92110-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92110-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92111-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92111-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92111-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92111-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92111-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92112-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92112-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92112-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92112-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92112-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92113-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92113-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92113-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92113-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92113-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92114-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92114-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92114-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92114-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92114-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92115-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92115-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92115-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92115-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92115-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92116-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92116-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92116-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92116-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92116-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92117-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92117-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92117-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92117-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92117-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92118-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92118-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92118-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92118-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92118-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92120-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92120-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92120-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92120-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92120-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92121-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92121-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92121-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92121-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92121-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92123-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92123-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92123-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92123-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92123-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92124-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92124-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92124-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92124-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92124-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92205-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92205-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92205-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92205-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92205-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92209-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92209-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92209-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92209-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92209-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92210-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92210-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92210-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92210-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92210-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92211-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92211-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92211-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92211-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92211-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92212-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92212-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92212-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92212-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92212-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92215-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92218-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92219-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92220-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92221-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92222-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92223-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92224-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92227-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92228-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92228-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92228-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92228-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92228-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92229-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92229-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92229-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92229-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92229-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92230-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92230-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92230-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92230-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92230-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92231-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92231-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92231-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92231-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92231-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92232-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92232-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92232-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92232-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92232-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92233-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92233-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92233-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92233-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92233-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92258-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92258-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92258-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92258-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92258-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92259-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92259-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92259-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92259-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92259-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92260-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92260-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92260-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92260-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92260-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92261-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92261-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92261-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92261-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92261-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92262-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92262-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92262-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92262-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92262-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92263-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92263-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92263-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92263-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92263-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92264-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92264-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92264-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92264-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92264-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92265-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92265-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92265-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92265-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92265-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92269-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92269-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92269-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92269-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92269-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92270-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92270-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92270-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92270-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92270-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92271-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92271-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92271-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92271-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92271-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92283-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92283-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92283-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92283-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92283-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92284-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92284-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92284-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92284-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92284-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92285-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92285-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92285-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92285-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92285-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92286-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92286-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92286-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92286-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92286-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92287-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92287-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92287-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92287-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92287-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92288-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92288-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92288-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92288-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92288-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92289-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92289-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92289-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92289-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92289-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92290-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92290-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92290-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92290-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92290-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92291-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92291-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92291-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92291-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92291-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92292-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92292-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92292-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92292-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92292-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92293-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92293-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92293-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92293-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92293-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92294-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92294-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92294-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92294-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92294-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92295-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92295-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92295-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92295-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92295-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92301-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92301-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92301-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92301-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92301-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92304-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92304-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92304-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92304-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92304-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92307-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92307-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92307-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92307-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92307-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92308-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92308-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92308-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92308-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92308-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92309-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92309-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92309-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92309-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92309-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92313-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92313-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92313-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92313-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92313-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92316-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92316-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92316-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92316-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92316-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92318-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92318-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92318-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92318-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92318-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92320-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92320-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92320-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92320-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92320-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92321-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92321-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92321-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92321-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92321-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92322-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92322-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92322-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92322-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92322-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92325-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92325-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92325-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92325-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92325-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92326-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92326-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92326-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92326-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92326-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92327-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92327-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92327-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92327-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92327-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +92328-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +92328-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +92328-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +92328-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +92328-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98538-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98538-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98538-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98538-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98538-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98539-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98539-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98539-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98539-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98539-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98540-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98540-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98540-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98540-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98540-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98541-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98541-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98541-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98541-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98541-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98542-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98542-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98542-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98542-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98542-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98543-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98543-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98543-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98543-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98543-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98544-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98544-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98544-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98544-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98544-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98545-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98545-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98545-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98545-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98545-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98546-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98546-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98546-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98546-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98546-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98547-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98547-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98547-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98547-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98547-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98548-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98548-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98548-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98548-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98548-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98549-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98549-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98549-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98549-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98549-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98550-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98550-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98550-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98550-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98550-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98551-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98551-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98551-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98551-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98551-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98552-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98552-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98552-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98552-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98552-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98553-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98553-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98553-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98553-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98553-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98554-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98554-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98554-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98554-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98554-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98555-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98555-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98555-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98555-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98555-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98556-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98556-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98556-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98556-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98556-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98557-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98557-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98557-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98557-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98557-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98558-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98558-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98558-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98558-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98558-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98559-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98559-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98559-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98559-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98559-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98560-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98560-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98560-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98560-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98560-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98561-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98561-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98561-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98561-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98561-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98562-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98562-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98562-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98562-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98562-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98563-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98563-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98563-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98563-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98563-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98564-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98564-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98564-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98564-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98564-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98565-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98565-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98565-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98565-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98565-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98566-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98566-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98566-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98566-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98566-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98567-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98567-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98567-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98567-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98567-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98568-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98568-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98568-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98568-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98568-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98569-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98569-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98569-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98569-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98569-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98570-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98570-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98570-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98570-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98570-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98571-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98571-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98571-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98571-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98571-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98572-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98572-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98572-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98572-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98572-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98573-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98573-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98573-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98573-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98573-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98574-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98574-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98574-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98574-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98574-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98575-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98575-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98575-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98575-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98575-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98576-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98576-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98576-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98576-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98576-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98577-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98577-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98577-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98577-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98577-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98578-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98578-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98578-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98578-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98578-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98579-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98579-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98579-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98579-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98579-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98580-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98580-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98580-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98580-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98580-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98581-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98581-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98581-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98581-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98581-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98582-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98582-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98582-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98582-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98582-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98583-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98583-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98583-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98583-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98583-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98584-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98584-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98584-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98584-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98584-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98585-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98585-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98585-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98585-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98585-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98586-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98586-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98586-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98586-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98586-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98587-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98587-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98587-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98587-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98587-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98588-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98588-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98588-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98588-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98588-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98589-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98589-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98589-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98589-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98589-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98590-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98590-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98590-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98590-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98590-3;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98591-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98591-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98591-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98591-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98591-1;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98592-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98592-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98592-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98592-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98592-9;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98593-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98593-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98593-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98593-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98593-7;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98594-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98594-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98594-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98594-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98594-5;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98595-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98595-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98595-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98595-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98595-2;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98596-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98596-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98596-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98596-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98596-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98597-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98597-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98597-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98597-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98597-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98598-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98598-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98598-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98598-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98598-6;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98599-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98599-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98599-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98599-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98599-4;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98600-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98600-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98600-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98600-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98600-0;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +98601-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA6568-5;1;Not at all;;; +98601-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13863-8;2;A little bit;;; +98601-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13909-9;3;Somewhat;;; +98601-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13902-4;4;Quite a bit;;; +98601-8;LL1017-4;[PROMIS] Not at all|Lit bit|Somwh|Qte bit|Ver much;LA13914-9;5;Very much;;; +61791-0;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA6270-8;1;Never;;; +61791-0;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13898-4;2;Once a week or less;;; +61791-0;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13899-2;3;Once every few days;;; +61791-0;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13897-6;4;Once a day;;; +61791-0;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13875-2;5;Every few hours;;; +79020-4;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA6270-8;1;Never;;; +79020-4;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13898-4;2;Once a week or less;;; +79020-4;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13899-2;3;Once every few days;;; +79020-4;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13897-6;4;Once a day;;; +79020-4;LL1020-8;[PROMIS] Never|<=1/W|1/few days|1/D|Every few H;LA13875-2;5;Every few hours;;; +61859-5;LL3326-7;PROMIS_21;LA6270-8;1;Never;;; +61859-5;LL3326-7;PROMIS_21;LA10066-1;2;Rarely;;; +61859-5;LL3326-7;PROMIS_21;LA10082-8;3;Sometimes;;; +61859-5;LL3326-7;PROMIS_21;LA10044-8;4;Often;;; +61859-5;LL3326-7;PROMIS_21;LA9933-8;5;Always;;; +61988-2;LL3326-7;PROMIS_21;LA6270-8;1;Never;;; +61988-2;LL3326-7;PROMIS_21;LA10066-1;2;Rarely;;; +61988-2;LL3326-7;PROMIS_21;LA10082-8;3;Sometimes;;; +61988-2;LL3326-7;PROMIS_21;LA10044-8;4;Often;;; +61988-2;LL3326-7;PROMIS_21;LA9933-8;5;Always;;; +61870-2;LL1018-2;[PROMIS] None|1 day|2-3 days|4-5 days|6-7 days;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +61870-2;LL1018-2;[PROMIS] None|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +61870-2;LL1018-2;[PROMIS] None|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +61870-2;LL1018-2;[PROMIS] None|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +61870-2;LL1018-2;[PROMIS] None|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +61881-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +61881-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +61881-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +61881-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +61881-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +61884-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +61884-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +61884-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +61884-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +61884-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +61885-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +61885-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +61885-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +61885-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +61885-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +61938-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +61944-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +61944-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +61944-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +61944-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +61944-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +61971-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +61971-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +61971-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +61971-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +61971-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62055-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62055-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62055-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62055-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62055-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62056-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62056-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62056-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62056-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62056-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62057-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62057-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62057-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62057-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62057-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62058-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62058-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62058-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62058-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62058-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62059-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62059-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62059-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62059-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62059-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62060-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62060-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62060-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62060-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62060-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62061-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62061-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62061-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62061-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62061-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62062-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62062-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62062-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62062-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62062-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62063-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62063-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62063-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62063-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62063-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62064-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62064-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62064-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62064-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62064-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62065-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62065-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62065-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62065-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62065-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62066-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62066-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62066-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62066-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62066-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62067-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62067-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62067-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62067-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62067-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62069-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62069-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62069-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62069-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62069-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62070-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62070-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62070-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62070-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62070-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62071-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62071-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62071-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62071-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62071-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62072-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62072-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62072-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62072-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62072-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62073-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62073-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62073-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62073-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62073-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62074-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62074-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62074-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62074-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62074-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62075-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62075-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62075-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62075-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62075-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62076-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62076-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62076-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62076-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62076-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62077-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62077-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62077-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62077-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62077-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62078-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62078-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62078-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62078-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62078-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62079-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62079-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62079-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62079-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62079-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62080-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62080-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62080-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62080-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62080-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62081-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62081-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62081-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62081-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62081-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62082-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62082-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62082-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62082-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62082-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62083-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62083-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62083-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62083-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62083-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62084-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62084-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62084-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62084-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62084-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62086-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62086-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62086-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62086-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62086-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62087-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62087-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62087-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62087-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62087-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62088-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62088-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62088-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62088-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62088-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62089-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62089-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62089-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62089-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62089-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62090-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62090-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62090-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62090-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62090-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62091-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62091-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62091-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62091-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62091-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62092-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62092-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62092-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62092-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62092-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62093-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62093-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62093-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62093-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62093-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62094-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62094-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62094-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62094-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62094-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62096-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62096-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62096-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62096-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62096-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62098-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62099-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62100-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62101-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62102-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62103-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62104-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62104-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62104-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62104-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62104-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62105-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62106-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62107-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62108-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62109-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62110-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62111-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62112-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62113-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62114-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62115-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62116-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62142-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62142-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62142-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62142-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62142-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62143-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62143-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62143-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62143-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62143-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62144-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62144-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62144-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62144-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62144-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62145-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62145-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62145-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62145-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62145-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62146-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62146-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62146-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62146-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62146-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62147-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62147-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62147-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62147-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62147-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62148-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62148-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62148-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62148-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62148-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62149-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62149-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62149-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62149-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62149-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62150-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62150-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62150-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62150-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62150-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62151-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62151-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62151-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62151-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62151-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62152-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62152-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62152-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62152-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62152-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62153-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62153-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62153-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62153-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62153-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62154-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62154-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62154-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62154-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62154-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62156-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62156-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62156-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62156-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62156-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62157-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62157-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62157-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62157-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62157-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62158-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62158-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62158-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62158-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62158-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62160-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62160-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62160-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62160-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62160-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62161-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62161-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62161-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62161-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62161-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62162-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62162-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62162-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62162-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62162-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62163-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62163-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62163-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62163-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62163-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62164-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62164-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62164-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62164-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62164-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62165-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62165-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62165-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62165-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62165-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62166-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62166-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62166-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62166-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62166-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62167-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62167-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62167-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62167-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62167-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62168-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62168-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62168-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62168-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62168-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62169-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62169-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62169-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62169-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62169-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62170-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62170-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62170-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62170-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62170-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62181-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62181-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62181-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62181-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62181-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62182-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62182-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62182-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62182-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62182-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62183-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62183-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62183-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62183-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62183-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62184-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62184-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62184-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62184-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62184-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62185-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62185-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62185-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62185-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62185-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62187-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62187-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62187-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62187-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62187-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62188-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62188-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62188-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62188-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62188-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62204-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62205-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62205-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62205-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62205-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62205-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62213-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62213-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62213-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62213-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62213-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62225-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62225-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62225-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62225-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62225-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62339-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62339-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62339-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62339-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62339-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +62340-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +62340-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +62340-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +62340-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +62340-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68160-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68160-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68160-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68160-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68160-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68161-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68161-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68161-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68161-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68161-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68162-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68162-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68162-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68162-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68162-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68163-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68163-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68163-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68163-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68163-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68164-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68164-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68164-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68164-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68164-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68166-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68166-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68166-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68166-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68166-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68167-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68167-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68167-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68167-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68167-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68168-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68168-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68168-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68168-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68168-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68169-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68169-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68169-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68169-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68169-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68170-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68170-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68170-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68170-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68170-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68171-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68171-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68171-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68171-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68171-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68172-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68172-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68172-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68172-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68172-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68173-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68173-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68173-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68173-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68173-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68181-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68181-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68181-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68181-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68181-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68182-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68182-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68182-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68182-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68182-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68183-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68183-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68183-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68183-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68183-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68186-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68186-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68186-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68186-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68186-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68187-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68187-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68187-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68187-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68187-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68188-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68188-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68188-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68188-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68188-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68189-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68189-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68189-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68189-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68189-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68190-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68190-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68190-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68190-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68190-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68191-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68191-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68191-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68191-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68191-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68192-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68192-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68192-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68192-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68192-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68193-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68193-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68193-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68193-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68193-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68194-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68194-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68194-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68194-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68194-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68195-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68195-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68195-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68195-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68195-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68196-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68196-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68196-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68196-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68196-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68197-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68197-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68197-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68197-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68197-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68198-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68198-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68198-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68198-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68198-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68199-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68199-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68199-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68199-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68199-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68200-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68200-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68200-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68200-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68200-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68201-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68201-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68201-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68201-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68201-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68202-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68202-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68202-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68202-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68202-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68203-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68203-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68203-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68203-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68203-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68204-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68204-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68204-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68204-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68204-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68205-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68205-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68205-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68205-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68205-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68206-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68206-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68206-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68206-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68206-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68207-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68207-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68207-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68207-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68207-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68208-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68208-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68208-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68208-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68208-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68209-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68209-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68209-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68209-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68209-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68210-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68210-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68210-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68210-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68210-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68211-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68211-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68211-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68211-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68211-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68212-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68212-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68212-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68212-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68212-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68213-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68213-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68213-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68213-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68213-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68241-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68241-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68241-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68241-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68241-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68242-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68242-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68242-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68242-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68242-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68244-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68244-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68244-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68244-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68244-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68245-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68245-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68245-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68245-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68245-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68322-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68322-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68322-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68322-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68322-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +68323-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +68323-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +68323-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +68323-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +68323-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +75899-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +75899-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +75899-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +75899-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +75899-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +75906-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +75906-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +75906-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +75906-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +75906-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78077-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78077-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78077-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78077-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78077-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78078-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78078-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78078-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78078-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78078-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78162-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78162-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78162-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78162-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78162-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78163-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78163-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78163-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78163-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78163-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78164-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78164-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78164-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78164-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78164-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78165-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78165-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78165-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78165-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78165-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78166-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78166-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78166-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78166-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78166-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78167-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78167-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78167-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78167-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78167-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78168-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78168-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78168-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78168-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78168-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +78169-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +78169-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +78169-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +78169-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +78169-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89934-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89934-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89934-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89934-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89934-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89937-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89937-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89937-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89937-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89937-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89938-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89938-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89938-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89938-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89938-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89939-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89939-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89939-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89939-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89939-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89940-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89940-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89940-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89940-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89940-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89941-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89941-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89941-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89941-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89941-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89942-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89942-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89942-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89942-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89942-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89943-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89943-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89943-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89943-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89943-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89944-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89944-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89944-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89944-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89944-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89945-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89945-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89945-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89945-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89945-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89946-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89946-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89946-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89946-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89946-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89947-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89947-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89947-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89947-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89947-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +89948-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +89948-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +89948-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +89948-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +89948-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90664-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90664-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90664-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90664-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90664-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90665-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90665-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90665-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90665-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90665-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90666-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90666-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90666-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90666-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90666-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90667-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90667-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90667-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90667-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90667-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90668-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90668-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90668-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90668-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90668-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90669-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90669-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90669-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90669-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90669-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90670-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90670-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90670-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90670-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90670-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90671-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90671-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90671-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90671-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90671-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90672-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90672-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90672-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90672-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90672-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90673-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90673-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90673-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90673-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90673-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90674-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90674-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90674-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90674-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90674-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90675-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90675-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90675-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90675-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90675-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90677-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90677-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90677-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90677-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90677-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +90678-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +90678-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +90678-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +90678-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +90678-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91394-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91394-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91394-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91394-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91394-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91395-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91395-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91395-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91395-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91395-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91396-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91396-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91396-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91396-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91396-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91397-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91397-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91397-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91397-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91397-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91398-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91398-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91398-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91398-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91398-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91399-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91399-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91399-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91399-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91399-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91400-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91400-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91400-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91400-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91400-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91401-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91401-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91401-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91401-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91401-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91402-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91402-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91402-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91402-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91402-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91403-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91403-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91403-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91403-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91403-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91404-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91404-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91404-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91404-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91404-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91405-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91405-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91405-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91405-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91405-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91408-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91408-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91408-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91408-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91408-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91409-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91409-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91409-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91409-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91409-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91410-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91410-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91410-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91410-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91410-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91411-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91411-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91411-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91411-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91411-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91412-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91412-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91412-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91412-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91412-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91413-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91413-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91413-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91413-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91413-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91414-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91414-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91414-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91414-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91414-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91415-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91415-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91415-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91415-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91415-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91416-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91416-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91416-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91416-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91416-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91417-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91417-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91417-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91417-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91417-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91418-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91418-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91418-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91418-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91418-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91419-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91419-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91419-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91419-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91419-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91420-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91420-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91420-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91420-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91420-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91421-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91421-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91421-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91421-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91421-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91422-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91422-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91422-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91422-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91422-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91423-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91423-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91423-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91423-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91423-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91424-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91424-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91424-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91424-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91424-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91910-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91910-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91910-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91910-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91910-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91912-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91912-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91912-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91912-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91912-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91913-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91913-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91913-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91913-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91913-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91914-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91914-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91914-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91914-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91914-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91915-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91915-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91915-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91915-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91915-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91916-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91916-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91916-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91916-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91916-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91917-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91917-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91917-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91917-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91917-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91918-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91918-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91918-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91918-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91918-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91919-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91919-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91919-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91919-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91919-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91920-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91920-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91920-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91920-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91920-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91921-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91921-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91921-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91921-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91921-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91922-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91922-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91922-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91922-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91922-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91923-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91923-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91923-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91923-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91923-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91924-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91924-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91924-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91924-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91924-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91925-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91925-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91925-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91925-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91925-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91926-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91926-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91926-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91926-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91926-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91927-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91927-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91927-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91927-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91927-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91929-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91929-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91929-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91929-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91929-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91931-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91931-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91931-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91931-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91931-6;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91932-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91932-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91932-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91932-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91932-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91989-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91989-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91989-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91989-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91989-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91990-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91990-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91990-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91990-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91990-2;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91991-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91991-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91991-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91991-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91991-0;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91992-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91992-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91992-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91992-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91992-8;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91994-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91994-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91994-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91994-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91994-4;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91995-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91995-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91995-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91995-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91995-1;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91996-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91996-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91996-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91996-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91996-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91997-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91997-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91997-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91997-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91997-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91998-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91998-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91998-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91998-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91998-5;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +91999-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +91999-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +91999-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +91999-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +91999-3;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +92000-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +92000-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +92000-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +92000-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +92000-9;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +92001-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA6270-8;1;Never;;; +92001-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13866-1;2;Almost never;;; +92001-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10082-8;3;Sometimes;;; +92001-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA10044-8;4;Often;;; +92001-7;LL1024-0;[PROMIS] Nev|Alm never|Sometimes|Often|Alm always;LA13865-3;5;Almost always;;; +61985-8;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +61985-8;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +61985-8;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +61985-8;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +61985-8;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +61986-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +61986-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +61986-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +61986-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +61986-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90131-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90131-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90131-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90131-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90131-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90132-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90132-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90132-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90132-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90132-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90133-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90133-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90133-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90133-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90133-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90141-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90141-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90141-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90141-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90141-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90145-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90145-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90145-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90145-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90145-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90147-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90147-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90147-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90147-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90147-0;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90149-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90149-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90149-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90149-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90149-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90151-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90151-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90151-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90151-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90151-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90159-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90159-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90159-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90159-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90159-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90163-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90163-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90163-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90163-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90163-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90165-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90165-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90165-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90165-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90165-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90169-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90169-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90169-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90169-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90169-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90178-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90178-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90178-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90178-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90178-5;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90179-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90179-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90179-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90179-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90179-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90180-1;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90180-1;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90180-1;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90180-1;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90180-1;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90188-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90188-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90188-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90188-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90188-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90192-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90192-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90192-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90192-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90192-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90194-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90194-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90194-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90194-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90194-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90196-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90196-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90196-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90196-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90196-7;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90198-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90198-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90198-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90198-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90198-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90206-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90206-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90206-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90206-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90206-4;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90210-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90210-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90210-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90210-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90210-6;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90212-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90212-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90212-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90212-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90212-2;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +90216-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA6568-5;1;Not at all;;; +90216-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13863-8;2;A little bit;;; +90216-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13909-9;3;Somewhat;;; +90216-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13902-4;4;Quite a bit;;; +90216-3;LL3325-9;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|VeryMuch(1);LA13914-9;5;Very much;;; +61987-4;LL1023-2;[PROMIS] Very poor|Poor|Fair|Good|Very good;LA9615-1;1;Very poor;;; +61987-4;LL1023-2;[PROMIS] Very poor|Poor|Fair|Good|Very good;LA8969-3;2;Poor;;; +61987-4;LL1023-2;[PROMIS] Very poor|Poor|Fair|Good|Very good;LA8968-5;3;Fair;;; +61987-4;LL1023-2;[PROMIS] Very poor|Poor|Fair|Good|Very good;LA8967-7;4;Good;;; +61987-4;LL1023-2;[PROMIS] Very poor|Poor|Fair|Good|Very good;LA13913-1;5;Very Good;;; +62104-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62104-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62104-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62104-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62104-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62142-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62142-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62142-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62142-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62142-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62143-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62143-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62143-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62143-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62143-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62144-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62144-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62144-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62144-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62144-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62145-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62145-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62145-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62145-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62145-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62146-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62146-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62146-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62146-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62146-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62147-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62147-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62147-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62147-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62147-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62148-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62148-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62148-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62148-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62148-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62149-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62149-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62149-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62149-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62149-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62150-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62150-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62150-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62150-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62150-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62151-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62151-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62151-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62151-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62151-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62152-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62152-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62152-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62152-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62152-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62153-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62153-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62153-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62153-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62153-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62154-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62154-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62154-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62154-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62154-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62156-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62157-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62157-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62157-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62157-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62157-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62158-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62158-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62158-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62158-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62158-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62159-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62159-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62159-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62159-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62159-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62160-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62160-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62160-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62160-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62160-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62161-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62161-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62161-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62161-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62161-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62162-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62162-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62162-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62162-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62162-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62163-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62164-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62164-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62164-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62164-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62164-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62165-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62166-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62167-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62168-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62169-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +62170-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +75906-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78077-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78077-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78077-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78077-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78077-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78078-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78078-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78078-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78078-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78078-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78079-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78079-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78079-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78079-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78079-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78162-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78162-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78162-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78162-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78162-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78163-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78163-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78163-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78163-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78163-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78164-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78164-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78164-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78164-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78164-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78165-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78165-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78165-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78165-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78165-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78166-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78166-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78166-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78166-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78166-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78167-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78167-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78167-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78167-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78167-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78168-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78168-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78168-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78168-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78168-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78169-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78169-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78169-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78169-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78169-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78171-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78171-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78171-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78171-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78171-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78172-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78172-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78172-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78172-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78172-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78173-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78173-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78173-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78173-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78173-2;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +78174-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +78174-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +78174-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +78174-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +78174-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89937-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89938-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89939-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89940-1;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89941-9;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89942-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89942-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89942-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89942-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89942-7;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89943-5;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89944-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89944-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89944-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89944-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89944-3;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89945-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89945-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89945-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89945-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89945-0;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89946-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89946-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89946-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89946-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89946-8;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89947-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89947-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89947-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89947-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89947-6;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA6270-8;1;Never;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13866-1;2;Almost never;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10082-8;3;Sometimes;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA10044-8;4;Often;;; +89948-4;LL3004-0;[PROMIS] Nev|alm nev|Some|Often|Alm Always;LA13865-3;5;Almost always;;; +62118-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62118-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62118-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62118-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62118-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62119-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62119-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62119-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62119-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62119-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62120-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62120-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62120-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62120-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62120-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62121-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62121-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62121-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62121-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62121-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62122-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62122-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62122-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62122-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62122-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62123-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62123-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62123-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62123-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62123-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62124-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62124-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62124-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62124-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62124-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62125-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62125-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62125-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62125-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62125-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62126-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62126-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62126-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62126-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62126-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62127-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62127-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62127-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62127-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62127-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62130-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62130-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62130-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62130-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62130-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62131-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62131-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62131-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62131-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62131-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62132-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62132-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62132-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62132-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62132-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62133-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62133-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62133-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62133-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62133-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62134-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62134-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62134-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62134-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62134-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62135-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62135-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62135-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62135-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62135-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62136-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62136-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62136-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62136-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62136-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62137-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62137-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62137-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62137-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62137-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62138-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62138-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62138-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62138-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62138-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62139-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62139-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62139-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62139-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62139-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62140-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62140-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62140-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62140-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62140-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62172-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62172-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62172-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62172-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62172-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62173-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62173-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62173-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62173-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62173-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62174-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62174-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62174-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62174-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62174-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62175-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62175-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62175-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62175-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62175-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62176-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62176-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62176-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62176-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62176-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62177-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62177-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62177-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62177-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62177-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62178-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62178-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62178-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62178-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62178-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62179-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62179-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62179-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62179-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62179-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62214-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62214-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62214-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62214-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62214-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62215-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62215-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62215-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62215-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62215-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62216-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62216-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62216-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62216-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62216-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62217-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62217-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62217-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62217-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62217-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62218-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62218-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62218-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62218-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62218-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62219-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62219-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62219-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62219-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62219-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62220-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62220-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62220-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62220-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62220-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62221-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62221-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62221-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62221-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62221-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62222-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62222-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62222-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62222-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62222-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62223-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62223-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62223-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62223-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62223-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62224-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62224-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62224-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62224-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62224-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62226-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62226-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62226-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62226-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62226-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62227-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62227-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62227-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62227-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62227-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62228-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62228-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62228-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62228-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62228-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62229-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62229-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62229-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62229-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62229-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62230-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62230-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62230-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62230-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62230-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62231-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62231-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62231-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62231-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62231-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62232-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62232-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62232-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62232-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62232-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62233-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +62233-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +62233-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +62233-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +62233-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68262-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68262-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68262-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68262-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68262-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68263-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68263-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68263-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68263-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68263-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68264-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68264-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68264-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68264-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68264-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68265-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68265-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68265-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68265-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68265-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68266-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68266-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68266-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68266-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68266-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68267-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68267-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68267-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68267-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68267-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68268-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68268-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68268-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68268-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68268-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68269-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68269-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68269-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68269-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68269-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68270-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68270-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68270-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68270-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68270-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68271-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68271-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68271-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68271-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68271-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68272-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68272-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68272-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68272-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68272-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68273-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68273-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68273-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68273-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68273-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68274-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68274-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68274-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68274-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68274-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68275-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68275-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68275-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68275-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68275-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68276-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68276-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68276-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68276-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68276-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68277-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68277-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68277-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68277-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68277-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68278-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68278-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68278-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68278-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68278-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68279-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68279-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68279-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68279-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68279-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68280-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68280-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68280-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68280-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68280-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68281-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68281-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68281-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68281-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68281-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68282-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68282-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68282-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68282-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68282-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68294-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68294-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68294-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68294-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68294-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68295-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68295-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68295-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68295-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68295-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68296-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68296-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68296-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68296-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68296-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68297-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68297-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68297-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68297-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68297-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68298-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68298-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68298-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68298-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68298-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68299-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68299-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68299-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68299-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68299-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68300-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68300-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68300-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68300-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68300-3;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68301-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68301-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68301-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68301-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68301-1;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68302-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68302-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68302-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68302-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68302-9;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68303-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68303-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68303-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68303-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68303-7;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68304-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68304-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68304-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68304-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68304-5;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68305-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68305-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68305-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68305-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68305-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68306-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68306-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68306-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68306-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68306-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68307-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68307-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68307-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68307-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68307-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68308-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68308-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68308-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68308-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68308-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68309-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68309-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68309-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68309-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68309-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68310-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68310-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68310-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68310-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68310-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68311-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68311-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68311-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68311-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68311-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68312-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68312-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68312-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68312-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68312-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +68313-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +68313-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +68313-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +68313-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +68313-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +78069-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +78069-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +78069-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +78069-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +78069-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +78070-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +78070-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +78070-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +78070-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +78070-0;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +78071-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +78071-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +78071-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +78071-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +78071-8;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +78072-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +78072-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +78072-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +78072-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +78072-6;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +78073-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +78073-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +78073-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +78073-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +78073-4;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +78074-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13953-7;1;With no trouble;;; +78074-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13954-5;2;With a little trouble;;; +78074-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13955-2;3;With some trouble;;; +78074-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13956-0;4;With a lot of trouble;;; +78074-2;LL1025-7;[PROMIS] W no troub|Lit tr|Some tr|Lot tr|Not able;LA13957-8;5;Not able to do;;; +62118-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62118-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62118-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62118-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62118-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62119-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62119-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62119-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62119-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62119-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62120-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62120-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62120-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62120-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62120-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62121-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62121-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62121-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62121-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62121-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62122-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62122-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62122-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62122-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62122-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62123-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62123-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62123-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62123-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62123-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62124-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62124-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62124-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62124-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62124-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62125-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62125-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62125-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62125-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62125-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62126-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62126-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62126-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62126-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62126-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62127-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62127-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62127-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62127-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62127-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62130-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62130-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62130-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62130-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62130-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62131-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62131-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62131-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62131-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62131-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62132-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62132-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62132-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62132-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62132-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62133-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62133-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62133-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62133-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62133-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62134-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62134-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62134-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62134-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62134-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62135-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62135-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62135-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62135-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62135-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62136-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62136-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62136-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62136-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62136-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62137-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62137-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62137-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62137-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62137-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62138-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62138-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62138-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62138-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62138-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62139-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62139-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62139-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62139-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62139-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +78074-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +78074-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +78074-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +78074-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +78074-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90681-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90681-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90681-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90681-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90681-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90682-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90682-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90682-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90682-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90682-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90683-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90683-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90683-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90683-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90683-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90684-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90684-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90684-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90684-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90684-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90685-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90685-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90685-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90685-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90685-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90686-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90686-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90686-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90686-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90686-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90687-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90687-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90687-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90687-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90687-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90688-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90688-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90688-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90688-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90688-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90689-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90689-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90689-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90689-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90689-1;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90690-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90690-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90690-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90690-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90690-9;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90691-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90691-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90691-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90691-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90691-7;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90692-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90692-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90692-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90692-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90692-5;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90693-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90693-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90693-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90693-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90693-3;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90695-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90695-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90695-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90695-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90695-8;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90696-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90696-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90696-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90696-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90696-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90697-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90697-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90697-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90697-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90697-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90698-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90698-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90698-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90698-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90698-2;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90699-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90699-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90699-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90699-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90699-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90700-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90700-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90700-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90700-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90700-6;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90701-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90701-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90701-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90701-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90701-4;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +90703-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +90703-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +90703-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +90703-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +90703-0;LL5175-6;No troub(5)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62118-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62118-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62118-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62118-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62118-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62119-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62119-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62119-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62119-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62119-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62120-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62120-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62120-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62120-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62120-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62121-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62121-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62121-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62121-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62121-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62122-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62122-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62122-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62122-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62122-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62123-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62123-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62123-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62123-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62123-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62124-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62124-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62124-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62124-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62124-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62125-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62125-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62125-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62125-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62125-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62126-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62126-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62126-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62126-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62126-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62127-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62127-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62127-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62127-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62127-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62128-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62128-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62128-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62128-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62128-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62129-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62129-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62129-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62129-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62129-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62130-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62130-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62130-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62130-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62130-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62131-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62131-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62131-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62131-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62131-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62132-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62132-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62132-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62132-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62132-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62133-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62133-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62133-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62133-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62133-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62134-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62134-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62134-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62134-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62134-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62135-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62135-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62135-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62135-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62135-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62136-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62136-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62136-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62136-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62136-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62137-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62137-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62137-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62137-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62137-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62138-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62138-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62138-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62138-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62138-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62139-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62139-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62139-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62139-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62139-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62140-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +62140-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +62140-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +62140-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +62140-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90681-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90682-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90682-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90682-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90682-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90682-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90683-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90684-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90684-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90684-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90684-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90684-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90685-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90685-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90685-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90685-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90685-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90686-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90686-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90686-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90686-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90686-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90687-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90688-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90688-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90688-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90688-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90688-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90689-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90690-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90690-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90690-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90690-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90690-9;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90691-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90691-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90691-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90691-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90691-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90692-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90692-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90692-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90692-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90692-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90693-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90695-8;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90696-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90697-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90697-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90697-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90697-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90697-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90698-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90698-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90698-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90698-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90698-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90699-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90699-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90699-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90699-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90699-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90700-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90701-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90701-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90701-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90701-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90701-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +90703-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +90703-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +90703-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +90703-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +90703-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94171-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94171-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94171-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94171-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94171-6;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94172-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94172-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94172-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94172-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94172-4;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94173-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94173-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94173-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94173-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94173-2;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94174-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94174-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94174-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94174-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94174-0;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94175-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94175-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94175-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94175-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94175-7;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94176-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94176-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94176-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94176-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94176-5;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94177-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94177-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94177-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94177-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94177-3;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +94178-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13953-7;1;With no trouble;;; +94178-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13954-5;2;With a little trouble;;; +94178-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13955-2;3;With some trouble;;; +94178-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13956-0;4;With a lot of trouble;;; +94178-1;LL5201-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(0);LA13957-8;5;Not able to do;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +62128-4;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +62129-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +62159-9;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +62159-9;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +62159-9;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +62159-9;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +62159-9;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +90676-8;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +90676-8;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +90676-8;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +90676-8;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +90676-8;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +90694-1;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +90694-1;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +90694-1;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +90694-1;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +90694-1;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +90702-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA6270-8;1;Never;;; +90702-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13866-1;2;Almost never;;; +90702-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10082-8;3;Sometimes;;; +90702-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA10044-8;4;Often;;; +90702-2;LL5176-4;Nev(5)|Alm never|Sometimes|Often|Alm always(1);LA13865-3;5;Almost always;;; +62140-9;LL5197-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(1);LA13953-7;1;With no trouble;;; +62140-9;LL5197-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(1);LA13954-5;2;With a little trouble;;; +62140-9;LL5197-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(1);LA13955-2;3;With some trouble;;; +62140-9;LL5197-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(1);LA13956-0;4;With a lot of trouble;;; +62140-9;LL5197-0;No troub(4)|Lit tr|Some tr|Lot tr|Not able(1);LA13957-8;5;Not able to do;;; +62237-3;LL1032-3;Cpenase;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +62237-3;LL1032-3;Cpenase;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +62237-3;LL1032-3;Cpenase;LA13967-7;3;Non-reportable Positive;;; +62237-3;LL1032-3;Cpenase;LA13968-5;4;Non-reportable Negative;;; +62302-5;LL1043-0;LDS;LA14036-0;1;Fabry disease;16652001;Fabry's disease (disorder);http://snomed.info/sct +62302-5;LL1043-0;LDS;LA14037-8;2;Pompe disease;274864009;Glycogen storage disease, type II (disorder);http://snomed.info/sct +62302-5;LL1043-0;LDS;LA14038-6;3;Krabbe disease;192782005;Galactosylceramide beta-galactosidase deficiency (disorder);http://snomed.info/sct +62302-5;LL1043-0;LDS;LA14040-2;4;Niemann Pick disease A/B;58459009;Sphingomyelin/cholesterol lipidosis (disorder);http://snomed.info/sct +62302-5;LL1043-0;LDS;LA14039-4;5;Gaucher disease;190794006;Glucosylceramide beta-glucosidase deficiency (disorder);http://snomed.info/sct +62302-5;LL1043-0;LDS;LA25797-4;6;Mucopolysaccharidosis type I;75610003;Mucopolysaccharidosis type I (disorder);http://snomed.info/sct +62357-9;LL1034-9;Normal|Abnormal|Clinical significance unknown;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +62357-9;LL1034-9;Normal|Abnormal|Clinical significance unknown;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +62357-9;LL1034-9;Normal|Abnormal|Clinical significance unknown;LA14007-1;3;Clinical significance unknown;;; +64090-4;LL1034-9;Normal|Abnormal|Clinical significance unknown;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +64090-4;LL1034-9;Normal|Abnormal|Clinical significance unknown;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +64090-4;LL1034-9;Normal|Abnormal|Clinical significance unknown;LA14007-1;3;Clinical significance unknown;;; +62358-7;LL1035-6;ISCN band lvl;LA14008-9;1;400;;; +62358-7;LL1035-6;ISCN band lvl;LA14112-9;2;425;;; +62358-7;LL1035-6;ISCN band lvl;LA14113-7;3;450;;; +62358-7;LL1035-6;ISCN band lvl;LA14009-7;4;500;;; +62358-7;LL1035-6;ISCN band lvl;LA14114-5;5;550;;; +62358-7;LL1035-6;ISCN band lvl;LA14115-2;6;575;;; +62358-7;LL1035-6;ISCN band lvl;LA14010-5;7;600;;; +62358-7;LL1035-6;ISCN band lvl;LA14116-0;8;650;;; +62358-7;LL1035-6;ISCN band lvl;LA14011-3;9;800;;; +62358-7;LL1035-6;ISCN band lvl;LA14012-1;10;850;;; +64087-0;LL1035-6;ISCN band lvl;LA14008-9;1;400;;; +64087-0;LL1035-6;ISCN band lvl;LA14112-9;2;425;;; +64087-0;LL1035-6;ISCN band lvl;LA14113-7;3;450;;; +64087-0;LL1035-6;ISCN band lvl;LA14009-7;4;500;;; +64087-0;LL1035-6;ISCN band lvl;LA14114-5;5;550;;; +64087-0;LL1035-6;ISCN band lvl;LA14115-2;6;575;;; +64087-0;LL1035-6;ISCN band lvl;LA14010-5;7;600;;; +64087-0;LL1035-6;ISCN band lvl;LA14116-0;8;650;;; +64087-0;LL1035-6;ISCN band lvl;LA14011-3;9;800;;; +64087-0;LL1035-6;ISCN band lvl;LA14012-1;10;850;;; +64093-8;LL1035-6;ISCN band lvl;LA14008-9;1;400;;; +64093-8;LL1035-6;ISCN band lvl;LA14112-9;2;425;;; +64093-8;LL1035-6;ISCN band lvl;LA14113-7;3;450;;; +64093-8;LL1035-6;ISCN band lvl;LA14009-7;4;500;;; +64093-8;LL1035-6;ISCN band lvl;LA14114-5;5;550;;; +64093-8;LL1035-6;ISCN band lvl;LA14115-2;6;575;;; +64093-8;LL1035-6;ISCN band lvl;LA14010-5;7;600;;; +64093-8;LL1035-6;ISCN band lvl;LA14116-0;8;650;;; +64093-8;LL1035-6;ISCN band lvl;LA14011-3;9;800;;; +64093-8;LL1035-6;ISCN band lvl;LA14012-1;10;850;;; +62359-5;LL1036-4;Banding;LA14013-9;1;G-banding;;; +62359-5;LL1036-4;Banding;LA14014-7;2;R-banding;;; +62359-5;LL1036-4;Banding;LA14015-4;3;Q-banding;;; +62359-5;LL1036-4;Banding;LA14016-2;4;C-banding;;; +62359-5;LL1036-4;Banding;LA14017-0;5;T-banding;;; +62366-0;LL1037-2;Genetic recommendation;LA14020-4;1;Genetic counseling recommended;;; +62366-0;LL1037-2;Genetic recommendation;LA14021-2;2;Confirmatory testing recommended;;; +62366-0;LL1037-2;Genetic recommendation;LA14022-0;3;Additional testing recommended;;; +62368-6;LL1038-0;Phase;LA14023-8;1;Metaphase;;; +62368-6;LL1038-0;Phase;LA14024-6;2;Interphase;;; +62373-6;LL1039-8;HumanReferenceSeqAssembly;LA14025-3;1;hg19;;; +62373-6;LL1039-8;HumanReferenceSeqAssembly;LA14026-1;2;hg18;;; +62373-6;LL1039-8;HumanReferenceSeqAssembly;LA14027-9;3;hg17;;; +62373-6;LL1039-8;HumanReferenceSeqAssembly;LA14028-7;4;hg16;;; +62374-4;LL1040-6;HumanRefSeqNCBIBuildId;LA14032-9;0;NCBI Build 34;;; +62374-4;LL1040-6;HumanRefSeqNCBIBuildId;LA14029-5;1;GRCh37;;; +62374-4;LL1040-6;HumanRefSeqNCBIBuildId;LA14030-3;2;NCBI Build 36.1;;; +62374-4;LL1040-6;HumanRefSeqNCBIBuildId;LA14031-1;3;NCBI Build 35;;; +62374-4;LL1040-6;HumanRefSeqNCBIBuildId;LA26806-2;4;GRCh38;;; +62378-5;LL1041-4;CopyNumberChangeType;LA14033-7;1;Copy number gain;;; +62378-5;LL1041-4;CopyNumberChangeType;LA14034-5;2;Copy number loss;;; +95231-7;LL1041-4;CopyNumberChangeType;LA14033-7;1;Copy number gain;;; +95231-7;LL1041-4;CopyNumberChangeType;LA14034-5;2;Copy number loss;;; +62428-8;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +62428-8;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +62428-8;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +62428-8;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +62428-8;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +62428-8;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +62428-8;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +62428-8;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +6317-2;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +6317-2;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +6317-2;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +6317-2;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +6317-2;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +6317-2;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +6317-2;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +6317-2;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +88582-2;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +88582-2;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +88582-2;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88582-2;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +88582-2;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +88582-2;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +88582-2;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +88582-2;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +88583-0;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +88583-0;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +88583-0;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +88583-0;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +88583-0;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +88583-0;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +88583-0;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +88583-0;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +91777-3;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +91777-3;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +91777-3;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +91777-3;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +91777-3;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +91777-3;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +91777-3;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +91777-3;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +91813-6;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +91813-6;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +91813-6;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +91813-6;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +91813-6;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +91813-6;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +91813-6;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +91813-6;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +91838-3;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +91838-3;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +91838-3;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +91838-3;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +91838-3;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +91838-3;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +91838-3;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +91838-3;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +91871-4;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +91871-4;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +91871-4;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +91871-4;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +91871-4;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +91871-4;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +91871-4;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +91871-4;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +91872-2;LL1056-2;Bordetella;LA11883-8;1;Not detected;;; +91872-2;LL1056-2;Bordetella;LA14118-6;2;Genus Bordetella;46466005;Genus Bordetella (organism);http://snomed.info/sct +91872-2;LL1056-2;Bordetella;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +91872-2;LL1056-2;Bordetella;LA13548-5;4;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +91872-2;LL1056-2;Bordetella;LA14117-8;5;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +91872-2;LL1056-2;Bordetella;LA14121-0;6;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +91872-2;LL1056-2;Bordetella;LA14119-4;7;Bordetella holmseii;;; +91872-2;LL1056-2;Bordetella;LA14120-2;8;Bordetella bronchiseptica;;; +62454-4;LL1590-0;HSV/VZV;LA16547-4;1;No Herpes-Simplex isolated;;; +62454-4;LL1590-0;HSV/VZV;LA16548-2;2;Herpes-Simplex isolated;;; +62454-4;LL1590-0;HSV/VZV;LA16545-8;3;No Varicella-Zoster isolated;;; +62454-4;LL1590-0;HSV/VZV;LA16546-6;4;Varicella-Zoster isolated;;; +62493-2;LL2300-3;S pneum/Haem/S agal;LA19341-9;1;Streptococcus pneumoniae;9861002;Streptococcus pneumoniae (organism);http://snomed.info/sct +62493-2;LL2300-3;S pneum/Haem/S agal;LA19339-3;2;Haemophilus influenza;;; +62493-2;LL2300-3;S pneum/Haem/S agal;LA19342-7;3;Streptococcus agalactiae;43492007;Streptococcus agalactiae (organism);http://snomed.info/sct +62780-2;LL1592-6;PhenX13_48_motor function child 2-4Y;LA15147-4;1;Has difficulty controlling head and trunk posture in most positions;;; +62780-2;LL1592-6;PhenX13_48_motor function child 2-4Y;LA15148-2;2;Can sit on own when placed on the floor and can move within a room;;; +62780-2;LL1592-6;PhenX13_48_motor function child 2-4Y;LA16553-2;3;Can sit on own and walk short distances with a walking aid (such as a walker, rollator, crutches, canes, etc.);;; +62780-2;LL1592-6;PhenX13_48_motor function child 2-4Y;LA16554-0;4;Can sit on own and usually moves by walking with a walking aid.;;; +62780-2;LL1592-6;PhenX13_48_motor function child 2-4Y;LA16555-7;5;Can sit on own and moves by walking without a walking aid.;;; +66061-3;LL1592-6;PhenX13_48_motor function child 2-4Y;LA15147-4;1;Has difficulty controlling head and trunk posture in most positions;;; +66061-3;LL1592-6;PhenX13_48_motor function child 2-4Y;LA15148-2;2;Can sit on own when placed on the floor and can move within a room;;; +66061-3;LL1592-6;PhenX13_48_motor function child 2-4Y;LA16553-2;3;Can sit on own and walk short distances with a walking aid (such as a walker, rollator, crutches, canes, etc.);;; +66061-3;LL1592-6;PhenX13_48_motor function child 2-4Y;LA16554-0;4;Can sit on own and usually moves by walking with a walking aid.;;; +66061-3;LL1592-6;PhenX13_48_motor function child 2-4Y;LA16555-7;5;Can sit on own and moves by walking without a walking aid.;;; +62781-0;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16558-1;1;Has difficulty sitting on their own and controlling their head and body posture in most positions;;; +62781-0;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16556-5;2;Can sit on their own but does not stand or walk without significant support and adult supervision.;;; +62781-0;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16560-7;3;Can walk on their own using a walking aid (such as a walker, rollator, crutches, canes, etc.);;; +62781-0;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16561-5;4;Can walk on their own without using a walking aid, but has difficulty walking long distances or on uneven surfaces.;;; +62781-0;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16557-3;5;Can walk on their own without using a walking aid, including fairly long distances, outdoors and on uneven surfaces.;;; +66062-1;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16558-1;1;Has difficulty sitting on their own and controlling their head and body posture in most positions;;; +66062-1;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16556-5;2;Can sit on their own but does not stand or walk without significant support and adult supervision.;;; +66062-1;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16560-7;3;Can walk on their own using a walking aid (such as a walker, rollator, crutches, canes, etc.);;; +66062-1;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16561-5;4;Can walk on their own without using a walking aid, but has difficulty walking long distances or on uneven surfaces.;;; +66062-1;LL1593-4;PhenX13_49_motor function child 4-6Y;LA16557-3;5;Can walk on their own without using a walking aid, including fairly long distances, outdoors and on uneven surfaces.;;; +62782-8;LL1594-2;PhenX13_50_motor function child 6-12Y;LA16558-1;1;Has difficulty sitting on their own and controlling their head and body posture in most positions;;; +62782-8;LL1594-2;PhenX13_50_motor function child 6-12Y;LA16556-5;2;Can sit on their own but does not stand or walk without significant support and adult supervision.;;; +62782-8;LL1594-2;PhenX13_50_motor function child 6-12Y;LA15150-8;3;Can stand on their own and only walks using a walking aid (such as a walker, rollator, crutches, canes, etc.);;; +62782-8;LL1594-2;PhenX13_50_motor function child 6-12Y;LA15151-6;4;Can walk on their own without using walking aids, but needs to hold the handrail when going up or down stairs;;; +62782-8;LL1594-2;PhenX13_50_motor function child 6-12Y;LA16552-4;5;Can walk on their own without using walking aids, and can go up or down stairs without needing to hold the handrail.;;; +66063-9;LL1594-2;PhenX13_50_motor function child 6-12Y;LA16558-1;1;Has difficulty sitting on their own and controlling their head and body posture in most positions;;; +66063-9;LL1594-2;PhenX13_50_motor function child 6-12Y;LA16556-5;2;Can sit on their own but does not stand or walk without significant support and adult supervision.;;; +66063-9;LL1594-2;PhenX13_50_motor function child 6-12Y;LA15150-8;3;Can stand on their own and only walks using a walking aid (such as a walker, rollator, crutches, canes, etc.);;; +66063-9;LL1594-2;PhenX13_50_motor function child 6-12Y;LA15151-6;4;Can walk on their own without using walking aids, but needs to hold the handrail when going up or down stairs;;; +66063-9;LL1594-2;PhenX13_50_motor function child 6-12Y;LA16552-4;5;Can walk on their own without using walking aids, and can go up or down stairs without needing to hold the handrail.;;; +62862-8;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +62862-8;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +62862-8;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81697-5;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81697-5;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81697-5;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81698-3;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81698-3;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81698-3;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81699-1;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81699-1;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81699-1;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81700-7;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81700-7;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81700-7;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81701-5;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81701-5;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81701-5;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81702-3;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81702-3;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81702-3;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81703-1;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81703-1;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81703-1;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81704-9;LL1057-0;Stable|Unstable|Indeterminate;LA14122-8;1;Stable;;; +81704-9;LL1057-0;Stable|Unstable|Indeterminate;LA14123-6;2;Unstable;;; +81704-9;LL1057-0;Stable|Unstable|Indeterminate;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +62920-4;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +62920-4;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +62920-4;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +62920-4;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66580-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66580-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66580-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66580-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66581-0;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66581-0;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66581-0;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66581-0;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66582-8;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66582-8;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66582-8;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66582-8;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66583-6;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66583-6;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66583-6;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66583-6;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66584-4;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66584-4;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66584-4;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66584-4;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66585-1;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66585-1;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66585-1;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66585-1;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66586-9;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66586-9;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66586-9;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66586-9;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66587-7;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66587-7;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66587-7;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66587-7;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66588-5;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66588-5;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66588-5;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66588-5;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66589-3;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66589-3;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66589-3;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66589-3;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66590-1;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66590-1;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66590-1;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66590-1;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66591-9;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66591-9;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66591-9;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66591-9;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66592-7;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66592-7;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66592-7;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66592-7;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66593-5;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66593-5;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66593-5;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66593-5;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66594-3;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66594-3;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66594-3;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66594-3;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66595-0;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66595-0;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66595-0;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66595-0;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66596-8;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66596-8;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66596-8;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66596-8;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66597-6;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66597-6;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66597-6;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66597-6;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66598-4;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66598-4;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66598-4;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66598-4;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66599-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66599-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66599-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66599-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66600-8;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66600-8;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66600-8;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66600-8;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66601-6;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66601-6;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66601-6;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66601-6;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66602-4;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66602-4;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66602-4;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66602-4;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66603-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66603-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66603-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66603-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66604-0;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66604-0;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66604-0;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66604-0;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66629-7;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66629-7;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66629-7;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66629-7;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66630-5;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66630-5;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66630-5;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66630-5;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66631-3;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66631-3;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66631-3;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66631-3;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66632-1;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66632-1;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66632-1;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66632-1;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66633-9;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66633-9;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66633-9;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66633-9;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66634-7;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66634-7;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66634-7;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66634-7;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66635-4;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66635-4;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66635-4;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66635-4;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66636-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66636-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66636-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66636-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66637-0;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66637-0;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66637-0;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66637-0;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66638-8;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66638-8;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66638-8;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66638-8;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66639-6;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66639-6;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66639-6;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66639-6;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66640-4;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66640-4;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66640-4;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66640-4;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66641-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66641-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66641-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66641-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66642-0;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66642-0;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66642-0;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66642-0;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66643-8;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66643-8;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66643-8;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66643-8;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66644-6;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66644-6;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66644-6;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66644-6;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66645-3;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66645-3;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66645-3;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66645-3;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66646-1;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66646-1;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66646-1;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66646-1;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66647-9;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66647-9;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66647-9;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66647-9;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66648-7;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66648-7;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66648-7;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66648-7;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66649-5;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66649-5;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66649-5;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66649-5;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66650-3;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66650-3;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66650-3;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66650-3;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66651-1;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66651-1;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66651-1;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66651-1;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66652-9;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66652-9;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66652-9;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66652-9;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66653-7;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66653-7;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66653-7;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66653-7;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66654-5;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66654-5;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66654-5;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66654-5;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66655-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66655-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66655-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66655-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66656-0;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66656-0;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66656-0;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66656-0;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66657-8;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66657-8;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66657-8;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66657-8;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66658-6;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66658-6;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66658-6;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66658-6;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66659-4;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66659-4;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66659-4;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66659-4;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66660-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66660-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66660-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66660-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66661-0;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66661-0;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66661-0;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66661-0;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +66684-2;LL1619-7;PhenX18_02;LA15357-9;1;Agree strongly;;; +66684-2;LL1619-7;PhenX18_02;LA15355-3;2;Agree some;;; +66684-2;LL1619-7;PhenX18_02;LA15354-6;3;Disagree some;;; +66684-2;LL1619-7;PhenX18_02;LA16642-3;4;Disagree strongly;;; +62921-2;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +62921-2;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +62921-2;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +62921-2;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66685-9;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66685-9;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66685-9;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66685-9;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66686-7;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66686-7;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66686-7;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66686-7;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66687-5;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66687-5;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66687-5;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66687-5;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66688-3;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66688-3;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66688-3;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66688-3;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66689-1;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66689-1;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66689-1;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66689-1;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66690-9;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66690-9;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66690-9;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66690-9;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66691-7;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66691-7;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66691-7;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66691-7;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66692-5;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66692-5;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66692-5;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66692-5;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66693-3;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66693-3;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66693-3;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66693-3;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66694-1;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66694-1;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66694-1;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66694-1;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66695-8;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66695-8;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66695-8;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66695-8;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66696-6;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66696-6;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66696-6;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66696-6;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66697-4;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66697-4;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66697-4;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66697-4;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66698-2;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66698-2;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66698-2;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66698-2;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66699-0;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66699-0;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66699-0;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66699-0;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66700-6;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66700-6;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66700-6;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66700-6;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66701-4;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66701-4;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66701-4;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66701-4;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66702-2;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66702-2;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66702-2;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66702-2;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66703-0;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66703-0;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66703-0;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66703-0;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66704-8;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66704-8;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66704-8;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66704-8;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66705-5;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66705-5;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66705-5;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66705-5;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66706-3;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66706-3;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66706-3;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66706-3;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66707-1;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66707-1;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66707-1;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66707-1;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66708-9;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66708-9;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66708-9;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66708-9;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66709-7;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66709-7;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66709-7;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66709-7;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66710-5;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66710-5;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66710-5;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66710-5;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66711-3;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66711-3;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66711-3;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66711-3;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66712-1;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66712-1;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66712-1;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66712-1;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +66713-9;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +66713-9;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +66713-9;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +66713-9;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +67280-8;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +67280-8;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +67280-8;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +67280-8;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +67281-6;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +67281-6;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +67281-6;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +67281-6;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +67282-4;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +67282-4;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +67282-4;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +67282-4;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +67283-2;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +67283-2;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +67283-2;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +67283-2;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +67284-0;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +67284-0;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +67284-0;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +67284-0;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +67285-7;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +67285-7;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +67285-7;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +67285-7;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +67287-3;LL1620-5;PhenX18_03;LA15358-7;1;Not at all like me;;; +67287-3;LL1620-5;PhenX18_03;LA15359-5;2;Not like me;;; +67287-3;LL1620-5;PhenX18_03;LA15360-3;3;Somewhat like me;;; +67287-3;LL1620-5;PhenX18_03;LA15361-1;4;Very much like me;;; +62947-7;LL1058-8;MPL ID'd;LA14124-4;1;MPL mutation identified;;; +62947-7;LL1058-8;MPL ID'd;LA14125-1;2;No MPL mutation identified;;; +62948-5;LL1059-6;MPL mut;LA14126-9;1;S505N;;; +62948-5;LL1059-6;MPL mut;LA14127-7;2;W515L;;; +62948-5;LL1059-6;MPL mut;LA14128-5;3;W515K;;; +63368-5;LL1061-2;Carbapenemase;LA14134-3;1;Class A gene detected (KPC);;; +63368-5;LL1061-2;Carbapenemase;LA14135-0;2;Class B gene detected (IMP);;; +63368-5;LL1061-2;Carbapenemase;LA14136-8;3;Class A gene not detected (KPC, IMP, SME);;; +63419-6;LL1063-8;PIK3CA;LA14137-6;1;H1047R;;; +63419-6;LL1063-8;PIK3CA;LA14138-4;2;E542K;;; +63419-6;LL1063-8;PIK3CA;LA14139-2;3;E545D;;; +63419-6;LL1063-8;PIK3CA;LA14140-0;4;E545K;;; +63421-2;LL1064-6;JAK2 exon12;LA14141-8;1;F537-K539delinsL;;; +63421-2;LL1064-6;JAK2 exon12;LA14142-6;2;H538QK539L;;; +63421-2;LL1064-6;JAK2 exon12;LA14143-4;3;K539L;;; +63421-2;LL1064-6;JAK2 exon12;LA14144-2;4;N542-E543del;;; +63490-7;LL1066-1;PhenX01_03_birthplace;LA14930-4;1;In the United States - Print name of state;;; +63490-7;LL1066-1;PhenX01_03_birthplace;LA15602-8;2;Outside the United States - Print U.S. Territory (e.g., Puerto Rico, U.S. Virgin Islands, Guam) or name of foreign country, etc.;;; +63493-1;LL1067-9;PhenX01_04_relative birthplace;LA14930-4;1;In the United States - Print name of state;;; +63493-1;LL1067-9;PhenX01_04_relative birthplace;LA15602-8;2;Outside the United States - Print U.S. Territory (e.g., Puerto Rico, U.S. Virgin Islands, Guam) or name of foreign country, etc.;;; +63493-1;LL1067-9;PhenX01_04_relative birthplace;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63494-9;LL1067-9;PhenX01_04_relative birthplace;LA14930-4;1;In the United States - Print name of state;;; +63494-9;LL1067-9;PhenX01_04_relative birthplace;LA15602-8;2;Outside the United States - Print U.S. Territory (e.g., Puerto Rico, U.S. Virgin Islands, Guam) or name of foreign country, etc.;;; +63494-9;LL1067-9;PhenX01_04_relative birthplace;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63495-6;LL1067-9;PhenX01_04_relative birthplace;LA14930-4;1;In the United States - Print name of state;;; +63495-6;LL1067-9;PhenX01_04_relative birthplace;LA15602-8;2;Outside the United States - Print U.S. Territory (e.g., Puerto Rico, U.S. Virgin Islands, Guam) or name of foreign country, etc.;;; +63495-6;LL1067-9;PhenX01_04_relative birthplace;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63496-4;LL1067-9;PhenX01_04_relative birthplace;LA14930-4;1;In the United States - Print name of state;;; +63496-4;LL1067-9;PhenX01_04_relative birthplace;LA15602-8;2;Outside the United States - Print U.S. Territory (e.g., Puerto Rico, U.S. Virgin Islands, Guam) or name of foreign country, etc.;;; +63496-4;LL1067-9;PhenX01_04_relative birthplace;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63515-1;LL1067-9;PhenX01_04_relative birthplace;LA14930-4;1;In the United States - Print name of state;;; +63515-1;LL1067-9;PhenX01_04_relative birthplace;LA15602-8;2;Outside the United States - Print U.S. Territory (e.g., Puerto Rico, U.S. Virgin Islands, Guam) or name of foreign country, etc.;;; +63515-1;LL1067-9;PhenX01_04_relative birthplace;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63503-7;LL1068-7;PhenX01_05_marital status;LA48-4;1;Married;;; +63503-7;LL1068-7;PhenX01_05_marital status;LA49-2;2;Widowed;;; +63503-7;LL1068-7;PhenX01_05_marital status;LA51-8;3;Divorced;;; +63503-7;LL1068-7;PhenX01_05_marital status;LA4288-2;4;Separated;;; +63503-7;LL1068-7;PhenX01_05_marital status;LA47-6;5;Never married;;; +63503-7;LL1068-7;PhenX01_05_marital status;LA15605-1;6;Living with partner;;; +63503-7;LL1068-7;PhenX01_05_marital status;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63503-7;LL1068-7;PhenX01_05_marital status;LA12688-0;8;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63504-5;LL1069-5;PhenX01_06_education;LA15606-9;1;Never attended/kindergarten only;;; +63504-5;LL1069-5;PhenX01_06_education;LA15607-7;2;1st grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15608-5;3;2nd grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15609-3;4;3rd grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15610-1;5;4th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15611-9;6;5th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15612-7;7;6th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15613-5;8;7th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15614-3;9;8th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15615-0;10;9th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15616-8;11;10th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15617-6;12;11th grade;;; +63504-5;LL1069-5;PhenX01_06_education;LA15618-4;13;12th grade, no diploma;;; +63504-5;LL1069-5;PhenX01_06_education;LA15564-0;14;High school graduate;;; +63504-5;LL1069-5;PhenX01_06_education;LA15619-2;15;GED or equivalent;;; +63504-5;LL1069-5;PhenX01_06_education;LA15620-0;16;Some college, no degree;;; +63504-5;LL1069-5;PhenX01_06_education;LA15621-8;17;Associate degree: occupational, technical, or vocational program;;; +63504-5;LL1069-5;PhenX01_06_education;LA15622-6;18;Associate degree: academic program;;; +63504-5;LL1069-5;PhenX01_06_education;LA12460-4;19;Bachelor's degree (e.g., BA, AB, BS);;; +63504-5;LL1069-5;PhenX01_06_education;LA12461-2;20;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +63504-5;LL1069-5;PhenX01_06_education;LA15625-9;21;Professional school degree (example: MD, DDS, DVM, JD);;; +63504-5;LL1069-5;PhenX01_06_education;LA15626-7;22;Doctoral degree (example: PhD, EdD);;; +63504-5;LL1069-5;PhenX01_06_education;LA4389-8;23;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63504-5;LL1069-5;PhenX01_06_education;LA12688-0;24;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63506-0;LL1070-3;PhenX01_07_family income 50k;LA15627-5;1;Less than $50,000;;; +63506-0;LL1070-3;PhenX01_07_family income 50k;LA15628-3;2;$50,000 or more;;; +63506-0;LL1070-3;PhenX01_07_family income 50k;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63506-0;LL1070-3;PhenX01_07_family income 50k;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63507-8;LL1071-1;PhenX01_08_family income 35k;LA15629-1;1;Less than $35,000;;; +63507-8;LL1071-1;PhenX01_08_family income 35k;LA15630-9;2;$35,000 or more;;; +63507-8;LL1071-1;PhenX01_08_family income 35k;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63507-8;LL1071-1;PhenX01_08_family income 35k;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63508-6;LL1072-9;PhenX01_09_family income poverty;LA15631-7;1;Less than ($9,500, $12,000, $15,000, $19,000, $22,500, $25,500 ,$29,000);;; +63508-6;LL1072-9;PhenX01_09_family income poverty;LA15632-5;2;($9,500, $12,000, $15,000, $19,000, $22,500, $25,500 ,$29,000) or more;;; +63508-6;LL1072-9;PhenX01_09_family income poverty;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63508-6;LL1072-9;PhenX01_09_family income poverty;LA12688-0;9;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63509-4;LL1073-7;PhenX01_10_family income 100k;LA15633-3;1;Less than $100,000;;; +63509-4;LL1073-7;PhenX01_10_family income 100k;LA15634-1;2;$100,000 or more;;; +63509-4;LL1073-7;PhenX01_10_family income 100k;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63509-4;LL1073-7;PhenX01_10_family income 100k;LA12688-0;9;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63510-2;LL1074-5;PhenX01_11_family income 75k;LA15635-8;1;Less than $75,000;;; +63510-2;LL1074-5;PhenX01_11_family income 75k;LA15636-6;2;$75,000 or more;;; +63510-2;LL1074-5;PhenX01_11_family income 75k;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63510-2;LL1074-5;PhenX01_11_family income 75k;LA12688-0;9;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63514-4;LL1076-0;PhenX01_13_health insurance;LA15651-5;1;Private health insurance;;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15652-3;2;Medicare;;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15653-1;3;Medi-Gap;;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15654-9;4;Medicaid (if available, display plan name);;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15655-6;5;SCHIP (CHIP/Children's health insurance program);;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15656-4;6;Military health care (tricare/VA, Champ-VA);;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15657-2;7;Indian health service;;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15658-0;8;State-sponsored health plan (if available, display state plan name);;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15659-8;9;Other government program;;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15660-6;10;Single service plan (e.g. dental, vision, prescriptions);;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA15661-4;11;No coverage of any type;;; +63514-4;LL1076-0;PhenX01_13_health insurance;LA4389-8;12;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63514-4;LL1076-0;PhenX01_13_health insurance;LA12688-0;13;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15637-4;1;Husband or wife;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15638-2;2;Son-in-law or daughter-in-law;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15639-0;3;Biological son or daughter;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15640-8;4;Other relative;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15641-6;5;Adopted son or daughter;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15642-4;6;Roomer or boarder;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15643-2;7;Stepson or stepdaughter;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15644-0;8;Housemate or roommate;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15645-7;9;Brother or sister;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15646-5;10;Unmarried partner;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15647-3;11;Father or mother;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15648-1;12;Foster child;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15315-7;13;Grandchild;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15649-9;14;Other nonrelative;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15650-7;15;Parent-in-law;;; +63517-7;LL1075-2;PhenX01_12_relative smoking;LA4389-8;16;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63517-7;LL1075-2;PhenX01_12_relative smoking;LA12688-0;17;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63517-7;LL1075-2;PhenX01_12_relative smoking;LA15312-4;18;Self;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15637-4;1;Husband or wife;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15638-2;2;Son-in-law or daughter-in-law;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15639-0;3;Biological son or daughter;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15640-8;4;Other relative;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15641-6;5;Adopted son or daughter;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15642-4;6;Roomer or boarder;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15643-2;7;Stepson or stepdaughter;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15644-0;8;Housemate or roommate;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15645-7;9;Brother or sister;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15646-5;10;Unmarried partner;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15647-3;11;Father or mother;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15648-1;12;Foster child;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15315-7;13;Grandchild;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15649-9;14;Other nonrelative;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15650-7;15;Parent-in-law;;; +63772-8;LL1075-2;PhenX01_12_relative smoking;LA4389-8;16;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63772-8;LL1075-2;PhenX01_12_relative smoking;LA12688-0;17;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63772-8;LL1075-2;PhenX01_12_relative smoking;LA15312-4;18;Self;;; +63562-3;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +63562-3;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63562-3;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63562-3;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA15842-0;4;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +63562-3;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA13538-6;5;Not tested;;; +63563-1;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +63563-1;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63563-1;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +63563-1;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA15842-0;4;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +63563-1;LL1436-6;Pos|Neg|Equiv|Quantity insuff|Not tested;LA13538-6;5;Not tested;;; +63564-9;LL1437-4;FecalEIA;LA15838-8;1;Giardia lamblia;78181009;Giardia lamblia (organism);http://snomed.info/sct +63564-9;LL1437-4;FecalEIA;LA15839-6;2;Entamoeba histolytica/dispar;;; +63564-9;LL1437-4;FecalEIA;LA15840-4;3;Cryptosporidium parvum;51504002;Cryptosporidium parvum (organism);http://snomed.info/sct +63564-9;LL1437-4;FecalEIA;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +63564-9;LL1437-4;FecalEIA;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +63566-4;LL1419-2;BM;LA15815-6;1;Linear;;; +63566-4;LL1419-2;BM;LA15816-4;2;Granular;;; +63567-2;LL1421-8;ANCA;LA15817-2;1;Diffuse granular cytoplasmic;;; +63567-2;LL1421-8;ANCA;LA15818-0;2;Perinuclear;;; +63567-2;LL1421-8;ANCA;LA15819-8;3;Fine speckled;;; +63567-2;LL1421-8;ANCA;LA15815-6;4;Linear;;; +63568-0;LL1421-8;ANCA;LA15817-2;1;Diffuse granular cytoplasmic;;; +63568-0;LL1421-8;ANCA;LA15818-0;2;Perinuclear;;; +63568-0;LL1421-8;ANCA;LA15819-8;3;Fine speckled;;; +63568-0;LL1421-8;ANCA;LA15815-6;4;Linear;;; +63571-4;LL1421-8;ANCA;LA15817-2;1;Diffuse granular cytoplasmic;;; +63571-4;LL1421-8;ANCA;LA15818-0;2;Perinuclear;;; +63571-4;LL1421-8;ANCA;LA15819-8;3;Fine speckled;;; +63571-4;LL1421-8;ANCA;LA15815-6;4;Linear;;; +63569-8;LL1420-0;ANA;LA15821-4;1;Rim;;; +63569-8;LL1420-0;ANA;LA15820-6;2;Homogenous;;; +63569-8;LL1420-0;ANA;LA15822-2;3;Speckled;;; +63569-8;LL1420-0;ANA;LA15823-0;4;Nucleolar;;; +63569-8;LL1420-0;ANA;LA15824-8;5;Diffuse;;; +63569-8;LL1420-0;ANA;LA15825-5;6;Centromere;;; +63570-6;LL1420-0;ANA;LA15821-4;1;Rim;;; +63570-6;LL1420-0;ANA;LA15820-6;2;Homogenous;;; +63570-6;LL1420-0;ANA;LA15822-2;3;Speckled;;; +63570-6;LL1420-0;ANA;LA15823-0;4;Nucleolar;;; +63570-6;LL1420-0;ANA;LA15824-8;5;Diffuse;;; +63570-6;LL1420-0;ANA;LA15825-5;6;Centromere;;; +63575-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63575-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63575-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63579-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63579-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63579-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63580-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63580-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63580-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63581-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63581-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63581-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63581-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63581-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63581-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63583-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63583-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63583-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63584-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63584-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63584-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63592-0;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63592-0;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63592-0;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63593-8;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63593-8;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63593-8;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63594-6;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63594-6;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63594-6;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63595-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63595-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63595-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63596-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63596-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63596-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63599-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63599-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63599-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63600-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63600-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63600-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63601-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63601-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63601-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63602-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63602-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63602-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63604-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63604-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63604-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63607-6;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63607-6;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63607-6;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63614-2;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63614-2;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63614-2;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63615-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63615-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63615-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63616-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63616-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63616-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63618-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63618-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63618-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63619-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63619-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63619-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63620-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63620-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63620-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63621-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63621-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63621-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63622-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63622-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63622-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63624-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63624-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63624-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63626-6;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63626-6;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63626-6;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63627-4;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63627-4;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63627-4;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63635-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63635-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63635-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63641-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63641-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63641-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63642-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63642-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63642-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63644-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63644-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63644-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63647-2;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63647-2;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63647-2;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63648-0;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63648-0;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63648-0;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63651-4;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63651-4;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63651-4;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63652-2;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63652-2;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63652-2;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63653-0;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63653-0;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63653-0;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63654-8;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63654-8;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63654-8;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63655-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63655-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63655-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63656-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63656-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63656-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63657-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63657-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63657-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63658-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63658-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63658-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63659-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63659-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63659-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63660-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63660-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63660-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63661-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63661-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63661-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63663-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63663-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63663-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63665-4;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63665-4;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63665-4;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63666-2;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63666-2;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63666-2;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63667-0;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63667-0;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63667-0;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63668-8;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63668-8;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63668-8;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63669-6;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63669-6;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63669-6;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63670-4;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63670-4;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63670-4;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63672-0;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63672-0;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63672-0;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63673-8;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63673-8;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63673-8;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63675-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63675-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63675-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63676-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63676-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63676-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63677-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63677-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63677-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63678-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63678-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63678-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63679-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63679-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63679-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63680-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63680-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63680-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63681-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63681-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63681-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63682-9;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63682-9;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63682-9;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63683-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63683-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63683-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63684-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63684-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63684-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63685-2;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63685-2;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63685-2;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63686-0;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63686-0;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63686-0;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63690-2;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63690-2;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63690-2;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63819-7;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63819-7;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63819-7;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63820-5;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63820-5;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63820-5;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63821-3;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63821-3;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63821-3;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63822-1;LL1353-3;PhenX03_01_alcohol responses;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63822-1;LL1353-3;PhenX03_01_alcohol responses;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63822-1;LL1353-3;PhenX03_01_alcohol responses;LA15775-2;3;Don't know/refused;;; +63582-1;LL1354-1;PhenX03_02_current cig smoking;LA14799-3;1;Every day;;; +63582-1;LL1354-1;PhenX03_02_current cig smoking;LA15776-0;2;Some days;;; +63582-1;LL1354-1;PhenX03_02_current cig smoking;LA6568-5;3;Not at all;;; +63582-1;LL1354-1;PhenX03_02_current cig smoking;LA15775-2;4;Don't know/refused;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15312-4;1;Self;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA10417-6;2;Mother;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA10416-8;3;Father;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15743-0;4;Child 1;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15744-8;5;Child 2;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15745-5;6;Child 3;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15746-3;7;Child 4;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15747-1;8;Child 5;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15748-9;9;Child 6;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15749-7;10;Child 7;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15750-5;11;Sibling 1;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15751-3;12;Sibling 2;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15752-1;13;Sibling 3;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15753-9;14;Sibling 4;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15754-7;15;Sibling 5;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15755-4;16;Sibling 6;;; +63588-8;LL1321-0;PhenX02_04_body image subject;LA15756-2;17;Sibling 7;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15757-0;1;Collins adult female;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15758-8;2;Collins adult male;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15759-6;3;Stunkard adult female;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15760-4;4;Stunkard adult male;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15761-2;5;Pulvers adult African American female;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15762-0;6;Pulvers adult African American male;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15763-8;7;Collins child female;;; +63589-6;LL1322-8;PhenX02_05_body image scale;LA15764-6;8;Collins child male;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA6112-2;1;1;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA15765-3;2;1.5;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA6113-0;3;2;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA15766-1;4;2.5;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA6114-8;5;3;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA15767-9;6;3.5;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA6115-5;7;4;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA15768-7;8;4.5;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA10137-0;9;5;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA15769-5;10;5.5;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA10138-8;11;6;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA15770-3;12;6.5;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA10139-6;13;7;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA10140-4;14;8;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA10141-2;15;9;;; +63590-4;LL1323-6;PhenX02_06_body image shape;LA4720-4;16;Not applicable;;; +63605-0;LL1440-8;PhenX03_12_health probs drinking;LA15858-6;1;Liver disease or yellow jaundice;;; +63605-0;LL1440-8;PhenX03_12_health probs drinking;LA15859-4;2;Stomach disease or vomiting blood;;; +63605-0;LL1440-8;PhenX03_12_health probs drinking;LA15860-2;3;Pancreatitis;;; +63605-0;LL1440-8;PhenX03_12_health probs drinking;LA15861-0;4;Damage to your heart, cardiomyopathy;;; +63605-0;LL1440-8;PhenX03_12_health probs drinking;LA15862-8;5;Memory problems even when you weren't drinking;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15848-7;1;Shakes, hands trembling;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15849-5;2;Unable to sleep;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15850-3;3;Feel anxious;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15851-1;4;Feel depressed or irritable;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15856-0;5;Heart beat fast or did you sweat;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15852-9;6;Have nausea or vomiting;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15853-7;7;Feel physically weak;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15854-5;8;Have headaches;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15855-2;9;See or hear things that weren't there;;; +63606-8;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15857-8;10;Fidgety or restless;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15848-7;1;Shakes, hands trembling;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15849-5;2;Unable to sleep;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15850-3;3;Feel anxious;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15851-1;4;Feel depressed or irritable;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15856-0;5;Heart beat fast or did you sweat;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15852-9;6;Have nausea or vomiting;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15853-7;7;Feel physically weak;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15854-5;8;Have headaches;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15855-2;9;See or hear things that weren't there;;; +63623-3;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15857-8;10;Fidgety or restless;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15848-7;1;Shakes, hands trembling;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15849-5;2;Unable to sleep;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15850-3;3;Feel anxious;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15851-1;4;Feel depressed or irritable;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15856-0;5;Heart beat fast or did you sweat;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15852-9;6;Have nausea or vomiting;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15853-7;7;Feel physically weak;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15854-5;8;Have headaches;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15855-2;9;See or hear things that weren't there;;; +63628-2;LL1439-0;PhenX03_11_alcohol withdraw probs;LA15857-8;10;Fidgety or restless;;; +63613-4;LL1355-8;PhenX03_03_30d smoke freq;LA14481-8;1;1 or 2 days;;; +63613-4;LL1355-8;PhenX03_03_30d smoke freq;LA15777-8;2;3 to 5 days;;; +63613-4;LL1355-8;PhenX03_03_30d smoke freq;LA15778-6;3;6 to 9 days;;; +63613-4;LL1355-8;PhenX03_03_30d smoke freq;LA15779-4;4;10 to 19 days;;; +63613-4;LL1355-8;PhenX03_03_30d smoke freq;LA15780-2;5;20 to 29 days;;; +63613-4;LL1355-8;PhenX03_03_30d smoke freq;LA15781-0;6;All 30 days;;; +63613-4;LL1355-8;PhenX03_03_30d smoke freq;LA15775-2;7;Don't know/refused;;; +63625-8;LL1438-2;PhenX03_10_emot/psych problems;LA15843-8;1;Feeling depressed or uninterested in things;;; +63625-8;LL1438-2;PhenX03_10_emot/psych problems;LA15844-6;2;Feeling jumpy or easily startled or nervous;;; +63625-8;LL1438-2;PhenX03_10_emot/psych problems;LA15846-1;3;Feeling paranoid or suspicious of people;;; +63625-8;LL1438-2;PhenX03_10_emot/psych problems;LA15847-9;4;Hearing, seeing, or smelling things that weren't really there;;; +63688-6;LL1438-2;PhenX03_10_emot/psych problems;LA15843-8;1;Feeling depressed or uninterested in things;;; +63688-6;LL1438-2;PhenX03_10_emot/psych problems;LA15844-6;2;Feeling jumpy or easily startled or nervous;;; +63688-6;LL1438-2;PhenX03_10_emot/psych problems;LA15846-1;3;Feeling paranoid or suspicious of people;;; +63688-6;LL1438-2;PhenX03_10_emot/psych problems;LA15847-9;4;Hearing, seeing, or smelling things that weren't really there;;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15782-8;1;Less than one cigarette per day;;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15783-6;2;1 cigarette per day;;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15784-4;3;2 to 5 cigarettes per day;;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15785-1;4;6 to 15 cigarettes per day (about 1/2 pack);;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15786-9;5;16 to 25 cigarettes per day (about 1 pack);;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15787-7;6;26 to 35 cigarettes per day (about 1 1/2 packs);;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15788-5;7;More than 35 cigarettes per day (about 2 packs or more);;; +63629-0;LL1356-6;PhenX03_04_30d smoke quant;LA15775-2;8;Don't know/refused;;; +63630-8;LL1357-4;PhenX03_05_smoke cessation;LA15789-3;1;More than 30 days ago but within the past 12 months;;; +63630-8;LL1357-4;PhenX03_05_smoke cessation;LA15790-1;2;More than 12 months ago but within the past 3 years;;; +63630-8;LL1357-4;PhenX03_05_smoke cessation;LA15791-9;3;More than 3 years ago;;; +63630-8;LL1357-4;PhenX03_05_smoke cessation;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63630-8;LL1357-4;PhenX03_05_smoke cessation;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63636-5;LL1450-7;PhenX03_22_first daily smoke;LA15792-7;1;Within 5 minutes (3 points);;; +63636-5;LL1450-7;PhenX03_22_first daily smoke;LA15793-5;2;6-30 minutes (2 points);;; +63636-5;LL1450-7;PhenX03_22_first daily smoke;LA15794-3;3;31-60 minutes (1 point);;; +63636-5;LL1450-7;PhenX03_22_first daily smoke;LA15795-0;4;After 60 minutes (0 points);;; +63637-3;LL1361-6;PhenX03_09_refrain from smoking difficulty;LA15798-4;1;Yes (1 point);;; +63637-3;LL1361-6;PhenX03_09_refrain from smoking difficulty;LA15799-2;2;No (0 points);;; +63638-1;LL1449-9;PhenX03_21_smoking status;LA15918-8;1;Every-day smoker;;; +63638-1;LL1449-9;PhenX03_21_smoking status;LA15919-6;2;Some-day smoker;;; +63638-1;LL1449-9;PhenX03_21_smoking status;LA15920-4;3;Former smoker;;; +63639-9;LL1360-8;PhenX03_08_when give up smoking;LA15796-8;1;The first one in the morning (1 point);;; +63639-9;LL1360-8;PhenX03_08_when give up smoking;LA15797-6;2;All others (0 points);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15912-1;1;10 or less (0 points);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15913-9;2;11-20 (1 point);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15914-7;3;21-30 (2 points);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15915-4;4;31 or more (3 points);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15912-1;1;10 or less (0 points);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15913-9;2;11-20 (1 point);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15914-7;3;21-30 (2 points);;; +63640-7;LL1447-3;PhenX03_19_1D smoke quant;LA15915-4;4;31 or more (3 points);;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15872-7;1;Sedatives, for example, sleeping pills, barbiturates, seconal, quaaludes, or chloral hydrate;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15904-8;2;Tranquilizers or anti-anxiety drugs, for example, valium, librium, muscle relaxants, or zanax;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15905-5;3;Painkillers, for example, codeine, darvon, percodan, oxycontin, dilaudid, demerol, celebrex or vioxx;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15906-3;4;Stimulants, for example, preludin, benzedrine, methedrine, ritalin, uppers, or speed;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15907-1;5;Marijuana, hash, THC, or grass;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15908-9;6;Cocaine or crack;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA7438-0;7;Hallucinations;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15910-5;8;Inhalants or solvents, for example, amyl nitrite, nitrous oxide, glue, toluene or gasoline;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15258-9;9;Heroin;387341002;Diamorphine (substance);http://snomed.info/sct +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15911-3;10;Any other medicines, or drugs, or substances, for example, methadone, elavil, steroids, thorazine or haldol;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15872-7;1;Sedatives, for example, sleeping pills, barbiturates, seconal, quaaludes, or chloral hydrate;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15904-8;2;Tranquilizers or anti-anxiety drugs, for example, valium, librium, muscle relaxants, or zanax;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15905-5;3;Painkillers, for example, codeine, darvon, percodan, oxycontin, dilaudid, demerol, celebrex or vioxx;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15906-3;4;Stimulants, for example, preludin, benzedrine, methedrine, ritalin, uppers, or speed;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15907-1;5;Marijuana, hash, THC, or grass;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15908-9;6;Cocaine or crack;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA7438-0;7;Hallucinations;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15910-5;8;Inhalants or solvents, for example, amyl nitrite, nitrous oxide, glue, toluene or gasoline;;; +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15258-9;9;Heroin;387341002;Diamorphine (substance);http://snomed.info/sct +63643-1;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15911-3;10;Any other medicines, or drugs, or substances, for example, methadone, elavil, steroids, thorazine or haldol;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15872-7;1;Sedatives, for example, sleeping pills, barbiturates, seconal, quaaludes, or chloral hydrate;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15904-8;2;Tranquilizers or anti-anxiety drugs, for example, valium, librium, muscle relaxants, or zanax;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15905-5;3;Painkillers, for example, codeine, darvon, percodan, oxycontin, dilaudid, demerol, celebrex or vioxx;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15906-3;4;Stimulants, for example, preludin, benzedrine, methedrine, ritalin, uppers, or speed;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15907-1;5;Marijuana, hash, THC, or grass;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15908-9;6;Cocaine or crack;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA7438-0;7;Hallucinations;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15910-5;8;Inhalants or solvents, for example, amyl nitrite, nitrous oxide, glue, toluene or gasoline;;; +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15258-9;9;Heroin;387341002;Diamorphine (substance);http://snomed.info/sct +63689-4;LL1446-5;PhenX03_18_lifetime/30D drug type;LA15911-3;10;Any other medicines, or drugs, or substances, for example, methadone, elavil, steroids, thorazine or haldol;;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31122-7;1;Cannabis (marijuana, pot, grass, hash, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31123-5;2;Cocaine (coke, crack, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31124-3;3;Prescription stimulants (Ritalin, Concerta, Dexedrine, Adderall, diet pills, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31125-0;4;Methamphetamine (speed, crystal meth, ice, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31126-8;5;Inhalants (nitrous oxide, glue, gas, paint thinner, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31127-6;6;Sedatives or sleeping pills (Valium, Serepax, Ativan, Xanax, Librium, Rohypnol, GHB, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31128-4;7;Hallucinogens (LSD, acid, mushrooms, PCP, Special K, ecstasy, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31129-2;8;Street opioids (heroin, opium, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA31130-0;9;Prescription opioids (fentanyl, oxycodone [OxyContin, Percocet], hydrocodone [Vicodin], methadone, buprenorphine, etc.);;; +63643-1;LL5625-0;Substances - NIDA-ASSIST;LA46-8;10;Other;;; +63649-8;LL1441-6;PhenX03_13_marijuana use probs;LA15843-8;1;Feeling depressed or uninterested in things;;; +63649-8;LL1441-6;PhenX03_13_marijuana use probs;LA15864-4;2;Having trouble concentrating or having such trouble thinking clearly;;; +63649-8;LL1441-6;PhenX03_13_marijuana use probs;LA15846-1;3;Feeling paranoid or suspicious of people;;; +63649-8;LL1441-6;PhenX03_13_marijuana use probs;LA15863-6;4;Decreased contact with friends or family;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA15257-1;1;Cocaine;387085005;Cocaine (substance);http://snomed.info/sct +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA15871-9;2;Stimulants;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA15872-7;3;Sedatives, for example, sleeping pills, barbiturates, seconal, quaaludes, or chloral hydrate;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA15873-5;4;Opiates;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA15874-3;5;PCP;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA7438-0;6;Hallucinations;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA15876-8;7;Solvents;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA15877-6;8;Combination drugs;;; +63662-1;LL1443-2;PhenX03_15_lifetime drug use type;LA46-8;9;Other;;; +63671-2;LL1444-0;PhenX03_16_ drug use >30D;LA15257-1;1;Cocaine;387085005;Cocaine (substance);http://snomed.info/sct +63671-2;LL1444-0;PhenX03_16_ drug use >30D;LA15871-9;2;Stimulants;;; +63671-2;LL1444-0;PhenX03_16_ drug use >30D;LA15872-7;3;Sedatives, for example, sleeping pills, barbiturates, seconal, quaaludes, or chloral hydrate;;; +63671-2;LL1444-0;PhenX03_16_ drug use >30D;LA15873-5;4;Opiates;;; +63671-2;LL1444-0;PhenX03_16_ drug use >30D;LA15878-4;5;Other drugs;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15879-2;1;Feel depressed;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15880-0;2;Feel restless;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15881-8;3;Feel tired, sleepy, or weak;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15866-9;4;Have trouble sleeping;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15882-6;5;Sleep too much;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15883-4;6;Have strong desire or craving for this drug;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15884-2;7;Feel slowed down, like you could hardly move;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15885-9;8;Have an increase in appetite;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15886-7;9;Have nightmares;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15887-5;10;Have diarrhea;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15888-3;11;Have stomach aches or stomach cramps;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15889-1;12;Eyes run;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15890-9;13;Nose run;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15891-7;14;Have muscle pains;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15892-5;15;Yawn;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15893-3;16;Pupils dilated or sensitive to light;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15894-1;17;Have gooseflesh, goose bumps, or get chills;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15895-8;18;Heart race;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15896-6;19;Sweat;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA7435-6;20;Fever;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15902-2;21;Nausea or vomiting;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15903-0;22;Headache;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15897-4;23;Nervous, tense, or irritable;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15898-2;24;Hands shake;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15867-7;25;Tremble or twitch;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA7428-1;26;Dizziness;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15899-0;27;Seizures;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15901-4;28;See, hear, or feel things that weren't really there;;; +63674-6;LL1445-7;PhenX03_17_drug withdraw probs;LA15900-6;29;Think that people were plotting to harm you (paranoid);;; +63691-0;LL1442-4;PhenX03_14_marijuana withdraw probs;LA15865-1;1;Feel nervous, tense, restless or irritable;;; +63691-0;LL1442-4;PhenX03_14_marijuana withdraw probs;LA15866-9;2;Have trouble sleeping;;; +63691-0;LL1442-4;PhenX03_14_marijuana withdraw probs;LA15867-7;3;Tremble or twitch;;; +63691-0;LL1442-4;PhenX03_14_marijuana withdraw probs;LA15868-5;4;Sweat or have a fever;;; +63691-0;LL1442-4;PhenX03_14_marijuana withdraw probs;LA15852-9;5;Have nausea or vomiting;;; +63691-0;LL1442-4;PhenX03_14_marijuana withdraw probs;LA15869-3;6;Have diarrhea or stomach aches;;; +63691-0;LL1442-4;PhenX03_14_marijuana withdraw probs;LA15870-1;7;Have a marked increase or decrease in appetite, that is, have a significant change from your normal level;;; +63692-8;LL1078-6;PhenX06_01_dwelling type;LA14148-3;1;Detached house;;; +63692-8;LL1078-6;PhenX06_01_dwelling type;LA14149-1;2;Duplex/triplex;;; +63692-8;LL1078-6;PhenX06_01_dwelling type;LA14150-9;3;Row house;;; +63692-8;LL1078-6;PhenX06_01_dwelling type;LA14151-7;4;Low rise apartment (1-3 floors);;; +63692-8;LL1078-6;PhenX06_01_dwelling type;LA14152-5;5;High rise apartment (>3 floors);;; +63692-8;LL1078-6;PhenX06_01_dwelling type;LA14153-3;6;Mobile home / trailer;;; +63692-8;LL1078-6;PhenX06_01_dwelling type;LA6310-2;7;Other (specify);;; +63710-8;LL1079-4;PhenX06_02_ house AC type;LA14154-1;1;Central unit/units;;; +63710-8;LL1079-4;PhenX06_02_ house AC type;LA14155-8;2;Window or wall unit/units;;; +63710-8;LL1079-4;PhenX06_02_ house AC type;LA14156-6;3;Portable unit/units;;; +63711-6;LL1080-2;PhenX06_03_months;LA14157-4;1;Jan.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14158-2;2;Feb.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14159-0;3;Mar.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14160-8;4;Apr.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14161-6;5;May;;; +63711-6;LL1080-2;PhenX06_03_months;LA14162-4;6;Jun.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14163-2;7;Jul.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14164-0;8;Aug.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14165-7;9;Sep.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14166-5;10;Oct.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14167-3;11;Nov.;;; +63711-6;LL1080-2;PhenX06_03_months;LA14168-1;12;Dec.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14157-4;1;Jan.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14158-2;2;Feb.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14159-0;3;Mar.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14160-8;4;Apr.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14161-6;5;May;;; +63712-4;LL1080-2;PhenX06_03_months;LA14162-4;6;Jun.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14163-2;7;Jul.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14164-0;8;Aug.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14165-7;9;Sep.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14166-5;10;Oct.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14167-3;11;Nov.;;; +63712-4;LL1080-2;PhenX06_03_months;LA14168-1;12;Dec.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14157-4;1;Jan.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14158-2;2;Feb.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14159-0;3;Mar.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14160-8;4;Apr.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14161-6;5;May;;; +63715-7;LL1080-2;PhenX06_03_months;LA14162-4;6;Jun.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14163-2;7;Jul.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14164-0;8;Aug.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14165-7;9;Sep.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14166-5;10;Oct.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14167-3;11;Nov.;;; +63715-7;LL1080-2;PhenX06_03_months;LA14168-1;12;Dec.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14157-4;1;Jan.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14158-2;2;Feb.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14159-0;3;Mar.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14160-8;4;Apr.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14161-6;5;May;;; +63716-5;LL1080-2;PhenX06_03_months;LA14162-4;6;Jun.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14163-2;7;Jul.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14164-0;8;Aug.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14165-7;9;Sep.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14166-5;10;Oct.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14167-3;11;Nov.;;; +63716-5;LL1080-2;PhenX06_03_months;LA14168-1;12;Dec.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14157-4;1;Jan.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14158-2;2;Feb.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14159-0;3;Mar.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14160-8;4;Apr.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14161-6;5;May;;; +64273-6;LL1080-2;PhenX06_03_months;LA14162-4;6;Jun.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14163-2;7;Jul.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14164-0;8;Aug.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14165-7;9;Sep.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14166-5;10;Oct.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14167-3;11;Nov.;;; +64273-6;LL1080-2;PhenX06_03_months;LA14168-1;12;Dec.;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14169-9;1;Gas: from underground pipes serving the neighborhood;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14170-7;2;Gas: bottled, tank, or LP;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14171-5;3;Electricity;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14172-3;4;Fuel oil, kerosene, etc;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14173-1;5;Coal or coke;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14174-9;6;Wood;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14175-6;7;Solar energy;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14176-4;8;Other fuel;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA14177-2;9;No fuel used;;; +63713-2;LL1081-0;PhenX06_04_heating fuel;LA12688-0;10;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63718-1;LL1082-8;PhenX06_05_house pet type;LA14178-0;1;Dog;;; +63718-1;LL1082-8;PhenX06_05_house pet type;LA14179-8;2;Cat;;; +63718-1;LL1082-8;PhenX06_05_house pet type;LA14180-6;3;Small furry animal;;; +63718-1;LL1082-8;PhenX06_05_house pet type;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63718-1;LL1082-8;PhenX06_05_house pet type;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63719-9;LL1083-6;PhenX06_06_drinking water source;LA14181-4;1;Private well;;; +63719-9;LL1083-6;PhenX06_06_drinking water source;LA14182-2;2;Community supply;;; +63719-9;LL1083-6;PhenX06_06_drinking water source;LA14183-0;3;Bottled water;;; +63719-9;LL1083-6;PhenX06_06_drinking water source;LA6310-2;4;Other (specify);;; +63720-7;LL1083-6;PhenX06_06_drinking water source;LA14181-4;1;Private well;;; +63720-7;LL1083-6;PhenX06_06_drinking water source;LA14182-2;2;Community supply;;; +63720-7;LL1083-6;PhenX06_06_drinking water source;LA14183-0;3;Bottled water;;; +63720-7;LL1083-6;PhenX06_06_drinking water source;LA6310-2;4;Other (specify);;; +63721-5;LL1084-4;PhenX06_07_well depth;LA14184-8;1;Less than 50 feet;;; +63721-5;LL1084-4;PhenX06_07_well depth;LA14185-5;2;50-100 feet;;; +63721-5;LL1084-4;PhenX06_07_well depth;LA14186-3;3;151-250 feet;;; +63721-5;LL1084-4;PhenX06_07_well depth;LA14187-1;4;251-500 feet;;; +63721-5;LL1084-4;PhenX06_07_well depth;LA14188-9;5;501 feet or more;;; +63721-5;LL1084-4;PhenX06_07_well depth;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63722-3;LL1085-1;PhenX06_08_well cased;LA14189-7;1;Cased;;; +63722-3;LL1085-1;PhenX06_08_well cased;LA14190-5;2;Not cased;;; +63722-3;LL1085-1;PhenX06_08_well cased;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63724-9;LL1086-9;PhenX06_09_water treatment;LA14191-3;1;Brita or other pitcher water filter;;; +63724-9;LL1086-9;PhenX06_09_water treatment;LA14192-1;2;Ceramic or charcoal filter;;; +63724-9;LL1086-9;PhenX06_09_water treatment;LA14193-9;3;Water softener;;; +63724-9;LL1086-9;PhenX06_09_water treatment;LA14194-7;4;Aerator;;; +63724-9;LL1086-9;PhenX06_09_water treatment;LA14195-4;5;Reverse osmosis;;; +63724-9;LL1086-9;PhenX06_09_water treatment;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63724-9;LL1086-9;PhenX06_09_water treatment;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63725-6;LL1451-5;PhenX06_33_residences;LA15663-0;1;Residence 1;;; +63725-6;LL1451-5;PhenX06_33_residences;LA15921-2;2;Residence 2;;; +63725-6;LL1451-5;PhenX06_33_residences;LA15922-0;3;Residence 3;;; +63729-8;LL1088-5;PhenX06_11_farm;LA14196-2;1;On farm;;; +63729-8;LL1088-5;PhenX06_11_farm;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63730-6;LL1087-7;PhenX06_10_res water supply;LA15662-2;1;City;;; +63730-6;LL1087-7;PhenX06_10_res water supply;LA14181-4;2;Private well;;; +63730-6;LL1087-7;PhenX06_10_res water supply;LA14197-0;3;Filtered water;;; +63730-6;LL1087-7;PhenX06_10_res water supply;LA14183-0;4;Bottled water;;; +63730-6;LL1087-7;PhenX06_10_res water supply;LA46-8;5;Other;;; +63733-0;LL1089-3;PhenX06_12_res location;LA14198-8;1;Center;;; +63733-0;LL1089-3;PhenX06_12_res location;LA14199-6;2;Margin;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15923-8;1;Asbestos;16369005;Asbestos (substance);http://snomed.info/sct +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15924-6;2;Chemicals/acids/solvents;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15925-3;3;Coal or stone dusts;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15926-1;4;Tar/pitch/asphalt;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15927-9;5;Diesel engine exhaust;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15928-7;6;Dyes;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15929-5;7;Formaldehyde;111095003;Formaldehyde (substance);http://snomed.info/sct +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15930-3;8;Gasoline exhaust;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15931-1;9;Pesticides/herbicides;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15932-9;10;Textile fibers/dusts;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15933-7;11;Wood dust;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA15934-5;12;X-rays/radioactive materials;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA17738-8;13;Ultraviolet light;;; +63736-3;LL1452-3;PhenX06_34_daily life exposure types;LA17739-6;14;Smoke from tobacco products;;; +63745-4;LL1454-9;PhenX06_36_job shift schedule;LA15941-0;1;A regular daytime schedule;;; +63745-4;LL1454-9;PhenX06_36_job shift schedule;LA15942-8;2;A regular evening shift;;; +63745-4;LL1454-9;PhenX06_36_job shift schedule;LA15943-6;3;A regular night shift;;; +63745-4;LL1454-9;PhenX06_36_job shift schedule;LA15944-4;4;A rotating shift;;; +63745-4;LL1454-9;PhenX06_36_job shift schedule;LA15945-1;5;Another schedule;;; +63745-4;LL1454-9;PhenX06_36_job shift schedule;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +63745-4;LL1454-9;PhenX06_36_job shift schedule;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63752-0;LL1091-9;PhenX06_14_job hx;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63752-0;LL1091-9;PhenX06_14_job hx;LA14201-0;2;No, housewife;;; +63752-0;LL1091-9;PhenX06_14_job hx;LA14202-8;3;No, never worked;;; +63752-0;LL1091-9;PhenX06_14_job hx;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63753-8;LL1453-1;PhenX06_35_jobs;LA15935-2;1;Job 1;;; +63753-8;LL1453-1;PhenX06_35_jobs;LA15936-0;2;Job 2;;; +63753-8;LL1453-1;PhenX06_35_jobs;LA15937-8;3;Job 3;;; +63753-8;LL1453-1;PhenX06_35_jobs;LA15938-6;4;Job 4;;; +63753-8;LL1453-1;PhenX06_35_jobs;LA15939-4;5;Job 5;;; +63753-8;LL1453-1;PhenX06_35_jobs;LA15940-2;6;Job 6;;; +63759-5;LL1092-7;PhenX06_15_fulltime job hx;LA14203-6;1;Full-time (Year-Round);;; +63759-5;LL1092-7;PhenX06_15_fulltime job hx;LA14205-1;2;Full-time (Seasonal);;; +63759-5;LL1092-7;PhenX06_15_fulltime job hx;LA14204-4;3;Part-time (Year-Round);;; +63759-5;LL1092-7;PhenX06_15_fulltime job hx;LA14206-9;4;Part-time (Seasonal);;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14207-7;1;Ma = Manufacturer;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14208-5;2;R = Retailer;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14209-3;3;W = Wholesaler;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14210-1;4;S = Service Provider;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14211-9;5;C = Construction;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14212-7;6;Mi = Mining;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14213-5;7;F = Farming/ Fishing/ Forestry;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14214-3;8;G = Government;;; +63760-3;LL1093-5;PhenX06_16_job hx industry;LA14215-0;9;O = Other;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14207-7;1;Ma = Manufacturer;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14208-5;2;R = Retailer;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14209-3;3;W = Wholesaler;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14210-1;4;S = Service Provider;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14211-9;5;C = Construction;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14212-7;6;Mi = Mining;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14213-5;7;F = Farming/ Fishing/ Forestry;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14214-3;8;G = Government;;; +64036-7;LL1093-5;PhenX06_16_job hx industry;LA14215-0;9;O = Other;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15946-9;1;Hobbies using glues;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15947-7;2;Hobbies using soldering;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15948-5;3;Hobbies developing photographs;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15949-3;4;Hobbies like oil painting;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15950-1;5;Hobbies like woodworking or refinishing furniture;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15951-9;6;Hobbies like ceramics or pottery making;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15952-7;7;Hobbies like leather crafting;;; +63764-5;LL1455-6;PhenX06_37_hobbies;LA15953-5;8;Other activities involving the use of chemicals;;; +63778-5;LL1096-8;PhenX06_19_twin type;LA14222-6;1;Identical;;; +63778-5;LL1096-8;PhenX06_19_twin type;LA14223-4;2;Not identical (fraternal);;; +63778-5;LL1096-8;PhenX06_19_twin type;LA4543-0;3;;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15750-5;1;Sibling 1;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15751-3;2;Sibling 2;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15752-1;3;Sibling 3;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15753-9;4;Sibling 4;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15754-7;5;Sibling 5;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15755-4;6;Sibling 6;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15756-2;7;Sibling 7;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15959-2;8;Sibling 8;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15960-0;9;Sibling 9;;; +63779-3;LL1457-2;PhenX06_39_siblings;LA15961-8;10;Sibling 10;;; +63782-7;LL1098-4;PhenX06_21_living sibling;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63782-7;LL1098-4;PhenX06_21_living sibling;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63782-7;LL1098-4;PhenX06_21_living sibling;LA14224-2;3;Respondent;;; +63782-7;LL1098-4;PhenX06_21_living sibling;LA4543-0;4;;;; +63784-3;LL1458-0;PhenX06_40_day care/preschools;LA15962-6;1;Day care 1;;; +63784-3;LL1458-0;PhenX06_40_day care/preschools;LA15963-4;2;Day care 2;;; +63784-3;LL1458-0;PhenX06_40_day care/preschools;LA15964-2;3;Day care 3;;; +63784-3;LL1458-0;PhenX06_40_day care/preschools;LA15965-9;4;Preschool 1;;; +63784-3;LL1458-0;PhenX06_40_day care/preschools;LA15966-7;5;Preschool 2;;; +63784-3;LL1458-0;PhenX06_40_day care/preschools;LA15967-5;6;Preschool 3;;; +63794-2;LL1464-8;PhenX06_46_rugs/drapes cleaning place;LA16005-3;1;In the house;;; +63794-2;LL1464-8;PhenX06_46_rugs/drapes cleaning place;LA16006-1;2;Somewhere else;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15968-3;1;Paints or solvents, paint thinners and removers, typewriter corrective fluids;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15969-1;2;Glues and adhesives;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15970-9;3;Gasoline lawn mower;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15971-7;4;Chain saw or other gasoline equipment;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15972-5;5;Sander and/or saw;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15973-3;6;Pesticides sprayed;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15974-1;7;Vacuuming;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15975-8;8;Sweeping indoors;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15976-6;9;Dusting;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15977-4;10;Cleaning solutions, including household cleaners and chemicals;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15978-2;11;Gardening;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15979-0;12;Woodworking;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15980-8;13;Metal working or welding;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15981-6;14;Broiling, smoking, grilling or frying inside the house;;; +63802-3;LL1460-6;PhenX06_42_air contaminant;LA15982-4;15;Broiling, smoking, grilling or frying outside the house;;; +63809-8;LL1100-8;PhenX06_23_where car parked;LA14227-5;1;A garage attached to your home;;; +63809-8;LL1100-8;PhenX06_23_where car parked;LA14228-3;2;A detached garage;;; +63809-8;LL1100-8;PhenX06_23_where car parked;LA14229-1;3;A carport attached to your home;;; +63810-6;LL1100-8;PhenX06_23_where car parked;LA14227-5;1;A garage attached to your home;;; +63810-6;LL1100-8;PhenX06_23_where car parked;LA14228-3;2;A detached garage;;; +63810-6;LL1100-8;PhenX06_23_where car parked;LA14229-1;3;A carport attached to your home;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15983-2;1;Organic compound 1;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15984-0;2;Organic compound 2;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15985-7;3;Organic compound 3;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15986-5;4;Organic compound 4;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15987-3;5;Organic compound 5;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15988-1;6;Allergen 1;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15989-9;7;Allergen 2;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15990-7;8;Allergen 3;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15991-5;9;Allergen 4;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15992-3;10;Allergen 5;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15993-1;11;Endotoxin 1;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15994-9;12;Endotoxin 2;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15995-6;13;Endotoxin 3;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15996-4;14;Endotoxin 4;;; +63814-8;LL1459-8;PhenX06_41_vacuum dust contaminant;LA15997-2;15;Endotoxin 5;;; +63817-1;LL1101-6;PhenX06_24_sunburn skin reaction;LA14230-9;1;A blistering sunburn;;; +63817-1;LL1101-6;PhenX06_24_sunburn skin reaction;LA14231-7;2;A sunburn without blisters;;; +63817-1;LL1101-6;PhenX06_24_sunburn skin reaction;LA14232-5;3;A mild sunburn that becomes a tan;;; +63817-1;LL1101-6;PhenX06_24_sunburn skin reaction;LA14233-3;4;A tan with no sunburn;;; +63817-1;LL1101-6;PhenX06_24_sunburn skin reaction;LA14234-1;5;No change in skin color;;; +63827-0;LL1462-2;PhenX06_44_UV exposure type;LA14230-9;1;A blistering sunburn;;; +63827-0;LL1462-2;PhenX06_44_UV exposure type;LA16002-0;2;Skin rash from sun exposure;;; +63827-0;LL1462-2;PhenX06_44_UV exposure type;LA16003-8;3;Sun lamp;;; +63827-0;LL1462-2;PhenX06_44_UV exposure type;LA16004-6;4;Tanning booth;;; +63828-8;LL1461-4;PhenX06_43_age range UV exposure;LA15998-0;1;Teens;;; +63828-8;LL1461-4;PhenX06_43_age range UV exposure;LA15999-8;2;Twenties;;; +63828-8;LL1461-4;PhenX06_43_age range UV exposure;LA16000-4;3;Thirties;;; +63828-8;LL1461-4;PhenX06_43_age range UV exposure;LA16001-2;4;Past ten years;;; +63829-6;LL1103-2;PhenX06_26_Hs in sun;LA12717-7;1;Less than 1 hour;;; +63829-6;LL1103-2;PhenX06_26_Hs in sun;LA14241-6;2;1 or 2 hours;;; +63829-6;LL1103-2;PhenX06_26_Hs in sun;LA14242-4;3;3 or 4 hours;;; +63829-6;LL1103-2;PhenX06_26_Hs in sun;LA14243-2;4;5 or 6 hours;;; +63830-4;LL1103-2;PhenX06_26_Hs in sun;LA12717-7;1;Less than 1 hour;;; +63830-4;LL1103-2;PhenX06_26_Hs in sun;LA14241-6;2;1 or 2 hours;;; +63830-4;LL1103-2;PhenX06_26_Hs in sun;LA14242-4;3;3 or 4 hours;;; +63830-4;LL1103-2;PhenX06_26_Hs in sun;LA14243-2;4;5 or 6 hours;;; +63831-2;LL1104-0;PhenX06_27_workspace renovation;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63831-2;LL1104-0;PhenX06_27_workspace renovation;LA14244-0;2;Yes, during the past 12 months;;; +63831-2;LL1104-0;PhenX06_27_workspace renovation;LA14245-7;3;Yes, 1-3 years ago;;; +63831-2;LL1104-0;PhenX06_27_workspace renovation;LA14246-5;4;Yes, more than 3 years ago;;; +63831-2;LL1104-0;PhenX06_27_workspace renovation;LA15599-6;5;I don’t know;;; +63832-0;LL1106-5;PhenX06_28_workspace floor material;LA14247-3;1;Concrete;;; +63832-0;LL1106-5;PhenX06_28_workspace floor material;LA14174-9;2;Wood;;; +63832-0;LL1106-5;PhenX06_28_workspace floor material;LA14248-1;3;Cork;;; +63832-0;LL1106-5;PhenX06_28_workspace floor material;LA14249-9;4;Vinyl;;; +63832-0;LL1106-5;PhenX06_28_workspace floor material;LA14250-7;5;Wall-to-wall carpet;;; +63832-0;LL1106-5;PhenX06_28_workspace floor material;LA46-8;6;Other;;; +63832-0;LL1106-5;PhenX06_28_workspace floor material;LA15599-6;7;I don’t know;;; +63834-6;LL1107-3;PhenX06_29_material on wall surface;LA14252-3;0;Yes, at least half of the wall surfaces;;; +63834-6;LL1107-3;PhenX06_29_material on wall surface;LA10974-6;1;No - could not recall;;; +63834-6;LL1107-3;PhenX06_29_material on wall surface;LA14251-5;2;Yes, less than half of the wall surfaces;;; +63835-3;LL1107-3;PhenX06_29_material on wall surface;LA14252-3;0;Yes, at least half of the wall surfaces;;; +63835-3;LL1107-3;PhenX06_29_material on wall surface;LA10974-6;1;No - could not recall;;; +63835-3;LL1107-3;PhenX06_29_material on wall surface;LA14251-5;2;Yes, less than half of the wall surfaces;;; +63841-1;LL1107-3;PhenX06_29_material on wall surface;LA14252-3;0;Yes, at least half of the wall surfaces;;; +63841-1;LL1107-3;PhenX06_29_material on wall surface;LA10974-6;1;No - could not recall;;; +63841-1;LL1107-3;PhenX06_29_material on wall surface;LA14251-5;2;Yes, less than half of the wall surfaces;;; +63842-9;LL1107-3;PhenX06_29_material on wall surface;LA14252-3;0;Yes, at least half of the wall surfaces;;; +63842-9;LL1107-3;PhenX06_29_material on wall surface;LA10974-6;1;No - could not recall;;; +63842-9;LL1107-3;PhenX06_29_material on wall surface;LA14251-5;2;Yes, less than half of the wall surfaces;;; +63838-7;LL1108-1;PhenX06_30_home repairs;LA14253-1;1;Painting, less than half of the wall area;;; +63838-7;LL1108-1;PhenX06_30_home repairs;LA14254-9;2;Painting, at least half of the wall area;;; +63838-7;LL1108-1;PhenX06_30_home repairs;LA14255-6;3;Wall-papering, less than half of the wall area;;; +63838-7;LL1108-1;PhenX06_30_home repairs;LA14256-4;4;Wall-papering, at least half of the wall area;;; +63838-7;LL1108-1;PhenX06_30_home repairs;LA14257-2;5;Lacquering of the floor;;; +63838-7;LL1108-1;PhenX06_30_home repairs;LA14258-0;6;Use of floor putty;;; +63838-7;LL1108-1;PhenX06_30_home repairs;LA46-8;7;Other;;; +63839-5;LL1109-9;PhenX06_31_flooring amt;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63839-5;LL1109-9;PhenX06_31_flooring amt;LA14259-8;2;Yes, less than half of the floor area;;; +63839-5;LL1109-9;PhenX06_31_flooring amt;LA14260-6;3;Yes, at least half of the floor area;;; +63840-3;LL1109-9;PhenX06_31_flooring amt;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63840-3;LL1109-9;PhenX06_31_flooring amt;LA14259-8;2;Yes, less than half of the floor area;;; +63840-3;LL1109-9;PhenX06_31_flooring amt;LA14260-6;3;Yes, at least half of the floor area;;; +63852-8;LL1102-4;PhenX06_25_age of exposure;LA14235-8;1;Under 5 Years Old;;; +63852-8;LL1102-4;PhenX06_25_age of exposure;LA14236-6;2;5 - 14 years old;;; +63852-8;LL1102-4;PhenX06_25_age of exposure;LA14237-4;3;15 - 24 years old;;; +63852-8;LL1102-4;PhenX06_25_age of exposure;LA14238-2;4;25 - 39 years old;;; +63852-8;LL1102-4;PhenX06_25_age of exposure;LA14239-0;5;40 - 64 years old;;; +63852-8;LL1102-4;PhenX06_25_age of exposure;LA14240-8;6;65 years old or older;;; +63854-4;LL1102-4;PhenX06_25_age of exposure;LA14235-8;1;Under 5 Years Old;;; +63854-4;LL1102-4;PhenX06_25_age of exposure;LA14236-6;2;5 - 14 years old;;; +63854-4;LL1102-4;PhenX06_25_age of exposure;LA14237-4;3;15 - 24 years old;;; +63854-4;LL1102-4;PhenX06_25_age of exposure;LA14238-2;4;25 - 39 years old;;; +63854-4;LL1102-4;PhenX06_25_age of exposure;LA14239-0;5;40 - 64 years old;;; +63854-4;LL1102-4;PhenX06_25_age of exposure;LA14240-8;6;65 years old or older;;; +63856-9;LL1163-6;PhenX06_32_UV exposure times;LA15694-5;1;1 or 2;;; +63856-9;LL1163-6;PhenX06_32_UV exposure times;LA15695-2;2;3 or 4;;; +63856-9;LL1163-6;PhenX06_32_UV exposure times;LA15696-0;3;5 - 9;;; +63856-9;LL1163-6;PhenX06_32_UV exposure times;LA15697-8;4;10 - 19;;; +63856-9;LL1163-6;PhenX06_32_UV exposure times;LA15698-6;5;20 or more;;; +63859-3;LL1110-7;PhenX07_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63859-3;LL1110-7;PhenX07_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63859-3;LL1110-7;PhenX07_01;LA14263-0;3;DK/Refused;;; +64005-2;LL1110-7;PhenX07_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64005-2;LL1110-7;PhenX07_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64005-2;LL1110-7;PhenX07_01;LA14263-0;3;DK/Refused;;; +63860-1;LL1111-5;PhenX07_02_drinking weekly age range;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63860-1;LL1111-5;PhenX07_02_drinking weekly age range;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +63860-1;LL1111-5;PhenX07_02_drinking weekly age range;LA14264-8;3;Not that old yet;;; +63862-7;LL1465-5;PhenX07_30_age range exercise;LA16008-7;1;During high school;;; +63862-7;LL1465-5;PhenX07_30_age range exercise;LA16009-5;2;Between 18 and 24;;; +63862-7;LL1465-5;PhenX07_30_age range exercise;LA16010-3;3;Between 25 and 34;;; +63862-7;LL1465-5;PhenX07_30_age range exercise;LA16011-1;4;Between 35 and 44;;; +63862-7;LL1465-5;PhenX07_30_age range exercise;LA16012-9;5;Between 45 and 54;;; +63862-7;LL1465-5;PhenX07_30_age range exercise;LA16013-7;6;In past 3 years;;; +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA15699-4;2;1/2 hr;;; +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA11828-3;3;1 hour;;; +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA15700-0;4;1 1/2 hrs;;; +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA11829-1;5;2 hours;123030002;2 hours (qualifier value);http://snomed.info/sct +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA11830-9;6;3 hours;;; +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA15703-4;7;4 - 6 hrs;;; +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA15704-2;8;7 - 10 hrs;;; +63863-5;LL1466-3;PhenX07_31_exercise Hs;LA15705-9;9;11 or more hrs;;; +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA15699-4;2;1/2 hr;;; +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA11828-3;3;1 hour;;; +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA15700-0;4;1 1/2 hrs;;; +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA11829-1;5;2 hours;123030002;2 hours (qualifier value);http://snomed.info/sct +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA11830-9;6;3 hours;;; +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA15703-4;7;4 - 6 hrs;;; +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA15704-2;8;7 - 10 hrs;;; +63865-0;LL1466-3;PhenX07_31_exercise Hs;LA15705-9;9;11 or more hrs;;; +63864-3;LL1165-1;PhenX07_26_Mos exercise freq;LA15706-7;1;1 - 3;;; +63864-3;LL1165-1;PhenX07_26_Mos exercise freq;LA15707-5;2;4 - 6;;; +63864-3;LL1165-1;PhenX07_26_Mos exercise freq;LA15708-3;3;7 - 9;;; +63864-3;LL1165-1;PhenX07_26_Mos exercise freq;LA15709-1;4;10 - 12;;; +63866-8;LL1165-1;PhenX07_26_Mos exercise freq;LA15706-7;1;1 - 3;;; +63866-8;LL1165-1;PhenX07_26_Mos exercise freq;LA15707-5;2;4 - 6;;; +63866-8;LL1165-1;PhenX07_26_Mos exercise freq;LA15708-3;3;7 - 9;;; +63866-8;LL1165-1;PhenX07_26_Mos exercise freq;LA15709-1;4;10 - 12;;; +63867-6;LL1467-1;PhenX07_32_phys activity past Y;LA16014-5;1;Casual walking;;; +63867-6;LL1467-1;PhenX07_32_phys activity past Y;LA16015-2;2;Doing housework;;; +63867-6;LL1467-1;PhenX07_32_phys activity past Y;LA16016-0;3;Standing or walking at work;;; +63867-6;LL1467-1;PhenX07_32_phys activity past Y;LA11868-9;4;Sitting;33586001;Sitting position (finding);http://snomed.info/sct +63867-6;LL1467-1;PhenX07_32_phys activity past Y;LA11864-8;5;Sleeping;;; +63873-4;LL1469-7;PhenX07_34_estrogen use;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63873-4;LL1469-7;PhenX07_34_estrogen use;LA16021-0;2;Yes, and I am currently taking estrogens;;; +63873-4;LL1469-7;PhenX07_34_estrogen use;LA16022-8;3;Yes, but I am no longer taking estrogens;;; +63875-9;LL1472-1;PhenX07_37_age range first hormone use;LA16027-7;1;Before age 45;;; +63875-9;LL1472-1;PhenX07_37_age range first hormone use;LA16028-5;2;45-49;;; +63875-9;LL1472-1;PhenX07_37_age range first hormone use;LA16029-3;3;50-54;;; +63875-9;LL1472-1;PhenX07_37_age range first hormone use;LA16030-1;4;55-59;;; +63875-9;LL1472-1;PhenX07_37_age range first hormone use;LA16031-9;5;60-64;;; +63875-9;LL1472-1;PhenX07_37_age range first hormone use;LA16032-7;6;65-69;;; +63875-9;LL1472-1;PhenX07_37_age range first hormone use;LA16033-5;7;70 or older;;; +63879-1;LL1472-1;PhenX07_37_age range first hormone use;LA16027-7;1;Before age 45;;; +63879-1;LL1472-1;PhenX07_37_age range first hormone use;LA16028-5;2;45-49;;; +63879-1;LL1472-1;PhenX07_37_age range first hormone use;LA16029-3;3;50-54;;; +63879-1;LL1472-1;PhenX07_37_age range first hormone use;LA16030-1;4;55-59;;; +63879-1;LL1472-1;PhenX07_37_age range first hormone use;LA16031-9;5;60-64;;; +63879-1;LL1472-1;PhenX07_37_age range first hormone use;LA16032-7;6;65-69;;; +63879-1;LL1472-1;PhenX07_37_age range first hormone use;LA16033-5;7;70 or older;;; +63883-3;LL1472-1;PhenX07_37_age range first hormone use;LA16027-7;1;Before age 45;;; +63883-3;LL1472-1;PhenX07_37_age range first hormone use;LA16028-5;2;45-49;;; +63883-3;LL1472-1;PhenX07_37_age range first hormone use;LA16029-3;3;50-54;;; +63883-3;LL1472-1;PhenX07_37_age range first hormone use;LA16030-1;4;55-59;;; +63883-3;LL1472-1;PhenX07_37_age range first hormone use;LA16031-9;5;60-64;;; +63883-3;LL1472-1;PhenX07_37_age range first hormone use;LA16032-7;6;65-69;;; +63883-3;LL1472-1;PhenX07_37_age range first hormone use;LA16033-5;7;70 or older;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA15131-8;1;Currently taking;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA16027-7;2;Before age 45;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA16028-5;3;45-49;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA16029-3;4;50-54;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA16030-1;5;55-59;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA16031-9;6;60-64;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA16032-7;7;65-69;;; +63876-7;LL1473-9;PhenX07_38_age range current hormone use;LA16033-5;8;70 or older;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA15131-8;1;Currently taking;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA16027-7;2;Before age 45;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA16028-5;3;45-49;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA16029-3;4;50-54;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA16030-1;5;55-59;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA16031-9;6;60-64;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA16032-7;7;65-69;;; +63880-9;LL1473-9;PhenX07_38_age range current hormone use;LA16033-5;8;70 or older;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA15131-8;1;Currently taking;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA16027-7;2;Before age 45;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA16028-5;3;45-49;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA16029-3;4;50-54;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA16030-1;5;55-59;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA16031-9;6;60-64;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA16032-7;7;65-69;;; +63884-1;LL1473-9;PhenX07_38_age range current hormone use;LA16033-5;8;70 or older;;; +63878-3;LL1112-3;PhenX07_03_premarin doses;LA14265-5;1;Green-0.3 mg;;; +63878-3;LL1112-3;PhenX07_03_premarin doses;LA14266-3;2;Brown/Red-0.625 mg;;; +63878-3;LL1112-3;PhenX07_03_premarin doses;LA14267-1;3;White-0.9 mg;;; +63878-3;LL1112-3;PhenX07_03_premarin doses;LA14268-9;4;Yellow/Orange-1.25 mg;;; +63878-3;LL1112-3;PhenX07_03_premarin doses;LA14269-7;5;Purple-2.5 mg;;; +63957-5;LL1112-3;PhenX07_03_premarin doses;LA14265-5;1;Green-0.3 mg;;; +63957-5;LL1112-3;PhenX07_03_premarin doses;LA14266-3;2;Brown/Red-0.625 mg;;; +63957-5;LL1112-3;PhenX07_03_premarin doses;LA14267-1;3;White-0.9 mg;;; +63957-5;LL1112-3;PhenX07_03_premarin doses;LA14268-9;4;Yellow/Orange-1.25 mg;;; +63957-5;LL1112-3;PhenX07_03_premarin doses;LA14269-7;5;Purple-2.5 mg;;; +63882-5;LL1497-8;PhenX07_46_progesterone/progestin use;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63882-5;LL1497-8;PhenX07_46_progesterone/progestin use;LA16133-3;2;Provera only;;; +63882-5;LL1497-8;PhenX07_46_progesterone/progestin use;LA16134-1;3;Another type only;;; +63882-5;LL1497-8;PhenX07_46_progesterone/progestin use;LA16135-8;4;Provera and another type only;;; +63882-5;LL1497-8;PhenX07_46_progesterone/progestin use;LA16136-6;5;Yes, but don't know type;;; +63891-6;LL1474-7;PhenX07_39_ menopause cause;LA16034-3;1;Natural;;; +63891-6;LL1474-7;PhenX07_39_ menopause cause;LA16035-0;2;Chemotherapy/medication induced;;; +63891-6;LL1474-7;PhenX07_39_ menopause cause;LA16036-8;3;Surgery on reproductive organs;;; +63891-6;LL1474-7;PhenX07_39_ menopause cause;LA46-8;4;Other;;; +63893-2;LL1475-4;PhenX07_40_pregnancy outcome;LA14270-5;1;Live birth;;; +63893-2;LL1475-4;PhenX07_40_pregnancy outcome;LA14271-3;2;Stillborn;;; +63893-2;LL1475-4;PhenX07_40_pregnancy outcome;LA14272-1;3;Miscarriage;;; +63893-2;LL1475-4;PhenX07_40_pregnancy outcome;LA14273-9;4;Induced abortion;;; +63895-7;LL5057-6;Currently breastfeeding | Not currenlty breastfeed;LA29252-6;1;Currently breastfeeding;;; +63895-7;LL5057-6;Currently breastfeeding | Not currenlty breastfeed;LA29253-4;2;Not currently breastfeeding;;; +63895-7;LL5057-6;Currently breastfeeding | Not currenlty breastfeed;LA29254-2;3;Exclusively breastfeeding;;; +63895-7;LL5057-6;Currently breastfeeding | Not currenlty breastfeed;LA29255-9;4;Supplementing;;; +63897-3;LL1595-9;Relatives;LA10417-6;1;Mother;;; +63897-3;LL1595-9;Relatives;LA10416-8;2;Father;;; +63897-3;LL1595-9;Relatives;LA10418-4;3;Sister;;; +63897-3;LL1595-9;Relatives;LA10415-0;4;Brother;;; +63897-3;LL1595-9;Relatives;LA10405-1;5;Daughter;;; +63897-3;LL1595-9;Relatives;LA10426-7;6;Son;;; +63897-3;LL1595-9;Relatives;LA10413-5;7;Maternal Grandmother;;; +63897-3;LL1595-9;Relatives;LA10412-7;8;Maternal Grandfather;;; +63897-3;LL1595-9;Relatives;LA10424-2;9;Paternal Grandmother;;; +63897-3;LL1595-9;Relatives;LA10423-4;10;Paternal Grandfather;;; +63897-3;LL1595-9;Relatives;LA10410-1;11;Maternal Aunt;;; +63897-3;LL1595-9;Relatives;LA10414-3;12;Maternal Uncle;;; +63897-3;LL1595-9;Relatives;LA10421-8;13;Paternal Aunt;;; +63897-3;LL1595-9;Relatives;LA10425-9;14;Paternal Uncle;;; +63897-3;LL1595-9;Relatives;LA15743-0;15;Child 1;;; +63897-3;LL1595-9;Relatives;LA15750-5;16;Sibling 1;;; +63897-3;LL1595-9;Relatives;LA15641-6;17;Adopted son or daughter;;; +63897-3;LL1595-9;Relatives;LA15314-0;18;Half sibling;;; +63897-3;LL1595-9;Relatives;LA10409-3;19;Half-sister;;; +63897-3;LL1595-9;Relatives;LA15643-2;20;Stepson or stepdaughter;;; +63897-3;LL1595-9;Relatives;LA15312-4;21;Self;;; +64761-0;LL1595-9;Relatives;LA10417-6;1;Mother;;; +64761-0;LL1595-9;Relatives;LA10416-8;2;Father;;; +64761-0;LL1595-9;Relatives;LA10418-4;3;Sister;;; +64761-0;LL1595-9;Relatives;LA10415-0;4;Brother;;; +64761-0;LL1595-9;Relatives;LA10405-1;5;Daughter;;; +64761-0;LL1595-9;Relatives;LA10426-7;6;Son;;; +64761-0;LL1595-9;Relatives;LA10413-5;7;Maternal Grandmother;;; +64761-0;LL1595-9;Relatives;LA10412-7;8;Maternal Grandfather;;; +64761-0;LL1595-9;Relatives;LA10424-2;9;Paternal Grandmother;;; +64761-0;LL1595-9;Relatives;LA10423-4;10;Paternal Grandfather;;; +64761-0;LL1595-9;Relatives;LA10410-1;11;Maternal Aunt;;; +64761-0;LL1595-9;Relatives;LA10414-3;12;Maternal Uncle;;; +64761-0;LL1595-9;Relatives;LA10421-8;13;Paternal Aunt;;; +64761-0;LL1595-9;Relatives;LA10425-9;14;Paternal Uncle;;; +64761-0;LL1595-9;Relatives;LA15743-0;15;Child 1;;; +64761-0;LL1595-9;Relatives;LA15750-5;16;Sibling 1;;; +64761-0;LL1595-9;Relatives;LA15641-6;17;Adopted son or daughter;;; +64761-0;LL1595-9;Relatives;LA15314-0;18;Half sibling;;; +64761-0;LL1595-9;Relatives;LA10409-3;19;Half-sister;;; +64761-0;LL1595-9;Relatives;LA15643-2;20;Stepson or stepdaughter;;; +64761-0;LL1595-9;Relatives;LA15312-4;21;Self;;; +64837-8;LL1595-9;Relatives;LA10417-6;1;Mother;;; +64837-8;LL1595-9;Relatives;LA10416-8;2;Father;;; +64837-8;LL1595-9;Relatives;LA10418-4;3;Sister;;; +64837-8;LL1595-9;Relatives;LA10415-0;4;Brother;;; +64837-8;LL1595-9;Relatives;LA10405-1;5;Daughter;;; +64837-8;LL1595-9;Relatives;LA10426-7;6;Son;;; +64837-8;LL1595-9;Relatives;LA10413-5;7;Maternal Grandmother;;; +64837-8;LL1595-9;Relatives;LA10412-7;8;Maternal Grandfather;;; +64837-8;LL1595-9;Relatives;LA10424-2;9;Paternal Grandmother;;; +64837-8;LL1595-9;Relatives;LA10423-4;10;Paternal Grandfather;;; +64837-8;LL1595-9;Relatives;LA10410-1;11;Maternal Aunt;;; +64837-8;LL1595-9;Relatives;LA10414-3;12;Maternal Uncle;;; +64837-8;LL1595-9;Relatives;LA10421-8;13;Paternal Aunt;;; +64837-8;LL1595-9;Relatives;LA10425-9;14;Paternal Uncle;;; +64837-8;LL1595-9;Relatives;LA15743-0;15;Child 1;;; +64837-8;LL1595-9;Relatives;LA15750-5;16;Sibling 1;;; +64837-8;LL1595-9;Relatives;LA15641-6;17;Adopted son or daughter;;; +64837-8;LL1595-9;Relatives;LA15314-0;18;Half sibling;;; +64837-8;LL1595-9;Relatives;LA10409-3;19;Half-sister;;; +64837-8;LL1595-9;Relatives;LA15643-2;20;Stepson or stepdaughter;;; +64837-8;LL1595-9;Relatives;LA15312-4;21;Self;;; +65670-2;LL1595-9;Relatives;LA10417-6;1;Mother;;; +65670-2;LL1595-9;Relatives;LA10416-8;2;Father;;; +65670-2;LL1595-9;Relatives;LA10418-4;3;Sister;;; +65670-2;LL1595-9;Relatives;LA10415-0;4;Brother;;; +65670-2;LL1595-9;Relatives;LA10405-1;5;Daughter;;; +65670-2;LL1595-9;Relatives;LA10426-7;6;Son;;; +65670-2;LL1595-9;Relatives;LA10413-5;7;Maternal Grandmother;;; +65670-2;LL1595-9;Relatives;LA10412-7;8;Maternal Grandfather;;; +65670-2;LL1595-9;Relatives;LA10424-2;9;Paternal Grandmother;;; +65670-2;LL1595-9;Relatives;LA10423-4;10;Paternal Grandfather;;; +65670-2;LL1595-9;Relatives;LA10410-1;11;Maternal Aunt;;; +65670-2;LL1595-9;Relatives;LA10414-3;12;Maternal Uncle;;; +65670-2;LL1595-9;Relatives;LA10421-8;13;Paternal Aunt;;; +65670-2;LL1595-9;Relatives;LA10425-9;14;Paternal Uncle;;; +65670-2;LL1595-9;Relatives;LA15743-0;15;Child 1;;; +65670-2;LL1595-9;Relatives;LA15750-5;16;Sibling 1;;; +65670-2;LL1595-9;Relatives;LA15641-6;17;Adopted son or daughter;;; +65670-2;LL1595-9;Relatives;LA15314-0;18;Half sibling;;; +65670-2;LL1595-9;Relatives;LA10409-3;19;Half-sister;;; +65670-2;LL1595-9;Relatives;LA15643-2;20;Stepson or stepdaughter;;; +65670-2;LL1595-9;Relatives;LA15312-4;21;Self;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15691-1;1;<50;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15692-9;2;50-64;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15693-7;3;65+;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15691-1;1;<50;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15692-9;2;50-64;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15693-7;3;65+;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15691-1;1;<50;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15692-9;2;50-64;;; +63900-5;LL1166-9;PhenX07_27_age range CA relative;LA15693-7;3;65+;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA14283-8;1;Breast cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15682-0;2;Ovarian cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15683-8;3;Endometrial cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15684-6;4;Cervix cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15685-3;5;Lymphoma;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA14279-6;6;Melanoma;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15686-1;7;Colon/rectal cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15687-9;8;Lung cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15688-7;9;Prostate cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA15689-5;10;Pancreas cancer;;; +63902-1;LL1167-7;PhenX07_28_first CA dx;LA14284-6;11;Other cancer;;; +63904-7;LL1168-5;PhenX07_29_2nd CA dx;LA14283-8;1;Breast cancer;;; +63904-7;LL1168-5;PhenX07_29_2nd CA dx;LA15682-0;2;Ovarian cancer;;; +63904-7;LL1168-5;PhenX07_29_2nd CA dx;LA15683-8;3;Endometrial cancer;;; +63904-7;LL1168-5;PhenX07_29_2nd CA dx;LA15686-1;4;Colon/rectal cancer;;; +63904-7;LL1168-5;PhenX07_29_2nd CA dx;LA14279-6;5;Melanoma;;; +63904-7;LL1168-5;PhenX07_29_2nd CA dx;LA15688-7;6;Prostate cancer;;; +63904-7;LL1168-5;PhenX07_29_2nd CA dx;LA14284-6;7;Other cancer;;; +63905-4;LL1114-9;PhenX07_05_lung cancer worry;LA15665-5;1;Rarely or never;;; +63905-4;LL1114-9;PhenX07_05_lung cancer worry;LA10082-8;2;Sometimes;;; +63905-4;LL1114-9;PhenX07_05_lung cancer worry;LA10044-8;3;Often;;; +63905-4;LL1114-9;PhenX07_05_lung cancer worry;LA6154-4;4;All of the time;;; +63906-2;LL1115-6;PhenX07_06_lung CA risk;LA15666-3;1;At much less risk;;; +63906-2;LL1115-6;PhenX07_06_lung CA risk;LA15667-1;2;At less risk;;; +63906-2;LL1115-6;PhenX07_06_lung CA risk;LA15668-9;3;At the same risk;;; +63906-2;LL1115-6;PhenX07_06_lung CA risk;LA15669-7;4;At higher risk;;; +63906-2;LL1115-6;PhenX07_06_lung CA risk;LA15670-5;5;At much higher risk;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14274-7;1;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14275-4;2;Angina pectoris;194828000;Angina (disorder);http://snomed.info/sct +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14276-2;3;Coronary bypass;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14277-0;4;Angioplasty or stent;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14278-8;5;Transient ischemic attack - TIA;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA12362-2;6;Stroke (CVA) or TIA;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA7425-7;7;Deep vein thrombosis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA7468-7;8;Pulmonary embolism;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14279-6;9;Melanoma;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14280-4;10;Basal cell skin cancer;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA15445-2;11;Squamous cell (epidermoid) carcinoma;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14282-0;12;Fibrocystic or other benign breast disease;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14283-8;13;Breast cancer;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14284-6;14;Other cancer;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14285-3;15;Colon or rectal polyp - benign;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14286-1;16;Ulcerative colitis or Crohn's;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14287-9;17;Gastric or duodenal ulcer;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14288-7;18;Barrett's Esophagus;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14289-5;19;Gallstones;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14290-3;20;Cholecystectomy;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14291-1;21;Diabetes mellitus;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14292-9;22;Elevated cholesterol;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14293-7;23;High blood pressure;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14294-5;24;Endometriosis - 1st diagnosis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14295-2;25;Uterine fibroids - 1st diagnosis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14296-0;26;Premenstrual syndrome - PMS;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14297-8;27;Kidney stones;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14298-6;28;Multiple Sclerosis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14299-4;29;Asthma, doctor diagnosed;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14300-0;30;Emphysema or chronic bronchitis, doctor diagnosis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14301-8;31;Pneumonia, x-ray confirmed;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14302-6;32;Graves' Disease - hyperthyroidism;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14303-4;33;Hypothyroidism;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14304-2;34;Thyroid nodule (benign);;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14305-9;35;Gout;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14306-7;36;SLE (systemic lupus);;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14307-5;37;Rheumatoid arthritis, doctor diagnosis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14308-3;38;Other arthritis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14309-1;39;Depression, clinician diagnosis;;; +63907-0;LL1116-4;PhenX07_07_conditions associated with cancer;LA14310-9;40;Other major illness or surgery;;; +63915-3;LL1117-2;PhenX07_08_gallstone dx method;LA14311-7;1;X-Ray or ultrasound;;; +63915-3;LL1117-2;PhenX07_08_gallstone dx method;LA46-8;2;Other;;; +63920-3;LL1118-0;PhenX07_09_Ca screening testing;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63920-3;LL1118-0;PhenX07_09_Ca screening testing;LA15671-3;2;Yes, once;;; +63920-3;LL1118-0;PhenX07_09_Ca screening testing;LA15672-1;3;Yes, more than once;;; +63920-3;LL1118-0;PhenX07_09_Ca screening testing;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16043-4;1;Chest x-ray;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16044-2;2;Test for blood in the stool;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16045-9;3;Colonoscopy, sigmoidoscopy, or barium enema;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16046-7;4;Mammogram;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16047-5;5;Pap smear;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16048-3;6;Pelvic examination;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16049-1;7;Ultrasound or scan of ovaries;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16050-9;8;Blood test for ovarian cancer;;; +63921-1;LL1478-8;PhenX07_43_CA screening type;LA16051-7;9;Rectal examination of prostate;;; +63922-9;LL1119-8;PhenX07_10_consider smoking cessation;LA14314-1;1;Yes, plan to stop within next 30 days;;; +63922-9;LL1119-8;PhenX07_10_consider smoking cessation;LA14315-8;2;Yes, plan to stop within next 6 months, but not within next 30 days;;; +63922-9;LL1119-8;PhenX07_10_consider smoking cessation;LA14316-6;3;No, not thinking of quitting In next 6 months;;; +63924-5;LL1120-6;PhenX07_11_longest time smoking cessation;LA14317-4;1;Less than 1 week;;; +63924-5;LL1120-6;PhenX07_11_longest time smoking cessation;LA14318-2;2;1 to 3 weeks;;; +63924-5;LL1120-6;PhenX07_11_longest time smoking cessation;LA14319-0;3;1 to 2 months;;; +63924-5;LL1120-6;PhenX07_11_longest time smoking cessation;LA14320-8;4;3 to 11 months;;; +63924-5;LL1120-6;PhenX07_11_longest time smoking cessation;LA14321-6;5;1 to 4 years;;; +63924-5;LL1120-6;PhenX07_11_longest time smoking cessation;LA13859-6;6;5 to 9 years;;; +63924-5;LL1120-6;PhenX07_11_longest time smoking cessation;LA13833-1;7;10 years or more;;; +63926-0;LL1121-4;PhenX07_12_smoke cessation products;LA14322-4;1;Nicotine gum;;; +63926-0;LL1121-4;PhenX07_12_smoke cessation products;LA14323-2;2;Nicotine patch;;; +63926-0;LL1121-4;PhenX07_12_smoke cessation products;LA14324-0;3;Nicotine nasal spray, inhaler, lozenge, or tablet;;; +63926-0;LL1121-4;PhenX07_12_smoke cessation products;LA14325-7;4;Prescription pill such as Zyban®;;; +63926-0;LL1121-4;PhenX07_12_smoke cessation products;LA14326-5;5;Buproprion, or Wellbutrin®;;; +63926-0;LL1121-4;PhenX07_12_smoke cessation products;LA14327-3;6;None of these;;; +63927-8;LL1122-2;PhenX07_13_smoke cessation advice;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63927-8;LL1122-2;PhenX07_13_smoke cessation advice;LA14328-1;2;No, was not advised to quit;;; +63927-8;LL1122-2;PhenX07_13_smoke cessation advice;LA14329-9;3;No, did not see a health professional in past 12 months;;; +63927-8;LL1122-2;PhenX07_13_smoke cessation advice;LA14330-7;4;No, did not smoke in past 12 months;;; +63930-2;LL1123-0;PhenX07_14_laterality;LA4585-1;1;Left;;; +63930-2;LL1123-0;PhenX07_14_laterality;LA4306-2;2;Right;;; +63930-2;LL1123-0;PhenX07_14_laterality;LA14331-5;3;Both;;; +63930-2;LL1123-0;PhenX07_14_laterality;LA4720-4;4;Not applicable;;; +63933-6;LL1479-6;PhenX07_44_ CA treatment type;LA14620-1;1;Surgery;;; +63933-6;LL1479-6;PhenX07_44_ CA treatment type;LA6172-6;2;Chemotherapy;;; +63933-6;LL1479-6;PhenX07_44_ CA treatment type;LA4351-8;3;Radiation;;; +63933-6;LL1479-6;PhenX07_44_ CA treatment type;LA16052-5;4;Hormonal therapy/;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14332-3;1;Adriamycin®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14333-1;2;Taxol® (Paclitaxel);;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14334-9;3;Taxotere® (Docetaxel);;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14335-6;4;Cytoxan®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14336-4;5;Xeloda®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14337-2;6;Leucovorin®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14338-0;7;Fluorouracil®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14339-8;8;Methotrexate;387381009;Methotrexate (substance);http://snomed.info/sct +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14340-6;9;Herceptin®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14341-4;10;Avastin®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14342-2;11;Aromasin®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA14343-0;12;Femara®;;; +63938-5;LL1125-5;PhenX07_16_chemo drugs;LA46-8;13;Other;;; +63940-1;LL1126-3;PhenX07_17_hormone therapy drugs;LA14344-8;1;Tamoxifen;373345002;Tamoxifen (substance);http://snomed.info/sct +63940-1;LL1126-3;PhenX07_17_hormone therapy drugs;LA14342-2;2;Aromasin®;;; +63940-1;LL1126-3;PhenX07_17_hormone therapy drugs;LA14343-0;3;Femara®;;; +63940-1;LL1126-3;PhenX07_17_hormone therapy drugs;LA46-8;4;Other;;; +63946-8;LL1128-9;PhenX07_19_pain med type;LA14345-5;1;'Baby' or low-dose aspirin;;; +63946-8;LL1128-9;PhenX07_19_pain med type;LA14346-3;2;Aspirin or aspirin-containing product;;; +63946-8;LL1128-9;PhenX07_19_pain med type;LA14347-1;3;Ibuprofen;387207008;Ibuprofen (substance);http://snomed.info/sct +63946-8;LL1128-9;PhenX07_19_pain med type;LA14348-9;4;Naproxen, ketoprofen or other non-steroidal;;; +63946-8;LL1128-9;PhenX07_19_pain med type;LA14349-7;5;Cox-2 inhibitor;;; +63946-8;LL1128-9;PhenX07_19_pain med type;LA14350-5;6;Acetaminophen;387517004;Paracetamol (substance);http://snomed.info/sct +63947-6;LL1129-7;PhenX07_20_pain med use;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63947-6;LL1129-7;PhenX07_20_pain med use;LA14351-3;2;No (0 Or <1 Per Week);;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14352-1;1;1-2;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14353-9;2;3-4;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA13945-3;3;4-5 days;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14354-7;4;5-6;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14355-4;5;7-8;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14356-2;6;9-10;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14357-0;7;11-12;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14358-8;8;13-14;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14359-6;9;15-21;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14360-4;10;22-28;;; +63948-4;LL1130-5;PhenX07_21_pain med tabs/W;LA14361-2;11;29+;;; +63949-2;LL1131-3;PhenX07_22_stop pain meds;LA14362-0;1;Never took regularly or did not stop use;;; +63949-2;LL1131-3;PhenX07_22_stop pain meds;LA14363-8;2;Yes, I stopped regular use;;; +63950-0;LL1132-1;PhenX07_23_stop pain med reason;LA14364-6;1;Condition improved;;; +63950-0;LL1132-1;PhenX07_23_stop pain med reason;LA14365-3;2;Don't work;;; +63950-0;LL1132-1;PhenX07_23_stop pain med reason;LA14366-1;3;I had side effects;;; +63950-0;LL1132-1;PhenX07_23_stop pain med reason;LA14367-9;4;I heard about side effects;;; +63950-0;LL1132-1;PhenX07_23_stop pain med reason;LA14368-7;5;Drug no longer available;;; +63950-0;LL1132-1;PhenX07_23_stop pain med reason;LA46-8;6;Other;;; +63951-8;LL1133-9;PhenX07_24_use steroids/statins;LA14369-5;1;Yes, regularly (daily for at least 2 months);;; +63951-8;LL1133-9;PhenX07_24_use steroids/statins;LA14370-3;2;Yes, but not regularly;;; +63951-8;LL1133-9;PhenX07_24_use steroids/statins;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +63952-6;LL1133-9;PhenX07_24_use steroids/statins;LA14369-5;1;Yes, regularly (daily for at least 2 months);;; +63952-6;LL1133-9;PhenX07_24_use steroids/statins;LA14370-3;2;Yes, but not regularly;;; +63952-6;LL1133-9;PhenX07_24_use steroids/statins;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +63953-4;LL1480-4;PhenX07_45_age range alcohol exposure;LA16053-3;1;Under 20 years of age;;; +63953-4;LL1480-4;PhenX07_45_age range alcohol exposure;LA16054-1;2;20-29 yrs of age;;; +63953-4;LL1480-4;PhenX07_45_age range alcohol exposure;LA16055-8;3;30-39 yrs of age;;; +63953-4;LL1480-4;PhenX07_45_age range alcohol exposure;LA16056-6;4;40-49 yrs of age;;; +63953-4;LL1480-4;PhenX07_45_age range alcohol exposure;LA16057-4;5;50-59 yrs of age;;; +63953-4;LL1480-4;PhenX07_45_age range alcohol exposure;LA16058-2;6;60 or older;;; +63955-9;LL1468-9;PhenX07_33_passive smoke exposure;LA16017-8;1;During childhood at home;;; +63955-9;LL1468-9;PhenX07_33_passive smoke exposure;LA16018-6;2;During adulthood at home;;; +63955-9;LL1468-9;PhenX07_33_passive smoke exposure;LA16019-4;3;During adulthood at work;;; +63955-9;LL1468-9;PhenX07_33_passive smoke exposure;LA16020-2;4;During In social settings such as bars, restaurants, bowling alleys, bingo halls, and friends' home;;; +63959-1;LL1471-3;PhenX07_36_estrogen use method;LA16023-6;1;By mouth;;; +63959-1;LL1471-3;PhenX07_36_estrogen use method;LA16024-4;2;By injection;;; +63959-1;LL1471-3;PhenX07_36_estrogen use method;LA16025-1;3;By patch or implant;;; +63959-1;LL1471-3;PhenX07_36_estrogen use method;LA16026-9;4;By vaginal cream or suppository;;; +63962-5;LL1476-2;PhenX07_41_pregnancies;LA16037-6;1;Pregnancy 1;;; +63962-5;LL1476-2;PhenX07_41_pregnancies;LA16038-4;2;Pregnancy 2;;; +63962-5;LL1476-2;PhenX07_41_pregnancies;LA16039-2;3;Pregnancy 3;;; +63962-5;LL1476-2;PhenX07_41_pregnancies;LA16040-0;4;Pregnancy 4;;; +63962-5;LL1476-2;PhenX07_41_pregnancies;LA16041-8;5;Pregnancy 5;;; +63962-5;LL1476-2;PhenX07_41_pregnancies;LA16042-6;6;Pregnancy 6;;; +64709-9;LL1476-2;PhenX07_41_pregnancies;LA16037-6;1;Pregnancy 1;;; +64709-9;LL1476-2;PhenX07_41_pregnancies;LA16038-4;2;Pregnancy 2;;; +64709-9;LL1476-2;PhenX07_41_pregnancies;LA16039-2;3;Pregnancy 3;;; +64709-9;LL1476-2;PhenX07_41_pregnancies;LA16040-0;4;Pregnancy 4;;; +64709-9;LL1476-2;PhenX07_41_pregnancies;LA16041-8;5;Pregnancy 5;;; +64709-9;LL1476-2;PhenX07_41_pregnancies;LA16042-6;6;Pregnancy 6;;; +63969-0;LL1134-7;PhenX08_01_baby to bed with bottle;LA14371-1;1;At most bedtimes, including naps;;; +63969-0;LL1134-7;PhenX08_01_baby to bed with bottle;LA14372-9;2;At most bedtimes, but not naps;;; +63969-0;LL1134-7;PhenX08_01_baby to bed with bottle;LA14373-7;3;At most naps, but not night bedtimes;;; +63969-0;LL1134-7;PhenX08_01_baby to bed with bottle;LA14374-5;4;Only occasionally at bedtimes, including naps;;; +63969-0;LL1134-7;PhenX08_01_baby to bed with bottle;LA6270-8;5;Never;;; +63971-6;LL1135-4;PhenX08_02_add items to baby bottle;LA6270-8;1;Never;;; +63971-6;LL1135-4;PhenX08_02_add items to baby bottle;LA14375-2;2;Only rarely;;; +63971-6;LL1135-4;PhenX08_02_add items to baby bottle;LA14376-0;3;Every few days;;; +63971-6;LL1135-4;PhenX08_02_add items to baby bottle;LA14377-8;4;About once a day;;; +63971-6;LL1135-4;PhenX08_02_add items to baby bottle;LA14378-6;5;At most feedings;;; +63971-6;LL1135-4;PhenX08_02_add items to baby bottle;LA14379-4;6;Every feeding;;; +77316-8;LL1135-4;PhenX08_02_add items to baby bottle;LA6270-8;1;Never;;; +77316-8;LL1135-4;PhenX08_02_add items to baby bottle;LA14375-2;2;Only rarely;;; +77316-8;LL1135-4;PhenX08_02_add items to baby bottle;LA14376-0;3;Every few days;;; +77316-8;LL1135-4;PhenX08_02_add items to baby bottle;LA14377-8;4;About once a day;;; +77316-8;LL1135-4;PhenX08_02_add items to baby bottle;LA14378-6;5;At most feedings;;; +77316-8;LL1135-4;PhenX08_02_add items to baby bottle;LA14379-4;6;Every feeding;;; +63972-4;LL1490-3;PhenX08_30_items added to babys milk;LA16117-6;1;Vitamins or minerals;;; +63972-4;LL1490-3;PhenX08_30_items added to babys milk;LA16118-4;2;Baby cereal;;; +63972-4;LL1490-3;PhenX08_30_items added to babys milk;LA16119-2;3;Sweetener;;; +63972-4;LL1490-3;PhenX08_30_items added to babys milk;LA16120-0;4;Medicine;;; +63972-4;LL1490-3;PhenX08_30_items added to babys milk;LA16121-8;5;Other things;;; +63973-2;LL1490-3;PhenX08_30_items added to babys milk;LA16117-6;1;Vitamins or minerals;;; +63973-2;LL1490-3;PhenX08_30_items added to babys milk;LA16118-4;2;Baby cereal;;; +63973-2;LL1490-3;PhenX08_30_items added to babys milk;LA16119-2;3;Sweetener;;; +63973-2;LL1490-3;PhenX08_30_items added to babys milk;LA16120-0;4;Medicine;;; +63973-2;LL1490-3;PhenX08_30_items added to babys milk;LA16121-8;5;Other things;;; +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14386-9;1;Cows' milk;;; +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14387-7;2;Water;11713004;Water (substance);http://snomed.info/sct +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14388-5;3;Flavored water;;; +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14389-3;4;Sugared beverages made from powder;;; +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14390-1;5;Sugar-free beverages made from powder;;; +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14391-9;6;Regular pop;;; +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14392-7;7;Diet pop;;; +63974-0;LL1137-0;PhenX08_04_beverage consumed type;LA14393-5;8;Sports drinks;;; +63977-3;LL1139-6;PhenX08_06_child beverage container;LA14398-4;1;Infant bottle;;; +63977-3;LL1139-6;PhenX08_06_child beverage container;LA14399-2;2;Open cup;;; +63977-3;LL1139-6;PhenX08_06_child beverage container;LA14400-8;3;Closed cup (sippy cup);;; +63977-3;LL1139-6;PhenX08_06_child beverage container;LA14401-6;4;Cup with nonspilling, straw mechanism;;; +63977-3;LL1139-6;PhenX08_06_child beverage container;LA14402-4;5;Water bottle;;; +63977-3;LL1139-6;PhenX08_06_child beverage container;LA14403-2;6;Product container (e.g. juice box, pop can or bottle);;; +63978-1;LL1140-4;PhenX08_07_child beverage at meals;LA14386-9;1;Cows' milk;;; +63978-1;LL1140-4;PhenX08_07_child beverage at meals;LA15673-9;2;Juice or juice drinks;;; +63978-1;LL1140-4;PhenX08_07_child beverage at meals;LA14387-7;3;Water;11713004;Water (substance);http://snomed.info/sct +63978-1;LL1140-4;PhenX08_07_child beverage at meals;LA15674-7;4;Regular soda pop or other sugared beverages;;; +63978-1;LL1140-4;PhenX08_07_child beverage at meals;LA15675-4;5;Diet soda pop or other sugar-free beverages;;; +63979-9;LL1141-2;PhenX08_08_child beverage between meals;LA14386-9;1;Cows' milk;;; +63979-9;LL1141-2;PhenX08_08_child beverage between meals;LA15673-9;2;Juice or juice drinks;;; +63979-9;LL1141-2;PhenX08_08_child beverage between meals;LA14387-7;3;Water;11713004;Water (substance);http://snomed.info/sct +63979-9;LL1141-2;PhenX08_08_child beverage between meals;LA15674-7;4;Regular soda pop or other sugared beverages;;; +63979-9;LL1141-2;PhenX08_08_child beverage between meals;LA15675-4;5;Diet soda pop or other sugar-free beverages;;; +63979-9;LL1141-2;PhenX08_08_child beverage between meals;LA46-8;6;Other;;; +63980-7;LL1142-0;PhenX08_09_child night feedings;LA14404-0;1;My child falls asleep with a bottle;;; +63980-7;LL1142-0;PhenX08_09_child night feedings;LA14405-7;2;My child has a bottle in the middle of the night;;; +63980-7;LL1142-0;PhenX08_09_child night feedings;LA14406-5;3;My child has a snack at bedtime;;; +63980-7;LL1142-0;PhenX08_09_child night feedings;LA14407-3;4;My child has a snack in the middle of the night;;; +63980-7;LL1142-0;PhenX08_09_child night feedings;LA9-3;5;None of the above;;; +63983-1;LL1143-8;PhenX08_10_mouth saliva amt;LA14408-1;1;Too little;;; +63983-1;LL1143-8;PhenX08_10_mouth saliva amt;LA14409-9;2;Too much;;; +63983-1;LL1143-8;PhenX08_10_mouth saliva amt;LA14410-7;3;Don't notice it;;; +63984-9;LL1144-6;PhenX08_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63984-9;LL1144-6;PhenX08_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63984-9;LL1144-6;PhenX08_11;LA12693-0;3;Not sure;;; +63985-6;LL1144-6;PhenX08_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63985-6;LL1144-6;PhenX08_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +63985-6;LL1144-6;PhenX08_11;LA12693-0;3;Not sure;;; +63986-4;LL1145-3;PhenX08_12_cleft lip dx;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63986-4;LL1145-3;PhenX08_12_cleft lip dx;LA14411-5;2;Cleft lip;;; +63986-4;LL1145-3;PhenX08_12_cleft lip dx;LA14412-3;3;Cleft palate;;; +63986-4;LL1145-3;PhenX08_12_cleft lip dx;LA14413-1;4;Cleft lip and palate;;; +63986-4;LL1145-3;PhenX08_12_cleft lip dx;LA14414-9;5;Submucous cleft palate;;; +63986-4;LL1145-3;PhenX08_12_cleft lip dx;LA14415-6;6;Don't know/Non-applicable/Refused;;; +63987-2;LL1489-5;PhenX08_29_cleft lip defect location;LA16110-1;1;Right lip;;; +63987-2;LL1489-5;PhenX08_29_cleft lip defect location;LA16111-9;2;Right alveolus;;; +63987-2;LL1489-5;PhenX08_29_cleft lip defect location;LA16112-7;3;Right hard palate;;; +63987-2;LL1489-5;PhenX08_29_cleft lip defect location;LA16113-5;4;Soft palate;;; +63987-2;LL1489-5;PhenX08_29_cleft lip defect location;LA16114-3;5;Left hard palate;;; +63987-2;LL1489-5;PhenX08_29_cleft lip defect location;LA16115-0;6;Left alveolus;;; +63987-2;LL1489-5;PhenX08_29_cleft lip defect location;LA16116-8;7;Left lip;;; +63988-0;LL1146-1;PhenX08_13_cleft lip code;LA14416-4;1;A = Yes, but unknown if complete or incomplete;;; +63988-0;LL1146-1;PhenX08_13_cleft lip code;LA14417-2;2;C = Complete;;; +63988-0;LL1146-1;PhenX08_13_cleft lip code;LA15676-2;3;I = Incomplete;;; +63988-0;LL1146-1;PhenX08_13_cleft lip code;LA14418-0;4;X = Not cleft;;; +63988-0;LL1146-1;PhenX08_13_cleft lip code;LA15677-0;5;? = Unknown;;; +63988-0;LL1146-1;PhenX08_13_cleft lip code;LA14419-8;6;* = Microform or submucous cleft;;; +63994-8;LL1147-9;PhenX08_14_teeth braces duration;LA4720-4;1;Not applicable;;; +63994-8;LL1147-9;PhenX08_14_teeth braces duration;LA13831-5;2;1 year or less;;; +63994-8;LL1147-9;PhenX08_14_teeth braces duration;LA14421-4;3;1-2 years;;; +63994-8;LL1147-9;PhenX08_14_teeth braces duration;LA14420-6;4;> 2 years;;; +63995-5;LL1148-7;PhenX08_15_natural teeth amt;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +63995-5;LL1148-7;PhenX08_15_natural teeth amt;LA14422-2;2;1-10;;; +63995-5;LL1148-7;PhenX08_15_natural teeth amt;LA14423-0;3;11-16;;; +63995-5;LL1148-7;PhenX08_15_natural teeth amt;LA14424-8;4;17-24;;; +63995-5;LL1148-7;PhenX08_15_natural teeth amt;LA14425-5;5;25-32;;; +63996-3;LL1148-7;PhenX08_15_natural teeth amt;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +63996-3;LL1148-7;PhenX08_15_natural teeth amt;LA14422-2;2;1-10;;; +63996-3;LL1148-7;PhenX08_15_natural teeth amt;LA14423-0;3;11-16;;; +63996-3;LL1148-7;PhenX08_15_natural teeth amt;LA14424-8;4;17-24;;; +63996-3;LL1148-7;PhenX08_15_natural teeth amt;LA14425-5;5;25-32;;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14426-3;1;Do not;;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14427-1;2;1/day;;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14428-9;3;2/day;;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14429-7;4;> 2/day;;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14430-5;5;Sporadically;;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14431-3;6;Not applicable (full dentures, upper and lower - FDUL);;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14432-1;7;1 or 2 /day;;; +63998-9;LL1149-5;PhenX08_16_brush teeth freq;LA14433-9;8;Unknown (missing);;; +63999-7;LL1150-3;PhenX08_17-dental floss freq;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +63999-7;LL1150-3;PhenX08_17-dental floss freq;LA10066-1;2;Rarely;;; +63999-7;LL1150-3;PhenX08_17-dental floss freq;LA15678-8;3;1-3x/week;;; +63999-7;LL1150-3;PhenX08_17-dental floss freq;LA14435-4;4;Daily;;; +63999-7;LL1150-3;PhenX08_17-dental floss freq;LA14431-3;5;Not applicable (full dentures, upper and lower - FDUL);;; +63999-7;LL1150-3;PhenX08_17-dental floss freq;LA14433-9;6;Unknown (missing);;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA14436-2;1;6 months or less;;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA14437-0;2;More than 6 months, but not more than 1 year ago;;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA14439-6;3;More than 2 years, but not more than 3 years ago;;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA14438-8;4;More than 1 year, but not more than 2 years ago;;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA14440-4;5;More than 3 years, but not more than 5 years ago;;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA14769-6;6;More than 5 years;;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA14442-0;7;Never have been;;; +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA4389-8;8;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64002-9;LL1152-9;PhenX08_19_ last dentist visit;LA12688-0;9;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64003-7;LL1153-7;PhenX08_20_dentist visit reason;LA14443-8;1;Went in on own for check-up, examination or cleaning;;; +64003-7;LL1153-7;PhenX08_20_dentist visit reason;LA14444-6;2;Was called in by the dentist for check-up, examination or cleaning;;; +64003-7;LL1153-7;PhenX08_20_dentist visit reason;LA14445-3;3;Something was wrong, bothering or hurting {me/sample person};;; +64003-7;LL1153-7;PhenX08_20_dentist visit reason;LA14446-1;4;Went for treatment of a condition that dentist discovered at earlier check-up or examination;;; +64003-7;LL1153-7;PhenX08_20_dentist visit reason;LA46-8;5;Other;;; +64003-7;LL1153-7;PhenX08_20_dentist visit reason;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64003-7;LL1153-7;PhenX08_20_dentist visit reason;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64004-5;LL1486-1;PhenX08_27_tobacco usage type;LA16102-8;1;At least 50 cigars;;; +64004-5;LL1486-1;PhenX08_27_tobacco usage type;LA16103-6;2;A pipe at least 50 times;;; +64004-5;LL1486-1;PhenX08_27_tobacco usage type;LA16104-4;3;Snuff, such as Skoal®, Skoal Bandit® or Copenhagen® at least 20 times;;; +64004-5;LL1486-1;PhenX08_27_tobacco usage type;LA16105-1;4;Chewing tobacco, such as Redman®, Levi Garrett® or Beechnut® at least 20 times;;; +64006-0;LL1487-9;PhenX08_28_toothache occasion;LA16106-9;1;Toothache when biting or chewing;;; +64006-0;LL1487-9;PhenX08_28_toothache occasion;LA16107-7;2;Pain in the jaw joint or in front of the ear;;; +64006-0;LL1487-9;PhenX08_28_toothache occasion;LA16108-5;3;Dull, aching pain across your face or cheek;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA16369-3;1;1 - mild;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA6113-0;2;2;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA6114-8;3;3;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA6115-5;4;4;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA10137-0;5;5;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA10138-8;6;6;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA10139-6;7;7;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA10140-4;8;8;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA10141-2;9;9;;; +64008-6;LL1561-1;Phenx11_78_numeric pain scale;LA16370-1;10;10 - severe;;; +64009-4;LL1154-5;PhenX08_21_pain duration;LA14447-9;1;Come and go;;; +64009-4;LL1154-5;PhenX08_21_pain duration;LA14448-7;2;Continuous/uninterrupted;;; +64009-4;LL1154-5;PhenX08_21_pain duration;LA46-8;3;Other;;; +64009-4;LL1154-5;PhenX08_21_pain duration;LA14449-5;4;DK (don't know);;; +64014-4;LL1136-2;PhenX08_03_breast feeding duration;LA14380-2;1;Less than 10 minutes;;; +64014-4;LL1136-2;PhenX08_03_breast feeding duration;LA14381-0;2;10 to 19 minutes;;; +64014-4;LL1136-2;PhenX08_03_breast feeding duration;LA14382-8;3;20 to 29 minutes;;; +64014-4;LL1136-2;PhenX08_03_breast feeding duration;LA14383-6;4;30 to 39 minutes;;; +64014-4;LL1136-2;PhenX08_03_breast feeding duration;LA14384-4;5;40 to 49 minutes;;; +64014-4;LL1136-2;PhenX08_03_breast feeding duration;LA14385-1;6;50 or more minutes;;; +64018-5;LL1491-1;PhenX08_31_cleft palate, presence, relative;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64018-5;LL1491-1;PhenX08_31_cleft palate, presence, relative;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64018-5;LL1491-1;PhenX08_31_cleft palate, presence, relative;LA14415-6;3;Don't know/Non-applicable/Refused;;; +64020-1;LL1138-8;PhenX08_05_cow milk type;LA13917-2;1;Whole milk;;; +64020-1;LL1138-8;PhenX08_05_cow milk type;LA14394-3;2;2% milk;;; +64020-1;LL1138-8;PhenX08_05_cow milk type;LA14395-0;3;1% milk;;; +64020-1;LL1138-8;PhenX08_05_cow milk type;LA13871-1;4;Chocolate milk;;; +64020-1;LL1138-8;PhenX08_05_cow milk type;LA14396-8;5;Other flavored milk (e.g., strawberry, vanilla);;; +64020-1;LL1138-8;PhenX08_05_cow milk type;LA14397-6;6;Doesn't drink milk;;; +64026-8;LL1506-6;PhenX09_34_pre-bronch FEV attempts;LA16192-9;1;Pre FEV1 1st;;; +64026-8;LL1506-6;PhenX09_34_pre-bronch FEV attempts;LA16193-7;2;Pre FEV1 2nd;;; +64026-8;LL1506-6;PhenX09_34_pre-bronch FEV attempts;LA16194-5;3;Pre FEV1 3rd;;; +64027-6;LL1507-4;PhenX09_35_pre-bronch FVC attempts;LA16195-2;1;Pre FVC 1st;;; +64027-6;LL1507-4;PhenX09_35_pre-bronch FVC attempts;LA16196-0;2;Pre FVC 2nd;;; +64027-6;LL1507-4;PhenX09_35_pre-bronch FVC attempts;LA16197-8;3;Pre FVC 3rd;;; +64028-4;LL1508-2;PhenX09_36_post-bronch FEV attempts;LA16198-6;1;Post FEV1 1st;;; +64028-4;LL1508-2;PhenX09_36_post-bronch FEV attempts;LA16199-4;2;Post FEV1 2nd;;; +64028-4;LL1508-2;PhenX09_36_post-bronch FEV attempts;LA16200-0;3;Post FEV1 3rd;;; +64029-2;LL1509-0;PhenX09_37_post-bronch FVC attempts;LA16201-8;1;Post FVC 1st;;; +64029-2;LL1509-0;PhenX09_37_post-bronch FVC attempts;LA16202-6;2;Post FVC 2nd;;; +64029-2;LL1509-0;PhenX09_37_post-bronch FVC attempts;LA16203-4;3;Post FVC 3rd;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16159-8;1;Lingual caries;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16160-6;2;Occlusal caries;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16161-4;3;Facial caries;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16162-2;4;Mesial caries;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16163-0;5;Distal caries;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16164-8;6;Lingual restoration;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16165-5;7;Occlusal restoration;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16166-3;8;Facial restoration;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16167-1;9;Mesial restoration;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16168-9;10;Distal Restoration;;; +64039-1;LL1504-1;PhenX08_32_decayed filled tooth;LA16169-7;11;Crown (short call for both primary and permanent teeth);;; +64040-9;LL1482-0;PhenX08_23_tooth location;LA16093-9;1;Distal facial, DF;;; +64040-9;LL1482-0;PhenX08_23_tooth location;LA16094-7;2;Mid-facial, MF;;; +64040-9;LL1482-0;PhenX08_23_tooth location;LA16095-4;3;Mesial-facial, MeF;;; +64040-9;LL1482-0;PhenX08_23_tooth location;LA16096-2;4;Mesial-lingual, MeL;;; +64040-9;LL1482-0;PhenX08_23_tooth location;LA16097-0;5;Mid-lingual, ML;;; +64040-9;LL1482-0;PhenX08_23_tooth location;LA16098-8;6;Distal-lingual, DL;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16062-4;1;Upper right 2M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16063-2;2;Upper right 1M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16064-0;3;Upper right 2B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16065-7;4;Upper right 1B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16066-5;5;Upper right C;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16067-3;6;Upper right LI;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16068-1;7;Upper right CI;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16069-9;8;Lower right 2M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16070-7;9;Lower right 1M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16071-5;10;Lower right 2B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16072-3;11;Lower right 1B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16073-1;12;Lower right C;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16074-9;13;Lower right LI;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16075-6;14;Lower right CI;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16076-4;15;Upper left 2M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16077-2;16;Upper left 1M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16078-0;17;Upper left 2B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16079-8;18;Upper left 1B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16080-6;19;Upper left C;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16081-4;20;Upper left LI;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16082-2;21;Upper left CI;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16083-0;22;Lower left 2M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16084-8;23;Lower left 1M;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16085-5;24;Lower left 2B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16086-3;25;Lower left 1B;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16087-1;26;Lower left C;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16088-9;27;Lower left LI;;; +64041-7;LL1481-2;PhenX08_22_tooth code caries;LA16090-5;28;Lower left CI;;; +64044-1;LL1956-3;PhenX08_36_bleeding on probling;LA9264-8;1;Bleeding on probing;;; +64044-1;LL1956-3;PhenX08_36_bleeding on probling;LA18128-1;2;No evidence of bleeding;;; +64045-8;LL1484-6;PhenX08_25_tooth position;LA16060-8;1;Posterior;;; +64045-8;LL1484-6;PhenX08_25_tooth position;LA16059-0;2;Anterior;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16061-6;1;Upper right 3M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16062-4;2;Upper right 2M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16063-2;3;Upper right 1M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16065-7;5;Upper right 1B;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16066-5;6;Upper right C;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16067-3;7;Upper right LI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16068-1;8;Upper right CI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16099-6;9;Lower right 3M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16069-9;10;Lower right 2M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16070-7;11;Lower right 1M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16071-5;12;Lower right 2B;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16072-3;13;Lower right 1B;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16073-1;14;Lower right C;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16074-9;15;Lower right LI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16075-6;16;Lower right CI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16089-7;17;Upper left 3M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16076-4;18;Upper left 2M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16077-2;19;Upper left 1M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16078-0;20;Upper left 2B;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16079-8;21;Upper left 1B;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16080-6;22;Upper left C;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16081-4;23;Upper left LI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16082-2;24;Upper left CI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16100-2;25;Lower left 3M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16083-0;26;Lower left 2M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16084-8;27;Lower left 1M;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16085-5;28;Lower left 2B;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16086-3;29;Lower left 1B;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16087-1;30;Lower left C;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16088-9;31;Lower left LI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16090-5;32;Lower left CI;;; +64046-6;LL1483-8;PhenX08_24_tooth code flourosis;LA16064-0;40;Upper right 2B;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16170-5;1;Enamel shows no evidence of fluorosis;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16171-3;2;Enamel shows definite evidence of fluorosis;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16172-1;3;Parchment-white fluorosis totals at least one-third of the visible surface, but less than two-thirds;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16173-9;4;Parchment-white fluorosis totals at least two-thirds of the visible surface;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16174-7;5;Enamel shows staining in conjunction with any of the preceding levels of fluorosis;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16175-4;6;Discrete pitting of the enamel exists, unaccompanied by evidence of staining of intact enamel;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16176-2;7;Both discrete pitting and staining of the intact enamel exist;;; +64047-4;LL1151-1;PhenX08_18_tooth surface index flourosis;LA16177-0;8;Confluent pitting of the enamel surface exists;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16178-8;1;Sound permanent tooth (no decay or filling on any surface);;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16179-6;2;Permanent tooth with surface condition;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16180-4;3;Sound primary (deciduous) tooth;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16181-2;4;Primary tooth with surface condition;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16182-0;5;Unerupted tooth;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16183-8;6;Missing due to dental disease (caries/periodontal disease);;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16184-6;7;Missing due to other causes (orthodontic/traumatic or other non-disease);;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16185-3;8;Missing due to dental disease but replaced by a fixed restoration;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16186-1;9;Missing due to other causes but replaced by a fixed restoration;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16187-9;10;Missing due to dental disease but replaced by a removable restoration;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16188-7;11;Missing due to other causes but replaced by a removable restoration;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16189-5;12;Permanent root tip is present but no restorative replacement is present;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16191-1;13;Permanent root tip is present but a restorative replacement is present;;; +64048-2;LL1510-8;PhenX08_34_filled tooth surfaces index;LA16190-3;14;Tooth present, condition cannot be assessed;;; +64049-0;LL1485-3;PhenX08_26_tooth aspect;LA9416-4;1;Buccal;;; +64049-0;LL1485-3;PhenX08_26_tooth aspect;LA9272-1;2;Lingual;;; +64049-0;LL1485-3;PhenX08_26_tooth aspect;LA16091-3;3;Occlusal;;; +64049-0;LL1485-3;PhenX08_26_tooth aspect;LA16092-1;4;Labial;;; +64097-9;LL1499-4;PhenX09_32;LA16140-8;1;0 = Nothing at all;;; +64097-9;LL1499-4;PhenX09_32;LA16141-6;2;0.5 = Very, very slight (just noticeable);;; +64097-9;LL1499-4;PhenX09_32;LA16142-4;3;1 = Very slight;;; +64097-9;LL1499-4;PhenX09_32;LA16143-2;4;2 = Slight (light);;; +64097-9;LL1499-4;PhenX09_32;LA16144-0;5;3 = Moderate;;; +64097-9;LL1499-4;PhenX09_32;LA16145-7;6;4 = Somewhat severe;;; +64097-9;LL1499-4;PhenX09_32;LA16146-5;7;5 = Severe (heavy);;; +64097-9;LL1499-4;PhenX09_32;LA10138-8;8;6;;; +64097-9;LL1499-4;PhenX09_32;LA16147-3;9;7 = Very severe;;; +64097-9;LL1499-4;PhenX09_32;LA10140-4;10;8;;; +64097-9;LL1499-4;PhenX09_32;LA10141-2;11;9;;; +64097-9;LL1499-4;PhenX09_32;LA16148-1;12;10 = Very, very severe (maximal);;; +64101-9;LL1499-4;PhenX09_32;LA16140-8;1;0 = Nothing at all;;; +64101-9;LL1499-4;PhenX09_32;LA16141-6;2;0.5 = Very, very slight (just noticeable);;; +64101-9;LL1499-4;PhenX09_32;LA16142-4;3;1 = Very slight;;; +64101-9;LL1499-4;PhenX09_32;LA16143-2;4;2 = Slight (light);;; +64101-9;LL1499-4;PhenX09_32;LA16144-0;5;3 = Moderate;;; +64101-9;LL1499-4;PhenX09_32;LA16145-7;6;4 = Somewhat severe;;; +64101-9;LL1499-4;PhenX09_32;LA16146-5;7;5 = Severe (heavy);;; +64101-9;LL1499-4;PhenX09_32;LA10138-8;8;6;;; +64101-9;LL1499-4;PhenX09_32;LA16147-3;9;7 = Very severe;;; +64101-9;LL1499-4;PhenX09_32;LA10140-4;10;8;;; +64101-9;LL1499-4;PhenX09_32;LA10141-2;11;9;;; +64101-9;LL1499-4;PhenX09_32;LA16148-1;12;10 = Very, very severe (maximal);;; +64112-6;LL1499-4;PhenX09_32;LA16140-8;1;0 = Nothing at all;;; +64112-6;LL1499-4;PhenX09_32;LA16141-6;2;0.5 = Very, very slight (just noticeable);;; +64112-6;LL1499-4;PhenX09_32;LA16142-4;3;1 = Very slight;;; +64112-6;LL1499-4;PhenX09_32;LA16143-2;4;2 = Slight (light);;; +64112-6;LL1499-4;PhenX09_32;LA16144-0;5;3 = Moderate;;; +64112-6;LL1499-4;PhenX09_32;LA16145-7;6;4 = Somewhat severe;;; +64112-6;LL1499-4;PhenX09_32;LA16146-5;7;5 = Severe (heavy);;; +64112-6;LL1499-4;PhenX09_32;LA10138-8;8;6;;; +64112-6;LL1499-4;PhenX09_32;LA16147-3;9;7 = Very severe;;; +64112-6;LL1499-4;PhenX09_32;LA10140-4;10;8;;; +64112-6;LL1499-4;PhenX09_32;LA10141-2;11;9;;; +64112-6;LL1499-4;PhenX09_32;LA16148-1;12;10 = Very, very severe (maximal);;; +64113-4;LL1499-4;PhenX09_32;LA16140-8;1;0 = Nothing at all;;; +64113-4;LL1499-4;PhenX09_32;LA16141-6;2;0.5 = Very, very slight (just noticeable);;; +64113-4;LL1499-4;PhenX09_32;LA16142-4;3;1 = Very slight;;; +64113-4;LL1499-4;PhenX09_32;LA16143-2;4;2 = Slight (light);;; +64113-4;LL1499-4;PhenX09_32;LA16144-0;5;3 = Moderate;;; +64113-4;LL1499-4;PhenX09_32;LA16145-7;6;4 = Somewhat severe;;; +64113-4;LL1499-4;PhenX09_32;LA16146-5;7;5 = Severe (heavy);;; +64113-4;LL1499-4;PhenX09_32;LA10138-8;8;6;;; +64113-4;LL1499-4;PhenX09_32;LA16147-3;9;7 = Very severe;;; +64113-4;LL1499-4;PhenX09_32;LA10140-4;10;8;;; +64113-4;LL1499-4;PhenX09_32;LA10141-2;11;9;;; +64113-4;LL1499-4;PhenX09_32;LA16148-1;12;10 = Very, very severe (maximal);;; +64099-5;LL1607-2;PhenX09_43_PEFR attempts;LA16616-7;1;PEFR 1;;; +64099-5;LL1607-2;PhenX09_43_PEFR attempts;LA16617-5;2;PEFR 2;;; +64099-5;LL1607-2;PhenX09_43_PEFR attempts;LA16618-3;3;PEFR 3;;; +64117-5;LL1511-6;Hb types;LA16208-3;1;Hb F;;; +64117-5;LL1511-6;Hb types;LA16209-1;2;Hb A;;; +64117-5;LL1511-6;Hb types;LA16210-9;3;Hb A - indeterminate;;; +64117-5;LL1511-6;Hb types;LA16211-7;4;Hb A2;;; +64117-5;LL1511-6;Hb types;LA16212-5;5;Hb A2 - elevated;;; +64117-5;LL1511-6;Hb types;LA16213-3;6;Hb Bart's - low level;;; +64117-5;LL1511-6;Hb types;LA16214-1;7;Hb Bart's - highly elevated;;; +64117-5;LL1511-6;Hb types;LA13002-3;8;Hb C;;; +64117-5;LL1511-6;Hb types;LA16215-8;9;Hb Constant Spring;;; +64117-5;LL1511-6;Hb types;LA13003-1;10;Hb D;;; +64117-5;LL1511-6;Hb types;LA16216-6;11;Hb D-Punjab;;; +64117-5;LL1511-6;Hb types;LA16217-4;12;Hb D/G;;; +64117-5;LL1511-6;Hb types;LA13005-6;13;Hb E;;; +64117-5;LL1511-6;Hb types;LA16218-2;14;Hb G;;; +64117-5;LL1511-6;Hb types;LA16219-0;15;Hb G-Philadelphia;;; +64117-5;LL1511-6;Hb types;LA16220-8;16;Hb H;;; +64117-5;LL1511-6;Hb types;LA16221-6;17;Hb Lepore Boston;;; +64117-5;LL1511-6;Hb types;LA16222-4;18;Hb O-Arab;;; +64117-5;LL1511-6;Hb types;LA13007-2;19;Hb S;;; +64117-5;LL1511-6;Hb types;LA16223-2;20;Hb unidentified;;; +64118-3;LL1511-6;Hb types;LA16208-3;1;Hb F;;; +64118-3;LL1511-6;Hb types;LA16209-1;2;Hb A;;; +64118-3;LL1511-6;Hb types;LA16210-9;3;Hb A - indeterminate;;; +64118-3;LL1511-6;Hb types;LA16211-7;4;Hb A2;;; +64118-3;LL1511-6;Hb types;LA16212-5;5;Hb A2 - elevated;;; +64118-3;LL1511-6;Hb types;LA16213-3;6;Hb Bart's - low level;;; +64118-3;LL1511-6;Hb types;LA16214-1;7;Hb Bart's - highly elevated;;; +64118-3;LL1511-6;Hb types;LA13002-3;8;Hb C;;; +64118-3;LL1511-6;Hb types;LA16215-8;9;Hb Constant Spring;;; +64118-3;LL1511-6;Hb types;LA13003-1;10;Hb D;;; +64118-3;LL1511-6;Hb types;LA16216-6;11;Hb D-Punjab;;; +64118-3;LL1511-6;Hb types;LA16217-4;12;Hb D/G;;; +64118-3;LL1511-6;Hb types;LA13005-6;13;Hb E;;; +64118-3;LL1511-6;Hb types;LA16218-2;14;Hb G;;; +64118-3;LL1511-6;Hb types;LA16219-0;15;Hb G-Philadelphia;;; +64118-3;LL1511-6;Hb types;LA16220-8;16;Hb H;;; +64118-3;LL1511-6;Hb types;LA16221-6;17;Hb Lepore Boston;;; +64118-3;LL1511-6;Hb types;LA16222-4;18;Hb O-Arab;;; +64118-3;LL1511-6;Hb types;LA13007-2;19;Hb S;;; +64118-3;LL1511-6;Hb types;LA16223-2;20;Hb unidentified;;; +64119-1;LL1511-6;Hb types;LA16208-3;1;Hb F;;; +64119-1;LL1511-6;Hb types;LA16209-1;2;Hb A;;; +64119-1;LL1511-6;Hb types;LA16210-9;3;Hb A - indeterminate;;; +64119-1;LL1511-6;Hb types;LA16211-7;4;Hb A2;;; +64119-1;LL1511-6;Hb types;LA16212-5;5;Hb A2 - elevated;;; +64119-1;LL1511-6;Hb types;LA16213-3;6;Hb Bart's - low level;;; +64119-1;LL1511-6;Hb types;LA16214-1;7;Hb Bart's - highly elevated;;; +64119-1;LL1511-6;Hb types;LA13002-3;8;Hb C;;; +64119-1;LL1511-6;Hb types;LA16215-8;9;Hb Constant Spring;;; +64119-1;LL1511-6;Hb types;LA13003-1;10;Hb D;;; +64119-1;LL1511-6;Hb types;LA16216-6;11;Hb D-Punjab;;; +64119-1;LL1511-6;Hb types;LA16217-4;12;Hb D/G;;; +64119-1;LL1511-6;Hb types;LA13005-6;13;Hb E;;; +64119-1;LL1511-6;Hb types;LA16218-2;14;Hb G;;; +64119-1;LL1511-6;Hb types;LA16219-0;15;Hb G-Philadelphia;;; +64119-1;LL1511-6;Hb types;LA16220-8;16;Hb H;;; +64119-1;LL1511-6;Hb types;LA16221-6;17;Hb Lepore Boston;;; +64119-1;LL1511-6;Hb types;LA16222-4;18;Hb O-Arab;;; +64119-1;LL1511-6;Hb types;LA13007-2;19;Hb S;;; +64119-1;LL1511-6;Hb types;LA16223-2;20;Hb unidentified;;; +64120-9;LL1511-6;Hb types;LA16208-3;1;Hb F;;; +64120-9;LL1511-6;Hb types;LA16209-1;2;Hb A;;; +64120-9;LL1511-6;Hb types;LA16210-9;3;Hb A - indeterminate;;; +64120-9;LL1511-6;Hb types;LA16211-7;4;Hb A2;;; +64120-9;LL1511-6;Hb types;LA16212-5;5;Hb A2 - elevated;;; +64120-9;LL1511-6;Hb types;LA16213-3;6;Hb Bart's - low level;;; +64120-9;LL1511-6;Hb types;LA16214-1;7;Hb Bart's - highly elevated;;; +64120-9;LL1511-6;Hb types;LA13002-3;8;Hb C;;; +64120-9;LL1511-6;Hb types;LA16215-8;9;Hb Constant Spring;;; +64120-9;LL1511-6;Hb types;LA13003-1;10;Hb D;;; +64120-9;LL1511-6;Hb types;LA16216-6;11;Hb D-Punjab;;; +64120-9;LL1511-6;Hb types;LA16217-4;12;Hb D/G;;; +64120-9;LL1511-6;Hb types;LA13005-6;13;Hb E;;; +64120-9;LL1511-6;Hb types;LA16218-2;14;Hb G;;; +64120-9;LL1511-6;Hb types;LA16219-0;15;Hb G-Philadelphia;;; +64120-9;LL1511-6;Hb types;LA16220-8;16;Hb H;;; +64120-9;LL1511-6;Hb types;LA16221-6;17;Hb Lepore Boston;;; +64120-9;LL1511-6;Hb types;LA16222-4;18;Hb O-Arab;;; +64120-9;LL1511-6;Hb types;LA13007-2;19;Hb S;;; +64120-9;LL1511-6;Hb types;LA16223-2;20;Hb unidentified;;; +64121-7;LL1511-6;Hb types;LA16208-3;1;Hb F;;; +64121-7;LL1511-6;Hb types;LA16209-1;2;Hb A;;; +64121-7;LL1511-6;Hb types;LA16210-9;3;Hb A - indeterminate;;; +64121-7;LL1511-6;Hb types;LA16211-7;4;Hb A2;;; +64121-7;LL1511-6;Hb types;LA16212-5;5;Hb A2 - elevated;;; +64121-7;LL1511-6;Hb types;LA16213-3;6;Hb Bart's - low level;;; +64121-7;LL1511-6;Hb types;LA16214-1;7;Hb Bart's - highly elevated;;; +64121-7;LL1511-6;Hb types;LA13002-3;8;Hb C;;; +64121-7;LL1511-6;Hb types;LA16215-8;9;Hb Constant Spring;;; +64121-7;LL1511-6;Hb types;LA13003-1;10;Hb D;;; +64121-7;LL1511-6;Hb types;LA16216-6;11;Hb D-Punjab;;; +64121-7;LL1511-6;Hb types;LA16217-4;12;Hb D/G;;; +64121-7;LL1511-6;Hb types;LA13005-6;13;Hb E;;; +64121-7;LL1511-6;Hb types;LA16218-2;14;Hb G;;; +64121-7;LL1511-6;Hb types;LA16219-0;15;Hb G-Philadelphia;;; +64121-7;LL1511-6;Hb types;LA16220-8;16;Hb H;;; +64121-7;LL1511-6;Hb types;LA16221-6;17;Hb Lepore Boston;;; +64121-7;LL1511-6;Hb types;LA16222-4;18;Hb O-Arab;;; +64121-7;LL1511-6;Hb types;LA13007-2;19;Hb S;;; +64121-7;LL1511-6;Hb types;LA16223-2;20;Hb unidentified;;; +64122-5;LL1511-6;Hb types;LA16208-3;1;Hb F;;; +64122-5;LL1511-6;Hb types;LA16209-1;2;Hb A;;; +64122-5;LL1511-6;Hb types;LA16210-9;3;Hb A - indeterminate;;; +64122-5;LL1511-6;Hb types;LA16211-7;4;Hb A2;;; +64122-5;LL1511-6;Hb types;LA16212-5;5;Hb A2 - elevated;;; +64122-5;LL1511-6;Hb types;LA16213-3;6;Hb Bart's - low level;;; +64122-5;LL1511-6;Hb types;LA16214-1;7;Hb Bart's - highly elevated;;; +64122-5;LL1511-6;Hb types;LA13002-3;8;Hb C;;; +64122-5;LL1511-6;Hb types;LA16215-8;9;Hb Constant Spring;;; +64122-5;LL1511-6;Hb types;LA13003-1;10;Hb D;;; +64122-5;LL1511-6;Hb types;LA16216-6;11;Hb D-Punjab;;; +64122-5;LL1511-6;Hb types;LA16217-4;12;Hb D/G;;; +64122-5;LL1511-6;Hb types;LA13005-6;13;Hb E;;; +64122-5;LL1511-6;Hb types;LA16218-2;14;Hb G;;; +64122-5;LL1511-6;Hb types;LA16219-0;15;Hb G-Philadelphia;;; +64122-5;LL1511-6;Hb types;LA16220-8;16;Hb H;;; +64122-5;LL1511-6;Hb types;LA16221-6;17;Hb Lepore Boston;;; +64122-5;LL1511-6;Hb types;LA16222-4;18;Hb O-Arab;;; +64122-5;LL1511-6;Hb types;LA13007-2;19;Hb S;;; +64122-5;LL1511-6;Hb types;LA16223-2;20;Hb unidentified;;; +64149-8;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64149-8;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64149-8;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64155-5;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64155-5;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64155-5;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64165-4;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64165-4;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64165-4;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64166-2;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64166-2;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64166-2;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64169-6;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64169-6;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64169-6;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64170-4;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64170-4;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64170-4;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64171-2;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64171-2;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64171-2;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64172-0;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64172-0;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64172-0;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64175-3;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64175-3;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64175-3;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64179-5;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64179-5;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64179-5;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64182-9;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64182-9;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64182-9;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64185-2;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64185-2;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64185-2;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64188-6;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64188-6;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64188-6;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64189-4;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64189-4;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64189-4;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64192-8;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64192-8;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64192-8;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64193-6;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64193-6;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64193-6;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64196-9;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64196-9;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64196-9;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64197-7;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64197-7;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64197-7;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64205-8;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64205-8;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64205-8;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64206-6;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64206-6;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64206-6;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64208-2;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64208-2;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64208-2;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64211-6;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64211-6;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64211-6;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64217-3;LL1155-2;PhenX09_01;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64217-3;LL1155-2;PhenX09_01;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64217-3;LL1155-2;PhenX09_01;LA14452-9;3;Does not apply;;; +64173-8;LL1500-9;PhenX09_33_cold to chest;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64173-8;LL1500-9;PhenX09_33_cold to chest;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64173-8;LL1500-9;PhenX09_33_cold to chest;LA16149-9;3;Don't get colds;;; +64210-8;LL1156-0;Mild|Moderate|Severe;LA6752-5;1;Mild;;; +64210-8;LL1156-0;Mild|Moderate|Severe;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +64210-8;LL1156-0;Mild|Moderate|Severe;LA6750-9;3;Severe;;; +64214-0;LL1156-0;Mild|Moderate|Severe;LA6752-5;1;Mild;;; +64214-0;LL1156-0;Mild|Moderate|Severe;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +64214-0;LL1156-0;Mild|Moderate|Severe;LA6750-9;3;Severe;;; +64750-3;LL1156-0;Mild|Moderate|Severe;LA6752-5;1;Mild;;; +64750-3;LL1156-0;Mild|Moderate|Severe;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +64750-3;LL1156-0;Mild|Moderate|Severe;LA6750-9;3;Severe;;; +94032-0;LL1156-0;Mild|Moderate|Severe;LA6752-5;1;Mild;;; +94032-0;LL1156-0;Mild|Moderate|Severe;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +94032-0;LL1156-0;Mild|Moderate|Severe;LA6750-9;3;Severe;;; +94033-8;LL1156-0;Mild|Moderate|Severe;LA6752-5;1;Mild;;; +94033-8;LL1156-0;Mild|Moderate|Severe;LA6751-7;2;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +94033-8;LL1156-0;Mild|Moderate|Severe;LA6750-9;3;Severe;;; +64220-7;LL1158-6;PhenX09_04- smoking inhalation;LA14452-9;1;Does not apply;;; +64220-7;LL1158-6;PhenX09_04- smoking inhalation;LA6568-5;2;Not at all;;; +64220-7;LL1158-6;PhenX09_04- smoking inhalation;LA14454-5;3;Slightly;;; +64220-7;LL1158-6;PhenX09_04- smoking inhalation;LA13939-6;4;Moderately;;; +64220-7;LL1158-6;PhenX09_04- smoking inhalation;LA14455-2;5;Deeply;;; +64226-4;LL1159-4;PhenX09_05_inhale pipe,cigars;LA14458-6;1;Never smoked;;; +64226-4;LL1159-4;PhenX09_05_inhale pipe,cigars;LA6568-5;2;Not at all;;; +64226-4;LL1159-4;PhenX09_05_inhale pipe,cigars;LA14454-5;3;Slightly;;; +64226-4;LL1159-4;PhenX09_05_inhale pipe,cigars;LA13939-6;4;Moderately;;; +64226-4;LL1159-4;PhenX09_05_inhale pipe,cigars;LA14455-2;5;Deeply;;; +64232-2;LL1159-4;PhenX09_05_inhale pipe,cigars;LA14458-6;1;Never smoked;;; +64232-2;LL1159-4;PhenX09_05_inhale pipe,cigars;LA6568-5;2;Not at all;;; +64232-2;LL1159-4;PhenX09_05_inhale pipe,cigars;LA14454-5;3;Slightly;;; +64232-2;LL1159-4;PhenX09_05_inhale pipe,cigars;LA13939-6;4;Moderately;;; +64232-2;LL1159-4;PhenX09_05_inhale pipe,cigars;LA14455-2;5;Deeply;;; +64238-9;LL1528-0;PhenX09_40_parent;LA10416-8;1;Father;;; +64238-9;LL1528-0;PhenX09_40_parent;LA10417-6;2;Mother;;; +64265-2;LL1173-5;PhenX09_12_wheezing amt;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +64265-2;LL1173-5;PhenX09_12_wheezing amt;LA14464-4;2;1 to 3;;; +64265-2;LL1173-5;PhenX09_12_wheezing amt;LA14465-1;3;4 to 12;;; +64265-2;LL1173-5;PhenX09_12_wheezing amt;LA14466-9;4;More than 12;;; +64283-5;LL1173-5;PhenX09_12_wheezing amt;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +64283-5;LL1173-5;PhenX09_12_wheezing amt;LA14464-4;2;1 to 3;;; +64283-5;LL1173-5;PhenX09_12_wheezing amt;LA14465-1;3;4 to 12;;; +64283-5;LL1173-5;PhenX09_12_wheezing amt;LA14466-9;4;More than 12;;; +64266-0;LL1171-9;PhenX09_10_wheezing freq;LA14461-0;1;Never woken with this problem;;; +64266-0;LL1171-9;PhenX09_10_wheezing freq;LA14462-8;2;Less than one night per week;;; +64266-0;LL1171-9;PhenX09_10_wheezing freq;LA14463-6;3;One or more nights per week;;; +64397-3;LL1171-9;PhenX09_10_wheezing freq;LA14461-0;1;Never woken with this problem;;; +64397-3;LL1171-9;PhenX09_10_wheezing freq;LA14462-8;2;Less than one night per week;;; +64397-3;LL1171-9;PhenX09_10_wheezing freq;LA14463-6;3;One or more nights per week;;; +64274-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA6568-5;1;Not at all;;; +64274-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA13940-4;2;A little;;; +64274-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA14467-7;3;A moderate amount;;; +64274-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA14468-5;4;A lot;;; +64405-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA6568-5;1;Not at all;;; +64405-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA13940-4;2;A little;;; +64405-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA14467-7;3;A moderate amount;;; +64405-4;LL1172-7;PhenX09_11_noise interfere w/ activities;LA14468-5;4;A lot;;; +64279-3;LL1175-0;PhenX09_14_itchy rash awakens freq;LA14469-3;1;Never in the last 12 months;;; +64279-3;LL1175-0;PhenX09_14_itchy rash awakens freq;LA14462-8;2;Less than one night per week;;; +64279-3;LL1175-0;PhenX09_14_itchy rash awakens freq;LA14463-6;3;One or more nights per week;;; +64410-4;LL1175-0;PhenX09_14_itchy rash awakens freq;LA14469-3;1;Never in the last 12 months;;; +64410-4;LL1175-0;PhenX09_14_itchy rash awakens freq;LA14462-8;2;Less than one night per week;;; +64410-4;LL1175-0;PhenX09_14_itchy rash awakens freq;LA14463-6;3;One or more nights per week;;; +64409-6;LL1174-3;PhenX09_13_first age rash;LA15710-9;1;Under 2 years;;; +64409-6;LL1174-3;PhenX09_13_first age rash;LA13841-4;2;2 to 4 years;;; +64409-6;LL1174-3;PhenX09_13_first age rash;LA15711-7;3;5 or more years;;; +64434-4;LL1494-5;PhenX09_31_medications;LA16130-9;1;Medication 1;;; +64434-4;LL1494-5;PhenX09_31_medications;LA16131-7;2;Medication 2;;; +64434-4;LL1494-5;PhenX09_31_medications;LA16132-5;3;Medication 3;;; +64438-5;LL1176-8;PhenX09_15_health self assess;LA13913-1;1;Very Good;;; +64438-5;LL1176-8;PhenX09_15_health self assess;LA8967-7;2;Good;;; +64438-5;LL1176-8;PhenX09_15_health self assess;LA8968-5;3;Fair;;; +64438-5;LL1176-8;PhenX09_15_health self assess;LA8969-3;4;Poor;;; +64438-5;LL1176-8;PhenX09_15_health self assess;LA9615-1;5;Very poor;;; +64439-3;LL1177-6;PhenX09_16_resp probs freq;LA14470-1;1;Most days a week;;; +64439-3;LL1177-6;PhenX09_16_resp probs freq;LA14471-9;2;Several days a week;;; +64439-3;LL1177-6;PhenX09_16_resp probs freq;LA14472-7;3;A few days a month;;; +64439-3;LL1177-6;PhenX09_16_resp probs freq;LA14473-5;4;Only with chest infections;;; +64439-3;LL1177-6;PhenX09_16_resp probs freq;LA6568-5;5;Not at all;;; +64440-1;LL1177-6;PhenX09_16_resp probs freq;LA14470-1;1;Most days a week;;; +64440-1;LL1177-6;PhenX09_16_resp probs freq;LA14471-9;2;Several days a week;;; +64440-1;LL1177-6;PhenX09_16_resp probs freq;LA14472-7;3;A few days a month;;; +64440-1;LL1177-6;PhenX09_16_resp probs freq;LA14473-5;4;Only with chest infections;;; +64440-1;LL1177-6;PhenX09_16_resp probs freq;LA6568-5;5;Not at all;;; +64441-9;LL1177-6;PhenX09_16_resp probs freq;LA14470-1;1;Most days a week;;; +64441-9;LL1177-6;PhenX09_16_resp probs freq;LA14471-9;2;Several days a week;;; +64441-9;LL1177-6;PhenX09_16_resp probs freq;LA14472-7;3;A few days a month;;; +64441-9;LL1177-6;PhenX09_16_resp probs freq;LA14473-5;4;Only with chest infections;;; +64441-9;LL1177-6;PhenX09_16_resp probs freq;LA6568-5;5;Not at all;;; +64442-7;LL1177-6;PhenX09_16_resp probs freq;LA14470-1;1;Most days a week;;; +64442-7;LL1177-6;PhenX09_16_resp probs freq;LA14471-9;2;Several days a week;;; +64442-7;LL1177-6;PhenX09_16_resp probs freq;LA14472-7;3;A few days a month;;; +64442-7;LL1177-6;PhenX09_16_resp probs freq;LA14473-5;4;Only with chest infections;;; +64442-7;LL1177-6;PhenX09_16_resp probs freq;LA6568-5;5;Not at all;;; +64443-5;LL1178-4;PhenX09_17_attacks of chest trouble amt;LA14474-3;1;More than 3 attacks;;; +64443-5;LL1178-4;PhenX09_17_attacks of chest trouble amt;LA14475-0;2;3 attacks;;; +64443-5;LL1178-4;PhenX09_17_attacks of chest trouble amt;LA14476-8;3;2 attacks;;; +64443-5;LL1178-4;PhenX09_17_attacks of chest trouble amt;LA14477-6;4;1 attack;;; +64443-5;LL1178-4;PhenX09_17_attacks of chest trouble amt;LA14478-4;5;No attacks;;; +64444-3;LL1179-2;PhenX09_18_last worst chest attack;LA14479-2;1;A week or more;;; +64444-3;LL1179-2;PhenX09_18_last worst chest attack;LA14480-0;2;3 or more days;;; +64444-3;LL1179-2;PhenX09_18_last worst chest attack;LA14481-8;3;1 or 2 days;;; +64444-3;LL1179-2;PhenX09_18_last worst chest attack;LA14482-6;4;Less than a day;;; +64445-0;LL1180-0;PhenX09_19_ good chest days;LA14483-4;1;No good days;;; +64445-0;LL1180-0;PhenX09_19_ good chest days;LA14484-2;2;1 or 2 good days;;; +64445-0;LL1180-0;PhenX09_19_ good chest days;LA14485-9;3;3 or 4 good days;;; +64445-0;LL1180-0;PhenX09_19_ good chest days;LA14486-7;4;Nearly every day is good;;; +64445-0;LL1180-0;PhenX09_19_ good chest days;LA14487-5;5;Every day is good;;; +64447-6;LL1935-7;PhenX09_44_chest condition description;LA14488-3;1;The most important problem I have;;; +64447-6;LL1935-7;PhenX09_44_chest condition description;LA14489-1;2;Causes me quite a lot of problems;;; +64447-6;LL1935-7;PhenX09_44_chest condition description;LA14490-9;3;Causes me a few problems;;; +64447-6;LL1935-7;PhenX09_44_chest condition description;LA14491-7;4;Causes me no problems;;; +64448-4;LL1181-8;PhenX09_20_chest trouble at work;LA14492-5;1;My chest trouble made me stop work altogether;;; +64448-4;LL1181-8;PhenX09_20_chest trouble at work;LA15712-5;2;My chest trouble interferes with my work or made me change my work;;; +64448-4;LL1181-8;PhenX09_20_chest trouble at work;LA14494-1;3;My chest trouble does not affect my work;;; +64449-2;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64449-2;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64450-0;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64450-0;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64451-8;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64451-8;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64452-6;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64452-6;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64453-4;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64453-4;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64454-2;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64454-2;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64455-9;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64455-9;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64456-7;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64456-7;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64457-5;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64457-5;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64458-3;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64458-3;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64459-1;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64459-1;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64460-9;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64460-9;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64461-7;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64461-7;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64462-5;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64462-5;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64463-3;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64463-3;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64464-1;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64464-1;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64465-8;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64465-8;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64466-6;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64466-6;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64467-4;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64467-4;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64468-2;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64468-2;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64469-0;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64469-0;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64470-8;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64470-8;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64471-6;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64471-6;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64472-4;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64472-4;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64473-2;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64473-2;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64474-0;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64474-0;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64475-7;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64475-7;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64476-5;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64476-5;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64477-3;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64477-3;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64478-1;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64478-1;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64479-9;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64479-9;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64480-7;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +64480-7;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +65642-1;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +65642-1;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +71799-1;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +71799-1;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74022-5;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74022-5;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74043-1;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74043-1;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74043-1;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74043-1;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74044-9;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74044-9;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74044-9;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74044-9;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74047-2;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74047-2;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74048-0;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74048-0;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +74049-8;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +74049-8;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +80408-8;LL1182-6;PhenX09_21;LA14495-8;1;True;;; +80408-8;LL1182-6;PhenX09_21;LA14496-6;2;False;;; +64482-3;LL1183-4;PhenX09_22_how chest prob affects you;LA14497-4;1;It does not stop me doing anything I would like to do;;; +64482-3;LL1183-4;PhenX09_22_how chest prob affects you;LA14498-2;2;It stops me doing one or two things I would like to do;;; +64482-3;LL1183-4;PhenX09_22_how chest prob affects you;LA14499-0;3;It stops me doing most of the things I would like to do;;; +64482-3;LL1183-4;PhenX09_22_how chest prob affects you;LA14500-5;4;It stops me doing everything I would like to do;;; +64487-2;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64487-2;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64487-2;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64490-6;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64490-6;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64490-6;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64500-2;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64500-2;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64500-2;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64501-0;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64501-0;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64501-0;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64502-8;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64502-8;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64502-8;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64503-6;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64503-6;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64503-6;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64504-4;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64504-4;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64504-4;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64505-1;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64505-1;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64505-1;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64506-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64506-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64506-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64507-7;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64507-7;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64507-7;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64508-5;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64508-5;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64508-5;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64509-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64509-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64509-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64510-1;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64510-1;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64510-1;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64511-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64511-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64511-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64512-7;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64512-7;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64512-7;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64513-5;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64513-5;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64513-5;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64514-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64514-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64514-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64515-0;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64515-0;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64515-0;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64516-8;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64516-8;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64516-8;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64517-6;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64517-6;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64517-6;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64518-4;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64518-4;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64518-4;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64520-0;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64520-0;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64520-0;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64521-8;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64521-8;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64521-8;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64522-6;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64522-6;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64522-6;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64523-4;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64523-4;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64523-4;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64524-2;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64524-2;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64524-2;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64525-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64525-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64525-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64526-7;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64526-7;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64526-7;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64527-5;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64527-5;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64527-5;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64528-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64528-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64528-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64529-1;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64529-1;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64529-1;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64530-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64530-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64530-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64531-7;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64531-7;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64531-7;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64532-5;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64532-5;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64532-5;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64533-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64533-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64533-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64534-1;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64534-1;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64534-1;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64535-8;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64535-8;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64535-8;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64536-6;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64536-6;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64536-6;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64538-2;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64538-2;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64538-2;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64539-0;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64539-0;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64539-0;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64540-8;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64540-8;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64540-8;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64547-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64547-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64547-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64548-1;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64548-1;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64548-1;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64549-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64549-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64549-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64550-7;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64550-7;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64550-7;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64551-5;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64551-5;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64551-5;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64552-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64552-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64552-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64553-1;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64553-1;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64553-1;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64554-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64554-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64554-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64555-6;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64555-6;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64555-6;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64556-4;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64556-4;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64556-4;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64559-8;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64559-8;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64559-8;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64560-6;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64560-6;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64560-6;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64561-4;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64561-4;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64561-4;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64562-2;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64562-2;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64562-2;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64563-0;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64563-0;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64563-0;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64564-8;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64564-8;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64564-8;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64565-5;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64565-5;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64565-5;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64566-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64566-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64566-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64568-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64568-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64568-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64570-5;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64570-5;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64570-5;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64573-9;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64573-9;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64573-9;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64575-4;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64575-4;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64575-4;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64576-2;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64576-2;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64576-2;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64577-0;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64577-0;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64577-0;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66174-4;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66174-4;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66174-4;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66419-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66419-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66419-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66570-3;LL1643-7;PhenX14_35;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66570-3;LL1643-7;PhenX14_35;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66570-3;LL1643-7;PhenX14_35;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64488-0;LL1184-2;PhenX09_23_snoring loudness;LA14501-3;1;Slightly louder than breathing;;; +64488-0;LL1184-2;PhenX09_23_snoring loudness;LA14502-1;2;As loud as talking;;; +64488-0;LL1184-2;PhenX09_23_snoring loudness;LA14503-9;3;Louder than talking;;; +64488-0;LL1184-2;PhenX09_23_snoring loudness;LA14504-7;4;Very loud can be heard in adjacent rooms;;; +64489-8;LL1185-9;PhenX09_24_snoring freq;LA6571-9;1;Nearly every day;;; +64489-8;LL1185-9;PhenX09_24_snoring freq;LA14505-4;2;3-4 times a week;;; +64489-8;LL1185-9;PhenX09_24_snoring freq;LA14506-2;3;1-2 times a week;;; +64489-8;LL1185-9;PhenX09_24_snoring freq;LA14507-0;4;1-2 times a month;;; +64489-8;LL1185-9;PhenX09_24_snoring freq;LA14508-8;5;Never or nearly never;;; +64491-4;LL1185-9;PhenX09_24_snoring freq;LA6571-9;1;Nearly every day;;; +64491-4;LL1185-9;PhenX09_24_snoring freq;LA14505-4;2;3-4 times a week;;; +64491-4;LL1185-9;PhenX09_24_snoring freq;LA14506-2;3;1-2 times a week;;; +64491-4;LL1185-9;PhenX09_24_snoring freq;LA14507-0;4;1-2 times a month;;; +64491-4;LL1185-9;PhenX09_24_snoring freq;LA14508-8;5;Never or nearly never;;; +64492-2;LL1185-9;PhenX09_24_snoring freq;LA6571-9;1;Nearly every day;;; +64492-2;LL1185-9;PhenX09_24_snoring freq;LA14505-4;2;3-4 times a week;;; +64492-2;LL1185-9;PhenX09_24_snoring freq;LA14506-2;3;1-2 times a week;;; +64492-2;LL1185-9;PhenX09_24_snoring freq;LA14507-0;4;1-2 times a month;;; +64492-2;LL1185-9;PhenX09_24_snoring freq;LA14508-8;5;Never or nearly never;;; +64493-0;LL1185-9;PhenX09_24_snoring freq;LA6571-9;1;Nearly every day;;; +64493-0;LL1185-9;PhenX09_24_snoring freq;LA14505-4;2;3-4 times a week;;; +64493-0;LL1185-9;PhenX09_24_snoring freq;LA14506-2;3;1-2 times a week;;; +64493-0;LL1185-9;PhenX09_24_snoring freq;LA14507-0;4;1-2 times a month;;; +64493-0;LL1185-9;PhenX09_24_snoring freq;LA14508-8;5;Never or nearly never;;; +64495-5;LL1185-9;PhenX09_24_snoring freq;LA6571-9;1;Nearly every day;;; +64495-5;LL1185-9;PhenX09_24_snoring freq;LA14505-4;2;3-4 times a week;;; +64495-5;LL1185-9;PhenX09_24_snoring freq;LA14506-2;3;1-2 times a week;;; +64495-5;LL1185-9;PhenX09_24_snoring freq;LA14507-0;4;1-2 times a month;;; +64495-5;LL1185-9;PhenX09_24_snoring freq;LA14508-8;5;Never or nearly never;;; +64497-1;LL5641-7;Questionnaire setting;LA14084-0;1;Home;;; +64497-1;LL5641-7;Questionnaire setting;LA26177-8;2;Doctor's office;;; +64497-1;LL5641-7;Questionnaire setting;LA31152-4;3;Other location;;; +64497-1;LL5641-7;Questionnaire setting;LA14084-0;1;Home;;; +64497-1;LL5641-7;Questionnaire setting;LA26177-8;2;Doctor's office;;; +64497-1;LL5641-7;Questionnaire setting;LA31152-4;3;Other location;;; +64497-1;LL5641-7;Questionnaire setting;LA14084-0;1;Home;;; +64497-1;LL5641-7;Questionnaire setting;LA26177-8;2;Doctor's office;;; +64497-1;LL5641-7;Questionnaire setting;LA31152-4;3;Other location;;; +64591-1;LL1187-5;PhenX09_26_spirometry data type;LA14514-6;1;Sp E S;;; +64591-1;LL1187-5;PhenX09_26_spirometry data type;LA14515-3;2;Sp I S;;; +64591-1;LL1187-5;PhenX09_26_spirometry data type;LA14516-1;3;Sp E B;;; +64591-1;LL1187-5;PhenX09_26_spirometry data type;LA14517-9;4;Sp I B;;; +64592-9;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13487-6;1;A;;; +64592-9;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14518-7;2;B;;; +64592-9;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14519-5;3;C;;; +64592-9;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14520-3;4;D;;; +64592-9;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13503-0;5;E;;; +64592-9;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13504-8;6;F;;; +64593-7;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13487-6;1;A;;; +64593-7;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14518-7;2;B;;; +64593-7;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14519-5;3;C;;; +64593-7;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14520-3;4;D;;; +64593-7;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13503-0;5;E;;; +64593-7;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13504-8;6;F;;; +64594-5;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13487-6;1;A;;; +64594-5;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14518-7;2;B;;; +64594-5;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14519-5;3;C;;; +64594-5;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA14520-3;4;D;;; +64594-5;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13503-0;5;E;;; +64594-5;LL1188-3;PhenX09_27_FVC, FEV1 attribute;LA13504-8;6;F;;; +64600-0;LL1189-1;PhenX09_28_review status;LA14521-1;1;N - Needs Review;;; +64600-0;LL1189-1;PhenX09_28_review status;LA15713-3;2;W - Was reviewed;;; +64608-3;LL1519-9;PhenX09_38_testing position;LA11870-5;1;Standing;10904000;Orthostatic body position (finding);http://snomed.info/sct +64608-3;LL1519-9;PhenX09_38_testing position;LA11868-9;2;Sitting;33586001;Sitting position (finding);http://snomed.info/sct +64608-3;LL1519-9;PhenX09_38_testing position;LA16254-7;3;Supine;;; +64609-1;LL1513-2;PhenX10_50_breast stage;LA16224-0;1;The nipple is raised a little in this stage. The rest of the breast is still flat.;;; +64609-1;LL1513-2;PhenX10_50_breast stage;LA16225-7;2;This is the breast bud stage. In this stage the nipple is raised more than in stage 1. The breast is a small mound. The dark area around the nipple (areola) is larger than in stage 1.;;; +64609-1;LL1513-2;PhenX10_50_breast stage;LA16226-5;3;The areola and the breast are both larger than in stage 2. The areola does not stick out away from the breast.;;; +64609-1;LL1513-2;PhenX10_50_breast stage;LA16227-3;4;The areola and the nipple make up a mound that sticks up above the shape of the breast. (note: this stage may not happen at all for some teenagers. Some teenagers develop from stage 3 to stage 5 with no stage 4.).;;; +64609-1;LL1513-2;PhenX10_50_breast stage;LA16228-1;5;This is the mature adult stage. The breasts are fully developed. Only the nipple sticks out in this stage. The areola has moved back in the general shape of the breast.;;; +64610-9;LL1514-0;PhenX10_51_pubic hair stage;LA16229-9;1;There is no pubic hair.;;; +64610-9;LL1514-0;PhenX10_51_pubic hair stage;LA16230-7;2;There is a little long, lightly colored hair. This hair may be straight or a little curly;;; +64610-9;LL1514-0;PhenX10_51_pubic hair stage;LA16231-5;3;The hair is darker in this stage. It is coarser and more curled. It has spread out and thinly covers a bigger area.;;; +64610-9;LL1514-0;PhenX10_51_pubic hair stage;LA16232-3;4;The hair is now as dark, curly, and coarse as that of an adult woman. However, the area that the hair covers is not as large as that of an adult woman. The hair has not spread out to the legs.;;; +64610-9;LL1514-0;PhenX10_51_pubic hair stage;LA16233-1;5;The hair is like that of an adult woman. It also covers the same area as that of an adult woman. The hair usually forms a triangular pattern as it spreads out to the legs.;;; +64611-7;LL1515-7;PhenX10_52_gential development stage;LA16234-9;1;The size and shape of the testes, scrotum (the sac holding the testes) and penis are about the same as when you were younger.;;; +64611-7;LL1515-7;PhenX10_52_gential development stage;LA16235-6;2;The penis is a little bit bigger. The scrotum has dropped and the skin of the scrotum has changed. The testes are bigger.;;; +64611-7;LL1515-7;PhenX10_52_gential development stage;LA16236-4;3;The penis has grown longer, the testes have grown and dropped lower.;;; +64611-7;LL1515-7;PhenX10_52_gential development stage;LA16237-2;4;The penis is longer and wider. The head of the penis is bigger, the scrotum is a darker color and bigger. The testes are bigger.;;; +64611-7;LL1515-7;PhenX10_52_gential development stage;LA16238-0;5;The penis, scrotum and testes are the size and shape of a man's.;;; +64612-5;LL1516-5;PhenX10_53_physical development stage;LA16239-8;1;There is no hair at all.;;; +64612-5;LL1516-5;PhenX10_53_physical development stage;LA16230-7;2;There is a little long, lightly colored hair. This hair may be straight or a little curly;;; +64612-5;LL1516-5;PhenX10_53_physical development stage;LA16241-4;3;The hair is darker and more curled. It has spread out and thinly covers a bigger area.;;; +64612-5;LL1516-5;PhenX10_53_physical development stage;LA16242-2;4;The hair is as dark and curly as that of a man, but it hasn't spread out to the legs.;;; +64612-5;LL1516-5;PhenX10_53_physical development stage;LA16243-0;5;The hair is like that of a man. It has spread out to the legs.;;; +64613-3;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64613-3;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64616-6;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64616-6;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64617-4;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64617-4;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64619-0;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64619-0;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64620-8;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64620-8;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64621-6;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64621-6;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64623-2;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64623-2;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64626-5;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64626-5;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64631-5;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64631-5;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65663-7;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65663-7;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65664-5;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65664-5;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66066-2;LL1555-3;PhenX10_59;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66066-2;LL1555-3;PhenX10_59;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64614-1;LL1190-9;PhenX10_01_pregnancy attempt services;LA14524-5;0;Infertility testing;;; +64614-1;LL1190-9;PhenX10_01_pregnancy attempt services;LA14523-7;1;Advice;;; +64614-1;LL1190-9;PhenX10_01_pregnancy attempt services;LA14525-2;3;Drugs to improve ovulation;;; +64614-1;LL1190-9;PhenX10_01_pregnancy attempt services;LA14526-0;4;Surgery to correct blocked tubes;;; +64614-1;LL1190-9;PhenX10_01_pregnancy attempt services;LA14527-8;5;Artificial insemination;;; +64614-1;LL1190-9;PhenX10_01_pregnancy attempt services;LA14528-6;6;Treatment for varicocele;;; +64614-1;LL1190-9;PhenX10_01_pregnancy attempt services;LA14529-4;7;Other types of medical help;;; +64615-8;LL1191-7;PhenX10_02_male infertility probs;LA14530-2;1;Sperm or semen problems;;; +64615-8;LL1191-7;PhenX10_02_male infertility probs;LA14531-0;2;Varicocele;;; +64615-8;LL1191-7;PhenX10_02_male infertility probs;LA46-8;3;Other;;; +64615-8;LL1191-7;PhenX10_02_male infertility probs;LA9-3;4;None of the above;;; +64618-2;LL1192-5;PhenX10_03_tubal ligation status;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64618-2;LL1192-5;PhenX10_03_tubal ligation status;LA14532-8;2;If vol: operation failed;;; +64618-2;LL1192-5;PhenX10_03_tubal ligation status;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +64618-2;LL1192-5;PhenX10_03_tubal ligation status;LA14533-6;4;If vol: operation already reversed;;; +64622-4;LL1193-3;PhenX10_04_vasectomy status;LA14534-4;1;Vasectomy;;; +64622-4;LL1193-3;PhenX10_04_vasectomy status;LA14535-1;2;Other operation;;; +64622-4;LL1193-3;PhenX10_04_vasectomy status;LA14532-8;3;If vol: operation failed;;; +64622-4;LL1193-3;PhenX10_04_vasectomy status;LA14533-6;4;If vol: operation already reversed;;; +64625-7;LL1194-1;PhenX10_05_Ys oral contraceptives;LA14536-9;1;One year or less;;; +64625-7;LL1194-1;PhenX10_05_Ys oral contraceptives;LA14537-7;2;More than one year but less than ten years;;; +64625-7;LL1194-1;PhenX10_05_Ys oral contraceptives;LA14538-5;3;Ten years or more;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14539-3;1;Birth control pills;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14540-1;2;Birth control patch;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14541-9;3;IUD;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14542-7;4;Injection;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14543-5;5;Condoms;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14544-3;6;Diaphragm;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14545-0;7;Cervical cap;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14546-8;8;Nuvaring®;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14547-6;9;Spermicidal foam or jelly;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14548-4;10;Vaginal sponge;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14549-2;11;Withdrawal;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14550-0;12;Abstinence;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14551-8;13;Rhythm/natural family planning;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14552-6;14;Morning after pill;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA14553-4;15;Vasectomy of husband/partner;;; +64629-9;LL1195-8;PhenX10_06_birth control methods;LA46-8;16;Other;;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16244-8;1;Condom or rubber;;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16245-5;2;Withdrawal or pulling out;;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16246-3;3;Vasectomy or male sterilization;;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16247-1;4;Pill;;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16248-9;5;"Tubal ligation (""""tubes tied"""") or female sterilization";;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16249-7;6;Injection (Depo-Provera® or Lunelle);;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16250-5;7;Spermicidal foam/jelly/cream/film/suppository;;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16251-3;8;Hormonal implant (Norplant®);;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16252-1;9;Rhythm or safe period;;; +64630-7;LL1518-1;PhenX10_54_birth control methods;LA16253-9;10;Something else;;; +64633-1;LL1198-2;PhenX10_09_hysterectomy;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64633-1;LL1198-2;PhenX10_09_hysterectomy;LA15714-1;2;Yes, one ovary only removed;;; +64633-1;LL1198-2;PhenX10_09_hysterectomy;LA15715-8;3;Yes, both ovaries removed;;; +64633-1;LL1198-2;PhenX10_09_hysterectomy;LA15716-6;4;Yes, and kept ovaries;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14554-2;1;9 or less;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA13942-0;2;10;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14557-5;3;11;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14558-3;4;12;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14559-1;5;13;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14560-9;6;14;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14561-7;7;15;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14562-5;8;16;;; +64634-9;LL1196-6;PhenX10_07_ age first period;LA14555-9;9;17 or more;;; +64635-6;LL1197-4;PhenX10_08_age full ht.;LA14563-3;1;Before age 13;;; +64635-6;LL1197-4;PhenX10_08_age full ht.;LA14564-1;2;13-17 years of age;;; +64635-6;LL1197-4;PhenX10_08_age full ht.;LA14565-8;3;After age 17;;; +64635-6;LL1197-4;PhenX10_08_age full ht.;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64636-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA14566-6;1;Earlier;;; +64636-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA14567-4;2;About the same time;;; +64636-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA12112-1;3;Later;;; +64636-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64638-0;LL1199-0;PhenX10_10_male puberty peer comparison;LA14566-6;1;Earlier;;; +64638-0;LL1199-0;PhenX10_10_male puberty peer comparison;LA14567-4;2;About the same time;;; +64638-0;LL1199-0;PhenX10_10_male puberty peer comparison;LA12112-1;3;Later;;; +64638-0;LL1199-0;PhenX10_10_male puberty peer comparison;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64641-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA14566-6;1;Earlier;;; +64641-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA14567-4;2;About the same time;;; +64641-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA12112-1;3;Later;;; +64641-4;LL1199-0;PhenX10_10_male puberty peer comparison;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65868-2;LL1199-0;PhenX10_10_male puberty peer comparison;LA14566-6;1;Earlier;;; +65868-2;LL1199-0;PhenX10_10_male puberty peer comparison;LA14567-4;2;About the same time;;; +65868-2;LL1199-0;PhenX10_10_male puberty peer comparison;LA12112-1;3;Later;;; +65868-2;LL1199-0;PhenX10_10_male puberty peer comparison;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64643-0;LL1200-6;PhenX10_11_puberty status;LA14568-2;1;Have not yet begun;;; +64643-0;LL1200-6;PhenX10_11_puberty status;LA14569-0;2;Have barely started;;; +64643-0;LL1200-6;PhenX10_11_puberty status;LA14570-8;3;Are definitely underway;;; +64643-0;LL1200-6;PhenX10_11_puberty status;LA14571-6;4;Seem completed;;; +64647-1;LL1201-4;PhenX10_12_Mos nolvadex use;LA157-0;1;Not used;;; +64647-1;LL1201-4;PhenX10_12_Mos nolvadex use;LA14572-4;2;1-4 months;;; +64647-1;LL1201-4;PhenX10_12_Mos nolvadex use;LA14573-2;3;5-9;;; +64647-1;LL1201-4;PhenX10_12_Mos nolvadex use;LA14574-0;4;10-14;;; +64647-1;LL1201-4;PhenX10_12_Mos nolvadex use;LA14575-7;5;15-19;;; +64647-1;LL1201-4;PhenX10_12_Mos nolvadex use;LA14576-5;6;20-24;;; +64647-1;LL1201-4;PhenX10_12_Mos nolvadex use;LA14577-3;7;Used only after 6/09;;; +64648-9;LL1202-2;PhenX10_13_evista nolvadex use;LA14578-1;1;No, not currently;;; +64648-9;LL1202-2;PhenX10_13_evista nolvadex use;LA14579-9;2;Yes, Evista®;;; +64648-9;LL1202-2;PhenX10_13_evista nolvadex use;LA14580-7;3;Yes, Nolvadex®;;; +64650-5;LL1213-9;PhenX10_24_natural hormones;LA14581-5;1;Soy estrogen products;;; +64650-5;LL1213-9;PhenX10_24_natural hormones;LA14582-3;2;Natural progesterone cream or wild yam cream;;; +64650-5;LL1213-9;PhenX10_24_natural hormones;LA14583-1;3;Dong Quai (e.g. Rejuvex);;; +64650-5;LL1213-9;PhenX10_24_natural hormones;LA14584-9;4;Black Cohosh (e.g. Remifemin®);;; +64650-5;LL1213-9;PhenX10_24_natural hormones;LA46-8;5;Other;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14572-4;1;1-4 months;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14573-2;2;5-9;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14574-0;3;10-14;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14575-7;4;15-19;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14585-6;5;20-25;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14586-4;6;26-30;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14587-2;7;31-35;;; +64652-1;LL1203-0;PhenX10_14_Mos female hormone use;LA14588-0;8;36+ months;;; +64654-7;LL1204-8;PhenX10_15_combined hormone use;LA14589-8;1;Prempro® (Beige);;; +64654-7;LL1204-8;PhenX10_15_combined hormone use;LA14590-6;2;Prempro® (Gold);;; +64654-7;LL1204-8;PhenX10_15_combined hormone use;LA14591-4;3;Prempro® (Peach);;; +64654-7;LL1204-8;PhenX10_15_combined hormone use;LA14592-2;4;Prempro® (Light Blue);;; +64654-7;LL1204-8;PhenX10_15_combined hormone use;LA14593-0;5;Premphase;;; +64654-7;LL1204-8;PhenX10_15_combined hormone use;LA14594-8;6;Combipatch;;; +64654-7;LL1204-8;PhenX10_15_combined hormone use;LA14595-5;7;FemHRT;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14596-3;1;Oral Premarin® or conjugated estrogens;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14597-1;2;Patch estrogen;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14598-9;3;Vaginal estrogen;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14599-7;4;Estrace®;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14600-3;5;Estrogen gels, creams, or sprays on skin;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14601-1;6;Estratest®;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14602-9;7;Ogen®;;; +64655-4;LL1205-5;PhenX10_16_ current estrogen type;LA14603-7;8;Other estrogen;;; +64657-0;LL1206-3;PhenX10_17_current progesterone type;LA14604-5;1;Provera®/Cycrin®/MPA;;; +64657-0;LL1206-3;PhenX10_17_current progesterone type;LA9459-4;2;Vaginal;;; +64657-0;LL1206-3;PhenX10_17_current progesterone type;LA14605-2;3;Micronized (e.g. Prometrium®);;; +64657-0;LL1206-3;PhenX10_17_current progesterone type;LA14606-0;4;Other progesterone;;; +64660-4;LL1207-1;PhenX10_18_oral conjugated estrogen dose;LA14607-8;1;0.30 mg/day or less;;; +64660-4;LL1207-1;PhenX10_18_oral conjugated estrogen dose;LA14608-6;2;0.45 mg/day or less;;; +64660-4;LL1207-1;PhenX10_18_oral conjugated estrogen dose;LA14609-4;3;0.625 mg/day or less;;; +64660-4;LL1207-1;PhenX10_18_oral conjugated estrogen dose;LA14610-2;4;0.9 mg/day or less;;; +64660-4;LL1207-1;PhenX10_18_oral conjugated estrogen dose;LA14611-0;5;1.25 mg/day or higher;;; +64660-4;LL1207-1;PhenX10_18_oral conjugated estrogen dose;LA14072-5;6;Unsure;;; +64660-4;LL1207-1;PhenX10_18_oral conjugated estrogen dose;LA14612-8;7;Did not take oral conjugated estrogen;;; +64661-2;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA157-0;1;Not used;;; +64661-2;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14613-6;2;<1 day/mo.;;; +64661-2;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14614-4;3;1-8 days;;; +64661-2;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14615-1;4;9-18;;; +64661-2;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14616-9;5;19-26;;; +64661-2;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14617-7;6;27+ days/mo.;;; +64662-0;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA157-0;1;Not used;;; +64662-0;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14613-6;2;<1 day/mo.;;; +64662-0;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14614-4;3;1-8 days;;; +64662-0;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14615-1;4;9-18;;; +64662-0;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14616-9;5;19-26;;; +64662-0;LL1208-9;PhenX10_19_Ds estrogen/progesterone;LA14617-7;6;27+ days/mo.;;; +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA14618-5;3;Doctor refused when asked;;; +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA14619-3;4;Don't know/not sure;;; +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA14618-5;3;Doctor refused when asked;;; +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA14619-3;4;Don't know/not sure;;; +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA14618-5;3;Doctor refused when asked;;; +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA14619-3;4;Don't know/not sure;;; +64663-8;LL1209-7;PhenX10_20_HPV vaccination;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64665-3;LL1210-5;PhenX10_21_HPV shots amt;LA15717-4;1;All shots;;; +64665-3;LL1210-5;PhenX10_21_HPV shots amt;LA14619-3;2;Don't know/not sure;;; +64665-3;LL1210-5;PhenX10_21_HPV shots amt;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64665-3;LL1210-5;PhenX10_21_HPV shots amt;LA15717-4;1;All shots;;; +64665-3;LL1210-5;PhenX10_21_HPV shots amt;LA14619-3;2;Don't know/not sure;;; +64665-3;LL1210-5;PhenX10_21_HPV shots amt;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64666-1;LL1211-3;PhenX10_22_male genitalia probs;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64666-1;LL1211-3;PhenX10_22_male genitalia probs;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64666-1;LL1211-3;PhenX10_22_male genitalia probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64668-7;LL1211-3;PhenX10_22_male genitalia probs;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64668-7;LL1211-3;PhenX10_22_male genitalia probs;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64668-7;LL1211-3;PhenX10_22_male genitalia probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64669-5;LL1211-3;PhenX10_22_male genitalia probs;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64669-5;LL1211-3;PhenX10_22_male genitalia probs;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64669-5;LL1211-3;PhenX10_22_male genitalia probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64672-9;LL1211-3;PhenX10_22_male genitalia probs;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64672-9;LL1211-3;PhenX10_22_male genitalia probs;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64672-9;LL1211-3;PhenX10_22_male genitalia probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64674-5;LL1211-3;PhenX10_22_male genitalia probs;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64674-5;LL1211-3;PhenX10_22_male genitalia probs;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64674-5;LL1211-3;PhenX10_22_male genitalia probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64667-9;LL1212-1;PhenX10_23_which testicle;LA4306-2;1;Right;;; +64667-9;LL1212-1;PhenX10_23_which testicle;LA4585-1;2;Left;;; +64667-9;LL1212-1;PhenX10_23_which testicle;LA14331-5;3;Both;;; +64670-3;LL1214-7;PhenX10_25_tx undescended testicle;LA14620-1;1;Surgery;;; +64670-3;LL1214-7;PhenX10_25_tx undescended testicle;LA4003-5;2;Hormones;;; +64670-3;LL1214-7;PhenX10_25_tx undescended testicle;LA6310-2;3;Other (specify);;; +64670-3;LL1214-7;PhenX10_25_tx undescended testicle;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64677-8;LL1215-4;PhenX10_26;LA13866-1;1;Almost never;;; +64677-8;LL1215-4;PhenX10_26;LA10082-8;2;Sometimes;;; +64677-8;LL1215-4;PhenX10_26;LA10044-8;3;Often;;; +64677-8;LL1215-4;PhenX10_26;LA13865-3;4;Almost always;;; +64678-6;LL1215-4;PhenX10_26;LA13866-1;1;Almost never;;; +64678-6;LL1215-4;PhenX10_26;LA10082-8;2;Sometimes;;; +64678-6;LL1215-4;PhenX10_26;LA10044-8;3;Often;;; +64678-6;LL1215-4;PhenX10_26;LA13865-3;4;Almost always;;; +64679-4;LL1215-4;PhenX10_26;LA13866-1;1;Almost never;;; +64679-4;LL1215-4;PhenX10_26;LA10082-8;2;Sometimes;;; +64679-4;LL1215-4;PhenX10_26;LA10044-8;3;Often;;; +64679-4;LL1215-4;PhenX10_26;LA13865-3;4;Almost always;;; +64680-2;LL1215-4;PhenX10_26;LA13866-1;1;Almost never;;; +64680-2;LL1215-4;PhenX10_26;LA10082-8;2;Sometimes;;; +64680-2;LL1215-4;PhenX10_26;LA10044-8;3;Often;;; +64680-2;LL1215-4;PhenX10_26;LA13865-3;4;Almost always;;; +64681-0;LL1216-2;PhenX10_27_erection probs;LA14621-9;1;No sexual activity;;; +64681-0;LL1216-2;PhenX10_27_erection probs;LA13926-3;2;Almost never or never;;; +64681-0;LL1216-2;PhenX10_27_erection probs;LA14622-7;3;A few times (much less than half the time);;; +64681-0;LL1216-2;PhenX10_27_erection probs;LA14623-5;4;Sometimes (about half the time);;; +64681-0;LL1216-2;PhenX10_27_erection probs;LA14624-3;5;Most times (much more than half the time);;; +64681-0;LL1216-2;PhenX10_27_erection probs;LA13927-1;6;Almost always or always;;; +64682-8;LL1216-2;PhenX10_27_erection probs;LA14621-9;1;No sexual activity;;; +64682-8;LL1216-2;PhenX10_27_erection probs;LA13926-3;2;Almost never or never;;; +64682-8;LL1216-2;PhenX10_27_erection probs;LA14622-7;3;A few times (much less than half the time);;; +64682-8;LL1216-2;PhenX10_27_erection probs;LA14623-5;4;Sometimes (about half the time);;; +64682-8;LL1216-2;PhenX10_27_erection probs;LA14624-3;5;Most times (much more than half the time);;; +64682-8;LL1216-2;PhenX10_27_erection probs;LA13927-1;6;Almost always or always;;; +64683-6;LL1217-0;PhenX10_28_sexual probs;LA14625-0;1;Did not attempt intercourse;;; +64683-6;LL1217-0;PhenX10_28_sexual probs;LA13926-3;2;Almost never or never;;; +64683-6;LL1217-0;PhenX10_28_sexual probs;LA14623-5;3;Sometimes (about half the time);;; +64683-6;LL1217-0;PhenX10_28_sexual probs;LA14622-7;4;A few times (much less than half the time);;; +64683-6;LL1217-0;PhenX10_28_sexual probs;LA14624-3;5;Most times (much more than half the time);;; +64683-6;LL1217-0;PhenX10_28_sexual probs;LA13927-1;6;Almost always or always;;; +64684-4;LL1217-0;PhenX10_28_sexual probs;LA14625-0;1;Did not attempt intercourse;;; +64684-4;LL1217-0;PhenX10_28_sexual probs;LA13926-3;2;Almost never or never;;; +64684-4;LL1217-0;PhenX10_28_sexual probs;LA14623-5;3;Sometimes (about half the time);;; +64684-4;LL1217-0;PhenX10_28_sexual probs;LA14622-7;4;A few times (much less than half the time);;; +64684-4;LL1217-0;PhenX10_28_sexual probs;LA14624-3;5;Most times (much more than half the time);;; +64684-4;LL1217-0;PhenX10_28_sexual probs;LA13927-1;6;Almost always or always;;; +64687-7;LL1217-0;PhenX10_28_sexual probs;LA14625-0;1;Did not attempt intercourse;;; +64687-7;LL1217-0;PhenX10_28_sexual probs;LA13926-3;2;Almost never or never;;; +64687-7;LL1217-0;PhenX10_28_sexual probs;LA14623-5;3;Sometimes (about half the time);;; +64687-7;LL1217-0;PhenX10_28_sexual probs;LA14622-7;4;A few times (much less than half the time);;; +64687-7;LL1217-0;PhenX10_28_sexual probs;LA14624-3;5;Most times (much more than half the time);;; +64687-7;LL1217-0;PhenX10_28_sexual probs;LA13927-1;6;Almost always or always;;; +64685-1;LL1218-8;PhenX10_29_maintain erection;LA14625-0;1;Did not attempt intercourse;;; +64685-1;LL1218-8;PhenX10_29_maintain erection;LA6574-3;2;Extremely difficult;;; +64685-1;LL1218-8;PhenX10_29_maintain erection;LA6575-0;3;Very difficult;;; +64685-1;LL1218-8;PhenX10_29_maintain erection;LA14626-8;4;Difficult;;; +64685-1;LL1218-8;PhenX10_29_maintain erection;LA14627-6;5;Slightly difficult;;; +64685-1;LL1218-8;PhenX10_29_maintain erection;LA14628-4;6;Not difficult;;; +64686-9;LL1219-6;PhenX10_30_intercourse attempts;LA14629-2;1;No attempts;;; +64686-9;LL1219-6;PhenX10_30_intercourse attempts;LA14630-0;2;One or two attempts;;; +64686-9;LL1219-6;PhenX10_30_intercourse attempts;LA14631-8;3;Three to four attempts;;; +64686-9;LL1219-6;PhenX10_30_intercourse attempts;LA14632-6;4;Five to six attempts;;; +64686-9;LL1219-6;PhenX10_30_intercourse attempts;LA14633-4;5;Seven to ten attempts;;; +64686-9;LL1219-6;PhenX10_30_intercourse attempts;LA14634-2;6;Eleven+ attempts;;; +64688-5;LL1220-4;PhenX10_31_intercourse enjoyment;LA15718-2;1;No intercourse;;; +64688-5;LL1220-4;PhenX10_31_intercourse enjoyment;LA15719-0;2;No enjoyment;;; +64688-5;LL1220-4;PhenX10_31_intercourse enjoyment;LA15720-8;3;Not very enjoyable;;; +64688-5;LL1220-4;PhenX10_31_intercourse enjoyment;LA15721-6;4;Fairly enjoyable;;; +64688-5;LL1220-4;PhenX10_31_intercourse enjoyment;LA15722-4;5;Highly enjoyable;;; +64688-5;LL1220-4;PhenX10_31_intercourse enjoyment;LA15723-2;6;Very highly enjoyable;;; +64689-3;LL1221-2;PhenX10_32_sexual stimulation;LA14635-9;1;No sexual stimulation/intercourse;;; +64689-3;LL1221-2;PhenX10_32_sexual stimulation;LA13926-3;2;Almost never or never;;; +64689-3;LL1221-2;PhenX10_32_sexual stimulation;LA14622-7;3;A few times (much less than half the time);;; +64689-3;LL1221-2;PhenX10_32_sexual stimulation;LA14623-5;4;Sometimes (about half the time);;; +64689-3;LL1221-2;PhenX10_32_sexual stimulation;LA14624-3;5;Most times (much more than half the time);;; +64689-3;LL1221-2;PhenX10_32_sexual stimulation;LA13927-1;6;Almost always or always;;; +64690-1;LL1221-2;PhenX10_32_sexual stimulation;LA14635-9;1;No sexual stimulation/intercourse;;; +64690-1;LL1221-2;PhenX10_32_sexual stimulation;LA13926-3;2;Almost never or never;;; +64690-1;LL1221-2;PhenX10_32_sexual stimulation;LA14622-7;3;A few times (much less than half the time);;; +64690-1;LL1221-2;PhenX10_32_sexual stimulation;LA14623-5;4;Sometimes (about half the time);;; +64690-1;LL1221-2;PhenX10_32_sexual stimulation;LA14624-3;5;Most times (much more than half the time);;; +64690-1;LL1221-2;PhenX10_32_sexual stimulation;LA13927-1;6;Almost always or always;;; +64691-9;LL1222-0;PhenX10_33_sexual desire;LA14636-7;1;Very low/none at all;;; +64691-9;LL1222-0;PhenX10_33_sexual desire;LA9194-7;2;Low;;; +64691-9;LL1222-0;PhenX10_33_sexual desire;LA6751-7;3;Moderate;;; +64691-9;LL1222-0;PhenX10_33_sexual desire;LA9193-9;4;High;;; +64691-9;LL1222-0;PhenX10_33_sexual desire;LA14637-5;5;Very high;;; +64692-7;LL1521-5;PhenX10_55_sexual desire level;LA13926-3;1;Almost never or never;;; +64692-7;LL1521-5;PhenX10_55_sexual desire level;LA14622-7;2;A few times (much less than half the time);;; +64692-7;LL1521-5;PhenX10_55_sexual desire level;LA14623-5;3;Sometimes (about half the time);;; +64692-7;LL1521-5;PhenX10_55_sexual desire level;LA14624-3;4;Most times (much more than half the time);;; +64692-7;LL1521-5;PhenX10_55_sexual desire level;LA13927-1;5;Almost always or always;;; +64693-5;LL1223-8;PhenX10_34_sexual satisfaction;LA14638-3;1;Very dissatisfied;;; +64693-5;LL1223-8;PhenX10_34_sexual satisfaction;LA14639-1;2;Moderately dissatisfied;;; +64693-5;LL1223-8;PhenX10_34_sexual satisfaction;LA14640-9;3;About equally satisfied and dissatisfied;;; +64693-5;LL1223-8;PhenX10_34_sexual satisfaction;LA14641-7;4;Moderately satisfied;;; +64693-5;LL1223-8;PhenX10_34_sexual satisfaction;LA14642-5;5;Very satisfied;;; +64694-3;LL1223-8;PhenX10_34_sexual satisfaction;LA14638-3;1;Very dissatisfied;;; +64694-3;LL1223-8;PhenX10_34_sexual satisfaction;LA14639-1;2;Moderately dissatisfied;;; +64694-3;LL1223-8;PhenX10_34_sexual satisfaction;LA14640-9;3;About equally satisfied and dissatisfied;;; +64694-3;LL1223-8;PhenX10_34_sexual satisfaction;LA14641-7;4;Moderately satisfied;;; +64694-3;LL1223-8;PhenX10_34_sexual satisfaction;LA14642-5;5;Very satisfied;;; +64695-0;LL1224-6;PhenX10_35_confidence to keep erection;LA14643-3;1;Very low;;; +64695-0;LL1224-6;PhenX10_35_confidence to keep erection;LA9194-7;2;Low;;; +64695-0;LL1224-6;PhenX10_35_confidence to keep erection;LA6751-7;3;Moderate;;; +64695-0;LL1224-6;PhenX10_35_confidence to keep erection;LA9193-9;4;High;;; +64695-0;LL1224-6;PhenX10_35_confidence to keep erection;LA14637-5;5;Very high;;; +64696-8;LL1225-3;PhenX10_36_no periods >3Mos;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64696-8;LL1225-3;PhenX10_36_no periods >3Mos;LA14644-1;2;Yes one time only;;; +64696-8;LL1225-3;PhenX10_36_no periods >3Mos;LA15672-1;3;Yes, more than once;;; +64696-8;LL1225-3;PhenX10_36_no periods >3Mos;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64697-6;LL1599-1;Phenx11_79;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64697-6;LL1599-1;Phenx11_79;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64697-6;LL1599-1;Phenx11_79;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64698-4;LL1599-1;Phenx11_79;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64698-4;LL1599-1;Phenx11_79;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64698-4;LL1599-1;Phenx11_79;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64780-0;LL1599-1;Phenx11_79;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64780-0;LL1599-1;Phenx11_79;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64780-0;LL1599-1;Phenx11_79;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64781-8;LL1599-1;Phenx11_79;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64781-8;LL1599-1;Phenx11_79;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64781-8;LL1599-1;Phenx11_79;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64699-2;LL1226-1;PhenX10_37_menstrual cycle pattern;LA14645-8;1;Regular (within 8 days);;; +64699-2;LL1226-1;PhenX10_37_menstrual cycle pattern;LA14646-6;2;Usually irregular;;; +64699-2;LL1226-1;PhenX10_37_menstrual cycle pattern;LA14647-4;3;Always irregular;;; +64699-2;LL1226-1;PhenX10_37_menstrual cycle pattern;LA14648-2;4;No periods;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA14649-0;1;Less than 21 days;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA14650-8;2;21-25 days;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA14651-6;3;26-32 days;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA14652-4;4;33-35 days;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA14653-2;5;36-90 days;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA14654-0;6;More than 90 days;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA14655-7;7;Too variable to say;;; +64700-8;LL1227-9;PhenX10_38_typical menstrual cycle;LA12688-0;8;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64701-6;LL1228-7;PhenX10_39_periods stopped;LA14656-5;1;Yes, no menstrual periods;;; +64701-6;LL1228-7;PhenX10_39_periods stopped;LA14657-3;2;Yes, but have periods now due to female hormones;;; +64701-6;LL1228-7;PhenX10_39_periods stopped;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +64701-6;LL1228-7;PhenX10_39_periods stopped;LA12693-0;4;Not sure;;; +64702-4;LL1229-5;PhenX10_40_age periods stopped;LA14658-1;1;Less than 35;;; +64702-4;LL1229-5;PhenX10_40_age periods stopped;LA14659-9;2;35 - 39;;; +64702-4;LL1229-5;PhenX10_40_age periods stopped;LA14660-7;3;40 - 44;;; +64702-4;LL1229-5;PhenX10_40_age periods stopped;LA14661-5;4;45 - 49;;; +64702-4;LL1229-5;PhenX10_40_age periods stopped;LA14662-3;5;50 - 54;;; +64702-4;LL1229-5;PhenX10_40_age periods stopped;LA14663-1;6;55 or more;;; +64703-2;LL1230-3;PhenX10_41_ night urination freq;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +64703-2;LL1230-3;PhenX10_41_ night urination freq;LA14312-5;2;Once;;; +64703-2;LL1230-3;PhenX10_41_ night urination freq;LA14664-9;3;Twice;;; +64703-2;LL1230-3;PhenX10_41_ night urination freq;LA14665-6;4;3 or more times;;; +64703-2;LL1230-3;PhenX10_41_ night urination freq;LA14666-4;5;Blank but applicable/cannot be determined;;; +64703-2;LL1230-3;PhenX10_41_ night urination freq;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64704-0;LL1231-1;PhenX10_42_urination probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64704-0;LL1231-1;PhenX10_42_urination probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64704-0;LL1231-1;PhenX10_42_urination probs;LA14666-4;3;Blank but applicable/cannot be determined;;; +64704-0;LL1231-1;PhenX10_42_urination probs;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64705-7;LL1231-1;PhenX10_42_urination probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64705-7;LL1231-1;PhenX10_42_urination probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64705-7;LL1231-1;PhenX10_42_urination probs;LA14666-4;3;Blank but applicable/cannot be determined;;; +64705-7;LL1231-1;PhenX10_42_urination probs;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64706-5;LL1231-1;PhenX10_42_urination probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64706-5;LL1231-1;PhenX10_42_urination probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64706-5;LL1231-1;PhenX10_42_urination probs;LA14666-4;3;Blank but applicable/cannot be determined;;; +64706-5;LL1231-1;PhenX10_42_urination probs;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64707-3;LL1231-1;PhenX10_42_urination probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64707-3;LL1231-1;PhenX10_42_urination probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64707-3;LL1231-1;PhenX10_42_urination probs;LA14666-4;3;Blank but applicable/cannot be determined;;; +64707-3;LL1231-1;PhenX10_42_urination probs;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64710-7;LL1232-9;PhenX10_43_pregnancy outcome;LA14270-5;1;Live birth;;; +64710-7;LL1232-9;PhenX10_43_pregnancy outcome;LA14667-2;2;Stillbirth;;; +64710-7;LL1232-9;PhenX10_43_pregnancy outcome;LA14272-1;3;Miscarriage;;; +64710-7;LL1232-9;PhenX10_43_pregnancy outcome;LA14668-0;4;Abortion;;; +64710-7;LL1232-9;PhenX10_43_pregnancy outcome;LA14669-8;5;Ectopic/Tubal;;; +64710-7;LL1232-9;PhenX10_43_pregnancy outcome;LA14670-6;6;Currently pregnant;;; +64710-7;LL1232-9;PhenX10_43_pregnancy outcome;LA46-8;7;Other;;; +64713-1;LL1233-7;PhenX10_44_pregnancy nausea;LA14671-4;1;Months 1-3 (first trimester);;; +64713-1;LL1233-7;PhenX10_44_pregnancy nausea;LA14672-2;2;Months 4-6 (second trimester);;; +64713-1;LL1233-7;PhenX10_44_pregnancy nausea;LA14673-0;3;Months 7-9 (third trimester);;; +64715-6;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14674-8;1;6 or more times;;; +64715-6;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14675-5;2;4 to 5 times;;; +64715-6;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14676-3;3;2 to 3 times;;; +64715-6;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14677-1;4;1 time;;; +64715-6;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14678-9;5;I didn't have 4 drinks or more in 1 sitting;;; +64717-2;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14674-8;1;6 or more times;;; +64717-2;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14675-5;2;4 to 5 times;;; +64717-2;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14676-3;3;2 to 3 times;;; +64717-2;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14677-1;4;1 time;;; +64717-2;LL1234-5;PhenX10_45_alcohol before/during pregnancy;LA14678-9;5;I didn't have 4 drinks or more in 1 sitting;;; +64716-4;LL1235-2;PhenX10_46_drinks during pregnancy;LA14679-7;1;14 drinks or more a week;;; +64716-4;LL1235-2;PhenX10_46_drinks during pregnancy;LA14680-5;2;7 to 13 drinks a week;;; +64716-4;LL1235-2;PhenX10_46_drinks during pregnancy;LA14681-3;3;4 to 6 drinks a week;;; +64716-4;LL1235-2;PhenX10_46_drinks during pregnancy;LA14682-1;4;1 to 3 drinks a week;;; +64716-4;LL1235-2;PhenX10_46_drinks during pregnancy;LA14683-9;5;Less than 1 drink a week;;; +64716-4;LL1235-2;PhenX10_46_drinks during pregnancy;LA14684-7;6;I didn't drink;;; +64796-6;LL1235-2;PhenX10_46_drinks during pregnancy;LA14679-7;1;14 drinks or more a week;;; +64796-6;LL1235-2;PhenX10_46_drinks during pregnancy;LA14680-5;2;7 to 13 drinks a week;;; +64796-6;LL1235-2;PhenX10_46_drinks during pregnancy;LA14681-3;3;4 to 6 drinks a week;;; +64796-6;LL1235-2;PhenX10_46_drinks during pregnancy;LA14682-1;4;1 to 3 drinks a week;;; +64796-6;LL1235-2;PhenX10_46_drinks during pregnancy;LA14683-9;5;Less than 1 drink a week;;; +64796-6;LL1235-2;PhenX10_46_drinks during pregnancy;LA14684-7;6;I didn't drink;;; +64726-3;LL1236-0;PhenX10_47_this pregnancy outcome;LA14270-5;1;Live birth;;; +64726-3;LL1236-0;PhenX10_47_this pregnancy outcome;LA14272-1;2;Miscarriage;;; +64726-3;LL1236-0;PhenX10_47_this pregnancy outcome;LA14667-2;3;Stillbirth;;; +64726-3;LL1236-0;PhenX10_47_this pregnancy outcome;LA14668-0;4;Abortion;;; +64726-3;LL1236-0;PhenX10_47_this pregnancy outcome;LA14669-8;5;Ectopic/Tubal;;; +64726-3;LL1236-0;PhenX10_47_this pregnancy outcome;LA14685-4;6;Molar pregnancy;;; +64734-7;LL1237-8;PhenX10_48_gender sexual attraction;LA14686-2;1;Only to females, never to males;;; +64734-7;LL1237-8;PhenX10_48_gender sexual attraction;LA14687-0;2;Mostly to females, and at least once to a male;;; +64734-7;LL1237-8;PhenX10_48_gender sexual attraction;LA14688-8;3;About equally often to females and to males;;; +64734-7;LL1237-8;PhenX10_48_gender sexual attraction;LA14689-6;4;Mostly to males, and at least once to a female;;; +64734-7;LL1237-8;PhenX10_48_gender sexual attraction;LA14690-4;5;Only to males, never to females;;; +64734-7;LL1237-8;PhenX10_48_gender sexual attraction;LA14691-2;6;I have never felt sexually attracted to anyone at all;;; +64737-0;LL1238-6;PhenX10_49_last same gender contact;LA14692-0;1;In the last 7 days;;; +64737-0;LL1238-6;PhenX10_49_last same gender contact;LA14693-8;2;Between 7 days and 4 weeks ago;;; +64737-0;LL1238-6;PhenX10_49_last same gender contact;LA14694-6;3;Between 4 weeks and 6 months ago;;; +64737-0;LL1238-6;PhenX10_49_last same gender contact;LA14695-3;4;Between 6 months and 1 year ago;;; +64737-0;LL1238-6;PhenX10_49_last same gender contact;LA14696-1;5;Between 1 year and 5 years ago;;; +64737-0;LL1238-6;PhenX10_49_last same gender contact;LA14697-9;6;Longer than 5 years ago;;; +64741-2;LL1240-2;PhenX11_02;LA4306-2;1;Right;;; +64741-2;LL1240-2;PhenX11_02;LA4585-1;2;Left;;; +65413-7;LL1240-2;PhenX11_02;LA4306-2;1;Right;;; +65413-7;LL1240-2;PhenX11_02;LA4585-1;2;Left;;; +66042-3;LL1240-2;PhenX11_02;LA4306-2;1;Right;;; +66042-3;LL1240-2;PhenX11_02;LA4585-1;2;Left;;; +67256-8;LL1240-2;PhenX11_02;LA4306-2;1;Right;;; +67256-8;LL1240-2;PhenX11_02;LA4585-1;2;Left;;; +64745-3;LL1530-6;PhenX10_56_eye problem;LA16274-5;1;Discomfort;;; +64745-3;LL1530-6;PhenX10_56_eye problem;LA16271-1;2;Grittiness;;; +64745-3;LL1530-6;PhenX10_56_eye problem;LA16272-9;3;Itchiness;;; +64745-3;LL1530-6;PhenX10_56_eye problem;LA16273-7;4;Watering;;; +64746-1;LL1239-4;PhenX11_01_eye/reading probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64746-1;LL1239-4;PhenX11_01_eye/reading probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64746-1;LL1239-4;PhenX11_01_eye/reading probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64746-1;LL1239-4;PhenX11_01_eye/reading probs;LA14698-7;4;Missing;;; +64884-0;LL1239-4;PhenX11_01_eye/reading probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64884-0;LL1239-4;PhenX11_01_eye/reading probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64884-0;LL1239-4;PhenX11_01_eye/reading probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64884-0;LL1239-4;PhenX11_01_eye/reading probs;LA14698-7;4;Missing;;; +64890-7;LL1239-4;PhenX11_01_eye/reading probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64890-7;LL1239-4;PhenX11_01_eye/reading probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64890-7;LL1239-4;PhenX11_01_eye/reading probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64890-7;LL1239-4;PhenX11_01_eye/reading probs;LA14698-7;4;Missing;;; +64892-3;LL1239-4;PhenX11_01_eye/reading probs;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64892-3;LL1239-4;PhenX11_01_eye/reading probs;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64892-3;LL1239-4;PhenX11_01_eye/reading probs;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64892-3;LL1239-4;PhenX11_01_eye/reading probs;LA14698-7;4;Missing;;; +64747-9;LL1243-6;PhenX11_05_which eye;LA14703-5;1;Right eye;;; +64747-9;LL1243-6;PhenX11_05_which eye;LA14704-3;2;Left eye;;; +64747-9;LL1243-6;PhenX11_05_which eye;LA14331-5;3;Both;;; +64747-9;LL1243-6;PhenX11_05_which eye;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64747-9;LL1243-6;PhenX11_05_which eye;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64748-7;LL5899-1;EuroSpine - Duration;LA32108-5;1;<3 months;;; +64748-7;LL5899-1;EuroSpine - Duration;LA32109-3;2;3-12 months;;; +64748-7;LL5899-1;EuroSpine - Duration;LA28563-7;3;>12 months;;; +64750-3;LL5473-5;None|A little|Medium|A lot;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +64750-3;LL5473-5;None|A little|Medium|A lot;LA13940-4;2;A little;;; +64750-3;LL5473-5;None|A little|Medium|A lot;LA8982-6;3;Medium;;; +64750-3;LL5473-5;None|A little|Medium|A lot;LA14468-5;4;A lot;;; +94068-4;LL5473-5;None|A little|Medium|A lot;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +94068-4;LL5473-5;None|A little|Medium|A lot;LA13940-4;2;A little;;; +94068-4;LL5473-5;None|A little|Medium|A lot;LA8982-6;3;Medium;;; +94068-4;LL5473-5;None|A little|Medium|A lot;LA14468-5;4;A lot;;; +94068-4;LL5473-5;None|A little|Medium|A lot;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +94068-4;LL5473-5;None|A little|Medium|A lot;LA13940-4;2;A little;;; +94068-4;LL5473-5;None|A little|Medium|A lot;LA8982-6;3;Medium;;; +94068-4;LL5473-5;None|A little|Medium|A lot;LA14468-5;4;A lot;;; +64752-9;LL1241-0;PhenX11_03_difficulty drawing,coloring;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64752-9;LL1241-0;PhenX11_03_difficulty drawing,coloring;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64752-9;LL1241-0;PhenX11_03_difficulty drawing,coloring;LA14699-5;3;Unable to color;;; +64752-9;LL1241-0;PhenX11_03_difficulty drawing,coloring;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64752-9;LL1241-0;PhenX11_03_difficulty drawing,coloring;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64756-0;LL1242-8;PhenX11_04_last eye exam;LA14700-1;1;Within the past 12 months;;; +64756-0;LL1242-8;PhenX11_04_last eye exam;LA14701-9;2;1-3 years ago;;; +64756-0;LL1242-8;PhenX11_04_last eye exam;LA14702-7;3;3-5 years ago;;; +64756-0;LL1242-8;PhenX11_04_last eye exam;LA6270-8;4;Never;;; +64756-0;LL1242-8;PhenX11_04_last eye exam;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64756-0;LL1242-8;PhenX11_04_last eye exam;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64757-8;LL1540-5;Phenx11_39_child vision problem;LA16299-2;1;Amblyopia;;; +64757-8;LL1540-5;Phenx11_39_child vision problem;LA16300-8;2;Strabismus;;; +64757-8;LL1540-5;Phenx11_39_child vision problem;LA16301-6;3;Myopia or nearsightedness;;; +64757-8;LL1540-5;Phenx11_39_child vision problem;LA16302-4;4;Glaucoma;;; +64757-8;LL1540-5;Phenx11_39_child vision problem;LA16303-2;5;Retinopathy of prematurity;;; +64757-8;LL1540-5;Phenx11_39_child vision problem;LA16304-0;6;Tumor;;; +64757-8;LL1540-5;Phenx11_39_child vision problem;LA16305-7;7;Retinoblastoma;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA14705-0;1;Glasses or contact lenses;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA14706-8;2;Patching;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA14707-6;3;Eye drops;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA14708-4;4;Vision therapy;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA14709-2;5;Eye muscle surgery;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA14710-0;6;Botulinum injections;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA46-8;7;Other;;; +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA137-2;8;None;260413007;None (qualifier value);http://snomed.info/sct +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA4389-8;9;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64768-5;LL1245-1;PhenX11_07_child strabismus tx;LA12688-0;10;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64770-1;LL1246-9;PhenX11_08_myopia tx;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64770-1;LL1246-9;PhenX11_08_myopia tx;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +64770-1;LL1246-9;PhenX11_08_myopia tx;LA14705-0;3;Glasses or contact lenses;;; +64770-1;LL1246-9;PhenX11_08_myopia tx;LA137-2;4;None;260413007;None (qualifier value);http://snomed.info/sct +64770-1;LL1246-9;PhenX11_08_myopia tx;LA46-8;5;Other;;; +64770-1;LL1246-9;PhenX11_08_myopia tx;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64770-1;LL1246-9;PhenX11_08_myopia tx;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64776-8;LL1247-7;PhenX11_09;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64776-8;LL1247-7;PhenX11_09;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64776-8;LL1247-7;PhenX11_09;LA12719-3;3;Uncertain;;; +64878-2;LL1247-7;PhenX11_09;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64878-2;LL1247-7;PhenX11_09;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +64878-2;LL1247-7;PhenX11_09;LA12719-3;3;Uncertain;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14711-8;1;Alphagan®;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14712-6;2;Betagen®;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14713-4;3;Betopic;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14714-2;4;Cosopt®;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14715-9;5;Pilocar®;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14716-7;6;Timolol;372880004;Timolol (substance);http://snomed.info/sct +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14717-5;7;Timoptic®;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA14718-3;8;Xalatan®;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA46-8;9;Other;;; +64777-6;LL1248-5;PhenX11_10_glaucoma drops;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +64779-2;LL1522-3;PhenX11_31_past dry eyes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64779-2;LL1522-3;PhenX11_31_past dry eyes;LA16257-0;2;OD - right eye;;; +64779-2;LL1522-3;PhenX11_31_past dry eyes;LA16258-8;3;OS - left eye;;; +64779-2;LL1522-3;PhenX11_31_past dry eyes;LA16259-6;4;OU - both eyes;;; +64779-2;LL1522-3;PhenX11_31_past dry eyes;LA14722-5;5;?Eye;;; +64779-2;LL1522-3;PhenX11_31_past dry eyes;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64792-5;LL1249-3;PhenX11_11;LA9206-9;1;Excellent;;; +64792-5;LL1249-3;PhenX11_11;LA13913-1;2;Very Good;;; +64792-5;LL1249-3;PhenX11_11;LA8967-7;3;Good;;; +64792-5;LL1249-3;PhenX11_11;LA8968-5;4;Fair;;; +64792-5;LL1249-3;PhenX11_11;LA8969-3;5;Poor;;; +64792-5;LL1249-3;PhenX11_11;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64792-5;LL1249-3;PhenX11_11;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64793-3;LL1249-3;PhenX11_11;LA9206-9;1;Excellent;;; +64793-3;LL1249-3;PhenX11_11;LA13913-1;2;Very Good;;; +64793-3;LL1249-3;PhenX11_11;LA8967-7;3;Good;;; +64793-3;LL1249-3;PhenX11_11;LA8968-5;4;Fair;;; +64793-3;LL1249-3;PhenX11_11;LA8969-3;5;Poor;;; +64793-3;LL1249-3;PhenX11_11;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64793-3;LL1249-3;PhenX11_11;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66576-0;LL1249-3;PhenX11_11;LA9206-9;1;Excellent;;; +66576-0;LL1249-3;PhenX11_11;LA13913-1;2;Very Good;;; +66576-0;LL1249-3;PhenX11_11;LA8967-7;3;Good;;; +66576-0;LL1249-3;PhenX11_11;LA8968-5;4;Fair;;; +66576-0;LL1249-3;PhenX11_11;LA8969-3;5;Poor;;; +66576-0;LL1249-3;PhenX11_11;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66576-0;LL1249-3;PhenX11_11;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64794-1;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16292-7;1;41 cigarettes or more;;; +64794-1;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16293-5;2;21 to 40 cigarettes;;; +64794-1;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16294-3;3;11 to 20 cigarettes;;; +64794-1;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16295-0;4;6 to 10 cigarettes;;; +64794-1;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16296-8;5;1 to 5 cigarettes;;; +64794-1;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16297-6;6;Less than 1 cigarette;;; +64794-1;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16298-4;7;None (0 cigarettes);;; +64795-8;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16292-7;1;41 cigarettes or more;;; +64795-8;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16293-5;2;21 to 40 cigarettes;;; +64795-8;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16294-3;3;11 to 20 cigarettes;;; +64795-8;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16295-0;4;6 to 10 cigarettes;;; +64795-8;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16296-8;5;1 to 5 cigarettes;;; +64795-8;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16297-6;6;Less than 1 cigarette;;; +64795-8;LL1539-7;PhenX10_58_cigarettes before/during pregnancy;LA16298-4;7;None (0 cigarettes);;; +64808-9;LL1526-4;PhenX11_36_sunlight protection;LA16264-6;1;Hat with a brim;;; +64808-9;LL1526-4;PhenX11_36_sunlight protection;LA16265-3;2;Prescription or non-prescription sunglasses;;; +64808-9;LL1526-4;PhenX11_36_sunlight protection;LA16266-1;3;Ordinary glasses or contact lenses;;; +64809-7;LL1250-1;PhenX11_12_sunlight protection;LA6270-8;1;Never;;; +64809-7;LL1250-1;PhenX11_12_sunlight protection;LA14723-3;2;Less than half the time;;; +64809-7;LL1250-1;PhenX11_12_sunlight protection;LA14724-1;3;More than half the time;;; +64809-7;LL1250-1;PhenX11_12_sunlight protection;LA14726-6;4;All the time;;; +64810-5;LL1250-1;PhenX11_12_sunlight protection;LA6270-8;1;Never;;; +64810-5;LL1250-1;PhenX11_12_sunlight protection;LA14723-3;2;Less than half the time;;; +64810-5;LL1250-1;PhenX11_12_sunlight protection;LA14724-1;3;More than half the time;;; +64810-5;LL1250-1;PhenX11_12_sunlight protection;LA14726-6;4;All the time;;; +64813-9;LL1250-1;PhenX11_12_sunlight protection;LA6270-8;1;Never;;; +64813-9;LL1250-1;PhenX11_12_sunlight protection;LA14723-3;2;Less than half the time;;; +64813-9;LL1250-1;PhenX11_12_sunlight protection;LA14724-1;3;More than half the time;;; +64813-9;LL1250-1;PhenX11_12_sunlight protection;LA14726-6;4;All the time;;; +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA9206-9;1;Excellent;;; +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA8967-7;2;Good;;; +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA8968-5;3;Fair;;; +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA8969-3;4;Poor;;; +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA9615-1;5;Very poor;;; +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA14727-4;6;Completely blind;;; +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64814-7;LL1251-9;PhenX11_13_bilateral eyesight;LA12688-0;8;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64815-4;LL1541-3;Phenx11_40_adult eye problem;LA16306-5;1;Cataracts;;; +64815-4;LL1541-3;Phenx11_40_adult eye problem;LA16302-4;2;Glaucoma;;; +64815-4;LL1541-3;Phenx11_40_adult eye problem;LA16307-3;3;Macular degeneration;;; +64821-2;LL1252-7;PhenX11_14_diabetic retinopathy surg;LA14728-2;1;Yes, laser treatment;;; +64821-2;LL1252-7;PhenX11_14_diabetic retinopathy surg;LA14729-0;2;Yes, surgery;;; +64821-2;LL1252-7;PhenX11_14_diabetic retinopathy surg;LA14730-8;3;Yes, both;;; +64821-2;LL1252-7;PhenX11_14_diabetic retinopathy surg;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +64821-2;LL1252-7;PhenX11_14_diabetic retinopathy surg;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +64821-2;LL1252-7;PhenX11_14_diabetic retinopathy surg;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64838-6;LL1542-1;Phenx11_41_strabismus treatment;LA16311-5;1;Glasses before age 6;;; +64838-6;LL1542-1;Phenx11_41_strabismus treatment;LA14706-8;2;Patching;;; +64838-6;LL1542-1;Phenx11_41_strabismus treatment;LA14709-2;3;Eye muscle surgery;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16312-3;1;Line 1;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16313-1;2;Line 2;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16314-9;3;Line 3;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16315-6;4;Line 4;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16316-4;5;Line 5;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16317-2;6;Line 6;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16318-0;7;Line 7;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16319-8;8;Line 8;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16320-6;9;Line 9;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16321-4;10;Line 10;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16322-2;11;Line 11;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16323-0;12;Line 12;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16324-8;13;Line 13;;; +64841-0;LL1544-7;Phenx11_43_ETDRS Visual Acuity Chart line;LA16325-5;14;Line 14;;; +64846-9;LL3116-2;PhenX_Overall health;LA9206-9;1;Excellent;;; +64846-9;LL3116-2;PhenX_Overall health;LA13913-1;2;Very Good;;; +64846-9;LL3116-2;PhenX_Overall health;LA8967-7;3;Good;;; +64846-9;LL3116-2;PhenX_Overall health;LA8968-5;4;Fair;;; +64846-9;LL3116-2;PhenX_Overall health;LA8969-3;5;Poor;;; +64846-9;LL5643-3;Vision clarity;LA31153-2;1;Perfectly clear;;; +64846-9;LL5643-3;Vision clarity;LA31154-0;2;Pretty clear;;; +64846-9;LL5643-3;Vision clarity;LA31155-7;3;Somewhat clear;;; +64846-9;LL5643-3;Vision clarity;LA31156-5;4;Not clear at all;;; +64846-9;LL5643-3;Vision clarity;LA31153-2;1;Perfectly clear;;; +64846-9;LL5643-3;Vision clarity;LA31154-0;2;Pretty clear;;; +64846-9;LL5643-3;Vision clarity;LA31155-7;3;Somewhat clear;;; +64846-9;LL5643-3;Vision clarity;LA31156-5;4;Not clear at all;;; +64847-7;LL1529-8;Phenx11_38_worry about eyesight;LA6297-1;1;None of the time;;; +64847-7;LL1529-8;Phenx11_38_worry about eyesight;LA14732-4;2;A little of the time;;; +64847-7;LL1529-8;Phenx11_38_worry about eyesight;LA14733-2;3;Some of the time;;; +64847-7;LL1529-8;Phenx11_38_worry about eyesight;LA14734-0;4;Most of the time;;; +64847-7;LL1529-8;Phenx11_38_worry about eyesight;LA6154-4;5;All of the time;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +64847-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98521-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98521-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98521-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98521-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98521-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98522-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98522-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98522-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98522-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98522-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98523-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98523-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98523-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98523-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98523-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98524-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98524-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98524-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98524-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98524-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98525-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98525-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98525-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98525-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98525-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98526-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98526-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98526-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98526-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98526-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98535-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98535-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98535-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98535-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98535-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98538-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98538-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98538-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98538-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98538-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98539-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98539-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98539-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98539-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98539-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98540-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98540-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98540-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98540-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98540-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98541-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98541-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98541-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98541-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98541-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98542-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98542-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98542-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98542-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98542-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98543-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98543-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98543-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98543-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98543-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98544-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98544-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98544-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98544-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98544-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98545-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98545-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98545-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98545-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98545-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98546-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98546-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98546-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98546-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98546-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98547-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98547-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98547-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98547-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98547-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98548-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98548-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98548-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98548-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98548-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98549-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98549-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98549-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98549-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98549-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98550-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98550-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98550-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98550-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98550-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98551-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98551-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98551-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98551-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98551-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98552-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98552-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98552-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98552-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98552-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98553-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98553-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98553-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98553-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98553-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98554-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98554-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98554-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98554-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98554-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98555-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98555-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98555-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98555-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98555-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98556-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98556-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98556-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98556-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98556-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98557-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98557-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98557-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98557-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98557-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98558-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98558-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98558-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98558-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98558-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98559-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98559-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98559-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98559-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98559-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98560-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98560-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98560-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98560-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98560-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98561-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98561-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98561-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98561-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98561-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98562-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98562-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98562-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98562-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98562-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98563-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98563-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98563-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98563-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98563-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98564-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98564-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98564-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98564-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98564-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98565-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98565-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98565-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98565-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98565-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98566-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98566-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98566-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98566-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98566-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98567-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98567-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98567-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98567-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98567-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98568-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98568-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98568-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98568-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98568-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98569-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98569-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98569-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98569-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98569-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98570-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98570-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98570-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98570-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98570-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98571-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98571-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98571-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98571-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98571-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98572-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98572-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98572-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98572-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98572-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98573-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98573-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98573-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98573-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98573-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98574-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98574-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98574-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98574-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98574-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98575-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98575-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98575-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98575-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98575-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98576-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98576-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98576-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98576-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98576-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98577-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98577-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98577-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98577-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98577-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98578-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98578-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98578-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98578-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98578-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98579-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98579-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98579-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98579-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98579-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98580-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98580-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98580-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98580-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98580-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98581-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98581-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98581-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98581-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98581-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98582-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98582-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98582-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98582-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98582-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98583-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98583-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98583-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98583-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98583-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98584-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98584-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98584-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98584-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98584-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98585-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98585-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98585-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98585-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98585-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98586-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98586-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98586-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98586-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98586-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98587-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98587-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98587-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98587-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98587-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98588-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98588-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98588-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98588-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98588-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98589-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98589-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98589-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98589-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98589-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98590-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98590-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98590-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98590-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98590-3;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98591-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98591-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98591-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98591-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98591-1;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98592-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98592-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98592-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98592-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98592-9;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98593-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98593-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98593-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98593-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98593-7;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98594-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98594-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98594-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98594-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98594-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98595-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98595-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98595-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98595-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98595-2;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98596-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98596-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98596-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98596-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98596-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98597-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98597-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98597-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98597-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98597-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98598-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98598-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98598-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98598-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98598-6;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98599-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98599-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98599-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98599-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98599-4;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98600-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98600-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98600-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98600-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98600-0;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +98601-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +98601-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +98601-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +98601-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +98601-8;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +99193-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6270-8;1;Never;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10066-1;2;Rarely;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6483-7;3;Occasionally;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA10082-8;4;Sometimes;;; +99211-5;LL5642-5;Nev-Rare-Occ-Some-All the Time;LA6154-4;5;All of the time;;; +64847-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA6154-4;1;All of the time;;; +64847-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA14734-0;2;Most of the time;;; +64847-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA10082-8;3;Sometimes;;; +64847-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA10066-1;4;Rarely;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA6154-4;1;All of the time;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA14734-0;2;Most of the time;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA10082-8;3;Sometimes;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA10066-1;4;Rarely;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA6154-4;1;All of the time;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA14734-0;2;Most of the time;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA10082-8;3;Sometimes;;; +96891-7;LL5803-3;PhenX - frequency (All of the time -> rarely);LA10066-1;4;Rarely;;; +64850-1;LL1254-3;PhenX11_16_driving;LA15728-1;1;Never drove;;; +64850-1;LL1254-3;PhenX11_16_driving;LA15729-9;2;Gave up;;; +64851-9;LL1256-8;PhenX11_18_reason not driving;LA14737-3;1;Mainly eyesight;;; +64851-9;LL1256-8;PhenX11_18_reason not driving;LA14738-1;2;Mainly other reasons;;; +64851-9;LL1256-8;PhenX11_18_reason not driving;LA14739-9;3;Both eyesight and other reasons;;; +64851-9;LL1256-8;PhenX11_18_reason not driving;LA14737-3;1;Mainly eyesight;;; +64851-9;LL1256-8;PhenX11_18_reason not driving;LA14738-1;2;Mainly other reasons;;; +64851-9;LL1256-8;PhenX11_18_reason not driving;LA14739-9;3;Both eyesight and other reasons;;; +64851-9;LL5647-4;Restriction cause (vision);LA31162-3;1;Mainly vision;;; +64851-9;LL5647-4;Restriction cause (vision);LA14738-1;2;Mainly other reasons;;; +64851-9;LL5647-4;Restriction cause (vision);LA31163-1;3;Both vision and other reasons;;; +64851-9;LL5647-4;Restriction cause (vision);LA31162-3;1;Mainly vision;;; +64851-9;LL5647-4;Restriction cause (vision);LA14738-1;2;Mainly other reasons;;; +64851-9;LL5647-4;Restriction cause (vision);LA31163-1;3;Both vision and other reasons;;; +64852-7;LL1255-0;PhenX11_17_ difficulty day driving;LA13948-7;1;No difficulty at all;;; +64852-7;LL1255-0;PhenX11_17_ difficulty day driving;LA15725-7;2;A little difficulty;;; +64852-7;LL1255-0;PhenX11_17_ difficulty day driving;LA15726-5;3;Moderate difficulty;;; +64852-7;LL1255-0;PhenX11_17_ difficulty day driving;LA15727-3;4;Extreme difficulty;;; +64852-7;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15227-4;1;No difficulty;;; +64852-7;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15725-7;2;A little difficulty;;; +64852-7;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA13950-3;3;Some difficulty;;; +64852-7;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15228-2;4;Much difficulty;;; +66058-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15227-4;1;No difficulty;;; +66058-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15725-7;2;A little difficulty;;; +66058-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA13950-3;3;Some difficulty;;; +66058-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15228-2;4;Much difficulty;;; +66082-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15227-4;1;No difficulty;;; +66082-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15725-7;2;A little difficulty;;; +66082-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA13950-3;3;Some difficulty;;; +66082-9;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15228-2;4;Much difficulty;;; +98893-1;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15227-4;1;No difficulty;;; +98893-1;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15725-7;2;A little difficulty;;; +98893-1;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA13950-3;3;Some difficulty;;; +98893-1;LL2069-4;No Diff | A little Diff | Some Diff | Much Diff;LA15228-2;4;Much difficulty;;; +64852-7;LL5648-2;Driving difficulty - day;LA13948-7;1;No difficulty at all;;; +64852-7;LL5648-2;Driving difficulty - day;LA15725-7;2;A little difficulty;;; +64852-7;LL5648-2;Driving difficulty - day;LA15726-5;3;Moderate difficulty;;; +64852-7;LL5648-2;Driving difficulty - day;LA13951-1;4;A lot of difficulty;;; +64852-7;LL5648-2;Driving difficulty - day;LA31164-9;5;Never drive during the daytime because of vision;;; +64852-7;LL5648-2;Driving difficulty - day;LA31165-6;6;Never drive during the daytime for other reasons;;; +64852-7;LL5648-2;Driving difficulty - day;LA13948-7;1;No difficulty at all;;; +64852-7;LL5648-2;Driving difficulty - day;LA15725-7;2;A little difficulty;;; +64852-7;LL5648-2;Driving difficulty - day;LA15726-5;3;Moderate difficulty;;; +64852-7;LL5648-2;Driving difficulty - day;LA13951-1;4;A lot of difficulty;;; +64852-7;LL5648-2;Driving difficulty - day;LA31164-9;5;Never drive during the daytime because of vision;;; +64852-7;LL5648-2;Driving difficulty - day;LA31165-6;6;Never drive during the daytime for other reasons;;; +64853-5;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +64853-5;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +64853-5;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +64853-5;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +64853-5;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +64853-5;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +64854-3;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +64854-3;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +64854-3;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +64854-3;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +64854-3;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +64854-3;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +64854-3;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +64854-3;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +64854-3;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +64854-3;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +64854-3;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +64854-3;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66055-5;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66055-5;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66055-5;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66055-5;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66055-5;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66055-5;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66056-3;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66056-3;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66056-3;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66056-3;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66056-3;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66056-3;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66057-1;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66057-1;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66057-1;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66057-1;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66057-1;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66057-1;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66058-9;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66058-9;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66058-9;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66058-9;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66058-9;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66058-9;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66059-7;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66059-7;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66059-7;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66059-7;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66059-7;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66059-7;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66060-5;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66060-5;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66060-5;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66060-5;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66060-5;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66060-5;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66077-9;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66077-9;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66077-9;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66077-9;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66077-9;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66077-9;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66078-7;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66078-7;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66078-7;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66078-7;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66078-7;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66078-7;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66079-5;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66079-5;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66079-5;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66079-5;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66079-5;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66079-5;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66080-3;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66080-3;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66080-3;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66080-3;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66080-3;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66080-3;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66081-1;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66081-1;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66081-1;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66081-1;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66081-1;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66081-1;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66082-9;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66082-9;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66082-9;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66082-9;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66082-9;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66082-9;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66083-7;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66083-7;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66083-7;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66083-7;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66083-7;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66083-7;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66084-5;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66084-5;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66084-5;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66084-5;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66084-5;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66084-5;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66085-2;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66085-2;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66085-2;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66085-2;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66085-2;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66085-2;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66086-0;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66086-0;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66086-0;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66086-0;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66086-0;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66086-0;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66087-8;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66087-8;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66087-8;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66087-8;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66087-8;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66087-8;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66338-5;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66338-5;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66338-5;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66338-5;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66338-5;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66338-5;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66339-3;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66339-3;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66339-3;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66339-3;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66339-3;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66339-3;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66340-1;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66340-1;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66340-1;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66340-1;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66340-1;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66340-1;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66341-9;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66341-9;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66341-9;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66341-9;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66341-9;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66341-9;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66342-7;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66342-7;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66342-7;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66342-7;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66342-7;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66342-7;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66343-5;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66343-5;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66343-5;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66343-5;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66343-5;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66343-5;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66344-3;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66344-3;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66344-3;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66344-3;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66344-3;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66344-3;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66345-0;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66345-0;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66345-0;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66345-0;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66345-0;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66345-0;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66346-8;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66346-8;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66346-8;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66346-8;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66346-8;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66346-8;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66347-6;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66347-6;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66347-6;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66347-6;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66347-6;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66347-6;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66348-4;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66348-4;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66348-4;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66348-4;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66348-4;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66348-4;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66349-2;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66349-2;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66349-2;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66349-2;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66349-2;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66349-2;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66350-0;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66350-0;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66350-0;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66350-0;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66350-0;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66350-0;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66351-8;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66351-8;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66351-8;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66351-8;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66351-8;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66351-8;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66352-6;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66352-6;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66352-6;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66352-6;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66352-6;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66352-6;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66353-4;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66353-4;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66353-4;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66353-4;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66353-4;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66353-4;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66354-2;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66354-2;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66354-2;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66354-2;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66354-2;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66354-2;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +66355-9;LL1253-5;PhenX11_15;LA13948-7;1;No difficulty at all;;; +66355-9;LL1253-5;PhenX11_15;LA15725-7;2;A little difficulty;;; +66355-9;LL1253-5;PhenX11_15;LA15726-5;3;Moderate difficulty;;; +66355-9;LL1253-5;PhenX11_15;LA15727-3;4;Extreme difficulty;;; +66355-9;LL1253-5;PhenX11_15;LA14735-7;5;Stopped doing this because of your eyesight;;; +66355-9;LL1253-5;PhenX11_15;LA14736-5;6;Stopped doing this for other reasons or not interested in doing this;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA13948-7;1;No difficulty at all;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA15725-7;2;A little difficulty;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA15726-5;3;Moderate difficulty;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA13951-1;4;A lot of difficulty;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA31168-0;5;Never drive in these conditions because of vision;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA31169-8;6;Never drive in these conditions for other reasons;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA13948-7;1;No difficulty at all;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA15725-7;2;A little difficulty;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA15726-5;3;Moderate difficulty;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA13951-1;4;A lot of difficulty;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA31168-0;5;Never drive in these conditions because of vision;;; +64854-3;LL5650-8;Driving difficulty - conditions;LA31169-8;6;Never drive in these conditions for other reasons;;; +64855-0;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +64855-0;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +64855-0;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +64855-0;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +64855-0;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +64856-8;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +64856-8;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +64856-8;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +64856-8;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +64856-8;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +64857-6;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +64857-6;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +64857-6;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +64857-6;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +64857-6;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65189-3;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65189-3;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65189-3;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65189-3;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65189-3;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65190-1;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65190-1;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65190-1;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65190-1;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65190-1;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65191-9;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65191-9;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65191-9;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65191-9;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65191-9;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65192-7;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65192-7;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65192-7;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65192-7;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65192-7;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65196-8;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65196-8;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65196-8;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65196-8;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65196-8;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65198-4;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65198-4;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65198-4;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65198-4;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65198-4;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65199-2;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65199-2;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65199-2;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65199-2;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65199-2;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65527-4;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65527-4;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65527-4;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65527-4;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65527-4;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +65528-2;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +65528-2;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +65528-2;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +65528-2;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +65528-2;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71903-9;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71903-9;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71903-9;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71903-9;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71903-9;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71904-7;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71904-7;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71904-7;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71904-7;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71904-7;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71905-4;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71905-4;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71905-4;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71905-4;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71905-4;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71906-2;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71906-2;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71906-2;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71906-2;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71906-2;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71907-0;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71907-0;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71907-0;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71907-0;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71907-0;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71908-8;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71908-8;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71908-8;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71908-8;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71908-8;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71909-6;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71909-6;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71909-6;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71909-6;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71909-6;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71910-4;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71910-4;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71910-4;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71910-4;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71910-4;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71911-2;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71911-2;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71911-2;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71911-2;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71911-2;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +71912-0;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +71912-0;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +71912-0;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +71912-0;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +71912-0;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +82669-3;LL1257-6;PhenX11_19;LA6154-4;1;All of the time;;; +82669-3;LL1257-6;PhenX11_19;LA14734-0;2;Most of the time;;; +82669-3;LL1257-6;PhenX11_19;LA14733-2;3;Some of the time;;; +82669-3;LL1257-6;PhenX11_19;LA14732-4;4;A little of the time;;; +82669-3;LL1257-6;PhenX11_19;LA6297-1;5;None of the time;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA16365-1;1;0 - bad as death;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA6112-2;2;1;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA6113-0;3;2;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA6114-8;4;3;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA6115-5;5;4;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA10137-0;6;5;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA10138-8;7;6;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA10139-6;8;7;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA10140-4;9;8;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA10141-2;10;9;;; +64858-4;LL1559-5;Phenx11_48_overall health;LA16366-9;11;10 - best possible health;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA16367-7;1;0 - as bad or worse than being blind;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA6112-2;2;1;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA6113-0;3;2;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA6114-8;4;3;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA6115-5;5;4;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA10137-0;6;5;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA10138-8;7;6;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA10139-6;8;7;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA10140-4;9;8;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA10141-2;10;9;;; +64859-2;LL1560-3;Phenx11_49_rate eyesight now;LA16368-5;11;10 - best possible eyesight;;; +64863-4;LL1259-2;PhenX11_21_contact lens type;LA14744-9;1;Soft;;; +64863-4;LL1259-2;PhenX11_21_contact lens type;LA14745-6;2;Hard;;; +64863-4;LL1259-2;PhenX11_21_contact lens type;LA14746-4;3;Gas permeable;;; +64863-4;LL1259-2;PhenX11_21_contact lens type;LA14748-0;4;Not known;;; +64864-2;LL1523-1;PhenX11_33_measurements;LA16260-4;1;Measurement 1;;; +64864-2;LL1523-1;PhenX11_33_measurements;LA16261-2;2;Measurement 2;;; +64864-2;LL1523-1;PhenX11_33_measurements;LA16262-0;3;Measurement 3;;; +64864-2;LL1523-1;PhenX11_33_measurements;LA16263-8;4;Measurement 4;;; +64869-1;LL1546-2;Phenx11_45_cities;LA16326-3;1;City at age 18;;; +64869-1;LL1546-2;Phenx11_45_cities;LA16327-1;2;City 2;;; +64869-1;LL1546-2;Phenx11_45_cities;LA16328-9;3;City 3;;; +64870-9;LL1545-4;Phenx11_44_sleep w/ contacts in;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64870-9;LL1545-4;Phenx11_44_sleep w/ contacts in;LA10082-8;2;Sometimes;;; +64870-9;LL1545-4;Phenx11_44_sleep w/ contacts in;LA14747-2;3;Usually;;; +64871-7;LL1260-0;PhenX11_22_child glasses, contacts;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +64871-7;LL1260-0;PhenX11_22_child glasses, contacts;LA14749-8;2;Glasses;;; +64871-7;LL1260-0;PhenX11_22_child glasses, contacts;LA14750-6;3;Contact lenses;;; +64872-5;LL1261-8;PhenX11_23;LA14726-6;1;All the time;;; +64872-5;LL1261-8;PhenX11_23;LA14734-0;2;Most of the time;;; +64872-5;LL1261-8;PhenX11_23;LA10082-8;3;Sometimes;;; +64872-5;LL1261-8;PhenX11_23;LA14751-4;4;Hardly ever;;; +64872-5;LL1261-8;PhenX11_23;LA14752-2;5;Only when eyes feel tired;;; +64883-2;LL1261-8;PhenX11_23;LA14726-6;1;All the time;;; +64883-2;LL1261-8;PhenX11_23;LA14734-0;2;Most of the time;;; +64883-2;LL1261-8;PhenX11_23;LA10082-8;3;Sometimes;;; +64883-2;LL1261-8;PhenX11_23;LA14751-4;4;Hardly ever;;; +64883-2;LL1261-8;PhenX11_23;LA14752-2;5;Only when eyes feel tired;;; +64885-7;LL1262-6;PhenX11_24_glasses type;LA14753-0;1;Single vision distance glasses only;;; +64885-7;LL1262-6;PhenX11_24_glasses type;LA14754-8;2;Single vision reading glasses only;;; +64885-7;LL1262-6;PhenX11_24_glasses type;LA14755-5;3;Separate reading and distance glasses;;; +64885-7;LL1262-6;PhenX11_24_glasses type;LA14756-3;4;Bifocals;;; +64885-7;LL1262-6;PhenX11_24_glasses type;LA14757-1;5;Multifocals;;; +64885-7;LL1262-6;PhenX11_24_glasses type;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +64885-7;LL1262-6;PhenX11_24_glasses type;LA14698-7;7;Missing;;; +64893-1;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64893-1;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64893-1;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64894-9;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64894-9;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64894-9;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64895-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64895-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64895-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64896-4;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64896-4;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64896-4;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64897-2;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64897-2;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64897-2;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64898-0;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64898-0;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64898-0;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64899-8;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64899-8;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64899-8;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64900-4;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64900-4;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64900-4;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64901-2;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64901-2;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64901-2;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64902-0;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64902-0;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64902-0;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64903-8;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64903-8;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64903-8;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64904-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64904-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64904-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64905-3;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64905-3;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64905-3;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64906-1;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64906-1;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64906-1;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64907-9;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64907-9;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64907-9;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64908-7;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64908-7;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64908-7;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64909-5;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64909-5;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64909-5;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64910-3;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64910-3;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64910-3;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64911-1;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64911-1;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64911-1;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64912-9;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64912-9;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64912-9;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64913-7;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64913-7;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64913-7;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64914-5;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64914-5;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64914-5;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64915-2;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64915-2;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64915-2;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64916-0;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64916-0;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64916-0;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64917-8;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64917-8;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64917-8;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64918-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64918-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64918-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64919-4;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64919-4;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64919-4;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64920-2;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64920-2;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64920-2;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64921-0;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64921-0;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64921-0;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64922-8;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64922-8;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64922-8;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64923-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64923-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64923-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64924-4;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64924-4;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64924-4;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64925-1;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64925-1;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64925-1;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64926-9;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64926-9;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64926-9;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64927-7;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64927-7;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64927-7;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64928-5;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64928-5;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64928-5;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64929-3;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64929-3;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64929-3;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64930-1;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64930-1;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64930-1;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64931-9;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64931-9;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64931-9;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64932-7;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64932-7;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64932-7;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64933-5;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64933-5;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64933-5;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64934-3;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64934-3;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64934-3;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64935-0;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64935-0;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64935-0;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64936-8;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64936-8;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64936-8;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64937-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64937-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64937-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64938-4;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64938-4;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64938-4;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64939-2;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64939-2;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64939-2;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64940-0;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64940-0;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64940-0;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64941-8;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64941-8;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64941-8;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64942-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64942-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64942-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64943-4;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64943-4;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64943-4;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64944-2;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64944-2;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64944-2;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64945-9;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64945-9;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64945-9;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64947-5;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64947-5;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64947-5;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64948-3;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64948-3;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64948-3;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64949-1;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64949-1;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64949-1;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64950-9;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64950-9;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64950-9;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64951-7;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64951-7;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64951-7;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64952-5;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64952-5;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64952-5;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64953-3;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64953-3;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64953-3;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64954-1;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64954-1;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64954-1;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64955-8;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64955-8;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64955-8;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64956-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64956-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64956-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64957-4;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64957-4;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64957-4;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64958-2;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +64958-2;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +64958-2;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +65885-6;LL1269-1;PhenX12_01;LA13866-1;1;Almost never;;; +65885-6;LL1269-1;PhenX12_01;LA10082-8;2;Sometimes;;; +65885-6;LL1269-1;PhenX12_01;LA10044-8;3;Often;;; +64987-1;LL1186-7;PhenX09_25_race/ethnicity;LA14509-6;1;American Indian;;; +64987-1;LL1186-7;PhenX09_25_race/ethnicity;LA14510-4;2;Asian-American;;; +64987-1;LL1186-7;PhenX09_25_race/ethnicity;LA14511-2;3;African-American;;; +64987-1;LL1186-7;PhenX09_25_race/ethnicity;LA7-7;4;Hispanic;;; +64987-1;LL1186-7;PhenX09_25_race/ethnicity;LA14512-0;5;White/Not Hispanic;;; +64987-1;LL1186-7;PhenX09_25_race/ethnicity;LA14513-8;6;Other or unknown;;; +64994-7;LL1532-2;VFC;LA16277-8;1;Not VFC eligible;;; +64994-7;LL1532-2;VFC;LA16278-6;2;VFC eligible-Medicaid/Medicaid Managed Care;;; +64994-7;LL1532-2;VFC;LA16279-4;3;VFC eligible- Uninsured;;; +64994-7;LL1532-2;VFC;LA16280-2;4;VFC eligible- American Indian/Alaskan Native;;; +64994-7;LL1532-2;VFC;LA16281-0;5;VFC eligible-Federally Qualified Health Center Patient (under-insured);;; +64994-7;LL1532-2;VFC;LA16282-8;6;VFC eligible- State specific eligibility (e.g. S-CHIP plan);;; +64994-7;LL1532-2;VFC;LA16283-6;7;VFC eligibility- Local-specific eligibility;;; +64994-7;LL1532-2;VFC;LA16284-4;8;Discontinued. Do not use this code.;;; +65001-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65001-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65001-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65001-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65002-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65002-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65002-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65002-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65003-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65003-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65003-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65003-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65004-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65004-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65004-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65004-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65005-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65005-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65005-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65005-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65006-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65006-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65006-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65006-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65007-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65007-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65007-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65007-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65008-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65008-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65008-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65008-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65009-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65009-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65009-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65009-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65010-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65010-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65010-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65010-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65011-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65011-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65011-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65011-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65012-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65012-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65012-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65012-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65013-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65013-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65013-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65013-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65014-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65014-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65014-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65014-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65015-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65015-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65015-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65015-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65016-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65016-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65016-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65016-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65017-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65017-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65017-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65017-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65018-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65018-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65018-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65018-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65019-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65019-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65019-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65019-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65020-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65020-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65020-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65020-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65021-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65021-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65021-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65021-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65022-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65022-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65022-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65022-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65023-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65023-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65023-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65023-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65024-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65024-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65024-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65024-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65025-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65025-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65025-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65025-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65026-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65026-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65026-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65026-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65027-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65027-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65027-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65027-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65028-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65028-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65028-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65028-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65029-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65029-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65029-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65029-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65030-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65030-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65030-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65030-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65031-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65031-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65031-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65031-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65032-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65032-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65032-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65032-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65033-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65033-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65033-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65033-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65034-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65034-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65034-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65034-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65035-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65035-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65035-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65035-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65036-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65036-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65036-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65036-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65037-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65037-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65037-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65037-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65038-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65038-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65038-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65038-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65039-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65039-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65039-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65039-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65040-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65040-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65040-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65040-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65041-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65041-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65041-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65041-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65042-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65042-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65042-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65042-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65043-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65043-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65043-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65043-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65044-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65044-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65044-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65044-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65045-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65045-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65045-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65045-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65046-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65046-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65046-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65046-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65047-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65047-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65047-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65047-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65048-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65048-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65048-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65048-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65049-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65049-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65049-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65049-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65050-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65050-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65050-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65050-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65051-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65051-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65051-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65051-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65052-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65052-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65052-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65052-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65053-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65053-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65053-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65053-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65054-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65054-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65054-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65054-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65055-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65055-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65055-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65055-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65056-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65056-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65056-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65056-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65057-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65057-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65057-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65057-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65058-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65058-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65058-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65058-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65059-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65059-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65059-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65059-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65060-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65060-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65060-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65060-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65061-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65061-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65061-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65061-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65062-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65062-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65062-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65062-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65063-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65063-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65063-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65063-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65064-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65064-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65064-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65064-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65065-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65065-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65065-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65065-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65066-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65066-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65066-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65066-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65067-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65067-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65067-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65067-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65068-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65068-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65068-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65068-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65069-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65069-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65069-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65069-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65070-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65070-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65070-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65070-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65071-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65071-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65071-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65071-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65072-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65072-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65072-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65072-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65073-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65073-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65073-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65073-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65074-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65074-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65074-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65074-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65075-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65075-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65075-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65075-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65076-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65076-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65076-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65076-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65077-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65077-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65077-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65077-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65078-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65078-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65078-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65078-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65079-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65079-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65079-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65079-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65080-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65080-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65080-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65080-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65081-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65081-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65081-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65081-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65082-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65082-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65082-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65082-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65083-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65083-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65083-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65083-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65084-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65084-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65084-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65084-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65085-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65085-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65085-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65085-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65086-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65086-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65086-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65086-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65087-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65087-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65087-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65087-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65088-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65088-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65088-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65088-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65089-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65089-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65089-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65089-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65090-3;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65090-3;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65090-3;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65090-3;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65091-1;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65091-1;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65091-1;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65091-1;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65092-9;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65092-9;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65092-9;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65092-9;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65093-7;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65093-7;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65093-7;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65093-7;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65094-5;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65094-5;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65094-5;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65094-5;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65095-2;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65095-2;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65095-2;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65095-2;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65096-0;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65096-0;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65096-0;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65096-0;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65097-8;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65097-8;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65097-8;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65097-8;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65098-6;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65098-6;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65098-6;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65098-6;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65099-4;LL1336-8;PhenX12_66;LA14941-1;1;Definitely agree;;; +65099-4;LL1336-8;PhenX12_66;LA14942-9;2;Slightly agree;;; +65099-4;LL1336-8;PhenX12_66;LA14943-7;3;Slightly disagree;;; +65099-4;LL1336-8;PhenX12_66;LA14944-5;4;Definitely disagree;;; +65145-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65145-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65145-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65145-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65145-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65146-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65146-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65146-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65146-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65146-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65147-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65147-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65147-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65147-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65147-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65148-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65148-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65148-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65148-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65148-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65149-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65149-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65149-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65149-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65149-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65150-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65150-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65150-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65150-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65150-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65151-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65151-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65151-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65151-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65151-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65152-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65152-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65152-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65152-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65152-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65153-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65153-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65153-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65153-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65153-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65154-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65154-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65154-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65154-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65154-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65155-4;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65155-4;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65155-4;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65155-4;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65155-4;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65156-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65156-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65156-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65156-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65156-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65157-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65157-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65157-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65157-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65157-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65158-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65158-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65158-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65158-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65158-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65159-6;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65159-6;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65159-6;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65159-6;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65159-6;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65160-4;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65160-4;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65160-4;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65160-4;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65160-4;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65161-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65161-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65161-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65161-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65161-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65162-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65162-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65162-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65162-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65162-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65163-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65163-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65163-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65163-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65163-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65164-6;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65164-6;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65164-6;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65164-6;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65164-6;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65165-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65165-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65165-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65165-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65165-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65166-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65166-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65166-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65166-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65166-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65167-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65167-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65167-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65167-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65167-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65168-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65168-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65168-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65168-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65168-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65169-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65169-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65169-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65169-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65169-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65170-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65170-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65170-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65170-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65170-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65171-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65171-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65171-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65171-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65171-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65172-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65172-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65172-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65172-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65172-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65173-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65173-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65173-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65173-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65173-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65174-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65174-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65174-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65174-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65174-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65175-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65175-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65175-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65175-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65175-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65176-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65176-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65176-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65176-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65176-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65177-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65177-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65177-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65177-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65177-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65178-6;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65178-6;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65178-6;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65178-6;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65178-6;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65179-4;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65179-4;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65179-4;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65179-4;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65179-4;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65180-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65180-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65180-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65180-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65180-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65181-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65181-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65181-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65181-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65181-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65182-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65182-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65182-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65182-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65182-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65183-6;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65183-6;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65183-6;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65183-6;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65183-6;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65184-4;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65184-4;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65184-4;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65184-4;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65184-4;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65185-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65185-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65185-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65185-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65185-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65186-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65186-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65186-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65186-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65186-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65187-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65187-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65187-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65187-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65187-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65188-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +65188-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +65188-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +65188-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +65188-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67614-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67614-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67614-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67614-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67614-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67615-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67615-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67615-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67615-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67615-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67616-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67616-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67616-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67616-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67616-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67617-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67617-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67617-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67617-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67617-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67618-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67618-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67618-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67618-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67618-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67619-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67619-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67619-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67619-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67619-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67620-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67620-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67620-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67620-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67620-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67621-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67621-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67621-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67621-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67621-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67622-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67622-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67622-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67622-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67622-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67623-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67623-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67623-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67623-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67623-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67624-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67624-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67624-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67624-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67624-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67625-4;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67625-4;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67625-4;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67625-4;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67625-4;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67626-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67626-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67626-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67626-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67626-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67627-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67627-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67627-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67627-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67627-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67628-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67628-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67628-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67628-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67628-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67629-6;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67629-6;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67629-6;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67629-6;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67629-6;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67630-4;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67630-4;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67630-4;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67630-4;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67630-4;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67631-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67631-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67631-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67631-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67631-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67632-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67632-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67632-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67632-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67632-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67633-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67633-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67633-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67633-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67633-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67634-6;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67634-6;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67634-6;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67634-6;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67634-6;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67635-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67635-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67635-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67635-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67635-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67636-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67636-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67636-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67636-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67636-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67637-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67637-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67637-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67637-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67637-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67638-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67638-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67638-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67638-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67638-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67639-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67639-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67639-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67639-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67639-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67640-3;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67640-3;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67640-3;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67640-3;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67640-3;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67641-1;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67641-1;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67641-1;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67641-1;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67641-1;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67642-9;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67642-9;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67642-9;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67642-9;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67642-9;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67643-7;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67643-7;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67643-7;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67643-7;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67643-7;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67644-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67644-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67644-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67644-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67644-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67645-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67645-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67645-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67645-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67645-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67646-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67646-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67646-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67646-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67646-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67647-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67647-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67647-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67647-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67647-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67648-6;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67648-6;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67648-6;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67648-6;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67648-6;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67649-4;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67649-4;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67649-4;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67649-4;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67649-4;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67650-2;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67650-2;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67650-2;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67650-2;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67650-2;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67651-0;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67651-0;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67651-0;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67651-0;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67651-0;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +67652-8;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +67652-8;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +67652-8;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +67652-8;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +67652-8;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +75413-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +75413-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +75413-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +75413-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +75413-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +75903-5;LL1352-5;PhenX12_82;LA15236-5;1;Strongly disagree;;; +75903-5;LL1352-5;PhenX12_82;LA15773-7;2;Disagree;;; +75903-5;LL1352-5;PhenX12_82;LA15240-7;3;Neither agree nor disagree;;; +75903-5;LL1352-5;PhenX12_82;LA15774-5;4;Agree;;; +75903-5;LL1352-5;PhenX12_82;LA15237-3;5;Strongly agree;;; +65193-5;LL1558-7;PhenX12_92_feelings freq past 30D;LA14978-3;1;A lot (more often than usual);;; +65193-5;LL1558-7;PhenX12_92_feelings freq past 30D;LA14979-1;2;Some (more often than usual);;; +65193-5;LL1558-7;PhenX12_92_feelings freq past 30D;LA14980-9;3;A little (more often than usual);;; +65193-5;LL1558-7;PhenX12_92_feelings freq past 30D;LA14981-7;4;About the same as usual;;; +65193-5;LL1558-7;PhenX12_92_feelings freq past 30D;LA14982-5;5;A little (less often than usual);;; +65193-5;LL1558-7;PhenX12_92_feelings freq past 30D;LA14983-3;6;Some (less often than usual);;; +65193-5;LL1558-7;PhenX12_92_feelings freq past 30D;LA14984-1;7;A lot (less often than usual);;; +65200-8;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65200-8;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65200-8;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65202-4;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65202-4;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65202-4;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65204-0;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65204-0;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65204-0;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65205-7;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65205-7;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65205-7;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65206-5;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65206-5;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65206-5;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65207-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65207-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65207-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65208-1;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65208-1;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65208-1;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65209-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65209-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65209-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65210-7;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65210-7;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65210-7;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65211-5;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65211-5;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65211-5;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65212-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65212-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65212-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65213-1;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65213-1;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65213-1;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65214-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65214-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65214-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65215-6;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65215-6;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65215-6;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65216-4;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65216-4;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65216-4;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65217-2;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65217-2;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65217-2;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65218-0;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65218-0;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65218-0;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65219-8;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65219-8;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65219-8;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65547-2;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65547-2;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65547-2;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65571-2;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65571-2;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65571-2;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65575-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65575-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65575-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65582-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65582-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65582-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65585-2;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65585-2;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65585-2;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65586-0;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65586-0;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65586-0;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65587-8;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65587-8;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65587-8;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65589-4;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65589-4;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65589-4;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65590-2;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65590-2;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65590-2;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65594-4;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65594-4;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65594-4;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65595-1;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65595-1;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65595-1;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65596-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65596-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65596-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65597-7;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65597-7;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65597-7;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65598-5;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65598-5;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65598-5;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65599-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65599-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65599-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65600-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65600-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65600-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65601-7;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65601-7;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65601-7;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65602-5;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65602-5;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65602-5;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65603-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65603-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65603-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65604-1;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65604-1;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65604-1;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65605-8;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65605-8;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65605-8;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65606-6;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65606-6;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65606-6;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65607-4;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65607-4;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65607-4;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65611-6;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65611-6;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65611-6;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65613-2;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65613-2;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65613-2;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65617-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65617-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65617-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65619-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65619-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65619-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65622-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65622-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65622-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65623-1;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65623-1;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65623-1;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65624-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65624-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65624-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65625-6;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65625-6;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65625-6;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65627-2;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65627-2;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65627-2;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65628-0;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65628-0;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65628-0;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65629-8;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65629-8;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65629-8;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65683-5;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65683-5;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65683-5;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65684-3;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65684-3;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65684-3;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65686-8;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65686-8;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65686-8;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67166-9;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67166-9;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67166-9;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67172-7;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67172-7;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67172-7;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67182-6;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67182-6;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67182-6;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67186-7;LL1557-9;PhenX10_61;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67186-7;LL1557-9;PhenX10_61;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67186-7;LL1557-9;PhenX10_61;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65224-8;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65224-8;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65224-8;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65224-8;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65224-8;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65225-5;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65225-5;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65225-5;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65225-5;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65225-5;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65226-3;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65226-3;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65226-3;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65226-3;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65226-3;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65227-1;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65227-1;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65227-1;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65227-1;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65227-1;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65228-9;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65228-9;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65228-9;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65228-9;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65228-9;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65229-7;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65229-7;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65229-7;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65229-7;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65229-7;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65230-5;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65230-5;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65230-5;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65230-5;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65230-5;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65231-3;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65231-3;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65231-3;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65231-3;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65231-3;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65232-1;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65232-1;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65232-1;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65232-1;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65232-1;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65233-9;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65233-9;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65233-9;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65233-9;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65233-9;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65234-7;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65234-7;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65234-7;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65234-7;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65234-7;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65235-4;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65235-4;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65235-4;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65235-4;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65235-4;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65236-2;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65236-2;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65236-2;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65236-2;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65236-2;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65237-0;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65237-0;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65237-0;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65237-0;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65237-0;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65238-8;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65238-8;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65238-8;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65238-8;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65238-8;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65239-6;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65239-6;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65239-6;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65239-6;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65239-6;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65240-4;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65240-4;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65240-4;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65240-4;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65240-4;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65241-2;LL1364-0;PhenX12_85;LA6270-8;1;Never;;; +65241-2;LL1364-0;PhenX12_85;LA10066-1;2;Rarely;;; +65241-2;LL1364-0;PhenX12_85;LA10082-8;3;Sometimes;;; +65241-2;LL1364-0;PhenX12_85;LA10044-8;4;Often;;; +65241-2;LL1364-0;PhenX12_85;LA14985-8;5;Very often;;; +65242-0;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65242-0;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65242-0;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65242-0;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65242-0;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65242-0;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65243-8;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65243-8;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65243-8;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65243-8;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65243-8;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65243-8;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65244-6;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65244-6;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65244-6;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65244-6;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65244-6;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65244-6;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65245-3;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65245-3;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65245-3;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65245-3;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65245-3;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65245-3;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65246-1;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65246-1;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65246-1;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65246-1;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65246-1;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65246-1;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65247-9;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65247-9;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65247-9;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65247-9;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65247-9;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65247-9;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65248-7;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65248-7;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65248-7;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65248-7;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65248-7;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65248-7;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65249-5;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65249-5;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65249-5;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65249-5;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65249-5;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65249-5;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65250-3;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65250-3;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65250-3;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65250-3;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65250-3;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65250-3;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65251-1;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65251-1;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65251-1;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65251-1;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65251-1;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65251-1;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65252-9;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65252-9;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65252-9;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65252-9;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65252-9;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65252-9;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65253-7;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65253-7;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65253-7;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65253-7;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65253-7;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65253-7;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65254-5;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65254-5;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65254-5;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65254-5;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65254-5;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65254-5;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65255-2;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65255-2;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65255-2;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65255-2;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65255-2;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65255-2;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65256-0;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65256-0;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65256-0;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65256-0;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65256-0;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65256-0;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65257-8;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65257-8;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65257-8;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65257-8;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65257-8;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65257-8;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65258-6;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65258-6;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65258-6;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65258-6;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65258-6;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65258-6;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65259-4;LL1363-2;PhenX12_84;LA14987-4;1;Below;;; +65259-4;LL1363-2;PhenX12_84;LA14988-2;2;Slightly below;;; +65259-4;LL1363-2;PhenX12_84;LA14989-0;3;Average;;; +65259-4;LL1363-2;PhenX12_84;LA14990-8;4;Slightly above;;; +65259-4;LL1363-2;PhenX12_84;LA14991-6;5;Above;;; +65259-4;LL1363-2;PhenX12_84;LA14992-4;6;Far above;;; +65260-2;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65260-2;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65260-2;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65260-2;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65261-0;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65261-0;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65261-0;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65261-0;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65262-8;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65262-8;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65262-8;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65262-8;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65263-6;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65263-6;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65263-6;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65263-6;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65264-4;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65264-4;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65264-4;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65264-4;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65265-1;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65265-1;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65265-1;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65265-1;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65266-9;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65266-9;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65266-9;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65266-9;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65267-7;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65267-7;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65267-7;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65267-7;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65268-5;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65268-5;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65268-5;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65268-5;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65269-3;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65269-3;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65269-3;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65269-3;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65270-1;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65270-1;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65270-1;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65270-1;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65271-9;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65271-9;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65271-9;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65271-9;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65272-7;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65272-7;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65272-7;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65272-7;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65273-5;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65273-5;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65273-5;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65273-5;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65274-3;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65274-3;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65274-3;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65274-3;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65275-0;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65275-0;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65275-0;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65275-0;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65276-8;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65276-8;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65276-8;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65276-8;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65277-6;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65277-6;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65277-6;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65277-6;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65278-4;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65278-4;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65278-4;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65278-4;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65279-2;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65279-2;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65279-2;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65279-2;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65280-0;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65280-0;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65280-0;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65280-0;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65281-8;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65281-8;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65281-8;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65281-8;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65282-6;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65282-6;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65282-6;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65282-6;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65283-4;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65283-4;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65283-4;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65283-4;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65284-2;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65284-2;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65284-2;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65284-2;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65285-9;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65285-9;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65285-9;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65285-9;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65286-7;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65286-7;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65286-7;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65286-7;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65287-5;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65287-5;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65287-5;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65287-5;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65288-3;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65288-3;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65288-3;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65288-3;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65289-1;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65289-1;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65289-1;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65289-1;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65290-9;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65290-9;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65290-9;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65290-9;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65291-7;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65291-7;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65291-7;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65291-7;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65292-5;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65292-5;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65292-5;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65292-5;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65293-3;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65293-3;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65293-3;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65293-3;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65294-1;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65294-1;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65294-1;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65294-1;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65295-8;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65295-8;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65295-8;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65295-8;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65296-6;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65296-6;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65296-6;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65296-6;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65297-4;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65297-4;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65297-4;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65297-4;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65298-2;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65298-2;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65298-2;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65298-2;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65299-0;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65299-0;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65299-0;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65299-0;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65300-6;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65300-6;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65300-6;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65300-6;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65301-4;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65301-4;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65301-4;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65301-4;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65302-2;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65302-2;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65302-2;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65302-2;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65303-0;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65303-0;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65303-0;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65303-0;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65304-8;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65304-8;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65304-8;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65304-8;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65305-5;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65305-5;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65305-5;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65305-5;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65306-3;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65306-3;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65306-3;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65306-3;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65307-1;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65307-1;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65307-1;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65307-1;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65308-9;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65308-9;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65308-9;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65308-9;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65309-7;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65309-7;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65309-7;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65309-7;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65310-5;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65310-5;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65310-5;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65310-5;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65311-3;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65311-3;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65311-3;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65311-3;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65312-1;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65312-1;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65312-1;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65312-1;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65313-9;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65313-9;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65313-9;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65313-9;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65314-7;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65314-7;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65314-7;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65314-7;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65315-4;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65315-4;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65315-4;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65315-4;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65316-2;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65316-2;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65316-2;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65316-2;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65317-0;LL1365-7;PhenX12_86;LA14495-8;1;True;;; +65317-0;LL1365-7;PhenX12_86;LA14993-2;2;Somewhat true;;; +65317-0;LL1365-7;PhenX12_86;LA14994-0;3;Somewhat false;;; +65317-0;LL1365-7;PhenX12_86;LA14496-6;4;False;;; +65365-9;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65365-9;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65365-9;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65365-9;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65366-7;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65366-7;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65366-7;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65366-7;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65367-5;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65367-5;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65367-5;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65367-5;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65368-3;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65368-3;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65368-3;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65368-3;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65369-1;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65369-1;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65369-1;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65369-1;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65370-9;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65370-9;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65370-9;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65370-9;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65371-7;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65371-7;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65371-7;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65371-7;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65372-5;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65372-5;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65372-5;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65372-5;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65373-3;LL1391-3;PhenX13_26;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65373-3;LL1391-3;PhenX13_26;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +65373-3;LL1391-3;PhenX13_26;LA15097-1;3;Possible;;; +65373-3;LL1391-3;PhenX13_26;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65375-8;LL1392-1;PhenX13_27_headache complications;LA15098-9;1;Nausea;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15099-7;2;Vomiting;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15100-3;3;One side of head only;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15101-1;4;Pulsating/throbbing headaches;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15102-9;5;Pain-free intervals of days or weeks between severe headache attacks;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15103-7;6;Sensitivity to light;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15104-5;7;Sensitivity to noise;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15105-2;8;Blurring of vision;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15106-0;9;Seeing shimmering lights, circles, other shapes, or colors before the eyes, before the headache starts;;; +65375-8;LL1392-1;PhenX13_27_headache complications;LA15107-8;10;Numbness of lips, tongue, fingers, or legs before the headache starts;;; +65377-4;LL1393-9;PhenX13_28_headache pain;LA15108-6;1;Extremely severe pain;;; +65377-4;LL1393-9;PhenX13_28_headache pain;LA15109-4;2;Severe pain;;; +65377-4;LL1393-9;PhenX13_28_headache pain;LA15110-2;3;Moderately severe pain;;; +65377-4;LL1393-9;PhenX13_28_headache pain;LA15111-0;4;Mild pain;;; +65378-2;LL1394-7;PhenX13_29_headache affects;LA15112-8;1;Able to work/function normally;;; +65378-2;LL1394-7;PhenX13_29_headache affects;LA15113-6;2;Working ability or activity impaired to some degree;;; +65378-2;LL1394-7;PhenX13_29_headache affects;LA15114-4;3;Working ability or activity severely impaired;;; +65378-2;LL1394-7;PhenX13_29_headache affects;LA15115-1;4;Bed rest required;;; +65379-0;LL1395-4;PhenX13_30_inability to work amt;LA15116-9;1;0 days (no activity restriction);;; +65379-0;LL1395-4;PhenX13_30_inability to work amt;LA15117-7;2;Less than 1 day;;; +65379-0;LL1395-4;PhenX13_30_inability to work amt;LA15118-5;3;1-2 days;;; +65379-0;LL1395-4;PhenX13_30_inability to work amt;LA15119-3;4;3-5 days;;; +65379-0;LL1395-4;PhenX13_30_inability to work amt;LA15120-1;5;6 or more days;;; +65388-1;LL1396-2;PhenX13_31_usual headache treatment;LA15121-9;1;Take non-prescription medications;;; +65388-1;LL1396-2;PhenX13_31_usual headache treatment;LA15122-7;2;Take prescription medications;;; +65388-1;LL1396-2;PhenX13_31_usual headache treatment;LA15123-5;3;Take both prescription and non-prescription medications;;; +65388-1;LL1396-2;PhenX13_31_usual headache treatment;LA15124-3;4;Take no medications;;; +65390-7;LL1397-0;PhenX13_32_other daily meds;LA15125-0;1;Water pill or prescription diuretic for high blood pressure;;; +65390-7;LL1397-0;PhenX13_32_other daily meds;LA15126-8;2;Prescription medicine (other than water pill) for high blood pressure;;; +65390-7;LL1397-0;PhenX13_32_other daily meds;LA15127-6;3;Prescription medicine for seizures, epilepsy, or fits;;; +65390-7;LL1397-0;PhenX13_32_other daily meds;LA15128-4;4;Prescription medicine for diabetes;;; +65390-7;LL1397-0;PhenX13_32_other daily meds;LA15130-0;5;Prescription medicine for depression or anxiety;;; +65391-5;LL1398-8;PhenX13_33_last took med range;LA15131-8;1;Currently taking;;; +65391-5;LL1398-8;PhenX13_33_last took med range;LA15132-6;2;Last took within the past 3 months;;; +65391-5;LL1398-8;PhenX13_33_last took med range;LA15133-4;3;Last took 3 to 12 months ago;;; +65391-5;LL1398-8;PhenX13_33_last took med range;LA15134-2;4;Last took more than 12 months ago;;; +65391-5;LL1398-8;PhenX13_33_last took med range;LA15135-9;5;Never took;;; +65393-1;LL1399-6;PhenX13_34_headache type;LA15136-7;1;Tension headaches;;; +65393-1;LL1399-6;PhenX13_34_headache type;LA15137-5;2;Sinus headaches;;; +65393-1;LL1399-6;PhenX13_34_headache type;LA15138-3;3;Cluster headaches;;; +65393-1;LL1399-6;PhenX13_34_headache type;LA15139-1;4;Stress headaches;;; +65393-1;LL1399-6;PhenX13_34_headache type;LA15140-9;5;"""Sick"" headaches";;; +65393-1;LL1399-6;PhenX13_34_headache type;LA15141-7;6;Migraine headaches;;; +65407-9;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65407-9;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65407-9;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65407-9;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65408-7;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65408-7;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65408-7;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65408-7;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65409-5;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65409-5;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65409-5;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65409-5;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65410-3;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65410-3;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65410-3;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65410-3;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65411-1;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65411-1;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65411-1;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65411-1;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65412-9;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65412-9;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65412-9;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65412-9;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65414-5;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65414-5;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65414-5;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65414-5;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65415-2;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65415-2;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65415-2;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65415-2;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65416-0;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65416-0;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65416-0;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65416-0;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65417-8;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65417-8;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65417-8;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65417-8;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65418-6;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65418-6;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65418-6;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65418-6;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65419-4;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65419-4;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65419-4;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65419-4;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65420-2;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65420-2;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65420-2;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65420-2;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65421-0;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65421-0;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65421-0;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65421-0;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65423-6;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65423-6;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65423-6;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65423-6;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65637-1;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65637-1;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65637-1;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65637-1;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65638-9;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65638-9;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65638-9;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65638-9;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65639-7;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65639-7;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65639-7;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65639-7;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65640-5;LL1402-8;PhenX13_37;LA15152-4;1;No visible tremor;;; +65640-5;LL1402-8;PhenX13_37;LA15153-2;2;Low-amplitude/barely perceivable tremor or intermittent tremor;;; +65640-5;LL1402-8;PhenX13_37;LA15154-0;3;"Tremor is of moderate amplitude (1-2 cm) and usually present; it is clearly oscillatory";;; +65640-5;LL1402-8;PhenX13_37;LA15155-7;4;Large-amplitude (>2 cm), violent, jerky tremor resulting in difficulty completing the task due to spilling or inability to hold a pen to paper;;; +65448-3;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65448-3;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65448-3;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65448-3;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65449-1;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65449-1;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65449-1;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65449-1;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65450-9;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65450-9;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65450-9;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65450-9;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65451-7;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65451-7;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65451-7;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65451-7;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65452-5;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65452-5;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65452-5;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65452-5;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65453-3;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65453-3;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65453-3;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65453-3;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65454-1;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65454-1;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65454-1;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65454-1;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65455-8;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65455-8;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65455-8;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65455-8;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65456-6;LL1274-1;PhenX12_06;LA14770-4;1;Never or hardly ever;;; +65456-6;LL1274-1;PhenX12_06;LA10082-8;2;Sometimes;;; +65456-6;LL1274-1;PhenX12_06;LA10044-8;3;Often;;; +65456-6;LL1274-1;PhenX12_06;LA14771-2;4;Very often, almost constantly;;; +65457-4;LL1275-8;PhenX12_07_ mania feeling today;LA14772-0;1;Much worse than usual;;; +65457-4;LL1275-8;PhenX12_07_ mania feeling today;LA14773-8;2;Worse than usual;;; +65457-4;LL1275-8;PhenX12_07_ mania feeling today;LA14774-6;3;A little worse than usual;;; +65457-4;LL1275-8;PhenX12_07_ mania feeling today;LA14775-3;4;Neither better nor worse than usual;;; +65457-4;LL1275-8;PhenX12_07_ mania feeling today;LA14776-1;5;A little better than usual;;; +65457-4;LL1275-8;PhenX12_07_ mania feeling today;LA14777-9;6;Better than usual;;; +65457-4;LL1275-8;PhenX12_07_ mania feeling today;LA14778-7;7;Much better than usual;;; +65458-2;LL1276-6;PhenX12_08_mania compared to others;LA14779-5;1;Is always rather stable and even;;; +65458-2;LL1276-6;PhenX12_08_mania compared to others;LA14780-3;2;Is generally higher;;; +65458-2;LL1276-6;PhenX12_08_mania compared to others;LA14781-1;3;Is generally lower;;; +65458-2;LL1276-6;PhenX12_08_mania compared to others;LA14782-9;4;Repeatedly shows periods of ups and downs;;; +65459-0;LL1278-2;PhenX12_10_others reaction to mania;LA14785-2;1;Positively (encouraging or supportive);;; +65459-0;LL1278-2;PhenX12_10_others reaction to mania;LA14786-0;2;Neutral;;; +65459-0;LL1278-2;PhenX12_10_others reaction to mania;LA14787-8;3;Negatively (concerned, annoyed, irritated, critical);;; +65459-0;LL1278-2;PhenX12_10_others reaction to mania;LA14788-6;4;Positively and negatively;;; +65459-0;LL1278-2;PhenX12_10_others reaction to mania;LA14789-4;5;No reactions;;; +65460-8;LL1279-0;PhenX12_11_len of mania highs;LA13943-8;1;1 day;;; +65460-8;LL1279-0;PhenX12_11_len of mania highs;LA13944-6;2;2-3 days;;; +65460-8;LL1279-0;PhenX12_11_len of mania highs;LA14791-0;3;4-7 days;;; +65460-8;LL1279-0;PhenX12_11_len of mania highs;LA14792-8;4;Longer than 1 week;;; +65460-8;LL1279-0;PhenX12_11_len of mania highs;LA14793-6;5;Longer than 1 month;;; +65460-8;LL1279-0;PhenX12_11_len of mania highs;LA14794-4;6;I can't judge/don't know;;; +65463-2;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65463-2;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65463-2;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65463-2;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65464-0;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65464-0;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65464-0;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65464-0;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65465-7;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65465-7;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65465-7;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65465-7;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65466-5;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65466-5;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65466-5;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65466-5;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65467-3;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65467-3;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65467-3;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65467-3;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65468-1;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65468-1;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65468-1;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65468-1;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65469-9;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65469-9;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65469-9;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65469-9;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65470-7;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65470-7;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65470-7;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65470-7;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65471-5;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65471-5;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65471-5;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65471-5;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65472-3;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65472-3;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65472-3;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65472-3;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65473-1;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65473-1;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65473-1;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65473-1;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65474-9;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65474-9;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65474-9;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65474-9;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65475-6;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65475-6;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65475-6;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65475-6;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65476-4;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65476-4;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65476-4;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65476-4;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65477-2;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65477-2;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65477-2;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65477-2;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65478-0;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65478-0;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65478-0;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65478-0;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65479-8;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65479-8;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65479-8;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65479-8;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65480-6;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65480-6;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65480-6;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65480-6;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65481-4;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65481-4;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65481-4;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65481-4;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65482-2;LL1280-8;PhenX12_12;LA6568-5;1;Not at all;;; +65482-2;LL1280-8;PhenX12_12;LA13940-4;2;A little;;; +65482-2;LL1280-8;PhenX12_12;LA14973-4;3;Some;;; +65482-2;LL1280-8;PhenX12_12;LA14468-5;4;A lot;;; +65485-5;LL1281-6;PhenX12_13_depression length;LA14795-1;1;All day long;;; +65485-5;LL1281-6;PhenX12_13_depression length;LA14796-9;2;Most of the day;;; +65485-5;LL1281-6;PhenX12_13_depression length;LA14797-7;3;About half of the day;;; +65485-5;LL1281-6;PhenX12_13_depression length;LA14798-5;4;Less than half of the day;;; +65485-5;LL1281-6;PhenX12_13_depression length;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65485-5;LL1281-6;PhenX12_13_depression length;LA14761-3;6;Not asked;;; +65486-3;LL1282-4;PhenX12_14_depresion freq;LA14799-3;1;Every day;;; +65486-3;LL1282-4;PhenX12_14_depresion freq;LA14800-9;2;Almost every day;;; +65486-3;LL1282-4;PhenX12_14_depresion freq;LA14801-7;3;Less often;;; +65486-3;LL1282-4;PhenX12_14_depresion freq;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65486-3;LL1282-4;PhenX12_14_depresion freq;LA14761-3;5;Not asked;;; +65488-9;LL1283-2;PhenX12_15_deression wt. gain, loss;LA14802-5;1;Gained;;; +65488-9;LL1283-2;PhenX12_15_deression wt. gain, loss;LA14803-3;2;Lost;;; +65488-9;LL1283-2;PhenX12_15_deression wt. gain, loss;LA14804-1;3;Both gained and lost weight;;; +65488-9;LL1283-2;PhenX12_15_deression wt. gain, loss;LA14805-8;4;Stayed about the same or on a diet;;; +65488-9;LL1283-2;PhenX12_15_deression wt. gain, loss;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65488-9;LL1283-2;PhenX12_15_deression wt. gain, loss;LA14761-3;6;Not asked;;; +65501-9;LL1272-5;PhenX12_04;LA14468-5;1;A lot;;; +65501-9;LL1272-5;PhenX12_04;LA14973-4;2;Some;;; +65501-9;LL1272-5;PhenX12_04;LA13940-4;3;A little;;; +65501-9;LL1272-5;PhenX12_04;LA6568-5;4;Not at all;;; +65501-9;LL1272-5;PhenX12_04;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65501-9;LL1272-5;PhenX12_04;LA14761-3;6;Not asked;;; +65539-9;LL1272-5;PhenX12_04;LA14468-5;1;A lot;;; +65539-9;LL1272-5;PhenX12_04;LA14973-4;2;Some;;; +65539-9;LL1272-5;PhenX12_04;LA13940-4;3;A little;;; +65539-9;LL1272-5;PhenX12_04;LA6568-5;4;Not at all;;; +65539-9;LL1272-5;PhenX12_04;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65539-9;LL1272-5;PhenX12_04;LA14761-3;6;Not asked;;; +65542-3;LL1272-5;PhenX12_04;LA14468-5;1;A lot;;; +65542-3;LL1272-5;PhenX12_04;LA14973-4;2;Some;;; +65542-3;LL1272-5;PhenX12_04;LA13940-4;3;A little;;; +65542-3;LL1272-5;PhenX12_04;LA6568-5;4;Not at all;;; +65542-3;LL1272-5;PhenX12_04;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65542-3;LL1272-5;PhenX12_04;LA14761-3;6;Not asked;;; +65502-7;LL1285-7;PhenX12_17_time to fall asleep;LA15736-4;1;Never take longer than 30 minutes to fall asleep;;; +65502-7;LL1285-7;PhenX12_17_time to fall asleep;LA14809-0;2;I take at least 30 minutes to fall asleep, less than half the time;;; +65502-7;LL1285-7;PhenX12_17_time to fall asleep;LA14810-8;3;I take at least 30 minutes to fall asleep, more than half the time;;; +65502-7;LL1285-7;PhenX12_17_time to fall asleep;LA14811-6;4;I take more than 60 minutes to fall asleep, more than half the time;;; +65503-5;LL1286-5;PhenX12_18_sleep during night;LA14812-4;1;I do not wake up at night;;; +65503-5;LL1286-5;PhenX12_18_sleep during night;LA14813-2;2;I have a restless, light sleep with a few brief awakenings each night;;; +65503-5;LL1286-5;PhenX12_18_sleep during night;LA14814-0;3;I wake up at least once a night, but I go back to sleep easily;;; +65503-5;LL1286-5;PhenX12_18_sleep during night;LA14815-7;4;I awaken more than once a night and stay awake for 20 minutes or more, more than half the time;;; +65504-3;LL1287-3;PhenX12_19_waking too early;LA14816-5;1;Most of the time, I awaken no more than 30 minutes before I need to get up;;; +65504-3;LL1287-3;PhenX12_19_waking too early;LA14817-3;2;More than half the time, I awaken no more than 30 minutes before I need to get up;;; +65504-3;LL1287-3;PhenX12_19_waking too early;LA14818-1;3;I almost always awaken at least one hour or so before I need to, but I go back to sleep eventually;;; +65504-3;LL1287-3;PhenX12_19_waking too early;LA14819-9;4;I awaken at least one hour before I need to, and can't go back to sleep;;; +65505-0;LL1288-1;PhenX12_20_sleep too much;LA14820-7;1;I sleep no longer than 7-8 hours/night, without napping during the day;;; +65505-0;LL1288-1;PhenX12_20_sleep too much;LA14821-5;2;I sleep no longer than 10 hours in a 24-hour period including naps;;; +65505-0;LL1288-1;PhenX12_20_sleep too much;LA14822-3;3;I sleep no longer than 12 hours in a 24-hour period including naps;;; +65505-0;LL1288-1;PhenX12_20_sleep too much;LA14823-1;4;I sleep longer than 12 hours in a 24-hour period including naps;;; +65506-8;LL1289-9;PhenX12_21_feeling sad;LA14824-9;1;I do not feel sad;;; +65506-8;LL1289-9;PhenX12_21_feeling sad;LA14825-6;2;I feel sad less than half the time;;; +65506-8;LL1289-9;PhenX12_21_feeling sad;LA14826-4;3;I feel sad more than half the time;;; +65506-8;LL1289-9;PhenX12_21_feeling sad;LA14827-2;4;I feel sad nearly all of the time;;; +65507-6;LL1290-7;PhenX12_22_appetite past 7D;LA14828-0;1;There is no change in my usual appetite.;;; +65507-6;LL1290-7;PhenX12_22_appetite past 7D;LA14829-8;2;I eat somewhat less often or lesser amounts of food than usual;;; +65507-6;LL1290-7;PhenX12_22_appetite past 7D;LA14830-6;3;I eat much less than usual and only with personal effort;;; +65507-6;LL1290-7;PhenX12_22_appetite past 7D;LA14831-4;4;I rarely eat within a 24-hour period, and only with extreme personal effort or when others persuade me to eat;;; +65508-4;LL1291-5;PhenX12_23_increased appetite past 7D;LA14828-0;1;There is no change in my usual appetite.;;; +65508-4;LL1291-5;PhenX12_23_increased appetite past 7D;LA15738-0;2;I feel a need to eat more frequently than usual;;; +65508-4;LL1291-5;PhenX12_23_increased appetite past 7D;LA15739-8;3;I regularly eat more often and/or greater amounts of food than usual;;; +65508-4;LL1291-5;PhenX12_23_increased appetite past 7D;LA15740-6;4;I feel driven to overeat both at mealtime and between meals;;; +65509-2;LL1292-3;PhenX12_24_wt. decrease;LA14836-3;1;I have not had a change in my weight;;; +65509-2;LL1292-3;PhenX12_24_wt. decrease;LA14833-0;2;I feel as if I've had a slight weight loss;;; +65509-2;LL1292-3;PhenX12_24_wt. decrease;LA14834-8;3;I have lost 2 pounds or more;;; +65509-2;LL1292-3;PhenX12_24_wt. decrease;LA14835-5;4;I have lost 5 pounds or more;;; +65510-0;LL1293-1;PhenX12_25_wt. increase;LA14836-3;1;I have not had a change in my weight;;; +65510-0;LL1293-1;PhenX12_25_wt. increase;LA14837-1;2;I feel as if I've had a slight weight gain;;; +65510-0;LL1293-1;PhenX12_25_wt. increase;LA14838-9;3;I have gained 2 pounds or more;;; +65510-0;LL1293-1;PhenX12_25_wt. increase;LA14839-7;4;I have gained 5 pounds or more;;; +65511-8;LL1294-9;PhenX12_26_concentration;LA14840-5;1;There is no change in my usual capacity to concentrate or make decisions.;;; +65511-8;LL1294-9;PhenX12_26_concentration;LA14841-3;2;I occasionally feel indecisive or find that my attention wanders;;; +65511-8;LL1294-9;PhenX12_26_concentration;LA14842-1;3;Most of the time, I struggle to focus my attention or to make decisions.;;; +65511-8;LL1294-9;PhenX12_26_concentration;LA14843-9;4;I cannot concentrate well enough to read or cannot make even minor decisions;;; +65512-6;LL1295-6;PhenX12_27_view of self;LA14844-7;1;I see myself as equally worthwhile and deserving as other people;;; +65512-6;LL1295-6;PhenX12_27_view of self;LA14845-4;2;I am more self-blaming than usual;;; +65512-6;LL1295-6;PhenX12_27_view of self;LA14846-2;3;I largely believe that I cause problems for others;;; +65512-6;LL1295-6;PhenX12_27_view of self;LA14847-0;4;I think almost constantly about major and minor defects in myself;;; +65513-4;LL1296-4;PhenX12_28_death thoughts;LA14848-8;1;I do not think of suicide or death.;;; +65513-4;LL1296-4;PhenX12_28_death thoughts;LA14849-6;2;I feel that life is empty or wonder if it's worth living;;; +65513-4;LL1296-4;PhenX12_28_death thoughts;LA14850-4;3;I think of suicide or death several times a week for several minutes;;; +65513-4;LL1296-4;PhenX12_28_death thoughts;LA14851-2;4;I think of suicide or death several times a day in some detail, or I have made specific plans for suicide or have actually tried to take my life;;; +65514-2;LL1297-2;PhenX12_29_general interest;LA14852-0;1;There is no change from usual in how interested I am in other people or activities.;;; +65514-2;LL1297-2;PhenX12_29_general interest;LA14853-8;2;I notice that I am less interested in people or activities;;; +65514-2;LL1297-2;PhenX12_29_general interest;LA14854-6;3;I find I have interest in only one or two of my formerly pursued activities;;; +65514-2;LL1297-2;PhenX12_29_general interest;LA14855-3;4;I have virtually no interest in formerly pursued activities;;; +65515-9;LL1298-0;PhenX12_30_energy level;LA14856-1;1;There is no change in my usual level of energy.;;; +65515-9;LL1298-0;PhenX12_30_energy level;LA14857-9;2;I get tired more easily than usual;;; +65515-9;LL1298-0;PhenX12_30_energy level;LA14858-7;3;I have to make a big effort to start or finish my usual daily activities (for example,shopping, homework, cooking or going to work);;; +65515-9;LL1298-0;PhenX12_30_energy level;LA14859-5;4;I really cannot carry out most of my usual daily activities because I just don't have the energy;;; +65516-7;LL1299-8;PhenX12_31_feeling slowed down;LA14860-3;1;I think, speak, and move at my usual rate of speed;;; +65516-7;LL1299-8;PhenX12_31_feeling slowed down;LA14861-1;2;I find that my thinking is slowed down or my voice sounds dull or flat;;; +65516-7;LL1299-8;PhenX12_31_feeling slowed down;LA14862-9;3;It takes me several seconds to respond to most questions and I'm sure my thinking is slowed.;;; +65516-7;LL1299-8;PhenX12_31_feeling slowed down;LA14863-7;4;I am often unable to respond to questions without extreme effort;;; +65517-5;LL1300-4;PhenX12_32_restlessness;LA14864-5;1;I do not feel restless.;;; +65517-5;LL1300-4;PhenX12_32_restlessness;LA14865-2;2;I'm often fidgety, wringing my hands, or need to shift how I am sitting;;; +65517-5;LL1300-4;PhenX12_32_restlessness;LA14866-0;3;I have impulses to move about and am quite restless;;; +65517-5;LL1300-4;PhenX12_32_restlessness;LA14867-8;4;At times, I am unable to stay seated and need to pace around;;; +65518-3;LL1536-3;PhenX12_87;LA16534-2;1;0 - not at all;;; +65518-3;LL1536-3;PhenX12_87;LA6112-2;2;1;;; +65518-3;LL1536-3;PhenX12_87;LA16535-9;3;2 - slightly;;; +65518-3;LL1536-3;PhenX12_87;LA6114-8;4;3;;; +65518-3;LL1536-3;PhenX12_87;LA16536-7;5;4 - moderately;;; +65518-3;LL1536-3;PhenX12_87;LA10137-0;6;5;;; +65518-3;LL1536-3;PhenX12_87;LA16537-5;7;6 - extremely;;; +65519-1;LL1536-3;PhenX12_87;LA16534-2;1;0 - not at all;;; +65519-1;LL1536-3;PhenX12_87;LA6112-2;2;1;;; +65519-1;LL1536-3;PhenX12_87;LA16535-9;3;2 - slightly;;; +65519-1;LL1536-3;PhenX12_87;LA6114-8;4;3;;; +65519-1;LL1536-3;PhenX12_87;LA16536-7;5;4 - moderately;;; +65519-1;LL1536-3;PhenX12_87;LA10137-0;6;5;;; +65519-1;LL1536-3;PhenX12_87;LA16537-5;7;6 - extremely;;; +65520-9;LL1536-3;PhenX12_87;LA16534-2;1;0 - not at all;;; +65520-9;LL1536-3;PhenX12_87;LA6112-2;2;1;;; +65520-9;LL1536-3;PhenX12_87;LA16535-9;3;2 - slightly;;; +65520-9;LL1536-3;PhenX12_87;LA6114-8;4;3;;; +65520-9;LL1536-3;PhenX12_87;LA16536-7;5;4 - moderately;;; +65520-9;LL1536-3;PhenX12_87;LA10137-0;6;5;;; +65520-9;LL1536-3;PhenX12_87;LA16537-5;7;6 - extremely;;; +65521-7;LL1536-3;PhenX12_87;LA16534-2;1;0 - not at all;;; +65521-7;LL1536-3;PhenX12_87;LA6112-2;2;1;;; +65521-7;LL1536-3;PhenX12_87;LA16535-9;3;2 - slightly;;; +65521-7;LL1536-3;PhenX12_87;LA6114-8;4;3;;; +65521-7;LL1536-3;PhenX12_87;LA16536-7;5;4 - moderately;;; +65521-7;LL1536-3;PhenX12_87;LA10137-0;6;5;;; +65521-7;LL1536-3;PhenX12_87;LA16537-5;7;6 - extremely;;; +65524-1;LL1302-0;PhenX12_35_D of control loss;LA6112-2;1;1;;; +65524-1;LL1302-0;PhenX12_35_D of control loss;LA6113-0;2;2;;; +65524-1;LL1302-0;PhenX12_35_D of control loss;LA6114-8;3;3;;; +65524-1;LL1302-0;PhenX12_35_D of control loss;LA6115-5;4;4;;; +65524-1;LL1302-0;PhenX12_35_D of control loss;LA10137-0;5;5;;; +65524-1;LL1302-0;PhenX12_35_D of control loss;LA10138-8;6;6;;; +65524-1;LL1302-0;PhenX12_35_D of control loss;LA10139-6;7;7;;; +65525-8;LL1303-8;PhenX12_36;LA6112-2;1;1;;; +65525-8;LL1303-8;PhenX12_36;LA6113-0;2;2;;; +65525-8;LL1303-8;PhenX12_36;LA6114-8;3;3;;; +65525-8;LL1303-8;PhenX12_36;LA6115-5;4;4;;; +65525-8;LL1303-8;PhenX12_36;LA10137-0;5;5;;; +65525-8;LL1303-8;PhenX12_36;LA10138-8;6;6;;; +65525-8;LL1303-8;PhenX12_36;LA10139-6;7;7;;; +65525-8;LL1303-8;PhenX12_36;LA10140-4;8;8;;; +65525-8;LL1303-8;PhenX12_36;LA10141-2;9;9;;; +65525-8;LL1303-8;PhenX12_36;LA13942-0;10;10;;; +65525-8;LL1303-8;PhenX12_36;LA14557-5;11;11;;; +65525-8;LL1303-8;PhenX12_36;LA14558-3;12;12;;; +65525-8;LL1303-8;PhenX12_36;LA14559-1;13;13;;; +65525-8;LL1303-8;PhenX12_36;LA14560-9;14;14;;; +65926-8;LL1303-8;PhenX12_36;LA6112-2;1;1;;; +65926-8;LL1303-8;PhenX12_36;LA6113-0;2;2;;; +65926-8;LL1303-8;PhenX12_36;LA6114-8;3;3;;; +65926-8;LL1303-8;PhenX12_36;LA6115-5;4;4;;; +65926-8;LL1303-8;PhenX12_36;LA10137-0;5;5;;; +65926-8;LL1303-8;PhenX12_36;LA10138-8;6;6;;; +65926-8;LL1303-8;PhenX12_36;LA10139-6;7;7;;; +65926-8;LL1303-8;PhenX12_36;LA10140-4;8;8;;; +65926-8;LL1303-8;PhenX12_36;LA10141-2;9;9;;; +65926-8;LL1303-8;PhenX12_36;LA13942-0;10;10;;; +65926-8;LL1303-8;PhenX12_36;LA14557-5;11;11;;; +65926-8;LL1303-8;PhenX12_36;LA14558-3;12;12;;; +65926-8;LL1303-8;PhenX12_36;LA14559-1;13;13;;; +65926-8;LL1303-8;PhenX12_36;LA14560-9;14;14;;; +65927-6;LL1303-8;PhenX12_36;LA6112-2;1;1;;; +65927-6;LL1303-8;PhenX12_36;LA6113-0;2;2;;; +65927-6;LL1303-8;PhenX12_36;LA6114-8;3;3;;; +65927-6;LL1303-8;PhenX12_36;LA6115-5;4;4;;; +65927-6;LL1303-8;PhenX12_36;LA10137-0;5;5;;; +65927-6;LL1303-8;PhenX12_36;LA10138-8;6;6;;; +65927-6;LL1303-8;PhenX12_36;LA10139-6;7;7;;; +65927-6;LL1303-8;PhenX12_36;LA10140-4;8;8;;; +65927-6;LL1303-8;PhenX12_36;LA10141-2;9;9;;; +65927-6;LL1303-8;PhenX12_36;LA13942-0;10;10;;; +65927-6;LL1303-8;PhenX12_36;LA14557-5;11;11;;; +65927-6;LL1303-8;PhenX12_36;LA14558-3;12;12;;; +65927-6;LL1303-8;PhenX12_36;LA14559-1;13;13;;; +65927-6;LL1303-8;PhenX12_36;LA14560-9;14;14;;; +65928-4;LL1303-8;PhenX12_36;LA6112-2;1;1;;; +65928-4;LL1303-8;PhenX12_36;LA6113-0;2;2;;; +65928-4;LL1303-8;PhenX12_36;LA6114-8;3;3;;; +65928-4;LL1303-8;PhenX12_36;LA6115-5;4;4;;; +65928-4;LL1303-8;PhenX12_36;LA10137-0;5;5;;; +65928-4;LL1303-8;PhenX12_36;LA10138-8;6;6;;; +65928-4;LL1303-8;PhenX12_36;LA10139-6;7;7;;; +65928-4;LL1303-8;PhenX12_36;LA10140-4;8;8;;; +65928-4;LL1303-8;PhenX12_36;LA10141-2;9;9;;; +65928-4;LL1303-8;PhenX12_36;LA13942-0;10;10;;; +65928-4;LL1303-8;PhenX12_36;LA14557-5;11;11;;; +65928-4;LL1303-8;PhenX12_36;LA14558-3;12;12;;; +65928-4;LL1303-8;PhenX12_36;LA14559-1;13;13;;; +65928-4;LL1303-8;PhenX12_36;LA14560-9;14;14;;; +65929-2;LL1303-8;PhenX12_36;LA6112-2;1;1;;; +65929-2;LL1303-8;PhenX12_36;LA6113-0;2;2;;; +65929-2;LL1303-8;PhenX12_36;LA6114-8;3;3;;; +65929-2;LL1303-8;PhenX12_36;LA6115-5;4;4;;; +65929-2;LL1303-8;PhenX12_36;LA10137-0;5;5;;; +65929-2;LL1303-8;PhenX12_36;LA10138-8;6;6;;; +65929-2;LL1303-8;PhenX12_36;LA10139-6;7;7;;; +65929-2;LL1303-8;PhenX12_36;LA10140-4;8;8;;; +65929-2;LL1303-8;PhenX12_36;LA10141-2;9;9;;; +65929-2;LL1303-8;PhenX12_36;LA13942-0;10;10;;; +65929-2;LL1303-8;PhenX12_36;LA14557-5;11;11;;; +65929-2;LL1303-8;PhenX12_36;LA14558-3;12;12;;; +65929-2;LL1303-8;PhenX12_36;LA14559-1;13;13;;; +65929-2;LL1303-8;PhenX12_36;LA14560-9;14;14;;; +65526-6;LL1538-9;PhenX12_89;LA14220-0;1;Less than 1 year;;; +65526-6;LL1538-9;PhenX12_89;LA14768-8;2;Between 1 and 5 years;;; +65526-6;LL1538-9;PhenX12_89;LA14769-6;3;More than 5 years;;; +65526-6;LL1538-9;PhenX12_89;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65526-6;LL1538-9;PhenX12_89;LA14761-3;5;Not asked;;; +65533-2;LL1537-1;PhenX12_88;LA14763-9;1;One thing;;; +65533-2;LL1537-1;PhenX12_88;LA14764-7;2;More than one thing;;; +65533-2;LL1537-1;PhenX12_88;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65533-2;LL1537-1;PhenX12_88;LA14761-3;4;Not asked;;; +65536-5;LL1271-7;PhenX12_03;LA10044-8;1;Often;;; +65536-5;LL1271-7;PhenX12_03;LA10082-8;2;Sometimes;;; +65536-5;LL1271-7;PhenX12_03;LA10066-1;3;Rarely;;; +65536-5;LL1271-7;PhenX12_03;LA6270-8;4;Never;;; +65536-5;LL1271-7;PhenX12_03;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65536-5;LL1271-7;PhenX12_03;LA14761-3;6;Not asked;;; +65537-3;LL1271-7;PhenX12_03;LA10044-8;1;Often;;; +65537-3;LL1271-7;PhenX12_03;LA10082-8;2;Sometimes;;; +65537-3;LL1271-7;PhenX12_03;LA10066-1;3;Rarely;;; +65537-3;LL1271-7;PhenX12_03;LA6270-8;4;Never;;; +65537-3;LL1271-7;PhenX12_03;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65537-3;LL1271-7;PhenX12_03;LA14761-3;6;Not asked;;; +65540-7;LL1273-3;PhenX12_05_upset with self;LA14765-4;1;Every time;;; +65540-7;LL1273-3;PhenX12_05_upset with self;LA14734-0;2;Most of the time;;; +65540-7;LL1273-3;PhenX12_05_upset with self;LA14733-2;3;Some of the time;;; +65540-7;LL1273-3;PhenX12_05_upset with self;LA14766-2;4;Only one or two times ever;;; +65540-7;LL1273-3;PhenX12_05_upset with self;LA6270-8;5;Never;;; +65540-7;LL1273-3;PhenX12_05_upset with self;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +65540-7;LL1273-3;PhenX12_05_upset with self;LA14761-3;7;Not asked;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA14298-6;1;Multiple Sclerosis;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15156-5;2;Celiac Disease;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15157-3;3;Thyroid Disease;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15158-1;4;Myasthenia Gravis;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15159-9;5;Pernicious Anemia;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15160-7;6;Lupus or SLE;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15161-5;7;Rheumatoid Arthritis;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15162-3;8;Inflammatory Bowel Disease;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15163-1;9;Vitiligo;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15307-4;10;Addison's disease;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA15165-6;11;Psoriasis;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA9-3;12;None of the above;;; +65544-9;LL1403-6;PhenX14_01_autoimmune diseases;LA12688-0;13;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA16285-1;1;Spouse;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA10417-6;2;Mother;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA10416-8;3;Father;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15743-0;4;Child 1;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15744-8;5;Child 2;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15745-5;6;Child 3;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15746-3;7;Child 4;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15747-1;8;Child 5;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15748-9;9;Child 6;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15750-5;10;Sibling 1;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15751-3;11;Sibling 2;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15752-1;12;Sibling 3;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15753-9;13;Sibling 4;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15754-7;14;Sibling 5;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15755-4;15;Sibling 6;;; +65545-6;LL1533-0;PhenX14_30_relative w/ diabetes;LA15756-2;16;Sibling 7;;; +65546-4;LL1534-8;PhenX14_31_diabetes problem;LA15807-3;1;Heart attack or M.I.;;; +65546-4;LL1534-8;PhenX14_31_diabetes problem;LA12741-7;2;Cardiac procedure such as coronary artery bypass graft (CABG) or angioplasty;;; +65546-4;LL1534-8;PhenX14_31_diabetes problem;LA15809-9;3;Stroke, cerebral hemorrhage, or brain attack;;; +65546-4;LL1534-8;PhenX14_31_diabetes problem;LA15810-7;4;Hypertension or high blood pressure;;; +65546-4;LL1534-8;PhenX14_31_diabetes problem;LA15811-5;5;Diabetes or high blood sugar;;; +92663-4;LL1534-8;PhenX14_31_diabetes problem;LA15807-3;1;Heart attack or M.I.;;; +92663-4;LL1534-8;PhenX14_31_diabetes problem;LA12741-7;2;Cardiac procedure such as coronary artery bypass graft (CABG) or angioplasty;;; +92663-4;LL1534-8;PhenX14_31_diabetes problem;LA15809-9;3;Stroke, cerebral hemorrhage, or brain attack;;; +92663-4;LL1534-8;PhenX14_31_diabetes problem;LA15810-7;4;Hypertension or high blood pressure;;; +92663-4;LL1534-8;PhenX14_31_diabetes problem;LA15811-5;5;Diabetes or high blood sugar;;; +65548-0;LL1337-6;PhenX12_67_job schedule;LA14946-0;1;Always works nights, sleeps during the day;;; +65548-0;LL1337-6;PhenX12_67_job schedule;LA14947-8;2;Schedule rotates/shift work;;; +65548-0;LL1337-6;PhenX12_67_job schedule;LA46-8;3;Other;;; +65550-6;LL1338-4;PhenX12_68_job shift;LA14948-6;1;Day shift (approx. 7am- 3pm);;; +65550-6;LL1338-4;PhenX12_68_job shift;LA14949-4;2;Evening shift (approx. 3pm- 11pm);;; +65550-6;LL1338-4;PhenX12_68_job shift;LA14950-2;3;Night shift (approx. 11pm- 7am);;; +65550-6;LL1338-4;PhenX12_68_job shift;LA46-8;4;Other;;; +65555-5;LL1340-0;PhenX12_70;LA6270-8;1;Never;;; +65555-5;LL1340-0;PhenX12_70;LA10082-8;2;Sometimes;;; +65555-5;LL1340-0;PhenX12_70;LA9933-8;3;Always;;; +65556-3;LL1340-0;PhenX12_70;LA6270-8;1;Never;;; +65556-3;LL1340-0;PhenX12_70;LA10082-8;2;Sometimes;;; +65556-3;LL1340-0;PhenX12_70;LA9933-8;3;Always;;; +65557-1;LL1340-0;PhenX12_70;LA6270-8;1;Never;;; +65557-1;LL1340-0;PhenX12_70;LA10082-8;2;Sometimes;;; +65557-1;LL1340-0;PhenX12_70;LA9933-8;3;Always;;; +65559-7;LL1340-0;PhenX12_70;LA6270-8;1;Never;;; +65559-7;LL1340-0;PhenX12_70;LA10082-8;2;Sometimes;;; +65559-7;LL1340-0;PhenX12_70;LA9933-8;3;Always;;; +65562-1;LL1340-0;PhenX12_70;LA6270-8;1;Never;;; +65562-1;LL1340-0;PhenX12_70;LA10082-8;2;Sometimes;;; +65562-1;LL1340-0;PhenX12_70;LA9933-8;3;Always;;; +65564-7;LL1340-0;PhenX12_70;LA6270-8;1;Never;;; +65564-7;LL1340-0;PhenX12_70;LA10082-8;2;Sometimes;;; +65564-7;LL1340-0;PhenX12_70;LA9933-8;3;Always;;; +65569-6;LL1340-0;PhenX12_70;LA6270-8;1;Never;;; +65569-6;LL1340-0;PhenX12_70;LA10082-8;2;Sometimes;;; +65569-6;LL1340-0;PhenX12_70;LA9933-8;3;Always;;; +65565-4;LL1341-8;PhenX12_71;LA6270-8;1;Never;;; +65565-4;LL1341-8;PhenX12_71;LA14953-6;2;Rarely (once a month or less);;; +65565-4;LL1341-8;PhenX12_71;LA14954-4;3;Sometimes (2-4 times per month);;; +65565-4;LL1341-8;PhenX12_71;LA14955-1;4;Often (5-15 times per month);;; +65565-4;LL1341-8;PhenX12_71;LA14956-9;5;Almost always (16-30 times per month);;; +65565-4;LL1341-8;PhenX12_71;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65566-2;LL1341-8;PhenX12_71;LA6270-8;1;Never;;; +65566-2;LL1341-8;PhenX12_71;LA14953-6;2;Rarely (once a month or less);;; +65566-2;LL1341-8;PhenX12_71;LA14954-4;3;Sometimes (2-4 times per month);;; +65566-2;LL1341-8;PhenX12_71;LA14955-1;4;Often (5-15 times per month);;; +65566-2;LL1341-8;PhenX12_71;LA14956-9;5;Almost always (16-30 times per month);;; +65566-2;LL1341-8;PhenX12_71;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65570-4;LL1341-8;PhenX12_71;LA6270-8;1;Never;;; +65570-4;LL1341-8;PhenX12_71;LA14953-6;2;Rarely (once a month or less);;; +65570-4;LL1341-8;PhenX12_71;LA14954-4;3;Sometimes (2-4 times per month);;; +65570-4;LL1341-8;PhenX12_71;LA14955-1;4;Often (5-15 times per month);;; +65570-4;LL1341-8;PhenX12_71;LA14956-9;5;Almost always (16-30 times per month);;; +65570-4;LL1341-8;PhenX12_71;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65572-0;LL1342-6;PhenX12_72_adapt to 3H sleep loss;LA14957-7;1;Not at all difficult;;; +65572-0;LL1342-6;PhenX12_72_adapt to 3H sleep loss;LA14958-5;2;Not very difficult;;; +65572-0;LL1342-6;PhenX12_72_adapt to 3H sleep loss;LA6573-5;3;Somewhat difficult;;; +65572-0;LL1342-6;PhenX12_72_adapt to 3H sleep loss;LA6575-0;4;Very difficult;;; +65572-0;LL1342-6;PhenX12_72_adapt to 3H sleep loss;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65574-6;LL1345-9;PhenX12_75_sleep loss recovery;LA14963-5;1;Within 1 day or less;;; +65574-6;LL1345-9;PhenX12_75_sleep loss recovery;LA14964-3;2;2 to 3 days;;; +65574-6;LL1345-9;PhenX12_75_sleep loss recovery;LA14965-0;3;4 or 5 days;;; +65574-6;LL1345-9;PhenX12_75_sleep loss recovery;LA14966-8;4;Over 5 days;;; +65574-6;LL1345-9;PhenX12_75_sleep loss recovery;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65576-1;LL1346-7;PhenX12_76_feel off no sleep;LA14967-6;1;None, feel the same;;; +65576-1;LL1346-7;PhenX12_76_feel off no sleep;LA14968-4;2;Yes, somewhat off;;; +65576-1;LL1346-7;PhenX12_76_feel off no sleep;LA14969-2;3;Yes, a great deal off;;; +65576-1;LL1346-7;PhenX12_76_feel off no sleep;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65577-9;LL1347-5;PhenX12_77_jet lag return normal;LA14963-5;1;Within 1 day or less;;; +65577-9;LL1347-5;PhenX12_77_jet lag return normal;LA14964-3;2;2 to 3 days;;; +65577-9;LL1347-5;PhenX12_77_jet lag return normal;LA14965-0;3;4 or 5 days;;; +65577-9;LL1347-5;PhenX12_77_jet lag return normal;LA14966-8;4;Over 5 days;;; +65577-9;LL1347-5;PhenX12_77_jet lag return normal;LA4543-0;5;;;; +65577-9;LL1347-5;PhenX12_77_jet lag return normal;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65579-5;LL1347-5;PhenX12_77_jet lag return normal;LA14963-5;1;Within 1 day or less;;; +65579-5;LL1347-5;PhenX12_77_jet lag return normal;LA14964-3;2;2 to 3 days;;; +65579-5;LL1347-5;PhenX12_77_jet lag return normal;LA14965-0;3;4 or 5 days;;; +65579-5;LL1347-5;PhenX12_77_jet lag return normal;LA14966-8;4;Over 5 days;;; +65579-5;LL1347-5;PhenX12_77_jet lag return normal;LA4543-0;5;;;; +65579-5;LL1347-5;PhenX12_77_jet lag return normal;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65578-7;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA14959-3;1;Improves;;; +65578-7;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA14960-1;2;Worsens;;; +65578-7;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA14331-5;3;Both;;; +65578-7;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65676-9;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA14959-3;1;Improves;;; +65676-9;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA14960-1;2;Worsens;;; +65676-9;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA14331-5;3;Both;;; +65676-9;LL1343-4;PhenX12_73_sleep loss affect mood, work;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65580-3;LL1348-3;PhenX12_78_mroning, evening person;LA14970-0;1;Neither type;;; +65580-3;LL1348-3;PhenX12_78_mroning, evening person;LA14971-8;2;Morning;;; +65580-3;LL1348-3;PhenX12_78_mroning, evening person;LA14972-6;3;Evening;;; +65581-1;LL1349-1;PhenX12_79_morning, evening preference;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +65581-1;LL1349-1;PhenX12_79_morning, evening preference;LA14973-4;2;Some;;; +65581-1;LL1349-1;PhenX12_79_morning, evening preference;LA14974-2;3;Strong;;; +65621-5;LL1350-9;PhenX12_80_sleepier than others;LA6568-5;1;Not at all;;; +65621-5;LL1350-9;PhenX12_80_sleepier than others;LA13909-9;2;Somewhat;;; +65621-5;LL1350-9;PhenX12_80_sleepier than others;LA14975-9;3;A lot more sleepy;;; +65621-5;LL1350-9;PhenX12_80_sleepier than others;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65630-6;LL1351-7;PhenX12_81_movement during night;LA14976-7;1;First half;;; +65630-6;LL1351-7;PhenX12_81_movement during night;LA14977-5;2;Second half;;; +65641-3;LL1547-0;PhenX09_41_activities make breathless;LA16330-5;1;Sitting or lying still;;; +65641-3;LL1547-0;PhenX09_41_activities make breathless;LA16331-3;2;Getting washed or dressed;;; +65641-3;LL1547-0;PhenX09_41_activities make breathless;LA16332-1;3;Walking around the home;;; +65641-3;LL1547-0;PhenX09_41_activities make breathless;LA16333-9;4;Walking outside on the level;;; +65641-3;LL1547-0;PhenX09_41_activities make breathless;LA16334-7;5;Walking up a flight of stairs;;; +65641-3;LL1547-0;PhenX09_41_activities make breathless;LA16335-4;6;Walking up hills;;; +65641-3;LL1547-0;PhenX09_41_activities make breathless;LA16336-2;7;Playing sports or games;;; +65653-8;LL1520-7;PhenX09_39_testing challenge respiratory;LA16255-4;1;Pre-bronchodilator;;; +65653-8;LL1520-7;PhenX09_39_testing challenge respiratory;LA16256-2;2;Post-bronchodilator;;; +65665-2;LL1548-8;Phenx11_46_Dr. reported child vision problem;LA16306-5;1;Cataracts;;; +65665-2;LL1548-8;Phenx11_46_Dr. reported child vision problem;LA16302-4;2;Glaucoma;;; +65665-2;LL1548-8;Phenx11_46_Dr. reported child vision problem;LA16303-2;3;Retinopathy of prematurity;;; +65665-2;LL1548-8;Phenx11_46_Dr. reported child vision problem;LA16337-0;4;Eye tumor, retinoblastoma;;; +65665-2;LL1548-8;Phenx11_46_Dr. reported child vision problem;LA16338-8;5;Optic nerve hypoplasia;;; +65665-2;LL1548-8;Phenx11_46_Dr. reported child vision problem;LA16339-6;6;Nasolacrimal duct obstruction;;; +65665-2;LL1548-8;Phenx11_46_Dr. reported child vision problem;LA16340-4;7;Cortical visual impairment;;; +65674-4;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14961-9;1;Increases;;; +65674-4;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14962-7;2;Decreases;;; +65674-4;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14331-5;3;Both;;; +65674-4;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65678-5;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14961-9;1;Increases;;; +65678-5;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14962-7;2;Decreases;;; +65678-5;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14331-5;3;Both;;; +65678-5;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65680-1;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14961-9;1;Increases;;; +65680-1;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14962-7;2;Decreases;;; +65680-1;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA14331-5;3;Both;;; +65680-1;LL1344-2;PhenX12_74_sleep loss affect irritability,eating;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65681-9;LL1549-6;Phenx11_47_glaucoma treatment;LA14707-6;1;Eye drops;;; +65681-9;LL1549-6;Phenx11_47_glaucoma treatment;LA16341-2;2;Laser;;; +65681-9;LL1549-6;Phenx11_47_glaucoma treatment;LA14620-1;3;Surgery;;; +65681-9;LL1549-6;Phenx11_47_glaucoma treatment;LA46-8;4;Other;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16349-5;1;Attention, concentration or memory problems;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16351-1;2;Errors or accidents at work or while driving;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16350-3;3;Social problems or poor work/school performance;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA7542-9;4;Fatigue;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16352-9;5;Sleepiness;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16353-7;6;Feeling tense or muscle tension;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA15903-0;7;Headache;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16354-5;8;Gastrointestinal symptoms;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16355-2;9;Mood changes-problems or irritability;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16356-0;10;Lack of motivation or energy to do things;;; +65682-7;LL1552-0;PhenX12_91_falling asleep problems;LA16357-8;11;Concerns or worries about sleep;;; +65685-0;LL1551-2;PhenX12_90_event w/ insomnia;LA16342-0;1;Changing schedule;;; +65685-0;LL1551-2;PhenX12_90_event w/ insomnia;LA16343-8;2;Noisy or uncomfortable surroundings;;; +65685-0;LL1551-2;PhenX12_90_event w/ insomnia;LA16344-6;3;Stress or major life event;;; +65685-0;LL1551-2;PhenX12_90_event w/ insomnia;LA16345-3;4;Other disturbances - children, pets, etc;;; +65685-0;LL1551-2;PhenX12_90_event w/ insomnia;LA16348-7;5;Emotional or mental condition;;; +65685-0;LL1551-2;PhenX12_90_event w/ insomnia;LA16346-1;6;Other medical condition;;; +65685-0;LL1551-2;PhenX12_90_event w/ insomnia;LA16347-9;7;Other drugs or medication;;; +65687-6;LL4128-6;Yes, specify | No | Unknown;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65687-6;LL4128-6;Yes, specify | No | Unknown;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65687-6;LL4128-6;Yes, specify | No | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65688-4;LL4128-6;Yes, specify | No | Unknown;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65688-4;LL4128-6;Yes, specify | No | Unknown;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65688-4;LL4128-6;Yes, specify | No | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65689-2;LL4128-6;Yes, specify | No | Unknown;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65689-2;LL4128-6;Yes, specify | No | Unknown;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65689-2;LL4128-6;Yes, specify | No | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65690-0;LL4128-6;Yes, specify | No | Unknown;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65690-0;LL4128-6;Yes, specify | No | Unknown;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65690-0;LL4128-6;Yes, specify | No | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65691-8;LL4128-6;Yes, specify | No | Unknown;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65691-8;LL4128-6;Yes, specify | No | Unknown;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65691-8;LL4128-6;Yes, specify | No | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65692-6;LL4128-6;Yes, specify | No | Unknown;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65692-6;LL4128-6;Yes, specify | No | Unknown;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65692-6;LL4128-6;Yes, specify | No | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65693-4;LL4128-6;Yes, specify | No | Unknown;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +65693-4;LL4128-6;Yes, specify | No | Unknown;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +65693-4;LL4128-6;Yes, specify | No | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +65695-9;LL3644-3;UPDRS_Finger taps;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65695-9;LL3644-3;UPDRS_Finger taps;LA24069-9;2;Mild slowing and/or reduction in amplitude;;; +65695-9;LL3644-3;UPDRS_Finger taps;LA24070-7;3;Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement;;; +65695-9;LL3644-3;UPDRS_Finger taps;LA24071-5;4;Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement;;; +65695-9;LL3644-3;UPDRS_Finger taps;LA24072-3;5;Can barely perform the task;;; +65696-7;LL3644-3;UPDRS_Finger taps;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65696-7;LL3644-3;UPDRS_Finger taps;LA24069-9;2;Mild slowing and/or reduction in amplitude;;; +65696-7;LL3644-3;UPDRS_Finger taps;LA24070-7;3;Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement;;; +65696-7;LL3644-3;UPDRS_Finger taps;LA24071-5;4;Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement;;; +65696-7;LL3644-3;UPDRS_Finger taps;LA24072-3;5;Can barely perform the task;;; +65697-5;LL3644-3;UPDRS_Finger taps;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65697-5;LL3644-3;UPDRS_Finger taps;LA24069-9;2;Mild slowing and/or reduction in amplitude;;; +65697-5;LL3644-3;UPDRS_Finger taps;LA24070-7;3;Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement;;; +65697-5;LL3644-3;UPDRS_Finger taps;LA24071-5;4;Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement;;; +65697-5;LL3644-3;UPDRS_Finger taps;LA24072-3;5;Can barely perform the task;;; +65698-3;LL3644-3;UPDRS_Finger taps;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65698-3;LL3644-3;UPDRS_Finger taps;LA24069-9;2;Mild slowing and/or reduction in amplitude;;; +65698-3;LL3644-3;UPDRS_Finger taps;LA24070-7;3;Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement;;; +65698-3;LL3644-3;UPDRS_Finger taps;LA24071-5;4;Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement;;; +65698-3;LL3644-3;UPDRS_Finger taps;LA24072-3;5;Can barely perform the task;;; +65699-1;LL3644-3;UPDRS_Finger taps;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65699-1;LL3644-3;UPDRS_Finger taps;LA24069-9;2;Mild slowing and/or reduction in amplitude;;; +65699-1;LL3644-3;UPDRS_Finger taps;LA24070-7;3;Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement;;; +65699-1;LL3644-3;UPDRS_Finger taps;LA24071-5;4;Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement;;; +65699-1;LL3644-3;UPDRS_Finger taps;LA24072-3;5;Can barely perform the task;;; +65701-5;LL3644-3;UPDRS_Finger taps;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65701-5;LL3644-3;UPDRS_Finger taps;LA24069-9;2;Mild slowing and/or reduction in amplitude;;; +65701-5;LL3644-3;UPDRS_Finger taps;LA24070-7;3;Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement;;; +65701-5;LL3644-3;UPDRS_Finger taps;LA24071-5;4;Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement;;; +65701-5;LL3644-3;UPDRS_Finger taps;LA24072-3;5;Can barely perform the task;;; +65702-3;LL3644-3;UPDRS_Finger taps;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65702-3;LL3644-3;UPDRS_Finger taps;LA24069-9;2;Mild slowing and/or reduction in amplitude;;; +65702-3;LL3644-3;UPDRS_Finger taps;LA24070-7;3;Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement;;; +65702-3;LL3644-3;UPDRS_Finger taps;LA24071-5;4;Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement;;; +65702-3;LL3644-3;UPDRS_Finger taps;LA24072-3;5;Can barely perform the task;;; +65699-1;LL5345-5;SARA_Fast alternating hand movements;LA30176-4;1;Normal, no irregularities (performs <10s);;; +65699-1;LL5345-5;SARA_Fast alternating hand movements;LA30177-2;2;Slightly irregular (performs <10s);;; +65699-1;LL5345-5;SARA_Fast alternating hand movements;LA30178-0;3;Clearly irregular, single movements difficult to distinguish or relevant interruptions, but performs <10s;;; +65699-1;LL5345-5;SARA_Fast alternating hand movements;LA30179-8;4;Very irregular, single movements difficult to distinguish or relevant interruptions, performs > 10s;;; +65699-1;LL5345-5;SARA_Fast alternating hand movements;LA30180-6;5;Unable to complete 10 cycles;;; +65700-7;LL5345-5;SARA_Fast alternating hand movements;LA30176-4;1;Normal, no irregularities (performs <10s);;; +65700-7;LL5345-5;SARA_Fast alternating hand movements;LA30177-2;2;Slightly irregular (performs <10s);;; +65700-7;LL5345-5;SARA_Fast alternating hand movements;LA30178-0;3;Clearly irregular, single movements difficult to distinguish or relevant interruptions, but performs <10s;;; +65700-7;LL5345-5;SARA_Fast alternating hand movements;LA30179-8;4;Very irregular, single movements difficult to distinguish or relevant interruptions, performs > 10s;;; +65700-7;LL5345-5;SARA_Fast alternating hand movements;LA30180-6;5;Unable to complete 10 cycles;;; +65700-7;LL3516-3;UPDRS_Handwriting;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65700-7;LL3516-3;UPDRS_Handwriting;LA23580-6;2;Slightly slow or small;;; +65700-7;LL3516-3;UPDRS_Handwriting;LA23581-4;3;"Moderately slow or small; all words are legible";;; +65700-7;LL3516-3;UPDRS_Handwriting;LA23582-2;4;"Severely affected; not all words are legible";;; +65700-7;LL3516-3;UPDRS_Handwriting;LA23583-0;5;The majority of words are not legible;;; +77693-0;LL3516-3;UPDRS_Handwriting;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77693-0;LL3516-3;UPDRS_Handwriting;LA23580-6;2;Slightly slow or small;;; +77693-0;LL3516-3;UPDRS_Handwriting;LA23581-4;3;"Moderately slow or small; all words are legible";;; +77693-0;LL3516-3;UPDRS_Handwriting;LA23582-2;4;"Severely affected; not all words are legible";;; +77693-0;LL3516-3;UPDRS_Handwriting;LA23583-0;5;The majority of words are not legible;;; +65703-1;LL3645-0;UPDRS_Arising from chair;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65703-1;LL3645-0;UPDRS_Arising from chair;LA24073-1;2;"Slow; or may need more than one attempt";;; +65703-1;LL3645-0;UPDRS_Arising from chair;LA24074-9;3;Pushes self up from arms of seat;;; +65703-1;LL3645-0;UPDRS_Arising from chair;LA24075-6;4;Tends to fall back and may have to try more than one time, but can get up without help;;; +65703-1;LL3645-0;UPDRS_Arising from chair;LA15014-6;5;Unable to arise without help;;; +65704-9;LL3646-8;UPDRS_Posture;LA15018-7;1;Normal erect;;; +65704-9;LL3646-8;UPDRS_Posture;LA24077-2;2;"Not quite erect, slightly stooped posture; could be normal for older person";;; +65704-9;LL3646-8;UPDRS_Posture;LA24078-0;3;"Moderately stooped posture, definitely abnormal; can be slightly leaning to one side";;; +65704-9;LL3646-8;UPDRS_Posture;LA24079-8;4;"Severely stooped posture with kyphosis; can be moderately leaning to one side";;; +65704-9;LL3646-8;UPDRS_Posture;LA15022-9;5;Marked flexion with extreme abnormality of posture;;; +65705-6;LL3647-6;UPDRS_Gait;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65705-6;LL3647-6;UPDRS_Gait;LA24081-4;2;Walks slowly, may shuffle with short steps, but no festination hastening steps or propulsion;;; +65705-6;LL3647-6;UPDRS_Gait;LA24082-2;3;"Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or propulsion";;; +65705-6;LL3647-6;UPDRS_Gait;LA24083-0;4;Severe disturbance of gait, requiring assistance;;; +65705-6;LL3647-6;UPDRS_Gait;LA23602-8;5;Cannot walk at all, even with assistance;;; +65706-4;LL3648-4;UPDRS_Postural stability;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65706-4;LL3648-4;UPDRS_Postural stability;LA24085-5;2;Retropulsion, but recovers unaided;;; +65706-4;LL3648-4;UPDRS_Postural stability;LA24086-3;3;"Absence of postural response; would fall if not caught by examiner";;; +65706-4;LL3648-4;UPDRS_Postural stability;LA24087-1;4;Very unstable, tends to lose balance spontaneously;;; +65706-4;LL3648-4;UPDRS_Postural stability;LA24092-1;5;Unable to stand without assistance;;; +65707-2;LL1375-6;PhenX13_10_sensory symptoms;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +65707-2;LL1375-6;PhenX13_10_sensory symptoms;LA15036-9;2;Extend up to and may include ankle;;; +65707-2;LL1375-6;PhenX13_10_sensory symptoms;LA15037-7;3;Extend up to and may include knee;;; +65707-2;LL1375-6;PhenX13_10_sensory symptoms;LA15038-5;4;Extends above knees;;; +65708-0;LL1376-4;PhenX13_11_ motor symptoms;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +65708-0;LL1376-4;PhenX13_11_ motor symptoms;LA15039-3;2;Trips, catches toes, slaps feet;;; +65708-0;LL1376-4;PhenX13_11_ motor symptoms;LA15040-1;3;AFO on at least 1 leg or ankle support;;; +65708-0;LL1376-4;PhenX13_11_ motor symptoms;LA15041-9;4;Cane, walker, ankle surgery;;; +65708-0;LL1376-4;PhenX13_11_ motor symptoms;LA15042-7;5;Wheelchair most of the time;;; +65709-8;LL1377-2;PhenX13_12_motor symptoms, arms;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +65709-8;LL1377-2;PhenX13_12_motor symptoms, arms;LA15043-5;2;Difficulty with buttons/zippers;;; +65709-8;LL1377-2;PhenX13_12_motor symptoms, arms;LA15044-3;3;Unable to do buttons or zippers but can write;;; +65709-8;LL1377-2;PhenX13_12_motor symptoms, arms;LA15045-0;4;Can not write or use keyboard;;; +65709-8;LL1377-2;PhenX13_12_motor symptoms, arms;LA15046-8;5;Proximal arms;;; +65710-6;LL1378-0;PhenX13_13;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65710-6;LL1378-0;PhenX13_13;LA15047-6;2;Reduced in fingers/toes;;; +65710-6;LL1378-0;PhenX13_13;LA15049-2;3;Reduced up to and may include elbow/knee;;; +65710-6;LL1378-0;PhenX13_13;LA15050-0;4;Reduced above elbow/knee;;; +65711-4;LL1378-0;PhenX13_13;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65711-4;LL1378-0;PhenX13_13;LA15047-6;2;Reduced in fingers/toes;;; +65711-4;LL1378-0;PhenX13_13;LA15049-2;3;Reduced up to and may include elbow/knee;;; +65711-4;LL1378-0;PhenX13_13;LA15050-0;4;Reduced above elbow/knee;;; +65712-2;LL1379-8;PhenX13_14_strength, legs;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65712-2;LL1379-8;PhenX13_14_strength, legs;LA15051-8;2;4+, 4, or 4- on foot dorsiflexion;;; +65712-2;LL1379-8;PhenX13_14_strength, legs;LA15052-6;3;<3 Foot dorsiflexion;;; +65712-2;LL1379-8;PhenX13_14_strength, legs;LA15053-4;4;<3 Dorsiflexion and plantar flexion;;; +65712-2;LL1379-8;PhenX13_14_strength, legs;LA15054-2;5;Proximal weakness;;; +65713-0;LL1380-6;PhenX13_15_strength, arms;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +65713-0;LL1380-6;PhenX13_15_strength, arms;LA15055-9;2;4+, 4, or 4- on intrinsics or finger extensors;;; +65713-0;LL1380-6;PhenX13_15_strength, arms;LA15056-7;3;<3 Intrinsics or finger extensors;;; +65713-0;LL1380-6;PhenX13_15_strength, arms;LA15057-5;4;<5 Wrist extensors;;; +65713-0;LL1380-6;PhenX13_15_strength, arms;LA15058-3;5;Weak above elbow;;; +65714-8;LL1381-4;PhenX13_16_ulnar CMAP;LA15059-1;1;> 6 mV;;; +65714-8;LL1381-4;PhenX13_16_ulnar CMAP;LA15060-9;2;4.0-5.9 mV;;; +65714-8;LL1381-4;PhenX13_16_ulnar CMAP;LA15061-7;3;2.0-3.9 mV;;; +65714-8;LL1381-4;PhenX13_16_ulnar CMAP;LA15062-5;4;0.1-1.9 mV;;; +65714-8;LL1381-4;PhenX13_16_ulnar CMAP;LA9634-2;5;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +65715-5;LL1382-2;PhenX13_17_ulnar CMAP median;LA15066-6;0;(0.1-1.1);;; +65715-5;LL1382-2;PhenX13_17_ulnar CMAP median;LA15063-3;1;(>4 mV);;; +65715-5;LL1382-2;PhenX13_17_ulnar CMAP median;LA15064-1;2;(2.8-3.9);;; +65715-5;LL1382-2;PhenX13_17_ulnar CMAP median;LA15065-8;3;(1.2-2.7);;; +65715-5;LL1382-2;PhenX13_17_ulnar CMAP median;LA9634-2;5;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +65716-3;LL1383-0;PhenX13_18_ulnar SNAP;LA15067-4;1;> 9 uV;;; +65716-3;LL1383-0;PhenX13_18_ulnar SNAP;LA15068-2;2;6.0 - 8.9 uV;;; +65716-3;LL1383-0;PhenX13_18_ulnar SNAP;LA15069-0;3;3.0-5.9 uV;;; +65716-3;LL1383-0;PhenX13_18_ulnar SNAP;LA15070-8;4;0.1-2.9 uV;;; +65716-3;LL1383-0;PhenX13_18_ulnar SNAP;LA9634-2;5;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +65717-1;LL1384-8;PhenX13_19_ulnar SNAP median;LA15071-6;1;(>22 uV);;; +65717-1;LL1384-8;PhenX13_19_ulnar SNAP median;LA15072-4;2;(14.0-21.9);;; +65717-1;LL1384-8;PhenX13_19_ulnar SNAP median;LA15073-2;3;(7.0-13.9);;; +65717-1;LL1384-8;PhenX13_19_ulnar SNAP median;LA15074-0;4;(0.1-6.9);;; +65717-1;LL1384-8;PhenX13_19_ulnar SNAP median;LA9634-2;5;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +65723-9;LL1385-5;PhenX13_20_speech change;LA15075-7;1;Slurred speech;289195008;slurred speech (finding);http://snomed.info/sct +65723-9;LL1385-5;PhenX13_20_speech change;LA15076-5;2;Wrong words came out;;; +65723-9;LL1385-5;PhenX13_20_speech change;LA15077-3;3;Words would not come out;;; +65723-9;LL1385-5;PhenX13_20_speech change;LA15078-1;4;Could not think of the right words;;; +65724-7;LL1553-8;PhenX13_39_chg in speech problems;LA16358-6;1;Numbness or tingling;;; +65724-7;LL1553-8;PhenX13_39_chg in speech problems;LA16359-4;2;Paralysis or weakness;;; +65724-7;LL1553-8;PhenX13_39_chg in speech problems;LA16360-2;3;Lightheadedness, dizziness, or loss of balance;;; +65724-7;LL1553-8;PhenX13_39_chg in speech problems;LA16361-0;4;Blackouts or fainting;;; +65724-7;LL1553-8;PhenX13_39_chg in speech problems;LA16362-8;5;Seizures or convulsions;;; +65724-7;LL1553-8;PhenX13_39_chg in speech problems;LA15903-0;6;Headache;;; +65724-7;LL1553-8;PhenX13_39_chg in speech problems;LA16363-6;7;Visual disturbances;;; +65726-2;LL1387-1;PhenX13_22_affected side;LA15079-9;1;Right side only;;; +65726-2;LL1387-1;PhenX13_22_affected side;LA15080-7;2;Left side only;;; +65726-2;LL1387-1;PhenX13_22_affected side;LA15081-5;3;Both sides;;; +65727-0;LL1386-3;PhenX13_21_visual disturbance;LA15082-3;1;Double vision;;; +65727-0;LL1386-3;PhenX13_21_visual disturbance;LA15083-1;2;Vision loss in right eye only;;; +65727-0;LL1386-3;PhenX13_21_visual disturbance;LA15084-9;3;Vision loss in left eye only;;; +65727-0;LL1386-3;PhenX13_21_visual disturbance;LA15085-6;4;Total loss of vision in both eyes;;; +65727-0;LL1386-3;PhenX13_21_visual disturbance;LA15086-4;5;Trouble in both eyes seeing to the right;;; +65727-0;LL1386-3;PhenX13_21_visual disturbance;LA15087-2;6;Trouble in both eyes seeing to the left;;; +65727-0;LL1386-3;PhenX13_21_visual disturbance;LA15088-0;7;Trouble in both eyes seeing to both sides or straight ahead;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA16364-4;1;Speech disturbance;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA16358-6;2;Numbness or tingling;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA16359-4;3;Paralysis or weakness;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA16360-2;4;Lightheadedness, dizziness, or loss of balance;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA16361-0;5;Blackouts or fainting;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA16362-8;6;Seizures or convulsions;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA15903-0;7;Headache;;; +65729-6;LL1564-5;PhenX13_41_loss of vision problems;LA16376-8;8;Flashing lights;;; +65733-8;LL1565-2;PhenX13_42_double vision problems;LA16364-4;1;Speech disturbance;;; +65733-8;LL1565-2;PhenX13_42_double vision problems;LA16358-6;2;Numbness or tingling;;; +65733-8;LL1565-2;PhenX13_42_double vision problems;LA16359-4;3;Paralysis or weakness;;; +65733-8;LL1565-2;PhenX13_42_double vision problems;LA16360-2;4;Lightheadedness, dizziness, or loss of balance;;; +65733-8;LL1565-2;PhenX13_42_double vision problems;LA16361-0;5;Blackouts or fainting;;; +65733-8;LL1565-2;PhenX13_42_double vision problems;LA16362-8;6;Seizures or convulsions;;; +65733-8;LL1565-2;PhenX13_42_double vision problems;LA15903-0;7;Headache;;; +65737-9;LL1566-0;PhenX13_43_body part;LA16377-6;1;Left arm or hand;;; +65737-9;LL1566-0;PhenX13_43_body part;LA16378-4;2;Left leg or foot;;; +65737-9;LL1566-0;PhenX13_43_body part;LA16379-2;3;Left side of face;;; +65737-9;LL1566-0;PhenX13_43_body part;LA16380-0;4;Right arm or hand;;; +65737-9;LL1566-0;PhenX13_43_body part;LA16381-8;5;Right leg or foot;;; +65737-9;LL1566-0;PhenX13_43_body part;LA16382-6;6;Right side of face;;; +65737-9;LL1566-0;PhenX13_43_body part;LA46-8;7;Other;;; +65739-5;LL1390-5;PhenX13_25_sensation spread;LA15095-5;1;Started in one part and spread to another;;; +65739-5;LL1390-5;PhenX13_25_sensation spread;LA15096-3;2;Stayed in one part;;; +65739-5;LL1390-5;PhenX13_25_sensation spread;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +65740-3;LL1567-8;PhenX13_44_tingling problems;LA16364-4;1;Speech disturbance;;; +65740-3;LL1567-8;PhenX13_44_tingling problems;LA16359-4;2;Paralysis or weakness;;; +65740-3;LL1567-8;PhenX13_44_tingling problems;LA16360-2;3;Lightheadedness, dizziness, or loss of balance;;; +65740-3;LL1567-8;PhenX13_44_tingling problems;LA16361-0;4;Blackouts or fainting;;; +65740-3;LL1567-8;PhenX13_44_tingling problems;LA16362-8;5;Seizures or convulsions;;; +65740-3;LL1567-8;PhenX13_44_tingling problems;LA15903-0;6;Headache;;; +65740-3;LL1567-8;PhenX13_44_tingling problems;LA7460-4;7;Pain;;; +65740-3;LL1567-8;PhenX13_44_tingling problems;LA16363-6;8;Visual disturbances;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA16364-4;1;Speech disturbance;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA16358-6;2;Numbness or tingling;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA16360-2;3;Lightheadedness, dizziness, or loss of balance;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA16361-0;4;Blackouts or fainting;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA16362-8;5;Seizures or convulsions;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA15903-0;6;Headache;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA7460-4;7;Pain;;; +65743-7;LL1568-6;PhenX13_45_paralysis, weakness problems;LA16363-6;8;Visual disturbances;;; +65747-8;LL1569-4;PhenX13_46_dizziness problems;LA16364-4;1;Speech disturbance;;; +65747-8;LL1569-4;PhenX13_46_dizziness problems;LA16359-4;2;Paralysis or weakness;;; +65747-8;LL1569-4;PhenX13_46_dizziness problems;LA16358-6;3;Numbness or tingling;;; +65747-8;LL1569-4;PhenX13_46_dizziness problems;LA16361-0;4;Blackouts or fainting;;; +65747-8;LL1569-4;PhenX13_46_dizziness problems;LA16362-8;5;Seizures or convulsions;;; +65747-8;LL1569-4;PhenX13_46_dizziness problems;LA15903-0;6;Headache;;; +65747-8;LL1569-4;PhenX13_46_dizziness problems;LA16363-6;7;Visual disturbances;;; +65749-4;LL1389-7;PhenX13_24_trouble seeing;LA15092-2;1;Trouble seeing to the right, but not to left;;; +65749-4;LL1389-7;PhenX13_24_trouble seeing;LA15093-0;2;Trouble seeing to the left, but not to right;;; +65749-4;LL1389-7;PhenX13_24_trouble seeing;LA15094-8;3;Trouble seeing both sides or straight ahead;;; +65756-9;LL1576-9;Sal_Serotype;LA16462-6;0;IV 48:z4,z24:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16469-1;1;IV 21:z38:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16468-3;2;IV 30:g,z51:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16467-5;3;IV 38:z4,z23:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16466-7;4;IV 43:z36,z38:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16465-9;5;IV 43:z4,z32:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16414-7;6;IV 44:undetermined;;; +65756-9;LL1576-9;Sal_Serotype;LA16464-2;7;IV 44:z4,z23;;; +65756-9;LL1576-9;Sal_Serotype;LA16463-4;8;IV 44:z4,z32:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16456-8;9;IV 48:nonmotile;;; +65756-9;LL1576-9;Sal_Serotype;LA16461-8;10;IV 50:z4z23:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16460-0;11;IV 51:z4,z23:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16413-9;12;IV Rough:g,z51:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16459-2;13;IV Rough:z36:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16457-6;14;IV Rough:z4,z32:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16453-5;15;66:z81:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16455-0;16;48:z35:-;;; +65756-9;LL1576-9;Sal_Serotype;LA16454-3;17;48:z81:-;;; +65811-2;LL3649-2;UPDRS_Body bradykinesia and hypokinesia;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +65811-2;LL3649-2;UPDRS_Body bradykinesia and hypokinesia;LA24088-9;2;"Minimal slowness, giving movement a deliberate character; could be normal for some persons. Possibly reduced amplitude";;; +65811-2;LL3649-2;UPDRS_Body bradykinesia and hypokinesia;LA24089-7;3;Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, some reduced amplitude;;; +65811-2;LL3649-2;UPDRS_Body bradykinesia and hypokinesia;LA24090-5;4;Moderate slowness, poverty or small amplitude of movement;;; +65811-2;LL3649-2;UPDRS_Body bradykinesia and hypokinesia;LA24091-3;5;Marked slowness, poverty or small amplitude of movement;;; +65812-0;LL1563-7;PhenX13_40_eye vision affected;LA16373-5;1;Only right eye;;; +65812-0;LL1563-7;PhenX13_40_eye vision affected;LA16374-3;2;Only left eye;;; +65812-0;LL1563-7;PhenX13_40_eye vision affected;LA15091-4;3;Both eyes;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +65825-2;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +65826-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +65827-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +65828-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +66184-3;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +66185-0;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +66186-8;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16371-9;1;0 - no distress/impairment;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6112-2;2;1;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6113-0;3;2;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6114-8;4;3;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA6115-5;5;4;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10137-0;6;5;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10138-8;7;6;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10139-6;8;7;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10140-4;9;8;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA10141-2;10;9;;; +66187-6;LL1562-9;PhenX12_93_numeric distress, impairment scale;LA16372-7;11;10 - very severe problems;;; +65830-2;LL1400-2;PhenX13_35_loss of consciousness;LA15142-5;1;No loc;;; +65830-2;LL1400-2;PhenX13_35_loss of consciousness;LA15143-3;2;<30 min;;; +65830-2;LL1400-2;PhenX13_35_loss of consciousness;LA15144-1;3;30 min-24 hrs;;; +65830-2;LL1400-2;PhenX13_35_loss of consciousness;LA15145-8;4;> 24 hrs;;; +65834-4;LL1572-8;Profit/Nonprofit;LA16385-9;1;Profit;;; +65834-4;LL1572-8;Profit/Nonprofit;LA16386-7;2;Nonprofit;;; +65836-9;LL1571-0;Dialysis service;LA16383-4;1;Incenter hemodialysis;;; +65836-9;LL1571-0;Dialysis service;LA10059-6;2;Peritoneal Dialysis;;; +65836-9;LL1571-0;Dialysis service;LA16384-2;3;Home dialysis training;;; +65841-9;LL1573-6;Draft|Final;LA16387-5;1;Draft;;; +65841-9;LL1573-6;Draft|Final;LA16388-3;2;Final;;; +65842-7;LL1574-4;Accepted|Rejected;LA16389-1;1;Accepted;;; +65842-7;LL1574-4;Accepted|Rejected;LA16390-9;2;Rejected;;; +65849-2;LL1575-1;PhenX09_42_child doesn't listen;LA14452-9;1;Does not apply;;; +65849-2;LL1575-1;PhenX09_42_child doesn't listen;LA16391-7;2;Applies just a little;;; +65849-2;LL1575-1;PhenX09_42_child doesn't listen;LA16392-5;3;Applies quite a bit;;; +65849-2;LL1575-1;PhenX09_42_child doesn't listen;LA16393-3;4;Definitely applies most of the time;;; +65869-0;LL1598-3;PhenX10_63_probs during pregnancy;LA15810-7;1;Hypertension or high blood pressure;;; +65869-0;LL1598-3;PhenX10_63_probs during pregnancy;LA16582-1;2;Preeclampsia - toxemia;;; +65869-0;LL1598-3;PhenX10_63_probs during pregnancy;LA15811-5;3;Diabetes or high blood sugar;;; +65869-0;LL1598-3;PhenX10_63_probs during pregnancy;LA16583-9;4;Other pregnancy-related complications;;; +65888-0;LL1581-9;PhenX12_98_panic attack problems;LA16495-6;1;Tightness, pain, or discomfort in your chest or stomach;;; +65888-0;LL1581-9;PhenX12_98_panic attack problems;LA15896-6;2;Sweat;;; +65888-0;LL1581-9;PhenX12_98_panic attack problems;LA16496-4;3;Tremble or shake;;; +65888-0;LL1581-9;PhenX12_98_panic attack problems;LA16497-2;4;Hot flashes or chills;;; +65888-0;LL1581-9;PhenX12_98_panic attack problems;LA16498-0;5;You, or things around you, seem unreal;;; +65898-9;LL1267-5;PhenX11_29_eye fields photo;LA15732-3;1;Can not be photographed;;; +65898-9;LL1267-5;PhenX11_29_eye fields photo;LA15733-1;2;Field 1;;; +65898-9;LL1267-5;PhenX11_29_eye fields photo;LA15734-9;3;Field 2;;; +65898-9;LL1267-5;PhenX11_29_eye fields photo;LA6310-2;4;Other (specify);;; +65904-5;LL1267-5;PhenX11_29_eye fields photo;LA15732-3;1;Can not be photographed;;; +65904-5;LL1267-5;PhenX11_29_eye fields photo;LA15733-1;2;Field 1;;; +65904-5;LL1267-5;PhenX11_29_eye fields photo;LA15734-9;3;Field 2;;; +65904-5;LL1267-5;PhenX11_29_eye fields photo;LA6310-2;4;Other (specify);;; +65908-6;LL1577-7;PhenX12_94_worried, anxious problems;LA16474-1;1;Restless;;; +65908-6;LL1577-7;PhenX12_94_worried, anxious problems;LA16475-8;2;Keyed up or on edge;;; +65908-6;LL1577-7;PhenX12_94_worried, anxious problems;LA16476-6;3;Easily tired;;; +65908-6;LL1577-7;PhenX12_94_worried, anxious problems;LA16477-4;4;Difficulty keeping your mind on what you were doing;;; +65908-6;LL1577-7;PhenX12_94_worried, anxious problems;LA16478-2;5;More irritable than usual;;; +65908-6;LL1577-7;PhenX12_94_worried, anxious problems;LA16479-0;6;Tense, sore, or aching muscles;;; +65910-2;LL1578-5;PhenX12_95_phobias;LA16480-8;1;Heights, storms, thunder, lightning, or being in still water, like a swimming pool or lakes;;; +65910-2;LL1578-5;PhenX12_95_phobias;LA16481-6;2;Being in a closed space like a cave, tunnel, elevator, or airplane;;; +65910-2;LL1578-5;PhenX12_95_phobias;LA16482-4;3;Snakes, birds, rats, bugs, or other animals;;; +65910-2;LL1578-5;PhenX12_95_phobias;LA16483-2;4;Seeing blood, getting a shot or injection, seeing a dentist, or going to a hospital;;; +65912-8;LL1580-1;PhenX12_97_agoraphobias;LA16490-7;1;Being in a crowd or standing in line;;; +65912-8;LL1580-1;PhenX12_97_agoraphobias;LA16491-5;2;Being away from home alone;;; +65912-8;LL1580-1;PhenX12_97_agoraphobias;LA16492-3;3;Traveling alone;;; +65912-8;LL1580-1;PhenX12_97_agoraphobias;LA16493-1;4;Traveling in a bus, train, or car;;; +65912-8;LL1580-1;PhenX12_97_agoraphobias;LA16494-9;5;Being in a public place like a department store;;; +65914-4;LL1579-3;PhenX12_96_social phobias;LA16484-0;1;Giving a speech or speaking in public;;; +65914-4;LL1579-3;PhenX12_96_social phobias;LA16485-7;2;Eating or drinking where someone could watch you;;; +65914-4;LL1579-3;PhenX12_96_social phobias;LA16486-5;3;Talking to people because you might have nothing to say or might sound foolish;;; +65914-4;LL1579-3;PhenX12_96_social phobias;LA16487-3;4;Writing while someone watches;;; +65914-4;LL1579-3;PhenX12_96_social phobias;LA16488-1;5;Taking part or speaking in a meeting or class;;; +65914-4;LL1579-3;PhenX12_96_social phobias;LA16489-9;6;Going to a party or other social outing;;; +65916-9;LL1582-7;PhenX12_99_life aspects;LA16499-8;1;Family life;;; +65916-9;LL1582-7;PhenX12_99_life aspects;LA16500-3;2;Social life;;; +65916-9;LL1582-7;PhenX12_99_life aspects;LA16501-1;3;Work;;; +65916-9;LL1582-7;PhenX12_99_life aspects;LA9374-5;4;Leisure;;; +65917-7;LL1277-4;PhenX12_09_ impact of life highs;LA14783-7;1;Positive and negative;;; +65917-7;LL1277-4;PhenX12_09_ impact of life highs;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +65917-7;LL1277-4;PhenX12_09_ impact of life highs;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +65917-7;LL1277-4;PhenX12_09_ impact of life highs;LA15735-6;4;No impact downs;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16502-9;1;Need less sleep;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16503-7;2;More energetic and more active;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16504-5;3;More self-confident;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16533-4;4;Enjoy my work more;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16505-2;5;More sociable, make more phone calls, go out more;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16506-0;6;Want to travel and do travel more;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16507-8;7;Tend to drive faster or take more risks when driving;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16508-6;8;Spend more or too much money;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16509-4;9;Take more risks in my daily life, my work, or other activities;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16510-2;10;Physically more active in sport, etc;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16511-0;11;Plan more activities or projects;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16512-8;12;Have more ideas, I am more creative;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16513-6;13;Less shy or inhibited;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16514-4;14;Wear more colorful and more extravagant clothes or make-up;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16515-1;15;Want to meet or actually do meet more people;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16516-9;16;More interested in sex, or have increased sexual desire;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16517-7;17;More flirtatious or am more sexually active;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16518-5;18;Talk more;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16519-3;19;Think faster;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16520-1;20;Make more jokes or puns when I am talking;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16521-9;21;More easily distracted;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16522-7;22;Engage in lots of new things;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16523-5;23;Thoughts jump from topic to topic;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16524-3;24;Do things more quickly or more easily;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16525-0;25;More impatient or get irritable more easily;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16526-8;26;Can be exhausting or irritating for others;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16527-6;27;Get into more quarrels;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16528-4;28;Mood is higher, more optimistic;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16529-2;29;Drink more coffee;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16530-0;30;Smoke more cigarettes;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16531-8;31;Drink more alcohol;;; +65918-5;LL1583-5;PhenX12_100_mania behavior;LA16532-6;32;Take more drugs such as sedatives, anxiolytics, stimulants;;; +65930-0;LL1304-6;PhenX12_37_missed mentrual periods;LA6112-2;1;1;;; +65930-0;LL1304-6;PhenX12_37_missed mentrual periods;LA6113-0;2;2;;; +65930-0;LL1304-6;PhenX12_37_missed mentrual periods;LA6114-8;3;3;;; +65930-0;LL1304-6;PhenX12_37_missed mentrual periods;LA6115-5;4;4;;; +65930-0;LL1304-6;PhenX12_37_missed mentrual periods;LA4720-4;5;Not applicable;;; +65932-6;LL1305-3;PhenX12_38_rating source;LA14869-4;1;Hospital case notes (charts);;; +65932-6;LL1305-3;PhenX12_38_rating source;LA14870-2;2;Structured interview with subject;;; +65932-6;LL1305-3;PhenX12_38_rating source;LA14871-0;3;Prepared abstract;;; +65932-6;LL1305-3;PhenX12_38_rating source;LA14872-8;4;Interview with informant;;; +65932-6;LL1305-3;PhenX12_38_rating source;LA14873-6;5;Combined sources including structured interview;;; +65933-4;LL1584-3;PhenX12_101_day type;LA16539-1;1;Work or school day;;; +65933-4;LL1584-3;PhenX12_101_day type;LA16540-9;2;Non-work, non-school day or weekend;;; +65935-9;LL1306-1;PhenX12_39_onset psych illness;LA14875-1;1;No episode;;; +65935-9;LL1306-1;PhenX12_39_onset psych illness;LA14876-9;2;Abrupt onset definable within hours or days;;; +65935-9;LL1306-1;PhenX12_39_onset psych illness;LA14877-7;3;Acute onset definable within one month;;; +65935-9;LL1306-1;PhenX12_39_onset psych illness;LA14878-5;4;Moderately acute onset definable within one month;;; +65935-9;LL1306-1;PhenX12_39_onset psych illness;LA14879-3;5;Gradual onset over period up to six months;;; +65935-9;LL1306-1;PhenX12_39_onset psych illness;LA14880-1;6;Insidious onset over period greater than six months;;; +65937-5;LL1585-0;PhenX12_102_psych stressor present;LA14881-9;1;Stressor not present;;; +65937-5;LL1585-0;PhenX12_102_psych stressor present;LA14882-7;2;Stressor present;;; +65939-1;LL1307-9;PhenX12_40_employment at onset;LA14883-5;1;Employed at onset (includes full time students and homemakers);;; +65939-1;LL1307-9;PhenX12_40_employment at onset;LA14884-3;2;Not employed at onset;;; +65940-9;LL1586-8;PhenX12_103_premorbid adjustment;LA14887-6;1;Good premorbid social adjustment;;; +65940-9;LL1586-8;PhenX12_103_premorbid adjustment;LA14888-4;2;Poor premorbid social adjustment;;; +65941-7;LL1586-8;PhenX12_103_premorbid adjustment;LA14887-6;1;Good premorbid social adjustment;;; +65941-7;LL1586-8;PhenX12_103_premorbid adjustment;LA14888-4;2;Poor premorbid social adjustment;;; +65943-3;LL1308-7;PhenX12_41_brain disease;LA14889-2;1;No prior brain disease present;;; +65943-3;LL1308-7;PhenX12_41_brain disease;LA14890-0;2;Prior brain disease present;;; +65945-8;LL1309-5;PhenX12_42_family hx schizophrenia;LA14891-8;1;No family history of schizophrenia;;; +65945-8;LL1309-5;PhenX12_42_family hx schizophrenia;LA14892-6;2;Family history of schizophrenia;;; +65946-6;LL1310-3;PhenX12_43_family hx other psych;LA14893-4;1;No family history;;; +65946-6;LL1310-3;PhenX12_43_family hx other psych;LA14894-2;2;Family history of psychiatric disorder other than schizophrenia;;; +65951-6;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65951-6;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65951-6;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65951-6;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65953-2;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65953-2;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65953-2;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65953-2;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65954-0;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65954-0;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65954-0;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65954-0;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65955-7;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65955-7;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65955-7;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65955-7;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65957-3;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65957-3;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65957-3;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65957-3;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65961-5;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65961-5;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65961-5;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65961-5;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65963-1;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65963-1;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65963-1;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65963-1;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65965-6;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65965-6;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65965-6;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65965-6;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65967-2;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65967-2;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65967-2;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65967-2;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65970-6;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +65970-6;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +65970-6;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +65970-6;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +66025-8;LL1312-9;PhenX12_45;LA14895-9;1;Not present;;; +66025-8;LL1312-9;PhenX12_45;LA14896-7;2;Present at least one week;;; +66025-8;LL1312-9;PhenX12_45;LA14897-5;3;Present at least two weeks;;; +66025-8;LL1312-9;PhenX12_45;LA14898-3;4;Present at least one month;;; +65956-5;LL1313-7;PhenX12_46_altered libido;LA64-1;1;No change;;; +65956-5;LL1313-7;PhenX12_46_altered libido;LA14899-1;2;Loss of libido for at least one week;;; +65956-5;LL1313-7;PhenX12_46_altered libido;LA14900-7;3;Increase in libido for at least one week;;; +65959-9;LL1314-5;PhenX12_47_ suicidal ideation;LA14895-9;1;Not present;;; +65959-9;LL1314-5;PhenX12_47_ suicidal ideation;LA14902-3;2;Suicidal ideation present at least two weeks;;; +65959-9;LL1314-5;PhenX12_47_ suicidal ideation;LA14903-1;3;Suicidal ideation present at least one month;;; +65962-3;LL1315-2;PhenX12_48_wt. loss amt;LA123-2;1;No loss;;; +65962-3;LL1315-2;PhenX12_48_wt. loss amt;LA14904-9;2;Loss of at least 1+ lb (0.5 kg) per week for 3 or more weeks or 4 lbs (2 kg) in less than 3 weeks;;; +65962-3;LL1315-2;PhenX12_48_wt. loss amt;LA14905-6;3;Loss of at least 2+ lbs (1 kg) per week for 3 or more weeks or 5 to 9 lbs (2.5 to 4.5 kg) in less than 3 weeks;;; +65962-3;LL1315-2;PhenX12_48_wt. loss amt;LA14906-4;4;Loss of at least 10+ lbs (5 kg) in less than 1 year;;; +65964-9;LL1316-0;PhenX12_49_wt. gain;LA14907-2;1;No gain;;; +65964-9;LL1316-0;PhenX12_49_wt. gain;LA14908-0;2;Gain of at least 1+ lb (0.5 kg) per week for 3 or more weeks or 4 lbs (2 kg) in less than 3 weeks;;; +65964-9;LL1316-0;PhenX12_49_wt. gain;LA14909-8;3;Gain of at least 2+ lbs (1 kg) per week for 3 or more weeks or 5 to 9 lbs (2.5 to 4.5 kg) in less than 3 weeks;;; +65964-9;LL1316-0;PhenX12_49_wt. gain;LA14910-6;4;Gain of at least 10+ lbs (5 kg) in less than 1 year;;; +65966-4;LL1317-8;PhenX12_50_middle insomnia;LA15741-4;1;No waking;;; +65966-4;LL1317-8;PhenX12_50_middle insomnia;LA15742-2;2;Middle insomnia present;;; +65971-4;LL1587-6;PhenX12_104_depression variation;LA16541-7;1;No depression, or not worse early;;; +65971-4;LL1587-6;PhenX12_104_depression variation;LA16542-5;2;Regularly feels worse early in the day;;; +65973-0;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65973-0;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65973-0;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65973-0;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65974-8;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65974-8;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65974-8;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65974-8;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65976-3;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65976-3;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65976-3;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65976-3;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65977-1;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65977-1;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65977-1;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65977-1;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65978-9;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65978-9;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65978-9;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65978-9;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65979-7;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65979-7;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65979-7;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65979-7;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65980-5;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65980-5;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65980-5;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65980-5;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65981-3;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65981-3;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65981-3;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65981-3;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65982-1;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65982-1;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65982-1;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65982-1;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65983-9;LL1318-6;PhenX12_51;LA14895-9;1;Not present;;; +65983-9;LL1318-6;PhenX12_51;LA14911-4;2;Present at least four days;;; +65983-9;LL1318-6;PhenX12_51;LA14896-7;3;Present at least one week;;; +65983-9;LL1318-6;PhenX12_51;LA14912-2;4;Present at least two weeks or if lasted < one week but hospitalized for affective disorder;;; +65985-4;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65985-4;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65985-4;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65987-0;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65987-0;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65987-0;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65988-8;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65988-8;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65988-8;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65989-6;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65989-6;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65989-6;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65990-4;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65990-4;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65990-4;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65992-0;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65992-0;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65992-0;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65993-8;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65993-8;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65993-8;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65994-6;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65994-6;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65994-6;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65995-3;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +65995-3;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +65995-3;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66001-9;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66001-9;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66001-9;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66002-7;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66002-7;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66002-7;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66003-5;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66003-5;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66003-5;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66004-3;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66004-3;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66004-3;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66005-0;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66005-0;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66005-0;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66006-8;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66006-8;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66006-8;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66007-6;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66007-6;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66007-6;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66013-4;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66013-4;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66013-4;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66014-2;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66014-2;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66014-2;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66015-9;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66015-9;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66015-9;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66016-7;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66016-7;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66016-7;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66023-3;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66023-3;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66023-3;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66026-6;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66026-6;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66026-6;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66027-4;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66027-4;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66027-4;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66028-2;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66028-2;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66028-2;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66030-8;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66030-8;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66030-8;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66031-6;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66031-6;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66031-6;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +66032-4;LL1319-4;PhenX12_52;LA14895-9;1;Not present;;; +66032-4;LL1319-4;PhenX12_52;LA14913-0;2;Present less than one month or duration unspecified;;; +66032-4;LL1319-4;PhenX12_52;LA14914-8;3;Present most of the time in a one month period or longer;;; +65997-9;LL1320-2;PhenX12_53_delusion screen;LA14915-5;1;No delusions;;; +65997-9;LL1320-2;PhenX12_53_delusion screen;LA14916-3;2;Delusions present;;; +65998-7;LL1324-4;PhenX12_54_delusions guilt presence;LA14917-1;1;No delusions of guilt;;; +65998-7;LL1324-4;PhenX12_54_delusions guilt presence;LA14896-7;2;Present at least one week;;; +65998-7;LL1324-4;PhenX12_54_delusions guilt presence;LA14897-5;3;Present at least two weeks;;; +65998-7;LL1324-4;PhenX12_54_delusions guilt presence;LA14898-3;4;Present at least one month;;; +65999-5;LL1325-1;PhenX12_55_poverty delusions presence;LA14918-9;1;No delusions of poverty;;; +65999-5;LL1325-1;PhenX12_55_poverty delusions presence;LA14896-7;2;Present at least one week;;; +65999-5;LL1325-1;PhenX12_55_poverty delusions presence;LA14897-5;3;Present at least two weeks;;; +65999-5;LL1325-1;PhenX12_55_poverty delusions presence;LA14898-3;4;Present at least one month;;; +66000-1;LL1326-9;PhenX12_56_nihilistic delusions presence;LA14919-7;1;No nihilistic delusions;;; +66000-1;LL1326-9;PhenX12_56_nihilistic delusions presence;LA14896-7;2;Present at least one week;;; +66000-1;LL1326-9;PhenX12_56_nihilistic delusions presence;LA14897-5;3;Present at least two weeks;;; +66000-1;LL1326-9;PhenX12_56_nihilistic delusions presence;LA14898-3;4;Present at least one month;;; +66009-2;LL1328-5;PhenX12_58_illness insight;LA14921-3;1;Insight impaired;;; +66009-2;LL1328-5;PhenX12_58_illness insight;LA14920-5;2;Insight present;;; +66010-0;LL1329-3;PhenX12_59_affective psych symptoms;LA14922-1;1;No co-occurrence;;; +66010-0;LL1329-3;PhenX12_59_affective psych symptoms;LA14923-9;2;Psychotic symptoms dominate the clinical picture although occasional affective disturbance may also occur.;;; +66010-0;LL1329-3;PhenX12_59_affective psych symptoms;LA14924-7;3;Psychotic and affective symptoms are balanced, with neither group of symptoms dominating the overall course of the illness.;;; +66010-0;LL1329-3;PhenX12_59_affective psych symptoms;LA14925-4;4;Affective symptoms predominate although psychotic symptoms may also occur.;;; +66012-6;LL1330-1;PhenX12_60_response antipsychotic meds;LA14926-2;1;No response to neuroleptics, never been psychotic, or never taken neuroleptics;;; +66012-6;LL1330-1;PhenX12_60_response antipsychotic meds;LA14927-0;2;Positive response to neuroleptics;;; +66018-3;LL1331-9;PhenX12_61_impairment incapacity;LA9606-0;1;No impairment;;; +66018-3;LL1331-9;PhenX12_61_impairment incapacity;LA14928-8;2;Subjective impairment only (at work, school, family or social functioning);;; +66018-3;LL1331-9;PhenX12_61_impairment incapacity;LA14929-6;3;Evidence of objective functional impairment in major life role with definite reduction in productivity and/or criticism about functioning or performance has been received;;; +66018-3;LL1331-9;PhenX12_61_impairment incapacity;LA14931-2;4;Inpatient treatment (any duration) has been received, or no functioning at all in major life role for more than two days, or active psychotic symptoms such as delusions or hallucinations have occurred.;;; +66019-1;LL1332-7;PhenX12_62_deterioration fr premorbid level;LA14932-0;1;No deterioration present;;; +66019-1;LL1332-7;PhenX12_62_deterioration fr premorbid level;LA14933-8;2;Deterioration from premorbid level of functioning;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14934-6;1;Single episode with good recovery;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14935-3;2;Multiple episodes with good recovery between;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14936-1;3;Multiple episodes with partial recovery between;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14937-9;4;Continuous chronic illness;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14938-7;5;Continuous chronic illness with deterioration;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14934-6;1;Single episode with good recovery;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14935-3;2;Multiple episodes with good recovery between;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14936-1;3;Multiple episodes with partial recovery between;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14937-9;4;Continuous chronic illness;;; +66020-9;LL1333-5;PhenX12_63_course of disorder;LA14938-7;5;Continuous chronic illness with deterioration;;; +66021-7;LL1334-3;PhenX12_64_rapport;LA15771-1;1;Rapport established without difficulty;;; +66021-7;LL1334-3;PhenX12_64_rapport;LA15772-9;2;Rapport difficult;;; +66022-5;LL1335-0;PhenX12_65_info credibility;LA14939-5;1;Information credible;;; +66022-5;LL1335-0;PhenX12_65_info credibility;LA14940-3;2;Information not credible;;; +66033-2;LL1589-2;PhenX12_106_marital status;LA16543-3;1;Are you married, have you ever been married or lived with the same partner for at least six months?;;; +66033-2;LL1589-2;PhenX12_106_marital status;LA16544-1;2;"Single; has never married or lived as married";;; +66035-7;LL3528-8;UPDRS_Tremor at rest;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66035-7;LL3528-8;UPDRS_Tremor at rest;LA23603-6;2;Slight and infrequently present;;; +66035-7;LL3528-8;UPDRS_Tremor at rest;LA23617-6;3;Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present;;; +66035-7;LL3528-8;UPDRS_Tremor at rest;LA23618-4;4;Moderate in amplitude and present most of the time;;; +66035-7;LL3528-8;UPDRS_Tremor at rest;LA23619-2;5;Marked in amplitude and present most of the time;;; +66040-7;LL3528-8;UPDRS_Tremor at rest;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66040-7;LL3528-8;UPDRS_Tremor at rest;LA23603-6;2;Slight and infrequently present;;; +66040-7;LL3528-8;UPDRS_Tremor at rest;LA23617-6;3;Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present;;; +66040-7;LL3528-8;UPDRS_Tremor at rest;LA23618-4;4;Moderate in amplitude and present most of the time;;; +66040-7;LL3528-8;UPDRS_Tremor at rest;LA23619-2;5;Marked in amplitude and present most of the time;;; +66189-2;LL3528-8;UPDRS_Tremor at rest;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66189-2;LL3528-8;UPDRS_Tremor at rest;LA23603-6;2;Slight and infrequently present;;; +66189-2;LL3528-8;UPDRS_Tremor at rest;LA23617-6;3;Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present;;; +66189-2;LL3528-8;UPDRS_Tremor at rest;LA23618-4;4;Moderate in amplitude and present most of the time;;; +66189-2;LL3528-8;UPDRS_Tremor at rest;LA23619-2;5;Marked in amplitude and present most of the time;;; +66190-0;LL3528-8;UPDRS_Tremor at rest;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66190-0;LL3528-8;UPDRS_Tremor at rest;LA23603-6;2;Slight and infrequently present;;; +66190-0;LL3528-8;UPDRS_Tremor at rest;LA23617-6;3;Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present;;; +66190-0;LL3528-8;UPDRS_Tremor at rest;LA23618-4;4;Moderate in amplitude and present most of the time;;; +66190-0;LL3528-8;UPDRS_Tremor at rest;LA23619-2;5;Marked in amplitude and present most of the time;;; +66191-8;LL3528-8;UPDRS_Tremor at rest;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66191-8;LL3528-8;UPDRS_Tremor at rest;LA23603-6;2;Slight and infrequently present;;; +66191-8;LL3528-8;UPDRS_Tremor at rest;LA23617-6;3;Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present;;; +66191-8;LL3528-8;UPDRS_Tremor at rest;LA23618-4;4;Moderate in amplitude and present most of the time;;; +66191-8;LL3528-8;UPDRS_Tremor at rest;LA23619-2;5;Marked in amplitude and present most of the time;;; +66036-5;LL3529-6;UPDRS_Action or postural tremor of hands;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66036-5;LL3529-6;UPDRS_Action or postural tremor of hands;LA23620-0;2;"Slight; present with action";;; +66036-5;LL3529-6;UPDRS_Action or postural tremor of hands;LA23621-8;3;Moderate in amplitude, present with action;;; +66036-5;LL3529-6;UPDRS_Action or postural tremor of hands;LA23622-6;4;Moderate in amplitude with posture holding as well as action;;; +66036-5;LL3529-6;UPDRS_Action or postural tremor of hands;LA23623-4;5;"Marked in amplitude; interferes with feeding";;; +66196-7;LL3529-6;UPDRS_Action or postural tremor of hands;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66196-7;LL3529-6;UPDRS_Action or postural tremor of hands;LA23620-0;2;"Slight; present with action";;; +66196-7;LL3529-6;UPDRS_Action or postural tremor of hands;LA23621-8;3;Moderate in amplitude, present with action;;; +66196-7;LL3529-6;UPDRS_Action or postural tremor of hands;LA23622-6;4;Moderate in amplitude with posture holding as well as action;;; +66196-7;LL3529-6;UPDRS_Action or postural tremor of hands;LA23623-4;5;"Marked in amplitude; interferes with feeding";;; +66037-3;LL3643-5;UPDRS_Rigidity;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66037-3;LL3643-5;UPDRS_Rigidity;LA15007-0;2;Slight or detectable only when activated by mirror or other movements;;; +66037-3;LL3643-5;UPDRS_Rigidity;LA15008-8;3;Mild to moderate;;; +66037-3;LL3643-5;UPDRS_Rigidity;LA15009-6;4;Marked, but full range of motion easily achieved;;; +66037-3;LL3643-5;UPDRS_Rigidity;LA24068-1;5;Severe, range of motion achieved with difficulty;;; +66192-6;LL3643-5;UPDRS_Rigidity;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66192-6;LL3643-5;UPDRS_Rigidity;LA15007-0;2;Slight or detectable only when activated by mirror or other movements;;; +66192-6;LL3643-5;UPDRS_Rigidity;LA15008-8;3;Mild to moderate;;; +66192-6;LL3643-5;UPDRS_Rigidity;LA15009-6;4;Marked, but full range of motion easily achieved;;; +66192-6;LL3643-5;UPDRS_Rigidity;LA24068-1;5;Severe, range of motion achieved with difficulty;;; +66193-4;LL3643-5;UPDRS_Rigidity;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66193-4;LL3643-5;UPDRS_Rigidity;LA15007-0;2;Slight or detectable only when activated by mirror or other movements;;; +66193-4;LL3643-5;UPDRS_Rigidity;LA15008-8;3;Mild to moderate;;; +66193-4;LL3643-5;UPDRS_Rigidity;LA15009-6;4;Marked, but full range of motion easily achieved;;; +66193-4;LL3643-5;UPDRS_Rigidity;LA24068-1;5;Severe, range of motion achieved with difficulty;;; +66194-2;LL3643-5;UPDRS_Rigidity;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66194-2;LL3643-5;UPDRS_Rigidity;LA15007-0;2;Slight or detectable only when activated by mirror or other movements;;; +66194-2;LL3643-5;UPDRS_Rigidity;LA15008-8;3;Mild to moderate;;; +66194-2;LL3643-5;UPDRS_Rigidity;LA15009-6;4;Marked, but full range of motion easily achieved;;; +66194-2;LL3643-5;UPDRS_Rigidity;LA24068-1;5;Severe, range of motion achieved with difficulty;;; +66195-9;LL3643-5;UPDRS_Rigidity;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +66195-9;LL3643-5;UPDRS_Rigidity;LA15007-0;2;Slight or detectable only when activated by mirror or other movements;;; +66195-9;LL3643-5;UPDRS_Rigidity;LA15008-8;3;Mild to moderate;;; +66195-9;LL3643-5;UPDRS_Rigidity;LA15009-6;4;Marked, but full range of motion easily achieved;;; +66195-9;LL3643-5;UPDRS_Rigidity;LA24068-1;5;Severe, range of motion achieved with difficulty;;; +66038-1;LL1366-5;PhenX13_01_speech, Parkinson's;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +66038-1;LL1366-5;PhenX13_01_speech, Parkinson's;LA14995-7;2;Slight loss of expression, diction, and/or volume;;; +66038-1;LL1366-5;PhenX13_01_speech, Parkinson's;LA14996-5;3;"Monotone, slurred but understandable; moderately impaired";;; +66038-1;LL1366-5;PhenX13_01_speech, Parkinson's;LA14997-3;4;Marked impairment, difficult to understand;;; +66038-1;LL1366-5;PhenX13_01_speech, Parkinson's;LA14998-1;5;Unintelligible;;; +66039-9;LL1367-3;PhenX13_02_facil expression;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +66039-9;LL1367-3;PhenX13_02_facil expression;LA15800-8;2;"Minimal hypomimia, could be normal ""Poker Face""";;; +66039-9;LL1367-3;PhenX13_02_facil expression;LA15801-6;3;Slight but definitely abnormal diminution of facial expression;;; +66039-9;LL1367-3;PhenX13_02_facil expression;LA15802-4;4;"Moderate hypomimia; lips parted some of time";;; +66039-9;LL1367-3;PhenX13_02_facil expression;LA15803-2;5;"Masked or fixed faces with severe or complete loss of facial expression; lips parted one fourth inch or more";;; +66049-8;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +66049-8;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +66049-8;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +66049-8;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +66049-8;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +66050-6;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +66050-6;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +66050-6;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +66050-6;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +66050-6;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +66051-4;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +66051-4;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +66051-4;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +66051-4;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +66051-4;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +66052-2;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +66052-2;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +66052-2;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +66052-2;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +66052-2;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +66053-0;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +66053-0;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +66053-0;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +66053-0;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +66053-0;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +66054-8;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +66054-8;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +66054-8;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +66054-8;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +66054-8;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +71899-9;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +71899-9;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +71899-9;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +71899-9;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +71899-9;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +71900-5;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +71900-5;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +71900-5;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +71900-5;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +71900-5;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +71901-3;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +71901-3;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +71901-3;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +71901-3;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +71901-3;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +71902-1;LL1258-4;PhenX11_20;LA14743-1;0;Definitely false;;; +71902-1;LL1258-4;PhenX11_20;LA14740-7;1;Definitely true;;; +71902-1;LL1258-4;PhenX11_20;LA14741-5;2;Mostly true;;; +71902-1;LL1258-4;PhenX11_20;LA12693-0;3;Not sure;;; +71902-1;LL1258-4;PhenX11_20;LA14742-3;4;Mostly false;;; +66058-9;LL5653-2;Difficulty - activities;LA13948-7;1;No difficulty at all;;; +66058-9;LL5653-2;Difficulty - activities;LA15725-7;2;A little difficulty;;; +66058-9;LL5653-2;Difficulty - activities;LA15726-5;3;Moderate difficulty;;; +66058-9;LL5653-2;Difficulty - activities;LA13951-1;4;A lot of difficulty;;; +66058-9;LL5653-2;Difficulty - activities;LA31170-6;5;Never try to do these activities because of vision;;; +66058-9;LL5653-2;Difficulty - activities;LA31171-4;6;Never try to do these activities for other reasons;;; +66058-9;LL5653-2;Difficulty - activities;LA13948-7;1;No difficulty at all;;; +66058-9;LL5653-2;Difficulty - activities;LA15725-7;2;A little difficulty;;; +66058-9;LL5653-2;Difficulty - activities;LA15726-5;3;Moderate difficulty;;; +66058-9;LL5653-2;Difficulty - activities;LA13951-1;4;A lot of difficulty;;; +66058-9;LL5653-2;Difficulty - activities;LA31170-6;5;Never try to do these activities because of vision;;; +66058-9;LL5653-2;Difficulty - activities;LA31171-4;6;Never try to do these activities for other reasons;;; +66078-7;LL5653-2;Difficulty - activities;LA13948-7;1;No difficulty at all;;; +66078-7;LL5653-2;Difficulty - activities;LA15725-7;2;A little difficulty;;; +66078-7;LL5653-2;Difficulty - activities;LA15726-5;3;Moderate difficulty;;; +66078-7;LL5653-2;Difficulty - activities;LA13951-1;4;A lot of difficulty;;; +66078-7;LL5653-2;Difficulty - activities;LA31170-6;5;Never try to do these activities because of vision;;; +66078-7;LL5653-2;Difficulty - activities;LA31171-4;6;Never try to do these activities for other reasons;;; +66078-7;LL5653-2;Difficulty - activities;LA13948-7;1;No difficulty at all;;; +66078-7;LL5653-2;Difficulty - activities;LA15725-7;2;A little difficulty;;; +66078-7;LL5653-2;Difficulty - activities;LA15726-5;3;Moderate difficulty;;; +66078-7;LL5653-2;Difficulty - activities;LA13951-1;4;A lot of difficulty;;; +66078-7;LL5653-2;Difficulty - activities;LA31170-6;5;Never try to do these activities because of vision;;; +66078-7;LL5653-2;Difficulty - activities;LA31171-4;6;Never try to do these activities for other reasons;;; +83446-5;LL5653-2;Difficulty - activities;LA13948-7;1;No difficulty at all;;; +83446-5;LL5653-2;Difficulty - activities;LA15725-7;2;A little difficulty;;; +83446-5;LL5653-2;Difficulty - activities;LA15726-5;3;Moderate difficulty;;; +83446-5;LL5653-2;Difficulty - activities;LA13951-1;4;A lot of difficulty;;; +83446-5;LL5653-2;Difficulty - activities;LA31170-6;5;Never try to do these activities because of vision;;; +83446-5;LL5653-2;Difficulty - activities;LA31171-4;6;Never try to do these activities for other reasons;;; +83446-5;LL5653-2;Difficulty - activities;LA13948-7;1;No difficulty at all;;; +83446-5;LL5653-2;Difficulty - activities;LA15725-7;2;A little difficulty;;; +83446-5;LL5653-2;Difficulty - activities;LA15726-5;3;Moderate difficulty;;; +83446-5;LL5653-2;Difficulty - activities;LA13951-1;4;A lot of difficulty;;; +83446-5;LL5653-2;Difficulty - activities;LA31170-6;5;Never try to do these activities because of vision;;; +83446-5;LL5653-2;Difficulty - activities;LA31171-4;6;Never try to do these activities for other reasons;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA14539-3;1;Birth control pills;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16568-0;2;Oral contraceptives for >2Mos;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16569-8;3;Depo-provera or injectables (shots);;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16570-6;4;Norplant (implants);;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16252-1;5;Rhythm or safe period;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16572-2;6;Natural family planning or safe period by temperature or cervical mucus test;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16573-0;7;Morning after pills or emergency contraception;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16574-8;8;Diaphragm with or without jelly or cream;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16575-5;9;Female condoms or vaginal pouches,;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16576-3;10;Foam;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA14545-0;11;Cervical cap;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16577-1;12;Suppository or an insert;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16578-9;13;Today sponge;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16579-7;14;IUD - coil, or loop;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16580-5;15;Lunelle - a once-a-month injection;;; +66064-7;LL1597-5;PhenX10_62_pregnancy prevention methods;LA16581-3;16;Contraceptive patch;;; +66077-9;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +66077-9;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +66077-9;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +66077-9;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +66078-7;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +66078-7;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +66078-7;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +66078-7;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +66082-9;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +66082-9;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +66082-9;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +66082-9;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +66082-9;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +66082-9;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +66082-9;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +66082-9;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +69501-5;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +69501-5;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +69501-5;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +69501-5;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +83446-5;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +83446-5;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +83446-5;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +83446-5;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99203-2;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99203-2;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99203-2;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99203-2;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99203-2;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99203-2;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99203-2;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99203-2;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99203-2;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99203-2;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99203-2;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99203-2;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99208-1;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99208-1;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99208-1;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99208-1;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99208-1;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99208-1;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99208-1;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99208-1;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99208-1;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99208-1;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99208-1;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99208-1;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99209-9;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99209-9;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99209-9;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99209-9;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99209-9;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99209-9;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99209-9;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99209-9;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +99209-9;LL5652-4;Difficulty;LA13948-7;1;No difficulty at all;;; +99209-9;LL5652-4;Difficulty;LA15725-7;2;A little difficulty;;; +99209-9;LL5652-4;Difficulty;LA15726-5;3;Moderate difficulty;;; +99209-9;LL5652-4;Difficulty;LA13951-1;4;A lot of difficulty;;; +66077-9;LL5655-7;Difficulty - task;LA13948-7;1;No difficulty at all;;; +66077-9;LL5655-7;Difficulty - task;LA15725-7;2;A little difficulty;;; +66077-9;LL5655-7;Difficulty - task;LA15726-5;3;Moderate difficulty;;; +66077-9;LL5655-7;Difficulty - task;LA13951-1;4;A lot of difficulty;;; +66077-9;LL5655-7;Difficulty - task;LA31174-8;5;Never try to do this because of vision;;; +66077-9;LL5655-7;Difficulty - task;LA31175-5;6;Never try to do this for other reasons;;; +66077-9;LL5655-7;Difficulty - task;LA13948-7;1;No difficulty at all;;; +66077-9;LL5655-7;Difficulty - task;LA15725-7;2;A little difficulty;;; +66077-9;LL5655-7;Difficulty - task;LA15726-5;3;Moderate difficulty;;; +66077-9;LL5655-7;Difficulty - task;LA13951-1;4;A lot of difficulty;;; +66077-9;LL5655-7;Difficulty - task;LA31174-8;5;Never try to do this because of vision;;; +66077-9;LL5655-7;Difficulty - task;LA31175-5;6;Never try to do this for other reasons;;; +66088-6;LL1284-0;PhenX12_depression trouble sleeping;LA14806-6;1;Every night;;; +66088-6;LL1284-0;PhenX12_depression trouble sleeping;LA14807-4;2;Nearly every night;;; +66088-6;LL1284-0;PhenX12_depression trouble sleeping;LA14801-7;3;Less often;;; +66088-6;LL1284-0;PhenX12_depression trouble sleeping;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66088-6;LL1284-0;PhenX12_depression trouble sleeping;LA14761-3;5;Not asked;;; +66089-4;LL1404-4;PhenX14_02;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66089-4;LL1404-4;PhenX14_02;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66089-4;LL1404-4;PhenX14_02;LA4389-8;3;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66089-4;LL1404-4;PhenX14_02;LA15168-0;4;Took no medicines;;; +66154-6;LL1406-9;PhenX14_04_medication for diabetes;LA15805-7;1;Insulin;67866001;Insulin (substance);http://snomed.info/sct +66154-6;LL1406-9;PhenX14_04_medication for diabetes;LA15806-5;2;Pills;;; +66179-3;LL1409-3;PhenX14_07_assay exclusion criteria glucose;LA15171-4;1;Taking oral medications for diabetes;;; +66179-3;LL1409-3;PhenX14_07_assay exclusion criteria glucose;LA15172-2;2;Taking insulin;;; +66179-3;LL1409-3;PhenX14_07_assay exclusion criteria glucose;LA15173-0;3;Pregnant;;; +66179-3;LL1409-3;PhenX14_07_assay exclusion criteria glucose;LA15174-8;4;Hemophilia;;; +66179-3;LL1409-3;PhenX14_07_assay exclusion criteria glucose;LA15175-5;5;Received cancer chemotherapy in the last 3 weeks;;; +66179-3;LL1409-3;PhenX14_07_assay exclusion criteria glucose;LA15176-3;6;Has not fasted at least 9 hours;;; +66179-3;LL1409-3;PhenX14_07_assay exclusion criteria glucose;LA15177-1;7;None – proceed with blood draw;;; +66197-5;LL1596-7;PhenX13_51_injuries;LA16563-1;1;Injury 1;;; +66197-5;LL1596-7;PhenX13_51_injuries;LA16564-9;2;Injury 2;;; +66197-5;LL1596-7;PhenX13_51_injuries;LA16565-6;3;Injury 3;;; +66197-5;LL1596-7;PhenX13_51_injuries;LA16566-4;4;Injury 4;;; +66197-5;LL1596-7;PhenX13_51_injuries;LA16567-2;5;Injury 5;;; +66204-9;LL1966-2;PhenX14_36_amount of dextrose consumed;LA18187-7;1;All;;; +66204-9;LL1966-2;PhenX14_36_amount of dextrose consumed;LA14973-4;2;Some;;; +66204-9;LL1966-2;PhenX14_36_amount of dextrose consumed;LA137-2;3;None;260413007;None (qualifier value);http://snomed.info/sct +66205-6;LL1413-5;PhenX14_11_solution consumed;LA15182-1;1;Yes – solution consumed in 10 minutes;;; +66205-6;LL1413-5;PhenX14_11_solution consumed;LA15183-9;2;No – solution not consumed in 10 minutes;;; +66214-8;LL1965-4;PhenX15_19_trial attempt;LA18185-1;1;Trial 1;;; +66214-8;LL1965-4;PhenX15_19_trial attempt;LA18186-9;2;Trial 2;;; +66218-9;LL1414-3;PhenX14_12_lap lengths;LA15812-3;1;15 meters;;; +66218-9;LL1414-3;PhenX14_12_lap lengths;LA15813-1;2;20 meters;;; +66226-2;LL1415-0;PhenX14_13_which hand;LA4306-2;1;Right;;; +66226-2;LL1415-0;PhenX14_13_which hand;LA4585-1;2;Left;;; +66226-2;LL1415-0;PhenX14_13_which hand;LA15814-9;3;Both left and right;;; +66227-0;LL1964-7;PhenX15_18;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66227-0;LL1964-7;PhenX15_18;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66227-0;LL1964-7;PhenX15_18;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66227-0;LL1964-7;PhenX15_18;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66228-8;LL1964-7;PhenX15_18;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66228-8;LL1964-7;PhenX15_18;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66228-8;LL1964-7;PhenX15_18;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66228-8;LL1964-7;PhenX15_18;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66229-6;LL1964-7;PhenX15_18;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66229-6;LL1964-7;PhenX15_18;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66229-6;LL1964-7;PhenX15_18;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66229-6;LL1964-7;PhenX15_18;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66231-2;LL1416-8;PhenX14_14_reason not to squeeze hand;LA15184-7;1;Unable to test/exclusion/didn't understand;;; +66231-2;LL1416-8;PhenX14_14_reason not to squeeze hand;LA4389-8;2;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66231-2;LL1416-8;PhenX14_14_reason not to squeeze hand;LA15185-4;3;Unable to complete;;; +66232-0;LL1416-8;PhenX14_14_reason not to squeeze hand;LA15184-7;1;Unable to test/exclusion/didn't understand;;; +66232-0;LL1416-8;PhenX14_14_reason not to squeeze hand;LA4389-8;2;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66232-0;LL1416-8;PhenX14_14_reason not to squeeze hand;LA15185-4;3;Unable to complete;;; +66240-3;LL1608-0;PhenX14_33_blood draws;LA16619-1;1;Blood draw 1;;; +66240-3;LL1608-0;PhenX14_33_blood draws;LA16620-9;2;Blood draw 2;;; +66241-1;LL1970-4;PhenX15_21_stretch test;LA18191-9;1;Sit and reach 1;;; +66241-1;LL1970-4;PhenX15_21_stretch test;LA18192-7;2;Sit and reach 2;;; +66241-1;LL1970-4;PhenX15_21_stretch test;LA18193-5;3;Sit and reach 3;;; +66248-6;LL1967-0;PhenX15_20_balance test;LA18188-5;1;Side by side stand;;; +66248-6;LL1967-0;PhenX15_20_balance test;LA18189-3;2;Semi tandem stand;;; +66248-6;LL1967-0;PhenX15_20_balance test;LA18190-1;3;Tandem stand;;; +66249-4;LL1417-6;PhenX14_15_balance test score;LA15186-2;1;Held for 10 sec - 1 point;;; +66249-4;LL1417-6;PhenX14_15_balance test score;LA15187-0;2;Not held for 10 sec - 0 points;;; +66249-4;LL1417-6;PhenX14_15_balance test score;LA15188-8;3;Not attempted - 0 points;;; +66250-2;LL1418-4;PhenX14_16_reason test failed;LA15189-6;1;Tried but unable;;; +66250-2;LL1418-4;PhenX14_16_reason test failed;LA15190-4;2;Participant could not hold position unassisted;;; +66250-2;LL1418-4;PhenX14_16_reason test failed;LA15191-2;3;Not attempted, you felt unsafe;;; +66250-2;LL1418-4;PhenX14_16_reason test failed;LA15192-0;4;Not attempted, participant felt unsafe;;; +66250-2;LL1418-4;PhenX14_16_reason test failed;LA15193-8;5;Participant unable to understand instructions;;; +66250-2;LL1418-4;PhenX14_16_reason test failed;LA6310-2;6;Other (specify);;; +66250-2;LL1418-4;PhenX14_16_reason test failed;LA15194-6;7;Participant refused;;; +66256-9;LL1423-4;PhenX14_17_aids for walk;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +66256-9;LL1423-4;PhenX14_17_aids for walk;LA15197-9;2;Cane;;; +66256-9;LL1423-4;PhenX14_17_aids for walk;LA46-8;3;Other;;; +66258-5;LL1424-2;PhenX14_18_4 meter walk;LA15198-7;1;Time is more than 8.70 sec - 1 point;;; +66258-5;LL1424-2;PhenX14_18_4 meter walk;LA15199-5;2;Time is 6.21 to 8.70 sec - 2 points;;; +66258-5;LL1424-2;PhenX14_18_4 meter walk;LA15200-1;3;Time is 4.82 to 6.20 sec - 3 points;;; +66258-5;LL1424-2;PhenX14_18_4 meter walk;LA15201-9;4;Time is less than 4.82 sec - 4 points;;; +66259-3;LL1425-9;PhenX14_19_3 meter walk;LA15202-7;1;Time is more than 6.52 sec - 1 point;;; +66259-3;LL1425-9;PhenX14_19_3 meter walk;LA15203-5;2;Time is 4.66 to 6.52 sec - 2 points;;; +66259-3;LL1425-9;PhenX14_19_3 meter walk;LA15204-3;3;Time is 3.62 to 4.65 sec - 3 points;;; +66259-3;LL1425-9;PhenX14_19_3 meter walk;LA15205-0;4;Time is less than 3.62 sec - 4 points;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18174-5;1;Watching TV;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18175-2;2;Watching videos-DVDs;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18176-0;3;Using computer for fun;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18177-8;4;Using computer for doing homework;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18178-6;5;Doing homework not on the computer;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18179-4;6;Reading for fun;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18180-2;7;Being tutored;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18181-0;8;Travel-car,bus,train;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18182-8;9;Doing crafts or hobbies;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18183-6;10;Sitting around-chatting with friends, on the phone;;; +66265-0;LL1963-9;PhenX15_17_sitting adolescent activities;LA18184-4;11;Playing-practicing a musical instrument;;; +66267-6;LL1897-9;PhenX15_10;LA17866-7;1;7:00-7:30am;;; +66267-6;LL1897-9;PhenX15_10;LA17867-5;2;7:30-8:00am;;; +66267-6;LL1897-9;PhenX15_10;LA17868-3;3;8:00-8:30am;;; +66267-6;LL1897-9;PhenX15_10;LA17869-1;4;8:30-9:00am;;; +66267-6;LL1897-9;PhenX15_10;LA17870-9;5;9:00-9:30am;;; +66267-6;LL1897-9;PhenX15_10;LA17871-7;6;9:30-10:00am;;; +66267-6;LL1897-9;PhenX15_10;LA17874-1;7;11:00-11:30am;;; +66267-6;LL1897-9;PhenX15_10;LA17875-8;8;11:30-12:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17876-6;9;12:00-12:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17877-4;10;12:30-1:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17878-2;11;1:00-1:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17879-0;12;1:30-2:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17880-8;13;2:00-2:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17881-6;14;2:30-3:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17882-4;15;3:30-4:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17883-2;16;4:00-4:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17884-0;17;4:30-5:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17885-7;18;5:00-5:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17886-5;19;5:30-6:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17887-3;20;6:00-6:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17888-1;21;6:30-7:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17889-9;22;7:00-7:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17890-7;23;7:30-8:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17891-5;24;8:00-8:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17892-3;25;8:30-9:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17893-1;26;9:00-9:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17894-9;27;9:30-10:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17895-6;28;10:00-10:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17896-4;29;10:30-11:00pm;;; +66267-6;LL1897-9;PhenX15_10;LA17897-2;30;11:00-11:30pm;;; +66267-6;LL1897-9;PhenX15_10;LA17898-0;31;11:30-12:00am;;; +66268-4;LL1898-7;PhenX15_11;LA17899-8;1;Eating a meal;;; +66268-4;LL1898-7;PhenX15_11;LA17900-4;2;Snacking;;; +66268-4;LL1898-7;PhenX15_11;LA17901-2;3;Working;;; +66268-4;LL1898-7;PhenX15_11;LA17902-0;4;Doing house chores;;; +66268-4;LL1898-7;PhenX15_11;LA17903-8;5;Yard work;;; +66268-4;LL1898-7;PhenX15_11;LA17904-6;6;Church;;; +66268-4;LL1898-7;PhenX15_11;LA17905-3;7;Hanging around;;; +66268-4;LL1898-7;PhenX15_11;LA17906-1;8;Homework;;; +66268-4;LL1898-7;PhenX15_11;LA17907-9;9;Listening to music;;; +66268-4;LL1898-7;PhenX15_11;LA17908-7;10;Marching band - flag - drill team;;; +66268-4;LL1898-7;PhenX15_11;LA17909-5;11;Music lesson - playing instrument;;; +66268-4;LL1898-7;PhenX15_11;LA17910-3;12;Playing video games - surfing internet;;; +66268-4;LL1898-7;PhenX15_11;LA17911-1;13;Reading;;; +66268-4;LL1898-7;PhenX15_11;LA17912-9;14;Shopping;;; +66268-4;LL1898-7;PhenX15_11;LA17913-7;15;Talking on phone;;; +66268-4;LL1898-7;PhenX15_11;LA17914-5;16;Watching TV or movie;;; +66268-4;LL1898-7;PhenX15_11;LA17915-2;17;Riding in a car - bus;;; +66268-4;LL1898-7;PhenX15_11;LA17916-0;18;Travel by walking;;; +66268-4;LL1898-7;PhenX15_11;LA17917-8;19;Travel by bicycling;;; +66268-4;LL1898-7;PhenX15_11;LA17918-6;20;Getting dressed;;; +66268-4;LL1898-7;PhenX15_11;LA17919-4;21;Getting ready - hair - make-up etc.;;; +66268-4;LL1898-7;PhenX15_11;LA17920-2;22;Showering - bathing;;; +66268-4;LL1898-7;PhenX15_11;LA11864-8;23;Sleeping;;; +66268-4;LL1898-7;PhenX15_11;LA17921-0;24;Club - student activity;;; +66268-4;LL1898-7;PhenX15_11;LA17922-8;25;Lunch - free time - study hall;;; +66268-4;LL1898-7;PhenX15_11;LA17923-6;26;Physical education (P.E.) class;;; +66268-4;LL1898-7;PhenX15_11;LA17924-4;27;R.O.T.C.;;; +66268-4;LL1898-7;PhenX15_11;LA17925-1;28;Sitting in class;;; +66268-4;LL1898-7;PhenX15_11;LA17926-9;29;Aerobics - aerobic dancing;;; +66268-4;LL1898-7;PhenX15_11;LA17927-7;30;Basketball;;; +66268-4;LL1898-7;PhenX15_11;LA11837-4;31;Bicycling;;; +66268-4;LL1898-7;PhenX15_11;LA17928-5;32;Bowling;;; +66268-4;LL1898-7;PhenX15_11;LA17929-3;33;Calisthenics - jumping jacks - sit-ups;;; +66268-4;LL1898-7;PhenX15_11;LA17930-1;34;Cheerleading;;; +66268-4;LL1898-7;PhenX15_11;LA17931-9;35;Dancing - social, recreational;;; +66268-4;LL1898-7;PhenX15_11;LA17932-7;36;Dancing - ballet, jazz, modern, tap;;; +66268-4;LL1898-7;PhenX15_11;LA17933-5;37;Field hockey;;; +66268-4;LL1898-7;PhenX15_11;LA17934-3;38;Frisbee;;; +66268-4;LL1898-7;PhenX15_11;LA17935-0;39;Golf;;; +66268-4;LL1898-7;PhenX15_11;LA17936-8;40;Horseback riding;;; +66268-4;LL1898-7;PhenX15_11;LA17937-6;41;Ice - rolling skating;;; +66268-4;LL1898-7;PhenX15_11;LA17938-4;42;Jogging - running;;; +66268-4;LL1898-7;PhenX15_11;LA17939-2;43;Karate - judo, martial arts, self defense;;; +66268-4;LL1898-7;PhenX15_11;LA17940-0;44;Rollerblading;;; +66268-4;LL1898-7;PhenX15_11;LA17941-8;45;Skateboarding;;; +66268-4;LL1898-7;PhenX15_11;LA17942-6;46;Soccer;;; +66268-4;LL1898-7;PhenX15_11;LA17943-4;47;Softball - baseball;;; +66268-4;LL1898-7;PhenX15_11;LA17944-2;48;Stationary exercise machines - cycle, ski machine, stairclimber, treadmill;;; +66268-4;LL1898-7;PhenX15_11;LA17945-9;49;Street hockey;;; +66268-4;LL1898-7;PhenX15_11;LA11838-2;50;Swimming;;; +66268-4;LL1898-7;PhenX15_11;LA17947-5;51;Tennis;;; +66268-4;LL1898-7;PhenX15_11;LA17948-3;52;Volleyball;;; +66268-4;LL1898-7;PhenX15_11;LA17949-1;53;Walking - briskly;;; +66268-4;LL1898-7;PhenX15_11;LA17950-9;54;Weight - circuit training;;; +66268-4;LL1898-7;PhenX15_11;LA17951-7;55;Gymnastics - tumbling;;; +66268-4;LL1898-7;PhenX15_11;LA17952-5;56;Kick boxing - Tae Bo;;; +66268-4;LL1898-7;PhenX15_11;LA17953-3;57;Track and field;;; +66268-4;LL1898-7;PhenX15_11;LA17954-1;58;Trampoline;;; +66268-4;LL1898-7;PhenX15_11;LA46-8;59;Other;;; +66270-0;LL1899-5;PhenX15_12_activity intensity;LA15831-3;1;Light;;; +66270-0;LL1899-5;PhenX15_12_activity intensity;LA6751-7;2;Moderate;;; +66270-0;LL1899-5;PhenX15_12_activity intensity;LA14745-6;3;Hard;;; +66270-0;LL1899-5;PhenX15_12_activity intensity;LA15832-1;4;Very hard;;; +66272-6;LL1428-3;PhenX14_22_days, start Monday;LA15206-8;1;Monday;;; +66272-6;LL1428-3;PhenX14_22_days, start Monday;LA15207-6;2;Tuesday;;; +66272-6;LL1428-3;PhenX14_22_days, start Monday;LA15208-4;3;Wednesday;;; +66272-6;LL1428-3;PhenX14_22_days, start Monday;LA15209-2;4;Thursday;;; +66272-6;LL1428-3;PhenX14_22_days, start Monday;LA15210-0;5;Friday;;; +66272-6;LL1428-3;PhenX14_22_days, start Monday;LA15211-8;6;Saturday;;; +66272-6;LL1428-3;PhenX14_22_days, start Monday;LA15212-6;7;Sunday;;; +66273-4;LL1429-1;PhenX14_23_days, start Sunday;LA15212-6;1;Sunday;;; +66273-4;LL1429-1;PhenX14_23_days, start Sunday;LA15206-8;2;Monday;;; +66273-4;LL1429-1;PhenX14_23_days, start Sunday;LA15207-6;3;Tuesday;;; +66273-4;LL1429-1;PhenX14_23_days, start Sunday;LA15208-4;4;Wednesday;;; +66273-4;LL1429-1;PhenX14_23_days, start Sunday;LA15209-2;5;Thursday;;; +66273-4;LL1429-1;PhenX14_23_days, start Sunday;LA15210-0;6;Friday;;; +66273-4;LL1429-1;PhenX14_23_days, start Sunday;LA15211-8;7;Saturday;;; +66276-7;LL1429-1;PhenX14_23_days, start Sunday;LA15212-6;1;Sunday;;; +66276-7;LL1429-1;PhenX14_23_days, start Sunday;LA15206-8;2;Monday;;; +66276-7;LL1429-1;PhenX14_23_days, start Sunday;LA15207-6;3;Tuesday;;; +66276-7;LL1429-1;PhenX14_23_days, start Sunday;LA15208-4;4;Wednesday;;; +66276-7;LL1429-1;PhenX14_23_days, start Sunday;LA15209-2;5;Thursday;;; +66276-7;LL1429-1;PhenX14_23_days, start Sunday;LA15210-0;6;Friday;;; +66276-7;LL1429-1;PhenX14_23_days, start Sunday;LA15211-8;7;Saturday;;; +66274-2;LL1952-2;PhenX15_13_adult activity;LA18125-7;1;Sleep;;; +66274-2;LL1952-2;PhenX15_13_adult activity;LA16501-1;2;Work;;; +66275-9;LL1600-7;PhenX15_01_day sequence;LA16584-7;1;Day 1;;; +66275-9;LL1600-7;PhenX15_01_day sequence;LA16585-4;2;Day 2;;; +66275-9;LL1600-7;PhenX15_01_day sequence;LA16586-2;3;Day 3;;; +66275-9;LL1600-7;PhenX15_01_day sequence;LA16587-0;4;Day 4;;; +66275-9;LL1600-7;PhenX15_01_day sequence;LA16588-8;5;Day 5;;; +66275-9;LL1600-7;PhenX15_01_day sequence;LA16589-6;6;Day 6;;; +66275-9;LL1600-7;PhenX15_01_day sequence;LA16590-4;7;Day 7;;; +66281-7;LL1957-1;PhenX15_14_physical activity comparison;LA16824-7;1;More;;; +66281-7;LL1957-1;PhenX15_14_physical activity comparison;LA16823-9;2;Less;;; +66281-7;LL1957-1;PhenX15_14_physical activity comparison;LA18129-9;3;About the same;;; +66282-5;LL1958-9;PhenX15_15_day segment;LA14971-8;1;Morning;;; +66282-5;LL1958-9;PhenX15_15_day segment;LA18130-7;2;Afternoon;;; +66282-5;LL1958-9;PhenX15_15_day segment;LA14972-6;3;Evening;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18135-6;1;Visit with friends or family;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18136-4;2;Go to the senior center;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18137-2;3;Do volunteer work;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18138-0;4;Attend church or take part in church activities;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18140-6;5;Use a computer;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18141-4;6;Dance - such a square, folk,line,ballroom;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18142-2;7;Woodworking, needlework, drawing, or other arts and craft;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18143-0;8;Play golf, carrying or pulling your equipment;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18144-8;9;Play golf, riding a cart;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18145-5;10;Attend a concert, movie, lecture, or sport event;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18146-3;11;Play cards, bingo or board games with other people;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18147-1;12;Shoot pool or billiards;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18148-9;13;Play singles tennis;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18149-7;14;Play doubles tennis;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18150-5;15;Skate - ice, roller, in line;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18151-3;16;Play a musical instrument;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18152-1;17;Read;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18153-9;18;Heavy work around the house;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18154-7;19;Light work around the house;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18155-4;20;Heavy gardening;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18156-2;21;Light gardening;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18157-0;22;Work on car, truck, lawn mower, or other machinery;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18158-8;23;Walk or hike uphill;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18159-6;24;Walk fast or briskly for exercise;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18160-4;25;Walk to do errands - to store or taking children to school;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18161-2;26;Walk leisurely for exercise or pleasure;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18162-0;27;Ride a bicycle or stationary cycle;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18163-8;28;Other aerobic machines - rowing or step;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18164-6;29;Water exercises;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18165-3;30;Swim moderately or fast;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18166-1;31;Swim gently;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18167-9;32;Stretching or flexibility exercises;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18168-7;33;Aerobics or aerobic dancing;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18169-5;34;Moderate to heavy strength training;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18170-3;35;Light strength training;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18171-1;36;General conditioning exercises;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18172-9;37;Play basketball, soccer, or racquetball, not on sidelines;;; +66283-3;LL1962-1;PhenX15_16_older adult activities;LA18173-7;38;Other types of physical activity not mentioned;;; +66285-8;LL1430-9;PhenX14_24_activity total Hs;LA12717-7;1;Less than 1 hour;;; +66285-8;LL1430-9;PhenX14_24_activity total Hs;LA15833-9;2;1-2½ hours;;; +66285-8;LL1430-9;PhenX14_24_activity total Hs;LA15834-7;3;3-4½ hours;;; +66285-8;LL1430-9;PhenX14_24_activity total Hs;LA15835-4;4;5-6½ hours;;; +66285-8;LL1430-9;PhenX14_24_activity total Hs;LA15836-2;5;7-8½ hours;;; +66285-8;LL1430-9;PhenX14_24_activity total Hs;LA15837-0;6;9 or more hours;;; +66293-2;LL1602-3;PhenX15_03_situations w/ sitting;LA16592-0;1;Traveling to and from places;;; +66293-2;LL1602-3;PhenX15_03_situations w/ sitting;LA16593-8;2;At work;;; +66293-2;LL1602-3;PhenX15_03_situations w/ sitting;LA16594-6;3;Watching television;;; +66293-2;LL1602-3;PhenX15_03_situations w/ sitting;LA16595-3;4;Using a computer;;; +66293-2;LL1602-3;PhenX15_03_situations w/ sitting;LA16596-1;5;Leisure time - visiting friends,movies,dining out etc;;; +66297-3;LL1431-7;PhenX14_25_reason no actigraph;LA15194-6;1;Participant refused;;; +66297-3;LL1431-7;PhenX14_25_reason no actigraph;LA15213-4;2;Cognitive impairment;;; +66297-3;LL1431-7;PhenX14_25_reason no actigraph;LA15214-2;3;No device available/schedule problem;;; +66297-3;LL1431-7;PhenX14_25_reason no actigraph;LA15215-9;4;Physical/medical problem;;; +66297-3;LL1431-7;PhenX14_25_reason no actigraph;LA46-8;5;Other;;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA15216-7;1;Cognitive problems;;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA15217-5;2;Dexterity problems;;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA15218-3;3;Vision problems;;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA15219-1;4;Travel plans interfered;;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA15220-9;5;"Participant took off; did not replace or restart correctly";;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA15222-5;6;Actigraph lost;;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA15194-6;7;Participant refused;;; +66316-1;LL1432-5;PhenX14_26_reason no activity recorded;LA6310-2;8;Other (specify);;; +66318-7;LL1433-3;PhenX14_27_diary completed;LA33-6;0;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66318-7;LL1433-3;PhenX14_27_diary completed;LA15223-3;2;No (no diary entries were made);;; +66318-7;LL1433-3;PhenX14_27_diary completed;LA15224-1;3;No (some diary entries were made);;; +66333-6;LL1708-8;PhenX15_08_job activities past Y;LA16892-4;1;No job or regular work;;; +66333-6;LL1708-8;PhenX15_08_job activities past Y;LA16893-2;2;Spent most of the day sitting or standing;;; +66333-6;LL1708-8;PhenX15_08_job activities past Y;LA16894-0;3;Spent most of the day walking or using my hands and arms;;; +66333-6;LL1708-8;PhenX15_08_job activities past Y;LA16895-7;4;Spent most of the day lifting or carrying heavy objects;;; +66333-6;LL1708-8;PhenX15_08_job activities past Y;LA16896-5;5;Spent most of the day doing hard physical labor;;; +66337-7;LL1709-6;PhenX15_09_leisure activities;LA16901-3;1;Spent without very much physical activity;;; +66337-7;LL1709-6;PhenX15_09_leisure activities;LA16897-3;2;Most weekends I was able to get outdoors for some light exercise;;; +66337-7;LL1709-6;PhenX15_09_leisure activities;LA16898-1;3;Three times per week, on the average, I engaged in some moderate activity;;; +66337-7;LL1709-6;PhenX15_09_leisure activities;LA16899-9;4;Engaged in a regular program of physical fitness involving some kind of heavy physical activity at least three times per week;;; +66337-7;LL1709-6;PhenX15_09_leisure activities;LA16900-5;5;Engaged in a regular program of physical fitness five or more times per week;;; +66356-7;LL1435-8;PhenX14_29_neighborhood housing;LA15229-0;1;Detached single-family housing;;; +66356-7;LL1435-8;PhenX14_29_neighborhood housing;LA15230-8;2;Townhouses, row houses, apartments, or condos of two-three stories;;; +66356-7;LL1435-8;PhenX14_29_neighborhood housing;LA15231-6;3;Mix of single-family residences and townhouses, row houses, apartments, or condos;;; +66356-7;LL1435-8;PhenX14_29_neighborhood housing;LA15232-4;4;Apartments or condos of 4-12 stories;;; +66356-7;LL1435-8;PhenX14_29_neighborhood housing;LA15233-2;5;Apartments or condos of more than 12 stories;;; +66356-7;LL1435-8;PhenX14_29_neighborhood housing;LA14619-3;6;Don't know/not sure;;; +66357-5;LL1603-1;PhenX15_04;LA15236-5;1;Strongly disagree;;; +66357-5;LL1603-1;PhenX15_04;LA15234-0;2;Somewhat disagree;;; +66357-5;LL1603-1;PhenX15_04;LA15235-7;3;Somewhat agree;;; +66357-5;LL1603-1;PhenX15_04;LA15237-3;4;Strongly agree;;; +66357-5;LL1603-1;PhenX15_04;LA14619-3;5;Don't know/not sure;;; +66358-3;LL1603-1;PhenX15_04;LA15236-5;1;Strongly disagree;;; +66358-3;LL1603-1;PhenX15_04;LA15234-0;2;Somewhat disagree;;; +66358-3;LL1603-1;PhenX15_04;LA15235-7;3;Somewhat agree;;; +66358-3;LL1603-1;PhenX15_04;LA15237-3;4;Strongly agree;;; +66358-3;LL1603-1;PhenX15_04;LA14619-3;5;Don't know/not sure;;; +66359-1;LL1603-1;PhenX15_04;LA15236-5;1;Strongly disagree;;; +66359-1;LL1603-1;PhenX15_04;LA15234-0;2;Somewhat disagree;;; +66359-1;LL1603-1;PhenX15_04;LA15235-7;3;Somewhat agree;;; +66359-1;LL1603-1;PhenX15_04;LA15237-3;4;Strongly agree;;; +66359-1;LL1603-1;PhenX15_04;LA14619-3;5;Don't know/not sure;;; +66360-9;LL1603-1;PhenX15_04;LA15236-5;1;Strongly disagree;;; +66360-9;LL1603-1;PhenX15_04;LA15234-0;2;Somewhat disagree;;; +66360-9;LL1603-1;PhenX15_04;LA15235-7;3;Somewhat agree;;; +66360-9;LL1603-1;PhenX15_04;LA15237-3;4;Strongly agree;;; +66360-9;LL1603-1;PhenX15_04;LA14619-3;5;Don't know/not sure;;; +66361-7;LL1603-1;PhenX15_04;LA15236-5;1;Strongly disagree;;; +66361-7;LL1603-1;PhenX15_04;LA15234-0;2;Somewhat disagree;;; +66361-7;LL1603-1;PhenX15_04;LA15235-7;3;Somewhat agree;;; +66361-7;LL1603-1;PhenX15_04;LA15237-3;4;Strongly agree;;; +66361-7;LL1603-1;PhenX15_04;LA14619-3;5;Don't know/not sure;;; +66362-5;LL1603-1;PhenX15_04;LA15236-5;1;Strongly disagree;;; +66362-5;LL1603-1;PhenX15_04;LA15234-0;2;Somewhat disagree;;; +66362-5;LL1603-1;PhenX15_04;LA15235-7;3;Somewhat agree;;; +66362-5;LL1603-1;PhenX15_04;LA15237-3;4;Strongly agree;;; +66362-5;LL1603-1;PhenX15_04;LA14619-3;5;Don't know/not sure;;; +66363-3;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66363-3;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66363-3;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66363-3;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66363-3;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66364-1;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66364-1;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66364-1;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66364-1;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66364-1;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66365-8;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66365-8;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66365-8;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66365-8;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66365-8;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66366-6;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66366-6;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66366-6;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66366-6;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66366-6;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66367-4;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66367-4;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66367-4;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66367-4;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66367-4;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66368-2;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66368-2;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66368-2;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66368-2;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66368-2;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66369-0;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66369-0;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66369-0;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66369-0;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66369-0;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66370-8;LL1606-4;PhenX15_07;LA15238-1;1;Disagree a lot;;; +66370-8;LL1606-4;PhenX15_07;LA15239-9;2;Disagree a little;;; +66370-8;LL1606-4;PhenX15_07;LA15240-7;3;Neither agree nor disagree;;; +66370-8;LL1606-4;PhenX15_07;LA15241-5;4;Agree a little;;; +66370-8;LL1606-4;PhenX15_07;LA15242-3;5;Agree a lot;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16597-9;1;Weather was very bad - hot, humid, rainy, cold;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16598-7;2;Bored by the program or activity;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16599-5;3;On vacation;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16600-1;4;Not interested in the activity;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16601-9;5;Felt pain or discomfort when exercising;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16602-7;6;Had to exercise alone;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16603-5;7;Not fun or enjoyable;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16604-3;8;Difficult to get to the exercise location;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16605-0;9;Didn't like the particular activity program that I was involved in;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16606-8;10;Schedule conflicted with my exercise session;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16607-6;11;Felt self-conscious about my appearance when I exercised;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16608-4;12;Instructor does not offer me any encouragement;;; +66371-6;LL1605-6;PhenX15_06_exercise circumstances;LA16609-2;13;Under personal stress of some kind;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15243-1;1;0%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15244-9;2;10%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15245-6;3;20%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15246-4;4;30%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15247-2;5;40%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15248-0;6;50%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15249-8;7;60%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15250-6;8;70%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15251-4;9;80%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15252-2;10;90%;;; +66372-4;LL1604-9;PhenX15_05_degree of confidence exercise;LA15253-0;11;100%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15243-1;1;0%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15244-9;2;10%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15245-6;3;20%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15246-4;4;30%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15247-2;5;40%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15248-0;6;50%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15249-8;7;60%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15250-6;8;70%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15251-4;9;80%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15252-2;10;90%;;; +72687-7;LL1604-9;PhenX15_05_degree of confidence exercise;LA15253-0;11;100%;;; +66392-2;LL1954-8;PhenX16_24_Booster sequence;LA16610-0;1;Booster 1;;; +66392-2;LL1954-8;PhenX16_24_Booster sequence;LA16611-8;2;Booster 2;;; +66392-2;LL1954-8;PhenX16_24_Booster sequence;LA16612-6;3;Booster 3;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA46-8;0;Other;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA10452-3;1;Diphtheria;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA18126-5;2;Hepatitis B;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA17014-4;3;Measles;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA10491-1;4;Mumps;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA17015-1;5;Pertussis/whooping cough;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA17016-9;6;Polio;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA10502-5;7;Rubella;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA16614-2;8;Smallpox;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA10510-8;9;Tetanus;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA10513-2;10;Tuberculosis;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA16615-9;11;Typhoid;;; +66393-0;LL1955-5;PhenX16_25_Booster type;LA18127-3;12;Other booster;;; +66412-8;LL1731-0;PhenX16_04;LA15270-4;1;Exposure country not ascertainable;;; +66412-8;LL1731-0;PhenX16_04;LA15271-2;2;Ship;;; +66412-8;LL1731-0;PhenX16_04;LA15272-0;3;Plane;;; +66413-6;LL1732-8;PhenX16_05;LA16909-6;1;Country 1;;; +66413-6;LL1732-8;PhenX16_05;LA16910-4;2;Country 2;;; +66413-6;LL1732-8;PhenX16_05;LA16911-2;3;Country 3;;; +66413-6;LL1732-8;PhenX16_05;LA16912-0;4;Country 4;;; +66415-1;LL1733-6;PhenX16_06;LA15273-8;1;Tourism;;; +66415-1;LL1733-6;PhenX16_06;LA15274-6;2;Business;;; +66415-1;LL1733-6;PhenX16_06;LA15275-3;3;Missionary/volunteer/researcher/aid work;;; +66415-1;LL1733-6;PhenX16_06;LA15276-1;4;Student;;; +66415-1;LL1733-6;PhenX16_06;LA15277-9;5;Medical tourism;;; +66415-1;LL1733-6;PhenX16_06;LA15278-7;6;Immigration;;; +66415-1;LL1733-6;PhenX16_06;LA15279-5;7;Visiting friends & relatives;;; +66415-1;LL1733-6;PhenX16_06;LA15280-3;8;Military;;; +66416-9;LL1769-0;PhenX16_10_travel risk;LA15281-1;1;Pre-arranged or organized travel;;; +66416-9;LL1769-0;PhenX16_10_travel risk;LA15282-9;2;Risk travel;;; +66416-9;LL1769-0;PhenX16_10_travel risk;LA15283-7;3;Expatriate;;; +66417-7;LL1770-8;PhenX16_11_clinical setting;LA15284-5;1;Seen during travel;;; +66417-7;LL1770-8;PhenX16_11_clinical setting;LA15285-2;2;Seen after travel;;; +66417-7;LL1770-8;PhenX16_11_clinical setting;LA15286-0;3;Immigration travel only;;; +66418-5;LL1771-6;PhenX16_12_pt type;LA6511-5;1;Inpatient;;; +66418-5;LL1771-6;PhenX16_12_pt type;LA15287-8;2;Outpatient;;; +66418-5;LL1771-6;PhenX16_12_pt type;LA15288-6;3;Teleconsult-outpatient;;; +66418-5;LL1771-6;PhenX16_12_pt type;LA15289-4;4;Teleconsult-inpatient;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16967-4;1;Cardiac/MI;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA7542-9;2;Fatigue;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16968-2;3;Gastrointestinal;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16969-0;4;Genitourinary;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16970-8;5;HEENT;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16971-6;6;Lymphatic;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16972-4;7;Musculoskeletal;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16973-2;8;Neurologic;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16974-0;9;Psychologic;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA16975-7;10;Respiratory;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA4332-8;11;Skin;;; +66422-7;LL1766-6;PhenX16_07_main symptom;LA46-8;12;Other;;; +66423-5;LL6330-6;Schmid med;LA33657-0;17;Anti-convulsants/tranquilizers or psychotropics/hypnotics;;; +66428-4;LL1767-4;PhenX16_08_working dx number;LA16976-5;1;Working diagnosis 1;;; +66428-4;LL1767-4;PhenX16_08_working dx number;LA16977-3;2;Working diagnosis 2;;; +66428-4;LL1767-4;PhenX16_08_working dx number;LA16978-1;3;Working diagnosis 3;;; +66429-2;LL1768-2;PhenX16_09_working dx status;LA15290-2;1;Confirmed;;; +66429-2;LL1768-2;PhenX16_09_working dx status;LA12746-6;2;Probable;;; +66429-2;LL1768-2;PhenX16_09_working dx status;LA15291-0;3;Suspected;;; +66429-2;LL1768-2;PhenX16_09_working dx status;LA15292-8;4;Exclusion of;;; +66429-2;LL1768-2;PhenX16_09_working dx status;LA15293-6;5;Status post (confirmed);;; +66429-2;LL1768-2;PhenX16_09_working dx status;LA15294-4;6;Status post (probable);;; +66429-2;LL1768-2;PhenX16_09_working dx status;LA15295-1;7;Status post (suspected);;; +66430-0;LL1961-3;PhenX16_27_travel related illness;LA15296-9;1;Not travel related;;; +66433-4;LL1434-1;PhenX14_28_difficulty standing 2H;LA15227-4;1;No difficulty;;; +66433-4;LL1434-1;PhenX14_28_difficulty standing 2H;LA13950-3;2;Some difficulty;;; +66433-4;LL1434-1;PhenX14_28_difficulty standing 2H;LA15228-2;3;Much difficulty;;; +66433-4;LL1434-1;PhenX14_28_difficulty standing 2H;LA13912-3;4;Unable to do;;; +66433-4;LL1434-1;PhenX14_28_difficulty standing 2H;LA15226-6;5;Do not do this activity;;; +66433-4;LL1434-1;PhenX14_28_difficulty standing 2H;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66433-4;LL1434-1;PhenX14_28_difficulty standing 2H;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66434-2;LL1773-2;PhenX16_14_inflammatory disorders;LA17006-0;1;Prominent rash on cheeks for more than 1 month;;; +66434-2;LL1773-2;PhenX16_14_inflammatory disorders;LA17007-8;2;Skin breaks out in the sun, not sunburn;;; +66434-2;LL1773-2;PhenX16_14_inflammatory disorders;LA17008-6;3;Sores in mouth for more than 2 weeks;;; +66434-2;LL1773-2;PhenX16_14_inflammatory disorders;LA17009-4;4;Arthritis or rheumatism for more than 3 months;;; +66434-2;LL1773-2;PhenX16_14_inflammatory disorders;LA17010-2;5;Pain for more than a few days when taking deep breath, pleurisy;;; +66434-2;LL1773-2;PhenX16_14_inflammatory disorders;LA17011-0;6;Protein in urine;;; +66434-2;LL1773-2;PhenX16_14_inflammatory disorders;LA17012-8;7;Low blood counts, anemia, low white blood cell count, or low platelet count;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15300-9;1;Systemic lupus erythematosus (SLE);;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15161-5;2;Rheumatoid Arthritis;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15301-7;3;Sjögren's syndrome;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15302-5;4;Discoid lupus;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15303-3;5;Autoimmune thyroid disease (AITD);;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15304-1;6;Type 1 diabetes (Juvenile onset);;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15305-8;7;Type 2 diabetes (Adult onset);;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15158-1;8;Myasthenia Gravis;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15306-6;9;Scleroderma;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15307-4;10;Addison's disease;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15308-2;11;Idiopathic thrombocytopenia (ITP);;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15309-0;12;Antiphospholipid syndrome;;; +66435-9;LL1953-0;PhenX16_23_Autoimmune disease, family hx;LA15310-8;13;Graying of all hair before age 35;;; +66436-7;LL1609-8;PhenX16_01_health problems;LA16621-7;1;Health problem 1;;; +66436-7;LL1609-8;PhenX16_01_health problems;LA16622-5;2;Health problem 2;;; +66436-7;LL1609-8;PhenX16_01_health problems;LA16623-3;3;Health problem 3;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA17013-6;1;Chicken pox;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA17014-4;2;Measles;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA10502-5;3;Rubella;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA7442-2;4;Hepatitis;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA17015-1;5;Pertussis/whooping cough;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA7465-3;6;Pneumonia;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA17016-9;7;Polio;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA10491-1;8;Mumps;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA17017-7;9;Scarlet fever;;; +66454-0;LL1775-7;PhenX16_16_infectious diseases;LA46-8;10;Other;;; +66455-7;LL4919-8;Condition status;LA17712-3;1;Unconfirmed;;; +66455-7;LL4919-8;Condition status;LA9044-4;2;Provisional;;; +66455-7;LL4919-8;Condition status;LA28708-8;3;Differential;;; +66455-7;LL4919-8;Condition status;LA15290-2;4;Confirmed;;; +66455-7;LL4919-8;Condition status;LA28709-6;5;Refuted;;; +99498-8;LL4919-8;Condition status;LA17712-3;1;Unconfirmed;;; +99498-8;LL4919-8;Condition status;LA9044-4;2;Provisional;;; +99498-8;LL4919-8;Condition status;LA28708-8;3;Differential;;; +99498-8;LL4919-8;Condition status;LA15290-2;4;Confirmed;;; +99498-8;LL4919-8;Condition status;LA28709-6;5;Refuted;;; +66456-5;LL1777-3;PhenX16_18_doctor visits;LA17021-9;1;Doctor visit 1;;; +66456-5;LL1777-3;PhenX16_18_doctor visits;LA17022-7;2;Doctor visit 2;;; +66456-5;LL1777-3;PhenX16_18_doctor visits;LA17023-5;3;Doctor visit 3;;; +66459-9;LL1851-6;PhenX16_20_surgery number;LA17729-7;1;Surgery 1;;; +66459-9;LL1851-6;PhenX16_20_surgery number;LA17730-5;2;Surgery 2;;; +66459-9;LL1851-6;PhenX16_20_surgery number;LA17731-3;3;Surgery 3;;; +66460-7;LL1855-7;PhenX16_21_lab, imaging sequence;LA17740-4;1;Lab or imaging 1;;; +66460-7;LL1855-7;PhenX16_21_lab, imaging sequence;LA17741-2;2;Lab or imaging 2;;; +66460-7;LL1855-7;PhenX16_21_lab, imaging sequence;LA17742-0;3;Lab or imaging 3;;; +66460-7;LL1855-7;PhenX16_21_lab, imaging sequence;LA17743-8;4;Lab or imaging 4;;; +66465-6;LL1857-3;PhenX16_22_PT/OT sequence;LA17745-3;1;Physical occupational therapy 1;;; +66465-6;LL1857-3;PhenX16_22_PT/OT sequence;LA17746-1;2;Physical occupational therapy 2;;; +66465-6;LL1857-3;PhenX16_22_PT/OT sequence;LA17747-9;3;Physical occupational therapy 3;;; +66465-6;LL1857-3;PhenX16_22_PT/OT sequence;LA17748-7;4;Physical occupational therapy 4;;; +66468-0;LL1960-5;PhenX16_26_injected drugs;LA15257-1;1;Cocaine;387085005;Cocaine (substance);http://snomed.info/sct +66468-0;LL1960-5;PhenX16_26_injected drugs;LA15258-9;2;Heroin;387341002;Diamorphine (substance);http://snomed.info/sct +66468-0;LL1960-5;PhenX16_26_injected drugs;LA15259-7;3;Methamphetamine;387499002;Metamfetamine (substance);http://snomed.info/sct +66468-0;LL1960-5;PhenX16_26_injected drugs;LA15260-5;4;Steroids;;; +66468-0;LL1960-5;PhenX16_26_injected drugs;LA15261-3;5;Any other drugs;;; +66468-0;LL1960-5;PhenX16_26_injected drugs;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66468-0;LL1960-5;PhenX16_26_injected drugs;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66480-5;LL1772-4;PhenX16_13-medical hx;LA16980-7;1;Acquired immunodeficiency syndrome, AIDS, or HIV positive;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16981-5;2;Arthritis;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16982-3;3;Asthma;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16983-1;4;Bronchitis;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA10524-9;5;Cancer;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16984-9;6;Chlamydia;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA10529-8;7;Diabetes;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA7428-1;8;Dizziness;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16985-6;9;Epilepsy;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16986-4;10;Eye problem;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16987-2;11;Fainting;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16988-0;12;Frequent or severe headaches;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16302-4;13;Glaucoma;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA10467-1;14;Gonorrhea;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16989-8;15;Hearing impairment;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16990-6;16;Heart condition;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA9975-9;17;Hemodialysis;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16991-4;18;Herpes;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16992-2;19;High blood cholesterol;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA14293-7;20;High blood pressure;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16993-0;21;Hypoglycemia;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA7450-5;22;Jaundice;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA10528-0;23;Kidney Disease;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16994-8;24;Low blood pressure;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA24759-5;25;Intellectual disabilities;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16996-3;26;Pain or pressure in chest;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16997-1;27;Palpitations;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16998-9;28;Periods of unconsciousness;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16999-7;29;Rheumatic fever;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA17000-3;30;Rheumatism;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA15899-0;31;Seizures;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA17001-1;32;Shortness of breath;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA17002-9;33;Stomach or liver problems;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA17003-7;34;Syphilis;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA10513-2;35;Tuberculosis;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA16304-0;36;Tumor;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA17004-5;37;Thyroid problems;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA17005-2;38;Urinary tract problems;;; +66480-5;LL1772-4;PhenX16_13-medical hx;LA46-8;39;Other;;; +66500-0;LL1645-2;PhenX16_03_autoimmune disroder presence;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +66500-0;LL1645-2;PhenX16_03_autoimmune disroder presence;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66500-0;LL1645-2;PhenX16_03_autoimmune disroder presence;LA6270-8;3;Never;;; +66501-8;LL1776-5;PhenX16_17_non infectious illnesses;LA17018-5;1;Noninfectious major illness 1;;; +66501-8;LL1776-5;PhenX16_17_non infectious illnesses;LA17019-3;2;Noninfectious major illness 2;;; +66501-8;LL1776-5;PhenX16_17_non infectious illnesses;LA17020-1;3;Noninfectious major illness 3;;; +66504-2;LL1410-1;PhenX14_08_assay exclusion criteria;LA15174-8;1;Hemophilia;;; +66504-2;LL1410-1;PhenX14_08_assay exclusion criteria;LA15175-5;2;Received cancer chemotherapy in the last 3 weeks;;; +66504-2;LL1410-1;PhenX14_08_assay exclusion criteria;LA15177-1;3;None – proceed with blood draw;;; +66505-9;LL1612-2;PhenX14_34_assay exclusion criteria, serum insulin;LA15172-2;1;Taking insulin;;; +66505-9;LL1612-2;PhenX14_34_assay exclusion criteria, serum insulin;LA15174-8;2;Hemophilia;;; +66505-9;LL1612-2;PhenX14_34_assay exclusion criteria, serum insulin;LA15175-5;3;Received cancer chemotherapy in the last 3 weeks;;; +66505-9;LL1612-2;PhenX14_34_assay exclusion criteria, serum insulin;LA15176-3;4;Has not fasted at least 9 hours;;; +66505-9;LL1612-2;PhenX14_34_assay exclusion criteria, serum insulin;LA15177-1;5;None – proceed with blood draw;;; +66507-5;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +66507-5;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +66510-9;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +66510-9;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +66513-3;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +66513-3;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +70740-6;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +70740-6;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +98736-2;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +98736-2;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +98772-7;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +98772-7;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +98775-0;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +98775-0;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +98783-4;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +98783-4;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +98786-7;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +98786-7;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +98802-2;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +98802-2;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +98804-8;LL1973-8;PhenX17_15_laterality;LA4585-1;1;Left;;; +98804-8;LL1973-8;PhenX17_15_laterality;LA4306-2;2;Right;;; +66508-3;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15321-5;1;Grade 1: doubtful narrowing of joint space and possible osteophytic lipping;;; +66508-3;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15322-3;2;Grade 2: definite osteophytes, definite narrowing of joint space;;; +66508-3;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15323-1;3;Grade 3: moderate multiple osteophytes, definite narrowing of joints space, some sclerosis and possible deformity of bone contour;;; +66508-3;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15324-9;4;Grade 4: large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone contour;;; +66511-7;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15321-5;1;Grade 1: doubtful narrowing of joint space and possible osteophytic lipping;;; +66511-7;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15322-3;2;Grade 2: definite osteophytes, definite narrowing of joint space;;; +66511-7;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15323-1;3;Grade 3: moderate multiple osteophytes, definite narrowing of joints space, some sclerosis and possible deformity of bone contour;;; +66511-7;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15324-9;4;Grade 4: large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone contour;;; +66514-1;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15321-5;1;Grade 1: doubtful narrowing of joint space and possible osteophytic lipping;;; +66514-1;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15322-3;2;Grade 2: definite osteophytes, definite narrowing of joint space;;; +66514-1;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15323-1;3;Grade 3: moderate multiple osteophytes, definite narrowing of joints space, some sclerosis and possible deformity of bone contour;;; +66514-1;LL1614-8;PhenX17_01_Kellgren-Lawrence score;LA15324-9;4;Grade 4: large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone contour;;; +66515-8;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66515-8;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66515-8;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66515-8;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66515-8;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66515-8;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66515-8;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66516-6;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66516-6;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66516-6;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66516-6;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66516-6;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66516-6;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66516-6;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66517-4;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66517-4;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66517-4;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66517-4;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66517-4;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66517-4;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66517-4;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66518-2;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66518-2;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66518-2;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66518-2;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66518-2;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66518-2;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66518-2;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66520-8;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66520-8;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66520-8;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66520-8;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66520-8;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66520-8;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66520-8;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66521-6;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66521-6;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66521-6;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66521-6;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66521-6;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66521-6;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66521-6;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66522-4;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66522-4;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66522-4;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66522-4;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66522-4;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66522-4;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66522-4;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66523-2;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66523-2;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66523-2;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66523-2;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66523-2;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66523-2;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66523-2;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66525-7;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66525-7;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66525-7;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66525-7;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66525-7;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66525-7;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66525-7;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66526-5;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66526-5;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66526-5;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66526-5;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66526-5;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66526-5;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66526-5;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66527-3;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66527-3;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66527-3;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66527-3;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66527-3;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66527-3;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66527-3;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66528-1;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66528-1;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66528-1;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66528-1;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66528-1;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66528-1;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66528-1;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66530-7;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66530-7;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66530-7;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66530-7;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66530-7;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66530-7;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66530-7;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66531-5;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66531-5;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66531-5;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66531-5;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66531-5;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66531-5;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66531-5;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66532-3;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66532-3;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66532-3;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66532-3;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66532-3;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66532-3;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66532-3;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66533-1;LL1615-5;PhenX17_02_eczema scores;LA16631-6;1;0 - absent;;; +66533-1;LL1615-5;PhenX17_02_eczema scores;LA16632-4;2;0.5;;; +66533-1;LL1615-5;PhenX17_02_eczema scores;LA16369-3;3;1 - mild;;; +66533-1;LL1615-5;PhenX17_02_eczema scores;LA15765-3;4;1.5;;; +66533-1;LL1615-5;PhenX17_02_eczema scores;LA16633-2;5;2 - moderate;;; +66533-1;LL1615-5;PhenX17_02_eczema scores;LA15766-1;6;2.5;;; +66533-1;LL1615-5;PhenX17_02_eczema scores;LA16634-0;7;3 - severe;;; +66519-0;LL1616-3;PhenX17_03_eczema area affected;LA16635-7;1;0 - none;;; +66519-0;LL1616-3;PhenX17_03_eczema area affected;LA16636-5;2;1 - 9%;;; +66519-0;LL1616-3;PhenX17_03_eczema area affected;LA16637-3;3;10 - 29%;;; +66519-0;LL1616-3;PhenX17_03_eczema area affected;LA16638-1;4;30 - 49%;;; +66519-0;LL1616-3;PhenX17_03_eczema area affected;LA16639-9;5;50 - 69%;;; +66519-0;LL1616-3;PhenX17_03_eczema area affected;LA16640-7;6;70 - 89%;;; +66519-0;LL1616-3;PhenX17_03_eczema area affected;LA16641-5;7;90 - 100%;;; +66524-0;LL1616-3;PhenX17_03_eczema area affected;LA16635-7;1;0 - none;;; +66524-0;LL1616-3;PhenX17_03_eczema area affected;LA16636-5;2;1 - 9%;;; +66524-0;LL1616-3;PhenX17_03_eczema area affected;LA16637-3;3;10 - 29%;;; +66524-0;LL1616-3;PhenX17_03_eczema area affected;LA16638-1;4;30 - 49%;;; +66524-0;LL1616-3;PhenX17_03_eczema area affected;LA16639-9;5;50 - 69%;;; +66524-0;LL1616-3;PhenX17_03_eczema area affected;LA16640-7;6;70 - 89%;;; +66524-0;LL1616-3;PhenX17_03_eczema area affected;LA16641-5;7;90 - 100%;;; +66529-9;LL1616-3;PhenX17_03_eczema area affected;LA16635-7;1;0 - none;;; +66529-9;LL1616-3;PhenX17_03_eczema area affected;LA16636-5;2;1 - 9%;;; +66529-9;LL1616-3;PhenX17_03_eczema area affected;LA16637-3;3;10 - 29%;;; +66529-9;LL1616-3;PhenX17_03_eczema area affected;LA16638-1;4;30 - 49%;;; +66529-9;LL1616-3;PhenX17_03_eczema area affected;LA16639-9;5;50 - 69%;;; +66529-9;LL1616-3;PhenX17_03_eczema area affected;LA16640-7;6;70 - 89%;;; +66529-9;LL1616-3;PhenX17_03_eczema area affected;LA16641-5;7;90 - 100%;;; +66534-9;LL1616-3;PhenX17_03_eczema area affected;LA16635-7;1;0 - none;;; +66534-9;LL1616-3;PhenX17_03_eczema area affected;LA16636-5;2;1 - 9%;;; +66534-9;LL1616-3;PhenX17_03_eczema area affected;LA16637-3;3;10 - 29%;;; +66534-9;LL1616-3;PhenX17_03_eczema area affected;LA16638-1;4;30 - 49%;;; +66534-9;LL1616-3;PhenX17_03_eczema area affected;LA16639-9;5;50 - 69%;;; +66534-9;LL1616-3;PhenX17_03_eczema area affected;LA16640-7;6;70 - 89%;;; +66534-9;LL1616-3;PhenX17_03_eczema area affected;LA16641-5;7;90 - 100%;;; +66537-2;LL1646-0;PhenX17_05;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66537-2;LL1646-0;PhenX17_05;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66537-2;LL1646-0;PhenX17_05;LA15331-4;3;Explanation;;; +66541-4;LL1646-0;PhenX17_05;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66541-4;LL1646-0;PhenX17_05;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +66541-4;LL1646-0;PhenX17_05;LA15331-4;3;Explanation;;; +66542-2;LL1860-7;PhenX17_11_psoriasis spot color;LA17763-6;1;0 - no redness;;; +66542-2;LL1860-7;PhenX17_11_psoriasis spot color;LA17853-5;2;1 - slight pink;;; +66542-2;LL1860-7;PhenX17_11_psoriasis spot color;LA17854-3;3;2 - pink;;; +66542-2;LL1860-7;PhenX17_11_psoriasis spot color;LA17855-0;4;3 - red;;; +66542-2;LL1860-7;PhenX17_11_psoriasis spot color;LA17764-4;5;4 - dark red;;; +66543-0;LL1895-3;PhenX17_12;LA17856-8;1;0 - no thickness;;; +66543-0;LL1895-3;PhenX17_12;LA17857-6;2;1 - feels firm;;; +66543-0;LL1895-3;PhenX17_12;LA17858-4;3;2 - raised;;; +66543-0;LL1895-3;PhenX17_12;LA17859-2;4;3 - thick;;; +66543-0;LL1895-3;PhenX17_12;LA17860-0;5;4 - very thick;;; +66544-8;LL1896-1;PhenX17_13;LA17861-8;1;0 - no scale;;; +66544-8;LL1896-1;PhenX17_13;LA17862-6;2;1 - slight scale;;; +66544-8;LL1896-1;PhenX17_13;LA17863-4;3;2 - scaly;;; +66544-8;LL1896-1;PhenX17_13;LA17864-2;4;3 - flaky;;; +66544-8;LL1896-1;PhenX17_13;LA17865-9;5;4 - very flaky;;; +66547-1;LL1493-7;PhenX09_30_smoking type;LA15332-2;1;Cigarettes;;; +66547-1;LL1493-7;PhenX09_30_smoking type;LA16128-3;2;Pipe;;; +66547-1;LL1493-7;PhenX09_30_smoking type;LA16129-1;3;Cigar;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16774-4;1;Dovonex;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA14339-8;2;Methotrexate;387381009;Methotrexate (substance);http://snomed.info/sct +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16775-1;3;Soriatane;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16776-9;4;Cyclosporine;387467008;Ciclosporin (substance);http://snomed.info/sct +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16779-3;5;Humira;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16780-1;6;Raptiva;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16781-9;7;Amevive;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16782-7;8;Remicade;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16783-5;9;PUVA;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16784-3;10;UVB;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16786-8;11;Other topicals;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16777-7;12;Other systemics;;; +66549-7;LL1647-8;PhenX17_06_psoriasis treatment;LA16785-0;13;Other biologicals;;; +66551-3;LL1648-6;PhenX17_07_psoriasis tx effective scale;LA16787-6;1;0 - not effective;;; +66551-3;LL1648-6;PhenX17_07_psoriasis tx effective scale;LA6112-2;2;1;;; +66551-3;LL1648-6;PhenX17_07_psoriasis tx effective scale;LA6113-0;3;2;;; +66551-3;LL1648-6;PhenX17_07_psoriasis tx effective scale;LA6114-8;4;3;;; +66551-3;LL1648-6;PhenX17_07_psoriasis tx effective scale;LA6115-5;5;4;;; +66551-3;LL1648-6;PhenX17_07_psoriasis tx effective scale;LA16788-4;6;5 - very effective;;; +66555-4;LL1617-1;PhenX17_04_skin types;LA15337-1;1;Skin-type I: very fair skin, blond or red hair, light eyes (blue or green), never tan and always sunburn after sun exposure;;; +66555-4;LL1617-1;PhenX17_04_skin types;LA15338-9;2;Skin-type II: fair skin, blond or light-brown hair, light eyes (blue or green), usual sunburn;;; +66555-4;LL1617-1;PhenX17_04_skin types;LA15339-7;3;Skin-type III: deep skin, brown hair, light to medium eye color;;; +66555-4;LL1617-1;PhenX17_04_skin types;LA15340-5;4;Skin-type IV: olive skin, dark-brown hair, brown eyes;;; +66555-4;LL1617-1;PhenX17_04_skin types;LA15341-3;5;Skin-type V: brown skin, black hair, black eyes;;; +66555-4;LL1617-1;PhenX17_04_skin types;LA15342-1;6;Skin-type VI: black skin, black hair, black eyes;;; +66556-2;LL3065-1;None|Few|Mod|Many;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +66556-2;LL3065-1;None|Few|Mod|Many;LA15680-4;1;Few;57176003;Few (qualifier value);http://snomed.info/sct +66556-2;LL3065-1;None|Few|Mod|Many;LA6751-7;2;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +66556-2;LL3065-1;None|Few|Mod|Many;LA15681-2;3;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +75663-5;LL3065-1;None|Few|Mod|Many;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +75663-5;LL3065-1;None|Few|Mod|Many;LA15680-4;1;Few;57176003;Few (qualifier value);http://snomed.info/sct +75663-5;LL3065-1;None|Few|Mod|Many;LA6751-7;2;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +75663-5;LL3065-1;None|Few|Mod|Many;LA15681-2;3;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +95597-1;LL3065-1;None|Few|Mod|Many;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +95597-1;LL3065-1;None|Few|Mod|Many;LA15680-4;1;Few;57176003;Few (qualifier value);http://snomed.info/sct +95597-1;LL3065-1;None|Few|Mod|Many;LA6751-7;2;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +95597-1;LL3065-1;None|Few|Mod|Many;LA15681-2;3;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +95598-9;LL3065-1;None|Few|Mod|Many;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +95598-9;LL3065-1;None|Few|Mod|Many;LA15680-4;1;Few;57176003;Few (qualifier value);http://snomed.info/sct +95598-9;LL3065-1;None|Few|Mod|Many;LA6751-7;2;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +95598-9;LL3065-1;None|Few|Mod|Many;LA15681-2;3;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +66557-0;LL1649-4;PhenX17_08_ number of moles;LA15343-9;1;More than 50;;; +66557-0;LL1649-4;PhenX17_08_ number of moles;LA15344-7;2;Fewer than 50;;; +66568-7;LL1779-9;PhenX17_10_leg stand attempt;LA17027-6;1;Leg stand attempt 1;;; +66568-7;LL1779-9;PhenX17_10_leg stand attempt;LA17028-4;2;Leg stand attempt 2;;; +66573-7;LL1629-6;PhenX18_12_language-speak,think;LA16645-6;1;(Language) all the time;;; +66573-7;LL1629-6;PhenX18_12_language-speak,think;LA16646-4;2;(Language) most of the time;;; +66573-7;LL1629-6;PhenX18_12_language-speak,think;LA16647-2;3;(Language) and English equally;;; +66573-7;LL1629-6;PhenX18_12_language-speak,think;LA16649-8;4;English most of the time;;; +66573-7;LL1629-6;PhenX18_12_language-speak,think;LA16648-0;5;English all the time;;; +66573-7;LL1629-6;PhenX18_12_language-speak,think;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66573-7;LL1629-6;PhenX18_12_language-speak,think;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66574-5;LL1629-6;PhenX18_12_language-speak,think;LA16645-6;1;(Language) all the time;;; +66574-5;LL1629-6;PhenX18_12_language-speak,think;LA16646-4;2;(Language) most of the time;;; +66574-5;LL1629-6;PhenX18_12_language-speak,think;LA16647-2;3;(Language) and English equally;;; +66574-5;LL1629-6;PhenX18_12_language-speak,think;LA16649-8;4;English most of the time;;; +66574-5;LL1629-6;PhenX18_12_language-speak,think;LA16648-0;5;English all the time;;; +66574-5;LL1629-6;PhenX18_12_language-speak,think;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66574-5;LL1629-6;PhenX18_12_language-speak,think;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66683-4;LL1629-6;PhenX18_12_language-speak,think;LA16645-6;1;(Language) all the time;;; +66683-4;LL1629-6;PhenX18_12_language-speak,think;LA16646-4;2;(Language) most of the time;;; +66683-4;LL1629-6;PhenX18_12_language-speak,think;LA16647-2;3;(Language) and English equally;;; +66683-4;LL1629-6;PhenX18_12_language-speak,think;LA16649-8;4;English most of the time;;; +66683-4;LL1629-6;PhenX18_12_language-speak,think;LA16648-0;5;English all the time;;; +66683-4;LL1629-6;PhenX18_12_language-speak,think;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66683-4;LL1629-6;PhenX18_12_language-speak,think;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66605-7;LL1632-0;PhenX18_15_fracture confirmation source;LA16678-7;1;Orthopedic notes;;; +66605-7;LL1632-0;PhenX18_15_fracture confirmation source;LA16679-5;2;X-ray report;;; +66605-7;LL1632-0;PhenX18_15_fracture confirmation source;LA16680-3;3;Discharge summary;;; +66605-7;LL1632-0;PhenX18_15_fracture confirmation source;LA16681-1;4;OR report;;; +66605-7;LL1632-0;PhenX18_15_fracture confirmation source;LA16682-9;5;ER notes;;; +66605-7;LL1632-0;PhenX18_15_fracture confirmation source;LA46-8;6;Other;;; +66612-3;LL1650-2;PhenX17_09;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66612-3;LL1650-2;PhenX17_09;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66612-3;LL1650-2;PhenX17_09;LA16789-2;3;Yes, more than 1;;; +66624-8;LL1650-2;PhenX17_09;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66624-8;LL1650-2;PhenX17_09;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66624-8;LL1650-2;PhenX17_09;LA16789-2;3;Yes, more than 1;;; +66663-6;LL1650-2;PhenX17_09;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66663-6;LL1650-2;PhenX17_09;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66663-6;LL1650-2;PhenX17_09;LA16789-2;3;Yes, more than 1;;; +66672-7;LL1650-2;PhenX17_09;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66672-7;LL1650-2;PhenX17_09;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66672-7;LL1650-2;PhenX17_09;LA16789-2;3;Yes, more than 1;;; +66679-2;LL1650-2;PhenX17_09;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66679-2;LL1650-2;PhenX17_09;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66679-2;LL1650-2;PhenX17_09;LA16789-2;3;Yes, more than 1;;; +66680-0;LL1618-9;PhenX18_01_speak,read,write English;LA8969-3;1;Poor;;; +66680-0;LL1618-9;PhenX18_01_speak,read,write English;LA8968-5;2;Fair;;; +66680-0;LL1618-9;PhenX18_01_speak,read,write English;LA8967-7;3;Good;;; +66680-0;LL1618-9;PhenX18_01_speak,read,write English;LA9206-9;4;Excellent;;; +66680-0;LL1618-9;PhenX18_01_speak,read,write English;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66680-0;LL1618-9;PhenX18_01_speak,read,write English;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66681-8;LL1618-9;PhenX18_01_speak,read,write English;LA8969-3;1;Poor;;; +66681-8;LL1618-9;PhenX18_01_speak,read,write English;LA8968-5;2;Fair;;; +66681-8;LL1618-9;PhenX18_01_speak,read,write English;LA8967-7;3;Good;;; +66681-8;LL1618-9;PhenX18_01_speak,read,write English;LA9206-9;4;Excellent;;; +66681-8;LL1618-9;PhenX18_01_speak,read,write English;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66681-8;LL1618-9;PhenX18_01_speak,read,write English;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66682-6;LL1618-9;PhenX18_01_speak,read,write English;LA8969-3;1;Poor;;; +66682-6;LL1618-9;PhenX18_01_speak,read,write English;LA8968-5;2;Fair;;; +66682-6;LL1618-9;PhenX18_01_speak,read,write English;LA8967-7;3;Good;;; +66682-6;LL1618-9;PhenX18_01_speak,read,write English;LA9206-9;4;Excellent;;; +66682-6;LL1618-9;PhenX18_01_speak,read,write English;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +66682-6;LL1618-9;PhenX18_01_speak,read,write English;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +66718-8;LL1853-2;RickImp;LA17732-1;1;Nonreactive. Results suggest no evidence of infection. If current infection is suspected, please collect a convalescent specimen at least 2 weeks after the acute.;;; +66718-8;LL1853-2;RickImp;LA17733-9;2;Reactive. Results suggest evidence of current or recent infection with Spotted Fever Group. If current infection is suspected, please collect a convalescent specimen at least 2 weeks after the acute.;;; +66718-8;LL1853-2;RickImp;LA17734-7;3;Reactive. Results suggest evidence of current or recent infection with Typhus Fever Group. If current infection is suspected, please collect a convalescent specimen at least 2 weeks after the acute.;;; +66746-9;LL1859-9;SpecType;LA30056-8;1;Amniotic fluid;;; +66746-9;LL1859-9;SpecType;LA17759-4;2;Blood;;; +66746-9;LL1859-9;SpecType;LA21012-2;3;Bone marrow;;; +66746-9;LL1859-9;SpecType;LA30055-0;4;Cerebrospinal fluid (CSF);;; +66746-9;LL1859-9;SpecType;LA30060-0;5;Hair;;; +66746-9;LL1859-9;SpecType;LA17761-0;6;Kaolin modified blood;;; +66746-9;LL1859-9;SpecType;LA17762-8;7;Kaolin-heparinase modified blood;;; +66746-9;LL1859-9;SpecType;LA30061-8;8;Nail;;; +66746-9;LL1859-9;SpecType;LA18005-1;9;Nasopharyngeal;;; +66746-9;LL1859-9;SpecType;LA13476-9;10;Pericardial fluid;;; +66746-9;LL1859-9;SpecType;LA13475-1;11;Peritoneal fluid;;; +66746-9;LL1859-9;SpecType;LA17760-2;12;Plasma;;; +66746-9;LL1859-9;SpecType;LA16975-7;13;Respiratory;;; +66746-9;LL1859-9;SpecType;LA4332-8;14;Skin;;; +66746-9;LL1859-9;SpecType;LA13477-7;15;Synovial fluid;;; +66746-9;LL1859-9;SpecType;LA30054-3;16;Urine;;; +66746-9;LL1859-9;SpecType;LA30063-4;17;Stool;;; +66749-3;LL1641-1;CircStatus;LA16769-4;1;Ventricular assist device;;; +66749-3;LL1641-1;CircStatus;LA16758-7;2;Baseline;;; +66749-3;LL1641-1;CircStatus;LA16762-9;3;On pump;;; +66749-3;LL1641-1;CircStatus;LA16759-5;4;Post protamine;;; +66749-3;LL1641-1;CircStatus;LA16764-5;5;Unclamped;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16651-4;1;Interested;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16652-2;2;Sad;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16653-0;3;Frightened;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA9340-6;4;Alert;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16654-8;5;Excited;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16655-5;6;Ashamed;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16656-3;7;Upset;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16657-1;8;Happy;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA14974-2;9;Strong;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16658-9;10;Nervous;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16659-7;11;Guilty;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16660-5;12;Energetic;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16661-3;13;Scared;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16662-1;14;Calm;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16663-9;15;Miserable;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16664-7;16;Jittery;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16665-4;17;Cheerful;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16666-2;18;Active;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16667-0;19;Proud;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16668-8;20;Afraid;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16669-6;21;Joyful;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16670-4;22;Lonely;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16671-2;23;Mad;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16672-0;24;Fearless;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16673-8;25;Disgusted;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16674-6;26;Delighted;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA15553-3;27;Blue;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16675-3;28;Daring;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16676-1;29;Gloomy;;; +66773-3;LL1631-2;PhenX18_14_feelings, emotions;LA16677-9;30;Lively;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16651-4;1;Interested;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16652-2;2;Sad;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16653-0;3;Frightened;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA9340-6;4;Alert;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16654-8;5;Excited;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16655-5;6;Ashamed;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16656-3;7;Upset;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16657-1;8;Happy;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA14974-2;9;Strong;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16658-9;10;Nervous;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16659-7;11;Guilty;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16660-5;12;Energetic;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16661-3;13;Scared;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16662-1;14;Calm;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16663-9;15;Miserable;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16664-7;16;Jittery;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16665-4;17;Cheerful;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16666-2;18;Active;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16667-0;19;Proud;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16668-8;20;Afraid;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16669-6;21;Joyful;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16670-4;22;Lonely;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16671-2;23;Mad;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16672-0;24;Fearless;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16673-8;25;Disgusted;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16674-6;26;Delighted;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA15553-3;27;Blue;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16675-3;28;Daring;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16676-1;29;Gloomy;;; +80296-7;LL1631-2;PhenX18_14_feelings, emotions;LA16677-9;30;Lively;;; +66774-1;LL1630-4;PhenX18_13_feelings in past few W;LA16650-6;1;Not much or not at all;;; +66774-1;LL1630-4;PhenX18_13_feelings in past few W;LA13940-4;2;A little;;; +66774-1;LL1630-4;PhenX18_13_feelings in past few W;LA14973-4;3;Some;;; +66774-1;LL1630-4;PhenX18_13_feelings in past few W;LA13902-4;4;Quite a bit;;; +66774-1;LL1630-4;PhenX18_13_feelings in past few W;LA14468-5;5;A lot;;; +66775-8;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66775-8;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66775-8;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66775-8;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66776-6;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66776-6;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66776-6;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66776-6;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66777-4;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66777-4;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66777-4;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66777-4;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66778-2;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66778-2;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66778-2;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66778-2;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66779-0;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66779-0;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66779-0;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66779-0;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66780-8;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66780-8;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66780-8;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66780-8;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66781-6;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66781-6;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66781-6;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66781-6;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66782-4;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66782-4;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66782-4;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66782-4;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66783-2;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66783-2;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66783-2;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66783-2;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66784-0;LL1621-3;PhenX18_04;LA15363-7;1;Not at all true;;; +66784-0;LL1621-3;PhenX18_04;LA15364-5;2;Hardly true;;; +66784-0;LL1621-3;PhenX18_04;LA15365-2;3;Moderately true;;; +66784-0;LL1621-3;PhenX18_04;LA15366-0;4;Exactly true;;; +66785-7;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66785-7;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66785-7;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66785-7;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66785-7;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66786-5;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66786-5;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66786-5;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66786-5;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66786-5;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66787-3;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66787-3;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66787-3;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66787-3;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66787-3;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66788-1;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66788-1;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66788-1;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66788-1;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66788-1;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66789-9;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66789-9;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66789-9;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66789-9;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66789-9;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66790-7;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66790-7;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66790-7;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66790-7;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66790-7;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66791-5;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66791-5;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66791-5;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66791-5;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66791-5;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66792-3;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66792-3;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66792-3;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66792-3;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66792-3;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66793-1;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66793-1;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66793-1;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66793-1;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66793-1;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66794-9;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66794-9;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66794-9;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66794-9;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66794-9;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66795-6;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66795-6;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66795-6;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66795-6;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66795-6;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66796-4;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66796-4;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66796-4;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66796-4;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66796-4;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66797-2;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66797-2;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66797-2;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66797-2;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66797-2;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66798-0;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66798-0;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66798-0;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66798-0;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66798-0;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66799-8;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66799-8;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66799-8;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66799-8;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66799-8;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66800-4;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66800-4;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66800-4;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66800-4;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66800-4;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66801-2;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66801-2;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66801-2;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66801-2;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66801-2;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66802-0;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66802-0;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66802-0;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66802-0;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66802-0;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66803-8;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66803-8;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66803-8;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66803-8;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66803-8;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66804-6;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66804-6;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66804-6;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66804-6;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66804-6;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66805-3;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66805-3;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66805-3;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66805-3;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66805-3;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66806-1;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66806-1;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66806-1;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66806-1;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66806-1;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66807-9;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66807-9;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66807-9;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66807-9;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66807-9;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66808-7;LL1622-1;PhenX18_05;LA16643-1;1;1 - Not at all;;; +66808-7;LL1622-1;PhenX18_05;LA6113-0;2;2;;; +66808-7;LL1622-1;PhenX18_05;LA6114-8;3;3;;; +66808-7;LL1622-1;PhenX18_05;LA6115-5;4;4;;; +66808-7;LL1622-1;PhenX18_05;LA6186-6;5;5 - very well;;; +66809-5;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66809-5;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66809-5;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66809-5;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66810-3;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66810-3;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66810-3;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66810-3;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66811-1;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66811-1;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66811-1;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66811-1;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66812-9;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66812-9;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66812-9;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66812-9;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66813-7;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66813-7;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66813-7;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66813-7;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66814-5;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66814-5;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66814-5;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66814-5;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66831-9;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66831-9;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66831-9;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66831-9;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66832-7;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66832-7;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66832-7;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66832-7;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66833-5;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66833-5;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66833-5;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66833-5;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66834-3;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66834-3;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66834-3;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66834-3;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66835-0;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66835-0;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66835-0;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66835-0;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66836-8;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66836-8;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66836-8;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66836-8;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66837-6;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66837-6;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66837-6;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66837-6;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66838-4;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66838-4;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66838-4;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66838-4;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66839-2;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66839-2;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66839-2;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66839-2;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66840-0;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66840-0;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66840-0;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66840-0;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66841-8;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66841-8;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66841-8;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66841-8;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66843-4;LL1623-9;PhenX18_06;LA14468-5;1;A lot;;; +66843-4;LL1623-9;PhenX18_06;LA14973-4;2;Some;;; +66843-4;LL1623-9;PhenX18_06;LA13940-4;3;A little;;; +66843-4;LL1623-9;PhenX18_06;LA6568-5;4;Not at all;;; +66815-2;LL1624-7;PhenX18_07;LA10044-8;1;Often;;; +66815-2;LL1624-7;PhenX18_07;LA10082-8;2;Sometimes;;; +66815-2;LL1624-7;PhenX18_07;LA10066-1;3;Rarely;;; +66815-2;LL1624-7;PhenX18_07;LA6270-8;4;Never;;; +66816-0;LL1624-7;PhenX18_07;LA10044-8;1;Often;;; +66816-0;LL1624-7;PhenX18_07;LA10082-8;2;Sometimes;;; +66816-0;LL1624-7;PhenX18_07;LA10066-1;3;Rarely;;; +66816-0;LL1624-7;PhenX18_07;LA6270-8;4;Never;;; +66817-8;LL1624-7;PhenX18_07;LA10044-8;1;Often;;; +66817-8;LL1624-7;PhenX18_07;LA10082-8;2;Sometimes;;; +66817-8;LL1624-7;PhenX18_07;LA10066-1;3;Rarely;;; +66817-8;LL1624-7;PhenX18_07;LA6270-8;4;Never;;; +66818-6;LL1624-7;PhenX18_07;LA10044-8;1;Often;;; +66818-6;LL1624-7;PhenX18_07;LA10082-8;2;Sometimes;;; +66818-6;LL1624-7;PhenX18_07;LA10066-1;3;Rarely;;; +66818-6;LL1624-7;PhenX18_07;LA6270-8;4;Never;;; +66819-4;LL1624-7;PhenX18_07;LA10044-8;1;Often;;; +66819-4;LL1624-7;PhenX18_07;LA10082-8;2;Sometimes;;; +66819-4;LL1624-7;PhenX18_07;LA10066-1;3;Rarely;;; +66819-4;LL1624-7;PhenX18_07;LA6270-8;4;Never;;; +66820-2;LL1624-7;PhenX18_07;LA10044-8;1;Often;;; +66820-2;LL1624-7;PhenX18_07;LA10082-8;2;Sometimes;;; +66820-2;LL1624-7;PhenX18_07;LA10066-1;3;Rarely;;; +66820-2;LL1624-7;PhenX18_07;LA6270-8;4;Never;;; +66842-6;LL1624-7;PhenX18_07;LA10044-8;1;Often;;; +66842-6;LL1624-7;PhenX18_07;LA10082-8;2;Sometimes;;; +66842-6;LL1624-7;PhenX18_07;LA10066-1;3;Rarely;;; +66842-6;LL1624-7;PhenX18_07;LA6270-8;4;Never;;; +66821-0;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66821-0;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66821-0;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66821-0;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66821-0;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66822-8;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66822-8;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66822-8;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66822-8;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66822-8;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66823-6;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66823-6;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66823-6;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66823-6;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66823-6;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66824-4;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66824-4;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66824-4;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66824-4;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66824-4;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66825-1;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66825-1;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66825-1;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66825-1;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66825-1;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66826-9;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66826-9;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66826-9;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66826-9;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66826-9;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66827-7;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66827-7;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66827-7;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66827-7;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66827-7;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66828-5;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66828-5;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66828-5;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66828-5;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66828-5;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66829-3;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66829-3;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66829-3;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66829-3;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66829-3;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66830-1;LL1625-4;PhenX18_08;LA6270-8;1;Never;;; +66830-1;LL1625-4;PhenX18_08;LA13866-1;2;Almost never;;; +66830-1;LL1625-4;PhenX18_08;LA10082-8;3;Sometimes;;; +66830-1;LL1625-4;PhenX18_08;LA16644-9;4;Fairly often;;; +66830-1;LL1625-4;PhenX18_08;LA14985-8;5;Very often;;; +66844-2;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66844-2;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66844-2;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66844-2;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66845-9;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66845-9;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66845-9;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66845-9;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66846-7;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66846-7;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66846-7;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66846-7;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66847-5;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66847-5;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66847-5;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66847-5;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66848-3;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66848-3;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66848-3;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66848-3;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66849-1;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66849-1;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66849-1;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66849-1;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66850-9;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66850-9;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66850-9;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66850-9;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66851-7;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66851-7;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66851-7;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66851-7;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66852-5;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +66852-5;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +66852-5;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +66852-5;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +67601-5;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +67601-5;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +67601-5;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +67601-5;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +67602-3;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +67602-3;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +67602-3;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +67602-3;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +67603-1;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +67603-1;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +67603-1;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +67603-1;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +67604-9;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +67604-9;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +67604-9;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +67604-9;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +67605-6;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +67605-6;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +67605-6;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +67605-6;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99664-5;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99664-5;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99664-5;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99664-5;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99665-2;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99665-2;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99665-2;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99665-2;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99666-0;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99666-0;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99666-0;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99666-0;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99667-8;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99667-8;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99667-8;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99667-8;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99669-4;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99669-4;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99669-4;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99669-4;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99670-2;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99670-2;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99670-2;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99670-2;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99671-0;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99671-0;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99671-0;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99671-0;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +99672-8;LL1626-2;PhenX18_09;LA15237-3;1;Strongly agree;;; +99672-8;LL1626-2;PhenX18_09;LA15774-5;2;Agree;;; +99672-8;LL1626-2;PhenX18_09;LA15773-7;3;Disagree;;; +99672-8;LL1626-2;PhenX18_09;LA15236-5;4;Strongly disagree;;; +66854-1;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66854-1;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66854-1;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66854-1;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66855-8;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66855-8;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66855-8;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66855-8;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66856-6;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66856-6;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66856-6;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66856-6;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66857-4;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66857-4;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66857-4;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66857-4;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66858-2;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66858-2;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66858-2;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66858-2;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66859-0;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66859-0;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66859-0;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66859-0;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66860-8;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66860-8;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66860-8;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66860-8;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66861-6;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66861-6;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66861-6;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66861-6;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66862-4;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66862-4;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66862-4;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66862-4;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66863-2;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66863-2;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66863-2;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66863-2;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66864-0;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66864-0;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66864-0;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66864-0;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66865-7;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66865-7;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66865-7;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66865-7;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66866-5;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66866-5;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66866-5;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66866-5;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66867-3;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66867-3;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66867-3;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66867-3;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66867-3;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66867-3;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66867-3;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66867-3;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66868-1;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66868-1;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66868-1;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66868-1;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66869-9;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66869-9;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66869-9;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66869-9;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66870-7;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66870-7;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66870-7;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66870-7;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66871-5;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66871-5;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66871-5;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66871-5;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66872-3;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66872-3;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66872-3;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66872-3;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66949-9;LL1627-0;PhenX18_10;LA6270-8;1;Never;;; +66949-9;LL1627-0;PhenX18_10;LA10066-1;2;Rarely;;; +66949-9;LL1627-0;PhenX18_10;LA10082-8;3;Sometimes;;; +66949-9;LL1627-0;PhenX18_10;LA9933-8;4;Always;;; +66936-6;LL1633-8;PhenX18_16_hip fracture location;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66936-6;LL1633-8;PhenX18_16_hip fracture location;LA16683-7;2;Intertrochanteric;;; +66936-6;LL1633-8;PhenX18_16_hip fracture location;LA16684-5;3;Femoral neck (subcapital);;; +66936-6;LL1633-8;PhenX18_16_hip fracture location;LA46-8;4;Other;;; +66938-2;LL1634-6;PhenX18_17_fracture treatment;LA16685-2;1;Open reduction internal fixation (ORIF or pinning);;; +66938-2;LL1634-6;PhenX18_17_fracture treatment;LA16686-0;2;Arthroplasty/hemiarthroplasty (femoral head replacement);;; +66938-2;LL1634-6;PhenX18_17_fracture treatment;LA46-8;3;Other;;; +66938-2;LL1634-6;PhenX18_17_fracture treatment;LA16687-8;4;Cast or other immobilization;;; +66938-2;LL1634-6;PhenX18_17_fracture treatment;LA137-2;5;None;260413007;None (qualifier value);http://snomed.info/sct +66938-2;LL1634-6;PhenX18_17_fracture treatment;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66941-6;LL1636-1;PhenX18_19_trauma location;LA16691-0;1;Outside;;; +66941-6;LL1636-1;PhenX18_19_trauma location;LA16690-2;2;Inside;;; +66941-6;LL1636-1;PhenX18_19_trauma location;LA46-8;3;Other;;; +66941-6;LL1636-1;PhenX18_19_trauma location;LA4543-0;4;;;; +66941-6;LL1636-1;PhenX18_19_trauma location;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66943-2;LL1637-9;PhenX18_20_time of fracture;LA16692-8;1;Daytime (6am-6pm);;; +66943-2;LL1637-9;PhenX18_20_time of fracture;LA16693-6;2;Night (6:01pm to 5:59am);;; +66943-2;LL1637-9;PhenX18_20_time of fracture;LA46-8;3;Other;;; +66943-2;LL1637-9;PhenX18_20_time of fracture;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66944-0;LL1959-7;PhenX17_14_death in hospitalization;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +66944-0;LL1959-7;PhenX17_14_death in hospitalization;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +66944-0;LL1959-7;PhenX17_14_death in hospitalization;LA18134-9;3;N/A, no hospitalization;;; +66944-0;LL1959-7;PhenX17_14_death in hospitalization;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA16688-6;1;Fall from standing height or less;;; +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA16694-4;2;Falls on stairs, steps or curbs;;; +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA16695-1;3;Fall from more than standing height, but NOT on stairs;;; +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA16696-9;4;Minimal trauma other than a fall;;; +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA16697-7;5;Moderate trauma other than a fall;;; +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA16698-5;6;Severe trauma other than a fall;;; +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA16699-3;7;Pathologic fracture-usually associated with cancer in bone;;; +66945-7;LL1638-7;PhenX18_21_fracture circumstances;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66952-3;LL1635-3;PhenX18_18_fracture circumstances;LA16688-6;1;Fall from standing height or less;;; +66952-3;LL1635-3;PhenX18_18_fracture circumstances;LA16689-4;2;Motor vehicle accident or fall from greater than standing height;;; +66952-3;LL1635-3;PhenX18_18_fracture circumstances;LA46-8;3;Other;;; +66952-3;LL1635-3;PhenX18_18_fracture circumstances;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA3973-0;1;Hip;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16684-5;2;Femoral neck (subcapital);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16683-7;3;Intertrochanteric;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA46-8;4;Other;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16700-9;5;Wrist (unspecified);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16701-7;6;"Distal radius (Colles'; Smith)";;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16702-5;7;Distal ulna;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16703-3;8;Both distal radius and ulna;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA4331-0;9;Skull;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16704-1;10;Facial bones (includes jaw, nose, cheek);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA12703-7;11;Neck;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16705-8;12;First cervical vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16706-6;13;Second cervical vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16707-4;14;Third cervical vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16708-2;15;Fourth cervical vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16709-0;16;Fifth cervical vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16710-8;17;Sixth cervical vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16711-6;18;Seventh cervical vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16712-4;19;Multiple cervical vertebrae;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA4298-1;20;Shoulder;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16756-1;21;Clavicle or collar bone;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16714-0;22;Scapula (shoulder blade);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16715-7;23;Arm (unspecified);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16716-5;24;Humerus (upper arm);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16717-3;25;Elbow;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16718-1;26;Radius a/o ulna, proximal or mid shaft;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16719-9;27;Hand;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16720-7;28;Fingers;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16721-5;29;Other small bones in wrist;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA4307-0;30;Ribs;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16722-3;31;Chest/sternum;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16723-1;32;Thoracic spine (unspecified);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16724-9;33;First thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16725-6;34;Second thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16726-4;35;Third thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16727-2;36;Fourth thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16728-0;37;Fifth thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16729-8;38;Sixth thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16730-6;39;Seventh thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16731-4;40;Eighth thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16732-2;41;Ninth thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16733-0;42;Tenth thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16734-8;43;Eleventh thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16735-5;44;Twelfth thoracic vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16736-3;45;Multiple thoracic vertebrae;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16737-1;46;Lumbar spine (unspecified);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16738-9;47;First lumbar vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16739-7;48;Second lumbar vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16740-5;49;Third lumbar vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16741-3;50;Fourth lumbar vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16742-1;51;Fifth lumbar vertebra;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16743-9;52;Multiple lumbar vertebrae;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16744-7;53;Pelvis;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16745-4;54;Tailbone/coccyx/sacrum;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16746-2;55;Leg (unspecified);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16747-0;56;Femur (not hip);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16748-8;57;Patella;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16749-6;58;Tibia;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16750-4;59;Fibula;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16751-2;60;Both tibia/fibula;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16752-0;61;Ankle (includes distal tibia and fibula);;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16753-8;62;Foot/metatarsal;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16754-6;63;Toes;;; +66953-1;LL1639-5;PhenX18_22_fracture location detail;LA16755-3;64;Heel/os calcis;;; +67040-6;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67040-6;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67040-6;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67041-4;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67041-4;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67041-4;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67042-2;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67042-2;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67042-2;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67043-0;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67043-0;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67043-0;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67044-8;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67044-8;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67044-8;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67045-5;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67045-5;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67045-5;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67046-3;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67046-3;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67046-3;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67047-1;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67047-1;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67047-1;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67048-9;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67048-9;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67048-9;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67049-7;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67049-7;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67049-7;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67050-5;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67050-5;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67050-5;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67051-3;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67051-3;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67051-3;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67052-1;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67052-1;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67052-1;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67053-9;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67053-9;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67053-9;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67054-7;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67054-7;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67054-7;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67055-4;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67055-4;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67055-4;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67056-2;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67056-2;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67056-2;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67057-0;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67057-0;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67057-0;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67058-8;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67058-8;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67058-8;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67059-6;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67059-6;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67059-6;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67060-4;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67060-4;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67060-4;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67061-2;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67061-2;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67061-2;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67062-0;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67062-0;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67062-0;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67063-8;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67063-8;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67063-8;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67064-6;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67064-6;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67064-6;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67065-3;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67065-3;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67065-3;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67066-1;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67066-1;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67066-1;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67067-9;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67067-9;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67067-9;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67068-7;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67068-7;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67068-7;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67069-5;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67069-5;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67069-5;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67070-3;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67070-3;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67070-3;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67071-1;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67071-1;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67071-1;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67072-9;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67072-9;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67072-9;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67073-7;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67073-7;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67073-7;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67074-5;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67074-5;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67074-5;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67075-2;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67075-2;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67075-2;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67076-0;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67076-0;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67076-0;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67077-8;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67077-8;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67077-8;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67078-6;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67078-6;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67078-6;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67079-4;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67079-4;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67079-4;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67080-2;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67080-2;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67080-2;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67081-0;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67081-0;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67081-0;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67082-8;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67082-8;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67082-8;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67083-6;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67083-6;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67083-6;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67084-4;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67084-4;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67084-4;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67085-1;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67085-1;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67085-1;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67086-9;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67086-9;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67086-9;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67087-7;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67087-7;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67087-7;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67088-5;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67088-5;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67088-5;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67089-3;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67089-3;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67089-3;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67090-1;LL1640-3;PhenX18_23;LA15368-6;1;Not true;;; +67090-1;LL1640-3;PhenX18_23;LA14993-2;2;Somewhat true;;; +67090-1;LL1640-3;PhenX18_23;LA15369-4;3;Very true;;; +67092-7;LL1652-8;PhenX18_24_careers;LA9401-6;1;Nurse;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16790-0;2;Writer;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16791-8;3;Farmer;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16792-6;4;Lawyer;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16793-4;5;Middle school teacher;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16794-2;6;Full time babysitter;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16795-9;7;Janitor;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16796-7;8;Personnel manager;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16801-5;9;Administrative assistant;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16802-3;10;Hair dresser;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16803-1;11;Bookkeeper;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16804-9;12;Security guard;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16805-6;13;Production manager;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16806-4;14;Factory operator;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16807-2;15;Computer programmer;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16808-0;16;Receptionist;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16809-8;17;Congressman;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16810-6;18;Taxi driver;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16811-4;19;Professor;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16812-2;20;Hotel bell boy;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16813-0;21;Policeman;;; +67092-7;LL1652-8;PhenX18_24_careers;LA16814-8;22;CEO;;; +67096-8;LL1653-6;PhenX18_25_social closeness;LA15595-4;1;Very close;;; +67096-8;LL1653-6;PhenX18_25_social closeness;LA16797-5;2;Close;;; +67096-8;LL1653-6;PhenX18_25_social closeness;LA16798-3;3;So, so;;; +67096-8;LL1653-6;PhenX18_25_social closeness;LA16799-1;4;Not close;;; +67096-8;LL1653-6;PhenX18_25_social closeness;LA16800-7;5;Not close at all;;; +67099-2;LL1642-9;PhenX16_02_medical devices;LA16772-8;1;Medical device 1;;; +67099-2;LL1642-9;PhenX16_02_medical devices;LA16773-6;2;Medical device 2;;; +67131-3;LL1655-1;PhenX19_01_gallbladder disease age range;LA16818-9;1;17-74 years;;; +67131-3;LL1655-1;PhenX19_01_gallbladder disease age range;LA16819-7;2;75+ years;;; +67132-1;LL1656-9;PhenX19_02_gallbladder pain area;LA16820-5;1;Area 1;;; +67132-1;LL1656-9;PhenX19_02_gallbladder pain area;LA16821-3;2;Area 2;;; +67132-1;LL1656-9;PhenX19_02_gallbladder pain area;LA16822-1;3;Area 3;;; +67136-2;LL1657-7;PhenX19_03_pain helped w/ movement;LA16824-7;1;More;;; +67136-2;LL1657-7;PhenX19_03_pain helped w/ movement;LA16823-9;2;Less;;; +67136-2;LL1657-7;PhenX19_03_pain helped w/ movement;LA16825-4;3;No difference;;; +67136-2;LL1657-7;PhenX19_03_pain helped w/ movement;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67138-8;LL1658-5;PhenX19_04_Dr. reported pain cause;LA16826-2;1;Gallstones/gallbladder problems;;; +67138-8;LL1658-5;PhenX19_04_Dr. reported pain cause;LA16827-0;2;Ulcer;56208002;Ulcer (morphologic abnormality);http://snomed.info/sct +67138-8;LL1658-5;PhenX19_04_Dr. reported pain cause;LA16828-8;3;Appendicitis or appendix problems;;; +67138-8;LL1658-5;PhenX19_04_Dr. reported pain cause;LA16829-6;4;Spastic colon or irritable bowel;;; +67138-8;LL1658-5;PhenX19_04_Dr. reported pain cause;LA16830-4;5;Diverticulitis or diverticulosis;;; +67138-8;LL1658-5;PhenX19_04_Dr. reported pain cause;LA46-8;6;Other;;; +67140-4;LL1659-3;PhenX19_05;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67140-4;LL1659-3;PhenX19_05;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67140-4;LL1659-3;PhenX19_05;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67143-8;LL1659-3;PhenX19_05;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67143-8;LL1659-3;PhenX19_05;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67143-8;LL1659-3;PhenX19_05;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67144-6;LL1659-3;PhenX19_05;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67144-6;LL1659-3;PhenX19_05;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67144-6;LL1659-3;PhenX19_05;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67146-1;LL1659-3;PhenX19_05;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67146-1;LL1659-3;PhenX19_05;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67146-1;LL1659-3;PhenX19_05;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67147-9;LL1659-3;PhenX19_05;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67147-9;LL1659-3;PhenX19_05;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +67147-9;LL1659-3;PhenX19_05;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67141-2;LL1660-1;PhenX19_06_reason Dr. visit;LA7460-4;1;Pain;;; +67141-2;LL1660-1;PhenX19_06_reason Dr. visit;LA46-8;2;Other;;; +67156-0;LL1661-9;PhenX19_07_abstract purpose;LA15370-2;1;Initial abstract;;; +67156-0;LL1661-9;PhenX19_07_abstract purpose;LA15371-0;2;Re-abstract for QA;;; +67160-2;LL1662-7;PhenX19_08_non-scannable items entered;LA6637-8;1;Completed;;; +67160-2;LL1662-7;PhenX19_08_non-scannable items entered;LA15372-8;2;None required;;; +67161-0;LL1663-5;PhenX19_09_data retrieval completed;LA15373-6;1;Attempted;;; +67161-0;LL1663-5;PhenX19_09_data retrieval completed;LA15372-8;2;None required;;; +67162-8;LL1664-3;PhenX19_10_colorectal evaulation disposition;LA15374-4;1;Interim complete (ICM);;; +67162-8;LL1664-3;PhenX19_10_colorectal evaulation disposition;LA15375-1;2;Final complete (FCM);;; +67162-8;LL1664-3;PhenX19_10_colorectal evaulation disposition;LA15376-9;3;Final incomplete (FIG);;; +67162-8;LL5235-8;CDC_Disposition after an event;LA14102-0;1;Discharged;;; +67162-8;LL5235-8;CDC_Disposition after an event;LA29760-8;2;Transferred within the facility;;; +67162-8;LL5235-8;CDC_Disposition after an event;LA20597-3;3;Transferred to another hospital;;; +67162-8;LL5235-8;CDC_Disposition after an event;LA18946-6;4;Died;;; +67162-8;LL5235-8;CDC_Disposition after an event;LA29761-6;5;No change in patient location;;; +67163-6;LL1665-0;PhenX19_11_diagnostic procedures performed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67163-6;LL1665-0;PhenX19_11_diagnostic procedures performed;LA15377-7;2;No, physician report;;; +67163-6;LL1665-0;PhenX19_11_diagnostic procedures performed;LA15378-5;3;No, participant self-report;;; +67164-4;LL1862-3;PhenX19_45_initial visit reason;LA17766-9;1;Symptomatic;;; +67164-4;LL1862-3;PhenX19_45_initial visit reason;LA17767-7;2;Follow-up of positive PLCO screen;;; +67164-4;LL1862-3;PhenX19_45_initial visit reason;LA46-8;3;Other;;; +67168-5;LL1667-6;PhenX19_13_cecum visualization;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67168-5;LL1667-6;PhenX19_13_cecum visualization;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67168-5;LL1667-6;PhenX19_13_cecum visualization;LA7338-2;3;Not available;;; +67169-3;LL1863-1;PhenX19_46_bowel prep;LA8914-9;0;Inadequate;;; +67169-3;LL1863-1;PhenX19_46_bowel prep;LA8913-1;1;Adequate;;; +67169-3;LL1863-1;PhenX19_46_bowel prep;LA7338-2;9;Not available;;; +67170-1;LL1668-4;PhenX19_14_hyperplastic polyps;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67170-1;LL1668-4;PhenX19_14_hyperplastic polyps;LA6306-0;2;One;;; +67170-1;LL1668-4;PhenX19_14_hyperplastic polyps;LA15382-7;3;Multiple;;; +67171-9;LL1666-8;PhenX19_12_colorectal procedure type;LA15379-3;1;Sigmoidoscopy;;; +67171-9;LL1666-8;PhenX19_12_colorectal procedure type;LA15380-1;2;Colonoscopy;;; +67171-9;LL1666-8;PhenX19_12_colorectal procedure type;LA3841-9;3;Endoscopy, NOS;;; +67176-8;LL1669-2;PhenX19_15_adenoma description;LA15383-5;1;Diminutive;;; +67176-8;LL1669-2;PhenX19_15_adenoma description;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +67176-8;LL1669-2;PhenX19_15_adenoma description;LA8981-8;3;Large;255509001;Large (qualifier value);http://snomed.info/sct +67176-8;LL1669-2;PhenX19_15_adenoma description;LA7338-2;4;Not available;;; +67177-6;LL1670-0;PhenX19_16_adenoma histology;LA15387-6;1;Tubular adenoma;;; +67177-6;LL1670-0;PhenX19_16_adenoma histology;LA15388-4;2;Tubular villous adenoma;;; +67177-6;LL1670-0;PhenX19_16_adenoma histology;LA15389-2;3;Villous adenoma;;; +67177-6;LL1670-0;PhenX19_16_adenoma histology;LA15390-0;4;Adenoma, NOS;;; +67178-4;LL1671-8;PhenX19_17_adenoma dysplasia;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67178-4;LL1671-8;PhenX19_17_adenoma dysplasia;LA15384-3;2;Mild (low grade);;; +67178-4;LL1671-8;PhenX19_17_adenoma dysplasia;LA15385-0;3;Moderate (low grade);;; +67178-4;LL1671-8;PhenX19_17_adenoma dysplasia;LA15386-8;4;Severe (high grade);;; +67178-4;LL1671-8;PhenX19_17_adenoma dysplasia;LA7338-2;5;Not available;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15391-8;1;Abdominal flat plate (plain film);;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15392-6;2;Barium enema radiograph;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15393-4;3;Biopsy;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15394-2;4;Chest radiograph;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15395-9;5;Clinical evaluation;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15396-7;6;CT scan - abdominal;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15397-5;7;CT scan - other;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15398-3;8;CT scan - pelvic;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15399-1;9;Cystoscopy;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15400-7;10;DRE;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15401-5;11;Intravenous pyelography (IVP)/excretory urography;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15402-3;12;MRI scan - abdominal;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15403-1;13;MRI scan - other;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15404-9;14;MRI scan - pelvic;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15405-6;15;PreoperatIve carcinoembryonic antigen (CEA);;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15406-4;16;Stool occult blood;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15407-2;17;Record review;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA8951-1;18;Resection;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15408-0;19;Abdominal ultrasound;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15409-8;20;CT scan - abdomen and pelvis combined;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15410-6;21;Hemicolectomy;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15411-4;22;Laparoscopy;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15412-2;23;Laparotomy;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15413-0;24;Lymphadenectomy/Lymph node sampling;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15414-8;25;Other radiograph;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15415-5;26;Ultrasound;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA15429-6;27;Upper GI evaluation – endoscopic/radiographic;;; +67183-4;LL1672-6;PhenX19_18_diagnostic, staging procedure;LA46-8;28;Other;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA12362-2;0;Stroke (CVA) or TIA;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7446-3;1;Infection;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15416-3;2;Fever requiring antibiotics;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7461-2;3;Perforation;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7441-4;4;Hemorrhage;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA9547-6;5;Respiratory arrest;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA9535-1;6;Cardiac arrest;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15417-1;7;Hospitalization;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15418-9;8;Pulmonary embolus/emboli;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA14274-7;9;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15419-7;10;Cardiac arrhythmia;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA16831-2;11;Cerebral vascular accident (CVA)/Stroke;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15420-5;12;Blood loss requiring transfusion;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7425-7;13;Deep vein thrombosis;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15421-3;14;Acute/chronic respiratory failure;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7443-0;15;Hypotension;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA12740-9;16;Congestive heart failure (CHF);;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15422-1;17;Wound dehiscence;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15423-9;18;Hypokalemia;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15424-7;19;Diarrhea;62315008;Diarrhea (finding);http://snomed.info/sct +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15425-4;20;Small bowel obstruction/partial or complete;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15426-2;21;Ileus;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15427-0;22;Rectal damage;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15428-8;23;Blood In stool;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA12362-2;0;Stroke (CVA) or TIA;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7446-3;1;Infection;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15416-3;2;Fever requiring antibiotics;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7461-2;3;Perforation;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7441-4;4;Hemorrhage;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA9547-6;5;Respiratory arrest;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA9535-1;6;Cardiac arrest;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15417-1;7;Hospitalization;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15418-9;8;Pulmonary embolus/emboli;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA14274-7;9;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15419-7;10;Cardiac arrhythmia;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA16831-2;11;Cerebral vascular accident (CVA)/Stroke;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15420-5;12;Blood loss requiring transfusion;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7425-7;13;Deep vein thrombosis;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15421-3;14;Acute/chronic respiratory failure;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA7443-0;15;Hypotension;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA12740-9;16;Congestive heart failure (CHF);;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15422-1;17;Wound dehiscence;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15423-9;18;Hypokalemia;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15424-7;19;Diarrhea;62315008;Diarrhea (finding);http://snomed.info/sct +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15425-4;20;Small bowel obstruction/partial or complete;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15426-2;21;Ileus;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15427-0;22;Rectal damage;;; +67187-5;LL1673-4;PhenX19_19_complication dx evaluation;LA15428-8;23;Blood In stool;;; +67189-1;LL1674-2;PhenX19_20_colorectal CA dx eval;LA15430-4;1;No malignancy;;; +67189-1;LL1674-2;PhenX19_20_colorectal CA dx eval;LA15431-2;2;No malignancy and no diagnostic/staging procedures performed;;; +67189-1;LL1674-2;PhenX19_20_colorectal CA dx eval;LA15432-0;3;Colorectal malignancy confirmed histologically (exclude carcinoma in situ);;; +67189-1;LL1674-2;PhenX19_20_colorectal CA dx eval;LA15433-8;4;Colorectal malignancy confirmed cytologically;;; +67189-1;LL1674-2;PhenX19_20_colorectal CA dx eval;LA15434-6;5;Colorectal malignancy diagnosed by clinical examination only;;; +67189-1;LL1674-2;PhenX19_20_colorectal CA dx eval;LA15435-3;6;Other malignancy confirmed histologicaly or cytologically;;; +67189-1;LL1674-2;PhenX19_20_colorectal CA dx eval;LA15436-1;7;No information available;;; +67192-5;LL1854-0;PhenX19_44_colorectal dx procedure;LA15379-3;1;Sigmoidoscopy;;; +67192-5;LL1854-0;PhenX19_44_colorectal dx procedure;LA15380-1;2;Colonoscopy;;; +67192-5;LL1854-0;PhenX19_44_colorectal dx procedure;LA17735-4;3;Polypectomy;;; +67192-5;LL1854-0;PhenX19_44_colorectal dx procedure;LA17736-2;4;Surgical resection;;; +67192-5;LL1854-0;PhenX19_44_colorectal dx procedure;LA17737-0;5;Local transanal or other resection;;; +67192-5;LL1854-0;PhenX19_44_colorectal dx procedure;LA9463-6;6;Endoscopy;;; +67197-4;LL1689-0;PhenX19_35_ICD-O-2 cancer - behavior;LA6112-2;1;1;;; +67197-4;LL1689-0;PhenX19_35_ICD-O-2 cancer - behavior;LA6114-8;2;3;;; +67197-4;LL1689-0;PhenX19_35_ICD-O-2 cancer - behavior;LA10141-2;3;9;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA6112-2;1;1;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA6113-0;2;2;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA6114-8;3;3;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA6115-5;4;4;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA10137-0;5;5;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA10138-8;6;6;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA10139-6;7;7;;; +67198-2;LL1688-2;PhenX19_34_ICD-O-2 cancer - grade;LA10141-2;8;9;;; +67199-0;LL1676-7;PhenX19_22_primary CA report;LA15441-1;1;Pathology/Histopathology (ATTACH COPY);;; +67199-0;LL1676-7;PhenX19_22_primary CA report;LA15442-9;2;Cytology/Cytopathology (ATTACH COPY);;; +67199-0;LL1676-7;PhenX19_22_primary CA report;LA7338-2;3;Not available;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA11900-0;1;Adenocarcinoma;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA15443-7;2;Mucinous (colloid) adenocarcinoma;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA15444-5;3;Signet ring cell carcinoma;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA15445-2;4;Squamous cell (epidermoid) carcinoma;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA15446-0;5;Adenosquamous carcinoma;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA15447-8;6;Undifferentiated carcinoma;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA15448-6;7;Carcinoma;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA46-8;8;Other;;; +67200-6;LL1677-5;PhenX19_23_CA histopathology type;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67202-2;LL1678-3;PhenX19_24_CA histopathology grade;LA15454-4;1;Grade cannot be assessed (GX);;; +67202-2;LL1678-3;PhenX19_24_CA histopathology grade;LA15453-6;2;Well differentiated (G1);;; +67202-2;LL1678-3;PhenX19_24_CA histopathology grade;LA15452-8;3;Moderately differentiated (G2);;; +67202-2;LL1678-3;PhenX19_24_CA histopathology grade;LA15450-2;4;Poorly differentiated (G3);;; +67202-2;LL1678-3;PhenX19_24_CA histopathology grade;LA15451-0;5;Undifferentiated (G4);;; +67202-2;LL1678-3;PhenX19_24_CA histopathology grade;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67203-0;LL1681-7;PhenX19_27_AJCC CA staging manual edition;LA15455-1;1;4th edition;;; +67203-0;LL1681-7;PhenX19_27_AJCC CA staging manual edition;LA15456-9;2;5th edition;;; +67205-5;LL1682-5;PhenX19_28_ CA tumor type;LA3601-7;1;TX;;; +67205-5;LL1682-5;PhenX19_28_ CA tumor type;LA3638-9;2;T0;;; +67205-5;LL1682-5;PhenX19_28_ CA tumor type;LA3637-1;3;T1;;; +67205-5;LL1682-5;PhenX19_28_ CA tumor type;LA3628-0;4;T2;;; +67205-5;LL1682-5;PhenX19_28_ CA tumor type;LA3624-9;5;T3;;; +67205-5;LL1682-5;PhenX19_28_ CA tumor type;LA3620-7;6;T4;;; +67205-5;LL1682-5;PhenX19_28_ CA tumor type;LA7338-2;7;Not available;;; +67209-7;LL1682-5;PhenX19_28_ CA tumor type;LA3601-7;1;TX;;; +67209-7;LL1682-5;PhenX19_28_ CA tumor type;LA3638-9;2;T0;;; +67209-7;LL1682-5;PhenX19_28_ CA tumor type;LA3637-1;3;T1;;; +67209-7;LL1682-5;PhenX19_28_ CA tumor type;LA3628-0;4;T2;;; +67209-7;LL1682-5;PhenX19_28_ CA tumor type;LA3624-9;5;T3;;; +67209-7;LL1682-5;PhenX19_28_ CA tumor type;LA3620-7;6;T4;;; +67209-7;LL1682-5;PhenX19_28_ CA tumor type;LA7338-2;7;Not available;;; +67206-3;LL1683-3;PhenX19_29_CA lymph node presence;LA4745-1;1;NX;;; +67206-3;LL1683-3;PhenX19_29_CA lymph node presence;LA4368-2;2;N0;;; +67206-3;LL1683-3;PhenX19_29_CA lymph node presence;LA4537-2;3;N1;;; +67206-3;LL1683-3;PhenX19_29_CA lymph node presence;LA4534-9;4;N2;;; +67206-3;LL1683-3;PhenX19_29_CA lymph node presence;LA4545-5;5;N3;;; +67206-3;LL1683-3;PhenX19_29_CA lymph node presence;LA7338-2;6;Not available;;; +67210-5;LL1683-3;PhenX19_29_CA lymph node presence;LA4745-1;1;NX;;; +67210-5;LL1683-3;PhenX19_29_CA lymph node presence;LA4368-2;2;N0;;; +67210-5;LL1683-3;PhenX19_29_CA lymph node presence;LA4537-2;3;N1;;; +67210-5;LL1683-3;PhenX19_29_CA lymph node presence;LA4534-9;4;N2;;; +67210-5;LL1683-3;PhenX19_29_CA lymph node presence;LA4545-5;5;N3;;; +67210-5;LL1683-3;PhenX19_29_CA lymph node presence;LA7338-2;6;Not available;;; +67207-1;LL1684-1;PhenX19_30_CA metastasis presence;LA4544-8;1;MX;;; +67207-1;LL1684-1;PhenX19_30_CA metastasis presence;LA4629-7;2;M0;;; +67207-1;LL1684-1;PhenX19_30_CA metastasis presence;LA4628-9;3;M1;;; +67207-1;LL1684-1;PhenX19_30_CA metastasis presence;LA7338-2;4;Not available;;; +67211-3;LL1684-1;PhenX19_30_CA metastasis presence;LA4544-8;1;MX;;; +67211-3;LL1684-1;PhenX19_30_CA metastasis presence;LA4629-7;2;M0;;; +67211-3;LL1684-1;PhenX19_30_CA metastasis presence;LA4628-9;3;M1;;; +67211-3;LL1684-1;PhenX19_30_CA metastasis presence;LA7338-2;4;Not available;;; +67213-9;LL5602-9;Stage I | Stage II | Stage IIA;LA3664-5;1;Stage I;;; +67213-9;LL5602-9;Stage I | Stage II | Stage IIA;LA3661-1;2;Stage II;;; +67213-9;LL5602-9;Stage I | Stage II | Stage IIA;LA3660-3;3;Stage IIA;;; +67213-9;LL5602-9;Stage I | Stage II | Stage IIA;LA3659-5;4;Stage IIB;;; +67213-9;LL5602-9;Stage I | Stage II | Stage IIA;LA3657-9;5;Stage III;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31358-7;1;CR or 1st PR;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31359-5;2;Not in CR or 1st PR;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31360-3;3;Chronic phase;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31361-1;4;Not in chronic phase;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31362-9;5;In remission;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31363-7;6;Not in remission;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31364-5;7;Morphologic remission;;; +67213-9;LL5707-6;PAM Revised - Disease stages;LA31365-2;8;Not morphologic remission;;; +67214-7;LL1686-6;PhenX19_32_Dukes scoring;LA13487-6;1;A;;; +67214-7;LL1686-6;PhenX19_32_Dukes scoring;LA14518-7;2;B;;; +67214-7;LL1686-6;PhenX19_32_Dukes scoring;LA14519-5;3;C;;; +67214-7;LL1686-6;PhenX19_32_Dukes scoring;LA7338-2;4;Not available;;; +67215-4;LL1687-4;PhenX19_33_modified Dukes - Astler-Coller;LA13487-6;1;A;;; +67215-4;LL1687-4;PhenX19_33_modified Dukes - Astler-Coller;LA13488-4;2;B1;;; +67215-4;LL1687-4;PhenX19_33_modified Dukes - Astler-Coller;LA13489-2;3;B2;;; +67215-4;LL1687-4;PhenX19_33_modified Dukes - Astler-Coller;LA13491-8;4;C1;;; +67215-4;LL1687-4;PhenX19_33_modified Dukes - Astler-Coller;LA13492-6;5;C2;;; +67215-4;LL1687-4;PhenX19_33_modified Dukes - Astler-Coller;LA14520-3;6;D;;; +67215-4;LL1687-4;PhenX19_33_modified Dukes - Astler-Coller;LA7338-2;7;Not available;;; +67216-2;LL1680-9;PhenX19_26_summary CA staging;LA3787-4;1;Localized;;; +67216-2;LL1680-9;PhenX19_26_summary CA staging;LA3697-5;2;Regional;;; +67216-2;LL1680-9;PhenX19_26_summary CA staging;LA4200-7;3;Distant;;; +67216-2;LL1680-9;PhenX19_26_summary CA staging;LA7338-2;4;Not available;;; +67217-0;LL1679-1;PhenX19_25_adenoma procedure;LA15379-3;1;Sigmoidoscopy;;; +67217-0;LL1679-1;PhenX19_25_adenoma procedure;LA15380-1;2;Colonoscopy;;; +67217-0;LL1679-1;PhenX19_25_adenoma procedure;LA3841-9;3;Endoscopy, NOS;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16833-8;1;Cecum;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16834-6;2;Ascending colon;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16835-3;3;Hepatic flexure;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16836-1;4;Transverse colon;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16837-9;5;Splenic flexure;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16838-7;6;Descending colon;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16839-5;7;Sigmoid colon;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16840-3;8;Rectum;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA16841-1;9;Appendix;;; +67218-8;LL1690-8;PhenX19_36_polyp location;LA7338-2;10;Not available;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16833-8;1;Cecum;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16834-6;2;Ascending colon;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16835-3;3;Hepatic flexure;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16836-1;4;Transverse colon;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16837-9;5;Splenic flexure;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16838-7;6;Descending colon;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16839-5;7;Sigmoid colon;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16840-3;8;Rectum;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA16841-1;9;Appendix;;; +84877-0;LL1690-8;PhenX19_36_polyp location;LA7338-2;10;Not available;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15462-7;1;Visible blood;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15463-5;2;Family history of colon cancer;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15464-3;3;Virtual (CT) colonography;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15465-0;4;Occult fecal blood;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15466-8;5;Diarrhea/constipation;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15467-6;6;Prior polyps;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15468-4;7;Abdominal pain;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15469-2;8;Barium enema;;; +67223-8;LL1691-6;PhenX19_37_reason for sigmoidoscopy;LA15470-0;9;Asymptomatic or routine screening;;; +67224-6;LL1692-4;PhenX19_38_GI conditions;LA16830-4;1;Diverticulitis or diverticulosis;;; +67224-6;LL1692-4;PhenX19_38_GI conditions;LA15686-1;2;Colon/rectal cancer;;; +67224-6;LL1692-4;PhenX19_38_GI conditions;LA16844-5;3;Gallbladder removal;;; +67224-6;LL1692-4;PhenX19_38_GI conditions;LA14287-9;4;Gastric or duodenal ulcer;;; +67224-6;LL1692-4;PhenX19_38_GI conditions;LA14288-7;5;Barrett's Esophagus;;; +67224-6;LL1692-4;PhenX19_38_GI conditions;LA14286-1;6;Ulcerative colitis or Crohn's;;; +67224-6;LL1692-4;PhenX19_38_GI conditions;LA16845-2;7;Gastrointestinal bleeding that required hospitalization or a transfusion;;; +67226-1;LL1693-2;PhenX19_39_bleeding site;LA4018-3;1;Esophagus;;; +67226-1;LL1693-2;PhenX19_39_bleeding site;LA4476-3;2;Stomach;;; +67226-1;LL1693-2;PhenX19_39_bleeding site;LA16846-0;3;Duodenum;;; +67226-1;LL1693-2;PhenX19_39_bleeding site;LA16847-8;4;Colon or rectum;;; +67226-1;LL1693-2;PhenX19_39_bleeding site;LA46-8;5;Other;;; +67226-1;LL1693-2;PhenX19_39_bleeding site;LA16848-6;6;Site unknown;;; +67228-7;LL1694-0;PhenX19_40_date range Y;LA16849-4;1;Before 1993;;; +67228-7;LL1694-0;PhenX19_40_date range Y;LA16850-2;2;Between 1993-1997;;; +67228-7;LL1694-0;PhenX19_40_date range Y;LA16851-0;3;Between 1998-1999;;; +67228-7;LL1694-0;PhenX19_40_date range Y;LA16852-8;4;Between 2000-2001;;; +67228-7;LL1694-0;PhenX19_40_date range Y;LA16853-6;5;Between 2002-2003;;; +67228-7;LL1694-0;PhenX19_40_date range Y;LA16854-4;6;Between 2004-2005;;; +67228-7;LL1694-0;PhenX19_40_date range Y;LA16855-1;7;2006 or later;;; +67229-5;LL1695-7;PhenX19_41_frequency;LA15471-8;1;0 days;;; +67229-5;LL1695-7;PhenX19_41_frequency;LA13943-8;2;1 day;;; +67229-5;LL1695-7;PhenX19_41_frequency;LA14964-3;3;2 to 3 days;;; +67229-5;LL1695-7;PhenX19_41_frequency;LA16856-9;4;4 to 7 days;;; +67230-3;LL1695-7;PhenX19_41_frequency;LA15471-8;1;0 days;;; +67230-3;LL1695-7;PhenX19_41_frequency;LA13943-8;2;1 day;;; +67230-3;LL1695-7;PhenX19_41_frequency;LA14964-3;3;2 to 3 days;;; +67230-3;LL1695-7;PhenX19_41_frequency;LA16856-9;4;4 to 7 days;;; +67233-7;LL1695-7;PhenX19_41_frequency;LA15471-8;1;0 days;;; +67233-7;LL1695-7;PhenX19_41_frequency;LA13943-8;2;1 day;;; +67233-7;LL1695-7;PhenX19_41_frequency;LA14964-3;3;2 to 3 days;;; +67233-7;LL1695-7;PhenX19_41_frequency;LA16856-9;4;4 to 7 days;;; +67234-5;LL1695-7;PhenX19_41_frequency;LA15471-8;1;0 days;;; +67234-5;LL1695-7;PhenX19_41_frequency;LA13943-8;2;1 day;;; +67234-5;LL1695-7;PhenX19_41_frequency;LA14964-3;3;2 to 3 days;;; +67234-5;LL1695-7;PhenX19_41_frequency;LA16856-9;4;4 to 7 days;;; +67231-1;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA15471-8;1;0 days;;; +67231-1;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA13943-8;2;1 day;;; +67231-1;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA14964-3;3;2 to 3 days;;; +67231-1;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA16856-9;4;4 to 7 days;;; +67232-9;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA15471-8;1;0 days;;; +67232-9;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA13943-8;2;1 day;;; +67232-9;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA14964-3;3;2 to 3 days;;; +67232-9;LL1696-5;PhenX19_42_stomach pain, nausea freq;LA16856-9;4;4 to 7 days;;; +67236-0;LL1697-3;PhenX20_01_ear tube presence;LA15472-6;1;Yes, right ear;;; +67236-0;LL1697-3;PhenX20_01_ear tube presence;LA15473-4;2;Yes, left ear;;; +67236-0;LL1697-3;PhenX20_01_ear tube presence;LA15474-2;3;Yes, both ears;;; +67236-0;LL1697-3;PhenX20_01_ear tube presence;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +67236-0;LL1697-3;PhenX20_01_ear tube presence;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67236-0;LL1697-3;PhenX20_01_ear tube presence;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67239-4;LL1698-1;PhenX20_02_ear, sinus problems had;LA15475-9;1;Cold;;; +67239-4;LL1698-1;PhenX20_02_ear, sinus problems had;LA15476-7;2;Sinus problem;;; +67239-4;LL1698-1;PhenX20_02_ear, sinus problems had;LA15477-5;3;Earache, right ear;;; +67239-4;LL1698-1;PhenX20_02_ear, sinus problems had;LA15478-3;4;Earache, left ear;;; +67239-4;LL1698-1;PhenX20_02_ear, sinus problems had;LA15479-1;5;Earache, both ears;;; +67239-4;LL1698-1;PhenX20_02_ear, sinus problems had;LA4389-8;6;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67239-4;LL1698-1;PhenX20_02_ear, sinus problems had;LA12688-0;7;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67242-8;LL1699-9;PhenX20_03_hear better in one ear;LA15472-6;1;Yes, right ear;;; +67242-8;LL1699-9;PhenX20_03_hear better in one ear;LA15473-4;2;Yes, left ear;;; +67242-8;LL1699-9;PhenX20_03_hear better in one ear;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67242-8;LL1699-9;PhenX20_03_hear better in one ear;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67242-8;LL1699-9;PhenX20_03_hear better in one ear;LA12688-0;5;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67243-6;LL1700-5;PhenX20_04_ear comments;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67243-6;LL1700-5;PhenX20_04_ear comments;LA15480-9;2;Excessive cerumen;;; +67243-6;LL1700-5;PhenX20_04_ear comments;LA15481-7;3;Impacted cerumen;;; +67243-6;LL1700-5;PhenX20_04_ear comments;LA15482-5;4;Abnormality, type unknown;;; +67243-6;LL1700-5;PhenX20_04_ear comments;LA15483-3;5;Collapsing ear canal;;; +67244-4;LL1700-5;PhenX20_04_ear comments;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67244-4;LL1700-5;PhenX20_04_ear comments;LA15480-9;2;Excessive cerumen;;; +67244-4;LL1700-5;PhenX20_04_ear comments;LA15481-7;3;Impacted cerumen;;; +67244-4;LL1700-5;PhenX20_04_ear comments;LA15482-5;4;Abnormality, type unknown;;; +67244-4;LL1700-5;PhenX20_04_ear comments;LA15483-3;5;Collapsing ear canal;;; +67249-3;LL1701-3;PhenX20_05_ear tested first;LA15485-8;1;Right ear;;; +67249-3;LL1701-3;PhenX20_05_ear tested first;LA15486-6;2;Left ear;;; +67250-1;LL1702-1;PhenX20_06_headphone type;LA15487-4;1;Regular;;; +67250-1;LL1702-1;PhenX20_06_headphone type;LA15488-2;2;Insert;;; +67251-9;LL1703-9;PhenX20_07_ear test mode;LA15489-0;1;Automatically;;; +67251-9;LL1703-9;PhenX20_07_ear test mode;LA15490-8;2;Manually;;; +67251-9;LL1703-9;PhenX20_07_ear test mode;LA11840-8;3;Mixed;;; +67257-6;LL1703-9;PhenX20_07_ear test mode;LA15489-0;1;Automatically;;; +67257-6;LL1703-9;PhenX20_07_ear test mode;LA15490-8;2;Manually;;; +67257-6;LL1703-9;PhenX20_07_ear test mode;LA11840-8;3;Mixed;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15491-6;1;1000 – First;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA14009-7;2;500;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15492-4;3;1000 – Second;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15493-2;4;2000;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15494-0;5;3000;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15495-7;6;4000;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15496-5;7;6000;;; +67252-7;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15497-3;8;8000;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15491-6;1;1000 – First;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA14009-7;2;500;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15492-4;3;1000 – Second;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15493-2;4;2000;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15494-0;5;3000;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15495-7;6;4000;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15496-5;7;6000;;; +67258-4;LL1704-7;PhenX20_08_Hertz for hearing test sequence;LA15497-3;8;8000;;; +67253-5;LL1705-4;PhenX20_09_frequncies for hearing test;LA16857-7;1;500 Hz;;; +67253-5;LL1705-4;PhenX20_09_frequncies for hearing test;LA16858-5;2;1000 Hz;;; +67253-5;LL1705-4;PhenX20_09_frequncies for hearing test;LA16859-3;3;2000 Hz;;; +67253-5;LL1705-4;PhenX20_09_frequncies for hearing test;LA16860-1;4;3000 Hz;;; +67253-5;LL1705-4;PhenX20_09_frequncies for hearing test;LA16861-9;5;4000 Hz;;; +67253-5;LL1705-4;PhenX20_09_frequncies for hearing test;LA16862-7;6;6000 Hz;;; +67253-5;LL1705-4;PhenX20_09_frequncies for hearing test;LA16863-5;7;8000 Hz;;; +67254-3;LL1706-2;PhenX20_10_thresholds;LA16864-3;1;First threshold;;; +67254-3;LL1706-2;PhenX20_10_thresholds;LA16865-0;2;Second threshold;;; +67261-8;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67261-8;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67261-8;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67261-8;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67261-8;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67261-8;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67261-8;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67262-6;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67262-6;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67262-6;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67262-6;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67262-6;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67262-6;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67262-6;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67263-4;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67263-4;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67263-4;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67263-4;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67263-4;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67263-4;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67263-4;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67264-2;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67264-2;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67264-2;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67264-2;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67264-2;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67264-2;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67264-2;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67265-9;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67265-9;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67265-9;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67265-9;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67265-9;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67265-9;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67265-9;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67266-7;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67266-7;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67266-7;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67266-7;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67266-7;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67266-7;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67266-7;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67267-5;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67267-5;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67267-5;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67267-5;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67267-5;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67267-5;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67267-5;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67268-3;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67268-3;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67268-3;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67268-3;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67268-3;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67268-3;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67268-3;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67269-1;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67269-1;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67269-1;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67269-1;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67269-1;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67269-1;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67269-1;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67270-9;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67270-9;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67270-9;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67270-9;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67270-9;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67270-9;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67270-9;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67271-7;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67271-7;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67271-7;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67271-7;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67271-7;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67271-7;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67271-7;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67272-5;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67272-5;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67272-5;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67272-5;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67272-5;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67272-5;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67272-5;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67273-3;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67273-3;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67273-3;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67273-3;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67273-3;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67273-3;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67273-3;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67274-1;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67274-1;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67274-1;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67274-1;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67274-1;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67274-1;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67274-1;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67275-8;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67275-8;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67275-8;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67275-8;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67275-8;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67275-8;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67275-8;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67276-6;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67276-6;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67276-6;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67276-6;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67276-6;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67276-6;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67276-6;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67277-4;LL1720-3;PhenX20_19;LA14643-3;1;Very low;;; +67277-4;LL1720-3;PhenX20_19;LA6113-0;2;2;;; +67277-4;LL1720-3;PhenX20_19;LA6114-8;3;3;;; +67277-4;LL1720-3;PhenX20_19;LA15498-1;4;Normal for age;;; +67277-4;LL1720-3;PhenX20_19;LA10137-0;5;5;;; +67277-4;LL1720-3;PhenX20_19;LA10138-8;6;6;;; +67277-4;LL1720-3;PhenX20_19;LA14637-5;7;Very high;;; +67278-2;LL1721-1;PhenX20_20_speaking volume;LA15499-9;1;Too soft;;; +67278-2;LL1721-1;PhenX20_20_speaking volume;LA6113-0;2;2;;; +67278-2;LL1721-1;PhenX20_20_speaking volume;LA6114-8;3;3;;; +67278-2;LL1721-1;PhenX20_20_speaking volume;LA15501-2;4;About loud enough;;; +67278-2;LL1721-1;PhenX20_20_speaking volume;LA10137-0;5;5;;; +67278-2;LL1721-1;PhenX20_20_speaking volume;LA10138-8;6;6;;; +67278-2;LL1721-1;PhenX20_20_speaking volume;LA15500-4;7;Too loud;;; +67279-0;LL1722-9;PhenX20_21_speaking freq;LA16903-9;1;Not often;;; +67279-0;LL1722-9;PhenX20_21_speaking freq;LA6113-0;2;2;;; +67279-0;LL1722-9;PhenX20_21_speaking freq;LA6114-8;3;3;;; +67279-0;LL1722-9;PhenX20_21_speaking freq;LA15503-8;4;About often enough;;; +67279-0;LL1722-9;PhenX20_21_speaking freq;LA10137-0;5;5;;; +67279-0;LL1722-9;PhenX20_21_speaking freq;LA10138-8;6;6;;; +67279-0;LL1722-9;PhenX20_21_speaking freq;LA15504-6;7;Too often;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16887-4;1;Spouse (current or previous);;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA6654-3;2;Parent;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16888-2;3;Father-in-law/mother-in-law;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA9949-4;4;Child;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16889-0;5;Sibling;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16890-8;6;Daughter-in-law;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16891-6;7;Son-in-law;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA15640-8;8;Other relative;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16867-6;9;Old neighbor;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16868-4;10;Current neighbor;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16869-2;11;School/class mate;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16870-0;12;Compatriot;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16871-8;13;Teacher;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA15276-1;14;Student;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16872-6;15;Current co-worker;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16873-4;16;Current boss/superior;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16874-2;17;Current subordinate;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16875-9;18;Co-worker, boss/superior, or subordinate from a previous firm;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16876-7;19;Client;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16877-5;20;Person working for another firm, but known through work relations;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16878-3;21;Someone from the same religious group;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16879-1;22;Someone from the same association, club or group;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16880-9;23;Close friend;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16881-7;24;Ordinary friend;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16882-5;25;Someone known because he/she provides a service to me or my family;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16883-3;26;Someone know from the Internet;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16884-1;27;An acquaintance;;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16885-8;28;Indirect relationship (known via someone else);;; +67286-5;LL1707-0;PhenX18_27_social relationships;LA16886-6;29;Else;;; +67288-1;LL1654-4;PhenX18_26_race, ethnicity;LA16815-5;1;White (non-Latino);;; +67288-1;LL1654-4;PhenX18_26_race, ethnicity;LA14511-2;2;African-American;;; +67288-1;LL1654-4;PhenX18_26_race, ethnicity;LA16816-3;3;Latino;;; +67288-1;LL1654-4;PhenX18_26_race, ethnicity;LA6156-9;4;Asian;2028-9;Asian;https://www.cdc.gov/phin +67288-1;LL1654-4;PhenX18_26_race, ethnicity;LA16817-1;5;Native american;;; +67288-1;LL1654-4;PhenX18_26_race, ethnicity;LA46-8;6;Other;;; +67289-9;LL1712-0;PhenX19_43_pain type;LA16902-1;1;Continuous;;; +67289-9;LL1712-0;PhenX19_43_pain type;LA14447-9;2;Come and go;;; +67289-9;LL1712-0;PhenX19_43_pain type;LA14331-5;3;Both;;; +67297-2;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67297-2;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67297-2;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67298-0;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67298-0;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67298-0;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67299-8;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67299-8;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67299-8;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67300-4;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67300-4;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67300-4;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67302-0;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67302-0;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67302-0;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67304-6;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67304-6;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67304-6;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67305-3;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67305-3;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67305-3;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67306-1;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67306-1;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67306-1;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67307-9;LL1710-4;PhenX20_11;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67307-9;LL1710-4;PhenX20_11;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67307-9;LL1710-4;PhenX20_11;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67320-2;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67320-2;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67320-2;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67321-0;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67321-0;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67321-0;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67322-8;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67322-8;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67322-8;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67323-6;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67323-6;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67323-6;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67324-4;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67324-4;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67324-4;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67325-1;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67325-1;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67325-1;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67326-9;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67326-9;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67326-9;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67327-7;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67327-7;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67327-7;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67328-5;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67328-5;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67328-5;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67329-3;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67329-3;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67329-3;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67330-1;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67330-1;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67330-1;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67331-9;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67331-9;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67331-9;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67332-7;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67332-7;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67332-7;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67333-5;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67333-5;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67333-5;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67334-3;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67334-3;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67334-3;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67335-0;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67335-0;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67335-0;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67336-8;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67336-8;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67336-8;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67337-6;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67337-6;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67337-6;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67338-4;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67338-4;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67338-4;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67339-2;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67339-2;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67339-2;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67340-0;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67340-0;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67340-0;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67341-8;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67341-8;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67341-8;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67342-6;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67342-6;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67342-6;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67343-4;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67343-4;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67343-4;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67344-2;LL1711-2;PhenX20_12;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67344-2;LL1711-2;PhenX20_12;LA10082-8;2;Sometimes;;; +67344-2;LL1711-2;PhenX20_12;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67345-9;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67345-9;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67345-9;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67346-7;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67346-7;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67346-7;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67347-5;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67347-5;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67347-5;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67348-3;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67348-3;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67348-3;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67349-1;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67349-1;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67349-1;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67350-9;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67350-9;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67350-9;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67351-7;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67351-7;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67351-7;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67352-5;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67352-5;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67352-5;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67353-3;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67353-3;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67353-3;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67354-1;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67354-1;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67354-1;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67355-8;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67355-8;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67355-8;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67356-6;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67356-6;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67356-6;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67357-4;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67357-4;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67357-4;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67358-2;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67358-2;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67358-2;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67359-0;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67359-0;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67359-0;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67360-8;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67360-8;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67360-8;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67361-6;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67361-6;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67361-6;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67362-4;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67362-4;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67362-4;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67363-2;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67363-2;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67363-2;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67364-0;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67364-0;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67364-0;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67365-7;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67365-7;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67365-7;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67366-5;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67366-5;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67366-5;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67367-3;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67367-3;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67367-3;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67368-1;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67368-1;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67368-1;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67369-9;LL1714-6;PhenX20_13;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67369-9;LL1714-6;PhenX20_13;LA10082-8;2;Sometimes;;; +67369-9;LL1714-6;PhenX20_13;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67370-7;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67370-7;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67370-7;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67370-7;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67370-7;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67371-5;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67371-5;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67371-5;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67371-5;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67371-5;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67372-3;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67372-3;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67372-3;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67372-3;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67372-3;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67373-1;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67373-1;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67373-1;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67373-1;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67373-1;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67374-9;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67374-9;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67374-9;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67374-9;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67374-9;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67375-6;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67375-6;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67375-6;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67375-6;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67375-6;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67376-4;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67376-4;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67376-4;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67376-4;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67376-4;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67377-2;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67377-2;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67377-2;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67377-2;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67377-2;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67378-0;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67378-0;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67378-0;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67378-0;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67378-0;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67379-8;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67379-8;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67379-8;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67379-8;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67379-8;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67380-6;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67380-6;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67380-6;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67380-6;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67380-6;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67381-4;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67381-4;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67381-4;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67381-4;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67381-4;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67382-2;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67382-2;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67382-2;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67382-2;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67382-2;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67383-0;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67383-0;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67383-0;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67383-0;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67383-0;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67384-8;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67384-8;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67384-8;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67384-8;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67384-8;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67385-5;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67385-5;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67385-5;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67385-5;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67385-5;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67386-3;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67386-3;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67386-3;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67386-3;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67386-3;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67387-1;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67387-1;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67387-1;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67387-1;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67387-1;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67388-9;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67388-9;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67388-9;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67388-9;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67388-9;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67389-7;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67389-7;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67389-7;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67389-7;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67389-7;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67390-5;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67390-5;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67390-5;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67390-5;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67390-5;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67391-3;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67391-3;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67391-3;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67391-3;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67391-3;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67392-1;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67392-1;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67392-1;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67392-1;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67392-1;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67393-9;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67393-9;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67393-9;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67393-9;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67393-9;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67394-7;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67394-7;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67394-7;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67394-7;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67394-7;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67395-4;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67395-4;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67395-4;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67395-4;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67395-4;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67396-2;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67396-2;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67396-2;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67396-2;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67396-2;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67397-0;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67397-0;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67397-0;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67397-0;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67397-0;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67398-8;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67398-8;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67398-8;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67398-8;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67398-8;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67399-6;LL1715-3;PhenX20_14;LA6270-8;1;Never;;; +67399-6;LL1715-3;PhenX20_14;LA13866-1;2;Almost never;;; +67399-6;LL1715-3;PhenX20_14;LA10082-8;3;Sometimes;;; +67399-6;LL1715-3;PhenX20_14;LA13865-3;4;Almost always;;; +67399-6;LL1715-3;PhenX20_14;LA9933-8;5;Always;;; +67401-0;LL1723-7;PhenX20_22_diffilculty development time;LA15509-5;1;Suddenly (over a few days);;; +67401-0;LL1723-7;PhenX20_22_diffilculty development time;LA15510-3;2;Over a few months;;; +67401-0;LL1723-7;PhenX20_22_diffilculty development time;LA15511-1;3;Over several years;;; +67402-8;LL1724-5;PhenX20_23_hearing difficulty reason known;LA15512-9;1;I have no idea about the cause of my hearing problem;;; +67402-8;LL1724-5;PhenX20_23_hearing difficulty reason known;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67718-7;LL1724-5;PhenX20_23_hearing difficulty reason known;LA15512-9;1;I have no idea about the cause of my hearing problem;;; +67718-7;LL1724-5;PhenX20_23_hearing difficulty reason known;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67403-6;LL1725-2;PhenX20_24_ears;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67403-6;LL1725-2;PhenX20_24_ears;LA15514-5;2;Yes, in my left ear;;; +67403-6;LL1725-2;PhenX20_24_ears;LA15515-2;3;Yes, in my right ear;;; +67403-6;LL1725-2;PhenX20_24_ears;LA15513-7;4;Yes, in both ears;;; +67406-9;LL1725-2;PhenX20_24_ears;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67406-9;LL1725-2;PhenX20_24_ears;LA15514-5;2;Yes, in my left ear;;; +67406-9;LL1725-2;PhenX20_24_ears;LA15515-2;3;Yes, in my right ear;;; +67406-9;LL1725-2;PhenX20_24_ears;LA15513-7;4;Yes, in both ears;;; +67409-3;LL1726-0;PhenX20_25_ ear discharge;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67409-3;LL1726-0;PhenX20_25_ ear discharge;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67409-3;LL1726-0;PhenX20_25_ ear discharge;LA15516-0;3;From my left ear;;; +67409-3;LL1726-0;PhenX20_25_ ear discharge;LA15517-8;4;From my right ear;;; +67410-1;LL1727-8;PhenX20_26;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67410-1;LL1727-8;PhenX20_26;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67410-1;LL1727-8;PhenX20_26;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67425-9;LL1727-8;PhenX20_26;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67425-9;LL1727-8;PhenX20_26;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67425-9;LL1727-8;PhenX20_26;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67426-7;LL1727-8;PhenX20_26;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67426-7;LL1727-8;PhenX20_26;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67426-7;LL1727-8;PhenX20_26;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67427-5;LL1727-8;PhenX20_26;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67427-5;LL1727-8;PhenX20_26;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67427-5;LL1727-8;PhenX20_26;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67431-7;LL1727-8;PhenX20_26;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67431-7;LL1727-8;PhenX20_26;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67431-7;LL1727-8;PhenX20_26;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67432-5;LL1727-8;PhenX20_26;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67432-5;LL1727-8;PhenX20_26;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67432-5;LL1727-8;PhenX20_26;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67435-8;LL1727-8;PhenX20_26;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67435-8;LL1727-8;PhenX20_26;LA12688-0;2;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67435-8;LL1727-8;PhenX20_26;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67411-9;LL1716-1;PhenX20_15_dizziness attack;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67411-9;LL1716-1;PhenX20_15_dizziness attack;LA15519-4;2;Yes, within the last year;;; +67411-9;LL1716-1;PhenX20_15_dizziness attack;LA15520-2;3;Yes, more than a year ago;;; +67421-8;LL1728-6;PhenX20_27_relative participation;LA15521-0;1;As far as I know, none of my relatives has already participated in this investigation;;; +67421-8;LL1728-6;PhenX20_27_relative participation;LA15522-8;2;One of my relatives has already participated in this investigation;;; +67424-2;LL1729-4;PhenX20_28_migraine freq;LA15523-6;1;Often (more than one attack a month);;; +67424-2;LL1729-4;PhenX20_28_migraine freq;LA15524-4;2;Regularly (an attack once a month on average);;; +67424-2;LL1729-4;PhenX20_28_migraine freq;LA15525-1;3;Sporadically (between 4 and 10 times a year);;; +67424-2;LL1729-4;PhenX20_28_migraine freq;LA15526-9;4;Rarely (less than one attack every 3 months);;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA10527-2;1;Osteoporosis;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17768-5;2;Osteoarthritis;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17769-3;3;Multiple sclerosis - MS;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA16985-6;4;Epilepsy;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17770-1;5;Lung problems;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17771-9;6;Allergy;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17772-7;7;Diseases of the stomach or intestine;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17773-5;8;Kidney diseases;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17774-3;9;Liver diseases;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17775-0;10;Skin diseases;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17776-8;11;Psychiatric problems;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17777-6;12;Blood diseases;;; +67437-4;LL1864-9;PhenX19_47_disease hx;LA17778-4;13;Diseases of the thyroid gland;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17779-2;1;Rheumatoid arthritis - rheumatism;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17780-0;2;Inflammatory bowel disease crohn's disease or colitis ulcerosa;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17781-8;3;Lupus erythematosus;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA15165-6;4;Psoriasis;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17782-6;5;Wegener's granulomatosis;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17783-4;6;Vasculitis;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17784-2;7;Nephritis;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17785-9;8;Hashimoto thyroiditis;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17786-7;9;Cogan's syndrome;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA17787-5;10;Behcet's syndrome;;; +67439-0;LL1865-6;PhenX19_48_autoimmune diseases;LA46-8;11;Other;;; +67449-9;LL1730-2;PhenX20_29_painkiller freq;LA6270-8;1;Never;;; +67449-9;LL1730-2;PhenX20_29_painkiller freq;LA16904-7;2;Less than 1 tablet a month;;; +67449-9;LL1730-2;PhenX20_29_painkiller freq;LA16905-4;3;Less than 1 tablet a week (but more than one each month);;; +67449-9;LL1730-2;PhenX20_29_painkiller freq;LA16906-2;4;2-5 tablets a week;;; +67449-9;LL1730-2;PhenX20_29_painkiller freq;LA16907-0;5;2-5 tablets a day;;; +67449-9;LL1730-2;PhenX20_29_painkiller freq;LA16908-8;6;More than 5 tablets a day;;; +67451-5;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA15527-7;1;3 months – 1 year;;; +67451-5;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA15528-5;2;1-5 years;;; +67451-5;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA14769-6;3;More than 5 years;;; +67453-1;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA15527-7;1;3 months – 1 year;;; +67453-1;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA15528-5;2;1-5 years;;; +67453-1;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA14769-6;3;More than 5 years;;; +67453-1;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA15527-7;1;3 months – 1 year;;; +67453-1;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA15528-5;2;1-5 years;;; +67453-1;LL1738-5;PhenX20_30_meds duration_aspirin, med duration;LA14769-6;3;More than 5 years;;; +67455-6;LL1781-5;PhenX20_42_weapon type;LA17029-2;1;Light weapons (rifles or shotguns);;; +67455-6;LL1781-5;PhenX20_42_weapon type;LA17030-0;2;Heavy weapons(artillery or bazookas);;; +67456-4;LL1739-3;PhenX20_31_shots per weapon;LA15529-3;1;Less than 10 shots;;; +67456-4;LL1739-3;PhenX20_31_shots per weapon;LA15530-1;2;10–100 shots;;; +67456-4;LL1739-3;PhenX20_31_shots per weapon;LA15531-9;3;101–1,000 shots;;; +67456-4;LL1739-3;PhenX20_31_shots per weapon;LA15532-7;4;1,001–10,000 shots;;; +67456-4;LL1739-3;PhenX20_31_shots per weapon;LA15533-5;5;More than 10,000 shots;;; +67457-2;LL1740-1;PhenX20_32_ear protection freq;LA9933-8;1;Always;;; +67457-2;LL1740-1;PhenX20_32_ear protection freq;LA14734-0;2;Most of the time;;; +67457-2;LL1740-1;PhenX20_32_ear protection freq;LA15534-3;3;More than 50% of the time;;; +67457-2;LL1740-1;PhenX20_32_ear protection freq;LA15535-0;4;Less than 50% of the time;;; +67457-2;LL1740-1;PhenX20_32_ear protection freq;LA6270-8;5;Never;;; +67458-0;LL1741-9;PhenX20_33_ear protection;LA15536-8;1;Plugs;;; +67458-0;LL1741-9;PhenX20_33_ear protection;LA15537-6;2;Earmuff;;; +67458-0;LL1741-9;PhenX20_33_ear protection;LA15538-4;3;'Active' protection;;; +67462-2;LL1742-7;PhenX20_34_loud sound exposure;LA16938-5;1;1-3 hours each week;;; +67462-2;LL1742-7;PhenX20_34_loud sound exposure;LA16939-3;2;3-10 hours each week;;; +67462-2;LL1742-7;PhenX20_34_loud sound exposure;LA16940-1;3;1-3 hours each day;;; +67462-2;LL1742-7;PhenX20_34_loud sound exposure;LA16941-9;4;More than 3 hours each day;;; +67467-1;LL1718-7;PhenX20_17_ear w/ hearing difficulty;LA4585-1;1;Left;;; +67467-1;LL1718-7;PhenX20_17_ear w/ hearing difficulty;LA4306-2;2;Right;;; +67467-1;LL1718-7;PhenX20_17_ear w/ hearing difficulty;LA14331-5;3;Both;;; +67471-3;LL1820-1;NEMSIS_33_pregnancy;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67471-3;LL1820-1;NEMSIS_33_pregnancy;LA17332-0;2;Possible, unconfirmed;;; +67471-3;LL1820-1;NEMSIS_33_pregnancy;LA17331-2;3;Yes, confirmed greater than 20 weeks;;; +67471-3;LL1820-1;NEMSIS_33_pregnancy;LA17330-4;4;Yes, confirmed 12 to 20 weeks;;; +67471-3;LL1820-1;NEMSIS_33_pregnancy;LA17329-6;5;Yes, confirmed less than 12 weeks;;; +67471-3;LL1820-1;NEMSIS_33_pregnancy;LA24406-3;6;Yes, Weeks Unknown;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA17579-6;1;Caller (uncooperative);;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA17183-7;2;Diversion/failure (of previous unit);;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA17580-4;3;High call volume;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA7540-3;4;Language barrier;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA17582-0;6;No EMS vehicles (units) available;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA18081-2;7;None/no delay;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA17059-9;8;Other (not listed);;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA17584-6;10;Technical failure (computer, phone etc.);;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA32992-2;11;Communication specialist-assignment error;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA32993-0;12;No receiving MD, bed, hospital;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA32994-8;13;Specialty team delay;;; +67480-4;LL1835-9;NEMSIS_48_dispatch delay;LA33039-1;14;Incomplete address information provided;;; +67482-0;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17177-9;1;Emergent (immediate response);;; +67482-0;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17178-7;2;Emergent downgraded to non-emergent;;; +67482-0;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17179-5;3;Non-emergent upgraded to emergent;;; +67482-0;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17180-3;4;Non-emergent;;; +67550-4;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17177-9;1;Emergent (immediate response);;; +67550-4;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17178-7;2;Emergent downgraded to non-emergent;;; +67550-4;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17179-5;3;Non-emergent upgraded to emergent;;; +67550-4;LL1800-3;NEMSIS_Response and Transport mode to/from scene;LA17180-3;4;Non-emergent;;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA23840-4;1;Air Transport-Helicopter;;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA23841-2;2;Air Transport-Fixed Wing;;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA32990-6;3;Ground transport (ALS equipped);;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA32989-8;4;Ground transport (BLS equipped);;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA32988-0;5;Ground transport (critical care equipped);;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA32987-2;6;Non-transport-medical treatment (ALS equipped);;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA32986-4;7;Non-transport-medical treatment (BLS equipped);;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA32991-4;8;Wheel chair van/ambulette;;; +67483-8;LL1834-2;NEMSIS_47_primary unit role;LA32985-6;9;Non-transport-no medical equipment;;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA23840-4;1;Air Transport-Helicopter;;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA23841-2;2;Air Transport-Fixed Wing;;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA32990-6;3;Ground transport (ALS equipped);;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA32989-8;4;Ground transport (BLS equipped);;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA32988-0;5;Ground transport (critical care equipped);;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA32987-2;6;Non-transport-medical treatment (ALS equipped);;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA32986-4;7;Non-transport-medical treatment (BLS equipped);;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA32991-4;8;Wheel chair van/ambulette;;; +71579-7;LL1834-2;NEMSIS_47_primary unit role;LA32985-6;9;Non-transport-no medical equipment;;; +67488-7;LL1797-1;NEMSIS_10_EMD performed;LA32-8;0;No;373067005;No (qualifier value);http://snomed.info/sct +67488-7;LL1797-1;NEMSIS_10_EMD performed;LA17151-4;1;Yes, with pre-arrival instructions;;; +67488-7;LL1797-1;NEMSIS_10_EMD performed;LA17152-2;2;Yes, without pre-arrival instructions;;; +67488-7;LL1797-1;NEMSIS_10_EMD performed;LA17153-0;3;Yes, unknown if pre-arrival instructions given;;; +67489-5;LL1841-7;NEMSIS_55_pts at scene;LA17717-2;1;Single;;; +67489-5;LL1841-7;NEMSIS_55_pts at scene;LA15382-7;2;Multiple;;; +67489-5;LL1841-7;NEMSIS_55_pts at scene;LA137-2;3;None;260413007;None (qualifier value);http://snomed.info/sct +67493-7;LL1843-3;NEMSIS_57_triage status at scene;LA17696-8;1;Critical (red);;; +67493-7;LL1843-3;NEMSIS_57_triage status at scene;LA17695-0;2;Emergent (yellow);;; +67493-7;LL1843-3;NEMSIS_57_triage status at scene;LA17694-3;3;Lower acuity (green);;; +67493-7;LL1843-3;NEMSIS_57_triage status at scene;LA17697-6;4;Dead without resuscitation efforts (black);;; +67493-7;LL1843-3;NEMSIS_57_triage status at scene;LA32920-3;5;Non-acute/routine;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA17335-3;1;Blunt;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA7318-4;2;Burn;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA46-8;3;Other;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA17336-1;4;Penetrating;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA17335-3;1;Blunt;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA7318-4;2;Burn;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA46-8;3;Other;;; +67494-5;LL1974-6;NEMSIS_83_mech of injury;LA17336-1;4;Penetrating;;; +67494-5;LL4749-9;Blunt|Burn|Blow|Shot|Stabbed|Penetrating|Other;LA17335-3;1;Blunt;;; +67494-5;LL4749-9;Blunt|Burn|Blow|Shot|Stabbed|Penetrating|Other;LA7318-4;2;Burn;;; +67494-5;LL4749-9;Blunt|Burn|Blow|Shot|Stabbed|Penetrating|Other;LA28138-8;3;Blow;;; +67494-5;LL4749-9;Blunt|Burn|Blow|Shot|Stabbed|Penetrating|Other;LA28136-2;4;Shot;;; +67494-5;LL4749-9;Blunt|Burn|Blow|Shot|Stabbed|Penetrating|Other;LA28137-0;5;Stabbed;;; +67494-5;LL4749-9;Blunt|Burn|Blow|Shot|Stabbed|Penetrating|Other;LA17336-1;6;Penetrating;;; +67494-5;LL4749-9;Blunt|Burn|Blow|Shot|Stabbed|Penetrating|Other;LA46-8;7;Other;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA23844-6;1;Glasgow Coma Score ≤ 13;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17338-7;2;Respiratory rate < 10 or >29 or (<20 in infant < one year);;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17339-5;3;Systolic blood pressure less than 90;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17340-3;4;Amputation proximal to wrist and ankle;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17341-1;5;Crushed, degloved, or mangled extremity;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17342-9;6;Flail chest;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17343-7;7;Open or depressed skull fracture;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17344-5;8;Paralysis;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17345-2;9;Pelvic fracture(s);;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17346-0;10;Penetrating injury to head, neck, torso, and extremities proximal to elbow and knee;;; +67495-2;LL1821-9;NEMSIS_34_field triage criteria;LA17347-8;11;Two or more proximal long-bone fractures;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA17360-1;1;Auto v. pedestrian/bicyclist thrown, run over, or > 20 MPH impact;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA17348-6;2;Fall adults: > 20 ft. (one story is equal to 10 ft.);;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA17349-4;3;Fall children: > 10 ft. or 2-3 times the height of the child;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA17352-8;4;Crash death in same passenger compartment;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA17353-6;5;Crash ejection (partial or complete) from vehicle;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA17357-7;6;"Crash intrusion: > 12 in. occupant site; > 18 in. any site";;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA18124-0;7;Crash vehicle telemetry data (AACN) consistent with high risk of injury;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA17350-2;8;Motorcycle crash > 20 mph;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA24412-1;9;SBP < 110 for age > 65;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA24407-1;10;Anticoagulants and Bleeding Disorders;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA24411-3;11;Pregnancy > 20 weeks;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA24410-5;12;EMS Provider Judgment;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA24409-7;13;Burn, without other trauma;;; +67496-0;LL1822-7;NEMSIS_35_inj risk factors;LA24408-9;14;Burn, with trauma mechanism;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA6112-2;1;1;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA6113-0;2;2;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA6114-8;3;3;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA6115-5;4;4;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA10137-0;5;5;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA10138-8;6;6;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA10139-6;7;7;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA10140-4;8;8;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA10141-2;9;9;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA13942-0;10;10;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA14557-5;11;11;;; +67497-8;LL1913-4;NEMSIS_78_impact on vehicle;LA14558-3;12;12;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17361-9;1;Front seat-left side (or motorcycle driver);;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17363-5;2;Front seat-middle;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17362-7;3;Front seat-right side;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17364-3;4;Second seat-left side (or motorcycle passenger);;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17365-0;5;Second seat-middle;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17366-8;6;Second seat-right side;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17367-6;7;Third row-left side (or motorcycle passenger);;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17369-2;8;Third row-middle;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17368-4;9;Third row-right side;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17370-0;10;Sleeper section of cab (truck);;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17371-8;11;Passenger in other enclosed passenger or cargo area (non-trailing unit such as a bus, etc.);;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17372-6;12;Passenger in unenclosed passenger or cargo area (non-trailing unit such as a pickup, etc.);;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17373-4;13;Trailing unit;;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA17374-2;14;Riding on vehicle exterior (non-trailing unit);;; +67498-6;LL1823-5;NEMSIS_36_pt loc in vehicle;LA4489-6;15;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17375-9;1;Child booster seat;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA9391-9;2;Eye protection;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17376-7;3;Helmet worn;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17377-5;4;Infant car seat forward facing;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17378-3;5;Infant car seat rear facing;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17379-1;6;Shoulder and lap belt used;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17380-9;7;Lap belt only used;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA137-2;8;None;260413007;None (qualifier value);http://snomed.info/sct +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17381-7;10;Personal floatation device;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA9392-7;11;Protective clothing;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA17382-5;12;Protective non-clothing gear;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA24961-7;13;Shoulder belt only used;;; +67499-4;LL1824-3;NEMSIS_37_safety equipment;LA11137-9;14;Unable to determine;;; +67499-4;LL4751-5;NTDS_I_15_Child specific restraint;LA28429-1;1;Child car seat;;; +67499-4;LL4751-5;NTDS_I_15_Child specific restraint;LA28430-9;2;Infant car seat;;; +67499-4;LL4751-5;NTDS_I_15_Child specific restraint;LA17375-9;3;Child booster seat;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA9382-8;2;Lap belt;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA17381-7;3;Personal floatation device;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA17382-5;4;Protective non-clothing gear;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA9391-9;5;Eye protection;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA28431-7;6;Child restraint (booster seat or child car seat);;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA9390-1;7;Helmet;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA28432-5;8;Airbag present;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA9392-7;9;Protective clothing;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA9381-0;10;Shoulder belt;;; +67499-4;LL4752-3;NTDS_I_14_Protective devices;LA46-8;11;Other;;; +67500-9;LL1825-0;NEMSIS_38_airbag deployment;LA17384-1;1;Airbag deployed front;;; +67500-9;LL1825-0;NEMSIS_38_airbag deployment;LA17385-8;2;Airbag deployed side;;; +67500-9;LL1825-0;NEMSIS_38_airbag deployment;LA17386-6;3;Airbag deployed other (knee, airbelt, etc.);;; +67500-9;LL1825-0;NEMSIS_38_airbag deployment;LA17387-4;4;No airbag deployed;;; +67500-9;LL1825-0;NEMSIS_38_airbag deployment;LA17388-2;5;No airbag present;;; +67502-5;LL1788-0;NEMSIS_01_cardiac arrest;LA17054-0;1;Yes, prior to any EMS arrival (includes Transport EMS & Medical First Responders);;; +67502-5;LL1788-0;NEMSIS_01_cardiac arrest;LA17055-7;2;Yes, after any EMS arrival (includes Transport EMS & Medical First Responders);;; +67502-5;LL1788-0;NEMSIS_01_cardiac arrest;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA17056-5;1;Cardiac (presumed);;; +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA17977-2;2;Drowning/submersion;;; +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA17978-0;3;Drug overdose;;; +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA9539-3;4;Electrocution;;; +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA17980-6;5;Respiratory/asphyxia;;; +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA32910-4;7;Traumatic cause;;; +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA17979-8;8;Exsanguination-Medical (Non-Traumatic);;; +67503-3;LL1789-8;NEMSIS_02_cardiac arrest etiology;LA17059-9;9;Other (not listed);;; +67504-1;LL1790-6;NEMSIS_03_reason resusc not attempted;LA17063-1;1;Considered futile;;; +67504-1;LL1790-6;NEMSIS_03_reason resusc not attempted;LA17064-9;2;DNR orders;;; +67504-1;LL1790-6;NEMSIS_03_reason resusc not attempted;LA17065-6;3;Signs of circulation;;; +67505-8;LL1926-6;NEMSIS_77_cardiac arrest witness;LA18023-4;1;Not witnessed;;; +67505-8;LL1926-6;NEMSIS_77_cardiac arrest witness;LA18020-0;2;Witnessed by family member;;; +67505-8;LL1926-6;NEMSIS_77_cardiac arrest witness;LA18021-8;3;Witnessed by healthcare provider;;; +67505-8;LL1926-6;NEMSIS_77_cardiac arrest witness;LA18022-6;4;Witnessed by bystander;;; +67507-4;LL1925-8;NEMSIS_76_CPR provider;LA9277-0;1;Family member;;; +67507-4;LL1925-8;NEMSIS_76_CPR provider;LA18016-8;2;First responder-fire, law, EMS;;; +67507-4;LL1925-8;NEMSIS_76_CPR provider;LA18017-6;3;Healthcare professional-non-EMS;;; +67507-4;LL1925-8;NEMSIS_76_CPR provider;LA18018-4;4;Lay person-non-family;;; +67507-4;LL1925-8;NEMSIS_76_CPR provider;LA18019-2;5;Other EMS professional - not part of dispatched response;;; +67509-0;LL1925-8;NEMSIS_76_CPR provider;LA9277-0;1;Family member;;; +67509-0;LL1925-8;NEMSIS_76_CPR provider;LA18016-8;2;First responder-fire, law, EMS;;; +67509-0;LL1925-8;NEMSIS_76_CPR provider;LA18017-6;3;Healthcare professional-non-EMS;;; +67509-0;LL1925-8;NEMSIS_76_CPR provider;LA18018-4;4;Lay person-non-family;;; +67509-0;LL1925-8;NEMSIS_76_CPR provider;LA18019-2;5;Other EMS professional - not part of dispatched response;;; +67508-2;LL1791-4;NEMSIS_04_AED prior;LA17066-4;1;Yes, with defibrillation;;; +67508-2;LL1791-4;NEMSIS_04_AED prior;LA17067-2;2;Yes, applied without defibrillation;;; +67508-2;LL1791-4;NEMSIS_04_AED prior;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17749-5;1;Compressions-manual;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17750-3;2;Compressions-external band type device;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17751-1;3;Compressions-external plunger type device;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17752-9;4;Compressions-external thumper type device;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17753-7;5;Compressions-intermittent with ventilation;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17754-5;6;Compressions-other device;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17755-2;7;Ventilation-bag valve mask;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17756-0;8;Ventilation-impedance threshold device;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17757-8;9;Ventilation-mouth to mouth;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA17758-6;10;Ventilation-pocket mask;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA32911-2;11;Compressions-hands only CPR;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA32912-0;12;Ventilation-with OPA/NPA;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA32913-8;13;Ventilation-advanced airway device;;; +67510-8;LL1858-1;NEMSIS_71_CPR technique;LA32914-6;14;Ventilation-passive ventilation with oxygen;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17068-0;1;Asystole;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17070-6;3;PEA;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17071-4;4;Unknown AED non-shockable rhythm;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17072-2;5;Unknown AED shockable rhythm;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17073-0;6;Ventricular fibrillation;71908006;ventricular fibrillation (disorder);http://snomed.info/sct +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17074-8;7;Ventricular tachycardia-pulseless;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17068-0;1;Asystole;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17070-6;3;PEA;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17071-4;4;Unknown AED non-shockable rhythm;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17072-2;5;Unknown AED shockable rhythm;;; +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17073-0;6;Ventricular fibrillation;71908006;ventricular fibrillation (disorder);http://snomed.info/sct +67512-4;LL1792-2;NEMSIS_05_first rhythm;LA17074-8;7;Ventricular tachycardia-pulseless;;; +67513-2;LL1793-0;NEMSIS_06_ return circulation;LA17075-5;1;Yes, prior to arrival at the ED;;; +67513-2;LL1793-0;NEMSIS_06_ return circulation;LA17076-3;2;Yes, at arrival at the ED;;; +67513-2;LL1793-0;NEMSIS_06_ return circulation;LA17077-1;3;Yes, sustained for 20 consecutive minutes;;; +67513-2;LL1793-0;NEMSIS_06_ return circulation;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +88670-5;LL1793-0;NEMSIS_06_ return circulation;LA17075-5;1;Yes, prior to arrival at the ED;;; +88670-5;LL1793-0;NEMSIS_06_ return circulation;LA17076-3;2;Yes, at arrival at the ED;;; +88670-5;LL1793-0;NEMSIS_06_ return circulation;LA17077-1;3;Yes, sustained for 20 consecutive minutes;;; +88670-5;LL1793-0;NEMSIS_06_ return circulation;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17083-9;1;Agonal/idioventricular;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17068-0;2;Asystole;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17084-7;3;Atrial fibrillation;49436004;Atrial fibrillation (disorder);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17085-4;4;Atrial flutter;5370000;Atrial flutter (disorder);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17086-2;5;AV block-1st degree;270492004;first degree atrioventricular block (disorder);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17087-0;6;AV block-2nd degree-type 1;195042002;Second degree atrioventricular block (disorder);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17088-8;7;AV block-2nd degree-type 2;195042002;Second degree atrioventricular block (disorder);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17089-6;8;AV block-3rd degree;27885002;complete atrioventricular block (disorder);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17090-4;9;Junctional;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17091-2;10;Left bundle branch block;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17718-0;11;Sinus rhythm;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17093-8;12;Paced rhythm;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17070-6;13;PEA;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17094-6;14;Premature atrial contractions;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17095-3;15;Premature ventricular contractions;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17096-1;16;Right bundle branch block;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17097-9;17;Sinus arrhythmia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17098-7;18;Sinus bradycardia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17099-5;19;Sinus tachycardia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17100-1;20;Supraventricular tachycardia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17101-9;21;Torsades de points;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17071-4;22;Unknown AED non-shockable rhythm;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17072-2;23;Unknown AED shockable rhythm;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17073-0;24;Ventricular fibrillation;71908006;ventricular fibrillation (disorder);http://snomed.info/sct +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17708-1;25;Ventricular tachycardia with pulse;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17074-8;26;Ventricular tachycardia-pulseless;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA12904-1;27;Artifact;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18206-5;28;Non-STEMI inferior ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18205-7;29;Non-STEMI anterior ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18207-3;30;Non-STEMI lateral ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18208-1;31;Non-STEMI posterior ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA32915-3;32;Non-STEMI septal ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17703-2;33;STEMI-anterior ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17704-0;34;STEMI-inferior ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17705-7;35;STEMI-lateral ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17706-5;36;STEMI-posterior ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA32916-1;37;STEMI septal ischemia;;; +67514-0;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17059-9;38;Other (not listed);;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17083-9;1;Agonal/idioventricular;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17068-0;2;Asystole;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17084-7;3;Atrial fibrillation;49436004;Atrial fibrillation (disorder);http://snomed.info/sct +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17085-4;4;Atrial flutter;5370000;Atrial flutter (disorder);http://snomed.info/sct +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17086-2;5;AV block-1st degree;270492004;first degree atrioventricular block (disorder);http://snomed.info/sct +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17087-0;6;AV block-2nd degree-type 1;195042002;Second degree atrioventricular block (disorder);http://snomed.info/sct +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17088-8;7;AV block-2nd degree-type 2;195042002;Second degree atrioventricular block (disorder);http://snomed.info/sct +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17089-6;8;AV block-3rd degree;27885002;complete atrioventricular block (disorder);http://snomed.info/sct +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17090-4;9;Junctional;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17091-2;10;Left bundle branch block;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17718-0;11;Sinus rhythm;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17093-8;12;Paced rhythm;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17070-6;13;PEA;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17094-6;14;Premature atrial contractions;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17095-3;15;Premature ventricular contractions;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17096-1;16;Right bundle branch block;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17097-9;17;Sinus arrhythmia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17098-7;18;Sinus bradycardia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17099-5;19;Sinus tachycardia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17100-1;20;Supraventricular tachycardia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17101-9;21;Torsades de points;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17071-4;22;Unknown AED non-shockable rhythm;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17072-2;23;Unknown AED shockable rhythm;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17073-0;24;Ventricular fibrillation;71908006;ventricular fibrillation (disorder);http://snomed.info/sct +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17708-1;25;Ventricular tachycardia with pulse;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17074-8;26;Ventricular tachycardia-pulseless;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA12904-1;27;Artifact;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18206-5;28;Non-STEMI inferior ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18205-7;29;Non-STEMI anterior ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18207-3;30;Non-STEMI lateral ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18208-1;31;Non-STEMI posterior ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA32915-3;32;Non-STEMI septal ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17703-2;33;STEMI-anterior ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17704-0;34;STEMI-inferior ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17705-7;35;STEMI-lateral ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17706-5;36;STEMI-posterior ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA32916-1;37;STEMI septal ischemia;;; +67519-9;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17059-9;38;Other (not listed);;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17083-9;1;Agonal/idioventricular;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17068-0;2;Asystole;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17084-7;3;Atrial fibrillation;49436004;Atrial fibrillation (disorder);http://snomed.info/sct +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17085-4;4;Atrial flutter;5370000;Atrial flutter (disorder);http://snomed.info/sct +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17086-2;5;AV block-1st degree;270492004;first degree atrioventricular block (disorder);http://snomed.info/sct +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17087-0;6;AV block-2nd degree-type 1;195042002;Second degree atrioventricular block (disorder);http://snomed.info/sct +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17088-8;7;AV block-2nd degree-type 2;195042002;Second degree atrioventricular block (disorder);http://snomed.info/sct +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17089-6;8;AV block-3rd degree;27885002;complete atrioventricular block (disorder);http://snomed.info/sct +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17090-4;9;Junctional;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17091-2;10;Left bundle branch block;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17718-0;11;Sinus rhythm;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17093-8;12;Paced rhythm;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17070-6;13;PEA;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17094-6;14;Premature atrial contractions;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17095-3;15;Premature ventricular contractions;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17096-1;16;Right bundle branch block;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17097-9;17;Sinus arrhythmia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17098-7;18;Sinus bradycardia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17099-5;19;Sinus tachycardia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17100-1;20;Supraventricular tachycardia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17101-9;21;Torsades de points;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17071-4;22;Unknown AED non-shockable rhythm;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17072-2;23;Unknown AED shockable rhythm;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17073-0;24;Ventricular fibrillation;71908006;ventricular fibrillation (disorder);http://snomed.info/sct +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17708-1;25;Ventricular tachycardia with pulse;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17074-8;26;Ventricular tachycardia-pulseless;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA12904-1;27;Artifact;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18206-5;28;Non-STEMI inferior ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18205-7;29;Non-STEMI anterior ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18207-3;30;Non-STEMI lateral ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA18208-1;31;Non-STEMI posterior ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA32915-3;32;Non-STEMI septal ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17703-2;33;STEMI-anterior ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17704-0;34;STEMI-inferior ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17705-7;35;STEMI-lateral ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17706-5;36;STEMI-posterior ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA32916-1;37;STEMI septal ischemia;;; +76281-5;LL1795-5;NEMSIS_08_cardiac rhythm-dest;LA17059-9;38;Other (not listed);;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17306-4;1;Cultural, custom, religious;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17307-2;2;Developmentally impaired;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17308-0;3;Hearing impaired;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17309-8;4;Language;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17318-9;5;None noted;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA6301-1;6;Obesity;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17310-6;7;Physical barrier (unable to access patient);;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17311-4;8;Physically impaired;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17312-2;9;Physically restrained;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17313-0;10;Psychologically impaired;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17314-8;11;Sight impaired;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17315-5;12;Speech impaired;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17316-3;13;Unattended or unsupervised (including minors);;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17711-5;14;Unconscious;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA17317-1;15;Uncooperative;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA23824-8;16;State of Emotional Distress;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA32961-7;17;Alcohol use, suspected;;; +67515-7;LL1817-7;NEMSIS_30_barriers to care;LA32960-9;18;Drug use, suspected;;; +67516-5;LL1818-5;NEMSIS_31_adv directive;LA17319-7;1;State EMS DNR or medical order form;;; +67516-5;LL1818-5;NEMSIS_31_adv directive;LA17320-5;2;Other healthcare advanced directive form;;; +67516-5;LL1818-5;NEMSIS_31_adv directive;LA17321-3;3;Living will;;; +67516-5;LL1818-5;NEMSIS_31_adv directive;LA17322-1;4;Family/guardian request DNR (but no documentation);;; +67516-5;LL1818-5;NEMSIS_31_adv directive;LA17059-9;5;Other (not listed);;; +67516-5;LL1818-5;NEMSIS_31_adv directive;LA137-2;6;None;260413007;None (qualifier value);http://snomed.info/sct +67520-7;LL1846-6;NEMSIS_60_CVA scale interpretation;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +67520-7;LL1846-6;NEMSIS_60_CVA scale interpretation;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +67520-7;LL1846-6;NEMSIS_60_CVA scale interpretation;LA17109-2;3;Non-conclusive;;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA33037-5;1;Cincinnati prehospital stroke scale (CPSS);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA33002-9;2;Los Angeles prehospital stroke screen (LAPSS);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA3774-2;3;Massachusetts stroke scale (MSS);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA17112-6;4;Miami Emergency Neurologic Deficit Exam (MEND);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA17113-4;5;NIH stroke scale (NIHSS);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA18300-6;6;Other stoke scale type;;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA24430-3;7;FAST-ED;;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA32997-1;8;Boston stroke scale (BOSS);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA32998-9;9;Ontario prehospital stroke scale (OPSS);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA32999-7;10;Melbourne ambulance stroke screen (MASS);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA33000-3;11;Rapid arterial occlusion evaluation (RACE);;; +67521-5;LL1847-4;NEMSIS_61_Stroke scale type;LA33001-1;12;Los angeles motor score (LAMS);;; +67523-1;LL1848-2;NEMSIS_62_ contra for thrombolytic;LA17114-2;1;Definite contraindications to thrombolytic use;;; +67523-1;LL1848-2;NEMSIS_62_ contra for thrombolytic;LA17115-9;2;Possible contraindications to thrombolytic Use;;; +67523-1;LL1848-2;NEMSIS_62_ contra for thrombolytic;LA17116-7;3;No contraindications to thrombolytic Use;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17197-7;1;Clammy;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA15475-9;2;Cold;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17198-5;3;Cyanotic;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA18217-2;4;Diaphoretic;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17199-3;5;Dry;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17201-7;6;Flushed;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17202-5;7;Hot;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17203-3;8;Jaundiced;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17204-1;9;Lividity;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17205-8;10;Mottled;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA6626-1;11;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17206-6;13;Pale;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA18218-0;14;Poor turgor;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17200-9;15;Red (erythematous);;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA18219-8;16;Tenting;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA17207-4;17;Warm;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA23806-5;18;Capillary Nail Bed Refill less than 2 seconds;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA23807-3;19;Capillary Nail Bed Refill 2-4 seconds;;; +67524-9;LL1804-5;NEMSIS_17_skin assessment;LA23808-1;20;Capillary Nail Bed Refill more than 4 seconds;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA7410-9;1;Abrasion;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA18220-6;2;Avulsion;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17208-2;3;Bleeding controlled;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17209-0;4;Bleeding uncontrolled;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA18221-4;5;Burn, blistering;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA18222-2;6;Burn, charring;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA18223-0;7;Burn, redness;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA18224-8;8;Burn, white/waxy;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17210-8;9;Decapitation;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA18225-5;10;Deformity;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17211-6;11;Drainage;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA18226-3;12;Foreign body;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA7452-1;13;Laceration;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17213-2;14;Mass/lesion;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA6626-1;15;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67525-6;LL1805-2;NEMSIS_18_head assessment;LA7460-4;17;Pain;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17214-0;18;Puncture/stab wound;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17212-4;19;Gunshot wound;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA7423-2;20;Contusion;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17229-8;21;Crush injury;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA22440-4;22;Swelling;;; +67525-6;LL1805-2;NEMSIS_18_head assessment;LA17709-9;23;Tenderness;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA7410-9;1;Abrasion;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17216-5;2;Asymmetric smile or droop;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA18220-6;3;Avulsion;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17208-2;5;Bleeding controlled;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17209-0;6;Bleeding uncontrolled;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA18221-4;7;Burn, blistering;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA18222-2;8;Burn, charring;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA18223-0;9;Burn, redness;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA18224-8;10;Burn, white/waxy;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA18225-5;11;Deformity;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17211-6;12;Drainage;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA18226-3;13;Foreign body;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA7452-1;14;Laceration;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17213-2;15;Mass/lesion;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA6626-1;16;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67526-4;LL1806-0;NEMSIS_19_face assessment;LA7460-4;18;Pain;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17214-0;19;Puncture/stab wound;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17212-4;22;Gunshot wound;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA7423-2;23;Contusion;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17229-8;24;Crush injury;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA22440-4;25;Swelling;;; +67526-4;LL1806-0;NEMSIS_19_face assessment;LA17709-9;26;Tenderness;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA7410-9;1;Abrasion;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18220-6;2;Avulsion;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17208-2;3;Bleeding controlled;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17209-0;4;Bleeding uncontrolled;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18221-4;5;Burn, blistering;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18222-2;6;Burn, charring;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18223-0;7;Burn, redness;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18224-8;8;Burn, white/waxy;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17210-8;9;Decapitation;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18226-3;10;Foreign body;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17217-3;11;Jugular vein distention - JVD;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA7452-1;12;Laceration;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA6626-1;13;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA7460-4;15;Pain;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17214-0;16;Puncture/stab wound;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17612-5;17;Stridor;70407001;stridor (finding);http://snomed.info/sct +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17219-9;18;Subcutaneous air;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18228-9;19;Tracheal deviation-left;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18227-1;20;Tracheal deviation-right;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17212-4;21;Gunshot wound;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17229-8;22;Crush injury;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA22440-4;23;Swelling;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA7423-2;24;Contusion;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA18225-5;25;Deformity;;; +67527-2;LL1807-8;NEMSIS_20_neck assessment;LA17709-9;26;Tenderness;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA7410-9;1;Abrasion;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18220-6;2;Avulsion;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17222-3;3;Accessory muscles used with breathing;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17208-2;4;Bleeding controlled;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17209-0;5;Bleeding uncontrolled;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17223-1;6;Breath sounds-absent-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17224-9;7;Breath sounds-absent-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17225-6;8;Breath sounds-decreased-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17226-4;9;Breath sounds-decreased-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18402-0;10;Breath sounds-equal;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17227-2;11;Breath sounds-normal-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17228-0;12;Breath sounds-normal-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18221-4;13;Burn, blistering;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18222-2;14;Burn, charring;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18223-0;15;Burn, redness;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18224-8;16;Burn, white/waxy;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17229-8;17;Crush injury;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18225-5;18;Deformity;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17230-6;19;Flail segment-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17231-4;20;Flail segment-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18226-3;21;Foreign body;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17232-2;22;Increased respiratory effort;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18236-2;23;Implanted device;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA7452-1;24;Laceration;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA6626-1;25;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA6630-3;26;Not done;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA7460-4;27;Pain;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17233-0;28;Pain with inspiration/expiration-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17234-8;29;Pain with inspiration/expiration-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17214-0;30;Puncture/stab wound;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18229-7;31;Rales-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18230-5;32;Rales-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18231-3;33;Retraction;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18232-1;34;Rhonchi-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18233-9;35;Rhonchi-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17236-3;36;Rhonchi/wheezing;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18234-7;37;Stridor-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18235-4;38;Stridor-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17237-1;39;Tenderness-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17238-9;40;Tenderness-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18238-8;41;Wheezing-expiratory-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18237-0;42;Wheezing-expiratory-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18239-6;43;Wheezing-inspiratory-left;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA18240-4;44;Wheezing-inspiratory-right;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA17212-4;45;Gunshot wound;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA22440-4;46;Swelling;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA7423-2;47;Contusion;;; +67528-0;LL1808-6;NEMSIS_21_chest/lung assessment;LA23810-7;48;Tenderness-General;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA17239-7;2;Heart sounds decreased;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA17240-5;3;Murmur-diastolic;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA17241-3;4;Murmur-systolic;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA18241-2;6;Clicks;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA18246-1;7;Rubs;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA18242-0;8;S1;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA18243-8;9;S2;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA18244-6;10;S3;;; +67529-8;LL1809-4;NEMSIS_22_heart assessment;LA18245-3;11;S4;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA7410-9;1;Abrasion;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18220-6;2;Avulsion;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17208-2;3;Bleeding controlled;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17209-0;4;Bleeding uncontrolled;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18247-9;5;Bowel sounds-absent;16268000;Bowel sounds absent (finding);http://snomed.info/sct +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18248-7;6;Bowel sounds-present;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18221-4;7;Burn, blistering;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18222-2;8;Burn, charring;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18223-0;9;Burn, redness;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18224-8;10;Burn, white/waxy;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17242-1;11;Distention;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18226-3;12;Foreign body;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17243-9;13;Guarding;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA7452-1;14;Laceration;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17213-2;15;Mass/lesion;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17246-2;16;Mass-pulsating;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA6626-1;17;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA7460-4;19;Pain;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17247-0;20;Pregnant-palpable uterus;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17214-0;21;Puncture/stab wound;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17709-9;22;Tenderness;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17212-4;23;Gunshot wound;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA17229-8;24;Crush injury;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA22440-4;25;Swelling;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA7423-2;26;Contusion;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA18225-5;27;Deformity;;; +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA23814-9;28;Rebound Tenderness;35611005;Rebound tenderness (finding);http://snomed.info/sct +67530-6;LL1810-2;NEMSIS_23_abd assessment;LA23815-6;29;Rigidity;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA7410-9;1;Abrasion;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA18220-6;2;Avulsion;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17208-2;3;Bleeding controlled;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17209-0;4;Bleeding uncontrolled;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17248-8;5;Bleeding-rectal;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17249-6;6;Bleeding-urethral;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17250-4;7;Bleeding-vaginal;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA18221-4;8;Burn, blistering;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA18222-2;9;Burn, charring;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA18223-0;10;Burn, redness;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA18224-8;11;Burn, white/waxy;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA18225-5;12;Deformity;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA18226-3;13;Foreign body;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17251-2;14;Genital injury;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA7452-1;15;Laceration;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17213-2;16;Mass/lesion;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA6626-1;17;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA7460-4;19;Pain;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17252-0;20;Pelvic fracture;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17253-8;21;Pelvic instability;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17254-6;22;Penile priapism/erection;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17255-3;23;Pregnant-crowning;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17214-0;24;Puncture/stab wound;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17709-9;25;Tenderness;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17212-4;26;Gunshot wound;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA17229-8;27;Crush injury;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA22440-4;28;Swelling;;; +67531-4;LL1811-0;NEMSIS_24_pelvic/GU assessment;LA7423-2;29;Contusion;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA7410-9;1;Abrasion;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA18220-6;2;Avulsion;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17208-2;3;Bleeding controlled;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17209-0;4;Bleeding uncontrolled;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA18221-4;5;Burn, blistering;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA18222-2;6;Burn, charring;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA18223-0;7;Burn, redness;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA18224-8;8;Burn, white/waxy;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA18225-5;9;Deformity;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA18226-3;10;Foreign body;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA7452-1;11;Laceration;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA6626-1;12;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA6630-3;13;Not done;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA7460-4;14;Pain;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17256-1;15;Pain with range of motion;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17214-0;16;Puncture/stab wound;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17257-9;17;Tenderness costovertebral angle (CVA);;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17258-7;18;Tenderness midline spinous process;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17259-5;19;Tenderness paraspinous;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17212-4;20;Gunshot wound;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17229-8;21;Crush injury;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA22440-4;22;Swelling;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA7423-2;23;Contusion;;; +67532-2;LL1812-8;NEMSIS_25_back/spine assessment;LA17709-9;24;Tenderness;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18221-4;0;Burn, blistering;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA7410-9;1;Abrasion;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17260-3;2;Amputation-acute;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17261-1;3;Amputation-previous;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18220-6;4;Avulsion;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17208-2;5;Bleeding controlled;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17209-0;6;Bleeding uncontrolled;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18222-2;7;Burn, charring;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18223-0;8;Burn, redness;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18224-8;9;Burn, white/waxy;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18249-5;10;Clubbing (of fingers);;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17229-8;11;Crush injury;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18225-5;12;Deformity;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17262-9;13;Dislocation;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17263-7;14;Edema;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA18226-3;15;Foreign body;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17264-5;16;Fracture-closed;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17265-2;17;Fracture-open;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA7452-1;18;Laceration;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17266-0;19;Motor function-abnormal/weakness;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17267-8;20;Motor function-absent;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17268-6;21;Motor function-normal;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA6626-1;22;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA7460-4;24;Pain;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17344-5;25;Paralysis;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17269-4;26;Pulse-abnormal;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17270-2;27;Pulse-absent;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17271-0;28;Pulse-normal;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17214-0;29;Puncture/stab wound;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17272-8;30;Sensation-abnormal;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17273-6;31;Sensation-absent;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17274-4;32;Sensation-normal;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17709-9;33;Tenderness;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA17212-4;34;Gunshot wound;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA22440-4;35;Swelling;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA7423-2;36;Contusion;;; +67533-0;LL1813-6;NEMSIS_26_extremity assessment;LA23816-4;37;Arm Drift;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17275-1;1;1 mm;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17276-9;2;2 mm;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17277-7;3;3 mm;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17278-5;4;4 mm;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17279-3;5;5 mm;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17280-1;6;6 mm;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17281-9;7;7 mm;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18258-6;8;8 mm or >;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17710-7;9;Blind;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18250-3;10;Cataract present;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17282-7;11;Clouded;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18225-5;12;Deformity;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18251-1;13;Dysconjugate gaze;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18226-3;14;Foreign body;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18252-9;15;Glaucoma present;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17283-5;16;Hyphema;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18253-7;17;Jaundiced sclera;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA14698-7;18;Missing;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA15256-3;19;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18254-5;21;Nonreactive prosthetic;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18255-2;22;Nystagmus noted;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17284-3;23;Open globe;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18256-0;24;PERRL;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17285-0;25;Pupil-irregular/teardrop;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA15255-5;26;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA18257-8;27;Sluggish;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA22440-4;28;Swelling;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA7423-2;29;Contusion;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA17214-0;30;Puncture/stab wound;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA32946-8;31;Pin Point;;; +67534-8;LL1814-4;NEMSIS_27_eye assessment;LA19576-0;32;Dilated;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17287-6;1;Combative;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA6560-2;2;Confused;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA7438-0;3;Hallucinations;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17286-8;4;Normal baseline for patient;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17288-4;6;Oriented-person;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17289-2;7;Oriented-place;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA18259-4;8;Oriented-event;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17290-0;9;Oriented-time;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA9343-0;10;Unresponsive;422768004;unresponsive (finding);http://snomed.info/sct +67535-5;LL1815-1;NEMSIS_28_mental status;LA6150-2;11;Agitation;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA23818-0;12;Somnolent;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17666-1;13;Stupor;89458003;stupor (finding);http://snomed.info/sct +67535-5;LL1815-1;NEMSIS_28_mental status;LA32951-8;14;Altered mental status, unspecified;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17307-2;15;Developmentally impaired;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17668-7;16;Disorientation, unspecified;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA32953-4;17;Pharmacologically paralyzed;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA32948-4;18;Pharmacologically sedated;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17313-0;19;Psychologically impaired;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA32950-0;20;Slowness and poor responsiveness;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17678-6;21;State of emotional shock and stress, unspecified;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA32956-7;22;Strange and inexplicable behavior;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA17317-1;23;Uncooperative;;; +67535-5;LL1815-1;NEMSIS_28_mental status;LA32955-9;24;Unspecified coma;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA18261-0;1;Aphagia;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA18262-8;2;Aphasia;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17291-8;3;Cerebellar function-abnormal;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17292-6;4;Cerebellar function-normal;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA18263-6;5;Decerebrate posturing;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA18264-4;6;Decorticate posturing;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17293-4;7;Gait-abnormal;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17294-2;8;Gait-normal;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17295-9;9;Hemiplegia-left;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17296-7;10;Hemiplegia-right;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17286-8;11;Normal baseline for patient;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA32958-3;13;Status seizure;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17297-5;14;Speech-normal;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17298-3;15;Speech-slurring;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA18265-1;16;Strength-asymmetric;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17299-1;17;Strength-normal;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17300-7;18;Strength-symmetric;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17301-5;19;Tremors;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17302-3;20;Weakness-facial droop-left;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17303-1;21;Weakness-facial droop-right;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17304-9;22;Weakness-left sided;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA17305-6;23;Weakness-right sided;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA23822-2;24;Arm Drift-Left;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA23823-0;25;Arm Drift-Right;;; +67536-3;LL1816-9;NEMSIS_29_neuro assessment;LA32959-1;26;Other seizures;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17398-1;1;Airway;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17491-4;2;Airway-failed;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17492-2;3;Airway-obstruction/foreign body;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17494-8;4;Airway-Rapid Sequence Induction (RSI-Paralytic);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17495-5;5;Airway-sedation assisted (nonparalytic);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17496-3;6;Cardiac arrest- asystole;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17499-7;7;Cardiac arrest-hypothermia-therapeutic;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17497-1;8;Cardiac arrest- pulseless electrical activity;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17498-9;9;Cardiac arrest- ventricular fibrillation/pulseless ventricular tachycardia;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17500-2;10;Cardiac arrest-post resuscitation care;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17501-0;11;Environmental-altitude sickness;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17502-8;12;Environmental-cold exposure;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17503-6;13;Environmental-frostbite/cold Injury;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17504-4;14;Environmental-heat exposure/exhaustion;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17505-1;15;Environmental-heat stroke/hyperthermia;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17506-9;16;Environmental-hypothermia;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17507-7;17;Exposure-airway/inhalation irritants;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17508-5;18;Exposure-biological/infectious;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17509-3;19;Exposure-blistering agents;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17511-9;20;Exposure-chemicals to eye;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17512-7;21;Exposure-cyanide;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17513-5;22;Exposure-explosive/blast injury;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17514-3;23;Exposure-nerve agents;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17515-0;24;Exposure-radiologic agents;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17516-8;25;General-back pain;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17517-6;26;General-behavioral/patient restraint;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA18269-3;27;General-cardiac arrest;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17518-4;28;General-dental problems;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17519-2;29;General-epistaxis;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17520-0;30;General-fever;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17521-8;31;General-individualized patient protocol;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17522-6;32;General-indwelling medical devices/equipment;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17523-4;33;General-IV access;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17524-2;34;General-medical device malfunction;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17525-9;35;General-pain control;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17526-7;36;General-spinal immobilization/clearance;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17527-5;37;General-universal patient care/initial patient contact;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17528-3;38;Injury-amputation;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17529-1;39;Injury-bites and envenomations-land;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17530-9;40;Injury-bites and envenomations-marine;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17531-7;41;Injury-bleeding/hemorrhage control;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17532-5;42;Injury-burns-thermal;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17537-4;43;Injury-electrical injuries;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17538-2;44;Injury-extremity;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17539-0;45;Injury-eye;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17540-8;46;Injury-head;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17541-6;47;Injury-impaled object;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17542-4;48;Injury-multisystem;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17543-2;49;Injury-spinal cord;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17544-0;50;Medical-abdominal pain;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17545-7;51;Medical-allergic reaction/anaphylaxis;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17546-5;52;Medical-altered mental status;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17547-3;53;Medical-bradycardia;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17548-1;54;Medical-cardiac chest pain;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17549-9;55;Medical-diarrhea;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17550-7;56;Medical-hyperglycemia;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17551-5;57;Medical-hypertension;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17552-3;58;Medical-hypoglycemia/diabetic emergency;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17553-1;59;Medical-hypotension/shock (non-trauma);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17554-9;60;Medical-influenza-like Illness/ upper respiratory infection;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17555-6;61;Medical-nausea/vomiting;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17556-4;62;Medical-newborn/ neonatal resuscitation;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23845-3;63;General-Overdose/Poisoning/Toxic Ingestion;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17558-0;64;Medical-pulmonary edema/CHF;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17559-8;65;Medical-respiratory distress/asthma/COPD/reactive airway disease;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17560-6;66;Medical-seizure;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17561-4;67;Medical-ST-elevation myocardial infarction (STEMI);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17562-2;68;Medical-stroke/TIA;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17563-0;69;Medical-supraventricular tachycardia (including atrial fibrillation);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17564-8;70;Medical-syncope;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17565-5;71;Medical-ventricular tachycardia (with pulse);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17566-3;73;OB/GYN-childbirth/labor/delivery;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17567-1;74;OB/GYN-eclampsia;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17568-9;75;OB/GYN-gynecologic emergencies;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17569-7;76;OB/GYN-pregnancy related emergencies;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17570-5;77;OB/GYN-post-partum hemorrhage;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA46-8;78;Other;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24135-8;79;Exposure-Carbon Monoxide;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24136-6;80;Cardiac Arrest-Do Not Resuscitate;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24137-4;81;Cardiac Arrest-Special Resuscitation Orders;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24138-2;82;Exposure-Smoke Inhalation;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24139-0;83;General-Community Paramedicine / Mobile Integrated Healthcare;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24140-8;84;General-Exception Protocol;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24141-6;85;General-Extended Care Guidelines;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24142-4;86;General-Interfacility Transfers;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24143-2;87;General-Law Enforcement - Blood for Legal Purposes;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24144-0;88;General-Law Enforcement - Assist with Law Enforcement Activity;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24145-7;89;General-Neglect or Abuse Suspected;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24146-5;90;General-Refusal of Care;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24147-3;91;Injury-Mass/Multiple Casualties;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24148-1;92;Injury-Thoracic;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24149-9;93;Medical-Adrenal Insufficiency;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24150-7;94;Medical-Apparent Life Threatening Event (ALTE);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA24151-5;95;Medical-Tachycardia;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23827-1;96;Cardiac Arrest-Determination of Death / Withholding Resuscitative Efforts;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23828-9;97;Injury-Conducted Electrical Weapon (e.g., Taser);;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23829-7;98;Injury-Facial Trauma;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23830-5;99;Injury-General Trauma Management;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23831-3;100;Injury-Lightning/Lightning Strike;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23832-1;101;Injury-SCUBA Injury/Accidents;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23833-9;102;Injury-Topical Chemical Burn;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23834-7;103;Medical-Beta Blocker Poisoning/Overdose;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23837-0;104;Medical-Respiratory Distress-Bronchiolitis;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23838-8;105;Medical-Respiratory Distress-Croup;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23839-6;106;Medical-Stimulant Poisoning/Overdose;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23835-4;107;Medical-Calcium Channel Blocker Poisoning/Overdose;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA23836-2;108;Medical-Opioid Poisoning/Overdose;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17533-3;109;Injury-cardiac arrest;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17534-1;110;Injury-crush syndrome;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17535-8;111;Injury-diving emergencies;;; +67537-1;LL1832-6;NEMSIS_45_protocol used;LA17536-6;112;Injury-drowning/near drowning;;; +67538-9;LL1833-4;NEMSIS_46_age category;LA17571-3;1;General;;; +67538-9;LL1833-4;NEMSIS_46_age category;LA17572-1;2;Adult only;;; +67538-9;LL1833-4;NEMSIS_46_age category;LA17573-9;3;Pediatric only;;; +67540-5;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA65-8;1;Improved;;; +67540-5;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA17181-1;2;Unchanged;;; +67540-5;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA11011-6;3;Worse;;; +67546-2;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA65-8;1;Improved;;; +67546-2;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA17181-1;2;Unchanged;;; +67546-2;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA11011-6;3;Worse;;; +67551-2;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA65-8;1;Improved;;; +67551-2;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA17181-1;2;Unchanged;;; +67551-2;LL1826-8;NEMSIS_39_response to meds/cond at destination;LA11011-6;3;Worse;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA17392-4;1;Altered mental status;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA17393-2;2;Apnea;1023001;Apnea (finding);http://snomed.info/sct +67541-3;LL1827-6;NEMSIS_40_med complication;LA7418-2;3;Bleeding;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA17394-0;4;Bradycardia;48867003;Bradycardia (finding);http://snomed.info/sct +67541-3;LL1827-6;NEMSIS_40_med complication;LA18266-9;5;Bradypnea;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA15424-7;6;Diarrhea;62315008;Diarrhea (finding);http://snomed.info/sct +67541-3;LL1827-6;NEMSIS_40_med complication;LA7434-9;7;Extravasation;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA7444-8;8;Hypertension;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA9540-1;9;Hyperthermia;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA7443-0;10;Hypotension;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA9541-9;11;Hypothermia;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA17396-5;12;Hypoxia;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA17713-1;13;Injury;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA20641-9;14;Itching;418290006;Itching (finding);http://snomed.info/sct +67541-3;LL1827-6;NEMSIS_40_med complication;LA15098-9;15;Nausea;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA137-2;16;None;260413007;None (qualifier value);http://snomed.info/sct +67541-3;LL1827-6;NEMSIS_40_med complication;LA17059-9;17;Other (not listed);;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA9548-4;18;Respiratory distress;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA17714-9;19;Tachycardia;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA18267-7;20;Tachypnea;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA20642-7;21;Urticaria;;; +67541-3;LL1827-6;NEMSIS_40_med complication;LA15099-7;22;Vomiting;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17392-4;1;Altered mental status;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17393-2;2;Apnea;1023001;Apnea (finding);http://snomed.info/sct +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA7418-2;3;Bleeding;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA18266-9;4;Bradypnea;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA15424-7;5;Diarrhea;62315008;Diarrhea (finding);http://snomed.info/sct +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17489-8;6;Esophageal intubation-immediately;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17490-6;7;Esophageal intubation-other;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA7434-9;8;Extravasation;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA7444-8;9;Hypertension;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA9540-1;10;Hyperthermia;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA7443-0;11;Hypotension;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA9541-9;12;Hypothermia;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17396-5;13;Hypoxia;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17713-1;14;Injury;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA15098-9;15;Nausea;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA137-2;16;None;260413007;None (qualifier value);http://snomed.info/sct +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17059-9;17;Other (not listed);;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA9548-4;19;Respiratory distress;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17714-9;20;Tachycardia;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA18267-7;21;Tachypnea;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA15099-7;22;Vomiting;;; +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA17394-0;23;Bradycardia;48867003;Bradycardia (finding);http://snomed.info/sct +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA20641-9;24;Itching;418290006;Itching (finding);http://snomed.info/sct +67545-4;LL1831-8;NEMSIS_44_procedure complication;LA20642-7;25;Urticaria;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA18212-3;1;Assist, agency;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA18213-1;2;Assist, public;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA18214-9;3;Assist, unit;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17155-5;4;Canceled (prior to arrival at scene);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA18215-6;5;Canceled on scene (no patient contact);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17156-3;6;Canceled on scene (no patient found);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA24388-3;7;Patient Dead at Scene-No Resuscitation Attempted (With Transport);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA24389-1;8;Patient Dead at Scene-No Resuscitation Attempted (Without Transport);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA24390-9;9;Patient Dead at Scene-Resuscitation Attempted (With Transport);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA24391-7;10;Patient Dead at Scene-Resuscitation Attempted (Without Transport);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17159-7;11;Patient evaluated, no treatment/transport required;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17160-5;12;Patient refused evaluation/care (with transport);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA18216-4;13;Patient refused evaluation/care (without transport);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17161-3;14;Patient treated, released (AMA);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA18080-4;15;Patient treated, released (per protocol);;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17162-1;16;Patient treated, transferred care to another EMS professional;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17154-8;17;Patient treated, transported by EMS;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17163-9;18;Patient treated, transported by law enforcement;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17164-7;19;Patient treated, transported by private vehicle;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17165-4;20;Standby-no services or support provided;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17166-2;21;Standby-public safety, fire, or EMS operational support provided;;; +67548-8;LL1798-9;NEMSIS_11_pt disposition;LA17167-0;22;Transport Non-Patient, Organs, etc.;;; +67548-8;LL5055-0;Patient dispositions at scene;LA18212-3;1;Assist, agency;;; +67548-8;LL5055-0;Patient dispositions at scene;LA18213-1;2;Assist, public;;; +67548-8;LL5055-0;Patient dispositions at scene;LA18214-9;3;Assist, unit;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17155-5;4;Canceled (prior to arrival at scene);;; +67548-8;LL5055-0;Patient dispositions at scene;LA18215-6;5;Canceled on scene (no patient contact);;; +67548-8;LL5055-0;Patient dispositions at scene;LA17156-3;6;Canceled on scene (no patient found);;; +67548-8;LL5055-0;Patient dispositions at scene;LA24388-3;7;Patient Dead at Scene-No Resuscitation Attempted (With Transport);;; +67548-8;LL5055-0;Patient dispositions at scene;LA24389-1;8;Patient Dead at Scene-No Resuscitation Attempted (Without Transport);;; +67548-8;LL5055-0;Patient dispositions at scene;LA24390-9;9;Patient Dead at Scene-Resuscitation Attempted (With Transport);;; +67548-8;LL5055-0;Patient dispositions at scene;LA24391-7;10;Patient Dead at Scene-Resuscitation Attempted (Without Transport);;; +67548-8;LL5055-0;Patient dispositions at scene;LA17159-7;11;Patient evaluated, no treatment/transport required;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17160-5;12;Patient refused evaluation/care (with transport);;; +67548-8;LL5055-0;Patient dispositions at scene;LA18216-4;13;Patient refused evaluation/care (without transport);;; +67548-8;LL5055-0;Patient dispositions at scene;LA29248-4;14;Patient refused transport;;; +67548-8;LL5055-0;Patient dispositions at scene;LA29249-2;15;Transport of patient not possible;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17161-3;16;Patient treated, released (AMA);;; +67548-8;LL5055-0;Patient dispositions at scene;LA18080-4;17;Patient treated, released (per protocol);;; +67548-8;LL5055-0;Patient dispositions at scene;LA17162-1;18;Patient treated, transferred care to another EMS professional;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17154-8;19;Patient treated, transported by EMS;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17163-9;20;Patient treated, transported by law enforcement;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17164-7;21;Patient treated, transported by private vehicle;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17165-4;22;Standby-no services or support provided;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17166-2;23;Standby-public safety, fire, or EMS operational support provided;;; +67548-8;LL5055-0;Patient dispositions at scene;LA17167-0;24;Transport Non-Patient, Organs, etc.;;; +67548-8;LL5055-0;Patient dispositions at scene;LA29250-0;25;Deliberate restrictive therapy;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17168-8;1;Ground-ambulance;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17169-6;2;Air medical-fixed wing;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17170-4;3;Air medical-rotor craft;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17171-2;4;Ground-ATV or rescue vehicle;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17172-0;5;Ground-bariatric;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17173-8;6;Ground-mass casualty bus/vehicle;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17175-3;7;Ground-other not listed;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17176-1;8;Water-boat;;; +67549-6;LL1799-7;NEMSIS_12_transport method;LA17174-6;9;Ground-wheelchair van;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17182-9;1;Closest facility;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA18301-4;2;Diversion;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17184-5;3;Family choice;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17185-2;4;Insurance status/requirement;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17186-0;5;Law enforcement choice;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17187-8;6;On-line medical direction;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17188-6;7;Patient's choice;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17189-4;8;Patient's physician's choice;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17190-2;9;Protocol;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17191-0;10;Regional specialty center;;; +67552-0;LL1802-9;NEMSIS_15_destination reason;LA17059-9;11;Other (not listed);;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17398-1;1;Airway;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA7318-4;2;Burn;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA16967-4;3;Cardiac/MI;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17057-3;4;Drowning;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17399-9;5;Spinal cord injury;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17400-5;6;STEMI/acute cardiac;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA9553-4;7;Stroke/CVA;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17058-1;8;Trauma;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17401-3;9;Traumatic brain injury;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17059-9;10;Other (not listed);;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17398-1;1;Airway;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA7318-4;2;Burn;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA16967-4;3;Cardiac/MI;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17057-3;4;Drowning;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17399-9;5;Spinal cord injury;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17400-5;6;STEMI/acute cardiac;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA9553-4;7;Stroke/CVA;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17058-1;8;Trauma;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17401-3;9;Traumatic brain injury;;; +67553-8;LL1828-4;NEMSIS_41_ill/inj registry;LA17059-9;10;Other (not listed);;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17402-1;2;Death-cardiac arrest;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17403-9;3;Death-injury related;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17404-7;4;Death-other (not listed);;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17405-4;5;Exposure-airborne respiratory/biological/aerosolized secretions;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17406-2;6;Exposure-body fluid contact to broken skin;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17407-0;7;Exposure-body fluid contact with eye;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17408-8;8;Exposure-body fluid contact with intact skin;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17409-6;9;Exposure-body fluid contact with mucosal surface;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17410-4;10;Exposure-needle stick with body fluid injection;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17411-2;11;Exposure-needle stick without body fluid injection;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17412-0;12;Exposure-toxin/chemical/hazmat;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17413-8;13;Injury-lifting/back/musculoskeletal;;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17414-6;14;Injury-other (not listed);;; +67555-3;LL1829-2;NEMSIS_42_blood/fluid exposure;LA17059-9;15;Other (not listed);;; +67556-1;LL1922-5;NEMSIS_75_EMS condition codes;;0;;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17585-3;1;Crowd;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17586-1;2;Directions/unable to locate;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17587-9;3;Distance;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA18301-4;4;Diversion;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17588-7;5;HazMat;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA18081-2;6;None/no delay;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17059-9;7;Other (not listed);;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA18270-1;8;Rendezvous transport unavailable;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA18271-9;9;Route obstruction (e.g., train);;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17583-8;10;Scene safety (not secure for EMS);;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17590-3;11;Staff delay;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17591-1;12;Traffic;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17592-9;13;Vehicle crash involving this unit;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17593-7;14;Vehicle failure of this unit;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA17594-5;15;Weather (other);;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA24421-2;16;Mechanical Issue-Unit, Equipment, etc.;;; +67557-9;LL1836-7;NEMSIS_49_response delay;LA24422-0;17;Flight Planning;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA18272-7;1;Awaiting air unit;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA18273-5;2;Awaiting ground unit;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17585-3;3;Crowd;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17586-1;4;Directions/unable to locate;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17587-9;5;Distance;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17595-2;6;Extrication;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17588-7;7;HazMat;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA7540-3;8;Language barrier;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA18081-2;9;None/no delay;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17059-9;10;Other (not listed);;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA18275-0;11;Patient access;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17596-0;12;Safety-crew/staging;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17597-8;13;Safety-patient;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17590-3;14;Staff delay;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17591-1;15;Traffic;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA18276-8;16;Triage/multiple patients;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17592-9;17;Vehicle crash involving this unit;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17593-7;18;Vehicle failure of this unit;;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA17594-5;19;Weather (other);;; +67558-7;LL1837-5;NEMSIS_50_scene delay;LA24421-2;20;Mechanical Issue-Unit, Equipment, etc.;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17585-3;1;Crowd;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17586-1;2;Directions/unable to locate;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17587-9;3;Distance;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA18301-4;4;Diversion;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17588-7;5;HazMat;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA18081-2;6;None/no delay;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17059-9;7;Other (not listed);;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA18270-1;8;Rendezvous transport unavailable;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA18271-9;9;Route obstruction (e.g., train);;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17589-5;10;Safety;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17590-3;11;Staff delay;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17591-1;12;Traffic;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17592-9;13;Vehicle crash involving this unit;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17593-7;14;Vehicle failure of this unit;;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA17594-5;15;Weather (other);;; +67559-5;LL1838-3;NEMSIS_51_transport delay;LA24424-6;16;Patient Condition Change (e.g., Unit Stopped);;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17598-6;1;Clean-up;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17599-4;2;Decontamination;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17587-9;3;Distance;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17600-0;4;Documentation;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17601-8;5;ED overcrowding/transfer of care;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA7497-6;6;Equipment failure;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17602-6;7;Equipment/supply replenishment;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA18081-2;8;None/no delay;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17059-9;9;Other (not listed);;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA18270-1;10;Rendezvous transport unavailable;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA18271-9;11;Route obstruction (e.g., train);;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17590-3;12;Staff delay;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17591-1;13;Traffic;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17592-9;14;Vehicle crash involving this unit;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17593-7;15;Vehicle failure of this unit;;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA17594-5;16;Weather (other);;; +67560-3;LL1839-1;NEMSIS_52_turnaround delay;LA24425-3;17;EMS Crew Accompanies Patient for Facility Procedure;;; +67569-4;LL1734-4;emm type;LA14558-3;1;12;;; +67569-4;LL1734-4;emm type;LA14560-9;2;14;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA23843-8;1;Abdominal Pain/Problems;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17117-5;2;Allergic reaction/stings;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17118-3;3;Animal bite;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17119-1;4;Assault;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17120-9;5;Automated crash notification;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17121-7;6;Back pain (non-traumatic);;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17122-5;7;Breathing problems;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17123-3;8;Burns/explosion;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17124-1;9;Carbon monoxide poisoning/hazmat/inhalation/chemical/biological/radiological/nuclear;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17125-8;10;Cardiac arrest/death;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17126-6;11;Chest pain (non-traumatic);;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17127-4;12;Choking;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17128-2;13;Convulsions/seizure;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17129-0;14;Diabetic problem;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17131-6;15;Electrocution/lightning;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17132-4;16;Eye problem/injury;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17133-2;17;Falls;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA18093-7;18;Fire;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA15903-0;19;Headache;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17134-0;20;Healthcare professional/admission;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17135-7;21;Heart problems/AICD;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17136-5;22;Heat/cold exposure;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17137-3;23;Hemorrhage/lacerations;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17138-1;24;Industrial accident/inaccessible incident/other entrapments (non-vehicle);;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA18210-7;25;Medical alarm;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA18209-9;26;No other appropriate choice;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17140-7;27;Overdose/poisoning/ingestion;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17141-5;28;Pandemic/epidemic/outbreak;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17142-3;29;Pregnancy/childbirth/miscarriage;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17143-1;30;Psychiatric problem/abnormal behavior/suicide attempt;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17144-9;31;Sick person;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17145-6;32;Stab/gunshot wound/penetrating trauma;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17150-6;33;Standby;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA9553-4;34;Stroke/CVA;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17146-4;35;Traffic/transportation incident;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17147-2;36;Transfer/interfacility/palliative Care;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA9555-9;37;Traumatic injury;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA18211-5;38;Well person check;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17148-0;39;Unconscious/fainting/near-fainting;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17149-8;40;Unknown problem person down;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17130-8;41;Drowning/diving/SCUBA accident;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA23800-8;42;Air Medical Transport;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA17392-4;43;Altered mental status;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA18716-3;44;Emergency response (intercept);;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA15098-9;45;Nausea;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA15099-7;46;Vomiting;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA32920-3;47;Non-acute/routine;;; +67570-2;LL1796-3;NEMSIS_09_complaint per dispatch;LA32921-1;48;Dead with resuscitation efforts (black);;; +67574-4;LL1794-8;NEMSIS_07_CPR d/c;LA17078-9;1;DNR;;; +67574-4;LL1794-8;NEMSIS_07_CPR d/c;LA17079-7;2;Medical control order;;; +67574-4;LL1794-8;NEMSIS_07_CPR d/c;LA17080-5;3;Obvious signs of death;;; +67574-4;LL1794-8;NEMSIS_07_CPR d/c;LA17081-3;4;Protocol/policy requirements completed;;; +67574-4;LL1794-8;NEMSIS_07_CPR d/c;LA17082-1;5;Return of spontaneous circulation (pulse or BP noted);;; +67574-4;LL1794-8;NEMSIS_07_CPR d/c;LA18204-0;6;Physically unable to perform;;; +67574-4;LL5971-8;Reason CPR discontinued;LA17078-9;1;DNR;;; +67574-4;LL5971-8;Reason CPR discontinued;LA17079-7;2;Medical control order;;; +67574-4;LL5971-8;Reason CPR discontinued;LA17080-5;3;Obvious signs of death;;; +67574-4;LL5971-8;Reason CPR discontinued;LA17081-3;4;Protocol/policy requirements completed;;; +67574-4;LL5971-8;Reason CPR discontinued;LA17082-1;5;Return of spontaneous circulation (pulse or BP noted);;; +67574-4;LL5971-8;Reason CPR discontinued;LA18204-0;6;Physically unable to perform;;; +67574-4;LL5971-8;Reason CPR discontinued;LA32333-9;7;Terminal disease;;; +67574-4;LL5971-8;Reason CPR discontinued;LA46-8;8;Other;;; +67575-1;LL1747-6;PhenX20_38_sunburn susceptability;LA13914-9;1;Very much;;; +67575-1;LL1747-6;PhenX20_38_sunburn susceptability;LA15550-9;2;Much;;; +67575-1;LL1747-6;PhenX20_38_sunburn susceptability;LA15551-7;3;Not very much;;; +67575-1;LL1747-6;PhenX20_38_sunburn susceptability;LA6568-5;4;Not at all;;; +67576-9;LL1748-4;PhenX20_39_eye color;LA15552-5;1;Very light blue or very light grey;;; +67576-9;LL1748-4;PhenX20_39_eye color;LA15553-3;2;Blue;;; +67576-9;LL1748-4;PhenX20_39_eye color;LA15554-1;3;Grey;;; +67576-9;LL1748-4;PhenX20_39_eye color;LA15555-8;4;Green;;; +67576-9;LL1748-4;PhenX20_39_eye color;LA15556-6;5;Light brown;;; +67576-9;LL1748-4;PhenX20_39_eye color;LA15557-4;6;Dark brown;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15561-6;1;Eighth grade or less;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15562-4;2;More than eighth grade, but did not graduate from high school;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15563-2;3;Went to a business, trade, or vocational school instead of high school;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15564-0;4;High school graduate;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15565-7;5;Completed a GED;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15566-5;6;Went to a business, trade, or vocational school after high school;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15567-3;7;Went to college, but did not graduate;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15568-1;8;Graduated from a college or university;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15569-9;9;Professional training beyond a four-year college or university;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15570-7;10;He/she never went to school;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15571-5;11;He/she went to school, but R doesn't know what level;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA15572-3;12;R doesn't know if she went to school;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA4389-8;13;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67577-7;LL1751-8;PhenX21_01_parent education;LA15573-1;14;Legitimate skip;;; +67577-7;LL1751-8;PhenX21_01_parent education;LA12688-0;15;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67578-5;LL1751-8;PhenX21_01_parent education;LA15561-6;1;Eighth grade or less;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15562-4;2;More than eighth grade, but did not graduate from high school;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15563-2;3;Went to a business, trade, or vocational school instead of high school;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15564-0;4;High school graduate;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15565-7;5;Completed a GED;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15566-5;6;Went to a business, trade, or vocational school after high school;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15567-3;7;Went to college, but did not graduate;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15568-1;8;Graduated from a college or university;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15569-9;9;Professional training beyond a four-year college or university;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15570-7;10;He/she never went to school;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15571-5;11;He/she went to school, but R doesn't know what level;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA15572-3;12;R doesn't know if she went to school;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA4389-8;13;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +67578-5;LL1751-8;PhenX21_01_parent education;LA15573-1;14;Legitimate skip;;; +67578-5;LL1751-8;PhenX21_01_parent education;LA12688-0;15;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +87300-0;LL1751-8;PhenX21_01_parent education;LA15561-6;1;Eighth grade or less;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15562-4;2;More than eighth grade, but did not graduate from high school;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15563-2;3;Went to a business, trade, or vocational school instead of high school;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15564-0;4;High school graduate;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15565-7;5;Completed a GED;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15566-5;6;Went to a business, trade, or vocational school after high school;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15567-3;7;Went to college, but did not graduate;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15568-1;8;Graduated from a college or university;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15569-9;9;Professional training beyond a four-year college or university;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15570-7;10;He/she never went to school;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15571-5;11;He/she went to school, but R doesn't know what level;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA15572-3;12;R doesn't know if she went to school;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA4389-8;13;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +87300-0;LL1751-8;PhenX21_01_parent education;LA15573-1;14;Legitimate skip;;; +87300-0;LL1751-8;PhenX21_01_parent education;LA12688-0;15;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15574-9;1;Your ancestry or national origin;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15575-6;2;Your gender;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15576-4;3;Your race;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15577-2;4;Your age;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15578-0;5;Your religion;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15579-8;6;Your height or weight;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15580-6;7;Your shade of skin color;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15581-4;8;Your sexual orientation;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15582-2;9;Your education or income level;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA15583-0;10;A physical disability;;; +67580-1;LL1752-6;PhenX21_02_reason for experience;LA46-8;11;Other;;; +67586-8;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67586-8;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67586-8;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67586-8;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67587-6;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67587-6;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67587-6;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67587-6;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67588-4;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67588-4;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67588-4;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67588-4;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67589-2;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67589-2;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67589-2;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67589-2;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67590-0;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67590-0;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67590-0;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67590-0;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67591-8;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67591-8;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67591-8;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67591-8;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67592-6;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67592-6;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67592-6;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67592-6;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67593-4;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67593-4;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67593-4;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67593-4;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67594-2;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67594-2;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67594-2;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67594-2;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67595-9;LL1753-4;PhenX21_03_personal treament response;LA15584-8;1;Four or more times;;; +67595-9;LL1753-4;PhenX21_03_personal treament response;LA15585-5;2;Two or more times;;; +67595-9;LL1753-4;PhenX21_03_personal treament response;LA14312-5;3;Once;;; +67595-9;LL1753-4;PhenX21_03_personal treament response;LA6270-8;4;Never;;; +67596-7;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15237-3;1;Strongly agree;;; +67596-7;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15774-5;2;Agree;;; +67596-7;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15240-7;3;Neither agree nor disagree;;; +67596-7;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15773-7;4;Disagree;;; +67596-7;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15236-5;5;Strongly disagree;;; +67597-5;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15237-3;1;Strongly agree;;; +67597-5;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15774-5;2;Agree;;; +67597-5;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15240-7;3;Neither agree nor disagree;;; +67597-5;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15773-7;4;Disagree;;; +67597-5;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15236-5;5;Strongly disagree;;; +67598-3;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15237-3;1;Strongly agree;;; +67598-3;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15774-5;2;Agree;;; +67598-3;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15240-7;3;Neither agree nor disagree;;; +67598-3;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15773-7;4;Disagree;;; +67598-3;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15236-5;5;Strongly disagree;;; +67611-4;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15237-3;1;Strongly agree;;; +67611-4;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15774-5;2;Agree;;; +67611-4;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15240-7;3;Neither agree nor disagree;;; +67611-4;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15773-7;4;Disagree;;; +67611-4;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15236-5;5;Strongly disagree;;; +67612-2;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15237-3;1;Strongly agree;;; +67612-2;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15774-5;2;Agree;;; +67612-2;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15240-7;3;Neither agree nor disagree;;; +67612-2;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15773-7;4;Disagree;;; +67612-2;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15236-5;5;Strongly disagree;;; +67613-0;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15237-3;1;Strongly agree;;; +67613-0;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15774-5;2;Agree;;; +67613-0;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15240-7;3;Neither agree nor disagree;;; +67613-0;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15773-7;4;Disagree;;; +67613-0;LL1755-9;PhenX21_04_neighborhood attribute agreement;LA15236-5;5;Strongly disagree;;; +67606-4;LL1756-7;PhenX21_05_neighbor response;LA15586-3;1;Very likely;;; +67606-4;LL1756-7;PhenX21_05_neighbor response;LA15587-1;2;Likely;;; +67606-4;LL1756-7;PhenX21_05_neighbor response;LA15588-9;3;Unlikely;;; +67606-4;LL1756-7;PhenX21_05_neighbor response;LA15589-7;4;Very unlikely;;; +67607-2;LL1756-7;PhenX21_05_neighbor response;LA15586-3;1;Very likely;;; +67607-2;LL1756-7;PhenX21_05_neighbor response;LA15587-1;2;Likely;;; +67607-2;LL1756-7;PhenX21_05_neighbor response;LA15588-9;3;Unlikely;;; +67607-2;LL1756-7;PhenX21_05_neighbor response;LA15589-7;4;Very unlikely;;; +67608-0;LL1756-7;PhenX21_05_neighbor response;LA15586-3;1;Very likely;;; +67608-0;LL1756-7;PhenX21_05_neighbor response;LA15587-1;2;Likely;;; +67608-0;LL1756-7;PhenX21_05_neighbor response;LA15588-9;3;Unlikely;;; +67608-0;LL1756-7;PhenX21_05_neighbor response;LA15589-7;4;Very unlikely;;; +67609-8;LL1756-7;PhenX21_05_neighbor response;LA15586-3;1;Very likely;;; +67609-8;LL1756-7;PhenX21_05_neighbor response;LA15587-1;2;Likely;;; +67609-8;LL1756-7;PhenX21_05_neighbor response;LA15588-9;3;Unlikely;;; +67609-8;LL1756-7;PhenX21_05_neighbor response;LA15589-7;4;Very unlikely;;; +67610-6;LL1756-7;PhenX21_05_neighbor response;LA15586-3;1;Very likely;;; +67610-6;LL1756-7;PhenX21_05_neighbor response;LA15587-1;2;Likely;;; +67610-6;LL1756-7;PhenX21_05_neighbor response;LA15588-9;3;Unlikely;;; +67610-6;LL1756-7;PhenX21_05_neighbor response;LA15589-7;4;Very unlikely;;; +67653-6;LL1759-1;PhenX21_08_closeness;LA15595-4;1;Very close;;; +67653-6;LL1759-1;PhenX21_08_closeness;LA15596-2;2;Sort of close;;; +67653-6;LL1759-1;PhenX21_08_closeness;LA15597-0;3;Not very close;;; +67654-4;LL1760-9;PhenX21_09_contact frequency;LA10044-8;1;Often;;; +67654-4;LL1760-9;PhenX21_09_contact frequency;LA6483-7;2;Occasionally;;; +67654-4;LL1760-9;PhenX21_09_contact frequency;LA14751-4;3;Hardly ever;;; +67655-1;LL1761-7;PhenX2_10_trust doctors;LA14468-5;1;A lot;;; +67655-1;LL1761-7;PhenX2_10_trust doctors;LA14734-0;2;Most of the time;;; +67655-1;LL1761-7;PhenX2_10_trust doctors;LA15551-7;3;Not very much;;; +67655-1;LL1761-7;PhenX2_10_trust doctors;LA14619-3;4;Don't know/not sure;;; +67656-9;LL1762-5;PhenX21_11_person response;LA16961-7;1;Listen to you when you were feeling down or upset;;; +67656-9;LL1762-5;PhenX21_11_person response;LA16962-5;2;Tell you they care about what happens to you;;; +67656-9;LL1762-5;PhenX21_11_person response;LA16963-3;3;Give you suggestions when you have a problem;;; +67656-9;LL1762-5;PhenX21_11_person response;LA16964-1;4;Try to help you with daily chores;;; +67656-9;LL1762-5;PhenX21_11_person response;LA16965-8;5;Help out when you are short of money by giving or loaning you money;;; +67657-7;LL1763-3;PhenX21_12_person cause problems;LA32-8;0;No;373067005;No (qualifier value);http://snomed.info/sct +67657-7;LL1763-3;PhenX21_12_person cause problems;LA14468-5;1;A lot;;; +67657-7;LL1763-3;PhenX21_12_person cause problems;LA10082-8;2;Sometimes;;; +67657-7;LL1763-3;PhenX21_12_person cause problems;LA16966-6;3;No, not really;;; +67669-2;LL1819-3;NEMSIS_32_alc/drug use;LA11137-9;1;Unable to determine;;; +67669-2;LL1819-3;NEMSIS_32_alc/drug use;LA17323-9;2;Alcohol containers/paraphernalia at scene;;; +67669-2;LL1819-3;NEMSIS_32_alc/drug use;LA17324-7;3;Drug paraphernalia at scene;;; +67669-2;LL1819-3;NEMSIS_32_alc/drug use;LA17325-4;4;Patient admits to alcohol use;;; +67669-2;LL1819-3;NEMSIS_32_alc/drug use;LA17326-2;5;Patient admits to drug use;;; +67669-2;LL1819-3;NEMSIS_32_alc/drug use;LA17327-0;6;Positive level known from law enforcement or hospital record;;; +67669-2;LL1819-3;NEMSIS_32_alc/drug use;LA32962-5;7;Physical exam indicates suspected alcohol or drug use;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA15554-1;1;Grey;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA17192-8;2;Pink;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA17193-6;3;Red;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA17194-4;4;Purple;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA17195-1;5;Yellow;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA4457-3;6;White;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA15553-3;7;Blue;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA17196-9;8;Orange;;; +67670-0;LL1803-7;NEMSIS_16_peds resusc tape;LA15555-8;9;Green;;; +67675-9;LL1764-1;PhenX21_13_experience;LA15600-2;1;Mostly good;;; +67675-9;LL1764-1;PhenX21_13_experience;LA15601-0;2;Mostly bad;;; +67675-9;LL1764-1;PhenX21_13_experience;LA4720-4;3;Not applicable;;; +67675-9;LL1764-1;PhenX21_13_experience;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67676-7;LL1765-8;PhenX21_14_event effect;LA6568-5;1;Not at all;;; +67676-7;LL1765-8;PhenX21_14_event effect;LA13940-4;2;A little;;; +67676-7;LL1765-8;PhenX21_14_event effect;LA14973-4;3;Some;;; +67676-7;LL1765-8;PhenX21_14_event effect;LA14468-5;4;A lot;;; +67676-7;LL1765-8;PhenX21_14_event effect;LA4720-4;5;Not applicable;;; +67676-7;LL1765-8;PhenX21_14_event effect;LA12688-0;6;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +67704-7;LL1735-1;FeedingType;LA16914-6;1;Breast milk;;; +67704-7;LL1735-1;FeedingType;LA16915-3;2;Lactose formula;;; +67704-7;LL1735-1;FeedingType;LA14041-0;3;Lactose free formula (including soy or hydrolyzed);;; +67704-7;LL1735-1;FeedingType;LA16917-9;4;NPO;;; +67704-7;LL1735-1;FeedingType;LA12418-2;5;TPN;;; +67704-7;LL1735-1;FeedingType;LA16918-7;6;Carnitine;59888006;Carnitine (substance);http://snomed.info/sct +67704-7;LL1735-1;FeedingType;LA16919-5;7;MCT (medium-chain triglyceride) oil;;; +67704-7;LL1735-1;FeedingType;LA16920-3;8;IV dextrose;;; +67704-7;LL1735-1;FeedingType;LA46-8;9;Other;;; +67704-7;LL1735-1;FeedingType;LA137-2;10;None;260413007;None (qualifier value);http://snomed.info/sct +67704-7;LL1735-1;FeedingType;LA4489-6;11;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67706-2;LL1736-9;MaternalFactors;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67706-2;LL1736-9;MaternalFactors;LA16928-6;2;HELLP syndrome;;; +67706-2;LL1736-9;MaternalFactors;LA16929-4;3;Fatty liver of pregnancy;;; +67706-2;LL1736-9;MaternalFactors;LA16930-2;4;Packed red blood cell (PRBC) transfusion;;; +67706-2;LL1736-9;MaternalFactors;LA16931-0;5;Steroid treatment;;; +67706-2;LL1736-9;MaternalFactors;LA16932-8;6;Thyroid treatment (including propylthiouracil (PTU), methimazole (Tapazole), or past treatment with radioactive iodine (I-131));;; +67706-2;LL1736-9;MaternalFactors;LA12418-2;7;TPN;;; +67706-2;LL1736-9;MaternalFactors;LA46-8;8;Other;;; +67719-5;LL1719-5;PhenX20_18_which ear;LA15486-6;1;Left ear;;; +67719-5;LL1719-5;PhenX20_18_which ear;LA15485-8;2;Right ear;;; +67725-2;LL1737-7;Mycobacteria;LA16933-6;1;Mycobacterium abscessus;;; +67725-2;LL1737-7;Mycobacteria;LA16934-4;2;Mycobacterium avium/intracellulare;;; +67725-2;LL1737-7;Mycobacteria;LA16935-1;3;Mycobacterium tuberculosis complex;;; +67725-2;LL1737-7;Mycobacteria;LA16936-9;4;Unidentified non-tuberculous mycobacteria;;; +67725-2;LL1737-7;Mycobacteria;LA16937-7;5;Not mycobacteria;;; +67725-2;LL1737-7;Mycobacteria;LA28425-9;6;Mycobacterium leprae;;; +67725-2;LL1737-7;Mycobacteria;LA28426-7;7;Mycobacterium microti;;; +67725-2;LL1737-7;Mycobacteria;LA19286-6;8;Mycobacterium bovis;;; +67725-2;LL1737-7;Mycobacteria;LA28427-5;9;Mycobacterium asiaticum;;; +67725-2;LL1737-7;Mycobacteria;LA20996-7;10;Mycobacterium tuberculosis;;; +88183-9;LL1737-7;Mycobacteria;LA16933-6;1;Mycobacterium abscessus;;; +88183-9;LL1737-7;Mycobacteria;LA16934-4;2;Mycobacterium avium/intracellulare;;; +88183-9;LL1737-7;Mycobacteria;LA16935-1;3;Mycobacterium tuberculosis complex;;; +88183-9;LL1737-7;Mycobacteria;LA16936-9;4;Unidentified non-tuberculous mycobacteria;;; +88183-9;LL1737-7;Mycobacteria;LA16937-7;5;Not mycobacteria;;; +88183-9;LL1737-7;Mycobacteria;LA28425-9;6;Mycobacterium leprae;;; +88183-9;LL1737-7;Mycobacteria;LA28426-7;7;Mycobacterium microti;;; +88183-9;LL1737-7;Mycobacteria;LA19286-6;8;Mycobacterium bovis;;; +88183-9;LL1737-7;Mycobacteria;LA28427-5;9;Mycobacterium asiaticum;;; +88183-9;LL1737-7;Mycobacteria;LA20996-7;10;Mycobacterium tuberculosis;;; +67726-0;LL1743-5;Rickettsia DNA;LA16942-7;1;Rickettsia DNA detected;;; +67726-0;LL1743-5;Rickettsia DNA;LA16943-5;2;Equivocal for Rickettsia prowazekii;;; +67726-0;LL1743-5;Rickettsia DNA;LA16944-3;3;Equivocal for Rickettsia rickettsii;;; +67726-0;LL1743-5;Rickettsia DNA;LA16945-0;4;Inconclusive for R.prowazekii and R.rickettsii;;; +67726-0;LL1743-5;Rickettsia DNA;LA16946-8;5;Negative for R.prowazekii and R.rickettsii;;; +67732-8;LL1745-0;PhenX20_36_white finger syndrome response;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +67732-8;LL1745-0;PhenX20_36_white finger syndrome response;LA15599-6;2;I don’t know;;; +67732-8;LL1745-0;PhenX20_36_white finger syndrome response;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +67737-7;LL1744-3;PhenX20_35_hrs exposed;LA15540-0;1;Less than 1 hour each day;;; +67737-7;LL1744-3;PhenX20_35_hrs exposed;LA16947-6;2;1-5 hours each day;;; +67737-7;LL1744-3;PhenX20_35_hrs exposed;LA16948-4;3;More than 5 hours each day;;; +67738-5;LL1746-8;PhenX20_37_noise type;LA15543-4;1;Constant noise;;; +67738-5;LL1746-8;PhenX20_37_noise type;LA15544-2;2;Impulse noise;;; +67738-5;LL1746-8;PhenX20_37_noise type;LA14331-5;3;Both;;; +67742-7;LL1750-0;PhenX20_41_avg drinks;LA14683-9;1;Less than 1 drink a week;;; +67742-7;LL1750-0;PhenX20_41_avg drinks;LA15559-0;2;1–5 drinks each week;;; +67742-7;LL1750-0;PhenX20_41_avg drinks;LA15560-8;3;1–3 drinks each day;;; +67742-7;LL1750-0;PhenX20_41_avg drinks;LA16952-6;4;More than 3 drinks each day;;; +67744-3;LL1749-2;PhenX20_40_avg cigarettes/day;LA15558-2;1;Less than 5 each day;;; +67744-3;LL1749-2;PhenX20_40_avg cigarettes/day;LA16949-2;2;5-10 each day;;; +67744-3;LL1749-2;PhenX20_40_avg cigarettes/day;LA16950-0;3;10-20 each day;;; +67744-3;LL1749-2;PhenX20_40_avg cigarettes/day;LA16951-8;4;More than 20 each day;;; +67745-0;LL1757-5;PhenX21_06_name generator;LA16953-4;1;I = Important Matters;;; +67745-0;LL1757-5;PhenX21_06_name generator;LA16954-2;2;H = Health;;; +67745-0;LL1757-5;PhenX21_06_name generator;LA16955-9;3;B = Both;;; +67746-8;LL1758-3;PhenX21_07_person;LA16956-7;1;Person 1;;; +67746-8;LL1758-3;PhenX21_07_person;LA16957-5;2;Person 2;;; +67746-8;LL1758-3;PhenX21_07_person;LA16958-3;3;Person 3;;; +67746-8;LL1758-3;PhenX21_07_person;LA16959-1;4;Person 4;;; +67746-8;LL1758-3;PhenX21_07_person;LA16960-9;5;Person 5;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA6112-2;1;1;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA6113-0;2;2;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA6114-8;3;3;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA6115-5;4;4;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA10137-0;5;5;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA10138-8;6;6;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA10139-6;7;7;;; +67747-6;LL1780-7;PhenX21_15_section generator;LA10140-4;8;8;;; +67772-4;LL1778-1;PhenX16_19_hospitaliztions;LA17024-3;1;Hospitalization 1;;; +67772-4;LL1778-1;PhenX16_19_hospitaliztions;LA17025-0;2;Hospitalization 2;;; +67772-4;LL1778-1;PhenX16_19_hospitaliztions;LA17026-8;3;Hospitalization 3;;; +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA9340-6;1;Alert;;; +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA17108-4;2;Verbal;;; +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA17107-6;3;Painful;;; +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA9343-0;4;Unresponsive;422768004;unresponsive (finding);http://snomed.info/sct +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA9340-6;1;Alert;;; +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA17108-4;2;Verbal;;; +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA17107-6;3;Painful;;; +67775-7;LL1845-8;NEMSIS_59_level of responsiveness;LA9343-0;4;Unresponsive;422768004;unresponsive (finding);http://snomed.info/sct +67845-8;LL1868-0;NEMSIS_68_GCS motor;LA6562-8;1;No motor response;;; +67845-8;LL1868-0;NEMSIS_68_GCS motor;LA6563-6;2;Extension to pain;;; +67845-8;LL1868-0;NEMSIS_68_GCS motor;LA6564-4;3;Flexion to pain;;; +67845-8;LL1868-0;NEMSIS_68_GCS motor;LA6565-1;4;Withdrawal from pain;;; +67845-8;LL1868-0;NEMSIS_68_GCS motor;LA6566-9;5;Localizing pain;;; +67845-8;LL1868-0;NEMSIS_68_GCS motor;LA17797-4;6;"Obeys commands (>2 yrs); Appropriate response to stimulation (<=2 yrs)";;; +67846-6;LL1867-2;NEMSIS_67_GCS verbal;LA6557-8;1;"No verbal response (>2 yrs); no vocal response (<=2 yrs)";;; +67846-6;LL1867-2;NEMSIS_67_GCS verbal;LA17793-3;2;"Incomprehensible sounds (>2 yrs); Inconsolable, agitated (<=2 yrs)";;; +67846-6;LL1867-2;NEMSIS_67_GCS verbal;LA17794-1;3;"Inappropriate words (>2 yrs); Inconsistently consolable, moaning (<=2 yrs)";;; +67846-6;LL1867-2;NEMSIS_67_GCS verbal;LA17795-8;4;"Confused (>2 yrs); Cries but is consolable, inappropriate interactions (<=2 yrs)";;; +67846-6;LL1867-2;NEMSIS_67_GCS verbal;LA17796-6;5;"Oriented (>2 yrs); Smiles, oriented to sounds, follows objects, interacts (<=2 yrs)";;; +67847-4;LL1869-8;NEMSIS_69_GCs eye;LA17798-2;1;No eye movement when assessed;;; +67847-4;LL1869-8;NEMSIS_69_GCs eye;LA9346-3;2;Opens eyes in response to verbal stimulation;;; +67847-4;LL1869-8;NEMSIS_69_GCs eye;LA9345-5;3;Opens eyes in response to painful stimulation;;; +67847-4;LL1869-8;NEMSIS_69_GCs eye;LA9347-1;4;Opens eyes spontaneously;;; +67850-8;LL1894-6;RxNorm;;0;;;; +67867-2;LL1871-4;Babesia;LA17806-3;1;No parasites;;; +67867-2;LL1871-4;Babesia;LA17805-5;2;Babesia microti;76828008;Babesia microti (organism);http://snomed.info/sct +67867-2;LL1871-4;Babesia;LA17804-8;3;Babesia sp;;; +67869-8;LL1911-8;FMQAI_18_Reason medicare entitlement;LA6662-6;1;Initial;;; +67869-8;LL1911-8;FMQAI_18_Reason medicare entitlement;LA17971-5;2;Re-entitlement;;; +67869-8;LL1911-8;FMQAI_18_Reason medicare entitlement;LA17972-3;3;Supplemental;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA17956-6;1;Unemployed;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA17957-4;2;Employed full time;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA17958-2;3;Employed part time;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA17959-0;4;Homemaker;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA17960-8;5;Retired due to age/preference;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA17961-6;6;Retired due to disability;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA17962-4;7;Medical leave of absence;;; +67874-8;LL1901-9;FMQAI_15_Employment status;LA15276-1;8;Student;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17956-6;1;Unemployed;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17957-4;2;Employed full time;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17958-2;3;Employed part time;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17959-0;4;Homemaker;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17960-8;5;Retired due to age/preference;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17961-6;6;Retired due to disability;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17962-4;7;Medical leave of absence;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA15276-1;8;Student;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17956-6;1;Unemployed;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17957-4;2;Employed full time;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17958-2;3;Employed part time;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17959-0;4;Homemaker;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17960-8;5;Retired due to age/preference;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17961-6;6;Retired due to disability;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA17962-4;7;Medical leave of absence;;; +67875-5;LL1901-9;FMQAI_15_Employment status;LA15276-1;8;Student;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA17956-6;1;Unemployed;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA17957-4;2;Employed full time;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA17958-2;3;Employed part time;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA17959-0;4;Homemaker;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA17960-8;5;Retired due to age/preference;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA17961-6;6;Retired due to disability;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA17962-4;7;Medical leave of absence;;; +85152-7;LL1901-9;FMQAI_15_Employment status;LA15276-1;8;Student;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA17956-6;1;Unemployed;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA17957-4;2;Employed full time;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA17958-2;3;Employed part time;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA17959-0;4;Homemaker;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA17960-8;5;Retired due to age/preference;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA17961-6;6;Retired due to disability;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA17962-4;7;Medical leave of absence;;; +97108-5;LL1901-9;FMQAI_15_Employment status;LA15276-1;8;Student;;; +67875-5;LL5337-2;PRAPARE_Unemp|PT-Temp|FT|Oth Unemp|Ch Not Answer;LA17956-6;1;Unemployed;;; +67875-5;LL5337-2;PRAPARE_Unemp|PT-Temp|FT|Oth Unemp|Ch Not Answer;LA30138-4;2;Part-time or temporary work;;; +67875-5;LL5337-2;PRAPARE_Unemp|PT-Temp|FT|Oth Unemp|Ch Not Answer;LA30136-8;3;Full-time work;;; +67875-5;LL5337-2;PRAPARE_Unemp|PT-Temp|FT|Oth Unemp|Ch Not Answer;LA30137-6;4;Otherwise unemployed but not seeking work (ex: student, retired, disabled, unpaid primary care giver);;; +67875-5;LL5337-2;PRAPARE_Unemp|PT-Temp|FT|Oth Unemp|Ch Not Answer;LA30122-8;5;I choose not to answer this question;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31780-2;1;Not at work since OP;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31781-0;2;Started partially, same job;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31782-8;3;Fully reintegrated;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31783-6;4;Resumed work, but quit again;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31784-4;5;Resumed work, different job;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31785-1;6;Has been dismissed;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31786-9;7;Retired since OP;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31787-7;8;Retired before OP;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31788-5;9;Housewife/man;;; +67875-5;LL5826-4;Spine Tango - Work status;LA31789-3;10;Child/student;;; +67875-5;LL5826-4;Spine Tango - Work status;LA46-8;11;Other;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31780-2;1;Not at work since OP;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31781-0;2;Started partially, same job;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31782-8;3;Fully reintegrated;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31783-6;4;Resumed work, but quit again;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31784-4;5;Resumed work, different job;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31785-1;6;Has been dismissed;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31786-9;7;Retired since OP;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31787-7;8;Retired before OP;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31788-5;9;Housewife/man;;; +97033-5;LL5826-4;Spine Tango - Work status;LA31789-3;10;Child/student;;; +97033-5;LL5826-4;Spine Tango - Work status;LA46-8;11;Other;;; +67875-5;LL6006-2;Employment Situations;LA32456-8;1;Paid Employment;;; +67875-5;LL6006-2;Employment Situations;LA32457-6;2;Formally self-employed;;; +67875-5;LL6006-2;Employment Situations;LA32458-4;3;Informal employment;;; +67875-5;LL6006-2;Employment Situations;LA32459-2;4;Volunteer or other non-remunerated work;;; +67875-5;LL6006-2;Employment Situations;LA17959-0;5;Homemaker;;; +67875-5;LL6006-2;Employment Situations;LA32460-0;6;Permanently unable to work (with benefits);;; +67875-5;LL6006-2;Employment Situations;LA32461-8;7;Permanently unable to work (without benefits);;; +67875-5;LL6006-2;Employment Situations;LA32462-6;8;Temporarily unable to work (with benefits, e.g., maternity leave);;; +67875-5;LL6006-2;Employment Situations;LA32463-4;9;Unemployed without benefits;;; +67875-5;LL6006-2;Employment Situations;LA32464-2;10;Unemployed with benefits;;; +67875-5;LL6006-2;Employment Situations;LA17991-3;11;Retired;;; +67875-5;LL6006-2;Employment Situations;LA15276-1;12;Student;;; +67875-5;LL6006-2;Employment Situations;LA46-8;13;Other;;; +67882-1;LL1875-5;FMQAI_04_Graft functioning;LA17816-2;1;Functioning;;; +67882-1;LL1875-5;FMQAI_04_Graft functioning;LA17817-0;2;Non-functioning;;; +67884-7;LL5596-3;PHVS_Race_CDC;;0;;;; +95370-3;LL5596-3;PHVS_Race_CDC;;0;;;; +67885-4;LL1872-2;FMQAI_01;LA17807-1;1;Yes, <6mos;;; +67885-4;LL1872-2;FMQAI_01;LA17808-9;2;Yes, 6-12 mos;;; +67885-4;LL1872-2;FMQAI_01;LA17809-7;3;Yes, >12 mos;;; +67885-4;LL1872-2;FMQAI_01;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +67885-4;LL1872-2;FMQAI_01;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67886-2;LL1872-2;FMQAI_01;LA17807-1;1;Yes, <6mos;;; +67886-2;LL1872-2;FMQAI_01;LA17808-9;2;Yes, 6-12 mos;;; +67886-2;LL1872-2;FMQAI_01;LA17809-7;3;Yes, >12 mos;;; +67886-2;LL1872-2;FMQAI_01;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +67886-2;LL1872-2;FMQAI_01;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67887-0;LL1872-2;FMQAI_01;LA17807-1;1;Yes, <6mos;;; +67887-0;LL1872-2;FMQAI_01;LA17808-9;2;Yes, 6-12 mos;;; +67887-0;LL1872-2;FMQAI_01;LA17809-7;3;Yes, >12 mos;;; +67887-0;LL1872-2;FMQAI_01;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +67887-0;LL1872-2;FMQAI_01;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +67888-8;LL1873-0;FMQAI_02_Access type;LA17810-5;1;Arteriovenous fistula (AVF);;; +67888-8;LL1873-0;FMQAI_02_Access type;LA17811-3;2;Graft;;; +67888-8;LL1873-0;FMQAI_02_Access type;LA17812-1;3;Catheter;;; +67888-8;LL1873-0;FMQAI_02_Access type;LA17813-9;4;Other access type;;; +67937-3;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67937-3;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67937-3;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67937-3;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67937-3;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67938-1;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67938-1;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67938-1;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67938-1;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67938-1;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67939-9;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67939-9;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67939-9;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67939-9;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67939-9;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67940-7;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67940-7;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67940-7;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67940-7;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67940-7;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67941-5;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67941-5;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67941-5;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67941-5;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67941-5;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67942-3;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67942-3;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67942-3;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67942-3;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67942-3;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67943-1;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67943-1;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67943-1;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67943-1;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67943-1;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67944-9;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67944-9;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67944-9;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67944-9;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67944-9;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67945-6;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67945-6;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67945-6;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67945-6;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67945-6;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67946-4;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67946-4;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67946-4;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67946-4;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67946-4;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67947-2;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67947-2;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67947-2;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67947-2;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67947-2;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67948-0;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67948-0;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67948-0;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67948-0;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67948-0;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67949-8;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67949-8;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67949-8;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67949-8;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67949-8;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67950-6;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67950-6;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67950-6;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67950-6;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67950-6;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67951-4;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67951-4;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67951-4;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67951-4;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67951-4;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67952-2;LL1879-7;NeuroQol_04;LA15227-4;1;No difficulty;;; +67952-2;LL1879-7;NeuroQol_04;LA15725-7;2;A little difficulty;;; +67952-2;LL1879-7;NeuroQol_04;LA13950-3;3;Some difficulty;;; +67952-2;LL1879-7;NeuroQol_04;LA13951-1;4;A lot of difficulty;;; +67952-2;LL1879-7;NeuroQol_04;LA17824-6;5;Can't do;;; +67953-0;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67953-0;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67953-0;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67953-0;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67953-0;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67954-8;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67954-8;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67954-8;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67954-8;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67954-8;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67955-5;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67955-5;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67955-5;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67955-5;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67955-5;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67956-3;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67956-3;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67956-3;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67956-3;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67956-3;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67957-1;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67957-1;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67957-1;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67957-1;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67957-1;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67958-9;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67958-9;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67958-9;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67958-9;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67958-9;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67959-7;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67959-7;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67959-7;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67959-7;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67959-7;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67960-5;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67960-5;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67960-5;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67960-5;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67960-5;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67961-3;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67961-3;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67961-3;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67961-3;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67961-3;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67962-1;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67962-1;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67962-1;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67962-1;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67962-1;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67963-9;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67963-9;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67963-9;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67963-9;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67963-9;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67964-7;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67964-7;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67964-7;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67964-7;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67964-7;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67965-4;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +67965-4;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +67965-4;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +67965-4;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +67965-4;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +68118-9;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +68118-9;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +68118-9;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +68118-9;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +68118-9;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +68119-7;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +68119-7;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +68119-7;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +68119-7;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +68119-7;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +68120-5;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +68120-5;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +68120-5;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +68120-5;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +68120-5;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +68121-3;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +68121-3;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +68121-3;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +68121-3;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +68121-3;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +68122-1;LL1881-3;NeuroQol_06;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +68122-1;LL1881-3;NeuroQol_06;LA13940-4;2;A little;;; +68122-1;LL1881-3;NeuroQol_06;LA13909-9;3;Somewhat;;; +68122-1;LL1881-3;NeuroQol_06;LA14468-5;4;A lot;;; +68122-1;LL1881-3;NeuroQol_06;LA13868-7;5;Cannot do;;; +67967-0;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67967-0;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67967-0;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67967-0;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67967-0;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67968-8;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67968-8;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67968-8;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67968-8;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67968-8;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67969-6;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67969-6;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67969-6;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67969-6;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67969-6;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67970-4;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67970-4;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67970-4;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67970-4;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67970-4;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67971-2;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67971-2;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67971-2;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67971-2;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67971-2;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67972-0;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67972-0;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67972-0;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67972-0;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67972-0;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67973-8;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67973-8;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67973-8;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67973-8;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67973-8;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67974-6;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67974-6;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67974-6;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67974-6;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67974-6;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67975-3;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67975-3;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67975-3;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67975-3;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67975-3;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67976-1;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67976-1;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67976-1;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67976-1;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67976-1;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67977-9;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67977-9;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67977-9;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67977-9;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67977-9;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67978-7;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67978-7;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67978-7;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67978-7;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67978-7;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67979-5;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67979-5;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67979-5;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67979-5;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67979-5;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67980-3;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67980-3;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67980-3;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67980-3;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67980-3;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67981-1;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67981-1;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67981-1;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67981-1;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67981-1;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67982-9;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67982-9;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67982-9;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67982-9;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67982-9;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +67983-7;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +67983-7;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +67983-7;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +67983-7;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +67983-7;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81460-8;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81460-8;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81460-8;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81460-8;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81460-8;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81461-6;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81461-6;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81461-6;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81461-6;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81461-6;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81462-4;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81462-4;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81462-4;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81462-4;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81462-4;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81463-2;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81463-2;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81463-2;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81463-2;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81463-2;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81464-0;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81464-0;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81464-0;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81464-0;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81464-0;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81465-7;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81465-7;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81465-7;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81465-7;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81465-7;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81466-5;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81466-5;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81466-5;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81466-5;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81466-5;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81467-3;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81467-3;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81467-3;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81467-3;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81467-3;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81468-1;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81468-1;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81468-1;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81468-1;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81468-1;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81469-9;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81469-9;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81469-9;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81469-9;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81469-9;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81470-7;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81470-7;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81470-7;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81470-7;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81470-7;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81471-5;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81471-5;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81471-5;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81471-5;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81471-5;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81472-3;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81472-3;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81472-3;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81472-3;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81472-3;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81473-1;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81473-1;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81473-1;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81473-1;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81473-1;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81474-9;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81474-9;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81474-9;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81474-9;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81474-9;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81475-6;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81475-6;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81475-6;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81475-6;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81475-6;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81476-4;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81476-4;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81476-4;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81476-4;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81476-4;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81477-2;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81477-2;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81477-2;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81477-2;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81477-2;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81478-0;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81478-0;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81478-0;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81478-0;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81478-0;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81479-8;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81479-8;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81479-8;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81479-8;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81479-8;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81480-6;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81480-6;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81480-6;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81480-6;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81480-6;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81481-4;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81481-4;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81481-4;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81481-4;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81481-4;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81482-2;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81482-2;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81482-2;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81482-2;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81482-2;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81483-0;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81483-0;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81483-0;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81483-0;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81483-0;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81484-8;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81484-8;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81484-8;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81484-8;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81484-8;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81485-5;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81485-5;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81485-5;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81485-5;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81485-5;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81486-3;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81486-3;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81486-3;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81486-3;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81486-3;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81487-1;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81487-1;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81487-1;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81487-1;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81487-1;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81488-9;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81488-9;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81488-9;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81488-9;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81488-9;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81489-7;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81489-7;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81489-7;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81489-7;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81489-7;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81490-5;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81490-5;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81490-5;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81490-5;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81490-5;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +81491-3;LL1882-1;NeuroQol_07;LA6270-8;1;Never;;; +81491-3;LL1882-1;NeuroQol_07;LA17826-1;2;Rarely (once);;; +81491-3;LL1882-1;NeuroQol_07;LA17827-9;3;Sometimes (2-3 times);;; +81491-3;LL1882-1;NeuroQol_07;LA17828-7;4;Often (once a day);;; +81491-3;LL1882-1;NeuroQol_07;LA17829-5;5;Very often (Several times a day);;; +68243-5;LL1876-3;NeuroQol_01;LA17818-8;1;Few seconds;;; +68243-5;LL1876-3;NeuroQol_01;LA17819-6;2;Few minutes;;; +68243-5;LL1876-3;NeuroQol_01;LA17820-4;3;Few hours;;; +68243-5;LL1876-3;NeuroQol_01;LA17821-2;4;Few days (less than a week);;; +68243-5;LL1876-3;NeuroQol_01;LA17822-0;5;More than a week;;; +68246-8;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68246-8;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68246-8;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68246-8;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68247-6;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68247-6;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68247-6;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68247-6;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68248-4;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68248-4;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68248-4;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68248-4;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68249-2;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68249-2;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68249-2;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68249-2;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68250-0;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68250-0;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68250-0;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68250-0;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68251-8;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68251-8;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68251-8;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68251-8;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68252-6;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68252-6;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68252-6;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68252-6;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68253-4;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68253-4;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68253-4;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68253-4;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68254-2;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68254-2;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68254-2;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68254-2;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68255-9;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68255-9;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68255-9;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68255-9;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68256-7;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68256-7;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68256-7;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68256-7;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68257-5;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68257-5;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68257-5;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68257-5;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68258-3;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68258-3;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68258-3;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68258-3;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68259-1;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68259-1;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68259-1;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68259-1;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68260-9;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68260-9;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68260-9;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68260-9;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68261-7;LL1877-1;NeuroQol_02;LA13953-7;1;With no trouble;;; +68261-7;LL1877-1;NeuroQol_02;LA13954-5;2;With a little trouble;;; +68261-7;LL1877-1;NeuroQol_02;LA13955-2;3;With some trouble;;; +68261-7;LL1877-1;NeuroQol_02;LA17823-8;4;With a little trouble/not able to do;;; +68283-1;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68283-1;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68283-1;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68283-1;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68283-1;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68284-9;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68284-9;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68284-9;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68284-9;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68284-9;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68285-6;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68285-6;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68285-6;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68285-6;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68285-6;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68286-4;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68286-4;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68286-4;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68286-4;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68286-4;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68287-2;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68287-2;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68287-2;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68287-2;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68287-2;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68288-0;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68288-0;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68288-0;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68288-0;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68288-0;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68289-8;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68289-8;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68289-8;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68289-8;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68289-8;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68290-6;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68290-6;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68290-6;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68290-6;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68290-6;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68291-4;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68291-4;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68291-4;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68291-4;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68291-4;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68292-2;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68292-2;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68292-2;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68292-2;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68292-2;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68293-0;LL1878-9;NeuroQol_03;LA13953-7;1;With no trouble;;; +68293-0;LL1878-9;NeuroQol_03;LA13954-5;2;With a little trouble;;; +68293-0;LL1878-9;NeuroQol_03;LA13955-2;3;With some trouble;;; +68293-0;LL1878-9;NeuroQol_03;LA13956-0;4;With a lot of trouble;;; +68293-0;LL1878-9;NeuroQol_03;LA13957-8;5;Not able to do;;; +68332-6;LL1887-0;FMQAI_08_Donor status;LA10939-9;1;Deceased;;; +68332-6;LL1887-0;FMQAI_08_Donor status;LA17839-4;2;Living, related;;; +68332-6;LL1887-0;FMQAI_08_Donor status;LA17840-2;3;Living, unrelated;;; +68334-2;LL1886-2;FMQAI_07_Dialysis tx site;LA14084-0;1;Home;;; +68334-2;LL1886-2;FMQAI_07_Dialysis tx site;LA17837-8;2;Dialysis facility/center;;; +68334-2;LL1886-2;FMQAI_07_Dialysis tx site;LA17838-6;3;Skilled nursing facility (SNF)/Long term care;;; +68442-3;LL1886-2;FMQAI_07_Dialysis tx site;LA14084-0;1;Home;;; +68442-3;LL1886-2;FMQAI_07_Dialysis tx site;LA17837-8;2;Dialysis facility/center;;; +68442-3;LL1886-2;FMQAI_07_Dialysis tx site;LA17838-6;3;Skilled nursing facility (SNF)/Long term care;;; +68336-7;LL1874-8;FMQAI_03_self dialysis training;LA9975-9;1;Hemodialysis;;; +68336-7;LL1874-8;FMQAI_03_self dialysis training;LA17814-7;2;Continuous ambulatory peritoneal dialysis (CAPD);;; +68336-7;LL1874-8;FMQAI_03_self dialysis training;LA17815-4;3;Continuous cycling peritoneal dialysis (CCPD);;; +68336-7;LL1874-8;FMQAI_03_self dialysis training;LA46-8;4;Other;;; +68443-1;LL1874-8;FMQAI_03_self dialysis training;LA9975-9;1;Hemodialysis;;; +68443-1;LL1874-8;FMQAI_03_self dialysis training;LA17814-7;2;Continuous ambulatory peritoneal dialysis (CAPD);;; +68443-1;LL1874-8;FMQAI_03_self dialysis training;LA17815-4;3;Continuous cycling peritoneal dialysis (CCPD);;; +68443-1;LL1874-8;FMQAI_03_self dialysis training;LA46-8;4;Other;;; +68337-5;LL1888-8;FMQAI_09_Self dialysis traning loc;LA14084-0;1;Home;;; +68337-5;LL1888-8;FMQAI_09_Self dialysis traning loc;LA17841-0;2;In center;;; +69430-7;LL1888-8;FMQAI_09_Self dialysis traning loc;LA14084-0;1;Home;;; +69430-7;LL1888-8;FMQAI_09_Self dialysis traning loc;LA17841-0;2;In center;;; +68341-7;LL1889-6;FMQAI_10_Dialysis at time of death;LA17842-8;1;In center hemodialysis;;; +68341-7;LL1889-6;FMQAI_10_Dialysis at time of death;LA17843-6;2;Home hemodialysis;;; +68341-7;LL1889-6;FMQAI_10_Dialysis at time of death;LA17814-7;3;Continuous ambulatory peritoneal dialysis (CAPD);;; +68341-7;LL1889-6;FMQAI_10_Dialysis at time of death;LA17815-4;4;Continuous cycling peritoneal dialysis (CCPD);;; +68341-7;LL1889-6;FMQAI_10_Dialysis at time of death;LA17844-4;5;Transplant;;; +68341-7;LL1889-6;FMQAI_10_Dialysis at time of death;LA46-8;6;Other;;; +68348-2;LL1890-4;FMQAI_11_Reason therapy disconintued;LA17845-1;1;Following hemodialysis (HD) or peritoneal dialysis (PD) access failure;;; +68348-2;LL1890-4;FMQAI_11_Reason therapy disconintued;LA17846-9;2;Following transplant failure;;; +68348-2;LL1890-4;FMQAI_11_Reason therapy disconintued;LA17847-7;3;Following chronic failure to thrive;;; +68348-2;LL1890-4;FMQAI_11_Reason therapy disconintued;LA17848-5;4;Following acute medical complication;;; +68348-2;LL1890-4;FMQAI_11_Reason therapy disconintued;LA46-8;5;Other;;; +68361-5;LL1884-7;FMQAI_05_Reason no transplant info given;LA17830-3;1;Medically unfit;;; +68361-5;LL1884-7;FMQAI_05_Reason no transplant info given;LA17831-1;2;Unsuitable due to age;;; +68361-5;LL1884-7;FMQAI_05_Reason no transplant info given;LA17832-9;3;Psychologically unfit;;; +68361-5;LL1884-7;FMQAI_05_Reason no transplant info given;LA17833-7;4;Patient declines information;;; +68361-5;LL1884-7;FMQAI_05_Reason no transplant info given;LA17834-5;5;Patient has not been assessed;;; +68361-5;LL1884-7;FMQAI_05_Reason no transplant info given;LA46-8;6;Other;;; +68364-9;LL1907-6;Pincer cell presence (ord);LA11910-9;1;Slight;;; +68364-9;LL1907-6;Pincer cell presence (ord);LA6751-7;2;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +68364-9;LL1907-6;Pincer cell presence (ord);LA17968-1;3;Marked;;; +68449-8;LL1885-4;FMQAI_06_Graft-fistula maturity;LA17835-2;1;Yes, present but not mature;;; +68449-8;LL1885-4;FMQAI_06_Graft-fistula maturity;LA17836-0;2;No, access not present, or present and not maturing;;; +68450-6;LL1885-4;FMQAI_06_Graft-fistula maturity;LA17835-2;1;Yes, present but not mature;;; +68450-6;LL1885-4;FMQAI_06_Graft-fistula maturity;LA17836-0;2;No, access not present, or present and not maturing;;; +68457-1;LL1906-8;Enterovirus+Parechovirus RNA;LA17966-5;1;Positive for Enteroviruses;;; +68457-1;LL1906-8;Enterovirus+Parechovirus RNA;LA17965-7;2;Positive for Parechoviruses;;; +68457-1;LL1906-8;Enterovirus+Parechovirus RNA;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68457-1;LL1906-8;Enterovirus+Parechovirus RNA;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +68461-3;LL1891-2;FMQAI_12_Payment source;LA17849-3;1;Medicaid;;; +68461-3;LL1891-2;FMQAI_12_Payment source;LA15652-3;2;Medicare;;; +68461-3;LL1891-2;FMQAI_12_Payment source;LA17850-1;3;Employer group health insurance;;; +68461-3;LL1891-2;FMQAI_12_Payment source;LA17851-9;4;Department of veteran's affairs;;; +68461-3;LL1891-2;FMQAI_12_Payment source;LA17852-7;5;Medicare advantage;;; +68461-3;LL1891-2;FMQAI_12_Payment source;LA46-8;6;Other;;; +68461-3;LL1891-2;FMQAI_12_Payment source;LA137-2;7;None;260413007;None (qualifier value);http://snomed.info/sct +68463-9;LL1908-4;R/S/Resistance possible;LA16549-0;1;Sensitive;;; +68463-9;LL1908-4;R/S/Resistance possible;LA6676-6;2;Resistant;;; +68463-9;LL1908-4;R/S/Resistance possible;LA17970-7;3;Resistance possible;;; +72276-9;LL1908-4;R/S/Resistance possible;LA16549-0;1;Sensitive;;; +72276-9;LL1908-4;R/S/Resistance possible;LA6676-6;2;Resistant;;; +72276-9;LL1908-4;R/S/Resistance possible;LA17970-7;3;Resistance possible;;; +72525-9;LL1908-4;R/S/Resistance possible;LA16549-0;1;Sensitive;;; +72525-9;LL1908-4;R/S/Resistance possible;LA6676-6;2;Resistant;;; +72525-9;LL1908-4;R/S/Resistance possible;LA17970-7;3;Resistance possible;;; +72526-7;LL1908-4;R/S/Resistance possible;LA16549-0;1;Sensitive;;; +72526-7;LL1908-4;R/S/Resistance possible;LA6676-6;2;Resistant;;; +72526-7;LL1908-4;R/S/Resistance possible;LA17970-7;3;Resistance possible;;; +68487-8;LL1893-8;NEMSIS_73_med/surg ICD code;;0;;;; +68503-2;LL2005-8;English speaking;LA15367-8;1;Very well;;; +68503-2;LL2005-8;English speaking;LA18365-9;2;Well;;; +68503-2;LL2005-8;English speaking;LA18366-7;3;Not well;;; +68503-2;LL2005-8;English speaking;LA6568-5;4;Not at all;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA17990-5;1;Employed;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA17956-6;2;Unemployed;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA17959-0;3;Homemaker;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA15276-1;4;Student;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA17991-3;5;Retired;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA17994-7;6;Disabled;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA17992-1;7;Part-time;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA17993-9;8;Full-time;;; +68505-7;LL1916-7;SAMSHA_03_occupational status;LA46-8;9;Other;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6568-5;1;Not at all;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6569-3;2;Several days;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA18938-3;3;More days than not;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6571-9;4;Nearly every day;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6568-5;1;Not at all;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6569-3;2;Several days;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA18938-3;3;More days than not;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6571-9;4;Nearly every day;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6568-5;1;Not at all;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6569-3;2;Several days;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA18938-3;3;More days than not;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6571-9;4;Nearly every day;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6568-5;1;Not at all;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6569-3;2;Several days;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA18938-3;3;More days than not;;; +68509-9;LL2184-1;SAMHSA-control worrying;LA6571-9;4;Nearly every day;;; +68514-9;LL1915-9;SAMSHA_02_reason fail to take meds;LA17984-8;1;You forget to take your medicine;;; +68514-9;LL1915-9;SAMSHA_02_reason fail to take meds;LA17985-5;2;Your medicine is costly;;; +68514-9;LL1915-9;SAMSHA_02_reason fail to take meds;LA17986-3;3;You are concerned about side effects;;; +68514-9;LL1915-9;SAMSHA_02_reason fail to take meds;LA17987-1;4;You don't think the medicine is helping you;;; +68514-9;LL1915-9;SAMSHA_02_reason fail to take meds;LA17988-9;5;You don't understand why you need this medicine;;; +68514-9;LL1915-9;SAMSHA_02_reason fail to take meds;LA17989-7;6;You don't take this medication because you don't want to;;; +68516-4;LL5872-8;Minutes;LA6111-4;1;0;;; +68516-4;LL5872-8;Minutes;LA13942-0;2;10;;; +68516-4;LL5872-8;Minutes;LA19282-5;3;20;;; +68516-4;LL5872-8;Minutes;LA28855-7;4;30;;; +68516-4;LL5872-8;Minutes;LA28858-1;5;40;;; +68516-4;LL5872-8;Minutes;LA28854-0;6;50;;; +68516-4;LL5872-8;Minutes;LA28853-2;7;60;;; +68516-4;LL5872-8;Minutes;LA28891-2;8;90;;; +68516-4;LL5872-8;Minutes;LA32059-0;9;120;;; +68516-4;LL5872-8;Minutes;LA32060-8;10;150 or greater;;; +68517-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +68517-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +68517-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +68517-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +68517-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +68524-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +68524-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +68524-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +68524-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +68524-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +75889-6;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +75889-6;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +75889-6;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +75889-6;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +75889-6;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +88037-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +88037-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +88037-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +88037-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +88037-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95430-5;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95430-5;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95430-5;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95430-5;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95430-5;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95431-3;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95431-3;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95431-3;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95431-3;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95431-3;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95432-1;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95432-1;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95432-1;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95432-1;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95432-1;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95433-9;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95433-9;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95433-9;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95433-9;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95433-9;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95434-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95434-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95434-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95434-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95434-7;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95435-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95435-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95435-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95435-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95435-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95436-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95436-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95436-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95436-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95436-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95437-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95437-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95437-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95437-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95437-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95438-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95438-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95438-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95438-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95438-8;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95529-4;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95530-2;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95531-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +96842-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA6270-8;1;Never;;; +96842-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA26460-8;2;Once or twice;;; +96842-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18876-5;3;Monthly;;; +96842-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +96842-0;LL5630-0;Never | Once or twice | Monthly | Weekly;LA18934-2;5;Daily or almost daily;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA6270-8;1;Never;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18926-8;2;Monthly or less;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18927-6;3;2-4 times a month;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18928-4;4;2-3 times a week;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18929-2;5;4 or more times a week;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA6270-8;1;Never;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18926-8;2;Monthly or less;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18927-6;3;2-4 times a month;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18928-4;4;2-3 times a week;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18929-2;5;4 or more times a week;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA6270-8;1;Never;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18926-8;2;Monthly or less;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18927-6;3;2-4 times a month;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18928-4;4;2-3 times a week;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18929-2;5;4 or more times a week;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA6270-8;1;Never;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18926-8;2;Monthly or less;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18927-6;3;2-4 times a month;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18928-4;4;2-3 times a week;;; +68518-0;LL2179-1;SAMHSA-how often alcohol;LA18929-2;5;4 or more times a week;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA15694-5;1;1 or 2;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA15695-2;2;3 or 4;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA18930-0;3;5 or 6;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA18931-8;4;7 to 9;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA18932-6;5;10 or more;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA15694-5;1;1 or 2;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA15695-2;2;3 or 4;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA18930-0;3;5 or 6;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA18931-8;4;7 to 9;;; +68519-8;LL2180-9;SAMHSA-drinks a day;LA18932-6;5;10 or more;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA6270-8;1;Never;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA18933-4;2;Less than monthly;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA18876-5;3;Monthly;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +68520-6;LL2181-7;SAMHSA-6 drinks;LA18934-2;5;Daily or almost daily;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA6270-8;1;Never;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA18933-4;2;Less than monthly;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA18876-5;3;Monthly;;; +68520-6;LL2181-7;SAMHSA-6 drinks;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +68520-6;LL2181-7;SAMHSA-6 drinks;LA18934-2;5;Daily or almost daily;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA18936-7;1;0 - no stress;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA6112-2;2;1;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA6113-0;3;2;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA6114-8;4;3;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA6115-5;5;4;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA10137-0;6;5;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA10138-8;7;6;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA10139-6;8;7;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA10140-4;9;8;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA10141-2;10;9;;; +68521-4;LL2183-3;SAMHSA-how much stress last week;LA18937-5;11;10 - extreme stress;;; +68522-2;LL2182-5;SAMHSA-common sources contribute to stress;LA6568-5;1;Not at all;;; +68522-2;LL2182-5;SAMHSA-common sources contribute to stress;LA13947-9;2;Very little;;; +68522-2;LL2182-5;SAMHSA-common sources contribute to stress;LA13909-9;3;Somewhat;;; +68522-2;LL2182-5;SAMHSA-common sources contribute to stress;LA13902-4;4;Quite a bit;;; +68522-2;LL2182-5;SAMHSA-common sources contribute to stress;LA18935-9;5;Greatly;;; +68523-0;LL1914-2;SAMSHA_01_sources of stress;LA17981-4;1;Financial;;; +68523-0;LL1914-2;SAMSHA_01_sources of stress;LA17982-2;2;Social/family;;; +68523-0;LL1914-2;SAMSHA_01_sources of stress;LA16501-1;3;Work;;; +68523-0;LL1914-2;SAMSHA_01_sources of stress;LA17983-0;4;Health;;; +68523-0;LL1914-2;SAMSHA_01_sources of stress;LA46-8;5;Other;;; +68900-0;LL1902-7;FMQAI_16_Albumin lab method;LA17963-2;1;BCG - bromocresol green;;; +68900-0;LL1902-7;FMQAI_16_Albumin lab method;LA17964-0;2;BCP - bromocresol purple;;; +68955-4;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +68955-4;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +68955-4;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +68955-4;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +74107-4;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74107-4;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +74107-4;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +74107-4;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +74111-6;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74111-6;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +74111-6;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +74111-6;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +74112-4;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74112-4;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +74112-4;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +74112-4;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +74113-2;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74113-2;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +74113-2;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +74113-2;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +74114-0;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74114-0;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +74114-0;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +74114-0;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +74115-7;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74115-7;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +74115-7;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +74115-7;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +80272-8;LL1904-3;Neg|Small|Mod|Large;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +80272-8;LL1904-3;Neg|Small|Mod|Large;LA8983-4;2;Small;255507004;Small (qualifier value);http://snomed.info/sct +80272-8;LL1904-3;Neg|Small|Mod|Large;LA6751-7;3;Moderate;;; +80272-8;LL1904-3;Neg|Small|Mod|Large;LA8981-8;4;Large;255509001;Large (qualifier value);http://snomed.info/sct +68961-2;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +68961-2;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +68961-2;LL1909-2;Reac/Non-reac/Indet/Invalid;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +68961-2;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +81641-3;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +81641-3;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +81641-3;LL1909-2;Reac/Non-reac/Indet/Invalid;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81641-3;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +86190-6;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +86190-6;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +86190-6;LL1909-2;Reac/Non-reac/Indet/Invalid;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +86190-6;LL1909-2;Reac/Non-reac/Indet/Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +68985-1;LL1977-9;serovars;LA18291-7;1;C1:gms:1;;; +68985-1;LL1977-9;serovars;LA18292-5;2;E:1,v:1,7;;; +69046-1;LL1921-7;Airway patency (nom);LA18010-1;1;Patent with support;;; +69046-1;LL1921-7;Airway patency (nom);LA18011-9;2;Patent without support;;; +69346-5;LL1918-3;Endotracheal tube activity;LA17995-4;1;Extubated;;; +69346-5;LL1918-3;Endotracheal tube activity;LA17973-1;2;Intubated;;; +69346-5;LL1918-3;Endotracheal tube activity;LA17996-2;3;Reintubated;;; +69346-5;LL1918-3;Endotracheal tube activity;LA17997-0;4;Repositioned;;; +69346-5;LL1918-3;Endotracheal tube activity;LA17998-8;5;Resecured;;; +69346-5;LL1918-3;Endotracheal tube activity;LA17999-6;6;Self-extubated;;; +69346-5;LL1918-3;Endotracheal tube activity;LA18000-2;7;Insertion site cleansed;;; +69346-5;LL1918-3;Endotracheal tube activity;LA18001-0;8;Oral care;;; +69347-3;LL1919-1;Artificial airway type;LA18002-8;1;Cuffed endotracheal tube;;; +69347-3;LL1919-1;Artificial airway type;LA18003-6;2;Uncuffed endotracheal tube;;; +69347-3;LL1919-1;Artificial airway type;LA18004-4;3;Tracheostomy tube;;; +69347-3;LL1919-1;Artificial airway type;LA18005-1;4;Nasopharyngeal;;; +69347-3;LL1919-1;Artificial airway type;LA18006-9;5;Oropharyngeal;;; +69347-3;LL1919-1;Artificial airway type;LA18007-7;6;Double lumen endotracheal tube;;; +69347-3;LL1919-1;Artificial airway type;LA18008-5;7;Emergency medicine tube;;; +69347-3;LL1919-1;Artificial airway type;LA18009-3;8;Continuous subglottic evacuation;;; +69348-1;LL1912-6;Airway support (nom);LA17973-1;1;Intubated;;; +69348-1;LL1912-6;Airway support (nom);LA17974-9;2;Ventilated - manual;;; +69348-1;LL1912-6;Airway support (nom);LA17975-6;3;Ventilated - per ventilator;;; +69348-1;LL1912-6;Airway support (nom);LA17976-4;4;Supplemental oxygen;;; +69348-1;LL1912-6;Airway support (nom);LA11849-9;5;Room air;;; +69372-1;LL1924-1;CARE_LTCH_A1050_Education level;LA18012-7;1;No schooling completed;;; +69372-1;LL1924-1;CARE_LTCH_A1050_Education level;LA18013-5;2;Nursery or preschool through grade 12;;; +69372-1;LL1924-1;CARE_LTCH_A1050_Education level;LA12457-0;3;High school graduate or GED completed;;; +69372-1;LL1924-1;CARE_LTCH_A1050_Education level;LA18014-3;4;Bachelor's degree or some college;;; +69372-1;LL1924-1;CARE_LTCH_A1050_Education level;LA18015-0;5;Graduate level degree or coursework;;; +69379-6;LL1928-2;vanA + vanB + vanC1 + vanC2;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69379-6;LL1928-2;vanA + vanB + vanC1 + vanC2;LA18025-9;2;vanA;;; +69379-6;LL1928-2;vanA + vanB + vanC1 + vanC2;LA18026-7;3;vanB;;; +69379-6;LL1928-2;vanA + vanB + vanC1 + vanC2;LA18027-5;4;vanC1;;; +69379-6;LL1928-2;vanA + vanB + vanC1 + vanC2;LA18028-3;5;vanC2;;; +69406-7;LL1930-8;FMQAI_20_Adult GFR method;LA18029-1;1;IDMS traceable MDRD study equation;;; +69406-7;LL1930-8;FMQAI_20_Adult GFR method;LA18030-9;2;Original MDRD study equation (GFR);;; +69407-5;LL1929-0;FMQAI_19_Peds GFR method;LA18031-7;1;Original Schwartz equation;;; +69407-5;LL1929-0;FMQAI_19_Peds GFR method;LA18032-5;2;Bedside IDMS traceable Schwartz equation;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA10078-6;1;Short-stay acute hospital (IPPS);;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA9951-0;2;Community based residence (e.g., assisted living residence, group home, adult foster care);;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA18066-3;3;Long-term care facility;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA6376-3;4;Skilled Nursing Facility;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA11504-0;5;Hospital emergency department;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA10000-0;6;Long-term care hospital (LTCH);;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA10928-2;7;Inpatient rehabilitation facility;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA9978-3;8;Home Health Care (HHA);;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA6216-1;9;Hospice;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA10053-9;10;Outpatient Services;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA18046-5;11;Mental retardation-developmental (MR/DD) disability facility;;; +69411-7;LL1933-2;CARE_A1810_LTCH_medical services;LA9-3;12;None of the above;;; +69431-5;LL1940-7;ESRD_medicare enrollment status;LA18070-5;1;Medicare application pending;;; +69431-5;LL1940-7;ESRD_medicare enrollment status;LA6284-9;2;No Medicare;;; +69431-5;LL1940-7;ESRD_medicare enrollment status;LA18071-3;3;Medicare coverage;;; +69432-3;LL1939-9;ESRD_dialysis time period;LA15804-0;1;Day;;; +69432-3;LL1939-9;ESRD_dialysis time period;LA18069-7;2;Nocturnal;;; +69433-1;LL1938-1;ESRD_citizenship status;LA18072-1;1;US citizen;;; +69433-1;LL1938-1;ESRD_citizenship status;LA18073-9;2;Non US citizen;;; +69433-1;LL1938-1;ESRD_citizenship status;LA18074-7;3;Foreign national US resident;;; +69433-1;LL1938-1;ESRD_citizenship status;LA18075-4;4;US resident;;; +69437-2;LL1945-6;Death certificate_certifier;LA18077-0;1;Certifying physician-To the best of my knowledge, death occurred due to the cause(s) and manner stated.;;; +69437-2;LL1945-6;Death certificate_certifier;LA18078-8;2;Pronouncing & Certifying physician-To the best of my knowledge, death occurred at the time, date, and place, and due to the cause(s) and manner stated.;;; +69437-2;LL1945-6;Death certificate_certifier;LA18079-6;3;Medical Examiner/Coroner-On the basis of examination, and/or investigation, in my opinion, death occurred at the time, date, and place, and due to the cause(s) and manner stated.;;; +69442-2;LL1943-1;Death certificate_pregnancy status;LA18040-8;1;Not pregnant within past year;;; +69442-2;LL1943-1;Death certificate_pregnancy status;LA18041-6;2;Pregnant at time of death;;; +69442-2;LL1943-1;Death certificate_pregnancy status;LA18042-4;3;Not pregnant, but pregnant within 42 days of death;;; +69442-2;LL1943-1;Death certificate_pregnancy status;LA18043-2;4;Not pregnant, but pregnant 43 days to 1 year before death;;; +69442-2;LL1943-1;Death certificate_pregnancy status;LA18044-0;5;Unknown if pregnant within the past year;;; +69443-0;LL1942-3;Death certificate_tobacco use;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69443-0;LL1942-3;Death certificate_tobacco use;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +69443-0;LL1942-3;Death certificate_tobacco use;LA18076-2;3;Probably;;; +69443-0;LL1942-3;Death certificate_tobacco use;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +69449-7;LL1944-9;Death certificate_manner of death;LA16034-3;1;Natural;;; +69449-7;LL1944-9;Death certificate_manner of death;LA18034-1;2;Accident;;; +69449-7;LL1944-9;Death certificate_manner of death;LA18036-6;3;Suicide;;; +69449-7;LL1944-9;Death certificate_manner of death;LA18033-3;4;Homicide;;; +69449-7;LL1944-9;Death certificate_manner of death;LA18035-8;5;Pending investigation;;; +69449-7;LL1944-9;Death certificate_manner of death;LA11137-9;6;Unable to determine;;; +69451-3;LL2532-1;Death certificate_Transport Role of Decedent;LA18037-4;1;Driver/operator;;; +69451-3;LL2532-1;Death certificate_Transport Role of Decedent;LA18038-2;2;Passenger;;; +69451-3;LL2532-1;Death certificate_Transport Role of Decedent;LA18039-0;3;Pedestrian;;; +69451-3;LL2532-1;Death certificate_Transport Role of Decedent;LA46-8;4;Other;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA18117-4;2;Yes, adult trauma;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA18118-2;3;Yes, cardiac arrest;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA18119-0;4;Yes, obstetrics;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA18120-8;5;Yes, other;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA18121-6;6;Yes, pediatric trauma;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA18122-4;7;Yes, STEMI;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA18123-2;8;Yes, stroke;;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA24962-5;9;Yes, trauma (General);;; +69462-0;LL1951-4;NEMSIS_82_healthcare facility activation;LA32937-7;10;Yes-sepsis;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18089-5;1;Biologic agent;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18090-3;2;Building failure;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18091-1;3;Chemical agent;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18092-9;4;Explosive device;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18093-7;5;Fire;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18094-5;6;Hostage event;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18095-2;7;Mass gathering;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18096-0;8;Mass illness;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18097-8;9;Nuclear agent;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18098-6;10;Radioactive device;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18099-4;11;Secondary destructive device;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18100-0;12;Shooting/sniper;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA18101-8;13;Vehicular;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA17594-5;14;Weather (other);;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA30037-8;15;Earthquake;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA30039-4;16;Flood;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA32967-4;17;Land slide;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA32968-2;18;Winter storm;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA30042-8;19;Tornado;;; +69463-8;LL1948-0;NEMSIS_79_disaster cause;LA30040-2;20;Hurricane;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18102-6;1;ALS, level 1;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18103-4;2;ALS, level 1 emergency;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18104-2;3;ALS, level 2;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18105-9;4;BLS;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18106-7;5;BLS, emergency;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18107-5;6;Fixed wing (airplane);;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18108-3;7;Paramedic intercept;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18109-1;8;Specialty care transport;;; +69464-6;LL1949-8;NEMSIS_80_CMS service level;LA18110-9;9;Rotary wing (helicopter);;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA9534-4;1;Behavioral / psychiatric disorder;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18277-6;2;Cardiovascular;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18278-4;3;CNS/neuro;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18279-2;4;Endocrine/metabolic;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA16968-2;5;Gastrointestinal;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18114-1;6;General/global;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18281-8;7;Lymphatic/immune;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18282-6;8;Musculoskeletal/skin;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18283-4;9;Pulmonary;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18284-2;10;Renal;;; +69468-7;LL1950-6;NEMSIS_81_anatomic organ system;LA18285-9;11;Reproductive;;; +69490-1;LL2361-5;Ethnicity OMB 1997;LA6214-6;1;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +69490-1;LL2361-5;Ethnicity OMB 1997;LA19555-4;2;Not Hispanic or Latino;2186-5;Not Hispanic or Latino;https://www.cdc.gov/phin +81888-0;LL2361-5;Ethnicity OMB 1997;LA6214-6;1;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +81888-0;LL2361-5;Ethnicity OMB 1997;LA19555-4;2;Not Hispanic or Latino;2186-5;Not Hispanic or Latino;https://www.cdc.gov/phin +69491-9;LL2003-3;OPTIMAL_Mobility aids;LA15197-9;1;Cane;;; +69491-9;LL2003-3;OPTIMAL_Mobility aids;LA18362-6;2;Walker, rolling walker, or rollator;;; +69491-9;LL2003-3;OPTIMAL_Mobility aids;LA18363-4;3;Manual wheelchair;;; +69491-9;LL2003-3;OPTIMAL_Mobility aids;LA18364-2;4;Motorized wheelchair;;; +69491-9;LL2003-3;OPTIMAL_Mobility aids;LA46-8;5;Other;;; +69497-6;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69497-6;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69497-6;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69497-6;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69497-6;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69497-6;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69498-4;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69498-4;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69498-4;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69498-4;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69498-4;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69498-4;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69499-2;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69499-2;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69499-2;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69499-2;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69499-2;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69499-2;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69500-7;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69500-7;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69500-7;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69500-7;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69500-7;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69500-7;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69501-5;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69501-5;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69501-5;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69501-5;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69501-5;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69501-5;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69502-3;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69502-3;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69502-3;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69502-3;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69502-3;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69502-3;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69503-1;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69503-1;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69503-1;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69503-1;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69503-1;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69503-1;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69504-9;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69504-9;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69504-9;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69504-9;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69504-9;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69504-9;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69505-6;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69505-6;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69505-6;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69505-6;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69505-6;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69505-6;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69506-4;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69506-4;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69506-4;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69506-4;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69506-4;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69506-4;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69507-2;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69507-2;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69507-2;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69507-2;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69507-2;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69507-2;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69508-0;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69508-0;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69508-0;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69508-0;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69508-0;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69508-0;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69509-8;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69509-8;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69509-8;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69509-8;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69509-8;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69509-8;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69510-6;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69510-6;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69510-6;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69510-6;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69510-6;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69510-6;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69511-4;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69511-4;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69511-4;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69511-4;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69511-4;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69511-4;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69512-2;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69512-2;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69512-2;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69512-2;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69512-2;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69512-2;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69513-0;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69513-0;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69513-0;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69513-0;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69513-0;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69513-0;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69514-8;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69514-8;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69514-8;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69514-8;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69514-8;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69514-8;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69515-5;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69515-5;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69515-5;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69515-5;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69515-5;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69515-5;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69516-3;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69516-3;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69516-3;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69516-3;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69516-3;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69516-3;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69517-1;LL1947-2;OPTIMAL_difficulty;LA18337-8;1;Able to do without any difficulty;;; +69517-1;LL1947-2;OPTIMAL_difficulty;LA18338-6;2;Able to do with little difficulty;;; +69517-1;LL1947-2;OPTIMAL_difficulty;LA18339-4;3;Able to do with moderate difficulty;;; +69517-1;LL1947-2;OPTIMAL_difficulty;LA18340-2;4;Able to do with much difficulty;;; +69517-1;LL1947-2;OPTIMAL_difficulty;LA13912-3;5;Unable to do;;; +69517-1;LL1947-2;OPTIMAL_difficulty;LA4720-4;6;Not applicable;;; +69501-5;LL6123-5;Lysholm - Squatting;LA32881-7;1;No problems;;; +69501-5;LL6123-5;Lysholm - Squatting;LA32882-5;2;Slightly impaired;;; +69501-5;LL6123-5;Lysholm - Squatting;LA32885-8;3;Not beyond 90 degrees;;; +69501-5;LL6123-5;Lysholm - Squatting;LA32884-1;4;Impossible;;; +69520-5;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69520-5;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69520-5;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69520-5;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69520-5;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69520-5;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69521-3;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69521-3;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69521-3;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69521-3;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69521-3;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69521-3;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69522-1;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69522-1;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69522-1;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69522-1;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69522-1;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69522-1;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69523-9;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69523-9;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69523-9;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69523-9;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69523-9;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69523-9;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69524-7;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69524-7;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69524-7;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69524-7;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69524-7;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69524-7;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69525-4;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69525-4;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69525-4;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69525-4;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69525-4;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69525-4;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69526-2;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69526-2;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69526-2;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69526-2;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69526-2;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69526-2;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69527-0;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69527-0;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69527-0;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69527-0;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69527-0;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69527-0;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69528-8;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69528-8;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69528-8;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69528-8;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69528-8;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69528-8;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69529-6;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69529-6;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69529-6;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69529-6;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69529-6;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69529-6;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69530-4;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69530-4;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69530-4;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69530-4;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69530-4;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69530-4;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69531-2;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69531-2;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69531-2;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69531-2;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69531-2;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69531-2;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69532-0;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69532-0;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69532-0;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69532-0;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69532-0;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69532-0;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69533-8;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69533-8;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69533-8;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69533-8;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69533-8;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69533-8;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69534-6;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69534-6;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69534-6;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69534-6;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69534-6;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69534-6;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69535-3;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69535-3;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69535-3;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69535-3;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69535-3;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69535-3;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69536-1;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69536-1;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69536-1;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69536-1;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69536-1;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69536-1;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69537-9;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69537-9;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69537-9;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69537-9;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69537-9;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69537-9;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69538-7;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69538-7;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69538-7;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69538-7;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69538-7;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69538-7;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69539-5;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69539-5;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69539-5;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69539-5;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69539-5;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69539-5;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69540-3;LL1946-4;OPTIMAL_confidence;LA18083-8;1;Fully confident in my ability to perform;;; +69540-3;LL1946-4;OPTIMAL_confidence;LA18084-6;2;Very confident;;; +69540-3;LL1946-4;OPTIMAL_confidence;LA18085-3;3;Moderate confidence;;; +69540-3;LL1946-4;OPTIMAL_confidence;LA18086-1;4;Some confidence;;; +69540-3;LL1946-4;OPTIMAL_confidence;LA18087-9;5;Not confident in my ability to perform;;; +69540-3;LL1946-4;OPTIMAL_confidence;LA4720-4;6;Not applicable;;; +69548-6;LL1971-2;Variant Assess;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +69548-6;LL1971-2;Variant Assess;LA9634-2;2;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +69548-6;LL1971-2;Variant Assess;LA18198-4;3;No call;;; +69548-6;LL1971-2;Variant Assess;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +69550-2;LL1972-0;Genetic Knowledge;LA18199-2;1;Disease;;; +69550-2;LL1972-0;Genetic Knowledge;LA18200-8;2;Drug;;; +69550-2;LL1972-0;Genetic Knowledge;LA18201-6;3;Gene;;; +69550-2;LL1972-0;Genetic Knowledge;LA18202-4;4;DNA sequence variant;;; +69550-2;LL1972-0;Genetic Knowledge;LA18203-2;5;Amino acid change;;; +69550-2;LL1972-0;Genetic Knowledge;LA7556-9;6;Test;;; +69564-3;LL1975-3;0|1|2|3|4|5|6;LA6111-4;1;0;;; +69564-3;LL1975-3;0|1|2|3|4|5|6;LA6112-2;2;1;;; +69564-3;LL1975-3;0|1|2|3|4|5|6;LA6113-0;3;2;;; +69564-3;LL1975-3;0|1|2|3|4|5|6;LA6114-8;4;3;;; +69564-3;LL1975-3;0|1|2|3|4|5|6;LA6115-5;5;4;;; +69564-3;LL1975-3;0|1|2|3|4|5|6;LA10137-0;6;5;;; +69564-3;LL1975-3;0|1|2|3|4|5|6;LA10138-8;7;6;;; +69565-0;LL1976-1;0 - Low|1 - Mod|2 - High;LA18287-5;1;0 - Low;;; +69565-0;LL1976-1;0 - Low|1 - Mod|2 - High;LA18288-3;2;1 - Moderate;;; +69565-0;LL1976-1;0 - Low|1 - Mod|2 - High;LA18289-1;3;2 - High;;; +69566-8;LL1976-1;0 - Low|1 - Mod|2 - High;LA18287-5;1;0 - Low;;; +69566-8;LL1976-1;0 - Low|1 - Mod|2 - High;LA18288-3;2;1 - Moderate;;; +69566-8;LL1976-1;0 - Low|1 - Mod|2 - High;LA18289-1;3;2 - High;;; +69567-6;LL1976-1;0 - Low|1 - Mod|2 - High;LA18287-5;1;0 - Low;;; +69567-6;LL1976-1;0 - Low|1 - Mod|2 - High;LA18288-3;2;1 - Moderate;;; +69567-6;LL1976-1;0 - Low|1 - Mod|2 - High;LA18289-1;3;2 - High;;; +69582-5;LL1980-3;Restriction enzyme;LA18294-1;1;Xbal;;; +69582-5;LL1980-3;Restriction enzyme;LA18295-8;2;Bilnl;;; +69582-5;LL1980-3;Restriction enzyme;LA18296-6;3;Spel;;; +69582-5;LL1980-3;Restriction enzyme;LA18297-4;4;Sfil;;; +69582-5;LL1980-3;Restriction enzyme;LA18298-2;5;Pacl;;; +69582-5;LL1980-3;Restriction enzyme;LA18299-0;6;Notl;;; +69667-4;LL1931-6;CARE_H0400_Bowel continence;LA11042-1;1;Always continent;;; +69667-4;LL1931-6;CARE_H0400_Bowel continence;LA11048-8;2;Occasionally incontinent (one episode of bowel incontinence);;; +69667-4;LL1931-6;CARE_H0400_Bowel continence;LA11049-6;3;Frequently incontinent (2 or more episodes of bowel incontinence, but at least one continent bowel movement);;; +69667-4;LL1931-6;CARE_H0400_Bowel continence;LA9934-6;4;Always incontinent;;; +69667-4;LL1931-6;CARE_H0400_Bowel continence;LA11051-2;5;Not rated, resident had an ostomy or did not have a bowel movement for the entire 7 days;;; +69668-2;LL1996-9;HIV Ab;LA15256-3;1;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +69668-2;LL1996-9;HIV Ab;LA18330-3;2;HIV-1 reactive;;; +69668-2;LL1996-9;HIV Ab;LA18331-1;3;HIV-2 reactive;;; +69668-2;LL1996-9;HIV Ab;LA18332-9;4;HIV Reactive (Undifferentiated);;; +69668-2;LL1996-9;HIV Ab;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +77685-6;LL1996-9;HIV Ab;LA15256-3;1;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +77685-6;LL1996-9;HIV Ab;LA18330-3;2;HIV-1 reactive;;; +77685-6;LL1996-9;HIV Ab;LA18331-1;3;HIV-2 reactive;;; +77685-6;LL1996-9;HIV Ab;LA18332-9;4;HIV Reactive (Undifferentiated);;; +77685-6;LL1996-9;HIV Ab;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +69671-6;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69671-6;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69671-6;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69672-4;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69672-4;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69672-4;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69673-2;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69673-2;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69673-2;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69674-0;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69674-0;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69674-0;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69675-7;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69675-7;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69675-7;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69676-5;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69676-5;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69676-5;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69677-3;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69677-3;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69677-3;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69678-1;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69678-1;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69678-1;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69679-9;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69679-9;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69679-9;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69680-7;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69680-7;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69680-7;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69681-5;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69681-5;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69681-5;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69682-3;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69682-3;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69682-3;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69717-7;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69717-7;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69717-7;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69731-8;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69731-8;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69731-8;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69732-6;LL1997-7;PHQ_01;LA18334-5;1;Not bothered;;; +69732-6;LL1997-7;PHQ_01;LA18335-2;2;Bothered a little;;; +69732-6;LL1997-7;PHQ_01;LA18336-0;3;Bothered a lot;;; +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA18356-8;1;Chemical;;; +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA18357-6;2;Dander/dust/mold/pollen;;; +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA18358-4;3;Food allergy;;; +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA18359-2;4;Insect sting;;; +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA18360-0;5;Latex;;; +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA137-2;6;None;260413007;None (qualifier value);http://snomed.info/sct +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA17059-9;7;Other (not listed);;; +69748-2;LL2001-7;NEMSIS_84_environ allergies;LA18361-8;8;Plant;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18367-5;1;No, not of Hispanic, Latino-a, or of Spanish origin;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18368-3;2;Yes, Mexican, Mexican-American, Chicano-a;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18369-1;3;Yes, Puerto Rican;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18370-9;4;Yes, Cuban;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18371-7;5;Yes, another Hispanic, Latino-a, or Spanish origin;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18367-5;1;No, not of Hispanic, Latino-a, or of Spanish origin;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18368-3;2;Yes, Mexican, Mexican-American, Chicano-a;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18369-1;3;Yes, Puerto Rican;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18370-9;4;Yes, Cuban;;; +69854-8;LL2006-6;Ethnicity - HHS Std;LA18371-7;5;Yes, another Hispanic, Latino-a, or Spanish origin;;; +69854-8;LL5283-8;Hispanic, Latino-a, Spanish origin;LA18367-5;1;No, not of Hispanic, Latino-a, or of Spanish origin;;; +69854-8;LL5283-8;Hispanic, Latino-a, Spanish origin;LA18368-3;2;Yes, Mexican, Mexican-American, Chicano-a;;; +69854-8;LL5283-8;Hispanic, Latino-a, Spanish origin;LA18369-1;3;Yes, Puerto Rican;;; +69854-8;LL5283-8;Hispanic, Latino-a, Spanish origin;LA18370-9;4;Yes, Cuban;;; +69854-8;LL5283-8;Hispanic, Latino-a, Spanish origin;LA18371-7;5;Yes, another Hispanic, Latino-a, or Spanish origin;;; +69854-8;LL5283-8;Hispanic, Latino-a, Spanish origin;LA33-6;6;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30254-9;1;No, not of Hispanic, Latino/a, or Spanish origin;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30255-6;2;Yes, Mexican, Mexican American, Chicano/a;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA18369-1;3;Yes, Puerto Rican;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA18370-9;4;Yes, Cuban;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30256-4;5;Yes, another Hispanic, Latino, or Spanish origin;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30257-2;6;Patient unable to respond;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30254-9;1;No, not of Hispanic, Latino/a, or Spanish origin;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30255-6;2;Yes, Mexican, Mexican American, Chicano/a;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA18369-1;3;Yes, Puerto Rican;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA18370-9;4;Yes, Cuban;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30256-4;5;Yes, another Hispanic, Latino, or Spanish origin;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30257-2;6;Patient unable to respond;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30254-9;1;No, not of Hispanic, Latino/a, or Spanish origin;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30255-6;2;Yes, Mexican, Mexican American, Chicano/a;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA18369-1;3;Yes, Puerto Rican;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA18370-9;4;Yes, Cuban;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30256-4;5;Yes, another Hispanic, Latino, or Spanish origin;;; +69854-8;LL5375-2;CMS A1005 Ethnicity;LA30257-2;6;Patient unable to respond;;; +69854-8;LL6303-3;Ethnicity;LA30254-9;1;No, not of Hispanic, Latino/a, or Spanish origin;;; +69854-8;LL6303-3;Ethnicity;LA30255-6;2;Yes, Mexican, Mexican American, Chicano/a;;; +69854-8;LL6303-3;Ethnicity;LA18369-1;3;Yes, Puerto Rican;;; +69854-8;LL6303-3;Ethnicity;LA18370-9;4;Yes, Cuban;;; +69854-8;LL6303-3;Ethnicity;LA30256-4;5;Yes, another Hispanic, Latino, or Spanish origin;;; +69854-8;LL6303-3;Ethnicity;LA30435-4;7;Resident unable to respond;;; +69854-8;LL6303-3;Ethnicity;LA33608-3;8;Resident declines to respond;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA4457-3;0;White;2106-3;White;https://www.cdc.gov/phin +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA10610-6;1;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA6155-1;2;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA14048-5;3;Asian Indian;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA4168-6;4;Chinese;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA3969-8;5;Filipino;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA4595-0;6;Japanese;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA4603-2;7;Korean;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA4443-3;8;Vietnamese;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA14049-3;9;Other Asian;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA14045-1;10;Native Hawaiian;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA18375-8;11;Guamanian or Chamorro;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA4300-5;12;Samoan;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA14047-7;13;Other Pacific Islander;;; +69855-5;LL5399-2;CMS_LCDS v5.0_Ethnicity (A1010);LA30257-2;14;Patient unable to respond;;; +69855-5;LL6304-1;Race;LA4457-3;0;White;2106-3;White;https://www.cdc.gov/phin +69855-5;LL6304-1;Race;LA10610-6;1;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +69855-5;LL6304-1;Race;LA6155-1;2;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +69855-5;LL6304-1;Race;LA14048-5;3;Asian Indian;;; +69855-5;LL6304-1;Race;LA4168-6;4;Chinese;;; +69855-5;LL6304-1;Race;LA3969-8;5;Filipino;;; +69855-5;LL6304-1;Race;LA4595-0;6;Japanese;;; +69855-5;LL6304-1;Race;LA4603-2;7;Korean;;; +69855-5;LL6304-1;Race;LA4443-3;8;Vietnamese;;; +69855-5;LL6304-1;Race;LA14049-3;9;Other Asian;;; +69855-5;LL6304-1;Race;LA14045-1;10;Native Hawaiian;;; +69855-5;LL6304-1;Race;LA18375-8;11;Guamanian or Chamorro;;; +69855-5;LL6304-1;Race;LA4300-5;12;Samoan;;; +69855-5;LL6304-1;Race;LA14047-7;13;Other Pacific Islander;;; +69855-5;LL6304-1;Race;LA30435-4;14;Resident unable to respond;;; +69855-5;LL6304-1;Race;LA33608-3;15;Resident declines to respond;;; +69855-5;LL6304-1;Race;LA9-3;16;None of the above;;; +69867-0;LL2008-2;CARE_LTCH-Pt. conditions from record;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +69867-0;LL2008-2;CARE_LTCH-Pt. conditions from record;LA14291-1;2;Diabetes mellitus;;; +69867-0;LL2008-2;CARE_LTCH-Pt. conditions from record;LA18401-2;3;Malnutrition;;; +69920-7;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69920-7;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69920-7;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69921-5;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69921-5;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69921-5;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69923-1;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69923-1;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69923-1;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69924-9;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69924-9;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69924-9;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69926-4;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69926-4;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69926-4;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69927-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69927-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69927-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69929-8;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69929-8;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69929-8;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69930-6;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69930-6;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69930-6;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69946-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69946-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69946-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69948-8;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69948-8;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69948-8;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69962-9;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +69962-9;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +69962-9;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70008-8;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70008-8;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70008-8;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70009-6;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70009-6;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70009-6;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70010-4;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70010-4;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70010-4;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70011-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70011-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70011-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70012-0;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70012-0;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70012-0;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70013-8;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70013-8;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70013-8;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70014-6;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70014-6;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70014-6;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70017-9;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70017-9;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70017-9;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70052-6;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70052-6;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70052-6;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70053-4;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70053-4;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70053-4;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70054-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70054-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70054-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70055-9;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70055-9;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70055-9;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70056-7;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70056-7;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70056-7;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70057-5;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70057-5;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70057-5;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70058-3;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70058-3;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70058-3;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70059-1;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70059-1;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70059-1;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +70060-9;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +70060-9;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +70060-9;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +72680-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72680-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72680-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +77950-4;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77950-4;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77950-4;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +77951-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77951-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77951-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +78018-9;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78018-9;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78018-9;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +78019-7;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +78019-7;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78019-7;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +82924-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82924-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82924-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +82932-5;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82932-5;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82932-5;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +82933-3;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82933-3;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82933-3;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +82936-6;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +82936-6;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +82936-6;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +85363-0;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85363-0;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85363-0;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +85364-8;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85364-8;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85364-8;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +85529-6;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85529-6;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85529-6;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +85530-4;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85530-4;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85530-4;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +85545-2;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85545-2;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85545-2;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +85546-0;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85546-0;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85546-0;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +85579-1;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85579-1;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85579-1;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +86711-9;LL2010-8;Pos|Neg|Borderline;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +86711-9;LL2010-8;Pos|Neg|Borderline;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86711-9;LL2010-8;Pos|Neg|Borderline;LA4259-3;3;Borderline;;; +69991-8;LL2011-6;PAP model;LA18403-8;1;S8 Elite;;; +69991-8;LL2011-6;PAP model;LA18404-6;2;S9 Autoset;;; +69991-8;LL2011-6;PAP model;LA18405-3;3;System One;;; +69991-8;LL2011-6;PAP model;LA18406-1;4;BiPAPautoSV;;; +69992-6;LL2012-4;PAP name;LA18411-1;1;Phillips Respironics;;; +69992-6;LL2012-4;PAP name;LA18407-9;2;ResMed;;; +69992-6;LL2012-4;PAP name;LA18408-7;3;BREAS;;; +69995-9;LL2013-2;PAP class;LA16902-1;1;Continuous;;; +69995-9;LL2013-2;PAP class;LA18409-5;2;Variable;;; +69995-9;LL2013-2;PAP class;LA18410-3;3;Bilevel;;; +70128-4;LL2015-7;CARE_A1970_Discharge return status;LA18412-9;1;Anticipated;;; +70128-4;LL2015-7;CARE_A1970_Discharge return status;LA18413-7;2;Not anticipated;;; +70129-2;LL2016-5;CARE_A4_other acute units prior;LA18414-5;1;Critical care/intensive care unit - 1-2 pts per nurse;;; +70129-2;LL2016-5;CARE_A4_other acute units prior;LA18415-2;2;Step-down/intermediate unit - 3-6 pts per nurse;;; +70129-2;LL2016-5;CARE_A4_other acute units prior;LA18416-0;3;General/medical unit or floor - 6 or more pts per nurse;;; +70129-2;LL2016-5;CARE_A4_other acute units prior;LA18417-8;4;No previous units or not applicable;;; +70183-9;LL2023-1;NIH Stroke Scale Interval;LA16758-7;1;Baseline;;; +70183-9;LL2023-1;NIH Stroke Scale Interval;LA18432-7;2;2 hours post treatment;;; +70183-9;LL2023-1;NIH Stroke Scale Interval;LA18433-5;3;24 hrs post onset of symptoms, plus or minus 20 minutes;;; +70183-9;LL2023-1;NIH Stroke Scale Interval;LA18434-3;4;7-10 days;;; +70183-9;LL2023-1;NIH Stroke Scale Interval;LA18435-0;5;3 months;;; +70183-9;LL2023-1;NIH Stroke Scale Interval;LA46-8;6;Other;;; +70184-7;LL2024-9;NIHSS - level of consciousness;LA18436-8;1;Alert, keenly responsive;;; +70184-7;LL2024-9;NIHSS - level of consciousness;LA18437-6;2;"Not alert; but arousable by minor stimulation to obey, answer, or respond";;; +70184-7;LL2024-9;NIHSS - level of consciousness;LA18438-4;3;"Not alert; requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped).";;; +70184-7;LL2024-9;NIHSS - level of consciousness;LA18439-2;4;Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid, and areflexic.;;; +70185-4;LL2025-6;NIHSS-LOC questions;LA18440-0;1;Answers both questions correctly;;; +70185-4;LL2025-6;NIHSS-LOC questions;LA18441-8;2;Answers one question correctly;;; +70185-4;LL2025-6;NIHSS-LOC questions;LA18442-6;3;Answers neither question correctly;;; +70186-2;LL2026-4;NIHSS-LOC commands;LA18443-4;1;Performs both tasks correctly;;; +70186-2;LL2026-4;NIHSS-LOC commands;LA18444-2;2;Performs one task correctly;;; +70186-2;LL2026-4;NIHSS-LOC commands;LA18445-9;3;Performs neither task correctly;;; +70187-0;LL2027-2;NIHSS-best gaze;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +70187-0;LL2027-2;NIHSS-best gaze;LA18446-7;2;"Partial gaze palsy; gaze is abnormal in one or both eyes, but forced deviation or total gaze paresis is not present";;; +70187-0;LL2027-2;NIHSS-best gaze;LA18447-5;3;Forced deviation, or total gaze paresis not overcome by the oculocephalic maneuver;;; +70188-8;LL2028-0;NIHSS-visual;LA18448-3;1;No visual loss;;; +70188-8;LL2028-0;NIHSS-visual;LA18449-1;2;Partial hemianopia;;; +70188-8;LL2028-0;NIHSS-visual;LA18450-9;3;Complete hemianopia;;; +70188-8;LL2028-0;NIHSS-visual;LA18451-7;4;Bilateral hemianopia (blind including cortical blindness);;; +70189-6;LL2029-8;NIHSS-facial palsy;LA18452-5;1;Normal symmetrical movements;;; +70189-6;LL2029-8;NIHSS-facial palsy;LA18453-3;2;Minor paralysis (flattened nasolabial fold, asymmetry on smiling);;; +70189-6;LL2029-8;NIHSS-facial palsy;LA18454-1;3;Partial paralysis (total or near-total paralysis of lower face);;; +70189-6;LL2029-8;NIHSS-facial palsy;LA18455-8;4;Complete paralysis of one or both sides (absence of facial movement in the upper and lower face);;; +70190-4;LL2030-6;NIHSS-motor arm;LA18456-6;1;"No drift; limb holds 90 (or 45) degrees for full 10 seconds";;; +70190-4;LL2030-6;NIHSS-motor arm;LA18457-4;2;"Drift; limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support";;; +70190-4;LL2030-6;NIHSS-motor arm;LA18458-2;3;"Some effort against gravity; limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed, but has some effort against gravity";;; +70190-4;LL2030-6;NIHSS-motor arm;LA18459-0;4;"No effort against gravity; limb falls";;; +70190-4;LL2030-6;NIHSS-motor arm;LA18460-8;5;No movement;;; +70190-4;LL2030-6;NIHSS-motor arm;LA18461-6;6;Amputation or joint fusion, explain:;;; +70967-5;LL2030-6;NIHSS-motor arm;LA18456-6;1;"No drift; limb holds 90 (or 45) degrees for full 10 seconds";;; +70967-5;LL2030-6;NIHSS-motor arm;LA18457-4;2;"Drift; limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support";;; +70967-5;LL2030-6;NIHSS-motor arm;LA18458-2;3;"Some effort against gravity; limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed, but has some effort against gravity";;; +70967-5;LL2030-6;NIHSS-motor arm;LA18459-0;4;"No effort against gravity; limb falls";;; +70967-5;LL2030-6;NIHSS-motor arm;LA18460-8;5;No movement;;; +70967-5;LL2030-6;NIHSS-motor arm;LA18461-6;6;Amputation or joint fusion, explain:;;; +70191-2;LL2031-4;NIHSS-motor leg;LA18462-4;1;"No drift; leg holds 30-degree position for full 5 seconds";;; +70191-2;LL2031-4;NIHSS-motor leg;LA18463-2;2;"Drift; leg falls by the end of the 5-second period but does not hit bed";;; +70191-2;LL2031-4;NIHSS-motor leg;LA18464-0;3;"Some effort against gravity; leg falls to bed by 5 seconds, but has some effort against gravity";;; +70191-2;LL2031-4;NIHSS-motor leg;LA18465-7;4;"No effort against gravity; leg falls to bed immediately";;; +70191-2;LL2031-4;NIHSS-motor leg;LA18460-8;5;No movement;;; +70191-2;LL2031-4;NIHSS-motor leg;LA18461-6;6;Amputation or joint fusion, explain:;;; +70968-3;LL2031-4;NIHSS-motor leg;LA18462-4;1;"No drift; leg holds 30-degree position for full 5 seconds";;; +70968-3;LL2031-4;NIHSS-motor leg;LA18463-2;2;"Drift; leg falls by the end of the 5-second period but does not hit bed";;; +70968-3;LL2031-4;NIHSS-motor leg;LA18464-0;3;"Some effort against gravity; leg falls to bed by 5 seconds, but has some effort against gravity";;; +70968-3;LL2031-4;NIHSS-motor leg;LA18465-7;4;"No effort against gravity; leg falls to bed immediately";;; +70968-3;LL2031-4;NIHSS-motor leg;LA18460-8;5;No movement;;; +70968-3;LL2031-4;NIHSS-motor leg;LA18461-6;6;Amputation or joint fusion, explain:;;; +70192-0;LL2032-2;NIHSS-limb ataxia;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +70192-0;LL2032-2;NIHSS-limb ataxia;LA18466-5;2;Present in one limb;;; +70192-0;LL2032-2;NIHSS-limb ataxia;LA18467-3;3;Present in two limbs;;; +70192-0;LL2032-2;NIHSS-limb ataxia;LA18461-6;4;Amputation or joint fusion, explain:;;; +70193-8;LL2033-0;NIHSS-sensory;LA18468-1;1;"Normal; no sensory loss";;; +70193-8;LL2033-0;NIHSS-sensory;LA18469-9;2;"Mild-to-moderate sensory loss; patient feels pinprick is less sharp or is dull on the affected side; or there is a loss of superficial pain with pinprick, but patient is aware of being touched";;; +70193-8;LL2033-0;NIHSS-sensory;LA18470-7;3;"Severe to total sensory loss; patient is not aware of being touched in the face, arm, and leg";;; +70194-6;LL2034-8;NIHSS-best language;LA18471-5;1;"No aphasia; normal";;; +70194-6;LL2034-8;NIHSS-best language;LA18472-3;2;"Mild-to-moderate aphasia; some obvious loss of fluency or facility of comprehension, without significant limitation on ideas expressed or form of expression";;; +70194-6;LL2034-8;NIHSS-best language;LA18473-1;3;"Severe aphasia; all communication is through fragmentary expression; great need for inference, questioning, and guessing by the listener";;; +70194-6;LL2034-8;NIHSS-best language;LA18474-9;4;"Mute, global aphasia; no usable speech or auditory comprehension";;; +70195-3;LL2035-5;NIHSS-dysarthria;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +70195-3;LL2035-5;NIHSS-dysarthria;LA18475-6;2;"Mild-to-moderate dysarthria; patient slurs at least some words and, at worst, can be understood with some difficulty";;; +70195-3;LL2035-5;NIHSS-dysarthria;LA18476-4;3;"Severe dysarthria; patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric";;; +70195-3;LL2035-5;NIHSS-dysarthria;LA18477-2;4;Intubated or other physical barrier, explain:;;; +70196-1;LL2036-3;NIHSS-extinction & inattention;LA18478-0;1;No abnormality;;; +70196-1;LL2036-3;NIHSS-extinction & inattention;LA18479-8;2;Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities;;; +70196-1;LL2036-3;NIHSS-extinction & inattention;LA18480-6;3;"Profound hemi-inattention or extinction to more than one modality; does not recognize own hand or orients to only one side of space";;; +70220-9;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70220-9;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70220-9;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70220-9;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70222-5;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70222-5;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70222-5;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70222-5;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70223-3;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70223-3;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70223-3;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70223-3;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70224-1;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70224-1;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70224-1;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70224-1;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70225-8;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70225-8;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70225-8;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70225-8;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70226-6;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70226-6;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70226-6;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70226-6;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70227-4;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70227-4;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70227-4;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70227-4;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70228-2;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70228-2;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70228-2;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70228-2;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70229-0;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70229-0;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70229-0;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70229-0;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70230-8;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70230-8;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70230-8;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70230-8;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70231-6;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70231-6;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70231-6;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70231-6;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70232-4;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70232-4;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70232-4;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70232-4;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70233-2;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70233-2;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70233-2;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70233-2;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70234-0;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70234-0;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70234-0;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70234-0;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70235-7;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70235-7;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70235-7;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70235-7;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70236-5;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70236-5;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70236-5;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70236-5;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70237-3;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +70237-3;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +70237-3;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +70237-3;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +71913-8;LL2037-1;PTSD Checklist - PCL;LA6568-5;1;Not at all;;; +71913-8;LL2037-1;PTSD Checklist - PCL;LA13863-8;2;A little bit;;; +71913-8;LL2037-1;PTSD Checklist - PCL;LA13939-6;3;Moderately;;; +71913-8;LL2037-1;PTSD Checklist - PCL;LA13902-4;4;Quite a bit;;; +70294-4;LL2039-7;Entamoeba sp;LA18481-4;1;E. histolytica;;; +70294-4;LL2039-7;Entamoeba sp;LA18482-2;2;E. dispar;;; +70294-4;LL2039-7;Entamoeba sp;LA18483-0;3;E. nuttalli;;; +70294-4;LL2039-7;Entamoeba sp;LA18633-0;4;E. ecuadoriensis;;; +90298-1;LL2039-7;Entamoeba sp;LA18481-4;1;E. histolytica;;; +90298-1;LL2039-7;Entamoeba sp;LA18482-2;2;E. dispar;;; +90298-1;LL2039-7;Entamoeba sp;LA18483-0;3;E. nuttalli;;; +90298-1;LL2039-7;Entamoeba sp;LA18633-0;4;E. ecuadoriensis;;; +70301-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70301-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70301-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70301-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70301-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70302-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70302-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70302-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70302-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70302-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70303-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70303-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70303-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70303-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70303-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70304-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70304-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70304-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70304-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70304-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70305-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70306-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70306-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70306-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70306-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70306-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70307-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70307-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70307-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70307-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70307-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70308-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70308-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70308-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70308-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70308-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70309-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70309-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70309-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70309-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70309-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70310-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70310-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70310-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70310-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70310-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70311-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70311-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70311-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70311-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70311-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70312-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70312-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70312-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70312-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70312-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70313-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70313-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70313-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70313-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70313-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70314-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70314-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70314-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70314-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70314-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70315-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70315-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70315-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70315-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70315-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70316-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70316-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70316-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70316-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70316-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70317-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70317-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70317-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70317-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70317-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70318-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70318-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70318-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70318-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70318-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70319-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70319-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70319-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70319-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70319-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70320-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70320-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70320-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70320-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70320-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70321-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70321-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70321-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70321-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70321-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70322-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70322-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70322-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70322-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70322-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70323-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70323-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70323-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70323-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70323-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70324-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70324-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70324-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70324-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70324-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70325-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70325-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70325-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70325-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70325-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70326-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70326-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70326-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70326-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70326-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70327-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70327-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70327-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70327-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70327-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70328-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70328-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70328-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70328-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70328-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70329-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70329-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70329-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70329-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70329-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70330-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70330-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70330-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70330-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70330-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70331-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70331-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70331-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70331-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70331-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70332-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70332-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70332-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70332-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70332-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70333-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70333-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70333-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70333-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70333-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70334-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70334-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70334-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70334-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70334-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70335-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70335-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70335-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70335-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70335-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70336-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70336-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70336-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70336-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70336-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70337-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70337-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70337-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70337-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70337-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70338-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70338-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70338-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70338-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70338-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70339-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70339-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70339-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70339-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70339-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70340-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70340-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70340-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70340-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70340-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70341-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70341-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70341-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70341-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70341-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70342-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70342-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70342-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70342-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70342-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70343-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70343-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70343-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70343-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70343-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70344-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70344-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70344-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70344-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70344-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70345-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70345-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70345-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70345-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70345-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70346-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70346-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70346-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70346-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70346-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70347-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70347-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70347-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70347-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70347-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70348-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70348-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70348-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70348-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70348-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70349-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70349-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70349-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70349-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70349-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70350-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70350-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70350-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70350-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70350-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70351-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70351-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70351-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70351-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70351-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70352-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70352-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70352-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70352-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70352-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70353-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70353-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70353-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70353-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70353-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70354-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70354-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70354-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70354-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70354-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70355-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70355-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70355-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70355-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70355-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70356-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70356-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70356-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70356-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70356-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70357-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70357-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70357-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70357-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70357-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70358-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70358-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70358-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70358-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70358-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70359-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70359-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70359-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70359-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70359-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70360-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70360-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70360-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70360-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70360-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70361-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70361-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70361-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70361-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70361-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70362-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70362-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70362-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70362-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70362-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70363-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70363-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70363-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70363-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70363-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70364-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70364-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70364-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70364-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70364-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70365-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70365-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70365-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70365-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70365-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70366-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70366-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70366-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70366-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70366-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70367-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70367-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70367-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70367-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70367-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70368-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70368-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70368-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70368-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70368-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70369-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70369-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70369-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70369-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70369-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70370-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70370-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70370-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70370-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70370-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70371-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70371-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70371-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70371-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70371-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70372-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70372-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70372-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70372-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70372-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70373-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70373-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70373-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70373-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70373-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70374-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70374-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70374-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70374-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70374-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70375-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70375-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70375-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70375-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70375-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70376-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70376-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70376-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70376-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70376-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70377-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70377-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70377-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70377-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70377-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70378-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70378-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70378-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70378-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70378-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70379-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70379-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70379-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70379-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70379-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70380-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70380-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70380-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70380-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70380-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70381-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70381-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70381-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70381-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70381-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70382-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70382-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70382-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70382-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70382-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70383-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70383-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70383-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70383-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70383-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70384-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70384-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70384-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70384-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70384-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70385-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70385-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70385-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70385-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70385-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70386-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70386-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70386-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70386-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70386-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70387-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70387-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70387-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70387-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70387-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70388-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70388-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70388-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70388-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70388-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70389-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70389-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70389-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70389-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70389-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70390-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70390-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70390-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70390-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70390-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70391-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70391-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70391-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70391-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70391-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70392-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70392-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70392-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70392-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70392-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70393-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70393-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70393-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70393-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70393-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70394-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70394-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70394-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70394-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70394-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70395-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70395-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70395-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70395-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70395-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70396-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70396-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70396-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70396-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70396-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70397-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70397-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70397-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70397-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70397-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70398-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70398-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70398-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70398-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70398-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70399-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70399-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70399-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70399-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70399-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70400-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70400-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70400-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70400-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70400-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70401-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70401-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70401-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70401-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70401-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70402-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70402-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70402-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70402-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70402-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70403-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70403-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70403-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70403-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70403-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70404-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70404-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70404-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70404-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70404-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70405-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70405-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70405-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70405-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70405-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70406-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70406-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70406-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70406-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70406-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70407-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70407-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70407-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70407-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70407-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70408-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70408-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70408-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70408-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70408-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70409-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70409-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70409-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70409-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70409-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70410-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70410-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70410-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70410-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70410-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70411-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70411-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70411-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70411-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70411-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70412-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70412-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70412-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70412-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70412-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70413-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70413-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70413-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70413-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70413-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70414-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70414-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70414-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70414-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70414-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70415-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70415-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70415-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70415-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70415-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70416-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70416-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70416-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70416-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70416-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70417-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70417-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70417-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70417-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70417-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70418-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70418-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70418-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70418-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70418-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70419-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70419-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70419-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70419-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70419-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70420-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70420-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70420-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70420-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70420-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70421-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70421-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70421-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70421-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70421-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70422-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70422-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70422-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70422-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70422-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70423-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70423-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70423-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70423-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70423-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70424-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70424-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70424-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70424-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70424-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70425-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70425-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70425-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70425-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70425-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70426-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70426-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70426-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70426-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70426-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70427-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70427-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70427-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70427-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70427-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70428-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70428-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70428-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70428-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70428-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70429-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70429-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70429-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70429-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70429-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70430-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70430-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70430-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70430-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70430-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70431-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70431-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70431-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70431-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70431-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70432-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70432-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70432-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70432-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70432-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70433-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70433-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70433-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70433-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70433-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70434-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70434-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70434-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70434-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70434-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70435-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70435-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70435-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70435-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70435-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70436-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70436-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70436-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70436-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70436-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70437-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70437-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70437-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70437-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70437-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70438-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70438-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70438-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70438-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70438-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70439-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70439-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70439-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70439-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70439-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70440-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70440-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70440-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70440-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70440-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70441-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70441-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70441-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70441-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70441-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70442-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70442-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70442-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70442-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70442-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70443-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70443-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70443-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70443-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70443-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70444-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70444-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70444-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70444-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70444-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70445-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70445-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70445-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70445-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70445-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70446-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70446-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70446-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70446-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70446-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70447-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70447-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70447-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70447-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70447-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70448-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70448-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70448-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70448-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70448-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70449-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70449-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70449-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70449-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70449-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70450-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70450-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70450-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70450-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70450-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70451-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70451-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70451-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70451-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70451-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70452-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70452-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70452-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70452-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70452-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70453-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70453-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70453-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70453-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70453-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70454-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70454-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70454-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70454-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70454-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70455-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70455-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70455-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70455-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70455-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70456-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70456-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70456-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70456-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70456-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70457-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70457-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70457-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70457-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70457-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70458-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70458-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70458-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70458-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70458-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70459-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70459-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70459-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70459-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70459-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70460-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70460-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70460-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70460-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70460-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70461-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70461-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70461-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70461-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70461-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70462-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70462-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70462-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70462-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70462-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70463-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70463-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70463-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70463-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70463-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70464-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70464-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70464-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70464-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70464-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70465-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70465-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70465-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70465-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70465-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70466-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70466-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70466-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70466-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70466-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70467-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70467-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70467-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70467-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70467-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70468-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70468-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70468-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70468-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70468-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70469-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70469-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70469-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70469-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70469-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70470-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70470-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70470-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70470-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70470-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70471-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70471-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70471-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70471-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70471-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70472-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70472-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70472-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70472-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70472-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70473-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70473-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70473-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70473-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70473-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70474-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70474-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70474-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70474-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70474-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70475-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70475-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70475-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70475-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70475-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70476-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70476-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70476-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70476-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70476-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70477-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70477-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70477-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70477-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70477-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70478-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70478-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70478-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70478-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70478-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70479-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70479-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70479-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70479-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70479-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70480-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70480-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70480-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70480-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70480-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70481-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70481-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70481-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70481-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70481-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70484-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70484-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70484-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70484-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70484-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70485-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70485-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70485-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70485-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70485-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70486-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70486-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70486-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70486-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70486-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70487-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70487-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70487-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70487-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70487-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70488-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70488-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70488-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70488-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70488-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70489-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70489-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70489-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70489-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70489-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70490-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70490-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70490-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70490-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70490-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70491-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70491-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70491-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70491-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70491-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70492-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70492-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70492-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70492-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70492-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70493-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70493-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70493-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70493-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70493-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70494-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70494-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70494-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70494-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70494-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70525-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70525-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70525-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70525-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70525-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70526-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70526-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70526-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70526-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70526-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70527-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70527-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70527-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70527-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70527-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70528-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70528-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70528-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70528-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70528-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70530-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70530-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70530-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70530-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70530-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70531-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70531-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70531-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70531-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70531-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70558-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70558-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70558-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70558-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70558-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70559-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70559-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70559-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70559-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70559-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70560-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70560-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70560-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70560-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70560-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70561-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70561-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70561-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70561-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70561-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70562-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70562-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70562-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70562-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70562-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70563-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70563-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70563-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70563-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70563-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70564-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70564-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70564-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70564-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70564-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70565-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70565-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70565-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70565-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70565-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70566-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70566-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70566-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70566-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70566-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70567-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70567-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70567-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70567-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70567-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70570-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70570-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70570-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70570-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70570-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70572-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70572-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70572-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70572-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70572-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70573-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70573-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70573-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70573-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70573-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70574-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70574-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70574-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70574-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70574-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70575-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70575-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70575-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70575-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70575-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70576-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70576-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70576-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70576-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70576-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70577-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70577-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70577-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70577-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70577-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70578-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70578-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70578-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70578-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70578-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70579-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70579-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70579-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70579-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70579-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70580-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70580-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70580-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70580-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70580-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70581-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70581-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70581-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70581-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70581-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70582-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70582-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70582-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70582-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70582-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70583-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70583-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70583-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70583-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70583-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70584-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70584-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70584-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70584-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70584-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70586-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70586-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70586-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70586-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70586-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70587-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70587-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70587-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70587-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70587-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70588-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70588-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70588-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70588-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70588-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70589-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70589-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70589-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70589-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70589-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70590-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70590-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70590-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70590-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70590-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70591-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70591-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70591-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70591-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70591-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70592-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70592-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70592-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70592-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70592-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70593-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70593-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70593-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70593-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70593-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70594-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70594-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70594-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70594-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70594-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70595-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70595-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70595-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70595-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70595-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70596-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70596-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70596-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70596-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70596-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70597-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70597-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70597-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70597-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70597-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70598-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70598-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70598-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70598-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70598-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70599-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70599-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70599-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70599-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70599-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70600-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70600-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70600-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70600-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70600-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70601-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70601-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70601-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70601-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70601-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70602-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70602-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70602-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70602-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70602-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70603-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70603-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70603-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70603-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70603-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70604-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70604-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70604-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70604-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70604-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70605-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70605-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70605-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70605-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70605-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70607-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70607-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70607-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70607-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70607-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70608-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70608-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70608-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70608-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70608-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70609-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70609-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70609-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70609-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70609-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70610-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70610-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70610-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70610-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70610-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70611-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70611-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70611-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70611-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70611-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70612-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70612-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70612-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70612-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70612-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70613-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70613-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70613-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70613-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70613-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70614-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70614-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70614-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70614-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70614-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70615-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70615-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70615-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70615-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70615-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70616-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70616-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70616-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70616-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70616-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70617-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70617-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70617-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70617-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70617-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70618-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70618-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70618-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70618-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70618-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70619-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70619-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70619-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70619-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70619-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70620-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70620-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70620-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70620-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70620-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70621-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70621-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70621-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70621-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70621-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70622-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70622-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70622-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70622-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70622-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70623-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70623-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70623-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70623-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70623-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70625-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70625-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70625-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70625-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70625-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70626-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70626-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70626-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70626-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70626-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70627-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70627-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70627-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70627-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70627-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70628-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70628-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70628-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70628-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70628-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70629-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70629-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70629-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70629-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70629-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70630-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70630-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70630-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70630-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70630-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70631-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70631-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70631-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70631-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70631-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70632-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70632-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70632-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70632-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70632-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70634-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70634-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70634-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70634-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70634-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70638-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70638-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70638-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70638-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70638-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70639-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70639-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70639-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70639-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70639-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70640-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70640-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70640-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70640-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70640-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70641-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70641-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70641-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70641-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70641-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70642-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70642-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70642-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70642-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70642-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70643-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70643-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70643-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70643-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70643-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70644-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70644-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70644-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70644-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70644-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70645-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70645-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70645-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70645-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70645-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70646-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70646-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70646-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70646-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70646-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70647-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70647-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70647-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70647-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70647-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70648-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70648-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70648-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70648-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70648-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70650-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70650-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70650-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70650-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70650-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70651-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70651-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70651-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70651-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70651-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70652-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70652-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70652-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70652-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70652-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70653-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70653-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70653-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70653-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70653-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70654-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70654-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70654-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70654-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70654-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70656-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70656-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70656-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70656-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70656-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70657-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70657-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70657-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70657-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70657-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70658-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70658-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70658-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70658-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70658-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70659-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70659-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70659-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70659-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70659-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70660-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70660-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70660-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70660-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70660-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70663-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70663-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70663-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70663-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70663-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70668-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70668-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70668-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70668-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70668-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70669-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70669-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70669-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70669-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70669-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70670-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70670-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70670-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70670-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70670-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70677-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70677-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70677-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70677-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70677-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70678-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70678-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70678-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70678-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70678-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70679-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70679-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70679-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70679-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70679-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70680-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70680-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70680-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70680-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70680-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70681-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70681-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70681-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70681-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70681-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70682-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70682-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70682-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70682-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70682-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70683-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70683-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70683-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70683-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70683-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70684-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70684-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70684-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70684-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70684-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70685-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70685-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70685-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70685-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70685-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70687-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70687-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70687-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70687-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70687-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70689-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70689-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70689-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70689-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70689-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70694-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70694-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70694-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70694-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70694-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70695-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70695-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70695-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70695-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70695-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70696-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70696-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70696-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70696-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70696-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70697-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70697-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70697-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70697-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70697-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70698-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70698-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70698-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70698-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70698-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70699-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70699-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70699-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70699-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70699-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70700-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70700-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70700-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70700-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70700-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70701-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70701-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70701-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70701-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70701-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70702-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70702-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70702-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70702-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70702-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70703-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70703-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70703-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70703-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70703-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70704-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70704-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70704-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70704-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70704-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70705-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70705-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70705-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70705-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70705-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70706-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70706-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70706-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70706-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70706-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70707-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70707-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70707-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70707-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70707-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70708-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70708-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70708-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70708-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70708-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70709-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70709-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70709-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70709-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70709-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70711-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70711-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70711-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70711-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70711-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70713-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70713-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70713-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70713-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70713-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70714-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70714-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70714-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70714-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70714-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70716-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70716-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70716-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70716-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70716-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70717-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70717-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70717-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70717-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70717-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70718-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70718-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70718-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70718-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70718-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70719-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70719-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70719-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70719-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70719-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70720-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70720-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70720-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70720-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70720-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70721-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70721-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70721-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70721-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70721-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70722-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70722-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70722-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70722-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70722-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70723-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70723-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70723-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70723-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70723-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70724-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70724-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70724-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70724-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70724-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70725-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70725-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70725-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70725-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70725-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70727-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70727-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70727-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70727-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70727-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70728-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70728-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70728-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70728-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70728-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70729-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70729-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70729-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70729-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70729-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70730-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70730-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70730-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70730-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70730-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70731-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70731-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70731-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70731-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70731-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70732-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70732-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70732-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70732-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70732-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70733-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70733-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70733-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70733-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70733-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70734-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70734-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70734-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70734-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70734-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70737-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70737-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70737-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70737-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70737-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70738-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70738-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70738-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70738-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70738-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70741-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70741-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70741-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70741-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70741-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70742-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70742-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70742-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70742-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70742-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70743-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70743-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70743-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70743-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70743-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70744-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70744-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70744-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70744-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70744-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70747-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70747-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70747-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70747-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70747-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70748-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70748-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70748-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70748-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70748-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70749-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70749-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70749-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70749-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70749-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70750-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70750-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70750-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70750-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70750-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70751-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70751-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70751-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70751-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70751-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70752-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70752-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70752-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70752-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70752-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70753-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70753-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70753-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70753-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70753-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70754-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70754-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70754-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70754-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70754-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70755-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70755-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70755-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70755-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70755-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70756-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70756-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70756-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70756-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70756-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70757-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70757-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70757-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70757-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70757-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70758-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70758-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70758-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70758-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70758-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70760-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70760-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70760-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70760-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70760-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70761-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70761-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70761-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70761-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70761-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70762-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70762-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70762-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70762-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70762-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70763-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70763-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70763-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70763-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70763-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70764-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70764-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70764-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70764-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70764-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70765-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70765-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70765-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70765-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70765-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70766-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70766-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70766-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70766-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70766-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70767-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70767-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70767-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70767-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70767-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70768-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70768-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70768-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70768-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70768-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70769-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70769-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70769-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70769-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70769-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70770-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70770-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70770-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70770-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70770-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70771-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70771-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70771-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70771-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70771-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70772-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70772-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70772-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70772-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70772-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70773-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70773-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70773-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70773-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70773-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70775-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70775-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70775-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70775-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70775-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70776-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70776-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70776-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70776-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70776-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70777-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70777-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70777-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70777-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70777-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70778-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70778-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70778-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70778-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70778-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70779-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70779-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70779-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70779-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70779-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70780-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70780-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70780-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70780-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70780-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70781-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70781-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70781-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70781-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70781-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70782-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70782-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70782-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70782-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70782-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70783-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70783-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70783-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70783-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70783-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70784-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70784-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70784-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70784-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70784-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70786-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70786-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70786-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70786-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70786-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70787-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70787-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70787-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70787-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70787-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70788-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70788-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70788-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70788-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70788-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70789-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70789-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70789-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70789-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70789-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70790-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70790-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70790-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70790-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70790-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70791-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70791-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70791-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70791-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70791-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70792-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70792-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70792-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70792-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70792-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70793-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70793-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70793-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70793-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70793-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70794-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70794-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70794-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70794-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70794-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70796-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70796-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70796-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70796-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70796-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70797-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70797-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70797-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70797-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70797-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70798-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70798-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70798-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70798-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70798-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70799-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70799-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70799-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70799-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70799-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70801-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70801-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70801-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70801-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70801-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70802-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70802-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70802-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70802-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70802-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70803-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70803-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70803-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70803-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70803-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70804-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70804-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70804-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70804-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70804-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70805-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70805-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70805-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70805-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70805-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70806-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70806-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70806-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70806-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70806-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70808-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70808-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70808-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70808-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70808-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70809-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70809-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70809-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70809-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70809-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70810-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70810-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70810-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70810-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70810-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70811-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70811-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70811-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70811-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70811-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70812-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70812-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70812-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70812-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70812-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70813-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70813-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70813-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70813-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70813-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70814-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70814-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70814-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70814-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70814-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70815-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70815-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70815-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70815-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70815-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70817-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70817-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70817-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70817-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70817-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70818-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70818-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70818-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70818-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70818-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70819-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70819-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70819-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70819-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70819-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70820-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70820-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70820-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70820-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70820-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70821-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70821-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70821-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70821-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70821-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70822-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70822-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70822-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70822-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70822-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70823-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70823-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70823-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70823-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70823-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70825-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70825-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70825-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70825-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70825-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70826-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70826-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70826-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70826-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70826-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70827-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70827-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70827-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70827-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70827-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70828-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70828-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70828-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70828-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70828-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70829-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70829-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70829-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70829-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70829-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70830-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70830-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70830-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70830-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70830-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70832-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70832-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70832-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70832-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70832-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70833-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70833-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70833-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70833-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70833-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70834-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70834-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70834-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70834-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70834-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70835-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70835-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70835-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70835-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70835-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70836-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70836-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70836-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70836-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70836-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70838-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70838-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70838-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70838-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70838-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70839-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70839-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70839-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70839-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70839-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70840-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70840-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70840-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70840-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70840-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70841-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70841-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70841-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70841-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70841-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70842-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70842-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70842-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70842-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70842-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70843-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70843-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70843-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70843-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70843-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70845-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70845-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70845-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70845-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70845-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70846-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70846-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70846-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70846-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70846-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70847-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70847-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70847-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70847-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70847-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70848-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +70848-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +70848-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +70848-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +70848-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71009-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71009-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71009-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71009-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71009-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71010-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71010-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71010-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71010-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71010-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71011-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71011-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71011-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71011-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71011-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71012-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71012-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71012-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71012-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71012-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71013-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71013-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71013-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71013-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71013-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71014-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71014-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71014-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71014-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71014-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71015-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71015-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71015-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71015-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71015-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71016-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71016-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71016-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71016-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71016-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71017-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71017-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71017-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71017-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71017-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71018-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71018-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71018-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71018-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71018-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71019-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71019-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71019-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71019-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71019-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71020-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71020-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71020-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71020-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71020-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71021-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71021-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71021-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71021-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71021-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71022-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71022-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71022-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71022-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71022-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71024-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71024-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71024-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71024-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71024-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71025-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71025-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71025-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71025-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71025-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71026-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71026-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71026-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71026-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71026-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71027-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71027-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71027-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71027-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71027-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71028-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71028-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71028-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71028-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71028-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71029-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71029-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71029-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71029-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71029-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71030-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71030-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71030-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71030-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71030-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71031-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71031-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71031-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71031-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71031-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71032-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71032-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71032-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71032-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71032-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71033-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71033-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71033-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71033-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71033-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71034-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71034-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71034-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71034-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71034-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71036-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71036-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71036-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71036-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71036-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71037-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71037-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71037-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71037-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71037-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71038-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71038-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71038-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71038-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71038-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71039-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71039-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71039-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71039-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71039-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71040-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71040-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71040-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71040-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71040-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71041-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71041-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71041-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71041-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71041-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71042-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71042-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71042-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71042-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71042-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71043-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71043-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71043-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71043-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71043-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71044-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71044-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71044-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71044-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71044-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71045-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71045-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71045-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71045-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71045-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71048-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71048-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71048-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71048-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71048-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71049-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71049-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71049-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71049-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71049-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71050-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71050-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71050-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71050-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71050-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71051-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71051-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71051-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71051-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71051-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71052-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71052-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71052-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71052-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71052-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71053-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71053-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71053-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71053-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71053-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71054-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71054-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71054-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71054-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71054-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71109-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71109-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71109-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71109-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71109-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71110-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71110-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71110-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71110-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71110-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71111-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71111-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71111-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71111-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71111-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71113-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71113-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71113-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71113-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71113-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71114-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71114-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71114-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71114-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71114-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71115-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71115-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71115-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71115-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71115-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71117-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71117-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71117-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71117-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71117-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71119-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71119-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71119-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71119-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71119-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71120-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71120-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71120-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71120-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71120-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71122-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71122-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71122-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71122-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71122-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71123-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71123-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71123-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71123-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71123-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71134-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71134-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71134-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71134-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71134-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71135-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71135-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71135-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71135-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71135-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71136-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71136-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71136-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71136-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71136-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71137-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71137-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71137-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71137-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71137-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71138-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71138-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71138-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71138-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71138-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71139-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71139-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71139-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71139-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71139-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71140-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71140-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71140-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71140-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71140-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71152-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71152-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71152-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71152-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71152-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71153-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71153-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71153-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71153-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71153-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71154-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71154-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71154-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71154-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71154-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71155-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71155-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71155-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71155-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71155-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71156-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71156-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71156-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71156-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71156-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71157-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71157-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71157-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71157-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71157-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71158-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71158-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71158-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71158-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71158-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71159-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71159-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71159-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71159-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71159-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71160-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71160-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71160-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71160-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71160-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71161-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71161-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71161-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71161-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71161-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71162-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71162-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71162-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71162-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71162-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71163-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71163-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71163-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71163-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71163-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71164-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71164-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71164-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71164-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71164-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71165-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71165-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71165-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71165-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71165-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71166-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71166-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71166-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71166-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71166-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71167-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71167-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71167-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71167-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71167-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71168-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71168-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71168-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71168-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71168-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71169-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71169-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71169-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71169-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71169-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71170-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71170-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71170-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71170-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71170-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71171-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71171-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71171-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71171-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71171-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71172-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71172-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71172-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71172-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71172-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71173-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71173-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71173-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71173-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71173-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71174-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71174-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71174-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71174-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71174-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71175-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71175-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71175-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71175-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71175-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71176-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71176-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71176-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71176-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71176-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71177-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71177-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71177-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71177-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71177-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71178-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71178-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71178-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71178-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71178-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71179-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71179-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71179-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71179-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71179-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71180-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71180-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71180-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71180-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71180-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71181-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71181-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71181-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71181-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71181-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71182-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71182-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71182-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71182-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71182-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71183-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71183-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71183-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71183-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71183-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71184-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71184-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71184-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71184-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71184-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71185-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71185-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71185-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71185-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71185-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71186-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71186-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71186-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71186-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71186-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71187-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71187-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71187-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71187-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71187-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71188-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71188-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71188-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71188-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71188-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71189-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71189-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71189-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71189-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71189-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71191-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71191-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71191-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71191-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71191-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71192-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71192-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71192-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71192-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71192-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71193-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71193-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71193-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71193-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71193-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71194-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71194-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71194-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71194-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71194-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71195-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71195-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71195-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71195-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71195-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71196-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71196-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71196-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71196-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71196-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71197-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71197-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71197-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71197-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71197-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71198-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71198-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71198-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71198-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71198-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71199-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71199-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71199-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71199-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71199-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71200-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71200-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71200-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71200-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71200-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71201-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71201-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71201-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71201-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71201-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71202-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71202-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71202-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71202-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71202-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71203-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71203-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71203-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71203-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71203-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71204-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71204-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71204-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71204-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71204-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71205-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71205-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71205-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71205-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71205-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71206-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71206-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71206-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71206-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71206-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71207-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71207-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71207-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71207-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71207-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71208-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71208-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71208-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71208-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71208-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71209-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71209-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71209-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71209-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71209-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71210-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71210-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71210-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71210-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71210-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71211-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71211-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71211-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71211-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71211-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71212-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71212-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71212-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71212-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71212-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71213-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71213-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71213-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71213-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71213-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71214-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71214-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71214-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71214-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71214-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71215-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71215-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71215-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71215-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71215-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71219-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71219-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71219-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71219-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71219-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71220-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71220-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71220-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71220-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71220-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71221-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71221-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71221-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71221-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71221-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71222-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71222-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71222-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71222-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71222-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71223-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71223-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71223-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71223-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71223-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71224-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71224-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71224-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71224-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71224-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71225-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71225-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71225-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71225-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71225-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71231-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71231-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71231-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71231-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71231-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71232-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71232-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71232-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71232-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71232-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71233-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71233-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71233-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71233-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71233-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71236-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71236-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71236-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71236-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71236-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71237-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71237-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71237-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71237-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71237-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71238-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71238-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71238-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71238-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71238-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71239-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71239-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71239-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71239-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71239-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71240-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71240-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71240-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71240-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71240-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71241-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71241-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71241-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71241-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71241-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71242-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71242-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71242-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71242-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71242-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71243-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71243-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71243-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71243-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71243-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71244-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71244-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71244-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71244-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71244-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71245-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71245-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71245-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71245-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71245-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71246-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71246-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71246-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71246-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71246-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71247-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71247-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71247-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71247-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71247-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71248-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71248-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71248-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71248-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71248-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71249-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71249-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71249-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71249-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71249-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71250-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71250-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71250-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71250-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71250-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71252-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71252-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71252-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71252-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71252-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71253-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71253-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71253-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71253-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71253-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71254-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71254-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71254-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71254-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71254-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71255-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71255-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71255-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71255-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71255-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71256-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71256-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71256-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71256-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71256-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71257-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71257-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71257-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71257-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71257-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71258-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71258-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71258-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71258-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71258-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71260-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71260-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71260-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71260-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71260-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71261-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71261-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71261-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71261-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71261-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71262-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71262-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71262-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71262-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71262-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71263-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71263-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71263-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71263-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71263-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71265-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71265-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71265-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71265-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71265-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71266-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71266-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71266-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71266-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71266-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71267-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71267-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71267-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71267-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71267-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71268-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71268-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71268-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71268-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71268-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71269-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71269-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71269-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71269-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71269-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71270-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71270-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71270-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71270-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71270-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71271-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71271-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71271-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71271-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71271-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71272-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71272-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71272-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71272-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71272-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71273-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71273-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71273-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71273-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71273-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71276-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71276-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71276-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71276-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71276-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71277-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71277-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71277-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71277-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71277-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71278-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71278-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71278-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71278-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71278-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71279-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71279-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71279-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71279-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71279-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71280-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71280-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71280-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71280-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71280-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71281-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71281-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71281-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71281-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71281-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71282-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71282-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71282-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71282-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71282-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71283-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71283-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71283-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71283-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71283-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71284-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71284-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71284-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71284-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71284-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71285-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71285-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71285-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71285-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71285-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71286-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71286-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71286-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71286-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71286-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71287-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71287-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71287-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71287-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71287-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71288-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71288-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71288-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71288-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71288-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71289-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71289-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71289-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71289-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71289-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71290-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71290-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71290-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71290-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71290-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71291-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71291-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71291-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71291-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71291-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71292-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71292-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71292-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71292-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71292-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71293-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71293-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71293-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71293-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71293-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71294-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71294-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71294-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71294-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71294-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71295-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71295-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71295-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71295-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71295-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71296-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71296-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71296-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71296-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71296-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71297-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71297-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71297-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71297-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71297-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71298-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71298-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71298-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71298-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71298-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71299-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71299-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71299-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71299-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71299-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71300-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71300-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71300-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71300-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71300-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71301-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71301-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71301-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71301-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71301-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71302-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71302-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71302-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71302-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71302-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71303-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71303-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71303-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71303-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71303-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71304-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71304-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71304-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71304-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71304-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71305-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71305-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71305-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71305-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71305-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71306-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71306-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71306-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71306-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71306-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71307-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71307-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71307-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71307-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71307-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71308-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71308-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71308-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71308-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71308-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71309-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71309-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71309-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71309-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71309-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71310-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71310-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71310-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71310-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71310-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71311-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71311-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71311-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71311-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71311-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71312-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71312-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71312-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71312-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71312-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71313-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71313-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71313-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71313-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71313-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71314-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71314-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71314-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71314-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71314-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71323-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71323-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71323-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71323-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71323-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71324-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71324-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71324-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71324-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71324-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71325-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71325-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71325-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71325-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71325-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71326-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71326-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71326-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71326-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71326-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71327-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71327-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71327-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71327-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71327-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71328-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71328-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71328-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71328-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71328-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71329-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71329-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71329-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71329-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71329-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71330-5;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71330-5;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71330-5;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71330-5;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71330-5;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71331-3;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71331-3;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71331-3;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71331-3;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71331-3;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71332-1;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71332-1;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71332-1;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71332-1;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71332-1;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71333-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71333-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71333-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71333-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71333-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71334-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71334-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71334-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71334-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71334-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71335-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71335-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71335-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71335-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71335-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71336-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71336-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71336-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71336-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71336-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71337-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71337-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71337-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71337-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71337-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71338-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71338-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71338-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71338-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71338-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71379-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71379-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71379-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71379-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71379-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71380-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71380-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71380-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71380-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71380-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71381-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71381-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71381-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71381-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71381-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71382-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71382-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71382-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71382-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71382-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71383-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71383-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71383-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71383-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71383-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71384-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71384-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71384-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71384-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71384-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71385-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71385-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71385-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71385-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71385-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71435-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71435-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71435-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71435-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71435-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71436-0;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71436-0;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71436-0;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71436-0;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71436-0;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71437-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71437-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71437-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71437-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71437-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +71438-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +71438-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +71438-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +71438-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +71438-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +98521-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +98521-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +98521-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +98521-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +98521-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +98522-6;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +98522-6;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +98522-6;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +98522-6;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +98522-6;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +98523-4;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +98523-4;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +98523-4;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +98523-4;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +98523-4;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +98524-2;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +98524-2;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +98524-2;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +98524-2;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +98524-2;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +98525-9;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +98525-9;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +98525-9;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +98525-9;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +98525-9;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +98526-7;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +98526-7;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +98526-7;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +98526-7;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +98526-7;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +98535-8;LL5215-0;Not at all 0 | Very much 4;LA6568-5;1;Not at all;;; +98535-8;LL5215-0;Not at all 0 | Very much 4;LA13863-8;2;A little bit;;; +98535-8;LL5215-0;Not at all 0 | Very much 4;LA13909-9;3;Somewhat;;; +98535-8;LL5215-0;Not at all 0 | Very much 4;LA13902-4;4;Quite a bit;;; +98535-8;LL5215-0;Not at all 0 | Very much 4;LA13914-9;5;Very much;;; +70305-8;LL6128-4;Shortness of breath - affect normal activities;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +70305-8;LL6128-4;Shortness of breath - affect normal activities;LA32889-0;2;Yes, but did not affect my normal activities;;; +70305-8;LL6128-4;Shortness of breath - affect normal activities;LA32890-8;3;Yes, did affect my normal activities (e.g. walking short distances);;; +70305-8;LL6128-4;Shortness of breath - affect normal activities;LA32891-6;4;Yes, even when I was sat or lying down;;; +70746-3;LL2042-1;FACIT bone pain score (ord);LA6111-4;1;0;;; +70746-3;LL2042-1;FACIT bone pain score (ord);LA6112-2;2;1;;; +70746-3;LL2042-1;FACIT bone pain score (ord);LA6113-0;3;2;;; +70746-3;LL2042-1;FACIT bone pain score (ord);LA6114-8;4;3;;; +70746-3;LL2042-1;FACIT bone pain score (ord);LA11844-0;5;4+;;; +70866-9;LL2067-8;RABV strain;LA18506-8;1;California Skunk Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18507-6;2;North Central Skunk Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18508-4;3;South Central Skunk Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18509-2;4;Arizona Gray Fox Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18510-0;5;Texas Gray Fox Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18511-8;6;Arctic Fox Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18512-6;7;Raccoon Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18513-4;8;Mongoose Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18514-2;9;Canine Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18515-9;10;Bat (not specified) Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18516-7;11;Eptesicus fuscus Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18517-5;12;Lasionycteris noctivagans Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18518-3;13;Tadarida brasiliensis Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18519-1;14;Parastrellus hesperus Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18520-9;15;Perimyotis subflavus Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18521-7;16;Lasiurus cinereus Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18522-5;17;Lasiurus borealis Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18523-3;18;Lasiurus seminolus Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18524-1;19;Desmodus rotundus Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18525-8;20;Myotis sp. Rabies Virus variant;;; +70866-9;LL2067-8;RABV strain;LA18526-6;21;Antrozous pallidus Rabies Virus Variant;;; +70867-7;LL2067-8;RABV strain;LA18506-8;1;California Skunk Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18507-6;2;North Central Skunk Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18508-4;3;South Central Skunk Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18509-2;4;Arizona Gray Fox Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18510-0;5;Texas Gray Fox Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18511-8;6;Arctic Fox Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18512-6;7;Raccoon Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18513-4;8;Mongoose Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18514-2;9;Canine Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18515-9;10;Bat (not specified) Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18516-7;11;Eptesicus fuscus Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18517-5;12;Lasionycteris noctivagans Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18518-3;13;Tadarida brasiliensis Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18519-1;14;Parastrellus hesperus Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18520-9;15;Perimyotis subflavus Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18521-7;16;Lasiurus cinereus Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18522-5;17;Lasiurus borealis Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18523-3;18;Lasiurus seminolus Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18524-1;19;Desmodus rotundus Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18525-8;20;Myotis sp. Rabies Virus variant;;; +70867-7;LL2067-8;RABV strain;LA18526-6;21;Antrozous pallidus Rabies Virus Variant;;; +70953-5;LL2040-5;Body Surface Area Methods-DICOM;;0;;;; +70958-4;LL2102-3;ESRD - dialysis method;LA9975-9;1;Hemodialysis;;; +70958-4;LL2102-3;ESRD - dialysis method;LA10059-6;2;Peritoneal Dialysis;;; +70958-4;LL2102-3;ESRD - dialysis method;LA18616-5;3;Equivalent renal clearance (ERK);;; +70958-4;LL2102-3;ESRD - dialysis method;LA18617-3;4;Kt/V (peritoneal dialysis adequacy index);;; +70971-7;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70971-7;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70971-7;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70971-7;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70971-7;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70972-5;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70972-5;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70972-5;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70972-5;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70972-5;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70973-3;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70973-3;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70973-3;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70973-3;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70973-3;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70974-1;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70974-1;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70974-1;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70974-1;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70974-1;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70975-8;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70975-8;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70975-8;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70975-8;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70975-8;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70976-6;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70976-6;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70976-6;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70976-6;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70976-6;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70977-4;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70977-4;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70977-4;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70977-4;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70977-4;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70978-2;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70978-2;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70978-2;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70978-2;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70978-2;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70979-0;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70979-0;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70979-0;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70979-0;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70979-0;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70980-8;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70980-8;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70980-8;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70980-8;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70980-8;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70984-0;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70984-0;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70984-0;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70984-0;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70984-0;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70985-7;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70985-7;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70985-7;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70985-7;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70985-7;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70986-5;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70986-5;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70986-5;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70986-5;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70986-5;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70987-3;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70987-3;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70987-3;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70987-3;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70987-3;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70988-1;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70988-1;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70988-1;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70988-1;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70988-1;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70989-9;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70989-9;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70989-9;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70989-9;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70989-9;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70990-7;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70990-7;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70990-7;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70990-7;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70990-7;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70991-5;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70991-5;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70991-5;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70991-5;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70991-5;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70992-3;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70992-3;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70992-3;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70992-3;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70992-3;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70993-1;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70993-1;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70993-1;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70993-1;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70993-1;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70994-9;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70994-9;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70994-9;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70994-9;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70994-9;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70995-6;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70995-6;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70995-6;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70995-6;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70995-6;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70996-4;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70996-4;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70996-4;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70996-4;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70996-4;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70997-2;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70997-2;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70997-2;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70997-2;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70997-2;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70998-0;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70998-0;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70998-0;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70998-0;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70998-0;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70999-8;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +70999-8;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +70999-8;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +70999-8;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +70999-8;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +71000-4;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +71000-4;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +71000-4;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +71000-4;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +71000-4;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +71001-2;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +71001-2;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +71001-2;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +71001-2;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +71001-2;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +71002-0;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +71002-0;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +71002-0;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +71002-0;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +71002-0;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +71003-8;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +71003-8;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +71003-8;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +71003-8;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +71003-8;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +71004-6;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +71004-6;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +71004-6;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +71004-6;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +71004-6;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +71005-3;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +71005-3;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +71005-3;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +71005-3;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +71005-3;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +71006-1;LL3980-1;Shortness of breath;LA26121-6;1;No shortness of breath;;; +71006-1;LL3980-1;Shortness of breath;LA26122-4;2;Mildly short of breath;;; +71006-1;LL3980-1;Shortness of breath;LA26123-2;3;Moderately short of breath;;; +71006-1;LL3980-1;Shortness of breath;LA26124-0;4;Severely short of breath;;; +71006-1;LL3980-1;Shortness of breath;LA26125-7;5;I did not do this in the past 7 days;;; +70981-6;LL2075-1;FACIT-dyspnea -reason activity not done;LA18538-1;1;I have stopped trying, or knew I could not do this activity because of my shortness of breath;;; +70981-6;LL2075-1;FACIT-dyspnea -reason activity not done;LA18539-9;2;I did not do this activity for some other reason (including not having a chance to do it, other health issues, etc.;;; +71056-6;LL2071-0;FACIT-TS-G - treatment expectations;LA18530-8;1;A lot worse;;; +71056-6;LL2071-0;FACIT-TS-G - treatment expectations;LA18342-8;2;A little worse;;; +71056-6;LL2071-0;FACIT-TS-G - treatment expectations;LA18129-9;3;About the same;;; +71056-6;LL2071-0;FACIT-TS-G - treatment expectations;LA18349-3;4;A little better;;; +71056-6;LL2071-0;FACIT-TS-G - treatment expectations;LA18531-6;5;A lot better;;; +71057-4;LL2071-0;FACIT-TS-G - treatment expectations;LA18530-8;1;A lot worse;;; +71057-4;LL2071-0;FACIT-TS-G - treatment expectations;LA18342-8;2;A little worse;;; +71057-4;LL2071-0;FACIT-TS-G - treatment expectations;LA18129-9;3;About the same;;; +71057-4;LL2071-0;FACIT-TS-G - treatment expectations;LA18349-3;4;A little better;;; +71057-4;LL2071-0;FACIT-TS-G - treatment expectations;LA18531-6;5;A lot better;;; +71058-2;LL2072-8;FACIT-TS-G-treatment effects;LA18387-3;1;No, not at all;;; +71058-2;LL2072-8;FACIT-TS-G-treatment effects;LA18532-4;2;Yes, to some extent;;; +71058-2;LL2072-8;FACIT-TS-G-treatment effects;LA18533-2;3;Yes, for the most part;;; +71058-2;LL2072-8;FACIT-TS-G-treatment effects;LA18534-0;4;Yes, completely;;; +71059-0;LL2072-8;FACIT-TS-G-treatment effects;LA18387-3;1;No, not at all;;; +71059-0;LL2072-8;FACIT-TS-G-treatment effects;LA18532-4;2;Yes, to some extent;;; +71059-0;LL2072-8;FACIT-TS-G-treatment effects;LA18533-2;3;Yes, for the most part;;; +71059-0;LL2072-8;FACIT-TS-G-treatment effects;LA18534-0;4;Yes, completely;;; +71060-8;LL2072-8;FACIT-TS-G-treatment effects;LA18387-3;1;No, not at all;;; +71060-8;LL2072-8;FACIT-TS-G-treatment effects;LA18532-4;2;Yes, to some extent;;; +71060-8;LL2072-8;FACIT-TS-G-treatment effects;LA18533-2;3;Yes, for the most part;;; +71060-8;LL2072-8;FACIT-TS-G-treatment effects;LA18534-0;4;Yes, completely;;; +71061-6;LL2070-2;FACIT-TS-G- treatment choice;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71061-6;LL2070-2;FACIT-TS-G- treatment choice;LA12696-3;2;Maybe;;; +71061-6;LL2070-2;FACIT-TS-G- treatment choice;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71062-4;LL2070-2;FACIT-TS-G- treatment choice;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71062-4;LL2070-2;FACIT-TS-G- treatment choice;LA12696-3;2;Maybe;;; +71062-4;LL2070-2;FACIT-TS-G- treatment choice;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71104-4;LL2070-2;FACIT-TS-G- treatment choice;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71104-4;LL2070-2;FACIT-TS-G- treatment choice;LA12696-3;2;Maybe;;; +71104-4;LL2070-2;FACIT-TS-G- treatment choice;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71105-1;LL2070-2;FACIT-TS-G- treatment choice;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71105-1;LL2070-2;FACIT-TS-G- treatment choice;LA12696-3;2;Maybe;;; +71105-1;LL2070-2;FACIT-TS-G- treatment choice;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71062-4;LL6192-0;Have or not have procedure again;LA33201-7;1;Yes, I would decide to have it again, because of my result;;; +71062-4;LL6192-0;Have or not have procedure again;LA33202-5;2;Yes, I would decide to have it again, despite my result;;; +71062-4;LL6192-0;Have or not have procedure again;LA33203-3;3;No, I would not decide to have it again, because of my result;;; +71062-4;LL6192-0;Have or not have procedure again;LA33204-1;4;No, I would not decide to have it again, despite my result;;; +71063-2;LL2073-6;FACIT-TS-G-treatment rating;LA8969-3;1;Poor;;; +71063-2;LL2073-6;FACIT-TS-G-treatment rating;LA8968-5;2;Fair;;; +71063-2;LL2073-6;FACIT-TS-G-treatment rating;LA8967-7;3;Good;;; +71063-2;LL2073-6;FACIT-TS-G-treatment rating;LA13913-1;4;Very Good;;; +71063-2;LL2073-6;FACIT-TS-G-treatment rating;LA9206-9;5;Excellent;;; +71106-9;LL2073-6;FACIT-TS-G-treatment rating;LA8969-3;1;Poor;;; +71106-9;LL2073-6;FACIT-TS-G-treatment rating;LA8968-5;2;Fair;;; +71106-9;LL2073-6;FACIT-TS-G-treatment rating;LA8967-7;3;Good;;; +71106-9;LL2073-6;FACIT-TS-G-treatment rating;LA13913-1;4;Very Good;;; +71106-9;LL2073-6;FACIT-TS-G-treatment rating;LA9206-9;5;Excellent;;; +71066-5;LL2074-4;FACIT-TS-G-visit rated;LA18535-7;1;My most recent visit;;; +71066-5;LL2074-4;FACIT-TS-G-visit rated;LA18536-5;2;Several of my most recent visits;;; +71066-5;LL2074-4;FACIT-TS-G-visit rated;LA18537-3;3;My experience in general;;; +71068-1;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71068-1;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71068-1;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71068-1;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71069-9;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71069-9;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71069-9;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71069-9;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71070-7;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71070-7;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71070-7;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71070-7;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71071-5;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71071-5;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71071-5;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71071-5;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71073-1;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71073-1;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71073-1;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71073-1;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71074-9;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71074-9;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71074-9;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71074-9;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71075-6;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71075-6;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71075-6;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71075-6;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71077-2;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71077-2;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71077-2;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71077-2;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71078-0;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71078-0;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71078-0;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71078-0;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71079-8;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71079-8;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71079-8;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71079-8;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71080-6;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71080-6;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71080-6;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71080-6;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71081-4;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71081-4;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71081-4;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71081-4;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71082-2;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71082-2;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71082-2;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71082-2;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71083-0;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71083-0;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71083-0;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71083-0;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71085-5;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71085-5;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71085-5;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71085-5;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71086-3;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71086-3;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71086-3;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71086-3;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71087-1;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71087-1;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71087-1;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71087-1;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71089-7;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71089-7;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71089-7;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71089-7;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71090-5;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71090-5;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71090-5;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71090-5;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71091-3;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71091-3;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71091-3;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71091-3;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71092-1;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71092-1;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71092-1;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71092-1;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71093-9;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71093-9;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71093-9;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71093-9;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71095-4;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71095-4;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71095-4;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71095-4;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71096-2;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71096-2;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71096-2;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71096-2;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71097-0;LL2087-6;FACIT-TS-PS-explanatons;LA18387-3;1;No, not at all;;; +71097-0;LL2087-6;FACIT-TS-PS-explanatons;LA18540-7;2;Yes, but not as much as I wanted;;; +71097-0;LL2087-6;FACIT-TS-PS-explanatons;LA18541-5;3;Yes, almost as much as I wanted;;; +71097-0;LL2087-6;FACIT-TS-PS-explanatons;LA18542-3;4;Yes, as much as I wanted;;; +71099-6;LL2088-4;FACIT-TS-PS-trust;LA18387-3;1;No, not at all;;; +71099-6;LL2088-4;FACIT-TS-PS-trust;LA18532-4;2;Yes, to some extent;;; +71099-6;LL2088-4;FACIT-TS-PS-trust;LA18533-2;3;Yes, for the most part;;; +71099-6;LL2088-4;FACIT-TS-PS-trust;LA18534-0;4;Yes, completely;;; +71100-2;LL2088-4;FACIT-TS-PS-trust;LA18387-3;1;No, not at all;;; +71100-2;LL2088-4;FACIT-TS-PS-trust;LA18532-4;2;Yes, to some extent;;; +71100-2;LL2088-4;FACIT-TS-PS-trust;LA18533-2;3;Yes, for the most part;;; +71100-2;LL2088-4;FACIT-TS-PS-trust;LA18534-0;4;Yes, completely;;; +71101-0;LL2088-4;FACIT-TS-PS-trust;LA18387-3;1;No, not at all;;; +71101-0;LL2088-4;FACIT-TS-PS-trust;LA18532-4;2;Yes, to some extent;;; +71101-0;LL2088-4;FACIT-TS-PS-trust;LA18533-2;3;Yes, for the most part;;; +71101-0;LL2088-4;FACIT-TS-PS-trust;LA18534-0;4;Yes, completely;;; +71102-8;LL2088-4;FACIT-TS-PS-trust;LA18387-3;1;No, not at all;;; +71102-8;LL2088-4;FACIT-TS-PS-trust;LA18532-4;2;Yes, to some extent;;; +71102-8;LL2088-4;FACIT-TS-PS-trust;LA18533-2;3;Yes, for the most part;;; +71102-8;LL2088-4;FACIT-TS-PS-trust;LA18534-0;4;Yes, completely;;; +71344-6;LL2076-9;Edinburgh Postnatal Depression-1;LA18376-6;1;As much as I always could;;; +71344-6;LL2076-9;Edinburgh Postnatal Depression-1;LA18377-4;2;Not quite so much now;;; +71344-6;LL2076-9;Edinburgh Postnatal Depression-1;LA18378-2;3;Definitely not so much now;;; +71344-6;LL2076-9;Edinburgh Postnatal Depression-1;LA6568-5;4;Not at all;;; +71345-3;LL2077-7;Edinburgh Postnatal Depression-2;LA18379-0;1;As much as I ever could;;; +71345-3;LL2077-7;Edinburgh Postnatal Depression-2;LA18380-8;2;Rather less than I used to;;; +71345-3;LL2077-7;Edinburgh Postnatal Depression-2;LA18381-6;3;Definitely less than I used to;;; +71345-3;LL2077-7;Edinburgh Postnatal Depression-2;LA18382-4;4;Hardly at all;;; +71346-1;LL2078-5;Edinburgh Postnatal Depression-3;LA18383-2;1;Yes, most of the time;;; +71346-1;LL2078-5;Edinburgh Postnatal Depression-3;LA18384-0;2;Yes, some of the time;;; +71346-1;LL2078-5;Edinburgh Postnatal Depression-3;LA18385-7;3;Not very often;;; +71346-1;LL2078-5;Edinburgh Postnatal Depression-3;LA18386-5;4;No, never;;; +71347-9;LL2079-3;Edinburgh Postnatal Depression-4;LA18387-3;1;No, not at all;;; +71347-9;LL2079-3;Edinburgh Postnatal Depression-4;LA14751-4;2;Hardly ever;;; +71347-9;LL2079-3;Edinburgh Postnatal Depression-4;LA18388-1;3;Yes, sometimes;;; +71347-9;LL2079-3;Edinburgh Postnatal Depression-4;LA18389-9;4;Yes, very often;;; +71348-7;LL2080-1;Edinburgh Postnatal Depression-5;LA18390-7;1;Yes, quite a lot;;; +71348-7;LL2080-1;Edinburgh Postnatal Depression-5;LA18388-1;2;Yes, sometimes;;; +71348-7;LL2080-1;Edinburgh Postnatal Depression-5;LA18391-5;3;No, not much;;; +71348-7;LL2080-1;Edinburgh Postnatal Depression-5;LA18387-3;4;No, not at all;;; +71349-5;LL2081-9;Edinburgh Postnatal Depression-6;LA18392-3;1;Yes, most of the time I haven't been able to cope at all;;; +71349-5;LL2081-9;Edinburgh Postnatal Depression-6;LA18393-1;2;Yes, sometimes I haven't been coping as well as usual;;; +71349-5;LL2081-9;Edinburgh Postnatal Depression-6;LA18394-9;3;No, most of the time I have coped quite well;;; +71349-5;LL2081-9;Edinburgh Postnatal Depression-6;LA18395-6;4;No, have been coping as well as ever;;; +71350-3;LL2082-7;Edinburgh Postnatal Depression-7;LA18383-2;1;Yes, most of the time;;; +71350-3;LL2082-7;Edinburgh Postnatal Depression-7;LA18388-1;2;Yes, sometimes;;; +71350-3;LL2082-7;Edinburgh Postnatal Depression-7;LA18385-7;3;Not very often;;; +71350-3;LL2082-7;Edinburgh Postnatal Depression-7;LA18387-3;4;No, not at all;;; +71351-1;LL2083-5;Edinburgh Postnatal Depression-8;LA18383-2;1;Yes, most of the time;;; +71351-1;LL2083-5;Edinburgh Postnatal Depression-8;LA18396-4;2;Yes, quite often;;; +71351-1;LL2083-5;Edinburgh Postnatal Depression-8;LA18385-7;3;Not very often;;; +71351-1;LL2083-5;Edinburgh Postnatal Depression-8;LA18387-3;4;No, not at all;;; +71352-9;LL2084-3;Edinburgh Postnatal Depression-9;LA18383-2;1;Yes, most of the time;;; +71352-9;LL2084-3;Edinburgh Postnatal Depression-9;LA18396-4;2;Yes, quite often;;; +71352-9;LL2084-3;Edinburgh Postnatal Depression-9;LA18397-2;3;Only occasionally;;; +71352-9;LL2084-3;Edinburgh Postnatal Depression-9;LA18386-5;4;No, never;;; +71353-7;LL2085-0;Edinburgh Postnatal Depression-10;LA18396-4;1;Yes, quite often;;; +71353-7;LL2085-0;Edinburgh Postnatal Depression-10;LA10082-8;2;Sometimes;;; +71353-7;LL2085-0;Edinburgh Postnatal Depression-10;LA14751-4;3;Hardly ever;;; +71353-7;LL2085-0;Edinburgh Postnatal Depression-10;LA6270-8;4;Never;;; +71440-2;LL2097-5;MDSv3-A0310G-Type of Discharge;LA18067-1;1;Planned discharge;;; +71440-2;LL2097-5;MDSv3-A0310G-Type of Discharge;LA18068-9;2;Unplanned discharge;;; +71440-2;LL2097-5;MDSv3-A0310G-Type of Discharge;LA18067-1;1;Planned discharge;;; +71440-2;LL2097-5;MDSv3-A0310G-Type of Discharge;LA18068-9;2;Unplanned discharge;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA20099-0;1;Planned;;; +71440-2;LL4619-4;MDSv3-A0310G-Type of Discharge Subset 2;LA28017-4;2;Unplanned;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18599-3;1;Serious mental illness;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18600-9;2;"Intellectual disability (""mental retardation"" in federal regulation)";;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18601-7;3;Other related conditions;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18599-3;1;Serious mental illness;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18600-9;2;"Intellectual disability (""mental retardation"" in federal regulation)";;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18601-7;3;Other related conditions;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18599-3;1;Serious mental illness;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18600-9;2;"Intellectual disability (""mental retardation"" in federal regulation)";;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18601-7;3;Other related conditions;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18599-3;1;Serious mental illness;;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18600-9;2;"Intellectual disability (""mental retardation"" in federal regulation)";;; +71441-0;LL2098-3;MDS-A1510-Level II PASRR;LA18601-7;3;Other related conditions;;; +71441-0;LL5153-3;CMS_MDS v17 A0300B;LA18599-3;1;Serious mental illness;;; +71441-0;LL5153-3;CMS_MDS v17 A0300B;LA29576-8;2;Intellectual disability;;; +71441-0;LL5153-3;CMS_MDS v17 A0300B;LA18601-7;3;Other related conditions;;; +71441-0;LL5153-3;CMS_MDS v17 A0300B;LA18599-3;1;Serious mental illness;;; +71441-0;LL5153-3;CMS_MDS v17 A0300B;LA29576-8;2;Intellectual disability;;; +71441-0;LL5153-3;CMS_MDS v17 A0300B;LA18601-7;3;Other related conditions;;; +71442-8;LL2099-1;MDSv3-K0310-Weight gain;LA11074-4;1;No or unknown;;; +71442-8;LL2099-1;MDSv3-K0310-Weight gain;LA11075-1;2;Yes, on physician-prescribed weight-loss regimen;;; +71442-8;LL2099-1;MDSv3-K0310-Weight gain;LA18603-3;3;Yes, not on physician-prescribed weight-gain regimen;;; +71443-6;LL2952-1;MDSv3_Q0490-Y/N/Info not available;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +71443-6;LL2952-1;MDSv3_Q0490-Y/N/Info not available;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +71443-6;LL2952-1;MDSv3_Q0490-Y/N/Info not available;LA21297-9;3;Information not available;;; +86797-8;LL2952-1;MDSv3_Q0490-Y/N/Info not available;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +86797-8;LL2952-1;MDSv3_Q0490-Y/N/Info not available;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86797-8;LL2952-1;MDSv3_Q0490-Y/N/Info not available;LA21297-9;3;Information not available;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71444-4;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA18607-4;4;Therapeutic diet (e.g. low salt, diabetic, low cholesterol);;; +71445-1;LL2100-7;MDSv3-K1510-Nutritional approaches;LA9-3;5;None of the above;;; +71444-4;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL4600-4;MDSv3-K1510-Nutritional approaches subset 1;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71444-4;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71445-1;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL5182-2;MDS v1.17.1 K1510 Nutritional approaches;LA9-3;3;None of the above;;; +71445-1;LL5228-3;MDS v1.17.1 K0510 Nutritional approaches;LA18604-1;1;Parenteral/IV feeding;;; +71445-1;LL5228-3;MDS v1.17.1 K0510 Nutritional approaches;LA18605-8;2;Feeding tube - nasogastric or abdominal (PEG);;; +71445-1;LL5228-3;MDS v1.17.1 K0510 Nutritional approaches;LA18606-6;3;Mechanically altered diet - require change in texture of food or liquids (e.g., pureed food, thickened liquids);;; +71445-1;LL5228-3;MDS v1.17.1 K0510 Nutritional approaches;LA9-3;4;None of the above;;; +71467-5;LL2104-9;ESRD-Erythropoiesis-Stimulating Agent;LA18620-7;1;Epoetin Alfa;;; +71467-5;LL2104-9;ESRD-Erythropoiesis-Stimulating Agent;LA18621-5;2;Epoetin Beta;;; +71467-5;LL2104-9;ESRD-Erythropoiesis-Stimulating Agent;LA18622-3;3;Darbepoetin Alfa;;; +71467-5;LL2104-9;ESRD-Erythropoiesis-Stimulating Agent;LA46-8;4;Other;;; +71473-3;LL2106-4;ESRD-RQMT_1266-dialysis infection site;LA18624-9;1;Hemodialysis - temporary, uncuffed catheter;;; +71473-3;LL2106-4;ESRD-RQMT_1266-dialysis infection site;LA18625-6;2;Hemodialysis - arteriovenous fistula;;; +71473-3;LL2106-4;ESRD-RQMT_1266-dialysis infection site;LA18626-4;3;Hemodialysis - tunneled catheter;;; +71473-3;LL2106-4;ESRD-RQMT_1266-dialysis infection site;LA18627-2;4;Hemodialysis - arteriovenous graft;;; +71473-3;LL2106-4;ESRD-RQMT_1266-dialysis infection site;LA18628-0;5;Peritoneal dialysis - catheter;;; +71480-8;LL1910-0;FMQAI_17_Place of death;LA6218-7;1;Hospital;;; +71480-8;LL1910-0;FMQAI_17_Place of death;LA10287-3;2;Dialysis unit;;; +71480-8;LL1910-0;FMQAI_17_Place of death;LA14084-0;3;Home;;; +71480-8;LL1910-0;FMQAI_17_Place of death;LA27-8;4;Nursing Home;;; +71480-8;LL1910-0;FMQAI_17_Place of death;LA46-8;5;Other;;; +71486-5;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18649-6;1;Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles;;; +71486-5;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18650-4;2;Documented, progressive thinning of the neuroretinal rim with an associated increase in cupping of the optic disc;;; +71486-5;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18651-2;3;Diffuse or localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles;;; +71486-5;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18652-0;4;Optic disc rim or peripapillary retinal nerve fiber layer hemorrhages;;; +71486-5;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18653-8;5;Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue;;; +71487-3;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18649-6;1;Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles;;; +71487-3;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18650-4;2;Documented, progressive thinning of the neuroretinal rim with an associated increase in cupping of the optic disc;;; +71487-3;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18651-2;3;Diffuse or localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles;;; +71487-3;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18652-0;4;Optic disc rim or peripapillary retinal nerve fiber layer hemorrhages;;; +71487-3;LL2118-9;Eye.PX-optic disc-retinal nerve abnormalities;LA18653-8;5;Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue;;; +71490-7;LL2117-1;Eye.PX-diabetic retinopathy;LA18643-9;1;No apparent retinopathy;;; +71490-7;LL2117-1;Eye.PX-diabetic retinopathy;LA18644-7;2;Mild non-proliferative retinopathy;;; +71490-7;LL2117-1;Eye.PX-diabetic retinopathy;LA18645-4;3;Moderate non-proliferative retinopathy;;; +71490-7;LL2117-1;Eye.PX-diabetic retinopathy;LA18646-2;4;Severe non-proliferative retinopathy;;; +71490-7;LL2117-1;Eye.PX-diabetic retinopathy;LA18648-8;5;Proliferative retinopathy;;; +71491-5;LL2117-1;Eye.PX-diabetic retinopathy;LA18643-9;1;No apparent retinopathy;;; +71491-5;LL2117-1;Eye.PX-diabetic retinopathy;LA18644-7;2;Mild non-proliferative retinopathy;;; +71491-5;LL2117-1;Eye.PX-diabetic retinopathy;LA18645-4;3;Moderate non-proliferative retinopathy;;; +71491-5;LL2117-1;Eye.PX-diabetic retinopathy;LA18646-2;4;Severe non-proliferative retinopathy;;; +71491-5;LL2117-1;Eye.PX-diabetic retinopathy;LA18648-8;5;Proliferative retinopathy;;; +71498-0;LL2138-7;ESRD - facility-owner or manager;LA18640-5;1;DaVita Dialysis Clinic, Inc;;; +71498-0;LL2138-7;ESRD - facility-owner or manager;LA18641-3;2;Fresenius Medical Care;;; +71499-8;LL2138-7;ESRD - facility-owner or manager;LA18640-5;1;DaVita Dialysis Clinic, Inc;;; +71499-8;LL2138-7;ESRD - facility-owner or manager;LA18641-3;2;Fresenius Medical Care;;; +71500-3;LL2135-3;ESRD-program type;LA17844-4;1;Transplant;;; +71500-3;LL2135-3;ESRD-program type;LA7216-0;2;Dialysis;;; +71501-1;LL2110-6;ESRD-open-closed status;LA9227-5;1;Open;;; +71501-1;LL2110-6;ESRD-open-closed status;LA9228-3;2;Closed;;; +71502-9;LL2112-2;ESRD - profit status;LA16385-9;1;Profit;;; +71502-9;LL2112-2;ESRD - profit status;LA18639-7;2;Not for profit;;; +71512-8;LL2111-4;ESRD - services offered;LA9975-9;1;Hemodialysis;;; +71512-8;LL2111-4;ESRD - services offered;LA10059-6;2;Peritoneal Dialysis;;; +71512-8;LL2111-4;ESRD - services offered;LA18638-9;3;Transplantation;;; +71512-8;LL2111-4;ESRD - services offered;LA18634-8;4;Home training - hemodialysis;;; +71512-8;LL2111-4;ESRD - services offered;LA18635-5;5;Home training - peritoneal dialysis;;; +71512-8;LL2111-4;ESRD - services offered;LA18637-1;6;Home support - hemodialysis;;; +71512-8;LL2111-4;ESRD - services offered;LA18636-3;7;Home support - peritoneal dialysis;;; +71513-6;LL2111-4;ESRD - services offered;LA9975-9;1;Hemodialysis;;; +71513-6;LL2111-4;ESRD - services offered;LA10059-6;2;Peritoneal Dialysis;;; +71513-6;LL2111-4;ESRD - services offered;LA18638-9;3;Transplantation;;; +71513-6;LL2111-4;ESRD - services offered;LA18634-8;4;Home training - hemodialysis;;; +71513-6;LL2111-4;ESRD - services offered;LA18635-5;5;Home training - peritoneal dialysis;;; +71513-6;LL2111-4;ESRD - services offered;LA18637-1;6;Home support - hemodialysis;;; +71513-6;LL2111-4;ESRD - services offered;LA18636-3;7;Home support - peritoneal dialysis;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18819-5;1;Pending certification;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA15652-3;2;Medicare;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18820-3;3;Prison;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18821-1;4;Acute;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18822-9;5;DME supplier;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA15280-3;6;Military;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18823-7;7;Special purpose;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18824-5;8;Air Force;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18825-2;9;Army;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18826-0;10;Navy;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA46-8;11;Other;;; +71522-7;LL2142-9;ESRD-facilities-certified program;LA18827-8;12;VA;;; +71524-3;LL2113-0;ESRD - partial owners;LA18640-5;1;DaVita Dialysis Clinic, Inc;;; +71524-3;LL2113-0;ESRD - partial owners;LA18641-3;2;Fresenius Medical Care;;; +71524-3;LL2113-0;ESRD - partial owners;LA18642-1;3;National Renal Administrators Association-NRAA;;; +71536-7;LL2116-3;ESRD - information source;LA18647-0;1;Electronic database;;; +71536-7;LL2116-3;ESRD - information source;LA4634-7;2;Patient;;; +71536-7;LL2116-3;ESRD - information source;LA46-8;3;Other;;; +71539-1;LL2109-8;ESRD - record status;LA16666-2;1;Active;;; +71539-1;LL2109-8;ESRD - record status;LA18632-2;2;Inactive;;; +71541-7;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71541-7;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71541-7;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71541-7;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71541-7;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71542-5;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71542-5;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71542-5;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71542-5;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71542-5;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71543-3;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71543-3;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71543-3;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71543-3;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71543-3;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71544-1;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71544-1;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71544-1;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71544-1;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71544-1;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71545-8;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71545-8;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71545-8;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71545-8;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71545-8;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71546-6;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71546-6;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71546-6;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71546-6;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71546-6;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71547-4;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71547-4;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71547-4;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71547-4;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71547-4;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71548-2;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71548-2;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71548-2;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71548-2;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71548-2;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71549-0;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71549-0;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71549-0;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71549-0;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71549-0;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71550-8;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71550-8;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71550-8;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71550-8;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71550-8;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71551-6;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71551-6;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71551-6;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71551-6;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71551-6;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71552-4;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71552-4;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71552-4;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71552-4;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71552-4;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71553-2;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71553-2;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71553-2;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71553-2;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71553-2;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71554-0;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71554-0;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71554-0;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71554-0;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71554-0;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71555-7;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71555-7;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71555-7;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71555-7;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71555-7;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71556-5;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71556-5;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71556-5;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71556-5;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71556-5;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71557-3;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71557-3;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71557-3;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71557-3;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71557-3;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71558-1;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71558-1;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71558-1;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71558-1;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71558-1;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71559-9;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71559-9;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71559-9;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71559-9;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71559-9;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71560-7;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71560-7;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71560-7;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71560-7;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71560-7;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71561-5;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71561-5;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71561-5;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71561-5;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71561-5;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71562-3;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71562-3;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71562-3;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71562-3;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71562-3;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71563-1;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71563-1;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71563-1;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71563-1;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71563-1;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71564-9;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71564-9;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71564-9;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71564-9;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71564-9;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71565-6;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71565-6;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71565-6;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71565-6;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71565-6;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71566-4;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71566-4;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71566-4;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71566-4;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71566-4;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71567-2;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71567-2;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71567-2;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71567-2;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71567-2;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71568-0;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71568-0;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71568-0;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71568-0;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71568-0;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71572-2;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71572-2;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71572-2;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71572-2;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71572-2;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71806-4;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71806-4;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71806-4;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71806-4;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71806-4;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71807-2;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71807-2;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71807-2;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71807-2;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71807-2;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71808-0;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71808-0;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71808-0;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71808-0;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71808-0;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71809-8;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71809-8;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71809-8;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71809-8;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71809-8;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71810-6;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71810-6;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71810-6;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71810-6;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71810-6;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71811-4;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71811-4;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71811-4;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71811-4;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71811-4;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71812-2;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71812-2;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71812-2;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71812-2;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71812-2;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71813-0;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71813-0;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71813-0;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71813-0;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71813-0;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71814-8;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71814-8;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71814-8;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71814-8;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71814-8;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71815-5;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71815-5;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71815-5;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71815-5;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71815-5;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71816-3;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71816-3;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71816-3;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71816-3;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71816-3;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71817-1;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71817-1;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71817-1;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71817-1;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71817-1;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71818-9;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71818-9;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71818-9;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71818-9;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71818-9;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71819-7;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71819-7;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71819-7;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71819-7;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71819-7;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71820-5;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71820-5;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71820-5;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71820-5;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71820-5;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71821-3;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71821-3;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71821-3;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71821-3;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71821-3;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71822-1;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71822-1;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71822-1;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71822-1;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71822-1;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71823-9;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71823-9;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71823-9;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71823-9;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71823-9;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71824-7;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71824-7;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71824-7;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71824-7;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71824-7;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71825-4;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71825-4;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71825-4;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71825-4;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71825-4;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71826-2;LL2115-5;M3-All answers;LA6568-5;1;Not at all;;; +71826-2;LL2115-5;M3-All answers;LA10066-1;2;Rarely;;; +71826-2;LL2115-5;M3-All answers;LA10082-8;3;Sometimes;;; +71826-2;LL2115-5;M3-All answers;LA10044-8;4;Often;;; +71826-2;LL2115-5;M3-All answers;LA14734-0;5;Most of the time;;; +71573-0;LL2119-7;NEMSIS-medication authorization;LA17187-8;1;On-line medical direction;;; +71573-0;LL2119-7;NEMSIS-medication authorization;LA18654-6;2;On-scene;;; +71573-0;LL2119-7;NEMSIS-medication authorization;LA18655-3;3;Protocol (standing order);;; +71573-0;LL2119-7;NEMSIS-medication authorization;LA18656-1;4;Written orders (patient specific);;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18657-9;1;Cricothyrotomy tube;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18658-7;2;Endotrachial tube;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18659-5;3;Other invasive airway;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18660-3;4;Supraglottic airway device-combitube;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18661-1;5;Supraglottic airway device-king;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18662-9;6;Supraglottic airway device-LMA;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18663-7;7;Supraglottic airway device-other;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18004-4;8;Tracheostomy tube;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18657-9;1;Cricothyrotomy tube;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18658-7;2;Endotrachial tube;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18659-5;3;Other invasive airway;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18660-3;4;Supraglottic airway device-combitube;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18661-1;5;Supraglottic airway device-king;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18662-9;6;Supraglottic airway device-LMA;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18663-7;7;Supraglottic airway device-other;;; +71574-8;LL2120-5;NEMSIS-airway device being confirmed;LA18004-4;8;Tracheostomy tube;;; +71575-5;LL2121-3;NEMSIS-ECG type;LA32996-3;1;2 lead ECG (pads or paddles);;; +71575-5;LL2121-3;NEMSIS-ECG type;LA18664-5;2;3 lead;;; +71575-5;LL2121-3;NEMSIS-ECG type;LA18665-2;3;4 lead;;; +71575-5;LL2121-3;NEMSIS-ECG type;LA18666-0;4;5 lead;;; +71575-5;LL2121-3;NEMSIS-ECG type;LA18667-8;5;12 lead-left sided (normal);;; +71575-5;LL2121-3;NEMSIS-ECG type;LA18668-6;6;12 lead-right sided;;; +71575-5;LL2121-3;NEMSIS-ECG type;LA18669-4;7;15 lead;;; +71575-5;LL2121-3;NEMSIS-ECG type;LA18670-2;8;18 lead;;; +71575-5;LL2121-3;NEMSIS-ECG type;LA46-8;9;Other;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18672-8;1;Auscultation;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18673-6;2;Bulb syringe aspiration;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18674-4;3;Colorimetric ETCO2;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18675-1;4;Condensation in tube;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18676-9;5;Digital (numeric) ETCO2;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18677-7;6;Direct re-visualization of tube in place;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18678-5;7;Endotracheal tube whistle (BAAM, etc);;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18679-3;8;Other airway device placement confirmation;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18680-1;9;Visualization of vocal cords;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18681-9;10;Waveform ETCO2;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA32909-6;11;Chest rise;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18672-8;1;Auscultation;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18673-6;2;Bulb syringe aspiration;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18674-4;3;Colorimetric ETCO2;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18675-1;4;Condensation in tube;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18676-9;5;Digital (numeric) ETCO2;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18677-7;6;Direct re-visualization of tube in place;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18678-5;7;Endotracheal tube whistle (BAAM, etc);;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18679-3;8;Other airway device placement confirmation;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18680-1;9;Visualization of vocal cords;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA18681-9;10;Waveform ETCO2;;; +71576-3;LL2122-1;NEMSIS-airway device placement confirmation;LA32909-6;11;Chest rise;;; +71577-1;LL2123-9;NEMSIS-ECG interpretation method;LA18682-7;1;Computer interpretation;;; +71577-1;LL2123-9;NEMSIS-ECG interpretation method;LA18683-5;2;Manual interpretation;;; +71577-1;LL2123-9;NEMSIS-ECG interpretation method;LA18684-3;3;Transmission with no interpretation;;; +71577-1;LL2123-9;NEMSIS-ECG interpretation method;LA18685-0;4;Transmission with remote interpretation;;; +71578-9;LL2124-7;NEMSIS-destination type;LA14084-0;1;Home;;; +71578-9;LL2124-7;NEMSIS-destination type;LA11504-0;2;Hospital emergency department;;; +71578-9;LL2124-7;NEMSIS-destination type;LA18686-8;3;Hospital non-emergency department bed;;; +71578-9;LL2124-7;NEMSIS-destination type;LA24318-0;4;Clinic;;; +71578-9;LL2124-7;NEMSIS-destination type;LA18688-4;5;Morgue/mortuary;;; +71578-9;LL2124-7;NEMSIS-destination type;LA18690-0;6;Other destination;;; +71578-9;LL2124-7;NEMSIS-destination type;LA18691-8;7;Other EMS responder (air);;; +71578-9;LL2124-7;NEMSIS-destination type;LA18692-6;8;Other EMS responder (ground);;; +71578-9;LL2124-7;NEMSIS-destination type;LA18693-4;9;Police/jail;;; +71578-9;LL2124-7;NEMSIS-destination type;LA24392-5;10;Urgent Care;;; +71578-9;LL2124-7;NEMSIS-destination type;LA24393-3;11;Freestanding Emergency Department;;; +71578-9;LL2124-7;NEMSIS-destination type;LA32926-0;12;Dialysis center;;; +71578-9;LL2124-7;NEMSIS-destination type;LA32924-5;13;Diagnostic services;;; +71578-9;LL2124-7;NEMSIS-destination type;LA21437-1;14;Assisted Living Facility;;; +71578-9;LL2124-7;NEMSIS-destination type;LA32923-7;15;Mental health facility;;; +71578-9;LL2124-7;NEMSIS-destination type;LA27-8;16;Nursing Home;;; +71578-9;LL2124-7;NEMSIS-destination type;LA32930-2;17;Other Recurring Care Center;;; +71578-9;LL2124-7;NEMSIS-destination type;LA32929-4;18;Physical rehabilitation facility;;; +71578-9;LL2124-7;NEMSIS-destination type;LA32927-8;19;Drug and/or alcohol rehabilitation facility;;; +71578-9;LL2124-7;NEMSIS-destination type;LA27338-5;20;Skilled nursing facility (SNF);;; +71580-5;LL2125-4;NEMSIS-crew member level;LA18696-7;1;Advanced emergency medical technician (AEMT);;; +71580-5;LL2125-4;NEMSIS-crew member level;LA32922-9;2;Emergency Medical Technician - Intermediate;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA18697-5;3;Emergency medical responder (EMR);;; +71580-5;LL2125-4;NEMSIS-crew member level;LA29903-4;4;Emergency medical technician (EMT);;; +71580-5;LL2125-4;NEMSIS-crew member level;LA25426-0;5;Paramedic;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA18704-9;9;Other healthcare professional;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA18705-6;10;Other non-healthcare professional;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA4687-5;11;Physician;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA9297-8;12;Respiratory therapist;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA15276-1;13;Student;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA18695-9;14;Critical care paramedic;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA18706-4;15;Community paramedicine;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA9292-9;16;Nurse practitioner;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA9296-0;17;Physician assistant;;; +71580-5;LL2125-4;NEMSIS-crew member level;LA24387-5;18;Licensed Practical Nurse (LPN);;; +71580-5;LL2125-4;NEMSIS-crew member level;LA9291-1;19;Registered nurse;;; +71581-3;LL2134-6;NEMSIS-crew member response role;LA18707-2;1;Driver/pilot-response;;; +71581-3;LL2134-6;NEMSIS-crew member response role;LA18708-0;2;Driver/pilot-transport;;; +71581-3;LL2134-6;NEMSIS-crew member response role;LA18709-8;3;Other crew member response role;;; +71581-3;LL2134-6;NEMSIS-crew member response role;LA18710-6;4;Other patient caregiver-at scene;;; +71581-3;LL2134-6;NEMSIS-crew member response role;LA18711-4;5;Other patient caregiver-transport;;; +71581-3;LL2134-6;NEMSIS-crew member response role;LA18712-2;6;Primary patient caregiver-at scene;;; +71581-3;LL2134-6;NEMSIS-crew member response role;LA18713-0;7;Primary patient caregiver-transport;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA18696-7;1;Advanced emergency medical technician (AEMT);;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA32922-9;2;Emergency Medical Technician - Intermediate;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA18697-5;3;Emergency medical responder (EMR);;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA29903-4;4;Emergency medical technician (EMT);;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA25426-0;5;Paramedic;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA18704-9;6;Other healthcare professional;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA18705-6;7;Other non-healthcare professional;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA4687-5;8;Physician;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA9297-8;9;Respiratory therapist;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA15276-1;10;Student;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA18695-9;11;Critical care paramedic;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA18706-4;12;Community paramedicine;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA9292-9;13;Nurse practitioner;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA9296-0;14;Physician assistant;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA24387-5;15;Licensed Practical Nurse (LPN);;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA9291-1;16;Registered nurse;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA4634-7;17;Patient;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA28538-9;18;Lay person;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA32964-1;19;Law enforcement;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA9277-0;20;Family member;;; +71582-1;LL2126-2;NEMSIS-person performing procedure;LA32966-6;21;Fire personnel (non EMS);;; +71583-9;LL2127-0;NEMSIS-service type requested;LA18715-5;1;Emergency response (primary response area);;; +71583-9;LL2127-0;NEMSIS-service type requested;LA18716-3;2;Emergency response (intercept);;; +71583-9;LL2127-0;NEMSIS-service type requested;LA18719-7;3;Mutual aid;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA18717-1;4;Hospital-to-hospital transfer;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32982-3;5;Hospital to non-hospital facility transfer;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32981-5;6;Non-hospital facility to non-hospital facility transfer;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32980-7;7;Non-hospital facility to hospital transfer;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32979-9;8;Other routine medical transport;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA18720-5;9;Public assistance;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA17150-6;10;Standby;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32978-1;11;Support Services;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA17595-2;12;Extrication;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32977-3;13;Crew transport only;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32984-9;14;Transport of organs or body parts;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32976-5;15;Mortuary services;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32975-7;16;Mobile integrated health care encounter;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32974-0;17;Evaluation for special referral/intake programs;;; +71583-9;LL2127-0;NEMSIS-service type requested;LA32973-2;18;Administrative operations;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA18719-7;1;Mutual aid;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA18720-5;2;Public assistance;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA17150-6;3;Standby;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32334-7;4;Follow on mission;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA18718-9;5;Medical transport;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32335-4;6;Additional claim for emergency physician;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA18715-5;7;Emergency response (primary response area);;; +71583-9;LL5972-6;Services requested of the EMS unit;LA18716-3;8;Emergency response (intercept);;; +71583-9;LL5972-6;Services requested of the EMS unit;LA18717-1;9;Hospital-to-hospital transfer;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32979-9;10;Other routine medical transport;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32983-1;11;Emergency response (mutual aid);;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32982-3;12;Hospital to non-hospital facility transfer;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32981-5;13;Non-hospital facility to non-hospital facility transfer;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32980-7;14;Non-hospital facility to hospital transfer;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32978-1;15;Support Services;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32977-3;16;Crew transport only;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32984-9;17;Transport of organs or body parts;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32976-5;18;Mortuary services;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32975-7;19;Mobile integrated health care encounter;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32974-0;20;Evaluation for special referral/intake programs;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA32973-2;21;Administrative operations;;; +71583-9;LL5972-6;Services requested of the EMS unit;LA33455-9;22;Non-Patient Care Rescue/Extrication;;; +71584-7;LL2128-8;NEMSIS-abd exam finding location;LA18721-3;1;Generalized;;; +71584-7;LL2128-8;NEMSIS-abd exam finding location;LA18722-1;2;Left lower quadrant;;; +71584-7;LL2128-8;NEMSIS-abd exam finding location;LA12698-9;3;Left upper quadrant;;; +71584-7;LL2128-8;NEMSIS-abd exam finding location;LA18724-7;4;Periumbilical;;; +71584-7;LL2128-8;NEMSIS-abd exam finding location;LA18725-4;5;Right lower quadrant;;; +71584-7;LL2128-8;NEMSIS-abd exam finding location;LA18723-9;6;Right upper quadrant;;; +71584-7;LL2128-8;NEMSIS-abd exam finding location;LA23813-1;7;Epigastric;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32944-3;1;Leg-whole leg-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32940-1;2;Foot-whole foot-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32941-9;3;Arm-whole arm and hand-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32942-7;4;Arm-whole arm and hand-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32943-5;5;Leg-whole leg-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18739-5;6;Ankle-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18740-3;7;Ankle-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18741-1;8;Arm-upper-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18742-9;9;Arm-upper-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18743-7;10;Elbow-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18744-5;11;Elbow-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18745-2;12;Finger-2nd (index)-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18746-0;13;Finger-2nd (index)-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18747-8;14;Finger-3rd (middle)-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18748-6;15;Finger-3rd (middle)-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18749-4;16;Finger-4th (ring)-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18750-2;17;Finger-4th (ring)-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18751-0;18;Finger-5th (smallest)-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18752-8;19;Finger-5th (smallest)-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18753-6;20;Foot-dorsal-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18754-4;21;Foot-dorsal-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18756-9;22;Foot-plantar-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18755-1;23;Foot-plantar-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18757-7;24;Arm-lower-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18758-5;25;Arm-lower-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18759-3;26;Hand-dorsal-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18760-1;27;Hand-dorsal-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18762-7;28;Hand-palm-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18761-9;29;Hand-palm-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18763-5;30;Hip-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18764-3;31;Hip-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18766-8;32;Wrist-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18765-0;33;Wrist-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18767-6;34;Knee-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18768-4;35;Knee-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18769-2;36;Leg-lower-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18770-0;37;Leg-lower-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18772-6;38;Leg-upper-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18771-8;39;Leg-upper-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18773-4;40;Shoulder-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18774-2;41;Shoulder-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18775-9;42;Thumb-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18776-7;43;Thumb-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18777-5;44;Toe-1st (big)-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18778-3;45;Toe-1st (big)-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18779-1;46;Toe-2nd-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18780-9;47;Toe-2nd-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18781-7;48;Toe-3rd-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18782-5;49;Toe-3rd-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18783-3;50;Toe-4th-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18784-1;51;Toe-4th-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18785-8;52;Toe-5th (smallest)-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA18786-6;53;Toe-5th (smallest)-right;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32938-5;54;Foot-whole foot-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32939-3;55;Hand-whole hand-left;;; +71585-4;LL2130-4;NEMSIS-extremity exam finding location;LA32945-0;56;Hand-whole hand-right;;; +71586-2;LL2131-2;NEMSIS-eye exam finding location;LA18787-4;1;Eyes-bilateral;;; +71586-2;LL2131-2;NEMSIS-eye exam finding location;LA18788-2;2;Eye-left;;; +71586-2;LL2131-2;NEMSIS-eye exam finding location;LA18789-0;3;Eye-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18790-8;1;Antecubital-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18791-6;2;Antecubital-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18792-4;3;External jugular-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18793-2;4;External jugular-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18794-0;5;Femoral-Left IV;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18795-7;6;Femoral-Right IV;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18796-5;7;Foot-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18797-3;8;Foot-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18757-7;9;Arm-lower-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18758-5;10;Arm-lower-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18799-9;11;Hand-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18798-1;12;Hand-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18800-5;13;Internal jugular-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18801-3;14;Internal jugular-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18806-2;15;IO-iliac crest-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18807-0;16;IO-iliac crest-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18802-1;17;IO-femur-left distal;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18803-9;18;IO-femur-right distal;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18804-7;19;IO-humerus-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18805-4;20;IO-humerus-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18808-8;21;IO-sternum;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18809-6;22;IO-tibia-left distal;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18811-2;23;IO-tibia-left proximal;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18810-4;24;IO-tibia-right distal;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18812-0;25;IO-tibia-right proximal;;; +71587-0;LL2132-0;NEMSIS-IV site;LA24413-9;26;Lower Extremity-Left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA24414-7;27;Lower Extremity-Right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18813-8;28;Other central access (PICC, portacath, not listed);;; +71587-0;LL2132-0;NEMSIS-IV site;LA18814-6;29;Other peripheral access (not listed);;; +71587-0;LL2132-0;NEMSIS-IV site;LA18815-3;30;Scalp;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18816-1;31;Subclavian-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18817-9;32;Subclavian-right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18818-7;33;Umbilical;;; +71587-0;LL2132-0;NEMSIS-IV site;LA24420-4;34;Venous Cutdown-Right Lower Extremity;;; +71587-0;LL2132-0;NEMSIS-IV site;LA24417-0;35;Upper Arm-Left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA24418-8;36;Upper Arm-Right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA24415-4;37;Radial-Left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA24416-2;38;Radial-Right;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18766-8;39;Wrist-left;;; +71587-0;LL2132-0;NEMSIS-IV site;LA18765-0;40;Wrist-right;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA12706-0;1;Abdomen;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA18111-7;2;Chest;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA12705-2;3;Back;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA18112-5;4;Extremity-lower;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA18113-3;5;Extremity-upper;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA18114-1;6;General/global;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA18115-8;7;Genitalia;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA18116-6;8;Head;;; +71588-8;LL2133-8;NEMSIS-chief complaint location;LA12703-7;9;Neck;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18726-2;1;Back-general;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18727-0;2;Cervical-left;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18728-8;3;Cervical-midline;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18729-6;4;Cervical-right;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18730-4;5;Lumbar-left;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18735-3;6;Lumbar-midline;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18731-2;7;Lumbar-right;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18733-8;8;Sacral-left;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18734-6;9;Sacral-midline;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18732-0;10;Sacral-right;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18737-9;11;Thoracic-left;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18736-1;13;Thoracic-midline;;; +71589-6;LL2129-6;NEMSIS-back/spine exam finding location;LA18738-7;14;Thoracic-right;;; +71590-4;LL2141-1;ESRD-facility - Hospital or ED;LA15417-1;1;Hospitalization;;; +71590-4;LL2141-1;ESRD-facility - Hospital or ED;LA10268-3;2;Emergency Department;;; +71592-0;LL2094-2;NBS Hb;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18557-1;2;Likely transfusion;10593005;Posttransfusion state (finding);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12614-6;3;Hb SS-disease (sickle cell anemia);127040003;Sickle cell-hemoglobin SS disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12606-2;4;Hb S (sickle)-carrier;16402000;Sickle cell trait (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18558-9;5;Hb S beta plus thalassemia;127042006;Sickle cell beta plus thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18559-7;6;Hb S beta zero thalassemia;127043001;Sickle cell-beta^0^-thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12615-3;7;Hb S beta-thalassemia;127041004;Sickle cell-beta-thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12616-1;8;Hb SC-disease;35434009;Sickle cell-hemoglobin C disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12617-9;9;Hb SD-disease;25472008;Sickle cell-hemoglobin D disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12618-7;10;Hb SE-disease;47024008;Sickle cell-hemoglobin E disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA13012-2;11;Hb S,O-Arab;;; +71592-0;LL2094-2;NBS Hb;LA18560-5;12;Hb S variant;;; +71592-0;LL2094-2;NBS Hb;LA18561-3;13;Hb S/Hereditary persistence of fetal hemoglobin;234391009;Sickle cell anemia with high hemoglobin F (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18562-1;14;Homozygous Hereditary persistence of fetal hemoglobin;191201002;Hereditary persistence of fetal hemoglobin (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18563-9;15;Beta plus thalassemia;79592006;Beta plus thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12611-2;16;Hb beta zero-thalassemia;86715000;Beta zero thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18564-7;17;Beta thalassemia;65959000;beta Thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12607-0;18;Hb C-disease;51053007;Hemoglobin C disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12602-1;19;Hb C-carrier;76050008;Hemoglobin C trait (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18565-4;20;Hb C beta plus thalassemia;119691000119106;Hemoglobin C/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18566-2;21;Hb C beta zero thalassemia;119691000119106;Hemoglobin C/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12608-8;22;Hb C beta-thalassemia;119691000119106;Hemoglobin C/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA19957-2;23;Hb Constant Spring carrier;;; +71592-0;LL2094-2;NBS Hb;LA12609-6;24;Hb D-disease;;; +71592-0;LL2094-2;NBS Hb;LA12603-9;25;Hb D-carrier;7391009;Hemoglobin D trait (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18567-0;26;Hb D beta plus thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18568-8;27;Hb D beta zero thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA12610-4;28;Hb D beta-thalassemia;119701000119106;Hemoglobin D/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12612-0;29;Hb E-disease;25065001;Hemoglobin E disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12604-7;30;Hb E-carrier;46248003;Hemoglobin E trait (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18569-6;31;Hb E beta plus thalassemia;234392002;Hemoglobin E/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18570-4;32;Hb E beta zero thalassemia;234392002;Hemoglobin E/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18571-2;33;Hb E delta beta thalassemia;234392002;Hemoglobin E/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA12613-8;34;Hb E beta-thalassemia;234392002;Hemoglobin E/beta thalassemia disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18572-0;35;Hb G disease;;; +71592-0;LL2094-2;NBS Hb;LA18573-8;36;Hb G carrier;;; +71592-0;LL2094-2;NBS Hb;LA18574-6;37;Hb G beta plus thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18575-3;38;Hb G beta thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18576-1;39;Hb G beta zero thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18577-9;40;Hb D/G disease;;; +71592-0;LL2094-2;NBS Hb;LA18578-7;41;Hb D/G carrier;;; +71592-0;LL2094-2;NBS Hb;LA18579-5;42;Hb D/G beta plus thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18580-3;43;Hb D/G beta thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18581-1;44;Hb D/G beta zero thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA12605-4;45;Hb O-Arab carrier;;; +71592-0;LL2094-2;NBS Hb;LA18582-9;46;Alpha thalassemia major;5300004;Hemoglobin Bart's hydrops syndrome (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18583-7;47;Alpha thalassemia trait;191187006;Alpha trait thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18584-5;48;Hb H disease;48553001;Hemoglobin H disease (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18585-2;49;Hb H Constant Spring disease;447117006;Hemoglobin H constant spring thalassemia (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18586-0;50;Hb H with other variant point mutations;;; +71592-0;LL2094-2;NBS Hb;LA18587-8;51;Other Hb disease;123772008;Homozygous hemoglobinopathy (disorder);http://snomed.info/sct +71592-0;LL2094-2;NBS Hb;LA18588-6;52;Other Hb carrier;;; +71592-0;LL2094-2;NBS Hb;LA18589-4;53;Other beta plus thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18590-2;54;Other beta zero thalassemia;;; +71592-0;LL2094-2;NBS Hb;LA18591-0;55;Other beta thalassemia;;; +71700-9;LL2093-4;Rotavirus;LA18553-0;1;Rotavirus A;;; +71700-9;LL2093-4;Rotavirus;LA18554-8;2;Rotavirus B;;; +71700-9;LL2093-4;Rotavirus;LA18555-5;3;Rotavirus C;;; +71701-7;LL2093-4;Rotavirus;LA18553-0;1;Rotavirus A;;; +71701-7;LL2093-4;Rotavirus;LA18554-8;2;Rotavirus B;;; +71701-7;LL2093-4;Rotavirus;LA18555-5;3;Rotavirus C;;; +71702-5;LL2093-4;Rotavirus;LA18553-0;1;Rotavirus A;;; +71702-5;LL2093-4;Rotavirus;LA18554-8;2;Rotavirus B;;; +71702-5;LL2093-4;Rotavirus;LA18555-5;3;Rotavirus C;;; +71759-5;LL2093-4;Rotavirus;LA18553-0;1;Rotavirus A;;; +71759-5;LL2093-4;Rotavirus;LA18554-8;2;Rotavirus B;;; +71759-5;LL2093-4;Rotavirus;LA18555-5;3;Rotavirus C;;; +71760-3;LL2093-4;Rotavirus;LA18553-0;1;Rotavirus A;;; +71760-3;LL2093-4;Rotavirus;LA18554-8;2;Rotavirus B;;; +71760-3;LL2093-4;Rotavirus;LA18555-5;3;Rotavirus C;;; +71761-1;LL2093-4;Rotavirus;LA18553-0;1;Rotavirus A;;; +71761-1;LL2093-4;Rotavirus;LA18554-8;2;Rotavirus B;;; +71761-1;LL2093-4;Rotavirus;LA18555-5;3;Rotavirus C;;; +71735-5;LL5906-4;EuroSpine - Surgeon Credentials;LA32134-1;1;Specialized spine;;; +71735-5;LL5906-4;EuroSpine - Surgeon Credentials;LA32135-8;2;Board certified orthopedic;;; +71735-5;LL5906-4;EuroSpine - Surgeon Credentials;LA32136-6;3;Board certified neuro;;; +71735-5;LL5906-4;EuroSpine - Surgeon Credentials;LA32137-4;4;Orthopedic in training;;; +71735-5;LL5906-4;EuroSpine - Surgeon Credentials;LA32138-2;5;Neuro in training;;; +71735-5;LL5906-4;EuroSpine - Surgeon Credentials;LA46-8;6;Other;;; +71735-5;LL5967-6;Example Credentials;LA20036-2;1;MD;;; +71735-5;LL5967-6;Example Credentials;LA20037-0;2;DO;;; +71735-5;LL5967-6;Example Credentials;LA22026-1;4;PA;;; +71735-5;LL5967-6;Example Credentials;LA32328-9;5;CNP;;; +71735-5;LL5967-6;Example Credentials;LA6367-2;6;RN;;; +71735-5;LL5967-6;Example Credentials;LA6353-2;7;PT;;; +71796-7;LL2096-7;PML protein;LA18597-7;1;Normal distribution pattern;;; +71796-7;LL2096-7;PML protein;LA18598-5;2;Aberrant distribution pattern matching the t(15,17) translocation;;; +71798-3;LL2146-0;CIHI-reason immuniz not given;LA6530-5;1;Pregnancy;;; +71798-3;LL2146-0;CIHI-reason immuniz not given;LA9532-8;2;Allergic reaction;;; +71798-3;LL2146-0;CIHI-reason immuniz not given;LA10058-8;3;Patient refused;;; +71798-3;LL2146-0;CIHI-reason immuniz not given;LA18840-1;4;Religious belief;;; +71800-7;LL2145-2;CIHI-reason med not prescribed;LA185-1;1;Not eligible;;; +71800-7;LL2145-2;CIHI-reason med not prescribed;LA18847-6;2;Patient age;;; +71800-7;LL2145-2;CIHI-reason med not prescribed;LA18840-1;3;Religious belief;;; +71800-7;LL2145-2;CIHI-reason med not prescribed;LA18848-4;4;Drug interaction;;; +71801-5;LL2147-8;CIHI-reason interven refusal;LA18840-1;1;Religious belief;;; +71801-5;LL2147-8;CIHI-reason interven refusal;LA10058-8;2;Patient refused;;; +71801-5;LL2147-8;CIHI-reason interven refusal;LA18841-9;3;Seeking alternative treatment;;; +71802-3;LL2148-6;CIHI-housing status;LA18835-1;1;Patient is homeless;;; +71802-3;LL2148-6;CIHI-housing status;LA18836-9;2;Patient lives in hospital;;; +71802-3;LL2148-6;CIHI-housing status;LA18837-7;3;Patient lives in nursing home;;; +71802-3;LL2148-6;CIHI-housing status;LA18838-5;4;Patient lives in hotel;;; +71802-3;LL2148-6;CIHI-housing status;LA18839-3;5;Patient lives in own home;;; +71802-3;LL5350-5;PRAPARE_Housing Situation;LA30189-7;0;I have housing;;; +71802-3;LL5350-5;PRAPARE_Housing Situation;LA30190-5;1;I do not have housing (staying with others, in a hotel, in a shelter, living outside on the street, on a beach, in a car, or in a park);;; +71802-3;LL5350-5;PRAPARE_Housing Situation;LA30122-8;2;I choose not to answer this question;;; +71802-3;LL5876-9;AHC HRSN - Living Situation;LA31993-1;1;I have a steady place to live;;; +71802-3;LL5876-9;AHC HRSN - Living Situation;LA31994-9;2;I have a place to live today, but I am worried about losing it in the future;;; +71802-3;LL5876-9;AHC HRSN - Living Situation;LA31995-6;3;I do not have a steady place to live (I am temporarily staying with others, in a hotel, in a shelter, living outside on the street, on a beach, in a car, abandoned building, bus or train station, or in a park);;; +71802-3;LL5876-9;AHC HRSN - Living Situation;LA31993-1;1;I have a steady place to live;;; +71802-3;LL5876-9;AHC HRSN - Living Situation;LA31994-9;2;I have a place to live today, but I am worried about losing it in the future;;; +71802-3;LL5876-9;AHC HRSN - Living Situation;LA31995-6;3;I do not have a steady place to live (I am temporarily staying with others, in a hotel, in a shelter, living outside on the street, on a beach, in a car, abandoned building, bus or train station, or in a park);;; +71803-1;LL2144-5;CIHI-Client status;LA18842-7;1;Patient active;;; +71803-1;LL2144-5;CIHI-Client status;LA18843-5;2;Patient inactive;;; +71803-1;LL2144-5;CIHI-Client status;LA18844-3;3;Patient care suspended;;; +71803-1;LL2144-5;CIHI-Client status;LA18845-0;4;Patient care terminated;;; +71803-1;LL2144-5;CIHI-Client status;LA10939-9;5;Deceased;;; +71827-0;LL2149-4;M3-total score value;LA15588-9;1;Unlikely;;; +71827-0;LL2149-4;M3-total score value;LA9194-7;2;Low;;; +71827-0;LL2149-4;M3-total score value;LA8982-6;3;Medium;;; +71827-0;LL2149-4;M3-total score value;LA9193-9;4;High;;; +71896-5;LL2150-2;NCQA-peds B/P percentile;LA18849-2;1;50th;;; +71896-5;LL2150-2;NCQA-peds B/P percentile;LA18850-0;2;80th;;; +71896-5;LL2150-2;NCQA-peds B/P percentile;LA18851-8;3;90th;;; +71896-5;LL2150-2;NCQA-peds B/P percentile;LA18852-6;4;95th;;; +71896-5;LL2150-2;NCQA-peds B/P percentile;LA18853-4;5;99th;;; +72164-7;LL2150-2;NCQA-peds B/P percentile;LA18849-2;1;50th;;; +72164-7;LL2150-2;NCQA-peds B/P percentile;LA18850-0;2;80th;;; +72164-7;LL2150-2;NCQA-peds B/P percentile;LA18851-8;3;90th;;; +72164-7;LL2150-2;NCQA-peds B/P percentile;LA18852-6;4;95th;;; +72164-7;LL2150-2;NCQA-peds B/P percentile;LA18853-4;5;99th;;; +72165-4;LL2150-2;NCQA-peds B/P percentile;LA18849-2;1;50th;;; +72165-4;LL2150-2;NCQA-peds B/P percentile;LA18850-0;2;80th;;; +72165-4;LL2150-2;NCQA-peds B/P percentile;LA18851-8;3;90th;;; +72165-4;LL2150-2;NCQA-peds B/P percentile;LA18852-6;4;95th;;; +72165-4;LL2150-2;NCQA-peds B/P percentile;LA18853-4;5;99th;;; +71897-3;LL2157-7;VA-36-how health has changed;LA18864-1;1;Much better;;; +71897-3;LL2157-7;VA-36-how health has changed;LA18350-1;2;Somewhat better;;; +71897-3;LL2157-7;VA-36-how health has changed;LA18129-9;3;About the same;;; +71897-3;LL2157-7;VA-36-how health has changed;LA18343-6;4;Somewhat worse;;; +71897-3;LL2157-7;VA-36-how health has changed;LA18865-8;5;Much worse;;; +71898-1;LL2157-7;VA-36-how health has changed;LA18864-1;1;Much better;;; +71898-1;LL2157-7;VA-36-how health has changed;LA18350-1;2;Somewhat better;;; +71898-1;LL2157-7;VA-36-how health has changed;LA18129-9;3;About the same;;; +71898-1;LL2157-7;VA-36-how health has changed;LA18343-6;4;Somewhat worse;;; +71898-1;LL2157-7;VA-36-how health has changed;LA18865-8;5;Much worse;;; +71914-6;LL2155-1;VA-36-body pain;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +71914-6;LL2155-1;VA-36-body pain;LA18862-5;2;Very mild;;; +71914-6;LL2155-1;VA-36-body pain;LA6752-5;3;Mild;;; +71914-6;LL2155-1;VA-36-body pain;LA6751-7;4;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +71914-6;LL2155-1;VA-36-body pain;LA6750-9;5;Severe;;; +71914-6;LL2155-1;VA-36-body pain;LA13958-6;6;Very severe;;; +71915-3;LL2154-4;VA-36-work/social activity limitations;LA6568-5;1;Not at all;;; +71915-3;LL2154-4;VA-36-work/social activity limitations;LA14454-5;2;Slightly;;; +71915-3;LL2154-4;VA-36-work/social activity limitations;LA13939-6;3;Moderately;;; +71915-3;LL2154-4;VA-36-work/social activity limitations;LA13902-4;4;Quite a bit;;; +71915-3;LL2154-4;VA-36-work/social activity limitations;LA14868-6;5;Extremely;;; +71916-1;LL2153-6;VA-36-work/daily activity limitations;LA18857-5;1;No, none of the time;;; +71916-1;LL2153-6;VA-36-work/daily activity limitations;LA18858-3;2;Yes, a little of the time;;; +71916-1;LL2153-6;VA-36-work/daily activity limitations;LA18384-0;3;Yes, some of the time;;; +71916-1;LL2153-6;VA-36-work/daily activity limitations;LA18383-2;4;Yes, most of the time;;; +71916-1;LL2153-6;VA-36-work/daily activity limitations;LA18859-1;5;Yes, all of the time;;; +71917-9;LL2153-6;VA-36-work/daily activity limitations;LA18857-5;1;No, none of the time;;; +71917-9;LL2153-6;VA-36-work/daily activity limitations;LA18858-3;2;Yes, a little of the time;;; +71917-9;LL2153-6;VA-36-work/daily activity limitations;LA18384-0;3;Yes, some of the time;;; +71917-9;LL2153-6;VA-36-work/daily activity limitations;LA18383-2;4;Yes, most of the time;;; +71917-9;LL2153-6;VA-36-work/daily activity limitations;LA18859-1;5;Yes, all of the time;;; +71918-7;LL2153-6;VA-36-work/daily activity limitations;LA18857-5;1;No, none of the time;;; +71918-7;LL2153-6;VA-36-work/daily activity limitations;LA18858-3;2;Yes, a little of the time;;; +71918-7;LL2153-6;VA-36-work/daily activity limitations;LA18384-0;3;Yes, some of the time;;; +71918-7;LL2153-6;VA-36-work/daily activity limitations;LA18383-2;4;Yes, most of the time;;; +71918-7;LL2153-6;VA-36-work/daily activity limitations;LA18859-1;5;Yes, all of the time;;; +71919-5;LL2153-6;VA-36-work/daily activity limitations;LA18857-5;1;No, none of the time;;; +71919-5;LL2153-6;VA-36-work/daily activity limitations;LA18858-3;2;Yes, a little of the time;;; +71919-5;LL2153-6;VA-36-work/daily activity limitations;LA18384-0;3;Yes, some of the time;;; +71919-5;LL2153-6;VA-36-work/daily activity limitations;LA18383-2;4;Yes, most of the time;;; +71919-5;LL2153-6;VA-36-work/daily activity limitations;LA18859-1;5;Yes, all of the time;;; +71920-3;LL2153-6;VA-36-work/daily activity limitations;LA18857-5;1;No, none of the time;;; +71920-3;LL2153-6;VA-36-work/daily activity limitations;LA18858-3;2;Yes, a little of the time;;; +71920-3;LL2153-6;VA-36-work/daily activity limitations;LA18384-0;3;Yes, some of the time;;; +71920-3;LL2153-6;VA-36-work/daily activity limitations;LA18383-2;4;Yes, most of the time;;; +71920-3;LL2153-6;VA-36-work/daily activity limitations;LA18859-1;5;Yes, all of the time;;; +71921-1;LL2153-6;VA-36-work/daily activity limitations;LA18857-5;1;No, none of the time;;; +71921-1;LL2153-6;VA-36-work/daily activity limitations;LA18858-3;2;Yes, a little of the time;;; +71921-1;LL2153-6;VA-36-work/daily activity limitations;LA18384-0;3;Yes, some of the time;;; +71921-1;LL2153-6;VA-36-work/daily activity limitations;LA18383-2;4;Yes, most of the time;;; +71921-1;LL2153-6;VA-36-work/daily activity limitations;LA18859-1;5;Yes, all of the time;;; +71922-9;LL2153-6;VA-36-work/daily activity limitations;LA18857-5;1;No, none of the time;;; +71922-9;LL2153-6;VA-36-work/daily activity limitations;LA18858-3;2;Yes, a little of the time;;; +71922-9;LL2153-6;VA-36-work/daily activity limitations;LA18384-0;3;Yes, some of the time;;; +71922-9;LL2153-6;VA-36-work/daily activity limitations;LA18383-2;4;Yes, most of the time;;; +71922-9;LL2153-6;VA-36-work/daily activity limitations;LA18859-1;5;Yes, all of the time;;; +71923-7;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71923-7;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71923-7;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71924-5;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71924-5;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71924-5;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71925-2;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71925-2;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71925-2;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71926-0;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71926-0;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71926-0;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71927-8;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71927-8;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71927-8;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71928-6;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71928-6;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71928-6;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71929-4;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71929-4;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71929-4;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71930-2;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71930-2;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71930-2;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71931-0;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71931-0;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71931-0;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +71932-8;LL2152-8;VA-36-daily activities;LA18854-2;1;Yes, limited a lot;;; +71932-8;LL2152-8;VA-36-daily activities;LA18855-9;2;Yes, limited a little;;; +71932-8;LL2152-8;VA-36-daily activities;LA18856-7;3;No, not limited at all;;; +72029-2;LL2170-0;ESRD-medical reason vaccination exclusion;LA18902-9;1;Patient allergic history;;; +72029-2;LL2170-0;ESRD-medical reason vaccination exclusion;LA18903-7;2;Potential adverse drug interaction;;; +72029-2;LL2170-0;ESRD-medical reason vaccination exclusion;LA18904-5;3;Other medical;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18881-5;1;Calderol;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18882-3;2;Delta D3;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18883-1;3;DHT Intensol;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18884-9;4;DHT;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18885-6;5;Drisdol;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18879-9;6;Hectorol (Doxercalciferol);;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18887-2;7;Rocaltrol;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18888-0;8;Vitamin D3;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18889-8;9;Vitamin D2;;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA18880-7;10;Zemplar (Paricalcitol);;; +72030-0;LL2166-8;ESRD-oral vitamin D analog;LA46-8;11;Other;;; +72032-6;LL2165-0;ESRD-non-oral vitamin D analog;LA18878-1;1;Calcijex (Calcitriol);;; +72032-6;LL2165-0;ESRD-non-oral vitamin D analog;LA18879-9;2;Hectorol (Doxercalciferol);;; +72032-6;LL2165-0;ESRD-non-oral vitamin D analog;LA18880-7;3;Zemplar (Paricalcitol);;; +72032-6;LL2165-0;ESRD-non-oral vitamin D analog;LA46-8;4;Other;;; +72035-9;LL2164-3;ESRD-graft assessment frequency;LA18875-7;1;At least every two weeks;;; +72035-9;LL2164-3;ESRD-graft assessment frequency;LA18876-5;2;Monthly;;; +72035-9;LL2164-3;ESRD-graft assessment frequency;LA18877-3;3;Quarterly;;; +72035-9;LL2164-3;ESRD-graft assessment frequency;LA46-8;4;Other;;; +72037-5;LL2164-3;ESRD-graft assessment frequency;LA18875-7;1;At least every two weeks;;; +72037-5;LL2164-3;ESRD-graft assessment frequency;LA18876-5;2;Monthly;;; +72037-5;LL2164-3;ESRD-graft assessment frequency;LA18877-3;3;Quarterly;;; +72037-5;LL2164-3;ESRD-graft assessment frequency;LA46-8;4;Other;;; +72042-5;LL2167-6;ESRD-dialysis access exam frequency;LA18890-6;1;At each treatment;;; +72042-5;LL2167-6;ESRD-dialysis access exam frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +72042-5;LL2167-6;ESRD-dialysis access exam frequency;LA18876-5;3;Monthly;;; +72042-5;LL2167-6;ESRD-dialysis access exam frequency;LA46-8;4;Other;;; +72044-1;LL2167-6;ESRD-dialysis access exam frequency;LA18890-6;1;At each treatment;;; +72044-1;LL2167-6;ESRD-dialysis access exam frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +72044-1;LL2167-6;ESRD-dialysis access exam frequency;LA18876-5;3;Monthly;;; +72044-1;LL2167-6;ESRD-dialysis access exam frequency;LA46-8;4;Other;;; +72046-6;LL2168-4;ESRD-AV fistula and graft status;LA18892-2;1;Not yet present;;; +72046-6;LL2168-4;ESRD-AV fistula and graft status;LA18893-0;2;Created;;; +72046-6;LL2168-4;ESRD-AV fistula and graft status;LA16666-2;3;Active;;; +72046-6;LL2168-4;ESRD-AV fistula and graft status;LA18632-2;4;Inactive;;; +72046-6;LL2168-4;ESRD-AV fistula and graft status;LA18894-8;5;Removed;;; +72047-4;LL2168-4;ESRD-AV fistula and graft status;LA18892-2;1;Not yet present;;; +72047-4;LL2168-4;ESRD-AV fistula and graft status;LA18893-0;2;Created;;; +72047-4;LL2168-4;ESRD-AV fistula and graft status;LA16666-2;3;Active;;; +72047-4;LL2168-4;ESRD-AV fistula and graft status;LA18632-2;4;Inactive;;; +72047-4;LL2168-4;ESRD-AV fistula and graft status;LA18894-8;5;Removed;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18895-5;1;Arteriovenous fistula only (with 2 needles);;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18896-3;2;Arteriovenous fistula combined with an AV graft;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18897-1;3;Arteriovenous fistula combined with a catheter;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18898-9;4;Arteriovenous graft only (with 2 needles);;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18899-7;5;Arteriovenous graft combined with a catheter;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18900-3;6;Catheter only;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18901-1;7;Port access only;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA4659-4;8;Other, Unknown;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18895-5;1;Arteriovenous fistula only (with 2 needles);;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18896-3;2;Arteriovenous fistula combined with an AV graft;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18897-1;3;Arteriovenous fistula combined with a catheter;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18898-9;4;Arteriovenous graft only (with 2 needles);;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18899-7;5;Arteriovenous graft combined with a catheter;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18900-3;6;Catheter only;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA18901-1;7;Port access only;;; +72050-8;LL2169-2;ESRD-dialysis access type;LA4659-4;8;Other, Unknown;;; +72059-9;LL2171-8;ESRD-reason no vaccination;LA18907-8;1;Patient reasons;;; +72059-9;LL2171-8;ESRD-reason no vaccination;LA18908-6;2;Medical reasons;;; +72063-1;LL2173-4;ESRD-oral iron type prescribed;LA18909-4;1;Ferrous fumarate (Feostat, Femiron);;; +72063-1;LL2173-4;ESRD-oral iron type prescribed;LA18910-2;2;Ferrous sulfate (Feosol, FerIron);;; +72063-1;LL2173-4;ESRD-oral iron type prescribed;LA18911-0;3;Ferrous gluconate (Ferate, Fergon, Ferralet, Simron);;; +72063-1;LL2173-4;ESRD-oral iron type prescribed;LA46-8;4;Other;;; +72065-6;LL2172-6;ESRD-IV iron type prescribed;LA18912-8;1;Iron dextran (Dexferrum, Infed);;; +72065-6;LL2172-6;ESRD-IV iron type prescribed;LA18913-6;2;Sodium ferric gluconate (Ferrlecit);;; +72065-6;LL2172-6;ESRD-IV iron type prescribed;LA18914-4;3;Iron sucrose (Venofer);;; +72065-6;LL2172-6;ESRD-IV iron type prescribed;LA46-8;4;Other;;; +72076-3;LL2159-3;ESRD-home BP value;LA9194-7;1;Low;;; +72076-3;LL2159-3;ESRD-home BP value;LA9193-9;2;High;;; +72076-3;LL2159-3;ESRD-home BP value;LA6626-1;3;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +72085-4;LL2175-9;ESRD-no vaccination-pt reason;LA18905-2;1;Cultural reasons;;; +72085-4;LL2175-9;ESRD-no vaccination-pt reason;LA18906-0;2;Personal choice;;; +72112-6;LL2178-3;NEMSIS-reason procedure not done;LA15185-4;1;Unable to complete;;; +72112-6;LL2178-3;NEMSIS-reason procedure not done;LA4216-3;2;Contraindicated;;; +72112-6;LL2178-3;NEMSIS-reason procedure not done;LA18925-0;3;Denied by order;;; +72112-6;LL2178-3;NEMSIS-reason procedure not done;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +72113-4;LL2177-5;NEMSIS-reason med not given;LA4216-3;1;Contraindicated;;; +72113-4;LL2177-5;NEMSIS-reason med not given;LA18925-0;2;Denied by order;;; +72113-4;LL2177-5;NEMSIS-reason med not given;LA18922-7;3;Medication allergy;;; +72113-4;LL2177-5;NEMSIS-reason med not given;LA18921-9;4;Medication already taken;;; +72113-4;LL2177-5;NEMSIS-reason med not given;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +72113-4;LL2177-5;NEMSIS-reason med not given;LA15185-4;6;Unable to complete;;; +72114-2;LL2176-7;NEMSIS-complaint type;LA18923-5;1;Chief - primary;;; +72114-2;LL2176-7;NEMSIS-complaint type;LA17059-9;2;Other (not listed);;; +72114-2;LL2176-7;NEMSIS-complaint type;LA18924-3;3;Secondary;;; +72115-9;LL2185-8;NEMSIS-resuscitation attempted;LA17060-7;1;Attempted defibrillation;;; +72115-9;LL2185-8;NEMSIS-resuscitation attempted;LA17061-5;2;Attempted ventilation;;; +72115-9;LL2185-8;NEMSIS-resuscitation attempted;LA17062-3;3;Initiated chest compressions;;; +72136-5;LL2160-1;Low|High;LA9194-7;1;Low;;; +72136-5;LL2160-1;Low|High;LA9193-9;2;High;;; +94077-5;LL2160-1;Low|High;LA9194-7;1;Low;;; +94077-5;LL2160-1;Low|High;LA9193-9;2;High;;; +72143-1;LL2191-6;Gender - HL7v3.0;LA2-8;1;Male;;; +72143-1;LL2191-6;Gender - HL7v3.0;LA3-6;2;Female;;; +72143-1;LL2191-6;Gender - HL7v3.0;LA18959-9;3;Undifferentiated;;; +81886-4;LL2191-6;Gender - HL7v3.0;LA2-8;1;Male;;; +81886-4;LL2191-6;Gender - HL7v3.0;LA3-6;2;Female;;; +81886-4;LL2191-6;Gender - HL7v3.0;LA18959-9;3;Undifferentiated;;; +91692-4;LL2191-6;Gender - HL7v3.0;LA2-8;1;Male;;; +91692-4;LL2191-6;Gender - HL7v3.0;LA3-6;2;Female;;; +91692-4;LL2191-6;Gender - HL7v3.0;LA18959-9;3;Undifferentiated;;; +91699-9;LL2191-6;Gender - HL7v3.0;LA2-8;1;Male;;; +91699-9;LL2191-6;Gender - HL7v3.0;LA3-6;2;Female;;; +91699-9;LL2191-6;Gender - HL7v3.0;LA18959-9;3;Undifferentiated;;; +72144-9;LL2187-4;RHEA-maternal vital status;LA14122-8;1;Stable;;; +72144-9;LL2187-4;RHEA-maternal vital status;LA6624-6;2;Referred;;; +72144-9;LL2187-4;RHEA-maternal vital status;LA18946-6;3;Died;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA18951-6;1;Intact;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA18952-4;2;1st degree laceration/vaginal graze;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA18953-2;3;2nd degree laceration;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA18954-0;4;3rd degree laceration;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA18955-7;5;Episiotomy;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA18956-5;6;Combined laceration and episiotomy;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA18957-3;7;4th degree laceration;;; +72145-6;LL2190-8;RHEA-perineal tear class;LA46-8;8;Other;;; +72146-4;LL2189-0;RHEA-neonatal vital delivery status;LA14270-5;1;Live birth;;; +72146-4;LL2189-0;RHEA-neonatal vital delivery status;LA14271-3;2;Stillborn;;; +72147-2;LL2196-5;RHEA - gestational age at birth;LA18950-8;1;Term;;; +72147-2;LL2196-5;RHEA - gestational age at birth;LA9209-3;2;Premature;;; +72148-0;LL2194-0;RHEA - person attending birth;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +72148-0;LL2194-0;RHEA - person attending birth;LA18966-4;2;Skilled health worker;;; +72148-0;LL2194-0;RHEA - person attending birth;LA9401-6;3;Nurse;;; +72148-0;LL2194-0;RHEA - person attending birth;LA18967-2;4;Midwife;;; +72148-0;LL2194-0;RHEA - person attending birth;LA18968-0;5;Doctor;;; +72149-8;LL2193-2;RHEA - delivery method;LA18963-1;1;Spontaneous vaginal;;; +72149-8;LL2193-2;RHEA - delivery method;LA18964-9;2;Vacuum extraction;;; +72149-8;LL2193-2;RHEA - delivery method;LA18965-6;3;Caesarean section;;; +72150-6;LL2195-7;RHEA - delivery location;LA18958-1;1;Facility;;; +72150-6;LL2195-7;RHEA - delivery location;LA14084-0;2;Home;;; +72150-6;LL2195-7;RHEA - delivery location;LA18958-1;1;Facility;;; +72150-6;LL2195-7;RHEA - delivery location;LA14084-0;2;Home;;; +72150-6;LL5580-7;Birth location;LA6218-7;1;Hospital;;; +72150-6;LL5580-7;Birth location;LA20032-1;2;Free-standing birthing center;;; +72150-6;LL5580-7;Birth location;LA14084-0;3;Home;;; +72150-6;LL5580-7;Birth location;LA30947-8;4;Non-Healthcare Facility;;; +72150-6;LL5580-7;Birth location;LA46-8;5;Other;;; +72153-0;LL2192-4;RHEA - last born child vital status;LA4247-8;1;Alive;;; +72153-0;LL2192-4;RHEA - last born child vital status;LA9627-6;2;Dead;;; +72153-0;LL2192-4;RHEA - last born child vital status;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +92276-5;LL2192-4;RHEA - last born child vital status;LA4247-8;1;Alive;;; +92276-5;LL2192-4;RHEA - last born child vital status;LA9627-6;2;Dead;;; +92276-5;LL2192-4;RHEA - last born child vital status;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA18969-8;1;Anemia;;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA17263-7;2;Edema;;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA18970-6;3;Proteinuria;;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA18971-4;4;Not gaining weight;;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA7418-2;5;Bleeding;;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA18972-2;6;High B/P(>140/90);;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA18973-0;7;Multiple birth;;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA18974-8;8;Abnormal breast exam/findings;;; +72154-8;LL2197-3;RHEA - pregnancy risk factors;LA18975-5;9;No risk factors;;; +72155-5;LL2188-2;RHEA-position in womb;LA18949-0;1;Cephalic;;; +72155-5;LL2188-2;RHEA-position in womb;LA18948-2;2;Breech;;; +72155-5;LL2188-2;RHEA-position in womb;LA18947-4;3;Normal lie;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA18976-3;1;Current every day smoker;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA18977-1;2;Current some day smoker;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA15920-4;3;Former smoker;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA18978-9;4;Never smoker;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA18979-7;5;Smoker, current status unknown;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA18980-5;6;Unknown if ever smoked;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA18981-3;7;Heavy tobacco smoker;;; +72166-2;LL2201-3;Smoking Status - HL7 Value Set;LA18982-1;8;Light tobacco smoker;;; +72169-6;LL2103-1;FERPA;LA18618-1;1;Yes (FERPA release on file);;; +72169-6;LL2103-1;FERPA;LA18619-9;2;No (No FERPA release on file);;; +72176-1;LL2202-1;RHEA-birth facility;LA6218-7;1;Hospital;;; +72176-1;LL2202-1;RHEA-birth facility;LA18983-9;2;Health center;;; +72185-2;LL2204-7;RHEA-medical history;LA10528-0;1;Kidney Disease;;; +72185-2;LL2204-7;RHEA-medical history;LA14293-7;2;High blood pressure;;; +72185-2;LL2204-7;RHEA-medical history;LA10529-8;3;Diabetes;;; +72185-2;LL2204-7;RHEA-medical history;LA18994-6;4;Uterine tumor;;; +72185-2;LL2204-7;RHEA-medical history;LA10523-1;5;Heart Disease;;; +72185-2;LL2204-7;RHEA-medical history;LA16982-3;6;Asthma;;; +72185-2;LL2204-7;RHEA-medical history;LA10513-2;7;Tuberculosis;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18984-7;1;Aborted successively;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18985-4;2;Gave birth to child who died the same day;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18986-2;3;Bleeding (≥ 500ml) soon after giving birth;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18987-0;4;Uterine rupture;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18988-8;5;Previously had postconvulsive loss of consciousness;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18989-6;6;Lost consciousness while pregnant or when she gave birth;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18991-2;7;Less than 150cm tall;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18992-0;8;Under 18 or over 35 years old;;; +72186-0;LL2203-9;RHEA-obstetrical risks;LA18993-8;9;First pregnancy and over 30 years old;;; +72200-9;LL2162-7;GenBank Inflza Virus A Neuraminidase;LA18866-6;1;JQ791014;;; +72200-9;LL2162-7;GenBank Inflza Virus A Neuraminidase;LA18867-4;2;JQ791006;;; +72200-9;LL2162-7;GenBank Inflza Virus A Neuraminidase;LA18868-2;3;JQ790998;;; +72201-7;LL2161-9;GenBank Inflza Virus A Matrix Protein;LA18869-0;1;JQ791015;;; +72201-7;LL2161-9;GenBank Inflza Virus A Matrix Protein;LA18870-8;2;JQ791007;;; +72201-7;LL2161-9;GenBank Inflza Virus A Matrix Protein;LA18871-6;3;JQ790999;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA10924-1;1;Community (private home/apt., board/care, assisted living, group home);;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA18066-3;2;Long-term care facility;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA6376-3;3;Skilled Nursing Facility;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA11504-0;4;Hospital emergency department;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA10078-6;5;Short-stay acute hospital (IPPS);;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA10000-0;6;Long-term care hospital (LTCH);;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA9985-8;7;Inpatient Rehabilitation Hospital (IRF);;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA10065-3;8;Psychiatric hospital or unit;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA10929-0;9;ID/DD facility;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA6216-1;10;Hospice;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA9965-0;11;Discharged against medical advice;;; +72202-5;LL2205-4;CARE-LTCH - discharge location;LA46-8;12;Other;;; +72206-6;LL2174-2;EBV NA-1 IgG & IgM impression;LA18915-1;1;Color of IgM > or = IgG: Positive, acute/current mononucleosis;;; +72206-6;LL2174-2;EBV NA-1 IgG & IgM impression;LA18916-9;2;Color of IgG > IgM: Negative, previous exposure;;; +72206-6;LL2174-2;EBV NA-1 IgG & IgM impression;LA18917-7;3;Faint or no color for IgG and IgM: Negative, no previous exposure, patient is susceptible to EBV;;; +72285-0;LL2221-1;Dressing purposes;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +72285-0;LL2221-1;Dressing purposes;LA19070-4;2;Primary dressing;;; +72285-0;LL2221-1;Dressing purposes;LA19071-2;3;Secondary dressing;;; +72285-0;LL2221-1;Dressing purposes;LA19072-0;4;Compression dressing;;; +72285-0;LL2221-1;Dressing purposes;LA19073-8;5;Surgical incision care and treatment;;; +72289-2;LL2219-5;Color of exudate;LA15553-3;1;Blue;;; +72289-2;LL2219-5;Color of exudate;LA15555-8;2;Green;;; +72289-2;LL2219-5;Color of exudate;LA17196-9;3;Orange;;; +72289-2;LL2219-5;Color of exudate;LA17192-8;4;Pink;;; +72289-2;LL2219-5;Color of exudate;LA17193-6;5;Red;;; +72289-2;LL2219-5;Color of exudate;LA4457-3;6;White;;; +72289-2;LL2219-5;Color of exudate;LA17195-1;7;Yellow;;; +72289-2;LL2219-5;Color of exudate;LA19058-9;8;Brown;;; +72289-2;LL2219-5;Color of exudate;LA19060-5;9;Clay;;; +72289-2;LL2219-5;Color of exudate;LA19061-3;10;Maroon;;; +72289-2;LL2219-5;Color of exudate;LA19062-1;11;Violet;;; +72289-2;LL2219-5;Color of exudate;LA19063-9;12;Tan;;; +72289-2;LL2219-5;Color of exudate;LA19059-7;13;Colorless;;; +72290-0;LL2220-3;Exudate appearance types;LA19065-4;1;Sanguinous;;; +72290-0;LL2220-3;Exudate appearance types;LA19066-2;2;Serosanguinous;;; +72290-0;LL2220-3;Exudate appearance types;LA19067-0;3;Serous;;; +72290-0;LL2220-3;Exudate appearance types;LA19064-7;4;Purulent;;; +72290-0;LL2220-3;Exudate appearance types;LA19068-8;5;Seropurulent;;; +72290-0;LL2220-3;Exudate appearance types;LA19069-6;6;Viscous;;; +72294-2;LL2218-7;Clock position;LA19055-5;1;12 o'clock;;; +72294-2;LL2218-7;Clock position;LA19053-0;2;3 o'clock;;; +72294-2;LL2218-7;Clock position;LA19056-3;3;6 o'clock;;; +72294-2;LL2218-7;Clock position;LA19057-1;4;11 o'clock;;; +72294-2;LL2218-7;Clock position;LA19054-8;5;1 o'clock;;; +72297-5;LL2218-7;Clock position;LA19055-5;1;12 o'clock;;; +72297-5;LL2218-7;Clock position;LA19053-0;2;3 o'clock;;; +72297-5;LL2218-7;Clock position;LA19056-3;3;6 o'clock;;; +72297-5;LL2218-7;Clock position;LA19057-1;4;11 o'clock;;; +72297-5;LL2218-7;Clock position;LA19054-8;5;1 o'clock;;; +72300-7;LL2215-3;Skin alterations;LA7410-9;1;Abrasion;;; +72300-7;LL2215-3;Skin alterations;LA18220-6;2;Avulsion;;; +72300-7;LL2215-3;Skin alterations;LA19023-3;3;Bite;;; +72300-7;LL2215-3;Skin alterations;LA19024-1;4;Blister;;; +72300-7;LL2215-3;Skin alterations;LA7318-4;5;Burn;;; +72300-7;LL2215-3;Skin alterations;LA17212-4;6;Gunshot wound;;; +72300-7;LL2215-3;Skin alterations;LA7423-2;7;Contusion;;; +72300-7;LL2215-3;Skin alterations;LA17229-8;8;Crush injury;;; +72300-7;LL2215-3;Skin alterations;LA7433-1;9;Erythema;;; +72300-7;LL2215-3;Skin alterations;LA19025-8;10;Fissure;;; +72300-7;LL2215-3;Skin alterations;LA7452-1;11;Laceration;;; +72300-7;LL2215-3;Skin alterations;LA19026-6;12;Maceration;;; +72300-7;LL2215-3;Skin alterations;LA19028-2;13;Pressure ulcer;;; +72300-7;LL2215-3;Skin alterations;LA16827-0;14;Ulcer;56208002;Ulcer (morphologic abnormality);http://snomed.info/sct +72300-7;LL2215-3;Skin alterations;LA19027-4;15;Puncture;;; +72300-7;LL2215-3;Skin alterations;LA7469-5;16;Rash;;; +72300-7;LL2215-3;Skin alterations;LA17811-3;17;Graft;;; +72300-7;LL2215-3;Skin alterations;LA19029-0;18;Surgical incision;;; +72300-7;LL2215-3;Skin alterations;LA17058-1;19;Trauma;;; +72302-3;LL2226-0;Nail Texture;LA19086-0;1;Normal (Smooth, firm, nail plate attached);;; +72302-3;LL2226-0;Nail Texture;LA14110-3;2;Thickened;;; +72302-3;LL2226-0;Nail Texture;LA19088-6;3;Pitted;;; +72302-3;LL2226-0;Nail Texture;LA19089-4;4;Brittle;;; +72303-1;LL2225-2;Nail Shape;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +72303-1;LL2225-2;Nail Shape;LA19080-3;2;Clubbing;;; +72303-1;LL2225-2;Nail Shape;LA19081-1;3;Spooning;;; +72304-9;LL2230-2;Edge of wound descriptions;LA19094-4;1;Attached;;; +72304-9;LL2230-2;Edge of wound descriptions;LA19098-5;2;Not attached;;; +72304-9;LL2230-2;Edge of wound descriptions;LA19097-7;3;Poorly defined;;; +72304-9;LL2230-2;Edge of wound descriptions;LA19099-3;4;Well-defined;;; +72304-9;LL2230-2;Edge of wound descriptions;LA19096-9;5;Scabbed;;; +72304-9;LL2230-2;Edge of wound descriptions;LA19095-1;6;Rolled;;; +72305-6;LL2223-7;Wound closure types;LA19076-1;1;Glue;;; +72305-6;LL2223-7;Wound closure types;LA19077-9;2;Staples;;; +72305-6;LL2223-7;Wound closure types;LA19078-7;3;Steri strips;;; +72305-6;LL2223-7;Wound closure types;LA19079-5;4;Suture;;; +72305-6;LL2223-7;Wound closure types;LA9227-5;5;Open;;; +72314-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72314-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72314-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72314-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72315-5;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72315-5;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72315-5;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72315-5;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72316-3;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72316-3;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72316-3;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72316-3;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72317-1;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72317-1;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72317-1;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72317-1;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72318-9;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72318-9;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72318-9;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72318-9;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72327-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72327-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72327-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72327-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72515-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72515-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72515-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72515-0;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72724-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72724-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +72724-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +72724-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +85095-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85095-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA4259-3;2;Borderline;;; +85095-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85095-8;LL2206-2;Neg|Borderline|Pos|Strong Pos;LA18996-1;4;Strong positive;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA19104-1;1;0 - no fatigue;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA6112-2;2;1;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA6113-0;3;2;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA6114-8;4;3;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA6115-5;5;4;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA10137-0;6;5;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA10138-8;7;6;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA10139-6;8;7;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA10140-4;9;8;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA10141-2;10;9;;; +72349-4;LL2234-4;Quality of life, fatigue (0 to 10);LA19105-8;11;10 - fatigue as bad as you can imagine;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA19102-5;1;0 - no pain;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA6112-2;2;1;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA6113-0;3;2;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA6114-8;4;3;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA6115-5;5;4;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA10137-0;6;5;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA10138-8;7;6;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA10139-6;8;7;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA10140-4;9;8;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA10141-2;10;9;;; +72350-2;LL2233-6;Quality of life, pain (0 to 10);LA19103-3;11;10 - pain as bad as you can imagine;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA19100-9;1;0 - as bad as it can be;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA6112-2;2;1;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA6113-0;3;2;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA6114-8;4;3;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA6115-5;5;4;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA10137-0;6;5;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA10138-8;7;6;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA10139-6;8;7;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA10140-4;9;8;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA10141-2;10;9;;; +72351-0;LL2232-8;Quality of life, general (0 to 10);LA19101-7;11;10 - as good as it can be;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA19100-9;1;0 - as bad as it can be;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA6112-2;2;1;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA6113-0;3;2;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA6114-8;4;3;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA6115-5;5;4;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA10137-0;6;5;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA10138-8;7;6;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA10139-6;8;7;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA10140-4;9;8;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA10141-2;10;9;;; +72352-8;LL2232-8;Quality of life, general (0 to 10);LA19101-7;11;10 - as good as it can be;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA19100-9;1;0 - as bad as it can be;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA6112-2;2;1;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA6113-0;3;2;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA6114-8;4;3;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA6115-5;5;4;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA10137-0;6;5;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA10138-8;7;6;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA10139-6;8;7;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA10140-4;9;8;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA10141-2;10;9;;; +72353-6;LL2232-8;Quality of life, general (0 to 10);LA19101-7;11;10 - as good as it can be;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA19100-9;1;0 - as bad as it can be;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA6112-2;2;1;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA6113-0;3;2;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA6114-8;4;3;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA6115-5;5;4;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA10137-0;6;5;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA10138-8;7;6;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA10139-6;8;7;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA10140-4;9;8;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA10141-2;10;9;;; +72354-4;LL2232-8;Quality of life, general (0 to 10);LA19101-7;11;10 - as good as it can be;;; +72356-9;LL2210-4;Influenza virus;LA11919-0;1;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +72356-9;LL2210-4;Influenza virus;LA13543-6;2;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +72356-9;LL2210-4;Influenza virus;LA19008-4;3;Influenza A and B virus;;; +72356-9;LL2210-4;Influenza virus;LA11883-8;4;Not detected;;; +72356-9;LL2210-4;Influenza virus;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +72366-8;LL2210-4;Influenza virus;LA11919-0;1;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +72366-8;LL2210-4;Influenza virus;LA13543-6;2;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +72366-8;LL2210-4;Influenza virus;LA19008-4;3;Influenza A and B virus;;; +72366-8;LL2210-4;Influenza virus;LA11883-8;4;Not detected;;; +72366-8;LL2210-4;Influenza virus;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88200-1;LL2210-4;Influenza virus;LA11919-0;1;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +88200-1;LL2210-4;Influenza virus;LA13543-6;2;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +88200-1;LL2210-4;Influenza virus;LA19008-4;3;Influenza A and B virus;;; +88200-1;LL2210-4;Influenza virus;LA11883-8;4;Not detected;;; +88200-1;LL2210-4;Influenza virus;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +88568-1;LL2210-4;Influenza virus;LA11919-0;1;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +88568-1;LL2210-4;Influenza virus;LA13543-6;2;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +88568-1;LL2210-4;Influenza virus;LA19008-4;3;Influenza A and B virus;;; +88568-1;LL2210-4;Influenza virus;LA11883-8;4;Not detected;;; +88568-1;LL2210-4;Influenza virus;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +91772-4;LL2210-4;Influenza virus;LA11919-0;1;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +91772-4;LL2210-4;Influenza virus;LA13543-6;2;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +91772-4;LL2210-4;Influenza virus;LA19008-4;3;Influenza A and B virus;;; +91772-4;LL2210-4;Influenza virus;LA11883-8;4;Not detected;;; +91772-4;LL2210-4;Influenza virus;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +72365-0;LL2214-6;Influenza A/B Sofia;LA19017-5;1;Influenza A virus positive;;; +72365-0;LL2214-6;Influenza A/B Sofia;LA19018-3;2;Influenza A virus negative;;; +72365-0;LL2214-6;Influenza A/B Sofia;LA19019-1;3;Influenza B virus positive;;; +72365-0;LL2214-6;Influenza A/B Sofia;LA19020-9;4;Influenza B virus negative;;; +72365-0;LL2214-6;Influenza A/B Sofia;LA19021-7;5;Procedure control valid;;; +72365-0;LL2214-6;Influenza A/B Sofia;LA19022-5;6;Procedure control invalid;;; +72371-8;LL2237-7;Wound bed appearance;LA19112-4;1;Approximated;;; +72371-8;LL2237-7;Wound bed appearance;LA19113-2;2;Dehisced;;; +72371-8;LL2237-7;Wound bed appearance;LA18951-6;3;Intact;;; +72371-8;LL2237-7;Wound bed appearance;LA19114-0;4;Non-blanchable erythema;;; +72371-8;LL2237-7;Wound bed appearance;LA19115-7;5;Epithelialization;;; +72371-8;LL2237-7;Wound bed appearance;LA19116-5;6;Eschar;;; +72371-8;LL2237-7;Wound bed appearance;LA19117-3;7;Fibrinous;;; +72371-8;LL2237-7;Wound bed appearance;LA19118-1;8;Granulation;;; +72371-8;LL2237-7;Wound bed appearance;LA19119-9;9;Necrotic;;; +72371-8;LL2237-7;Wound bed appearance;LA19120-7;10;Sloughing;;; +72371-8;LL5199-6;[PUSH 3.0] Tissue type;LA29660-0;1;Necrotic Tissue (Eschar);;; +72371-8;LL5199-6;[PUSH 3.0] Tissue type;LA29661-8;2;Slough;;; +72371-8;LL5199-6;[PUSH 3.0] Tissue type;LA29662-6;3;Granulation tissue;;; +72371-8;LL5199-6;[PUSH 3.0] Tissue type;LA29663-4;4;Epithelial tissue;;; +72371-8;LL5199-6;[PUSH 3.0] Tissue type;LA29664-2;5;Closed/Resurfaced;;; +72373-4;LL2211-2;pos-neg-name of virus identified;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72373-4;LL2211-2;pos-neg-name of virus identified;LA11884-6;2;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +72373-4;LL2211-2;pos-neg-name of virus identified;LA19009-2;3;Echovirus Type 9;;; +72374-2;LL2211-2;pos-neg-name of virus identified;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72374-2;LL2211-2;pos-neg-name of virus identified;LA11884-6;2;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +72374-2;LL2211-2;pos-neg-name of virus identified;LA19009-2;3;Echovirus Type 9;;; +72412-0;LL2217-9;BKV subtypes;LA19049-8;1;BK virus subtype I;;; +72412-0;LL2217-9;BKV subtypes;LA19050-6;2;BK virus subtype II;;; +72412-0;LL2217-9;BKV subtypes;LA19051-4;3;BK virus subtype III;;; +72412-0;LL2217-9;BKV subtypes;LA19052-2;4;BK virus subtype IV;;; +72413-8;LL2217-9;BKV subtypes;LA19049-8;1;BK virus subtype I;;; +72413-8;LL2217-9;BKV subtypes;LA19050-6;2;BK virus subtype II;;; +72413-8;LL2217-9;BKV subtypes;LA19051-4;3;BK virus subtype III;;; +72413-8;LL2217-9;BKV subtypes;LA19052-2;4;BK virus subtype IV;;; +72482-3;LL2217-9;BKV subtypes;LA19049-8;1;BK virus subtype I;;; +72482-3;LL2217-9;BKV subtypes;LA19050-6;2;BK virus subtype II;;; +72482-3;LL2217-9;BKV subtypes;LA19051-4;3;BK virus subtype III;;; +72482-3;LL2217-9;BKV subtypes;LA19052-2;4;BK virus subtype IV;;; +72483-1;LL2217-9;BKV subtypes;LA19049-8;1;BK virus subtype I;;; +72483-1;LL2217-9;BKV subtypes;LA19050-6;2;BK virus subtype II;;; +72483-1;LL2217-9;BKV subtypes;LA19051-4;3;BK virus subtype III;;; +72483-1;LL2217-9;BKV subtypes;LA19052-2;4;BK virus subtype IV;;; +72484-9;LL2217-9;BKV subtypes;LA19049-8;1;BK virus subtype I;;; +72484-9;LL2217-9;BKV subtypes;LA19050-6;2;BK virus subtype II;;; +72484-9;LL2217-9;BKV subtypes;LA19051-4;3;BK virus subtype III;;; +72484-9;LL2217-9;BKV subtypes;LA19052-2;4;BK virus subtype IV;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA6111-4;1;0;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA6112-2;2;1;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA6113-0;3;2;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA6114-8;4;3;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA6115-5;5;4;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA10137-0;6;5;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA10138-8;7;6;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA10139-6;8;7;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA10140-4;9;8;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA10141-2;10;9;;; +72514-3;LL2335-9;Numeric rating scale from 0-10;LA13942-0;11;10;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6111-4;1;0;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6112-2;2;1;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6113-0;3;2;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6114-8;4;3;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6115-5;5;4;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10137-0;6;5;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10138-8;7;6;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10139-6;8;7;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10140-4;9;8;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10141-2;10;9;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA13942-0;11;10;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6111-4;1;0;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6112-2;2;1;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6113-0;3;2;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6114-8;4;3;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6115-5;5;4;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10137-0;6;5;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10138-8;7;6;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10139-6;8;7;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10140-4;9;8;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10141-2;10;9;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA13942-0;11;10;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6111-4;1;0;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6112-2;2;1;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6113-0;3;2;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6114-8;4;3;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6115-5;5;4;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10137-0;6;5;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10138-8;7;6;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10139-6;8;7;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10140-4;9;8;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10141-2;10;9;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA13942-0;11;10;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6111-4;1;0;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6112-2;2;1;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6113-0;3;2;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6114-8;4;3;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA6115-5;5;4;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10137-0;6;5;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10138-8;7;6;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10139-6;8;7;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10140-4;9;8;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA10141-2;10;9;;; +75893-8;LL2335-9;Numeric rating scale from 0-10;LA13942-0;11;10;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA6111-4;1;0;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA6112-2;2;1;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA6113-0;3;2;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA6114-8;4;3;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA6115-5;5;4;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA10137-0;6;5;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA10138-8;7;6;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA10139-6;8;7;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA10140-4;9;8;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA10141-2;10;9;;; +82289-0;LL2335-9;Numeric rating scale from 0-10;LA13942-0;11;10;;; +72518-4;LL2336-7;CHEK2 gene targeted mutation analysis;LA19441-7;1;470C>T mutation present;;; +72518-4;LL2336-7;CHEK2 gene targeted mutation analysis;LA19442-5;2;1100delC mutation present;;; +72519-2;LL2330-0;Birth Certificate_Infections during pregnancy;LA10467-1;1;Gonorrhea;;; +72519-2;LL2330-0;Birth Certificate_Infections during pregnancy;LA17003-7;2;Syphilis;;; +72519-2;LL2330-0;Birth Certificate_Infections during pregnancy;LA16984-9;3;Chlamydia;;; +72519-2;LL2330-0;Birth Certificate_Infections during pregnancy;LA18126-5;4;Hepatitis B;;; +72519-2;LL2330-0;Birth Certificate_Infections during pregnancy;LA19423-5;5;Hepatitis C;;; +72519-2;LL2330-0;Birth Certificate_Infections during pregnancy;LA19424-3;6;None of the above listed infections were present and/or treated during this pregnancy;;; +72527-5;LL2337-5;NPUAP Pressure Ulcer Stages;LA19443-3;1;Category/Stage I: Non-blanchable erythema;;; +72527-5;LL2337-5;NPUAP Pressure Ulcer Stages;LA19444-1;2;Category/Stage II: Partial thickness;;; +72527-5;LL2337-5;NPUAP Pressure Ulcer Stages;LA19445-8;3;Category/Stage III: Full thickness skin loss;;; +72527-5;LL2337-5;NPUAP Pressure Ulcer Stages;LA19446-6;4;Category/Stage IV: Full thickness tissue loss;;; +72527-5;LL2337-5;NPUAP Pressure Ulcer Stages;LA19447-4;5;Unstageable/Unclassified: Full thickness skin or tissue loss – depth unknown;;; +72527-5;LL2337-5;NPUAP Pressure Ulcer Stages;LA19448-2;6;Suspected Deep Tissue Injury – depth unknown;;; +76505-7;LL2337-5;NPUAP Pressure Ulcer Stages;LA19443-3;1;Category/Stage I: Non-blanchable erythema;;; +76505-7;LL2337-5;NPUAP Pressure Ulcer Stages;LA19444-1;2;Category/Stage II: Partial thickness;;; +76505-7;LL2337-5;NPUAP Pressure Ulcer Stages;LA19445-8;3;Category/Stage III: Full thickness skin loss;;; +76505-7;LL2337-5;NPUAP Pressure Ulcer Stages;LA19446-6;4;Category/Stage IV: Full thickness tissue loss;;; +76505-7;LL2337-5;NPUAP Pressure Ulcer Stages;LA19447-4;5;Unstageable/Unclassified: Full thickness skin or tissue loss – depth unknown;;; +76505-7;LL2337-5;NPUAP Pressure Ulcer Stages;LA19448-2;6;Suspected Deep Tissue Injury – depth unknown;;; +72605-9;LL2326-8;CMV gp;LA19228-8;1;gB1;;; +72605-9;LL2326-8;CMV gp;LA19229-6;2;gB2;;; +72605-9;LL2326-8;CMV gp;LA19230-4;3;gB3;;; +72605-9;LL2326-8;CMV gp;LA19231-2;4;gB4;;; +72605-9;LL2326-8;CMV gp;LA19416-9;5;gH1;;; +72605-9;LL2326-8;CMV gp;LA19417-7;6;gH2;;; +72606-7;LL2328-4;HDV genotype;LA20154-3;1;HDV-1;;; +72606-7;LL2328-4;HDV genotype;LA20155-0;2;HDV-2;;; +72606-7;LL2328-4;HDV genotype;LA20156-8;3;HDV-3;;; +72606-7;LL2328-4;HDV genotype;LA20157-6;4;HDV-4;;; +72606-7;LL2328-4;HDV genotype;LA20158-4;5;HDV-5;;; +72606-7;LL2328-4;HDV genotype;LA20159-2;6;HDV-6;;; +72606-7;LL2328-4;HDV genotype;LA20160-0;7;HDV-7;;; +72606-7;LL2328-4;HDV genotype;LA20161-8;8;HDV-8;;; +72637-2;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72637-2;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72637-2;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72637-2;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72637-2;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72638-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72638-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72638-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72638-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72638-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72639-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72639-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72639-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72639-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72639-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72640-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72640-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72640-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72640-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72640-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72641-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72641-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72641-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72641-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72641-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72681-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72681-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72681-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72681-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72681-0;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72682-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72682-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72682-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72682-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72682-8;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72683-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72683-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72683-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72683-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72683-6;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72684-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72684-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72684-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72684-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72684-4;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72685-1;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72685-1;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72685-1;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72685-1;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72685-1;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72686-9;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA6568-5;1;Not at all;;; +72686-9;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA14312-5;2;Once;;; +72686-9;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28443-2;3;2-3 times;;; +72686-9;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28444-0;4;4-6 times;;; +72686-9;LL4755-6;Not at all | Once | 2-3 times | 4-6 times | Daily;LA28445-7;5;Daily or more often;;; +72654-7;LL2351-6;SNRPN gene 15q11;LA19537-2;1;15q11-13(SNRPNx2);;; +72654-7;LL2351-6;SNRPN gene 15q11;LA19538-0;2;del(15)(q11-13)(SNRPN-);;; +72690-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72690-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72690-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72690-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72690-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72691-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72691-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72691-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72691-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72691-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72692-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72692-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72692-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72692-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72692-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72698-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72698-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72698-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72698-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72698-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72699-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72699-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72699-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72699-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72699-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72700-8;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72700-8;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72700-8;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72700-8;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72700-8;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72701-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72701-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72701-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72701-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72701-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72702-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72702-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72702-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72702-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72702-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72703-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72703-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72703-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72703-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72703-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72704-0;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72704-0;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72704-0;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72704-0;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72704-0;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72705-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72705-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72705-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72705-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72705-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72706-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72706-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72706-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72706-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72706-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72707-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72707-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72707-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72707-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72707-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72708-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72708-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72708-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72708-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72708-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72709-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72709-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72709-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72709-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72709-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72710-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72710-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72710-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72710-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72710-7;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72711-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72711-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72711-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72711-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72711-5;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72712-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72712-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72712-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72712-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72712-3;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72713-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72713-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72713-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72713-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72713-1;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72714-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72714-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72714-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72714-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72714-9;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72715-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72715-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72715-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72715-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72715-6;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72716-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72716-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72716-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72716-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72716-4;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72717-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA6568-5;1;Not at all;;; +72717-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA13940-4;2;A little;;; +72717-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28439-0;3;Rather;;; +72717-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA15550-9;4;Much;;; +72717-2;LL4754-9;Not at all | A little | Rather | Much | Very stron;LA28441-6;5;Very strong;;; +72696-8;LL2295-5;SLC40A1 alleles;LA19319-5;1;A77D;;; +72696-8;LL2295-5;SLC40A1 alleles;LA19320-3;2;D157G;;; +72696-8;LL2295-5;SLC40A1 alleles;LA19321-1;3;Q182H;;; +72696-8;LL2295-5;SLC40A1 alleles;LA19322-9;4;D181V;;; +72696-8;LL2295-5;SLC40A1 alleles;LA19323-7;5;G267D;;; +72696-8;LL2295-5;SLC40A1 alleles;LA19328-6;6;Q248H;;; +72725-5;LL2352-4;"t(11;14) MYEOV/IGH";LA19539-8;1;(11q13,14q32)x2[100];;; +72725-5;LL2352-4;"t(11;14) MYEOV/IGH";LA19540-6;2;"t(11;14)(q13;q32)[67]/(11q13,14q32)x2[33]";;; +72726-3;LL2356-5;"t(4;14)(FGFR3,IGH)";LA19546-3;1;(4p16,14q32)x2[100];;; +72726-3;LL2356-5;"t(4;14)(FGFR3,IGH)";LA19545-5;2;"t(4;14)(p16;q32)[x80]/(4p16,14q32)x2[20]";;; +72728-9;LL2358-1;del(13)(q14);LA19550-5;1;nuc ish(13q14)x2[100];;; +72728-9;LL2358-1;del(13)(q14);LA19551-3;2;nuc ish(13q14x1)[60]/(13q14x2)[40];;; +72767-7;LL2163-5;GenBank Inflza Virus A Hemagglutinin;LA18872-4;1;JQ791012;;; +72767-7;LL2163-5;GenBank Inflza Virus A Hemagglutinin;LA18873-2;2;JQ791004;;; +72767-7;LL2163-5;GenBank Inflza Virus A Hemagglutinin;LA18874-0;3;JQ790996;;; +72824-6;LL2357-3;del(17)(p13);LA19552-1;1;nuc ish(17p13)x2[100];;; +72824-6;LL2357-3;del(17)(p13);LA19553-9;2;nuc ish(17p13x1)[60)/(17p13x2)[40];;; +72826-1;LL2359-9;Race OMB 1997;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +72826-1;LL2359-9;Race OMB 1997;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +72826-1;LL2359-9;Race OMB 1997;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +72826-1;LL2359-9;Race OMB 1997;LA10611-4;4;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +72826-1;LL2359-9;Race OMB 1997;LA4457-3;5;White;2106-3;White;https://www.cdc.gov/phin +81887-2;LL2359-9;Race OMB 1997;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +81887-2;LL2359-9;Race OMB 1997;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +81887-2;LL2359-9;Race OMB 1997;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +81887-2;LL2359-9;Race OMB 1997;LA10611-4;4;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +81887-2;LL2359-9;Race OMB 1997;LA4457-3;5;White;2106-3;White;https://www.cdc.gov/phin +72827-9;LL2360-7;"dic(9;20)";LA19547-1;1;(wcp9,wcp20)x2[100];;; +72827-9;LL2360-7;"dic(9;20)";LA19548-9;2;"der(9)t(9;20)(p11-13;q11)(wcp9+,wcp20+)";;; +72833-7;LL2327-6;CMV UL97;LA19418-5;1;M460V;;; +72833-7;LL2327-6;CMV UL97;LA19420-1;2;A594T;;; +72833-7;LL2327-6;CMV UL97;LA19419-3;3;A594V;;; +72833-7;LL2327-6;CMV UL97;LA19421-9;4;L595S;;; +72838-6;LL2325-0;HSV;LA19414-4;1;Herpes simplex type 1;;; +72838-6;LL2325-0;HSV;LA19415-1;2;Herpes simplex type 2;;; +72838-6;LL2325-0;HSV;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +72838-6;LL2325-0;HSV;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88127-6;LL2325-0;HSV;LA19414-4;1;Herpes simplex type 1;;; +88127-6;LL2325-0;HSV;LA19415-1;2;Herpes simplex type 2;;; +88127-6;LL2325-0;HSV;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +88127-6;LL2325-0;HSV;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88606-9;LL2325-0;HSV;LA19414-4;1;Herpes simplex type 1;;; +88606-9;LL2325-0;HSV;LA19415-1;2;Herpes simplex type 2;;; +88606-9;LL2325-0;HSV;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +88606-9;LL2325-0;HSV;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91773-2;LL2325-0;HSV;LA19414-4;1;Herpes simplex type 1;;; +91773-2;LL2325-0;HSV;LA19415-1;2;Herpes simplex type 2;;; +91773-2;LL2325-0;HSV;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +91773-2;LL2325-0;HSV;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +72840-2;LL2315-1;HBV codon 250;LA19384-9;1;M250;;; +72840-2;LL2315-1;HBV codon 250;LA19385-6;2;I250;;; +72840-2;LL2315-1;HBV codon 250;LA19386-4;3;L250;;; +72840-2;LL2315-1;HBV codon 250;LA19387-2;4;V250;;; +72841-0;LL2322-7;HBV codon 237;LA19402-9;1;P237;;; +72841-0;LL2322-7;HBV codon 237;LA19403-7;2;T237;;; +72842-8;LL2314-4;HBV codon 233;LA19382-3;1;I233;;; +72842-8;LL2314-4;HBV codon 233;LA19383-1;2;V233;;; +72844-4;LL2318-5;HBV codon 214;LA19393-0;1;V214;;; +72844-4;LL2318-5;HBV codon 214;LA19394-8;2;I214;;; +72845-1;LL2312-8;HBV codon 202;LA19377-3;0;I202;;; +72845-1;LL2312-8;HBV codon 202;LA19374-0;1;S202;;; +72845-1;LL2312-8;HBV codon 202;LA19375-7;2;C202;;; +72845-1;LL2312-8;HBV codon 202;LA19376-5;3;G202;;; +72846-9;LL2311-0;HBV codon 194;LA19372-4;1;A194;;; +72846-9;LL2311-0;HBV codon 194;LA19373-2;2;T194;;; +72847-7;LL2319-3;HBV codon 191;LA19395-5;1;V191;;; +72847-7;LL2319-3;HBV codon 191;LA19396-3;2;I191;;; +72848-5;LL2310-2;HBV codon 184;LA19368-2;1;T184;;; +72848-5;LL2310-2;HBV codon 184;LA19369-0;2;I184;;; +72848-5;LL2310-2;HBV codon 184;LA19370-8;3;S184;;; +72848-5;LL2310-2;HBV codon 184;LA19371-6;4;G184;;; +72849-3;LL2306-0;HBV codon 169;LA19358-3;1;I169;;; +72849-3;LL2306-0;HBV codon 169;LA19359-1;2;T169;;; +72850-1;LL2320-1;HBV codon 85;LA19397-1;1;S85;;; +72850-1;LL2320-1;HBV codon 85;LA19398-9;2;T85;;; +72850-1;LL2320-1;HBV codon 85;LA19399-7;3;A85;;; +72851-9;LL2321-9;HBV codon 84;LA19400-3;1;V84;;; +72851-9;LL2321-9;HBV codon 84;LA19401-1;2;A84;;; +72872-5;LL2424-1;MCM6 gene mutation analysis;LA19727-9;1;-13910 C/C, -13915 T/G;;; +72872-5;LL2424-1;MCM6 gene mutation analysis;LA19728-7;2;-13910 C/T, -13915 T/G;;; +72877-4;LL605-7;MG_11;LA10315-2;1;Ultrarapid metabolizer;;; +72877-4;LL605-7;MG_11;LA10316-0;2;Extensive metabolizer;;; +72877-4;LL605-7;MG_11;LA10317-8;3;Intermediate metabolizer;;; +72877-4;LL605-7;MG_11;LA9657-3;4;Poor metabolizer;;; +72877-4;LL605-7;MG_11;LA9663-1;5;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +72877-4;LL605-7;MG_11;LA9664-9;6;Failure;;; +72879-0;LL605-7;MG_11;LA10315-2;1;Ultrarapid metabolizer;;; +72879-0;LL605-7;MG_11;LA10316-0;2;Extensive metabolizer;;; +72879-0;LL605-7;MG_11;LA10317-8;3;Intermediate metabolizer;;; +72879-0;LL605-7;MG_11;LA9657-3;4;Poor metabolizer;;; +72879-0;LL605-7;MG_11;LA9663-1;5;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +72879-0;LL605-7;MG_11;LA9664-9;6;Failure;;; +72880-8;LL605-7;MG_11;LA10315-2;1;Ultrarapid metabolizer;;; +72880-8;LL605-7;MG_11;LA10316-0;2;Extensive metabolizer;;; +72880-8;LL605-7;MG_11;LA10317-8;3;Intermediate metabolizer;;; +72880-8;LL605-7;MG_11;LA9657-3;4;Poor metabolizer;;; +72880-8;LL605-7;MG_11;LA9663-1;5;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +72880-8;LL605-7;MG_11;LA9664-9;6;Failure;;; +72881-6;LL2250-0;UGT2B15 example genotypes;LA19163-7;1;UGT2B15*1/*1;;; +72881-6;LL2250-0;UGT2B15 example genotypes;LA19164-5;2;UGT2B15*1/*2;;; +72881-6;LL2250-0;UGT2B15 example genotypes;LA19165-2;3;UGT2B15*2/*2;;; +72882-4;LL2249-2;CYP2B6 example genotypes;LA19167-8;1;CYP2B6*1/*1;;; +72882-4;LL2249-2;CYP2B6 example genotypes;LA19166-0;2;CYP2B6*1/*18;;; +72882-4;LL2249-2;CYP2B6 example genotypes;LA19168-6;3;CYP2B6*1/*4;;; +72883-2;LL2292-2;CYP2E1 example genotypes;LA19303-9;1;CYP2E1*1A/*2;;; +72883-2;LL2292-2;CYP2E1 example genotypes;LA19307-0;2;CYP2E1*1B/*4;;; +72883-2;LL2292-2;CYP2E1 example genotypes;LA19304-7;3;CYP2E1*2/*3;;; +72883-2;LL2292-2;CYP2E1 example genotypes;LA19305-4;4;CYP2E1*1A/*3;;; +72883-2;LL2292-2;CYP2E1 example genotypes;LA19306-2;5;CYP2E1*4/*7;;; +72884-0;LL2235-1;CYP1A2 *C, *K, *F genotypes;LA19108-2;1;CYP1A2 *1C/*1C;;; +72884-0;LL2235-1;CYP1A2 *C, *K, *F genotypes;LA19106-6;2;CYP1A2 *1F/*1F;;; +72884-0;LL2235-1;CYP1A2 *C, *K, *F genotypes;LA19107-4;3;CYP1A2 *1F/*1K;;; +72884-0;LL2235-1;CYP1A2 *C, *K, *F genotypes;LA19109-0;4;CYP1A2 *1K/*1C;;; +72917-8;LL2334-2;HNA 5 genotype;LA19439-1;1;HNA 5a/5a;;; +72917-8;LL2334-2;HNA 5 genotype;LA19438-3;2;HNA 5a/5b;;; +72917-8;LL2334-2;HNA 5 genotype;LA19440-9;3;HNA 5b/5b;;; +72918-6;LL2333-4;HNA 4 genotype;LA19435-9;1;HNA 4a/4a;;; +72918-6;LL2333-4;HNA 4 genotype;LA19436-7;2;HNA 4a/4b;;; +72918-6;LL2333-4;HNA 4 genotype;LA19437-5;3;HNA 4b/4b;;; +72919-4;LL2332-6;HNA 3 genotype;LA19432-6;1;HNA 3a/3a;;; +72919-4;LL2332-6;HNA 3 genotype;LA19433-4;2;HNA 3a/3b;;; +72919-4;LL2332-6;HNA 3 genotype;LA19434-2;3;HNA 3b/3b;;; +72921-0;LL2331-8;HNA 1 genotype;LA19426-8;1;HNA 1a/1a;;; +72921-0;LL2331-8;HNA 1 genotype;LA19427-6;2;HNA 1a/1b;;; +72921-0;LL2331-8;HNA 1 genotype;LA19428-4;3;HNA 1b/1b;;; +72921-0;LL2331-8;HNA 1 genotype;LA19429-2;4;HNA 1a/1a/1c;;; +72921-0;LL2331-8;HNA 1 genotype;LA19430-0;5;HNA 1a/1b/1c;;; +72921-0;LL2331-8;HNA 1 genotype;LA19431-8;6;HNA 1b/1b/1c;;; +72923-6;LL2363-1;Specimen source synovial fluid;LA18767-6;1;Knee-left;;; +72923-6;LL2363-1;Specimen source synovial fluid;LA18768-4;2;Knee-right;;; +72923-6;LL2363-1;Specimen source synovial fluid;LA18763-5;3;Hip-left;;; +72923-6;LL2363-1;Specimen source synovial fluid;LA18764-3;4;Hip-right;;; +72923-6;LL2363-1;Specimen source synovial fluid;LA18773-4;5;Shoulder-left;;; +72923-6;LL2363-1;Specimen source synovial fluid;LA18774-2;6;Shoulder-right;;; +73558-9;LL2365-6;S. aureus - CoNS;LA19568-7;1;Positive S. aureus;;; +73558-9;LL2365-6;S. aureus - CoNS;LA19569-5;2;Positive CoNS;;; +73558-9;LL2365-6;S. aureus - CoNS;LA19570-3;3;Positive S. aureus and CoNS;;; +73558-9;LL2365-6;S. aureus - CoNS;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73560-5;LL2362-3;Mumps virus IgG and IgM Imp;LA19556-2;1;Results suggest prior exposure and immunity to mumps, or a convalescent stage of infection.;;; +73560-5;LL2362-3;Mumps virus IgG and IgM Imp;LA19557-0;2;Results suggest that patient is not immune to mumps.;;; +73560-5;LL2362-3;Mumps virus IgG and IgM Imp;LA19558-8;3;Results suggest that patient is not immune to mumps. Suggests evidence of recent infection.;;; +73560-5;LL2362-3;Mumps virus IgG and IgM Imp;LA19559-6;4;Results suggest prior exposure to mumps. Unable to interpret IgM result.;;; +73654-6;LL2471-2;HCV NS3;LA19895-4;1;T54A;;; +73654-6;LL2471-2;HCV NS3;LA19897-0;2;R155K;;; +73654-6;LL2471-2;HCV NS3;LA19898-8;3;R155T;;; +73654-6;LL2471-2;HCV NS3;LA19899-6;4;A156S;;; +73654-6;LL2471-2;HCV NS3;LA19900-2;5;A156V;;; +73654-6;LL2471-2;HCV NS3;LA19901-0;6;A156T;;; +73654-6;LL2471-2;HCV NS3;LA19902-8;7;V170A;;; +73655-3;LL2470-4;HCV NS5;LA19891-3;1;H95Q;;; +73655-3;LL2470-4;HCV NS5;LA19892-1;2;N411S;;; +73655-3;LL2470-4;HCV NS5;LA19893-9;3;M414T;;; +73655-3;LL2470-4;HCV NS5;LA19894-7;4;Y448H;;; +73656-1;LL2469-6;VZV ORF28;LA19883-0;1;E512K;;; +73656-1;LL2469-6;VZV ORF28;LA19884-8;2;K662E;;; +73656-1;LL2469-6;VZV ORF28;LA19885-5;3;V666L;;; +73656-1;LL2469-6;VZV ORF28;LA19886-3;4;R665G;;; +73656-1;LL2469-6;VZV ORF28;LA19887-1;5;V680A;;; +73656-1;LL2469-6;VZV ORF28;LA19888-9;6;A773V;;; +73656-1;LL2469-6;VZV ORF28;LA19889-7;7;N7795S;;; +73656-1;LL2469-6;VZV ORF28;LA19890-5;8;V855M;;; +73657-9;LL2468-8;VZV ORF36;LA19878-0;1;D18N;;; +73657-9;LL2468-8;VZV ORF36;LA19879-8;2;G24E;;; +73657-9;LL2468-8;VZV ORF36;LA19880-6;3;D129N;;; +73657-9;LL2468-8;VZV ORF36;LA19881-4;4;L332P;;; +73657-9;LL2468-8;VZV ORF36;LA19882-2;5;E59G;;; +73658-7;LL2475-3;HIV 1 subtype;LA13487-6;1;A;;; +73658-7;LL2475-3;HIV 1 subtype;LA14518-7;2;B;;; +73658-7;LL2475-3;HIV 1 subtype;LA14519-5;3;C;;; +73658-7;LL2475-3;HIV 1 subtype;LA14520-3;4;D;;; +73658-7;LL2475-3;HIV 1 subtype;LA13504-8;5;F;;; +73658-7;LL2475-3;HIV 1 subtype;LA19150-4;6;G;;; +73658-7;LL2475-3;HIV 1 subtype;LA19174-4;7;H;;; +73658-7;LL2475-3;HIV 1 subtype;LA19928-3;8;CRF01;;; +73658-7;LL2475-3;HIV 1 subtype;LA19929-1;9;CRF02;;; +73658-7;LL2475-3;HIV 1 subtype;LA19931-7;10;CRF04;;; +87962-7;LL2475-3;HIV 1 subtype;LA13487-6;1;A;;; +87962-7;LL2475-3;HIV 1 subtype;LA14518-7;2;B;;; +87962-7;LL2475-3;HIV 1 subtype;LA14519-5;3;C;;; +87962-7;LL2475-3;HIV 1 subtype;LA14520-3;4;D;;; +87962-7;LL2475-3;HIV 1 subtype;LA13504-8;5;F;;; +87962-7;LL2475-3;HIV 1 subtype;LA19150-4;6;G;;; +87962-7;LL2475-3;HIV 1 subtype;LA19174-4;7;H;;; +87962-7;LL2475-3;HIV 1 subtype;LA19928-3;8;CRF01;;; +87962-7;LL2475-3;HIV 1 subtype;LA19929-1;9;CRF02;;; +87962-7;LL2475-3;HIV 1 subtype;LA19931-7;10;CRF04;;; +73659-5;LL2476-1;HIV 2 subtype;LA13487-6;1;A;;; +73659-5;LL2476-1;HIV 2 subtype;LA14518-7;2;B;;; +73659-5;LL2476-1;HIV 2 subtype;LA14519-5;3;C;;; +73659-5;LL2476-1;HIV 2 subtype;LA14520-3;4;D;;; +73659-5;LL2476-1;HIV 2 subtype;LA13504-8;5;F;;; +73659-5;LL2476-1;HIV 2 subtype;LA19150-4;6;G;;; +73659-5;LL2476-1;HIV 2 subtype;LA19174-4;7;H;;; +73666-0;LL2464-7;Beta-haemolytic streptococci type;LA19854-1;1;Beta-haemolytic streptococci Lancefield group A;;; +73666-0;LL2464-7;Beta-haemolytic streptococci type;LA19855-8;2;Beta-haemolytic streptococci Lancefield group B;;; +73666-0;LL2464-7;Beta-haemolytic streptococci type;LA19856-6;3;Beta-haemolytic streptococci Lancefield group C;;; +73666-0;LL2464-7;Beta-haemolytic streptococci type;LA19857-4;4;Beta-haemolytic enterococci Lancefield group D;;; +73666-0;LL2464-7;Beta-haemolytic streptococci type;LA19858-2;5;Beta-haemolytic streptococci Lancefield group F;;; +73666-0;LL2464-7;Beta-haemolytic streptococci type;LA19859-0;6;Beta-haemolytic streptococci Lancefield group G;;; +73671-0;LL2460-5;Legionella pneumophila serotype;LA19836-8;1;Legionella pneumophila serotype 1;;; +73671-0;LL2460-5;Legionella pneumophila serotype;LA19837-6;2;Legionella pneumophila serotype 2;;; +73671-0;LL2460-5;Legionella pneumophila serotype;LA19839-2;3;Legionella pneumophila serotype 3;;; +73672-8;LL2466-2;Salmonella sp phage types;LA19873-1;1;Salmonella Typhimurium phage type DT010;;; +73672-8;LL2466-2;Salmonella sp phage types;LA19876-4;2;Salmonella Typhimurium phage type DT104;;; +73672-8;LL2466-2;Salmonella sp phage types;LA19874-9;3;Salmonella Enteritidis phage type 14b;;; +73672-8;LL2466-2;Salmonella sp phage types;LA19875-6;4;Salmonella Enteritidis phage type 8;;; +73672-8;LL2466-2;Salmonella sp phage types;LA19872-3;5;Salmonella Enteritidis phage type LT 8/7;;; +73673-6;LL2463-9;Yersinia enterocolitica serotype;LA19850-9;1;Yersinia enterocolitica O3;;; +73673-6;LL2463-9;Yersinia enterocolitica serotype;LA19851-7;2;Yersinia enterocolitica O5;;; +73673-6;LL2463-9;Yersinia enterocolitica serotype;LA19852-5;3;Yersinia enterocolitica O8;;; +73673-6;LL2463-9;Yersinia enterocolitica serotype;LA19853-3;4;Yersinia enterocolitica O9;;; +73674-4;LL2462-1;Streptococcus pneumoniae serotype;LA19845-9;1;Streptococcus pneumoniae 1;;; +73674-4;LL2462-1;Streptococcus pneumoniae serotype;LA19846-7;2;Streptococcus pneumoniae 4;;; +73674-4;LL2462-1;Streptococcus pneumoniae serotype;LA19847-5;3;Streptococcus pneumoniae 5;;; +73674-4;LL2462-1;Streptococcus pneumoniae serotype;LA19848-3;4;Streptococcus pneumoniae 11A;;; +73674-4;LL2462-1;Streptococcus pneumoniae serotype;LA19849-1;5;Streptococcus pneumoniae 7F;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19861-6;1;CYP2D6*1A;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19867-3;2;CYP2D6*2A;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19862-4;3;CYP2D6*1B;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19863-2;4;CYP2D6*1C;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19865-7;5;CYP2D6*1E;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19866-5;6;CYP2D6*1XN;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19870-7;7;CYP2D6*4X2;;; +73681-9;LL2465-4;CYP2D6 alleles;LA19871-5;8;CYP2D6*6B;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19861-6;1;CYP2D6*1A;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19867-3;2;CYP2D6*2A;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19862-4;3;CYP2D6*1B;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19863-2;4;CYP2D6*1C;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19865-7;5;CYP2D6*1E;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19866-5;6;CYP2D6*1XN;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19870-7;7;CYP2D6*4X2;;; +73682-7;LL2465-4;CYP2D6 alleles;LA19871-5;8;CYP2D6*6B;;; +73694-2;LL2212-0;Microscopic observation results;LA19010-0;1;Fungal elements not seen;;; +73694-2;LL2212-0;Microscopic observation results;LA19011-8;2;Fungal hyphae not seen, yeast cells present;;; +73694-2;LL2212-0;Microscopic observation results;LA19013-4;3;Fungal hyphae present;;; +73694-2;LL2212-0;Microscopic observation results;LA19012-6;4;Fungal hyphae present, yeast cells also seen;;; +73694-2;LL2212-0;Microscopic observation results;LA19014-2;5;Fungal hyphae not seen, yeast cells & pseudohyphae present;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24453-5;1;V234L;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19752-7;2;K13K/E;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19753-5;3;K20R;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19754-3;4;E28D;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19755-0;5;M41M/L;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25848-5;6;G359S;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25847-7;7;V35I;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19756-8;8;K14R;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19757-6;9;V31I;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24451-9;10;G193E;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24454-3;11;D288N;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19758-4;12;I62V;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25851-9;13;Q18K;;; +73695-9;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25852-7;14;E35D;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24453-5;1;V234L;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19752-7;2;K13K/E;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19753-5;3;K20R;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19754-3;4;E28D;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19755-0;5;M41M/L;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25848-5;6;G359S;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25847-7;7;V35I;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19756-8;8;K14R;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19757-6;9;V31I;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24451-9;10;G193E;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24454-3;11;D288N;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19758-4;12;I62V;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25851-9;13;Q18K;;; +80689-3;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25852-7;14;E35D;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24453-5;1;V234L;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19752-7;2;K13K/E;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19753-5;3;K20R;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19754-3;4;E28D;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19755-0;5;M41M/L;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25848-5;6;G359S;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25847-7;7;V35I;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19756-8;8;K14R;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19757-6;9;V31I;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24451-9;10;G193E;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24454-3;11;D288N;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19758-4;12;I62V;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25851-9;13;Q18K;;; +80692-7;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25852-7;14;E35D;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24453-5;1;V234L;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19752-7;2;K13K/E;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19753-5;3;K20R;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19754-3;4;E28D;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19755-0;5;M41M/L;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25848-5;6;G359S;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25847-7;7;V35I;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19756-8;8;K14R;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19757-6;9;V31I;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24451-9;10;G193E;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA24454-3;11;D288N;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA19758-4;12;I62V;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25851-9;13;Q18K;;; +80693-5;LL2436-5;Example HIV-1 mutations in RT, PR, and IN regions;LA25852-7;14;E35D;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19819-4;1;Prior prenatal diagnosis of CCHD;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19820-2;2;Prior postnatal diagnosis of CCHD;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19821-0;3;Early discharge;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19822-8;4;Transfer prior to screening;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19823-6;5;Infant in NICU;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19824-4;6;Medically unstable and inappropriate for screen;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19825-1;7;Receiving supplemental oxygen;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19826-9;8;Infant deceased;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19827-7;9;Parental refusal based on religious beliefs;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA19828-5;10;Parental refusal for reasons other than religious beliefs;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA7497-6;11;Equipment failure;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA20946-2;12;Diagnostic testing begun in lieu of screening based on clinical suspicion for CCHD;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA20947-0;13;Infant being monitored or treated for non-CCHD condition;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA25798-2;14;Comfort care only;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA25799-0;15;Echocardiography normal;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA25800-6;16;Missed/not documented;;; +73698-3;LL2458-9;Reason CCHD NBS not performed;LA46-8;17;Other;;; +73699-1;LL2454-8;0|1|2|3 or more|Unknown;LA6111-4;1;0;;; +73699-1;LL2454-8;0|1|2|3 or more|Unknown;LA6112-2;2;1;;; +73699-1;LL2454-8;0|1|2|3 or more|Unknown;LA6113-0;3;2;;; +73699-1;LL2454-8;0|1|2|3 or more|Unknown;LA19812-9;4;3 or more;;; +73699-1;LL2454-8;0|1|2|3 or more|Unknown;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73700-7;LL2453-0;NBS interpretations - CCHD;LA18592-8;1;In range;;; +73700-7;LL2453-0;NBS interpretations - CCHD;LA18593-6;2;Out of range;;; +73700-7;LL2453-0;NBS interpretations - CCHD;LA19816-0;3;Inconclusive, repeat screen needed;;; +73700-7;LL2453-0;NBS interpretations - CCHD;LA19817-8;4;Attempted but unsuccessful - technical fail;;; +73700-7;LL2453-0;NBS interpretations - CCHD;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +73702-3;LL2461-3;N meningitidis serosubtype;LA19840-0;1;Neisseria meningitidis A:4.21:P1.9;;; +73702-3;LL2461-3;N meningitidis serosubtype;LA19841-8;2;Neisseria meningitidis B:4:P1.9;;; +73702-3;LL2461-3;N meningitidis serosubtype;LA19842-6;3;Neisseria meningitidis C:2a:P1.2;;; +73702-3;LL2461-3;N meningitidis serosubtype;LA19843-4;4;Neisseria meningitidis B:4:P1.7;;; +73702-3;LL2461-3;N meningitidis serosubtype;LA19844-2;5;Neisseria meningitidis W135:2a:P1.5;;; +73733-8;LL2473-8;Bacteria biovars;LA19921-8;1;Aeromonas veronii biovar sobria;;; +73733-8;LL2473-8;Bacteria biovars;LA19918-4;2;Brucella melitensis biovar 1;;; +73733-8;LL2473-8;Bacteria biovars;LA19920-0;3;Brucella melitensis biovar 2;;; +73733-8;LL2473-8;Bacteria biovars;LA19919-2;4;Brucella abortus biovar 3;;; +73733-8;LL2473-8;Bacteria biovars;LA19917-6;5;Vibrio splendidus biovar 1;;; +73733-8;LL2473-8;Bacteria biovars;LA19915-0;6;Francisella tularensis biovar tularensis (type A);;; +73733-8;LL2473-8;Bacteria biovars;LA19916-8;7;Francisella tularensis biovar palaearctica (type B);;; +73735-3;LL2953-9;ACADVL gene_Example Mutations;LA21298-7;1;"g.7126518A>C; rs118204015 SNP";;; +73735-3;LL2953-9;ACADVL gene_Example Mutations;LA21299-5;2;"g.7127184G>A; rs2309689 SNP";;; +73735-3;LL2953-9;ACADVL gene_Example Mutations;LA21300-1;3;"g.7128285C>T; rs118204014 SNP";;; +73739-5;LL2769-9;NBS_hear_reason not performed;LA12408-3;1;Attempted, but unsuccessful - technical fail;103709008;Failed attempted procedure (situation);http://snomed.info/sct +73739-5;LL2769-9;NBS_hear_reason not performed;LA12409-1;2;Not performed, medical exclusion - not indicated;410534003;Not indicated (qualifier value);http://snomed.info/sct +73739-5;LL2769-9;NBS_hear_reason not performed;LA20644-3;3;Patient died;397709008;Patient died (finding);http://snomed.info/sct +73739-5;LL2769-9;NBS_hear_reason not performed;LA6644-4;4;Parental refusal;609589008;Refused by parents of subject (qualifier value);http://snomed.info/sct +73739-5;LL2769-9;NBS_hear_reason not performed;LA20643-5;5;Procedure refused for religious reason;183945002;Procedure declined for religious reason (situation);http://snomed.info/sct +73742-9;LL2769-9;NBS_hear_reason not performed;LA12408-3;1;Attempted, but unsuccessful - technical fail;103709008;Failed attempted procedure (situation);http://snomed.info/sct +73742-9;LL2769-9;NBS_hear_reason not performed;LA12409-1;2;Not performed, medical exclusion - not indicated;410534003;Not indicated (qualifier value);http://snomed.info/sct +73742-9;LL2769-9;NBS_hear_reason not performed;LA20644-3;3;Patient died;397709008;Patient died (finding);http://snomed.info/sct +73742-9;LL2769-9;NBS_hear_reason not performed;LA6644-4;4;Parental refusal;609589008;Refused by parents of subject (qualifier value);http://snomed.info/sct +73742-9;LL2769-9;NBS_hear_reason not performed;LA20643-5;5;Procedure refused for religious reason;183945002;Procedure declined for religious reason (situation);http://snomed.info/sct +73748-6;LL2474-6;APOB gene R3500Q and R3500W;LA19922-6;1;One copy of the p.R3500Q mutation was detected.;;; +73748-6;LL2474-6;APOB gene R3500Q and R3500W;LA19924-2;2;One copy of the p.R3500W mutation was detected.;;; +73748-6;LL2474-6;APOB gene R3500Q and R3500W;LA19925-9;3;One copy each of the p.R3500Q and p.R3500W mutation was detected.;;; +73748-6;LL2474-6;APOB gene R3500Q and R3500W;LA19926-7;4;Two copies of the p.R3500Q mutation were detected.;;; +73748-6;LL2474-6;APOB gene R3500Q and R3500W;LA19927-5;5;Two copies of the p.R3500W mutation were detected.;;; +73748-6;LL2474-6;APOB gene R3500Q and R3500W;LA19943-2;6;A mutation was NOT detected;;; +73749-4;LL2480-3;4p16.3 FISH;LA19941-6;1;ish 4p16.3(WHSx2);;; +73749-4;LL2480-3;4p16.3 FISH;LA19937-4;2;ish del(4)(p16.3p16.3)(WHS-);;; +73750-2;LL2484-5;17p11.2 FISH;LA19936-6;1;ish 17p11.2(SMSx2);;; +73751-0;LL2482-9;5p15.2 FISH;LA19935-8;1;ish del(5)(p15.2p15.2)(D5S630-);;; +73752-8;LL2467-0;Syphillis interpretation;LA19958-0;1;No serological evidence of current or past infection;;; +73752-8;LL2467-0;Syphillis interpretation;LA19959-8;2;Biological false positive;;; +73752-8;LL2467-0;Syphillis interpretation;LA19960-6;3;Early primary syphilis;;; +73752-8;LL2467-0;Syphillis interpretation;LA19961-4;4;Treated syphilis;;; +73752-8;LL2467-0;Syphillis interpretation;LA19962-2;5;Person from a country endemic for yaws, pinta or bejel;;; +73752-8;LL2467-0;Syphillis interpretation;LA19963-0;6;May represent a biological false positive;;; +73752-8;LL2467-0;Syphillis interpretation;LA19964-8;7;May be infectious syphilis if no previous history of syphilis;;; +73752-8;LL2467-0;Syphillis interpretation;LA19877-2;8;Consistent with active infectious syphilis;;; +73757-7;LL2514-9;Yes-no-Infant transferred,status unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +73757-7;LL2514-9;Yes-no-Infant transferred,status unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +73757-7;LL2514-9;Yes-no-Infant transferred,status unk;LA20052-9;3;Infant transferred, status unknown;;; +73761-9;LL2517-2;Cephalic-Breech-Other;LA18949-0;1;Cephalic;;; +73761-9;LL2517-2;Cephalic-Breech-Other;LA18948-2;2;Breech;;; +73761-9;LL2517-2;Cephalic-Breech-Other;LA46-8;3;Other;;; +73761-9;LL2517-2;Cephalic-Breech-Other;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73762-7;LL2518-0;Route/method of delivery;LA20039-6;1;Vaginal/Spontaneous;;; +73762-7;LL2518-0;Route/method of delivery;LA20040-4;2;Vaginal/Forceps;;; +73762-7;LL2518-0;Route/method of delivery;LA20041-2;3;Vaginal/Vacuum;;; +73762-7;LL2518-0;Route/method of delivery;LA20042-0;4;Cesarean;;; +73762-7;LL2518-0;Route/method of delivery;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73764-3;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20036-2;1;MD;;; +73764-3;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20037-0;2;DO;;; +73764-3;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20038-8;3;CNM/CM;;; +73764-3;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20053-7;4;Other midwife;;; +73764-3;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA6310-2;5;Other (specify);;; +73764-3;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88081-5;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20036-2;1;MD;;; +88081-5;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20037-0;2;DO;;; +88081-5;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20038-8;3;CNM/CM;;; +88081-5;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA20053-7;4;Other midwife;;; +88081-5;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA6310-2;5;Other (specify);;; +88081-5;LL2511-5;MD-DO-CNM/CM-Other Midwife-Other;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73765-0;LL2533-9;Planned to deliver at home;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +73765-0;LL2533-9;Planned to deliver at home;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +73765-0;LL2533-9;Planned to deliver at home;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73766-8;LL2513-1;Type of place where birth occurred;LA6218-7;1;Hospital;;; +73766-8;LL2513-1;Type of place where birth occurred;LA20032-1;2;Free-standing birthing center;;; +73766-8;LL2513-1;Type of place where birth occurred;LA20033-9;3;Home birth;;; +73766-8;LL2513-1;Type of place where birth occurred;LA20034-7;4;Clinic/doctor's office;;; +73766-8;LL2513-1;Type of place where birth occurred;LA46-8;5;Other;;; +73766-8;LL2513-1;Type of place where birth occurred;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85712-8;LL2513-1;Type of place where birth occurred;LA6218-7;1;Hospital;;; +85712-8;LL2513-1;Type of place where birth occurred;LA20032-1;2;Free-standing birthing center;;; +85712-8;LL2513-1;Type of place where birth occurred;LA20033-9;3;Home birth;;; +85712-8;LL2513-1;Type of place where birth occurred;LA20034-7;4;Clinic/doctor's office;;; +85712-8;LL2513-1;Type of place where birth occurred;LA46-8;5;Other;;; +85712-8;LL2513-1;Type of place where birth occurred;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73767-6;LL2529-7;Performed/Not performed/Planned;LA19974-7;1;Performed;;; +73767-6;LL2529-7;Performed/Not performed/Planned;LA7304-4;2;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +73767-6;LL2529-7;Performed/Not performed/Planned;LA20099-0;3;Planned;;; +73768-4;LL2527-1;Autopsy was performed;LA20097-4;1;Autopsy examination;;; +73768-4;LL2527-1;Autopsy was performed;LA20098-2;2;Autopsy not performed;;; +73768-4;LL2527-1;Autopsy was performed;LA19977-0;3;Autopsy planned;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA10467-1;1;Gonorrhea;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA17003-7;2;Syphilis;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA16984-9;3;Chlamydia;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA20064-4;4;Listeria;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA20065-1;5;Group B Streptococcus;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA20066-9;6;Cytomegalovirus;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA20067-7;7;Parvovirus;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA10511-6;8;Toxoplasmosis;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA9-3;9;None of the above;;; +73769-2;LL2534-7;Fetal Death Report_Infections during pregnancy;LA6310-2;10;Other (specify);;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA6112-2;1;1;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA6113-0;2;2;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA6114-8;3;3;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA6115-5;4;4;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA10137-0;5;5;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA10138-8;6;6;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA10139-6;7;7;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA10140-4;8;8;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA10141-2;9;9;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA13942-0;10;10;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA14557-5;11;11;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA14558-3;12;12;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA4720-4;13;Not applicable;;; +73771-8;LL2521-4;First-Second-Third-Fourth-etc.;LA4489-6;14;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +73774-2;LL2516-4;Onset of Labor;LA20068-5;1;Premature rupture of membranes;;; +73774-2;LL2516-4;Onset of Labor;LA20069-3;2;Precipitous labor;;; +73774-2;LL2516-4;Onset of Labor;LA20070-1;3;Prolonged labor;;; +73774-2;LL2516-4;Onset of Labor;LA9-3;4;None of the above;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA19978-8;1;Diabetes prepregnancy;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA19979-6;2;Diabetes gestatational;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA19980-4;3;Hypertension prepregnancy;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA19981-2;4;Hypertension gestational;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA19982-0;5;Hypertension eclampsia;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA20055-2;6;Previous preterm birth;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA20056-0;7;Previous poor pregnancy outcome;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA20057-8;8;Infertility treatment;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA20058-6;9;Fertility-enhancing drugs, Artificial insemination or Intrauterine insemination;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA20059-4;10;Assisted reproductive technology;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA20060-2;11;Previous cesarean delivery;;; +73775-9;LL2515-6;Risk factors current pregnancy;LA9-3;12;None of the above;;; +73778-3;LL2524-8;Karyotype confirmed-pending;LA20092-5;1;Karyotype confirmed;;; +73778-3;LL2524-8;Karyotype confirmed-pending;LA20091-7;2;Karyotype pending;;; +73779-1;LL2524-8;Karyotype confirmed-pending;LA20092-5;1;Karyotype confirmed;;; +73779-1;LL2524-8;Karyotype confirmed-pending;LA20091-7;2;Karyotype pending;;; +73780-9;LL2522-2;Congenital anomalies;LA20078-4;1;Anencephaly;;; +73780-9;LL2522-2;Congenital anomalies;LA20079-2;2;Meningomyelocele/Spina Bifida;;; +73780-9;LL2522-2;Congenital anomalies;LA20080-0;3;Cyanotic congenital heart disease;;; +73780-9;LL2522-2;Congenital anomalies;LA20081-8;4;Congenital diaphragmatic hernia;;; +73780-9;LL2522-2;Congenital anomalies;LA20082-6;5;Omphalocele;;; +73780-9;LL2522-2;Congenital anomalies;LA19590-1;6;Gastroschisis;;; +73780-9;LL2522-2;Congenital anomalies;LA20085-9;7;Limb reduction defect;;; +73780-9;LL2522-2;Congenital anomalies;LA20086-7;8;Cleft Lip with or without Cleft Palate;;; +73780-9;LL2522-2;Congenital anomalies;LA20087-5;9;Cleft Palate alone;;; +73780-9;LL2522-2;Congenital anomalies;LA20088-3;10;Down syndrome;;; +73780-9;LL2522-2;Congenital anomalies;LA20089-1;11;Suspected chromosomal disorder;;; +73780-9;LL2522-2;Congenital anomalies;LA20090-9;12;Hypospadias;;; +73780-9;LL2522-2;Congenital anomalies;LA9-3;13;None of the above;;; +73781-7;LL2520-6;Maternal morbity - L&D complications;LA20044-6;1;Maternal transfusion;;; +73781-7;LL2520-6;Maternal morbity - L&D complications;LA20045-3;2;Third or fourth degree perineal laceration;;; +73781-7;LL2520-6;Maternal morbity - L&D complications;LA20046-1;3;Ruptured uterus;;; +73781-7;LL2520-6;Maternal morbity - L&D complications;LA20047-9;4;Unplanned hysterectomy;;; +73781-7;LL2520-6;Maternal morbity - L&D complications;LA20048-7;5;Admission to intensive care unit;;; +73781-7;LL2520-6;Maternal morbity - L&D complications;LA20049-5;6;Unplanned operating room procedure following delivery;;; +73781-7;LL2520-6;Maternal morbity - L&D complications;LA9-3;7;None of the above;;; +73782-5;LL2510-7;At risk, no risk;LA19952-3;1;At risk;;; +73782-5;LL2510-7;At risk, no risk;LA19983-8;2;No risk;;; +88124-3;LL2510-7;At risk, no risk;LA19952-3;1;At risk;;; +88124-3;LL2510-7;At risk, no risk;LA19983-8;2;No risk;;; +73784-1;LL2500-8;Moisture - NSRAS;LA9607-8;1;Constantly moist;;; +73784-1;LL2500-8;Moisture - NSRAS;LA20004-0;2;"Moist - Skin is often but not always moist/damp; linen must be changed at least once a shift";;; +73784-1;LL2500-8;Moisture - NSRAS;LA20005-7;3;Occasionally moist - Skin is occasionally moist/damp. Requiring an extra linen change approximately once a day.;;; +73784-1;LL2500-8;Moisture - NSRAS;LA20006-5;4;Rarely moist - Skin is usually dry, linen requires changing only every 24 hours.;;; +73785-8;LL2499-3;Nutrition - NSRAS;LA20000-8;1;Very poor - NPO on intravenous fluids;;; +73785-8;LL2499-3;Nutrition - NSRAS;LA20001-6;2;Inadequate - Receives less than optimum amount of liquid diet for growth (formula/breast milk) and supplemented with intravenous fluids;;; +73785-8;LL2499-3;Nutrition - NSRAS;LA20002-4;3;Adequate - Is on tube feedings which meet nutritional needs for growth;;; +73785-8;LL2499-3;Nutrition - NSRAS;LA20003-2;4;Excellent - Bottle/breastfeeds every meal which meets nutritional needs for growth;;; +73786-6;LL2498-5;Activity - NSRAS;LA19948-1;1;"Completely bedbound - In a radiant warmer with a clear plastic ""saran"" tent";;; +73786-6;LL2498-5;Activity - NSRAS;LA19949-9;2;"Limited bedbound - In a radiant warmer without a clear plastic ""saran"" tent";;; +73786-6;LL2498-5;Activity - NSRAS;LA19998-6;3;Slightly limited - In a double walled isolette;;; +73786-6;LL2498-5;Activity - NSRAS;LA19999-4;4;Unlimited - In an open crib;;; +73787-4;LL2496-9;Mobility - NSRAS;LA19994-5;1;Completely immobile - Does not make even slight changes in body or extremity position without assistance (e.g. Pavulon);;; +73787-4;LL2496-9;Mobility - NSRAS;LA19995-2;2;Very limited - Makes occasional slight changes in body or extremity but unable to make frequent changes independently;;; +73787-4;LL2496-9;Mobility - NSRAS;LA19996-0;3;Slightly limited - Makes frequent though slight changes in body or extremity position independently;;; +73787-4;LL2496-9;Mobility - NSRAS;LA19997-8;4;No limitations - Makes major and frequent changes in position without assistance (e.g., turn head);;; +73788-2;LL2495-1;Mental Status - NSRAS;LA19988-7;1;Completely limited - Unresponsive (does not flinch, grasp, moan, increase blood pressure, or heart rate) to painful stimuli due to diminished level of consciousness or sedation.;;; +73788-2;LL2495-1;Mental Status - NSRAS;LA19989-5;2;Very limited - Responds only to painful stimuli (flinches, grasps, moans, increased blood pressure or heart rate);;; +73788-2;LL2495-1;Mental Status - NSRAS;LA19990-3;3;Slightly limited - Lethargic;;; +73788-2;LL2495-1;Mental Status - NSRAS;LA19991-1;4;No impairment - Alert and active;;; +73789-0;LL2494-4;General Physical Condition - NSRAS;LA19984-6;1;Gestational age <28 weeks;;; +73789-0;LL2494-4;General Physical Condition - NSRAS;LA19985-3;2;Gestational age >28 weeks but <33 weeks;;; +73789-0;LL2494-4;General Physical Condition - NSRAS;LA19986-1;3;Gestational age >33 weeks but <38 weeks;;; +73789-0;LL2494-4;General Physical Condition - NSRAS;LA19987-9;4;Gestational age >38 weeks to posterm;;; +73792-4;LL2459-7;Infant activity during measurement;LA11864-8;1;Sleeping;;; +73792-4;LL2459-7;Infant activity during measurement;LA19830-1;2;Awake and quiet;;; +73792-4;LL2459-7;Infant activity during measurement;LA19831-9;3;Awake and crying;;; +73792-4;LL2459-7;Infant activity during measurement;LA19832-7;4;Feeding;;; +73796-5;LL2459-7;Infant activity during measurement;LA11864-8;1;Sleeping;;; +73796-5;LL2459-7;Infant activity during measurement;LA19830-1;2;Awake and quiet;;; +73796-5;LL2459-7;Infant activity during measurement;LA19831-9;3;Awake and crying;;; +73796-5;LL2459-7;Infant activity during measurement;LA19832-7;4;Feeding;;; +73800-5;LL2457-1;Sensor wrap size;LA13524-6;1;Adult;;; +73800-5;LL2457-1;Sensor wrap size;LA19834-3;2;Pediatric;;; +73800-5;LL2457-1;Sensor wrap size;LA8983-4;3;Small;255507004;Small (qualifier value);http://snomed.info/sct +73800-5;LL2457-1;Sensor wrap size;LA8982-6;4;Medium;;; +73800-5;LL2457-1;Sensor wrap size;LA8981-8;5;Large;255509001;Large (qualifier value);http://snomed.info/sct +73801-3;LL2456-3;Sensor wrap types;LA19813-7;1;Cloth;;; +73801-3;LL2456-3;Sensor wrap types;LA16576-3;2;Foam;;; +73801-3;LL2456-3;Sensor wrap types;LA19814-5;3;Velcro;;; +73803-9;LL2455-5;Sensor type - single-use, reusable;LA19810-3;1;Disposable;;; +73803-9;LL2455-5;Sensor type - single-use, reusable;LA19811-1;2;Reusable;;; +73807-0;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73807-0;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73807-0;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +73808-8;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73808-8;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73808-8;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +73809-6;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +73809-6;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +73809-6;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97312-3;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97312-3;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97312-3;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97313-1;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97313-1;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97313-1;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97314-9;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97314-9;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97314-9;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97315-6;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97315-6;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97315-6;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97316-4;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97316-4;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97316-4;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97317-2;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97317-2;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97317-2;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97318-0;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97318-0;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97318-0;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97319-8;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97319-8;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97319-8;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97320-6;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97320-6;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97320-6;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +97321-4;LL2451-4;pos-neg-undetermined;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97321-4;LL2451-4;pos-neg-undetermined;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97321-4;LL2451-4;pos-neg-undetermined;LA14100-4;3;Undetermined;;; +73811-2;LL2503-2;Estimated Timing of Fetal death;LA20011-5;1;Dead at time of first assessment, no labor ongoing;;; +73811-2;LL2503-2;Estimated Timing of Fetal death;LA20012-3;2;Dead at time of first assessment, labor ongoing;;; +73811-2;LL2503-2;Estimated Timing of Fetal death;LA20013-1;3;Died during labor, after first assessment;;; +73811-2;LL2503-2;Estimated Timing of Fetal death;LA20014-9;4;Unknown time of fetal death;;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA20015-6;1;Assisted ventilation required immediately following delivery;;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA20016-4;2;Assisted ventilation required for more than six hours;;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA20017-2;3;NICU admission;;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA20018-0;4;Newborn given surfactant replacement therapy;;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA20019-8;5;Antibiotics received by the newborn for suspected neonatal sepsis;;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA20020-6;6;Seizure or serious neurologic dysfunction;;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA20021-4;7;Significant birth injury (skeletal fracture(s), peripheral nerve injury, and/or soft tissue/solid organ hemorrhage which requires intervention);;; +73812-0;LL2505-7;Abnormal Conditions Newborn;LA9-3;8;None of the above;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20022-2;1;Induction of labor;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20023-0;2;Augmentation of labor;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20024-8;3;Non-vertex presentation;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20025-5;4;Steroids (glucocorticoids) for fetal lung maturation received by the mother prior to delivery;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20026-3;5;Antibiotics received by the mother during labor;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20027-1;6;Clinical chorioamnionitis diagnosed during labor or maternal temperature >38°C (100.4°F);;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20028-9;7;Moderate/heavy meconium staining of the amniotic fluid;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20029-7;8;Fetal intolerance of labor such that one or more of the following actions was taken: in-utero resuscitative measures, further fetal assessment, or operative delivery;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA20030-5;9;Epidural or spinal anesthesia during labor;;; +73813-8;LL2507-3;Characteristics of Labor and Delivery;LA9-3;10;None of the above;;; +73814-6;LL2501-6;Cervical cerclage-tocolysis-cephalic version-none;LA20007-3;1;Cervical cerclage;;; +73814-6;LL2501-6;Cervical cerclage-tocolysis-cephalic version-none;LA20008-1;2;Tocolysis;;; +73814-6;LL2501-6;Cervical cerclage-tocolysis-cephalic version-none;LA20009-9;3;External cephalic version;;; +73814-6;LL2501-6;Cervical cerclage-tocolysis-cephalic version-none;LA9-3;4;None of the above;;; +73820-3;LL4865-3;External cephalic version successful | failed;LA28524-9;1;Successful - Fetus was converted to a vertex presentation;;; +73820-3;LL4865-3;External cephalic version successful | failed;LA28525-6;2;Failed - Fetus was not converted to a vertex presentation;;; +73820-3;LL4865-3;External cephalic version successful | failed;LA28526-4;3;External cephalic version not attempted;;; +73822-9;LL2479-5;Male-female-aneuploidy;LA19938-2;1;Male fetus (XY);;; +73822-9;LL2479-5;Male-female-aneuploidy;LA19939-0;2;Female fetus (XX);;; +73822-9;LL2479-5;Male-female-aneuploidy;LA19940-8;3;Aneuploidy;;; +73824-5;LL2353-2;High risk|Low risk;LA19542-2;1;Low risk;;; +73824-5;LL2353-2;High risk|Low risk;LA19541-4;2;High risk;;; +73825-2;LL2353-2;High risk|Low risk;LA19542-2;1;Low risk;;; +73825-2;LL2353-2;High risk|Low risk;LA19541-4;2;High risk;;; +75544-7;LL2353-2;High risk|Low risk;LA19542-2;1;Low risk;;; +75544-7;LL2353-2;High risk|Low risk;LA19541-4;2;High risk;;; +83009-1;LL2353-2;High risk|Low risk;LA19542-2;1;Low risk;;; +83009-1;LL2353-2;High risk|Low risk;LA19541-4;2;High risk;;; +87759-7;LL2353-2;High risk|Low risk;LA19542-2;1;Low risk;;; +87759-7;LL2353-2;High risk|Low risk;LA19541-4;2;High risk;;; +93307-7;LL2353-2;High risk|Low risk;LA19542-2;1;Low risk;;; +93307-7;LL2353-2;High risk|Low risk;LA19541-4;2;High risk;;; +73833-6;LL2493-6;neg-pos-number of cells;LA19970-5;1;>25 typical bacilli with 3+ to 4+ cell wall fluorescence/smear, result is positive;;; +73833-6;LL2493-6;neg-pos-number of cells;LA19971-3;2;< 25 typical bacilli with 3+ to 4+ cell wall fluorescence/smear, number of cells stained are reported;;; +73833-6;LL2493-6;neg-pos-number of cells;LA19973-9;3;No typical bacilli with 3+ to 4+ cell wall fluorescence/smear, result is negative;;; +73834-4;LL5495-8;Carbapenemase Producing Organism Screening;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +73834-4;LL5495-8;Carbapenemase Producing Organism Screening;LA30663-1;2;Coliforms;;; +73834-4;LL5495-8;Carbapenemase Producing Organism Screening;LA30664-9;3;Pseudomonas sp;;; +73834-4;LL5495-8;Carbapenemase Producing Organism Screening;LA30665-6;4;Acinetobacter sp;;; +73834-4;LL5495-8;Carbapenemase Producing Organism Screening;LA30666-4;5;Other gram negative bacterium;;; +94151-8;LL5495-8;Carbapenemase Producing Organism Screening;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +94151-8;LL5495-8;Carbapenemase Producing Organism Screening;LA30663-1;2;Coliforms;;; +94151-8;LL5495-8;Carbapenemase Producing Organism Screening;LA30664-9;3;Pseudomonas sp;;; +94151-8;LL5495-8;Carbapenemase Producing Organism Screening;LA30665-6;4;Acinetobacter sp;;; +94151-8;LL5495-8;Carbapenemase Producing Organism Screening;LA30666-4;5;Other gram negative bacterium;;; +73907-8;LL2489-4;Human poliovirus identified;LA19953-1;1;Not isolated, specimen unsatisfactory;;; +73907-8;LL2489-4;Human poliovirus identified;LA19956-4;2;Human poliovirus 1;;; +73907-8;LL2489-4;Human poliovirus identified;LA19955-6;3;Human poliovirus 2;;; +73907-8;LL2489-4;Human poliovirus identified;LA19954-9;4;Human poliovirus 3;;; +73960-7;LL2490-2;Organism identified in mouth culture;LA19967-1;1;Culture negative for Corynebacterium diphtheriae;;; +73960-7;LL2490-2;Organism identified in mouth culture;LA19965-5;2;Culture negative for Group A, C or G beta haemolytic streptococci;;; +73960-7;LL2490-2;Organism identified in mouth culture;LA19966-3;3;Culture negative for Staphylococcus aureus;;; +73960-7;LL2490-2;Organism identified in mouth culture;LA19968-9;4;Culture negative for yeast;;; +73960-7;LL2490-2;Organism identified in mouth culture;LA19969-7;5;Culture positive for Candida albicans;;; +73961-5;LL2364-9;E Coli - K pneumoniae - P aeruginosa;LA19566-1;0;Negative Klebsiella pneumoniae;;; +73961-5;LL2364-9;E Coli - K pneumoniae - P aeruginosa;LA19562-0;1;Positive Escherichia coli;;; +73961-5;LL2364-9;E Coli - K pneumoniae - P aeruginosa;LA19563-8;2;Positive Klebsiella pneumoniae;;; +73961-5;LL2364-9;E Coli - K pneumoniae - P aeruginosa;LA19564-6;3;Positive Pseudomonas aeruginosa;;; +73961-5;LL2364-9;E Coli - K pneumoniae - P aeruginosa;LA19565-3;4;Negative Escherichia coli;;; +73961-5;LL2364-9;E Coli - K pneumoniae - P aeruginosa;LA19567-9;6;Negative Pseudomonas aeruginosa;;; +73962-3;LL2445-6;Candida sp identified by FISH probe;LA19783-2;1;Positive Candida albicans and/or Candida parapsilosis;;; +73962-3;LL2445-6;Candida sp identified by FISH probe;LA19785-7;2;Positive Candida glabrata and/or Candida krusei;;; +73962-3;LL2445-6;Candida sp identified by FISH probe;LA19784-0;3;Positive Candida tropicalis;;; +73962-3;LL2445-6;Candida sp identified by FISH probe;LA19786-5;4;Negative Candida albicans and Candida parapsilosis;;; +73962-3;LL2445-6;Candida sp identified by FISH probe;LA19788-1;5;Negative Candida glabrata and Candida krusei;;; +73962-3;LL2445-6;Candida sp identified by FISH probe;LA19787-3;6;Negative Candida tropicalis;;; +73963-1;LL2447-2;Enterococcus sp - E. faecalis + OE;LA19792-3;1;Negative Enterococcus faecalis and other enterococci;;; +73963-1;LL2447-2;Enterococcus sp - E. faecalis + OE;LA19793-1;2;Positive Enterococcus faecalis and other enterococci;;; +73963-1;LL2447-2;Enterococcus sp - E. faecalis + OE;LA19794-9;3;Positive Enterococcus faecalis, negative other enterococci;;; +73963-1;LL2447-2;Enterococcus sp - E. faecalis + OE;LA19795-6;4;Positive other enterococci, negative Enterococcus faecalis;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA11838-2;1;Swimming;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33427-8;2;Golfing (18 holes);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33428-6;3;Road Cycling (>30mins);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA15978-2;4;Gardening;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA17928-5;5;Bowling;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33429-4;6;Racquet Sports (Tennis, Racquetball, etc.);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33430-2;7;Distance Walking;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33431-0;8;Dancing / Ballet;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33432-8;9;Stretching Exercises (stretching out your muscles);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33433-6;10;Weight-lifting;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33434-4;11;Leg Extensions;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33435-1;12;Stair-Climber;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33436-9;13;Stationary Biking / Spinning;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33437-7;14;Leg Press;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA11835-8;15;Jogging;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33438-5;16;Elliptical Trainer;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33439-3;17;Aerobic Exercises;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA11838-2;1;Swimming;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33427-8;2;Golfing (18 holes);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33428-6;3;Road Cycling (>30mins);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA15978-2;4;Gardening;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA17928-5;5;Bowling;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33429-4;6;Racquet Sports (Tennis, Racquetball, etc.);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33430-2;7;Distance Walking;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33431-0;8;Dancing / Ballet;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33432-8;9;Stretching Exercises (stretching out your muscles);;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33433-6;10;Weight-lifting;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33434-4;11;Leg Extensions;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33435-1;12;Stair-Climber;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33436-9;13;Stationary Biking / Spinning;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33437-7;14;Leg Press;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA11835-8;15;Jogging;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33438-5;16;Elliptical Trainer;;; +73985-4;LL6247-2;Important recreational/workout/gym activities;LA33439-3;17;Aerobic Exercises;;; +73986-2;LL2555-2;Aerobic-Anaerobic exercise;LA20163-4;1;Aerobic exercise;;; +73986-2;LL2555-2;Aerobic-Anaerobic exercise;LA20162-6;2;Anaerobic exercise;;; +74003-5;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +74003-5;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +74003-5;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +75727-8;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +75727-8;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +75727-8;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +92931-5;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +92931-5;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +92931-5;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +92934-9;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +92934-9;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +92934-9;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +94411-6;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +94411-6;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +94411-6;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +94412-4;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +94412-4;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +94412-4;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +94415-7;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +94415-7;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +94415-7;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +94471-0;LL2556-0;Genotypes A/A, A/G, G/G;LA20172-5;1;AA (Wildtype);;; +94471-0;LL2556-0;Genotypes A/A, A/G, G/G;LA20173-3;2;A/G (heterozygous);;; +94471-0;LL2556-0;Genotypes A/A, A/G, G/G;LA20174-1;3;G/G (homozygous);;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20117-0;1;rs1128503 C/C;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20119-6;2;rs1128503 C/T;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20120-4;3;rs1128503 T/T;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20121-2;4;rs2032582 G/G;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20122-0;5;rs2032582 G/T;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20123-8;6;rs2032582 T/T;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20124-6;7;rs1045642 C/C;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20125-3;8;rs1045642 C/T;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA20126-1;9;rs1045642 T/T;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA29699-8;10;rs2032583 C/C;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA29697-2;11;rs2032583 T/C;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA29698-0;12;rs2032583 T/T;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA29702-0;13;rs2235015 G/G;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA29701-2;14;rs2235015 T/G;;; +74004-3;LL2539-6;ABCB1 mutation analysis example genotypes;LA29700-4;15;rs2235015 T/T;;; +74008-4;LL2553-7;Exercise intensity;LA20164-2;1;Light exercise intensity;;; +74008-4;LL2553-7;Exercise intensity;LA20165-9;2;Moderate exercise intensity;;; +74008-4;LL2553-7;Exercise intensity;LA20166-7;3;Vigorous exercise intensity;;; +82288-2;LL2553-7;Exercise intensity;LA20164-2;1;Light exercise intensity;;; +82288-2;LL2553-7;Exercise intensity;LA20165-9;2;Moderate exercise intensity;;; +82288-2;LL2553-7;Exercise intensity;LA20166-7;3;Vigorous exercise intensity;;; +74017-5;LL2545-3;Active|Inactive|Resolved;LA16666-2;1;Active;;; +74017-5;LL2545-3;Active|Inactive|Resolved;LA18632-2;2;Inactive;;; +74017-5;LL2545-3;Active|Inactive|Resolved;LA9041-0;3;Resolved;;; +99493-9;LL2545-3;Active|Inactive|Resolved;LA16666-2;1;Active;;; +99493-9;LL2545-3;Active|Inactive|Resolved;LA18632-2;2;Inactive;;; +99493-9;LL2545-3;Active|Inactive|Resolved;LA9041-0;3;Resolved;;; +74018-3;LL2559-4;DE-084_Alert types;LA7262-4;1;Administrative;;; +74018-3;LL2559-4;DE-084_Alert types;LA20176-6;2;Clinical or Medical;;; +74018-3;LL2559-4;DE-084_Alert types;LA20177-4;3;Home environment;;; +74018-3;LL2559-4;DE-084_Alert types;LA20178-2;4;Infection risk;;; +74018-3;LL2559-4;DE-084_Alert types;LA20179-0;5;Safety and security;;; +74018-3;LL2559-4;DE-084_Alert types;LA20180-8;6;Special mental health;;; +74018-3;LL2559-4;DE-084_Alert types;LA20181-6;7;Special needs and/or preferences;;; +74021-7;LL2558-6;Genetic algorithms;LA20167-5;1;BRCAPRO;;; +74021-7;LL2558-6;Genetic algorithms;LA20171-7;2;MelaPRO;;; +74021-7;LL2558-6;Genetic algorithms;LA20170-9;3;MMRpro;;; +74021-7;LL2558-6;Genetic algorithms;LA20169-1;4;BOADICEA;;; +74021-7;LL2558-6;Genetic algorithms;LA20168-3;5;IBIS;;; +74031-6;LL2538-8;Arbovirus EEE - SLE - WEE - CE - Neg;LA20113-9;1;Eastern Equine Encephalitis (EEE);;; +74031-6;LL2538-8;Arbovirus EEE - SLE - WEE - CE - Neg;LA20115-4;2;St. Louis Encephalitis Group (SLE);;; +74031-6;LL2538-8;Arbovirus EEE - SLE - WEE - CE - Neg;LA20112-1;3;Western Equine Encephalitis (WEE);;; +74031-6;LL2538-8;Arbovirus EEE - SLE - WEE - CE - Neg;LA20114-7;4;California Encephalitis Group (CE);;; +74031-6;LL2538-8;Arbovirus EEE - SLE - WEE - CE - Neg;LA20116-2;5;No Arbovirus Identified;;; +74033-2;LL2754-1;Pos-neg-unsat-cancel;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +74033-2;LL2754-1;Pos-neg-unsat-cancel;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74033-2;LL2754-1;Pos-neg-unsat-cancel;LA20552-8;3;Unsatisfactory;;; +74033-2;LL2754-1;Pos-neg-unsat-cancel;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +74035-7;LL2536-2;TSE by IB or IHC;LA20104-8;1;Bovine spongiform encephalopathy (BSE) - C type;;; +74035-7;LL2536-2;TSE by IB or IHC;LA20106-3;2;Atypical Bovine spongiform encephalopathy (BSE) - H type;;; +74035-7;LL2536-2;TSE by IB or IHC;LA20107-1;3;Atypical Bovine spongiform encephalopathy (BSE) - L type;;; +74035-7;LL2536-2;TSE by IB or IHC;LA20108-9;4;Scrapie;;; +74035-7;LL2536-2;TSE by IB or IHC;LA20109-7;5;Atypical scrapie;;; +74035-7;LL2536-2;TSE by IB or IHC;LA20111-3;6;Nor98;;; +74035-7;LL2536-2;TSE by IB or IHC;LA20110-5;7;Chronic wasting disease (CWD);;; +74035-7;LL2536-2;TSE by IB or IHC;LA6577-6;8;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74036-5;LL2536-2;TSE by IB or IHC;LA20104-8;1;Bovine spongiform encephalopathy (BSE) - C type;;; +74036-5;LL2536-2;TSE by IB or IHC;LA20106-3;2;Atypical Bovine spongiform encephalopathy (BSE) - H type;;; +74036-5;LL2536-2;TSE by IB or IHC;LA20107-1;3;Atypical Bovine spongiform encephalopathy (BSE) - L type;;; +74036-5;LL2536-2;TSE by IB or IHC;LA20108-9;4;Scrapie;;; +74036-5;LL2536-2;TSE by IB or IHC;LA20109-7;5;Atypical scrapie;;; +74036-5;LL2536-2;TSE by IB or IHC;LA20111-3;6;Nor98;;; +74036-5;LL2536-2;TSE by IB or IHC;LA20110-5;7;Chronic wasting disease (CWD);;; +74036-5;LL2536-2;TSE by IB or IHC;LA6577-6;8;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74037-3;LL2535-4;TSE by Light Microscopy;LA20104-8;1;Bovine spongiform encephalopathy (BSE) - C type;;; +74037-3;LL2535-4;TSE by Light Microscopy;LA20105-5;2;Atypical Bovine spongiform encephalopathy (BSE) - H or L type;;; +74037-3;LL2535-4;TSE by Light Microscopy;LA20108-9;3;Scrapie;;; +74037-3;LL2535-4;TSE by Light Microscopy;LA20109-7;4;Atypical scrapie;;; +74037-3;LL2535-4;TSE by Light Microscopy;LA20111-3;5;Nor98;;; +74037-3;LL2535-4;TSE by Light Microscopy;LA20110-5;6;Chronic wasting disease (CWD);;; +74037-3;LL2535-4;TSE by Light Microscopy;LA6577-6;7;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA20272-3;1;Cutaneous, topical application, including ointment, spray, patch;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9451-1;2;Subcutaneous;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9444-6;3;Ophthalmic;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA20324-2;4;Oral, including sublingual or buccal;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9445-3;5;Otic;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9263-0;6;Nasal;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9427-1;7;Inhalation;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9437-0;8;Intravenous;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9429-7;9;Intramuscular;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9435-4;10;Intrathecal;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9418-0;11;Epidural;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA20332-5;12;Gastric;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9369-5;13;Rectal;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA9459-4;14;Vaginal;;; +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA4489-6;15;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74050-6;LL2682-4;AHRQ_Medication_Q28_Q29;LA20318-4;16;Other: PLEASE SPECIFY;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA20272-3;1;Cutaneous, topical application, including ointment, spray, patch;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9451-1;2;Subcutaneous;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9444-6;3;Ophthalmic;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA20324-2;4;Oral, including sublingual or buccal;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9445-3;5;Otic;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9263-0;6;Nasal;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9427-1;7;Inhalation;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9437-0;8;Intravenous;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9429-7;9;Intramuscular;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9435-4;10;Intrathecal;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9418-0;11;Epidural;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA20332-5;12;Gastric;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9369-5;13;Rectal;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA9459-4;14;Vaginal;;; +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA4489-6;15;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74051-4;LL2682-4;AHRQ_Medication_Q28_Q29;LA20318-4;16;Other: PLEASE SPECIFY;;; +74052-2;LL2828-3;AHRQ_Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74052-2;LL2828-3;AHRQ_Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74053-0;LL2828-3;AHRQ_Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74053-0;LL2828-3;AHRQ_Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74550-5;LL2828-3;AHRQ_Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74550-5;LL2828-3;AHRQ_Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74551-3;LL2828-3;AHRQ_Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74551-3;LL2828-3;AHRQ_Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74706-3;LL2828-3;AHRQ_Y/N;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74706-3;LL2828-3;AHRQ_Y/N;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20279-8;1;Purchasing;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20291-3;2;Storing;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20292-1;3;Prescribing/ordering;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20293-9;4;Transcribing;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20294-7;5;Preparing;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20295-4;6;Dispensing;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20296-2;7;Administering;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20297-0;8;Monitoring;;; +74063-9;LL2669-1;AHRQ_Medication_Q16;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74063-9;LL2669-1;AHRQ_Medication_Q16;LA20318-4;10;Other: PLEASE SPECIFY;;; +74064-7;LL2668-3;AHRQ_Medication_Q15;LA20274-9;1;Drug-drug;;; +74064-7;LL2668-3;AHRQ_Medication_Q15;LA20316-8;2;Drug-food;;; +74064-7;LL2668-3;AHRQ_Medication_Q15;LA20317-6;3;Drug-disease;;; +74064-7;LL2668-3;AHRQ_Medication_Q15;LA20318-4;4;Other: PLEASE SPECIFY;;; +74065-4;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74065-4;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74065-4;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74556-2;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74556-2;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74556-2;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74562-0;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74562-0;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74562-0;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74565-3;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74565-3;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74565-3;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74567-9;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74567-9;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74567-9;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74568-7;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74568-7;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74568-7;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74707-1;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74707-1;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74707-1;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74708-9;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74708-9;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74708-9;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74709-7;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74709-7;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74709-7;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74721-2;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74721-2;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74721-2;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74722-0;LL2817-6;AHRQ_Y/N/UNK;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74722-0;LL2817-6;AHRQ_Y/N/UNK;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74722-0;LL2817-6;AHRQ_Y/N/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74067-0;LL2665-9;AHRQ_Medication_Q12;LA20281-4;1;Too high;;; +74067-0;LL2665-9;AHRQ_Medication_Q12;LA20289-7;2;Too low;;; +74067-0;LL2665-9;AHRQ_Medication_Q12;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74068-8;LL2664-2;AHRQ_Medication_Q11;LA20282-2;1;Too quickly;;; +74068-8;LL2664-2;AHRQ_Medication_Q11;LA20288-9;2;Too slowly;;; +74068-8;LL2664-2;AHRQ_Medication_Q11;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74069-6;LL2663-4;AHRQ_Medication_Q10;LA20280-6;1;Too early;;; +74069-6;LL2663-4;AHRQ_Medication_Q10;LA20290-5;2;Too late;;; +74069-6;LL2663-4;AHRQ_Medication_Q10;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74070-4;LL2662-6;AHRQ_Medication_Q9;LA20277-2;1;Overdose;;; +74070-4;LL2662-6;AHRQ_Medication_Q9;LA20300-2;2;Underdose;;; +74070-4;LL2662-6;AHRQ_Medication_Q9;LA20301-0;3;Missed or omitted dose;;; +74070-4;LL2662-6;AHRQ_Medication_Q9;LA7271-5;4;Extra dose;;; +74070-4;LL2662-6;AHRQ_Medication_Q9;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20276-4;1;Incorrect patient;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20302-8;2;Incorrect medication/substance;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20303-6;3;Incorrect dose(s);;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20304-4;4;Incorrect route of administration;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20305-1;5;Incorrect timing;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20306-9;6;Incorrect rate;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20307-7;7;Incorrect duration of administration or course of therapy;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20308-5;8;Incorrect dosage form (e.g., sustained release instead of immediate release);;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20309-3;9;Incorrect strength or concentration;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20310-1;10;Incorrect preparation, including inappropriate cutting of tablets, error in compounding, mixing, etc.;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20311-9;11;Expired or deteriorated medication/substance;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20312-7;12;Medication/substance that is known to be an allergen to the patient;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20345-7;13;Medication/substance that is known to be contraindicated for the patient;;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20313-5;14;Incorrect patient/family action (e.g., self-administration error);;; +74071-2;LL2661-8;AHRQ_Medication_Q8;LA20318-4;15;Other: PLEASE SPECIFY;;; +74072-0;LL2660-0;AHRQ_Medication_Q7;LA20275-6;1;Incorrect action (process failure or error) (e.g., such as administering overdose or incorrect medication);;; +74072-0;LL2660-0;AHRQ_Medication_Q7;LA20314-3;2;Unsafe condition;;; +74072-0;LL2660-0;AHRQ_Medication_Q7;LA20315-0;3;Adverse reaction in patient to the administered substance without any apparent incorrect action;;; +74072-0;LL2660-0;AHRQ_Medication_Q7;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74073-8;LL2659-2;AHRQ_Medication_Q6;LA20273-1;1;Dietary supplements (other than vitamins or minerals);;; +74073-8;LL2659-2;AHRQ_Medication_Q6;LA16117-6;2;Vitamins or minerals;;; +74073-8;LL2659-2;AHRQ_Medication_Q6;LA20320-0;3;Enteral nutritional products, including infant formula;;; +74073-8;LL2659-2;AHRQ_Medication_Q6;LA20321-8;4;Parenteral nutritional products;;; +74073-8;LL2659-2;AHRQ_Medication_Q6;LA20318-4;5;Other: PLEASE SPECIFY;;; +74074-6;LL2657-6;AHRQ_Medication_Q4;LA20283-0;1;Vaccines;;; +74074-6;LL2657-6;AHRQ_Medication_Q4;LA20287-1;2;Other biological products (e.g., thrombolytic);;; +74075-3;LL2655-0;AHRQ_Medication_Q2;LA20278-0;1;Prescription or over-the-counter (including herbal supplements);;; +74075-3;LL2655-0;AHRQ_Medication_Q2;LA20298-8;2;Compounded preparations;;; +74075-3;LL2655-0;AHRQ_Medication_Q2;LA20299-6;3;Investigational drugs;;; +74075-3;LL2655-0;AHRQ_Medication_Q2;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20271-5;1;Medications;;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20335-8;2;Biological products;;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20336-6;3;Nutritional products;;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20337-4;4;Expressed human breast milk;;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20338-2;5;Medical gases (e.g., oxygen, nitrogen, nitrous oxide);;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20339-0;6;Contrast media;;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20340-8;7;Radiopharmaceuticals;;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20341-6;8;Patient food (not suspected in drug-food interactions);;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20342-4;9;Drug-drug, drug-food, or adverse drug reaction as a result of a prescription and/or administration of a drug and/or food prior to admission;;; +74076-1;LL2654-3;AHRQ_Medication_Q1;LA20343-2;10;Other substance: PLEASE SPECIFY;;; +74079-5;LL2683-2;AHRQ_HERF_Q2;LA20347-3;1;Incident;;; +74079-5;LL2683-2;AHRQ_HERF_Q2;LA20346-5;2;Near miss;;; +74079-5;LL2683-2;AHRQ_HERF_Q2;LA20314-3;3;Unsafe condition;;; +74159-5;LL2690-7;PHVS_WorkSchedule_ODH;;0;;;; +74165-2;LL2689-9;PHVS_EmploymentStatus_ODH;;0;;;; +74172-8;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74172-8;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74172-8;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74172-8;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74172-8;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74173-6;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74173-6;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74173-6;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74173-6;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74173-6;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74174-4;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74174-4;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74174-4;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74174-4;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74174-4;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74175-1;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74175-1;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74175-1;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74175-1;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74175-1;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74176-9;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74176-9;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74176-9;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74176-9;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74176-9;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74177-7;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74177-7;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74177-7;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74177-7;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74177-7;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74178-5;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74178-5;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74178-5;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74178-5;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74178-5;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74179-3;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74179-3;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74179-3;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74179-3;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74179-3;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74180-1;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74180-1;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74180-1;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74180-1;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74180-1;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74181-9;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +74181-9;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +74181-9;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +74181-9;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +74181-9;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +75335-0;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +75335-0;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +75335-0;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +75335-0;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +75335-0;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +75337-6;LL2712-9;Subjective agreement scale (ord);LA15236-5;1;Strongly disagree;;; +75337-6;LL2712-9;Subjective agreement scale (ord);LA15773-7;2;Disagree;;; +75337-6;LL2712-9;Subjective agreement scale (ord);LA14786-0;3;Neutral;;; +75337-6;LL2712-9;Subjective agreement scale (ord);LA15774-5;4;Agree;;; +75337-6;LL2712-9;Subjective agreement scale (ord);LA15237-3;5;Strongly agree;;; +74183-5;LL2691-5;NMMDS_Job class;LA20390-3;1;Direct care staff;;; +74183-5;LL2691-5;NMMDS_Job class;LA20391-1;2;Management;;; +74183-5;LL2691-5;NMMDS_Job class;LA7262-4;3;Administrative;;; +74183-5;LL2691-5;NMMDS_Job class;LA20393-7;4;Support staff;;; +74185-0;LL2753-3;Percent US Fed Poverty Level;LA20523-9;1;<100% of the Federal (USA) Poverty Level;;; +74185-0;LL2753-3;Percent US Fed Poverty Level;LA20522-1;2;101-200% of the Federal (USA) Poverty Level;;; +74185-0;LL2753-3;Percent US Fed Poverty Level;LA20520-5;3;201-300% of the Federal (USA) Poverty Level;;; +74185-0;LL2753-3;Percent US Fed Poverty Level;LA20515-5;4;>300% of the Federal (USA) Poverty Level;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA17849-3;1;Medicaid;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA20189-9;2;Not billed (for any reason);;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA20190-7;3;Self pay;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA20191-5;4;Private/Commercial insurance;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA20192-3;5;No Fault Automobile;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA15652-3;6;Medicare;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA20193-1;7;Other Government;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA6452-2;8;Workers' compensation;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA20195-6;9;Blue Cross/Blue Shield;;; +74202-3;LL2563-6;NTDS_F01_Payment source;LA46-8;10;Other;;; +74202-3;LL4750-7;NTDS_F01_Payment source_v2;LA17849-3;1;Medicaid;;; +74202-3;LL4750-7;NTDS_F01_Payment source_v2;LA20189-9;2;Not billed (for any reason);;; +74202-3;LL4750-7;NTDS_F01_Payment source_v2;LA6369-8;3;Self-pay;;; +74202-3;LL4750-7;NTDS_F01_Payment source_v2;LA20191-5;4;Private/Commercial insurance;;; +74202-3;LL4750-7;NTDS_F01_Payment source_v2;LA15652-3;5;Medicare;;; +74202-3;LL4750-7;NTDS_F01_Payment source_v2;LA20193-1;6;Other Government;;; +74202-3;LL4750-7;NTDS_F01_Payment source_v2;LA46-8;7;Other;;; +74203-1;LL2552-9;NTDS_ED_21_Signs of life;LA20152-7;1;Arrived with NO signs of life;;; +74203-1;LL2552-9;NTDS_ED_21_Signs of life;LA20153-5;2;Arrived with signs of life;;; +74204-9;LL2551-1;NTDS_ED_18_Drug Use;LA20146-9;1;No (not tested);;; +74204-9;LL2551-1;NTDS_ED_18_Drug Use;LA20147-7;2;No (confirmed by test);;; +74204-9;LL2551-1;NTDS_ED_18_Drug Use;LA20150-1;3;Yes (confirmed by test [prescription drugs]);;; +74204-9;LL2551-1;NTDS_ED_18_Drug Use;LA20151-9;4;Yes (confirmed by test [illegal use drug]);;; +74205-6;LL2550-3;NTDS_ED_17_Alcohol Use;LA20146-9;1;No (not tested);;; +74205-6;LL2550-3;NTDS_ED_17_Alcohol Use;LA20147-7;2;No (confirmed by test);;; +74205-6;LL2550-3;NTDS_ED_17_Alcohol Use;LA20148-5;3;Yes (confirmed by test [trace levels]);;; +74205-6;LL2550-3;NTDS_ED_17_Alcohol Use;LA20149-3;4;Yes (confirmed by test [beyond legal limit]);;; +74206-4;LL2549-5;NTDS_ED_09_Supplemental oxygen;LA20142-8;1;No supplemental oxygen;;; +74206-4;LL2549-5;NTDS_ED_09_Supplemental oxygen;LA17976-4;2;Supplemental oxygen;;; +74210-6;LL2548-7;NTDS_ED_07_Respiratory rate assistance;LA20140-2;1;Unassisted respiratory rate;;; +74210-6;LL2548-7;NTDS_ED_07_Respiratory rate assistance;LA20141-0;2;Assisted respiratory rate;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26787-4;1;Acute myeloid leukemia;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26788-2;2;Acute promyelocytic leukemia;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26789-0;3;B-cell lymphoblastic leukemia/lymphoma;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26790-8;4;Chronic lymphocytic leukemia/small lymphocytic lymphoma;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26791-6;5;Chronic myelogenous leukemia;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26792-4;6;Hodgkin lymphoma;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26793-2;7;Mature B-cell neoplasm;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26794-0;8;Mature T-or NK-cell neoplasm;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26795-7;9;Metastatic Malignancy;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26796-5;10;Myelodysplastic syndrome;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26797-3;11;Myelodysplastic/myeloproliferative neoplasm;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26798-1;12;Myeloproliferative neoplasm;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26799-9;13;Plasma cell neoplasm;;; +74224-7;LL4164-1;WHO classification_Hematologic cancers categories;LA26800-5;14;T-cell lymphoblastic leukemia/lymphoma;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26787-4;1;Acute myeloid leukemia;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26788-2;2;Acute promyelocytic leukemia;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26789-0;3;B-cell lymphoblastic leukemia/lymphoma;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26790-8;4;Chronic lymphocytic leukemia/small lymphocytic lymphoma;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26791-6;5;Chronic myelogenous leukemia;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26792-4;6;Hodgkin lymphoma;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26793-2;7;Mature B-cell neoplasm;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26794-0;8;Mature T-or NK-cell neoplasm;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26795-7;9;Metastatic Malignancy;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26796-5;10;Myelodysplastic syndrome;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26797-3;11;Myelodysplastic/myeloproliferative neoplasm;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26798-1;12;Myeloproliferative neoplasm;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26799-9;13;Plasma cell neoplasm;;; +96060-9;LL4164-1;WHO classification_Hematologic cancers categories;LA26800-5;14;T-cell lymphoblastic leukemia/lymphoma;;; +74283-3;LL2757-4;NTDS_D_06_Alternate residence status;LA20561-9;1;Homeless;;; +74283-3;LL2757-4;NTDS_D_06_Alternate residence status;LA20562-7;2;Undocumented citizen;;; +74283-3;LL2757-4;NTDS_D_06_Alternate residence status;LA20563-5;3;Migrant worker;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20565-0;1;Acute kidney injury;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20566-8;2;Acute lung injury/Acute respiratory distress syndrome (ARDS);;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20567-6;3;Cardiac arrest with resuscitative efforts by healthcare provider;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20568-4;4;Decubitus ulcer;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20569-2;5;Deep surgical site infection;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20570-0;6;Drug or alcohol withdrawal syndrome;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20571-8;7;Deep Vein Thrombosis (DVT)/thrombophlebitis;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20572-6;8;Extremity compartment syndrome;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20573-4;9;Graft/prosthesis/flap failure;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA14274-7;10;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20575-9;11;Organ/space surgical site infection;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA7465-3;12;Pneumonia;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA7468-7;13;Pulmonary embolism;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA9553-4;14;Stroke/CVA;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20579-1;15;Superficial surgical site infection;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20580-9;16;Unplanned intubation;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA6437-3;17;Urinary tract infection;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20582-5;18;Catheter-related blood stream infection;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20583-3;19;Osteomyelitis;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20584-1;20;Unplanned return to the OR;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20585-8;21;Unplanned return to the ICU;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA20586-6;22;Severe sepsis;;; +74284-1;LL2759-0;NTDS_Q_01_Hospital Complications;LA46-8;23;Other;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA46-8;1;Other;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20565-0;2;Acute kidney injury;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA28203-0;3;Acute respiratory distress syndrome;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20567-6;4;Cardiac arrest with resuscitative efforts by healthcare provider;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20569-2;5;Deep surgical site infection;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA7425-7;6;Deep vein thrombosis;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20572-6;7;Extremity compartment syndrome;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA14274-7;8;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20575-9;9;Organ/space surgical site infection;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA7468-7;10;Pulmonary embolism;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA9553-4;11;Stroke/CVA;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20580-9;12;Unplanned intubation;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20583-3;13;Osteomyelitis;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20584-1;14;Unplanned return to the OR;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA28433-3;15;Unplanned admission to the ICU;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA20586-6;16;Severe sepsis;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA28434-1;17;Catheter-associated urinary tract infection;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA28435-8;18;Central line-associated bloodstream infection;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA28436-6;19;Ventilator-associated pneumonia;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA28201-4;20;Alcohol withdrawal syndrome;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA19028-2;21;Pressure ulcer;;; +74284-1;LL4753-1;NTDS_Q_01_Hospital Complications_v2;LA28202-2;22;Superficial incisional surgical site infection;;; +74286-6;LL2762-4;NTDS_P_07_Transport mode;LA9315-8;1;Ground ambulance;;; +74286-6;LL2762-4;NTDS_P_07_Transport mode;LA9316-6;2;Helicopter ambulance;;; +74286-6;LL2762-4;NTDS_P_07_Transport mode;LA9317-4;3;Fixed-wing air ambulance;;; +74286-6;LL2762-4;NTDS_P_07_Transport mode;LA20598-1;4;Private/Public Vehicle/Walk-in;;; +74286-6;LL2762-4;NTDS_P_07_Transport mode;LA20185-7;5;Police;;; +74286-6;LL2762-4;NTDS_P_07_Transport mode;LA46-8;6;Other;;; +74289-0;LL2762-4;NTDS_P_07_Transport mode;LA9315-8;1;Ground ambulance;;; +74289-0;LL2762-4;NTDS_P_07_Transport mode;LA9316-6;2;Helicopter ambulance;;; +74289-0;LL2762-4;NTDS_P_07_Transport mode;LA9317-4;3;Fixed-wing air ambulance;;; +74289-0;LL2762-4;NTDS_P_07_Transport mode;LA20598-1;4;Private/Public Vehicle/Walk-in;;; +74289-0;LL2762-4;NTDS_P_07_Transport mode;LA20185-7;5;Police;;; +74289-0;LL2762-4;NTDS_P_07_Transport mode;LA46-8;6;Other;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20526-2;1;Business and Financial Operations Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20530-4;2;Architecture and Engineering Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20531-2;3;Community and Social Services Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20532-0;4;Education, Training, and Library Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20533-8;5;Healthcare Practititioners and Technical Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20534-6;6;Protective Service Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20535-3;7;Building and Grounds Cleaning and Maintenance;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20536-1;8;Sales and Related Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20537-9;9;Farming, Fishing, and Forestry Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20538-7;10;Installation, Maintenance, and Repair Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20539-5;11;Transportation and Material Moving Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20540-3;12;Management Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20541-1;13;Computer and Mathematical Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20542-9;14;Life, Physical, and Social Science Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20543-7;15;Legal Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20544-5;16;Arts, Design, Entertainment, Sports, and Media;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20545-2;17;Healthcare Support Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20546-0;18;Food Preparation and Serving Related;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20547-8;19;Personal Care and Service Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20548-6;20;Office and Administrative Support Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20549-4;21;Construction and Extraction Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20550-2;22;Production Occupations;;; +74287-4;LL2763-2;NTDS_I_05_Patient Occupation;LA20551-0;23;Military Specific Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20526-2;1;Business and Financial Operations Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20530-4;2;Architecture and Engineering Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20531-2;3;Community and Social Services Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20532-0;4;Education, Training, and Library Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20533-8;5;Healthcare Practititioners and Technical Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20534-6;6;Protective Service Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20535-3;7;Building and Grounds Cleaning and Maintenance;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20536-1;8;Sales and Related Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20537-9;9;Farming, Fishing, and Forestry Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20538-7;10;Installation, Maintenance, and Repair Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20539-5;11;Transportation and Material Moving Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20540-3;12;Management Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20541-1;13;Computer and Mathematical Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20542-9;14;Life, Physical, and Social Science Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20543-7;15;Legal Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20544-5;16;Arts, Design, Entertainment, Sports, and Media;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20545-2;17;Healthcare Support Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20546-0;18;Food Preparation and Serving Related;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20547-8;19;Personal Care and Service Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20548-6;20;Office and Administrative Support Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20549-4;21;Construction and Extraction Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20550-2;22;Production Occupations;;; +85658-3;LL2763-2;NTDS_I_05_Patient Occupation;LA20551-0;23;Military Specific Occupations;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20600-5;1;Finance, Insurance, and Real Estate;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20599-9;2;Manufacturing;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20601-3;3;Retail Trade;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20602-1;4;Transportation and Public Utilities;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20603-9;5;Agriculture, Forestry, Fishing;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20604-7;6;Professional and Business Services;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20605-4;7;Education and Health Services;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20606-2;8;Construction;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20607-0;9;Government;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20608-8;10;Natural Resources and Mining;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20609-6;11;Information Services;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20610-4;12;Wholesale Trade;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20611-2;13;Leisure and Hospitality;;; +74288-2;LL2764-0;NTDS_I_04_Occupational industry;LA20612-0;14;Other Services;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20600-5;1;Finance, Insurance, and Real Estate;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20599-9;2;Manufacturing;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20601-3;3;Retail Trade;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20602-1;4;Transportation and Public Utilities;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20603-9;5;Agriculture, Forestry, Fishing;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20604-7;6;Professional and Business Services;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20605-4;7;Education and Health Services;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20606-2;8;Construction;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20607-0;9;Government;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20608-8;10;Natural Resources and Mining;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20609-6;11;Information Services;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20610-4;12;Wholesale Trade;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20611-2;13;Leisure and Hospitality;;; +85078-4;LL2764-0;NTDS_I_04_Occupational industry;LA20612-0;14;Other Services;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20616-1;1;Discharged/Transferred to a short-term general hospital for inpatient care;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20617-9;2;Discharged/Transferred to an Intermediate Care Facility (ICF);;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20613-8;3;Discharged/Transferred to home under care of organized home health service;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20622-9;4;Left against medical advice or discontinued care;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA10325-1;5;Expired;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20614-6;6;Discharged home with no home services;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20619-5;7;Discharged/Transferred to Skilled Nursing Facility;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20615-3;8;Discharged/Transferred to hospice care;;; +74290-8;LL2766-5;NTDS_O_05_Hospital Discharge Disposition;LA20618-7;9;Discharged/Transferred to another type of rehabilitation or long-term care facility;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA46-8;1;Other;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20350-7;2;Alcoholism;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20351-5;3;Ascites within 30 days;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20352-3;4;Bleeding disorder;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20353-1;5;Currently receiving chemotherapy for cancer;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20354-9;6;Congenital anomalies;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA12740-9;7;Congestive heart failure (CHF);;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20356-4;8;Current smoker;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20357-2;9;Chronic renal failure;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20359-8;10;CVA/residual neurological deficit;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA14291-1;11;Diabetes mellitus;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20360-6;12;Disseminated cancer;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20361-4;13;Advanced directive limiting care;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20362-2;14;Esophageal varices;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20363-0;15;Functionally dependent health status;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20364-8;16;History of angina within 30 days;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20365-5;17;History of myocardial infarction;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20366-3;18;History of PVD;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20367-1;19;Hypertension requiring medication;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20368-9;21;Prematurity;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA6301-1;22;Obesity;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20369-7;23;Respiratory disease;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20370-5;24;Steroid use;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA9639-1;25;Cirrhosis;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20372-1;26;Dementia;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20373-9;27;Major psychiatric illness;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20374-7;28;Drug abuse or dependence;;; +74291-6;LL2685-7;NTDS_DG_01_Co-morbid Conditions;LA20375-4;29;Pre-hospital cardiac arrest with resuscitative efforts by healthcare provider;;; +74310-4;LL2756-6;PRRSV strains;LA20560-1;1;IngelvacMLV like Wild Type;;; +74310-4;LL2756-6;PRRSV strains;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74314-6;LL2713-7;PRRSV RNA RFLP pattern;LA20427-3;1;2-5-2;;; +74314-6;LL2713-7;PRRSV RNA RFLP pattern;LA20428-1;2;1-24-2;;; +74384-9;LL2687-3;Example specimen containers;LA20376-2;1;Vial;;; +74384-9;LL2687-3;Example specimen containers;LA20379-6;2;Syringe;;; +74384-9;LL2687-3;Example specimen containers;LA20378-8;3;IV bag;;; +74411-0;LL2755-8;Soft-Rubbery-Hard-Rocky;LA14744-9;1;Soft;;; +74411-0;LL2755-8;Soft-Rubbery-Hard-Rocky;LA20557-7;2;Rubbery;;; +74411-0;LL2755-8;Soft-Rubbery-Hard-Rocky;LA14745-6;3;Hard;;; +74411-0;LL2755-8;Soft-Rubbery-Hard-Rocky;LA20556-9;4;Rocky;;; +74470-6;LL2771-5;ISS body region;LA20645-0;1;Head or neck;;; +74470-6;LL2771-5;ISS body region;LA20646-8;2;Face;;; +74470-6;LL2771-5;ISS body region;LA18111-7;3;Chest;;; +74470-6;LL2771-5;ISS body region;LA20648-4;4;Abdomen or pelvic contents;;; +74470-6;LL2771-5;ISS body region;LA20649-2;5;Extremities or pelvic girdle;;; +74470-6;LL2771-5;ISS body region;LA11877-0;6;External;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20631-0;1;Demographic information is incomplete or invalid;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20632-8;2;Demographic information on filter paper does not match electronically submitted information;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20633-6;3;Serial number on filter paper does not match serial number on patient information form;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20634-4;4;Specimen submitted on expired filter paper;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20635-1;5;Sample collected too early;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20636-9;6;Specimen unsatisfactory due to delay in transit;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20637-7;7;Specimen results inconsistent;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20638-5;8;Assay interference;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20639-3;9;Unable to analyze specimen due to laboratory accident;;; +74482-1;LL2768-1;NBS reason sample unsatisfactory;LA20629-4;10;Unsuitable for other reasons;;; +74485-4;LL2692-3;Double stain_CD3 & CD20;LA20399-4;1;Positive for CD20, negative for CD3;;; +74485-4;LL2692-3;Double stain_CD3 & CD20;LA20398-6;2;Positive for CD3, negative for CD20;;; +74485-4;LL2692-3;Double stain_CD3 & CD20;LA20400-0;3;Negative for CD3 and CD20;;; +74486-2;LL2703-8;Triple stain_CK5 & p63 & LMW;LA20401-8;1;Positive for CK5, negative for p63 and Cytokeratin AE1;;; +74486-2;LL2703-8;Triple stain_CK5 & p63 & LMW;LA20402-6;2;Positive for Cytokeratin AE1, negative for p63 and CK5;;; +74486-2;LL2703-8;Triple stain_CK5 & p63 & LMW;LA20403-4;3;Negative for p63, Cytokeratin AE1 and CK5;;; +74487-0;LL2701-2;Triple stain_P504S & p63 & CK903;LA20404-2;1;Positive for P504S, negative for p63 and CK903;;; +74487-0;LL2701-2;Triple stain_P504S & p63 & CK903;LA20406-7;2;Positive for CK903 and p63, negative for P504S;;; +74487-0;LL2701-2;Triple stain_P504S & p63 & CK903;LA20405-9;3;Positive for CK903, negative for p63 and P504S;;; +74487-0;LL2701-2;Triple stain_P504S & p63 & CK903;LA20407-5;4;Negative for CK903, p63 and P504S;;; +74488-8;LL2705-3;Triple stain_p63 & MHCSM & CK8;LA20408-3;1;Positive for SM-MHC, negative for p63 and CK8;;; +74488-8;LL2705-3;Triple stain_p63 & MHCSM & CK8;LA20410-9;2;Positive for CK8 and p63, negative for SM-MHC;;; +74488-8;LL2705-3;Triple stain_p63 & MHCSM & CK8;LA20409-1;3;Positive for CK8, negative for p63 and SM-MHC;;; +74488-8;LL2705-3;Triple stain_p63 & MHCSM & CK8;LA20411-7;4;Negative for CK8, p63 and SM-MHC;;; +74489-6;LL2694-9;Double stain_Melan-A & Ki67;LA20412-5;1;Positive for Melan-A, negative for Ki67;;; +74489-6;LL2694-9;Double stain_Melan-A & Ki67;LA20413-3;2;Positive for Ki67, negative for Melan-A;;; +74489-6;LL2694-9;Double stain_Melan-A & Ki67;LA20414-1;3;Negative for Ki67 and Melan-A;;; +74490-4;LL2696-4;Double stain_PAX5 & BCL-2;LA20416-6;1;Positive for BCL-2, negative for PAX5;;; +74490-4;LL2696-4;Double stain_PAX5 & BCL-2;LA20415-8;2;Positive for PAX5, negative for BCL-2;;; +74490-4;LL2696-4;Double stain_PAX5 & BCL-2;LA20417-4;3;Negative for BCL-2 and PAX5;;; +74491-2;LL2697-2;Double stain_CK7 & TTF-1;LA20419-0;1;Positive for CK7, negative for TTF-1;;; +74491-2;LL2697-2;Double stain_CK7 & TTF-1;LA20420-8;2;Positive for TTF-1, negative for CK7;;; +74491-2;LL2697-2;Double stain_CK7 & TTF-1;LA20418-2;3;Negative for CK7 and TTF-1;;; +74492-0;LL2698-0;Double stain_PAX5 & CD43;LA20421-6;1;Positive for PAX5, negative for CD43;;; +74492-0;LL2698-0;Double stain_PAX5 & CD43;LA20422-4;2;Positive for CD43, negative for PAX5;;; +74492-0;LL2698-0;Double stain_PAX5 & CD43;LA20423-2;3;Negative for CD43 and PAX5;;; +74493-8;LL2699-8;Double stain_PAX5 & CD5;LA20426-5;1;Positive for PAX5, negative for CD5;;; +74493-8;LL2699-8;Double stain_PAX5 & CD5;LA20425-7;2;Positive for CD5, negative for PAX5;;; +74493-8;LL2699-8;Double stain_PAX5 & CD5;LA20424-0;3;Negative for CD5 and PAX5;;; +74494-6;LL2700-4;Double stain_CD34 & Factor XIII;LA20394-5;1;Positive for CD34, negative for Factor XIII;;; +74494-6;LL2700-4;Double stain_CD34 & Factor XIII;LA20396-0;2;Positive for Factor XIII, negative for CD34;;; +74494-6;LL2700-4;Double stain_CD34 & Factor XIII;LA20397-8;3;Negative for Factor XIII and CD34;;; +74496-1;LL2787-1;ICD-10CM Y92-;;0;;;; +74498-7;LL2850-7;Y/N/NA;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74498-7;LL2850-7;Y/N/NA;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +74498-7;LL2850-7;Y/N/NA;LA4720-4;3;Not applicable;;; +76515-6;LL2850-7;Y/N/NA;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76515-6;LL2850-7;Y/N/NA;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76515-6;LL2850-7;Y/N/NA;LA4720-4;3;Not applicable;;; +79761-3;LL2850-7;Y/N/NA;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79761-3;LL2850-7;Y/N/NA;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79761-3;LL2850-7;Y/N/NA;LA4720-4;3;Not applicable;;; +86647-5;LL2850-7;Y/N/NA;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86647-5;LL2850-7;Y/N/NA;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +86647-5;LL2850-7;Y/N/NA;LA4720-4;3;Not applicable;;; +86648-3;LL2850-7;Y/N/NA;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86648-3;LL2850-7;Y/N/NA;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +86648-3;LL2850-7;Y/N/NA;LA4720-4;3;Not applicable;;; +96915-4;LL2850-7;Y/N/NA;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96915-4;LL2850-7;Y/N/NA;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96915-4;LL2850-7;Y/N/NA;LA4720-4;3;Not applicable;;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20736-7;1;Neonate (0-28 days);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20737-5;2;Infant (>28 days <1 year);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20738-3;3;Child (1-12 years);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20739-1;4;Adolescent (13-17 years);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20740-9;5;Adult (18-64 years);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20741-7;6;Mature adult (65-74 years);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20742-5;7;Older adult (75-84 years);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA20743-3;8;Aged adult (85+ years);;; +74500-0;LL2814-3;AHRQ_PIF_1;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20769-8;1;Blood or Blood Product;;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20770-6;2;Device or Medical/Surgical Supply, including Health Information Technology (HIT);;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA7238-4;3;Fall;;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20771-4;4;Healthcare-associated Infection;;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20772-2;5;Medication or Other Substance;;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20773-0;6;Perinatal;;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA19028-2;7;Pressure ulcer;;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20774-8;8;Surgery or Anesthesia (includes invasive procedure);;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20775-5;9;Venous Thromboembolism;;; +74552-1;LL2825-9;AHRQ_HERF_Q7;LA20318-4;10;Other: PLEASE SPECIFY;;; +74557-0;LL2822-6;AHRQ_PIF_10;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +74557-0;LL2822-6;AHRQ_PIF_10;LA20755-7;2;No (or not anticipated);;; +74557-0;LL2822-6;AHRQ_PIF_10;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74558-8;LL2821-8;AHRQ_PIF_9;LA20752-4;1;Within 24 hours;;; +74558-8;LL2821-8;AHRQ_PIF_9;LA20753-2;2;After 24 hours but before 3 days;;; +74558-8;LL2821-8;AHRQ_PIF_9;LA20754-0;3;Three days or later;;; +74558-8;LL2821-8;AHRQ_PIF_9;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74559-6;LL2820-0;AHRQ_PIF_8;LA20750-8;1;Permanent: not expected to revert to approximately normal (i.e., patient's baseline);;; +74559-6;LL2820-0;AHRQ_PIF_8;LA20751-6;2;Temporary: expected to revert to approximately normal (i.e., patient's baseline);;; +74559-6;LL2820-0;AHRQ_PIF_8;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74560-4;LL2819-2;AHRQ_PIF_7;LA20747-4;1;Death: Dead at time of assessment.;;; +74560-4;LL2819-2;AHRQ_PIF_7;LA20748-2;2;Severe harm: Bodily or psychological injury (including pain or disfigurement) that interferes significantly with functional ability or quality of life.;;; +74560-4;LL2819-2;AHRQ_PIF_7;LA20749-0;3;Moderate harm: Bodily or psychological injury adversely affecting functional ability or quality of life, but not at the level of severe harm.;;; +74560-4;LL2819-2;AHRQ_PIF_7;LA21150-0;4;Mild harm: Bodily or psychological injury resulting in minimal symptoms or loss of function, or injury limited to additional treatment, monitoring, and/or increased length of stay.;;; +74560-4;LL2819-2;AHRQ_PIF_7;LA21151-8;5;No harm: Event reached patient, but no harm was evident.;;; +74560-4;LL2819-2;AHRQ_PIF_7;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74561-2;LL2818-4;AHRQ_PIF_6;LA20745-8;1;Transfer, including transfer to a higher level care area within facility, transfer to another facility, or hospital admission (from outpatient);;; +74561-2;LL2818-4;AHRQ_PIF_6;LA20746-6;2;Monitoring, including observation, physiological examination, laboratory testing, phlebotomy, and/or imaging studies;;; +74561-2;LL2818-4;AHRQ_PIF_6;LA21144-3;3;Medication therapy, including administration of antidote, change in pre-incident dose or route;;; +74561-2;LL2818-4;AHRQ_PIF_6;LA21145-0;4;Surgical/procedural intervention;;; +74561-2;LL2818-4;AHRQ_PIF_6;LA21146-8;5;Respiratory support (e.g., ventilation, tracheotomy);;; +74561-2;LL2818-4;AHRQ_PIF_6;LA21147-6;6;Blood transfusion;;; +74561-2;LL2818-4;AHRQ_PIF_6;LA21148-4;7;Counseling or psychotherapy;;; +74561-2;LL2818-4;AHRQ_PIF_6;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74561-2;LL2818-4;AHRQ_PIF_6;LA21149-2;9;Other intervention: PLEASE SPECIFY;;; +74563-8;LL2837-4;AHRQ_SIR_12;LA20864-7;1;Almost certainly could have been prevented;;; +74563-8;LL2837-4;AHRQ_SIR_12;LA20865-4;2;Likely could have been prevented;;; +74563-8;LL2837-4;AHRQ_SIR_12;LA20866-2;3;Likely could not have been prevented;;; +74563-8;LL2837-4;AHRQ_SIR_12;LA20867-0;4;Almost certainly could not have been prevented;;; +74563-8;LL2837-4;AHRQ_SIR_12;LA20868-8;5;Provider does not make this determination by policy;;; +74563-8;LL2837-4;AHRQ_SIR_12;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74564-6;LL2835-8;AHRQ_SIR_10;LA20829-0;1;Surgery or other invasive procedure performed on the wrong site;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20830-8;2;Surgery or other invasive procedure performed on the wrong patient;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20831-6;3;Wrong surgical or other invasive procedure performed on a patient;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20832-4;4;Unintended retention of a foreign object in a patient after surgery or other invasive procedure;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20833-2;5;Intraoperative or immediately postoperative/postprocedure death in an ASA Class 1 patient;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20835-7;6;Patient death or serious injury associated with the use of contaminated drugs, devices, or biologics provided by the healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20836-5;7;Patient death or serious injury associated with the use or function of a device in patient care, in which the device is used or functions other than as intended;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20837-3;8;Patient death or serious injury associated with intravascular air embolism that occurs while being cared for in healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20839-9;9;Discharge or release of a patient/resident of any age, who is unable to make decisions, to other than an authorized person;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20840-7;10;Patient death or serious injury associated with patient elopement (disappearance);;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20841-5;11;Patient suicide, attempted suicide, or self-harm that results in serious injury, while being cared for in a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20843-1;12;Patient death or serious injury associated with a medication error (e.g., errors involving the wrong drug, wrong dose, wrong patient, wrong time, wrong rate, wrong preparation, or wrong route of administration);;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20844-9;13;Patient death or serious injury associated with unsafe administration of blood products;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20845-6;14;Maternal death or serious injury associated with labor or delivery in a low-risk pregnancy while being cared for in a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20846-4;15;Death or serious injury of a neonate associated with labor or delivery in a low-risk pregnancy;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20847-2;16;Patient death or serious injury associated with a fall while being cared for in a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20848-0;17;Any Stage 3, Stage 4, and unstageable pressure ulcers acquired after admission/presentation to a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20849-8;18;Artificial insemination with the wrong donor sperm or wrong egg;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20850-6;19;Patient death or serious injury resulting from the irretrievable loss of an irreplaceable biological specimen;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20851-4;20;Patient death or serious injury resulting from failure to follow up or communicate laboratory, pathology, or radiology test results;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20853-0;21;Patient or staff death or serious injury associated with an electric shock in the course of a patient care process in a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20854-8;22;Any incident in which systems designated for oxygen or other gas to be delivered to a patient contains no gas, the wrong gas, or is contaminated by toxic substances;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20855-5;23;Patient or staff death or serious injury associated with a burn incurred from any source in the course of a patient care process in a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20856-3;24;Patient death or serious injury associated with the use of physical restraints or bedrails while being cared for in a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20858-9;25;Death or serious injury of a patient or staff associated with the introduction of a metallic object into the MRI area;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20860-5;26;Any instance of care ordered by or provided by someone impersonating a physician, nurse, pharmacist, or other licensed healthcare provider;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20861-3;27;Abduction of a patient/resident of any age;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20862-1;28;Sexual abuse/assault on a patient or staff member within or on the grounds of a healthcare setting;;; +74564-6;LL2835-8;AHRQ_SIR_10;LA20863-9;29;Death or serious injury of a patient or staff member resulting from a physical assault (i.e., battery) that occurs within or on the grounds of a healthcare setting;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20806-8;1;Environment: Culture of safety, management;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20807-6;2;Environment: Physical surroundings (e.g., lighting, noise);;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20809-2;3;Staff qualifications: Competence (e.g., qualifications, experience);;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20810-0;4;Staff qualifications: Training;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20812-6;5;Supervision/support: Clinical supervision;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20813-4;6;Supervision/support: Managerial supervision;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20815-9;7;Policies and procedures, includes clinical protocols: Presence of policies;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20816-7;8;Policies and procedures, includes clinical protocols: Clarity of policies;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20818-3;9;Data: Availability;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20819-1;10;Data: Accuracy;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20820-9;11;Data: Legibility;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20822-5;12;Communication: Supervisor to staff;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20823-3;13;Communication: Among staff or team members;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20824-1;14;Communication: Staff to patient (or family);;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20825-8;15;Human factors: Fatigue;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20821-7;16;Human factors: Stress;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20817-5;17;Human factors: Inattention;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20826-6;18;Human factors: Cognitive factors;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20827-4;19;Human factors: Health issues;;; +74566-1;LL2834-1;AHRQ_SIR_8;LA20318-4;20;Other: PLEASE SPECIFY;;; +74569-5;LL2833-3;AHRQ_SIR_5;LA20801-9;1;Fail-safe designed into the process and/or a safeguard worked effectively;;; +74569-5;LL2833-3;AHRQ_SIR_5;LA20802-7;2;Practitioner or staff who made the error noticed and recovered from this error (avoiding any possibility of it reaching the patient);;; +74569-5;LL2833-3;AHRQ_SIR_5;LA20803-5;3;Spontaneous action by a practitioner or staff member prevented the event from reaching the patient;;; +74569-5;LL2833-3;AHRQ_SIR_5;LA20804-3;4;Action by the patient's family member prevented the event from reaching the patient;;; +74569-5;LL2833-3;AHRQ_SIR_5;LA20318-4;5;Other: PLEASE SPECIFY;;; +74569-5;LL2833-3;AHRQ_SIR_5;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74571-1;LL2831-7;AHRQ_SIR_3;LA20797-9;1;Doctor, dentist (including student);;; +74571-1;LL2831-7;AHRQ_SIR_3;LA20798-7;2;Nurse, nurse practitioner, physician assistant (including student or trainee);;; +74571-1;LL2831-7;AHRQ_SIR_3;LA20799-5;3;Pharmacist, pharmacy technician (including student);;; +74571-1;LL2831-7;AHRQ_SIR_3;LA20800-1;4;Allied health professional (including paramedic, speech, physical and occupational therapist, dietician);;; +74572-9;LL2830-9;AHRQ_SIR_2;LA20793-8;1;Healthcare professional;;; +74572-9;LL2830-9;AHRQ_SIR_2;LA20794-6;2;Healthcare worker;;; +74572-9;LL2830-9;AHRQ_SIR_2;LA20795-3;3;Emergency service personnel;;; +74572-9;LL2830-9;AHRQ_SIR_2;LA20796-1;4;Patient, family member, volunteer, caregiver, or home assistant;;; +74572-9;LL2830-9;AHRQ_SIR_2;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74572-9;LL2830-9;AHRQ_SIR_2;LA20318-4;6;Other: PLEASE SPECIFY;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20784-7;1;Inpatient general care area (e.g., medical/surgical unit);;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20785-4;2;Special care area (e.g., ICU, CCU, NICU);;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20786-2;3;Labor and delivery;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20787-0;4;Operating room or procedure area (e.g., cardiac catheter lab, endoscopy area), including PACU or recovery area;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20788-8;5;Radiology/imaging department, including onsite mobile units;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA7223-6;6;Pharmacy;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20789-6;7;Laboratory, including pathology department and blood bank;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA10268-3;8;Emergency Department;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20790-4;9;Other area within the facility;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20791-2;10;Outpatient care area;;; +74573-7;LL2829-1;AHRQ_SIR_1;LA20792-0;11;Outside area (i.e., grounds of this facility);;; +74573-7;LL2829-1;AHRQ_SIR_1;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74573-7;LL2829-1;AHRQ_SIR_1;LA20318-4;13;Other: PLEASE SPECIFY;;; +74676-8;LL2781-4;Carbapenemase detection;LA20670-8;1;KPC carbapenemase detected;;; +74676-8;LL2781-4;Carbapenemase detection;LA20671-6;2;VIM, IMP, and/or NDM carbapenemase(s) detected;;; +74676-8;LL2781-4;Carbapenemase detection;LA20672-4;3;OXA-48 carbapenemase detected;;; +74676-8;LL2781-4;Carbapenemase detection;LA20673-2;4;Carbapenemases detected, but unable to determine the type present, and more than one type of carbapenamase may be present.;;; +74693-3;LL2816-8;AHRQ_PIF_3;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +74693-3;LL2816-8;AHRQ_PIF_3;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +74693-3;LL2816-8;AHRQ_PIF_3;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +74693-3;LL2816-8;AHRQ_PIF_3;LA10611-4;4;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +74693-3;LL2816-8;AHRQ_PIF_3;LA4457-3;5;White;2106-3;White;https://www.cdc.gov/phin +74693-3;LL2816-8;AHRQ_PIF_3;LA20744-1;6;More than one race;;; +74693-3;LL2816-8;AHRQ_PIF_3;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74694-1;LL2815-0;AHRQ_PIF_2;LA6214-6;1;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +74694-1;LL2815-0;AHRQ_PIF_2;LA19555-4;2;Not Hispanic or Latino;2186-5;Not Hispanic or Latino;https://www.cdc.gov/phin +74694-1;LL2815-0;AHRQ_PIF_2;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74698-2;LL2827-5;AHRQ_M/F/UNK;LA2-8;1;Male;;; +74698-2;LL2827-5;AHRQ_M/F/UNK;LA3-6;2;Female;;; +74698-2;LL2827-5;AHRQ_M/F/UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74700-6;LL2846-5;AHRQ_Device_15;LA20919-9;1;Hardware location (e.g., awkward placement for use);;; +74700-6;LL2846-5;AHRQ_Device_15;LA20920-7;2;Data entry or selection (e.g., entry or selection of wrong patient, wrong provider, wrong drug, wrong dose);;; +74700-6;LL2846-5;AHRQ_Device_15;LA20921-5;3;Information display or interpretation (e.g., font size, color of font, location of information in display screen);;; +74700-6;LL2846-5;AHRQ_Device_15;LA21156-7;4;Alert fatigue/alarm fatigue;;; +74700-6;LL2846-5;AHRQ_Device_15;LA20318-4;5;Other: PLEASE SPECIFY;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20912-4;1;Loss or delay of data;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20913-2;2;System returns or stores data that does not match patient;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20914-0;3;Image measurement/corruption issue;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20915-7;4;Image orientation incorrect;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20916-5;5;Incorrect test results;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20917-3;6;Incorrect software programming calculation;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20918-1;7;Incorrect or inappropriate alert;;; +74701-4;LL2845-7;AHRQ_Device_14;LA20318-4;8;Other: PLEASE SPECIFY;;; +74702-2;LL2844-0;AHRQ_Device_13;LA20905-8;1;Incompatibility between devices;;; +74702-2;LL2844-0;AHRQ_Device_13;LA20906-6;2;Equipment/device function;;; +74702-2;LL2844-0;AHRQ_Device_13;LA20907-4;3;Equipment/device maintenance;;; +74702-2;LL2844-0;AHRQ_Device_13;LA20908-2;4;Hardware failure or problem;;; +74702-2;LL2844-0;AHRQ_Device_13;LA20909-0;5;Network failure or problem;;; +74702-2;LL2844-0;AHRQ_Device_13;LA20910-8;6;Ergonomics, including human/device interface issue;;; +74702-2;LL2844-0;AHRQ_Device_13;LA20911-6;7;Security, virus, or other malware issue;;; +74702-2;LL2844-0;AHRQ_Device_13;LA21155-9;8;Unexpected software design issue;;; +74702-2;LL2844-0;AHRQ_Device_13;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74702-2;LL2844-0;AHRQ_Device_13;LA20318-4;10;Other: PLEASE SPECIFY;;; +74703-0;LL2843-2;AHRQ_Device_12;LA20899-3;1;Computerized provider order entry (CPOE) system;;; +74703-0;LL2843-2;AHRQ_Device_12;LA20900-9;2;Pharmacy system;;; +74703-0;LL2843-2;AHRQ_Device_12;LA20901-7;3;Electronic medication administration record (e-MAR);;; +74703-0;LL2843-2;AHRQ_Device_12;LA20902-5;4;Clinical documentation system (e.g., progress notes);;; +74703-0;LL2843-2;AHRQ_Device_12;LA20903-3;5;Clinical decision support (CDS) system;;; +74703-0;LL2843-2;AHRQ_Device_12;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74703-0;LL2843-2;AHRQ_Device_12;LA20318-4;7;Other: PLEASE SPECIFY;;; +74704-8;LL2842-4;AHRQ_Device_11;LA20896-9;1;Master patient index;;; +74704-8;LL2842-4;AHRQ_Device_11;LA20897-7;2;Registration/appointment scheduling system;;; +74704-8;LL2842-4;AHRQ_Device_11;LA20898-5;3;Coding/billing system;;; +74704-8;LL2842-4;AHRQ_Device_11;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74704-8;LL2842-4;AHRQ_Device_11;LA20318-4;5;Other: PLEASE SPECIFY;;; +74705-5;LL2841-6;AHRQ_Device_10;LA20892-8;1;Administrative/billing or practice management system;;; +74705-5;LL2841-6;AHRQ_Device_10;LA20893-6;2;Automated dispensing system;;; +74705-5;LL2841-6;AHRQ_Device_10;LA20894-4;3;Electronic health record (EHR) or component of EHR;;; +74705-5;LL2841-6;AHRQ_Device_10;LA20895-1;4;Human interface device (e.g., keyboard, mouse, touchscreen, speech recognition system, monitor/display, printer);;; +74705-5;LL2841-6;AHRQ_Device_10;LA21152-6;5;Laboratory information system (LIS), including microbiology and pathology systems;;; +74705-5;LL2841-6;AHRQ_Device_10;LA21153-4;6;Radiology/diagnostic imaging system, including picture archiving and communications system (PACS);;; +74705-5;LL2841-6;AHRQ_Device_10;LA20318-4;7;Other: PLEASE SPECIFY;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20882-9;1;Model number;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20883-7;2;Software version;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20884-5;3;Firmware version;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20885-2;4;Serial number;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20886-0;5;Lot or batch number;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20887-8;6;Other unique product identifier;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20888-6;7;Date of expiration;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20889-4;8;Unique Device Identifier;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20890-2;9;Asset tag;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20891-0;10;No identifiers known;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20882-9;1;Model number;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20883-7;2;Software version;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20884-5;3;Firmware version;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20885-2;4;Serial number;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20886-0;5;Lot or batch number;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20887-8;6;Other unique product identifier;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20888-6;7;Date of expiration;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20889-4;8;Unique Device Identifier;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20890-2;9;Asset tag;;; +74718-8;LL2840-8;AHRQ_Device_5;LA20891-0;10;No identifiers known;;; +74723-8;LL2839-0;AHRQ_Device_2;LA20878-7;1;Implantable device (i.e., device intended to be inserted into, and remain permanently in, tissue);;; +74723-8;LL2839-0;AHRQ_Device_2;LA20879-5;2;Medical equipment (e.g., walker, hearing aid);;; +74723-8;LL2839-0;AHRQ_Device_2;LA20880-3;3;Medical/surgical supply, including disposable product (e.g., incontinence supply);;; +74723-8;LL2839-0;AHRQ_Device_2;LA20881-1;4;HIT device;;; +74724-6;LL2838-2;AHRQ_Device_1;LA20875-3;1;Device defect or failure, including HIT;;; +74724-6;LL2838-2;AHRQ_Device_1;LA20876-1;2;Use error;;; +74724-6;LL2838-2;AHRQ_Device_1;LA20877-9;3;Combination or interaction of device defect or failure and use error;;; +74724-6;LL2838-2;AHRQ_Device_1;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +74727-9;LL2863-0;Body Condition Score;LA20938-9;0;Emaciated;;; +74727-9;LL2863-0;Body Condition Score;LA20941-3;1;Thin;;; +74727-9;LL2863-0;Body Condition Score;LA6751-7;2;Moderate;;; +74727-9;LL2863-0;Body Condition Score;LA20939-7;3;Stout;;; +74727-9;LL2863-0;Body Condition Score;LA20940-5;4;Obese;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20976-9;1;Staphylococcus species.tuf gene;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20977-7;2;Staphylococcus aureus.tuf gene;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20978-5;3;Staphylococcus aureus.tuf and mecA genes (MRSE);;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20979-3;4;Staphylococcus epidemidis.gyrB gene;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20980-1;5;Staphylococcus epidemidis.gyrB and mecA genes (MRSE);;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20981-9;6;Staphylococcus lugdunensis.sodA gene;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20984-3;7;Enterococcus faecalis.hsp60 gene;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20982-7;8;Enterococcus faecalis.hsp60 and vanA genes (VRE);;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20983-5;9;Enterococcus faecalis.hsp60 and vanB genes (VRE);;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20985-0;10;Enterococcus faecium.hsp60 gene;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20986-8;11;Enterococcus faecium.hsp60 gene and vanA genes (VRE);;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20987-6;12;Enterococcus faecium.hsp60 gene and vanB genes (VRE);;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20988-4;13;Streptococcus species;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA19342-7;14;Streptococcus agalactiae;43492007;Streptococcus agalactiae (organism);http://snomed.info/sct +74731-1;LL2876-2;Gram positive bacteria identified;LA20990-0;15;Streptococcus anginosus group;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20992-6;16;Streptococcus pyogenes;80166006;Streptococcus pyogenes (organism);http://snomed.info/sct +74731-1;LL2876-2;Gram positive bacteria identified;LA20993-4;17;Listeria species;;; +74731-1;LL2876-2;Gram positive bacteria identified;LA20994-2;18;No organisms found that can be detected by panel;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20976-9;1;Staphylococcus species.tuf gene;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20977-7;2;Staphylococcus aureus.tuf gene;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20978-5;3;Staphylococcus aureus.tuf and mecA genes (MRSE);;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20979-3;4;Staphylococcus epidemidis.gyrB gene;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20980-1;5;Staphylococcus epidemidis.gyrB and mecA genes (MRSE);;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20981-9;6;Staphylococcus lugdunensis.sodA gene;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20984-3;7;Enterococcus faecalis.hsp60 gene;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20982-7;8;Enterococcus faecalis.hsp60 and vanA genes (VRE);;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20983-5;9;Enterococcus faecalis.hsp60 and vanB genes (VRE);;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20985-0;10;Enterococcus faecium.hsp60 gene;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20986-8;11;Enterococcus faecium.hsp60 gene and vanA genes (VRE);;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20987-6;12;Enterococcus faecium.hsp60 gene and vanB genes (VRE);;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20988-4;13;Streptococcus species;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA19342-7;14;Streptococcus agalactiae;43492007;Streptococcus agalactiae (organism);http://snomed.info/sct +88261-3;LL2876-2;Gram positive bacteria identified;LA20990-0;15;Streptococcus anginosus group;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20992-6;16;Streptococcus pyogenes;80166006;Streptococcus pyogenes (organism);http://snomed.info/sct +88261-3;LL2876-2;Gram positive bacteria identified;LA20993-4;17;Listeria species;;; +88261-3;LL2876-2;Gram positive bacteria identified;LA20994-2;18;No organisms found that can be detected by panel;;; +74733-7;LL2878-8;Mycobacterium species;LA16933-6;1;Mycobacterium abscessus;;; +74733-7;LL2878-8;Mycobacterium species;LA20997-5;2;Mycobacterium avium;;; +74733-7;LL2878-8;Mycobacterium species;LA21003-1;3;Mycobacterium gordonae;;; +74733-7;LL2878-8;Mycobacterium species;LA19287-4;4;Mycobacterium kansasii;;; +74733-7;LL2878-8;Mycobacterium species;LA21001-5;5;Mycobacterium malmoense;;; +74733-7;LL2878-8;Mycobacterium species;LA21002-3;6;Mycobacterium marinum;;; +74733-7;LL2878-8;Mycobacterium species;LA20996-7;7;Mycobacterium tuberculosis;;; +74733-7;LL2878-8;Mycobacterium species;LA20998-3;8;Mycobacterium xenopi;;; +74733-7;LL2878-8;Mycobacterium species;LA20995-9;9;Negative for tested species of Mycobacterium;;; +88167-2;LL2878-8;Mycobacterium species;LA16933-6;1;Mycobacterium abscessus;;; +88167-2;LL2878-8;Mycobacterium species;LA20997-5;2;Mycobacterium avium;;; +88167-2;LL2878-8;Mycobacterium species;LA21003-1;3;Mycobacterium gordonae;;; +88167-2;LL2878-8;Mycobacterium species;LA19287-4;4;Mycobacterium kansasii;;; +88167-2;LL2878-8;Mycobacterium species;LA21001-5;5;Mycobacterium malmoense;;; +88167-2;LL2878-8;Mycobacterium species;LA21002-3;6;Mycobacterium marinum;;; +88167-2;LL2878-8;Mycobacterium species;LA20996-7;7;Mycobacterium tuberculosis;;; +88167-2;LL2878-8;Mycobacterium species;LA20998-3;8;Mycobacterium xenopi;;; +88167-2;LL2878-8;Mycobacterium species;LA20995-9;9;Negative for tested species of Mycobacterium;;; +88168-0;LL2878-8;Mycobacterium species;LA16933-6;1;Mycobacterium abscessus;;; +88168-0;LL2878-8;Mycobacterium species;LA20997-5;2;Mycobacterium avium;;; +88168-0;LL2878-8;Mycobacterium species;LA21003-1;3;Mycobacterium gordonae;;; +88168-0;LL2878-8;Mycobacterium species;LA19287-4;4;Mycobacterium kansasii;;; +88168-0;LL2878-8;Mycobacterium species;LA21001-5;5;Mycobacterium malmoense;;; +88168-0;LL2878-8;Mycobacterium species;LA21002-3;6;Mycobacterium marinum;;; +88168-0;LL2878-8;Mycobacterium species;LA20996-7;7;Mycobacterium tuberculosis;;; +88168-0;LL2878-8;Mycobacterium species;LA20998-3;8;Mycobacterium xenopi;;; +88168-0;LL2878-8;Mycobacterium species;LA20995-9;9;Negative for tested species of Mycobacterium;;; +88266-2;LL2878-8;Mycobacterium species;LA16933-6;1;Mycobacterium abscessus;;; +88266-2;LL2878-8;Mycobacterium species;LA20997-5;2;Mycobacterium avium;;; +88266-2;LL2878-8;Mycobacterium species;LA21003-1;3;Mycobacterium gordonae;;; +88266-2;LL2878-8;Mycobacterium species;LA19287-4;4;Mycobacterium kansasii;;; +88266-2;LL2878-8;Mycobacterium species;LA21001-5;5;Mycobacterium malmoense;;; +88266-2;LL2878-8;Mycobacterium species;LA21002-3;6;Mycobacterium marinum;;; +88266-2;LL2878-8;Mycobacterium species;LA20996-7;7;Mycobacterium tuberculosis;;; +88266-2;LL2878-8;Mycobacterium species;LA20998-3;8;Mycobacterium xenopi;;; +88266-2;LL2878-8;Mycobacterium species;LA20995-9;9;Negative for tested species of Mycobacterium;;; +90306-2;LL2878-8;Mycobacterium species;LA16933-6;1;Mycobacterium abscessus;;; +90306-2;LL2878-8;Mycobacterium species;LA20997-5;2;Mycobacterium avium;;; +90306-2;LL2878-8;Mycobacterium species;LA21003-1;3;Mycobacterium gordonae;;; +90306-2;LL2878-8;Mycobacterium species;LA19287-4;4;Mycobacterium kansasii;;; +90306-2;LL2878-8;Mycobacterium species;LA21001-5;5;Mycobacterium malmoense;;; +90306-2;LL2878-8;Mycobacterium species;LA21002-3;6;Mycobacterium marinum;;; +90306-2;LL2878-8;Mycobacterium species;LA20996-7;7;Mycobacterium tuberculosis;;; +90306-2;LL2878-8;Mycobacterium species;LA20998-3;8;Mycobacterium xenopi;;; +90306-2;LL2878-8;Mycobacterium species;LA20995-9;9;Negative for tested species of Mycobacterium;;; +74750-1;LL2778-0;Pres/None;LA20667-4;1;None seen;;; +74750-1;LL2778-0;Pres/None;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +80725-5;LL2778-0;Pres/None;LA20667-4;1;None seen;;; +80725-5;LL2778-0;Pres/None;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +81138-0;LL2778-0;Pres/None;LA20667-4;1;None seen;;; +81138-0;LL2778-0;Pres/None;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +95074-1;LL2778-0;Pres/None;LA20667-4;1;None seen;;; +95074-1;LL2778-0;Pres/None;LA9633-4;2;Present;52101004;Present (qualifier value);http://snomed.info/sct +74753-5;LL2864-8;BB Ag testing;LA20927-2;1;Fya Ag - positive;;; +74753-5;LL2864-8;BB Ag testing;LA20928-0;2;Fyb Ag - positive;;; +74753-5;LL2864-8;BB Ag testing;LA20929-8;3;Jka Ag - positive;;; +74753-5;LL2864-8;BB Ag testing;LA20930-6;4;Jkb Ag - negative;;; +74753-5;LL2864-8;BB Ag testing;LA20931-4;5;S Ag - negative;;; +74753-5;LL2864-8;BB Ag testing;LA20932-2;6;s Ag - positive;;; +74754-3;LL2786-3;IS/BB/Antigens;LA20655-9;0;c Ag - Negative;;; +74754-3;LL2786-3;IS/BB/Antigens;LA20654-2;1;C Ag - Positive;;; +74754-3;LL2786-3;IS/BB/Antigens;LA20656-7;2;E Ag - Negative;;; +74754-3;LL2786-3;IS/BB/Antigens;LA20657-5;3;e Ag - Positive;;; +74780-8;LL2848-1;CPT1A Gene;LA20922-3;0;Heterozygous for the P479L variant;;; +74780-8;LL2848-1;CPT1A Gene;LA20923-1;1;Homozygous for the P479L variant;;; +74784-0;LL2785-5;Flu Virus B Lineage;LA11883-8;1;Not detected;;; +74784-0;LL2785-5;Flu Virus B Lineage;LA20659-1;2;Influenza B virus Victoria lineage;;; +74784-0;LL2785-5;Flu Virus B Lineage;LA20660-9;3;Influenza B virus Yamagata lineage;;; +74784-0;LL2785-5;Flu Virus B Lineage;LA20661-7;4;Inconclusive for influenza B lineage;;; +74784-0;LL2785-5;Flu Virus B Lineage;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +74785-7;LL2782-2;Detected|Not det|Spec unsat for eval;LA11882-0;0;Detected;;; +74785-7;LL2782-2;Detected|Not det|Spec unsat for eval;LA11883-8;1;Not detected;;; +74785-7;LL2782-2;Detected|Not det|Spec unsat for eval;LA13548-5;2;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +74786-5;LL2782-2;Detected|Not det|Spec unsat for eval;LA11882-0;0;Detected;;; +74786-5;LL2782-2;Detected|Not det|Spec unsat for eval;LA11883-8;1;Not detected;;; +74786-5;LL2782-2;Detected|Not det|Spec unsat for eval;LA13548-5;2;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +85821-7;LL2782-2;Detected|Not det|Spec unsat for eval;LA11882-0;0;Detected;;; +85821-7;LL2782-2;Detected|Not det|Spec unsat for eval;LA11883-8;1;Not detected;;; +85821-7;LL2782-2;Detected|Not det|Spec unsat for eval;LA13548-5;2;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +74810-3;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74810-3;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +74818-6;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74818-6;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +76660-0;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76660-0;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +77733-4;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77733-4;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +79139-2;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79139-2;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +79141-8;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79141-8;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +79144-2;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79144-2;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +79148-3;LL2873-9;Neg/Further testing;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79148-3;LL2873-9;Neg/Further testing;LA20972-8;2;Further testing indicated;;; +74816-0;LL2889-5;Eye Culture;LA21123-7;0;No growth;;; +74816-0;LL2889-5;Eye Culture;LA18050-7;1;Haemophilus influenzae type A;;; +74816-0;LL2889-5;Eye Culture;LA19341-9;2;Streptococcus pneumoniae;9861002;Streptococcus pneumoniae (organism);http://snomed.info/sct +74816-0;LL2889-5;Eye Culture;LA21126-0;3;Moraxella species;;; +74816-0;LL2889-5;Eye Culture;LA19247-8;4;Staphylococcus epidermidis;;; +74816-0;LL2889-5;Eye Culture;LA21129-4;5;Peptostreptococcus spp.;;; +74819-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +74819-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +74819-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +74819-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75270-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75270-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75270-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75270-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75758-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75758-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75758-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75758-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75759-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75759-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75759-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75759-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75760-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75760-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75760-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75760-9;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75761-7;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75761-7;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75761-7;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75761-7;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75762-5;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75762-5;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75762-5;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75762-5;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75763-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75763-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75763-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75763-3;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75764-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75764-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75764-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75764-1;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75765-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75765-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75765-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75765-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75766-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75766-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75766-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75766-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75767-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75767-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75767-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75767-4;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75768-2;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75768-2;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75768-2;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75768-2;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75769-0;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75769-0;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75769-0;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75769-0;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75770-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75770-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75770-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75770-8;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75771-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75771-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75771-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75771-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +75813-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75813-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20973-6;2;Small amount;;; +75813-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20974-4;3;Moderate amount;;; +75813-6;LL2875-4;Neg|Small amount|Mod amount|Large amount;LA20975-1;4;Large amount;;; +74836-8;LL2881-2;Transplant type;LA4591-9;1;Kidney;;; +74836-8;LL2881-2;Transplant type;LA4584-4;2;Liver;;; +74836-8;LL2881-2;Transplant type;LA21012-2;3;Bone marrow;;; +74836-8;LL2881-2;Transplant type;LA4579-4;4;Lung;;; +74836-8;LL2881-2;Transplant type;LA21016-3;5;Heart;;; +74856-6;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +74856-6;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +74856-6;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +74857-4;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +74857-4;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +74857-4;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +74858-2;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +74858-2;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +74858-2;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75540-5;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +75540-5;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +75540-5;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75542-1;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +75542-1;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +75542-1;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +82297-3;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +82297-3;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +82297-3;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85361-4;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +85361-4;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +85361-4;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85368-9;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +85368-9;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +85368-9;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85582-5;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +85582-5;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +85582-5;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85583-3;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +85583-3;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +85583-3;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +85584-1;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +85584-1;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +85584-1;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +91678-3;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +91678-3;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +91678-3;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94761-4;LL2888-7;React/Non/Inval;LA15256-3;0;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +94761-4;LL2888-7;React/Non/Inval;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +94761-4;LL2888-7;React/Non/Inval;LA15841-2;2;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +74873-1;LL2907-5;Metabolic disorder being monitored;LA21161-7;1;Argininemia;;; +74873-1;LL2907-5;Metabolic disorder being monitored;LA21162-5;2;Argininosuccinic aciduria;;; +74873-1;LL2907-5;Metabolic disorder being monitored;LA21163-3;3;Carnitine uptake defect;;; +74873-1;LL2907-5;Metabolic disorder being monitored;LA12482-8;5;Citrullinemia, type I;398680004;Citrullinemia (disorder);http://snomed.info/sct +74873-1;LL2907-5;Metabolic disorder being monitored;LA21165-8;6;Classical galactosemia;;; +74873-1;LL2907-5;Metabolic disorder being monitored;LA21166-6;7;Gyrate atrophy;;; +74873-1;LL2907-5;Metabolic disorder being monitored;LA21167-4;8;Hyperphenylalaninemia;68528007;Hyperphenylalaninemia (disorder);http://snomed.info/sct +74873-1;LL2907-5;Metabolic disorder being monitored;LA21168-2;9;Maple syrup urine disease;27718001;Maple syrup urine disease (disorder);http://snomed.info/sct +74873-1;LL2907-5;Metabolic disorder being monitored;LA21169-0;10;Phenylketonuria;;; +74873-1;LL2907-5;Metabolic disorder being monitored;LA21170-8;11;Tyrosinemia type I;410056006;Tyrosinemia type I (disorder);http://snomed.info/sct +74873-1;LL2907-5;Metabolic disorder being monitored;LA21171-6;12;Tyrosinemia type II;;; +74873-1;LL2907-5;Metabolic disorder being monitored;LA21172-4;13;Tyrosinemia type III;415764005;Tyrosinemia type III (disorder);http://snomed.info/sct +75022-4;LL2892-9;Urine fat;LA21133-6;0;Fat not seen;;; +75022-4;LL2892-9;Urine fat;LA21132-8;1;Fat seen;;; +75161-0;LL2855-6;Initiate/Discontinue;LA20934-8;1;initiate;;; +75161-0;LL2855-6;Initiate/Discontinue;LA9508-8;2;Discontinue;;; +75162-8;LL2855-6;Initiate/Discontinue;LA20934-8;1;initiate;;; +75162-8;LL2855-6;Initiate/Discontinue;LA9508-8;2;Discontinue;;; +75163-6;LL2913-3;CDC.CS_11b_Trimester of first prenatal visit;LA21196-3;1;1st trimester;;; +75163-6;LL2913-3;CDC.CS_11b_Trimester of first prenatal visit;LA21197-1;2;2nd trimester;;; +75163-6;LL2913-3;CDC.CS_11b_Trimester of first prenatal visit;LA21198-9;3;3rd trimester;;; +75163-6;LL2913-3;CDC.CS_11b_Trimester of first prenatal visit;LA14945-2;4;Unk;;; +75164-4;LL2916-6;CDC.CS_Y,N,Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75164-4;LL2916-6;CDC.CS_Y,N,Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75164-4;LL2916-6;CDC.CS_Y,N,Unk;LA14945-2;3;Unk;;; +75165-1;LL2916-6;CDC.CS_Y,N,Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75165-1;LL2916-6;CDC.CS_Y,N,Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75165-1;LL2916-6;CDC.CS_Y,N,Unk;LA14945-2;3;Unk;;; +75166-9;LL2916-6;CDC.CS_Y,N,Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75166-9;LL2916-6;CDC.CS_Y,N,Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75166-9;LL2916-6;CDC.CS_Y,N,Unk;LA14945-2;3;Unk;;; +75205-5;LL2916-6;CDC.CS_Y,N,Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75205-5;LL2916-6;CDC.CS_Y,N,Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75205-5;LL2916-6;CDC.CS_Y,N,Unk;LA14945-2;3;Unk;;; +75206-3;LL2916-6;CDC.CS_Y,N,Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75206-3;LL2916-6;CDC.CS_Y,N,Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75206-3;LL2916-6;CDC.CS_Y,N,Unk;LA14945-2;3;Unk;;; +75207-1;LL2916-6;CDC.CS_Y,N,Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75207-1;LL2916-6;CDC.CS_Y,N,Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75207-1;LL2916-6;CDC.CS_Y,N,Unk;LA14945-2;3;Unk;;; +75168-5;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +75168-5;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +75168-5;LL2918-2;CDC.CS_16_React,NonR,Unk;LA14945-2;3;Unk;;; +75171-9;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +75171-9;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +75171-9;LL2918-2;CDC.CS_16_React,NonR,Unk;LA14945-2;3;Unk;;; +75175-0;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +75175-0;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +75175-0;LL2918-2;CDC.CS_16_React,NonR,Unk;LA14945-2;3;Unk;;; +75178-4;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +75178-4;LL2918-2;CDC.CS_16_React,NonR,Unk;LA15256-3;2;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +75178-4;LL2918-2;CDC.CS_16_React,NonR,Unk;LA14945-2;3;Unk;;; +75174-3;LL2936-4;CDC.CS_17_Treponemal test type;LA21250-8;1;EIA or CLIA;;; +75174-3;LL2936-4;CDC.CS_17_Treponemal test type;LA21251-6;2;TP-PA;;; +75174-3;LL2936-4;CDC.CS_17_Treponemal test type;LA46-8;3;Other;;; +75174-3;LL2936-4;CDC.CS_17_Treponemal test type;LA14945-2;4;Unk;;; +75177-6;LL2936-4;CDC.CS_17_Treponemal test type;LA21250-8;1;EIA or CLIA;;; +75177-6;LL2936-4;CDC.CS_17_Treponemal test type;LA21251-6;2;TP-PA;;; +75177-6;LL2936-4;CDC.CS_17_Treponemal test type;LA46-8;3;Other;;; +75177-6;LL2936-4;CDC.CS_17_Treponemal test type;LA14945-2;4;Unk;;; +75179-2;LL2919-0;CDC.CS_18_Mother's HIV status;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75179-2;LL2919-0;CDC.CS_18_Mother's HIV status;LA21206-0;2;equivocal test;;; +75179-2;LL2919-0;CDC.CS_18_Mother's HIV status;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75179-2;LL2919-0;CDC.CS_18_Mother's HIV status;LA21205-2;4;patient not tested;;; +75179-2;LL2919-0;CDC.CS_18_Mother's HIV status;LA14945-2;5;Unk;;; +75180-0;LL2921-6;CDC.CS_19_Mother's clinical stage of syphilis;LA21208-6;1;Primary;;; +75180-0;LL2921-6;CDC.CS_19_Mother's clinical stage of syphilis;LA18924-3;2;Secondary;;; +75180-0;LL2921-6;CDC.CS_19_Mother's clinical stage of syphilis;LA21207-8;3;early latent;;; +75180-0;LL2921-6;CDC.CS_19_Mother's clinical stage of syphilis;LA21210-2;4;late or late latent;;; +75180-0;LL2921-6;CDC.CS_19_Mother's clinical stage of syphilis;LA21211-0;5;previously treated/serofast;;; +75180-0;LL2921-6;CDC.CS_19_Mother's clinical stage of syphilis;LA46-8;6;Other;;; +75180-0;LL2921-6;CDC.CS_19_Mother's clinical stage of syphilis;LA14945-2;7;Unk;;; +75181-8;LL2922-4;CDC.CS_20_Mother's surv stage of syphilis;LA21208-6;1;Primary;;; +75181-8;LL2922-4;CDC.CS_20_Mother's surv stage of syphilis;LA18924-3;2;Secondary;;; +75181-8;LL2922-4;CDC.CS_20_Mother's surv stage of syphilis;LA21207-8;3;early latent;;; +75181-8;LL2922-4;CDC.CS_20_Mother's surv stage of syphilis;LA21210-2;4;late or late latent;;; +75181-8;LL2922-4;CDC.CS_20_Mother's surv stage of syphilis;LA46-8;5;Other;;; +75181-8;LL2922-4;CDC.CS_20_Mother's surv stage of syphilis;LA14945-2;6;Unk;;; +75183-4;LL2924-0;CDC.CS_21_Treatment timing;LA21212-8;1;Before pregnancy;;; +75183-4;LL2924-0;CDC.CS_21_Treatment timing;LA21196-3;2;1st trimester;;; +75183-4;LL2924-0;CDC.CS_21_Treatment timing;LA21197-1;3;2nd trimester;;; +75183-4;LL2924-0;CDC.CS_21_Treatment timing;LA21198-9;4;3rd trimester;;; +75183-4;LL2924-0;CDC.CS_21_Treatment timing;LA21213-6;5;No Treatment;;; +75183-4;LL2924-0;CDC.CS_21_Treatment timing;LA14945-2;9;Unk;;; +75184-2;LL2925-7;CDC.CS_22_Mother's treatment;LA21214-4;1;2.4 M units benzathine penicillin;;; +75184-2;LL2925-7;CDC.CS_22_Mother's treatment;LA21215-1;2;4.8 M units benzathine penicillin;;; +75184-2;LL2925-7;CDC.CS_22_Mother's treatment;LA21216-9;3;7.2 M units benzathine penicillin;;; +75184-2;LL2925-7;CDC.CS_22_Mother's treatment;LA46-8;4;Other;;; +75184-2;LL2925-7;CDC.CS_22_Mother's treatment;LA14945-2;5;Unk;;; +75185-9;LL2926-5;CDC.CS_Appropriate serologic response;LA21217-7;1;Yes, appropriate response;;; +75185-9;LL2926-5;CDC.CS_Appropriate serologic response;LA21218-5;2;No, inappropriate response: evidence of treatment failure or reinfection;;; +75185-9;LL2926-5;CDC.CS_Appropriate serologic response;LA21219-3;3;Response could not be determined from available non-treponemal titer information;;; +75185-9;LL2926-5;CDC.CS_Appropriate serologic response;LA21220-1;4;Not enough time for titer to change;;; +75186-7;LL2927-3;CDC.CS_25_Vital status;LA4247-8;1;Alive;;; +75186-7;LL2927-3;CDC.CS_25_Vital status;LA21222-7;2;Born alive, then died;;; +75186-7;LL2927-3;CDC.CS_25_Vital status;LA14271-3;3;Stillborn;;; +75186-7;LL2927-3;CDC.CS_25_Vital status;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75187-5;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75187-5;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75187-5;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA21224-3;3;No test;;; +75187-5;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA14945-2;4;Unk;;; +75190-9;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75190-9;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75190-9;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA21224-3;3;No test;;; +75190-9;LL2928-1;CDC.CS_29a_Y, N, No test, Unk;LA14945-2;4;Unk;;; +75192-5;LL2929-9;CDC.CS_31_Ypos, Yneg, No test, No spec, Unk;LA21225-0;1;Yes, positive;;; +75192-5;LL2929-9;CDC.CS_31_Ypos, Yneg, No test, No spec, Unk;LA21226-8;2;Yes, negative;;; +75192-5;LL2929-9;CDC.CS_31_Ypos, Yneg, No test, No spec, Unk;LA21224-3;3;No test;;; +75192-5;LL2929-9;CDC.CS_31_Ypos, Yneg, No test, No spec, Unk;LA21227-6;4;No lesions and no tissue to test;;; +75192-5;LL2929-9;CDC.CS_31_Ypos, Yneg, No test, No spec, Unk;LA14945-2;5;Unk;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA21232-6;1;no signs/asymptomatic;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA21233-4;2;condyloma lata;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA21234-2;3;snuffles;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA21235-9;4;syphilitic skin rash;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA21228-4;5;hepatosplenomegaly;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA21229-2;6;jaundice/hepatitis;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA21230-0;7;pseudo paralysis;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA17263-7;8;Edema;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA46-8;9;Other;;; +75193-3;LL2930-7;CDC.CS_32_Signs of CS;LA14945-2;10;Unk;;; +75194-1;LL2931-5;CDC.CS_Yes CS, Yes no CS, No, Unk;LA21236-7;1;Yes, changes consistent with CS;;; +75194-1;LL2931-5;CDC.CS_Yes CS, Yes no CS, No, Unk;LA21237-5;2;Yes, no signs of CS;;; +75194-1;LL2931-5;CDC.CS_Yes CS, Yes no CS, No, Unk;LA21247-4;3;No X-rays;;; +75194-1;LL2931-5;CDC.CS_Yes CS, Yes no CS, No, Unk;LA14945-2;4;Unk;;; +75195-8;LL2932-3;CDC.CS_34_Y reac, Y no reac, No test, Unk;LA21248-2;1;Yes, reactive;;; +75195-8;LL2932-3;CDC.CS_34_Y reac, Y no reac, No test, Unk;LA21249-0;2;Yes, nonreactive;;; +75195-8;LL2932-3;CDC.CS_34_Y reac, Y no reac, No test, Unk;LA21224-3;3;No test;;; +75195-8;LL2932-3;CDC.CS_34_Y reac, Y no reac, No test, Unk;LA14945-2;4;Unk;;; +75196-6;LL2933-1;CDC.CS_CSF WBC protein test;LA21252-4;1;Yes, CSF WBC count elevated;;; +75196-6;LL2933-1;CDC.CS_CSF WBC protein test;LA21253-2;2;Yes, CSF protein elevated;;; +75196-6;LL2933-1;CDC.CS_CSF WBC protein test;LA21238-3;3;both tests elevated;;; +75196-6;LL2933-1;CDC.CS_CSF WBC protein test;LA21239-1;4;neither test elevated;;; +75196-6;LL2933-1;CDC.CS_CSF WBC protein test;LA21224-3;5;No test;;; +75196-6;LL2933-1;CDC.CS_CSF WBC protein test;LA14945-2;6;Unk;;; +75197-4;LL2934-9;CDC.CS_36_Treatment for CS;LA21240-9;1;Yes, with aqueous or procaine penicillin for 10 days;;; +75197-4;LL2934-9;CDC.CS_36_Treatment for CS;LA21241-7;2;Yes, with benzathine penicillin x 1;;; +75197-4;LL2934-9;CDC.CS_36_Treatment for CS;LA21242-5;3;Yes, with other treatment;;; +75197-4;LL2934-9;CDC.CS_36_Treatment for CS;LA21213-6;4;No Treatment;;; +75197-4;LL2934-9;CDC.CS_36_Treatment for CS;LA14945-2;5;Unk;;; +75198-2;LL2935-6;CDC.CS_37_Case classification;LA21243-3;1;Not a case;;; +75198-2;LL2935-6;CDC.CS_37_Case classification;LA21244-1;2;Confirmed case;;; +75198-2;LL2935-6;CDC.CS_37_Case classification;LA21245-8;3;Syphilitic stillbirth;;; +75198-2;LL2935-6;CDC.CS_37_Case classification;LA21246-6;4;Probable case;;; +75204-8;LL2939-8;CDC.CS_11a1_Prenatal care indicator;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75204-8;LL2939-8;CDC.CS_11a1_Prenatal care indicator;LA21278-9;2;No prenatal care;;; +75204-8;LL2939-8;CDC.CS_11a1_Prenatal care indicator;LA14945-2;3;Unk;;; +75222-0;LL2867-1;Albert's Stain;LA20953-8;1;Corynebacterium diphtheriae shaped bacilli not seen;;; +75222-0;LL2867-1;Albert's Stain;LA20954-6;2;Club shaped bacilli with metachromatic granules;;; +75222-0;LL2867-1;Albert's Stain;LA20955-3;3;Club shaped bacilli in Chinese character-like arrangements;;; +75222-0;LL2867-1;Albert's Stain;LA20956-1;4;Corynebacterium diphtheriae shaped bacilli seen;;; +75222-0;LL2867-1;Albert's Stain;LA20957-9;5;Occasional Corynebacterium diphtheriae shaped bacilli seen;;; +75222-0;LL2867-1;Albert's Stain;LA20958-7;6;Corynebacterium diphtheriae shaped bacilli ++++;;; +75222-0;LL2867-1;Albert's Stain;LA20960-3;7;Corynebacterium diphtheriae shaped bacilli ++;;; +75223-8;LL2866-3;Dengue Fever;LA20952-0;1;IgM and IgG positive;;; +75223-8;LL2866-3;Dengue Fever;LA20951-2;2;IgM positive;;; +75223-8;LL2866-3;Dengue Fever;LA20950-4;3;IgG Positive;;; +75223-8;LL2866-3;Dengue Fever;LA6577-6;4;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75223-8;LL2866-3;Dengue Fever;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75224-6;LL2898-6;Present;LA9633-4;0;Present;52101004;Present (qualifier value);http://snomed.info/sct +75244-4;LL2943-0;Norton Scale_Physical condition;LA8967-7;1;Good;;; +75244-4;LL2943-0;Norton Scale_Physical condition;LA8968-5;2;Fair;;; +75244-4;LL2943-0;Norton Scale_Physical condition;LA8969-3;3;Poor;;; +75244-4;LL2943-0;Norton Scale_Physical condition;LA21282-1;4;Very bad;;; +75245-1;LL2944-8;Norton Scale_Mental Condition;LA9340-6;1;Alert;;; +75245-1;LL2944-8;Norton Scale_Mental Condition;LA21279-7;2;Apathetic;;; +75245-1;LL2944-8;Norton Scale_Mental Condition;LA6560-2;3;Confused;;; +75245-1;LL2944-8;Norton Scale_Mental Condition;LA17666-1;4;Stupor;89458003;stupor (finding);http://snomed.info/sct +75246-9;LL2946-3;Norton Scale_Activity;LA21285-4;1;Ambulant;;; +75246-9;LL2946-3;Norton Scale_Activity;LA21286-2;2;Walk/help;;; +75246-9;LL2946-3;Norton Scale_Activity;LA6743-4;3;Chairbound;;; +75246-9;LL2946-3;Norton Scale_Activity;LA4270-0;4;Bedridden;;; +75247-7;LL2947-1;Norton Scale_Mobility;LA19682-6;1;Full;;; +75247-7;LL2947-1;Norton Scale_Mobility;LA11910-9;2;Slight;;; +75247-7;LL2947-1;Norton Scale_Mobility;LA6484-5;3;Limited;;; +75247-7;LL2947-1;Norton Scale_Mobility;LA21289-6;4;Very limited, Immobile;;; +75248-5;LL2948-9;Norton Scale_Incontinence;LA21291-2;1;Not;;; +75248-5;LL2948-9;Norton Scale_Incontinence;LA20948-8;2;Occasional;;; +75248-5;LL2948-9;Norton Scale_Incontinence;LA21292-0;3;Usually-urine;;; +75248-5;LL2948-9;Norton Scale_Incontinence;LA21293-8;4;Doubly;;; +75257-6;LL2917-4;CDC.CS_15_Mother's marital status;LA21200-3;1;Single, never married;;; +75257-6;LL2917-4;CDC.CS_15_Mother's marital status;LA48-4;2;Married;;; +75257-6;LL2917-4;CDC.CS_15_Mother's marital status;LA21201-1;3;Separated/Divorced;;; +75257-6;LL2917-4;CDC.CS_15_Mother's marital status;LA21202-9;4;Widow;;; +75257-6;LL2917-4;CDC.CS_15_Mother's marital status;LA46-8;5;Other;;; +75257-6;LL2917-4;CDC.CS_15_Mother's marital status;LA14945-2;6;Unk;;; +75260-0;LL2951-3;[PROMIS] No pain|Mild|Mod|Severe|Very severe;LA131-5;1;No pain;;; +75260-0;LL2951-3;[PROMIS] No pain|Mild|Mod|Severe|Very severe;LA6752-5;2;Mild;;; +75260-0;LL2951-3;[PROMIS] No pain|Mild|Mod|Severe|Very severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +75260-0;LL2951-3;[PROMIS] No pain|Mild|Mod|Severe|Very severe;LA6750-9;4;Severe;;; +75260-0;LL2951-3;[PROMIS] No pain|Mild|Mod|Severe|Very severe;LA13958-6;5;Very severe;;; +75261-8;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA13879-4;1;Had no pain;;; +75261-8;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA6752-5;2;Mild;;; +75261-8;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +75261-8;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA6750-9;4;Severe;;; +75261-8;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA13958-6;5;Very severe;;; +75262-6;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA13879-4;1;Had no pain;;; +75262-6;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA6752-5;2;Mild;;; +75262-6;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +75262-6;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA6750-9;4;Severe;;; +75262-6;LL2949-7;[PROMIS] Had no pain|Mild|Mod|Severe|Very severe;LA13958-6;5;Very severe;;; +75269-1;LL2886-1;Genital Culture;LA21116-1;1;No Neisseria gonorrhoeae isolated;;; +75269-1;LL2886-1;Genital Culture;LA21117-9;2;Enterococcus > = 10 E6 CFU/L with sensitivities as appropriate;;; +75269-1;LL2886-1;Genital Culture;LA21118-7;3;Neisseria gonorrhoeae isolated (do not quantitate) with betalactamase result;;; +75269-1;LL2886-1;Genital Culture;LA21119-5;4;Enterobacteriaceae > = 10 E6 CFU/L with sensitivities as appropriate;;; +75269-1;LL2886-1;Genital Culture;LA21192-2;5;Actinomyces spp;;; +75274-1;LL2961-2;PHVS_ResidenceAccommodationType;;0;;;; +75278-2;LL2957-0;Status;LA6637-8;0;Completed;;; +75293-1;LL3889-4;NUTR_Phys Findings;;0;;;; +75294-9;LL2912-5;Adequate|Inadequate|Excessive;LA8914-9;0;Inadequate;;; +75294-9;LL2912-5;Adequate|Inadequate|Excessive;LA8913-1;1;Adequate;;; +75294-9;LL2912-5;Adequate|Inadequate|Excessive;LA21195-5;2;Excessive;;; +80449-2;LL2912-5;Adequate|Inadequate|Excessive;LA8914-9;0;Inadequate;;; +80449-2;LL2912-5;Adequate|Inadequate|Excessive;LA8913-1;1;Adequate;;; +80449-2;LL2912-5;Adequate|Inadequate|Excessive;LA21195-5;2;Excessive;;; +80485-6;LL2912-5;Adequate|Inadequate|Excessive;LA8914-9;0;Inadequate;;; +80485-6;LL2912-5;Adequate|Inadequate|Excessive;LA8913-1;1;Adequate;;; +80485-6;LL2912-5;Adequate|Inadequate|Excessive;LA21195-5;2;Excessive;;; +75305-3;LL2911-7;Nutr Dx;;0;;;; +75309-5;LL3154-3;Mental function;;0;;;; +75312-9;LL3043-8;PHVS_ProblemList_HITSP;;0;;;; +75318-6;LL3043-8;PHVS_ProblemList_HITSP;;0;;;; +75321-0;LL3043-8;PHVS_ProblemList_HITSP;;0;;;; +75326-9;LL3043-8;PHVS_ProblemList_HITSP;;0;;;; +75505-8;LL3043-8;PHVS_ProblemList_HITSP;;0;;;; +75618-9;LL3043-8;PHVS_ProblemList_HITSP;;0;;;; +92238-5;LL3043-8;PHVS_ProblemList_HITSP;;0;;;; +75320-2;LL2990-1;PHVS_AdvanceDirectiveType_HL7_CCD;;0;;;; +75324-4;LL3152-7;Functional performance;;0;;;; +75332-7;LL2995-0;SD/D/SWD/SWA/A/SA;LA15236-5;1;Strongly disagree;;; +75332-7;LL2995-0;SD/D/SWD/SWA/A/SA;LA15773-7;2;Disagree;;; +75332-7;LL2995-0;SD/D/SWD/SWA/A/SA;LA15234-0;3;Somewhat disagree;;; +75332-7;LL2995-0;SD/D/SWD/SWA/A/SA;LA15235-7;4;Somewhat agree;;; +75332-7;LL2995-0;SD/D/SWD/SWA/A/SA;LA15774-5;5;Agree;;; +75332-7;LL2995-0;SD/D/SWD/SWA/A/SA;LA15237-3;6;Strongly agree;;; +75334-3;LL2995-0;SD/D/SWD/SWA/A/SA;LA15236-5;1;Strongly disagree;;; +75334-3;LL2995-0;SD/D/SWD/SWA/A/SA;LA15773-7;2;Disagree;;; +75334-3;LL2995-0;SD/D/SWD/SWA/A/SA;LA15234-0;3;Somewhat disagree;;; +75334-3;LL2995-0;SD/D/SWD/SWA/A/SA;LA15235-7;4;Somewhat agree;;; +75334-3;LL2995-0;SD/D/SWD/SWA/A/SA;LA15774-5;5;Agree;;; +75334-3;LL2995-0;SD/D/SWD/SWA/A/SA;LA15237-3;6;Strongly agree;;; +75336-8;LL2995-0;SD/D/SWD/SWA/A/SA;LA15236-5;1;Strongly disagree;;; +75336-8;LL2995-0;SD/D/SWD/SWA/A/SA;LA15773-7;2;Disagree;;; +75336-8;LL2995-0;SD/D/SWD/SWA/A/SA;LA15234-0;3;Somewhat disagree;;; +75336-8;LL2995-0;SD/D/SWD/SWA/A/SA;LA15235-7;4;Somewhat agree;;; +75336-8;LL2995-0;SD/D/SWD/SWA/A/SA;LA15774-5;5;Agree;;; +75336-8;LL2995-0;SD/D/SWD/SWA/A/SA;LA15237-3;6;Strongly agree;;; +75333-5;LL2996-8;RN/S/O/AA;LA21376-1;1;Rarely/Never;;; +75333-5;LL2996-8;RN/S/O/AA;LA10082-8;2;Sometimes;;; +75333-5;LL2996-8;RN/S/O/AA;LA10044-8;3;Often;;; +75333-5;LL2996-8;RN/S/O/AA;LA21377-9;4;Almost always/Always;;; +75338-4;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75338-4;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75339-2;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75339-2;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75340-0;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75340-0;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75341-8;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75341-8;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75342-6;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75342-6;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75343-4;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75343-4;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75344-2;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75344-2;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75345-9;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75345-9;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75348-3;LL2988-5;Impaired/Intact;LA13035-3;1;Impaired;;; +75348-3;LL2988-5;Impaired/Intact;LA18951-6;2;Intact;;; +75357-4;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +75357-4;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +75357-4;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +75357-4;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +75357-4;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +75357-4;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +75357-4;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +75357-4;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +75357-4;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87933-8;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87933-8;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87933-8;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87933-8;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87933-8;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87933-8;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87933-8;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87933-8;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87933-8;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87934-6;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87934-6;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87934-6;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87934-6;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87934-6;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87934-6;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87934-6;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87934-6;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87934-6;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87935-3;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87935-3;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87935-3;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87935-3;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87935-3;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87935-3;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87935-3;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87935-3;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87935-3;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87936-1;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87936-1;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87936-1;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87936-1;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87936-1;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87936-1;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87936-1;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87936-1;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87936-1;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87937-9;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87937-9;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87937-9;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87937-9;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87937-9;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87937-9;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87937-9;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87937-9;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87937-9;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87938-7;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87938-7;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87938-7;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87938-7;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87938-7;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87938-7;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87938-7;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87938-7;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87938-7;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87939-5;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87939-5;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87939-5;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87939-5;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87939-5;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87939-5;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87939-5;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87939-5;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87939-5;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87940-3;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87940-3;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87940-3;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87940-3;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87940-3;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87940-3;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87940-3;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87940-3;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87940-3;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87941-1;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87941-1;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87941-1;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87941-1;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87941-1;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87941-1;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87941-1;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87941-1;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87941-1;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87942-9;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87942-9;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87942-9;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87942-9;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87942-9;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87942-9;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87942-9;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87942-9;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87942-9;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87943-7;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87943-7;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87943-7;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87943-7;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87943-7;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87943-7;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87943-7;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87943-7;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87943-7;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87944-5;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87944-5;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87944-5;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87944-5;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87944-5;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87944-5;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87944-5;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87944-5;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87944-5;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +87955-1;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +87955-1;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +87955-1;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +87955-1;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +87955-1;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +87955-1;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +87955-1;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +87955-1;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +87955-1;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +88139-1;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +88139-1;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +88139-1;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +88139-1;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +88139-1;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +88139-1;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +88139-1;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +88139-1;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +88139-1;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +88683-8;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +88683-8;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +88683-8;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +88683-8;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +88683-8;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +88683-8;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +88683-8;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +88683-8;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +88683-8;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +90273-4;LL2975-2;Abscess culture;LA21123-7;0;No growth;;; +90273-4;LL2975-2;Abscess culture;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +90273-4;LL2975-2;Abscess culture;LA21342-3;2;Streptococcus group D;;; +90273-4;LL2975-2;Abscess culture;LA19246-0;3;Staphylococcus aureus;;; +90273-4;LL2975-2;Abscess culture;LA21341-5;4;Peptostreptococcus spp;;; +90273-4;LL2975-2;Abscess culture;LA21340-7;5;Bacteroides spp;;; +90273-4;LL2975-2;Abscess culture;LA21339-9;6;Fusobacterium spp;;; +90273-4;LL2975-2;Abscess culture;LA21338-1;7;Clostridium spp;;; +90273-4;LL2975-2;Abscess culture;LA21337-3;8;Prevotella spp;;; +75358-2;LL2974-5;BMC;LA21123-7;0;No growth;;; +75358-2;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +75358-2;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +75358-2;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +75358-2;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +75358-2;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +75358-2;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +75359-0;LL2974-5;BMC;LA21123-7;0;No growth;;; +75359-0;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +75359-0;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +75359-0;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +75359-0;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +75359-0;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +75359-0;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +87929-6;LL2974-5;BMC;LA21123-7;0;No growth;;; +87929-6;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +87929-6;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +87929-6;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +87929-6;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +87929-6;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +87929-6;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +87930-4;LL2974-5;BMC;LA21123-7;0;No growth;;; +87930-4;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +87930-4;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +87930-4;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +87930-4;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +87930-4;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +87930-4;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +87931-2;LL2974-5;BMC;LA21123-7;0;No growth;;; +87931-2;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +87931-2;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +87931-2;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +87931-2;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +87931-2;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +87931-2;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +87932-0;LL2974-5;BMC;LA21123-7;0;No growth;;; +87932-0;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +87932-0;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +87932-0;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +87932-0;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +87932-0;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +87932-0;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +87954-4;LL2974-5;BMC;LA21123-7;0;No growth;;; +87954-4;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +87954-4;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +87954-4;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +87954-4;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +87954-4;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +87954-4;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +88141-7;LL2974-5;BMC;LA21123-7;0;No growth;;; +88141-7;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +88141-7;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +88141-7;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +88141-7;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +88141-7;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +88141-7;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +88142-5;LL2974-5;BMC;LA21123-7;0;No growth;;; +88142-5;LL2974-5;BMC;LA21332-4;1;Enterococcus faecium;;; +88142-5;LL2974-5;BMC;LA19246-0;2;Staphylococcus aureus;;; +88142-5;LL2974-5;BMC;LA21329-0;3;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +88142-5;LL2974-5;BMC;LA21330-8;4;Salmonella paratyphi A;;; +88142-5;LL2974-5;BMC;LA21333-2;5;Brucella sp;;; +88142-5;LL2974-5;BMC;LA21334-0;6;Enterococcus sp;;; +75371-5;LL2904-2;Bartlett score;LA21387-8;0;-2 Lack of inflammation and possible contamination with saliva;;; +75371-5;LL2904-2;Bartlett score;LA21388-6;1;-1 Lack of inflammation and possible contamination with saliva;;; +75371-5;LL2904-2;Bartlett score;LA21389-4;2;0 Lack of inflammation and possible contamination with saliva;;; +75371-5;LL2904-2;Bartlett score;LA21390-2;3;+1 Active inflammation;;; +75371-5;LL2904-2;Bartlett score;LA21391-0;4;+2 Active inflammation;;; +75371-5;LL2904-2;Bartlett score;LA21392-8;5;+3 Active inflammation;;; +75376-4;LL2900-0;Not present|Slight|Occasional|Mod|Marked;LA14895-9;1;Not present;;; +75376-4;LL2900-0;Not present|Slight|Occasional|Mod|Marked;LA11910-9;2;Slight;;; +75376-4;LL2900-0;Not present|Slight|Occasional|Mod|Marked;LA20948-8;3;Occasional;;; +75376-4;LL2900-0;Not present|Slight|Occasional|Mod|Marked;LA6751-7;4;Moderate;;; +75376-4;LL2900-0;Not present|Slight|Occasional|Mod|Marked;LA17968-1;5;Marked;;; +75392-1;LL2977-8;Fetal carrier status;LA21344-9;1;Normal fetus (no copies of the expanded gene detected);;; +75392-1;LL2977-8;Fetal carrier status;LA21343-1;2;Carrier of the expanded gene;;; +75392-1;LL2977-8;Fetal carrier status;LA21345-6;3;Affected fetus (carries two copies of the expanded gene);;; +75406-9;LL2997-6;HPV 16 18/45;LA21378-7;0;Negative - 16, Negative - 18/45;;; +75406-9;LL2997-6;HPV 16 18/45;LA21379-5;1;Negative - 16, Positive - 16/45;;; +75406-9;LL2997-6;HPV 16 18/45;LA21380-3;2;Positive - 16, Negative - 18/45;;; +75406-9;LL2997-6;HPV 16 18/45;LA21381-1;3;Positive - 16, Positive - 18/45;;; +75406-9;LL2997-6;HPV 16 18/45;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +82354-2;LL2997-6;HPV 16 18/45;LA21378-7;0;Negative - 16, Negative - 18/45;;; +82354-2;LL2997-6;HPV 16 18/45;LA21379-5;1;Negative - 16, Positive - 16/45;;; +82354-2;LL2997-6;HPV 16 18/45;LA21380-3;2;Positive - 16, Negative - 18/45;;; +82354-2;LL2997-6;HPV 16 18/45;LA21381-1;3;Positive - 16, Positive - 18/45;;; +82354-2;LL2997-6;HPV 16 18/45;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +75411-9;LL2999-2;Ebola Zaire rRT-PCR;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75411-9;LL2999-2;Ebola Zaire rRT-PCR;LA12719-3;2;Uncertain;;; +75411-9;LL2999-2;Ebola Zaire rRT-PCR;LA6576-8;3;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +75412-7;LL3005-7;CAHPS_healthcare_rating;LA21399-3;1;0 - worst health care;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA6112-2;2;1;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA6113-0;3;2;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA6114-8;4;3;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA6115-5;5;4;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA10137-0;6;5;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA10138-8;7;6;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA10139-6;8;7;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA10140-4;9;8;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA10141-2;10;9;;; +75412-7;LL3005-7;CAHPS_healthcare_rating;LA21400-9;11;10 - best health care;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA21399-3;1;0 - worst health care;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA6112-2;2;1;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA6113-0;3;2;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA6114-8;4;3;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA6115-5;5;4;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA10137-0;6;5;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA10138-8;7;6;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA10139-6;8;7;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA10140-4;9;8;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA10141-2;10;9;;; +75901-9;LL3005-7;CAHPS_healthcare_rating;LA21400-9;11;10 - best health care;;; +75414-3;LL3002-4;PROMIS_16_PedsGlobal;LA6270-8;1;Never;;; +75414-3;LL3002-4;PROMIS_16_PedsGlobal;LA10066-1;2;Rarely;;; +75414-3;LL3002-4;PROMIS_16_PedsGlobal;LA10082-8;3;Sometimes;;; +75414-3;LL3002-4;PROMIS_16_PedsGlobal;LA10044-8;4;Often;;; +75414-3;LL3002-4;PROMIS_16_PedsGlobal;LA9933-8;5;Always;;; +75415-0;LL3002-4;PROMIS_16_PedsGlobal;LA6270-8;1;Never;;; +75415-0;LL3002-4;PROMIS_16_PedsGlobal;LA10066-1;2;Rarely;;; +75415-0;LL3002-4;PROMIS_16_PedsGlobal;LA10082-8;3;Sometimes;;; +75415-0;LL3002-4;PROMIS_16_PedsGlobal;LA10044-8;4;Often;;; +75415-0;LL3002-4;PROMIS_16_PedsGlobal;LA9933-8;5;Always;;; +75414-3;LL3121-2;PROMIS_19;LA9933-8;1;Always;;; +75414-3;LL3121-2;PROMIS_19;LA10044-8;2;Often;;; +75414-3;LL3121-2;PROMIS_19;LA10082-8;3;Sometimes;;; +75414-3;LL3121-2;PROMIS_19;LA10066-1;4;Rarely;;; +75414-3;LL3121-2;PROMIS_19;LA6270-8;5;Never;;; +75415-0;LL3121-2;PROMIS_19;LA9933-8;1;Always;;; +75415-0;LL3121-2;PROMIS_19;LA10044-8;2;Often;;; +75415-0;LL3121-2;PROMIS_19;LA10082-8;3;Sometimes;;; +75415-0;LL3121-2;PROMIS_19;LA10066-1;4;Rarely;;; +75415-0;LL3121-2;PROMIS_19;LA6270-8;5;Never;;; +75896-1;LL3121-2;PROMIS_19;LA9933-8;1;Always;;; +75896-1;LL3121-2;PROMIS_19;LA10044-8;2;Often;;; +75896-1;LL3121-2;PROMIS_19;LA10082-8;3;Sometimes;;; +75896-1;LL3121-2;PROMIS_19;LA10066-1;4;Rarely;;; +75896-1;LL3121-2;PROMIS_19;LA6270-8;5;Never;;; +75897-9;LL3121-2;PROMIS_19;LA9933-8;1;Always;;; +75897-9;LL3121-2;PROMIS_19;LA10044-8;2;Often;;; +75897-9;LL3121-2;PROMIS_19;LA10082-8;3;Sometimes;;; +75897-9;LL3121-2;PROMIS_19;LA10066-1;4;Rarely;;; +75897-9;LL3121-2;PROMIS_19;LA6270-8;5;Never;;; +75417-6;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +75417-6;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +75417-6;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +75417-6;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +75417-6;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76706-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76706-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76706-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76706-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76706-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76707-9;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76707-9;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76707-9;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76707-9;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76707-9;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76708-7;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76708-7;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76708-7;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76708-7;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76708-7;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76709-5;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76709-5;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76709-5;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76709-5;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76709-5;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76710-3;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76710-3;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76710-3;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76710-3;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76710-3;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76711-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76711-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76711-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76711-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76711-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76712-9;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76712-9;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76712-9;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76712-9;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76712-9;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76831-7;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76831-7;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76831-7;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76831-7;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76831-7;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76832-5;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76832-5;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76832-5;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76832-5;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76832-5;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76833-3;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76833-3;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76833-3;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76833-3;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76833-3;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76834-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76834-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76834-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76834-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76834-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76835-8;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76835-8;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76835-8;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76835-8;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76835-8;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76836-6;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76836-6;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76836-6;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76836-6;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76836-6;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76837-4;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76837-4;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76837-4;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76837-4;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76837-4;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76838-2;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76838-2;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76838-2;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76838-2;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76838-2;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76839-0;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76839-0;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76839-0;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76839-0;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76839-0;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76840-8;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76840-8;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76840-8;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76840-8;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76840-8;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76841-6;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76841-6;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76841-6;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76841-6;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76841-6;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76842-4;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76842-4;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76842-4;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76842-4;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76842-4;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76843-2;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76843-2;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76843-2;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76843-2;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76843-2;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76844-0;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76844-0;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76844-0;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76844-0;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76844-0;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76845-7;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76845-7;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76845-7;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76845-7;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76845-7;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76846-5;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76846-5;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76846-5;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76846-5;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76846-5;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76847-3;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76847-3;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76847-3;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76847-3;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76847-3;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76848-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76848-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76848-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76848-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76848-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76849-9;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76849-9;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76849-9;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76849-9;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76849-9;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76850-7;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76850-7;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76850-7;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76850-7;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76850-7;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76851-5;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76851-5;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76851-5;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76851-5;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76851-5;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76852-3;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76852-3;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76852-3;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76852-3;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76852-3;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76853-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76853-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76853-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76853-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76853-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76854-9;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76854-9;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76854-9;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76854-9;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76854-9;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76855-6;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76855-6;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76855-6;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76855-6;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76855-6;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76856-4;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76856-4;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76856-4;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76856-4;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76856-4;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76857-2;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76857-2;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76857-2;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76857-2;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76857-2;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76858-0;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76858-0;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76858-0;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76858-0;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76858-0;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76859-8;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76859-8;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76859-8;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76859-8;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76859-8;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76860-6;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76860-6;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76860-6;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76860-6;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76860-6;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76861-4;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76861-4;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76861-4;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76861-4;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76861-4;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76862-2;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76862-2;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76862-2;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76862-2;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76862-2;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76863-0;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76863-0;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76863-0;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76863-0;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76863-0;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76864-8;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76864-8;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76864-8;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76864-8;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76864-8;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76865-5;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76865-5;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76865-5;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76865-5;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76865-5;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76866-3;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76866-3;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76866-3;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76866-3;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76866-3;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76867-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76867-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76867-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76867-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76867-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76868-9;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76868-9;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76868-9;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76868-9;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76868-9;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76869-7;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76869-7;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76869-7;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76869-7;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76869-7;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76870-5;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76870-5;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76870-5;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76870-5;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76870-5;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76871-3;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76871-3;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76871-3;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76871-3;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76871-3;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76872-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76872-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76872-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76872-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76872-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76873-9;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76873-9;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76873-9;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76873-9;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76873-9;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76874-7;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76874-7;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76874-7;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76874-7;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76874-7;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76875-4;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76875-4;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76875-4;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76875-4;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76875-4;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76876-2;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76876-2;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76876-2;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76876-2;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76876-2;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76877-0;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76877-0;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76877-0;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76877-0;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76877-0;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76878-8;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76878-8;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76878-8;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76878-8;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76878-8;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76879-6;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76879-6;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76879-6;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76879-6;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76879-6;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76880-4;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76880-4;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76880-4;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76880-4;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76880-4;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76881-2;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76881-2;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76881-2;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76881-2;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76881-2;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76882-0;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76882-0;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76882-0;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76882-0;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76882-0;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76883-8;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76883-8;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76883-8;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76883-8;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76883-8;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76884-6;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76884-6;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76884-6;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76884-6;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76884-6;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76885-3;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76885-3;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76885-3;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76885-3;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76885-3;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76886-1;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76886-1;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76886-1;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76886-1;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76886-1;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76887-9;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76887-9;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76887-9;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76887-9;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76887-9;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +76888-7;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +76888-7;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +76888-7;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +76888-7;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +76888-7;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +89084-8;LL3003-2;PROMIS_17_Social;LA6270-8;1;Never;;; +89084-8;LL3003-2;PROMIS_17_Social;LA10066-1;2;Rarely;;; +89084-8;LL3003-2;PROMIS_17_Social;LA10082-8;3;Sometimes;;; +89084-8;LL3003-2;PROMIS_17_Social;LA14747-2;4;Usually;;; +89084-8;LL3003-2;PROMIS_17_Social;LA9933-8;5;Always;;; +75514-0;LL3015-6;Lupus anticoagulant 2 screen;LA21416-5;1;Lupus anticoagulant not detected (2 screening test panel);;; +75514-0;LL3015-6;Lupus anticoagulant 2 screen;LA21415-7;2;Lupus anticoagulant present (2 screening test panel);;; +75514-0;LL3015-6;Lupus anticoagulant 2 screen;LA21417-3;3;Lupus anticoagulant indeterminate (2 screening test panel);;; +75518-1;LL2968-7;CSF Bacteria Id;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +75518-1;LL2968-7;CSF Bacteria Id;LA18049-9;2;Haemophilus influenzae;44470000;Haemophilus influenzae (organism);http://snomed.info/sct +75518-1;LL2968-7;CSF Bacteria Id;LA19341-9;3;Streptococcus pneumoniae;9861002;Streptococcus pneumoniae (organism);http://snomed.info/sct +75518-1;LL2968-7;CSF Bacteria Id;LA21314-2;4;Neisseria meningitidis A;;; +75518-1;LL2968-7;CSF Bacteria Id;LA21315-9;5;Neisseria meningitidis B;;; +75518-1;LL2968-7;CSF Bacteria Id;LA21316-7;6;Neisseria meningitidis C;;; +88236-5;LL2968-7;CSF Bacteria Id;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88236-5;LL2968-7;CSF Bacteria Id;LA18049-9;2;Haemophilus influenzae;44470000;Haemophilus influenzae (organism);http://snomed.info/sct +88236-5;LL2968-7;CSF Bacteria Id;LA19341-9;3;Streptococcus pneumoniae;9861002;Streptococcus pneumoniae (organism);http://snomed.info/sct +88236-5;LL2968-7;CSF Bacteria Id;LA21314-2;4;Neisseria meningitidis A;;; +88236-5;LL2968-7;CSF Bacteria Id;LA21315-9;5;Neisseria meningitidis B;;; +88236-5;LL2968-7;CSF Bacteria Id;LA21316-7;6;Neisseria meningitidis C;;; +75520-7;LL3009-9;Y=Yes/N=No;LA33-6;0;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75520-7;LL3009-9;Y=Yes/N=No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +86952-9;LL3009-9;Y=Yes/N=No;LA33-6;0;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86952-9;LL3009-9;Y=Yes/N=No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +86955-2;LL3009-9;Y=Yes/N=No;LA33-6;0;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +86955-2;LL3009-9;Y=Yes/N=No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89251-3;LL3009-9;Y=Yes/N=No;LA33-6;0;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89251-3;LL3009-9;Y=Yes/N=No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +75521-5;LL3012-3;PCORI_Information data source;LA21411-6;0;Patient reported;;; +75521-5;LL3012-3;PCORI_Information data source;LA21412-4;1;Healthcare delivery setting;;; +75521-5;LL3012-3;PCORI_Information data source;LA21413-2;2;No information;;; +75521-5;LL3012-3;PCORI_Information data source;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75521-5;LL3012-3;PCORI_Information data source;LA46-8;4;Other;;; +75521-5;LL3012-3;PCORI_Information data source;LA21411-6;0;Patient reported;;; +75521-5;LL3012-3;PCORI_Information data source;LA21412-4;1;Healthcare delivery setting;;; +75521-5;LL3012-3;PCORI_Information data source;LA21413-2;2;No information;;; +75521-5;LL3012-3;PCORI_Information data source;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75521-5;LL3012-3;PCORI_Information data source;LA46-8;4;Other;;; +75521-5;LL3012-3;PCORI_Information data source;LA21411-6;0;Patient reported;;; +75521-5;LL3012-3;PCORI_Information data source;LA21412-4;1;Healthcare delivery setting;;; +75521-5;LL3012-3;PCORI_Information data source;LA21413-2;2;No information;;; +75521-5;LL3012-3;PCORI_Information data source;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75521-5;LL3012-3;PCORI_Information data source;LA46-8;4;Other;;; +75525-6;LL3016-4;Encounter type;LA21424-9;0;Ambulatory Visit;;; +75525-6;LL3016-4;Encounter type;LA10268-3;1;Emergency Department;;; +75525-6;LL3016-4;Encounter type;LA21427-2;2;Inpatient hospital;;; +75525-6;LL3016-4;Encounter type;LA21428-0;3;Non-acute institutional stay;;; +75525-6;LL3016-4;Encounter type;LA21429-8;4;Other ambulatory visit;;; +75527-2;LL3017-2;Discharge vital status;LA21431-4;0;Discharged alive;;; +75527-2;LL3017-2;Discharge vital status;LA10325-1;1;Expired;;; +75527-2;LL3017-2;Discharge vital status;LA21413-2;2;No information;;; +75527-2;LL3017-2;Discharge vital status;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75527-2;LL3017-2;Discharge vital status;LA46-8;4;Other;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21435-5;1;Adult Foster Home;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21437-1;2;Assisted Living Facility;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21440-5;3;Against medical advise;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21442-1;4;Absent without leave;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA10325-1;5;Expired;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21446-2;6;Home Health;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21449-6;7;Home/Self care;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA6216-1;8;Hospice;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21452-0;9;Other Acute Inpatient Hospital;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA27-8;10;Nursing Home;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21455-3;11;Rehab facility;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21470-2;12;Residential Facility;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA21457-9;13;Still in hospital;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA6376-3;14;Skilled Nursing Facility;;; +75528-0;LL3018-0;MSCDM_Discharge status;LA4489-6;15;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75529-8;LL3068-5;MSCDM_Admitting Source;LA21435-5;1;Adult Foster Home;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA21437-1;2;Assisted Living Facility;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA21424-9;3;Ambulatory Visit;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA10268-3;4;Emergency Department;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA21446-2;5;Home Health;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA21449-6;6;Home/Self care;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA6216-1;7;Hospice;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA21452-0;8;Other Acute Inpatient Hospital;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA21586-5;9;Nursing Home (Includes ICF);;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA46-8;10;Other;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA6357-3;11;Rehabilitation facility;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA21470-2;12;Residential Facility;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA6376-3;13;Skilled Nursing Facility;;; +75529-8;LL3068-5;MSCDM_Admitting Source;LA4489-6;14;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75531-4;LL3019-8;Enroll basis;LA21462-9;1;Insurance;;; +75531-4;LL3019-8;Enroll basis;LA21464-5;2;Geography;;; +75531-4;LL3019-8;Enroll basis;LA21465-2;3;Algorithmic;;; +75531-4;LL3019-8;Enroll basis;LA21466-0;4;Encounter based;;; +75531-4;LL3019-8;Enroll basis;LA21920-6;5;Catchment area;;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21572-5;1;The Joint Commission Accreditation;;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21573-3;2;Accreditation Association for Ambulatory Health Care (AAAHC);;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21574-1;3;Accreditation Commission for Health Care, Inc. (ACHC);;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21575-8;4;American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF);;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21576-6;5;American Osteopathic Association (AOA) Accreditation Program;;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21577-4;6;Healthcare Facilities Accreditation Program (HFAP);;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21578-2;7;Community Health Accreditation Program (CHAP);;; +75532-2;LL3062-8;NMMDS_Accrediting Agencies;LA21579-0;8;DNV (Det Norske Veritas) Healthcare Accreditation;;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21572-5;1;The Joint Commission Accreditation;;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21573-3;2;Accreditation Association for Ambulatory Health Care (AAAHC);;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21574-1;3;Accreditation Commission for Health Care, Inc. (ACHC);;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21575-8;4;American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF);;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21576-6;5;American Osteopathic Association (AOA) Accreditation Program;;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21577-4;6;Healthcare Facilities Accreditation Program (HFAP);;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21578-2;7;Community Health Accreditation Program (CHAP);;; +75534-8;LL3062-8;NMMDS_Accrediting Agencies;LA21579-0;8;DNV (Det Norske Veritas) Healthcare Accreditation;;; +75535-5;LL3063-6;NMMDS_Certification Agencies;LA21580-8;1;The Joint Commission Certification;;; +75535-5;LL3063-6;NMMDS_Certification Agencies;LA21581-6;2;DNV (Det Norske Veritas) Healthcare Certification;;; +75535-5;LL3063-6;NMMDS_Certification Agencies;LA21582-4;3;Medicare Certification;;; +75536-3;LL3063-6;NMMDS_Certification Agencies;LA21580-8;1;The Joint Commission Certification;;; +75536-3;LL3063-6;NMMDS_Certification Agencies;LA21581-6;2;DNV (Det Norske Veritas) Healthcare Certification;;; +75536-3;LL3063-6;NMMDS_Certification Agencies;LA21582-4;3;Medicare Certification;;; +75537-1;LL3064-4;NMMDS_Licensing Agency;LA21584-0;1;State Licensure;;; +75538-9;LL3064-4;NMMDS_Licensing Agency;LA21584-0;1;State Licensure;;; +75543-9;LL3114-7;B19 cutoff;LA21756-4;1;B19 < cutoff value;;; +75543-9;LL3114-7;B19 cutoff;LA21757-2;2;B19 >= cutoff value;;; +75552-0;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75552-0;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75552-0;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75552-0;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75558-7;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75558-7;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75558-7;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75558-7;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75564-5;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75564-5;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75564-5;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75564-5;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75570-2;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75570-2;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75570-2;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75570-2;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75572-8;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75572-8;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75572-8;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75572-8;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75578-5;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75578-5;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75578-5;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75578-5;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75584-3;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75584-3;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75584-3;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75584-3;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75590-0;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75590-0;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75590-0;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75590-0;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75596-7;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75596-7;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75596-7;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75596-7;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75602-3;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +75602-3;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +75602-3;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +75602-3;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +96979-0;LL3000-8;NIPS Panorama;LA19542-2;1;Low risk;;; +96979-0;LL3000-8;NIPS Panorama;LA19541-4;2;High risk;;; +96979-0;LL3000-8;NIPS Panorama;LA21393-6;3;Risk unchanged;;; +96979-0;LL3000-8;NIPS Panorama;LA13546-9;4;Test not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +75613-0;LL3034-7;ED Episode Care;LA21589-9;1;Initial patient assessment;;; +75613-0;LL3034-7;ED Episode Care;LA21590-7;2;Follow-up visit;;; +75613-0;LL3034-7;ED Episode Care;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78030-4;LL3034-7;ED Episode Care;LA21589-9;1;Initial patient assessment;;; +78030-4;LL3034-7;ED Episode Care;LA21590-7;2;Follow-up visit;;; +78030-4;LL3034-7;ED Episode Care;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75614-8;LL3054-5;NAMCS three level triage;LA19759-2;0;Emergent;;; +75614-8;LL3054-5;NAMCS three level triage;LA21544-4;1;Urgent;;; +75614-8;LL3054-5;NAMCS three level triage;LA21545-1;2;Nonurgent;;; +75615-5;LL3053-7;NAMCS Four level triage;LA21538-6;0;Resuscitation;;; +75615-5;LL3053-7;NAMCS Four level triage;LA19759-2;1;Emergent;;; +75615-5;LL3053-7;NAMCS Four level triage;LA21544-4;3;Urgent;;; +75615-5;LL3053-7;NAMCS Four level triage;LA21545-1;4;Nonurgent;;; +75616-3;LL3052-9;NAMCS five level triage;LA21538-6;0;Resuscitation;;; +75616-3;LL3052-9;NAMCS five level triage;LA19759-2;1;Emergent;;; +75616-3;LL3052-9;NAMCS five level triage;LA21544-4;2;Urgent;;; +75616-3;LL3052-9;NAMCS five level triage;LA21587-3;3;Less urgent;;; +75616-3;LL3052-9;NAMCS five level triage;LA21545-1;4;Nonurgent;;; +75617-1;LL3031-3;Patient Residence Type;LA21588-1;1;Client's or patient's home;;; +75617-1;LL3031-3;Patient Residence Type;LA27-8;2;Nursing Home;;; +75617-1;LL3031-3;Patient Residence Type;LA20561-9;3;Homeless;;; +75617-1;LL3031-3;Patient Residence Type;LA46-8;4;Other;;; +75617-1;LL3031-3;Patient Residence Type;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +75618-9;LL5731-6;Comorbidities;LA31445-2;1;Previous myocardial infarction;;; +75618-9;LL5731-6;Comorbidities;LA31446-0;2;Cerebrovascular disease;;; +75618-9;LL5731-6;Comorbidities;LA31447-8;3;Perhipheral vascular disease;;; +75618-9;LL5731-6;Comorbidities;LA31448-6;4;Diabetes without complications;;; +75618-9;LL5731-6;Comorbidities;LA31449-4;5;Congestive heart failure;;; +75618-9;LL5731-6;Comorbidities;LA31451-0;6;Diabetes with end organ damage;;; +75618-9;LL5731-6;Comorbidities;LA31452-8;7;Chronic pulmonary disease;;; +75618-9;LL5731-6;Comorbidities;LA31453-6;8;Mild liver or renal disease;;; +75618-9;LL5731-6;Comorbidities;LA31454-4;9;Any tumor (including lymphoma or leukemia);;; +75618-9;LL5731-6;Comorbidities;LA20372-1;10;Dementia;;; +75618-9;LL5731-6;Comorbidities;LA31455-1;11;Connective tissue disease;;; +75618-9;LL5731-6;Comorbidities;LA10430-9;12;AIDS;;; +75618-9;LL5731-6;Comorbidities;LA31456-9;13;Moderate or severe liver or renal disease;;; +75618-9;LL5731-6;Comorbidities;LA31457-7;14;Metastatic solid tumor;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32622-5;1;HIV;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32623-3;2;Hepatitis B virus (HBV);;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32624-1;3;Hepatitis C virus (HCV);;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32625-8;4;Tuberculosis (TB);;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA7444-8;5;Hypertension;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA10529-8;6;Diabetes;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32626-6;7;Chronic kidney disease;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA10524-9;8;Cancer;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32627-4;9;Cardiovascular disease;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA16982-3;10;Asthma;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA28200-6;11;Chronic obstructive pulmonary disease;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA10576-9;12;Depression;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32628-2;13;Alcohol or substance abuse disorder;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32629-0;14;Other mental health condition;;; +75618-9;LL6047-6;Health Conditions - code Y=1, N=0;LA32630-8;15;Other chronic condition;;; +75634-6;LL2998-4;Disease activity score level;LA9194-7;1;Low;;; +75634-6;LL2998-4;Disease activity score level;LA6751-7;2;Moderate;;; +75634-6;LL2998-4;Disease activity score level;LA9193-9;3;High;;; +75636-1;LL3056-0;Emerg Sev Index;LA21567-5;1;Requires immediate life-saving intervention;;; +75636-1;LL3056-0;Emerg Sev Index;LA21752-3;2;High risk or confused/lethargic/disoriented or severe pain/distress;;; +75636-1;LL3056-0;Emerg Sev Index;LA21753-1;3;Needs 2 or more resources;;; +75636-1;LL3056-0;Emerg Sev Index;LA21754-9;4;Needs 1 resource;;; +75636-1;LL3056-0;Emerg Sev Index;LA21755-6;5;Needs no resources;;; +75652-8;LL2899-4;Few|Mod|Many;LA15680-4;1;Few;57176003;Few (qualifier value);http://snomed.info/sct +75652-8;LL2899-4;Few|Mod|Many;LA6751-7;2;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +75652-8;LL2899-4;Few|Mod|Many;LA15681-2;3;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +88978-2;LL2899-4;Few|Mod|Many;LA15680-4;1;Few;57176003;Few (qualifier value);http://snomed.info/sct +88978-2;LL2899-4;Few|Mod|Many;LA6751-7;2;Moderate;260354000;Moderate number (qualifier value);http://snomed.info/sct +88978-2;LL2899-4;Few|Mod|Many;LA15681-2;3;Many;260396001;Numerous (qualifier value);http://snomed.info/sct +75665-0;LL3008-1;Urine O&P;LA21402-5;0;No ova, cysts or parasites seen;;; +75665-0;LL3008-1;Urine O&P;LA21401-7;1;Schistosoma haematobium eggs;;; +75666-8;LL3021-4;HIV 1+2 Ab&HIV1 p24 Ag;LA21479-3;0;Ag (+) and Ab (-);;; +75666-8;LL3021-4;HIV 1+2 Ab&HIV1 p24 Ag;LA21480-1;1;Ag (-) and Ab (+);;; +75666-8;LL3021-4;HIV 1+2 Ab&HIV1 p24 Ag;LA21481-9;2;Ag (+) and Ab (+);;; +75666-8;LL3021-4;HIV 1+2 Ab&HIV1 p24 Ag;LA21482-7;3;Ag (-) and Ab (-);;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21499-1;1;Acinetobacter species.rpsA gene;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21500-6;2;Citrobacter species.ompA and mrkC genes;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21501-4;3;Enterobacter species.gyrB and metB genes;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21502-2;4;Proteus species.atpD gene;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21503-0;5;Escherichia coli.oppA gene;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21494-2;6;Klebsiella pneumoniae.yggE gene;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21496-7;7;Klebsiella oxytoca.ompA gene;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21498-3;8;Pseudomonas aeruginosa.sodA gene;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21489-2;9;Acinetobacter species;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21490-0;10;Citrobacter species;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21491-8;11;Enterobacter species;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21492-6;12;Proteus species;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21335-7;13;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +75688-2;LL3025-5;Gram negative bacteria identified;LA21336-5;14;Klebsiella pneumoniae;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA21495-9;15;Klebsiella oxytoca;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA19340-1;16;Pseudomonas aeruginosa;;; +75688-2;LL3025-5;Gram negative bacteria identified;LA20994-2;17;No organisms found that can be detected by panel;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21499-1;1;Acinetobacter species.rpsA gene;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21500-6;2;Citrobacter species.ompA and mrkC genes;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21501-4;3;Enterobacter species.gyrB and metB genes;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21502-2;4;Proteus species.atpD gene;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21503-0;5;Escherichia coli.oppA gene;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21494-2;6;Klebsiella pneumoniae.yggE gene;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21496-7;7;Klebsiella oxytoca.ompA gene;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21498-3;8;Pseudomonas aeruginosa.sodA gene;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21489-2;9;Acinetobacter species;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21490-0;10;Citrobacter species;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21491-8;11;Enterobacter species;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21492-6;12;Proteus species;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21335-7;13;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +88259-7;LL3025-5;Gram negative bacteria identified;LA21336-5;14;Klebsiella pneumoniae;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA21495-9;15;Klebsiella oxytoca;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA19340-1;16;Pseudomonas aeruginosa;;; +88259-7;LL3025-5;Gram negative bacteria identified;LA20994-2;17;No organisms found that can be detected by panel;;; +75691-6;LL3060-2;NCI CTC;LA21594-9;1;Loss of deep tendon reflexes or paresthesia (including tingling) but not interfering with function;;; +75691-6;LL3060-2;NCI CTC;LA21595-6;2;Objective sensory loss or paresthesia (including tingling), interfering with function, but not interfering with ADL;;; +75691-6;LL3060-2;NCI CTC;LA21596-4;3;Sensory loss or paresthesia interfering with ADL;;; +75691-6;LL3060-2;NCI CTC;LA21597-2;4;Permanent sensory loss that interferes with function;;; +75692-4;LL3061-0;Cancer Detect Basis;LA21591-5;0;Screening;;; +75692-4;LL3061-0;Cancer Detect Basis;LA21592-3;1;History/Symptoms;;; +75692-4;LL3061-0;Cancer Detect Basis;LA21593-1;2;Incidental;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21609-5;1;1 - Very heavy;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21721-8;2;2 - Very heavy;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21610-3;3;3 - Heavy;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21722-6;4;4 - Heavy;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21614-5;5;5 - Moderate;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21725-9;6;6 - Moderate;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21615-2;7;7 - Light;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21723-4;8;8 - Light;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21720-0;9;9 - Very light;;; +75699-9;LL3081-8;COOP_Physical activity scale;LA21613-7;10;10 - Very light;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21609-5;1;1 - Very heavy;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21721-8;2;2 - Very heavy;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21610-3;3;3 - Heavy;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21722-6;4;4 - Heavy;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21614-5;5;5 - Moderate;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21725-9;6;6 - Moderate;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21615-2;7;7 - Light;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21723-4;8;8 - Light;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21720-0;9;9 - Very light;;; +75809-4;LL3081-8;COOP_Physical activity scale;LA21613-7;10;10 - Very light;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA16643-1;1;1 - Not at all;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21710-1;2;2 - Not at all;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21622-8;3;3 - Slightly;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21727-5;4;4 - Slightly;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21623-6;5;5 - Moderately;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21728-3;6;6 - Moderately;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21624-4;7;7 - Quite a bit;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21729-1;8;8 - Quite a bit;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21718-4;9;9 - Extremely;;; +75700-5;LL3083-4;COOP_Feelings_Social Activities scale;LA21625-1;10;10 - Extremely;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA16643-1;1;1 - Not at all;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21710-1;2;2 - Not at all;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21622-8;3;3 - Slightly;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21727-5;4;4 - Slightly;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21623-6;5;5 - Moderately;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21728-3;6;6 - Moderately;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21624-4;7;7 - Quite a bit;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21729-1;8;8 - Quite a bit;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21718-4;9;9 - Extremely;;; +75702-1;LL3083-4;COOP_Feelings_Social Activities scale;LA21625-1;10;10 - Extremely;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA16643-1;1;1 - Not at all;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21710-1;2;2 - Not at all;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21622-8;3;3 - Slightly;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21727-5;4;4 - Slightly;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21623-6;5;5 - Moderately;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21728-3;6;6 - Moderately;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21624-4;7;7 - Quite a bit;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21729-1;8;8 - Quite a bit;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21718-4;9;9 - Extremely;;; +75806-0;LL3083-4;COOP_Feelings_Social Activities scale;LA21625-1;10;10 - Extremely;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA16643-1;1;1 - Not at all;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21710-1;2;2 - Not at all;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21622-8;3;3 - Slightly;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21727-5;4;4 - Slightly;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21623-6;5;5 - Moderately;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21728-3;6;6 - Moderately;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21624-4;7;7 - Quite a bit;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21729-1;8;8 - Quite a bit;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21718-4;9;9 - Extremely;;; +75808-6;LL3083-4;COOP_Feelings_Social Activities scale;LA21625-1;10;10 - Extremely;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21616-0;1;1 - No difficulty at all;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21711-9;2;2 - No difficulty at all;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21617-8;3;3 - A little bit of difficulty;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21730-9;4;4 - A little bit of difficulty;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21618-6;5;5 - Some difficulty;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21726-7;6;6 - Some difficulty;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21619-4;7;7 - Much difficulty;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21733-3;8;8 - Much difficulty;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21719-2;9;9 - Could not do;;; +75701-3;LL3085-9;COOP_Daily Activities scale;LA21620-2;10;10 - Could not do;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21616-0;1;1 - No difficulty at all;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21711-9;2;2 - No difficulty at all;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21617-8;3;3 - A little bit of difficulty;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21730-9;4;4 - A little bit of difficulty;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21618-6;5;5 - Some difficulty;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21726-7;6;6 - Some difficulty;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21619-4;7;7 - Much difficulty;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21733-3;8;8 - Much difficulty;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21719-2;9;9 - Could not do;;; +75807-8;LL3085-9;COOP_Daily Activities scale;LA21620-2;10;10 - Could not do;;; +75703-9;LL3086-7;COOP_Pain scale;LA21626-9;1;1 - No pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21709-3;2;2 - No pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21627-7;3;3 - Very mild pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21724-2;4;4 - Very mild pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21628-5;5;5 - Mild pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21732-5;6;6 - Mild pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21629-3;7;7 - Moderate pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21731-7;8;8 - Moderate pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21717-6;9;9 - Severe pain;;; +75703-9;LL3086-7;COOP_Pain scale;LA21630-1;10;10 - Severe pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21626-9;1;1 - No pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21709-3;2;2 - No pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21627-7;3;3 - Very mild pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21724-2;4;4 - Very mild pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21628-5;5;5 - Mild pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21732-5;6;6 - Mild pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21629-3;7;7 - Moderate pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21731-7;8;8 - Moderate pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21717-6;9;9 - Severe pain;;; +75805-2;LL3086-7;COOP_Pain scale;LA21630-1;10;10 - Severe pain;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21631-9;1;1 - Much better;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21708-5;2;2 - Much better;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21632-7;3;3 - A little better;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21734-1;4;4 - A little better;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21633-5;5;5 - About the same;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21735-8;6;6 - About the same;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21634-3;7;7 - A little worse;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21736-6;8;8 - A little worse;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21716-8;9;9 - Much worse;;; +75704-7;LL3088-3;COOP_Change in Health scale;LA21635-0;10;10 - Much worse;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21636-8;1;1 - Excellent;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21707-7;2;2 - Excellent;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21637-6;3;3 - Very good;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21737-4;4;4 - Very good;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21638-4;5;5 - Good;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21738-2;6;6 - Good;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21639-2;7;7 - Fair;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21739-0;8;8 - Fair;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21715-0;9;9 - Poor;;; +75705-4;LL3089-1;COOP_Overall Health scale;LA21640-0;10;10 - Poor;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21636-8;1;1 - Excellent;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21707-7;2;2 - Excellent;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21637-6;3;3 - Very good;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21737-4;4;4 - Very good;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21638-4;5;5 - Good;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21738-2;6;6 - Good;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21639-2;7;7 - Fair;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21739-0;8;8 - Fair;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21715-0;9;9 - Poor;;; +75803-7;LL3089-1;COOP_Overall Health scale;LA21640-0;10;10 - Poor;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21636-8;1;1 - Excellent;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21707-7;2;2 - Excellent;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21637-6;3;3 - Very good;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21737-4;4;4 - Very good;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21638-4;5;5 - Good;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21738-2;6;6 - Good;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21639-2;7;7 - Fair;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21739-0;8;8 - Fair;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21715-0;9;9 - Poor;;; +75804-5;LL3089-1;COOP_Overall Health scale;LA21640-0;10;10 - Poor;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21641-8;1;1 - Yes, as much as I wanted;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21706-9;2;2 - Yes, as much as I wanted;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21642-6;3;3 - Yes, quite a bit;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21740-8;4;4 - Yes, quite a bit;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21643-4;5;5 - Yes, some;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21741-6;6;6 - Yes, some;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21644-2;7;7 - Yes, a little;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21742-4;8;8 - Yes, a little;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21714-3;9;9 - No, not at all;;; +75706-2;LL3090-9;COOP_Social Support scale;LA21645-9;10;10 - No, not at all;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21641-8;1;1 - Yes, as much as I wanted;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21706-9;2;2 - Yes, as much as I wanted;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21642-6;3;3 - Yes, quite a bit;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21740-8;4;4 - Yes, quite a bit;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21643-4;5;5 - Yes, some;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21741-6;6;6 - Yes, some;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21644-2;7;7 - Yes, a little;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21742-4;8;8 - Yes, a little;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21714-3;9;9 - No, not at all;;; +75802-9;LL3090-9;COOP_Social Support scale;LA21645-9;10;10 - No, not at all;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21646-7;1;1 - Very well: could hardly be better;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21705-1;2;2 - Very well: could hardly be better;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21647-5;3;3 - Pretty good;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21743-2;4;4 - Pretty good;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21648-3;5;5 - Good & bad parts about equal;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21744-0;6;6 - Good & bad parts about equal;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21649-1;7;7 - Pretty bad;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21745-7;8;8 - Pretty bad;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21713-5;9;9 - Very bad: could hardly be worse;;; +75707-0;LL3091-7;COOP_Qualtiy of Life scale;LA21650-9;10;10 - Very bad: could hardly be worse;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21646-7;1;1 - Very well: could hardly be better;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21705-1;2;2 - Very well: could hardly be better;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21647-5;3;3 - Pretty good;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21743-2;4;4 - Pretty good;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21648-3;5;5 - Good & bad parts about equal;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21744-0;6;6 - Good & bad parts about equal;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21649-1;7;7 - Pretty bad;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21745-7;8;8 - Pretty bad;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21713-5;9;9 - Very bad: could hardly be worse;;; +75801-1;LL3091-7;COOP_Qualtiy of Life scale;LA21650-9;10;10 - Very bad: could hardly be worse;;; +75713-8;LL3049-5;Genotypes C/C, C/G, G/G;LA13521-2;1;C/C (wild type);;; +75713-8;LL3049-5;Genotypes C/C, C/G, G/G;LA21535-2;2;C/G (heterozygous);;; +75713-8;LL3049-5;Genotypes C/C, C/G, G/G;LA20174-1;3;G/G (homozygous);;; +93192-3;LL3049-5;Genotypes C/C, C/G, G/G;LA13521-2;1;C/C (wild type);;; +93192-3;LL3049-5;Genotypes C/C, C/G, G/G;LA21535-2;2;C/G (heterozygous);;; +93192-3;LL3049-5;Genotypes C/C, C/G, G/G;LA20174-1;3;G/G (homozygous);;; +94474-4;LL3049-5;Genotypes C/C, C/G, G/G;LA13521-2;1;C/C (wild type);;; +94474-4;LL3049-5;Genotypes C/C, C/G, G/G;LA21535-2;2;C/G (heterozygous);;; +94474-4;LL3049-5;Genotypes C/C, C/G, G/G;LA20174-1;3;G/G (homozygous);;; +75714-6;LL3046-1;Genotypes T/T,T/delT,delT/delT;LA21504-8;1;T/T (wild type);;; +75714-6;LL3046-1;Genotypes T/T,T/delT,delT/delT;LA21533-7;2;T/delT (heterozygous);;; +75714-6;LL3046-1;Genotypes T/T,T/delT,delT/delT;LA21534-5;3;delT/delT (homozygous);;; +75716-1;LL3050-3;Genotypes A/A,A/T,T/T;LA21537-8;1;A/A (wild type);;; +75716-1;LL3050-3;Genotypes A/A,A/T,T/T;LA21507-1;2;A/T (heterozygous);;; +75716-1;LL3050-3;Genotypes A/A,A/T,T/T;LA13523-8;3;T/T (homozygous);;; +75722-9;LL3026-3;Genotypes C/C, C/A, A/A;LA13521-2;1;C/C (wild type);;; +75722-9;LL3026-3;Genotypes C/C, C/A, A/A;LA21510-5;2;C/A (heterozygous);;; +75722-9;LL3026-3;Genotypes C/C, C/A, A/A;LA19934-1;3;A/A (homozygous);;; +75724-5;LL3026-3;Genotypes C/C, C/A, A/A;LA13521-2;1;C/C (wild type);;; +75724-5;LL3026-3;Genotypes C/C, C/A, A/A;LA21510-5;2;C/A (heterozygous);;; +75724-5;LL3026-3;Genotypes C/C, C/A, A/A;LA19934-1;3;A/A (homozygous);;; +75728-6;LL3026-3;Genotypes C/C, C/A, A/A;LA13521-2;1;C/C (wild type);;; +75728-6;LL3026-3;Genotypes C/C, C/A, A/A;LA21510-5;2;C/A (heterozygous);;; +75728-6;LL3026-3;Genotypes C/C, C/A, A/A;LA19934-1;3;A/A (homozygous);;; +91137-0;LL3026-3;Genotypes C/C, C/A, A/A;LA13521-2;1;C/C (wild type);;; +91137-0;LL3026-3;Genotypes C/C, C/A, A/A;LA21510-5;2;C/A (heterozygous);;; +91137-0;LL3026-3;Genotypes C/C, C/A, A/A;LA19934-1;3;A/A (homozygous);;; +75730-2;LL3029-7;Genotypes G/G, G/C, C/C;LA19932-5;1;G/G (wild type);;; +75730-2;LL3029-7;Genotypes G/G, G/C, C/C;LA21511-3;2;G/C (heterozygous);;; +75730-2;LL3029-7;Genotypes G/G, G/C, C/C;LA21506-3;3;C/C (homozygous);;; +92933-1;LL3029-7;Genotypes G/G, G/C, C/C;LA19932-5;1;G/G (wild type);;; +92933-1;LL3029-7;Genotypes G/G, G/C, C/C;LA21511-3;2;G/C (heterozygous);;; +92933-1;LL3029-7;Genotypes G/G, G/C, C/C;LA21506-3;3;C/C (homozygous);;; +94401-7;LL3029-7;Genotypes G/G, G/C, C/C;LA19932-5;1;G/G (wild type);;; +94401-7;LL3029-7;Genotypes G/G, G/C, C/C;LA21511-3;2;G/C (heterozygous);;; +94401-7;LL3029-7;Genotypes G/G, G/C, C/C;LA21506-3;3;C/C (homozygous);;; +75731-0;LL3030-5;Genotypes T/T, T/C, C/C;LA21504-8;1;T/T (wild type);;; +75731-0;LL3030-5;Genotypes T/T, T/C, C/C;LA21505-5;2;T/C (heterozygous);;; +75731-0;LL3030-5;Genotypes T/T, T/C, C/C;LA21506-3;3;C/C (homozygous);;; +92930-7;LL3030-5;Genotypes T/T, T/C, C/C;LA21504-8;1;T/T (wild type);;; +92930-7;LL3030-5;Genotypes T/T, T/C, C/C;LA21505-5;2;T/C (heterozygous);;; +92930-7;LL3030-5;Genotypes T/T, T/C, C/C;LA21506-3;3;C/C (homozygous);;; +92932-3;LL3030-5;Genotypes T/T, T/C, C/C;LA21504-8;1;T/T (wild type);;; +92932-3;LL3030-5;Genotypes T/T, T/C, C/C;LA21505-5;2;T/C (heterozygous);;; +92932-3;LL3030-5;Genotypes T/T, T/C, C/C;LA21506-3;3;C/C (homozygous);;; +93190-7;LL3030-5;Genotypes T/T, T/C, C/C;LA21504-8;1;T/T (wild type);;; +93190-7;LL3030-5;Genotypes T/T, T/C, C/C;LA21505-5;2;T/C (heterozygous);;; +93190-7;LL3030-5;Genotypes T/T, T/C, C/C;LA21506-3;3;C/C (homozygous);;; +94413-2;LL3030-5;Genotypes T/T, T/C, C/C;LA21504-8;1;T/T (wild type);;; +94413-2;LL3030-5;Genotypes T/T, T/C, C/C;LA21505-5;2;T/C (heterozygous);;; +94413-2;LL3030-5;Genotypes T/T, T/C, C/C;LA21506-3;3;C/C (homozygous);;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21931-3;1;Stage 0 - All three ancillaries not installed (laboratory, pharmacy, and radiology);;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21932-1;2;Stage 1 - Ancillaries - Lab, Rad, Pharmacy - all installed;;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21933-9;3;"Stage 2 - Clinical Data Repository (CDR), Controlled Medical Vocabulary, Clinical Decision Support (CDS), may have Document Imaging; Health Information Exchange (HIE) capable";;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21934-7;4;Stage 3 - Nursing/clinical documentation (flow sheets), CDSS (error checking), Picture Archive and Communication Systems (PACS) available outside Radiology;;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21935-4;5;Stage 4 - Computerized Practitioner Order Entry (CPOE), Clinical Decision Support (clinical protocols);;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21936-2;6;Stage 5 - The closed loop medication administration with bar coded unit dose medications environment is fully implemented;;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21937-0;7;Stage 6 - Physician documentation (structured templates), full CDSS (variance & compliance), full Radiology-PACS;;; +75745-0;LL3104-8;NMMDS_EHR Implementation Stages;LA21938-8;8;"Stage 7 - Complete EMR; CCD transactions to share data; Data warehousing; Data continuity with ED, ambulatory, OP";;; +75756-7;LL2991-9;Gram Negative;LA21335-7;0;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +75756-7;LL2991-9;Gram Negative;LA21336-5;1;Klebsiella pneumoniae;;; +75756-7;LL2991-9;Gram Negative;LA21368-8;2;Salmonella sp;;; +75756-7;LL2991-9;Gram Negative;LA19340-1;3;Pseudomonas aeruginosa;;; +75756-7;LL2991-9;Gram Negative;LA21369-6;4;Enterobacter cloacae;;; +90274-2;LL2991-9;Gram Negative;LA21335-7;0;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +90274-2;LL2991-9;Gram Negative;LA21336-5;1;Klebsiella pneumoniae;;; +90274-2;LL2991-9;Gram Negative;LA21368-8;2;Salmonella sp;;; +90274-2;LL2991-9;Gram Negative;LA19340-1;3;Pseudomonas aeruginosa;;; +90274-2;LL2991-9;Gram Negative;LA21369-6;4;Enterobacter cloacae;;; +75787-2;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75787-2;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75787-2;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75787-2;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75787-2;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75787-2;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75787-2;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75787-2;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75788-0;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75788-0;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75788-0;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75788-0;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75788-0;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75788-0;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75788-0;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75788-0;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75789-8;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75789-8;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75789-8;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75789-8;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75789-8;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75789-8;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75789-8;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75789-8;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75790-6;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75790-6;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75790-6;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75790-6;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75790-6;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75790-6;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75790-6;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75790-6;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75791-4;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75791-4;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75791-4;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75791-4;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75791-4;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75791-4;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75791-4;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75791-4;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75792-2;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75792-2;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75792-2;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75792-2;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75792-2;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +75792-2;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +75792-2;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +75792-2;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +81342-8;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81342-8;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +81342-8;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +81342-8;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +81351-9;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81351-9;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +81351-9;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +81351-9;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +81352-7;LL3139-4;Y/N/UTD/NI;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81352-7;LL3139-4;Y/N/UTD/NI;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +81352-7;LL3139-4;Y/N/UTD/NI;LA11137-9;3;Unable to determine;;; +81352-7;LL3139-4;Y/N/UTD/NI;LA21413-2;4;No information;;; +75819-3;LL2868-9;Chromasia;LA20962-9;0;Hypochromic;;; +75819-3;LL2868-9;Chromasia;LA11224-5;1;Normochromic;;; +75819-3;LL2868-9;Chromasia;LA11225-2;2;Polychromasia;;; +75820-1;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75820-1;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75820-1;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75820-1;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75821-9;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75821-9;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75821-9;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75821-9;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75822-7;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75822-7;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75822-7;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75822-7;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75823-5;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75823-5;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75823-5;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75823-5;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75824-3;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75824-3;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75824-3;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75824-3;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75825-0;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75825-0;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75825-0;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75825-0;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75826-8;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75826-8;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75826-8;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75826-8;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75827-6;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75827-6;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75827-6;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75827-6;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75828-4;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75828-4;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75828-4;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75828-4;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75829-2;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75829-2;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75829-2;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75829-2;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75830-0;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75830-0;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75830-0;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75830-0;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75831-8;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75831-8;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75831-8;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75831-8;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75832-6;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75832-6;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75832-6;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75832-6;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75833-4;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75833-4;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75833-4;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75833-4;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75834-2;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75834-2;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75834-2;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75834-2;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75835-9;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75835-9;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75835-9;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75835-9;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75836-7;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75836-7;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75836-7;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75836-7;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75837-5;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75837-5;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75837-5;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75837-5;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75838-3;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75838-3;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75838-3;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75838-3;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75839-1;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75839-1;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75839-1;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75839-1;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75848-2;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75848-2;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75848-2;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75848-2;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75849-0;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75849-0;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75849-0;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75849-0;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75850-8;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75850-8;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75850-8;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75850-8;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75851-6;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75851-6;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75851-6;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75851-6;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75852-4;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +75852-4;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +75852-4;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +75852-4;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +90030-8;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +90030-8;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +90030-8;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +90030-8;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +90031-6;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +90031-6;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +90031-6;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +90031-6;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +90032-4;LL3066-9;Difficulty level;LA13921-4;1;Without any difficulty;;; +90032-4;LL3066-9;Difficulty level;LA13920-6;2;With some difficulty;;; +90032-4;LL3066-9;Difficulty level;LA13919-8;3;With much difficulty;;; +90032-4;LL3066-9;Difficulty level;LA13912-3;4;Unable to do;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA21651-7;1;0 - Very well;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA6112-2;2;1;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA6113-0;3;2;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA6114-8;4;3;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA6115-5;5;4;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA10137-0;6;5;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA10138-8;7;6;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA10139-6;8;7;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA10140-4;9;8;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA10141-2;10;9;;; +75844-1;LL3120-4;0-10 scale, Very well to Very poor;LA21652-5;11;10 - Very poor;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21651-7;1;0 - Very well;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA16632-4;2;0.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6112-2;3;1;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15765-3;4;1.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6113-0;5;2;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15766-1;6;2.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6114-8;7;3;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15767-9;8;3.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6115-5;9;4;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15768-7;10;4.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10137-0;11;5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15769-5;12;5.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10138-8;13;6;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15770-3;14;6.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10139-6;15;7;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21653-3;16;7.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10140-4;17;8;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21654-1;18;8.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10141-2;19;9;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21655-8;20;9.5;;; +75846-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21652-5;21;10 - Very poor;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21651-7;1;0 - Very well;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA16632-4;2;0.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6112-2;3;1;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15765-3;4;1.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6113-0;5;2;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15766-1;6;2.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6114-8;7;3;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15767-9;8;3.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA6115-5;9;4;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15768-7;10;4.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10137-0;11;5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15769-5;12;5.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10138-8;13;6;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA15770-3;14;6.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10139-6;15;7;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21653-3;16;7.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10140-4;17;8;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21654-1;18;8.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA10141-2;19;9;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21655-8;20;9.5;;; +75894-6;LL3092-5;0-10 scale, 0.5 increments, Very well to Very poor;LA21652-5;21;10 - Very poor;;; +75857-3;LL3024-8;DocAccessRestrict;LA21488-4;0;42 CFR Part 2;;; +75859-9;LL3112-1;Modified Rankin Scale;LA6111-4;1;0;;; +75859-9;LL3112-1;Modified Rankin Scale;LA6112-2;2;1;;; +75859-9;LL3112-1;Modified Rankin Scale;LA6113-0;3;2;;; +75859-9;LL3112-1;Modified Rankin Scale;LA6114-8;4;3;;; +75859-9;LL3112-1;Modified Rankin Scale;LA6115-5;5;4;;; +75859-9;LL3112-1;Modified Rankin Scale;LA10137-0;6;5;;; +75859-9;LL3112-1;Modified Rankin Scale;LA10138-8;7;6;;; +75872-2;LL3095-8;PAS_Aids or Devices;LA15197-9;1;Cane;;; +75872-2;LL3095-8;PAS_Aids or Devices;LA21660-8;2;Crutches;;; +75872-2;LL3095-8;PAS_Aids or Devices;LA10117-2;3;Walker;;; +75872-2;LL3095-8;PAS_Aids or Devices;LA21662-4;4;Wheelchair;;; +75872-2;LL3095-8;PAS_Aids or Devices;LA21663-2;5;Built up or special utensils;;; +75872-2;LL3095-8;PAS_Aids or Devices;LA21664-0;6;Special or built up chair;;; +75872-2;LL3095-8;PAS_Aids or Devices;LA21665-7;7;Devices used for dressing (button hook, zipper pull, long handled shoe horn);;; +75872-2;LL3095-8;PAS_Aids or Devices;LA6310-2;8;Other (specify);;; +75873-0;LL3097-4;PAS_Categories for help;LA21666-5;1;Dressing and grooming;;; +75873-0;LL3097-4;PAS_Categories for help;LA21667-3;2;Arising;;; +75873-0;LL3097-4;PAS_Categories for help;LA21668-1;3;Eating;;; +75873-0;LL3097-4;PAS_Categories for help;LA11834-1;4;Walking;;; +75878-9;LL3102-2;PAS_Categories help needed;LA21675-6;1;Hygiene;;; +75878-9;LL3102-2;PAS_Categories help needed;LA21676-4;2;Reach;;; +75878-9;LL3102-2;PAS_Categories help needed;LA21677-2;3;Gripping and opening things;;; +75878-9;LL3102-2;PAS_Categories help needed;LA21678-0;4;Errands and chores;;; +75879-7;LL3099-0;PAS_Aids or devices for usual acitivies;LA21670-7;1;Bathtub bar;;; +75879-7;LL3099-0;PAS_Aids or devices for usual acitivies;LA21671-5;2;Raised toilet seat;;; +75879-7;LL3099-0;PAS_Aids or devices for usual acitivies;LA21672-3;3;Jar opener for jars previously opened;;; +75879-7;LL3099-0;PAS_Aids or devices for usual acitivies;LA21673-1;4;Long-handled appliances for reach;;; +75879-7;LL3099-0;PAS_Aids or devices for usual acitivies;LA21674-9;5;Long-handled appliances in bathroom;;; +75879-7;LL3099-0;PAS_Aids or devices for usual acitivies;LA6310-2;6;Other (specify);;; +75882-1;LL3115-4;Lupus anticoagulant 3 screen;LA21759-8;1;Lupus anticoagulant present (3 screening test panel);;; +75882-1;LL3115-4;Lupus anticoagulant 3 screen;LA21760-6;2;Lupus anticoagulant not detected (3 screening test panel);;; +75882-1;LL3115-4;Lupus anticoagulant 3 screen;LA21761-4;3;Lupus anticoagulant indeterminate (3 screening test panel);;; +75889-6;LL5804-1;NIDA - Frequency;LA18934-2;1;Daily or almost daily;;; +75889-6;LL5804-1;NIDA - Frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +75889-6;LL5804-1;NIDA - Frequency;LA18876-5;3;Monthly;;; +75889-6;LL5804-1;NIDA - Frequency;LA18933-4;4;Less than monthly;;; +75889-6;LL5804-1;NIDA - Frequency;LA6270-8;5;Never;;; +88037-7;LL5804-1;NIDA - Frequency;LA18934-2;1;Daily or almost daily;;; +88037-7;LL5804-1;NIDA - Frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +88037-7;LL5804-1;NIDA - Frequency;LA18876-5;3;Monthly;;; +88037-7;LL5804-1;NIDA - Frequency;LA18933-4;4;Less than monthly;;; +88037-7;LL5804-1;NIDA - Frequency;LA6270-8;5;Never;;; +96842-0;LL5804-1;NIDA - Frequency;LA18934-2;1;Daily or almost daily;;; +96842-0;LL5804-1;NIDA - Frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +96842-0;LL5804-1;NIDA - Frequency;LA18876-5;3;Monthly;;; +96842-0;LL5804-1;NIDA - Frequency;LA18933-4;4;Less than monthly;;; +96842-0;LL5804-1;NIDA - Frequency;LA6270-8;5;Never;;; +96842-0;LL5804-1;NIDA - Frequency;LA18934-2;1;Daily or almost daily;;; +96842-0;LL5804-1;NIDA - Frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +96842-0;LL5804-1;NIDA - Frequency;LA18876-5;3;Monthly;;; +96842-0;LL5804-1;NIDA - Frequency;LA18933-4;4;Less than monthly;;; +96842-0;LL5804-1;NIDA - Frequency;LA6270-8;5;Never;;; +96843-8;LL5804-1;NIDA - Frequency;LA18934-2;1;Daily or almost daily;;; +96843-8;LL5804-1;NIDA - Frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +96843-8;LL5804-1;NIDA - Frequency;LA18876-5;3;Monthly;;; +96843-8;LL5804-1;NIDA - Frequency;LA18933-4;4;Less than monthly;;; +96843-8;LL5804-1;NIDA - Frequency;LA6270-8;5;Never;;; +96843-8;LL5804-1;NIDA - Frequency;LA18934-2;1;Daily or almost daily;;; +96843-8;LL5804-1;NIDA - Frequency;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +96843-8;LL5804-1;NIDA - Frequency;LA18876-5;3;Monthly;;; +96843-8;LL5804-1;NIDA - Frequency;LA18933-4;4;Less than monthly;;; +96843-8;LL5804-1;NIDA - Frequency;LA6270-8;5;Never;;; +75891-2;LL3156-8;AIS Severity Score;LA21939-6;1;1 - minor;;; +75891-2;LL3156-8;AIS Severity Score;LA16633-2;2;2 - moderate;;; +75891-2;LL3156-8;AIS Severity Score;LA21945-3;3;3 - serious;;; +75891-2;LL3156-8;AIS Severity Score;LA21946-1;4;4 - severe;;; +75891-2;LL3156-8;AIS Severity Score;LA21944-6;5;5 - critical;;; +75891-2;LL3156-8;AIS Severity Score;LA21943-8;6;6 - maximal;;; +75892-0;LL2969-5;BCR-ABL1 break points;LA21317-5;1;Major (p210);;; +75892-0;LL2969-5;BCR-ABL1 break points;LA21318-3;2;Minor (p190);;; +75892-0;LL2969-5;BCR-ABL1 break points;LA21319-1;3;Micro (p230);;; +75892-0;LL2969-5;BCR-ABL1 break points;LA9663-1;4;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +75893-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77565-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77566-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77567-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77568-4;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77569-2;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77570-0;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77571-8;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +77572-6;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +91145-3;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6111-4;1;0;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6112-2;2;1;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6113-0;3;2;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6114-8;4;3;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA6115-5;5;4;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10137-0;6;5;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10138-8;7;6;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10139-6;8;7;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10140-4;9;8;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA10141-2;10;9;;; +91146-1;LL3622-9;0-No Interfere|1|2|3|4|5|6|7|8|9|10-Completely;LA13942-0;11;10;;; +75910-0;LL3059-4;CTAS Triage scale;LA6112-2;1;1;;; +75910-0;LL3059-4;CTAS Triage scale;LA6113-0;2;2;;; +75910-0;LL3059-4;CTAS Triage scale;LA6114-8;3;3;;; +75910-0;LL3059-4;CTAS Triage scale;LA6115-5;4;4;;; +75910-0;LL3059-4;CTAS Triage scale;LA10137-0;5;5;;; +75915-9;LL3124-6;IEEE_air curtain status;LA21762-2;1;Air curtain off;;; +75915-9;LL3124-6;IEEE_air curtain status;LA21763-0;2;Air curtain on;;; +75915-9;LL3124-6;IEEE_air curtain status;LA21764-8;3;Air curtain disabled by user;;; +75916-7;LL3126-1;IEEE_bed type;LA21787-9;1;Radiant warmer (open);;; +75916-7;LL3126-1;IEEE_bed type;LA21788-7;2;Incubator operating as a warmer (combination);;; +75916-7;LL3126-1;IEEE_bed type;LA21789-5;3;Incubator (closed);;; +75917-5;LL3130-3;IEEE_bed status;LA9227-5;1;Open;;; +75917-5;LL3130-3;IEEE_bed status;LA21765-5;2;Partially open;;; +75917-5;LL3130-3;IEEE_bed status;LA9228-3;3;Closed;;; +75922-5;LL3131-1;IEEE_Fan speed;LA9194-7;1;Low;;; +75922-5;LL3131-1;IEEE_Fan speed;LA9193-9;2;High;;; +75926-6;LL3132-9;IEEE_heater type;LA21770-5;1;Radiant;;; +75926-6;LL3132-9;IEEE_heater type;LA21771-3;2;Convective;;; +75926-6;LL3132-9;IEEE_heater type;LA137-2;3;None;260413007;None (qualifier value);http://snomed.info/sct +75961-3;LL3133-7;IEEE_heater control type;LA21772-1;1;Servo;;; +75961-3;LL3133-7;IEEE_heater control type;LA19016-7;2;Manual;;; +75975-3;LL3140-2;Aneuploidy detection (Ord);LA21879-4;1;No aneuploidy detected;;; +75975-3;LL3140-2;Aneuploidy detection (Ord);LA21880-2;2;Aneuploidy suspected;;; +75975-3;LL3140-2;Aneuploidy detection (Ord);LA21881-0;3;Aneuploidy detected;;; +75977-9;LL3140-2;Aneuploidy detection (Ord);LA21879-4;1;No aneuploidy detected;;; +75977-9;LL3140-2;Aneuploidy detection (Ord);LA21880-2;2;Aneuploidy suspected;;; +75977-9;LL3140-2;Aneuploidy detection (Ord);LA21881-0;3;Aneuploidy detected;;; +75980-3;LL3140-2;Aneuploidy detection (Ord);LA21879-4;1;No aneuploidy detected;;; +75980-3;LL3140-2;Aneuploidy detection (Ord);LA21880-2;2;Aneuploidy suspected;;; +75980-3;LL3140-2;Aneuploidy detection (Ord);LA21881-0;3;Aneuploidy detected;;; +75981-1;LL3140-2;Aneuploidy detection (Ord);LA21879-4;1;No aneuploidy detected;;; +75981-1;LL3140-2;Aneuploidy detection (Ord);LA21880-2;2;Aneuploidy suspected;;; +75981-1;LL3140-2;Aneuploidy detection (Ord);LA21881-0;3;Aneuploidy detected;;; +75982-9;LL3140-2;Aneuploidy detection (Ord);LA21879-4;1;No aneuploidy detected;;; +75982-9;LL3140-2;Aneuploidy detection (Ord);LA21880-2;2;Aneuploidy suspected;;; +75982-9;LL3140-2;Aneuploidy detection (Ord);LA21881-0;3;Aneuploidy detected;;; +75983-7;LL3140-2;Aneuploidy detection (Ord);LA21879-4;1;No aneuploidy detected;;; +75983-7;LL3140-2;Aneuploidy detection (Ord);LA21880-2;2;Aneuploidy suspected;;; +75983-7;LL3140-2;Aneuploidy detection (Ord);LA21881-0;3;Aneuploidy detected;;; +77619-5;LL3140-2;Aneuploidy detection (Ord);LA21879-4;1;No aneuploidy detected;;; +77619-5;LL3140-2;Aneuploidy detection (Ord);LA21880-2;2;Aneuploidy suspected;;; +77619-5;LL3140-2;Aneuploidy detection (Ord);LA21881-0;3;Aneuploidy detected;;; +75976-1;LL3144-4;Trisomy 21 Interp;LA21885-1;1;Consistent with diploid chromosome 21;;; +75976-1;LL3144-4;Trisomy 21 Interp;LA21886-9;2;Borderline result suggestive of trisomy 21;;; +75976-1;LL3144-4;Trisomy 21 Interp;LA21887-7;3;Consistent with trisomy 21;;; +75978-7;LL3142-8;Trisomy 18 Interp;LA21882-8;1;Consistent with diploid chromosome 18;;; +75978-7;LL3142-8;Trisomy 18 Interp;LA21883-6;2;Borderline result suggestive of trisomy 18;;; +75978-7;LL3142-8;Trisomy 18 Interp;LA21890-1;3;Consistent with trisomy 13;;; +75979-5;LL3143-6;Trisomy 13 Interp;LA21888-5;1;Consistent with diploid chromosome 13;;; +75979-5;LL3143-6;Trisomy 13 Interp;LA21889-3;2;Borderline result suggestive of trisomy 13;;; +75979-5;LL3143-6;Trisomy 13 Interp;LA21890-1;3;Consistent with trisomy 13;;; +76060-3;LL3134-5;Cause Fetal Death;LA21773-9;1;Maternal conditions/diseases (specify);;; +76060-3;LL3134-5;Cause Fetal Death;LA21777-0;2;Rupture of membranes prior to onset of labor;;; +76060-3;LL3134-5;Cause Fetal Death;LA21778-8;3;Abruptio placenta;;; +76060-3;LL3134-5;Cause Fetal Death;LA21921-4;4;Placental insufficiency;;; +76060-3;LL3134-5;Cause Fetal Death;LA21779-6;5;Prolapsed cord;;; +76060-3;LL3134-5;Cause Fetal Death;LA21780-4;6;Chorioamnionitis;;; +76060-3;LL3134-5;Cause Fetal Death;LA21781-2;7;Other complications of placenta, cord, or membranes (specify);;; +76060-3;LL3134-5;Cause Fetal Death;LA21782-0;8;Other obstetrical or pregnancy complications (specify);;; +76060-3;LL3134-5;Cause Fetal Death;LA21783-8;9;Fetal anomaly (specify);;; +76060-3;LL3134-5;Cause Fetal Death;LA21784-6;10;Fetal injury (specify);;; +76060-3;LL3134-5;Cause Fetal Death;LA21785-3;11;Fetal infection (specify);;; +76060-3;LL3134-5;Cause Fetal Death;LA21786-1;12;Other fetal conditions/disorders (specify);;; +76060-3;LL3134-5;Cause Fetal Death;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +76061-1;LL3134-5;Cause Fetal Death;LA21773-9;1;Maternal conditions/diseases (specify);;; +76061-1;LL3134-5;Cause Fetal Death;LA21777-0;2;Rupture of membranes prior to onset of labor;;; +76061-1;LL3134-5;Cause Fetal Death;LA21778-8;3;Abruptio placenta;;; +76061-1;LL3134-5;Cause Fetal Death;LA21921-4;4;Placental insufficiency;;; +76061-1;LL3134-5;Cause Fetal Death;LA21779-6;5;Prolapsed cord;;; +76061-1;LL3134-5;Cause Fetal Death;LA21780-4;6;Chorioamnionitis;;; +76061-1;LL3134-5;Cause Fetal Death;LA21781-2;7;Other complications of placenta, cord, or membranes (specify);;; +76061-1;LL3134-5;Cause Fetal Death;LA21782-0;8;Other obstetrical or pregnancy complications (specify);;; +76061-1;LL3134-5;Cause Fetal Death;LA21783-8;9;Fetal anomaly (specify);;; +76061-1;LL3134-5;Cause Fetal Death;LA21784-6;10;Fetal injury (specify);;; +76061-1;LL3134-5;Cause Fetal Death;LA21785-3;11;Fetal infection (specify);;; +76061-1;LL3134-5;Cause Fetal Death;LA21786-1;12;Other fetal conditions/disorders (specify);;; +76061-1;LL3134-5;Cause Fetal Death;LA4489-6;13;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +76066-0;LL3147-7;AIS Version Code;LA21922-2;1;AIS Revision 2015;;; +76066-0;LL3147-7;AIS Version Code;LA21923-0;2;AIS Revision 2005 Update 2008;;; +76066-0;LL3147-7;AIS Version Code;LA21924-8;3;AIS Revision 2005;;; +76066-0;LL3147-7;AIS Version Code;LA21925-5;4;AIS Revision 1990 Update 1998;;; +76066-0;LL3147-7;AIS Version Code;LA21926-3;5;AIS Revision 1990;;; +76073-6;LL3077-6;Aspergillus niger;LA21123-7;0;No growth;;; +76073-6;LL3077-6;Aspergillus niger;LA21606-1;1;Positive for Aspergillus niger;;; +76073-6;LL3077-6;Aspergillus niger;LA21601-2;2;Positive for Aspergillus fumigatus;;; +76081-9;LL3103-0;MRSA;LA21679-8;0;Positive for staphylococcus aureus strain resistant to beta-lactam antibiotics and all oxacillin;;; +76081-9;LL3103-0;MRSA;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76082-7;LL3074-3;Methenamine silver stain;LA21107-0;0;No organisms seen;;; +76082-7;LL3074-3;Methenamine silver stain;LA21697-0;1;Positive for Cryptococcus neoformans;;; +76082-7;LL3074-3;Methenamine silver stain;LA21698-8;2;Positive for Pneumocystis jirovecii;;; +76083-5;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +76083-5;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +79375-2;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +79375-2;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +79376-0;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +79376-0;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +88169-8;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +88169-8;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +88171-4;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +88171-4;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +88172-2;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +88172-2;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +88173-0;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +88173-0;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +88234-0;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +88234-0;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +88366-0;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +88366-0;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +88631-7;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +88631-7;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +94856-2;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +94856-2;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +94857-0;LL3073-5;Acid fast stain;LA21602-0;0;No acid fast bacillus seen;;; +94857-0;LL3073-5;Acid fast stain;LA21603-8;1;Acid fast bacillus seen;;; +76142-9;LL2871-3;None|Occasional|1+|2+|3+|4+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +76142-9;LL2871-3;None|Occasional|1+|2+|3+|4+;LA20948-8;2;Occasional;;; +76142-9;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11841-6;3;1+;;; +76142-9;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11842-4;4;2+;;; +76142-9;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11843-2;5;3+;;; +76142-9;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11844-0;6;4+;;; +77159-2;LL2871-3;None|Occasional|1+|2+|3+|4+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77159-2;LL2871-3;None|Occasional|1+|2+|3+|4+;LA20948-8;2;Occasional;;; +77159-2;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11841-6;3;1+;;; +77159-2;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11842-4;4;2+;;; +77159-2;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11843-2;5;3+;;; +77159-2;LL2871-3;None|Occasional|1+|2+|3+|4+;LA11844-0;6;4+;;; +76324-3;LL3200-4;20150115-IEEEInfusion_1;LA22386-9;1;Alarm - physiological;;; +76324-3;LL3200-4;20150115-IEEEInfusion_1;LA22387-7;2;Alarm - technical;;; +76324-3;LL3200-4;20150115-IEEEInfusion_1;LA22388-5;3;Alert - advisory;;; +76325-0;LL3201-2;20150115-IEEEInfusion_2;LA22389-3;1;comm-status-offline;;; +76325-0;LL3201-2;20150115-IEEEInfusion_2;LA22390-1;2;comm-status-online;;; +76326-8;LL3202-0;20150115-IEEEInfusion_3;LA18632-2;1;Inactive;;; +76326-8;LL3202-0;20150115-IEEEInfusion_3;LA16666-2;2;Active;;; +76326-8;LL3202-0;20150115-IEEEInfusion_3;LA22391-9;3;latched;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22392-7;1;IV Fluid pressure is too high.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22393-5;2;Plunger out of position.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22394-3;3;Flange out of position.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22395-0;4;MDC_EVT_SYRINGE_BARREL_CAPTURE;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22396-8;5;Pressure disc out of position.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22397-6;6;End of plunger travel.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22398-4;7;Syringe is empty.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22399-2;8;Door is unlocked.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22400-8;9;Handset is detached from unit.;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22401-6;10;MDC_EVT_PCA_MAX_LIMIT;;; +76327-6;LL3203-8;20150115-IEEEInfusion_4;LA22402-4;11;MDC_EVT_PCA_PAUSED;;; +76328-4;LL3204-6;20150115-IEEEInfusion_5;LA22403-2;1;PN;;; +76328-4;LL3204-6;20150115-IEEEInfusion_5;LA22404-0;2;PL;;; +76328-4;LL3204-6;20150115-IEEEInfusion_5;LA14952-8;3;PM;;; +76328-4;LL3204-6;20150115-IEEEInfusion_5;LA22405-7;4;PH;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22406-5;1;pump-mode-drug-dosing;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22407-3;2;pump-mode-ramp-taper;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22408-1;3;pump-mode-multi-step;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22409-9;4;pump-mode-multi-dosing;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22410-7;5;pump-mode-loading-dose;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22411-5;6;pump-mode-continuous;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22412-3;7;pump-mode-piggyback;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22413-1;8;pump-mode-concurrent;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22414-9;9;pump-mode-clinician-dose;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22415-6;10;pump-mode-kvo;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22416-4;11;pump-mode-flushing;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22417-2;12;The infusion pump is programmed to allow patient-initiated drug dosing (e.g., PCA). Replaced pump-mode-pca that has the same value.;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22418-0;13;The pump is currently priming the fluid line. Though it is moving fluid, it is not intended to be delivered to the patient, but rather to fill the line, purge air, etc.;;; +76329-2;LL3205-3;20150115-IEEEInfusion_6;LA22419-8;14;The pump is programmed in an operational mode that does not match one of the defined modes.;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22406-5;1;pump-mode-drug-dosing;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22407-3;2;pump-mode-ramp-taper;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22408-1;3;pump-mode-multi-step;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22409-9;4;pump-mode-multi-dosing;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22410-7;5;pump-mode-loading-dose;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22411-5;6;pump-mode-continuous;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22412-3;7;pump-mode-piggyback;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22413-1;8;pump-mode-concurrent;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22414-9;9;pump-mode-clinician-dose;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22415-6;10;pump-mode-kvo;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22416-4;11;pump-mode-flushing;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22417-2;12;The infusion pump is programmed to allow patient-initiated drug dosing (e.g., PCA). Replaced pump-mode-pca that has the same value.;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22418-0;13;The pump is currently priming the fluid line. Though it is moving fluid, it is not intended to be delivered to the patient, but rather to fill the line, purge air, etc.;;; +76330-0;LL3205-3;20150115-IEEEInfusion_6;LA22419-8;14;The pump is programmed in an operational mode that does not match one of the defined modes.;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22406-5;1;pump-mode-drug-dosing;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22407-3;2;pump-mode-ramp-taper;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22408-1;3;pump-mode-multi-step;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22409-9;4;pump-mode-multi-dosing;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22410-7;5;pump-mode-loading-dose;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22411-5;6;pump-mode-continuous;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22412-3;7;pump-mode-piggyback;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22413-1;8;pump-mode-concurrent;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22414-9;9;pump-mode-clinician-dose;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22415-6;10;pump-mode-kvo;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22416-4;11;pump-mode-flushing;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22417-2;12;The infusion pump is programmed to allow patient-initiated drug dosing (e.g., PCA). Replaced pump-mode-pca that has the same value.;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22418-0;13;The pump is currently priming the fluid line. Though it is moving fluid, it is not intended to be delivered to the patient, but rather to fill the line, purge air, etc.;;; +76331-8;LL3205-3;20150115-IEEEInfusion_6;LA22419-8;14;The pump is programmed in an operational mode that does not match one of the defined modes.;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22420-6;1;pump-stopped-nos;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22421-4;2;pump-stopped-off;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22422-2;3;pump-stopped-ready-not-started;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22423-0;4;pump-stopped-delayed-start;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22424-8;5;pump-stopped-standby;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22425-5;6;pump-stopped-clinician-paused;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22426-3;7;pump-stopped-alarm;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22427-1;8;pump-stopped-delivery-complete;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22428-9;9;pump-stopped-between-doses;;; +76332-6;LL3206-1;20150115-IEEEInfusion_7;LA22429-7;10;pump-stopped-transitioning;;; +76346-6;LL3210-3;Bacteria/Fungi identified by MALDI-TOF;;0;;;; +76356-5;LL3212-9;NMMDS_Employment position;LA22446-1;1;Advanced practice registered nurse (APRN);;; +76356-5;LL3212-9;NMMDS_Employment position;LA22447-9;2;Advanced Practice Nurse (APN);;; +76356-5;LL3212-9;NMMDS_Employment position;LA22448-7;3;Nurse Consultant (NC);;; +76356-5;LL3212-9;NMMDS_Employment position;LA22449-5;4;Nurse Researcher (NR);;; +76356-5;LL3212-9;NMMDS_Employment position;LA22450-3;5;Nurse Executive (NE);;; +76356-5;LL3212-9;NMMDS_Employment position;LA22451-1;6;Nurse Manager (NM);;; +76356-5;LL3212-9;NMMDS_Employment position;LA22452-9;7;Nurse Faculty (NF);;; +76356-5;LL3212-9;NMMDS_Employment position;LA22453-7;8;Staff Nurse (SN);;; +76366-4;LL3213-7;NMMDS_Age category;LA22455-2;1;15-19 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22456-0;2;20-24 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22457-8;3;25-29 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22458-6;4;30-34 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22459-4;5;35-39 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22460-2;6;40-44 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22461-0;7;45-49 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22462-8;8;50-54 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22463-6;9;55-59 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22464-4;10;60-64 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22465-1;11;65-69 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22467-7;12;70-74 years old;;; +76366-4;LL3213-7;NMMDS_Age category;LA22468-5;13;75+ years old;;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22469-3;1;Licensed Practical/Licensed Vocational degree - Nursing;;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22470-1;2;Associate degree - Nursing;;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22471-9;3;Diploma - Nursing;;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22549-2;4;Baccalaureate degree - Nursing;;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22472-7;5;Master's degree - Nursing;;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22473-5;6;Doctoral degree - Nursing Practice (DNP);;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22474-3;7;Doctoral degree - Nursing (PhD);;; +76370-6;LL3673-2;NMMDS_Entry Level of Education, Nursing;LA22475-0;8;Doctoral degree - Nursing, Other;;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22469-3;1;Licensed Practical/Licensed Vocational degree - Nursing;;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22470-1;2;Associate degree - Nursing;;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22471-9;3;Diploma - Nursing;;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22549-2;4;Baccalaureate degree - Nursing;;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22472-7;5;Master's degree - Nursing;;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22473-5;6;Doctoral degree - Nursing Practice (DNP);;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22474-3;7;Doctoral degree - Nursing (PhD);;; +76374-8;LL3215-2;NMMDS_Highest Level of Education, Nursing;LA22475-0;8;Doctoral degree - Nursing, Other;;; +76378-9;LL3216-0;NMMDS_Level of Eductation, Non-nursing;LA22476-8;1;Associate degree - Non-Nursing;;; +76378-9;LL3216-0;NMMDS_Level of Eductation, Non-nursing;LA22477-6;2;Baccalaureate degree - Non-Nursing;;; +76378-9;LL3216-0;NMMDS_Level of Eductation, Non-nursing;LA22478-4;3;Master's degree - Non-Nursing;;; +76378-9;LL3216-0;NMMDS_Level of Eductation, Non-nursing;LA22479-2;4;Doctoral degree - Non-Nursing;;; +76382-1;LL3214-5;NMMDS_License type;LA9295-2;1;Licensed practical nurse or licensed vocational nurse;;; +76382-1;LL3214-5;NMMDS_License type;LA9291-1;2;Registered nurse;;; +76382-1;LL3214-5;NMMDS_License type;LA22446-1;3;Advanced practice registered nurse (APRN);;; +76386-2;LL3218-6;NMMDS_Certification;LA22480-0;1;Acute Care NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22481-8;2;Adult NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22482-6;3;Adult Psychiatric-Mental Health NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22483-4;4;Adult-Gerontology Acute Care NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22484-2;5;Adult-Gerontology Primary Care NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22485-9;6;Diabetes Management - Advanced;;; +76386-2;LL3218-6;NMMDS_Certification;LA22486-7;7;Family NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22487-5;8;Family Psychiatric - Mental Health NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22488-3;9;Gerontological NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22489-1;10;Pediatric NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22490-9;11;School NP;;; +76386-2;LL3218-6;NMMDS_Certification;LA22491-7;12;Adult - Gerontology CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22492-5;13;Adult Health CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22493-3;14;Adult Psychiatric - Mental Health CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22494-1;15;Child or Adolescent Psychiatric - Mental Health CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22498-2;16;Gerontological CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22499-0;17;Home Health CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22500-5;18;Pediatric CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22501-3;19;Public/Community Health CNS;;; +76386-2;LL3218-6;NMMDS_Certification;LA22502-1;20;Ambulatory Care Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22503-9;21;Cardiac Rehabilitation Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22504-7;22;Cardiac - Vascular Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22505-4;23;Certified Vascular Nurse;;; +76386-2;LL3218-6;NMMDS_Certification;LA22506-2;24;College Health Nurse;;; +76386-2;LL3218-6;NMMDS_Certification;LA22507-0;25;Community Health Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22509-6;26;General Nursing Practice;;; +76386-2;LL3218-6;NMMDS_Certification;LA22510-4;27;Gerontological Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22511-2;28;High-Risk Perinatal Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22512-0;29;Home Health Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22513-8;30;Informatics Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22514-6;31;Medical - Surgical Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22515-3;32;Nurse Executive;;; +76386-2;LL3218-6;NMMDS_Certification;LA22516-1;33;Nurse Executive, Advanced;;; +76386-2;LL3218-6;NMMDS_Certification;LA22517-9;34;Nursing Case Management;;; +76386-2;LL3218-6;NMMDS_Certification;LA22518-7;35;Nursing Professional Development;;; +76386-2;LL3218-6;NMMDS_Certification;LA22519-5;36;Pain Management Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22520-3;37;Pediatric Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22521-1;38;Perinatal Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22522-9;39;Psychiatric - Mental Health Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22523-7;40;Public Health Nursing - Advanced;;; +76386-2;LL3218-6;NMMDS_Certification;LA22524-5;41;School Nursing;;; +76386-2;LL3218-6;NMMDS_Certification;LA22525-2;42;CWOCN;;; +76386-2;LL3218-6;NMMDS_Certification;LA22526-0;43;CWCN;;; +76386-2;LL3218-6;NMMDS_Certification;LA22527-8;44;CWON;;; +76386-2;LL3218-6;NMMDS_Certification;LA22529-4;45;CCCN;;; +76386-2;LL3218-6;NMMDS_Certification;LA22528-6;46;COCN;;; +76386-2;LL3218-6;NMMDS_Certification;LA22530-2;47;Certified Nurse-Midwives (CNMs);;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22531-0;1;Acute care/Critical care;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA7169-1;2;Anesthesia;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22533-6;3;Geriatric/Gerontology;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA21446-2;4;Home Health;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22535-1;5;Informatics;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22536-9;6;Maternal-Child Health;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22537-7;7;Medical/Surgical;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22538-5;8;Occupational Health;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22539-3;9;Oncology;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22540-1;10;Palliative Care;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22541-9;11;Pediatrics/Neonatal;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22542-7;12;Public Health;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22543-5;13;Psychiatric/Mental Health/Substance Abuse;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA7200-4;14;Rehabilitation;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22545-0;15;School Health;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA17058-1;16;Trauma;;; +76390-4;LL3219-4;NMMDS_Employment Specialty;LA22042-8;17;Women's Health;;; +76397-9;LL3177-4;Prognostic Lymph Node Status;LA21989-1;0;Lymph node negative;;; +76397-9;LL3177-4;Prognostic Lymph Node Status;LA21990-9;1;Lymph node positive (1-3 positive nodes);;; +76412-6;LL3159-2;PrP Codon 141;LA21960-2;1;LL;;; +76412-6;LL3159-2;PrP Codon 141;LA21961-0;2;LF;;; +76412-6;LL3159-2;PrP Codon 141;LA21962-8;3;FF;;; +76413-4;LL3173-3;Prp codon 112;LA21963-6;1;TT;;; +76413-4;LL3173-3;Prp codon 112;LA21964-4;2;TM;;; +76413-4;LL3173-3;Prp codon 112;LA21965-1;3;MM;;; +76414-2;LL3163-4;PrP codon 136;LA21966-9;1;AA;;; +76414-2;LL3163-4;PrP codon 136;LA21418-1;2;AV;;; +76414-2;LL3163-4;PrP codon 136;LA21988-3;3;AT;;; +76414-2;LL3163-4;PrP codon 136;LA21963-6;4;TT;;; +76414-2;LL3163-4;PrP codon 136;LA21969-3;5;TV;;; +76414-2;LL3163-4;PrP codon 136;LA21970-1;6;VV;;; +76415-9;LL3162-6;PrP Codon 154;LA21971-9;1;RR;;; +76415-9;LL3162-6;PrP Codon 154;LA21972-7;2;RH;;; +76415-9;LL3162-6;PrP Codon 154;LA21447-0;3;HH;;; +76416-7;LL3161-8;PrP codon 171;LA21975-0;1;QQ;;; +76416-7;LL3161-8;PrP codon 171;LA21976-8;2;QR;;; +76416-7;LL3161-8;PrP codon 171;LA21977-6;3;QH;;; +76416-7;LL3161-8;PrP codon 171;LA21978-4;4;QK;;; +76416-7;LL3161-8;PrP codon 171;LA21971-9;5;RR;;; +76416-7;LL3161-8;PrP codon 171;LA21987-5;6;RK;;; +76416-7;LL3161-8;PrP codon 171;LA21972-7;7;RH;;; +76416-7;LL3161-8;PrP codon 171;LA21982-6;8;KK;;; +76416-7;LL3161-8;PrP codon 171;LA21983-4;9;KH;;; +76416-7;LL3161-8;PrP codon 171;LA21447-0;10;HH;;; +76421-7;LL3179-0;20150106-APTASet1_2;LA22037-8;1;Physical therapist;;; +76421-7;LL3179-0;20150106-APTASet1_2;LA22038-6;2;Physical therapist assistant;;; +76421-7;LL3179-0;20150106-APTASet1_2;LA29256-7;3;Student Physical therapist;;; +76421-7;LL3179-0;20150106-APTASet1_2;LA29257-5;4;Student Physical therapy assistant;;; +76421-7;LL3179-0;20150106-APTASet1_2;LA46-8;5;Other;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA22039-4;1;Cardiovascular and Pulmonary;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA22040-2;2;Geriatrics;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA7190-7;3;Neurology;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA22041-0;4;Orthopaedics;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA7197-2;5;Pediatrics;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA9373-7;6;Sports;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA22042-8;7;Women's Health;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA22043-6;8;Clinical Electrophysiology;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA22539-3;9;Oncology;;; +76422-5;LL3180-8;20150106-APTASet1_3;LA137-2;10;None;260413007;None (qualifier value);http://snomed.info/sct +76437-3;LL3184-0;20150106-APTASet1_7;LA22073-3;1;"Private Insurance (includes ""no-fault"", BCBS, United Health, etc)";;; +76437-3;LL3184-0;20150106-APTASet1_7;LA15652-3;2;Medicare;;; +76437-3;LL3184-0;20150106-APTASet1_7;LA17849-3;3;Medicaid;;; +76437-3;LL3184-0;20150106-APTASet1_7;LA22074-1;4;Worker's Compensation;;; +76437-3;LL3184-0;20150106-APTASet1_7;LA22075-8;5;Veterans Administration;;; +76437-3;LL3184-0;20150106-APTASet1_7;LA22076-6;6;"Other Government (e.g. Bureau of Indian Affairs; Crippled Children's Services; Dept. of Vocational Rehab)";;; +76437-3;LL3184-0;20150106-APTASet1_7;LA22077-4;7;No Pay (indigent, no resources);;; +76437-3;LL3184-0;20150106-APTASet1_7;LA22078-2;8;"Private funds (e.g., self-pay; hometown fund raisers)";;; +76437-3;LL3184-0;20150106-APTASet1_7;LA22079-0;9;"Other, unclassified (e.g., SCI system patient care funds, TRICARE; Champus; Homebound, victim's assistance funds, etc.)";;; +76437-3;LL3184-0;20150106-APTASet1_7;LA22080-8;10;Declined/Participant doesn't know;;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22073-3;1;"Private Insurance (includes ""no-fault"", BCBS, United Health, etc)";;; +76438-1;LL3184-0;20150106-APTASet1_7;LA15652-3;2;Medicare;;; +76438-1;LL3184-0;20150106-APTASet1_7;LA17849-3;3;Medicaid;;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22074-1;4;Worker's Compensation;;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22075-8;5;Veterans Administration;;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22076-6;6;"Other Government (e.g. Bureau of Indian Affairs; Crippled Children's Services; Dept. of Vocational Rehab)";;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22077-4;7;No Pay (indigent, no resources);;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22078-2;8;"Private funds (e.g., self-pay; hometown fund raisers)";;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22079-0;9;"Other, unclassified (e.g., SCI system patient care funds, TRICARE; Champus; Homebound, victim's assistance funds, etc.)";;; +76438-1;LL3184-0;20150106-APTASet1_7;LA22080-8;10;Declined/Participant doesn't know;;; +76437-3;LL4962-8;ADAPTABLE Insurance list;LA28804-5;1;Aetna;;; +76437-3;LL4962-8;ADAPTABLE Insurance list;LA28805-2;2;Anthem;;; +76437-3;LL4962-8;ADAPTABLE Insurance list;LA28806-0;3;Humana;;; +76437-3;LL4962-8;ADAPTABLE Insurance list;LA28807-8;4;United Healthcare;;; +76437-3;LL4962-8;ADAPTABLE Insurance list;LA9-3;5;None of the above;;; +76437-3;LL5352-1;PRAPARE_Main Insurance;LA30194-7;1;None/uninsured;;; +76437-3;LL5352-1;PRAPARE_Main Insurance;LA17849-3;2;Medicaid;;; +76437-3;LL5352-1;PRAPARE_Main Insurance;LA30195-4;3;CHIP Medicaid;;; +76437-3;LL5352-1;PRAPARE_Main Insurance;LA15652-3;4;Medicare;;; +76437-3;LL5352-1;PRAPARE_Main Insurance;LA30196-2;5;Other public insurance (not CHIP);;; +76437-3;LL5352-1;PRAPARE_Main Insurance;LA30197-0;6;Other public insurance (CHIP);;; +76437-3;LL5352-1;PRAPARE_Main Insurance;LA6350-8;7;Private insurance;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA17849-3;1;Medicaid;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA15652-3;2;Medicare;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA31418-9;3;Other Public Insurance including non-Medicaid Children's Health Insurance Plan;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA6350-8;4;Private insurance;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA31419-7;5;Sliding Fee Scale (Self-Pay);;; +76437-3;LL5717-5;AAPCHO - Insurance;LA12724-3;6;Other, specify;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA30122-8;7;I choose not to answer this question;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA31369-4;8;Question not administered;;; +76437-3;LL5717-5;AAPCHO - Insurance;LA31370-2;9;Skipped question;;; +76439-9;LL3185-7;20150106-APTASet1_8;LA22081-6;1;Care transfer (other facility/ level of care);;; +76439-9;LL3185-7;20150106-APTASet1_8;LA4687-5;2;Physician;;; +76439-9;LL3185-7;20150106-APTASet1_8;LA15312-4;3;Self;;; +76439-9;LL3185-7;20150106-APTASet1_8;LA22037-8;4;Physical therapist;;; +76439-9;LL3185-7;20150106-APTASet1_8;LA46-8;5;Other;;; +76440-7;LL3186-5;20150106-APTASet1_9;LA28-6;1;Acute care hospital;;; +76440-7;LL3186-5;20150106-APTASet1_9;LA22082-4;2;Long term care hospital;;; +76440-7;LL3186-5;20150106-APTASet1_9;LA10928-2;3;Inpatient rehabilitation facility;;; +76440-7;LL3186-5;20150106-APTASet1_9;LA6376-3;4;Skilled Nursing Facility;;; +76440-7;LL3186-5;20150106-APTASet1_9;LA22083-2;5;Home health agency;;; +76440-7;LL3186-5;20150106-APTASet1_9;LA22084-0;6;Outpatient facility;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA16981-5;1;Arthritis;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22088-1;2;Cardio/pulm: Claudication;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22244-0;3;Cerebrovascular accident;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22093-1;4;Chronic pain;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA20354-9;5;Congenital anomalies;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA14291-1;6;Diabetes mellitus;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22219-2;7;Fractures;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22090-7;8;Head injury;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA7444-8;9;Hypertension;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22091-5;10;Infectious disease;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA25513-5;11;Malignant neoplasm;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22092-3;12;Neurological disorder;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA6301-1;13;Obesity;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA17768-5;14;Osteoarthritis;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA10527-2;15;Osteoporosis;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22095-6;16;Neuro: Peripheral neuropathy;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA25514-3;17;Peripheral vascular disease;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22096-4;18;Psychiatric disorder;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA20369-7;19;Respiratory disease;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA22098-0;20;Integumentary: Skin disorder (e.g. fungal rashes, contact dermatitis, moisture associated dermatitis, psoriasis );;; +76441-5;LL3187-3;20150106-APTASet1_10;LA17399-9;21;Spinal cord injury;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA46-8;22;Other;;; +76441-5;LL3187-3;20150106-APTASet1_10;LA137-2;23;None;260413007;None (qualifier value);http://snomed.info/sct +76442-3;LL3195-6;20150106-APTASet1_18;LA22196-2;1;Cardio/pulm: Adult respiratory distress syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25628-1;2;Cardio/pulm: Aneurysm;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25629-9;3;Cardio/pulm: Angina;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25630-7;4;Cardio/pulm: Arterial system abnormality;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25631-5;5;Cardio/pulm: Asthma;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25632-3;6;Cardio/pulm: Atelectasis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25633-1;7;Cardio/pulm: Bronchiectasis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22197-0;8;Cardio/pulm: Cardiac arrhythmia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22199-6;9;Cardio/pulm: Chronic obstructive lung disease;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22088-1;10;Cardio/pulm: Claudication;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22201-0;11;Cardio/pulm: Congenital anomaly of heart (eg, atrial septal defect, tetralogy of fallot);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25635-6;12;Cardio/pulm: Congestive heart failure;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25636-4;13;Cardio/pulm: Coronary artery disease;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25637-2;14;Cardio/pulm: Cystic fibrosis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22203-6;15;Cardio/pulm: Emphysema;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25638-0;16;Cardio/pulm: Fibrosis of lung;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25639-8;17;Cardio/pulm: Heart failure;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25532-5;18;Cardio/pulm: Heart transplant;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25641-4;19;Cardio/pulm: Heart valve disorder;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25642-2;20;Cardio/pulm: Hypertensive disorder;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25534-1;21;Cardio/pulm: Lung transplant;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25644-8;22;Cardio/pulm: Lymphatic system abnormality;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25645-5;23;Cardio/pulm: Malignant tumor of lung;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25646-3;24;Cardio/pulm: Myocardial infarction;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25647-1;25;"Cardio/pulm: Peripheral nervous system abnormality (e.g. neuropathic wounds; offloading Charcot fracture)";;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25648-9;26;Cardio/pulm: Peripheral vascular disease;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25649-7;27;Cardio/pulm: Pleural effusion;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25650-5;28;Cardio/pulm: Pleurisy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25651-3;29;Cardio/pulm: Pneumonia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25652-1;30;Cardio/pulm: Pneumothorax;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25653-9;31;Cardio/pulm: Pulmonary edema;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25654-7;32;Cardio/pulm: Pulmonary embolism;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25655-4;33;Cardio/pulm: Pulmonary hypertension;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22207-7;34;Cardio/pulm: Respiratory failure;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25656-2;35;Cardio/pulm: Venous system abnormality;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22253-1;36;ElectroPhys: Mononeuropathy (e.g., Median, ulnar, radial, axillary, musculocutaneous, suprascapular, tibial, fibular, and sural);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22251-5;37;ElectroPhys: Motor neuron disease;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22257-2;38;ElectroPhys: Myopathy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25627-3;39;ElectroPhys: Nerve plexus disorder;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22258-0;40;ElectroPhys: Neuromuscular Junction Disorders (e.g., Myasthenia Gravis & Lambert Eaton Syndrome);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22254-9;41;ElectroPhys: Polyneuropathy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22255-6;42;ElectroPhys: Radiculopathy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25661-2;43;Integumentary: Burn;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25662-0;44;Integumentary: Neuropathic wounds due to diabetes;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22311-7;45;Integumentary: Pressure ulcer;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25663-8;46;Integumentary: Scar tissue (e.g. skin, pelvic, abdominal, perineal);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22098-0;47;Integumentary: Skin disorder (e.g. fungal rashes, contact dermatitis, moisture associated dermatitis, psoriasis );;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22309-1;48;Integumentary: Surgical wound complication;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25664-6;49;Integumentary: Traumatic wound abnormality;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25665-3;50;Integumentary: Wound disorder, other;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22194-7;51;Med: Acute infectious disease (e.g. cellulitis, UTI, C-diff);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22208-5;52;Med: amputation;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25666-1;53;Med: Anemia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25667-9;54;Med: Autoimmune disorders (e.g. RA, lupus);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25668-7;55;Med: Bone density below reference range (e.g. osteopenia/osteoporosis);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25669-5;56;Med: Colorectal disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25670-3;57;Med: Constipation;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25671-1;58;Med: Dehydration;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25672-9;59;Med: Dementia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25673-7;60;Med: Diabetes mellitus;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22314-1;61;Med: Diabetic neuropathy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22285-3;62;Med: Dyspareunia (Psychologic);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25675-2;63;Med: Electrolyte imbalance;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25676-0;64;Med: Falls;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25677-8;65;Med: Fecal incontinence;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25678-6;66;Med: Frailty;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25679-4;67;Med: Hyperlipidemia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22291-1;68;Med: Interstitial Cystitis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22292-9;69;Med: Irritable bowel syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25680-2;70;Med: Lymphedema;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25681-0;71;Med: Malignant neoplastic disease;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25682-8;72;Med: Nocturnal enuresis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25683-6;73;Med: Obesity;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25684-4;74;Med: Renal failure syndrome (acute/chronic);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25685-1;75;Med: Retention of urine;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25686-9;76;Med: Sepsis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25687-7;77;Med: Sports injury, non-musculoskeletal (e.g. Heat-related illness, skin lesions, exercise –induced asthma);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25688-5;78;Med: Transplant, other (e.g. kidney and liver);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25689-3;79;Med: Urinary frequency;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22303-4;80;Med: Urinary Incontinence (stress, urge, mixed);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25690-1;81;Med: Urinary urgency;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22218-4;82;MSK: Chronic pain syndromes (e.g. fibromyalgia);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25691-9;83;MSK: Connective tissue disorder (e.g. Marfan, Ehlers-Danlos, lupus);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22284-6;84;MSK: Diastasis recti;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25692-7;85;MSK: Musculoskeletal pain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25693-5;86;MSK: Osteogenesis imperfecta;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25747-9;87;MSK-Ankle/foot: Fracture;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25748-7;88;MSK-Ankle/foot: Hallux valgus;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25749-5;89;MSK-Ankle/foot: Ligamentous injuries;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25752-9;90;MSK-Ankle/foot: Other disorders of ankle or foot;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25750-3;91;MSK-Ankle/foot: Plantar fasciitis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25751-1;92;MSK-Ankle/foot: Tendinopathies;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25725-5;93;MSK-Elbow: Cubital tunnel syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25726-3;94;MSK-Elbow: Fracture (includes forearm);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25727-1;95;MSK-Elbow: Instability (e.g. subluxation/dislocation, ligamentous);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25729-7;96;MSK-Elbow: Other disorders of the elbow or forearm;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25728-9;97;MSK-Elbow: Tendinopathies;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22213-5;98;MSK-Hand/wrist: Carpal tunnel syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25730-5;99;MSK-Hand/wrist: Fracture (including fingers);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25731-3;100;MSK-Hand/wrist: Instability including fingers (e.g. subluxation/dislocation, ligamentous);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25733-9;101;MSK-Hand/wrist: Other disorders of the wrist, hand or fingers;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25732-1;102;MSK-Hand/wrist: Tendinopathies including fingers;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25694-3;103;MSK-Head/neck: Cervicogenic headache;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25695-0;104;MSK-Head/neck: Other disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22214-3;105;MSK-Head/neck: Temporomandibular dysfunction;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22225-9;106;MSK-Hip: Femoroacetabular impingement;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22086-5;107;MSK-Hip: Fracture;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25735-4;108;MSK-Hip: Osteoarthritis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25736-2;109;MSK-Hip: Osteochondral defect (femoral head);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25739-6;110;MSK-Hip: Other disorders of the hip and thigh;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25737-0;111;MSK-Hip: Tendinopathies;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30065-9;112;MSK-Hip: Total replacement;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25738-8;113;MSK-Hip: Trochanteric bursitis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25740-4;114;MSK-Knee: Fracture (patella, distal femur, proximal tibia);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25741-2;115;MSK-Knee: Ligamentous injuries;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25742-0;116;MSK-Knee: Meniscal disorder;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25743-8;117;MSK-Knee: Osteoarthritis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25744-6;118;MSK-Knee: Osteochondral defect (distal femur, tibial or patella);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25746-1;119;MSK-Knee: Other disorders of the knee;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22222-6;120;MSK-Knee: Patellofemoral dysfunction (Disorder of patellofemoral joint);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25745-3;121;MSK-Knee: Tendinopathies;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30066-7;122;MSK-Knee: Total replacement;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22212-7;123;MSK-Shld: Adhesive capsulitis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25719-8;124;MSK-Shld: Complex/upper arm fracture;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25720-6;125;MSK-Shld: Injury of glenoid labrum;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25721-4;126;MSK-Shld: Instability (eg, subluxation/dislocation, ligamentous);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22085-7;127;MSK-Shld: Osteoarthritis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25722-2;128;MSK-Shld: Osteochondral defect (humeral head);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25724-8;129;MSK-Shld: Other disorders of the shoulder complex;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22224-2;130;MSK-Shld: Rotator cuff syndromes;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25696-8;131;MSK-Spine: Cervical disc disorder (e.g. DDD, protrusion, herniation);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25697-6;132;MSK-Spine: Cervical instability;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25702-4;133;MSK-Spine: Cervical other disorder;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25698-4;134;MSK-Spine: Cervical radiculopathy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25699-2;135;MSK-Spine: Cervical sprain/strain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25700-8;136;MSK-Spine: Cervical stenosis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25701-6;137;MSK-Spine: Curvature of spine (eg, scoliosis, kyphosis, lordosis);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25708-1;138;MSK-Spine: Lumbar disc disorder (eg, DDD, protrusion, hermiation);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25709-9;139;MSK-Spine: Lumbar instability;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25714-9;140;MSK-Spine: Lumbar other disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25710-7;141;MSK-Spine: Lumbar radiculopathy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25711-5;142;MSK-Spine: Lumbar spondylosis/spondylolisthesis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25712-3;143;MSK-Spine: Lumbar stenosis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25713-1;144;MSK-Spine: Lumbar strain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30064-2;145;MSK-Spine: Neck pain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25718-0;146;MSK-Spine: Pelvic other disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25715-6;147;MSK-Spine: Pelvic pain in the coccyx;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25716-4;148;MSK-Spine: Pelvic piriformis syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25717-2;149;MSK-Spine: Pelvic sacroiliac dysfunction;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25707-3;150;MSK-Spine: Thoracic other disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25703-2;151;MSK-Spine: Thoracic outlet syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25704-0;152;MSK-Spine: Thoracic rib dysfunction;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25705-7;153;MSK-Spine: Thoracic sprain/strain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25706-5;154;MSK-Spine: Thoracic stenosis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22236-6;155;Neuro: Acquired brain injury;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22237-4;156;Neuro: Anoxia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25754-5;157;Neuro: Brachial plexus injury;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22242-4;158;Neuro: Central nervous system infections (eg, Viral or bacterial infections of the central nervous system);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22243-2;159;Neuro: Central nervous system neoplasms;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22239-0;160;Neuro: Cerebellar disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22240-8;161;Neuro: Cerebral palsy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25758-6;162;Neuro: Cerebrovascular accident;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25759-4;163;Neuro: Concussion;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25760-2;164;Neuro: Encephalopathy (toxic, metabolic, anoxic);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25761-0;165;Neuro: Hypotonia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25762-8;166;Neuro: Multiple Sclerosis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25763-6;167;Neuro: Neurogenic bladder;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25764-4;168;Neuro: Neurologic disorder, progressive (e.g. ALS, Huntington's disease);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22248-1;169;Neuro: Normal pressure hydrocephalus;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22249-9;170;Neuro: Parkinson's disease;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22095-6;171;Neuro: Peripheral neuropathy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25765-1;172;Neuro: Spinal cord injury;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22250-7;173;Neuro: Vestibular disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30069-1;174;Onc: Leukemia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30070-9;175;Onc: Malignant lymphoma;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30071-7;176;Onc: Malignant melanoma;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30072-5;177;Onc: Malignant neoplasm of brain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30073-3;178;Onc: Malignant neoplasm of breast;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30074-1;179;Onc: Malignant neoplasm of central nervous system;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30075-8;180;Onc: Malignant neoplasm of testis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30076-6;181;Onc: Malignant neoplasm of uterus;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30077-4;182;Onc: Malignant tumor of cervix;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30078-2;183;Onc: Malignant tumor of head and/or neck;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30079-0;184;Onc: Malignant tumor of kidney;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30080-8;185;Onc: Malignant tumor of large intestine;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30081-6;186;Onc: Malignant tumor of lung;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30082-4;187;Onc: Malignant tumor of ovary;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30083-2;188;Onc: Malignant tumor of pancreas;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30084-0;189;Onc: Malignant tumor of prostate;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30085-7;190;Onc: Malignant tumor of stomach;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30086-5;191;Onc: Malignant tumor of thyroid gland;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30087-3;192;Onc: Malignant tumor of urinary bladder;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30088-1;193;Onc: Multiple myeloma;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30089-9;194;Onc: Osteosarcoma;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA30090-7;195;Onc: Sarcoma;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22259-8;196;Pediatric: Arthrogryposis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22261-4;197;Pediatric: Autism spectrum disorders (autistic disorder);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22262-2;198;Pediatric: Bronchopulmonary dysplasia of newborn;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25766-9;199;Pediatric: Complications of prematurity (e.g. osteopenia, RSD, IVH, BD);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25767-7;200;Pediatric: Congenital leg length discrepancy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22264-8;201;Pediatric: Developmental coordination disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22265-5;202;Pediatric: Developmental delay;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22266-3;203;Pediatric: Down syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22267-1;204;Pediatric: Genetic syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22270-5;205;Pediatric: High risk infant;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22271-3;206;Pediatric: Juvenile idiopathic arthritis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25768-5;207;Pediatric: Juvenile osteochondrosis of tibial tubercle;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22273-9;208;Pediatric: Muscular dystrophy (eg, Duchenne, Becker, SMA);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22274-7;209;Pediatric: Myelodysplasia/Spina Bifida (e.g. spina bifida, Arnold-Chiari, hydrocephalus);;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22277-0;210;Pediatric: Rett syndrome;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25769-3;211;Pediatric: Sensory processing disorders;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25770-1;212;Pediatric: Torticollis/plagiocephaly;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22280-4;213;Women's health: Amenorrhea/dysmenorrhea;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22286-1;214;Women's health: Endometriosis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22287-9;215;Women's health: Female athlete/female athlete triad;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22288-7;216;Women's health: Gynecologic conditions/surgery;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22289-5;217;Women's health: High-risk pregnancy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22290-3;218;Women's health: Hysterectomy;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22295-2;219;Women's health: Menopause;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25626-5;220;Women's health: Neoplasm of breast;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA25625-7;221;Women's health: Neoplasm of ovary;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22304-2;222;Women's health: Neoplasm of uterus;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22297-8;223;Women's health: Pelvic adhesions;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22130-1;224;Women's health: Pelvic girdle pain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22300-0;225;Women's health: Pelvic organ prolapse;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22301-8;226;Women's health: Pelvic pain;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22305-9;227;Women's health: Vaginismus;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22306-7;228;Women's health: Vulvar vestibulitis;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA22307-5;229;Women's health: Vulvodynia;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA46-8;230;Other;;; +76442-3;LL3195-6;20150106-APTASet1_18;LA137-2;231;None;260413007;None (qualifier value);http://snomed.info/sct +76472-0;LL3195-6;20150106-APTASet1_18;LA22196-2;1;Cardio/pulm: Adult respiratory distress syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25628-1;2;Cardio/pulm: Aneurysm;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25629-9;3;Cardio/pulm: Angina;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25630-7;4;Cardio/pulm: Arterial system abnormality;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25631-5;5;Cardio/pulm: Asthma;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25632-3;6;Cardio/pulm: Atelectasis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25633-1;7;Cardio/pulm: Bronchiectasis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22197-0;8;Cardio/pulm: Cardiac arrhythmia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22199-6;9;Cardio/pulm: Chronic obstructive lung disease;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22088-1;10;Cardio/pulm: Claudication;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22201-0;11;Cardio/pulm: Congenital anomaly of heart (eg, atrial septal defect, tetralogy of fallot);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25635-6;12;Cardio/pulm: Congestive heart failure;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25636-4;13;Cardio/pulm: Coronary artery disease;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25637-2;14;Cardio/pulm: Cystic fibrosis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22203-6;15;Cardio/pulm: Emphysema;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25638-0;16;Cardio/pulm: Fibrosis of lung;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25639-8;17;Cardio/pulm: Heart failure;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25532-5;18;Cardio/pulm: Heart transplant;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25641-4;19;Cardio/pulm: Heart valve disorder;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25642-2;20;Cardio/pulm: Hypertensive disorder;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25534-1;21;Cardio/pulm: Lung transplant;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25644-8;22;Cardio/pulm: Lymphatic system abnormality;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25645-5;23;Cardio/pulm: Malignant tumor of lung;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25646-3;24;Cardio/pulm: Myocardial infarction;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25647-1;25;"Cardio/pulm: Peripheral nervous system abnormality (e.g. neuropathic wounds; offloading Charcot fracture)";;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25648-9;26;Cardio/pulm: Peripheral vascular disease;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25649-7;27;Cardio/pulm: Pleural effusion;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25650-5;28;Cardio/pulm: Pleurisy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25651-3;29;Cardio/pulm: Pneumonia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25652-1;30;Cardio/pulm: Pneumothorax;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25653-9;31;Cardio/pulm: Pulmonary edema;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25654-7;32;Cardio/pulm: Pulmonary embolism;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25655-4;33;Cardio/pulm: Pulmonary hypertension;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22207-7;34;Cardio/pulm: Respiratory failure;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25656-2;35;Cardio/pulm: Venous system abnormality;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22253-1;36;ElectroPhys: Mononeuropathy (e.g., Median, ulnar, radial, axillary, musculocutaneous, suprascapular, tibial, fibular, and sural);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22251-5;37;ElectroPhys: Motor neuron disease;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22257-2;38;ElectroPhys: Myopathy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25627-3;39;ElectroPhys: Nerve plexus disorder;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22258-0;40;ElectroPhys: Neuromuscular Junction Disorders (e.g., Myasthenia Gravis & Lambert Eaton Syndrome);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22254-9;41;ElectroPhys: Polyneuropathy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22255-6;42;ElectroPhys: Radiculopathy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25661-2;43;Integumentary: Burn;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25662-0;44;Integumentary: Neuropathic wounds due to diabetes;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22311-7;45;Integumentary: Pressure ulcer;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25663-8;46;Integumentary: Scar tissue (e.g. skin, pelvic, abdominal, perineal);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22098-0;47;Integumentary: Skin disorder (e.g. fungal rashes, contact dermatitis, moisture associated dermatitis, psoriasis );;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22309-1;48;Integumentary: Surgical wound complication;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25664-6;49;Integumentary: Traumatic wound abnormality;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25665-3;50;Integumentary: Wound disorder, other;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22194-7;51;Med: Acute infectious disease (e.g. cellulitis, UTI, C-diff);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22208-5;52;Med: amputation;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25666-1;53;Med: Anemia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25667-9;54;Med: Autoimmune disorders (e.g. RA, lupus);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25668-7;55;Med: Bone density below reference range (e.g. osteopenia/osteoporosis);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25669-5;56;Med: Colorectal disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25670-3;57;Med: Constipation;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25671-1;58;Med: Dehydration;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25672-9;59;Med: Dementia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25673-7;60;Med: Diabetes mellitus;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22314-1;61;Med: Diabetic neuropathy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22285-3;62;Med: Dyspareunia (Psychologic);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25675-2;63;Med: Electrolyte imbalance;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25676-0;64;Med: Falls;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25677-8;65;Med: Fecal incontinence;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25678-6;66;Med: Frailty;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25679-4;67;Med: Hyperlipidemia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22291-1;68;Med: Interstitial Cystitis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22292-9;69;Med: Irritable bowel syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25680-2;70;Med: Lymphedema;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25681-0;71;Med: Malignant neoplastic disease;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25682-8;72;Med: Nocturnal enuresis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25683-6;73;Med: Obesity;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25684-4;74;Med: Renal failure syndrome (acute/chronic);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25685-1;75;Med: Retention of urine;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25686-9;76;Med: Sepsis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25687-7;77;Med: Sports injury, non-musculoskeletal (e.g. Heat-related illness, skin lesions, exercise –induced asthma);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25688-5;78;Med: Transplant, other (e.g. kidney and liver);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25689-3;79;Med: Urinary frequency;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22303-4;80;Med: Urinary Incontinence (stress, urge, mixed);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25690-1;81;Med: Urinary urgency;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22218-4;82;MSK: Chronic pain syndromes (e.g. fibromyalgia);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25691-9;83;MSK: Connective tissue disorder (e.g. Marfan, Ehlers-Danlos, lupus);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22284-6;84;MSK: Diastasis recti;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25692-7;85;MSK: Musculoskeletal pain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25693-5;86;MSK: Osteogenesis imperfecta;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25747-9;87;MSK-Ankle/foot: Fracture;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25748-7;88;MSK-Ankle/foot: Hallux valgus;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25749-5;89;MSK-Ankle/foot: Ligamentous injuries;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25752-9;90;MSK-Ankle/foot: Other disorders of ankle or foot;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25750-3;91;MSK-Ankle/foot: Plantar fasciitis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25751-1;92;MSK-Ankle/foot: Tendinopathies;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25725-5;93;MSK-Elbow: Cubital tunnel syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25726-3;94;MSK-Elbow: Fracture (includes forearm);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25727-1;95;MSK-Elbow: Instability (e.g. subluxation/dislocation, ligamentous);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25729-7;96;MSK-Elbow: Other disorders of the elbow or forearm;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25728-9;97;MSK-Elbow: Tendinopathies;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22213-5;98;MSK-Hand/wrist: Carpal tunnel syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25730-5;99;MSK-Hand/wrist: Fracture (including fingers);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25731-3;100;MSK-Hand/wrist: Instability including fingers (e.g. subluxation/dislocation, ligamentous);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25733-9;101;MSK-Hand/wrist: Other disorders of the wrist, hand or fingers;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25732-1;102;MSK-Hand/wrist: Tendinopathies including fingers;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25694-3;103;MSK-Head/neck: Cervicogenic headache;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25695-0;104;MSK-Head/neck: Other disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22214-3;105;MSK-Head/neck: Temporomandibular dysfunction;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22225-9;106;MSK-Hip: Femoroacetabular impingement;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22086-5;107;MSK-Hip: Fracture;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25735-4;108;MSK-Hip: Osteoarthritis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25736-2;109;MSK-Hip: Osteochondral defect (femoral head);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25739-6;110;MSK-Hip: Other disorders of the hip and thigh;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25737-0;111;MSK-Hip: Tendinopathies;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30065-9;112;MSK-Hip: Total replacement;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25738-8;113;MSK-Hip: Trochanteric bursitis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25740-4;114;MSK-Knee: Fracture (patella, distal femur, proximal tibia);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25741-2;115;MSK-Knee: Ligamentous injuries;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25742-0;116;MSK-Knee: Meniscal disorder;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25743-8;117;MSK-Knee: Osteoarthritis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25744-6;118;MSK-Knee: Osteochondral defect (distal femur, tibial or patella);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25746-1;119;MSK-Knee: Other disorders of the knee;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22222-6;120;MSK-Knee: Patellofemoral dysfunction (Disorder of patellofemoral joint);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25745-3;121;MSK-Knee: Tendinopathies;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30066-7;122;MSK-Knee: Total replacement;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22212-7;123;MSK-Shld: Adhesive capsulitis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25719-8;124;MSK-Shld: Complex/upper arm fracture;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25720-6;125;MSK-Shld: Injury of glenoid labrum;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25721-4;126;MSK-Shld: Instability (eg, subluxation/dislocation, ligamentous);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22085-7;127;MSK-Shld: Osteoarthritis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25722-2;128;MSK-Shld: Osteochondral defect (humeral head);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25724-8;129;MSK-Shld: Other disorders of the shoulder complex;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22224-2;130;MSK-Shld: Rotator cuff syndromes;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25696-8;131;MSK-Spine: Cervical disc disorder (e.g. DDD, protrusion, herniation);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25697-6;132;MSK-Spine: Cervical instability;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25702-4;133;MSK-Spine: Cervical other disorder;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25698-4;134;MSK-Spine: Cervical radiculopathy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25699-2;135;MSK-Spine: Cervical sprain/strain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25700-8;136;MSK-Spine: Cervical stenosis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25701-6;137;MSK-Spine: Curvature of spine (eg, scoliosis, kyphosis, lordosis);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25708-1;138;MSK-Spine: Lumbar disc disorder (eg, DDD, protrusion, hermiation);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25709-9;139;MSK-Spine: Lumbar instability;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25714-9;140;MSK-Spine: Lumbar other disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25710-7;141;MSK-Spine: Lumbar radiculopathy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25711-5;142;MSK-Spine: Lumbar spondylosis/spondylolisthesis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25712-3;143;MSK-Spine: Lumbar stenosis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25713-1;144;MSK-Spine: Lumbar strain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30064-2;145;MSK-Spine: Neck pain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25718-0;146;MSK-Spine: Pelvic other disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25715-6;147;MSK-Spine: Pelvic pain in the coccyx;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25716-4;148;MSK-Spine: Pelvic piriformis syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25717-2;149;MSK-Spine: Pelvic sacroiliac dysfunction;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25707-3;150;MSK-Spine: Thoracic other disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25703-2;151;MSK-Spine: Thoracic outlet syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25704-0;152;MSK-Spine: Thoracic rib dysfunction;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25705-7;153;MSK-Spine: Thoracic sprain/strain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25706-5;154;MSK-Spine: Thoracic stenosis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22236-6;155;Neuro: Acquired brain injury;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22237-4;156;Neuro: Anoxia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25754-5;157;Neuro: Brachial plexus injury;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22242-4;158;Neuro: Central nervous system infections (eg, Viral or bacterial infections of the central nervous system);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22243-2;159;Neuro: Central nervous system neoplasms;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22239-0;160;Neuro: Cerebellar disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22240-8;161;Neuro: Cerebral palsy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25758-6;162;Neuro: Cerebrovascular accident;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25759-4;163;Neuro: Concussion;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25760-2;164;Neuro: Encephalopathy (toxic, metabolic, anoxic);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25761-0;165;Neuro: Hypotonia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25762-8;166;Neuro: Multiple Sclerosis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25763-6;167;Neuro: Neurogenic bladder;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25764-4;168;Neuro: Neurologic disorder, progressive (e.g. ALS, Huntington's disease);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22248-1;169;Neuro: Normal pressure hydrocephalus;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22249-9;170;Neuro: Parkinson's disease;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22095-6;171;Neuro: Peripheral neuropathy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25765-1;172;Neuro: Spinal cord injury;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22250-7;173;Neuro: Vestibular disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30069-1;174;Onc: Leukemia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30070-9;175;Onc: Malignant lymphoma;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30071-7;176;Onc: Malignant melanoma;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30072-5;177;Onc: Malignant neoplasm of brain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30073-3;178;Onc: Malignant neoplasm of breast;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30074-1;179;Onc: Malignant neoplasm of central nervous system;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30075-8;180;Onc: Malignant neoplasm of testis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30076-6;181;Onc: Malignant neoplasm of uterus;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30077-4;182;Onc: Malignant tumor of cervix;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30078-2;183;Onc: Malignant tumor of head and/or neck;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30079-0;184;Onc: Malignant tumor of kidney;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30080-8;185;Onc: Malignant tumor of large intestine;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30081-6;186;Onc: Malignant tumor of lung;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30082-4;187;Onc: Malignant tumor of ovary;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30083-2;188;Onc: Malignant tumor of pancreas;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30084-0;189;Onc: Malignant tumor of prostate;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30085-7;190;Onc: Malignant tumor of stomach;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30086-5;191;Onc: Malignant tumor of thyroid gland;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30087-3;192;Onc: Malignant tumor of urinary bladder;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30088-1;193;Onc: Multiple myeloma;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30089-9;194;Onc: Osteosarcoma;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA30090-7;195;Onc: Sarcoma;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22259-8;196;Pediatric: Arthrogryposis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22261-4;197;Pediatric: Autism spectrum disorders (autistic disorder);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22262-2;198;Pediatric: Bronchopulmonary dysplasia of newborn;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25766-9;199;Pediatric: Complications of prematurity (e.g. osteopenia, RSD, IVH, BD);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25767-7;200;Pediatric: Congenital leg length discrepancy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22264-8;201;Pediatric: Developmental coordination disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22265-5;202;Pediatric: Developmental delay;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22266-3;203;Pediatric: Down syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22267-1;204;Pediatric: Genetic syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22270-5;205;Pediatric: High risk infant;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22271-3;206;Pediatric: Juvenile idiopathic arthritis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25768-5;207;Pediatric: Juvenile osteochondrosis of tibial tubercle;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22273-9;208;Pediatric: Muscular dystrophy (eg, Duchenne, Becker, SMA);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22274-7;209;Pediatric: Myelodysplasia/Spina Bifida (e.g. spina bifida, Arnold-Chiari, hydrocephalus);;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22277-0;210;Pediatric: Rett syndrome;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25769-3;211;Pediatric: Sensory processing disorders;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25770-1;212;Pediatric: Torticollis/plagiocephaly;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22280-4;213;Women's health: Amenorrhea/dysmenorrhea;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22286-1;214;Women's health: Endometriosis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22287-9;215;Women's health: Female athlete/female athlete triad;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22288-7;216;Women's health: Gynecologic conditions/surgery;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22289-5;217;Women's health: High-risk pregnancy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22290-3;218;Women's health: Hysterectomy;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22295-2;219;Women's health: Menopause;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25626-5;220;Women's health: Neoplasm of breast;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA25625-7;221;Women's health: Neoplasm of ovary;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22304-2;222;Women's health: Neoplasm of uterus;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22297-8;223;Women's health: Pelvic adhesions;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22130-1;224;Women's health: Pelvic girdle pain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22300-0;225;Women's health: Pelvic organ prolapse;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22301-8;226;Women's health: Pelvic pain;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22305-9;227;Women's health: Vaginismus;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22306-7;228;Women's health: Vulvar vestibulitis;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA22307-5;229;Women's health: Vulvodynia;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA46-8;230;Other;;; +76472-0;LL3195-6;20150106-APTASet1_18;LA137-2;231;None;260413007;None (qualifier value);http://snomed.info/sct +76444-9;LL3190-7;20150106-APTASet1_13;LA22106-1;1;Global mental functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22107-9;2;Specific mental functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22108-7;3;Seeing and related functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22109-5;4;Hearing;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22110-3;5;Vestibular functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22111-1;6;Proprioceptive and touch functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22112-9;7;Other sensory functions, pain, voice and speech functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22113-7;8;Functions of the cardiovascular system;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22114-5;9;Functions of the immunological and hematological systems;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22115-2;10;Functions of the respiratory system;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22116-0;11;Functions of the digestive system;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22117-8;12;Functions related to metabolism and endocrine system;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22118-6;13;Urinary functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22119-4;14;Genital and reproductive functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22120-2;15;Functions of the joints and bones;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22121-0;16;Muscle functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22122-8;17;Movement functions;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22123-6;18;Functions of the skin;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA22124-4;19;Functions of the hair and nails;;; +76444-9;LL3190-7;20150106-APTASet1_13;LA137-2;20;None;260413007;None (qualifier value);http://snomed.info/sct +76445-6;LL3191-5;20150106-APTASet1_14;LA22125-1;1;Structures Related to Movement;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22126-9;2;General/no specific body location;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22127-7;3;Head cervical spine;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22128-5;4;Thoracic spine;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22129-3;5;Lumbar spine;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22130-1;6;Women's health: Pelvic girdle pain;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22131-9;7;R hip;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22132-7;8;R thigh;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22133-5;9;R knee;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22134-3;10;R calf;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22135-0;11;R foot/ankle;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22136-8;12;R toes;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22137-6;13;R shoulder;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22138-4;14;R arm;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22139-2;15;R elbow;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22140-0;16;R wrist;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22141-8;17;R hand;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22142-6;18;R fingers;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22143-4;19;L hip;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22144-2;20;L thigh;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22145-9;21;L knee;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22146-7;22;L calf;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22147-5;23;L foot/ankle;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22148-3;24;L toes;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22149-1;25;L shoulder;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22150-9;26;L arm;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22151-7;27;L elbow;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22152-5;28;L wrist;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22153-3;29;L hand;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22154-1;30;L fingers;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22155-8;31;Structures Involved in Voice, Speech, Swallowing;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22156-6;32;Nose;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22157-4;33;Mouth;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22158-2;34;Tongue;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22159-0;35;Pharynx;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22160-8;36;Larynx;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22161-6;37;Other Structures;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22162-4;38;Eye and related structures;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22163-2;39;Ear and related structures;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22164-0;40;Structures of the central nervous system;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22165-7;41;Structures of the peripheral nervous system;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22166-5;42;Structures of the cardiovascular, immunological and respiratory systems;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22167-3;43;Structures related to the digestive, metabolic, and endocrine systems;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22168-1;44;Structures related to the genitourinary and reproductive system;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA22169-9;45;Skin and related structures;;; +76445-6;LL3191-5;20150106-APTASet1_14;LA137-2;46;None;260413007;None (qualifier value);http://snomed.info/sct +76446-4;LL3192-3;20150106-APTASet1_15;LA22170-7;1;Purposeful sensory experiences;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22171-5;2;Basic learning;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22172-3;3;Applying knowledge;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22173-1;4;General tasks and demands;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22174-9;5;Communication reception;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22175-6;6;Communication expression;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22176-4;7;Conversation and use of communication devices;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22177-2;8;Changing and maintaining body position;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22178-0;9;Carrying, moving and handling objects;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22179-8;10;Walking and moving around;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22180-6;11;Moving around using transportation;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22181-4;12;Self-care;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22182-2;13;Acquisition of necessities;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22183-0;14;Household tasks, caring for household objects and assisting others;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22184-8;15;General interpersonal interactions;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22185-5;16;Education;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22186-3;17;Work and employment;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22187-1;18;Economic life;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22188-9;19;Community;;; +76446-4;LL3192-3;20150106-APTASet1_15;LA22189-7;20;Social and civic life (e.g., sports);;; +76449-8;LL3256-6;APTA_functionallimitation;LA22659-9;1;"Mobility; walking and moving around";G8978;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22177-2;2;Changing and maintaining body position;;; +76449-8;LL3256-6;APTA_functionallimitation;LA22661-5;3;Carrying, handling and moving objects;G8984;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22181-4;4;Self-care;;; +76449-8;LL3256-6;APTA_functionallimitation;LA22662-3;5;Other PT/OT primary;G8990;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22663-1;6;Other PT/OT subsequent;G8993;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22664-9;7;Swallowing;G8996;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22665-6;8;Motor speech;G8999;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22666-4;9;Spoken language comprehension;G9159;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22667-2;10;Spoken language expressive;G9162;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22668-0;11;Attention;G9165;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22669-8;12;Memory;G9168;;CMS/HCPCS +76449-8;LL3256-6;APTA_functionallimitation;LA22670-6;13;Voice;G9171;;CMS/HCPCS +76450-6;LL3255-8;APTA_functionallimitationpercent;LA22652-4;1;0% impaired, limited, or restricted;CH;;CMS/HCPCS +76450-6;LL3255-8;APTA_functionallimitationpercent;LA22653-2;2;At least 1% but less than 20% impaired, limited, or restricted;CI;;CMS/HCPCS +76450-6;LL3255-8;APTA_functionallimitationpercent;LA22654-0;3;At least 20% but less than 40% impaired, limited, or restricted;CJ;;CMS/HCPCS +76450-6;LL3255-8;APTA_functionallimitationpercent;LA22655-7;4;At least 40% but less than 60% impaired, limited, or restricted;CK;;CMS/HCPCS +76450-6;LL3255-8;APTA_functionallimitationpercent;LA22656-5;5;At least 60% but less than 80% impaired, limited, or restricted;CL;;CMS/HCPCS +76450-6;LL3255-8;APTA_functionallimitationpercent;LA22657-3;6;At least 80% but less than 100% impaired, limited, or restricted;CM;;CMS/HCPCS +76450-6;LL3255-8;APTA_functionallimitationpercent;LA22658-1;7;100% impaired, limited, or restricted;CN;;CMS/HCPCS +76451-4;LL3255-8;APTA_functionallimitationpercent;LA22652-4;1;0% impaired, limited, or restricted;CH;;CMS/HCPCS +76451-4;LL3255-8;APTA_functionallimitationpercent;LA22653-2;2;At least 1% but less than 20% impaired, limited, or restricted;CI;;CMS/HCPCS +76451-4;LL3255-8;APTA_functionallimitationpercent;LA22654-0;3;At least 20% but less than 40% impaired, limited, or restricted;CJ;;CMS/HCPCS +76451-4;LL3255-8;APTA_functionallimitationpercent;LA22655-7;4;At least 40% but less than 60% impaired, limited, or restricted;CK;;CMS/HCPCS +76451-4;LL3255-8;APTA_functionallimitationpercent;LA22656-5;5;At least 60% but less than 80% impaired, limited, or restricted;CL;;CMS/HCPCS +76451-4;LL3255-8;APTA_functionallimitationpercent;LA22657-3;6;At least 80% but less than 100% impaired, limited, or restricted;CM;;CMS/HCPCS +76451-4;LL3255-8;APTA_functionallimitationpercent;LA22658-1;7;100% impaired, limited, or restricted;CN;;CMS/HCPCS +76457-1;LL3181-6;20150106-APTASet1_4;LA22044-4;1;Cardiovascular and Pulmonary Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22045-1;2;Geriatrics Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22046-9;3;Neurology Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22047-7;4;Orthopaedics Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22048-5;5;Pediatrics Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22049-3;6;Sports Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22050-1;7;Women's Health Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22051-9;8;Clinical Electrophysiology Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22052-7;9;Wound Care Management Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22053-5;10;Higher Education Leadership Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22054-3;11;Hand Therapy Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22055-0;12;Movement System Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22056-8;13;Neonatology Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22057-6;14;Orthopaedic Manual Physical Therapy Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22058-4;15;Spine Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22059-2;16;Sports Division I Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22060-0;17;Acute Care Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22061-8;18;Education Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22062-6;19;Critical Care Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22063-4;20;Oncology Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA22064-2;21;Upper Extremity Athlete Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA26308-9;22;Performing Arts Fellowship;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA26307-1;23;Faculty Residency;;; +76457-1;LL3181-6;20150106-APTASet1_4;LA137-2;24;None;260413007;None (qualifier value);http://snomed.info/sct +76460-5;LL3189-9;20150106-APTASet1_12;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +76460-5;LL3189-9;20150106-APTASet1_12;LA22103-8;2;Less than 90 minutes/week;;; +76460-5;LL3189-9;20150106-APTASet1_12;LA22104-6;3;90-150 minutes/week;;; +76460-5;LL3189-9;20150106-APTASet1_12;LA22105-3;4;Over 150 minutes/week;;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22315-8;1;Goals met;;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22316-6;2;Lack of progress;;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22317-4;3;Patient/ caregiver request (self-discharge);;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22318-2;4;Medical complication;;; +76462-1;LL3197-2;20150106-APTASet1_20;LA10939-9;5;Deceased;;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22319-0;6;Frequent no show/ cancellation (noncompliance);;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22320-8;7;Unable to pay (insurance benefits expired);;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22081-6;8;Care transfer (other facility/ level of care);;; +76462-1;LL3197-2;20150106-APTASet1_20;LA22321-6;9;Data not known;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA22097-2;1;Cardio/pulm: Angioplasty;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25527-5;2;Cardio/pulm: Aorta-iliac-femoral vascular bypass;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25528-3;3;Cardio/pulm: Aortic dissection repair;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25529-1;4;Cardio/pulm: Coronary bypass grafting;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25530-9;5;Cardio/pulm: Defibrillator;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25531-7;6;Cardio/pulm: Heart surgery (general);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25532-5;7;Cardio/pulm: Heart transplant;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25533-3;8;Cardio/pulm: Lung lobectomy (Wedge resection);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25534-1;9;Cardio/pulm: Lung transplant;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25535-8;10;Cardio/pulm: Lung volume reduction surgery;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25536-6;11;Cardio/pulm: Maze procedure;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25537-4;12;Cardio/pulm: Pacemaker placment;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25538-2;13;Cardio/pulm: Pneumonectomy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25539-0;14;Cardio/pulm: Stent placement;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25540-8;15;Cardio/pulm: Valve replace/repair-Aortic;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25541-6;16;Cardio/pulm: Valve replace/repair-Mitral;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25542-4;17;Cardio/pulm: Valve replace/repair-Pulmonary;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25543-2;18;Cardio/pulm: Valve replace/repair-Tricuspid;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25544-0;19;Cardio/pulm: Ventricular assistive device;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25545-7;20;Med: Abdominal surgery;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25546-5;21;Med: Amputation-Above knee;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25547-3;22;Med: Amputation-Below knee;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25548-1;23;Med: Amputation-Transmetatarsal;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25549-9;24;Med: Bariatric surgery;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25550-7;25;Med: Breast reconstruction;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25551-5;26;Med: Breast removal;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25552-3;27;Med: Colon resection;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25553-1;28;Med: Esophagectomy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25554-9;29;Med: Kyphoplasty;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25555-6;30;Med: Lumpectomy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25556-4;31;Med: NG tube, G-tube placement;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25557-2;32;Med: Perineoplasty;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25558-0;33;Med: Prostatectomy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25559-8;34;Med: Transverse Rectus Abdominis Myocutaneous (TRAM) Flap;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25560-6;35;Med: Urinary Incontinence-Implantation of Sacral Nerve Stimulator or Pudendal Nerve Stimulator;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25561-4;36;Med: Urinary Incontinence-Pubovaginal (Suburethral) Slings;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25562-2;37;Med: Urinary Incontinence-Retropubic (Burch) Colposuspension;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25563-0;38;Neuro: Aneurysm clipping;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25564-8;39;Neuro: Baclofen pump placement;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25565-5;40;Neuro: Brain blood clot resection/removal;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25566-3;41;Neuro: Brain tumor resection/biopsy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25567-1;42;Neuro: Craniotomy for pressure relief;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25568-9;43;Neuro: Deep brain stimulator implant;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25569-7;44;Neuro: Dorsal rhizotomy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25570-5;45;Neuro: Neuroma excisions;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25571-3;46;Neuro: Shunt placement;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25572-1;47;Neuro: Tethered cord release;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25573-9;48;Ortho-Spine: Cervical fusion;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25574-7;49;Ortho-Spine: Laminectomy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25575-4;50;Ortho-Spine: Lumbar disc removal;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25576-2;51;Ortho-Spine: Lumbar fusion;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25577-0;52;Ortho-Spine: Rod placements (eg. Harrington Rods);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25578-8;53;Ortho-Spine: Thoracic fusion;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25579-6;54;Ortho-Shd: Biceps tenodesis or release;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25580-4;55;Ortho-Shd: Cartilage restoration of the glenohumeral joint (Microfracture);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25581-2;56;Ortho-Shd: Clavicle distal excision;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25582-0;57;Ortho-Shd: Dislocation repair (recurrent);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25583-8;58;Ortho-Shd: Hemiarthroplasty;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25584-6;59;Ortho-Shd: ORIF-Humerus;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25585-3;60;Ortho-Shd: Pectoralis major repair;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25586-1;61;Ortho-Shd: Rotator cuff repair;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25587-9;62;Ortho-Shd: Stabilization (e.g. Remplissage Latarjet, Bankhart);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25588-7;63;Ortho-Shd: Subacromial decompression;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25589-5;64;Ortho-Shd: Superior labrum anterior to posterior;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25590-3;65;Ortho-Shd: Total replacement;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25591-1;66;Ortho-Shd: Total replacement (Reverse);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25592-9;67;Ortho: Tendon lengthening procedures;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25593-7;68;Ortho-Elbow/wrist/hand: Arthroscopic debridement of elbow;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25594-5;69;Ortho-Elbow/wrist/hand: Carpal tunnel surgery;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25595-2;70;Ortho-Elbow/wrist/hand: ORIF of wrist;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25596-0;71;Ortho-Elbow/wrist/hand: Osteochondritis dissecans;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25597-8;72;Ortho-Elbow/wrist/hand: UCL reconstruction of elbow;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25598-6;73;Ortho-Hip/thigh: Arthroplasty;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25599-4;74;Ortho-Hip/thigh: Arthroscopy with capsular modifications;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25600-0;75;Ortho-Hip/thigh: Arthroscopy with labral debridement/repair;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25601-8;76;Ortho-Hip/thigh: Femoroplasty;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25602-6;77;Ortho-Hip/thigh: Hip resurfacing;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25603-4;78;Ortho-Hip/thigh: Leg lengthening procedures (e.g. Ilizarov);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25604-2;79;Ortho-Hip/thigh: ORIF-Femur;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25605-9;80;Ortho-Hip/thigh: ORIF-greater trochanter;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25606-7;81;Ortho-Hip/thigh: Proximal hamstring repair;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25607-5;82;Ortho-Knee: ACL recon- bone-patellar tendon-bone Allograft;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25608-3;83;Ortho-Knee: ACL recon- bone-patellar tendon-bone Autograft;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25609-1;84;Ortho-Knee: ACL Recon-hamstrings Allograft;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25610-9;85;Ortho-Knee: ACL Recon-hamstrings Autograft;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25611-7;86;Ortho-Knee: Arthroplasty;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25612-5;87;Ortho-Knee: Athroscopy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25613-3;88;"Ortho-Knee: Cartilage repair/restoration (Autologous Chondrocyte Implantation (ACI); Microfracture; Osteochondral Allograft Transplantation; Osteochondral Autograft Transplantation (OATs))";;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25614-1;89;Ortho-Knee: Extensor tendon repair (patellar tendon repair);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25615-8;90;Ortho-Knee: MCL reconstruction;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25616-6;91;Ortho-Knee: Meniscal surgery (arthroscopic debridement, excision (menisectomy), or repair);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25617-4;92;Ortho-Knee: Meniscal transplantation Allograft;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25618-2;93;Ortho-Knee: Osteochondritis dessicans treatment;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25619-0;94;Ortho-Knee: Osteotomy (medial wedge high tibial, lateral femoral , tibial tubercle);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25620-8;95;Ortho-Knee: Patellar instability- arthroscopic lateral release;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25621-6;96;Ortho-Knee: PCL reconstruction;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25622-4;97;Ortho-Foot/ankle: Achilles tendon repair;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25623-2;98;Ortho-Foot/ankle: Achillies tendon refelease;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25624-0;99;Ortho-Foot/ankle: Bunion procedures;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25516-8;100;Ortho-Foot/ankle: Cheilectomies;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25515-0;101;Ortho-Foot/ankle: ORIF– bimalleolar/trimalleolar;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25517-6;102;Ortho-Foot/ankle: Plantar fascia release;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25518-4;103;Ortho-Foot/ankle: Posterior tib tendon repair;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25519-2;104;Ortho-Foot/ankle: Syndesmotic repairs;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25520-0;105;Women's Health: C-section;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25521-8;106;Women's Health: Episiotomy;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25522-6;107;Women's Health: Hysterectomy (TVH or TAH);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25523-4;108;"Women's Health: Pelvic prolapse repair: (Abdominal sacral colpopexy: Colpocleisis; Enterocele repair; Iliococcygeal vaginal suspension; Sacrospinous ligament suspension; sling; Uterosacral ligament suspension)";;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA25524-2;109;Women's Health: Urinary Incontinence-Tension-free Vaginal Tape (TVT);;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA46-8;110;Other;;; +76467-0;LL3882-9;[APTA] Surgery relevant to physical therapy;LA137-2;111;None;260413007;None (qualifier value);http://snomed.info/sct +76492-8;LL3252-5;Preliminary pos|Neg;LA22648-2;1;Preliminary positive;;; +76492-8;LL3252-5;Preliminary pos|Neg;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA15832-1;1;Very hard;;; +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA14745-6;2;Hard;;; +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA22683-9;3;Somewhat hard;;; +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA22682-1;4;Not very hard;;; +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA15832-1;1;Very hard;;; +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA14745-6;2;Hard;;; +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA22683-9;3;Somewhat hard;;; +76513-1;LL3266-5;Very hard/Hard/Somewhat Hard/Not very hard;LA22682-1;4;Not very hard;;; +76513-1;LL5867-8;Very hard|Somewhat hard|Not hard;LA15832-1;1;Very hard;;; +76513-1;LL5867-8;Very hard|Somewhat hard|Not hard;LA22683-9;2;Somewhat hard;;; +76513-1;LL5867-8;Very hard|Somewhat hard|Not hard;LA31980-8;3;Not hard at all;;; +76542-0;LL3267-3;Not at all/Little/Some extent/Rather much/Very;LA6568-5;1;Not at all;;; +76542-0;LL3267-3;Not at all/Little/Some extent/Rather much/Very;LA22687-0;2;Only a little;;; +76542-0;LL3267-3;Not at all/Little/Some extent/Rather much/Very;LA22686-2;3;To some extent;;; +76542-0;LL3267-3;Not at all/Little/Some extent/Rather much/Very;LA22685-4;4;Rather much;;; +76542-0;LL3267-3;Not at all/Little/Some extent/Rather much/Very;LA13914-9;5;Very much;;; +76572-7;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76572-7;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76572-7;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76573-5;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76573-5;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76573-5;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76574-3;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76574-3;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76574-3;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76575-0;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76575-0;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76575-0;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76576-8;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76576-8;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76576-8;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76577-6;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76577-6;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76577-6;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76578-4;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76578-4;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76578-4;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76579-2;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76579-2;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76579-2;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76580-0;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76580-0;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76580-0;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76581-8;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76581-8;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76581-8;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76582-6;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76582-6;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76582-6;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76583-4;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76583-4;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76583-4;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76584-2;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21375-3;0;Low (< 10^5 bacteria);;; +76584-2;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21374-6;1;Medium (10^5-10^7 bacteria);;; +76584-2;LL2994-3;Low (< 10^5)|Medium (10^5-10^7)|High (> 10^7);LA21373-8;2;High (> 10^7 bacteria);;; +76628-7;LL3248-3;Norovirus genogroup I & II (Nom);LA22675-5;1;Target genes not detected;;; +76628-7;LL3248-3;Norovirus genogroup I & II (Nom);LA22646-6;2;Norovirus genogroup I detected;;; +76628-7;LL3248-3;Norovirus genogroup I & II (Nom);LA22647-4;3;Norovirus genogroup II detected;;; +76628-7;LL3248-3;Norovirus genogroup I & II (Nom);LA22674-8;4;Norovirus genogroups I and II detected;;; +76628-7;LL3248-3;Norovirus genogroup I & II (Nom);LA9663-1;5;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +76628-7;LL3248-3;Norovirus genogroup I & II (Nom);LA13548-5;6;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +90449-0;LL3248-3;Norovirus genogroup I & II (Nom);LA22675-5;1;Target genes not detected;;; +90449-0;LL3248-3;Norovirus genogroup I & II (Nom);LA22646-6;2;Norovirus genogroup I detected;;; +90449-0;LL3248-3;Norovirus genogroup I & II (Nom);LA22647-4;3;Norovirus genogroup II detected;;; +90449-0;LL3248-3;Norovirus genogroup I & II (Nom);LA22674-8;4;Norovirus genogroups I and II detected;;; +90449-0;LL3248-3;Norovirus genogroup I & II (Nom);LA9663-1;5;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +90449-0;LL3248-3;Norovirus genogroup I & II (Nom);LA13548-5;6;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +76645-1;LL3254-1;Cardiac stress test types;LA22649-0;1;Resting (baseline);;; +76645-1;LL3254-1;Cardiac stress test types;LA22651-6;2;Exercise;;; +76645-1;LL3254-1;Cardiac stress test types;LA22650-8;3;Medication;416608005;Drug therapy (procedure);http://snomed.info/sct +76645-1;LL3254-1;Cardiac stress test types;LA46-8;4;Other;;; +76661-8;LL3275-6;NMMDS_Gender;LA3-6;1;Female;;; +76661-8;LL3275-6;NMMDS_Gender;LA2-8;2;Male;;; +76661-8;LL3275-6;NMMDS_Gender;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +76663-4;LL3276-4;NMMDS_Race/Ethnicity;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +76663-4;LL3276-4;NMMDS_Race/Ethnicity;LA6156-9;2;Asian;2028-9;Asian;https://www.cdc.gov/phin +76663-4;LL3276-4;NMMDS_Race/Ethnicity;LA14042-8;3;Black/African American;2054-5;Black or African American;https://www.cdc.gov/phin +76663-4;LL3276-4;NMMDS_Race/Ethnicity;LA10611-4;4;Native Hawaiian or Other Pacific Islander;2076-8;Native Hawaiian or Other Pacific Islander;https://www.cdc.gov/phin +76663-4;LL3276-4;NMMDS_Race/Ethnicity;LA23729-9;5;White/Caucasian;2106-3;White;https://www.cdc.gov/phin +76663-4;LL3276-4;NMMDS_Race/Ethnicity;LA6214-6;6;Hispanic or Latino;2135-2;Hispanic or Latino;https://www.cdc.gov/phin +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21891-9;1;Consistent with two sex chromosomes (XY - Male);;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21892-7;2;Consistent with two sex chromosomes (XX -Female);;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21893-5;3;Consistent with three sex chromosomes (XXX);;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21894-3;4;Consistent with three sex chromosomes (XXY);;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21895-0;5;Consistent with three sex chromosomes (XYY);;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21896-8;6;Sex chromosome determination inconclusive;;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21897-6;7;Consistent with the absence of a Y chromosome;;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21898-4;8;Consistent with the presence of a Y chromosome;;; +76664-2;LL3220-2;Prenatal_XYaneuploidy_interp;LA21899-2;9;Consistent with one sex chromosome (X0 or Turner Syndrome);;; +76679-0;LL2893-7;Colorless/bloody;LA19059-7;0;Colorless;;; +76679-0;LL2893-7;Colorless/bloody;LA19736-0;1;Bloody;;; +76680-8;LL2893-7;Colorless/bloody;LA19059-7;0;Colorless;;; +76680-8;LL2893-7;Colorless/bloody;LA19736-0;1;Bloody;;; +76681-6;LL2893-7;Colorless/bloody;LA19059-7;0;Colorless;;; +76681-6;LL2893-7;Colorless/bloody;LA19736-0;1;Bloody;;; +76682-4;LL2893-7;Colorless/bloody;LA19059-7;0;Colorless;;; +76682-4;LL2893-7;Colorless/bloody;LA19736-0;1;Bloody;;; +76687-3;LL3070-1;Mycobacterium spp.;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76687-3;LL3070-1;Mycobacterium spp.;LA21696-2;1;Mycobacterium lentiflavum;;; +76687-3;LL3070-1;Mycobacterium spp.;LA20996-7;2;Mycobacterium tuberculosis;;; +76689-9;LL3324-2;Sex assigned at birth;LA2-8;1;Male;;; +76689-9;LL3324-2;Sex assigned at birth;LA3-6;2;Female;;; +76689-9;LL3324-2;Sex assigned at birth;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +76690-7;LL3323-4;Sexual orientation;LA22877-7;1;Bisexual;42035005;Bisexual (finding);http://snomed.info/sct +76690-7;LL3323-4;Sexual orientation;LA22876-9;2;Heterosexual;20430005;Heterosexual (finding);http://snomed.info/sct +76690-7;LL3323-4;Sexual orientation;LA22875-1;3;Homosexual;38628009;Homosexual (finding);http://snomed.info/sct +76690-7;LL3323-4;Sexual orientation;LA46-8;4;Other;;; +76690-7;LL3323-4;Sexual orientation;LA20384-6;5;Asked but unknown;;; +76690-7;LL3323-4;Sexual orientation;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +76691-5;LL3322-6;Gender identity;LA22878-5;1;Identifies as male;446151000124109;Identifies as male gender (finding);http://snomed.info/sct +76691-5;LL3322-6;Gender identity;LA22879-3;2;Identifies as female;446141000124107;Identifies as female gender (finding);http://snomed.info/sct +76691-5;LL3322-6;Gender identity;LA22880-1;3;Female-to-male transsexual;407377005;Female-to-male transsexual (finding);http://snomed.info/sct +76691-5;LL3322-6;Gender identity;LA22881-9;4;Male-to-female transsexual;407376001;Male-to-female transsexual (finding);http://snomed.info/sct +76691-5;LL3322-6;Gender identity;LA22882-7;5;Identifies as non-conforming;446131000124102;Identifies as non-conforming gender (finding);http://snomed.info/sct +76691-5;LL3322-6;Gender identity;LA46-8;6;Other;;; +76691-5;LL3322-6;Gender identity;LA20384-6;7;Asked but unknown;;; +76693-1;LL2890-3;BPU Culture;LA21123-7;0;No growth;;; +76693-1;LL2890-3;BPU Culture;LA21130-2;1;Coagulase-negative staphylococci;;; +76693-1;LL2890-3;BPU Culture;LA21131-0;2;Streptococcus viridans;;; +76693-1;LL2890-3;BPU Culture;LA19246-0;3;Staphylococcus aureus;;; +76698-0;LL5044-4;Aetna | Anthem | Humana | United;LA28804-5;1;Aetna;;; +76698-0;LL5044-4;Aetna | Anthem | Humana | United;LA28805-2;2;Anthem;;; +76698-0;LL5044-4;Aetna | Anthem | Humana | United;LA28806-0;3;Humana;;; +76698-0;LL5044-4;Aetna | Anthem | Humana | United;LA28807-8;4;United Healthcare;;; +76698-0;LL5327-3;Assigning authority examples;LA6218-7;1;Hospital;;; +76698-0;LL5327-3;Assigning authority examples;LA4198-3;2;Dept of Motor Vehicles;;; +76698-0;LL5327-3;Assigning authority examples;LA30117-8;3;Social Security Administration;;; +76699-8;LL3273-1;Filaria;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +76699-8;LL3273-1;Filaria;LA21608-7;1;Mansonella perstans;;; +76699-8;LL3273-1;Filaria;LA22702-7;2;Mansonella streptocerca;;; +76699-8;LL3273-1;Filaria;LA22703-5;3;Onchocerca volvulus;;; +76699-8;LL3273-1;Filaria;LA22704-3;4;Loa loa;;; +76713-7;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76713-7;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76713-7;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76713-7;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76713-7;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76714-5;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76714-5;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76714-5;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76714-5;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76714-5;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76715-2;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76715-2;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76715-2;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76715-2;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76715-2;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76716-0;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76716-0;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76716-0;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76716-0;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76716-0;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76717-8;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76717-8;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76717-8;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76717-8;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76717-8;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76718-6;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76718-6;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76718-6;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76718-6;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76718-6;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76719-4;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76719-4;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76719-4;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76719-4;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76719-4;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76720-2;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76720-2;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76720-2;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76720-2;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76720-2;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76721-0;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76721-0;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76721-0;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76721-0;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76721-0;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76722-8;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76722-8;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76722-8;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76722-8;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76722-8;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76723-6;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76723-6;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76723-6;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76723-6;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76723-6;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76724-4;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76724-4;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76724-4;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76724-4;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76724-4;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76725-1;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76725-1;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76725-1;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76725-1;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76725-1;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76726-9;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76726-9;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76726-9;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76726-9;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76726-9;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76727-7;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76727-7;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76727-7;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76727-7;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76727-7;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76728-5;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76728-5;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76728-5;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76728-5;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76728-5;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76729-3;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76729-3;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76729-3;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76729-3;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76729-3;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76730-1;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76730-1;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76730-1;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76730-1;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76730-1;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76745-9;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76745-9;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76745-9;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76745-9;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76745-9;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76746-7;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76746-7;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76746-7;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76746-7;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76746-7;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76747-5;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76747-5;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76747-5;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76747-5;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76747-5;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76748-3;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76748-3;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76748-3;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76748-3;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76748-3;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76749-1;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76749-1;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76749-1;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76749-1;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76749-1;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76749-1;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76749-1;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76749-1;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76749-1;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76749-1;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76750-9;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76750-9;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76750-9;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76750-9;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76750-9;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76751-7;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76751-7;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76751-7;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76751-7;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76751-7;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76752-5;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76752-5;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76752-5;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76752-5;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76752-5;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76753-3;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76753-3;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76753-3;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76753-3;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76753-3;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76754-1;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76754-1;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76754-1;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76754-1;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76754-1;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76755-8;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76755-8;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76755-8;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76755-8;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76755-8;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76756-6;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76756-6;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76756-6;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76756-6;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76756-6;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76757-4;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76757-4;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76757-4;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76757-4;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76757-4;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76758-2;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76758-2;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76758-2;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76758-2;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76758-2;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76759-0;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76759-0;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76759-0;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76759-0;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76759-0;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76760-8;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76760-8;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76760-8;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76760-8;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76760-8;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76761-6;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76761-6;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76761-6;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76761-6;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76761-6;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76762-4;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76762-4;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76762-4;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76762-4;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76762-4;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76763-2;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76763-2;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76763-2;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76763-2;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76763-2;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76764-0;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +76764-0;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +76764-0;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +76764-0;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +76764-0;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +85032-1;LL3327-5;PROMIS_22;LA6270-8;1;Never;;; +85032-1;LL3327-5;PROMIS_22;LA10066-1;2;Rarely;;; +85032-1;LL3327-5;PROMIS_22;LA10082-8;3;Sometimes;;; +85032-1;LL3327-5;PROMIS_22;LA14747-2;4;Usually;;; +85032-1;LL3327-5;PROMIS_22;LA9933-8;5;Always;;; +76900-0;LL3570-0;PROMIS_24;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +76900-0;LL3570-0;PROMIS_24;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +76901-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76901-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76901-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76901-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76901-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76902-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76902-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76902-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76902-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76902-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76906-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76906-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76906-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76906-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76906-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76907-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76907-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76907-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76907-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76907-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76908-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76908-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76908-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76908-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76908-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76910-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76910-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76910-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76910-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76910-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76912-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76912-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76912-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76912-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76912-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76913-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76913-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76913-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76913-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76913-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76914-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76914-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76914-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76914-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76914-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76915-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76915-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76915-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76915-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76915-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76916-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76916-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76916-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76916-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76916-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76917-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76917-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76917-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76917-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76917-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76918-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76918-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76918-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76918-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76918-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76919-0;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76919-0;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76919-0;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76919-0;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76919-0;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76920-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76920-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76920-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76920-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76920-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76921-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76921-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76921-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76921-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76921-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76922-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76922-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76922-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76922-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76922-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76923-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76923-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76923-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76923-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76923-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76924-0;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76924-0;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76924-0;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76924-0;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76924-0;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76925-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76925-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76925-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76925-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76925-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76926-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76926-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76926-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76926-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76926-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76927-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76927-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76927-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76927-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76927-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76928-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76928-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76928-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76928-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76928-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76929-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76929-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76929-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76929-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76929-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76930-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76930-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76930-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76930-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76930-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76931-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76931-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76931-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76931-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76931-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76932-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76932-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76932-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76932-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76932-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76933-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76933-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76933-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76933-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76933-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76934-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76934-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76934-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76934-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76934-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76935-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76935-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76935-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76935-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76935-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76936-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76936-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76936-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76936-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76936-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76937-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76937-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76937-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76937-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76937-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76952-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76952-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76952-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76952-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76952-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76953-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76953-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76953-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76953-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76953-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76954-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76954-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76954-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76954-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76954-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76955-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76955-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76955-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76955-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76955-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76956-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76956-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76956-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76956-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76956-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76957-0;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76957-0;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76957-0;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76957-0;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76957-0;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76958-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76958-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76958-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76958-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76958-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76959-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76959-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76959-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76959-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76959-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76960-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76960-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76960-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76960-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76960-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76961-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76961-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76961-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76961-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76961-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76962-0;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76962-0;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76962-0;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76962-0;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76962-0;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76963-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76963-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76963-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76963-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76963-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76964-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76964-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76964-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76964-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76964-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76965-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76965-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76965-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76965-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76965-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76966-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76966-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76966-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76966-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76966-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76967-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76967-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76967-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76967-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76967-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76968-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76968-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76968-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76968-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76968-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76969-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76969-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76969-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76969-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76969-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76970-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76970-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76970-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76970-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76970-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76971-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76971-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76971-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76971-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76971-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76972-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76972-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76972-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76972-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76972-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76973-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76973-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76973-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76973-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76973-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76974-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76974-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76974-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76974-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76974-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76975-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76975-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76975-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76975-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76975-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76976-0;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76976-0;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76976-0;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76976-0;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76976-0;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76977-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76977-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76977-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76977-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76977-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76978-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76978-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76978-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76978-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76978-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76979-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76979-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76979-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76979-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76979-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76980-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76980-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76980-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76980-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76980-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76981-0;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76981-0;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76981-0;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76981-0;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76981-0;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76982-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76982-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76982-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76982-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76982-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76983-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76983-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76983-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76983-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76983-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76984-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76984-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76984-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76984-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76984-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76985-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76985-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76985-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76985-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76985-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76986-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76986-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76986-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76986-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76986-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76987-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76987-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76987-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76987-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76987-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76988-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76988-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76988-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76988-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76988-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76989-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76989-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76989-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76989-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76989-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76990-1;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76990-1;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76990-1;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76990-1;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76990-1;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76991-9;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76991-9;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76991-9;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76991-9;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76991-9;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76992-7;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76992-7;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76992-7;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76992-7;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76992-7;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76993-5;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76993-5;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76993-5;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76993-5;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76993-5;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76994-3;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76994-3;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76994-3;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76994-3;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76994-3;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76995-0;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76995-0;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76995-0;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76995-0;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76995-0;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76996-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76996-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76996-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76996-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76996-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76997-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76997-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76997-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76997-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76997-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76998-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76998-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76998-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76998-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76998-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76999-2;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +76999-2;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +76999-2;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +76999-2;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +76999-2;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +77000-8;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +77000-8;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +77000-8;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +77000-8;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +77000-8;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +77001-6;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +77001-6;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +77001-6;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +77001-6;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +77001-6;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +77002-4;LL3546-0;PROMIS_23;LA6270-8;1;Never;;; +77002-4;LL3546-0;PROMIS_23;LA10066-1;2;Rarely;;; +77002-4;LL3546-0;PROMIS_23;LA10082-8;3;Sometimes;;; +77002-4;LL3546-0;PROMIS_23;LA10044-8;4;Often;;; +77002-4;LL3546-0;PROMIS_23;LA13865-3;5;Almost always;;; +76903-4;LL3573-4;PROMIS_26;LA6270-8;1;Never;;; +76903-4;LL3573-4;PROMIS_26;LA23695-2;2;1-2 times;;; +76903-4;LL3573-4;PROMIS_26;LA23698-6;3;3-5 times;;; +76903-4;LL3573-4;PROMIS_26;LA23702-6;4;6-10 times;;; +76903-4;LL3573-4;PROMIS_26;LA23703-4;5;More than 10 times;;; +76904-2;LL3572-6;PROMIS_25;LA23696-0;1;1-2 drinks;;; +76904-2;LL3572-6;PROMIS_25;LA23697-8;2;3-4 drinks;;; +76904-2;LL3572-6;PROMIS_25;LA23699-4;3;5-6 drinks;;; +76904-2;LL3572-6;PROMIS_25;LA23700-0;4;7-10 drinks;;; +76904-2;LL3572-6;PROMIS_25;LA23701-8;5;More than 10 drinks;;; +76909-1;LL3572-6;PROMIS_25;LA23696-0;1;1-2 drinks;;; +76909-1;LL3572-6;PROMIS_25;LA23697-8;2;3-4 drinks;;; +76909-1;LL3572-6;PROMIS_25;LA23699-4;3;5-6 drinks;;; +76909-1;LL3572-6;PROMIS_25;LA23700-0;4;7-10 drinks;;; +76909-1;LL3572-6;PROMIS_25;LA23701-8;5;More than 10 drinks;;; +76905-9;LL3575-9;PROMIS_28;LA6270-8;1;Never;;; +76905-9;LL3575-9;PROMIS_28;LA14677-1;2;1 time;;; +76905-9;LL3575-9;PROMIS_28;LA23711-7;3;2 times;;; +76905-9;LL3575-9;PROMIS_28;LA23712-5;4;3 times;;; +76905-9;LL3575-9;PROMIS_28;LA23713-3;5;4 or more times;;; +76911-7;LL3574-2;PROMIS_27;LA23704-2;1;1-7 drinks;;; +76911-7;LL3574-2;PROMIS_27;LA23705-9;2;8-14 drinks;;; +76911-7;LL3574-2;PROMIS_27;LA23706-7;3;15-21 drinks;;; +76911-7;LL3574-2;PROMIS_27;LA23707-5;4;22-28 drinks;;; +76911-7;LL3574-2;PROMIS_27;LA23708-3;5;More than 28 drinks;;; +77011-5;LL3282-2;Trisomy screening results;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77011-5;LL3282-2;Trisomy screening results;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77011-5;LL3282-2;Trisomy screening results;LA22730-8;3;Not reportable;;; +77011-5;LL3282-2;Trisomy screening results;LA15842-0;4;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +77012-3;LL3282-2;Trisomy screening results;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77012-3;LL3282-2;Trisomy screening results;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77012-3;LL3282-2;Trisomy screening results;LA22730-8;3;Not reportable;;; +77012-3;LL3282-2;Trisomy screening results;LA15842-0;4;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +77013-1;LL3282-2;Trisomy screening results;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77013-1;LL3282-2;Trisomy screening results;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77013-1;LL3282-2;Trisomy screening results;LA22730-8;3;Not reportable;;; +77013-1;LL3282-2;Trisomy screening results;LA15842-0;4;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +77014-9;LL3286-3;Trisomy risk;LA19542-2;1;Low risk;;; +77014-9;LL3286-3;Trisomy risk;LA19541-4;2;High risk;;; +77014-9;LL3286-3;Trisomy risk;LA22730-8;3;Not reportable;;; +77014-9;LL3286-3;Trisomy risk;LA15842-0;4;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +77015-6;LL3286-3;Trisomy risk;LA19542-2;1;Low risk;;; +77015-6;LL3286-3;Trisomy risk;LA19541-4;2;High risk;;; +77015-6;LL3286-3;Trisomy risk;LA22730-8;3;Not reportable;;; +77015-6;LL3286-3;Trisomy risk;LA15842-0;4;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +77017-2;LL3289-7;Gene mutation impression;LA22756-3;1;Negative for the mutations and variants analyzed;;; +77017-2;LL3289-7;Gene mutation impression;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77017-2;LL3289-7;Gene mutation impression;LA15842-0;3;Quantity insufficient;281268007;Insufficient sample (finding);http://snomed.info/sct +77020-6;LL3576-7;Fetal sex consistent with;LA23714-1;1;Consistent with a male fetus;;; +77020-6;LL3576-7;Fetal sex consistent with;LA23715-8;2;Consistent with a female fetus;;; +77152-7;LL3317-6;NEMSIS - Arrest outcome;LA22792-8;1;Expired in ED;;; +77152-7;LL3317-6;NEMSIS - Arrest outcome;LA22793-6;2;Expired in the Field;;; +77152-7;LL3317-6;NEMSIS - Arrest outcome;LA22794-4;3;Ongoing Resuscitation in ED;;; +77152-7;LL3317-6;NEMSIS - Arrest outcome;LA22795-1;4;ROSC in the Field;;; +77152-7;LL3317-6;NEMSIS - Arrest outcome;LA22796-9;5;ROSC in the ED;;; +77152-7;LL3317-6;NEMSIS - Arrest outcome;LA22797-7;6;Ongoing Resuscitation by Other EMS;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22798-5;1;Intersection Navigation-Against Normal Light Patterns;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22799-3;2;Intersection Navigation-With Automated Light Changing Technology;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22800-9;3;Intersection Navigation-With Normal Light Patterns;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22801-7;4;Speed-Enhanced per Local Policy;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22802-5;5;Speed-Normal Traffic;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22803-3;6;Lights and Sirens;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22804-1;7;Lights and No Sirens;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22805-8;8;No Lights or Sirens;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22806-6;9;Initial No Lights or Sirens, Upgraded to Lights and Sirens;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22807-4;10;Initial Lights and Sirens, Downgraded to No Lights or Sirens;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22866-0;11;Scheduled;;; +77153-5;LL3321-8;NEMSIS - Transportation qualifier;LA22869-4;12;Unscheduled;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22808-2;1;Hospital-Burn;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22809-0;2;Hospital-Cath Lab;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22810-8;3;Hospital-CCU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22811-6;4;Hospital-Endoscopy;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22812-4;5;Hospital-Hospice;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22813-2;6;Hospital-Hyperbaric Oxygen Treatment;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22814-0;7;Hospital-ICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22815-7;8;Hospital-Labor & Delivery;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22816-5;9;Hospital-Med/Surg;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22817-3;10;Hospital-Mental Health;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22818-1;11;Hospital-MICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22819-9;12;Hospital-NICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22820-7;13;Hospital-Nursery;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22821-5;14;Hospital-Peds (General);;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22822-3;15;Hospital-Peds ICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22823-1;16;Hospital-OR;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22824-9;17;Hospital-Orthopedic;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22825-6;18;Hospital-Other;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22826-4;19;Hospital-Out-Patient Bed;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22827-2;20;Hospital-Radiology Services - MRI;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22828-0;21;Hospital-Radiology Services - CT/PET;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22829-8;22;Hospital-Radiology Services - X-Ray;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22830-6;23;Hospital-Radiation;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22831-4;24;Hospital-Rehab;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22832-2;25;Hospital-SICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA24394-1;26;Hospital-Oncology;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA24395-8;27;Hospital-Outpatient Surgery;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22808-2;1;Hospital-Burn;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22809-0;2;Hospital-Cath Lab;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22810-8;3;Hospital-CCU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22811-6;4;Hospital-Endoscopy;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22812-4;5;Hospital-Hospice;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22813-2;6;Hospital-Hyperbaric Oxygen Treatment;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22814-0;7;Hospital-ICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22815-7;8;Hospital-Labor & Delivery;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22816-5;9;Hospital-Med/Surg;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22817-3;10;Hospital-Mental Health;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22818-1;11;Hospital-MICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22819-9;12;Hospital-NICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22820-7;13;Hospital-Nursery;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22821-5;14;Hospital-Peds (General);;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22822-3;15;Hospital-Peds ICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22823-1;16;Hospital-OR;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22824-9;17;Hospital-Orthopedic;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22825-6;18;Hospital-Other;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22826-4;19;Hospital-Out-Patient Bed;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22827-2;20;Hospital-Radiology Services - MRI;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22828-0;21;Hospital-Radiology Services - CT/PET;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22829-8;22;Hospital-Radiology Services - X-Ray;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22830-6;23;Hospital-Radiation;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22831-4;24;Hospital-Rehab;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA22832-2;25;Hospital-SICU;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA24394-1;26;Hospital-Oncology;;; +77154-3;LL3319-2;NEMSIS - Hospital Inpatient Destination;LA24395-8;27;Hospital-Outpatient Surgery;;; +77154-3;LL5036-0;Inpatient destination;LA28363-2;1;Trauma center;;; +77154-3;LL5036-0;Inpatient destination;LA15287-8;2;Outpatient;;; +77154-3;LL5036-0;Inpatient destination;LA7222-8;3;Operating room;;; +77154-3;LL5036-0;Inpatient destination;LA10268-3;4;Emergency Department;;; +77154-3;LL5036-0;Inpatient destination;LA20596-5;5;Intensive care unit (ICU);;; +77154-3;LL5036-0;Inpatient destination;LA26181-0;6;Hospital ward;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22833-0;1;Behavioral Health;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22834-8;2;Burn Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22835-5;3;Critical Access Hospital;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22836-3;4;Hospital (General);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22837-1;5;Neonatal Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22838-9;6;Pediatric Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22842-1;7;Rehab Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22843-9;8;Trauma Center Level 1;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22844-7;9;Trauma Center Level 2;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22845-4;10;Trauma Center Level 3;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22846-2;11;Trauma Center Level 4;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22847-0;12;Trauma Center Level 5;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22848-8;13;Cardiac-STEMI/PCI Capable;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22849-6;14;Cardiac-STEMI/PCI Capable (24/7);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22850-4;15;Cardiac-STEMI/Non-PCI Capable;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32931-0;16;Stroke-acute stroke ready hospital (ASRH);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32934-4;17;Stroke-primary stroke center (PSC);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32935-1;18;Stroke-thrombectomy-capable stroke center (TSC);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32936-9;19;Stroke-comprehensive stroke center (CSC);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32933-6;20;Cancer center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA20786-2;21;Labor and delivery;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22833-0;1;Behavioral Health;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22834-8;2;Burn Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22835-5;3;Critical Access Hospital;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22836-3;4;Hospital (General);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22837-1;5;Neonatal Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22838-9;6;Pediatric Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22842-1;7;Rehab Center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22843-9;8;Trauma Center Level 1;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22844-7;9;Trauma Center Level 2;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22845-4;10;Trauma Center Level 3;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22846-2;11;Trauma Center Level 4;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22847-0;12;Trauma Center Level 5;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22848-8;13;Cardiac-STEMI/PCI Capable;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22849-6;14;Cardiac-STEMI/PCI Capable (24/7);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA22850-4;15;Cardiac-STEMI/Non-PCI Capable;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32931-0;16;Stroke-acute stroke ready hospital (ASRH);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32934-4;17;Stroke-primary stroke center (PSC);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32935-1;18;Stroke-thrombectomy-capable stroke center (TSC);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32936-9;19;Stroke-comprehensive stroke center (CSC);;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA32933-6;20;Cancer center;;; +77155-0;LL3318-4;NEMSIS - Hospital Designation;LA20786-2;21;Labor and delivery;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22851-2;2;BLS-First Responder/EMR;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22852-0;3;BLS-Basic /EMT;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22853-8;4;BLS-AEMT;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22854-6;5;BLS-Intermediate;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22855-3;6;ALS-AEMT;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22856-1;7;ALS-Intermediate;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22857-9;8;ALS-Paramedic;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22858-7;9;ALS-Community Paramedicine;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22859-5;10;ALS-Nurse;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22860-3;11;ALS-Physician;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22861-1;12;Specialty Critical Care;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22862-9;13;BLS-Community Paramedicine;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22851-2;2;BLS-First Responder/EMR;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22852-0;3;BLS-Basic /EMT;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22853-8;4;BLS-AEMT;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22854-6;5;BLS-Intermediate;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22855-3;6;ALS-AEMT;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22856-1;7;ALS-Intermediate;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22857-9;8;ALS-Paramedic;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22858-7;9;ALS-Community Paramedicine;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22859-5;10;ALS-Nurse;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22860-3;11;ALS-Physician;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22861-1;12;Specialty Critical Care;;; +77156-8;LL3320-0;NEMSIS - Level of Care of This Unit;LA22862-9;13;BLS-Community Paramedicine;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22798-5;1;Intersection Navigation-Against Normal Light Patterns;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22799-3;2;Intersection Navigation-With Automated Light Changing Technology;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22800-9;3;Intersection Navigation-With Normal Light Patterns;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22866-0;4;Scheduled;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22801-7;5;Speed-Enhanced per Local Policy;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22802-5;6;Speed-Normal Traffic;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22869-4;7;Unscheduled;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22803-3;8;Lights and Sirens;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22804-1;9;Lights and No Sirens;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22805-8;10;No Lights or Sirens;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22806-6;11;Initial No Lights or Sirens, Upgraded to Lights and Sirens;;; +77157-6;LL3316-8;NEMSIS - Additional Response Mode Descriptors;LA22807-4;12;Initial Lights and Sirens, Downgraded to No Lights or Sirens;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA7424-0;1;Death;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA23718-2;2;Vegetative state;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA23719-0;3;Lower severe disability;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA23720-8;4;Upper severe disability;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA23721-6;5;Lower moderate disability;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA23722-4;6;Upper moderate disability;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA23723-2;7;Lower good recovery;;; +77160-0;LL3579-1;Glasgow Outcome Scale Extended;LA23724-0;8;Upper good recovery;;; +77171-7;LL3292-1;KIT Exon 11 mutations;LA22771-2;1;p.L589P;;; +77171-7;LL3292-1;KIT Exon 11 mutations;LA22769-6;2;p.I563_D572del;;; +77171-7;LL3292-1;KIT Exon 11 mutations;LA22770-4;3;p.I563_L576del;;; +77171-7;LL3292-1;KIT Exon 11 mutations;LA22756-3;4;Negative for the mutations and variants analyzed;;; +77172-5;LL3291-3;KIT Exon 9 mutations;LA22764-7;1;p.A502_Y503dup;;; +77172-5;LL3291-3;KIT Exon 9 mutations;LA22765-4;2;P.K499K;;; +77172-5;LL3291-3;KIT Exon 9 mutations;LA22766-2;3;p.E490G;;; +77172-5;LL3291-3;KIT Exon 9 mutations;LA22767-0;4;p.K499Q;;; +77172-5;LL3291-3;KIT Exon 9 mutations;LA22768-8;5;p.F508_K509insFAF;;; +77172-5;LL3291-3;KIT Exon 9 mutations;LA22756-3;6;Negative for the mutations and variants analyzed;;; +77174-1;LL3290-5;CALR gene mutations;LA22757-1;1;p.L367fs*46;;; +77174-1;LL3290-5;CALR gene mutations;LA22760-5;2;p.K385fs*47;;; +77174-1;LL3290-5;CALR gene mutations;LA22759-7;3;p.K368fs*51;;; +77174-1;LL3290-5;CALR gene mutations;LA22758-9;4;p.E364fs*46;;; +77174-1;LL3290-5;CALR gene mutations;LA22756-3;5;Negative for the mutations and variants analyzed;;; +77193-1;LL3272-3;Uterine culture;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77193-1;LL3272-3;Uterine culture;LA22701-9;1;Prevotella bivia;;; +77200-4;LL3278-0;SI gene mutations;LA22719-1;0;c.1730T>G;;; +77200-4;LL3278-0;SI gene mutations;LA22722-5;1;c.1859T>C;;; +77200-4;LL3278-0;SI gene mutations;LA22720-9;2;c.3218G>A;;; +77200-4;LL3278-0;SI gene mutations;LA22721-7;3;c.3686G>A;;; +77200-4;LL3278-0;SI gene mutations;LA22718-3;4;c.5234T>G;;; +77218-6;LL4543-6;KCCQ - HF Satisfied;LA27750-1;1;Not at all satisfied;;; +77218-6;LL4543-6;KCCQ - HF Satisfied;LA24976-5;2;Mostly dissatisfied;;; +77218-6;LL4543-6;KCCQ - HF Satisfied;LA27752-7;3;Somewhat satisfied;;; +77218-6;LL4543-6;KCCQ - HF Satisfied;LA24974-0;4;Mostly satisfied;;; +77218-6;LL4543-6;KCCQ - HF Satisfied;LA27754-3;5;Completely satisfied;;; +86489-2;LL4543-6;KCCQ - HF Satisfied;LA27750-1;1;Not at all satisfied;;; +86489-2;LL4543-6;KCCQ - HF Satisfied;LA24976-5;2;Mostly dissatisfied;;; +86489-2;LL4543-6;KCCQ - HF Satisfied;LA27752-7;3;Somewhat satisfied;;; +86489-2;LL4543-6;KCCQ - HF Satisfied;LA24974-0;4;Mostly satisfied;;; +86489-2;LL4543-6;KCCQ - HF Satisfied;LA27754-3;5;Completely satisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA14642-5;1;Very satisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA27752-7;2;Somewhat satisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA31733-1;3;Neither satisfied nor dissatisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA29849-9;4;Somewhat dissatisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA14638-3;5;Very dissatisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA14642-5;1;Very satisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA27752-7;2;Somewhat satisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA31733-1;3;Neither satisfied nor dissatisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA29849-9;4;Somewhat dissatisfied;;; +77218-6;LL5815-7;Very satisfied/Very dissatisfied;LA14638-3;5;Very dissatisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA14642-5;1;Very satisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA27752-7;2;Somewhat satisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA31733-1;3;Neither satisfied nor dissatisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA29849-9;4;Somewhat dissatisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA14638-3;5;Very dissatisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA14642-5;1;Very satisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA27752-7;2;Somewhat satisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA31733-1;3;Neither satisfied nor dissatisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA29849-9;4;Somewhat dissatisfied;;; +97331-3;LL5815-7;Very satisfied/Very dissatisfied;LA14638-3;5;Very dissatisfied;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23736-4;1;Knowledge required Level 1;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23737-2;2;Knowledge required Level 2-1;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23738-0;3;Knowledge required Level 2-2;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23739-8;4;Knowledge required Level 3-1;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23740-6;5;Knowledge required Level 3-2;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23741-4;6;Knowledge required Level 4-1;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23742-2;7;Knowledge required Level 4-2;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23743-0;8;Knowledge required Level 5;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23744-8;9;Knowledge required Level 6;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23745-5;10;Knowledge required Level 7;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23746-3;11;Knowledge required Level 8;;; +77222-8;LL3587-4;NMMDS_Knowledge Required Level;LA23747-1;12;Knowledge required Level 9;;; +77224-4;LL3586-6;NMMDS_Decision-making required level;LA23748-9;1;Decision-making required level 1;;; +77224-4;LL3586-6;NMMDS_Decision-making required level;LA23749-7;2;Decision-making required level 2;;; +77224-4;LL3586-6;NMMDS_Decision-making required level;LA23750-5;3;Decision-making required level 3;;; +77224-4;LL3586-6;NMMDS_Decision-making required level;LA23751-3;4;Decision-making required level 4;;; +77224-4;LL3586-6;NMMDS_Decision-making required level;LA23752-1;5;Decision-making required level 5;;; +77224-4;LL3586-6;NMMDS_Decision-making required level;LA23753-9;6;Decision-making required level 6;;; +77227-7;LL3585-8;NMMDS_Time Load Level;LA23754-7;1;Time load level 1;;; +77227-7;LL3585-8;NMMDS_Time Load Level;LA23755-4;2;Time load level 2;;; +77227-7;LL3585-8;NMMDS_Time Load Level;LA23756-2;3;Time load level 3;;; +77229-3;LL3588-2;NMMDS_Mental Effort Load Level;LA23757-0;1;Mental effort load level 1;;; +77229-3;LL3588-2;NMMDS_Mental Effort Load Level;LA23758-8;2;Mental effort load level 2;;; +77229-3;LL3588-2;NMMDS_Mental Effort Load Level;LA23759-6;3;Mental effort load level 3;;; +77231-9;LL3584-1;NMMDS_Psychological stress load level;LA23760-4;1;Psychological stress load level 1;;; +77231-9;LL3584-1;NMMDS_Psychological stress load level;LA23761-2;2;Psychological stress load level 2;;; +77231-9;LL3584-1;NMMDS_Psychological stress load level;LA23762-0;3;Psychological stress load level 3;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA9933-8;1;Always;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA14747-2;2;Usually;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA10082-8;3;Sometimes;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA10066-1;4;Rarely;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA6270-8;5;Never;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA4720-4;6;Not applicable;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA14619-3;7;Don't know/not sure;;; +77234-3;LL3268-1;Always/Usually/Sometimes/Rarely/Never;LA4389-8;8;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +77242-6;LL3294-7;PHVS_PhysicalActivityBehavior_HW;;0;;;; +77243-4;LL3295-4;PHVS_DietaryBehavior_HW;;0;;;; +77244-2;LL3296-2;Income range;LA22774-6;1;Less than 5,000;;; +77244-2;LL3296-2;Income range;LA22775-3;2;5,000 to 7,499;;; +77244-2;LL3296-2;Income range;LA22776-1;3;7,500 to 9,999;;; +77244-2;LL3296-2;Income range;LA22777-9;4;10,000 to 12,499;;; +77244-2;LL3296-2;Income range;LA22778-7;5;12,500 to 14,999;;; +77244-2;LL3296-2;Income range;LA22779-5;6;15,000 to 19,999;;; +77244-2;LL3296-2;Income range;LA22780-3;7;20,000 to 24,999;;; +77244-2;LL3296-2;Income range;LA22781-1;8;25,000 to 29,999;;; +77244-2;LL3296-2;Income range;LA22782-9;9;30,000 to 34,999;;; +77244-2;LL3296-2;Income range;LA22783-7;10;35,000 to 39,999;;; +77244-2;LL3296-2;Income range;LA22784-5;11;40,000 to 49,999;;; +77244-2;LL3296-2;Income range;LA22785-2;12;50,000 to 59,999;;; +77244-2;LL3296-2;Income range;LA22786-0;13;60,000 to 74,999;;; +77244-2;LL3296-2;Income range;LA22787-8;14;75,000 to 99,999;;; +77244-2;LL3296-2;Income range;LA22788-6;15;100,000 to 149,999;;; +77244-2;LL3296-2;Income range;LA22789-4;16;150,000 or more;;; +77244-2;LL3296-2;Income range;LA22774-6;1;Less than 5,000;;; +77244-2;LL3296-2;Income range;LA22775-3;2;5,000 to 7,499;;; +77244-2;LL3296-2;Income range;LA22776-1;3;7,500 to 9,999;;; +77244-2;LL3296-2;Income range;LA22777-9;4;10,000 to 12,499;;; +77244-2;LL3296-2;Income range;LA22778-7;5;12,500 to 14,999;;; +77244-2;LL3296-2;Income range;LA22779-5;6;15,000 to 19,999;;; +77244-2;LL3296-2;Income range;LA22780-3;7;20,000 to 24,999;;; +77244-2;LL3296-2;Income range;LA22781-1;8;25,000 to 29,999;;; +77244-2;LL3296-2;Income range;LA22782-9;9;30,000 to 34,999;;; +77244-2;LL3296-2;Income range;LA22783-7;10;35,000 to 39,999;;; +77244-2;LL3296-2;Income range;LA22784-5;11;40,000 to 49,999;;; +77244-2;LL3296-2;Income range;LA22785-2;12;50,000 to 59,999;;; +77244-2;LL3296-2;Income range;LA22786-0;13;60,000 to 74,999;;; +77244-2;LL3296-2;Income range;LA22787-8;14;75,000 to 99,999;;; +77244-2;LL3296-2;Income range;LA22788-6;15;100,000 to 149,999;;; +77244-2;LL3296-2;Income range;LA22789-4;16;150,000 or more;;; +77244-2;LL3296-2;Income range;LA22774-6;1;Less than 5,000;;; +77244-2;LL3296-2;Income range;LA22775-3;2;5,000 to 7,499;;; +77244-2;LL3296-2;Income range;LA22776-1;3;7,500 to 9,999;;; +77244-2;LL3296-2;Income range;LA22777-9;4;10,000 to 12,499;;; +77244-2;LL3296-2;Income range;LA22778-7;5;12,500 to 14,999;;; +77244-2;LL3296-2;Income range;LA22779-5;6;15,000 to 19,999;;; +77244-2;LL3296-2;Income range;LA22780-3;7;20,000 to 24,999;;; +77244-2;LL3296-2;Income range;LA22781-1;8;25,000 to 29,999;;; +77244-2;LL3296-2;Income range;LA22782-9;9;30,000 to 34,999;;; +77244-2;LL3296-2;Income range;LA22783-7;10;35,000 to 39,999;;; +77244-2;LL3296-2;Income range;LA22784-5;11;40,000 to 49,999;;; +77244-2;LL3296-2;Income range;LA22785-2;12;50,000 to 59,999;;; +77244-2;LL3296-2;Income range;LA22786-0;13;60,000 to 74,999;;; +77244-2;LL3296-2;Income range;LA22787-8;14;75,000 to 99,999;;; +77244-2;LL3296-2;Income range;LA22788-6;15;100,000 to 149,999;;; +77244-2;LL3296-2;Income range;LA22789-4;16;150,000 or more;;; +77244-2;LL6102-9;NEI - Household income;LA32769-4;1;Less than $25,000;;; +77244-2;LL6102-9;NEI - Household income;LA32770-2;2;$25,000-$49,999;;; +77244-2;LL6102-9;NEI - Household income;LA32771-0;3;$50,000-$74,999;;; +77244-2;LL6102-9;NEI - Household income;LA32772-8;4;$75,000-$99,999;;; +77244-2;LL6102-9;NEI - Household income;LA32773-6;5;$100,000-$149,000;;; +77244-2;LL6102-9;NEI - Household income;LA32774-4;6;$150,000 or more;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA6112-2;1;1;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA6113-0;2;2;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA6114-8;3;3;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA6115-5;4;4;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA10137-0;5;5;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA10138-8;6;6;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA10139-6;7;7;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA10140-4;8;8;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA10141-2;9;9;;; +77245-9;LL3297-0;Readiness for change score, scale 1-10;LA13942-0;10;10;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA6112-2;1;1;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA6113-0;2;2;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA6114-8;3;3;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA6115-5;4;4;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA10137-0;5;5;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA10138-8;6;6;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA10139-6;7;7;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA10140-4;8;8;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA10141-2;9;9;;; +77246-7;LL3297-0;Readiness for change score, scale 1-10;LA13942-0;10;10;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA6112-2;1;1;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA6113-0;2;2;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA6114-8;3;3;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA6115-5;4;4;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA10137-0;5;5;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA10138-8;6;6;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA10139-6;7;7;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA10140-4;8;8;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA10141-2;9;9;;; +77247-5;LL3297-0;Readiness for change score, scale 1-10;LA13942-0;10;10;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA6112-2;1;1;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA6113-0;2;2;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA6114-8;3;3;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA6115-5;4;4;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA10137-0;5;5;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA10138-8;6;6;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA10139-6;7;7;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA10140-4;8;8;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA10141-2;9;9;;; +77248-3;LL3297-0;Readiness for change score, scale 1-10;LA13942-0;10;10;;; +77286-3;LL3589-0;NMMDS_Direct Care Staff;LA23763-8;1;Advanced Practice Nurses;;; +77286-3;LL3589-0;NMMDS_Direct Care Staff;LA23764-6;2;Registered Nurses reporting to department of nursing;;; +77286-3;LL3589-0;NMMDS_Direct Care Staff;LA23765-3;3;Licensed Practical Nurses/Licensed Vocational Nurses reporting to department of nursing;;; +77286-3;LL3589-0;NMMDS_Direct Care Staff;LA23766-1;4;Nurse Aids or Equivalent extenders;;; +77286-3;LL3589-0;NMMDS_Direct Care Staff;LA23767-9;5;Nursing Students;;; +77286-3;LL3589-0;NMMDS_Direct Care Staff;LA23768-7;6;Agency/Travelers Staff;;; +77286-3;LL3589-0;NMMDS_Direct Care Staff;LA23769-5;7;Independent Contractors/ Sub-contractors;;; +77287-1;LL3590-8;NMMDS_Management, Administrative, Support Staff;LA23770-3;1;Case Manager;;; +77287-1;LL3590-8;NMMDS_Management, Administrative, Support Staff;LA23771-1;2;Nurse Manager;;; +77287-1;LL3590-8;NMMDS_Management, Administrative, Support Staff;LA23772-9;3;Staff Development/ Educators;;; +77287-1;LL3590-8;NMMDS_Management, Administrative, Support Staff;LA23773-7;4;Researchers;;; +77287-1;LL3590-8;NMMDS_Management, Administrative, Support Staff;LA23774-5;5;Nursing Quality Improvement (QI) Staff;;; +77287-1;LL3590-8;NMMDS_Management, Administrative, Support Staff;LA23775-2;6;Support Staff (e.g. unit clerks, environmental aids, techs);;; +77305-1;LL3581-7;Location or facility transferred from;LA14084-0;1;Home;;; +77305-1;LL3581-7;Location or facility transferred from;LA28-6;2;Acute care hospital;;; +77305-1;LL3581-7;Location or facility transferred from;LA6376-3;3;Skilled Nursing Facility;;; +77308-5;LL3279-8;Frequency of eating French fries or chips;LA22723-3;1;No, the patient didn't eat any French fries or chips yesterday;;; +77308-5;LL3279-8;Frequency of eating French fries or chips;LA22724-1;2;Yes, the patient ate French fries or chips 1 time yesterday;;; +77308-5;LL3279-8;Frequency of eating French fries or chips;LA22725-8;3;Yes, the patient ate French fries or chips 2 times yesterday;;; +77308-5;LL3279-8;Frequency of eating French fries or chips;LA22726-6;4;Yes, the patient ate French fries or chips 3 or more times yesterday;;; +77351-5;LL3578-3;High|Medium|Low;LA9193-9;1;High;;; +77351-5;LL3578-3;High|Medium|Low;LA8982-6;2;Medium;;; +77351-5;LL3578-3;High|Medium|Low;LA9194-7;3;Low;;; +91352-5;LL3578-3;High|Medium|Low;LA9193-9;1;High;;; +91352-5;LL3578-3;High|Medium|Low;LA8982-6;2;Medium;;; +91352-5;LL3578-3;High|Medium|Low;LA9194-7;3;Low;;; +98852-7;LL3578-3;High|Medium|Low;LA9193-9;1;High;;; +98852-7;LL3578-3;High|Medium|Low;LA8982-6;2;Medium;;; +98852-7;LL3578-3;High|Medium|Low;LA9194-7;3;Low;;; +77354-9;LL3293-9;Colorectal cancer results;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77354-9;LL3293-9;Colorectal cancer results;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77354-9;LL3293-9;Colorectal cancer results;LA22772-0;2;Sample could not be processed;;; +77354-9;LL3293-9;Colorectal cancer results;LA22773-8;3;No result obtained;;; +77375-4;LL2978-6;HR HVP INTERP;LA11883-8;0;Not detected;;; +77375-4;LL2978-6;HR HVP INTERP;LA21346-4;1;HR HPV Detected;;; +77394-5;LL2978-6;HR HVP INTERP;LA11883-8;0;Not detected;;; +77394-5;LL2978-6;HR HVP INTERP;LA21346-4;1;HR HPV Detected;;; +77395-2;LL2978-6;HR HVP INTERP;LA11883-8;0;Not detected;;; +77395-2;LL2978-6;HR HVP INTERP;LA21346-4;1;HR HPV Detected;;; +77396-0;LL2978-6;HR HVP INTERP;LA11883-8;0;Not detected;;; +77396-0;LL2978-6;HR HVP INTERP;LA21346-4;1;HR HPV Detected;;; +77399-4;LL2978-6;HR HVP INTERP;LA11883-8;0;Not detected;;; +77399-4;LL2978-6;HR HVP INTERP;LA21346-4;1;HR HPV Detected;;; +77400-0;LL2978-6;HR HVP INTERP;LA11883-8;0;Not detected;;; +77400-0;LL2978-6;HR HVP INTERP;LA21346-4;1;HR HPV Detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA22705-0;1;HPV type 16 detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA22706-8;2;HPV type 18 detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA22707-6;3;Other HR HPV detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA22711-8;4;HPV type 16, Other HR HPV detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA22712-6;5;HPV type 18, Other HR HPV detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA22713-4;6;HPV type 16, HPV type 18 detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA22714-2;7;HPV type 16, HPV type 18, Other HR HPV detected;;; +77377-0;LL3274-9;HR HPV RSLTS;LA11883-8;8;Not detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA22705-0;1;HPV type 16 detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA22706-8;2;HPV type 18 detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA22707-6;3;Other HR HPV detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA22711-8;4;HPV type 16, Other HR HPV detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA22712-6;5;HPV type 18, Other HR HPV detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA22713-4;6;HPV type 16, HPV type 18 detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA22714-2;7;HPV type 16, HPV type 18, Other HR HPV detected;;; +77379-6;LL3274-9;HR HPV RSLTS;LA11883-8;8;Not detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA22705-0;1;HPV type 16 detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA22706-8;2;HPV type 18 detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA22707-6;3;Other HR HPV detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA22711-8;4;HPV type 16, Other HR HPV detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA22712-6;5;HPV type 18, Other HR HPV detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA22713-4;6;HPV type 16, HPV type 18 detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA22714-2;7;HPV type 16, HPV type 18, Other HR HPV detected;;; +77380-4;LL3274-9;HR HPV RSLTS;LA11883-8;8;Not detected;;; +77498-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77498-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77499-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77499-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77500-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77500-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77501-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77501-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77502-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77502-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77503-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77503-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77504-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77504-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77505-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77505-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77506-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77506-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77507-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77507-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77508-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77508-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77509-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77509-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77510-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77510-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77511-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77511-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77512-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77512-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77513-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77513-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77514-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77514-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77515-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77515-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77516-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77516-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77517-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77517-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77518-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77518-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77519-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77519-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77520-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77520-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77521-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77521-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77522-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77522-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77523-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77523-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77524-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77524-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77525-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77525-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77526-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77526-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77527-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77527-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77528-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77528-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77529-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77529-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77530-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77530-4;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77531-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77531-2;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77532-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77532-0;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77533-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77533-8;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77534-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77534-6;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77535-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77535-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77536-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77536-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77537-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77537-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77538-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77538-7;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77539-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77539-5;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77540-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77540-3;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77541-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77541-1;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77542-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77542-9;LL3620-3;Y/N (Word pronounced correctly or incorrectly);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77556-9;LL3621-1;NMMDS_Method for patient connection;LA11834-1;1;Walking;;; +77556-9;LL3621-1;NMMDS_Method for patient connection;LA24006-1;2;Motorized vehicle;;; +77556-9;LL3621-1;NMMDS_Method for patient connection;LA24007-9;3;Nonmotorized vehicle (e.g. bicycle);;; +77556-9;LL3621-1;NMMDS_Method for patient connection;LA24008-7;4;Asynchronous electronic communication (e.g., email, blogging);;; +77556-9;LL3621-1;NMMDS_Method for patient connection;LA24009-5;5;Synchronous communication (e.g., telephone, telehealth video visit);;; +77556-9;LL3621-1;NMMDS_Method for patient connection;LA24010-3;6;Monitoring from the nurses' station (e.g., remote camera monitoring);;; +77556-9;LL3621-1;NMMDS_Method for patient connection;LA24011-1;7;Monitoring in the client(s) room (e.g., sitting in client room);;; +77563-5;LL2870-5;Leukocyte esterase;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77563-5;LL2870-5;Leukocyte esterase;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +77563-5;LL2870-5;Leukocyte esterase;LA11841-6;3;1+;;; +77563-5;LL2870-5;Leukocyte esterase;LA11842-4;4;2+;;; +77563-5;LL2870-5;Leukocyte esterase;LA11843-2;5;3+;;; +77595-7;LL3923-1;IPAQ_Physical activity score (Low, Moderate, High);LA9194-7;1;Low;;; +77595-7;LL3923-1;IPAQ_Physical activity score (Low, Moderate, High);LA6751-7;2;Moderate;;; +77595-7;LL3923-1;IPAQ_Physical activity score (Low, Moderate, High);LA9193-9;3;High;;; +77627-8;LL3599-9;HBB gene;LA23851-1;1;c.19G>A;;; +77627-8;LL3599-9;HBB gene;LA23852-9;2;c.20A>T;;; +77627-8;LL3599-9;HBB gene;LA23853-7;3;c.220G>A;;; +77627-8;LL3599-9;HBB gene;LA23854-5;4;c.251G>A;;; +77627-8;LL3599-9;HBB gene;LA23855-2;5;c.79G>A;;; +77628-6;LL3605-4;Example PSEN2 gene variants;LA23943-6;1;p.Asn141Ile;;; +77628-6;LL3605-4;Example PSEN2 gene variants;LA23944-4;2;p.Met239Val;;; +77628-6;LL3605-4;Example PSEN2 gene variants;LA23945-1;3;p.Asp439Ala;;; +77628-6;LL3605-4;Example PSEN2 gene variants;LA23946-9;4;p.Thr430Met;;; +77628-6;LL3605-4;Example PSEN2 gene variants;LA23947-7;5;p.Thr122Pro;;; +77629-4;LL3606-2;Example PARK7 gene variants;LA23948-5;1;p.Leu166Pro;;; +77629-4;LL3606-2;Example PARK7 gene variants;LA23949-3;2;p.Met26Ile;;; +77629-4;LL3606-2;Example PARK7 gene variants;LA23950-1;3;p.Asp149Ala;;; +77629-4;LL3606-2;Example PARK7 gene variants;LA23951-9;4;p.Glu163Lys;;; +77630-2;LL3607-0;Example ALS2 gene variants;LA23953-5;1;c.1867_1868delCT;;; +77630-2;LL3607-0;Example ALS2 gene variants;LA23952-7;2;c.138delA;;; +77630-2;LL3607-0;Example ALS2 gene variants;LA23955-0;3;c.3619delA;;; +77630-2;LL3607-0;Example ALS2 gene variants;LA23957-6;4;c.4721delT;;; +77631-0;LL3608-8;Example VAPB gene variants;LA23959-2;1;c.166C>T;;; +77631-0;LL3608-8;Example VAPB gene variants;LA23958-4;2;c.137C>T;;; +77632-8;LL3609-6;Example ANG gene variants;LA23972-5;1;p.Lys17Ile;;; +77632-8;LL3609-6;Example ANG gene variants;LA23973-3;2;p.Lys17Glu;;; +77632-8;LL3609-6;Example ANG gene variants;LA23974-1;3;p.Arg31Lys;;; +77632-8;LL3609-6;Example ANG gene variants;LA23975-8;4;p.Cys39Trp;;; +77633-6;LL3610-4;Example TARDBP gene variants;LA23967-5;1;p.Gln331Lys;;; +77633-6;LL3610-4;Example TARDBP gene variants;LA23968-3;2;p.Gly294Ala;;; +77633-6;LL3610-4;Example TARDBP gene variants;LA23969-1;3;p.Gly290Ala;;; +77633-6;LL3610-4;Example TARDBP gene variants;LA23970-9;4;p.Gly298Ser;;; +77633-6;LL3610-4;Example TARDBP gene variants;LA23971-7;5;p.Asp169Gly;;; +77634-4;LL3611-2;Example FUS gene variants;LA23960-0;1;p.His517Gln;;; +77634-4;LL3611-2;Example FUS gene variants;LA23963-4;2;p.Arg518Lys;;; +77634-4;LL3611-2;Example FUS gene variants;LA23962-6;3;p.Arg521Cys;;; +77634-4;LL3611-2;Example FUS gene variants;LA23961-8;4;p.Gly206Ser;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23930-3;1;HLA-C*01:02+HLA-C*07:02;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23932-9;2;HLA-C*01:02+HLA-C*16:01;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23933-7;3;HLA-C*03:04+HLA-C*04:01;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23931-1;4;HLA-C*04:01+HLA-C*01:02;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23929-5;5;HLA-C*07:01+HLA-C*07:02;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23934-5;6;HLA-C*16:01+HLA-C*04:94:01;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23935-2;7;HLA-C*01:02:12+HLA-C*03:03:04;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23936-0;8;HLA-C*08:02:10+HLA-C*16:15:01;;; +77636-9;LL3603-9;HLA-C high-resolution genotype;LA23937-8;9;HLA-C*12:03:17+HLA-C*16:15:02;;; +77641-9;LL3601-3;HLA-A antibodies;LA23858-6;1;Anti-A1;;; +77641-9;LL3601-3;HLA-A antibodies;LA23859-4;2;Anti-A2;;; +77641-9;LL3601-3;HLA-A antibodies;LA23860-2;3;Anti-A3;;; +77641-9;LL3601-3;HLA-A antibodies;LA23861-0;4;Anti-A9;;; +77641-9;LL3601-3;HLA-A antibodies;LA23863-6;6;Anti-A11;;; +77641-9;LL3601-3;HLA-A antibodies;LA23864-4;7;Anti-A28;;; +77641-9;LL3601-3;HLA-A antibodies;LA23865-1;8;Anti-A29;;; +77642-7;LL3633-6;HLA-B antibodies;LA23870-1;1;Anti-B7;;; +77642-7;LL3633-6;HLA-B antibodies;LA23871-9;2;Anti-B8;;; +77642-7;LL3633-6;HLA-B antibodies;LA23872-7;3;Anti-B12;;; +77642-7;LL3633-6;HLA-B antibodies;LA23873-5;4;Anti-B13;;; +77642-7;LL3633-6;HLA-B antibodies;LA23874-3;5;Anti-B14;;; +77642-7;LL3633-6;HLA-B antibodies;LA23876-8;6;Anti-B22;;; +77642-7;LL3633-6;HLA-B antibodies;LA23877-6;7;Anti-B27;;; +77642-7;LL3633-6;HLA-B antibodies;LA23878-4;8;Anti-B35;;; +77642-7;LL3633-6;HLA-B antibodies;LA23879-2;9;Anti-B40;;; +77642-7;LL3633-6;HLA-B antibodies;LA23880-0;10;Anti-B41;;; +77642-7;LL3633-6;HLA-B antibodies;LA23881-8;11;Anti-B42;;; +77642-7;LL3633-6;HLA-B antibodies;LA23882-6;12;Anti-B47;;; +77642-7;LL3633-6;HLA-B antibodies;LA23883-4;13;Anti-B53;;; +77642-7;LL3633-6;HLA-B antibodies;LA23884-2;14;Anti-B67;;; +77642-7;LL3633-6;HLA-B antibodies;LA23885-9;15;Anti-B81;;; +77643-5;LL3634-4;HLA-C antibodies;LA23886-7;1;Anti-Cw1;;; +77643-5;LL3634-4;HLA-C antibodies;LA23887-5;2;Anti-Cw2;;; +77643-5;LL3634-4;HLA-C antibodies;LA23890-9;3;Anti-Cw3;;; +77643-5;LL3634-4;HLA-C antibodies;LA23888-3;4;Anti-Cw4;;; +77643-5;LL3634-4;HLA-C antibodies;LA23889-1;5;Anti-Cw5;;; +77643-5;LL3634-4;HLA-C antibodies;LA23891-7;6;Anti-Cw6;;; +77643-5;LL3634-4;HLA-C antibodies;LA23892-5;7;Anti-Cw7;;; +77643-5;LL3634-4;HLA-C antibodies;LA23893-3;8;Anti-Cw8;;; +77644-3;LL3635-1;HLA-DP antibodies;LA23895-8;1;Anti-DP1;;; +77644-3;LL3635-1;HLA-DP antibodies;LA23894-1;2;Anti-DP2;;; +77644-3;LL3635-1;HLA-DP antibodies;LA23897-4;3;Anti-DP3;;; +77644-3;LL3635-1;HLA-DP antibodies;LA23896-6;4;Anti-DP4;;; +77644-3;LL3635-1;HLA-DP antibodies;LA23898-2;5;Anti-DP5;;; +77644-3;LL3635-1;HLA-DP antibodies;LA23899-0;6;Anti-DP6;;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23909-7;1;Anti-DQ1;;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23906-3;2;Anti-DQ2;;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23907-1;3;Anti-DQ3;;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23908-9;4;Anti-DQ4;;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23903-0;5;Anti-DQ5(1);;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23902-2;6;Anti-DQ6(1);;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23904-8;7;Anti-DQ7(3);;; +77645-0;LL3636-9;HLA-DQ antibodies;LA23905-5;8;Anti-DQ8(3);;; +77646-8;LL3637-7;HLA-DR antibodies;LA23910-5;1;Anti-DR1;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23914-7;2;Anti-DR3;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23915-4;3;Anti-DR4;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23916-2;4;Anti-DR7;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23917-0;5;Anti-DR8;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23918-8;6;Anti-DR10;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23919-6;7;Anti-DR11(5);;; +77646-8;LL3637-7;HLA-DR antibodies;LA23920-4;8;Anti-DR12(5);;; +77646-8;LL3637-7;HLA-DR antibodies;LA23923-8;9;Anti-DR14(6);;; +77646-8;LL3637-7;HLA-DR antibodies;LA23927-9;10;Anti-DR51;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23926-1;11;Anti-DR52;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23928-7;12;Anti-DR53;;; +77646-8;LL3637-7;HLA-DR antibodies;LA23911-3;13;Anti-DR103;;; +77653-4;LL3582-5;CYTO ANORECTAL;LA23730-7;0;Negative for malignant cells;;; +77653-4;LL3582-5;CYTO ANORECTAL;LA23731-5;1;Atypical cells of uncertain significance;;; +77653-4;LL3582-5;CYTO ANORECTAL;LA23732-3;2;Atypical squamous cells, cannot exclude high grade squamous intraepithelial lesion;;; +77653-4;LL3582-5;CYTO ANORECTAL;LA23733-1;3;Low grade intraepithelial lesion;;; +77653-4;LL3582-5;CYTO ANORECTAL;LA23734-9;4;High grade intraepithelial lesion;;; +77653-4;LL3582-5;CYTO ANORECTAL;LA23735-6;5;Squamous cell carcinoma;;; +77686-4;LL3509-8;UPDRS_Intellectual impairment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77686-4;LL3509-8;UPDRS_Intellectual impairment;LA23554-1;2;Mild. Consistent forgetfulness with partial recollection of events and no other difficulties;;; +77686-4;LL3509-8;UPDRS_Intellectual impairment;LA23555-8;3;Moderate memory loss, with disorientation and moderate difficulty handling complex problems, Mild but definite impairment of function at home with need of occasional prompting;;; +77686-4;LL3509-8;UPDRS_Intellectual impairment;LA23556-6;4;Severe memory loss with disorientation for time and often to place. Severe impairment in handling problems;;; +77686-4;LL3509-8;UPDRS_Intellectual impairment;LA23557-4;5;Severe memory loss with orientation preserved to person only. Unable to make judgments or solve problems. Requires much help with personal care. Cannot be left alone at all;;; +77687-2;LL3510-6;UPDRS_Thought disorder;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77687-2;LL3510-6;UPDRS_Thought disorder;LA23558-2;2;Vivid dreaming;;; +77687-2;LL3510-6;UPDRS_Thought disorder;LA23559-0;3;Benign hallucinations with insight retained;;; +77687-2;LL3510-6;UPDRS_Thought disorder;LA23560-8;4;"Occasional to frequent hallucinations or delusions; without insight; could interfere with daily activities";;; +77687-2;LL3510-6;UPDRS_Thought disorder;LA23561-6;5;Persistent hallucinations, delusions, or florrid psychosis. Not able to care for self;;; +77688-0;LL3511-4;UPDRS_Depression;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77688-0;LL3511-4;UPDRS_Depression;LA23562-4;2;Periods of sadness or guilt greater than normal, never sustained for days or weeks;;; +77688-0;LL3511-4;UPDRS_Depression;LA23563-2;3;Sustained depression 1 week or more;;; +77688-0;LL3511-4;UPDRS_Depression;LA23564-0;4;Sustained depression with vegetative symptoms insomnia, anorexia, weight loss, loss of interest;;; +77688-0;LL3511-4;UPDRS_Depression;LA23565-7;5;Sustained depression with vegetative symptoms and suicidal thoughts or intent;;; +77689-8;LL3512-2;UPDRS_Motivation or initiative;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77689-8;LL3512-2;UPDRS_Motivation or initiative;LA23566-5;2;"Less assertive than usual; more passive";;; +77689-8;LL3512-2;UPDRS_Motivation or initiative;LA23567-3;3;Loss of initiative or disinterest in elective nonroutine activities;;; +77689-8;LL3512-2;UPDRS_Motivation or initiative;LA23568-1;4;Loss of initiative or disinterest in day to day routine activities;;; +77689-8;LL3512-2;UPDRS_Motivation or initiative;LA23569-9;5;Withdrawn, complete loss of motivation;;; +77690-6;LL4670-7;UPDRS_Speech;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77690-6;LL4670-7;UPDRS_Speech;LA28186-7;2;Mildly affected. No difficulty being understood.;;; +77690-6;LL4670-7;UPDRS_Speech;LA28187-5;3;Moderately affected. Sometimes asked to repeat statements.;;; +77690-6;LL4670-7;UPDRS_Speech;LA28188-3;4;Severely affected. Frequently asked to repeat statements.;;; +77690-6;LL4670-7;UPDRS_Speech;LA28189-1;5;Unintelligible most of the time.;;; +77691-4;LL3492-7;UPDRS_Salivation;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77691-4;LL3492-7;UPDRS_Salivation;LA23498-1;2;"Slight but definite excess of saliva in mouth; may have nighttime drooling";;; +77691-4;LL3492-7;UPDRS_Salivation;LA23499-9;3;"Moderately excessive saliva; may have minimal drooling";;; +77691-4;LL3492-7;UPDRS_Salivation;LA23500-4;4;Marked excess of saliva with some drooling;;; +77691-4;LL3492-7;UPDRS_Salivation;LA23501-2;5;Marked drooling, requires constant tissue or handkerchief;;; +77692-2;LL3515-5;UPDRS_Swallowing;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77692-2;LL3515-5;UPDRS_Swallowing;LA23576-4;2;Rare choking;;; +77692-2;LL3515-5;UPDRS_Swallowing;LA23577-2;3;Occasional choking;;; +77692-2;LL3515-5;UPDRS_Swallowing;LA23578-0;4;Requires soft food;;; +77692-2;LL3515-5;UPDRS_Swallowing;LA23579-8;5;Requires NG tube or gastrostomy feeding;;; +77694-8;LL3517-1;UPDRS_Cutting food and handling utensils;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77694-8;LL3517-1;UPDRS_Cutting food and handling utensils;LA23511-1;2;Somewhat slow and clumsy, but no help needed;;; +77694-8;LL3517-1;UPDRS_Cutting food and handling utensils;LA23584-8;3;"Can cut most foods, although clumsy and slow; some help needed";;; +77694-8;LL3517-1;UPDRS_Cutting food and handling utensils;LA23513-7;4;Food must be cut by someone, but can still feed slowly;;; +77694-8;LL3517-1;UPDRS_Cutting food and handling utensils;LA23514-5;5;Needs to be fed;;; +77695-5;LL3518-9;UPDRS_Dressing;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77695-5;LL3518-9;UPDRS_Dressing;LA23585-5;2;Somewhat slow, but no help needed;;; +77695-5;LL3518-9;UPDRS_Dressing;LA23586-3;3;Occasional assistance with buttoning, getting arms in sleeves;;; +77695-5;LL3518-9;UPDRS_Dressing;LA23587-1;4;Considerable help required, but can do some things alone;;; +77695-5;LL3518-9;UPDRS_Dressing;LA23525-1;5;Helpless;;; +77696-3;LL3519-7;UPDRS_Hygiene;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77696-3;LL3519-7;UPDRS_Hygiene;LA23585-5;2;Somewhat slow, but no help needed;;; +77696-3;LL3519-7;UPDRS_Hygiene;LA23588-9;3;"Needs help to shower or bathe; or very slow in hygienic care";;; +77696-3;LL3519-7;UPDRS_Hygiene;LA23589-7;4;Requires assistance for washing, brushing teeth, combing hair, going to bathroom;;; +77696-3;LL3519-7;UPDRS_Hygiene;LA23590-5;5;Foley catheter or other mechanical aids;;; +77697-1;LL3499-2;UPDRS_Turning in bed and adjusting bed clothes;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77697-1;LL3499-2;UPDRS_Turning in bed and adjusting bed clothes;LA23511-1;2;Somewhat slow and clumsy, but no help needed;;; +77697-1;LL3499-2;UPDRS_Turning in bed and adjusting bed clothes;LA23523-6;3;Can turn alone or adjust sheets, but with great difficulty;;; +77697-1;LL3499-2;UPDRS_Turning in bed and adjusting bed clothes;LA23524-4;4;Can initiate, but not turn or adjust sheets alone;;; +77697-1;LL3499-2;UPDRS_Turning in bed and adjusting bed clothes;LA23525-1;5;Helpless;;; +77698-9;LL4671-5;UPDRS_Falling;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77698-9;LL4671-5;UPDRS_Falling;LA28190-9;2;Rare falling;;; +77698-9;LL4671-5;UPDRS_Falling;LA28191-7;3;Occasionally falls, less than once per day;;; +77698-9;LL4671-5;UPDRS_Falling;LA28192-5;4;Falls an average of once daily;;; +77698-9;LL4671-5;UPDRS_Falling;LA28193-3;5;Falls more than once daily;;; +77699-7;LL3522-1;UPDRS_Freezing when walking;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77699-7;LL3522-1;UPDRS_Freezing when walking;LA23595-4;2;"Rare freezing when walking; may have start hesitation";;; +77699-7;LL3522-1;UPDRS_Freezing when walking;LA23596-2;3;Occasional freezing when walking;;; +77699-7;LL3522-1;UPDRS_Freezing when walking;LA23597-0;4;Frequent freezing. Occasionally falls from freezing;;; +77699-7;LL3522-1;UPDRS_Freezing when walking;LA23598-8;5;Frequent falls from freezing;;; +77700-3;LL3523-9;UPDRS_Walking;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +77700-3;LL3523-9;UPDRS_Walking;LA23599-6;2;Mild difficulty. May not swing arms or may tend to drag leg;;; +77700-3;LL3523-9;UPDRS_Walking;LA23600-2;3;Moderate difficulty, but requires little or no assistance;;; +77700-3;LL3523-9;UPDRS_Walking;LA23601-0;4;Severe disturbance of walking, requiring assistance;;; +77700-3;LL3523-9;UPDRS_Walking;LA23602-8;5;Cannot walk at all, even with assistance;;; +77701-1;LL3524-7;UPDRS_Tremor;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +77701-1;LL3524-7;UPDRS_Tremor;LA23603-6;2;Slight and infrequently present;;; +77701-1;LL3524-7;UPDRS_Tremor;LA23604-4;3;"Moderate; bothersome to patient";;; +77701-1;LL3524-7;UPDRS_Tremor;LA23605-1;4;"Severe; interferes with many activities";;; +77701-1;LL3524-7;UPDRS_Tremor;LA23606-9;5;"Marked; interferes with most activities";;; +77702-9;LL3525-4;UPDRS_Sensory complaints related to parkinsonism;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77702-9;LL3525-4;UPDRS_Sensory complaints related to parkinsonism;LA23607-7;2;Occasionally has numbness, tingling, or mild aching;;; +77702-9;LL3525-4;UPDRS_Sensory complaints related to parkinsonism;LA23608-5;3;"Frequently has numbness, tingling, or aching; not distressing";;; +77702-9;LL3525-4;UPDRS_Sensory complaints related to parkinsonism;LA23609-3;4;Frequent painful sensations;;; +77702-9;LL3525-4;UPDRS_Sensory complaints related to parkinsonism;LA23610-1;5;Excruciating pain;;; +77703-7;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77703-7;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23650-7;2;1-25% of day;;; +77703-7;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23651-5;3;26-50% of day;;; +77703-7;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23652-3;4;51-75% of day;;; +77703-7;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23653-1;5;76-100% of day;;; +77710-2;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77710-2;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23650-7;2;1-25% of day;;; +77710-2;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23651-5;3;26-50% of day;;; +77710-2;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23652-3;4;51-75% of day;;; +77710-2;LL3537-9;"UPDRS_Ave proportion waking day patient is ""off""";LA23653-1;5;76-100% of day;;; +77704-5;LL3538-7;UPDRS_Level of disabling - not to completely;LA23654-9;1;Not disabling;;; +77704-5;LL3538-7;UPDRS_Level of disabling - not to completely;LA23655-6;2;Mildly disabling;;; +77704-5;LL3538-7;UPDRS_Level of disabling - not to completely;LA23656-4;3;Moderately disabling;;; +77704-5;LL3538-7;UPDRS_Level of disabling - not to completely;LA23657-2;4;Severely disabling;;; +77704-5;LL3538-7;UPDRS_Level of disabling - not to completely;LA23658-0;5;Completely disabled;;; +77705-2;LL3539-5;UPDRS_Level of dyskinesias pain;LA23659-8;1;No painful dyskinesias;;; +77705-2;LL3539-5;UPDRS_Level of dyskinesias pain;LA11910-9;2;Slight;;; +77705-2;LL3539-5;UPDRS_Level of dyskinesias pain;LA6751-7;3;Moderate;;; +77705-2;LL3539-5;UPDRS_Level of dyskinesias pain;LA6750-9;4;Severe;;; +77705-2;LL3539-5;UPDRS_Level of dyskinesias pain;LA17968-1;5;Marked;;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23661-4;1;No signs of disease;;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23662-2;2;Unilateral disease;;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23663-0;3;Unilateral plus axial involvement;;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23664-8;4;Bilateral disease, without impairment of balance;;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23665-5;5;Mild bilateral disease, with recovery on pull test;;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23666-3;6;"Mild to moderate bilateral disease; some postural instability; physically independent";;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23667-1;7;"Severe disability; still able to walk or stand unassisted";;; +77714-4;LL3542-9;Modified Hoehn and Yahr Staging;LA23668-9;8;Wheelchair bound or bedridden unless aided;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23669-7;1;Completely independent. Able to do all chores without slowness, difficulty or impairment. Essentially normal. Unaware of any difficulty;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23670-5;2;Completely independent. Able to do all chores with some degree of slowness, difficulty and impairment. Might take twice as long. Beginning to be aware of difficulty;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23671-3;3;Completely independent in most chores. Takes twice as long. Conscious of difficulty and slowness;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23672-1;4;Not completely independent. More difficulty with some chores. Three to four times as long in some. Must spend a large part of the day with chores;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23673-9;5;"Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; some impossible";;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23674-7;6;More dependent. Help with half, slower, etc. Difficulty with everything.;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23675-4;7;Very dependent. Can assist with all chores, but few alone;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23676-2;8;With effort, now and then does a few chores alone or begins alone. Much help needed;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23677-0;9;Nothing alone. Can be a slight help with some chores. Severe invalid;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23678-8;10;Totally dependent, helpless. Complete invalid;;; +77715-1;LL3543-7;Schwab and England ADL Scale;LA23679-6;11;Vegetative functions such as swallowing, bladder and bowel functions are not functioning. Bedridden;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23669-7;1;Completely independent. Able to do all chores without slowness, difficulty or impairment. Essentially normal. Unaware of any difficulty;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23670-5;2;Completely independent. Able to do all chores with some degree of slowness, difficulty and impairment. Might take twice as long. Beginning to be aware of difficulty;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23671-3;3;Completely independent in most chores. Takes twice as long. Conscious of difficulty and slowness;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23672-1;4;Not completely independent. More difficulty with some chores. Three to four times as long in some. Must spend a large part of the day with chores;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23673-9;5;"Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; some impossible";;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23674-7;6;More dependent. Help with half, slower, etc. Difficulty with everything.;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23675-4;7;Very dependent. Can assist with all chores, but few alone;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23676-2;8;With effort, now and then does a few chores alone or begins alone. Much help needed;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23677-0;9;Nothing alone. Can be a slight help with some chores. Severe invalid;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23678-8;10;Totally dependent, helpless. Complete invalid;;; +77716-9;LL3543-7;Schwab and England ADL Scale;LA23679-6;11;Vegetative functions such as swallowing, bladder and bowel functions are not functioning. Bedridden;;; +77736-7;LL3595-7;M. Abscess RT-PCR Imp Clarithromycin;LA11883-8;1;Not detected;;; +77736-7;LL3595-7;M. Abscess RT-PCR Imp Clarithromycin;LA23797-6;2;Full length erm(41) present, suggests inducible clarithromycin resistance. Culture is required to confirm these results.;;; +77736-7;LL3595-7;M. Abscess RT-PCR Imp Clarithromycin;LA23798-4;3;Truncated erm(41) present, suggests clarthromycin susceptibility. Culture is required to confirm these results.;;; +77738-3;LL3638-5;Heparin|Saline|None|Other|Unknown;LA24058-2;1;Heparin;372877000;Heparin (substance);http://snomed.info/sct +77738-3;LL3638-5;Heparin|Saline|None|Other|Unknown;LA24059-0;2;Saline;;; +77738-3;LL3638-5;Heparin|Saline|None|Other|Unknown;LA137-2;3;None;260413007;None (qualifier value);http://snomed.info/sct +77738-3;LL3638-5;Heparin|Saline|None|Other|Unknown;LA46-8;4;Other;;; +77738-3;LL3638-5;Heparin|Saline|None|Other|Unknown;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +77739-1;LL3639-3;Positive|Negative|Not tested|Unknown;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +77739-1;LL3639-3;Positive|Negative|Not tested|Unknown;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +77739-1;LL3639-3;Positive|Negative|Not tested|Unknown;LA13538-6;3;Not tested;;; +77739-1;LL3639-3;Positive|Negative|Not tested|Unknown;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +77744-1;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24063-2;0;Negative for HTLV antibodies;;; +77744-1;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24066-5;1;Positive for HTLV-I antibodies;;; +77744-1;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24067-3;2;Positive for HTLV-II antibodies;;; +77744-1;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24065-7;3;Positive for HTLV antibodies (untypable);;; +77744-1;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24064-0;4;Indeterminate for HTLV antibodies, further investigation needed;;; +93742-5;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24063-2;0;Negative for HTLV antibodies;;; +93742-5;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24066-5;1;Positive for HTLV-I antibodies;;; +93742-5;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24067-3;2;Positive for HTLV-II antibodies;;; +93742-5;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24065-7;3;Positive for HTLV antibodies (untypable);;; +93742-5;LL3642-7;HTLV I/II Neg|Pos|untypable|indeter;LA24064-0;4;Indeterminate for HTLV antibodies, further investigation needed;;; +77749-0;LL3629-4;Genotypes T/T|T/G|G/G;LA21504-8;1;T/T (wild type);;; +77749-0;LL3629-4;Genotypes T/T|T/G|G/G;LA24044-2;2;T/G (heterozygous);;; +77749-0;LL3629-4;Genotypes T/T|T/G|G/G;LA20174-1;3;G/G (homozygous);;; +92935-6;LL3629-4;Genotypes T/T|T/G|G/G;LA21504-8;1;T/T (wild type);;; +92935-6;LL3629-4;Genotypes T/T|T/G|G/G;LA24044-2;2;T/G (heterozygous);;; +92935-6;LL3629-4;Genotypes T/T|T/G|G/G;LA20174-1;3;G/G (homozygous);;; +77750-8;LL3631-0;Example DLD gene variants;LA24048-3;1;c.104dupA;;; +77750-8;LL3631-0;Example DLD gene variants;LA24049-1;2;c.685G>T;;; +77750-8;LL3631-0;Example DLD gene variants;LA24055-8;3;c.1436A>T;;; +77750-8;LL3631-0;Example DLD gene variants;LA24054-1;4;c.1483A>G;;; +77751-6;LL3630-2;Genotypes G/G|G/T| T/T;LA19932-5;1;G/G (wild type);;; +77751-6;LL3630-2;Genotypes G/G|G/T| T/T;LA24047-5;2;G/T (heterozygous);;; +77751-6;LL3630-2;Genotypes G/G|G/T| T/T;LA13523-8;3;T/T (homozygous);;; +94418-1;LL3630-2;Genotypes G/G|G/T| T/T;LA19932-5;1;G/G (wild type);;; +94418-1;LL3630-2;Genotypes G/G|G/T| T/T;LA24047-5;2;G/T (heterozygous);;; +94418-1;LL3630-2;Genotypes G/G|G/T| T/T;LA13523-8;3;T/T (homozygous);;; +77911-6;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77911-6;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +77911-6;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6752-5;3;Mild;;; +77911-6;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23856-0;4;Mild-to-moderate;;; +77911-6;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6751-7;5;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +77911-6;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23857-8;6;Moderate-to-severe;;; +77911-6;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6750-9;7;Severe;;; +77912-4;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77912-4;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +77912-4;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6752-5;3;Mild;;; +77912-4;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23856-0;4;Mild-to-moderate;;; +77912-4;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6751-7;5;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +77912-4;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23857-8;6;Moderate-to-severe;;; +77912-4;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6750-9;7;Severe;;; +77915-7;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77915-7;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +77915-7;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6752-5;3;Mild;;; +77915-7;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23856-0;4;Mild-to-moderate;;; +77915-7;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6751-7;5;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +77915-7;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23857-8;6;Moderate-to-severe;;; +77915-7;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6750-9;7;Severe;;; +77916-5;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77916-5;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +77916-5;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6752-5;3;Mild;;; +77916-5;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23856-0;4;Mild-to-moderate;;; +77916-5;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6751-7;5;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +77916-5;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23857-8;6;Moderate-to-severe;;; +77916-5;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6750-9;7;Severe;;; +77919-9;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +77919-9;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +77919-9;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6752-5;3;Mild;;; +77919-9;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23856-0;4;Mild-to-moderate;;; +77919-9;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6751-7;5;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +77919-9;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23857-8;6;Moderate-to-severe;;; +77919-9;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6750-9;7;Severe;;; +78183-1;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +78183-1;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA11832-5;2;Trace;260405006;Trace (qualifier value);http://snomed.info/sct +78183-1;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6752-5;3;Mild;;; +78183-1;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23856-0;4;Mild-to-moderate;;; +78183-1;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6751-7;5;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +78183-1;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA23857-8;6;Moderate-to-severe;;; +78183-1;LL3600-5;None|Trace|Mild|Mild-to-mod|Mod|Mod-to-sev|Severe;LA6750-9;7;Severe;;; +77941-3;LL3597-3;NEMSIS_19_eDisposition;LA17696-8;1;Critical (red);;; +77941-3;LL3597-3;NEMSIS_19_eDisposition;LA17695-0;2;Emergent (yellow);;; +77941-3;LL3597-3;NEMSIS_19_eDisposition;LA17694-3;3;Lower acuity (green);;; +77941-3;LL3597-3;NEMSIS_19_eDisposition;LA17697-6;4;Dead without resuscitation efforts (black);;; +77941-3;LL3597-3;NEMSIS_19_eDisposition;LA32921-1;5;Dead with resuscitation efforts (black);;; +77941-3;LL3597-3;NEMSIS_19_eDisposition;LA32920-3;6;Non-acute/routine;;; +77958-7;LL3672-4;DENV1&2&3&4;LA24234-9;0;Dengue virus 1 detected;;; +77958-7;LL3672-4;DENV1&2&3&4;LA24235-6;1;Dengue virus 2 detected;;; +77958-7;LL3672-4;DENV1&2&3&4;LA24236-4;2;Dengue virus 3 detected;;; +77958-7;LL3672-4;DENV1&2&3&4;LA24237-2;3;Dengue virus 4 detected;;; +77958-7;LL3672-4;DENV1&2&3&4;LA24238-0;4;Dengue virus 1, 2, 3 and 4 not detected;;; +88203-5;LL3672-4;DENV1&2&3&4;LA24234-9;0;Dengue virus 1 detected;;; +88203-5;LL3672-4;DENV1&2&3&4;LA24235-6;1;Dengue virus 2 detected;;; +88203-5;LL3672-4;DENV1&2&3&4;LA24236-4;2;Dengue virus 3 detected;;; +88203-5;LL3672-4;DENV1&2&3&4;LA24237-2;3;Dengue virus 4 detected;;; +88203-5;LL3672-4;DENV1&2&3&4;LA24238-0;4;Dengue virus 1, 2, 3 and 4 not detected;;; +77965-2;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77965-2;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77965-2;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +77974-4;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77974-4;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77974-4;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +77978-5;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77978-5;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77978-5;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +77980-1;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77980-1;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77980-1;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +77996-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +77996-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +77996-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78026-2;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78026-2;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78026-2;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78027-0;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78027-0;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78027-0;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78924-8;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78924-8;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78924-8;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78925-5;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78925-5;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78925-5;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78926-3;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78926-3;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78926-3;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78929-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78929-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78929-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78930-5;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78930-5;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78930-5;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78931-3;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78931-3;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78931-3;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78932-1;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78932-1;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78932-1;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78934-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78934-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78934-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78935-4;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78935-4;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78935-4;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78936-2;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +78936-2;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +78936-2;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79734-0;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79734-0;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79734-0;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +80270-2;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80270-2;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +80270-2;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +80726-3;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80726-3;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +80726-3;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +80727-1;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +80727-1;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +80727-1;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82312-0;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82312-0;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82312-0;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82314-6;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82314-6;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82314-6;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82751-9;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82751-9;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82751-9;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82761-8;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82761-8;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82761-8;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82762-6;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82762-6;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82762-6;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85473-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85473-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85473-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85656-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85656-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85656-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85687-2;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85687-2;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85687-2;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85689-8;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85689-8;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85689-8;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85694-8;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85694-8;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85694-8;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85696-3;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85696-3;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85696-3;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85697-1;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85697-1;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85697-1;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85699-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85699-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85699-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85700-3;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85700-3;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85700-3;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85702-9;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85702-9;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85702-9;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85705-2;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85705-2;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85705-2;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85708-6;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85708-6;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85708-6;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85709-4;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85709-4;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85709-4;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85710-2;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85710-2;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85710-2;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85711-0;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85711-0;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85711-0;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85713-6;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85713-6;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85713-6;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85716-9;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85716-9;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85716-9;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85717-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85717-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85717-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85721-9;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85721-9;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85721-9;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85723-5;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85723-5;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85723-5;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85727-6;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85727-6;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85727-6;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85730-0;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85730-0;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85730-0;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85733-4;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85733-4;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85733-4;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85794-6;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85794-6;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85794-6;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +90366-6;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90366-6;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +90366-6;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +91515-7;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +91515-7;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +91515-7;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +92573-5;LL3044-6;Yes/No/Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +92573-5;LL3044-6;Yes/No/Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +92573-5;LL3044-6;Yes/No/Unk;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +77967-8;LL3660-9;PHVS_County_FIPS_6-4;;0;;;; +77987-6;LL3660-9;PHVS_County_FIPS_6-4;;0;;;; +87721-7;LL3660-9;PHVS_County_FIPS_6-4;;0;;;; +77968-6;LL3650-0;PHVS_National reporting jurisdiction_NND;;0;;;; +77982-7;LL3664-1;PHVS_City_USGS_GNIS;;0;;;; +77986-8;LL3664-1;PHVS_City_USGS_GNIS;;0;;;; +77983-5;LL3662-5;PHVS_Country_ISO_3166-1;;0;;;; +77984-3;LL3662-5;PHVS_Country_ISO_3166-1;;0;;;; +82764-2;LL3662-5;PHVS_Country_ISO_3166-1;;0;;;; +91514-0;LL3662-5;PHVS_Country_ISO_3166-1;;0;;;; +94651-7;LL3662-5;PHVS_Country_ISO_3166-1;;0;;;; +96546-7;LL3662-5;PHVS_Country_ISO_3166-1;;0;;;; +77988-4;LL3657-5;PHVS_BinationalReportingCriteria_CDC;;0;;;; +77989-2;LL3658-3;PHVS_CaseTransmissionMode_NND;;0;;;; +77990-0;LL3659-1;PHVS_CaseClassStatus_NETSS;;0;;;; +78004-9;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +78004-9;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +88705-9;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +88705-9;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +88706-7;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +88706-7;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +88707-5;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +88707-5;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89480-8;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89480-8;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89481-6;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89481-6;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89482-4;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89482-4;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89483-2;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89483-2;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89484-0;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89484-0;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89485-7;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89485-7;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89487-3;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89487-3;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89488-1;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89488-1;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89489-9;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89489-9;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89490-7;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89490-7;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +89491-5;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +89491-5;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +92241-9;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +92241-9;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +92242-7;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +92242-7;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +92255-9;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +92255-9;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96107-8;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96107-8;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96108-6;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96108-6;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96109-4;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96109-4;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96110-2;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96110-2;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96111-0;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96111-0;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96112-8;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96112-8;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96113-6;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96113-6;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96114-4;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96114-4;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +96566-5;LL3666-6;Resistant|Susceptible;LA6676-6;1;Resistant;;; +96566-5;LL3666-6;Resistant|Susceptible;LA24225-7;2;Susceptible;;; +78014-8;LL3158-4;HLA-A low resolution both alleles;LA24226-5;1;HLA-A*01+HLA-A*02;;; +78014-8;LL3158-4;HLA-A low resolution both alleles;LA24227-3;2;HLA-A*01+HLA-A*24;;; +78014-8;LL3158-4;HLA-A low resolution both alleles;LA21949-5;3;HLA-A*02+HLA-A*03;;; +78014-8;LL3158-4;HLA-A low resolution both alleles;LA24228-1;4;HLA-A*03+HLA-A*24;;; +78015-5;LL3668-2;HLA-B low resolution both alleles;LA24230-7;1;HLA-B*08+HLA-B*13;;; +78015-5;LL3668-2;HLA-B low resolution both alleles;LA21951-1;2;HLA-B*08+HLA-B*58;;; +78015-5;LL3668-2;HLA-B low resolution both alleles;LA24231-5;3;HLA-B*13+HLA-B*51;;; +78015-5;LL3668-2;HLA-B low resolution both alleles;LA24229-9;4;HLA-B*37+HLA-B*44;;; +78016-3;LL3669-0;HLA-DRB low resolution both alleles;LA21954-5;1;HLA-DRB1*03+HLA-DRB1*11;;; +78016-3;LL3669-0;HLA-DRB low resolution both alleles;LA21952-9;2;HLA-DRB1*04+HLA-DRB1*15;;; +78016-3;LL3669-0;HLA-DRB low resolution both alleles;LA21950-3;3;HLA-DRB1*04+HLA-DRB1*16;;; +78016-3;LL3669-0;HLA-DRB low resolution both alleles;LA21953-7;4;HLA-DRB1*15+HLA-DRB1*16;;; +96663-0;LL3669-0;HLA-DRB low resolution both alleles;LA21954-5;1;HLA-DRB1*03+HLA-DRB1*11;;; +96663-0;LL3669-0;HLA-DRB low resolution both alleles;LA21952-9;2;HLA-DRB1*04+HLA-DRB1*15;;; +96663-0;LL3669-0;HLA-DRB low resolution both alleles;LA21950-3;3;HLA-DRB1*04+HLA-DRB1*16;;; +96663-0;LL3669-0;HLA-DRB low resolution both alleles;LA21953-7;4;HLA-DRB1*15+HLA-DRB1*16;;; +78017-1;LL3670-8;HLA-DQB1 low resolution both alleles;LA21955-2;1;HLA-DQB1*02+HLA-DQB1*05;;; +78017-1;LL3670-8;HLA-DQB1 low resolution both alleles;LA21956-0;2;HLA-DQB1*02+HLA-DQB1*06;;; +78017-1;LL3670-8;HLA-DQB1 low resolution both alleles;LA24232-3;3;HLA-DQB1*03+HLA-DQB1*05;;; +78017-1;LL3670-8;HLA-DQB1 low resolution both alleles;LA24233-1;4;HLA-DQB1*05+HLA-DQB1*06;;; +78020-5;LL3652-6;[NHCS] Priority of admission;LA19759-2;1;Emergent;;; +78020-5;LL3652-6;[NHCS] Priority of admission;LA21544-4;2;Urgent;;; +78020-5;LL3652-6;[NHCS] Priority of admission;LA19760-0;3;Elective;;; +78020-5;LL3652-6;[NHCS] Priority of admission;LA10403-6;4;Newborn;;; +78020-5;LL3652-6;[NHCS] Priority of admission;LA24212-5;5;Non-urgent Trauma;;; +78020-5;LL3652-6;[NHCS] Priority of admission;LA24213-3;6;Emergent Trauma;;; +78020-5;LL3652-6;[NHCS] Priority of admission;LA21297-9;7;Information not available;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10143-8;1;Adult Burn Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24094-7;2;Adult Medical Cardiac Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10146-1;3;Adult Medical Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24095-4;4;Adult Med-Surg Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24098-8;5;Adult Neurology Critical Care and Stroke Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24099-6;6;Adult Neurosurgery Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10148-7;7;Adult Pulmonary Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10149-5;8;Adult Surgical Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10144-6;9;Adult Cardiothoracic Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10150-3;10;Adult Trauma Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24103-6;11;Prenatal Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24096-2;12;Neonatal Critical Care Unit (Level II/III);;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24097-0;13;Neonatal Critical Care Unit (Level III);;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10197-4;14;Pediatric Burn Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10200-6;15;Pediatric Medical Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24100-2;16;Pediatric Med-Surg Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10201-4;17;Pediatric Neurology Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA24102-8;18;Pediatric Neurosurgery Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10202-2;19;Pediatric Pulmonary Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10198-2;20;Pediatric Cardiothoracic Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10203-0;21;Pediatric Surgical Critical Care Unit;;; +78021-3;LL3653-4;[NHCS] Critical care unit types;LA10204-8;22;Pediatric Trauma Critical Care Unit;;; +78022-1;LL3654-2;PHVS_Healthcare Service Location_NHSN;;0;;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24239-8;1;Discharged to home or self care;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA20616-1;2;Discharged/Transferred to a short-term general hospital for inpatient care;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24241-4;3;Discharged/Transferred to Skilled Nursing Facility with Medicare Certification in anticipation of skilled care;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24242-2;4;Discharged/Transferred to a Facility that provides custodial or supportive care;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24243-0;5;Discharged to a Designated Cancer Center or Children's Hospital;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24244-8;6;Discharged/Transferred to home under care of an organized Home Health Service Organization in anticipation of covered skilled care;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA20622-9;7;Left against medical advice or discontinued care;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA10325-1;8;Expired;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24245-5;9;Discharged/Transferred to Court/Law Enforcement;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24246-3;10;Discharged/Transferred to a Federal Healthcare Facility;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24247-1;11;Discharged to Hospice - Home care;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24248-9;12;Discharged to Hospice - Facility;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24249-7;13;Discharged/Transferred to a hospital-based Medicare-approved swing-bed;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24250-5;14;Discharged/Transferred to an Inpatient Rehabilitation Facility;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24251-3;15;Discharged/Transferred to a Medicare Certified Long Term Care Hospital;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24252-1;16;Discharged/Transferred to a Nursing facility certified under Medicaid but not certified under Medicare;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24253-9;17;Discharged/Transferred to a Psychiatric Hospital or Psychiatric distinct part unit of a hospital;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24254-7;18;Discharged/Transferred to a Critical Access Hospital (CAH);;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24255-4;19;Discharged/Transferred to another type of healthcare institution not defined elsewhare in this code list;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24256-2;20;Discharged to home or self care with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24257-0;21;Discharged/Transferred to a short-term General Hospital for Inpatient Care with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24258-8;22;Discharged/Transferred to Skilled Nursing Facility with Medicare Certification with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24259-6;23;Discharged/Transferred to a Facility that provides custodial or supportive care with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24260-4;24;Discharged to a Designated Cancer Center or Children's Hospital with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24261-2;25;Discharged/Transferred to home under care of an organized Home Health Service Organization with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24262-0;26;Discharged/Transferred to Court/Law Enforcement with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24263-8;27;Discharged/Transferred to a Federal Healthcare Facility with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24264-6;28;Discharged/Transferred to a hospital-based Medicare-approved swing-bed with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24265-3;29;Discharged/Transferred to an Inpatient Rehabilitation Facility with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24266-1;30;Discharged/Transferred to a Medicare Certified Long Term Care Hospital with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24267-9;31;Discharged/Transferred to a Nursing facility certified under Medicaid but not certified under Medicare with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24268-7;32;Discharged/Transferred to a Psychiatric Hospital or Psychiatric distinct part unit of a hospital with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24269-5;33;Discharged/Transferred to a Critical Access Hospital (CAH) with a planned Acute Care Hospital readmission;;; +78023-9;LL3675-7;[NHCS] Inpatient discharge disposition;LA24270-3;34;Discharged/Transferred to another type of healthcare institution not defined elsewhare in this code list with a planned Acute Care Hospital readmission;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24271-1;1;Return to referring physician/provider;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24277-8;2;Refer to other physician/provider;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24272-9;3;Return in less than 1 week;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24273-7;4;Return in 1 week to less than 2 months;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24275-2;5;Return in 2 months or greater;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24274-5;6;Return at unspecified time;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24276-0;7;Return as needed (p.r.n.);;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24278-6;8;Refer to E.R. for Admission to Hospital;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA46-8;9;Other;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24279-4;10;Routine discharge to customary residence;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24280-2;11;Discharge to observation status;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24281-0;12;Discharge to post-surgical/recovery care facility;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24282-8;13;Admitted to hospital as inpatient;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24324-8;14;Referred to ED;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24283-6;15;Surgery terminated;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24284-4;16;Procedure cancelled on arrival to Ambulatory Surgical Unit;;; +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA4489-6;17;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78025-4;LL3676-5;[NHCS] Outpatient visit discharge disposition;LA24285-1;18;Move to observation/post surgical/recovery area in the same hospital, i.e., not admitted as an inpatient;;; +78028-8;LL3656-7;[NHCS] Surgery 24H post-op follow-up outcomes;LA24214-1;1;Patient unavailable;;; +78028-8;LL3656-7;[NHCS] Surgery 24H post-op follow-up outcomes;LA24215-8;2;No complaints;;; +78028-8;LL3656-7;[NHCS] Surgery 24H post-op follow-up outcomes;LA24216-6;3;Patient reported problems and sought medical care;;; +78028-8;LL3656-7;[NHCS] Surgery 24H post-op follow-up outcomes;LA24217-4;4;Patient reported problems and was advised by ambulatory surgical staff to seek medical care;;; +78028-8;LL3656-7;[NHCS] Surgery 24H post-op follow-up outcomes;LA24218-2;5;Patient reported problems, but no follow-up medical care was needed;;; +78028-8;LL3656-7;[NHCS] Surgery 24H post-op follow-up outcomes;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +78028-8;LL3656-7;[NHCS] Surgery 24H post-op follow-up outcomes;LA46-8;7;Other;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA21297-9;1;Information not available;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24308-1;2;Transfer from a different hospital;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24312-3;3;Transfer from one distinct unit of the hospital to another distinct unit of the hospital resulting in a separate claim to the payer;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24310-7;4;Transfer from jail or court under supervision of law enforcement;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24313-1;5;Transfer from Ambulatory Surgery Center;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24314-9;6;Transfer from a Hospice Facility;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24315-6;7;Transfer from Skilled Nursing Facility;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24316-4;8;Transfer from Intermediate Care Facility;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24317-2;9;Transfer from Assisted Living Facility;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24318-0;10;Clinic;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA4685-9;11;Physician's Office;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24321-4;12;Newborn born inside this hospital;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24322-2;13;Newborn born outside this hospital;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24311-5;14;Transfer from another type of Healthcare facility NOS;;; +78029-6;LL3674-0;[NHCS] Patient point of origin;LA24323-0;15;Non-Healthcare facility point of origin;;; +78033-8;LL5729-0;Length of Stay;LA31441-1;1;<1 day;;; +78033-8;LL5729-0;Length of Stay;LA13943-8;2;1 day;;; +78033-8;LL5729-0;Length of Stay;LA31458-5;3;2 days;;; +78033-8;LL5729-0;Length of Stay;LA31459-3;4;3 days;;; +78033-8;LL5729-0;Length of Stay;LA31442-9;5;4 to 6 days;;; +78033-8;LL5729-0;Length of Stay;LA31443-7;6;7 to 13 days;;; +78033-8;LL5729-0;Length of Stay;LA31444-5;7;>=14 days;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24326-3;1;Prenatal ultrasound;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24327-1;2;Postnatal ultrasound;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24328-9;3;MRI scan;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24329-7;4;CT scan;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24330-5;5;Echocardiogram;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24331-3;6;Electrocardiogram;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24332-1;7;Amniocentesis;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA15393-4;8;Biopsy;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA10388-9;9;Auditory brain stem response;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA10389-7;10;Otoacoustic emissions;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24336-2;11;Bronchoscopy;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA7214-5;12;Cardiac catheterization;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24338-8;13;High-resolution karyotype;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24339-6;14;Molecular genetic testing;;; +78034-6;LL3679-9;Diagnostic Procedures/Tests for Birth Defects;LA24340-4;15;Biochemical testing;;; +78356-3;LL2887-9;Implant Culture;LA21123-7;0;No growth;;; +78356-3;LL2887-9;Implant Culture;LA21120-3;1;S. aureus;;; +78356-3;LL2887-9;Implant Culture;LA21121-1;2;Beta-haemolytic streptococci;;; +78356-3;LL2887-9;Implant Culture;LA20990-0;3;Streptococcus anginosus group;;; +78370-4;LL3683-1;[NCQA] Meets dx thres|Does not meet dx thresh;LA24348-7;1;Meets diagnostic threshold;;; +78370-4;LL3683-1;[NCQA] Meets dx thres|Does not meet dx thresh;LA24349-5;2;Does not meet diagnostic threshold;;; +78382-9;LL1986-0;CFTR gene;LA18306-3;1;c.1521_1523delCTT (deltaF508);;; +78382-9;LL1986-0;CFTR gene;LA18307-1;2;c.579+1G>T (711+1G>T);;; +78382-9;LL1986-0;CFTR gene;LA18308-9;3;c.3528delC (3659delC);;; +78382-9;LL1986-0;CFTR gene;LA18309-7;4;c.3744delA (3876delA);;; +78382-9;LL1986-0;CFTR gene;LA22750-6;5;c.1624G>T;;; +78382-9;LL1986-0;CFTR gene;LA22751-4;6;c.1652G>A;;; +78382-9;LL1986-0;CFTR gene;LA22752-2;7;c.3846G>A;;; +78382-9;LL1986-0;CFTR gene;LA22754-8;8;c.350G>A;;; +78382-9;LL1986-0;CFTR gene;LA22753-0;9;c.3909C>G;;; +78382-9;LL1986-0;CFTR gene;LA22755-5;10;c.1657C>T;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24370-1;1;Escherichia coli extended-spectrum beta-lactamases (ESBL) isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24371-9;2;Pseudomonas aeruginosa multidrug resistant isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24372-7;3;Acinetobacter baumannii isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24373-5;4;Enterobacteriaceae plasmid AMPC isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24374-3;5;Enterobacteriaceae carbapenemase isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24375-0;6;Stenotrophomonas maltophilia isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24553-2;7;Enterobacter cloacae isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24552-4;8;Klebsiella pneumoniae isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24555-7;9;Salmonella enterica isolated;;; +78702-8;LL3691-4;Multiple Drug Resistant Bacilli;LA24554-0;10;Proteus mirabilis isolated;;; +78746-5;LL3663-3;PHVS_BirthCountry_CDC;;0;;;; +78896-8;LL3686-4;Diseased coronary segment categories;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +78896-8;LL3686-4;Diseased coronary segment categories;LA24356-0;1;1 vessel without left main coronary artery;;; +78896-8;LL3686-4;Diseased coronary segment categories;LA24358-6;2;2 vessels without left main coronary artery;;; +78896-8;LL3686-4;Diseased coronary segment categories;LA24360-2;3;3 vessels without left main coronary artery;;; +78896-8;LL3686-4;Diseased coronary segment categories;LA24354-5;4;Left main coronary artery alone;;; +78896-8;LL3686-4;Diseased coronary segment categories;LA24355-2;5;1 vessel and left main coronary artery;;; +78896-8;LL3686-4;Diseased coronary segment categories;LA24357-8;6;2 vessels and left main coronary artery;;; +78896-8;LL3686-4;Diseased coronary segment categories;LA24359-4;7;3 vessels and left main coronary artery;;; +78897-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78897-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78897-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78897-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78897-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78897-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78897-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78898-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78898-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78898-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78898-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78898-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78898-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78898-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78899-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78899-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78899-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78899-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78899-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78899-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78899-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78900-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78900-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78900-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78900-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78900-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78900-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78900-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78901-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78901-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78901-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78901-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78901-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78901-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78901-6;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78902-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78902-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78902-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78902-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78902-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78902-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78902-4;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78903-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78903-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78903-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78903-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78903-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78903-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78903-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78904-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78904-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78904-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78904-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78904-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78904-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78904-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78905-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78905-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78905-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78905-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78905-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78905-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78905-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78906-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78906-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78906-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78906-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78906-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78906-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78906-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78907-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78907-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78907-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78907-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78907-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78907-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78907-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78908-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78908-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78908-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78908-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78908-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78908-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78908-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78909-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78909-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78909-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78909-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78909-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78909-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78909-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78910-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78910-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78910-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78910-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78910-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78910-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78910-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78911-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78911-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78911-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78911-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78911-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78911-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78911-5;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78912-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78912-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78912-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78912-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78912-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78912-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78912-3;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78913-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +78913-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +78913-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +78913-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +78913-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +78913-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +78913-1;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +80227-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +80227-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +80227-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +80227-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +80227-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +80227-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +80227-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +80228-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +80228-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +80228-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +80228-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +80228-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +80228-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +80228-0;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +80229-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +80229-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +80229-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +80229-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +80229-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +80229-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +80229-8;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +80239-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +80239-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +80239-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +80239-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +80239-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +80239-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +80239-7;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +80728-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +80728-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +80728-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +80728-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +80728-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +80728-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +80728-9;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +80915-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15243-1;1;0%;;; +80915-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24352-9;2;1-24%;;; +80915-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24431-1;3;25-49%;;; +80915-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15328-0;4;50-69%;;; +80915-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15329-8;5;70-89%;;; +80915-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA24351-1;6;90-99%;;; +80915-2;LL3685-6;0%|1-24|25-49|50-69|70-89|90-99|100%;LA15253-0;7;100%;;; +78919-8;LL3690-6;Sensory or Speech Status;LA18262-8;0;Aphasia;;; +78919-8;LL3690-6;Sensory or Speech Status;LA24486-5;1;Dysphasia;;; +78919-8;LL3690-6;Sensory or Speech Status;LA24487-3;2;Conductive hearing loss;;; +78919-8;LL3690-6;Sensory or Speech Status;LA24488-1;3;Anosmia;;; +78919-8;LL3690-6;Sensory or Speech Status;LA24489-9;4;Parageusia;;; +78919-8;LL3690-6;Sensory or Speech Status;LA24490-7;5;Acquired night blindness;;; +78919-8;LL3690-6;Sensory or Speech Status;LA24491-5;6;Blindness, bilateral;;; +78937-0;LL3702-9;Cardiac procedure complications;LA20591-6;1;Died/Expired;;; +78937-0;LL3702-9;Cardiac procedure complications;LA14274-7;2;Myocardial infarction;22298006;Myocardial infarction (disorder);http://snomed.info/sct +78937-0;LL3702-9;Cardiac procedure complications;LA24492-3;3;Cardiac tamponade;;; +78937-0;LL3702-9;Cardiac procedure complications;LA17687-7;4;Cardiogenic shock;;; +78937-0;LL3702-9;Cardiac procedure complications;LA24493-1;5;Stent thrombosis (onset prior to discharge);;; +78937-0;LL3702-9;Cardiac procedure complications;LA24494-9;6;Access site hemorrhage requiring blood transfusion;;; +78937-0;LL3702-9;Cardiac procedure complications;LA24495-6;7;Non-access site hemorrhage requiring blood transfusion;;; +78937-0;LL3702-9;Cardiac procedure complications;LA24496-4;8;Emergency surgery;;; +78937-0;LL3702-9;Cardiac procedure complications;LA46-8;9;Other;;; +78945-3;LL3703-7;4 Fr|5 Fr|6 Fr|7 Fr|8 Fr;LA24497-2;1;4 Fr;;; +78945-3;LL3703-7;4 Fr|5 Fr|6 Fr|7 Fr|8 Fr;LA24498-0;2;5 Fr;;; +78945-3;LL3703-7;4 Fr|5 Fr|6 Fr|7 Fr|8 Fr;LA24499-8;3;6 Fr;;; +78945-3;LL3703-7;4 Fr|5 Fr|6 Fr|7 Fr|8 Fr;LA24500-3;4;7 Fr;;; +78945-3;LL3703-7;4 Fr|5 Fr|6 Fr|7 Fr|8 Fr;LA24501-1;5;8 Fr;;; +78972-7;LL5511-2;CYP2C8 genotypes;LA30978-3;12;CYP2C8*1C/*1C;;; +78972-7;LL5511-2;CYP2C8 genotypes;LA30980-9;14;CYP2C8*1/*3;;; +78972-7;LL5511-2;CYP2C8 genotypes;LA30981-7;15;CYP2C8*3/*4;;; +78972-7;LL5511-2;CYP2C8 genotypes;LA30979-1;16;CYP2C8*2/*2;;; +78974-3;LL3709-4;Contrast agent names;LA24536-7;1;Diatrizoate;;; +78974-3;LL3709-4;Contrast agent names;LA24537-5;2;Metrizoate;;; +78974-3;LL3709-4;Contrast agent names;LA24538-3;3;Ioxaglate;;; +78974-3;LL3709-4;Contrast agent names;LA24539-1;4;Iopamidol;;; +78974-3;LL3709-4;Contrast agent names;LA24540-9;5;Iohexol;;; +78974-3;LL3709-4;Contrast agent names;LA24541-7;6;Iodixanol;;; +78975-0;LL3708-6;Contrast agent types;LA24532-6;1;Iodinated, ionic, high-osmolar;;; +78975-0;LL3708-6;Contrast agent types;LA24535-9;2;Iodinated, ionic, low-osmolar;;; +78975-0;LL3708-6;Contrast agent types;LA24534-2;3;Iodinated, non-ionic, iso-osmolar;;; +78975-0;LL3708-6;Contrast agent types;LA24533-4;4;Iodinated, non-ionic, low-osmolar;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24432-9;1;Stable angina;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24433-7;2;Unstable angina;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24434-5;3;Non-ST-segment elevation myocardial infarction (NSTEMI);;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24436-0;4;ST-segment elevation myocardial infarction (STEMI);;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24435-2;5;Silent myocardial ischemia;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA20365-5;6;History of myocardial infarction;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA17719-8;7;Ventricular tachycardia;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24542-5;8;Acute heart failure;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA20080-0;9;Cyanotic congenital heart disease;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA22210-1;10;Vascular aneurysms;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA7432-3;11;Endocarditis;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA25773-5;12;Myocarditis;;; +78976-8;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA28658-5;13;Staged percutaneous coronary intervention (PCI);;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24432-9;1;Stable angina;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24433-7;2;Unstable angina;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24434-5;3;Non-ST-segment elevation myocardial infarction (NSTEMI);;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24436-0;4;ST-segment elevation myocardial infarction (STEMI);;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24435-2;5;Silent myocardial ischemia;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA20365-5;6;History of myocardial infarction;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA17719-8;7;Ventricular tachycardia;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA24542-5;8;Acute heart failure;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA20080-0;9;Cyanotic congenital heart disease;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA22210-1;10;Vascular aneurysms;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA7432-3;11;Endocarditis;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA25773-5;12;Myocarditis;;; +80258-7;LL3695-5;[JCS] Ischemic heart disease diagnoses;LA28658-5;13;Staged percutaneous coronary intervention (PCI);;; +79105-3;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79105-3;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79106-1;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79106-1;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79107-9;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79107-9;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79108-7;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79108-7;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79109-5;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79109-5;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79110-3;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79110-3;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79111-1;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79111-1;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79112-9;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79112-9;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79113-7;LL3716-9;Correct (1)|Incorrect (0);LA9960-1;1;Correct;;; +79113-7;LL3716-9;Correct (1)|Incorrect (0);LA7342-4;2;Incorrect;;; +79118-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79118-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79118-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +79118-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA4543-0;4;;;; +79119-4;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79119-4;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79119-4;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +79119-4;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA4543-0;4;;;; +79120-2;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79120-2;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79120-2;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +79120-2;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA4543-0;4;;;; +79121-0;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79121-0;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79121-0;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +79121-0;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA4543-0;4;;;; +79122-8;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79122-8;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79122-8;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +79122-8;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA4543-0;4;;;; +79123-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79123-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +79123-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +79123-6;LL3718-5;Yes (0)|No (1)|Don't Know (1)|N/A (1);LA4543-0;4;;;; +79140-0;LL3682-3;Neg|Will Follow;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79140-0;LL3682-3;Neg|Will Follow;LA24347-9;1;Positive screen. Confirmatory result to follow;;; +79146-7;LL3682-3;Neg|Will Follow;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +79146-7;LL3682-3;Neg|Will Follow;LA24347-9;1;Positive screen. Confirmatory result to follow;;; +79151-7;LL3720-1;NEMSIS_eHistory.07;;0;;;; +79177-2;LL3696-3;C difficile glutamate dehydrogenase & toxins A+B;LA24437-8;1;Positive for C. difficile glutamate dehydrogenase and negative for toxins A+B;;; +79177-2;LL3696-3;C difficile glutamate dehydrogenase & toxins A+B;LA24438-6;2;Positive for C. difficile glutamate dehydrogenase and toxins A+B;;; +79177-2;LL3696-3;C difficile glutamate dehydrogenase & toxins A+B;LA24455-0;3;Negative for C. difficile glutamate dehydrogenase and toxins A+B;;; +79177-2;LL3696-3;C difficile glutamate dehydrogenase & toxins A+B;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +79177-2;LL3696-3;C difficile glutamate dehydrogenase & toxins A+B;LA24439-4;5;Indeterminate. Negative for C. difficile glutamate dehydrogenase, Positive for toxins A+B;;; +79211-9;LL3710-2;Aneuploidy risk;LA24543-3;1;No aneuploidy;;; +79211-9;LL3710-2;Aneuploidy risk;LA24544-1;2;Increased risk;;; +79212-7;LL3711-0;Not detected|Increased risk;LA11883-8;1;Not detected;;; +79212-7;LL3711-0;Not detected|Increased risk;LA24544-1;2;Increased risk;;; +79390-1;LL3717-7;Enteric pathogens detected;LA24556-5;1;Campylobacter;;; +79390-1;LL3717-7;Enteric pathogens detected;LA24557-3;2;Salmonella;;; +79390-1;LL3717-7;Enteric pathogens detected;LA24558-1;3;Shigella/EIEC;;; +79390-1;LL3717-7;Enteric pathogens detected;LA24564-9;4;Vibrio cholerae and/or parahaemolyticus;;; +79390-1;LL3717-7;Enteric pathogens detected;LA19324-5;5;Yersinia enterocolitica;65255000;Yersinia enterocolitica (organism);http://snomed.info/sct +79390-1;LL3717-7;Enteric pathogens detected;LA16137-4;6;Shiga toxin 1;;; +79390-1;LL3717-7;Enteric pathogens detected;LA16138-2;7;Shiga toxin 2;;; +79390-1;LL3717-7;Enteric pathogens detected;LA24561-5;8;Norovirus;;; +79390-1;LL3717-7;Enteric pathogens detected;LA24562-3;9;Adenovirus;;; +79390-1;LL3717-7;Enteric pathogens detected;LA18553-0;10;Rotavirus A;;; +88516-0;LL3717-7;Enteric pathogens detected;LA24556-5;1;Campylobacter;;; +88516-0;LL3717-7;Enteric pathogens detected;LA24557-3;2;Salmonella;;; +88516-0;LL3717-7;Enteric pathogens detected;LA24558-1;3;Shigella/EIEC;;; +88516-0;LL3717-7;Enteric pathogens detected;LA24564-9;4;Vibrio cholerae and/or parahaemolyticus;;; +88516-0;LL3717-7;Enteric pathogens detected;LA19324-5;5;Yersinia enterocolitica;65255000;Yersinia enterocolitica (organism);http://snomed.info/sct +88516-0;LL3717-7;Enteric pathogens detected;LA16137-4;6;Shiga toxin 1;;; +88516-0;LL3717-7;Enteric pathogens detected;LA16138-2;7;Shiga toxin 2;;; +88516-0;LL3717-7;Enteric pathogens detected;LA24561-5;8;Norovirus;;; +88516-0;LL3717-7;Enteric pathogens detected;LA24562-3;9;Adenovirus;;; +88516-0;LL3717-7;Enteric pathogens detected;LA18553-0;10;Rotavirus A;;; +79566-6;LL3860-5;DBS collection method;LA25402-1;1;Heel stick;;; +79566-6;LL3860-5;DBS collection method;LA25403-9;2;Capillary tube;;; +79566-6;LL3860-5;DBS collection method;LA25404-7;3;Line draw;;; +79566-6;LL3860-5;DBS collection method;LA46-8;4;Other;;; +79566-6;LL3860-5;DBS collection method;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79568-2;LL3861-3;Example ABCD1 gene variants;LA25405-4;1;c.1415_1416delAG;;; +79568-2;LL3861-3;Example ABCD1 gene variants;LA25406-2;2;c.871G>A;;; +79568-2;LL3861-3;Example ABCD1 gene variants;LA25407-0;3;c.1165C>T;;; +79568-2;LL3861-3;Example ABCD1 gene variants;LA25408-8;4;c.1202G>A;;; +79569-0;LL3859-7;Blood products;LA25396-5;1;Blood product transfusion that includes Red Blood Cells (RBC);;; +79569-0;LL3859-7;Blood products;LA25397-3;2;Blood product transfusion that does NOT include Red Blood Cells (RBC);;; +79569-0;LL3859-7;Blood products;LA25398-1;3;Extracorporeal life support (ECLS)/Extracorporeal membrane oxygenation (ECMO);;; +79569-0;LL3859-7;Blood products;LA25399-9;4;Intrauterine Fetal Blood Transfusion that includes Red Blood Cells (RBC);;; +79569-0;LL3859-7;Blood products;LA25400-5;5;Intrauterine Fetal Blood Transfusion that does not includes Red Blood Cells (RBC);;; +79569-0;LL3859-7;Blood products;LA25401-3;6;Other blood product transfusion;;; +79722-5;LL3858-9;[CPIC func act] Increased|Nl|Decreased|Poor;LA25392-4;1;Increased function;;; +79722-5;LL3858-9;[CPIC func act] Increased|Nl|Decreased|Poor;LA25393-2;2;Normal function;;; +79722-5;LL3858-9;[CPIC func act] Increased|Nl|Decreased|Poor;LA25395-7;3;Decreased function;;; +79722-5;LL3858-9;[CPIC func act] Increased|Nl|Decreased|Poor;LA25394-0;4;Poor function;;; +79725-8;LL3722-7;[NEI] Amblyopia type;LA24816-3;1;None / absent;;; +79725-8;LL3722-7;[NEI] Amblyopia type;LA24631-6;2;Anisometropic;;; +79725-8;LL3722-7;[NEI] Amblyopia type;LA11840-8;3;Mixed;;; +79725-8;LL3722-7;[NEI] Amblyopia type;LA24905-4;4;Strabismic;;; +79725-8;LL3722-7;[NEI] Amblyopia type;LA46-8;5;Other;;; +79725-8;LL3722-7;[NEI] Amblyopia type;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79725-8;LL3722-7;[NEI] Amblyopia type;LA4720-4;7;Not applicable;;; +79728-2;LL3723-5;[NEI] Coloboma location;LA25448-4;1;Eyelid;;; +79728-2;LL3723-5;[NEI] Coloboma location;LA24762-9;2;Iris;;; +79728-2;LL3723-5;[NEI] Coloboma location;LA25447-6;3;Lens;;; +79728-2;LL3723-5;[NEI] Coloboma location;LA24828-8;4;Optic nerve;;; +79728-2;LL3723-5;[NEI] Coloboma location;LA24874-2;5;Retina/choroid;;; +79728-2;LL3723-5;[NEI] Coloboma location;LA46-8;6;Other;;; +79728-2;LL3723-5;[NEI] Coloboma location;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79729-0;LL3723-5;[NEI] Coloboma location;LA25448-4;1;Eyelid;;; +79729-0;LL3723-5;[NEI] Coloboma location;LA24762-9;2;Iris;;; +79729-0;LL3723-5;[NEI] Coloboma location;LA25447-6;3;Lens;;; +79729-0;LL3723-5;[NEI] Coloboma location;LA24828-8;4;Optic nerve;;; +79729-0;LL3723-5;[NEI] Coloboma location;LA24874-2;5;Retina/choroid;;; +79729-0;LL3723-5;[NEI] Coloboma location;LA46-8;6;Other;;; +79729-0;LL3723-5;[NEI] Coloboma location;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79730-8;LL3724-3;[NEI] Color vision findings;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +79730-8;LL3724-3;[NEI] Color vision findings;LA24869-2;2;Red-green defect;;; +79730-8;LL3724-3;[NEI] Color vision findings;LA24648-0;3;Blue-yellow defect;;; +79730-8;LL3724-3;[NEI] Color vision findings;LA24817-1;4;Non-specific defect;;; +79730-8;LL3724-3;[NEI] Color vision findings;LA46-8;5;Other;;; +79730-8;LL3724-3;[NEI] Color vision findings;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79730-8;LL3724-3;[NEI] Color vision findings;LA13538-6;7;Not tested;;; +79731-6;LL3724-3;[NEI] Color vision findings;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +79731-6;LL3724-3;[NEI] Color vision findings;LA24869-2;2;Red-green defect;;; +79731-6;LL3724-3;[NEI] Color vision findings;LA24648-0;3;Blue-yellow defect;;; +79731-6;LL3724-3;[NEI] Color vision findings;LA24817-1;4;Non-specific defect;;; +79731-6;LL3724-3;[NEI] Color vision findings;LA46-8;5;Other;;; +79731-6;LL3724-3;[NEI] Color vision findings;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79731-6;LL3724-3;[NEI] Color vision findings;LA13538-6;7;Not tested;;; +79732-4;LL3725-0;[NEI] Color vision test method;LA25450-0;1;Cambridge color test;;; +79732-4;LL3725-0;[NEI] Color vision test method;LA24723-1;2;Farnsworth D-15 dichotomous;;; +79732-4;LL3725-0;[NEI] Color vision test method;LA24724-9;3;Farnsworth-Munsell 100 hue test;;; +79732-4;LL3725-0;[NEI] Color vision test method;LA24745-4;4;HRR color test;;; +79732-4;LL3725-0;[NEI] Color vision test method;LA24766-0;5;Ishihara pseudochromatic plates;;; +79732-4;LL3725-0;[NEI] Color vision test method;LA46-8;6;Other;;; +79732-4;LL3725-0;[NEI] Color vision test method;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79733-2;LL3726-8;Normal|Abnormal_specify|UNK;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +79733-2;LL3726-8;Normal|Abnormal_specify|UNK;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +79733-2;LL3726-8;Normal|Abnormal_specify|UNK;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA24811-4;1;No evidence of myopathy;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA24621-7;2;Abnormal ECG;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA24622-5;3;Abnormal EMG;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA24772-8;4;Lactic acidosis in blood;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA24773-6;5;Lactic acidosis in CSF;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA24867-6;6;Ragged red fibers absent on muscle biopsy;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA24866-8;7;Ragged red fibers present on muscle biopsy;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA25446-8;8;Other abnormality on muscle biopsy;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA46-8;9;Other;;; +79735-7;LL3727-6;[NEI] Findings supporting myopathy;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA24668-8;1;Congenital fibrosis of the extraocular muscles (CFEOM);;; +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA24703-3;2;Duane-radial ray syndrome;;; +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA24702-5;3;Duane syndrome retraction;;; +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA24743-9;4;Horizontal gaze palsy with progressive scoliosis (HGPPS);;; +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA24744-7;5;HOXA1 syndromes (BSAS and ABDS);;; +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA24796-7;6;Moebius syndrome;;; +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA46-8;7;Other;;; +79736-5;LL3728-4;[NEI] Type of congenital cranial dysinnervation (C;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79737-3;LL3729-2;[NEI] Gross eye defects;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79737-3;LL3729-2;[NEI] Gross eye defects;LA24632-4;2;Anopthalmia;;; +79737-3;LL3729-2;[NEI] Gross eye defects;LA24794-2;3;Microphthalmia;;; +79737-3;LL3729-2;[NEI] Gross eye defects;LA24802-3;4;Nanophthalmos;;; +79737-3;LL3729-2;[NEI] Gross eye defects;LA24939-3;5;Uveal coloboma;;; +79737-3;LL3729-2;[NEI] Gross eye defects;LA46-8;6;Other;;; +79737-3;LL3729-2;[NEI] Gross eye defects;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79738-1;LL3729-2;[NEI] Gross eye defects;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79738-1;LL3729-2;[NEI] Gross eye defects;LA24632-4;2;Anopthalmia;;; +79738-1;LL3729-2;[NEI] Gross eye defects;LA24794-2;3;Microphthalmia;;; +79738-1;LL3729-2;[NEI] Gross eye defects;LA24802-3;4;Nanophthalmos;;; +79738-1;LL3729-2;[NEI] Gross eye defects;LA24939-3;5;Uveal coloboma;;; +79738-1;LL3729-2;[NEI] Gross eye defects;LA46-8;6;Other;;; +79738-1;LL3729-2;[NEI] Gross eye defects;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79741-5;LL3730-0;[NEI] Eye-related MRI findings;LA24654-8;1;Normal brain MRI;;; +79741-5;LL3730-0;[NEI] Eye-related MRI findings;LA24655-5;2;Abnormal brain MRI;;; +79741-5;LL3730-0;[NEI] Eye-related MRI findings;LA24717-3;3;Abnormal orbit(s)/optic nerve(s);;; +79741-5;LL3730-0;[NEI] Eye-related MRI findings;LA46-8;4;Other;;; +79741-5;LL3730-0;[NEI] Eye-related MRI findings;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA24640-7;1;Autosomal dominant;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA24641-5;2;Autosomal recessive;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA24789-2;3;Mitochondrial;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA24949-2;4;Isolated;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA24947-6;5;X-linked;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA24812-2;6;No family history of disease and no other systemic findings;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA46-8;7;Other;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA21413-2;8;No information;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA4720-4;9;Not applicable;;; +79742-3;LL3731-8;[NEI] Inheritance pattern from family history;LA24722-3;10;Family history is unknown or not recorded;;; +79743-1;LL3732-6;[NEI] International classification (ABC) of intra;LA24815-5;1;No tumor;;; +79743-1;LL3732-6;[NEI] International classification (ABC) of intra;LA19710-5;2;Group A;112144000;Blood group A (finding);http://snomed.info/sct +79743-1;LL3732-6;[NEI] International classification (ABC) of intra;LA19709-7;3;Group B;112149005;Blood group B (finding);http://snomed.info/sct +79743-1;LL3732-6;[NEI] International classification (ABC) of intra;LA24737-1;4;Group C;;; +79743-1;LL3732-6;[NEI] International classification (ABC) of intra;LA24738-9;5;Group D;;; +79743-1;LL3732-6;[NEI] International classification (ABC) of intra;LA24739-7;6;Group E;;; +79743-1;LL3732-6;[NEI] International classification (ABC) of intra;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79744-9;LL3732-6;[NEI] International classification (ABC) of intra;LA24815-5;1;No tumor;;; +79744-9;LL3732-6;[NEI] International classification (ABC) of intra;LA19710-5;2;Group A;112144000;Blood group A (finding);http://snomed.info/sct +79744-9;LL3732-6;[NEI] International classification (ABC) of intra;LA19709-7;3;Group B;112149005;Blood group B (finding);http://snomed.info/sct +79744-9;LL3732-6;[NEI] International classification (ABC) of intra;LA24737-1;4;Group C;;; +79744-9;LL3732-6;[NEI] International classification (ABC) of intra;LA24738-9;5;Group D;;; +79744-9;LL3732-6;[NEI] International classification (ABC) of intra;LA24739-7;6;Group E;;; +79744-9;LL3732-6;[NEI] International classification (ABC) of intra;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79745-6;LL3732-6;[NEI] International classification (ABC) of intra;LA24815-5;1;No tumor;;; +79745-6;LL3732-6;[NEI] International classification (ABC) of intra;LA19710-5;2;Group A;112144000;Blood group A (finding);http://snomed.info/sct +79745-6;LL3732-6;[NEI] International classification (ABC) of intra;LA19709-7;3;Group B;112149005;Blood group B (finding);http://snomed.info/sct +79745-6;LL3732-6;[NEI] International classification (ABC) of intra;LA24737-1;4;Group C;;; +79745-6;LL3732-6;[NEI] International classification (ABC) of intra;LA24738-9;5;Group D;;; +79745-6;LL3732-6;[NEI] International classification (ABC) of intra;LA24739-7;6;Group E;;; +79745-6;LL3732-6;[NEI] International classification (ABC) of intra;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79746-4;LL3732-6;[NEI] International classification (ABC) of intra;LA24815-5;1;No tumor;;; +79746-4;LL3732-6;[NEI] International classification (ABC) of intra;LA19710-5;2;Group A;112144000;Blood group A (finding);http://snomed.info/sct +79746-4;LL3732-6;[NEI] International classification (ABC) of intra;LA19709-7;3;Group B;112149005;Blood group B (finding);http://snomed.info/sct +79746-4;LL3732-6;[NEI] International classification (ABC) of intra;LA24737-1;4;Group C;;; +79746-4;LL3732-6;[NEI] International classification (ABC) of intra;LA24738-9;5;Group D;;; +79746-4;LL3732-6;[NEI] International classification (ABC) of intra;LA24739-7;6;Group E;;; +79746-4;LL3732-6;[NEI] International classification (ABC) of intra;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79747-2;LL3733-4;[NEI] International classification for extraocular;LA4323-7;0;Stage 0;;; +79747-2;LL3733-4;[NEI] International classification for extraocular;LA3664-5;1;Stage I;;; +79747-2;LL3733-4;[NEI] International classification for extraocular;LA3661-1;2;Stage II;;; +79747-2;LL3733-4;[NEI] International classification for extraocular;LA3657-9;3;Stage III;;; +79747-2;LL3733-4;[NEI] International classification for extraocular;LA3651-2;4;Stage IV;;; +79747-2;LL3733-4;[NEI] International classification for extraocular;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79748-0;LL3733-4;[NEI] International classification for extraocular;LA4323-7;0;Stage 0;;; +79748-0;LL3733-4;[NEI] International classification for extraocular;LA3664-5;1;Stage I;;; +79748-0;LL3733-4;[NEI] International classification for extraocular;LA3661-1;2;Stage II;;; +79748-0;LL3733-4;[NEI] International classification for extraocular;LA3657-9;3;Stage III;;; +79748-0;LL3733-4;[NEI] International classification for extraocular;LA3651-2;4;Stage IV;;; +79748-0;LL3733-4;[NEI] International classification for extraocular;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79749-8;LL3789-6;No|Yes, please specify;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +79749-8;LL3789-6;No|Yes, please specify;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79750-6;LL3789-6;No|Yes, please specify;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +79750-6;LL3789-6;No|Yes, please specify;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79752-2;LL3734-2;[NEI] Oculary history;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79752-2;LL3734-2;[NEI] Oculary history;LA24635-7;2;Astigmatism;;; +79752-2;LL3734-2;[NEI] Oculary history;LA24676-1;3;Corneal erosions, recurrent;;; +79752-2;LL3734-2;[NEI] Oculary history;LA24690-2;4;Decrease in best corrected visual acuity;;; +79752-2;LL3734-2;[NEI] Oculary history;LA24734-8;5;Glare causing decrease in acuity;;; +79752-2;LL3734-2;[NEI] Oculary history;LA7449-7;6;Irritation;;; +79752-2;LL3734-2;[NEI] Oculary history;LA7460-4;7;Pain;;; +79752-2;LL3734-2;[NEI] Oculary history;LA24849-4;8;Photophobia;;; +79752-2;LL3734-2;[NEI] Oculary history;LA24912-0;9;Sudden onset of vision loss;;; +79752-2;LL3734-2;[NEI] Oculary history;LA24921-1;10;Excessive tearing (watery eyes);;; +79752-2;LL3734-2;[NEI] Oculary history;LA25477-3;11;Retinal tear;;; +79752-2;LL3734-2;[NEI] Oculary history;LA46-8;12;Other;;; +79753-0;LL3734-2;[NEI] Oculary history;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79753-0;LL3734-2;[NEI] Oculary history;LA24635-7;2;Astigmatism;;; +79753-0;LL3734-2;[NEI] Oculary history;LA24676-1;3;Corneal erosions, recurrent;;; +79753-0;LL3734-2;[NEI] Oculary history;LA24690-2;4;Decrease in best corrected visual acuity;;; +79753-0;LL3734-2;[NEI] Oculary history;LA24734-8;5;Glare causing decrease in acuity;;; +79753-0;LL3734-2;[NEI] Oculary history;LA7449-7;6;Irritation;;; +79753-0;LL3734-2;[NEI] Oculary history;LA7460-4;7;Pain;;; +79753-0;LL3734-2;[NEI] Oculary history;LA24849-4;8;Photophobia;;; +79753-0;LL3734-2;[NEI] Oculary history;LA24912-0;9;Sudden onset of vision loss;;; +79753-0;LL3734-2;[NEI] Oculary history;LA24921-1;10;Excessive tearing (watery eyes);;; +79753-0;LL3734-2;[NEI] Oculary history;LA25477-3;11;Retinal tear;;; +79753-0;LL3734-2;[NEI] Oculary history;LA46-8;12;Other;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA24643-1;1;Avellino;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA25445-0;2;Fuchs;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA15816-4;3;Granular;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA24777-7;4;Lattice;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA24790-0;5;Meesman;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA24870-0;6;Reis bucklers;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA24927-8;7;Thiel-behnke;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA46-8;8;Other;;; +79754-8;LL3735-9;[NEI] Corneal dystrophy type;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA6172-6;2;Chemotherapy;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24680-3;3;Cryotherapy;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24710-8;4;Enucleation;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24715-7;5;Excimer laser phototherapeutic keratectomy;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24774-4;6;Lamellar keratectomy;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA16341-2;7;Laser;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24824-7;8;Nystagmus surgery;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA14706-8;9;Patching;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24841-1;10;Penetrating keratoplasty;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24859-3;11;Prisms;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24863-5;12;Ptosis surgery;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24901-3;13;Spectacles;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24907-0;14;Strabismus surgery;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24913-8;15;Superficial keratectomy;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24946-8;16;X ray therapy;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24832-0;17;Other medication;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24833-8;18;Other surgery;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24835-3;19;Other unlisted treatment;;; +79755-5;LL3736-7;[NEI] Previous ophthalmologic treatment;LA4489-6;20;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA6172-6;2;Chemotherapy;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24680-3;3;Cryotherapy;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24710-8;4;Enucleation;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24715-7;5;Excimer laser phototherapeutic keratectomy;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24774-4;6;Lamellar keratectomy;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA16341-2;7;Laser;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24824-7;8;Nystagmus surgery;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA14706-8;9;Patching;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24841-1;10;Penetrating keratoplasty;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24859-3;11;Prisms;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24863-5;12;Ptosis surgery;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24901-3;13;Spectacles;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24907-0;14;Strabismus surgery;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24913-8;15;Superficial keratectomy;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24946-8;16;X ray therapy;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24832-0;17;Other medication;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24833-8;18;Other surgery;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA24835-3;19;Other unlisted treatment;;; +79756-3;LL3736-7;[NEI] Previous ophthalmologic treatment;LA4489-6;20;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79757-1;LL3737-5;No|Yes_please describe test and result;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +79757-1;LL3737-5;No|Yes_please describe test and result;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +79758-9;LL3870-4;[NEI] Progression of problem;LA25478-1;1;Progressive;;; +79758-9;LL3870-4;[NEI] Progression of problem;LA25479-9;2;Nonprogressive/congenital;;; +79758-9;LL3870-4;[NEI] Progression of problem;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79759-7;LL3738-3;[NEI] Strabismus type;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79759-7;LL3738-3;[NEI] Strabismus type;LA24620-9;2;A pattern;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24627-4;3;Accomodative;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24663-9;4;Comitant;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24697-7;5;Dissociated vertical deviation;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24753-8;6;Incomitant;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24760-3;7;Intermittent;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA25436-9;8;Left esophoria;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24779-3;9;Left esotropia;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24780-1;10;Left exotropia;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24781-9;11;Left hypertropia (right hypotropia);;; +79759-7;LL3738-3;[NEI] Strabismus type;LA25435-1;12;Right esophoria;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24881-7;13;Right esotropia;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24882-5;14;Right exotropia;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24883-3;15;Right hypertropia (left hypotropia);;; +79759-7;LL3738-3;[NEI] Strabismus type;LA24940-1;16;V pattern;;; +79759-7;LL3738-3;[NEI] Strabismus type;LA46-8;17;Other;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24636-5;2;Ataxia;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24638-1;3;Autism;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24650-6;4;Cardiac defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24660-5;5;Cleft lip or palate;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24682-9;6;CSF protein (>100mg/dl);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24691-0;7;Decreased bone density;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24693-6;8;Delayed motor milestones;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA20372-1;9;Dementia;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA22265-5;10;Pediatric: Developmental delay;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA14291-1;11;Diabetes mellitus;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24705-8;12;Dystonia;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24714-0;13;Esophageal defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24720-7;14;Facial weakness;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24730-6;15;Gastrointestinal defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24731-4;16;Gastrointestinal symptoms, recurrent;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24733-0;17;Genitourinary defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24741-3;18;Headache, recurrent;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24742-1;19;Hearing defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24751-2;20;Hypotonia;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24759-5;21;Intellectual disabilities;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24771-0;22;Klippel-feil;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24778-5;23;Learning disability;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24785-0;24;Limb malformations;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24786-8;25;Limb weakness;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24801-5;26;Myoclonus;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24851-0;27;Pigmentation of skin different from other family members;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA25437-7;28;Polydactyly (digit abnormalities);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24872-6;29;Renal defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24873-4;30;Renal tubular dysfunction (Fanconi type);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA22278-8;31;Scoliosis;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24892-4;32;Seizures (history of, or treated);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24894-0;33;Short stature;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24895-7;34;Skeletal defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24908-8;35;Stroke-like episodes associated with seizures;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24922-9;36;Teeth defect(s);;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA24936-9;37;Umbilical abnormalities;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA46-8;38;Other;;; +79760-5;LL3739-1;[NEI] Ophthalmologic disease related systemic find;LA4489-6;39;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79764-7;LL3742-5;[NEI] Tonometer device type;LA24732-2;1;GAT- Goldmann applanation tonometer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24838-7;2;PAT - Perkins applanation tonometer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24920-3;3;TAT - Tono-Pen applanation tonometer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24829-6;4;ORA - Ocular Response Analyzer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24804-9;5;NCT - Non-contact tonometer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24689-4;6;DCT - Dynamic Contour Tonometer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24861-9;7;PT - Pneumatonometer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24857-7;8;PPT- Phosphene tonometer;;; +79764-7;LL3742-5;[NEI] Tonometer device type;LA24834-6;9;Other tonometer;;; +79765-4;LL3743-3;[NEI] Ocular alignment findings;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +79765-4;LL3743-3;[NEI] Ocular alignment findings;LA24713-2;2;Esodeviation;;; +79765-4;LL3743-3;[NEI] Ocular alignment findings;LA24716-5;3;Exodeviation;;; +79765-4;LL3743-3;[NEI] Ocular alignment findings;LA24747-0;4;Hyperdeviation;;; +79765-4;LL3743-3;[NEI] Ocular alignment findings;LA24749-6;5;Hypodeviation;;; +79765-4;LL3743-3;[NEI] Ocular alignment findings;LA24830-4;6;Ortho;;; +79765-4;LL3743-3;[NEI] Ocular alignment findings;LA46-8;7;Other;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA24814-8;1;No null position;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA25449-2;2;Central null position;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA24656-3;3;Chin down;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA24657-1;4;Chin up;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA24718-1;5;Face turns to the left;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA24719-9;6;Face turns to the right;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA24929-4;7;Tilting of the head to the right;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA24930-2;8;Tilting the head to the left;;; +79766-2;LL3744-1;[NEI] Nystagmus null-point head posture;LA46-8;9;Other;;; +79767-0;LL3745-8;[NEI] Nystagmus frequency;LA24898-1;1;Slow;;; +79767-0;LL3745-8;[NEI] Nystagmus frequency;LA8982-6;2;Medium;;; +79767-0;LL3745-8;[NEI] Nystagmus frequency;LA24868-4;3;Rapid;;; +79768-8;LL3746-6;[NEI] Whole mount exam findings;LA24626-6;1;Absent platelet dense bodies;;; +79768-8;LL3746-6;[NEI] Whole mount exam findings;LA24858-5;2;Present platelet dense bodies;;; +79768-8;LL3746-6;[NEI] Whole mount exam findings;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79771-2;LL3790-4;Normal|Abnormal_specify|Not performed;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +79771-2;LL3790-4;Normal|Abnormal_specify|Not performed;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +79771-2;LL3790-4;Normal|Abnormal_specify|Not performed;LA7304-4;3;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79772-0;LL3790-4;Normal|Abnormal_specify|Not performed;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +79772-0;LL3790-4;Normal|Abnormal_specify|Not performed;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +79772-0;LL3790-4;Normal|Abnormal_specify|Not performed;LA7304-4;3;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79789-4;LL3747-4;[NEI] Oscillatory potentials findings;LA24831-2;1;Oscillatory potentials present;;; +79789-4;LL3747-4;[NEI] Oscillatory potentials findings;LA24567-2;2;Oscillatory potentials absent;;; +79789-4;LL3747-4;[NEI] Oscillatory potentials findings;LA24570-6;3;Waveform normal;;; +79789-4;LL3747-4;[NEI] Oscillatory potentials findings;LA24569-8;4;Waveform abnormal;;; +79789-4;LL3747-4;[NEI] Oscillatory potentials findings;LA46-8;5;Other;;; +79790-2;LL3747-4;[NEI] Oscillatory potentials findings;LA24831-2;1;Oscillatory potentials present;;; +79790-2;LL3747-4;[NEI] Oscillatory potentials findings;LA24567-2;2;Oscillatory potentials absent;;; +79790-2;LL3747-4;[NEI] Oscillatory potentials findings;LA24570-6;3;Waveform normal;;; +79790-2;LL3747-4;[NEI] Oscillatory potentials findings;LA24569-8;4;Waveform abnormal;;; +79790-2;LL3747-4;[NEI] Oscillatory potentials findings;LA46-8;5;Other;;; +79791-0;LL3748-2;[NEI] Reference electrode location;LA24706-6;1;Earlobe;;; +79791-0;LL3748-2;[NEI] Reference electrode location;LA24788-4;2;Mastoid;;; +79791-0;LL3748-2;[NEI] Reference electrode location;LA24727-2;3;Forehead;;; +79791-0;LL3748-2;[NEI] Reference electrode location;LA46-8;4;Other;;; +79792-8;LL3749-0;[NEI] Electroretinogram findings;LA24818-9;1;Normal full-field results;;; +79792-8;LL3749-0;[NEI] Electroretinogram findings;LA24623-3;2;Abnormal full-field results;;; +79792-8;LL3749-0;[NEI] Electroretinogram findings;LA24819-7;3;Normal multifocal results;;; +79792-8;LL3749-0;[NEI] Electroretinogram findings;LA24624-1;4;Abnormal multifocal results;;; +79792-8;LL3749-0;[NEI] Electroretinogram findings;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79793-6;LL3749-0;[NEI] Electroretinogram findings;LA24818-9;1;Normal full-field results;;; +79793-6;LL3749-0;[NEI] Electroretinogram findings;LA24623-3;2;Abnormal full-field results;;; +79793-6;LL3749-0;[NEI] Electroretinogram findings;LA24819-7;3;Normal multifocal results;;; +79793-6;LL3749-0;[NEI] Electroretinogram findings;LA24624-1;4;Abnormal multifocal results;;; +79793-6;LL3749-0;[NEI] Electroretinogram findings;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79794-4;LL3750-8;[NEI] ERG procedure standard followed;LA24615-9;1;2015 ISCEV standard;;; +79794-4;LL3750-8;[NEI] ERG procedure standard followed;LA24614-2;2;2012 ISCEV standard;;; +79794-4;LL3750-8;[NEI] ERG procedure standard followed;LA24695-1;3;Did nof follow specific standard;;; +79794-4;LL3750-8;[NEI] ERG procedure standard followed;LA46-8;4;Other;;; +79794-4;LL3750-8;[NEI] ERG procedure standard followed;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79799-3;LL3751-6;[NEI] ERG vendor and model used;LA24694-4;1;Diagnosys;;; +79799-3;LL3751-6;[NEI] ERG vendor and model used;LA24708-2;2;Electro-Diagnostic Imaging;;; +79799-3;LL3751-6;[NEI] ERG vendor and model used;LA24791-8;3;Metrovision;;; +79799-3;LL3751-6;[NEI] ERG vendor and model used;LA24808-0;4;Neuro-ERG;;; +79799-3;LL3751-6;[NEI] ERG vendor and model used;LA46-8;5;Other;;; +79800-9;LL3752-4;[NEI] ISCEV standard protocol used;LA24685-2;1;Dark-adapted 0.01 ERG (rod ERG);;; +79800-9;LL3752-4;[NEI] ISCEV standard protocol used;LA24687-8;2;Dark-adapted 3 ERG (combined rod-cone standard flash ERG);;; +79800-9;LL3752-4;[NEI] ISCEV standard protocol used;LA24686-0;3;Dark-adapted 10 ERG (strong flash ERG);;; +79800-9;LL3752-4;[NEI] ISCEV standard protocol used;LA24688-6;4;Dark-adapted 3 oscillatory potentials;;; +79800-9;LL3752-4;[NEI] ISCEV standard protocol used;LA24783-5;5;"Light-adapted 3 ERG (standard flash ""cone"" ERG)";;; +79800-9;LL3752-4;[NEI] ISCEV standard protocol used;LA24784-3;6;Light-adapted 30 Hz flicker ERG;;; +79800-9;LL3752-4;[NEI] ISCEV standard protocol used;LA46-8;7;Other;;; +79801-7;LL3753-2;[NEI] Recording electrode type;LA14750-6;1;Contact lenses;;; +79801-7;LL3753-2;[NEI] Recording electrode type;LA24666-2;2;Conductive fibers and foils;;; +79801-7;LL3753-2;[NEI] Recording electrode type;LA24670-4;3;Conjunctival wire loops;;; +79801-7;LL3753-2;[NEI] Recording electrode type;LA24677-9;4;Corneal wicks;;; +79801-7;LL3753-2;[NEI] Recording electrode type;LA24897-3;5;Skin electrodes;;; +79802-5;LL3754-0;[NEI] Reference electrode type;LA24647-2;1;Bipolar;;; +79802-5;LL3754-0;[NEI] Reference electrode type;LA24799-1;2;Monopolar;;; +79802-5;LL3754-0;[NEI] Reference electrode type;LA24896-5;3;Skin Electrode;;; +79803-3;LL3756-5;[NEI] Ocular motility findings;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +79803-3;LL3756-5;[NEI] Ocular motility findings;LA24664-7;2;Complete horizontal gaze palsy;;; +79803-3;LL3756-5;[NEI] Ocular motility findings;LA24735-5;3;Globe retraction;;; +79803-3;LL3756-5;[NEI] Ocular motility findings;LA24823-9;4;Nystagmus;;; +79803-3;LL3756-5;[NEI] Ocular motility findings;LA24906-2;5;Strabismus (limitation of movement);;; +79803-3;LL3756-5;[NEI] Ocular motility findings;LA46-8;6;Other;;; +79803-3;LL3756-5;[NEI] Ocular motility findings;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79804-1;LL3758-1;[NEI] Visual field defect findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24651-4;2;Cecocentral scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24652-2;3;Central scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24671-2;4;Constriction or contraction scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24756-1;5;Inferior arcuate scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25461-7;6;Inferior scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25460-9;7;Inferonasal scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25462-5;8;Inferotemporal scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25454-2;9;Nasal scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24803-1;10;Nasal step scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24837-9;11;Paracentral scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25455-9;12;Peripheral scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24914-6;13;Superior arcuate scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25458-3;14;Superior scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25459-1;15;Superonasal scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25457-5;16;Superotemporal scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA25456-7;17;Temporal scotoma;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA24928-6;18;Threatening fixation;;; +79804-1;LL3758-1;[NEI] Visual field defect findings;LA46-8;19;Other;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24651-4;2;Cecocentral scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24652-2;3;Central scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24671-2;4;Constriction or contraction scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24756-1;5;Inferior arcuate scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25461-7;6;Inferior scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25460-9;7;Inferonasal scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25462-5;8;Inferotemporal scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25454-2;9;Nasal scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24803-1;10;Nasal step scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24837-9;11;Paracentral scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25455-9;12;Peripheral scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24914-6;13;Superior arcuate scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25458-3;14;Superior scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25459-1;15;Superonasal scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25457-5;16;Superotemporal scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA25456-7;17;Temporal scotoma;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA24928-6;18;Threatening fixation;;; +79805-8;LL3758-1;[NEI] Visual field defect findings;LA46-8;19;Other;;; +79806-6;LL3759-9;[NEI] Visual field defects method;LA24842-9;1;Perimetry;;; +79806-6;LL3759-9;[NEI] Visual field defects method;LA24919-5;2;Tangent screen exam;;; +79806-6;LL3759-9;[NEI] Visual field defects method;LA24639-9;3;Automated perimetry exam;;; +79806-6;LL3759-9;[NEI] Visual field defects method;LA24736-3;4;Goldmann visual field exam;;; +79806-6;LL3759-9;[NEI] Visual field defects method;LA24746-2;5;Humphrey field exam;;; +79807-4;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24810-6;1;No defects;;; +79807-4;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24729-8;2;Full (VFFTC);;; +79807-4;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24757-9;3;Inferonasal defect;;; +79807-4;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24758-7;4;Inferotemporal defect;;; +79807-4;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24915-3;5;Superonasal defect;;; +79807-4;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24916-1;6;Superotemporal defect;;; +79807-4;LL3760-7;[NEI] Visual field findings by confrontatoin;LA46-8;7;Other;;; +79808-2;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24810-6;1;No defects;;; +79808-2;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24729-8;2;Full (VFFTC);;; +79808-2;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24757-9;3;Inferonasal defect;;; +79808-2;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24758-7;4;Inferotemporal defect;;; +79808-2;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24915-3;5;Superonasal defect;;; +79808-2;LL3760-7;[NEI] Visual field findings by confrontatoin;LA24916-1;6;Superotemporal defect;;; +79808-2;LL3760-7;[NEI] Visual field findings by confrontatoin;LA46-8;7;Other;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA24809-8;1;No abnormal findings;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA24653-0;2;Central hypofluorescence surrounded by hyperfluorescence;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA24659-7;3;Choroidal neovascular membrane seen;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA24684-5;4;Dark choroid;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA24701-7;5;Drusen staining;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA24754-6;6;Increased autofluorescence;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA25476-5;7;Other abnormal findings;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA46-8;8;Other;;; +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79809-0;LL3761-5;[NEI] Ocular fundus angiography findings;LA7304-4;10;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA24809-8;1;No abnormal findings;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA24653-0;2;Central hypofluorescence surrounded by hyperfluorescence;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA24659-7;3;Choroidal neovascular membrane seen;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA24684-5;4;Dark choroid;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA24701-7;5;Drusen staining;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA24754-6;6;Increased autofluorescence;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA25476-5;7;Other abnormal findings;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA46-8;8;Other;;; +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79810-8;LL3761-5;[NEI] Ocular fundus angiography findings;LA7304-4;10;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA24809-8;1;No abnormal findings;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA24653-0;2;Central hypofluorescence surrounded by hyperfluorescence;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA24659-7;3;Choroidal neovascular membrane seen;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA24684-5;4;Dark choroid;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA24701-7;5;Drusen staining;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA24754-6;6;Increased autofluorescence;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA25476-5;7;Other abnormal findings;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA46-8;8;Other;;; +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79811-6;LL3761-5;[NEI] Ocular fundus angiography findings;LA7304-4;10;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA24809-8;1;No abnormal findings;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA24653-0;2;Central hypofluorescence surrounded by hyperfluorescence;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA24659-7;3;Choroidal neovascular membrane seen;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA24684-5;4;Dark choroid;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA24701-7;5;Drusen staining;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA24754-6;6;Increased autofluorescence;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA25476-5;7;Other abnormal findings;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA46-8;8;Other;;; +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79812-4;LL3761-5;[NEI] Ocular fundus angiography findings;LA7304-4;10;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +79815-7;LL3762-3;[NEI] Pupillary response findings;LA25441-9;1;Reactive to light;;; +79815-7;LL3762-3;[NEI] Pupillary response findings;LA24899-9;2;Sluggishly reactive to light;;; +79815-7;LL3762-3;[NEI] Pupillary response findings;LA25442-7;3;Not reactive to light;;; +79815-7;LL3762-3;[NEI] Pupillary response findings;LA25443-5;4;Reactive to accomodation;;; +79815-7;LL3762-3;[NEI] Pupillary response findings;LA25444-3;5;Not reactive to accomodation;;; +79815-7;LL3762-3;[NEI] Pupillary response findings;LA46-8;6;Other;;; +79899-1;LL3762-3;[NEI] Pupillary response findings;LA25441-9;1;Reactive to light;;; +79899-1;LL3762-3;[NEI] Pupillary response findings;LA24899-9;2;Sluggishly reactive to light;;; +79899-1;LL3762-3;[NEI] Pupillary response findings;LA25442-7;3;Not reactive to light;;; +79899-1;LL3762-3;[NEI] Pupillary response findings;LA25443-5;4;Reactive to accomodation;;; +79899-1;LL3762-3;[NEI] Pupillary response findings;LA25444-3;5;Not reactive to accomodation;;; +79899-1;LL3762-3;[NEI] Pupillary response findings;LA46-8;6;Other;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24809-8;1;No abnormal findings;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24637-3;2;Atrophy;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25465-8;3;Cystoid macular edema;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25463-3;4;Disruption in Bruchs membrane;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24864-3;5;Epiretinal membrane;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25464-1;6;Photoreceptor layer remodeling;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24889-0;7;Schisis cysts;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25503-6;8;Sub-RPE deposition;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA46-8;9;Other;;; +79818-1;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24809-8;1;No abnormal findings;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24637-3;2;Atrophy;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25465-8;3;Cystoid macular edema;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25463-3;4;Disruption in Bruchs membrane;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24864-3;5;Epiretinal membrane;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25464-1;6;Photoreceptor layer remodeling;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA24889-0;7;Schisis cysts;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA25503-6;8;Sub-RPE deposition;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA46-8;9;Other;;; +79819-9;LL3763-1;[NEI] Optical coherent tomography (OCT) findings;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79820-7;LL3765-6;[NEI] Macula exam findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79820-7;LL3765-6;[NEI] Macula exam findings;LA24625-8;2;Abnormal vessels crossing macula;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24637-3;3;Atrophy;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24681-1;4;Crystals;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24683-7;5;Cystic changes;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24692-8;6;Degeneration;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24700-9;7;Drusen;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA17263-7;8;Edema;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24725-6;9;Folds;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24728-0;10;Foveal aplasia or hypoplasia;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24748-8;11;Hyperpigmentation;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24750-4;12;Hypopigmentation;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24806-4;13;Neovascular membrane;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24850-2;14;Pigment spicules;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24852-8;15;Flecks;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24860-1;16;Pseudohypopyon;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24864-3;17;Epiretinal membrane;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24879-1;18;Retinoschisis;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24887-4;19;Scar;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24911-2;20;Subretinal hemorrhage;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24924-5;21;Temporal macular dragging;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24941-9;22;Vitelliform lesion;;; +79820-7;LL3765-6;[NEI] Macula exam findings;LA24942-7;23;Vitelliruptive phase;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79821-5;LL3765-6;[NEI] Macula exam findings;LA24625-8;2;Abnormal vessels crossing macula;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24637-3;3;Atrophy;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24681-1;4;Crystals;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24683-7;5;Cystic changes;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24692-8;6;Degeneration;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24700-9;7;Drusen;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA17263-7;8;Edema;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24725-6;9;Folds;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24728-0;10;Foveal aplasia or hypoplasia;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24748-8;11;Hyperpigmentation;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24750-4;12;Hypopigmentation;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24806-4;13;Neovascular membrane;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24850-2;14;Pigment spicules;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24852-8;15;Flecks;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24860-1;16;Pseudohypopyon;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24864-3;17;Epiretinal membrane;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24879-1;18;Retinoschisis;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24887-4;19;Scar;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24911-2;20;Subretinal hemorrhage;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24924-5;21;Temporal macular dragging;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24941-9;22;Vitelliform lesion;;; +79821-5;LL3765-6;[NEI] Macula exam findings;LA24942-7;23;Vitelliruptive phase;;; +79822-3;LL3872-0;[NEI] Pigmentation;LA25482-3;1;Normal pigmentation;;; +79822-3;LL3872-0;[NEI] Pigmentation;LA25483-1;2;Blonde fundus;;; +79822-3;LL3872-0;[NEI] Pigmentation;LA25484-9;3;Hypopigmentation with choroidal show;;; +79822-3;LL3872-0;[NEI] Pigmentation;LA46-8;4;Other;;; +79822-3;LL3872-0;[NEI] Pigmentation;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79823-1;LL3767-2;[NEI] Glaucoma type;LA24629-0;1;Angle-closure;;; +79823-1;LL3767-2;[NEI] Glaucoma type;LA24667-0;2;Congenital;;; +79823-1;LL3767-2;[NEI] Glaucoma type;LA24768-6;3;Juvenile open angle;;; +79823-1;LL3767-2;[NEI] Glaucoma type;LA24805-6;4;Neovascular;;; +79823-1;LL3767-2;[NEI] Glaucoma type;LA24820-5;5;Normal tension;;; +79823-1;LL3767-2;[NEI] Glaucoma type;LA24826-2;6;Open angle;;; +79823-1;LL3767-2;[NEI] Glaucoma type;LA46-8;7;Other;;; +79824-9;LL3769-8;[NEI] Ophthalmoscopy method;LA24903-9;1;Standard scope W dilation;;; +79824-9;LL3769-8;[NEI] Ophthalmoscopy method;LA24904-7;2;Standard scope WO dilation;;; +79824-9;LL3769-8;[NEI] Ophthalmoscopy method;LA24886-6;3;Scanning laser (wide-field scope) WO dilation;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA6111-4;1;0;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24576-3;2;0.15;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24578-9;3;0.3;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24581-3;4;0.45;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24583-9;5;0.6;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24585-4;6;0.75;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24587-0;7;0.9;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24588-8;8;1.05;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24589-6;9;1.2;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24590-4;10;1.35;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA15765-3;11;1.5;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24591-2;12;1.65;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24592-0;13;1.8;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24593-8;14;1.95;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24596-1;15;2.1;;; +79827-2;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24597-9;16;2.25;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA6111-4;1;0;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24576-3;2;0.15;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24578-9;3;0.3;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24581-3;4;0.45;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24583-9;5;0.6;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24585-4;6;0.75;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24587-0;7;0.9;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24588-8;8;1.05;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24589-6;9;1.2;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24590-4;10;1.35;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA15765-3;11;1.5;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24591-2;12;1.65;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24592-0;13;1.8;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24593-8;14;1.95;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24596-1;15;2.1;;; +79828-0;LL3770-6;[NEI] Contrast sensitivity findings by Pelli-Robso;LA24597-9;16;2.25;;; +79841-3;LL3771-4;[NEI] Objective refraction method;LA24880-9;1;Retinoscopy;;; +79841-3;LL3771-4;[NEI] Objective refraction method;LA46-8;2;Other;;; +79841-3;LL3771-4;[NEI] Objective refraction method;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79854-6;LL3788-8;[NEI] Refraction method;LA25451-8;1;Loose lenses;;; +79854-6;LL3788-8;[NEI] Refraction method;LA24847-8;2;Phoropter;;; +79854-6;LL3788-8;[NEI] Refraction method;LA24880-9;3;Retinoscopy;;; +79854-6;LL3788-8;[NEI] Refraction method;LA24933-6;4;Trial frame;;; +79854-6;LL3788-8;[NEI] Refraction method;LA46-8;5;Other;;; +79854-6;LL3788-8;[NEI] Refraction method;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79857-9;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79857-9;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA24634-0;2;Anterior segment dysgenesis (ASD);;; +79857-9;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA24854-4;3;Posterior embryotoxon;;; +79857-9;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA46-8;4;Other;;; +79858-7;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79858-7;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA24634-0;2;Anterior segment dysgenesis (ASD);;; +79858-7;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA24854-4;3;Posterior embryotoxon;;; +79858-7;LL3773-0;[NEI] Anterior chamber slit lamp findings;LA46-8;4;Other;;; +79859-5;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79859-5;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA24726-4;2;Follicles;;; +79859-5;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA14542-7;3;Injection;;; +79859-5;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA24836-1;4;Papilla;;; +79859-5;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA46-8;5;Other;;; +79860-3;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79860-3;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA24726-4;2;Follicles;;; +79860-3;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA14542-7;3;Injection;;; +79860-3;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA24836-1;4;Papilla;;; +79860-3;LL3774-8;[NEI] Conjunctiva and sclera slit lamp findings;LA46-8;5;Other;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24649-8;2;Bullae;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24674-6;3;Corneal crystals;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24675-3;4;Corneal erosions;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24711-6;5;Epithelial edema;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24712-4;6;Epithelial microcysts;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24769-4;7;Keloids;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24770-2;8;Keratopathy;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24792-6;9;Microcornea;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA24909-6;10;Stromal edema;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA17844-4;11;Transplant;;; +79861-1;LL3775-5;[NEI] Cornea slit lamp findings;LA46-8;12;Other;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24649-8;2;Bullae;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24674-6;3;Corneal crystals;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24675-3;4;Corneal erosions;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24711-6;5;Epithelial edema;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24712-4;6;Epithelial microcysts;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24769-4;7;Keloids;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24770-2;8;Keratopathy;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24792-6;9;Microcornea;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA24909-6;10;Stromal edema;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA17844-4;11;Transplant;;; +79862-9;LL3775-5;[NEI] Cornea slit lamp findings;LA46-8;12;Other;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24630-8;2;Aniridia;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24662-1;3;Coloboma;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24673-8;4;Corectopia;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA19594-3;5;Hypoplastic;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24761-1;6;Iridocorneal adhesions;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24764-5;7;Iris transillumination;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24856-9;8;Posterior synechiae;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24845-2;9;Peripheral iridocorneal adhesions;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA25453-4;10;Persistent pupillary membrane;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24871-8;11;Remnant;;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA24885-8;12;Rubeosis iridis (neovascularization);;; +79863-7;LL3776-3;[NEI] Iris slit lamp findings;LA46-8;13;Other;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24630-8;2;Aniridia;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24662-1;3;Coloboma;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24673-8;4;Corectopia;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA19594-3;5;Hypoplastic;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24761-1;6;Iridocorneal adhesions;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24764-5;7;Iris transillumination;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24856-9;8;Posterior synechiae;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24845-2;9;Peripheral iridocorneal adhesions;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA25453-4;10;Persistent pupillary membrane;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24871-8;11;Remnant;;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA24885-8;12;Rubeosis iridis (neovascularization);;; +79864-5;LL3776-3;[NEI] Iris slit lamp findings;LA46-8;13;Other;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA25472-4;2;Anterior subcapsular cataract;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA25474-0;3;Blue dot cataract;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA25471-6;4;Cortical cataract;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA25470-8;5;Nuclear cataract;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA25473-2;6;Posterior subcapsular cataract;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA24707-4;7;Ectopia lentis;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA25469-0;8;Lens droplets;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA24793-4;9;Microphakia;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA24795-9;10;Microspherophakia;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA24825-4;11;Opacity;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA25453-4;12;Persistent pupillary membrane;;; +79865-2;LL3777-1;[NEI] Lens slit lamp findings;LA46-8;13;Other;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA25472-4;2;Anterior subcapsular cataract;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA25474-0;3;Blue dot cataract;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA25471-6;4;Cortical cataract;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA25470-8;5;Nuclear cataract;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA25473-2;6;Posterior subcapsular cataract;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA24707-4;7;Ectopia lentis;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA25469-0;8;Lens droplets;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA24793-4;9;Microphakia;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA24795-9;10;Microspherophakia;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA24825-4;11;Opacity;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA25453-4;12;Persistent pupillary membrane;;; +79866-0;LL3777-1;[NEI] Lens slit lamp findings;LA46-8;13;Other;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24633-2;1;Anterior polar opacity;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24678-7;2;Cortical/peripheral opacity;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24775-1;3;Lamellar/zonular opacity;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24822-1;4;Nuclear/central opacity;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24855-1;5;Posterior polar opacity;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24865-0;6;Pulverulent/punctate opacity;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24918-7;7;Sutural opacity;;; +79867-8;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24932-8;8;Total opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24633-2;1;Anterior polar opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24678-7;2;Cortical/peripheral opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24775-1;3;Lamellar/zonular opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24822-1;4;Nuclear/central opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24855-1;5;Posterior polar opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24865-0;6;Pulverulent/punctate opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24918-7;7;Sutural opacity;;; +79868-6;LL3778-9;[NEI] Lens opacity slit lamp findings;LA24932-8;8;Total opacity;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA25468-2;2;Abnormal meibomian glands;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA25467-4;3;Absence of meibomian glands;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA24698-5;4;Distichiasis;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA24787-6;5;Madarosis;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA24853-6;6;Poliosis;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA24862-7;7;Ptosis;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA24934-4;8;Trichiasis;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA25466-6;9;Trichomegaly;;; +79869-4;LL3779-7;[NEI] Lids and lashes slit lamp findings;LA46-8;10;Other;;; +79870-2;LL3780-5;[NEI] Pupil shape slit lamp findings;LA24884-1;1;Round;;; +79870-2;LL3780-5;[NEI] Pupil shape slit lamp findings;LA19583-6;2;Irregular;;; +79870-2;LL3780-5;[NEI] Pupil shape slit lamp findings;LA24673-8;3;Corectopia;;; +79870-2;LL3780-5;[NEI] Pupil shape slit lamp findings;LA46-8;4;Other;;; +79871-0;LL3780-5;[NEI] Pupil shape slit lamp findings;LA24884-1;1;Round;;; +79871-0;LL3780-5;[NEI] Pupil shape slit lamp findings;LA19583-6;2;Irregular;;; +79871-0;LL3780-5;[NEI] Pupil shape slit lamp findings;LA24673-8;3;Corectopia;;; +79871-0;LL3780-5;[NEI] Pupil shape slit lamp findings;LA46-8;4;Other;;; +79872-8;LL3781-3;[NEI] Vitreous slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79872-8;LL3781-3;[NEI] Vitreous slit lamp findings;LA24943-5;2;Vitreoretinal adhesions;;; +79872-8;LL3781-3;[NEI] Vitreous slit lamp findings;LA24944-3;3;Vitreous membranes;;; +79872-8;LL3781-3;[NEI] Vitreous slit lamp findings;LA46-8;4;Other;;; +79873-6;LL3781-3;[NEI] Vitreous slit lamp findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +79873-6;LL3781-3;[NEI] Vitreous slit lamp findings;LA24943-5;2;Vitreoretinal adhesions;;; +79873-6;LL3781-3;[NEI] Vitreous slit lamp findings;LA24944-3;3;Vitreous membranes;;; +79873-6;LL3781-3;[NEI] Vitreous slit lamp findings;LA46-8;4;Other;;; +79874-4;LL3782-1;[NEI] Iris transillumination findings;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +79874-4;LL3782-1;[NEI] Iris transillumination findings;LA6752-5;2;Mild;;; +79874-4;LL3782-1;[NEI] Iris transillumination findings;LA6751-7;3;Moderate;;; +79874-4;LL3782-1;[NEI] Iris transillumination findings;LA24665-4;4;Complete/severe;;; +79875-1;LL3782-1;[NEI] Iris transillumination findings;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +79875-1;LL3782-1;[NEI] Iris transillumination findings;LA6752-5;2;Mild;;; +79875-1;LL3782-1;[NEI] Iris transillumination findings;LA6751-7;3;Moderate;;; +79875-1;LL3782-1;[NEI] Iris transillumination findings;LA24665-4;4;Complete/severe;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24579-7;1;-0.3;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24575-5;2;-0.1;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6111-4;3;0;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24574-8;4;0.1;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24577-1;5;0.2;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24578-9;6;0.3;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24580-5;7;0.4;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA16632-4;8;0.5;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24582-1;9;0.55;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24583-9;10;0.6;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24584-7;11;0.7;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24586-2;12;0.8;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24587-0;13;0.9;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6112-2;14;1;;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24679-5;15;Count fingers (CF);;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24740-5;16;Hand motion (HM);;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24782-7;17;Light perception (LP);;; +79876-9;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24813-0;18;No light perception (NLP);;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24579-7;1;-0.3;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24575-5;2;-0.1;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6111-4;3;0;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24574-8;4;0.1;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24577-1;5;0.2;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24578-9;6;0.3;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24580-5;7;0.4;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA16632-4;8;0.5;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24582-1;9;0.55;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24583-9;10;0.6;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24584-7;11;0.7;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24586-2;12;0.8;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24587-0;13;0.9;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6112-2;14;1;;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24679-5;15;Count fingers (CF);;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24740-5;16;Hand motion (HM);;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24782-7;17;Light perception (LP);;; +79877-7;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24813-0;18;No light perception (NLP);;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24579-7;1;-0.3;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24575-5;2;-0.1;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6111-4;3;0;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24574-8;4;0.1;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24577-1;5;0.2;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24578-9;6;0.3;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24580-5;7;0.4;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA16632-4;8;0.5;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24582-1;9;0.55;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24583-9;10;0.6;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24584-7;11;0.7;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24586-2;12;0.8;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24587-0;13;0.9;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6112-2;14;1;;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24679-5;15;Count fingers (CF);;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24740-5;16;Hand motion (HM);;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24782-7;17;Light perception (LP);;; +79878-5;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24813-0;18;No light perception (NLP);;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24579-7;1;-0.3;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24575-5;2;-0.1;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6111-4;3;0;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24574-8;4;0.1;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24577-1;5;0.2;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24578-9;6;0.3;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24580-5;7;0.4;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA16632-4;8;0.5;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24582-1;9;0.55;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24583-9;10;0.6;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24584-7;11;0.7;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24586-2;12;0.8;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24587-0;13;0.9;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA6112-2;14;1;;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24679-5;15;Count fingers (CF);;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24740-5;16;Hand motion (HM);;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24782-7;17;Light perception (LP);;; +79879-3;LL3783-9;[NEI] Visual acuity findings on ETDRS eye chart;LA24813-0;18;No light perception (NLP);;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24598-7;1;20/10;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24601-9;2;20/15;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24603-5;3;20/20;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24605-0;4;20/25;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24606-8;5;20/30;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24608-4;6;20/40;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24610-0;7;20/50;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24611-8;8;20/60;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24612-6;9;20/70;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24613-4;10;20/80;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24599-5;11;20/100;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24600-1;12;20/125;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24602-7;13;20/150;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24604-3;14;20/200;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24607-6;15;20/300;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24609-2;16;20/400;;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24679-5;17;Count fingers (CF);;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24740-5;18;Hand motion (HM);;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24782-7;19;Light perception (LP);;; +79880-1;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24813-0;20;No light perception (NLP);;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24598-7;1;20/10;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24601-9;2;20/15;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24603-5;3;20/20;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24605-0;4;20/25;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24606-8;5;20/30;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24608-4;6;20/40;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24610-0;7;20/50;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24611-8;8;20/60;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24612-6;9;20/70;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24613-4;10;20/80;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24599-5;11;20/100;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24600-1;12;20/125;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24602-7;13;20/150;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24604-3;14;20/200;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24607-6;15;20/300;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24609-2;16;20/400;;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24679-5;17;Count fingers (CF);;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24740-5;18;Hand motion (HM);;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24782-7;19;Light perception (LP);;; +79881-9;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24813-0;20;No light perception (NLP);;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24598-7;1;20/10;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24601-9;2;20/15;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24603-5;3;20/20;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24605-0;4;20/25;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24606-8;5;20/30;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24608-4;6;20/40;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24610-0;7;20/50;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24611-8;8;20/60;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24612-6;9;20/70;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24613-4;10;20/80;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24599-5;11;20/100;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24600-1;12;20/125;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24602-7;13;20/150;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24604-3;14;20/200;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24607-6;15;20/300;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24609-2;16;20/400;;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24679-5;17;Count fingers (CF);;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24740-5;18;Hand motion (HM);;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24782-7;19;Light perception (LP);;; +79882-7;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24813-0;20;No light perception (NLP);;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24598-7;1;20/10;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24601-9;2;20/15;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24603-5;3;20/20;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24605-0;4;20/25;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24606-8;5;20/30;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24608-4;6;20/40;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24610-0;7;20/50;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24611-8;8;20/60;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24612-6;9;20/70;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24613-4;10;20/80;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24599-5;11;20/100;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24600-1;12;20/125;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24602-7;13;20/150;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24604-3;14;20/200;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24607-6;15;20/300;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24609-2;16;20/400;;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24679-5;17;Count fingers (CF);;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24740-5;18;Hand motion (HM);;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24782-7;19;Light perception (LP);;; +79883-5;LL3784-7;[NEI] Visual acuity findings on Snellen eye chart;LA24813-0;20;No light perception (NLP);;; +79884-3;LL3871-2;[NEI] VEP result;LA25480-7;1;Normal visual evoked potential (VEP);;; +79884-3;LL3871-2;[NEI] VEP result;LA25481-5;2;Abnormal visual evoked potential (VEP);;; +79884-3;LL3871-2;[NEI] VEP result;LA46-8;3;Other;;; +79884-3;LL3871-2;[NEI] VEP result;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79884-3;LL3871-2;[NEI] VEP result;LA13538-6;5;Not tested;;; +79885-0;LL3871-2;[NEI] VEP result;LA25480-7;1;Normal visual evoked potential (VEP);;; +79885-0;LL3871-2;[NEI] VEP result;LA25481-5;2;Abnormal visual evoked potential (VEP);;; +79885-0;LL3871-2;[NEI] VEP result;LA46-8;3;Other;;; +79885-0;LL3871-2;[NEI] VEP result;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +79885-0;LL3871-2;[NEI] VEP result;LA13538-6;5;Not tested;;; +79886-8;LL3785-4;[NEI] Anterior chamber cell findings;LA24572-2;1;0 cells;;; +79886-8;LL3785-4;[NEI] Anterior chamber cell findings;LA24619-1;2;5-10 cells;;; +79886-8;LL3785-4;[NEI] Anterior chamber cell findings;LA24595-3;3;11-20 cells;;; +79886-8;LL3785-4;[NEI] Anterior chamber cell findings;LA24616-7;4;21-50 cells;;; +79886-8;LL3785-4;[NEI] Anterior chamber cell findings;LA24571-4;5;>50 cells;;; +79887-6;LL3785-4;[NEI] Anterior chamber cell findings;LA24572-2;1;0 cells;;; +79887-6;LL3785-4;[NEI] Anterior chamber cell findings;LA24619-1;2;5-10 cells;;; +79887-6;LL3785-4;[NEI] Anterior chamber cell findings;LA24595-3;3;11-20 cells;;; +79887-6;LL3785-4;[NEI] Anterior chamber cell findings;LA24616-7;4;21-50 cells;;; +79887-6;LL3785-4;[NEI] Anterior chamber cell findings;LA24571-4;5;>50 cells;;; +79888-4;LL3786-2;[NEI] Anterior chamber flare findings;LA24709-0;1;Empty/None;;; +79888-4;LL3786-2;[NEI] Anterior chamber flare findings;LA24721-5;2;Faint;;; +79888-4;LL3786-2;[NEI] Anterior chamber flare findings;LA6751-7;3;Moderate;;; +79888-4;LL3786-2;[NEI] Anterior chamber flare findings;LA17968-1;4;Marked;;; +79888-4;LL3786-2;[NEI] Anterior chamber flare findings;LA6750-9;5;Severe;;; +79889-2;LL3786-2;[NEI] Anterior chamber flare findings;LA24709-0;1;Empty/None;;; +79889-2;LL3786-2;[NEI] Anterior chamber flare findings;LA24721-5;2;Faint;;; +79889-2;LL3786-2;[NEI] Anterior chamber flare findings;LA6751-7;3;Moderate;;; +79889-2;LL3786-2;[NEI] Anterior chamber flare findings;LA17968-1;4;Marked;;; +79889-2;LL3786-2;[NEI] Anterior chamber flare findings;LA6750-9;5;Severe;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24628-2;1;Acquired;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24672-0;2;Convergence retraction;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24699-3;3;Downbeat;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA8993-3;4;Horizontal;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24755-3;5;Infantile;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24767-8;6;Jerk;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24776-9;7;Latent;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24797-5;8;Monocular (left);;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24798-3;9;Monocular (right);;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24840-3;10;Pendular;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24843-7;11;Periodic alternating;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24891-6;12;See-saw;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24893-2;13;Sensory defect;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24931-0;14;Torsional;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA24938-5;15;Upbeat;;; +79891-8;LL3787-0;[NEI] Nystagmus type;LA46-8;16;Other;;; +79901-5;LL3873-8;[NEI] Nystagmus direction;LA8993-3;1;Horizontal;;; +79901-5;LL3873-8;[NEI] Nystagmus direction;LA8994-1;2;Vertical;;; +79901-5;LL3873-8;[NEI] Nystagmus direction;LA24931-0;3;Torsional;;; +79901-5;LL3873-8;[NEI] Nystagmus direction;LA24767-8;4;Jerk;;; +79901-5;LL3873-8;[NEI] Nystagmus direction;LA24840-3;5;Pendular;;; +79901-5;LL3873-8;[NEI] Nystagmus direction;LA24891-6;6;See-saw;;; +79902-3;LL3874-6;[NEI] Retinal vessels;LA25485-6;1;Attenuation;;; +79902-3;LL3874-6;[NEI] Retinal vessels;LA25486-4;2;Tortuous;;; +79902-3;LL3874-6;[NEI] Retinal vessels;LA24805-6;3;Neovascular;;; +79902-3;LL3874-6;[NEI] Retinal vessels;LA25488-0;4;Aneuritic;;; +79902-3;LL3874-6;[NEI] Retinal vessels;LA19040-7;5;Hemorrhagic;;; +79903-1;LL3874-6;[NEI] Retinal vessels;LA25485-6;1;Attenuation;;; +79903-1;LL3874-6;[NEI] Retinal vessels;LA25486-4;2;Tortuous;;; +79903-1;LL3874-6;[NEI] Retinal vessels;LA24805-6;3;Neovascular;;; +79903-1;LL3874-6;[NEI] Retinal vessels;LA25488-0;4;Aneuritic;;; +79903-1;LL3874-6;[NEI] Retinal vessels;LA19040-7;5;Hemorrhagic;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24598-7;1;20/10;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24601-9;2;20/15;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24603-5;3;20/20;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24605-0;4;20/25;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24606-8;5;20/30;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24608-4;6;20/40;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24610-0;7;20/50;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24611-8;8;20/60;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24612-6;9;20/70;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24613-4;10;20/80;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24599-5;11;20/100;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24600-1;12;20/125;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24602-7;13;20/150;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24604-3;14;20/200;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24607-6;15;20/300;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24609-2;16;20/400;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA25490-6;17;Central steady maintain;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA25491-4;18;Central unsteady maintain;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA25492-2;19;Fix and follow;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA25493-0;20;Blinks for lights;;; +79904-9;LL3875-3;[NEI] Pediatric visual acuity;LA24813-0;21;No light perception (NLP);;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24598-7;1;20/10;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24601-9;2;20/15;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24603-5;3;20/20;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24605-0;4;20/25;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24606-8;5;20/30;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24608-4;6;20/40;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24610-0;7;20/50;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24611-8;8;20/60;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24612-6;9;20/70;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24613-4;10;20/80;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24599-5;11;20/100;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24600-1;12;20/125;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24602-7;13;20/150;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24604-3;14;20/200;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24607-6;15;20/300;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24609-2;16;20/400;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA25490-6;17;Central steady maintain;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA25491-4;18;Central unsteady maintain;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA25492-2;19;Fix and follow;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA25493-0;20;Blinks for lights;;; +79905-6;LL3875-3;[NEI] Pediatric visual acuity;LA24813-0;21;No light perception (NLP);;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24598-7;1;20/10;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24601-9;2;20/15;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24603-5;3;20/20;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24605-0;4;20/25;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24606-8;5;20/30;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24608-4;6;20/40;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24610-0;7;20/50;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24611-8;8;20/60;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24612-6;9;20/70;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24613-4;10;20/80;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24599-5;11;20/100;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24600-1;12;20/125;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24602-7;13;20/150;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24604-3;14;20/200;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24607-6;15;20/300;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24609-2;16;20/400;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA25490-6;17;Central steady maintain;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA25491-4;18;Central unsteady maintain;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA25492-2;19;Fix and follow;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA25493-0;20;Blinks for lights;;; +79906-4;LL3875-3;[NEI] Pediatric visual acuity;LA24813-0;21;No light perception (NLP);;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24598-7;1;20/10;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24601-9;2;20/15;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24603-5;3;20/20;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24605-0;4;20/25;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24606-8;5;20/30;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24608-4;6;20/40;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24610-0;7;20/50;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24611-8;8;20/60;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24612-6;9;20/70;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24613-4;10;20/80;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24599-5;11;20/100;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24600-1;12;20/125;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24602-7;13;20/150;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24604-3;14;20/200;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24607-6;15;20/300;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24609-2;16;20/400;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA25490-6;17;Central steady maintain;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA25491-4;18;Central unsteady maintain;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA25492-2;19;Fix and follow;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA25493-0;20;Blinks for lights;;; +79907-2;LL3875-3;[NEI] Pediatric visual acuity;LA24813-0;21;No light perception (NLP);;; +79908-0;LL3876-1;[NEI] Pediatric visual acuity method;LA25494-8;1;Teller;;; +79908-0;LL3876-1;[NEI] Pediatric visual acuity method;LA25495-5;2;Allen figure;;; +79908-0;LL3876-1;[NEI] Pediatric visual acuity method;LA25496-3;3;HOTV;;; +79908-0;LL3876-1;[NEI] Pediatric visual acuity method;LA25497-1;4;Numbers;;; +79908-0;LL3876-1;[NEI] Pediatric visual acuity method;LA25498-9;5;Snellen;;; +80101-9;LL3757-3;[NEI] Anterior chamber angle findings;LA25504-4;1;Normal/wide and open;;; +80101-9;LL3757-3;[NEI] Anterior chamber angle findings;LA24644-9;2;Barkan membrane;;; +80101-9;LL3757-3;[NEI] Anterior chamber angle findings;LA24661-3;3;Closed and blocked;;; +80101-9;LL3757-3;[NEI] Anterior chamber angle findings;LA24763-7;4;Iris processes;;; +80101-9;LL3757-3;[NEI] Anterior chamber angle findings;LA9191-3;5;Narrow;;; +80101-9;LL3757-3;[NEI] Anterior chamber angle findings;LA46-8;6;Other;;; +80102-7;LL3757-3;[NEI] Anterior chamber angle findings;LA25504-4;1;Normal/wide and open;;; +80102-7;LL3757-3;[NEI] Anterior chamber angle findings;LA24644-9;2;Barkan membrane;;; +80102-7;LL3757-3;[NEI] Anterior chamber angle findings;LA24661-3;3;Closed and blocked;;; +80102-7;LL3757-3;[NEI] Anterior chamber angle findings;LA24763-7;4;Iris processes;;; +80102-7;LL3757-3;[NEI] Anterior chamber angle findings;LA9191-3;5;Narrow;;; +80102-7;LL3757-3;[NEI] Anterior chamber angle findings;LA46-8;6;Other;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24642-3;2;Avascular retina;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24658-9;3;Choroidal atrophy;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24681-1;4;Crystals;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24750-4;5;Hypopigmentation;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24846-0;6;Peripheral schisis;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24848-6;7;Photocoagulation scars;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24850-2;8;Pigment spicules;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24875-9;9;Retinal atrophy-peripheral;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24876-7;10;Retinal detachment;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24877-5;11;Retinal neovascularization;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24878-3;12;Retinal traction;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24888-2;13;Macular schisis;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24890-8;14;Scleral buckle;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24910-4;15;Sub-, intra-retinal exudation;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA24923-7;16;Temporal fibrovascular mass;;; +80103-5;LL3764-9;[NEI] Chorioretinal findings;LA46-8;17;Other;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24642-3;2;Avascular retina;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24658-9;3;Choroidal atrophy;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24681-1;4;Crystals;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24750-4;5;Hypopigmentation;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24846-0;6;Peripheral schisis;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24848-6;7;Photocoagulation scars;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24850-2;8;Pigment spicules;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24875-9;9;Retinal atrophy-peripheral;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24876-7;10;Retinal detachment;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24877-5;11;Retinal neovascularization;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24878-3;12;Retinal traction;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24888-2;13;Macular schisis;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24890-8;14;Scleral buckle;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24910-4;15;Sub-, intra-retinal exudation;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA24923-7;16;Temporal fibrovascular mass;;; +80104-3;LL3764-9;[NEI] Chorioretinal findings;LA46-8;17;Other;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA24637-3;2;Atrophy;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA19594-3;3;Hypoplastic;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA24696-9;4;Tilted disc;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA24704-1;5;Dysplastic or anomalous;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA19452-4;6;Gray;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA24807-2;7;Myelinated nerve fiber layer;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA25505-1;8;Waxy pallor;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA25506-9;9;Peripapillary atrophy;;; +80105-0;LL3768-0;[NEI] Optic nerve exam findings;LA46-8;10;Other;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA24637-3;2;Atrophy;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA19594-3;3;Hypoplastic;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA24696-9;4;Tilted disc;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA24704-1;5;Dysplastic or anomalous;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA19452-4;6;Gray;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA24807-2;7;Myelinated nerve fiber layer;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA25505-1;8;Waxy pallor;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA25506-9;9;Peripapillary atrophy;;; +80106-8;LL3768-0;[NEI] Optic nerve exam findings;LA46-8;10;Other;;; +80107-6;LL3772-2;[NEI] Stereopsis findings;LA24618-3;1;40 secs or better;;; +80107-6;LL3772-2;[NEI] Stereopsis findings;LA24646-4;2;Between 40 secs & 2000 secs;;; +80107-6;LL3772-2;[NEI] Stereopsis findings;LA24645-6;3;Below 2000 secs;;; +80107-6;LL3772-2;[NEI] Stereopsis findings;LA24937-7;4;Unable;;; +80107-6;LL3772-2;[NEI] Stereopsis findings;LA7304-4;5;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +80108-4;LL3878-7;[NEI] Stereopsis Titmus;LA6626-1;0;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +80108-4;LL3878-7;[NEI] Stereopsis Titmus;LA25507-7;1;Abnormal, flywings;;; +80108-4;LL3878-7;[NEI] Stereopsis Titmus;LA25508-5;2;Abnormal, animals;;; +80108-4;LL3878-7;[NEI] Stereopsis Titmus;LA25509-3;3;Abnormal, dots;;; +80109-2;LL3877-9;Pregnancy risk factors;LA25499-7;1;Advanced maternal age;;; +80109-2;LL3877-9;Pregnancy risk factors;LA25501-0;2;Abnormal maternal serum screening;;; +80109-2;LL3877-9;Pregnancy risk factors;LA25500-2;3;Abnormal ultrasound;;; +80109-2;LL3877-9;Pregnancy risk factors;LA25502-8;4;Personal/Family history;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24959-1;1;HIV Negative;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24952-6;2;HIV-1 Indeterminate;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24953-4;3;HIV-2 Indeterminate;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24954-2;4;HIV Indeterminate;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24955-9;5;HIV-1 Positive;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24956-7;6;HIV-2 Positive;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24957-5;7;HIV-2 Positive with HIV-1 cross-reactivity;;; +80203-3;LL3795-3;HIV|Neg|INDET||POS|POS CR|POS UNTYP;LA24958-3;8;HIV Positive untypable (undifferentiated);;; +80204-1;LL3796-1;FLU A & b;LA25510-1;0;No Influenza A virus, Influenza B virus, isolated in cell culture;;; +80204-1;LL3796-1;FLU A & b;LA25511-9;1;Influenza A virus isolated in cell culture;;; +80204-1;LL3796-1;FLU A & b;LA25512-7;2;Influenza B virus isolated in cell culture;;; +80224-9;LL3706-0;Right coronary catheters;LA24518-5;1;JR 3.5;;; +80224-9;LL3706-0;Right coronary catheters;LA24519-3;2;JR 4;;; +80224-9;LL3706-0;Right coronary catheters;LA24520-1;3;JR 5;;; +80224-9;LL3706-0;Right coronary catheters;LA24521-9;4;JR 6;;; +80224-9;LL3706-0;Right coronary catheters;LA24523-5;5;AR I;;; +80224-9;LL3706-0;Right coronary catheters;LA24524-3;6;AR II;;; +80224-9;LL3706-0;Right coronary catheters;LA24525-0;7;AR III;;; +80224-9;LL3706-0;Right coronary catheters;LA24526-8;8;AR mod;;; +80225-6;LL3705-2;Left coronary catheters;LA24510-2;1;JL 3.5;;; +80225-6;LL3705-2;Left coronary catheters;LA24511-0;2;JL 4;;; +80225-6;LL3705-2;Left coronary catheters;LA24513-6;3;JL 4.5;;; +80225-6;LL3705-2;Left coronary catheters;LA24512-8;4;JL 5;;; +80225-6;LL3705-2;Left coronary catheters;LA24514-4;5;JL 6;;; +80225-6;LL3705-2;Left coronary catheters;LA24515-1;6;AL I;;; +80225-6;LL3705-2;Left coronary catheters;LA24516-9;7;AL II;;; +80225-6;LL3705-2;Left coronary catheters;LA24517-7;8;AL III;;; +80226-4;LL3707-8;Pigtail catheters;LA24528-4;1;Pigtail 145;;; +80226-4;LL3707-8;Pigtail catheters;LA24529-2;2;Pigtail 155;;; +80226-4;LL3707-8;Pigtail catheters;LA24527-6;3;Standard pigtail;;; +80238-9;LL3704-5;Acetylcholine|Methylergonovine;LA24503-7;1;Acetylcholine;57308006;Acetylcholine (substance);http://snomed.info/sct +80238-9;LL3704-5;Acetylcholine|Methylergonovine;LA24502-9;2;Methylergonovine;126074008;Methylergometrine (substance);http://snomed.info/sct +80243-9;LL3721-9;Cardiac cath access sites;LA24509-4;1;Femoral artery - left;;; +80243-9;LL3721-9;Cardiac cath access sites;LA24508-6;2;Femoral artery - right;;; +80243-9;LL3721-9;Cardiac cath access sites;LA24507-8;3;Brachial artery - left;;; +80243-9;LL3721-9;Cardiac cath access sites;LA24506-0;4;Brachial artery - right;;; +80243-9;LL3721-9;Cardiac cath access sites;LA24505-2;5;Radial artery - left;;; +80243-9;LL3721-9;Cardiac cath access sites;LA24504-5;6;Radial artery - right;;; +80243-9;LL3721-9;Cardiac cath access sites;LA46-8;7;Other;;; +80260-3;LL3805-0;Bowel elimination pattern;LA22282-0;1;Constipation;14760008;Constipation (finding);http://snomed.info/sct +80260-3;LL3805-0;Bowel elimination pattern;LA15424-7;2;Diarrhea;62315008;Diarrhea (finding);http://snomed.info/sct +80260-3;LL3805-0;Bowel elimination pattern;LA24993-0;3;Flatulence;162076009;Excessive upper gastrointestinal gas (finding);http://snomed.info/sct +80260-3;LL3805-0;Bowel elimination pattern;LA24994-8;4;Impaction;;; +80260-3;LL3805-0;Bowel elimination pattern;LA24995-5;5;Incontinent of bowels;72042002;incontinence of feces (finding);http://snomed.info/sct +80260-3;LL3805-0;Bowel elimination pattern;LA24996-3;6;Normal bowel pattern for Patient;55019002;normal bowel habits (finding);http://snomed.info/sct +80261-1;LL3806-8;Bowel frequency;LA18891-4;1;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +80261-1;LL3806-8;Bowel frequency;LA24998-9;2;Every 3 days;396128003;Every three days (qualifier value);http://snomed.info/sct +80261-1;LL3806-8;Bowel frequency;LA24997-1;3;Every other day;225760004;Alternate days (qualifier value);http://snomed.info/sct +80261-1;LL3806-8;Bowel frequency;LA25000-3;4;1-3 times per day;396108002;one to three times a day (qualifier value);http://snomed.info/sct +80261-1;LL3806-8;Bowel frequency;LA24999-7;5;Greater than 3 times per day;;; +80262-9;LL3807-6;Bowel movement usual time of day;LA14971-8;1;Morning;;; +80262-9;LL3807-6;Bowel movement usual time of day;LA25003-7;2;Morning and night;;; +80262-9;LL3807-6;Bowel movement usual time of day;LA18130-7;3;Afternoon;;; +80262-9;LL3807-6;Bowel movement usual time of day;LA25005-2;4;Night;;; +80263-7;LL3808-4;Bowel regularity;LA19583-6;1;Irregular;;; +80263-7;LL3808-4;Bowel regularity;LA15487-4;2;Regular;;; +80264-5;LL3809-2;Stool usual consistency;LA17199-3;1;Dry;;; +80264-5;LL3809-2;Stool usual consistency;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +80264-5;LL3809-2;Stool usual consistency;LA14745-6;3;Hard;;; +80264-5;LL3809-2;Stool usual consistency;LA25011-0;4;Liquid;;; +80264-5;LL3809-2;Stool usual consistency;LA25012-8;5;Loose;;; +80264-5;LL3809-2;Stool usual consistency;LA14744-9;6;Soft;;; +80266-0;LL3810-0;Bowel sounds;LA25025-0;1;Bowel sounds absent;16268000;Bowel sounds absent (finding);http://snomed.info/sct +80266-0;LL3810-0;Bowel sounds;LA25026-8;2;Hyperactive bowel sounds;18101008;Bowel sounds hyperactive (finding);http://snomed.info/sct +80266-0;LL3810-0;Bowel sounds;LA25027-6;3;Bowel sounds loud;276382003;Bowel sounds loud (finding);http://snomed.info/sct +80266-0;LL3810-0;Bowel sounds;LA25028-4;4;Bowel sounds quiet;276381005;Bowel sounds quiet (finding);http://snomed.info/sct +80266-0;LL3810-0;Bowel sounds;LA25029-2;5;Hypoactive bowel sounds;;; +80266-0;LL3810-0;Bowel sounds;LA25030-0;6;Normal bowel sounds;61539000;normal bowel sounds (finding);http://snomed.info/sct +80266-0;LL3810-0;Bowel sounds;LA25031-8;7;Tympanic bowel sound;297209005;tympanitic bowel sound (finding);http://snomed.info/sct +8026-7;LL2302-9;Micro stains;LA19348-4;1;Gram stain;;; +8026-7;LL2302-9;Micro stains;LA19349-2;2;Wright stain;;; +8026-7;LL2302-9;Micro stains;LA19350-0;3;Ziehl-Neelson stain;;; +8026-7;LL2302-9;Micro stains;LA19351-8;4;Kinyoun stain;;; +80267-8;LL3811-8;Bowel sounds quality;LA25032-6;1;Tinkling;;; +80267-8;LL3811-8;Bowel sounds quality;LA25033-4;2;Borborygmi;413681009;Borborygmi (finding);http://snomed.info/sct +80267-8;LL3811-8;Bowel sounds quality;LA25034-2;3;High-pitched;;; +80267-8;LL3811-8;Bowel sounds quality;LA25035-9;4;Low-pitched;;; +80268-6;LL3812-6;Quadrant;LA25036-7;1;RLQ;;; +80268-6;LL3812-6;Quadrant;LA25037-5;2;RUQ;;; +80268-6;LL3812-6;Quadrant;LA25038-3;3;LLQ;;; +80268-6;LL3812-6;Quadrant;LA25039-1;4;LUQ;;; +80269-4;LL3813-4;Abdomen appearance;LA25040-9;1;Irregular contour;;; +80269-4;LL3813-4;Abdomen appearance;LA19589-3;2;Distended;;; +80269-4;LL3813-4;Abdomen appearance;LA25042-5;3;Mass;;; +80269-4;LL3813-4;Abdomen appearance;LA25043-3;4;Rigid;;; +80269-4;LL3813-4;Abdomen appearance;LA25044-1;5;Distended abdominal veins;;; +80269-4;LL3813-4;Abdomen appearance;LA25045-8;6;Cullen's sign;35187000;Cullen's sign (finding);http://snomed.info/sct +80269-4;LL3813-4;Abdomen appearance;LA25046-6;7;Distinct protrusions;;; +80269-4;LL3813-4;Abdomen appearance;LA7469-5;8;Rash;;; +80269-4;LL3813-4;Abdomen appearance;LA25048-2;9;Firm;;; +80269-4;LL3813-4;Abdomen appearance;LA9212-7;10;Flat;;; +80269-4;LL3813-4;Abdomen appearance;LA25050-8;11;Inguinal hernia;396232000;Inguinal hernia (disorder);http://snomed.info/sct +80269-4;LL3813-4;Abdomen appearance;LA25051-6;12;Symmetrical contour;;; +80269-4;LL3813-4;Abdomen appearance;LA20940-5;13;Obese;;; +80269-4;LL3813-4;Abdomen appearance;LA25053-2;14;Pendulous;;; +80269-4;LL3813-4;Abdomen appearance;LA15173-0;15;Pregnant;;; +80269-4;LL3813-4;Abdomen appearance;LA25055-7;16;Prominent abdominal veins;161991006;Prominent abdominal veins (finding);http://snomed.info/sct +80269-4;LL3813-4;Abdomen appearance;LA25056-5;17;Concave (scaphoid);;; +80269-4;LL3813-4;Abdomen appearance;LA24887-4;18;Scar;;; +80269-4;LL3813-4;Abdomen appearance;LA25058-1;19;Shiny;;; +80269-4;LL3813-4;Abdomen appearance;LA25059-9;20;Taut;;; +80269-4;LL3813-4;Abdomen appearance;LA25060-7;21;Umbilical hernia;396347007;Umbilical hernia (disorder);http://snomed.info/sct +80269-4;LL3813-4;Abdomen appearance;LA25061-5;22;Vascularity;;; +80269-4;LL3813-4;Abdomen appearance;LA25062-3;23;Pulsations (aorta);;; +80269-4;LL3813-4;Abdomen appearance;LA25063-1;24;Visible peristalsis;271837007;Visible peristalsis (finding);http://snomed.info/sct +80269-4;LL3813-4;Abdomen appearance;LA25064-9;25;Wrinkled;;; +80271-0;LL3814-2;Abdominal palpation;LA17243-9;1;Guarding;;; +80271-0;LL3814-2;Abdominal palpation;LA25042-5;2;Mass;;; +80271-0;LL3814-2;Abdominal palpation;LA25043-3;3;Rigid;;; +80271-0;LL3814-2;Abdominal palpation;LA25048-2;4;Firm;;; +80271-0;LL3814-2;Abdominal palpation;LA25069-8;5;No guarding;;; +80271-0;LL3814-2;Abdominal palpation;LA25070-6;6;Tender;;; +80271-0;LL3814-2;Abdominal palpation;LA23814-9;7;Rebound Tenderness;35611005;Rebound tenderness (finding);http://snomed.info/sct +80271-0;LL3814-2;Abdominal palpation;LA25059-9;8;Taut;;; +80273-6;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80273-6;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80285-0;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80285-0;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80293-4;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80293-4;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80313-0;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80313-0;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80314-8;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80314-8;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80317-1;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80317-1;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80320-5;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80320-5;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80328-8;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80328-8;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80335-3;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80335-3;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80338-7;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80338-7;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80339-5;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80339-5;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80343-7;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +80343-7;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +81672-8;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +81672-8;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +81675-1;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +81675-1;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +81678-5;LL3816-7;Nursing WDL or assessment text;LA25085-4;1;Within Defined Limits;;; +81678-5;LL3816-7;Nursing WDL or assessment text;LA46-8;2;Other;;; +80276-9;LL3819-1;Heart sounds;LA25107-6;1;Abnormal S1;;; +80276-9;LL3819-1;Heart sounds;LA18245-3;2;S4;;; +80276-9;LL3819-1;Heart sounds;LA25109-2;3;Abnormal S2;;; +80276-9;LL3819-1;Heart sounds;LA18244-6;4;S3;;; +80276-9;LL3819-1;Heart sounds;LA25111-8;5;Absent S2;;; +80276-9;LL3819-1;Heart sounds;LA25112-6;6;Split S1;;; +80276-9;LL3819-1;Heart sounds;LA25113-4;7;Normal heart sounds;301132007;heart sounds normal (finding);http://snomed.info/sct +80276-9;LL3819-1;Heart sounds;LA25114-2;8;Loud S1;;; +80276-9;LL3819-1;Heart sounds;LA18242-0;9;S1;;; +80276-9;LL3819-1;Heart sounds;LA25116-7;10;Normal S2;;; +80276-9;LL3819-1;Heart sounds;LA25117-5;11;Normal S3 in young person;;; +80276-9;LL3819-1;Heart sounds;LA25118-3;12;S3 Gallop;;; +80276-9;LL3819-1;Heart sounds;LA25119-1;13;Reduced Intensity S1;;; +80276-9;LL3819-1;Heart sounds;LA25388-2;14;Split S2;;; +80278-5;LL3821-7;Heart murmur grade;LA25121-7;1;Heart Murmur Grade I;46909005;cardiac murmur, intensity grade I/VI (finding);http://snomed.info/sct +80278-5;LL3821-7;Heart murmur grade;LA25122-5;2;Heart Murmur Grade II;36680007;cardiac murmur, intensity grade II/VI (finding);http://snomed.info/sct +80278-5;LL3821-7;Heart murmur grade;LA25123-3;3;Heart Murmur Grade III;15157000;cardiac murmur, intensity grade III/VI (finding);http://snomed.info/sct +80278-5;LL3821-7;Heart murmur grade;LA25124-1;4;Heart Murmur Grade IV;25311008;cardiac murmur, intensity grade IV/VI (finding);http://snomed.info/sct +80278-5;LL3821-7;Heart murmur grade;LA25125-8;5;Heart Murmur Grade V;37531003;cardiac murmur, intensity grade V/VI (finding);http://snomed.info/sct +80278-5;LL3821-7;Heart murmur grade;LA25126-6;6;Heart Murmur Grade VI;62967000;cardiac murmur, intensity grade VI/VI (finding);http://snomed.info/sct +80279-3;LL3822-5;Heart murmur quality;LA25127-4;1;Musical;;; +80279-3;LL3822-5;Heart murmur quality;LA25128-2;2;Squeaking;;; +80279-3;LL3822-5;Heart murmur quality;LA25129-0;3;Blowing;;; +80279-3;LL3822-5;Heart murmur quality;LA25130-8;4;Harsh;;; +80279-3;LL3822-5;Heart murmur quality;LA25131-6;5;Rumbling;;; +80280-1;LL3823-3;Heart mumur pitch;LA25132-4;1;Crescendo murmur;43889001;crescendo cardiac murmur (finding);http://snomed.info/sct +80280-1;LL3823-3;Heart mumur pitch;LA25133-2;2;Crescendo-decrescendo murmur;80547003;crescendo-decrescendo cardiac murmur (finding);http://snomed.info/sct +80280-1;LL3823-3;Heart mumur pitch;LA25134-0;3;Decrescendo murmur;89884001;decrescendo cardiac murmur (finding);http://snomed.info/sct +80280-1;LL3823-3;Heart mumur pitch;LA25034-2;4;High-pitched;;; +80280-1;LL3823-3;Heart mumur pitch;LA25035-9;5;Low-pitched;;; +80280-1;LL3823-3;Heart mumur pitch;LA25137-3;6;Medium-pitched;;; +80281-9;LL3824-1;Heart murmur timing in cycle;LA25138-1;1;Early diastolic;;; +80281-9;LL3824-1;Heart murmur timing in cycle;LA25139-9;2;Early systolic;;; +80281-9;LL3824-1;Heart murmur timing in cycle;LA25140-7;3;Late diastolic;;; +80281-9;LL3824-1;Heart murmur timing in cycle;LA25141-5;4;Late systolic;;; +80281-9;LL3824-1;Heart murmur timing in cycle;LA25142-3;5;Mid diastolic;;; +80281-9;LL3824-1;Heart murmur timing in cycle;LA25143-1;6;Mid systolic;;; +80281-9;LL3824-1;Heart murmur timing in cycle;LA25144-9;7;Pansystolic/holosystolic;;; +80282-7;LL3825-8;Heart murmur location;LA25151-4;1;Apical;;; +80282-7;LL3825-8;Heart murmur location;LA25152-2;2;Base;;; +80282-7;LL3825-8;Heart murmur location;LA25150-6;3;2nd intercostal space;243939008;Entire second intercostal space (body structure);http://snomed.info/sct +80282-7;LL3825-8;Heart murmur location;LA25153-0;4;3rd intercostal space;243940005;Entire third intercostal space (body structure);http://snomed.info/sct +80282-7;LL3825-8;Heart murmur location;LA25146-4;5;4th intercostal space;243941009;Entire fourth intercostal space (body structure);http://snomed.info/sct +80282-7;LL3825-8;Heart murmur location;LA25145-6;6;5th intercostal space;243942002;Entire fifth intercostal space (body structure);http://snomed.info/sct +80282-7;LL3825-8;Heart murmur location;LA25147-2;7;Left midclavicular line;;; +80282-7;LL3825-8;Heart murmur location;LA25148-0;8;Left sternal border;;; +80282-7;LL3825-8;Heart murmur location;LA25149-8;9;Right sternal border;;; +80283-5;LL3826-6;Murmur radiating to body location;LA25154-8;1;Apex;;; +80283-5;LL3826-6;Murmur radiating to body location;LA25155-5;2;Left axilla;;; +80283-5;LL3826-6;Murmur radiating to body location;LA12703-7;3;Neck;;; +80288-4;LL3828-2;Level of consciousness;LA6560-2;1;Confused;;; +80288-4;LL3828-2;Level of consciousness;LA25161-3;2;Lethargic;;; +80288-4;LL3828-2;Level of consciousness;LA25162-1;3;Obtunded;;; +80288-4;LL3828-2;Level of consciousness;LA25163-9;4;Stuporous;;; +80288-4;LL3828-2;Level of consciousness;LA9343-0;5;Unresponsive;422768004;unresponsive (finding);http://snomed.info/sct +80288-4;LL3828-2;Level of consciousness;LA9340-6;6;Alert;;; +80294-2;LL3830-8;Arousal Level;LA9347-1;1;Opens eyes spontaneously;;; +80294-2;LL3830-8;Arousal Level;LA25177-9;2;Arouses to voice;;; +80294-2;LL3830-8;Arousal Level;LA25175-3;3;Arouses to touch/gentle shaking;;; +80294-2;LL3830-8;Arousal Level;LA25174-6;4;Arouses to repeated stimulation;;; +80294-2;LL3830-8;Arousal Level;LA25176-1;5;Arouses to vigorous stimulation;;; +80294-2;LL3830-8;Arousal Level;LA25173-8;6;Arouses to pain;;; +80294-2;LL3830-8;Arousal Level;LA9343-0;7;Unresponsive;422768004;unresponsive (finding);http://snomed.info/sct +80295-9;LL3831-6;Speech intelligibility;LA25186-0;1;Appropriate for developmental age;;; +80295-9;LL3831-6;Speech intelligibility;LA25181-1;2;Coherent;;; +80295-9;LL3831-6;Speech intelligibility;LA25185-2;3;Slurred;;; +80295-9;LL3831-6;Speech intelligibility;LA25184-5;4;Rambling;;; +80295-9;LL3831-6;Speech intelligibility;LA25183-7;5;Limited enunciation;424650008;limited enunciation (finding);http://snomed.info/sct +80295-9;LL3831-6;Speech intelligibility;LA25182-9;6;Incoherent;;; +80297-5;LL3833-2;Memory;LA25189-4;1;Long-term memory intact;247587007;Long-term memory within normal limits (finding);http://snomed.info/sct +80297-5;LL3833-2;Memory;LA25188-6;2;Long-term memory poor;247588002;Poor long-term memory (finding);http://snomed.info/sct +80297-5;LL3833-2;Memory;LA25191-0;3;Short-term memory intact;247590001;Short-term memory within normal limits (finding);http://snomed.info/sct +80297-5;LL3833-2;Memory;LA25190-2;4;Short-term memory poor;247592009;Poor short-term memory (finding);http://snomed.info/sct +80298-3;LL3835-7;Ability to concentrate;LA25192-8;1;No difficulty concentrating;;; +80298-3;LL3835-7;Ability to concentrate;LA25193-6;2;Poor Concentration;26329005;Poor concentration (finding);http://snomed.info/sct +80298-3;LL3835-7;Ability to concentrate;LA25194-4;3;Difficulty concentrating;;; +80298-3;LL3835-7;Ability to concentrate;LA25195-1;4;Unable to concentrate;60032008;Unable to concentrate (finding);http://snomed.info/sct +80299-1;LL3836-5;Ability to direct attention;LA25196-9;1;Difficulty directing attention;288773008;Difficulty directing attention (finding);http://snomed.info/sct +80299-1;LL3836-5;Ability to direct attention;LA25197-7;2;Directs attention;288771005;Does direct attention (finding);http://snomed.info/sct +80299-1;LL3836-5;Ability to direct attention;LA25198-5;3;Does not direct attention;288772003;Does not direct attention (finding);http://snomed.info/sct +80299-1;LL3836-5;Ability to direct attention;LA25199-3;4;Unable to direct attention;288770006;Unable to direct attention (finding);http://snomed.info/sct +80301-5;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80301-5;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80302-3;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80302-3;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80303-1;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80303-1;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80304-9;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80304-9;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80305-6;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80305-6;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80306-4;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80306-4;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80307-2;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80307-2;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80308-0;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80308-0;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80309-8;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +80309-8;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +90101-7;LL3837-3;Pass|Fail;LA10392-1;1;Pass;;; +90101-7;LL3837-3;Pass|Fail;LA25389-0;2;Fail;;; +80311-4;LL3839-9;Pupil shape;LA19576-0;1;Dilated;;; +80311-4;LL3839-9;Pupil shape;LA25222-3;2;Cat eye;;; +80311-4;LL3839-9;Pupil shape;LA25223-1;3;Pinpoint;;; +80311-4;LL3839-9;Pupil shape;LA19583-6;4;Irregular;;; +80311-4;LL3839-9;Pupil shape;LA24884-1;5;Round;;; +80311-4;LL3839-9;Pupil shape;LA25226-4;6;Teardrop;;; +80312-2;LL3839-9;Pupil shape;LA19576-0;1;Dilated;;; +80312-2;LL3839-9;Pupil shape;LA25222-3;2;Cat eye;;; +80312-2;LL3839-9;Pupil shape;LA25223-1;3;Pinpoint;;; +80312-2;LL3839-9;Pupil shape;LA19583-6;4;Irregular;;; +80312-2;LL3839-9;Pupil shape;LA24884-1;5;Round;;; +80312-2;LL3839-9;Pupil shape;LA25226-4;6;Teardrop;;; +80316-3;LL3883-7;Pain scale types;LA25254-6;1;Reported;;; +80316-3;LL3883-7;Pain scale types;LA25253-8;2;Pain severity 0-10;;; +80316-3;LL3883-7;Pain scale types;LA25255-3;3;FLACC;;; +80316-3;LL3883-7;Pain scale types;LA25256-1;4;Neonatal faces;;; +80316-3;LL3883-7;Pain scale types;LA25257-9;5;Wong-Baker FACES;;; +80319-7;LL3841-5;Breath sound qualifier;LA19732-9;1;Clear;;; +80319-7;LL3841-5;Breath sound qualifier;LA17235-5;2;Rales (respiratory crackles);;; +80319-7;LL3841-5;Breath sound qualifier;LA17612-5;3;Stridor;70407001;stridor (finding);http://snomed.info/sct +80319-7;LL3841-5;Breath sound qualifier;LA25243-9;4;Rhonchus;;; +80319-7;LL3841-5;Breath sound qualifier;LA25244-7;5;Wheezes;;; +80322-1;LL3885-2;Muscle strength;LA46-8;1;Other;;; +80322-1;LL3885-2;Muscle strength;LA25264-5;2;Decreased muscle strength;;; +80322-1;LL3885-2;Muscle strength;LA25085-4;3;Within Defined Limits;;; +80323-9;LL3842-3;Involuntary movements;LA25245-4;1;Coarse tremor;;; +80323-9;LL3842-3;Involuntary movements;LA25246-2;2;Fine tremor;;; +80323-9;LL3842-3;Involuntary movements;LA25247-0;3;Intention tremor;;; +80323-9;LL3842-3;Involuntary movements;LA25248-8;4;Parkinsonian tremor;;; +80323-9;LL3842-3;Involuntary movements;LA25249-6;5;Spasm/Tic;;; +80326-2;LL3844-9;Paralysis type;LA25274-4;1;Hemiplegia;;; +80326-2;LL3844-9;Paralysis type;LA25275-1;2;Monoplegia;;; +80326-2;LL3844-9;Paralysis type;LA25276-9;3;Paraplegia;;; +80326-2;LL3844-9;Paralysis type;LA25277-7;4;Quadriplegia/Tetraplegia;;; +80327-0;LL3845-6;Parasthesia sensation;LA25279-3;1;Burning;;; +80327-0;LL3845-6;Parasthesia sensation;LA25280-1;2;Skin-crawling;;; +80327-0;LL3845-6;Parasthesia sensation;LA20641-9;3;Itching;418290006;Itching (finding);http://snomed.info/sct +80327-0;LL3845-6;Parasthesia sensation;LA25282-7;4;Numbness and Tingling;;; +80327-0;LL3845-6;Parasthesia sensation;LA25283-5;5;Pins and Needles;62507009;Pins and needles (finding);http://snomed.info/sct +80327-0;LL3845-6;Parasthesia sensation;LA25284-3;6;Prickling;;; +80332-0;LL3849-8;Voiding characteristics;LA25308-0;1;Anuria;2472002;Anuria (finding);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25309-8;2;Hesitancy;;; +80332-0;LL3849-8;Voiding characteristics;LA25310-6;3;Dribbling;;; +80332-0;LL3849-8;Voiding characteristics;LA17661-2;4;Dysuria;49650001;dysuria (finding);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25312-2;5;Put on hemodialysis;;; +80332-0;LL3849-8;Voiding characteristics;LA7445-5;6;Incontinence;48340000;incontinence (finding);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25314-8;7;Condom catheter;;; +80332-0;LL3849-8;Voiding characteristics;LA25315-5;8;Increased urinary frequency;;; +80332-0;LL3849-8;Voiding characteristics;LA25316-3;9;Intermittent urinary incontinence;450841000;intermittent urinary incontinence (finding);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25317-1;10;Strains to void;;; +80332-0;LL3849-8;Voiding characteristics;LA25318-9;11;Nocturia;139394000;nocturia (finding);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25319-7;12;Enuresis;;; +80332-0;LL3849-8;Voiding characteristics;LA25320-5;13;Voids spontaneously without difficulty;;; +80332-0;LL3849-8;Voiding characteristics;LA25321-3;14;Oliguria;83128009;oliguria (finding);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25322-1;15;Patient on peritoneal dialysis;;; +80332-0;LL3849-8;Voiding characteristics;LA25323-9;16;Polyuria;28442001;polyuria (finding);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25324-7;17;Suprapubic catheter;286861005;suprapubic catheter (physical object);http://snomed.info/sct +80332-0;LL3849-8;Voiding characteristics;LA25325-4;18;Unable to void;;; +80332-0;LL3849-8;Voiding characteristics;LA25326-2;19;Urethral catheter;;; +80332-0;LL3849-8;Voiding characteristics;LA25327-0;20;Urgency;;; +80332-0;LL3849-8;Voiding characteristics;LA25328-8;21;Urostomy;;; +80333-8;LL3850-6;Urine contents;LA25329-6;1;Mucous threads;;; +80333-8;LL3850-6;Urine contents;LA25330-4;2;Stones;;; +80333-8;LL3850-6;Urine contents;LA25331-2;3;Sediment;;; +80333-8;LL3850-6;Urine contents;LA25774-3;4;Clots;;; +80334-6;LL3886-0;Urine collection device;LA25314-8;1;Condom catheter;;; +80334-6;LL3886-0;Urine collection device;LA25324-7;2;Suprapubic catheter;286861005;suprapubic catheter (physical object);http://snomed.info/sct +80334-6;LL3886-0;Urine collection device;LA25326-2;3;Urethral catheter;;; +80334-6;LL3886-0;Urine collection device;LA25775-0;4;Foley catheter;;; +80334-6;LL3886-0;Urine collection device;LA25328-8;5;Urostomy;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25338-7;1;Massage;387854002;Massage physiotherapy (regime/therapy);http://snomed.info/sct +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25339-5;2;Aromatherapy;394615007;Aromatherapy (regime/therapy);http://snomed.info/sct +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25340-3;3;Heat therapy;266694003;Heat therapy (procedure);http://snomed.info/sct +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25341-1;4;Cold therapy;182660006;Cold therapy (regime/therapy);http://snomed.info/sct +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25342-9;5;Birthing ball;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25343-7;6;Aqua K Pad;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA19765-9;7;Brace;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25345-2;8;Corset;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25346-0;9;Breathing;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25347-8;10;Decreased Environmental Stimuli;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25348-6;11;Distraction;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25349-4;12;Elevation;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA22651-6;13;Exercise;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25351-0;14;Guided Imagery;228565006;Imagery technique (regime/therapy);http://snomed.info/sct +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25352-8;15;Immobilize;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25353-6;16;Music;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25354-4;17;Reposition;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25355-1;18;Relaxation;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25356-9;19;Rest;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA25357-7;20;TENS Unit;;; +80340-3;LL3852-2;Pain nonpharmacologic intervention method;LA11834-1;21;Walking;;; +80341-1;LL3854-8;Respiratory effort;LA25370-0;1;Unlabored;;; +80341-1;LL3854-8;Respiratory effort;LA25371-8;2;Labored;;; +80341-1;LL3854-8;Respiratory effort;LA25372-6;3;Accessory muscles used;;; +80341-1;LL3854-8;Respiratory effort;LA25373-4;4;Orthopnea;;; +80341-1;LL3854-8;Respiratory effort;LA17611-7;5;Dyspnea;267036007;dyspnea (finding);http://snomed.info/sct +80342-9;LL3853-0;Breath sounds location;LA25359-3;1;Left lung;;; +80342-9;LL3853-0;Breath sounds location;LA25360-1;2;Right lung;;; +80342-9;LL3853-0;Breath sounds location;LA25361-9;3;Bilateral lungs;;; +80342-9;LL3853-0;Breath sounds location;LA25362-7;4;Right upper lobe;;; +80342-9;LL3853-0;Breath sounds location;LA25363-5;5;Left upper lobe;;; +80342-9;LL3853-0;Breath sounds location;LA25364-3;6;Right lower lobe;;; +80342-9;LL3853-0;Breath sounds location;LA25365-0;7;Left lower lobe;;; +80342-9;LL3853-0;Breath sounds location;LA25366-8;8;Right middle lobe;;; +80342-9;LL3853-0;Breath sounds location;LA25367-6;9;Left lung base;;; +80342-9;LL3853-0;Breath sounds location;LA25368-4;10;Right lung base;;; +80342-9;LL3853-0;Breath sounds location;LA25369-2;11;Bilateral lung bases;;; +80344-5;LL3855-5;Intact|Not intact;LA18951-6;1;Intact;;; +80344-5;LL3855-5;Intact|Not intact;LA25376-7;2;Not intact;;; +80347-8;LL3855-5;Intact|Not intact;LA18951-6;1;Intact;;; +80347-8;LL3855-5;Intact|Not intact;LA25376-7;2;Not intact;;; +80345-2;LL3888-6;Skin pressure points;LA25776-8;1;Occiput (back of head);;; +80345-2;LL3888-6;Skin pressure points;LA21929-7;2;Ear;;; +80345-2;LL3888-6;Skin pressure points;LA4298-1;3;Shoulder;;; +80345-2;LL3888-6;Skin pressure points;LA16717-3;4;Elbow;;; +80345-2;LL3888-6;Skin pressure points;LA3973-0;5;Hip;;; +80345-2;LL3888-6;Skin pressure points;LA25777-6;6;Buttock;;; +80345-2;LL3888-6;Skin pressure points;LA25779-2;7;Thigh;;; +80345-2;LL3888-6;Skin pressure points;LA22232-5;8;Knee;;; +80345-2;LL3888-6;Skin pressure points;LA25778-4;9;Heel;;; +80345-2;LL3888-6;Skin pressure points;LA16754-6;10;Toes;;; +80369-2;LL3890-2;N gonorr|N mening|Not detected;LA11883-8;1;Not detected;;; +80369-2;LL3890-2;N gonorr|N mening|Not detected;LA25785-9;2;Neisseria gonorrhoeae;68704007;Neisseria gonorrhoeae (organism);http://snomed.info/sct +80369-2;LL3890-2;N gonorr|N mening|Not detected;LA16626-6;3;Neisseria meningitidis;17872004;Neisseria meningitidis (organism);http://snomed.info/sct +80389-0;LL3862-1;Special medical needs;LA25410-4;1;Ventilator;;; +80389-0;LL3862-1;Special medical needs;LA7216-0;2;Dialysis;;; +80389-0;LL3862-1;Special medical needs;LA25411-2;3;Oxygen;;; +80389-0;LL3862-1;Special medical needs;LA25409-6;4;Do not resuscitate (DNR) order;;; +80391-6;LL3863-9;Evacuation destination requirement;LA20596-5;1;Intensive care unit (ICU);;; +80391-6;LL3863-9;Evacuation destination requirement;LA25414-6;2;Hospital floor;;; +80391-6;LL3863-9;Evacuation destination requirement;LA25413-8;3;Discharge ready;;; +80392-4;LL3864-7;Special accommodations;LA25416-1;1;Security Supervision Needs;;; +80392-4;LL3864-7;Special accommodations;LA25415-3;2;National Disaster Medical System (NDMS) patient;;; +80394-0;LL3869-6;Incident type;LA18356-8;1;Chemical;;; +80394-0;LL3869-6;Incident type;LA25433-6;2;Biological;;; +80394-0;LL3869-6;Incident type;LA25432-8;3;Nuclear;;; +80394-0;LL3869-6;Incident type;LA25430-2;4;Explosives;;; +80394-0;LL3869-6;Incident type;LA25431-0;5;Natural disaster;;; +80394-0;LL3869-6;Incident type;LA25429-4;6;Day-to-day;;; +80402-1;LL3891-0;Self|Non-self;LA15312-4;1;Self;;; +80402-1;LL3891-0;Self|Non-self;LA25786-7;2;Non-self;;; +80405-4;LL3867-0;Certification level;LA18700-7;1;First responder;;; +80405-4;LL3867-0;Certification level;LA25424-5;2;EMT - Basic;;; +80405-4;LL3867-0;Certification level;LA25425-2;3;EMT - Advanced;;; +80405-4;LL3867-0;Certification level;LA25426-0;4;Paramedic;;; +80407-0;LL3865-4;True|False|Unknown;LA14495-8;1;True;;; +80407-0;LL3865-4;True|False|Unknown;LA14496-6;2;False;;; +80407-0;LL3865-4;True|False|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +92240-1;LL3865-4;True|False|Unknown;LA14495-8;1;True;;; +92240-1;LL3865-4;True|False|Unknown;LA14496-6;2;False;;; +92240-1;LL3865-4;True|False|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +80409-6;LL3866-2;Bed type;LA19834-3;1;Pediatric;;; +80409-6;LL3866-2;Bed type;LA7318-4;2;Burn;;; +80409-6;LL3866-2;Bed type;LA25421-1;3;Psychiatric;;; +80409-6;LL3866-2;Bed type;LA25422-9;4;MedicalSurgical;;; +80409-6;LL3866-2;Bed type;LA25423-7;5;CriticalCare;;; +80475-7;LL3881-1;NUTR_Enteral composition Phys Find Nutrition;;0;;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA24562-3;1;Adenovirus;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA25838-6;2;Human metapneumovirus;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA11919-0;3;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +80602-6;LL3897-7;Respiratory pathogens detected;LA13023-9;4;Influenza A (H1);;; +80602-6;LL3897-7;Respiratory pathogens detected;LA13024-7;5;Influenza A (H3);;; +80602-6;LL3897-7;Respiratory pathogens detected;LA13543-6;6;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +80602-6;LL3897-7;Respiratory pathogens detected;LA19236-1;7;Parainfluenza virus 1;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA19237-9;8;Parainfluenza virus 2;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA19238-7;9;Parainfluenza virus 3;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA25846-9;10;Parainfluenza virus 4;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA25843-6;11;Rhinovirus;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA25844-4;12;Respiratory syncytial virus A;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA25845-1;13;Respiratory syncytial virus B;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA25839-4;14;Bordetella parapertussis and/or B. bronchiseptica;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA25841-0;15;Bordetella holmesii;;; +80602-6;LL3897-7;Respiratory pathogens detected;LA14117-8;16;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +80626-5;LL3895-1;PHVS_ActivityType_NCHS;;0;;;; +80661-2;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA25958-2;1;Pale yellow;;; +80661-2;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA17195-1;2;Yellow;;; +80661-2;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA25957-4;3;Pink-tinged;;; +80661-2;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA17192-8;4;Pink;;; +80661-2;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA17193-6;5;Red;;; +96715-8;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA25958-2;1;Pale yellow;;; +96715-8;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA17195-1;2;Yellow;;; +96715-8;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA25957-4;3;Pink-tinged;;; +96715-8;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA17192-8;4;Pink;;; +96715-8;LL3917-3;Pale Yel|Yel|P tinge|Pink|Red;LA17193-6;5;Red;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA19757-6;1;V31I;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24443-6;2;V72I;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24440-2;3;T97A;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24444-4;4;L101I;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24445-1;5;V113I;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24442-8;6;S119S/T;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24446-9;7;T124A;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24447-7;8;E138D;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24441-0;9;Y143R;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24449-3;10;E157E/Q;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24450-1;11;K188R;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24451-9;12;G193E;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24452-7;13;V201I;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24453-5;14;V234L;;; +80691-9;LL3697-1;HIV1 Integrase 2;LA24454-3;15;D288N;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA19757-6;1;V31I;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24443-6;2;V72I;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24440-2;3;T97A;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24444-4;4;L101I;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24445-1;5;V113I;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24442-8;6;S119S/T;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24446-9;7;T124A;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24447-7;8;E138D;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24441-0;9;Y143R;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24449-3;10;E157E/Q;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24450-1;11;K188R;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24451-9;12;G193E;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24452-7;13;V201I;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24453-5;14;V234L;;; +88542-6;LL3697-1;HIV1 Integrase 2;LA24454-3;15;D288N;;; +80715-6;LL3934-8;FSHR gene mutations found;LA22756-3;1;Negative for the mutations and variants analyzed;;; +80715-6;LL3934-8;FSHR gene mutations found;LA25985-5;2;p.Thr307Ala;;; +80715-6;LL3934-8;FSHR gene mutations found;LA25986-3;3;p.Pro348Arg;;; +80715-6;LL3934-8;FSHR gene mutations found;LA25987-1;4;p.Pro519Thr;;; +80715-6;LL3934-8;FSHR gene mutations found;LA25984-8;5;p.Asn680Ser;;; +80729-7;LL3700-3;De novo stenosis|Restenosis;LA24479-0;1;De novo stenosis;;; +80729-7;LL3700-3;De novo stenosis|Restenosis;LA24480-8;2;Restenosis;;; +80730-5;LL3701-1;[AHA/ACC] Type A|Type B1|Type B2|Type C;LA24481-6;1;Type A;;; +80730-5;LL3701-1;[AHA/ACC] Type A|Type B1|Type B2|Type C;LA24482-4;2;Type B1;;; +80730-5;LL3701-1;[AHA/ACC] Type A|Type B1|Type B2|Type C;LA24483-2;3;Type B2;;; +80730-5;LL3701-1;[AHA/ACC] Type A|Type B1|Type B2|Type C;LA24484-0;4;Type C;;; +80738-8;LL3715-1;Example TPMT gene variants;LA24547-4;1;c.238G>C;;; +80738-8;LL3715-1;Example TPMT gene variants;LA24548-2;2;c.460G>A and c.719A>G;;; +80738-8;LL3715-1;Example TPMT gene variants;LA24549-0;3;c.460G>A;;; +80738-8;LL3715-1;Example TPMT gene variants;LA24550-8;4;c.719A>G;;; +80738-8;LL3715-1;Example TPMT gene variants;LA24551-6;5;intron 9/exon10 splice junction mutation;;; +80884-0;LL3797-9;Not | 1 in 5 | half | almst always;LA6568-5;1;Not at all;;; +80884-0;LL3797-9;Not | 1 in 5 | half | almst always;LA24478-2;2;Less than 1 time in 5;;; +80884-0;LL3797-9;Not | 1 in 5 | half | almst always;LA14723-3;3;Less than half the time;;; +80884-0;LL3797-9;Not | 1 in 5 | half | almst always;LA24963-3;4;About half the time;;; +80884-0;LL3797-9;Not | 1 in 5 | half | almst always;LA14724-1;5;More than half the time;;; +80884-0;LL3797-9;Not | 1 in 5 | half | almst always;LA13865-3;6;Almost always;;; +80885-7;LL3797-9;Not | 1 in 5 | half | almst always;LA6568-5;1;Not at all;;; +80885-7;LL3797-9;Not | 1 in 5 | half | almst always;LA24478-2;2;Less than 1 time in 5;;; +80885-7;LL3797-9;Not | 1 in 5 | half | almst always;LA14723-3;3;Less than half the time;;; +80885-7;LL3797-9;Not | 1 in 5 | half | almst always;LA24963-3;4;About half the time;;; +80885-7;LL3797-9;Not | 1 in 5 | half | almst always;LA14724-1;5;More than half the time;;; +80885-7;LL3797-9;Not | 1 in 5 | half | almst always;LA13865-3;6;Almost always;;; +80886-5;LL3797-9;Not | 1 in 5 | half | almst always;LA6568-5;1;Not at all;;; +80886-5;LL3797-9;Not | 1 in 5 | half | almst always;LA24478-2;2;Less than 1 time in 5;;; +80886-5;LL3797-9;Not | 1 in 5 | half | almst always;LA14723-3;3;Less than half the time;;; +80886-5;LL3797-9;Not | 1 in 5 | half | almst always;LA24963-3;4;About half the time;;; +80886-5;LL3797-9;Not | 1 in 5 | half | almst always;LA14724-1;5;More than half the time;;; +80886-5;LL3797-9;Not | 1 in 5 | half | almst always;LA13865-3;6;Almost always;;; +80887-3;LL3797-9;Not | 1 in 5 | half | almst always;LA6568-5;1;Not at all;;; +80887-3;LL3797-9;Not | 1 in 5 | half | almst always;LA24478-2;2;Less than 1 time in 5;;; +80887-3;LL3797-9;Not | 1 in 5 | half | almst always;LA14723-3;3;Less than half the time;;; +80887-3;LL3797-9;Not | 1 in 5 | half | almst always;LA24963-3;4;About half the time;;; +80887-3;LL3797-9;Not | 1 in 5 | half | almst always;LA14724-1;5;More than half the time;;; +80887-3;LL3797-9;Not | 1 in 5 | half | almst always;LA13865-3;6;Almost always;;; +80888-1;LL3797-9;Not | 1 in 5 | half | almst always;LA6568-5;1;Not at all;;; +80888-1;LL3797-9;Not | 1 in 5 | half | almst always;LA24478-2;2;Less than 1 time in 5;;; +80888-1;LL3797-9;Not | 1 in 5 | half | almst always;LA14723-3;3;Less than half the time;;; +80888-1;LL3797-9;Not | 1 in 5 | half | almst always;LA24963-3;4;About half the time;;; +80888-1;LL3797-9;Not | 1 in 5 | half | almst always;LA14724-1;5;More than half the time;;; +80888-1;LL3797-9;Not | 1 in 5 | half | almst always;LA13865-3;6;Almost always;;; +80889-9;LL3797-9;Not | 1 in 5 | half | almst always;LA6568-5;1;Not at all;;; +80889-9;LL3797-9;Not | 1 in 5 | half | almst always;LA24478-2;2;Less than 1 time in 5;;; +80889-9;LL3797-9;Not | 1 in 5 | half | almst always;LA14723-3;3;Less than half the time;;; +80889-9;LL3797-9;Not | 1 in 5 | half | almst always;LA24963-3;4;About half the time;;; +80889-9;LL3797-9;Not | 1 in 5 | half | almst always;LA14724-1;5;More than half the time;;; +80889-9;LL3797-9;Not | 1 in 5 | half | almst always;LA13865-3;6;Almost always;;; +80890-7;LL3961-1;None | 1 | 2 | 3 | 4 | 5 or more;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +80890-7;LL3961-1;None | 1 | 2 | 3 | 4 | 5 or more;LA14677-1;2;1 time;;; +80890-7;LL3961-1;None | 1 | 2 | 3 | 4 | 5 or more;LA23711-7;3;2 times;;; +80890-7;LL3961-1;None | 1 | 2 | 3 | 4 | 5 or more;LA23712-5;4;3 times;;; +80890-7;LL3961-1;None | 1 | 2 | 3 | 4 | 5 or more;LA26056-4;5;4 times;;; +80890-7;LL3961-1;None | 1 | 2 | 3 | 4 | 5 or more;LA26057-2;6;5 or more times;;; +80902-0;LL3922-3;PHVS_NewbornGivenSurfactantReplacement_NCHS;;0;;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25832-9;1;Burial;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25833-7;2;Cremation;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25834-5;3;Donation;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25835-2;4;Entombment;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25836-0;5;Removal from state;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA46-8;6;Other;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25832-9;1;Burial;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25833-7;2;Cremation;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25834-5;3;Donation;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25835-2;4;Entombment;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA25836-0;5;Removal from state;;; +80905-3;LL3896-9;Burial | Crem | Don | Entomb | Rem |Oth;LA46-8;6;Other;;; +80906-1;LL3927-2;PHVS_NCHSBridgedRace_NCHS;;0;;;; +88119-3;LL3927-2;PHVS_NCHSBridgedRace_NCHS;;0;;;; +88120-1;LL3927-2;PHVS_NCHSBridgedRace_NCHS;;0;;;; +80908-7;LL3928-0;PHVS_NCHSEthnicityDetail_NCHS;;0;;;; +80916-0;LL3699-7;Coronary artery segments;LA24460-0;1;Proximal right coronary artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24461-8;2;Mid right coronary artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24462-6;3;Distal right coronary artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24473-3;4;Posterior descending from right coronary artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24474-1;5;Atrioventricular nodal artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24477-4;6;Posterolateral from right coronary artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24463-4;7;Left main coronary artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24472-5;8;Proximal left anterior descending artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24471-7;9;Mid left anterior descending artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24470-9;10;Distal left anterior descending artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24459-2;11;Proximal left circumflex artery;;; +80916-0;LL3699-7;Coronary artery segments;LA30588-0;12;High lateral branch;;; +80916-0;LL3699-7;Coronary artery segments;LA24458-4;13;Mid and distal left circumflex artery;;; +80916-0;LL3699-7;Coronary artery segments;LA28662-7;14;Mid left circumflex artery;;; +80916-0;LL3699-7;Coronary artery segments;LA28663-5;15;Distal left circumflex artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24467-5;16;Diagonal artery 1;;; +80916-0;LL3699-7;Coronary artery segments;LA24475-8;17;Additional diagonal artery 1;;; +80916-0;LL3699-7;Coronary artery segments;LA24468-3;18;Diagonal artery 2;;; +80916-0;LL3699-7;Coronary artery segments;LA24476-6;19;Additional diagonal artery 2;;; +80916-0;LL3699-7;Coronary artery segments;LA24469-1;20;Obtuse marginal artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24466-7;21;Posterolateral from left circumflex artery;;; +80916-0;LL3699-7;Coronary artery segments;LA24464-2;22;Ramus intermedius from left main coronary artery;;; +80916-0;LL3699-7;Coronary artery segments;LA30559-1;23;Saphenous vein graft - Left anterior descending (SVG-LAD);;; +80916-0;LL3699-7;Coronary artery segments;LA30560-9;24;Saphenous vein graft - Left circumflex (SVG-LCX);;; +80916-0;LL3699-7;Coronary artery segments;LA30561-7;25;Saphenous vein graft - Right coronary artery (SVG-RCA);;; +80916-0;LL3699-7;Coronary artery segments;LA30562-5;26;Arterial graft - Left anterior descending (AG-LAD);;; +80916-0;LL3699-7;Coronary artery segments;LA30563-3;27;Arterial graft - Left circumflex (AG-LCX);;; +80916-0;LL3699-7;Coronary artery segments;LA30564-1;28;Arterial graft - Right coronary artery (AG-RCA);;; +80916-0;LL3699-7;Coronary artery segments;LA46-8;29;Other;;; +80919-4;LL3699-7;Coronary artery segments;LA24460-0;1;Proximal right coronary artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24461-8;2;Mid right coronary artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24462-6;3;Distal right coronary artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24473-3;4;Posterior descending from right coronary artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24474-1;5;Atrioventricular nodal artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24477-4;6;Posterolateral from right coronary artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24463-4;7;Left main coronary artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24472-5;8;Proximal left anterior descending artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24471-7;9;Mid left anterior descending artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24470-9;10;Distal left anterior descending artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24459-2;11;Proximal left circumflex artery;;; +80919-4;LL3699-7;Coronary artery segments;LA30588-0;12;High lateral branch;;; +80919-4;LL3699-7;Coronary artery segments;LA24458-4;13;Mid and distal left circumflex artery;;; +80919-4;LL3699-7;Coronary artery segments;LA28662-7;14;Mid left circumflex artery;;; +80919-4;LL3699-7;Coronary artery segments;LA28663-5;15;Distal left circumflex artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24467-5;16;Diagonal artery 1;;; +80919-4;LL3699-7;Coronary artery segments;LA24475-8;17;Additional diagonal artery 1;;; +80919-4;LL3699-7;Coronary artery segments;LA24468-3;18;Diagonal artery 2;;; +80919-4;LL3699-7;Coronary artery segments;LA24476-6;19;Additional diagonal artery 2;;; +80919-4;LL3699-7;Coronary artery segments;LA24469-1;20;Obtuse marginal artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24466-7;21;Posterolateral from left circumflex artery;;; +80919-4;LL3699-7;Coronary artery segments;LA24464-2;22;Ramus intermedius from left main coronary artery;;; +80919-4;LL3699-7;Coronary artery segments;LA30559-1;23;Saphenous vein graft - Left anterior descending (SVG-LAD);;; +80919-4;LL3699-7;Coronary artery segments;LA30560-9;24;Saphenous vein graft - Left circumflex (SVG-LCX);;; +80919-4;LL3699-7;Coronary artery segments;LA30561-7;25;Saphenous vein graft - Right coronary artery (SVG-RCA);;; +80919-4;LL3699-7;Coronary artery segments;LA30562-5;26;Arterial graft - Left anterior descending (AG-LAD);;; +80919-4;LL3699-7;Coronary artery segments;LA30563-3;27;Arterial graft - Left circumflex (AG-LCX);;; +80919-4;LL3699-7;Coronary artery segments;LA30564-1;28;Arterial graft - Right coronary artery (AG-RCA);;; +80919-4;LL3699-7;Coronary artery segments;LA46-8;29;Other;;; +80923-6;LL3699-7;Coronary artery segments;LA24460-0;1;Proximal right coronary artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24461-8;2;Mid right coronary artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24462-6;3;Distal right coronary artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24473-3;4;Posterior descending from right coronary artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24474-1;5;Atrioventricular nodal artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24477-4;6;Posterolateral from right coronary artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24463-4;7;Left main coronary artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24472-5;8;Proximal left anterior descending artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24471-7;9;Mid left anterior descending artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24470-9;10;Distal left anterior descending artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24459-2;11;Proximal left circumflex artery;;; +80923-6;LL3699-7;Coronary artery segments;LA30588-0;12;High lateral branch;;; +80923-6;LL3699-7;Coronary artery segments;LA24458-4;13;Mid and distal left circumflex artery;;; +80923-6;LL3699-7;Coronary artery segments;LA28662-7;14;Mid left circumflex artery;;; +80923-6;LL3699-7;Coronary artery segments;LA28663-5;15;Distal left circumflex artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24467-5;16;Diagonal artery 1;;; +80923-6;LL3699-7;Coronary artery segments;LA24475-8;17;Additional diagonal artery 1;;; +80923-6;LL3699-7;Coronary artery segments;LA24468-3;18;Diagonal artery 2;;; +80923-6;LL3699-7;Coronary artery segments;LA24476-6;19;Additional diagonal artery 2;;; +80923-6;LL3699-7;Coronary artery segments;LA24469-1;20;Obtuse marginal artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24466-7;21;Posterolateral from left circumflex artery;;; +80923-6;LL3699-7;Coronary artery segments;LA24464-2;22;Ramus intermedius from left main coronary artery;;; +80923-6;LL3699-7;Coronary artery segments;LA30559-1;23;Saphenous vein graft - Left anterior descending (SVG-LAD);;; +80923-6;LL3699-7;Coronary artery segments;LA30560-9;24;Saphenous vein graft - Left circumflex (SVG-LCX);;; +80923-6;LL3699-7;Coronary artery segments;LA30561-7;25;Saphenous vein graft - Right coronary artery (SVG-RCA);;; +80923-6;LL3699-7;Coronary artery segments;LA30562-5;26;Arterial graft - Left anterior descending (AG-LAD);;; +80923-6;LL3699-7;Coronary artery segments;LA30563-3;27;Arterial graft - Left circumflex (AG-LCX);;; +80923-6;LL3699-7;Coronary artery segments;LA30564-1;28;Arterial graft - Right coronary artery (AG-RCA);;; +80923-6;LL3699-7;Coronary artery segments;LA46-8;29;Other;;; +80926-9;LL3699-7;Coronary artery segments;LA24460-0;1;Proximal right coronary artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24461-8;2;Mid right coronary artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24462-6;3;Distal right coronary artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24473-3;4;Posterior descending from right coronary artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24474-1;5;Atrioventricular nodal artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24477-4;6;Posterolateral from right coronary artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24463-4;7;Left main coronary artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24472-5;8;Proximal left anterior descending artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24471-7;9;Mid left anterior descending artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24470-9;10;Distal left anterior descending artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24459-2;11;Proximal left circumflex artery;;; +80926-9;LL3699-7;Coronary artery segments;LA30588-0;12;High lateral branch;;; +80926-9;LL3699-7;Coronary artery segments;LA24458-4;13;Mid and distal left circumflex artery;;; +80926-9;LL3699-7;Coronary artery segments;LA28662-7;14;Mid left circumflex artery;;; +80926-9;LL3699-7;Coronary artery segments;LA28663-5;15;Distal left circumflex artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24467-5;16;Diagonal artery 1;;; +80926-9;LL3699-7;Coronary artery segments;LA24475-8;17;Additional diagonal artery 1;;; +80926-9;LL3699-7;Coronary artery segments;LA24468-3;18;Diagonal artery 2;;; +80926-9;LL3699-7;Coronary artery segments;LA24476-6;19;Additional diagonal artery 2;;; +80926-9;LL3699-7;Coronary artery segments;LA24469-1;20;Obtuse marginal artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24466-7;21;Posterolateral from left circumflex artery;;; +80926-9;LL3699-7;Coronary artery segments;LA24464-2;22;Ramus intermedius from left main coronary artery;;; +80926-9;LL3699-7;Coronary artery segments;LA30559-1;23;Saphenous vein graft - Left anterior descending (SVG-LAD);;; +80926-9;LL3699-7;Coronary artery segments;LA30560-9;24;Saphenous vein graft - Left circumflex (SVG-LCX);;; +80926-9;LL3699-7;Coronary artery segments;LA30561-7;25;Saphenous vein graft - Right coronary artery (SVG-RCA);;; +80926-9;LL3699-7;Coronary artery segments;LA30562-5;26;Arterial graft - Left anterior descending (AG-LAD);;; +80926-9;LL3699-7;Coronary artery segments;LA30563-3;27;Arterial graft - Left circumflex (AG-LCX);;; +80926-9;LL3699-7;Coronary artery segments;LA30564-1;28;Arterial graft - Right coronary artery (AG-RCA);;; +80926-9;LL3699-7;Coronary artery segments;LA46-8;29;Other;;; +80927-7;LL3699-7;Coronary artery segments;LA24460-0;1;Proximal right coronary artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24461-8;2;Mid right coronary artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24462-6;3;Distal right coronary artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24473-3;4;Posterior descending from right coronary artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24474-1;5;Atrioventricular nodal artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24477-4;6;Posterolateral from right coronary artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24463-4;7;Left main coronary artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24472-5;8;Proximal left anterior descending artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24471-7;9;Mid left anterior descending artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24470-9;10;Distal left anterior descending artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24459-2;11;Proximal left circumflex artery;;; +80927-7;LL3699-7;Coronary artery segments;LA30588-0;12;High lateral branch;;; +80927-7;LL3699-7;Coronary artery segments;LA24458-4;13;Mid and distal left circumflex artery;;; +80927-7;LL3699-7;Coronary artery segments;LA28662-7;14;Mid left circumflex artery;;; +80927-7;LL3699-7;Coronary artery segments;LA28663-5;15;Distal left circumflex artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24467-5;16;Diagonal artery 1;;; +80927-7;LL3699-7;Coronary artery segments;LA24475-8;17;Additional diagonal artery 1;;; +80927-7;LL3699-7;Coronary artery segments;LA24468-3;18;Diagonal artery 2;;; +80927-7;LL3699-7;Coronary artery segments;LA24476-6;19;Additional diagonal artery 2;;; +80927-7;LL3699-7;Coronary artery segments;LA24469-1;20;Obtuse marginal artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24466-7;21;Posterolateral from left circumflex artery;;; +80927-7;LL3699-7;Coronary artery segments;LA24464-2;22;Ramus intermedius from left main coronary artery;;; +80927-7;LL3699-7;Coronary artery segments;LA30559-1;23;Saphenous vein graft - Left anterior descending (SVG-LAD);;; +80927-7;LL3699-7;Coronary artery segments;LA30560-9;24;Saphenous vein graft - Left circumflex (SVG-LCX);;; +80927-7;LL3699-7;Coronary artery segments;LA30561-7;25;Saphenous vein graft - Right coronary artery (SVG-RCA);;; +80927-7;LL3699-7;Coronary artery segments;LA30562-5;26;Arterial graft - Left anterior descending (AG-LAD);;; +80927-7;LL3699-7;Coronary artery segments;LA30563-3;27;Arterial graft - Left circumflex (AG-LCX);;; +80927-7;LL3699-7;Coronary artery segments;LA30564-1;28;Arterial graft - Right coronary artery (AG-RCA);;; +80927-7;LL3699-7;Coronary artery segments;LA46-8;29;Other;;; +80999-6;LL3699-7;Coronary artery segments;LA24460-0;1;Proximal right coronary artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24461-8;2;Mid right coronary artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24462-6;3;Distal right coronary artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24473-3;4;Posterior descending from right coronary artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24474-1;5;Atrioventricular nodal artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24477-4;6;Posterolateral from right coronary artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24463-4;7;Left main coronary artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24472-5;8;Proximal left anterior descending artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24471-7;9;Mid left anterior descending artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24470-9;10;Distal left anterior descending artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24459-2;11;Proximal left circumflex artery;;; +80999-6;LL3699-7;Coronary artery segments;LA30588-0;12;High lateral branch;;; +80999-6;LL3699-7;Coronary artery segments;LA24458-4;13;Mid and distal left circumflex artery;;; +80999-6;LL3699-7;Coronary artery segments;LA28662-7;14;Mid left circumflex artery;;; +80999-6;LL3699-7;Coronary artery segments;LA28663-5;15;Distal left circumflex artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24467-5;16;Diagonal artery 1;;; +80999-6;LL3699-7;Coronary artery segments;LA24475-8;17;Additional diagonal artery 1;;; +80999-6;LL3699-7;Coronary artery segments;LA24468-3;18;Diagonal artery 2;;; +80999-6;LL3699-7;Coronary artery segments;LA24476-6;19;Additional diagonal artery 2;;; +80999-6;LL3699-7;Coronary artery segments;LA24469-1;20;Obtuse marginal artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24466-7;21;Posterolateral from left circumflex artery;;; +80999-6;LL3699-7;Coronary artery segments;LA24464-2;22;Ramus intermedius from left main coronary artery;;; +80999-6;LL3699-7;Coronary artery segments;LA30559-1;23;Saphenous vein graft - Left anterior descending (SVG-LAD);;; +80999-6;LL3699-7;Coronary artery segments;LA30560-9;24;Saphenous vein graft - Left circumflex (SVG-LCX);;; +80999-6;LL3699-7;Coronary artery segments;LA30561-7;25;Saphenous vein graft - Right coronary artery (SVG-RCA);;; +80999-6;LL3699-7;Coronary artery segments;LA30562-5;26;Arterial graft - Left anterior descending (AG-LAD);;; +80999-6;LL3699-7;Coronary artery segments;LA30563-3;27;Arterial graft - Left circumflex (AG-LCX);;; +80999-6;LL3699-7;Coronary artery segments;LA30564-1;28;Arterial graft - Right coronary artery (AG-RCA);;; +80999-6;LL3699-7;Coronary artery segments;LA46-8;29;Other;;; +81436-8;LL3699-7;Coronary artery segments;LA24460-0;1;Proximal right coronary artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24461-8;2;Mid right coronary artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24462-6;3;Distal right coronary artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24473-3;4;Posterior descending from right coronary artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24474-1;5;Atrioventricular nodal artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24477-4;6;Posterolateral from right coronary artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24463-4;7;Left main coronary artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24472-5;8;Proximal left anterior descending artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24471-7;9;Mid left anterior descending artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24470-9;10;Distal left anterior descending artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24459-2;11;Proximal left circumflex artery;;; +81436-8;LL3699-7;Coronary artery segments;LA30588-0;12;High lateral branch;;; +81436-8;LL3699-7;Coronary artery segments;LA24458-4;13;Mid and distal left circumflex artery;;; +81436-8;LL3699-7;Coronary artery segments;LA28662-7;14;Mid left circumflex artery;;; +81436-8;LL3699-7;Coronary artery segments;LA28663-5;15;Distal left circumflex artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24467-5;16;Diagonal artery 1;;; +81436-8;LL3699-7;Coronary artery segments;LA24475-8;17;Additional diagonal artery 1;;; +81436-8;LL3699-7;Coronary artery segments;LA24468-3;18;Diagonal artery 2;;; +81436-8;LL3699-7;Coronary artery segments;LA24476-6;19;Additional diagonal artery 2;;; +81436-8;LL3699-7;Coronary artery segments;LA24469-1;20;Obtuse marginal artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24466-7;21;Posterolateral from left circumflex artery;;; +81436-8;LL3699-7;Coronary artery segments;LA24464-2;22;Ramus intermedius from left main coronary artery;;; +81436-8;LL3699-7;Coronary artery segments;LA30559-1;23;Saphenous vein graft - Left anterior descending (SVG-LAD);;; +81436-8;LL3699-7;Coronary artery segments;LA30560-9;24;Saphenous vein graft - Left circumflex (SVG-LCX);;; +81436-8;LL3699-7;Coronary artery segments;LA30561-7;25;Saphenous vein graft - Right coronary artery (SVG-RCA);;; +81436-8;LL3699-7;Coronary artery segments;LA30562-5;26;Arterial graft - Left anterior descending (AG-LAD);;; +81436-8;LL3699-7;Coronary artery segments;LA30563-3;27;Arterial graft - Left circumflex (AG-LCX);;; +81436-8;LL3699-7;Coronary artery segments;LA30564-1;28;Arterial graft - Right coronary artery (AG-RCA);;; +81436-8;LL3699-7;Coronary artery segments;LA46-8;29;Other;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA6111-4;1;0;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA6112-2;2;1;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA6113-0;3;2;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA6114-8;4;3;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA6115-5;5;4;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA10137-0;6;5;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA10138-8;7;6;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA10139-6;8;7;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA10140-4;9;8;;; +80918-6;LL3966-0;0-9 scale, numbers only;LA10141-2;10;9;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA6111-4;1;0;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA6112-2;2;1;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA6113-0;3;2;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA6114-8;4;3;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA6115-5;5;4;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA10137-0;6;5;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA10138-8;7;6;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA10139-6;8;7;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA10140-4;9;8;;; +80921-0;LL3966-0;0-9 scale, numbers only;LA10141-2;10;9;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA6111-4;1;0;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA6112-2;2;1;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA6113-0;3;2;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA6114-8;4;3;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA6115-5;5;4;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA10137-0;6;5;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA10138-8;7;6;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA10139-6;8;7;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA10140-4;9;8;;; +80925-1;LL3966-0;0-9 scale, numbers only;LA10141-2;10;9;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA6111-4;1;0;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA6112-2;2;1;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA6113-0;3;2;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA6114-8;4;3;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA6115-5;5;4;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA10137-0;6;5;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA10138-8;7;6;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA10139-6;8;7;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA10140-4;9;8;;; +80928-5;LL3966-0;0-9 scale, numbers only;LA10141-2;10;9;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA6111-4;1;0;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA6112-2;2;1;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA6113-0;3;2;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA6114-8;4;3;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA6115-5;5;4;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA10137-0;6;5;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA10138-8;7;6;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA10139-6;8;7;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA10140-4;9;8;;; +80931-9;LL3966-0;0-9 scale, numbers only;LA10141-2;10;9;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA6155-1;1;American Indian or Alaska Native;1002-5;American Indian or Alaska Native;https://www.cdc.gov/phin +80977-2;LL3971-0;NCHS_Tabulated Race;LA14048-5;2;Asian Indian;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA10610-6;3;Black or African American;2054-5;Black or African American;https://www.cdc.gov/phin +80977-2;LL3971-0;NCHS_Tabulated Race;LA4168-6;4;Chinese;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA3969-8;5;Filipino;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA18375-8;6;Guamanian or Chamorro;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA4595-0;7;Japanese;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA4603-2;8;Korean;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA14045-1;9;Native Hawaiian;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA46-8;10;Other;2131-1;Other Race;https://www.cdc.gov/phin +80977-2;LL3971-0;NCHS_Tabulated Race;LA14049-3;11;Other Asian;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA14047-7;12;Other Pacific Islander;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA4300-5;13;Samoan;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA4443-3;14;Vietnamese;;; +80977-2;LL3971-0;NCHS_Tabulated Race;LA4457-3;15;White;2106-3;White;https://www.cdc.gov/phin +80978-0;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4190-0;1;Cuban;;; +80978-0;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA26078-8;2;Hispanic or Latino (Other Hispanic);;; +80978-0;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4611-5;3;Mexican;;; +80978-0;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4364-1;4;Puerto Rican;;; +80978-0;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88117-7;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4190-0;1;Cuban;;; +88117-7;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA26078-8;2;Hispanic or Latino (Other Hispanic);;; +88117-7;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4611-5;3;Mexican;;; +88117-7;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4364-1;4;Puerto Rican;;; +88117-7;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88118-5;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4190-0;1;Cuban;;; +88118-5;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA26078-8;2;Hispanic or Latino (Other Hispanic);;; +88118-5;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4611-5;3;Mexican;;; +88118-5;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4364-1;4;Puerto Rican;;; +88118-5;LL3972-8;NCHS_Tabulated Ethnicity Detail;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +81000-2;LL3960-3;TIMI grade;LA26047-3;1;TIMI 0;;; +81000-2;LL3960-3;TIMI grade;LA26048-1;2;TIMI 1;;; +81000-2;LL3960-3;TIMI grade;LA26049-9;3;TIMI 2;;; +81000-2;LL3960-3;TIMI grade;LA26050-7;4;TIMI 3;;; +81001-0;LL3960-3;TIMI grade;LA26047-3;1;TIMI 0;;; +81001-0;LL3960-3;TIMI grade;LA26048-1;2;TIMI 1;;; +81001-0;LL3960-3;TIMI grade;LA26049-9;3;TIMI 2;;; +81001-0;LL3960-3;TIMI grade;LA26050-7;4;TIMI 3;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA26041-6;1;Balloon;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA26042-4;2;Drug dissolution balloon;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA26043-2;3;Metal stent;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA26044-0;4;Drug elution stent;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA26046-5;5;Rotational ablator;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA26045-7;6;Bioabsorbable scaffold;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA28659-3;7;Thrombus aspiration device;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA28661-9;8;Directional coronary atherectomy (DCA) device;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA28660-1;9;Distal protection device;;; +81002-8;LL3958-7;Devices used for cardiac catheterization;LA46-8;10;Other;;; +81090-3;LL3801-9;IPSS_Quality Of Life;LA16674-6;1;Delighted;;; +81090-3;LL3801-9;IPSS_Quality Of Life;LA24973-2;2;Pleased;;; +81090-3;LL3801-9;IPSS_Quality Of Life;LA24974-0;3;Mostly satisfied;;; +81090-3;LL3801-9;IPSS_Quality Of Life;LA24975-7;4;Mixed (about equally satisfied and dissatisfied);;; +81090-3;LL3801-9;IPSS_Quality Of Life;LA24976-5;5;Mostly dissatisfied;;; +81090-3;LL3801-9;IPSS_Quality Of Life;LA24977-3;6;Unhappy;;; +81090-3;LL3801-9;IPSS_Quality Of Life;LA24978-1;7;Terrible;;; +81139-8;LL3935-5;CYP3A4 allele genotypes;LA25988-9;1;CYP3A4*1/*1;;; +81139-8;LL3935-5;CYP3A4 allele genotypes;LA25989-7;2;CYP3A4*1/*22;;; +81139-8;LL3935-5;CYP3A4 allele genotypes;LA25990-5;3;CYP3A4*22/*22;;; +81140-6;LL2543-8;CYP3A5 allele genotype;LA25991-3;1;CYP3A5*1/*1;;; +81140-6;LL2543-8;CYP3A5 allele genotype;LA20131-1;2;CYP3A5*1/*2;;; +81140-6;LL2543-8;CYP3A5 allele genotype;LA20127-9;3;CYP3A5*1/*3;;; +81140-6;LL2543-8;CYP3A5 allele genotype;LA25995-4;4;CYP3A5*1/*6;;; +81140-6;LL2543-8;CYP3A5 allele genotype;LA20132-9;5;CYP3A5*3/*3;;; +81140-6;LL2543-8;CYP3A5 allele genotype;LA20133-7;6;CYP3A5*3/*5;;; +81140-6;LL2543-8;CYP3A5 allele genotype;LA25998-8;7;CYP3A5*3/*6;;; +81141-4;LL4011-4;Good|Medium|Poor;LA8967-7;1;Good;;; +81141-4;LL4011-4;Good|Medium|Poor;LA8982-6;2;Medium;;; +81141-4;LL4011-4;Good|Medium|Poor;LA8969-3;3;Poor;;; +81166-1;LL3944-7;Gastric cancer surgical resection types;LA26014-3;1;Esophagogastrectomy;;; +81166-1;LL3944-7;Gastric cancer surgical resection types;LA26072-1;2;Total gastrectomy;;; +81166-1;LL3944-7;Gastric cancer surgical resection types;LA26075-4;3;Subtotal (proximal or distal) gastrectomy;;; +81166-1;LL3944-7;Gastric cancer surgical resection types;LA46-8;4;Other;;; +81167-9;LL3942-1;Preoperative cancer treatments;LA6172-6;1;Chemotherapy;;; +81167-9;LL3942-1;Preoperative cancer treatments;LA26008-5;2;Chemo-radiotherapy;;; +81167-9;LL3942-1;Preoperative cancer treatments;LA26009-3;3;Radiotherapy;;; +81168-7;LL3943-9;Absent | Pancreas | Spleen | Liver | Other;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +81168-7;LL3943-9;Absent | Pancreas | Spleen | Liver | Other;LA4654-5;2;Pancreas;;; +81168-7;LL3943-9;Absent | Pancreas | Spleen | Liver | Other;LA26010-1;3;Spleen;;; +81168-7;LL3943-9;Absent | Pancreas | Spleen | Liver | Other;LA4584-4;4;Liver;;; +81168-7;LL3943-9;Absent | Pancreas | Spleen | Liver | Other;LA46-8;5;Other;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26016-8;1;Type 0-I;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26017-6;2;Type 0-IIa;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26019-2;3;Type 0-IIb;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26021-8;4;Type 0-IIc;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26020-0;5;Type 0-III;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26022-6;6;Type I;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26023-4;7;Type II;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26024-2;8;Type III;;; +81174-5;LL3947-0;Macroscopic tumor type;LA26025-9;9;Type IV;;; +81177-8;LL3954-6;Macroscopic serosal appearance types;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +81177-8;LL3954-6;Macroscopic serosal appearance types;LA15255-5;2;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +81177-8;LL3954-6;Macroscopic serosal appearance types;LA26039-0;3;Nodular;;; +81177-8;LL3954-6;Macroscopic serosal appearance types;LA26040-8;4;Colloid;;; +81179-4;LL3948-8;Lauren classification_Gastric tumor types;LA26027-5;1;Intestinal;;; +81179-4;LL3948-8;Lauren classification_Gastric tumor types;LA15824-8;2;Diffuse;;; +81179-4;LL3948-8;Lauren classification_Gastric tumor types;LA11840-8;3;Mixed;;; +81179-4;LL3948-8;Lauren classification_Gastric tumor types;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81180-2;LL3949-6;Expanding | Infiltrating;LA26029-1;1;Expanding;;; +81180-2;LL3949-6;Expanding | Infiltrating;LA26030-9;2;Infiltrating;;; +81188-5;LL3973-6;Proximal 1/3 | Middle 1/3 | Distal 1/3;LA26086-1;1;Proximal 1/3;;; +81188-5;LL3973-6;Proximal 1/3 | Middle 1/3 | Distal 1/3;LA26087-9;2;Middle 1/3;;; +81188-5;LL3973-6;Proximal 1/3 | Middle 1/3 | Distal 1/3;LA26088-7;3;Distal 1/3;;; +81189-3;LL3951-2;Complete (0)|Moderate (1)|Minimal (2)|Poor (3)|NA;LA26032-5;1;Complete;;; +81189-3;LL3951-2;Complete (0)|Moderate (1)|Minimal (2)|Poor (3)|NA;LA6751-7;2;Moderate;;; +81189-3;LL3951-2;Complete (0)|Moderate (1)|Minimal (2)|Poor (3)|NA;LA26031-7;3;Minimal;;; +81189-3;LL3951-2;Complete (0)|Moderate (1)|Minimal (2)|Poor (3)|NA;LA8969-3;4;Poor;;; +81189-3;LL3951-2;Complete (0)|Moderate (1)|Minimal (2)|Poor (3)|NA;LA4720-4;5;Not applicable;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA11900-0;1;Adenocarcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26093-7;2;Papillary adenocarcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26094-5;3;Tubular adenocarcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA15443-7;4;Mucinous (colloid) adenocarcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26095-2;5;Poorly cohesive carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26096-0;6;Mixed carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA15446-0;7;Adenosquamous carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26098-6;8;Carcinoma with lymphoid stroma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26097-8;9;Hepatoid adenocarcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA15445-2;10;Squamous cell (epidermoid) carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA15447-8;11;Undifferentiated carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26099-4;12;Neuroendocrine carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26100-0;13;Large cell neuroendocrine carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26101-8;14;Small cell neuroendocrine carcinoma;;; +81190-1;LL3974-4;WHO classification_Gastric tumor types;LA26102-6;15;Mixed adenoneuroendocrine carcinoma;;; +81228-9;LL3975-1;JC_Tobacco types;LA15332-2;1;Cigarettes;;; +81228-9;LL3975-1;JC_Tobacco types;LA15333-0;2;Cigars;;; +81228-9;LL3975-1;JC_Tobacco types;LA26091-1;3;Pipe tobacco;;; +81228-9;LL3975-1;JC_Tobacco types;LA26092-9;4;Smokeless tobacco;;; +81229-7;LL3976-9;JC_Tobacco Frequency;LA26103-4;1;Some day smoker;;; +81229-7;LL3976-9;JC_Tobacco Frequency;LA26104-2;2;Every day smoker;;; +81248-7;LL3998-3;Trans refseq coding system;LA26214-9;1;NCBI NM;;; +81248-7;LL3998-3;Trans refseq coding system;LA26358-4;2;Ensembl ENST;;; +81248-7;LL3998-3;Trans refseq coding system;LA26357-6;3;Other transcript reference sequence source;;; +81249-5;LL4036-1;Genomic refseq code system;LA26359-2;1;NCBI NG/NC;;; +81249-5;LL4036-1;Genomic refseq code system;LA26215-6;2;Ensembl ENSG;;; +81249-5;LL4036-1;Genomic refseq code system;LA26356-8;3;Other genomic reference sequence source;;; +81263-6;LL3999-1;Complex variant types;LA26217-2;1;Compound heterozygous;;; +81263-6;LL3999-1;Complex variant types;LA26220-6;2;Double heterozygous;;; +81263-6;LL3999-1;Complex variant types;LA26218-0;3;Haplotype;;; +81263-6;LL3999-1;Complex variant types;LA6707-9;4;Hemizygous;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26172-9;1;Athletics;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26173-7;2;College;;; +81267-7;LL3991-8;CDC_Transmission setting;LA22188-9;3;Community;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26175-2;4;Correctional facility;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26176-0;5;Daycare;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26177-8;6;Doctor's office;;; +81267-7;LL3991-8;CDC_Transmission setting;LA14084-0;7;Home;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26179-4;8;Hospital ER;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26180-2;9;Hospital outpatient clinic;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26181-0;10;Hospital ward;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26182-8;11;International travel;;; +81267-7;LL3991-8;CDC_Transmission setting;LA15280-3;12;Military;;; +81267-7;LL3991-8;CDC_Transmission setting;LA26184-4;13;Place of worship;;; +81267-7;LL3991-8;CDC_Transmission setting;LA14086-5;14;School;;; +81267-7;LL3991-8;CDC_Transmission setting;LA16501-1;15;Work;;; +81267-7;LL3991-8;CDC_Transmission setting;LA46-8;16;Other;;; +81267-7;LL3991-8;CDC_Transmission setting;LA4489-6;17;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +81271-9;LL3990-0;1st TRI|2nd TRI|3rd TRI;LA21196-3;1;1st trimester;;; +81271-9;LL3990-0;1st TRI|2nd TRI|3rd TRI;LA21197-1;2;2nd trimester;;; +81271-9;LL3990-0;1st TRI|2nd TRI|3rd TRI;LA21198-9;3;3rd trimester;;; +81289-1;LL5064-2;Structural variant types;LA14033-7;1;Copy number gain;;; +81289-1;LL5064-2;Structural variant types;LA14034-5;2;Copy number loss;;; +81289-1;LL5064-2;Structural variant types;LA6686-5;3;Duplication;;; +81289-1;LL5064-2;Structural variant types;LA6692-3;4;Deletion;;; +81289-1;LL5064-2;Structural variant types;LA6687-3;5;Insertion;;; +81289-1;LL5064-2;Structural variant types;LA26324-6;6;Mobile element insertion;;; +81289-1;LL5064-2;Structural variant types;LA26325-3;7;Novel sequence insertion;;; +81289-1;LL5064-2;Structural variant types;LA26326-1;8;Tandem duplication;;; +81289-1;LL5064-2;Structural variant types;LA6689-9;9;Inversion;;; +81289-1;LL5064-2;Structural variant types;LA26327-9;10;Intrachromosomal breakpoint;;; +81289-1;LL5064-2;Structural variant types;LA26328-7;11;Interchromosomal breakpoint;;; +81289-1;LL5064-2;Structural variant types;LA26331-1;12;Translocation;;; +81289-1;LL5064-2;Structural variant types;LA26330-3;13;Complex;;; +81289-1;LL5064-2;Structural variant types;LA26329-5;14;Sequence alteration;;; +81304-8;LL4048-6;Structural variant analysis method;LA26398-0;1;Sequencing;;; +81304-8;LL4048-6;Structural variant analysis method;LA26399-8;2;Oligo aCGH;;; +81304-8;LL4048-6;Structural variant analysis method;LA26400-4;3;SNP array;;; +81304-8;LL4048-6;Structural variant analysis method;LA26401-2;4;BAC aCGH;;; +81304-8;LL4048-6;Structural variant analysis method;LA26402-0;5;Curated;;; +81304-8;LL4048-6;Structural variant analysis method;LA26403-8;6;Digital array;;; +81304-8;LL4048-6;Structural variant analysis method;LA26404-6;7;FISH;;; +81304-8;LL4048-6;Structural variant analysis method;LA26405-3;8;Gene expression array;;; +81304-8;LL4048-6;Structural variant analysis method;LA26406-1;9;Karyotyping;;; +81304-8;LL4048-6;Structural variant analysis method;LA26407-9;10;MAPH;;; +81304-8;LL4048-6;Structural variant analysis method;LA26408-7;11;MALDI-TOF;;; +81304-8;LL4048-6;Structural variant analysis method;LA26808-8;12;Merging;;; +81304-8;LL4048-6;Structural variant analysis method;LA26414-5;13;Multiple complete digestion;;; +81304-8;LL4048-6;Structural variant analysis method;LA26415-2;14;MLPA;;; +81304-8;LL4048-6;Structural variant analysis method;LA26417-8;15;Optical mapping;;; +81304-8;LL4048-6;Structural variant analysis method;LA26418-6;16;PCR;;; +81304-8;LL4048-6;Structural variant analysis method;LA26419-4;17;qPCR (real-time PCR);;; +81304-8;LL4048-6;Structural variant analysis method;LA26420-2;18;ROMA;;; +81304-8;LL4048-6;Structural variant analysis method;LA26809-6;19;Denaturing high-pressure liquid chromatography (DHPLC);;; +81304-8;LL4048-6;Structural variant analysis method;LA26810-4;20;DNA hybridization;;; +81304-8;LL4048-6;Structural variant analysis method;LA26811-2;21;Computational analysis;;; +81304-8;LL4048-6;Structural variant analysis method;LA26812-0;22;Single-stranded conformational polymorphism (SSCP);;; +81304-8;LL4048-6;Structural variant analysis method;LA26813-8;23;Restriction fragment length polymorphism (RFLP);;; +81311-3;LL3894-4;Strong Pos|Weak to Mod Pos|Neg;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81311-3;LL3894-4;Strong Pos|Weak to Mod Pos|Neg;LA25821-2;2;Weak to moderate positive;;; +81311-3;LL3894-4;Strong Pos|Weak to Mod Pos|Neg;LA18996-1;3;Strong positive;;; +81316-2;LL4008-0;T Vag Pres|T Vag Not Pres;LA26252-9;1;Trichomonas vaginalis present;;; +81316-2;LL4008-0;T Vag Pres|T Vag Not Pres;LA26253-7;2;Trichomonas vaginalis not present;;; +81317-0;LL4009-8;Pathologic findings in stomach cancer;LA26033-3;1;Gastritis;;; +81317-0;LL4009-8;Pathologic findings in stomach cancer;LA26256-0;2;Helicobacter infection;;; +81317-0;LL4009-8;Pathologic findings in stomach cancer;LA26257-8;3;Intestinal metaplasia;;; +81317-0;LL4009-8;Pathologic findings in stomach cancer;LA26258-6;4;Gastric polyps;;; +81317-0;LL4009-8;Pathologic findings in stomach cancer;LA26259-4;5;Barrett's mucosa;;; +81420-2;LL3941-3;Neg|Pos NRAS|Pos KRAS|Pos NRAS+KRAS;LA26004-4;1;NEGATIVE - No KRAS or NRAS mutations were detected in exons 2, 3 and 4;;; +81420-2;LL3941-3;Neg|Pos NRAS|Pos KRAS|Pos NRAS+KRAS;LA26005-1;2;POSITIVE - NRAS mutation was detected in the provided specimen. No KRAS mutations were detected in exons 2, 3 and 4. No KRAS mutations were detected in exons 2, 3 and 4.;;; +81420-2;LL3941-3;Neg|Pos NRAS|Pos KRAS|Pos NRAS+KRAS;LA26006-9;3;POSITIVE - KRAS mutation was detected in the provided specimen. No NRAS mutations were detected in exons 2, 3 and 4. POSITIVE;;; +81420-2;LL3941-3;Neg|Pos NRAS|Pos KRAS|Pos NRAS+KRAS;LA26007-7;4;POSITIVE - KRAS and NRAS mutations were detected in the provided specimen;;; +81460-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81460-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81460-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81460-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81460-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81461-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81461-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81461-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81461-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81461-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81462-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81462-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81462-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81462-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81462-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81463-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81463-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81463-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81463-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81463-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81464-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81464-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81464-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81464-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81464-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81465-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81465-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81465-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81465-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81465-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81466-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81466-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81466-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81466-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81466-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81467-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81467-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81467-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81467-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81467-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81468-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81468-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81468-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81468-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81468-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81469-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81469-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81469-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81469-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81469-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81470-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81470-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81470-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81470-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81470-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81471-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81471-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81471-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81471-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81471-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81472-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81472-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81472-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81472-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81472-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81473-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81473-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81473-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81473-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81473-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81474-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81474-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81474-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81474-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81474-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81475-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81475-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81475-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81475-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81475-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81476-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81476-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81476-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81476-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81476-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81477-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81477-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81477-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81477-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81477-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81478-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81478-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81478-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81478-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81478-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81479-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81479-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81479-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81479-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81479-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81480-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81480-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81480-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81480-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81480-6;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81481-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81481-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81481-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81481-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81481-4;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81482-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81482-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81482-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81482-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81482-2;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81483-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81483-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81483-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81483-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81483-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81484-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81484-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81484-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81484-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81484-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81485-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81485-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81485-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81485-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81485-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81486-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81486-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81486-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81486-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81486-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81487-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81487-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81487-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81487-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81487-1;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81488-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81488-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81488-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81488-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81488-9;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81489-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81489-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81489-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81489-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81489-7;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81490-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81490-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81490-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81490-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81490-5;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81491-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +81491-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +81491-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +81491-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +81491-3;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +90411-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +90411-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +90411-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +90411-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +90411-0;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +90412-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA6270-8;1;Never;;; +90412-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17826-1;2;Rarely (once);;; +90412-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29533-9;3;Sometimes (Two or three times);;; +90412-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA29534-7;4;Often (About once a day);;; +90412-8;LL5147-5;Never(1)|Rare(2)|Sometimes(3)|Often(4)|V.often(5);LA17829-5;5;Very often (Several times a day);;; +81636-3;LL4010-6;Very High|High|Moderate|Mild|No Risk;LA14637-5;1;Very high;;; +81636-3;LL4010-6;Very High|High|Moderate|Mild|No Risk;LA9193-9;2;High;;; +81636-3;LL4010-6;Very High|High|Moderate|Mild|No Risk;LA6751-7;3;Moderate;;; +81636-3;LL4010-6;Very High|High|Moderate|Mild|No Risk;LA6752-5;4;Mild;;; +81636-3;LL4010-6;Very High|High|Moderate|Mild|No Risk;LA19983-8;5;No risk;;; +81653-8;LL3965-2;Neg|Pos B derm |Pos H capsul;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +81653-8;LL3965-2;Neg|Pos B derm |Pos H capsul;LA26061-4;2;Positive for Blastomyces dermatitidis;;; +81653-8;LL3965-2;Neg|Pos B derm |Pos H capsul;LA26062-2;3;Positive for Histoplasma capsulatum;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26199-2;1;No organism(s) detected;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26140-6;2;Influenza A (H3N2);;; +81654-6;LL3988-4;Resp bact & virus screen;LA26141-4;3;Influenza A (H1N1) pdm09;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26142-2;4;Influenza A (H1N1);;; +81654-6;LL3988-4;Resp bact & virus screen;LA26143-0;5;Influenza A (H5N1);;; +81654-6;LL3988-4;Resp bact & virus screen;LA26144-8;6;Influenza A (H7N9);;; +81654-6;LL3988-4;Resp bact & virus screen;LA26145-5;7;Influenza A untypable;;; +81654-6;LL3988-4;Resp bact & virus screen;LA13543-6;8;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +81654-6;LL3988-4;Resp bact & virus screen;LA24562-3;9;Adenovirus;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26147-1;10;Coronavirus 229E;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26148-9;11;Coronavirus OC43;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26149-7;12;Coronavirus NL63;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26150-5;13;Coronavirus HKU1;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26151-3;14;MERS- CoV;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26152-1;15;Enterovirus or rhinovirus;;; +81654-6;LL3988-4;Resp bact & virus screen;LA25838-6;16;Human metapneumovirus;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26155-4;17;HSV-1;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26156-2;18;HSV-2;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26157-0;19;Parechovirus;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26158-8;20;Parainfluenza 1;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26159-6;21;Parainfluenza 2;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26160-4;22;Parainfluenza 3;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26161-2;23;Parainfluenza 4;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26162-0;24;Respiratory syncytial virus subtype A;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26163-8;25;Respiratory syncytial virus subtype B;;; +81654-6;LL3988-4;Resp bact & virus screen;LA26164-6;26;Varicella zoster virus (VZV);;; +81654-6;LL3988-4;Resp bact & virus screen;LA14117-8;27;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +81654-6;LL3988-4;Resp bact & virus screen;LA25841-0;28;Bordetella holmesii;;; +81654-6;LL3988-4;Resp bact & virus screen;LA14121-0;29;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +81655-3;LL3988-4;Resp bact & virus screen;LA26199-2;1;No organism(s) detected;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26140-6;2;Influenza A (H3N2);;; +81655-3;LL3988-4;Resp bact & virus screen;LA26141-4;3;Influenza A (H1N1) pdm09;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26142-2;4;Influenza A (H1N1);;; +81655-3;LL3988-4;Resp bact & virus screen;LA26143-0;5;Influenza A (H5N1);;; +81655-3;LL3988-4;Resp bact & virus screen;LA26144-8;6;Influenza A (H7N9);;; +81655-3;LL3988-4;Resp bact & virus screen;LA26145-5;7;Influenza A untypable;;; +81655-3;LL3988-4;Resp bact & virus screen;LA13543-6;8;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +81655-3;LL3988-4;Resp bact & virus screen;LA24562-3;9;Adenovirus;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26147-1;10;Coronavirus 229E;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26148-9;11;Coronavirus OC43;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26149-7;12;Coronavirus NL63;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26150-5;13;Coronavirus HKU1;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26151-3;14;MERS- CoV;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26152-1;15;Enterovirus or rhinovirus;;; +81655-3;LL3988-4;Resp bact & virus screen;LA25838-6;16;Human metapneumovirus;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26155-4;17;HSV-1;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26156-2;18;HSV-2;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26157-0;19;Parechovirus;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26158-8;20;Parainfluenza 1;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26159-6;21;Parainfluenza 2;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26160-4;22;Parainfluenza 3;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26161-2;23;Parainfluenza 4;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26162-0;24;Respiratory syncytial virus subtype A;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26163-8;25;Respiratory syncytial virus subtype B;;; +81655-3;LL3988-4;Resp bact & virus screen;LA26164-6;26;Varicella zoster virus (VZV);;; +81655-3;LL3988-4;Resp bact & virus screen;LA14117-8;27;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +81655-3;LL3988-4;Resp bact & virus screen;LA25841-0;28;Bordetella holmesii;;; +81655-3;LL3988-4;Resp bact & virus screen;LA14121-0;29;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +82125-6;LL3988-4;Resp bact & virus screen;LA26199-2;1;No organism(s) detected;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26140-6;2;Influenza A (H3N2);;; +82125-6;LL3988-4;Resp bact & virus screen;LA26141-4;3;Influenza A (H1N1) pdm09;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26142-2;4;Influenza A (H1N1);;; +82125-6;LL3988-4;Resp bact & virus screen;LA26143-0;5;Influenza A (H5N1);;; +82125-6;LL3988-4;Resp bact & virus screen;LA26144-8;6;Influenza A (H7N9);;; +82125-6;LL3988-4;Resp bact & virus screen;LA26145-5;7;Influenza A untypable;;; +82125-6;LL3988-4;Resp bact & virus screen;LA13543-6;8;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +82125-6;LL3988-4;Resp bact & virus screen;LA24562-3;9;Adenovirus;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26147-1;10;Coronavirus 229E;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26148-9;11;Coronavirus OC43;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26149-7;12;Coronavirus NL63;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26150-5;13;Coronavirus HKU1;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26151-3;14;MERS- CoV;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26152-1;15;Enterovirus or rhinovirus;;; +82125-6;LL3988-4;Resp bact & virus screen;LA25838-6;16;Human metapneumovirus;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26155-4;17;HSV-1;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26156-2;18;HSV-2;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26157-0;19;Parechovirus;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26158-8;20;Parainfluenza 1;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26159-6;21;Parainfluenza 2;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26160-4;22;Parainfluenza 3;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26161-2;23;Parainfluenza 4;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26162-0;24;Respiratory syncytial virus subtype A;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26163-8;25;Respiratory syncytial virus subtype B;;; +82125-6;LL3988-4;Resp bact & virus screen;LA26164-6;26;Varicella zoster virus (VZV);;; +82125-6;LL3988-4;Resp bact & virus screen;LA14117-8;27;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +82125-6;LL3988-4;Resp bact & virus screen;LA25841-0;28;Bordetella holmesii;;; +82125-6;LL3988-4;Resp bact & virus screen;LA14121-0;29;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +82127-2;LL3988-4;Resp bact & virus screen;LA26199-2;1;No organism(s) detected;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26140-6;2;Influenza A (H3N2);;; +82127-2;LL3988-4;Resp bact & virus screen;LA26141-4;3;Influenza A (H1N1) pdm09;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26142-2;4;Influenza A (H1N1);;; +82127-2;LL3988-4;Resp bact & virus screen;LA26143-0;5;Influenza A (H5N1);;; +82127-2;LL3988-4;Resp bact & virus screen;LA26144-8;6;Influenza A (H7N9);;; +82127-2;LL3988-4;Resp bact & virus screen;LA26145-5;7;Influenza A untypable;;; +82127-2;LL3988-4;Resp bact & virus screen;LA13543-6;8;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +82127-2;LL3988-4;Resp bact & virus screen;LA24562-3;9;Adenovirus;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26147-1;10;Coronavirus 229E;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26148-9;11;Coronavirus OC43;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26149-7;12;Coronavirus NL63;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26150-5;13;Coronavirus HKU1;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26151-3;14;MERS- CoV;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26152-1;15;Enterovirus or rhinovirus;;; +82127-2;LL3988-4;Resp bact & virus screen;LA25838-6;16;Human metapneumovirus;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26155-4;17;HSV-1;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26156-2;18;HSV-2;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26157-0;19;Parechovirus;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26158-8;20;Parainfluenza 1;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26159-6;21;Parainfluenza 2;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26160-4;22;Parainfluenza 3;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26161-2;23;Parainfluenza 4;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26162-0;24;Respiratory syncytial virus subtype A;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26163-8;25;Respiratory syncytial virus subtype B;;; +82127-2;LL3988-4;Resp bact & virus screen;LA26164-6;26;Varicella zoster virus (VZV);;; +82127-2;LL3988-4;Resp bact & virus screen;LA14117-8;27;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +82127-2;LL3988-4;Resp bact & virus screen;LA25841-0;28;Bordetella holmesii;;; +82127-2;LL3988-4;Resp bact & virus screen;LA14121-0;29;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +82134-8;LL3988-4;Resp bact & virus screen;LA26199-2;1;No organism(s) detected;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26140-6;2;Influenza A (H3N2);;; +82134-8;LL3988-4;Resp bact & virus screen;LA26141-4;3;Influenza A (H1N1) pdm09;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26142-2;4;Influenza A (H1N1);;; +82134-8;LL3988-4;Resp bact & virus screen;LA26143-0;5;Influenza A (H5N1);;; +82134-8;LL3988-4;Resp bact & virus screen;LA26144-8;6;Influenza A (H7N9);;; +82134-8;LL3988-4;Resp bact & virus screen;LA26145-5;7;Influenza A untypable;;; +82134-8;LL3988-4;Resp bact & virus screen;LA13543-6;8;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +82134-8;LL3988-4;Resp bact & virus screen;LA24562-3;9;Adenovirus;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26147-1;10;Coronavirus 229E;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26148-9;11;Coronavirus OC43;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26149-7;12;Coronavirus NL63;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26150-5;13;Coronavirus HKU1;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26151-3;14;MERS- CoV;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26152-1;15;Enterovirus or rhinovirus;;; +82134-8;LL3988-4;Resp bact & virus screen;LA25838-6;16;Human metapneumovirus;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26155-4;17;HSV-1;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26156-2;18;HSV-2;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26157-0;19;Parechovirus;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26158-8;20;Parainfluenza 1;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26159-6;21;Parainfluenza 2;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26160-4;22;Parainfluenza 3;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26161-2;23;Parainfluenza 4;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26162-0;24;Respiratory syncytial virus subtype A;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26163-8;25;Respiratory syncytial virus subtype B;;; +82134-8;LL3988-4;Resp bact & virus screen;LA26164-6;26;Varicella zoster virus (VZV);;; +82134-8;LL3988-4;Resp bact & virus screen;LA14117-8;27;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +82134-8;LL3988-4;Resp bact & virus screen;LA25841-0;28;Bordetella holmesii;;; +82134-8;LL3988-4;Resp bact & virus screen;LA14121-0;29;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +82135-5;LL3988-4;Resp bact & virus screen;LA26199-2;1;No organism(s) detected;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26140-6;2;Influenza A (H3N2);;; +82135-5;LL3988-4;Resp bact & virus screen;LA26141-4;3;Influenza A (H1N1) pdm09;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26142-2;4;Influenza A (H1N1);;; +82135-5;LL3988-4;Resp bact & virus screen;LA26143-0;5;Influenza A (H5N1);;; +82135-5;LL3988-4;Resp bact & virus screen;LA26144-8;6;Influenza A (H7N9);;; +82135-5;LL3988-4;Resp bact & virus screen;LA26145-5;7;Influenza A untypable;;; +82135-5;LL3988-4;Resp bact & virus screen;LA13543-6;8;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +82135-5;LL3988-4;Resp bact & virus screen;LA24562-3;9;Adenovirus;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26147-1;10;Coronavirus 229E;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26148-9;11;Coronavirus OC43;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26149-7;12;Coronavirus NL63;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26150-5;13;Coronavirus HKU1;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26151-3;14;MERS- CoV;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26152-1;15;Enterovirus or rhinovirus;;; +82135-5;LL3988-4;Resp bact & virus screen;LA25838-6;16;Human metapneumovirus;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26155-4;17;HSV-1;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26156-2;18;HSV-2;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26157-0;19;Parechovirus;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26158-8;20;Parainfluenza 1;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26159-6;21;Parainfluenza 2;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26160-4;22;Parainfluenza 3;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26161-2;23;Parainfluenza 4;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26162-0;24;Respiratory syncytial virus subtype A;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26163-8;25;Respiratory syncytial virus subtype B;;; +82135-5;LL3988-4;Resp bact & virus screen;LA26164-6;26;Varicella zoster virus (VZV);;; +82135-5;LL3988-4;Resp bact & virus screen;LA14117-8;27;Bordetella pertussis;5247005;Bordetella pertussis (organism);http://snomed.info/sct +82135-5;LL3988-4;Resp bact & virus screen;LA25841-0;28;Bordetella holmesii;;; +82135-5;LL3988-4;Resp bact & virus screen;LA14121-0;29;Bordetella parapertussis;26183002;Bordetella parapertussis (organism);http://snomed.info/sct +81658-7;LL3979-3;TN_Suspected Organism;LA26105-9;1;Human herpes simplex virus;19965007;Human herpes simplex virus (organism);http://snomed.info/sct +81658-7;LL3979-3;TN_Suspected Organism;LA24556-5;2;Campylobacter;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26108-3;3;Shiga toxin-producing Escherichia coli;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26109-1;4;Enteric bacterium;;; +81658-7;LL3979-3;TN_Suspected Organism;LA24557-3;5;Salmonella;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26112-5;6;Shigella;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26111-7;7;Vibrio;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26113-3;8;Yersinia;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26114-1;9;Cyclospora;103560006;Cyclospora (organism);http://snomed.info/sct +81658-7;LL3979-3;TN_Suspected Organism;LA26115-8;10;Giardia;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26116-6;11;Cryptosporidium;83821001;Cryptosporidium (organism);http://snomed.info/sct +81658-7;LL3979-3;TN_Suspected Organism;LA26117-4;12;Histoplasma;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26118-2;13;Blastomyces;;; +81658-7;LL3979-3;TN_Suspected Organism;LA26119-0;14;Coccidioides;;; +81658-7;LL3979-3;TN_Suspected Organism;LA10446-5;15;Cryptococcosis;;; +81660-3;LL3982-7;None|Mild|Moderate|Severe|Resolved;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +81660-3;LL3982-7;None|Mild|Moderate|Severe|Resolved;LA6752-5;2;Mild;;; +81660-3;LL3982-7;None|Mild|Moderate|Severe|Resolved;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +81660-3;LL3982-7;None|Mild|Moderate|Severe|Resolved;LA6750-9;4;Severe;;; +81660-3;LL3982-7;None|Mild|Moderate|Severe|Resolved;LA9041-0;5;Resolved;;; +81663-7;LL3984-3;Diet types;LA15487-4;1;Regular;;; +81663-7;LL3984-3;Diet types;LA26134-9;2;Diabetic;;; +81663-7;LL3984-3;Diet types;LA26131-5;3;Mechanical soft;;; +81663-7;LL3984-3;Diet types;LA25011-0;4;Liquid;;; +81663-7;LL3984-3;Diet types;LA26129-9;5;Clear liquid;;; +81663-7;LL3984-3;Diet types;LA26133-1;6;Sips;;; +81663-7;LL3984-3;Diet types;LA26132-3;7;Formula;;; +81663-7;LL3984-3;Diet types;LA16917-9;8;NPO;;; +81676-9;LL3985-0;Dehydration status;LA26139-8;1;Well-hydrated;;; +81676-9;LL3985-0;Dehydration status;LA26136-4;2;Mildly dehydrated;;; +81676-9;LL3985-0;Dehydration status;LA26137-2;3;Moderately dehydrated;;; +81676-9;LL3985-0;Dehydration status;LA26138-0;4;Severely dehydrated;;; +81681-9;LL4012-2;Yes|Other_comment;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81681-9;LL4012-2;Yes|Other_comment;LA46-8;2;Other;;; +81682-7;LL4012-2;Yes|Other_comment;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81682-7;LL4012-2;Yes|Other_comment;LA46-8;2;Other;;; +81683-5;LL4012-2;Yes|Other_comment;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81683-5;LL4012-2;Yes|Other_comment;LA46-8;2;Other;;; +81684-3;LL4012-2;Yes|Other_comment;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81684-3;LL4012-2;Yes|Other_comment;LA46-8;2;Other;;; +81685-0;LL4012-2;Yes|Other_comment;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81685-0;LL4012-2;Yes|Other_comment;LA46-8;2;Other;;; +81686-8;LL4012-2;Yes|Other_comment;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81686-8;LL4012-2;Yes|Other_comment;LA46-8;2;Other;;; +81687-6;LL4012-2;Yes|Other_comment;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +81687-6;LL4012-2;Yes|Other_comment;LA46-8;2;Other;;; +81690-0;LL4019-7;Legionella longbeacheae serogroup;LA11883-8;1;Not detected;;; +81690-0;LL4019-7;Legionella longbeacheae serogroup;LA26301-4;2;Legionella longbeachae serogroup 1 detected;;; +81690-0;LL4019-7;Legionella longbeacheae serogroup;LA26302-2;3;Legionella longbeachae serogroup 2 detected;;; +81691-8;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26197-6;1;Intact nuclear expression;;; +81691-8;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26198-4;2;Loss of nuclear expression;;; +81691-8;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA14100-4;3;Undetermined;;; +81692-6;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26197-6;1;Intact nuclear expression;;; +81692-6;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26198-4;2;Loss of nuclear expression;;; +81692-6;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA14100-4;3;Undetermined;;; +81693-4;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26197-6;1;Intact nuclear expression;;; +81693-4;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26198-4;2;Loss of nuclear expression;;; +81693-4;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA14100-4;3;Undetermined;;; +81694-2;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26197-6;1;Intact nuclear expression;;; +81694-2;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26198-4;2;Loss of nuclear expression;;; +81694-2;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA14100-4;3;Undetermined;;; +83058-8;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26197-6;1;Intact nuclear expression;;; +83058-8;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26198-4;2;Loss of nuclear expression;;; +83058-8;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA14100-4;3;Undetermined;;; +96271-2;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26197-6;1;Intact nuclear expression;;; +96271-2;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26198-4;2;Loss of nuclear expression;;; +96271-2;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA14100-4;3;Undetermined;;; +96272-0;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26197-6;1;Intact nuclear expression;;; +96272-0;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA26198-4;2;Loss of nuclear expression;;; +96272-0;LL3993-4;Intact nuc express|Loss of nuc express|Undet;LA14100-4;3;Undetermined;;; +81695-9;LL3994-2;Stable|MSI-L|MSI-H|Indeterminate;LA14122-8;1;Stable;;; +81695-9;LL3994-2;Stable|MSI-L|MSI-H|Indeterminate;LA26202-4;2;MSI-L;;; +81695-9;LL3994-2;Stable|MSI-L|MSI-H|Indeterminate;LA26203-2;3;MSI-H;;; +81695-9;LL3994-2;Stable|MSI-L|MSI-H|Indeterminate;LA11884-6;4;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +81707-2;LL3995-9;Tissue dissection methods;LA26208-1;1;Laser capture;;; +81707-2;LL3995-9;Tissue dissection methods;LA26209-9;2;Microdissection;;; +81707-2;LL3995-9;Tissue dissection methods;LA26210-7;3;Microdissection under microscopy;;; +81707-2;LL3995-9;Tissue dissection methods;LA26221-4;4;Manual dissection;;; +81707-2;LL3995-9;Tissue dissection methods;LA26222-2;5;Cored from block;;; +81707-2;LL3995-9;Tissue dissection methods;LA26223-0;6;Whole tissue section employed;;; +81744-5;LL3997-5;Culture|Culture-indep|;LA26211-5;1;Culture-independent;;; +81744-5;LL3997-5;Culture|Culture-indep|;LA7508-0;2;Culture;;; +81889-8;LL4022-1;Physical therapy degree;LA26309-7;1;Baccalaureate degree;;; +81889-8;LL4022-1;Physical therapy degree;LA26310-5;2;Post-baccalaureate certificate;;; +81889-8;LL4022-1;Physical therapy degree;LA26311-3;3;Master's degree;;; +81889-8;LL4022-1;Physical therapy degree;LA26312-1;4;Doctoral degree;;; +81889-8;LL4022-1;Physical therapy degree;LA46-8;5;Other;;; +81890-6;LL4023-9;Physical therapy highest education;LA26309-7;1;Baccalaureate degree;;; +81890-6;LL4023-9;Physical therapy highest education;LA26311-3;2;Master's degree;;; +81890-6;LL4023-9;Physical therapy highest education;LA26313-9;3;PhD (or equivalent);;; +81890-6;LL4023-9;Physical therapy highest education;LA26314-7;4;DPT (entry-level);;; +81890-6;LL4023-9;Physical therapy highest education;LA26315-4;5;tDPT (transition);;; +81890-6;LL4023-9;Physical therapy highest education;LA26316-2;6;PhD (or equivalent) and DPT;;; +81890-6;LL4023-9;Physical therapy highest education;LA26317-0;7;PhD (or equivalent) and tDPT;;; +81890-6;LL4023-9;Physical therapy highest education;LA46-8;8;Other;;; +82116-5;LL4049-4;Medication usage suggestion;LA26421-0;1;Consider alternative medication;;; +82116-5;LL4049-4;Medication usage suggestion;LA26422-8;2;Decrease dose;;; +82116-5;LL4049-4;Medication usage suggestion;LA26423-6;3;Increase dose;;; +82116-5;LL4049-4;Medication usage suggestion;LA26424-4;4;Use caution;;; +82116-5;LL4049-4;Medication usage suggestion;LA26425-1;5;Normal response expected;;; +82120-7;LL4025-4;Allelic phase;LA26814-6;1;1st set of variants in cis relation to each other;;; +82120-7;LL4025-4;Allelic phase;LA26815-3;2;2nd set of variants in cis relation to each other;;; +82120-7;LL4025-4;Allelic phase;LA26816-1;3;3rd set of variants in cis relation to each other;;; +82120-7;LL4025-4;Allelic phase;LA26817-9;4;4th set of variants in cis relation to each other;;; +82120-7;LL4025-4;Allelic phase;LA26818-7;5;5th set of variants in cis relation to each other;;; +82120-7;LL4025-4;Allelic phase;LA26320-4;6;Maternal;;; +82120-7;LL4025-4;Allelic phase;LA26321-2;7;Paternal;;; +82120-7;LL4025-4;Allelic phase;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82120-7;LL4025-4;Allelic phase;LA46-8;9;Other;;; +82122-3;LL4024-7;ClinVar|COSMIC|Other;LA26318-8;1;ClinVar;;; +82122-3;LL4024-7;ClinVar|COSMIC|Other;LA26319-6;2;COSMIC;;; +82122-3;LL4024-7;ClinVar|COSMIC|Other;LA46-8;3;Other;;; +82145-4;LL4029-6;Yes | No | Parents not married | DK/NS | Refused;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82145-4;LL4029-6;Yes | No | Parents not married | DK/NS | Refused;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82145-4;LL4029-6;Yes | No | Parents not married | DK/NS | Refused;LA26322-0;3;Parents not married;;; +82145-4;LL4029-6;Yes | No | Parents not married | DK/NS | Refused;LA14619-3;4;Don't know/not sure;;; +82145-4;LL4029-6;Yes | No | Parents not married | DK/NS | Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82146-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA6270-8;1;Never;;; +82146-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14312-5;2;Once;;; +82146-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14313-3;3;More than once;;; +82146-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14619-3;4;Don't know/not sure;;; +82146-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82147-0;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA6270-8;1;Never;;; +82147-0;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14312-5;2;Once;;; +82147-0;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14313-3;3;More than once;;; +82147-0;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14619-3;4;Don't know/not sure;;; +82147-0;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82148-8;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA6270-8;1;Never;;; +82148-8;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14312-5;2;Once;;; +82148-8;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14313-3;3;More than once;;; +82148-8;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14619-3;4;Don't know/not sure;;; +82148-8;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82149-6;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA6270-8;1;Never;;; +82149-6;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14312-5;2;Once;;; +82149-6;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14313-3;3;More than once;;; +82149-6;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14619-3;4;Don't know/not sure;;; +82149-6;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82150-4;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA6270-8;1;Never;;; +82150-4;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14312-5;2;Once;;; +82150-4;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14313-3;3;More than once;;; +82150-4;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14619-3;4;Don't know/not sure;;; +82150-4;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82151-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA6270-8;1;Never;;; +82151-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14312-5;2;Once;;; +82151-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14313-3;3;More than once;;; +82151-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA14619-3;4;Don't know/not sure;;; +82151-2;LL4030-4;Never | Once | More than once | DK/NS | Refused;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +82227-0;LL3898-5;[NDI] Section 1: Pain Intensity;LA25853-5;1;I have no pain at the moment.;;; +82227-0;LL3898-5;[NDI] Section 1: Pain Intensity;LA25854-3;2;The pain is very mild at the moment.;;; +82227-0;LL3898-5;[NDI] Section 1: Pain Intensity;LA25855-0;3;The pain is moderate at the moment.;;; +82227-0;LL3898-5;[NDI] Section 1: Pain Intensity;LA25856-8;4;The pain is fairly severe at the moment.;;; +82227-0;LL3898-5;[NDI] Section 1: Pain Intensity;LA25857-6;5;The pain is very severe at the moment.;;; +82227-0;LL3898-5;[NDI] Section 1: Pain Intensity;LA25858-4;6;The pain is the worst imaginable at the moment.;;; +82228-8;LL3899-3;[NDI] Section 2: Personal Care;LA25859-2;1;I can look after myself normally without causing extra pain.;;; +82228-8;LL3899-3;[NDI] Section 2: Personal Care;LA25860-0;2;I can look after myself normally but it causes extra pain.;;; +82228-8;LL3899-3;[NDI] Section 2: Personal Care;LA25861-8;3;It is painful to look after myself and I am slow and careful.;;; +82228-8;LL3899-3;[NDI] Section 2: Personal Care;LA25862-6;4;I need some help but can manage most of my personal care.;;; +82228-8;LL3899-3;[NDI] Section 2: Personal Care;LA25863-4;5;I need help every day in most aspects of self-care.;;; +82228-8;LL3899-3;[NDI] Section 2: Personal Care;LA25864-2;6;I do not get dressed, I wash with difficulty and stay in bed.;;; +82229-6;LL3900-9;[NDI] Section 3: Lifting;LA25865-9;1;I can lift heavy weights without extra pain.;;; +82229-6;LL3900-9;[NDI] Section 3: Lifting;LA25866-7;2;I can lift heavy weights but it gives extra pain.;;; +82229-6;LL3900-9;[NDI] Section 3: Lifting;LA25867-5;3;Pain prevents me lifting heavy weights off the floor, but I can manage if they are conveniently placed, for example on a table.;;; +82229-6;LL3900-9;[NDI] Section 3: Lifting;LA25868-3;4;Pain prevents me from lifting heavy weights but I can manage light to medium weights if they are conveniently positioned.;;; +82229-6;LL3900-9;[NDI] Section 3: Lifting;LA25869-1;5;I can only lift very light weights.;;; +82229-6;LL3900-9;[NDI] Section 3: Lifting;LA25870-9;6;I cannot lift or carry anything.;;; +82230-4;LL3901-7;[NDI] Section 4: Reading;LA25871-7;1;I can read as much as I want to with no pain in my neck.;;; +82230-4;LL3901-7;[NDI] Section 4: Reading;LA25872-5;2;I can read as much as I want to with slight pain in my neck.;;; +82230-4;LL3901-7;[NDI] Section 4: Reading;LA25873-3;3;I can read as much as I want with moderate pain in my neck.;;; +82230-4;LL3901-7;[NDI] Section 4: Reading;LA25874-1;4;I can't read as much as I want because of moderate pain in my neck.;;; +82230-4;LL3901-7;[NDI] Section 4: Reading;LA25875-8;5;I can hardly read at all because of severe pain in my neck.;;; +82230-4;LL3901-7;[NDI] Section 4: Reading;LA25876-6;6;I can't read at all.;;; +82231-2;LL3902-5;[NDI] Section 5: Headaches;LA25877-4;1;I have no headaches at all.;;; +82231-2;LL3902-5;[NDI] Section 5: Headaches;LA26365-9;2;I have slight headaches, which come infrequently.;;; +82231-2;LL3902-5;[NDI] Section 5: Headaches;LA26366-7;3;I have moderate headaches, which come infrequently.;;; +82231-2;LL3902-5;[NDI] Section 5: Headaches;LA26367-5;4;I have moderate headaches, which come frequently.;;; +82231-2;LL3902-5;[NDI] Section 5: Headaches;LA26368-3;5;I have severe headaches, which come frequently.;;; +82231-2;LL3902-5;[NDI] Section 5: Headaches;LA26369-1;6;I have headaches almost all the time.;;; +82232-0;LL3903-3;[NDI] Section 6: Concentration;LA25878-2;1;I can concentrate fully when I want to with no difficulty.;;; +82232-0;LL3903-3;[NDI] Section 6: Concentration;LA25879-0;2;I can concentrate fully when I want to with slight difficulty.;;; +82232-0;LL3903-3;[NDI] Section 6: Concentration;LA25880-8;3;I have a fair degree of difficulty in concentrating when I want to.;;; +82232-0;LL3903-3;[NDI] Section 6: Concentration;LA25881-6;4;I have a lot of difficulty in concentrating when I want to.;;; +82232-0;LL3903-3;[NDI] Section 6: Concentration;LA25882-4;5;I have a great deal of difficulty in concentrating when I want to.;;; +82232-0;LL3903-3;[NDI] Section 6: Concentration;LA25883-2;6;I can't concentrate at all.;;; +82233-8;LL3904-1;[NDI] Section 7: Work;LA25884-0;1;I can do as much work as I want to.;;; +82233-8;LL3904-1;[NDI] Section 7: Work;LA25885-7;2;I can only do my usual work, but no more.;;; +82233-8;LL3904-1;[NDI] Section 7: Work;LA25886-5;3;I can do most of my usual work, but no more.;;; +82233-8;LL3904-1;[NDI] Section 7: Work;LA25887-3;4;I cannot do my usual work.;;; +82233-8;LL3904-1;[NDI] Section 7: Work;LA25888-1;5;I can hardly do any work at all.;;; +82233-8;LL3904-1;[NDI] Section 7: Work;LA25889-9;6;I can't do any work at all.;;; +82234-6;LL3905-8;[NDI] Section 8: Driving;LA25890-7;1;I can drive my car without any neck pain.;;; +82234-6;LL3905-8;[NDI] Section 8: Driving;LA25891-5;2;I can drive my car as long as I want with slight pain in my neck.;;; +82234-6;LL3905-8;[NDI] Section 8: Driving;LA25892-3;3;I can drive my car as long as I want with moderate pain in my neck.;;; +82234-6;LL3905-8;[NDI] Section 8: Driving;LA25893-1;4;I can't drive my car as long as I want because of moderate pain in my neck.;;; +82234-6;LL3905-8;[NDI] Section 8: Driving;LA25894-9;5;I can hardly drive at all because of severe pain in my neck.;;; +82234-6;LL3905-8;[NDI] Section 8: Driving;LA25895-6;6;I can't drive my car at all.;;; +82235-3;LL3906-6;[NDI] Section 9: Sleeping;LA25896-4;1;I have no trouble sleeping.;;; +82235-3;LL3906-6;[NDI] Section 9: Sleeping;LA25897-2;2;My sleep is slightly disturbed (less than 1 hr sleepless).;;; +82235-3;LL3906-6;[NDI] Section 9: Sleeping;LA25898-0;3;My sleep is mildly disturbed (1-2 hrs sleepless).;;; +82235-3;LL3906-6;[NDI] Section 9: Sleeping;LA25899-8;4;My sleep is moderately disturbed (2-3 hrs sleepless).;;; +82235-3;LL3906-6;[NDI] Section 9: Sleeping;LA25900-4;5;My sleep is greatly disturbed (3-5 hrs sleepless).;;; +82235-3;LL3906-6;[NDI] Section 9: Sleeping;LA25901-2;6;My sleep is completely disturbed (5-7 hrs sleepless).;;; +82236-1;LL3907-4;[NDI] Section 10: Recreation;LA25902-0;1;I am able to engage in all my recreation activities with no neck pain at all.;;; +82236-1;LL3907-4;[NDI] Section 10: Recreation;LA25903-8;2;I am able to engage in all my recreation activities, with some pain in my neck.;;; +82236-1;LL3907-4;[NDI] Section 10: Recreation;LA25904-6;3;I am able to engage in most, but not all of my usual recreation activities because of pain in my neck.;;; +82236-1;LL3907-4;[NDI] Section 10: Recreation;LA25905-3;4;I am able to engage in a few of my usual recreation activities because of pain in my neck.;;; +82236-1;LL3907-4;[NDI] Section 10: Recreation;LA25906-1;5;I can hardly do any recreation activities because of pain in my neck.;;; +82236-1;LL3907-4;[NDI] Section 10: Recreation;LA25907-9;6;I can't do any recreation activities due at all.;;; +82277-5;LL4005-6;Sources used for predicted RMR;LA26231-3;1;Mifflin-St Jeor;;; +82277-5;LL4005-6;Sources used for predicted RMR;LA26232-1;2;Owen;;; +82277-5;LL4005-6;Sources used for predicted RMR;LA26230-5;3;Harris-Benedict;;; +82277-5;LL4005-6;Sources used for predicted RMR;LA26233-9;4;WHO/FAO/UNU;;; +82277-5;LL4005-6;Sources used for predicted RMR;LA46-8;5;Other;;; +82280-9;LL4003-1;Sources used to estimate activity metabolic rate;LA26238-8;1;Compendium of Physical Activities;;; +82280-9;LL4003-1;Sources used to estimate activity metabolic rate;LA26239-6;2;Modified Bruce protocol;;; +82280-9;LL4003-1;Sources used to estimate activity metabolic rate;LA26240-4;3;Balke protocol;;; +82280-9;LL4003-1;Sources used to estimate activity metabolic rate;LA46-8;5;Other;;; +82281-7;LL4002-3;Sources used for activity metabolic rate;LA26242-0;1;Activity tracker;;; +82281-7;LL4002-3;Sources used for activity metabolic rate;LA26243-8;2;Physical activity questionnaire;;; +82281-7;LL4002-3;Sources used for activity metabolic rate;LA26251-1;3;Activity log/diary;;; +82282-5;LL4006-4;Sources used for population RMR;LA26244-6;1;McMurray 2014;;; +82282-5;LL4006-4;Sources used for population RMR;LA26245-3;2;Byrne 2005;;; +82282-5;LL4006-4;Sources used for population RMR;LA26241-2;3;Wilms 2014;;; +82282-5;LL4006-4;Sources used for population RMR;LA46-8;4;Other;;; +82283-3;LL4004-9;Sources used to adjust exercise MET;LA26234-7;1;Wilms 2014 male;;; +82283-3;LL4004-9;Sources used to adjust exercise MET;LA26235-4;2;Wilms 2014 female;;; +82283-3;LL4004-9;Sources used to adjust exercise MET;LA26236-2;3;Harris-Benedict male;;; +82283-3;LL4004-9;Sources used to adjust exercise MET;LA26237-0;4;Harris-Benedict female;;; +82283-3;LL4004-9;Sources used to adjust exercise MET;LA46-8;5;Other;;; +82292-4;LL4035-3;Not meeting|Meeting|Exceeding;LA26337-8;1;Not meeting the recommended guidelines;;; +82292-4;LL4035-3;Not meeting|Meeting|Exceeding;LA26336-0;2;Meeting the recommended guidelines;;; +82292-4;LL4035-3;Not meeting|Meeting|Exceeding;LA26338-6;3;Exceeding the recommended guidelines;;; +82294-0;LL4007-2;Physical Activity Guidelines;LA26249-5;1;2008 EU Physical Activity Guidelines;;; +82294-0;LL4007-2;Physical Activity Guidelines;LA26246-1;2;2008 Physical Activity Guidelines for Americans (PAG);;; +82294-0;LL4007-2;Physical Activity Guidelines;LA26248-7;3;American College of Sports Medicine (ACSM) exercise guidelines;;; +82294-0;LL4007-2;Physical Activity Guidelines;LA26247-9;4;Caring for Our Children, 3rd Edition (CFOC3);;; +82294-0;LL4007-2;Physical Activity Guidelines;LA26250-3;5;2010 Global recommendations on physical activity for health;;; +82294-0;LL4007-2;Physical Activity Guidelines;LA46-8;6;Other;;; +82296-5;LL4037-9;Calorimetry methods;LA26360-0;1;Direct calorimetry: metabolic chamber;;; +82296-5;LL4037-9;Calorimetry methods;LA26362-6;2;Indirect calorimetry: hood/canopy open circuit;;; +82296-5;LL4037-9;Calorimetry methods;LA26363-4;3;Indirect calorimetry: open circuit expiratory collection;;; +82296-5;LL4037-9;Calorimetry methods;LA26361-8;4;Indirect calorimetry: room open circuit;;; +82296-5;LL4037-9;Calorimetry methods;LA26364-2;5;Indirect calorimetry: total collection Douglas bag;;; +82296-5;LL4037-9;Calorimetry methods;LA46-8;6;Other;;; +82298-1;LL3794-6;Isolat|Not isolat;LA24949-2;0;Isolated;;; +82298-1;LL3794-6;Isolat|Not isolat;LA18372-5;1;Not isolated;;; +82298-1;LL3794-6;Isolat|Not isolat;LA20552-8;2;Unsatisfactory;;; +82298-1;LL3794-6;Isolat|Not isolat;LA21123-7;3;No growth;;; +82298-1;LL3794-6;Isolat|Not isolat;LA24951-8;4;Testing not performed;;; +82300-5;LL3794-6;Isolat|Not isolat;LA24949-2;0;Isolated;;; +82300-5;LL3794-6;Isolat|Not isolat;LA18372-5;1;Not isolated;;; +82300-5;LL3794-6;Isolat|Not isolat;LA20552-8;2;Unsatisfactory;;; +82300-5;LL3794-6;Isolat|Not isolat;LA21123-7;3;No growth;;; +82300-5;LL3794-6;Isolat|Not isolat;LA24951-8;4;Testing not performed;;; +82301-3;LL3794-6;Isolat|Not isolat;LA24949-2;0;Isolated;;; +82301-3;LL3794-6;Isolat|Not isolat;LA18372-5;1;Not isolated;;; +82301-3;LL3794-6;Isolat|Not isolat;LA20552-8;2;Unsatisfactory;;; +82301-3;LL3794-6;Isolat|Not isolat;LA21123-7;3;No growth;;; +82301-3;LL3794-6;Isolat|Not isolat;LA24951-8;4;Testing not performed;;; +82302-1;LL3794-6;Isolat|Not isolat;LA24949-2;0;Isolated;;; +82302-1;LL3794-6;Isolat|Not isolat;LA18372-5;1;Not isolated;;; +82302-1;LL3794-6;Isolat|Not isolat;LA20552-8;2;Unsatisfactory;;; +82302-1;LL3794-6;Isolat|Not isolat;LA21123-7;3;No growth;;; +82302-1;LL3794-6;Isolat|Not isolat;LA24951-8;4;Testing not performed;;; +82303-9;LL3794-6;Isolat|Not isolat;LA24949-2;0;Isolated;;; +82303-9;LL3794-6;Isolat|Not isolat;LA18372-5;1;Not isolated;;; +82303-9;LL3794-6;Isolat|Not isolat;LA20552-8;2;Unsatisfactory;;; +82303-9;LL3794-6;Isolat|Not isolat;LA21123-7;3;No growth;;; +82303-9;LL3794-6;Isolat|Not isolat;LA24951-8;4;Testing not performed;;; +82304-7;LL3794-6;Isolat|Not isolat;LA24949-2;0;Isolated;;; +82304-7;LL3794-6;Isolat|Not isolat;LA18372-5;1;Not isolated;;; +82304-7;LL3794-6;Isolat|Not isolat;LA20552-8;2;Unsatisfactory;;; +82304-7;LL3794-6;Isolat|Not isolat;LA21123-7;3;No growth;;; +82304-7;LL3794-6;Isolat|Not isolat;LA24951-8;4;Testing not performed;;; +86322-5;LL3794-6;Isolat|Not isolat;LA24949-2;0;Isolated;;; +86322-5;LL3794-6;Isolat|Not isolat;LA18372-5;1;Not isolated;;; +86322-5;LL3794-6;Isolat|Not isolat;LA20552-8;2;Unsatisfactory;;; +86322-5;LL3794-6;Isolat|Not isolat;LA21123-7;3;No growth;;; +86322-5;LL3794-6;Isolat|Not isolat;LA24951-8;4;Testing not performed;;; +82309-6;LL4050-2;Basis for allelic phase;LA26426-9;1;Directly measured;;; +82309-6;LL4050-2;Basis for allelic phase;LA26427-7;2;Family DNA;;; +82309-6;LL4050-2;Basis for allelic phase;LA26428-5;3;Family history;;; +82309-6;LL4050-2;Basis for allelic phase;LA26429-3;4;Inferred from population data;;; +82317-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82317-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82317-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82317-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82317-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82318-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82318-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82318-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82318-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82318-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82319-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82319-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82319-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82319-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82319-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82320-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82320-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82320-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82320-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82320-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82321-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82321-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82321-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82321-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82321-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82322-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82322-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82322-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82322-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82322-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82325-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82325-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82325-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82325-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82325-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82326-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82326-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82326-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82326-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82326-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82327-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82327-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82327-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82327-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82327-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82328-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82328-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82328-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82328-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82328-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82329-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82329-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82329-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82329-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82329-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82330-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82330-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82330-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82330-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82330-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82331-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82331-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +82331-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +82331-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +82331-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88747-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88747-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88747-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88747-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88747-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88748-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88748-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88748-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88748-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88748-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88749-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88749-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88749-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88749-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88749-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88750-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88750-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88750-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88750-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88750-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88751-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88751-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88751-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88751-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88751-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88752-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88752-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88752-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88752-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88752-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88753-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88753-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88753-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88753-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88753-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88754-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88754-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88754-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88754-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88754-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88756-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88756-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88756-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88756-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88756-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88760-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88760-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88760-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88760-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88760-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88761-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88761-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88761-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88761-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88761-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88762-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88762-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88762-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88762-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88762-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88763-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88763-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88763-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88763-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88763-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88764-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88764-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88764-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88764-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88764-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88765-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88765-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88765-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88765-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88765-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88766-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88766-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88766-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88766-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88766-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88768-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88768-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88768-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88768-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88768-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88769-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88769-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88769-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88769-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88769-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88770-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88770-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88770-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88770-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88770-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88771-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88771-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88771-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88771-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88771-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88772-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88772-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88772-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88772-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88772-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88773-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88773-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88773-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88773-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88773-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88774-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88774-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88774-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88774-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88774-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88775-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88775-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88775-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88775-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88775-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88776-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88776-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88776-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88776-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88776-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88777-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88777-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88777-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88777-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88777-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88778-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88778-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88778-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88778-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88778-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88779-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88779-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88779-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88779-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88779-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88780-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88780-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88780-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88780-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88780-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88787-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88787-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88787-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88787-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88787-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88788-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88788-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88788-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88788-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88788-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88789-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88789-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88789-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88789-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88789-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88790-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88790-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88790-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88790-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88790-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88791-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88791-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88791-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88791-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88791-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88792-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88792-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88792-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88792-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88792-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88798-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88798-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88798-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88798-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88798-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88802-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88802-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88802-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88802-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88802-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88803-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88803-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88803-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88803-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88803-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88804-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88804-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88804-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88804-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88804-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88805-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88805-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88805-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88805-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88805-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88807-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88807-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88807-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88807-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88807-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88808-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88808-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88808-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88808-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88808-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88809-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88809-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88809-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88809-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88809-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88810-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88810-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88810-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88810-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88810-7;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88811-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88811-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88811-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88811-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88811-5;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88812-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88812-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88812-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88812-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88812-3;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88813-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88813-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88813-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88813-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88813-1;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88814-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88814-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88814-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88814-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88814-9;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88815-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88815-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88815-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88815-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88815-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88816-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88816-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88816-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88816-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88816-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88817-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88817-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88817-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88817-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88817-2;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88818-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88818-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88818-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88818-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88818-0;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88819-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88819-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88819-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88819-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88819-8;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88820-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88820-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88820-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88820-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88820-6;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +88821-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88821-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6752-5;2;Mild;;; +88821-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88821-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA6750-9;4;Severe;;; +88821-4;LL4051-0;None(0)|Mild(1)|Moderate(2)|Severe(3)|Extreme(4);LA11912-5;5;Extreme;;; +82376-5;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82376-5;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82377-3;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82377-3;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82378-1;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82378-1;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82379-9;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82379-9;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82382-3;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82382-3;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82520-8;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82520-8;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82521-6;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82521-6;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82522-4;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82522-4;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82523-2;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +82523-2;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +91897-9;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +91897-9;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +92733-5;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +92733-5;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +92734-3;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +92734-3;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +92735-0;LL4039-5;PRED | NOT PRED;LA26373-3;1;Resistance predicted;;; +92735-0;LL4039-5;PRED | NOT PRED;LA26374-1;2;Resistance not predicted;;; +82380-7;LL4043-7;L31M | Y93H | NONE DETECTED;LA19544-8;1;None detected;;; +82380-7;LL4043-7;L31M | Y93H | NONE DETECTED;LA26376-6;2;Y93H;;; +82380-7;LL4043-7;L31M | Y93H | NONE DETECTED;LA26380-8;3;L31M;;; +82381-5;LL4044-5;S282T | NONE;LA26381-6;1;S282T;;; +82381-5;LL4044-5;S282T | NONE;LA26389-9;2;L320F;;; +82381-5;LL4044-5;S282T | NONE;LA26390-7;3;C223H/Y;;; +82381-5;LL4044-5;S282T | NONE;LA137-2;4;None;260413007;None (qualifier value);http://snomed.info/sct +82461-5;LL4045-2;FLUAV | FLUBV | 2009 H1N1;LA26382-4;1;"Flu A postive; 2009 H1N1 not detected; Flu B negative H1N1 NOT DETECTED; Flu B NEGATIVE";;; +82461-5;LL4045-2;FLUAV | FLUBV | 2009 H1N1;LA26383-2;2;"Flu A positive; 2009 H1N1 detected; Flu B negative";;; +82461-5;LL4045-2;FLUAV | FLUBV | 2009 H1N1;LA26384-0;3;"Flu A negative; 2009 H1N1 not detected; Flu B positive";;; +82461-5;LL4045-2;FLUAV | FLUBV | 2009 H1N1;LA26385-7;4;"Flu A positive; 2009 H1N1 not detected; Flu B positive";;; +82461-5;LL4045-2;FLUAV | FLUBV | 2009 H1N1;LA26386-5;5;"Flu A negative; 2009 H1N1 not detected; Flu B negative";;; +82461-5;LL4045-2;FLUAV | FLUBV | 2009 H1N1;LA26387-3;6;"Flu A positive; 2009 H1N1 detected; Flu B positive";;; +82465-6;LL4055-1;Aedes aegypti | Aedes albopictus;LA26447-5;1;Aedes aegypti;;; +82465-6;LL4055-1;Aedes aegypti | Aedes albopictus;LA26448-3;2;Aedes albopictus;;; +82465-6;LL4055-1;Aedes aegypti | Aedes albopictus;LA26453-3;3;Anopheles freeborni;;; +82465-6;LL4055-1;Aedes aegypti | Aedes albopictus;LA26452-5;4;Anopheles quadrimaculatus;;; +82465-6;LL4055-1;Aedes aegypti | Aedes albopictus;LA26449-1;5;Culex pipiens;;; +82465-6;LL4055-1;Aedes aegypti | Aedes albopictus;LA26450-9;6;Culex tarsalis;;; +82465-6;LL4055-1;Aedes aegypti | Aedes albopictus;LA26451-7;7;Culiseta melanura;;; +82512-5;LL4038-7;NOT DET |1|1a|1b;LA11883-8;1;Not detected;;; +82512-5;LL4038-7;NOT DET |1|1a|1b;LA6112-2;2;1;;; +82512-5;LL4038-7;NOT DET |1|1a|1b;LA19241-1;3;1A;;; +82512-5;LL4038-7;NOT DET |1|1a|1b;LA19242-9;4;1B;;; +82514-1;LL4042-9;Y93H | P58R/S | A30K/S/T/V | M28V | NONE DETECT;LA19544-8;1;None detected;;; +82514-1;LL4042-9;Y93H | P58R/S | A30K/S/T/V | M28V | NONE DETECT;LA26376-6;2;Y93H;;; +82514-1;LL4042-9;Y93H | P58R/S | A30K/S/T/V | M28V | NONE DETECT;LA26379-0;3;P58R/S;;; +82514-1;LL4042-9;Y93H | P58R/S | A30K/S/T/V | M28V | NONE DETECT;LA26378-2;4;A30K/S/T/V;;; +82589-3;LL5338-0;Highest Education Level;LA35-1;1;No schooling;;; +82589-3;LL5338-0;Highest Education Level;LA36-9;2;8th grade/less;;; +82589-3;LL5338-0;Highest Education Level;LA37-7;3;9-11 grades;;; +82589-3;LL5338-0;Highest Education Level;LA38-5;4;High school;;; +82589-3;LL5338-0;Highest Education Level;LA39-3;5;Technical or trade school;;; +82589-3;LL5338-0;Highest Education Level;LA40-1;6;Some college;;; +82589-3;LL5338-0;Highest Education Level;LA12459-6;7;Associate degree (e.g., AA, AS);;; +82589-3;LL5338-0;Highest Education Level;LA12460-4;8;Bachelor's degree (e.g., BA, AB, BS);;; +82589-3;LL5338-0;Highest Education Level;LA12461-2;9;Master's degree (e.g., MA, MS, MEng, MEd, MSW, MBA);;; +82589-3;LL5338-0;Highest Education Level;LA30185-5;10;Doctoral degree (e.g., PhD, EdD);;; +82589-3;LL5338-0;Highest Education Level;LA30186-3;11;Professional degree (e.g., MD, DDS, DVM, LLB, JD);;; +82589-3;LL5338-0;Highest Education Level;LA4489-6;12;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82589-3;LL5351-3;PRAPARE_Highest Education;LA30191-3;1;Less than high school degree;;; +82589-3;LL5351-3;PRAPARE_Highest Education;LA30192-1;2;High school diploma or GED;;; +82589-3;LL5351-3;PRAPARE_Highest Education;LA30193-9;3;More than high school;;; +82589-3;LL5351-3;PRAPARE_Highest Education;LA30122-8;4;I choose not to answer this question;;; +82589-3;LL6008-8;Education level - Highest acheived;LA32465-9;1;No formal education;;; +82589-3;LL6008-8;Education level - Highest acheived;LA32466-7;2;Primary school education;;; +82589-3;LL6008-8;Education level - Highest acheived;LA32467-5;3;High school education;;; +82589-3;LL6008-8;Education level - Highest acheived;LA32468-3;4;Attended some years of university;;; +82589-3;LL6008-8;Education level - Highest acheived;LA32469-1;5;University undergraduate degree;;; +82589-3;LL6008-8;Education level - Highest acheived;LA32470-9;6;Postgraduate degree;;; +82589-3;LL6101-1;NEI - Education level;LA12455-4;1;8th grade or less;;; +82589-3;LL6101-1;NEI - Education level;LA32764-5;2;Some high school, but did not graduate;;; +82589-3;LL6101-1;NEI - Education level;LA32765-2;3;High school graduate or GED;;; +82589-3;LL6101-1;NEI - Education level;LA32766-0;4;Some college or 2-year degree;;; +82589-3;LL6101-1;NEI - Education level;LA32767-8;5;4-year college graduate;;; +82589-3;LL6101-1;NEI - Education level;LA32768-6;6;More than 4-yearcollege degree;;; +82606-5;LL4063-5;Low criticality|High criticality|UTD;LA26478-0;1;Low criticality;;; +82606-5;LL4063-5;Low criticality|High criticality|UTD;LA26479-8;2;High criticality;;; +82606-5;LL4063-5;Low criticality|High criticality|UTD;LA26480-6;3;Unable to determine criticality;;; +82670-1;LL4057-7;More than once a day | 3 to 6 times a week | Not;LA15267-0;1;More than once a day;;; +82670-1;LL4057-7;More than once a day | 3 to 6 times a week | Not;LA13897-6;2;Once a day;;; +82670-1;LL4057-7;More than once a day | 3 to 6 times a week | Not;LA26456-6;3;3 to 6 times a week;;; +82670-1;LL4057-7;More than once a day | 3 to 6 times a week | Not;LA26457-4;4;Once or twice a week;;; +82670-1;LL4057-7;More than once a day | 3 to 6 times a week | Not;LA6568-5;5;Not at all;;; +82671-9;LL4058-5;4 or more nights a week | Not at all;LA26458-2;1;4 or more nights a week;;; +82671-9;LL4058-5;4 or more nights a week | Not at all;LA26459-0;2;2 to 3 nights a week;;; +82671-9;LL4058-5;4 or more nights a week | Not at all;LA26461-6;3;Once a week;;; +82671-9;LL4058-5;4 or more nights a week | Not at all;LA26460-8;4;Once or twice;;; +82671-9;LL4058-5;4 or more nights a week | Not at all;LA6568-5;5;Not at all;;; +82672-7;LL4059-3;3 or more times per day | Not at all;LA13850-5;1;3 or more times per day;;; +82672-7;LL4059-3;3 or more times per day | Not at all;LA26462-4;2;1 or 2 times per day;;; +82672-7;LL4059-3;3 or more times per day | Not at all;LA26463-2;3;2 or 3 times per week;;; +82672-7;LL4059-3;3 or more times per day | Not at all;LA13898-4;4;Once a week or less;;; +82672-7;LL4059-3;3 or more times per day | Not at all;LA6568-5;5;Not at all;;; +82673-5;LL4060-1;Not at all controlled | Well controlled;LA26465-7;1;Not at all controlled;;; +82673-5;LL4060-1;Not at all controlled | Well controlled;LA26466-5;2;Poorly controlled;;; +82673-5;LL4060-1;Not at all controlled | Well controlled;LA26467-3;3;Somewhat controlled;;; +82673-5;LL4060-1;Not at all controlled | Well controlled;LA26468-1;4;Well controlled;;; +82673-5;LL4060-1;Not at all controlled | Well controlled;LA26469-9;5;Completely controlled;;; +82746-9;LL4116-1;Wild-type strain|Vaccine-type strain;LA26650-4;1;Wild-type strain;;; +82746-9;LL4116-1;Wild-type strain|Vaccine-type strain;LA26651-2;2;Vaccine-type strain;;; +82746-9;LL4116-1;Wild-type strain|Vaccine-type strain;LA27090-2;3;Unable to type;;; +82750-1;LL4117-9;Before delivery|After delivery;LA26652-0;1;Before delivery;;; +82750-1;LL4117-9;Before delivery|After delivery;LA26653-8;2;After delivery;;; +82753-5;LL3651-8;County;;0;;;; +89202-6;LL3651-8;County;;0;;;; +82757-6;LL4119-5;Immunodeficiency diagnoses;LA26660-3;1;DiGeorge syndrome;;; +82757-6;LL4119-5;Immunodeficiency diagnoses;LA26658-7;2;Hypogammaglobulinemia;;; +82757-6;LL4119-5;Immunodeficiency diagnoses;LA26659-5;3;Job syndrome;;; +82757-6;LL4119-5;Immunodeficiency diagnoses;LA26661-1;4;Leukocyte adhesion deficiency;;; +82763-4;LL4118-7;Outdoor activities;LA26654-6;1;Camping;;; +82763-4;LL4118-7;Outdoor activities;LA26655-3;2;Hiking;;; +82763-4;LL4118-7;Outdoor activities;LA26656-1;3;Hunting;;; +82763-4;LL4118-7;Outdoor activities;LA17903-8;4;Yard work;;; +82763-4;LL4118-7;Outdoor activities;LA46-8;5;Other;;; +82768-3;LL4124-5;Expedite|Routine|Stat|NI|UN|OT;LA9035-2;1;Routine;;; +82768-3;LL4124-5;Expedite|Routine|Stat|NI|UN|OT;LA26675-1;2;Expedite;;; +82768-3;LL4124-5;Expedite|Routine|Stat|NI|UN|OT;LA26677-7;3;Stat;;; +82768-3;LL4124-5;Expedite|Routine|Stat|NI|UN|OT;LA21413-2;4;No information;;; +82768-3;LL4124-5;Expedite|Routine|Stat|NI|UN|OT;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82768-3;LL4124-5;Expedite|Routine|Stat|NI|UN|OT;LA46-8;6;Other;;; +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA26671-0;1;Smoked tobacco only;;; +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA26672-8;2;Non-smoked tobacco only;;; +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA26673-6;3;Use of both smoked and non-smoked tobacco products;;; +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA137-2;4;None;260413007;None (qualifier value);http://snomed.info/sct +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA26674-4;5;Use of smoked tobacco but no information about non-smoked tobacco use;;; +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA21413-2;6;No information;;; +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82769-1;LL4123-7;PCORI_Smoked_v_non-smoked_tobacco;LA46-8;8;Other;;; +82770-9;LL4122-9;yes|no|no info|unk|other;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +82770-9;LL4122-9;yes|no|no info|unk|other;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +82770-9;LL4122-9;yes|no|no info|unk|other;LA21413-2;3;No information;;; +82770-9;LL4122-9;yes|no|no info|unk|other;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82770-9;LL4122-9;yes|no|no info|unk|other;LA46-8;5;Other;;; +82771-7;LL4125-2;Laboratory|POC|NI|UN|OT;LA26678-5;1;Laboratory;;; +82771-7;LL4125-2;Laboratory|POC|NI|UN|OT;LA26679-3;2;Point of care;;; +82771-7;LL4125-2;Laboratory|POC|NI|UN|OT;LA21413-2;3;No information;;; +82771-7;LL4125-2;Laboratory|POC|NI|UN|OT;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82771-7;LL4125-2;Laboratory|POC|NI|UN|OT;LA46-8;5;Other;;; +82784-0;LL4120-3;PCORI_response_method;LA26662-9;1;Paper;;; +82784-0;LL4120-3;PCORI_response_method;LA26663-7;2;Electronic;;; +82784-0;LL4120-3;PCORI_response_method;LA26664-5;3;Telephone;;; +82784-0;LL4120-3;PCORI_response_method;LA26665-2;4;Telephone with interactive voice response;;; +82784-0;LL4120-3;PCORI_response_method;LA21413-2;5;No information;;; +82784-0;LL4120-3;PCORI_response_method;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82784-0;LL4120-3;PCORI_response_method;LA46-8;7;Other;;; +82791-5;LL4126-0;PCORI_Cause_of_death_rank;LA26682-7;1;Immediate/Primary;;; +82791-5;LL4126-0;PCORI_Cause_of_death_rank;LA26680-1;2;Contributory;;; +82791-5;LL4126-0;PCORI_Cause_of_death_rank;LA26681-9;3;Underlying;;; +82791-5;LL4126-0;PCORI_Cause_of_death_rank;LA46-8;4;Other;;; +82791-5;LL4126-0;PCORI_Cause_of_death_rank;LA21413-2;5;No information;;; +82791-5;LL4126-0;PCORI_Cause_of_death_rank;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +82937-4;LL4054-4;SAP/XIAP Interpretation;LA26442-6;1;SAP or XIAP deficiency not suspected.;;; +82937-4;LL4054-4;SAP/XIAP Interpretation;LA26443-4;2;SAP deficiency cannot be ruled out. Advise to repeat the test.;;; +82937-4;LL4054-4;SAP/XIAP Interpretation;LA26444-2;3;XIAP deficiency cannot be ruled out. Advise to repeat the test.;;; +82937-4;LL4054-4;SAP/XIAP Interpretation;LA26445-9;4;SAP deficiency suspected. SH2D1A gene testing is necessary to confirm the diagnosis of XLP.;;; +82937-4;LL4054-4;SAP/XIAP Interpretation;LA26446-7;5;XIAP deficiency suspected. BIRC4 gene testing is necessary to confirm the diagnosis of HLH (XLP-2).;;; +82940-8;LL4091-6;[ALSFRS-R] Speech;LA26567-0;1;Normal speech processes;;; +82940-8;LL4091-6;[ALSFRS-R] Speech;LA26568-8;2;Detectable speech disturbance;;; +82940-8;LL4091-6;[ALSFRS-R] Speech;LA26569-6;3;Intelligible with repeating;;; +82940-8;LL4091-6;[ALSFRS-R] Speech;LA26570-4;4;Speech combined with nonvocal communication;;; +82940-8;LL4091-6;[ALSFRS-R] Speech;LA26571-2;5;Loss of useful speech;;; +82941-6;LL4170-8;[ALSFRS] Salivation;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +82941-6;LL4170-8;[ALSFRS] Salivation;LA23498-1;2;"Slight but definite excess of saliva in mouth; may have nighttime drooling";;; +82941-6;LL4170-8;[ALSFRS] Salivation;LA23499-9;3;"Moderately excessive saliva; may have minimal drooling";;; +82941-6;LL4170-8;[ALSFRS] Salivation;LA23500-4;4;Marked excess of saliva with some drooling;;; +82941-6;LL4170-8;[ALSFRS] Salivation;LA23501-2;5;Marked drooling, requires constant tissue or handkerchief;;; +82942-4;LL4092-4;[ALSFRS-R] Swallowing;LA26573-8;1;Normal eating habits;;; +82942-4;LL4092-4;[ALSFRS-R] Swallowing;LA26574-6;2;Early eating problems - occasional choking;;; +82942-4;LL4092-4;[ALSFRS-R] Swallowing;LA26575-3;3;Dietary consistency changes;;; +82942-4;LL4092-4;[ALSFRS-R] Swallowing;LA26576-1;4;Needs supplemental tube feeding;;; +82942-4;LL4092-4;[ALSFRS-R] Swallowing;LA26577-9;5;NPO (exclusively parenteral or enteral feeding);;; +82943-2;LL4093-2;[ALSFRS-R] Handwriting;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +82943-2;LL4093-2;[ALSFRS-R] Handwriting;LA26578-7;2;Slow or sloppy, all words are legible;;; +82943-2;LL4093-2;[ALSFRS-R] Handwriting;LA26579-5;3;Not all words are legible;;; +82943-2;LL4093-2;[ALSFRS-R] Handwriting;LA26580-3;4;Able to grip pen but unable to write;;; +82943-2;LL4093-2;[ALSFRS-R] Handwriting;LA26581-1;5;Unable to grip pen;;; +82944-0;LL4171-6;[ALSFRS] Cutting food;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +82944-0;LL4171-6;[ALSFRS] Cutting food;LA23511-1;2;Somewhat slow and clumsy, but no help needed;;; +82944-0;LL4171-6;[ALSFRS] Cutting food;LA23584-8;3;"Can cut most foods, although clumsy and slow; some help needed";;; +82944-0;LL4171-6;[ALSFRS] Cutting food;LA23513-7;4;Food must be cut by someone, but can still feed slowly;;; +82944-0;LL4171-6;[ALSFRS] Cutting food;LA23514-5;5;Needs to be fed;;; +82945-7;LL4094-0;[ALSFRS-R] Alternative scale for cutting food;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +82945-7;LL4094-0;[ALSFRS-R] Alternative scale for cutting food;LA26584-5;2;Clumsy but able to perform all manipulations independently;;; +82945-7;LL4094-0;[ALSFRS-R] Alternative scale for cutting food;LA26585-2;3;Some help needed with closures and fasteners;;; +82945-7;LL4094-0;[ALSFRS-R] Alternative scale for cutting food;LA26586-0;4;Provides minimal assistance to caregiver;;; +82945-7;LL4094-0;[ALSFRS-R] Alternative scale for cutting food;LA26587-8;5;Unable to perform any aspect of task;;; +82946-5;LL4095-7;[ALSFRS-R] Dressing and hygiene;LA25393-2;1;Normal function;;; +82946-5;LL4095-7;[ALSFRS-R] Dressing and hygiene;LA26588-6;2;Independent and complete self-care with effort or decreased efficiency;;; +82946-5;LL4095-7;[ALSFRS-R] Dressing and hygiene;LA26589-4;3;Intermittent assistance or substitute methods;;; +82946-5;LL4095-7;[ALSFRS-R] Dressing and hygiene;LA26590-2;4;Needs attendant for self-care;;; +82946-5;LL4095-7;[ALSFRS-R] Dressing and hygiene;LA114-1;5;Total dependence;;; +82947-3;LL4168-2;[ALSFRS] Turning in bed;LA6626-1;0;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +82947-3;LL4168-2;[ALSFRS] Turning in bed;LA23511-1;1;Somewhat slow and clumsy, but no help needed;;; +82947-3;LL4168-2;[ALSFRS] Turning in bed;LA23523-6;2;Can turn alone or adjust sheets, but with great difficulty;;; +82947-3;LL4168-2;[ALSFRS] Turning in bed;LA23524-4;3;Can initiate, but not turn or adjust sheets alone;;; +82947-3;LL4168-2;[ALSFRS] Turning in bed;LA23525-1;4;Helpless;;; +82948-1;LL4097-3;[ALSFRS-R] Walking;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +82948-1;LL4097-3;[ALSFRS-R] Walking;LA26591-0;2;Early ambulation difficulties;;; +82948-1;LL4097-3;[ALSFRS-R] Walking;LA26592-8;3;Walks with assistance;;; +82948-1;LL4097-3;[ALSFRS-R] Walking;LA26593-6;4;Nonambulatory functional movement;;; +82948-1;LL4097-3;[ALSFRS-R] Walking;LA26594-4;5;No purposeful leg movement;;; +82949-9;LL4099-9;[ALSFRS-R] Climbing stairs;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +82949-9;LL4099-9;[ALSFRS-R] Climbing stairs;LA24898-1;2;Slow;;; +82949-9;LL4099-9;[ALSFRS-R] Climbing stairs;LA26595-1;3;Mild unsteadiness or fatigue;;; +82949-9;LL4099-9;[ALSFRS-R] Climbing stairs;LA26596-9;4;Needs assistance;;; +82949-9;LL4099-9;[ALSFRS-R] Climbing stairs;LA13868-7;5;Cannot do;;; +82950-7;LL4100-5;[ALSFRS-R] Dyspnea;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82950-7;LL4100-5;[ALSFRS-R] Dyspnea;LA26597-7;2;Occurs when walking;;; +82950-7;LL4100-5;[ALSFRS-R] Dyspnea;LA26598-5;3;Occurs with one or more of the following: eating, bathing, dressing (ADL);;; +82950-7;LL4100-5;[ALSFRS-R] Dyspnea;LA26599-3;4;Occurs at rest, difficulty breathing when either sitting or lying;;; +82950-7;LL4100-5;[ALSFRS-R] Dyspnea;LA26600-9;5;Significant difficulty, considering using mechanical respiratory support;;; +82951-5;LL4101-3;[ALSFRS-R] Orthopnea;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82951-5;LL4101-3;[ALSFRS-R] Orthopnea;LA26601-7;2;Some difficulty sleeping at night due to shortness of breath, does not routinely use more than two pillows;;; +82951-5;LL4101-3;[ALSFRS-R] Orthopnea;LA26602-5;3;Needs extra pillows in order to sleep (more than two);;; +82951-5;LL4101-3;[ALSFRS-R] Orthopnea;LA26603-3;4;Can only sleep sitting up;;; +82951-5;LL4101-3;[ALSFRS-R] Orthopnea;LA15849-5;5;Unable to sleep;;; +82952-3;LL4102-1;[ALSFRS-R] Respiratory insufficiency;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +82952-3;LL4102-1;[ALSFRS-R] Respiratory insufficiency;LA26604-1;2;Intermittent use of BiPAP;;; +82952-3;LL4102-1;[ALSFRS-R] Respiratory insufficiency;LA26605-8;3;Continuous use of BiPAP during the night;;; +82952-3;LL4102-1;[ALSFRS-R] Respiratory insufficiency;LA26606-6;4;Continuous use of BiPAP during the night and day;;; +82952-3;LL4102-1;[ALSFRS-R] Respiratory insufficiency;LA26607-4;5;Invasive mechanical ventilation by intubation or tracheostomy;;; +83005-9;LL4165-8;Simple variant|Structural variant;LA26801-3;1;Simple variant;;; +83005-9;LL4165-8;Simple variant|Structural variant;LA26802-1;2;Structural variant;;; +83006-7;LL4166-6;No del-dup found|Del-dup detected|Incon;LA26803-9;1;No deletion or duplication detected in studied region;;; +83006-7;LL4166-6;No del-dup found|Del-dup detected|Incon;LA26804-7;2;Deletion and/or duplication detected in studied regions;;; +83006-7;LL4166-6;No del-dup found|Del-dup detected|Incon;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +83057-0;LL4167-4;High expression|Low expression|No express;LA26821-1;1;No expression;;; +83057-0;LL4167-4;High expression|Low expression|No express;LA26820-3;2;Low expression;;; +83057-0;LL4167-4;High expression|Low expression|No express;LA26819-5;3;High expression;;; +83129-7;LL4174-0;Example respondent type;LA15312-4;1;Self;;; +83129-7;LL4174-0;Example respondent type;LA26831-0;2;Guardian;;; +83146-1;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83146-1;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83147-9;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83147-9;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83148-7;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83148-7;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83149-5;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83149-5;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83150-3;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83150-3;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83151-1;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83151-1;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83152-9;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83152-9;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83153-7;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83153-7;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83154-5;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83154-5;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83155-2;LL4175-7;Yes (1) | No (0) | If no, record time;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83155-2;LL4175-7;Yes (1) | No (0) | If no, record time;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83181-8;LL5788-6;Barthel: bathing;LA12304-4;1;Dependent;;; +83181-8;LL5788-6;Barthel: bathing;LA31636-6;2;Independent (or in shower);;; +83182-6;LL5789-4;Barthel: dressing;LA12304-4;1;Dependent;;; +83182-6;LL5789-4;Barthel: dressing;LA31637-4;2;Needs help but can do about half unaided;;; +83182-6;LL5789-4;Barthel: dressing;LA31638-2;3;Independent (including buttons, zips, laces, etc.);;; +83183-4;LL5786-0;Barthel: toileting;LA12304-4;1;Dependent;;; +83183-4;LL5786-0;Barthel: toileting;LA31631-7;2;Needs some help, but can do something alone;;; +83183-4;LL5786-0;Barthel: toileting;LA31632-5;3;Independent (on and off, dressing, wiping);;; +83183-4;LL6328-0;Schmid elimination;LA33651-3;9;Independent in elimination;;; +83183-4;LL6328-0;Schmid elimination;LA33652-1;10;Independent with frequency or diarrhea;;; +83183-4;LL6328-0;Schmid elimination;LA33653-9;11;Needs assistance with toileting;;; +83183-4;LL6328-0;Schmid elimination;LA7445-5;12;Incontinence;48340000;incontinence (finding);http://snomed.info/sct +83184-2;LL5785-2;Barthel: feeding;LA24937-7;1;Unable;;; +83184-2;LL5785-2;Barthel: feeding;LA31630-9;2;Needs help cutting, spreading butter, etc., or requires modified diet;;; +83184-2;LL5785-2;Barthel: feeding;LA12302-8;3;Independent;;; +83185-9;LL5787-8;Barthel: transfer;LA31633-3;1;Unable, no sitting balance;;; +83185-9;LL5787-8;Barthel: transfer;LA31634-1;2;Major help (one or two people, physical), can sit;;; +83185-9;LL5787-8;Barthel: transfer;LA31635-8;3;Minor help (verbal or physical);;; +83185-9;LL5787-8;Barthel: transfer;LA12302-8;4;Independent;;; +83186-7;LL5790-2;Barthel: mobility;LA31639-0;1;Immobile or <50 yards;;; +83186-7;LL5790-2;Barthel: mobility;LA31640-8;2;Wheelchair independent, including corners, >50 yards;;; +83186-7;LL5790-2;Barthel: mobility;LA31641-6;3;Walks with help of one person (verbal or physical) >50 yards;;; +83186-7;LL5790-2;Barthel: mobility;LA31642-4;4;"Independent (but may use any aid; for example, stick) >50 yards";;; +83186-7;LL6322-3;Champs Mobility;LA33636-4;3;Mobility impairment not observed;;; +83186-7;LL6322-3;Champs Mobility;LA33637-2;4;Mobility impairment observed;;; +83186-7;LL6326-4;Schmid mobility;LA33643-0;1;Ambulates with no gait disturbance;;; +83186-7;LL6326-4;Schmid mobility;LA33644-8;2;Ambulates or transfers with assistive device or assistance;;; +83186-7;LL6326-4;Schmid mobility;LA33645-5;3;Ambulates with unsteady gait and no assistance;;; +83186-7;LL6326-4;Schmid mobility;LA33646-3;4;Unable to ambulate or transfer;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83189-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83191-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83193-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83195-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83197-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83203-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83205-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83217-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83219-6;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83221-2;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83223-8;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83225-3;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85653-4;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +96098-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +96098-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +96098-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +96098-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +96098-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +96098-9;LL4154-2;CMS IRFPAI_GG Functional Goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83187-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83199-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83201-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83207-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83209-7;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83211-3;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83213-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83215-4;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83227-9;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83229-5;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83231-1;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83236-0;LL4620-2;CMS_MDS Self Care Discharge goal;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83188-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83190-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83192-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83194-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83196-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83198-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83200-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83202-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83204-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83206-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83208-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83210-5;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83212-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83214-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83216-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83218-8;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83220-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83222-0;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83224-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83226-1;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83228-7;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83230-3;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83232-9;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +83235-2;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +85652-6;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA10058-8;7;Patient refused;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA4720-4;8;Not applicable;;; +85926-4;LL4153-4;CMS IRFPAI_GG Functional Abilies;LA26735-3;9;Not attempted due to medical condition or safety concerns;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83188-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83200-6;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83202-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83208-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83210-5;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83212-1;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83214-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83216-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83228-7;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83230-3;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83232-9;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27993-7;0;Independent - Resident completes the activity by themself with no assistance from a helper.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27994-5;1;"Setup or clean-up assistance - Helper sets up or cleans up; resident completes activity. Helper assists only prior to or following the activity.";;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27995-2;2;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as resident completes activity. Assistance may be provided throughout the activity or intermittently.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27996-0;3;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds, or supports trunk or limbs, but provides less than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA11759-0;4;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27998-6;5;Dependent - Helper does all of the effort. Resident does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the resident to complete the activity.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA27999-4;6;Resident refused;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28000-0;7;Not applicable.;;; +83235-2;LL4616-0;CMS_MDS Self Care;LA28001-8;8;Not attempted due to medical condition or safety concerns.;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10117-2;4;Walker;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA10046-3;5;Orthotics/Prosthetics;;; +83234-5;LL4152-6;CMS IRFPAI_GG0110 Prior Device Use;LA9-3;6;None of the above;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA9-3;4;None of the above;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA9-3;4;None of the above;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA18363-4;1;Manual wheelchair;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA26730-4;2;Motorized wheelchair and/or scooter;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA11549-5;3;Mechanical lift;;; +83234-5;LL4471-0;CMS_LCDS Prior device use;LA9-3;4;None of the above;;; +83238-6;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26833-6;1;Always continent (no documented incontinence);;; +83238-6;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26736-1;2;Stress incontinence only;;; +83238-6;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26834-4;3;Incontinent less than daily (e.g., once or twice during the 3-day assessment period);;; +83238-6;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA9979-1;4;Incontinent daily (at least once a day);;; +83238-6;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA9934-6;5;Always incontinent;;; +83238-6;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26738-7;6;No urine output (e.g., renal failure);;; +83238-6;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA11693-1;7;Not applicable (e.g., indwelling catheter);;; +95735-7;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26833-6;1;Always continent (no documented incontinence);;; +95735-7;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26736-1;2;Stress incontinence only;;; +95735-7;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26834-4;3;Incontinent less than daily (e.g., once or twice during the 3-day assessment period);;; +95735-7;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA9979-1;4;Incontinent daily (at least once a day);;; +95735-7;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA9934-6;5;Always incontinent;;; +95735-7;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA26738-7;6;No urine output (e.g., renal failure);;; +95735-7;LL4155-9;CMS IRFPAI_H0350 Bladder Continence;LA11693-1;7;Not applicable (e.g., indwelling catheter);;; +83240-2;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA9962-7;1;Current season;;; +83240-2;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA9998-1;2;Location of own room;;; +83240-2;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA10085-1;3;Staff names and faces;;; +83240-2;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA26728-8;4;That he or she is in a hospital/hospital unit;;; +83240-2;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA26729-6;5;None of the above were recalled;;; +88333-0;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA9962-7;1;Current season;;; +88333-0;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA9998-1;2;Location of own room;;; +88333-0;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA10085-1;3;Staff names and faces;;; +88333-0;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA26728-8;4;That he or she is in a hospital/hospital unit;;; +88333-0;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA26729-6;5;None of the above were recalled;;; +95743-1;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA9962-7;1;Current season;;; +95743-1;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA9998-1;2;Location of own room;;; +95743-1;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA10085-1;3;Staff names and faces;;; +95743-1;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA26728-8;4;That he or she is in a hospital/hospital unit;;; +95743-1;LL4150-0;CMS IRFPAI_C0900 Memory/Recall;LA26729-6;5;None of the above were recalled;;; +83242-8;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11042-1;1;Always continent;;; +83242-8;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11048-8;2;Occasionally incontinent (one episode of bowel incontinence);;; +83242-8;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11049-6;3;Frequently incontinent (2 or more episodes of bowel incontinence, but at least one continent bowel movement);;; +83242-8;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11050-4;4;Always incontinent (no episodes of continent bowel movements);;; +83242-8;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA26835-1;5;Not rated, patient had an ostomy or did not have a bowel movement for the entire 3 days;;; +95736-5;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11042-1;1;Always continent;;; +95736-5;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11048-8;2;Occasionally incontinent (one episode of bowel incontinence);;; +95736-5;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11049-6;3;Frequently incontinent (2 or more episodes of bowel incontinence, but at least one continent bowel movement);;; +95736-5;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA11050-4;4;Always incontinent (no episodes of continent bowel movements);;; +95736-5;LL4156-7;CMS IRFPAI_H0400 Bowel Continence;LA26835-1;5;Not rated, patient had an ostomy or did not have a bowel movement for the entire 3 days;;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA9-3;3;None of the above;;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA9-3;3;None of the above;;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA9-3;3;None of the above;;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA9-3;3;None of the above;;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +83243-6;LL4157-5;CMS_IRF-PAI Comorbidities/Coexisting Conditions;LA9-3;3;None of the above;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27517-4;1;Severe and metastatic cancers;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA18399-8;2;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27518-2;3;Chronic kidney disease, stage 5;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27519-0;4;Acute renal failure;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27520-8;5;Septicemia, sepsis, systemic inflammatory response syndrome/shock;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27521-6;6;Central nervous system infections, opportunistic infections, bone/joint/muscle infections/necrosis;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27539-8;7;Diabetes mellitus (DM);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27522-4;8;Major lower limb amputation (e.g., above knee, below knee);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA22099-8;9;Stroke;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA20372-1;10;Dementia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27523-2;11;Hemiplegia or hemiparesis;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA25276-9;12;Paraplegia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27528-1;13;Complete tetraplegia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27529-9;14;Incomplete tetraplegia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27530-7;15;Other spinal cord disorder/injury (e.g., myelitis, cauda equina syndrome);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27531-5;16;Multiple sclerosis (MS);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27532-3;17;Huntington's disease;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27533-1;18;Parkinson's disease;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27534-9;19;Amyotrophic lateral sclerosis;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27535-6;20;Locked-in state;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27536-4;21;Severe anoxic brain damage, cerebral edema, or compression of brain;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27537-2;22;Malnutrition (protein or calorie);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27538-0;23;At risk for malnutrition;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA9-3;24;None of the above;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27517-4;1;Severe and metastatic cancers;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA18399-8;2;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27518-2;3;Chronic kidney disease, stage 5;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27519-0;4;Acute renal failure;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27520-8;5;Septicemia, sepsis, systemic inflammatory response syndrome/shock;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27521-6;6;Central nervous system infections, opportunistic infections, bone/joint/muscle infections/necrosis;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27539-8;7;Diabetes mellitus (DM);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27522-4;8;Major lower limb amputation (e.g., above knee, below knee);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA22099-8;9;Stroke;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA20372-1;10;Dementia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27523-2;11;Hemiplegia or hemiparesis;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA25276-9;12;Paraplegia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27528-1;13;Complete tetraplegia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27529-9;14;Incomplete tetraplegia;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27530-7;15;Other spinal cord disorder/injury (e.g., myelitis, cauda equina syndrome);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27531-5;16;Multiple sclerosis (MS);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27532-3;17;Huntington's disease;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27533-1;18;Parkinson's disease;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27534-9;19;Amyotrophic lateral sclerosis;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27535-6;20;Locked-in state;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27536-4;21;Severe anoxic brain damage, cerebral edema, or compression of brain;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27537-2;22;Malnutrition (protein or calorie);;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA27538-0;23;At risk for malnutrition;;; +83243-6;LL4465-2;CMS_LCDS Comorbidities and co-existing conditions;LA9-3;24;None of the above;;; +83243-6;LL4493-4;CMS_OASIS Comorbiditites;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4493-4;CMS_OASIS Comorbiditites;LA27539-8;2;Diabetes mellitus (DM);;; +83243-6;LL4493-4;CMS_OASIS Comorbiditites;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4493-4;CMS_OASIS Comorbiditites;LA27539-8;2;Diabetes mellitus (DM);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28289-9;1;Metastatic cancer;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28290-7;2;Severe cancer;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28298-0;3;Severe left systolic/ventricular dysfunction (known ejection fraction <= 30%);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA18399-8;4;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27518-2;5;Chronic kidney disease, stage 5;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27519-0;6;Acute renal failure;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27520-8;7;Septicemia, sepsis, systemic inflammatory response syndrome/shock;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27521-6;8;Central nervous system infections, opportunistic infections, bone/joint/muscle infections/necrosis;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27539-8;9;Diabetes mellitus (DM);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27522-4;10;Major lower limb amputation (e.g., above knee, below knee);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA22099-8;11;Stroke;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA20372-1;12;Dementia;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27523-2;13;Hemiplegia or hemiparesis;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA25276-9;14;Paraplegia;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27528-1;15;Complete tetraplegia;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27529-9;16;Incomplete tetraplegia;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27530-7;17;Other spinal cord disorder/injury (e.g., myelitis, cauda equina syndrome);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27531-5;18;Multiple sclerosis (MS);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27532-3;19;Huntington's disease;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27533-1;20;Parkinson's disease;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27534-9;21;Amyotrophic lateral sclerosis;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28291-5;22;Other progressive neuromuscular disease;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27535-6;23;Locked-in state;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27536-4;24;Severe anoxic brain damage, cerebral edema, or compression of brain;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28292-3;25;Other severe neurological injury, disease, or dysfunction;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27537-2;26;Malnutrition (protein or calorie);;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA27538-0;27;At risk for malnutrition;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28293-1;28;Lung transplant;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28294-9;29;Heart transplant;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28295-6;30;Liver transplant;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28296-4;31;Kidney transplant;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA28297-2;32;Bone marrow transplant;;; +83243-6;LL4704-4;CMS_LCDS v4 Comorbid conditions;LA9-3;33;None of the above;;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA27539-8;2;Diabetes mellitus (DM);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA9-3;3;None of the above;;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA27539-8;2;Diabetes mellitus (DM);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA9-3;3;None of the above;;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA27539-8;2;Diabetes mellitus (DM);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA9-3;3;None of the above;;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA27539-8;2;Diabetes mellitus (DM);;; +83243-6;LL4873-7;CMS_OASIS D Comorbidities;LA9-3;3;None of the above;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28289-9;1;Metastatic cancer;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28290-7;2;Severe cancer;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28298-0;3;Severe left systolic/ventricular dysfunction (known ejection fraction <= 30%);;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA18399-8;4;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27518-2;5;Chronic kidney disease, stage 5;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27519-0;6;Acute renal failure;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27520-8;7;Septicemia, sepsis, systemic inflammatory response syndrome/shock;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27521-6;8;Central nervous system infections, opportunistic infections, bone/joint/muscle infections/necrosis;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27539-8;9;Diabetes mellitus (DM);;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27522-4;10;Major lower limb amputation (e.g., above knee, below knee);;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA22099-8;11;Stroke;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA20372-1;12;Dementia;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27523-2;13;Hemiplegia or hemiparesis;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA25276-9;14;Paraplegia;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27528-1;15;Complete tetraplegia;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27529-9;16;Incomplete tetraplegia;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27530-7;17;Other spinal cord disorder/injury (e.g., myelitis, cauda equina syndrome);;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27531-5;18;Multiple sclerosis (MS);;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27532-3;19;Huntington's disease;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27533-1;20;Parkinson's disease;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27534-9;21;Amyotrophic lateral sclerosis;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28291-5;22;Other progressive neuromuscular disease;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27535-6;23;Locked-in state;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27536-4;24;Severe anoxic brain damage, cerebral edema, or compression of brain;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28292-3;25;Other severe neurological injury, disease, or dysfunction;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA27537-2;26;Malnutrition (protein or calorie);;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28293-1;27;Lung transplant;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28294-9;28;Heart transplant;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28295-6;29;Liver transplant;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28296-4;30;Kidney transplant;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA28297-2;31;Bone marrow transplant;;; +83243-6;LL5410-7;CMS_LCDS v5 Comorbid conditions;LA9-3;32;None of the above;;; +83243-6;LL6132-6;Current health conditions;LA32901-3;1;Organ transplant recipient;;; +83243-6;LL6132-6;Current health conditions;LA32902-1;2;Diabetes (Type I or II);;; +83243-6;LL6132-6;Current health conditions;LA32903-9;3;Heart disease or heart problems;;; +83243-6;LL6132-6;Current health conditions;LA32904-7;4;Hypertension (high blood pressure);;; +83243-6;LL6132-6;Current health conditions;LA32905-4;5;Overweight;;; +83243-6;LL6132-6;Current health conditions;LA22099-8;6;Stroke;;; +83243-6;LL6132-6;Current health conditions;LA10528-0;7;Kidney Disease;;; +83243-6;LL6132-6;Current health conditions;LA25810-5;8;Liver disease;;; +83243-6;LL6132-6;Current health conditions;LA18969-8;9;Anemia;;; +83243-6;LL6132-6;Current health conditions;LA16982-3;10;Asthma;;; +83243-6;LL6132-6;Current health conditions;LA32906-2;11;Other lung condition such as COPD, bronchitis or emphysema;;; +83243-6;LL6132-6;Current health conditions;LA10524-9;12;Cancer;;; +83243-6;LL6132-6;Current health conditions;LA32907-0;13;Condition affecting the brain and nerves (e.g. Dementia, Parkinson's, Multiple Sclerosis);;; +83243-6;LL6132-6;Current health conditions;LA32908-8;14;A weakend immune system/reduced ability to deal with infections (as a result of a disease or treatment);;; +83243-6;LL6132-6;Current health conditions;LA10576-9;15;Depression;;; +83243-6;LL6132-6;Current health conditions;LA10574-4;16;Anxiety;;; +83243-6;LL6132-6;Current health conditions;LA22096-4;17;Psychiatric disorder;;; +83248-5;LL4485-0;CMS_No (resident is rarely understood)|Yes;LA27578-6;1;No (patient is rarely/never understood);;; +83248-5;LL4485-0;CMS_No (resident is rarely understood)|Yes;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83249-3;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10110-7;1;Understands: clear comprehension without cues or repetitions;;; +83249-3;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10113-1;2;Usually understands: understands most conversations, but misses some part/intent of message. Requires cues at times to understand;;; +83249-3;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10083-6;3;Sometimes understands: understands only basic conversations or simple, direct phrases. Frequently requires cues to understand;;; +83249-3;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA81-5;4;Rarely/never understands;;; +87503-9;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10110-7;1;Understands: clear comprehension without cues or repetitions;;; +87503-9;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10113-1;2;Usually understands: understands most conversations, but misses some part/intent of message. Requires cues at times to understand;;; +87503-9;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10083-6;3;Sometimes understands: understands only basic conversations or simple, direct phrases. Frequently requires cues to understand;;; +87503-9;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA81-5;4;Rarely/never understands;;; +95740-7;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10110-7;1;Understands: clear comprehension without cues or repetitions;;; +95740-7;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10113-1;2;Usually understands: understands most conversations, but misses some part/intent of message. Requires cues at times to understand;;; +95740-7;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA10083-6;3;Sometimes understands: understands only basic conversations or simple, direct phrases. Frequently requires cues to understand;;; +95740-7;LL4145-0;CMS IRFPAI_BB0800 Understanding Verbal Content;LA81-5;4;Rarely/never understands;;; +83250-1;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA9967-6;1;Expresses complex messages without difficulty and with speech that is clear and easy to understand;;; +83250-1;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA9966-8;2;Exhibits some difficulty with expressing needs and ideas (e.g., some words or finishing thoughts) or speech is not clear;;; +83250-1;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA9972-6;3;Frequently exhibits difficulty with expressing needs and ideas;;; +83250-1;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA11713-7;4;Rarely/Never expresses self or speech is very difficult to understand;;; +95737-3;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA9967-6;1;Expresses complex messages without difficulty and with speech that is clear and easy to understand;;; +95737-3;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA9966-8;2;Exhibits some difficulty with expressing needs and ideas (e.g., some words or finishing thoughts) or speech is not clear;;; +95737-3;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA9972-6;3;Frequently exhibits difficulty with expressing needs and ideas;;; +95737-3;LL4144-3;CMS IRFPAI_BB0700 Expression of Ideas/Wants;LA11713-7;4;Rarely/Never expresses self or speech is very difficult to understand;;; +83252-7;LL4159-1;CMS_IRF-PAI Special treatments;LA10101-6;1;Total parenteral nutrition;;; +83252-7;LL4159-1;CMS_IRF-PAI Special treatments;LA10101-6;1;Total parenteral nutrition;;; +83252-7;LL4159-1;CMS_IRF-PAI Special treatments;LA10101-6;1;Total parenteral nutrition;;; +83252-7;LL4159-1;CMS_IRF-PAI Special treatments;LA10101-6;1;Total parenteral nutrition;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA27540-6;1;Invasive mechanical ventilator: weaning;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA27541-4;2;Invasive mechanical ventilator: non-weaning;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA27542-2;3;Non-invasive ventilator (BIPAP, CPAP);;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA7216-0;4;Dialysis;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA10101-6;5;Total parenteral nutrition;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA9-3;6;None of the above;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA27540-6;1;Invasive mechanical ventilator: weaning;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA27541-4;2;Invasive mechanical ventilator: non-weaning;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA27542-2;3;Non-invasive ventilator (BIPAP, CPAP);;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA7216-0;4;Dialysis;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA10101-6;5;Total parenteral nutrition;;; +83252-7;LL4467-8;CMS_LCDS Special treatments;LA9-3;6;None of the above;;; +83252-7;LL4679-8;CMS_LCDS v4 Special treatments;LA27542-2;1;Non-invasive ventilator (BIPAP, CPAP);;; +83252-7;LL4679-8;CMS_LCDS v4 Special treatments;LA27972-1;2;IV medications;;; +83252-7;LL4679-8;CMS_LCDS v4 Special treatments;LA28269-1;3;Vasoactive medications (i.e., continuous infusions of vasopressors or inotropes);;; +83252-7;LL4679-8;CMS_LCDS v4 Special treatments;LA7216-0;4;Dialysis;;; +83252-7;LL4679-8;CMS_LCDS v4 Special treatments;LA10101-6;5;Total parenteral nutrition;;; +83252-7;LL4679-8;CMS_LCDS v4 Special treatments;LA9-3;6;None of the above;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA6172-6;1;Chemotherapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30275-4;2;Chemotherapy - IV;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30276-2;3;Chemotherapy - Oral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30277-0;4;Chemotherapy - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA4351-8;5;Radiation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27962-2;6;Oxygen therapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30278-8;7;Oxygen therapy - Continuous;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30279-6;8;Oxygen therapy - Intermittent;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30280-4;9;Oxygen therapy - High-concentration;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27963-0;10;Suctioning;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30359-6;11;Suctioning - Scheduled;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30360-4;12;Suctioning - As Needed;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27964-8;13;Tracheostomy care;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA28889-6;14;Invasive mechanical ventilator (ventilator or respirator);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30281-2;15;Non-invasive mechanical ventilator;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30282-0;16;Non-invasive mechanical ventilator - BiPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30283-8;17;Non-invasive mechanical ventilator - CPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27972-1;18;IV medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30284-6;19;IV medications - Vasoactive medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30285-3;20;IV medications - Antibiotics;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30286-1;21;IV medications - Anticoagulation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30287-9;22;IV medications - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27966-3;23;Transfusions;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA7216-0;24;Dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30288-7;25;Dialysis - Hemodialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30289-5;26;Dialysis - Peritoneal dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30290-3;27;IV Access;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30291-1;28;IV Access - Peripheral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30292-9;29;IV Access - Midline;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30293-7;30;IV Access - Central (e.g., PICC, tunneled, port);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA9-3;31;None of the above;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA6172-6;1;Chemotherapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30275-4;2;Chemotherapy - IV;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30276-2;3;Chemotherapy - Oral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30277-0;4;Chemotherapy - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA4351-8;5;Radiation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27962-2;6;Oxygen therapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30278-8;7;Oxygen therapy - Continuous;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30279-6;8;Oxygen therapy - Intermittent;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30280-4;9;Oxygen therapy - High-concentration;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27963-0;10;Suctioning;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30359-6;11;Suctioning - Scheduled;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30360-4;12;Suctioning - As Needed;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27964-8;13;Tracheostomy care;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA28889-6;14;Invasive mechanical ventilator (ventilator or respirator);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30281-2;15;Non-invasive mechanical ventilator;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30282-0;16;Non-invasive mechanical ventilator - BiPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30283-8;17;Non-invasive mechanical ventilator - CPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27972-1;18;IV medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30284-6;19;IV medications - Vasoactive medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30285-3;20;IV medications - Antibiotics;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30286-1;21;IV medications - Anticoagulation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30287-9;22;IV medications - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27966-3;23;Transfusions;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA7216-0;24;Dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30288-7;25;Dialysis - Hemodialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30289-5;26;Dialysis - Peritoneal dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30290-3;27;IV Access;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30291-1;28;IV Access - Peripheral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30292-9;29;IV Access - Midline;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30293-7;30;IV Access - Central (e.g., PICC, tunneled, port);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA9-3;31;None of the above;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA6172-6;1;Chemotherapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30275-4;2;Chemotherapy - IV;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30276-2;3;Chemotherapy - Oral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30277-0;4;Chemotherapy - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA4351-8;5;Radiation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27962-2;6;Oxygen therapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30278-8;7;Oxygen therapy - Continuous;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30279-6;8;Oxygen therapy - Intermittent;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30280-4;9;Oxygen therapy - High-concentration;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27963-0;10;Suctioning;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30359-6;11;Suctioning - Scheduled;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30360-4;12;Suctioning - As Needed;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27964-8;13;Tracheostomy care;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA28889-6;14;Invasive mechanical ventilator (ventilator or respirator);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30281-2;15;Non-invasive mechanical ventilator;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30282-0;16;Non-invasive mechanical ventilator - BiPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30283-8;17;Non-invasive mechanical ventilator - CPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27972-1;18;IV medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30284-6;19;IV medications - Vasoactive medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30285-3;20;IV medications - Antibiotics;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30286-1;21;IV medications - Anticoagulation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30287-9;22;IV medications - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27966-3;23;Transfusions;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA7216-0;24;Dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30288-7;25;Dialysis - Hemodialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30289-5;26;Dialysis - Peritoneal dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30290-3;27;IV Access;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30291-1;28;IV Access - Peripheral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30292-9;29;IV Access - Midline;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30293-7;30;IV Access - Central (e.g., PICC, tunneled, port);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA9-3;31;None of the above;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA6172-6;1;Chemotherapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30275-4;2;Chemotherapy - IV;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30276-2;3;Chemotherapy - Oral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30277-0;4;Chemotherapy - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA4351-8;5;Radiation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27962-2;6;Oxygen therapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30278-8;7;Oxygen therapy - Continuous;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30279-6;8;Oxygen therapy - Intermittent;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30280-4;9;Oxygen therapy - High-concentration;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27963-0;10;Suctioning;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30359-6;11;Suctioning - Scheduled;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30360-4;12;Suctioning - As Needed;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27964-8;13;Tracheostomy care;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA28889-6;14;Invasive mechanical ventilator (ventilator or respirator);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30281-2;15;Non-invasive mechanical ventilator;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30282-0;16;Non-invasive mechanical ventilator - BiPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30283-8;17;Non-invasive mechanical ventilator - CPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27972-1;18;IV medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30284-6;19;IV medications - Vasoactive medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30285-3;20;IV medications - Antibiotics;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30286-1;21;IV medications - Anticoagulation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30287-9;22;IV medications - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27966-3;23;Transfusions;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA7216-0;24;Dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30288-7;25;Dialysis - Hemodialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30289-5;26;Dialysis - Peritoneal dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30290-3;27;IV Access;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30291-1;28;IV Access - Peripheral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30292-9;29;IV Access - Midline;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30293-7;30;IV Access - Central (e.g., PICC, tunneled, port);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA9-3;31;None of the above;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA6172-6;1;Chemotherapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30275-4;2;Chemotherapy - IV;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30276-2;3;Chemotherapy - Oral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30277-0;4;Chemotherapy - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA4351-8;5;Radiation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27962-2;6;Oxygen therapy;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30278-8;7;Oxygen therapy - Continuous;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30279-6;8;Oxygen therapy - Intermittent;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30280-4;9;Oxygen therapy - High-concentration;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27963-0;10;Suctioning;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30359-6;11;Suctioning - Scheduled;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30360-4;12;Suctioning - As Needed;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27964-8;13;Tracheostomy care;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA28889-6;14;Invasive mechanical ventilator (ventilator or respirator);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30281-2;15;Non-invasive mechanical ventilator;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30282-0;16;Non-invasive mechanical ventilator - BiPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30283-8;17;Non-invasive mechanical ventilator - CPAP;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27972-1;18;IV medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30284-6;19;IV medications - Vasoactive medications;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30285-3;20;IV medications - Antibiotics;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30286-1;21;IV medications - Anticoagulation;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30287-9;22;IV medications - Other;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27966-3;23;Transfusions;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA7216-0;24;Dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30288-7;25;Dialysis - Hemodialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30289-5;26;Dialysis - Peritoneal dialysis;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30290-3;27;IV Access;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30291-1;28;IV Access - Peripheral;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30292-9;29;IV Access - Midline;;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30293-7;30;IV Access - Central (e.g., PICC, tunneled, port);;; +83252-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA9-3;31;None of the above;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA6172-6;1;Chemotherapy;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30275-4;2;Chemotherapy - IV;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30276-2;3;Chemotherapy - Oral;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30277-0;4;Chemotherapy - Other;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA4351-8;5;Radiation;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27962-2;6;Oxygen therapy;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30278-8;7;Oxygen therapy - Continuous;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30279-6;8;Oxygen therapy - Intermittent;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30280-4;9;Oxygen therapy - High-concentration;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27963-0;10;Suctioning;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30359-6;11;Suctioning - Scheduled;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30360-4;12;Suctioning - As Needed;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27964-8;13;Tracheostomy care;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA28889-6;14;Invasive mechanical ventilator (ventilator or respirator);;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30281-2;15;Non-invasive mechanical ventilator;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30282-0;16;Non-invasive mechanical ventilator - BiPAP;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30283-8;17;Non-invasive mechanical ventilator - CPAP;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27972-1;18;IV medications;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30284-6;19;IV medications - Vasoactive medications;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30285-3;20;IV medications - Antibiotics;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30286-1;21;IV medications - Anticoagulation;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30287-9;22;IV medications - Other;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA27966-3;23;Transfusions;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA7216-0;24;Dialysis;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30288-7;25;Dialysis - Hemodialysis;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30289-5;26;Dialysis - Peritoneal dialysis;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30290-3;27;IV Access;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30291-1;28;IV Access - Peripheral;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30292-9;29;IV Access - Midline;;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA30293-7;30;IV Access - Central (e.g., PICC, tunneled, port);;; +93185-7;LL5385-1;CMS IRF_PAI v4.0 -Treat,Procedure,Program(O0110);LA9-3;31;None of the above;;; +8326-1;LL3628-6;Temperature measurement devices;LA24040-0;0;Digital thermometer;;; +8326-1;LL3628-6;Temperature measurement devices;LA24043-4;1;Liquid-crystal temperature-sensitive strip;;; +8326-1;LL3628-6;Temperature measurement devices;LA24038-4;2;Mercury thermometer;;; +8326-1;LL3628-6;Temperature measurement devices;LA24037-6;3;Non-contact infrared thermometer (NCIT);;; +8326-1;LL3628-6;Temperature measurement devices;LA24042-6;4;Temporal artery infrared thermometer;;; +8326-1;LL3628-6;Temperature measurement devices;LA24039-2;5;Thermal scanner camera;;; +8326-1;LL3628-6;Temperature measurement devices;LA24041-8;6;Tympanic infrared thermometer;;; +83270-9;LL4183-1;CMS IRFPAI_GG0170H1 Patient walks;LA26845-0;1;No, and walking goal is not clinically indicated;;; +83270-9;LL4183-1;CMS IRFPAI_GG0170H1 Patient walks;LA26846-8;2;No, and walking goal is clinically indicated;;; +83270-9;LL4183-1;CMS IRFPAI_GG0170H1 Patient walks;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83272-5;LL4186-4;Manual | Motorized;LA19016-7;1;Manual;;; +83272-5;LL4186-4;Manual | Motorized;LA26847-6;2;Motorized;;; +89408-9;LL4186-4;Manual | Motorized;LA19016-7;1;Manual;;; +89408-9;LL4186-4;Manual | Motorized;LA26847-6;2;Motorized;;; +95739-9;LL4186-4;Manual | Motorized;LA19016-7;1;Manual;;; +95739-9;LL4186-4;Manual | Motorized;LA26847-6;2;Motorized;;; +83278-2;LL4185-6;No (0) | Yes (2);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +83278-2;LL4185-6;No (0) | Yes (2);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +8327-9;LL3155-0;Body temp measurement sites;LA9370-3;1;Axillary;;; +8327-9;LL3155-0;Body temp measurement sites;LA9367-9;2;Oral;;; +8327-9;LL3155-0;Body temp measurement sites;LA21929-7;3;Ear;;; +8327-9;LL3155-0;Body temp measurement sites;LA9368-7;4;Tympanic membrane;;; +8327-9;LL3155-0;Body temp measurement sites;LA21928-9;5;Temporal artery (forehead);;; +8327-9;LL3155-0;Body temp measurement sites;LA9369-5;6;Rectal;;; +8327-9;LL3155-0;Body temp measurement sites;LA9371-1;7;Urinary bladder;;; +8327-9;LL3155-0;Body temp measurement sites;LA9263-0;8;Nasal;;; +8327-9;LL3155-0;Body temp measurement sites;LA18005-1;9;Nasopharyngeal;;; +8327-9;LL3155-0;Body temp measurement sites;LA11862-2;10;Finger;;; +8327-9;LL3155-0;Body temp measurement sites;LA21930-5;11;Toe;;; +83312-9;LL4140-1;Yes|No|Not asked|Refused to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83312-9;LL4140-1;Yes|No|Not asked|Refused to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83312-9;LL4140-1;Yes|No|Not asked|Refused to answer;LA14761-3;3;Not asked;;; +83312-9;LL4140-1;Yes|No|Not asked|Refused to answer;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +83313-7;LL4140-1;Yes|No|Not asked|Refused to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83313-7;LL4140-1;Yes|No|Not asked|Refused to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83313-7;LL4140-1;Yes|No|Not asked|Refused to answer;LA14761-3;3;Not asked;;; +83313-7;LL4140-1;Yes|No|Not asked|Refused to answer;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +83314-5;LL4140-1;Yes|No|Not asked|Refused to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83314-5;LL4140-1;Yes|No|Not asked|Refused to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83314-5;LL4140-1;Yes|No|Not asked|Refused to answer;LA14761-3;3;Not asked;;; +83314-5;LL4140-1;Yes|No|Not asked|Refused to answer;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +83315-2;LL4140-1;Yes|No|Not asked|Refused to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83315-2;LL4140-1;Yes|No|Not asked|Refused to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83315-2;LL4140-1;Yes|No|Not asked|Refused to answer;LA14761-3;3;Not asked;;; +83315-2;LL4140-1;Yes|No|Not asked|Refused to answer;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +83316-0;LL4140-1;Yes|No|Not asked|Refused to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83316-0;LL4140-1;Yes|No|Not asked|Refused to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83316-0;LL4140-1;Yes|No|Not asked|Refused to answer;LA14761-3;3;Not asked;;; +83316-0;LL4140-1;Yes|No|Not asked|Refused to answer;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +83317-8;LL4140-1;Yes|No|Not asked|Refused to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83317-8;LL4140-1;Yes|No|Not asked|Refused to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83317-8;LL4140-1;Yes|No|Not asked|Refused to answer;LA14761-3;3;Not asked;;; +83317-8;LL4140-1;Yes|No|Not asked|Refused to answer;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +83318-6;LL4140-1;Yes|No|Not asked|Refused to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +83318-6;LL4140-1;Yes|No|Not asked|Refused to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +83318-6;LL4140-1;Yes|No|Not asked|Refused to answer;LA14761-3;3;Not asked;;; +83318-6;LL4140-1;Yes|No|Not asked|Refused to answer;LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +83319-4;LL4139-3;Confirmed|Probable|No|Unknown;LA15290-2;1;Confirmed;;; +83319-4;LL4139-3;Confirmed|Probable|No|Unknown;LA12746-6;2;Probable;;; +83319-4;LL4139-3;Confirmed|Probable|No|Unknown;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +83319-4;LL4139-3;Confirmed|Probable|No|Unknown;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +83322-8;LL4196-3;[PCAM] Safety and stability in home environment;LA26865-8;1;Consistently safe, supportive, stable, no identified problems;;; +83322-8;LL4196-3;[PCAM] Safety and stability in home environment;LA26866-6;2;Safe, stable, but with some inconsistency;;; +83322-8;LL4196-3;[PCAM] Safety and stability in home environment;LA26867-4;3;Safety/stability questionable;;; +83322-8;LL4196-3;[PCAM] Safety and stability in home environment;LA26868-2;4;Unsafe and unstable;;; +83323-6;LL4197-1;[PCAM] Impact of daily activities;LA26869-0;1;No identified problems or perceived positive benefits;;; +83323-6;LL4197-1;[PCAM] Impact of daily activities;LA26870-8;2;Some general dissatisfaction but no concern;;; +83323-6;LL4197-1;[PCAM] Impact of daily activities;LA26871-6;3;Contributes to low mood or stress at times;;; +83323-6;LL4197-1;[PCAM] Impact of daily activities;LA26872-4;4;Severe impact on poor mental well-being;;; +83324-4;LL4199-7;[PCAM] Rating of social network;LA26873-2;1;Good participation with social networks;;; +83324-4;LL4199-7;[PCAM] Rating of social network;LA26874-0;2;Adequate participation with social networks;;; +83324-4;LL4199-7;[PCAM] Rating of social network;LA26875-7;3;Restricted participation with some degree of social isolation;;; +83324-4;LL4199-7;[PCAM] Rating of social network;LA26876-5;4;Little participation, lonely and socially isolated;;; +83328-5;LL4189-8;[PCAM] Physical health needs investigation;LA26851-8;1;No identified areas of uncertainty or problems already being investigated;;; +83328-5;LL4189-8;[PCAM] Physical health needs investigation;LA26852-6;2;"Mild vague physical symptoms or problems; but do not impact on daily life or are not of concern to client";;; +83328-5;LL4189-8;[PCAM] Physical health needs investigation;LA26853-4;3;Mod to severe symptoms or problems that impact on daily life;;; +83328-5;LL4189-8;[PCAM] Physical health needs investigation;LA26854-2;4;Severe symptoms or problems that cause significant impact on daily life;;; +83330-1;LL4192-2;[PCAM] Physical health and mental well being;LA26855-9;1;No identified areas of concern;;; +83330-1;LL4192-2;[PCAM] Physical health and mental well being;LA26856-7;2;"Mild impact on mental well-being e.g. ""feeling fed-up"", ""reduced enjoyment""";;; +83330-1;LL4192-2;[PCAM] Physical health and mental well being;LA26857-5;3;Moderate to severe impact upon mental well-being and preventing enjoyment of usual activities;;; +83330-1;LL4192-2;[PCAM] Physical health and mental well being;LA26858-3;4;Severe impact upon mental well-being and preventing engagement with usual activities;;; +83332-7;LL4193-0;[PCAM] Lifestyle behavior problems;LA26855-9;1;No identified areas of concern;;; +83332-7;LL4193-0;[PCAM] Lifestyle behavior problems;LA26859-1;2;Some mild concern of potential negative impact on well-being;;; +83332-7;LL4193-0;[PCAM] Lifestyle behavior problems;LA26860-9;3;Mod to severe impact on client's well-being, preventing enjoyment of usual activities;;; +83332-7;LL4193-0;[PCAM] Lifestyle behavior problems;LA26861-7;4;Severe impact on client's well-being with additional potential impact on others;;; +83333-5;LL4194-8;[PCAM] Other concerns about mental well-being;LA26855-9;1;No identified areas of concern;;; +83333-5;LL4194-8;[PCAM] Other concerns about mental well-being;LA26862-5;2;Mild problems- don't interfere with function;;; +83333-5;LL4194-8;[PCAM] Other concerns about mental well-being;LA26863-3;3;Mod to severe problems that interfere with function;;; +83333-5;LL4194-8;[PCAM] Other concerns about mental well-being;LA26864-1;4;Severe problems impairing most daily functions;;; +83335-0;LL4200-3;[PCAM] Rating of financial resources;LA26877-3;1;Financially secure, resources adequate, no identified problems;;; +83335-0;LL4200-3;[PCAM] Rating of financial resources;LA26878-1;2;Financially secure, some resource challenges;;; +83335-0;LL4200-3;[PCAM] Rating of financial resources;LA26879-9;3;Financially insecure, some resource challenges;;; +83335-0;LL4200-3;[PCAM] Rating of financial resources;LA26880-7;4;Financially insecure, very few resources, immediate challenges;;; +83337-6;LL4201-1;[PCAM] Understanding health and well-being;LA26881-5;1;Reasonable to good understanding and already engages in managing health or is willing to undertake better management;;; +83337-6;LL4201-1;[PCAM] Understanding health and well-being;LA26882-3;2;Reasonable to good understanding but do not feel able to engage with advice at this time;;; +83337-6;LL4201-1;[PCAM] Understanding health and well-being;LA26883-1;3;Little understanding which impacts on their ability to undertake better management;;; +83337-6;LL4201-1;[PCAM] Understanding health and well-being;LA26884-9;4;Poor understanding with significant impact on ability to manage health;;; +83338-4;LL4202-9;[PCAM] Engagement in healthcare discussions;LA26885-6;1;Clear and open communication, no identified barriers;;; +83338-4;LL4202-9;[PCAM] Engagement in healthcare discussions;LA26886-4;2;Adequate communication, with or without minor barriers;;; +83338-4;LL4202-9;[PCAM] Engagement in healthcare discussions;LA26887-2;3;Some difficulties in communication with or without moderate barriers;;; +83338-4;LL4202-9;[PCAM] Engagement in healthcare discussions;LA26888-0;4;Serious difficulties in communication, with severe barriers;;; +83340-0;LL4204-5;[PCAM] Other service coordination;LA26889-8;1;Other care/services not required at this time;;; +83340-0;LL4204-5;[PCAM] Other service coordination;LA26890-6;2;Other care/services in place and adequate;;; +83340-0;LL4204-5;[PCAM] Other service coordination;LA26891-4;3;Other care/services in place but not sufficient;;; +83340-0;LL4204-5;[PCAM] Other service coordination;LA26892-2;4;Other care/services not in place and required;;; +83341-8;LL4205-2;[PCAM] Coordination of current services;LA26893-0;1;All required care/services in place and well coordinated;;; +83341-8;LL4205-2;[PCAM] Coordination of current services;LA26894-8;2;Required care/services in place and adequately coordinated;;; +83341-8;LL4205-2;[PCAM] Coordination of current services;LA26901-1;3;Required care/services in place with some coordination barriers;;; +83341-8;LL4205-2;[PCAM] Coordination of current services;LA26902-9;4;Required care/services missing and/or fragmented;;; +83373-1;LL4000-7;Cont|Intermitt|Sched|Off;LA16902-1;1;Continuous;;; +83373-1;LL4000-7;Cont|Intermitt|Sched|Off;LA24760-3;2;Intermittent;;; +83373-1;LL4000-7;Cont|Intermitt|Sched|Off;LA22866-0;3;Scheduled;;; +83373-1;LL4000-7;Cont|Intermitt|Sched|Off;LA26227-1;4;Off;;; +83374-9;LL4001-5;Aerosolizer|Pneumatic;LA26228-9;1;Aerosolizer;;; +83374-9;LL4001-5;Aerosolizer|Pneumatic;LA26229-7;2;Pneumatic;;; +8352-7;LL742-8;Clothes;LA11871-3;1;Underwear or less;;; +8352-7;LL742-8;Clothes;LA11872-1;2;Street clothes, no shoes;;; +8352-7;LL742-8;Clothes;LA11873-9;3;Street clothes & shoes;;; +8356-8;LL5676-3;Weight Measurement Device;LA31242-3;1;Broselow Luten color coding system for pediatric weight estimation;;; +8356-8;LL5676-3;Weight Measurement Device;LA31243-1;2;Patient sling;;; +8356-8;LL5676-3;Weight Measurement Device;LA31244-9;3;Bed scale;;; +8356-8;LL5676-3;Weight Measurement Device;LA31245-6;4;Wheelchair scale;;; +8356-8;LL5676-3;Weight Measurement Device;LA31246-4;5;Floor scale, electronic;;; +8356-8;LL5676-3;Weight Measurement Device;LA31247-2;6;Floor scale, mechanical;;; +8356-8;LL5676-3;Weight Measurement Device;LA31248-0;7;Infant scale;;; +8356-8;LL5676-3;Weight Measurement Device;LA31249-8;8;Chair scale;;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA24013-7;0;Auscultation - automatic;;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA24012-9;1;Auscultation - manual;;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA24014-5;2;Oscillometry;;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA24016-0;3;Continuous noninvasive arterial pressure (CNAP);;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA24015-2;4;Invasive (intravascular transducer);;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA25780-0;5;Arterial line;;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA19771-7;6;Doppler;;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA25782-6;7;Cuff-manual palpated only;;; +8357-6;LL3623-7;Blood pressure monitoring methods;LA25783-4;8;Venous line;;; +8358-4;LL719-6;BP cuff size;LA11162-7;1;Adult standard;;; +8358-4;LL719-6;BP cuff size;LA11163-5;2;Adult large;;; +8358-4;LL719-6;BP cuff size;LA11164-3;3;Thigh extra large;;; +8361-8;LL741-0;Position;LA11868-9;1;Sitting;33586001;Sitting position (finding);http://snomed.info/sct +8361-8;LL741-0;Position;LA11869-7;2;Lying;;; +8361-8;LL741-0;Position;LA11870-5;3;Standing;10904000;Orthostatic body position (finding);http://snomed.info/sct +83844-1;LL4132-8;Measured|Reported;LA26694-2;1;Measured;;; +83844-1;LL4132-8;Measured|Reported;LA25254-6;2;Reported;;; +83849-0;LL4130-2;Dose change reason;LA26686-8;1;Dosage adjusted to body weight;;; +83849-0;LL4130-2;Dose change reason;LA26685-0;2;Puberty;;; +83849-0;LL4130-2;Dose change reason;LA26687-6;3;Efficacy;;; +84299-7;LL4133-6;Reasons for missed treatment;LA26701-5;0;Ran out of needle/cartridge;;; +84299-7;LL4133-6;Reasons for missed treatment;LA26695-9;1;Forgot to take medication;;; +84299-7;LL4133-6;Reasons for missed treatment;LA26696-7;2;Holidays/long weekend/not sleeping at home;;; +84299-7;LL4133-6;Reasons for missed treatment;LA26697-5;3;Medical reason;;; +84299-7;LL4133-6;Reasons for missed treatment;LA26698-3;4;Tired of injections;;; +84299-7;LL4133-6;Reasons for missed treatment;LA26699-1;5;Technical problems;;; +84299-7;LL4133-6;Reasons for missed treatment;LA26700-7;6;Forgot drug;;; +98870-9;LL4133-6;Reasons for missed treatment;LA26701-5;0;Ran out of needle/cartridge;;; +98870-9;LL4133-6;Reasons for missed treatment;LA26695-9;1;Forgot to take medication;;; +98870-9;LL4133-6;Reasons for missed treatment;LA26696-7;2;Holidays/long weekend/not sleeping at home;;; +98870-9;LL4133-6;Reasons for missed treatment;LA26697-5;3;Medical reason;;; +98870-9;LL4133-6;Reasons for missed treatment;LA26698-3;4;Tired of injections;;; +98870-9;LL4133-6;Reasons for missed treatment;LA26699-1;5;Technical problems;;; +98870-9;LL4133-6;Reasons for missed treatment;LA26700-7;6;Forgot drug;;; +84300-3;LL4131-0;Parent/legal guardian|Parent supervision|Self;LA26688-4;1;Parent/legal guardian;;; +84300-3;LL4131-0;Parent/legal guardian|Parent supervision|Self;LA26689-2;2;Patient self-injection without supervision;;; +84300-3;LL4131-0;Parent/legal guardian|Parent supervision|Self;LA26690-0;3;Patient self-injection with supervision;;; +84875-4;LL4070-0;Tumor perforation type;LA26473-1;1;Through tumor prior to surgery;;; +84875-4;LL4070-0;Tumor perforation type;LA26474-9;2;Through tumor during surgery mobilization;;; +84875-4;LL4070-0;Tumor perforation type;LA26475-6;3;Away from tumor;;; +84880-4;LL4072-6;Entirely above|Astride|Entirely below;LA26481-4;1;Entirely above;;; +84880-4;LL4072-6;Entirely above|Astride|Entirely below;LA26482-2;2;Astride;;; +84880-4;LL4072-6;Entirely above|Astride|Entirely below;LA26483-0;3;Entirely below;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA15390-0;1;Adenoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26485-5;2;Tubular adenoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26486-3;3;Villous adenoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26487-1;4;Tubulovillous adenoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26488-9;5;Glandular intraepithelial neoplasia, low grade;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26489-7;6;Glandular intraepithelial neoplasia, high grade;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26490-5;7;Sessile serrated adenoma/polyp;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26491-3;8;Serrated polyposis;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26492-1;9;Traditional serrated adenoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26493-9;10;Adenocarcinoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26494-7;11;Cribriform comedo-type adenocarcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26495-4;12;Medullary carcinoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26496-2;13;Micropapillary carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26497-0;14;Colloid carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26498-8;15;Serrated adenocarcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA15444-5;16;Signet ring cell carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA15446-0;17;Adenosquamous carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26501-9;18;Spindle cell carcinoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA15447-8;19;Undifferentiated carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26504-3;20;Neuroendocrine tumor G1 (NET G1)/Carcinoid;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26505-0;21;Neuroendocrine tumor G2 (NET G2);;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26506-8;22;Neuroendocrine carcinoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26100-0;23;Large cell neuroendocrine carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26101-8;24;Small cell neuroendocrine carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26102-6;25;Mixed adenoneuroendocrine carcinoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26510-0;26;Enterochromaffin cell (EC), serotonin-producing;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26512-6;27;L cell, Glucagon-like peptide-producing and PP/PYY-producing NETs;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26513-4;28;Leiomyoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26514-2;29;Lipoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26515-9;30;Angiosarcoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26516-7;31;Gastrointestinal stromal tumor, malignant;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26517-5;32;Kaposi sarcoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26518-3;33;Leiomyosarcoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26519-1;34;Schwannoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26520-9;35;Perineurioma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26521-7;36;Ganglioneuroma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26522-5;37;Granular cell tumor, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26523-3;38;Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma);;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26524-1;39;Mantle cell lymphoma;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26525-8;40;Diffuse large B-cell lymphoma (DLBCL), NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26526-6;41;Burkitt lymphoma, NOS;;; +84882-0;LL4073-4;WHO classification_Colon and Rectum tumor types;LA26527-4;42;B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma;;; +84883-8;LL4074-2;Deepest extent of tumor invasion;LA26528-2;1;Tumor invades submucosa;;; +84883-8;LL4074-2;Deepest extent of tumor invasion;LA26529-0;2;Tumor invades muscularis propria;;; +84883-8;LL4074-2;Deepest extent of tumor invasion;LA26530-8;3;Tumor invades through the muscularis propria into pericolorectal tissues;;; +84883-8;LL4074-2;Deepest extent of tumor invasion;LA26531-6;4;Tumor penetrates the visceral peritoneum;;; +84883-8;LL4074-2;Deepest extent of tumor invasion;LA26532-4;5;Tumor directly invades or is adherent to other organs or structures;;; +84884-6;LL4075-9;Involved, distal|Involved, proximal|Not involved;LA26533-2;1;Involved, distal margin;;; +84884-6;LL4075-9;Involved, distal|Involved, proximal|Not involved;LA26534-0;2;Involved, proximal margin;;; +84884-6;LL4075-9;Involved, distal|Involved, proximal|Not involved;LA26535-7;3;Not involved;;; +84885-3;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +84885-3;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +84887-9;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +84887-9;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +84906-7;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +84906-7;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +98263-7;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +98263-7;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +98264-5;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +98264-5;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +98265-2;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +98265-2;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +98266-0;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +98266-0;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +98267-8;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +98267-8;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +98268-6;LL4076-7;Involved|Not Involved;LA26536-5;1;Involved;;; +98268-6;LL4076-7;Involved|Not Involved;LA26535-7;2;Not involved;;; +84891-1;LL4077-5;Tumor response to neoadjuvant therapy;LA26537-3;1;No prior treatment;;; +84891-1;LL4077-5;Tumor response to neoadjuvant therapy;LA26538-1;2;Complete response (Grade 0 - No viable cancer cells);;; +84891-1;LL4077-5;Tumor response to neoadjuvant therapy;LA26539-9;3;Moderate response (Grade 1 - Single cells or small groups of cancer cells);;; +84891-1;LL4077-5;Tumor response to neoadjuvant therapy;LA26540-7;4;Mminimal response (Grade 2 - Residual cancer outgrown by fibrosis);;; +84891-1;LL4077-5;Tumor response to neoadjuvant therapy;LA26541-5;5;"Poor response (Grade 3 - Minimal or no tumor kill; extensive)";;; +84892-9;LL4078-3;R0|R1|R2;LA26542-3;1;R0;;; +84892-9;LL4078-3;R0|R1|R2;LA26543-1;2;R1;;; +84892-9;LL4078-3;R0|R1|R2;LA26544-9;3;R2;;; +84897-8;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26548-0;1;Right anterior;;; +84897-8;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26550-6;2;Left anterior;;; +84897-8;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26549-8;3;Right posterior;;; +84897-8;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26551-4;4;Left posterior;;; +84900-0;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26548-0;1;Right anterior;;; +84900-0;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26550-6;2;Left anterior;;; +84900-0;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26549-8;3;Right posterior;;; +84900-0;LL4079-1;R Ant|Left Ant|R Post|L Post;LA26551-4;4;Left posterior;;; +84898-6;LL4080-9;Apex|Mid|Base;LA25154-8;1;Apex;;; +84898-6;LL4080-9;Apex|Mid|Base;LA26546-4;2;Mid;;; +84898-6;LL4080-9;Apex|Mid|Base;LA25152-2;3;Base;;; +84901-8;LL4080-9;Apex|Mid|Base;LA25154-8;1;Apex;;; +84901-8;LL4080-9;Apex|Mid|Base;LA26546-4;2;Mid;;; +84901-8;LL4080-9;Apex|Mid|Base;LA25152-2;3;Base;;; +84903-4;LL4082-5;Focal|Non-focal;LA26555-5;1;Focal;;; +84903-4;LL4082-5;Focal|Non-focal;LA26556-3;2;Non-focal;;; +98260-3;LL4082-5;Focal|Non-focal;LA26555-5;1;Focal;;; +98260-3;LL4082-5;Focal|Non-focal;LA26556-3;2;Non-focal;;; +84905-9;LL4083-3;Extraprostatic extension|Intraprostatic;LA26558-9;1;Extraprostatic extension (EPE);;; +84905-9;LL4083-3;Extraprostatic extension|Intraprostatic;LA26557-1;2;Intraprostatic (capsular incision);;; +85042-0;LL4188-0;GISA|hGISA;LA26849-2;1;GISA;;; +85042-0;LL4188-0;GISA|hGISA;LA26850-0;2;hGISA;;; +85045-3;LL4187-2;GISA or hGISA detected|Not detected;LA26848-4;1;GISA or hGISA detected;;; +85045-3;LL4187-2;GISA or hGISA detected|Not detected;LA11883-8;2;Not detected;;; +85058-6;LL4207-8;Imputed parts of DOD;LA26903-7;1;Both month and day imputed;;; +85058-6;LL4207-8;Imputed parts of DOD;LA26905-2;2;Day imputed;;; +85058-6;LL4207-8;Imputed parts of DOD;LA26904-5;3;Month imputed;;; +85058-6;LL4207-8;Imputed parts of DOD;LA26906-0;4;Not imputed;;; +85058-6;LL4207-8;Imputed parts of DOD;LA21413-2;5;No information;;; +85058-6;LL4207-8;Imputed parts of DOD;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85058-6;LL4207-8;Imputed parts of DOD;LA46-8;7;Other;;; +85059-4;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA9206-9;1;Excellent;;; +85059-4;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA8968-5;2;Fair;;; +85059-4;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA8969-3;3;Poor;;; +85059-4;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA21413-2;4;No information;;; +85059-4;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85059-4;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA46-8;6;Other;;; +85060-2;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA9206-9;1;Excellent;;; +85060-2;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA8968-5;2;Fair;;; +85060-2;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA8969-3;3;Poor;;; +85060-2;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA21413-2;4;No information;;; +85060-2;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85060-2;LL4208-6;Excellent|Fair|Poor|NI|UN|OT;LA46-8;6;Other;;; +85062-8;LL4136-9;Anticoagulant medications;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +85062-8;LL4136-9;Anticoagulant medications;LA26712-2;1;Apixaban;698090000;Apixaban (substance);http://snomed.info/sct +85062-8;LL4136-9;Anticoagulant medications;LA26711-4;2;Bivalirudin;;; +85062-8;LL4136-9;Anticoagulant medications;LA26709-8;3;Dalteparin;;; +85062-8;LL4136-9;Anticoagulant medications;LA26708-0;4;Enoxaparin;;; +85062-8;LL4136-9;Anticoagulant medications;LA26707-2;5;Tirofiban;;; +85062-8;LL4136-9;Anticoagulant medications;LA28654-4;6;Warfarin;;; +85062-8;LL4136-9;Anticoagulant medications;LA28655-1;7;Dabigatran;;; +85062-8;LL4136-9;Anticoagulant medications;LA28657-7;8;Edoxaban;;; +85062-8;LL4136-9;Anticoagulant medications;LA28656-9;9;Rivaroxaban;;; +85062-8;LL4136-9;Anticoagulant medications;LA46-8;10;Other;;; +85063-6;LL4135-1;Platelet aggregation inhibitors;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +85063-6;LL4135-1;Platelet aggregation inhibitors;LA26702-3;1;Aspirin;;; +85063-6;LL4135-1;Platelet aggregation inhibitors;LA26704-9;2;Clopidogrel;;; +85063-6;LL4135-1;Platelet aggregation inhibitors;LA26703-1;3;Dipyridamole;387371005;Dipyridamole (substance);http://snomed.info/sct +85063-6;LL4135-1;Platelet aggregation inhibitors;LA26705-6;4;Ticagrelor;;; +85063-6;LL4135-1;Platelet aggregation inhibitors;LA26706-4;5;Cilostazol;;; +85063-6;LL4135-1;Platelet aggregation inhibitors;LA28653-6;6;Prasugrel;;; +85063-6;LL4135-1;Platelet aggregation inhibitors;LA46-8;7;Other;;; +85064-4;LL4137-7;Preoperative procedures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +85064-4;LL4137-7;Preoperative procedures;LA16043-4;2;Chest x-ray;;; +85064-4;LL4137-7;Preoperative procedures;LA26714-8;3;Coronary angiography;;; +85064-4;LL4137-7;Preoperative procedures;LA24330-5;4;Echocardiogram;;; +85064-4;LL4137-7;Preoperative procedures;LA24331-3;5;Electrocardiogram;;; +85064-4;LL4137-7;Preoperative procedures;LA26713-0;6;Spasm load test;;; +85064-4;LL4137-7;Preoperative procedures;LA28649-4;7;Stress echocardiogram;;; +85064-4;LL4137-7;Preoperative procedures;LA28650-2;8;Stress electrocardiogram;;; +85064-4;LL4137-7;Preoperative procedures;LA28651-0;9;Stress cardiac MRI;;; +85064-4;LL4137-7;Preoperative procedures;LA28652-8;10;Fractional flow reserve (FFR);;; +85064-4;LL4137-7;Preoperative procedures;LA30558-3;11;Fractional flow reserve (FFR) by CT;;; +85064-4;LL4137-7;Preoperative procedures;LA28648-6;12;Coronary CT;;; +85064-4;LL4137-7;Preoperative procedures;LA28958-9;13;Nuclear stress test;;; +85064-4;LL4137-7;Preoperative procedures;LA46-8;14;Other;;; +85070-1;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA26832-8;2;Needed some help - Patient needed partial assistance from another person to complete activities.;;; +85070-1;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11541-2;3;Dependent - A helper completed the activities for the patient.;;; +85070-1;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA26832-8;2;Needed some help - Patient needed partial assistance from another person to complete activities.;;; +85071-9;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11541-2;3;Dependent - A helper completed the activities for the patient.;;; +85071-9;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA26832-8;2;Needed some help - Patient needed partial assistance from another person to complete activities.;;; +85072-7;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11541-2;3;Dependent - A helper completed the activities for the patient.;;; +85072-7;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA26832-8;2;Needed some help - Patient needed partial assistance from another person to complete activities.;;; +85073-5;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA11541-2;3;Dependent - A helper completed the activities for the patient.;;; +85073-5;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4151-8;CMS IRFPAI_GG0100 Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30364-6;2;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA30365-3;3;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4309-2;Independent | Needed some help | Dependent | Uknwn;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28862-3;1;Independent - Resident completed the activities by him/herself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28863-1;2;Needed Some Help - Resident needed partial assistance from another person to complete activities.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA28864-9;3;Dependent - A helper completed the activities for the resident.;;; +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL4970-1;CMS MDS Prior Functioning;LA4720-4;5;Not applicable;;; +85070-1;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85070-1;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30364-6;3;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85070-1;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30365-3;4;Dependent - A helper completed all the activities for the patient.;;; +85070-1;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85070-1;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4720-4;6;Not applicable;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30364-6;3;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30365-3;4;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4720-4;6;Not applicable;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30364-6;3;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30365-3;4;Dependent - A helper completed all the activities for the patient.;;; +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85071-9;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4720-4;6;Not applicable;;; +85072-7;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85072-7;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30364-6;3;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85072-7;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30365-3;4;Dependent - A helper completed all the activities for the patient.;;; +85072-7;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85072-7;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4720-4;6;Not applicable;;; +85073-5;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA11539-6;1;Independent - Patient completed all the activities by themself, with or without an assistive device, with no assistance from a helper.;;; +85073-5;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30364-6;3;Needed some help - Patient needed partial assistance from another person to complete any activities.;;; +85073-5;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA30365-3;4;Dependent - A helper completed all the activities for the patient.;;; +85073-5;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85073-5;LL5420-6;CMS IRFPAI v4.0_GG0100 Prior Functioning;LA4720-4;6;Not applicable;;; +85104-8;LL4172-4;Employment type;LA26824-5;1;Paid work, self-employed;;; +85104-8;LL4172-4;Employment type;LA26823-7;2;Paid work, not self-employed;;; +85104-8;LL4172-4;Employment type;LA26822-9;3;Unpaid work, self-employed;;; +85104-8;LL4172-4;Employment type;LA26827-8;4;Unpaid work, not self-employed;;; +85104-8;LL4172-4;Employment type;LA26828-6;5;Paid work, local/state government;;; +85104-8;LL4172-4;Employment type;LA26829-4;6;Paid work, federal government;;; +85104-8;LL4172-4;Employment type;LA26830-2;7;Paid work, U.S. Armed Forces;;; +85104-8;LL4172-4;Employment type;LA26826-0;8;Voluntary work;;; +85150-1;LL4308-4;Bone age method;LA27058-9;1;Greulich and Pyle (GP) Atlas;;; +85150-1;LL4308-4;Bone age method;LA27059-7;2;TW2 20 bones;;; +85150-1;LL4308-4;Bone age method;LA27061-3;3;TW2 radius-ulna-short (RUS) bones;;; +85150-1;LL4308-4;Bone age method;LA27062-1;4;TW3;;; +85270-7;LL4311-8;Furcation site;LA9416-4;1;Buccal;;; +85270-7;LL4311-8;Furcation site;LA9272-1;2;Lingual;;; +85270-7;LL4311-8;Furcation site;LA27065-4;3;Mesial;;; +85270-7;LL4311-8;Furcation site;LA25386-6;4;Distal;;; +85271-5;LL4312-6;Frenum involvement site;LA27066-2;1;Lower labial frenum;;; +85271-5;LL4312-6;Frenum involvement site;LA27067-0;2;Upper labial frenum;;; +85271-5;LL4312-6;Frenum involvement site;LA27068-8;3;Lower buccal frenum;;; +85271-5;LL4312-6;Frenum involvement site;LA27069-6;4;Upper buccal frenum;;; +85275-6;LL4370-4;CAP_adjacent organs colon ca;LA27201-5;1;Coccyx;;; +85275-6;LL4370-4;CAP_adjacent organs colon ca;LA16846-0;2;Duodenum;;; +85275-6;LL4370-4;CAP_adjacent organs colon ca;LA4654-5;3;Pancreas;;; +85275-6;LL4370-4;CAP_adjacent organs colon ca;LA4476-3;4;Stomach;;; +85275-6;LL4370-4;CAP_adjacent organs colon ca;LA9371-1;5;Urinary bladder;;; +85275-6;LL4370-4;CAP_adjacent organs colon ca;LA4447-4;6;Uterus;;; +85283-0;LL4370-4;CAP_adjacent organs colon ca;LA27201-5;1;Coccyx;;; +85283-0;LL4370-4;CAP_adjacent organs colon ca;LA16846-0;2;Duodenum;;; +85283-0;LL4370-4;CAP_adjacent organs colon ca;LA4654-5;3;Pancreas;;; +85283-0;LL4370-4;CAP_adjacent organs colon ca;LA4476-3;4;Stomach;;; +85283-0;LL4370-4;CAP_adjacent organs colon ca;LA9371-1;5;Urinary bladder;;; +85283-0;LL4370-4;CAP_adjacent organs colon ca;LA4447-4;6;Uterus;;; +85281-4;LL4371-2;CAP_lymphocytic response;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +85281-4;LL4371-2;CAP_lymphocytic response;LA15008-8;2;Mild to moderate;;; +85281-4;LL4371-2;CAP_lymphocytic response;LA17968-1;3;Marked;;; +85284-8;LL4371-2;CAP_lymphocytic response;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +85284-8;LL4371-2;CAP_lymphocytic response;LA15008-8;2;Mild to moderate;;; +85284-8;LL4371-2;CAP_lymphocytic response;LA17968-1;3;Marked;;; +85285-5;LL4351-4;Polyp type;LA11904-2;1;None identified;;; +85285-5;LL4351-4;Polyp type;LA15387-6;2;Tubular adenoma;;; +85285-5;LL4351-4;Polyp type;LA15389-2;3;Villous adenoma;;; +85285-5;LL4351-4;Polyp type;LA15388-4;4;Tubular villous adenoma;;; +85285-5;LL4351-4;Polyp type;LA26492-1;5;Traditional serrated adenoma;;; +85285-5;LL4351-4;Polyp type;LA27155-3;6;Sessile serrated adenoma;;; +85285-5;LL4351-4;Polyp type;LA27156-1;7;Hamartomatous polyp;;; +85285-5;LL4351-4;Polyp type;LA11884-6;8;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +85286-3;LL4352-2;Methylation techniques;LA27157-9;1;Methylation-specific real-time polymerase chain reaction (MSP);;; +85286-3;LL4352-2;Methylation techniques;LA27159-5;2;Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA);;; +85286-3;LL4352-2;Methylation techniques;LA27158-7;3;Pyrosequencing (PSQ);;; +85286-3;LL4352-2;Methylation techniques;LA46-8;4;Other;;; +85290-5;LL4381-1;CAP_surgical margins;LA27250-2;1;Surgical margin not involved by tumor;55182004;Surgical margin uninvolved by tumor (finding);http://snomed.info/sct +85290-5;LL4381-1;CAP_surgical margins;LA27251-0;2;Surgical margin involved by tumor;370109009;Surgical margin involved by tumor (finding);http://snomed.info/sct +85290-5;LL4381-1;CAP_surgical margins;LA27144-7;3;Cannot be assessed;;; +85291-3;LL4381-1;CAP_surgical margins;LA27250-2;1;Surgical margin not involved by tumor;55182004;Surgical margin uninvolved by tumor (finding);http://snomed.info/sct +85291-3;LL4381-1;CAP_surgical margins;LA27251-0;2;Surgical margin involved by tumor;370109009;Surgical margin involved by tumor (finding);http://snomed.info/sct +85291-3;LL4381-1;CAP_surgical margins;LA27144-7;3;Cannot be assessed;;; +85292-1;LL4381-1;CAP_surgical margins;LA27250-2;1;Surgical margin not involved by tumor;55182004;Surgical margin uninvolved by tumor (finding);http://snomed.info/sct +85292-1;LL4381-1;CAP_surgical margins;LA27251-0;2;Surgical margin involved by tumor;370109009;Surgical margin involved by tumor (finding);http://snomed.info/sct +85292-1;LL4381-1;CAP_surgical margins;LA27144-7;3;Cannot be assessed;;; +85293-9;LL4381-1;CAP_surgical margins;LA27250-2;1;Surgical margin not involved by tumor;55182004;Surgical margin uninvolved by tumor (finding);http://snomed.info/sct +85293-9;LL4381-1;CAP_surgical margins;LA27251-0;2;Surgical margin involved by tumor;370109009;Surgical margin involved by tumor (finding);http://snomed.info/sct +85293-9;LL4381-1;CAP_surgical margins;LA27144-7;3;Cannot be assessed;;; +85295-4;LL4381-1;CAP_surgical margins;LA27250-2;1;Surgical margin not involved by tumor;55182004;Surgical margin uninvolved by tumor (finding);http://snomed.info/sct +85295-4;LL4381-1;CAP_surgical margins;LA27251-0;2;Surgical margin involved by tumor;370109009;Surgical margin involved by tumor (finding);http://snomed.info/sct +85295-4;LL4381-1;CAP_surgical margins;LA27144-7;3;Cannot be assessed;;; +86743-2;LL4381-1;CAP_surgical margins;LA27250-2;1;Surgical margin not involved by tumor;55182004;Surgical margin uninvolved by tumor (finding);http://snomed.info/sct +86743-2;LL4381-1;CAP_surgical margins;LA27251-0;2;Surgical margin involved by tumor;370109009;Surgical margin involved by tumor (finding);http://snomed.info/sct +86743-2;LL4381-1;CAP_surgical margins;LA27144-7;3;Cannot be assessed;;; +85300-2;LL4383-7;[CAP] Mitotic Rate;LA27225-4;1;Score 1;;; +85300-2;LL4383-7;[CAP] Mitotic Rate;LA27226-2;2;Score 2;;; +85300-2;LL4383-7;[CAP] Mitotic Rate;LA27227-0;3;Score 3;;; +85300-2;LL4383-7;[CAP] Mitotic Rate;LA27220-5;4;No residual invasive carcinoma after presurgical (neoadjuvant) therapy;;; +85300-2;LL4383-7;[CAP] Mitotic Rate;LA27221-3;5;Score cannot be determined;;; +85301-0;LL4389-4;CAP_breast cancer extension;LA27776-6;1;Dermis;;; +85301-0;LL4389-4;CAP_breast cancer extension;LA27777-4;2;Epidermis;;; +85301-0;LL4389-4;CAP_breast cancer extension;LA27778-2;3;Nipple epidermis;;; +85301-0;LL4389-4;CAP_breast cancer extension;LA27779-0;4;Skeletal muscle;;; +85301-0;LL4389-4;CAP_breast cancer extension;LA4178-5;5;Chest Wall;;; +85322-6;LL4389-4;CAP_breast cancer extension;LA27776-6;1;Dermis;;; +85322-6;LL4389-4;CAP_breast cancer extension;LA27777-4;2;Epidermis;;; +85322-6;LL4389-4;CAP_breast cancer extension;LA27778-2;3;Nipple epidermis;;; +85322-6;LL4389-4;CAP_breast cancer extension;LA27779-0;4;Skeletal muscle;;; +85322-6;LL4389-4;CAP_breast cancer extension;LA4178-5;5;Chest Wall;;; +85302-8;LL4384-5;[CAP] Architectural Patterns;LA27228-8;1;Comedo pattern;443336007;Comedo neoplasm pattern (finding);http://snomed.info/sct +85302-8;LL4384-5;[CAP] Architectural Patterns;LA27229-6;2;Paget disease (DCIS involving nipple skin);;; +85302-8;LL4384-5;[CAP] Architectural Patterns;LA27230-4;3;Cribriform pattern;443987001;Cribriform neoplasm pattern (finding);http://snomed.info/sct +85302-8;LL4384-5;[CAP] Architectural Patterns;LA27231-2;4;Micropapillary pattern;443715007;Micropapillary neoplasm pattern (finding);http://snomed.info/sct +85302-8;LL4384-5;[CAP] Architectural Patterns;LA27269-2;5;Papillary pattern;369756006;Papillary tumor configuration (finding);http://snomed.info/sct +85302-8;LL4384-5;[CAP] Architectural Patterns;LA27232-0;6;Solid pattern;369757002;Solid tumor configuration (finding);http://snomed.info/sct +85302-8;LL4384-5;[CAP] Architectural Patterns;LA46-8;7;Other;;; +85303-6;LL4390-2;CAP_breast specimen origin;LA27257-7;1;Left breast;80248007;Left breast structure (body structure);http://snomed.info/sct +85303-6;LL4390-2;CAP_breast specimen origin;LA27258-5;2;Right breast;73056007;Right breast structure (body structure);http://snomed.info/sct +85303-6;LL4390-2;CAP_breast specimen origin;LA46-8;3;Other;;; +85310-1;LL4358-9;Weak|Moderate|Strong;LA13034-6;1;Weak;;; +85310-1;LL4358-9;Weak|Moderate|Strong;LA6751-7;2;Moderate;;; +85310-1;LL4358-9;Weak|Moderate|Strong;LA14974-2;3;Strong;;; +85331-7;LL4358-9;Weak|Moderate|Strong;LA13034-6;1;Weak;;; +85331-7;LL4358-9;Weak|Moderate|Strong;LA6751-7;2;Moderate;;; +85331-7;LL4358-9;Weak|Moderate|Strong;LA14974-2;3;Strong;;; +85311-9;LL4394-4;CAP_Surgical margin carcinoma extent;LA27268-4;1;Surgical margin not involved by invasive carcinoma;;; +85311-9;LL4394-4;CAP_Surgical margin carcinoma extent;LA27265-0;2;Surgical margin focal involvement by carcinoma;;; +85311-9;LL4394-4;CAP_Surgical margin carcinoma extent;LA27266-8;3;Surgical margin moderate involvement by carcinoma;;; +85311-9;LL4394-4;CAP_Surgical margin carcinoma extent;LA27267-6;4;Surgical margin extensive involvement by carcinoma;;; +85312-7;LL4394-4;CAP_Surgical margin carcinoma extent;LA27268-4;1;Surgical margin not involved by invasive carcinoma;;; +85312-7;LL4394-4;CAP_Surgical margin carcinoma extent;LA27265-0;2;Surgical margin focal involvement by carcinoma;;; +85312-7;LL4394-4;CAP_Surgical margin carcinoma extent;LA27266-8;3;Surgical margin moderate involvement by carcinoma;;; +85312-7;LL4394-4;CAP_Surgical margin carcinoma extent;LA27267-6;4;Surgical margin extensive involvement by carcinoma;;; +85313-5;LL4394-4;CAP_Surgical margin carcinoma extent;LA27268-4;1;Surgical margin not involved by invasive carcinoma;;; +85313-5;LL4394-4;CAP_Surgical margin carcinoma extent;LA27265-0;2;Surgical margin focal involvement by carcinoma;;; +85313-5;LL4394-4;CAP_Surgical margin carcinoma extent;LA27266-8;3;Surgical margin moderate involvement by carcinoma;;; +85313-5;LL4394-4;CAP_Surgical margin carcinoma extent;LA27267-6;4;Surgical margin extensive involvement by carcinoma;;; +85314-3;LL4394-4;CAP_Surgical margin carcinoma extent;LA27268-4;1;Surgical margin not involved by invasive carcinoma;;; +85314-3;LL4394-4;CAP_Surgical margin carcinoma extent;LA27265-0;2;Surgical margin focal involvement by carcinoma;;; +85314-3;LL4394-4;CAP_Surgical margin carcinoma extent;LA27266-8;3;Surgical margin moderate involvement by carcinoma;;; +85314-3;LL4394-4;CAP_Surgical margin carcinoma extent;LA27267-6;4;Surgical margin extensive involvement by carcinoma;;; +85315-0;LL4394-4;CAP_Surgical margin carcinoma extent;LA27268-4;1;Surgical margin not involved by invasive carcinoma;;; +85315-0;LL4394-4;CAP_Surgical margin carcinoma extent;LA27265-0;2;Surgical margin focal involvement by carcinoma;;; +85315-0;LL4394-4;CAP_Surgical margin carcinoma extent;LA27266-8;3;Surgical margin moderate involvement by carcinoma;;; +85315-0;LL4394-4;CAP_Surgical margin carcinoma extent;LA27267-6;4;Surgical margin extensive involvement by carcinoma;;; +85316-8;LL4394-4;CAP_Surgical margin carcinoma extent;LA27268-4;1;Surgical margin not involved by invasive carcinoma;;; +85316-8;LL4394-4;CAP_Surgical margin carcinoma extent;LA27265-0;2;Surgical margin focal involvement by carcinoma;;; +85316-8;LL4394-4;CAP_Surgical margin carcinoma extent;LA27266-8;3;Surgical margin moderate involvement by carcinoma;;; +85316-8;LL4394-4;CAP_Surgical margin carcinoma extent;LA27267-6;4;Surgical margin extensive involvement by carcinoma;;; +85319-2;LL4396-9;0|1+|2+|3+|Indeterminate;LA6111-4;1;0;;; +85319-2;LL4396-9;0|1+|2+|3+|Indeterminate;LA11841-6;2;1+;;; +85319-2;LL4396-9;0|1+|2+|3+|Indeterminate;LA11842-4;3;2+;;; +85319-2;LL4396-9;0|1+|2+|3+|Indeterminate;LA11843-2;4;3+;;; +85319-2;LL4396-9;0|1+|2+|3+|Indeterminate;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +90044-9;LL4396-9;0|1+|2+|3+|Indeterminate;LA6111-4;1;0;;; +90044-9;LL4396-9;0|1+|2+|3+|Indeterminate;LA11841-6;2;1+;;; +90044-9;LL4396-9;0|1+|2+|3+|Indeterminate;LA11842-4;3;2+;;; +90044-9;LL4396-9;0|1+|2+|3+|Indeterminate;LA11843-2;4;3+;;; +90044-9;LL4396-9;0|1+|2+|3+|Indeterminate;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +85320-0;LL4397-7;CAP_Histologic focality;LA27270-0;1;Single focus of invasive carcinoma;;; +85320-0;LL4397-7;CAP_Histologic focality;LA27271-8;2;Multiple foci of invasive carcinoma;;; +85320-0;LL4397-7;CAP_Histologic focality;LA27220-5;3;No residual invasive carcinoma after presurgical (neoadjuvant) therapy;;; +85320-0;LL4397-7;CAP_Histologic focality;LA11899-4;4;Cannot be determined;;; +85321-8;LL4380-3;[CAP] Glandular (Acinar)/Tubular Differentiation;LA27216-3;1;Score 1: >75% of tumor area forming glandular/tubular structures;;; +85321-8;LL4380-3;[CAP] Glandular (Acinar)/Tubular Differentiation;LA27217-1;2;Score 2: 10% to 75% of tumor area forming glandular/tubular structures;;; +85321-8;LL4380-3;[CAP] Glandular (Acinar)/Tubular Differentiation;LA27218-9;3;Score 3: <10% of tumor area forming glandular/tubular structures;;; +85321-8;LL4380-3;[CAP] Glandular (Acinar)/Tubular Differentiation;LA27219-7;4;Only microinvasion present (not graded);;; +85321-8;LL4380-3;[CAP] Glandular (Acinar)/Tubular Differentiation;LA27220-5;5;No residual invasive carcinoma after presurgical (neoadjuvant) therapy;;; +85321-8;LL4380-3;[CAP] Glandular (Acinar)/Tubular Differentiation;LA27221-3;6;Score cannot be determined;;; +85323-4;LL4386-0;[CAP] Neoadj therapy breast response;LA27236-1;1;No known presurgical therapy;;; +85323-4;LL4386-0;[CAP] Neoadj therapy breast response;LA27237-9;2;No definite response to presurgical therapy in the invasive carcinoma;;; +85323-4;LL4386-0;[CAP] Neoadj therapy breast response;LA27238-7;3;Probable or definite response to presurgical therapy in the invasive carcinoma;;; +85323-4;LL4386-0;[CAP] Neoadj therapy breast response;LA27239-5;4;No residual invasive carcinoma is present in the breast after presurgical therapy;;; +85334-1;LL4398-5;CAP_Margin DCIS;LA27259-3;1;No DCIS present;;; +85334-1;LL4398-5;CAP_Margin DCIS;LA27272-6;2;Margins uninvolved by DCIS;;; +85334-1;LL4398-5;CAP_Margin DCIS;LA27273-4;3;Margin(s) positive for DCIS;;; +85336-6;LL4392-8;CAP_DCIS extent;LA27259-3;1;No DCIS present;;; +85336-6;LL4392-8;CAP_DCIS extent;LA27260-1;2;DCIS present without extensive intraductal component (EIC);;; +85336-6;LL4392-8;CAP_DCIS extent;LA27261-9;3;DCIS present with extensive intraductal component (EIC);373395001;Invasive ductal carcinoma with an extensive intraductal component (morphologic abnormality);http://snomed.info/sct +85336-6;LL4392-8;CAP_DCIS extent;LA27262-7;4;Only DCIS is present after neoadjuvant therapy;;; +85340-8;LL4385-2;[CAP] Necrosis;LA11902-6;1;Not identified;;; +85340-8;LL4385-2;[CAP] Necrosis;LA27234-6;2;Present, focal (small or single cell necrosis);;; +85340-8;LL4385-2;[CAP] Necrosis;LA27235-3;3;"Present, central (expansive ""comedo"" necrosis)";;; +85342-4;LL4379-5;[CAP] Lymph Node Sampling;LA27212-2;1;Sentinel lymph nodes;441709004;Specimen from sentinel lymph node (specimen);http://snomed.info/sct +85342-4;LL4379-5;[CAP] Lymph Node Sampling;LA27213-0;2;Axillary dissection (partial or complete dissection);373192005;Lymph node from axillary dissection (specimen);http://snomed.info/sct +85342-4;LL4379-5;[CAP] Lymph Node Sampling;LA27214-8;3;Lymph nodes present within the breast specimen (i.e. intramammary lymph nodes);;; +85342-4;LL4379-5;[CAP] Lymph Node Sampling;LA27215-5;4;Other lymph nodes (e.g. supraclavicular or location not identified) specify location if provided;258589002;Lymph node specimen (specimen);http://snomed.info/sct +85345-7;LL4388-6;[CAP] Dermal Lymph-Vascular Invasion;LA27246-0;1;No skin present;;; +85345-7;LL4388-6;[CAP] Dermal Lymph-Vascular Invasion;LA11902-6;2;Not identified;;; +85345-7;LL4388-6;[CAP] Dermal Lymph-Vascular Invasion;LA9633-4;3;Present;52101004;Present (qualifier value);http://snomed.info/sct +85345-7;LL4388-6;[CAP] Dermal Lymph-Vascular Invasion;LA11899-4;4;Cannot be determined;;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA27207-2;1;Excision without image-guidance localization;;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA27208-0;2;Excision with image-guidance localization;;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA27209-8;3;Total mastectomy (including nipple and skin);;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA26037-4;4;Colectomy;;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA15410-6;5;Hemicolectomy;;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA17735-4;6;Polypectomy;;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA46-8;7;Other;;; +85348-1;LL4376-1;[CAP] Procedure for tumor specimen collection;LA27211-4;8;Not specified;;; +85349-9;LL4387-8;[CAP] Neoadj therapy response LN;LA27236-1;1;No known presurgical therapy;;; +85349-9;LL4387-8;[CAP] Neoadj therapy response LN;LA27241-1;2;No lymph nodes removed;;; +85349-9;LL4387-8;[CAP] Neoadj therapy response LN;LA27242-9;3;No definitive response to presurgical therapy in metastatic carcinoma;;; +85349-9;LL4387-8;[CAP] Neoadj therapy response LN;LA27243-7;4;Probable or definite response to presurgical therapy in metastatic carcinoma;;; +85349-9;LL4387-8;[CAP] Neoadj therapy response LN;LA27244-5;5;No lymph node metastases. Fibrous scarring, possibly related to prior lymph node metastases with pathologic complete response;;; +85349-9;LL4387-8;[CAP] Neoadj therapy response LN;LA27245-2;6;No lymph node metastases and no prominent fibrous scarring in the nodes;;; +85380-4;LL4332-4;NoEvidence|HIV1|HIV2|PosNotDifferentiated|AcuteHIV;LA27091-0;0;No serologic evidence of infection with HIV. Cannot exclude incubating or early HIV infection. Submit second sample in 3-4 weeks if clinically indicated.;;; +85380-4;LL4332-4;NoEvidence|HIV1|HIV2|PosNotDifferentiated|AcuteHIV;LA27092-8;1;Serologic evidence of HIV-1 infection is present. Refer to physician for care.;;; +85380-4;LL4332-4;NoEvidence|HIV1|HIV2|PosNotDifferentiated|AcuteHIV;LA27115-7;2;Positive for HIV antibodies but could not be differentiated as HIV-1 or HIV-2. Refer to physician for care.;;; +85380-4;LL4332-4;NoEvidence|HIV1|HIV2|PosNotDifferentiated|AcuteHIV;LA27114-0;3;Serologic evidence of HIV-2 infection is present. Refer to physician for care.;;; +85380-4;LL4332-4;NoEvidence|HIV1|HIV2|PosNotDifferentiated|AcuteHIV;LA27116-5;4;Serologic evidence of acute HIV infection is present. Refer to physician for care and follow-up NAT testing. If NAT is nonreactive or not tested, submit second sample in 3-4 weeks to rule out HIV infection.;;; +85397-8;LL4426-4;CMS Admission Class;LA27331-0;1;Initial rehab;;; +85397-8;LL4426-4;CMS Admission Class;LA27332-8;2;Evaluation;;; +85397-8;LL4426-4;CMS Admission Class;LA4395-5;3;Readmission;;; +85397-8;LL4426-4;CMS Admission Class;LA18068-9;4;Unplanned discharge;;; +85397-8;LL4426-4;CMS Admission Class;LA27335-1;5;Continuing rehabilitation;;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA11501-6;1;Community residential setting (e.g., private home, assisted living, group home, adult foster care);;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA18066-3;2;Long-term care facility;;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA11504-0;4;Hospital emergency department;;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA10078-6;5;Short-stay acute hospital (IPPS);;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA10000-0;6;Long-term care hospital (LTCH);;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA27548-9;7;Inpatient rehabilitation facility or unit (IRF);;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA10065-3;8;Psychiatric hospital or unit;;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA10929-0;9;ID/DD facility;;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA6216-1;10;Hospice;;; +85398-6;LL4468-6;CMS_LCDS Admitted from;LA9-3;11;None of the above;;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA11501-6;1;Community residential setting (e.g., private home, assisted living, group home, adult foster care);;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA18066-3;2;Long-term care facility;;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA11504-0;4;Hospital emergency department;;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA10078-6;5;Short-stay acute hospital (IPPS);;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA10000-0;6;Long-term care hospital (LTCH);;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA27548-9;7;Inpatient rehabilitation facility or unit (IRF);;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA10065-3;8;Psychiatric hospital or unit;;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA28224-6;9;Intellectually disabled/developmentally disabled (ID/DD) facility;;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA6216-1;10;Hospice;;; +85398-6;LL4678-0;CMS_LCDS v4 Admitted from;LA9-3;11;None of the above;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30358-8;1;Home (private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements);;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27337-7;2;Short-term General Hospital;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27338-5;3;Skilled nursing facility (SNF);;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27339-3;4;Intermediate care;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27340-1;5;Home under care of organized home health service organization;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27341-9;6;Hospice (home);;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30259-8;7;Hospice (medical facility);;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA10883-9;8;Swing bed;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA10000-0;10;Long-term care hospital (LTCH);;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27346-8;11;Medicaid Nursing Facility;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27347-6;12;Inpatient Psychiatric Facility;;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30261-4;13;Critical Access Hospital (CAH);;; +85398-6;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27349-2;14;Not listed;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30358-8;1;Home (private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27337-7;2;Short-term General Hospital;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27338-5;3;Skilled nursing facility (SNF);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27339-3;4;Intermediate care;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27340-1;5;Home under care of organized home health service organization;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27341-9;6;Hospice (home);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30259-8;7;Hospice (medical facility);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA10883-9;8;Swing bed;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA10000-0;10;Long-term care hospital (LTCH);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27346-8;11;Medicaid Nursing Facility;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27347-6;12;Inpatient Psychiatric Facility;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30261-4;13;Critical Access Hospital (CAH);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27349-2;14;Not listed;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30358-8;1;Home (private home/apt., board/care, assisted living, group home, transitional living, other residential care arrangements);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27337-7;2;Short-term General Hospital;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27338-5;3;Skilled nursing facility (SNF);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27339-3;4;Intermediate care;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27340-1;5;Home under care of organized home health service organization;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27341-9;6;Hospice (home);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30259-8;7;Hospice (medical facility);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA10883-9;8;Swing bed;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27344-3;9;Another Inpatient Rehabilitation Facility;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA10000-0;10;Long-term care hospital (LTCH);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27346-8;11;Medicaid Nursing Facility;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27347-6;12;Inpatient Psychiatric Facility;;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA30261-4;13;Critical Access Hospital (CAH);;; +85399-4;LL5376-0;CMS IRF_PAI v4.0 - Admitted From (15A);LA27349-2;14;Not listed;;; +85400-0;LL4428-0;CMS Living arrangement;LA27350-0;1;Alone;;; +85400-0;LL4428-0;CMS Living arrangement;LA27351-8;2;Family/Relatives;;; +85400-0;LL4428-0;CMS Living arrangement;LA27352-6;3;Friends;;; +85400-0;LL4428-0;CMS Living arrangement;LA27353-4;4;Attendant;;; +85400-0;LL4428-0;CMS Living arrangement;LA46-8;5;Other;;; +85402-6;LL4429-8;Medicare fee for service | Medicare-Medicare Adv;LA27354-2;1;Medicare Fee For Service;;; +85402-6;LL4429-8;Medicare fee for service | Medicare-Medicare Adv;LA27355-9;2;Medicare-Medicare Advantage;;; +85402-6;LL4429-8;Medicare fee for service | Medicare-Medicare Adv;LA27349-2;3;Not listed;;; +85403-4;LL4429-8;Medicare fee for service | Medicare-Medicare Adv;LA27354-2;1;Medicare Fee For Service;;; +85403-4;LL4429-8;Medicare fee for service | Medicare-Medicare Adv;LA27355-9;2;Medicare-Medicare Advantage;;; +85403-4;LL4429-8;Medicare fee for service | Medicare-Medicare Adv;LA27349-2;3;Not listed;;; +85417-4;LL4939-6;Alone | Family/Relatives | Friends | Attendant;LA27350-0;1;Alone;;; +85417-4;LL4939-6;Alone | Family/Relatives | Friends | Attendant;LA27351-8;2;Family/Relatives;;; +85417-4;LL4939-6;Alone | Family/Relatives | Friends | Attendant;LA27352-6;3;Friends;;; +85417-4;LL4939-6;Alone | Family/Relatives | Friends | Attendant;LA27353-4;4;Attendant;;; +85417-4;LL4939-6;Alone | Family/Relatives | Friends | Attendant;LA46-8;5;Other;;; +85431-5;LL3270-7;NHANES III_Marital status;LA22689-6;1;Married - spouse in household;;; +85431-5;LL3270-7;NHANES III_Marital status;LA22690-4;2;Married - spouse not in household;;; +85431-5;LL3270-7;NHANES III_Marital status;LA22691-2;3;Living as married;;; +85431-5;LL3270-7;NHANES III_Marital status;LA49-2;4;Widowed;;; +85431-5;LL3270-7;NHANES III_Marital status;LA51-8;5;Divorced;;; +85431-5;LL3270-7;NHANES III_Marital status;LA4288-2;6;Separated;;; +85431-5;LL3270-7;NHANES III_Marital status;LA47-6;7;Never married;;; +85431-5;LL3270-7;NHANES III_Marital status;LA22692-0;8;Blank but applicable;;; +85431-5;LL3270-7;NHANES III_Marital status;LA12688-0;9;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +85432-3;LL4313-4;Caregiver_Mother|Father|Legal guardian;LA10417-6;1;Mother;;; +85432-3;LL4313-4;Caregiver_Mother|Father|Legal guardian;LA10416-8;2;Father;;; +85432-3;LL4313-4;Caregiver_Mother|Father|Legal guardian;LA26831-0;3;Guardian;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27117-3;0;Streptococcus pneumoniae Danish serotype 1;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27122-3;1;Streptococcus pneumoniae Danish serotype 14;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27123-1;2;Streptococcus pneumoniae Danish serotype 16F;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27124-9;3;Streptococcus pneumoniae Danish serotype 19A;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27125-6;4;Streptococcus pneumoniae Danish serotype 19F;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27118-1;5;Streptococcus pneumoniae Danish serotype 2;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27126-4;6;Streptococcus pneumoniae Danish serotype 23A;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27127-2;7;Streptococcus pneumoniae Danish serotype 23F;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27119-9;8;Streptococcus pneumoniae Danish serotype 3;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27120-7;9;Streptococcus pneumoniae Danish serotype 4;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27121-5;10;Streptococcus pneumoniae Danish serotype 5;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27132-2;11;Streptococcus pneumoniae Danish serotypes 11A/11D;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27133-0;12;Streptococcus pneumoniae Danish serotypes 12F/12A/44/46;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27134-8;13;Streptococcus pneumoniae Danish serotypes 15A/15F;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27135-5;14;Streptococcus pneumoniae Danish serotypes 18A/18B/18C/18F;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27136-3;15;Streptococcus pneumoniae Danish serotypes 22F/22A;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27137-1;16;Streptococcus pneumoniae Danish serotypes 33F/33A/37;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27128-0;17;Streptococcus pneumoniae Danish serotypes 6A/6B/6C/6D;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27129-8;18;Streptococcus pneumoniae Danish serotypes 6C/6D;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27130-6;19;Streptococcus pneumoniae Danish serotypes 7F/7A;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27131-4;20;Streptococcus pneumoniae Danish serotypes 9V/9A;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA6577-6;21;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27090-2;22;Unable to type;;; +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA9663-1;23;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +85496-8;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA18373-3;24;Test not done;373121007;Test not done (qualifier value);http://snomed.info/sct +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27117-3;0;Streptococcus pneumoniae Danish serotype 1;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27122-3;1;Streptococcus pneumoniae Danish serotype 14;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27123-1;2;Streptococcus pneumoniae Danish serotype 16F;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27124-9;3;Streptococcus pneumoniae Danish serotype 19A;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27125-6;4;Streptococcus pneumoniae Danish serotype 19F;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27118-1;5;Streptococcus pneumoniae Danish serotype 2;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27126-4;6;Streptococcus pneumoniae Danish serotype 23A;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27127-2;7;Streptococcus pneumoniae Danish serotype 23F;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27119-9;8;Streptococcus pneumoniae Danish serotype 3;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27120-7;9;Streptococcus pneumoniae Danish serotype 4;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27121-5;10;Streptococcus pneumoniae Danish serotype 5;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27132-2;11;Streptococcus pneumoniae Danish serotypes 11A/11D;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27133-0;12;Streptococcus pneumoniae Danish serotypes 12F/12A/44/46;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27134-8;13;Streptococcus pneumoniae Danish serotypes 15A/15F;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27135-5;14;Streptococcus pneumoniae Danish serotypes 18A/18B/18C/18F;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27136-3;15;Streptococcus pneumoniae Danish serotypes 22F/22A;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27137-1;16;Streptococcus pneumoniae Danish serotypes 33F/33A/37;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27128-0;17;Streptococcus pneumoniae Danish serotypes 6A/6B/6C/6D;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27129-8;18;Streptococcus pneumoniae Danish serotypes 6C/6D;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27130-6;19;Streptococcus pneumoniae Danish serotypes 7F/7A;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27131-4;20;Streptococcus pneumoniae Danish serotypes 9V/9A;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA6577-6;21;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA27090-2;22;Unable to type;;; +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA9663-1;23;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +88722-4;LL4346-4;Serotypes 1-7|9|11|12|14|15|16|18|19|22|23|33|37;LA18373-3;24;Test not done;373121007;Test not done (qualifier value);http://snomed.info/sct +85592-4;LL4432-2;NKDEP_Dialysis location;LA27445-8;1;In-center;;; +85592-4;LL4432-2;NKDEP_Dialysis location;LA27446-6;2;At home;;; +85592-4;LL4432-2;NKDEP_Dialysis location;LA12719-3;3;Uncertain;;; +85593-2;LL4433-0;NKDEP_Donor kidney;LA10939-9;1;Deceased;;; +85593-2;LL4433-0;NKDEP_Donor kidney;LA27447-4;2;Living;;; +85593-2;LL4433-0;NKDEP_Donor kidney;LA12719-3;3;Uncertain;;; +85594-0;LL4434-8;NKDEP_Dialysis type;LA9975-9;1;Hemodialysis;;; +85594-0;LL4434-8;NKDEP_Dialysis type;LA10059-6;2;Peritoneal Dialysis;;; +85594-0;LL4434-8;NKDEP_Dialysis type;LA27448-2;3;Undecided;;; +85595-7;LL4435-5;NKDEP_Hospice care;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85595-7;LL4435-5;NKDEP_Hospice care;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +85595-7;LL4435-5;NKDEP_Hospice care;LA12719-3;3;Uncertain;;; +85596-5;LL4463-7;NKDEP_RRT treatment preference;LA9975-9;1;Hemodialysis;;; +85596-5;LL4463-7;NKDEP_RRT treatment preference;LA10059-6;2;Peritoneal Dialysis;;; +85596-5;LL4463-7;NKDEP_RRT treatment preference;LA17844-4;3;Transplant;;; +85596-5;LL4463-7;NKDEP_RRT treatment preference;LA27512-5;4;Supportive care with no Renal Replacement Therapy (RRT);;; +85596-5;LL4463-7;NKDEP_RRT treatment preference;LA27448-2;5;Undecided;;; +85596-5;LL4463-7;NKDEP_RRT treatment preference;LA46-8;6;Other;;; +85598-1;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85598-1;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85598-1;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85598-1;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85598-1;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85598-1;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85599-9;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85599-9;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85599-9;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85599-9;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85599-9;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85599-9;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85600-5;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85600-5;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85600-5;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85600-5;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85600-5;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85600-5;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85601-3;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85601-3;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85601-3;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85601-3;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85601-3;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85601-3;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85602-1;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85602-1;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85602-1;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85602-1;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85602-1;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85602-1;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85603-9;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85603-9;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85603-9;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85603-9;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85603-9;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85603-9;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85604-7;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85604-7;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85604-7;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85604-7;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85604-7;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85604-7;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85605-4;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85605-4;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85605-4;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85605-4;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85605-4;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85605-4;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85606-2;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85606-2;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85606-2;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85606-2;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85606-2;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85606-2;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85607-0;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85607-0;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85607-0;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85607-0;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85607-0;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85607-0;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85608-8;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85608-8;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85608-8;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85608-8;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85608-8;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85608-8;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85610-4;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85610-4;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85610-4;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85610-4;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85610-4;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85610-4;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85611-2;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85611-2;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85611-2;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85611-2;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85611-2;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85611-2;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85612-0;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85612-0;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85612-0;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85612-0;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85612-0;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85612-0;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85613-8;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85613-8;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85613-8;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85613-8;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85613-8;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85613-8;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85614-6;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85614-6;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85614-6;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85614-6;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85614-6;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85614-6;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85615-3;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85615-3;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85615-3;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85615-3;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85615-3;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85615-3;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85616-1;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85616-1;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85616-1;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85616-1;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85616-1;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85616-1;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85617-9;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85617-9;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85617-9;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85617-9;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85617-9;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85617-9;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85619-5;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85619-5;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85619-5;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85619-5;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85619-5;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85619-5;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85620-3;LL4460-3;0|1|2|3|4|5;LA6111-4;1;0;;; +85620-3;LL4460-3;0|1|2|3|4|5;LA6112-2;2;1;;; +85620-3;LL4460-3;0|1|2|3|4|5;LA6113-0;3;2;;; +85620-3;LL4460-3;0|1|2|3|4|5;LA6114-8;4;3;;; +85620-3;LL4460-3;0|1|2|3|4|5;LA6115-5;5;4;;; +85620-3;LL4460-3;0|1|2|3|4|5;LA10137-0;6;5;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL4475-1;CMS_LCDS Facilty type;LA28448-1;1;Long-term care hospital;;; +85632-8;LL5225-9;Nursing home (SNF/NF);LA10882-1;1;Nursing home (SNF/NF);;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27513-3;1;Acute onset respiratory condition (e.g., aspiration and specified bacterial pneumonias);;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27514-1;2;Chronic respiratory condition (e.g., chronic obstructive pulmonary disease);;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27515-8;3;Acute onset and chronic respiratory conditions;;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27516-6;4;Chronic cardiac condition (e.g., heart failure);;; +85633-6;LL4464-5;CMS_primary medical condition category;LA16346-1;5;Other medical condition;;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27513-3;1;Acute onset respiratory condition (e.g., aspiration and specified bacterial pneumonias);;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27514-1;2;Chronic respiratory condition (e.g., chronic obstructive pulmonary disease);;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27515-8;3;Acute onset and chronic respiratory conditions;;; +85633-6;LL4464-5;CMS_primary medical condition category;LA27516-6;4;Chronic cardiac condition (e.g., heart failure);;; +85633-6;LL4464-5;CMS_primary medical condition category;LA16346-1;5;Other medical condition;;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27513-3;1;Acute onset respiratory condition (e.g., aspiration and specified bacterial pneumonias);;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27514-1;2;Chronic respiratory condition (e.g., chronic obstructive pulmonary disease);;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27515-8;3;Acute onset and chronic respiratory conditions;;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27516-6;4;Chronic cardiac condition (e.g., heart failure);;; +89045-9;LL4464-5;CMS_primary medical condition category;LA16346-1;5;Other medical condition;;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27513-3;1;Acute onset respiratory condition (e.g., aspiration and specified bacterial pneumonias);;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27514-1;2;Chronic respiratory condition (e.g., chronic obstructive pulmonary disease);;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27515-8;3;Acute onset and chronic respiratory conditions;;; +89045-9;LL4464-5;CMS_primary medical condition category;LA27516-6;4;Chronic cardiac condition (e.g., heart failure);;; +89045-9;LL4464-5;CMS_primary medical condition category;LA16346-1;5;Other medical condition;;; +96095-5;LL4464-5;CMS_primary medical condition category;LA27513-3;1;Acute onset respiratory condition (e.g., aspiration and specified bacterial pneumonias);;; +96095-5;LL4464-5;CMS_primary medical condition category;LA27514-1;2;Chronic respiratory condition (e.g., chronic obstructive pulmonary disease);;; +96095-5;LL4464-5;CMS_primary medical condition category;LA27515-8;3;Acute onset and chronic respiratory conditions;;; +96095-5;LL4464-5;CMS_primary medical condition category;LA27516-6;4;Chronic cardiac condition (e.g., heart failure);;; +96095-5;LL4464-5;CMS_primary medical condition category;LA16346-1;5;Other medical condition;;; +85675-7;LL4359-7;Susceptible|Immune|Unknown;LA24225-7;1;Susceptible;;; +85675-7;LL4359-7;Susceptible|Immune|Unknown;LA27183-5;2;Immune;;; +85675-7;LL4359-7;Susceptible|Immune|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85676-5;LL4360-5;Physician|Healthcare professional|Parent|Other;LA4687-5;1;Physician;;; +85676-5;LL4360-5;Physician|Healthcare professional|Parent|Other;LA20793-8;2;Healthcare professional;;; +85676-5;LL4360-5;Physician|Healthcare professional|Parent|Other;LA6654-3;3;Parent;;; +85676-5;LL4360-5;Physician|Healthcare professional|Parent|Other;LA46-8;4;Other;;; +85677-3;LL4362-1;Confirmed|Prob|Infect only|Not CRS|Stillbirth|Unk;LA15290-2;1;Confirmed;;; +85677-3;LL4362-1;Confirmed|Prob|Infect only|Not CRS|Stillbirth|Unk;LA12746-6;2;Probable;;; +85677-3;LL4362-1;Confirmed|Prob|Infect only|Not CRS|Stillbirth|Unk;LA15097-1;3;Possible;;; +85677-3;LL4362-1;Confirmed|Prob|Infect only|Not CRS|Stillbirth|Unk;LA27184-3;4;Infection only;;; +85677-3;LL4362-1;Confirmed|Prob|Infect only|Not CRS|Stillbirth|Unk;LA27185-0;5;Not congenital rubella syndrome;;; +85677-3;LL4362-1;Confirmed|Prob|Infect only|Not CRS|Stillbirth|Unk;LA14667-2;6;Stillbirth;;; +85677-3;LL4362-1;Confirmed|Prob|Infect only|Not CRS|Stillbirth|Unk;LA4489-6;7;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85690-6;LL4363-9;RV genotype;LA27186-8;1;Rubella virus genotype 1a;;; +85690-6;LL4363-9;RV genotype;LA27187-6;2;Rubella virus genotype 1B;;; +85690-6;LL4363-9;RV genotype;LA27188-4;3;Rubella virus genotype 1C;;; +85690-6;LL4363-9;RV genotype;LA27189-2;4;Rubella virus genotype 1D;;; +85690-6;LL4363-9;RV genotype;LA27190-0;5;Rubella virus genotype 1E;;; +85690-6;LL4363-9;RV genotype;LA27191-8;6;Rubella virus genotype 1F;;; +85690-6;LL4363-9;RV genotype;LA27192-6;7;Rubella virus genotype 1G;;; +85690-6;LL4363-9;RV genotype;LA27193-4;8;Rubella virus genotype 1H;;; +85690-6;LL4363-9;RV genotype;LA27194-2;9;Rubella virus genotype 1I;;; +85690-6;LL4363-9;RV genotype;LA27195-9;10;Rubella virus genotype 1J;;; +85690-6;LL4363-9;RV genotype;LA27196-7;11;Rubella virus genotype 2A;;; +85690-6;LL4363-9;RV genotype;LA27197-5;12;Rubella virus genotype 2B;;; +85690-6;LL4363-9;RV genotype;LA27198-3;13;Rubella virus genotype 2C;;; +85690-6;LL4363-9;RV genotype;LA46-8;14;Other;;; +85690-6;LL4363-9;RV genotype;LA4489-6;15;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85693-0;LL4354-8;Antibody test results;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +85693-0;LL4354-8;Antibody test results;LA6577-6;2;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +85693-0;LL4354-8;Antibody test results;LA11884-6;3;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +85693-0;LL4354-8;Antibody test results;LA27176-9;4;Signficant rise in IgG;;; +85693-0;LL4354-8;Antibody test results;LA27177-7;5;No significant rise in IgG;;; +85693-0;LL4354-8;Antibody test results;LA6631-1;6;Results pending;;; +85693-0;LL4354-8;Antibody test results;LA6630-3;7;Not done;;; +85693-0;LL4354-8;Antibody test results;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85707-8;LL4356-3;Relationships;LA10416-8;1;Father;;; +85707-8;LL4356-3;Relationships;LA10417-6;2;Mother;;; +85707-8;LL4356-3;Relationships;LA27180-1;3;Grandparent;;; +85707-8;LL4356-3;Relationships;LA10415-0;4;Brother;;; +85707-8;LL4356-3;Relationships;LA10418-4;5;Sister;;; +85707-8;LL4356-3;Relationships;LA16285-1;6;Spouse;;; +85707-8;LL4356-3;Relationships;LA9949-4;7;Child;;; +85707-8;LL4356-3;Relationships;LA6656-8;8;Friend;;; +85707-8;LL4356-3;Relationships;LA27179-3;9;Neighbor;;; +85707-8;LL4356-3;Relationships;LA46-8;10;Other;;; +85707-8;LL4356-3;Relationships;LA4489-6;11;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +94546-9;LL4356-3;Relationships;LA10416-8;1;Father;;; +94546-9;LL4356-3;Relationships;LA10417-6;2;Mother;;; +94546-9;LL4356-3;Relationships;LA27180-1;3;Grandparent;;; +94546-9;LL4356-3;Relationships;LA10415-0;4;Brother;;; +94546-9;LL4356-3;Relationships;LA10418-4;5;Sister;;; +94546-9;LL4356-3;Relationships;LA16285-1;6;Spouse;;; +94546-9;LL4356-3;Relationships;LA9949-4;7;Child;;; +94546-9;LL4356-3;Relationships;LA6656-8;8;Friend;;; +94546-9;LL4356-3;Relationships;LA27179-3;9;Neighbor;;; +94546-9;LL4356-3;Relationships;LA46-8;10;Other;;; +94546-9;LL4356-3;Relationships;LA4489-6;11;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85718-5;LL4364-7;Private sector|Public sector|Unknown;LA27200-7;1;Private sector;;; +85718-5;LL4364-7;Private sector|Public sector|Unknown;LA27199-1;2;Public sector;;; +85718-5;LL4364-7;Private sector|Public sector|Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +85786-2;LL4046-0;Detected|Not detected|N/A;LA11882-0;1;Detected;;; +85786-2;LL4046-0;Detected|Not detected|N/A;LA11883-8;2;Not detected;;; +85786-2;LL4046-0;Detected|Not detected|N/A;LA4543-0;3;;;; +85787-0;LL4046-0;Detected|Not detected|N/A;LA11882-0;1;Detected;;; +85787-0;LL4046-0;Detected|Not detected|N/A;LA11883-8;2;Not detected;;; +85787-0;LL4046-0;Detected|Not detected|N/A;LA4543-0;3;;;; +85788-8;LL4046-0;Detected|Not detected|N/A;LA11882-0;1;Detected;;; +85788-8;LL4046-0;Detected|Not detected|N/A;LA11883-8;2;Not detected;;; +85788-8;LL4046-0;Detected|Not detected|N/A;LA4543-0;3;;;; +85793-8;LL4479-3;Mother|Infant|Donor;LA19747-7;1;Infant;;; +85793-8;LL4479-3;Mother|Infant|Donor;LA10417-6;2;Mother;;; +85793-8;LL4479-3;Mother|Infant|Donor;LA27572-9;3;Donor;;; +85807-6;LL4422-3;MuV genotype;LA27310-4;1;Mumps virus genotype A;;; +85807-6;LL4422-3;MuV genotype;LA27311-2;2;Mumps virus genotype B;;; +85807-6;LL4422-3;MuV genotype;LA27313-8;3;Mumps virus genotype C;;; +85807-6;LL4422-3;MuV genotype;LA27314-6;4;Mumps virus genotype D;;; +85807-6;LL4422-3;MuV genotype;LA27316-1;6;Mumps virus genotype F;;; +85807-6;LL4422-3;MuV genotype;LA27317-9;7;Mumps virus genotype G;;; +85807-6;LL4422-3;MuV genotype;LA27318-7;8;Mumps virus genotype H;;; +85807-6;LL4422-3;MuV genotype;LA27319-5;9;Mumps virus genotype I;;; +85807-6;LL4422-3;MuV genotype;LA27320-3;10;Mumps virus genotype J;;; +85807-6;LL4422-3;MuV genotype;LA27321-1;11;Mumps virus genotype K;;; +85807-6;LL4422-3;MuV genotype;LA27322-9;12;Mumps virus genotype L;;; +85807-6;LL4422-3;MuV genotype;LA27323-7;13;Mumps virus genotype N;;; +85807-6;LL4422-3;MuV genotype;LA27324-5;14;Mumps virus genotype unclassified;;; +85845-6;LL4950-3;CMS Impairment group 2;;0;;;; +85846-4;LL4430-6;CMS Swallow Status;LA27356-7;1;Regular food: solids and liquids swallowed safely without supervision or modified food consistency;;; +85846-4;LL4430-6;CMS Swallow Status;LA27357-5;2;Modified food consistency/supervision: subject requires modified food consistency and/or needs supervision for safety;;; +85846-4;LL4430-6;CMS Swallow Status;LA10103-2;3;Tube/parenteral feeding: Tube/parenteral feeding used wholly or partially as a means of sustenance.;;; +85915-7;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85915-7;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85916-5;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +85916-5;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89910-4;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +89910-4;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +90079-5;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +90079-5;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93070-1;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93070-1;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93070-1;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93070-1;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98527-5;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98527-5;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98528-3;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98528-3;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98529-1;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98529-1;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98530-9;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98530-9;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98531-7;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98531-7;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98532-5;LL4256-5;No (0) | Yes (1);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98532-5;LL4256-5;No (0) | Yes (1);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +85920-7;LL4489-2;CMS_Symptom control rating;LA27597-6;1;Asymptomatic, no treatment needed at this time;;; +85920-7;LL4489-2;CMS_Symptom control rating;LA27598-4;2;Symptoms well controlled with current therapy;;; +85920-7;LL4489-2;CMS_Symptom control rating;LA27599-2;3;"Symptoms controlled with difficulty, affecting daily functioning; patient needs ongoing monitoring";;; +85920-7;LL4489-2;CMS_Symptom control rating;LA27600-8;4;"Symptoms poorly controlled; patient needs frequent adjustment in treatment and dose monitoring";;; +85920-7;LL4489-2;CMS_Symptom control rating;LA27601-6;5;"Symptoms poorly controlled; history of re-hospitalizations";;; +85927-2;LL4594-9;CMS_OASIS Functional abilities and goals;LA9983-3;1;Independent - Patient completes the activity by themself with no assistance from a helper.;;; +85927-2;LL4594-9;CMS_OASIS Functional abilities and goals;LA10073-7;2;"Setup or clean-up assistance - Helper sets up or cleans up; patient completes activity. Helper assists only prior to or following the activity.";;; +85927-2;LL4594-9;CMS_OASIS Functional abilities and goals;LA11757-4;3;Supervision or touching assistance - Helper provides verbal cues or touching/steadying assistance as patient completes activity. Assistance may be provided throughout the activity or intermittently.;;; +85927-2;LL4594-9;CMS_OASIS Functional abilities and goals;LA11758-2;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports truck or limbs, but provides less than half the effort.;;; +85927-2;LL4594-9;CMS_OASIS Functional abilities and goals;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +85927-2;LL4594-9;CMS_OASIS Functional abilities and goals;LA27665-1;6;Dependent - Helper does all of the effort. Patient does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the patient to complete the activity.;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27650-3;1;Patient lives alone - around the clock;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27651-1;2;Patient lives alone - regular daytime;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27652-9;3;Patient lives alone - regular nighttime;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27653-7;4;Patient lives alone - occasional/short-term assistance;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27654-5;5;Patient lives alone - no assistance available;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27655-2;6;Patient lives with other person(s) in the home - around the clock;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27656-0;7;Patient lives with other person(s) in the home - regular daytime;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27657-8;8;Patient lives with other person(s) in the home - regular nighttime;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27658-6;9;Patient lives with other person(s) in the home - occasional/short-term assistance;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27659-4;10;Patient lives with other person(s) in the home - no assistance available;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27660-2;11;Patient lives in congregate situation (for example, assisted living, residential care home) - around the clock;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27661-0;12;Patient lives in congregate situation (for example, assisted living, residential care home) - regular daytime;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27662-8;13;Patient lives in congregate situation (for example, assisted living, residential care home) - regular nighttime;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27663-6;14;Patient lives in congregate situation (for example, assisted living, residential care home) - occasional/short-term assistance;;; +85950-4;LL4514-7;CMS_Living arrangement;LA27664-4;15;Patient lives in congregate situation (for example, assisted living, residential care home) - no assistance available;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA19732-9;1;Clear;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA4457-3;2;White;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA17195-1;3;Yellow;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA15555-8;4;Green;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA17192-8;5;Pink;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA17193-6;6;Red;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA19058-9;7;Brown;;; +86242-5;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA4267-6;8;Black;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA19732-9;1;Clear;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA4457-3;2;White;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA17195-1;3;Yellow;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA15555-8;4;Green;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA17192-8;5;Pink;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA17193-6;6;Red;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA19058-9;7;Brown;;; +86243-3;LL4473-6;Yel,Wht,Clr,Grn,Pnk,Red,Brn,Blck;LA4267-6;8;Black;;; +86472-8;LL4536-0;KCCQ - HF Times during day;LA6154-4;1;All of the time;;; +86472-8;LL4536-0;KCCQ - HF Times during day;LA27729-5;2;Several times per day;;; +86472-8;LL4536-0;KCCQ - HF Times during day;LA27730-3;3;At least once a day;;; +86472-8;LL4536-0;KCCQ - HF Times during day;LA27770-9;4;3 or more times per week but not every day;;; +86472-8;LL4536-0;KCCQ - HF Times during day;LA13834-9;5;1-2 times per week;;; +86472-8;LL4536-0;KCCQ - HF Times during day;LA27722-0;6;Less than once a week;;; +86472-8;LL4536-0;KCCQ - HF Times during day;LA27723-8;7;Never over the past 2 weeks;;; +86481-9;LL4536-0;KCCQ - HF Times during day;LA6154-4;1;All of the time;;; +86481-9;LL4536-0;KCCQ - HF Times during day;LA27729-5;2;Several times per day;;; +86481-9;LL4536-0;KCCQ - HF Times during day;LA27730-3;3;At least once a day;;; +86481-9;LL4536-0;KCCQ - HF Times during day;LA27770-9;4;3 or more times per week but not every day;;; +86481-9;LL4536-0;KCCQ - HF Times during day;LA13834-9;5;1-2 times per week;;; +86481-9;LL4536-0;KCCQ - HF Times during day;LA27722-0;6;Less than once a week;;; +86481-9;LL4536-0;KCCQ - HF Times during day;LA27723-8;7;Never over the past 2 weeks;;; +86473-6;LL4532-9;KCCQ- Limited by HF;LA27701-4;1;Extremely limited;;; +86473-6;LL4532-9;KCCQ- Limited by HF;LA27702-2;2;Quite a bit limited;;; +86473-6;LL4532-9;KCCQ- Limited by HF;LA6460-5;3;Moderately limited;;; +86473-6;LL4532-9;KCCQ- Limited by HF;LA9605-2;4;Slightly limited;;; +86473-6;LL4532-9;KCCQ- Limited by HF;LA27707-1;5;Not at all limited;;; +86473-6;LL4532-9;KCCQ- Limited by HF;LA27708-9;6;Limited for other reasons or did not do the activity;;; +86474-4;LL4532-9;KCCQ- Limited by HF;LA27701-4;1;Extremely limited;;; +86474-4;LL4532-9;KCCQ- Limited by HF;LA27702-2;2;Quite a bit limited;;; +86474-4;LL4532-9;KCCQ- Limited by HF;LA6460-5;3;Moderately limited;;; +86474-4;LL4532-9;KCCQ- Limited by HF;LA9605-2;4;Slightly limited;;; +86474-4;LL4532-9;KCCQ- Limited by HF;LA27707-1;5;Not at all limited;;; +86474-4;LL4532-9;KCCQ- Limited by HF;LA27708-9;6;Limited for other reasons or did not do the activity;;; +86475-1;LL4532-9;KCCQ- Limited by HF;LA27701-4;1;Extremely limited;;; +86475-1;LL4532-9;KCCQ- Limited by HF;LA27702-2;2;Quite a bit limited;;; +86475-1;LL4532-9;KCCQ- Limited by HF;LA6460-5;3;Moderately limited;;; +86475-1;LL4532-9;KCCQ- Limited by HF;LA9605-2;4;Slightly limited;;; +86475-1;LL4532-9;KCCQ- Limited by HF;LA27707-1;5;Not at all limited;;; +86475-1;LL4532-9;KCCQ- Limited by HF;LA27708-9;6;Limited for other reasons or did not do the activity;;; +86476-9;LL4532-9;KCCQ- Limited by HF;LA27701-4;1;Extremely limited;;; +86476-9;LL4532-9;KCCQ- Limited by HF;LA27702-2;2;Quite a bit limited;;; +86476-9;LL4532-9;KCCQ- Limited by HF;LA6460-5;3;Moderately limited;;; +86476-9;LL4532-9;KCCQ- Limited by HF;LA9605-2;4;Slightly limited;;; +86476-9;LL4532-9;KCCQ- Limited by HF;LA27707-1;5;Not at all limited;;; +86476-9;LL4532-9;KCCQ- Limited by HF;LA27708-9;6;Limited for other reasons or did not do the activity;;; +86477-7;LL4532-9;KCCQ- Limited by HF;LA27701-4;1;Extremely limited;;; +86477-7;LL4532-9;KCCQ- Limited by HF;LA27702-2;2;Quite a bit limited;;; +86477-7;LL4532-9;KCCQ- Limited by HF;LA6460-5;3;Moderately limited;;; +86477-7;LL4532-9;KCCQ- Limited by HF;LA9605-2;4;Slightly limited;;; +86477-7;LL4532-9;KCCQ- Limited by HF;LA27707-1;5;Not at all limited;;; +86477-7;LL4532-9;KCCQ- Limited by HF;LA27708-9;6;Limited for other reasons or did not do the activity;;; +86483-5;LL4532-9;KCCQ- Limited by HF;LA27701-4;1;Extremely limited;;; +86483-5;LL4532-9;KCCQ- Limited by HF;LA27702-2;2;Quite a bit limited;;; +86483-5;LL4532-9;KCCQ- Limited by HF;LA6460-5;3;Moderately limited;;; +86483-5;LL4532-9;KCCQ- Limited by HF;LA9605-2;4;Slightly limited;;; +86483-5;LL4532-9;KCCQ- Limited by HF;LA27707-1;5;Not at all limited;;; +86483-5;LL4532-9;KCCQ- Limited by HF;LA27708-9;6;Limited for other reasons or did not do the activity;;; +86478-5;LL4533-7;KCCQ - HF Better Worse;LA18865-8;1;Much worse;;; +86478-5;LL4533-7;KCCQ - HF Better Worse;LA27710-5;2;Slightly worse;;; +86478-5;LL4533-7;KCCQ - HF Better Worse;LA27711-3;3;Not changed;;; +86478-5;LL4533-7;KCCQ - HF Better Worse;LA27712-1;4;Slightly better;;; +86478-5;LL4533-7;KCCQ - HF Better Worse;LA18864-1;5;Much better;;; +86478-5;LL4533-7;KCCQ - HF Better Worse;LA27717-0;6;I've had no symptoms over the last 2 weeks;;; +86479-3;LL4534-5;KCCQ - HF Times in morning;LA27719-6;1;Every morning;;; +86479-3;LL4534-5;KCCQ - HF Times in morning;LA27720-4;2;3 or more times a week, but not every day;;; +86479-3;LL4534-5;KCCQ - HF Times in morning;LA14506-2;3;1-2 times a week;;; +86479-3;LL4534-5;KCCQ - HF Times in morning;LA27722-0;4;Less than once a week;;; +86479-3;LL4534-5;KCCQ - HF Times in morning;LA27723-8;5;Never over the past 2 weeks;;; +86480-1;LL4535-2;KCCQ - Swelling;LA27766-7;1;Extremely bothersome;;; +86480-1;LL4535-2;KCCQ - Swelling;LA27724-6;2;Quite a bit bothersome;;; +86480-1;LL4535-2;KCCQ - Swelling;LA27725-3;3;Moderately bothersome;;; +86480-1;LL4535-2;KCCQ - Swelling;LA27726-1;4;Slightly bothersome;;; +86480-1;LL4535-2;KCCQ - Swelling;LA24969-0;5;Not at all bothersome;;; +86480-1;LL4535-2;KCCQ - Swelling;LA27718-8;6;I've had no swelling;;; +86482-7;LL4537-8;KCCQ - Fatigue;LA27766-7;1;Extremely bothersome;;; +86482-7;LL4537-8;KCCQ - Fatigue;LA27724-6;2;Quite a bit bothersome;;; +86482-7;LL4537-8;KCCQ - Fatigue;LA27725-3;3;Moderately bothersome;;; +86482-7;LL4537-8;KCCQ - Fatigue;LA27726-1;4;Slightly bothersome;;; +86482-7;LL4537-8;KCCQ - Fatigue;LA24969-0;5;Not at all bothersome;;; +86482-7;LL4537-8;KCCQ - Fatigue;LA27733-7;6;I've had no fatigue;;; +86484-3;LL4538-6;KCCQ - SOB;LA27766-7;1;Extremely bothersome;;; +86484-3;LL4538-6;KCCQ - SOB;LA27724-6;2;Quite a bit bothersome;;; +86484-3;LL4538-6;KCCQ - SOB;LA27725-3;3;Moderately bothersome;;; +86484-3;LL4538-6;KCCQ - SOB;LA27726-1;4;Slightly bothersome;;; +86484-3;LL4538-6;KCCQ - SOB;LA24969-0;5;Not at all bothersome;;; +86484-3;LL4538-6;KCCQ - SOB;LA27734-5;6;I've had no shortness of breath;;; +86485-0;LL4539-4;KCCQ - HF Night|Sleeping;LA14806-6;1;Every night;;; +86485-0;LL4539-4;KCCQ - HF Night|Sleeping;LA27720-4;2;3 or more times a week, but not every day;;; +86485-0;LL4539-4;KCCQ - HF Night|Sleeping;LA14506-2;3;1-2 times a week;;; +86485-0;LL4539-4;KCCQ - HF Night|Sleeping;LA27722-0;4;Less than once a week;;; +86485-0;LL4539-4;KCCQ - HF Night|Sleeping;LA27723-8;5;Never over the past 2 weeks;;; +86486-8;LL4540-2;KCCQ - HF Sureness;LA27735-2;1;Not at all sure;;; +86486-8;LL4540-2;KCCQ - HF Sureness;LA27736-0;2;Not very sure;;; +86486-8;LL4540-2;KCCQ - HF Sureness;LA27737-8;3;Somewhat sure;;; +86486-8;LL4540-2;KCCQ - HF Sureness;LA27738-6;4;Mostly sure;;; +86486-8;LL4540-2;KCCQ - HF Sureness;LA27739-4;5;Completely sure;;; +86487-6;LL4541-0;KCCQ - HF Understanding;LA27740-2;1;Do not understand at all;;; +86487-6;LL4541-0;KCCQ - HF Understanding;LA27741-0;2;Do not understand very well;;; +86487-6;LL4541-0;KCCQ - HF Understanding;LA27742-8;3;Somewhat understand;;; +86487-6;LL4541-0;KCCQ - HF Understanding;LA27743-6;4;Mostly understand;;; +86487-6;LL4541-0;KCCQ - HF Understanding;LA27744-4;5;Completely understand;;; +86488-4;LL4542-8;KCCQ - HF Enjoyment Limited;LA27745-1;1;It has extremely limited my enjoyment of life;;; +86488-4;LL4542-8;KCCQ - HF Enjoyment Limited;LA27746-9;2;It has limited my enjoyment of life quite a bit;;; +86488-4;LL4542-8;KCCQ - HF Enjoyment Limited;LA27747-7;3;It has moderately limited my enjoyment of life;;; +86488-4;LL4542-8;KCCQ - HF Enjoyment Limited;LA27748-5;4;It has slightly limited my enjoyment of life;;; +86488-4;LL4542-8;KCCQ - HF Enjoyment Limited;LA27749-3;5;It has not limited my enjoyment of life at all;;; +86490-0;LL4544-4;KCCQ - HF Time Feelings;LA27755-0;1;I felt that way all of the time;;; +86490-0;LL4544-4;KCCQ - HF Time Feelings;LA27756-8;2;I felt that way most of the time;;; +86490-0;LL4544-4;KCCQ - HF Time Feelings;LA27757-6;3;I occasionally felt that way;;; +86490-0;LL4544-4;KCCQ - HF Time Feelings;LA27758-4;4;I rarely felt that way;;; +86490-0;LL4544-4;KCCQ - HF Time Feelings;LA27759-2;5;I never felt that way;;; +86491-8;LL4545-1;KCCQ - Limited by HF 2;LA27761-8;1;Severely limited;;; +86491-8;LL4545-1;KCCQ - Limited by HF 2;LA27760-0;2;Limited quite a bit;;; +86491-8;LL4545-1;KCCQ - Limited by HF 2;LA6460-5;3;Moderately limited;;; +86491-8;LL4545-1;KCCQ - Limited by HF 2;LA9605-2;4;Slightly limited;;; +86491-8;LL4545-1;KCCQ - Limited by HF 2;LA27764-2;5;Did not limit at all;;; +86491-8;LL4545-1;KCCQ - Limited by HF 2;LA27765-9;6;Does not apply or did not do for other reasons;;; +86492-6;LL4545-1;KCCQ - Limited by HF 2;LA27761-8;1;Severely limited;;; +86492-6;LL4545-1;KCCQ - Limited by HF 2;LA27760-0;2;Limited quite a bit;;; +86492-6;LL4545-1;KCCQ - Limited by HF 2;LA6460-5;3;Moderately limited;;; +86492-6;LL4545-1;KCCQ - Limited by HF 2;LA9605-2;4;Slightly limited;;; +86492-6;LL4545-1;KCCQ - Limited by HF 2;LA27764-2;5;Did not limit at all;;; +86492-6;LL4545-1;KCCQ - Limited by HF 2;LA27765-9;6;Does not apply or did not do for other reasons;;; +86493-4;LL4545-1;KCCQ - Limited by HF 2;LA27761-8;1;Severely limited;;; +86493-4;LL4545-1;KCCQ - Limited by HF 2;LA27760-0;2;Limited quite a bit;;; +86493-4;LL4545-1;KCCQ - Limited by HF 2;LA6460-5;3;Moderately limited;;; +86493-4;LL4545-1;KCCQ - Limited by HF 2;LA9605-2;4;Slightly limited;;; +86493-4;LL4545-1;KCCQ - Limited by HF 2;LA27764-2;5;Did not limit at all;;; +86493-4;LL4545-1;KCCQ - Limited by HF 2;LA27765-9;6;Does not apply or did not do for other reasons;;; +86494-2;LL4545-1;KCCQ - Limited by HF 2;LA27761-8;1;Severely limited;;; +86494-2;LL4545-1;KCCQ - Limited by HF 2;LA27760-0;2;Limited quite a bit;;; +86494-2;LL4545-1;KCCQ - Limited by HF 2;LA6460-5;3;Moderately limited;;; +86494-2;LL4545-1;KCCQ - Limited by HF 2;LA9605-2;4;Slightly limited;;; +86494-2;LL4545-1;KCCQ - Limited by HF 2;LA27764-2;5;Did not limit at all;;; +86494-2;LL4545-1;KCCQ - Limited by HF 2;LA27765-9;6;Does not apply or did not do for other reasons;;; +86502-2;LL4414-0;VZV DNA Types;LA27278-3;1;Varicella-zoster virus Wild-type DNA detected;;; +86502-2;LL4414-0;VZV DNA Types;LA27279-1;2;Varicella-zoster virus Vaccine-strain DNA detected;;; +86502-2;LL4414-0;VZV DNA Types;LA27280-9;3;Varicella-zoster virus DNA detected, unable to type;;; +86503-0;LL4419-9;Streptococcus pneumoniae Serotypes 1 2 5 9 24;LA27117-3;1;Streptococcus pneumoniae Danish serotype 1;;; +86503-0;LL4419-9;Streptococcus pneumoniae Serotypes 1 2 5 9 24;LA27118-1;2;Streptococcus pneumoniae Danish serotype 2;;; +86503-0;LL4419-9;Streptococcus pneumoniae Serotypes 1 2 5 9 24;LA27121-5;3;Streptococcus pneumoniae Danish serotype 5;;; +86503-0;LL4419-9;Streptococcus pneumoniae Serotypes 1 2 5 9 24;LA27291-6;4;Streptococcus pneumoniae Danish serotype 9;;; +86503-0;LL4419-9;Streptococcus pneumoniae Serotypes 1 2 5 9 24;LA27292-4;5;Streptococcus pneumoniae Danish serotype 24;;; +86505-5;LL4552-7;Quest answer;LA27785-7;1;To seek the Holy Grail;;; +86506-3;LL4553-5;Blue|Yellow;LA15553-3;1;Blue;;; +86506-3;LL4553-5;Blue|Yellow;LA17195-1;2;Yellow;;; +86507-1;LL4554-3;Capital of Assyria;LA27786-5;1;I don't know that;;; +86507-1;LL4554-3;Capital of Assyria;LA27787-3;2;Ashur;;; +86507-1;LL4554-3;Capital of Assyria;LA27788-1;3;Calah;;; +86507-1;LL4554-3;Capital of Assyria;LA27789-9;4;Nineveh;;; +86509-7;LL4417-3;VZV Virus Clades;LA27282-5;1;Varicella-zoster virus clade 1;;; +86509-7;LL4417-3;VZV Virus Clades;LA27283-3;2;Varicella-zoster virus clade 2;;; +86509-7;LL4417-3;VZV Virus Clades;LA27285-8;3;Varicella-zoster virus clade 3;;; +86509-7;LL4417-3;VZV Virus Clades;LA27286-6;4;Varicella-zoster virus clade 4;;; +86509-7;LL4417-3;VZV Virus Clades;LA27287-4;5;Varicella-zoster virus clade 5;;; +86509-7;LL4417-3;VZV Virus Clades;LA27288-2;6;Varicella-zoster virus clade VI;;; +86509-7;LL4417-3;VZV Virus Clades;LA27289-0;7;Varicella-zoster virus clade VII;;; +86509-7;LL4417-3;VZV Virus Clades;LA27090-2;8;Unable to type;;; +86509-7;LL4417-3;VZV Virus Clades;LA9663-1;9;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +86509-7;LL4417-3;VZV Virus Clades;LA18373-3;10;Test not done;373121007;Test not done (qualifier value);http://snomed.info/sct +86509-7;LL4417-3;VZV Virus Clades;LA18409-5;11;Variable;;; +86526-1;LL4605-3;CMS_MDS Unit certification or licensure designat;LA27983-8;1;Unit is neither Medicare nor Medicaid certified and MDS data is not required by the State;;; +86526-1;LL4605-3;CMS_MDS Unit certification or licensure designat;LA27984-6;2;Unit is neither Medicare nor Medicaid certified but MDS data is required by the State;;; +86526-1;LL4605-3;CMS_MDS Unit certification or licensure designat;LA27985-3;3;Unit is Medicare and/or Medicaid certified;;; +86527-9;LL4555-0;CMS_ID conditions;LA20088-3;0;Down syndrome;;; +86527-9;LL4555-0;CMS_ID conditions;LA24638-1;1;Autism;;; +86527-9;LL4555-0;CMS_ID conditions;LA16985-6;2;Epilepsy;;; +86527-9;LL4555-0;CMS_ID conditions;LA27792-3;3;Other organic condition related to ID/DD;;; +86527-9;LL4555-0;CMS_ID conditions;LA27793-1;4;ID/DD with no organic condition;;; +86527-9;LL4555-0;CMS_ID conditions;LA9-3;5;None of the above;;; +86551-9;LL4461-1;Seasonal|Non-seasonal;LA27511-7;1;Seasonal;;; +86551-9;LL4461-1;Seasonal|Non-seasonal;LA27510-9;2;Non-seasonal;;; +86583-2;LL4556-8;CMS MDS_C0900 Memory/Recall;LA9962-7;1;Current season;;; +86583-2;LL4556-8;CMS MDS_C0900 Memory/Recall;LA9998-1;2;Location of own room;;; +86583-2;LL4556-8;CMS MDS_C0900 Memory/Recall;LA10085-1;3;Staff names and faces;;; +86583-2;LL4556-8;CMS MDS_C0900 Memory/Recall;LA27794-9;4;That he or she is in a nursing home/hospital swing bed;;; +86583-2;LL4556-8;CMS MDS_C0900 Memory/Recall;LA26729-6;5;None of the above were recalled;;; +8659-5;LL353-4;ART_4_Family planning;LA6523-0;1;Condom;;; +8659-5;LL353-4;ART_4_Family planning;LA6524-8;2;Oral contraceptive pill;;; +8659-5;LL353-4;ART_4_Family planning;LA6525-5;3;Injectable/implantable hormone;;; +8659-5;LL353-4;ART_4_Family planning;LA6526-3;4;Diaphragm/cervical cap;;; +8659-5;LL353-4;ART_4_Family planning;LA6527-1;5;Intrauterine device;;; +8659-5;LL353-4;ART_4_Family planning;LA6528-9;6;Vasectomy/tubal ligation/hysterectomy;;; +86597-2;LL4557-6;CMS_MDS Indicators of psychosis;LA27795-6;0;Hallucinations (perceptual experiences in the absence of real external sensory stimuli);;; +86597-2;LL4557-6;CMS_MDS Indicators of psychosis;LA27796-4;1;Delusions (misconceptions or beliefs that are firmly held, contrary to reality);;; +86597-2;LL4557-6;CMS_MDS Indicators of psychosis;LA9-3;2;None of the above;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27797-2;1;Choosing clothes to wear;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27798-0;2;Caring for personal belongings;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27799-8;3;Receiving tub bath;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27800-4;4;Receiving shower;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27815-2;5;Receiving bed bath;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27801-2;6;Receiving sponge bath;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27802-0;7;Snacks between meals;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27803-8;8;Staying up past 8:00 p.m.;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27804-6;9;Family or significant other involvement in care discussions;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27805-3;10;Use of phone in private;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27806-1;11;Place to lock personal belongings;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27807-9;12;Reading books, newspapers, or magazines;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA17907-9;13;Listening to music;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27808-7;14;Being around animals such as pets;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27809-5;15;Keeping up with the news;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27810-3;16;Doing things with groups of people;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27811-1;17;Participating in favorite activities;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27812-9;18;Spending time away from the nursing home;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27813-7;19;Spending time outdoors;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA27814-5;20;Participating in religious activities or practices;;; +86599-8;LL4558-4;CMS_MDS Activity preferences;LA9-3;21;None of the above;;; +86602-0;LL4559-2;CMS_MDS Mobility devices;LA9941-1;1;Cane/crutch;;; +86602-0;LL4559-2;CMS_MDS Mobility devices;LA10117-2;2;Walker;;; +86602-0;LL4559-2;CMS_MDS Mobility devices;LA27816-0;3;Wheelchair (manual or electric);;; +86602-0;LL4559-2;CMS_MDS Mobility devices;LA27818-6;4;Limb prosthesis;;; +86602-0;LL4559-2;CMS_MDS Mobility devices;LA28019-0;5;None of the above were used;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27819-4;0;Indwelling catheter (including suprapubic catheter and nephrostomy tube);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27820-2;1;External catheter;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27821-0;2;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA27822-8;3;Intermittent catheterization;;; +86624-4;LL4560-0;CMS_MDS Bladder bowel appliances;LA9-3;4;None of the above;;; +86624-4;LL5166-5;CMS_MDS - IPA Bladder bowel appliances;LA27821-0;1;Ostomy (including urostomy, ileostomy, and colostomy);;; +86624-4;LL5166-5;CMS_MDS - IPA Bladder bowel appliances;LA27822-8;2;Intermittent catheterization;;; +86624-4;LL5166-5;CMS_MDS - IPA Bladder bowel appliances;LA9-3;3;None of the above;;; +86637-6;LL4575-8;Provider role;LA18968-0;1;Doctor;;; +86637-6;LL4575-8;Provider role;LA9291-1;2;Registered nurse;;; +86637-6;LL4575-8;Provider role;LA18967-2;3;Midwife;;; +86637-6;LL4575-8;Provider role;LA9292-9;4;Nurse practitioner;;; +86637-6;LL4575-8;Provider role;LA9296-0;5;Physician assistant;;; +86637-6;LL4575-8;Provider role;LA22037-8;6;Physical therapist;;; +86637-6;LL4575-8;Provider role;LA22038-6;7;Physical therapist assistant;;; +86637-6;LL4575-8;Provider role;LA46-8;8;Other;;; +86637-6;LL4575-8;Provider role;LA29256-7;9;Student Physical therapist;;; +86637-6;LL4575-8;Provider role;LA29257-5;10;Student Physical therapy assistant;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31579-8;1;General Enabling Services Provider;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31580-6;2;Administrator/Clerk/Facility Staff;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA23770-3;3;Case Manager;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31582-2;4;Community Health Worker;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31584-8;5;Counselor/Therapist;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31585-5;6;Counselor/Therapist (certified or licensed);;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31586-3;7;Dental Personnel;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31587-1;8;Eligibility/Financial Worker;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31588-9;9;Health Educator;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31589-7;10;Interpreter;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31590-5;11;Medical Assistant;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA9292-9;12;Nurse practitioner;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA9291-1;13;Registered nurse;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31591-3;14;Certified Nurse Midwife;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31592-1;15;Licensed vocational nurse;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31593-9;16;Nutritionist;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31594-7;17;Outreach Worker;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31595-4;18;Pharmacist;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31596-2;19;Physician (MD or DO);;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA9296-0;20;Physician assistant;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA6657-6;21;Social worker;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31597-0;22;Licensed Clinical Social Worker;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31598-8;23;Traditional Healer;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31946-9;24;Transportation provider;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA20382-0;25;Volunteer;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA30122-8;26;I choose not to answer this question;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31369-4;27;Question not administered;;; +86637-6;LL5772-0;AAPCHO - Primary Job Type;LA31370-2;28;Skipped question;;; +86640-0;LL4682-2;Proficient in English|Not proficient in English;LA28228-7;1;Proficient in English;;; +86640-0;LL4682-2;Proficient in English|Not proficient in English;LA28229-5;2;Not proficient in English;;; +86643-4;LL4577-4;Pregnancy status source;LA21411-6;1;Patient reported;;; +86643-4;LL4577-4;Pregnancy status source;LA26678-5;2;Laboratory;;; +86643-4;LL4577-4;Pregnancy status source;LA26679-3;3;Point of care;;; +86645-9;LL4053-6;Yes|OK either way|No|Unsure;LA26438-4;1;Yes, I want to become pregnant;;; +86645-9;LL4053-6;Yes|OK either way|No|Unsure;LA26439-2;2;I'm OK either way;;; +86645-9;LL4053-6;Yes|OK either way|No|Unsure;LA26440-0;3;No, I don't want to become pregnant;;; +86645-9;LL4053-6;Yes|OK either way|No|Unsure;LA14072-5;4;Unsure;;; +86649-1;LL4578-2;Birth control methods;LA27901-0;1;Implantable rod;;; +86649-1;LL4578-2;Birth control methods;LA27902-8;2;IUD with Progestin;;; +86649-1;LL4578-2;Birth control methods;LA27903-6;3;IUD copper;;; +86649-1;LL4578-2;Birth control methods;LA27904-4;4;IUD unspecified;;; +86649-1;LL4578-2;Birth control methods;LA27905-1;5;Female sterilization;;; +86649-1;LL4578-2;Birth control methods;LA14534-4;6;Vasectomy;;; +86649-1;LL4578-2;Birth control methods;LA27907-7;7;Injectables;;; +86649-1;LL4578-2;Birth control methods;LA27908-5;8;Combined oral contraceptive pills;;; +86649-1;LL4578-2;Birth control methods;LA27909-3;9;Progestin only contraceptive pills;;; +86649-1;LL4578-2;Birth control methods;LA16581-3;10;Contraceptive patch;;; +86649-1;LL4578-2;Birth control methods;LA33038-3;11;Contraceptive gel;;; +86649-1;LL4578-2;Birth control methods;LA27911-9;12;Vaginal ring;;; +86649-1;LL4578-2;Birth control methods;LA27912-7;13;Male condom;;; +86649-1;LL4578-2;Birth control methods;LA27913-5;14;Diaphragm or cervical cap;;; +86649-1;LL4578-2;Birth control methods;LA27914-3;15;Female condom;;; +86649-1;LL4578-2;Birth control methods;LA14549-2;16;Withdrawal;;; +86649-1;LL4578-2;Birth control methods;LA27916-8;17;Spermicide;;; +86649-1;LL4578-2;Birth control methods;LA27917-6;18;Sponge;;; +86649-1;LL4578-2;Birth control methods;LA27918-4;19;Fertility awareness-based methods;;; +86649-1;LL4578-2;Birth control methods;LA27919-2;20;Lactational amenorrhea method;;; +86649-1;LL4578-2;Birth control methods;LA27920-0;21;Male relying on female method;;; +86649-1;LL4578-2;Birth control methods;LA27921-8;22;Emergency contraception;;; +86649-1;LL4578-2;Birth control methods;LA27922-6;23;Decline to answer;;; +86649-1;LL4578-2;Birth control methods;LA137-2;24;None;260413007;None (qualifier value);http://snomed.info/sct +86651-7;LL4578-2;Birth control methods;LA27901-0;1;Implantable rod;;; +86651-7;LL4578-2;Birth control methods;LA27902-8;2;IUD with Progestin;;; +86651-7;LL4578-2;Birth control methods;LA27903-6;3;IUD copper;;; +86651-7;LL4578-2;Birth control methods;LA27904-4;4;IUD unspecified;;; +86651-7;LL4578-2;Birth control methods;LA27905-1;5;Female sterilization;;; +86651-7;LL4578-2;Birth control methods;LA14534-4;6;Vasectomy;;; +86651-7;LL4578-2;Birth control methods;LA27907-7;7;Injectables;;; +86651-7;LL4578-2;Birth control methods;LA27908-5;8;Combined oral contraceptive pills;;; +86651-7;LL4578-2;Birth control methods;LA27909-3;9;Progestin only contraceptive pills;;; +86651-7;LL4578-2;Birth control methods;LA16581-3;10;Contraceptive patch;;; +86651-7;LL4578-2;Birth control methods;LA33038-3;11;Contraceptive gel;;; +86651-7;LL4578-2;Birth control methods;LA27911-9;12;Vaginal ring;;; +86651-7;LL4578-2;Birth control methods;LA27912-7;13;Male condom;;; +86651-7;LL4578-2;Birth control methods;LA27913-5;14;Diaphragm or cervical cap;;; +86651-7;LL4578-2;Birth control methods;LA27914-3;15;Female condom;;; +86651-7;LL4578-2;Birth control methods;LA14549-2;16;Withdrawal;;; +86651-7;LL4578-2;Birth control methods;LA27916-8;17;Spermicide;;; +86651-7;LL4578-2;Birth control methods;LA27917-6;18;Sponge;;; +86651-7;LL4578-2;Birth control methods;LA27918-4;19;Fertility awareness-based methods;;; +86651-7;LL4578-2;Birth control methods;LA27919-2;20;Lactational amenorrhea method;;; +86651-7;LL4578-2;Birth control methods;LA27920-0;21;Male relying on female method;;; +86651-7;LL4578-2;Birth control methods;LA27921-8;22;Emergency contraception;;; +86651-7;LL4578-2;Birth control methods;LA27922-6;23;Decline to answer;;; +86651-7;LL4578-2;Birth control methods;LA137-2;24;None;260413007;None (qualifier value);http://snomed.info/sct +86650-9;LL4579-0;Reason for no birth control;LA14550-0;1;Abstinence;;; +86650-9;LL4579-0;Reason for no birth control;LA27925-9;2;Same sex partner;;; +86650-9;LL4579-0;Reason for no birth control;LA46-8;3;Other;;; +86650-9;LL4579-0;Reason for no birth control;LA27927-5;4;Sterile for non-contraceptive reasons;;; +86650-9;LL4579-0;Reason for no birth control;LA27928-3;5;Seeking pregnancy;;; +86653-3;LL4579-0;Reason for no birth control;LA14550-0;1;Abstinence;;; +86653-3;LL4579-0;Reason for no birth control;LA27925-9;2;Same sex partner;;; +86653-3;LL4579-0;Reason for no birth control;LA46-8;3;Other;;; +86653-3;LL4579-0;Reason for no birth control;LA27927-5;4;Sterile for non-contraceptive reasons;;; +86653-3;LL4579-0;Reason for no birth control;LA27928-3;5;Seeking pregnancy;;; +86652-5;LL4580-8;Method for providing birth control;LA27929-1;1;Provided on site;;; +86652-5;LL4580-8;Method for providing birth control;LA27930-9;2;Referral;;; +86652-5;LL4580-8;Method for providing birth control;LA27931-7;3;Prescription;;; +86666-5;LL4439-7;[CAP] Tumor site within lymph node;LA27462-3;1;Subcapsular;;; +86666-5;LL4439-7;[CAP] Tumor site within lymph node;LA27876-4;2;Intramedullary;;; +86666-5;LL4439-7;[CAP] Tumor site within lymph node;LA27877-2;3;Subcapsular and intramedullary;;; +92829-1;LL4439-7;[CAP] Tumor site within lymph node;LA27462-3;1;Subcapsular;;; +92829-1;LL4439-7;[CAP] Tumor site within lymph node;LA27876-4;2;Intramedullary;;; +92829-1;LL4439-7;[CAP] Tumor site within lymph node;LA27877-2;3;Subcapsular and intramedullary;;; +86667-3;LL4442-1;[CAP] Anatomic Level;LA15458-5;1;II;;; +86667-3;LL4442-1;[CAP] Anatomic Level;LA15459-3;2;III;;; +86667-3;LL4442-1;[CAP] Anatomic Level;LA15460-1;3;IV;;; +86667-3;LL4442-1;[CAP] Anatomic Level;LA27466-4;4;V;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7444-8;7;Hypertension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA9639-1;10;Cirrhosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7465-3;18;Pneumonia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10591-8;19;Septicemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10513-2;20;Tuberculosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27852-5;25;Hyponatremia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10527-2;30;Osteoporosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27857-4;32;Other fracture;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18262-8;34;Aphasia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA25276-9;39;Paraplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27861-6;40;Quadriplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27532-3;42;Huntington's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27873-1;55;Respiratory failure;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7444-8;7;Hypertension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA9639-1;10;Cirrhosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7465-3;18;Pneumonia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10591-8;19;Septicemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10513-2;20;Tuberculosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27852-5;25;Hyponatremia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10527-2;30;Osteoporosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27857-4;32;Other fracture;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18262-8;34;Aphasia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA25276-9;39;Paraplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27861-6;40;Quadriplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27532-3;42;Huntington's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27873-1;55;Respiratory failure;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7444-8;7;Hypertension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA9639-1;10;Cirrhosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7465-3;18;Pneumonia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10591-8;19;Septicemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10513-2;20;Tuberculosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27852-5;25;Hyponatremia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10527-2;30;Osteoporosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27857-4;32;Other fracture;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18262-8;34;Aphasia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA25276-9;39;Paraplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27861-6;40;Quadriplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27532-3;42;Huntington's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27873-1;55;Respiratory failure;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7444-8;7;Hypertension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA9639-1;10;Cirrhosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7465-3;18;Pneumonia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10591-8;19;Septicemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10513-2;20;Tuberculosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27852-5;25;Hyponatremia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10527-2;30;Osteoporosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27857-4;32;Other fracture;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18262-8;34;Aphasia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA25276-9;39;Paraplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27861-6;40;Quadriplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27532-3;42;Huntington's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27873-1;55;Respiratory failure;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7444-8;7;Hypertension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA9639-1;10;Cirrhosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7465-3;18;Pneumonia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10591-8;19;Septicemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10513-2;20;Tuberculosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27852-5;25;Hyponatremia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10527-2;30;Osteoporosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27857-4;32;Other fracture;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18262-8;34;Aphasia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA25276-9;39;Paraplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27861-6;40;Quadriplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27532-3;42;Huntington's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27873-1;55;Respiratory failure;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7444-8;7;Hypertension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA9639-1;10;Cirrhosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7465-3;18;Pneumonia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10591-8;19;Septicemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10513-2;20;Tuberculosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27852-5;25;Hyponatremia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10527-2;30;Osteoporosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27857-4;32;Other fracture;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18262-8;34;Aphasia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA25276-9;39;Paraplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27861-6;40;Quadriplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27532-3;42;Huntington's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27873-1;55;Respiratory failure;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7444-8;7;Hypertension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA9639-1;10;Cirrhosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA7465-3;18;Pneumonia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10591-8;19;Septicemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10513-2;20;Tuberculosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27852-5;25;Hyponatremia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA10527-2;30;Osteoporosis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27857-4;32;Other fracture;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA18262-8;34;Aphasia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA25276-9;39;Paraplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27861-6;40;Quadriplegia;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27532-3;42;Huntington's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27873-1;55;Respiratory failure;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL4565-9;CMS_MDS Active Diagnoses;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA7465-3;0;Pneumonia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA10591-8;1;Septicemia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27858-2;3;Cerebral palsy;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27523-2;4;Hemiplegia or hemiparesis;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27861-6;5;Quadriplegia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27531-5;6;Multiple sclerosis (MS);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27533-1;7;Parkinson's disease;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27872-3;8;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27873-1;9;Respiratory failure;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA7465-3;0;Pneumonia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA10591-8;1;Septicemia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27858-2;3;Cerebral palsy;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27523-2;4;Hemiplegia or hemiparesis;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27861-6;5;Quadriplegia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27531-5;6;Multiple sclerosis (MS);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27533-1;7;Parkinson's disease;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27872-3;8;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27873-1;9;Respiratory failure;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA7465-3;0;Pneumonia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA10591-8;1;Septicemia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA26741-1;2;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27858-2;3;Cerebral palsy;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27523-2;4;Hemiplegia or hemiparesis;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27861-6;5;Quadriplegia;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27531-5;6;Multiple sclerosis (MS);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27533-1;7;Parkinson's disease;;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27872-3;8;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4595-6;CMS_MDS Active diagnoses subset 1;LA27873-1;9;Respiratory failure;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA7465-3;4;Pneumonia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA10591-8;5;Septicemia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27849-1;6;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA26741-1;7;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27858-2;8;Cerebral palsy;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27523-2;9;Hemiplegia or hemiparesis;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27861-6;10;Quadriplegia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27531-5;11;Multiple sclerosis (MS);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27532-3;12;Huntington's disease;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27533-1;13;Parkinson's disease;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27862-4;14;Tourette's syndrome;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27865-7;15;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27866-5;16;Anxiety disorder;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27868-1;17;Manic depression (bipolar disease);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27869-9;18;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27870-7;19;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27871-5;20;Post traumatic stress disorder (PTSD);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27872-3;21;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27873-1;22;Respiratory failure;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA7465-3;4;Pneumonia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA10591-8;5;Septicemia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27849-1;6;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA26741-1;7;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27858-2;8;Cerebral palsy;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27523-2;9;Hemiplegia or hemiparesis;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27861-6;10;Quadriplegia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27531-5;11;Multiple sclerosis (MS);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27532-3;12;Huntington's disease;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27533-1;13;Parkinson's disease;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27862-4;14;Tourette's syndrome;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27865-7;15;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27866-5;16;Anxiety disorder;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27868-1;17;Manic depression (bipolar disease);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27869-9;18;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27870-7;19;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27871-5;20;Post traumatic stress disorder (PTSD);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27872-3;21;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27873-1;22;Respiratory failure;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA7465-3;4;Pneumonia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA10591-8;5;Septicemia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27849-1;6;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA26741-1;7;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27858-2;8;Cerebral palsy;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27523-2;9;Hemiplegia or hemiparesis;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27861-6;10;Quadriplegia;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27531-5;11;Multiple sclerosis (MS);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27532-3;12;Huntington's disease;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27533-1;13;Parkinson's disease;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27862-4;14;Tourette's syndrome;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27865-7;15;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27866-5;16;Anxiety disorder;;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27868-1;17;Manic depression (bipolar disease);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27869-9;18;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27870-7;19;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27871-5;20;Post traumatic stress disorder (PTSD);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27872-3;21;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4596-4;CMS_MDS Active diagnoses subset 2;LA27873-1;22;Respiratory failure;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27532-3;6;Huntington's disease;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27866-5;9;Anxiety disorder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27868-1;10;Manic depression (bipolar disease);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27532-3;6;Huntington's disease;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27866-5;9;Anxiety disorder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27868-1;10;Manic depression (bipolar disease);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27532-3;6;Huntington's disease;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27866-5;9;Anxiety disorder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27868-1;10;Manic depression (bipolar disease);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27532-3;6;Huntington's disease;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27866-5;9;Anxiety disorder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27868-1;10;Manic depression (bipolar disease);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27532-3;6;Huntington's disease;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27866-5;9;Anxiety disorder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27868-1;10;Manic depression (bipolar disease);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27532-3;6;Huntington's disease;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27866-5;9;Anxiety disorder;;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27868-1;10;Manic depression (bipolar disease);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4597-2;CMS_MDS Active diagnoses subset 3;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7444-8;7;Hypertension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7465-3;18;Pneumonia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10591-8;19;Septicemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10513-2;20;Tuberculosis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27852-5;25;Hyponatremia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27857-4;32;Other fracture;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18262-8;34;Aphasia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA25276-9;39;Paraplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27861-6;40;Quadriplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27532-3;42;Huntington's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27873-1;55;Respiratory failure;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7444-8;7;Hypertension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7465-3;18;Pneumonia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10591-8;19;Septicemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10513-2;20;Tuberculosis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27852-5;25;Hyponatremia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27857-4;32;Other fracture;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18262-8;34;Aphasia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA25276-9;39;Paraplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27861-6;40;Quadriplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27532-3;42;Huntington's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27873-1;55;Respiratory failure;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7444-8;7;Hypertension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7465-3;18;Pneumonia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10591-8;19;Septicemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10513-2;20;Tuberculosis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27852-5;25;Hyponatremia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27857-4;32;Other fracture;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18262-8;34;Aphasia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA25276-9;39;Paraplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27861-6;40;Quadriplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27532-3;42;Huntington's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27873-1;55;Respiratory failure;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7444-8;7;Hypertension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7465-3;18;Pneumonia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10591-8;19;Septicemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10513-2;20;Tuberculosis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27852-5;25;Hyponatremia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27857-4;32;Other fracture;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18262-8;34;Aphasia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA25276-9;39;Paraplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27861-6;40;Quadriplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27532-3;42;Huntington's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27873-1;55;Respiratory failure;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7444-8;7;Hypertension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA7465-3;18;Pneumonia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10591-8;19;Septicemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA10513-2;20;Tuberculosis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27852-5;25;Hyponatremia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA19699-0;26;Hyperkalemia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27857-4;32;Other fracture;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA18262-8;34;Aphasia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27858-2;35;Cerebral palsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA25276-9;39;Paraplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27861-6;40;Quadriplegia;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27532-3;42;Huntington's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27533-1;43;Parkinson's disease;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27866-5;48;Anxiety disorder;;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27868-1;50;Manic depression (bipolar disease);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL4598-0;CMS_MDS Active Diagnoses subset 4;LA27873-1;55;Respiratory failure;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA7444-8;7;Hypertension;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA9639-1;10;Cirrhosis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA7465-3;18;Pneumonia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA10591-8;19;Septicemia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA10513-2;20;Tuberculosis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27852-5;25;Hyponatremia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA19699-0;26;Hyperkalemia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA10527-2;30;Osteoporosis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27857-4;32;Other fracture;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA18262-8;34;Aphasia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27858-2;35;Cerebral palsy;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA25276-9;39;Paraplegia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27861-6;40;Quadriplegia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27532-3;42;Huntington's disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27533-1;43;Parkinson's disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27866-5;48;Anxiety disorder;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA29615-4;50;Bipolar Disorder;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27873-1;55;Respiratory failure;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27837-6;3;Atrial fibrillation or other dysrhythmias (e.g. bradycardias and tachycardias);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27838-4;4;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27839-2;5;Deep venous thrombosis (DVT), pulmonary embolus (PE), or Pulmonary thrombo-embolism (PTE);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27840-0;6;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA7444-8;7;Hypertension;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27841-8;8;Orthostatic hypotension;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA18399-8;9;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA9639-1;10;Cirrhosis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27842-6;11;Gastroesophageal reflux disease (GERD) or ulcer (e.g., esophageal, gastric, and peptic ulcers);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27843-4;12;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27844-2;13;Benign prostatic hyperplasia (BPH);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27845-9;14;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27846-7;15;Neurogenic bladder;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27847-5;16;Obstructive uropathy;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27848-3;17;Multidrug-resistant organism (MDRO);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA7465-3;18;Pneumonia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA10591-8;19;Septicemia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA10513-2;20;Tuberculosis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27849-1;21;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27850-9;22;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27851-7;23;Wound infection (other than foot);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA26741-1;24;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27852-5;25;Hyponatremia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA19699-0;26;Hyperkalemia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27853-3;27;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27854-1;28;Thyroid disorder (e.g., hypothyroidism, hyperthyroidism, and Hashimoto's thyroiditis);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27855-8;29;Arthritis (e.g., degenerative joint disease (DJD), osteoarthritis, and rheumatoid arthritis (RA));;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA10527-2;30;Osteoporosis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27856-6;31;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27857-4;32;Other fracture;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA22313-3;33;Alzheimer's disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA18262-8;34;Aphasia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27858-2;35;Cerebral palsy;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27859-0;36;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27860-8;37;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27523-2;38;Hemiplegia or hemiparesis;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA25276-9;39;Paraplegia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27861-6;40;Quadriplegia;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27531-5;41;Multiple sclerosis (MS);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27532-3;42;Huntington's disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27533-1;43;Parkinson's disease;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27862-4;44;Tourette's syndrome;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27863-2;45;Seizure disorder or epilepsy;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27864-0;46;Traumatic brain injury (TBI);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27865-7;47;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27866-5;48;Anxiety disorder;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27867-3;49;Depression (other than bipolar);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA29615-4;50;Bipolar Disorder;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27869-9;51;Psychotic disorder (other than schizophrenia);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27870-7;52;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27871-5;53;Post traumatic stress disorder (PTSD);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27872-3;54;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27873-1;55;Respiratory failure;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27874-9;56;Cataracts, glaucoma, or macular degeneration;;; +86671-5;LL5170-7;CMS_MDS v1.17.1 Active Diagnoses - NC;LA27875-6;57;None of the above active diagnoses within the last 7 days;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27532-3;6;Huntington's disease;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27866-5;9;Anxiety disorder;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA29615-4;10;Bipolar Disorder;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA18399-8;1;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27846-7;2;Neurogenic bladder;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27847-5;3;Obstructive uropathy;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27849-1;4;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA26741-1;5;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27532-3;6;Huntington's disease;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27862-4;7;Tourette's syndrome;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27865-7;8;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27866-5;9;Anxiety disorder;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA29615-4;10;Bipolar Disorder;;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27869-9;11;Psychotic disorder (other than schizophrenia);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27870-7;12;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL5171-5;CMS_MDS v1.17.1 Active diagnoses - ND, SD;LA27871-5;13;Post traumatic stress disorder (PTSD);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27838-4;3;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27840-0;4;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA7444-8;5;Hypertension;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27841-8;6;Orthostatic hypotension;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA18399-8;7;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27843-4;8;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27845-9;9;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27846-7;10;Neurogenic bladder;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27847-5;11;Obstructive uropathy;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27848-3;12;Multidrug-resistant organism (MDRO);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA7465-3;13;Pneumonia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA10591-8;14;Septicemia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA10513-2;15;Tuberculosis;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27849-1;16;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27850-9;17;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27851-7;18;Wound infection (other than foot);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA26741-1;19;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27852-5;20;Hyponatremia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA19699-0;21;Hyperkalemia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27853-3;22;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27856-6;23;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27857-4;24;Other fracture;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA22313-3;25;Alzheimer's disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA18262-8;26;Aphasia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27858-2;27;Cerebral palsy;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27859-0;28;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27860-8;29;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27523-2;30;Hemiplegia or hemiparesis;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA25276-9;31;Paraplegia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27861-6;32;Quadriplegia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27531-5;33;Multiple sclerosis (MS);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27532-3;34;Huntington's disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27533-1;35;Parkinson's disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27862-4;36;Tourette's syndrome;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27863-2;37;Seizure disorder or epilepsy;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27864-0;38;Traumatic brain injury (TBI);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27865-7;39;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27866-5;40;Anxiety disorder;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27867-3;41;Depression (other than bipolar);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA29615-4;42;Bipolar Disorder;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27869-9;43;Psychotic disorder (other than schizophrenia);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27870-7;44;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27871-5;45;Post traumatic stress disorder (PTSD);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27872-3;46;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27873-1;47;Respiratory failure;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27838-4;3;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27840-0;4;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA7444-8;5;Hypertension;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27841-8;6;Orthostatic hypotension;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA18399-8;7;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27843-4;8;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27845-9;9;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27846-7;10;Neurogenic bladder;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27847-5;11;Obstructive uropathy;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27848-3;12;Multidrug-resistant organism (MDRO);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA7465-3;13;Pneumonia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA10591-8;14;Septicemia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA10513-2;15;Tuberculosis;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27849-1;16;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27850-9;17;Viral hepatitis (e.g., Hepatitis A, B, C, D, and E);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27851-7;18;Wound infection (other than foot);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA26741-1;19;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27852-5;20;Hyponatremia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA19699-0;21;Hyperkalemia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27853-3;22;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27856-6;23;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27857-4;24;Other fracture;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA22313-3;25;Alzheimer's disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA18262-8;26;Aphasia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27858-2;27;Cerebral palsy;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27859-0;28;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27860-8;29;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27523-2;30;Hemiplegia or hemiparesis;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA25276-9;31;Paraplegia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27861-6;32;Quadriplegia;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27531-5;33;Multiple sclerosis (MS);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27532-3;34;Huntington's disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27533-1;35;Parkinson's disease;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27862-4;36;Tourette's syndrome;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27863-2;37;Seizure disorder or epilepsy;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27864-0;38;Traumatic brain injury (TBI);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27865-7;39;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27866-5;40;Anxiety disorder;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27867-3;41;Depression (other than bipolar);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA29615-4;42;Bipolar Disorder;;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27869-9;43;Psychotic disorder (other than schizophrenia);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27870-7;44;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27871-5;45;Post traumatic stress disorder (PTSD);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27872-3;46;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL5172-3;CMS_MDS v1.17.1 Active Diagnoses - NQ, NP;LA27873-1;47;Respiratory failure;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27987-9;1;Cancer (with or without metastasis);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27836-8;2;Anemia (e.g. aplastic, iron deficiency, pernicious, and sickle cell);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27838-4;3;Coronary artery disease (CAD) (e.g., angina, myocardial infarction, and atherosclerotic heart disease (ASHD));;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27840-0;4;Heart failure (e.g., congestive heart failure (CHF) and pulmonary edema);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA7444-8;5;Hypertension;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27841-8;6;Orthostatic hypotension;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA18399-8;7;Peripheral vascular disease (PVD) or peripheral arterial disease (PAD);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27843-4;8;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27845-9;9;Renal insufficiency, renal failure, or end-stage renal disease (ESRD);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27846-7;10;Neurogenic bladder;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27847-5;11;Obstructive uropathy;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27848-3;12;Multidrug-resistant organism (MDRO);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA7465-3;13;Pneumonia;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA10591-8;14;Septicemia;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA10513-2;15;Tuberculosis;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27849-1;16;Urinary tract infection (UTI) (last 30 days);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27851-7;17;Wound infection (other than foot);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA26741-1;18;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27852-5;19;Hyponatremia;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA19699-0;20;Hyperkalemia;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27853-3;21;Hyperlipidemia (e.g., hypercholesterolemia);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27856-6;22;Hip fracture - any hip fracture that has a relationship to current status, treatments, monitoring (e.g., sub-capital fractures, and fractures of the trochanter and femoral neck);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27857-4;23;Other fracture;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA18262-8;24;Aphasia;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27858-2;25;Cerebral palsy;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27859-0;26;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27860-8;27;"Non-Alzheimer's dementia (e.g., Lewy body dementia, vascular or multi-infarct dementia; mixed dementia; frontotemporal dementia such as Pick's disease; and dementia related to stroke, Parkinson's or Creutzfeldt-Jakob diseases)";;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27523-2;28;Hemiplegia or hemiparesis;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA25276-9;29;Paraplegia;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27861-6;30;Quadriplegia;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27531-5;31;Multiple sclerosis (MS);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27532-3;32;Huntington's disease;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27533-1;33;Parkinson's disease;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27862-4;34;Tourette's syndrome;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27863-2;35;Seizure disorder or epilepsy;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27864-0;36;Traumatic brain injury (TBI);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27865-7;37;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27866-5;38;Anxiety disorder;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27867-3;39;Depression (other than bipolar);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA29615-4;40;Bipolar Disorder;;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27869-9;41;Psychotic disorder (other than schizophrenia);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27870-7;42;Schizophrenia (e.g., schizoaffective and schizophreniform disorders);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27871-5;43;Post traumatic stress disorder (PTSD);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27872-3;44;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL5173-1;CMS_MDS v1.17.1 Active Diagnoses - SP;LA27873-1;45;Respiratory failure;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27843-4;1;Ulcerative colitis, Crohn's disease, or inflammatory bowel disease;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27848-3;2;Multidrug-resistant organism (MDRO);;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA7465-3;3;Pneumonia;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA10591-8;4;Septicemia;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27851-7;5;Wound infection (other than foot);;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA26741-1;6;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA18262-8;7;Aphasia;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27858-2;8;Cerebral palsy;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27859-0;9;Cerebrovascular accident (CVA), transient ischemic attack (TIA), or stroke;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27523-2;10;Hemiplegia or hemiparesis;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27861-6;11;Quadriplegia;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27531-5;12;Multiple sclerosis (MS);;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27533-1;13;Parkinson's disease;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27864-0;14;Traumatic brain injury (TBI);;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27865-7;15;Malnutrition (protein or calorie) or at risk for malnutrition;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27872-3;16;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27873-1;17;Respiratory failure;;; +86671-5;LL5174-9;CMS_MDS v1.17.1 Active Diagnoses - IPA;LA27875-6;18;None of the above active diagnoses within the last 7 days;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA7465-3;1;Pneumonia;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA10591-8;2;Septicemia;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA26741-1;3;Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy);;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA18262-8;4;Aphasia;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27858-2;5;Cerebral palsy;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27523-2;6;Hemiplegia or hemiparesis;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27861-6;7;Quadriplegia;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27531-5;8;Multiple sclerosis (MS);;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27533-1;9;Parkinson's disease;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27872-3;10;Asthma, chronic obstructive pulmonary disease (COPD), or chronic lung disease (e.g., chronic bronchitis and restrictive lung diseases such as asbestosis);;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27873-1;11;Respiratory failure;;; +86671-5;LL5177-2;CMS_MDS v1.17.1 Active Diagnoses - OSA;LA27875-6;12;None of the above active diagnoses within the last 7 days;;; +86673-1;LL4632-7;CMS_MDS Pain indicators;LA10034-9;1;Non-verbal sounds (e.g., crying, whining, gasping, moaning, or groaning);;; +86673-1;LL4632-7;CMS_MDS Pain indicators;LA10116-4;2;Vocal complaints of pain (e.g., that hurts, ouch, stop);;; +86673-1;LL4632-7;CMS_MDS Pain indicators;LA9968-4;3;Facial Expressions (e.g., grimaces, winces, wrinkled forehead, furrowed brow, clenched teeth or jaw);;; +86673-1;LL4632-7;CMS_MDS Pain indicators;LA10063-8;4;Protective body movements or postures (e.g., bracing, guarding, rubbing or massaging a body part/area, clutching or holding a body part during movement);;; +86673-1;LL4632-7;CMS_MDS Pain indicators;LA10032-3;5;None of these signs observed or documented;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27988-7;1;Shortness of breath or trouble breathing with exertion (e.g., walking, bathing, transferring);;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27989-5;2;Shortness of breath or trouble breathing when sitting at rest;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA27990-3;3;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4606-1;CMS_MDS Shortness of breath;LA9-3;4;None of the above;;; +86675-6;LL4614-5;MDSv3_Shortness of breath when lying flat;LA27990-3;1;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4614-5;MDSv3_Shortness of breath when lying flat;LA27990-3;1;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL4614-5;MDSv3_Shortness of breath when lying flat;LA27990-3;1;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL5179-8;CMS_MDS v1.17.1 J1100 Shortness of breathe-IPA,OSA;LA27990-3;1;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL5179-8;CMS_MDS v1.17.1 J1100 Shortness of breathe-IPA,OSA;LA9-3;2;None of the above;;; +86675-6;LL5179-8;CMS_MDS v1.17.1 J1100 Shortness of breathe-IPA,OSA;LA27990-3;1;Shortness of breath or trouble breathing when lying flat;;; +86675-6;LL5179-8;CMS_MDS v1.17.1 J1100 Shortness of breathe-IPA,OSA;LA9-3;2;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA7435-6;0;Fever;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA15099-7;1;Vomiting;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27897-0;2;Dehydrated;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA27898-8;3;Internal bleeding;;; +86676-4;LL4571-7;CMS_MDS Problem conditions;LA9-3;4;None of the above;;; +86676-4;LL4599-8;CMS_MDS Problem conditions subset 1;LA7435-6;0;Fever;;; +86676-4;LL4599-8;CMS_MDS Problem conditions subset 1;LA15099-7;1;Vomiting;;; +86676-4;LL4599-8;CMS_MDS Problem conditions subset 1;LA7435-6;0;Fever;;; +86676-4;LL4599-8;CMS_MDS Problem conditions subset 1;LA15099-7;1;Vomiting;;; +86676-4;LL4599-8;CMS_MDS Problem conditions subset 1;LA7435-6;0;Fever;;; +86676-4;LL4599-8;CMS_MDS Problem conditions subset 1;LA15099-7;1;Vomiting;;; +86676-4;LL5180-6;CMS_MDS Problem conditions - IPA;LA7435-6;0;Fever;;; +86676-4;LL5180-6;CMS_MDS Problem conditions - IPA;LA15099-7;1;Vomiting;;; +86676-4;LL5180-6;CMS_MDS Problem conditions - IPA;LA9-3;2;None of the above;;; +86677-2;LL4573-3;CMS_MDS Swallowing disorder;LA10001-8;1;Loss of liquids/solids from mouth when eating or drinking;;; +86677-2;LL4573-3;CMS_MDS Swallowing disorder;LA9977-5;2;Holding food in mouth/cheeks or residual food in mouth after meals;;; +86677-2;LL4573-3;CMS_MDS Swallowing disorder;LA9961-9;3;Coughing or choking during meals or when swallowing medications;;; +86677-2;LL4573-3;CMS_MDS Swallowing disorder;LA9952-8;4;Complaints of difficulty or pain with swallowing;;; +86677-2;LL4573-3;CMS_MDS Swallowing disorder;LA9-3;5;None of the above;;; +86678-0;LL4574-1;CMS_MDS Weight gain;LA11074-4;1;No or unknown;;; +86678-0;LL4574-1;CMS_MDS Weight gain;LA18602-5;2;Yes, on physician-prescribed weight-gain regimen;;; +86678-0;LL4574-1;CMS_MDS Weight gain;LA18603-3;3;Yes, not on physician-prescribed weight-gain regimen;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27932-5;0;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27933-3;1;No natural teeth or tooth fragment(s) (edentulous);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27934-1;2;Abnormal mouth tissue (ulcers, masses, oral lesions, including under denture or partial if one is worn);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27935-8;3;Obvious or likely cavity or broken natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27936-6;4;Inflamed or bleeding gums or loose natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27937-4;5;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27938-2;6;Unable to examine;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27939-0;7;None of the above were present;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27932-5;0;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27933-3;1;No natural teeth or tooth fragment(s) (edentulous);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27934-1;2;Abnormal mouth tissue (ulcers, masses, oral lesions, including under denture or partial if one is worn);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27935-8;3;Obvious or likely cavity or broken natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27936-6;4;Inflamed or bleeding gums or loose natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27937-4;5;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27938-2;6;Unable to examine;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27939-0;7;None of the above were present;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27932-5;0;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27933-3;1;No natural teeth or tooth fragment(s) (edentulous);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27934-1;2;Abnormal mouth tissue (ulcers, masses, oral lesions, including under denture or partial if one is worn);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27935-8;3;Obvious or likely cavity or broken natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27936-6;4;Inflamed or bleeding gums or loose natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27937-4;5;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27938-2;6;Unable to examine;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27939-0;7;None of the above were present;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27932-5;0;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27933-3;1;No natural teeth or tooth fragment(s) (edentulous);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27934-1;2;Abnormal mouth tissue (ulcers, masses, oral lesions, including under denture or partial if one is worn);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27935-8;3;Obvious or likely cavity or broken natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27936-6;4;Inflamed or bleeding gums or loose natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27937-4;5;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27938-2;6;Unable to examine;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27939-0;7;None of the above were present;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27932-5;0;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27933-3;1;No natural teeth or tooth fragment(s) (edentulous);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27934-1;2;Abnormal mouth tissue (ulcers, masses, oral lesions, including under denture or partial if one is worn);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27935-8;3;Obvious or likely cavity or broken natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27936-6;4;Inflamed or bleeding gums or loose natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27937-4;5;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27938-2;6;Unable to examine;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27939-0;7;None of the above were present;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27932-5;0;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27933-3;1;No natural teeth or tooth fragment(s) (edentulous);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27934-1;2;Abnormal mouth tissue (ulcers, masses, oral lesions, including under denture or partial if one is worn);;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27935-8;3;Obvious or likely cavity or broken natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27936-6;4;Inflamed or bleeding gums or loose natural teeth;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27937-4;5;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27938-2;6;Unable to examine;;; +86706-9;LL4581-6;CMS_MDS Dental problems;LA27939-0;7;None of the above were present;;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27932-5;1;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27937-4;2;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27932-5;1;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27937-4;2;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27932-5;1;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27937-4;2;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27932-5;1;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27937-4;2;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27932-5;1;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27937-4;2;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27932-5;1;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27937-4;2;Mouth or facial pain, discomfort or difficulty with chewing;;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27932-5;1;Broken or loosely fitting full or partial denture (chipped, cracked, uncleanable, or loose);;; +86706-9;LL4627-7;CMS_MDS Dental subset 2;LA27937-4;2;Mouth or facial pain, discomfort or difficulty with chewing;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27940-8;0;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27941-6;1;Formal assessment instrument/tool (e.g., Braden, Norton, or other);;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA27942-4;2;Clinical assessment;;; +86708-5;LL4582-4;CMS_MDS Determination of pressure ulcer risk;LA9-3;3;None of the above;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86708-5;LL4615-2;CMS_MDS Determination of Pressure Ulcer Risk 2;LA27940-8;1;Resident has a stage 1 or greater, a scar over bony prominence, or a non-removable dressing/device;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA11883-8;1;Not detected;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27682-6;2;Actinobacillus pleuropneumoniae serotype 1;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27683-4;3;Actinobacillus pleuropneumoniae serotype 2;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27684-2;4;Actinobacillus pleuropneumoniae serotype 3;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27685-9;5;Actinobacillus pleuropneumoniae serotype 4;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27686-7;6;Actinobacillus pleuropneumoniae serotype 5;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27687-5;7;Actinobacillus pleuropneumoniae serotype 6;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27688-3;8;Actinobacillus pleuropneumoniae serotype 7;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27689-1;9;Actinobacillus pleuropneumoniae serotype 8;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27690-9;10;Actinobacillus pleuropneumoniae serotype 9;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27691-7;11;Actinobacillus pleuropneumoniae serotype 10;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27692-5;12;Actinobacillus pleuropneumoniae serotype 11;;; +86721-8;LL4521-2;Actinobacillus pleuropneumoniae serotypes;LA27693-3;13;Actinobacillus pleuropneumoniae serotype 12;;; +86742-4;LL4453-8;[CAP] Growth Phase;LA27480-5;1;Radial growth phase;402556000;Malignant melanoma (radial growth phase) (disorder);http://snomed.info/sct +86742-4;LL4453-8;[CAP] Growth Phase;LA27482-1;2;Vertical growth phase;402558004;Malignant melanoma (vertical growth phase) (disorder);http://snomed.info/sct +86742-4;LL4453-8;[CAP] Growth Phase;LA11899-4;3;Cannot be determined;;; +86744-0;LL4590-7;[HL7] Care team types;LA27975-4;1;Event-focused care team;;; +86744-0;LL4590-7;[HL7] Care team types;LA27976-2;2;Encounter-focused care team;;; +86744-0;LL4590-7;[HL7] Care team types;LA27977-0;3;Episode of care-focused care team;;; +86744-0;LL4590-7;[HL7] Care team types;LA27978-8;4;Condition-focused care team;;; +86744-0;LL4590-7;[HL7] Care team types;LA28865-6;5;Longitudinal care-coordination focused care team;;; +86744-0;LL4590-7;[HL7] Care team types;LA28866-4;6;Home & Community Based Services (HCBS)-focused care team;;; +86744-0;LL4590-7;[HL7] Care team types;LA27980-4;7;Clinical research-focused care team;;; +86744-0;LL4590-7;[HL7] Care team types;LA28867-2;8;Public health-focused care team;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27951-5;0;Pressure reducing device for chair;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27952-3;1;Pressure reducing device for bed;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27953-1;2;Turning/repositioning program;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27954-9;3;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27955-6;4;Pressure ulcer care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27956-4;5;Surgical wound care;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27957-2;6;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27958-0;7;Applications of ointments/medications other than to feet;;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27959-8;8;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4584-0;CMS_MDS Skin and ulcer treatments;LA27960-6;9;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27951-5;1;Pressure reducing device for chair;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27952-3;2;Pressure reducing device for bed;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27953-1;3;Turning/repositioning program;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27954-9;4;Nutrition or hydration intervention to manage skin problems;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA28888-8;5;Pressure ulcer/injury care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27956-4;6;Surgical wound care;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27957-2;7;Application of nonsurgical dressings (with or without topical medications) other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27958-0;8;Applications of ointments/medications other than to feet;;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27959-8;9;Application of dressings to feet (with or without topical medications);;; +86748-1;LL4976-8;CMS MDS Skin treatments;LA27960-6;10;None of the above were provided;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA6172-6;0;Chemotherapy;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA4351-8;1;Radiation;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27962-2;2;Oxygen therapy;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27963-0;3;Suctioning;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27964-8;4;Tracheostomy care;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27965-5;5;Ventilator or respirator;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27971-3;6;BiPAP/CPAP;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27972-1;7;IV medications;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27966-3;8;Transfusions;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA7216-0;9;Dialysis;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA6217-9;10;Hospice care;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA9-3;13;None of the above;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA6172-6;0;Chemotherapy;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA4351-8;1;Radiation;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27962-2;2;Oxygen therapy;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27963-0;3;Suctioning;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27964-8;4;Tracheostomy care;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27965-5;5;Ventilator or respirator;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27971-3;6;BiPAP/CPAP;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27972-1;7;IV medications;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27966-3;8;Transfusions;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA7216-0;9;Dialysis;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA6217-9;10;Hospice care;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA9-3;13;None of the above;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA6172-6;0;Chemotherapy;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA4351-8;1;Radiation;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27962-2;2;Oxygen therapy;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27963-0;3;Suctioning;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27964-8;4;Tracheostomy care;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27965-5;5;Ventilator or respirator;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27971-3;6;BiPAP/CPAP;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27972-1;7;IV medications;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27966-3;8;Transfusions;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA7216-0;9;Dialysis;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA6217-9;10;Hospice care;;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86760-6;LL4586-5;CMS_MDS Special procedures - not a resident;LA9-3;13;None of the above;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA6172-6;1;Chemotherapy;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA4351-8;2;Radiation;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27963-0;4;Suctioning;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27965-5;6;Ventilator or respirator;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27972-1;7;IV medications;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27966-3;8;Transfusions;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA7216-0;9;Dialysis;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA6172-6;1;Chemotherapy;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA4351-8;2;Radiation;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27963-0;4;Suctioning;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27965-5;6;Ventilator or respirator;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27972-1;7;IV medications;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27966-3;8;Transfusions;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA7216-0;9;Dialysis;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA6172-6;1;Chemotherapy;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA4351-8;2;Radiation;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27963-0;4;Suctioning;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27965-5;6;Ventilator or respirator;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27972-1;7;IV medications;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA27966-3;8;Transfusions;;; +86760-6;LL4604-6;CMS_MDS Special procedures-while not resident set1;LA7216-0;9;Dialysis;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA6172-6;1;Chemotherapy;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA4351-8;2;Radiation;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27963-0;4;Suctioning;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA28890-4;7;Non-invasive mechanical ventilator (BiPAP/CPAP);;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27972-1;8;IV medications;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27966-3;9;Transfusions;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA7216-0;10;Dialysis;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA6217-9;11;Hospice care;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA9-3;13;None of the above;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA6172-6;1;Chemotherapy;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA4351-8;2;Radiation;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27963-0;4;Suctioning;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA28890-4;7;Non-invasive mechanical ventilator (BiPAP/CPAP);;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27972-1;8;IV medications;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27966-3;9;Transfusions;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA7216-0;10;Dialysis;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA6217-9;11;Hospice care;;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86760-6;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA9-3;13;None of the above;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA6172-6;1;Chemotherapy;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA4351-8;2;Radiation;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27963-0;4;Suctioning;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA28890-4;7;Non-invasive mechanical ventilator (BiPAP/CPAP);;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27972-1;8;IV medications;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27966-3;9;Transfusions;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA7216-0;10;Dialysis;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA6217-9;11;Hospice care;;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4977-6;CMS_MDS 1.16.1 Special procedures - not a resident;LA9-3;13;None of the above;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA6172-6;1;Chemotherapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA4351-8;2;Radiation;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27963-0;4;Suctioning;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27972-1;7;IV medications;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27966-3;8;Transfusions;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA7216-0;9;Dialysis;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA6172-6;1;Chemotherapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA4351-8;2;Radiation;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27963-0;4;Suctioning;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27972-1;7;IV medications;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27966-3;8;Transfusions;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA7216-0;9;Dialysis;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA6172-6;1;Chemotherapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA4351-8;2;Radiation;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27963-0;4;Suctioning;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27972-1;7;IV medications;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27966-3;8;Transfusions;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA7216-0;9;Dialysis;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA6172-6;1;Chemotherapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA4351-8;2;Radiation;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27962-2;3;Oxygen therapy;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27963-0;4;Suctioning;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27964-8;5;Tracheostomy care;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27972-1;7;IV medications;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA27966-3;8;Transfusions;;; +86760-6;LL4978-4;CMS_MDS 1.16 Special procedures - not a resident_2;LA7216-0;9;Dialysis;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA6172-6;1;Chemotherapy;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA4351-8;2;Radiation;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA27962-2;3;Oxygen therapy;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA27963-0;4;Suctioning;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA27964-8;5;Tracheostomy care;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA27972-1;7;IV medications;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA27966-3;8;Transfusions;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA7216-0;9;Dialysis;;; +86760-6;LL5245-7;CMS_MDS 1.17 Special procedures - not a resident_1;LA9-3;10;None of the above;;; +86760-6;LL5285-3;CMS_MDS 1.17 Special procedures - dialysis;LA7216-0;1;Dialysis;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6172-6;0;Chemotherapy;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA4351-8;1;Radiation;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27962-2;2;Oxygen therapy;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27963-0;3;Suctioning;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27965-5;5;Ventilator or respirator;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27971-3;6;BiPAP/CPAP;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27972-1;7;IV medications;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27966-3;8;Transfusions;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA7216-0;9;Dialysis;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6217-9;10;Hospice care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6365-6;11;Respite care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA9-3;13;None of the above;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6172-6;0;Chemotherapy;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA4351-8;1;Radiation;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27962-2;2;Oxygen therapy;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27963-0;3;Suctioning;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27965-5;5;Ventilator or respirator;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27971-3;6;BiPAP/CPAP;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27972-1;7;IV medications;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27966-3;8;Transfusions;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA7216-0;9;Dialysis;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6217-9;10;Hospice care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6365-6;11;Respite care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA9-3;13;None of the above;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6172-6;0;Chemotherapy;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA4351-8;1;Radiation;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27962-2;2;Oxygen therapy;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27963-0;3;Suctioning;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27965-5;5;Ventilator or respirator;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27971-3;6;BiPAP/CPAP;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27972-1;7;IV medications;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27966-3;8;Transfusions;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA7216-0;9;Dialysis;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6217-9;10;Hospice care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA6365-6;11;Respite care;;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA27970-5;12;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4585-7;CMS_MDS Special procedures - while resident;LA9-3;13;None of the above;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA6172-6;1;Chemotherapy;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA4351-8;2;Radiation;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27965-5;5;Ventilator or respirator;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27972-1;6;IV medications;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27966-3;7;Transfusions;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA7216-0;8;Dialysis;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27970-5;9;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA6172-6;1;Chemotherapy;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA4351-8;2;Radiation;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27965-5;5;Ventilator or respirator;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27972-1;6;IV medications;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27966-3;7;Transfusions;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA7216-0;8;Dialysis;;; +86761-4;LL4601-2;CMS_MDS Special procedures - while resident subset;LA27970-5;9;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4602-0;CMS_MDS Special procedures-while resident subset 2;LA6217-9;1;Hospice care;;; +86761-4;LL4602-0;CMS_MDS Special procedures-while resident subset 2;LA6217-9;1;Hospice care;;; +86761-4;LL4602-0;CMS_MDS Special procedures-while resident subset 2;LA6217-9;1;Hospice care;;; +86761-4;LL4602-0;CMS_MDS Special procedures-while resident subset 2;LA6217-9;1;Hospice care;;; +86761-4;LL4602-0;CMS_MDS Special procedures-while resident subset 2;LA6217-9;1;Hospice care;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA6172-6;1;Chemotherapy;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA4351-8;2;Radiation;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27963-0;4;Suctioning;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27965-5;6;Ventilator or respirator;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27972-1;7;IV medications;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27966-3;8;Transfusions;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA7216-0;9;Dialysis;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA6217-9;10;Hospice care;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA6172-6;1;Chemotherapy;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA4351-8;2;Radiation;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27963-0;4;Suctioning;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27965-5;6;Ventilator or respirator;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27972-1;7;IV medications;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27966-3;8;Transfusions;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA7216-0;9;Dialysis;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA6217-9;10;Hospice care;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA6172-6;1;Chemotherapy;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA4351-8;2;Radiation;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27963-0;4;Suctioning;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27965-5;6;Ventilator or respirator;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27972-1;7;IV medications;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27966-3;8;Transfusions;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA7216-0;9;Dialysis;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA6217-9;10;Hospice care;;; +86761-4;LL4603-8;CMS_MDS Special procedures-while resident subset 3;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6172-6;1;Chemotherapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA4351-8;2;Radiation;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27965-5;6;Ventilator or respirator;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27972-1;7;IV medications;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27966-3;8;Transfusions;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA7216-0;9;Dialysis;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6217-9;10;Hospice care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6172-6;1;Chemotherapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA4351-8;2;Radiation;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27965-5;6;Ventilator or respirator;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27972-1;7;IV medications;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27966-3;8;Transfusions;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA7216-0;9;Dialysis;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6217-9;10;Hospice care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6172-6;1;Chemotherapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA4351-8;2;Radiation;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27965-5;6;Ventilator or respirator;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27972-1;7;IV medications;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27966-3;8;Transfusions;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA7216-0;9;Dialysis;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6217-9;10;Hospice care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6172-6;1;Chemotherapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA4351-8;2;Radiation;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27965-5;6;Ventilator or respirator;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27972-1;7;IV medications;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27966-3;8;Transfusions;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA7216-0;9;Dialysis;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA6217-9;10;Hospice care;;; +86761-4;LL4617-8;CMS_MDS Special procedures-while resident subset 4;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4621-0;CMS_MDS Special procedures-while resident subset 5;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4621-0;CMS_MDS Special procedures-while resident subset 5;LA27965-5;5;Ventilator or respirator;;; +86761-4;LL4621-0;CMS_MDS Special procedures-while resident subset 5;LA27970-5;9;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4621-0;CMS_MDS Special procedures-while resident subset 5;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4621-0;CMS_MDS Special procedures-while resident subset 5;LA27965-5;5;Ventilator or respirator;;; +86761-4;LL4621-0;CMS_MDS Special procedures-while resident subset 5;LA27970-5;9;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA27964-8;1;Tracheostomy care;;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA27965-5;2;Ventilator or respirator;;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA6217-9;3;Hospice care;;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA27970-5;4;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA27964-8;1;Tracheostomy care;;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA27965-5;2;Ventilator or respirator;;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA6217-9;3;Hospice care;;; +86761-4;LL4622-8;CMS_MDS Special procedures-while resident subset 6;LA27970-5;4;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA6172-6;1;Chemotherapy;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA4351-8;2;Radiation;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA27963-0;4;Suctioning;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA28890-4;7;Non-invasive mechanical ventilator (BiPAP/CPAP);;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA27972-1;8;IV medications;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA27966-3;9;Transfusions;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA7216-0;10;Dialysis;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA6217-9;11;Hospice care;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA6365-6;12;Respite care;;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA27970-5;13;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4979-2;CMS_MDS 16 Special procedures - while resident;LA9-3;14;None of the above;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6172-6;1;Chemotherapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA4351-8;2;Radiation;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27963-0;4;Suctioning;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27972-1;7;IV medications;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27966-3;8;Transfusions;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA7216-0;9;Dialysis;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6217-9;10;Hospice care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6172-6;1;Chemotherapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA4351-8;2;Radiation;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27963-0;4;Suctioning;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27972-1;7;IV medications;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27966-3;8;Transfusions;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA7216-0;9;Dialysis;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6217-9;10;Hospice care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6172-6;1;Chemotherapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA4351-8;2;Radiation;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27963-0;4;Suctioning;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27972-1;7;IV medications;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27966-3;8;Transfusions;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA7216-0;9;Dialysis;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6217-9;10;Hospice care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6172-6;1;Chemotherapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA4351-8;2;Radiation;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27963-0;4;Suctioning;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27964-8;5;Tracheostomy care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27972-1;7;IV medications;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27966-3;8;Transfusions;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA7216-0;9;Dialysis;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA6217-9;10;Hospice care;;; +86761-4;LL4980-0;CMS_MDS 16 Special procedures-while resident set 3;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA6172-6;1;Chemotherapy;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA4351-8;2;Radiation;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA28889-6;5;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27972-1;6;IV medications;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27966-3;7;Transfusions;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA7216-0;8;Dialysis;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA6217-9;9;Hospice care;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27970-5;10;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA6172-6;1;Chemotherapy;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA4351-8;2;Radiation;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA28889-6;5;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27972-1;6;IV medications;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27966-3;7;Transfusions;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA7216-0;8;Dialysis;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA6217-9;9;Hospice care;;; +86761-4;LL4981-8;CMS_MDS 16 Special procedures-while resident set 4;LA27970-5;10;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA6172-6;1;Chemotherapy;;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA4351-8;2;Radiation;;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA27962-2;3;Oxygen therapy;;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA27964-8;4;Tracheostomy care;;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA28889-6;5;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA27972-1;6;IV medications;;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA27966-3;7;Transfusions;;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA7216-0;8;Dialysis;;; +86761-4;LL4982-6;CMS_MDS16 Special procedures - while resident set1;LA27970-5;9;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4983-4;CMS_MDS 16 Special procedures-while resident set 5;LA27964-8;1;Tracheostomy care;;; +86761-4;LL4983-4;CMS_MDS 16 Special procedures-while resident set 5;LA28889-6;2;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4983-4;CMS_MDS 16 Special procedures-while resident set 5;LA27970-5;3;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL4984-2;CMS_MDS 16 Special procedures-while resident set 6;LA27964-8;1;Tracheostomy care;;; +86761-4;LL4984-2;CMS_MDS 16 Special procedures-while resident set 6;LA28889-6;2;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL4984-2;CMS_MDS 16 Special procedures-while resident set 6;LA6217-9;3;Hospice care;;; +86761-4;LL4984-2;CMS_MDS 16 Special procedures-while resident set 6;LA27970-5;4;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA6172-6;1;Chemotherapy;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA4351-8;2;Radiation;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA27962-2;3;Oxygen therapy;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA27963-0;4;Suctioning;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA27964-8;5;Tracheostomy care;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA27972-1;7;IV medications;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA27966-3;8;Transfusions;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA7216-0;9;Dialysis;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA6217-9;10;Hospice care;;; +86761-4;LL5237-4;CMS_MDS 17 Special procedures-while resident set 1;LA27970-5;11;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA6172-6;1;Chemotherapy;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA4351-8;2;Radiation;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27962-2;3;Oxygen therapy;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27963-0;4;Suctioning;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27964-8;5;Tracheostomy care;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27972-1;7;IV medications;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27966-3;8;Transfusions;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA7216-0;9;Dialysis;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27970-5;10;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA9-3;11;None of the above;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA6172-6;1;Chemotherapy;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA4351-8;2;Radiation;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27962-2;3;Oxygen therapy;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27963-0;4;Suctioning;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27964-8;5;Tracheostomy care;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27972-1;7;IV medications;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27966-3;8;Transfusions;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA7216-0;9;Dialysis;;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA27970-5;10;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL5244-0;CMS_MDS 17 Special procedures set 2;LA9-3;11;None of the above;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA6172-6;1;Chemotherapy;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA4351-8;2;Radiation;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA27962-2;3;Oxygen therapy;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA27963-0;4;Suctioning;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA27964-8;5;Tracheostomy care;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA28889-6;6;Invasive mechanical ventilator (ventilator or respirator);;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA30281-2;7;Non-invasive mechanical ventilator;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA27972-1;8;IV medications;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA27966-3;9;Transfusions;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA7216-0;10;Dialysis;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA6217-9;12;Hospice care;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA27970-5;13;Isolation or quarantine for active infectious disease (does not include standard body/fluid precautions);;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA30290-3;14;IV Access;;; +86761-4;LL6301-7;***** CLONED FROM - LL5385-1 *****;LA9-3;18;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11019-9;1;Resident;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA11116-3;2;If not resident, then family or significant other;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA12652-6;3;If not resident, family, or significant other, then guardian or legally authorized representative;;; +86798-6;LL4589-9;CMS_MED Resident | If not resident;LA9-3;4;None of the above;;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA28332-7;1;Not fully liberated at discharge (i.e., patient required partial or full invasive mechanical ventilation support within 2 calendar days prior to discharge);;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA28333-5;2;Fully liberated at discharge (i.e., patient did not require any invasive mechanical ventilation support for at least 2 consecutive calendar days immediately prior to discharge);;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA12334-1;3;;;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA28332-7;1;Not fully liberated at discharge (i.e., patient required partial or full invasive mechanical ventilation support within 2 calendar days prior to discharge);;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA28333-5;2;Fully liberated at discharge (i.e., patient did not require any invasive mechanical ventilation support for at least 2 consecutive calendar days immediately prior to discharge);;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA12334-1;3;;;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA28332-7;1;Not fully liberated at discharge (i.e., patient required partial or full invasive mechanical ventilation support within 2 calendar days prior to discharge);;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA28333-5;2;Fully liberated at discharge (i.e., patient did not require any invasive mechanical ventilation support for at least 2 consecutive calendar days immediately prior to discharge);;; +86851-3;LL4713-5;CMS_LCDS Ventilator liberation;LA12334-1;3;;;; +86851-3;LL5407-3;CMS_LCDS v5.0 - Ventilator Liberation;LA28332-7;1;Not fully liberated at discharge (i.e., patient required partial or full invasive mechanical ventilation support within 2 calendar days prior to discharge);;; +86851-3;LL5407-3;CMS_LCDS v5.0 - Ventilator Liberation;LA28333-5;2;Fully liberated at discharge (i.e., patient did not require any invasive mechanical ventilation support for at least 2 consecutive calendar days immediately prior to discharge);;; +86851-3;LL5407-3;CMS_LCDS v5.0 - Ventilator Liberation;LA30356-2;4;Not applicable (code only if the patient was not on invasive mechanical ventilator support upon admission [O0150A = 0] or the patient was determined to be non-weaning upon admission [O0150A2 = 0]);;; +86851-3;LL5407-3;CMS_LCDS v5.0 - Ventilator Liberation;LA28332-7;1;Not fully liberated at discharge (i.e., patient required partial or full invasive mechanical ventilation support within 2 calendar days prior to discharge);;; +86851-3;LL5407-3;CMS_LCDS v5.0 - Ventilator Liberation;LA28333-5;2;Fully liberated at discharge (i.e., patient did not require any invasive mechanical ventilation support for at least 2 consecutive calendar days immediately prior to discharge);;; +86851-3;LL5407-3;CMS_LCDS v5.0 - Ventilator Liberation;LA30356-2;4;Not applicable (code only if the patient was not on invasive mechanical ventilator support upon admission [O0150A = 0] or the patient was determined to be non-weaning upon admission [O0150A2 = 0]);;; +86900-8;LL4476-9;Plasma cell monotypic population type;LA27565-3;1;No monotypic plasma cells;;; +86900-8;LL4476-9;Plasma cell monotypic population type;LA27566-1;2;Monotypic kappa plasma cells;;; +86900-8;LL4476-9;Plasma cell monotypic population type;LA27567-9;3;Monotypic lambda plasma cells;;; +86900-8;LL4476-9;Plasma cell monotypic population type;LA27568-7;4;Suspicious for kappa plasma cells;;; +86900-8;LL4476-9;Plasma cell monotypic population type;LA27569-5;5;Suspicious for lambda plasma cells;;; +86900-8;LL4476-9;Plasma cell monotypic population type;LA27570-3;6;Light-chain negative plasma cells;;; +93362-2;LL4476-9;Plasma cell monotypic population type;LA27565-3;1;No monotypic plasma cells;;; +93362-2;LL4476-9;Plasma cell monotypic population type;LA27566-1;2;Monotypic kappa plasma cells;;; +93362-2;LL4476-9;Plasma cell monotypic population type;LA27567-9;3;Monotypic lambda plasma cells;;; +93362-2;LL4476-9;Plasma cell monotypic population type;LA27568-7;4;Suspicious for kappa plasma cells;;; +93362-2;LL4476-9;Plasma cell monotypic population type;LA27569-5;5;Suspicious for lambda plasma cells;;; +93362-2;LL4476-9;Plasma cell monotypic population type;LA27570-3;6;Light-chain negative plasma cells;;; +86903-2;LL4625-1;CMS_MDS Pressure ulcer tissue type;LA11082-7;1;Epithelial tissue - new skin growing in superficial ulcer. It can be light pink and shiny, even in persons with darkly pigmented skin.;;; +86903-2;LL4625-1;CMS_MDS Pressure ulcer tissue type;LA11083-5;2;Granulation tissue - pink or red tissue with shiny, moist, granular appearance;;; +86903-2;LL4625-1;CMS_MDS Pressure ulcer tissue type;LA11084-3;3;Slough - yellow or white tissue that adheres to the ulcer bed in strings or thick clumps, or is mucinous;;; +86903-2;LL4625-1;CMS_MDS Pressure ulcer tissue type;LA28022-4;4;Eschar - black, brown, or tan tissue that adheres firmly to the wound bed or ulcer edges, may be softer or harder than surrounding skin;;; +86903-2;LL4625-1;CMS_MDS Pressure ulcer tissue type;LA9-3;5;None of the above;;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28049-7;1;Etiology and progressive nature of chronic kidney disease (CKD);;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28050-5;2;Complications or symptoms from untreated or progressive kidney disease;;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28051-3;3;Prevention and risk factors for decline, including avoidance of acute kidney injury (AKI);;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28052-1;4;Renal replacement therapy: Hemodialysis, in-center and home;;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28053-9;5;Renal replacement therapy: Peritoneal dialysis;;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28054-7;6;Renal replacement therapy: Kidney transplantation;;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28055-4;7;Conservative management of chronic kidney disease (CKD);;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA28056-2;8;Nutrition/diet;;; +86906-5;LL4636-8;NIDDK_CKD education topics;LA46-8;9;Other;;; +86907-3;LL4635-0;NIDDK_Patient understanding of discussion;LA8913-1;1;Adequate;;; +86907-3;LL4635-0;NIDDK_Patient understanding of discussion;LA28048-9;2;Inadequate or not discussed;;; +86932-1;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86932-1;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86932-1;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86932-1;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86932-1;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86934-7;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86934-7;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86934-7;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86934-7;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86934-7;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86935-4;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86935-4;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86935-4;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86935-4;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86935-4;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86936-2;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86936-2;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86936-2;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86936-2;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86936-2;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86937-0;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86937-0;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86937-0;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86937-0;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86937-0;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86938-8;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86938-8;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86938-8;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86938-8;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86938-8;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86939-6;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86939-6;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86939-6;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86939-6;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86939-6;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86940-4;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86940-4;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86940-4;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86940-4;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86940-4;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86941-2;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86941-2;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86941-2;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86941-2;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86941-2;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86942-0;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86942-0;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86942-0;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86942-0;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86942-0;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86943-8;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86943-8;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86943-8;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86943-8;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86943-8;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86944-6;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86944-6;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86944-6;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86944-6;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86944-6;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +86945-3;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +86945-3;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +86945-3;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +86945-3;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +86945-3;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87676-3;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87676-3;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87676-3;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87676-3;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87676-3;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87677-1;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87677-1;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87677-1;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87677-1;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87677-1;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87678-9;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87678-9;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87678-9;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87678-9;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87678-9;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87679-7;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87679-7;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87679-7;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87679-7;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87679-7;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87680-5;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87680-5;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87680-5;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87680-5;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87680-5;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87681-3;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87681-3;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87681-3;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87681-3;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87681-3;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87682-1;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87682-1;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87682-1;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87682-1;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87682-1;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87683-9;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87683-9;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87683-9;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87683-9;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87683-9;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87684-7;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87684-7;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87684-7;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87684-7;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87684-7;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87685-4;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87685-4;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87685-4;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87685-4;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87685-4;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87686-2;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87686-2;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87686-2;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87686-2;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87686-2;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87687-0;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87687-0;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87687-0;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87687-0;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87687-0;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87688-8;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87688-8;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87688-8;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87688-8;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87688-8;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87690-4;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87690-4;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87690-4;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87690-4;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87690-4;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87691-2;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87691-2;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87691-2;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87691-2;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87691-2;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87692-0;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87692-0;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87692-0;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87692-0;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87692-0;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87693-8;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87693-8;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87693-8;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87693-8;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87693-8;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87694-6;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87694-6;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87694-6;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87694-6;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87694-6;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87695-3;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87695-3;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87695-3;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87695-3;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87695-3;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87696-1;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87696-1;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87696-1;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87696-1;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87696-1;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87697-9;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87697-9;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87697-9;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87697-9;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87697-9;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87698-7;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87698-7;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87698-7;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87698-7;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87698-7;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87699-5;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87699-5;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87699-5;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87699-5;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87699-5;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87700-1;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87700-1;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87700-1;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87700-1;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87700-1;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87701-9;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87701-9;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87701-9;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87701-9;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87701-9;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +87702-7;LL4638-4;DS | D | A | AS | NA;LA16642-3;1;Disagree strongly;;; +87702-7;LL4638-4;DS | D | A | AS | NA;LA15773-7;2;Disagree;;; +87702-7;LL4638-4;DS | D | A | AS | NA;LA15774-5;3;Agree;;; +87702-7;LL4638-4;DS | D | A | AS | NA;LA15357-9;4;Agree strongly;;; +87702-7;LL4638-4;DS | D | A | AS | NA;LA4543-0;5;;;; +8693-4;LL5028-7;German DIMD_Mental status;LA17286-8;1;Normal baseline for patient;;; +8693-4;LL5028-7;German DIMD_Mental status;LA27144-7;2;Cannot be assessed;;; +8693-4;LL5028-7;German DIMD_Mental status;LA7438-0;3;Hallucinations;;; +8693-4;LL5028-7;German DIMD_Mental status;LA6150-2;4;Agitation;;; +8693-4;LL5028-7;German DIMD_Mental status;LA29197-3;5;Depressed;;; +8693-4;LL5028-7;German DIMD_Mental status;LA6560-2;6;Confused;;; +8693-4;LL5028-7;German DIMD_Mental status;LA17287-6;7;Combative;;; +8693-4;LL5028-7;German DIMD_Mental status;LA10574-4;8;Anxiety;;; +8693-4;LL5028-7;German DIMD_Mental status;LA29198-1;9;Suicidal;;; +8693-4;LL5028-7;German DIMD_Mental status;LA17666-1;10;Stupor;89458003;stupor (finding);http://snomed.info/sct +8693-4;LL5028-7;German DIMD_Mental status;LA29200-5;11;Euphoric;;; +8693-4;LL5028-7;German DIMD_Mental status;LA16474-1;12;Restless;;; +8693-4;LL5028-7;German DIMD_Mental status;LA46-8;13;Other;;; +8693-4;LL5028-7;German DIMD_Mental status;LA9348-9;14;Not assessed;;; +8693-4;LL5028-7;German DIMD_Mental status;LA17286-8;1;Normal baseline for patient;;; +8693-4;LL5028-7;German DIMD_Mental status;LA27144-7;2;Cannot be assessed;;; +8693-4;LL5028-7;German DIMD_Mental status;LA7438-0;3;Hallucinations;;; +8693-4;LL5028-7;German DIMD_Mental status;LA6150-2;4;Agitation;;; +8693-4;LL5028-7;German DIMD_Mental status;LA29197-3;5;Depressed;;; +8693-4;LL5028-7;German DIMD_Mental status;LA6560-2;6;Confused;;; +8693-4;LL5028-7;German DIMD_Mental status;LA17287-6;7;Combative;;; +8693-4;LL5028-7;German DIMD_Mental status;LA10574-4;8;Anxiety;;; +8693-4;LL5028-7;German DIMD_Mental status;LA29198-1;9;Suicidal;;; +8693-4;LL5028-7;German DIMD_Mental status;LA17666-1;10;Stupor;89458003;stupor (finding);http://snomed.info/sct +8693-4;LL5028-7;German DIMD_Mental status;LA29200-5;11;Euphoric;;; +8693-4;LL5028-7;German DIMD_Mental status;LA16474-1;12;Restless;;; +8693-4;LL5028-7;German DIMD_Mental status;LA46-8;13;Other;;; +8693-4;LL5028-7;German DIMD_Mental status;LA9348-9;14;Not assessed;;; +8693-4;LL6327-2;Schmid mentation;LA33647-1;5;Alert, oriented x3;;; +8693-4;LL6327-2;Schmid mentation;LA33648-9;6;Periodic confusion;;; +8693-4;LL6327-2;Schmid mentation;LA33649-7;7;Confusion at all times;;; +8693-4;LL6327-2;Schmid mentation;LA33650-5;8;Comatose/unresponsive;;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28842-5;1;Chest pain;;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28843-3;2;Heart attack (myocardial infarction);;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28844-1;3;Non-surgical heart artery balloon/stent procedure (percutaneous coronary intervention);;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28845-8;4;Heart bypass surgery (coronary artery bypass graft surgery);;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28846-6;5;Temporary stroke like symptoms (TIA - transient ischemic attack/mini-stroke);;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA22099-8;6;Stroke;;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28848-2;7;Major bleeding episode that required a blood transfusion;;; +86947-9;LL4968-5;ADAPTABLE Reasons for hospitalization;LA9-3;8;None of the above;;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28842-5;1;Chest pain;;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28843-3;2;Heart attack (myocardial infarction);;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28844-1;3;Non-surgical heart artery balloon/stent procedure (percutaneous coronary intervention);;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28845-8;4;Heart bypass surgery (coronary artery bypass graft surgery);;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28846-6;5;Temporary stroke like symptoms (TIA - transient ischemic attack/mini-stroke);;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA22099-8;6;Stroke;;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA28848-2;7;Major bleeding episode that required a blood transfusion;;; +89079-8;LL4968-5;ADAPTABLE Reasons for hospitalization;LA9-3;8;None of the above;;; +86953-7;LL4421-5;Prescreen Influenza Sample;LA27298-1;1;Influenza A;;; +86953-7;LL4421-5;Prescreen Influenza Sample;LA26146-3;2;Influenza B;;; +86953-7;LL4421-5;Prescreen Influenza Sample;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +86953-7;LL4421-5;Prescreen Influenza Sample;LA46-8;4;Other;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA6630-3;1;Not done;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA17286-8;2;Normal baseline for patient;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32341-2;3;Single-sided symptoms (pupil, extremities);;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32340-4;4;No smile;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA31047-6;5;Vision impairment;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA17315-5;6;Speech impaired;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA20372-1;7;Dementia;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32339-6;8;Paraplegic symptoms;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32338-8;9;Babinski sign;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA17660-4;10;Meningismus;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32337-0;11;Pre-existing neurological condition;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA46-8;12;Other;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32336-2;13;Unable to assess/Inconclusive results;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA6630-3;1;Not done;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA17286-8;2;Normal baseline for patient;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32341-2;3;Single-sided symptoms (pupil, extremities);;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32340-4;4;No smile;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA31047-6;5;Vision impairment;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA17315-5;6;Speech impaired;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA20372-1;7;Dementia;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32339-6;8;Paraplegic symptoms;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32338-8;9;Babinski sign;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA17660-4;10;Meningismus;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32337-0;11;Pre-existing neurological condition;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA46-8;12;Other;;; +8705-6;LL5973-4;DIMDI_Neurological assessment;LA32336-2;13;Unable to assess/Inconclusive results;;; +8709-8;LL5027-9;Physical findings of skin;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +8709-8;LL5027-9;Physical findings of skin;LA18219-8;2;Tenting;;; +8709-8;LL5027-9;Physical findings of skin;LA22310-9;3;Decubitus;;; +8709-8;LL5027-9;Physical findings of skin;LA19035-7;4;Edematous;;; +8709-8;LL5027-9;Physical findings of skin;LA29194-0;5;Exanthema;;; +8709-8;LL5027-9;Physical findings of skin;LA18217-2;6;Diaphoretic;;; +8709-8;LL5027-9;Physical findings of skin;LA15475-9;7;Cold;;; +8709-8;LL5027-9;Physical findings of skin;LA17197-7;8;Clammy;;; +8709-8;LL5027-9;Physical findings of skin;LA29195-7;9;Pathological findings;;; +8709-8;LL5027-9;Physical findings of skin;LA9348-9;10;Not assessed;;; +8709-8;LL5027-9;Physical findings of skin;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +8709-8;LL5027-9;Physical findings of skin;LA18219-8;2;Tenting;;; +8709-8;LL5027-9;Physical findings of skin;LA22310-9;3;Decubitus;;; +8709-8;LL5027-9;Physical findings of skin;LA19035-7;4;Edematous;;; +8709-8;LL5027-9;Physical findings of skin;LA29194-0;5;Exanthema;;; +8709-8;LL5027-9;Physical findings of skin;LA18217-2;6;Diaphoretic;;; +8709-8;LL5027-9;Physical findings of skin;LA15475-9;7;Cold;;; +8709-8;LL5027-9;Physical findings of skin;LA17197-7;8;Clammy;;; +8709-8;LL5027-9;Physical findings of skin;LA29195-7;9;Pathological findings;;; +8709-8;LL5027-9;Physical findings of skin;LA9348-9;10;Not assessed;;; +87212-7;LL4663-2;CMS_MDS Care area;LA7426-5;0;Delirium;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28159-4;1;Cognitive loss/dementia;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28160-2;2;Visual function;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28161-0;3;Communication;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28162-8;4;ADL functional/rehabilitation potential;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28163-6;5;Urinary incontinence and indwelling catheter;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28165-1;6;Psychosocial well-being;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28166-9;7;Mood state;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28167-7;8;Behavioral symptoms;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28168-5;9;Activities;;; +87212-7;LL4663-2;CMS_MDS Care area;LA17133-2;10;Falls;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28169-3;11;Nutritional status;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28170-1;12;Feeding tube;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28171-9;13;Dehydration/fluid maintenance;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28172-7;14;Dental care;;; +87212-7;LL4663-2;CMS_MDS Care area;LA19028-2;15;Pressure ulcer;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28173-5;16;Psychotropic drug use;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28174-3;17;Physical restraints;;; +87212-7;LL4663-2;CMS_MDS Care area;LA7460-4;18;Pain;;; +87212-7;LL4663-2;CMS_MDS Care area;LA28175-0;19;Return to community referral;;; +87213-5;LL4663-2;CMS_MDS Care area;LA7426-5;0;Delirium;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28159-4;1;Cognitive loss/dementia;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28160-2;2;Visual function;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28161-0;3;Communication;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28162-8;4;ADL functional/rehabilitation potential;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28163-6;5;Urinary incontinence and indwelling catheter;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28165-1;6;Psychosocial well-being;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28166-9;7;Mood state;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28167-7;8;Behavioral symptoms;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28168-5;9;Activities;;; +87213-5;LL4663-2;CMS_MDS Care area;LA17133-2;10;Falls;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28169-3;11;Nutritional status;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28170-1;12;Feeding tube;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28171-9;13;Dehydration/fluid maintenance;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28172-7;14;Dental care;;; +87213-5;LL4663-2;CMS_MDS Care area;LA19028-2;15;Pressure ulcer;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28173-5;16;Psychotropic drug use;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28174-3;17;Physical restraints;;; +87213-5;LL4663-2;CMS_MDS Care area;LA7460-4;18;Pain;;; +87213-5;LL4663-2;CMS_MDS Care area;LA28175-0;19;Return to community referral;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA7512-2;0;Transcription error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28176-8;1;Data entry error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28177-6;2;Software product error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28178-4;3;Item coding error;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28179-2;4;End of Therapy - Resumption (EOT-R) date;;; +87217-6;LL4664-0;CMS_MDS Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA7512-2;1;Transcription error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28176-8;2;Data entry error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28177-6;3;Software product error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28178-4;4;Item coding error;;; +87217-6;LL5248-1;CMS_MDS 17 Reason for modification;LA28180-0;5;Other error requiring modification;;; +87225-9;LL4665-7;CMS_MDS Reasons for inactivation;LA28181-8;0;Event did not occur;;; +87225-9;LL4665-7;CMS_MDS Reasons for inactivation;LA28183-4;1;Other error requiring inactivation;;; +87292-9;LL4662-4;Name not yet chosen;LA28158-6;0;Name not yet chosen;;; +87293-7;LL4631-9;Father of baby | Other relative |Hospital employee;LA28031-5;0;Father of baby;;; +87293-7;LL4631-9;Father of baby | Other relative |Hospital employee;LA15640-8;1;Other relative;;; +87293-7;LL4631-9;Father of baby | Other relative |Hospital employee;LA28032-3;2;Hospital employee;;; +87293-7;LL4631-9;Father of baby | Other relative |Hospital employee;LA46-8;3;Other;;; +87302-6;LL4660-8;PHVS_YesNoNotApplicable_NCHS;;0;;;; +87304-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87304-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87304-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87304-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87305-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87305-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87305-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87305-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87306-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87306-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87306-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87306-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87307-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87307-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87307-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87307-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87313-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87313-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87313-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87313-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87314-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87314-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87314-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87314-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87315-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87315-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87315-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87315-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87316-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87316-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87316-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87316-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87382-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87382-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87382-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87382-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87388-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87388-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87388-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87388-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87397-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87397-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87397-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87397-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87399-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +87399-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87399-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +87399-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +90324-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90324-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90324-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +90324-5;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +93755-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93755-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93755-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +93755-7;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +93758-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93758-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93758-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +93758-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94507-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94507-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94507-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94507-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94508-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94508-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94508-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94508-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94597-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94597-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94597-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94597-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94598-0;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94598-0;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94598-0;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94598-0;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94599-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94599-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94599-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94599-8;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94600-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94600-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94600-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94600-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94601-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94601-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94601-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94601-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94618-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94618-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94618-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94618-6;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94619-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94619-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94619-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94619-4;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94620-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +94620-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +94620-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +94620-2;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96355-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96355-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96355-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +96355-3;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96356-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96356-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96356-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +96356-1;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96357-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96357-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96357-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA15291-0;2;Suspected;;; +96357-9;LL4623-6;Pos|Neg|Suspect|Invalid;LA15841-2;3;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +87337-2;LL4639-2;RFLP pattern;LA28063-8;1;1-1-2;;; +87337-2;LL4639-2;RFLP pattern;LA28061-2;2;4-2-2;;; +87337-2;LL4639-2;RFLP pattern;LA28060-4;3;3-2-1;;; +87337-2;LL4639-2;RFLP pattern;LA28062-0;4;?-2-1;;; +87338-0;LL4518-8;PCV2a, PCV2b, PCV2c, m PCV2b, PCV2d, PCV2e;LA27674-3;1;PCV2a;;; +87338-0;LL4518-8;PCV2a, PCV2b, PCV2c, m PCV2b, PCV2d, PCV2e;LA27676-8;2;PCV2b;;; +87338-0;LL4518-8;PCV2a, PCV2b, PCV2c, m PCV2b, PCV2d, PCV2e;LA27677-6;3;PCV2c;;; +87338-0;LL4518-8;PCV2a, PCV2b, PCV2c, m PCV2b, PCV2d, PCV2e;LA27678-4;4;m PCV2b;;; +87338-0;LL4518-8;PCV2a, PCV2b, PCV2c, m PCV2b, PCV2d, PCV2e;LA27679-2;5;PCV2d;;; +87338-0;LL4518-8;PCV2a, PCV2b, PCV2c, m PCV2b, PCV2d, PCV2e;LA27680-0;6;PCV2e;;; +87369-5;LL4641-8;Lawsonia VNTR pattern;LA28067-9;1;0-7-12-0;;; +87369-5;LL4641-8;Lawsonia VNTR pattern;LA28064-6;2;13-11-13-10;;; +87369-5;LL4641-8;Lawsonia VNTR pattern;LA28065-3;3;14-8-14-8;;; +87369-5;LL4641-8;Lawsonia VNTR pattern;LA28066-1;4;16-8-0-0;;; +87410-7;LL4462-9;High | Normal;LA9193-9;1;High;;; +87410-7;LL4462-9;High | Normal;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +87413-1;LL4633-5;Brachyspira species;LA28057-0;6;Brachyspira hyodysenteriae;113515000;Brachyspira hyodysenteriae (organism);http://snomed.info/sct +87413-1;LL4633-5;Brachyspira species;LA28034-9;7;Brachyspira hampsonii;;; +87413-1;LL4633-5;Brachyspira species;LA28035-6;8;Brachyspira pilosicoli;113517008;Brachyspira pilosicoli (organism);http://snomed.info/sct +87413-1;LL4633-5;Brachyspira species;LA28036-4;9;Brachyspira intermedia;;; +87413-1;LL4633-5;Brachyspira species;LA28037-2;10;Brachyspira murdochii;3421000146106;Brachyspira murdochii (organism);http://snomed.info/sct +87413-1;LL4633-5;Brachyspira species;LA28038-0;11;Brachyspira innocens;113516004;Brachyspira innocens (organism);http://snomed.info/sct +87419-8;LL4669-9;Inconsist with IBS | Consist with IBS;LA28184-2;1;Inconsistent with IBS;;; +87419-8;LL4669-9;Inconsist with IBS | Consist with IBS;LA28185-9;2;Consistent with IBS;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28039-8;1;Results suggest the absence of Zika and dengue antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28040-6;2;Results suggest the presence of Zika and dengue antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28041-4;3;Results suggest the presence of dengue antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28043-0;4;Results suggest the presence of Zika antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28042-2;5;Results suggest the presence of Zika antibodies and indeterminate for dengue antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28044-8;6;Indeterminate results for the presence of Zika antibodies and nonreactive for dengue antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28045-5;7;Indeterminate results for the presence of Zika antibodies and reactive for dengue antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28046-3;8;Nonreactive results for the presence of Zika antibodies and indeterminate for dengue antibodies.;;; +87438-8;LL4634-3;Zika and Dengue Ab results;LA28047-1;9;Indeterminate results for the presence of both Zika and dengue antibodies.;;; +87514-6;LL4629-3;NTDB_Cerebral Monitor;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +87514-6;LL4629-3;NTDB_Cerebral Monitor;LA28024-0;1;Intraventricular drain/catheter;;; +87514-6;LL4629-3;NTDB_Cerebral Monitor;LA28025-7;2;Intraparenchymal pressure monitor;;; +87514-6;LL4629-3;NTDB_Cerebral Monitor;LA28026-5;3;Intraparenchymal oxygen monitor;;; +87514-6;LL4629-3;NTDB_Cerebral Monitor;LA28027-3;4;Jugular venous bulb monitor;;; +87515-3;LL4630-1;NTDB_Pupillary response findings_both pupils;LA28028-1;1;Both reactive;;; +87515-3;LL4630-1;NTDB_Pupillary response findings_both pupils;LA28029-9;2;One reactive;;; +87515-3;LL4630-1;NTDB_Pupillary response findings_both pupils;LA28030-7;3;Neither reactive;;; +87520-3;LL4668-1;Coverage Type and Self-Pay Codes;;0;;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28299-8;1;Maximize length of life;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28300-4;2;Maximize quality of life;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28301-2;3;Maximize ability to function;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28302-0;4;Avoid major health events;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28303-8;5;Manage symptoms;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28304-6;6;Address mental health issues;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA46-8;7;Other;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28299-8;1;Maximize length of life;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28300-4;2;Maximize quality of life;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28301-2;3;Maximize ability to function;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28302-0;4;Avoid major health events;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28303-8;5;Manage symptoms;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA28304-6;6;Address mental health issues;;; +87528-6;LL4705-1;NIDDK_patient health goals;LA46-8;7;Other;;; +87529-4;LL4706-9;NIDDK_functional areas;LA28305-3;1;Performing activities of daily living;;; +87529-4;LL4706-9;NIDDK_functional areas;LA28306-1;2;Having sex;;; +87529-4;LL4706-9;NIDDK_functional areas;LA28307-9;3;Reproductive function;;; +87529-4;LL4706-9;NIDDK_functional areas;LA28308-7;4;Cognitive function;;; +87529-4;LL4706-9;NIDDK_functional areas;LA46-8;5;Other;;; +87530-2;LL4707-7;NIDDK_Health events;LA15417-1;1;Hospitalization;;; +87530-2;LL4707-7;NIDDK_Health events;LA28309-5;2;Disease progression;;; +87530-2;LL4707-7;NIDDK_Health events;LA28310-3;3;New disease diagnosis;;; +87530-2;LL4707-7;NIDDK_Health events;LA16993-0;4;Hypoglycemia;;; +87530-2;LL4707-7;NIDDK_Health events;LA46-8;5;Other;;; +87531-0;LL4708-5;NIDDK_Symptoms;LA7460-4;1;Pain;;; +87531-0;LL4708-5;NIDDK_Symptoms;LA20641-9;2;Itching;418290006;Itching (finding);http://snomed.info/sct +87531-0;LL4708-5;NIDDK_Symptoms;LA27492-0;3;Cramping;;; +87531-0;LL4708-5;NIDDK_Symptoms;LA15098-9;4;Nausea;;; +87531-0;LL4708-5;NIDDK_Symptoms;LA7542-9;5;Fatigue;;; +87531-0;LL4708-5;NIDDK_Symptoms;LA28314-5;6;Sexual dysfunction;;; +87531-0;LL4708-5;NIDDK_Symptoms;LA6436-5;7;Urinary incontinence;;; +87531-0;LL4708-5;NIDDK_Symptoms;LA46-8;8;Other;;; +87532-8;LL4709-3;NIDDK_Mental health issues;LA10576-9;1;Depression;;; +87532-8;LL4709-3;NIDDK_Mental health issues;LA10574-4;2;Anxiety;;; +87532-8;LL4709-3;NIDDK_Mental health issues;LA28315-2;3;Coping with diagnosis;;; +87532-8;LL4709-3;NIDDK_Mental health issues;LA46-8;4;Other;;; +87535-1;LL4710-1;NIDDK_Challenges;LA28316-0;1;Financial concerns;;; +87535-1;LL4710-1;NIDDK_Challenges;LA28317-8;2;Lack of insurance;;; +87535-1;LL4710-1;NIDDK_Challenges;LA28318-6;3;Side effects;;; +87535-1;LL4710-1;NIDDK_Challenges;LA28319-4;4;Transportation limitations;;; +87535-1;LL4710-1;NIDDK_Challenges;LA28320-2;5;Schedule/time challenges;;; +87535-1;LL4710-1;NIDDK_Challenges;LA7545-2;6;Stress;;; +87535-1;LL4710-1;NIDDK_Challenges;LA28321-0;7;Lack of neighborhood resources (e.g., supermarkets, side walks);;; +87535-1;LL4710-1;NIDDK_Challenges;LA28322-8;8;Low health literacy;;; +87535-1;LL4710-1;NIDDK_Challenges;LA46-8;9;Other;;; +87536-9;LL4711-9;NIDDK_Treatment affected by challenges;LA28323-6;1;Taking medications;;; +87536-9;LL4711-9;NIDDK_Treatment affected by challenges;LA28324-4;2;Following diet plan;;; +87536-9;LL4711-9;NIDDK_Treatment affected by challenges;LA28325-1;3;Following physical activity plan;;; +87536-9;LL4711-9;NIDDK_Treatment affected by challenges;LA28326-9;4;Quitting smoking;;; +87536-9;LL4711-9;NIDDK_Treatment affected by challenges;LA28327-7;5;Attending appointments;;; +87536-9;LL4711-9;NIDDK_Treatment affected by challenges;LA28328-5;6;Understanding disease status;;; +87536-9;LL4711-9;NIDDK_Treatment affected by challenges;LA46-8;7;Other;;; +87539-3;LL4712-7;CMS_LCDS Ventilation support;LA28329-3;1;No, not on invasive mechanical ventilation support;;; +87539-3;LL4712-7;CMS_LCDS Ventilation support;LA28330-1;2;Yes, weaning;;; +87539-3;LL4712-7;CMS_LCDS Ventilation support;LA28331-9;3;Yes, non-weaning;;; +87539-3;LL4712-7;CMS_LCDS Ventilation support;LA28329-3;1;No, not on invasive mechanical ventilation support;;; +87539-3;LL4712-7;CMS_LCDS Ventilation support;LA28330-1;2;Yes, weaning;;; +87539-3;LL4712-7;CMS_LCDS Ventilation support;LA28331-9;3;Yes, non-weaning;;; +87539-3;LL5405-7;CMS_LCDS - Spontaneous Breathing (O0150);LA28329-3;1;No, not on invasive mechanical ventilation support;;; +87539-3;LL5405-7;CMS_LCDS - Spontaneous Breathing (O0150);LA30353-9;2;Yes, on invasive mechanical ventilation support upon admission;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28073-7;1;Enlisted Military Personnel 1;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28074-5;2;Enlisted Military Personnel 2;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28075-2;3;Enlisted Military Personnel 3;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28076-0;4;Enlisted Military Personnel 4;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28077-8;5;Enlisted Military Personnel 5;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28089-3;6;Enlisted Military Personnel 6;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28090-1;7;Enlisted Military Personnel 7;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28091-9;8;Enlisted Military Personnel 8;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28092-7;9;Enlisted Military Personnel 9;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28093-5;10;Commissioned Officer 1;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28094-3;11;Commissioned Officer 2;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28095-0;12;Commissioned Officer 3;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28096-8;13;Commissioned Officer 4;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28097-6;14;Commissioned Officer 5;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28098-4;15;Commissioned Officer 6;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28099-2;16;Commissioned Officer 7;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28100-8;17;Commissioned Officer 8;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28101-6;18;Commissioned Officer 9;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28102-4;19;Commissioned Officer 10;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28103-2;20;Warrant Officer 1;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28104-0;21;Warrant Officer 2;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28105-7;22;Warrant Officer 3;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28106-5;24;Warrant Officer 4;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28107-3;25;Warrant Officer 5;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28108-1;26;Civilian 1st Line Supervisor;;; +87707-6;LL4644-2;NIOSH_Supervisory level;LA28109-9;27;Civilian Manager;;; +87829-8;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87829-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +87829-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +87829-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +87829-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +87830-6;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +87830-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +87830-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +87830-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +87830-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +96270-4;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96270-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +96270-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +96270-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +96270-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99859-1;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99859-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99859-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99859-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99859-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99863-3;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99863-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99863-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99863-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99863-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99865-8;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99865-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99865-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99865-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99865-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99869-0;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99869-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99869-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99869-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99869-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99872-4;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99872-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99872-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99872-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99872-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99875-7;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99875-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99875-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99875-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99875-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99878-1;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99878-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99878-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99878-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99878-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99881-5;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99881-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99881-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99881-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99881-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99885-6;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99885-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99885-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99885-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99885-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99888-0;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99888-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99888-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99888-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99888-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99891-4;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99891-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99891-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99891-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99891-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99894-8;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99894-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99894-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99894-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99894-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99897-1;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99897-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99897-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99897-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99897-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99900-3;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99900-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99900-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99900-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99900-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99903-7;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99903-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99903-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99903-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99903-7;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99909-4;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99909-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99909-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99909-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99909-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99912-8;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99912-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99912-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99912-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99912-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99915-1;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99915-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99915-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99915-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99915-1;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99918-5;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99918-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99918-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99918-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99918-5;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99921-9;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99921-9;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99921-9;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99921-9;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99921-9;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99924-3;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99924-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99924-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99924-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99924-3;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99926-8;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99926-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99926-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99926-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99926-8;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99928-4;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99928-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99928-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99928-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99928-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99930-0;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99930-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99930-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99930-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99930-0;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99932-6;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99932-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99932-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99932-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99932-6;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +99933-4;LL3105-5;Neg, 1+,2+,3+,4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +99933-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11841-6;1;1+;;; +99933-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11842-4;2;2+;;; +99933-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11843-2;3;3+;;; +99933-4;LL3105-5;Neg, 1+,2+,3+,4+;LA11844-0;4;4+;;; +87945-2;LL4490-0;Borrelia species examples;LA27602-4;1;Borrelia afzelii;;; +87945-2;LL4490-0;Borrelia species examples;LA19334-4;2;Borrelia burgdorferi;76327009;Borrelia burgdorferi (organism);http://snomed.info/sct +87945-2;LL4490-0;Borrelia species examples;LA27603-2;3;Borrelia garinii;;; +87945-2;LL4490-0;Borrelia species examples;LA27604-0;4;Borrelia hermsii;62748005;Borrelia hermsii (organism);http://snomed.info/sct +87945-2;LL4490-0;Borrelia species examples;LA27605-7;5;Borrelia mayonii;;; +87945-2;LL4490-0;Borrelia species examples;LA27606-5;6;Borrelia miyamotoi;;; +87945-2;LL4490-0;Borrelia species examples;LA27607-3;7;Borrelia valaisiana;;; +87945-2;LL4490-0;Borrelia species examples;LA11883-8;8;Not detected;;; +87946-0;LL4490-0;Borrelia species examples;LA27602-4;1;Borrelia afzelii;;; +87946-0;LL4490-0;Borrelia species examples;LA19334-4;2;Borrelia burgdorferi;76327009;Borrelia burgdorferi (organism);http://snomed.info/sct +87946-0;LL4490-0;Borrelia species examples;LA27603-2;3;Borrelia garinii;;; +87946-0;LL4490-0;Borrelia species examples;LA27604-0;4;Borrelia hermsii;62748005;Borrelia hermsii (organism);http://snomed.info/sct +87946-0;LL4490-0;Borrelia species examples;LA27605-7;5;Borrelia mayonii;;; +87946-0;LL4490-0;Borrelia species examples;LA27606-5;6;Borrelia miyamotoi;;; +87946-0;LL4490-0;Borrelia species examples;LA27607-3;7;Borrelia valaisiana;;; +87946-0;LL4490-0;Borrelia species examples;LA11883-8;8;Not detected;;; +87947-8;LL4490-0;Borrelia species examples;LA27602-4;1;Borrelia afzelii;;; +87947-8;LL4490-0;Borrelia species examples;LA19334-4;2;Borrelia burgdorferi;76327009;Borrelia burgdorferi (organism);http://snomed.info/sct +87947-8;LL4490-0;Borrelia species examples;LA27603-2;3;Borrelia garinii;;; +87947-8;LL4490-0;Borrelia species examples;LA27604-0;4;Borrelia hermsii;62748005;Borrelia hermsii (organism);http://snomed.info/sct +87947-8;LL4490-0;Borrelia species examples;LA27605-7;5;Borrelia mayonii;;; +87947-8;LL4490-0;Borrelia species examples;LA27606-5;6;Borrelia miyamotoi;;; +87947-8;LL4490-0;Borrelia species examples;LA27607-3;7;Borrelia valaisiana;;; +87947-8;LL4490-0;Borrelia species examples;LA11883-8;8;Not detected;;; +88581-4;LL4490-0;Borrelia species examples;LA27602-4;1;Borrelia afzelii;;; +88581-4;LL4490-0;Borrelia species examples;LA19334-4;2;Borrelia burgdorferi;76327009;Borrelia burgdorferi (organism);http://snomed.info/sct +88581-4;LL4490-0;Borrelia species examples;LA27603-2;3;Borrelia garinii;;; +88581-4;LL4490-0;Borrelia species examples;LA27604-0;4;Borrelia hermsii;62748005;Borrelia hermsii (organism);http://snomed.info/sct +88581-4;LL4490-0;Borrelia species examples;LA27605-7;5;Borrelia mayonii;;; +88581-4;LL4490-0;Borrelia species examples;LA27606-5;6;Borrelia miyamotoi;;; +88581-4;LL4490-0;Borrelia species examples;LA27607-3;7;Borrelia valaisiana;;; +88581-4;LL4490-0;Borrelia species examples;LA11883-8;8;Not detected;;; +87976-7;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +87976-7;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +87976-7;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +87976-7;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +87976-7;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +87977-5;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +87977-5;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +87977-5;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +87977-5;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +87977-5;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +87978-3;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +87978-3;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +87978-3;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +87978-3;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +87978-3;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +87979-1;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +87979-1;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +87979-1;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +87979-1;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +87979-1;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +87980-9;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +87980-9;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +87980-9;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +87980-9;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +87980-9;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +87981-7;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +87981-7;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +87981-7;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +87981-7;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +87981-7;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +88143-3;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +88143-3;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +88143-3;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +88143-3;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +88143-3;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +88686-1;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +88686-1;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +88686-1;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +88686-1;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +88686-1;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +88687-9;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +88687-9;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +88687-9;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +88687-9;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +88687-9;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +98025-0;LL4715-0;Fungus types;LA28337-6;1;Aspergillus sp;;; +98025-0;LL4715-0;Fungus types;LA28339-2;2;Blastomyces sp;;; +98025-0;LL4715-0;Fungus types;LA28338-4;3;Coccidioides sp;;; +98025-0;LL4715-0;Fungus types;LA28340-0;4;Cryptococcus sp;;; +98025-0;LL4715-0;Fungus types;LA28341-8;5;Histoplasma sp;;; +87995-7;LL4726-7;Strongyloides species;LA28387-1;1;Strongyloides fuelleborni;;; +87995-7;LL4726-7;Strongyloides species;LA28388-9;2;Strongyloides papillosus;;; +87995-7;LL4726-7;Strongyloides species;LA28386-3;3;Strongyloides stercoralis;;; +88003-9;LL4732-5;TOAST Classification;LA28403-6;1;Large-artery atherosclerosis (embolus/thrombosis);;; +88003-9;LL4732-5;TOAST Classification;LA28399-6;2;Cardioembolism (high-risk/medium-risk);;; +88003-9;LL4732-5;TOAST Classification;LA28400-2;3;Small-artery occlusion (lacune);;; +88003-9;LL4732-5;TOAST Classification;LA28401-0;4;Stroke of other determined etiology;;; +88003-9;LL4732-5;TOAST Classification;LA28402-8;5;Stroke of undetermined etiology;;; +88020-3;LL4734-1;NYHA FA: Class I | Class II | Class III | Class IV;LA28404-4;1;Class I;;; +88020-3;LL4734-1;NYHA FA: Class I | Class II | Class III | Class IV;LA28405-1;2;Class II;;; +88020-3;LL4734-1;NYHA FA: Class I | Class II | Class III | Class IV;LA28406-9;3;Class III;;; +88020-3;LL4734-1;NYHA FA: Class I | Class II | Class III | Class IV;LA28407-7;4;Class IV;;; +88021-1;LL4735-8;NYHA OA: Class I | Class II | Class III | Class IV;LA28408-5;1;No objective evidence of cardiovascular disease;;; +88021-1;LL4735-8;NYHA OA: Class I | Class II | Class III | Class IV;LA28409-3;2;Objective evidence of minimal cardiovascular disease;;; +88021-1;LL4735-8;NYHA OA: Class I | Class II | Class III | Class IV;LA28410-1;3;Objective evidence of moderately severe cardiovascular disease;;; +88021-1;LL4735-8;NYHA OA: Class I | Class II | Class III | Class IV;LA28411-9;4;Objective evidence of severe cardiovascular disease;;; +88027-8;LL4700-2;Common antigens in Rh blood group;LA28275-8;1;Rh blood group antigen Cw;31317005;Blood group antigen C^w^ (substance);http://snomed.info/sct +88027-8;LL4700-2;Common antigens in Rh blood group;LA28274-1;2;Rh blood group antigen G;21642002;Blood group antigen G (substance);http://snomed.info/sct +88027-8;LL4700-2;Common antigens in Rh blood group;LA28271-7;3;Rh blood group antigen V;18082002;Blood group antigen V (substance);http://snomed.info/sct +88027-8;LL4700-2;Common antigens in Rh blood group;LA28272-5;4;Rh blood group antigen VS;66906008;Blood group antigen VS (substance);http://snomed.info/sct +88027-8;LL4700-2;Common antigens in Rh blood group;LA28277-4;5;Rh blood group antigen f;55660005;Blood group antigen f (substance);http://snomed.info/sct +88027-8;LL4700-2;Common antigens in Rh blood group;LA28273-3;6;Rh null;;; +88031-0;LL4729-1;Current every day user | Current some day user;LA28391-3;1;Current every day user;;; +88031-0;LL4729-1;Current every day user | Current some day user;LA28392-1;2;Current some day user;;; +88031-0;LL4729-1;Current every day user | Current some day user;LA28393-9;3;Former user;;; +88031-0;LL4729-1;Current every day user | Current some day user;LA4519-0;4;Never used;;; +88031-0;LL4729-1;Current every day user | Current some day user;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88040-1;LL4721-8;Complete|Partial|Stable|Progressive|Not assessed;LA28366-5;1;Complete response;;; +88040-1;LL4721-8;Complete|Partial|Stable|Progressive|Not assessed;LA28369-9;2;Partial response;;; +88040-1;LL4721-8;Complete|Partial|Stable|Progressive|Not assessed;LA28371-5;3;Stable disease;;; +88040-1;LL4721-8;Complete|Partial|Stable|Progressive|Not assessed;LA28370-7;4;Progressive disease;;; +88040-1;LL4721-8;Complete|Partial|Stable|Progressive|Not assessed;LA9348-9;5;Not assessed;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28206-3;2;Loop electrosurgical excision procedure;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28208-9;3;Cyrosurgery;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28209-7;4;Conization;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28210-5;5;Pelvic radiation;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28211-3;6;Colposcopy;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28217-0;7;Hysterectomy;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28212-1;8;Total hysterectomy;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28213-9;9;Partial hysterectomy;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28214-7;10;Dilation and curettage;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA6172-6;11;Chemotherapy;;; +88057-5;LL4675-6;Treatments or procedures for abnormal Pap;LA28216-2;12;Laser ablation;;; +88066-6;LL4647-5;Assistant physician/resident|Specialist;LA28115-6;1;Assistant physician/resident;;; +88066-6;LL4647-5;Assistant physician/resident|Specialist;LA28116-4;2;Specialist;;; +88067-4;LL4643-4;EMS unit type;LA27668-5;1;Emergency physician rapid response cars/Emergency physician vehicle;;; +88067-4;LL4643-4;EMS unit type;LA27669-3;2;Medical transport vehicle with an emergency physician;;; +88067-4;LL4643-4;EMS unit type;LA28084-4;3;Medical transport vehicle without an emergency physician;;; +88067-4;LL4643-4;EMS unit type;LA28082-8;4;Van-type ambulance used for non-emergency transport;;; +88067-4;LL4643-4;EMS unit type;LA28083-6;5;Intensive care helicopter;;; +88067-4;LL4643-4;EMS unit type;LA28085-1;6;Rescue helicopter;;; +88067-4;LL4643-4;EMS unit type;LA28086-9;7;Water rescue services;;; +88067-4;LL4643-4;EMS unit type;LA28088-5;8;Mountain rescue services;;; +88067-4;LL4643-4;EMS unit type;LA28087-7;9;Other EMS unit;;; +88067-4;LL4643-4;EMS unit type;LA27668-5;1;Emergency physician rapid response cars/Emergency physician vehicle;;; +88067-4;LL4643-4;EMS unit type;LA27669-3;2;Medical transport vehicle with an emergency physician;;; +88067-4;LL4643-4;EMS unit type;LA28084-4;3;Medical transport vehicle without an emergency physician;;; +88067-4;LL4643-4;EMS unit type;LA28082-8;4;Van-type ambulance used for non-emergency transport;;; +88067-4;LL4643-4;EMS unit type;LA28083-6;5;Intensive care helicopter;;; +88067-4;LL4643-4;EMS unit type;LA28085-1;6;Rescue helicopter;;; +88067-4;LL4643-4;EMS unit type;LA28086-9;7;Water rescue services;;; +88067-4;LL4643-4;EMS unit type;LA28088-5;8;Mountain rescue services;;; +88067-4;LL4643-4;EMS unit type;LA28087-7;9;Other EMS unit;;; +88068-2;LL4657-4;Intoxication cause;LA28145-3;1;Patient is not intoxicated;;; +88068-2;LL4657-4;Intoxication cause;LA28144-6;2;Unknown substance;;; +88068-2;LL4657-4;Intoxication cause;LA28139-6;3;Alcohol;;; +88068-2;LL4657-4;Intoxication cause;LA22650-8;4;Medication;416608005;Drug therapy (procedure);http://snomed.info/sct +88068-2;LL4657-4;Intoxication cause;LA28141-2;5;Illegal drug;;; +88068-2;LL4657-4;Intoxication cause;LA28142-0;6;Multiple substances;;; +88068-2;LL4657-4;Intoxication cause;LA46-8;8;Other;;; +88076-5;LL4661-6;NACA Score 0-7;LA28157-8;1;NACA 0;;; +88076-5;LL4661-6;NACA Score 0-7;LA28150-3;2;NACA 1;;; +88076-5;LL4661-6;NACA Score 0-7;LA28151-1;3;NACA 2;;; +88076-5;LL4661-6;NACA Score 0-7;LA28152-9;4;NACA 3;;; +88076-5;LL4661-6;NACA Score 0-7;LA28153-7;5;NACA 4;;; +88076-5;LL4661-6;NACA Score 0-7;LA28154-5;6;NACA 5;;; +88076-5;LL4661-6;NACA Score 0-7;LA28155-2;7;NACA 6;;; +88076-5;LL4661-6;NACA Score 0-7;LA28156-0;8;NACA 7;;; +88077-3;LL4652-5;<3 meters | >3 meters | Unknown;LA28131-3;1;Less than 3 meters;;; +88077-3;LL4652-5;<3 meters | >3 meters | Unknown;LA28130-5;2;Greater than 3 meters;;; +88077-3;LL4652-5;<3 meters | >3 meters | Unknown;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88086-4;LL4515-4;Infant 1-7 days old|Infant 8-28 days old;LA27666-9;1;Infant 1-7 days old;;; +88086-4;LL4515-4;Infant 1-7 days old|Infant 8-28 days old;LA27667-7;2;Infant 8-28 days old;;; +88086-4;LL4515-4;Infant 1-7 days old|Infant 8-28 days old;LA27666-9;1;Infant 1-7 days old;;; +88086-4;LL4515-4;Infant 1-7 days old|Infant 8-28 days old;LA27667-7;2;Infant 8-28 days old;;; +88089-8;LL4719-2;Stroke unit|Cardiac cath lab|Trauma center;LA28361-6;1;Stroke unit;;; +88089-8;LL4719-2;Stroke unit|Cardiac cath lab|Trauma center;LA24168-9;2;Cardiac Catheterization Lab;;; +88089-8;LL4719-2;Stroke unit|Cardiac cath lab|Trauma center;LA28363-2;3;Trauma center;;; +88090-6;LL4646-7;Physician specialty;LA28110-7;1;Anesthesiology;;; +88090-6;LL4646-7;Physician specialty;LA14620-1;2;Surgery;;; +88090-6;LL4646-7;Physician specialty;LA28111-5;3;Internal medicine;;; +88090-6;LL4646-7;Physician specialty;LA19834-3;4;Pediatric;;; +88090-6;LL4646-7;Physician specialty;LA7190-7;5;Neurology;;; +88090-6;LL4646-7;Physician specialty;LA28112-3;6;General medicine;;; +88090-6;LL4646-7;Physician specialty;LA28113-1;7;Additional qualification intensive care medicine;;; +88090-6;LL4646-7;Physician specialty;LA28428-3;8;Emergency medicine;;; +88090-6;LL4646-7;Physician specialty;LA28114-9;9;Other specialization;;; +88093-0;LL4649-1;Healthy|Mild disease|Mild systemic|Severe systemic;LA28121-4;1;Healthy;;; +88093-0;LL4649-1;Healthy|Mild disease|Mild systemic|Severe systemic;LA28122-2;2;Mild disease without limitations;;; +88093-0;LL4649-1;Healthy|Mild disease|Mild systemic|Severe systemic;LA28123-0;3;Mild systemic disease;;; +88093-0;LL4649-1;Healthy|Mild disease|Mild systemic|Severe systemic;LA28124-8;4;Severe systemic disease that is a threat to life;;; +88093-0;LL4649-1;Healthy|Mild disease|Mild systemic|Severe systemic;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88094-8;LL4650-9;Sufficient|Insufficient|None;LA28126-3;1;Sufficient;;; +88094-8;LL4650-9;Sufficient|Insufficient|None;LA28127-1;2;Insufficient;;; +88094-8;LL4650-9;Sufficient|Insufficient|None;LA137-2;3;None;260413007;None (qualifier value);http://snomed.info/sct +88102-9;LL4720-0;Paramedic|Emergency physician;LA25426-0;1;Paramedic;;; +88102-9;LL4720-0;Paramedic|Emergency physician;LA28365-7;2;Emergency physician;;; +88102-9;LL4720-0;Paramedic|Emergency physician;LA18700-7;3;First responder;;; +88102-9;LL4720-0;Paramedic|Emergency physician;LA32332-1;4;First aider;;; +88104-5;LL4659-0;Rhythmic|Arrhythmic;LA28148-7;1;Rhythmic;;; +88104-5;LL4659-0;Rhythmic|Arrhythmic;LA19581-0;2;Arrhythmic;;; +88105-2;LL5553-4;Injured body region;LA12706-0;1;Abdomen;;; +88105-2;LL5553-4;Injured body region;LA30842-1;2;Craniocerebral;;; +88105-2;LL5553-4;Injured body region;LA20646-8;3;Face;;; +88105-2;LL5553-4;Injured body region;LA30846-2;4;Lower extremity;;; +88105-2;LL5553-4;Injured body region;LA12703-7;5;Neck;;; +88105-2;LL5553-4;Injured body region;LA30844-7;6;Pelvis or pelvic girdle;;; +88105-2;LL5553-4;Injured body region;LA4340-1;7;Spine;;; +88105-2;LL5553-4;Injured body region;LA30843-9;8;Thorax or chest;;; +88105-2;LL5553-4;Injured body region;LA30845-4;9;Upper extremity;;; +88105-2;LL5553-4;Injured body region;LA30847-0;10;Other external injury;;; +88109-4;LL4653-3;Role of person in accident;LA18039-0;1;Pedestrian;;; +88109-4;LL4653-3;Role of person in accident;LA28133-9;2;Bicyclist;;; +88109-4;LL4653-3;Role of person in accident;LA28134-7;3;Motorcyclist;;; +88109-4;LL4653-3;Role of person in accident;LA28135-4;4;Occupant of motor vehicle;;; +88109-4;LL4653-3;Role of person in accident;LA46-8;5;Other;;; +88109-4;LL4653-3;Role of person in accident;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88115-1;LL4701-0;1+|2+|3+;LA11841-6;1;1+;;; +88115-1;LL4701-0;1+|2+|3+;LA11842-4;2;2+;;; +88115-1;LL4701-0;1+|2+|3+;LA11843-2;3;3+;;; +88122-7;LL5586-4;Often true | Sometimes true | Never true | DK;LA28397-0;1;Often true;;; +88122-7;LL5586-4;Often true | Sometimes true | Never true | DK;LA6729-3;2;Sometimes true;;; +88122-7;LL5586-4;Often true | Sometimes true | Never true | DK;LA28398-8;3;Never true;;; +88122-7;LL5586-4;Often true | Sometimes true | Never true | DK;LA30968-4;4;DK or Refused;;; +88123-5;LL5586-4;Often true | Sometimes true | Never true | DK;LA28397-0;1;Often true;;; +88123-5;LL5586-4;Often true | Sometimes true | Never true | DK;LA6729-3;2;Sometimes true;;; +88123-5;LL5586-4;Often true | Sometimes true | Never true | DK;LA28398-8;3;Never true;;; +88123-5;LL5586-4;Often true | Sometimes true | Never true | DK;LA30968-4;4;DK or Refused;;; +95248-1;LL5586-4;Often true | Sometimes true | Never true | DK;LA28397-0;1;Often true;;; +95248-1;LL5586-4;Often true | Sometimes true | Never true | DK;LA6729-3;2;Sometimes true;;; +95248-1;LL5586-4;Often true | Sometimes true | Never true | DK;LA28398-8;3;Never true;;; +95248-1;LL5586-4;Often true | Sometimes true | Never true | DK;LA30968-4;4;DK or Refused;;; +95256-4;LL5586-4;Often true | Sometimes true | Never true | DK;LA28397-0;1;Often true;;; +95256-4;LL5586-4;Often true | Sometimes true | Never true | DK;LA6729-3;2;Sometimes true;;; +95256-4;LL5586-4;Often true | Sometimes true | Never true | DK;LA28398-8;3;Never true;;; +95256-4;LL5586-4;Often true | Sometimes true | Never true | DK;LA30968-4;4;DK or Refused;;; +95257-2;LL5586-4;Often true | Sometimes true | Never true | DK;LA28397-0;1;Often true;;; +95257-2;LL5586-4;Often true | Sometimes true | Never true | DK;LA6729-3;2;Sometimes true;;; +95257-2;LL5586-4;Often true | Sometimes true | Never true | DK;LA28398-8;3;Never true;;; +95257-2;LL5586-4;Often true | Sometimes true | Never true | DK;LA30968-4;4;DK or Refused;;; +95258-0;LL5586-4;Often true | Sometimes true | Never true | DK;LA28397-0;1;Often true;;; +95258-0;LL5586-4;Often true | Sometimes true | Never true | DK;LA6729-3;2;Sometimes true;;; +95258-0;LL5586-4;Often true | Sometimes true | Never true | DK;LA28398-8;3;Never true;;; +95258-0;LL5586-4;Often true | Sometimes true | Never true | DK;LA30968-4;4;DK or Refused;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA28397-0;1;Often true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA6729-3;2;Sometimes true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA28398-8;3;Never true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA28397-0;1;Often true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA6729-3;2;Sometimes true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA28398-8;3;Never true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA28397-0;1;Often true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA6729-3;2;Sometimes true;;; +88122-7;LL5890-0;Often|Sometimes|Never true;LA28398-8;3;Never true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA28397-0;1;Often true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA6729-3;2;Sometimes true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA28398-8;3;Never true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA28397-0;1;Often true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA6729-3;2;Sometimes true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA28398-8;3;Never true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA28397-0;1;Often true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA6729-3;2;Sometimes true;;; +88123-5;LL5890-0;Often|Sometimes|Never true;LA28398-8;3;Never true;;; +88126-8;LL4656-6;Minimal|Moderate|Severe;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88126-8;LL4656-6;Minimal|Moderate|Severe;LA26031-7;2;Minimal;;; +88126-8;LL4656-6;Minimal|Moderate|Severe;LA6751-7;3;Moderate;6736007;Moderate (severity modifier) (qualifier value);http://snomed.info/sct +88126-8;LL4656-6;Minimal|Moderate|Severe;LA30751-4;4;Serious;;; +88126-8;LL4656-6;Minimal|Moderate|Severe;LA6750-9;5;Severe;;; +88126-8;LL4656-6;Minimal|Moderate|Severe;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88126-8;LL4656-6;Minimal|Moderate|Severe;LA9348-9;7;Not assessed;;; +88241-5;LL4674-9;Burial | Crem | Hospital | Donation |Removal | Oth;LA25832-9;1;Burial;;; +88241-5;LL4674-9;Burial | Crem | Hospital | Donation |Removal | Oth;LA25833-7;2;Cremation;;; +88241-5;LL4674-9;Burial | Crem | Hospital | Donation |Removal | Oth;LA28205-5;3;Hospital Disposition;;; +88241-5;LL4674-9;Burial | Crem | Hospital | Donation |Removal | Oth;LA25834-5;4;Donation;;; +88241-5;LL4674-9;Burial | Crem | Hospital | Donation |Removal | Oth;LA25836-0;5;Removal from state;;; +88241-5;LL4674-9;Burial | Crem | Hospital | Donation |Removal | Oth;LA46-8;6;Other;;; +88296-9;LL4762-2;CMS_MDS Antipsychotic medications;LA28462-2;1;No - Antipsychotics were not received;;; +88296-9;LL4762-2;CMS_MDS Antipsychotic medications;LA28463-0;2;Yes - Antipsychotics were received on a routine basis only;;; +88296-9;LL4762-2;CMS_MDS Antipsychotic medications;LA28464-8;3;Yes - Antipsychotics were received on a PRN basis only;;; +88296-9;LL4762-2;CMS_MDS Antipsychotic medications;LA28465-5;4;Yes - Antipsychotics were received on a routine and PRN basis;;; +88299-3;LL4764-8;CMS_MDS GDR documented;LA28466-3;1;No - GDR has not been documented by a physician as clinically contraindicated;;; +88299-3;LL4764-8;CMS_MDS GDR documented;LA28467-1;2;Yes - GDR has been documented by a physician as clinically contraindicated;;; +88335-5;LL4703-6;Categories of Leukocytes;LA28282-4;1;Neutrophils;;; +88335-5;LL4703-6;Categories of Leukocytes;LA12895-1;2;Eosinophils;;; +88335-5;LL4703-6;Categories of Leukocytes;LA28286-5;3;Lymphocytes;;; +88335-5;LL4703-6;Categories of Leukocytes;LA28287-3;4;Basophils;;; +88335-5;LL4703-6;Categories of Leukocytes;LA28288-1;5;Monocytes;;; +88335-5;LL4703-6;Categories of Leukocytes;LA46-8;6;Other;;; +88337-1;LL4702-8;Ear mites;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +88337-1;LL4702-8;Ear mites;LA28278-2;2;Otodectes cynotis;78180005;Otodectes cynotis (organism);http://snomed.info/sct +88337-1;LL4702-8;Ear mites;LA28279-0;3;Psoroptes sp;33040007;Psoroptes (organism);http://snomed.info/sct +88337-1;LL4702-8;Ear mites;LA28280-8;4;Unidentified;69910005;Unidentified (qualifier value);http://snomed.info/sct +88338-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88338-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA20948-8;2;Occasional;;; +88338-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6752-5;3;Mild;;; +88338-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6751-7;4;Moderate;;; +88338-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA17968-1;5;Marked;;; +88339-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88339-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA20948-8;2;Occasional;;; +88339-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6752-5;3;Mild;;; +88339-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6751-7;4;Moderate;;; +88339-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA17968-1;5;Marked;;; +88340-5;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88340-5;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA20948-8;2;Occasional;;; +88340-5;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6752-5;3;Mild;;; +88340-5;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6751-7;4;Moderate;;; +88340-5;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA17968-1;5;Marked;;; +88341-3;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88341-3;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA20948-8;2;Occasional;;; +88341-3;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6752-5;3;Mild;;; +88341-3;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6751-7;4;Moderate;;; +88341-3;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA17968-1;5;Marked;;; +88342-1;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88342-1;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA20948-8;2;Occasional;;; +88342-1;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6752-5;3;Mild;;; +88342-1;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6751-7;4;Moderate;;; +88342-1;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA17968-1;5;Marked;;; +88343-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88343-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA20948-8;2;Occasional;;; +88343-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6752-5;3;Mild;;; +88343-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6751-7;4;Moderate;;; +88343-9;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA17968-1;5;Marked;;; +88344-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +88344-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA20948-8;2;Occasional;;; +88344-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6752-5;3;Mild;;; +88344-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA6751-7;4;Moderate;;; +88344-7;LL4697-0;None|Occasional|Mild|Moderate|Marked;LA17968-1;5;Marked;;; +88381-9;LL4866-1;Yes(1)|No(0)|DK/NS(8)|Refused(9);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +88381-9;LL4866-1;Yes(1)|No(0)|DK/NS(8)|Refused(9);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +88381-9;LL4866-1;Yes(1)|No(0)|DK/NS(8)|Refused(9);LA14619-3;3;Don't know/not sure;;; +88381-9;LL4866-1;Yes(1)|No(0)|DK/NS(8)|Refused(9);LA4389-8;4;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +88447-8;LL4773-9;Liver fibrosis interpretation;LA9635-9;0;No fibrosis;;; +88447-8;LL4773-9;Liver fibrosis interpretation;LA28483-8;1;Minimal fibrosis;;; +88447-8;LL4773-9;Liver fibrosis interpretation;LA28484-6;2;Moderate fibrosis;;; +88447-8;LL4773-9;Liver fibrosis interpretation;LA28485-3;3;Severe fibrosis;;; +88448-6;LL4774-7;Necroinflammatory activity;LA9640-9;0;No activity;;; +88448-6;LL4774-7;Necroinflammatory activity;LA9641-7;1;Minimal activity;;; +88448-6;LL4774-7;Necroinflammatory activity;LA28486-1;2;Significant activity;;; +88448-6;LL4774-7;Necroinflammatory activity;LA9643-3;3;Severe activity;;; +88456-9;LL4772-1;Recent or past infection;LA28480-4;0;Ab not detected;;; +88456-9;LL4772-1;Recent or past infection;LA28481-2;1;Past infection;;; +88456-9;LL4772-1;Recent or past infection;LA28482-0;2;Recent infection;;; +88700-0;LL4772-1;Recent or past infection;LA28480-4;0;Ab not detected;;; +88700-0;LL4772-1;Recent or past infection;LA28481-2;1;Past infection;;; +88700-0;LL4772-1;Recent or past infection;LA28482-0;2;Recent infection;;; +90365-8;LL4772-1;Recent or past infection;LA28480-4;0;Ab not detected;;; +90365-8;LL4772-1;Recent or past infection;LA28481-2;1;Past infection;;; +90365-8;LL4772-1;Recent or past infection;LA28482-0;2;Recent infection;;; +93871-2;LL4772-1;Recent or past infection;LA28480-4;0;Ab not detected;;; +93871-2;LL4772-1;Recent or past infection;LA28481-2;1;Past infection;;; +93871-2;LL4772-1;Recent or past infection;LA28482-0;2;Recent infection;;; +94475-1;LL4772-1;Recent or past infection;LA28480-4;0;Ab not detected;;; +94475-1;LL4772-1;Recent or past infection;LA28481-2;1;Past infection;;; +94475-1;LL4772-1;Recent or past infection;LA28482-0;2;Recent infection;;; +94661-6;LL4772-1;Recent or past infection;LA28480-4;0;Ab not detected;;; +94661-6;LL4772-1;Recent or past infection;LA28481-2;1;Past infection;;; +94661-6;LL4772-1;Recent or past infection;LA28482-0;2;Recent infection;;; +88469-2;LL4863-8;SAQ_Enjoyment of life;LA27745-1;1;It has extremely limited my enjoyment of life;;; +88469-2;LL4863-8;SAQ_Enjoyment of life;LA27746-9;2;It has limited my enjoyment of life quite a bit;;; +88469-2;LL4863-8;SAQ_Enjoyment of life;LA27747-7;3;It has moderately limited my enjoyment of life;;; +88469-2;LL4863-8;SAQ_Enjoyment of life;LA27748-5;4;It has slightly limited my enjoyment of life;;; +88469-2;LL4863-8;SAQ_Enjoyment of life;LA27749-3;5;It has not limited my enjoyment of life at all;;; +88473-4;LL4864-6;SAQ_Rest of your life with angina;LA28523-1;1;Not satisfied at all;;; +88473-4;LL4864-6;SAQ_Rest of your life with angina;LA24976-5;2;Mostly dissatisfied;;; +88473-4;LL4864-6;SAQ_Rest of your life with angina;LA27752-7;3;Somewhat satisfied;;; +88473-4;LL4864-6;SAQ_Rest of your life with angina;LA24974-0;4;Mostly satisfied;;; +88473-4;LL4864-6;SAQ_Rest of your life with angina;LA27754-3;5;Completely satisfied;;; +88475-9;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA28518-1;1;4 or more times per day;;; +88475-9;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA25000-3;2;1-3 times per day;396108002;one to three times a day (qualifier value);http://snomed.info/sct +88475-9;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA27770-9;3;3 or more times per week but not every day;;; +88475-9;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA13834-9;4;1-2 times per week;;; +88475-9;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA27722-0;5;Less than once a week;;; +88475-9;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA28522-3;6;None over the past 4 weeks;;; +88476-7;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA28518-1;1;4 or more times per day;;; +88476-7;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA25000-3;2;1-3 times per day;396108002;one to three times a day (qualifier value);http://snomed.info/sct +88476-7;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA27770-9;3;3 or more times per week but not every day;;; +88476-7;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA13834-9;4;1-2 times per week;;; +88476-7;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA27722-0;5;Less than once a week;;; +88476-7;LL4861-2;SAQ_Chest pain, tightness or angina frequency;LA28522-3;6;None over the past 4 weeks;;; +88477-5;LL4859-6;SAQ_Activity;LA27701-4;1;Extremely limited;;; +88477-5;LL4859-6;SAQ_Activity;LA27702-2;2;Quite a bit limited;;; +88477-5;LL4859-6;SAQ_Activity;LA6460-5;3;Moderately limited;;; +88477-5;LL4859-6;SAQ_Activity;LA9605-2;4;Slightly limited;;; +88477-5;LL4859-6;SAQ_Activity;LA27707-1;5;Not at all limited;;; +88477-5;LL4859-6;SAQ_Activity;LA27708-9;6;Limited for other reasons or did not do the activity;;; +88478-3;LL4859-6;SAQ_Activity;LA27701-4;1;Extremely limited;;; +88478-3;LL4859-6;SAQ_Activity;LA27702-2;2;Quite a bit limited;;; +88478-3;LL4859-6;SAQ_Activity;LA6460-5;3;Moderately limited;;; +88478-3;LL4859-6;SAQ_Activity;LA9605-2;4;Slightly limited;;; +88478-3;LL4859-6;SAQ_Activity;LA27707-1;5;Not at all limited;;; +88478-3;LL4859-6;SAQ_Activity;LA27708-9;6;Limited for other reasons or did not do the activity;;; +88480-9;LL4859-6;SAQ_Activity;LA27701-4;1;Extremely limited;;; +88480-9;LL4859-6;SAQ_Activity;LA27702-2;2;Quite a bit limited;;; +88480-9;LL4859-6;SAQ_Activity;LA6460-5;3;Moderately limited;;; +88480-9;LL4859-6;SAQ_Activity;LA9605-2;4;Slightly limited;;; +88480-9;LL4859-6;SAQ_Activity;LA27707-1;5;Not at all limited;;; +88480-9;LL4859-6;SAQ_Activity;LA27708-9;6;Limited for other reasons or did not do the activity;;; +88509-5;LL4769-7;H pylori 23S rRNA variants clarithromycin;LA28472-1;1;A2142G;;; +88509-5;LL4769-7;H pylori 23S rRNA variants clarithromycin;LA28471-3;2;A2142C;;; +88509-5;LL4769-7;H pylori 23S rRNA variants clarithromycin;LA28470-5;3;A2143G;;; +88509-5;LL4769-7;H pylori 23S rRNA variants clarithromycin;LA28473-9;4;G2142A;;; +88509-5;LL4769-7;H pylori 23S rRNA variants clarithromycin;LA28575-1;5;T2182C;;; +88509-5;LL4769-7;H pylori 23S rRNA variants clarithromycin;LA11883-8;6;Not detected;;; +88543-4;LL4855-4;HIV1 Protease mutations;LA19758-4;1;I62V;;; +88543-4;LL4855-4;HIV1 Protease mutations;LA25851-9;2;Q18K;;; +88543-4;LL4855-4;HIV1 Protease mutations;LA25852-7;3;E35D;;; +88544-2;LL4854-7;HIV1 RT mutations;LA19752-7;1;K13K/E;;; +88544-2;LL4854-7;HIV1 RT mutations;LA19753-5;2;K20R;;; +88544-2;LL4854-7;HIV1 RT mutations;LA19754-3;3;E28D;;; +88544-2;LL4854-7;HIV1 RT mutations;LA19755-0;4;M41M/L;;; +88544-2;LL4854-7;HIV1 RT mutations;LA25848-5;5;G359S;;; +88544-2;LL4854-7;HIV1 RT mutations;LA25847-7;6;V35I;;; +88571-5;LL4771-3;High probability|Low probability;LA28478-8;1;High probability;;; +88571-5;LL4771-3;High probability|Low probability;LA28479-6;2;Low probability;;; +88572-3;LL4771-3;High probability|Low probability;LA28478-8;1;High probability;;; +88572-3;LL4771-3;High probability|Low probability;LA28479-6;2;Low probability;;; +88580-6;LL4723-4;Burkholderia sp;LA28373-1;1;Burkholderia mallei;;; +88580-6;LL4723-4;Burkholderia sp;LA28374-9;2;Burkholderia pseudomallei;;; +88636-6;LL4894-3;Patient exposures to diseases and hazards;LA10030-7;1;None known;;; +88636-6;LL4894-3;Patient exposures to diseases and hazards;LA28576-9;2;Zika virus;;; +88636-6;LL4894-3;Patient exposures to diseases and hazards;LA28577-7;3;Human immunodeficiency virus (HIV);;; +88636-6;LL4894-3;Patient exposures to diseases and hazards;LA28578-5;4;Lead;;; +88636-6;LL4894-3;Patient exposures to diseases and hazards;LA28579-3;5;Pesticides;;; +88636-6;LL4894-3;Patient exposures to diseases and hazards;LA28580-1;6;Mold;;; +88636-6;LL5552-6;COVID19 exposures;LA30830-6;1;Travel to Wuhan;;; +88636-6;LL5552-6;COVID19 exposures;LA30831-4;2;Travel to Hubei;;; +88636-6;LL5552-6;COVID19 exposures;LA30832-2;3;Travel to mainland China;;; +88636-6;LL5552-6;COVID19 exposures;LA30833-0;4;Travel to other non-US country;;; +88636-6;LL5552-6;COVID19 exposures;LA30834-8;5;Household contact with another lab confirmed COVID-19 case-patient;;; +88636-6;LL5552-6;COVID19 exposures;LA30835-5;6;Community contact with another lab-confirmed COVID-19 case-patient;;; +88636-6;LL5552-6;COVID19 exposures;LA30836-3;7;Any healthcare contact with another lab-confirmed COVID-19 case-patient;;; +88636-6;LL5552-6;COVID19 exposures;LA30837-1;8;Any healthcare contact with a Patient who is lab-confirmed COVID-19 case-patient;;; +88636-6;LL5552-6;COVID19 exposures;LA30838-9;9;Any healthcare contact with a Visitor who is lab-confirmed COVID-19 case-patient;;; +88636-6;LL5552-6;COVID19 exposures;LA30839-7;10;Any healthcare contact with Healthcare Worker who is lab-confirmed COVID-19 case-patient;;; +88636-6;LL5552-6;COVID19 exposures;LA30840-5;11;Animal exposure;;; +88636-6;LL5552-6;COVID19 exposures;LA30841-3;12;Exposure to a cluster of patients with severe acute lower respiratory distress of unknown etiology;;; +88636-6;LL5552-6;COVID19 exposures;LA46-8;13;Other;;; +88636-6;LL5552-6;COVID19 exposures;LA4489-6;14;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +88657-2;LL4907-3;<3|3-4|5-6|7-9 hours;LA28680-9;1;<3 hours;;; +88657-2;LL4907-3;<3|3-4|5-6|7-9 hours;LA28681-7;2;3-4 hours;;; +88657-2;LL4907-3;<3|3-4|5-6|7-9 hours;LA28682-5;3;5-6 hours;;; +88657-2;LL4907-3;<3|3-4|5-6|7-9 hours;LA28683-3;4;7-9 hours;;; +88657-2;LL4907-3;<3|3-4|5-6|7-9 hours;LA11884-6;5;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +88658-0;LL4908-1;Use of supplemental oxygen;LA28684-1;1;Continuously depending on high oxygen flow;;; +88658-0;LL4908-1;Use of supplemental oxygen;LA28685-8;2;Continuously depending on low oxygen flow;;; +88658-0;LL4908-1;Use of supplemental oxygen;LA28686-6;3;Intermittent oxygen consumption;;; +88659-8;LL4867-9;Timing for thrombolysis admin at cardiac arrest;LA28527-2;1;Before cardiac arrest;;; +88659-8;LL4867-9;Timing for thrombolysis admin at cardiac arrest;LA28528-0;2;During cardiac arrest;;; +88659-8;LL4867-9;Timing for thrombolysis admin at cardiac arrest;LA28529-8;3;After return of spontaneous circulation;;; +88662-2;LL4868-7;AED|Manual external defibrillator;LA28536-3;1;Automated external defibrillator;;; +88662-2;LL4868-7;AED|Manual external defibrillator;LA28537-1;2;Manual external defibrillator;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA28538-9;1;Lay person;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA18700-7;2;First responder;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA25426-0;3;Paramedic;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA4687-5;4;Physician;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA28538-9;1;Lay person;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA18700-7;2;First responder;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA25426-0;3;Paramedic;;; +88663-0;LL4869-5;Lay person|First responder|Paramedic|Physician;LA4687-5;4;Physician;;; +88664-8;LL4870-3;Monophasic|Biphasic;LA28542-1;1;Monophasic;;; +88664-8;LL4870-3;Monophasic|Biphasic;LA28543-9;2;Biphasic;;; +88668-9;LL4871-1;Therapeutic hypothermia methods;LA28544-7;1;Active cooling with infusions;;; +88668-9;LL4871-1;Therapeutic hypothermia methods;LA28545-4;2;Active cooling with cool packs;;; +88668-9;LL4871-1;Therapeutic hypothermia methods;LA28546-2;3;Technical cooling;;; +88668-9;LL4871-1;Therapeutic hypothermia methods;LA28547-0;4;No active cooling;;; +88670-5;LL5056-8;Return of spontaneous circulation;LA17075-5;1;Yes, prior to arrival at the ED;;; +88670-5;LL5056-8;Return of spontaneous circulation;LA17076-3;2;Yes, at arrival at the ED;;; +88670-5;LL5056-8;Return of spontaneous circulation;LA17077-1;3;Yes, sustained for 20 consecutive minutes;;; +88670-5;LL5056-8;Return of spontaneous circulation;LA29251-8;4;Insufficient, sustained but only for a limited time;;; +88670-5;LL5056-8;Return of spontaneous circulation;LA32-8;5;No;373067005;No (qualifier value);http://snomed.info/sct +88671-3;LL4904-0;Body position &or immobilizers;LA28664-3;1;Shock position;;; +88671-3;LL4904-0;Body position &or immobilizers;LA28665-0;2;Trendelenburg position;;; +88671-3;LL4904-0;Body position &or immobilizers;LA28666-8;3;Raised upper body;;; +88671-3;LL4904-0;Body position &or immobilizers;LA28667-6;4;Lying flat;;; +88671-3;LL4904-0;Body position &or immobilizers;LA28668-4;5;Prone position;;; +88671-3;LL4904-0;Body position &or immobilizers;LA30804-1;6;Recovery position;;; +88671-3;LL4904-0;Body position &or immobilizers;LA30962-7;7;Stable side position;;; +88671-3;LL4904-0;Body position &or immobilizers;LA11868-9;8;Sitting;33586001;Sitting position (finding);http://snomed.info/sct +88671-3;LL4904-0;Body position &or immobilizers;LA30799-3;9;Cervical collar or neck brace;;; +88671-3;LL4904-0;Body position &or immobilizers;LA30800-9;10;Vacuum mattress;;; +88671-3;LL4904-0;Body position &or immobilizers;LA30802-5;11;Clamshell or Scoop stretcher;;; +88671-3;LL4904-0;Body position &or immobilizers;LA30805-8;12;Spinal board;;; +88671-3;LL4904-0;Body position &or immobilizers;LA30806-6;13;Vacuum splint;;; +88671-3;LL4904-0;Body position &or immobilizers;LA30963-5;14;Incubator or humidicrib;;; +88671-3;LL4904-0;Body position &or immobilizers;LA46-8;15;Other;;; +88672-1;LL4872-9;Body warming methods;LA28548-8;1;Rescue blanket;;; +88672-1;LL4872-9;Body warming methods;LA28549-6;2;Warm infusions;;; +88672-1;LL4872-9;Body warming methods;LA28550-4;3;Heater/fan;;; +88673-9;LL4905-7;Handover;LA28670-0;1;Handing over patient to a transport with emergency physician;;; +88673-9;LL4905-7;Handover;LA28671-8;2;Receiving patient from transport with emergency physician;;; +88673-9;LL4905-7;Handover;LA28672-6;3;At least one facility is refusing patient;;; +88673-9;LL4905-7;Handover;LA28673-4;4;Forced allocation of patient;;; +88674-7;LL4906-5;Factors related to rescue;LA28674-2;1;Confinement of patient;;; +88674-7;LL4906-5;Factors related to rescue;LA28675-9;2;Increased hygienic measures;;; +88674-7;LL4906-5;Factors related to rescue;LA28676-7;3;Difficult technical rescue;;; +88674-7;LL4906-5;Factors related to rescue;LA28677-5;4;Oversize load;;; +88674-7;LL4906-5;Factors related to rescue;LA28678-3;5;Leading emergency physician at scene;;; +88674-7;LL4906-5;Factors related to rescue;LA28679-1;6;Treatment of several patients;;; +88674-7;LL4906-5;Factors related to rescue;LA46-8;7;Other;;; +88676-2;LL4718-4;Open wound|Covered injury;LA22312-5;1;Open wound;;; +88676-2;LL4718-4;Open wound|Covered injury;LA28360-8;2;Covered injury;;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27943-2;1;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27944-0;2;Diabetic foot ulcer(s);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27945-7;3;Other open lesion(s) on the foot;;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27946-5;4;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27947-3;5;Surgical wound(s);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27948-1;6;Burn(s) (second or third degree);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27939-0;7;None of the above were present;;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27943-2;1;Infection of the foot (e.g., cellulitis, purulent drainage);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27944-0;2;Diabetic foot ulcer(s);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27945-7;3;Other open lesion(s) on the foot;;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27946-5;4;Open lesion(s) other than ulcers, rashes, cuts (e.g., cancer lesion);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27947-3;5;Surgical wound(s);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27948-1;6;Burn(s) (second or third degree);;; +88696-0;LL5242-4;CMS_MDS Ulcers, wounds, and skin problems - IPA;LA27939-0;7;None of the above were present;;; +88717-4;LL4689-7;Candida species;LA32401-4;1;Candida albicans;;; +88717-4;LL4689-7;Candida species;LA32402-2;2;Candida auris;;; +88717-4;LL4689-7;Candida species;LA28230-3;3;Candida bracarensis;;; +88717-4;LL4689-7;Candida species;LA28232-9;4;Candida catenulata;;; +88717-4;LL4689-7;Candida species;LA28233-7;5;Candida ciferrii;;; +88717-4;LL4689-7;Candida species;LA28234-5;6;Candida colliculosa;;; +88717-4;LL4689-7;Candida species;LA28241-0;7;Candida fabianii;;; +88717-4;LL4689-7;Candida species;LA28242-8;8;Candida famata;;; +88717-4;LL4689-7;Candida species;LA28243-6;9;Candida fermentati;;; +88717-4;LL4689-7;Candida species;LA32403-0;10;Candida galli;;; +88717-4;LL4689-7;Candida species;LA28244-4;11;Candida glabrata;;; +88717-4;LL4689-7;Candida species;LA32404-8;12;Candida kefyr;;; +88717-4;LL4689-7;Candida species;LA28245-1;13;Other candida species;;; +98393-2;LL4689-7;Candida species;LA32401-4;1;Candida albicans;;; +98393-2;LL4689-7;Candida species;LA32402-2;2;Candida auris;;; +98393-2;LL4689-7;Candida species;LA28230-3;3;Candida bracarensis;;; +98393-2;LL4689-7;Candida species;LA28232-9;4;Candida catenulata;;; +98393-2;LL4689-7;Candida species;LA28233-7;5;Candida ciferrii;;; +98393-2;LL4689-7;Candida species;LA28234-5;6;Candida colliculosa;;; +98393-2;LL4689-7;Candida species;LA28241-0;7;Candida fabianii;;; +98393-2;LL4689-7;Candida species;LA28242-8;8;Candida famata;;; +98393-2;LL4689-7;Candida species;LA28243-6;9;Candida fermentati;;; +98393-2;LL4689-7;Candida species;LA32403-0;10;Candida galli;;; +98393-2;LL4689-7;Candida species;LA28244-4;11;Candida glabrata;;; +98393-2;LL4689-7;Candida species;LA32404-8;12;Candida kefyr;;; +98393-2;LL4689-7;Candida species;LA28245-1;13;Other candida species;;; +98394-0;LL4689-7;Candida species;LA32401-4;1;Candida albicans;;; +98394-0;LL4689-7;Candida species;LA32402-2;2;Candida auris;;; +98394-0;LL4689-7;Candida species;LA28230-3;3;Candida bracarensis;;; +98394-0;LL4689-7;Candida species;LA28232-9;4;Candida catenulata;;; +98394-0;LL4689-7;Candida species;LA28233-7;5;Candida ciferrii;;; +98394-0;LL4689-7;Candida species;LA28234-5;6;Candida colliculosa;;; +98394-0;LL4689-7;Candida species;LA28241-0;7;Candida fabianii;;; +98394-0;LL4689-7;Candida species;LA28242-8;8;Candida famata;;; +98394-0;LL4689-7;Candida species;LA28243-6;9;Candida fermentati;;; +98394-0;LL4689-7;Candida species;LA32403-0;10;Candida galli;;; +98394-0;LL4689-7;Candida species;LA28244-4;11;Candida glabrata;;; +98394-0;LL4689-7;Candida species;LA32404-8;12;Candida kefyr;;; +98394-0;LL4689-7;Candida species;LA28245-1;13;Other candida species;;; +88755-4;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA6270-8;1;Never;;; +88755-4;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10066-1;2;Rarely;;; +88755-4;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10082-8;3;Sometimes;;; +88755-4;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10044-8;4;Often;;; +88755-4;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA9933-8;5;Always;;; +88795-0;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA6270-8;1;Never;;; +88795-0;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10066-1;2;Rarely;;; +88795-0;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10082-8;3;Sometimes;;; +88795-0;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10044-8;4;Often;;; +88795-0;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA9933-8;5;Always;;; +88796-8;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA6270-8;1;Never;;; +88796-8;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10066-1;2;Rarely;;; +88796-8;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10082-8;3;Sometimes;;; +88796-8;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10044-8;4;Often;;; +88796-8;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA9933-8;5;Always;;; +88797-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA6270-8;1;Never;;; +88797-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10066-1;2;Rarely;;; +88797-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10082-8;3;Sometimes;;; +88797-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10044-8;4;Often;;; +88797-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA9933-8;5;Always;;; +93157-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA6270-8;1;Never;;; +93157-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10066-1;2;Rarely;;; +93157-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10082-8;3;Sometimes;;; +93157-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA10044-8;4;Often;;; +93157-6;LL4911-5;Never(0)Rarely(1)Sometimes(2)Often(3)Always(4);LA9933-8;5;Always;;; +88757-0;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA6568-5;1;Not at all;;; +88757-0;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA28567-8;2;Mildly;;; +88757-0;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA13939-6;3;Moderately;;; +88757-0;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA28568-6;4;Severely;;; +88757-0;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA14868-6;5;Extremely;;; +88799-2;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA6568-5;1;Not at all;;; +88799-2;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA28567-8;2;Mildly;;; +88799-2;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA13939-6;3;Moderately;;; +88799-2;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA28568-6;4;Severely;;; +88799-2;LL4915-6;Not at all,Mildly,Moderately,Severly,Extremely;LA14868-6;5;Extremely;;; +88758-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA6568-5;1;Not at all;;; +88758-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA28567-8;2;Mildly;;; +88758-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA13939-6;3;Moderately;;; +88758-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA28568-6;4;Severely;;; +88758-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA28569-4;5;Totally;;; +88800-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA6568-5;1;Not at all;;; +88800-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA28567-8;2;Mildly;;; +88800-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA13939-6;3;Moderately;;; +88800-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA28568-6;4;Severely;;; +88800-8;LL4899-2;Not at all|Mildly|Moderately|Severely|Totally;LA28569-4;5;Totally;;; +88759-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA6270-8;1;Never;;; +88759-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA18876-5;2;Monthly;;; +88759-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA18891-4;3;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +88759-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA14435-4;4;Daily;;; +88759-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA6174-2;5;Constantly;;; +88801-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA6270-8;1;Never;;; +88801-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA18876-5;2;Monthly;;; +88801-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA18891-4;3;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +88801-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA14435-4;4;Daily;;; +88801-6;LL4895-0;Never|Monthly|Weekly|Daily|Constantly;LA6174-2;5;Constantly;;; +88767-9;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA6270-8;1;Never;;; +88767-9;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA18876-5;2;Monthly;;; +88767-9;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA18891-4;3;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +88767-9;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA14435-4;4;Daily;;; +88767-9;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA9933-8;5;Always;;; +88806-5;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA6270-8;1;Never;;; +88806-5;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA18876-5;2;Monthly;;; +88806-5;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA18891-4;3;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +88806-5;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA14435-4;4;Daily;;; +88806-5;LL4902-4;Never(0)Monthly(1)Weekly(2)Daily(3)Always(4);LA9933-8;5;Always;;; +88793-5;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA9933-8;1;Always;;; +88793-5;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA10044-8;2;Often;;; +88793-5;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA10082-8;3;Sometimes;;; +88793-5;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA10066-1;4;Rarely;;; +88793-5;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA6270-8;5;Never;;; +88794-3;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA9933-8;1;Always;;; +88794-3;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA10044-8;2;Often;;; +88794-3;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA10082-8;3;Sometimes;;; +88794-3;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA10066-1;4;Rarely;;; +88794-3;LL4882-8;Always(0)Often(1)Sometimes(2)Rarely(3)Never(4);LA6270-8;5;Never;;; +88855-2;LL4877-8;Time interval from diagnosis to transplant, months;LA28555-3;1;<12 months;;; +88855-2;LL4877-8;Time interval from diagnosis to transplant, months;LA28563-7;2;>12 months;;; +88855-2;LL4877-8;Time interval from diagnosis to transplant, months;LA28555-3;1;<12 months;;; +88855-2;LL4877-8;Time interval from diagnosis to transplant, months;LA28563-7;2;>12 months;;; +8885-6;LL3627-8;Heart rate measurement sites;LA24033-5;0;Brachial artery;;; +8885-6;LL3627-8;Heart rate measurement sites;LA24031-9;1;Carotid artery;;; +8885-6;LL3627-8;Heart rate measurement sites;LA24034-3;2;Dorsalis pedis artery;;; +8885-6;LL3627-8;Heart rate measurement sites;LA24032-7;3;Femoral artery;;; +8885-6;LL3627-8;Heart rate measurement sites;LA24035-0;4;Posterior tibial artery;;; +8885-6;LL3627-8;Heart rate measurement sites;LA24030-1;5;Radial artery;;; +8885-6;LL3627-8;Heart rate measurement sites;LA24036-8;6;Cardiac apex;;; +88857-8;LL4876-0;Donor recipient gender combination (HSCT);LA28553-8;1;Female donor, male recipient;;; +88857-8;LL4876-0;Donor recipient gender combination (HSCT);LA28554-6;2;All other donor-recipient combinations;;; +88857-8;LL4876-0;Donor recipient gender combination (HSCT);LA28553-8;1;Female donor, male recipient;;; +88857-8;LL4876-0;Donor recipient gender combination (HSCT);LA28554-6;2;All other donor-recipient combinations;;; +88858-6;LL4875-2;Donor type (HSCT);LA28551-2;1;HLA-identical sibling donor;;; +88858-6;LL4875-2;Donor type (HSCT);LA28552-0;2;Unrelated donor, other;;; +88858-6;LL4875-2;Donor type (HSCT);LA28551-2;1;HLA-identical sibling donor;;; +88858-6;LL4875-2;Donor type (HSCT);LA28552-0;2;Unrelated donor, other;;; +88859-4;LL4879-4;Disease stage (HSCT);LA28731-0;1;Early disease stage;;; +88859-4;LL4879-4;Disease stage (HSCT);LA28732-8;2;Intermediate disease stage;;; +88859-4;LL4879-4;Disease stage (HSCT);LA28733-6;3;Late disease stage;;; +88859-4;LL4879-4;Disease stage (HSCT);LA28731-0;1;Early disease stage;;; +88859-4;LL4879-4;Disease stage (HSCT);LA28732-8;2;Intermediate disease stage;;; +88859-4;LL4879-4;Disease stage (HSCT);LA28733-6;3;Late disease stage;;; +88860-2;LL4880-2;<2 years | 2-10 years | 11-20 years | 21-40 years;LA28725-2;1;<2 years;;; +88860-2;LL4880-2;<2 years | 2-10 years | 11-20 years | 21-40 years;LA28726-0;2;2-10 years;;; +88860-2;LL4880-2;<2 years | 2-10 years | 11-20 years | 21-40 years;LA28727-8;3;11-20 years;;; +88860-2;LL4880-2;<2 years | 2-10 years | 11-20 years | 21-40 years;LA28728-6;4;21-40 years;;; +88860-2;LL4880-2;<2 years | 2-10 years | 11-20 years | 21-40 years;LA28729-4;5;41-65 years;;; +88860-2;LL4880-2;<2 years | 2-10 years | 11-20 years | 21-40 years;LA28730-2;6;>65 years;;; +88860-2;LL4926-3;<20 years | 20-40 years | >40 years;LA28564-5;1;<20 years;;; +88860-2;LL4926-3;<20 years | 20-40 years | >40 years;LA28565-2;2;20-40 years;;; +88860-2;LL4926-3;<20 years | 20-40 years | >40 years;LA28566-0;3;>40 years;;; +88860-2;LL5854-6;FINDRISC - Age Category;LA31987-3;1;Under 45 years;;; +88860-2;LL5854-6;FINDRISC - Age Category;LA31988-1;2;45-54 years;;; +88860-2;LL5854-6;FINDRISC - Age Category;LA31989-9;3;55-64 years;;; +88860-2;LL5854-6;FINDRISC - Age Category;LA31990-7;4;Over 64 years;;; +88860-2;LL6323-1;Champs Age 36M;LA33638-0;1;Age 36 months or greater;;; +88860-2;LL6323-1;Champs Age 36M;LA33639-8;2;Age less than 36 months;;; +88862-8;LL4925-5;EBMT HSCT risk interpretation;LA28721-1;1;Low risk (EBMT);;; +88862-8;LL4925-5;EBMT HSCT risk interpretation;LA28722-9;2;Intermediate risk (EBMT);;; +88862-8;LL4925-5;EBMT HSCT risk interpretation;LA28723-7;3;Poor risk (EBMT);;; +8886-4;LL3626-0;Heart rate measurement methods;LA24025-1;0;Acoustic monitoring;;; +8886-4;LL3626-0;Heart rate measurement methods;LA24012-9;1;Auscultation - manual;;; +8886-4;LL3626-0;Heart rate measurement methods;LA24029-3;2;EKG/ECG;;; +8886-4;LL3626-0;Heart rate measurement methods;LA24014-5;3;Oscillometry;;; +8886-4;LL3626-0;Heart rate measurement methods;LA24028-5;4;Palpation;;; +8886-4;LL3626-0;Heart rate measurement methods;LA24027-7;5;Pulse oximetry;;; +88922-0;LL2261-7;Actinomyces;LA19188-4;1;Actinomyces israelii;;; +88922-0;LL2261-7;Actinomyces;LA19189-2;2;Actinomyces naeslundii;;; +88922-0;LL2261-7;Actinomyces;LA19190-0;3;Actinomyces bovis;;; +88922-0;LL2261-7;Actinomyces;LA19191-8;4;Actinomyces canis;;; +90458-1;LL2261-7;Actinomyces;LA19188-4;1;Actinomyces israelii;;; +90458-1;LL2261-7;Actinomyces;LA19189-2;2;Actinomyces naeslundii;;; +90458-1;LL2261-7;Actinomyces;LA19190-0;3;Actinomyces bovis;;; +90458-1;LL2261-7;Actinomyces;LA19191-8;4;Actinomyces canis;;; +9816-0;LL2261-7;Actinomyces;LA19188-4;1;Actinomyces israelii;;; +9816-0;LL2261-7;Actinomyces;LA19189-2;2;Actinomyces naeslundii;;; +9816-0;LL2261-7;Actinomyces;LA19190-0;3;Actinomyces bovis;;; +9816-0;LL2261-7;Actinomyces;LA19191-8;4;Actinomyces canis;;; +88982-4;LL4942-0;CDAI_Interpretation;LA28783-1;1;Remission;;; +88982-4;LL4942-0;CDAI_Interpretation;LA28784-9;2;Low activity;;; +88982-4;LL4942-0;CDAI_Interpretation;LA9642-5;3;Moderate activity;;; +88982-4;LL4942-0;CDAI_Interpretation;LA28786-4;4;High activity;;; +88983-2;LL4940-4;Joints;LA18773-4;1;Shoulder-left;;; +88983-2;LL4940-4;Joints;LA18774-2;2;Shoulder-right;;; +88983-2;LL4940-4;Joints;LA18743-7;3;Elbow-left;;; +88983-2;LL4940-4;Joints;LA18744-5;4;Elbow-right;;; +88983-2;LL4940-4;Joints;LA18766-8;5;Wrist-left;;; +88983-2;LL4940-4;Joints;LA18765-0;6;Wrist-right;;; +88983-2;LL4940-4;Joints;LA28760-9;7;Metacarpophalangeal 1-left;;; +88983-2;LL4940-4;Joints;LA28761-7;8;Metacarpophalangeal 1-right;;; +88983-2;LL4940-4;Joints;LA28762-5;9;Metacarpophalangeal 2-left;;; +88983-2;LL4940-4;Joints;LA28763-3;10;Metacarpophalangeal 2-right;;; +88983-2;LL4940-4;Joints;LA28764-1;11;Metacarpophalangeal 3-left;;; +88983-2;LL4940-4;Joints;LA28765-8;12;Metacarpophalangeal 3-right;;; +88983-2;LL4940-4;Joints;LA28766-6;13;Metacarpophalangeal 4-left;;; +88983-2;LL4940-4;Joints;LA28767-4;14;Metacarpophalangeal 4-right;;; +88983-2;LL4940-4;Joints;LA28768-2;15;Metacarpophalangeal 5-left;;; +88983-2;LL4940-4;Joints;LA28769-0;16;Metacarpophalangeal 5-right;;; +88983-2;LL4940-4;Joints;LA28770-8;17;Proximal Interphalangeal 1-left;;; +88983-2;LL4940-4;Joints;LA28771-6;18;Proximal Interphalangeal 1-right;;; +88983-2;LL4940-4;Joints;LA28772-4;19;Proximal Interphalangeal 2-left;;; +88983-2;LL4940-4;Joints;LA28773-2;20;Proximal Interphalangeal 2-right;;; +88983-2;LL4940-4;Joints;LA28774-0;21;Proximal Interphalangeal 3-left;;; +88983-2;LL4940-4;Joints;LA28775-7;22;Proximal Interphalangeal 3-right;;; +88983-2;LL4940-4;Joints;LA28776-5;23;Proximal Interphalangeal 4-left;;; +88983-2;LL4940-4;Joints;LA28777-3;24;Proximal Interphalangeal 4-right;;; +88983-2;LL4940-4;Joints;LA28778-1;25;Proximal Interphalangeal 5-left;;; +88983-2;LL4940-4;Joints;LA28779-9;26;Proximal Interphalangeal 5-right;;; +88983-2;LL4940-4;Joints;LA18767-6;27;Knee-left;;; +88983-2;LL4940-4;Joints;LA18768-4;28;Knee-right;;; +88984-0;LL4940-4;Joints;LA18773-4;1;Shoulder-left;;; +88984-0;LL4940-4;Joints;LA18774-2;2;Shoulder-right;;; +88984-0;LL4940-4;Joints;LA18743-7;3;Elbow-left;;; +88984-0;LL4940-4;Joints;LA18744-5;4;Elbow-right;;; +88984-0;LL4940-4;Joints;LA18766-8;5;Wrist-left;;; +88984-0;LL4940-4;Joints;LA18765-0;6;Wrist-right;;; +88984-0;LL4940-4;Joints;LA28760-9;7;Metacarpophalangeal 1-left;;; +88984-0;LL4940-4;Joints;LA28761-7;8;Metacarpophalangeal 1-right;;; +88984-0;LL4940-4;Joints;LA28762-5;9;Metacarpophalangeal 2-left;;; +88984-0;LL4940-4;Joints;LA28763-3;10;Metacarpophalangeal 2-right;;; +88984-0;LL4940-4;Joints;LA28764-1;11;Metacarpophalangeal 3-left;;; +88984-0;LL4940-4;Joints;LA28765-8;12;Metacarpophalangeal 3-right;;; +88984-0;LL4940-4;Joints;LA28766-6;13;Metacarpophalangeal 4-left;;; +88984-0;LL4940-4;Joints;LA28767-4;14;Metacarpophalangeal 4-right;;; +88984-0;LL4940-4;Joints;LA28768-2;15;Metacarpophalangeal 5-left;;; +88984-0;LL4940-4;Joints;LA28769-0;16;Metacarpophalangeal 5-right;;; +88984-0;LL4940-4;Joints;LA28770-8;17;Proximal Interphalangeal 1-left;;; +88984-0;LL4940-4;Joints;LA28771-6;18;Proximal Interphalangeal 1-right;;; +88984-0;LL4940-4;Joints;LA28772-4;19;Proximal Interphalangeal 2-left;;; +88984-0;LL4940-4;Joints;LA28773-2;20;Proximal Interphalangeal 2-right;;; +88984-0;LL4940-4;Joints;LA28774-0;21;Proximal Interphalangeal 3-left;;; +88984-0;LL4940-4;Joints;LA28775-7;22;Proximal Interphalangeal 3-right;;; +88984-0;LL4940-4;Joints;LA28776-5;23;Proximal Interphalangeal 4-left;;; +88984-0;LL4940-4;Joints;LA28777-3;24;Proximal Interphalangeal 4-right;;; +88984-0;LL4940-4;Joints;LA28778-1;25;Proximal Interphalangeal 5-left;;; +88984-0;LL4940-4;Joints;LA28779-9;26;Proximal Interphalangeal 5-right;;; +88984-0;LL4940-4;Joints;LA18767-6;27;Knee-left;;; +88984-0;LL4940-4;Joints;LA18768-4;28;Knee-right;;; +88999-8;LL4892-7;Omega-3 index risk;LA28572-8;0;Index <2.2: High risk of cardiovascular disease;;; +88999-8;LL4892-7;Omega-3 index risk;LA28573-6;1;Index 2.2-3.2: Moderate risk of cardiovascular disease;;; +88999-8;LL4892-7;Omega-3 index risk;LA28574-4;2;Index >3.2: Low risk of cardiovascular disease;;; +89009-5;LL4988-3;Encounter location type;LA14084-0;1;Home;;; +89009-5;LL4988-3;Encounter location type;LA18689-2;2;Nursing home/assisted living facility;;; +89009-5;LL4988-3;Encounter location type;LA16501-1;3;Work;;; +89009-5;LL4988-3;Encounter location type;LA28893-8;4;Sports facility;;; +89009-5;LL4988-3;Encounter location type;LA18687-6;5;Medical office/clinic;;; +89009-5;LL4988-3;Encounter location type;LA11504-0;6;Hospital emergency department;;; +89009-5;LL4988-3;Encounter location type;LA28900-1;7;Hospital non-emergency department;;; +89009-5;LL4988-3;Encounter location type;LA28895-3;8;Birth house;;; +89009-5;LL4988-3;Encounter location type;LA28896-1;9;Public place;;; +89009-5;LL4988-3;Encounter location type;LA28897-9;10;Street;;; +89009-5;LL4988-3;Encounter location type;LA28898-7;11;Educational institution;;; +89009-5;LL5712-6;AAPCHO - Encounter Type;LA31379-3;1;Face to face;;; +89009-5;LL5712-6;AAPCHO - Encounter Type;LA31380-1;2;Phone-based telehealth;;; +89009-5;LL5712-6;AAPCHO - Encounter Type;LA31382-7;3;Video-based telehealth;;; +89009-5;LL5712-6;AAPCHO - Encounter Type;LA31383-5;4;Off-site;;; +89009-5;LL5712-6;AAPCHO - Encounter Type;LA31384-3;5;Others;;; +89012-9;LL4648-3;Emergency personnel training level;LA28117-2;1;Paramedic with 2 years of training;;; +89012-9;LL4648-3;Emergency personnel training level;LA28118-0;2;Paramedic with 3 years of training;;; +89012-9;LL4648-3;Emergency personnel training level;LA28119-8;3;Paramedic with 520 hours of training;;; +89012-9;LL4648-3;Emergency personnel training level;LA28120-6;4;Intensive care nurse;;; +89041-8;LL4916-4;Lung cancer antibody panel interpretation;LA28695-7;0;No significant level of autoantibodies detected;;; +89041-8;LL4916-4;Lung cancer antibody panel interpretation;LA28696-5;1;Moderate level of one or more autoantibodies detected;;; +89041-8;LL4916-4;Lung cancer antibody panel interpretation;LA28697-3;2;High level of one or more autoantibodies detected;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA16346-1;14;Other medical condition;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA16346-1;14;Other medical condition;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA16346-1;14;Other medical condition;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA16346-1;14;Other medical condition;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL4973-5;CMS MDS 1.16.1 primary medical condition category;LA16346-1;14;Other medical condition;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL5227-5;CMS MDS 1.17.1 primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA22099-8;1;Stroke;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28875-5;2;Non-traumatic brain dysfunction;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28876-3;3;Traumatic brain dysfunction;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28877-1;4;Non-traumatic spinal cord dysfunction;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28878-9;5;Traumatic spinal cord dysfunction;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28879-7;6;Progressive neurological conditions;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28880-5;7;Other neurological conditions;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28881-3;8;Amputation;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28882-1;9;Hip and knee replacement;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28883-9;10;Fractures and other multiple trauma;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28884-7;11;Other orthopedic conditions;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28885-4;12;Debility, cardiorespiratory conditions;;; +89045-9;LL5250-7;CMS MDS 17 IPA primary medical condition category;LA28886-2;13;Medically complex conditions;;; +89054-1;LL4999-0;Circulatory assistive devices;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +89054-1;LL4999-0;Circulatory assistive devices;LA28959-7;2;Percutaneous cardiopulmonary support (PCPS);;; +89054-1;LL4999-0;Circulatory assistive devices;LA28960-5;3;Intra-aortic balloon pump (IABP);;; +89054-1;LL4999-0;Circulatory assistive devices;LA9994-0;4;Left Ventricular Assistive Device (LVAD);;; +89054-1;LL4999-0;Circulatory assistive devices;LA28961-3;5;Intra-cardiac indwelling pump device (IIPD);;; +89054-1;LL4999-0;Circulatory assistive devices;LA46-8;6;Other;;; +89055-8;LL4999-0;Circulatory assistive devices;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +89055-8;LL4999-0;Circulatory assistive devices;LA28959-7;2;Percutaneous cardiopulmonary support (PCPS);;; +89055-8;LL4999-0;Circulatory assistive devices;LA28960-5;3;Intra-aortic balloon pump (IABP);;; +89055-8;LL4999-0;Circulatory assistive devices;LA9994-0;4;Left Ventricular Assistive Device (LVAD);;; +89055-8;LL4999-0;Circulatory assistive devices;LA28961-3;5;Intra-cardiac indwelling pump device (IIPD);;; +89055-8;LL4999-0;Circulatory assistive devices;LA46-8;6;Other;;; +89056-6;LL4999-0;Circulatory assistive devices;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +89056-6;LL4999-0;Circulatory assistive devices;LA28959-7;2;Percutaneous cardiopulmonary support (PCPS);;; +89056-6;LL4999-0;Circulatory assistive devices;LA28960-5;3;Intra-aortic balloon pump (IABP);;; +89056-6;LL4999-0;Circulatory assistive devices;LA9994-0;4;Left Ventricular Assistive Device (LVAD);;; +89056-6;LL4999-0;Circulatory assistive devices;LA28961-3;5;Intra-cardiac indwelling pump device (IIPD);;; +89056-6;LL4999-0;Circulatory assistive devices;LA46-8;6;Other;;; +89057-4;LL4959-4;Permission granted | Permission not granted;LA28800-3;1;Permission granted;;; +89057-4;LL4959-4;Permission granted | Permission not granted;LA28801-1;2;Permission not granted;;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA28788-0;1;Brilinta (Ticagrelor);;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA28789-8;2;Coumadin (Warfarin);;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA28790-6;3;Eliquis (Apixaban);;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA28791-4;4;Pradaxa (Dabigatran);;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA28792-2;5;Savaysa (Edoxaban);;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA28793-0;6;Xarelto (Rivaroxaban);;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA46-8;7;Other;;; +89063-2;LL4955-2;Anticoagulant medications - ADAPTABLE;LA28794-8;8;I'm not taking any of these;;; +89064-0;LL4967-7;Medications for stomach upset;LA28825-0;1;Cimetidine (Tagamet);;; +89064-0;LL4967-7;Medications for stomach upset;LA28826-8;2;Dexlansoprazole (Dexilant, Kapidex);;; +89064-0;LL4967-7;Medications for stomach upset;LA28834-2;3;Esomeprazole (Nexium);;; +89064-0;LL4967-7;Medications for stomach upset;LA28835-9;4;Famotidine (Pepcid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28836-7;5;Lansoprazole (Prevacid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28837-5;6;Nizadtidine (Axid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28838-3;7;Omeprazole (Prilosec, Zegerid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28839-1;8;Pantoprazole (Protonix);;; +89064-0;LL4967-7;Medications for stomach upset;LA28840-9;9;Rabeprazole (Aciphex);;; +89064-0;LL4967-7;Medications for stomach upset;LA28841-7;10;Ranitidine (Zantac);;; +89064-0;LL4967-7;Medications for stomach upset;LA28824-3;11;I don't take any of these routinely;;; +89064-0;LL4967-7;Medications for stomach upset;LA28825-0;1;Cimetidine (Tagamet);;; +89064-0;LL4967-7;Medications for stomach upset;LA28826-8;2;Dexlansoprazole (Dexilant, Kapidex);;; +89064-0;LL4967-7;Medications for stomach upset;LA28834-2;3;Esomeprazole (Nexium);;; +89064-0;LL4967-7;Medications for stomach upset;LA28835-9;4;Famotidine (Pepcid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28836-7;5;Lansoprazole (Prevacid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28837-5;6;Nizadtidine (Axid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28838-3;7;Omeprazole (Prilosec, Zegerid);;; +89064-0;LL4967-7;Medications for stomach upset;LA28839-1;8;Pantoprazole (Protonix);;; +89064-0;LL4967-7;Medications for stomach upset;LA28840-9;9;Rabeprazole (Aciphex);;; +89064-0;LL4967-7;Medications for stomach upset;LA28841-7;10;Ranitidine (Zantac);;; +89064-0;LL4967-7;Medications for stomach upset;LA28824-3;11;I don't take any of these routinely;;; +89065-7;LL4966-9;NSAIDs;LA28827-6;1;Celecoxib (Celebrex);;; +89065-7;LL4966-9;NSAIDs;LA28828-4;2;Diclofenac (Voltaren);;; +89065-7;LL4966-9;NSAIDs;LA28829-2;3;Ibuprofen (Motrin, Advil);;; +89065-7;LL4966-9;NSAIDs;LA28830-0;4;Indomethacin (Indocin);;; +89065-7;LL4966-9;NSAIDs;LA28831-8;5;Naproxen (Aleve, Anaprox, Naprosyn);;; +89065-7;LL4966-9;NSAIDs;LA28832-6;6;Ketorolac (Toradol);;; +89065-7;LL4966-9;NSAIDs;LA28833-4;7;Meloxicam (Mobic);;; +89065-7;LL4966-9;NSAIDs;LA28824-3;8;I don't take any of these routinely;;; +89065-7;LL4966-9;NSAIDs;LA28827-6;1;Celecoxib (Celebrex);;; +89065-7;LL4966-9;NSAIDs;LA28828-4;2;Diclofenac (Voltaren);;; +89065-7;LL4966-9;NSAIDs;LA28829-2;3;Ibuprofen (Motrin, Advil);;; +89065-7;LL4966-9;NSAIDs;LA28830-0;4;Indomethacin (Indocin);;; +89065-7;LL4966-9;NSAIDs;LA28831-8;5;Naproxen (Aleve, Anaprox, Naprosyn);;; +89065-7;LL4966-9;NSAIDs;LA28832-6;6;Ketorolac (Toradol);;; +89065-7;LL4966-9;NSAIDs;LA28833-4;7;Meloxicam (Mobic);;; +89065-7;LL4966-9;NSAIDs;LA28824-3;8;I don't take any of these routinely;;; +89067-3;LL4965-1;Blood thinning medications;LA28819-3;1;Effient (prasugrel);;; +89067-3;LL4965-1;Blood thinning medications;LA28820-1;2;Plavix (clopidogrel);;; +89067-3;LL4965-1;Blood thinning medications;LA28821-9;3;Pletal (cilostazol);;; +89067-3;LL4965-1;Blood thinning medications;LA28822-7;4;Ticlid (ticlopidine);;; +89067-3;LL4965-1;Blood thinning medications;LA28823-5;5;Zontivity (vorapaxar);;; +89067-3;LL4965-1;Blood thinning medications;LA28824-3;6;I don't take any of these routinely;;; +89067-3;LL4965-1;Blood thinning medications;LA28819-3;1;Effient (prasugrel);;; +89067-3;LL4965-1;Blood thinning medications;LA28820-1;2;Plavix (clopidogrel);;; +89067-3;LL4965-1;Blood thinning medications;LA28821-9;3;Pletal (cilostazol);;; +89067-3;LL4965-1;Blood thinning medications;LA28822-7;4;Ticlid (ticlopidine);;; +89067-3;LL4965-1;Blood thinning medications;LA28823-5;5;Zontivity (vorapaxar);;; +89067-3;LL4965-1;Blood thinning medications;LA28824-3;6;I don't take any of these routinely;;; +89072-3;LL4963-6;81 mg | 162 mg | 325 mg;LA28808-6;1;81 mg;;; +89072-3;LL4963-6;81 mg | 162 mg | 325 mg;LA28809-4;2;162 mg;;; +89072-3;LL4963-6;81 mg | 162 mg | 325 mg;LA28810-2;3;325 mg;;; +89072-3;LL4963-6;81 mg | 162 mg | 325 mg;LA46-8;4;Other;;; +89081-4;LL4963-6;81 mg | 162 mg | 325 mg;LA28808-6;1;81 mg;;; +89081-4;LL4963-6;81 mg | 162 mg | 325 mg;LA28809-4;2;162 mg;;; +89081-4;LL4963-6;81 mg | 162 mg | 325 mg;LA28810-2;3;325 mg;;; +89081-4;LL4963-6;81 mg | 162 mg | 325 mg;LA46-8;4;Other;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28811-0;1;I stopped because of GI upset;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28812-8;2;I stopped because of bleeding;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28816-9;3;I stopped because of other:;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28813-6;4;My doctor told me to stop taking aspirin because of GI upset;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28814-4;5;My doctor told me to stop taking aspirin because of need for a different medication;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28815-1;6;My doctor told me to stop taking aspirin because of bleeding;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28817-7;7;My doctor told me to stop taking aspirin because of other:;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28818-5;8;Not sure why my doctor wanted to stop it;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28811-0;1;I stopped because of GI upset;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28812-8;2;I stopped because of bleeding;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28816-9;3;I stopped because of other:;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28813-6;4;My doctor told me to stop taking aspirin because of GI upset;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28814-4;5;My doctor told me to stop taking aspirin because of need for a different medication;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28815-1;6;My doctor told me to stop taking aspirin because of bleeding;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28817-7;7;My doctor told me to stop taking aspirin because of other:;;; +89073-1;LL4964-4;ADAPTABLE Reasons to stop take aspirin;LA28818-5;8;Not sure why my doctor wanted to stop it;;; +89075-6;LL4951-1;Yes | No | Not currently taking aspirin;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89075-6;LL4951-1;Yes | No | Not currently taking aspirin;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89075-6;LL4951-1;Yes | No | Not currently taking aspirin;LA28787-2;3;Not currently taking aspirin;;; +89077-2;LL4957-8;Too brief | Just right | Too long;LA28797-1;1;Too brief;;; +89077-2;LL4957-8;Too brief | Just right | Too long;LA28798-9;2;Just right;;; +89077-2;LL4957-8;Too brief | Just right | Too long;LA28799-7;3;Too long;;; +89080-6;LL4956-0;Easy to navigate | Moderate | Hard or confusing;LA28795-5;1;Easy to navigate;;; +89080-6;LL4956-0;Easy to navigate | Moderate | Hard or confusing;LA6751-7;2;Moderate;;; +89080-6;LL4956-0;Easy to navigate | Moderate | Hard or confusing;LA28796-3;3;Hard or confusing;;; +89089-7;LL5005-5;Immigration status;LA29147-8;1;Alien;;; +89089-7;LL5005-5;Immigration status;LA29152-8;2;Asylee;;; +89089-7;LL5005-5;Immigration status;LA27161-1;3;Immigrant;;; +89089-7;LL5005-5;Immigration status;LA29149-4;4;Lawful permanent resident (LPR);;; +89089-7;LL5005-5;Immigration status;LA29154-4;5;Native-born citizen;;; +89089-7;LL5005-5;Immigration status;LA29155-1;6;Naturalized citizen;;; +89089-7;LL5005-5;Immigration status;LA29151-0;7;Parolee;;; +89089-7;LL5005-5;Immigration status;LA29156-9;8;Public charge;;; +89089-7;LL5005-5;Immigration status;LA29153-6;9;Refugee;;; +89089-7;LL5005-5;Immigration status;LA29150-2;10;Returning resident;;; +89092-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89092-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89092-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89092-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89092-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89093-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89093-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89093-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89093-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89093-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89094-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89094-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89094-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89094-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89094-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89095-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89095-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89095-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89095-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89095-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89096-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89096-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89096-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89096-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89096-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89097-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89097-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89097-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89097-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89097-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89098-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89098-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89098-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89098-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89098-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89099-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89099-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89099-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89099-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89099-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89100-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89100-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89100-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89100-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89100-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89101-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89101-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89101-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89101-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89101-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89102-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89102-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89102-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89102-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89102-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89103-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89103-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89103-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89103-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89103-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89104-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89104-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89104-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89104-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89104-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89105-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89105-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89105-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89105-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89105-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89106-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89106-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89106-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89106-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89106-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89107-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89107-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89107-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89107-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89107-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89108-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89108-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89108-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89108-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89108-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89109-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89109-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89109-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89109-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89109-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89110-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89110-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89110-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89110-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89110-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89111-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89111-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89111-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89111-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89111-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89112-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89112-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89112-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89112-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89112-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89113-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89113-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89113-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89113-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89113-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89114-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89114-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89114-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89114-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89114-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89115-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89115-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89115-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89115-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89115-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89116-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89116-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89116-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89116-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89116-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89117-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89117-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89117-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89117-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89117-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89118-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89118-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89118-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89118-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89118-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89119-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89119-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89119-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89119-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89119-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89120-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89120-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89120-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89120-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89120-0;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89121-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89121-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89121-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89121-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89121-8;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89122-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89122-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89122-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89122-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89122-6;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89123-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89123-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89123-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89123-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89123-4;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89124-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89124-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89124-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89124-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89124-2;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89125-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89125-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89125-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89125-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89125-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89126-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89126-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89126-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89126-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89126-7;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89127-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89127-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89127-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89127-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89127-5;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89128-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89128-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89128-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89128-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89128-3;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89129-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89129-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89129-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89129-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89129-1;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89130-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29137-9;1;No change or actually performs better than 10 years ago;;; +89130-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29138-7;2;Occasionally performs the task worse but not all of the time;;; +89130-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29139-5;3;Consistently performs the task a little worse than 10 years ago;;; +89130-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA29140-3;4;Consistently performs the task much worse than 10 years ago;;; +89130-9;LL5035-2;ECog_P_Better|Occ worse|Little worse|Much worse|DK;LA15599-6;5;I don’t know;;; +89135-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89135-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89135-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89135-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89135-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89136-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89136-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89136-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89136-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89136-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89137-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89137-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89137-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89137-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89137-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89138-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89138-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89138-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89138-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89138-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89139-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89139-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89139-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89139-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89139-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89140-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89140-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89140-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89140-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89140-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89141-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89141-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89141-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89141-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89141-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89142-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89142-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89142-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89142-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89142-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89143-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89143-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89143-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89143-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89143-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89144-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89144-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89144-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89144-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89144-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89145-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89145-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89145-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89145-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89145-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89146-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89146-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89146-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89146-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89146-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89147-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89147-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89147-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89147-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89147-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89148-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89148-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89148-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89148-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89148-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89149-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89149-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89149-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89149-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89149-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89150-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89150-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89150-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89150-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89150-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89151-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89151-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89151-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89151-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89151-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89152-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89152-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89152-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89152-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89152-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89153-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89153-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89153-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89153-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89153-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89154-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89154-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89154-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89154-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89154-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89155-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89155-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89155-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89155-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89155-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89156-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89156-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89156-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89156-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89156-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89157-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89157-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89157-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89157-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89157-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89158-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89158-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89158-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89158-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89158-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89159-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89159-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89159-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89159-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89159-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89160-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89160-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89160-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89160-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89160-6;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89161-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89161-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89161-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89161-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89161-4;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89162-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89162-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89162-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89162-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89162-2;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89163-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89163-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89163-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89163-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89163-0;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89164-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89164-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89164-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89164-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89164-8;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89165-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89165-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89165-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89165-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89165-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89166-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89166-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89166-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89166-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89166-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89167-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89167-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89167-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89167-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89167-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89168-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89168-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89168-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89168-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89168-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89169-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89169-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89169-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89169-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89169-7;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89170-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89170-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89170-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89170-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89170-5;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89171-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89171-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89171-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89171-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89171-3;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89172-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89172-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89172-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89172-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89172-1;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89173-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28962-1;1;There has been no change in my ability or I actually perform better compared to 10 years ago;;; +89173-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA28963-9;2;I occasionally perform the task worse but not all of the time;;; +89173-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29135-3;3;I consistently perform the task a little worse than 10 years ago;;; +89173-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA29136-1;4;I consistently perform the task much worse than 10 years ago;;; +89173-9;LL4995-8;ECog_Better|Occ worse|Little worse|Much worse|IDK;LA15599-6;5;I don’t know;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89179-6;LL5012-1;APTA_Therapeutic exercise;LA28970-4;2;Aerobic capacity/endurance conditioning or reconditioning;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA28971-2;3;Aerobic capacity/endurance conditioning or reconditioning: Aquatic programs;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA28972-0;4;Aerobic capacity/endurance conditioning or reconditioning: Gait and locomotor training;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA28973-8;5;Aerobic capacity/endurance conditioning or reconditioning: Increased workload over time;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA28974-6;6;Aerobic capacity/endurance conditioning or reconditioning: Movement efficiency and energy conservation training;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA28975-3;7;Aerobic capacity/endurance conditioning or reconditioning: Walking and wheelchair propulsion programs;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29030-6;8;Flexibility exercises;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29031-4;9;Flexibility exercises: Muscle lengthening;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29032-2;10;Flexibility exercises: Range of motion;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29033-0;11;Flexibility exercises: Stretching;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29086-8;12;Neuromotor development training;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29087-6;13;Neuromotor development training: Developmental activities training;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29088-4;14;Neuromotor development training: Motor training;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29089-2;15;Neuromotor development training: Movement pattern training;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29090-0;16;Neuromotor development training: Neuromuscular education or reeducation;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA25355-1;17;Relaxation;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29107-2;18;Relaxation: Breathing strategies;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29108-0;19;Relaxation: Movement strategies;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29109-8;20;Relaxation: Relaxation techniques;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29110-6;21;Relaxation: Standardized, programmatic, complementary exercise approaches;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29116-3;22;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29117-1;23;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Active assistive, active, and resistive exercises (including concentric, dynamic/isotonic, eccentric, isokinetic, isometric, and plyometric);;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29118-9;24;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Aquatic programs;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29119-7;25;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Standardized, programmatic, or complementary exercise approaches;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA29120-5;26;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Task-specific performance training;;; +89179-6;LL5012-1;APTA_Therapeutic exercise;LA46-8;27;Other;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +92565-1;LL5012-1;APTA_Therapeutic exercise;LA28970-4;2;Aerobic capacity/endurance conditioning or reconditioning;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA28971-2;3;Aerobic capacity/endurance conditioning or reconditioning: Aquatic programs;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA28972-0;4;Aerobic capacity/endurance conditioning or reconditioning: Gait and locomotor training;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA28973-8;5;Aerobic capacity/endurance conditioning or reconditioning: Increased workload over time;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA28974-6;6;Aerobic capacity/endurance conditioning or reconditioning: Movement efficiency and energy conservation training;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA28975-3;7;Aerobic capacity/endurance conditioning or reconditioning: Walking and wheelchair propulsion programs;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29030-6;8;Flexibility exercises;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29031-4;9;Flexibility exercises: Muscle lengthening;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29032-2;10;Flexibility exercises: Range of motion;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29033-0;11;Flexibility exercises: Stretching;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29086-8;12;Neuromotor development training;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29087-6;13;Neuromotor development training: Developmental activities training;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29088-4;14;Neuromotor development training: Motor training;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29089-2;15;Neuromotor development training: Movement pattern training;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29090-0;16;Neuromotor development training: Neuromuscular education or reeducation;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA25355-1;17;Relaxation;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29107-2;18;Relaxation: Breathing strategies;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29108-0;19;Relaxation: Movement strategies;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29109-8;20;Relaxation: Relaxation techniques;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29110-6;21;Relaxation: Standardized, programmatic, complementary exercise approaches;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29116-3;22;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29117-1;23;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Active assistive, active, and resistive exercises (including concentric, dynamic/isotonic, eccentric, isokinetic, isometric, and plyometric);;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29118-9;24;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Aquatic programs;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29119-7;25;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Standardized, programmatic, or complementary exercise approaches;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA29120-5;26;Strength, power, and endurance training for head, neck, limb, pelvic-floor, trunk, and ventilatory muscles: Task-specific performance training;;; +92565-1;LL5012-1;APTA_Therapeutic exercise;LA46-8;27;Other;;; +89180-4;LL5011-3;APTA_Motor function training;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89180-4;LL5011-3;APTA_Motor function training;LA28979-5;2;Balance training;;; +89180-4;LL5011-3;APTA_Motor function training;LA28980-3;3;Balance training: Developmental activities training;;; +89180-4;LL5011-3;APTA_Motor function training;LA28981-1;4;Balance training: Motor control training or retraining;;; +89180-4;LL5011-3;APTA_Motor function training;LA28982-9;5;Balance training: Neuromuscular education or reeducation;;; +89180-4;LL5011-3;APTA_Motor function training;LA28983-7;6;Balance training: Perceptual training;;; +89180-4;LL5011-3;APTA_Motor function training;LA28984-5;7;Balance training: Standardized, programmatic, and complementary exercise approaches;;; +89180-4;LL5011-3;APTA_Motor function training;LA28985-2;8;Balance training: Task-specific performance training;;; +89180-4;LL5011-3;APTA_Motor function training;LA28986-0;9;Balance training: Vestibular training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29043-9;10;Gait and locomotion training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29044-7;11;Gait and locomotion training: Developmental activities training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29045-4;12;Gait and locomotion training: Implement and device training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29046-2;13;Gait and locomotion training: Perceptual training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29047-0;14;Gait and locomotion training: Standardized, programmatic, and complementary exercise approaches;;; +89180-4;LL5011-3;APTA_Motor function training;LA29048-8;15;Gait and locomotion training: Training of specific components of gait;;; +89180-4;LL5011-3;APTA_Motor function training;LA29049-6;16;Gait and locomotion training: Wheelchair feature and propulsion training (manual and motorized wheelchairs);;; +89180-4;LL5011-3;APTA_Motor function training;LA29097-5;17;Posture training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29098-3;18;Posture training: Developmental activities training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29099-1;19;Posture training: Neuromuscular education or reeducation;;; +89180-4;LL5011-3;APTA_Motor function training;LA29100-7;20;Posture training: Postural awareness training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29101-5;21;Posture training: Postural control training;;; +89180-4;LL5011-3;APTA_Motor function training;LA29102-3;22;Posture training: Postural stabilization activities;;; +89180-4;LL5011-3;APTA_Motor function training;LA29103-1;23;Posture training: Vestibular training;;; +89180-4;LL5011-3;APTA_Motor function training;LA46-8;24;Other;;; +92560-2;LL5011-3;APTA_Motor function training;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +92560-2;LL5011-3;APTA_Motor function training;LA28979-5;2;Balance training;;; +92560-2;LL5011-3;APTA_Motor function training;LA28980-3;3;Balance training: Developmental activities training;;; +92560-2;LL5011-3;APTA_Motor function training;LA28981-1;4;Balance training: Motor control training or retraining;;; +92560-2;LL5011-3;APTA_Motor function training;LA28982-9;5;Balance training: Neuromuscular education or reeducation;;; +92560-2;LL5011-3;APTA_Motor function training;LA28983-7;6;Balance training: Perceptual training;;; +92560-2;LL5011-3;APTA_Motor function training;LA28984-5;7;Balance training: Standardized, programmatic, and complementary exercise approaches;;; +92560-2;LL5011-3;APTA_Motor function training;LA28985-2;8;Balance training: Task-specific performance training;;; +92560-2;LL5011-3;APTA_Motor function training;LA28986-0;9;Balance training: Vestibular training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29043-9;10;Gait and locomotion training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29044-7;11;Gait and locomotion training: Developmental activities training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29045-4;12;Gait and locomotion training: Implement and device training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29046-2;13;Gait and locomotion training: Perceptual training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29047-0;14;Gait and locomotion training: Standardized, programmatic, and complementary exercise approaches;;; +92560-2;LL5011-3;APTA_Motor function training;LA29048-8;15;Gait and locomotion training: Training of specific components of gait;;; +92560-2;LL5011-3;APTA_Motor function training;LA29049-6;16;Gait and locomotion training: Wheelchair feature and propulsion training (manual and motorized wheelchairs);;; +92560-2;LL5011-3;APTA_Motor function training;LA29097-5;17;Posture training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29098-3;18;Posture training: Developmental activities training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29099-1;19;Posture training: Neuromuscular education or reeducation;;; +92560-2;LL5011-3;APTA_Motor function training;LA29100-7;20;Posture training: Postural awareness training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29101-5;21;Posture training: Postural control training;;; +92560-2;LL5011-3;APTA_Motor function training;LA29102-3;22;Posture training: Postural stabilization activities;;; +92560-2;LL5011-3;APTA_Motor function training;LA29103-1;23;Posture training: Vestibular training;;; +92560-2;LL5011-3;APTA_Motor function training;LA46-8;24;Other;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29071-0;2;Manual lymphatic drainage;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29072-8;3;Manual traction;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA25338-7;4;Massage;387854002;Massage physiotherapy (regime/therapy);http://snomed.info/sct +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29074-4;5;Massage: Connective tissue massage;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29075-1;6;Massage: Therapeutic massage;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29081-9;7;Mobilization/manipulation;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29082-7;8;Mobilization/manipulation: Dry needling;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29083-5;9;Mobilization/manipulation: Soft tissue;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29084-3;10;Mobilization/manipulation: Spinal and peripheral joints;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29085-0;11;Neural tissue mobilization;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA29093-4;12;Passive range of motion;;; +89181-2;LL5017-0;APTA_Manual therapy techniques;LA46-8;13;Other;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29071-0;2;Manual lymphatic drainage;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29072-8;3;Manual traction;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA25338-7;4;Massage;387854002;Massage physiotherapy (regime/therapy);http://snomed.info/sct +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29074-4;5;Massage: Connective tissue massage;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29075-1;6;Massage: Therapeutic massage;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29081-9;7;Mobilization/manipulation;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29082-7;8;Mobilization/manipulation: Dry needling;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29083-5;9;Mobilization/manipulation: Soft tissue;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29084-3;10;Mobilization/manipulation: Spinal and peripheral joints;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29085-0;11;Neural tissue mobilization;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA29093-4;12;Passive range of motion;;; +92559-4;LL5017-0;APTA_Manual therapy techniques;LA46-8;13;Other;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA28989-4;2;Biophysical agents;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA28990-2;3;Biophysical agents: Electrical stimulation;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA28991-0;4;Biophysical agents: Hyperbaric oxygen therapy;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA28992-8;5;Biophysical agents: Light therapies (eg, ultraviolet-C, low-level laser);;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA28993-6;6;Biophysical agents: Negative pressure wound therapy;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA28994-4;7;Biophysical agents: Pneumatic compression therapy;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA28995-1;8;Biophysical agents: Ultrasound (high and low frequency);;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29006-6;9;Debridement;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29007-4;10;Debridement: Autolytic (support through proper dressing utilization);;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29008-2;11;Debridement: Biologic (maggots or leeches);;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29009-0;12;Debridement: Low-frequency, contact ultrasound;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29010-8;13;Debridement: Mechanical;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29011-6;14;Debridement: Pulsed lavage with suction;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29012-4;15;Debridement: Sharp or selective (with instruments such as forceps, scalpels, or scissors);;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29018-1;16;Dressings;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29019-9;17;Dressings: Antimicrobial dressings;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29020-7;18;Dressings: Cellular-based and tissue-based products;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29021-5;19;Dressings: Compression bandages/systems;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29022-3;20;Dressings: Primary and secondary dressings;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29125-4;21;Topical agents;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29126-2;22;Topical agents: Anti-inflammatories;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29127-0;23;Topical agents: Cleansers;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29128-8;24;Topical agents: Creams;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29129-6;25;Topical agents: Enzymes;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29130-4;26;Topical agents: Moisturizers;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29131-2;27;Topical agents: Ointments;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA29132-0;28;Topical agents: Sealants;;; +89182-0;LL5015-4;APTA_Integumentary repair and protection;LA46-8;29;Other;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA28989-4;2;Biophysical agents;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA28990-2;3;Biophysical agents: Electrical stimulation;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA28991-0;4;Biophysical agents: Hyperbaric oxygen therapy;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA28992-8;5;Biophysical agents: Light therapies (eg, ultraviolet-C, low-level laser);;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA28993-6;6;Biophysical agents: Negative pressure wound therapy;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA28994-4;7;Biophysical agents: Pneumatic compression therapy;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA28995-1;8;Biophysical agents: Ultrasound (high and low frequency);;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29006-6;9;Debridement;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29007-4;10;Debridement: Autolytic (support through proper dressing utilization);;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29008-2;11;Debridement: Biologic (maggots or leeches);;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29009-0;12;Debridement: Low-frequency, contact ultrasound;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29010-8;13;Debridement: Mechanical;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29011-6;14;Debridement: Pulsed lavage with suction;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29012-4;15;Debridement: Sharp or selective (with instruments such as forceps, scalpels, or scissors);;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29018-1;16;Dressings;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29019-9;17;Dressings: Antimicrobial dressings;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29020-7;18;Dressings: Cellular-based and tissue-based products;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29021-5;19;Dressings: Compression bandages/systems;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29022-3;20;Dressings: Primary and secondary dressings;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29125-4;21;Topical agents;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29126-2;22;Topical agents: Anti-inflammatories;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29127-0;23;Topical agents: Cleansers;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29128-8;24;Topical agents: Creams;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29129-6;25;Topical agents: Enzymes;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29130-4;26;Topical agents: Moisturizers;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29131-2;27;Topical agents: Ointments;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA29132-0;28;Topical agents: Sealants;;; +92558-6;LL5015-4;APTA_Integumentary repair and protection;LA46-8;29;Other;;; +89183-8;LL5013-9;APTA_Functional training;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89183-8;LL5013-9;APTA_Functional training;LA28957-1;2;ADL training;;; +89183-8;LL5013-9;APTA_Functional training;LA28964-7;3;ADL training: Bathing;;; +89183-8;LL5013-9;APTA_Functional training;LA28965-4;4;ADL training: Bed mobility and transfer training;;; +89183-8;LL5013-9;APTA_Functional training;LA28966-2;5;ADL training: Dressing;;; +89183-8;LL5013-9;APTA_Functional training;LA28967-0;6;ADL training: Eating;;; +89183-8;LL5013-9;APTA_Functional training;LA28968-8;7;ADL training: Grooming;;; +89183-8;LL5013-9;APTA_Functional training;LA28969-6;8;ADL training: Toileting;;; +89183-8;LL5013-9;APTA_Functional training;LA28987-8;9;Barrier accommodations or modifications;;; +89183-8;LL5013-9;APTA_Functional training;LA29013-2;10;Developmental activities;;; +89183-8;LL5013-9;APTA_Functional training;LA29014-0;11;Device and equipment use and training;;; +89183-8;LL5013-9;APTA_Functional training;LA29015-7;12;Device and equipment use and training: Assistive and adaptive device or equipment training during IADL;;; +89183-8;LL5013-9;APTA_Functional training;LA29016-5;13;Device and equipment use and training: Orthotic, protective, or supportive device or equipment training during IADL;;; +89183-8;LL5013-9;APTA_Functional training;LA29017-3;14;Device and equipment use and training: Prosthetic device or equipment training during IADL;;; +89183-8;LL5013-9;APTA_Functional training;LA29034-8;15;Functional training programs;;; +89183-8;LL5013-9;APTA_Functional training;LA29035-5;16;Functional training programs: Back schools;;; +89183-8;LL5013-9;APTA_Functional training;LA29036-3;17;Functional training programs: Job coaching;;; +89183-8;LL5013-9;APTA_Functional training;LA29037-1;18;Functional training programs: Simulated environments and tasks;;; +89183-8;LL5013-9;APTA_Functional training;LA29038-9;19;Functional training programs: Task adaptation;;; +89183-8;LL5013-9;APTA_Functional training;LA29039-7;20;Functional training programs: Task training;;; +89183-8;LL5013-9;APTA_Functional training;LA29040-5;21;Functional training programs: Travel training;;; +89183-8;LL5013-9;APTA_Functional training;LA29041-3;22;Functional training programs: Work conditioning;;; +89183-8;LL5013-9;APTA_Functional training;LA29042-1;23;Functional training programs: Work hardening;;; +89183-8;LL5013-9;APTA_Functional training;LA29058-7;24;IADL training;;; +89183-8;LL5013-9;APTA_Functional training;LA29059-5;25;IADL training: Community service training;;; +89183-8;LL5013-9;APTA_Functional training;LA29060-3;26;IADL training: School and play activities training;;; +89183-8;LL5013-9;APTA_Functional training;LA29061-1;27;IADL training: Work training;;; +89183-8;LL5013-9;APTA_Functional training;LA29063-7;28;Injury prevention or reduction;;; +89183-8;LL5013-9;APTA_Functional training;LA29064-5;29;Injury prevention or reduction: Injury prevention education during domestic, education, work, community, social, and civic integration or reintegration;;; +89183-8;LL5013-9;APTA_Functional training;LA29065-2;30;Injury prevention or reduction: Injury prevention education with the use of devices and equipment;;; +89183-8;LL5013-9;APTA_Functional training;LA29066-0;31;Injury prevention or reduction: Safety awareness training during work, community, social, and civic life integration or reintegration;;; +89183-8;LL5013-9;APTA_Functional training;LA46-8;32;Other;;; +92556-0;LL5013-9;APTA_Functional training;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +92556-0;LL5013-9;APTA_Functional training;LA28957-1;2;ADL training;;; +92556-0;LL5013-9;APTA_Functional training;LA28964-7;3;ADL training: Bathing;;; +92556-0;LL5013-9;APTA_Functional training;LA28965-4;4;ADL training: Bed mobility and transfer training;;; +92556-0;LL5013-9;APTA_Functional training;LA28966-2;5;ADL training: Dressing;;; +92556-0;LL5013-9;APTA_Functional training;LA28967-0;6;ADL training: Eating;;; +92556-0;LL5013-9;APTA_Functional training;LA28968-8;7;ADL training: Grooming;;; +92556-0;LL5013-9;APTA_Functional training;LA28969-6;8;ADL training: Toileting;;; +92556-0;LL5013-9;APTA_Functional training;LA28987-8;9;Barrier accommodations or modifications;;; +92556-0;LL5013-9;APTA_Functional training;LA29013-2;10;Developmental activities;;; +92556-0;LL5013-9;APTA_Functional training;LA29014-0;11;Device and equipment use and training;;; +92556-0;LL5013-9;APTA_Functional training;LA29015-7;12;Device and equipment use and training: Assistive and adaptive device or equipment training during IADL;;; +92556-0;LL5013-9;APTA_Functional training;LA29016-5;13;Device and equipment use and training: Orthotic, protective, or supportive device or equipment training during IADL;;; +92556-0;LL5013-9;APTA_Functional training;LA29017-3;14;Device and equipment use and training: Prosthetic device or equipment training during IADL;;; +92556-0;LL5013-9;APTA_Functional training;LA29034-8;15;Functional training programs;;; +92556-0;LL5013-9;APTA_Functional training;LA29035-5;16;Functional training programs: Back schools;;; +92556-0;LL5013-9;APTA_Functional training;LA29036-3;17;Functional training programs: Job coaching;;; +92556-0;LL5013-9;APTA_Functional training;LA29037-1;18;Functional training programs: Simulated environments and tasks;;; +92556-0;LL5013-9;APTA_Functional training;LA29038-9;19;Functional training programs: Task adaptation;;; +92556-0;LL5013-9;APTA_Functional training;LA29039-7;20;Functional training programs: Task training;;; +92556-0;LL5013-9;APTA_Functional training;LA29040-5;21;Functional training programs: Travel training;;; +92556-0;LL5013-9;APTA_Functional training;LA29041-3;22;Functional training programs: Work conditioning;;; +92556-0;LL5013-9;APTA_Functional training;LA29042-1;23;Functional training programs: Work hardening;;; +92556-0;LL5013-9;APTA_Functional training;LA29058-7;24;IADL training;;; +92556-0;LL5013-9;APTA_Functional training;LA29059-5;25;IADL training: Community service training;;; +92556-0;LL5013-9;APTA_Functional training;LA29060-3;26;IADL training: School and play activities training;;; +92556-0;LL5013-9;APTA_Functional training;LA29061-1;27;IADL training: Work training;;; +92556-0;LL5013-9;APTA_Functional training;LA29063-7;28;Injury prevention or reduction;;; +92556-0;LL5013-9;APTA_Functional training;LA29064-5;29;Injury prevention or reduction: Injury prevention education during domestic, education, work, community, social, and civic integration or reintegration;;; +92556-0;LL5013-9;APTA_Functional training;LA29065-2;30;Injury prevention or reduction: Injury prevention education with the use of devices and equipment;;; +92556-0;LL5013-9;APTA_Functional training;LA29066-0;31;Injury prevention or reduction: Safety awareness training during work, community, social, and civic life integration or reintegration;;; +92556-0;LL5013-9;APTA_Functional training;LA46-8;32;Other;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +89184-6;LL5018-8;APTA_Biophysical agent;LA28977-9;2;Athermal agents;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA28978-7;3;Athermal agents: Pulsed electromagnetic fields;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA28988-6;4;Biofeedback;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA28996-9;5;Compression therapies;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA28997-7;6;Compression therapies: Compression bandaging;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA28998-5;7;Compression therapies: Compression garments;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA28999-3;8;Compression therapies: Taping;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29000-9;9;Compression therapies: Total contact casting;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29001-7;10;Compression therapies: Vasopneumatic compression devices;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA24680-3;11;Cryotherapy;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29003-3;12;Cryotherapy: Cold packs;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29004-1;13;Cryotherapy: Ice massage;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29005-8;14;Cryotherapy: Vapocoolant spray;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29023-1;15;Electrical stimulation (muscle and nerve);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29024-9;16;Electrical stimulation (muscle and nerve): Electrical muscle stimulation (EMS);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29025-6;17;Electrical stimulation (muscle and nerve): Electrical stimulation for tissue repair (ESTR);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29026-4;18;Electrical stimulation (muscle and nerve): Functional electrical stimulation (FES);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29027-2;19;Electrical stimulation (muscle and nerve): High-voltage pulsed current (HVPC);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29028-0;20;Electrical stimulation (muscle and nerve): Neuromuscular electrical stimulation (NMES);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29029-8;21;Electrical stimulation (muscle and nerve): Transcutaneous electrical nerve stimulation (TENS);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29051-2;22;Hydrotherapy;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29052-0;23;Hydrotherapy: Contrast bath;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29053-8;24;Hydrotherapy: Fluidotherapy;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29054-6;25;Hydrotherapy: Pools;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29055-3;26;Hydrotherapy: Pulsatile lavage;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29056-1;27;Hydrotherapy: Whirlpool tanks;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA24174-7;28;Hyperbaric Oxygen Center;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29067-8;29;Light agents;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29068-6;30;Light agents: Infrared;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29069-4;31;Light agents: Laser;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29070-2;32;Light agents: Ultraviolet;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29076-9;33;Mechanical devices;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29077-7;34;Mechanical devices: Continuous passive motion (CPM);;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29078-5;35;Mechanical devices: Standing frame;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29079-3;36;Mechanical devices: Tilt table;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29080-1;37;Mechanical devices: Traction devices;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29113-0;38;Sound agents;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29114-8;39;Sound agents: Phonophoresis;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29115-5;40;Sound agents: Ultrasound;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29121-3;41;Thermotherapy;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29122-1;42;Thermotherapy: Dry heat;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29123-9;43;Thermotherapy: Hot packs;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA29124-7;44;Thermotherapy: Paraffin baths;;; +89184-6;LL5018-8;APTA_Biophysical agent;LA46-8;45;Other;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +92555-2;LL5018-8;APTA_Biophysical agent;LA28977-9;2;Athermal agents;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA28978-7;3;Athermal agents: Pulsed electromagnetic fields;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA28988-6;4;Biofeedback;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA28996-9;5;Compression therapies;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA28997-7;6;Compression therapies: Compression bandaging;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA28998-5;7;Compression therapies: Compression garments;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA28999-3;8;Compression therapies: Taping;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29000-9;9;Compression therapies: Total contact casting;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29001-7;10;Compression therapies: Vasopneumatic compression devices;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA24680-3;11;Cryotherapy;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29003-3;12;Cryotherapy: Cold packs;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29004-1;13;Cryotherapy: Ice massage;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29005-8;14;Cryotherapy: Vapocoolant spray;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29023-1;15;Electrical stimulation (muscle and nerve);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29024-9;16;Electrical stimulation (muscle and nerve): Electrical muscle stimulation (EMS);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29025-6;17;Electrical stimulation (muscle and nerve): Electrical stimulation for tissue repair (ESTR);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29026-4;18;Electrical stimulation (muscle and nerve): Functional electrical stimulation (FES);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29027-2;19;Electrical stimulation (muscle and nerve): High-voltage pulsed current (HVPC);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29028-0;20;Electrical stimulation (muscle and nerve): Neuromuscular electrical stimulation (NMES);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29029-8;21;Electrical stimulation (muscle and nerve): Transcutaneous electrical nerve stimulation (TENS);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29051-2;22;Hydrotherapy;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29052-0;23;Hydrotherapy: Contrast bath;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29053-8;24;Hydrotherapy: Fluidotherapy;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29054-6;25;Hydrotherapy: Pools;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29055-3;26;Hydrotherapy: Pulsatile lavage;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29056-1;27;Hydrotherapy: Whirlpool tanks;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA24174-7;28;Hyperbaric Oxygen Center;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29067-8;29;Light agents;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29068-6;30;Light agents: Infrared;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29069-4;31;Light agents: Laser;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29070-2;32;Light agents: Ultraviolet;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29076-9;33;Mechanical devices;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29077-7;34;Mechanical devices: Continuous passive motion (CPM);;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29078-5;35;Mechanical devices: Standing frame;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29079-3;36;Mechanical devices: Tilt table;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29080-1;37;Mechanical devices: Traction devices;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29113-0;38;Sound agents;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29114-8;39;Sound agents: Phonophoresis;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29115-5;40;Sound agents: Ultrasound;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29121-3;41;Thermotherapy;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29122-1;42;Thermotherapy: Dry heat;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29123-9;43;Thermotherapy: Hot packs;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA29124-7;44;Thermotherapy: Paraffin baths;;; +92555-2;LL5018-8;APTA_Biophysical agent;LA46-8;45;Other;;; +89185-3;LL5014-7;APTA_Assistive technology;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +89185-3;LL5014-7;APTA_Assistive technology;LA28976-1;2;Aids for locomotion (eg, crutches, canes, walkers, rollators, manual wheelchairs, power wheelchairs, power-operated vehicles);;; +89185-3;LL5014-7;APTA_Assistive technology;LA29091-8;3;Orthoses (eg, ankle-foot orthoses [AFOs], knee-ankle-foot orthoses [KAFOs], body jackets, wrist cock-up splints, shoe inserts);;; +89185-3;LL5014-7;APTA_Assistive technology;LA29104-9;4;Prostheses (eg, transtibial and transfemoral prostheses, upper extremity prostheses);;; +89185-3;LL5014-7;APTA_Assistive technology;LA29112-2;5;Seating and positioning technologies (eg, custom-molded seating, removable lateral trunk supports and upper extremity support trays for wheelchairs, sidelyers, prone standers, manual or power recline systems for wheelchairs);;; +89185-3;LL5014-7;APTA_Assistive technology;LA29092-6;6;Other assistive technologies to improve safety, function, and independence, such as transfer technologies (eg, transfer boards, mechanical lifts/hoists) and bathroom technologies (eg, raised toilet commodes, adaptive commodes, transfer benches, sliders);;; +92554-5;LL5014-7;APTA_Assistive technology;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +92554-5;LL5014-7;APTA_Assistive technology;LA28976-1;2;Aids for locomotion (eg, crutches, canes, walkers, rollators, manual wheelchairs, power wheelchairs, power-operated vehicles);;; +92554-5;LL5014-7;APTA_Assistive technology;LA29091-8;3;Orthoses (eg, ankle-foot orthoses [AFOs], knee-ankle-foot orthoses [KAFOs], body jackets, wrist cock-up splints, shoe inserts);;; +92554-5;LL5014-7;APTA_Assistive technology;LA29104-9;4;Prostheses (eg, transtibial and transfemoral prostheses, upper extremity prostheses);;; +92554-5;LL5014-7;APTA_Assistive technology;LA29112-2;5;Seating and positioning technologies (eg, custom-molded seating, removable lateral trunk supports and upper extremity support trays for wheelchairs, sidelyers, prone standers, manual or power recline systems for wheelchairs);;; +92554-5;LL5014-7;APTA_Assistive technology;LA29092-6;6;Other assistive technologies to improve safety, function, and independence, such as transfer technologies (eg, transfer boards, mechanical lifts/hoists) and bathroom technologies (eg, raised toilet commodes, adaptive commodes, transfer benches, sliders);;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28941-5;2;Breathing strategy: Active cycle of breathing or forced expiratory techniques;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28943-1;3;Breathing strategy: Assisted cough/huff techniques;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28944-9;4;Breathing strategy: Autogenic drainage;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28945-6;5;Breathing strategy: Paced breathing;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28946-4;6;Breathing strategy: Pursed lip breathing;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28947-2;7;Manual/mechanical technique: Assistive devices;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28949-8;8;Manual/mechanical technique: Chest percussion, vibration, and shaking;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28950-6;9;Manual/mechanical technique: Chest wall manipulation;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28951-4;10;Manual/mechanical technique: Suctioning;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28952-2;11;Manual/mechanical technique: Ventilator aids;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28953-0;12;Positioning: Positioning to alter work of breathing;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28954-8;13;Positioning: Positioning to maximize ventilation;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28955-5;14;Positioning: Pulmonary postural drainage;;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA28956-3;15;Supplemental oxygen therapy: Techniques to maximize ventilation (e.g., inspiratory hold maneuver, staircase breathing, manual hyperinflation, incentive spirometry);;; +89186-1;LL5009-7;APTA_Airway clearance techniques;LA46-8;16;Other;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28941-5;2;Breathing strategy: Active cycle of breathing or forced expiratory techniques;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28943-1;3;Breathing strategy: Assisted cough/huff techniques;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28944-9;4;Breathing strategy: Autogenic drainage;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28945-6;5;Breathing strategy: Paced breathing;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28946-4;6;Breathing strategy: Pursed lip breathing;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28947-2;7;Manual/mechanical technique: Assistive devices;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28949-8;8;Manual/mechanical technique: Chest percussion, vibration, and shaking;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28950-6;9;Manual/mechanical technique: Chest wall manipulation;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28951-4;10;Manual/mechanical technique: Suctioning;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28952-2;11;Manual/mechanical technique: Ventilator aids;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28953-0;12;Positioning: Positioning to alter work of breathing;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28954-8;13;Positioning: Positioning to maximize ventilation;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28955-5;14;Positioning: Pulmonary postural drainage;;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA28956-3;15;Supplemental oxygen therapy: Techniques to maximize ventilation (e.g., inspiratory hold maneuver, staircase breathing, manual hyperinflation, incentive spirometry);;; +92553-7;LL5009-7;APTA_Airway clearance techniques;LA46-8;16;Other;;; +89187-9;LL5016-2;APTA_Instruction provided;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +89187-9;LL5016-2;APTA_Instruction provided;LA29050-4;2;Health, wellness, and fitness programs;;; +89187-9;LL5016-2;APTA_Instruction provided;LA29062-9;3;Impairments in body functions and structures, activity limitations, and participation restrictions;;; +89187-9;LL5016-2;APTA_Instruction provided;LA29094-2;4;Pathology or health condition;;; +89187-9;LL5016-2;APTA_Instruction provided;LA29095-9;5;Performance enhancement;;; +89187-9;LL5016-2;APTA_Instruction provided;LA29096-7;6;Plan of care;;; +89187-9;LL5016-2;APTA_Instruction provided;LA29105-6;7;Psychosocial influences on treatment (eg, fear-avoidance beliefs, behavior change techniques);;; +89187-9;LL5016-2;APTA_Instruction provided;LA29111-4;8;Risk factors for pathology or health condition, impairments in body functions and structures, activity limitations, and participation restrictions;;; +89187-9;LL5016-2;APTA_Instruction provided;LA29133-8;9;Transitions across new settings;;; +89187-9;LL5016-2;APTA_Instruction provided;LA29134-6;10;Transitions to new roles;;; +89187-9;LL5016-2;APTA_Instruction provided;LA46-8;11;Other;;; +92557-8;LL5016-2;APTA_Instruction provided;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +92557-8;LL5016-2;APTA_Instruction provided;LA29050-4;2;Health, wellness, and fitness programs;;; +92557-8;LL5016-2;APTA_Instruction provided;LA29062-9;3;Impairments in body functions and structures, activity limitations, and participation restrictions;;; +92557-8;LL5016-2;APTA_Instruction provided;LA29094-2;4;Pathology or health condition;;; +92557-8;LL5016-2;APTA_Instruction provided;LA29095-9;5;Performance enhancement;;; +92557-8;LL5016-2;APTA_Instruction provided;LA29096-7;6;Plan of care;;; +92557-8;LL5016-2;APTA_Instruction provided;LA29105-6;7;Psychosocial influences on treatment (eg, fear-avoidance beliefs, behavior change techniques);;; +92557-8;LL5016-2;APTA_Instruction provided;LA29111-4;8;Risk factors for pathology or health condition, impairments in body functions and structures, activity limitations, and participation restrictions;;; +92557-8;LL5016-2;APTA_Instruction provided;LA29133-8;9;Transitions across new settings;;; +92557-8;LL5016-2;APTA_Instruction provided;LA29134-6;10;Transitions to new roles;;; +92557-8;LL5016-2;APTA_Instruction provided;LA46-8;11;Other;;; +89188-7;LL5019-6;APTA_Medication documentation status;LA29167-6;1;Patient reports that they are not currently taking any medications;;; +89188-7;LL5019-6;APTA_Medication documentation status;LA29168-4;2;All known prescriptions, over the counters, herbals, and vitamin/mineral/dietary (nutritional) supplements are documented and include the medications' name, dosages, frequency and route of administration;;; +89188-7;LL5019-6;APTA_Medication documentation status;LA29169-2;3;Incomplete list of medication is documented;;; +89189-5;LL5020-4;APTA_Clinical presentation status;LA14122-8;1;Stable;;; +89189-5;LL5020-4;APTA_Clinical presentation status;LA14123-6;2;Unstable;;; +89189-5;LL5020-4;APTA_Clinical presentation status;LA29170-0;3;Evolving;;; +89200-0;LL5008-9;Phenotypic method for antibiotic resistance;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89200-0;LL5008-9;Phenotypic method for antibiotic resistance;LA29164-3;2;Carbapemenase Inactivation Method (CIM);;; +89200-0;LL5008-9;Phenotypic method for antibiotic resistance;LA29165-0;3;Modified Carbapemenase Inactivation Method (mCIM);;; +89200-0;LL5008-9;Phenotypic method for antibiotic resistance;LA29162-7;4;Carba NP;;; +89200-0;LL5008-9;Phenotypic method for antibiotic resistance;LA29163-5;5;Modified Hodge Test (MHT);;; +89200-0;LL5008-9;Phenotypic method for antibiotic resistance;LA29166-8;6;Metallo beta-lactamase (MBL) gradient strip;;; +89200-0;LL5008-9;Phenotypic method for antibiotic resistance;LA46-8;7;Other;;; +89201-8;LL5007-1;Molecular lab test antibiotic resistance method;LA7304-4;1;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +89201-8;LL5007-1;Molecular lab test antibiotic resistance method;LA29158-5;2;VIM gene detection;;; +89201-8;LL5007-1;Molecular lab test antibiotic resistance method;LA29161-9;3;IMP gene detection;;; +89201-8;LL5007-1;Molecular lab test antibiotic resistance method;LA29159-3;4;OXA-48 gene detection;;; +89201-8;LL5007-1;Molecular lab test antibiotic resistance method;LA29160-1;5;NDM gene detection;;; +89201-8;LL5007-1;Molecular lab test antibiotic resistance method;LA29157-7;6;KPC gene detection;;; +89201-8;LL5007-1;Molecular lab test antibiotic resistance method;LA46-8;7;Other;;; +89203-4;LL4990-9;Manual|Mechanical;LA19016-7;1;Manual;;; +89203-4;LL4990-9;Manual|Mechanical;LA19743-6;2;Mechanical;;; +89212-5;LL5023-8;Reason for difficult intubation;LA28906-8;1;Congenital condition;;; +89212-5;LL5023-8;Reason for difficult intubation;LA7446-3;2;Infection;;; +89212-5;LL5023-8;Reason for difficult intubation;LA28908-4;3;Epiglottitis;;; +89212-5;LL5023-8;Reason for difficult intubation;LA28909-2;4;Facial/neck trauma or burns;;; +89212-5;LL5023-8;Reason for difficult intubation;LA28910-0;5;Tumors in the head/neck region;;; +89212-5;LL5023-8;Reason for difficult intubation;LA6301-1;6;Obesity;;; +89212-5;LL5023-8;Reason for difficult intubation;LA29173-4;7;Mallampati classification grade III or IV;;; +89212-5;LL5023-8;Reason for difficult intubation;LA29174-2;8;Cormack-Lehane classification grade III or IV;;; +89212-5;LL5023-8;Reason for difficult intubation;LA46-8;9;Other;;; +89245-5;LL4986-7;Karnofsky performance status;LA29175-9;1;"Normal; no complaints; no evidence of disease";;; +89245-5;LL4986-7;Karnofsky performance status;LA29176-7;2;"Able to carry on normal activity; minor signs or symptoms of disease";;; +89245-5;LL4986-7;Karnofsky performance status;LA29177-5;3;"Normal activity with effort; some signs or symptoms of disease";;; +89245-5;LL4986-7;Karnofsky performance status;LA29178-3;4;"Cares for self; unable to carry on normal activity or do active work";;; +89245-5;LL4986-7;Karnofsky performance status;LA29179-1;5;Requires occasional assistance but is able to care for most needs;;; +89245-5;LL4986-7;Karnofsky performance status;LA29180-9;6;Requires considerable assistance and frequent medical care;;; +89245-5;LL4986-7;Karnofsky performance status;LA29181-7;7;"Disabled; requires special care and assistance";;; +89245-5;LL4986-7;Karnofsky performance status;LA29182-5;8;"Severely disabled; hospitalization is indicated, although death not imminent";;; +89245-5;LL4986-7;Karnofsky performance status;LA29183-3;9;"Very sick; hospitalization necessary; active supportive treatment necessary";;; +89245-5;LL4986-7;Karnofsky performance status;LA29184-1;10;"Moribund; fatal processes progressing rapidly";;; +89245-5;LL4986-7;Karnofsky performance status;LA9627-6;11;Dead;;; +89248-9;LL4766-3;Species of the index case;LA21336-5;0;Klebsiella pneumoniae;;; +89248-9;LL4766-3;Species of the index case;LA19340-1;1;Pseudomonas aeruginosa;;; +89248-9;LL4766-3;Species of the index case;LA21369-6;2;Enterobacter cloacae;;; +89248-9;LL4766-3;Species of the index case;LA28469-7;3;Enterobacter aerogenes;;; +89249-7;LL4768-9;Index case carbapenemase resistance gene;LA27072-0;0;blaKPC;;; +89249-7;LL4768-9;Index case carbapenemase resistance gene;LA27075-3;1;blaIMP;;; +89249-7;LL4768-9;Index case carbapenemase resistance gene;LA27073-8;2;blaNDM;;; +89249-7;LL4768-9;Index case carbapenemase resistance gene;LA27076-1;3;blaOXA-48;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA4277-5;0;Bone;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28734-4;1;Blood vessel;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28735-1;2;Cartilage;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28736-9;3;Fascia;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28737-7;4;Joint capsule;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28738-5;5;Mesh;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA24800-7;6;Muscle;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28739-3;7;Musculoskeletal implant;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA19768-3;8;Pin;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28740-1;9;Prosthesis;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28741-9;10;Subcutaneous tissue;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA28742-7;11;Tendon;;; +89250-5;LL4935-4;Wound internal or body structure visible;LA18226-3;12;Foreign body;;; +89252-1;LL4937-0;Episode of a wound;LA6662-6;0;Initial;;; +89252-1;LL4937-0;Episode of a wound;LA28751-8;1;Recurrent;;; +89253-9;LL4938-8;Trend;LA65-8;0;Improved;;; +89253-9;LL4938-8;Trend;LA66-6;1;Deteriorated;;; +89253-9;LL4938-8;Trend;LA6635-2;2;Stabilized;;; +89253-9;LL4938-8;Trend;LA9041-0;3;Resolved;;; +89261-2;LL4997-4;Clinical course;LA18821-1;0;Acute;;; +89261-2;LL4997-4;Clinical course;LA28752-6;1;Chronic;;; +89261-2;LL4997-4;Clinical course;LA28939-9;2;Acute-on-chronic;;; +89275-2;LL5025-3;Reason rescue operation was canceled;LA17155-5;1;Canceled (prior to arrival at scene);;; +89275-2;LL5025-3;Reason rescue operation was canceled;LA17156-3;2;Canceled on scene (no patient found);;; +89275-2;LL5025-3;Reason rescue operation was canceled;LA29188-2;3;Patient already transported;;; +89275-2;LL5025-3;Reason rescue operation was canceled;LA29185-8;4;Mal-intended call out;;; +89275-2;LL5025-3;Reason rescue operation was canceled;LA29186-6;5;Canceled due to technical reasons;;; +89275-2;LL5025-3;Reason rescue operation was canceled;LA29187-4;6;Canceled due to weather conditions;;; +89275-2;LL5025-3;Reason rescue operation was canceled;LA46-8;7;Other;;; +89370-1;LL4993-3;Zika IgM Neg|PR-Neg|PR-Pos|PR-IgM Pos;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +89370-1;LL4993-3;Zika IgM Neg|PR-Neg|PR-Pos|PR-IgM Pos;LA28914-2;2;Presumptive recent Zika negative;;; +89370-1;LL4993-3;Zika IgM Neg|PR-Neg|PR-Pos|PR-IgM Pos;LA28915-9;3;Presumptive recent Zika positive;;; +89370-1;LL4993-3;Zika IgM Neg|PR-Neg|PR-Pos|PR-IgM Pos;LA28916-7;4;Presumptive Zika IgM positive;;; +89373-5;LL4992-5;HAV Genotype;LA28917-5;1;Hepatitis A virus genotype I;;; +89373-5;LL4992-5;HAV Genotype;LA28918-3;2;Hepatitis A virus genotype II;;; +89373-5;LL4992-5;HAV Genotype;LA28919-1;3;Hepatitis A virus genotype III;;; +89373-5;LL4992-5;HAV Genotype;LA28920-9;4;Hepatitis A virus genotype IV;;; +89373-5;LL4992-5;HAV Genotype;LA28921-7;5;Hepatitis A virus genotype V;;; +89373-5;LL4992-5;HAV Genotype;LA28923-3;6;Hepatitis A virus subgenotype IA;;; +89373-5;LL4992-5;HAV Genotype;LA28924-1;7;Hepatitis A virus subgenotype IB;;; +89373-5;LL4992-5;HAV Genotype;LA28925-8;8;Hepatitis A virus subgenotype IIA;;; +89373-5;LL4992-5;HAV Genotype;LA28926-6;9;Hepatitis A virus subgenotype IIB;;; +89373-5;LL4992-5;HAV Genotype;LA28927-4;10;Hepatitis A virus subgenotype IIIA;;; +89373-5;LL4992-5;HAV Genotype;LA28928-2;11;Hepatitis A virus subgenotype IIIB;;; +89373-5;LL4992-5;HAV Genotype;LA13538-6;12;Not tested;;; +89373-5;LL4992-5;HAV Genotype;LA28929-0;13;Unable to complete sequencing;;; +89435-2;LL5053-5;Yes (X)|No;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +89435-2;LL5053-5;Yes (X)|No;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +89494-9;LL4786-1;PHVS_PlacentalConditions_HL7;;0;;;; +89495-6;LL4903-2;Drugs of abuse;LA28581-9;0;1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine;;; +89495-6;LL4903-2;Drugs of abuse;LA28582-7;1;1-Methyl-4-phenyl-4-propionoxypiperidine;;; +89495-6;LL4903-2;Drugs of abuse;LA28583-5;2;3-Methylfentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28584-3;3;3-Methylthiofentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28585-0;4;Acetyl Fentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28586-8;5;Acetyl-alpha-methylfentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28587-6;6;Acetyldihydrocodeine;;; +89495-6;LL4903-2;Drugs of abuse;LA28588-4;7;Acetylmethadol;;; +89495-6;LL4903-2;Drugs of abuse;LA28589-2;8;Alpha-methylfentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28590-0;9;Alpha-methylthiofentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28591-8;10;Beta-hydroxy-3-methylfentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28592-6;11;Beta-hydroxyfentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28593-4;12;Beta-hydroxythiofentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28594-2;13;Betamethadol;;; +89495-6;LL4903-2;Drugs of abuse;LA28595-9;14;Butyryl Fentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28646-0;15;Carfentanil;;; +89495-6;LL4903-2;Drugs of abuse;LA15257-1;16;Cocaine;387085005;Cocaine (substance);http://snomed.info/sct +89495-6;LL4903-2;Drugs of abuse;LA28597-5;17;Codeine;;; +89495-6;LL4903-2;Drugs of abuse;LA28598-3;18;Codeine methylbromide;;; +89495-6;LL4903-2;Drugs of abuse;LA28599-1;19;Codeine-N-oxide;;; +89495-6;LL4903-2;Drugs of abuse;LA28600-7;20;Dextropropoxyphene, bulk (non-dosage forms);;; +89495-6;LL4903-2;Drugs of abuse;LA28601-5;21;Dextropropoxyphene dosage forms;;; +89495-6;LL4903-2;Drugs of abuse;LA28602-3;22;Fentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28603-1;23;Furanyl fentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA15258-9;24;Heroin;387341002;Diamorphine (substance);http://snomed.info/sct +89495-6;LL4903-2;Drugs of abuse;LA28605-6;25;Hydrocodone;;; +89495-6;LL4903-2;Drugs of abuse;LA28606-4;26;Hydromorphone;;; +89495-6;LL4903-2;Drugs of abuse;LA28607-2;27;Levo-alphacetylmethadol;;; +89495-6;LL4903-2;Drugs of abuse;LA28608-0;28;Meperidine;;; +89495-6;LL4903-2;Drugs of abuse;LA28419-2;29;Methadone;;; +89495-6;LL4903-2;Drugs of abuse;LA28610-6;30;Methadone intermediate;;; +89495-6;LL4903-2;Drugs of abuse;LA28611-4;31;Morphine;;; +89495-6;LL4903-2;Drugs of abuse;LA28612-2;32;Morphine methylbromide;;; +89495-6;LL4903-2;Drugs of abuse;LA28613-0;33;Morphine methylsulfonate;;; +89495-6;LL4903-2;Drugs of abuse;LA28614-8;34;Opium;;; +89495-6;LL4903-2;Drugs of abuse;LA28421-8;35;Oxycodone;;; +89495-6;LL4903-2;Drugs of abuse;LA28616-3;36;Oxymorphone;;; +89495-6;LL4903-2;Drugs of abuse;LA28617-1;37;Para-Fluorofentanyl;;; +89495-6;LL4903-2;Drugs of abuse;LA28618-9;38;Tramadol;;; +89495-6;LL4903-2;Drugs of abuse;LA15259-7;39;Methamphetamine;387499002;Metamfetamine (substance);http://snomed.info/sct +89495-6;LL4903-2;Drugs of abuse;LA28620-5;40;Barbituric acid derivative;;; +89495-6;LL4903-2;Drugs of abuse;LA28621-3;41;Pentobarbital;;; +89495-6;LL4903-2;Drugs of abuse;LA28622-1;42;Phenobarbital;;; +89495-6;LL4903-2;Drugs of abuse;LA28623-9;43;Alprazolam;;; +89495-6;LL4903-2;Drugs of abuse;LA28624-7;44;Benzodiazepine;;; +89495-6;LL4903-2;Drugs of abuse;LA28625-4;45;Chlorodiazepoxide;;; +89495-6;LL4903-2;Drugs of abuse;LA28626-2;46;Diazepam;;; +89495-6;LL4903-2;Drugs of abuse;LA28627-0;47;Lorazepam;;; +89495-6;LL4903-2;Drugs of abuse;LA28628-8;48;Triazolam;;; +89495-6;LL4903-2;Drugs of abuse;LA28629-6;49;Gamma Hydroxybutyric Acid;;; +89495-6;LL4903-2;Drugs of abuse;LA28630-4;50;Gamma Hydroxybutyric Acid Preparations;;; +89495-6;LL4903-2;Drugs of abuse;LA28631-2;51;Flunitrazepam;;; +89495-6;LL4903-2;Drugs of abuse;LA28632-0;52;3-4 Methylenedioxymethamphetamine;;; +89495-6;LL4903-2;Drugs of abuse;LA28633-8;53;Ketamine;;; +89495-6;LL4903-2;Drugs of abuse;LA28634-6;54;Lysergic Acid Diethylamide;;; +89495-6;LL4903-2;Drugs of abuse;LA28635-3;55;Mescaline;;; +89495-6;LL4903-2;Drugs of abuse;LA28636-1;56;Psilocybin;;; +89495-6;LL4903-2;Drugs of abuse;LA28422-6;57;Phencyclidine;;; +89495-6;LL4903-2;Drugs of abuse;LA28638-7;58;Marijuana;;; +89495-6;LL4903-2;Drugs of abuse;LA28639-5;59;MDPV (3,4-Methylenedioxypyrovalerone);;; +89495-6;LL4903-2;Drugs of abuse;LA28640-3;60;Mephedrone (4-Methyl-N-methylcathinone);;; +89495-6;LL4903-2;Drugs of abuse;LA28641-1;61;Cathine;;; +89495-6;LL4903-2;Drugs of abuse;LA28642-9;62;Cathinone;;; +89495-6;LL4903-2;Drugs of abuse;LA28643-7;63;Dextromethorphan;;; +89495-6;LL4903-2;Drugs of abuse;LA28644-5;64;Salvia Divinorum (Leaf);;; +89495-6;LL4903-2;Drugs of abuse;LA28645-2;65;Salvia Divinorum (Whole);;; +89496-4;LL4788-7;PHVS_MaternalExposures_HL7;;0;;;; +89497-2;LL4789-5;PHVS_BirthDefectsDiagnosticConfirmation_HL7;;0;;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA6111-4;1;0;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA6112-2;2;1;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA6113-0;3;2;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA6114-8;4;3;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA6115-5;5;4;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA10137-0;6;5;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA10138-8;7;6;;; +89555-7;LL5870-2;0 to 7 Scoreless;LA10139-6;8;7;;; +89564-9;LL5045-1;CUBS_Employment status;LA29204-7;1;I maintain permanent employment with adequate income and benefits;;; +89564-9;LL5045-1;CUBS_Employment status;LA29205-4;2;I'm employed full time with adequate pay and benefits;;; +89564-9;LL5045-1;CUBS_Employment status;LA29206-2;3;I'm employed full time with inadequate pay and few or no benefits;;; +89564-9;LL5045-1;CUBS_Employment status;LA29207-0;4;I'm temporary, part-time, or seasonal with inadequate pay and no benefits;;; +89564-9;LL5045-1;CUBS_Employment status;LA29208-8;5;I do not have a job;;; +89565-6;LL5046-9;CUBS_Housing status;LA29209-6;1;My household is safe, adequate, unsubsidized housing;;; +89565-6;LL5046-9;CUBS_Housing status;LA29210-4;2;My household is in safe, adequate subsidized housing;;; +89565-6;LL5046-9;CUBS_Housing status;LA29211-2;3;I'm in stable housing that is safe but only marginally adequate;;; +89565-6;LL5046-9;CUBS_Housing status;LA29212-0;4;"I'm in transitional, temporary or substandard housing; and/or current rent/mortgage is unaffordable (over 30% of income)";;; +89565-6;LL5046-9;CUBS_Housing status;LA29213-8;5;I'm homeless or threatened with eviction;;; +89566-4;LL5047-7;CUBS_Income status;LA29214-6;1;"My income is sufficient, well managed; has discretionary income and is able to save";;; +89566-4;LL5047-7;CUBS_Income status;LA29215-3;2;I can meet basic needs and manage debt without assistance;;; +89566-4;LL5047-7;CUBS_Income status;LA29216-1;3;"I can meet basic needs with subsidy; appropriate spending";;; +89566-4;LL5047-7;CUBS_Income status;LA29217-9;4;I have inadequate income and/or spontaneous or inappropriate spending;;; +89566-4;LL5047-7;CUBS_Income status;LA29218-7;5;I have no income;;; +89567-2;LL5048-5;CUBS_Food insecurity status;LA29219-5;1;I can choose to purchase any food household desires;;; +89567-2;LL5048-5;CUBS_Food insecurity status;LA29220-3;2;I can meet basic food needs without assistance;;; +89567-2;LL5048-5;CUBS_Food insecurity status;LA29221-1;3;I can meet basic food needs, but require occasional assistance;;; +89567-2;LL5048-5;CUBS_Food insecurity status;LA29222-9;4;My household is on food stamps;;; +89567-2;LL5048-5;CUBS_Food insecurity status;LA29223-7;5;I have no food or means to prepare it. I rely to a significant degree on other sources of free or low-cost food;;; +89568-0;LL5049-3;CUBS_Child care status;LA29224-5;1;NA - Not Applicable;;; +89568-0;LL5049-3;CUBS_Child care status;LA29225-2;2;I'm able to select quality childcare of choice;;; +89568-0;LL5049-3;CUBS_Child care status;LA29226-0;3;I have reliable childcare with no need for subsidies;;; +89568-0;LL5049-3;CUBS_Child care status;LA29227-8;4;Affordable childcare is available, but limited;;; +89568-0;LL5049-3;CUBS_Child care status;LA29228-6;5;My childcare is unreliable or unaffordable, inadequate supervision is a problem for childcare that is available;;; +89568-0;LL5049-3;CUBS_Child care status;LA29229-4;6;I need childcare, but none is available/accessible and/or child is not eligible;;; +89569-8;LL5050-1;CUBS_Transportation/mobility status;LA29230-2;1;My transportation is readily available, affordable, and car is adequately insured;;; +89569-8;LL5050-1;CUBS_Transportation/mobility status;LA29231-0;2;My transportation is generally accessible to meet basic travel needs;;; +89569-8;LL5050-1;CUBS_Transportation/mobility status;LA29232-8;3;"My transportation is available and reliable, but limited and/or inconvenient; drivers are licensed and minimally insured";;; +89569-8;LL5050-1;CUBS_Transportation/mobility status;LA29233-6;4;"My transportation is available, but unreliable, unpredictable, unaffordable; may have car but no insurance, license, etc.";;; +89569-8;LL5050-1;CUBS_Transportation/mobility status;LA29234-4;5;"I have no access to transportation, public or private; may have car that is inoperable";;; +89570-6;LL5051-9;CUBS_Criminal involvement;LA29235-1;1;I have no active criminal justice involvement in more than 12 months and/or no felony criminal history;;; +89570-6;LL5051-9;CUBS_Criminal involvement;LA29236-9;2;I have successfully completed probation/parole within past 12 months, no new charges filed;;; +89570-6;LL5051-9;CUBS_Criminal involvement;LA29237-7;3;I'm fully compliant with probation/parole terms;;; +89570-6;LL5051-9;CUBS_Criminal involvement;LA29238-5;4;I have current charges/trial pending, noncompliance with probation/parole;;; +89570-6;LL5051-9;CUBS_Criminal involvement;LA29239-3;5;I have current outstanding tickets or warrants;;; +89571-4;LL5052-7;CUBS_Disability;LA29240-1;1;I'm Thriving - no identified disability;;; +89571-4;LL5052-7;CUBS_Disability;LA29241-9;2;I'm Building Capacity - I have an asymptomatic condition controlled by services or medication;;; +89571-4;LL5052-7;CUBS_Disability;LA29242-7;3;I'm Safe - I rarely have acute or chronic symptoms affecting housing, employment, social interactions, etc.;;; +89571-4;LL5052-7;CUBS_Disability;LA29243-5;4;I'm Vulnerable - I sometimes or periodically have acute or chronic symptoms affecting housing, employment, social interactions, etc.;;; +89571-4;LL5052-7;CUBS_Disability;LA29244-3;5;I'm in Crisis - acute or chronic symptoms affecting housing, employment, social interactions, etc.;;; +89575-5;LL5066-7;Troponin interpretation;LA11883-8;1;Not detected;;; +89575-5;LL5066-7;Troponin interpretation;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +89575-5;LL5066-7;Troponin interpretation;LA29258-3;3;Greater than 99th percentile upper reference limit;;; +89578-9;LL5066-7;Troponin interpretation;LA11883-8;1;Not detected;;; +89578-9;LL5066-7;Troponin interpretation;LA11885-3;2;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +89578-9;LL5066-7;Troponin interpretation;LA29258-3;3;Greater than 99th percentile upper reference limit;;; +89655-5;LL4722-6;Viral culture;LA20066-9;1;Cytomegalovirus;;; +89655-5;LL4722-6;Viral culture;LA19414-4;2;Herpes simplex type 1;;; +89655-5;LL4722-6;Viral culture;LA19415-1;3;Herpes simplex type 2;;; +89655-5;LL4722-6;Viral culture;LA26164-6;4;Varicella zoster virus (VZV);;; +89655-5;LL4722-6;Viral culture;LA25843-6;5;Rhinovirus;;; +89655-5;LL4722-6;Viral culture;LA24562-3;6;Adenovirus;;; +89792-6;LL5074-1;Activate(1)|Deactivate(2);LA29299-7;1;Activate;;; +89792-6;LL5074-1;Activate(1)|Deactivate(2);LA29300-3;2;Deactivate;;; +89843-7;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29279-9;1;Light skin tone;1F3FB;EMOJI MODIFIER FITZPATRICK TYPE-1-2;Unicode +89843-7;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29280-7;2;Medium-light skin tone;1F3FB;EMOJI MODIFIER FITZPATRICK TYPE-1-2;Unicode +89843-7;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29281-5;3;Medium skin tone;1F3FD;EMOJI MODIFIER FITZPATRICK TYPE-4;Unicode +89843-7;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29282-3;4;Medium-dark skin tone;1F3FE;EMOJI MODIFIER FITZPATRICK TYPE-5;Unicode +89843-7;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29283-1;5;Dark skin tone;1F3FF;EMOJI MODIFIER FITZPATRICK TYPE-6;Unicode +94535-2;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29279-9;1;Light skin tone;1F3FB;EMOJI MODIFIER FITZPATRICK TYPE-1-2;Unicode +94535-2;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29280-7;2;Medium-light skin tone;1F3FB;EMOJI MODIFIER FITZPATRICK TYPE-1-2;Unicode +94535-2;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29281-5;3;Medium skin tone;1F3FD;EMOJI MODIFIER FITZPATRICK TYPE-4;Unicode +94535-2;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29282-3;4;Medium-dark skin tone;1F3FE;EMOJI MODIFIER FITZPATRICK TYPE-5;Unicode +94535-2;LL5071-7;Unicode_v8.0_Emoji modifier skin tone;LA29283-1;5;Dark skin tone;1F3FF;EMOJI MODIFIER FITZPATRICK TYPE-6;Unicode +89863-5;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29328-4;1;No days;;; +89863-5;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA15118-5;2;1-2 days;;; +89863-5;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29325-0;3;3-4 days;;; +89863-5;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29326-8;4;5-6 days;;; +89863-5;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA14799-3;5;Every day;;; +89864-3;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29328-4;1;No days;;; +89864-3;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA15118-5;2;1-2 days;;; +89864-3;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29325-0;3;3-4 days;;; +89864-3;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29326-8;4;5-6 days;;; +89864-3;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA14799-3;5;Every day;;; +89865-0;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29328-4;1;No days;;; +89865-0;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA15118-5;2;1-2 days;;; +89865-0;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29325-0;3;3-4 days;;; +89865-0;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29326-8;4;5-6 days;;; +89865-0;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA14799-3;5;Every day;;; +89866-8;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29328-4;1;No days;;; +89866-8;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA15118-5;2;1-2 days;;; +89866-8;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29325-0;3;3-4 days;;; +89866-8;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29326-8;4;5-6 days;;; +89866-8;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA14799-3;5;Every day;;; +89867-6;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29328-4;1;No days;;; +89867-6;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA15118-5;2;1-2 days;;; +89867-6;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29325-0;3;3-4 days;;; +89867-6;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29326-8;4;5-6 days;;; +89867-6;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA14799-3;5;Every day;;; +89868-4;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29328-4;1;No days;;; +89868-4;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA15118-5;2;1-2 days;;; +89868-4;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29325-0;3;3-4 days;;; +89868-4;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29326-8;4;5-6 days;;; +89868-4;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA14799-3;5;Every day;;; +89869-2;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29328-4;1;No days;;; +89869-2;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA15118-5;2;1-2 days;;; +89869-2;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29325-0;3;3-4 days;;; +89869-2;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA29326-8;4;5-6 days;;; +89869-2;LL5082-4;No days(0)|1-2(1)|3-4(2)|5-6(3)|Everyday(4);LA14799-3;5;Every day;;; +89875-9;LL5909-8;Elapsed time;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +89875-9;LL5909-8;Elapsed time;LA32004-6;2;<1 hour;;; +89875-9;LL5909-8;Elapsed time;LA32149-9;3;1-2 hours;;; +89875-9;LL5909-8;Elapsed time;LA32150-7;4;2-3 hours;;; +89875-9;LL5909-8;Elapsed time;LA28681-7;5;3-4 hours;;; +89875-9;LL5909-8;Elapsed time;LA32152-3;6;4-5 hours;;; +89875-9;LL5909-8;Elapsed time;LA28682-5;7;5-6 hours;;; +89875-9;LL5909-8;Elapsed time;LA32154-9;8;6-8 hours;;; +89875-9;LL5909-8;Elapsed time;LA32155-6;9;8-10 hours;;; +89875-9;LL5909-8;Elapsed time;LA32156-4;10;>10 hours;;; +90003-5;LL5067-5;Acinetobacter species;LA19179-3;0;Acinetobacter baumanii;;; +90003-5;LL5067-5;Acinetobacter species;LA29259-1;1;Acinetobacter calcoaceticus;;; +90003-5;LL5067-5;Acinetobacter species;LA29260-9;2;Acinetobacter species not identified;;; +90004-3;LL4770-5;Significance levels;LA24821-3;1;Not significant;;; +90004-3;LL4770-5;Significance levels;LA28474-7;2;Significant;;; +90004-3;LL4770-5;Significance levels;LA28476-2;3;Moderately significant;;; +90004-3;LL4770-5;Significance levels;LA28477-0;4;Highly significant;;; +90017-5;LL5076-6;Amount of meal eaten;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +90017-5;LL5076-6;Amount of meal eaten;LA29307-8;2;Less than one-quarter of the meal;;; +90017-5;LL5076-6;Amount of meal eaten;LA29308-6;3;One-quarter of the meal;;; +90017-5;LL5076-6;Amount of meal eaten;LA29309-4;4;More than one-half but less than three-quarters of the meal;;; +90017-5;LL5076-6;Amount of meal eaten;LA29310-2;5;Three-quarters or more, but not all of the meal;;; +90017-5;LL5076-6;Amount of meal eaten;LA29311-0;6;All of the meal;;; +90017-5;LL5076-6;Amount of meal eaten;LA4389-8;7;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +90017-5;LL5076-6;Amount of meal eaten;LA12688-0;8;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +90019-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90019-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90019-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90019-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90019-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90020-9;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90020-9;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90020-9;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90020-9;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90020-9;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90021-7;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90021-7;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90021-7;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90021-7;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90021-7;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90022-5;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90022-5;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90022-5;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90022-5;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90022-5;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90023-3;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90023-3;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90023-3;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90023-3;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90023-3;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90024-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90024-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90024-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90024-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90024-1;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90025-8;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90025-8;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90025-8;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90025-8;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90025-8;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90026-6;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29468-8;1;I agree: Not at all;;; +90026-6;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29469-6;2;I agree: Slightly;;; +90026-6;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29470-4;3;I agree: Moderately;;; +90026-6;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29466-2;4;I agree: Mainly;;; +90026-6;LL5122-8;I agree:Not at all|Slightly|Mod|Mainly|Absolutely;LA29467-0;5;I agree: Absolutely;;; +90033-2;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13921-4;1;Without any difficulty;;; +90033-2;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13920-6;2;With some difficulty;;; +90033-2;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13919-8;3;With much difficulty;;; +90033-2;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13912-3;4;Unable to do;;; +90034-0;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13921-4;1;Without any difficulty;;; +90034-0;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13920-6;2;With some difficulty;;; +90034-0;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13919-8;3;With much difficulty;;; +90034-0;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13912-3;4;Unable to do;;; +90035-7;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13921-4;1;Without any difficulty;;; +90035-7;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13920-6;2;With some difficulty;;; +90035-7;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13919-8;3;With much difficulty;;; +90035-7;LL5123-6;W/o diff(0)|Some(1.1)|Much(2.2)|Unable to Do(3.3);LA13912-3;4;Unable to do;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA19102-5;1;0 - no pain;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA16632-4;2;0.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA6112-2;3;1;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA15765-3;4;1.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA6113-0;5;2;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA15766-1;6;2.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA6114-8;7;3;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA15767-9;8;3.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA6115-5;9;4;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA15768-7;10;4.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA10137-0;11;5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA15769-5;12;5.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA10138-8;13;6;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA15770-3;14;6.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA10139-6;15;7;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA21653-3;16;7.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA10140-4;17;8;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA21654-1;18;8.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA10141-2;19;9;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA21655-8;20;9.5;;; +90036-5;LL5120-2;0-10 scale,0.5 increments,No pain to bad as can be;LA29463-9;21;10 - Pain as bad as it could be;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA21651-7;1;0 - Very well;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA16632-4;2;0.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA6112-2;3;1;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA15765-3;4;1.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA6113-0;5;2;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA15766-1;6;2.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA6114-8;7;3;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA15767-9;8;3.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA6115-5;9;4;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA15768-7;10;4.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA10137-0;11;5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA15769-5;12;5.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA10138-8;13;6;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA15770-3;14;6.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA10139-6;15;7;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA21653-3;16;7.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA10140-4;17;8;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA21654-1;18;8.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA10141-2;19;9;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA21655-8;20;9.5;;; +90037-3;LL5119-4;0-10 scale,0.5 increments,Very well to Very poorly;LA29462-1;21;10 - Very poorly;;; +90041-5;LL5072-5;Specimen collection facility;LA14084-0;0;Home;;; +90041-5;LL5072-5;Specimen collection facility;LA26678-5;1;Laboratory;;; +90041-5;LL5072-5;Specimen collection facility;LA24318-0;2;Clinic;;; +90045-6;LL5073-3;Treatment on specimen;LA137-2;0;None;260413007;None (qualifier value);http://snomed.info/sct +90045-6;LL5073-3;Treatment on specimen;LA29305-2;1;Mechanical mixing;;; +90045-6;LL5073-3;Treatment on specimen;LA29306-0;2;Enzymatic digestion;;; +90045-6;LL5073-3;Treatment on specimen;LA29449-8;3;Addition of bromelin;;; +90045-6;LL5073-3;Treatment on specimen;LA29450-6;4;Addition of chymotrypsin;;; +90045-6;LL5073-3;Treatment on specimen;LA29451-4;5;Concentration of specimen;;; +90061-3;LL5110-3;EOC public document types;LA29445-6;1;Situational report;;; +90061-3;LL5110-3;EOC public document types;LA29446-4;2;Surveillance report;;; +90061-3;LL5110-3;EOC public document types;LA29447-2;3;Public health warning;;; +90061-3;LL5110-3;EOC public document types;LA29448-0;4;Public health alert;;; +90061-3;LL5110-3;EOC public document types;LA46-8;5;Other;;; +90066-2;LL5093-1;Coryneform bacteria;LA19544-8;0;None detected;;; +90066-2;LL5093-1;Coryneform bacteria;LA29376-3;1;Corynebacterium accolens;;; +90066-2;LL5093-1;Coryneform bacteria;LA29377-1;2;Corynebacterium bovis;;; +90066-2;LL5093-1;Coryneform bacteria;LA29378-9;3;Corynebacterium glucuronolyticum;;; +90066-2;LL5093-1;Coryneform bacteria;LA29379-7;4;Corynebacterium kutscheri;;; +90066-2;LL5093-1;Coryneform bacteria;LA29380-5;5;Corynebacterium macginleyi;;; +90066-2;LL5093-1;Coryneform bacteria;LA29381-3;6;Corynebacterium urealyticum;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA19544-8;0;None detected;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA29360-7;1;Citrobacter freundii;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA28469-7;2;Enterobacter aerogenes;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA21369-6;3;Enterobacter cloacae;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA29345-8;4;Escherichia coli 1;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA29346-6;5;Escherichia coli 2;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA21495-9;6;Klebsiella oxytoca;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA29347-4;7;Klebsiella pneumoniae ssp ozaenae;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA29348-2;8;Klebsiella pneumoniae ssp pneumoniae;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA29349-0;9;Klebsiella pneumoniae ssp rhinoscleromatis;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA21370-4;10;Proteus vulgaris group;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA21329-0;11;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +90067-0;LL5090-7;Enterobacteriaceae species;LA19302-1;12;Shigella sonnei;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA19324-5;13;Yersinia enterocolitica;65255000;Yersinia enterocolitica (organism);http://snomed.info/sct +90067-0;LL5090-7;Enterobacteriaceae species;LA19327-8;14;Yersinia kristensenii;;; +90067-0;LL5090-7;Enterobacteriaceae species;LA19347-6;15;Yersinia pestis;54365000;Yersinia pestis (organism);http://snomed.info/sct +90068-8;LL5087-3;Gram negative bacilli;LA19544-8;0;None detected;;; +90068-8;LL5087-3;Gram negative bacilli;LA28469-7;1;Enterobacter aerogenes;;; +90068-8;LL5087-3;Gram negative bacilli;LA21369-6;2;Enterobacter cloacae;;; +90068-8;LL5087-3;Gram negative bacilli;LA29345-8;3;Escherichia coli 1;;; +90068-8;LL5087-3;Gram negative bacilli;LA29346-6;4;Escherichia coli 2;;; +90068-8;LL5087-3;Gram negative bacilli;LA29347-4;5;Klebsiella pneumoniae ssp ozaenae;;; +90068-8;LL5087-3;Gram negative bacilli;LA29348-2;6;Klebsiella pneumoniae ssp pneumoniae;;; +90068-8;LL5087-3;Gram negative bacilli;LA29349-0;7;Klebsiella pneumoniae ssp rhinoscleromatis;;; +90068-8;LL5087-3;Gram negative bacilli;LA21370-4;8;Proteus vulgaris group;;; +90068-8;LL5087-3;Gram negative bacilli;LA21368-8;9;Salmonella sp;;; +90068-8;LL5087-3;Gram negative bacilli;LA21329-0;10;Salmonella typhi;5595000;Salmonella enterica subspecies enterica serovar Typhi (organism);http://snomed.info/sct +90068-8;LL5087-3;Gram negative bacilli;LA19302-1;11;Shigella sonnei;;; +90069-6;LL5108-7;Gram positive bacilli;LA19544-8;0;None detected;;; +90069-6;LL5108-7;Gram positive bacilli;LA29438-1;1;Bacillus cereus 1;;; +90069-6;LL5108-7;Gram positive bacilli;LA29439-9;2;Bacillus cereus 2;;; +90069-6;LL5108-7;Gram positive bacilli;LA29440-7;3;Bacillus mycoides;;; +90069-6;LL5108-7;Gram positive bacilli;LA29441-5;4;Bacillus pumilus;;; +90069-6;LL5108-7;Gram positive bacilli;LA29442-3;5;Bacillus smithii;;; +90069-6;LL5108-7;Gram positive bacilli;LA29444-9;6;Paenibacillus alvei;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA19544-8;0;None detected;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA19246-0;1;Staphylococcus aureus;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA19247-8;2;Staphylococcus epidermidis;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA29435-7;3;Staphylococcus haemolyticus;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA29430-8;4;Staphylococcus intermedius;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA29436-5;5;Staphylococcus lentus;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA19248-6;6;Staphylococcus xylosus;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA29431-6;7;Kocuria rosea;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA29432-4;8;Kocuria varians;;; +90070-4;LL5079-0;Catalase producing gram positive genera;LA29433-2;9;Rothia mucilaginosa;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA19544-8;0;None detected;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA21332-4;1;Enterococcus faecium;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA29364-9;2;Gardnerella vaginalis;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA29365-6;3;Lactococcus species;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA20993-4;4;Listeria species;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA19342-7;5;Streptococcus agalactiae;43492007;Streptococcus agalactiae (organism);http://snomed.info/sct +90071-2;LL5091-5;Non-catalase producing cocci;LA29339-1;6;Streptococcus anginosus;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA29342-5;7;Streptococcus mitus 1;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA29343-3;8;Streptococcus mitus 2;;; +90071-2;LL5091-5;Non-catalase producing cocci;LA19341-9;9;Streptococcus pneumoniae;9861002;Streptococcus pneumoniae (organism);http://snomed.info/sct +90071-2;LL5091-5;Non-catalase producing cocci;LA20992-6;10;Streptococcus pyogenes;80166006;Streptococcus pyogenes (organism);http://snomed.info/sct +90072-0;LL5089-9;Haemophilus species;LA19544-8;0;None detected;;; +90072-0;LL5089-9;Haemophilus species;LA29355-7;1;Haemophilus aphrophilus;;; +90072-0;LL5089-9;Haemophilus species;LA18056-4;2;Haemophilus influenzae, biotype I;;; +90072-0;LL5089-9;Haemophilus species;LA18057-2;3;Haemophilus influenzae, biotype II;;; +90072-0;LL5089-9;Haemophilus species;LA18058-0;4;Haemophilus influenzae, biotype III;;; +90072-0;LL5089-9;Haemophilus species;LA29356-5;5;Haemophilus parainfluenzae, biotype I;;; +90072-0;LL5089-9;Haemophilus species;LA29357-3;6;Haemophilus parainfluenzae, biotype II;;; +90072-0;LL5089-9;Haemophilus species;LA29358-1;7;Haemophilus parainfluenzae, biotype III;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA19544-8;0;None detected;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29437-3;1;Bacillus anthracis;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29438-1;2;Bacillus cereus 1;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29439-9;3;Bacillus cereus 2;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29440-7;4;Bacillus mycoides;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29441-5;5;Bacillus pumilus;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29442-3;6;Bacillus smithii;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29444-9;7;Paenibacillus alvei;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29452-2;8;Lactobacillus acidophilus 1;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29453-0;9;Lactobacillus acidophilus 2;;; +90073-8;LL5107-9;Lactobacillales (Lactic acid bacteria);LA29454-8;10;Lactobacillus acidophilus 3;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA19544-8;0;None detected;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA29361-5;1;Acinetobacter haemolyticus;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA21006-4;2;Acinetobacter lwoffii;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA14120-2;3;Bordetella bronchiseptica;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA29321-9;4;Burkholderia cepacia;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA28374-9;5;Burkholderia pseudomallei;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA21126-0;6;Moraxella species;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA29362-3;7;Pasteurella species;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA19340-1;8;Pseudomonas aeruginosa;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA29363-1;9;Pseudomonas fluorescens;;; +90075-3;LL5078-2;Non Enterbacteriaceae gram neg bacilli;LA19260-1;10;Vibrio cholerae;;; +90076-1;LL5095-6;Staphylococcus species;LA19544-8;0;None detected;;; +90076-1;LL5095-6;Staphylococcus species;LA19246-0;1;Staphylococcus aureus;;; +90076-1;LL5095-6;Staphylococcus species;LA19247-8;2;Staphylococcus epidermidis;;; +90076-1;LL5095-6;Staphylococcus species;LA29388-8;3;Staphylococcus saprophyticus (beta-galactosidase positive);;; +90077-9;LL5097-2;Urinary pathogens;LA19544-8;0;None detected;;; +90077-9;LL5097-2;Urinary pathogens;LA21335-7;1;Escherichia coli;112283007;Escherichia coli (organism);http://snomed.info/sct +90077-9;LL5097-2;Urinary pathogens;LA21336-5;2;Klebsiella pneumoniae;;; +90077-9;LL5097-2;Urinary pathogens;LA24554-0;3;Proteus mirabilis isolated;;; +90077-9;LL5097-2;Urinary pathogens;LA19340-1;4;Pseudomonas aeruginosa;;; +90077-9;LL5097-2;Urinary pathogens;LA21369-6;5;Enterobacter cloacae;;; +90077-9;LL5097-2;Urinary pathogens;LA29312-8;6;Proteus vulgaris;;; +90077-9;LL5097-2;Urinary pathogens;LA29360-7;7;Citrobacter freundii;;; +90077-9;LL5097-2;Urinary pathogens;LA29400-1;8;Acinetobacter spp;;; +90077-9;LL5097-2;Urinary pathogens;LA21495-9;9;Klebsiella oxytoca;;; +90077-9;LL5097-2;Urinary pathogens;LA19246-0;10;Staphylococcus aureus;;; +90077-9;LL5097-2;Urinary pathogens;LA19247-8;11;Staphylococcus epidermidis;;; +90078-7;LL5096-4;Yeast species;LA19544-8;0;None detected;;; +90078-7;LL5096-4;Yeast species;LA29389-6;1;Candida albicans 1;;; +90078-7;LL5096-4;Yeast species;LA29390-4;2;Candida albicans 2;;; +90078-7;LL5096-4;Yeast species;LA29391-2;3;Candida boidinii;;; +90078-7;LL5096-4;Yeast species;LA29392-0;4;Candida dattila;;; +90078-7;LL5096-4;Yeast species;LA28244-4;5;Candida glabrata;;; +90078-7;LL5096-4;Yeast species;LA29394-6;6;Candida hellenica;;; +90078-7;LL5096-4;Yeast species;LA29395-3;7;Candida intermedia;;; +90078-7;LL5096-4;Yeast species;LA29396-1;8;Candida lipolytica;;; +90078-7;LL5096-4;Yeast species;LA29397-9;9;Cryptococcus neoformans;;; +90078-7;LL5096-4;Yeast species;LA29398-7;10;Saccharomyces cerevisiae;;; +90078-7;LL5096-4;Yeast species;LA29399-5;11;Trichosporon inkin;;; +98403-9;LL5096-4;Yeast species;LA19544-8;0;None detected;;; +98403-9;LL5096-4;Yeast species;LA29389-6;1;Candida albicans 1;;; +98403-9;LL5096-4;Yeast species;LA29390-4;2;Candida albicans 2;;; +98403-9;LL5096-4;Yeast species;LA29391-2;3;Candida boidinii;;; +98403-9;LL5096-4;Yeast species;LA29392-0;4;Candida dattila;;; +98403-9;LL5096-4;Yeast species;LA28244-4;5;Candida glabrata;;; +98403-9;LL5096-4;Yeast species;LA29394-6;6;Candida hellenica;;; +98403-9;LL5096-4;Yeast species;LA29395-3;7;Candida intermedia;;; +98403-9;LL5096-4;Yeast species;LA29396-1;8;Candida lipolytica;;; +98403-9;LL5096-4;Yeast species;LA29397-9;9;Cryptococcus neoformans;;; +98403-9;LL5096-4;Yeast species;LA29398-7;10;Saccharomyces cerevisiae;;; +98403-9;LL5096-4;Yeast species;LA29399-5;11;Trichosporon inkin;;; +98408-8;LL5096-4;Yeast species;LA19544-8;0;None detected;;; +98408-8;LL5096-4;Yeast species;LA29389-6;1;Candida albicans 1;;; +98408-8;LL5096-4;Yeast species;LA29390-4;2;Candida albicans 2;;; +98408-8;LL5096-4;Yeast species;LA29391-2;3;Candida boidinii;;; +98408-8;LL5096-4;Yeast species;LA29392-0;4;Candida dattila;;; +98408-8;LL5096-4;Yeast species;LA28244-4;5;Candida glabrata;;; +98408-8;LL5096-4;Yeast species;LA29394-6;6;Candida hellenica;;; +98408-8;LL5096-4;Yeast species;LA29395-3;7;Candida intermedia;;; +98408-8;LL5096-4;Yeast species;LA29396-1;8;Candida lipolytica;;; +98408-8;LL5096-4;Yeast species;LA29397-9;9;Cryptococcus neoformans;;; +98408-8;LL5096-4;Yeast species;LA29398-7;10;Saccharomyces cerevisiae;;; +98408-8;LL5096-4;Yeast species;LA29399-5;11;Trichosporon inkin;;; +90080-3;LL5075-8;Susc|PLR|LR|IR|HR;LA24225-7;0;Susceptible;;; +90080-3;LL5075-8;Susc|PLR|LR|IR|HR;LA29301-1;1;Potential low-level resistance;;; +90080-3;LL5075-8;Susc|PLR|LR|IR|HR;LA29302-9;2;Low-level resistance;;; +90080-3;LL5075-8;Susc|PLR|LR|IR|HR;LA29303-7;3;Intermediate resistance;;; +90080-3;LL5075-8;Susc|PLR|LR|IR|HR;LA29304-5;4;High-level resistance;;; +90082-9;LL5196-2;Emergency communication templates;LA29653-5;1;First 48 Hours Checklist;;; +90082-9;LL5196-2;Emergency communication templates;LA29657-6;2;Immediate Response Checklist;;; +90082-9;LL5196-2;Emergency communication templates;LA29655-0;3;CERC Message Template;;; +90082-9;LL5196-2;Emergency communication templates;LA29658-4;4;CERC Plan Checklist;;; +90082-9;LL5196-2;Emergency communication templates;LA29654-3;5;New Release Template;;; +90083-7;LL5141-8;CDC EOC_Target population;LA29505-7;1;General population;;; +90083-7;LL5141-8;CDC EOC_Target population;LA29506-5;2;Specific population;;; +90083-7;LL5141-8;CDC EOC_Target population;LA29507-3;3;Pregnant women;;; +90090-2;LL5202-8;EOC Inter-agency document types;LA29445-6;1;Situational report;;; +90090-2;LL5202-8;EOC Inter-agency document types;LA9340-6;2;Alert;;; +90090-2;LL5202-8;EOC Inter-agency document types;LA29666-7;3;Warning release;;; +90090-2;LL5202-8;EOC Inter-agency document types;LA46-8;4;Other;;; +90094-4;LL5129-3;RAPID3_Near remis|Low|Mod|High severity;LA29471-2;1;Near remission;;; +90094-4;LL5129-3;RAPID3_Near remis|Low|Mod|High severity;LA29472-0;2;Low severity;;; +90094-4;LL5129-3;RAPID3_Near remis|Low|Mod|High severity;LA29473-8;3;Moderate severity;;; +90094-4;LL5129-3;RAPID3_Near remis|Low|Mod|High severity;LA29474-6;4;High severity;;; +90098-5;LL5127-7;Adhoc|Daily|Weekly|Monthly;LA29484-5;1;Adhoc;;; +90098-5;LL5127-7;Adhoc|Daily|Weekly|Monthly;LA14435-4;2;Daily;;; +90098-5;LL5127-7;Adhoc|Daily|Weekly|Monthly;LA18891-4;3;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +90098-5;LL5127-7;Adhoc|Daily|Weekly|Monthly;LA18876-5;4;Monthly;;; +90100-9;LL5094-9;Listeria species;LA19544-8;0;None detected;;; +90100-9;LL5094-9;Listeria species;LA29382-1;1;Listeria grayi;;; +90100-9;LL5094-9;Listeria species;LA29383-9;2;Listeria innocua;;; +90100-9;LL5094-9;Listeria species;LA29384-7;3;Listeria ivanovii;;; +90100-9;LL5094-9;Listeria species;LA29385-4;4;Listeria monocytogenes;;; +90100-9;LL5094-9;Listeria species;LA29386-2;5;Listeria seeligeri;;; +90100-9;LL5094-9;Listeria species;LA29387-0;6;Listeria welshimeri;;; +90122-3;LL5130-1;Pending|Dispatching;LA29487-8;1;Pending;;; +90122-3;LL5130-1;Pending|Dispatching;LA29488-6;2;Dispatching;;; +90127-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90127-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90127-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90127-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90127-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90128-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90128-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90128-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90128-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90128-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90134-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90134-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90134-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90134-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90134-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90135-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90135-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90135-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90135-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90135-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90136-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90136-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90136-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90136-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90136-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90137-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90137-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90137-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90137-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90137-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90138-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90138-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90138-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90138-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90138-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90139-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90139-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90139-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90139-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90139-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90140-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90140-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90140-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90140-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90140-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90142-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90142-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90142-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90142-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90142-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90143-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90143-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90143-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90143-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90143-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90144-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90144-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90144-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90144-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90144-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90146-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90146-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90146-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90146-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90146-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90148-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90148-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90148-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90148-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90148-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90150-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90150-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90150-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90150-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90150-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90158-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90158-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90158-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90158-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90158-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90162-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90162-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90162-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90162-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90162-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90164-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90164-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90164-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90164-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90164-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90168-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90168-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90168-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90168-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90168-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90174-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90174-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90174-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90174-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90174-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90175-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90175-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90175-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90175-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90175-1;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90176-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90176-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90176-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90176-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90176-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90181-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90181-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90181-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90181-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90181-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90182-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90182-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90182-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90182-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90182-7;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90183-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90183-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90183-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90183-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90183-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90184-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90184-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90184-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90184-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90184-3;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90185-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90185-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90185-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90185-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90185-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90186-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90186-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90186-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90186-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90186-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90187-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90187-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90187-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90187-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90187-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90189-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90189-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90189-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90189-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90189-2;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90190-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90190-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90190-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90190-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90190-0;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90191-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90191-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90191-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90191-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90191-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90193-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90193-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90193-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90193-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90193-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90195-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90195-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90195-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90195-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90195-9;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90197-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90197-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90197-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90197-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90197-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90205-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90205-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90205-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90205-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90205-6;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90209-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90209-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90209-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90209-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90209-8;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90211-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90211-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90211-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90211-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90211-4;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90215-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6297-1;1;None of the time;;; +90215-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14732-4;2;A little of the time;;; +90215-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14733-2;3;Some of the time;;; +90215-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA14734-0;4;Most of the time;;; +90215-5;LL5131-9;None(5)|Little(4)|Some(3)|Most(2)|All the time(1);LA6154-4;5;All of the time;;; +90130-6;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90130-6;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90130-6;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90130-6;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90130-6;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90130-6;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90153-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90153-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90153-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90153-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90153-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90153-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90155-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90155-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90155-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90155-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90155-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90155-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90157-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90157-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90157-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90157-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90157-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90157-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90161-1;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90161-1;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90161-1;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90161-1;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90161-1;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90161-1;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90167-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90167-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90167-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90167-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90167-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90167-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90177-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90177-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90177-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90177-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90177-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90177-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90200-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90200-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90200-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90200-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90200-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90200-7;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90202-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90202-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90202-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90202-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90202-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90202-3;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90204-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90204-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90204-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90204-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90204-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90204-9;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90208-0;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90208-0;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90208-0;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90208-0;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90208-0;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90208-0;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90214-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA6568-5;1;Not at all;;; +90214-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13863-8;2;A little bit;;; +90214-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13909-9;3;Somewhat;;; +90214-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13902-4;4;Quite a bit;;; +90214-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA13914-9;5;Very much;;; +90214-8;LL5132-7;NotAtAll(5)|Little(4)|Some(3)|Quite(2)|Very(1)|NA;LA4720-4;6;Not applicable;;; +90152-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90152-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90152-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90152-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90152-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90152-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90154-6;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90154-6;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90154-6;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90154-6;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90154-6;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90154-6;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90156-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90156-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90156-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90156-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90156-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90156-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90160-3;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90160-3;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90160-3;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90160-3;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90160-3;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90160-3;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90166-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90166-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90166-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90166-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90166-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90166-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90199-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90199-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90199-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90199-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90199-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90199-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90201-5;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90201-5;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90201-5;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90201-5;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90201-5;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90201-5;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90203-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90203-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90203-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90203-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90203-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90203-1;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90207-2;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90207-2;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90207-2;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90207-2;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90207-2;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90207-2;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90213-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA6297-1;1;None of the time;;; +90213-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14732-4;2;A little of the time;;; +90213-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14733-2;3;Some of the time;;; +90213-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14734-0;4;Most of the time;;; +90213-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA14726-6;5;All the time;;; +90213-0;LL5133-5;None(5)|Little(4)|Some(3)|Most(2)|AllTheTime(1)|NA;LA4720-4;6;Not applicable;;; +90232-0;LL5099-8;Histoplasma capsulatum antibody bands;LA29407-6;0;M band present;;; +90232-0;LL5099-8;Histoplasma capsulatum antibody bands;LA29408-4;1;H band present;;; +90232-0;LL5099-8;Histoplasma capsulatum antibody bands;LA29409-2;2;H and M bands present;;; +90232-0;LL5099-8;Histoplasma capsulatum antibody bands;LA29410-0;3;No band present;;; +91682-5;LL5099-8;Histoplasma capsulatum antibody bands;LA29407-6;0;M band present;;; +91682-5;LL5099-8;Histoplasma capsulatum antibody bands;LA29408-4;1;H band present;;; +91682-5;LL5099-8;Histoplasma capsulatum antibody bands;LA29409-2;2;H and M bands present;;; +91682-5;LL5099-8;Histoplasma capsulatum antibody bands;LA29410-0;3;No band present;;; +90255-1;LL5136-8;ISAR_KneeHip replacement satisfaction;LA14638-3;1;Very dissatisfied;;; +90255-1;LL5136-8;ISAR_KneeHip replacement satisfaction;LA29496-9;2;Dissatisfied;;; +90255-1;LL5136-8;ISAR_KneeHip replacement satisfaction;LA14786-0;3;Neutral;;; +90255-1;LL5136-8;ISAR_KneeHip replacement satisfaction;LA29495-1;4;Satisfied;;; +90255-1;LL5136-8;ISAR_KneeHip replacement satisfaction;LA14642-5;5;Very satisfied;;; +90292-4;LL5112-9;Liver cancer antibody and antigen panel interp;LA29457-1;0;No significant level of biomarkers detected;;; +90292-4;LL5112-9;Liver cancer antibody and antigen panel interp;LA29489-4;1;Moderate level;;; +90292-4;LL5112-9;Liver cancer antibody and antigen panel interp;LA29490-2;2;High level;;; +90300-5;LL5137-6;Helminths identified;LA11883-8;1;Not detected;;; +90300-5;LL5137-6;Helminths identified;LA28386-3;2;Strongyloides stercoralis;;; +90300-5;LL5137-6;Helminths identified;LA29497-7;3;Ascaris lumbricoides;;; +90300-5;LL5137-6;Helminths identified;LA29499-3;4;Ancylostoma ceylanicum;;; +90300-5;LL5137-6;Helminths identified;LA29498-5;5;Ancylostoma duodenale;;; +90300-5;LL5137-6;Helminths identified;LA29500-8;6;Necator americanus;;; +90300-5;LL5137-6;Helminths identified;LA29501-6;7;Trichuris trichiura;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29284-9;0;Haemophilus parasuis serotype 1;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29285-6;1;Haemophilus parasuis serotype 2;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29286-4;2;Haemophilus parasuis serotype 3;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29287-2;3;Haemophilus parasuis serotype 4;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29288-0;4;Haemophilus parasuis serotype 5;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29289-8;5;Haemophilus parasuis serotype 6;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29290-6;6;Haemophilus parasuis serotype 7;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29291-4;7;Haemophilus parasuis serotype 8;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29292-2;8;Haemophilus parasuis serotype 9;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29293-0;9;Haemophilus parasuis serotype 10;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29294-8;10;Haemophilus parasuis serotype 11;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29295-5;11;Haemophilus parasuis serotype 12;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29296-3;12;Haemophilus parasuis serotype 13;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA29297-1;13;Haemophilus parasuis serotype 14;;; +90322-9;LL4998-2;Haemophilus parasuis serotypes;LA28940-7;14;Untypable;;; +90369-0;LL5140-0;Drug level blood draw timing;LA29502-4;1;Peak;;; +90369-0;LL5140-0;Drug level blood draw timing;LA29503-2;2;Trough;;; +90369-0;LL5140-0;Drug level blood draw timing;LA29504-0;3;Random;;; +90376-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90376-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90376-5;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90376-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90376-5;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90377-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90377-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90377-3;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90377-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90377-3;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90378-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90378-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90378-1;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90378-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90378-1;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90379-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90379-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90379-9;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90379-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90379-9;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90380-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90380-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90380-7;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90380-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90380-7;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90381-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90381-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90381-5;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90381-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90381-5;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90382-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90382-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90382-3;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90382-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90382-3;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90383-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90383-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90383-1;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90383-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90383-1;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90384-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90384-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90384-9;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90384-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90384-9;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90385-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90385-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90385-6;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90385-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90385-6;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90386-4;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90386-4;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90386-4;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90386-4;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90386-4;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90387-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90387-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90387-2;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90387-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90387-2;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90388-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90388-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90388-0;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90388-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90388-0;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90389-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90389-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90389-8;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90389-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90389-8;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90390-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90390-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90390-6;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90390-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90390-6;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90391-4;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90391-4;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90391-4;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90391-4;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90391-4;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90392-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90392-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90392-2;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90392-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90392-2;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90393-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90393-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90393-0;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90393-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90393-0;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90394-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90394-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90394-8;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90394-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90394-8;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90395-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90395-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90395-5;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90395-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90395-5;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90396-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90396-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90396-3;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90396-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90396-3;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90397-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90397-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90397-1;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90397-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90397-1;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90398-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90398-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90398-9;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90398-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90398-9;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90399-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90399-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90399-7;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90399-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90399-7;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90400-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90400-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90400-3;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90400-3;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90400-3;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90401-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90401-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90401-1;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90401-1;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90401-1;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90402-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90402-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90402-9;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90402-9;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90402-9;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90403-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90403-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90403-7;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90403-7;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90403-7;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90404-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90404-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90404-5;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90404-5;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90404-5;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90405-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90405-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90405-2;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90405-2;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90405-2;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90406-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90406-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90406-0;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90406-0;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90406-0;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90407-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90407-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90407-8;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90407-8;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90407-8;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90408-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15227-4;1;No difficulty;;; +90408-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15725-7;2;A little difficulty;;; +90408-6;LL5145-9;Activity_Shortness of breath difficulty level;LA13950-3;3;Some difficulty;;; +90408-6;LL5145-9;Activity_Shortness of breath difficulty level;LA15228-2;4;Much difficulty;;; +90408-6;LL5145-9;Activity_Shortness of breath difficulty level;LA26125-7;5;I did not do this in the past 7 days;;; +90426-8;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90426-8;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90426-8;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90427-6;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90427-6;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90427-6;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90428-4;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90428-4;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90428-4;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90429-2;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90429-2;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90429-2;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90430-0;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90430-0;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90430-0;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90431-8;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90431-8;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90431-8;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90432-6;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90432-6;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90432-6;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90433-4;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90433-4;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90433-4;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90434-2;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90434-2;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90434-2;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90435-9;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90435-9;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90435-9;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90436-7;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90436-7;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90436-7;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90437-5;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90437-5;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90437-5;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90438-3;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +90438-3;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +90438-3;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +91590-0;LL5121-0;Negative to date;LA6576-8;0;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +91590-0;LL5121-0;Negative to date;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +91590-0;LL5121-0;Negative to date;LA29465-4;2;Negative to date;;; +90522-4;LL5249-9;No;LA32-8;0;No;373067005;No (qualifier value);http://snomed.info/sct +90522-4;LL5249-9;No;LA32-8;0;No;373067005;No (qualifier value);http://snomed.info/sct +90524-0;LL5152-5;CMS_MDS A0300B;LA12624-5;1;Start of therapy assessment;;; +90524-0;LL5152-5;CMS_MDS A0300B;LA12625-2;2;End of therapy assessment;;; +90524-0;LL5152-5;CMS_MDS A0300B;LA12626-0;3;Both Start and End of therapy assessment;;; +90524-0;LL5152-5;CMS_MDS A0300B;LA18612-4;4;Change of therapy assessment;;; +90524-0;LL5152-5;CMS_MDS A0300B;LA29575-0;5;Other payment assessment;;; +90660-2;LL5162-4;PESI PE risk score interpretation;LA29597-4;1;Very low risk;;; +90660-2;LL5162-4;PESI PE risk score interpretation;LA19542-2;2;Low risk;;; +90660-2;LL5162-4;PESI PE risk score interpretation;LA22380-2;3;Intermediate risk;;; +90660-2;LL5162-4;PESI PE risk score interpretation;LA19541-4;4;High risk;;; +90660-2;LL5162-4;PESI PE risk score interpretation;LA29598-2;5;Very high risk;;; +90661-0;LL5159-0;Geneva PE risk score interpretation;LA19542-2;1;Low risk;;; +90661-0;LL5159-0;Geneva PE risk score interpretation;LA22380-2;2;Intermediate risk;;; +90661-0;LL5159-0;Geneva PE risk score interpretation;LA19541-4;3;High risk;;; +90662-8;LL5160-8;Wells PE risk score interpretation;LA29601-4;1;Two tier interpretation model: PE unlikely;;; +90662-8;LL5160-8;Wells PE risk score interpretation;LA29600-6;2;Two tier interpretation model: PE likely;;; +90662-8;LL5160-8;Wells PE risk score interpretation;LA29602-2;3;Three tier interpretation model: Low risk;;; +90662-8;LL5160-8;Wells PE risk score interpretation;LA29599-0;4;Three tier interpretation model: Moderate risk;;; +90662-8;LL5160-8;Wells PE risk score interpretation;LA29603-0;5;Three tier interpretation model: High risk;;; +90663-6;LL5164-0;PERC PE risk score interpretation;LA29595-8;1;No need for further workup, as <2% chance of pulmonary embolus (PE);;; +90663-6;LL5164-0;PERC PE risk score interpretation;LA29596-6;2;If any criteria are positive, the PERC rule cannot be used to rule out pulmonary embolus (PE) in this patient;;; +90694-1;LL5509-6;Nev|alm nev|some|often|always;LA6270-8;1;Never;;; +90694-1;LL5509-6;Nev|alm nev|some|often|always;LA13866-1;2;Almost never;;; +90694-1;LL5509-6;Nev|alm nev|some|often|always;LA10082-8;3;Sometimes;;; +90694-1;LL5509-6;Nev|alm nev|some|often|always;LA10044-8;4;Often;;; +90694-1;LL5509-6;Nev|alm nev|some|often|always;LA13865-3;5;Almost always;;; +90702-2;LL5509-6;Nev|alm nev|some|often|always;LA6270-8;1;Never;;; +90702-2;LL5509-6;Nev|alm nev|some|often|always;LA13866-1;2;Almost never;;; +90702-2;LL5509-6;Nev|alm nev|some|often|always;LA10082-8;3;Sometimes;;; +90702-2;LL5509-6;Nev|alm nev|some|often|always;LA10044-8;4;Often;;; +90702-2;LL5509-6;Nev|alm nev|some|often|always;LA13865-3;5;Almost always;;; +90730-3;LL5124-4;Perception of body weight;LA29475-3;1;Very underweight;;; +90730-3;LL5124-4;Perception of body weight;LA29476-1;2;Slightly underweight;;; +90730-3;LL5124-4;Perception of body weight;LA29477-9;3;About the right weight;;; +90730-3;LL5124-4;Perception of body weight;LA29478-7;4;Slightly overweight;;; +90730-3;LL5124-4;Perception of body weight;LA29479-5;5;Very overweight;;; +90731-1;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA6270-8;1;Never;;; +90731-1;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18933-4;2;Less than monthly;;; +90731-1;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18876-5;3;Monthly;;; +90731-1;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +90731-1;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA14435-4;6;Daily;;; +90732-9;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA6270-8;1;Never;;; +90732-9;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18933-4;2;Less than monthly;;; +90732-9;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18876-5;3;Monthly;;; +90732-9;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +90732-9;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA14435-4;6;Daily;;; +90733-7;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA6270-8;1;Never;;; +90733-7;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18933-4;2;Less than monthly;;; +90733-7;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18876-5;3;Monthly;;; +90733-7;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +90733-7;LL5143-4;Never|Less than monthly|Monthly|Weekly|Daily;LA14435-4;6;Daily;;; +90734-5;LL5125-1;Body weight goal;LA29480-3;1;Lose weight;;; +90734-5;LL5125-1;Body weight goal;LA29481-1;2;Gain weight;;; +90734-5;LL5125-1;Body weight goal;LA29482-9;3;Stay the same weight;;; +90734-5;LL5125-1;Body weight goal;LA29483-7;4;I am not trying to do anything about my weight;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29540-4;1;Knee Replacement - partial or total;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29541-2;2;Hip Replacement - partial or total;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29542-0;3;Ankle Replacement - partial or total;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29543-8;4;Shoulder Replacement - partial or total;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29544-6;5;Spinal surgery involving the spinal cord or major spinal nerves;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29545-3;6;Spinal surgery involving fusion of spinal bones;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29546-1;7;Spinal surgery involving lamina, discs, or facets;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29547-9;8;Other major spinal surgery;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29548-7;9;Repair fractures of the shoulder (including clavicle and scapula) or arm (but not hand);;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29549-5;10;Repair fractures of the pelvis, hip, leg, knee, or ankle (not foot);;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29550-3;11;Repair but not replace joints;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29551-1;12;Repair other bones (such as hand, foot, jaw);;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29552-9;13;Other major orthopedic surgery;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29553-7;14;Neurological surgery involving the brain, surrounding tissue or blood vessels, (excludes skull and skin but includes cranial nerves);;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29554-5;15;Neurological surgery involving the peripheral or autonomic nervous system - open or percutaneous;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29555-2;16;Insertion or removal of spinal or brain neurostimulators, electrodes, catheters, or CSF drainage devices;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29556-0;17;Other major neurological surgery;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29557-8;18;Cardiopulmonary surgery involving the heart or major blood vessels - open or percutaneous procedures;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29558-6;19;Cardiopulmonary surgery involving the respiratory system, including lungs, bronchi, trachea, larynx, or vocal cords - open or endoscopic;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29562-8;20;Other major cardiopulmonary surgery;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29563-6;21;Involving genital systems (such as prostate, testes, ovaries, uterus, vagina, external genitalia);;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29564-4;22;Genitourinary surgery involving the kidneys, ureters, adrenal glands, or bladder - open or laparoscopic (includes creation or removal of nephrostomies or urostomies);;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29566-9;23;Other major genitourinary surgery;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29567-7;24;Other major surgery involving tendons, ligaments, or muscles;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29568-5;25;Other major surgery involving the gastrointestinal tract or abdominal contents from esophagus to anus, biliary tree, gall bladder, liver, pancreas, or spleen-open or laparoscopic;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29569-3;26;Other major surgery involving the endocrine organs (such as thyroid, parathyroid), neck, lymph nodes, or thymus - open;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29570-1;27;Other major surgery involving the breast;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29571-9;28;Repair of deep ulcers, internal brachytherapy, bone marrow or stem cell harvest or transplant;;; +90745-1;LL5178-0;CMS_MDS J Surgical procedures;LA29572-7;29;Other major surgery not listed above;;; +90775-8;LL6089-8;NRS 2002 - Disease Severity;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +90775-8;LL6089-8;NRS 2002 - Disease Severity;LA6752-5;2;Mild;;; +90775-8;LL6089-8;NRS 2002 - Disease Severity;LA6751-7;3;Moderate;;; +90775-8;LL6089-8;NRS 2002 - Disease Severity;LA6750-9;4;Severe;;; +90778-2;LL5144-2;Personal pronouns;LA29518-0;1;he/him/his/his/himself;;; +90778-2;LL5144-2;Personal pronouns;LA29519-8;2;she/her/her/hers/herself;;; +90778-2;LL5144-2;Personal pronouns;LA29520-6;3;they/them/their/theirs/themselves;;; +90778-2;LL5144-2;Personal pronouns;LA29523-0;4;ze/zir/zir/zirs/zirself;;; +90778-2;LL5144-2;Personal pronouns;LA29521-4;5;"xie/hir (""here"")/hir/hirs/hirself";;; +90778-2;LL5144-2;Personal pronouns;LA29515-6;6;co/co/cos/cos/coself;;; +90778-2;LL5144-2;Personal pronouns;LA29516-4;7;en/en/ens/ens/enself;;; +90778-2;LL5144-2;Personal pronouns;LA29517-2;8;ey/em/eir/eirs/emself;;; +90778-2;LL5144-2;Personal pronouns;LA29522-2;9;yo/yo/yos/yos/yoself;;; +90778-2;LL5144-2;Personal pronouns;LA29524-8;10;ve/vis/ver/ver/verself;;; +90855-8;LL5142-6;Posterior inter-arch deviation;LA29508-1;1;Anterior deviation;;; +90855-8;LL5142-6;Posterior inter-arch deviation;LA29509-9;2;Posterior deviation;;; +90855-8;LL5142-6;Posterior inter-arch deviation;LA9019-6;3;Posterior crossbite;;; +90855-8;LL5142-6;Posterior inter-arch deviation;LA29512-3;4;Posterior openbite;;; +90864-0;LL5195-4;Dental abnormalities;LA29648-5;1;Ectopic tooth;;; +90864-0;LL5195-4;Dental abnormalities;LA29649-3;2;Absent tooth;;; +90864-0;LL5195-4;Dental abnormalities;LA29650-1;3;Impacted tooth;;; +90864-0;LL5195-4;Dental abnormalities;LA29651-9;4;Ankylosis of tooth;;; +90864-0;LL5195-4;Dental abnormalities;LA29652-7;5;Supernumerary tooth;;; +90865-7;LL5194-7;Craniofacial anomalies;LA14411-5;1;Cleft lip;;; +90865-7;LL5194-7;Craniofacial anomalies;LA14412-3;2;Cleft palate;;; +90865-7;LL5194-7;Craniofacial anomalies;LA14413-1;3;Cleft lip and palate;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29637-8;4;Cleft lip & alveolus;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29638-6;5;Hemifacial microsomia;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29639-4;6;Craniosynostosis syndrome;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29640-2;7;Cleidocranial dysostosis;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29641-0;8;Treacher Collins syndrome;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29642-8;9;Arthrogryposis;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29645-1;10;Complete trisomy 21 syndrome;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29643-6;11;Marfan syndrome;;; +90865-7;LL5194-7;Craniofacial anomalies;LA29644-4;12;Juvenile rheumatoid arthritis;;; +90867-3;LL5168-1;Airway problems;LA29608-9;1;Sleep apnea;;; +90867-3;LL5168-1;Airway problems;LA29609-7;2;Obstructive apnea;;; +90867-3;LL5168-1;Airway problems;LA29607-1;3;Mouth breathing;;; +90870-7;LL5193-9;Finger/thumb sucking|Tongue thrusting;LA29635-2;1;Finger or thumb sucking;;; +90870-7;LL5193-9;Finger/thumb sucking|Tongue thrusting;LA29636-0;2;Tongue thrusting;;; +90908-5;LL5181-4;OmegaCheck High risk|Moderate risk|Low risk;LA19541-4;1;High risk;;; +90908-5;LL5181-4;OmegaCheck High risk|Moderate risk|Low risk;LA29616-2;2;Moderate risk;;; +90908-5;LL5181-4;OmegaCheck High risk|Moderate risk|Low risk;LA19542-2;3;Low risk;;; +90928-3;LL5167-3;Abnormalities of mandibular condyle;LA29604-8;1;Aplasia of mandibular condyle;;; +90928-3;LL5167-3;Abnormalities of mandibular condyle;LA29605-5;2;Bifidity of mandibular condyle;;; +90928-3;LL5167-3;Abnormalities of mandibular condyle;LA29606-3;3;Trifidity of mandibular condyle;;; +90932-5;LL5198-8;Orthodontic Severe Traumatic Deviations;LA29646-9;1;Loss of a premaxilla segment due to burns or by accident;;; +90932-5;LL5198-8;Orthodontic Severe Traumatic Deviations;LA20583-3;2;Osteomyelitis;;; +90932-5;LL5198-8;Orthodontic Severe Traumatic Deviations;LA29659-2;3;Defects due to trauma, tumor, or infection;;; +90990-3;LL5149-1;Monoclonal protein isotype;LA29537-0;1;No monoclonal protein detected;;; +90990-3;LL5149-1;Monoclonal protein isotype;LA29536-2;2;Monoclonal IgA lambda;;; +90990-3;LL5149-1;Monoclonal protein isotype;LA29538-8;3;Monoclonal IgG kappa;;; +90990-3;LL5149-1;Monoclonal protein isotype;LA29539-6;4;Monoclonal IgM kappa;;; +91013-3;LL5192-1;Minimal|Minor|Moderate|Major|Severe;LA26031-7;1;Minimal;;; +91013-3;LL5192-1;Minimal|Minor|Moderate|Major|Severe;LA29633-7;2;Minor;;; +91013-3;LL5192-1;Minimal|Minor|Moderate|Major|Severe;LA6751-7;3;Moderate;;; +91013-3;LL5192-1;Minimal|Minor|Moderate|Major|Severe;LA29634-5;4;Major;;; +91013-3;LL5192-1;Minimal|Minor|Moderate|Major|Severe;LA6750-9;5;Severe;;; +9110-8;LL5910-6;Blood loss;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +9110-8;LL5910-6;Blood loss;LA32157-2;2;<100 ml;;; +9110-8;LL5910-6;Blood loss;LA32158-0;3;100-500 ml;;; +9110-8;LL5910-6;Blood loss;LA32159-8;4;500-1000 ml;;; +9110-8;LL5910-6;Blood loss;LA32160-6;5;1000-2000 ml;;; +9110-8;LL5910-6;Blood loss;LA32161-4;6;>2000 ml;;; +91144-6;LL5188-9;Pregnancy prevention status;LA29627-9;1;I am already doing something to prevent pregnancy;;; +91144-6;LL5188-9;Pregnancy prevention status;LA29628-7;2;I want to start preventing pregnancy;;; +91144-6;LL5188-9;Pregnancy prevention status;LA29629-5;3;I don't want to prevent pregnancy;;; +91144-6;LL5188-9;Pregnancy prevention status;LA29630-3;4;I am unsure whether I want to prevent pregnancy;;; +91144-6;LL5188-9;Pregnancy prevention status;LA29631-1;5;I prefer not to answer;;; +91144-6;LL5188-9;Pregnancy prevention status;LA29632-9;6;This question does not apply to me;;; +91150-3;LL5203-6;NPUAP pressure injury staging;LA29668-3;1;Stage 1 Pressure Injury: Non-blanchable erythema of intact skin;;; +91150-3;LL5203-6;NPUAP pressure injury staging;LA29669-1;2;Stage 2 Pressure Injury: Partial-thickness skin loss with exposed dermis;;; +91150-3;LL5203-6;NPUAP pressure injury staging;LA29670-9;3;Stage 3 Pressure Injury: Full-thickness skin loss;;; +91150-3;LL5203-6;NPUAP pressure injury staging;LA29671-7;4;Stage 4 Pressure Injury: Full-thickness skin and tissue loss;;; +91150-3;LL5203-6;NPUAP pressure injury staging;LA29672-5;5;Unstageable Pressure Injury: Obscured full-thickness skin and tissue loss;;; +91150-3;LL5203-6;NPUAP pressure injury staging;LA29673-3;6;Deep Tissue Pressure Injury: Persistent non-blanchable deep red, maroon or purple discoloration;;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29617-0;1;Delivery of a child more than 3 weeks before the expected due date;;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29618-8;2;Delivery of a child weighing less than 5 lb 8 oz (or 2500 grams);;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29619-6;3;Spontaneous preterm delivery (<37 weeks);;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29620-4;4;Early or preterm rupture of the membranes;;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29621-2;5;Preeclampsia, eclampsia, toxemia or pregnancy induced hypertension;;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29622-0;6;Induction of labor due to low amniotic fluid or poor fetal growth;;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA14667-2;7;Stillbirth;;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29624-6;8;Delivery of an infant with a birth defect;;; +91151-1;LL5185-5;NuMoM2b_Pregnancy Complications;LA29625-3;9;Other pregnancy complication;;; +91205-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91205-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91205-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91205-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91205-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91206-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91206-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91206-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91206-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91206-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91207-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91207-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91207-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91207-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91207-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91209-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91209-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91209-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91209-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91209-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91210-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91210-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91210-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91210-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91210-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91211-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91211-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91211-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91211-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91211-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91212-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91212-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91212-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91212-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91212-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91213-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91213-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91213-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91213-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91213-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91214-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91214-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91214-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91214-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91214-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91217-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91217-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91217-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91217-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91217-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91218-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91218-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91218-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91218-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91218-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91219-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91219-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91219-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91219-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91219-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91221-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91221-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91221-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91221-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91221-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91222-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91222-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91222-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91222-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91222-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91223-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91223-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91223-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91223-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91223-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91224-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91224-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91224-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91224-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91224-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91225-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91225-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91225-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91225-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91225-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91226-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91226-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91226-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91226-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91226-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91326-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91326-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91326-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91326-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91326-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91327-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91327-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91327-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91327-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91327-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91328-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91328-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91328-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91328-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91328-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91329-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91329-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91329-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91329-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91329-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91330-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91330-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91330-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91330-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91330-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91331-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91331-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91331-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91331-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91331-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91332-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91332-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91332-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91332-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91332-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91333-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91333-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91333-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91333-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91333-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91334-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91334-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91334-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91334-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91334-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91335-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91335-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91335-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91335-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91335-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91336-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91336-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91336-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91336-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91336-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91337-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91337-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91337-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91337-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91337-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91500-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91500-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91500-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91500-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91500-9;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91501-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91501-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91501-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91501-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91501-7;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91502-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91502-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91502-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91502-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91502-5;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91503-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91503-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91503-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91503-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91503-3;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91504-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91504-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91504-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91504-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91504-1;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91505-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91505-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91505-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91505-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91505-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91506-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91506-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91506-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91506-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91506-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91507-4;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91507-4;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91507-4;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91507-4;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91507-4;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91508-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91508-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91508-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91508-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91508-2;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91509-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91509-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91509-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91509-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91509-0;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91510-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91510-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91510-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91510-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91510-8;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91511-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA29328-4;1;No days;;; +91511-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13943-8;2;1 day;;; +91511-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13944-6;3;2-3 days;;; +91511-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13945-3;4;4-5 days;;; +91511-6;LL5208-5;[PROMIS] No days|1 day|2-3 days|4-5 days|6-7 days;LA13946-1;5;6-7 days;;; +91340-0;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91340-0;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91341-8;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91341-8;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91342-6;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91342-6;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91343-4;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91343-4;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91344-2;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91344-2;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91345-9;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91345-9;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91346-7;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91346-7;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91347-5;LL5211-9;Disagree | Agree;LA15773-7;0;Disagree;;; +91347-5;LL5211-9;Disagree | Agree;LA15774-5;1;Agree;;; +91348-3;LL5212-7;Not at all|Slightly|Moderately|Very much|Extreme;LA6568-5;1;Not at all;;; +91348-3;LL5212-7;Not at all|Slightly|Moderately|Very much|Extreme;LA14454-5;2;Slightly;;; +91348-3;LL5212-7;Not at all|Slightly|Moderately|Very much|Extreme;LA13939-6;3;Moderately;;; +91348-3;LL5212-7;Not at all|Slightly|Moderately|Very much|Extreme;LA13914-9;4;Very much;;; +91348-3;LL5212-7;Not at all|Slightly|Moderately|Very much|Extreme;LA14868-6;5;Extremely;;; +91389-7;LL5214-3;Alcohol | Illegal drugs | Prescription drugs;LA28139-6;1;Alcohol;;; +91389-7;LL5214-3;Alcohol | Illegal drugs | Prescription drugs;LA29718-6;2;Illegal drugs;;; +91389-7;LL5214-3;Alcohol | Illegal drugs | Prescription drugs;LA29719-4;3;Prescription drugs;;; +91389-7;LL5220-0;Opioid Risk Tool question 1;LA28139-6;1;Alcohol;;; +91389-7;LL5220-0;Opioid Risk Tool question 1;LA29718-6;2;Illegal drugs;;; +91389-7;LL5220-0;Opioid Risk Tool question 1;LA29719-4;3;Prescription drugs;;; +91390-5;LL5219-2;ORT Preadolescence sexual abuse;LA33-6;0;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +91391-3;LL5217-6;Mental health diagnosis;LA29720-2;0;Attention deficit disorder;;; +91391-3;LL5217-6;Mental health diagnosis;LA24647-2;1;Bipolar;;; +91391-3;LL5217-6;Mental health diagnosis;LA10584-3;2;Schizophrenia;;; +91391-3;LL5217-6;Mental health diagnosis;LA10581-9;3;Obsessive Compulsive Disorder;;; +91391-3;LL5217-6;Mental health diagnosis;LA29721-0;4;PTSD;;; +91391-3;LL5217-6;Mental health diagnosis;LA10576-9;5;Depression;;; +91391-3;LL5217-6;Mental health diagnosis;LA29720-2;0;Attention deficit disorder;;; +91391-3;LL5217-6;Mental health diagnosis;LA24647-2;1;Bipolar;;; +91391-3;LL5217-6;Mental health diagnosis;LA10584-3;2;Schizophrenia;;; +91391-3;LL5217-6;Mental health diagnosis;LA10581-9;3;Obsessive Compulsive Disorder;;; +91391-3;LL5217-6;Mental health diagnosis;LA29721-0;4;PTSD;;; +91391-3;LL5217-6;Mental health diagnosis;LA10576-9;5;Depression;;; +91541-3;LL5216-8;Disease outcome type;LA29716-0;0;Full recovery;;; +91541-3;LL5216-8;Disease outcome type;LA29717-8;1;Partial recovery;;; +91541-3;LL5216-8;Disease outcome type;LA7424-0;2;Death;;; +91547-0;LL5206-9;No angina | Non-limiting angina | Exercise angina;LA29681-6;0;No angina;;; +91547-0;LL5206-9;No angina | Non-limiting angina | Exercise angina;LA29682-4;1;Non-limiting angina;;; +91547-0;LL5206-9;No angina | Non-limiting angina | Exercise angina;LA29683-2;2;Exercising-limiting angina;;; +91547-0;LL5206-9;No angina | Non-limiting angina | Exercise angina;LA29681-6;0;No angina;;; +91547-0;LL5206-9;No angina | Non-limiting angina | Exercise angina;LA29682-4;1;Non-limiting angina;;; +91547-0;LL5206-9;No angina | Non-limiting angina | Exercise angina;LA29683-2;2;Exercising-limiting angina;;; +91548-8;LL5210-1;Duke Treadmill Low risk|Moderate risk|High risk;LA19542-2;1;Low risk;;; +91548-8;LL5210-1;Duke Treadmill Low risk|Moderate risk|High risk;LA29616-2;2;Moderate risk;;; +91548-8;LL5210-1;Duke Treadmill Low risk|Moderate risk|High risk;LA19541-4;3;High risk;;; +91558-7;LL5229-1;Coinfection;LA10434-1;0;Babesiosis;;; +91558-7;LL5229-1;Coinfection;LA10487-9;1;Lyme disease;;; +91558-7;LL5229-1;Coinfection;LA29738-4;2;Ehrlichiosis;;; +91558-7;LL5229-1;Coinfection;LA29739-2;3;Anaplasmosis;;; +91558-7;LL5229-1;Coinfection;LA10449-9;4;Cyclosporiasis;;; +91558-7;LL5229-1;Coinfection;LA28577-7;5;Human immunodeficiency virus (HIV);;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA14799-3;1;Every day;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6571-9;2;Nearly every day;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29694-9;3;3 to 4 times a week;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29693-1;4;2 times a week;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA26461-6;5;Once a week;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29691-5;6;2 to 3 times a month;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6304-5;7;Once a month;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29689-9;8;7 to 11 times in the last year;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29688-1;9;3 to 6 times in the last year;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29687-3;10;1 or 2 times in the last year;;; +91569-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29686-5;11;Never in the last year;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA14799-3;1;Every day;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6571-9;2;Nearly every day;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29694-9;3;3 to 4 times a week;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29693-1;4;2 times a week;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA26461-6;5;Once a week;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29691-5;6;2 to 3 times a month;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6304-5;7;Once a month;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29689-9;8;7 to 11 times in the last year;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29688-1;9;3 to 6 times in the last year;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29687-3;10;1 or 2 times in the last year;;; +91573-6;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29686-5;11;Never in the last year;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA14799-3;1;Every day;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6571-9;2;Nearly every day;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29694-9;3;3 to 4 times a week;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29693-1;4;2 times a week;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA26461-6;5;Once a week;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29691-5;6;2 to 3 times a month;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6304-5;7;Once a month;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29689-9;8;7 to 11 times in the last year;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29688-1;9;3 to 6 times in the last year;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29687-3;10;1 or 2 times in the last year;;; +91574-4;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29686-5;11;Never in the last year;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA14799-3;1;Every day;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6571-9;2;Nearly every day;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29694-9;3;3 to 4 times a week;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29693-1;4;2 times a week;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA26461-6;5;Once a week;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29691-5;6;2 to 3 times a month;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6304-5;7;Once a month;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29689-9;8;7 to 11 times in the last year;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29688-1;9;3 to 6 times in the last year;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29687-3;10;1 or 2 times in the last year;;; +91575-1;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29686-5;11;Never in the last year;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA14799-3;1;Every day;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6571-9;2;Nearly every day;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29694-9;3;3 to 4 times a week;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29693-1;4;2 times a week;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA26461-6;5;Once a week;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29691-5;6;2 to 3 times a month;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA6304-5;7;Once a month;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29689-9;8;7 to 11 times in the last year;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29688-1;9;3 to 6 times in the last year;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29687-3;10;1 or 2 times in the last year;;; +91576-9;LL5205-1;Frequency 12Mo_Every day to Never in the last year;LA29686-5;11;Never in the last year;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA15267-0;1;More than once a day;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA13897-6;2;Once a day;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA29740-0;3;More than once a week;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA26461-6;4;Once a week;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA29741-8;5;More than once a month;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA6304-5;6;Once a month;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA6251-8;7;Less than once a month;;; +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA4389-8;8;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +91571-0;LL5230-9;>1x/d|1x/d|>1x/w|1x/w|>1x/mo|1x/mo|<1x/mo;LA12688-0;9;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +91578-5;LL5224-2;VeryUnlikely|Unlikely|Likely|VeryLikely|AlmostCert;LA15589-7;1;Very unlikely;;; +91578-5;LL5224-2;VeryUnlikely|Unlikely|Likely|VeryLikely|AlmostCert;LA15588-9;2;Unlikely;;; +91578-5;LL5224-2;VeryUnlikely|Unlikely|Likely|VeryLikely|AlmostCert;LA15587-1;3;Likely;;; +91578-5;LL5224-2;VeryUnlikely|Unlikely|Likely|VeryLikely|AlmostCert;LA15586-3;4;Very likely;;; +91578-5;LL5224-2;VeryUnlikely|Unlikely|Likely|VeryLikely|AlmostCert;LA29737-6;5;Almost certain;;; +91582-7;LL5222-6;Report status type;LA29732-7;1;Preliminary;;; +91582-7;LL5222-6;Report status type;LA29728-5;2;Revised - amended;;; +91582-7;LL5222-6;Report status type;LA29729-3;3;Revised - a change in client-provided information;;; +91582-7;LL5222-6;Report status type;LA29730-1;4;Revised - addendum;;; +91582-7;LL5222-6;Report status type;LA29731-9;5;Revised - other reason;;; +91582-7;LL5222-6;Report status type;LA16388-3;6;Final;;; +91585-0;LL5246-5;Level of reliability;LA23776-0;1;Reliable;;; +91585-0;LL5246-5;Level of reliability;LA29784-8;2;Usually reliable;;; +91585-0;LL5246-5;Level of reliability;LA29785-5;3;Fairly reliable;;; +91585-0;LL5246-5;Level of reliability;LA29786-3;4;Not usually reliable;;; +91585-0;LL5246-5;Level of reliability;LA23777-8;5;Unreliable;;; +91585-0;LL5246-5;Level of reliability;LA29788-9;6;Cannot be judged;;; +91586-8;LL5251-5;Coding system;LA29742-6;1;LOINC;;; +91586-8;LL5251-5;Coding system;LA29743-4;2;CDC;;; +91586-8;LL5251-5;Coding system;LA29797-0;3;CPT;;; +91586-8;LL5251-5;Coding system;LA29744-2;4;SNOMED CT;;; +91587-6;LL5247-3;Confirmed|ProbTrue|PossTrue|DoubtTrue|Improbable;LA15290-2;1;Confirmed;;; +91587-6;LL5247-3;Confirmed|ProbTrue|PossTrue|DoubtTrue|Improbable;LA29789-7;2;Probably true;;; +91587-6;LL5247-3;Confirmed|ProbTrue|PossTrue|DoubtTrue|Improbable;LA29790-5;3;Possibly true;;; +91587-6;LL5247-3;Confirmed|ProbTrue|PossTrue|DoubtTrue|Improbable;LA29791-3;4;Doubtfully true;;; +91587-6;LL5247-3;Confirmed|ProbTrue|PossTrue|DoubtTrue|Improbable;LA29792-1;5;Improbable;;; +91587-6;LL5247-3;Confirmed|ProbTrue|PossTrue|DoubtTrue|Improbable;LA29788-9;6;Cannot be judged;;; +91599-1;LL5238-2;EOC activation level;LA29762-4;1;Level 3: Normal operations/steady-state;;; +91599-1;LL5238-2;EOC activation level;LA29763-2;2;Level 2: Enhanced steady-state/partial activation;;; +91599-1;LL5238-2;EOC activation level;LA29764-0;3;Level 1: Full activation;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA29872-1;1;0 - Very depressed;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA6112-2;2;1;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA6113-0;3;2;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA6114-8;4;3;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA6115-5;5;4;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA10137-0;6;5;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA10138-8;7;6;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA10139-6;8;7;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA10140-4;9;8;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA10141-2;10;9;;; +91615-5;LL5272-1;0=Very depressed|2|3|4|5|6|7|8|9|10=Very cheerful;LA29873-9;11;10 - Very cheerful;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA29870-5;1;0 - No energy at all, listless;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA6112-2;2;1;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA6113-0;3;2;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA6114-8;4;3;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA6115-5;5;4;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA10137-0;6;5;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA10138-8;7;6;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA10139-6;8;7;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA10140-4;9;8;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA10141-2;10;9;;; +91616-3;LL5271-3;0=No energy|2|3|4|5|6|7|8|9|10=Very energetic;LA29871-3;11;10 - Very energetic, dynamic;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA29868-9;1;0 - Very relaxed;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA6112-2;2;1;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA6113-0;3;2;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA6114-8;4;3;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA6115-5;5;4;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA10137-0;6;5;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA10138-8;7;6;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA10139-6;8;7;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA10140-4;9;8;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA10141-2;10;9;;; +91617-1;LL5270-5;0/VeryRelaxed(10)|2|3|4|5|6|7|8|9|10/VeryTense(0);LA29869-7;11;10 - Very tense;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA29866-3;1;0 - Not concerned at all;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA6112-2;2;1;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA6113-0;3;2;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA6114-8;4;3;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA6115-5;5;4;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA10137-0;6;5;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA10138-8;7;6;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA10139-6;8;7;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA10140-4;9;8;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA10141-2;10;9;;; +91618-9;LL5269-7;0/NotCon(10)|1|2|3|4|5|6|7|8|9|10/VeryCon(0);LA29867-1;11;10 - Very concerned;;; +91619-7;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA6154-4;1;All of the time;;; +91619-7;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14734-0;2;Most of the time;;; +91619-7;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA18860-9;3;A good bit of the time;;; +91619-7;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14733-2;4;Some of the time;;; +91619-7;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14732-4;5;A little of the time;;; +91619-7;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA6297-1;6;None of the time;;; +91630-4;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA6154-4;1;All of the time;;; +91630-4;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14734-0;2;Most of the time;;; +91630-4;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA18860-9;3;A good bit of the time;;; +91630-4;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14733-2;4;Some of the time;;; +91630-4;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14732-4;5;A little of the time;;; +91630-4;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA6297-1;6;None of the time;;; +91631-2;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA6154-4;1;All of the time;;; +91631-2;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14734-0;2;Most of the time;;; +91631-2;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA18860-9;3;A good bit of the time;;; +91631-2;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14733-2;4;Some of the time;;; +91631-2;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA14732-4;5;A little of the time;;; +91631-2;LL5264-8;AllTime(0)|MostTime|GoodbitTime|LittleTime|None(5);LA6297-1;6;None of the time;;; +91620-5;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA6154-4;1;All of the time;;; +91620-5;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA14734-0;2;Most of the time;;; +91620-5;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA18860-9;3;A good bit of the time;;; +91620-5;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA14733-2;4;Some of the time;;; +91620-5;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA14732-4;5;A little of the time;;; +91620-5;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA6297-1;6;None of the time;;; +91621-3;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA6154-4;1;All of the time;;; +91621-3;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA14734-0;2;Most of the time;;; +91621-3;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA18860-9;3;A good bit of the time;;; +91621-3;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA14733-2;4;Some of the time;;; +91621-3;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA14732-4;5;A little of the time;;; +91621-3;LL5293-7;AllTime(5)|MostTime|GoodbitTime|LittleTime|None(0);LA6297-1;6;None of the time;;; +91622-1;LL5294-5;GWB_Waking refreshed, rested;LA14799-3;1;Every day;;; +91622-1;LL5294-5;GWB_Waking refreshed, rested;LA29859-8;2;Most every day;;; +91622-1;LL5294-5;GWB_Waking refreshed, rested;LA16644-9;3;Fairly often;;; +91622-1;LL5294-5;GWB_Waking refreshed, rested;LA14723-3;4;Less than half the time;;; +91622-1;LL5294-5;GWB_Waking refreshed, rested;LA10066-1;5;Rarely;;; +91622-1;LL5294-5;GWB_Waking refreshed, rested;LA6297-1;6;None of the time;;; +91623-9;LL5273-9;GWB Schedule_Level of concern;LA6568-5;1;Not at all;;; +91623-9;LL5273-9;GWB Schedule_Level of concern;LA22687-0;2;Only a little;;; +91623-9;LL5273-9;GWB Schedule_Level of concern;LA29851-5;3;Some -- but not enough to be concerned or worried about;;; +91623-9;LL5273-9;GWB Schedule_Level of concern;LA29852-3;4;Some and I have been a little concerned;;; +91623-9;LL5273-9;GWB Schedule_Level of concern;LA29853-1;5;Some and I am quite concerned;;; +91623-9;LL5273-9;GWB Schedule_Level of concern;LA29854-9;6;Yes, very much so and I am very concerned;;; +91624-7;LL5274-7;GWB Schedule_Level of happiness, satisfaction;LA29845-7;1;Extremely happy -- could not have been more satisfied or pleased;;; +91624-7;LL5274-7;GWB Schedule_Level of happiness, satisfaction;LA29846-5;2;Very happy;;; +91624-7;LL5274-7;GWB Schedule_Level of happiness, satisfaction;LA29847-3;3;Fairly happy;;; +91624-7;LL5274-7;GWB Schedule_Level of happiness, satisfaction;LA29848-1;4;Satisfied -- pleased;;; +91624-7;LL5274-7;GWB Schedule_Level of happiness, satisfaction;LA29849-9;5;Somewhat dissatisfied;;; +91624-7;LL5274-7;GWB Schedule_Level of happiness, satisfaction;LA14638-3;6;Very dissatisfied;;; +91625-4;LL5275-4;GWB Schedule_Level of sadness, discouraged;LA29839-0;1;Extremely so -- to the point that I have just about given up;;; +91625-4;LL5275-4;GWB Schedule_Level of sadness, discouraged;LA29829-1;2;Very much so;;; +91625-4;LL5275-4;GWB Schedule_Level of sadness, discouraged;LA13902-4;3;Quite a bit;;; +91625-4;LL5275-4;GWB Schedule_Level of sadness, discouraged;LA29831-7;4;Some -- enough to bother me;;; +91625-4;LL5275-4;GWB Schedule_Level of sadness, discouraged;LA13863-8;5;A little bit;;; +91625-4;LL5275-4;GWB Schedule_Level of sadness, discouraged;LA6568-5;6;Not at all;;; +91626-2;LL5276-2;GWB Schedule_Level of behavior control;LA29833-3;1;Yes, definitely so;;; +91626-2;LL5276-2;GWB Schedule_Level of behavior control;LA18533-2;2;Yes, for the most part;;; +91626-2;LL5276-2;GWB Schedule_Level of behavior control;LA29835-8;3;Generally so;;; +91626-2;LL5276-2;GWB Schedule_Level of behavior control;LA29836-6;4;Not too well;;; +91626-2;LL5276-2;GWB Schedule_Level of behavior control;LA29837-4;5;No, and I am somewhat disturbed;;; +91626-2;LL5276-2;GWB Schedule_Level of behavior control;LA29838-2;6;No, and I am very disturbed;;; +91627-0;LL5268-9;GWB Schedule_Level of being bothered by nerves;LA29828-3;1;Extremely so -- to the point where I could not work or take care of things;;; +91627-0;LL5268-9;GWB Schedule_Level of being bothered by nerves;LA29829-1;2;Very much so;;; +91627-0;LL5268-9;GWB Schedule_Level of being bothered by nerves;LA13902-4;3;Quite a bit;;; +91627-0;LL5268-9;GWB Schedule_Level of being bothered by nerves;LA29831-7;4;Some -- enough to bother me;;; +91627-0;LL5268-9;GWB Schedule_Level of being bothered by nerves;LA13940-4;5;A little;;; +91627-0;LL5268-9;GWB Schedule_Level of being bothered by nerves;LA6568-5;6;Not at all;;; +91628-8;LL5263-0;GWB Schedule_Feeling in general;LA29822-6;1;In excellent spirits;;; +91628-8;LL5263-0;GWB Schedule_Feeling in general;LA29823-4;2;In very good spirits;;; +91628-8;LL5263-0;GWB Schedule_Feeling in general;LA29824-2;3;In good spirits mostly;;; +91628-8;LL5263-0;GWB Schedule_Feeling in general;LA29825-9;4;I've been up and down in spirits a lot;;; +91628-8;LL5263-0;GWB Schedule_Feeling in general;LA29826-7;5;In low spirits mostly;;; +91628-8;LL5263-0;GWB Schedule_Feeling in general;LA29827-5;6;In very low spirits;;; +91632-0;LL5265-5;GWB Schedule_Level of anxious, worried, upset;LA29855-6;1;Extremely so -- to the point of being sick, or almost sick;;; +91632-0;LL5265-5;GWB Schedule_Level of anxious, worried, upset;LA29829-1;2;Very much so;;; +91632-0;LL5265-5;GWB Schedule_Level of anxious, worried, upset;LA13902-4;3;Quite a bit;;; +91632-0;LL5265-5;GWB Schedule_Level of anxious, worried, upset;LA29831-7;4;Some -- enough to bother me;;; +91632-0;LL5265-5;GWB Schedule_Level of anxious, worried, upset;LA13863-8;5;A little bit;;; +91632-0;LL5265-5;GWB Schedule_Level of anxious, worried, upset;LA6568-5;6;Not at all;;; +91633-8;LL5266-3;GWB Schedule_Level of strain, stress, or pressure;LA29840-8;1;Yes -- almost more than I could bear or stand;;; +91633-8;LL5266-3;GWB Schedule_Level of strain, stress, or pressure;LA29841-6;2;Yes -- quite a bit of pressure;;; +91633-8;LL5266-3;GWB Schedule_Level of strain, stress, or pressure;LA29842-4;3;Yes -- some - more than usual;;; +91633-8;LL5266-3;GWB Schedule_Level of strain, stress, or pressure;LA29843-2;4;Yes -- some - but about usual;;; +91633-8;LL5266-3;GWB Schedule_Level of strain, stress, or pressure;LA29844-0;5;Yes - a little;;; +91633-8;LL5266-3;GWB Schedule_Level of strain, stress, or pressure;LA6568-5;6;Not at all;;; +91634-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91634-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91634-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91634-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91634-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91635-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91635-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91635-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91635-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91635-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91636-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91636-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91636-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91636-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91636-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91637-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91637-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91637-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91637-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91637-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91638-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91638-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91638-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91638-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91638-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91639-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91639-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91639-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91639-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91639-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91640-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91640-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91640-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91640-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91640-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91641-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91641-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91641-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91641-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91641-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91652-8;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91652-8;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91652-8;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91652-8;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91652-8;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91653-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91653-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91653-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91653-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91653-6;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91654-4;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91654-4;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91654-4;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91654-4;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91654-4;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91655-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91655-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91655-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91655-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91655-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91656-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91656-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91656-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91656-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91656-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91657-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91657-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91657-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91657-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91657-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91658-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91658-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91658-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91658-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91658-5;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91659-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91659-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91659-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91659-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91659-3;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91660-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91660-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91660-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91660-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91660-1;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91661-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91661-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91661-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91661-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91661-9;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91662-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA6297-1;1;None of the time;;; +91662-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14732-4;2;A little of the time;;; +91662-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14733-2;3;Some of the time;;; +91662-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA14734-0;4;Most of the time;;; +91662-7;LL5278-8;None|ALittle|Some|Most|All of the time;LA6154-4;5;All of the time;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA7262-4;1;Administrative;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA28428-3;2;Emergency medicine;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA7264-0;3;Environmental hazard/safety;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA19834-3;5;Pediatric;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA7190-7;6;Neurology;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA9401-6;7;Nurse;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA28112-3;8;General medicine;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA6657-6;10;Social worker;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA14620-1;11;Surgery;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA29891-1;12;Engineer;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA20606-2;13;Construction;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA29893-7;14;Firefighter;;; +91700-5;LL5236-6;Emergency response volunteer specialties;LA28114-9;15;Other specialization;;; +91701-3;LL5241-6;Shelter category types;LA29775-6;1;Congregate shelter;;; +91701-3;LL5241-6;Shelter category types;LA29776-4;2;Evacuation shelter;;; +91701-3;LL5241-6;Shelter category types;LA29777-2;3;General population shelter;;; +91701-3;LL5241-6;Shelter category types;LA29779-8;4;Spontaneous/ad-hoc shelter;;; +91701-3;LL5241-6;Shelter category types;LA29780-6;5;Medical needs shelter;;; +91701-3;LL5241-6;Shelter category types;LA29781-4;6;Household pet shelter;;; +91712-0;LL4021-3;G/G| G/A |A/A;LA19932-5;1;G/G (wild type);;; +91712-0;LL4021-3;G/G| G/A |A/A;LA19933-3;2;G/A (heterozygous);;; +91712-0;LL4021-3;G/G| G/A |A/A;LA19934-1;3;A/A (homozygous);;; +91878-9;LL5252-3;Communication mode;LA29799-6;1;E-mail;;; +91878-9;LL5252-3;Communication mode;LA26664-5;2;Telephone;;; +91878-9;LL5252-3;Communication mode;LA29798-8;3;Text message;;; +91887-0;LL5259-8;Agency types;LA22542-7;1;Public Health;;; +91887-0;LL5259-8;Agency types;LA29803-6;2;Medical agency;;; +91887-0;LL5259-8;Agency types;LA6218-7;3;Hospital;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29805-1;1;Adult intensive care unit (ICU) beds;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29806-9;2;Adult medical/surgical beds;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29807-7;3;Burn intensive care unit (ICU) beds;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29808-5;4;Pediatric intensive care unit (ICU) beds;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29809-3;5;Pediatric medical/surgical beds;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29810-1;6;Psychiatric beds;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29811-9;7;Airborne infection isolation beds;;; +91891-2;LL5260-6;HAvBED_Bed types;LA29812-7;8;Operating room beds;;; +91901-9;LL5289-5;Emergency response teams;LA29900-0;1;Special Weapons and Tactics (SWAT);;; +91901-9;LL5289-5;Emergency response teams;LA29901-8;2;Joint Terrorism Task Force (JTTF);;; +91901-9;LL5289-5;Emergency response teams;LA29902-6;3;Hazardous Materials Management (HAZMAT);;; +91901-9;LL5289-5;Emergency response teams;LA29903-4;4;Emergency medical technician (EMT);;; +91901-9;LL5289-5;Emergency response teams;LA29904-2;5;Community emergency response team (CERT);;; +91901-9;LL5289-5;Emergency response teams;LA29905-9;6;Firefighters;;; +91901-9;LL5289-5;Emergency response teams;LA20185-7;7;Police;;; +91911-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA6270-8;1;Never;;; +91911-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA13866-1;2;Almost never;;; +91911-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA10082-8;3;Sometimes;;; +91911-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA10044-8;4;Often;;; +91911-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA13865-3;5;Almost always;;; +91930-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA6270-8;1;Never;;; +91930-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA13866-1;2;Almost never;;; +91930-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA10082-8;3;Sometimes;;; +91930-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA10044-8;4;Often;;; +91930-8;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA13865-3;5;Almost always;;; +91993-6;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA6270-8;1;Never;;; +91993-6;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA13866-1;2;Almost never;;; +91993-6;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA10082-8;3;Sometimes;;; +91993-6;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA10044-8;4;Often;;; +91993-6;LL5292-9;[PROMIS] Nev(1)|Al nev(2)(|Som(3)|Oft(4)|Al alw(4);LA13865-3;5;Almost always;;; +92022-3;LL5253-1;PHVS_CauseOfDeath_ICD-10_CDC;;0;;;; +92023-1;LL5253-1;PHVS_CauseOfDeath_ICD-10_CDC;;0;;;; +92027-2;LL5295-2;Advisory:No action|Alert:Action;LA29907-5;1;Advisory: No action required;;; +92027-2;LL5295-2;Advisory:No action|Alert:Action;LA29908-3;2;Alert: Action required;;; +92049-6;LL5213-5;MRSA|MSSA|MSSA+CoNS|Mixed|Negative;LA29705-3;1;Methicillin-resistant Staphylococcus aureus (MRSA);;; +92049-6;LL5213-5;MRSA|MSSA|MSSA+CoNS|Mixed|Negative;LA29703-8;2;Methicillin-sensitive Staphylococcus aureus (MSSA);;; +92049-6;LL5213-5;MRSA|MSSA|MSSA+CoNS|Mixed|Negative;LA29704-6;3;Methicillin-sensitive Staphylococcus aureus (MSSA) and coagulase-negative staphylococci (CoNS);;; +92049-6;LL5213-5;MRSA|MSSA|MSSA+CoNS|Mixed|Negative;LA21130-2;4;Coagulase-negative staphylococci;;; +92049-6;LL5213-5;MRSA|MSSA|MSSA+CoNS|Mixed|Negative;LA29706-1;5;Mixed infection;;; +92049-6;LL5213-5;MRSA|MSSA|MSSA+CoNS|Mixed|Negative;LA6577-6;6;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +92097-5;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA6568-5;1;Not at all;;; +92097-5;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13863-8;2;A little bit;;; +92097-5;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13909-9;3;Somewhat;;; +92097-5;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13902-4;4;Quite a bit;;; +92097-5;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13914-9;5;Very much;;; +92119-7;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA6568-5;1;Not at all;;; +92119-7;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13863-8;2;A little bit;;; +92119-7;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13909-9;3;Somewhat;;; +92119-7;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13902-4;4;Quite a bit;;; +92119-7;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13914-9;5;Very much;;; +92122-1;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA6568-5;1;Not at all;;; +92122-1;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13863-8;2;A little bit;;; +92122-1;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13909-9;3;Somewhat;;; +92122-1;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13902-4;4;Quite a bit;;; +92122-1;LL5209-3;[PROMIS]NotAtAll(1|Lit bit(1|Som(2|Qte bit(3|Ver(4;LA13914-9;5;Very much;;; +92150-2;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92150-2;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92150-2;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92150-2;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92150-2;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92151-0;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92151-0;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92151-0;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92151-0;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92151-0;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92152-8;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92152-8;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92152-8;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92152-8;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92152-8;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92153-6;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92153-6;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92153-6;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92153-6;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92153-6;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92154-4;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92154-4;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92154-4;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92154-4;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92154-4;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92155-1;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92155-1;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92155-1;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92155-1;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92155-1;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92156-9;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92156-9;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92156-9;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92156-9;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92156-9;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92157-7;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92157-7;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92157-7;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92157-7;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92157-7;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92158-5;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92158-5;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92158-5;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92158-5;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92158-5;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92159-3;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92159-3;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92159-3;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92159-3;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92159-3;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92160-1;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92160-1;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92160-1;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92160-1;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92160-1;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92161-9;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92161-9;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92161-9;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92161-9;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92161-9;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92162-7;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92162-7;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92162-7;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92162-7;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92162-7;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92163-5;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92163-5;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92163-5;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92163-5;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92163-5;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92164-3;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92164-3;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92164-3;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92164-3;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92164-3;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92165-0;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92165-0;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92165-0;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92165-0;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92165-0;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92166-8;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92166-8;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92166-8;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92166-8;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92166-8;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92167-6;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92167-6;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92167-6;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92167-6;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92167-6;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92168-4;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92168-4;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92168-4;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92168-4;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92168-4;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92169-2;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92169-2;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92169-2;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92169-2;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92169-2;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92170-0;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92170-0;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92170-0;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92170-0;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92170-0;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92171-8;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92171-8;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92171-8;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92171-8;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92171-8;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92172-6;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92172-6;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92172-6;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92172-6;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92172-6;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92173-4;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92173-4;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92173-4;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92173-4;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92173-4;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92174-2;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92174-2;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92174-2;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92174-2;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92174-2;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92175-9;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92175-9;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92175-9;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92175-9;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92175-9;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92176-7;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92176-7;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92176-7;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92176-7;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92176-7;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92177-5;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92177-5;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92177-5;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92177-5;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92177-5;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92178-3;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92178-3;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92178-3;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92178-3;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92178-3;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92179-1;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92179-1;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92179-1;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92179-1;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92179-1;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92180-9;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92180-9;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92180-9;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92180-9;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92180-9;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92181-7;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92181-7;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92181-7;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92181-7;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92181-7;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92182-5;LL5305-9;PROMIS - Shortness of Breath;LA26121-6;1;No shortness of breath;;; +92182-5;LL5305-9;PROMIS - Shortness of Breath;LA26122-4;2;Mildly short of breath;;; +92182-5;LL5305-9;PROMIS - Shortness of Breath;LA26123-2;3;Moderately short of breath;;; +92182-5;LL5305-9;PROMIS - Shortness of Breath;LA26124-0;4;Severely short of breath;;; +92182-5;LL5305-9;PROMIS - Shortness of Breath;LA26125-7;5;I did not do this in the past 7 days;;; +92194-0;LL5240-8;Bed status categories;LA29769-9;1;Licensed beds;;; +92194-0;LL5240-8;Bed status categories;LA29770-7;2;Physically available beds;;; +92194-0;LL5240-8;Bed status categories;LA29771-5;3;Staffed beds;;; +92194-0;LL5240-8;Bed status categories;LA29772-3;4;Unstaffed beds;;; +92194-0;LL5240-8;Bed status categories;LA29773-1;5;Occupied beds;;; +92194-0;LL5240-8;Bed status categories;LA29774-9;6;Vacant/available beds;;; +92235-1;LL5299-4;Lab order result status;LA29923-2;0;"Order received; specimen not yet received";;; +92235-1;LL5299-4;Lab order result status;LA29924-0;1;"No results available; specimen received, procedure incomplete";;; +92235-1;LL5299-4;Lab order result status;LA29925-7;2;"No results available; procedure scheduled, but not done";;; +92235-1;LL5299-4;Lab order result status;LA29926-5;3;Some, but not all, results available;;; +92235-1;LL5299-4;Lab order result status;LA29927-3;4;Preliminary: A verified early result is available, final results not yet obtained;;; +92235-1;LL5299-4;Lab order result status;LA29928-1;5;Correction to results;;; +92235-1;LL5299-4;Lab order result status;LA29929-9;6;"Results stored; not yet verified";;; +92235-1;LL5299-4;Lab order result status;LA29930-7;7;"Final results; results stored and verified. Can only be changed with a corrected result.";;; +92235-1;LL5299-4;Lab order result status;LA29931-5;8;"No results available; Order canceled.";;; +92235-1;LL5299-4;Lab order result status;LA29932-3;9;No order on record for this test. (Used only on queries);;; +92235-1;LL5299-4;Lab order result status;LA29933-1;10;No record of this patient. (Used only on queries);;; +92236-9;LL5298-6;Laboratory observation result status;LA29909-1;0;Record coming over is a correction and thus replaces a final result;;; +92236-9;LL5298-6;Laboratory observation result status;LA29910-9;1;Deletes the OBX record;;; +92236-9;LL5298-6;Laboratory observation result status;LA29911-7;2;"Final results; Can only be changed with a corrected result";;; +92236-9;LL5298-6;Laboratory observation result status;LA29912-5;3;"Specimen in lab; results pending";;; +92236-9;LL5298-6;Laboratory observation result status;LA29913-3;4;"Not asked; used to affirmatively document that the observation identified in the OBX was not sought when the universal service ID in OBR-4 implies that it would be sought";;; +92236-9;LL5298-6;Laboratory observation result status;LA29914-1;5;Order detail description only (no result);;; +92236-9;LL5298-6;Laboratory observation result status;LA29915-8;6;Preliminary results;;; +92236-9;LL5298-6;Laboratory observation result status;LA29916-6;7;Results entered - not verified;;; +92236-9;LL5298-6;Laboratory observation result status;LA29917-4;8;Partial results;;; +92236-9;LL5298-6;Laboratory observation result status;LA29918-2;9;Results cannot be obtained for this observation;;; +92236-9;LL5298-6;Laboratory observation result status;LA29919-0;10;Results status change to final without retransmitting results already sent as 'preliminary.' E.g., radiology changes status from preliminary to final;;; +92236-9;LL5298-6;Laboratory observation result status;LA29922-4;11;Post original as wrong, e.g., transmitted for wrong patient;;; +92237-7;LL5300-0;Lab observation sub-type;LA29934-9;0;Micro isolate related;;; +92237-7;LL5300-0;Lab observation sub-type;LA29935-6;1;Micro non-isolate related;;; +92237-7;LL5300-0;Lab observation sub-type;LA29936-4;2;Micro isolate related modifier;;; +92237-7;LL5300-0;Lab observation sub-type;LA29937-2;3;Susceptibility related;;; +92237-7;LL5300-0;Lab observation sub-type;LA29938-0;4;Supplemental result;;; +92237-7;LL5300-0;Lab observation sub-type;LA14093-1;5;Unspecified;;; +92237-7;LL5300-0;Lab observation sub-type;LA29939-8;6;Ask at order entry;;; +92237-7;LL5300-0;Lab observation sub-type;LA29940-6;7;Ask at specimen collection;;; +92239-3;LL5303-4;Carrier of infectious disease;LA29941-4;1;Carrier of typhoid;;; +92239-3;LL5303-4;Carrier of infectious disease;LA29942-2;2;Carrier of diphtheria;;; +92239-3;LL5303-4;Carrier of infectious disease;LA29944-8;3;Carrier of Methicillin resistant Staphylococcus aureus;;; +92239-3;LL5303-4;Carrier of infectious disease;LA29945-5;4;Carrier of Group B streptococcus;;; +92239-3;LL5303-4;Carrier of infectious disease;LA29946-3;5;Carrier of other infectious diseases;;; +92239-3;LL5303-4;Carrier of infectious disease;LA29947-1;6;Carrier status unknown;;; +92239-3;LL5303-4;Carrier of infectious disease;LA29948-9;7;Not a carrier of infectious disease;;; +92253-4;LL5310-9;PHVS_Organism_SCT_CDC;;0;;;; +92273-2;LL5279-6;PRAMS_newborn duration in hospital post delivery;LA29874-7;1;Less than 24 hours (less than 1 day);;; +92273-2;LL5279-6;PRAMS_newborn duration in hospital post delivery;LA29875-4;2;24 to 48 hours (1 to 2 days);;; +92273-2;LL5279-6;PRAMS_newborn duration in hospital post delivery;LA15777-8;3;3 to 5 days;;; +92273-2;LL5279-6;PRAMS_newborn duration in hospital post delivery;LA29877-0;4;6 to 14 days;;; +92273-2;LL5279-6;PRAMS_newborn duration in hospital post delivery;LA29878-8;5;More than 14 days;;; +92273-2;LL5279-6;PRAMS_newborn duration in hospital post delivery;LA29879-6;6;My baby was not born in a hospital;;; +92273-2;LL5279-6;PRAMS_newborn duration in hospital post delivery;LA29880-4;7;My baby is still in the hospital;;; +92274-0;LL5306-7;PATH_Rule statements for tobacco use inside home;LA29954-7;1;It is not allowed anywhere or at any time inside my home;;; +92274-0;LL5306-7;PATH_Rule statements for tobacco use inside home;LA29955-4;2;It is allowed in some places or at some times inside my home;;; +92274-0;LL5306-7;PATH_Rule statements for tobacco use inside home;LA29956-2;3;It is allowed anywhere and at anytime inside my home;;; +92274-0;LL5306-7;PATH_Rule statements for tobacco use inside home;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +92274-0;LL5306-7;PATH_Rule statements for tobacco use inside home;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +92279-9;LL5306-7;PATH_Rule statements for tobacco use inside home;LA29954-7;1;It is not allowed anywhere or at any time inside my home;;; +92279-9;LL5306-7;PATH_Rule statements for tobacco use inside home;LA29955-4;2;It is allowed in some places or at some times inside my home;;; +92279-9;LL5306-7;PATH_Rule statements for tobacco use inside home;LA29956-2;3;It is allowed anywhere and at anytime inside my home;;; +92279-9;LL5306-7;PATH_Rule statements for tobacco use inside home;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +92279-9;LL5306-7;PATH_Rule statements for tobacco use inside home;LA4389-8;5;Refused;443390004;Refused (qualifier value);http://snomed.info/sct +92281-5;LL5307-5;Cigarrette brands;LA29984-4;1;Alpine;;; +92281-5;LL5307-5;Cigarrette brands;LA29958-8;2;American Spirit;;; +92281-5;LL5307-5;Cigarrette brands;LA29985-1;3;Barclay;;; +92281-5;LL5307-5;Cigarrette brands;LA29959-6;4;Basic;;; +92281-5;LL5307-5;Cigarrette brands;LA29986-9;5;Belair;;; +92281-5;LL5307-5;Cigarrette brands;LA29960-4;6;Benson & Hedges;;; +92281-5;LL5307-5;Cigarrette brands;LA29987-7;7;Best Value;;; +92281-5;LL5307-5;Cigarrette brands;LA29988-5;9;Bristol;;; +92281-5;LL5307-5;Cigarrette brands;LA29989-3;10;Bugler (roll-your-own);;; +92281-5;LL5307-5;Cigarrette brands;LA29990-1;11;Cambridge;;; +92281-5;LL5307-5;Cigarrette brands;LA29961-2;12;Camel;;; +92281-5;LL5307-5;Cigarrette brands;LA29962-0;13;Capri;;; +92281-5;LL5307-5;Cigarrette brands;LA29963-8;14;Carlton;;; +92281-5;LL5307-5;Cigarrette brands;LA29991-9;15;Century;;; +92281-5;LL5307-5;Cigarrette brands;LA29992-7;16;Chesterfield;;; +92281-5;LL5307-5;Cigarrette brands;LA29964-6;17;Doral;;; +92281-5;LL5307-5;Cigarrette brands;LA29993-5;18;Eve;;; +92281-5;LL5307-5;Cigarrette brands;LA29965-3;19;GPC;;; +92281-5;LL5307-5;Cigarrette brands;LA29994-3;20;Harley Davidson;;; +92281-5;LL5307-5;Cigarrette brands;LA29967-9;21;Kent;;; +92281-5;LL5307-5;Cigarrette brands;LA29968-7;22;Kool;;; +92281-5;LL5307-5;Cigarrette brands;LA29996-8;23;L&M;;; +92281-5;LL5307-5;Cigarrette brands;LA29995-0;24;Lark;;; +92281-5;LL5307-5;Cigarrette brands;LA29969-5;25;Liggett Select;;; +92281-5;LL5307-5;Cigarrette brands;LA29997-6;26;Lucky Strike;;; +92281-5;LL5307-5;Cigarrette brands;LA29998-4;27;Magna;;; +92281-5;LL5307-5;Cigarrette brands;LA29970-3;28;Marlboro;;; +92281-5;LL5307-5;Cigarrette brands;LA29999-2;29;Maverick;;; +92281-5;LL5307-5;Cigarrette brands;LA30000-6;30;Max;;; +92281-5;LL5307-5;Cigarrette brands;LA29971-1;31;Merit;;; +92281-5;LL5307-5;Cigarrette brands;LA29972-9;32;Misty;;; +92281-5;LL5307-5;Cigarrette brands;LA29973-7;33;Monarch;;; +92281-5;LL5307-5;Cigarrette brands;LA30001-4;34;Montclair;;; +92281-5;LL5307-5;Cigarrette brands;LA16824-7;35;More;;; +92281-5;LL5307-5;Cigarrette brands;LA29975-2;36;Newport;;; +92281-5;LL5307-5;Cigarrette brands;LA30002-2;37;Now;;; +92281-5;LL5307-5;Cigarrette brands;LA30003-0;38;Old Gold;;; +92281-5;LL5307-5;Cigarrette brands;LA29976-0;39;Pall Mall;;; +92281-5;LL5307-5;Cigarrette brands;LA29977-8;40;Parliament;;; +92281-5;LL5307-5;Cigarrette brands;LA30004-8;41;Players;;; +92281-5;LL5307-5;Cigarrette brands;LA30005-5;42;Private Label;;; +92281-5;LL5307-5;Cigarrette brands;LA30006-3;43;Pyramid;;; +92281-5;LL5307-5;Cigarrette brands;LA30007-1;44;Raleigh;;; +92281-5;LL5307-5;Cigarrette brands;LA30008-9;45;Richland;;; +92281-5;LL5307-5;Cigarrette brands;LA29978-6;46;Salem;;; +92281-5;LL5307-5;Cigarrette brands;LA30009-7;47;Saratoga;;; +92281-5;LL5307-5;Cigarrette brands;LA30010-5;48;Satin;;; +92281-5;LL5307-5;Cigarrette brands;LA30011-3;49;State Express;;; +92281-5;LL5307-5;Cigarrette brands;LA30012-1;50;Sterling;;; +92281-5;LL5307-5;Cigarrette brands;LA30013-9;51;Tareyton;;; +92281-5;LL5307-5;Cigarrette brands;LA30014-7;52;Top (roll-your-own);;; +92281-5;LL5307-5;Cigarrette brands;LA14495-8;53;True;;; +92281-5;LL5307-5;Cigarrette brands;LA29979-4;54;USA Gold;;; +92281-5;LL5307-5;Cigarrette brands;LA29980-2;55;Vantage;;; +92281-5;LL5307-5;Cigarrette brands;LA29981-0;56;Viceroy;;; +92281-5;LL5307-5;Cigarrette brands;LA29982-8;57;Virginia Slims;;; +92281-5;LL5307-5;Cigarrette brands;LA29983-6;58;Winston;;; +92281-5;LL5307-5;Cigarrette brands;LA29966-1;59;Brand not on this list;;; +92331-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92331-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92331-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92331-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92331-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92332-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92332-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92332-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92332-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92332-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92333-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92333-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92333-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92333-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92333-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92334-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92334-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92334-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92334-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92334-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92335-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92335-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92335-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92335-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92335-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92336-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92336-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92336-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92336-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92336-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92337-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92337-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92337-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92337-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92337-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92338-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92338-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92338-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92338-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92338-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92339-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92339-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92339-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92339-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92339-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92340-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92340-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92340-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92340-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92340-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92341-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92341-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92341-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92341-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92341-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92342-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92342-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92342-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92342-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92342-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92343-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92343-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92343-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92343-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92343-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92344-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92344-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92344-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92344-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92344-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92345-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92345-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92345-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92345-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92345-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92346-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92346-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92346-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92346-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92346-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92347-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92347-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92347-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92347-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92347-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92348-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92348-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92348-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92348-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92348-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92349-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92349-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92349-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92349-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92349-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92350-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92350-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92350-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92350-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92350-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92351-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92351-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92351-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92351-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92351-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92352-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92352-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92352-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92352-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92352-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92353-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92353-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92353-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92353-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92353-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92354-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92354-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92354-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92354-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92354-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92355-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92355-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92355-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92355-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92355-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92356-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92356-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92356-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92356-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92356-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92357-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92357-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92357-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92357-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92357-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92358-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92358-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92358-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92358-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92358-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92359-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92359-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92359-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92359-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92359-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92360-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92360-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92360-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92360-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92360-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92361-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92361-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92361-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92361-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92361-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92362-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92362-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92362-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92362-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92362-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92363-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92363-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92363-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92363-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92363-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92364-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92364-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92364-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92364-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92364-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92365-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92365-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92365-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92365-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92365-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92366-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92366-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92366-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92366-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92366-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92367-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92367-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92367-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92367-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92367-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92368-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92368-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92368-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92368-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92368-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92369-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92369-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92369-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92369-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92369-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92370-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92370-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92370-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92370-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92370-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92371-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92371-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92371-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92371-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92371-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92372-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92372-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92372-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92372-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92372-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92373-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92373-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92373-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92373-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92373-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92374-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92374-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92374-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92374-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92374-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92375-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92375-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92375-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92375-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92375-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92376-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92376-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92376-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92376-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92376-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92377-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92377-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92377-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92377-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92377-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92378-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92378-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92378-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92378-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92378-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92379-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92379-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92379-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92379-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92379-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92380-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92380-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92380-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92380-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92380-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92381-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92381-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92381-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92381-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92381-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92382-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92382-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92382-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92382-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92382-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92383-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92383-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92383-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92383-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92383-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92384-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92384-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92384-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92384-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92384-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92385-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92385-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92385-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92385-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92385-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92386-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92386-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92386-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92386-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92386-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92387-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92387-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92387-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92387-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92387-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92388-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92388-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92388-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92388-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92388-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92389-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92389-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92389-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92389-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92389-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92390-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92390-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92390-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92390-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92390-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92395-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92395-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92395-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92395-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92395-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92396-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92396-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92396-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92396-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92396-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92397-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92397-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92397-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92397-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92397-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92398-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92398-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92398-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92398-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92398-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92399-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92399-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92399-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92399-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92399-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92400-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92400-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92400-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92400-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92400-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92401-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92401-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92401-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92401-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92401-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92402-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92402-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92402-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92402-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92402-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92403-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92403-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92403-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92403-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92403-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92404-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92404-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92404-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92404-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92404-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92405-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92405-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92405-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92405-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92405-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92406-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92406-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92406-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92406-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92406-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92407-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92407-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92407-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92407-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92407-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92408-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92408-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92408-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92408-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92408-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92409-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92409-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92409-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92409-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92409-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92410-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92410-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92410-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92410-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92410-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92411-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92411-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92411-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92411-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92411-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92412-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92412-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92412-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92412-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92412-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92413-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92413-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92413-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92413-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92413-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92414-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92414-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92414-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92414-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92414-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92415-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92415-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92415-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92415-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92415-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92416-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92416-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92416-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92416-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92416-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92417-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92417-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92417-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92417-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92417-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92420-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92420-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92420-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92420-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92420-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92421-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92421-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92421-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92421-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92421-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92422-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92422-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92422-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92422-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92422-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92423-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92423-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92423-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92423-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92423-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92424-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92424-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92424-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92424-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92424-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92425-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92425-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92425-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92425-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92425-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92426-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92426-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92426-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92426-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92426-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92427-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92427-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92427-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92427-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92427-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92428-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92428-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92428-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92428-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92428-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92429-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92429-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92429-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92429-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92429-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92430-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92430-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92430-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92430-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92430-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92431-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92431-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92431-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92431-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92431-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92432-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92432-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92432-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92432-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92432-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92433-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92433-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92433-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92433-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92433-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92434-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92434-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92434-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92434-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92434-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92435-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92435-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92435-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92435-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92435-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92436-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92436-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92436-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92436-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92436-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92437-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92437-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92437-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92437-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92437-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92438-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92438-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92438-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92438-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92438-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92439-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92439-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92439-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92439-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92439-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92440-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92440-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92440-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92440-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92440-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92441-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92441-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92441-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92441-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92441-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92442-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92442-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92442-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92442-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92442-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92443-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92443-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92443-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92443-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92443-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92444-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92444-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92444-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92444-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92444-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92445-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92445-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92445-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92445-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92445-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92450-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92450-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92450-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92450-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92450-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92451-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92451-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92451-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92451-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92451-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92452-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92452-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92452-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92452-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92452-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92453-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92453-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92453-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92453-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92453-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92454-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92454-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92454-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92454-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92454-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92455-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92455-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92455-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92455-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92455-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92456-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92456-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92456-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92456-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92456-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92457-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92457-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92457-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92457-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92457-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92458-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92458-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92458-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92458-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92458-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92459-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92459-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92459-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92459-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92459-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92460-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92460-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92460-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92460-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92460-5;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92461-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92461-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92461-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92461-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92461-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92462-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92462-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92462-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92462-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92462-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92463-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92463-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92463-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92463-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92463-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92464-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92464-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92464-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92464-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92464-7;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92465-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92465-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92465-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92465-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92465-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92466-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92466-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92466-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92466-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92466-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92467-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92467-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92467-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92467-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92467-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92468-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92468-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92468-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92468-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92468-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92469-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92469-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92469-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92469-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92469-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92470-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92470-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92470-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92470-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92470-4;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92471-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92471-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92471-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92471-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92471-2;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92472-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92472-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92472-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92472-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92472-0;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92473-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92473-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92473-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92473-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92473-8;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92474-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92474-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92474-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92474-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92474-6;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92475-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92475-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92475-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92475-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92475-3;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92476-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92476-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92476-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92476-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92476-1;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92477-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30024-6;0;I am not at all confident;;; +92477-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30026-1;1;I am a little confident;;; +92477-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30027-9;2;I am somewhat confident;;; +92477-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30028-7;3;I am quite confident;;; +92477-9;LL5311-7;PROMIS Confidence Levels (1-5);LA30029-5;4;I am very confident;;; +92478-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92478-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92479-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92479-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92480-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92480-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92481-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92481-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92482-9;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92482-9;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92483-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92483-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92484-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92484-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92485-2;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92485-2;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92486-0;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92486-0;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92487-8;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92487-8;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92488-6;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92488-6;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92489-4;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92489-4;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92490-2;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92490-2;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92491-0;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92491-0;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92492-8;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92492-8;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92493-6;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92493-6;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92494-4;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92494-4;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92495-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92495-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92496-9;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92496-9;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92497-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92497-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92498-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92498-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92499-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92499-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92500-8;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92500-8;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92501-6;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92501-6;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92502-4;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92502-4;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92503-2;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92503-2;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92504-0;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92504-0;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92505-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92505-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92506-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92506-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92507-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92507-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92508-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92508-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92509-9;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92509-9;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92510-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92510-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92511-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92511-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92512-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92512-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92513-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92513-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92516-4;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92516-4;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92517-2;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92517-2;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92518-0;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92518-0;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92519-8;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92519-8;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92520-6;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92520-6;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92521-4;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92521-4;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92522-2;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92522-2;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92523-0;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92523-0;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92524-8;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92524-8;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92525-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92525-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92526-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92526-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92527-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92527-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92528-9;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92528-9;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92529-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92529-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92530-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92530-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92531-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92531-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92532-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92532-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92533-9;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92533-9;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92534-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92534-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92535-4;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92535-4;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92536-2;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92536-2;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92537-0;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92537-0;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92538-8;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92538-8;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92539-6;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92539-6;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92540-4;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92540-4;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92541-2;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92541-2;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92542-0;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92542-0;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92543-8;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92543-8;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92544-6;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92544-6;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92545-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92545-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92546-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92546-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92547-9;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92547-9;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92548-7;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92548-7;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92549-5;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92549-5;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92550-3;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92550-3;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92551-1;LL5243-2;Pos(+)|Neg(0);LA26053-1;0;Positive (+);;; +92551-1;LL5243-2;Pos(+)|Neg(0);LA29782-2;1;Negative (0);;; +92568-5;LL5315-8;Monochorionic | Dichorionic | Unknown | NA;LA30047-7;0;Monochorionic;;; +92568-5;LL5315-8;Monochorionic | Dichorionic | Unknown | NA;LA30048-5;1;Dichorionic;;; +92568-5;LL5315-8;Monochorionic | Dichorionic | Unknown | NA;LA4489-6;2;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +92568-5;LL5315-8;Monochorionic | Dichorionic | Unknown | NA;LA30049-3;3;Not applicable (not a twin pregnancy);;; +925-8;LL2418-3;Blood prod disposition;LA19705-5;1;Given;;; +925-8;LL2418-3;Blood prod disposition;LA19706-3;2;Partially given;;; +925-8;LL2418-3;Blood prod disposition;LA19707-1;3;Discarded;;; +92634-5;LL5317-4;Primary | Secondary | Alternative;LA21208-6;0;Primary;;; +92634-5;LL5317-4;Primary | Secondary | Alternative;LA18924-3;1;Secondary;;; +92634-5;LL5317-4;Primary | Secondary | Alternative;LA30091-5;2;Alternative;;; +92634-5;LL5317-4;Primary | Secondary | Alternative;LA16501-1;3;Work;;; +92634-5;LL5317-4;Primary | Secondary | Alternative;LA30092-3;4;Residential;;; +92634-5;LL5317-4;Primary | Secondary | Alternative;LA30093-1;5;Mailing;;; +92636-0;LL5284-6;APOL1 genotypes;LA29894-5;1;APOL1 Homozygous wild type;;; +92636-0;LL5284-6;APOL1 genotypes;LA29895-2;2;APOL1 Heterozygous wild type/G1;;; +92636-0;LL5284-6;APOL1 genotypes;LA29896-0;3;APOL1 Heterozygous wild type/G2;;; +92636-0;LL5284-6;APOL1 genotypes;LA29898-6;4;APOL1 Homozygous G1/G1;;; +92636-0;LL5284-6;APOL1 genotypes;LA29899-4;5;APOL1 Homozygous G2/G2;;; +92636-0;LL5284-6;APOL1 genotypes;LA29897-8;6;APOL1 Heterozygous G1/G2;;; +92660-0;LL5316-6;<7d|7-14d|15-21d|>21d;LA30050-1;1;Less than 7 days;;; +92660-0;LL5316-6;<7d|7-14d|15-21d|>21d;LA30051-9;2;7-14 days;;; +92660-0;LL5316-6;<7d|7-14d|15-21d|>21d;LA30052-7;3;15-21 days;;; +92660-0;LL5316-6;<7d|7-14d|15-21d|>21d;LA30053-5;4;More than 21 days;;; +9267-6;LL355-9;GCS_1_Eye;LA6553-7;1;No eye opening;;; +9267-6;LL355-9;GCS_1_Eye;LA6554-5;2;Eye opening to pain;;; +9267-6;LL355-9;GCS_1_Eye;LA6555-2;3;Eye opening to verbal command;;; +9267-6;LL355-9;GCS_1_Eye;LA6556-0;4;Eyes open spontaneously;;; +9268-4;LL357-5;GCS_3_Motor;LA6562-8;1;No motor response;;; +9268-4;LL357-5;GCS_3_Motor;LA6563-6;2;Extension to pain;;; +9268-4;LL357-5;GCS_3_Motor;LA6564-4;3;Flexion to pain;;; +9268-4;LL357-5;GCS_3_Motor;LA6565-1;4;Withdrawal from pain;;; +9268-4;LL357-5;GCS_3_Motor;LA6566-9;5;Localizing pain;;; +9268-4;LL357-5;GCS_3_Motor;LA6567-7;6;Obeys commands;;; +9270-0;LL356-7;GCS_2_Verbal;LA6557-8;1;"No verbal response (>2 yrs); no vocal response (<=2 yrs)";;; +9270-0;LL356-7;GCS_2_Verbal;LA6558-6;2;Incomprehensible sounds;;; +9270-0;LL356-7;GCS_2_Verbal;LA6559-4;3;Inappropriate words;;; +9270-0;LL356-7;GCS_2_Verbal;LA6560-2;4;Confused;;; +9270-0;LL356-7;GCS_2_Verbal;LA6561-0;5;Oriented;;; +92702-0;LL5324-0;BV positive/negative;LA30107-9;1;Bacterial vaginosis positive;;; +92702-0;LL5324-0;BV positive/negative;LA30108-7;2;Bacterial vaginosis negative;;; +92704-6;LL5325-7;PT frequency of visits;LA30109-5;1;3 times a week;;; +92704-6;LL5325-7;PT frequency of visits;LA30110-3;2;1 time a week;;; +92704-6;LL5325-7;PT frequency of visits;LA30111-1;3;3 times a week for 4 weeks followed by 1 time a week for 4 weeks;;; +92704-6;LL5325-7;PT frequency of visits;LA30112-9;4;4 times a week tapered to 1 time a week as appropriate over 6 weeks;;; +9275-9;LL3625-2;Respiratory rate measurement methods;LA24012-9;0;Auscultation - manual;;; +9275-9;LL3625-2;Respiratory rate measurement methods;LA24026-9;1;Direct observation;;; +9275-9;LL3625-2;Respiratory rate measurement methods;LA24023-6;2;Capnography;;; +9275-9;LL3625-2;Respiratory rate measurement methods;LA24024-4;3;Impedance pneumography;;; +9275-9;LL3625-2;Respiratory rate measurement methods;LA24025-1;4;Acoustic monitoring;;; +9275-9;LL3625-2;Respiratory rate measurement methods;LA24027-7;5;Pulse oximetry;;; +928-2;LL2415-9;Bld prod rx;LA19697-4;1;Febrile reaction;;; +928-2;LL2415-9;Bld prod rx;LA7413-3;2;Anaphylaxis;;; +928-2;LL2415-9;Bld prod rx;LA19698-2;3;Hives;;; +928-2;LL2415-9;Bld prod rx;LA7469-5;4;Rash;;; +928-2;LL2415-9;Bld prod rx;LA7443-0;5;Hypotension;;; +928-2;LL2415-9;Bld prod rx;LA19699-0;6;Hyperkalemia;;; +928-2;LL2415-9;Bld prod rx;LA19700-6;7;IgA deficient patient;;; +92822-6;LL5323-2;Genomic coordinate system;LA30100-4;1;0-based interval counting;;; +92822-6;LL5323-2;Genomic coordinate system;LA30101-2;2;0-based character counting;;; +92822-6;LL5323-2;Genomic coordinate system;LA30102-0;3;1-based character counting;;; +92827-5;LL4779-6;Mycobacterium complex;LA28506-6;0;Mycobacterium africanum;;; +92827-5;LL4779-6;Mycobacterium complex;LA19286-6;1;Mycobacterium bovis;;; +92827-5;LL4779-6;Mycobacterium complex;LA20996-7;2;Mycobacterium tuberculosis;;; +92827-5;LL4779-6;Mycobacterium complex;LA28507-4;3;No sequence;;; +92827-5;LL4779-6;Mycobacterium complex;LA11883-8;4;Not detected;;; +94576-6;LL4779-6;Mycobacterium complex;LA28506-6;0;Mycobacterium africanum;;; +94576-6;LL4779-6;Mycobacterium complex;LA19286-6;1;Mycobacterium bovis;;; +94576-6;LL4779-6;Mycobacterium complex;LA20996-7;2;Mycobacterium tuberculosis;;; +94576-6;LL4779-6;Mycobacterium complex;LA28507-4;3;No sequence;;; +94576-6;LL4779-6;Mycobacterium complex;LA11883-8;4;Not detected;;; +92836-6;LL5326-5;Desmoplastic melanoma;LA11902-6;1;Not identified;;; +92836-6;LL5326-5;Desmoplastic melanoma;LA30115-2;2;>90% desmoplastic melanoma;;; +92836-6;LL5326-5;Desmoplastic melanoma;LA30116-0;3;Mixed desmoplastic and non-desmoplastic melanoma;;; +92939-8;LL5318-2;Never | One | More than one | Unknown;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +92939-8;LL5318-2;Never | One | More than one | Unknown;LA6306-0;2;One;;; +92939-8;LL5318-2;Never | One | More than one | Unknown;LA30123-6;3;More than one;;; +92939-8;LL5318-2;Never | One | More than one | Unknown;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +92943-0;LL5314-1;Extreme weather events;LA30037-8;0;Earthquake;;; +92943-0;LL5314-1;Extreme weather events;LA30038-6;1;Extreme heat;;; +92943-0;LL5314-1;Extreme weather events;LA30039-4;2;Flood;;; +92943-0;LL5314-1;Extreme weather events;LA30040-2;3;Hurricane;;; +92943-0;LL5314-1;Extreme weather events;LA30041-0;4;Landslide/mudslide;;; +92943-0;LL5314-1;Extreme weather events;LA7524-7;5;Lighting;;; +92943-0;LL5314-1;Extreme weather events;LA30042-8;6;Tornado;;; +92943-0;LL5314-1;Extreme weather events;LA30043-6;7;Tsunami;;; +92943-0;LL5314-1;Extreme weather events;LA30044-4;8;Volcano;;; +92943-0;LL5314-1;Extreme weather events;LA30045-1;9;Wildfire;;; +92943-0;LL5314-1;Extreme weather events;LA30046-9;10;Winter weather;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30030-3;0;Boiler;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30031-1;1;Vehicle;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30032-9;2;Generator;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30033-7;3;Heater;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30034-5;4;Gas stove;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30103-8;5;Paint;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30104-6;6;Dust;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30105-3;7;Soil;;; +92944-8;LL5312-5;Carbon dioxide exposure source;LA30106-1;8;Drinking water;;; +92945-5;LL5313-3;Intentional | Unintentional | Unkwn;LA30035-2;0;Self-harm/assault (intentional);;; +92945-5;LL5313-3;Intentional | Unintentional | Unkwn;LA30036-0;1;Accidental (unintentional);;; +92945-5;LL5313-3;Intentional | Unintentional | Unkwn;LA4489-6;2;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +92946-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92946-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92946-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92946-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92946-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92946-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92947-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92947-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92947-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92947-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92947-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92947-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92948-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92948-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92948-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92948-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92948-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92948-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92949-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92949-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92949-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92949-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92949-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92949-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92950-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92950-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92950-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92950-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92950-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92950-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92951-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92951-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92951-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92951-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92951-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92951-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92952-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92952-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92952-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92952-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92952-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92952-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92953-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92953-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92953-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92953-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92953-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92953-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92954-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92954-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92954-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92954-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92954-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92954-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92955-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92955-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92955-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92955-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92955-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92955-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92959-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92959-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92959-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92959-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92959-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92959-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92960-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92960-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92960-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92960-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92960-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92960-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92961-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92961-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92961-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92961-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92961-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92961-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92962-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92962-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92962-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92962-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92962-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92962-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92965-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92965-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92965-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92965-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92965-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92965-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92966-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92966-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92966-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92966-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92966-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92966-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92970-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92970-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92970-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92970-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92970-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92970-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92971-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92971-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92971-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92971-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92971-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92971-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92972-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92972-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92972-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92972-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92972-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92972-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92973-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92973-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92973-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92973-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92973-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92973-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92974-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92974-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92974-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92974-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92974-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92974-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92975-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92975-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92975-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92975-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92975-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92975-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92980-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92980-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92980-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92980-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92980-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92980-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92981-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92981-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92981-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92981-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92981-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92981-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92982-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92982-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92982-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92982-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92982-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92982-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92983-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92983-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92983-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92983-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92983-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92983-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92984-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92984-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92984-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92984-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92984-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92984-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92985-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92985-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92985-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92985-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92985-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92985-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92988-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92988-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92988-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92988-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92988-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92988-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +92989-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +92989-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +92989-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +92989-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +92989-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +92989-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96317-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96317-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96317-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96317-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96317-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96317-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96318-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96318-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96318-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96318-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96318-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96318-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96319-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96319-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96319-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96319-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96319-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96319-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96320-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96320-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96320-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96320-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96320-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96320-7;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96321-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96321-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96321-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96321-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96321-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96321-5;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96322-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96322-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96322-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96322-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96322-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96322-3;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96323-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96323-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96323-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96323-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96323-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96323-1;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96324-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96324-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96324-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96324-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96324-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96324-9;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96325-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96325-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96325-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96325-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96325-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96325-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96326-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96326-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96326-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96326-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96326-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96326-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96327-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96327-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96327-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96327-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96327-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96327-2;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96328-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96328-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96328-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96328-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96328-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96328-0;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96329-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96329-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96329-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96329-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96329-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96329-8;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96330-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96330-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96330-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96330-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96330-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96330-6;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +96331-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30121-0;1;<10^3.5 copies/mL;;; +96331-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29765-7;2;10^3.5 - <10^4.5 copies/mL;;; +96331-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29766-5;3;10^4.5 - <10^5.5 copies/mL;;; +96331-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29767-3;4;10^5.5 - <10^6.5 copies/mL;;; +96331-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA29768-1;5;10^6.5 - <10^7.5 copies/mL;;; +96331-4;LL5239-0;Copies/mL (<10^3.5 copies/mL to 10^>=7.5 copies/mL;LA30120-2;6;>=10^7.5 copies/mL;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +93003-2;LL5346-3;SARA_Heel-shine slide;LA30181-4;2;Slightly abnormal, contact to shin maintained;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA30182-2;3;Clearly abnormal, goes off shin up to 3 times during 3 cycles;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA30183-0;4;Severely abnormal, goes off shin 4 or more times during 3 cycles;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA30184-8;5;Unable to perform the task;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +93003-2;LL5346-3;SARA_Heel-shine slide;LA30181-4;2;Slightly abnormal, contact to shin maintained;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA30182-2;3;Clearly abnormal, goes off shin up to 3 times during 3 cycles;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA30183-0;4;Severely abnormal, goes off shin 4 or more times during 3 cycles;;; +93003-2;LL5346-3;SARA_Heel-shine slide;LA30184-8;5;Unable to perform the task;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +93004-0;LL5346-3;SARA_Heel-shine slide;LA30181-4;2;Slightly abnormal, contact to shin maintained;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA30182-2;3;Clearly abnormal, goes off shin up to 3 times during 3 cycles;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA30183-0;4;Severely abnormal, goes off shin 4 or more times during 3 cycles;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA30184-8;5;Unable to perform the task;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +93004-0;LL5346-3;SARA_Heel-shine slide;LA30181-4;2;Slightly abnormal, contact to shin maintained;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA30182-2;3;Clearly abnormal, goes off shin up to 3 times during 3 cycles;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA30183-0;4;Severely abnormal, goes off shin 4 or more times during 3 cycles;;; +93004-0;LL5346-3;SARA_Heel-shine slide;LA30184-8;5;Unable to perform the task;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30171-5;1;No tremor;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30172-3;2;Tremor with an amplitude < 2 cm;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30173-1;3;Tremor with an amplitude < 5 cm;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30174-9;4;Tremor with an amplitude > 5 cm;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30170-7;5;Unable to perform 5 pointing movements;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30171-5;1;No tremor;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30172-3;2;Tremor with an amplitude < 2 cm;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30173-1;3;Tremor with an amplitude < 5 cm;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30174-9;4;Tremor with an amplitude > 5 cm;;; +93007-3;LL5344-8;SARA_Nose-finger test;LA30170-7;5;Unable to perform 5 pointing movements;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30171-5;1;No tremor;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30172-3;2;Tremor with an amplitude < 2 cm;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30173-1;3;Tremor with an amplitude < 5 cm;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30174-9;4;Tremor with an amplitude > 5 cm;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30170-7;5;Unable to perform 5 pointing movements;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30171-5;1;No tremor;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30172-3;2;Tremor with an amplitude < 2 cm;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30173-1;3;Tremor with an amplitude < 5 cm;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30174-9;4;Tremor with an amplitude > 5 cm;;; +93008-1;LL5344-8;SARA_Nose-finger test;LA30170-7;5;Unable to perform 5 pointing movements;;; +93010-7;LL5343-0;SARA_Finger chase;LA30166-5;1;No dysmetria;;; +93010-7;LL5343-0;SARA_Finger chase;LA30167-3;2;Dysmetria, under/overshooting target <5 cm;;; +93010-7;LL5343-0;SARA_Finger chase;LA30168-1;3;Dysmetria, under/overshooting target < 15 cm;;; +93010-7;LL5343-0;SARA_Finger chase;LA30169-9;4;Dysmetria, under/overshooting target > 15 cm;;; +93010-7;LL5343-0;SARA_Finger chase;LA30170-7;5;Unable to perform 5 pointing movements;;; +93010-7;LL5343-0;SARA_Finger chase;LA30166-5;1;No dysmetria;;; +93010-7;LL5343-0;SARA_Finger chase;LA30167-3;2;Dysmetria, under/overshooting target <5 cm;;; +93010-7;LL5343-0;SARA_Finger chase;LA30168-1;3;Dysmetria, under/overshooting target < 15 cm;;; +93010-7;LL5343-0;SARA_Finger chase;LA30169-9;4;Dysmetria, under/overshooting target > 15 cm;;; +93010-7;LL5343-0;SARA_Finger chase;LA30170-7;5;Unable to perform 5 pointing movements;;; +93011-5;LL5343-0;SARA_Finger chase;LA30166-5;1;No dysmetria;;; +93011-5;LL5343-0;SARA_Finger chase;LA30167-3;2;Dysmetria, under/overshooting target <5 cm;;; +93011-5;LL5343-0;SARA_Finger chase;LA30168-1;3;Dysmetria, under/overshooting target < 15 cm;;; +93011-5;LL5343-0;SARA_Finger chase;LA30169-9;4;Dysmetria, under/overshooting target > 15 cm;;; +93011-5;LL5343-0;SARA_Finger chase;LA30170-7;5;Unable to perform 5 pointing movements;;; +93011-5;LL5343-0;SARA_Finger chase;LA30166-5;1;No dysmetria;;; +93011-5;LL5343-0;SARA_Finger chase;LA30167-3;2;Dysmetria, under/overshooting target <5 cm;;; +93011-5;LL5343-0;SARA_Finger chase;LA30168-1;3;Dysmetria, under/overshooting target < 15 cm;;; +93011-5;LL5343-0;SARA_Finger chase;LA30169-9;4;Dysmetria, under/overshooting target > 15 cm;;; +93011-5;LL5343-0;SARA_Finger chase;LA30170-7;5;Unable to perform 5 pointing movements;;; +93012-3;LL5340-6;SARA_Stance;LA30148-3;1;Normal, able to stand in tandem for > 10 s;;; +93012-3;LL5340-6;SARA_Stance;LA30149-1;2;Able to stand with feet together without sway, but not in tandem for > 10s;;; +93012-3;LL5340-6;SARA_Stance;LA30150-9;3;Able to stand with feet together for > 10 s, but only with sway;;; +93012-3;LL5340-6;SARA_Stance;LA30151-7;4;Able to stand for > 10 s without support in natural position but not with feet together;;; +93012-3;LL5340-6;SARA_Stance;LA30152-5;5;Able to stand for >10 s in natural position only with intermittent support;;; +93012-3;LL5340-6;SARA_Stance;LA30153-3;6;Able to stand >10 s in natural position only with constant support of one arm;;; +93012-3;LL5340-6;SARA_Stance;LA30154-1;7;Unable to stand for >10 s even with constant support of one arm;;; +93014-9;LL5340-6;SARA_Stance;LA30148-3;1;Normal, able to stand in tandem for > 10 s;;; +93014-9;LL5340-6;SARA_Stance;LA30149-1;2;Able to stand with feet together without sway, but not in tandem for > 10s;;; +93014-9;LL5340-6;SARA_Stance;LA30150-9;3;Able to stand with feet together for > 10 s, but only with sway;;; +93014-9;LL5340-6;SARA_Stance;LA30151-7;4;Able to stand for > 10 s without support in natural position but not with feet together;;; +93014-9;LL5340-6;SARA_Stance;LA30152-5;5;Able to stand for >10 s in natural position only with intermittent support;;; +93014-9;LL5340-6;SARA_Stance;LA30153-3;6;Able to stand >10 s in natural position only with constant support of one arm;;; +93014-9;LL5340-6;SARA_Stance;LA30154-1;7;Unable to stand for >10 s even with constant support of one arm;;; +93012-3;LL5342-2;SARA_Speech disturbance;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +93012-3;LL5342-2;SARA_Speech disturbance;LA30160-8;2;Suggestion of speech disturbance;;; +93012-3;LL5342-2;SARA_Speech disturbance;LA30161-6;3;Impaired speech, but easy to understand;;; +93012-3;LL5342-2;SARA_Speech disturbance;LA30162-4;4;Occasional words difficult to understand;;; +93012-3;LL5342-2;SARA_Speech disturbance;LA30163-2;5;Many words difficult to understand;;; +93012-3;LL5342-2;SARA_Speech disturbance;LA30164-0;6;Only single words understandable;;; +93012-3;LL5342-2;SARA_Speech disturbance;LA30165-7;7;Speech unintelligible / anarthria;;; +93014-9;LL5342-2;SARA_Speech disturbance;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +93014-9;LL5342-2;SARA_Speech disturbance;LA30160-8;2;Suggestion of speech disturbance;;; +93014-9;LL5342-2;SARA_Speech disturbance;LA30161-6;3;Impaired speech, but easy to understand;;; +93014-9;LL5342-2;SARA_Speech disturbance;LA30162-4;4;Occasional words difficult to understand;;; +93014-9;LL5342-2;SARA_Speech disturbance;LA30163-2;5;Many words difficult to understand;;; +93014-9;LL5342-2;SARA_Speech disturbance;LA30164-0;6;Only single words understandable;;; +93014-9;LL5342-2;SARA_Speech disturbance;LA30165-7;7;Speech unintelligible / anarthria;;; +93013-1;LL5341-4;SARA_Sitting;LA30155-8;1;Normal, no difficulties sitting >10 sec;;; +93013-1;LL5341-4;SARA_Sitting;LA30156-6;2;Slight difficulties, intermittent sway;;; +93013-1;LL5341-4;SARA_Sitting;LA30157-4;3;Constant sway, but able to sit > 10 s without support;;; +93013-1;LL5341-4;SARA_Sitting;LA30158-2;4;Able to sit for > 10 s only with intermittent support;;; +93013-1;LL5341-4;SARA_Sitting;LA30159-0;5;Unable to sit for >10 s without continuous support;;; +93013-1;LL5341-4;SARA_Sitting;LA30155-8;1;Normal, no difficulties sitting >10 sec;;; +93013-1;LL5341-4;SARA_Sitting;LA30156-6;2;Slight difficulties, intermittent sway;;; +93013-1;LL5341-4;SARA_Sitting;LA30157-4;3;Constant sway, but able to sit > 10 s without support;;; +93013-1;LL5341-4;SARA_Sitting;LA30158-2;4;Able to sit for > 10 s only with intermittent support;;; +93013-1;LL5341-4;SARA_Sitting;LA30159-0;5;Unable to sit for >10 s without continuous support;;; +93015-6;LL5339-8;SARA_Gait;LA30139-2;1;Normal, no difficulties in walking, turning and walking tandem (up to one misstep allowed);;; +93015-6;LL5339-8;SARA_Gait;LA30140-0;2;Slight difficulties, only visible when walking 10 consecutive steps in tandem;;; +93015-6;LL5339-8;SARA_Gait;LA30141-8;3;Clearly abnormal, tandem walking >10 steps not possible;;; +93015-6;LL5339-8;SARA_Gait;LA30142-6;4;Considerable staggering, difficulties in half-turn, but without support;;; +93015-6;LL5339-8;SARA_Gait;LA30143-4;5;Marked staggering, intermittent support of the wall required;;; +93015-6;LL5339-8;SARA_Gait;LA30144-2;6;Severe staggering, permanent support of one stick or light support by one arm required;;; +93015-6;LL5339-8;SARA_Gait;LA30145-9;7;Walking > 10 m only with strong support (two special sticks or stroller or accompanying person);;; +93015-6;LL5339-8;SARA_Gait;LA30146-7;8;Walking < 10 m only with strong support (two special sticks or stroller or accompanying person);;; +93015-6;LL5339-8;SARA_Gait;LA30147-5;9;Unable to walk, even supported;;; +93015-6;LL5339-8;SARA_Gait;LA30139-2;1;Normal, no difficulties in walking, turning and walking tandem (up to one misstep allowed);;; +93015-6;LL5339-8;SARA_Gait;LA30140-0;2;Slight difficulties, only visible when walking 10 consecutive steps in tandem;;; +93015-6;LL5339-8;SARA_Gait;LA30141-8;3;Clearly abnormal, tandem walking >10 steps not possible;;; +93015-6;LL5339-8;SARA_Gait;LA30142-6;4;Considerable staggering, difficulties in half-turn, but without support;;; +93015-6;LL5339-8;SARA_Gait;LA30143-4;5;Marked staggering, intermittent support of the wall required;;; +93015-6;LL5339-8;SARA_Gait;LA30144-2;6;Severe staggering, permanent support of one stick or light support by one arm required;;; +93015-6;LL5339-8;SARA_Gait;LA30145-9;7;Walking > 10 m only with strong support (two special sticks or stroller or accompanying person);;; +93015-6;LL5339-8;SARA_Gait;LA30146-7;8;Walking < 10 m only with strong support (two special sticks or stroller or accompanying person);;; +93015-6;LL5339-8;SARA_Gait;LA30147-5;9;Unable to walk, even supported;;; +93026-3;LL5333-1;PRAPARE_Y|N|Unsure|Choose not to answer;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93026-3;LL5333-1;PRAPARE_Y|N|Unsure|Choose not to answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93026-3;LL5333-1;PRAPARE_Y|N|Unsure|Choose not to answer;LA14072-5;3;Unsure;;; +93026-3;LL5333-1;PRAPARE_Y|N|Unsure|Choose not to answer;LA30122-8;4;I choose not to answer this question;;; +93029-7;LL5335-6;PRAPARE_<1/wk|1-2/wk|3-5/wk|5+/wk|choose not answe;LA27722-0;0;Less than once a week;;; +93029-7;LL5335-6;PRAPARE_<1/wk|1-2/wk|3-5/wk|5+/wk|choose not answe;LA30130-1;1;1 or 2 times a week;;; +93029-7;LL5335-6;PRAPARE_<1/wk|1-2/wk|3-5/wk|5+/wk|choose not answe;LA30131-9;2;3 to 5 times a week;;; +93029-7;LL5335-6;PRAPARE_<1/wk|1-2/wk|3-5/wk|5+/wk|choose not answe;LA30132-7;3;5 or more times a week;;; +93029-7;LL5335-6;PRAPARE_<1/wk|1-2/wk|3-5/wk|5+/wk|choose not answe;LA30122-8;4;I choose not to answer this question;;; +93030-5;LL5336-4;PRAPARE_Y-medical|Y-non-medical|No|Ch Not Answer;LA30133-5;0;Yes, it has kept me from medical appointments or from getting my medications;;; +93030-5;LL5336-4;PRAPARE_Y-medical|Y-non-medical|No|Ch Not Answer;LA30134-3;1;Yes, it has kept me from non-medical meetings, appointments, work, or from getting things that I need;;; +93030-5;LL5336-4;PRAPARE_Y-medical|Y-non-medical|No|Ch Not Answer;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +93030-5;LL5336-4;PRAPARE_Y-medical|Y-non-medical|No|Ch Not Answer;LA30122-8;3;I choose not to answer this question;;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA30125-1;1;Food;;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA30126-9;2;Clothing;;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA30124-4;3;Utilities;;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA30127-7;4;Child care;;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA30128-5;5;Medicine or Any Health Care (Medical, Dental, Mental Health, Vision);;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA30129-3;6;Phone;;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA46-8;7;Other;;; +93031-3;LL5334-9;PRAPARE_Food|Util|Med|Phone|Clothing|ChildCare|Oth;LA30122-8;8;I choose not to answer this question;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA6568-5;1;Not at all;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13863-8;2;A little bit;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13909-9;3;Somewhat;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13902-4;4;Quite a bit;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13914-9;5;Very much;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA30122-8;6;I choose not to answer this question;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA6568-5;1;Not at all;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13863-8;2;A little bit;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13909-9;3;Somewhat;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13902-4;4;Quite a bit;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13914-9;5;Very much;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA30122-8;6;I choose not to answer this question;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA6568-5;1;Not at all;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13863-8;2;A little bit;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13909-9;3;Somewhat;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13902-4;4;Quite a bit;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA13914-9;5;Very much;;; +93038-8;LL5354-7;PRAPARE_Not|lil bit|somwht|qt bit|v much|not answe;LA30122-8;6;I choose not to answer this question;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30200-2;1;Very strong evidence pathogenic;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30201-0;2;Strong evidence pathogenic;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30202-8;3;Moderate evidence pathogenic;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30203-6;4;Supporting evidence pathogenic;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30204-4;5;Supporting evidence benign;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30205-1;6;Strong evidence benign;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30206-9;7;Stand-alone evidence pathogenic;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA30207-7;8;Stand-alone evidence benign;;; +93044-6;LL5356-2;ACMG_Level of evidence;LA26333-7;9;Uncertain significance;;; +93046-1;LL5357-0;CDC_Exposure treatment site;LA30209-3;1;On-site at healthcare facility where exposure occurred;;; +93046-1;LL5357-0;CDC_Exposure treatment site;LA30210-1;2;On-site at non-healthcare facility where exposure occurred;;; +93046-1;LL5357-0;CDC_Exposure treatment site;LA30211-9;3;Transported to off-site healthcare facility;;; +9304-7;LL3840-7;Respiratory rhythm;LA25227-2;1;Acidotic Hyperventilation;399164003;Acidotic hyperventilation (finding);http://snomed.info/sct +9304-7;LL3840-7;Respiratory rhythm;LA25228-0;2;Air Hunger;399322006;Air hunger (finding);http://snomed.info/sct +9304-7;LL3840-7;Respiratory rhythm;LA25229-8;3;Apneustic;;; +9304-7;LL3840-7;Respiratory rhythm;LA25230-6;4;Biot's;;; +9304-7;LL3840-7;Respiratory rhythm;LA25231-4;5;Cheyne-Stokes;309155007;Cheyne-Stokes respiration (finding);http://snomed.info/sct +9304-7;LL3840-7;Respiratory rhythm;LA25232-2;6;Cluster Breathing;7013003;cluster breathing (finding);http://snomed.info/sct +9304-7;LL3840-7;Respiratory rhythm;LA17611-7;7;Dyspnea;267036007;dyspnea (finding);http://snomed.info/sct +9304-7;LL3840-7;Respiratory rhythm;LA25234-8;8;Gasping for Air;23141003;Gasping for breath (finding);http://snomed.info/sct +9304-7;LL3840-7;Respiratory rhythm;LA25235-5;9;Irregular Breathing;248585001;irregular breathing (finding);http://snomed.info/sct +9304-7;LL3840-7;Respiratory rhythm;LA25239-7;10;Sighing;;; +9304-7;LL5546-8;Breathing pattern - cluster;LA30814-0;1;Normal breathing;;; +9304-7;LL5546-8;Breathing pattern - cluster;LA17611-7;2;Dyspnea;267036007;dyspnea (finding);http://snomed.info/sct +9304-7;LL5546-8;Breathing pattern - cluster;LA25234-8;3;Gasping for Air;23141003;Gasping for breath (finding);http://snomed.info/sct +9304-7;LL5546-8;Breathing pattern - cluster;LA30815-7;4;Other pathological breathing pattern or cluster;;; +9304-7;LL5546-8;Breathing pattern - cluster;LA17393-2;5;Apnea;1023001;Apnea (finding);http://snomed.info/sct +9304-7;LL5546-8;Breathing pattern - cluster;LA17613-3;6;Hyperventilation;;; +9304-7;LL5546-8;Breathing pattern - cluster;LA30817-3;7;Ventilation;;; +9304-7;LL5546-8;Breathing pattern - cluster;LA4489-6;8;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +9304-7;LL5546-8;Breathing pattern - cluster;LA9348-9;9;Not assessed;;; +93047-9;LL5347-1;SpecimenCondition_HL7_2x;;0;;;; +93048-7;LL5353-9;PHVS_SpecimenRejectReason_HL7_2x;;0;;;; +93059-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93059-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93059-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93059-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93059-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93059-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93060-2;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93060-2;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93060-2;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93060-2;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93060-2;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93060-2;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93061-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93061-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93061-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93061-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93061-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93061-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93062-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93062-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93062-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93062-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93062-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93062-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93063-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93063-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93063-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93063-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93063-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93063-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93067-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93067-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93067-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93067-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93067-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93067-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93068-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93068-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93068-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93068-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93068-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93068-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93069-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93069-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93069-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93069-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93069-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93069-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93072-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93072-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93072-7;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93073-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93073-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93073-5;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93074-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93074-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93074-3;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93075-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93075-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93075-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93076-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93076-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93076-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93078-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93078-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93078-4;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93080-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93080-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93080-0;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93081-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93081-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93081-8;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93082-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA6568-5;1;Not at all;;; +93082-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13909-9;2;Somewhat;;; +93082-6;LL5083-2;Not at all (0)|Somewhat(1)|Very much(2);LA13914-9;3;Very much;;; +93059-4;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93059-4;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93059-4;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93060-2;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93060-2;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93060-2;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93061-0;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93061-0;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93061-0;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93062-8;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93062-8;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93062-8;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93063-6;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93063-6;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93063-6;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93064-4;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93064-4;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93064-4;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93065-1;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93065-1;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93065-1;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93066-9;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93066-9;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93066-9;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93067-7;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93067-7;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93067-7;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93068-5;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93068-5;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93068-5;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93069-3;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93069-3;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93069-3;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93070-1;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA6568-5;1;Not at all;;; +93070-1;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13909-9;2;Somewhat;;; +93070-1;LL5360-4;Not at all (1)|Somewhat(2)|Very much(3);LA13914-9;3;Very much;;; +93077-6;LL5359-6;Vomiting|Swollen feet|Backaches|Other;LA15099-7;1;Vomiting;;; +93077-6;LL5359-6;Vomiting|Swollen feet|Backaches|Other;LA30214-3;2;Swollen feet;;; +93077-6;LL5359-6;Vomiting|Swollen feet|Backaches|Other;LA30215-0;3;Backaches;;; +93077-6;LL5359-6;Vomiting|Swollen feet|Backaches|Other;LA46-8;4;Other;;; +93089-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93089-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93089-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93089-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93089-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93089-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93090-9;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93090-9;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93090-9;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93090-9;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93090-9;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93090-9;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93091-7;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93091-7;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93091-7;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93091-7;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93091-7;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93091-7;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93092-5;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93092-5;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93092-5;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93092-5;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93092-5;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93092-5;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93093-3;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93093-3;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93093-3;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93093-3;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93093-3;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93093-3;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93094-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93094-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93094-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93094-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93094-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93094-1;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93095-8;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93095-8;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93095-8;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93095-8;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93095-8;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93095-8;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93096-6;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30222-6;1;Disagree completely;;; +93096-6;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15773-7;2;Disagree;;; +93096-6;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30224-2;3;Disagree slightly;;; +93096-6;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30225-9;4;Agree slightly;;; +93096-6;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA15774-5;5;Agree;;; +93096-6;LL5363-8;DC | Disagree | DS | AS | Agree | AC;LA30223-4;6;Agree completely;;; +93097-4;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30222-6;1;Disagree completely;;; +93097-4;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15773-7;2;Disagree;;; +93097-4;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30224-2;3;Disagree slightly;;; +93097-4;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30225-9;4;Agree slightly;;; +93097-4;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15774-5;5;Agree;;; +93097-4;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30223-4;6;Agree completely;;; +93108-9;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30222-6;1;Disagree completely;;; +93108-9;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15773-7;2;Disagree;;; +93108-9;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30224-2;3;Disagree slightly;;; +93108-9;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30225-9;4;Agree slightly;;; +93108-9;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15774-5;5;Agree;;; +93108-9;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30223-4;6;Agree completely;;; +93109-7;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30222-6;1;Disagree completely;;; +93109-7;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15773-7;2;Disagree;;; +93109-7;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30224-2;3;Disagree slightly;;; +93109-7;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30225-9;4;Agree slightly;;; +93109-7;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15774-5;5;Agree;;; +93109-7;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30223-4;6;Agree completely;;; +93110-5;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30222-6;1;Disagree completely;;; +93110-5;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15773-7;2;Disagree;;; +93110-5;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30224-2;3;Disagree slightly;;; +93110-5;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30225-9;4;Agree slightly;;; +93110-5;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15774-5;5;Agree;;; +93110-5;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30223-4;6;Agree completely;;; +93111-3;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30222-6;1;Disagree completely;;; +93111-3;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15773-7;2;Disagree;;; +93111-3;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30224-2;3;Disagree slightly;;; +93111-3;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30225-9;4;Agree slightly;;; +93111-3;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA15774-5;5;Agree;;; +93111-3;LL5364-6;DC | Disagree | DS | AS | Agree | AC Reverse;LA30223-4;6;Agree completely;;; +93098-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93098-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93098-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93098-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93098-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93098-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93098-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93099-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93099-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93099-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93099-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93099-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93099-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93099-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93100-6;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93100-6;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93100-6;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93100-6;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93100-6;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93100-6;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93100-6;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93101-4;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93101-4;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93101-4;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93101-4;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93101-4;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93101-4;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93101-4;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93102-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93102-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93102-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93102-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93102-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93102-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93102-2;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93103-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93103-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93103-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93103-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93103-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93103-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93103-0;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93104-8;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93104-8;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93104-8;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93104-8;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93104-8;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93104-8;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93104-8;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93105-5;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93105-5;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93105-5;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93105-5;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93105-5;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93105-5;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93105-5;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93106-3;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93106-3;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93106-3;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93106-3;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93106-3;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93106-3;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93106-3;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93107-1;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30222-6;1;Disagree completely;;; +93107-1;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15773-7;2;Disagree;;; +93107-1;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30224-2;3;Disagree slightly;;; +93107-1;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30225-9;4;Agree slightly;;; +93107-1;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA15774-5;5;Agree;;; +93107-1;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30223-4;6;Agree completely;;; +93107-1;LL5362-0;DC | Disagree | DS | AS | Agree | AC | NA;LA30226-7;7;Not applicable (N/A);;; +93122-0;LL5365-3;PHVS_VaccineType_NND;;0;;;; +93123-8;LL5365-3;PHVS_VaccineType_NND;;0;;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30297-8;1;Antipsychotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30298-6;2;Anticoagulant;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30299-4;3;Antibiotic;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA28420-0;4;Opioid;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30300-0;5;Antiplatelet;;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA30301-8;6;Hypoglycemic (including insulin);;; +93153-5;LL5388-5;CMS IRF_PAI v4.0 - HiRisk DrugUse Taking (N0415-1);LA9-3;7;None of the above;;; +93153-5;LL6311-6;High-risk drug classes;LA30297-8;1;Antipsychotic;;; +93153-5;LL6311-6;High-risk drug classes;LA30457-8;2;Antianxiety;;; +93153-5;LL6311-6;High-risk drug classes;LA30458-6;3;Antidepressant;;; +93153-5;LL6311-6;High-risk drug classes;LA30459-4;4;Hypnotic;;; +93153-5;LL6311-6;High-risk drug classes;LA30460-2;5;Anticoagulant (e.g., warfarin, heparin, or low-molecular weight heparin);;; +93153-5;LL6311-6;High-risk drug classes;LA30299-4;6;Antibiotic;;; +93153-5;LL6311-6;High-risk drug classes;LA30461-0;7;Diuretic;;; +93153-5;LL6311-6;High-risk drug classes;LA28420-0;8;Opioid;;; +93153-5;LL6311-6;High-risk drug classes;LA30300-0;9;Antiplatelet;;; +93153-5;LL6311-6;High-risk drug classes;LA30301-8;10;Hypoglycemic (including insulin);;; +93153-5;LL6311-6;High-risk drug classes;LA9-3;11;None of the above;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30297-8;1;Antipsychotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30298-6;2;Anticoagulant;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30299-4;3;Antibiotic;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA28420-0;4;Opioid;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30300-0;5;Antiplatelet;;; +93154-3;LL5415-6;CMS_IRF-PAI v4.0 - HighRsk DrgUse IndNot (N0415-2);LA30301-8;6;Hypoglycemic (including insulin);;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30297-8;1;Antipsychotic;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30457-8;2;Antianxiety;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30458-6;3;Antidepressant;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30459-4;4;Hypnotic;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30298-6;5;Anticoagulant;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30299-4;6;Antibiotic;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30461-0;7;Diuretic;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA28420-0;8;Opioid;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30300-0;9;Antiplatelet;;; +93154-3;LL6312-4;High-risk drug classes - indication noted;LA30301-8;10;Hypoglycemic (including insulin);;; +93156-8;LL5381-0;CMS IRF_PAI v4.0 Pain Effect on Sleep (J0510);LA30272-1;0;Does not apply - I have not had any pain or hurting in the past 5 days;;; +93156-8;LL5381-0;CMS IRF_PAI v4.0 Pain Effect on Sleep (J0510);LA30273-9;1;Rarely or not at all;;; +93156-8;LL5381-0;CMS IRF_PAI v4.0 Pain Effect on Sleep (J0510);LA6483-7;2;Occasionally;;; +93156-8;LL5381-0;CMS IRF_PAI v4.0 Pain Effect on Sleep (J0510);LA6482-9;3;Frequently;;; +93156-8;LL5381-0;CMS IRF_PAI v4.0 Pain Effect on Sleep (J0510);LA11055-3;4;Almost constantly;;; +93156-8;LL5381-0;CMS IRF_PAI v4.0 Pain Effect on Sleep (J0510);LA11054-6;5;Unable to answer;;; +93156-8;LL6300-9;***** CLONED FROM - LL5497-4 *****;LA30273-9;1;Rarely or not at all;;; +93156-8;LL6300-9;***** CLONED FROM - LL5497-4 *****;LA6483-7;2;Occasionally;;; +93156-8;LL6300-9;***** CLONED FROM - LL5497-4 *****;LA6482-9;3;Frequently;;; +93156-8;LL6300-9;***** CLONED FROM - LL5497-4 *****;LA11055-3;4;Almost constantly;;; +93156-8;LL6300-9;***** CLONED FROM - LL5497-4 *****;LA11054-6;5;Unable to answer;;; +93157-6;LL6305-8;Never|Rare|Sometimes|Often|Always|declines|unable;LA6270-8;1;Never;;; +93157-6;LL6305-8;Never|Rare|Sometimes|Often|Always|declines|unable;LA10066-1;2;Rarely;;; +93157-6;LL6305-8;Never|Rare|Sometimes|Often|Always|declines|unable;LA10082-8;3;Sometimes;;; +93157-6;LL6305-8;Never|Rare|Sometimes|Often|Always|declines|unable;LA10044-8;4;Often;;; +93157-6;LL6305-8;Never|Rare|Sometimes|Often|Always|declines|unable;LA9933-8;5;Always;;; +93157-6;LL6305-8;Never|Rare|Sometimes|Often|Always|declines|unable;LA33608-3;6;Resident declines to respond;;; +93157-6;LL6305-8;Never|Rare|Sometimes|Often|Always|declines|unable;LA30435-4;7;Resident unable to respond;;; +93158-4;LL5383-6;CMS IRF_PAI v4.0 Pain Interfere Daily Act (J0530);LA30273-9;2;Rarely or not at all;;; +93158-4;LL5383-6;CMS IRF_PAI v4.0 Pain Interfere Daily Act (J0530);LA6483-7;3;Occasionally;;; +93158-4;LL5383-6;CMS IRF_PAI v4.0 Pain Interfere Daily Act (J0530);LA6482-9;4;Frequently;;; +93158-4;LL5383-6;CMS IRF_PAI v4.0 Pain Interfere Daily Act (J0530);LA11055-3;5;Almost constantly;;; +93158-4;LL5383-6;CMS IRF_PAI v4.0 Pain Interfere Daily Act (J0530);LA11054-6;6;Unable to answer;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA6270-8;1;Never;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10066-1;2;Rarely;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10082-8;3;Sometimes;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10044-8;4;Often;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA9933-8;5;Always;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA30257-2;6;Patient unable to respond;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA6270-8;1;Never;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10066-1;2;Rarely;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10082-8;3;Sometimes;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10044-8;4;Often;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA9933-8;5;Always;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA30257-2;6;Patient unable to respond;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA6270-8;1;Never;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10066-1;2;Rarely;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10082-8;3;Sometimes;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10044-8;4;Often;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA9933-8;5;Always;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA30257-2;6;Patient unable to respond;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA6270-8;1;Never;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10066-1;2;Rarely;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10082-8;3;Sometimes;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10044-8;4;Often;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA9933-8;5;Always;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA30257-2;6;Patient unable to respond;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA6270-8;1;Never;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10066-1;2;Rarely;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10082-8;3;Sometimes;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10044-8;4;Often;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA9933-8;5;Always;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA30257-2;6;Patient unable to respond;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA6270-8;1;Never;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10066-1;2;Rarely;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10082-8;3;Sometimes;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10044-8;4;Often;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA9933-8;5;Always;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA30257-2;6;Patient unable to respond;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA6270-8;1;Never;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10066-1;2;Rarely;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10082-8;3;Sometimes;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA10044-8;4;Often;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA9933-8;5;Always;;; +93159-2;LL5416-4;Nev(0)Rare(1)Somet(2)Oft(3)Alwy(4)PtUnAbletoRes(8);LA30257-2;6;Patient unable to respond;;; +93159-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA6270-8;2;Never;;; +93159-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA10066-1;3;Rarely;;; +93159-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA10082-8;4;Sometimes;;; +93159-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA10044-8;5;Often;;; +93159-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA9933-8;6;Always;;; +99627-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA6270-8;2;Never;;; +99627-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA10066-1;3;Rarely;;; +99627-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA10082-8;4;Sometimes;;; +99627-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA10044-8;5;Often;;; +99627-2;LL5869-4;Nev|Rare|Some|Oft|Always;LA9933-8;6;Always;;; +93159-2;LL6298-5;Never|Rare|Sometime|Often|Always;LA6270-8;1;Never;;; +93159-2;LL6298-5;Never|Rare|Sometime|Often|Always;LA10066-1;2;Rarely;;; +93159-2;LL6298-5;Never|Rare|Sometime|Often|Always;LA10082-8;3;Sometimes;;; +93159-2;LL6298-5;Never|Rare|Sometime|Often|Always;LA10044-8;4;Often;;; +93159-2;LL6298-5;Never|Rare|Sometime|Often|Always;LA9933-8;5;Always;;; +93159-2;LL6298-5;Never|Rare|Sometime|Often|Always;LA33608-3;6;Resident declines to respond;;; +93159-2;LL6298-5;Never|Rare|Sometime|Often|Always;LA30435-4;7;Resident unable to respond;;; +931-6;LL2412-6;Bld prod source;LA19690-9;1;Autologous;;; +931-6;LL2412-6;Bld prod source;LA19691-7;2;Directed donor;;; +931-6;LL2412-6;Bld prod source;LA19692-5;3;Anonymous donor;;; +93160-0;LL5382-8;CMS IRF_PAI v4.0 Pain Interfere Therapy (J0520);LA30274-7;1;Does not apply - I have not received rehabilitation therapy in the past 5 days;;; +93160-0;LL5382-8;CMS IRF_PAI v4.0 Pain Interfere Therapy (J0520);LA30273-9;2;Rarely or not at all;;; +93160-0;LL5382-8;CMS IRF_PAI v4.0 Pain Interfere Therapy (J0520);LA6483-7;3;Occasionally;;; +93160-0;LL5382-8;CMS IRF_PAI v4.0 Pain Interfere Therapy (J0520);LA6482-9;4;Frequently;;; +93160-0;LL5382-8;CMS IRF_PAI v4.0 Pain Interfere Therapy (J0520);LA11055-3;5;Almost constantly;;; +93160-0;LL5382-8;CMS IRF_PAI v4.0 Pain Interfere Therapy (J0520);LA11054-6;6;Unable to answer;;; +93181-6;LL5379-4;CMS IRF_PAI v4.0_Rec Med List to Patient (A2123);LA30269-7;0;No - Current reconciled medication list not provided to the patient, family and/or caregiver;;; +93181-6;LL5379-4;CMS IRF_PAI v4.0_Rec Med List to Patient (A2123);LA30270-5;1;Yes - Current reconciled medication list provided to the patient, family and/or caregiver;;; +93182-4;LL5377-8;CMS Rec Med List to Provider;LA30262-2;1;No - Current reconciled medication list not provided to the subsequent provider;;; +93182-4;LL5377-8;CMS Rec Med List to Provider;LA30263-0;2;Yes - Current reconciled medication list provided to the subsequent provider;;; +99286-7;LL5377-8;CMS Rec Med List to Provider;LA30262-2;1;No - Current reconciled medication list not provided to the subsequent provider;;; +99286-7;LL5377-8;CMS Rec Med List to Provider;LA30263-0;2;Yes - Current reconciled medication list provided to the subsequent provider;;; +93183-2;LL5380-2;CMS IRF_PAI v4.0 Rte Med List to Patient (A2124);LA30271-3;1;Electronic health record (e.g., electronic access to patient portal);;; +93183-2;LL5380-2;CMS IRF_PAI v4.0 Rte Med List to Patient (A2124);LA30265-5;2;Health information exchange;;; +93183-2;LL5380-2;CMS IRF_PAI v4.0 Rte Med List to Patient (A2124);LA30266-3;3;Verbal (e.g., in-person, telephone, video conferencing);;; +93183-2;LL5380-2;CMS IRF_PAI v4.0 Rte Med List to Patient (A2124);LA30267-1;4;Paper-based (e.g., fax, copies, printouts);;; +93183-2;LL5380-2;CMS IRF_PAI v4.0 Rte Med List to Patient (A2124);LA30268-9;5;Other methods (e.g., texting, email, CDs);;; +93184-0;LL5378-6;CMS IRF_PAI v4.0_Rte Rec Med List to Provid(A2122);LA30264-8;0;Electronic health record;;; +93184-0;LL5378-6;CMS IRF_PAI v4.0_Rte Rec Med List to Provid(A2122);LA30265-5;1;Health information exchange;;; +93184-0;LL5378-6;CMS IRF_PAI v4.0_Rte Rec Med List to Provid(A2122);LA30266-3;2;Verbal (e.g., in-person, telephone, video conferencing);;; +93184-0;LL5378-6;CMS IRF_PAI v4.0_Rte Rec Med List to Provid(A2122);LA30267-1;3;Paper-based (e.g., fax, copies, printouts);;; +93184-0;LL5378-6;CMS IRF_PAI v4.0_Rte Rec Med List to Provid(A2122);LA30268-9;4;Other methods (e.g., texting, email, CDs);;; +93197-2;LL5373-7;CYP4F2 example genotypes;LA30244-0;4;CYP4F2 *1/*1;;; +93197-2;LL5373-7;CYP4F2 example genotypes;LA30245-7;5;CYP4F2 *1/*3;;; +93197-2;LL5373-7;CYP4F2 example genotypes;LA30246-5;6;CYP4F2 *3/*3;;; +93202-0;LL5406-5;CMS_LCDS - Ventilator Weaning (O0150A2);LA30354-7;4;No, determined to be non-weaning upon admission;;; +93202-0;LL5406-5;CMS_LCDS - Ventilator Weaning (O0150A2);LA30355-4;5;Yes, determined to be weaning upon admission;;; +93246-7;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93246-7;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93246-7;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93246-7;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93246-7;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93246-7;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93247-5;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93247-5;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93247-5;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93247-5;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93247-5;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93247-5;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93248-3;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93248-3;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93248-3;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93248-3;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93248-3;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93248-3;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93249-1;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93249-1;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93249-1;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93249-1;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93249-1;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93249-1;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93250-9;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93250-9;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93250-9;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93250-9;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93250-9;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93250-9;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93253-3;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93253-3;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93253-3;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93253-3;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93253-3;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93253-3;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93255-8;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93255-8;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93255-8;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93255-8;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93255-8;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93255-8;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93259-0;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93259-0;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93259-0;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93259-0;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93259-0;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93259-0;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93261-6;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93261-6;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93261-6;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93261-6;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93261-6;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93261-6;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93263-2;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93263-2;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93263-2;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93263-2;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93263-2;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93263-2;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93265-7;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93265-7;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93265-7;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93265-7;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93265-7;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93265-7;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93267-3;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93267-3;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93269-9;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93269-9;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93295-4;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93295-4;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93295-4;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93295-4;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93295-4;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93295-4;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93296-2;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93296-2;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93296-2;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93296-2;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93296-2;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93296-2;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93297-0;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93297-0;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93297-0;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93297-0;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93297-0;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93297-0;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93298-8;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93298-8;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93298-8;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93298-8;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93298-8;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93298-8;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93299-6;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93299-6;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93299-6;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93299-6;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93299-6;LL5384-4;C-SSRS - Yes, Describe|No;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +93299-6;LL5384-4;C-SSRS - Yes, Describe|No;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +93251-7;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30314-1;0;Fleeting - few seconds or minutes;;; +93251-7;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30315-8;1;Less than one hour/some of the time;;; +93251-7;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30316-6;2;1-4 hours/a lot of time;;; +93251-7;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30317-4;3;4-8 hours/most of day;;; +93251-7;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30318-2;4;More than 8 hours/persistent or continuous;;; +93252-5;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30314-1;0;Fleeting - few seconds or minutes;;; +93252-5;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30315-8;1;Less than one hour/some of the time;;; +93252-5;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30316-6;2;1-4 hours/a lot of time;;; +93252-5;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30317-4;3;4-8 hours/most of day;;; +93252-5;LL5392-7;C-SSRS - Intensity of Ideation - Duration;LA30318-2;4;More than 8 hours/persistent or continuous;;; +93271-5;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30335-6;0;No physical damage or very minor physical damage (e.g., surface scratches);;; +93271-5;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30336-4;1;"Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains)";;; +93271-5;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30337-2;2;"Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree burns; bleeding of major vessel)";;; +93271-5;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30338-0;3;"Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major fractures)";;; +93271-5;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30339-8;4;"Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third-degree burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area)";;; +93271-5;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA7424-0;5;Death;;; +93283-0;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30335-6;0;No physical damage or very minor physical damage (e.g., surface scratches);;; +93283-0;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30336-4;1;"Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains)";;; +93283-0;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30337-2;2;"Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree burns; bleeding of major vessel)";;; +93283-0;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30338-0;3;"Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major fractures)";;; +93283-0;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30339-8;4;"Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third-degree burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area)";;; +93283-0;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA7424-0;5;Death;;; +93284-8;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30335-6;0;No physical damage or very minor physical damage (e.g., surface scratches);;; +93284-8;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30336-4;1;"Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains)";;; +93284-8;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30337-2;2;"Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree burns; bleeding of major vessel)";;; +93284-8;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30338-0;3;"Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major fractures)";;; +93284-8;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA30339-8;4;"Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third-degree burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area)";;; +93284-8;LL5397-6;C-SSRS - Actual Lethality/Medical Damage Type;LA7424-0;5;Death;;; +93272-3;LL5398-4;C-SSRS - Potential Lethality;LA30341-4;0;Behavior not likely to result in injury;;; +93272-3;LL5398-4;C-SSRS - Potential Lethality;LA30342-2;1;Behavior likely to result in injury but not likely to cause death;;; +93272-3;LL5398-4;C-SSRS - Potential Lethality;LA30343-0;2;Behavior likely to result in death despite available medical care;;; +93281-4;LL5398-4;C-SSRS - Potential Lethality;LA30341-4;0;Behavior not likely to result in injury;;; +93281-4;LL5398-4;C-SSRS - Potential Lethality;LA30342-2;1;Behavior likely to result in injury but not likely to cause death;;; +93281-4;LL5398-4;C-SSRS - Potential Lethality;LA30343-0;2;Behavior likely to result in death despite available medical care;;; +93282-2;LL5398-4;C-SSRS - Potential Lethality;LA30341-4;0;Behavior not likely to result in injury;;; +93282-2;LL5398-4;C-SSRS - Potential Lethality;LA30342-2;1;Behavior likely to result in injury but not likely to cause death;;; +93282-2;LL5398-4;C-SSRS - Potential Lethality;LA30343-0;2;Behavior likely to result in death despite available medical care;;; +93285-5;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30330-7;0;Completely to get attention, revenge or a reaction from others;;; +93285-5;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30331-5;1;Mostly to get attention, revenge or a reaction from others;;; +93285-5;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30332-3;2;Equally to get attention, revenge or a reaction from others and to end/stop the pain;;; +93285-5;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30333-1;3;Mostly to end or stop the pain (you couldn't go on living with the pain or how you were feeling);;; +93285-5;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30334-9;4;Completely to end or stop the pain (you couldn't go on living with the pain or how you were feeling);;; +93285-5;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA14452-9;5;Does not apply;;; +93286-3;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30330-7;0;Completely to get attention, revenge or a reaction from others;;; +93286-3;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30331-5;1;Mostly to get attention, revenge or a reaction from others;;; +93286-3;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30332-3;2;Equally to get attention, revenge or a reaction from others and to end/stop the pain;;; +93286-3;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30333-1;3;Mostly to end or stop the pain (you couldn't go on living with the pain or how you were feeling);;; +93286-3;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA30334-9;4;Completely to end or stop the pain (you couldn't go on living with the pain or how you were feeling);;; +93286-3;LL5396-8;C-SSRS - Intensity of Ideation - Reasons;LA14452-9;5;Does not apply;;; +93287-1;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30325-7;0;Deterrents definitely stopped you from attempting suicide;;; +93287-1;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30326-5;1;Deterrents probably stopped you;;; +93287-1;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30327-3;2;Uncertain that deterrents stopped you;;; +93287-1;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30328-1;3;Deterrents most likely did not stop you;;; +93287-1;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30329-9;4;Deterrents definitely did not stop you;;; +93287-1;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA14452-9;5;Does not apply;;; +93288-9;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30325-7;0;Deterrents definitely stopped you from attempting suicide;;; +93288-9;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30326-5;1;Deterrents probably stopped you;;; +93288-9;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30327-3;2;Uncertain that deterrents stopped you;;; +93288-9;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30328-1;3;Deterrents most likely did not stop you;;; +93288-9;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA30329-9;4;Deterrents definitely did not stop you;;; +93288-9;LL5395-0;C-SSRS - Intensity of Ideation - Deterrents;LA14452-9;5;Does not apply;;; +93289-7;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30319-0;0;Easily able to control thoughts;;; +93289-7;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30320-8;1;Can control thoughts with little difficulty;;; +93289-7;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30321-6;2;Can control thoughts with some difficulty;;; +93289-7;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30322-4;3;Can control thoughts with a lot of difficulty;;; +93289-7;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30323-2;4;Unable to control thoughts;;; +93289-7;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30324-0;5;Does not attempt to control thoughts;;; +93290-5;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30319-0;0;Easily able to control thoughts;;; +93290-5;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30320-8;1;Can control thoughts with little difficulty;;; +93290-5;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30321-6;2;Can control thoughts with some difficulty;;; +93290-5;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30322-4;3;Can control thoughts with a lot of difficulty;;; +93290-5;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30323-2;4;Unable to control thoughts;;; +93290-5;LL5394-3;C-SSRS - Intensity of Ideation - Controlability;LA30324-0;5;Does not attempt to control thoughts;;; +93291-3;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA27722-0;0;Less than once a week;;; +93291-3;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA26461-6;1;Once a week;;; +93291-3;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA30311-7;2;2-5 times in week;;; +93291-3;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA18934-2;3;Daily or almost daily;;; +93291-3;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA30312-5;4;Many times each day;;; +93292-1;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA27722-0;0;Less than once a week;;; +93292-1;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA26461-6;1;Once a week;;; +93292-1;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA30311-7;2;2-5 times in week;;; +93292-1;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA18934-2;3;Daily or almost daily;;; +93292-1;LL5390-1;C-SSRS - Intensity of Ideation - Frequency;LA30312-5;4;Many times each day;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30370-3;1;Wish to be dead;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30371-1;2;Non-specific active suicidal thoughts;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30372-9;3;Active suicidal ideation with any methods (not plan) without intent to act;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30373-7;4;Active suicidal ideation with some intent to act, without specific plan;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30374-5;5;Active suicidal ideation with specific plan and intent;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30370-3;1;Wish to be dead;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30371-1;2;Non-specific active suicidal thoughts;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30372-9;3;Active suicidal ideation with any methods (not plan) without intent to act;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30373-7;4;Active suicidal ideation with some intent to act, without specific plan;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30374-5;5;Active suicidal ideation with specific plan and intent;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30370-3;1;Wish to be dead;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30371-1;2;Non-specific active suicidal thoughts;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30372-9;3;Active suicidal ideation with any methods (not plan) without intent to act;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30373-7;4;Active suicidal ideation with some intent to act, without specific plan;;; +93293-9;LL5434-7;C-SSRS Ideation Types;LA30374-5;5;Active suicidal ideation with specific plan and intent;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30370-3;1;Wish to be dead;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30371-1;2;Non-specific active suicidal thoughts;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30372-9;3;Active suicidal ideation with any methods (not plan) without intent to act;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30373-7;4;Active suicidal ideation with some intent to act, without specific plan;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30374-5;5;Active suicidal ideation with specific plan and intent;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30370-3;1;Wish to be dead;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30371-1;2;Non-specific active suicidal thoughts;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30372-9;3;Active suicidal ideation with any methods (not plan) without intent to act;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30373-7;4;Active suicidal ideation with some intent to act, without specific plan;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30374-5;5;Active suicidal ideation with specific plan and intent;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30370-3;1;Wish to be dead;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30371-1;2;Non-specific active suicidal thoughts;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30372-9;3;Active suicidal ideation with any methods (not plan) without intent to act;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30373-7;4;Active suicidal ideation with some intent to act, without specific plan;;; +93294-7;LL5434-7;C-SSRS Ideation Types;LA30374-5;5;Active suicidal ideation with specific plan and intent;;; +933-2;LL2423-3;Blood prod type;LA19720-4;1;Whole blood;;; +933-2;LL2423-3;Blood prod type;LA19721-2;2;Packed cells;;; +933-2;LL2423-3;Blood prod type;LA19722-0;3;Fresh frozen plasma;;; +933-2;LL2423-3;Blood prod type;LA19723-8;4;Irradiated blood;;; +933-2;LL2423-3;Blood prod type;LA19724-6;5;Leucocyte free blood;;; +933-2;LL2423-3;Blood prod type;LA19725-3;6;Cryoprecipitate;;; +933-2;LL2423-3;Blood prod type;LA19726-1;7;Platelets;;; +93343-2;LL5374-5;Cancer therapies;LA30251-5;1;Binimetinib;;; +93343-2;LL5374-5;Cancer therapies;LA30253-1;2;Imatinib;;; +93343-2;LL5374-5;Cancer therapies;LA30250-7;3;Sunitinib;;; +93343-2;LL5374-5;Cancer therapies;LA30252-3;4;Trametinib;;; +93343-2;LL5374-5;Cancer therapies;LA30247-3;5;Midostaurin;;; +93343-2;LL5374-5;Cancer therapies;LA30248-1;6;Sorafenib;;; +93343-2;LL5374-5;Cancer therapies;LA30249-9;7;Ponatinib;;; +93344-0;LL5374-5;Cancer therapies;LA30251-5;1;Binimetinib;;; +93344-0;LL5374-5;Cancer therapies;LA30253-1;2;Imatinib;;; +93344-0;LL5374-5;Cancer therapies;LA30250-7;3;Sunitinib;;; +93344-0;LL5374-5;Cancer therapies;LA30252-3;4;Trametinib;;; +93344-0;LL5374-5;Cancer therapies;LA30247-3;5;Midostaurin;;; +93344-0;LL5374-5;Cancer therapies;LA30248-1;6;Sorafenib;;; +93344-0;LL5374-5;Cancer therapies;LA30249-9;7;Ponatinib;;; +93347-3;LL5374-5;Cancer therapies;LA30251-5;1;Binimetinib;;; +93347-3;LL5374-5;Cancer therapies;LA30253-1;2;Imatinib;;; +93347-3;LL5374-5;Cancer therapies;LA30250-7;3;Sunitinib;;; +93347-3;LL5374-5;Cancer therapies;LA30252-3;4;Trametinib;;; +93347-3;LL5374-5;Cancer therapies;LA30247-3;5;Midostaurin;;; +93347-3;LL5374-5;Cancer therapies;LA30248-1;6;Sorafenib;;; +93347-3;LL5374-5;Cancer therapies;LA30249-9;7;Ponatinib;;; +93348-1;LL5374-5;Cancer therapies;LA30251-5;1;Binimetinib;;; +93348-1;LL5374-5;Cancer therapies;LA30253-1;2;Imatinib;;; +93348-1;LL5374-5;Cancer therapies;LA30250-7;3;Sunitinib;;; +93348-1;LL5374-5;Cancer therapies;LA30252-3;4;Trametinib;;; +93348-1;LL5374-5;Cancer therapies;LA30247-3;5;Midostaurin;;; +93348-1;LL5374-5;Cancer therapies;LA30248-1;6;Sorafenib;;; +93348-1;LL5374-5;Cancer therapies;LA30249-9;7;Ponatinib;;; +93349-9;LL5374-5;Cancer therapies;LA30251-5;1;Binimetinib;;; +93349-9;LL5374-5;Cancer therapies;LA30253-1;2;Imatinib;;; +93349-9;LL5374-5;Cancer therapies;LA30250-7;3;Sunitinib;;; +93349-9;LL5374-5;Cancer therapies;LA30252-3;4;Trametinib;;; +93349-9;LL5374-5;Cancer therapies;LA30247-3;5;Midostaurin;;; +93349-9;LL5374-5;Cancer therapies;LA30248-1;6;Sorafenib;;; +93349-9;LL5374-5;Cancer therapies;LA30249-9;7;Ponatinib;;; +93359-8;LL5361-2;DNA Ploidy;LA30218-4;1;Diploid;;; +93359-8;LL5361-2;DNA Ploidy;LA30221-8;2;Hypodiploid;;; +93359-8;LL5361-2;DNA Ploidy;LA30219-2;3;Hyperdiploid;;; +93359-8;LL5361-2;DNA Ploidy;LA30220-0;4;Tetraploid;;; +93442-2;LL5367-9;Document format type;LA30379-4;1;Original paper document;;; +93442-2;LL5367-9;Document format type;LA30380-2;2;Paper copy;;; +93442-2;LL5367-9;Document format type;LA26663-7;3;Electronic;;; +93442-2;LL5367-9;Document format type;LA15436-1;4;No information available;;; +93443-0;LL5366-1;Self-care ability;LA30228-3;0;Patient is able to eat chopped bread;;; +93443-0;LL5366-1;Self-care ability;LA30227-5;1;Patient is able to sit up in bed;;; +93443-0;LL5366-1;Self-care ability;LA30229-1;2;Patient is able to wash self with left arm;;; +93444-8;LL5372-9;Accessibility of Home Entrance;LA30240-8;0;Number of steps to elevator (please specify);;; +93444-8;LL5372-9;Accessibility of Home Entrance;LA30241-6;1;Accessible elevator;;; +93444-8;LL5372-9;Accessibility of Home Entrance;LA30243-2;2;Broken ramp;;; +93444-8;LL5372-9;Accessibility of Home Entrance;LA30242-4;3;No steps;;; +93446-3;LL5371-1;Home interior accessibility;LA30239-0;1;Free from hazards;;; +93446-3;LL5371-1;Home interior accessibility;LA30238-2;2;Door frames not wide enough for wheelchair access;;; +93446-3;LL5371-1;Home interior accessibility;LA30377-8;3;Two sets of uncarpeted stairs;;; +93446-3;LL5371-1;Home interior accessibility;LA30378-6;4;Main floor bathroom has safety rails;;; +93447-1;LL5370-3;Home accessibility mods - responsible party;LA30236-6;0;Responsible party (please specify);;; +93448-9;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA30233-3;0;Performed on (specify date);;; +93448-9;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA30234-1;1;Scheduled for (specify date);;; +93448-9;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA7304-4;2;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +93448-9;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA30235-8;3;Not neccessary;;; +96394-2;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA30233-3;0;Performed on (specify date);;; +96394-2;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA30234-1;1;Scheduled for (specify date);;; +96394-2;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA7304-4;2;Not performed;262008008;Not performed (qualifier value);http://snomed.info/sct +96394-2;LL5369-5;Performed|Scheduled|Not Perform|Not Necess;LA30235-8;3;Not neccessary;;; +93449-7;LL5368-7;Appointment of Legal Guardian;LA30231-7;1;Guardian was appointed by court;;; +93449-7;LL5368-7;Appointment of Legal Guardian;LA30375-2;2;Guardian selected by parents prior to their death;;; +93449-7;LL5368-7;Appointment of Legal Guardian;LA30376-0;3;Court hearing related to guardianship has not occured;;; +93479-4;LL5433-9;ObservationInterpretationCodes_HL7_FHIR;;0;;;; +93599-9;LL5460-2;Frequency (C-SSRS);LA30454-5;1;Only one time;;; +93599-9;LL5460-2;Frequency (C-SSRS);LA30455-2;2;A few times;;; +93599-9;LL5460-2;Frequency (C-SSRS);LA14468-5;3;A lot;;; +93599-9;LL5460-2;Frequency (C-SSRS);LA14726-6;4;All the time;;; +93599-9;LL5460-2;Frequency (C-SSRS);LA30456-0;5;Don't know/Not applicable;;; +93600-5;LL5460-2;Frequency (C-SSRS);LA30454-5;1;Only one time;;; +93600-5;LL5460-2;Frequency (C-SSRS);LA30455-2;2;A few times;;; +93600-5;LL5460-2;Frequency (C-SSRS);LA14468-5;3;A lot;;; +93600-5;LL5460-2;Frequency (C-SSRS);LA14726-6;4;All the time;;; +93600-5;LL5460-2;Frequency (C-SSRS);LA30456-0;5;Don't know/Not applicable;;; +93690-6;LL4972-7;BRAF Neg|V600E|V600K|Both;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93690-6;LL4972-7;BRAF Neg|V600E|V600K|Both;LA28872-2;2;V600E mutation;;; +93690-6;LL4972-7;BRAF Neg|V600E|V600K|Both;LA28873-0;3;V600K mutation;;; +93690-6;LL4972-7;BRAF Neg|V600E|V600K|Both;LA28874-8;4;V600E and V600K mutations;;; +93690-6;LL4972-7;BRAF Neg|V600E|V600K|Both;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +97025-1;LL4972-7;BRAF Neg|V600E|V600K|Both;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97025-1;LL4972-7;BRAF Neg|V600E|V600K|Both;LA28872-2;2;V600E mutation;;; +97025-1;LL4972-7;BRAF Neg|V600E|V600K|Both;LA28873-0;3;V600K mutation;;; +97025-1;LL4972-7;BRAF Neg|V600E|V600K|Both;LA28874-8;4;V600E and V600K mutations;;; +97025-1;LL4972-7;BRAF Neg|V600E|V600K|Both;LA15841-2;5;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +93693-0;LL5455-2;NASH grade;LA4368-2;1;N0;;; +93693-0;LL5455-2;NASH grade;LA4537-2;2;N1;;; +93693-0;LL5455-2;NASH grade;LA4534-9;3;N2;;; +93693-0;LL5455-2;NASH grade;LA4545-5;4;N3;;; +93694-8;LL5457-8;NASH interpretation;LA30440-4;1;No nonalcoholic steatohepatitis (NASH);;; +93694-8;LL5457-8;NASH interpretation;LA30441-2;2;Mild nonalcoholic steatohepatitis (NASH);;; +93694-8;LL5457-8;NASH interpretation;LA30442-0;3;Moderate nonalcoholic steatohepatitis (NASH);;; +93694-8;LL5457-8;NASH interpretation;LA30443-8;4;Severe nonalcoholic steatohepatitis (NASH);;; +93696-3;LL5456-0;Steatosis stage;LA30438-8;1;S0;;; +93696-3;LL5456-0;Steatosis stage;LA18242-0;2;S1;;; +93696-3;LL5456-0;Steatosis stage;LA30439-6;3;S2S3;;; +93697-1;LL5458-6;Steatosis interpretation;LA30444-6;1;No steatosis (<5%);;; +93697-1;LL5458-6;Steatosis interpretation;LA30445-3;2;Mild steatosis (5-33%);;; +93697-1;LL5458-6;Steatosis interpretation;LA30446-1;3;Moderate/severe steatosis (34-100%);;; +93718-5;LL5459-4;Francisella tularensis interpretation;LA30447-9;1;No antibodies to Francisella tularensis detected. Antibody response may be negative in samples collected too soon following infection/exposure. Repeat testing on a new sample if clinically indicated.;;; +93718-5;LL5459-4;Francisella tularensis interpretation;LA30448-7;2;IgM class antibodies to Francisella tularensis detected, suggesting current or recent infection. Repeat testing in 2-3 weeks to detect seroconversion of IgG may be considered to confirm the diagnosis.;;; +93718-5;LL5459-4;Francisella tularensis interpretation;LA30449-5;3;Questionable presence of IgM antibodies to Francisella tularensis. Consider repeat testing in 1-2 weeks.;;; +93718-5;LL5459-4;Francisella tularensis interpretation;LA30450-3;4;IgG class antibodies to Francisella tularensis detected suggesting recent or past infection. Clinical correlation alongside presentation, exposure history and other laboratory findings required.;;; +93718-5;LL5459-4;Francisella tularensis interpretation;LA30451-1;5;Questionable presence of IgG antibodies to Francisella tularensis. Consider repeat testing in 1-2 weeks.;;; +93718-5;LL5459-4;Francisella tularensis interpretation;LA30452-9;6;Questionable presence of IgM and IgG class antibodies to Francisella tularensis. Consider repeat testing in 1-2 weeks.;;; +93718-5;LL5459-4;Francisella tularensis interpretation;LA30453-7;7;IgM and IgG class antibodies to Francisella tularensis detected suggesting current, recent or past infection. Clinical correlation alongside presentation, exposure history and other laboratory findings required.;;; +93779-7;LL5436-2;B-cell lymphoma type and cell of origin;LA30366-1;0;Primary mediastinal large B-cell lymphoma (PMBCL);;; +93779-7;LL5436-2;B-cell lymphoma type and cell of origin;LA30367-9;1;Germinal center B-cell type of diffuse large B-cell lymphoma;;; +93779-7;LL5436-2;B-cell lymphoma type and cell of origin;LA30368-7;2;Activated B-cell type of diffuse large B-cell lymphoma;;; +93779-7;LL5436-2;B-cell lymphoma type and cell of origin;LA10109-9;3;Unclear or unknown;;; +93782-1;LL5429-7;WHO classification_Large B-cell lymphoma type;LA26525-8;0;Diffuse large B-cell lymphoma (DLBCL), NOS;;; +93782-1;LL5429-7;WHO classification_Large B-cell lymphoma type;LA30366-1;1;Primary mediastinal large B-cell lymphoma (PMBCL);;; +93783-9;LL5430-5;WHO subtypes_Diffuse large B-cell lymphoma;LA30368-7;0;Activated B-cell type of diffuse large B-cell lymphoma;;; +93783-9;LL5430-5;WHO subtypes_Diffuse large B-cell lymphoma;LA30367-9;1;Germinal center B-cell type of diffuse large B-cell lymphoma;;; +93783-9;LL5430-5;WHO subtypes_Diffuse large B-cell lymphoma;LA30369-5;2;Unclassifiable B-cell;;; +93788-8;LL5465-1;Factor V HR2 & Leiden Co-Interpretation;LA30466-9;1;POSITIVE FOR ONE COPY OF THE FACTOR V LEIDEN (R506Q) MUTATION;;; +93788-8;LL5465-1;Factor V HR2 & Leiden Co-Interpretation;LA30467-7;2;POSITIVE FOR TWO COPIES OF THE FACTOR V LEIDEN (R506Q) MUTATION;;; +93788-8;LL5465-1;Factor V HR2 & Leiden Co-Interpretation;LA30468-5;3;POSITIVE FOR TWO COPIES OF THE FACTOR V LEIDEN (R506Q) VARIANT;;; +93788-8;LL5465-1;Factor V HR2 & Leiden Co-Interpretation;LA30469-3;4;"POSITIVE FOR THE HETEROZYGOUS PRESENCE OF THE FACTOR V LEIDEN (R506Q) MUTATION; HETEROZYGOUS FOR THE HR2 POLYMORPHISM.";;; +93788-8;LL5465-1;Factor V HR2 & Leiden Co-Interpretation;LA30470-1;5;POSITIVE FOR THE HOMOZYGOUS PRESENCE OF THE FACTOR V LEIDEN (R506Q) MUTATION. NEGATIVE FOR THE HR2 POLYMORPHISM.;;; +93788-8;LL5465-1;Factor V HR2 & Leiden Co-Interpretation;LA30471-9;6;POSITIVE FOR ONE COPY OF THE FACTOR V HR2 VARIANT;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30473-5;1;Homozygous *36 (TA5/TA5);;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30474-3;2;Heterozygous *36 (TA5/TA6);;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30475-0;3;Heterozygous *36 and Heterozygous *28 (TA5/TA7);;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30477-6;4;Heterozygous *28 (TA6/TA7);;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30478-4;5;Homozygous *28 (TA7/TA7);;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30479-2;6;Homozygous *36 (TA5/TA5) and Heterozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30480-0;7;Heterozygous *36 (TA5/TA6) and Heterozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30481-8;8;Heterozygous *36, Heterozygous *28 (TA5/TA7), and Heterozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30482-6;9;Heterozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30483-4;10;Heterozygous *28 (TA6/TA7) and Heterozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30484-2;11;Homozygous *28 (TA7/TA7) and Heterozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30486-7;12;Homozygous *36 (TA5/TA5) and Homozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30487-5;13;Heterozygous *36 (TA5/TA6) and Homozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30488-3;14;Heterozygous *36, Heterozygous *28 (TA5/TA7), and Homozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30489-1;15;Homozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30490-9;16;Heterozygous *28 (TA6/TA7), and Homozygous *6;;; +93845-6;LL5467-7;UGT1A1 Genotype;LA30491-7;17;Homozygous *28 (TA7/TA7) and Homozygous *6;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA26176-0;0;Daycare;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30302-6;1;Healthcare;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30303-4;2;Hotel;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA14086-5;3;School;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30304-2;4;Sports or athletics arena;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA27-8;5;Nursing Home;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA26175-2;6;Correctional facility;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30305-9;7;Shelter;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30306-7;8;Restaurant;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30307-5;9;Single family house;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30308-3;10;Duplex/townhouse;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30309-1;11;Apartment building;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA30310-9;12;Mobile dwelling;;; +93848-0;LL5389-3;Setting of exposure to hazard;LA46-8;13;Other;;; +93917-3;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93917-3;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93917-3;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93918-1;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93918-1;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93918-1;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93919-9;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93919-9;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93919-9;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93920-7;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93920-7;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93920-7;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93921-5;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93921-5;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93921-5;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93924-9;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93924-9;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93924-9;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93925-6;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93925-6;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93925-6;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93926-4;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93926-4;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93926-4;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93927-2;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93927-2;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93927-2;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93928-0;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93928-0;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93928-0;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93930-6;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93930-6;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93930-6;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93934-8;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93934-8;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93934-8;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93935-5;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93935-5;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93935-5;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93936-3;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93936-3;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93936-3;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93937-1;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93937-1;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93937-1;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93938-9;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93938-9;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93938-9;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93940-5;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93940-5;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93940-5;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93942-1;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93942-1;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93942-1;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93943-9;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93943-9;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93943-9;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93944-7;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93944-7;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93944-7;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93945-4;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93945-4;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93945-4;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93946-2;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93946-2;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93946-2;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +93948-8;LL5464-4;Pos|Neg|Double Population;LA30465-1;1;Double population;;; +93948-8;LL5464-4;Pos|Neg|Double Population;LA6576-8;2;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +93948-8;LL5464-4;Pos|Neg|Double Population;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +9397-1;LL3884-5;Stool color;LA25014-4;0;Clay-colored;;; +9397-1;LL3884-5;Stool color;LA25015-1;1;Black, tarry;;; +9397-1;LL3884-5;Stool color;LA25016-9;2;Blood-tinged;;; +9397-1;LL3884-5;Stool color;LA25017-7;3;Blood, frank;;; +9397-1;LL3884-5;Stool color;LA25018-5;4;Bright red stool;;; +9397-1;LL3884-5;Stool color;LA25019-3;5;Dark red stool;;; +9397-1;LL3884-5;Stool color;LA19058-9;6;Brown;;; +9397-1;LL3884-5;Stool color;LA15555-8;7;Green;;; +9397-1;LL3884-5;Stool color;LA17195-1;8;Yellow;;; +9397-1;LL3884-5;Stool color;LA25023-5;9;Orange stool;;; +9397-1;LL3884-5;Stool color;LA25024-3;10;Red streaked stool;;; +94023-9;LL5478-4;Normal|Mild|Moderate|Severe|Very Severe;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +94023-9;LL5478-4;Normal|Mild|Moderate|Severe|Very Severe;LA6752-5;2;Mild;;; +94023-9;LL5478-4;Normal|Mild|Moderate|Severe|Very Severe;LA6751-7;3;Moderate;;; +94023-9;LL5478-4;Normal|Mild|Moderate|Severe|Very Severe;LA6750-9;4;Severe;;; +94023-9;LL5478-4;Normal|Mild|Moderate|Severe|Very Severe;LA13958-6;5;Very severe;;; +94025-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +94025-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6752-5;2;Mild;;; +94025-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6751-7;3;Moderate;;; +94025-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6750-9;4;Severe;;; +94028-8;LL5479-2;Normal|Mild|Moderate|Severe;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +94028-8;LL5479-2;Normal|Mild|Moderate|Severe;LA6752-5;2;Mild;;; +94028-8;LL5479-2;Normal|Mild|Moderate|Severe;LA6751-7;3;Moderate;;; +94028-8;LL5479-2;Normal|Mild|Moderate|Severe;LA6750-9;4;Severe;;; +94030-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +94030-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6752-5;2;Mild;;; +94030-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6751-7;3;Moderate;;; +94030-4;LL5479-2;Normal|Mild|Moderate|Severe;LA6750-9;4;Severe;;; +98973-1;LL5479-2;Normal|Mild|Moderate|Severe;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98973-1;LL5479-2;Normal|Mild|Moderate|Severe;LA6752-5;2;Mild;;; +98973-1;LL5479-2;Normal|Mild|Moderate|Severe;LA6751-7;3;Moderate;;; +98973-1;LL5479-2;Normal|Mild|Moderate|Severe;LA6750-9;4;Severe;;; +94026-2;LL5476-8;Bipolar disorder types;LA30538-5;1;Bipolar disorder, Type 1;;; +94026-2;LL5476-8;Bipolar disorder types;LA30539-3;2;Bipolar disorder, Type 2;;; +94026-2;LL5476-8;Bipolar disorder types;LA30595-5;3;Bipolar disorder, unspecified;;; +94031-2;LL5477-6;ADHD types;LA7546-0;1;Inattention;;; +94031-2;LL5477-6;ADHD types;LA30541-9;2;Hyperactivity-impulsivity;;; +94031-2;LL5477-6;ADHD types;LA30596-3;4;Combined;;; +94036-1;LL5475-0;Suicide risk factors;LA6394-6;1;Thoughts of suicide;;; +94036-1;LL5475-0;Suicide risk factors;LA30536-9;2;Affected by the suicide of another;;; +94036-1;LL5475-0;Suicide risk factors;LA30537-7;3;Past suicide attempts;;; +94036-1;LL5475-0;Suicide risk factors;LA30589-8;4;No thoughts of suicide;;; +94036-1;LL5475-0;Suicide risk factors;LA30590-6;5;Not affected by the suicide of another;;; +94036-1;LL5475-0;Suicide risk factors;LA30591-4;6;No past suicide attempts;;; +94037-9;LL5472-7;Suicide ideations;LA30533-6;1;Thoughts of death several days in the last 2 weeks;;; +94037-9;LL5472-7;Suicide ideations;LA30592-2;2;Thoughts of death more than half the days in the last 2 weeks;;; +94037-9;LL5472-7;Suicide ideations;LA30593-0;3;Thoughts of death nearly everyday in the last 2 weeks;;; +94037-9;LL5472-7;Suicide ideations;LA30534-4;4;Thoughts of their own death;;; +94037-9;LL5472-7;Suicide ideations;LA30594-8;5;No suicidal ideation reported;;; +94041-1;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94041-1;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94041-1;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94041-1;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94042-9;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94042-9;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94042-9;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94042-9;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94043-7;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94043-7;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94043-7;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94043-7;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94044-5;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94044-5;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94044-5;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94044-5;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94045-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94045-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94045-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94045-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94046-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94046-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94046-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94046-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94047-8;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94047-8;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94047-8;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94047-8;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94048-6;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94048-6;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94048-6;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94048-6;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94049-4;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94049-4;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94049-4;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94049-4;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94050-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94050-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94050-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94050-2;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94051-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA30556-7;1;Definitely;;; +94051-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13938-8;2;Mostly;;; +94051-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA13909-9;3;Somewhat;;; +94051-0;LL5474-3;Definitely | Mostly | Somewhat | Not at all;LA6568-5;4;Not at all;;; +94054-4;LL5449-5;katG gene mutations;LA30416-4;1;V1L;;; +94054-4;LL5449-5;katG gene mutations;LA30417-2;2;N138S;;; +94054-4;LL5449-5;katG gene mutations;LA30418-0;3;N138D;;; +94054-4;LL5449-5;katG gene mutations;LA30419-8;4;Y155S;;; +94054-4;LL5449-5;katG gene mutations;LA30420-6;5;W191G;;; +94054-4;LL5449-5;katG gene mutations;LA30421-4;6;W300C;;; +94055-1;LL5448-7;inhA gene mutations;LA30411-5;1;I16T;;; +94055-1;LL5448-7;inhA gene mutations;LA30412-3;2;I21V;;; +94055-1;LL5448-7;inhA gene mutations;LA30413-1;3;S94A;;; +94055-1;LL5448-7;inhA gene mutations;LA30414-9;4;I194T;;; +94055-1;LL5448-7;inhA gene mutations;LA30415-6;5;I194F;;; +94056-9;LL5445-3;fabG1 gene mutations;LA30398-4;1;T-8A;;; +94056-9;LL5445-3;fabG1 gene mutations;LA30399-2;2;T-8C;;; +94056-9;LL5445-3;fabG1 gene mutations;LA30400-8;3;T-8G;;; +94056-9;LL5445-3;fabG1 gene mutations;LA30401-6;4;C-15T;;; +94057-7;LL5443-8;ahpC gene mutations;LA30390-1;1;G-48A;;; +94057-7;LL5443-8;ahpC gene mutations;LA30391-9;2;G-52T;;; +94057-7;LL5443-8;ahpC gene mutations;LA30392-7;3;C-54T;;; +94057-7;LL5443-8;ahpC gene mutations;LA30393-5;4;G-74A;;; +94060-1;LL5447-9;gyrA gene mutations;LA30404-0;1;H70R;;; +94060-1;LL5447-9;gyrA gene mutations;LA30405-7;2;A74S;;; +94060-1;LL5447-9;gyrA gene mutations;LA30406-5;3;T80A;;; +94060-1;LL5447-9;gyrA gene mutations;LA30407-3;4;G88C;;; +94060-1;LL5447-9;gyrA gene mutations;LA30408-1;5;G88A;;; +94060-1;LL5447-9;gyrA gene mutations;LA30409-9;6;D89N;;; +94060-1;LL5447-9;gyrA gene mutations;LA30410-7;7;A90V;;; +94061-9;LL5446-1;gidB gene mutations;LA30402-4;1;S70N;;; +94061-9;LL5446-1;gidB gene mutations;LA30403-2;2;S70R;;; +94062-7;LL5451-1;rrs gene mutations;LA30427-1;1;C513T;;; +94062-7;LL5451-1;rrs gene mutations;LA30428-9;2;A514C;;; +94062-7;LL5451-1;rrs gene mutations;LA30429-7;3;A514T;;; +94062-7;LL5451-1;rrs gene mutations;LA30430-5;4;C517T;;; +94062-7;LL5451-1;rrs gene mutations;LA30431-3;5;C799T;;; +94062-7;LL5451-1;rrs gene mutations;LA30432-1;6;A1401G;;; +94062-7;LL5451-1;rrs gene mutations;LA30433-9;7;C1402A;;; +94062-7;LL5451-1;rrs gene mutations;LA30434-7;8;G1484T;;; +94063-5;LL5450-3;rpsL gene mutations;LA30422-2;1;K43R;;; +94063-5;LL5450-3;rpsL gene mutations;LA30423-0;2;K88T;;; +94063-5;LL5450-3;rpsL gene mutations;LA30424-8;3;K88Q;;; +94063-5;LL5450-3;rpsL gene mutations;LA30425-5;4;K88R;;; +94063-5;LL5450-3;rpsL gene mutations;LA30426-3;5;K43T;;; +94064-3;LL5444-6;eis gene mutations;LA30394-3;1;G-10A;;; +94064-3;LL5444-6;eis gene mutations;LA30395-0;2;C-12T;;; +94064-3;LL5444-6;eis gene mutations;LA30396-8;3;C-14T;;; +94064-3;LL5444-6;eis gene mutations;LA30397-6;4;C-37A;;; +94078-3;LL5483-4;PDX1 gene variants;LA30550-0;7;p.Asp76Asn;;; +94078-3;LL5483-4;PDX1 gene variants;LA30551-8;8;p.Gln59Leu;;; +94078-3;LL5483-4;PDX1 gene variants;LA30552-6;9;p.Glu224Lys;;; +94079-1;LL5482-6;TYMP gene variants;LA30547-6;4;p.Glu289Ala;;; +94079-1;LL5482-6;TYMP gene variants;LA30548-4;5;p.Gly145Arg;;; +94079-1;LL5482-6;TYMP gene variants;LA30549-2;6;p.Val208Met;;; +94080-9;LL5481-8;RRM2B gene variants;LA30544-3;1;c.979C >T;;; +94080-9;LL5481-8;RRM2B gene variants;LA30545-0;2;c.121C>T;;; +94080-9;LL5481-8;RRM2B gene variants;LA30546-8;3;c.329G>A;;; +94084-1;LL5470-1;Non-verbal pain indicators;LA30506-2;1;Activity alteration;129855000;Activity alteration (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30507-0;2;Aggressive behavior;61372001;Aggressive behavior (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA10574-4;3;Anxiety;48694002;Anxiety (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30508-8;4;Change in sleep pattern;;; +94084-1;LL5470-1;Non-verbal pain indicators;LA30509-6;5;Clenching teeth;110302009;Clenching teeth (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30510-4;6;Constant hand movements;;; +94084-1;LL5470-1;Non-verbal pain indicators;LA30511-2;7;Contracted limbs;;; +94084-1;LL5470-1;Non-verbal pain indicators;LA29193-2;8;Crying;304534000;Crying (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30513-8;9;Excessive sweating;52613005;Excessive sweating (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30514-6;10;Eyes open wide;;; +94084-1;LL5470-1;Non-verbal pain indicators;LA30515-3;11;Feeling agitated;24199005;Feeling agitated (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30516-1;12;Feeling irritable;55929007;Feeling irritable (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30517-9;13;Flailing;;; +94084-1;LL5470-1;Non-verbal pain indicators;LA30518-7;14;Frowning;;; +94084-1;LL5470-1;Non-verbal pain indicators;LA30519-5;15;Gasping for breath;23141003;Gasping for breath (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30520-3;16;Grimaces;39960009;Grimaces (disorder);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30521-1;17;Groaning respiration;248575002;Groaning respiration (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30522-9;18;Grunting respiration;62085005;Grunting respiration (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30523-7;19;Loss of appetite;79890006;Loss of appetite (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30524-5;20;Muscle tension;250069006;Muscle tension (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30525-2;21;Pacing up and down;74691006;Pacing up and down (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30526-0;22;Protective muscle spasm;250072004;Protective muscle spasm (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30527-8;23;Repetitive rocking movements;30189004;Repetitive rocking movements (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30528-6;24;Repetitive rubbing of body parts;247939009;Repetitive rubbing of body parts (finding);http://snomed.info/sct +94084-1;LL5470-1;Non-verbal pain indicators;LA30529-4;25;Restlessness;162221009;Restlessness (finding);http://snomed.info/sct +94085-8;LL5471-9;Chest pain | Labor pain | Postoperative pain;LA28842-5;1;Chest pain;29857009;Chest pain (finding);http://snomed.info/sct +94085-8;LL5471-9;Chest pain | Labor pain | Postoperative pain;LA30531-0;2;Labor pain;247412007;Labor pain (finding);http://snomed.info/sct +94085-8;LL5471-9;Chest pain | Labor pain | Postoperative pain;LA30532-8;3;Postoperative pain;213299007;Postoperative pain (finding);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA9203-6;1;Square;56924007;Square (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30493-3;3;Rectangular;59410002;Rectangular (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30494-1;4;Club shape;73847003;Club shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30495-8;5;Dumbbell shape;102281001;Dumbbell shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30496-6;6;Funnel shape;36394000;Funnel shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30497-4;7;Fusiform shape;42620005;Fusiform shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30498-2;8;Horseshoe shape;63068002;Horseshoe shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30499-0;9;J shaped;260666003;J-shaped (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30500-5;10;Ovoid shape;84360004;Ovoid shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30501-3;11;Pear shape;65101006;Pear shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30502-1;12;Quadrangular;30899007;Quadrangular (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30503-9;13;Saddle shape;71712007;Saddle shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30504-7;14;V shaped;255294004;V-shaped (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30505-4;15;Wedge shape;20446002;Wedge shape (qualifier value);http://snomed.info/sct +94086-6;LL5469-3;Wound shapes;LA30557-5;16;Round shape;42700002;Round shape (qualifier value);http://snomed.info/sct +94186-4;LL5489-1;Origin of Genetic Variance;LA26320-4;1;Maternal;;; +94186-4;LL5489-1;Origin of Genetic Variance;LA26321-2;2;Paternal;;; +94186-4;LL5489-1;Origin of Genetic Variance;LA26807-0;6;De novo;;; +94186-4;LL5489-1;Origin of Genetic Variance;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +94186-4;LL5489-1;Origin of Genetic Variance;LA30680-5;10;Parental;;; +94417-3;LL5512-0;5-HTTLPR allele genotype;LA30674-8;1;L/L;;; +94417-3;LL5512-0;5-HTTLPR allele genotype;LA30675-5;2;S/L;;; +94417-3;LL5512-0;5-HTTLPR allele genotype;LA30676-3;3;S/S;;; +94429-8;LL3602-1;HLA class II antibodies;LA23895-8;1;Anti-DP1;;; +94429-8;LL3602-1;HLA class II antibodies;LA23894-1;2;Anti-DP2;;; +94429-8;LL3602-1;HLA class II antibodies;LA23897-4;3;Anti-DP3;;; +94429-8;LL3602-1;HLA class II antibodies;LA23896-6;4;Anti-DP4;;; +94429-8;LL3602-1;HLA class II antibodies;LA23898-2;5;Anti-DP5;;; +94429-8;LL3602-1;HLA class II antibodies;LA23899-0;6;Anti-DP6;;; +94429-8;LL3602-1;HLA class II antibodies;LA23909-7;7;Anti-DQ1;;; +94429-8;LL3602-1;HLA class II antibodies;LA23906-3;8;Anti-DQ2;;; +94429-8;LL3602-1;HLA class II antibodies;LA23907-1;9;Anti-DQ3;;; +94429-8;LL3602-1;HLA class II antibodies;LA23908-9;10;Anti-DQ4;;; +94429-8;LL3602-1;HLA class II antibodies;LA23903-0;11;Anti-DQ5(1);;; +94429-8;LL3602-1;HLA class II antibodies;LA23902-2;12;Anti-DQ6(1);;; +94429-8;LL3602-1;HLA class II antibodies;LA23904-8;13;Anti-DQ7(3);;; +94429-8;LL3602-1;HLA class II antibodies;LA23905-5;14;Anti-DQ8(3);;; +94429-8;LL3602-1;HLA class II antibodies;LA23910-5;15;Anti-DR1;;; +94429-8;LL3602-1;HLA class II antibodies;LA23914-7;16;Anti-DR3;;; +94429-8;LL3602-1;HLA class II antibodies;LA23915-4;17;Anti-DR4;;; +94429-8;LL3602-1;HLA class II antibodies;LA23922-0;18;Anti-DR6;;; +94429-8;LL3602-1;HLA class II antibodies;LA23916-2;19;Anti-DR7;;; +94429-8;LL3602-1;HLA class II antibodies;LA23917-0;20;Anti-DR8;;; +94429-8;LL3602-1;HLA class II antibodies;LA23918-8;21;Anti-DR10;;; +94429-8;LL3602-1;HLA class II antibodies;LA23919-6;22;Anti-DR11(5);;; +94429-8;LL3602-1;HLA class II antibodies;LA23920-4;23;Anti-DR12(5);;; +94429-8;LL3602-1;HLA class II antibodies;LA23921-2;24;Anti-DR13(6);;; +94429-8;LL3602-1;HLA class II antibodies;LA23923-8;25;Anti-DR14(6);;; +94429-8;LL3602-1;HLA class II antibodies;LA23924-6;26;Anti-DR15(2);;; +94429-8;LL3602-1;HLA class II antibodies;LA23925-3;27;Anti-DR16(2);;; +94429-8;LL3602-1;HLA class II antibodies;LA23912-1;28;Anti-DR17(3);;; +94429-8;LL3602-1;HLA class II antibodies;LA23913-9;29;Anti-DR18(3);;; +94429-8;LL3602-1;HLA class II antibodies;LA23927-9;30;Anti-DR51;;; +94429-8;LL3602-1;HLA class II antibodies;LA23926-1;31;Anti-DR52;;; +94429-8;LL3602-1;HLA class II antibodies;LA23928-7;32;Anti-DR53;;; +94429-8;LL3602-1;HLA class II antibodies;LA23911-3;33;Anti-DR103;;; +94432-2;LL3602-1;HLA class II antibodies;LA23895-8;1;Anti-DP1;;; +94432-2;LL3602-1;HLA class II antibodies;LA23894-1;2;Anti-DP2;;; +94432-2;LL3602-1;HLA class II antibodies;LA23897-4;3;Anti-DP3;;; +94432-2;LL3602-1;HLA class II antibodies;LA23896-6;4;Anti-DP4;;; +94432-2;LL3602-1;HLA class II antibodies;LA23898-2;5;Anti-DP5;;; +94432-2;LL3602-1;HLA class II antibodies;LA23899-0;6;Anti-DP6;;; +94432-2;LL3602-1;HLA class II antibodies;LA23909-7;7;Anti-DQ1;;; +94432-2;LL3602-1;HLA class II antibodies;LA23906-3;8;Anti-DQ2;;; +94432-2;LL3602-1;HLA class II antibodies;LA23907-1;9;Anti-DQ3;;; +94432-2;LL3602-1;HLA class II antibodies;LA23908-9;10;Anti-DQ4;;; +94432-2;LL3602-1;HLA class II antibodies;LA23903-0;11;Anti-DQ5(1);;; +94432-2;LL3602-1;HLA class II antibodies;LA23902-2;12;Anti-DQ6(1);;; +94432-2;LL3602-1;HLA class II antibodies;LA23904-8;13;Anti-DQ7(3);;; +94432-2;LL3602-1;HLA class II antibodies;LA23905-5;14;Anti-DQ8(3);;; +94432-2;LL3602-1;HLA class II antibodies;LA23910-5;15;Anti-DR1;;; +94432-2;LL3602-1;HLA class II antibodies;LA23914-7;16;Anti-DR3;;; +94432-2;LL3602-1;HLA class II antibodies;LA23915-4;17;Anti-DR4;;; +94432-2;LL3602-1;HLA class II antibodies;LA23922-0;18;Anti-DR6;;; +94432-2;LL3602-1;HLA class II antibodies;LA23916-2;19;Anti-DR7;;; +94432-2;LL3602-1;HLA class II antibodies;LA23917-0;20;Anti-DR8;;; +94432-2;LL3602-1;HLA class II antibodies;LA23918-8;21;Anti-DR10;;; +94432-2;LL3602-1;HLA class II antibodies;LA23919-6;22;Anti-DR11(5);;; +94432-2;LL3602-1;HLA class II antibodies;LA23920-4;23;Anti-DR12(5);;; +94432-2;LL3602-1;HLA class II antibodies;LA23921-2;24;Anti-DR13(6);;; +94432-2;LL3602-1;HLA class II antibodies;LA23923-8;25;Anti-DR14(6);;; +94432-2;LL3602-1;HLA class II antibodies;LA23924-6;26;Anti-DR15(2);;; +94432-2;LL3602-1;HLA class II antibodies;LA23925-3;27;Anti-DR16(2);;; +94432-2;LL3602-1;HLA class II antibodies;LA23912-1;28;Anti-DR17(3);;; +94432-2;LL3602-1;HLA class II antibodies;LA23913-9;29;Anti-DR18(3);;; +94432-2;LL3602-1;HLA class II antibodies;LA23927-9;30;Anti-DR51;;; +94432-2;LL3602-1;HLA class II antibodies;LA23926-1;31;Anti-DR52;;; +94432-2;LL3602-1;HLA class II antibodies;LA23928-7;32;Anti-DR53;;; +94432-2;LL3602-1;HLA class II antibodies;LA23911-3;33;Anti-DR103;;; +94433-0;LL3602-1;HLA class II antibodies;LA23895-8;1;Anti-DP1;;; +94433-0;LL3602-1;HLA class II antibodies;LA23894-1;2;Anti-DP2;;; +94433-0;LL3602-1;HLA class II antibodies;LA23897-4;3;Anti-DP3;;; +94433-0;LL3602-1;HLA class II antibodies;LA23896-6;4;Anti-DP4;;; +94433-0;LL3602-1;HLA class II antibodies;LA23898-2;5;Anti-DP5;;; +94433-0;LL3602-1;HLA class II antibodies;LA23899-0;6;Anti-DP6;;; +94433-0;LL3602-1;HLA class II antibodies;LA23909-7;7;Anti-DQ1;;; +94433-0;LL3602-1;HLA class II antibodies;LA23906-3;8;Anti-DQ2;;; +94433-0;LL3602-1;HLA class II antibodies;LA23907-1;9;Anti-DQ3;;; +94433-0;LL3602-1;HLA class II antibodies;LA23908-9;10;Anti-DQ4;;; +94433-0;LL3602-1;HLA class II antibodies;LA23903-0;11;Anti-DQ5(1);;; +94433-0;LL3602-1;HLA class II antibodies;LA23902-2;12;Anti-DQ6(1);;; +94433-0;LL3602-1;HLA class II antibodies;LA23904-8;13;Anti-DQ7(3);;; +94433-0;LL3602-1;HLA class II antibodies;LA23905-5;14;Anti-DQ8(3);;; +94433-0;LL3602-1;HLA class II antibodies;LA23910-5;15;Anti-DR1;;; +94433-0;LL3602-1;HLA class II antibodies;LA23914-7;16;Anti-DR3;;; +94433-0;LL3602-1;HLA class II antibodies;LA23915-4;17;Anti-DR4;;; +94433-0;LL3602-1;HLA class II antibodies;LA23922-0;18;Anti-DR6;;; +94433-0;LL3602-1;HLA class II antibodies;LA23916-2;19;Anti-DR7;;; +94433-0;LL3602-1;HLA class II antibodies;LA23917-0;20;Anti-DR8;;; +94433-0;LL3602-1;HLA class II antibodies;LA23918-8;21;Anti-DR10;;; +94433-0;LL3602-1;HLA class II antibodies;LA23919-6;22;Anti-DR11(5);;; +94433-0;LL3602-1;HLA class II antibodies;LA23920-4;23;Anti-DR12(5);;; +94433-0;LL3602-1;HLA class II antibodies;LA23921-2;24;Anti-DR13(6);;; +94433-0;LL3602-1;HLA class II antibodies;LA23923-8;25;Anti-DR14(6);;; +94433-0;LL3602-1;HLA class II antibodies;LA23924-6;26;Anti-DR15(2);;; +94433-0;LL3602-1;HLA class II antibodies;LA23925-3;27;Anti-DR16(2);;; +94433-0;LL3602-1;HLA class II antibodies;LA23912-1;28;Anti-DR17(3);;; +94433-0;LL3602-1;HLA class II antibodies;LA23913-9;29;Anti-DR18(3);;; +94433-0;LL3602-1;HLA class II antibodies;LA23927-9;30;Anti-DR51;;; +94433-0;LL3602-1;HLA class II antibodies;LA23926-1;31;Anti-DR52;;; +94433-0;LL3602-1;HLA class II antibodies;LA23928-7;32;Anti-DR53;;; +94433-0;LL3602-1;HLA class II antibodies;LA23911-3;33;Anti-DR103;;; +94447-0;LL3602-1;HLA class II antibodies;LA23895-8;1;Anti-DP1;;; +94447-0;LL3602-1;HLA class II antibodies;LA23894-1;2;Anti-DP2;;; +94447-0;LL3602-1;HLA class II antibodies;LA23897-4;3;Anti-DP3;;; +94447-0;LL3602-1;HLA class II antibodies;LA23896-6;4;Anti-DP4;;; +94447-0;LL3602-1;HLA class II antibodies;LA23898-2;5;Anti-DP5;;; +94447-0;LL3602-1;HLA class II antibodies;LA23899-0;6;Anti-DP6;;; +94447-0;LL3602-1;HLA class II antibodies;LA23909-7;7;Anti-DQ1;;; +94447-0;LL3602-1;HLA class II antibodies;LA23906-3;8;Anti-DQ2;;; +94447-0;LL3602-1;HLA class II antibodies;LA23907-1;9;Anti-DQ3;;; +94447-0;LL3602-1;HLA class II antibodies;LA23908-9;10;Anti-DQ4;;; +94447-0;LL3602-1;HLA class II antibodies;LA23903-0;11;Anti-DQ5(1);;; +94447-0;LL3602-1;HLA class II antibodies;LA23902-2;12;Anti-DQ6(1);;; +94447-0;LL3602-1;HLA class II antibodies;LA23904-8;13;Anti-DQ7(3);;; +94447-0;LL3602-1;HLA class II antibodies;LA23905-5;14;Anti-DQ8(3);;; +94447-0;LL3602-1;HLA class II antibodies;LA23910-5;15;Anti-DR1;;; +94447-0;LL3602-1;HLA class II antibodies;LA23914-7;16;Anti-DR3;;; +94447-0;LL3602-1;HLA class II antibodies;LA23915-4;17;Anti-DR4;;; +94447-0;LL3602-1;HLA class II antibodies;LA23922-0;18;Anti-DR6;;; +94447-0;LL3602-1;HLA class II antibodies;LA23916-2;19;Anti-DR7;;; +94447-0;LL3602-1;HLA class II antibodies;LA23917-0;20;Anti-DR8;;; +94447-0;LL3602-1;HLA class II antibodies;LA23918-8;21;Anti-DR10;;; +94447-0;LL3602-1;HLA class II antibodies;LA23919-6;22;Anti-DR11(5);;; +94447-0;LL3602-1;HLA class II antibodies;LA23920-4;23;Anti-DR12(5);;; +94447-0;LL3602-1;HLA class II antibodies;LA23921-2;24;Anti-DR13(6);;; +94447-0;LL3602-1;HLA class II antibodies;LA23923-8;25;Anti-DR14(6);;; +94447-0;LL3602-1;HLA class II antibodies;LA23924-6;26;Anti-DR15(2);;; +94447-0;LL3602-1;HLA class II antibodies;LA23925-3;27;Anti-DR16(2);;; +94447-0;LL3602-1;HLA class II antibodies;LA23912-1;28;Anti-DR17(3);;; +94447-0;LL3602-1;HLA class II antibodies;LA23913-9;29;Anti-DR18(3);;; +94447-0;LL3602-1;HLA class II antibodies;LA23927-9;30;Anti-DR51;;; +94447-0;LL3602-1;HLA class II antibodies;LA23926-1;31;Anti-DR52;;; +94447-0;LL3602-1;HLA class II antibodies;LA23928-7;32;Anti-DR53;;; +94447-0;LL3602-1;HLA class II antibodies;LA23911-3;33;Anti-DR103;;; +94448-8;LL3602-1;HLA class II antibodies;LA23895-8;1;Anti-DP1;;; +94448-8;LL3602-1;HLA class II antibodies;LA23894-1;2;Anti-DP2;;; +94448-8;LL3602-1;HLA class II antibodies;LA23897-4;3;Anti-DP3;;; +94448-8;LL3602-1;HLA class II antibodies;LA23896-6;4;Anti-DP4;;; +94448-8;LL3602-1;HLA class II antibodies;LA23898-2;5;Anti-DP5;;; +94448-8;LL3602-1;HLA class II antibodies;LA23899-0;6;Anti-DP6;;; +94448-8;LL3602-1;HLA class II antibodies;LA23909-7;7;Anti-DQ1;;; +94448-8;LL3602-1;HLA class II antibodies;LA23906-3;8;Anti-DQ2;;; +94448-8;LL3602-1;HLA class II antibodies;LA23907-1;9;Anti-DQ3;;; +94448-8;LL3602-1;HLA class II antibodies;LA23908-9;10;Anti-DQ4;;; +94448-8;LL3602-1;HLA class II antibodies;LA23903-0;11;Anti-DQ5(1);;; +94448-8;LL3602-1;HLA class II antibodies;LA23902-2;12;Anti-DQ6(1);;; +94448-8;LL3602-1;HLA class II antibodies;LA23904-8;13;Anti-DQ7(3);;; +94448-8;LL3602-1;HLA class II antibodies;LA23905-5;14;Anti-DQ8(3);;; +94448-8;LL3602-1;HLA class II antibodies;LA23910-5;15;Anti-DR1;;; +94448-8;LL3602-1;HLA class II antibodies;LA23914-7;16;Anti-DR3;;; +94448-8;LL3602-1;HLA class II antibodies;LA23915-4;17;Anti-DR4;;; +94448-8;LL3602-1;HLA class II antibodies;LA23922-0;18;Anti-DR6;;; +94448-8;LL3602-1;HLA class II antibodies;LA23916-2;19;Anti-DR7;;; +94448-8;LL3602-1;HLA class II antibodies;LA23917-0;20;Anti-DR8;;; +94448-8;LL3602-1;HLA class II antibodies;LA23918-8;21;Anti-DR10;;; +94448-8;LL3602-1;HLA class II antibodies;LA23919-6;22;Anti-DR11(5);;; +94448-8;LL3602-1;HLA class II antibodies;LA23920-4;23;Anti-DR12(5);;; +94448-8;LL3602-1;HLA class II antibodies;LA23921-2;24;Anti-DR13(6);;; +94448-8;LL3602-1;HLA class II antibodies;LA23923-8;25;Anti-DR14(6);;; +94448-8;LL3602-1;HLA class II antibodies;LA23924-6;26;Anti-DR15(2);;; +94448-8;LL3602-1;HLA class II antibodies;LA23925-3;27;Anti-DR16(2);;; +94448-8;LL3602-1;HLA class II antibodies;LA23912-1;28;Anti-DR17(3);;; +94448-8;LL3602-1;HLA class II antibodies;LA23913-9;29;Anti-DR18(3);;; +94448-8;LL3602-1;HLA class II antibodies;LA23927-9;30;Anti-DR51;;; +94448-8;LL3602-1;HLA class II antibodies;LA23926-1;31;Anti-DR52;;; +94448-8;LL3602-1;HLA class II antibodies;LA23928-7;32;Anti-DR53;;; +94448-8;LL3602-1;HLA class II antibodies;LA23911-3;33;Anti-DR103;;; +97999-7;LL3602-1;HLA class II antibodies;LA23895-8;1;Anti-DP1;;; +97999-7;LL3602-1;HLA class II antibodies;LA23894-1;2;Anti-DP2;;; +97999-7;LL3602-1;HLA class II antibodies;LA23897-4;3;Anti-DP3;;; +97999-7;LL3602-1;HLA class II antibodies;LA23896-6;4;Anti-DP4;;; +97999-7;LL3602-1;HLA class II antibodies;LA23898-2;5;Anti-DP5;;; +97999-7;LL3602-1;HLA class II antibodies;LA23899-0;6;Anti-DP6;;; +97999-7;LL3602-1;HLA class II antibodies;LA23909-7;7;Anti-DQ1;;; +97999-7;LL3602-1;HLA class II antibodies;LA23906-3;8;Anti-DQ2;;; +97999-7;LL3602-1;HLA class II antibodies;LA23907-1;9;Anti-DQ3;;; +97999-7;LL3602-1;HLA class II antibodies;LA23908-9;10;Anti-DQ4;;; +97999-7;LL3602-1;HLA class II antibodies;LA23903-0;11;Anti-DQ5(1);;; +97999-7;LL3602-1;HLA class II antibodies;LA23902-2;12;Anti-DQ6(1);;; +97999-7;LL3602-1;HLA class II antibodies;LA23904-8;13;Anti-DQ7(3);;; +97999-7;LL3602-1;HLA class II antibodies;LA23905-5;14;Anti-DQ8(3);;; +97999-7;LL3602-1;HLA class II antibodies;LA23910-5;15;Anti-DR1;;; +97999-7;LL3602-1;HLA class II antibodies;LA23914-7;16;Anti-DR3;;; +97999-7;LL3602-1;HLA class II antibodies;LA23915-4;17;Anti-DR4;;; +97999-7;LL3602-1;HLA class II antibodies;LA23922-0;18;Anti-DR6;;; +97999-7;LL3602-1;HLA class II antibodies;LA23916-2;19;Anti-DR7;;; +97999-7;LL3602-1;HLA class II antibodies;LA23917-0;20;Anti-DR8;;; +97999-7;LL3602-1;HLA class II antibodies;LA23918-8;21;Anti-DR10;;; +97999-7;LL3602-1;HLA class II antibodies;LA23919-6;22;Anti-DR11(5);;; +97999-7;LL3602-1;HLA class II antibodies;LA23920-4;23;Anti-DR12(5);;; +97999-7;LL3602-1;HLA class II antibodies;LA23921-2;24;Anti-DR13(6);;; +97999-7;LL3602-1;HLA class II antibodies;LA23923-8;25;Anti-DR14(6);;; +97999-7;LL3602-1;HLA class II antibodies;LA23924-6;26;Anti-DR15(2);;; +97999-7;LL3602-1;HLA class II antibodies;LA23925-3;27;Anti-DR16(2);;; +97999-7;LL3602-1;HLA class II antibodies;LA23912-1;28;Anti-DR17(3);;; +97999-7;LL3602-1;HLA class II antibodies;LA23913-9;29;Anti-DR18(3);;; +97999-7;LL3602-1;HLA class II antibodies;LA23927-9;30;Anti-DR51;;; +97999-7;LL3602-1;HLA class II antibodies;LA23926-1;31;Anti-DR52;;; +97999-7;LL3602-1;HLA class II antibodies;LA23928-7;32;Anti-DR53;;; +97999-7;LL3602-1;HLA class II antibodies;LA23911-3;33;Anti-DR103;;; +94430-6;LL5520-3;HLA class I antibodies;LA23858-6;1;Anti-A1;;; +94430-6;LL5520-3;HLA class I antibodies;LA23859-4;2;Anti-A2;;; +94430-6;LL5520-3;HLA class I antibodies;LA23860-2;3;Anti-A3;;; +94430-6;LL5520-3;HLA class I antibodies;LA23861-0;4;Anti-A9;;; +94430-6;LL5520-3;HLA class I antibodies;LA23863-6;5;Anti-A11;;; +94430-6;LL5520-3;HLA class I antibodies;LA23864-4;6;Anti-A28;;; +94430-6;LL5520-3;HLA class I antibodies;LA23865-1;7;Anti-A29;;; +94430-6;LL5520-3;HLA class I antibodies;LA23870-1;8;Anti-B7;;; +94430-6;LL5520-3;HLA class I antibodies;LA23872-7;9;Anti-B12;;; +94430-6;LL5520-3;HLA class I antibodies;LA23873-5;10;Anti-B13;;; +94430-6;LL5520-3;HLA class I antibodies;LA23876-8;11;Anti-B22;;; +94430-6;LL5520-3;HLA class I antibodies;LA23877-6;12;Anti-B27;;; +94430-6;LL5520-3;HLA class I antibodies;LA23878-4;13;Anti-B35;;; +94430-6;LL5520-3;HLA class I antibodies;LA23880-0;14;Anti-B41;;; +94430-6;LL5520-3;HLA class I antibodies;LA23886-7;15;Anti-Cw1;;; +94430-6;LL5520-3;HLA class I antibodies;LA23888-3;16;Anti-Cw4;;; +94430-6;LL5520-3;HLA class I antibodies;LA23889-1;17;Anti-Cw5;;; +94430-6;LL5520-3;HLA class I antibodies;LA23890-9;18;Anti-Cw3;;; +94430-6;LL5520-3;HLA class I antibodies;LA23892-5;19;Anti-Cw7;;; +94441-3;LL5520-3;HLA class I antibodies;LA23858-6;1;Anti-A1;;; +94441-3;LL5520-3;HLA class I antibodies;LA23859-4;2;Anti-A2;;; +94441-3;LL5520-3;HLA class I antibodies;LA23860-2;3;Anti-A3;;; +94441-3;LL5520-3;HLA class I antibodies;LA23861-0;4;Anti-A9;;; +94441-3;LL5520-3;HLA class I antibodies;LA23863-6;5;Anti-A11;;; +94441-3;LL5520-3;HLA class I antibodies;LA23864-4;6;Anti-A28;;; +94441-3;LL5520-3;HLA class I antibodies;LA23865-1;7;Anti-A29;;; +94441-3;LL5520-3;HLA class I antibodies;LA23870-1;8;Anti-B7;;; +94441-3;LL5520-3;HLA class I antibodies;LA23872-7;9;Anti-B12;;; +94441-3;LL5520-3;HLA class I antibodies;LA23873-5;10;Anti-B13;;; +94441-3;LL5520-3;HLA class I antibodies;LA23876-8;11;Anti-B22;;; +94441-3;LL5520-3;HLA class I antibodies;LA23877-6;12;Anti-B27;;; +94441-3;LL5520-3;HLA class I antibodies;LA23878-4;13;Anti-B35;;; +94441-3;LL5520-3;HLA class I antibodies;LA23880-0;14;Anti-B41;;; +94441-3;LL5520-3;HLA class I antibodies;LA23886-7;15;Anti-Cw1;;; +94441-3;LL5520-3;HLA class I antibodies;LA23888-3;16;Anti-Cw4;;; +94441-3;LL5520-3;HLA class I antibodies;LA23889-1;17;Anti-Cw5;;; +94441-3;LL5520-3;HLA class I antibodies;LA23890-9;18;Anti-Cw3;;; +94441-3;LL5520-3;HLA class I antibodies;LA23892-5;19;Anti-Cw7;;; +94442-1;LL5520-3;HLA class I antibodies;LA23858-6;1;Anti-A1;;; +94442-1;LL5520-3;HLA class I antibodies;LA23859-4;2;Anti-A2;;; +94442-1;LL5520-3;HLA class I antibodies;LA23860-2;3;Anti-A3;;; +94442-1;LL5520-3;HLA class I antibodies;LA23861-0;4;Anti-A9;;; +94442-1;LL5520-3;HLA class I antibodies;LA23863-6;5;Anti-A11;;; +94442-1;LL5520-3;HLA class I antibodies;LA23864-4;6;Anti-A28;;; +94442-1;LL5520-3;HLA class I antibodies;LA23865-1;7;Anti-A29;;; +94442-1;LL5520-3;HLA class I antibodies;LA23870-1;8;Anti-B7;;; +94442-1;LL5520-3;HLA class I antibodies;LA23872-7;9;Anti-B12;;; +94442-1;LL5520-3;HLA class I antibodies;LA23873-5;10;Anti-B13;;; +94442-1;LL5520-3;HLA class I antibodies;LA23876-8;11;Anti-B22;;; +94442-1;LL5520-3;HLA class I antibodies;LA23877-6;12;Anti-B27;;; +94442-1;LL5520-3;HLA class I antibodies;LA23878-4;13;Anti-B35;;; +94442-1;LL5520-3;HLA class I antibodies;LA23880-0;14;Anti-B41;;; +94442-1;LL5520-3;HLA class I antibodies;LA23886-7;15;Anti-Cw1;;; +94442-1;LL5520-3;HLA class I antibodies;LA23888-3;16;Anti-Cw4;;; +94442-1;LL5520-3;HLA class I antibodies;LA23889-1;17;Anti-Cw5;;; +94442-1;LL5520-3;HLA class I antibodies;LA23890-9;18;Anti-Cw3;;; +94442-1;LL5520-3;HLA class I antibodies;LA23892-5;19;Anti-Cw7;;; +94449-6;LL5520-3;HLA class I antibodies;LA23858-6;1;Anti-A1;;; +94449-6;LL5520-3;HLA class I antibodies;LA23859-4;2;Anti-A2;;; +94449-6;LL5520-3;HLA class I antibodies;LA23860-2;3;Anti-A3;;; +94449-6;LL5520-3;HLA class I antibodies;LA23861-0;4;Anti-A9;;; +94449-6;LL5520-3;HLA class I antibodies;LA23863-6;5;Anti-A11;;; +94449-6;LL5520-3;HLA class I antibodies;LA23864-4;6;Anti-A28;;; +94449-6;LL5520-3;HLA class I antibodies;LA23865-1;7;Anti-A29;;; +94449-6;LL5520-3;HLA class I antibodies;LA23870-1;8;Anti-B7;;; +94449-6;LL5520-3;HLA class I antibodies;LA23872-7;9;Anti-B12;;; +94449-6;LL5520-3;HLA class I antibodies;LA23873-5;10;Anti-B13;;; +94449-6;LL5520-3;HLA class I antibodies;LA23876-8;11;Anti-B22;;; +94449-6;LL5520-3;HLA class I antibodies;LA23877-6;12;Anti-B27;;; +94449-6;LL5520-3;HLA class I antibodies;LA23878-4;13;Anti-B35;;; +94449-6;LL5520-3;HLA class I antibodies;LA23880-0;14;Anti-B41;;; +94449-6;LL5520-3;HLA class I antibodies;LA23886-7;15;Anti-Cw1;;; +94449-6;LL5520-3;HLA class I antibodies;LA23888-3;16;Anti-Cw4;;; +94449-6;LL5520-3;HLA class I antibodies;LA23889-1;17;Anti-Cw5;;; +94449-6;LL5520-3;HLA class I antibodies;LA23890-9;18;Anti-Cw3;;; +94449-6;LL5520-3;HLA class I antibodies;LA23892-5;19;Anti-Cw7;;; +94450-4;LL5520-3;HLA class I antibodies;LA23858-6;1;Anti-A1;;; +94450-4;LL5520-3;HLA class I antibodies;LA23859-4;2;Anti-A2;;; +94450-4;LL5520-3;HLA class I antibodies;LA23860-2;3;Anti-A3;;; +94450-4;LL5520-3;HLA class I antibodies;LA23861-0;4;Anti-A9;;; +94450-4;LL5520-3;HLA class I antibodies;LA23863-6;5;Anti-A11;;; +94450-4;LL5520-3;HLA class I antibodies;LA23864-4;6;Anti-A28;;; +94450-4;LL5520-3;HLA class I antibodies;LA23865-1;7;Anti-A29;;; +94450-4;LL5520-3;HLA class I antibodies;LA23870-1;8;Anti-B7;;; +94450-4;LL5520-3;HLA class I antibodies;LA23872-7;9;Anti-B12;;; +94450-4;LL5520-3;HLA class I antibodies;LA23873-5;10;Anti-B13;;; +94450-4;LL5520-3;HLA class I antibodies;LA23876-8;11;Anti-B22;;; +94450-4;LL5520-3;HLA class I antibodies;LA23877-6;12;Anti-B27;;; +94450-4;LL5520-3;HLA class I antibodies;LA23878-4;13;Anti-B35;;; +94450-4;LL5520-3;HLA class I antibodies;LA23880-0;14;Anti-B41;;; +94450-4;LL5520-3;HLA class I antibodies;LA23886-7;15;Anti-Cw1;;; +94450-4;LL5520-3;HLA class I antibodies;LA23888-3;16;Anti-Cw4;;; +94450-4;LL5520-3;HLA class I antibodies;LA23889-1;17;Anti-Cw5;;; +94450-4;LL5520-3;HLA class I antibodies;LA23890-9;18;Anti-Cw3;;; +94450-4;LL5520-3;HLA class I antibodies;LA23892-5;19;Anti-Cw7;;; +98003-7;LL5520-3;HLA class I antibodies;LA23858-6;1;Anti-A1;;; +98003-7;LL5520-3;HLA class I antibodies;LA23859-4;2;Anti-A2;;; +98003-7;LL5520-3;HLA class I antibodies;LA23860-2;3;Anti-A3;;; +98003-7;LL5520-3;HLA class I antibodies;LA23861-0;4;Anti-A9;;; +98003-7;LL5520-3;HLA class I antibodies;LA23863-6;5;Anti-A11;;; +98003-7;LL5520-3;HLA class I antibodies;LA23864-4;6;Anti-A28;;; +98003-7;LL5520-3;HLA class I antibodies;LA23865-1;7;Anti-A29;;; +98003-7;LL5520-3;HLA class I antibodies;LA23870-1;8;Anti-B7;;; +98003-7;LL5520-3;HLA class I antibodies;LA23872-7;9;Anti-B12;;; +98003-7;LL5520-3;HLA class I antibodies;LA23873-5;10;Anti-B13;;; +98003-7;LL5520-3;HLA class I antibodies;LA23876-8;11;Anti-B22;;; +98003-7;LL5520-3;HLA class I antibodies;LA23877-6;12;Anti-B27;;; +98003-7;LL5520-3;HLA class I antibodies;LA23878-4;13;Anti-B35;;; +98003-7;LL5520-3;HLA class I antibodies;LA23880-0;14;Anti-B41;;; +98003-7;LL5520-3;HLA class I antibodies;LA23886-7;15;Anti-Cw1;;; +98003-7;LL5520-3;HLA class I antibodies;LA23888-3;16;Anti-Cw4;;; +98003-7;LL5520-3;HLA class I antibodies;LA23889-1;17;Anti-Cw5;;; +98003-7;LL5520-3;HLA class I antibodies;LA23890-9;18;Anti-Cw3;;; +98003-7;LL5520-3;HLA class I antibodies;LA23892-5;19;Anti-Cw7;;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30743-1;1;Anti-DP1 (DPA1*01:03, DPB1*01:01);;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30744-9;2;Anti-DP1 (DPA1*02:01, DPB1*01:01);;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30745-6;3;Anti-DP3 (DPA1*01:05, DPB1*03:01);;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30746-4;4;Anti-DP5 (DPA1*02:01, DPB1*05:01);;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30747-2;5;Anti-DP28 (DPA1*01:03, DPB1*28:01);;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30748-0;6;Anti-DP13 (DPA1*02:01, DPB1*13:01);;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30749-8;7;Anti-DP14 (DPA1*02:01, DPB1*14:01);;; +94434-8;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30750-6;8;Anti-DP15 (DPA1*02:01, DPB1*15:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30743-1;1;Anti-DP1 (DPA1*01:03, DPB1*01:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30744-9;2;Anti-DP1 (DPA1*02:01, DPB1*01:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30745-6;3;Anti-DP3 (DPA1*01:05, DPB1*03:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30746-4;4;Anti-DP5 (DPA1*02:01, DPB1*05:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30747-2;5;Anti-DP28 (DPA1*01:03, DPB1*28:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30748-0;6;Anti-DP13 (DPA1*02:01, DPB1*13:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30749-8;7;Anti-DP14 (DPA1*02:01, DPB1*14:01);;; +94435-5;LL5531-0;HLA-DPA1 & DPB1 antibodies SAB;LA30750-6;8;Anti-DP15 (DPA1*02:01, DPB1*15:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30735-7;1;Anti-DQ2 (DQA1*02:01, DQB1*02:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30736-5;2;Anti-DQ2 (DQA1*03:01, DQB1*02:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30737-3;3;Anti-DQ4 (DQA1*02:01, DQB1*04:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30738-1;4;Anti-DQ4 (DQA1*03:03, DQB1*04:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30739-9;5;Anti-DQ5 (DQA1*01:01, DQB1*05:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30740-7;6;Anti-DQ7 (DQA1*05:03, DQB1*03:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30741-5;7;Anti-DQ7 (DQA1*05:05, DQB1*03:01);;; +94436-3;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30742-3;8;Anti-DQ9 (DQA1*02:01, DQB1*03:03);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30735-7;1;Anti-DQ2 (DQA1*02:01, DQB1*02:01);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30736-5;2;Anti-DQ2 (DQA1*03:01, DQB1*02:01);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30737-3;3;Anti-DQ4 (DQA1*02:01, DQB1*04:01);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30738-1;4;Anti-DQ4 (DQA1*03:03, DQB1*04:01);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30739-9;5;Anti-DQ5 (DQA1*01:01, DQB1*05:01);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30740-7;6;Anti-DQ7 (DQA1*05:03, DQB1*03:01);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30741-5;7;Anti-DQ7 (DQA1*05:05, DQB1*03:01);;; +94437-1;LL5530-2;HLA-DQA1 & DQB1 antibodies SAB;LA30742-3;8;Anti-DQ9 (DQA1*02:01, DQB1*03:03);;; +94438-9;LL5528-6;HLA-DRB3,4,5 antibodies;LA30720-9;33;Anti-DR52 (DRB3*01:01);;; +94438-9;LL5528-6;HLA-DRB3,4,5 antibodies;LA30721-7;34;Anti-DR52 (DRB3*02:02);;; +94438-9;LL5528-6;HLA-DRB3,4,5 antibodies;LA30722-5;35;Anti-DR52 (DRB3*03:01);;; +94438-9;LL5528-6;HLA-DRB3,4,5 antibodies;LA30723-3;36;Anti-DR53 (DRB4*01:01);;; +94438-9;LL5528-6;HLA-DRB3,4,5 antibodies;LA30724-1;37;Anti-DR53 (DRB4*01:03);;; +94438-9;LL5528-6;HLA-DRB3,4,5 antibodies;LA30725-8;38;Anti-DR51 (DRB5*01:01);;; +94438-9;LL5528-6;HLA-DRB3,4,5 antibodies;LA30726-6;39;Anti-DR51 (DRB5*02:02);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30727-4;1;Anti-DR1 (DRB1*01:02);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30728-2;2;Anti-DR4 (DRB1*04:01);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30729-0;3;Anti-DR4 (DRB1*04:02);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30730-8;4;Anti-DR7 (DRB1*07:01);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30731-6;5;Anti-DR9 (DRB1*09:01);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30732-4;6;Anti-DR10 (DRB1*10:01);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30733-2;7;Anti-DR15 (DRB1*15:01);;; +94439-7;LL5529-4;HLA-DRB1 antibodies single antigen beads;LA30734-0;8;Anti-DR15 (DRB1*15:02);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30712-6;25;Anti-Cw1 (C*01:02);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30713-4;26;Anti-Cw10 (C*03:02);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30714-2;27;Anti-Cw10 (C*03:04);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30715-9;28;Anti-Cw4 (C*04:01);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30716-7;29;Anti-Cw5 (C*05:01);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30717-5;30;Anti-Cw12 (C*12:03);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30718-3;31;Anti-Cw15 (C*15:02);;; +94443-9;LL5527-8;HLA-C antibodies to support single antigen beads;LA30719-1;32;Anti-Cw16 (C*16:01);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30704-3;17;Anti-B7 (B*07:02);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30705-0;18;Anti-B75 (B*15:02);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30706-8;19;Anti-B18 (B*18:01);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30707-6;20;Anti-B27 (B*27:08);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30708-4;21;Anti-B37 (B*37:01);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30709-2;22;Anti-B57 (B*57:01);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30710-0;23;Anti-B57 (B*57:03);;; +94444-7;LL5526-0;HLA-B antibodies to support single antigen beads;LA30711-8;24;Anti-B82 (B*82:01);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30696-1;9;Anti-A2 (A*02:01);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30697-9;10;Anti-A2 (A*02:03);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30698-7;11;Anti-A11 (A*11:01);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30699-5;12;Anti-A25 (A*25:01);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30700-1;13;Anti-A29 (A*29:02);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30701-9;14;Anti-A36 (A*36:01);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30702-7;15;Anti-A68 (A*68:02);;; +94445-4;LL5522-9;HLA-A antibodies to support single antigen beads;LA30703-5;16;Anti-A74 (A*74:01);;; +94472-8;LL5513-8;Genotypes C/C, C/T, C/G, T/T, G/G;LA13521-2;1;C/C (wild type);;; +94472-8;LL5513-8;Genotypes C/C, C/T, C/G, T/T, G/G;LA13522-0;2;C/T (heterozygous);;; +94472-8;LL5513-8;Genotypes C/C, C/T, C/G, T/T, G/G;LA21535-2;3;C/G (heterozygous);;; +94472-8;LL5513-8;Genotypes C/C, C/T, C/G, T/T, G/G;LA13523-8;4;T/T (homozygous);;; +94472-8;LL5513-8;Genotypes C/C, C/T, C/G, T/T, G/G;LA20174-1;5;G/G (homozygous);;; +94473-6;LL5514-6;Genotypes A/A, A/C, C/C, A/T, T/T;LA21537-8;1;A/A (wild type);;; +94473-6;LL5514-6;Genotypes A/A, A/C, C/C, A/T, T/T;LA29485-2;2;A/C (heterozygous);;; +94473-6;LL5514-6;Genotypes A/A, A/C, C/C, A/T, T/T;LA21507-1;3;A/T (heterozygous);;; +94473-6;LL5514-6;Genotypes A/A, A/C, C/C, A/T, T/T;LA21506-3;4;C/C (homozygous);;; +94473-6;LL5514-6;Genotypes A/A, A/C, C/C, A/T, T/T;LA13523-8;5;T/T (homozygous);;; +94495-9;LL5548-4;HLA-DQA1 molecular typing;LA30821-5;1;HLA-DQA1*02:01;;; +94495-9;LL5548-4;HLA-DQA1 molecular typing;LA30822-3;2;HLA-DQA1*03;;; +94495-9;LL5548-4;HLA-DQA1 molecular typing;LA30823-1;3;HLA-DQA1*05;;; +94495-9;LL5548-4;HLA-DQA1 molecular typing;LA30824-9;4;HLA-DQA1*01:01:01:06;;; +94512-1;LL5519-5;Staphylococcus aureus and MRSA;LA30691-2;1;MRSA positive, SA positive;;; +94512-1;LL5519-5;Staphylococcus aureus and MRSA;LA30692-0;2;MRSA negative, SA positive;;; +94512-1;LL5519-5;Staphylococcus aureus and MRSA;LA30693-8;3;MRSA negative, SA negative;;; +94512-1;LL5519-5;Staphylococcus aureus and MRSA;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +94536-0;LL5549-2;Black | Blonde | Brown | Red | Gray;LA4267-6;1;Black;;; +94536-0;LL5549-2;Black | Blonde | Brown | Red | Gray;LA30825-6;2;Blonde;;; +94536-0;LL5549-2;Black | Blonde | Brown | Red | Gray;LA19058-9;3;Brown;;; +94536-0;LL5549-2;Black | Blonde | Brown | Red | Gray;LA17193-6;4;Red;;; +94536-0;LL5549-2;Black | Blonde | Brown | Red | Gray;LA15554-1;5;Grey;;; +94542-8;LL5516-1;Leprosy Types;LA30695-3;1;Lepromatous leprosy;21560005;Lepromatous leprosy (disorder);http://snomed.info/sct +94542-8;LL5516-1;Leprosy Types;LA30694-6;2;Borderline lepromatous leprosy;240403008;Borderline lepromatous leprosy (disorder);http://snomed.info/sct +94542-8;LL5516-1;Leprosy Types;LA30682-1;3;Tuberculoid leprosy;70143003;Tuberculoid leprosy (disorder);http://snomed.info/sct +94542-8;LL5516-1;Leprosy Types;LA30683-9;4;Borderline tuberculoid leprosy;240402003;Borderline tuberculoid leprosy (disorder);http://snomed.info/sct +94542-8;LL5516-1;Leprosy Types;LA30684-7;5;Indeterminate leprosy;14386001;Indeterminate leprosy (disorder);http://snomed.info/sct +94542-8;LL5516-1;Leprosy Types;LA30685-4;6;Borderline leprosy;400008009;Borderline leprosy (disorder);http://snomed.info/sct +94542-8;LL5516-1;Leprosy Types;LA30686-2;7;Other forms of leprosy;;; +94542-8;LL5516-1;Leprosy Types;LA14093-1;8;Unspecified;;; +94544-4;LL5515-3;Exposure source;LA30681-3;1;Animal;;; +94544-4;LL5515-3;Exposure source;LA14387-7;2;Water;11713004;Water (substance);http://snomed.info/sct +94544-4;LL5515-3;Exposure source;LA30103-8;3;Paint;;; +94544-4;LL5515-3;Exposure source;LA30105-3;4;Soil;;; +94544-4;LL5515-3;Exposure source;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +94734-1;LL5543-5;ISUP grade;LA30794-4;1;ISUP Grade (Grade Group) 1 (Gleason score <=6);;; +94734-1;LL5543-5;ISUP grade;LA30795-1;2;ISUP Grade (Grade Group) 2 (Gleason score 3+4=7);;; +94734-1;LL5543-5;ISUP grade;LA30796-9;3;ISUP Grade (Grade Group) 3 (Gleason score 4+3=7);;; +94734-1;LL5543-5;ISUP grade;LA30797-7;4;ISUP Grade (Grade Group) 4 (Gleason score 8);;; +94734-1;LL5543-5;ISUP grade;LA30798-5;5;ISUP Grade (Group Group) 5 (Gleason score 9-10);;; +94734-1;LL5543-5;ISUP grade;LA11884-6;6;Indeterminate;82334004;Indeterminate (qualifier value);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30774-6;1;Lateral middle regional part of peripheral zone of right half prostate;716968002;Entire lateral middle regional part of peripheral zone of right half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30775-3;2;Apical part of peripheral zone of right half prostate;716985000;Entire apical part of peripheral zone of right half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30776-1;3;Middle regional part of anterior fibromuscular stroma of right half prostate;716960009;Entire middle regional part of anterior fibromuscular stroma of right half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30777-9;4;Basal part of anterior fibromuscular stroma of right half prostate;716943004;Entire basal part of anterior fibromuscular stroma of right half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30778-7;5;Middle regional part of transition zone of right half prostate;716962001;Entire middle regional part of transition zone of right half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30779-5;6;Lateral middle regional part of peripheral zone of left half prostate;716969005;Entire lateral middle regional part of peripheral zone of left half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30780-3;7;Apical part of peripheral zone of left half prostate;716986004;Entire apical part of peripheral zone of left half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30781-1;8;Basal part of anterior fibromuscular stroma of left half prostate;716944005;Entire basal part of anterior fibromuscular stroma of left half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30782-9;9;Middle regional part of transition zone of left half prostate;716963006;Entire middle regional part of transition zone of left half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30783-7;10;Basal part of peripheral zone of right half prostate;716953003;Entire basal part of peripheral zone of right half prostate (body structure);http://snomed.info/sct +94738-2;LL5538-5;Prostate sites;LA30784-5;11;Basal part of peripheral zone of left half prostate;716954009;Entire basal part of peripheral zone of left half prostate (body structure);http://snomed.info/sct +94739-0;LL5537-7;ISUP grade sample basis;LA30769-6;1;Based on largest tumor nodule;;; +94739-0;LL5537-7;ISUP grade sample basis;LA30772-0;2;Based on highest grade tumor;;; +94739-0;LL5537-7;ISUP grade sample basis;LA30773-8;3;Based on composite (global) grade;;; +94740-8;LL5536-9;Gleason score sample basis;LA30769-6;1;Based on largest tumor nodule;;; +94740-8;LL5536-9;Gleason score sample basis;LA30770-4;2;Based on highest tumor score;;; +94740-8;LL5536-9;Gleason score sample basis;LA30771-2;3;Based on composite (global) score;;; +94742-4;LL5562-5;Disease stage classification methods;LA30877-7;1;COVID-19 Clinical-Therapeutic Staging ©2020 ISHLT;;; +94742-4;LL5562-5;Disease stage classification methods;LA30886-8;2;WHO Clinical Staging System for HIV/AIDS;;; +94742-4;LL5562-5;Disease stage classification methods;LA30887-6;3;Modified Glaucoma Staging System (Modified GSS);;; +94742-4;LL5562-5;Disease stage classification methods;LA30888-4;4;Enhanced Glaucoma Staging System (Enhanced GSS);;; +94742-4;LL5562-5;Disease stage classification methods;LA30889-2;5;Revised International Staging System (RISS) for multiple myeloma;;; +94742-4;LL5562-5;Disease stage classification methods;LA30890-0;6;National Pressure Ulcer Staging System;;; +94847-1;LL5563-3;Reasons specimen not collected;LA30878-5;1;Physical limitation;;; +94847-1;LL5563-3;Reasons specimen not collected;LA30879-3;2;Participant ill or emergency;;; +94847-1;LL5563-3;Reasons specimen not collected;LA30880-1;3;Collection supplies malfunctioned;;; +94847-1;LL5563-3;Reasons specimen not collected;LA30881-9;4;Language issue;;; +94847-1;LL5563-3;Reasons specimen not collected;LA30882-7;5;No time;;; +94847-1;LL5563-3;Reasons specimen not collected;LA10058-8;6;Patient refused;;; +94847-1;LL5563-3;Reasons specimen not collected;LA46-8;7;Other;;; +94879-4;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94879-4;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94879-4;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94879-4;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94879-4;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94880-2;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94880-2;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94880-2;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94880-2;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94880-2;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94881-0;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94881-0;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94881-0;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94881-0;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94881-0;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94882-8;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94882-8;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94882-8;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94882-8;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94882-8;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94883-6;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94883-6;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94883-6;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94883-6;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94883-6;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94884-4;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94884-4;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94884-4;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94884-4;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94884-4;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94885-1;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94885-1;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94885-1;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94885-1;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94885-1;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94886-9;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94886-9;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94886-9;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94886-9;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94886-9;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94887-7;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94887-7;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94887-7;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94887-7;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94887-7;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94888-5;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94888-5;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94888-5;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94888-5;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94888-5;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94889-3;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94889-3;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94889-3;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94889-3;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94889-3;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94890-1;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94890-1;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94890-1;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94890-1;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94890-1;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94891-9;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94891-9;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94891-9;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94891-9;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94891-9;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94892-7;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94892-7;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94892-7;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94892-7;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94892-7;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94893-5;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94893-5;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94893-5;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94893-5;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94893-5;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94894-3;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94894-3;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94894-3;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94894-3;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94894-3;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94895-0;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94895-0;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94895-0;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94895-0;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94895-0;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94896-8;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94896-8;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94896-8;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94896-8;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94896-8;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94897-6;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94897-6;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94897-6;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94897-6;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94897-6;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94898-4;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94898-4;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94898-4;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94898-4;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94898-4;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94899-2;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94899-2;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94899-2;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94899-2;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94899-2;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94900-8;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94900-8;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94900-8;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94900-8;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94900-8;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94901-6;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94901-6;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94901-6;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94901-6;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94901-6;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94902-4;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94902-4;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94902-4;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94902-4;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94902-4;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94903-2;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94903-2;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94903-2;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94903-2;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94903-2;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94904-0;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94904-0;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94904-0;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94904-0;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94904-0;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94905-7;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94905-7;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94905-7;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94905-7;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94905-7;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94906-5;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94906-5;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94906-5;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94906-5;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94906-5;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94907-3;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94907-3;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94907-3;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94907-3;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94907-3;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94908-1;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94908-1;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94908-1;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94908-1;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94908-1;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94910-7;LL5572-4;CMS FASI Assistive Devices;LA30918-9;1;Assistive device needed and available - Person needs this device to complete daily activities and has the device in the home.;;; +94910-7;LL5572-4;CMS FASI Assistive Devices;LA30919-7;2;Assistive device needed but current device unsuitable - Device is in home but no longer meets person's needs.;;; +94910-7;LL5572-4;CMS FASI Assistive Devices;LA30920-5;3;Assistive device needed but not available - Person needs the device but it is not available in the home.;;; +94910-7;LL5572-4;CMS FASI Assistive Devices;LA30921-3;4;Person refused - Person chooses to not use needed device.;;; +94910-7;LL5572-4;CMS FASI Assistive Devices;LA30922-1;5;Not applicable - Person does not need this device.;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30948-6;1;Stair glide;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30949-4;2;Pillbox;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30950-2;3;Cognitive aids, such as computer or electrical assistive devices to aid in memory, attention or other cognitive challenges;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30951-0;4;Voice recognition program;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30952-8;5;Computer or device screen reader;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30953-6;6;Computer screen enlargement applications;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30954-4;7;Automatic page turners;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30955-1;8;Book holder;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30956-9;9;Adapted pencil grips;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30957-7;10;Adaptive switches;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30948-6;1;Stair glide;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30949-4;2;Pillbox;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30950-2;3;Cognitive aids, such as computer or electrical assistive devices to aid in memory, attention or other cognitive challenges;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30951-0;4;Voice recognition program;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30952-8;5;Computer or device screen reader;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30953-6;6;Computer screen enlargement applications;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30954-4;7;Automatic page turners;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30955-1;8;Book holder;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30956-9;9;Adapted pencil grips;;; +94909-9;LL5581-5;CMS FASI Example Assistive Devices;LA30957-7;10;Adaptive switches;;; +94913-1;LL5577-3;CMS FASI Level of Assistance;LA12345-7;1;No assistance received;;; +94913-1;LL5577-3;CMS FASI Level of Assistance;LA30934-6;2;Occasional/short term assistance;;; +94913-1;LL5577-3;CMS FASI Level of Assistance;LA30935-3;3;Regular night-time;;; +94913-1;LL5577-3;CMS FASI Level of Assistance;LA12164-2;4;Regular daytime;;; +94913-1;LL5577-3;CMS FASI Level of Assistance;LA12163-4;5;Around the clock;;; +94914-9;LL5577-3;CMS FASI Level of Assistance;LA12345-7;1;No assistance received;;; +94914-9;LL5577-3;CMS FASI Level of Assistance;LA30934-6;2;Occasional/short term assistance;;; +94914-9;LL5577-3;CMS FASI Level of Assistance;LA30935-3;3;Regular night-time;;; +94914-9;LL5577-3;CMS FASI Level of Assistance;LA12164-2;4;Regular daytime;;; +94914-9;LL5577-3;CMS FASI Level of Assistance;LA12163-4;5;Around the clock;;; +94915-6;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94915-6;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94915-6;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94915-6;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94915-6;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94915-6;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94915-6;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94916-4;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94916-4;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94916-4;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94916-4;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94916-4;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94916-4;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94916-4;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94917-2;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94917-2;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94917-2;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94917-2;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94917-2;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94917-2;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94917-2;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94918-0;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94918-0;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94918-0;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94918-0;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94918-0;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94918-0;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94918-0;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94919-8;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94919-8;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94919-8;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94919-8;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94919-8;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94919-8;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94919-8;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94920-6;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94920-6;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94920-6;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94920-6;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94920-6;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94920-6;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94920-6;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94921-4;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94921-4;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94921-4;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94921-4;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94921-4;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94921-4;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94921-4;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94922-2;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94922-2;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94922-2;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94922-2;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94922-2;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94922-2;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94922-2;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94923-0;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94923-0;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94923-0;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94923-0;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94923-0;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94923-0;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94923-0;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94924-8;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94924-8;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94924-8;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94924-8;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94924-8;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94924-8;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94924-8;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94925-5;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94925-5;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94925-5;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94925-5;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94925-5;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94925-5;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94925-5;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94926-3;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94926-3;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94926-3;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94926-3;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94926-3;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94926-3;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94926-3;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94927-1;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94927-1;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94927-1;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94927-1;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94927-1;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94927-1;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94927-1;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94928-9;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94928-9;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94928-9;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94928-9;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94928-9;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94928-9;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94928-9;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94929-7;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94929-7;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94929-7;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94929-7;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94929-7;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94929-7;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94929-7;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94930-5;LL5578-1;CMS FASI Assistance Availability;LA30938-7;1;Assistance not needed - No assistance needed.;;; +94930-5;LL5578-1;CMS FASI Assistance Availability;LA30939-5;2;Caregiver(s) currently provide assistance - Person's usual caregiver(s) willing and able to provide needed assistance.;;; +94930-5;LL5578-1;CMS FASI Assistance Availability;LA30940-3;3;Caregiver(s) need training/supportive services to provide assistance - Caregiver(s) available and need assistance to provide support.;;; +94930-5;LL5578-1;CMS FASI Assistance Availability;LA30941-1;4;Unclear if caregiver(s) will provide assistance - Caregiver(s) available in the home but it is not clear if caregiver(s) will provide needed assistance.;;; +94930-5;LL5578-1;CMS FASI Assistance Availability;LA30942-9;5;Assistance needed but no caregiver(s) available - Person needs assistance but no caregiver(s) available in the home.;;; +94930-5;LL5578-1;CMS FASI Assistance Availability;LA30943-7;6;Assistance needed but person declines assistance - Person needs caregiving but declines this assistance.;;; +94930-5;LL5578-1;CMS FASI Assistance Availability;LA30944-5;7;Not applicable - Person does not do this activity.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94933-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94934-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94935-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94936-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94937-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94938-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94939-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94940-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94941-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94942-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94943-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94944-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94945-3;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94946-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94947-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94948-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94949-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94950-3;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94951-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94952-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94953-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94954-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94955-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94956-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94957-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94958-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94959-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94960-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94961-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94962-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94963-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94964-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94965-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94966-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94967-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94968-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94969-3;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94970-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94971-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94972-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94973-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94974-3;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94976-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94977-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94978-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94979-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94980-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94981-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94982-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94983-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94984-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94985-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94986-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94987-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94989-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94990-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94991-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94992-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94993-3;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94994-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94995-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94996-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94997-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94998-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +94999-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95000-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95001-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95002-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95003-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95004-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95005-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95006-3;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95007-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95008-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95009-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95010-5;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95011-3;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95012-1;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95013-9;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95014-7;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95015-4;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95016-2;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95017-0;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95018-8;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95019-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA30909-8;1;Independent - Person completes the activity by themself with no assistance from a helper.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA30910-6;2;"Setup or cleanup assistance - Helper sets up or cleans up; person completes activity. Helper assists only prior to or following the activity.";;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA30911-4;3;Supervision or touching assistance - Helper provides verbal cues and/or touching/steadying and/or contact guard assistance as person completes activity. Assistance may be provided throughout the activity or intermittently.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA10055-4;4;Partial/moderate assistance - Helper does less than half the effort. Helper lifts, holds or supports trunk or limbs, but provides less than half the effort.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA11759-0;5;Substantial/maximal assistance - Helper does more than half the effort. Helper lifts or holds trunk or limbs and provides more than half the effort.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA30914-8;6;Dependent - Helper does all of the effort. Person does none of the effort to complete the activity. Or, the assistance of 2 or more helpers is required for the person to complete the activity.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA30915-5;7;Person refused.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA30916-3;8;Not applicable - Person does not usually do this activity.;;; +95043-6;LL5571-6;CMS FASI Self-care and Mobility;LA30917-1;9;Not attempted due to short-term medical condition or safety concerns.;;; +94975-0;LL5574-0;CMS FASI Living arrangements;LA30925-4;1;Person lives alone - no other residents in the home.;;; +94975-0;LL5574-0;CMS FASI Living arrangements;LA30926-2;2;Person lives with others in the home - for example, family, friends, or paid caregiver.;;; +94975-0;LL5574-0;CMS FASI Living arrangements;LA30927-0;3;Person lives in congregate home - for example, assisted living, or residential care home.;;; +94975-0;LL5574-0;CMS FASI Living arrangements;LA30928-8;4;Person does not have a permanent home or is homeless.;;; +94975-0;LL5574-0;CMS FASI Living arrangements;LA30929-6;5;Person was in a medical facility.;;; +94988-3;LL5574-0;CMS FASI Living arrangements;LA30925-4;1;Person lives alone - no other residents in the home.;;; +94988-3;LL5574-0;CMS FASI Living arrangements;LA30926-2;2;Person lives with others in the home - for example, family, friends, or paid caregiver.;;; +94988-3;LL5574-0;CMS FASI Living arrangements;LA30927-0;3;Person lives in congregate home - for example, assisted living, or residential care home.;;; +94988-3;LL5574-0;CMS FASI Living arrangements;LA30928-8;4;Person does not have a permanent home or is homeless.;;; +94988-3;LL5574-0;CMS FASI Living arrangements;LA30929-6;5;Person was in a medical facility.;;; +95038-6;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95038-6;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95038-6;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95038-6;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95040-2;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95040-2;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95040-2;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95040-2;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95046-9;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95046-9;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95046-9;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95046-9;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95047-7;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95047-7;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95047-7;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95047-7;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95048-5;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95048-5;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95048-5;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95048-5;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95050-1;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95050-1;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95050-1;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95050-1;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95051-9;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95051-9;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95051-9;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95051-9;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95208-5;LL5521-1;Yes/No/Unk/Not Assessed;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95208-5;LL5521-1;Yes/No/Unk/Not Assessed;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95208-5;LL5521-1;Yes/No/Unk/Not Assessed;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95208-5;LL5521-1;Yes/No/Unk/Not Assessed;LA9348-9;4;Not assessed;;; +95039-4;LL5541-9;Catheter type;LA30787-8;1;Chest tube;;; +95039-4;LL5541-9;Catheter type;LA30790-2;2;Urinary;;; +95039-4;LL5541-9;Catheter type;LA9440-4;3;Nasogastric;;; +95039-4;LL5541-9;Catheter type;LA9437-0;4;Intravenous;;; +95039-4;LL5541-9;Catheter type;LA30789-4;5;Intraosseous;;; +95045-1;LL5540-1;Entrapment;LA30786-0;1;Yes - by accident;;; +95045-1;LL5540-1;Entrapment;LA30785-2;2;Yes - by natural disaster;;; +95045-1;LL5540-1;Entrapment;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +95045-1;LL5540-1;Entrapment;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95045-1;LL5540-1;Entrapment;LA9348-9;5;Not assessed;;; +95049-3;LL5547-6;Bag-mask-ventilation;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95049-3;LL5547-6;Bag-mask-ventilation;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95049-3;LL5547-6;Bag-mask-ventilation;LA4489-6;3;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95049-3;LL5547-6;Bag-mask-ventilation;LA9348-9;4;Not assessed;;; +95049-3;LL5547-6;Bag-mask-ventilation;LA30818-1;5;Controlled bag-mask ventilation;;; +95049-3;LL5547-6;Bag-mask-ventilation;LA30819-9;6;Assisted bag-mask ventilation;;; +95049-3;LL5547-6;Bag-mask-ventilation;LA30820-7;7;Bag-mask ventilation not possible;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA30807-4;1;Feedback system;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA30808-2;2;Mechanical thorax compression system;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA30809-0;3;12 channel ECG/EKG;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA30813-2;4;Radio transmission of ECG/EKG;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA30810-8;5;External pacemaker;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA30811-6;6;Syringe pump;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA30812-4;7;Cardioversion;;; +95052-7;LL5545-0;EMS Mechanical Technology;LA15415-5;8;Ultrasound;;; +95143-4;LL5560-9;UGT1A1 TA Repeat Genotype;LA30473-5;1;Homozygous *36 (TA5/TA5);;; +95143-4;LL5560-9;UGT1A1 TA Repeat Genotype;LA30474-3;2;Heterozygous *36 (TA5/TA6);;; +95143-4;LL5560-9;UGT1A1 TA Repeat Genotype;LA30475-0;3;Heterozygous *36 and Heterozygous *28 (TA5/TA7);;; +95143-4;LL5560-9;UGT1A1 TA Repeat Genotype;LA30477-6;4;Heterozygous *28 (TA6/TA7);;; +95143-4;LL5560-9;UGT1A1 TA Repeat Genotype;LA30478-4;5;Homozygous *28 (TA7/TA7);;; +95143-4;LL5560-9;UGT1A1 TA Repeat Genotype;LA30876-9;6;Homozygous *37 (TA8/TA8);;; +95232-5;LL5587-2;Microalb_SQ;LA30974-2;2;Microalbumin normal;;; +95232-5;LL5587-2;Microalb_SQ;LA30975-9;3;Microalbumin 1+;;; +95232-5;LL5587-2;Microalb_SQ;LA30976-7;4;Microalbumin 2+;;; +95232-5;LL5587-2;Microalb_SQ;LA30977-5;5;Microalbumin 3+;;; +95232-5;LL5587-2;Microalb_SQ;LA31053-4;6;Microalbumin 4+;;; +95233-3;LL5566-6;Normal|Abnormal|High Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +95233-3;LL5566-6;Normal|Abnormal|High Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +95233-3;LL5566-6;Normal|Abnormal|High Abnormal;LA30896-7;3;High abnormal;;; +98121-7;LL5566-6;Normal|Abnormal|High Abnormal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98121-7;LL5566-6;Normal|Abnormal|High Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +98121-7;LL5566-6;Normal|Abnormal|High Abnormal;LA30896-7;3;High abnormal;;; +95247-3;LL5583-1;U.S. Household Food Security Survey Module.HH1;LA30964-3;1;Enough of the kinds of food we want to eat;;; +95247-3;LL5583-1;U.S. Household Food Security Survey Module.HH1;LA30965-0;2;Enough but not always the kinds of food we want;;; +95247-3;LL5583-1;U.S. Household Food Security Survey Module.HH1;LA30966-8;3;Sometimes not enough to eat;;; +95247-3;LL5583-1;U.S. Household Food Security Survey Module.HH1;LA30967-6;4;Often not enough to eat;;; +95247-3;LL5583-1;U.S. Household Food Security Survey Module.HH1;LA30968-4;5;DK or Refused;;; +95249-9;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95249-9;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95249-9;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95251-5;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95251-5;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95251-5;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95252-3;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95252-3;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95252-3;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95253-1;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95253-1;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95253-1;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95254-9;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95254-9;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95254-9;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95259-8;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95259-8;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95259-8;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95261-4;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95261-4;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95261-4;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95262-2;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95262-2;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95262-2;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95265-5;LL5584-9;Yes | No | DK;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95265-5;LL5584-9;Yes | No | DK;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95265-5;LL5584-9;Yes | No | DK;LA14226-7;3;DK;;; +95250-7;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30970-0;1;Almost every month;;; +95250-7;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30971-8;2;Some months but not every month;;; +95250-7;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30972-6;3;Only 1 or 2 months;;; +95250-7;LL5585-6;Almost every month | Some months | Only 1 or 2;LA14226-7;4;DK;;; +95255-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30970-0;1;Almost every month;;; +95255-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30971-8;2;Some months but not every month;;; +95255-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30972-6;3;Only 1 or 2 months;;; +95255-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA14226-7;4;DK;;; +95260-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30970-0;1;Almost every month;;; +95260-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30971-8;2;Some months but not every month;;; +95260-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA30972-6;3;Only 1 or 2 months;;; +95260-6;LL5585-6;Almost every month | Some months | Only 1 or 2;LA14226-7;4;DK;;; +95264-8;LL5588-0;High food security | Marginal | Low | Very low;LA30983-3;1;High food security;;; +95264-8;LL5588-0;High food security | Marginal | Low | Very low;LA30984-1;2;Marginal food security;;; +95264-8;LL5588-0;High food security | Marginal | Low | Very low;LA30985-8;3;Low food security;;; +95264-8;LL5588-0;High food security | Marginal | Low | Very low;LA30986-6;4;Very low food security;;; +95268-9;LL5592-2;Clinical factors affecting result interpretation;LA31020-3;1;IVIG therapy in the past month;;; +95268-9;LL5592-2;Clinical factors affecting result interpretation;LA31021-1;2;Platelet transfusion in the last 3 days;;; +95268-9;LL5592-2;Clinical factors affecting result interpretation;LA16931-0;3;Steroid treatment;;; +95268-9;LL5592-2;Clinical factors affecting result interpretation;LA28199-0;4;Anticoagulant therapy;;; +95268-9;LL5592-2;Clinical factors affecting result interpretation;LA17976-4;5;Supplemental oxygen;;; +95290-3;LL5575-7;Diopter increment;LA31062-5;1;0.01 diop;;; +95290-3;LL5575-7;Diopter increment;LA30932-0;2;0.06 diop;;; +95290-3;LL5575-7;Diopter increment;LA30930-4;3;0.12 diop;;; +95290-3;LL5575-7;Diopter increment;LA30931-2;4;0.25 diop;;; +95299-4;LL5575-7;Diopter increment;LA31062-5;1;0.01 diop;;; +95299-4;LL5575-7;Diopter increment;LA30932-0;2;0.06 diop;;; +95299-4;LL5575-7;Diopter increment;LA30930-4;3;0.12 diop;;; +95299-4;LL5575-7;Diopter increment;LA30931-2;4;0.25 diop;;; +95320-8;LL5575-7;Diopter increment;LA31062-5;1;0.01 diop;;; +95320-8;LL5575-7;Diopter increment;LA30932-0;2;0.06 diop;;; +95320-8;LL5575-7;Diopter increment;LA30930-4;3;0.12 diop;;; +95320-8;LL5575-7;Diopter increment;LA30931-2;4;0.25 diop;;; +95323-2;LL5575-7;Diopter increment;LA31062-5;1;0.01 diop;;; +95323-2;LL5575-7;Diopter increment;LA30932-0;2;0.06 diop;;; +95323-2;LL5575-7;Diopter increment;LA30930-4;3;0.12 diop;;; +95323-2;LL5575-7;Diopter increment;LA30931-2;4;0.25 diop;;; +95291-1;LL5576-5;Axis increment;LA31063-3;3;1 degree;;; +95291-1;LL5576-5;Axis increment;LA31064-1;4;5 degrees;;; +95300-0;LL5576-5;Axis increment;LA31063-3;3;1 degree;;; +95300-0;LL5576-5;Axis increment;LA31064-1;4;5 degrees;;; +95321-6;LL5576-5;Axis increment;LA31063-3;3;1 degree;;; +95321-6;LL5576-5;Axis increment;LA31064-1;4;5 degrees;;; +95292-9;LL5573-2;Mode +/-/mix;LA30924-7;1;-;;; +95292-9;LL5573-2;Mode +/-/mix;LA30923-9;2;+;;; +95292-9;LL5573-2;Mode +/-/mix;LA11840-8;3;Mixed;;; +95301-8;LL5573-2;Mode +/-/mix;LA30924-7;1;-;;; +95301-8;LL5573-2;Mode +/-/mix;LA30923-9;2;+;;; +95301-8;LL5573-2;Mode +/-/mix;LA11840-8;3;Mixed;;; +95322-4;LL5573-2;Mode +/-/mix;LA30924-7;1;-;;; +95322-4;LL5573-2;Mode +/-/mix;LA30923-9;2;+;;; +95322-4;LL5573-2;Mode +/-/mix;LA11840-8;3;Mixed;;; +98371-8;LL5573-2;Mode +/-/mix;LA30924-7;1;-;;; +98371-8;LL5573-2;Mode +/-/mix;LA30923-9;2;+;;; +98371-8;LL5573-2;Mode +/-/mix;LA11840-8;3;Mixed;;; +98433-6;LL5573-2;Mode +/-/mix;LA30924-7;1;-;;; +98433-6;LL5573-2;Mode +/-/mix;LA30923-9;2;+;;; +98433-6;LL5573-2;Mode +/-/mix;LA11840-8;3;Mixed;;; +98462-5;LL5573-2;Mode +/-/mix;LA30924-7;1;-;;; +98462-5;LL5573-2;Mode +/-/mix;LA30923-9;2;+;;; +98462-5;LL5573-2;Mode +/-/mix;LA11840-8;3;Mixed;;; +95293-7;LL5593-0;Ophthalmology Device Mode;LA31023-7;1;CAT (Cataract);;; +95293-7;LL5593-0;Ophthalmology Device Mode;LA31024-5;2;IOL (Intraocular Lens);;; +95293-7;LL5593-0;Ophthalmology Device Mode;LA31025-2;3;REF (Refractometer);;; +95293-7;LL5593-0;Ophthalmology Device Mode;LA31026-0;4;KRT (Keratometer);;; +95319-0;LL5567-4;Lens type;LA30899-1;1;Standard lens;;; +95319-0;LL5567-4;Lens type;LA30959-3;2;Bifocal lens;;; +95319-0;LL5567-4;Lens type;LA30958-5;3;Multifocal lens;;; +95319-0;LL5567-4;Lens type;LA30898-3;4;Progressive lens;;; +95319-0;LL5567-4;Lens type;LA30961-9;5;Framed lens;;; +95319-0;LL5567-4;Lens type;LA30960-1;6;Single lens;;; +95319-0;LL5567-4;Lens type;LA30897-5;7;Contact lens;;; +95324-0;LL5564-1;Prism mode;LA26227-1;1;Off;;; +95324-0;LL5564-1;Prism mode;LA30891-8;2;P-B;;; +95324-0;LL5564-1;Prism mode;LA30892-6;3;X-Y;;; +95365-3;LL5595-5;Reason for case classification;LA31029-4;1;Meets clinical criteria AND epidemiologic evidence with no confirmatory lab testing;;; +95365-3;LL5595-5;Reason for case classification;LA31030-2;2;Meets presumptive lab evidence AND either clinical criteria OR epidemiologic evidence;;; +95365-3;LL5595-5;Reason for case classification;LA31031-0;3;Meets vital records criteria with no confirmatory lab testing;;; +95372-9;LL5600-3;Workplace example answers;LA6218-7;1;Hospital;;; +95372-9;LL5600-3;Workplace example answers;LA6357-3;2;Rehabilitation facility;;; +95372-9;LL5600-3;Workplace example answers;LA31050-0;3;Grocery store;;; +95372-9;LL5600-3;Workplace example answers;LA31051-8;4;Bank;;; +95374-5;LL5601-1;Critical infrastructure;LA31049-2;1;Healthcare facility;;; +95374-5;LL5601-1;Critical infrastructure;LA31050-0;2;Grocery store;;; +95374-5;LL5601-1;Critical infrastructure;LA31054-2;3;Emergency services;;; +95374-5;LL5601-1;Critical infrastructure;LA31055-9;4;Financial institution;;; +95374-5;LL5601-1;Critical infrastructure;LA31056-7;5;Government facilities;;; +95374-5;LL5601-1;Critical infrastructure;LA31058-3;6;Critical manufacturing;;; +95375-2;LL5597-1;U.S. Case contact;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95375-2;LL5597-1;U.S. Case contact;LA31032-8;2;No, this person was an international case and contact occurred abroad;;; +95375-2;LL5597-1;U.S. Case contact;LA31033-6;3;Unknown if U.S. or international case;;; +95376-0;LL5598-9;Animal exposure;LA31034-4;1;Bat;;; +95376-0;LL5598-9;Animal exposure;LA14178-0;2;Dog;;; +95376-0;LL5598-9;Animal exposure;LA31036-9;3;Pig;;; +95376-0;LL5598-9;Animal exposure;LA31038-5;4;Rodent;;; +95376-0;LL5598-9;Animal exposure;LA31039-3;5;Goat;;; +95376-0;LL5598-9;Animal exposure;LA31040-1;6;Reptile;;; +95376-0;LL5598-9;Animal exposure;LA31041-9;7;Cow;;; +95376-0;LL5598-9;Animal exposure;LA31042-7;8;Horse;;; +95376-0;LL5598-9;Animal exposure;LA46-8;9;Other;;; +95376-0;LL5598-9;Animal exposure;LA4489-6;10;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95377-8;LL5599-7;Disability type;LA31043-5;1;Neurologic disability;;; +95377-8;LL5599-7;Disability type;LA31044-3;2;Neurodevelopment disability;;; +95377-8;LL5599-7;Disability type;LA29576-8;3;Intellectual disability;;; +95377-8;LL5599-7;Disability type;LA31046-8;4;Physical disability;;; +95377-8;LL5599-7;Disability type;LA31047-6;5;Vision impairment;;; +95377-8;LL5599-7;Disability type;LA16989-8;6;Hearing impairment;;; +95383-6;LL5603-7;Still symptomatic | Symptoms resolved | Uk;LA31059-1;1;Still symptomatic;;; +95383-6;LL5603-7;Still symptomatic | Symptoms resolved | Uk;LA31060-9;2;Symptoms resolved;;; +95383-6;LL5603-7;Still symptomatic | Symptoms resolved | Uk;LA31061-7;3;Unknown if symptoms resolved;;; +95384-4;LL5558-3;Symptoms;LA30863-7;1;Chills;;; +95384-4;LL5558-3;Symptoms;LA30864-5;2;Limp or worn out;;; +95384-4;LL5558-3;Symptoms;LA30865-2;3;Aching limbs;;; +95384-4;LL5558-3;Symptoms;LA30866-0;4;Persistent cough;;; +95384-4;LL5558-3;Symptoms;LA15475-9;5;Cold;;; +95384-4;LL5558-3;Symptoms;LA15424-7;6;Diarrhea;62315008;Diarrhea (finding);http://snomed.info/sct +95384-4;LL5558-3;Symptoms;LA30867-8;7;Sore throat;;; +95384-4;LL5558-3;Symptoms;LA15903-0;8;Headache;;; +95384-4;LL5558-3;Symptoms;LA30868-6;9;Out of breath;;; +95384-4;LL5558-3;Symptoms;LA30869-4;10;Loss of taste or smell;;; +95387-7;LL5559-1;SEEK Impression;LA30870-2;1;Parental depression;;; +95387-7;LL5559-1;SEEK Impression;LA30871-0;2;Parental substance abuse;;; +95387-7;LL5559-1;SEEK Impression;LA30872-8;3;Major parental stress;;; +95387-7;LL5559-1;SEEK Impression;LA30873-6;4;Intimate partner violence;;; +95387-7;LL5559-1;SEEK Impression;LA30874-4;5;Food insecurity;;; +95387-7;LL5559-1;SEEK Impression;LA30875-1;6;Harsh punishment;;; +95399-2;LL4730-9;Often true|Sometimes true|Never true|DK;LA28397-0;1;Often true;;; +95399-2;LL4730-9;Often true|Sometimes true|Never true|DK;LA6729-3;2;Sometimes true;;; +95399-2;LL4730-9;Often true|Sometimes true|Never true|DK;LA28398-8;3;Never true;;; +95399-2;LL4730-9;Often true|Sometimes true|Never true|DK;LA15775-2;4;Don't know/refused;;; +95400-8;LL4730-9;Often true|Sometimes true|Never true|DK;LA28397-0;1;Often true;;; +95400-8;LL4730-9;Often true|Sometimes true|Never true|DK;LA6729-3;2;Sometimes true;;; +95400-8;LL4730-9;Often true|Sometimes true|Never true|DK;LA28398-8;3;Never true;;; +95400-8;LL4730-9;Often true|Sometimes true|Never true|DK;LA15775-2;4;Don't know/refused;;; +95417-2;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95417-2;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95417-2;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA31066-6;4;Refused to answer;;; +95417-2;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA20384-6;5;Asked but unknown;;; +95417-2;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95418-0;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95418-0;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95418-0;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA31066-6;4;Refused to answer;;; +95418-0;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA20384-6;5;Asked but unknown;;; +95418-0;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95419-8;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95419-8;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95419-8;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA31066-6;4;Refused to answer;;; +95419-8;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA20384-6;5;Asked but unknown;;; +95419-8;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95420-6;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95420-6;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95420-6;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA31066-6;4;Refused to answer;;; +95420-6;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA20384-6;5;Asked but unknown;;; +95420-6;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95421-4;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95421-4;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +95421-4;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA31066-6;4;Refused to answer;;; +95421-4;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA20384-6;5;Asked but unknown;;; +95421-4;LL5605-2;Yes|No|Refused to answer|Asked Unk|Unk;LA4489-6;6;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +95423-0;LL5604-5;SARS-CoV-2|FLUAV|FLUAB|Not det|Unsat|Invalid;LA11919-0;1;Influenza A virus;407479009;Influenza A virus (organism);http://snomed.info/sct +95423-0;LL5604-5;SARS-CoV-2|FLUAV|FLUAB|Not det|Unsat|Invalid;LA13543-6;2;Influenza B virus;407480007;Influenza B virus (organism);http://snomed.info/sct +95423-0;LL5604-5;SARS-CoV-2|FLUAV|FLUAB|Not det|Unsat|Invalid;LA31065-8;3;SARS coronavirus 2;840533007;Severe acute respiratory syndrome coronavirus 2 (organism);http://snomed.info/sct +95423-0;LL5604-5;SARS-CoV-2|FLUAV|FLUAB|Not det|Unsat|Invalid;LA11883-8;4;Not detected;;; +95423-0;LL5604-5;SARS-CoV-2|FLUAV|FLUAB|Not det|Unsat|Invalid;LA13548-5;5;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +95423-0;LL5604-5;SARS-CoV-2|FLUAV|FLUAB|Not det|Unsat|Invalid;LA15841-2;6;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95425-5;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11882-0;1;Detected;;; +95425-5;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11883-8;2;Not detected;;; +95425-5;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95425-5;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95608-6;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11882-0;1;Detected;;; +95608-6;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11883-8;2;Not detected;;; +95608-6;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95608-6;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95609-4;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11882-0;1;Detected;;; +95609-4;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11883-8;2;Not detected;;; +95609-4;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95609-4;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95823-1;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11882-0;1;Detected;;; +95823-1;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11883-8;2;Not detected;;; +95823-1;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95823-1;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95824-9;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11882-0;1;Detected;;; +95824-9;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA11883-8;2;Not detected;;; +95824-9;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA9663-1;3;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +95824-9;LL5508-8;Detected|Not det|Inconclusive|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +95426-3;LL5608-6;Impairment of independence;LA31078-1;1;Minor impairment of independence;;; +95426-3;LL5608-6;Impairment of independence;LA31079-9;2;Considerable impairment of independence;;; +95426-3;LL5608-6;Impairment of independence;LA31080-7;3;Severe impairment of independence;;; +95426-3;LL5608-6;Impairment of independence;LA31081-5;4;Severely impaired independence;;; +95430-5;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95430-5;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95430-5;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95430-5;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95430-5;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95431-3;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95431-3;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95431-3;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95431-3;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95431-3;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95432-1;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95432-1;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95432-1;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95432-1;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95432-1;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95433-9;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95433-9;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95433-9;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95433-9;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95433-9;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95434-7;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95434-7;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95434-7;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95434-7;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95434-7;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95435-4;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95435-4;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95435-4;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95435-4;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95435-4;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95436-2;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95436-2;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95436-2;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95436-2;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95436-2;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95437-0;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95437-0;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95437-0;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95437-0;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95437-0;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95438-8;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95438-8;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95438-8;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95438-8;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95438-8;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95439-6;LL5626-8;NIDA-Modified ASSIST Q2;LA6270-8;1;Never;;; +95439-6;LL5626-8;NIDA-Modified ASSIST Q2;LA26460-8;2;Once or twice;;; +95439-6;LL5626-8;NIDA-Modified ASSIST Q2;LA18876-5;3;Monthly;;; +95439-6;LL5626-8;NIDA-Modified ASSIST Q2;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95439-6;LL5626-8;NIDA-Modified ASSIST Q2;LA18934-2;5;Daily or almost daily;;; +95440-4;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95440-4;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95440-4;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95440-4;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95440-4;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95441-2;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95441-2;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95441-2;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95441-2;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95441-2;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95442-0;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95442-0;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95442-0;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95442-0;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95442-0;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95443-8;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95443-8;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95443-8;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95443-8;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95443-8;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95444-6;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95444-6;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95444-6;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95444-6;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95444-6;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95445-3;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95445-3;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95445-3;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95445-3;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95445-3;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95446-1;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95446-1;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95446-1;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95446-1;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95446-1;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95447-9;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95447-9;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95447-9;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95447-9;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95447-9;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95448-7;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95448-7;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95448-7;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95448-7;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95448-7;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95449-5;LL5627-6;NIDA-Modified ASSIST Q3;LA6270-8;1;Never;;; +95449-5;LL5627-6;NIDA-Modified ASSIST Q3;LA26460-8;2;Once or twice;;; +95449-5;LL5627-6;NIDA-Modified ASSIST Q3;LA18876-5;3;Monthly;;; +95449-5;LL5627-6;NIDA-Modified ASSIST Q3;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95449-5;LL5627-6;NIDA-Modified ASSIST Q3;LA18934-2;5;Daily or almost daily;;; +95450-3;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95450-3;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95450-3;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95450-3;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95450-3;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95451-1;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95451-1;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95451-1;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95451-1;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95451-1;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95452-9;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95452-9;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95452-9;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95452-9;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95452-9;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95453-7;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95453-7;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95453-7;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95453-7;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95453-7;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95454-5;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95454-5;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95454-5;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95454-5;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95454-5;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95455-2;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95455-2;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95455-2;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95455-2;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95455-2;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95456-0;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95456-0;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95456-0;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95456-0;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95456-0;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95457-8;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95457-8;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95457-8;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95457-8;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95457-8;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95458-6;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95458-6;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95458-6;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95458-6;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95458-6;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95459-4;LL5628-4;NIDA-Modified ASSIST Q4;LA6270-8;1;Never;;; +95459-4;LL5628-4;NIDA-Modified ASSIST Q4;LA26460-8;2;Once or twice;;; +95459-4;LL5628-4;NIDA-Modified ASSIST Q4;LA18876-5;3;Monthly;;; +95459-4;LL5628-4;NIDA-Modified ASSIST Q4;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95459-4;LL5628-4;NIDA-Modified ASSIST Q4;LA18934-2;5;Daily or almost daily;;; +95460-2;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95460-2;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95460-2;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95460-2;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95460-2;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95461-0;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95461-0;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95461-0;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95461-0;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95461-0;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95462-8;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95462-8;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95462-8;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95462-8;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95462-8;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95463-6;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95463-6;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95463-6;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95463-6;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95463-6;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95464-4;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95464-4;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95464-4;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95464-4;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95464-4;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95465-1;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95465-1;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95465-1;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95465-1;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95465-1;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95466-9;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95466-9;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95466-9;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95466-9;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95466-9;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95467-7;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95467-7;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95467-7;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95467-7;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95467-7;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95468-5;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95468-5;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95468-5;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95468-5;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95468-5;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95469-3;LL5629-2;NIDA-Modified ASSIST Q5;LA6270-8;1;Never;;; +95469-3;LL5629-2;NIDA-Modified ASSIST Q5;LA26460-8;2;Once or twice;;; +95469-3;LL5629-2;NIDA-Modified ASSIST Q5;LA18876-5;3;Monthly;;; +95469-3;LL5629-2;NIDA-Modified ASSIST Q5;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +95469-3;LL5629-2;NIDA-Modified ASSIST Q5;LA18934-2;5;Daily or almost daily;;; +95470-1;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95470-1;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95470-1;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95471-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95471-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95471-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95472-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95472-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95472-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95473-5;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95473-5;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95473-5;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95474-3;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95474-3;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95474-3;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95475-0;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95475-0;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95475-0;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95476-8;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95476-8;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95476-8;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95477-6;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95477-6;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95477-6;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95478-4;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95478-4;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95478-4;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95479-2;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95479-2;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95479-2;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95482-6;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95482-6;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95482-6;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95483-4;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95483-4;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95483-4;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95484-2;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95484-2;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95484-2;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95485-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95485-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95485-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95486-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95486-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95486-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95487-5;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95487-5;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95487-5;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95488-3;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95488-3;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95488-3;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95489-1;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95489-1;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95489-1;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95490-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95490-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95490-9;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95491-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA18386-5;1;No, never;;; +95491-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31150-8;2;Yes, but not in the past 3 months;;; +95491-7;LL5639-1;NIDA-Modified ASSIST Q6, Q7;LA31151-6;3;Yes, in the past 3 months;;; +95481-8;LL5631-8;Alcohol | Tobacco | Steroids;LA28139-6;1;Alcohol;;; +95481-8;LL5631-8;Alcohol | Tobacco | Steroids;LA31131-8;2;Tobacco;;; +95481-8;LL5631-8;Alcohol | Tobacco | Steroids;LA15260-5;3;Steroids;;; +95481-8;LL5631-8;Alcohol | Tobacco | Steroids;LA31132-6;4;Illegal/illicit drugs;;; +95494-1;LL5631-8;Alcohol | Tobacco | Steroids;LA28139-6;1;Alcohol;;; +95494-1;LL5631-8;Alcohol | Tobacco | Steroids;LA31131-8;2;Tobacco;;; +95494-1;LL5631-8;Alcohol | Tobacco | Steroids;LA15260-5;3;Steroids;;; +95494-1;LL5631-8;Alcohol | Tobacco | Steroids;LA31132-6;4;Illegal/illicit drugs;;; +95500-5;LL5631-8;Alcohol | Tobacco | Steroids;LA28139-6;1;Alcohol;;; +95500-5;LL5631-8;Alcohol | Tobacco | Steroids;LA31131-8;2;Tobacco;;; +95500-5;LL5631-8;Alcohol | Tobacco | Steroids;LA15260-5;3;Steroids;;; +95500-5;LL5631-8;Alcohol | Tobacco | Steroids;LA31132-6;4;Illegal/illicit drugs;;; +95501-3;LL5631-8;Alcohol | Tobacco | Steroids;LA28139-6;1;Alcohol;;; +95501-3;LL5631-8;Alcohol | Tobacco | Steroids;LA31131-8;2;Tobacco;;; +95501-3;LL5631-8;Alcohol | Tobacco | Steroids;LA15260-5;3;Steroids;;; +95501-3;LL5631-8;Alcohol | Tobacco | Steroids;LA31132-6;4;Illegal/illicit drugs;;; +95502-1;LL5631-8;Alcohol | Tobacco | Steroids;LA28139-6;1;Alcohol;;; +95502-1;LL5631-8;Alcohol | Tobacco | Steroids;LA31131-8;2;Tobacco;;; +95502-1;LL5631-8;Alcohol | Tobacco | Steroids;LA15260-5;3;Steroids;;; +95502-1;LL5631-8;Alcohol | Tobacco | Steroids;LA31132-6;4;Illegal/illicit drugs;;; +95503-9;LL5631-8;Alcohol | Tobacco | Steroids;LA28139-6;1;Alcohol;;; +95503-9;LL5631-8;Alcohol | Tobacco | Steroids;LA31131-8;2;Tobacco;;; +95503-9;LL5631-8;Alcohol | Tobacco | Steroids;LA15260-5;3;Steroids;;; +95503-9;LL5631-8;Alcohol | Tobacco | Steroids;LA31132-6;4;Illegal/illicit drugs;;; +95492-5;LL5640-9;NIDA-Modified ASSIST Q8;LA18386-5;1;No, never;;; +95492-5;LL5640-9;NIDA-Modified ASSIST Q8;LA31150-8;2;Yes, but not in the past 3 months;;; +95492-5;LL5640-9;NIDA-Modified ASSIST Q8;LA31151-6;3;Yes, in the past 3 months;;; +95524-5;LL5632-6;HIV-1 & HIV-2 results with cross reactivity;LA24959-1;1;HIV Negative;;; +95524-5;LL5632-6;HIV-1 & HIV-2 results with cross reactivity;LA24952-6;2;HIV-1 Indeterminate;;; +95524-5;LL5632-6;HIV-1 & HIV-2 results with cross reactivity;LA24955-9;3;HIV-1 Positive;;; +95524-5;LL5632-6;HIV-1 & HIV-2 results with cross reactivity;LA24956-7;4;HIV-2 Positive;;; +95524-5;LL5632-6;HIV-1 & HIV-2 results with cross reactivity;LA31133-4;5;HIV-1 Positive with HIV-2 cross-reactivity;;; +95524-5;LL5632-6;HIV-1 & HIV-2 results with cross reactivity;LA24957-5;6;HIV-2 Positive with HIV-1 cross-reactivity;;; +95557-5;LL5565-8;Mode of discovery for tumor;LA21593-1;1;Incidental;;; +95557-5;LL5565-8;Mode of discovery for tumor;LA30894-2;2;Cancer staging;;; +95557-5;LL5565-8;Mode of discovery for tumor;LA30895-9;3;As part of clinical testing;;; +95557-5;LL5565-8;Mode of discovery for tumor;LA46-8;4;Other;;; +95613-6;LL5624-3;CHI Informal Support Relationship;LA31119-3;1;Child or child-in-law;;; +95613-6;LL5624-3;CHI Informal Support Relationship;LA16285-1;2;Spouse;;; +95613-6;LL5624-3;CHI Informal Support Relationship;LA31120-1;3;Partner/significant other;;; +95613-6;LL5624-3;CHI Informal Support Relationship;LA15640-8;4;Other relative;;; +95613-6;LL5624-3;CHI Informal Support Relationship;LA27179-3;5;Neighbor;;; +95613-6;LL5624-3;CHI Informal Support Relationship;LA6656-8;6;Friend;;; +95613-6;LL5624-3;CHI Informal Support Relationship;LA31121-9;7;No informal helper;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95615-1;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95616-9;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95617-7;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6270-8;1;Never;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10066-1;2;Rarely;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA10082-8;3;Sometimes;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA16644-9;4;Fairly often;;; +95618-5;LL5622-7;Nev, Rare, Some, Fair Oft, Freq;LA6482-9;5;Frequently;;; +95615-1;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6270-8;1;Never;;; +95615-1;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10066-1;2;Rarely;;; +95615-1;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10082-8;3;Sometimes;;; +95615-1;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA16644-9;4;Fairly often;;; +95615-1;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6482-9;5;Frequently;;; +95616-9;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6270-8;1;Never;;; +95616-9;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10066-1;2;Rarely;;; +95616-9;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10082-8;3;Sometimes;;; +95616-9;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA16644-9;4;Fairly often;;; +95616-9;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6482-9;5;Frequently;;; +95617-7;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6270-8;1;Never;;; +95617-7;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10066-1;2;Rarely;;; +95617-7;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10082-8;3;Sometimes;;; +95617-7;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA16644-9;4;Fairly often;;; +95617-7;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6482-9;5;Frequently;;; +95618-5;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6270-8;1;Never;;; +95618-5;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10066-1;2;Rarely;;; +95618-5;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA10082-8;3;Sometimes;;; +95618-5;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA16644-9;4;Fairly often;;; +95618-5;LL6156-5;Nev|Rare|Some|Fair Oft|Freq;LA6482-9;5;Frequently;;; +95622-7;LL5609-4;NPASS_Pain: Cry/Irritability;LA31082-3;1;No pain signs;;; +95622-7;LL5609-4;NPASS_Pain: Cry/Irritability;LA31083-1;2;Irritable or crying at intervals, consolable;;; +95622-7;LL5609-4;NPASS_Pain: Cry/Irritability;LA31084-9;3;"High-pitched or silent-continuous cry; Inconsolable";;; +95622-7;LL5959-3;NIPS - Cry;LA32300-8;1;No cry;;; +95622-7;LL5959-3;NIPS - Cry;LA32301-6;2;Whimper;;; +95622-7;LL5959-3;NIPS - Cry;LA32302-4;3;Vigorous cry;;; +95623-5;LL5610-2;NPASS_Pain: Behavior State;LA31082-3;1;No pain signs;;; +95623-5;LL5610-2;NPASS_Pain: Behavior State;LA31085-6;2;"Restless, squirming; Awakens frequently";;; +95623-5;LL5610-2;NPASS_Pain: Behavior State;LA31086-4;3;"Arching, kicking; Constantly awake or arouses minimally/no movement (not sedated)";;; +95623-5;LL5952-8;NIPS - Arousal;LA11864-8;1;Sleeping;;; +95623-5;LL5952-8;NIPS - Arousal;LA32297-6;2;Awake (quiet);;; +95623-5;LL5952-8;NIPS - Arousal;LA32298-4;3;Fussy (alert, restless, and/or thrashing);;; +95624-3;LL5611-0;NPASS_Pain: Facial Expression;LA31082-3;1;No pain signs;;; +95624-3;LL5611-0;NPASS_Pain: Facial Expression;LA31087-2;2;Any pain expression intermittent;;; +95624-3;LL5611-0;NPASS_Pain: Facial Expression;LA31088-0;3;Any pain expression continual;;; +95624-3;LL5958-5;NIPS - Facial expression;LA32283-6;1;Relaxed;;; +95624-3;LL5958-5;NIPS - Facial expression;LA32299-2;2;Grimace;;; +95625-0;LL5612-8;NPASS_Pain: Extremities Tone;LA31082-3;1;No pain signs;;; +95625-0;LL5612-8;NPASS_Pain: Extremities Tone;LA31089-8;2;"Intermittent clenched toes, fists, or finger splay; Body is not tense";;; +95625-0;LL5612-8;NPASS_Pain: Extremities Tone;LA31090-6;3;"Continual clenched toes, fists, or finger splay; Body is tense";;; +95626-8;LL5613-6;NPASS_Pain: Vital Signs Variability;LA31082-3;1;No pain signs;;; +95626-8;LL5613-6;NPASS_Pain: Vital Signs Variability;LA31091-4;2;Increased 10-20% from baseline. SpO2 76-85% with stimulation--quick increase;;; +95626-8;LL5613-6;NPASS_Pain: Vital Signs Variability;LA31092-2;3;Increased >20% from baseline. SpO2 > or equal to 75% with stimulation--slow increase. Out of synch/fighting vent;;; +95628-4;LL5674-8;NPASS - Pain/Agitation Level;LA31236-5;1;Mild: Score of +1 to +3;;; +95628-4;LL5674-8;NPASS - Pain/Agitation Level;LA31237-3;2;Moderate: Score of +4 to +6;;; +95628-4;LL5674-8;NPASS - Pain/Agitation Level;LA31238-1;3;Severe: Score of +7 to +10 (or +11 for premature infant);;; +95630-0;LL5614-4;NPASS_Sedation: Crying/Irritability;LA31093-0;1;No sedation signs;;; +95630-0;LL5614-4;NPASS_Sedation: Crying/Irritability;LA31094-8;2;Moans or cries minimally with painful stimuli;;; +95630-0;LL5614-4;NPASS_Sedation: Crying/Irritability;LA31095-5;3;No cry with painful stimuli;;; +95631-8;LL5615-1;NPASS_Sedation: Behavior State;LA31093-0;1;No sedation signs;;; +95631-8;LL5615-1;NPASS_Sedation: Behavior State;LA31096-3;2;Arouses minimally to stimuli. Little spontaneous movement;;; +95631-8;LL5615-1;NPASS_Sedation: Behavior State;LA31097-1;3;No arousal to any stimuli. No spontaneous movement;;; +95632-6;LL5616-9;NPASS_Sedation: Facial Expression;LA31093-0;1;No sedation signs;;; +95632-6;LL5616-9;NPASS_Sedation: Facial Expression;LA31098-9;2;Minimal expression with stimuli;;; +95632-6;LL5616-9;NPASS_Sedation: Facial Expression;LA31099-7;3;Mouth is lax. No expression;;; +95633-4;LL5617-7;NPASS_Sedation: Extremities Tone;LA31093-0;1;No sedation signs;;; +95633-4;LL5617-7;NPASS_Sedation: Extremities Tone;LA31100-3;2;Weak grasp reflex. Decreased muscle tone;;; +95633-4;LL5617-7;NPASS_Sedation: Extremities Tone;LA31101-1;3;No grasp reflex. Flaccid tone;;; +95634-2;LL5618-5;NPASS_Sedation: Vital Signs;LA31093-0;1;No sedation signs;;; +95634-2;LL5618-5;NPASS_Sedation: Vital Signs;LA31102-9;2;<10% variability from baseline with stimuli;;; +95634-2;LL5618-5;NPASS_Sedation: Vital Signs;LA31103-7;3;No variability with stimuli. Hypoventilation or apnea;;; +95634-2;LL5618-5;NPASS_Sedation: Vital Signs;LA31093-0;1;No sedation signs;;; +95634-2;LL5618-5;NPASS_Sedation: Vital Signs;LA31102-9;2;<10% variability from baseline with stimuli;;; +95634-2;LL5618-5;NPASS_Sedation: Vital Signs;LA31103-7;3;No variability with stimuli. Hypoventilation or apnea;;; +95636-7;LL5675-5;NPASS - Sedation Level;LA31239-9;1;Light: Score of -1 to -3;;; +95636-7;LL5675-5;NPASS - Sedation Level;LA31240-7;2;Moderate: Score of -4 to -6;;; +95636-7;LL5675-5;NPASS - Sedation Level;LA31241-5;3;Deep: Score of -7 to -10;;; +95656-5;LL5619-3;NPASS_Pain: Gestational Age <30 weeks;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95656-5;LL5619-3;NPASS_Pain: Gestational Age <30 weeks;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95656-5;LL5619-3;NPASS_Pain: Gestational Age <30 weeks;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +95656-5;LL5619-3;NPASS_Pain: Gestational Age <30 weeks;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +95657-3;LL5638-3;Flavivirus species;LA31145-8;1;West Nile virus;;; +95657-3;LL5638-3;Flavivirus species;LA31146-6;2;Yellow fever virus;;; +95657-3;LL5638-3;Flavivirus species;LA31147-4;3;Dengue virus;;; +95657-3;LL5638-3;Flavivirus species;LA31148-2;4;Japanese encephalitis virus;;; +95657-3;LL5638-3;Flavivirus species;LA31149-0;5;Powassan virus;;; +95715-9;LL5672-2;Population groups;LA31202-7;1;Deployed & mission essential personnel;;; +95715-9;LL5672-2;Population groups;LA31203-5;2;Essential military support & sustainment personnel;;; +95715-9;LL5672-2;Population groups;LA31204-3;3;Intelligence services;;; +95715-9;LL5672-2;Population groups;LA31205-0;4;National Guard personnel;;; +95715-9;LL5672-2;Population groups;LA31206-8;5;Other domestic national security personnel;;; +95715-9;LL5672-2;Population groups;LA31207-6;6;Other active duty military & essential support;;; +95715-9;LL5672-2;Population groups;LA31208-4;7;Public health personnel;;; +95715-9;LL5672-2;Population groups;LA31209-2;8;Inpatient health care providers;;; +95715-9;LL5672-2;Population groups;LA31210-0;9;Outpatient & home health providers;;; +95715-9;LL5672-2;Population groups;LA31211-8;10;Health care providers in long-term care facilities;;; +95715-9;LL5672-2;Population groups;LA31212-6;11;Pharmacists & pharmacy technicians;;; +95715-9;LL5672-2;Population groups;LA31213-4;12;Community support & emergency management;;; +95715-9;LL5672-2;Population groups;LA31214-2;13;Mortuary services personnel;;; +95715-9;LL5672-2;Population groups;LA31215-9;14;Other health care personnel;;; +95715-9;LL5672-2;Population groups;LA31216-7;15;Emergency services & public safety sector personnel (EMS, law enforcement, & fire services);;; +95715-9;LL5672-2;Population groups;LA31217-5;16;Manufacturers of pandemic vaccine & antivirals;;; +95715-9;LL5672-2;Population groups;LA31218-3;17;Communications/information technology (IT), electricity, nuclear, oil & gas, water sector personnel, & financial clearing & settlement personnel;;; +95715-9;LL5672-2;Population groups;LA31219-1;18;Critical government personnel - operational & regulatory functions;;; +95715-9;LL5672-2;Population groups;LA31220-9;19;Banking & finance, chemical, food & agriculture, pharmaceutical, postal & shipping, & transportation sector personnel (critical infrastructure with greater redundancy);;; +95715-9;LL5672-2;Population groups;LA31221-7;20;Other critical government personnel;;; +95715-9;LL5672-2;Population groups;LA29507-3;21;Pregnant women;;; +95715-9;LL5672-2;Population groups;LA31223-3;22;Infants & toddlers 6-35 months old;;; +95715-9;LL5672-2;Population groups;LA31224-1;23;Household contacts of infants;;; +95715-9;LL5672-2;Population groups;LA31225-8;24;Children 3-18 years old with high risk condition;;; +95715-9;LL5672-2;Population groups;LA31226-6;25;Children 3-18 years old without high risk condition;;; +95715-9;LL5672-2;Population groups;LA31227-4;26;Adults 19-64 years old with high risk condition;;; +95715-9;LL5672-2;Population groups;LA31228-2;27;Adults >65 years old;;; +95715-9;LL5672-2;Population groups;LA31229-0;28;Healthy adults 19-64 years old;;; +95722-5;LL3593-2;Pos|Weak pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95722-5;LL3593-2;Pos|Weak pos|Neg;LA19422-7;2;Weak positive;;; +95722-5;LL3593-2;Pos|Weak pos|Neg;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95723-3;LL3593-2;Pos|Weak pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95723-3;LL3593-2;Pos|Weak pos|Neg;LA19422-7;2;Weak positive;;; +95723-3;LL3593-2;Pos|Weak pos|Neg;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95724-1;LL3593-2;Pos|Weak pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95724-1;LL3593-2;Pos|Weak pos|Neg;LA19422-7;2;Weak positive;;; +95724-1;LL3593-2;Pos|Weak pos|Neg;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95725-8;LL3593-2;Pos|Weak pos|Neg;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +95725-8;LL3593-2;Pos|Weak pos|Neg;LA19422-7;2;Weak positive;;; +95725-8;LL3593-2;Pos|Weak pos|Neg;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +95735-7;LL6306-6;Urinary continence;LA11042-1;1;Always continent;;; +95735-7;LL6306-6;Urinary continence;LA11043-9;2;Occasionally incontinent (less than 7 episodes of incontinence);;; +95735-7;LL6306-6;Urinary continence;LA11044-7;3;Frequently incontinent (7 or more episodes of urinary incontinence, but with at least one episode of continent voiding);;; +95735-7;LL6306-6;Urinary continence;LA11050-4;4;Always incontinent (no episodes of continent bowel movements);;; +95735-7;LL6306-6;Urinary continence;LA11046-2;5;Not rated, resident had a catheter (indwelling, condom), urinary ostomy, or no urine output for the entire 7 days;;; +95736-5;LL6310-8;Urinary incontinence;LA11042-1;1;Always continent;;; +95736-5;LL6310-8;Urinary incontinence;LA11048-8;2;Occasionally incontinent (one episode of bowel incontinence);;; +95736-5;LL6310-8;Urinary incontinence;LA11049-6;3;Frequently incontinent (2 or more episodes of bowel incontinence, but at least one continent bowel movement);;; +95736-5;LL6310-8;Urinary incontinence;LA11050-4;4;Always incontinent (no episodes of continent bowel movements);;; +95736-5;LL6310-8;Urinary incontinence;LA11046-2;5;Not rated, resident had a catheter (indwelling, condom), urinary ostomy, or no urine output for the entire 7 days;;; +95743-1;LL6297-7;***** CLONED FROM - LL4556-8 *****;LA9962-7;1;Current season;;; +95743-1;LL6297-7;***** CLONED FROM - LL4556-8 *****;LA9998-1;2;Location of own room;;; +95743-1;LL6297-7;***** CLONED FROM - LL4556-8 *****;LA10085-1;3;Staff names and faces;;; +95743-1;LL6297-7;***** CLONED FROM - LL4556-8 *****;LA33609-1;4;That they are in a nursing home/hospital swing bed.;;; +95743-1;LL6297-7;***** CLONED FROM - LL4556-8 *****;LA26729-6;5;None of the above were recalled;;; +95793-6;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31231-6;1;Tier 1;;; +95793-6;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31232-4;2;Tier 2;;; +95793-6;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31233-2;3;Tier 3;;; +95793-6;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31234-0;4;Tier 4;;; +97001-2;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31231-6;1;Tier 1;;; +97001-2;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31232-4;2;Tier 2;;; +97001-2;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31233-2;3;Tier 3;;; +97001-2;LL5673-0;Tier 1 | Tier 2 | Tier 3 | Tier 4;LA31234-0;4;Tier 4;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA9933-8;1;Always;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10044-8;2;Often;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10082-8;3;Sometimes;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6483-7;4;Occasionally;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6270-8;5;Never;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA9933-8;1;Always;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10044-8;2;Often;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10082-8;3;Sometimes;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6483-7;4;Occasionally;;; +95867-8;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6270-8;5;Never;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA9933-8;1;Always;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10044-8;2;Often;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10082-8;3;Sometimes;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6483-7;4;Occasionally;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6270-8;5;Never;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA9933-8;1;Always;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10044-8;2;Often;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10082-8;3;Sometimes;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6483-7;4;Occasionally;;; +95868-6;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6270-8;5;Never;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA9933-8;1;Always;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10044-8;2;Often;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10082-8;3;Sometimes;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6483-7;4;Occasionally;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6270-8;5;Never;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA9933-8;1;Always;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10044-8;2;Often;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA10082-8;3;Sometimes;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6483-7;4;Occasionally;;; +95869-4;LL5668-0;Always|Often|Sometimes|Occasionally|Never;LA6270-8;5;Never;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA6568-5;1;Not at all;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA13863-8;2;A little bit;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA13909-9;3;Somewhat;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA13902-4;4;Quite a bit;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA14868-6;5;Extremely;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA6568-5;1;Not at all;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA13863-8;2;A little bit;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA13909-9;3;Somewhat;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA13902-4;4;Quite a bit;;; +95870-2;LL5669-8;Not at all|Li'l bit|Somew|Quite bit|Extrem;LA14868-6;5;Extremely;;; +95931-2;LL5671-4;Drugs for Vasodilatory Test;LA31199-5;1;Inhaled nitrous oxide;;; +95931-2;LL5671-4;Drugs for Vasodilatory Test;LA31200-1;2;IV epoprostenol;;; +95931-2;LL5671-4;Drugs for Vasodilatory Test;LA31201-9;3;IV adenosine;;; +95931-2;LL5671-4;Drugs for Vasodilatory Test;LA31230-8;4;Inhaled iloprost;;; +95931-2;LL5671-4;Drugs for Vasodilatory Test;LA31366-0;5;100% oxygen;;; +95932-0;LL5623-5;WHO Pulmonary Hypertension Groups;LA31114-4;1;Group 1: Pulmonary arterial hypertension (PAH);;; +95932-0;LL5623-5;WHO Pulmonary Hypertension Groups;LA31115-1;2;Group 2: Pulmonary Hypertension due to left heart disease;;; +95932-0;LL5623-5;WHO Pulmonary Hypertension Groups;LA31116-9;3;Group 3: Pulmonary Hypertension due to chronic lung disease and hypoxemia;;; +95932-0;LL5623-5;WHO Pulmonary Hypertension Groups;LA31117-7;4;Group 4: Chronic Thromboembolic Pulmonary Hypertension (CTEPH);;; +95932-0;LL5623-5;WHO Pulmonary Hypertension Groups;LA31118-5;5;Group 5: Pulmonary hypertension due to unclear multifactorial mechanisms;;; +95934-6;LL5635-9;Volume estimate;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +95934-6;LL5635-9;Volume estimate;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +95934-6;LL5635-9;Volume estimate;LA31281-1;3;Mildly enlarged;;; +95934-6;LL5635-9;Volume estimate;LA31282-9;4;Moderately enlarged;;; +95934-6;LL5635-9;Volume estimate;LA31283-7;5;Severely enlarged;;; +95935-3;LL5635-9;Volume estimate;LA8983-4;1;Small;255507004;Small (qualifier value);http://snomed.info/sct +95935-3;LL5635-9;Volume estimate;LA6626-1;2;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +95935-3;LL5635-9;Volume estimate;LA31281-1;3;Mildly enlarged;;; +95935-3;LL5635-9;Volume estimate;LA31282-9;4;Moderately enlarged;;; +95935-3;LL5635-9;Volume estimate;LA31283-7;5;Severely enlarged;;; +95936-1;LL5636-7;Decrease level;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +95936-1;LL5636-7;Decrease level;LA31137-5;2;Mildly decreased;;; +95936-1;LL5636-7;Decrease level;LA31138-3;3;Moderately decreased;;; +95936-1;LL5636-7;Decrease level;LA31139-1;4;Severely decreased;;; +95936-1;LL5636-7;Decrease level;LA24377-6;5;Increased;;; +95980-9;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95980-9;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95980-9;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95980-9;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95980-9;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95980-9;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95980-9;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95981-7;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95981-7;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95981-7;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95981-7;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95981-7;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95981-7;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95981-7;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95982-5;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95982-5;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95982-5;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95982-5;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95982-5;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95982-5;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95982-5;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95983-3;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95983-3;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95983-3;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95983-3;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95983-3;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95983-3;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95983-3;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95984-1;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95984-1;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95984-1;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95984-1;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95984-1;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95984-1;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95984-1;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95985-8;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95985-8;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95985-8;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95985-8;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95985-8;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95985-8;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95985-8;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95986-6;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95986-6;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95986-6;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95986-6;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95986-6;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95986-6;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95986-6;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95987-4;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95987-4;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95987-4;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95987-4;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95987-4;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95987-4;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95987-4;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95988-2;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95988-2;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95988-2;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95988-2;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95988-2;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95988-2;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95988-2;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95989-0;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95989-0;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95989-0;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95989-0;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95989-0;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95989-0;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95989-0;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95990-8;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95990-8;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95990-8;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95990-8;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95990-8;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95990-8;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95990-8;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95991-6;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95991-6;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95991-6;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95991-6;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95991-6;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95991-6;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95991-6;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95992-4;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95992-4;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95992-4;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95992-4;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95992-4;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95992-4;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95992-4;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95993-2;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95993-2;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95993-2;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95993-2;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95993-2;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95993-2;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95993-2;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95994-0;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95994-0;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95994-0;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95994-0;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95994-0;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95994-0;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95994-0;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +95995-7;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +95995-7;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +95995-7;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +95995-7;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +95995-7;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +95995-7;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +95995-7;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +96031-0;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +96031-0;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +96031-0;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +96031-0;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +96031-0;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +96031-0;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +96031-0;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +96032-8;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +96032-8;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +96032-8;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +96032-8;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +96032-8;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +96032-8;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +96032-8;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +96033-6;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +96033-6;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +96033-6;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +96033-6;LL5689-6;Bothered - Never to Always;LA31298-5;1;0 - Never bothered;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6112-2;2;1;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6113-0;3;2;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6114-8;4;3;;; +96033-6;LL5689-6;Bothered - Never to Always;LA6115-5;5;4;;; +96033-6;LL5689-6;Bothered - Never to Always;LA10137-0;6;5;;; +96033-6;LL5689-6;Bothered - Never to Always;LA31299-3;7;6 - Always bothered;;; +96001-3;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96001-3;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96001-3;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96001-3;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96001-3;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96002-1;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96002-1;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96002-1;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96002-1;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96002-1;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96003-9;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96003-9;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96003-9;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96003-9;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96003-9;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96004-7;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96004-7;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96004-7;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96004-7;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96004-7;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96005-4;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96005-4;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96005-4;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96005-4;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96005-4;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96006-2;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96006-2;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96006-2;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96006-2;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96006-2;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96007-0;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96007-0;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96007-0;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96007-0;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96007-0;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96008-8;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96008-8;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96008-8;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96008-8;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96008-8;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96009-6;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96009-6;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96009-6;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96009-6;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96009-6;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96010-4;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96010-4;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96010-4;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96010-4;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96010-4;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96011-2;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96011-2;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96011-2;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96011-2;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96011-2;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96012-0;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96012-0;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96012-0;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96012-0;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96012-0;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96013-8;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96013-8;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96013-8;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96013-8;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96013-8;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96014-6;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96014-6;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96014-6;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96014-6;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96014-6;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96015-3;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96015-3;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96015-3;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96015-3;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96015-3;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96016-1;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96016-1;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96016-1;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96016-1;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96016-1;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96017-9;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96017-9;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96017-9;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96017-9;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96017-9;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96018-7;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96018-7;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96018-7;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96018-7;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96018-7;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96019-5;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96019-5;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96019-5;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96019-5;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96019-5;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96020-3;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96020-3;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96020-3;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96020-3;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96020-3;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96021-1;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96021-1;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96021-1;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96021-1;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96021-1;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96022-9;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96022-9;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96022-9;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96022-9;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96022-9;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96023-7;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96023-7;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96023-7;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96023-7;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96023-7;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96024-5;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96024-5;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96024-5;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96024-5;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96024-5;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96025-2;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96025-2;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96025-2;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96025-2;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96025-2;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96026-0;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96026-0;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96026-0;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96026-0;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96026-0;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96027-8;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96027-8;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96027-8;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96027-8;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96027-8;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96028-6;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96028-6;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96028-6;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96028-6;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96028-6;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96029-4;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96029-4;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96029-4;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96029-4;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96029-4;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96030-2;LL5690-4;Never (1) to All the Time (5);LA6270-8;1;Never;;; +96030-2;LL5690-4;Never (1) to All the Time (5);LA10066-1;2;Rarely;;; +96030-2;LL5690-4;Never (1) to All the Time (5);LA10082-8;3;Sometimes;;; +96030-2;LL5690-4;Never (1) to All the Time (5);LA10044-8;4;Often;;; +96030-2;LL5690-4;Never (1) to All the Time (5);LA14726-6;5;All the time;;; +96037-7;LL5681-3;WIfI Wound Grade;LA31269-6;1;Grade 0: no ulcer, no gangrene;;; +96037-7;LL5681-3;WIfI Wound Grade;LA31270-4;2;Grade 1: small/shallow ulcer, no gangrene;;; +96037-7;LL5681-3;WIfI Wound Grade;LA31271-2;3;Grade 2: deeper ulcer, gangrene limited to toes;;; +96037-7;LL5681-3;WIfI Wound Grade;LA31272-0;4;Grade 3: extensive, deep ulcer, extensive gangrene;;; +96038-5;LL5682-1;WIfI Ischemia Grade;LA31273-8;1;Grade 0: no signs of ischemia (e.g., ABI>0.80, ankle SBP >100 mm Hg, or toe pressure >=60 mm Hg);;; +96038-5;LL5682-1;WIfI Ischemia Grade;LA31274-6;2;Grade 1: mild signs of ischemia (e.g., ABI 0.60-0.79, ankle SBP 70-100 mm Hg, or toe pressure 40-59 mm Hg);;; +96038-5;LL5682-1;WIfI Ischemia Grade;LA31275-3;3;Grade 2: moderate signs of ischemia (e.g., ABI 0.40-0.59, ankle SBP 50-70 mm Hg, or toe pressure 30-39 mm Hg);;; +96038-5;LL5682-1;WIfI Ischemia Grade;LA31276-1;4;Grade 3: severe signs of ischemia (e.g., ABI <0.39, ankle SBP <50 mm Hg, or toe pressure <30 mm Hg);;; +96039-3;LL5683-9;WIfi Infection Grade;LA31277-9;1;Grade 0: no symptoms or signs of infection;;; +96039-3;LL5683-9;WIfi Infection Grade;LA31278-7;2;Grade 1: local infection involving only skin/subcutaneous tissue;;; +96039-3;LL5683-9;WIfi Infection Grade;LA31279-5;3;Grade 2: local infection with >2cm erythema/purulence or involvement of deeper structures;;; +96039-3;LL5683-9;WIfi Infection Grade;LA31280-3;4;Grade 3: local infection with signs of systemic inflammatory response syndrome (SIRS);;; +96041-9;LL5684-7;WIfI Amputation Risk;LA29597-4;1;Very low risk;;; +96041-9;LL5684-7;WIfI Amputation Risk;LA19542-2;2;Low risk;;; +96041-9;LL5684-7;WIfI Amputation Risk;LA29616-2;3;Moderate risk;;; +96041-9;LL5684-7;WIfI Amputation Risk;LA19541-4;4;High risk;;; +96052-6;LL5579-9;Additional Power Mode;LA30945-2;1;Add;;; +96052-6;LL5579-9;Additional Power Mode;LA30946-0;2;NSPH;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31346-2;32;Acute lymphoid leukemia;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA26787-4;33;Acute myeloid leukemia;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31347-0;34;Chronic lymphoid leukemia;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31348-8;35;Chronic myeloid leukemia;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA26525-8;36;Diffuse large B-cell lymphoma (DLBCL), NOS;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA26792-4;37;Hodgkin lymphoma;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31349-6;38;Indolent non-Hodgkin lymphoma;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA26524-1;39;Mantle cell lymphoma;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31350-4;40;Multiple myeloma;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA26796-5;41;Myelodysplastic syndrome;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31351-2;42;Myeloproliferative syndrome;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31352-0;43;T cell lymphoma--extra nodal;;; +96060-9;LL5705-0;PAM Revised - Hematologic Malignancy Types;LA31353-8;44;T cell lymphoma--nodal;;; +96061-7;LL5594-8;HLA donor match status;LA31027-8;1;HLA-matched;;; +96061-7;LL5594-8;HLA donor match status;LA31028-6;2;HLA-mismatched;;; +96061-7;LL5594-8;HLA donor match status;LA4720-4;3;Not applicable;;; +96061-7;LL5594-8;HLA donor match status;LA31027-8;1;HLA-matched;;; +96061-7;LL5594-8;HLA donor match status;LA31028-6;2;HLA-mismatched;;; +96061-7;LL5594-8;HLA donor match status;LA4720-4;3;Not applicable;;; +96091-4;LL5695-3;Pos|Presump Pos|Neg|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96091-4;LL5695-3;Pos|Presump Pos|Neg|Invalid;LA31317-3;2;Presumptive positive;;; +96091-4;LL5695-3;Pos|Presump Pos|Neg|Invalid;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96091-4;LL5695-3;Pos|Presump Pos|Neg|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96101-1;LL5670-6;Frequency: Daily to <1xMo;LA14435-4;1;Daily;;; +96101-1;LL5670-6;Frequency: Daily to <1xMo;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +96101-1;LL5670-6;Frequency: Daily to <1xMo;LA26461-6;3;Once a week;;; +96101-1;LL5670-6;Frequency: Daily to <1xMo;LA29740-0;4;More than once a week;;; +96101-1;LL5670-6;Frequency: Daily to <1xMo;LA31198-7;5;Weekends only;;; +96101-1;LL5670-6;Frequency: Daily to <1xMo;LA6304-5;6;Once a month;;; +96101-1;LL5670-6;Frequency: Daily to <1xMo;LA6251-8;7;Less than once a month;;; +97060-8;LL5670-6;Frequency: Daily to <1xMo;LA14435-4;1;Daily;;; +97060-8;LL5670-6;Frequency: Daily to <1xMo;LA18891-4;2;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97060-8;LL5670-6;Frequency: Daily to <1xMo;LA26461-6;3;Once a week;;; +97060-8;LL5670-6;Frequency: Daily to <1xMo;LA29740-0;4;More than once a week;;; +97060-8;LL5670-6;Frequency: Daily to <1xMo;LA31198-7;5;Weekends only;;; +97060-8;LL5670-6;Frequency: Daily to <1xMo;LA6304-5;6;Once a month;;; +97060-8;LL5670-6;Frequency: Daily to <1xMo;LA6251-8;7;Less than once a month;;; +96104-5;LL5685-4;UT Diabetic Wound Stage;LA31284-5;1;Stage A: no infection or ischemia;;; +96104-5;LL5685-4;UT Diabetic Wound Stage;LA31285-2;2;Stage B: infection;;; +96104-5;LL5685-4;UT Diabetic Wound Stage;LA31286-0;3;Stage C: ischemia;;; +96104-5;LL5685-4;UT Diabetic Wound Stage;LA31287-8;4;Stage D: infection and ischemia;;; +96105-2;LL5686-2;UT Diabetic Foot Ulcer Grade;LA31288-6;1;Grade 0: pre- or postulcerative lesions completely epithelialized;;; +96105-2;LL5686-2;UT Diabetic Foot Ulcer Grade;LA31289-4;2;Grade 1: superficial wound, not involving tendon, capsule or bone;;; +96105-2;LL5686-2;UT Diabetic Foot Ulcer Grade;LA31290-2;3;Grade 2: wound penetrating to tendon or capsule;;; +96105-2;LL5686-2;UT Diabetic Foot Ulcer Grade;LA31291-0;4;Grade 3: wound penetrating to bone or joint;;; +96115-1;LL5687-0;Haggitt level;LA31292-8;1;Carcinoma in situ or intramucosal carcinoma;;; +96115-1;LL5687-0;Haggitt level;LA31293-6;2;Invasion of the submucosa, but limited to the head of the polyp;;; +96115-1;LL5687-0;Haggitt level;LA31294-4;3;Invasion extending into the neck of the polyp;;; +96115-1;LL5687-0;Haggitt level;LA31295-1;4;Invasion into any part of the stalk;;; +96115-1;LL5687-0;Haggitt level;LA31296-9;5;Invasion beyond the stalk into the submucosa of the bowel wall below the stalk but above the muscularis propria;;; +96116-9;LL5678-9;High|Low|Ultra-low;LA9193-9;1;High;;; +96116-9;LL5678-9;High|Low|Ultra-low;LA9194-7;2;Low;;; +96116-9;LL5678-9;High|Low|Ultra-low;LA31250-6;3;Ultra-low;;; +96117-7;LL5677-1;Adequate|Inadequate;LA8913-1;1;Adequate;;; +96117-7;LL5677-1;Adequate|Inadequate;LA8914-9;2;Inadequate;;; +96203-5;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96203-5;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96203-5;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96204-3;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96204-3;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96204-3;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96205-0;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96205-0;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96205-0;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96206-8;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96206-8;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96206-8;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96207-6;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96207-6;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96207-6;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96208-4;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96208-4;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96208-4;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96209-2;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96209-2;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96209-2;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96210-0;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96210-0;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96210-0;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96211-8;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96211-8;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96211-8;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96212-6;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96212-6;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96212-6;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96213-4;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96213-4;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96213-4;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96214-2;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96214-2;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96214-2;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96215-9;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96215-9;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96215-9;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96216-7;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96216-7;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96216-7;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96217-5;LL5708-4;Stable|Worse|Improved;LA14122-8;1;Stable;;; +96217-5;LL5708-4;Stable|Worse|Improved;LA11011-6;2;Worse;;; +96217-5;LL5708-4;Stable|Worse|Improved;LA65-8;3;Improved;;; +96300-9;LL5688-8;Growth | No Growth;LA21123-7;1;No growth;;; +96300-9;LL5688-8;Growth | No Growth;LA31297-7;2;Growth;;; +96449-4;LL5688-8;Growth | No Growth;LA21123-7;1;No growth;;; +96449-4;LL5688-8;Growth | No Growth;LA31297-7;2;Growth;;; +96381-9;LL5718-3;Immunosuppressed|Normal immune status;LA31420-5;1;Immunosuppressed;;; +96381-9;LL5718-3;Immunosuppressed|Normal immune status;LA31421-3;2;Normal immune function;;; +96384-3;LL5722-5;Behaviors related to wound healing;LA23588-9;1;"Needs help to shower or bathe; or very slow in hygienic care";;; +96384-3;LL5722-5;Behaviors related to wound healing;LA12264-0;2;Able to bathe self in shower or tub independently, including getting in and out of tub/shower.;;; +96384-3;LL5722-5;Behaviors related to wound healing;LA14946-0;3;Always works nights, sleeps during the day;;; +96384-3;LL5722-5;Behaviors related to wound healing;LA22729-0;4;Exercises regularly;;; +96384-3;LL5722-5;Behaviors related to wound healing;LA22727-4;5;Avoids even trivial exercise;;; +96385-0;LL5723-3;Treatment adherence;LA31431-2;1;Adherent to treatment;;; +96385-0;LL5723-3;Treatment adherence;LA31432-0;2;Not adherent to treatment;;; +96387-6;LL5556-7;Numbness | Paraesthesia | Pain;LA30857-9;1;Numbness;;; +96387-6;LL5556-7;Numbness | Paraesthesia | Pain;LA30858-7;2;Paraesthesia;;; +96387-6;LL5556-7;Numbness | Paraesthesia | Pain;LA7460-4;3;Pain;;; +96388-4;LL5725-8;Psychosocial effects;LA31435-3;1;Shame;;; +96388-4;LL5725-8;Psychosocial effects;LA31436-1;2;Disgust;;; +96388-4;LL5725-8;Psychosocial effects;LA31437-9;3;Distress;;; +96388-4;LL5725-8;Psychosocial effects;LA31438-7;4;Embarrassment;;; +96389-2;LL5557-5;Quality of life impact;LA30859-5;1;Retreat from friends;;; +96389-2;LL5557-5;Quality of life impact;LA30860-3;2;Retreat from public life;;; +96389-2;LL5557-5;Quality of life impact;LA30861-1;3;Reduced choice of clothes;;; +96389-2;LL5557-5;Quality of life impact;LA30862-9;4;Loss of job;;; +96390-0;LL5719-1;Emotional impact;LA16670-4;1;Lonely;;; +96390-0;LL5719-1;Emotional impact;LA17675-2;2;Irritability and anger;;; +96390-0;LL5719-1;Emotional impact;LA31422-1;3;Worried;;; +96390-0;LL5719-1;Emotional impact;LA16652-2;4;Sad;;; +96392-6;LL5721-7;Debridement method;LA19743-6;1;Mechanical;;; +96392-6;LL5721-7;Debridement method;LA31426-2;2;Surgical;;; +96392-6;LL5721-7;Debridement method;LA31427-0;3;Ultrawave;;; +96392-6;LL5721-7;Debridement method;LA31428-8;4;Autolytic;;; +96392-6;LL5721-7;Debridement method;LA31429-6;5;Enzyme;;; +96392-6;LL5721-7;Debridement method;LA31430-4;6;Biologic;;; +96392-6;LL5721-7;Debridement method;LA46-8;7;Other;;; +96393-4;LL5720-9;Hygiene recommendations;LA31423-9;1;Wash feet daily;;; +96393-4;LL5720-9;Hygiene recommendations;LA31424-7;2;Keep dressing dry;;; +96393-4;LL5720-9;Hygiene recommendations;LA31425-4;3;Use hypoallergenic soap;;; +96395-9;LL5724-1;Treatment acceptance;LA31433-8;2;Accepting of treatment;;; +96395-9;LL5724-1;Treatment acceptance;LA31434-6;3;Not accepting of treatment;;; +96429-6;LL5680-5;Borrelia bands;LA31252-2;1;93kd;;; +96429-6;LL5680-5;Borrelia bands;LA31253-0;2;88kd;;; +96429-6;LL5680-5;Borrelia bands;LA31254-8;3;75kd;;; +96429-6;LL5680-5;Borrelia bands;LA31255-5;4;64kd;;; +96429-6;LL5680-5;Borrelia bands;LA31256-3;5;62kd;;; +96429-6;LL5680-5;Borrelia bands;LA31257-1;6;58kd;;; +96429-6;LL5680-5;Borrelia bands;LA31258-9;7;56kd;;; +96429-6;LL5680-5;Borrelia bands;LA31259-7;8;54kd;;; +96429-6;LL5680-5;Borrelia bands;LA31260-5;9;45kd;;; +96429-6;LL5680-5;Borrelia bands;LA31261-3;10;44kd;;; +96429-6;LL5680-5;Borrelia bands;LA31262-1;11;41kd;;; +96429-6;LL5680-5;Borrelia bands;LA31263-9;12;36kd;;; +96429-6;LL5680-5;Borrelia bands;LA31264-7;13;31kd;;; +96429-6;LL5680-5;Borrelia bands;LA31265-4;14;30kd;;; +96429-6;LL5680-5;Borrelia bands;LA31266-2;15;24kd;;; +96429-6;LL5680-5;Borrelia bands;LA31267-0;16;18kd;;; +96429-6;LL5680-5;Borrelia bands;LA31268-8;17;21kd;;; +96431-2;LL5680-5;Borrelia bands;LA31252-2;1;93kd;;; +96431-2;LL5680-5;Borrelia bands;LA31253-0;2;88kd;;; +96431-2;LL5680-5;Borrelia bands;LA31254-8;3;75kd;;; +96431-2;LL5680-5;Borrelia bands;LA31255-5;4;64kd;;; +96431-2;LL5680-5;Borrelia bands;LA31256-3;5;62kd;;; +96431-2;LL5680-5;Borrelia bands;LA31257-1;6;58kd;;; +96431-2;LL5680-5;Borrelia bands;LA31258-9;7;56kd;;; +96431-2;LL5680-5;Borrelia bands;LA31259-7;8;54kd;;; +96431-2;LL5680-5;Borrelia bands;LA31260-5;9;45kd;;; +96431-2;LL5680-5;Borrelia bands;LA31261-3;10;44kd;;; +96431-2;LL5680-5;Borrelia bands;LA31262-1;11;41kd;;; +96431-2;LL5680-5;Borrelia bands;LA31263-9;12;36kd;;; +96431-2;LL5680-5;Borrelia bands;LA31264-7;13;31kd;;; +96431-2;LL5680-5;Borrelia bands;LA31265-4;14;30kd;;; +96431-2;LL5680-5;Borrelia bands;LA31266-2;15;24kd;;; +96431-2;LL5680-5;Borrelia bands;LA31267-0;16;18kd;;; +96431-2;LL5680-5;Borrelia bands;LA31268-8;17;21kd;;; +96433-8;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96433-8;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96433-8;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96433-8;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96433-8;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96433-8;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96438-7;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96438-7;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96438-7;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96438-7;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96438-7;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96438-7;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96440-3;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96440-3;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96440-3;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96440-3;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96440-3;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96440-3;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96443-7;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96443-7;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96443-7;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96443-7;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96443-7;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96443-7;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96445-2;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96445-2;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96445-2;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96445-2;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96445-2;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96445-2;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96753-9;LL5726-6;Yes|No|Maybe Later;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96753-9;LL5726-6;Yes|No|Maybe Later;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96753-9;LL5726-6;Yes|No|Maybe Later;LA31439-5;3;Maybe Later;;; +96556-6;LL5696-1;HIV 1|HIV 2|Nonreactive|Invalid;LA20963-7;1;Positive for HIV 1;;; +96556-6;LL5696-1;HIV 1|HIV 2|Nonreactive|Invalid;LA20964-5;2;Positive for HIV 2;;; +96556-6;LL5696-1;HIV 1|HIV 2|Nonreactive|Invalid;LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +96556-6;LL5696-1;HIV 1|HIV 2|Nonreactive|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96558-2;LL5732-4;Exudation|Granulation|Epithelialization;LA31460-1;1;Exudation;;; +96558-2;LL5732-4;Exudation|Granulation|Epithelialization;LA19118-1;2;Granulation;;; +96558-2;LL5732-4;Exudation|Granulation|Epithelialization;LA19115-7;3;Epithelialization;;; +96571-5;LL5730-8;Yes(3)\No(0);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96571-5;LL5730-8;Yes(3)\No(0);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96575-6;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96575-6;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96575-6;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96577-2;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96577-2;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96577-2;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96579-8;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96579-8;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96579-8;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96580-6;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96580-6;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96580-6;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96581-4;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96581-4;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96581-4;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96582-2;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96582-2;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96582-2;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96583-0;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96583-0;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96583-0;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96584-8;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96584-8;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96584-8;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96585-5;LL5727-4;A Lot|Sometimes|Never;LA14468-5;1;A lot;;; +96585-5;LL5727-4;A Lot|Sometimes|Never;LA10082-8;2;Sometimes;;; +96585-5;LL5727-4;A Lot|Sometimes|Never;LA6270-8;3;Never;;; +96601-0;LL5764-7;None|1+|2+|3+|4+|5+|6+;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +96601-0;LL5764-7;None|1+|2+|3+|4+|5+|6+;LA11841-6;3;1+;;; +96601-0;LL5764-7;None|1+|2+|3+|4+|5+|6+;LA11842-4;4;2+;;; +96601-0;LL5764-7;None|1+|2+|3+|4+|5+|6+;LA11843-2;5;3+;;; +96601-0;LL5764-7;None|1+|2+|3+|4+|5+|6+;LA11844-0;6;4+;;; +96601-0;LL5764-7;None|1+|2+|3+|4+|5+|6+;LA31560-8;7;5+;;; +96601-0;LL5764-7;None|1+|2+|3+|4+|5+|6+;LA31561-6;8;6+;;; +96610-1;LL5765-4;Observation setting;LA26176-0;1;Daycare;;; +96610-1;LL5765-4;Observation setting;LA20034-7;2;Clinic/doctor's office;;; +96610-1;LL5765-4;Observation setting;LA14084-0;3;Home;;; +96610-1;LL5765-4;Observation setting;LA6218-7;4;Hospital;;; +96610-1;LL5765-4;Observation setting;LA14086-5;5;School;;; +96610-1;LL5765-4;Observation setting;LA16501-1;6;Work;;; +96613-5;LL5757-1;HLA-A HighRes;LA31532-7;1;HLA-A*02:07;;; +96613-5;LL5757-1;HLA-A HighRes;LA31533-5;2;HLA-A*03:01:02;;; +96613-5;LL5757-1;HLA-A HighRes;LA31534-3;3;HLA-A*02:21;;; +96613-5;LL5757-1;HLA-A HighRes;LA31535-0;4;HLA-A*23:06;;; +96618-4;LL5758-9;HLA-B HighRes;LA31536-8;1;HLA-B*07:15;;; +96618-4;LL5758-9;HLA-B HighRes;LA31537-6;2;HLA-B*08:02;;; +96618-4;LL5758-9;HLA-B HighRes;LA31538-4;3;HLA-B*14:02:01;;; +96618-4;LL5758-9;HLA-B HighRes;LA31539-2;4;HLA-B*27:40;;; +96621-8;LL5759-7;HLA-C HighRes;LA31540-0;1;HLA-C*01:02;;; +96621-8;LL5759-7;HLA-C HighRes;LA31541-8;2;HLA-C*04:01;;; +96621-8;LL5759-7;HLA-C HighRes;LA31542-6;3;HLA-C*07:02;;; +96621-8;LL5759-7;HLA-C HighRes;LA31543-4;4;HLA-C*16:15:01;;; +96626-7;LL5760-5;HLA-A LowRes Single allele;LA31544-2;5;HLA-A*01;;; +96626-7;LL5760-5;HLA-A LowRes Single allele;LA31545-9;6;HLA-A*24;;; +96626-7;LL5760-5;HLA-A LowRes Single allele;LA31546-7;7;HLA-A*02;;; +96626-7;LL5760-5;HLA-A LowRes Single allele;LA31547-5;8;HLA-A*03;;; +96627-5;LL5733-2;HLA-A Serotypes;LA31461-9;2;HLA-A3;;; +96627-5;LL5733-2;HLA-A Serotypes;LA31462-7;3;HLA-A19;;; +96627-5;LL5733-2;HLA-A Serotypes;LA31463-5;4;HLA-A11;;; +96627-5;LL5733-2;HLA-A Serotypes;LA31464-3;5;HLA-A24;;; +96630-9;LL5761-3;HLA-B LowRes Single allele;LA31548-3;5;HLA-B*08;;; +96630-9;LL5761-3;HLA-B LowRes Single allele;LA31549-1;6;HLA-B*37;;; +96630-9;LL5761-3;HLA-B LowRes Single allele;LA31550-9;7;HLA-B*44;;; +96630-9;LL5761-3;HLA-B LowRes Single allele;LA31551-7;8;HLA-B*51;;; +96631-7;LL5734-0;HLA-B Serotypes;LA31465-0;1;HLA-B8;;; +96631-7;LL5734-0;HLA-B Serotypes;LA31466-8;2;HLA-B7;;; +96631-7;LL5734-0;HLA-B Serotypes;LA31467-6;3;HLA-B60;;; +96631-7;LL5734-0;HLA-B Serotypes;LA31468-4;4;HLA-B27;;; +96632-5;LL5693-8;Bw_HLA_Type;LA31315-7;1;Bw4;;; +96632-5;LL5693-8;Bw_HLA_Type;LA31316-5;2;Bw6;;; +96633-3;LL5693-8;Bw_HLA_Type;LA31315-7;1;Bw4;;; +96633-3;LL5693-8;Bw_HLA_Type;LA31316-5;2;Bw6;;; +96634-1;LL5736-5;HLA-C Low resolution;LA31474-2;1;HLA-C*03;;; +96634-1;LL5736-5;HLA-C Low resolution;LA31475-9;2;HLA-C*07;;; +96634-1;LL5736-5;HLA-C Low resolution;LA31476-7;3;HLA-C*10;;; +96634-1;LL5736-5;HLA-C Low resolution;LA31477-5;4;HLA-C*15;;; +96636-6;LL5736-5;HLA-C Low resolution;LA31474-2;1;HLA-C*03;;; +96636-6;LL5736-5;HLA-C Low resolution;LA31475-9;2;HLA-C*07;;; +96636-6;LL5736-5;HLA-C Low resolution;LA31476-7;3;HLA-C*10;;; +96636-6;LL5736-5;HLA-C Low resolution;LA31477-5;4;HLA-C*15;;; +96635-8;LL5735-7;HLA-C Serotype;LA31469-2;1;HLA-Cw10;;; +96635-8;LL5735-7;HLA-C Serotype;LA31470-0;2;HLA-Cw7;;; +96635-8;LL5735-7;HLA-C Serotype;LA31471-8;3;HLA-Cw6;;; +96635-8;LL5735-7;HLA-C Serotype;LA31472-6;4;HLA-Cw5;;; +96635-8;LL5735-7;HLA-C Serotype;LA31473-4;5;HLA-Cw3;;; +96641-6;LL5746-4;HLA-DPA1 HighRes;LA31496-5;1;HLA-DPA1*01:03:03;;; +96641-6;LL5746-4;HLA-DPA1 HighRes;LA31497-3;2;HLA-DPA1*02:04;;; +96641-6;LL5746-4;HLA-DPA1 HighRes;LA31498-1;3;HLA-DPA1*03:01;;; +96642-4;LL5703-5;HLA-DPA1LowResolution;LA31340-5;1;HLA-DPA1*01;;; +96642-4;LL5703-5;HLA-DPA1LowResolution;LA31341-3;2;HLA-DPA1*02;;; +96643-2;LL5703-5;HLA-DPA1LowResolution;LA31340-5;1;HLA-DPA1*01;;; +96643-2;LL5703-5;HLA-DPA1LowResolution;LA31341-3;2;HLA-DPA1*02;;; +96646-5;LL5747-2;HLA-DPB1 HighRes;LA31499-9;1;HLA-DPB1*02:01:07;;; +96646-5;LL5747-2;HLA-DPB1 HighRes;LA31500-4;2;HLA-DPB1*02:02;;; +96646-5;LL5747-2;HLA-DPB1 HighRes;LA31501-2;3;HLA-DPB1*04:02;;; +96646-5;LL5747-2;HLA-DPB1 HighRes;LA31502-0;4;HLA-DPB1*05:01:01;;; +96647-3;LL5702-7;HLA-DPB1LowResolution;LA31335-5;1;HLA-DPB1*105;;; +96647-3;LL5702-7;HLA-DPB1LowResolution;LA31336-3;2;HLA-DPB1*04;;; +96647-3;LL5702-7;HLA-DPB1LowResolution;LA31337-1;3;HLA-DPB1*03;;; +96647-3;LL5702-7;HLA-DPB1LowResolution;LA31338-9;4;HLA-DPB1*09;;; +96647-3;LL5702-7;HLA-DPB1LowResolution;LA31339-7;5;HLA-DPB1*124;;; +96648-1;LL5702-7;HLA-DPB1LowResolution;LA31335-5;1;HLA-DPB1*105;;; +96648-1;LL5702-7;HLA-DPB1LowResolution;LA31336-3;2;HLA-DPB1*04;;; +96648-1;LL5702-7;HLA-DPB1LowResolution;LA31337-1;3;HLA-DPB1*03;;; +96648-1;LL5702-7;HLA-DPB1LowResolution;LA31338-9;4;HLA-DPB1*09;;; +96648-1;LL5702-7;HLA-DPB1LowResolution;LA31339-7;5;HLA-DPB1*124;;; +96649-9;LL5697-9;Permissive;LA31318-1;1;Permissive;;; +96649-9;LL5697-9;Permissive;LA31319-9;2;Non-permissive;;; +96652-3;LL5745-6;HLA-DQA1 HighRes;LA30821-5;1;HLA-DQA1*02:01;;; +96652-3;LL5745-6;HLA-DQA1 HighRes;LA30824-9;2;HLA-DQA1*01:01:01:06;;; +96652-3;LL5745-6;HLA-DQA1 HighRes;LA31495-7;3;HLA-DQA1*05:09;;; +96653-1;LL5701-9;HLA-DQA1LowResolution;LA30822-3;2;HLA-DQA1*03;;; +96653-1;LL5701-9;HLA-DQA1LowResolution;LA30823-1;3;HLA-DQA1*05;;; +96653-1;LL5701-9;HLA-DQA1LowResolution;LA31334-8;4;HLA-DQA1*01;;; +96654-9;LL5701-9;HLA-DQA1LowResolution;LA30822-3;2;HLA-DQA1*03;;; +96654-9;LL5701-9;HLA-DQA1LowResolution;LA30823-1;3;HLA-DQA1*05;;; +96654-9;LL5701-9;HLA-DQA1LowResolution;LA31334-8;4;HLA-DQA1*01;;; +96657-2;LL5744-9;HLA-DQB1 HighRes;LA31492-4;1;HLA-DQB1*03:01:01;;; +96657-2;LL5744-9;HLA-DQB1 HighRes;LA31493-2;2;HLA-DQB1*03:12;;; +96657-2;LL5744-9;HLA-DQB1 HighRes;LA31494-0;3;HLA-DQB1*05:04;;; +96658-0;LL5762-1;HLA-DQB1 LowRes Single allele;LA31552-5;5;HLA-DQB1*02;;; +96658-0;LL5762-1;HLA-DQB1 LowRes Single allele;LA31553-3;6;HLA-DQB1*05;;; +96658-0;LL5762-1;HLA-DQB1 LowRes Single allele;LA31554-1;7;HLA-DQB1*03;;; +96658-0;LL5762-1;HLA-DQB1 LowRes Single allele;LA31555-8;8;HLA-DQB1*06;;; +96659-8;LL5737-3;HLA-DQB1 Serotype;LA31478-3;1;HLA-DQ2;;; +96659-8;LL5737-3;HLA-DQB1 Serotype;LA31479-1;2;HLA-DQ3;;; +96659-8;LL5737-3;HLA-DQB1 Serotype;LA31480-9;3;HLA-DQ4;;; +96659-8;LL5737-3;HLA-DQB1 Serotype;LA31481-7;4;HLA-DQ8(3);;; +96662-2;LL5740-7;HLA-DRB1 HighRes;LA31486-6;1;HLA-DRB1*01:01:01;;; +96662-2;LL5740-7;HLA-DRB1 HighRes;LA31487-4;2;HLA-DRB1*01:01:06;;; +96662-2;LL5740-7;HLA-DRB1 HighRes;LA31488-2;3;HLA-DRB1*03:01:01:02;;; +96662-2;LL5740-7;HLA-DRB1 HighRes;LA31489-0;4;HLA-DRB1*01:18;;; +96664-8;LL5763-9;HLA-DRB1 LowRes Single allele;LA31556-6;5;HLA-DRB1*04;;; +96664-8;LL5763-9;HLA-DRB1 LowRes Single allele;LA31557-4;6;HLA-DRB1*03;;; +96664-8;LL5763-9;HLA-DRB1 LowRes Single allele;LA31558-2;7;HLA-DRB1*15;;; +96664-8;LL5763-9;HLA-DRB1 LowRes Single allele;LA31559-0;8;HLA-DRB1*11;;; +96665-5;LL5738-1;HLA-DRB1 Serotype;LA31482-5;1;HLA-DR1;;; +96665-5;LL5738-1;HLA-DRB1 Serotype;LA31483-3;2;HLA-DR3;;; +96665-5;LL5738-1;HLA-DRB1 Serotype;LA31484-1;3;HLA-DR17(3);;; +96665-5;LL5738-1;HLA-DRB1 Serotype;LA31485-8;4;HLA-DR4;;; +96668-9;LL5700-1;HLA-DRB345HighRes;LA31326-4;1;HLA-DRB3*02:02;;; +96668-9;LL5700-1;HLA-DRB345HighRes;LA31328-0;2;HLA-DRB4*01:03;;; +96668-9;LL5700-1;HLA-DRB345HighRes;LA31329-8;3;HLA-DRB3*01:01;;; +96668-9;LL5700-1;HLA-DRB345HighRes;LA31330-6;4;HLA-DRB3*03:01;;; +96668-9;LL5700-1;HLA-DRB345HighRes;LA31331-4;5;HLA-DRB4*01:01;;; +96668-9;LL5700-1;HLA-DRB345HighRes;LA31332-2;6;HLA-DRB5*01:01;;; +96668-9;LL5700-1;HLA-DRB345HighRes;LA31333-0;7;HLA-DRB5*02:02;;; +96671-3;LL5700-1;HLA-DRB345HighRes;LA31326-4;1;HLA-DRB3*02:02;;; +96671-3;LL5700-1;HLA-DRB345HighRes;LA31328-0;2;HLA-DRB4*01:03;;; +96671-3;LL5700-1;HLA-DRB345HighRes;LA31329-8;3;HLA-DRB3*01:01;;; +96671-3;LL5700-1;HLA-DRB345HighRes;LA31330-6;4;HLA-DRB3*03:01;;; +96671-3;LL5700-1;HLA-DRB345HighRes;LA31331-4;5;HLA-DRB4*01:01;;; +96671-3;LL5700-1;HLA-DRB345HighRes;LA31332-2;6;HLA-DRB5*01:01;;; +96671-3;LL5700-1;HLA-DRB345HighRes;LA31333-0;7;HLA-DRB5*02:02;;; +96669-7;LL5698-7;HLA-DRB345LowRes;LA31320-7;1;HLA-DRB3*02;;; +96669-7;LL5698-7;HLA-DRB345LowRes;LA31321-5;2;HLA-DRB4*01;;; +96669-7;LL5698-7;HLA-DRB345LowRes;LA31322-3;3;HLA-DRB4*03;;; +96672-1;LL5698-7;HLA-DRB345LowRes;LA31320-7;1;HLA-DRB3*02;;; +96672-1;LL5698-7;HLA-DRB345LowRes;LA31321-5;2;HLA-DRB4*01;;; +96672-1;LL5698-7;HLA-DRB345LowRes;LA31322-3;3;HLA-DRB4*03;;; +96670-5;LL5699-5;HLA-DRB345Serotype;LA31323-1;1;DR51;;; +96670-5;LL5699-5;HLA-DRB345Serotype;LA31324-9;2;DR52;;; +96670-5;LL5699-5;HLA-DRB345Serotype;LA31325-6;3;DR53;;; +96673-9;LL5699-5;HLA-DRB345Serotype;LA31323-1;1;DR51;;; +96673-9;LL5699-5;HLA-DRB345Serotype;LA31324-9;2;DR52;;; +96673-9;LL5699-5;HLA-DRB345Serotype;LA31325-6;3;DR53;;; +96716-6;LL5679-7;Odor of body fluid;LA25300-7;2;Without foul odor;;; +96716-6;LL5679-7;Odor of body fluid;LA25302-3;4;Ammonia;;; +96716-6;LL5679-7;Odor of body fluid;LA25303-1;5;Fishy;;; +96716-6;LL5679-7;Odor of body fluid;LA25304-9;6;Sweet smelling;;; +96716-6;LL5679-7;Odor of body fluid;LA31251-4;7;Chlorine;;; +96723-2;LL5679-7;Odor of body fluid;LA25300-7;2;Without foul odor;;; +96723-2;LL5679-7;Odor of body fluid;LA25302-3;4;Ammonia;;; +96723-2;LL5679-7;Odor of body fluid;LA25303-1;5;Fishy;;; +96723-2;LL5679-7;Odor of body fluid;LA25304-9;6;Sweet smelling;;; +96723-2;LL5679-7;Odor of body fluid;LA31251-4;7;Chlorine;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31403-1;1;10 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31404-9;2;20 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31405-6;3;30 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31406-4;4;40 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31407-2;5;60 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31408-0;6;80 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31409-8;7;100 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31410-6;8;120 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31411-4;9;140 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31412-2;10;160 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31413-0;11;180 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31414-8;12;200 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31415-5;13;220 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31416-3;14;240 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31417-1;15;260 minutes;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA30122-8;16;I choose not to answer this question;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31369-4;17;Question not administered;;; +96744-8;LL5716-7;AAPCHO - Intervention/Enabling Minutes;LA31370-2;18;Skipped question;;; +96745-5;LL5715-9;AAPCHO - Group Size;LA12070-1;1;Individual;;; +96745-5;LL5715-9;AAPCHO - Group Size;LA31401-5;2;Small group (2-12);;; +96745-5;LL5715-9;AAPCHO - Group Size;LA31402-3;3;Large group (13 or more);;; +96745-5;LL5715-9;AAPCHO - Group Size;LA12070-1;1;Individual;;; +96745-5;LL5715-9;AAPCHO - Group Size;LA31401-5;2;Small group (2-12);;; +96745-5;LL5715-9;AAPCHO - Group Size;LA31402-3;3;Large group (13 or more);;; +96746-3;LL5714-2;Appointment Type;LA22866-0;1;Scheduled;;; +96746-3;LL5714-2;Appointment Type;LA31398-3;2;Walk-in;;; +96746-3;LL5714-2;Appointment Type;LA31399-1;3;Open access;;; +96746-3;LL5714-2;Appointment Type;LA31400-7;4;Other (e.g., email, patient portal, text message);;; +96746-3;LL5714-2;Appointment Type;LA22866-0;1;Scheduled;;; +96746-3;LL5714-2;Appointment Type;LA31398-3;2;Walk-in;;; +96746-3;LL5714-2;Appointment Type;LA31399-1;3;Open access;;; +96746-3;LL5714-2;Appointment Type;LA31400-7;4;Other (e.g., email, patient portal, text message);;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31385-0;1;Social Services Assessment;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA12064-4;2;Case management;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31386-8;3;Referral - Health;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31387-6;4;Referral - Social Services;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31388-4;5;Eligibility Assistance/Financial Counseling;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31389-2;6;Health Education - Individual;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31390-0;7;Health Education - Small Group (2-12);;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31391-8;8;Health Education - Large Group (13 or more);;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31392-6;9;Supportive Counseling;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31393-4;10;Interpretation;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31394-2;11;Outreach;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31395-9;12;Inreach;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31396-7;13;Transportation - Health;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA31397-5;14;Transportation - Social Services;;; +96748-9;LL5713-4;AAPCHO - Services Provided;LA46-8;15;Other;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31385-0;1;Social Services Assessment;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA12064-4;2;Case management;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31386-8;3;Referral - Health;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31387-6;4;Referral - Social Services;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31388-4;5;Eligibility Assistance/Financial Counseling;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31389-2;6;Health Education - Individual;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31390-0;7;Health Education - Small Group (2-12);;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31391-8;8;Health Education - Large Group (13 or more);;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31392-6;9;Supportive Counseling;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31393-4;10;Interpretation;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31394-2;11;Outreach;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31395-9;12;Inreach;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31396-7;13;Transportation - Health;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA31397-5;14;Transportation - Social Services;;; +96748-9;LL5770-4;AAPCHO - Provided Services;LA46-8;15;Other;;; +96750-5;LL5769-6;0|1|2|3|4 or more;LA6111-4;1;0;;; +96750-5;LL5769-6;0|1|2|3|4 or more;LA6112-2;2;1;;; +96750-5;LL5769-6;0|1|2|3|4 or more;LA6113-0;3;2;;; +96750-5;LL5769-6;0|1|2|3|4 or more;LA6114-8;4;3;;; +96750-5;LL5769-6;0|1|2|3|4 or more;LA31440-3;5;>=4;;; +96751-3;LL5775-3;SARS-CoV-2 S gene mutations;LA31603-6;1;D614G;;; +96751-3;LL5775-3;SARS-CoV-2 S gene mutations;LA31604-4;2;N501Y;;; +96751-3;LL5775-3;SARS-CoV-2 S gene mutations;LA31605-1;3;K417N;;; +96751-3;LL5775-3;SARS-CoV-2 S gene mutations;LA31606-9;4;E484K;;; +96758-8;LL5783-7;Barthel: stairs;LA24937-7;1;Unable;;; +96758-8;LL5783-7;Barthel: stairs;LA31629-1;2;Needs help (verbal, physical, carrying aid);;; +96758-8;LL5783-7;Barthel: stairs;LA12302-8;3;Independent;;; +96758-8;LL5783-7;Barthel: stairs;LA24937-7;1;Unable;;; +96758-8;LL5783-7;Barthel: stairs;LA31629-1;2;Needs help (verbal, physical, carrying aid);;; +96758-8;LL5783-7;Barthel: stairs;LA12302-8;3;Independent;;; +96758-8;LL6122-7;Lysholm - Stair-climbing;LA32881-7;1;No problems;;; +96758-8;LL6122-7;Lysholm - Stair-climbing;LA32882-5;2;Slightly impaired;;; +96758-8;LL6122-7;Lysholm - Stair-climbing;LA32883-3;3;One step at a time;;; +96758-8;LL6122-7;Lysholm - Stair-climbing;LA32884-1;4;Impossible;;; +96759-6;LL5766-2;Barthel: bowels;LA31627-5;1;Incontinent (or needs to be given enemas);;; +96759-6;LL5766-2;Barthel: bowels;LA31626-7;2;Occasional accident;;; +96759-6;LL5766-2;Barthel: bowels;LA31625-9;3;Continent;;; +96759-6;LL5766-2;Barthel: bowels;LA31627-5;1;Incontinent (or needs to be given enemas);;; +96759-6;LL5766-2;Barthel: bowels;LA31626-7;2;Occasional accident;;; +96759-6;LL5766-2;Barthel: bowels;LA31625-9;3;Continent;;; +96760-4;LL5782-9;Barthel: bladder;LA31628-3;1;Incontinent, or catheterized and unable to manage alone;;; +96760-4;LL5782-9;Barthel: bladder;LA31626-7;2;Occasional accident;;; +96760-4;LL5782-9;Barthel: bladder;LA31625-9;3;Continent;;; +96760-4;LL5782-9;Barthel: bladder;LA31628-3;1;Incontinent, or catheterized and unable to manage alone;;; +96760-4;LL5782-9;Barthel: bladder;LA31626-7;2;Occasional accident;;; +96760-4;LL5782-9;Barthel: bladder;LA31625-9;3;Continent;;; +96767-9;LL5777-9;Barthel: grooming;LA31643-2;1;Needs help with personal care;;; +96767-9;LL5777-9;Barthel: grooming;LA31644-0;2;Independent face/hair/teeth/shaving (implements provided);;; +96767-9;LL5777-9;Barthel: grooming;LA31643-2;1;Needs help with personal care;;; +96767-9;LL5777-9;Barthel: grooming;LA31644-0;2;Independent face/hair/teeth/shaving (implements provided);;; +96768-7;LL5778-7;Stillbirth/Miscarriage/NB illness/NB death;LA14667-2;2;Stillbirth;;; +96768-7;LL5778-7;Stillbirth/Miscarriage/NB illness/NB death;LA14272-1;3;Miscarriage;;; +96768-7;LL5778-7;Stillbirth/Miscarriage/NB illness/NB death;LA31613-5;4;Newborn illness;;; +96768-7;LL5778-7;Stillbirth/Miscarriage/NB illness/NB death;LA31614-3;5;Newborn death;;; +96769-5;LL5781-1;Medication immunosuppressive examples;LA14339-8;1;Methotrexate;387381009;Methotrexate (substance);http://snomed.info/sct +96769-5;LL5781-1;Medication immunosuppressive examples;LA16776-9;2;Cyclosporine;387467008;Ciclosporin (substance);http://snomed.info/sct +96769-5;LL5781-1;Medication immunosuppressive examples;LA31622-6;3;Sirolimus;;; +96769-5;LL5781-1;Medication immunosuppressive examples;LA31623-4;4;Mycophenolate;;; +96769-5;LL5781-1;Medication immunosuppressive examples;LA31624-2;5;Azathioprine;;; +96778-6;LL5877-7;Habitat Issues;LA31996-4;1;Pests such as bugs, ants, or mice;;; +96778-6;LL5877-7;Habitat Issues;LA28580-1;2;Mold;;; +96778-6;LL5877-7;Habitat Issues;LA31997-2;3;Lead paint or pipes;;; +96778-6;LL5877-7;Habitat Issues;LA31998-0;4;Lack of heat;;; +96778-6;LL5877-7;Habitat Issues;LA31999-8;5;Oven or stove not working;;; +96778-6;LL5877-7;Habitat Issues;LA32000-4;6;Smoke detectors missing or not working;;; +96778-6;LL5877-7;Habitat Issues;LA32001-2;7;Water leaks;;; +96778-6;LL5877-7;Habitat Issues;LA9-3;8;None of the above;;; +96778-6;LL5877-7;Habitat Issues;LA31996-4;1;Pests such as bugs, ants, or mice;;; +96778-6;LL5877-7;Habitat Issues;LA28580-1;2;Mold;;; +96778-6;LL5877-7;Habitat Issues;LA31997-2;3;Lead paint or pipes;;; +96778-6;LL5877-7;Habitat Issues;LA31998-0;4;Lack of heat;;; +96778-6;LL5877-7;Habitat Issues;LA31999-8;5;Oven or stove not working;;; +96778-6;LL5877-7;Habitat Issues;LA32000-4;6;Smoke detectors missing or not working;;; +96778-6;LL5877-7;Habitat Issues;LA32001-2;7;Water leaks;;; +96778-6;LL5877-7;Habitat Issues;LA9-3;8;None of the above;;; +96778-6;LL5877-7;Habitat Issues;LA31996-4;1;Pests such as bugs, ants, or mice;;; +96778-6;LL5877-7;Habitat Issues;LA28580-1;2;Mold;;; +96778-6;LL5877-7;Habitat Issues;LA31997-2;3;Lead paint or pipes;;; +96778-6;LL5877-7;Habitat Issues;LA31998-0;4;Lack of heat;;; +96778-6;LL5877-7;Habitat Issues;LA31999-8;5;Oven or stove not working;;; +96778-6;LL5877-7;Habitat Issues;LA32000-4;6;Smoke detectors missing or not working;;; +96778-6;LL5877-7;Habitat Issues;LA32001-2;7;Water leaks;;; +96778-6;LL5877-7;Habitat Issues;LA9-3;8;None of the above;;; +96778-6;LL6078-1;Adverse conditions in home;LA32691-0;1;Bug infestation;;; +96778-6;LL6078-1;Adverse conditions in home;LA28580-1;2;Mold;;; +96778-6;LL6078-1;Adverse conditions in home;LA32693-6;3;Lead paint/pipes;;; +96778-6;LL6078-1;Adverse conditions in home;LA32694-4;4;Inadequate heat;;; +96778-6;LL6078-1;Adverse conditions in home;LA32695-1;5;Non-functioning oven/stove;;; +96778-6;LL6078-1;Adverse conditions in home;LA32696-9;6;No or non-working smoke detectors;;; +96778-6;LL6078-1;Adverse conditions in home;LA32001-2;7;Water leaks;;; +96779-4;LL5878-5;Utility shut off risk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96779-4;LL5878-5;Utility shut off risk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96779-4;LL5878-5;Utility shut off risk;LA32002-0;3;Already shut off;;; +96779-4;LL5878-5;Utility shut off risk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96779-4;LL5878-5;Utility shut off risk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96779-4;LL5878-5;Utility shut off risk;LA32002-0;3;Already shut off;;; +96779-4;LL5878-5;Utility shut off risk;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +96779-4;LL5878-5;Utility shut off risk;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +96779-4;LL5878-5;Utility shut off risk;LA32002-0;3;Already shut off;;; +96780-2;LL5868-6;Help finding work;LA31981-6;1;Yes, help finding work;;; +96780-2;LL5868-6;Help finding work;LA31982-4;2;Yes, help keeping work;;; +96780-2;LL5868-6;Help finding work;LA31983-2;3;I do not need or want help;;; +96781-0;LL5866-0;Need help;LA31976-6;1;I don't need any help;;; +96781-0;LL5866-0;Need help;LA31977-4;2;I get all the help I need;;; +96781-0;LL5866-0;Need help;LA31978-2;3;I could use a little more help;;; +96781-0;LL5866-0;Need help;LA31979-0;4;I need a lot more help;;; +96781-0;LL5866-0;Need help;LA31976-6;1;I don't need any help;;; +96781-0;LL5866-0;Need help;LA31977-4;2;I get all the help I need;;; +96781-0;LL5866-0;Need help;LA31978-2;3;I could use a little more help;;; +96781-0;LL5866-0;Need help;LA31979-0;4;I need a lot more help;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96785-1;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96786-9;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96787-7;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA9206-9;1;Excellent;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8967-7;3;Good;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8968-5;4;Fair;;; +96788-5;LL5784-5;Excellent/Good/Fair/Poor - w/score;LA8969-3;5;Poor;;; +96832-1;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96832-1;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96832-1;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96832-1;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96833-9;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96833-9;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96833-9;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96833-9;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96875-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96875-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96875-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96875-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96876-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96876-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96876-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96876-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96877-6;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96877-6;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96877-6;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96877-6;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96878-4;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96878-4;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96878-4;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96878-4;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96879-2;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96879-2;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96879-2;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96879-2;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96880-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96880-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96880-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96880-0;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96881-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15236-5;1;Strongly disagree;;; +96881-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15234-0;2;Somewhat disagree;;; +96881-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15235-7;3;Somewhat agree;;; +96881-8;LL5773-8;Strongly/Somewhat Disagree/Agree;LA15237-3;4;Strongly agree;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96835-4;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96836-2;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96837-0;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96838-8;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA6568-5;1;Not at all;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA31600-2;2;Rare, less than a day or two;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA6569-3;3;Several days;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA31601-0;4;More than 7 days;;; +96839-6;LL5774-6;PhenX Frequency of Anxiety;LA31602-8;5;Nearly every day over the last 2 weeks;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA14468-5;1;A lot;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA13909-9;2;Somewhat;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA13940-4;3;A little;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA6568-5;4;Not at all;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA14468-5;1;A lot;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA13909-9;2;Somewhat;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA13940-4;3;A little;;; +96882-6;LL5799-3;A lot|Some|Little|Not at all;LA6568-5;4;Not at all;;; +96883-4;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96883-4;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96883-4;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96883-4;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96883-4;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96883-4;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96883-4;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96883-4;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96884-2;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96884-2;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96884-2;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96884-2;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96884-2;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96884-2;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96884-2;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96884-2;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96885-9;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96885-9;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96885-9;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96885-9;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96885-9;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96885-9;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96885-9;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96885-9;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96886-7;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96886-7;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96886-7;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96886-7;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96886-7;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96886-7;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96886-7;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96886-7;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96887-5;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96887-5;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96887-5;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96887-5;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96887-5;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96887-5;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96887-5;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96887-5;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96888-3;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96888-3;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96888-3;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96888-3;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96888-3;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96888-3;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96888-3;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96888-3;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96889-1;LL5800-9;PhenX 5 day frequency;LA31668-9;1;None of the days (0 days);;; +96889-1;LL5800-9;PhenX 5 day frequency;LA31669-7;2;A few days (1-2 days);;; +96889-1;LL5800-9;PhenX 5 day frequency;LA31670-5;3;Most days (3-4 days);;; +96889-1;LL5800-9;PhenX 5 day frequency;LA14799-3;4;Every day;;; +96889-1;LL5802-5;PhenX 5 day frequency + IDK;LA31668-9;1;None of the days (0 days);;; +96889-1;LL5802-5;PhenX 5 day frequency + IDK;LA31669-7;2;A few days (1-2 days);;; +96889-1;LL5802-5;PhenX 5 day frequency + IDK;LA31670-5;3;Most days (3-4 days);;; +96889-1;LL5802-5;PhenX 5 day frequency + IDK;LA14799-3;4;Every day;;; +96889-1;LL5802-5;PhenX 5 day frequency + IDK;LA31676-2;5;I don't know;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31671-3;1;A lot less than normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31672-1;2;Somewhat less than normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31675-4;3;About the same as normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31673-9;4;More than normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31674-7;5;A lot more than normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31671-3;1;A lot less than normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31672-1;2;Somewhat less than normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31675-4;3;About the same as normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31673-9;4;More than normal;;; +96890-9;LL5801-7;PhenX - Freqency from normal;LA31674-7;5;A lot more than normal;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31687-9;1;SARS-CoV-2 clade 19A;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31688-7;2;SARS-CoV-2 clade 19B;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31689-5;3;SARS-CoV-2 clade 20A;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31690-3;4;SARS-CoV-2 clade 20B;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31691-1;5;SARS-CoV-2 clade 20C;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31692-9;6;SARS-CoV-2 clade 20D;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31693-7;7;SARS-CoV-2 clade 20E;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31694-5;8;SARS-CoV-2 clade 20F;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31695-2;9;SARS-CoV-2 clade 20G;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31696-0;10;SARS-CoV-2 clade 20H;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31697-8;11;SARS-CoV-2 clade 20I;;; +96896-6;LL5806-6;Nextstrain SARS-CoV-2 clades;LA31698-6;12;SARS-CoV-2 clade 20J;;; +96914-7;LL5824-9;CT dose and image quality category;LA31752-1;1;Abdomen and Pelvis Low Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31753-9;2;Abdomen and Pelvis Routine Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31754-7;3;Abdomen and Pelvis High Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31755-4;4;Cardiac Low Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31756-2;5;Cardiac Routine Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31757-0;6;Cardiac High Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31758-8;7;Chest Low Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31759-6;8;Chest Routine Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31760-4;9;Chest High Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31761-2;10;Cardiac High Dose or Chest High Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31762-0;11;Head Low Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31763-8;12;Head Routine Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31764-6;13;Head High Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31765-3;14;Extremity;;; +96914-7;LL5824-9;CT dose and image quality category;LA31766-1;15;Neck or Cervical Spine;;; +96914-7;LL5824-9;CT dose and image quality category;LA31767-9;16;Thoracic or Lumbar Spine;;; +96914-7;LL5824-9;CT dose and image quality category;LA31768-7;17;Simultaneous Chest and Abdomen and Pelvis;;; +96914-7;LL5824-9;CT dose and image quality category;LA31851-1;18;Simultaneous Thoracic and Lumbar Spine;;; +96914-7;LL5824-9;CT dose and image quality category;LA31769-5;19;Simultaneous Head and Neck Routine Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31770-3;20;Simultaneous Head and Neck High Dose;;; +96914-7;LL5824-9;CT dose and image quality category;LA31771-1;21;Full Body;;; +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA13940-4;2;A little;;; +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA11911-7;3;Quite a lot;;; +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA11912-5;4;Extreme;;; +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA13940-4;2;A little;;; +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA11911-7;3;Quite a lot;;; +96938-6;LL5793-6;None/A little/Quite a lot/Extreme;LA11912-5;4;Extreme;;; +96958-4;LL5837-1;Pos|Neg|Inconcl|Invalid;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +96958-4;LL5837-1;Pos|Neg|Inconcl|Invalid;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +96958-4;LL5837-1;Pos|Neg|Inconcl|Invalid;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +96958-4;LL5837-1;Pos|Neg|Inconcl|Invalid;LA9663-1;5;Inconclusive;419984006;Inconclusive (qualifier value);http://snomed.info/sct +96963-4;LL5822-3;Grimontia holisae|Vibrio fluvialis|Vibrio harveyi;LA31747-1;1;Grimontia holisae;;; +96963-4;LL5822-3;Grimontia holisae|Vibrio fluvialis|Vibrio harveyi;LA19344-3;2;Vibrio fluvialis;;; +96963-4;LL5822-3;Grimontia holisae|Vibrio fluvialis|Vibrio harveyi;LA31748-9;3;Vibrio harveyi;;; +96963-4;LL5822-3;Grimontia holisae|Vibrio fluvialis|Vibrio harveyi;LA11883-8;4;Not detected;;; +96982-4;LL5814-0;Information delivery method;LA28452-3;1;Email;;; +96982-4;LL5814-0;Information delivery method;LA31729-9;2;Fax;;; +96982-4;LL5814-0;Information delivery method;LA31730-7;3;Mail - U.S. Postal Service;;; +96982-4;LL5814-0;Information delivery method;LA31731-5;4;Mail - FedEx;;; +96982-4;LL5814-0;Information delivery method;LA31732-3;5;Mail - UPS;;; +96986-5;LL6282-9;COVID-19 Pos/Neg/Unsat;LA33551-5;1;COVID-19 positive;;; +96986-5;LL6282-9;COVID-19 Pos/Neg/Unsat;LA33552-3;2;COVID-19 negative;;; +96986-5;LL6282-9;COVID-19 Pos/Neg/Unsat;LA13548-5;3;Specimen unsatisfactory for evaluation;125154007;Specimen unsatisfactory for evaluation (finding);http://snomed.info/sct +96990-7;LL5862-9;Vaccine administration location;LA31936-0;1;Commercial vaccination service provider;;; +96990-7;LL5862-9;Vaccine administration location;LA31937-8;2;Corrections/detention health services;;; +96990-7;LL5862-9;Vaccine administration location;LA31957-6;3;Health center - community;;; +96990-7;LL5862-9;Vaccine administration location;LA31958-4;4;Health center - migrant or refugee;;; +96990-7;LL5862-9;Vaccine administration location;LA31959-2;5;Health center - occupational;;; +96990-7;LL5862-9;Vaccine administration location;LA31960-0;6;Health center - STD/HIV clinic;;; +96990-7;LL5862-9;Vaccine administration location;LA31961-8;7;Health center - student;;; +96990-7;LL5862-9;Vaccine administration location;LA31939-4;8;Home health care provider;;; +96990-7;LL5862-9;Vaccine administration location;LA6218-7;9;Hospital;;; +96990-7;LL5862-9;Vaccine administration location;LA15657-2;10;Indian health service;;; +96990-7;LL5862-9;Vaccine administration location;LA31941-0;11;Tribal health;;; +96990-7;LL5862-9;Vaccine administration location;LA31942-8;12;Medical practice - family medicine;;; +96990-7;LL5862-9;Vaccine administration location;LA31962-6;13;Medical practice - pediatrics;;; +96990-7;LL5862-9;Vaccine administration location;LA31963-4;14;Medical practice - internal medicine;;; +96990-7;LL5862-9;Vaccine administration location;LA31964-2;15;Medical practice - OB/GYN;;; +96990-7;LL5862-9;Vaccine administration location;LA31965-9;16;Medical practice - other specialty;;; +96990-7;LL5862-9;Vaccine administration location;LA31966-7;17;Pharmacy - chain;;; +96990-7;LL5862-9;Vaccine administration location;LA31967-5;18;Pharmacy - independent;;; +96990-7;LL5862-9;Vaccine administration location;LA31944-4;19;Public health provider - public health clinic;;; +96990-7;LL5862-9;Vaccine administration location;LA31968-3;20;Public health provider - Federally Qualified Health Center;;; +96990-7;LL5862-9;Vaccine administration location;LA31969-1;21;Public health provider - Rural Health Clinic;;; +96990-7;LL5862-9;Vaccine administration location;LA31945-1;22;Long-term care - nursing home, skilled nursing facility, federally certified;;; +96990-7;LL5862-9;Vaccine administration location;LA31970-9;23;Long-term care - nursing home, skilled nursing facility, non-federally certified;;; +96990-7;LL5862-9;Vaccine administration location;LA31971-7;24;Long-term care - assisted living;;; +96990-7;LL5862-9;Vaccine administration location;LA31972-5;25;Long-term care - intellectual or developmental disability;;; +96990-7;LL5862-9;Vaccine administration location;LA31973-3;26;Long-term care - combination;;; +96990-7;LL5862-9;Vaccine administration location;LA24392-5;27;Urgent Care;;; +96990-7;LL5862-9;Vaccine administration location;LA46-8;28;Other;;; +96990-7;LL5862-9;Vaccine administration location;LA4489-6;29;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +96993-1;LL5861-1;Federal Agency Code;LA31930-3;1;DD2;;; +96993-1;LL5861-1;Federal Agency Code;LA31931-1;2;HS2;;; +96993-1;LL5861-1;Federal Agency Code;LA31932-9;3;DS2;;; +96993-1;LL5861-1;Federal Agency Code;LA31933-7;4;BP2;;; +96993-1;LL5861-1;Federal Agency Code;LA31934-5;5;IH2;;; +96993-1;LL5861-1;Federal Agency Code;LA31935-2;6;VA2;;; +97004-6;LL5805-8;Insulin types;LA31677-0;1;Human insulin;;; +97004-6;LL5805-8;Insulin types;LA31678-8;2;Porcine insulin;;; +97004-6;LL5805-8;Insulin types;LA31686-1;3;Bovine insulin;;; +97004-6;LL5805-8;Insulin types;LA31685-3;4;Aspart;;; +97004-6;LL5805-8;Insulin types;LA31680-4;5;Lispro;;; +97004-6;LL5805-8;Insulin types;LA31681-2;6;Glulisine;;; +97004-6;LL5805-8;Insulin types;LA31682-0;7;Detemir;;; +97004-6;LL5805-8;Insulin types;LA31683-8;8;Degludec;;; +97004-6;LL5805-8;Insulin types;LA31684-6;9;Glargine;;; +97004-6;LL5805-8;Insulin types;LA19544-8;10;None detected;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31772-9;1;Upper cervical;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31773-7;2;Mid lower cervical;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31774-5;3;Cervicothoracic;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31775-2;4;Cervico-thoraco-lumbar;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA22229-1;5;Thoracic;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31776-0;6;Thoracolumbar;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31777-8;7;Thoraco-lumbo-sacral;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA22230-9;8;Lumbar;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31778-6;9;Lumbo-sacral;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31779-4;10;Sacral;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31772-9;1;Upper cervical;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31773-7;2;Mid lower cervical;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31774-5;3;Cervicothoracic;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31775-2;4;Cervico-thoraco-lumbar;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA22229-1;5;Thoracic;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31776-0;6;Thoracolumbar;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31777-8;7;Thoraco-lumbo-sacral;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA22230-9;8;Lumbar;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31778-6;9;Lumbo-sacral;;; +97030-1;LL5825-6;Spine Tango - Level of Intervention;LA31779-4;10;Sacral;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31713-3;1;6 weeks;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA18435-0;2;3 months;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31716-6;3;6 months;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31718-2;4;1 year;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31719-0;5;2 years;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA46-8;6;Other;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31713-3;1;6 weeks;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA18435-0;2;3 months;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31716-6;3;6 months;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31718-2;4;1 year;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA31719-0;5;2 years;;; +97032-7;LL5827-2;Spine Tango - Follow-up Interval;LA46-8;6;Other;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31790-1;2;Axial pain relief;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31791-9;3;Peripheral pain relief;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31792-7;4;Functional improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31793-5;5;Motor improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31794-3;6;Sensory improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31795-0;7;Bowel/bladder function improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31796-8;8;Spinal stabilization;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31797-6;9;Stop deformity progression;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31798-4;10;Deformity correction;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31799-2;11;Prophylactic decompression;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31800-8;12;Cosmetic improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31801-6;13;Diagnostic measures;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA46-8;14;Other;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31790-1;2;Axial pain relief;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31791-9;3;Peripheral pain relief;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31792-7;4;Functional improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31793-5;5;Motor improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31794-3;6;Sensory improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31795-0;7;Bowel/bladder function improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31796-8;8;Spinal stabilization;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31797-6;9;Stop deformity progression;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31798-4;10;Deformity correction;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31799-2;11;Prophylactic decompression;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31800-8;12;Cosmetic improvement;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31801-6;13;Diagnostic measures;;; +97034-3;LL5828-0;Spine Tango - Therapeutic goals/measures;LA46-8;14;Other;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31790-1;2;Axial pain relief;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31791-9;3;Peripheral pain relief;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31792-7;4;Functional improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31793-5;5;Motor improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31794-3;6;Sensory improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31795-0;7;Bowel/bladder function improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31796-8;8;Spinal stabilization;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31797-6;9;Stop deformity progression;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31798-4;10;Deformity correction;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31799-2;11;Prophylactic decompression;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31800-8;12;Cosmetic improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31801-6;13;Diagnostic measures;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA46-8;14;Other;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31790-1;2;Axial pain relief;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31791-9;3;Peripheral pain relief;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31792-7;4;Functional improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31793-5;5;Motor improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31794-3;6;Sensory improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31795-0;7;Bowel/bladder function improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31796-8;8;Spinal stabilization;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31797-6;9;Stop deformity progression;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31798-4;10;Deformity correction;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31799-2;11;Prophylactic decompression;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31800-8;12;Cosmetic improvement;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31801-6;13;Diagnostic measures;;; +97035-0;LL5828-0;Spine Tango - Therapeutic goals/measures;LA46-8;14;Other;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31790-1;2;Axial pain relief;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31791-9;3;Peripheral pain relief;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31792-7;4;Functional improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31793-5;5;Motor improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31794-3;6;Sensory improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31795-0;7;Bowel/bladder function improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31796-8;8;Spinal stabilization;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31797-6;9;Stop deformity progression;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31798-4;10;Deformity correction;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31799-2;11;Prophylactic decompression;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31800-8;12;Cosmetic improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31801-6;13;Diagnostic measures;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA46-8;14;Other;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31790-1;2;Axial pain relief;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31791-9;3;Peripheral pain relief;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31792-7;4;Functional improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31793-5;5;Motor improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31794-3;6;Sensory improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31795-0;7;Bowel/bladder function improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31796-8;8;Spinal stabilization;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31797-6;9;Stop deformity progression;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31798-4;10;Deformity correction;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31799-2;11;Prophylactic decompression;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31800-8;12;Cosmetic improvement;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA31801-6;13;Diagnostic measures;;; +97036-8;LL5828-0;Spine Tango - Therapeutic goals/measures;LA46-8;14;Other;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31802-4;2;NSAID, Paracetamol (WHO I);;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31803-2;3;Weak opiates (WHO II);;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31804-0;4;Strong opiates (WHO III);;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA15260-5;5;Steroids;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31807-3;6;Antidepressives;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31808-1;7;Vitamin B complex;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31809-9;8;Antibiotics;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA46-8;9;Other;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31802-4;2;NSAID, Paracetamol (WHO I);;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31803-2;3;Weak opiates (WHO II);;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31804-0;4;Strong opiates (WHO III);;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA15260-5;5;Steroids;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31807-3;6;Antidepressives;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31808-1;7;Vitamin B complex;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA31809-9;8;Antibiotics;;; +97037-6;LL5829-8;Spine Tango - Meds Spinal surgery/pathology;LA46-8;9;Other;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA31844-6;2;Home-based;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA31845-3;3;Outpatient rehab/physio;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA31846-1;4;Inpatient rehab/physio;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA46-8;5;Other;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA31844-6;2;Home-based;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA31845-3;3;Outpatient rehab/physio;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA31846-1;4;Inpatient rehab/physio;;; +97038-4;LL5835-5;Spine Tango - Rehabilitation;LA46-8;5;Other;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA4720-4;1;Not applicable;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA9206-9;2;Excellent;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA8967-7;3;Good;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA8968-5;4;Fair;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA8969-3;5;Poor;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA4720-4;1;Not applicable;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA9206-9;2;Excellent;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA8967-7;3;Good;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA8968-5;4;Fair;;; +97039-2;LL5830-6;Spine Tango - Surgery outcome;LA8969-3;5;Poor;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31847-9;1;No further follow-up;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31848-7;2;Further follow-up;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31849-5;3;Revision foreseen;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31850-3;4;Other primary intervention foreseen;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31847-9;1;No further follow-up;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31848-7;2;Further follow-up;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31849-5;3;Revision foreseen;;; +97040-0;LL5836-3;Spine Tango - Follow-up Decision;LA31850-3;4;Other primary intervention foreseen;;; +97044-2;LL5831-4;Spine Tango - Complications timing;LA31810-7;1;Early, Op-day - 28 days postop;;; +97044-2;LL5831-4;Spine Tango - Complications timing;LA31811-5;2;Sub-acute, 2 - 6 months;;; +97044-2;LL5831-4;Spine Tango - Complications timing;LA31812-3;3;Late, > 6 months;;; +97044-2;LL5831-4;Spine Tango - Complications timing;LA31810-7;1;Early, Op-day - 28 days postop;;; +97044-2;LL5831-4;Spine Tango - Complications timing;LA31811-5;2;Sub-acute, 2 - 6 months;;; +97044-2;LL5831-4;Spine Tango - Complications timing;LA31812-3;3;Late, > 6 months;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31813-1;1;Sensory dysfunction;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31814-9;2;Motor dysfunction;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31815-6;3;Bowel/bladder dysfunction;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31816-4;4;Non-union;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31817-2;5;Implant failure;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31818-0;6;Instability;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31819-8;7;CSF leak/pseudomeningocele;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31820-6;8;Wound infection superficial;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31821-4;9;Wound infection deep;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31822-2;10;Spondylitis;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31823-0;11;Discitis;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31824-8;12;Epidural hematoma;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31825-5;13;Extravertebral hematoma;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31826-3;14;Wrong level;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31827-1;15;Implant malposition;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31828-9;16;Recurrence of symptoms;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31829-7;17;Graft complication;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31830-5;18;Sequelae anaesthesia;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31831-3;19;Adjacent segment pathology;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31832-1;20;Recurrent tumor;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31833-9;21;Decompensation of spine;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA18277-6;22;Cardiovascular;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA16968-2;23;Gastrointestinal;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA4174-4;24;Central Nervous System;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31835-4;25;Fx vertebral structures;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31836-2;26;Thromboembolism;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA46-8;27;Other;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31813-1;1;Sensory dysfunction;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31814-9;2;Motor dysfunction;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31815-6;3;Bowel/bladder dysfunction;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31816-4;4;Non-union;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31817-2;5;Implant failure;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31818-0;6;Instability;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31819-8;7;CSF leak/pseudomeningocele;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31820-6;8;Wound infection superficial;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31821-4;9;Wound infection deep;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31822-2;10;Spondylitis;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31823-0;11;Discitis;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31824-8;12;Epidural hematoma;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31825-5;13;Extravertebral hematoma;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31826-3;14;Wrong level;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31827-1;15;Implant malposition;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31828-9;16;Recurrence of symptoms;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31829-7;17;Graft complication;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31830-5;18;Sequelae anaesthesia;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31831-3;19;Adjacent segment pathology;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31832-1;20;Recurrent tumor;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31833-9;21;Decompensation of spine;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA18277-6;22;Cardiovascular;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA16968-2;23;Gastrointestinal;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA4174-4;24;Central Nervous System;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31835-4;25;Fx vertebral structures;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA31836-2;26;Thromboembolism;;; +97045-9;LL5832-2;Spine Tango - Complications Type;LA46-8;27;Other;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA31837-0;2;Non-operative inpatient;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA31838-8;3;Non-operative outpatient;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA31839-6;4;Reintervention;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA46-8;5;Other;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA31837-0;2;Non-operative inpatient;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA31838-8;3;Non-operative outpatient;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA31839-6;4;Reintervention;;; +97046-7;LL5833-0;Spine Tango - Therapeutic consequences;LA46-8;5;Other;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31840-4;2;Increased pain;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31841-2;3;Prolonged impairment;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31842-0;4;Reduced social activities;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31843-8;5;Permanent impairment;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA46-8;6;Other;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31840-4;2;Increased pain;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31841-2;3;Prolonged impairment;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31842-0;4;Reduced social activities;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA31843-8;5;Permanent impairment;;; +97047-5;LL5834-8;Sping Tango - Individual Consequences;LA46-8;6;Other;;; +97057-4;LL5873-6;FINDRISC - BMI;LA31984-0;1;Lower than 25 kg/m^2;;; +97057-4;LL5873-6;FINDRISC - BMI;LA31985-7;2;25-30 kg/m^2;;; +97057-4;LL5873-6;FINDRISC - BMI;LA31986-5;3;Higher than 30 kg/m^2;;; +97057-4;LL5873-6;FINDRISC - BMI;LA31984-0;1;Lower than 25 kg/m^2;;; +97057-4;LL5873-6;FINDRISC - BMI;LA31985-7;2;25-30 kg/m^2;;; +97057-4;LL5873-6;FINDRISC - BMI;LA31986-5;3;Higher than 30 kg/m^2;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31920-4;1;Men: less than 94 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31921-2;2;Men: 94-102 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31922-0;3;Men: more than 102 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31923-8;4;Women: less than 80 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31924-6;5;Women: 80-88 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31925-3;6;Women: more than 88 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31920-4;1;Men: less than 94 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31921-2;2;Men: 94-102 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31922-0;3;Men: more than 102 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31923-8;4;Women: less than 80 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31924-6;5;Women: 80-88 cm;;; +97058-2;LL5855-3;FINDRISC - Waist Circumference;LA31925-3;6;Women: more than 88 cm;;; +97060-8;LL5857-9;Every day (0)/Not every day (1);LA14799-3;1;Every day;;; +97060-8;LL5857-9;Every day (0)/Not every day (1);LA31926-1;2;Not every day;;; +97062-4;LL5858-7;No (0)/Yes (5);LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97062-4;LL5858-7;No (0)/Yes (5);LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97063-2;LL5859-5;FINDRISC - Fam Hx Diabetes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97063-2;LL5859-5;FINDRISC - Fam Hx Diabetes;LA31927-9;2;Yes: grandparent, aunt, uncle, or first cousin (but not own parent, brother, sister or child);;; +97063-2;LL5859-5;FINDRISC - Fam Hx Diabetes;LA31928-7;3;Yes: parent, brother, sister, or own child;;; +97076-4;LL5881-9;News sources;LA32010-3;1;Print newspaper or magazines;;; +97076-4;LL5881-9;News sources;LA32011-1;2;Radio;;; +97076-4;LL5881-9;News sources;LA32012-9;3;TV (local, network, cable);;; +97076-4;LL5881-9;News sources;LA32013-7;4;Social media;;; +97076-4;LL5881-9;News sources;LA32014-5;5;News website or app;;; +97076-4;LL5881-9;News sources;LA32015-2;6;Family, friends, or neighbors;;; +97076-4;LL5881-9;News sources;LA32010-3;1;Print newspaper or magazines;;; +97076-4;LL5881-9;News sources;LA32011-1;2;Radio;;; +97076-4;LL5881-9;News sources;LA32012-9;3;TV (local, network, cable);;; +97076-4;LL5881-9;News sources;LA32013-7;4;Social media;;; +97076-4;LL5881-9;News sources;LA32014-5;5;News website or app;;; +97076-4;LL5881-9;News sources;LA32015-2;6;Family, friends, or neighbors;;; +97077-2;LL5880-1;Hours per day;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97077-2;LL5880-1;Hours per day;LA32004-6;2;<1 hour;;; +97077-2;LL5880-1;Hours per day;LA32005-3;3;1 hour - <2 hours;;; +97077-2;LL5880-1;Hours per day;LA32006-1;4;2 hours - <3 hours;;; +97077-2;LL5880-1;Hours per day;LA32007-9;5;3 hours - <4 hours;;; +97077-2;LL5880-1;Hours per day;LA32008-7;6;4 hours - <5 hours;;; +97077-2;LL5880-1;Hours per day;LA32009-5;7;5 or more hours per day;;; +97077-2;LL5880-1;Hours per day;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97077-2;LL5880-1;Hours per day;LA32004-6;2;<1 hour;;; +97077-2;LL5880-1;Hours per day;LA32005-3;3;1 hour - <2 hours;;; +97077-2;LL5880-1;Hours per day;LA32006-1;4;2 hours - <3 hours;;; +97077-2;LL5880-1;Hours per day;LA32007-9;5;3 hours - <4 hours;;; +97077-2;LL5880-1;Hours per day;LA32008-7;6;4 hours - <5 hours;;; +97077-2;LL5880-1;Hours per day;LA32009-5;7;5 or more hours per day;;; +97078-0;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97078-0;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97078-0;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97078-0;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97078-0;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97078-0;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97078-0;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97078-0;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97079-8;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97079-8;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97079-8;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97079-8;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97079-8;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97079-8;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97079-8;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97079-8;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97080-6;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97080-6;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97080-6;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97080-6;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97080-6;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97080-6;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97080-6;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97080-6;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97081-4;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97081-4;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97081-4;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97081-4;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97081-4;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97081-4;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97081-4;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97081-4;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97082-2;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97082-2;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97082-2;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97082-2;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97082-2;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97082-2;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97082-2;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97082-2;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97083-0;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97083-0;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97083-0;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97083-0;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97083-0;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97083-0;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97083-0;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97083-0;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97084-8;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97084-8;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97084-8;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97084-8;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97084-8;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97084-8;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97084-8;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97084-8;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97085-5;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97085-5;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97085-5;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97085-5;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97085-5;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97085-5;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97085-5;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97085-5;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97086-3;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97086-3;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97086-3;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97086-3;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97086-3;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97086-3;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97086-3;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97086-3;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97087-1;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97087-1;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97087-1;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97087-1;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97087-1;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97087-1;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97087-1;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97087-1;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97093-9;LL5879-3;Positve-Negative Media Source;LA6576-8;1;Positive;10828004;Positive (qualifier value);http://snomed.info/sct +97093-9;LL5879-3;Positve-Negative Media Source;LA14786-0;2;Neutral;;; +97093-9;LL5879-3;Positve-Negative Media Source;LA6577-6;3;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97093-9;LL5879-3;Positve-Negative Media Source;LA32003-8;4;I don't use this source;;; +97108-5;LL5882-7;COVEX Work Situation;LA32016-0;1;Working full time;;; +97108-5;LL5882-7;COVEX Work Situation;LA32017-8;2;Working part time;;; +97108-5;LL5882-7;COVEX Work Situation;LA32018-6;3;Self-employed;;; +97108-5;LL5882-7;COVEX Work Situation;LA32019-4;4;Looking for work, unemployed;;; +97108-5;LL5882-7;COVEX Work Situation;LA32020-2;5;Unemployed, not looking;;; +97108-5;LL5882-7;COVEX Work Situation;LA32021-0;6;Temporarily laid off;;; +97108-5;LL5882-7;COVEX Work Situation;LA17991-3;7;Retired;;; +97108-5;LL5882-7;COVEX Work Situation;LA17959-0;8;Homemaker;;; +97108-5;LL5882-7;COVEX Work Situation;LA32023-6;9;Maternity leave;;; +97108-5;LL5882-7;COVEX Work Situation;LA32024-4;10;Illness/sick leave;;; +97108-5;LL5882-7;COVEX Work Situation;LA17994-7;11;Disabled;;; +97108-5;LL5882-7;COVEX Work Situation;LA46-8;12;Other;;; +97110-1;LL5883-5;COVEX Work Settings;LA27446-6;1;At home;;; +97110-1;LL5883-5;COVEX Work Settings;LA32026-9;2;In a medical setting (hospital, clinic, doctor's office, urgent care center, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32027-7;3;In an office or apartment building;;; +97110-1;LL5883-5;COVEX Work Settings;LA32028-5;4;In a private household(s) (nanny, housekeeper, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32029-3;5;In a setting with regular customer interaction (delivery, transport, retail, food service, restaurant, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32030-1;6;In the community as a first responder (police, EMS, firefighter, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32032-7;7;In a warehouse or factory;;; +97110-1;LL5883-5;COVEX Work Settings;LA32031-9;8;Outside (gardening, construction, road work, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA46-8;9;Other;;; +97110-1;LL5883-5;COVEX Work Settings;LA27446-6;1;At home;;; +97110-1;LL5883-5;COVEX Work Settings;LA32026-9;2;In a medical setting (hospital, clinic, doctor's office, urgent care center, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32027-7;3;In an office or apartment building;;; +97110-1;LL5883-5;COVEX Work Settings;LA32028-5;4;In a private household(s) (nanny, housekeeper, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32029-3;5;In a setting with regular customer interaction (delivery, transport, retail, food service, restaurant, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32030-1;6;In the community as a first responder (police, EMS, firefighter, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA32032-7;7;In a warehouse or factory;;; +97110-1;LL5883-5;COVEX Work Settings;LA32031-9;8;Outside (gardening, construction, road work, etc.);;; +97110-1;LL5883-5;COVEX Work Settings;LA46-8;9;Other;;; +97114-3;LL5883-5;COVEX Work Settings;LA27446-6;1;At home;;; +97114-3;LL5883-5;COVEX Work Settings;LA32026-9;2;In a medical setting (hospital, clinic, doctor's office, urgent care center, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32027-7;3;In an office or apartment building;;; +97114-3;LL5883-5;COVEX Work Settings;LA32028-5;4;In a private household(s) (nanny, housekeeper, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32029-3;5;In a setting with regular customer interaction (delivery, transport, retail, food service, restaurant, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32030-1;6;In the community as a first responder (police, EMS, firefighter, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32032-7;7;In a warehouse or factory;;; +97114-3;LL5883-5;COVEX Work Settings;LA32031-9;8;Outside (gardening, construction, road work, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA46-8;9;Other;;; +97114-3;LL5883-5;COVEX Work Settings;LA27446-6;1;At home;;; +97114-3;LL5883-5;COVEX Work Settings;LA32026-9;2;In a medical setting (hospital, clinic, doctor's office, urgent care center, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32027-7;3;In an office or apartment building;;; +97114-3;LL5883-5;COVEX Work Settings;LA32028-5;4;In a private household(s) (nanny, housekeeper, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32029-3;5;In a setting with regular customer interaction (delivery, transport, retail, food service, restaurant, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32030-1;6;In the community as a first responder (police, EMS, firefighter, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA32032-7;7;In a warehouse or factory;;; +97114-3;LL5883-5;COVEX Work Settings;LA32031-9;8;Outside (gardening, construction, road work, etc.);;; +97114-3;LL5883-5;COVEX Work Settings;LA46-8;9;Other;;; +97111-9;LL5884-3;COVEX Job loss;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97111-9;LL5884-3;COVEX Job loss;LA32033-5;2;Yes, I was laid off from a job;;; +97111-9;LL5884-3;COVEX Job loss;LA32034-3;3;Yes, I was furloughed from a job;;; +97111-9;LL5884-3;COVEX Job loss;LA32035-0;4;Yes, I lost all my jobs;;; +97111-9;LL5884-3;COVEX Job loss;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97111-9;LL5884-3;COVEX Job loss;LA32033-5;2;Yes, I was laid off from a job;;; +97111-9;LL5884-3;COVEX Job loss;LA32034-3;3;Yes, I was furloughed from a job;;; +97111-9;LL5884-3;COVEX Job loss;LA32035-0;4;Yes, I lost all my jobs;;; +97113-5;LL5885-0;COVEX Work Changes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97113-5;LL5885-0;COVEX Work Changes;LA32036-8;2;Yes, switched to working remotely;;; +97113-5;LL5885-0;COVEX Work Changes;LA32037-6;3;Yes, increase in work hours;;; +97113-5;LL5885-0;COVEX Work Changes;LA32038-4;4;Yes, decrease in work hours;;; +97113-5;LL5885-0;COVEX Work Changes;LA32039-2;5;Yes, increase in workload;;; +97113-5;LL5885-0;COVEX Work Changes;LA32040-0;6;Yes, decrease in workload;;; +97113-5;LL5885-0;COVEX Work Changes;LA32041-8;7;Yes, salary or wages cut;;; +97113-5;LL5885-0;COVEX Work Changes;LA32042-6;8;Yes, salary or wages increased;;; +97113-5;LL5885-0;COVEX Work Changes;LA32043-4;9;Yes, other significant change;;; +97113-5;LL5885-0;COVEX Work Changes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97113-5;LL5885-0;COVEX Work Changes;LA32036-8;2;Yes, switched to working remotely;;; +97113-5;LL5885-0;COVEX Work Changes;LA32037-6;3;Yes, increase in work hours;;; +97113-5;LL5885-0;COVEX Work Changes;LA32038-4;4;Yes, decrease in work hours;;; +97113-5;LL5885-0;COVEX Work Changes;LA32039-2;5;Yes, increase in workload;;; +97113-5;LL5885-0;COVEX Work Changes;LA32040-0;6;Yes, decrease in workload;;; +97113-5;LL5885-0;COVEX Work Changes;LA32041-8;7;Yes, salary or wages cut;;; +97113-5;LL5885-0;COVEX Work Changes;LA32042-6;8;Yes, salary or wages increased;;; +97113-5;LL5885-0;COVEX Work Changes;LA32043-4;9;Yes, other significant change;;; +97115-0;LL5886-8;COVEX Student Status;LA32044-2;1;Full time student;;; +97115-0;LL5886-8;COVEX Student Status;LA32045-9;2;Part time student;;; +97115-0;LL5886-8;COVEX Student Status;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +97116-8;LL5887-6;COVEX Continued Student;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97116-8;LL5887-6;COVEX Continued Student;LA32046-7;2;No, graduated or finished program early;;; +97116-8;LL5887-6;COVEX Continued Student;LA33-6;3;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97118-4;LL5888-4;Increase|Decrease|NoChange;LA32048-3;1;Increase;;; +97118-4;LL5888-4;Increase|Decrease|NoChange;LA32049-1;2;Decrease;;; +97118-4;LL5888-4;Increase|Decrease|NoChange;LA64-1;3;No change;;; +97118-4;LL5888-4;Increase|Decrease|NoChange;LA32048-3;1;Increase;;; +97118-4;LL5888-4;Increase|Decrease|NoChange;LA32049-1;2;Decrease;;; +97118-4;LL5888-4;Increase|Decrease|NoChange;LA64-1;3;No change;;; +97122-6;LL5889-2;COVEX - Household Members;LA32050-9;1;Partner;;; +97122-6;LL5889-2;COVEX - Household Members;LA32051-7;2;Parents;;; +97122-6;LL5889-2;COVEX - Household Members;LA32052-5;3;My children;;; +97122-6;LL5889-2;COVEX - Household Members;LA32053-3;4;Siblings;;; +97122-6;LL5889-2;COVEX - Household Members;LA16276-0;5;Grandparents;;; +97122-6;LL5889-2;COVEX - Household Members;LA32055-8;6;Other family members (e.g., aunt, uncle, cousin);;; +97122-6;LL5889-2;COVEX - Household Members;LA32056-6;7;Friend(s);;; +97122-6;LL5889-2;COVEX - Household Members;LA32057-4;8;Other household members/roomates;;; +97122-6;LL5889-2;COVEX - Household Members;LA46-8;9;Other;;; +97122-6;LL5889-2;COVEX - Household Members;LA32050-9;1;Partner;;; +97122-6;LL5889-2;COVEX - Household Members;LA32051-7;2;Parents;;; +97122-6;LL5889-2;COVEX - Household Members;LA32052-5;3;My children;;; +97122-6;LL5889-2;COVEX - Household Members;LA32053-3;4;Siblings;;; +97122-6;LL5889-2;COVEX - Household Members;LA16276-0;5;Grandparents;;; +97122-6;LL5889-2;COVEX - Household Members;LA32055-8;6;Other family members (e.g., aunt, uncle, cousin);;; +97122-6;LL5889-2;COVEX - Household Members;LA32056-6;7;Friend(s);;; +97122-6;LL5889-2;COVEX - Household Members;LA32057-4;8;Other household members/roomates;;; +97122-6;LL5889-2;COVEX - Household Members;LA46-8;9;Other;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97124-2;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97125-9;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97126-7;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97127-5;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97128-3;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97129-1;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97130-9;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97131-7;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97132-5;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97134-1;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97136-6;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97137-4;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97138-2;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97139-0;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97140-8;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97141-6;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97142-4;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97143-2;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97144-0;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA32069-9;1;Not at all/I didn't try this;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA14454-5;2;Slightly;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA13909-9;3;Somewhat;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA13939-6;4;Moderately;;; +97146-5;LL5892-6;Coping Strategy Helpfulness;LA13914-9;5;Very much;;; +97135-8;LL5942-9;COVEX - Positive Impact;LA32275-2;1;No positive impact;;; +97135-8;LL5942-9;COVEX - Positive Impact;LA32276-0;2;Small positive impact;;; +97135-8;LL5942-9;COVEX - Positive Impact;LA32277-8;3;Moderate/medium positive impact;;; +97135-8;LL5942-9;COVEX - Positive Impact;LA32278-6;4;Large positive impact;;; +97155-6;LL5931-2;SARS-CoV-2 immunization status;LA32254-7;1;Received all required doses > 14 days ago;;; +97155-6;LL5931-2;SARS-CoV-2 immunization status;LA32256-2;2;Received all required doses <=14 days ago;;; +97155-6;LL5931-2;SARS-CoV-2 immunization status;LA32255-4;3;Unimmunized/partial series;;; +97155-6;LL5931-2;SARS-CoV-2 immunization status;LA4489-6;4;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31947-7;1;14-00-02-03-02-12-06-06;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31948-5;2;18-05-03-01-01-10-01-05;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31949-3;3;12-03-03-05-01-11-01-04;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31950-1;4;18-05-03-01-01-12-01-05;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31951-9;5;12-03-03-05-01-11-02-03;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31952-7;6;14-02-01-03-02-07-05-05;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31953-5;7;12-02-02-05-01-11-02-04;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31954-3;8;12-01-01-02-01-10-02-04;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31955-0;9;12-01-01-02-01-09-02-05;;; +97325-5;LL5863-7;Staph aureus VNTR pattern;LA31956-8;10;16-01-01-05-01-11-07-06;;; +97328-9;LL5810-8;Examination interval;LA31711-7;1;Before surgery;;; +97328-9;LL5810-8;Examination interval;LA31712-5;2;4 weeks;;; +97328-9;LL5810-8;Examination interval;LA31713-3;3;6 weeks;;; +97328-9;LL5810-8;Examination interval;LA31714-1;4;2 months;;; +97328-9;LL5810-8;Examination interval;LA18435-0;5;3 months;;; +97328-9;LL5810-8;Examination interval;LA31716-6;6;6 months;;; +97328-9;LL5810-8;Examination interval;LA31717-4;7;9 months;;; +97328-9;LL5810-8;Examination interval;LA31718-2;8;1 year;;; +97328-9;LL5810-8;Examination interval;LA31719-0;9;2 years;;; +97328-9;LL5810-8;Examination interval;LA31720-8;10;3 years;;; +97328-9;LL5810-8;Examination interval;LA31721-6;11;4 years;;; +97328-9;LL5810-8;Examination interval;LA31722-4;12;5 years;;; +97328-9;LL5810-8;Examination interval;LA31723-2;13;Other: years;;; +97328-9;LL5810-8;Examination interval;LA31711-7;1;Before surgery;;; +97328-9;LL5810-8;Examination interval;LA31712-5;2;4 weeks;;; +97328-9;LL5810-8;Examination interval;LA31713-3;3;6 weeks;;; +97328-9;LL5810-8;Examination interval;LA31714-1;4;2 months;;; +97328-9;LL5810-8;Examination interval;LA18435-0;5;3 months;;; +97328-9;LL5810-8;Examination interval;LA31716-6;6;6 months;;; +97328-9;LL5810-8;Examination interval;LA31717-4;7;9 months;;; +97328-9;LL5810-8;Examination interval;LA31718-2;8;1 year;;; +97328-9;LL5810-8;Examination interval;LA31719-0;9;2 years;;; +97328-9;LL5810-8;Examination interval;LA31720-8;10;3 years;;; +97328-9;LL5810-8;Examination interval;LA31721-6;11;4 years;;; +97328-9;LL5810-8;Examination interval;LA31722-4;12;5 years;;; +97328-9;LL5810-8;Examination interval;LA31723-2;13;Other: years;;; +97328-9;LL5810-8;Examination interval;LA31711-7;1;Before surgery;;; +97328-9;LL5810-8;Examination interval;LA31712-5;2;4 weeks;;; +97328-9;LL5810-8;Examination interval;LA31713-3;3;6 weeks;;; +97328-9;LL5810-8;Examination interval;LA31714-1;4;2 months;;; +97328-9;LL5810-8;Examination interval;LA18435-0;5;3 months;;; +97328-9;LL5810-8;Examination interval;LA31716-6;6;6 months;;; +97328-9;LL5810-8;Examination interval;LA31717-4;7;9 months;;; +97328-9;LL5810-8;Examination interval;LA31718-2;8;1 year;;; +97328-9;LL5810-8;Examination interval;LA31719-0;9;2 years;;; +97328-9;LL5810-8;Examination interval;LA31720-8;10;3 years;;; +97328-9;LL5810-8;Examination interval;LA31721-6;11;4 years;;; +97328-9;LL5810-8;Examination interval;LA31722-4;12;5 years;;; +97328-9;LL5810-8;Examination interval;LA31723-2;13;Other: years;;; +97329-7;LL5811-6;Neck pain troubles;LA31724-0;1;Neck pain;;; +97329-7;LL5811-6;Neck pain troubles;LA31725-7;2;Arm/shoulder pain;;; +97329-7;LL5811-6;Neck pain troubles;LA31726-5;3;Sensory disturbances in the neck/arm/shoulder, e.g. tingling, 'pins and needles', numbness;;; +97329-7;LL5811-6;Neck pain troubles;LA9-3;4;None of the above;;; +97329-7;LL5811-6;Neck pain troubles;LA31724-0;1;Neck pain;;; +97329-7;LL5811-6;Neck pain troubles;LA31725-7;2;Arm/shoulder pain;;; +97329-7;LL5811-6;Neck pain troubles;LA31726-5;3;Sensory disturbances in the neck/arm/shoulder, e.g. tingling, 'pins and needles', numbness;;; +97329-7;LL5811-6;Neck pain troubles;LA9-3;4;None of the above;;; +97888-2;LL5811-6;Neck pain troubles;LA31724-0;1;Neck pain;;; +97888-2;LL5811-6;Neck pain troubles;LA31725-7;2;Arm/shoulder pain;;; +97888-2;LL5811-6;Neck pain troubles;LA31726-5;3;Sensory disturbances in the neck/arm/shoulder, e.g. tingling, 'pins and needles', numbness;;; +97888-2;LL5811-6;Neck pain troubles;LA9-3;4;None of the above;;; +97330-5;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +97330-5;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +97330-5;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +97330-5;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +97330-5;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +97330-5;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +97330-5;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +97330-5;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +97330-5;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +97330-5;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98920-2;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98920-2;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98920-2;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98920-2;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98920-2;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98921-0;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98921-0;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98921-0;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98921-0;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98921-0;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98922-8;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98922-8;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98922-8;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98922-8;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98922-8;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98923-6;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98923-6;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98923-6;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98923-6;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98923-6;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98924-4;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98924-4;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98924-4;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98924-4;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98924-4;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98925-1;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98925-1;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98925-1;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98925-1;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98925-1;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98926-9;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98926-9;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98926-9;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98926-9;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98926-9;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98927-7;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98927-7;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98927-7;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98927-7;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98927-7;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98928-5;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98928-5;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98928-5;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98928-5;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98928-5;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98929-3;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98929-3;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98929-3;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98929-3;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98929-3;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98930-1;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98930-1;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98930-1;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98930-1;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98930-1;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +98931-9;LL5813-2;Not at all/Extremely;LA6568-5;1;Not at all;;; +98931-9;LL5813-2;Not at all/Extremely;LA13863-8;2;A little bit;;; +98931-9;LL5813-2;Not at all/Extremely;LA13939-6;3;Moderately;;; +98931-9;LL5813-2;Not at all/Extremely;LA13902-4;4;Quite a bit;;; +98931-9;LL5813-2;Not at all/Extremely;LA14868-6;5;Extremely;;; +97332-1;LL5816-5;Very good/Very bad;LA13913-1;1;Very Good;;; +97332-1;LL5816-5;Very good/Very bad;LA8967-7;2;Good;;; +97332-1;LL5816-5;Very good/Very bad;LA6751-7;3;Moderate;;; +97332-1;LL5816-5;Very good/Very bad;LA31734-9;4;Bad;;; +97332-1;LL5816-5;Very good/Very bad;LA21282-1;5;Very bad;;; +97332-1;LL5816-5;Very good/Very bad;LA13913-1;1;Very Good;;; +97332-1;LL5816-5;Very good/Very bad;LA8967-7;2;Good;;; +97332-1;LL5816-5;Very good/Very bad;LA6751-7;3;Moderate;;; +97332-1;LL5816-5;Very good/Very bad;LA31734-9;4;Bad;;; +97332-1;LL5816-5;Very good/Very bad;LA21282-1;5;Very bad;;; +97332-1;LL5816-5;Very good/Very bad;LA13913-1;1;Very Good;;; +97332-1;LL5816-5;Very good/Very bad;LA8967-7;2;Good;;; +97332-1;LL5816-5;Very good/Very bad;LA6751-7;3;Moderate;;; +97332-1;LL5816-5;Very good/Very bad;LA31734-9;4;Bad;;; +97332-1;LL5816-5;Very good/Very bad;LA21282-1;5;Very bad;;; +97333-9;LL5817-3;None/More than 21 days;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97333-9;LL5817-3;None/More than 21 days;LA31735-6;2;Between 1 and 7 days;;; +97333-9;LL5817-3;None/More than 21 days;LA31736-4;3;Between 8 and 14 days;;; +97333-9;LL5817-3;None/More than 21 days;LA31737-2;4;Between 15 and 21 days;;; +97333-9;LL5817-3;None/More than 21 days;LA30053-5;5;More than 21 days;;; +97333-9;LL5817-3;None/More than 21 days;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97333-9;LL5817-3;None/More than 21 days;LA31735-6;2;Between 1 and 7 days;;; +97333-9;LL5817-3;None/More than 21 days;LA31736-4;3;Between 8 and 14 days;;; +97333-9;LL5817-3;None/More than 21 days;LA31737-2;4;Between 15 and 21 days;;; +97333-9;LL5817-3;None/More than 21 days;LA30053-5;5;More than 21 days;;; +97333-9;LL5817-3;None/More than 21 days;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97333-9;LL5817-3;None/More than 21 days;LA31735-6;2;Between 1 and 7 days;;; +97333-9;LL5817-3;None/More than 21 days;LA31736-4;3;Between 8 and 14 days;;; +97333-9;LL5817-3;None/More than 21 days;LA31737-2;4;Between 15 and 21 days;;; +97333-9;LL5817-3;None/More than 21 days;LA30053-5;5;More than 21 days;;; +97334-7;LL5817-3;None/More than 21 days;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97334-7;LL5817-3;None/More than 21 days;LA31735-6;2;Between 1 and 7 days;;; +97334-7;LL5817-3;None/More than 21 days;LA31736-4;3;Between 8 and 14 days;;; +97334-7;LL5817-3;None/More than 21 days;LA31737-2;4;Between 15 and 21 days;;; +97334-7;LL5817-3;None/More than 21 days;LA30053-5;5;More than 21 days;;; +97334-7;LL5817-3;None/More than 21 days;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97334-7;LL5817-3;None/More than 21 days;LA31735-6;2;Between 1 and 7 days;;; +97334-7;LL5817-3;None/More than 21 days;LA31736-4;3;Between 8 and 14 days;;; +97334-7;LL5817-3;None/More than 21 days;LA31737-2;4;Between 15 and 21 days;;; +97334-7;LL5817-3;None/More than 21 days;LA30053-5;5;More than 21 days;;; +97334-7;LL5817-3;None/More than 21 days;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97334-7;LL5817-3;None/More than 21 days;LA31735-6;2;Between 1 and 7 days;;; +97334-7;LL5817-3;None/More than 21 days;LA31736-4;3;Between 8 and 14 days;;; +97334-7;LL5817-3;None/More than 21 days;LA31737-2;4;Between 15 and 21 days;;; +97334-7;LL5817-3;None/More than 21 days;LA30053-5;5;More than 21 days;;; +97335-4;LL5818-1;No/Neck complications;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97335-4;LL5818-1;No/Neck complications;LA32165-5;3;Wound healing;;; +97335-4;LL5818-1;No/Neck complications;LA17344-5;4;Paralysis;;; +97335-4;LL5818-1;No/Neck complications;LA32166-3;5;Sensory disturbances;;; +97335-4;LL5949-4;No/ Yes, please describe these;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97335-4;LL5949-4;No/ Yes, please describe these;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97335-4;LL5949-4;No/ Yes, please describe these;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97335-4;LL5949-4;No/ Yes, please describe these;LA33-6;2;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA24969-0;1;Not at all bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27726-1;2;Slightly bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27725-3;3;Moderately bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA31187-0;4;Very bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27766-7;5;Extremely bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA24969-0;1;Not at all bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27726-1;2;Slightly bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27725-3;3;Moderately bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA31187-0;4;Very bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27766-7;5;Extremely bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA24969-0;1;Not at all bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27726-1;2;Slightly bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27725-3;3;Moderately bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA31187-0;4;Very bothersome;;; +97336-2;LL5819-9;Not at all bothersom/Extremely bothersome;LA27766-7;5;Extremely bothersome;;; +97337-0;LL5820-7;Further operations;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97337-0;LL5820-7;Further operations;LA31740-6;2;Yes, but at a different level of the spine;;; +97337-0;LL5820-7;Further operations;LA31741-4;3;Yes, at the same level of the spine (same segment);;; +97337-0;LL5820-7;Further operations;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97337-0;LL5820-7;Further operations;LA31740-6;2;Yes, but at a different level of the spine;;; +97337-0;LL5820-7;Further operations;LA31741-4;3;Yes, at the same level of the spine (same segment);;; +97337-0;LL5820-7;Further operations;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97337-0;LL5820-7;Further operations;LA31740-6;2;Yes, but at a different level of the spine;;; +97337-0;LL5820-7;Further operations;LA31741-4;3;Yes, at the same level of the spine (same segment);;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31742-2;1;Helped a lot;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31743-0;2;Helped;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31744-8;3;Helped only a little;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31745-5;4;Didn't help;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31746-3;5;Made things worse;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31742-2;1;Helped a lot;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31743-0;2;Helped;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31744-8;3;Helped only a little;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31745-5;4;Didn't help;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31746-3;5;Made things worse;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31742-2;1;Helped a lot;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31743-0;2;Helped;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31744-8;3;Helped only a little;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31745-5;4;Didn't help;;; +97338-8;LL5821-5;Helped a lot/Made things worse;LA31746-3;5;Made things worse;;; +97509-4;LL5946-0;Condition stability status;LA32281-0;1;No edvidence of disease;;; +97509-4;LL5946-0;Condition stability status;LA65-8;2;Improved;;; +97509-4;LL5946-0;Condition stability status;LA14122-8;3;Stable;;; +97509-4;LL5946-0;Condition stability status;LA32282-8;4;Worsened;;; +97509-4;LL5946-0;Condition stability status;LA14100-4;5;Undetermined;;; +97518-5;LL5798-5;Paracoccidioides Ab band pattern;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97518-5;LL5798-5;Paracoccidioides Ab band pattern;LA31661-4;2;Band(s) of partial identity;;; +97518-5;LL5798-5;Paracoccidioides Ab band pattern;LA31662-2;3;Bands of non-identity;;; +97518-5;LL5798-5;Paracoccidioides Ab band pattern;LA31667-1;4;Band of identity present;;; +97519-3;LL5795-1;Blastomyces Ab band pattern;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97519-3;LL5795-1;Blastomyces Ab band pattern;LA31661-4;2;Band(s) of partial identity;;; +97519-3;LL5795-1;Blastomyces Ab band pattern;LA31662-2;3;Bands of non-identity;;; +97519-3;LL5795-1;Blastomyces Ab band pattern;LA31663-0;4;A band present;;; +97520-1;LL5797-7;Histoplasma Ab band pattern;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97520-1;LL5797-7;Histoplasma Ab band pattern;LA31661-4;2;Band(s) of partial identity;;; +97520-1;LL5797-7;Histoplasma Ab band pattern;LA31662-2;3;Bands of non-identity;;; +97520-1;LL5797-7;Histoplasma Ab band pattern;LA29408-4;4;H band present;;; +97520-1;LL5797-7;Histoplasma Ab band pattern;LA29407-6;5;M band present;;; +97520-1;LL5797-7;Histoplasma Ab band pattern;LA29409-2;6;H and M bands present;;; +97521-9;LL5796-9;Coccidioides Ab band pattern;LA6577-6;1;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +97521-9;LL5796-9;Coccidioides Ab band pattern;LA31661-4;2;Band(s) of partial identity;;; +97521-9;LL5796-9;Coccidioides Ab band pattern;LA31662-2;3;Bands of non-identity;;; +97521-9;LL5796-9;Coccidioides Ab band pattern;LA31664-8;4;TP band present;;; +97521-9;LL5796-9;Coccidioides Ab band pattern;LA31665-5;5;F band present;;; +97521-9;LL5796-9;Coccidioides Ab band pattern;LA31666-3;6;TP and F bands present;;; +97568-0;LL5929-6;Animal owner;LA4634-7;1;Patient;;; +97568-0;LL5929-6;Animal owner;LA32250-5;2;Private - friend, acquaintance;;; +97568-0;LL5929-6;Animal owner;LA32248-9;3;Commercial - zoo, petting zoo, pet store;;; +97568-0;LL5929-6;Animal owner;LA32249-7;4;Wild animal;;; +97592-0;LL5874-4;Good response|Poor response;LA31991-5;1;Good response;;; +97592-0;LL5874-4;Good response|Poor response;LA31992-3;2;Poor response;;; +97603-5;LL5908-0;Elevated|Not elevated|Repeat test;LA32146-5;1;Elevated;;; +97603-5;LL5908-0;Elevated|Not elevated|Repeat test;LA32147-3;2;Not elevated;;; +97603-5;LL5908-0;Elevated|Not elevated|Repeat test;LA32148-1;3;Repeat test;;; +97734-8;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97734-8;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97734-8;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97734-8;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97734-8;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97734-8;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97734-8;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97734-8;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97734-8;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97734-8;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97735-5;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97735-5;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97735-5;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97735-5;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97735-5;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97735-5;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97735-5;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97735-5;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97735-5;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97735-5;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97736-3;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97736-3;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97736-3;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97736-3;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97736-3;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97736-3;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97736-3;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97736-3;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97736-3;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97736-3;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97737-1;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97737-1;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97737-1;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97737-1;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97737-1;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97737-1;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97737-1;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97737-1;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97737-1;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97737-1;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97738-9;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97738-9;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97738-9;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97738-9;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97738-9;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97738-9;LL5943-7;Drinking frequency;LA6270-8;1;Never;;; +97738-9;LL5943-7;Drinking frequency;LA18933-4;2;Less than monthly;;; +97738-9;LL5943-7;Drinking frequency;LA18876-5;3;Monthly;;; +97738-9;LL5943-7;Drinking frequency;LA18891-4;4;Weekly;14497002;weekly (qualifier value);http://snomed.info/sct +97738-9;LL5943-7;Drinking frequency;LA18934-2;5;Daily or almost daily;;; +97739-7;LL5944-5;No/Yes/Past year;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97739-7;LL5944-5;No/Yes/Past year;LA32279-4;2;Yes, but not in the last year;;; +97739-7;LL5944-5;No/Yes/Past year;LA32280-2;3;Yes, during the last year;;; +97739-7;LL5944-5;No/Yes/Past year;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97739-7;LL5944-5;No/Yes/Past year;LA32279-4;2;Yes, but not in the last year;;; +97739-7;LL5944-5;No/Yes/Past year;LA32280-2;3;Yes, during the last year;;; +97740-5;LL5944-5;No/Yes/Past year;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97740-5;LL5944-5;No/Yes/Past year;LA32279-4;2;Yes, but not in the last year;;; +97740-5;LL5944-5;No/Yes/Past year;LA32280-2;3;Yes, during the last year;;; +97740-5;LL5944-5;No/Yes/Past year;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +97740-5;LL5944-5;No/Yes/Past year;LA32279-4;2;Yes, but not in the last year;;; +97740-5;LL5944-5;No/Yes/Past year;LA32280-2;3;Yes, during the last year;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31856-0;1;Disc herniation;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31857-8;2;Central stenosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31858-6;3;Lateral stenosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31859-4;4;Foraminal stenosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31860-2;5;Degenerative disc disease;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31861-0;6;Degenerative deformity;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31862-8;7;Degenerative spondylolisthesis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31863-6;8;Other instability;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31864-4;9;Myelopathy;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31865-1;10;Facet joint arthrosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31866-9;11;Synovial cyst;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31867-7;12;SI joint;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA46-8;13;Other;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31856-0;1;Disc herniation;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31857-8;2;Central stenosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31858-6;3;Lateral stenosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31859-4;4;Foraminal stenosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31860-2;5;Degenerative disc disease;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31861-0;6;Degenerative deformity;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31862-8;7;Degenerative spondylolisthesis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31863-6;8;Other instability;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31864-4;9;Myelopathy;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31865-1;10;Facet joint arthrosis;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31866-9;11;Synovial cyst;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA31867-7;12;SI joint;;; +97785-0;LL5838-9;Spine Tango - Degeneration Type;LA46-8;13;Other;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31856-0;2;Disc herniation;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31857-8;3;Central stenosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31858-6;4;Lateral stenosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31859-4;5;Foraminal stenosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31860-2;6;Degenerative disc disease;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31861-0;7;Degenerative deformity;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31862-8;8;Degenerative spondylolisthesis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31863-6;9;Other instability;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31864-4;10;Myelopathy;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31865-1;11;Facet joint arthrosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31866-9;12;Synovial cyst;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31867-7;13;SI joint;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA46-8;14;Other;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31856-0;2;Disc herniation;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31857-8;3;Central stenosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31858-6;4;Lateral stenosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31859-4;5;Foraminal stenosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31860-2;6;Degenerative disc disease;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31861-0;7;Degenerative deformity;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31862-8;8;Degenerative spondylolisthesis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31863-6;9;Other instability;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31864-4;10;Myelopathy;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31865-1;11;Facet joint arthrosis;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31866-9;12;Synovial cyst;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA31867-7;13;SI joint;;; +97786-8;LL5961-9;Spine Tango - Degeneration Type_Secondary;LA46-8;14;Other;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA22278-8;1;Scoliosis;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA31868-5;2;Kyphosis;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA31869-3;3;Frontal imbalance;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA31870-1;4;Sagittal imbalance;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA46-8;5;Other;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA22278-8;1;Scoliosis;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA31868-5;2;Kyphosis;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA31869-3;3;Frontal imbalance;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA31870-1;4;Sagittal imbalance;;; +97787-6;LL5839-7;Spine Tango - Deformity Type;LA46-8;5;Other;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31871-9;1;Idiopathic;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA24667-0;2;Congenital;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31872-7;3;Neuromuscular;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31873-5;4;Posttraumatic;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31874-3;5;M. Scheuermann;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31875-0;6;Syndromic;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA46-8;7;Other;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31871-9;1;Idiopathic;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA24667-0;2;Congenital;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31872-7;3;Neuromuscular;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31873-5;4;Posttraumatic;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31874-3;5;M. Scheuermann;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA31875-0;6;Syndromic;;; +97788-4;LL5840-5;Spine Tango - Predominant Etiology;LA46-8;7;Other;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31876-8;1;Condylar (C0);;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31877-6;2;C0/1 dissociation;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31878-4;3;C1 fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31879-2;4;C1/2 instability;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31880-0;5;C2 dens fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31881-8;6;C2 other fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31882-6;7;Soft tissue injury neck;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31883-4;8;Fracture C3-C7;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31884-2;9;Fracture Th1-L5/S1;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31885-9;10;Sacrum fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA46-8;11;Other;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31876-8;1;Condylar (C0);;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31877-6;2;C0/1 dissociation;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31878-4;3;C1 fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31879-2;4;C1/2 instability;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31880-0;5;C2 dens fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31881-8;6;C2 other fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31882-6;7;Soft tissue injury neck;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31883-4;8;Fracture C3-C7;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31884-2;9;Fracture Th1-L5/S1;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA31885-9;10;Sacrum fracture;;; +97789-2;LL5841-3;Spine Tango - Fracture/Trauma Type;LA46-8;11;Other;;; +97790-0;LL5842-1;I/II/III;LA15457-7;1;I;;; +97790-0;LL5842-1;I/II/III;LA15458-5;2;II;;; +97790-0;LL5842-1;I/II/III;LA15459-3;3;III;;; +97790-0;LL5842-1;I/II/III;LA15457-7;1;I;;; +97790-0;LL5842-1;I/II/III;LA15458-5;2;II;;; +97790-0;LL5842-1;I/II/III;LA15459-3;3;III;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA31886-7;1;A0;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA19212-2;2;A1;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA19213-0;3;A2;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA31888-3;4;A3;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA31889-1;5;A4;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA13488-4;6;B1;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA13489-2;7;B2;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA13490-0;8;B3;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA14519-5;9;C;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA31886-7;1;A0;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA19212-2;2;A1;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA19213-0;3;A2;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA31888-3;4;A3;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA31889-1;5;A4;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA13488-4;6;B1;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA13489-2;7;B2;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA13490-0;8;B3;;; +97791-8;LL5843-9;C3-L5 or S1 AO fracture type;LA14519-5;9;C;;; +97792-6;LL5844-7;AO neurologic injury;LA4368-2;1;N0;;; +97792-6;LL5844-7;AO neurologic injury;LA4537-2;2;N1;;; +97792-6;LL5844-7;AO neurologic injury;LA4534-9;3;N2;;; +97792-6;LL5844-7;AO neurologic injury;LA4545-5;4;N3;;; +97792-6;LL5844-7;AO neurologic injury;LA21874-5;5;N4;;; +97792-6;LL5844-7;AO neurologic injury;LA4745-1;6;NX;;; +97792-6;LL5844-7;AO neurologic injury;LA4368-2;1;N0;;; +97792-6;LL5844-7;AO neurologic injury;LA4537-2;2;N1;;; +97792-6;LL5844-7;AO neurologic injury;LA4534-9;3;N2;;; +97792-6;LL5844-7;AO neurologic injury;LA4545-5;4;N3;;; +97792-6;LL5844-7;AO neurologic injury;LA21874-5;5;N4;;; +97792-6;LL5844-7;AO neurologic injury;LA4745-1;6;NX;;; +97793-4;LL5891-8;AO Modifiers;LA32331-3;1;No modifiers;;; +97793-4;LL5891-8;AO Modifiers;LA4628-9;2;M1;;; +97793-4;LL5891-8;AO Modifiers;LA32062-4;3;M2;;; +97793-4;LL5891-8;AO Modifiers;LA32063-2;4;M3;;; +97793-4;LL5891-8;AO Modifiers;LA32064-0;5;M4;;; +97793-4;LL5891-8;AO Modifiers;LA23939-4;6;F1;;; +97793-4;LL5891-8;AO Modifiers;LA23940-2;7;F2;;; +97793-4;LL5891-8;AO Modifiers;LA23941-0;8;F3;;; +97793-4;LL5891-8;AO Modifiers;LA23942-8;9;F4;;; +97793-4;LL5891-8;AO Modifiers;LA32068-1;10;BL;;; +97793-4;LL5891-8;AO Modifiers;LA32331-3;1;No modifiers;;; +97793-4;LL5891-8;AO Modifiers;LA4628-9;2;M1;;; +97793-4;LL5891-8;AO Modifiers;LA32062-4;3;M2;;; +97793-4;LL5891-8;AO Modifiers;LA32063-2;4;M3;;; +97793-4;LL5891-8;AO Modifiers;LA32064-0;5;M4;;; +97793-4;LL5891-8;AO Modifiers;LA23939-4;6;F1;;; +97793-4;LL5891-8;AO Modifiers;LA23940-2;7;F2;;; +97793-4;LL5891-8;AO Modifiers;LA23941-0;8;F3;;; +97793-4;LL5891-8;AO Modifiers;LA23942-8;9;F4;;; +97793-4;LL5891-8;AO Modifiers;LA32068-1;10;BL;;; +97794-2;LL5845-4;Pathological fracture cause;LA10527-2;1;Osteoporosis;;; +97794-2;LL5845-4;Pathological fracture cause;LA16304-0;2;Tumor;;; +97794-2;LL5845-4;Pathological fracture cause;LA46-8;3;Other;;; +97794-2;LL5845-4;Pathological fracture cause;LA10527-2;1;Osteoporosis;;; +97794-2;LL5845-4;Pathological fracture cause;LA16304-0;2;Tumor;;; +97794-2;LL5845-4;Pathological fracture cause;LA46-8;3;Other;;; +97795-9;LL5846-2;Fracture age;LA31891-7;1;Fresh fracture;;; +97795-9;LL5846-2;Fracture age;LA31892-5;2;Old fracture;;; +97795-9;LL5846-2;Fracture age;LA31891-7;1;Fresh fracture;;; +97795-9;LL5846-2;Fracture age;LA31892-5;2;Old fracture;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31893-3;1;OF1;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31894-1;2;OF2;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31895-8;3;OF3;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31896-6;4;OF4;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31897-4;5;OF5;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31893-3;1;OF1;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31894-1;2;OF2;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31895-8;3;OF3;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31896-6;4;OF4;;; +97796-7;LL5847-0;Osteoporotic vertebral fractures classification;LA31897-4;5;OF5;;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31898-2;1;Type I (congenital, dysplastic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31899-0;2;Type II (isthmic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31900-6;3;Type III see type of degeneration;;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31901-4;4;Type IV (traumatic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31903-0;5;Type V (pathologic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31904-8;6;Type VI (postsurgical);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31898-2;1;Type I (congenital, dysplastic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31899-0;2;Type II (isthmic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31900-6;3;Type III see type of degeneration;;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31901-4;4;Type IV (traumatic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31903-0;5;Type V (pathologic);;; +97797-5;LL5848-8;Spondylolisthesis Types;LA31904-8;6;Type VI (postsurgical);;; +97798-3;LL5849-6;Spondylolisthesis grade;LA9628-4;1;Grade 0;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA3967-2;2;Grade I;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA3992-0;3;Grade II;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA4027-4;4;Grade III;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA3982-1;5;Grade IV;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA31905-5;6;Spondyloptosis (V);;; +97798-3;LL5849-6;Spondylolisthesis grade;LA9628-4;1;Grade 0;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA3967-2;2;Grade I;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA3992-0;3;Grade II;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA4027-4;4;Grade III;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA3982-1;5;Grade IV;;; +97798-3;LL5849-6;Spondylolisthesis grade;LA31905-5;6;Spondyloptosis (V);;; +97799-1;LL5850-4;Infection specification;LA31906-3;1;Pyogenic;;; +97799-1;LL5850-4;Infection specification;LA31907-1;2;Tuberculotic;;; +97799-1;LL5850-4;Infection specification;LA31908-9;3;Multi-resistant;;; +97799-1;LL5850-4;Infection specification;LA46-8;4;Other;;; +97799-1;LL5850-4;Infection specification;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +97799-1;LL5850-4;Infection specification;LA31906-3;1;Pyogenic;;; +97799-1;LL5850-4;Infection specification;LA31907-1;2;Tuberculotic;;; +97799-1;LL5850-4;Infection specification;LA31908-9;3;Multi-resistant;;; +97799-1;LL5850-4;Infection specification;LA46-8;4;Other;;; +97799-1;LL5850-4;Infection specification;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +97800-7;LL5851-2;Affected structures;LA31822-2;1;Spondylitis;;; +97800-7;LL5851-2;Affected structures;LA31823-0;2;Discitis;;; +97800-7;LL5851-2;Affected structures;LA31909-7;3;Epidural space;;; +97800-7;LL5851-2;Affected structures;LA31910-5;4;Paravertebral;;; +97800-7;LL5851-2;Affected structures;LA46-8;5;Other;;; +97800-7;LL5851-2;Affected structures;LA31822-2;1;Spondylitis;;; +97800-7;LL5851-2;Affected structures;LA31823-0;2;Discitis;;; +97800-7;LL5851-2;Affected structures;LA31909-7;3;Epidural space;;; +97800-7;LL5851-2;Affected structures;LA31910-5;4;Paravertebral;;; +97800-7;LL5851-2;Affected structures;LA46-8;5;Other;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31911-3;1;Primary malignant;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31912-1;2;Primary benign;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31913-9;3;Secondary malignant;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31914-7;4;Tumor like lesion;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA46-8;5;Other;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31911-3;1;Primary malignant;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31912-1;2;Primary benign;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31913-9;3;Secondary malignant;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA31914-7;4;Tumor like lesion;;; +97801-5;LL5852-0;Spine Tango - Tumor Type;LA46-8;5;Other;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31915-4;1;Extraosseous soft tissues;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA30789-4;2;Intraosseous;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31917-0;3;Extraosseous (extradural);;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31918-8;4;Intradural intermedullary;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31919-6;5;Intradural extramedullary;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA46-8;6;Other;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31915-4;1;Extraosseous soft tissues;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA30789-4;2;Intraosseous;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31917-0;3;Extraosseous (extradural);;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31918-8;4;Intradural intermedullary;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA31919-6;5;Intradural extramedullary;;; +97802-3;LL5853-8;Spine Tango - Tumor localization;LA46-8;6;Other;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32219-0;1;Hardware removal;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31816-4;2;Non-union;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31818-0;3;Instability;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32072-3;4;Failure to reach therapeutic goals;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32074-9;6;Neurocompression;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32075-6;7;Postop infection superficial;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32076-4;8;Postop infection deep;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31827-1;9;Implant malposition;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31817-2;10;Implant failure;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31870-1;11;Sagittal imbalance;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31831-3;12;Adjacent segment pathology;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA46-8;13;Other;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32219-0;1;Hardware removal;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31816-4;2;Non-union;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31818-0;3;Instability;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32072-3;4;Failure to reach therapeutic goals;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32074-9;6;Neurocompression;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32075-6;7;Postop infection superficial;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA32076-4;8;Postop infection deep;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31827-1;9;Implant malposition;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31817-2;10;Implant failure;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31870-1;11;Sagittal imbalance;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA31831-3;12;Adjacent segment pathology;;; +97803-1;LL5893-4;EuroSpine Repeat Surgery Reason;LA46-8;13;Other;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32078-0;1;C0;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA13491-8;2;C1;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA13492-6;3;C2;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32080-6;4;C3;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32081-4;5;C4;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32082-2;6;C5;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32083-0;7;C6;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32084-8;8;C7;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA3637-1;9;T1;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA3628-0;10;T2;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA3624-9;11;T3;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA3620-7;12;T4;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32086-3;13;T5;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32087-1;14;T6;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32088-9;15;T7;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32089-7;16;T8;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32090-5;17;T9;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32091-3;18;T10;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32092-1;19;T11;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32093-9;20;T12;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32094-7;21;L1;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32095-4;22;L2;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32096-2;23;L3;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32097-0;24;L4;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32098-8;25;L5;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA18242-0;26;S1;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32100-2;27;SA;;; +97804-9;LL5894-2;EuroSpine - Segment or vertebral body;LA32101-0;28;Ilium;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97804-9;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97821-3;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97823-9;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97826-2;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97828-8;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97830-4;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32078-0;1;C0;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA13491-8;2;C1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA13492-6;3;C2;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32080-6;4;C3;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32081-4;5;C4;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32082-2;6;C5;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32083-0;7;C6;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32084-8;8;C7;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3637-1;9;T1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3628-0;10;T2;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3624-9;11;T3;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA3620-7;12;T4;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32086-3;13;T5;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32087-1;14;T6;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32088-9;15;T7;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32089-7;16;T8;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32090-5;17;T9;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32091-3;18;T10;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32092-1;19;T11;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32093-9;20;T12;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32094-7;21;L1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32095-4;22;L2;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32096-2;23;L3;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32097-0;24;L4;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32098-8;25;L5;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA18242-0;26;S1;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32100-2;27;SA;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA21996-6;28;CO;;; +97832-0;LL5913-0;EuroSpine - Spine Level;LA32101-0;29;Ilium;;; +97805-6;LL5895-9;1->4;LA6112-2;1;1;;; +97805-6;LL5895-9;1->4;LA6113-0;2;2;;; +97805-6;LL5895-9;1->4;LA6114-8;3;3;;; +97805-6;LL5895-9;1->4;LA6115-5;4;4;;; +97805-6;LL5895-9;1->4;LA32102-8;5;>4;;; +97805-6;LL5895-9;1->4;LA6112-2;1;1;;; +97805-6;LL5895-9;1->4;LA6113-0;2;2;;; +97805-6;LL5895-9;1->4;LA6114-8;3;3;;; +97805-6;LL5895-9;1->4;LA6115-5;4;4;;; +97805-6;LL5895-9;1->4;LA32102-8;5;>4;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97806-4;LL5896-7;EuroSpine - Pathologies;LA31861-0;2;Degenerative deformity;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32103-6;3;Fracture/trauma;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32104-4;4;Pathological fracture;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32105-1;5;Spondylolisthesis (non-degenerative);;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32106-9;6;Chiari;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA7446-3;7;Infection;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA16304-0;8;Tumor;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32107-7;9;Repeat surgery;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32305-7;10;Other: specify;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97806-4;LL5896-7;EuroSpine - Pathologies;LA31861-0;2;Degenerative deformity;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32103-6;3;Fracture/trauma;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32104-4;4;Pathological fracture;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32105-1;5;Spondylolisthesis (non-degenerative);;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32106-9;6;Chiari;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA7446-3;7;Infection;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA16304-0;8;Tumor;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32107-7;9;Repeat surgery;;; +97806-4;LL5896-7;EuroSpine - Pathologies;LA32305-7;10;Other: specify;;; +97807-2;LL5898-3;0 - >4;LA6111-4;1;0;;; +97807-2;LL5898-3;0 - >4;LA6112-2;2;1;;; +97807-2;LL5898-3;0 - >4;LA6113-0;3;2;;; +97807-2;LL5898-3;0 - >4;LA6114-8;4;3;;; +97807-2;LL5898-3;0 - >4;LA6115-5;5;4;;; +97807-2;LL5898-3;0 - >4;LA32102-8;6;>4;;; +97808-0;LL5898-3;0 - >4;LA6111-4;1;0;;; +97808-0;LL5898-3;0 - >4;LA6112-2;2;1;;; +97808-0;LL5898-3;0 - >4;LA6113-0;3;2;;; +97808-0;LL5898-3;0 - >4;LA6114-8;4;3;;; +97808-0;LL5898-3;0 - >4;LA6115-5;5;4;;; +97808-0;LL5898-3;0 - >4;LA32102-8;6;>4;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31790-1;1;Axial pain relief;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31791-9;2;Peripheral pain relief;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31792-7;3;Functional improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31793-5;4;Motor improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31794-3;5;Sensory improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31795-0;6;Bowel/bladder function improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31796-8;7;Spinal stabilization;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31797-6;8;Stop deformity progression;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31798-4;9;Deformity correction;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31799-2;10;Prophylactic decompression;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31800-8;11;Cosmetic improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31801-6;12;Diagnostic measures;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA46-8;13;Other;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31790-1;1;Axial pain relief;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31791-9;2;Peripheral pain relief;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31792-7;3;Functional improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31793-5;4;Motor improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31794-3;5;Sensory improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31795-0;6;Bowel/bladder function improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31796-8;7;Spinal stabilization;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31797-6;8;Stop deformity progression;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31798-4;9;Deformity correction;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31799-2;10;Prophylactic decompression;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31800-8;11;Cosmetic improvement;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA31801-6;12;Diagnostic measures;;; +97812-2;LL5901-5;EuroSpine - Therapeutic goals;LA46-8;13;Other;;; +97813-0;LL5902-3;EuroSPine - Components;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97813-0;LL5902-3;EuroSPine - Components;LA32112-7;2;with description;;; +97813-0;LL5902-3;EuroSPine - Components;LA32113-5;3;without description;;; +97813-0;LL5902-3;EuroSPine - Components;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97813-0;LL5902-3;EuroSPine - Components;LA32112-7;2;with description;;; +97813-0;LL5902-3;EuroSPine - Components;LA32113-5;3;without description;;; +97814-8;LL5903-1;Anterior access;LA32114-3;1;No anterior access;;; +97814-8;LL5903-1;Anterior access;LA32115-0;2;Transoral;;; +97814-8;LL5903-1;Anterior access;LA25379-1;3;Anterolateral;;; +97814-8;LL5903-1;Anterior access;LA32117-6;4;Cervicothoracic anterolateral;;; +97814-8;LL5903-1;Anterior access;LA32118-4;5;Cervicothoracic with sternotomy;;; +97814-8;LL5903-1;Anterior access;LA26013-5;6;Thoracotomy;;; +97814-8;LL5903-1;Anterior access;LA32120-0;7;Thoracoabdominal;;; +97814-8;LL5903-1;Anterior access;LA32121-8;8;Retroperitoneal;;; +97814-8;LL5903-1;Anterior access;LA32122-6;9;Transperitoneal;;; +97814-8;LL5903-1;Anterior access;LA32123-4;10;Trans-psoas (XLIF);;; +97814-8;LL5903-1;Anterior access;LA46-8;11;Other;;; +97814-8;LL5903-1;Anterior access;LA32114-3;1;No anterior access;;; +97814-8;LL5903-1;Anterior access;LA32115-0;2;Transoral;;; +97814-8;LL5903-1;Anterior access;LA25379-1;3;Anterolateral;;; +97814-8;LL5903-1;Anterior access;LA32117-6;4;Cervicothoracic anterolateral;;; +97814-8;LL5903-1;Anterior access;LA32118-4;5;Cervicothoracic with sternotomy;;; +97814-8;LL5903-1;Anterior access;LA26013-5;6;Thoracotomy;;; +97814-8;LL5903-1;Anterior access;LA32120-0;7;Thoracoabdominal;;; +97814-8;LL5903-1;Anterior access;LA32121-8;8;Retroperitoneal;;; +97814-8;LL5903-1;Anterior access;LA32122-6;9;Transperitoneal;;; +97814-8;LL5903-1;Anterior access;LA32123-4;10;Trans-psoas (XLIF);;; +97814-8;LL5903-1;Anterior access;LA46-8;11;Other;;; +97815-5;LL5904-9;Posterior access;LA32124-2;1;No posterior access;;; +97815-5;LL5904-9;Posterior access;LA27460-7;2;Midline;;; +97815-5;LL5904-9;Posterior access;LA32126-7;3;Paramedian;;; +97815-5;LL5904-9;Posterior access;LA26554-8;4;Posterolateral;;; +97815-5;LL5904-9;Posterior access;LA32128-3;5;Para-coccygeal (AxiALIF);;; +97815-5;LL5904-9;Posterior access;LA46-8;6;Other;;; +97815-5;LL5904-9;Posterior access;LA32124-2;1;No posterior access;;; +97815-5;LL5904-9;Posterior access;LA27460-7;2;Midline;;; +97815-5;LL5904-9;Posterior access;LA32126-7;3;Paramedian;;; +97815-5;LL5904-9;Posterior access;LA26554-8;4;Posterolateral;;; +97815-5;LL5904-9;Posterior access;LA32128-3;5;Para-coccygeal (AxiALIF);;; +97815-5;LL5904-9;Posterior access;LA46-8;6;Other;;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +97816-3;LL5905-6;EuroSpine Morbidity state;LA32129-1;2;ASA1 (no disturbance);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32130-9;3;ASA2 (mild/moderate);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32131-7;4;ASA3 (severe);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32132-5;5;ASA4 (life threatening);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32133-3;6;ASA5 (moribund);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA4489-6;1;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +97816-3;LL5905-6;EuroSpine Morbidity state;LA32129-1;2;ASA1 (no disturbance);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32130-9;3;ASA2 (mild/moderate);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32131-7;4;ASA3 (severe);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32132-5;5;ASA4 (life threatening);;; +97816-3;LL5905-6;EuroSpine Morbidity state;LA32133-3;6;ASA5 (moribund);;; +97817-1;LL5907-2;EuroSpine - Technology;LA32139-0;1;Conventional;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32140-8;2;MISS/LISS;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32141-6;3;Intraop. 3D-imaging;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32142-4;4;Endoscope;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32143-2;5;CASS/navigation;;; +97817-1;LL5907-2;EuroSpine - Technology;LA8990-9;6;Microscope;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32145-7;7;Neuromonitoring;;; +97817-1;LL5907-2;EuroSpine - Technology;LA46-8;8;Other;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32139-0;1;Conventional;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32140-8;2;MISS/LISS;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32141-6;3;Intraop. 3D-imaging;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32142-4;4;Endoscope;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32143-2;5;CASS/navigation;;; +97817-1;LL5907-2;EuroSpine - Technology;LA8990-9;6;Microscope;;; +97817-1;LL5907-2;EuroSpine - Technology;LA32145-7;7;Neuromonitoring;;; +97817-1;LL5907-2;EuroSpine - Technology;LA46-8;8;Other;;; +97818-9;LL5911-4;Blood transfusion;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97818-9;LL5911-4;Blood transfusion;LA32162-2;2;<2 units;;; +97818-9;LL5911-4;Blood transfusion;LA32163-0;3;>= 2 units;;; +97818-9;LL5911-4;Blood transfusion;LA32164-8;4;Cell saver;;; +97818-9;LL5911-4;Blood transfusion;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +97818-9;LL5911-4;Blood transfusion;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97818-9;LL5911-4;Blood transfusion;LA32162-2;2;<2 units;;; +97818-9;LL5911-4;Blood transfusion;LA32163-0;3;>= 2 units;;; +97818-9;LL5911-4;Blood transfusion;LA32164-8;4;Cell saver;;; +97818-9;LL5911-4;Blood transfusion;LA4489-6;5;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +97820-5;LL5912-2;Decompression;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97820-5;LL5912-2;Decompression;LA32167-1;2;Discectomy partial/total;;; +97820-5;LL5912-2;Decompression;LA32168-9;3;Vertebrectomy partial;;; +97820-5;LL5912-2;Decompression;LA32169-7;4;Vertebrectomy full;;; +97820-5;LL5912-2;Decompression;LA32170-5;5;Laminotomy;;; +97820-5;LL5912-2;Decompression;LA32171-3;6;Hemi-laminectomy;;; +97820-5;LL5912-2;Decompression;LA32172-1;7;Laminectomy;;; +97820-5;LL5912-2;Decompression;LA32173-9;8;Facet joint resection partial;;; +97820-5;LL5912-2;Decompression;LA32174-7;9;Facet joint resection full;;; +97820-5;LL5912-2;Decompression;LA32175-4;10;Sequestrectomy;;; +97820-5;LL5912-2;Decompression;LA32176-2;11;Flavectomy;;; +97820-5;LL5912-2;Decompression;LA32177-0;12;Foraminotomy;;; +97820-5;LL5912-2;Decompression;LA32178-8;13;Laminoplasty;;; +97820-5;LL5912-2;Decompression;LA32179-6;14;Uncoforaminotomy;;; +97820-5;LL5912-2;Decompression;LA46-8;15;Other;;; +97820-5;LL5912-2;Decompression;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97820-5;LL5912-2;Decompression;LA32167-1;2;Discectomy partial/total;;; +97820-5;LL5912-2;Decompression;LA32168-9;3;Vertebrectomy partial;;; +97820-5;LL5912-2;Decompression;LA32169-7;4;Vertebrectomy full;;; +97820-5;LL5912-2;Decompression;LA32170-5;5;Laminotomy;;; +97820-5;LL5912-2;Decompression;LA32171-3;6;Hemi-laminectomy;;; +97820-5;LL5912-2;Decompression;LA32172-1;7;Laminectomy;;; +97820-5;LL5912-2;Decompression;LA32173-9;8;Facet joint resection partial;;; +97820-5;LL5912-2;Decompression;LA32174-7;9;Facet joint resection full;;; +97820-5;LL5912-2;Decompression;LA32175-4;10;Sequestrectomy;;; +97820-5;LL5912-2;Decompression;LA32176-2;11;Flavectomy;;; +97820-5;LL5912-2;Decompression;LA32177-0;12;Foraminotomy;;; +97820-5;LL5912-2;Decompression;LA32178-8;13;Laminoplasty;;; +97820-5;LL5912-2;Decompression;LA32179-6;14;Uncoforaminotomy;;; +97820-5;LL5912-2;Decompression;LA46-8;15;Other;;; +97822-1;LL5914-8;Fusion promoting measures;LA32181-2;1;Interbody fusion (A-IF);;; +97822-1;LL5914-8;Fusion promoting measures;LA32182-0;2;Interbody fusion (PLIF);;; +97822-1;LL5914-8;Fusion promoting measures;LA32183-8;3;Interbody fusion (TLIF);;; +97822-1;LL5914-8;Fusion promoting measures;LA32184-6;4;Interbody fusion (XLIF);;; +97822-1;LL5914-8;Fusion promoting measures;LA32185-3;5;Other interbody fusion;;; +97822-1;LL5914-8;Fusion promoting measures;LA32186-1;6;Posterolateral fusion;;; +97822-1;LL5914-8;Fusion promoting measures;LA32187-9;7;Posterior fusion;;; +97822-1;LL5914-8;Fusion promoting measures;LA32188-7;8;Ilio-sacral fusion;;; +97822-1;LL5914-8;Fusion promoting measures;LA46-8;9;Other;;; +97822-1;LL5968-4;Spine Fusion Measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97822-1;LL5968-4;Spine Fusion Measures;LA32181-2;2;Interbody fusion (A-IF);;; +97822-1;LL5968-4;Spine Fusion Measures;LA32182-0;3;Interbody fusion (PLIF);;; +97822-1;LL5968-4;Spine Fusion Measures;LA32183-8;4;Interbody fusion (TLIF);;; +97822-1;LL5968-4;Spine Fusion Measures;LA32184-6;5;Interbody fusion (XLIF);;; +97822-1;LL5968-4;Spine Fusion Measures;LA32185-3;6;Other interbody fusion;;; +97822-1;LL5968-4;Spine Fusion Measures;LA32186-1;7;Posterolateral fusion;;; +97822-1;LL5968-4;Spine Fusion Measures;LA32187-9;8;Posterior fusion;;; +97822-1;LL5968-4;Spine Fusion Measures;LA32188-7;9;Ilio-sacral fusion;;; +97822-1;LL5968-4;Spine Fusion Measures;LA46-8;10;Other;;; +97824-7;LL5915-5;Fusion material;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97824-7;LL5915-5;Fusion material;LA32189-5;2;Autol. bone harvested;;; +97824-7;LL5915-5;Fusion material;LA32190-3;3;Autol. bone locally procured;;; +97824-7;LL5915-5;Fusion material;LA32191-1;4;Allog. bone;;; +97824-7;LL5915-5;Fusion material;LA32192-9;5;Bone subst.;;; +97824-7;LL5915-5;Fusion material;LA32193-7;6;Cement;;; +97824-7;LL5915-5;Fusion material;LA32194-5;7;BMP or similar;;; +97824-7;LL5915-5;Fusion material;LA46-8;8;Other;;; +97824-7;LL5915-5;Fusion material;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97824-7;LL5915-5;Fusion material;LA32189-5;2;Autol. bone harvested;;; +97824-7;LL5915-5;Fusion material;LA32190-3;3;Autol. bone locally procured;;; +97824-7;LL5915-5;Fusion material;LA32191-1;4;Allog. bone;;; +97824-7;LL5915-5;Fusion material;LA32192-9;5;Bone subst.;;; +97824-7;LL5915-5;Fusion material;LA32193-7;6;Cement;;; +97824-7;LL5915-5;Fusion material;LA32194-5;7;BMP or similar;;; +97824-7;LL5915-5;Fusion material;LA46-8;8;Other;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32195-2;2;Interbody stabil. with cage;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32196-0;3;Interbody stabil. with auto-/allograft;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32197-8;4;Vertebral body replacement by cage;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32198-6;5;Vertebral body replacement by auto-/allograft;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32199-4;6;Plates;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32200-0;7;Pedicle screws cemented;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32201-8;8;Pedicle screws uncemented;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32202-6;9;Facet screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32203-4;10;Transarticular screws C1-C2;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32204-2;11;Laminar hooks;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32205-9;12;Pedicle hooks;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32206-7;13;Sublaminar band/wire;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32207-5;14;Lateral mass screw;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32208-3;15;Odontoid screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32209-1;16;Laminar screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32210-9;17;Iliac screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA46-8;18;Other;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32195-2;2;Interbody stabil. with cage;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32196-0;3;Interbody stabil. with auto-/allograft;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32197-8;4;Vertebral body replacement by cage;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32198-6;5;Vertebral body replacement by auto-/allograft;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32199-4;6;Plates;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32200-0;7;Pedicle screws cemented;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32201-8;8;Pedicle screws uncemented;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32202-6;9;Facet screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32203-4;10;Transarticular screws C1-C2;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32204-2;11;Laminar hooks;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32205-9;12;Pedicle hooks;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32206-7;13;Sublaminar band/wire;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32207-5;14;Lateral mass screw;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32208-3;15;Odontoid screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32209-1;16;Laminar screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA32210-9;17;Iliac screws;;; +97825-4;LL5916-3;EuroSpine - Stabilized rigid;LA46-8;18;Other;;; +97827-0;LL5917-1;Deformity correction;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97827-0;LL5917-1;Deformity correction;LA32211-7;2;Ponte/Smith-Petersen;;; +97827-0;LL5917-1;Deformity correction;LA32212-5;3;PSO;;; +97827-0;LL5917-1;Deformity correction;LA32213-3;4;VCR;;; +97827-0;LL5917-1;Deformity correction;LA46-8;5;Other;;; +97827-0;LL5917-1;Deformity correction;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97827-0;LL5917-1;Deformity correction;LA32211-7;2;Ponte/Smith-Petersen;;; +97827-0;LL5917-1;Deformity correction;LA32212-5;3;PSO;;; +97827-0;LL5917-1;Deformity correction;LA32213-3;4;VCR;;; +97827-0;LL5917-1;Deformity correction;LA46-8;5;Other;;; +97829-6;LL5918-9;Stabilization motion preserving;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97829-6;LL5918-9;Stabilization motion preserving;LA32214-1;2;Disc replacement;;; +97829-6;LL5918-9;Stabilization motion preserving;LA32215-8;3;Dynamic stabilization;;; +97829-6;LL5918-9;Stabilization motion preserving;LA32216-6;4;Interspin. spacer;;; +97829-6;LL5918-9;Stabilization motion preserving;LA46-8;5;Other;;; +97829-6;LL5918-9;Stabilization motion preserving;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97829-6;LL5918-9;Stabilization motion preserving;LA32214-1;2;Disc replacement;;; +97829-6;LL5918-9;Stabilization motion preserving;LA32215-8;3;Dynamic stabilization;;; +97829-6;LL5918-9;Stabilization motion preserving;LA32216-6;4;Interspin. spacer;;; +97829-6;LL5918-9;Stabilization motion preserving;LA46-8;5;Other;;; +97831-2;LL5919-7;Other surgial measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97831-2;LL5919-7;Other surgial measures;LA32217-4;2;Vb augmentation with body restoration;;; +97831-2;LL5919-7;Other surgial measures;LA32218-2;3;Vb augmentation w/o body restorat.;;; +97831-2;LL5919-7;Other surgial measures;LA32219-0;4;Hardware removal;;; +97831-2;LL5919-7;Other surgial measures;LA32220-8;5;Wound drain;;; +97831-2;LL5919-7;Other surgial measures;LA46-8;6;Other;;; +97831-2;LL5919-7;Other surgial measures;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97831-2;LL5919-7;Other surgial measures;LA32217-4;2;Vb augmentation with body restoration;;; +97831-2;LL5919-7;Other surgial measures;LA32218-2;3;Vb augmentation w/o body restorat.;;; +97831-2;LL5919-7;Other surgial measures;LA32219-0;4;Hardware removal;;; +97831-2;LL5919-7;Other surgial measures;LA32220-8;5;Wound drain;;; +97831-2;LL5919-7;Other surgial measures;LA46-8;6;Other;;; +97833-8;LL5920-5;Intraop adverse event;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97833-8;LL5920-5;Intraop adverse event;LA32221-6;2;Nerve root damage;;; +97833-8;LL5920-5;Intraop adverse event;LA32222-4;3;Spinal cord damage;;; +97833-8;LL5920-5;Intraop adverse event;LA32223-2;4;Dural lesion;;; +97833-8;LL5920-5;Intraop adverse event;LA32224-0;5;Vascular injury;;; +97833-8;LL5920-5;Intraop adverse event;LA31835-4;6;Fx vertebral structures;;; +97833-8;LL5920-5;Intraop adverse event;LA46-8;7;Other;;; +97833-8;LL5920-5;Intraop adverse event;LA32226-5;8;Not documented;;; +97833-8;LL5920-5;Intraop adverse event;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97833-8;LL5920-5;Intraop adverse event;LA32221-6;2;Nerve root damage;;; +97833-8;LL5920-5;Intraop adverse event;LA32222-4;3;Spinal cord damage;;; +97833-8;LL5920-5;Intraop adverse event;LA32223-2;4;Dural lesion;;; +97833-8;LL5920-5;Intraop adverse event;LA32224-0;5;Vascular injury;;; +97833-8;LL5920-5;Intraop adverse event;LA31835-4;6;Fx vertebral structures;;; +97833-8;LL5920-5;Intraop adverse event;LA46-8;7;Other;;; +97833-8;LL5920-5;Intraop adverse event;LA32226-5;8;Not documented;;; +97834-6;LL5921-3;Measures during index surgery;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97834-6;LL5921-3;Measures during index surgery;LA19079-5;2;Suture;;; +97834-6;LL5921-3;Measures during index surgery;LA19076-1;3;Glue;;; +97834-6;LL5921-3;Measures during index surgery;LA32227-3;4;Implant reposition;;; +97834-6;LL5921-3;Measures during index surgery;LA46-8;5;Other;;; +97834-6;LL5921-3;Measures during index surgery;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97834-6;LL5921-3;Measures during index surgery;LA19079-5;2;Suture;;; +97834-6;LL5921-3;Measures during index surgery;LA19076-1;3;Glue;;; +97834-6;LL5921-3;Measures during index surgery;LA32227-3;4;Implant reposition;;; +97834-6;LL5921-3;Measures during index surgery;LA46-8;5;Other;;; +97835-3;LL5922-1;Intraop general complications;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97835-3;LL5922-1;Intraop general complications;LA32228-1;2;Anesthesiological;;; +97835-3;LL5922-1;Intraop general complications;LA18277-6;3;Cardiovascular;;; +97835-3;LL5922-1;Intraop general complications;LA18283-4;4;Pulmonary;;; +97835-3;LL5922-1;Intraop general complications;LA31836-2;5;Thromboembolism;;; +97835-3;LL5922-1;Intraop general complications;LA7424-0;6;Death;;; +97835-3;LL5922-1;Intraop general complications;LA46-8;7;Other;;; +97835-3;LL5922-1;Intraop general complications;LA32226-5;8;Not documented;;; +97835-3;LL5922-1;Intraop general complications;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97835-3;LL5922-1;Intraop general complications;LA32228-1;2;Anesthesiological;;; +97835-3;LL5922-1;Intraop general complications;LA18277-6;3;Cardiovascular;;; +97835-3;LL5922-1;Intraop general complications;LA18283-4;4;Pulmonary;;; +97835-3;LL5922-1;Intraop general complications;LA31836-2;5;Thromboembolism;;; +97835-3;LL5922-1;Intraop general complications;LA7424-0;6;Death;;; +97835-3;LL5922-1;Intraop general complications;LA46-8;7;Other;;; +97835-3;LL5922-1;Intraop general complications;LA32226-5;8;Not documented;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97837-9;LL5923-9;PostOp Surgical Complications;LA31824-8;2;Epidural hematoma;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32229-9;3;Other hematoma;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32230-7;4;Radiculopathy;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31819-8;5;CSF leak/pseudomeningocele;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31814-9;6;Motor dysfunction;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31813-1;7;Sensory dysfunction;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31815-6;8;Bowel/bladder dysfunction;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31820-6;9;Wound infection superficial;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31821-4;10;Wound infection deep;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31827-1;11;Implant malposition;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31817-2;12;Implant failure;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31826-3;13;Wrong level;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32231-5;14;Recurrent nerve paresis;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA46-8;15;Other;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32226-5;16;Not documented;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97837-9;LL5923-9;PostOp Surgical Complications;LA31824-8;2;Epidural hematoma;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32229-9;3;Other hematoma;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32230-7;4;Radiculopathy;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31819-8;5;CSF leak/pseudomeningocele;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31814-9;6;Motor dysfunction;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31813-1;7;Sensory dysfunction;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31815-6;8;Bowel/bladder dysfunction;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31820-6;9;Wound infection superficial;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31821-4;10;Wound infection deep;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31827-1;11;Implant malposition;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31817-2;12;Implant failure;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA31826-3;13;Wrong level;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32231-5;14;Recurrent nerve paresis;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA46-8;15;Other;;; +97837-9;LL5923-9;PostOp Surgical Complications;LA32226-5;16;Not documented;;; +97838-7;LL5924-7;PostOp General Complications;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97838-7;LL5924-7;PostOp General Complications;LA18277-6;2;Cardiovascular;;; +97838-7;LL5924-7;PostOp General Complications;LA18283-4;3;Pulmonary;;; +97838-7;LL5924-7;PostOp General Complications;LA32232-3;4;Cerebral;;; +97838-7;LL5924-7;PostOp General Complications;LA32233-1;5;Kidney/urinary;;; +97838-7;LL5924-7;PostOp General Complications;LA32234-9;6;Liver/GI;;; +97838-7;LL5924-7;PostOp General Complications;LA31836-2;7;Thromboembolism;;; +97838-7;LL5924-7;PostOp General Complications;LA32235-6;8;Positioning-related;;; +97838-7;LL5924-7;PostOp General Complications;LA7424-0;9;Death;;; +97838-7;LL5924-7;PostOp General Complications;LA46-8;10;Other;;; +97838-7;LL5924-7;PostOp General Complications;LA32226-5;11;Not documented;;; +97838-7;LL5924-7;PostOp General Complications;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97838-7;LL5924-7;PostOp General Complications;LA18277-6;2;Cardiovascular;;; +97838-7;LL5924-7;PostOp General Complications;LA18283-4;3;Pulmonary;;; +97838-7;LL5924-7;PostOp General Complications;LA32232-3;4;Cerebral;;; +97838-7;LL5924-7;PostOp General Complications;LA32233-1;5;Kidney/urinary;;; +97838-7;LL5924-7;PostOp General Complications;LA32234-9;6;Liver/GI;;; +97838-7;LL5924-7;PostOp General Complications;LA31836-2;7;Thromboembolism;;; +97838-7;LL5924-7;PostOp General Complications;LA32235-6;8;Positioning-related;;; +97838-7;LL5924-7;PostOp General Complications;LA7424-0;9;Death;;; +97838-7;LL5924-7;PostOp General Complications;LA46-8;10;Other;;; +97838-7;LL5924-7;PostOp General Complications;LA32226-5;11;Not documented;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97839-5;LL5925-4;Re-intervention after index surgery;LA32236-4;2;Hematoma evacuation;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA19079-5;3;Suture;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA19076-1;4;Glue;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32219-0;5;Hardware removal;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32238-0;6;Hardware re-implantation;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32239-8;7;Abscess drainage;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32240-6;8;(further) decompression;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA46-8;9;Other;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32226-5;10;Not documented;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +97839-5;LL5925-4;Re-intervention after index surgery;LA32236-4;2;Hematoma evacuation;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA19079-5;3;Suture;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA19076-1;4;Glue;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32219-0;5;Hardware removal;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32238-0;6;Hardware re-implantation;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32239-8;7;Abscess drainage;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32240-6;8;(further) decompression;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA46-8;9;Other;;; +97839-5;LL5925-4;Re-intervention after index surgery;LA32226-5;10;Not documented;;; +97840-3;LL5926-2;Hospital stay;LA32241-4;1;Uneventful;;; +97840-3;LL5926-2;Hospital stay;LA32242-2;2;ICU >2 days;;; +97840-3;LL5926-2;Hospital stay;LA32243-0;3;Extended stay;;; +97840-3;LL5926-2;Hospital stay;LA32241-4;1;Uneventful;;; +97840-3;LL5926-2;Hospital stay;LA32242-2;2;ICU >2 days;;; +97840-3;LL5926-2;Hospital stay;LA32243-0;3;Extended stay;;; +97841-1;LL5927-0;Status of Complications;LA9041-0;1;Resolved;;; +97841-1;LL5927-0;Status of Complications;LA65-8;2;Improved;;; +97841-1;LL5927-0;Status of Complications;LA32244-8;3;Persisting;;; +97841-1;LL5927-0;Status of Complications;LA9041-0;1;Resolved;;; +97841-1;LL5927-0;Status of Complications;LA65-8;2;Improved;;; +97841-1;LL5927-0;Status of Complications;LA32244-8;3;Persisting;;; +97842-9;LL5928-8;Goals achieved;LA32245-5;1;Achieved;;; +97842-9;LL5928-8;Goals achieved;LA32246-3;2;Partially achieved;;; +97842-9;LL5928-8;Goals achieved;LA32247-1;3;Not achieved;;; +97842-9;LL5928-8;Goals achieved;LA32245-5;1;Achieved;;; +97842-9;LL5928-8;Goals achieved;LA32246-3;2;Partially achieved;;; +97842-9;LL5928-8;Goals achieved;LA32247-1;3;Not achieved;;; +97843-7;LL5900-7;ASIA impairment scale;LA13487-6;1;A;;; +97843-7;LL5900-7;ASIA impairment scale;LA14518-7;2;B;;; +97843-7;LL5900-7;ASIA impairment scale;LA14519-5;3;C;;; +97843-7;LL5900-7;ASIA impairment scale;LA14520-3;4;D;;; +97843-7;LL5900-7;ASIA impairment scale;LA13503-0;5;E;;; +97843-7;LL5900-7;ASIA impairment scale;LA32111-9;6;Not assessable/applicable;;; +97843-7;LL5900-7;ASIA impairment scale;LA13487-6;1;A;;; +97843-7;LL5900-7;ASIA impairment scale;LA14518-7;2;B;;; +97843-7;LL5900-7;ASIA impairment scale;LA14519-5;3;C;;; +97843-7;LL5900-7;ASIA impairment scale;LA14520-3;4;D;;; +97843-7;LL5900-7;ASIA impairment scale;LA13503-0;5;E;;; +97843-7;LL5900-7;ASIA impairment scale;LA32111-9;6;Not assessable/applicable;;; +97846-0;LL5950-2;HL7_Name use;;0;;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32289-3;1;Uninfected - No clinical or virological evidence of infection;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32290-1;2;Ambulatory - No limitation of activities;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32291-9;3;Ambulatory - Limitation of activities;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32292-7;4;Hospitalized - mild disease, no oxygen therapy;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32293-5;5;Hospitalized - mild disease, oxygen by mask or nasal prongs;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32294-3;6;Hospitalized - severe disease, non-invasive ventilation or high-flow oxygen;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32295-0;7;Hospitalized - severe disease, intubation and mechanical ventilation;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA32296-8;8;Hospitalized - severe disease, ventilation and additional organ support - pressors, RRT, ECMO;;; +97852-8;LL5951-0;WHO Ordinal Scale for Clinical Improvement;LA9627-6;9;Dead;;; +97888-2;LL5823-1;Back pain troubles;LA31749-7;1;Back pain;;; +97888-2;LL5823-1;Back pain troubles;LA31750-5;2;Leg/buttock pain;;; +97888-2;LL5823-1;Back pain troubles;LA31751-3;3;Sensory disturbances in the back/leg/buttocks, e.g. tingling, 'pins and needles', numbness;;; +97888-2;LL5823-1;Back pain troubles;LA9-3;4;None of the above;;; +97937-7;LL5791-0;CultureGrowthTemperatureAnswers;LA31645-7;1;Growth at 25 and 30 degrees C;;; +97937-7;LL5791-0;CultureGrowthTemperatureAnswers;LA31646-5;2;Growth at 30 degrees C;;; +97937-7;LL5791-0;CultureGrowthTemperatureAnswers;LA21123-7;3;No growth;;; +97937-7;LL5791-0;CultureGrowthTemperatureAnswers;LA31647-3;4;No growth at 25 degrees C;;; +97937-7;LL5791-0;CultureGrowthTemperatureAnswers;LA31648-1;5;No growth at 25, 30, and 37 degrees C;;; +97937-7;LL5791-0;CultureGrowthTemperatureAnswers;LA31649-9;6;Poor growth at 25 degrees C;;; +97937-7;LL5791-0;CultureGrowthTemperatureAnswers;LA31650-7;7;Poor growth at 30 degrees C;;; +97938-5;LL5792-8;CultureColor;LA4267-6;1;Black;;; +97938-5;LL5792-8;CultureColor;LA19058-9;3;Brown;;; +97938-5;LL5792-8;CultureColor;LA17192-8;5;Pink;;; +97938-5;LL5792-8;CultureColor;LA15555-8;6;Green;;; +97938-5;LL5792-8;CultureColor;LA17193-6;7;Red;;; +97938-5;LL5792-8;CultureColor;LA31651-5;8;Golden-yellow;;; +97938-5;LL5792-8;CultureColor;LA31652-3;9;Wine red;;; +97938-5;LL5792-8;CultureColor;LA4457-3;10;White;;; +97938-5;LL5792-8;CultureColor;LA21915-6;11;Cream;;; +97943-5;LL5792-8;CultureColor;LA4267-6;1;Black;;; +97943-5;LL5792-8;CultureColor;LA19058-9;3;Brown;;; +97943-5;LL5792-8;CultureColor;LA17192-8;5;Pink;;; +97943-5;LL5792-8;CultureColor;LA15555-8;6;Green;;; +97943-5;LL5792-8;CultureColor;LA17193-6;7;Red;;; +97943-5;LL5792-8;CultureColor;LA31651-5;8;Golden-yellow;;; +97943-5;LL5792-8;CultureColor;LA31652-3;9;Wine red;;; +97943-5;LL5792-8;CultureColor;LA4457-3;10;White;;; +97943-5;LL5792-8;CultureColor;LA21915-6;11;Cream;;; +98406-2;LL5792-8;CultureColor;LA4267-6;1;Black;;; +98406-2;LL5792-8;CultureColor;LA19058-9;3;Brown;;; +98406-2;LL5792-8;CultureColor;LA17192-8;5;Pink;;; +98406-2;LL5792-8;CultureColor;LA15555-8;6;Green;;; +98406-2;LL5792-8;CultureColor;LA17193-6;7;Red;;; +98406-2;LL5792-8;CultureColor;LA31651-5;8;Golden-yellow;;; +98406-2;LL5792-8;CultureColor;LA31652-3;9;Wine red;;; +98406-2;LL5792-8;CultureColor;LA4457-3;10;White;;; +98406-2;LL5792-8;CultureColor;LA21915-6;11;Cream;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31653-1;1;Kelley's medium: Broad-based buds yeast at 37C;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31654-9;2;Kelley's medium: Yeast phase cells at 37C;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31655-6;3;No conversion on BHI medium at 37C;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31656-4;4;No conversion on Kelley's medium at 37C;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31657-2;5;No conversion on Pine's medium at 37C;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31658-0;6;Pine's medium: Narrow-budding yeast at 37C;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31659-8;7;Pine's medium: Yeast phase cells at 37C;;; +97939-3;LL5794-4;YeastConversionInVitro;LA31660-6;8;Small budding yeast at 37C on BHIB;;; +97941-9;LL5860-3;Growth|NoGr|PartialInhib;LA21123-7;1;No growth;;; +97941-9;LL5860-3;Growth|NoGr|PartialInhib;LA31297-7;2;Growth;;; +97941-9;LL5860-3;Growth|NoGr|PartialInhib;LA31929-5;3;Partial growth;;; +97942-7;LL5962-7;ColonyTexture;LA32306-5;1;Cottony;;; +97942-7;LL5962-7;ColonyTexture;LA17199-3;2;Dry;;; +97942-7;LL5962-7;ColonyTexture;LA32307-3;3;Floccose;;; +97942-7;LL5962-7;ColonyTexture;LA15816-4;4;Granular;;; +97942-7;LL5962-7;ColonyTexture;LA25082-1;5;Mucoid;;; +97942-7;LL5962-7;ColonyTexture;LA32308-1;6;powdery;;; +97942-7;LL5962-7;ColonyTexture;LA32309-9;7;Smooth;;; +97942-7;LL5962-7;ColonyTexture;LA32310-7;8;Woolly;;; +97942-7;LL5962-7;ColonyTexture;LA12883-7;9;Fungi.yeastlike;;; +97944-3;LL5963-5;ColonyColor_CGB;LA15555-8;6;Green;;; +97944-3;LL5963-5;ColonyColor_CGB;LA32311-5;7;Yellowish-green;;; +97944-3;LL5963-5;ColonyColor_CGB;LA15553-3;8;Blue;;; +97945-0;LL5964-3;ColonyColor_mold;LA15555-8;6;Green;;; +97945-0;LL5964-3;ColonyColor_mold;LA17193-6;7;Red;;; +97945-0;LL5964-3;ColonyColor_mold;LA32312-3;8;Buff;;; +97945-0;LL5964-3;ColonyColor_mold;LA32313-1;9;Yellow-grey;;; +97945-0;LL5964-3;ColonyColor_mold;LA15553-3;10;Blue;;; +97945-0;LL5964-3;ColonyColor_mold;LA32314-9;11;Lilac;;; +97945-0;LL5964-3;ColonyColor_mold;LA17196-9;12;Orange;;; +97945-0;LL5964-3;ColonyColor_mold;LA17194-4;13;Purple;;; +97945-0;LL5964-3;ColonyColor_mold;LA19063-9;14;Tan;;; +97945-0;LL5964-3;ColonyColor_mold;LA19062-1;15;Violet;;; +98395-7;LL5964-3;ColonyColor_mold;LA15555-8;6;Green;;; +98395-7;LL5964-3;ColonyColor_mold;LA17193-6;7;Red;;; +98395-7;LL5964-3;ColonyColor_mold;LA32312-3;8;Buff;;; +98395-7;LL5964-3;ColonyColor_mold;LA32313-1;9;Yellow-grey;;; +98395-7;LL5964-3;ColonyColor_mold;LA15553-3;10;Blue;;; +98395-7;LL5964-3;ColonyColor_mold;LA32314-9;11;Lilac;;; +98395-7;LL5964-3;ColonyColor_mold;LA17196-9;12;Orange;;; +98395-7;LL5964-3;ColonyColor_mold;LA17194-4;13;Purple;;; +98395-7;LL5964-3;ColonyColor_mold;LA19063-9;14;Tan;;; +98395-7;LL5964-3;ColonyColor_mold;LA19062-1;15;Violet;;; +98397-3;LL5964-3;ColonyColor_mold;LA15555-8;6;Green;;; +98397-3;LL5964-3;ColonyColor_mold;LA17193-6;7;Red;;; +98397-3;LL5964-3;ColonyColor_mold;LA32312-3;8;Buff;;; +98397-3;LL5964-3;ColonyColor_mold;LA32313-1;9;Yellow-grey;;; +98397-3;LL5964-3;ColonyColor_mold;LA15553-3;10;Blue;;; +98397-3;LL5964-3;ColonyColor_mold;LA32314-9;11;Lilac;;; +98397-3;LL5964-3;ColonyColor_mold;LA17196-9;12;Orange;;; +98397-3;LL5964-3;ColonyColor_mold;LA17194-4;13;Purple;;; +98397-3;LL5964-3;ColonyColor_mold;LA19063-9;14;Tan;;; +98397-3;LL5964-3;ColonyColor_mold;LA19062-1;15;Violet;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA17192-8;5;Pink;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA15555-8;6;Green;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA17193-6;7;Red;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA17195-1;8;Yellow;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA15553-3;9;Blue;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA32315-6;10;Lavender;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA17196-9;11;Orange;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA17194-4;12;Purple;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA19063-9;13;Tan;;; +97946-8;LL5965-0;ColonyColor_Chrom;LA19062-1;14;Violet;;; +97998-9;LL5966-8;HPA_Antibodies;LA32316-4;1;Anti-HPA-1a;;; +97998-9;LL5966-8;HPA_Antibodies;LA32317-2;2;Anti-HPA-1b;;; +97998-9;LL5966-8;HPA_Antibodies;LA32318-0;3;Anti-HPA-2a;;; +97998-9;LL5966-8;HPA_Antibodies;LA32319-8;4;Anti-HPA-2b;;; +97998-9;LL5966-8;HPA_Antibodies;LA32320-6;5;Anti-HPA-3a;;; +97998-9;LL5966-8;HPA_Antibodies;LA32321-4;6;Anti-HPA-4b;;; +97998-9;LL5966-8;HPA_Antibodies;LA32322-2;7;Anti-HPA-8b;;; +97998-9;LL5966-8;HPA_Antibodies;LA32323-0;8;Anti-HPA-15a;;; +97998-9;LL5966-8;HPA_Antibodies;LA32324-8;9;Anti-HPA-17b;;; +97998-9;LL5966-8;HPA_Antibodies;LA32325-5;10;Anti-HPA-30b;;; +97998-9;LL5966-8;HPA_Antibodies;LA32326-3;11;Anti-HPA-35b;;; +98000-3;LL5939-5;HLA High Res;LA31486-6;1;HLA-DRB1*01:01:01;;; +98000-3;LL5939-5;HLA High Res;LA31487-4;2;HLA-DRB1*01:01:06;;; +98000-3;LL5939-5;HLA High Res;LA31488-2;3;HLA-DRB1*03:01:01:02;;; +98000-3;LL5939-5;HLA High Res;LA31489-0;4;HLA-DRB1*01:18;;; +98000-3;LL5939-5;HLA High Res;LA31555-8;5;HLA-DQB1*06;;; +98000-3;LL5939-5;HLA High Res;LA31554-1;6;HLA-DQB1*03;;; +98000-3;LL5939-5;HLA High Res;LA31543-4;7;HLA-C*16:15:01;;; +98000-3;LL5939-5;HLA High Res;LA31541-8;8;HLA-C*04:01;;; +98000-3;LL5939-5;HLA High Res;LA31539-2;9;HLA-B*27:40;;; +98000-3;LL5939-5;HLA High Res;LA31537-6;10;HLA-B*08:02;;; +98000-3;LL5939-5;HLA High Res;LA31535-0;11;HLA-A*23:06;;; +98000-3;LL5939-5;HLA High Res;LA31533-5;12;HLA-A*03:01:02;;; +98000-3;LL5939-5;HLA High Res;LA31532-7;13;HLA-A*02:07;;; +98000-3;LL5939-5;HLA High Res;LA31499-9;14;HLA-DPB1*02:01:07;;; +98000-3;LL5939-5;HLA High Res;LA31502-0;15;HLA-DPB1*05:01:01;;; +98000-3;LL5939-5;HLA High Res;LA31496-5;16;HLA-DPA1*01:03:03;;; +98000-3;LL5939-5;HLA High Res;LA31495-7;17;HLA-DQA1*05:09;;; +98000-3;LL5939-5;HLA High Res;LA31492-4;18;HLA-DQB1*03:01:01;;; +98000-3;LL5939-5;HLA High Res;LA31490-8;19;HLA-DRB5*01:05;;; +98000-3;LL5939-5;HLA High Res;LA31339-7;20;HLA-DPB1*124;;; +98000-3;LL5939-5;HLA High Res;LA31332-2;21;HLA-DRB5*01:01;;; +98000-3;LL5939-5;HLA High Res;LA31331-4;22;HLA-DRB4*01:01;;; +98000-3;LL5939-5;HLA High Res;LA31329-8;23;HLA-DRB3*01:01;;; +98000-3;LL5939-5;HLA High Res;LA31326-4;24;HLA-DRB3*02:02;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31552-5;5;HLA-DQB1*02;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31553-3;6;HLA-DQB1*05;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31554-1;7;HLA-DQB1*03;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31555-8;8;HLA-DQB1*06;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31340-5;9;HLA-DPA1*01;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31341-3;10;HLA-DPA1*02;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31337-1;11;HLA-DPB1*03;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31336-3;12;HLA-DPB1*04;;; +98001-1;LL5957-7;HLA Class II LowRes;LA30822-3;13;HLA-DQA1*03;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31557-4;14;HLA-DRB1*03;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31556-6;15;HLA-DRB1*04;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31321-5;16;HLA-DRB4*01;;; +98001-1;LL5957-7;HLA Class II LowRes;LA31320-7;17;HLA-DRB3*02;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31544-2;5;HLA-A*01;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31545-9;6;HLA-A*24;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31546-7;7;HLA-A*02;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31547-5;8;HLA-A*03;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31548-3;9;HLA-B*08;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31549-1;10;HLA-B*37;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31550-9;11;HLA-B*44;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31551-7;12;HLA-B*51;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31474-2;13;HLA-C*03;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31475-9;14;HLA-C*07;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31476-7;15;HLA-C*10;;; +98002-9;LL5956-9;HLA Class I LowRes;LA31477-5;16;HLA-C*15;;; +98004-5;LL5937-9;HLA Serotypes;LA31465-0;1;HLA-B8;;; +98004-5;LL5937-9;HLA Serotypes;LA31466-8;2;HLA-B7;;; +98004-5;LL5937-9;HLA Serotypes;LA31467-6;3;HLA-B60;;; +98004-5;LL5937-9;HLA Serotypes;LA31468-4;4;HLA-B27;;; +98004-5;LL5937-9;HLA Serotypes;LA31462-7;5;HLA-A19;;; +98004-5;LL5937-9;HLA Serotypes;LA31463-5;6;HLA-A11;;; +98004-5;LL5937-9;HLA Serotypes;LA31464-3;7;HLA-A24;;; +98004-5;LL5937-9;HLA Serotypes;LA31469-2;8;HLA-Cw10;;; +98004-5;LL5937-9;HLA Serotypes;LA31470-0;9;HLA-Cw7;;; +98004-5;LL5937-9;HLA Serotypes;LA31471-8;10;HLA-Cw6;;; +98004-5;LL5937-9;HLA Serotypes;LA31472-6;11;HLA-Cw5;;; +98004-5;LL5937-9;HLA Serotypes;LA31473-4;12;HLA-Cw3;;; +98004-5;LL5937-9;HLA Serotypes;LA31482-5;13;HLA-DR1;;; +98004-5;LL5937-9;HLA Serotypes;LA31483-3;14;HLA-DR3;;; +98004-5;LL5937-9;HLA Serotypes;LA31485-8;15;HLA-DR4;;; +98004-5;LL5937-9;HLA Serotypes;LA31478-3;16;HLA-DQ2;;; +98004-5;LL5937-9;HLA Serotypes;LA31479-1;17;HLA-DQ3;;; +98004-5;LL5937-9;HLA Serotypes;LA31480-9;18;HLA-DQ4;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31546-7;4;HLA-A*02;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31547-5;5;HLA-A*03;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31545-9;6;HLA-A*24;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31544-2;7;HLA-A*01;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31551-7;8;HLA-B*51;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31549-1;9;HLA-B*37;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31548-3;10;HLA-B*08;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31477-5;11;HLA-C*15;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31476-7;12;HLA-C*10;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31475-9;13;HLA-C*07;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31320-7;14;HLA-DRB3*02;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31321-5;15;HLA-DRB4*01;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31322-3;16;HLA-DRB4*03;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31557-4;17;HLA-DRB1*03;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31558-2;18;HLA-DRB1*15;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA30822-3;19;HLA-DQA1*03;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA30823-1;20;HLA-DQA1*05;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31553-3;21;HLA-DQB1*05;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31552-5;22;HLA-DQB1*02;;; +98005-2;LL5933-8;HLA-Class I&II-LowRes;LA31555-8;23;HLA-DQB1*06;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23895-8;1;Anti-DP1;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23894-1;2;Anti-DP2;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23897-4;3;Anti-DP3;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23896-6;4;Anti-DP4;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23898-2;5;Anti-DP5;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23899-0;6;Anti-DP6;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23909-7;7;Anti-DQ1;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23906-3;8;Anti-DQ2;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23907-1;9;Anti-DQ3;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23908-9;10;Anti-DQ4;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23903-0;11;Anti-DQ5(1);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23902-2;12;Anti-DQ6(1);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23904-8;13;Anti-DQ7(3);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23905-5;14;Anti-DQ8(3);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23910-5;15;Anti-DR1;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23914-7;16;Anti-DR3;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23915-4;17;Anti-DR4;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23922-0;18;Anti-DR6;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23916-2;19;Anti-DR7;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23917-0;20;Anti-DR8;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23918-8;21;Anti-DR10;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23919-6;22;Anti-DR11(5);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23920-4;23;Anti-DR12(5);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23921-2;24;Anti-DR13(6);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23923-8;25;Anti-DR14(6);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23924-6;26;Anti-DR15(2);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23925-3;27;Anti-DR16(2);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23912-1;28;Anti-DR17(3);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23913-9;29;Anti-DR18(3);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23927-9;30;Anti-DR51;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23926-1;31;Anti-DR52;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23928-7;32;Anti-DR53;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23911-3;33;Anti-DR103;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23858-6;34;Anti-A1;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23859-4;35;Anti-A2;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23860-2;36;Anti-A3;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23863-6;37;Anti-A11;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23865-1;38;Anti-A29;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23870-1;39;Anti-B7;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23872-7;40;Anti-B12;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23873-5;41;Anti-B13;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23874-3;42;Anti-B14;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23875-0;43;Anti-B21(49);;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23883-4;44;Anti-B53;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23881-8;45;Anti-B42;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23879-2;46;Anti-B40;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23884-2;47;Anti-B67;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23886-7;49;Anti-Cw1;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23887-5;50;Anti-Cw2;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23888-3;51;Anti-Cw4;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23889-1;52;Anti-Cw5;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23890-9;53;Anti-Cw3;;; +98006-0;LL5935-3;HLAClassI&II-Ab;LA23892-5;54;Anti-Cw7;;; +98009-4;LL5947-8;NIPS - Breathing Patterns;LA32283-6;1;Relaxed;;; +98009-4;LL5947-8;NIPS - Breathing Patterns;LA32284-4;2;Change in breathing (e.g., indrawing, irregular, faster than usual, gagging, or breath holding);;; +98010-2;LL5948-6;NIPS - Rigidity;LA32285-1;1;Restrained;;; +98010-2;LL5948-6;NIPS - Rigidity;LA32283-6;2;Relaxed;;; +98010-2;LL5948-6;NIPS - Rigidity;LA32286-9;3;Flexed (tense or rigid);;; +98010-2;LL5948-6;NIPS - Rigidity;LA32287-7;4;Extended (tense or rigid);;; +98011-0;LL5948-6;NIPS - Rigidity;LA32285-1;1;Restrained;;; +98011-0;LL5948-6;NIPS - Rigidity;LA32283-6;2;Relaxed;;; +98011-0;LL5948-6;NIPS - Rigidity;LA32286-9;3;Flexed (tense or rigid);;; +98011-0;LL5948-6;NIPS - Rigidity;LA32287-7;4;Extended (tense or rigid);;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA131-5;1;No pain;;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA15111-0;2;Mild pain;;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA135-6;3;Moderate pain;;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA15109-4;4;Severe pain;;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA131-5;1;No pain;;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA15111-0;2;Mild pain;;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA135-6;3;Moderate pain;;; +98013-6;LL5953-6;NIPS - Pain Interpretation;LA15109-4;4;Severe pain;;; +98070-6;LL5974-2;MRC breathlessness scale;LA9629-2;1;Grade 1;;; +98070-6;LL5974-2;MRC breathlessness scale;LA9630-0;2;Grade 2;;; +98070-6;LL5974-2;MRC breathlessness scale;LA9631-8;3;Grade 3;;; +98070-6;LL5974-2;MRC breathlessness scale;LA11897-8;4;Grade 4;;; +98070-6;LL5974-2;MRC breathlessness scale;LA11898-6;5;Grade 5;;; +98072-2;LL5979-1;PCFS Grade;LA9628-4;1;Grade 0;;; +98072-2;LL5979-1;PCFS Grade;LA9629-2;2;Grade 1;;; +98072-2;LL5979-1;PCFS Grade;LA9630-0;3;Grade 2;;; +98072-2;LL5979-1;PCFS Grade;LA9631-8;4;Grade 3;;; +98072-2;LL5979-1;PCFS Grade;LA11897-8;5;Grade 4;;; +98072-2;LL5979-1;PCFS Grade;LA32347-9;6;Grade D;;; +98076-3;LL5991-6;Wish to discuss contraception;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98076-3;LL5991-6;Wish to discuss contraception;LA32389-1;2;No - I do not want to talk about contraception today because I am here for something else;;; +98076-3;LL5991-6;Wish to discuss contraception;LA32390-9;3;No - This question does not apply to me/I prefer not to answer;;; +98076-3;LL5991-6;Wish to discuss contraception;LA32393-3;4;No - I am already using contraception;;; +98076-3;LL5991-6;Wish to discuss contraception;LA32391-7;5;No - I am unsure or don't want to use contraception;;; +98076-3;LL5991-6;Wish to discuss contraception;LA32392-5;6;No - I am hoping to become pregnant in the near future;;; +98150-6;LL6009-6;Encephalopathy Grades;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +98150-6;LL6009-6;Encephalopathy Grades;LA9629-2;2;Grade 1;;; +98150-6;LL6009-6;Encephalopathy Grades;LA9630-0;3;Grade 2;;; +98150-6;LL6009-6;Encephalopathy Grades;LA9631-8;4;Grade 3;;; +98150-6;LL6009-6;Encephalopathy Grades;LA11897-8;5;Grade 4;;; +98151-4;LL6010-4;Absent|Slight|Moderate;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98151-4;LL6010-4;Absent|Slight|Moderate;LA11910-9;2;Slight;;; +98151-4;LL6010-4;Absent|Slight|Moderate;LA6751-7;3;Moderate;;; +98156-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98156-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98156-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98156-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98156-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98156-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98156-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98156-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98156-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98157-1;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98157-1;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98157-1;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98157-1;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98157-1;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98157-1;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98157-1;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98157-1;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98157-1;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98158-9;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98158-9;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98158-9;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98158-9;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98158-9;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98158-9;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98158-9;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98158-9;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98158-9;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98159-7;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98159-7;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98159-7;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98159-7;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98159-7;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98159-7;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98159-7;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98159-7;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98159-7;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98160-5;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98160-5;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98160-5;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98160-5;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98160-5;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98160-5;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98160-5;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98160-5;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98160-5;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98171-2;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98171-2;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98171-2;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98171-2;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98171-2;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98171-2;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98172-0;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98172-0;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98172-0;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98172-0;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98172-0;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98172-0;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98174-6;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98174-6;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98174-6;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98174-6;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98174-6;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98174-6;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98174-6;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98174-6;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98174-6;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98175-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98175-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98175-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98175-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98175-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98175-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98175-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98175-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98175-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98176-1;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98176-1;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98176-1;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98176-1;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98176-1;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98176-1;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98176-1;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98176-1;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98176-1;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98177-9;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98177-9;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98177-9;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98177-9;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98177-9;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98177-9;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98177-9;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98177-9;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98177-9;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98178-7;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98178-7;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98178-7;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98178-7;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98178-7;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98178-7;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98178-7;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98178-7;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98178-7;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98179-5;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98179-5;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98179-5;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98180-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98180-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98180-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98873-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98873-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98873-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98875-8;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98875-8;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98875-8;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98949-1;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98949-1;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98949-1;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98953-3;LL6004-7;Yes|No|Not applicable;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98953-3;LL6004-7;Yes|No|Not applicable;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98953-3;LL6004-7;Yes|No|Not applicable;LA4720-4;3;Not applicable;;; +98161-3;LL6021-1;Monthly income - Euros;LA32542-5;1;Less than 100 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32543-3;2;100 € to 299 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32544-1;3;300 € to 499 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32545-8;4;500 € to 999 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32546-6;5;1000 € to 1999 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32547-4;6;2000 € to 2999 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32548-2;7;3000 € to 3999 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32549-0;8;4000 € to 4999 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32550-8;9;5000 € to 5999 €;;; +98161-3;LL6021-1;Monthly income - Euros;LA32551-6;10;More than 6000 €;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA32554-0;1;Several times each day;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA13897-6;2;Once a day;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA18928-4;3;2-3 times a week;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA26461-6;4;Once a week;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA27722-0;5;Less than once a week;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA32554-0;1;Several times each day;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA13897-6;2;Once a day;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA18928-4;3;2-3 times a week;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA26461-6;4;Once a week;;; +98164-7;LL6022-9;Frequency: several x day to <1x per week;LA27722-0;5;Less than once a week;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98167-0;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98168-8;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98169-6;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98170-4;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98943-4;LL6005-4;Nev|Rare|Oft|V Often;LA6270-8;1;Never;;; +98943-4;LL6005-4;Nev|Rare|Oft|V Often;LA10066-1;2;Rarely;;; +98943-4;LL6005-4;Nev|Rare|Oft|V Often;LA10044-8;3;Often;;; +98943-4;LL6005-4;Nev|Rare|Oft|V Often;LA14985-8;4;Very often;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32557-3;1;Lack of trust in its efficacy;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32558-1;2;Fear of adverse side effects;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32559-9;3;I have had COVID-19 already;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32560-7;4;I am afraid that adverse effects will be worse than the disease itself;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32561-5;5;I prefer others to get the vaccine first before I do;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32562-3;6;I believe there are other (better) ways to prevent COVID-19 than with a vaccine;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32557-3;1;Lack of trust in its efficacy;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32558-1;2;Fear of adverse side effects;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32559-9;3;I have had COVID-19 already;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32560-7;4;I am afraid that adverse effects will be worse than the disease itself;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32561-5;5;I prefer others to get the vaccine first before I do;;; +98173-8;LL6023-7;Reason for not accepting COVID-19 vaccine;LA32562-3;6;I believe there are other (better) ways to prevent COVID-19 than with a vaccine;;; +98181-1;LL5978-3;Medical Equipment;;0;;;; +98221-5;LL5980-9;Treponema pallidum Ab bands;LA19544-8;1;None detected;;; +98221-5;LL5980-9;Treponema pallidum Ab bands;LA32348-7;2;Tp15 band;;; +98221-5;LL5980-9;Treponema pallidum Ab bands;LA32349-5;3;Tp17 band;;; +98221-5;LL5980-9;Treponema pallidum Ab bands;LA32350-3;4;Tp47 band;;; +98221-5;LL5980-9;Treponema pallidum Ab bands;LA32351-1;5;Tp257 band;;; +98221-5;LL5980-9;Treponema pallidum Ab bands;LA32352-9;6;Tp453 band;;; +98221-5;LL5980-9;Treponema pallidum Ab bands;LA32353-7;7;TmpA band;;; +98222-3;LL5980-9;Treponema pallidum Ab bands;LA19544-8;1;None detected;;; +98222-3;LL5980-9;Treponema pallidum Ab bands;LA32348-7;2;Tp15 band;;; +98222-3;LL5980-9;Treponema pallidum Ab bands;LA32349-5;3;Tp17 band;;; +98222-3;LL5980-9;Treponema pallidum Ab bands;LA32350-3;4;Tp47 band;;; +98222-3;LL5980-9;Treponema pallidum Ab bands;LA32351-1;5;Tp257 band;;; +98222-3;LL5980-9;Treponema pallidum Ab bands;LA32352-9;6;Tp453 band;;; +98222-3;LL5980-9;Treponema pallidum Ab bands;LA32353-7;7;TmpA band;;; +98223-1;LL5980-9;Treponema pallidum Ab bands;LA19544-8;1;None detected;;; +98223-1;LL5980-9;Treponema pallidum Ab bands;LA32348-7;2;Tp15 band;;; +98223-1;LL5980-9;Treponema pallidum Ab bands;LA32349-5;3;Tp17 band;;; +98223-1;LL5980-9;Treponema pallidum Ab bands;LA32350-3;4;Tp47 band;;; +98223-1;LL5980-9;Treponema pallidum Ab bands;LA32351-1;5;Tp257 band;;; +98223-1;LL5980-9;Treponema pallidum Ab bands;LA32352-9;6;Tp453 band;;; +98223-1;LL5980-9;Treponema pallidum Ab bands;LA32353-7;7;TmpA band;;; +98224-9;LL5980-9;Treponema pallidum Ab bands;LA19544-8;1;None detected;;; +98224-9;LL5980-9;Treponema pallidum Ab bands;LA32348-7;2;Tp15 band;;; +98224-9;LL5980-9;Treponema pallidum Ab bands;LA32349-5;3;Tp17 band;;; +98224-9;LL5980-9;Treponema pallidum Ab bands;LA32350-3;4;Tp47 band;;; +98224-9;LL5980-9;Treponema pallidum Ab bands;LA32351-1;5;Tp257 band;;; +98224-9;LL5980-9;Treponema pallidum Ab bands;LA32352-9;6;Tp453 band;;; +98224-9;LL5980-9;Treponema pallidum Ab bands;LA32353-7;7;TmpA band;;; +98245-4;LL5993-2;Sperm_Motil_Grade;LA32396-6;1;0 - no motion;;; +98245-4;LL5993-2;Sperm_Motil_Grade;LA32397-4;2;1 - sperm moving but no forward motion;;; +98245-4;LL5993-2;Sperm_Motil_Grade;LA32398-2;3;2 - sperm moving with a meandering, slow forward motion;;; +98245-4;LL5993-2;Sperm_Motil_Grade;LA32399-0;4;3 - sperm moving in an almost straight line with moderate speed;;; +98245-4;LL5993-2;Sperm_Motil_Grade;LA32400-6;5;4 - sperm moving in a straight line with high speed;;; +98248-8;LL5982-5;New primary|Recurrent tumor|Distant metastasis;LA32354-5;1;New primary tumor;;; +98248-8;LL5982-5;New primary|Recurrent tumor|Distant metastasis;LA32355-2;2;Local recurrent tumor;;; +98248-8;LL5982-5;New primary|Recurrent tumor|Distant metastasis;LA32356-0;3;Distant metastasis;;; +98250-4;LL5985-8;Neuroendocrine tumor type;LA26100-0;1;Large cell neuroendocrine carcinoma;;; +98250-4;LL5985-8;Neuroendocrine tumor type;LA26101-8;2;Small cell neuroendocrine carcinoma;;; +98250-4;LL5985-8;Neuroendocrine tumor type;LA32361-0;3;Typical carcinoid tumor;;; +98250-4;LL5985-8;Neuroendocrine tumor type;LA32362-8;4;Atypical carcinoid tumor;;; +98252-0;LL5992-4;Low grade|High grade;LA32394-1;1;Low grade;;; +98252-0;LL5992-4;Low grade|High grade;LA32395-8;2;High grade;;; +98256-1;LL5990-8;Less than half|Half or more;LA32387-5;1;Less than half;;; +98256-1;LL5990-8;Less than half|Half or more;LA32388-3;2;Half or more;;; +98261-1;LL4441-3;Present|Not identified|Cannot be determined;LA9633-4;1;Present;52101004;Present (qualifier value);http://snomed.info/sct +98261-1;LL4441-3;Present|Not identified|Cannot be determined;LA11902-6;2;Not identified;;; +98261-1;LL4441-3;Present|Not identified|Cannot be determined;LA11899-4;3;Cannot be determined;;; +98269-4;LL5986-6;Adnexa involvement sites;LA32363-6;1;Entire uterine adnexa;;; +98269-4;LL5986-6;Adnexa involvement sites;LA32364-4;2;Fallopian tubes (left and right);;; +98269-4;LL5986-6;Adnexa involvement sites;LA32365-1;3;Ovaries (left and right);;; +98269-4;LL5986-6;Adnexa involvement sites;LA32366-9;4;Suspensory ligament of ovary;;; +98269-4;LL5986-6;Adnexa involvement sites;LA32367-7;5;Mesometrium;;; +98269-4;LL5986-6;Adnexa involvement sites;LA32368-5;6;Mesovarium;;; +98269-4;LL5986-6;Adnexa involvement sites;LA32369-3;7;Mesosalpinx;;; +98269-4;LL5986-6;Adnexa involvement sites;LA32370-1;8;Uterosacral ligament;;; +98269-4;LL5986-6;Adnexa involvement sites;LA32371-9;9;Parametrium;;; +98270-2;LL5987-4;Background endometrium findings;LA32372-7;1;Cyclical;;; +98270-2;LL5987-4;Background endometrium findings;LA32373-5;2;Atrophic/Inactive;;; +98270-2;LL5987-4;Background endometrium findings;LA32374-3;3;Hormone effect;;; +98270-2;LL5987-4;Background endometrium findings;LA32375-0;4;Polyp(s);;; +98270-2;LL5987-4;Background endometrium findings;LA32376-8;5;Hyperplasia without atypia;;; +98270-2;LL5987-4;Background endometrium findings;LA32377-6;6;Atypical hyperplasia/Endometrial intraepithelial neoplasia;;; +98271-0;LL5988-2;Proliferative|Pre-ovulatory|Ovulation|Secretory;LA32378-4;1;Proliferative phase;;; +98271-0;LL5988-2;Proliferative|Pre-ovulatory|Ovulation|Secretory;LA32379-2;2;Pre-ovulatory phase;;; +98271-0;LL5988-2;Proliferative|Pre-ovulatory|Ovulation|Secretory;LA32380-0;3;Ovulation;;; +98271-0;LL5988-2;Proliferative|Pre-ovulatory|Ovulation|Secretory;LA32381-8;4;Secretory phase;;; +98367-6;LL6028-6;Refraction type;LA31303-3;1;Uncorrected;;; +98367-6;LL6028-6;Refraction type;LA31304-1;2;Current Lenses;;; +98367-6;LL6028-6;Refraction type;LA31305-8;3;Objective;;; +98367-6;LL6028-6;Refraction type;LA31307-4;4;Last Prescription;;; +98367-6;LL6028-6;Refraction type;LA31301-7;5;Best Corrected;;; +98367-6;LL6028-6;Refraction type;LA31300-9;6;Final Prescription;;; +98369-2;LL6027-8;Vision distance being tested;LA32577-1;1;Far;;; +98369-2;LL6027-8;Vision distance being tested;LA32578-9;2;Near;;; +98369-2;LL6027-8;Vision distance being tested;LA16550-8;3;Intermediate;;; +98384-1;LL5692-0;Visual Acuity Condition Types;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98384-1;LL5692-0;Visual Acuity Condition Types;LA31309-0;2;Pinhole;;; +98384-1;LL5692-0;Visual Acuity Condition Types;LA31310-8;3;Contrast;;; +98384-1;LL5692-0;Visual Acuity Condition Types;LA31311-6;4;Glare;;; +98384-1;LL5692-0;Visual Acuity Condition Types;LA31312-4;5;Single Optotype;;; +98384-1;LL5692-0;Visual Acuity Condition Types;LA31313-2;6;Crowded Optotype;;; +98384-1;LL5692-0;Visual Acuity Condition Types;LA31314-0;7;Optokinetic;;; +98454-2;LL5692-0;Visual Acuity Condition Types;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98454-2;LL5692-0;Visual Acuity Condition Types;LA31309-0;2;Pinhole;;; +98454-2;LL5692-0;Visual Acuity Condition Types;LA31310-8;3;Contrast;;; +98454-2;LL5692-0;Visual Acuity Condition Types;LA31311-6;4;Glare;;; +98454-2;LL5692-0;Visual Acuity Condition Types;LA31312-4;5;Single Optotype;;; +98454-2;LL5692-0;Visual Acuity Condition Types;LA31313-2;6;Crowded Optotype;;; +98454-2;LL5692-0;Visual Acuity Condition Types;LA31314-0;7;Optokinetic;;; +98475-7;LL5692-0;Visual Acuity Condition Types;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98475-7;LL5692-0;Visual Acuity Condition Types;LA31309-0;2;Pinhole;;; +98475-7;LL5692-0;Visual Acuity Condition Types;LA31310-8;3;Contrast;;; +98475-7;LL5692-0;Visual Acuity Condition Types;LA31311-6;4;Glare;;; +98475-7;LL5692-0;Visual Acuity Condition Types;LA31312-4;5;Single Optotype;;; +98475-7;LL5692-0;Visual Acuity Condition Types;LA31313-2;6;Crowded Optotype;;; +98475-7;LL5692-0;Visual Acuity Condition Types;LA31314-0;7;Optokinetic;;; +98392-4;LL5989-0;Sarcoma carcinosarcoma pattern;LA32385-9;2;Homologous sarcoma;;; +98392-4;LL5989-0;Sarcoma carcinosarcoma pattern;LA32386-7;3;Heterologous sarcoma;;; +98398-1;LL5995-7;Fungal_ID;LA32431-1;1;Absidia corymbifera;;; +98398-1;LL5995-7;Fungal_ID;LA28337-6;2;Aspergillus sp;;; +98398-1;LL5995-7;Fungal_ID;LA19329-4;3;Aspergillus fumigatus;;; +98398-1;LL5995-7;Fungal_ID;LA19331-0;4;Aspergillus terreus;;; +98398-1;LL5995-7;Fungal_ID;LA32407-1;5;Beauveria bassiana;;; +98398-1;LL5995-7;Fungal_ID;LA32406-3;6;Blastomyces dermatitidis;;; +98398-1;LL5995-7;Fungal_ID;LA28339-2;7;Blastomyces sp;;; +98398-1;LL5995-7;Fungal_ID;LA32401-4;8;Candida albicans;;; +98398-1;LL5995-7;Fungal_ID;LA28338-4;9;Coccidioides sp;;; +98398-1;LL5995-7;Fungal_ID;LA32402-2;10;Candida auris;;; +98398-1;LL5995-7;Fungal_ID;LA28340-0;11;Cryptococcus sp;;; +98398-1;LL5995-7;Fungal_ID;LA29397-9;12;Cryptococcus neoformans;;; +98398-1;LL5995-7;Fungal_ID;LA32446-9;13;Dematiaceous mold - no further identification;;; +98398-1;LL5995-7;Fungal_ID;LA32408-9;14;Exserohilum rostratum;;; +98398-1;LL5995-7;Fungal_ID;LA32435-2;15;Fusarium moniliforme;;; +98398-1;LL5995-7;Fungal_ID;LA28341-8;16;Histoplasma sp;;; +98398-1;LL5995-7;Fungal_ID;LA32405-5;17;Histoplasma capsulatum;;; +98398-1;LL5995-7;Fungal_ID;LA32409-7;18;Irpex lacteus;;; +98398-1;LL5995-7;Fungal_ID;LA32445-1;19;Ramularia sp;;; +98398-1;LL5995-7;Fungal_ID;LA32447-7;20;Rhodotorula rubra;;; +98399-9;LL5995-7;Fungal_ID;LA32431-1;1;Absidia corymbifera;;; +98399-9;LL5995-7;Fungal_ID;LA28337-6;2;Aspergillus sp;;; +98399-9;LL5995-7;Fungal_ID;LA19329-4;3;Aspergillus fumigatus;;; +98399-9;LL5995-7;Fungal_ID;LA19331-0;4;Aspergillus terreus;;; +98399-9;LL5995-7;Fungal_ID;LA32407-1;5;Beauveria bassiana;;; +98399-9;LL5995-7;Fungal_ID;LA32406-3;6;Blastomyces dermatitidis;;; +98399-9;LL5995-7;Fungal_ID;LA28339-2;7;Blastomyces sp;;; +98399-9;LL5995-7;Fungal_ID;LA32401-4;8;Candida albicans;;; +98399-9;LL5995-7;Fungal_ID;LA28338-4;9;Coccidioides sp;;; +98399-9;LL5995-7;Fungal_ID;LA32402-2;10;Candida auris;;; +98399-9;LL5995-7;Fungal_ID;LA28340-0;11;Cryptococcus sp;;; +98399-9;LL5995-7;Fungal_ID;LA29397-9;12;Cryptococcus neoformans;;; +98399-9;LL5995-7;Fungal_ID;LA32446-9;13;Dematiaceous mold - no further identification;;; +98399-9;LL5995-7;Fungal_ID;LA32408-9;14;Exserohilum rostratum;;; +98399-9;LL5995-7;Fungal_ID;LA32435-2;15;Fusarium moniliforme;;; +98399-9;LL5995-7;Fungal_ID;LA28341-8;16;Histoplasma sp;;; +98399-9;LL5995-7;Fungal_ID;LA32405-5;17;Histoplasma capsulatum;;; +98399-9;LL5995-7;Fungal_ID;LA32409-7;18;Irpex lacteus;;; +98399-9;LL5995-7;Fungal_ID;LA32445-1;19;Ramularia sp;;; +98399-9;LL5995-7;Fungal_ID;LA32447-7;20;Rhodotorula rubra;;; +98400-5;LL5995-7;Fungal_ID;LA32431-1;1;Absidia corymbifera;;; +98400-5;LL5995-7;Fungal_ID;LA28337-6;2;Aspergillus sp;;; +98400-5;LL5995-7;Fungal_ID;LA19329-4;3;Aspergillus fumigatus;;; +98400-5;LL5995-7;Fungal_ID;LA19331-0;4;Aspergillus terreus;;; +98400-5;LL5995-7;Fungal_ID;LA32407-1;5;Beauveria bassiana;;; +98400-5;LL5995-7;Fungal_ID;LA32406-3;6;Blastomyces dermatitidis;;; +98400-5;LL5995-7;Fungal_ID;LA28339-2;7;Blastomyces sp;;; +98400-5;LL5995-7;Fungal_ID;LA32401-4;8;Candida albicans;;; +98400-5;LL5995-7;Fungal_ID;LA28338-4;9;Coccidioides sp;;; +98400-5;LL5995-7;Fungal_ID;LA32402-2;10;Candida auris;;; +98400-5;LL5995-7;Fungal_ID;LA28340-0;11;Cryptococcus sp;;; +98400-5;LL5995-7;Fungal_ID;LA29397-9;12;Cryptococcus neoformans;;; +98400-5;LL5995-7;Fungal_ID;LA32446-9;13;Dematiaceous mold - no further identification;;; +98400-5;LL5995-7;Fungal_ID;LA32408-9;14;Exserohilum rostratum;;; +98400-5;LL5995-7;Fungal_ID;LA32435-2;15;Fusarium moniliforme;;; +98400-5;LL5995-7;Fungal_ID;LA28341-8;16;Histoplasma sp;;; +98400-5;LL5995-7;Fungal_ID;LA32405-5;17;Histoplasma capsulatum;;; +98400-5;LL5995-7;Fungal_ID;LA32409-7;18;Irpex lacteus;;; +98400-5;LL5995-7;Fungal_ID;LA32445-1;19;Ramularia sp;;; +98400-5;LL5995-7;Fungal_ID;LA32447-7;20;Rhodotorula rubra;;; +98401-3;LL5996-5;Yeast morphology;LA30497-4;1;Fusiform shape;;; +98401-3;LL5996-5;Yeast morphology;LA32410-5;2;Globose;;; +98401-3;LL5996-5;Yeast morphology;LA32411-3;3;Oval shape;;; +98401-3;LL5996-5;Yeast morphology;LA32412-1;4;Spindle shape;;; +98402-1;LL6002-1;Mold morphology;LA32448-5;1;Conidiating;;; +98402-1;LL6002-1;Mold morphology;LA32449-3;2;Hyaline;;; +98402-1;LL6002-1;Mold morphology;LA32450-1;3;Hyaline, becoming pigmented;;; +98402-1;LL6002-1;Mold morphology;LA32451-9;4;Mycelium Aseptate;;; +98402-1;LL6002-1;Mold morphology;LA32452-7;5;Mycelium Septate;;; +98402-1;LL6002-1;Mold morphology;LA32453-5;6;Mycelium with clamp connections;;; +98402-1;LL6002-1;Mold morphology;LA32454-3;7;Non-conidiating;;; +98402-1;LL6002-1;Mold morphology;LA32455-0;8;Mycelium septate and conidiating;;; +98404-7;LL6000-5;Mold species;LA32431-1;1;Absidia corymbifera;;; +98404-7;LL6000-5;Mold species;LA32432-9;2;Bipolaris spicifera;;; +98404-7;LL6000-5;Mold species;LA32433-7;3;Coelomycete fungus;;; +98404-7;LL6000-5;Mold species;LA32434-5;4;Exophiala dermatitidis;;; +98404-7;LL6000-5;Mold species;LA32435-2;5;Fusarium moniliforme;;; +98404-7;LL6000-5;Mold species;LA32436-0;6;Geotrichum penicillatum;;; +98409-6;LL6000-5;Mold species;LA32431-1;1;Absidia corymbifera;;; +98409-6;LL6000-5;Mold species;LA32432-9;2;Bipolaris spicifera;;; +98409-6;LL6000-5;Mold species;LA32433-7;3;Coelomycete fungus;;; +98409-6;LL6000-5;Mold species;LA32434-5;4;Exophiala dermatitidis;;; +98409-6;LL6000-5;Mold species;LA32435-2;5;Fusarium moniliforme;;; +98409-6;LL6000-5;Mold species;LA32436-0;6;Geotrichum penicillatum;;; +98405-4;LL5999-9;Malassezia species;LA32427-9;1;Malassezia fufur;;; +98405-4;LL5999-9;Malassezia species;LA32428-7;2;Malassezia pachydermatis;;; +98405-4;LL5999-9;Malassezia species;LA32429-5;3;Malassezia obtusa;;; +98405-4;LL5999-9;Malassezia species;LA32430-3;4;Malassezia slooffiae;;; +98407-0;LL6001-3;Conidia morphology;LA32437-8;1;Alternate arthrospores;;; +98407-0;LL6001-3;Conidia morphology;LA32438-6;2;Arthroconidia;;; +98407-0;LL6001-3;Conidia morphology;LA32439-4;3;Branching chains;;; +98407-0;LL6001-3;Conidia morphology;LA32440-2;4;Holoblastic with macroconidia and microconidia;;; +98407-0;LL6001-3;Conidia morphology;LA32441-0;5;Phialides;;; +98407-0;LL6001-3;Conidia morphology;LA32442-8;6;Pycnidium with conidia;;; +98407-0;LL6001-3;Conidia morphology;LA32443-6;7;Tuberculate macroconidia;;; +98410-4;LL5998-1;Cryptococcus genotype;LA32414-7;1;Cryptococcus VGI;;; +98410-4;LL5998-1;Cryptococcus genotype;LA32415-4;2;Cryptococcus VGIII;;; +98410-4;LL5998-1;Cryptococcus genotype;LA32416-2;3;Cryptococcus VGIIb;;; +98410-4;LL5998-1;Cryptococcus genotype;LA32421-2;4;Cryptococcus VGIV;;; +98410-4;LL5998-1;Cryptococcus genotype;LA32422-0;5;Cryptococcus VNI;;; +98410-4;LL5998-1;Cryptococcus genotype;LA32423-8;6;Cryptococcus VNII;;; +98410-4;LL5998-1;Cryptococcus genotype;LA32426-1;7;Cryptococcus VNIV;;; +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32510-2;1;ABR - frequency specific;252618004;Auditory brainstem response threshold test (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32514-4;2;ABR - click;252618004;Auditory brainstem response threshold test (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32515-1;3;ABR - bone conduction;252618004;Auditory brainstem response threshold test (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32516-9;4;Other diagnostic ABR;;; +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32511-0;5;ASSR;252621002;Frequency following response measurement (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32517-7;6;OAE;252623004;Oto-acoustic emission test (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32518-5;7;Immittance - Tympanometry - 226 Hz;91573000;Tympanometry testing (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32508-6;8;Immittance - Tympanometry - 1000 Hz;277404009;High frequency tympanometry (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32509-4;9;Immittance - acoustic reflexes;48423005;Acoustic reflex testing (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32513-6;10;Behavioral audiometry - conventional;252576004;Behavioral test of hearing acuity (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32519-3;11;Behavioral audiometry - play;6339003;Conditioning play audiometry (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32512-8;12;Behavioral audiometry - VRA;252588002;Visual Reinforcement audiometry (procedure);http://snomed.info/sct +98419-5;LL6018-7;Diagnostic audiology tests performed;LA32520-1;13;Other/unspecified;;; +98421-1;LL6015-3;Hearing Loss - Type;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98421-1;LL6015-3;Hearing Loss - Type;LA32485-7;2;Sensorineural;60700002;Sensorineural hearing loss (disorder);http://snomed.info/sct +98421-1;LL6015-3;Hearing Loss - Type;LA32486-5;3;Conductive - transient;44057004;Conductive hearing loss (disorder);http://snomed.info/sct +98421-1;LL6015-3;Hearing Loss - Type;LA32487-3;4;Conductive - permanent;44057004;Conductive hearing loss (disorder);http://snomed.info/sct +98421-1;LL6015-3;Hearing Loss - Type;LA32488-1;5;Conductive - undetermined;44057004;Conductive hearing loss (disorder);http://snomed.info/sct +98421-1;LL6015-3;Hearing Loss - Type;LA11840-8;6;Mixed;77507001;Mixed conductive AND sensorineural hearing loss (disorder);http://snomed.info/sct +98421-1;LL6015-3;Hearing Loss - Type;LA32489-9;7;Auditory neuropahty/Neural;443805006;Auditory neuropathy spectrum disorder (disorder);http://snomed.info/sct +98421-1;LL6015-3;Hearing Loss - Type;LA32490-7;8;Undetermined/Inconclusive;;; +98426-0;LL6015-3;Hearing Loss - Type;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98426-0;LL6015-3;Hearing Loss - Type;LA32485-7;2;Sensorineural;60700002;Sensorineural hearing loss (disorder);http://snomed.info/sct +98426-0;LL6015-3;Hearing Loss - Type;LA32486-5;3;Conductive - transient;44057004;Conductive hearing loss (disorder);http://snomed.info/sct +98426-0;LL6015-3;Hearing Loss - Type;LA32487-3;4;Conductive - permanent;44057004;Conductive hearing loss (disorder);http://snomed.info/sct +98426-0;LL6015-3;Hearing Loss - Type;LA32488-1;5;Conductive - undetermined;44057004;Conductive hearing loss (disorder);http://snomed.info/sct +98426-0;LL6015-3;Hearing Loss - Type;LA11840-8;6;Mixed;77507001;Mixed conductive AND sensorineural hearing loss (disorder);http://snomed.info/sct +98426-0;LL6015-3;Hearing Loss - Type;LA32489-9;7;Auditory neuropahty/Neural;443805006;Auditory neuropathy spectrum disorder (disorder);http://snomed.info/sct +98426-0;LL6015-3;Hearing Loss - Type;LA32490-7;8;Undetermined/Inconclusive;;; +98422-9;LL6016-1;Hearing Loss - Degree;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98422-9;LL6016-1;Hearing Loss - Degree;LA32491-5;2;Slight (16-25 dB HL);;; +98422-9;LL6016-1;Hearing Loss - Degree;LA32492-3;3;Mild (26-40 dB HL);;; +98422-9;LL6016-1;Hearing Loss - Degree;LA32493-1;4;Moderate (41-55 dB HL);;; +98422-9;LL6016-1;Hearing Loss - Degree;LA32494-9;5;Moderately severe (56-70 dB HL);;; +98422-9;LL6016-1;Hearing Loss - Degree;LA32495-6;6;Severe (71-90 dB HL);;; +98422-9;LL6016-1;Hearing Loss - Degree;LA32496-4;7;Profound (91+ dB HL);;; +98422-9;LL6016-1;Hearing Loss - Degree;LA14100-4;8;Undetermined;;; +98423-7;LL6016-1;Hearing Loss - Degree;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98423-7;LL6016-1;Hearing Loss - Degree;LA32491-5;2;Slight (16-25 dB HL);;; +98423-7;LL6016-1;Hearing Loss - Degree;LA32492-3;3;Mild (26-40 dB HL);;; +98423-7;LL6016-1;Hearing Loss - Degree;LA32493-1;4;Moderate (41-55 dB HL);;; +98423-7;LL6016-1;Hearing Loss - Degree;LA32494-9;5;Moderately severe (56-70 dB HL);;; +98423-7;LL6016-1;Hearing Loss - Degree;LA32495-6;6;Severe (71-90 dB HL);;; +98423-7;LL6016-1;Hearing Loss - Degree;LA32496-4;7;Profound (91+ dB HL);;; +98423-7;LL6016-1;Hearing Loss - Degree;LA14100-4;8;Undetermined;;; +98424-5;LL6016-1;Hearing Loss - Degree;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98424-5;LL6016-1;Hearing Loss - Degree;LA32491-5;2;Slight (16-25 dB HL);;; +98424-5;LL6016-1;Hearing Loss - Degree;LA32492-3;3;Mild (26-40 dB HL);;; +98424-5;LL6016-1;Hearing Loss - Degree;LA32493-1;4;Moderate (41-55 dB HL);;; +98424-5;LL6016-1;Hearing Loss - Degree;LA32494-9;5;Moderately severe (56-70 dB HL);;; +98424-5;LL6016-1;Hearing Loss - Degree;LA32495-6;6;Severe (71-90 dB HL);;; +98424-5;LL6016-1;Hearing Loss - Degree;LA32496-4;7;Profound (91+ dB HL);;; +98424-5;LL6016-1;Hearing Loss - Degree;LA14100-4;8;Undetermined;;; +98427-8;LL6016-1;Hearing Loss - Degree;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98427-8;LL6016-1;Hearing Loss - Degree;LA32491-5;2;Slight (16-25 dB HL);;; +98427-8;LL6016-1;Hearing Loss - Degree;LA32492-3;3;Mild (26-40 dB HL);;; +98427-8;LL6016-1;Hearing Loss - Degree;LA32493-1;4;Moderate (41-55 dB HL);;; +98427-8;LL6016-1;Hearing Loss - Degree;LA32494-9;5;Moderately severe (56-70 dB HL);;; +98427-8;LL6016-1;Hearing Loss - Degree;LA32495-6;6;Severe (71-90 dB HL);;; +98427-8;LL6016-1;Hearing Loss - Degree;LA32496-4;7;Profound (91+ dB HL);;; +98427-8;LL6016-1;Hearing Loss - Degree;LA14100-4;8;Undetermined;;; +98428-6;LL6016-1;Hearing Loss - Degree;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98428-6;LL6016-1;Hearing Loss - Degree;LA32491-5;2;Slight (16-25 dB HL);;; +98428-6;LL6016-1;Hearing Loss - Degree;LA32492-3;3;Mild (26-40 dB HL);;; +98428-6;LL6016-1;Hearing Loss - Degree;LA32493-1;4;Moderate (41-55 dB HL);;; +98428-6;LL6016-1;Hearing Loss - Degree;LA32494-9;5;Moderately severe (56-70 dB HL);;; +98428-6;LL6016-1;Hearing Loss - Degree;LA32495-6;6;Severe (71-90 dB HL);;; +98428-6;LL6016-1;Hearing Loss - Degree;LA32496-4;7;Profound (91+ dB HL);;; +98428-6;LL6016-1;Hearing Loss - Degree;LA14100-4;8;Undetermined;;; +98429-4;LL6016-1;Hearing Loss - Degree;LA32484-0;1;No hearing loss;17621005;Normal (qualifier value);http://snomed.info/sct +98429-4;LL6016-1;Hearing Loss - Degree;LA32491-5;2;Slight (16-25 dB HL);;; +98429-4;LL6016-1;Hearing Loss - Degree;LA32492-3;3;Mild (26-40 dB HL);;; +98429-4;LL6016-1;Hearing Loss - Degree;LA32493-1;4;Moderate (41-55 dB HL);;; +98429-4;LL6016-1;Hearing Loss - Degree;LA32494-9;5;Moderately severe (56-70 dB HL);;; +98429-4;LL6016-1;Hearing Loss - Degree;LA32495-6;6;Severe (71-90 dB HL);;; +98429-4;LL6016-1;Hearing Loss - Degree;LA32496-4;7;Profound (91+ dB HL);;; +98429-4;LL6016-1;Hearing Loss - Degree;LA14100-4;8;Undetermined;;; +98425-2;LL6019-5;Hearing Loss - Configuration;LA9212-7;1;Flat;;; +98425-2;LL6019-5;Hearing Loss - Configuration;LA32521-9;2;Sloping;;; +98425-2;LL6019-5;Hearing Loss - Configuration;LA32522-7;3;High-frequency;;; +98425-2;LL6019-5;Hearing Loss - Configuration;LA32523-5;4;Mid-frequency;;; +98425-2;LL6019-5;Hearing Loss - Configuration;LA32524-3;5;Low-frequency;;; +98425-2;LL6019-5;Hearing Loss - Configuration;LA32525-0;6;Corner;;; +98425-2;LL6019-5;Hearing Loss - Configuration;LA46-8;7;Other;;; +98430-2;LL6019-5;Hearing Loss - Configuration;LA9212-7;1;Flat;;; +98430-2;LL6019-5;Hearing Loss - Configuration;LA32521-9;2;Sloping;;; +98430-2;LL6019-5;Hearing Loss - Configuration;LA32522-7;3;High-frequency;;; +98430-2;LL6019-5;Hearing Loss - Configuration;LA32523-5;4;Mid-frequency;;; +98430-2;LL6019-5;Hearing Loss - Configuration;LA32524-3;5;Low-frequency;;; +98430-2;LL6019-5;Hearing Loss - Configuration;LA32525-0;6;Corner;;; +98430-2;LL6019-5;Hearing Loss - Configuration;LA46-8;7;Other;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32526-8;1;Audiologic monitoring for possible late onset hearing loss;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32527-6;2;Return to complete audiologic diagnostic assessment;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32528-4;3;Referral to audiology services not available at this location;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32529-2;4;Referral to primary care provider;703978000;Referral to primary care service (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32530-0;5;Referral to ENT;183544005;Referral to ear, nose and throat service (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32531-8;6;Referral to genetics evaluation;306119003;Referral to genetics service (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32532-6;7;Referral to ophthalmology;183543004;Referral to ophthalmology service (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32533-4;8;Referral to hearing assistance technologies;306218001;Referral to hearing aid service (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32534-2;9;Referral to cardiology;183519002;Referral to cardiology service (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32535-9;10;Referral to Part C intervention services;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32536-7;11;Referral to parent support services;711281004;Referral to support group (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32537-5;12;Referral to deaf/blind services;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32538-3;13;Referral to deaf mentor/role model;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32539-1;14;Referral to case coordination for children with special needs;;; +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32540-9;15;Referral to other education services;415271004;Referral to education service (procedure);http://snomed.info/sct +98431-0;LL6020-3;Diagnostic audiology - recommendations;LA32541-7;16;Referral to home visiting programs;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32497-2;1;Infant died;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32498-0;2;Parent declined;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32499-8;3;Infant was medically fragile/NICU;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32500-3;4;Appointment cancelled by patient;185332005;Appointment canceled by patient (finding);http://snomed.info/sct +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32501-1;5;Appointment cancelled by provider;185333000;Appointment canceled by doctor (finding);http://snomed.info/sct +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32502-9;6;Unable to contact;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32503-7;7;Parents/family contacted but unresponsive;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32504-5;8;Moved out of jurisdiction/nonresident;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32505-2;9;No show - reason unknown;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32506-0;10;Not completed - uncooperative;;; +98432-8;LL6017-9;Reason diagnostic audiology testing not performed;LA32507-8;11;Not completed - equipment broken;405651005;Equipment problem (finding);http://snomed.info/sct +98483-1;LL6024-5;APOE phenotypes;LA32563-1;7;ApoE phenotype E2/E2;;; +98483-1;LL6024-5;APOE phenotypes;LA32564-9;8;ApoE phenotype E2/E3;;; +98483-1;LL6024-5;APOE phenotypes;LA32565-6;9;ApoE phenotype E3/E3 (wild type);;; +98483-1;LL6024-5;APOE phenotypes;LA32566-4;10;ApoE phenotype E2/E4;;; +98483-1;LL6024-5;APOE phenotypes;LA32567-2;11;ApoE phenotype E3/E4;;; +98483-1;LL6024-5;APOE phenotypes;LA32568-0;12;ApoE phenotype E4/E4;;; +98484-9;LL6026-0;APOE Interpretations;LA32571-4;1;The E2/E2 combination of ApoE isoforms is considered lower risk with a 0.6 odds ratio for the development of Alzheimer's disease versus the most common combination of ApoE isoforms (E3/E3).;;; +98484-9;LL6026-0;APOE Interpretations;LA32572-2;2;The E2/E3 combination of ApoE isoforms is considered lower risk with a 0.6 odds ratio for the development of Alzheimer's disease versus the most common combination of ApoE isoforms (E3/E3).;;; +98484-9;LL6026-0;APOE Interpretations;LA32573-0;3;The E3/E3 combination of ApoE isoforms is the most common and is considered average risk with a 1.0 odds ratio for the development of Alzheimer's disease.;;; +98484-9;LL6026-0;APOE Interpretations;LA32574-8;4;The E2/E4 combination of ApoE isoforms is considered higher risk with a 2.6 odds ratio for the development of Alzheimer's disease versus the most common combination of ApoE isoforms (E3/E3).;;; +98484-9;LL6026-0;APOE Interpretations;LA32575-5;5;The E3/E4 combination of ApoE isoforms is considered higher risk with a 3.2 odds ratio for the development of Alzheimer's disease versus the most common combination of ApoE isoforms (E3/E3).;;; +98484-9;LL6026-0;APOE Interpretations;LA32576-3;6;The E4/E4 combination of ApoE isoforms is considered high risk with a 14.9 odds ratio for the development of Alzheimer's disease versus the most common combination of ApoE isoforms (E3/E3).;;; +98496-3;LL6032-8;Color blindness types;LA32588-8;1;Red-green color blindness;;; +98496-3;LL6032-8;Color blindness types;LA32589-6;2;Red-green color blindness: Deuteranomaly;;; +98496-3;LL6032-8;Color blindness types;LA32590-4;3;Red-green color blindness: Protanomaly;;; +98496-3;LL6032-8;Color blindness types;LA32591-2;4;Red-green color blindness: Protanopia;;; +98496-3;LL6032-8;Color blindness types;LA32592-0;5;Red-green color blindness: Deuteranopia;;; +98496-3;LL6032-8;Color blindness types;LA32593-8;6;Blue-yellow color blindness;;; +98496-3;LL6032-8;Color blindness types;LA32594-6;7;Blue-yellow color blindness: Tritanomaly;;; +98496-3;LL6032-8;Color blindness types;LA32595-3;8;Blue-yellow color blindness: Tritanopia;;; +98496-3;LL6032-8;Color blindness types;LA32596-1;9;Complete color blindness;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA32611-8;1;0 - When I had shortness of breath, it felt very mild;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6112-2;2;1;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6113-0;3;2;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6114-8;4;3;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6115-5;5;4;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10137-0;6;5;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10138-8;7;6;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10139-6;8;7;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10140-4;9;8;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10141-2;10;9;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA32612-6;11;10 - When I had shortness of breath, it felt very severe;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA32611-8;1;0 - When I had shortness of breath, it felt very mild;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6112-2;2;1;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6113-0;3;2;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6114-8;4;3;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA6115-5;5;4;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10137-0;6;5;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10138-8;7;6;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10139-6;8;7;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10140-4;9;8;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA10141-2;10;9;;; +98514-3;LL6037-7;0=Mild SOB|2|3|4|5|6|7|8|9|10=Severe SOB;LA32612-6;11;10 - When I had shortness of breath, it felt very severe;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA32613-4;1;0 - I never had shortness of breath;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6112-2;2;1;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6113-0;3;2;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6114-8;4;3;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6115-5;5;4;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10137-0;6;5;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10138-8;7;6;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10139-6;8;7;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10140-4;9;8;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10141-2;10;9;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA32614-2;11;10 - I always had shortness of breath;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA32613-4;1;0 - I never had shortness of breath;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6112-2;2;1;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6113-0;3;2;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6114-8;4;3;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA6115-5;5;4;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10137-0;6;5;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10138-8;7;6;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10139-6;8;7;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10140-4;9;8;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA10141-2;10;9;;; +98516-8;LL6038-5;0=Never had SOB|2|3|4|5|6|7|8|9|10=Always had SOB;LA32614-2;11;10 - I always had shortness of breath;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA32615-9;1;0 - When I had shortness of breath, it lasted only for a moment;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6112-2;2;1;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6113-0;3;2;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6114-8;4;3;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6115-5;5;4;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10137-0;6;5;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10138-8;7;6;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10139-6;8;7;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10140-4;9;8;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10141-2;10;9;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA32616-7;11;10 - When I had shortness of breath, it lasted for a very long time;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA32615-9;1;0 - When I had shortness of breath, it lasted only for a moment;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6112-2;2;1;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6113-0;3;2;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6114-8;4;3;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA6115-5;5;4;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10137-0;6;5;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10138-8;7;6;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10139-6;8;7;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10140-4;9;8;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA10141-2;10;9;;; +98517-6;LL6039-3;0=Brief shortness|2|3|4|5|6|7|8|9|10=Lengthy SOB;LA32616-7;11;10 - When I had shortness of breath, it lasted for a very long time;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA32609-2;1;0 - No shortness of breath;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6112-2;2;1;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6113-0;3;2;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6114-8;4;3;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6115-5;5;4;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10137-0;6;5;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10138-8;7;6;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10139-6;8;7;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10140-4;9;8;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10141-2;10;9;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA32610-0;11;10 - Worst possible shortness of breath;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA32609-2;1;0 - No shortness of breath;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6112-2;2;1;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6113-0;3;2;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6114-8;4;3;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA6115-5;5;4;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10137-0;6;5;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10138-8;7;6;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10139-6;8;7;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10140-4;9;8;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA10141-2;10;9;;; +98518-4;LL6036-9;0=No shortness|2|3|4|5|6|7|8|9|10=Worst SOB;LA32610-0;11;10 - Worst possible shortness of breath;;; +98708-1;LL6040-1;At rest|After exercise;LA32617-5;1;At rest;;; +98708-1;LL6040-1;At rest|After exercise;LA32618-3;2;After exercise;;; +98720-6;LL6042-7;0, 1+, 2+, 3+, 4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98720-6;LL6042-7;0, 1+, 2+, 3+, 4+;LA11841-6;1;1+;;; +98720-6;LL6042-7;0, 1+, 2+, 3+, 4+;LA11842-4;2;2+;;; +98720-6;LL6042-7;0, 1+, 2+, 3+, 4+;LA11843-2;3;3+;;; +98720-6;LL6042-7;0, 1+, 2+, 3+, 4+;LA11844-0;4;4+;;; +98721-4;LL6042-7;0, 1+, 2+, 3+, 4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98721-4;LL6042-7;0, 1+, 2+, 3+, 4+;LA11841-6;1;1+;;; +98721-4;LL6042-7;0, 1+, 2+, 3+, 4+;LA11842-4;2;2+;;; +98721-4;LL6042-7;0, 1+, 2+, 3+, 4+;LA11843-2;3;3+;;; +98721-4;LL6042-7;0, 1+, 2+, 3+, 4+;LA11844-0;4;4+;;; +98722-2;LL6042-7;0, 1+, 2+, 3+, 4+;LA6577-6;0;Negative;260385009;Negative (qualifier value);http://snomed.info/sct +98722-2;LL6042-7;0, 1+, 2+, 3+, 4+;LA11841-6;1;1+;;; +98722-2;LL6042-7;0, 1+, 2+, 3+, 4+;LA11842-4;2;2+;;; +98722-2;LL6042-7;0, 1+, 2+, 3+, 4+;LA11843-2;3;3+;;; +98722-2;LL6042-7;0, 1+, 2+, 3+, 4+;LA11844-0;4;4+;;; +98725-5;LL6043-5;None|Abnormal;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +98725-5;LL6043-5;None|Abnormal;LA12748-2;2;Abnormal;263654008;Abnormal (qualifier value);http://snomed.info/sct +98726-3;LL6044-3;Normal|Reduced|Early;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98726-3;LL6044-3;Normal|Reduced|Early;LA32619-1;2;Reduced;;; +98726-3;LL6044-3;Normal|Reduced|Early;LA12111-3;3;Early;;; +98727-1;LL6045-0;None|Reduced|Single unit|Full;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +98727-1;LL6045-0;None|Reduced|Single unit|Full;LA32619-1;2;Reduced;;; +98727-1;LL6045-0;None|Reduced|Single unit|Full;LA32620-9;3;Single unit;;; +98727-1;LL6045-0;None|Reduced|Single unit|Full;LA19682-6;4;Full;;; +98728-9;LL6046-8;None|Poor|Maximal;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +98728-9;LL6046-8;None|Poor|Maximal;LA8969-3;2;Poor;;; +98728-9;LL6046-8;None|Poor|Maximal;LA32621-7;3;Maximal;;; +98735-4;LL6033-6;Worth 4 dot interpretation;LA32597-9;1;Normal fusion;;; +98735-4;LL6033-6;Worth 4 dot interpretation;LA32598-7;2;Diplopia;;; +98735-4;LL6033-6;Worth 4 dot interpretation;LA32599-5;3;Right eye suppression;;; +98735-4;LL6033-6;Worth 4 dot interpretation;LA32600-1;4;Left eye suppression;;; +98737-0;LL6033-6;Worth 4 dot interpretation;LA32597-9;1;Normal fusion;;; +98737-0;LL6033-6;Worth 4 dot interpretation;LA32598-7;2;Diplopia;;; +98737-0;LL6033-6;Worth 4 dot interpretation;LA32599-5;3;Right eye suppression;;; +98737-0;LL6033-6;Worth 4 dot interpretation;LA32600-1;4;Left eye suppression;;; +98738-8;LL6034-4;AC/A ratio type;LA32602-7;1;Gradient;;; +98738-8;LL6034-4;AC/A ratio type;LA32601-9;2;Calculated;;; +98740-4;LL6035-1;Phoria exam method;LA32603-5;1;Polarized cross;;; +98740-4;LL6035-1;Phoria exam method;LA32604-3;2;Cross ring;;; +98740-4;LL6035-1;Phoria exam method;LA32605-0;3;Von Graefe;;; +98740-4;LL6035-1;Phoria exam method;LA32606-8;4;Maddox;;; +98740-4;LL6035-1;Phoria exam method;LA32607-6;5;Mallet;;; +98740-4;LL6035-1;Phoria exam method;LA32608-4;6;Schober;;; +98855-0;LL6050-0;Therapeutic Antibody Treatment;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +98855-0;LL6050-0;Therapeutic Antibody Treatment;LA32647-2;2;Daratumumab;;; +98855-0;LL6050-0;Therapeutic Antibody Treatment;LA32648-0;3;Elotuzumab;;; +98855-0;LL6050-0;Therapeutic Antibody Treatment;LA32649-8;4;Isatuximab;;; +98855-0;LL6050-0;Therapeutic Antibody Treatment;LA32650-6;5;Rituximab;;; +98855-0;LL6050-0;Therapeutic Antibody Treatment;LA46-8;6;Other;;; +98865-9;LL6048-4;Medication refill arrangements - w/codes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98865-9;LL6048-4;Medication refill arrangements - w/codes;LA32631-6;2;You have been able to arrange for some medication refills but not all;;; +98865-9;LL6048-4;Medication refill arrangements - w/codes;LA32632-4;3;You are waiting to hear from your physician on how to refill medications;;; +98865-9;LL6048-4;Medication refill arrangements - w/codes;LA32633-2;4;Yes, home delivery;;; +98865-9;LL6048-4;Medication refill arrangements - w/codes;LA32634-0;5;Yes, you will be picking up from the pharmacy;;; +98865-9;LL6048-4;Medication refill arrangements - w/codes;LA32635-7;6;Yes, someone will be picking up your medications for you;;; +98865-9;LL6052-6;Medication refill arrangements - w/o codes;LA32-8;1;No;373067005;No (qualifier value);http://snomed.info/sct +98865-9;LL6052-6;Medication refill arrangements - w/o codes;LA32631-6;2;You have been able to arrange for some medication refills but not all;;; +98865-9;LL6052-6;Medication refill arrangements - w/o codes;LA32632-4;3;You are waiting to hear from your physician on how to refill medications;;; +98865-9;LL6052-6;Medication refill arrangements - w/o codes;LA32633-2;4;Yes, home delivery;;; +98865-9;LL6052-6;Medication refill arrangements - w/o codes;LA32634-0;5;Yes, you will be picking up from the pharmacy;;; +98865-9;LL6052-6;Medication refill arrangements - w/o codes;LA32635-7;6;Yes, someone will be picking up your medications for you;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32636-5;1;Your clinic cancelled your appointment because of COVID-19;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32637-3;2;Your clinic is closed because of COVID-19;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32638-1;3;You had symptoms of COVID-19, so you stayed home;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32639-9;4;You cancelled the appointment to avoid being around others;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32640-7;5;You cancelled the appointment because you did not want to be in a healthcare setting;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32641-5;6;You felt okay or good enough;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32642-3;7;You didn't have money or insurance;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32643-1;8;You didn't want to take public transportation and had no other way to get there;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32644-9;9;You forgot to go/just missed your appointment;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32645-6;10;You felt disrespected by the office or medical staff;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA32646-4;11;You were drinking or using drugs;;; +98868-3;LL6049-2;Reason for missed appointments w/code;LA46-8;12;Other;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32651-4;1;You couldn't get your medications because the pharmacy closed;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32652-2;2;You couldn't get to the pharmacy because of COVID-19 shutdowns;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32653-0;3;You couldn't get to the pharmacy because you wanted to avoid being around others;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32654-8;4;You felt good, didn't need your medications;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32655-5;5;Your doctor advised you to delay treatment;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32656-3;6;You were worried about side effects;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32657-1;7;You didn't have money or insurance to get medicine;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32658-9;8;You didn't want to take public transportation to pick up your prescription and had no other way to get there;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32646-4;9;You were drinking or using drugs;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA32659-7;10;You forgot to take your medications;;; +98870-9;LL6057-5;Reason for missed medication w/code;LA46-8;11;Other;;; +98876-6;LL6030-2;CVD-19 - school age - reason not follow learning;LA32584-7;1;Distance learning was not organized at the school;;; +98876-6;LL6030-2;CVD-19 - school age - reason not follow learning;LA32585-4;2;I was not interested/I was bored;;; +98876-6;LL6030-2;CVD-19 - school age - reason not follow learning;LA32586-2;3;I could not rely on good techncial mans (computer or WiFi);;; +98876-6;LL6030-2;CVD-19 - school age - reason not follow learning;LA46-8;4;Other;;; +98952-5;LL6030-2;CVD-19 - school age - reason not follow learning;LA32584-7;1;Distance learning was not organized at the school;;; +98952-5;LL6030-2;CVD-19 - school age - reason not follow learning;LA32585-4;2;I was not interested/I was bored;;; +98952-5;LL6030-2;CVD-19 - school age - reason not follow learning;LA32586-2;3;I could not rely on good techncial mans (computer or WiFi);;; +98952-5;LL6030-2;CVD-19 - school age - reason not follow learning;LA46-8;4;Other;;; +98876-6;LL6031-0;Barriers to distance learning;LA16598-7;1;Bored by the program or activity;;; +98876-6;LL6031-0;Barriers to distance learning;LA20177-4;2;Home environment;;; +98876-6;LL6031-0;Barriers to distance learning;LA32587-0;3;Lack of support;;; +98876-6;LL6031-0;Barriers to distance learning;LA26699-1;4;Technical problems;;; +98952-5;LL6031-0;Barriers to distance learning;LA16598-7;1;Bored by the program or activity;;; +98952-5;LL6031-0;Barriers to distance learning;LA20177-4;2;Home environment;;; +98952-5;LL6031-0;Barriers to distance learning;LA32587-0;3;Lack of support;;; +98952-5;LL6031-0;Barriers to distance learning;LA26699-1;4;Technical problems;;; +98878-2;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98878-2;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98878-2;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98878-2;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98879-0;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98879-0;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98879-0;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98879-0;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98880-8;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98880-8;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98880-8;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98880-8;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98881-6;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98881-6;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98881-6;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98881-6;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98882-4;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98882-4;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98882-4;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98882-4;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98883-2;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98883-2;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98883-2;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98883-2;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98884-0;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98884-0;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98884-0;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98884-0;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98885-7;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98885-7;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98885-7;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98885-7;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98886-5;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98886-5;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98886-5;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98886-5;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98887-3;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98887-3;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98887-3;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98887-3;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98888-1;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98888-1;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98888-1;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98888-1;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98890-7;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98890-7;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98890-7;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98890-7;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98901-2;LL6060-9;Assistance recevied/applied for;LA32660-5;1;Received;;; +98901-2;LL6060-9;Assistance recevied/applied for;LA32661-3;2;Applied and waiting to receive;;; +98901-2;LL6060-9;Assistance recevied/applied for;LA32662-1;3;Tried but was not able to apply for, or was not eligible;;; +98901-2;LL6060-9;Assistance recevied/applied for;LA32663-9;4;Did not apply for;;; +98891-5;LL6061-7;Expense coverage;LA32664-7;1;By putting it on my credit card and paying it off in full at the next statement;;; +98891-5;LL6061-7;Expense coverage;LA32665-4;2;By putting it on my credit card and paying it off over time;;; +98891-5;LL6061-7;Expense coverage;LA32666-2;3;With the money currently in my checking/savings account or with cash;;; +98891-5;LL6061-7;Expense coverage;LA32667-0;4;Using a bank loan or line of credit;;; +98891-5;LL6061-7;Expense coverage;LA32668-8;5;By borrowing from a friend or family member;;; +98891-5;LL6061-7;Expense coverage;LA32669-6;6;Using a payday loan, deposit advance, or overdraft;;; +98891-5;LL6061-7;Expense coverage;LA32670-4;7;By selling something;;; +98891-5;LL6061-7;Expense coverage;LA32671-2;8;By using my stimulus payment;;; +98891-5;LL6061-7;Expense coverage;LA32672-0;9;By asking my landlord or mortgage provider for an extension;;; +98891-5;LL6061-7;Expense coverage;LA32673-8;10;I wouldn't be able to pay for the expense right now;;; +98891-5;LL6061-7;Expense coverage;LA46-8;11;Other;;; +98892-3;LL6061-7;Expense coverage;LA32664-7;1;By putting it on my credit card and paying it off in full at the next statement;;; +98892-3;LL6061-7;Expense coverage;LA32665-4;2;By putting it on my credit card and paying it off over time;;; +98892-3;LL6061-7;Expense coverage;LA32666-2;3;With the money currently in my checking/savings account or with cash;;; +98892-3;LL6061-7;Expense coverage;LA32667-0;4;Using a bank loan or line of credit;;; +98892-3;LL6061-7;Expense coverage;LA32668-8;5;By borrowing from a friend or family member;;; +98892-3;LL6061-7;Expense coverage;LA32669-6;6;Using a payday loan, deposit advance, or overdraft;;; +98892-3;LL6061-7;Expense coverage;LA32670-4;7;By selling something;;; +98892-3;LL6061-7;Expense coverage;LA32671-2;8;By using my stimulus payment;;; +98892-3;LL6061-7;Expense coverage;LA32672-0;9;By asking my landlord or mortgage provider for an extension;;; +98892-3;LL6061-7;Expense coverage;LA32673-8;10;I wouldn't be able to pay for the expense right now;;; +98892-3;LL6061-7;Expense coverage;LA46-8;11;Other;;; +98891-5;LL6062-5;Paying for expenses;LA32666-2;1;With the money currently in my checking/savings account or with cash;;; +98891-5;LL6062-5;Paying for expenses;LA32674-6;2;Credit card;;; +98891-5;LL6062-5;Paying for expenses;LA32668-8;3;By borrowing from a friend or family member;;; +98891-5;LL6062-5;Paying for expenses;LA32675-3;4;Loan;;; +98892-3;LL6062-5;Paying for expenses;LA32666-2;1;With the money currently in my checking/savings account or with cash;;; +98892-3;LL6062-5;Paying for expenses;LA32674-6;2;Credit card;;; +98892-3;LL6062-5;Paying for expenses;LA32668-8;3;By borrowing from a friend or family member;;; +98892-3;LL6062-5;Paying for expenses;LA32675-3;4;Loan;;; +98893-1;LL6065-8;Difficult - Very to Not at all w/code;LA6575-0;1;Very difficult;;; +98893-1;LL6065-8;Difficult - Very to Not at all w/code;LA6573-5;2;Somewhat difficult;;; +98893-1;LL6065-8;Difficult - Very to Not at all w/code;LA14957-7;3;Not at all difficult;;; +98893-1;LL6065-8;Difficult - Very to Not at all w/code;LA12688-0;4;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +98894-9;LL6051-8;Worried levels - w/o score or code;LA27028-2;1;Not worried at all;;; +98894-9;LL6051-8;Worried levels - w/o score or code;LA27029-0;2;A little bit worried;;; +98894-9;LL6051-8;Worried levels - w/o score or code;LA27030-8;3;Somewhat worried;;; +98894-9;LL6051-8;Worried levels - w/o score or code;LA27031-6;4;A lot worried;;; +98895-6;LL6051-8;Worried levels - w/o score or code;LA27028-2;1;Not worried at all;;; +98895-6;LL6051-8;Worried levels - w/o score or code;LA27029-0;2;A little bit worried;;; +98895-6;LL6051-8;Worried levels - w/o score or code;LA27030-8;3;Somewhat worried;;; +98895-6;LL6051-8;Worried levels - w/o score or code;LA27031-6;4;A lot worried;;; +98894-9;LL6064-1;Worried - very to not at all;LA32679-5;1;Very worried;;; +98894-9;LL6064-1;Worried - very to not at all;LA27030-8;2;Somewhat worried;;; +98894-9;LL6064-1;Worried - very to not at all;LA32680-3;3;Not very worried;;; +98894-9;LL6064-1;Worried - very to not at all;LA32681-1;4;Not at all worried;;; +98895-6;LL6064-1;Worried - very to not at all;LA32679-5;1;Very worried;;; +98895-6;LL6064-1;Worried - very to not at all;LA27030-8;2;Somewhat worried;;; +98895-6;LL6064-1;Worried - very to not at all;LA32680-3;3;Not very worried;;; +98895-6;LL6064-1;Worried - very to not at all;LA32681-1;4;Not at all worried;;; +98896-4;LL6063-3;Household income change;LA32676-1;1;Yes, my household income is more;;; +98896-4;LL6063-3;Household income change;LA32677-9;2;Yes, my household income is less;;; +98896-4;LL6063-3;Household income change;LA32678-7;3;No, my household income is about the same;;; +98906-1;LL6066-6;Normal|Decreased|Equivocal;LA6626-1;1;Normal;17621005;Normal (qualifier value);http://snomed.info/sct +98906-1;LL6066-6;Normal|Decreased|Equivocal;LA24378-4;2;Decreased;;; +98906-1;LL6066-6;Normal|Decreased|Equivocal;LA11885-3;3;Equivocal;42425007;Equivocal (qualifier value);http://snomed.info/sct +98908-7;LL6068-2;Bright|Dim;LA25332-0;1;Bright;;; +98908-7;LL6068-2;Bright|Dim;LA32683-7;2;Dim;;; +98918-6;LL6071-6;Very poor|Poor|Neither|Good|Very good;LA9615-1;1;Very poor;;; +98918-6;LL6071-6;Very poor|Poor|Neither|Good|Very good;LA8969-3;2;Poor;;; +98918-6;LL6071-6;Very poor|Poor|Neither|Good|Very good;LA32716-5;3;Neither poor nor good;;; +98918-6;LL6071-6;Very poor|Poor|Neither|Good|Very good;LA8967-7;4;Good;;; +98918-6;LL6071-6;Very poor|Poor|Neither|Good|Very good;LA13913-1;5;Very Good;;; +98919-4;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98919-4;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98919-4;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98919-4;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98919-4;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98919-4;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98933-5;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98933-5;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98933-5;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98933-5;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98933-5;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98933-5;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98934-3;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98934-3;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98934-3;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98934-3;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98934-3;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98934-3;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98935-0;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98935-0;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98935-0;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98935-0;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98935-0;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98935-0;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98936-8;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98936-8;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98936-8;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98936-8;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98936-8;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98936-8;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98937-6;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98937-6;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98937-6;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98937-6;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98937-6;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98937-6;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98938-4;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98938-4;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98938-4;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98938-4;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98938-4;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98938-4;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98939-2;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98939-2;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98939-2;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98939-2;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98939-2;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98939-2;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98940-0;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98940-0;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98940-0;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98940-0;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98940-0;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98940-0;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98941-8;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98941-8;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98941-8;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98941-8;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98941-8;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98941-8;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98942-6;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +98942-6;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +98942-6;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +98942-6;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +98942-6;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +98942-6;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +99221-4;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +99221-4;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +99221-4;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +99221-4;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +99221-4;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +99221-4;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +99221-4;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +99221-4;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +99221-4;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +99221-4;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +99750-2;LL5657-3;Satisfaction;LA27754-3;1;Completely satisfied;;; +99750-2;LL5657-3;Satisfaction;LA14642-5;2;Very satisfied;;; +99750-2;LL5657-3;Satisfaction;LA27752-7;3;Somewhat satisfied;;; +99750-2;LL5657-3;Satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +99750-2;LL5657-3;Satisfaction;LA14638-3;5;Very dissatisfied;;; +99750-2;LL5657-3;Satisfaction;LA31177-1;6;Completely dissatisfied;;; +98919-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98919-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98919-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98919-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98919-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98933-5;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98933-5;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98933-5;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98933-5;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98933-5;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98934-3;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98934-3;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98934-3;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98934-3;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98934-3;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98935-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98935-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98935-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98935-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98935-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98936-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98936-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98936-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98936-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98936-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98937-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98937-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98937-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98937-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98937-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98938-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98938-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98938-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98938-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98938-4;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98939-2;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98939-2;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98939-2;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98939-2;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98939-2;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98940-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98940-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98940-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98940-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98940-0;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98941-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98941-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98941-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98941-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98941-8;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98942-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14638-3;1;Very dissatisfied;;; +98942-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29496-9;2;Dissatisfied;;; +98942-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA31733-1;3;Neither satisfied nor dissatisfied;;; +98942-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA29495-1;4;Satisfied;;; +98942-6;LL6072-4;Very diss|Dissatisfied|Neither|Satisfied|Very Sat;LA14642-5;5;Very satisfied;;; +98920-2;LL6073-2;Amounts - Not at all to Extreme;LA6568-5;1;Not at all;;; +98920-2;LL6073-2;Amounts - Not at all to Extreme;LA13940-4;2;A little;;; +98920-2;LL6073-2;Amounts - Not at all to Extreme;LA14467-7;3;A moderate amount;;; +98920-2;LL6073-2;Amounts - Not at all to Extreme;LA13914-9;4;Very much;;; +98920-2;LL6073-2;Amounts - Not at all to Extreme;LA32688-6;5;An extreme amount;;; +98921-0;LL6073-2;Amounts - Not at all to Extreme;LA6568-5;1;Not at all;;; +98921-0;LL6073-2;Amounts - Not at all to Extreme;LA13940-4;2;A little;;; +98921-0;LL6073-2;Amounts - Not at all to Extreme;LA14467-7;3;A moderate amount;;; +98921-0;LL6073-2;Amounts - Not at all to Extreme;LA13914-9;4;Very much;;; +98921-0;LL6073-2;Amounts - Not at all to Extreme;LA32688-6;5;An extreme amount;;; +98922-8;LL6073-2;Amounts - Not at all to Extreme;LA6568-5;1;Not at all;;; +98922-8;LL6073-2;Amounts - Not at all to Extreme;LA13940-4;2;A little;;; +98922-8;LL6073-2;Amounts - Not at all to Extreme;LA14467-7;3;A moderate amount;;; +98922-8;LL6073-2;Amounts - Not at all to Extreme;LA13914-9;4;Very much;;; +98922-8;LL6073-2;Amounts - Not at all to Extreme;LA32688-6;5;An extreme amount;;; +98923-6;LL6073-2;Amounts - Not at all to Extreme;LA6568-5;1;Not at all;;; +98923-6;LL6073-2;Amounts - Not at all to Extreme;LA13940-4;2;A little;;; +98923-6;LL6073-2;Amounts - Not at all to Extreme;LA14467-7;3;A moderate amount;;; +98923-6;LL6073-2;Amounts - Not at all to Extreme;LA13914-9;4;Very much;;; +98923-6;LL6073-2;Amounts - Not at all to Extreme;LA32688-6;5;An extreme amount;;; +98924-4;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA6568-5;1;Not at all;;; +98924-4;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA13940-4;2;A little;;; +98924-4;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA14467-7;3;A moderate amount;;; +98924-4;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA13914-9;4;Very much;;; +98924-4;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA14868-6;5;Extremely;;; +98925-1;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA6568-5;1;Not at all;;; +98925-1;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA13940-4;2;A little;;; +98925-1;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA14467-7;3;A moderate amount;;; +98925-1;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA13914-9;4;Very much;;; +98925-1;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA14868-6;5;Extremely;;; +98926-9;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA6568-5;1;Not at all;;; +98926-9;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA13940-4;2;A little;;; +98926-9;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA14467-7;3;A moderate amount;;; +98926-9;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA13914-9;4;Very much;;; +98926-9;LL6074-0;Not at all|Lil|Mod|V much|Ext w/score;LA14868-6;5;Extremely;;; +98927-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA6568-5;1;Not at all;;; +98927-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13940-4;2;A little;;; +98927-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13939-6;3;Moderately;;; +98927-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13938-8;4;Mostly;;; +98927-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13937-0;5;Completely;;; +98928-5;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA6568-5;1;Not at all;;; +98928-5;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13940-4;2;A little;;; +98928-5;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13939-6;3;Moderately;;; +98928-5;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13938-8;4;Mostly;;; +98928-5;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13937-0;5;Completely;;; +98929-3;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA6568-5;1;Not at all;;; +98929-3;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13940-4;2;A little;;; +98929-3;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13939-6;3;Moderately;;; +98929-3;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13938-8;4;Mostly;;; +98929-3;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13937-0;5;Completely;;; +98930-1;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA6568-5;1;Not at all;;; +98930-1;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13940-4;2;A little;;; +98930-1;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13939-6;3;Moderately;;; +98930-1;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13938-8;4;Mostly;;; +98930-1;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13937-0;5;Completely;;; +98931-9;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA6568-5;1;Not at all;;; +98931-9;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13940-4;2;A little;;; +98931-9;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13939-6;3;Moderately;;; +98931-9;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13938-8;4;Mostly;;; +98931-9;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13937-0;5;Completely;;; +98932-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA6568-5;1;Not at all;;; +98932-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13940-4;2;A little;;; +98932-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13939-6;3;Moderately;;; +98932-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13938-8;4;Mostly;;; +98932-7;LL6058-3;Not at all|A lit|Mod|Mos|Comp w/score;LA13937-0;5;Completely;;; +98943-4;LL6077-3;Nev|Seldom|QOft|VOft|Alw;LA6270-8;1;Never;;; +98943-4;LL6077-3;Nev|Seldom|QOft|VOft|Alw;LA32689-4;2;Seldom;;; +98943-4;LL6077-3;Nev|Seldom|QOft|VOft|Alw;LA32690-2;3;Quite often;;; +98943-4;LL6077-3;Nev|Seldom|QOft|VOft|Alw;LA14985-8;4;Very often;;; +98943-4;LL6077-3;Nev|Seldom|QOft|VOft|Alw;LA9933-8;5;Always;;; +98973-1;LL6088-0;NRS 2002 - Nutrition;LA9634-2;1;Absent;2667000;Absent (qualifier value);http://snomed.info/sct +98973-1;LL6088-0;NRS 2002 - Nutrition;LA6752-5;2;Mild;;; +98973-1;LL6088-0;NRS 2002 - Nutrition;LA6751-7;3;Moderate;;; +98973-1;LL6088-0;NRS 2002 - Nutrition;LA6750-9;4;Severe;;; +98976-4;LL6090-6;Yes (a)|No (b);LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98976-4;LL6090-6;Yes (a)|No (b);LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +98978-0;LL6091-4;Homelessness;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +98978-0;LL6091-4;Homelessness;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99042-4;LL6082-3;Vertical deviation;LA32713-2;1;Upward;;; +99042-4;LL6082-3;Vertical deviation;LA32714-0;2;No vertical deviation;;; +99042-4;LL6082-3;Vertical deviation;LA32715-7;3;Downward;;; +99043-2;LL6081-5;Lateral deviation;LA32709-0;1;Rightward;;; +99043-2;LL6081-5;Lateral deviation;LA32710-8;2;No lateral deviation;;; +99043-2;LL6081-5;Lateral deviation;LA32712-4;3;Leftward;;; +99044-0;LL6079-9;Anterior/Posterior deviation;LA32698-5;1;Forward;;; +99044-0;LL6079-9;Anterior/Posterior deviation;LA32699-3;2;No front/back deviation;;; +99044-0;LL6079-9;Anterior/Posterior deviation;LA32700-9;3;Backward;;; +99045-7;LL6080-7;Organs donated;LA32701-7;1;Bone and soft tissue;;; +99045-7;LL6080-7;Organs donated;LA32702-5;2;Corneas;;; +99045-7;LL6080-7;Organs donated;LA21016-3;3;Heart;;; +99045-7;LL6080-7;Organs donated;LA32708-2;4;Kidneys;;; +99045-7;LL6080-7;Organs donated;LA4584-4;5;Liver;;; +99045-7;LL6080-7;Organs donated;LA32707-4;6;Lungs;;; +99045-7;LL6080-7;Organs donated;LA4654-5;7;Pancreas;;; +99045-7;LL6080-7;Organs donated;LA4332-8;8;Skin;;; +99045-7;LL6080-7;Organs donated;LA32704-1;9;Small intestine;;; +99045-7;LL6080-7;Organs donated;LA46-8;10;Other;;; +99135-6;LL6261-3;Housing issues;LA31996-4;1;Pests such as bugs, ants, or mice;;; +99135-6;LL6261-3;Housing issues;LA28580-1;2;Mold;;; +99135-6;LL6261-3;Housing issues;LA31997-2;3;Lead paint or pipes;;; +99135-6;LL6261-3;Housing issues;LA31998-0;4;Lack of heat;;; +99135-6;LL6261-3;Housing issues;LA31999-8;5;Oven or stove not working;;; +99135-6;LL6261-3;Housing issues;LA32000-4;6;Smoke detectors missing or not working;;; +99135-6;LL6261-3;Housing issues;LA32001-2;7;Water leaks;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA14740-7;1;Definitely true;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA14741-5;2;Mostly true;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +99194-3;LL5644-1;Definitely True to Definitely False;LA14742-3;4;Mostly false;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA14743-1;5;Definitely false;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA14740-7;1;Definitely true;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA14741-5;2;Mostly true;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +99194-3;LL5644-1;Definitely True to Definitely False;LA14742-3;4;Mostly false;;; +99194-3;LL5644-1;Definitely True to Definitely False;LA14743-1;5;Definitely false;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA14740-7;1;Definitely true;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA14741-5;2;Mostly true;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +99198-4;LL5644-1;Definitely True to Definitely False;LA14742-3;4;Mostly false;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA14743-1;5;Definitely false;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA14740-7;1;Definitely true;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA14741-5;2;Mostly true;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +99198-4;LL5644-1;Definitely True to Definitely False;LA14742-3;4;Mostly false;;; +99198-4;LL5644-1;Definitely True to Definitely False;LA14743-1;5;Definitely false;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA14740-7;1;Definitely true;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA14741-5;2;Mostly true;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +99199-2;LL5644-1;Definitely True to Definitely False;LA14742-3;4;Mostly false;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA14743-1;5;Definitely false;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA14740-7;1;Definitely true;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA14741-5;2;Mostly true;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA12688-0;3;Don't know;456791000124100;Do not know (qualifier value);http://snomed.info/sct +99199-2;LL5644-1;Definitely True to Definitely False;LA14742-3;4;Mostly false;;; +99199-2;LL5644-1;Definitely True to Definitely False;LA14743-1;5;Definitely false;;; +99195-0;LL5645-8;Frequency;LA6154-4;1;All of the time;;; +99195-0;LL5645-8;Frequency;LA14734-0;2;Most of the time;;; +99195-0;LL5645-8;Frequency;LA14733-2;3;Some of the time;;; +99195-0;LL5645-8;Frequency;LA14751-4;4;Hardly ever;;; +99195-0;LL5645-8;Frequency;LA6270-8;5;Never;;; +99195-0;LL5645-8;Frequency;LA6154-4;1;All of the time;;; +99195-0;LL5645-8;Frequency;LA14734-0;2;Most of the time;;; +99195-0;LL5645-8;Frequency;LA14733-2;3;Some of the time;;; +99195-0;LL5645-8;Frequency;LA14751-4;4;Hardly ever;;; +99195-0;LL5645-8;Frequency;LA6270-8;5;Never;;; +99196-8;LL5645-8;Frequency;LA6154-4;1;All of the time;;; +99196-8;LL5645-8;Frequency;LA14734-0;2;Most of the time;;; +99196-8;LL5645-8;Frequency;LA14733-2;3;Some of the time;;; +99196-8;LL5645-8;Frequency;LA14751-4;4;Hardly ever;;; +99196-8;LL5645-8;Frequency;LA6270-8;5;Never;;; +99196-8;LL5645-8;Frequency;LA6154-4;1;All of the time;;; +99196-8;LL5645-8;Frequency;LA14734-0;2;Most of the time;;; +99196-8;LL5645-8;Frequency;LA14733-2;3;Some of the time;;; +99196-8;LL5645-8;Frequency;LA14751-4;4;Hardly ever;;; +99196-8;LL5645-8;Frequency;LA6270-8;5;Never;;; +99197-6;LL5646-6;Clear vision - when;LA31157-3;1;With the aid of glasses to see in the distance;;; +99197-6;LL5646-6;Clear vision - when;LA31158-1;2;With the aid of glasses for reading;;; +99197-6;LL5646-6;Clear vision - when;LA31159-9;3;With the aid of contact lenses to see in the distance;;; +99197-6;LL5646-6;Clear vision - when;LA31160-7;4;With the aid of contact lenses for reading;;; +99197-6;LL5646-6;Clear vision - when;LA31161-5;5;Without glasses or contact lenses;;; +99197-6;LL5646-6;Clear vision - when;LA31157-3;1;With the aid of glasses to see in the distance;;; +99197-6;LL5646-6;Clear vision - when;LA31158-1;2;With the aid of glasses for reading;;; +99197-6;LL5646-6;Clear vision - when;LA31159-9;3;With the aid of contact lenses to see in the distance;;; +99197-6;LL5646-6;Clear vision - when;LA31160-7;4;With the aid of contact lenses for reading;;; +99197-6;LL5646-6;Clear vision - when;LA31161-5;5;Without glasses or contact lenses;;; +99202-4;LL5649-0;Driving difficulty - night;LA13948-7;1;No difficulty at all;;; +99202-4;LL5649-0;Driving difficulty - night;LA15725-7;2;A little difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA15726-5;3;Moderate difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA13951-1;4;A lot of difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA31166-4;5;Never drive at night because of vision;;; +99202-4;LL5649-0;Driving difficulty - night;LA31167-2;6;Never drive at night for other reasons;;; +99202-4;LL5649-0;Driving difficulty - night;LA13948-7;1;No difficulty at all;;; +99202-4;LL5649-0;Driving difficulty - night;LA15725-7;2;A little difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA15726-5;3;Moderate difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA13951-1;4;A lot of difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA31166-4;5;Never drive at night because of vision;;; +99202-4;LL5649-0;Driving difficulty - night;LA31167-2;6;Never drive at night for other reasons;;; +99202-4;LL5649-0;Driving difficulty - night;LA13948-7;1;No difficulty at all;;; +99202-4;LL5649-0;Driving difficulty - night;LA15725-7;2;A little difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA15726-5;3;Moderate difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA13951-1;4;A lot of difficulty;;; +99202-4;LL5649-0;Driving difficulty - night;LA31166-4;5;Never drive at night because of vision;;; +99202-4;LL5649-0;Driving difficulty - night;LA31167-2;6;Never drive at night for other reasons;;; +99205-7;LL5654-0;Yes,many|Yes, a few|No;LA31172-2;1;Yes, many;;; +99205-7;LL5654-0;Yes,many|Yes, a few|No;LA31173-0;2;Yes, a few;;; +99205-7;LL5654-0;Yes,many|Yes, a few|No;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99207-3;LL5654-0;Yes,many|Yes, a few|No;LA31172-2;1;Yes, many;;; +99207-3;LL5654-0;Yes,many|Yes, a few|No;LA31173-0;2;Yes, a few;;; +99207-3;LL5654-0;Yes,many|Yes, a few|No;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99207-3;LL6098-9;Y-may,Y-Few, No;LA31172-2;1;Yes, many;;; +99207-3;LL6098-9;Y-may,Y-Few, No;LA32762-9;2;Yes, one or a few;;; +99207-3;LL6098-9;Y-may,Y-Few, No;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99207-3;LL6098-9;Y-may,Y-Few, No;LA31172-2;1;Yes, many;;; +99207-3;LL6098-9;Y-may,Y-Few, No;LA32762-9;2;Yes, one or a few;;; +99207-3;LL6098-9;Y-may,Y-Few, No;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99210-7;LL5656-5;Difficulty - vision changes;LA31176-3;1;Don't have changes in the clarity of my vision;;; +99210-7;LL5656-5;Difficulty - vision changes;LA13948-7;2;No difficulty at all;;; +99210-7;LL5656-5;Difficulty - vision changes;LA15725-7;3;A little difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA15726-5;4;Moderate difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA13951-1;5;A lot of difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA31176-3;1;Don't have changes in the clarity of my vision;;; +99210-7;LL5656-5;Difficulty - vision changes;LA13948-7;2;No difficulty at all;;; +99210-7;LL5656-5;Difficulty - vision changes;LA15725-7;3;A little difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA15726-5;4;Moderate difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA13951-1;5;A lot of difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA31176-3;1;Don't have changes in the clarity of my vision;;; +99210-7;LL5656-5;Difficulty - vision changes;LA13948-7;2;No difficulty at all;;; +99210-7;LL5656-5;Difficulty - vision changes;LA15725-7;3;A little difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA15726-5;4;Moderate difficulty;;; +99210-7;LL5656-5;Difficulty - vision changes;LA13951-1;5;A lot of difficulty;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA6154-4;1;All of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14734-0;2;Most of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14733-2;3;Some of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14732-4;4;A little of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA6297-1;5;None of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA6154-4;1;All of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14734-0;2;Most of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14733-2;3;Some of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14732-4;4;A little of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA6297-1;5;None of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA6154-4;1;All of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14734-0;2;Most of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14733-2;3;Some of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA14732-4;4;A little of the time;;; +99212-3;LL6096-3;All of the time|Most|Some|Little|None;LA6297-1;5;None of the time;;; +99213-1;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99213-1;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99213-1;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99213-1;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99213-1;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99213-1;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99213-1;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99213-1;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99229-7;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99229-7;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99229-7;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99229-7;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99229-7;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99229-7;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99229-7;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99229-7;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99229-7;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99229-7;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99229-7;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99229-7;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99244-6;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99244-6;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99244-6;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99244-6;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99244-6;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99244-6;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99244-6;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99244-6;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99244-6;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99244-6;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99244-6;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99244-6;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99252-9;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99252-9;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99252-9;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99252-9;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99252-9;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99252-9;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99252-9;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99252-9;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99252-9;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99252-9;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99252-9;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99252-9;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99253-7;LL5660-7;Vision Problem When;LA31182-1;1;Yes, but ONLY when NOT wearing glasses or contact lenses;;; +99253-7;LL5660-7;Vision Problem When;LA31183-9;2;Yes, but ONLY when wearing glasses or contact lenses;;; +99253-7;LL5660-7;Vision Problem When;LA31184-7;3;Yes, when wearing AND when not wearing glasses or contacts;;; +99253-7;LL5660-7;Vision Problem When;LA18387-3;4;No, not at all;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99214-9;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99216-4;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99218-0;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA29696-4;1;Very;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA13909-9;2;Somewhat;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA13940-4;3;A little;;; +99220-6;LL6084-9;Very|Somewhat|A little|Not at all;LA6568-5;4;Not at all;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA31178-9;1;0: Eye problem(s) had no effect on my work;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6112-2;2;1;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6113-0;3;2;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6114-8;4;3;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6115-5;5;4;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10137-0;6;5;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10138-8;7;6;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10139-6;8;7;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10140-4;9;8;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10141-2;10;9;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA31179-7;11;10: Eye problem(s) completely prevented me from working;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA31178-9;1;0: Eye problem(s) had no effect on my work;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6112-2;2;1;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6113-0;3;2;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6114-8;4;3;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6115-5;5;4;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10137-0;6;5;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10138-8;7;6;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10139-6;8;7;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10140-4;9;8;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10141-2;10;9;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA31179-7;11;10: Eye problem(s) completely prevented me from working;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA31178-9;1;0: Eye problem(s) had no effect on my work;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6112-2;2;1;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6113-0;3;2;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6114-8;4;3;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA6115-5;5;4;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10137-0;6;5;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10138-8;7;6;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10139-6;8;7;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10140-4;9;8;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA10141-2;10;9;;; +99226-3;LL5658-1;Eye Problems Effect Work;LA31179-7;11;10: Eye problem(s) completely prevented me from working;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA31180-5;1;0: Eye problem(s) had no effect on my daily activities;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6112-2;2;1;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6113-0;3;2;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6114-8;4;3;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6115-5;5;4;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10137-0;6;5;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10138-8;7;6;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10139-6;8;7;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10140-4;9;8;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10141-2;10;9;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA31181-3;11;10: Eye problem(s) completely prevented me from doing my regular activities;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA31180-5;1;0: Eye problem(s) had no effect on my daily activities;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6112-2;2;1;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6113-0;3;2;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6114-8;4;3;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6115-5;5;4;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10137-0;6;5;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10138-8;7;6;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10139-6;8;7;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10140-4;9;8;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10141-2;10;9;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA31181-3;11;10: Eye problem(s) completely prevented me from doing my regular activities;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA31180-5;1;0: Eye problem(s) had no effect on my daily activities;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6112-2;2;1;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6113-0;3;2;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6114-8;4;3;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA6115-5;5;4;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10137-0;6;5;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10138-8;7;6;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10139-6;8;7;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10140-4;9;8;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA10141-2;10;9;;; +99227-1;LL5659-9;Eye Problems Effect Activity;LA31181-3;11;10: Eye problem(s) completely prevented me from doing my regular activities;;; +99228-9;LL6085-6;Corrective lens use;LA31185-4;1;I do not use glasses or contact lenses;;; +99228-9;LL6085-6;Corrective lens use;LA32719-9;2;I use glasses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32720-7;3;I use glasses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA32721-5;4;I use soft contact lenses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32722-3;5;I use soft contact lenses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA32723-1;6;I use hard (rigid gas permeable) contact lenses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32724-9;7;I use hard (rigid gas permeable) contact lenses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA31185-4;1;I do not use glasses or contact lenses;;; +99228-9;LL6085-6;Corrective lens use;LA32719-9;2;I use glasses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32720-7;3;I use glasses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA32721-5;4;I use soft contact lenses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32722-3;5;I use soft contact lenses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA32723-1;6;I use hard (rigid gas permeable) contact lenses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32724-9;7;I use hard (rigid gas permeable) contact lenses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA31185-4;1;I do not use glasses or contact lenses;;; +99228-9;LL6085-6;Corrective lens use;LA32719-9;2;I use glasses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32720-7;3;I use glasses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA32721-5;4;I use soft contact lenses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32722-3;5;I use soft contact lenses to correct my vision for reading;;; +99228-9;LL6085-6;Corrective lens use;LA32723-1;6;I use hard (rigid gas permeable) contact lenses to correct my vision for distance;;; +99228-9;LL6085-6;Corrective lens use;LA32724-9;7;I use hard (rigid gas permeable) contact lenses to correct my vision for reading;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99230-5;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99237-0;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99245-3;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA31185-4;1;I do not use glasses or contact lenses;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA6270-8;2;Never;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA10066-1;3;Rarely;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA10082-8;4;Sometimes;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA10044-8;5;Often;;; +99253-7;LL5661-5;Corrective Lenses Do Not Use to Always;LA9933-8;6;Always;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99231-3;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99238-8;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99246-1;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA6270-8;1;Never;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10066-1;2;Rarely;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10082-8;3;Sometimes;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA10044-8;4;Often;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA9933-8;5;Always;;; +99254-5;LL5662-3;Corrective Lenses Never to Always Use;LA31186-2;6;I always use glasses or contact lenses;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99232-1;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99239-6;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99247-9;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA27766-7;2;Extremely bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31187-0;3;Very bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31188-8;4;Somewhat bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA31189-6;5;A little bothersome;;; +99255-2;LL5663-1;Corrective Lenses - Bothersome (don't wear);LA24969-0;6;Not at all bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99233-9;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99240-4;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99248-7;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA27766-7;1;Extremely bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31187-0;2;Very bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31188-8;3;Somewhat bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31189-6;4;A little bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA24969-0;5;Not at all bothersome;;; +99256-0;LL5664-9;Corrective Lenses - Bothersome (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99234-7;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99241-2;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99249-5;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31185-4;1;I do not use glasses or contact lenses;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13948-7;2;No difficulty at all;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31190-4;3;Very little difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA15726-5;4;Moderate difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA13951-1;5;A lot of difficulty;;; +99257-8;LL5665-6;Corrective lenses - Difficulty (don't wear);LA31191-2;6;So much difficulty that I can no longer do some of my usual activities;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99235-4;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99242-0;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99250-3;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13948-7;1;No difficulty at all;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31190-4;2;Very little difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA15726-5;3;Moderate difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA13951-1;4;A lot of difficulty;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31191-2;5;So much difficulty that I can no longer do some of my usual activities;;; +99258-6;LL5666-4;Corrective Lenses - Difficulty (always wear);LA31186-2;6;I always use glasses or contact lenses;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99236-2;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99243-8;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99251-1;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31185-4;1;I do not use glasses or contact lenses;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31192-0;2;Go away completely;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31193-8;3;Go away mostly;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31194-6;4;Go away a little;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31195-3;5;Not change;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31196-1;6;Get a little worse;;; +99259-4;LL5667-2;Vision correction - go away/get worse;LA31197-9;7;Get a lot worse;;; +99260-2;LL6086-4;Sources of information;LA4687-5;1;Physician;;; +99260-2;LL6086-4;Sources of information;LA32725-6;2;Eye care professional;;; +99260-2;LL6086-4;Sources of information;LA32726-4;3;Internet websites;;; +99260-2;LL6086-4;Sources of information;LA27807-9;4;Reading books, newspapers, or magazines;;; +99260-2;LL6086-4;Sources of information;LA32015-2;5;Family, friends, or neighbors;;; +99260-2;LL6086-4;Sources of information;LA21969-3;6;TV;;; +99260-2;LL6086-4;Sources of information;LA32011-1;7;Radio;;; +99260-2;LL6086-4;Sources of information;LA46-8;8;Other;;; +99260-2;LL6087-2;LASIK Information Sources;LA32727-2;1;Discussions with LASIK surgeon;;; +99260-2;LL6087-2;LASIK Information Sources;LA32728-0;2;Discussions with any other eye care professional (e.g., ophthalmologist or optometrist);;; +99260-2;LL6087-2;LASIK Information Sources;LA32729-8;3;Discussions with another physician, not an opthalmologist;;; +99260-2;LL6087-2;LASIK Information Sources;LA32730-6;4;Eye care professional's office pamphlets;;; +99260-2;LL6087-2;LASIK Information Sources;LA32731-4;5;Eye care professional's office videos;;; +99260-2;LL6087-2;LASIK Information Sources;LA32726-4;6;Internet websites;;; +99260-2;LL6087-2;LASIK Information Sources;LA32732-2;7;Newspaper or magazine articles;;; +99260-2;LL6087-2;LASIK Information Sources;LA32733-0;8;Television/Radio;;; +99260-2;LL6087-2;LASIK Information Sources;LA32734-8;9;Discussion with another patient;;; +99260-2;LL6087-2;LASIK Information Sources;LA32735-5;10;Discussions with family or friends who have not had LASIK surgery;;; +99260-2;LL6087-2;LASIK Information Sources;LA32736-3;11;Discussions with family or friends who have had LASIK surgery;;; +99260-2;LL6087-2;LASIK Information Sources;LA46-8;12;Other;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32751-2;1;Level 10;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32752-0;2;Level 9;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32753-8;3;Level 8;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32754-6;4;Level 7;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32755-3;5;Level 6;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32756-1;6;Level 5;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32757-9;7;Level 4;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32758-7;8;Level 3;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32759-5;9;Level 2;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32760-3;10;Level 1;;; +99284-2;LL6097-1;Tegner Activity Scale;LA32761-1;11;Level 0;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32751-2;1;Level 10;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32752-0;2;Level 9;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32753-8;3;Level 8;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32754-6;4;Level 7;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32755-3;5;Level 6;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32756-1;6;Level 5;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32757-9;7;Level 4;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32758-7;8;Level 3;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32759-5;9;Level 2;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32760-3;10;Level 1;;; +99285-9;LL6097-1;Tegner Activity Scale;LA32761-1;11;Level 0;;; +99284-2;LL6103-7;Physical activity levels;LA32775-1;1;Sedentary;;; +99284-2;LL6103-7;Physical activity levels;LA32776-9;2;Low active;;; +99284-2;LL6103-7;Physical activity levels;LA16666-2;3;Active;;; +99284-2;LL6103-7;Physical activity levels;LA32778-5;4;Very active;;; +99285-9;LL6103-7;Physical activity levels;LA32775-1;1;Sedentary;;; +99285-9;LL6103-7;Physical activity levels;LA32776-9;2;Low active;;; +99285-9;LL6103-7;Physical activity levels;LA16666-2;3;Active;;; +99285-9;LL6103-7;Physical activity levels;LA32778-5;4;Very active;;; +99311-3;LL6116-9;Seizure onset;LA32841-1;1;Focal Onset - Aware;;; +99311-3;LL6116-9;Seizure onset;LA32842-9;2;Focal Onset - Impaired Awareness;;; +99311-3;LL6116-9;Seizure onset;LA32843-7;3;Focal Onset - to Bilateral Tonic-clonic;;; +99311-3;LL6116-9;Seizure onset;LA32844-5;4;Generalized Onset - Motor Tonic-clonic;;; +99311-3;LL6116-9;Seizure onset;LA32845-2;5;Generalized Onset - Other Motor;;; +99311-3;LL6116-9;Seizure onset;LA32846-0;6;Generalized Onset - Nonmotor (Absence);;; +99311-3;LL6116-9;Seizure onset;LA32847-8;7;Unknown Onset (if focal or generalized) - Motor Tonic-clonic;;; +99311-3;LL6116-9;Seizure onset;LA32848-6;8;Unknown Onset (if focal or generalized) - Other Motor;;; +99311-3;LL6116-9;Seizure onset;LA32849-4;9;Unknown Onset (if focal or generalized) - Nonmotor;;; +99311-3;LL6116-9;Seizure onset;LA32850-2;10;Unclassified (i.e., unsure if epileptic or not);;; +99311-3;LL6116-9;Seizure onset;LA32851-0;11;Nonepileptic (i.e., psychogenic or physiologic);;; +99312-1;LL6117-7;Seizure frequency;LA32852-8;1;Innumerable (i.e., >= 10 per day most days);;; +99312-1;LL6117-7;Seizure frequency;LA32853-6;2;Multiple per day (i.e., 4 days per week with >= 2 seizures);;; +99312-1;LL6117-7;Seizure frequency;LA32854-4;3;Daily (i.e., 4 or more days per week);;; +99312-1;LL6117-7;Seizure frequency;LA32855-1;4;Weekly but not daily (i.e., 1-3 per week);;; +99312-1;LL6117-7;Seizure frequency;LA32856-9;5;Monthly but not weekly (i.e., 1-3 per month);;; +99312-1;LL6117-7;Seizure frequency;LA32857-7;6;At least once per year, but not every month (i.e., 10 or fewer in past 12 months);;; +99312-1;LL6117-7;Seizure frequency;LA32858-5;7;Less than once per year;;; +99312-1;LL6117-7;Seizure frequency;LA32859-3;8;Frequency not well defined;;; +99312-1;LL6117-7;Seizure frequency;LA4489-6;9;Unknown;261665006;Unknown (qualifier value);http://snomed.info/sct +99313-9;LL6118-5;Time since last;LA32860-1;1;Today;;; +99313-9;LL6118-5;Time since last;LA32861-9;2;1-6 days ago;;; +99313-9;LL6118-5;Time since last;LA32862-7;3;1-4 weeks ago;;; +99313-9;LL6118-5;Time since last;LA32863-5;4;5-12 weeks ago;;; +99313-9;LL6118-5;Time since last;LA32864-3;5;13-26 weeks ago;;; +99313-9;LL6118-5;Time since last;LA32865-0;6;6-12 months ago (27-52 weeks ago);;; +99313-9;LL6118-5;Time since last;LA32866-8;7;13-24 months ago (53-104 weeks ago);;; +99313-9;LL6118-5;Time since last;LA32867-6;8;More than 2 years ago (more than 105 weeks ago);;; +99313-9;LL6118-5;Time since last;LA14072-5;9;Unsure;;; +99314-7;LL6125-0;SARS-CoV-2 RdRp gene mutations;LA32886-6;5;F480P;;; +99314-7;LL6125-0;SARS-CoV-2 RdRp gene mutations;LA32887-4;6;P227L;;; +99314-7;LL6125-0;SARS-CoV-2 RdRp gene mutations;LA32888-2;7;P323L;;; +99342-8;LL6092-2;Days ago;LA32737-1;1;1 day ago;;; +99342-8;LL6092-2;Days ago;LA32738-9;2;2 days ago;;; +99342-8;LL6092-2;Days ago;LA32739-7;3;3 days ago;;; +99342-8;LL6092-2;Days ago;LA32740-5;4;4 days ago;;; +99342-8;LL6092-2;Days ago;LA32741-3;5;5 days ago;;; +99342-8;LL6092-2;Days ago;LA32742-1;6;6 days ago;;; +99342-8;LL6092-2;Days ago;LA32743-9;7;7 days ago;;; +99342-8;LL6092-2;Days ago;LA32744-7;8;Can't remember;;; +99342-8;LL6092-2;Days ago;LA32737-1;1;1 day ago;;; +99342-8;LL6092-2;Days ago;LA32738-9;2;2 days ago;;; +99342-8;LL6092-2;Days ago;LA32739-7;3;3 days ago;;; +99342-8;LL6092-2;Days ago;LA32740-5;4;4 days ago;;; +99342-8;LL6092-2;Days ago;LA32741-3;5;5 days ago;;; +99342-8;LL6092-2;Days ago;LA32742-1;6;6 days ago;;; +99342-8;LL6092-2;Days ago;LA32743-9;7;7 days ago;;; +99342-8;LL6092-2;Days ago;LA32744-7;8;Can't remember;;; +99343-6;LL6093-0;Days since symptom end;LA32737-1;1;1 day ago;;; +99343-6;LL6093-0;Days since symptom end;LA32738-9;2;2 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32739-7;3;3 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32740-5;4;4 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32741-3;5;5 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32742-1;6;6 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32743-9;7;7 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32744-7;8;Can't remember;;; +99343-6;LL6093-0;Days since symptom end;LA32745-4;9;I still have it/them;;; +99343-6;LL6093-0;Days since symptom end;LA32737-1;1;1 day ago;;; +99343-6;LL6093-0;Days since symptom end;LA32738-9;2;2 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32739-7;3;3 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32740-5;4;4 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32741-3;5;5 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32742-1;6;6 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32743-9;7;7 days ago;;; +99343-6;LL6093-0;Days since symptom end;LA32744-7;8;Can't remember;;; +99343-6;LL6093-0;Days since symptom end;LA32745-4;9;I still have it/them;;; +99345-1;LL6094-8;Medical care type;LA24320-6;1;Clinic or physician's office;;; +99345-1;LL6094-8;Medical care type;LA10268-3;2;Emergency Department;;; +99345-1;LL6094-8;Medical care type;LA24179-6;3;Urgent Care Center;;; +99345-1;LL6094-8;Medical care type;LA31595-4;4;Pharmacist;;; +99345-1;LL6094-8;Medical care type;LA31380-1;5;Phone-based telehealth;;; +99345-1;LL6095-5;Medical attention type;LA32746-2;1;Contacted NHS 111, by phone or online;;; +99345-1;LL6095-5;Medical attention type;LA32747-0;2;Visitied pharmacist;;; +99345-1;LL6095-5;Medical attention type;LA32748-8;3;Consulted GP/practice nurse over the phone or online;;; +99345-1;LL6095-5;Medical attention type;LA32749-6;4;Consulted GP/practice nurse face to face;;; +99345-1;LL6095-5;Medical attention type;LA32750-4;5;Walk-in centre;;; +99345-1;LL6095-5;Medical attention type;LA46-8;6;Other;;; +99348-5;LL6129-2;COVID-19 Contact;LA32892-4;1;Yes, I was in contact with a confirmed/test COVID-19 case;;; +99348-5;LL6129-2;COVID-19 Contact;LA32893-2;2;Yes, I was in contact with a suspected COVID-19 case;;; +99348-5;LL6129-2;COVID-19 Contact;LA32894-0;3;No, not to my knowledge;;; +99349-3;LL6131-8;Confirmed by test or suspected;LA32898-1;1;Yes, confirmed by a positive test;;; +99349-3;LL6131-8;Confirmed by test or suspected;LA32899-9;2;Yes, suspected by a doctor but not tested;;; +99349-3;LL6131-8;Confirmed by test or suspected;LA32900-5;3;Yes, my own suspicions;;; +99349-3;LL6131-8;Confirmed by test or suspected;LA32-8;4;No;373067005;No (qualifier value);http://snomed.info/sct +99359-2;LL6130-0;Who measured;LA32895-7;1;A doctor/nurse or other health professional;;; +99359-2;LL6130-0;Who measured;LA32896-5;2;I did;;; +99359-2;LL6130-0;Who measured;LA32897-3;3;It was taken by someone else;;; +99359-2;LL6144-1;Measured by;LA31590-5;1;Medical Assistant;;; +99359-2;LL6144-1;Measured by;LA9401-6;2;Nurse;;; +99359-2;LL6144-1;Measured by;LA18968-0;3;Doctor;;; +99359-2;LL6144-1;Measured by;LA15312-4;4;Self;;; +99494-7;LL6107-8;Diagnosis type;LA32792-6;1;Admitting diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32793-4;2;Autopsy diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32794-2;3;Clinical diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32795-9;4;Cytology diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32796-7;5;Death diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32797-5;6;Diagnosis of exclusion;;; +99494-7;LL6107-8;Diagnosis type;LA32798-3;7;Differential diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32799-1;8;Established diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32800-7;9;Final diagnosis (discharge);;; +99494-7;LL6107-8;Diagnosis type;LA32801-5;10;Laboratory diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32802-3;11;Morphologic diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32803-1;12;Palpatory diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32804-9;13;Pathology diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32805-6;14;Post-op diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32806-4;15;Pre-op diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32807-2;16;Preliminary diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32808-0;17;Principal diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32809-8;18;Prior diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32810-6;19;Referral diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32811-4;20;Revised diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32812-2;21;Secondary diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32813-0;22;Segmental diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32814-8;23;Suggested billing diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32815-5;24;Transfer admissions diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32817-1;25;Transfer diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32818-9;26;Working diagnosis;;; +99494-7;LL6107-8;Diagnosis type;LA32819-7;27;X-ray diagnosis;;; +99496-2;LL6110-2;Condition cause;LA32826-2;1;Heredity/genetic;;; +99496-2;LL6110-2;Condition cause;LA31871-9;2;Idiopathic;;; +99496-2;LL6110-2;Condition cause;LA7446-3;3;Infection;;; +99496-2;LL6110-2;Condition cause;LA17713-1;4;Injury;;; +99496-2;LL6110-2;Condition cause;LA32823-9;5;Lifestyle;;; +99499-6;LL6109-4;Condition Severity;LA6752-5;1;Mild;;; +99499-6;LL6109-4;Condition Severity;LA15008-8;2;Mild to moderate;;; +99499-6;LL6109-4;Condition Severity;LA6751-7;3;Moderate;;; +99499-6;LL6109-4;Condition Severity;LA32820-5;4;Moderate to severe;;; +99499-6;LL6109-4;Condition Severity;LA6750-9;5;Severe;;; +99499-6;LL6109-4;Condition Severity;LA32821-3;6;Life threatening severity;;; +99499-6;LL6109-4;Condition Severity;LA32822-1;7;Fatal;;; +99501-9;LL6114-4;FemaleSFCU|MaleSFCU|SpecifiedSFCU|UnknownSFCU;LA33456-7;5;Female sex for clinical use;;; +99501-9;LL6114-4;FemaleSFCU|MaleSFCU|SpecifiedSFCU|UnknownSFCU;LA33457-5;6;Male sex for clinical use;;; +99501-9;LL6114-4;FemaleSFCU|MaleSFCU|SpecifiedSFCU|UnknownSFCU;LA33458-3;7;Specified sex for clinical use;;; +99501-9;LL6114-4;FemaleSFCU|MaleSFCU|SpecifiedSFCU|UnknownSFCU;LA33459-1;8;Unknown sex for clinical use;;; +99502-7;LL6134-2;F|M|X|<;LA13504-8;1;F;;; +99502-7;LL6134-2;F|M|X|<;LA15170-6;2;M;;; +99502-7;LL6134-2;F|M|X|<;LA32969-0;3;X;;; +99502-7;LL6134-2;F|M|X|<;LA32970-8;4;<;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33003-7;1;I stay at home most of the time because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33004-5;2;I change position frequently to try to get my back comfortable.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33005-2;3;I walk more slowly than usual because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33006-0;4;Because of my back, I am not doing any jobs that I usually do around the house.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33007-8;5;Because of my back, I use a handrail to get upstairs.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33008-6;6;Because of my back, I lie down to rest more often.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33009-4;7;Because of my back, I have to hold on to something to get out of an easy chair.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33010-2;8;Because of my back, I try to get other people to do things for me.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33011-0;9;I get dressed more slowly than usual because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33012-8;10;Because of my back, I try not to bend or kneel down.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33013-6;11;I find it difficult to get out of a chair because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33014-4;12;My back is painful almost all of the time.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33015-1;13;I find it difficulty to turn over in bed because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33016-9;14;My appetite is not very good because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33017-7;15;I have trouble putting on my sock (or stockings) because of the pain in my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33018-5;16;I can only walk short distances because of my back pain.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33020-1;17;I sleep less well because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33021-9;18;Because of my back pain, I get dressed with the help of someone else.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33022-7;19;I sit down for most of the day because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33023-5;20;I avoid heavy jobs around the house because of my back.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33024-3;21;Because of back pain, I am more irritable and bad tempered with people than usual.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33025-0;22;Because of my back, I go upstairs more slowly than usual.;;; +99576-1;LL6137-5;Roland-Morris Low Back Pain;LA33026-8;23;I stay in bed most of the time because of my back.;;; +99584-5;LL6111-0;Lysholm - Limp;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +99584-5;LL6111-0;Lysholm - Limp;LA32828-8;2;Slight or periodical;;; +99584-5;LL6111-0;Lysholm - Limp;LA32829-6;3;Severe and constant;;; +99585-2;LL6112-8;Lysholm -Support;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +99585-2;LL6112-8;Lysholm -Support;LA32831-2;2;Stick or crutch;;; +99585-2;LL6112-8;Lysholm -Support;LA32832-0;3;Weight-bearing impossible;;; +99586-0;LL6113-6;Lysholm - Locking;LA32833-8;1;No locking and no catching sensations;;; +99586-0;LL6113-6;Lysholm - Locking;LA32834-6;2;Catching sensation but no locking;;; +99586-0;LL6113-6;Lysholm - Locking;LA32835-3;3;Locking occasionally;;; +99586-0;LL6113-6;Lysholm - Locking;LA32836-1;4;Locking frequently;;; +99586-0;LL6113-6;Lysholm - Locking;LA32837-9;5;Locked joint on examination;;; +99587-8;LL6119-3;Lysholm - Instability;LA32868-4;1;Never giving way;;; +99587-8;LL6119-3;Lysholm - Instability;LA32869-2;2;Rarely during athletics or other severe exertion;;; +99587-8;LL6119-3;Lysholm - Instability;LA32870-0;3;Frequently during athletics or other sever exertion (or incapable of participation);;; +99587-8;LL6119-3;Lysholm - Instability;LA32871-8;4;Occasionally in daily activities;;; +99587-8;LL6119-3;Lysholm - Instability;LA32872-6;5;Often in daily activities;;; +99587-8;LL6119-3;Lysholm - Instability;LA32873-4;6;Every step;;; +99588-6;LL6120-1;Lysholm - Pain;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +99588-6;LL6120-1;Lysholm - Pain;LA32874-2;2;Inconstant and slight during severe exertion;;; +99588-6;LL6120-1;Lysholm - Pain;LA32875-9;3;Marked during severe exertion;;; +99588-6;LL6120-1;Lysholm - Pain;LA32876-7;4;Marked on or after walking more than 2 km;;; +99588-6;LL6120-1;Lysholm - Pain;LA32877-5;5;Marked on or after walking less than 2 km;;; +99588-6;LL6120-1;Lysholm - Pain;LA32878-3;6;Constant;;; +99589-4;LL6121-9;Lysholm - Swelling;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +99589-4;LL6121-9;Lysholm - Swelling;LA32879-1;2;On severe exertion;;; +99589-4;LL6121-9;Lysholm - Swelling;LA32880-9;3;On ordinary exertion;;; +99589-4;LL6121-9;Lysholm - Swelling;LA32878-3;4;Constant;;; +99594-4;LL6155-7;Transportation impact;LA33093-8;1;Yes, it has kept me from medical appointments or getting medications;;; +99594-4;LL6155-7;Transportation impact;LA30134-3;2;Yes, it has kept me from non-medical meetings, appointments, work, or from getting things that I need;;; +99594-4;LL6155-7;Transportation impact;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99634-8;LL6161-5;Yes|No|Unsure;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99634-8;LL6161-5;Yes|No|Unsure;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99634-8;LL6161-5;Yes|No|Unsure;LA14072-5;3;Unsure;;; +99638-9;LL6161-5;Yes|No|Unsure;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99638-9;LL6161-5;Yes|No|Unsure;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99638-9;LL6161-5;Yes|No|Unsure;LA14072-5;3;Unsure;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33094-6;1;Fever or chills;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33095-3;2;Runny or stuffy nose;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33096-1;3;Chest congestion;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33097-9;4;Skin rash;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA16122-6;5;Cough;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA30867-8;6;Sore throat;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33098-7;7;Sneezing;76067001;Sneezing (finding);http://snomed.info/sct +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33099-5;8;Muscle or body aches;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33100-1;9;Headaches;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33101-9;10;Fatigue or tiredness;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA17001-1;11;Shortness of breath;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33102-7;12;Abdominal discomfort;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA15099-7;13;Vomiting;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33104-3;14;Hair loss;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33105-0;15;Dry skin;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33106-8;16;Body temperature higher than 100.4 F or 38.0 C;;; +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA15424-7;17;Diarrhea;62315008;Diarrhea (finding);http://snomed.info/sct +99635-5;LL6157-3;Symptoms of Coronavirus Experience;LA33107-6;18;Lost sense of smell;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33108-4;1;Gone out to a bar, club, or other place where people gather;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33109-2;2;Gone to the grocery store or pharmacy;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33110-0;3;Gone to a friend, neighbor, or relative's residence (that isn't your own);;; +99636-3;LL6159-9;Activities/Outings during health event;LA33111-8;4;Had visitors such as friends, neighbors, or relatives at your residence;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33112-6;5;Attended a gathering with more than 10 people, such as a reunion, wedding, funeral, birthday party, concert, or religious service;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33113-4;6;Sought care from a hospital or health care facility;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33114-2;7;Been placed in isolation or quarantine;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33115-9;8;Remained in your residence at all times, except for essential activities or exercise;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33116-7;9;Shared items like towels or utensils with other people;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33117-5;10;Had close contact (within 6 feet) with people who live with you;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33118-3;11;Had close contact (within 6 feet) with people who don't live with you;;; +99636-3;LL6159-9;Activities/Outings during health event;LA33119-1;12;Gone outside to walk, hike, or exercise;;; +99637-1;LL6160-7;Actions to prevent infection;LA33120-9;1;Washed your hands with soap or used hand sanitizer several times per day;;; +99637-1;LL6160-7;Actions to prevent infection;LA33121-7;2;Canceled or postponed air travel for work;;; +99637-1;LL6160-7;Actions to prevent infection;LA33122-5;3;Canceled or postponed air travel for pleasure;;; +99637-1;LL6160-7;Actions to prevent infection;LA33123-3;4;Canceled or postponed work or school activities;;; +99637-1;LL6160-7;Actions to prevent infection;LA33124-1;5;Canceled or postponed personal or social activities;;; +99637-1;LL6160-7;Actions to prevent infection;LA33125-8;6;Visited a doctor;;; +99637-1;LL6160-7;Actions to prevent infection;LA33126-6;7;Canceled a doctor's appointment;;; +99637-1;LL6160-7;Actions to prevent infection;LA33127-4;8;Stockpiled food or water;;; +99637-1;LL6160-7;Actions to prevent infection;LA33128-2;9;Avoided contact with people who could be high-risk;;; +99637-1;LL6160-7;Actions to prevent infection;LA33129-0;10;Avoided public spaces, gatherings or crowds;;; +99637-1;LL6160-7;Actions to prevent infection;LA33130-8;11;Prayed;;; +99637-1;LL6160-7;Actions to prevent infection;LA33131-6;12;Avoided eating at restaurants;;; +99637-1;LL6160-7;Actions to prevent infection;LA33132-4;13;Stockpiled hand sanitizer or disinfectant wipes;;; +99637-1;LL6160-7;Actions to prevent infection;LA33133-2;14;Worked or studied at home;;; +99637-1;LL6160-7;Actions to prevent infection;LA33134-0;15;Worn a mask or other face covering;;; +99637-1;LL6160-7;Actions to prevent infection;LA33135-7;16;Stockpiled medication;;; +99639-7;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99639-7;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99639-7;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99639-7;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99639-7;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99640-5;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99640-5;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99640-5;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99640-5;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99640-5;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99641-3;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99641-3;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99641-3;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99641-3;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99641-3;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99642-1;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99642-1;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99642-1;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99642-1;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99642-1;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99643-9;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99643-9;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99643-9;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99643-9;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99643-9;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99644-7;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99644-7;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99644-7;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99644-7;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99644-7;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99645-4;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99645-4;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99645-4;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99645-4;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99645-4;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99646-2;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99646-2;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99646-2;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99646-2;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99646-2;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99647-0;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99647-0;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99647-0;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99647-0;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99647-0;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99648-8;LL6162-3;Effectiveness;LA33136-5;1;Extremely ineffective;;; +99648-8;LL6162-3;Effectiveness;LA33137-3;2;Somewhat ineffective;;; +99648-8;LL6162-3;Effectiveness;LA33138-1;3;Somewhat effective;;; +99648-8;LL6162-3;Effectiveness;LA33139-9;4;Extremely effective;;; +99648-8;LL6162-3;Effectiveness;LA14072-5;5;Unsure;;; +99649-6;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99649-6;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99649-6;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99649-6;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99649-6;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99650-4;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99650-4;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99650-4;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99650-4;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99650-4;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99651-2;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99651-2;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99651-2;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99651-2;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99651-2;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99652-0;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99652-0;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99652-0;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99652-0;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99652-0;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99653-8;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99653-8;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99653-8;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99653-8;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99653-8;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99654-6;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99654-6;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99654-6;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99654-6;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99654-6;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99655-3;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99655-3;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99655-3;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99655-3;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99655-3;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99656-1;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99656-1;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99656-1;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99656-1;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99656-1;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99657-9;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99657-9;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99657-9;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99657-9;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99657-9;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99658-7;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99658-7;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99658-7;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99658-7;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99658-7;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99659-5;LL6163-1;Safety level;LA33140-7;1;Extremely safe;;; +99659-5;LL6163-1;Safety level;LA33141-5;2;Somewhat safe;;; +99659-5;LL6163-1;Safety level;LA33142-3;3;Somewhat unsafe;;; +99659-5;LL6163-1;Safety level;LA33143-1;4;Extremely unsafe;;; +99659-5;LL6163-1;Safety level;LA14072-5;5;Unsure;;; +99668-6;LL6164-9;V unlik|Some unlik|Some lik|V lik;LA15589-7;1;Very unlikely;;; +99668-6;LL6164-9;V unlik|Some unlik|Some lik|V lik;LA33144-9;2;Somewhat unlikely;;; +99668-6;LL6164-9;V unlik|Some unlik|Some lik|V lik;LA33145-6;3;Somewhat likely;;; +99668-6;LL6164-9;V unlik|Some unlik|Some lik|V lik;LA15586-3;4;Very likely;;; +99668-6;LL6164-9;V unlik|Some unlik|Some lik|V lik;LA14072-5;5;Unsure;;; +99684-3;LL6145-8;Pacemaker mode;LA33046-6;1;Atrial asynchronous;;; +99684-3;LL6145-8;Pacemaker mode;LA33047-4;2;Atrial demand;;; +99684-3;LL6145-8;Pacemaker mode;LA33048-2;3;Ventricular asynchronous;;; +99684-3;LL6145-8;Pacemaker mode;LA33052-4;4;Ventricular demand;;; +99684-3;LL6145-8;Pacemaker mode;LA33049-0;5;Dual chamber asynchronous;;; +99684-3;LL6145-8;Pacemaker mode;LA33051-6;6;Dual chamber demand;;; +99686-8;LL6146-6;Pacemaker type;LA33053-2;1;Single chamber;;; +99686-8;LL6146-6;Pacemaker type;LA33054-0;2;Dual chamber;;; +99686-8;LL6146-6;Pacemaker type;LA33055-7;3;Biventricular;;; +99687-6;LL6147-4;Pacing method;LA33057-3;1;Transvenous;;; +99687-6;LL6147-4;Pacing method;LA33058-1;2;Transcutaneous;;; +99687-6;LL6147-4;Pacing method;LA33059-9;3;Epicardial;;; +99687-6;LL6147-4;Pacing method;LA33060-7;4;Transesophageal;;; +99696-7;LL6148-2;Pacemaker wire status;LA33061-5;1;Attached to pacer;;; +99696-7;LL6148-2;Pacemaker wire status;LA33062-3;2;Secure and protected;;; +99696-7;LL6148-2;Pacemaker wire status;LA7337-4;3;Disconnected;;; +99708-0;LL6149-0;CRRT mode;LA33064-9;1;Slow continuous ultrafiltration (SCUF);;; +99708-0;LL6149-0;CRRT mode;LA33065-6;2;Continuous veno-venous hemofiltration (CVVH);;; +99708-0;LL6149-0;CRRT mode;LA33066-4;3;Continuous veno-venous hemodialysis (CVVHD);;; +99708-0;LL6149-0;CRRT mode;LA33067-2;4;Continuous veno-venous hemodiafiltration (CVVHDF);;; +99716-3;LL6150-8;Access site appearance;LA7418-2;1;Bleeding;;; +99716-3;LL6150-8;Access site appearance;LA17211-6;2;Drainage;;; +99716-3;LL6150-8;Access site appearance;LA19034-0;3;Ecchymotic;;; +99716-3;LL6150-8;Access site appearance;LA19036-5;4;Erythematous;;; +99716-3;LL6150-8;Access site appearance;LA7439-8;5;Hematoma;;; +99716-3;LL6150-8;Access site appearance;LA33068-0;6;Infiltrated;;; +99716-3;LL6150-8;Access site appearance;LA9348-9;7;Not assessed;;; +99716-3;LL6150-8;Access site appearance;LA33069-8;8;Old blood;;; +99716-3;LL6150-8;Access site appearance;LA33070-6;9;Oozing;;; +99716-3;LL6150-8;Access site appearance;LA33071-4;10;Purulent drainage;;; +99716-3;LL6150-8;Access site appearance;LA22439-6;11;Redness;;; +99716-3;LL6150-8;Access site appearance;LA22440-4;12;Swelling;;; +99716-3;LL6150-8;Access site appearance;LA4439-1;13;Within Normal Limits;;; +99726-2;LL6154-0;Dialysis fluid;LA33087-0;1;1.5% Dextrose;;; +99726-2;LL6154-0;Dialysis fluid;LA33088-8;2;2.5% Dextrose;;; +99726-2;LL6154-0;Dialysis fluid;LA33089-6;3;4.25% Dextrose;;; +99726-2;LL6154-0;Dialysis fluid;LA33090-4;4;1.5% Glucose;;; +99726-2;LL6154-0;Dialysis fluid;LA33091-2;5;2.5% Glucose;;; +99726-2;LL6154-0;Dialysis fluid;LA33092-0;6;4.25% Glucose;;; +99732-0;LL6151-6;Dialysate fluid;LA33072-2;1;Normal saline;;; +99732-0;LL6151-6;Dialysate fluid;LA33073-0;2;Prismasate K0;;; +99732-0;LL6151-6;Dialysate fluid;LA33074-8;3;Prismasate K2;;; +99732-0;LL6151-6;Dialysate fluid;LA33075-5;4;Prismasate K4;;; +99736-1;LL6152-4;Filter change reason;LA33076-3;1;Filter clotted;;; +99736-1;LL6152-4;Filter change reason;LA33077-1;2;Filter clogged;;; +99736-1;LL6152-4;Filter change reason;LA33078-9;3;Line change;;; +99744-5;LL6153-2;Dialysis catheter type;LA33079-7;1;Single cuff;;; +99744-5;LL6153-2;Dialysis catheter type;LA33080-5;2;Double cuff;;; +99744-5;LL6153-2;Dialysis catheter type;LA33081-3;3;Swan neck;;; +99744-5;LL6153-2;Dialysis catheter type;LA33082-1;4;Disc-bead single cuff;;; +99744-5;LL6153-2;Dialysis catheter type;LA33083-9;5;Disc-bead double cuff;;; +99744-5;LL6153-2;Dialysis catheter type;LA33084-7;6;Straight Tenckhoff;;; +99744-5;LL6153-2;Dialysis catheter type;LA33085-4;7;Coiled Tenckhoff;;; +99744-5;LL6153-2;Dialysis catheter type;LA33086-2;8;Extended swan neck;;; +99748-6;LL6184-7;Change in quality of life;LA33180-3;1;Yes, the quality of my life has gotten a lot worse;;; +99748-6;LL6184-7;Change in quality of life;LA33181-1;2;Yes, the quality of my life has gotten a little bit worse;;; +99748-6;LL6184-7;Change in quality of life;LA33182-9;3;No, the quality of my life has not been affected;;; +99748-6;LL6184-7;Change in quality of life;LA33183-7;4;Yes, the quality of my life has gotten a little bit better;;; +99748-6;LL6184-7;Change in quality of life;LA33184-5;5;Yes, the quality of my life has gotten a lot better;;; +99749-4;LL6185-4;Y-def|Y-some|No;LA33185-2;1;Yes, definitely;;; +99749-4;LL6185-4;Y-def|Y-some|No;LA33172-0;2;Yes, somewhat;;; +99749-4;LL6185-4;Y-def|Y-some|No;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99754-4;LL6185-4;Y-def|Y-some|No;LA33185-2;1;Yes, definitely;;; +99754-4;LL6185-4;Y-def|Y-some|No;LA33172-0;2;Yes, somewhat;;; +99754-4;LL6185-4;Y-def|Y-some|No;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99751-0;LL6186-2;Level of satis/dissatisfaction LASIK;LA27754-3;1;Completely satisfied;;; +99751-0;LL6186-2;Level of satis/dissatisfaction LASIK;LA14642-5;2;Very satisfied;;; +99751-0;LL6186-2;Level of satis/dissatisfaction LASIK;LA27752-7;3;Somewhat satisfied;;; +99751-0;LL6186-2;Level of satis/dissatisfaction LASIK;LA29849-9;4;Somewhat dissatisfied;;; +99751-0;LL6186-2;Level of satis/dissatisfaction LASIK;LA14638-3;5;Very dissatisfied;;; +99751-0;LL6186-2;Level of satis/dissatisfaction LASIK;LA31177-1;6;Completely dissatisfied;;; +99751-0;LL6186-2;Level of satis/dissatisfaction LASIK;LA33187-8;7;Never had any improvement in my vision after LASIK surgery;;; +99752-8;LL6187-0;LASIK postop discomfort satisfaction;LA27754-3;1;Completely satisfied;;; +99752-8;LL6187-0;LASIK postop discomfort satisfaction;LA14642-5;2;Very satisfied;;; +99752-8;LL6187-0;LASIK postop discomfort satisfaction;LA27752-7;3;Somewhat satisfied;;; +99752-8;LL6187-0;LASIK postop discomfort satisfaction;LA29849-9;4;Somewhat dissatisfied;;; +99752-8;LL6187-0;LASIK postop discomfort satisfaction;LA14638-3;5;Very dissatisfied;;; +99752-8;LL6187-0;LASIK postop discomfort satisfaction;LA31177-1;6;Completely dissatisfied;;; +99752-8;LL6187-0;LASIK postop discomfort satisfaction;LA33188-6;7;Never had any post-operative symptoms of discomfort after LASIK surgery;;; +99753-6;LL6188-8;Understood/misunderstood;LA33189-4;1;Completely understood;;; +99753-6;LL6188-8;Understood/misunderstood;LA33190-2;2;Somewhat understood;;; +99753-6;LL6188-8;Understood/misunderstood;LA33191-0;3;Somewhat misunderstood;;; +99753-6;LL6188-8;Understood/misunderstood;LA33193-6;4;Completely misunderstood;;; +99755-1;LL6189-6;No|Y-some|Y-most|Y-all;LA18857-5;1;No, none of the time;;; +99755-1;LL6189-6;No|Y-some|Y-most|Y-all;LA18384-0;2;Yes, some of the time;;; +99755-1;LL6189-6;No|Y-some|Y-most|Y-all;LA18383-2;3;Yes, most of the time;;; +99755-1;LL6189-6;No|Y-some|Y-most|Y-all;LA18859-1;4;Yes, all of the time;;; +99756-9;LL6190-4;Achieved goal;LA33194-4;1;Yes, fully achieved;;; +99756-9;LL6190-4;Achieved goal;LA33195-1;2;Yes, partially achieved;;; +99756-9;LL6190-4;Achieved goal;LA32-8;3;No;373067005;No (qualifier value);http://snomed.info/sct +99757-7;LL6191-2;Happiness/Unhappiness levels;LA33196-9;1;Completely happy;;; +99757-7;LL6191-2;Happiness/Unhappiness levels;LA29846-5;2;Very happy;;; +99757-7;LL6191-2;Happiness/Unhappiness levels;LA33197-7;3;Somewhat happy;;; +99757-7;LL6191-2;Happiness/Unhappiness levels;LA33198-5;4;Somewhat unhappy;;; +99757-7;LL6191-2;Happiness/Unhappiness levels;LA33199-3;5;Very unhappy;;; +99757-7;LL6191-2;Happiness/Unhappiness levels;LA33200-9;6;Completely unhappy;;; +99759-3;LL6193-8;Recommend procedure or not;LA33205-8;1;Yes, I would recommend it because of my result;;; +99759-3;LL6193-8;Recommend procedure or not;LA33206-6;2;Yes, I would recommend it despite my result;;; +99759-3;LL6193-8;Recommend procedure or not;LA33207-4;3;No, I would not recommend it because of my result;;; +99759-3;LL6193-8;Recommend procedure or not;LA33208-2;4;No, I would not recommend it despite my result;;; +99760-1;LL6194-6;Reason not to repeat/recommend procedure;LA33209-0;1;Did not like the facility;;; +99760-1;LL6194-6;Reason not to repeat/recommend procedure;LA33210-8;2;Did not like the surgeon;;; +99760-1;LL6194-6;Reason not to repeat/recommend procedure;LA33211-6;3;Did not like the staff;;; +99760-1;LL6194-6;Reason not to repeat/recommend procedure;LA33212-4;4;Did not like the procedure;;; +99760-1;LL6194-6;Reason not to repeat/recommend procedure;LA33213-2;5;Did not like the results;;; +99760-1;LL6194-6;Reason not to repeat/recommend procedure;LA46-8;6;Other;;; +99772-6;LL6182-1;Reactive|Non-Reactive|Invalid|Borderline;LA15255-5;1;Reactive;11214006;Reactive (qualifier value);http://snomed.info/sct +99772-6;LL6182-1;Reactive|Non-Reactive|Invalid|Borderline;LA4259-3;2;Borderline;;; +99772-6;LL6182-1;Reactive|Non-Reactive|Invalid|Borderline;LA15256-3;3;Nonreactive;131194007;Non-reactive (qualifier value);http://snomed.info/sct +99772-6;LL6182-1;Reactive|Non-Reactive|Invalid|Borderline;LA15841-2;4;Invalid;455371000124106;Invalid result (qualifier value);http://snomed.info/sct +99780-9;LL6195-3;MRGN classification;LA33214-0;1;2MRGN;;; +99780-9;LL6195-3;MRGN classification;LA33215-7;2;3MRGN;;; +99780-9;LL6195-3;MRGN classification;LA33216-5;3;4MRGN;;; +99794-0;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99794-0;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99794-0;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99794-0;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99794-0;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99794-0;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99794-0;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99794-0;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99794-0;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99794-0;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99794-0;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99795-7;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99795-7;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99795-7;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99795-7;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99795-7;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99795-7;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99795-7;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99795-7;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99795-7;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99795-7;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99795-7;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99796-5;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99796-5;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99796-5;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99796-5;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99796-5;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99796-5;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99796-5;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99796-5;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99796-5;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99796-5;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99796-5;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99797-3;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99797-3;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99797-3;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99797-3;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99797-3;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99797-3;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99797-3;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99797-3;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99797-3;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99797-3;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99797-3;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99798-1;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99798-1;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99798-1;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99798-1;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99798-1;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99798-1;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99798-1;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99798-1;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99798-1;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99798-1;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99798-1;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99806-2;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99806-2;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99806-2;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99806-2;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99806-2;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99806-2;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99806-2;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99806-2;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99806-2;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99806-2;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99806-2;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99807-0;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99807-0;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99807-0;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99807-0;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99807-0;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99807-0;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99807-0;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99807-0;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99807-0;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99807-0;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99807-0;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99810-4;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99810-4;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99810-4;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99810-4;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99810-4;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99810-4;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99810-4;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99810-4;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99810-4;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99810-4;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99810-4;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99812-0;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99812-0;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99812-0;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99812-0;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99812-0;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99812-0;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99812-0;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99812-0;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99812-0;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99812-0;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99812-0;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99814-6;LL6198-7;0-10, numbers only;LA6111-4;1;0;;; +99814-6;LL6198-7;0-10, numbers only;LA6112-2;2;1;;; +99814-6;LL6198-7;0-10, numbers only;LA6113-0;3;2;;; +99814-6;LL6198-7;0-10, numbers only;LA6114-8;4;3;;; +99814-6;LL6198-7;0-10, numbers only;LA6115-5;5;4;;; +99814-6;LL6198-7;0-10, numbers only;LA10137-0;6;5;;; +99814-6;LL6198-7;0-10, numbers only;LA10138-8;7;6;;; +99814-6;LL6198-7;0-10, numbers only;LA10139-6;8;7;;; +99814-6;LL6198-7;0-10, numbers only;LA10140-4;9;8;;; +99814-6;LL6198-7;0-10, numbers only;LA10141-2;10;9;;; +99814-6;LL6198-7;0-10, numbers only;LA13942-0;11;10;;; +99801-3;LL6167-2;Internet types;LA33147-2;1;Dedicated household internet or wifi;;; +99801-3;LL6167-2;Internet types;LA33148-0;2;Dedicated cellular hotspot;;; +99801-3;LL6167-2;Internet types;LA33149-8;3;Hotspot through someone's mobile phone;;; +99801-3;LL6167-2;Internet types;LA46-8;4;Other;;; +99802-1;LL6196-1;Devices for internet access;LA33217-3;1;A laptop, chromebook, or desktop computer;;; +99802-1;LL6196-1;Devices for internet access;LA33218-1;2;A tablet or iPad;;; +99802-1;LL6196-1;Devices for internet access;LA33219-9;3;A smartphone;;; +99808-8;LL6197-9;Yes|No|Other;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99808-8;LL6197-9;Yes|No|Other;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99808-8;LL6197-9;Yes|No|Other;LA46-8;3;Other;;; +99811-2;LL6197-9;Yes|No|Other;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99811-2;LL6197-9;Yes|No|Other;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99811-2;LL6197-9;Yes|No|Other;LA46-8;3;Other;;; +99813-8;LL6197-9;Yes|No|Other;LA33-6;1;Yes;373066001;Yes (qualifier value);http://snomed.info/sct +99813-8;LL6197-9;Yes|No|Other;LA32-8;2;No;373067005;No (qualifier value);http://snomed.info/sct +99813-8;LL6197-9;Yes|No|Other;LA46-8;3;Other;;; +99809-6;LL6168-0;Education provider;LA33150-6;1;The school;;; +99809-6;LL6168-0;Education provider;LA33151-4;2;Me or my spouse/partner;;; +99809-6;LL6168-0;Education provider;LA33152-2;3;The child;;; +99809-6;LL6168-0;Education provider;LA33153-0;4;Other household members;;; +99809-6;LL6168-0;Education provider;LA46-8;5;Other;;; +99816-1;LL6169-8;Post high school plans;LA33154-8;1;No plans;;; +99816-1;LL6169-8;Post high school plans;LA15280-3;2;Military;;; +99816-1;LL6169-8;Post high school plans;LA33155-5;3;Employment;;; +99816-1;LL6169-8;Post high school plans;LA33156-3;4;Technical training;;; +99816-1;LL6169-8;Post high school plans;LA33157-1;5;Community college;;; +99816-1;LL6169-8;Post high school plans;LA33158-9;6;Four-year college;;; +99816-1;LL6169-8;Post high school plans;LA33159-7;7;Remain in high school;;; +99816-1;LL6169-8;Post high school plans;LA46-8;8;Other;;; +99818-7;LL6169-8;Post high school plans;LA33154-8;1;No plans;;; +99818-7;LL6169-8;Post high school plans;LA15280-3;2;Military;;; +99818-7;LL6169-8;Post high school plans;LA33155-5;3;Employment;;; +99818-7;LL6169-8;Post high school plans;LA33156-3;4;Technical training;;; +99818-7;LL6169-8;Post high school plans;LA33157-1;5;Community college;;; +99818-7;LL6169-8;Post high school plans;LA33158-9;6;Four-year college;;; +99818-7;LL6169-8;Post high school plans;LA33159-7;7;Remain in high school;;; +99818-7;LL6169-8;Post high school plans;LA46-8;8;Other;;; +99819-5;LL6199-5;Child care providers;LA33220-7;1;You;;; +99819-5;LL6199-5;Child care providers;LA33221-5;2;Your spouse or partner;;; +99819-5;LL6199-5;Child care providers;LA33222-3;3;A sibling;;; +99819-5;LL6199-5;Child care providers;LA33223-1;4;Other extended family members such as grandparents, aunts and uncles, and cousins.;;; +99819-5;LL6199-5;Child care providers;LA33224-9;5;A paid child care provider such as a nanny or au pair;;; +99819-5;LL6199-5;Child care providers;LA33225-6;6;A child care facility not located in your home;;; +99819-5;LL6199-5;Child care providers;LA46-8;7;Other;;; +99820-3;LL6170-6;Level of ease;LA33160-5;1;Very easy;;; +99820-3;LL6170-6;Level of ease;LA33161-3;2;Somewhat easy;;; +99820-3;LL6170-6;Level of ease;LA6573-5;3;Somewhat difficult;;; +99820-3;LL6170-6;Level of ease;LA6575-0;4;Very difficult;;; +99821-1;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15236-5;1;Strongly disagree;;; +99821-1;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15773-7;2;Disagree;;; +99821-1;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15774-5;3;Agree;;; +99821-1;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15237-3;4;Strongly agree;;; +99822-9;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15236-5;1;Strongly disagree;;; +99822-9;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15773-7;2;Disagree;;; +99822-9;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15774-5;3;Agree;;; +99822-9;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15237-3;4;Strongly agree;;; +99823-7;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15236-5;1;Strongly disagree;;; +99823-7;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15773-7;2;Disagree;;; +99823-7;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15774-5;3;Agree;;; +99823-7;LL6171-4;Str Dis|diagree|agree|Str Agr;LA15237-3;4;Strongly agree;;; +99853-4;LL6208-4;NOMS FCMS Swallow Solids;LA33257-9;1;Regular (no modifications);;; +99853-4;LL6208-4;NOMS FCMS Swallow Solids;LA33256-1;2;Soft & bite sized;;; +99853-4;LL6208-4;NOMS FCMS Swallow Solids;LA33255-3;3;Minced & moist;;; +99853-4;LL6208-4;NOMS FCMS Swallow Solids;LA33254-6;4;Pureed;;; +99853-4;LL6208-4;NOMS FCMS Swallow Solids;LA33253-8;5;Liquidized;;; +99853-4;LL6208-4;NOMS FCMS Swallow Solids;LA33252-0;6;No solids;;; +99854-2;LL6212-6;NOMS FCMS Swallow Liquids;LA33267-8;1;Thin liquids (no modifications);;; +99854-2;LL6212-6;NOMS FCMS Swallow Liquids;LA33268-6;2;Slightly thick;;; +99854-2;LL6212-6;NOMS FCMS Swallow Liquids;LA33269-4;3;Mildly thick;;; +99854-2;LL6212-6;NOMS FCMS Swallow Liquids;LA33270-2;4;Moderately thick;;; +99854-2;LL6212-6;NOMS FCMS Swallow Liquids;LA33271-0;5;Extremely thick;;; +99854-2;LL6212-6;NOMS FCMS Swallow Liquids;LA33272-8;6;No liquids;;; +99855-9;LL6213-4;NOMS FCMS Swallow Daily Diet;LA137-2;1;None;260413007;None (qualifier value);http://snomed.info/sct +99855-9;LL6213-4;NOMS FCMS Swallow Daily Diet;LA33274-4;2;<=25% of calorie intake;;; +99855-9;LL6213-4;NOMS FCMS Swallow Daily Diet;LA33275-1;3;26-49% of calorie intake;;; +99855-9;LL6213-4;NOMS FCMS Swallow Daily Diet;LA33276-9;4;50-75% of calorie intake;;; +99855-9;LL6213-4;NOMS FCMS Swallow Daily Diet;LA33277-7;5;>75% of calorie intake;;; +99935-9;LL6200-1;MPSS occurrence of pain;LA33227-2;1;"Pain does not occur on a daily basis or there is daily pain lasting less than a day. If the patient has been pain free during the last 4 weeks ""1"" should be recorded.";;; +99935-9;LL6200-1;MPSS occurrence of pain;LA33228-0;2;"Pain occurs several times per day. Pain intensity most often returns to zero (e.g. ""0"" on a numerical rating scale). There are pain free intervals.";;; +99935-9;LL6200-1;MPSS occurrence of pain;LA33229-8;3;Pain is continuously present, pain intensity does generally not go back to zero. There are only rare moments without pain, e.g. during sleep.;;; +99936-7;LL6201-9;MPSS pain duration;LA33230-6;1;Pain lasted for several hours or less;;; +99936-7;LL6201-9;MPSS pain duration;LA33231-4;2;Pain usually lasted for several days, at most for one week;;; +99936-7;LL6201-9;MPSS pain duration;LA33232-2;3;Pain usually persisted for more than a week or was continuous;;; +99937-5;LL6202-7;MPSS pain intensity;LA33233-0;1;Fluctuation of 2 or more points on a ten point numerical rating scale, two or more times per week;;; +99937-5;LL6202-7;MPSS pain intensity;LA33235-5;2;Fluctuation of 2 or more points on a ten point numerical scale, less than twice per week;;; +99937-5;LL6202-7;MPSS pain intensity;LA33236-3;3;Pain intensity does not change or hardly changes;;; +99938-3;LL6203-5;MPSS episodic pain intensity;LA33237-1;1;"Intensity of pain episodes usually varied more than 2 points on a ten point numerical scale. Definition of ""usually"": intensity changed in 50 or more percent of the episodes.";;; +99938-3;LL6203-5;MPSS episodic pain intensity;LA33238-9;2;"Intensity of pain episodes rarely varied 2 points on a ten point numerical scale. Definition of ""rarely"": intensity changed in less than 50% of the pain episodes.";;; +99938-3;LL6203-5;MPSS episodic pain intensity;LA33239-7;3;Pain intensity hardly or never changed.;;; +99939-1;LL6204-3;MPSS pain distribution;LA33240-5;1;Patient complains about one pain in one or more body areas, he or she feels, however, these pain areas belong together.;;; +99939-1;LL6204-3;MPSS pain distribution;LA33241-3;2;Patient complains about 2 definable pains located in one or more areas of the body.;;; +99939-1;LL6204-3;MPSS pain distribution;LA33242-1;3;Patient complains about more than two definable pains or his pain areas covers more than 50% of his body surface.;;; +99940-9;LL6205-0;MPSS drug use;LA33243-9;1;No drugs or group I-drug-intake on less than 15 days in the last 4 weeks.;;; +99940-9;LL6205-0;MPSS drug use;LA33244-7;2;Up to maximally 2 drugs of group I on more than 15 days in the last 4 weeks.;;; +99940-9;LL6205-0;MPSS drug use;LA33245-4;3;More than 2 drugs of group I or one or more drugs of group II or III on at least 15 days in the last 4 weeks.;;; +99941-7;LL6206-8;MPSS drug withdrawal tx;LA33246-2;1;No drug withdrawal treatment or significant dose reduction in the past history.;;; +99941-7;LL6206-8;MPSS drug withdrawal tx;LA33247-0;2;One account of drug withdrawal or one attempt of dose reduction in the past history.;;; +99941-7;LL6206-8;MPSS drug withdrawal tx;LA33248-8;3;Two or more drug withdrawals or several dose reduction attempts in the past history.;;; +99942-5;LL6207-6;MPSS change of physician;LA33249-6;1;No change of personal, pain managing physician;;; +99942-5;LL6207-6;MPSS change of physician;LA33250-4;2;Maximum three changes of personal, pain managing physician;;; +99942-5;LL6207-6;MPSS change of physician;LA33251-2;3;More than three changes of personal, pain managing physician;;; +99943-3;LL6209-2;MPSS pain hospitalizations;LA33258-7;1;No or one pain related hospitalization (for diagnosis and/or treatment);;; +99943-3;LL6209-2;MPSS pain hospitalizations;LA33259-5;2;Two to three pain related hospitalizations;;; +99943-3;LL6209-2;MPSS pain hospitalizations;LA33260-3;3;More than three pain related hospitalizations;;; +99944-1;LL6210-0;MPSS pain operations;LA33261-1;1;No or one pain related surgical procedure;;; +99944-1;LL6210-0;MPSS pain operations;LA33262-9;2;Two to three pain related surgical procedures;;; +99944-1;LL6210-0;MPSS pain operations;LA33263-7;3;More than three pain related surgical procedures;;; +99945-8;LL6211-8;MPSS pain rehabilitation;LA33264-5;1;No pain related stay in a rehabilitation or pain center;;; +99945-8;LL6211-8;MPSS pain rehabilitation;LA33265-2;2;One or two pain related stays in a rehabilitation or pain center;;; +99945-8;LL6211-8;MPSS pain rehabilitation;LA33266-0;3;More than two pain related stays in a rehabilitation or pain center;;; +99947-4;LL6142-5;Telecom type;LA14084-0;1;Home;;; +99947-4;LL6142-5;Telecom type;LA16501-1;2;Work;;; +99947-4;LL6142-5;Telecom type;LA33027-6;3;Temporary;;; +99947-4;LL6142-5;Telecom type;LA33028-4;4;Prior;;; +99947-4;LL6142-5;Telecom type;LA33035-9;5;Mobile;;; +99949-0;LL6141-7;Telecom mode;LA30129-3;1;Phone;;; +99949-0;LL6141-7;Telecom mode;LA31729-9;2;Fax;;; +99949-0;LL6141-7;Telecom mode;LA28452-3;3;Email;;; +99949-0;LL6141-7;Telecom mode;LA33032-6;4;Pager;;; +99949-0;LL6141-7;Telecom mode;LA33033-4;5;URL;;; +99949-0;LL6141-7;Telecom mode;LA33034-2;6;SMS;;; +99957-3;LL6139-1;Address - Home, work, temp;LA14084-0;1;Home;;; +99957-3;LL6139-1;Address - Home, work, temp;LA16501-1;2;Work;;; +99957-3;LL6139-1;Address - Home, work, temp;LA33027-6;3;Temporary;;; +99957-3;LL6139-1;Address - Home, work, temp;LA33028-4;4;Prior;;; +99957-3;LL6139-1;Address - Home, work, temp;LA33029-2;5;Billing;;; +99958-1;LL6140-9;Address type - phys/mail;LA33030-0;1;Postal;;; +99958-1;LL6140-9;Address type - phys/mail;LA33031-8;2;Physical;;; +99958-1;LL6140-9;Address type - phys/mail;LA14331-5;3;Both;;; diff --git a/src/SatusehatIntegrationServiceProvider.php b/src/SatusehatIntegrationServiceProvider.php index 03b0417..87f59b7 100644 --- a/src/SatusehatIntegrationServiceProvider.php +++ b/src/SatusehatIntegrationServiceProvider.php @@ -75,6 +75,28 @@ public function boot() ], 'icd9cm'); } + // Publish LOINC & LOINC answer csv data + $this->publishes([ + __DIR__.'/../database/seeders/csv/loinc.csv.stub' => database_path('/seeders/csv/loinc.csv'), + ], 'loinc'); + + $this->publishes([ + __DIR__.'/../database/seeders/csv/loinc_answer.csv.stub' => database_path('/seeders/csv/loinc_answer.csv'), + ], 'loinc'); + + // Publish Seeder for LOINC & LOINC Answer + if (! class_exists('LoincSeeder')) { + $this->publishes([ + __DIR__.'/../database/seeders/LoincSeeder.php.stub' => database_path('/seeders/LoincSeeder.php'), + ], 'loinc'); + } + + if (! class_exists('LoincAnswerSeeder')) { + $this->publishes([ + __DIR__.'/../database/seeders/LoincAnswerSeeder.php.stub' => database_path('/seeders/LoincAnswerSeeder.php'), + ], 'loinc'); + } + // Publish Migrations for Kode Wilayah Indonesia if (! class_exists('CreateKodeWilayahIndonesiaTable')) { $timestamp = date('Y_m_d_His', time()); diff --git a/src/Terminology/Loinc.php b/src/Terminology/Loinc.php new file mode 100644 index 0000000..3002093 --- /dev/null +++ b/src/Terminology/Loinc.php @@ -0,0 +1,51 @@ +connection)) { + $this->setConnection(config('satusehatintegration.database_connection_master')); + } + + if (! isset($this->table)) { + $this->setTable(config('satusehatintegration.loinc_table_name')); + } + + parent::__construct($attributes); + } + + protected $primaryKey = 'id'; + + public $incrementing = false; + + protected $casts = []; +} diff --git a/src/Terminology/LoincAnswer.php b/src/Terminology/LoincAnswer.php new file mode 100644 index 0000000..022e901 --- /dev/null +++ b/src/Terminology/LoincAnswer.php @@ -0,0 +1,46 @@ +connection)) { + $this->setConnection(config('satusehatintegration.database_connection_master')); + } + + if (! isset($this->table)) { + $this->setTable(config('satusehatintegration.loinc_answer_table_name')); + } + + parent::__construct($attributes); + } + + protected $primaryKey = 'id'; + + public $incrementing = false; + + protected $casts = []; +} diff --git a/tests/ArchTest.php b/tests/ArchTest.php index f7f70b1..022538d 100644 --- a/tests/ArchTest.php +++ b/tests/ArchTest.php @@ -4,7 +4,7 @@ class ArchTest extends TestCase { - public function testDebuggingFunctionsNotUsed() + public function test_debugging_functions_not_used() { $debuggingFunctions = ['dd', 'dump', 'ray']; $this->assertNotContainsAny($debuggingFunctions);